{"text_format":"1","workbook":"xlsx","n_sheets":4,"sheets":["Aktualni databaze","AKTUALNI - 2014","ARCHIV - WOS 2009-2013","krivka Jimp"],"not_rendered":{"charts":1,"images":5,"macros":1,"external_links":0,"defined_names":6,"comments":0,"pivot_tables":1},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":1,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Aktualni databaze","index":0,"n_rows":371,"n_cols":14,"rows_kept":371,"cut":false,"hidden":false,"merged":[]}
[]
[]
[]
[]
[]
[]
[]
["číslo","Autoři","Název","Periodikum","Druh","Rok/ročník/číslo/strany","IF13","Body RIV","domácí z/ze všech autorů","Autorský podíl","korespondující autor","první autor","UT:WOS","URL"]
[1,"Bartak, V; Kratky, Z; Popelka, S","Tumour-Like Lesion of the Forefoot due to a Retained Toothpick Fragment. Case Report","Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca","Article","2014/81/2/152-154",0.41499999999999998,11.022779999999999,"2 z/ze 3",0.66666666666666663,"ano","ano","WOS:000335368900008","http://www.achot.cz/detail.php?stat=675"]
[1,"Fulin, P; Pokorny, D; Slouf, M; Vackova, T; Dybal, J; Sosna, A","Effect of Sterilisation with Formaldehyde, Gamma Irradiation and Ethylene Oxide on the Properties of Polyethylene Joint Replacement Components","Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca","Article","2014/81/1/33-39",0.41499999999999998,11.022779999999999,"3 z/ze 6",0.5,"ano","ano","WOS:000332921300003","http://www.achot.cz/detail.php?stat=672"]
[1,"Rybka, V; Vavrik, P; Landor, I; Denk, F; Hach, J; Kruta, T; Sibr, M","All-Polyethylene Tibial Component in Walter-Motorlet Total Knee Arthroplasty. Long-Term Outcomes","Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca","Article","2014/81/2/122-128",0.41499999999999998,11.022779999999999,"6 z/ze 7",0.8571428571428571,"ano","ano","WOS:000335368900004","http://www.achot.cz/detail.php?stat=679"]
[1,"Stolz, AJ; Harustiak, T; Simonek, J; Schutzner, J; Lischke, R","Pneumonectomy for Non-Small Cell Lung Cancer : Predictors of Early Mortality and Morbidity","Acta Chirurgica Belgica","Article","2014/114/1/25-30",0.44,11.53975,"5 z/ze 5",1,"ano","ano","WOS:000333499600004","http://www.ncbi.nlm.nih.gov/pubmed/24720134"]
[1,"Teyssler, P; Kolostova, K; Bobek, V","The impact of platelet-rich plasma on chronic synovitis in hemophilia","Acta Orthopaedica Belgica","Article","2014/80/1/11-17",0.56699999999999995,12.81366,"1 z/ze 3",0.33333333333333331,"ne","ano","WOS:000335620900002","http://www.ncbi.nlm.nih.gov/pubmed/24873079"]
[1,"Kraus, J; Nartova, E; Pavlik, E; Katra, R; Sterzl, I; Astl, J","Prevalence of Helicobacter pylori in adenotonsillar hypertrophy in children","Acta Oto-Laryngologica","Article","2014/134/1/88-92",0.99,19.135169999999999,"3 z/ze 6",0.5,"ne","ne","WOS:000329058700013","http://dx.doi.org/10.3109/00016489.2013.840924"]
[1,"Fedorova, P; Srnec, R; Pencik, J; Schmid, P; Amler, E; Urbanova, L; Necas, A","Mechanical testing of newly developed biomaterial designed for intra-articular reinforcement of partially ruptured cranial cruciate ligament: ex vivo pig model","Acta Veterinaria Brno","Article","2014/83/1/55-60",0.44800000000000001,15.90766,"1 z/ze 7",0.14285714285714285,"ne","ne","WOS:000335204700010","http://dx.doi.org/10.2754/avb201483010055"]
[1,"Stepan-Buksakowska, I; Szabo, N; Horinek, D; Toth, E; Hort, J; Warner, J; Charvat, F; Vecsei, L; Rocek, M; Kincses, ZT","Cortical and Subcortical Atrophy in Alzheimer Disease Parallel Atrophy of Thalamus and Hippocampus","Alzheimer Disease & Associated Disorders","Article","2014/28/1/65-72",2.6880000000000002,38.307749999999999,"3 z/ze 10",0.3,"ano","ano","WOS:000332086700010","http://dx.doi.org/10.1097/WAD.0b013e318299d3d6"]
[1,"Veselka, J; Hajek, P; Tomasov, P; Tesar, D; Bruhova, H; Matejovic, M; Branny, M; Studencan, M; Zemanek, D","Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study)","American Journal of Cardiology","Article","2014/113/3/446-451",3.4249999999999998,42.086849999999998,"5 z/ze 9",0.55555555555555558,"ano","ano","WOS:000331161700007","http://dx.doi.org/10.1016/j.amjcard.2013.10.026"]
[1,"Durila, M; Malosek, M","Rotational thromboelastometry along with thromboelastography plays a critical role in the management of traumatic bleeding","American Journal of Emergency Medicine","Article","2014/32/3/-",1.1519999999999999,25.094249999999999,"2 z/ze 2",1,"ano","ano","WOS:000332525500030","http://dx.doi.org/10.1016/j.ajem.2013.09.038"]
[1,"Zmolikova, M; Puchmajerova, A; Hecht, P; Lebl, J; Trkova, M; Krepelova, A","Coarctation of the Aorta in Noonan-Like Syndrome With Loose Anagen Hair","American Journal of Medical Genetics Part A","Article","2014/164/5/1218-1221",2.048,18.455020000000001,"5 z/ze 6",0.83333333333333337,"ano","ano","WOS:000334290300021","http://dx.doi.org/10.1002/ajmg.a.36404"]
[1,"Tmejova, K; Krejcova, L; Hynek, D; Adam, V; Babula, P; Trnkova, L; Stiborova, M; Eckschlager, T; Kizek, R","Electrochemical Study of Ellipticine Interaction with Single and Double Stranded Oligonucleotides","Anti-Cancer Agents in Medicinal Chemistry","Article","2014/14/2/331-340",2.9390000000000001,32.757959999999997,"1 z/ze 9",0.1111111111111111,"ne","ne","WOS:000331462800016","http://dx.doi.org/10.2174/18715206113139990316"]
[1,"Plzak, J; Zabrodsky, M; Lukes, P","Zenker's Diverticulum: Carbon Dioxide Laser Endoscopic Surgery","Biomed Research International","Article","2014///-",0,10,"3 z/ze 3",1,"ano","ano","WOS:000332896400001","http://dx.doi.org/10.1155/2014/516231"]
[1,"Capkova, M; Sachova, J; Strnad, H; Kolar, M; Hroudova, M; Chovanec, M; Cada, Z; Steffl, M; Valach, J; Kastner, J; Vlcek, C; Smetana, K; Plzak, J","Microarray Analysis of Serum mRNA in Patients with Head and Neck Squamous Cell Carcinoma at Whole-Genome Scale","Biomed Research International","Article","2014///-",0,10,"6 z/ze 13",0.46153846153846156,"ano","ano","WOS:000335235800001","http://dx.doi.org/10.1155/2014/408683"]
[1,"Plzak, J; Macokova, P; Zabrodsky, M; Kastner, J; Lastuvka, P; Astl, J","Influence of Radiofrequency Surgery on Architecture of the Palatine Tonsils","Biomed Research International","Article","2014///-",0,10,"6 z/ze 6",1,"ano","ano","WOS:000333911600001","http://dx.doi.org/10.1155/2014/598257"]
[1,"Lukesova, E; Boucek, J; Rotnaglova, E; Salakova, M; Koslabova, E; Grega, M; Eckschlager, T; Rihova, B; Prochazka, B; Klozar, J; Tachezy, R","High Level of Tregs Is a Positive Prognostic Marker in Patients with HPV- Positive Oral and Oropharyngeal Squamous Cell Carcinomas","Biomed Research International","Article","2014///-",0,10,"7 z/ze 11",0.63636363636363635,"ne","ano","WOS:000335233200001","http://dx.doi.org/10.1155/2014/303929"]
[1,"Fik, Z; Astl, J; Zabrodsky, M; Lukes, P; Merunka, I; Betka, J; Chovanec, M","Minimally Invasive Video-Assisted versus Minimally Invasive Nonendoscopic Thyroidectomy","Biomed Research International","Article","2014///-",0,10,"7 z/ze 7",1,"ano","ano","WOS:000334770300001","http://dx.doi.org/10.1155/2014/450170"]
[1,"Urdzikova, LM; Sedlacek, R; Suchy, T; Amemori, T; Ruzicka, J; Lesny, P; Havlas, V; Sykova, E; Jendelova, P","Human multipotent mesenchymal stem cells improve healing after collagenase tendon injury in the rat","Biomedical Engineering Online","Article","2014/13//-",1.746,28.012149999999998,"4 z/ze 9",0.44444444444444442,"ne","ne","WOS:000335059400001","http://dx.doi.org/10.1186/1475-925X-13-42"]
[1,"Slavicek, L; Pavlik, T; Tomasek, J; Bortlicek, Z; Buchler, T; Melichar, B; Vyzula, R; Prausova, J; Finek, J; Majek, O; Dusek, L","Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry","BMC Gastroenterology","Article","2014/14//-",2.113,21.039539999999999,"1 z/ze 11",9.0909090909090912E-2,"ne","ne","WOS:000334417600002","http://dx.doi.org/10.1186/1471-230X-14-53"]
[1,"Fulin, P; Pokorny, D; Slouf, M; Nevoralova, M; Vackova, T; Dybal, J; Pilar, J","Quantification of structural changes of UHMWPE components in total joint replacements","BMC Musculoskeletal Disorders","Article","2014/15//-",1.8979999999999999,26.598669999999998,"2 z/ze 7",0.2857142857142857,"ano","ano","WOS:000335183900002","http://dx.doi.org/10.1186/1471-2474-15-109"]
[1,"Bontant, T; Sedlacek, P; Balduzzi, A; Gaspar, B; Cesaro, S; Einsele, H; Peters, C; Dalle, JH","Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the Inborn Errors, Infectious Diseases and Pediatric Diseases Working Parties of EBMT","Bone Marrow Transplantation","Article","2014/49/2/276-279",3.4660000000000002,39.933770000000003,"1 z/ze 8",0.125,"ne","ne","WOS:000331229900022","http://dx.doi.org/10.1038/bmt.2013.164"]
[1,"Vlcek, M; Landor, I; Horak, Z; Musil, V; Sosna, A; Jonas, D","Mathematical modelling for the comparison of plate and intramedullary osteosynthesis stability in intraarticular distal radius fractures","Bratislava Medical Journal-Bratislavske Lekarske Listy","Article","2014/115/2/107-111",0.44600000000000001,13.924149999999999,"3 z/ze 6",0.5,"ano","ano","WOS:000331992300012","http://dx.doi.org/10.4149/BLL_2014_023"]
[1,"Mojzikova, R; Koralkova, P; Holub, D; Zidova, Z; Pospisilova, D; Cermak, J; Laluhova, ZS; Indrak, K; Sukova, M; Partschova, M; Kucerova, J; Horvathova, M; Divoky, V","Iron status in patients with pyruvate kinase deficiency: neonatal hyperferritinaemia associated with a novel frameshift deletion in the PKLR gene (p.Arg518fs), and low hepcidin to ferritin ratios","British Journal of Haematology","Article","2014/165/4/556-563",4.9589999999999996,79.357770000000002,"1 z/ze 13",7.6923076923076927E-2,"ne","ne","WOS:000334686500015","http://dx.doi.org/10.1111/bjh.12779"]
[1,"Veselka, J","Historical Milestones and Progress in the Research on Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy","Canadian Journal of Cardiology","Review","2014/30/1/46-51",3.94,52.640819999999998,"1 z/ze 1",1,"ano","ano","WOS:000329072300010","http://dx.doi.org/10.1016/j.cjca.2013.10.001"]
[1,"Pavlik, T; Majek, O; Buchler, T; Vyzula, R; Petera, J; Ryska, M; Ryska, A; Cibula, D; Babjuk, M; Abrahamova, J; Vorlicek, J; Muzik, J; Dusek, L","Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008","Cancer Epidemiology","Article","2014/38/1/28-34",2.5579999999999998,31.745270000000001,"2 z/ze 13",0.15384615384615385,"ne","ne","WOS:000334029800005","http://dx.doi.org/10.1016/j.canep.2013.11.002"]
[1,"Kriz, J","Comment on article authors and Novak Ondrusova","Česká a slovenská neurologie a neurochirurgie","Editorial Material","2014/77/2/179-179",0.159,10.296110000000001,"1 z/ze 1",1,"ano","ano","WOS:000333662100006","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/komentar-k-clanku-autorek-ondrusova-a-novakovaortostaticka-hypotenze-jako-autonomni-dysregulacni-porucha-po-p-48188"]
[1,"Ridzon, P; Ehler, E; Urban, P; Prochazka, B; Mazanec, R; Latta, J; Matulova, H; Otruba, P","Normative Values of Nerve Conduction Studies of the Ulnar and Median Nerves Measured in a Standardized Way","Česká a slovenská neurologie a neurochirurgie","Article","2014/77/2/210-215",0.159,10.296110000000001,"1 z/ze 8",0.125,"ne","ne","WOS:000333662100011","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/normativni-hodnoty-parametru-vedeni-pro-nervus-ulnaris-a-nervus-medianus-merene-standardizovanym-zpusobem-48194"]
[1,"Forgac, M; Uher, T; Zamecnik, J","Nemaline Myopathy Associated with Monoclonal Gammopathy - a Case Report","Česká a slovenská neurologie a neurochirurgie","Article","2014/77/2/247-250",0.159,10.296110000000001,"1 z/ze 3",0.33333333333333331,"ne","ne","WOS:000333662100018","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/nemalinova-myopatie-asociovana-s-monoklonalni-gamapatii-kazuistika-48201"]
[1,"Ehler, E; Kopal, A; Mandysova, P; Vojtisek, P; Zamecnik, J","Stiff-person Syndrome Associated with Myotonic Dystrophy Type 2-a Case Report","Česká a slovenská neurologie a neurochirurgie","Article","2014/77/1/104-108",0.159,10.296110000000001,"1 z/ze 5",0.2,"ne","ne","WOS:000331010400017","http://www.prolekare.cz/en/czech-slovak-neurology-article/stiff-person-syndrome-associated-with-myotonic-dystrophy-type-2-a-case-report-47220"]
[1,"Kriz, J; Rejchrt, M","Autonomic Dysreflexia - a Serious Complication of Spinal Cord Injury","Česká a slovenská neurologie a neurochirurgie","Article","2014/77/2/168-173",0.159,10.296110000000001,"2 z/ze 2",1,"ano","ano","WOS:000333662100004","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/autonomni-dysreflexie-zavazna-komplikace-u-pacientu-po-poraneni-michy-48186"]
[1,"Kriz, J; Hysperska, V","Development of Neurological and Functional Clinical Picture after Spinal Cord Injury","Česká a slovenská neurologie a neurochirurgie","Article","2014/77/2/186-195",0.159,10.296110000000001,"2 z/ze 2",1,"ano","ano","WOS:000333662100008","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/vyvoj-neurologickeho-a-funkcniho-obrazu-po-poraneni-michy-48190"]
[1,"Strenkova, J; Vohanka, S; Haberlova, J; Junkerova, J; Mazanec, R; Mrazova, L; Parmova, O; Ridzon, P; Stanek, J; Siskova, D; Vondracek, P; Brabec, P; Snajdrova, L","REaDY - Czech Registry of Muscular Dystrophies","Česká a slovenská neurologie a neurochirurgie","Article","2014/77/2/230-234",0.159,10.296110000000001,"2 z/ze 13",0.15384615384615385,"ne","ne","WOS:000333662100014","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/ready-cesky-registr-svalovych-dystrofii-48197"]
[1,"Raudenska, J; Javurkova, A; Kozak, J; Amlerova, J","Neuropathic Pain Relief through Distraction Technique - a Case Report","Česká a slovenská neurologie a neurochirurgie","Article","2014/77/1/114-116",0.159,10.296110000000001,"3 z/ze 4",0.75,"ano","ano","WOS:000331010400019","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/uleva-od-neuropaticke-bolesti-pomoci-odvraceni-pozornosti-kazustika-47222"]
[1,"Kriz, J; Hakova, R; Hysperska, V; Hlinkova, Z; Lukas, R; Andel, R","International Standards for Neurological Classification of Spinal Cord Injury - Revision 2013","Česká a slovenská neurologie a neurochirurgie","Review","2014/77/1/77-81",0.159,10.296110000000001,"4 z/ze 6",0.66666666666666663,"ano","ano","WOS:000331010400011","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/mezinarodni-standardy-pro-neurologickou-klasifikaci-misniho-poraneni-revize-2013-47214"]
[1,"Oldgren, J; Healey, JS; Ezekowitz, M; Commerford, P; Avezum, A; Pais, P; Zhu, J; Jansky, P; Sigamani, A; Morillo, CA; Liu, LS; Damasceno, A; Grinvalds, A; Nakamya, J; Reilly, PA; Keltai, K; Van Gelder, IC; Yusufali, AH; Watanabe, E; Wallentin, L; Connolly, SJ; Yusuf, S","Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries The RE-LY Atrial Fibrillation Registry","Circulation","Article","2014/129/15/1568-1576",14.948,284.39909999999998,"1 z/ze 22",4.5454545454545456E-2,"ne","ne","WOS:000334321100010","http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005451"]
[1,"Nagel, B; Janousek, J; Koestenberger, M; Maier, R; Sauseng, W; Strenger, V; Gamillscheg, A; Zartner, P","Remote Monitoring Leads to Early Recognition and Treatment of Critical Arrhythmias in Adults After Atrial Switch Operation for Transposition of the Great Arteries","Circulation Journal","Article","2014/78/2/450-456",3.6850000000000001,45.574190000000002,"1 z/ze 8",0.125,"ne","ne","WOS:000330422300029","http://dx.doi.org/10.1253/circj.CJ-13-0670"]
[1,"Boublikova, L; Buchler, T; Stary, J; Abrahamova, J; Trka, J","Molecular biology of testicular germ cell tumors: Unique features awaiting clinical application","Critical Reviews in Oncology Hematology","Review","2014/89/3/366-385",4.0460000000000003,52.397210000000001,"5 z/ze 5",1,"ano","ano","WOS:000332357200004","http://dx.doi.org/10.1016/j.critrevonc.2013.10.001"]
[1,"Janousek, J; Kubus, P","What's new in cardiac pacing in children?","Current Opinion in Cardiology","Review","2014/29/1/76-82",2.59,29.875219999999999,"2 z/ze 2",1,"ano","ano","WOS:000327996800010","http://dx.doi.org/10.1097/HCO.0000000000000025"]
[1,"Stuchly, J; Kalina, T","Analyses of Large Flow Cytometry Datasets","Cytometry Part A","Editorial Material","2014/85/3/203-205",3.0659999999999998,29.178650000000001,"2 z/ze 2",1,"ano","ano","WOS:000331451500002","http://dx.doi.org/10.1002/cyto.a.22431"]
[1,"Fialova, J; Vojackova, N; Vanousova, D; Hercogova, J","Juvenile generalized pustular psoriasis treated with etanercept","Dermatologic Therapy","Article","2014/27/2/105-108",1.478,23.292490000000001,"4 z/ze 4",1,"ano","ano","WOS:000333809400011","http://dx.doi.org/10.1111/dth.12065"]
[1,"Petruzelkova, L; Ananieva-Jordanova, R; Vcelakova, J; Vesely, Z; Stechova, K; Lebl, J; Dusatkova, P; Sumnik, Z; Coles, R; Powell, M; Furmaniak, J; Smith, BR; Kolouskova, S","The dynamic changes of zinc transporter 8 autoantibodies in Czech children from the onset of Type 1 diabetes mellitus","Diabetic Medicine","Article","2014/31/2/165-171",3.0640000000000001,29.016819999999999,"8 z/ze 13",0.61538461538461542,"ano","ano","WOS:000329806900007","http://dx.doi.org/10.1111/dme.12308"]
[1,"Stanik, J; Dusatkova, P; Cinek, O; Valentinova, L; Huckova, M; Skopkova, M; Dusatkova, L; Stanikova, D; Pura, M; Klimes, I; Lebl, J; Gasperikova, D; Pruhova, S","De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed","Diabetologia","Article","2014/57/3/480-484",6.88,121.69799999999999,"5 z/ze 13",0.38461538461538464,"ne","ne","WOS:000331558400007","http://dx.doi.org/10.1007/s00125-013-3119-2"]
[1,"Brabcova, D; Krsek, P; Kohout, J; Zarubova, J","Psychometric properties of the modified Czech version of the children self-report Quality-of-life Measure for Children with Epilepsy (CHEQOL-25)","Epilepsy & Behavior","Article","2014/33//31-38",2.0609999999999999,21.82687,"1 z/ze 4",0.25,"ne","ne","WOS:000334655200007","http://dx.doi.org/10.1016/j.yebeh.2014.02.013"]
[1,"Nartova, E; Kraus, J; Pavlik, E; Lukes, P; Katra, R; Plzak, J; Kolarova, L; Sterzl, I; Betka, J; Astl, J","Presence of different genotypes of Helicobacter pylori in patients with chronic tonsillitis and sleep apnoea syndrome","European Archives of Oto-Rhino-Laryngology","Article","2014/271/3/607-613",1.6080000000000001,46.071210000000001,"5 z/ze 10",0.5,"ano","ano","WOS:000331706100028","http://dx.doi.org/10.1007/s00405-013-2607-9"]
[1,"Lukes, P; Pavlik, E; Potuznikova, B; Nartova, E; Foltynova, E; Plzak, J; Katra, R; Sterzl, I; Bartunkova, J; Betka, J; Astl, J","Detection of Helicobacter pylori in oropharyngeal lymphatic tissue with real-time PCR and assessment of its carcinogenic potential","European Archives of Oto-Rhino-Laryngology","Article","2014/271/2/399-405",1.6080000000000001,46.071210000000001,"8 z/ze 11",0.72727272727272729,"ano","ano","WOS:000329996400028","http://dx.doi.org/10.1007/s00405-013-2574-1"]
[1,"Verheecke, M; Halaska, MJ; Lok, CA; Ottevanger, PB; Fruscio, R; Dahl-Steffensen, K; Kolawa, W; Gziri, MM; Han, SN; Van Calsteren, K; Van den Heuvel, F; De Vleeschouwer, S; Clement, PM; Menten, J; Amant, F","Primary brain tumours, meningiomas and brain metastases in pregnancy: Report on 27 cases and review of literature","European Journal of Cancer","Review","2014/50/8/1462-1471",4.819,62.87941,"1 z/ze 15",6.6666666666666666E-2,"ne","ne","WOS:000334314600007","http://dx.doi.org/10.1016/j.ejca.2014.02.018"]
[1,"Tabernero, J; Van Cutsem, E; Lakomy, R; Prausova, J; Ruff, P; van Hazel, GA; Moiseyenko, VM; Ferry, DR; McKendrick, JJ; Soussan-Lazard, K; Chevalier, S; Allegra, CJ","Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial","European Journal of Cancer","Article","2014/50/2/320-331",4.819,62.87941,"1 z/ze 12",8.3333333333333329E-2,"ne","ne","WOS:000329986500008","http://dx.doi.org/10.1016/j.ejca.2013.09.013"]
[1,"Leoncini, E; Ricciardi, W; Cadoni, G; Arzani, D; Petrelli, L; Paludetti, G; Brennan, P; Luce, D; Stucker, I; Matsuo, K; Talamini, R; La Vecchia, C; Olshan, AF; Winn, DM; Herrero, R; Franceschi, S; Castellsague, X; Muscat, J; Morgenstern, H; Zhang, ZF; Levi, F; Dal Maso, L; Kelsey, K; McClean, M; Vaughan, T; Lazarus, P; Purdue, MP; Hayes, RB; Chen, C; Schwartz, SM; Shangina, O; Koifman, S; Ahrens, W; Matos, E; Lagiou, P; Lissowska, J; Szeszenia-Dabrowska, N; Fernandez, L; Menezes, A; Agudo, A; Daudt, AW; Richiardi, L; Kjaerheim, K; Mates, D; Betka, J; Yu, GP; Schantz, S; Simonato, L; Brenner, H; Conway, DI; Macfarlane, TV; Thomson, P; Fabianova, E; Znaor, A; Rudnai, P; Healy, C; Boffetta, P; Chuang, SC; Lee, YCA; Hashibe, M; Boccia, S","Adult height and head and neck cancer: a pooled analysis within the INHANCE Consortium","European Journal of Epidemiology","Article","2014/29/1/35-48",5.1470000000000002,170.0736,"1 z/ze 61",1.6393442622950821E-2,"ne","ne","WOS:000331645200004","http://dx.doi.org/10.1007/s10654-013-9863-2"]
[1,"Korecova, M; Hladikova, M","Treatment of mild and moderate type-2 diabetes: open prospective trial with Hintonia latiflora extract","European Journal of Medical Research","Article","2014/19//-",1.3979999999999999,16.439029999999999,"1 z/ze 2",0.5,"ne","ne","WOS:000334473900001","http://dx.doi.org/10.1186/2047-783X-19-16"]
[1,"Halaska, MJ; Komar, M; Vlk, R; Tomek, V; Skultety, J; Robova, H; Rob, L","A pilot study on peak systolic velocity monitoring of fetal anemia after administration of chemotherapy during pregnancy","European Journal of Obstetrics & Gynecology and Reproductive Biology","Article","2014/174//76-79",1.627,17.801130000000001,"7 z/ze 7",1,"ano","ano","WOS:000333505500013","http://dx.doi.org/10.1016/j.ejogrb.2013.12.021"]
[1,"Nevoral, J; Kotalova, R; Hradsky, O; Valtrova, V; Zarubova, K; Lastovicka, J; Neubertova, E; Trnkova, M; Bronsky, J","Symptom positivity is essential for omitting biopsy in children with suspected celiac disease according to the new ESPGHAN guidelines","European Journal of Pediatrics","Article","2014/173/4/497-502",1.9830000000000001,44.317169999999997,"7 z/ze 9",0.77777777777777779,"ano","ano","WOS:000332964600013","http://dx.doi.org/10.1007/s00431-013-2215-0"]
[1,"Jahodova, A; Krsek, P; Kyncl, M; Jezdik, P; Kudr, M; Komarek, V; Jayakar, P; Miller, I; Resnick, T; Duchowny, M","Distinctive MRI features of the epileptogenic zone in children with tuberous sclerosis","European Journal of Radiology","Article","2014/83/4/703-709",2.16,37.167000000000002,"5 z/ze 10",0.5,"ne","ano","WOS:000332405200016","http://dx.doi.org/10.1016/j.ejrad.2013.12.024"]
[1,"Kerem, E; Viviani, L; Zolin, A; MacNeill, S; Hatziagorou, E; Ellemunter, H; Drevinek, P; Gulmans, V; Krivec, U; Olesen, H","Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry","European Respiratory Journal","Article","2014/43/1/125-133",7.125,149.63630000000001,"1 z/ze 10",0.1,"ne","ne","WOS:000329552200018","http://dx.doi.org/10.1183/09031936.00166412"]
[1,"Suchomel, P; Jurak, L; Antinheimo, J; Pohjola, J; Stulik, J; Meisel, HJ; Cabraja, M; Woiciechowsky, C; Bruchmann, B; Shackleford, I; Arregui, R; Sola, S","Does sagittal position of the CTDR-related centre of rotation influence functional outcome? Prospective 2-year follow-up analysis","European Spine Journal","Review","2014/23/5/1124-1134",2.4729999999999999,42.838470000000001,"1 z/ze 12",8.3333333333333329E-2,"ne","ne","WOS:000335507600019","http://dx.doi.org/10.1007/s00586-014-3223-0"]
[1,"Colombel, M; Heidenreich, A; Martinez-Pineiro, L; Babjuk, M; Korneyev, I; Surcel, C; Yakovlev, P; Colombo, R; Radziszewski, P; Witjes, F; Schipper, R; Mulders, P; Witjes, WPJ","Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: Overview and the Unmet Clinical Need for Alternative Adjuvant Therapy as Studied in the MAGNOLIA Trial","European Urology","Editorial Material","2014/65/3/509-511",12.48,305,"1 z/ze 13",7.6923076923076927E-2,"ne","ne","WOS:000330572600005","http://dx.doi.org/10.1016/j.eururo.2013.10.056"]
[1,"Rieken, M; Xylinas, E; Kluth, L; Crivelli, JJ; Chrystal, J; Faison, T; Lotan, Y; Karakiewicz, PI; Holmang, S; Babjuk, M; Fajkovic, H; Seitz, C; Klatte, T; Pycha, A; Bachmann, A; Scherr, DS; Shariat, SF","Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder","European Urology","Article","2014/65/1/201-209",12.48,305,"1 z/ze 17",5.8823529411764705E-2,"ne","ne","WOS:000327766500037","http://dx.doi.org/10.1016/j.eururo.2013.08.034"]
[1,"Horak, M; Handl, M; Podskubka, A; Kana, R; Adler, J; Povysil, C","Comparison of the Cellular Composition of Two Different Chondrocyte-Seeded Biomaterials and the Results of Their Transplantation in Humans","Folia Biologica","Article","2014/60/1/1-9",1.167,15.888909999999999,"1 z/ze 6",0.16666666666666666,"ne","ne","WOS:000332143400001","http://www.ncbi.nlm.nih.gov/pubmed/24594051"]
[1,"Tomasov, P; Minarik, M; Zemanek, D; Cadova, P; Homolova, S; Curila, K; Penicka, M; Benesova, L; Belsanova, B; Gregor, P; Veselka, J","Genetic Testing in the Management of Relatives of Patients with Hypertrophic Cardiomyopathy","Folia Biologica","Article","2014/60/1/28-34",1.167,15.888909999999999,"5 z/ze 11",0.45454545454545453,"ano","ano","WOS:000332143400004","http://www.ncbi.nlm.nih.gov/pubmed/24594054"]
[1,"Fila, L; Grandcourtova, A; Chladek, J; Musil, J","Oxidative stress in cystic fibrosis patients with Burkholderia cenocepacia airway colonization: relation of 8-isoprostane concentration in exhaled breath condensate to lung function decline","Folia Microbiologica","Article","2014/59/3/217-222",1.145,14.01282,"2 z/ze 4",0.5,"ano","ano","WOS:000334171300005","http://dx.doi.org/10.1007/s12223-013-0285-z"]
[1,"Picha, D; Moravcova, L; Vanousova, D; Hercogova, J; Blechova, Z","DNA persistence after treatment of Lyme borreliosis","Folia Microbiologica","Article","2014/59/2/115-125",1.145,14.01282,"5 z/ze 5",1,"ano","ano","WOS:000332115200004","http://dx.doi.org/10.1007/s12223-013-0272-4"]
[1,"Vlcek, K; Laczo, J","Neural correlates of spatial navigation changes in mild cognitive impairment and Alzheimer's disease","Frontiers in Behavioral Neuroscience","Review","2014/8//-",4.16,59.660910000000001,"1 z/ze 2",0.5,"ne","ne","WOS:000332830600001","http://dx.doi.org/10.3389/fnbeh.2014.00089"]
[1,"Marciniak, R; Sheardova, K; Cermakova, P; Hudecek, D; Sumec, R; Hort, J","Effect of meditation on cognitive functions in context of aging and neurodegenerative diseases","Frontiers in Behavioral Neuroscience","Review","2014/8//-",4.16,59.660910000000001,"1 z/ze 6",0.16666666666666666,"ne","ne","WOS:000330541800001","http://dx.doi.org/10.3389/fnbeh.2014.00017"]
[1,"Urbanova, B; Tomek, A; Mikulik, R; Magerova, H; Horinek, D; Hort, J","Neurosonological examination: a non-invasive approach for the detection of cerebrovascular impairment in AD","Frontiers in Behavioral Neuroscience","Review","2014/8//-",4.16,59.660910000000001,"4 z/ze 6",0.66666666666666663,"ano","ano","WOS:000330513600002","http://dx.doi.org/10.3389/fnbeh.2014.00004"]
[1,"Yang, JJ; Park, TS; Lee, ST; Seo, JY; Oh, SH; Cho, EH; Strehl, S; Muhlegger, N; Dworzak, MN; Zuna, J; Pospisilova, D; Meyer, C; Marschalek, R; Kim, HJ; Kim, SH","Molecular characterization and clinical impact of t(11;15)(q23;q14-15) MLL-CASC5 rearrangement","Haematologica","Letter","2014/99/1/-",5.8680000000000003,145.48339999999999,"1 z/ze 15",6.6666666666666666E-2,"ne","ne","WOS:000335890500004","http://dx.doi.org/10.3324/haematol.2013.095638"]
[1,"Meissner, B; Bartram, T; Eckert, C; Trka, J; Panzer-Grumayer, R; Hermanova, I; Ellinghaus, E; Franke, A; Moricke, A; Schrauder, A; Teigler-Schlegel, A; Dorge, P; von Stackelberg, A; Basso, G; Bartram, CR; Kirschner-Schwabe, R; Bornhauser, B; Bourquin, JP; Cazzaniga, G; Hauer, J; Attarbaschi, A; Izraeli, S; Zaliova, M; Cario, G; Zimmermann, M; Avigad, S; Sokalska-Duhme, M; Metzler, M; Schrappe, M; Koehler, R; te Kronnie, G; Stanulla, M","Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia","Human Molecular Genetics","Article","2014/23/3/590-601",6.6769999999999996,106.98609999999999,"3 z/ze 32",9.375E-2,"ne","ne","WOS:000330841700003","http://dx.doi.org/10.1093/hmg/ddt447"]
[1,"Novakova, M; Sumova, A","New methods to assess circadian clocks in humans","Indian Journal of Experimental Biology","Review","2014/52/5/404-412",0.753,16.59019,"1 z/ze 2",0.5,"ne","ano","WOS:000335629000005","http://www.ncbi.nlm.nih.gov/pubmed/24851402"]
[1,"Veselka, J; Spacek, M; Homolova, I; Zimolova, P","Obesity paradox in female patients after stent implantation for carotid artery disease","International Journal of Cardiology","Letter","2014/172/3/600-601",6.1749999999999998,122.31019999999999,"4 z/ze 4",1,"ano","ano","WOS:000333101000069","http://dx.doi.org/10.1016/j.ijcard.2014.01.092"]
[1,"Veselka, J; Krejci, J; Tomasov, P; Durdil, V; Riedlbauchova, L; Honek, J; Honek, T; Zemanek, D","Outcome of patients after alcohol septal ablation with permanent pacemaker implanted for periprocedural complete heart block","International Journal of Cardiology","Letter","2014/171/2/E37-E38",6.1749999999999998,122.31019999999999,"6 z/ze 8",0.75,"ano","ano","WOS:000329982200014","http://dx.doi.org/10.1016/j.ijcard.2013.11.119"]
[1,"Amant, F; Halaska, MJ; Fumagalli, M; Steffensen, KD; Lok, C; Van Calsteren, K; Han, SN; Mir, O; Fruscio, R; Uzan, C; Maxwell, C; Dekrem, J; Strauven, G; Mhallem Gziri, M; Kesic, V; Berveiller, P; van den Heuvel, F; Ottevanger, PB; Vergote, I; Lishner, M; Morice, P; Nulman, I","Gynecologic Cancers in Pregnancy Guidelines of a Second International Consensus Meeting","International Journal of Gynecological Cancer","Review","2014/24/3/394-403",1.9490000000000001,22.37677,"1 z/ze 22",4.5454545454545456E-2,"ne","ne","WOS:000332519000005","http://dx.doi.org/10.1097/IGC.0000000000000062"]
[1,"St'astny, E; Trc, T; Handl, M; Kos, P; Kautzner, J; Philippou, T; Lisy, J","Mid-term results of revision total hip arthroplasty using the oval-shaped uncemented Trc-Cingr cup","International Orthopaedics","Article","2014/38/5/935-940",2.0190000000000001,40.55791,"7 z/ze 7",1,"ano","ano","WOS:000335147900004","http://dx.doi.org/10.1007/s00264-013-2269-7"]
[1,"Honek, J; Sramek, M; Sefc, L; Januska, J; Fiedler, J; Horvath, M; Tomek, A; Novotny, S; Honek, T; Veselka, J","Effect of Catheter-Based Patent Foramen Ovale Closure on the Occurrence of Arterial Bubbles in Scuba Divers","JACC-Cardiovascular Interventions","Article","2014/7/4/403-408",7.44,175.8092,"7 z/ze 10",0.7,"ano","ano","WOS:000334509600012","http://dx.doi.org/10.1016/j.jcin.2013.12.199"]
[1,"Pochop, P; Mahelkova, G; Cendelin, J; Petruskova, D","Early detection of recurrent primary iris stromal cyst using ultrasound biomicroscopy","Journal of AAPOS","Article","2014/18/2/184-186",1.1419999999999999,16.876390000000001,"4 z/ze 4",1,"ano","ano","WOS:000334652200019","http://dx.doi.org/10.1016/j.jaapos.2013.09.017"]
[1,"IJspeert, H; Driessen, GJ; Moorhouse, MJ; Hartwig, NG; Wolska-Kusnierz, B; Kalwak, K; Pituch-Noworolska, A; Kondratenko, I; van Montfrans, JM; Mejstrikova, E; Lankester, AC; Langerak, AW; van Gent, DC; Stubbs, AP; van Dongen, JJM; van der Burg, M","Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes","Journal of Allergy and Clinical Immunology","Article","2014/133/4/1124-+",11.247999999999999,211.3297,"1 z/ze 16",6.25E-2,"ne","ne","WOS:000333531700024","http://dx.doi.org/10.1016/j.jaci.2013.11.028"]
[1,"Marciano, BE; Huang, CY; Joshi, G; Rezaei, N; Carvalho, BC; Allwood, Z; Ikinciogullari, A; Reda, SM; Gennery, A; Thon, V; Espinosa-Rosales, F; Al-Herz, W; Porras, O; Shcherbina, A; Szaflarska, A; Kilic, S; Franco, JL; Raccio, ACG; Roxo, P; Esteves, I; Galal, N; Grumach, AS; Al-Tamemi, S; Yildiran, A; Orellana, JC; Yamada, M; Morio, T; Liberatore, D; Ohtsuka, Y; Lau, YL; Nishikomori, R; Torres-Lozano, C; Mazzucchelli, JTL; Vilela, MMS; Tavares, FS; Cunha, L; Pinto, JA; Espinosa-Padilla, SE; Hernandez-Nieto, L; Elfeky, RA; Ariga, T; Toshio, H; Dogu, F; Cipe, F; Formankova, R; Nunez-Nunez, ME; Bezrodnik, L; Marques, JG; Pereira, MI; Listello, V; Slatter, MA; Nademi, Z; Kowalczyk, D; Fleisher, TA; Davies, G; Neven, B; Rosenzweig, SD","BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies","Journal of Allergy and Clinical Immunology","Article","2014/133/4/1134-1141",11.247999999999999,211.3297,"1 z/ze 57",1.7543859649122806E-2,"ne","ne","WOS:000333531700025","http://dx.doi.org/10.1016/j.jaci.2014.02.028"]
[1,"Maly, J; Szarszoi, O; Netuka, I; Dorazilova, Z; Pirk, J","Fungal Infections Associated with Long-Term Mechanical Circulatory Support-Diagnosis and Management","Journal of Cardiac Surgery","Review","2014/29/1/95-100",0.88800000000000001,14.076779999999999,"1 z/ze 5",0.2,"ne","ano","WOS:000329307000015","http://dx.doi.org/10.1111/jocs.12258"]
[1,"Navardauskaite, R; Dusatkova, P; Obermannova, B; Pfaeffle, RW; Blum, WF; Adukauskiene, D; Smetanina, N; Cinek, O; Verkauskiene, R; Lebl, J","High Prevalence of PROP1 Defects in Lithuania: Phenotypic Findings in an Ethnically Homogenous Cohort of Patients With Multiple Pituitary Hormone Deficiency","Journal of Clinical Endocrinology & Metabolism","Article","2014/99/1/299-306",6.31,108.1782,"4 z/ze 10",0.4,"ano","ne","WOS:000333402200067","http://dx.doi.org/10.1210/jc.2013-3090"]
[1,"Stary, J; Zimmermann, M; Campbell, M; Castillo, L; Dibar, E; Donska, S; Gonzalez, A; Izraeli, S; Janic, D; Jazbec, J; Konja, J; Kaiserova, E; Kowalczyk, J; Kovacs, G; Li, CK; Magyarosy, E; Popa, A; Stark, B; Jabali, Y; Trka, J; Hrusak, O; Riehm, H; Masera, G; Schrappe, M","Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002","Journal of Clinical Oncology","Article","2014/32/3/174-+",17.96,224.60419999999999,"3 z/ze 24",0.125,"ano","ano","WOS:000330627900004","http://dx.doi.org/10.1200/JCO.2013.48.6522"]
[1,"Goetz, M; Surman, CBH","Prolonged Penile Erections Associated With the Use of Atomoxetine and Aripiprazole in an 11-Year-Old Boy","Journal of Clinical Psychopharmacology","Letter","2014/34/2/275-276",3.7610000000000001,61.01979,"1 z/ze 2",0.5,"ano","ano","WOS:000335328000021","http://dx.doi.org/10.1097/01.jcp.0000445185.90518.84"]
[1,"Sommerburg, O; Krulisova, V; Hammermann, J; Lindner, M; Stahl, M; Muckenthaler, M; Kohlmueller, D; Happich, M; Kulozik, AE; Votava, F; Balascakova, M; Skalicka, V; Stopsack, M; Gahr, M; Macek, M; Mall, MA; Hoffinann, GF","Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations","Journal of Cystic Fibrosis","Article","2014/13/1/15-23",3.82,71.547290000000004,"4 z/ze 17",0.23529411764705882,"ne","ne","WOS:000329951600003","http://dx.doi.org/10.1016/j.jcf.2013.06.003"]
[1,"Fajkosova, K; Machovcova, A; Onder, M; Fritz, K","Selective Radiofrequency Therapy as a Non-Invasive Approach for Contact less Body Contouring and Circumferential Reduction","Journal of Drugs in Dermatology","Article","2014/13/3/291-296",1.32,18.931190000000001,"1 z/ze 4",0.25,"ne","ne","WOS:000333003900012","http://www.ncbi.nlm.nih.gov/pubmed/24595574"]
[1,"Majer, F; Pelak, O; Kalina, T; Vlaskova, H; Dvorakova, L; Honzik, T; Palecek, T; Kuchynka, P; Masek, M; Zeman, J; Elleder, M; Sikora, J","Mosaic tissue distribution of the tandem duplication of LAMP2 exons 4 and 5 demonstrates the limits of Danon disease cellular and molecular diagnostics","Journal of Inherited Metabolic Disease","Article","2014/37/1/117-124",4.1379999999999999,52.856769999999997,"2 z/ze 12",0.16666666666666666,"ne","ne","WOS:000329100200015","http://dx.doi.org/10.1007/s10545-013-9617-z"]
[1,"Bladen, CL; Thompson, R; Jackson, JM; Garland, C; Wegel, C; Ambrosini, A; Pisano, P; Walter, MC; Schreiber, O; Lusakowska, A; Jedrzejowska, M; Kostera-Pruszczyk, A; van der Pol, L; Wadman, RI; Gredal, O; Karaduman, A; Topaloglu, H; Yilmaz, O; Matyushenko, V; Rasic, VM; Kosac, A; Karcagi, V; Garami, M; Herczegfalvi, A; Monges, S; Moresco, A; Chertkoff, L; Chamova, T; Guergueltcheva, V; Butoianu, N; Craiu, D; Korngut, L; Campbell, C; Haberlova, J; Strenkova, J; Alejandro, M; Jimenez, A; Ortiz, GG; Enriquez, GVG; Rodrigues, M; Roxburgh, R; Dawkins, H; Youngs, L; Lahdetie, J; Angelkova, N; Saugier-Veber, P; Cuisset, JM; Bloetzer, C; Jeannet, PY; Klein, A; Nascimento, A; Tizzano, E; Salgado, D; Mercuri, E; Sejersen, T; Kirschner, J; Rafferty, K; Straub, V; Bushby, K; Verschuuren, J; Beroud, C; Lochmuller, H","Mapping the differences in care for 5,000 Spinal Muscular Atrophy patients, a survey of 24 national registries in North America, Australasia and Europe","Journal of Neurology","Article","2014/261/1/152-163",3.8410000000000002,66.168059999999997,"1 z/ze 62",1.6129032258064516E-2,"ne","ne","WOS:000330962500017","http://dx.doi.org/10.1007/s00415-013-7154-1"]
[1,"Hradsky, O; Ohem, J; Zarubova, K; Mitrova, K; Durilova, M; Kotalova, R; Nevoral, J; Zemanova, I; Dryak, P; Bronsky, J","Disease Activity Is an Important Factor for Indeterminate Interferon-gamma Release Assay Results in Children With Inflammatory Bowel Disease","Journal of Pediatric Gastroenterology and Nutrition","Article","2014/58/3/320-324",2.8730000000000002,44.624830000000003,"8 z/ze 10",0.8,"ano","ano","WOS:000333297300014","http://dx.doi.org/10.1097/MPG.0000000000000205"]
[1,"Gkalpakiotis, S; Arenberger, P; Gkalpakioti, P; Meluzinova, E; Chandran, D; Arenbergerova, M","Management of psoriasis vulgaris and multiple sclerosis with fumaric acid","Journal of The American Academy of Dermatology","Letter","2014/70/3/E60-E61",5.0039999999999996,189.9391,"1 z/ze 6",0.16666666666666666,"ne","ne","WOS:000331607400006","http://dx.doi.org/10.1016/j.jaad.2013.10.031"]
[1,"Klatte, T; Xylinas, E; Rieken, M; Kluth, LA; Roupret, M; Pycha, A; Fajkovic, H; Seitz, C; Karakiewicz, PI; Lotan, Y; Babjuk, M; de Martino, M; Scherr, DS; Shariat, SF","Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer","Journal of Urology","Article","2014/191/5/1238-1243",3.7530000000000001,102.71980000000001,"1 z/ze 14",7.1428571428571425E-2,"ne","ne","WOS:000335147100009","http://dx.doi.org/10.1016/j.juro.2013.11.106"]
[1,"Lipska, BS; Ranchin, B; Iatropoulos, P; Gellermann, J; Melk, A; Ozaltin, F; Caridi, G; Seeman, T; Tory, K; Jankauskiene, A; Zurowska, A; Szczepanska, M; Wasilewska, A; Harambat, J; Trautmann, A; Peco-Antic, A; Borzecka, H; Moczulska, A; Saeed, B; Bogdanovic, R; Kalyoncu, M; Simkova, E; Erdogan, O; Vrljicak, K; Teixeira, A; Azocar, M; Schaefer, F","Genotype-phenotype associations in WT1 glomerulopathy","Kidney International","Article","2014/85/5/1169-1178",8.52,206.51140000000001,"1 z/ze 27",3.7037037037037035E-2,"ne","ne","WOS:000335713300025","http://dx.doi.org/10.1038/ki.2013.519"]
[1,"Castinetti, F; Qi, XP; Walz, MK; Maia, AL; Sanso, G; Peczkowska, M; Hasse-Lazar, K; Links, TP; Dvorakova, S; Toledo, RA; Mian, C; Bugalho, MJ; Wohllk, N; Kollyukh, O; Canu, L; Loli, P; Bergmann, SR; Costa, JB; Makay, O; Patocs, A; Pfeifer, M; Shah, NS; Cuny, T; Brauckhoff, M; Bausch, B; von Dobschuetz, E; Letizia, C; Barczynski, M; Alevizaki, MK; Czetwertynska, M; Ugurlu, MU; Valk, G; Plukker, JTM; Sartorato, P; Siqueira, DR; Barontini, M; Szperl, M; Jarzab, B; Verbeek, HHG; Zelinka, T; Vlcek, P; Toledo, SPA; Coutinho, FL; Mannelli, M; Recasens, M; Demarquet, L; Petramala, L; Yaremchuk, S; Zabolotnyi, D; Schiavi, F; Opocher, G; Racz, K; Januszewicz, A; Weryha, G; Henry, JF; Brue, T; Conte-Devolx, B; Eng, C; Neumann, HPH","Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study","Lancet Oncology","Article","2014/15/6/648-655",24.725000000000001,258.85300000000001,"1 z/ze 59",1.6949152542372881E-2,"ne","ne","WOS:000335512100052","http://dx.doi.org/10.1016/S1470-2045(14)70154-8"]
[1,"Remlova, E; Dostalova, T; Michalusova, I; Vranova, J; Jelinkova, H; Hubacek, M","Infantile hemangioma: pulsed dye laser versus surgical therapy","Laser Physics","Article","2014/24/5/-",1.0249999999999999,17.921279999999999,"3 z/ze 6",0.5,"ne","ne","WOS:000334598300012","http://dx.doi.org/10.1088/1054-660X/24/5/055601"]
[1,"Dostalova, T; Jelinkova, H; Sulc, J; Nemec, M; Buckova, M; Kasparova, M; Bradna, P","Er:YAG laser delivery systems and sonic-activated bulk composite restoration: sculpturing and microleakage evaluation","Lasers in Dentistry XX","Proceedings Paper","2014/8929//-","není v JCR",10,"3 z/ze 7",0.42857142857142855,"ano","ano","WOS:000334341900008","http://dx.doi.org/10.1117/12.2036771"]
[1,"Hemminki, K; Musak, L; Vymetalkova, V; Smerhovsky, Z; Halasova, E; Osina, O; Letkova, L; Forsti, A; Vodickova, L; Buchancova, J; Vodicka, P","Cyclin D1 splice site variant triggers chromosomal aberrations in healthy humans","Leukemia","Letter","2014/28/3/721-722",9.3789999999999996,186.94900000000001,"1 z/ze 11",9.0909090909090912E-2,"ne","ne","WOS:000332845700033","http://dx.doi.org/10.1038/leu.2013.353"]
[1,"Aalbers, AM; van der Velden, VHJ; Yoshimi, A; Fischer, A; Noellke, P; Zwaan, CM; Baumann, I; Beverloo, HB; Dworzak, M; Hasle, H; Locatelli, F; De Moerloose, B; Gohring, G; Schmugge, M; Stary, J; Zecca, M; Langerak, AW; van Dongen, JJM; Pieters, R; Niemeyer, CM; van den Heuvel-Eibrink, MM","The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS","Leukemia","Letter","2014/28/1/189-192",9.3789999999999996,186.94900000000001,"1 z/ze 21",4.7619047619047616E-2,"ne","ne","WOS:000329441200022","http://dx.doi.org/10.1038/leu.2013.195"]
[1,"Zaliova, M; Zimmermannova, O; Dorge, P; Eckert, C; Moricke, A; Zimmermann, M; Stuchly, J; Teigler-Schlegel, A; Meissner, B; Koehler, R; Bartram, CR; Karawajew, L; Rhein, P; Zuna, J; Schrappe, M; Cario, G; Stanulla, M","ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia","Leukemia","Letter","2014/28/1/182-185",9.3789999999999996,186.94900000000001,"4 z/ze 17",0.23529411764705882,"ne","ano","WOS:000329441200020","http://dx.doi.org/10.1038/leu.2013.282"]
[1,"Slamova, L; Starkova, J; Fronkova, E; Zaliova, M; Reznickova, L; van Delft, FW; Vodickova, E; Volejnikova, J; Zemanova, Z; Polgarova, K; Cario, G; Figueroa, M; Kalina, T; Fiser, K; Bourquin, JP; Bornhauser, B; Dworzak, M; Zuna, J; Trka, J; Stary, J; Hrusak, O; Mejstrikova, E","CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage","Leukemia","Article","2014/28/3/609-620",9.3789999999999996,186.94900000000001,"15 z/ze 22",0.68181818181818177,"ano","ano","WOS:000332845700013","http://dx.doi.org/10.1038/leu.2013.354"]
[1,"Salek, D; Vesela, P; Boudova, L; Janikova, A; Klener, P; Vokurka, S; Jankovska, M; Pytlik, R; Belada, D; Pirnos, J; Moulis, M; Kodet, R; Michal, M; Janousova, E; Muzik, J; Mayer, J; Trneny, M","Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database","Leukemia & Lymphoma","Article","2014/55/4/802-810",2.605,25.90371,"1 z/ze 17",5.8823529411764705E-2,"ne","ne","WOS:000333582600013","http://dx.doi.org/10.3109/10428194.2013.815349"]
[1,"Novotny, J; Bhatnagar, JP; Xu, Y; Huq, MS","Long-term stability of the Leksell Gamma Knife((R)) Perfexion (TM) patient positioning system (PPS)","Medical Physics","Article","2014/41/3/-",3.012,62.790080000000003,"1 z/ze 4",0.25,"ano","ano","WOS:000332485600013","http://dx.doi.org/10.1118/1.4866225"]
[1,"Ptacek, R; Kuzelova, H; Stefano, GB; Raboch, J; Sadkova, T; Goetz, M; Kream, RM","Disruptive patterns of eating behaviors and associated lifestyles in males with ADHD","Medical Science Monitor","Article","2014/20//608-613",1.216,15.264720000000001,"1 z/ze 7",0.14285714285714285,"ne","ne","WOS:000334362300001","http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999164/"]
[1,"Raudenska, M; Gumulec, J; Podlaha, O; Sztalmachova, M; Babula, P; Eckschlager, T; Adam, V; Kizekb, R; Masarik, M","Metallothionein polymorphisms in pathological processes","Metallomics","Review","2014/6/1/55-68",3.9780000000000002,43.951300000000003,"1 z/ze 9",0.1111111111111111,"ne","ne","WOS:000328891100004","http://dx.doi.org/10.1039/c3mt00132f"]
[1,"Kaprova-Pleskacova, J; Stoop, H; Bruggenwirth, H; Cools, M; Wolffenbuttel, KP; Drop, SLS; Snajderova, M; Lebl, J; Oosterhuis, JW; Looijenga, LHJ","Complete androgen insensitivity syndrome: factors influencing gonadal histology including germ cell pathology","Modern Pathology","Article","2014/27/5/721-730",6.3639999999999999,154.27369999999999,"3 z/ze 10",0.3,"ano","ano","WOS:000335428600010","http://www.nature.com/modpathol/journal/v27/n5/full/modpathol2013193a.html"]
[1,"Kuncova, K; Sedlackova, M; Vencovsky, J; Mann, H; Tomcik, M; Wenchich, L; Zamecnik, J","Inflammatory myopathy associated with statins: report of three cases","Modern Rheumatology","Article","2014/24/2/366-371",2.206,22.38288,"2 z/ze 7",0.2857142857142857,"ano","ano","WOS:000332483500027","http://dx.doi.org/10.3109/14397595.2013.852848"]
[1,"Trachta, P; Dostalova, I; Haluzikova, D; Kasalicky, M; Kavalkova, P; Drapalova, J; Urbanova, M; Lacinova, Z; Mraz, M; Haluzik, M","Laparoscopic sleeve gastrectomy ameliorates mRNA expression of inflammation-related genes in subcutaneous adipose tissue but not in peripheral monocytes of obese patients","Molecular and Cellular Endocrinology","Article","2014/383/41671/96-102",4.2409999999999997,44.137889999999999,"1 z/ze 10",0.1,"ne","ne","WOS:000332049400010","http://dx.doi.org/10.1016/j.mce.2013.11.013"]
[1,"Brisset, S; Slamova, Z; Dusatkova, P; Briand-Suleau, A; Milcent, K; Metay, C; Simandlova, M; Sumnik, Z; Tosca, L; Goossens, M; Labrune, P; Zemankova, E; Lebl, J; Tachdjian, G; Sedlacek, Z","Anophthalmia, hearing loss, abnormal pituitary development and response to growth hormone therapy in three children with microdeletions of 14q22q23","Molecular Cytogenetics","Article","2014/7//-",2.6619999999999999,25.808520000000001,"6 z/ze 15",0.4,"ano","ne","WOS:000333270100002","http://dx.doi.org/10.1186/1755-8166-7-17"]
[1,"Papaemmanuil, E; Rapado, I; Li, YL; Potter, NE; Wedge, DC; Tubio, J; Alexandrov, LB; Van Loo, P; Cooke, SL; Marshall, J; Martincorena, I; Hinton, J; Gundem, G; van Delft, FW; Nik-Zainal, S; Jones, DR; Ramakrishna, M; Titley, I; Stebbings, L; Leroy, C; Menzies, A; Gamble, J; Robinson, B; Mudie, L; Raine, K; O'Meara, S; Teague, JW; Butler, AP; Cazzaniga, G; Biondi, A; Zuna, J; Kempski, H; Muschen, M; Ford, AM; Stratton, MR; Greaves, M; Campbell, PJ","RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia","Nature Genetics","Article","2014/46/2/116-+",29.648,274.86709999999999,"1 z/ze 37",2.7027027027027029E-2,"ne","ne","WOS:000331208300007","http://dx.doi.org/10.1038/ng.2874"]
[1,"Sousa, SB; Jenkins, D; Chanudet, E; Tasseva, G; Ishida, M; Anderson, G; Docker, J; Ryten, M; Sa, J; Saraiva, JM; Barnicoat, A; Scott, R; Calder, A; Wattanasirichaigoon, D; Chrzanowska, K; Simandlova, M; Van Maldergem, L; Stanier, P; Beales, PL; Vance, JE; Moore, GE","Gain-of-function mutations in the phosphatidylserine synthase 1 (PTDSS1) gene cause Lenz-Majewski syndrome","Nature Genetics","Article","2014/46/1/70-+",29.648,274.86709999999999,"1 z/ze 21",4.7619047619047616E-2,"ne","ne","WOS:000329113500016","http://dx.doi.org/10.1038/ng.2829"]
[1,"Capkova, L; Koubkova, L; Kodet, R","Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study","Neoplasma","Article","2014/61/2/161-169",1.6419999999999999,14.617459999999999,"3 z/ze 3",1,"ano","ano","WOS:000331008000006","http://dx.doi.org/10.4149/neo_2014_031"]
[1,"Bonthuis, M; van Stralen, KJ; Jager, KJ; Baiko, S; Jahnukainen, T; Laube, GF; Podracka, L; Seeman, T; Tyerman, K; Ulinski, T; Groothoff, JW; Schaefer, F; Verrina, E","Dyslipidaemia in children on renal replacement therapy","Nephrology Dialysis Transplantation","Article","2014/29/3/594-603",3.488,66.390209999999996,"1 z/ze 13",7.6923076923076927E-2,"ne","ne","WOS:000332381900020","http://dx.doi.org/10.1093/ndt/gft429"]
[1,"Hort, J; Andel, R; Mokrisova, I; Gazova, I; Amlerova, J; Valis, M; Coulson, EJ; Harrison, J; Windisch, M; Laczo, J","Effect of Donepezil in Alzheimer Disease Can Be Measured by a Computerized Human Analog of the Morris Water Maze","Neurodegenerative Diseases","Article; Proceedings Paper","2014/13/41700/192-196",3.4540000000000002,42.523820000000001,"5 z/ze 10",0.5,"ano","ano","WOS:000330752200036","http://dx.doi.org/10.1159/000355517"]
[1,"Dudova, I; Kasparova, M; Markova, D; Zemankova, J; Beranova, S; Urbanek, T; Hrdlicka, M","Screening for autism in preterm children with extremely low and very low birth weight","Neuropsychiatric Disease and Treatment","Article","2014/10//277-282",2.1539999999999999,24.68618,"4 z/ze 7",0.5714285714285714,"ano","ano","WOS:000331079900001","http://dx.doi.org/10.2147/NDT.S57057"]
[1,"Vysata, O; Kukal, J; Valis, M; Pazdera, L; Hort, J; Prochazka, A","Lag Synchronisation in the Human Brain: Evidence from 17,722 Healthy Subjects' EEG Analyses","Neuroquantology","Article","2014/12/1/40-45",0.439,10.796580000000001,"1 z/ze 6",0.16666666666666666,"ne","ne","WOS:000333899200005","http://dx.doi.org/10.14704/nq.2014.12.1.700"]
[1,"Profant, O; Skoch, A; Balogova, Z; Tintera, J; Hlinka, J; Syka, J","DIFFUSION TENSOR IMAGING AND MR MORPHOMETRY OF THE CENTRAL AUDITORY PATHWAY AND AUDITORY CORTEX IN AGING","Neuroscience","Article","2014/260//87-97",3.327,31.214590000000001,"2 z/ze 6",0.33333333333333331,"ano","ano","WOS:000330598100008","http://dx.doi.org/10.1016/j.neuroscience.2013.12.010"]
[1,"Kleteckova, L; Tsenov, G; Kubova, H; Stuchlik, A; Vales, K","Neuroprotective effect of the 3 alpha 5 beta-pregnanolone glutamate treatment in the model of focal cerebral ischemia in immature rats","Neuroscience Letters","Article","2014/564//11-15",2.0550000000000002,16.504259999999999,"1 z/ze 5",0.2,"ne","ano","WOS:000334985700003","http://dx.doi.org/10.1016/j.neulet.2014.01.057"]
[1,"Heger, Z; Cernei, N; Gumulec, J; Masarik, M; Eckschlager, T; Hrabec, R; Zitka, O; Adam, V; Kizek, R","Determination of common urine substances as an assay for improving prostate carcinoma diagnostics","Oncology Reports","Article","2014/31/4/1846-1854",2.1909999999999998,19.29316,"1 z/ze 9",0.1111111111111111,"ne","ne","WOS:000334345600046","http://dx.doi.org/10.3892/or.2014.3054"]
[1,"Poljakova, J; Groh, T; Gudino, ZO; Hrabeta, J; Borek-Dohalska, L; Kizek, R; Doktorova, H; Eckschlager, T; Stiborova, M","Hypoxia-mediated histone acetylation and expression of N-myc transcription factor dictate aggressiveness of neuroblastoma cells","Oncology Reports","Article","2014/31/4/1928-1934",2.1909999999999998,19.29316,"3 z/ze 9",0.33333333333333331,"ne","ne","WOS:000334345600057","http://dx.doi.org/10.3892/or.2014.2999"]
[1,"Lassuthova, P; Siskova, D; Haberlova, J; Sakmaryova, I; Filous, A; Seeman, P","Congenital cataract, facial dysmorphism and demyelinating neuropathy (CCFDN) in 10 Czech gypsy children - frequent and underestimated cause of disability among Czech gypsies","Orphanet Journal of Rare Diseases","Article","2014/9//-",3.9580000000000002,56.075449999999996,"5 z/ze 6",0.83333333333333337,"ano","ano","WOS:000335257500001","http://dx.doi.org/10.1186/1750-1172-9-46"]
[1,"Rygl, M; Vyhnanek, M; Kucera, A; Mixa, V; Kyncl, M; Snajdauf, J","Technical innovation in minimally invasive repair of pectus excavatum","Pediatric Surgery International","Article","2014/30/1/113-117",1.0609999999999999,17.442550000000001,"6 z/ze 6",1,"ano","ano","WOS:000329237900015","http://dx.doi.org/10.1007/s00383-013-3435-0"]
[1,"Stovicek, J; Liskova, P; Lisy, J; Hlava, S; Keil, R","Crohn's disease: Is there a place for neurological screening?","Scandinavian Journal of Gastroenterology","Article","2014/49/2/173-176",2.3290000000000002,24.338429999999999,"5 z/ze 5",1,"ano","ano","WOS:000329874800006","http://dx.doi.org/10.3109/00365521.2013.867358"]
[1,"Kriz, J; Relichova, Z","Intermittent self-catheterization in tetraplegic patients: a 6-year experience gained in the spinal cord unit in Prague","Spinal Cord","Article","2014/52/2/163-166",1.6990000000000001,24.426310000000001,"2 z/ze 2",1,"ano","ano","WOS:000331082700013","http://dx.doi.org/10.1038/sc.2013.154"]
[1,"Soukup, V; Duskova, J; Pesl, M; Capoun, O; Feherova, Z; Zamecnik, L; Hanus, T; Babjuk, M","The Prognostic Value of T1 Bladder Cancer Substaging: A Singlle Institution Retrospective Study","Urologia Internationalis","Article","2014/92/2/150-156",1.151,15.574159999999999,"1 z/ze 8",0.125,"ne","ne","WOS:000332500400005","http://dx.doi.org/10.1159/000355358"]
[1,"Poprach, A; Pavlik, T; Melichar, B; Kubackova, K; Bortlicek, Z; Svoboda, M; Lakomy, R; Vyzula, R; Kiss, I; Dusek, L; Buehler, T","Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines","Urologic Oncology-Seminars and Original Investigations","Article","2014/32/4/488-495",3.363,49.029150000000001,"1 z/ze 11",9.0909090909090912E-2,"ne","ne","WOS:000335422300017","http://dx.doi.org/10.1016/j.urolonc.2013.09.011"]
[1,"Kasalicky, M; Dolezel, R; Vernerova, E; Haluzik, M","Laparoscopic sleeve gastrectomy without over-sewing of the staple line is effective and safe","Videosurgery and Other Miniinvasive Techniques","Article","2014/9/1/46-52",1.0920000000000001,17.801130000000001,"3 z/ze 4",0.75,"ano","ano","WOS:000333727200008","http://dx.doi.org/10.5114/wiitm.2014.40387"]
[1,"Zdarska, DJ; Kvapil, M; Rusavy, Z; Krcma, M; Broz, J; Krivska, B; Kadlecova, P","Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: The COBIN2 study","Wiener Klinische Wochenschrift","Article","2014/126/41858/228-237",0.79100000000000004,17.818480000000001,"3 z/ze 7",0.42857142857142855,"ano","ano","WOS:000335170200008","http://dx.doi.org/10.1007/s00508-014-0508-6"]
[1,"Stepan, J; Ehrlichova, J; Hladikova, M","Efficacy and safety of symphytum herb extract cream in the treatment of pressure ulcers","Zeitschrift Fur Gerontologie Und Geriatrie","Article","2014/47/3/228-235",1.0229999999999999,13.1477,"3 z/ze 3",1,"ano","ano","WOS:000334579800007","http://dx.doi.org/10.1007/s00391-013-0522-8"]
[2,"Pietrzak, A; Bartosinska, J; Dybiec, E; Chodorowska, G; Krasowska, D; Hercogova, J; Lotti, T","Hepato-Splenic and Lipid Profile Abnormalities - Do They Exist in Children Affected with Vitiligo?","ACTA DERMATOVENEROLOGICA CROATICA","Article","2014/22/1/19-25",0.58099999999999996,11.75705,"1 z/ze 7",0.1429,"ne","ne","WOS:000336639800003","http://www.ncbi.nlm.nih.gov/pubmed/24813837"]
[2,"Stulik, J; Adamek, S; Barna, M; Kasprikova, N; Polanecky, O; Kryl, J","Axial Lumbar Interbody Fusion: Prospective Monocentric Study","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA","Article","2014/81/3/203-211",0.41499999999999998,11.022779999999999,"5 z/ze 6",0.83330000000000004,"ano","ano","WOS:000338490300004","http://www.achot.cz/detail.php?stat=693"]
[2,"Sebesta, P; Hach, J; St Tlusty, Z","Middle-Third Clavicle Fracture with Ipsilateral Acromioclavicular Dislocation","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA","Article","2014/81/3/238-240",0.41499999999999998,11.022779999999999,"1 z/ze 3",0.33329999999999999,"ne","ne","WOS:000338490300009","http://www.achot.cz/detail.php?stat=688"]
[2,"Vojtech, Z; Malikova, H; Kramska, L; Anyz, J; Syrucek, M; Zamecnik, J; Liscak, R; Vladyka, V","Long-term seizure outcome after stereotactic amygdalohippocampectomy","ACTA NEUROCHIRURGICA","Article","2014/156/8/1529-1537",1.788,25.205030000000001,"1 z/ze 8",0.125,"ne","ne","WOS:000339724900017","http://dx.doi.org/10.1007/s00701-014-2126-5"]
[2,"Krhut, J; Mazanec, R; Seeman, P; Mann-Gow, T; Zvara, P","Lower urinary tract functions in a series of Charcot-Marie-Tooth neuropathy patients","ACTA NEUROLOGICA SCANDINAVICA","Article","2014/129/5/319-324",2.4369999999999998,28.548310000000001,"2 z/ze 5",0.4,"ne","ne","WOS:000333732500008","http://dx.doi.org/10.1111/ane.12176"]
[2,"Kutilek, P; Socha, V; Cakrt, O; Svoboda, Z","Differences in evaluation methods of trunk sway using different MoCap systems","ACTA OF BIOENGINEERING AND BIOMECHANICS","Article","2014/16/2/85-94",0.97899999999999998,13.80768,"1 z/ze 4",0.25,"ne","ne","WOS:000340324900010","http://dx.doi.org/10.5277/abb140210"]
[2,"Zieg, J","Evaluation and management of hyponatraemia in children","ACTA PAEDIATRICA","Review","2014/103/10/1027-1034",1.8420000000000001,35.912289999999999,"1 z/ze 1",1,"ano","ano","WOS:000342753400014","http://dx.doi.org/10.1111/apa.12705"]
[2,"Bukovjan, K; Toman, A; Kutlvasr, K; Marada, P; Kodet, R; Slama, P; Krikava, L","Contents of chemical elements in tissues of European badger (Meles meles) affected by ovarian tumour - a case report","ACTA VETERINARIA BRNO","Article","2014/83/2/139-143",0.44800000000000001,15.90766,"1 z/ze 7",0.1429,"ne","ne","WOS:000339086600012","http://dx.doi.org/10.2754/avb201483020139"]
[2,"Veselka, J","Pre-percutaneous coronary intervention statin therapy: Is it necessary?","AMERICAN HEART JOURNAL","Letter","2014/168/2/-",4.5549999999999997,66.482470000000006,"1 z/ze 1",1,"ano","ano","WOS:000340207700003","http://dx.doi.org/10.1016/j.ahj.2014.06.001"]
[2,"Stepan-Buksakowska, IL; Accurso, JM; Diehn, FE; Huston, J; Kaufmann, TJ; Luetmer, PH; Wood, CP; Yang, X; Blezek, DJ; Carter, R; Hagen, C; Horinek, D; Hejcl, A; Rocek, M; Erickson, BJ","Computer-Aided Diagnosis Improves Detection of Small Intracranial Aneurysms on MRA in a Clinical Setting","AMERICAN JOURNAL OF NEURORADIOLOGY","Article","2014/35/10/1897-1902",3.6749999999999998,71.85445,"2 z/ze 15",0.1333,"ne","ano","WOS:000342885700010","http://dx.doi.org/10.3174/ajnr.A3996"]
[2,"May, M; Brookman-May, S; Burger, M; Gilfrich, C; Fritsche, HM; Rink, M; Chun, F; Fisch, M; Roghmann, F; Noldus, J; Mayr, R; Pycha, A; Novotny, V; Wirth, M; Vallo, S; Haferkamp, A; Roigas, J; Brisuda, A; Stredele, R; Volkmer, B; Dechet, C; Schnabel, M; Denzinger, S; Stief, CG; Bastian, PJ; Aziz, A","Concomitant Seminal Vesicle Invasion in pT4a Urothelial Carcinoma of the Bladder with Contiguous Prostatic Infiltration is an Adverse Prognosticator for Cancer-Specific Survival after Radical Cystectomy","ANNALS OF SURGICAL ONCOLOGY","Article","2014/21/12/4034-4040",3.9430000000000001,74.810180000000003,"1 z/ze 26",3.85E-2,"ne","ne","WOS:000343085600052","http://link.springer.com/article/10.1245%2Fs10434-014-3827-y"]
[2,"Tesfaye, H; Branova, R; Klapkova, E; Prusa, R; Janeckova, D; Riha, P; Sedlacek, P; Keslova, P; Malis, J","The importance of Therapeutic Drug Monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for Hematopoietic Stem Cell Transplantation (HSCT) in children","ANNALS OF TRANSPLANTATION","Article","2014/19//214-224",1.43,19.384879999999999,"9 z/ze 9",1,"ano","ano","WOS:000342975900001","http://www.ncbi.nlm.nih.gov/pubmed/24811685"]
[2,"Zabrodsky, M; Lukes, P; Lukesova, E; Boucek, J; Plzak, J","The Role of Narrow Band Imaging in the Detection of Recurrent Laryngeal and Hypopharyngeal Cancer after Curative Radiotherapy","BIOMED RESEARCH INTERNATIONAL","Article","2014///-",0,10,"5 z/ze 5",1,"ano","ano","WOS:000338855000001","http://dx.doi.org/10.1155/2014/175398"]
[2,"Lukes, P; Zabrodsky, M; Lukesova, E; Chovanec, M; Astl, J; Betka, JA; Plzak, J","The Role of NBI HDTV Magnifying Endoscopy in the Prehistologic Diagnosis of Laryngeal Papillomatosis and Spinocellular Cancer","BIOMED RESEARCH INTERNATIONAL","Article","2014///-",0,10,"7 z/ze 7",1,"ano","ano","WOS:000338103300001","http://dx.doi.org/10.1155/2014/285486"]
[2,"Lisy, J; Groh, D; Chovanec, M; Markova, M; Suchanek, V; Polaskova, P; Travnicek, M","Balloon Dilatation of Pediatric Subglottic Laryngeal Stenosis during the Artificial Apneic Pause: Experience in 5 Children","BIOMED RESEARCH INTERNATIONAL","Article","2014///-",0,10,"7 z/ze 7",1,"ano","ano","WOS:000337834800001","http://dx.doi.org/10.1155/2014/397295"]
[2,"Betka, J; Zverina, E; Balogova, Z; Profant, O; Skrivan, J; Kraus, J; Lisy, J; Syka, J; Chovanec, A","Complications of Microsurgery of Vestibular Schwannoma","BIOMED RESEARCH INTERNATIONAL","Article","2014///-",0,10,"8 z/ze 9",0.88890000000000002,"ano","ano","WOS:000337404700001","http://dx.doi.org/10.1155/2014/315952"]
[2,"Boucek, J; Zabrodsky, M; Kuchar, M; Fanta, O; Skrivan, J; Betka, J","A New Strategy for the Surgical Management of RLN Infiltrated by Well-Differentiated Thyroid Carcinoma","BIOMED RESEARCH INTERNATIONAL","Article","2014///-",0,10,"5 z/ze 6",0.83330000000000004,"ano","ano","WOS:000336321600001","http://dx.doi.org/10.1155/2014/616521"]
[2,"Kasparova, M; Prochazka, A; Grajciarova, L; Yadollahi, M; Vysata, O; Dostalova, T","Evaluation of dental morphometrics during the orthodontic treatment","BIOMEDICAL ENGINEERING ONLINE","Article","2014/13//-",1.746,28.012149999999998,"2 z/ze 6",0.33329999999999999,"ne","ano","WOS:000337327700001","http://dx.doi.org/10.1186/1475-925X-13-68"]
[2,"Hrabeta, J; Stiborova, M; Adam, V; Kizek, R; Eckschlager, T","Histone deacetylase inhibitors in cancer therapy. A review","BIOMEDICAL PAPERS-OLOMOUC","Review","2014/158/2/161-169",1.661,18.60192,"2 z/ze 5",0.4,"ano","ano","WOS:000338628200001","http://dx.doi.org/10.5507/bp.2013.085"]
[2,"Vavrinkova, B; Binder, T; Hadacova, I; Hrachovinova, I; Salaj, P; Hruda, M","Does asymptomatic carriage of FV Leiden and FII prothrombin mutations in heterozygous configuration pose an increased risk of thrombembolic complications in the course of pregnancy, labor and puerperium?","BIOMEDICAL PAPERS-OLOMOUC","Article","2014/158/2/238-241",1.661,18.60192,"4 z/ze 6",0.66669999999999996,"ano","ano","WOS:000338628200013","http://dx.doi.org/10.5507/bp.2012.070"]
[2,"Votrubova, J; Juzlova, K; Smerhovsky, Z; Fialova, J; Gopfertova, D; Vojackova, N; Hercogova, J","Risk factors for comorbidities in Czech psoriatic patients: Results of a hospital-based case-control study","BIOMEDICAL PAPERS-OLOMOUC","Article","2014/158/2/288-294",1.661,18.60192,"7 z/ze 7",1,"ano","ano","WOS:000338628200020","http://dx.doi.org/10.5507/bp.2013.062"]
[2,"van der Veer, A; Zaliova, M; Mottadelli, F; De Lorenzo, P; te Kronnie, G; Harrison, CJ; Cave, H; Trka, J; Saha, V; Schrappe, M; Pieters, R; Biondi, A; Valsecchi, MG; Stanulla, M; den Boer, ML; Cazzaniga, G","IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL","BLOOD","Article","2014/123/11/1691-1698",9.7750000000000004,240.29470000000001,"2 z/ze 16",0.125,"ne","ne","WOS:000335847700016","http://dx.doi.org/10.1182/blood-2013-06-509794"]
[2,"Aalbers, AM; van den Heuvel-Eibrink, MM; Baumann, I; Beverloo, HB; Driessen, GJ; Dworzak, M; Fischer, A; Gohring, G; Hasle, H; Locatelli, F; De Moerloose, B; Noellke, P; Schmugge, M; Stary, J; Yoshimi, A; Zecca, M; Zwaan, CM; van Dongen, JJM; Pieters, R; Niemeyer, CM; van der Velden, VHJ; Langerak, AW","T-cell receptor V beta skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS","BLOOD CANCER JOURNAL","Article","2014/4//-",2.8839999999999999,29.262720000000002,"1 z/ze 22",4.5499999999999999E-2,"ne","ne","WOS:000337229900003","http://dx.doi.org/10.1038/bcj.2014.28"]
[2,"Weber, ML; Hsin, HY; Kalay, E; Brozkova, DS; Shimizu, T; Bayram, M; Deeley, K; Kuchler, EC; Forella, J; Ruff, TD; Trombetta, VM; Sencak, RC; Hummel, M; Briseno-Ruiz, J; Revu, SK; Granjeiro, JM; Antunes, LS; Antunes, LA; Abreu, FV; Costa, MC; Tannure, PN; Koruyucu, M; Patir, A; Poletta, FA; Mereb, JC; Castilla, EE; Orioli, LM; Marazita, ML; Ouyang, H; Jayaraman, T; Seymen, F; Vieira, AR","Role of estrogen related receptor beta (ESRRB) in DFN35B hearing impairment and dental decay","BMC MEDICAL GENETICS","Article","2014/15//-",2.4500000000000002,21.94577,"1 z/ze 32",3.1300000000000001E-2,"ne","ne","WOS:000339517900001","http://dx.doi.org/10.1186/1471-2350-15-81"]
[2,"Stehlikova, K; Skalova, D; Zidkova, J; Mrazova, L; Vondracek, P; Mazanec, R; Vohanka, S; Haberlova, J; Hermanova, M; Zamecnik, J; Soucek, O; Oslejskova, H; Dvorackova, N; Solarova, P; Fajkusova, L","Autosomal recessive limb-girdle muscular dystrophies in the Czech Republic","BMC NEUROLOGY","Article","2014/14//-",2.4860000000000002,30.069299999999998,"4 z/ze 15",0.26669999999999999,"ne","ne","WOS:000341666400001","http://dx.doi.org/10.1186/s12883-014-0154-7"]
[2,"Vlcek, M; Jaganjac, E; Pech, J; Jonas, D; Kebrle, R","Is minimally invasive application by intramedullary osteosynthesis in comparison with volar plating real benefit in the treatment of distal radius fractures?","BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES","Article","2014/14/2/81-88",0.41299999999999998,11.250590000000001,"4 z/ze 5",0.8,"ano","ano","WOS:000337769800005","http://www.ncbi.nlm.nih.gov/pubmed/24856379"]
[2,"Hytych, V; Pohnan, R; Taskova, A; Horazdovsky, P; Konopa, Z; Demes, R; Cermak, J; Vrabcova, A; Hoferka, P","Importance of histological verification of mediastinal lymphadenopathy in exact staging of non-small cell bronchogenic carcinoma","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY","Article","2014/115/9/585-587",0.44600000000000001,13.924149999999999,"1 z/ze 9",0.1111,"ne","ne","WOS:000343078300012","http://dx.doi.org/10.4149/BLL_2014_113"]
[2,"Skrivan, J; Cada, Z; Kluh, J; Boucek, J; Profant, O; Betka, J","Revision operations after previous stapes surgery for persisting hearing loss","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY","Article","2014/115/7/442-444",0.44600000000000001,13.924149999999999,"6 z/ze 6",1,"ano","ano","WOS:000340863400011","http://dx.doi.org/10.4149/BLL_2014_087"]
[2,"Veselka, J; Krejci, J; Tomasov, P; Jahnlova, D; Honek, T; Januska, J; Branny, M; Zemanek, D","Survival of Patients <= 50 Years of Age After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy","CANADIAN JOURNAL OF CARDIOLOGY","Article","2014/30/6/634-638",3.94,52.640819999999998,"4 z/ze 8",0.5,"ano","ano","WOS:000339250300008","http://dx.doi.org/10.1016/j.cjca.2014.03.041"]
[2,"Brenner, DR; Wozniak, MB; Feyt, C; Holcatova, I; Janout, V; Foretova, L; Fabianova, E; Shonova, O; Martinek, A; Ryska, M; Adamcakova, Z; Flaska, E; Moskal, A; Brennan, P; Scelo, G","Physical activity and risk of pancreatic cancer in a central European multicenter case-control study","CANCER CAUSES & CONTROL","Article","2014/25/6/669-681",2.9609999999999999,46.418999999999997,"1 z/ze 15",6.6699999999999995E-2,"ne","ne","WOS:000336023600003","http://dx.doi.org/10.1007/s10552-014-0370-x"]
[2,"Veselka, J; Lawrenz, T; Stellbrink, C; Zemanek, D; Branny, M; Januska, J; Sitar, J; Dimitrow, P; Krejci, J; Dabrowski, M; Mizera, S; Bartel, T; Kuhn, H","Early Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A European Multicenter and Multinational Study","CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS","Article","2014/84/1/101-107",2.3959999999999999,27.584520000000001,"2 z/ze 13",0.15379999999999999,"ano","ano","WOS:000337970100021","http://dx.doi.org/10.1002/ccd.25236"]
[2,"Spacek, M; Veselka, J","Microembolization Following Balloon Deflation During Proximally Protected Carotid Artery Stenting-A Potential Focus of Procedure Improvement?","CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS","Letter","2014/83/7/1185-1186",2.3959999999999999,27.584520000000001,"2 z/ze 2",1,"ano","ano","WOS:000335953900040","http://dx.doi.org/10.1002/ccd.24969"]
[2,"Rampichova, M; Buzgo, M; Chvojka, J; Prosecka, E; Kofronova, O; Amler, E","Cell penetration to nanofibrous scaffolds","CELL ADHESION & MIGRATION","Article","2014/8/1/36-41",3.395,27.078499999999998,"1 z/ze 6",0.16669999999999999,"ne","ne","WOS:000332460300006","http://dx.doi.org/10.4161/cam.27477"]
[2,"Brunnerova, R; Lebl, J","The occurrence of ocular diseases in patients with Turner syndrome","CENTRAL EUROPEAN JOURNAL OF MEDICINE","Article","2014/9/5/680-686",0.20899999999999999,11.44923,"1 z/ze 2",0.5,"ne","ne","WOS:000339938100013","http://dx.doi.org/10.2478/s11536-013-0323-x"]
[2,"Musova, Z; Kaiserova, M; Kriegova, E; Fillerova, R; Vasovcak, P; Santava, A; Mensikova, K; Zumrova, A; Krepelova, A; Sedlacek, Z; Kanovsky, P","A Novel Frameshift Mutation in the AFG3L2 Gene in a Patient with Spinocerebellar Ataxia","CEREBELLUM","Article","2014/13/3/331-337",2.8639999999999999,24.099209999999999,"5 z/ze 11",0.45450000000000002,"ano","ano","WOS:000335739600004","http://dx.doi.org/10.1007/s12311-013-0538-z"]
[2,"Urbanova, M; Vyhnalek, M; Nikolai, T; Michalec, J; Sheardova, K; Laczo, J; Hudecek, D; Hort, J","Validity of Enhanced Cued Recall Test in the Diagnosis of Alzheimer Dementia and Behavioral Variant of Frontotemporal Dementia","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE","Article","2014/77/5/576-581",0.159,10.296110000000001,"4 z/ze 8",0.5,"ano","ne","WOS:000343022100005","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/validita-testu-16-slov-pro-diferencialni-dia-gnostiku-demence-alzheimerova-typu-a-behavioralni-formy-fron-49674"]
[2,"Liba, Z; Hanzalova, J; Sebronova, V; Komarek, V","Anti-N-Methyl-D-Aspartate Receptor Encephalitis","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE","Article","2014/77/5/624-630",0.159,10.296110000000001,"4 z/ze 4",1,"ano","ano","WOS:000343022100014","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/anti-n-metyl-d-aspartat-receptorova-encefalitida-49685"]
[2,"Libertinova, J; Meluzinova, E; Matoska, V; Zajac, M; Hyncicova, E; Tomek, A; Bojar, M","Neutralising Antibodies and Myxovirus Resistance Protein A as a Marker of Biological Response to Interferon beta","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE","Article","2014/77/5/638-641",0.159,10.296110000000001,"7 z/ze 7",1,"ano","ano","WOS:000343022100016","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/neutralizacni-protilatky-a-myxovirus-resistance-protein-a-pri-sledovani-bio-logicke-ucinnosti-interferonu--49688"]
[2,"Kuzelova, H; Macek, M; Raboch, J; Ptacek, R","Genetic Variability in Attention Deficit Hyperactivity Disorder","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE","Review","2014/77/4/423-427",0.159,10.296110000000001,"2 z/ze 4",0.5,"ano","ano","WOS:000339709800003","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/geneticka-variabilita-u-poruchy-pozornosti-s-hyperaktivitou-adhd-49297"]
[2,"Cerman, J; Laczo, J; Vyhnalek, M; Vlcek, K; Lerch, O; Sheardova, K; Hort, J","Differences in Spatial Navigation Impairment in Neurodegenerative Dementias","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE","Article","2014/77/4/449-455",0.159,10.296110000000001,"5 z/ze 7",0.71430000000000005,"ano","ano","WOS:000339709800007","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/rozdily-v-postizeni-prostorove-orientace-u-demenci-neurodegenerativni-etiologie-49301"]
[2,"Brozkova, DS; Mazanec, R; Bohm, J; Vysata, O; Auer-Grumbach, M; Windpassinger, C; Neupauerova, J; Barankova, L; Nevsimalova, S; Seeman, P","Hereditary Ulceromutilating Sensory Neuropathy - Clinical, Electrophysiological and Molecular Genetic Study of Three Families","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE","Article","2014/77/4/479-486",0.159,10.296110000000001,"5 z/ze 10",0.5,"ano","ano","WOS:000339709800011","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/dedicne-ulceromutilujici-senzitivni-neuropatie-klinicka-elektrofyziologicka-a-molekularne-geneticka-studie-tri-rodin-49307"]
[2,"Javurkova, A; Amlerova, J; Raudenska, J","Long-term Observation of Cognitive, Emotional and Behavioral Changes in Patient with Multiple Sclerosis - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE","Article","2014/77/4/501-504",0.159,10.296110000000001,"2 z/ze 3",0.66669999999999996,"ano","ne","WOS:000339709800015","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/dlouhodobe-sledovani-kognitivnich-emocnich-a-behavioralnich-zmen-u-pacientky-s-roztrousenou-sklerozou-kazuistika-49312"]
[2,"Stepankova, H; Smolik, F; Vyhnalek, M; Nikolai, T; Horakova, K; Niederlova, M","Propositional density in seniors' responses","CESKOSLOVENSKA PSYCHOLOGIE","Article","2014/58/4/317-325",0.29199999999999998,12.58039,"2 z/ze 6",0.33329999999999999,"ne","ne","WOS:000341461800001","http://cspsych.psu.cas.cz/result.php?from=853&to=853"]
[2,"Kubus, P; Vit, P; Gebauer, RA; Materna, O; Janousek, J","Electrophysiologic Profile and Results of Invasive Risk Stratification in Asymptomatic Children and Adolescents With the Wolff-Parkinson-White Electrocardiographic Pattern","CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY","Article","2014/7/2/218-223",5.4169999999999998,84.755070000000003,"3 z/ze 5",0.6,"ano","ano","WOS:000335209700008","http://dx.doi.org/10.1161/CIRCEP.113.000930"]
[2,"Kelbich, P; Hejcl, A; Krulichova, IS; Prochazka, J; Hanuljakova, E; Peruthova, J; Koudelkova, M; Sames, M; Krejsek, J","Coefficient of energy balance, a new parameter for basic investigation of the cerebrospinal fluid","CLINICAL CHEMISTRY AND LABORATORY MEDICINE","Article","2014/52/7/1009-1017",2.9550000000000001,86.565669999999997,"1 z/ze 9",0.1111,"ne","ne","WOS:000338852700019","http://dx.doi.org/10.1515/cclm-2013-0953"]
[2,"Kayserova, J; Vcelakova, J; Stechova, K; Dudkova, E; Hromadkova, H; Sumnik, Z; Kolouskova, S; Spisek, R; Sediva, A","Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients","CLINICAL IMMUNOLOGY","Article","2014/153/1/49-55",3.992,47.088500000000003,"9 z/ze 9",1,"ano","ano","WOS:000337935900007","http://dx.doi.org/10.1016/j.clim.2014.03.018"]
[2,"Riedlbauchova, L; Nedelka, T; Schlenker, J","Symptomatic arrhythmias due to syringomyelia-induced severe autonomic dysfunction","CLINICAL RESEARCH IN CARDIOLOGY","Letter","2014/103/10/839-845",4.1669999999999998,61.911099999999998,"2 z/ze 3",0.66669999999999996,"ano","ano","WOS:000341909800011","http://dx.doi.org/10.1007/s00392-014-0725-z"]
[2,"Lotti, T; D'Erme, AM; Hercogova, J","The role of neuropeptides in the control of regional immunity","CLINICS IN DERMATOLOGY","Article","2014/32/5/633-645",1.93,36.854419999999998,"1 z/ze 3",0.33329999999999999,"ne","ne","WOS:000341403800012","http://dx.doi.org/10.1016/j.clindermato1.2014.04.011"]
[2,"Bockenhauer, D; Zieg, J","Electrolyte Disorders","CLINICS IN PERINATOLOGY","Article","2014/41/3/575-+",2.13,41.05359,"1 z/ze 2",0.5,"ne","ne","WOS:000342181400009","http://dx.doi.org/10.1016/j.clp.2014.05.007"]
[2,"Zukic, D; Vlasak, A; Egger, J; Horinek, D; Nimsky, C; Kolb, A","Robust Detection and Segmentation for Diagnosis of Vertebral Diseases Using Routine MR Images","COMPUTER GRAPHICS FORUM","Article","2014/33/6/190-204",1.595,64.476240000000004,"1 z/ze 6",0.16669999999999999,"ano","ne","WOS:000342802200014","http://dx.doi.org/10.1111/cgf.12343"]
[2,"Navratil, L; Navratil, V; Hajkova, S; Hlinakova, P; Dostalova, T; Vranova, J","Comprehensive treatment of temporomandibular joint disorders","CRANIO-THE JOURNAL OF CRANIOMANDIBULAR PRACTICE","Article","2014/32/1/24-30",0.72299999999999998,12.96706,"2 z/ze 6",0.33329999999999999,"ne","ne","WOS:000337046600004","http://dx.doi.org/10.1179/0886963413Z.0000000002"]
[2,"Klozar, J; Tachezy, R","What are the implications of human papillomavirus status in oropharyngeal tumors for clinical practice?","CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY","Review","2014/22/2/90-94",1.3919999999999999,28.813110000000002,"1 z/ze 2",0.5,"ano","ano","WOS:000333287400002","http://dx.doi.org/10.1097/MOO.0000000000000030"]
[2,"Labikova, J; Vcelakova, J; Ulmannova, T; Petruzelkova, L; Kolouskova, S; Stechova, K","The cytokine production of peripheral blood mononuclear cells reflects the autoantibody profile of patients suffering from type 1 diabetes","CYTOKINE","Article","2014/69/2/189-195",2.8740000000000001,24.653510000000001,"6 z/ze 6",1,"ano","ano","WOS:000341478100004","http://dx.doi.org/10.1016/j.cyto.2014.06.013"]
[2,"Hrusak, O; Basso, G; Ratei, R; Gaipa, G; Luria, D; Mejstrikova, E; Karawajew, L; Buldini, B; Rozenthal, E; Bourquin, JP; Kalina, T; Sartor, M; Dworzak, MN","Flow Diagnostics Essential Code: A Simple and Brief Format for the Summary of Leukemia Phenotyping","CYTOMETRY PART B-CLINICAL CYTOMETRY","Article","2014/86/4/288-291",2.2829999999999999,38.71904,"3 z/ze 13",0.23080000000000001,"ano","ano","WOS:000340544300009","http://dx.doi.org/10.1002/cyto.b.21144"]
[2,"Tichy, M; Hercogova, J","Manifestation of Crohn's disease in a young woman during the course of treatment for severe form of chronic plaque psoriasis with etanercept","DERMATOLOGIC THERAPY","Article","2014/27/4/211-214",1.478,23.292490000000001,"1 z/ze 2",0.5,"ne","ne","WOS:000340279600005","http://dx.doi.org/10.1111/dth.12119"]
[2,"Juzlova, K; Votrubova, J; Kacerovska, D; Lukas, M; Bortlik, M; Rohacova, H; Nohynkova, E; Vojackova, N; Fialova, J; Hercogova, J","Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences","DERMATOLOGIC THERAPY","Article","2014/27/3/131-134",1.478,23.292490000000001,"6 z/ze 10",0.6,"ano","ano","WOS:000337524100002","http://dx.doi.org/10.1111/dth.12083"]
[2,"Secnikova, Z; Juzlova, K; Vojackova, N; Kazakov, DV; Hoskova, L; Fialova, J; Dzambova, M; Hercogova, J","The rare case of Alternaria alternata cutaneous and pulmonary infection in a heart transplant recipient treated by azole antifungals","DERMATOLOGIC THERAPY","Article","2014/27/3/140-143",1.478,23.292490000000001,"6 z/ze 8",0.75,"ano","ano","WOS:000337524100004","http://dx.doi.org/10.1111/dth.12096"]
[2,"Konkolova, R; Provaznikova, DH; Jirakova, A; Hercogova, J","Can melanoma therapy change attitudes toward prevention and tanning?","DERMATOLOGIC THERAPY","Article","2014/27/3/156-158",1.478,23.292490000000001,"3 z/ze 4",0.75,"ano","ano","WOS:000337524100008","http://dx.doi.org/10.1111/dth.12100"]
[2,"Tichy, M; Urbanek, J; Sternbersky, J; Ditrichova, D; Hercogova, J","Life-threatening course of pemphigus vulgaris complicated by sepsis caused by azathioprine-induced bone marrow suppression, successfully managed with combination therapy","DERMATOLOGIC THERAPY","Article","2014/27/3/183-186",1.478,23.292490000000001,"1 z/ze 5",0.2,"ne","ne","WOS:000337524100015","http://dx.doi.org/10.1111/dth.12114"]
[2,"Dusatkova, P; Fang, MY; Pruhova, S; Gjesing, AP; Cinek, O; Hansen, T; Pedersen, OB; Xu, X; Lebl, J","Lessons from whole-exome sequencing in MODYX families","DIABETES RESEARCH AND CLINICAL PRACTICE","Article","2014/104/3/E72-E74",2.536,23.12754,"4 z/ze 9",0.44440000000000002,"ano","ano","WOS:000338715200006","http://dx.doi.org/10.1016/j.diabres.2014.03.008"]
[2,"Czupryniak, L; Barkai, L; Bolgarska, S; Bronisz, A; Broz, J; Cypryk, K; Honka, M; Janez, A; Krnic, M; Lalic, N; Martinka, E; Rahelic, D; Roman, G; Tankova, T; Varkonyi, T; Wolnik, B; Zherdova, N","Self-Monitoring of Blood Glucose in Diabetes: From Evidence to Clinical Reality in Central and Eastern Europe-Recommendations from the International Central-Eastern European Expert Group","DIABETES TECHNOLOGY & THERAPEUTICS","Review","2014/16/7/460-475",2.2930000000000001,20.507930000000002,"2 z/ze 17",0.1176,"ne","ne","WOS:000338186100009","http://dx.doi.org/10.1089/dia.2013.0302"]
[2,"Cinek, O; Stene, LC; Kramna, L; Tapia, G; Oikarinen, S; Witso, E; Rasmussen, T; Torjesen, PA; Hyoty, H; Ronningen, KS","Enterovirus RNA in longitudinal blood samples and risk of islet autoimmunity in children with a high genetic risk of type 1 diabetes: the MIDIA study","DIABETOLOGIA","Article","2014/57/10/2193-2200",6.88,121.69799999999999,"2 z/ze 10",0.2,"ano","ano","WOS:000341708900022","http://dx.doi.org/10.1007/s00125-014-3327-4"]
[2,"Poetsch, AR; Lipka, DB; Witte, T; Claus, R; Nollke, P; Zucknick, M; Olk-Batz, C; Fluhr, S; Dworzak, M; De Moerloose, B; Stary, J; Zecca, M; Hasle, H; Schmugge, M; van den Heuvel-Eibrink, MM; Locatelli, F; Niemeyer, CM; Flotho, C; Plass, C","RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia","EPIGENETICS","Article","2014/9/9/1252-1260",5.1079999999999997,72.93141,"1 z/ze 19",5.2600000000000001E-2,"ne","ne","WOS:000342564500007","http://dx.doi.org/10.4161/epi.29941"]
[2,"Harris, RA; Nagy-Szakal, D; Mir, SAV; Frank, E; Szigeti, R; Kaplan, JL; Bronsky, J; Opekun, A; Ferry, GD; Winter, H; Kellermayer, R","DNA methylation-associated colonic mucosal immune and defense responses in treatment-naive pediatric ulcerative colitis","EPIGENETICS","Article","2014/9/8/1131-1137",5.1079999999999997,72.93141,"1 z/ze 11",9.0899999999999995E-2,"ne","ne","WOS:000341360600008","http://dx.doi.org/10.4161/epi.29446"]
[2,"Amlerova, J; Cavanna, AE; Bradac, O; Javurkova, A; Raudenska, J; Marusic, P","Emotion recognition and social cognition in temporal lobe epilepsy and the effect of epilepsy surgery","EPILEPSY & BEHAVIOR","Article","2014/36//86-89",2.0609999999999999,21.82687,"4 z/ze 6",0.66669999999999996,"ano","ano","WOS:000339136500018","http://dx.doi.org/10.1016/j.yebeh.2014.05.001"]
[2,"Vydrova, R; Krsek, P; Kyncl, M; Jahodova, A; Dvorak, J; Komarek, V; Delalande, O; Tichy, M","Peri-ictal headache due to epileptiform activity in a disconnected hemisphere","EPILEPTIC DISORDERS","Article","2014/16/2/213-217",0.89900000000000002,12.78647,"7 z/ze 8",0.875,"ano","ano","WOS:000337629400009","http://dx.doi.org/10.1684/epd.2014.0653"]
[2,"Kovac, M; Vaskova, M; Petrackova, D; Pelkova, V; Mejstrikova, E; Kalina, T; Zaliova, M; Weiser, J; Stary, J; Hrusak, O","Cytokines, growth, and environment factors in bone marrow plasma of acute lymphoblastic leukemia pediatric patients","EUROPEAN CYTOKINE NETWORK","Article","2014/25/1/8-13",1.8,13.891780000000001,"8 z/ze 10",0.8,"ano","ano","WOS:000341329400002","http://dx.doi.org/10.1684/ecn.2014.0348"]
[2,"Veselka, J; Krejci, J; Tomasov, P; Zemanek, D","Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population","EUROPEAN HEART JOURNAL","Article","2014/35/30/2040-+",14.723000000000001,236.22739999999999,"3 z/ze 4",0.75,"ano","ano","WOS:000342232400013","http://dx.doi.org/10.1093/eurheartj/eht495"]
[2,"Halvorsen, S; Atar, D; Yang, HQ; De Caterina, R; Erol, C; Garcia, D; Granger, CB; Hanna, M; Held, C; Husted, S; Hylek, EM; Jansky, P; Lopes, RD; Ruzyllo, W; Thomas, L; Wallentin, L","Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","EUROPEAN HEART JOURNAL","Article","2014/35/28/1864-1872",14.723000000000001,236.22739999999999,"1 z/ze 16",6.25E-2,"ne","ne","WOS:000340068200011","http://dx.doi.org/10.1093/eurheartj/ehu046"]
[2,"Krizova, E; Byma, S","The integration of homoeopathy into Czech Health Care - A 10-year follow-up","EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE","Article","2014/6/3/277-285",0.64900000000000002,13.696210000000001,"1 z/ze 2",0.5,"ano","ano","WOS:000341296300005","http://dx.doi.org/10.1016/j.eujim.2013.12.023"]
[2,"Hasenclever, D; Kurch, L; Mauz-Korholz, C; Elsner, A; Georgi, T; Wallace, H; Landman-Parker, J; Moryl-Bujakowska, A; Cepelova, M; Karlen, J; Fernandez-Teijeiro, AA; Attarbaschi, A; Fossa, A; Pears, J; Hraskova, A; Bergstrasser, E; Beishuizen, A; Uyttebroeck, A; Schomerus, E; Sabri, O; Korholz, D; Kluge, R","qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma","EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING","Article","2014/41/7/1301-1308",5.2169999999999996,159.93600000000001,"1 z/ze 22",4.5499999999999999E-2,"ne","ne","WOS:000337286200005","http://dx.doi.org/10.1007/s00259-014-2715-9"]
[2,"Patockova, J; Sliva, J; Marhol, P; Crkovska, J; Stipek, S","The influence of vitamin-rich diet on the extent of lipoperoxidation in brain of mice during an acute post-insulin hypoglycaemia","EUROPEAN JOURNAL OF PHARMACOLOGY","Article","2014/740//641-644",2.6840000000000002,33.820059999999998,"1 z/ze 5",0.2,"ano","ne","WOS:000341163700078","http://dx.doi.org/10.1016/j.ejphar.2014.06.015"]
[2,"Bruthans, J; Cifkova, R; Lanska, V; O'Flaherty, M; Critchley, JA; Holub, J; Jansky, P; Zvarova, J; Capewell, S","Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007","EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY","Article","2014/21/7/829-839",2.6749999999999998,31.803989999999999,"1 z/ze 9",0.1111,"ne","ne","WOS:000337571700005","http://dx.doi.org/10.1177/2047487312469476"]
[2,"Midulla, F; Lombardi, E; Rottier, B; Lindblad, A; Grigg, J; Bohlin, K; Rusconi, F; Pohunek, P; Eber, E","Paediatrics in Barcelona","EUROPEAN RESPIRATORY JOURNAL","Article","2014/44/2/457-474",7.125,149.63630000000001,"1 z/ze 9",0.1111,"ne","ne","WOS:000340017300023","http://dx.doi.org/10.1183/09031936.00046414"]
[2,"Bobek, V; Matkowski, R; Gurlich, R; Grabowski, K; Szelachowska, J; Lischke, R; Schutzner, J; Harustiak, T; Pazdro, A; Rzechonek, A; Kolostova, K","Cultivation of circulating tumor cells in esophageal cancer","FOLIA HISTOCHEMICA ET CYTOBIOLOGICA","Article","2014/52/3/171-177",1,11.607340000000001,"5 z/ze 11",0.45450000000000002,"ano","ano","WOS:000343055500002","http://dx.doi.org/10.5603/FHC.2014.0020"]
[2,"Creutzig, U; Zimmermann, M; Dworzak, MN; Gibson, B; Tamminga, R; Abrahamsson, J; Ha, SY; Hasle, H; Maschan, A; Bertrand, Y; Leverger, G; von Neuhoff, C; Razzouk, B; Rizzari, C; Smisek, P; Smith, OP; Stark, B; Reinhardt, D; Kaspers, GL","The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01","HAEMATOLOGICA","Article","2014/99/9/1472-1478",5.8680000000000003,145.48339999999999,"1 z/ze 19",5.2600000000000001E-2,"ne","ne","WOS:000342834900020","http://dx.doi.org/10.3324/haematol.2014.104182"]
[2,"Pospisilova, D; Holub, D; Zidova, Z; Sulovska, L; Houda, J; Mihal, V; Hadacova, I; Radova, L; Dzubak, P; Hajduch, M; Divoky, V; Horvathova, M","Hepcidin levels in Diamond-Blackfan anemia reflect erythropoietic activity and transfusion dependency","HAEMATOLOGICA","Letter","2014/99/7/-",5.8680000000000003,145.48339999999999,"1 z/ze 12",8.3299999999999999E-2,"ne","ne","WOS:000342833500008","http://dx.doi.org/10.3324/haematol.2014.104034"]
[2,"Angelucci, E; Matthes-Martin, S; Baronciani, D; Bernaudin, F; Bonanomi, S; Cappellini, MD; Dalle, JH; Di Bartolomeo, P; de Heredia, CD; Dickerhoff, R; Giardini, C; Gluckman, E; Hussein, AA; Kamani, N; Minkov, M; Locatelli, F; Rocha, V; Sedlacek, P; Smiers, F; Thuret, I; Yaniv, I; Cavazzana, M; Peters, C","Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","HAEMATOLOGICA","Article","2014/99/5/811-820",5.8680000000000003,145.48339999999999,"1 z/ze 23",4.3499999999999997E-2,"ne","ne","WOS:000336257500008","http://dx.doi.org/10.3324/haematol.2013.099747"]
[2,"Yoshimi, A; van den Heuvel-Eibrink, MM; Baumann, I; Schwarz, S; Simonitsch-Klupp, I; de Paepe, P; Campr, V; Kerndrup, GB; O'Sullivan, M; Devito, R; Leguit, R; Hernandez, M; Dworzak, M; de Moerloose, B; Stary, J; Hasle, H; Smith, OP; Zecca, M; Catala, A; Schmugge, M; Locatelli, F; Fuhrer, M; Fischer, A; Guderle, A; Nollke, P; Strahm, B; Niemeyer, CM","Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood","HAEMATOLOGICA","Article","2014/99/4/656-663",5.8680000000000003,145.48339999999999,"2 z/ze 27",7.4099999999999999E-2,"ne","ne","WOS:000336256100016","http://dx.doi.org/10.3324/haematol.2013.095786"]
[2,"Teyssler, P; Kolostova, K; Bobek, V","Assessment of pain threshold in haemophilic patients","HAEMOPHILIA","Article","2014/20/2/207-211",2.468,26.430530000000001,"1 z/ze 3",0.33329999999999999,"ne","ano","WOS:000331459600027","http://www.ncbi.nlm.nih.gov/pubmed/24533950"]
[2,"Bahannan, AA; Slavicek, A; Cerny, L; Vokral, J; Valenta, Z; Lohynska, R; Chovanec, M; Betka, J","Effectiveness of transoral laser microsurgery for precancerous lesions and early glottic cancer guided by analysis of voice quality","HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK","Article","2014/36/6/763-767",3.0059999999999998,134.28280000000001,"5 z/ze 8",0.625,"ne","ano","WOS:000336493200003","http://dx.doi.org/10.1002/hed.23368"]
[2,"Kang, KT; Potts, JE; Radbill, AE; La Page, MJ; Papagiannis, J; Garnreiter, JM; Kubus, P; Kantoch, MJ; Von Bergen, NH; Fournier, A; Cote, JM; Paul, T; Anderson, CC; Cannon, BC; Miyake, CY; Blaufox, AD; Etheridge, SP; Sanatani, S","Permanent junctional reciprocating tachycardia in children: A multicenter experience","HEART RHYTHM","Article","2014/11/8/1426-1432",4.9180000000000001,69.004059999999996,"1 z/ze 18",5.5599999999999997E-2,"ne","ne","WOS:000341437200017","http://dx.doi.org/10.1016/j.hrthm.2014.04.033"]
[2,"Taube, JR; Sperle, K; Banser, L; Seeman, P; Cavan, BCV; Garbern, JY; Hobson, GM","PMD patient mutations reveal a long-distance intronic interaction that regulates PLP1/DM20 alternative splicing","HUMAN MOLECULAR GENETICS","Article","2014/23/20/5464-5478",6.6769999999999996,106.98609999999999,"1 z/ze 7",0.1429,"ne","ne","WOS:000343202400014","http://dx.doi.org/10.1093/hmg/ddu271"]
[2,"Ballantyne, KN; Ralf, A; Aboukhalid, R; Achakzai, NM; Anjos, MJ; Ayub, Q; Balazic, J; Ballantyne, J; Ballard, DJ; Berger, B; Bobillo, C; Bouabdellah, M; Burri, H; Capal, T; Caratti, S; Cardenas, J; Cartault, F; Carvalho, EF; Carvalho, M; Cheng, BW; Coble, MD; Comas, D; Corach, D; D'Amato, ME; Davison, S; de Knijff, P; De Ungria, MCA; Decorte, R; Dobosz, T; Dupuy, BM; Elmrghni, S; Gliwinski, M; Gomes, SC; Grol, L; Haas, C; Hanson, E; Henke, J; Henke, L; Herrera-Rodriguez, F; Hill, CR; Holmlund, G; Honda, K; Immel, UD; Inokuchi, S; Jobling, MA; Kaddura, M; Kim, JS; Kim, SH; Kim, W; King, TE; Klausriegler, E; Kling, D; Kovacevic, L; Kovatsi, L; Krajewski, P; Kravchenko, S; Larmuseau, MHD; Lee, EY; Lessig, R; Livshits, LA; Marjanovic, D; Minarik, M; Mizuno, N; Moreira, H; Morling, N; Mukherjee, M; Munier, P; Nagaraju, J; Neuhuber, F; Nie, SJ; Nilasitsataporn, P; Nishi, T; Oh, HH; Olofsson, J; Onofri, V; Palo, JU; Pamjav, H; Parson, W; Petlach, M; Phillips, C; Ploski, R; Prasad, SPR; Primorac, D; Purnomo, GA; Purps, J; Rangel-Villalobos, H; Rebala, K; Rerkamnuaychoke, B; Gonzalez, DR; Robino, C; Roewer, L; Rosa, A; Sajantila, A; Sala, A; Salvador, JM; Sanz, P; Schmitt, C; Sharma, AK; Silva, DA; Shin, KJ; Sijen, T; Sirker, M; Sivakova, D; Skaro, V; Solano-Matamoros, C; Souto, L; Stenzl, V; Sudoyo, H; Syndercombe-Court, D; Tagliabracci, A; Taylor, D; Tillmar, A; Tsybovsky, IS; Tyler-Smith, C; van der Gaag, KJ; Vanek, D; Volgyi, A; Ward, D; Willemse, P; Yap, EPH; Yong, RYY; Pajnic, IZ; Kayser, M","Toward Male Individualization with Rapidly Mutating Y-Chromosomal Short Tandem Repeats","HUMAN MUTATION","Article","2014/35/8/1021-1032",5.1219999999999999,80.591939999999994,"1 z/ze 123",8.0999999999999996E-3,"ne","ne","WOS:000339431600016","http://dx.doi.org/10.1002/humu.22599"]
[2,"Harper, J; Geraedts, J; Borry, P; Cornel, MC; Dondorp, WJ; Gianaroli, L; Harton, G; Milachich, T; Kaariainen, H; Liebaers, I; Morris, M; Sequeiros, J; Sermon, K; Shenfield, F; Skirton, H; Soini, S; Spits, C; Veiga, A; Vermeesch, JR; Viville, S; de Wert, G; Macek, M","Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy","HUMAN REPRODUCTION","Article","2014/29/8/1603-U24",4.585,213.33090000000001,"1 z/ze 22",4.5499999999999999E-2,"ne","ne","WOS:000340071000002","http://dx.doi.org/10.1093/humrep/deu130"]
[2,"Truxova, I; Pokorna, K; Kloudova, K; Partlova, S; Spisek, R; Fucikova, J","Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs","IMMUNOLOGY LETTERS","Article","2014/160/1/39-49",2.367,18.562719999999999,"4 z/ze 6",0.66669999999999996,"ano","ano","WOS:000337208200006","http://dx.doi.org/10.1016/j.imlet.2014.03.010"]
[2,"Lenicek, M; Duricova, D; Hradsky, O; Dusatkova, P; Jiraskova, A; Lukas, M; Nachtigal, P; Vitek, L","The Relationship Between Serum Bilirubin and Crohn's Disease","INFLAMMATORY BOWEL DISEASES","Article","2014/20/3/481-487",5.4749999999999996,100.83240000000001,"2 z/ze 8",0.25,"ne","ne","WOS:000335650700007","http://dx.doi.org/10.1097/01.MIB.0000440817.84251.98"]
[2,"Bortlik, M; Duricova, D; Machkova, N; Kozeluhova, J; Kohout, P; Hrdlicka, L; Durilova, M; Mitrova, K; Hradsky, O; Bronsky, J; Malickova, K; Lukas, M","Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children","INFLAMMATORY BOWEL DISEASES","Article","2014/20/3/495-501",5.4749999999999996,100.83240000000001,"4 z/ze 12",0.33329999999999999,"ne","ne","WOS:000335650700009","http://dx.doi.org/10.1097/01.MIB.0000440984.86659.4f"]
[2,"de Ridder, L; Turner, D; Wilson, DC; Koletzko, S; Martin-de-Carpi, J; Fagerberg, UL; Spray, C; Sladek, M; Shaoul, R; Roma-Giannikou, E; Bronsky, J; Serban, DE; Cucchiara, S; Veres, G; Ruemmele, FM; Hojsak, I; Kolho, KL; Davies, IH; Aloi, M; Lionetti, P; Veereman-Wauters, G; Braegger, CP; Trindade, E; Wewer, AV; Hauer, A; Levine, A","Malignancy and Mortality in Pediatric Patients with Inflammatory Bowel Disease: A Multinational Study from the Porto Pediatric IBD Group","INFLAMMATORY BOWEL DISEASES","Article","2014/20/2/291-300",5.4749999999999996,100.83240000000001,"1 z/ze 26",3.85E-2,"ne","ne","WOS:000335790000016","http://dx.doi.org/10.1097/01.MIB.0000439066.69340.3c"]
[2,"Tlaskal, T; Gebauer, R; Gilik, J; Tomek, V","Experience with the surgical treatment of atrioventricular septal defect with left ventricular outflow tract obstruction","INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY","Article; Proceedings Paper","2014/18/6/789-795",1.109,14.568049999999999,"4 z/ze 4",1,"ano","ano","WOS:000336505800021","http://dx.doi.org/10.1093/icvts/ivu026"]
[2,"Fucikova, J; Moserova, I; Truxova, I; Hermanova, I; Vancurova, I; Partlova, S; Fialova, A; Sojka, L; Cartron, PF; Houska, M; Rob, L; Bartunkova, J; Spisek, R","High hydrostatic pressure induces immunogenic cell death in human tumor cells","INTERNATIONAL JOURNAL OF CANCER","Article","2014/135/5/1165-1177",5.0069999999999997,73.839129999999997,"7 z/ze 13",0.53849999999999998,"ano","ano","WOS:000337608300017","http://dx.doi.org/10.1002/ijc.28766"]
[2,"Kensova, R; Hynek, D; Kynicky, J; Konecna, M; Eckschlager, T; Adam, V; Hubalek, J; Kizek, R","Determination of Metal Ions in the Plasma of Children with Tumour Diseases by Differential Pulse Voltammetry","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE","Article","2014/9/8/4675-4691",1.956,21.222239999999999,"1 z/ze 8",0.125,"ne","ne","WOS:000338320000049","http://www.electrochemsci.org/papers/vol9/90804675.pdf"]
[2,"Nechvatal, L; Petrosova, H; Grillova, L; Pospisilova, P; Mikalova, L; Strnadel, R; Kuklova, I; Kojanova, M; Kreidlova, M; Vanousova, D; Prochazka, P; Zakoucka, H; Krchnakova, A; Smajs, D","Syphilis-causing strains belong to separate SS14-like or Nichols-like groups as defined by multilocus analysis of 19 Treponema pallidum strains","INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY","Article","2014/304/41795/645-653",3.42,43.111330000000002,"1 z/ze 14",7.1400000000000005E-2,"ne","ne","WOS:000339775600016","http://dx.doi.org/10.1016/j.ijmm.2014.04.007"]
[2,"Urdzikova, LM; Ruzicka, J; LaBagnara, M; Karova, K; Kubinova, S; Jirakova, K; Murali, R; Sykova, E; Jhanwar-Uniyal, M; Jendelova, P","Human Mesenchymal Stem Cells Modulate Inflammatory Cytokines after Spinal Cord Injury in Rat","INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES","Article","2014/15/7/11275-11293",2.339,37.185369999999999,"4 z/ze 10",0.4,"ne","ne","WOS:000340038500006","http://dx.doi.org/10.3390/ijms150711275"]
[2,"Plencner, M; East, B; Tonar, Z; Otahal, M; Prosecka, E; Rampichova, M; Krejci, T; Litvinec, A; Buzgo, M; Mickova, A; Necas, A; Hoch, J; Amler, E","Abdominal closure reinforcement by using polypropylene mesh functionalized with poly-epsilon-caprolactone nanofibers and growth factors for prevention of incisional hernia formation","INTERNATIONAL JOURNAL OF NANOMEDICINE","Article","2014/9//3263-3277",4.1950000000000003,62.430459999999997,"6 z/ze 13",0.46150000000000002,"ano","ano","WOS:000338659700001","http://dx.doi.org/10.2147/IJN.S63095"]
[2,"Katra, R; Kabelka, Z; Jurovcik, M; Hradsky, O; Kraus, J; Pavlik, E; Nartova, E; Lukes, P; Astl, J","Pilot study: Association between Helicobacter pylori in adenoid hyperplasia and reflux episodes detected by multiple intraluminal impedance in children","INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY","Article","2014/78/8/1243-1249",1.319,23.218669999999999,"6 z/ze 9",0.66669999999999996,"ano","ano","WOS:000340304800008","http://dx.doi.org/10.1016/j.ijporl.2014.04.040"]
[2,"Astl, J; Chovanec, M; Lukes, P; Katra, R; Dvorakova, M; Vlcek, P; Sykorova, P; Betka, J","Thyroid carcinoma surgery in children and adolescents - 15 years experience surgery of pediatric thyroid carcinoma","INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY","Article","2014/78/7/990-994",1.319,23.218669999999999,"8 z/ze 8",1,"ano","ano","WOS:000338608100005","http://dx.doi.org/10.1016/j.ijporl.2014.03.005"]
[2,"Kautzner, J; Trc, T; Havlas, V","Comparison of conservative against surgical treatment of anterior-superior iliac spine avulsion fractures in children and adolescents","INTERNATIONAL ORTHOPAEDICS","Article","2014/38/7/1495-1498",2.0190000000000001,40.55791,"3 z/ze 3",1,"ano","ano","WOS:000338496100023","http://dx.doi.org/10.1007/s00264-014-2323-0"]
[2,"Garg, AX; Devereaux, PJ; Yusuf, S; Cuerden, MS; Parikh, CR; Coca, SG; Walsh, M; Novick, R; Cook, RJ; Jain, AR; Pan, XB; Noiseux, N; Vik, K; Stolf, NA; Ritchie, A; Favaloro, RR; Parvathaneni, S; Whitlock, RP; Ou, YN; Lawrence, M; Lamy, A","Kidney Function After Off-Pump or On-Pump Coronary Artery Bypass Graft Surgery A Randomized Clinical Trial","JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION","Article","2014/311/21/2191-2198",30.387,247.44300000000001,"1 z/ze 21",4.7600000000000003E-2,"ne","ne","WOS:000336668400020","http://dx.doi.org/10.1001/jama.2014.4952"]
[2,"Dvorak, CC; Hassan, A; Slatter, MA; Honig, M; Lankester, AC; Buckley, RH; Pulsipher, MA; Davis, JH; Gungor, T; Gabriel, M; Bleesing, JH; Bunin, N; Sedlacek, P; Connell, JA; Crawford, DF; Notarangelo, LD; Pai, SY; Hassid, J; Veys, P; Gennery, AR; Cowan, MJ","Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency","JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY","Article","2014/134/4/935-U263",11.247999999999999,211.3297,"1 z/ze 21",4.7600000000000003E-2,"ne","ne","WOS:000343155700023","http://dx.doi.org/10.1016/j.jaci.2014.06.021"]
[2,"Gathmann, B; Mahlaoui, N; Gerard, L; Oksenhendler, E; Warnatz, K; Schulze, I; Kindle, G; Kuijpers, TW; van Beem, RT; Guzman, D; Workman, S; Soler-Palacin, P; De Gracia, J; Witte, T; Schmidt, RE; Litzman, J; Hlavackova, E; Thon, V; Borte, M; Borte, S; Kumararatne, D; Kumararatne, D; Longhurst, H; Helbert, M; Szaflarska, A; Sediva, A; Belohradsky, BH; Jones, A; Baumann, U; Meyts, I; Kutukculer, N; Wagstrom, P; Galal, NM; Roesler, J; Farmaki, E; Zinovieva, N; Ciznar, P; Papadopoulou-Alataki, E; Bienemann, K; Velbri, S; Panahloo, Z; Grimbacher, B","Clinical picture and treatment of 2212 patients with common variable immunodeficiency","JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY","Article","2014/134/1/116-+",11.247999999999999,211.3297,"1 z/ze 42",2.3800000000000002E-2,"ne","ne","WOS:000338930300016","http://dx.doi.org/10.1016/j.jaci.2013.12.1077"]
[2,"Kracker, S; Curtis, J; Ibrahim, MAA; Sediva, A; Salisbury, J; Campr, V; Debre, M; Edgar, JDM; Imai, K; Picard, C; Casanova, JL; Fischer, A; Nejentsev, S; Durandy, A","Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase delta syndrome","JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY","Letter","2014/134/1/233-236",11.247999999999999,211.3297,"2 z/ze 14",0.1429,"ne","ne","WOS:000338930300034","http://dx.doi.org/10.1016/j.jaci.2014.02.020"]
[2,"Kristofikova, Z; Ricny, J; Kolarova, M; Vyhnalek, M; Hort, J; Laczo, J; Sirova, J; Ripova, D","Interactions between Amyloid-beta and Tau in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Alzheimer's Disease","JOURNAL OF ALZHEIMERS DISEASE","Article","2014/42//S91-S98",3.6120000000000001,37.659829999999999,"3 z/ze 8",0.375,"ne","ne","WOS:000341595800011","http://dx.doi.org/10.3233/JAD-132393"]
[2,"Vyhnalek, M; Nikolai, T; Andel, R; Nedelska, Z; Rubinova, E; Markova, H; Laczo, J; Bezdicek, O; Sheardova, K; Hort, J","Neuropsychological Correlates of Hippocampal Atrophy in Memory Testing in Nondemented Older Adults","JOURNAL OF ALZHEIMERS DISEASE","Article","2014/42//S81-S90",3.6120000000000001,37.659829999999999,"5 z/ze 10",0.5,"ano","ano","WOS:000341595800010","http://dx.doi.org/10.3233/JAD-132642"]
[2,"Kopecka, M; Kosek, D; Kukacka, Z; Rezabkova, L; Man, P; Novak, P; Obsil, T; Obsilova, V","Role of the EF-hand-like Motif in the 14-3-3 Protein- mediated Activation of Yeast Neutral Trehalase Nth1","JOURNAL OF BIOLOGICAL CHEMISTRY","Article","2014/289/20/13948-13961",4.5999999999999996,57.18974,"1 z/ze 8",0.125,"ne","ano","WOS:000335984600026","http://dx.doi.org/10.1074/jbc.M113.544551"]
[2,"Klocperk, A; Grecova, J; Sismova, K; Kayserova, J; Fronkova, E; Sediva, A","Helios Expression in T-regulatory Cells in Patients with di George Syndrome","JOURNAL OF CLINICAL IMMUNOLOGY","Article","2014/34/7/864-870",2.6539999999999999,23.387899999999998,"6 z/ze 6",1,"ano","ano","WOS:000342212000016","http://dx.doi.org/10.1007/s10875-014-0071-y"]
[2,"Mitrova, K; Karpisek, M; Durilova, M; Dragusin, LG; Nevoral, J; Bronsky, J","Development of High-Sensitive ELISA Method for Detection of Adipophilin Levels in Human Colostrum and Breast Milk","JOURNAL OF CLINICAL LABORATORY ANALYSIS","Article","2014/28/4/255-260",1.1439999999999999,16.663799999999998,"4 z/ze 6",0.66669999999999996,"ano","ano","WOS:000339551900001","http://dx.doi.org/10.1002/jcla.21675"]
[2,"Grillova, L; Petrosova, H; Mikalova, L; Strnadel, R; Dastychova, E; Kuklova, I; Kojanova, M; Kreidlova, M; Vanousova, D; Hercogova, J; Prochazka, P; Zakoucka, H; Krchnakova, A; Vasku, V; Smajs, D","Molecular Typing of Treponema pallidum in the Czech Republic during 2011 to 2013: Increased Prevalence of Identified Genotypes and of Isolates with Macrolide Resistance","JOURNAL OF CLINICAL MICROBIOLOGY","Article","2014/52/10/3693-3700",4.2320000000000002,66.194389999999999,"2 z/ze 15",0.1333,"ne","ne","WOS:000342371700024","http://dx.doi.org/10.1128/JCM.01292-14"]
[2,"Viprey, VF; Gregory, WM; Corrias, MV; Tchirkov, A; Swerts, K; Vicha, A; Dallorso, S; Brock, P; Luksch, R; Valteau-Couanet, D; Papadakis, V; Laureys, G; Pearson, AD; Ladenstein, R; Burchill, SA","Neuroblastoma mRNAs Predict Outcome in Children With Stage 4 Neuroblastoma: AEuropean HR-NBL1/SIOPEN Study","JOURNAL OF CLINICAL ONCOLOGY","Article","2014/32/10/1074-+",17.879000000000001,224.60419999999999,"1 z/ze 15",6.6699999999999995E-2,"ne","ne","WOS:000335138400017","http://dx.doi.org/10.1200/JCO.2013.53.3604"]
[2,"Conway, S; Balfour-Lynn, IM; De Rijcke, K; Drevinek, P; Foweraker, J; Havermans, T; Heijerman, H; Lannefors, L; Lindblad, A; Macek, M; Madge, S; Moran, M; Morrison, L; Morton, A; Noordhoek, J; Sands, D; Vertommen, A; Peckham, D","European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre","JOURNAL OF CYSTIC FIBROSIS","Review","2014/13//S3-S22",3.82,71.547290000000004,"2 z/ze 18",0.1111,"ne","ne","WOS:000338814100002","http://dx.doi.org/10.1016/j.jcf.2014.03.009"]
[2,"Kolostova, K; Zhang, Y; Hoffman, RM; Bobek, V","In Vitro Culture and Characterization of Human Lung Cancer Circulating Tumor Cells Isolated by Size Exclusion from an Orthotopic Nude-Mouse Model Expressing Fluorescent Protein","JOURNAL OF FLUORESCENCE","Article","2014/24/5/1531-1536",1.667,17.87228,"1 z/ze 4",0.25,"ano","ne","WOS:000342064100020","http://dx.doi.org/10.1007/s10895-014-1439-3"]
[2,"Lassuthova, P; Zaliova, M; Inoue, K; Haberlova, J; Sixtova, K; Sakmaryova, I; Paderova, K; Mazanec, R; Zamecnik, J; Siskova, D; Garbern, J; Seeman, P","Three New PLP1 Splicing Mutations Demonstrate Pathogenic and Phenotypic Diversity of Pelizaeus-Merzbacher Disease","JOURNAL OF CHILD NEUROLOGY","Article","2014/29/7/924-931",1.6659999999999999,23.035419999999998,"8 z/ze 12",0.66669999999999996,"ano","ano","WOS:000340170000007","http://dx.doi.org/10.1177/0883073813492387"]
[2,"Ulmannova, T; Bartaskova, D; Spalova, I; Zoban, P; Vesely, Z; Stechova, K","Maternal BMI and HDL as predictors of pregnancy outcome in women with type 1 diabetes","JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE","Article","2014/27/15/1580-1583",1.208,14.774800000000001,"6 z/ze 6",1,"ano","ano","WOS:000341928900017","http://dx.doi.org/10.3109/14767058.2013.871252"]
[2,"Stechova, K; Cerny, M; Brabec, R; Ulmannova, T; Bartaskova, D; Spalova, I; Zoban, P","Experience with real time continuous glucose monitoring in stabilising fluctuating glycaemia during intensive care of the preterm infant of a diabetic mother","JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE","Article","2014/27/13/1389-1391",1.208,14.774800000000001,"7 z/ze 7",1,"ano","ano","WOS:000340448800022","http://dx.doi.org/10.3109/14767058.2013.858686"]
[2,"Kotaska, K; Kolarova, J; Jedlickova, B; Cepova, J; Kotaska, J; Prusa, R","LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A(2) IS INCREASED IN PATIENTS WITH IMPAIRED BONE DENSITY","JOURNAL OF MEDICAL BIOCHEMISTRY","Article","2014/33/4/317-322",0.72099999999999997,10.987310000000001,"6 z/ze 6",1,"ano","ano","WOS:000340863100003","http://dx.doi.org/10.2478/jomb-2014-0027"]
[2,"Kriz, J; Andel, R; Hakova, R","Delayed diagnosis of an unsuspected pelvic fracture in a patient with tetraplegia","JOURNAL OF SPINAL CORD MEDICINE","Article","2014/37/4/425-428",1.8779999999999999,21.53416,"2 z/ze 3",0.66669999999999996,"ano","ano","WOS:000342577700013","http://dx.doi.org/10.1179/2045772313Y.0000000178"]
[2,"Hylek, EM; Held, C; Alexander, JH; Lopes, RD; De Caterina, R; Wojdyla, DM; Huber, K; Jansky, P; Steg, PG; Hanna, M; Thomas, L; Wallentin, L; Granger, CB","Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin","JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY","Article","2014/63/20/2141-2147",15.343,305,"1 z/ze 13",7.6899999999999996E-2,"ne","ne","WOS:000336372700015","http://dx.doi.org/10.1016/j.jacc.2014.02.549"]
[2,"Chvatal, A","Jiri Prochaska (1749-1820): Part 1: A Significant Czech Anatomist, Physiologist and Neuroscientist of the Eighteenth Century","JOURNAL OF THE HISTORY OF THE NEUROSCIENCES","Article","2014/23/4/367-376",0.53700000000000003,18.185300000000002,"1 z/ze 1",1,"ano","ano","WOS:000343234400003","http://dx.doi.org/10.1080/0964704X.2014.881310"]
[2,"Schwabova, J; Maly, T; Laczo, J; Zumrova, A; Komarek, V; Musova, Z; Zahalka, F","Application of a Scale for the Assessment and Rating of Ataxia (SARA) in Friedreich's ataxia patients according to posturography is limited","JOURNAL OF THE NEUROLOGICAL SCIENCES","Article","2014/341/41671/64-67",2.262,21.549099999999999,"6 z/ze 7",0.85709999999999997,"ano","ano","WOS:000337262200014","http://dx.doi.org/10.1016/j.jns.2014.04.001"]
[2,"Ruffini, E; Detterbeck, F; Van Raemdonck, D; Rocco, G; Thomas, P; Weder, W; Brunelli, A; Guerrera, F; Keshavjee, S; Altorki, N; Schutzner, J; Arame, A; Spaggiari, L; Lim, E; Toker, A; Venuta, F","Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database","JOURNAL OF THORACIC ONCOLOGY","Article","2014/9/4/541-548",5.8,106.66849999999999,"1 z/ze 16",6.25E-2,"ne","ne","WOS:000333145300021","http://dx.doi.org/10.1097/JTO.0000000000000128"]
[2,"Malik, J; Kudlicka, J; Novakova, L; Adamec, J; Malikova, H; Kavan, J","Surveillance of arteriovenous accesses with the use of duplex Doppler ultrasonography","JOURNAL OF VASCULAR ACCESS","Article","2014/15//S28-S32",1.0169999999999999,11.94079,"1 z/ze 6",0.16669999999999999,"ne","ne","WOS:000342265900006","http://dx.doi.org/10.5301/jva.5000240"]
[2,"van Stralen, KJ; Borzych-Duzalka, D; Hataya, H; Kennedy, SE; Jager, KJ; Verrina, E; Inward, C; Ronnholm, K; Vondrak, K; Warady, BA; Zurowska, AM; Schaefer, F; Cochat, P","Survival and clinical outcomes of children starting renal replacement therapy in the neonatal period","KIDNEY INTERNATIONAL","Article","2014/86/1/168-174",8.52,206.51140000000001,"1 z/ze 13",7.6899999999999996E-2,"ne","ne","WOS:000338601700025","http://dx.doi.org/10.1038/ki.2013.561"]
[2,"Coenen, EA; Zwaan, CM; Stary, J; Baruchel, A; de Haas, V; Stam, RW; Reinhardt, D; Kaspers, GJL; Arentsen-Peters, STCJM; Meyer, C; Marschalek, R; Nigro, LL; Dworzak, M; Pieters, R; van den Heuvel-Eibrinkt, MM","Unique BHLHB3 overexpression in pediatric acute myeloid leukemia with t(6;11)(q27;q23)","LEUKEMIA","Letter","2014/28/7/1564-1568",9.3789999999999996,186.94900000000001,"1 z/ze 15",6.6699999999999995E-2,"ne","ne","WOS:000339705500028","http://dx.doi.org/10.1038/leu.2014.82"]
[2,"Emmrich, S; Katsman-Kuipers, JE; Henke, K; Khatib, ME; Jammal, R; Engeland, F; Dasci, F; Zwaan, CM; den Boer, ML; Verboon, L; Stary, J; Baruchel, A; de Haas, V; Danen-van Oorschot, AA; Fornerod, M; Pieters, R; Reinhardt, D; Klusmann, JH; van den Heuvel-Eibrink, MM","miR-9 is a tumor suppressor in pediatric AML with t(8;21)","LEUKEMIA","Article","2014/28/5/1022-1032",9.3789999999999996,186.94900000000001,"1 z/ze 19",5.2600000000000001E-2,"ne","ne","WOS:000336661500006","http://dx.doi.org/10.1038/leu.2013.357"]
[2,"Kortum, F; Abdollahpour, H; Alawi, M; Korenke, G; Seemanova, E; Tinschert, S; Zenker, M; Rosenberger, G; Kutsche, K","Exome sequencing for identification of disease genes for rare syndromes. Experiences from Hamburg","MEDIZINISCHE GENETIK","Article","2014/26/2/246-254",0.222,10.29613,"1 z/ze 9",0.1111,"ne","ne","WOS:000339886900004","http://dx.doi.org/10.1007/s11825-014-0446-8"]
[2,"Jiruska, P; de Curtis, M; Jefferys, JGR","Modern Concepts of Focal Epileptic Networks","MODERN CONCEPTS OF FOCAL EPILEPTIC NETWORKS","Review; Book Chapter","2014/114//1-7",2.4569999999999999,10,"1 z/ze 3",0.33329999999999999,"ano","ano","WOS:000340439500001","http://dx.doi.org/10.1016/B978-0-12-418693-4.00001-7"]
[2,"Blauwblomme, T; Jiruska, P; Huberfeld, G","Mechanisms of Ictogenesis","MODERN CONCEPTS OF FOCAL EPILEPTIC NETWORKS","Review; Book Chapter","2014/114//155-185",2.4569999999999999,10,"1 z/ze 3",0.33329999999999999,"ne","ne","WOS:000340439500007","http://dx.doi.org/10.1016/B978-0-12-418693-4.00007-8"]
[2,"Martinkovic, L; Hecimovic, H; Sulc, V; Marecek, R; Marusic, P","Modern Techniques of Epileptic Focus Localization","MODERN CONCEPTS OF FOCAL EPILEPTIC NETWORKS","Review; Book Chapter","2014/114//245-278",2.4569999999999999,10,"3 z/ze 5",0.6,"ano","ano","WOS:000340439500010","http://dx.doi.org/10.1016/B978-0-12-418693-4.00010-8"]
[2,"Drabova, J; Trkova, M; Hancarova, M; Novotna, D; Hejtmankova, M; Havlovicova, M; Sedlacek, Z","A 15 Mb large paracentric chromosome 21 inversion identified in Czech population through a pair of flanking duplications","MOLECULAR CYTOGENETICS","Article","2014/7//-",2.6619999999999999,25.808520000000001,"5 z/ze 7",0.71430000000000005,"ano","ano","WOS:000341508700001","http://dx.doi.org/10.1186/1755-8166-7-51"]
[2,"Amler, E; Filova, E; Buzgo, M; Prosecka, E; Rampichova, M; Necas, A; Nooeaid, P; Boccaccini, AR","Functionalized nanofibers as drug-delivery systems for osteochondral regeneration","NANOMEDICINE","Review","2014/9/7/1083-1094",5.8239999999999998,77.501689999999996,"2 z/ze 8",0.25,"ano","ano","WOS:000338783800018","http://dx.doi.org/10.2217/NNM.14.57"]
[2,"Ripke, S; Neale, BM; Corvin, A; Walters, JTR; Farh, KH; Holmans, PA; Lee, P; Bulik-Sullivan, B; Collier, DA; Huang, HL; Pers, TH; Agartz, I; Agerbo, E; Albus, M; Alexander, M; Amin, F; Bacanu, SA; Begemann, M; Belliveau, RA; Bene, J; Bergen, SE; Bevilacqua, E; Bigdeli, TB; Black, DW; Bruggeman, R; Buccola, NG; Buckner, RL; Byerley, W; Cahn, W; Cai, GQ; Campion, D; Cantor, RM; Carr, VJ; Carrera, N; Catts, SV; Chambert, KD; Chan, RCK; Chen, RYL; Chen, EYH; Cheng, W; Cheung, EFC; Chong, SA; Cloninger, CR; Cohen, D; Cohen, N; Cormican, P; Craddock, N; Crowley, JJ; Curtis, D; Davidson, M; Davis, KL; Degenhardt, F; Del Favero, J; Demontis, D; Dikeos, D; Dinan, T; Djurovic, S; Donohoe, G; Drapeau, E; Duan, J; Dudbridge, F; Durmishi, N; Eichhammer, P; Eriksson, J; Escott-Price, V; Essioux, L; Fanous, AH; Farrell, MS; Frank, J; Franke, L; Freedman, R; Freimer, NB; Friedl, M; Friedman, JI; Fromer, M; Genovese, G; Georgieva, L; Giegling, I; Giusti-Rodriguez, P; Godard, S; Goldstein, JI; Golimbet, V; Gopal, S; Gratten, J; de Haan, L; Hammer, C; Hamshere, ML; Hansen, M; Hansen, T; Haroutunian, V; Hartmann, AM; Henskens, FA; Herms, S; Hirschhorn, JN; Hoffmann, P; Hofman, A; Hollegaard, MV; Hougaard, DM; Ikeda, M; Joa, I; Julia, A; Kahn, RS; Kalaydjieva, L; Karachanak-Yankova, S; Karjalainen, J; Kavanagh, D; Keller, MC; Kennedy, JL; Khrunin, A; Kim, Y; Klovins, J; Knowles, JA; Konte, B; Kucinskas, V; Kucinskiene, ZA; Kuzelova-Ptackova, H; Kahler, AK; Laurent, C; Keong, JLC; Lee, SH; Legge, SE; Lerer, B; Li, MX; Li, T; Liang, KY; Lieberman, J; Limborska, S; Loughland, CM; Lubinski, J; Lonnqvist, J; Macek, M; Magnusson, PKE; Maher, BS; Maier, W; Mallet, J; Marsal, S; Mattheisen, M; Mattingsdal, M; McCarley, RW; McDonald, C; McIntosh, AM; Meier, S; Meijer, CJ; Melegh, B; Melle, I; Mesholam-Gately, RI; Metspalu, A; Michie, PT; Milani, L; Milanova, V; Mokrab, Y; Morris, DW; Mors, O; Murphy, KC; Murray, RM; Myin-Germeys, I; Muller-Myhsok, B; Nelis, M; Nenadic, I; Nertney, DA; Nestadt, G; Nicodemus, KK; Nikitina-Zake, L; Nisenbaum, L; Nordin, A; O'Callaghan, E; O'Dushlaine, C; O'Neill, FA; Oh, SY; Olincy, A; Olsen, L; Van Os, J; Pantelis, C; Papadimitriou, GN; Papiol, S; Parkhomenko, E; Pato, MT; Paunio, T; Pejovic-Milovancevic, M; Perkins, DO; Pietilainen, O; Pimm, J; Pocklington, AJ; Powell, J; Price, A; Pulver, AE; Purcell, SM; Quested, D; Rasmussen, HB; Reichenberg, A; Reimers, MA; Richards, AL; Roffman, JL; Roussos, P; Ruderfer, DM; Salomaa, V; Sanders, AR; Schall, U; Schubert, CR; Schulze, TG; Schwab, SG; Scolnick, EM; Scott, RJ; Seidman, LJ; Shi, JX; Sigurdsson, E; Silagadze, T; Silverman, JM; Sim, K; Slominsky, P; Smoller, JW; So, HC; Spencer, CCA; Stahl, EA; Stefansson, H; Steinberg, S; Stogmann, E; Straub, RE; Strengman, E; Strohmaier, J; Stroup, TS; Subramaniam, M; Suvisaari, J; Svrakic, DM; Szatkiewicz, JP; Soderman, E; Thirumalai, S; Toncheva, D; Tosato, S; Veijola, J; Waddington, J; Walsh, D; Wang, D; Wang, Q; Webb, BT; Weiser, M; Wildenauer, DB; Williams, NM; Williams, S; Witt, SH; Wolen, AR; Wong, EHM; Wormley, BK; Xi, HS; Zai, CC; Zheng, XB; Zimprich, F; Wray, NR; Stefansson, K; Visscher, PM; Adolfsson, R; Andreassen, OA; Blackwood, DHR; Bramon, E; Buxbaum, JD; Borglum, AD; Cichon, S; Darvasi, A; Domenici, E; Ehrenreich, H; Esko, T; Gejman, PV; Gill, M; Gurling, H; Hultman, CM; Iwata, N; Jablensky, AV; Jonsson, EG; Kendler, KS; Kirov, G; Knight, J; Lencz, T; Levinson, DF; Li, QQS; Liu, JJ; Malhotra, AK; McCarroll, SA; McQuillin, A; Moran, JL; Mortensen, PB; Mowry, BJ; Nothen, MM; Ophoff, RA; Owen, MJ; Palotie, A; Pato, CN; Petryshen, TL; Posthuma, D; Rietschel, M; Riley, BP; Rujescu, D; Sham, PC; Sklar, P; St Clair, D; Weinberger, DR; Wendland, JR; Werge, T; Daly, MJ; Sullivan, PF; O'Donovan, MC","Biological insights from 108 schizophrenia-associated genetic loci","NATURE","Article","2014/511/7510/421-+",42.350999999999999,305,"2 z/ze 300",6.7000000000000002E-3,"ne","ne","WOS:000339335700037","http://dx.doi.org/10.1038/nature13595"]
[2,"Northcott, PA; Lee, C; Zichner, T; Stutz, AM; Erkek, S; Kawauchi, D; Shih, DJH; Hovestadt, V; Zapatka, M; Sturm, D; Jones, DTW; Kool, M; Remke, M; Cavalli, FMG; Zuyderduyn, S; Bader, GD; VandenBerg, S; Esparza, LA; Ryzhova, M; Wang, W; Wittmann, A; Stark, S; Sieber, L; Seker-Cin, H; Linke, L; Kratochwil, F; Jager, N; Buchhalter, I; Imbusch, CD; Zipprich, G; Raeder, B; Schmidt, S; Diessl, N; Wolf, S; Wiemann, S; Brors, B; Lawerenz, C; Eils, J; Warnatz, HJ; Risch, T; Yaspo, ML; Weber, UD; Bartholomae, CC; von Kalle, C; Turanyi, E; Hauser, P; Sanden, E; Darabi, A; Siesjo, P; Sterba, J; Zitterbart, K; Sumerauer, D; van Sluis, P; Versteeg, R; Volckmann, R; Koster, J; Schuhmann, MU; Ebinger, M; Grimes, HL; Robinson, GW; Gajjar, A; Mynarek, M; von Hoff, K; Rutkowski, S; Pietsch, T; Scheurlen, W; Felsberg, J; Reifenberger, G; Kulozik, AE; von Deimling, A; Witt, O; Eils, R; Gilbertson, RJ; Korshunov, A; Taylor, MD; Lichter, P; Korbel, JO; Wechsler-Reya, RJ; Pfister, SM","Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma","NATURE","Article","2014/511/7510/428-+",42.350999999999999,305,"1 z/ze 79",1.2699999999999999E-2,"ne","ne","WOS:000339335700038","http://dx.doi.org/10.1038/nature13379"]
[2,"Ptacek, R; Kuzelova, H; Stefano, GB; Raboch, J; Kream, RM; Goetz, M","ADHD and growth: questions still unanswered","NEUROENDOCRINOLOGY LETTERS","Article","2014/35/1/1-6",0.93500000000000005,12.08958,"1 z/ze 6",0.16669999999999999,"ne","ne","WOS:000340153500001","www.ncbi.nlm.nih.gov/pubmed/24625909"]
[2,"Charvat, J; Svab, P; Havlin, J; Bilek, R; Zamrazil, V","The significance of plasma adrenomedullin and calcitonin gene-related peptide concentration in patients with Type 2 diabetes mellitus who are treated for cardiovascular risk factors","NEUROENDOCRINOLOGY LETTERS","Article","2014/35/2/154-158",0.93500000000000005,12.08958,"5 z/ze 5",1,"ano","ano","WOS:000340153900012","http://www.ncbi.nlm.nih.gov/pubmed/24878981"]
[2,"Sulc, V; Stykel, S; Hanson, DP; Brinkmann, BH; Jones, DT; Holmes, DR; Robb, RA; Senjem, ML; Mullan, BP; Watson, RE; Horinek, D; Cascino, GD; Wong-Kisiel, LC; Britton, JW; So, EL; Worrell, GA","Statistical SPECT processing in MRI-negative epilepsy surgery","NEUROLOGY","Article","2014/82/11/932-939",8.3030000000000008,183.74529999999999,"1 z/ze 16",6.25E-2,"ne","ano","WOS:000336262500010","http://dx.doi.org/10.1212/WNL.0000000000000209"]
[2,"Laczo, J; Andel, R; Vyhnalek, M; Vlcek, K; Nedelska, Z; Matoska, V; Gazova, I; Mokrisova, I; Sheardova, K; Hort, J","APOE and Spatial Navigation in Amnestic MCI: Results From a Computer-Based Test","NEUROPSYCHOLOGY","Article","2014/28/5/676-684",3.4249999999999998,42.580939999999998,"6 z/ze 10",0.6,"ne","ano","WOS:000341291800002","http://dx.doi.org/10.1037/neu0000072"]
[2,"Demlova, R; Mrkvicova, M; Sterba, J; Bernatikova, H; Stary, J; Sukova, M; Mikuskova, A; Chocholova, A; Mladosievicova, B; Soltysova, A; Behulova, D; Pilatova, K; Zdrazilova-Dubska, L; Valik, D","Augmenting Clinical Interpretability of Thiopurine Methyltransferase Laboratory Evaluation","ONCOLOGY","Article","2014/86/3/152-158",2.613,23.73658,"2 z/ze 14",0.1429,"ne","ne","WOS:000335939300004","http://dx.doi.org/10.1159/000357407"]
[2,"Mahelkova, G; Ferrova, K; Pochop, P; Odehnal, M; Dotrelova, D","Corneal Confocal Microscopy for Vision Disturbance After an Epithelial Abrasion","OPTOMETRY AND VISION SCIENCE","Article","2014/91/1/E18-E20",2.0379999999999998,34.963500000000003,"5 z/ze 5",1,"ano","ano","WOS:000336215200004","http://dx.doi.org/10.1097/OPX.0000000000000109"]
[2,"Berankova, K; Uhlik, J; Honkova, L; Pohunek, P","Structural changes in the bronchial mucosa of young children at risk of developing asthma","PEDIATRIC ALLERGY AND IMMUNOLOGY","Article","2014/25/2/136-142",3.859,68.721649999999997,"4 z/ze 4",1,"ano","ano","WOS:000332968000005","http://dx.doi.org/10.1111/pai.12145"]
[2,"Forbes, TA; Watson, AR; Zurowska, A; Shroff, R; Bakkaloglu, S; Vondrak, K; Fischbach, M; Van de Walle, J; Ariceta, G; Edefonti, A; Aufricht, C; Jankauskiene, A; Holta, T; Ekim, M; Schmitt, CP; Stefanidis, C","Adherence to transition guidelines in European paediatric nephrology units","PEDIATRIC NEPHROLOGY","Article","2014/29/9/1617-1624",2.8809999999999998,68.736310000000003,"1 z/ze 16",6.25E-2,"ne","ne","WOS:000341377700017","http://dx.doi.org/10.1007/s00467-014-2809-4"]
[2,"Azukaitis, K; Loirat, C; Malina, M; Adomaitiene, I; Jankauskiene, A","Macrovascular involvement in a child with atypical hemolytic uremic syndrome","PEDIATRIC NEPHROLOGY","Article","2014/29/7/1273-1277",2.8809999999999998,68.736310000000003,"1 z/ze 5",0.2,"ne","ne","WOS:000336434600020","http://dx.doi.org/10.1007/s00467-013-2713-3"]
[2,"Kocova, H; Dvorackova, O; Vondracek, P; Haberlova, J","Health-Related Quality of Life in Children and Adolescents With Spinal Muscular Atrophy in the Czech Republic","PEDIATRIC NEUROLOGY","Article","2014/50/6/591-594",1.504,19.57414,"1 z/ze 4",0.25,"ne","ne","WOS:000336643700010","http://dx.doi.org/10.1016/j.pediatrneurol.2014.01.037"]
[2,"Quizon, A; Minic, P; Pohunek, P; Tal, A; Colin, AA","Obliterative Lower Airway Lesions in Childhood: Bronchoscopic Diagnosis and Clinical Spectrum","PEDIATRIC PULMONOLOGY","Article","2014/49/3/E27-E34",2.2970000000000002,32.21293,"1 z/ze 5",0.2,"ne","ne","WOS:000331354900004","http://dx.doi.org/10.1002/ppul.22775"]
[2,"Vargova, L; Sykova, E","Astrocytes and extracellular matrix in extrasynaptic volume transmission","PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES","Review","2014/369/1654/-",6.3140000000000001,145.7157,"2 z/ze 2",1,"ano","ano","WOS:000342357600017","http://dx.doi.org/10.1098/rstb.2013.0608"]
[2,"Spevacek, V; Pilarova, K; Koncekova, J; Koncek, O","The influence of antioxidant THPC on the properties of polymer gel dosimeter","PHYSICS IN MEDICINE AND BIOLOGY","Article","2014/59/17/5141-5161",2.9220000000000002,61.46414,"1 z/ze 4",0.25,"ne","ne","WOS:000341328200023","http://dx.doi.org/10.1088/0031-9155/59/17/5141"]
[2,"Koblihova, E; Mrazova, I; Vernerova, Z; Ryska, M","Acute Liver Failure Induced by Thioacetamide: Selection of Optimal Dosage in Wistar and Lewis Rats","PHYSIOLOGICAL RESEARCH","Article","2014/63/4/491-503",1.4870000000000001,14.87317,"2 z/ze 4",0.5,"ano","ano","WOS:000342568400010","http://www.biomed.cas.cz/physiolres/pdf/63/63_491.pdf"]
[2,"Pokorny, M; Cervenka, L; Netuka, I; Pirk, J; Konarik, M; Maly, J","Ventricular Assist Devices in Heart Failure: How to Support the Heart but Prevent Atrophy?","PHYSIOLOGICAL RESEARCH","Review","2014/63/2/147-156",1.4870000000000001,14.87317,"2 z/ze 6",0.33329999999999999,"ano","ano","WOS:000336459800002","http://www.biomed.cas.cz/physiolres/pdf/63/63_147.pdf"]
[2,"Urbanova, M; Dostalova, I; Trachta, P; Drapalova, J; Kavalkova, P; Haluzikova, D; Matoulek, M; Lacinova, Z; Mraz, M; Kasalicky, M; Haluzik, M","Serum Concentrations and Subcutaneous Adipose Tissue mRNA Expression of Omentin in Morbid Obesity and Type 2 Diabetes Mellitus: the Effect of Very-Low-Calorie Diet, Physical Activity and Laparoscopic Sleeve Gastrectomy","PHYSIOLOGICAL RESEARCH","Article","2014/63/2/207-218",1.4870000000000001,14.87317,"1 z/ze 11",9.0899999999999995E-2,"ne","ne","WOS:000336459800008","http://www.biomed.cas.cz/physiolres/pdf/63/63_207.pdf"]
[2,"Zaloudikova, M; Herget, J; Vizek, M","The Contractile Response of Isolated Small Pulmonary Arteries Induced by Activated Macrophages","PHYSIOLOGICAL RESEARCH","Article","2014/63/2/267-270",1.4870000000000001,14.87317,"3 z/ze 3",1,"ano","ano","WOS:000336459800015","http://www.biomed.cas.cz/physiolres/pdf/63/63_267.pdf"]
[2,"Sheardova, K; Laczo, J; Vyhnalek, M; Andel, R; Mokrisova, I; Vlcek, K; Amlerova, J; Hort, J","Famous Landmark Identification in Amnestic Mild Cognitive Impairment and Alzheimer's Disease","PLOS ONE","Article","2014/9/8/-",3.5339999999999998,88.41883,"6 z/ze 8",0.75,"ano","ne","WOS:000341106100100","http://dx.doi.org/10.1371/journal.pone.0105623"]
[2,"Malikova, J; Camats, N; Fernandez-Cancio, M; Heath, K; Gonzalez, I; Caimari, M; del Campo, M; Albisu, M; Kolouskova, S; Audi, L; Fluck, CE","Human NR5A1/SF-1 Mutations Show Decreased Activity on BDNF (Brain-Derived Neurotrophic Factor), an Important Regulator of Energy Balance: Testing Impact of Novel SF-1 Mutations Beyond Steroidogenesis","PLOS ONE","Article","2014/9/8/-",3.5339999999999998,88.41883,"1 z/ze 11",9.0899999999999995E-2,"ne","ano","WOS:000341017000063","http://dx.doi.org/10.1371/journal.pone.0104838"]
[2,"Adkins, I; Kamanova, J; Kocourkova, A; Svedova, M; Tomala, J; Janova, H; Masin, J; Chladkova, B; Bumba, L; Kovar, M; Ross, PJ; Tuckova, L; Spisek, R; Mills, KHG; Sebo, P","Bordetella Adenylate Cyclase Toxin Differentially Modulates Toll-Like Receptor-Stimulated Activation, Migration and T Cell Stimulatory Capacity of Dendritic Cells","PLOS ONE","Article","2014/9/8/-",3.5339999999999998,88.41883,"2 z/ze 15",0.1333,"ne","ne","WOS:000339819800123","http://dx.doi.org/10.1371/journal.pone.0104064"]
[2,"Kunicka, T; Vaclavikova, R; Hlavac, V; Vrana, D; Pecha, V; Raus, K; Trnkova, M; Kubackova, K; Ambrus, M; Vodickova, L; Vodicka, P; Soucek, P","Non-Coding Polymorphisms in Nucleotide Binding Domain 1 in ABCC1 Gene Associate with Transcript Level and Survival of Patients with Breast Cancer","PLOS ONE","Article","2014/9/7/-",3.5339999999999998,88.41883,"1 z/ze 12",8.3299999999999999E-2,"ne","ne","WOS:000339954800008","http://dx.doi.org/10.1371/journal.pone.0101740"]
[2,"Prochazka, V; Pytlik, R; Janikova, A; Belada, D; Salek, D; Papajik, T; Campr, V; Furst, T; Furstova, J; Trneny, M","A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent","PLOS ONE","Article","2014/9/7/-",3.5339999999999998,88.41883,"1 z/ze 10",0.1,"ne","ne","WOS:000341354800028","http://dx.doi.org/10.1371/journal.pone.0102594"]
[2,"Gumulec, J; Masarik, M; Adam, V; Eckschlager, T; Provaznik, I; Kizek, R","Serum and Tissue Zinc in Epithelial Malignancies: A Meta-Analysis","PLOS ONE","Article","2014/9/6/-",3.5339999999999998,88.41883,"1 z/ze 6",0.16669999999999999,"ne","ne","WOS:000338508200042","http://dx.doi.org/10.1371/journal.pone.0099790"]
[2,"Vaclavikova, E; Dvorakova, S; Skaba, R; Pos, L; Sykorova, V; Halkova, T; Vcelak, J; Bendlova, B","RET Variants and Haplotype Analysis in a Cohort of Czech Patients with Hirschsprung Disease","PLOS ONE","Article","2014/9/6/-",3.5339999999999998,88.41883,"2 z/ze 8",0.25,"ne","ne","WOS:000338430700102","http://dx.doi.org/10.1371/journal.pone.0098957"]
[2,"Powell, AD; Saintot, PP; Gill, KK; Bharathan, A; Buck, SC; Morris, G; Jiruska, P; Jefferys, JGR","Reduced Gamma Oscillations in a Mouse Model of Intellectual Disability: A Role for Impaired Repetitive Neurotransmission?","PLOS ONE","Article","2014/9/5/-",3.5339999999999998,88.41883,"1 z/ze 8",0.125,"ne","ne","WOS:000338029800036","http://dx.doi.org/10.1371/journal.pone.0095871"]
[2,"Kuchar, M; Vankova, L; Petrokova, H; Cerny, J; Osicka, R; Pelak, O; Sipova, H; Schneider, B; Homola, J; Sebo, P; Kalina, T; Maly, P","Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells","PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS","Article","2014/82/6/975-989",2.9209999999999998,28.22317,"2 z/ze 12",0.16669999999999999,"ne","ne","WOS:000335955300009","http://dx.doi.org/10.1002/prot.24472"]
[2,"Solny, P; Zimak, J","Research on radiation exposure from CT part of hybrid camera and diagnostic CT","RADIATION PHYSICS AND CHEMISTRY","Article; Proceedings Paper","2014/104//260-266",1.1890000000000001,21.076000000000001,"2 z/ze 2",1,"ano","ano","WOS:000341463600054","http://dx.doi.org/10.1016/j.radphyschem.2014.05.044"]
[2,"Chandak, P; Kessaris, N; Uwechue, RU; Abboudi, H; Hossain, M; Harris, F; Jones, K; Fronek, J","Successful Excision of a Suspected Mycotic Transplant Renal Artery Patch Aneurysm With Renal Allograft Autotransplantation","TRANSPLANTATION","Letter","2014/97/3/E25-E26",3.5350000000000001,60.052680000000002,"1 z/ze 8",0.125,"ne","ne","WOS:000335838500006","http://dx.doi.org/10.1097/01.TP.0000438628.75848.9a"]
[2,"Buchler, T; Bortlicek, Z; Poprach, A; Kubackova, K; Kiss, I; Zemanova, M; Fiala, O; Dusek, L; Vyzula, R; Melichar, B","Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis","UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS","Article","2014/32/5/569-575",3.363,49.029150000000001,"1 z/ze 10",0.1,"ne","ne","WOS:000338090800009","http://dx.doi.org/10.1016/j.urolonc.2013.12.007"]
[2,"Klatte, T; Xylinas, E; Rieken, M; Roupret, M; Fajkovic, H; Seitz, C; Karakiewicz, PI; Lotan, Y; Babjuk, M; de Martino, M; Shariat, SF","Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy","UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS","Article","2014/32/5/625-630",3.363,49.029150000000001,"1 z/ze 11",9.0899999999999995E-2,"ne","ne","WOS:000338090800017","http://dx.doi.org/10.1016/j.urolonc.2013.11.010"]
[2,"Kutlvasr, K; Bukovjan, K; Kodet, R","Bilateral low grade serous adenocarcinoma of the ovaries in a badger (Meles meles L.) and its association with a borderline serous ovarian tumour: a case report","VETERINARNI MEDICINA","Article","2014/59/1/44-50",0.75600000000000001,19.80444,"1 z/ze 3",0.33329999999999999,"ano","ne","WOS:000339608900006","http://vri.cz/docs/vetmed/59-1-44.pdf"]
[2,"Jirsa, M; Bronsky, J; Dvorakova, L; Sperl, J; Smajstrla, V; Horak, J; Nevoral, J; Hrebicek, M","ABCB4 mutations underlie hormonal cholestasis but not pediatric idiopathic gallstones","WORLD JOURNAL OF GASTROENTEROLOGY","Article","2014/20/19/5867-5874",2.4329999999999998,26.721530000000001,"2 z/ze 8",0.25,"ne","ne","WOS:000336048200032","http://dx.doi.org/10.3748/wjg.v20.i19.5867"]
[3,"Chladek, P; Musalek, M; Zahradnik, P","Femoroacetabular Impingement Syndrome: First Experience with Surgical Treatment","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA","Article","2014/815/328-334",0.41499999999999998,11.022779999999999,"1 z/ze 3",0.33333333333333331,"ano","ano","WOS:000344046700005","http://www.achot.cz/detail.php?stat=709"]
[3,"Pech, J; Veigl, D; Hromadka, R; Dobias, J; Zatrapa, T","Shape-Memory Osteosynthesis for Trapeziometacarpal Joint Arthrodesis","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA","Article","2014/815/335-339",0.41499999999999998,11.022779999999999,"5 z/ze 5",1,"ano","ano","WOS:000344046700006","http://www.achot.cz/detail.php?stat=708"]
[3,"Vlasak, A; Horinek, D; Sames, M","Radiographic changes after anterior cervical discectomy and their clinical impact","ACTA NEUROCHIRURGICA","Letter","2014/15611/2153-2154",1.788,25.205030000000001,"1 z/ze 3",0.33333333333333331,"ano","ano","WOS:000343884400017","http://dx.doi.org/10.1007/s00701-014-2110-0"]
[3,"Zoremba, N; Homola, A; Rossaint, R; Sykova, E","Interstitial lactate, lactate/pyruvate and glucose in rat muscle before, during and in the recovery from global hypoxia","ACTA VETERINARIA SCANDINAVICA","Article","2014/56/-",1.3819999999999999,52.179160000000003,"2 z/ze 4",0.5,"ne","ne","WOS:000344889000001","http://dx.doi.org/10.1186/s13028-014-0072-0"]
[3,"Magerova, H; Vyhnalek, M; Laczo, J; Andel, R; Rektorova, I; Kadlecova, A; Bojar, M; Hort, J","Odor Identification in Frontotemporal Lobar Degeneration Subtypes","AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS","Article","2014/298/762-768",1.4259999999999999,16.70842,"6 z/ze 8",0.75,"ano","ano","WOS:000345335300017","http://dx.doi.org/10.1177/1533317514539033"]
[3,"Havlin, J; Matousovic, K; Schuck, O","A \"Lingering Mystery\" of Postdialysis Serum Bicarbonate Concentration","AMERICAN JOURNAL OF KIDNEY DISEASES","Letter","2014/646/1000-1001",5.7560000000000002,155.3048,"3 z/ze 3",1,"ano","ano","WOS:000345404200025","http://dx.doi.org/10.1053/j.ajkd.2014.09.010"]
[3,"Krutova, M; Nyc, O; Kuijper, EJ; Geigerova, L; Matejkova, J; Bergerova, T; Arvand, M","A case of imported Clostridium difficile PCR-ribotype 027 infection within the Czech Republic which has a high prevalence of C-difficile ribotype 176","ANAEROBE","Article","2014/30/153-155",2.3639999999999999,23.701360000000001,"5 z/ze 7",0.7142857142857143,"ano","ano","WOS:000347768400027","http://dx.doi.org/10.1016/j.anaerobe.2014.09.020"]
[3,"Spenerova, M; Dzubak, P; Srovnal, J; Radova, L; Burianova, R; Konecny, P; Salkova, S; Novak, Z; Pospisilova, D; Stary, J; Blazek, B; Hak, J; Votava, T; Timr, P; Kaiserova, E; Bubanska, E; Mihal, V; Hajduch, M","Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia","BIOMEDICAL PAPERS-OLOMOUC","Article","2014/1583/422-427",1.661,18.60192,"1 z/ze 18",5.5555555555555552E-2,"ne","ne","WOS:000345398500014","http://dx.doi.org/10.5507/bp.2012.059"]
[3,"Vranova, J; Arenbergerova, M; Arenberger, P; Vrana, A; Zivcak, J; Kolarova, H; Rosina, J","Malignant melanoma in the Czech Republic: Incidence and mortality according to sex, age and disease stage","BIOMEDICAL PAPERS-OLOMOUC","Article","2014/1583/438-446",1.661,18.60192,"1 z/ze 7",0.14285714285714285,"ne","ne","WOS:000345398500017","http://dx.doi.org/10.5507/bp.2012.081"]
[3,"Pochop, P; Darsova, D; Uhlik, J; Lestak, J; Kukacka, J; Kodetova, D; Klapkova, E; Malis, J; Vajner, L","Retinal toxicity after repeated intravitreal carboplatin injection into rabbit eyes","BIOMEDICAL PAPERS-OLOMOUC","Article","2014/1584/552-556",1.661,18.60192,"8 z/ze 9",0.88888888888888884,"ano","ano","WOS:000347173200009","http://dx.doi.org/10.5507/bp.2012.106"]
[3,"Ivica, J; Wilhelm, J","Lipophilic fluorescent products of free radicals","BIOMEDICAL PAPERS-OLOMOUC","Article","2014/1583/365-372",1.661,18.60192,"1 z/ze 2",0.5,"ano","ano","WOS:000345398500006","http://dx.doi.org/10.5507/bp.2012.112"]
[3,"Vesely, S; Jarolim, L; Duskova, K; Schmidt, M; Dusek, P; Babjuk, M","The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy","BMC UROLOGY","Article","2014/14/-",1.9370000000000001,31.416139999999999,"6 z/ze 6",1,"ano","ano","WOS:000345463700001","http://dx.doi.org/10.1186/1471-2490-14-79"]
[3,"van Gestel, JPJ; Bierings, MB; Dauger, S; Dalle, JH; Pavlicek, P; Sedlacek, P; Monteiro, LM; Lankester, A; Bollen, CW","Outcome of invasive mechanical ventilation after pediatric allogeneic hematopoietic SCT: results from a prospective, multicenter registry","BONE MARROW TRANSPLANTATION","Article","2014/4910/1287-1292",3.4660000000000002,39.933770000000003,"2 z/ze 9",0.22222222222222221,"ne","ne","WOS:000343660300007","http://dx.doi.org/10.1038/bmt.2014.147"]
[3,"Mares, P; Ticha, K; Mikulecka, A","Anticonvulsant and behavioral effects of muscimol in immature rats","BRAIN RESEARCH","Article","2014/1582/227-236",2.8279999999999998,23.265419999999999,"1 z/ze 3",0.33333333333333331,"ne","ne","WOS:000343357100022","http://dx.doi.org/10.1016/j.brainres.2014.07.038"]
[3,"Melichercik, P; Klapkova, E; Landor, I; Judl, T; Sibek, M; Jahoda, D","The effect of Vancomycin degradation products in the topical treatment of osteomyelitis","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY","Article","2014/11512/796-799",0.44600000000000001,13.924149999999999,"6 z/ze 6",1,"ano","ano","WOS:000348244100013","http://dx.doi.org/10.4149/BLL_2014_154"]
[3,"Polanecky, O; Adamek, S; Sedy, J; Skorepa, J; Hladik, P; Smejkal, M; Pafko, P; Lischke, R","Postoperative rectal anastomotic complications","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY","Article","2014/11512/781-785",0.44600000000000001,13.924149999999999,"7 z/ze 8",0.875,"ano","ano","WOS:000348244100010","http://dx.doi.org/10.4149/BLL_2014_151"]
[3,"Bartelheim, K; Sumerauer, D; Behrends, U; Kodetova, D; Kucera, F; Leuschner, I; Neumayer, P; Oyen, F; Rube, C; Siebert, R; Schneppenheim, R; Seeringer, A; Vasovcak, P; Fruhwald, MC","Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB)","CANCER GENETICS","Article","2014/2079/379-383",2.4169999999999998,20.904540000000001,"4 z/ze 14",0.2857142857142857,"ne","ne","WOS:000346819600007","http://dx.doi.org/10.1016/j.cancergen.2014.04.005"]
[3,"Koci, Z; Turnovcova, K; Dubsky, M; Baranovicova, L; Holan, V; Chudickova, M; Sykova, E; Kubinova, S","Characterization of human adipose tissue-derived stromal cells isolated from diabetic patient's distal limbs with critical ischemia","CELL BIOCHEMISTRY AND FUNCTION","Article","2014/327/597-604",2.1339999999999999,16.043030000000002,"2 z/ze 8",0.25,"ano","ano","WOS:000343798900007","http://dx.doi.org/10.1002/cbf.3056"]
[3,"Lukas, R; Stulik, J; Sram, J; Pazour, J; Kriz, J; Nesnidal, P","The Effect of Suboptimal Surgical Treatment of Spinal Fractures on the Course of Spinal Cord Injury","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE","Article","2014/776/734-740",0.159,10.296110000000001,"3 z/ze 6",0.5,"ne","ne","WOS:000346229200009","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/vliv-neoptimalniho-chirurgickeho-osetreni-patere-na-prubeh-misniho-poraneni-50238"]
[3,"Sramek, M; Ruzickova, T; Kesnerova, P; Kadlecova, P; Mikulik, R","Reducing the Door-to-needle Interval, Experience from the Stroke Centre in Kladno","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE","Article","2014/776/747-752",0.159,10.296110000000001,"3 z/ze 5",0.6,"ano","ano","WOS:000346229200011","http://www.prolekare.cz/ceska-slovenska-neurologie-clanek/zkraceni-door-to-needle-intervalu-zkusenosti-z-iktoveho-centra-kladno-50245"]
[3,"Kubus, P; Materna, O; Tax, P; Tomek, V; Janousek, J","Successful Permanent Resynchronization for Failing Right Ventricle After Repair of Tetralogy of Fallot","CIRCULATION","Editorial Material","2014/13022/E186-E190",14.948,284.39909999999998,"5 z/ze 5",1,"ano","ano","WOS:000345517100001","http://dx.doi.org/10.1161/CIRCULATIONAHA.114.012205"]
[3,"Sediva, A; Chapel, H; Gardulf, A","Europe Immunoglobulin Map","CLINICAL AND EXPERIMENTAL IMMUNOLOGY","Article","2014/178/141-143",3.278,31.034089999999999,"1 z/ze 3",0.33333333333333331,"ano","ano","WOS:000346976700058","http://dx.doi.org/10.1111/cei.12546"]
[3,"Sporkova, A; Jichova, S; Huskova, Z; Kopkan, L; Nishiyama, A; Hwang, SH; Hammock, BD; Imig, JD; Kompanowska-Jezierska, E; Sadowski, J; Kramer, HJ; Cervenka, L","Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: Studies in Cyp1a1-Ren-2 transgenic rats","CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY","Article","2014/4112/1003-1013",2.4049999999999998,27.519110000000001,"1 z/ze 12",8.3333333333333329E-2,"ne","ne","WOS:000346726900008","http://dx.doi.org/10.1111/1440-1681.12310"]
[3,"Sediva, A; Horvath, R; Manasek, V; Gregorova, A; Plevova, P; Horackova, M; Tesarova, M; Toplak, N; Debeljak, M","Cluster of patients with Familial Mediterranean fever and heterozygous carriers of mutations in MEFV gene in the Czech Republic","CLINICAL GENETICS","Article","2014/866/564-569",3.6520000000000001,44.012349999999998,"3 z/ze 9",0.33333333333333331,"ano","ano","WOS:000345363900010","http://dx.doi.org/10.1111/cge.12323"]
[3,"Hradsky, O; Ohem, J; Mitrova, K; Durilova, M; Kotalova, R; Nevoral, J; Kolho, KL; Bronsky, J","Fecal Calprotectin Levels in Children is more tightly Associated with Histological than with Macroscopic Endoscopy Findings","CLINICAL LABORATORY","Article","2014/6012/1993-2000",1.0840000000000001,15.67356,"7 z/ze 8",0.875,"ano","ano","WOS:000347667300006","http://dx.doi.org/10.7754/Clin.Lab.2014.140203"]
[3,"Vicha, A; Taieb, D; Pacak, K","Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma","ENDOCRINE-RELATED CANCER","Review","2014/213/R261-R277",4.907,69.968549999999993,"1 z/ze 3",0.33333333333333331,"ne","ano","WOS:000344787700017","http://dx.doi.org/10.1530/ERC-13-0398"]
[3,"Drevinek, P","Burkholderla cepacla complex: epidemiology and diagnosis of infection in patients with cystic fibrosis","EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE","Article","2014/631/18-26",0.36099999999999999,10.557130000000001,"1 z/ze 1",1,"ano","ano","WOS:000343635100004","http://www.prolekare.cz/epidemiologie-clanek/bakterie-komplexu-burkholderia-cepacia-epidemiologie-a-diagnostika-infekci-u-pacientu-s-cystickou-fibrozou-48386"]
[3,"Krutova, M; Matejkova, J; Zajac, M; Hubacek, P; Nyc, O","Diagnosis of Clostridium difficile infections: Comparative study of two immuno enzyme assays with confirmation by PCR and culture followed by PCR ribotyping","EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE","Article","2014/632/99-102",0.36099999999999999,10.557130000000001,"5 z/ze 5",1,"ano","ano","WOS:000343635300005","http://www.prolekare.cz/epidemiologie-clanek/diagnostika-clostridium-difficile-infekci-porovnavaci-studie-dvou-imunoenzymatickych-metod-s-konfirmaci-pomo-49178"]
[3,"Chrenkova, V; Hubacek, P; Sedlacek, P; Riha, P; Kodetova, D; Bebrova, E","Post-mortem analysis of Candida albicans breakthrough infection during echinocandin treatment in haematopoietic stem cell transplant recipient","EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE","Article","2014/632/121-124",0.36099999999999999,10.557130000000001,"6 z/ze 6",1,"ano","ano","WOS:000343635300010","http://www.prolekare.cz/en/epidemiology-article/post-mortem-analysis-of-candida-albicans-breakthrough-infection-during-echinocandin-treatment-in-haematopoietic-stem-49183"]
[3,"Cho, JR; Koo, DL; Joo, EY; Seo, DW; Hong, SC; Jiruska, P; Hong, SB","Resection of individually identified high-rate high-frequency oscillations region is associated with favorable outcome in neocortical epilepsy","EPILEPSIA","Article","2014/5511/1872-1883",4.5839999999999996,88.467820000000003,"1 z/ze 7",0.14285714285714285,"ne","ne","WOS:000345227400030","http://dx.doi.org/10.1111/epi.12808"]
[3,"Rehulka, P; Dolezalova, I; Janousova, E; Tomasek, M; Marusic, P; Brazdil, M; Kuba, R","Ictal and postictal semiology in patients with bilateral temporal lobe epilepsy","EPILEPSY & BEHAVIOR","Article","2014/41/40-46",2.0609999999999999,21.82687,"2 z/ze 7",0.2857142857142857,"ne","ne","WOS:000346187700010","http://dx.doi.org/10.1016/j.yebeh.2014.09.033"]
[3,"Kubus, P; Vit, P; Gebauer, RA; Zaoral, L; Peichl, P; Fiala, M; Janousek, J","Long-term results of paediatric radiofrequency catheter ablation: a population-based study","EUROPACE","Article","2014/1612/1808-1813",3.05,36.341349999999998,"2 z/ze 7",0.2857142857142857,"ano","ano","WOS:000347104900022","http://dx.doi.org/10.1093/europace/euu087"]
[3,"Spacek, M; Fiedler, J; Suchanek, V; Veselka, J","Echocardiographic detection of myocardial crypts in hypertrophic cardiomyopathy: a first report in phenotype-positive patient","EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING","Editorial Material","2014/1510/1180-1180",3.669,44.357759999999999,"4 z/ze 4",1,"ano","ano","WOS:000345188700018","http://dx.doi.org/10.1093/ehjci/jeu087"]
[3,"Horak, P; Peppard, J; Sykora, J; Gala, TM","EAHP survey and European Statements of Hospital Pharmacy - can we achieve a perfect match?","EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE","Article","2014/215/291-293",0.47099999999999997,11.49446,"1 z/ze 4",0.25,"ano","ano","WOS:000346137200013","http://dx.doi.org/10.1136/ejhpharm-2014-000541"]
[3,"Bobek, V; Kolostova, K; Kucera, E","Circulating endometrial cells in peripheral blood","EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY","Article","2014/181/267-274",1.627,17.801130000000001,"1 z/ze 3",0.33333333333333331,"ano","ano","WOS:000343952000048","http://dx.doi.org/10.1016/j.ejogrb.2014.07.037"]
[3,"Witjes, JA; Babjuk, M; Gontero, P; Jacqmin, D; Karl, A; Kruck, S; Mariappan, P; Redorta, JP; Stenzl, A; van Velthoven, R; Zaak, D","Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations","EUROPEAN UROLOGY","Review","2014/665/863-871",12.48,305,"1 z/ze 11",9.0909090909090912E-2,"ne","ne","WOS:000344693500022","http://dx.doi.org/10.1016/j.eururo.2014.06.037"]
[3,"Lukas, J; Drabek, J; Dudesek, B; Vazan, P; Stranska, J; Jancik, S; Mackova, M; Syrucek, M; Lukas, D; Duskova, J; Dundr, P; Hintnausova, B; Jiskra, J","Correlation among the BRAF Gene Mutation Status, Clinicopathological Features of Primary Tumour, and Lymph Node Metastasizing of Papillary Thyroid Carcinoma","EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES","Article","2014/1225/268-272",1.76,16.439029999999999,"1 z/ze 13",7.6923076923076927E-2,"ne","ne","WOS:000346268000003","http://dx.doi.org/10.1055/s-0034-1372624"]
[3,"Fik, Z; Dvorankova, B; Kodet, O; Boucek, J; Betka, JA; Betka, J; Andre, S; Gabius, HJ; Snajdr, P; Smetana, K; Chovanec, M","Towards Dissecting Molecular Routes of Intercellular Communication in the Tumour Microenvironment: Phenotypic Plasticity of Stem Cell-Associated Markers in Co-culture (Carcinoma Cell/Fibroblast) Systems","FOLIA BIOLOGICA","Article","2014/605/205-212",1.167,15.888909999999999,"4 z/ze 11",0.36363636363636365,"ano","ano","WOS:000346234100001","http://fb.cuni.cz/file/5753/fb2014a0040.pdf"]
[3,"Krutova, M; Matejkova, J; Nyc, O","C-difficile ribotype 027 or 176?","FOLIA MICROBIOLOGICA","Article","2014/596/523-526",1.145,14.01282,"3 z/ze 3",1,"ano","ano","WOS:000343812600010","http://dx.doi.org/10.1007/s12223-014-0323-5"]
[3,"Robova, H; Halaska, MJ; Pluta, M; Skapa, P; Matecha, J; Lisy, J; Rob, L","Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer","GYNECOLOGIC ONCOLOGY","Article","2014/1352/213-216",3.6869999999999998,63.74212,"7 z/ze 7",1,"ano","ano","WOS:000345605200008","http://dx.doi.org/10.1016/j.ygyno.2014.08.021"]
[3,"Valerio, DG; Katsman-Kuipers, JE; Jansen, JH; Verboon, LJ; de Haas, V; Stary, J; Baruchel, A; Zimmermann, M; Pieters, R; Reinhardt, D; van den Heuvel-Eibrink, MM; Zwaan, CM","Mapping epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia","HAEMATOLOGICA","Letter","2014/998/E130-E132",5.8680000000000003,145.48339999999999,"1 z/ze 12",8.3333333333333329E-2,"ne","ne","WOS:000342834300002","http://dx.doi.org/10.3324/haematol.2013.094565"]
[3,"Materna, O; Kubus, P; Janousek, J","Right ventricular resynchronization in a child with hypoplastic left heart syndrome","HEART RHYTHM","Article","2014/1112/2303-2305",4.9180000000000001,69.004059999999996,"3 z/ze 3",1,"ano","ano","WOS:000345400500028","http://dx.doi.org/10.1016/j.hrthm.2014.09.001"]
[3,"Malikova, J; Fluck, CE","Novel Insight into Etiology, Diagnosis and Management of Primary Adrenal Insufficiency","HORMONE RESEARCH IN PAEDIATRICS","Review","2014/823/145-157",1.7130000000000001,21.858720000000002,"1 z/ze 2",0.5,"ne","ano","WOS:000345448500002","http://dx.doi.org/10.1159/000363107"]
[3,"Konecna, R; Nguyen, HV; Stanisavljevic, M; Blazkova, I; Krizkova, S; Vaculovicova, M; Stiborova, M; Eckschlager, T; Zitka, O; Adam, V; Kizek, R","Doxorubicin Encapsulation Investigated by Capillary Electrophoresis with Laser-Induced Fluorescence Detection","CHROMATOGRAPHIA","Article","2014/7721-22/1469-1476",1.37,15.24816,"1 z/ze 11",9.0909090909090912E-2,"ne","ne","WOS:000345004800008","http://dx.doi.org/10.1007/s10337-014-2733-6"]
[3,"Uhlik, J; Simunkova, P; Zaloudikova, M; Partlova, S; Jarkovsky, J; Vajner, L","Airway Wall Remodeling in Young and Adult Rats with Experimentally Provoked Bronchial Asthma","INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY","Article","2014/1644/289-300",2.4329999999999998,20.208680000000001,"5 z/ze 6",0.83333333333333337,"ano","ano","WOS:000343614500005","http://dx.doi.org/10.1159/000366278"]
[3,"Veselka, J; Spacek, M; Hajek, P; Horvath, M; Stechovsky, C; Zimolova, P","Impact of single versus double vessel carotid disease on long-term survival in patients treated with carotid stenting","INTERNATIONAL JOURNAL OF CARDIOLOGY","Letter","2014/1763/1299-1300",6.1749999999999998,122.31019999999999,"6 z/ze 6",1,"ano","ano","WOS:000343893300204","http://dx.doi.org/10.1016/j.ijcard.2014.07.165"]
[3,"Honek, J; Sramek, M; Sefc, L; Januska, J; Fiedler, J; Horvath, M; Tomek, A; Novotny, S; Honek, T; Veselka, J","Effect of conservative dive profiles on the occurrence of venous and arterial bubbles in divers with a patent foramen ovale: A pilot study","INTERNATIONAL JOURNAL OF CARDIOLOGY","Letter","2014/1763/1001-1002",6.1749999999999998,122.31019999999999,"7 z/ze 10",0.7,"ano","ano","WOS:000343893300092","http://dx.doi.org/10.1016/j.ijcard.2014.04.218"]
[3,"Im, TS; Chun, EJ; Lee, MS; Adla, T; Kim, JA; Choi, SI","Grade-response relationship between blood pressure and severity of coronary atherosclerosis in asymptomatic adults: assessment with coronary CT angiography","INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING","Article","2014/30/105-112",2.3220000000000001,32.156730000000003,"1 z/ze 6",0.16666666666666666,"ne","ne","WOS:000345097400004","http://dx.doi.org/10.1007/s10554-014-0522-9"]
[3,"Cegan, M; Kolostova, K; Matkowski, R; Broul, M; Schraml, J; Fiutowski, M; Bobek, V","In vitro culturing of viable circulating tumor cells of urinary bladder cancer","INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY","Article","2014/710/7164-7171",1.7829999999999999,17.31175,"1 z/ze 7",0.14285714285714285,"ano","ne","WOS:000345135900094","http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230057/"]
[3,"Stiborova, M; Poljakova, J; Mrizova, I; Borek-Dohalska, L; Eckschlager, T; Adam, V; Kizek, R; Frei, E","Expression Levels of Enzymes Metabolizing an Anticancer Drug Ellipticine Determined by Electromigration Assays Influence its Cytotoxicity to Cancer Cells - A Comparative Study","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE","Article","2014/910/5675-5689",1.956,21.222239999999999,"1 z/ze 8",0.125,"ne","ne","WOS:000345261700024","http://www.electrochemsci.org/papers/vol9/91005675.pdf"]
[3,"Novotna, B; Koblizek, V; Zatloukal, J; Plutinsky, M; Hejduk, K; Zbozinkova, Z; Jarkovsky, J; Sobotik, O; Dvorak, T; Safranek, P","Czech multicenter research database of severe COPD","INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE","Article","2014/9/1265-1274","není v JCR",10,"1 z/ze 10",0.1,"ne","ano","WOS:000344926200001","http://dx.doi.org/10.2147/COPD.S71828"]
[3,"Tomek, A; Urbanova, B; Hort, J","Utility of Transcranial Ultrasound in Predicting Alzheimer's Disease Risk","JOURNAL OF ALZHEIMERS DISEASE","Review","2014/42/S365-S374",3.6120000000000001,37.659829999999999,"3 z/ze 3",1,"ano","ano","WOS:000343893000005","http://dx.doi.org/10.3233/JAD-141803"]
[3,"Rubinova, E; Nikolai, T; Markova, H; Siffelova, K; Laczo, J; Hort, J; Vyhnalek, M","Clock Drawing Test and the diagnosis of amnestic mild cognitive impairment: Can more detailed scoring systems do the work?","JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY","Article","2014/3610/1076-1083",2.1579999999999999,26.129059999999999,"4 z/ze 7",0.5714285714285714,"ne","ne","WOS:000346842300007","http://dx.doi.org/10.1080/13803395.2014.977233"]
[3,"Ruemmele, FM; Veres, G; Kolho, KL; Griffiths, A; Levine, A; Escher, JC; Dias, JA; Barabino, A; Braegger, CP; Bronsky, J; Buderus, S; Martin-de-Carpi, J; De Ridder, L; Fagerberg, UL; Hugot, JP; Kierkus, J; Kolacek, S; Koletzkou, S; Lionetti, P; Miele, E; Lopez, VMN; Paerregaard, A; Russell, RK; Serban, DE; Shaoul, R; Van Rheenen, P; Veereman, G; Weiss, B; Wilson, D; Dignass, A; Eliakim, A; Winter, H; Turner, D","Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease","JOURNAL OF CROHNS & COLITIS","Article","2014/810/1179-1207",3.5619999999999998,49.832239999999999,"1 z/ze 33",3.0303030303030304E-2,"ne","ne","WOS:000344128100004","http://dx.doi.org/10.1016/j.crohns.2014.04.005"]
[3,"McDaniel, D; Fritz, K; Machovcova, A; Bernardy, J","A Focused Monopolar Radiofrequency Causes Apoptosis: A Porcine Model","JOURNAL OF DRUGS IN DERMATOLOGY","Article","2014/1311/1336-1340",1.32,18.931190000000001,"1 z/ze 4",0.25,"ne","ne","WOS:000344976800008","http://www.ncbi.nlm.nih.gov/pubmed/25607699"]
[3,"Davies, KA; Longshaw, CM; Davis, GL; Bouza, E; Barbut, F; Barna, Z; Delmee, M; Fitzpatrick, F; Ivanova, K; Kuijper, E; Macovei, IS; Mentula, S; Mastrantonio, P; von Muller, L; Oleastro, M; Petinaki, E; Pituch, H; Noren, T; Novakova, E; Nyc, O; Rupnik, M; Schmid, D; Wilcox, MH","Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID)","LANCET INFECTIOUS DISEASES","Article","2014/1412/1208-1219",19.446000000000002,305,"1 z/ze 23",4.3478260869565216E-2,"ne","ne","WOS:000345720200033","http://dx.doi.org/10.1016/S1473-3099(14)70991-0"]
[3,"McKone, EF; Borowitz, D; Drevinek, P; Griese, M; Konstan, MW; Wainwright, C; Ratjen, F; Sermet-Gaudelus, I; Plant, B; Munck, A; Jiang, Y; Gilmartin, G; Davies, JC","Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","LANCET RESPIRATORY MEDICINE","Article","2014/211/902-910","není v JCR",10,"1 z/ze 13",7.6923076923076927E-2,"ne","ne","WOS:000344909400016","http://dx.doi.org/10.1016/52213-2600(14)70218-8"]
[3,"Hlavac, V; Brynychova, V; Vaclavikova, R; Ehrlichova, M; Vrana, D; Pecha, V; Trnkova, M; Kodet, R; Mrhalova, M; Kubackova, K; Gatek, J; Vazan, P; Soucek, P","The Role of Cytochromes P450 and Aldo-Keto Reductases in Prognosis of Breast Carcinoma Patients","MEDICINE","Article","2014/9328/-",4.867,113.82810000000001,"3 z/ze 13",0.23076923076923078,"ne","ne","WOS:000346762200020","http://dx.doi.org/10.1097/MD.0000000000000255"]
[3,"Lizcova, L; Zemanova, Z; Lhotska, H; Zuna, J; Hovorkova, L; Mejstrikova, E; Malinova, E; Rabasova, J; Raska, I; Sramkova, L; Stary, J; Michalova, K","An unusual case of high hyperdiploid childhood ALL with cryptic BCR/ABL1 rearrangement","MOLECULAR CYTOGENETICS","Article","2014/7/-",2.6619999999999999,25.808520000000001,"5 z/ze 12",0.41666666666666669,"ne","ne","WOS:000344119500001","http://dx.doi.org/10.1186/s13039-014-0072-9"]
[3,"Scelo, G; Riazalhosseini, Y; Greger, L; Letourneau, L; Gonzalez-Porta, M; Wozniak, MB; Bourgey, M; Harnden, P; Egevad, L; Jackson, SM; Karimzadeh, M; Arseneault, M; Lepage, P; How-Kit, A; Daunay, A; Renault, V; Blanche, H; Tubacher, E; Sehmoun, J; Viksna, J; Celms, E; Opmanis, M; Zarins, A; Vasudev, NS; Seywright, M; Abedi-Ardekani, B; Carreira, C; Selby, PJ; Cartledge, JJ; Byrnes, G; Zavadil, J; Su, J; Holcatova, I; Brisuda, A; Zaridze, D; Moukeria, A; Foretova, L; Navratilova, M; Mates, D; Jinga, V; Artemov, A; Nedoluzhko, A; Mazur, A; Rastorguev, S; Boulygina, E; Heath, S; Gut, M; Bihoreau, MT; Lechner, D; Foglio, M; Gut, IG; Skryabin, K; Prokhortchouk, E; Cambon-Thomsen, A; Rung, J; Bourque, G; Brennan, P; Tost, J; Banks, RE; Brazma, A; Lathrop, GM","Variation in genomic landscape of clear cell renal cell carcinoma across Europe","NATURE COMMUNICATIONS","Article","2014/5/-",10.742000000000001,182.18979999999999,"1 z/ze 61",1.6393442622950821E-2,"ne","ne","WOS:000343980300009","http://dx.doi.org/10.1038/ncomms6135"]
[3,"Mannil, M; Solari, A; Leha, A; Pelayo-Negro, AL; Berciano, J; Schlotter-Weigel, B; Walter, MC; Rautenstrauss, B; Schnizer, TJ; Schenone, A; Seeman, P; Kadian, C; Schreiber, O; Angarita, NG; Fabrizi, GM; Gemignani, F; Padua, L; Santoro, L; Quattrone, A; Vita, G; Calabrese, D; Young, P; Laura, M; Haberlova, J; Mazanec, R; Paulus, W; Beissbarth, T; Shy, ME; Reilly, MM; Pareyson, D; Sereda, MW","Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients","NEUROMUSCULAR DISORDERS","Article","2014/2411/1003-1017",3.1339999999999999,34.522069999999999,"2 z/ze 31",6.4516129032258063E-2,"ne","ne","WOS:000345733600011","http://dx.doi.org/10.1016/j.nmd.2014.06.431"]
[3,"Dudova, I; Markova, D; Kasparova, M; Zemankova, J; Beranova, S; Urbanek, T; Hrdlicka, M","Comparison of three screening tests for autism in preterm children with birth weights less than 1,500 grams","NEUROPSYCHIATRIC DISEASE AND TREATMENT","Article","2014/10/2201-2208",2.1539999999999999,24.68618,"4 z/ze 7",0.5714285714285714,"ano","ano","WOS:000344930800001","http://dx.doi.org/10.2147/NDT.S72921"]
[3,"Bloy, N; Pol, J; Aranda, F; Eggermont, A; Cremer, I; Fridman, WH; Fucikova, J; Galon, J; Tartour, E; Spisek, R; Dhodapkar, MV; Zitvogel, L; Kroemer, G; Galluzzi, L","Trial watch: Dendritic cell-based anticancer therapy","ONCOIMMUNOLOGY","Review","2014/311/-",6.2830000000000004,100.28919999999999,"2 z/ze 14",0.14285714285714285,"ne","ne","WOS:000346923100008","http://dx.doi.org/10.4161/21624011.2014.963424"]
[3,"Kepp, O; Senovilla, L; Vitale, I; Vacchelli, E; Adjemian, S; Agostinis, P; Apetoh, L; Aranda, F; Barnaba, V; Bloy, N; Bracci, L; Breckpot, K; Brough, D; Buque, A; Castro, MG; Cirone, M; Colombo, MI; Cremer, I; Demaria, S; Dini, L; Eliopoulos, AG; Faggioni, A; Formenti, SC; Fucikova, J; Gabriele, L; Gaipl, US; Galon, J; Garg, A; Ghiringhelli, F; Giese, NA; Guo, ZS; Hemminki, A; Herrmann, M; Hodge, JW; Holdenrieder, S; Honeychurch, J; Hu, HM; Huang, X; Illidge, TM; Kono, K; Korbelik, M; Krysko, DV; Loi, S; Lowenstein, PR; Lugli, E; Ma, YT; Madeo, F; Manfredi, AA; Martins, I; Mavilio, D; Menger, L; Merendino, N; Michaud, M; Mignot, G; Mossman, KL; Multhoff, G; Oehler, R; Palombo, F; Panaretakis, T; Pol, J; Proietti, E; Ricci, JE; Riganti, C; Rovere-Querini, P; Rubartelli, A; Sistigu, A; Smyth, MJ; Sonnemann, J; Spisek, R; Stagg, J; Sukkurwala, AQ; Tartour, E; Thorburn, A; Thorne, SH; Vandenabeele, P; Velotti, F; Workenhe, ST; Yang, HN; Zong, WX; Zitvogel, L; Kroemer, G; Galluzzi, L","Consensus guidelines for the detection of immunogenic cell death","ONCOIMMUNOLOGY","Review","2014/39/-",6.2830000000000004,100.28919999999999,"2 z/ze 82",2.4390243902439025E-2,"ne","ne","WOS:000346922400019","http://dx.doi.org/10.4161/21624011.2014.955691"]
[3,"Adkins, I; Fucikova, J; Garg, AD; Agostinis, P; Spisek, R","Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy","ONCOIMMUNOLOGY","Article","2014/312/-",6.2830000000000004,100.28919999999999,"3 z/ze 5",0.6,"ano","ano","WOS:000347679800010","http://dx.doi.org/10.4161/21624011.2014.968434"]
[3,"Honkova, L; Uhlik, J; Berankova, K; Svobodova, T; Pohunek, P","Epithelial basement membrane thickening is related to TGF-Beta 1 expression in children with chronic respiratory diseases","PEDIATRIC ALLERGY AND IMMUNOLOGY","Article","2014/256/593-599",3.859,68.721649999999997,"5 z/ze 5",1,"ano","ano","WOS:000344872400011","http://dx.doi.org/10.1111/pai.12275"]
[3,"Mazurek, H; Chiron, R; Kucerova, T; Geidel, C; Bolbas, K; Chuchalin, A; Blanco-Aparicio, M; Santoro, D; Varoli, G; Zibellini, M; Cicirello, HG; Antipkin, YG","Long-Term Efficacy and Safety of Aerosolized Tobramycin 300 mg/4 ml in Cystic Fibrosis","PEDIATRIC PULMONOLOGY","Article","2014/4911/1076-1089",2.2970000000000002,32.21293,"1 z/ze 12",8.3333333333333329E-2,"ne","ne","WOS:000344175400005","http://dx.doi.org/10.1002/ppul.22989"]
[3,"Moorthy, LN; Roy, E; Kurra, V; Peterson, MGE; Hassett, AL; Lehman, TJA; Scot, C; El-Ghoneimy, D; Saad, S; El Feky, R; Al-Mayouf, S; Dolezalova, P; Malcova, H; Herlin, T; Nielsen, S; Wulffraat, N; van Royen, A; Marks, SD; Belot, A; Brunner, J; Huemer, C; Foeldvari, I; Horneff, G; Saurenman, T; Schroeder, S; Pratsidou-Gertsi, P; Trachana, M; Uziel, Y; Aggarwal, A; Constantin, T; Cimaz, R; Giani, T; Cantarini, L; Falcini, F; Manzoni, SM; Ravelli, A; Rigante, D; Zulian, F; Miyamae, T; Yokota, S; Sato, J; Magalhaes, CS; Len, CA; Appenzeller, S; Knupp, SO; Rodrigues, MC; Sztajnbok, F; de Almeida, RG; de Jesus, AA; Campos, LMD; Silva, C; Lazar, C; Susic, G; Avcin, T; Cuttica, R; Burgos-Vargas, R; Faugier, E; Anton, J; Modesto, C; Vazquez, L; Barillas, L; Barinstein, L; Sterba, G; Maldonado, I; Ozen, S; Kasapcopur, O; Demirkaya, E; Benseler, S","Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration","PEDIATRIC RHEUMATOLOGY","Article","2014/12/-",1.6220000000000001,20.174489999999999,"1 z/ze 68",1.4705882352941176E-2,"ne","ne","WOS:000346520700001","http://dx.doi.org/10.1186/1546-0096-12-49"]
[3,"Cooper, DN; Brand, A; Dolzan, V; Fortina, P; Innocenti, F; Lee, MTM; Macek, M; Al-Mulla, F; Prainsack, B; Squassina, A; Vayena, E; Vozikis, A; Williams, MS; Patrinos, GP","Bridging genomics research between developed and developing countries: the Genomic Medicine Alliance","PERSONALIZED MEDICINE","Article","2014/117/615-623",1.1319999999999999,14.81495,"1 z/ze 14",7.1428571428571425E-2,"ne","ne","WOS:000344931400002","http://dx.doi.org/10.2217/pme.14.59"]
[3,"Hromadnikova, I; Kotlabova, K; Hympanova, L; Doucha, J; Krofta, L","First Trimester Screening of Circulating C19MC microRNAs Can Predict Subsequent Onset of Gestational Hypertension","PLOS ONE","Article","2014/912/-",3.5339999999999998,88.41883,"1 z/ze 5",0.2,"ne","ne","WOS:000346607100007","http://dx.doi.org/10.1371/journal.pone.0113735"]
[3,"Petrovova, M; Tkadlec, J; Dvoracek, L; Streitova, E; Licha, I","NAD(P)H-Hydrate Dehydratase- A Metabolic Repair Enzyme and Its Role in Bacillus subtilis Stress Adaptation","PLOS ONE","Article","2014/911/-",3.5339999999999998,88.41883,"2 z/ze 5",0.4,"ne","ne","WOS:000347709300076","http://dx.doi.org/10.1371/journal.pone.0112590"]
[3,"Fronkova, E; Klocperk, A; Svaton, M; Novakova, M; Kotrova, M; Kayserova, J; Kallna, T; Keslova, P; Votava, F; Vinohradska, H; Freiberger, T; Mejstrikova, E; Trka, J; Sediva, A","The TREC/KREC Assay for the Diagnosis and Monitoring of Patients with DiGeorge Syndrome","PLOS ONE","Article","2014/912/-",3.5339999999999998,88.41883,"11 z/ze 14",0.7857142857142857,"ano","ano","WOS:000346907600065","http://dx.doi.org/10.1371/journal.pone.0114514"]
[3,"Forostyak, S; Homola, A; Turnovcova, K; Svitil, P; Jendelova, P; Sykova, E","Intrathecal Delivery of Mesenchymal Stromal Cells Protects the Structure of Altered Perineuronal Nets in SOD1 Rats and Amends the Course of ALS","STEM CELLS","Article","2014/3212/3163-3172",7.133,120.5484,"6 z/ze 6",1,"ano","ano","WOS:000345593700012","http://dx.doi.org/10.1002/stem.1812"]
[3,"Malikova, H; Kramska, L; Vojtech, Z; Liscak, R; Sroubek, J; Lukavsky, J; Druga, R","Different Surgical Approaches for Mesial Temporal Epilepsy: Resection Extent, Seizure, and Neuropsychological Outcomes","STEREOTACTIC AND FUNCTIONAL NEUROSURGERY","Article","2014/926/372-380",1.4770000000000001,18.111409999999999,"1 z/ze 7",0.14285714285714285,"ne","ne","WOS:000346276500006","http://dx.doi.org/10.1159/000366003"]
[3,"Vickova, M; Hancarova, M; Drabova, J; Slamova, Z; Koudova, M; Alanova, R; Mannik, K; Kurg, A; Sedlacek, Z","Monozygotic Twins with 17q21.31 Microdeletion Syndrome","TWIN RESEARCH AND HUMAN GENETICS","Article","2014/175/405-410",1.9179999999999999,21.746310000000001,"7 z/ze 9",0.77777777777777779,"ano","ano","WOS:000343964200008","http://dx.doi.org/10.1017/thg.2014.29"]
[3,"Rieken, M; Xylinas, E; Kluth, L; Crivelli, JJ; Chrystal, J; Faison, T; Lotan, Y; Karakiewicz, PI; Sun, M; Fajkovic, H; Babjuk, M; Bachmann, A; Scherr, DS; Shariat, SF","Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma","UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS","Article","2014/321/-",3.363,49.029150000000001,"1 z/ze 14",7.1428571428571425E-2,"ne","ne","WOS:000347243300098","http://dx.doi.org/10.1016/j.urolonc.2013.07.006"]
[3,"Vesela, P; Tonar, Z; Salek, D; Vokurka, S; Trneny, M; Kodet, R; Moulis, M; Kasparova, P; Vernerova, Z; Velenska, Z; Stritesky, J; Michal, M; Boudova, L","Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases","VIRCHOWS ARCHIV","Article","2014/4655/587-597",2.56,42.057929999999999,"1 z/ze 13",7.6923076923076927E-2,"ne","ne","WOS:000344399200011","http://dx.doi.org/10.1007/s00428-014-1632-4"]
[3,"Bobek, V; Gurlich, R; Eliasova, P; Kolostova, K","Circulating tumor cells in pancreatic cancer patients: Enrichment and cultivation","WORLD JOURNAL OF GASTROENTEROLOGY","Article","2014/2045/17163-17170",2.4329999999999998,26.721530000000001,"1 z/ze 4",0.25,"ano","ano","WOS:000346050700038","http://dx.doi.org/10.3748/wjg.v20.i45.17163"]

{"sheet":"AKTUALNI - 2014","index":1,"n_rows":365,"n_cols":60,"rows_kept":365,"cut":false,"hidden":false,"merged":[]}
["INFO: podkladový export z WoS pro publikační okénko, resp. dále i OBD"]
["PT","AU","BA","BE","GP","AF","BF","CA","TI","SO","SE","BS","LA","DT","CT","CY","CL","SP","HO","DE","ID","AB","C1","RP","EM","RI","OI","FU","FX","CR","NR","TC","Z9","PU","PI","PA","SN","EI","BN","J9","JI","PD","PY","VL","IS","PN","SU","SI","MA","BP","EP","AR","DI","D2","PG","WC","SC","GA","UT","PM"]
["J","Novakova, M; Sumova, A",null,null,null,"Novakova, Marta; Sumova, Alena",null,null,"New methods to assess circadian clocks in humans","INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY",null,null,"English","Review",null,null,null,null,null,"Circadian; Clock; Human; Methods","BLOOD MONONUCLEAR-CELLS; CORE BODY-TEMPERATURE; HAIR FOLLICLE CELLS; GENE-EXPRESSION; SUPRACHIASMATIC NUCLEUS; PLASMA MELATONIN; HUMAN-LEUKOCYTES; MORNINGNESS-EVENINGNESS; ALTERED EXPRESSION; ACTION SPECTRUM","Proper function of the circadian system seems crucial for human health. New advances in methods for assessment of the functional state of the human circadian system facilitate our understanding of the relationship between the disruption of the circadian system and various diseases. Based on the results of such studies, new directions for the diagnosis and treatment of diseases emerge. This communication aims to summarize current methods for evaluating the human circadian system in the laboratory as well as in field studies. The advantages and limitations of the current methods and various approaches used for both in vivo and in vitro assessment of the human circadian system are discussed.","[Novakova, Marta] Charles Univ Prague, Fac Med 2, Prague 15006, Czech Republic; [Novakova, Marta; Sumova, Alena] Acad Sci Czech Republic, Inst Physiol, Dept Neurohumoral Regulat, Vvi, CR-14220 Prague, Czech Republic","Sumova, A (reprint author), Acad Sci Czech Republic, Inst Physiol, Dept Neurohumoral Regulat, Vvi, Videnska 1083, CR-14220 Prague, Czech Republic.","sumova@biomed.cas.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NT11474-4/2010]; Grant Agency of Charles University in Prague [22810, AVOZ50110509, RVO: 7985823]","The study was supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic, grant no. NT11474-4/2010; the Grant Agency of Charles University in Prague, no. 22810; and research project nos. AVOZ50110509 and RVO: 7985823. The authors declare that they have no conflicts of interests.",null,90,0,0,"NATL INST SCIENCE COMMUNICATION-NISCAIR","NEW DELHI","DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA","0019-5189","0975-1009",null,"INDIAN J EXP BIOL","Indian J. Exp. Biol.","MAY",2014,52,5,null,null,null,null,404,412,null,null,null,9,"Biology","Life Sciences & Biomedicine - Other Topics","AG7WH","WOS:000335629000005"]
["J","Lipska, BS; Ranchin, B; Iatropoulos, P; Gellermann, J; Melk, A; Ozaltin, F; Caridi, G; Seeman, T; Tory, K; Jankauskiene, A; Zurowska, A; Szczepanska, M; Wasilewska, A; Harambat, J; Trautmann, A; Peco-Antic, A; Borzecka, H; Moczulska, A; Saeed, B; Bogdanovic, R; Kalyoncu, M; Simkova, E; Erdogan, O; Vrljicak, K; Teixeira, A; Azocar, M; Schaefer, F",null,null,null,"Lipska, Beata S.; Ranchin, Bruno; Iatropoulos, Paraskevas; Gellermann, Jutta; Melk, Anette; Ozaltin, Fatih; Caridi, Gianluca; Seeman, Tomas; Tory, Kalman; Jankauskiene, Augustina; Zurowska, Aleksandra; Szczepanska, Maria; Wasilewska, Anna; Harambat, Jerome; Trautmann, Agnes; Peco-Antic, Amira; Borzecka, Halina; Moczulska, Anna; Saeed, Bassam; Bogdanovic, Radovan; Kalyoncu, Mukaddes; Simkova, Eva; Erdogan, Ozlem; Vrljicak, Kristina; Teixeira, Ana; Azocar, Marta; Schaefer, Franz",null,"PodoNet Consortium","Genotype-phenotype associations in WT1 glomerulopathy","KIDNEY INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"Denys-Drash syndrome; diffuse mesangial sclerosis; focal segmental glomerulosclerosis; Frasier syndrome; steroid-resistant nephrotic syndrome; WT1","DENYS-DRASH SYNDROME; RESISTANT NEPHROTIC SYNDROME; SUPPRESSOR GENE WT1; SPLICE-SITE MUTATIONS; WILMS-TUMOR; STEROID-RESISTANT; FRASIER-SYNDROME; BINDING ACTIVITY; PROTEIN WT1; EXPRESSION","WT1 mutations cause a wide spectrum of renal and extrarenal manifestations. Here we evaluated disease prevalence, phenotype spectrum, and genotype-phenotype correlations of 61 patients with WT1-related steroid-resistant nephrotic syndrome relative to 700 WT1-negative patients, all with steroid-resistant nephrotic syndrome. WT1 patients more frequently presented with chronic kidney disease and hypertension at diagnosis and exhibited more rapid disease progression. Focal segmental glomerulosclerosis was equally prevalent in both cohorts, but diffuse mesangial sclerosis was largely specific for WT1 disease and was present in 34% of cases. Sex reversal and/or urogenital abnormalities (52%), Wilms tumor (38%), and gonadoblastoma (5%) were almost exclusive to WT1 disease. Missense substitutions affecting DNA-binding residues were associated with diffuse mesangial sclerosis (74%), early steroid-resistant nephrotic syndrome onset, and rapid progression to ESRD. Truncating mutations conferred the highest Wilms tumor risk (78%) but typically late-onset steroid-resistant nephrotic syndrome. Intronic (KTS) mutations were most likely to present as isolated steroid-resistant nephrotic syndrome (37%) with a median onset at an age of 4.5 years, focal segmental glomerulosclerosis on biopsy, and slow progression (median ESRD age 13.6 years). Thus, there is a wide range of expressivity, solid genotype-phenotype associations, and a high risk and significance of extrarenal complications in WT1-associated nephropathy. We suggest that all children with steroid-resistant nephrotic syndrome undergo WT1 gene screening.","[Lipska, Beata S.] Med Univ Gdansk, Dept Biol & Genet, PL-80211 Gdansk, Poland; [Lipska, Beata S.; Trautmann, Agnes; Schaefer, Franz] Heidelberg Univ, Ctr Pediat & Adolescent Med, Div Pediat Nephrol, Heidelberg, Germany; [Ranchin, Bruno] Hosp Civils Lyon, Hop Femme Mere Enfant, Ctr Reference Malad Renales Rares, Serv Nephrol Pediat, Bron, France; [Ranchin, Bruno] Univ Lyon, Bron, France; [Iatropoulos, Paraskevas] Clin Res Ctr Rare Dis Aldo & Cele Dacco, IRCCS Ist Ric Farmacol Mario Negri, Bergamo, Italy; [Gellermann, Jutta] Charite Campus Virchow Klinikum, Klin Pediat Nephrol, Berlin, Germany; [Melk, Anette] MHH Childrens Hosp, Hannover, Germany; [Ozaltin, Fatih] Hacettepe Univ, Fac Med, Dept Pediat Nephrol & Rheumatol, TR-06100 Ankara, Turkey; [Ozaltin, Fatih] Hacettepe Univ, Fac Med, Nephrogenet Lab, TR-06100 Ankara, Turkey; [Caridi, Gianluca] Ist Giannina Gaslini, Lab Fisiopatol Uremia, I-16148 Genoa, Italy; [Caridi, Gianluca] Ist Giannina Gaslini, UOC Nefrol Dialisi & Trapianto, I-16148 Genoa, Italy; [Seeman, Tomas] Univ Hosp Motol, Dept Pediat 1, Prague, Czech Republic; [Seeman, Tomas] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Tory, Kalman] Semmelweis Univ, Dept Pediat 1, H-1085 Budapest, Hungary; [Jankauskiene, Augustina] Vilnius Univ, Vilnius, Lithuania; [Zurowska, Aleksandra] Med Univ Gdansk, Dept Paediat Nephrol & Hypertens, Gdansk, Poland; [Szczepanska, Maria] Med Univ Silesia, Dept & Clin Pediat, Dialysis Div Children, Zabrze, Poland; [Wasilewska, Anna] Univ Bialystok, Dept Pediat Nephrol, Bialystok, Poland; [Harambat, Jerome] Ctr Hosp Univ Bordeaux, Ctr Reference Malad Renales Rares Sud Quest, Serv Pediat, Bordeaux, France; [Peco-Antic, Amira] Univ Childrens Hosp, Div Pediat Nephrol, Belgrade, Serbia; [Borzecka, Halina] Med Univ Lublin, Lublin, Poland; [Moczulska, Anna] Jagiellonian Univ, Coll Med, Dept Pediat Nephrol, Krakow, Poland; [Saeed, Bassam] Kidney Hosp, Dept Pediat Nephrol, Damascus, Syria; [Bogdanovic, Radovan] Inst Mother & Child Healthcare Serbia, Dept Nephrol, Belgrade, Serbia; [Kalyoncu, Mukaddes] Karadeniz Tech Univ, Fac Med, Pediat Nephrol Dept, Trabzon, Turkey; [Simkova, Eva] Dubai Hosp, Dept Paediat, Dubai, U Arab Emirates; [Erdogan, Ozlem] Dr Sami Ulus Matern & Childrens Hosp, Dept Pediat Nephrol, Ankara, Turkey; [Vrljicak, Kristina] Univ Zagreb, Dept Pediat, Div Nephrol, Zagreb Univ Hosp Ctr, Zagreb 41000, Croatia; [Teixeira, Ana] Univ Childrens Hosp, Oporto, Portugal; [Azocar, Marta] Univ Chile, Fac Med, Unidad Nefrol Infantil, Hosp Luis Calvo Mackenna, Santiago 7, Chile","Lipska, BS (reprint author), Med Univ Gdansk, Dept Biol & Genet, Debinki St 1, PL-80211 Gdansk, Poland.","b.lipska@gumed.edu.pl",null,null,"E-Rare (PodoNet project); Polish Ministry of Science and Education [N402631840]; German Research Foundation [477/11-1]; Scientific and Technological Research Council of Turkey [108S417]; Hacettepe University Infrastructure Projects [06A101008, 011A101003]; Bolyai Janos research fellowship of the Hungarian Academy of Sciences","This study has been performed within the frames of the PodoNet Consortium (Supplementary Material Si online). This work has been financed by E-Rare (PodoNet project), the 7th Framework Programme (EURenOmics, grant 2012-305608), the Polish Ministry of Science and Education (grant N402631840), and the German Research Foundation (Scha 477/11-1). FO was supported by the Scientific and Technological Research Council of Turkey (grant 108S417) and by the Hacettepe University Infrastructure Projects (grants 06A101008 and 011A101003). KT was supported by a Bolyai Janos research fellowship of the Hungarian Academy of Sciences. We are grateful to M Koczkowska from the Department of Biology and Genetics at Medical University of Gdansk, Poland, for help with the array-CGH analyses.",null,31,0,0,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","0085-2538","1523-1755",null,"KIDNEY INT","Kidney Int.","MAY",2014,85,5,null,null,null,null,1169,1178,null,"10.1038/ki.2013.519",null,10,"Urology & Nephrology","Urology & Nephrology","AG9BJ","WOS:000335713300025"]
["J","Castinetti, F; Qi, XP; Walz, MK; Maia, AL; Sanso, G; Peczkowska, M; Hasse-Lazar, K; Links, TP; Dvorakova, S; Toledo, RA; Mian, C; Bugalho, MJ; Wohllk, N; Kollyukh, O; Canu, L; Loli, P; Bergmann, SR; Costa, JB; Makay, O; Patocs, A; Pfeifer, M; Shah, NS; Cuny, T; Brauckhoff, M; Bausch, B; von Dobschuetz, E; Letizia, C; Barczynski, M; Alevizaki, MK; Czetwertynska, M; Ugurlu, MU; Valk, G; Plukker, JTM; Sartorato, P; Siqueira, DR; Barontini, M; Szperl, M; Jarzab, B; Verbeek, HHG; Zelinka, T; Vlcek, P; Toledo, SPA; Coutinho, FL; Mannelli, M; Recasens, M; Demarquet, L; Petramala, L; Yaremchuk, S; Zabolotnyi, D; Schiavi, F; Opocher, G; Racz, K; Januszewicz, A; Weryha, G; Henry, JF; Brue, T; Conte-Devolx, B; Eng, C; Neumann, HPH",null,null,null,"Castinetti, Frederic; Qi, Xiao-Ping; Walz, Martin K.; Maia, Ana Luiza; Sanso, Gabriela; Peczkowska, Mariola; Hasse-Lazar, Kornelia; Links, Thera P.; Dvorakova, Sarka; Toledo, Rodrigo A.; Mian, Caterina; Bugalho, Maria Joao; Wohllk, Nelson; Kollyukh, Oleg; Canu, Letizia; Loli, Paola; Bergmann, Simona R.; Costa, Josefina Biarnes; Makay, Ozer; Patocs, Attila; Pfeifer, Marija; Shah, Nalini S.; Cuny, Thomas; Brauckhoff, Michael; Bausch, Birke; von Dobschuetz, Ernst; Letizia, Claudio; Barczynski, Marcin; Alevizaki, Maria K.; Czetwertynska, Malgorzata; Ugurlu, M. Umit; Valk, Gerlof; Plukker, John T. M.; Sartorato, Paola; Siqueira, Debora R.; Barontini, Marta; Szperl, Malgorzata; Jarzab, Barbara; Verbeek, Hans H. G.; Zelinka, Tomas; Vlcek, Petr; Toledo, Sergio P. A.; Coutinho, Flavia L.; Mannelli, Massimo; Recasens, Monica; Demarquet, Lea; Petramala, Luigi; Yaremchuk, Svetlana; Zabolotnyi, Dmitry; Schiavi, Francesca; Opocher, Giuseppe; Racz, Karoly; Januszewicz, Andrzej; Weryha, Georges; Henry, Jean-Francois; Brue, Thierry; Conte-Devolx, Bernard; Eng, Charis; Neumann, Hartmut P. H.",null,null,"Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study","LANCET ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"MEDULLARY-THYROID CARCINOMA; RET PROTOONCOGENE; GERMLINE MUTATIONS; DISEASE; 2A; MANAGEMENT","Background The prevention of medullary thyroid cancer in patients with multiple endocrine neoplasia type 2 syndrome has demonstrated the ability of molecular diagnosis and prophylactic surgery to improve patient outcomes. However, the other major neoplasia associated with multiple endocrine neoplasia type 2, phaeochromocytoma, is not as well characterised in terms of occurrence and treatment outcomes. In this study, we aimed to systematically characterise the outcomes of management of phaeochromocytoma associated with multiple endocrine neoplasia type 2. Methods This multinational observational retrospective population-based study compiled data on patients with multiple endocrine neoplasia type 2 from 30 academic medical centres across Europe, the Americas, and Asia. Patients were included if they were carriers of germline pathogenic mutations of the RET gene, or were first-degree relatives with histologically proven medullary thyroid cancer and phaeochromocytoma. We gathered clinical information about patients' RET genotype, type of treatment for phaeochromocytoma (ie, unilateral or bilateral operations as adrenalectomy or adrenal-sparing surgery, and as open or endoscopic operations), and postoperative outcomes (adrenal function, malignancy, and death). The type of surgery was decided by each investigator and the timing of surgery was patient driven. The primary aim of our analysis was to compare disease-free survival after either adrenal-sparing surgery or adrenalectomy. Findings 1210 patients with multiple endocrine neoplasia type 2 were included in our database, 563 of whom had phaeochromocytoma. Treatment was adrenalectomy in 438 (79%) of 552 operated patients, and adrenal-sparing surgery in 114 (21%). Phaeochromocytoma recurrence occurred in four (3%) of 153 of the operated glands after adrenal-sparing surgery after 6-13 years, compared with 11 (2%) of 717 glands operated by adrenalectomy (p=0.57). Postoperative adrenal insufficiency or steroid dependency developed in 292 (86%) of 339 patients with bilateral phaeochromocytoma who underwent surgery. However, 47 (57%) of 82 patients with bilateral phaeochromocytoma who underwent adrenal-sparing surgery did not become steroid dependent. Interpretation The treatment of multiple endocrine neoplasia type 2-related phaeochromocytoma continues to rely on adrenalectomies with their associated Addisonian-like complications and consequent lifelong dependency on steroids. Adrenal-sparing surgery, a highly successful treatment option in experienced centres, should be the surgical approach of choice to reduce these complications.","[Castinetti, Frederic; Brue, Thierry; Conte-Devolx, Bernard] Aix Marseille Univ, La Timone Hosp, Hop Marseille, Dept Endocrinol, F-13005 Marseille, France; [Castinetti, Frederic; Brue, Thierry; Conte-Devolx, Bernard] Aix Marseille Univ, Ctr Rech Neurobiol & Neurophysiol Marseille, F-13005 Marseille, France; [Qi, Xiao-Ping] Anhui Med Univ, PLA Hangzhou Clin Coll, PLA Hosp 117, Dept Oncol, Hangzhou, Zhejiang, Peoples R China; [Qi, Xiao-Ping] Anhui Med Univ, PLA Hangzhou Clin Coll, PLA Hosp 117, Dept Urol Surg, Hangzhou, Zhejiang, Peoples R China; [Walz, Martin K.] Kliniken Essen Mitte, Dept Surg, Essen, Germany; [Walz, Martin K.] Kliniken Essen Mitte, Ctr Minimally Invas Surg, Essen, Germany; [Maia, Ana Luiza; Siqueira, Debora R.] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Endocrinol, Thyroid Sect, BR-90046900 Porto Alegre, RS, Brazil; [Sanso, Gabriela; Barontini, Marta] Hosp Ninos Dr Ricardo Gutierrez, Ctr Endocrinol Invest, Buenos Aires, DF, Argentina; [Peczkowska, Mariola; Szperl, Malgorzata; Januszewicz, Andrzej] Inst Cardiol, Dept Hypertens, Warsaw, Poland; [Hasse-Lazar, Kornelia; Jarzab, Barbara] Maria Sklodowska Curie Mem Ctr & Inst Oncol, Dept Nucl Med & Endocrine Oncol, Gliwice Branch, Gliwice, Poland; [Links, Thera P.; Verbeek, Hans H. G.] Univ Groningen, Univ Med Ctr Groningen, Dept Endocrinol, NL-9700 AB Groningen, Netherlands; [Dvorakova, Sarka] Res Inst Endocrinol, Dept Mol Endocrinol, CR-11694 Prague, Czech Republic; [Toledo, Rodrigo A.; Toledo, Sergio P. A.; Coutinho, Flavia L.] Univ Sao Paulo, Sch Med, Dept Endocrinol, Sao Paulo, Brazil; [Mian, Caterina] Univ Padua, Endocrinol Dept Med DIMED, Operat Unit, Padua, Italy; [Bugalho, Maria Joao] Univ Nova Lisboa, Inst Portugues Oncol Lisboa Francisco Gentil EPE, Serv Endocrinol, P-1200 Lisbon, Portugal; [Bugalho, Maria Joao] Univ Nova Lisboa, Fac Ciencias Med, P-1200 Lisbon, Portugal; [Wohllk, Nelson] Univ Chile, Hosp Salvador, Endocrine Sect, Santiago, Chile; [Kollyukh, Oleg] Inst Endocrinol, Kiev, Ukraine; [Canu, Letizia; Mannelli, Massimo] Univ Florence, Dept Expt & Clin Biomed Sci, Endocrinol Unit, Florence, Italy; [Loli, Paola] Osped Niguarda Ca Granda, Dept Endocrinol, Milan, Italy; [Bergmann, Simona R.] Univ Marburg, Fac Med, Div Endocrinol & Diabetol, Marburg, Germany; [Costa, Josefina Biarnes; Recasens, Monica] Hosp Univ Girona, Gerencia Terr Girona, Inst Catala Salut, Girona, Spain; [Makay, Ozer] Ege Univ Hosp, Div Endocrine Surg, Dept Gen Surg, Izmir, Turkey; [Patocs, Attila] Hungarian Acad Sci, HSA SE Lendulet Hereditary Endocrine Tumor Res Gr, Mol Med Res Grp, Budapest, Hungary; [Patocs, Attila] Semmelweis Univ, H-1085 Budapest, Hungary; [Pfeifer, Marija] Univ Med Ctr Ljubljana, Dept Endocrinol, Ljubljana, Slovenia; [Shah, Nalini S.] Kings Edward Mem Hosp, Seth GS Med Coll, Mumbai, Maharashtra, India; [Cuny, Thomas; Demarquet, Lea; Weryha, Georges] Univ Hosp, Dept Endocrinol, Nancy, France; [Brauckhoff, Michael] Univ Bergen, Dept Endocrine Surg, Bergen, Norway; [Bausch, Birke] Univ Freiburg, Univ Med Ctr, Dept Med 2, D-79106 Freiburg, Germany; [von Dobschuetz, Ernst] Univ Freiburg, Univ Med Ctr, Dept Visceral Surg, D-79106 Freiburg, Germany; [Neumann, Hartmut P. H.] Univ Freiburg, Univ Med Ctr, Dept Nephrol & Gen Med, Sect Prevent Med, D-79106 Freiburg, Germany; [Letizia, Claudio; Petramala, Luigi] Univ Roma La Sapienza, Dept Internal Med & Med Specialties, Rome, Italy; [Barczynski, Marcin] Jagiellonian Univ, Coll Med, Chair Gen Surg 3, Dept Endocrine Surg, Krakow, Poland; [Alevizaki, Maria K.] Univ Athens, Sch Med, Evgenide Hosp, Endocrine Unit, GR-11527 Athens, Greece; [Alevizaki, Maria K.] Univ Athens, Sch Med, Alexandra Hosp, Dept Med Therapeut, GR-11527 Athens, Greece; [Czetwertynska, Malgorzata] Maria Sklodowska Curie Mem Ctr & Inst Oncol, Warsaw, Poland; [Ugurlu, M. Umit] Marmara Univ, Dept Gen Surg, Breast & Endocrine Surg Unit, Istanbul, Turkey; [Valk, Gerlof] Univ Med Ctr Utrecht, Dept Internal Med, Utrecht, Netherlands; [Plukker, John T. M.] Univ Med Ctr Groningen, Dept Surg, NL-9713 AV Groningen, Netherlands; [Sartorato, Paola] Gen Hosp, Dept Internal Med, Treviso, Italy; [Zelinka, Tomas] Charles Univ Prague, Fac Med 1, Dept Endocrinol & Metab, Dept Med, Prague, Czech Republic; [Zelinka, Tomas] Gen Univ Hosp, Prague, Czech Republic; [Vlcek, Petr] Charles Univ Prague, Fac Med 2, Dept Nucl Med & Endocrinol, Prague, Czech Republic; [Yaremchuk, Svetlana; Zabolotnyi, Dmitry] Inst Otolaryngol NAMS Ukraine, Kiev, Ukraine; [Schiavi, Francesca] IRCCS Padova, Veneto Inst Oncol, Padua, Italy; [Opocher, Giuseppe] Univ Padua, Dept Med DIMED, Padua, Italy; [Racz, Karoly] Semmelweis Univ, Dept Internal Med 2, H-1085 Budapest, Hungary; [Henry, Jean-Francois] Aix Marseille Univ, La Timone Hosp, Dept Endocrine Surg, F-13005 Marseille, France; [Eng, Charis] Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44106 USA; [Eng, Charis] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA","Castinetti, F (reprint author), Aix Marseille Univ, La Timone Hosp, Dept Endocrinol, F-13005 Marseille, France.","frederic.castinetti@ap-hm.fr",null,null,"European Union; German Cancer Foundation; Arthur Blank Foundation; Italian Government; Charles University; Czech Ministry of Health; Nanjing Military Command; National Science Centre Poland; National Research Council for Scientific and Technological Development; State of Sao Paulo Research Foundation","European Union, German Cancer Foundation, Arthur Blank Foundation, Italian Government, Charles University, Czech Ministry of Health, Nanjing Military Command, National Science Centre Poland, National Research Council for Scientific and Technological Development, and State of Sao Paulo Research Foundation.",null,19,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1470-2045","1474-5488",null,"LANCET ONCOL","Lancet Oncol.","MAY",2014,15,6,null,null,null,null,648,655,null,"10.1016/S1470-2045(14)70154-8",null,8,"Oncology","Oncology","AG6ES","WOS:000335512100052"]
["J","Suchomel, P; Jurak, L; Antinheimo, J; Pohjola, J; Stulik, J; Meisel, HJ; Cabraja, M; Woiciechowsky, C; Bruchmann, B; Shackleford, I; Arregui, R; Sola, S",null,null,null,"Suchomel, P.; Jurak, L.; Antinheimo, J.; Pohjola, J.; Stulik, J.; Meisel, H. -J.; Cabraja, M.; Woiciechowsky, C.; Bruchmann, B.; Shackleford, I.; Arregui, R.; Sola, S.",null,null,"Does sagittal position of the CTDR-related centre of rotation influence functional outcome? Prospective 2-year follow-up analysis","EUROPEAN SPINE JOURNAL",null,null,"English","Review",null,null,null,null,null,"Cervical total disc replacement; Semi-constrained disc prosthesis; Activ C (TM); Centre of rotation; Heterotopic ossification","ANTERIOR CERVICAL FUSION; ARTIFICIAL DISC REPLACEMENT; LEVEL INTRADISCAL PRESSURE; IN-VIVO; HETEROTOPIC OSSIFICATION; FLEXION-EXTENSION; CLINICAL-TRIAL; DEVICE EXEMPTION; PRODISC-C; ARTHROPLASTY","Recent studies describe significant rates of heterotopic ossification (HO) after cervical total disc replacement (CTDR). Little is known about the reasons, and one aspect that requires further in vivo investigation is the biomechanical alteration after CTDR and the role of the implant-related centre of rotation (CORi) in particular. The role of the sagittal position of the CORi on functional outcome in two versions of a semi-constrained disc prosthesis with sagittally different CORi is the topic of this study. Patients were candidates for single-level CTDR between C3 and C7 who suffered from CDDD and received a standard or flat version of activ C (TM) (Aesculap AG, Tuttlingen). Clinical and radiographic assessments were determined preoperatively, intraoperatively, at discharge and again at 6 weeks, 6 months, 1 and 2 years. Radiographic examinations were performed independently using specialized quantitative motion analysis software. Clinical outcome improved significantly regarding NDI as well as VAS on neck and arm pain with no differences in mean improvement by study group. Segmental angle measures show a significantly better lordotic alignment for both groups after surgery, but the degree of correction achieved is higher in the flat group. Correlation analysis proves that the more anterior the CORi is positioned, the higher the lordotic correction is achieved (Pearson rho -0.385). Segmental ROM decreased in the standard group but was maintained for flat implants. At present, our data do not demonstrate a correlation between CORi and ROM at 2 years. Two years after surgery, severe HO grade III-IV was present in 31.6 % standard and 13.1 % flat cases with significant differences. Grouping according to HO severity showed comparable sagittal positions of CORi for flat implants but a more posterior position in the severe HO group for standard implants. Our results confirm the influence of CORi location on segmental alignment, kinematics and HO for a semi-constrained CTDR, but it also indicates a multifactorial process.","[Suchomel, P.; Jurak, L.] Reg Hosp Liberec, Neuroctr, Liberec 46063, Czech Republic; [Antinheimo, J.; Pohjola, J.] Univ Helsinki, Dept Neurosurg, Helsinki, Finland; [Stulik, J.] Univ Hosp Motol, Prague, Czech Republic; [Meisel, H. -J.] BG Clin Bergmannstrost, Dept Neurosurg, Halle, Germany; [Cabraja, M.] Charite Univ Hosp & Sch Med, Dept Neurosurg, Berlin, Germany; [Bruchmann, B.] Katholisches Klinikum Koblenz, Koblenz, Germany; [Shackleford, I.] Warrington Dist Gen Hosp, Dept Orthopaed & Trauma, Warrington, Cheshire, England; [Arregui, R.] Hosp Maz, Dept Neurosurg, Zaragoza, Spain; [Sola, S.] Univ Rostock, Dept Neurosurg, D-18055 Rostock, Germany","Suchomel, P (reprint author), Reg Hosp Liberec, Neuroctr, Husova 10, Liberec 46063, Czech Republic.","petr.suchomel@nemlib.cz",null,null,"Aesculap AG (Tuttlingen, Germany)","The authors wish to thank Mrs Nele Borm, frictionless GmbH, Kiel, Germany for her contributions to this study, especially in monitoring data collection, performing statistical analyses, supervising the conduct of the study and writing the final draft of the article. Funding for the study was received from Aesculap AG (Tuttlingen, Germany). Although none of the authors has received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article, benefits have been or will be received but will be directed solely to research funds, foundations, educational institutions, or other nonprofit organizations with which one or more of the authors are associated. PS, SS, HJM, CW and BB are consultants of Aesculap AG (Tuttlingen, Germany).",null,52,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0940-6719","1432-0932",null,"EUR SPINE J","Eur. Spine J.","MAY",2014,23,5,null,null,null,null,1124,1134,null,"10.1007/s00586-014-3223-0",null,11,"Clinical Neurology; Orthopedics","Neurosciences & Neurology; Orthopedics","AG6DB","WOS:000335507600019"]
["J","St'astny, E; Trc, T; Handl, M; Kos, P; Kautzner, J; Philippou, T; Lisy, J",null,null,null,"St'astny, Eduard; Trc, Tomas; Handl, Milan; Kos, Petr; Kautzner, Jakub; Philippou, Theodoros; Lisy, Jiri",null,null,"Mid-term results of revision total hip arthroplasty using the oval-shaped uncemented Trc-Cingr cup","INTERNATIONAL ORTHOPAEDICS",null,null,"English","Article",null,null,null,null,null,"Revision oval cup; Bone tissue remodelling; Pull-out test; Locking screws; Computed tomography","CEMENTLESS OBLONG CUP; FOLLOW-UP; ACETABULAR COMPONENT; COMPUTED-TOMOGRAPHY; PROSTHESIS; RECONSTRUCTION; CLASSIFICATION; REPLACEMENT; DEFECTS","Purpose The aim of the present study was to introduce a novel oblong revision cup type TC for use in revision total hip arthroplasty (THA), and to evaluate mid-term results in terms of bone tissue remodelling in the immediate area of the implant. Methods The results of 31 patients that underwent revision THA between 2004 and 2008 are presented. The mean follow-up interval was 7.1 years (range 5.3-9.3 years, minimum of five years following revision). Osteointegration of the implant and bone tissue remodelling around the implant and ribs were assessed by X-ray and computed tomography (CT). Results The average Harris hip score increased from 39.8 to 85.3. Excellent results were achieved in nine patients, good in 16, fair in three and poor in three. According to X-ray results, 25 hips had a well-fixed, bone-ingrown cup and five had a stable fibrous union in the middle and the distal third of the implant. Proximal migration of the cup was noted in one case. Pelvic CT was additionally performed in ten patients. In all cases, we detected bone remodelling in the space between the implant ribs. Kaplan-Maier survivorship of the acetabular components was 94.2 % at 7.1 years. Conclusions Our results show that the novel oblong revision cup type TC is relatively simple to implant, and is associated with reliable primary fixation and documented osteointegration and bone remodelling in the immediate area.","[St'astny, Eduard; Trc, Tomas; Handl, Milan; Kos, Petr; Kautzner, Jakub; Philippou, Theodoros] Charles Univ Prague, Dept Paediat & Adult Orthopaed Surg & Traumatol, Fac Med 2, Prague 15400 5, Czech Republic; [St'astny, Eduard; Trc, Tomas; Handl, Milan; Kos, Petr; Kautzner, Jakub; Philippou, Theodoros; Lisy, Jiri] Motol Univ Hosp, Prague 15400 5, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Dept Radiol, Fac Med 2, Prague 15400 5, Czech Republic","St'astny, E (reprint author), Charles Univ Prague, Dept Paediat & Adult Orthopaed Surg & Traumatol, Fac Med 2, V Uvalu 84, Prague 15400 5, Czech Republic.","stastnyed@seznam.cz",null,null,null,null,null,21,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0341-2695","1432-5195",null,"INT ORTHOP","Int. Orthop.","MAY",2014,38,5,null,null,null,null,935,940,null,"10.1007/s00264-013-2269-7",null,6,"Orthopedics","Orthopedics","AG1AT","WOS:000335147900004"]
["J","Klatte, T; Xylinas, E; Rieken, M; Kluth, LA; Roupret, M; Pycha, A; Fajkovic, H; Seitz, C; Karakiewicz, PI; Lotan, Y; Babjuk, M; de Martino, M; Scherr, DS; Shariat, SF",null,null,null,"Klatte, Tobias; Xylinas, Evanguelos; Rieken, Malte; Kluth, Luis A.; Roupret, Morgan; Pycha, Armin; Fajkovic, Harun; Seitz, Christian; Karakiewicz, Pierre I.; Lotan, Yair; Babjuk, Marko; de Martino, Michela; Scherr, Douglas S.; Shariat, Shahrokh F.",null,null,"Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer","JOURNAL OF UROLOGY",null,null,"English","Article",null,null,null,null,null,"urinary bladder; carcinoma; ABO blood-group system; neoplasm recurrence, local; disease progression","EORTC RISK TABLES; TRANSURETHRAL RESECTION; PREDICTING RECURRENCE; CELL CARCINOMA; STAGE; GENE; PROGRESSION; TUMORS; EXPRESSION","Purpose: ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma. Materials and Methods: We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index. Results: The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type O had worse recurrence and progression rates than those with A (p = 0.015 and 0.031) or B (p = 0.004 and 0.075, respectively). The concordance index of multivariable base models increased after including ABO blood type. Conclusions: In patients with nonmuscle invasive bladder urothelial carcinoma the ABO blood type may predict the outcome. Those with blood type O showed the highest recurrence and progression rates. Including ABO blood type in multivariable models increases the accuracy of standard prognostic factors. Since the ABO blood type is available for most patients, it may represent an ideal adjunctive marker to predict recurrence and progression. The biological explanation and prognostic value of this finding must be further elucidated.","[Klatte, Tobias; Fajkovic, Harun; Seitz, Christian; de Martino, Michela; Shariat, Shahrokh F.] Med Univ Vienna, Dept Urol, Vienna Gen Hosp, A-1090 Vienna, Austria; [Xylinas, Evanguelos; Rieken, Malte; Kluth, Luis A.; Scherr, Douglas S.; Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA; [Xylinas, Evanguelos] Paris Descartes Univ, Cochin Hosp, Assistance Publ Hop Paris, Paris, France; [Roupret, Morgan] Univ Paris 06, Grp Hosp Pitie Salpetriere, Assistance Publ Hop Paris, Fac Med Pierre & Marie Curie,Inst Univ Cancerol G, Paris, France; [Roupret, Morgan] Univ Basel Hosp, CH-4031 Basel, Switzerland; [Kluth, Luis A.] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Pycha, Armin] Cent Hosp Bolzano, Bolzano, Italy; [Karakiewicz, Pierre I.] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Babjuk, Marko] Charles Univ Prague, Fac Med 2, Hosp Motol, Prague, Czech Republic","Shariat, SF (reprint author), Med Univ Vienna, Dept Urol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.","sfshariat@gmail.com",null,null,null,null,null,26,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0022-5347","1527-3792",null,"J UROLOGY","J. Urol.","MAY",2014,191,5,null,null,null,null,1238,1243,null,"10.1016/j.juro.2013.11.106",null,6,"Urology & Nephrology","Urology & Nephrology","AG1AL","WOS:000335147100009"]
["J","Kaprova-Pleskacova, J; Stoop, H; Bruggenwirth, H; Cools, M; Wolffenbuttel, KP; Drop, SLS; Snajderova, M; Lebl, J; Oosterhuis, JW; Looijenga, LHJ",null,null,null,"Kaprova-Pleskacova, Jana; Stoop, Hans; Bruggenwirth, Hennie; Cools, Martine; Wolffenbuttel, Katja P.; Drop, Stenvert L. S.; Snajderova, Marta; Lebl, Jan; Oosterhuis, J. Wolter; Looijenga, Leendert H. J.",null,null,"Complete androgen insensitivity syndrome: factors influencing gonadal histology including germ cell pathology","MODERN PATHOLOGY",null,null,"English","Article",null,null,null,null,null,"complete androgen insensitivity syndrome; delayed germ cell maturation; gonads; intratubular germ cell neoplasia; KITLG; POU5F1","TESTICULAR FEMINIZATION SYNDROME; CARCINOMA IN-SITU; RECEPTOR GENE; MOLECULAR ANALYSIS; BINDING DOMAIN; DNA-BINDING; TUMORS; TESTIS; SUBSTITUTION; EXPRESSION","Patients with complete androgen insensitivity syndrome are at an increased risk for the development of gonadal germ cell cancer. Residual androgen receptor (AR) activity and abnormal gonadal location may influence the survival of atypical germ cells and the development of other histopathological features. To assess this, we evaluated 37 gonads from 19 patients with complete androgen insensitivity (ranging in age from 3 months to 18 years). Histological abnormalities were examined using hematoxylin and eosin-stained sections and sections stained for POU5F1 and KITLG, markers of early changes in germ cells at risk for malignant transformation. Hamartomatous nodules (HNs), Leydig cell hyperplasia (LCH), decreased germ cells, tubular atrophy and stromal fibrosis were more pronounced as age increased (P<0.001). Expected residual AR activity acted as a positive predictor only for non-malignant germ cell survival in (post)pubertal patients (P<0.05). Immunohistochemical studies indicated that delayed maturation of germ cells was present in three patients, whereas intermediate changes that occurred between delayed maturation and intratubular germ cell neoplasia, designated pre-intratubular germ cell neoplasia, were identified in four cases. Intratubular germ cell neoplasia was observed in one patient. Neither POU5F1 nor KITLG expression was dependent on expected residual AR activity. An independent effect of inguinal versus abdominal position of the gonads was difficult to assess because inguinal gonads were present primarily in the youngest individuals. In conclusion, many histological changes occur increasingly with age. Expected residual AR activity contributes to better survival of the general germ cell population in (post)pubertal age; however, it did not seem to have an important role in the survival of the germ cells at risk for malignant transformation (defined by POU5F1 positivity and KITLG overexpression) in complete androgen insensitivity. Comparison of the high percentage of patients in our study that were carrying germ cells with delayed maturation or pre-intratubular germ cell neoplasia with previously reported cumulative risk of tumor development in adult patients indicates that not all such precursor lesions in complete androgen insensitivity will progress to invasive germ cell cancer.","[Kaprova-Pleskacova, Jana; Snajderova, Marta; Lebl, Jan] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague 15006 5, Czech Republic; [Kaprova-Pleskacova, Jana; Snajderova, Marta; Lebl, Jan] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Stoop, Hans; Oosterhuis, J. Wolter; Looijenga, Leendert H. J.] Erasmus MC, Dept Pathol, Rotterdam, Netherlands; [Bruggenwirth, Hennie] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands; [Cools, Martine] Univ Ghent, Dept Pediat, Div Pediat Endocrinol, Univ Hosp Ghent, B-9000 Ghent, Belgium; [Wolffenbuttel, Katja P.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Urol, Rotterdam, Netherlands; [Drop, Stenvert L. S.] Sophia Childrens Univ Hosp, Dept Pediat Endocrinol, Erasmus MC, Rotterdam, Netherlands","Kaprova-Pleskacova, J (reprint author), Charles Univ Prague, Dept Pediat, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","kapr.jana@seznam.cz",null,null,"Novo Nordisk A/S (Ministry of Health, Czech Republic) [00064203]; Flanders Research Foundation (FWO)","This work was supported by an ESPE Research Fellowship granted by Novo Nordisk A/S and by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic). MC is supported by the Flanders Research Foundation (FWO). Special thanks in memoriam to Dr Zun.tova from Department of Pathology, University Hospital Motol, Prague, who collected the Czech samples and to Dr Lanska for statistical analysis.",null,31,0,0,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","0893-3952","1530-0285",null,"MODERN PATHOL","Mod. Pathol.","MAY",2014,27,5,null,null,null,null,721,730,null,null,null,10,"Pathology","Pathology","AG4ZJ","WOS:000335428600010"]
["J","Poprach, A; Pavlik, T; Melichar, B; Kubackova, K; Bortlicek, Z; Svoboda, M; Lakomy, R; Vyzula, R; Kiss, I; Dusek, L; Buehler, T",null,null,null,"Poprach, Alexandr; Pavlik, Tomas; Melichar, Bohuslav; Kubackova, Katerina; Bortlicek, Zbynek; Svoboda, Marek; Lakomy, Radek; Vyzula, Rostislav; Kiss, Igor; Dusek, Ladislav; Buehler, Tomas",null,"Czech Renal Canc Cooperative Grp","Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines","UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS",null,null,"English","Article",null,null,null,null,null,"renal cell carcinoma; prognosis; survival; sunitinib; sorafenib","PHASE-III TRIAL; INTERFERON-ALPHA; SURVIVAL; VALIDATION; EFFICACY; DATABASE; CANCER; MODEL","Objectives: The aim of this retrospective study was to analyze prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors (TKIs) sunitinib or sorafenib after progression on cytokine therapy. Materials and methods: A national database of patients treated with targeted agents was used as the data source. A total of 319 patients treated with sunitinib (n = 181) or sorafenib (n = 138) after progression on cytokine therapy were analyzed. Results: Prognostic factors significantly associated with poor overall survival in a multivariable Cox model included the time from diagnosis to the start of treatment with TKIs <1 year, increased neutrophil counts, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. The parameters showing statistically significant association with progression-free survival included time from diagnosis to the beginning of treatment with TKI <1 year, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. We have also validated the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model in our cohort of patients. Conclusion: We demonstrate that the International Database Consortium prognostic model performs well for European patients treated with TKIs, including sunitinib or sorafenib, after progression on cytokines and suggest that a reduction from original 6 down to 4 parameters is possible. (C) 2014 Elsevier Inc. All rights reserved.","[Poprach, Alexandr; Svoboda, Marek; Lakomy, Radek; Vyzula, Rostislav; Kiss, Igor] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic; [Pavlik, Tomas; Bortlicek, Zbynek; Dusek, Ladislav] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic; [Melichar, Bohuslav] Palacky Univ, Sch Med, Dept Oncol, CR-77147 Olomouc, Czech Republic; [Melichar, Bohuslav] Teaching Hosp, Olomouc, Czech Republic; [Kubackova, Katerina] Charles Univ Prague, Univ Hosp Motol, Dept Oncol, Prague, Czech Republic; [Buehler, Tomas] Thomayer Hosp, Dept Oncol, Prague, Czech Republic; [Buehler, Tomas] Thomayer Hosp, Fac Med 1, Prague, Czech Republic; [Buehler, Tomas] Charles Univ Prague, Prague, Czech Republic","Buehler, T (reprint author), Thomayer Hosp, Dept Oncol, Prague, Czech Republic.","tomas.buchler@ftn.cz",null,null,"Bayer; Pfizer","T.B. has received honoraria for lectures from Bayer and Pfizer. LK. has participated on advisory board for Bayer. K.K. has received travel grants and lecture fees from Bayer and Pfizer. B.M. has received honoraria for lectures from Bayer.",null,23,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1078-1439","1873-2496",null,"UROL ONCOL-SEMIN ORI","Urol. Oncol.-Semin. Orig. Investig.","MAY",2014,32,4,null,null,null,null,488,495,null,"10.1016/j.urolonc.2013.09.011",null,8,"Oncology; Urology & Nephrology","Oncology; Urology & Nephrology","AG4WY","WOS:000335422300017"]
["J","Zmolikova, M; Puchmajerova, A; Hecht, P; Lebl, J; Trkova, M; Krepelova, A",null,null,null,"Zmolikova, Michaela; Puchmajerova, Alena; Hecht, Petr; Lebl, Jan; Trkova, Marie; Krepelova, Anna",null,null,"Coarctation of the Aorta in Noonan-Like Syndrome With Loose Anagen Hair","AMERICAN JOURNAL OF MEDICAL GENETICS PART A",null,null,"English","Article",null,null,null,null,null,"Noonan-like syndrome with loose anagen hair; SHOC2; coarctation of the aorta; RASopathies","SHOC2 MUTATION; PHENOTYPE; SPECTRUM","Noonan-like syndrome with loose anagen hair (NS/LAH; OMIM 607721) due to a missense mutation c.4A>G in SHOC2 predicting p.Ser2Gly has been described recently. This condition is characterized by facial features similar to Noonan syndrome, reduced growth, cardiac defects, and typical abnormal hair. We report on a patient with molecularly confirmed NS/LAH with coarctation of the aorta. The girl was precipitously born at 37 weeks of gestation at home and required a 3-min resuscitation. Increased nuchal translucency and aortic coarctation with a small ventricular septal defect were described prenatally, hypertrophic cardiomyopathy was detected postnatally. The patient presented with facial dysmorphism typical of NS with redundant skin over the nape and on the back. Short stature, relative macrocephaly, failure-to-thrive together with dystrophic appearance, developmental delay mainly in motor milestones and very thin, sparse, slow-growing hair occurred a few weeks after birth. Endocrine evaluation revealed low IGF-1 levels and borderline growth hormone deficiency. Growth hormone therapy started at 16 months had a partial effect and prevented further growth deterioration. Coarctation of the aorta is not a typical heart defect among individuals with NS/LAH, therefore our observation extends the phenotypic spectrum of this disorder. (c) 2014 Wiley Periodicals, Inc.","[Zmolikova, Michaela; Puchmajerova, Alena; Krepelova, Anna] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 16900, Czech Republic; [Zmolikova, Michaela; Puchmajerova, Alena; Lebl, Jan; Krepelova, Anna] Motol Univ Hosp, Prague 16900, Czech Republic; [Hecht, Petr] Motol Univ Hosp, Childrens Heart Ctr, Prague 16900, Czech Republic; [Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 16900, Czech Republic; [Trkova, Marie] Gennet, Prague, Czech Republic","Zmolikova, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, V Uvalu 84, Prague 16900, Czech Republic.","michaela.zmolikova@fnmotol.cz",null,null,"Conceptual development of research organisation University Hospital Motol [00064203]","Grant sponsor: Conceptual development of research organisation University Hospital Motol; Grant number: 00064203.",null,18,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1552-4825","1552-4833",null,"AM J MED GENET A","Am. J. Med. Genet. A","MAY",2014,164,5,null,null,null,null,1218,1221,null,"10.1002/ajmg.a.36404",null,4,"Genetics & Heredity","Genetics & Heredity","AE8YZ","WOS:000334290300021"]
["J","Mojzikova, R; Koralkova, P; Holub, D; Zidova, Z; Pospisilova, D; Cermak, J; Laluhova, ZS; Indrak, K; Sukova, M; Partschova, M; Kucerova, J; Horvathova, M; Divoky, V",null,null,null,"Mojzikova, Renata; Koralkova, Pavla; Holub, Dusan; Zidova, Zuzana; Pospisilova, Dagmar; Cermak, Jaroslav; Laluhova, Zuzana Striezencova; Indrak, Karel; Sukova, Martina; Partschova, Martina; Kucerova, Jana; Horvathova, Monika; Divoky, Vladimir",null,null,"Iron status in patients with pyruvate kinase deficiency: neonatal hyperferritinaemia associated with a novel frameshift deletion in the PKLR gene (p.Arg518fs), and low hepcidin to ferritin ratios","BRITISH JOURNAL OF HAEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"red blood cell; iron overload; hepcidin; pyruvate kinase deficiency; ferritin","NONSPHEROCYTIC HEMOLYTIC-ANEMIA; BETA-THALASSEMIA; HEMOCHROMATOSIS; EXPRESSION; ERYTHROPOIESIS; GENOTYPE; MUTATION","Pyruvate kinase (PK) deficiency is an iron-loading anaemia characterized by chronic haemolysis, ineffective erythropoiesis and a requirement for blood transfusion in most cases. We studied 11 patients from 10 unrelated families and found nine different disease-causing PKLR mutations. Two of these mutations - the point mutation c.878A>T (p.Asp293Val) and the frameshift deletion c.1553delG (p.(Arg518Leufs*12)) - have not been previously described in the literature. This frameshift deletion was associated with an unusually severe phenotype involving neonatal hyperferritinaemia that is not typical of PK deficiency. No disease-causing mutations in genes associated with haemochromatosis could be found. Inappropriately low levels of hepcidin with respect to iron loading were detected in all PK-deficient patients with increased ferritin, confirming the predominant effect of accelerated erythropoiesis on hepcidin production. Although the levels of a putative hepcidin suppressor, growth differentiation factor-15, were increased in PK-deficient patients, no negative correlation with hepcidin was found. This result indicates the existence of another as-yet unidentified erythroid regulator of hepcidin synthesis in PK deficiency.","[Mojzikova, Renata; Koralkova, Pavla; Zidova, Zuzana; Partschova, Martina; Kucerova, Jana; Horvathova, Monika; Divoky, Vladimir] Palacky Univ, Fac Med & Dent, Dept Biol, Olomouc 77515, Czech Republic; [Holub, Dusan] Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Olomouc 77515, Czech Republic; [Pospisilova, Dagmar] Palacky Univ, Univ Hosp, Dept Paediat, Olomouc 77515, Czech Republic; [Pospisilova, Dagmar; Indrak, Karel; Divoky, Vladimir] Palacky Univ, Fac Med & Dent, Olomouc 77515, Czech Republic; [Cermak, Jaroslav] Inst Hematol & Blood Transfus, Prague, Czech Republic; [Laluhova, Zuzana Striezencova] Childrens Fac Hosp Policlin, Bratislava, Slovakia; [Indrak, Karel; Divoky, Vladimir] Palacky Univ, Univ Hosp, Dept Haematooncol, Olomouc 77515, Czech Republic; [Sukova, Martina] Univ Hosp Motol, Dept Paediat Haematol & Oncol, Prague, Czech Republic","Horvathova, M (reprint author), Palacky Univ, Fac Med & Dent, Dept Biol, Hnevotinska 3, Olomouc 77515, Czech Republic.","priwitzer@seznam.cz",null,null,"Ministry of Health, Czech Republic [NT/11208, NT/13587]; Internal Grant Agency of Palacky University [LF_2013_010]; Ministry of Education, Youth and Sports, Czech Republic [CZ.1.05/2.1.00/01.0030]; Czech Science Foundation [P305/11/1745]","This work was supported by grant NT/11208 (Ministry of Health, Czech Republic) and partially supported by grant LF_2013_010 (Internal Grant Agency of Palacky University). DH was partially supported by CZ.1.05/2.1.00/01.0030 (Ministry of Education, Youth and Sports, Czech Republic), MS was supported by NT/13587 (Ministry of Health, Czech Republic) and MH and VD were partially supported by P305/11/1745 (Czech Science Foundation). We thank Prof. Thomas Ganz (UCLA) for the validation of our HPLC-MS-based hepcidin measurements, Prof. Tomas Adam (Palacky University) for some biochemical measurements, and Lenka Radova (Masaryk University in Brno, Czech Republic) for statistical analyses.",null,33,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0007-1048","1365-2141",null,"BRIT J HAEMATOL","Br. J. Haematol.","MAY",2014,165,4,null,null,null,null,556,563,null,"10.1111/bjh.12779",null,8,"Hematology","Hematology","AF4MI","WOS:000334686500015"]
["J","Verheecke, M; Halaska, MJ; Lok, CA; Ottevanger, PB; Fruscio, R; Dahl-Steffensen, K; Kolawa, W; Gziri, MM; Han, SN; Van Calsteren, K; Van den Heuvel, F; De Vleeschouwer, S; Clement, PM; Menten, J; Amant, F",null,null,null,"Verheecke, Magali; Halaska, Michael J.; Lok, Christianne A.; Ottevanger, Petronella B.; Fruscio, Robert; Dahl-Steffensen, Karina; Kolawa, Wojciech; Gziri, Mina Mhallem; Han, Sileny Naeyu; Van Calsteren, Kristel; Van den Heuvel, Frank; De Vleeschouwer, Steven; Clement, Paul M.; Menten, Johannes; Amant, Frederic",null,"ESGO Task Force Canc Pregnancy","Primary brain tumours, meningiomas and brain metastases in pregnancy: Report on 27 cases and review of literature","EUROPEAN JOURNAL OF CANCER",null,null,"English","Review",null,null,null,null,null,"Pregnancy; Brain tumour; Surgery; Radiotherapy; Chemotherapy","RADIATION-THERAPY; TRANSPLACENTAL TRANSFER; INTRACRANIAL NEOPLASMS; SURGICAL INTERVENTION; CLINICAL MANAGEMENT; BABOON MODEL; RADIOTHERAPY; OUTCOMES; CANCER; GLIOBLASTOMA","Background: The concurrence of intracranial tumours with pregnancy is rare. The purpose of this study was to describe all reported patients registered in the international Cancer in Pregnancy registration study (CIP study; http://www.cancerinpregnancy.org), and to review the literature in order to obtain better insight into outcome and possibilities of treatment in pregnancy. Methods: We collected all intracranial tumours (primary brain tumour, cerebral metastasis, or meningioma) diagnosed during pregnancy, registered prospectively and retrospectively by international collaboration since 1973. Patients diagnosed postpartum were excluded. We summarised the demographic features, treatment decisions, obstetrical and neonatal outcomes. Results: The mean age of the 27 eligible patients was 31 years (range 23-41 years), of which 13 and 12 patients were diagnosed in the second and third trimesters, respectively. Eight patients (30%) underwent brain surgery, seven patients (26%) had radiotherapy and in three patients (11%) chemotherapy was administered during gestation. Two patients died during pregnancy and four pregnancies were terminated. In 16 (59%) patients elective caesarean section was performed of which 14 (52%) were still preterm (range 30-36 weeks, mean 33 weeks). Five patients had a vaginal delivery (range 36-40 weeks). Of the 21 ongoing pregnancies all children were born alive without visible congenital malformations and the available long-term follow-up data (range 2-25 years) of six children were reassuring. Conclusion: Adherence to standard protocol for the treatment of brain tumours during pregnancy appears to allow a term delivery and a higher probability of a vaginal delivery. (C) 2014 Elsevier Ltd. All rights reserved.","[Verheecke, Magali; Gziri, Mina Mhallem; Han, Sileny Naeyu; Van Calsteren, Kristel; De Vleeschouwer, Steven; Clement, Paul M.; Menten, Johannes; Amant, Frederic] Univ Hosp Leuven, B-3000 Louvain, Belgium; [Verheecke, Magali; Gziri, Mina Mhallem; Han, Sileny Naeyu; Van Calsteren, Kristel; Clement, Paul M.; Amant, Frederic] KULeuven, Div Oncol, B-3000 Louvain, Belgium; [Halaska, Michael J.] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, CR-11636 Prague 1, Czech Republic; [Lok, Christianne A.] Ctr Gynecol Oncol, Dept Gynecol Oncol, NL-1066 CX Amsterdam, Netherlands; [Ottevanger, Petronella B.] Radboud Univ Nijmegen, Med Ctr, Dept Obstet & Gynecol, NL-6525 GA Nijmegen, Netherlands; [Fruscio, Robert] Univ Milano Bicocca, San Gerardo Hosp, Div Obstet & Gynecol, I-20900 Monza, Italy; [Dahl-Steffensen, Karina] Vejle Hosp, Dept Radiotherapy & Clin Oncol, DK-7100 Vejle, Denmark; [Kolawa, Wojciech] Jagiellonian Univ, Dept Gynecol & Oncol, Univ Hosp Krakow, Krakow, Poland; [Van den Heuvel, Frank] Univ Hosp Leuven, Phys Dept Radiat Oncol, B-3000 Louvain, Belgium","Amant, F (reprint author), Univ Hosp Leuven, Herestr 49, B-3000 Louvain, Belgium.","frederic.amant@uzleuven.be","Van den Heuvel, Frank/G-6992-2011","Van den Heuvel, Frank/0000-0001-9904-502X","Research Foundation-Flanders; Belgian Cancer Plan, Ministry of Health, Belgium","Funding by the Research Foundation-Flanders and the Belgian Cancer Plan, Ministry of Health, Belgium. The funding sources had no involvement in study design; in the writing of the manuscript; nor in the decision to submit the paper for publication.",null,36,0,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0959-8049","1879-0852",null,"EUR J CANCER","Eur. J. Cancer","MAY",2014,50,8,null,null,null,null,1462,1471,null,"10.1016/j.ejca.2014.02.018",null,10,"Oncology","Oncology","AE9GQ","WOS:000334314600007"]
["J","Fila, L; Grandcourtova, A; Chladek, J; Musil, J",null,null,null,"Fila, Libor; Grandcourtova, Alzbeta; Chladek, Jaroslav; Musil, Jaromir",null,null,"Oxidative stress in cystic fibrosis patients with Burkholderia cenocepacia airway colonization: relation of 8-isoprostane concentration in exhaled breath condensate to lung function decline","FOLIA MICROBIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"CEPACIA COMPLEX; HYDROGEN-PEROXIDE; EXACERBATIONS; MORTALITY","The association between oxidative stress and neutrophilic inflammation in cystic fibrosis (CF) lung disease is well recognized. 8-Isoprostane is a product of non-enzymatic oxidation of arachidonic acid. The aim of the present study was to examine the relationship between lung function decline and 8-isoprostane concentrations in exhaled breath condensate (EBC) in CF patients with Burkholderia cenocepacia airway colonization. Concentrations of 8-isoprostane in EBC were measured in 24 stable CF patients with B. cenocepacia airway colonization. The median (interquartile range) age of the cohort was 23.9 (22.0; 26.6) years. All patients underwent clinical examinations and pulmonary function tests at the time of EBC collection and in 1-, 3-, and 5-year intervals. 8-Isoprostane concentrations in EBC correlated to 1- and 3-year declines of forced expiratory volume in 1 s (FEV1) with r (S) values of -0.511 (p = 0.0011) and -0.495 (p = 0.016), respectively. In multiple regression analysis, 8-isoprostane concentrations in EBC were the only independent predictor for 1-year FEV1 decline (p = 0.01). When the median value of 8-isoprostane concentration in EBC (10.0 pg/mL) was used as a cutoff, subgroups of patients with lower and higher level of oxidative stress had significantly different median (interquartile range) FEV1 declines in 1-year interval, -2.4 % (-5.3; 0.8) and -7.3 % (-10.3; -5.8) predicted (p = 0.009). In conclusion, 8-isoprostane concentrations in EBC correlated to short-term lung function decline in CF patients with B. cenocepacia airway colonization. This correlation reflects the role of oxidative stress in CF lung pathogenesis and contributes to prediction of prognosis in these patients.","[Fila, Libor; Grandcourtova, Alzbeta] Charles Univ Prague, Dept Pneumol, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic; [Chladek, Jaroslav] Charles Univ Prague, Dept Pharmacol, Fac Med Hradec Kralove, Hradec Kralove 50038, Czech Republic; [Musil, Jaromir] Hosp Melnik, Dept Pulm, Melnik 27601, Czech Republic","Fila, L (reprint author), Charles Univ Prague, Dept Pneumol, Fac Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006, Czech Republic.","libor_fila@seznam.cz",null,null,"Ministry of Health of the Czech Republic; Ministry of Health of the Czech Republic [00064203, NS10543-3, NT12405-5]","This study was supported by the project (Ministry of Health of the Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic) and by grants from the Ministry of Health of the Czech Republic NS10543-3 and NT12405-5. The authors wish to thank Ms. Vera Lopotova for help with collection of EBC and preparation of samples for analyses, Ms. Venuse Flegrova for help with lung function tests, and Ms. Jana Prokopova for help with EBC analyses.",null,32,0,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632","1874-9356",null,"FOLIA MICROBIOL","Folia Microbiol.","MAY",2014,59,3,null,null,null,null,217,222,null,"10.1007/s12223-013-0285-z",null,6,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","AE7IQ","WOS:000334171300005"]
["J","Remlova, E; Dostalova, T; Michalusova, I; Vranova, J; Jelinkova, H; Hubacek, M",null,null,null,"Remlova, E.; Dostalova, T.; Michalusova, I.; Vranova, J.; Jelinkova, H.; Hubacek, M.",null,null,"Infantile hemangioma: pulsed dye laser versus surgical therapy","LASER PHYSICS",null,null,"English","Article",null,null,null,null,null,"infantile hemangioma; pulsed dye laser; surgical therapy","PORT-WINE STAINS; VASCULAR MALFORMATIONS","Hemangioma is a mesenchymal benign tumor formed by blood vessels. Anomalies affect up to 10% of children and they are more common in females than in males. The aim of our study was to compare the treatment efficacy, namely the curative effect and adverse events, such as loss of pigment and appearance of scarring, between classical surgery techniques and laser techniques. For that reason a group of 223 patients with hemangioma was retrospectively reviewed. For treatment, a pulsed dye laser (PDL) (Rhodamine G, wavelength 595 nm, pulsewidth between 0.45 and 40 ms, spot diameter 7 mm, energy density 9-11 J cm(-2)) was used and the results were compared with a control group treated with classical surgical therapy under general anesthesia. The curative effects, mainly number of sessions, appearance of scars, loss of pigment, and relapses were evaluated as a marker of successful treatment. From the results it was evident that the therapeutic effects of both systems are similar. The PDL was successful in all cases. The surgery patients had four relapses. Classical surgery is directly connected with the presence of scars, but the system is safe for larger hemangiomas. It was confirmed that the PDL had the optimal curative effect without scars for small lesions (approximately 10 mm). Surgical treatment under general anesthesia is better for large hemangiomas; the disadvantage is the presence of scars.","[Remlova, E.] AVE LASER CENTRUM, Olomouc, Czech Republic; [Dostalova, T.; Michalusova, I.; Hubacek, M.] Charles Univ Prague, Fac Med 2, Dept Stomatol, Prague 5, Czech Republic; [Vranova, J.] Charles Univ Prague, Fac Med 3, Dept Med Biophys & Med Informat, Prague, Czech Republic; [Vranova, J.] Czech Tech Univ, Fac Biomed Engn, Kladno, Czech Republic; [Jelinkova, H.] Czech Tech Univ, Fac Nucl Sci & Phys Engn, Prague, Czech Republic","Remlova, E (reprint author), AVE LASER CENTRUM, Olomouc, Czech Republic.","evareml@centrum.cz",null,null,"IGA MZCR [13351-4, 00064203]","This research has been supported by IGA MZCR 13351-4 and 00064203 (FN Motol).",null,19,0,0,"IOP PUBLISHING LTD","BRISTOL","TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND","1054-660X","1555-6611",null,"LASER PHYS","Laser Phys.","MAY",2014,24,5,null,null,null,null,null,null,55601,"10.1088/1054-660X/24/5/055601",null,6,"Optics; Physics, Applied","Optics; Physics","AF3GA","WOS:000334598300012"]
["J","Oldgren, J; Healey, JS; Ezekowitz, M; Commerford, P; Avezum, A; Pais, P; Zhu, J; Jansky, P; Sigamani, A; Morillo, CA; Liu, LS; Damasceno, A; Grinvalds, A; Nakamya, J; Reilly, PA; Keltai, K; Van Gelder, IC; Yusufali, AH; Watanabe, E; Wallentin, L; Connolly, SJ; Yusuf, S",null,null,null,"Oldgren, Jonas; Healey, Jeff S.; Ezekowitz, Michael; Commerford, Patrick; Avezum, Alvaro; Pais, Prem; Zhu, Jun; Jansky, Petr; Sigamani, Alben; Morillo, Carlos A.; Liu, Lisheng; Damasceno, Albertino; Grinvalds, Alex; Nakamya, Juliet; Reilly, Paul A.; Keltai, Katalin; Van Gelder, Isabelle C.; Yusufali, Afzal Hussein; Watanabe, Eiichi; Wallentin, Lars; Connolly, Stuart J.; Yusuf, Salim",null,"RE-LY Atrial Fibrillation Registry","Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries The RE-LY Atrial Fibrillation Registry","CIRCULATION",null,null,"English","Article",null,null,null,null,null,"anticoagulants; atrial fibrillation; epidemiology; hypertension; registries","RHEUMATIC HEART-DISEASE; RISK-FACTORS; RHYTHM CONTROL; STROKE; WARFARIN; ANTICOAGULATION; PREVALENCE; PROGNOSIS; THERAPY; GUIDELINES","Background Atrial fibrillation (AF) is the most common sustained arrhythmia; however, little is known about patients in a primary care setting from high-, middle-, and low-income countries. Methods and Results This prospective registry enrolled patients presenting to an emergency department with AF at 164 sites in 46 countries representing all inhabited continents. Patient characteristics were compared among 9 major geographic regions. Between September 2008 and April 2011, 15 400 patients were enrolled. The average age was 65.9, standard deviation 14.8 years, ranging from 57.2, standard deviation 18.8 years in Africa, to 70.1, standard deviation 13.4 years in North America, P<0.001. Hypertension was globally the most common risk factor for AF, ranging in prevalence from 41.6% in India to 80.7% in Eastern Europe, P<0.001. Rheumatic heart disease was present in only 2.2% of North American patients, in comparison with 21.5% in Africa and 31.5% in India, P<0.001. The use of oral anticoagulation among patients with a CHADS(2) score of 2 was greatest in North America (65.7%) but was only 11.2% in China, P<0.001. The mean time in the therapeutic range was 62.4% in Western Europe, 50.9% in North America, but only between 32% and 40% in India, China, Southeast Asia, and Africa, P<0.001. Conclusions There is a large global variation in age, risk factors, concomitant diseases, and treatment of AF among regions. Improving outcomes globally requires an understanding of this variation and the conduct of research focused on AF associated with different underlying conditions and treatment of AF and predisposing conditions in different socioeconomic settings.","[Oldgren, Jonas; Wallentin, Lars] Uppsala Univ, Uppsala Clin Res Ctr, S-75237 Uppsala, Sweden; [Oldgren, Jonas; Wallentin, Lars] Uppsala Univ, Dept Med Sci, S-75237 Uppsala, Sweden; [Healey, Jeff S.; Morillo, Carlos A.; Grinvalds, Alex; Nakamya, Juliet; Connolly, Stuart J.; Yusuf, Salim] Populat Hlth Res Inst, Hamilton, ON, Canada; [Ezekowitz, Michael] Jefferson Med Coll, Wynnewood, PA USA; [Ezekowitz, Michael] Cardiovasc Res Fdn, New York, NY USA; [Commerford, Patrick] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa; [Avezum, Alvaro] Inst Dante Pazzanesse Cardiol, Sao Paulo, Brazil; [Pais, Prem; Sigamani, Alben] St Johns Med Coll, Bangalore, Karnataka, India; [Zhu, Jun; Liu, Lisheng] Cardiovasc Inst, Beijing, Peoples R China; [Zhu, Jun; Liu, Lisheng] Fuwai Hosp, Beijing, Peoples R China; [Jansky, Petr] Univ Hosp Motol, Prague, Czech Republic; [Damasceno, Albertino] Eduardo Mondlane Univ, Maputo, Mozambique; [Reilly, Paul A.] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; [Keltai, Katalin] Semmelweis Univ, H-1085 Budapest, Hungary; [Van Gelder, Isabelle C.] Univ Groningen, Univ Med Ctr Groningen, Thoraxctr, NL-9700 AB Groningen, Netherlands; Dubai Hlth Author, Dubai Hosp, Dubai, U Arab Emirates; [Watanabe, Eiichi] Fujita Hlth Univ, Sch Med, Dept Cardiol, Toyoake, Aichi 47011, Japan","Oldgren, J (reprint author), Uppsala Univ, Uppsala Clin Res Ctr, S-75237 Uppsala, Sweden.","Jonas.Oldgren@ucr.uu.se",null,null,"Boehringer-Ingelheim","The RE-LY AF Registry was funded by an unconditional grant from Boehringer-Ingelheim.",null,41,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322","1524-4539",null,"CIRCULATION","Circulation","APR 15",2014,129,15,null,null,null,null,1568,1576,null,"10.1161/CIRCULATIONAHA.113.005451",null,9,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","Cardiovascular System & Cardiology","AE9II","WOS:000334321100010"]
["J","Ptacek, R; Kuzelova, H; Stefano, GB; Raboch, J; Sadkova, T; Goetz, M; Kream, RM",null,null,null,"Ptacek, Radek; Kuzelova, Hana; Stefano, George B.; Raboch, Jiri; Sadkova, Tereza; Goetz, Michal; Kream, Richard M.",null,null,"Disruptive patterns of eating behaviors and associated lifestyles in males with ADHD","MEDICAL SCIENCE MONITOR",null,null,"English","Article",null,null,null,null,null,"Attention Deficit Disorder with Hyperactivity - diagnosis; Attention Deficit Disorder with Hyperactivity - psychology; Feeding Behavior - psychology; Life Style; Pediatric Obesity","ANTHROPOMETRIC CHANGES; PSYCHIATRIC-DISORDERS; CHILDREN; OBESITY; POPULATION; PREVALENCE; GROWTH; BOYS","Background: Attention deficit hyperactivity disorder (ADHD) is a neurological/behavioral disorder characterized by inattention or hyperactivity and impulsivity, or combined symptomatology. Children with ADHD are predisposed to irregular and/or impulsive eating patterns often leading to compromised physical condition. The goal of the present study was to statistically evaluate parental scoring of patterned eating behaviors and associated lifestyles within a cohort of 100 boys diagnosed with ADHD in comparison to age-matched male controls. Material/Methods: The study population consisted of 100 boys aged 6-10 years diagnosed with mixed type ADHD by DSM-IV criteria and 100 aged-matched healthy male control subjects. Patterns of eating behaviors and associated lifestyles were scored by structured parental interviews using a nominal rating scale. Results: Interview scores indicated statistically significant differences in patterned eating behaviors in subjects with ADHD in comparison to healthy controls. Notably, subjects diagnosed with ADHD exhibited markedly diminished adherence to a traditional breakfast, lunch, and dinner schedule, which was linked to a significantly higher frequency (>5/day) of irregular eating times. In the ADHD cohort, disruptive patterns of eating behaviors were associated with diminished nutritional value of ingested food (expressed as lowered content of fruits and vegetables) and increased consumption of sweetened beverages. Conclusions: Disruptive patterns of eating behaviors, metabolically unfavorable nutritional status, and diminished physical activities of male children diagnosed with ADHD are linked to compromised growth and development and appearance of metabolic diseases in adulthood.","[Ptacek, Radek; Kuzelova, Hana; Stefano, George B.; Raboch, Jiri; Sadkova, Tereza; Kream, Richard M.] Charles Univ Prague, Med Fac 1, Dept Psychiat, Ctr Cognit & Mol Neurosci, Prague, Czech Republic; [Stefano, George B.; Kream, Richard M.] SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA; [Goetz, Michal] Charles Univ Prague, Dept Paediat Psychiat, Fac Med 2, Prague, Czech Republic","Ptacek, R (reprint author), Charles Univ Prague, Med Fac 1, Dept Psychiat, Ctr Cognit & Mol Neurosci, Prague, Czech Republic.","ptacek@neuro.cz",null,null,null,null,null,30,0,0,"INT SCIENTIFIC LITERATURE, INC","SMITHTOWN","361 FOREST LANE, SMITHTOWN, NY 11787 USA","1643-3750",null,null,"MED SCI MONITOR","Med. Sci. Monitor","APR 14",2014,20,null,null,null,null,null,608,613,null,null,null,6,"Medicine, Research & Experimental","Research & Experimental Medicine","AE9WN","WOS:000334362300001"]
["J","Urdzikova, LM; Sedlacek, R; Suchy, T; Amemori, T; Ruzicka, J; Lesny, P; Havlas, V; Sykova, E; Jendelova, P",null,null,null,"Urdzikova, Lucia Machova; Sedlacek, Radek; Suchy, Tomas; Amemori, Takashi; Ruzicka, Jiri; Lesny, Petr; Havlas, Vojtech; Sykova, Eva; Jendelova, Pavla",null,null,"Human multipotent mesenchymal stem cells improve healing after collagenase tendon injury in the rat","BIOMEDICAL ENGINEERING ONLINE",null,null,"English","Article",null,null,null,null,null,"Achilles tendon; Mesenchymal stromal cells; Osteogenesis","HUMAN PLATELET LYSATE; STROMAL CELLS; TENOGENIC DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; PROGENITOR CELLS; MESSENGER-RNA; ROTATOR CUFF; IN-VITRO; REPAIR; PROLIFERATION","Background: Mesenchymal stromal cells attract much interest in tissue regeneration because of their capacity to differentiate into mesodermal origin cells, their paracrine properties and their possible use in autologous transplantations. The aim of this study was to investigate the safety and reparative potential of implanted human mesenchymal stromal cells (hMSCs), prepared under Good Manufacturing Practice (GMP) conditions utilizing human mixed platelet lysate as a culture supplement, in a collagenase Achilles tendon injury model in rats. Methods: Eighty-one rats with collagenase-induced injury were divided into two groups. The first group received human mesenchymal stromal cells injected into the site of injury 3 days after lesion induction, while the second group received saline. Biomechanical testing, morphometry and semiquantitative immunohistochemistry of collagens I, II and III, versican and aggrecan, neovascularization, and hMSC survival were performed 2, 4, and 6 weeks after injury. Results: Human mesenchymal stromal cell-treated rats had a significantly better extracellular matrix structure and a larger amount of collagen I and collagen III. Neovascularization was also increased in hMSC-treated rats 2 and 4 weeks after tendon injury. MTCO2 (Cytochrome c oxidase subunit II) positivity confirmed the presence of hMSCs 2, 4 and 6 weeks after transplantation. Collagen II deposits and alizarin red staining for bone were found in 6 hMSC-and 2 saline-treated tendons 6 weeks after injury. The intensity of anti-versican and anti-aggrecan staining did not differ between the groups. Conclusions: hMSCs can support tendon healing through better vascularization as well as through larger deposits and better organization of the extracellular matrix. The treatment procedure was found to be safe; however, cartilage and bone formation at the implantation site should be taken into account when planning subsequent in vivo and clinical trials on tendinopathy as an expected adverse event.","[Urdzikova, Lucia Machova; Amemori, Takashi; Ruzicka, Jiri; Sykova, Eva; Jendelova, Pavla] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Lesny, Petr; Sykova, Eva; Jendelova, Pavla] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Havlas, Vojtech] Charles Univ Prague, Fac Med 2, Dept Orthoped & Traumatol, Prague, Czech Republic; [Sedlacek, Radek; Suchy, Tomas] Czech Tech Univ, Fac Mech Engn, Dept Mech Biomech & Mechatron, Lab Biomech, CR-16635 Prague, Czech Republic","Urdzikova, LM (reprint author), Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic.","urdzikl@saske.sk",null,null,"GACR [P304/10/0326, CZ.1.05/1.1.00/02.0109];  [00064203]","Supported by the grant project GACR - P304/10/0326, grant CZ.1.05/1.1.00/02.0109 and the research institution grant project No. 00064203.",null,32,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1475-925X",null,null,"BIOMED ENG ONLINE","Biomed. Eng. Online","APR 9",2014,13,null,null,null,null,null,null,null,42,"10.1186/1475-925X-13-42",null,15,"Engineering, Biomedical","Engineering","AF9UF","WOS:000335059400001"]
["J","Kleteckova, L; Tsenov, G; Kubova, H; Stuchlik, A; Vales, K",null,null,null,"Kleteckova, Lenka; Tsenov, Grygoriy; Kubova, Hana; Stuchlik, Ales; Vales, Karel",null,null,"Neuroprotective effect of the 3 alpha 5 beta-pregnanolone glutamate treatment in the model of focal cerebral ischemia in immature rats","NEUROSCIENCE LETTERS",null,null,"English","Article",null,null,null,null,null,"3 alpha 5 beta-Pregnanolone glutamate; NMDA receptors; Immature rats; Focal cerebral ischemia; Endothelin-1","CLINICAL RATING SCORES; SPINAL-CORD ISCHEMIA; NMDA RECEPTOR; INTRAHIPPOCAMPAL INJECTION; BRAIN; ENDOTHELIN-1; NEUROTOXICITY; MEMANTINE; STROKE; MK-801","The perinatal hypoxic-ischemic insult frequently leads to mortality, morbidity and plays a key role in the later pathological consequences. The ischemic insult causes a massive release of glutamate and subsequent excitotoxic damage. The neuroactive steroid 3 alpha 5 beta-pregnanolone glutamate (PG) is a NMDA receptor antagonist acting via use-dependent mechanism and can be used as a neuroprotective agent that may alleviate glutamatergic excitotoxicity in the brain. First, a possible neurotoxic effect of the PG, a novel use-dependent NMDA antagonist, was studied in immature rats. In addition, to compare this effect with a well-described non-competitive NMDA antagonist, the MK-801 (positive control) was used. Animals at postnatal day 12 (P12) were injected intraperitoneally with PG in a doses 1 or 10 mg/kg or with MK-801 in a dose 1 mg/kg. Effect of PG treatment on the immature brain was evaluated on Fluoro Jade B (FJB) stained sections. Second, a neuroprotective effect of the PG was studied in the model of focal cerebral ischemia in P12. Focal cerebral ischemia was induced by the infusion of the endothelin-1 (ET-1) into the right dorsal hippocampus. PG at the doses 1 or 10 mg/kg was administrated intraperitoneally 5 min after the end of ET-1 infusion. To evaluate the neuroprotective effect after the PG treatment FIB staining was used. Our results demonstrate a lack of the neurotoxicity of the PG in intact P12. In the second part of the study in the model of the focal ischemia we detected significantly lower occurrence of FJB-positive cells in the afflicted hippocampus in PG treated groups, while animals without PG treatment exhibited massive neurodegeneration. The neuroprotective potential of the PG can serve in the development of therapeutic strategies for brain damage induced by the glutamate excitotoxicity. (C) 2014 Elsevier Ireland Ltd. All rights reserved.","[Kleteckova, Lenka; Stuchlik, Ales; Vales, Karel] Vvi Acad Sci Czech Republ, Inst Physiol, Dept Neurophysiol Memory, Prague 14220 4, Czech Republic; [Tsenov, Grygoriy; Kubova, Hana] Vvi Acad Sci Czech Republ, Inst Physiol, Dept Dev Epileptol, Prague 14220 4, Czech Republic; [Kleteckova, Lenka] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Vales, K (reprint author), Vvi Acad Sci Czech Republ, Inst Physiol, Dept Neurophysiol Memory, Videnska 1083, Prague 14220 4, Czech Republic.","vales@biomed.cas.cz","Kubova, Hana/C-4210-2012; Kleteckova, Lenka/G-3938-2014; Vales, Karel/C-2941-2012",null,"GACR [P304/11/P386 P304/14/20613S P304/12/G069, P303/12/1464 TACR-TE01020028, GAUK 604412]","We gratefully acknowledge the expert technical help by Mrs. Blanka Cejkova and Mrs. Michaela Fialova. We are appreciative to Dr. Ladislav Vyklicky, Dr. Hana Chodounska and Dr. Eva Kudova for scientific inspiration and for steroid synthesis. We would also like to express our gratitude to Dr. Jaroslava Folbergrova for critical reading of the manuscript and her inspiring comments. Last but not least, we want to express thank to Ms. Thuy Hua for language check. This study was supported by GACR grants P304/11/P386 P304/14/20613S P304/12/G069, P303/12/1464 TACR-TE01020028 and GAUK 604412, institutional support RVO: 67985823.",null,37,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0304-3940","1872-7972",null,"NEUROSCI LETT","Neurosci. Lett.","APR 3",2014,564,null,null,null,null,null,11,15,null,"10.1016/j.neulet.2014.01.057",null,5,"Neurosciences","Neurosciences & Neurology","AF8SK","WOS:000334985700003"]
["J","Rybka, V; Vavrik, P; Landor, I; Denk, F; Hach, J; Kruta, T; Sibr, M",null,null,null,"Rybka, V.; Vavrik, P.; Landor, I.; Denk, F.; Hach, J.; Kruta, T.; Sibr, M.",null,null,"All-Polyethylene Tibial Component in Walter-Motorlet Total Knee Arthroplasty. Long-Term Outcomes","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"ALL-POLY tibial component; total knee arthroplasty; long-term results","JOINT; SURVIVORSHIP; REPLACEMENT; FAILURE; WEAR","PURPOSE OF THE STUDY An analysis of long-term results of the all-polyethylene tibial component in Walter-Motorlet cemented condylar knee arthroplasty, with a standard tibial plateau (STP) of our own design. MATERIAL AND METHODS A total of 49 patients underwent knee replacement; of them, 35 (71.4%) with 38 Walter-Motorlet implants using the STP were evaluated. The average age at the time of evaluation was 87.3 years. The follow-up ranged from 18 to 27 years (average, 24.6 years). Mechanical properties of the STP were tested by experimental measurements and in a photoelasticimetric study. The clinical results were evaluated according to the EULAR Knee Assessment Chart (EKACH). Twenty-four patients (26 knees; 49%) had osteoarthritis (OA) and 11 (12 knees; 23%) had rheumatoid arthritis (RA). Of the 14 (28.6%) patients not included in evaluation, seven (14.3%), with seven knees, required revision arthroplasty and seven (14.3%), with 10 knees, were lost to follow-up. RESULTS Of the 38 implants evaluated by the EKACH at an average of 24.6 years, subjectively, 14 (36.8%) knees were free from pain and 14 (36.8%) were mildly painful. The remaining 10 (26.4%) joints were acutely painful on walking up or down the hill. In 14 (36.8%) cases the patients experienced their knees as stable. Light domestic chores were routinely performed by 17 patients (10 OA and 7 RA; 48.6%). One (2.9%) OA patient had a full-time job, and nine (25.7%) patients were socially independent. The functional outcome was significantly related to the patient's age at the time of evaluation. Complications included SIP aseptic loosening in five (13.1%) and late infection in two (5.2%) knees. Radiography showed translucent zones below an all-polyethylene component in 14 (36.8%) knees. DISCUSSION The five cases of aseptic loosening may have been due to insufficient hardness of a U-shaped polyethylene component and long-term stress at the bone-implant interface. In the majority of knees the anterior cruciate ligament was defective or missing completely. Maintenance of the posterior cruciate ligament facilitates absorption of the greater part of forces at the cement-bone interface, as also reported by other authors. The high incidence of complications associated with patellar components, as described in the literature of the late 1970s and the early 1980s, led us to avoid the primary use of a patellar implant. CONCLUSIONS Our evaluation showed that, in 73% of the cases, the all-polyethylene tibial component was a suitable and inexpensive implant with very good or good long-term results on average at 24.6 years of follow-up. Since the quality of currently produced polyethylene is high, we recommend the use of all-polyethylene tibial components in all indicated cases.","[Rybka, V.; Vavrik, P.; Landor, I.; Denk, F.; Hach, J.; Kruta, T.] LF UK, I Ortoped Klin 1, Prague, Czech Republic; [Sibr, M.] MEDIN Orthopaed As, Prague, Czech Republic","Rybka, V (reprint author), FN Motol, LF UK, I Ortoped Klin 1, V Uvalu 84, Prague 15006 5, Czech Republic.","rybkaprof@volny.cz",null,null,null,null,null,41,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2014,81,2,null,null,null,null,122,128,null,null,null,7,"Orthopedics","Orthopedics","AG4DG","WOS:000335368900004"]
["J","Bartak, V; Kratky, Z; Popelka, S",null,null,null,"Bartak, V.; Kratky, Z.; Popelka, S.",null,null,"Tumour-Like Lesion of the Forefoot due to a Retained Toothpick Fragment. Case Report","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"pseudotumour; forefoot; toothpick; retained","FOREIGN-BODIES; SOFT-TISSUES; BONE; OSTEOMYELITIS; METATARSAL; THORN","The case of a 17-year-old patient with a pseudotumour of the forefoot caused by a retained toothpick fragment is reported. The patient had several examinations in a two-year period and was treated for synovialitis of the first and third metatarsophalangeal joints. However, radiography of the plantar surface was the only examination done during these two years. Therapy was unsuccessful. After admission to our department, ultrasonography was performed and a foreign body in granulation tissue was detected. Computed tomography and MRI confirmed the finding. The foreign body granuloma was removed by surgery and the patient healed successfully. Options for visualising wooden foreign bodies not detected on X-ray images are discussed.","[Bartak, V.; Popelka, S.] 1 LF UK FN Motol, Ortoped Klin 1, Prague 15006, Czech Republic; [Bartak, V.; Kratky, Z.] Nemocnice Prachatice, Ortoped Traumatol Oddelenf, Prachatice, Czech Republic","Bartak, V (reprint author), 1 LF UK FN Motol, Ortoped Klin 1, V Uvalu 84, Prague 15006, Czech Republic.","vbartak@email.cz",null,null,null,null,null,10,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2014,81,2,null,null,null,null,152,154,null,null,null,3,"Orthopedics","Orthopedics","AG4DG","WOS:000335368900008"]
["J","Goetz, M; Surman, CBH",null,null,null,"Goetz, Michal; Surman, Craig Bruce Hackett",null,null,"Prolonged Penile Erections Associated With the Use of Atomoxetine and Aripiprazole in an 11-Year-Old Boy","JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY",null,null,"English","Letter",null,null,null,null,null,null,"ATYPICAL ANTIPSYCHOTIC MEDICATIONS; PRIAPISM; CHILD",null,"[Goetz, Michal] Charles Univ Prague, Fac Med 2, Dept Paediat Psychiat, Prague, Czech Republic; [Goetz, Michal] Motol Univ Hosp, Prague, Czech Republic; [Surman, Craig Bruce Hackett] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Clin & Res Program Pediat Psychopharmacol & Adult, Boston, MA USA","Goetz, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat Psychiat, Prague, Czech Republic.","michal.goetz@lfmotol.cuni.cz",null,null,null,null,null,8,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0271-0749","1533-712X",null,"J CLIN PSYCHOPHARM","J. Clin. Psychopharmacol.","APR",2014,34,2,null,null,null,null,275,276,null,"10.1097/01.jcp.0000445185.90518.84",null,2,"Pharmacology & Pharmacy; Psychiatry","Pharmacology & Pharmacy; Psychiatry","AG3OC","WOS:000335328000021"]
["J","Lassuthova, P; Siskova, D; Haberlova, J; Sakmaryova, I; Filous, A; Seeman, P",null,null,null,"Lassuthova, Petra; Siskova, Dana; Haberlova, Jana; Sakmaryova, Iva; Filous, Ales; Seeman, Pavel",null,null,"Congenital cataract, facial dysmorphism and demyelinating neuropathy (CCFDN) in 10 Czech gypsy children - frequent and underestimated cause of disability among Czech gypsies","ORPHANET JOURNAL OF RARE DISEASES",null,null,"English","Article",null,null,null,null,null,"Gypsies/genetics; Cataract/congenital; Nervous system diseases/*genetics; Facial nerve diseases/*congenital/genetics; Face/*abnormalities","ROMA PEOPLE; HEALTH","Background: Congenital Cataract Facial Dysmorphism and demyelinating Neuropathy (CCFDN, OMIM 604468) is an autosomal recessive multi-system disorder which was first described in Bulgarian Gypsies in 1999. It is caused by the homozygous founder mutation c. 863 + 389C > T in the CTDP1 gene. The syndrome has been described exclusively in patients of Gypsy ancestry. The prevalence of this disorder in the Gypsy population in the Czech Republic and Central Europe is not known and is probably underestimated and under-diagnosed. Methods: We clinically diagnosed and assessed 10 CCFDN children living in the Czech Republic. All patients are children of different ages, all of Gypsy origin born in the Czech Republic. Molecular genetic testing for the founder CTDP1 gene mutation was performed. Results: All patients are homozygous for the c. 863 + 389C > T mutation in the CTDP1 gene. All patients presented a bilateral congenital cataract and microphthalmos and had early cataract surgery. Correct diagnosis was not made until the age of two. All patients had variably delayed motor milestones. Gait is characteristically paleocerebellar in all the patients. Mental retardation was variable and usually mild. Conclusions: Clinical diagnosis of CCFDN should be easy for an informed pediatrician or neurologist by the obligate signalling trias of congenital bilateral cataract, developmental delay and later demyelinating neuropathy. Our data indicate a probably high prevalence of CCFDN in the Czech Gypsy ethnic subpopulation.","[Lassuthova, Petra; Haberlova, Jana; Sakmaryova, Iva; Seeman, Pavel] Charles Univ Prague, Fac Med 2, Dept Paediat Neurol, DNA Lab, Prague, Czech Republic; [Lassuthova, Petra; Haberlova, Jana; Sakmaryova, Iva; Filous, Ales; Seeman, Pavel] Univ Hosp Motol, Prague, Czech Republic; [Siskova, Dana] Thomayers Hosp, Dept Paediat Neurol, Prague, Czech Republic; [Filous, Ales] Charles Univ Prague, Fac Med 2, Dept Ophthalmol, Prague, Czech Republic","Lassuthova, P (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat Neurol, DNA Lab, Prague, Czech Republic.","petra.lassuthova@gmail.com",null,null,"IGA MHCR [NT11521-4]; MH CZ-DRO; University Hospital Motol, Prague,Czech Republic [00064203]","We would like to thank all the patients and their families for participating in the study. Research was supported by IGA MHCR NT11521-4 and by MH CZ-DRO, University Hospital Motol, Prague,Czech Republic 00064203.",null,17,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1750-1172",null,null,"ORPHANET J RARE DIS","Orphanet J. Rare Dis.","APR 1",2014,9,null,null,null,null,null,null,null,46,"10.1186/1750-1172-9-46",null,10,"Genetics & Heredity; Medicine, Research & Experimental","Genetics & Heredity; Research & Experimental Medicine","AG2PC","WOS:000335257500001"]
["J","Zdarska, DJ; Kvapil, M; Rusavy, Z; Krcma, M; Broz, J; Krivska, B; Kadlecova, P",null,null,null,"Zdarska, Denisa Janickova; Kvapil, Milan; Rusavy, Zdenek; Krcma, Michal; Broz, Jan; Krivska, Bohumila; Kadlecova, Pavla",null,null,"Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: The COBIN2 study","WIENER KLINISCHE WOCHENSCHRIFT",null,null,"English","Article",null,null,null,null,null,"Glucose variability; Insulin glargine; Type 2 diabetes mellitus; Continuous glucose-monitoring system","SUBCUTANEOUS INJECTION; GLYCEMIC VARIABILITY; DISEASE; PHARMACOKINETICS; HYPOGLYCEMIA; RISK","Glucose variability combined with glycosylated hemoglobin (HbA1c) assessments more reliably represents the level of glycemic control. The study was aimed to compare blood glucose variability with insulin glargine vs. neutral protamine Hagedorn (NPH) in patients with type 2 diabetes mellitus using a continuous glucose-monitoring system (CGMS), in patients treated with basal insulin using stable dose of oral antidiabetic agents and HbA1c in the range of 4.5-8.0 % International Federation of Clinical Chemistry (IFCC) units. [6.2-9.4 % Diabetes Control and Complications Trial (DCCT) units]. This was a multicenter, prospective, open-label, single-arm study in patients (N = 116) treated for a parts per thousand yenaEuro parts per thousand 2 months with NPH and metformin combined with sulfonylurea or glinide. Glucose variability was measured after a 4-week NPH treatment phase and after a subsequent 12-week glargine treatment phase using CGMS. Based on 72-hour CGMS, glucose variability was assessed by area under the curve [AUC (mmol/L center dot h)]. Differences (glargine-NPH) in AUC within 24 h in the glucose ranges of a parts per thousand currency signaEuro parts per thousand 3.3, a parts per thousand currency signaEuro parts per thousand 3.9, 7.5-3.9 (margins excluding), a parts per thousand yenaEuro parts per thousand 7.5, a parts per thousand yenaEuro parts per thousand 10, and a parts per thousand yenaEuro parts per thousand 15 mmol/L were evaluated. Circadian fluctuation of glucose was assessed by M-value (log-transformation of the deviation from an arbitrary standard). AUCs of glucose in the lowest ranges (a parts per thousand currency signaEuro parts per thousand 3.3 and a parts per thousand currency signaEuro parts per thousand 3.9 mmol/L) did not change significantly after treatment with glargine. Those in the higher ranges (a parts per thousand yenaEuro parts per thousand 7.5, a parts per thousand yenaEuro parts per thousand 10, and a parts per thousand yenaEuro parts per thousand 15 mmol/L) were significantly lower (p < 0.001 for all ranges), whereas AUC of glucose in the normal range (3.9-7.5 mmol/L) was significantly higher (p < 0.001) at the end of glargine treatment phase. Circadian fluctuation of glucose assessed by M-value showed a significant decrease after glargine treatment (p < 0.003). No significant differences in hypoglycemia confirmed by glucose value a parts per thousand currency signaEuro parts per thousand 3.3 mmol/L were found between treatment phases. This trial is registered at ClinicalTrials.gov, NCT00659477. As monitored by CGMS, switching from NPH to glargine with active titration shifted glucose from abnormally high to normal levels with reduced fluctuation and without increased risk of hypoglycemia.","[Zdarska, Denisa Janickova; Kvapil, Milan; Broz, Jan] Charles Univ Prague, Fac Med 2, Dept Med, Prague, Czech Republic; [Rusavy, Zdenek; Krcma, Michal] Charles Univ Prague, Univ Hosp, Dept Med, Plzen, Czech Republic; [Rusavy, Zdenek; Krcma, Michal] Charles Univ Prague, Fac Med, Plzen, Czech Republic; [Krivska, Bohumila] Sanofi Aventis, Prague, Czech Republic; [Kadlecova, Pavla] ADDS, Brno, Czech Republic","Zdarska, DJ (reprint author), Charles Univ Prague, Fac Med 2, Dept Med, Prague, Czech Republic.","denisa.janickova.zdarska@email.cz",null,null,"Sanofi-Aventis","The study was sponsored by Sanofi-Aventis. The sponsors had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,17,0,0,"SPRINGER WIEN","WIEN","SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA","0043-5325","1613-7671",null,"WIEN KLIN WOCHENSCHR","Wien. Klin. Wochen.","APR",2014,126,"2014-08-07",null,null,null,null,228,237,null,"10.1007/s00508-014-0508-6",null,10,"Medicine, General & Internal","General & Internal Medicine","AG1JB","WOS:000335170200008"]
["J","Brabcova, D; Krsek, P; Kohout, J; Zarubova, J",null,null,null,"Brabcova, Dana; Krsek, Pavel; Kohout, Jiri; Zarubova, Jana",null,null,"Psychometric properties of the modified Czech version of the children self-report Quality-of-life Measure for Children with Epilepsy (CHEQOL-25)","EPILEPSY & BEHAVIOR",null,null,"English","Article",null,null,null,null,null,"Quality of life; Children; Epilepsy; Adaptation; Psychometric properties","CONSTRUCT-VALIDITY; CHILDHOOD EPILEPSY; CHINESE VERSION; ADOLESCENTS; VALIDATION; SCALE; RELIABILITY; PREDICTORS; IMPACT; YOUTH","Quality of life (QoL) is a crucial factor in the treatment of individuals suffering from epilepsy. We aimed to adapt the children's version of the CHEQOL-25 questionnaire to allow the QoL measurement in children suffering from epilepsy in the Czech Republic. The adaptation was conducted on a group of 250 children and adolescents aged 8-15 years. It was found that the questionnaire required modification to fit the Czech pediatric population. Indirect questions were changed to direct questions, and two items were omitted from the original version of the questionnaire. The reasons for these modifications are discussed. The modified questionnaire was subjected to exploratory factor analysis, and a 4-factor structure was favored over the 5-factor structure of the original version. The internal consistency measured using Cronbach's alpha was found to be in the range of 0.78-0.83 for the individual scales, and test-retest reliability was expressed using intraclass correlation coefficient which was found to be in the range of 0.65-0.75. The modified Czech version of the CHEQOL-25 questionnaire displayed very good results with regard to construct validity. Its strength is its simplicity and clarity which allows it to be used in children with impaired cognitive functions. The results showed that the modified version of the Czech CHEQOL-25 has very good psychometric properties and could be used in further research and clinical practice. (C) 2014 Elsevier Inc. All rights reserved.","[Brabcova, Dana] Univ South Bohemia, Pedag Fac, Dept Pedag & Psychol, Ceske Budejovice 37115, Czech Republic; [Krsek, Pavel] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Pediat Neurol, Prague, Czech Republic; [Kohout, Jiri] Univ W Bohemia, Plzen 30614, Czech Republic; [Zarubova, Jana] Thomayers Hosp, Prague, Czech Republic","Brabcova, D (reprint author), Tocnik 4, Klatovy 33901, Czech Republic.","dannab@seznam.cz",null,null,"Quality of Life of Children Living with Epilepsy implemented under the Promising Strategies Program; IBE - the International Bureau for Epilepsy; MH CZ-DRO, University Hospital Motol, Prague, Czech Republic [00064203];  [GAJU 037/2010/S]","We would like to thank all the physicians and patients who took part in this study. This research project was supported by Quality of Life of Children Living with Epilepsy implemented under the Promising Strategies 2010 Program, which is a program by IBE - the International Bureau for Epilepsy, and by the grants GAJU 037/2010/S and MH CZ-DRO, University Hospital Motol, Prague, Czech Republic, 00064203. The use of the Health-related Quality of Life Questionnaire in Children with Epilepsy, authored by Dr. Gabriel Ronen et. al., was made under license from McMaster University, Hamilton, Canada.",null,31,0,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1525-5050","1525-5069",null,"EPILEPSY BEHAV","Epilepsy Behav.","APR",2014,33,null,null,null,null,null,31,38,null,"10.1016/j.yebeh.2014.02.013",null,8,"Behavioral Sciences; Clinical Neurology; Psychiatry","Behavioral Sciences; Neurosciences & Neurology; Psychiatry","AF4BA","WOS:000334655200007"]
["J","Pochop, P; Mahelkova, G; Cendelin, J; Petruskova, D",null,null,null,"Pochop, Pavel; Mahelkova, Gabriela; Cendelin, Jiri; Petruskova, Denisa",null,null,"Early detection of recurrent primary iris stromal cyst using ultrasound biomicroscopy","JOURNAL OF AAPOS",null,null,"English","Article",null,null,null,null,null,null,"MANAGEMENT","Primary iris stromal cyst characteristically presents as a smooth, round, translucent mass in the anterior chamber. In small children it tends to grow rapidly and may be confused with intraocular malignancy. Management is difficult, and recurrences are frequent. We report 2 cases of primary iris stromal cyst in which recurrence was detected relatively early using ultrasound biomicroscopy and successfully managed with iridectomy.","Charles Univ Prague, Fac Med 2, Dept Ophtalmol, CR-11636 Prague 1, Czech Republic; Univ Hosp Motol, Prague 15006 5, Czech Republic","Pochop, P (reprint author), Univ Hosp Motol, Dept Ophtalmol, V Uvalu 84, Prague 15006 5, Czech Republic.","pavel.pochop@gmail.com",null,null,"Ministry of Health, Czech Republic; University Hospital Motol, Prague, Czech Republic [00064203]","Supported by the Ministry of Health, Czech Republic conceptual development of research organization, University Hospital Motol, Prague, Czech Republic, 00064203.",null,10,0,0,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","1091-8531","1528-3933",null,"J AAPOS","J. AAPOS","APR",2014,18,2,null,null,null,null,184,186,null,"10.1016/j.jaapos.2013.09.017",null,3,"Ophthalmology; Pediatrics","Ophthalmology; Pediatrics","AF3ZW","WOS:000334652200019"]
["J","Stepan, J; Ehrlichova, J; Hladikova, M",null,null,null,"Stepan, J.; Ehrlichova, J.; Hladikova, M.",null,null,"Efficacy and safety of symphytum herb extract cream in the treatment of pressure ulcers","ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE",null,null,"German","Article",null,null,null,null,null,"Pressure ulcer; Comfrey; Skin care; Prospective studies; Bed sore","TOPICAL TREATMENT; OINTMENT; SORES; RISK","In an open, prospective use study, 161 patients with 198 decubitus ulcers (pressure ulcers, ITT population) in stages II and III were treated with the topical preparation symphytum herb extract cream. The bandages with the cream were changed every 2-3 days. The primary parameters evaluated were the area of the sore and the depth of the wound (planimetrically in mm). In all, 151 patients with a total of 184 pressure sores (PP population) were included and received treatment over a period of 4 weeks in order to evaluate the treatment results. Complete healing of the pressure sores within 4 weeks was observed in 85.9 % (PP population)/79.8 % (ITT population) of the treated ulcers. Over a treatment duration of 25-30 days, a 89.2 % reduction of the total decubitus area was observed. The same result was found for the depth of the pressure ulcer with a reduction of 88 %. The overall treatment success was from both the perspective of the physician and the patient considered successful in 90.4 % (5-point scale) of cases and 87.9% (100 mm VAS, PP population). Two cases of local irritation were observed after 25/30 days (1.2 % of the patients with exposure), thus showing very good skin compatibility. The efficacy of symphytum herb extract cream is surprisingly good in the treatment of pressure ulcers.","[Stepan, J.; Ehrlichova, J.] Karls Univ, Med Fak 2, Abt Langstationare Patienten, Klin Motol, Prague, Czech Republic; [Hladikova, M.] Karls Univ, Med Fak 2, Abt Med Informat, Prague, Czech Republic","Stepan, J (reprint author), Karls Univ, Med Fak 2, Abt Langstationare Patienten, Klin Motol, Prague, Czech Republic.","j.a.stepan@centrum.cz",null,null,null,null,null,26,0,0,"SPRINGER HEIDELBERG","HEIDELBERG","TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY","0948-6704","1435-1269",null,"Z GERONTOL GERIATR","Z. Gerontol. Geriatr.","APR",2014,47,3,null,null,null,null,228,235,null,"10.1007/s00391-013-0522-8",null,8,"Geriatrics & Gerontology; Gerontology","Geriatrics & Gerontology","AF2ZA","WOS:000334579800007"]
["J","Honek, J; Sramek, M; Sefc, L; Januska, J; Fiedler, J; Horvath, M; Tomek, A; Novotny, S; Honek, T; Veselka, J",null,null,null,"Honek, Jakub; Sramek, Martin; Sefc, Ludek; Januska, Jaroslav; Fiedler, Jiri; Horvath, Martin; Tomek, Ales; Novotny, Stepan; Honek, Tomas; Veselka, Josef",null,null,"Effect of Catheter-Based Patent Foramen Ovale Closure on the Occurrence of Arterial Bubbles in Scuba Divers","JACC-CARDIOVASCULAR INTERVENTIONS",null,null,"English","Article",null,null,null,null,null,"catheter-based closure; decompression sickness; paradoxical embolization; patent foramen ovale","VENOUS GAS EMBOLI; TO-LEFT SHUNT; DECOMPRESSION-SICKNESS; TRANSCATHETER CLOSURE; BRAIN-LESIONS; FOLLOW-UP; ILLNESS; RISK; SONOGRAPHY; SIZE","Objectives This study sought to evaluate the effect of catheter-based patent foramen ovale (PFO) closure on the occurrence of arterial bubbles after simulated dives. Background PFO is a risk factor of decompression sickness in divers due to paradoxical embolization of bubbles. To date, the effectiveness of catheter-based PFO closure in the reduction of arterial bubbles has not been demonstrated. Methods A total of 47 divers (age 35.4 +/- 8.6 years, 81% men) with a PFO (PFO group) or treated with a catheter-based PFO closure (closure group) were enrolled in this case-controlled observational trial. All divers were examined after a simulated dive in a hyperbaric chamber: 34 divers (19 in the PFO group, 15 in the closure group) performed a dive to 18 m for 80 min, and 13 divers (8 in the PFO group, 5 in the closure group) performed a dive to 50 m for 20 min. Within 60 min after surfacing, the presence of venous and arterial bubbles was assessed by transthoracic echocardiography and transcranial color-coded sonography, respectively. Results After the 18-m dive, venous bubbles were detected in 74% of divers in the PFO group versus 80% in the closure group (p = 1.0), and arterial bubbles were detected in 32% versus 0%, respectively (p = 0.02). After the 50-m dive, venous bubbles were detected in 88% versus 100%, respectively (p = 1.0), and arterial bubbles were detected in 88% versus 0%, respectively (p < 0.01). Conclusions No difference was observed in the occurrence of venous bubbles between the PFO and closure groups, but the catheter-based PFO closure led to complete elimination of arterial bubbles after simulated dives. (C) 2014 by the American College of Cardiology Foundation","[Honek, Jakub; Fiedler, Jiri; Horvath, Martin; Honek, Tomas; Veselka, Josef] Charles Univ Prague, Fac Med 2, Dept Cardiol, Prague, Czech Republic; [Honek, Jakub; Sramek, Martin; Fiedler, Jiri; Horvath, Martin; Tomek, Ales; Honek, Tomas; Veselka, Josef] Motol Univ Hosp, Prague 15006 5, Czech Republic; [Honek, Jakub; Sramek, Martin; Sefc, Ludek] Charles Univ Prague, Fac Med 1, Inst Pathol Physiol, Prague, Czech Republic; [Sramek, Martin; Tomek, Ales] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague, Czech Republic; [Januska, Jaroslav] Hosp Podlesi, Cardioctr, Trinec, Czech Republic; [Novotny, Stepan] Kladno Reg Hosp, Hyperbar Chamber, Kladno, Czech Republic","Veselka, J (reprint author), Motol Univ Hosp, Dept Cardiol, Uvalu 84, Prague 15006 5, Czech Republic.","veselka.josef@seznam.cz",null,null,"University Hospital Motol [MH CZ-DRO 00064203]; Charles University [SVV-2013-266509]; Charles University-First Faculty of Medicine [PRVOUK-P24/LF1/3]","This study was supported by the following grants: #MH CZ-DRO 00064203 from the University Hospital Motol; #SVV-2013-266509 from the Charles University; and #PRVOUK-P24/LF1/3 of the Charles University-First Faculty of Medicine. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.",null,29,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1936-8798","1876-7605",null,"JACC-CARDIOVASC INTE","JACC-Cardiovasc. Interv.","APR",2014,7,4,null,null,null,null,403,408,null,"10.1016/j.jcin.2013.12.199",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AF1YK","WOS:000334509600012"]
["J","Heger, Z; Cernei, N; Gumulec, J; Masarik, M; Eckschlager, T; Hrabec, R; Zitka, O; Adam, V; Kizek, R",null,null,null,"Heger, Zbynek; Cernei, Natalia; Gumulec, Jaromir; Masarik, Michal; Eckschlager, Tomas; Hrabec, Roman; Zitka, Ondrej; Adam, Vojtech; Kizek, Rene",null,null,"Determination of common urine substances as an assay for improving prostate carcinoma diagnostics","ONCOLOGY REPORTS",null,null,"English","Article",null,null,null,null,null,"PSA; immunoenzymometric assay; ion-exchange liquid chromatography; sarcosine; spectrophotometry; proline","ACUTE KIDNEY INJURY; PROLINE-OXIDASE; CANCER PROGRESSION; MASS-SPECTROMETRY; RENAL-CANCER; METABOLISM; SARCOSINE; SERUM; ACID; BIOMARKERS","Recently, interest in the identification of non-invasive markers for prostate carcinoma detectable in the urine of patients has increased. In this study, we monitored the abundance of potential non-invasive markers of prostate carcinoma such as amino acid sarcosine, involved in the metabolism of amino acids and methylation processes, ongoing during the progression of prostate carcinoma. In addition, other potential prostate tumor markers were studied. The most significant markers, prostate-specific antigen (PSA) and free PSA (fPSA), already used in clinical diagnosis, were analyzed using an immunoenzymometric assay. Whole amino acid profiles were also determined to evaluate the status of amino acids in patient urine samples and to elucidate the possibility of their utilization for prostate carcinoma diagnosis. To obtain the maximum amount of information, the biochemical parameters were determined using various spectrophotometric methods. All results were subjected to statistical processing for revealing different correlations between the studied parameters. We observed alterations in most of the analyzed substances. Based on the results obtained, we concluded that the specificity of prostate carcinoma diagnosis could be improved by determination of common urine metabolites, since we compiled a set of tests, including the analysis of sarcosine, proline, PSA and uric acid in the urine. These metabolites were not observed in the urine obtained from healthy subjects, while their levels were elevated in all patients suffering from prostate carcinoma.","[Heger, Zbynek; Cernei, Natalia; Zitka, Ondrej; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Cernei, Natalia; Gumulec, Jaromir; Masarik, Michal; Zitka, Ondrej; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Gumulec, Jaromir; Masarik, Michal] Masaryk Univ, Dept Pathol Physiol, Fac Med, CZ-62500 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Hrabec, Roman] St Annes Univ Hosp, Dept Urol, CZ-65691 Brno, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Masarik, Michal/D-9920-2012; Gumulec, Jaromir/D-7638-2012","Gumulec, Jaromir/0000-0002-9658-3444","CEITEC [CZ.1.05/1.1.00/02.0068];  [00064203]","The present study was financially supported by the CEITEC CZ.1.05/1.1.00/02.0068 and the project for conceptual development of research organization 00064203.",null,59,0,0,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1021-335X","1791-2431",null,"ONCOL REP","Oncol. Rep.","APR",2014,31,4,null,null,null,null,1846,1854,null,"10.3892/or.2014.3054",null,9,"Oncology","Oncology","AE9RF","WOS:000334345600046"]
["J","Poljakova, J; Groh, T; Gudino, ZO; Hrabeta, J; Borek-Dohalska, L; Kizek, R; Doktorova, H; Eckschlager, T; Stiborova, M",null,null,null,"Poljakova, Jitka; Groh, Tomas; Gudino, Zaneta Omana; Hrabeta, Jan; Borek-Dohalska, Lucie; Kizek, Rene; Doktorova, Helena; Eckschlager, Tomas; Stiborova, Marie",null,null,"Hypoxia-mediated histone acetylation and expression of N-myc transcription factor dictate aggressiveness of neuroblastoma cells","ONCOLOGY REPORTS",null,null,"English","Article",null,null,null,null,null,"N-myc expression; histone acetylation; neuroblastoma; hypoxia","DEACETYLASE INHIBITORS; CANCER-CELLS; C-MYC; TUMOR; CHROMATIN; HIF-1-ALPHA; ELLIPTICINE; BINDING; ENIGMA; H4","Cells of solid malignancies generally adapt to entire lack of oxygen. Hypoxia induces the expression of several genes, which allows the cells to survive. For DNA transcription, it is necessary that DNA structure is loosened. In addition to structural characteristics of DNA, its epigenetic alterations influence a proper DNA transcription. Since histones play a key role in epigenetics, changes in expression levels of acetylated histones H3 and H4 as well as of hypoxia-inducible factor-1 alpha (HIF-1 alpha) in human neuroblastoma cell lines cultivated under standard or hypoxic conditions (1% O-2) were investigated. Moreover, the effect of hypoxia on the expression of two transcription factors, c-Myc and N-myc, was studied. Hypoxic stress increased levels of acetylated histones H3 and H4 in UKF-NB-3 and UKF-NB-4 neuroblastoma cells with N-myc amplification, whereas almost no changes in acetylation of these histones were found in an SK-N-AS neuroblastoma cell line, the line with diploid N-myc status. An increase in histone H4 acetylation caused by hypoxia in UKF-NB-3 and UKF-NB-4 corresponds to increased levels of N-myc transcription factor in these cells.","[Poljakova, Jitka; Groh, Tomas; Gudino, Zaneta Omana; Borek-Dohalska, Lucie; Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12840 2, Czech Republic; [Hrabeta, Jan; Doktorova, Helena; Eckschlager, Tomas] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Hrabeta, Jan; Doktorova, Helena; Eckschlager, Tomas] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Brno 61300, Czech Republic; [Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, Brno 61600, Czech Republic","Stiborova, M (reprint author), Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, Prague 12840 2, Czech Republic.","stiborov@natur.cuni.cz",null,null,"GACR [P301/10/0356]; Charles University in Prague [635712/2012, 620612/2012, UNCE 204025/2012]; MH CZ-DRO, University Hospital Motol, Prague, Czech Republic [00064203]","The present study was supported by GACR (P301/10/0356), Charles University in Prague (635712/2012, 620612/2012 and UNCE 204025/2012) and MH CZ-DRO, University Hospital Motol, Prague, Czech Republic 00064203.",null,33,0,0,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1021-335X","1791-2431",null,"ONCOL REP","Oncol. Rep.","APR",2014,31,4,null,null,null,null,1928,1934,null,"10.3892/or.2014.2999",null,7,"Oncology","Oncology","AE9RF","WOS:000334345600057"]
["J","IJspeert, H; Driessen, GJ; Moorhouse, MJ; Hartwig, NG; Wolska-Kusnierz, B; Kalwak, K; Pituch-Noworolska, A; Kondratenko, I; van Montfrans, JM; Mejstrikova, E; Lankester, AC; Langerak, AW; van Gent, DC; Stubbs, AP; van Dongen, JJM; van der Burg, M",null,null,null,"IJspeert, Hanna; Driessen, Gertjan J.; Moorhouse, Michael J.; Hartwig, Nico G.; Wolska-Kusnierz, Beata; Kalwak, Krzysztof; Pituch-Noworolska, Anna; Kondratenko, Irina; van Montfrans, Joris M.; Mejstrikova, Ester; Lankester, Arjan C.; Langerak, Anton W.; van Gent, Dik C.; Stubbs, Andrew P.; van Dongen, Jacques J. M.; van der Burg, Mirjam",null,null,"Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes","JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"RAG deficiency; V(D)J recombination; B- and T-cell receptor repertoire; receptor editing; autoimmunity; next generation sequencing; immune repertoire analysis","T-CELL-RECEPTOR; SEVERE COMBINED IMMUNODEFICIENCY; IMMUNOGLOBULIN-SECRETING CELLS; COMBINED IMMUNE-DEFICIENCY; OMENN-SYNDROME; V(D)J RECOMBINATION; SEQUENCE-ANALYSIS; SCID PATIENTS; BONE-MARROW; REARRANGEMENTS","Background: V(D)J recombination takes place during lymphocyte development to generate a large repertoire of T-and B-cell receptors. Mutations in recombination-activating gene 1 (RAG1) and RAG2 result in loss or reduction of V(D) J recombination. It is known that different mutations in RAG genes vary in residual recombinase activity and give rise to a broad spectrum of clinical phenotypes. Objective: We sought to study the immunologic mechanisms causing the clinical spectrum of RAG deficiency. Methods: We included 22 patients with similar RAG1 mutations (c.519delT or c.368_369delAA) resulting in N-terminal truncated RAG1 protein with residual recombination activity but presenting with different clinical phenotypes. We studied precursor B-cell development, immunoglobulin and T-cell receptor repertoire formation, receptor editing, and B-and T-cell numbers. Results: Clinically, patients were divided into 3 main categories: T-B- severe combined immunodeficiency, Omenn syndrome, and combined immunodeficiency. All patients showed a block in the precursor B-cell development, low B-and T-cell numbers, normal immunoglobulin gene use, limited B-and T-cell repertoires, and slightly impaired receptor editing. Conclusion: This study demonstrates that similar RAG mutations can result in similar immunobiological effects but different clinical phenotypes, indicating that the level of residual recombinase activity is not the only determinant for clinical outcome. We postulate a model in which the type and moment of antigenic pressure affect the clinical phenotypes of these patients.","[IJspeert, Hanna; Driessen, Gertjan J.; Langerak, Anton W.; van Dongen, Jacques J. M.; van der Burg, Mirjam] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [IJspeert, Hanna; Driessen, Gertjan J.; Hartwig, Nico G.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Pediat, Rotterdam, Netherlands; [Moorhouse, Michael J.] Stichting Sanquin Bloedvoorziening, Dept Blood Cell Res, Amsterdam, Netherlands; [Wolska-Kusnierz, Beata] Childrens Mem Hlth Inst, Dept Immunol, Warsaw, Poland; [Kalwak, Krzysztof] Wroclaw Med Univ, Dept Pediat Hematol Oncol & Bone Marrow Transplan, Wroclaw, Poland; [Pituch-Noworolska, Anna] Jagiellonian Univ, Coll Med, Dept Clin Immunol, Polish Amer Inst Pediat, Krakow, Poland; [Kondratenko, Irina] Russian State Childrens Hosp, Dept Clin Immunol, Moscow, Russia; [van Montfrans, Joris M.] Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, Utrecht, Netherlands; [van Montfrans, Joris M.] Wilhelmina Childrens Hosp, Utrecht, Netherlands; [Mejstrikova, Ester] Teaching Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Mejstrikova, Ester] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Lankester, Arjan C.] Leiden Univ, Dept Pediat, Med Ctr, NL-2300 RA Leiden, Netherlands; [van Gent, Dik C.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Cell Biol & Genet, Rotterdam, Netherlands; [Stubbs, Andrew P.] Erasmus Univ, Dept Bioinformat, Med Ctr Rotterdam, NL-3000 DR Rotterdam, Netherlands","van der Burg, M (reprint author), Erasmus MC, Dept Immunol, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.","m.vanderburg@erasmusmc.nl",null,null,"foundation \"Sophia Kinderziekenhuis Fonds\" [589]; Dutch Organization for Scientific Research (NWO/ZonMw VIDI) [91712323]; IGA [NT/13271]; MH CZ-DRO, University Hospital Motol, Prague, Czech Republic [00064203]; Sophia Kinderziekenhuis Fonds [589]; Baxter; Russian Children's Clinical Hospital; Russian National Scientific Medical University; ZonMW [91712323]","Supported by grants from the foundation \"Sophia Kinderziekenhuis Fonds\" (grant 589 to H. I. and M.v.d.B.), the Dutch Organization for Scientific Research (NWO/ZonMw VIDI grant 91712323 to M.v.d.B.), and the IGA NT/13271, MH CZ-DRO, University Hospital Motol, Prague, Czech Republic (grant 00064203 to E. M.).H. IJspeert has received research support from Sophia Kinderziekenhuis Fonds (grant 589). G. J. Driessen has received research support from Baxter. I. Kondratenko has received consultancy fees from and is employed by Russian Children's Clinical Hospital and has received lecture fees from and has received payment for manuscript preparation from Russian National Scientific Medical University. M. van der Burg has received research support from ZonMW (Vidi grant 91712323). The rest of the authors declare that they have no relevant conflicts of interest.",null,47,0,0,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0091-6749","1097-6825",null,"J ALLERGY CLIN IMMUN","J. Allergy Clin. Immunol.","APR",2014,133,4,null,null,null,null,1124,"+",null,"10.1016/j.jaci.2013.11.028",null,11,"Allergy; Immunology","Allergy; Immunology","AD8QW","WOS:000333531700024"]
["J","Marciano, BE; Huang, CY; Joshi, G; Rezaei, N; Carvalho, BC; Allwood, Z; Ikinciogullari, A; Reda, SM; Gennery, A; Thon, V; Espinosa-Rosales, F; Al-Herz, W; Porras, O; Shcherbina, A; Szaflarska, A; Kilic, S; Franco, JL; Raccio, ACG; Roxo, P; Esteves, I; Galal, N; Grumach, AS; Al-Tamemi, S; Yildiran, A; Orellana, JC; Yamada, M; Morio, T; Liberatore, D; Ohtsuka, Y; Lau, YL; Nishikomori, R; Torres-Lozano, C; Mazzucchelli, JTL; Vilela, MMS; Tavares, FS; Cunha, L; Pinto, JA; Espinosa-Padilla, SE; Hernandez-Nieto, L; Elfeky, RA; Ariga, T; Toshio, H; Dogu, F; Cipe, F; Formankova, R; Nunez-Nunez, ME; Bezrodnik, L; Marques, JG; Pereira, MI; Listello, V; Slatter, MA; Nademi, Z; Kowalczyk, D; Fleisher, TA; Davies, G; Neven, B; Rosenzweig, SD",null,null,null,"Marciano, Beatriz E.; Huang, Chiung-Yu; Joshi, Gyan; Rezaei, Nima; Carvalho, Beatriz Costa; Allwood, Zoe; Ikinciogullari, Aydan; Reda, Shereen M.; Gennery, Andrew; Thon, Vojtech; Espinosa-Rosales, Francisco; Al-Herz, Waleed; Porras, Oscar; Shcherbina, Anna; Szaflarska, Anna; Kilic, Sebnem; Franco, Jose L.; Gomez Raccio, Andrea C.; Roxo, Persio, Jr.; Esteves, Isabel; Galal, Nermeen; Grumach, Anete Sevciovic; Al-Tamemi, Salem; Yildiran, Alisan; Orellana, Julio C.; Yamada, Masafumi; Morio, Tomohiro; Liberatore, Diana; Ohtsuka, Yoshitoshi; Lau, Yu-Lung; Nishikomori, Ryuta; Torres-Lozano, Carlos; Mazzucchelli, Juliana T. L.; Vilela, Maria M. S.; Tavares, Fabiola S.; Cunha, Luciana; Pinto, Jorge A.; Espinosa-Padilla, Sara E.; Hernandez-Nieto, Leticia; Elfeky, Reem A.; Ariga, Tadashi; Toshio, Heike; Dogu, Figen; Cipe, Funda; Formankova, Renata; Enriqueta Nunez-Nunez, M.; Bezrodnik, Liliana; Marques, Jose Goncalo; Pereira, Maria I.; Listello, Viviana; Slatter, Mary A.; Nademi, Zohreh; Kowalczyk, Danuta; Fleisher, Thomas A.; Davies, Graham; Neven, Benedicte; Rosenzweig, Sergio D.",null,null,"BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies","JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Primary immunodeficiency; severe combined immunodeficiency; vaccine; BCG; mycobacteria; newborn screening; hematopoietic stem cell transplant; immune reconstitution syndrome","BACILLUS-CALMETTE-GUERIN; CENTRAL-NERVOUS-SYSTEM; IMMUNOCOMPROMISED CHILDREN; TUBERCULOUS MENINGITIS; VACCINES; INFANTS","Background: Severe combined immunodeficiency (SCID) is a syndrome characterized by profound T-cell deficiency. BCG vaccine is contraindicated in patients with SCID. Because most countries encourage BCG vaccination at birth, a high percentage of patients with SCID are vaccinated before their immune defect is detected. Objectives: We sought to describe the complications and risks associated with BCG vaccination in patients with SCID. Methods: An extensive standardized questionnaire evaluating complications, therapeutics, and outcomes regarding BCG vaccination in patients given a diagnosis of SCID was widely distributed. Summary statistics and association analysis was performed. Results: Data on 349 BCG-vaccinated patients with SCID from 28 centers in 17 countries were analyzed. Fifty-one percent of the patients had BCG-associated complications, 34% disseminated and 17% localized (a 33,000- and 400-fold increase, respectively, over the general population). Patients receiving early vaccination (<= 3 1 month) showed an increased prevalence of complications (P = 5.006) and death caused by BCG-associated complications (P < .0001). The odds of experiencing complications among patients with T-cell numbers of 250/mu L or less at diagnosis was 2.1 times higher (95% CI, 1.4-3.4 times higher; P = .001) than among those with T-cell numbers of greater than 250/mL. BCG-associated complications were reported in 2 of 78 patients who received antimycobacterial therapy while asymptomatic, and no deaths caused by BCG-associated complications occurred in this group. In contrast, 46 BCG-associated deaths were reported among 160 patients treated with antimycobacterial therapy for a symptomatic BCG infection (P < .0001). Conclusions: BCG vaccine has a very high rate of complications in patients with SCID, which increase morbidity and mortality rates. Until safer and more efficient antituberculosis vaccines become available, delay in BCG vaccination should be considered to protect highly vulnerable populations from preventable complications.","[Marciano, Beatriz E.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Huang, Chiung-Yu; Joshi, Gyan] NIAID, Biostat Res Branch, NIH, Bethesda, MD 20892 USA; [Rezaei, Nima] Univ Tehran Med Sci, Pediat Ctr Excellence, Childrens Med Ctr Hosp, Tehran, Iran; [Carvalho, Beatriz Costa; Mazzucchelli, Juliana T. L.; Vilela, Maria M. S.; Tavares, Fabiola S.] Univ Fed Sao Paulo, Dept Pediat, Sao Paulo, Brazil; [Allwood, Zoe; Davies, Graham] Great Ormond St Hosp Sick Children, Dept Immunol, London, England; [Ikinciogullari, Aydan; Dogu, Figen; Cipe, Funda] Ankara Univ, Sch Med, Dept Pediat Immunol & Allergy, TR-06100 Ankara, Turkey; [Reda, Shereen M.; Elfeky, Reem A.] Ain Shams Univ, Dept Pediat Allergy & Immunol, Childrens Hosp, Cairo, Egypt; [Gennery, Andrew; Slatter, Mary A.; Nademi, Zohreh] Great North Childrens Hosp, Paediat Immunol Dept, Newcastle Upon Tyne, Tyne & Wear, England; [Thon, Vojtech] Masaryk Univ, Dept Clin Immunol & Allergy, Fac Med, St Annes Univ Hosp, Brno, Czech Republic; [Espinosa-Rosales, Francisco; Espinosa-Padilla, Sara E.; Hernandez-Nieto, Leticia] Natl Inst Pediat, Mexico City, DF, Mexico; [Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Al Sabah Hosp, Kuwait, Kuwait; [Porras, Oscar] Natl Childrens Hosp Dr Carlos Saenz Herrera, Dept Immunol & Rheumatol, San Jose, Costa Rica; [Shcherbina, Anna] Ctr Pediat Hematol Oncol & Immunol, Dept Clin Immunol, Moscow, Russia; [Szaflarska, Anna; Kowalczyk, Danuta] Childrens Univ Hosp, Dept Clin Immunol & Transplantol, Krakow, Poland; [Kilic, Sebnem] Uludag Univ, Fac Med, Pediat Immunol Div, Bursa, Turkey; [Franco, Jose L.] Univ Antioquia, Primary Immunodeficiency Grp, Medellin, Colombia; [Gomez Raccio, Andrea C.; Bezrodnik, Liliana] Childrens Hosp Ricardo Gutierrez, Immunol Unit, Buenos Aires, DF, Argentina; [Roxo, Persio, Jr.] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-05508 Sao Paulo, Brazil; [Esteves, Isabel; Marques, Jose Goncalo] Hosp Santa Maria, Primary Immunodeficiency Ctr, Lisbon Acad Ctr, Lisbon, Portugal; [Galal, Nermeen] Cairo Univ, Santo Andre, SP, Brazil; [Grumach, Anete Sevciovic] ABC, Fac Med, Sao Paulo, Brazil; [Al-Tamemi, Salem] Sultan Qaboos Univ Hosp, Dept Child Hlth, Muscat, Oman; [Yildiran, Alisan] Ondokuz Mayis Univ, Dept Pediat Immunol, Atakum, Samsun, Turkey; [Orellana, Julio C.; Pereira, Maria I.; Listello, Viviana] Santisima Trinidad Childrens Hosp, Div Allergy & Clin Immunol, Cordoba, Argentina; [Yamada, Masafumi; Ariga, Tadashi] Hokkaido Univ, Dept Pediat, Grad Sch Med, Sapporo, Hokkaido, Japan; [Morio, Tomohiro] Tokyo Med & Dent Univ, Tokyo, Japan; [Liberatore, Diana] Italian Hosp, Buenos Aires, DF, Argentina; [Ohtsuka, Yoshitoshi] Hyogo Coll Med, Nishinomiya, Hyogo, Japan; [Lau, Yu-Lung] Univ Hong Kong, Dept Pediat & Adolescent Med, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China; [Nishikomori, Ryuta; Toshio, Heike] Kyoto Univ Hosp, Dept Pediat, Kyoto, Japan; [Torres-Lozano, Carlos; Enriqueta Nunez-Nunez, M.] Western Natl Med Ctr, Dept Clin Immunol & Allergol, Guadalajara, Jalisco, Mexico; [Cunha, Luciana; Pinto, Jorge A.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil; [Formankova, Renata] Charles Univ Prague, Prague, Czech Republic; [Formankova, Renata] Univ Hosp Motol, Prague, Czech Republic; [Fleisher, Thomas A.] NIH, Serv Immunol, DLM CC, Bethesda, MD 20892 USA; [Neven, Benedicte] Hop Necker Enfants Malad, Immunol Hematol & Rheumatol Serv, Paris, France; [Rosenzweig, Sergio D.] NIAID, Primary Immunodeficiency Clin, LHD, NIH, Bethesda, MD 20892 USA; [Rosenzweig, Sergio D.] NIAID, Infect Dis Susceptibil Unit, NIH, Bethesda, MD 20892 USA","Rosenzweig, SD (reprint author), NIH, Serv Immunol, DLM CC, 10 Ctr Dr,Bldg 10,2C410F, Bethesda, MD 20892 USA.","srosenzweig@cc.nih.gov",null,null,"Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Disease; European Community [201549 (EURO-PADnet HEALTH-F2-2008-201549)]; Tehran University Med Sci; American Academy of Allergy, Asthma & Immunology (AAAAI) Young Investigator Award; EURO-PADnet HEALTH [F2-2008-201549]; Baxter; Kedrion; Grifols; SHIRE; CSL; Japan Science and Technology Agency; Ministry of Education, Culture, and Sport; Ministry of Health, Labour, and Welfare in Japan; Abbvie; CSL Behring; Chugai Pharmaceutical; Meiji Pharmaceuticals; Teijin Pharma; Toray Medical; InPractice; UpToDate","Supported by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Disease. V. T. was supported by the European Community's Seventh Framework Program FP7/2007-2013 under grant agreement no. 201549 (EURO-PADnet HEALTH-F2-2008-201549).N. Rezaei is employed by and has received research support from Tehran University Med Sci, has received royalties from Springer, and has been supported by an American Academy of Allergy, Asthma & Immunology (AAAAI) Young Investigator Award. B. Costa Carvalho has received payment for development of educational presentations from the Federal University of Sao Paulo (FAPESP) and has received travel support from Octapharma. V. Thon has received research support from EURO-PADnet HEALTH (F2-2008-201549). J. L. Franco has received consultancy fees from Baxter and Kedrion and has received lecture fees from Grifols. A. Sevciovic Grumach is a board member for Latin American Society for Immunodeficiencies and has received consultancy fees and lecture fees from SHIRE and CSL. T. Morio has received grant-in-aids for scientific research from the Japan Science and Technology Agency; the Ministry of Education, Culture, and Sport; and the Ministry of Health, Labour, and Welfare in Japan and has received lecture fees from Abbvie, CSL Behring, Chugai Pharmaceutical, Meiji Pharmaceuticals, Teijin Pharma, and Toray Medical. S. D. Rosenzweig has received consultancy fees from InPractice and UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.",null,29,0,0,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0091-6749","1097-6825",null,"J ALLERGY CLIN IMMUN","J. Allergy Clin. Immunol.","APR",2014,133,4,null,null,null,null,1134,1141,null,"10.1016/j.jaci.2014.02.028",null,8,"Allergy; Immunology","Allergy; Immunology","AD8QW","WOS:000333531700025"]
["J","Salek, D; Vesela, P; Boudova, L; Janikova, A; Klener, P; Vokurka, S; Jankovska, M; Pytlik, R; Belada, D; Pirnos, J; Moulis, M; Kodet, R; Michal, M; Janousova, E; Muzik, J; Mayer, J; Trneny, M",null,null,null,"Salek, David; Vesela, Pavla; Boudova, Ludmila; Janikova, Andrea; Klener, Pavel; Vokurka, Samuel; Jankovska, Milada; Pytlik, Robert; Belada, David; Pirnos, Jan; Moulis, Mojmir; Kodet, Roman; Michal, Michal; Janousova, Eva; Muzik, Jan; Mayer, Jiri; Trneny, Marek",null,null,"Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database","LEUKEMIA & LYMPHOMA",null,null,"English","Article",null,null,null,null,null,"Mantle cell lymphoma; MIPI; Ki-67; proliferation; immunochemotherapy; prognosis","PROSPECTIVE RANDOMIZED-TRIAL; PROGRESSION-FREE SURVIVAL; EUROPEAN-MCL-NETWORK; RESPONSE CRITERIA; IMPROVES RESPONSE; HYPER-CVAD; TRANSPLANTATION; IMMUNOCHEMOTHERAPY; CYCLOPHOSPHAMIDE; THERAPY","Although a prognostic model (MIPI, Mantle Cell Lymphoma International Prognostic Index) for patients with mantle cell lymphoma (MCL) has been established, its clinical significance for daily practice in the rituximab era remains controversial. Data of 235 unselected patients with MCL from the Czech Lymphoma Project Database were analyzed. MIPI, simplified MIPI (s-MIPI) and Ki-67 proliferation index were assessed for all patients and for a subgroup of 155 rituximab-treated (RT) patients. MIPI divided all patients into subgroups of low-risk (22%), intermediate-risk (29%) and high-risk (49%), with median overall survival 105.8 vs. 54.1 vs. 24.6 months, respectively (p < 0.001). s-MIPI revealed similar results. The validity of both indexes was confirmed in RT patients. We confirmed the Ki-67 index to be a powerful single prognostic factor for overall survival (64.4 vs. 20.1 months, p < 0.001) for all patients and for the RT subset. Our results confirm the clinical relevance of MIPI, s-MIPI and Ki-67 for risk stratification in MCL also in the rituximab era.","[Salek, David; Janikova, Andrea; Mayer, Jiri] Masaryk Univ, Dept Hematol & Oncol, Brno 62500, Czech Republic; [Moulis, Mojmir] Masaryk Univ, Dept Pathol, Brno 62500, Czech Republic; [Moulis, Mojmir] Univ Hosp Brno, Brno 62500, Czech Republic; [Vesela, Pavla; Boudova, Ludmila; Michal, Michal] Charles Univ Prague, Fac Med, Sikls Dept Pathol, Plzen, Czech Republic; [Vokurka, Samuel] Charles Univ Prague, Dept Hematooncol, Plzen, Czech Republic; [Vokurka, Samuel] Univ Hosp Plzen, Plzen, Czech Republic; [Klener, Pavel; Pytlik, Robert; Trneny, Marek] Charles Univ Prague, Gen Hosp, Dept Med 1, Prague, Czech Republic; [Jankovska, Milada] Univ Hosp Kralovske Vinohrady, Dept Hematol, Prague, Czech Republic; [Belada, David] Univ Hosp Hradec Kralove, Dept Clin Hematol, Hradec Kralove, Czech Republic; [Pirnos, Jan] Hosp Ceske Budejovice, Dept Oncol, Ceske Budejovice, Czech Republic; [Kodet, Roman] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Kodet, Roman] Fac Hosp Motol, Prague, Czech Republic; [Janousova, Eva; Muzik, Jan] Masaryk Univ, Inst Biostat & Anal, Fac Med, Brno 62500, Czech Republic; [Janousova, Eva; Muzik, Jan] Masaryk Univ, Fac Sci, Brno 62500, Czech Republic","Janikova, A (reprint author), Masaryk Univ, Dept Hematol & Oncol, Jihlavska 20, Brno 62500, Czech Republic.","ajanikova@fnbrno.cz",null,null,"Ministry of Education and Youth of the Czech Republic [MSM0021620819, FAD 200647]; Ministry of Health of the Czech Republic [IGA MZ CR NR/9453-3]; CLSG","This work was supported by research grants from the Ministry of Education and Youth of the Czech Republic (MSM0021620819 and FAD 200647) (L.B.) and by a grant from the Ministry of Health of the Czech Republic (IGA MZ CR NR/9453-3); on behalf of the CLSG.",null,38,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","1042-8194","1029-2403",null,"LEUKEMIA LYMPHOMA","Leuk. Lymphoma","APR",2014,55,4,null,null,null,null,802,810,null,"10.3109/10428194.2013.815349",null,9,"Oncology; Hematology","Oncology; Hematology","AD9JZ","WOS:000333582600013"]
["J","Veselka, J; Spacek, M; Homolova, I; Zimolova, P",null,null,null,"Veselka, Josef; Spacek, Miloslav; Homolova, Inge; Zimolova, Petra",null,null,"Obesity paradox in female patients after stent implantation for carotid artery disease","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Letter",null,null,null,null,null,"Carotid stenting; Survival; Body mass index",null,null,"[Veselka, Josef; Spacek, Miloslav; Homolova, Inge; Zimolova, Petra] Charles Univ Prague, Dept Cardiol, Sch Med 2, Univ Hosp Motol, Prague, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Dept Cardiol, Sch Med 2, Univ Hosp Motol, Prague, Czech Republic.","veselka.josef@seznam.cz",null,null,null,null,null,4,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273","1874-1754",null,"INT J CARDIOL","Int. J. Cardiol.","APR 1",2014,172,3,null,null,null,null,600,601,null,"10.1016/j.ijcard.2014.01.092",null,2,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AD2XU","WOS:000333101000069"]
["J","Nevoral, J; Kotalova, R; Hradsky, O; Valtrova, V; Zarubova, K; Lastovicka, J; Neubertova, E; Trnkova, M; Bronsky, J",null,null,null,"Nevoral, Jiri; Kotalova, Radana; Hradsky, Ondrej; Valtrova, Vera; Zarubova, Kristyna; Lastovicka, Jan; Neubertova, Eva; Trnkova, Marketa; Bronsky, Jiri",null,null,"Symptom positivity is essential for omitting biopsy in children with suspected celiac disease according to the new ESPGHAN guidelines","EUROPEAN JOURNAL OF PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"Celiac disease; Guidelines; Diagnosis; Children","SMALL-BOWEL BIOPSY; TISSUE TRANSGLUTAMINASE; ANTIBODIES; DIAGNOSIS; HISTOPATHOLOGY; POPULATIONS; CRITERIA; TIME","The aim of this study was to assess the accuracy of serological tests in combination with clinical symptoms for diagnosing celiac disease (CD) according to the new proposed European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) criteria. We retrospectively assessed children and adolescents aged 16 months -19 years who were examined for suspicion of CD (n = 345). Evaluation of clinical symptoms and the presence of tissue transglutaminase (anti-TG-IgA) and endomysial antibodies (EMA-IgA) as well as intestinal biopsies was performed in all patients. Human leukocyte antigens (HLAs) were not included. Among 345 biopsied children, 213 (62 %) children had anti-TG titers > 10 times the upper limit of normal (ULN) and positive EMA antibodies. Ninety-nine (29 %) children also had symptoms suggestive of CD in addition to EMA positivity and elevated titers of anti-TG > 10 times the ULN. In patients who were asymptomatic, but positive for EMA, and had anti-TG antibodies > 10 times the ULN, the specificity of tests for Marsh 2-3 was only 85 %, while in symptomatic patients with the same antibodies levels, the specificity was 99 %. Conclusion: Our results reveal that intestinal biopsies could be omitted in 28 % of patients when the new ESPGHAN guidelines are applied. Due to high accuracy of serological tests in combination with clinical symptoms for diagnosis of CD, the new guideline seems to be applicable even without the use of HLA testing.","[Nevoral, Jiri; Kotalova, Radana; Hradsky, Ondrej; Valtrova, Vera; Zarubova, Kristyna; Bronsky, Jiri] Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Sch Med 2, Prague 15006 5, Czech Republic; [Lastovicka, Jan] Charles Univ Prague, Univ Hosp Motol, Inst Immunol, Sch Med 2, Prague 15006 5, Czech Republic; [Neubertova, Eva; Trnkova, Marketa] BIOLAB Praha Sro, Prague 6, Czech Republic","Hradsky, O (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","ondrej.hradsky@lfmotol.cuni.cz",null,null,"University Hospital Motol (VZ FNM) [64203/6001]","This work was supported by a research grant from the University Hospital Motol (VZ FNM) 64203/6001.",null,23,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199","1432-1076",null,"EUR J PEDIATR","Eur. J. Pediatr.","APR",2014,173,4,null,null,null,null,497,502,null,"10.1007/s00431-013-2215-0",null,6,"Pediatrics","Pediatrics","AD0ZX","WOS:000332964600013"]
["J","Jahodova, A; Krsek, P; Kyncl, M; Jezdik, P; Kudr, M; Komarek, V; Jayakar, P; Miller, I; Resnick, T; Duchowny, M",null,null,null,"Jahodova, A.; Krsek, P.; Kyncl, M.; Jezdik, P.; Kudr, M.; Komarek, V.; Jayakar, P.; Miller, I.; Resnick, T.; Duchowny, M.",null,null,"Distinctive MRI features of the epileptogenic zone in children with tuberous sclerosis","EUROPEAN JOURNAL OF RADIOLOGY",null,null,"English","Article",null,null,null,null,null,"Tuberous sclerosis complex; Epilepsy surgery; Magnetic resonance; Cortical dysplasia","FOCAL CORTICAL DYSPLASIA; EPILEPSY SURGERY; COMPLEX; IDENTIFICATION; CHALLENGES","Objective: Localization of the epileptogenic zone (EZ) is challenging in children with tuberous sclerosis complex (TSC). We sought to ascertain whether brain MRI could identify the EZ in TSC patients independent of the clinical and diagnostic data. Methods: Presurgical MRI's of 34 children with TSC who underwent epilepsy surgery at Miami Children's Hospital were retrospectively reevaluated by experts blinded to all other data. Changes typical of TSC (tubers, calcifications, cystic changes) and abnormalities of the perituberal cortex typical of focal cortical dysplasia (FCD) (increased cortical thickness, abnormal gyration, transmantle change, gray/white matter junction blurring) were identified and their localization was compared with the resection site. Sensitivity, specificity and accuracy of individual MRI features to localize the EZ were determined and statistically compared between postoperatively seizure-free and non-seizure-free patients as well as clusters of features typical of FCD and TSC. Results: MRI alone correctly localized the resection cavity in all 19 postoperatively seizure-free patients and 12 of 15 non-seizure-free subjects. Sensitivity, specificity and accuracy of MRI features typical of FCD to localize EZ (90%, 96% and 96%, respectively) were superior to those typical of TCS (79%, 75% and 75%, p < 0.0001). Increased cortical thickness and abnormal gyral formation outside tubers occurred only in the resection site. Resection sites were better predicted by MRI in seizure-free than in non-seizure-free patients. Conclusion: Thorough MRI evaluation identifies the EZ in a significant proportion of TSC patients. Epileptogenic regions were mostly characterized by \"FCD-like\" changes outside cortical tubers. The findings may have important practical consequences for surgical planning in TSC. (C) 2014 Elsevier Ireland Ltd. All rights reserved.","[Jahodova, A.; Krsek, P.; Kudr, M.; Komarek, V.] Charles Univ Prague, Dept Pediat Neurol, Med Sch 2, Motol Univ Hosp, Prague 15006 5, Czech Republic; [Kyncl, M.] Charles Univ Prague, Dept Radiol, Med Sch 2, Motol Univ Hosp, Prague 15006 5, Czech Republic; [Jezdik, P.] Czech Tech Univ, Fac Elect, Dept Measurement, CZ-16627 Prague 6, Czech Republic; [Jayakar, P.; Miller, I.; Resnick, T.; Duchowny, M.] Miami Childrens Hosp, Dept Neurol, Inst Brain, Miami, FL 33155 USA; [Jayakar, P.; Miller, I.; Resnick, T.; Duchowny, M.] Miami Childrens Hosp, Comprehens Epilepsy Program, Inst Brain, Miami, FL USA; [Resnick, T.; Duchowny, M.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA","Duchowny, M (reprint author), Miami Childrens Hosp, Dept Neurol, Inst Brain, 3200 SW 60th Court, Miami, FL 33155 USA.","a.jagoda@email.cz; pavel.krsek@post.cz; martinkyn@seznam.cz; jezdip1@feld.cvut.cz; mat.kudr@gmail.com; vladimir.komarek@fnmotol.cz; Prasanna.Jayakar@mch.com; ian.miller@mchdocs.com; trevor.resnick@mch.com; michael.duchowny@mch.com",null,null,null,null,null,30,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0720-048X","1872-7727",null,"EUR J RADIOL","Eur. J. Radiol.","APR",2014,83,4,null,null,null,null,703,709,null,"10.1016/j.ejrad.2013.12.024",null,7,"Radiology, Nuclear Medicine & Medical Imaging","Radiology, Nuclear Medicine & Medical Imaging","AC3GR","WOS:000332405200016"]
["J","Fulin, P; Pokorny, D; Slouf, M; Nevoralova, M; Vackova, T; Dybal, J; Pilar, J",null,null,null,"Fulin, Petr; Pokorny, David; Slouf, Miroslav; Nevoralova, Martina; Vackova, Tatana; Dybal, Jiri; Pilar, Jan",null,null,"Quantification of structural changes of UHMWPE components in total joint replacements","BMC MUSCULOSKELETAL DISORDERS",null,null,"English","Article",null,null,null,null,null,"UHMWPE; Oxidative damage; Residual radicals; Infrared spectroscopy; Electron spin resonance","MOLECULAR-WEIGHT POLYETHYLENE; GAMMA-RADIATION; WEAR; STERILIZATION; OXIDATION; RESISTANCE","Background: At present time the number of implantations of joint replacements as well as their revisions increases. Higher demands are required on the quality and longevity of implants. The aim of this work was to determine the degree of oxidative degradation and the amount of free/residual radicals in selected ultra-high molecular weight polyethylene (UHMWPE) components of the joint replacements and demonstrate that the measured values are closely connected with quality and lifetime of the polymer components. Methods: We tested both new (4 samples) and explanted (4 samples) UHMWPE polymers for total joint replacements. The samples were characterized by infrared spectroscopy (IR), electron spin resonance (ESR) and microhardness (MH) test. The IR measurements yielded the values of oxidation index and trans-vinylene index. The ESR measurements gave the free radicals concentration. Results: In the group of new polyethylene components, we found oxidation index values ranging from 0.00-0.03 to 0.24. The trans-vinylene index values ranged from 0.044 to 0.080. The value of free radical concentration was zero in virgin and also in sample of Beznoska Company and non-zero in the other samples. In the group of explanted components, the measured values were associated with their history, micromechanical properties and performance in vivo. Conclusions: We demonstrated that measuring of oxidative damage may help the orthopaedic surgeon in estimating the quality of UHMWPE replacement component and thus radically to avoid early joint replacement failure due to worse polyethylene quality.","[Fulin, Petr] Charles Univ Prague, Fac Med 1, Dept Orthopaed, Prague 15006 5, Czech Republic; [Fulin, Petr; Pokorny, David] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Slouf, Miroslav; Nevoralova, Martina; Vackova, Tatana; Dybal, Jiri; Pilar, Jan] Acad Sci Czech Republic, Inst Macromol Chem, Prague 16206 6, Czech Republic","Fulin, P (reprint author), Charles Univ Prague, Fac Med 1, Dept Orthopaed, V Uvalu 84, Prague 15006 5, Czech Republic.","petrfulin@gmail.com","Dybal, Jiri/A-8290-2008","Dybal, Jiri/0000-0002-9148-3655","Charles University [P25/LF1/2]; University Hospital Motol Prague [00064203];  [TACR - TA01011406];  [IGA - NT12229-4/2011]","This research was supported by grant projects listed in acknowledgement.1) For financial support by grant projects: TACR - TA01011406 (analysis of samples).2) For financial support by grant project: IGA - NT12229-4/2011 (prepare of study, collection and storage of samples)3) For financial support by grant project: Research programme of Charles University P25/LF1/2 (preparation of samples)4) For financial support by grant project: Project for conceptual development of research organization 00064203 (University Hospital Motol Prague) (collection and records of samples)5) To Ing. Fencl Jaroslav for preparation of samples (2 mm plates cut under intensive cooling).",null,23,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2474",null,null,"BMC MUSCULOSKEL DIS","BMC Musculoskelet. Disord.","MAR 28",2014,15,null,null,null,null,null,null,null,109,"10.1186/1471-2474-15-109",null,8,"Orthopedics; Rheumatology","Orthopedics; Rheumatology","AG1OB","WOS:000335183900002"]
["J","Korecova, M; Hladikova, M",null,null,null,"Korecova, Marta; Hladikova, Marie",null,null,"Treatment of mild and moderate type-2 diabetes: open prospective trial with Hintonia latiflora extract","EUROPEAN JOURNAL OF MEDICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Hintonia latiflora; Type 2 diabetes; HbA(1c); Blood glucose; Liver values; Blood lipids","DOUBLE-BLIND; MELLITUS; PLACEBO; EFFICACY; DIET; RATS","Background: Extracts from the bark of Hintonia latiflora are used as dietetic measures to support the regulation of glucose metabolism and the stabilization of blood glucose values. Methods: A dry concentrated extract from the bark of Hintonia latiflora in capsule form was tested in an open, prospective clinical study in 41 dietetically stabilized subjects with type 2 diabetes. The effects on parameters of blood glucose control were documented over a period of six months. Results: Fasting and postprandial glucose and the HbA(1c) value declined significantly. In the case of HbA(1c), this meant a reduction of the absolute value from 7.49 +/- 0.72% to 6.82 +/- 0.67% (from 58.4 to 51.0 mmol/mol Hb; intention to treat (ITT) population). Furthermore, cholesterol and triglycerides were slightly reduced and no negative effect on other laboratory parameters and no change of the liver values were observed. Tolerance was very good. In particular, no side effects and no hypoglycemic episodes or worsening of diabetic symptoms occurred. Conclusions: The study confirms the positive effect of extracts from the bark of Hintonia latiflora on blood glucose values suggesting a potential benefit in the management of glucose metabolism in cases of type 2 diabetes.","[Korecova, Marta] IDF President, Dept Diabet, SK-91101 Trencin, Slovakia; [Hladikova, Marie] Charles Univ Prague, Fac Med 2, Dept Med Informat, CZ-15006 Prague 5, Czech Republic","Korecova, M (reprint author), IDF President, Dept Diabet, Rc 425201-734,Velkomoravska 2, SK-91101 Trencin, Slovakia.","statistika.hladikova@seznam.cz",null,null,"Gehrlicher Extrakte, Germany","M.K. and M. H. declare that they have no conflict of interests. The study was financially supported by Gehrlicher Extrakte, Germany. The sponsor also provided the test preparation. The authors alone were, however, responsible for the performance of the study, the evaluation and the publication of the results.",null,25,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","0949-2321","2047-783X",null,"EUR J MED RES","Eur. J. Med. Res.","MAR 28",2014,19,null,null,null,null,null,null,null,null,"10.1186/2047-783X-19-16",null,6,"Medicine, Research & Experimental","Research & Experimental Medicine","AF1KX","WOS:000334473900001"]
["J","Slavicek, L; Pavlik, T; Tomasek, J; Bortlicek, Z; Buchler, T; Melichar, B; Vyzula, R; Prausova, J; Finek, J; Majek, O; Dusek, L",null,null,null,"Slavicek, Lubomir; Pavlik, Tomas; Tomasek, Jiri; Bortlicek, Zbynek; Buchler, Tomas; Melichar, Bohuslav; Vyzula, Rostislav; Prausova, Jana; Finek, Jindrich; Majek, Ondrej; Dusek, Ladislav",null,null,"Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry","BMC GASTROENTEROLOGY",null,null,"English","Article",null,null,null,null,null,"Anti-angiogenic therapy; Chemotherapy; Elderly patients; Overall survival; Progression-free survival","POOLED ANALYSIS; OLDER PATIENTS; CHEMOTHERAPY; SURVIVAL; CAPECITABINE; FLUOROURACIL; COMBINATION; TRIALS","Background: Patients aged 65 years and older represent the majority of patients with metastatic colorectal cancer (mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in the clinical practice. Methods: We have analysed the outcomes of 3,187 mCRC patients treated with first-line bevacizumab based on data from the Czech national registry of mCRC patients aiming to compare the treatment efficacy and safety according to the age categories. Results: In total, 2,126 (66.7%), 932 (29.2%), and 129 (4.0%) patients were aged < 65 years, 65 to 75 years, and 75+ years, respectively. Median progression-free survival (PFS) was 11.4, 11.3, and 11.8 months for patients aged < 65 years, 65 to 75 years, and 75+ years, respectively (p = 0.94). Median overall survival (OS) was 26.9, 27.5, and 25.1 months for patients aged < 65 years, 65 to 75 years, and 75+ years, respectively (p = 0.73). Using multivariable Cox model for both PFS and OS, the patient age was not significantly associated with either PFS or OS. No increase in bevacizumab-related toxicity was observed among the elderly mCRC patients with the exception of hypertension, which was observed in 71 (3.3%), 34 (3.6%), and 10 (7.8%) patients aged < 65 years, 65 to 75 years, and 75+ years, respectively. Conclusions: The results of the present study suggest similar outcome in terms of OS and PFS with bevacizumab-containing therapy in elderly mCRC patients fit for chemotherapy combined with targeted therapy compared to younger patients. Thus, chronological age should not be considered to represent a limitation in prescribing bevacizumab-containing therapy in mCRC patients.","[Slavicek, Lubomir] Hosp Jihlava, Dept Oncol, Jihlava, Czech Republic; [Pavlik, Tomas; Bortlicek, Zbynek; Majek, Ondrej; Dusek, Ladislav] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic; [Tomasek, Jiri; Vyzula, Rostislav] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic; [Buchler, Tomas] Charles Univ Prague, Dept Oncol, Prague, Czech Republic; [Buchler, Tomas] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Melichar, Bohuslav] Palacky Univ, Med Sch & Teaching Hosp, Dept Oncol, CR-77147 Olomouc, Czech Republic; [Prausova, Jana] Motol Hosp, Dept Oncol, Prague, Czech Republic; [Prausova, Jana] Charles Univ Prague, Prague, Czech Republic; [Finek, Jindrich] Univ Hosp Plzen, Dept Oncol, Plzen, Czech Republic","Dusek, L (reprint author), Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic.","dusek@iba.muni.cz",null,null,"Roche, Merck, and Amgen","The CORECT database maintenance is supported by unrestricted research grants from Roche, Merck, and Amgen. The funding bodies had no role in design, collection, analysis or interpretation of the data, writing of the manuscript or the decision to submit the manuscript for publication.",null,26,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-230X",null,null,"BMC GASTROENTEROL","BMC Gastroenterol.","MAR 25",2014,14,null,null,null,null,null,null,null,53,"10.1186/1471-230X-14-53",null,8,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","AF0PX","WOS:000334417600002"]
["J","Vlcek, K; Laczo, J",null,null,null,"Vlcek, Kamil; Laczo, Jan",null,null,"Neural correlates of spatial navigation changes in mild cognitive impairment and Alzheimer's disease","FRONTIERS IN BEHAVIORAL NEUROSCIENCE",null,null,"English","Review",null,null,null,null,null,"Alzheimer's disease; mild cognitive impairment; spatial navigation; spatial disorientation; brain changes","VOXEL-BASED MORPHOMETRY; MEDIAL TEMPORAL-LOBE; GETTING LOST; DEFINED SUBTYPES; VIRTUAL-REALITY; LOCATION MEMORY; ORDER MEMORY; SERIAL MRI; DEMENTIA; HIPPOCAMPUS","Although the memory impairment is a hallmark of Alzheimer's disease (AD), AD has also been characterized by spatial disorientation, which is present from its early stages. Spatial disorientation in AD manifests itself in getting lost in familiar and unfamiliar places and have been characterized more specifically using spatial navigation tests in both real space and virtual environments as an impairment in multiple spatial abilities, including allocentric and egocentric navigation strategies, visuo-spatial perception, or selection of relevant information for successful navigation. Patients suffering mild cognitive impairment (MCI), who are at a high risk of development of dementia, show impairment in a subset of these abilities, mainly connected with allocentric and egocentric processing. While spatial disorientation in typical AD patients probably reflects neurodegenerative changes in medial and posterior temporal, parietal, and frontal lobes, and retrosplenial cortex, the impairment of spatial navigation in MCI seem to be connected mainly with the medial temporal and also parietal brain changes. In this review, we will summarize the signs of brain disease in most MCI and AD patients showing in various tasks of spatial memory and navigation.","[Vlcek, Kamil] Acad Sci Czech Republic, Inst Physiol, Dept Neurophysiol Memory, CR-14220 Prague 4, Czech Republic; [Vlcek, Kamil; Laczo, Jan] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Laczo, Jan] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague, Czech Republic; [Laczo, Jan] Motol Univ Hosp, Prague, Czech Republic","Vlcek, K (reprint author), Acad Sci Czech Republic, Inst Physiol, Videnska 1083, CR-14220 Prague 4, Czech Republic.","kamil@biomed.cas.cz",null,null,"MHCR - IGA [NT13386]; ERDF - Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; ESF; Young Talent Incubator II [CZ.1.07/2.3.00/20.0117]; MHCR - DRO (University Hospital Motol, Prague, Czech Republic) [00064203]; Institutional Support of Laboratory Research [2/2012 (699002)];  [AV0Z 50110509];  [RVO:67985823]","We would like to thank to Jakub Hort for his thorough revisions and comments. The study was supported by MHCR - IGA grant NT13386; ERDF - Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123); ESF and the State Budget of the CR; Young Talent Incubator II (Reg. no. CZ.1.07/2.3.00/20.0117); MHCR - DRO (University Hospital Motol, Prague, Czech Republic, 00064203); Institutional Support of Laboratory Research Grant No. 2/2012 (699002); research projects AV0Z 50110509 and RVO:67985823.",null,88,0,0,"FRONTIERS RESEARCH FOUNDATION","LAUSANNE","PO BOX 110, LAUSANNE, 1015, SWITZERLAND","1662-5153",null,null,"FRONT BEHAV NEUROSCI","Front. Behav. Neurosci.","MAR 17",2014,8,null,null,null,null,null,null,null,89,"10.3389/fnbeh.2014.00089",null,6,"Behavioral Sciences; Neurosciences","Behavioral Sciences; Neurosciences & Neurology","AC9CB","WOS:000332830600001"]
["J","Trachta, P; Dostalova, I; Haluzikova, D; Kasalicky, M; Kavalkova, P; Drapalova, J; Urbanova, M; Lacinova, Z; Mraz, M; Haluzik, M",null,null,null,"Trachta, P.; Dostalova, I.; Haluzikova, D.; Kasalicky, M.; Kavalkova, P.; Drapalova, J.; Urbanova, M.; Lacinova, Z.; Mraz, M.; Haluzik, M.",null,null,"Laparoscopic sleeve gastrectomy ameliorates mRNA expression of inflammation-related genes in subcutaneous adipose tissue but not in peripheral monocytes of obese patients","MOLECULAR AND CELLULAR ENDOCRINOLOGY",null,null,"English","Article",null,null,null,null,null,"Obesity; Laparoscopic sleeve gastrectomy; Adipose tissue; Peripheral monocytes","MIGRATION INHIBITORY FACTOR; INSULIN-RESISTANCE; BARIATRIC SURGERY; ADIPOCYTES; MECHANISMS; DISEASE; TOLL-LIKE-RECEPTOR-4; ACTIVATION; REDUCTION","Low-grade inflammation links obesity, insulin resistance, and cardiovascular diseases. We investigated the effects of laparoscopic sleeve gastrectomy (LSG) on expression profile of genes involved in inflammatory pathways in subcutaneous adipose tissue (SCAT) and peripheral monocytes (PM). At baseline, obese group had significantly increased mRNA expression of proinflammatory chemokines (CCL-3, -17, -22), chemokine receptor CCRI and cytokines (IL-10, IL-18) in SCAT and chemokine and other proinflammatory receptors (CCR-1, -2, -3, TLR-2, -4) in PM relative to control group. LSG decreased body weight, improved metabolic profile and reduced mRNA expression of up-regulated chemokine receptors, chemokines and cytokines in SCAT. In contrast, expression profiles in PM were largely unaffected by LSG. We conclude that LSG improved proinflammatory profile in subcutaneous fat but not in peripheral monocytes. The sustained proinflammatory and chemotactic profile in PM even 2 years after LSG may contribute to partial persistence of metabolic complications in obese patients after metabolic surgery. (C) 2013 Elsevier Ireland Ltd. All rights reserved.","[Trachta, P.; Dostalova, I.; Haluzikova, D.; Kavalkova, P.; Drapalova, J.; Urbanova, M.; Lacinova, Z.; Mraz, M.; Haluzik, M.] Charles Univ Prague, Fac Med 1, Dept Med 3, Prague, Czech Republic; [Trachta, P.; Dostalova, I.; Haluzikova, D.; Kavalkova, P.; Drapalova, J.; Urbanova, M.; Lacinova, Z.; Mraz, M.; Haluzik, M.] Gen Univ Hosp, Prague, Czech Republic; [Haluzikova, D.] Charles Univ Prague, Fac Med 1, Dept Sports Med, Prague, Czech Republic; [Kasalicky, M.] Charles Univ Prague, Fac Med 2, Dept Surg, Prague, Czech Republic; [Kasalicky, M.] Mil Univ Hosp, Prague, Czech Republic","Haluzik, M (reprint author), 1st Fac Med, Dept Med 3, Nemocnice 1, Prague 12808 2, Czech Republic.","mhalu@lfl.cuni.cz",null,null,"OP Prague Competitiveness [RVO-VFN64165, SVV264503, IGA-NT13299, IGA-NT13046-4/2012, CZ.2.16/3.1.00/24012]","This work was supported by RVO-VFN64165, SVV264503, IGA-NT13299, IGA-NT13046-4/2012 and project reg.no. CZ.2.16/3.1.00/24012 from OP Prague Competitiveness.",null,30,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0303-7207",null,null,"MOL CELL ENDOCRINOL","Mol. Cell. Endocrinol.","MAR 5",2014,383,"2014-02-01",null,null,null,null,96,102,null,"10.1016/j.mce.2013.11.013",null,7,"Cell Biology; Endocrinology & Metabolism","Cell Biology; Endocrinology & Metabolism","AB8OH","WOS:000332049400010"]
["J","Teyssler, P; Kolostova, K; Bobek, V",null,null,null,"Teyssler, Petr; Kolostova, Katarina; Bobek, Vladimir",null,null,"The impact of platelet-rich plasma on chronic synovitis in hemophilia","ACTA ORTHOPAEDICA BELGICA",null,null,"English","Article",null,null,null,null,null,"haemophilia; arthropathy; platelet rich plasma; growth factor; synovitis","STEM-CELLS; TISSUE REGENERATION; HYALURONIC-ACID; IN-VITRO; PROLIFERATION; RELEASATE; INJECTION; PATHOLOGY; IMPROVES; SURGERY","Untreated chronic haemophiliac synovitis leads to the development of haemophilic arthropathy (HA) by affecting the metabolism of chondrocytes. Symptoms are progressive and often surgical intervention is required to prevent total loss of joint function. The focus of our study was to influence the chronic haemophiliac synovitis by means of autologous platelet-rich plasma (PRP) injection. Six patients with hemophilia (PWH), aged between 9 and 45 and manifesting chronic synovitis of the ankle joint on one or on both sides (8 joints in total) were included into the PRP-study. The patients were classified depending on their joint status using the Hemophilia Joint Health Score (HJHS) prior to and again two months after treatment. Three to five ml of PRP was injected into the joint cavity within 30 seconds. In all of the tested PWH pain relief has been reported subjectively by means of the HJHS and VAS scoring systems, comparing the pain intensity before PRP injection and two months after. The difference of pain perception has been found statistically significant for the VAS-scores. Considering the objective synovitis signs shown on MRI before and after PRP injection we recorded a decrease in the volume of free synovial fluid after PRP. All of the tested patients reported benefit of the PRP therapy.","[Teyssler, Petr] Charles Univ Prague, Dept Orthopaed, Fac Med 2, Prague, Czech Republic; [Teyssler, Petr] Univ Hosp Motol, Prague, Czech Republic; [Teyssler, Petr; Kolostova, Katarina; Bobek, Vladimir] Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Prague, Czech Republic; [Bobek, Vladimir] Wroclaw Med Univ, Dept Histol & Embryol, Wroclaw, Poland","Bobek, V (reprint author), Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Prague, Czech Republic.","vbobek@centrum.cz",null,null,null,null,null,33,0,0,"ACTA MEDICA BELGICA","BRUSSELS","AVENUE WINSTON CHURCHILL, WINSTON CHURCHILL-LAAN, 11 BOX 30, B-1180 BRUSSELS, BELGIUM","0001-6462",null,null,"ACTA ORTHOP BELG","Acta Orthop. Belg.","MAR",2014,80,1,null,null,null,null,11,17,null,null,null,7,"Orthopedics","Orthopedics","AG7TF","WOS:000335620900002"]
["J","Stuchly, J; Kalina, T",null,null,null,"Stuchly, Jan; Kalina, Tomas",null,null,"Analyses of Large Flow Cytometry Datasets","CYTOMETRY PART A",null,null,"English","Editorial Material",null,null,null,null,null,"data analysis; flow cytometry; normalization; clinical trial","STANDARDIZATION; FUTURE",null,"[Stuchly, Jan; Kalina, Tomas] Charles Univ Prague, Dept Pediat Hematol Oncol, Fac Med 2, Prague, Czech Republic","Kalina, T (reprint author), Charles Univ Prague, Dept Pediat Hematol Oncol, Fac Med 2, Prague, Czech Republic.","tomas.kalina@lfmotol.cuni.cz",null,null,null,null,null,12,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1552-4922","1552-4930",null,"CYTOM PART A","Cytom. Part A","MAR",2014,85,3,null,null,null,null,203,205,null,"10.1002/cyto.a.22431",null,3,"Biochemical Research Methods; Cell Biology","Biochemistry & Molecular Biology; Cell Biology","AA9ZL","WOS:000331451500002"]
["J","Fialova, J; Vojackova, N; Vanousova, D; Hercogova, J",null,null,null,"Fialova, Jorga; Vojackova, Nadezda; Vanousova, Daniela; Hercogova, Jana",null,null,"Juvenile generalized pustular psoriasis treated with etanercept","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"childhood generalized pustular psoriasis; etanercept; juvenile generalized pustular psoriasis","CHILDHOOD","An 8-year-old boy with general pustular psoriasis (GPP) and iatrogenic secondary Cushing syndrome was treated successfully with etanercept after he had failed on acitretin, methotrexate, and methylprednisolone therapy. GPP is a severe and very rare variant of psoriasis in children often accompanied by life-threatening complications. Retinoids, cyclosporine, methotrexate, or dapsone used in a small number of case series and case reports were effective. Etanercept is a recombinant human tumor necrosis factor-alpha (TNF-alpha) receptor protein fused with Fc portion of IgG1 that binds to TNF-alpha, approved by Food and Drug Administration for the treatment of moderate-to-severe plaque psoriasis in children and teens who have not responded to other psoriasis treatments. In our patient, etanercept demonstrated significant clinical response associated with long-term efficacy without acute exacerbation, excellent tolerability, and good safety profile.","[Fialova, Jorga] Charles Univ Prague, Fac Med 2, Dept Dermatovenereol, Prague 18081 8, Czech Republic; [Fialova, Jorga] Bulovka Hosp, Prague 18081 8, Czech Republic","Fialova, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Dermatovenereol, Budinova 2, Prague 18081 8, Czech Republic.","fialova.jorga@seznam.cz",null,null,null,null,null,10,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296","1529-8019",null,"DERMATOL THER","Dermatol. Ther.","MAR",2014,27,2,null,null,null,null,105,108,null,"10.1111/dth.12065",null,4,"Dermatology","Dermatology","AE2NH","WOS:000333809400011"]
["J","Hradsky, O; Ohem, J; Zarubova, K; Mitrova, K; Durilova, M; Kotalova, R; Nevoral, J; Zemanova, I; Dryak, P; Bronsky, J",null,null,null,"Hradsky, Ondrej; Ohem, Jan; Zarubova, Kristyna; Mitrova, Katarina; Durilova, Marianna; Kotalova, Radana; Nevoral, Jiri; Zemanova, Ilona; Dryak, Pavel; Bronsky, Jiri",null,null,"Disease Activity Is an Important Factor for Indeterminate Interferon-gamma Release Assay Results in Children With Inflammatory Bowel Disease","JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION",null,null,"English","Article",null,null,null,null,null,"immunosuppressive therapy; inflammatory bowel disease; infliximab; interferon- release tests; latent tuberculosis","PEDIATRIC CROHNS-DISEASE; ULCERATIVE-COLITIS; ACTIVITY INDEX; TUBERCULOSIS; THERAPY; TB; ADALIMUMAB; INFECTION; SAFETY; RISK","Background:Interferon- release assay (IGRA) is widely used for screening of latent tuberculosis (TB) before and during biological therapy (BT). An indeterminate result of IGRA represents a limitation in the management of inflammatory bowel disease (IBD). Data on factors influencing IGRA results are scarce in children. The aim of the study was to identify factors influencing IGRA results in children with IBD.Methods:Seventy-two children with IBD (59 Crohn disease, 11 ulcerative colitis, 2 IBD-unclassified) indicated for BT were tested for TB infection (history, TB skin test, chest radiograph, IGRA; QuantiFERONTB Gold in tube [QFT]) and consecutively retested using QFT in 1-year intervals.Results:We recorded 165 results of QFT (3% positive, 87% negative, and 10% indeterminate results). During follow-up we identified 4 conversions of negative QFT to positivity (3%) and 4 reversions (4%). Patients with indeterminate results of QFT had significantly lower actual weight-for-height z score (P=0.022), higher platelet count (P=0.00017), and lower levels of serum albumin (P=0.015) compared with patients with positive or negative QFT. Indeterminate QFT was associated with corticosteroid treatment, BT, and disease activity, but not with treatment by immunomodulators. In a subanalysis of patients with Crohn disease alone, Pediatric Crohn's Disease Activity Index was identified as single independent risk factor for indeterminate results (P=0.00037).Conclusions:Although corticosteroid treatment is traditionally considered to be the main risk factor for indeterminate results of IGRA, the disease activity of IBD has even more profound effects on the results.","[Hradsky, Ondrej; Ohem, Jan; Zarubova, Kristyna; Mitrova, Katarina; Durilova, Marianna; Kotalova, Radana; Nevoral, Jiri; Bronsky, Jiri] Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Hradsky, Ondrej; Ohem, Jan; Zarubova, Kristyna; Mitrova, Katarina; Durilova, Marianna; Kotalova, Radana; Nevoral, Jiri; Bronsky, Jiri] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Zemanova, Ilona] Na Bulovce Hosp, Natl Erence Lab Mycobacteria, Natl Inst Publ Hlth, Prague, Czech Republic; [Dryak, Pavel] Na Bulovce Hosp, Dept Clin Microbiol, Prague, Czech Republic","Hradsky, O (reprint author), Univ Hosp Motol, Uvalu 84, Prague 15006 5, Czech Republic.","ondrej.hradsky@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic [00064203]","This study was supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic).",null,30,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0277-2116","1536-4801",null,"J PEDIATR GASTR NUTR","J. Pediatr. Gastroenterol. Nutr.","MAR",2014,58,3,null,null,null,null,320,324,null,"10.1097/MPG.0000000000000205",null,5,"Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","AD5MO","WOS:000333297300014"]
["J","Halaska, MJ; Komar, M; Vlk, R; Tomek, V; Skultety, J; Robova, H; Rob, L",null,null,null,"Halaska, M. J.; Komar, M.; Vlk, R.; Tomek, V.; Skultety, J.; Robova, H.; Rob, L.",null,null,"A pilot study on peak systolic velocity monitoring of fetal anemia after administration of chemotherapy during pregnancy","EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY",null,null,"English","Article",null,null,null,null,null,"Chemotherapy; Pregnancy; Treatment; PSV; Anemia","RED-CELL ALLOIMMUNIZATION; DOPPLER; ERYTHROPOIETIN; MANAGEMENT; DIAGNOSIS; FETUS","Objectives: To monitor fetal anemia during administration of chemotherapy to the fetus's mother. Study design: Between 2007 and 2012 six patients with malignancy diagnosed during pregnancy were included in our prospective study. For evaluation of fetal anemia, peak systolic velocimetry (PSV) of the middle cerebral artery is considered the best method. The patients were repeatedly examined one day before and on the third day after the administration of chemotherapy. At least three measurements were performed and the highest value was used as appropriate. Multiples of the median (MoM) were calculated using the website http://www.perinatology.com/calculators/MCA.htm. When the MoM reached 1.29, moderate anemia was diagnosed. Results: The women's average age was 30 years. The average gestational age at diagnosis was 20.7 weeks of pregnancy. Borderline fetal anemia was detected in only in one patient. After delivery newborns were examined by standard pediatric evaluation and blood count was provided. There was no evidence of any newborn anemia. Conclusions: Chemotherapy administered during pregnancy is becoming more frequent due to increasing knowledge and data on such cases. Close monitoring of the fetus should be performed in specialized. centers. For detection of chemotherapy-induced anemia, PSV measurement should be employed. (C) 2013 Elsevier Ireland Ltd. All rights reserved.","[Halaska, M. J.; Komar, M.; Vlk, R.; Skultety, J.; Robova, H.; Rob, L.] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, Prague 15000 5, Czech Republic; [Tomek, V.] Charles Univ Prague, Fac Med 2, Dept Children Cardioctr, Prague 15000 5, Czech Republic","Halaska, MJ (reprint author), Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, V Uvalu 84, Prague 15000 5, Czech Republic.","mhalaska@seznam.cz",null,null," [OPPK CZ.2.16/3.1.00/24022]","The work was supported by a grant OPPK CZ.2.16/3.1.00/24022.",null,23,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0301-2115","1872-7654",null,"EUR J OBSTET GYN R B","Eur. J. Obstet. Gynecol. Reprod. Biol.","MAR",2014,174,null,null,null,null,null,76,79,null,"10.1016/j.ejogrb.2013.12.021",null,4,"Obstetrics & Gynecology; Reproductive Biology","Obstetrics & Gynecology; Reproductive Biology","AD8GW","WOS:000333505500013"]
["J","Slamova, L; Starkova, J; Fronkova, E; Zaliova, M; Reznickova, L; van Delft, FW; Vodickova, E; Volejnikova, J; Zemanova, Z; Polgarova, K; Cario, G; Figueroa, M; Kalina, T; Fiser, K; Bourquin, JP; Bornhauser, B; Dworzak, M; Zuna, J; Trka, J; Stary, J; Hrusak, O; Mejstrikova, E",null,null,null,"Slamova, L.; Starkova, J.; Fronkova, E.; Zaliova, M.; Reznickova, L.; van Delft, F. W.; Vodickova, E.; Volejnikova, J.; Zemanova, Z.; Polgarova, K.; Cario, G.; Figueroa, M.; Kalina, T.; Fiser, K.; Bourquin, J. P.; Bornhauser, B.; Dworzak, M.; Zuna, J.; Trka, J.; Stary, J.; Hrusak, O.; Mejstrikova, E.",null,null,"CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"minimal residual disease; lineage switch; CCAAT/ enhancer-binding protein alpha; acute lymphoblastic leukemia; Monocytes; CD2 Antigen","MINIMAL RESIDUAL DISEASE; ACUTE MYELOID-LEUKEMIA; GENE REARRANGEMENTS; FLOW-CYTOMETRY; ERG DELETION; PCR DATA; CHILDHOOD; EXPRESSION; PROGNOSIS; CHILDREN","Switches from the lymphoid to myeloid lineage during B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treatment are considered rare and thus far have been detected in MLL-rearranged leukemia. Here, we describe a novel BCP-ALL subset, switching BCP-ALL or swALL, which demonstrated monocytosis early during treatment. Despite their monocytic phenotype, 'monocytoids' share immunoreceptor gene rearrangements with leukemic B lymphoblasts. All swALLs demonstrated BCP-ALL with CD2 positivity and no MLL alterations, and the proportion of swALLs cases among BCP-ALLs was unexpectedly high (4%). The upregulation of CEBPa and demethylation of the CEBPA gene were significant in blasts at diagnosis, prior to the time when most of the switching occurs. Intermediate stages between CD14(neg)CD19(pos)CD34(pos) B lymphoblasts and CD14(pos)CD19(neg)CD34(neg) 'monocytoids' were detected, and changes in the expression of PAX5, PU1, M-CSFR, GM-CSFR and other genes accompanied the switch. Alterations in the Ikaros and ERG genes were more frequent in swALL patients; however, both were altered in only a minority of swALLs. Moreover, switching could be recapitulated in vitro and in mouse xenografts. Although children with swALL respond slowly to initial therapy, risk-based ALL therapy appears the treatment of choice for swALL. SwALL shows that transdifferentiating into monocytic lineage is specifically associated with CEBPa changes and CD2 expression.","[Slamova, L.; Starkova, J.; Fronkova, E.; Zaliova, M.; Reznickova, L.; Volejnikova, J.; Polgarova, K.; Kalina, T.; Fiser, K.; Zuna, J.; Trka, J.; Stary, J.; Hrusak, O.; Mejstrikova, E.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague 15006, Czech Republic; [Slamova, L.; Starkova, J.; Fronkova, E.; Zaliova, M.; Reznickova, L.; Volejnikova, J.; Polgarova, K.; Kalina, T.; Fiser, K.; Zuna, J.; Trka, J.; Stary, J.; Hrusak, O.; Mejstrikova, E.] Univ Hosp Motol, Prague, Czech Republic; [van Delft, F. W.] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Vodickova, E.] Univ Hosp Motol, Dept Clin Hematol, Prague, Czech Republic; [Zemanova, Z.] Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Fac Med 1, Prague 15006, Czech Republic; [Cario, G.] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany; [Figueroa, M.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA; [Bourquin, J. P.; Bornhauser, B.] Univ Zurich, Univ Childrens Hosp, Div Oncol, Zurich, Switzerland; [Bourquin, J. P.; Bornhauser, B.] Univ Zurich, Univ Childrens Hosp, Childrens Res Ctr, Zurich, Switzerland; [Dworzak, M.] Med Univ Vienna, Childrens Canc Res Inst, Vienna, Austria; [Dworzak, M.] Med Univ Vienna, St Anna Childrens Hosp, Dept Pediat, Vienna, Austria","Mejstrikova, E (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","ester.mejstrikova@lfmotol.cuni.cz",null,null,"EU [CZ.2.16/3.1.00/24022]; Kay Kendall Leukaemia Fund; project for conceptual development of research organization [CZ.2.16/3.1.00/24022, 00064203];  [Sciex 09.043];  [NT 12397-4];  [GAUK 914613];  [GACR P301/10/1877];  [NT13462];  [RVO-VFN64165/2012]","This work was supported by grants: Sciex 09.043 (LS), NT 12397-4 (EF), GAUK 914613 (LS), GACR P301/10/1877 and NT13462 (EM). The FACS Aria instrument was supported by EU-Prague project CZ.2.16/3.1.00/24022, FWvD was supported by the Kay Kendall Leukaemia Fund and ZZ was supported by RVO-VFN64165/2012. This work was also supported by the project for conceptual development of research organization 00064203 and CZ.2.16/3.1.00/24022. We thank Alzbeta Vazna for sequencing; Iveta Janotova for data management; Veronika Kanderova for performence of the in vitro experiments; Pavel Semerak for technical assistance in sorting; Daniel Thurner, Angela Schumich and Daniela Morf for processing of FC samples; Katerina Muzikova for PCR analyses of sorted samples; and the Czech Pediatric Hematology Group for collaboration (Doctors Sterba, Timr, Mihal, Cerna, Prochazkova, Blazek and Hak) and for providing clinical information (Doctors. Timr, Smisek, Votava and Hak).",null,55,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924","1476-5551",null,"LEUKEMIA","Leukemia","MAR",2014,28,3,null,null,null,null,609,620,null,"10.1038/leu.2013.354",null,12,"Oncology; Hematology","Oncology; Hematology","AC9HR","WOS:000332845700013"]
["J","Hemminki, K; Musak, L; Vymetalkova, V; Smerhovsky, Z; Halasova, E; Osina, O; Letkova, L; Forsti, A; Vodickova, L; Buchancova, J; Vodicka, P",null,null,null,"Hemminki, K.; Musak, L.; Vymetalkova, V.; Smerhovsky, Z.; Halasova, E.; Osina, O.; Letkova, L.; Foersti, A.; Vodickova, L.; Buchancova, J.; Vodicka, P.",null,null,"Cyclin D1 splice site variant triggers chromosomal aberrations in healthy humans","LEUKEMIA",null,null,"English","Letter",null,null,null,null,null,null,"MULTIPLE-MYELOMA; CANCER; LYMPHOCYTES; DAMAGE; RISK; TRANSLOCATIONS; POLYMORPHISM",null,"[Hemminki, K.; Foersti, A.] German Canc Res Ctr Heidelberg DKFZ, Dept Mol Genet Epidemiol, Heidelberg, Germany; [Hemminki, K.; Foersti, A.] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden; [Musak, L.; Osina, O.] Comenius Univ, Jessenius Fac Med, Clin Occupat Med & Toxicol, Martin, Slovakia; [Musak, L.; Osina, O.] Univ Hosp Martin, Martin, Slovakia; [Vymetalkova, V.; Vodickova, L.; Vodicka, P.] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Vymetalkova, V.; Smerhovsky, Z.; Vodickova, L.; Vodicka, P.] Charles Univ Prague, Inst Biol & Med Genet, Fac Med 1, Prague, Czech Republic; [Smerhovsky, Z.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Halasova, E.] Comenius Univ, Jessenius Fac Med, Dept Med Biol, Martin, Slovakia; [Letkova, L.] Comenius Univ, Jessenius Fac Med, Dept Med Biochem, Martin, Slovakia; [Buchancova, J.] Comenius Univ, Jessenius Fac Med, Dept Publ Hlth, Martin, Slovakia","Hemminki, K (reprint author), German Canc Res Ctr Heidelberg DKFZ, Dept Mol Genet Epidemiol, Heidelberg, Germany.","k.hemminki@dkfz.de",null,null,null,null,null,13,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924","1476-5551",null,"LEUKEMIA","Leukemia","MAR",2014,28,3,null,null,null,null,721,722,null,"10.1038/leu.2013.353",null,2,"Oncology; Hematology","Oncology; Hematology","AC9HR","WOS:000332845700033"]
["J","Durila, M; Malosek, M",null,null,null,"Durila, Miroslav; Malosek, Martin",null,null,"Rotational thromboelastometry along with thromboelastography plays a critical role in the management of traumatic bleeding","AMERICAN JOURNAL OF EMERGENCY MEDICINE",null,null,"English","Article",null,null,null,null,null,null,null,"Massive posttraumatic bleeding is the leading cause of potentially preventable death among patients with severe trauma. Immediate diagnosis and treatment of traumatic coagulopathy and its differentiation from surgical bleeding after major trauma are critical in the management of such patients. In this case report, we present a 33-year-old woman who had multiple injuries to the head and trunk in motor vehicle collision, resulting in severe bleeding and necessitating emergency surgery. We demonstrate how repeated rotational thromboelastometry and thromboelastography analyses were used to direct the choice of therapy to stabilize her circulatory system for surgery and to differentiate surgical bleed from coagulopathy. Therapy based on massive transfusion protocol and on laboratory coagulation tests would be insufficient to stop bleeding. We conclude that rotational thromboelastometry/thromboelastography analysis plays a critical role in the management of traumatic bleeding and helps us provide more aggressive and targeted therapy for coagulopathy both in the acute and later phases of treatment of severe bleeding.","[Durila, Miroslav; Malosek, Martin] Charles Univ Prague, Fac Med 2, Dept Anesthesiol & Crit Care Med, Prague, Czech Republic","Durila, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Anesthesiol & Crit Care Med, Prague, Czech Republic.","durila4@gmail.com",null,null,null,null,null,7,0,0,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0735-6757","1532-8171",null,"AM J EMERG MED","Am. J. Emerg. Med.","MAR",2014,32,3,null,null,null,null,null,null,"288.e1","10.1016/j.ajem.2013.09.038",null,3,"Emergency Medicine","Emergency Medicine","AC4XV","WOS:000332525500030"]
["J","Amant, F; Halaska, MJ; Fumagalli, M; Steffensen, KD; Lok, C; Van Calsteren, K; Han, SN; Mir, O; Fruscio, R; Uzan, C; Maxwell, C; Dekrem, J; Strauven, G; Mhallem Gziri, M; Kesic, V; Berveiller, P; van den Heuvel, F; Ottevanger, PB; Vergote, I; Lishner, M; Morice, P; Nulman, I",null,null,null,"Amant, Frederic; Halaska, Michael J.; Fumagalli, Monica; Steffensen, Karina Dahl; Lok, Christianne; Van Calsteren, Kristel; Han, Sileny N.; Mir, Olivier; Fruscio, Robert; Uzan, Catherine; Maxwell, Cynthia; Dekrem, Jana; Strauven, Goedele; Mhallem Gziri, Mina; Kesic, Vesna; Berveiller, Paul; van den Heuvel, Frank; Ottevanger, Petronella B.; Vergote, Ignace; Lishner, Michael; Morice, Philippe; Nulman, Irena",null,"ESGO Task Force Canc Pregnancy","Gynecologic Cancers in Pregnancy Guidelines of a Second International Consensus Meeting","INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER",null,null,"English","Review",null,null,null,null,null,"Cancer; Pregnancy; Chemotherapy; Consensus; Gynecologic","OF-THE-LITERATURE; CERVICAL-CANCER; OVARIAN-CANCER; FETAL OUTCOMES; CHEMOTHERAPY; MANAGEMENT; BREAST; RISK","Objectives This study aimed to provide timely and effective guidance for pregnant women and health care providers to optimize maternal treatment and fetal protection and to promote effective management of the mother, fetus, and neonate when administering potentially teratogenic medications. New insights and more experience were gained since the first consensus meeting 5 years ago. Methods Members of the European Society of Gynecological Oncology task force Cancer in Pregnancy in concert with other international experts reviewed the existing literature on their respective areas of expertise. The summaries were subsequently merged into a complete article that served as a basis for discussion during the consensus meeting. All participants approved the final article. Results In the experts' view, cancer can be successfully treated during pregnancy in collaboration with a multidisciplinary team, optimizing maternal treatment while considering fetal safety. To maximize the maternal outcome, cancer treatment should follow a standard treatment protocol as for nonpregnant patients. Iatrogenic prematurity should be avoided. Individualization of treatment and effective psychologic support is imperative to provide throughout the pregnancy period. Diagnostic procedures, including staging examinations and imaging, such as magnetic resonance imaging and sonography, are preferable. Pelvic surgery, either open or laparoscopic, as part of a treatment protocol, may reveal beneficial outcomes and is preferably performed by experts. Most standard regimens of chemotherapy can be administered from 14 weeks gestational age onward. Apart from cervical and vulvar cancer, as well as important vulvar scarring, the mode of delivery is determined by the obstetrician. Term delivery is aimed for. Breast-feeding should be considered based on individual drug safety and neonatologist-breast-feeding expert's consult. Conclusions Despite limited evidence-based information, cancer treatment during pregnancy can succeed. State-of-the-art treatment should be provided for this vulnerable population to preserve maternal and fetal prognosis. Supplementary Information Supplementary data on teratogenic effects, ionizing examinations, sentinel lymph node biopsy, tumor markers during pregnancy, as well as additional references and tables are available at the extended online version of this consensus article, go to http://links.lww.com/IGC/A197.","[Amant, Frederic; Han, Sileny N.; Dekrem, Jana; Strauven, Goedele; Mhallem Gziri, Mina; Vergote, Ignace] Katholieke Univ Leuven, Dept Oncol, Louvain, Belgium; [Amant, Frederic; Han, Sileny N.; Dekrem, Jana; Strauven, Goedele; Mhallem Gziri, Mina; Vergote, Ignace] Univ Hosp Leuven, Louvain, Belgium; [Halaska, Michael J.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Fumagalli, Monica] Fdn IRCCS CaGranda Osped Maggiore Policlin, Dept Clin Sci & Community Hlth, Milan, Italy; [Steffensen, Karina Dahl] Vejle Hosp, Vejle, Denmark; [Lok, Christianne] Ctr Gynecol Oncol Amsterdam, Amsterdam, Netherlands; [Van Calsteren, Kristel; van den Heuvel, Frank] Katholieke Univ Leuven, Univ Hosp Leuven, Louvain, Belgium; [Mir, Olivier] Paris Descartes Univ, Cochin Teaching Hosp, Paris, France; [Fruscio, Robert] Osped San Gerardo, Monza, Italy; [Uzan, Catherine; Morice, Philippe] Inst Cancerol Gustave Roussy, Villejuif, France; [Maxwell, Cynthia] Mt Sinai Hosp, Maternal Fetal Med Unit, Toronto, ON M5G 1X5, Canada; [Kesic, Vesna] Univ Belgrade, Fac Med, Clin Ctr Serbia, Belgrade, Serbia; [Berveiller, Paul] Univ Paris 06, Hop Trousseau, AP HP, Dept Gynecol & Obstet, Paris, France; [Ottevanger, Petronella B.] Radboudziekenhuis, Nijmegen, Netherlands; [Lishner, Michael] Dept Hematol & Bone Marrow Transplantat, Haifa, Israel; [Nulman, Irena] Univ Toronto, Hosp Sick Children, Motherisk Program, Toronto, ON M5G 1X8, Canada","Amant, F (reprint author), Katholieke Univ Leuven, Dept Oncol, Louvain, Belgium.","Frederic.amant@uzleuven.be","Van den Heuvel, Frank/G-6992-2011","Van den Heuvel, Frank/0000-0001-9904-502X",null,null,null,30,1,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X","1525-1438",null,"INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","MAR",2014,24,3,null,null,null,null,394,403,null,"10.1097/IGC.0000000000000062",null,10,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","AC4VK","WOS:000332519000005"]
["J","Fajkosova, K; Machovcova, A; Onder, M; Fritz, K",null,null,null,"Fajkosova, Katerina; Machovcova, Alena; Onder, Meltem; Fritz, Klaus",null,null,"Selective Radiofrequency Therapy as a Non-Invasive Approach for Contact less Body Contouring and Circumferential Reduction","JOURNAL OF DRUGS IN DERMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"SUBCUTANEOUS FAT; DEVICE","In this study, the efficacy of non-contact, selective radiofrequency (RE) were evaluated for body contouring as non-invasive fat and circumferential reduction of the abdomen. 40 healthy (36 female, 4 male) subjects showing significant volume of subcutaneous fat tissue on the abdomen and waistline were included. Once a week for 30 minutes, 4 sessions were performed. The applicator was placed on a supplied spacer covering the treatment area. Maximum power was 200W, which induced heat in the fat and connective tissue layer. The homogeneity of heat distribution and temperature of the skin surface were controlled. The circumferential reduction was measured at the baseline and after the last treatment. The photographs and adverse effects were recorded. Participants completed the self-evaluation questionnaires and rated their level of satisfaction. All subjects tolerated the treatments well. The only side effect was mild to moderate erythema. 35 subjects finished the protocol as planned and 5 subjects dropped off due to events not related to the study. 32 subjects had a 1-13 cm decrease in abdominal circumference and 3 subjects did not show significant response (0-1 cm). Most likely, a very thin fat layer was the reason for lack of response (the non-responding group was the thinnest patient group). No significant differences were found between men and women. The average decrease of 4.93cm was calculated as a result of circumferential reduction statistical evidence. This study demonstrates that the selective RF system designed for contactless deep tissue heating is a painless, safe, and effective treatment for non-surgical body contouring and circumferential fat reduction.","[Fajkosova, Katerina] Aesthet Med Clin, Prague, Czech Republic; [Machovcova, Alena] Univ Hosp Motol, Dept Dermatol & Venerol, Prague 5, Czech Republic; [Machovcova, Alena] Charles Univ Prague, Fac Med 1, Dept Occupat Med, Prague 2, Czech Republic; [Onder, Meltem; Fritz, Klaus] Dermatol & Laser Ctr, Landau, Germany; [Fritz, Klaus] Carol Davila Univ, Bucharest, Romania","Fritz, K (reprint author), Dermatol & Laser Ctr, Landau, Germany.","Drklausfritz@t-online.de",null,null,null,null,null,8,0,0,"JOURNAL OF DRUGS IN DERMATOLOGY","NEW YORK","377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA","1545-9616",null,null,"J DRUGS DERMATOL","J. Drugs Dermatol.","MAR",2014,13,3,null,null,null,null,291,296,null,null,null,6,"Dermatology","Dermatology","AD1OS","WOS:000333003900012"]
["J","Novotny, J; Bhatnagar, JP; Xu, Y; Huq, MS",null,null,null,"Novotny, J., Jr.; Bhatnagar, J. P.; Xu, Y.; Huq, M. S.",null,null,"Long-term stability of the Leksell Gamma Knife((R)) Perfexion (TM) patient positioning system (PPS)","MEDICAL PHYSICS",null,null,"English","Article",null,null,null,null,null,"Leksell gamma knife Perfexion; Patient Positioning System; patient setup accuracy","4C","Purpose: To assess the long-term mechanical stability and accuracy of the patient positioning system (PPS) of the Leksell Gamma Knife (R) Perfexion (TM) (LGK PFX). Methods: The mechanical stability of the PPS of the LGK PFX was evaluated using measurements obtained between September 2007 and June 2011. Three methods were employed to measure the deviation of the coincidence of the radiological focus point (RFP) and the PPS calibration center point (CCP). In the first method, the onsite diode test tool with single diode detector was used together with the 4 mm collimator on a daily basis. In the second method, a service diode test tool with three diode detectors was used biannually at the time of the routine preventive maintenance. The test performed with the service diode test tool measured the deviations for all three collimators 4, 8, and 16 mm and also for three different positions of the PPS. The third method employed the conventional film pin-prick method. This test was performed annually for the 4 mm collimator at the time of the routine annual QA. To estimate the effect of the patient weight on the performance of the PPS, the focus precision tests were also conducted with varying weights on the PPS using a set of lead bricks. Results: The average deviations measured from the 641 daily focus precision tests were 0.1 +/- 0.1, 0.0 +/- 0.0, and 0.0 +/- 0.0 mm, respectively, for the 4 mm collimator in the X (left/ right of the patient), Y (anterior/ posterior of the patient), and Z (superior/inferior of the patient) directions. The average of the total radial deviations as measured during ten semiannual measurements with the service diode test tool were 0.070 +/- 0.029, 0.060 +/- 0.022, and 0.103 +/- 0.028 mm, respectively for the central, long, and short diodes for the 4 mm collimator. Similarly, the average total radial deviations measured during the semiannual measurements for the 4, 8, and 16 mm collimators and using the central diode were 0.070 +/- 0.029, 0.097 +/- 0.025, 0.159 +/- 0.028 mm, respectively. The average values of the deviations as obtained from the five annual film pin-prick tests for the 4 mm collimator were 0.10 +/- 0.06, 0.06 +/- 0.09, and 0.03 +/- 0.03 mm for the X, Y, Z stereotactic directions, respectively. Only a minor change was observed in the total radial deviations of the PPS as a function of the simulated patient weight up to 202 kg on the PPS. Conclusions: Excellent long-term mechanical stability and high accuracy was observed for the PPS of the LGK PFX. No PPS recalibration or any adjustment in the PPS was needed during the monitored period of time. Similarly, the weight on the PPS did not cause any significant disturbance in the performance of the PPS for up to 202 kg simulated patient weight. (C) 2014 American Association of Physicists in Medicine.","[Novotny, J., Jr.; Bhatnagar, J. P.; Xu, Y.; Huq, M. S.] Univ Pittsburgh, Inst Canc, Dept Radiat Oncol, Med Phys Div, Pittsburgh, PA 15213 USA; [Novotny, J., Jr.] Na Homolce Hosp, Dept Med Phys, Prague 15030, Czech Republic; [Novotny, J., Jr.] Charles Univ Prague, Fac Med 1, Inst Biophys & Informat, Prague 12000, Czech Republic; [Novotny, J., Jr.] Czech Tech Univ, Fac Nucl Sci & Phys Engn, Dept Dosimetry & Applicat Ionizing Radiat, CR-11519 Prague, Czech Republic; [Novotny, J., Jr.] Univ Hosp Motol, Dept Radiat Oncol, Prague 15006, Czech Republic","Novotny, J (reprint author), Univ Pittsburgh, Inst Canc, Dept Radiat Oncol, Med Phys Div, Pittsburgh, PA 15213 USA.","josef.novotnyml@homolka.cz",null,null,null,null,null,9,0,0,"AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS","MELVILLE","STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA","0094-2405",null,null,"MED PHYS","Med. Phys.","MAR",2014,41,3,null,null,null,null,null,null,31711,"10.1118/1.4866225",null,9,"Radiology, Nuclear Medicine & Medical Imaging","Radiology, Nuclear Medicine & Medical Imaging","AC4IW","WOS:000332485600013"]
["J","Boublikova, L; Buchler, T; Stary, J; Abrahamova, J; Trka, J",null,null,null,"Boublikova, Ludmila; Buchler, Tomas; Stary, Jan; Abrahamova, Jitka; Trka, Jan",null,null,"Molecular biology of testicular germ cell tumors: Unique features awaiting clinical application","CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY",null,null,"English","Review",null,null,null,null,null,"Testicular germ cell tumor; Etiopathogenesis; Molecular aberration; Stem cell genes; p53; Chemotherapy resistance; Prognostic factor","CARCINOMA IN-SITU; DNA-DAMAGE RESPONSE; EMBRYONIC STEM-CELLS; EPIGENETIC TRANSGENERATIONAL TOXICOLOGY; HORMONE-METABOLIZING GENES; GENOME-WIDE ASSOCIATION; ANDROGEN RECEPTOR GENE; SUPPRESSOR GENE; CISPLATIN RESISTANCE; MICROSATELLITE INSTABILITY","Testicular germ cell tumors (TGCTs) are the most common solid tumors in young adult men characterized by distinct biologic features and clinical behavior. Both genetic predispositions and environmental factors probably play a substantial role in their etiology. TGTCs arise from a malignant transformation of primordial germ cells in a process that starts prenatally, is often associated with a certain degree of gonadal dysgenesis, and involves the acquirement of several specific aberrations, including activation of SCF-CKIT, amplification of 12p with up-regulation of stem cell genes, and subsequent genetic and epigenetic alterations. Their embryonic and germ origin determines the unique sensitivity of TGCTs to platinum-based chemotherapy. Contrary to the vast majority of other malignancies, no molecular prognostic/predictive factors nor targeted therapy is available for patients with these tumors. This review summarizes the principal molecular characteristics of TGCTs that could represent a potential basis for development of novel diagnostic and treatment approaches. (C) 2013 Elsevier Ireland Ltd. All rights reserved.","[Boublikova, Ludmila; Stary, Jan; Trka, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Motol, Czech Republic; [Boublikova, Ludmila; Stary, Jan; Trka, Jan] Univ Hosp Motol, Prague 15006 5, Motol, Czech Republic; [Boublikova, Ludmila; Buchler, Tomas; Abrahamova, Jitka] Charles Univ Prague, Fac Med 1, Dept Oncol, Prague 15006 5, Motol, Czech Republic; [Boublikova, Ludmila; Buchler, Tomas; Abrahamova, Jitka] Thomayer Hosp, Prague, Czech Republic","Boublikova, L (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","ludmila.boublikova@lfmotol.cuni.cz",null,null,"IGA [NT/12414-5]","Supported by grant IGA NT/12414-5.",null,182,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1040-8428","1879-0461",null,"CRIT REV ONCOL HEMAT","Crit. Rev. Oncol./Hematol.","MAR",2014,89,3,null,null,null,null,366,385,null,"10.1016/j.critrevonc.2013.10.001",null,20,"Oncology; Hematology","Oncology; Hematology","AC2TP","WOS:000332357200004"]
["J","Kuncova, K; Sedlackova, M; Vencovsky, J; Mann, H; Tomcik, M; Wenchich, L; Zamecnik, J",null,null,null,"Kuncova, Klara; Sedlackova, Marie; Vencovsky, Jiri; Mann, Herman; Tomcik, Michal; Wenchich, Laszlo; Zamecnik, Josef",null,null,"Inflammatory myopathy associated with statins: report of three cases","MODERN RHEUMATOLOGY",null,null,"English","Article",null,null,null,null,null,"Drug-induced myopathy; Muscle biopsy; Inflammatory myopathy; Statins","COA REDUCTASE INHIBITORS; MEDIATED NECROTIZING MYOPATHY; RETICULUM STRESS-RESPONSE; INDUCED DERMATOMYOSITIS; AUTOIMMUNE MYOSITIS; POLYMYOSITIS; SIMVASTATIN; ACTIVATION; MUTATIONS; THERAPY","Statins are well-established lipid-lowering drugs that reduce morbidity and mortality due to cardiovascular disease and cause adverse effects relatively rarely. It is still unclear whether statins are capable of inducing an immune-mediated response directed against skeletal muscle. Here, we present the cases of three patients who developed inflammatory myopathy in the course of statin treatment. Moreover, multiple mitochondrial DNA deletions were found in two of them. The ability of statins to induce an immune-mediated response and their interactions with mitochondrial metabolism pathways are discussed.","[Kuncova, Klara; Zamecnik, Josef] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Kuncova, Klara; Zamecnik, Josef] Charles Univ Prague, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Sedlackova, Marie] Thomayer Hosp, Dept Rheumatol & Rehabil, Prague 4, Czech Republic; [Vencovsky, Jiri; Mann, Herman; Tomcik, Michal] Charles Univ Prague, Fac Med 1, Inst Rheumatol, Dept Rheumatol, Prague 2, Czech Republic; [Wenchich, Laszlo] Charles Univ Prague, Fac Med 1, Dept Pediat, Prague 2, Czech Republic","Zamecnik, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Uvalu 84, Prague 15006 5, Czech Republic.","josef.zamecnik@lf2.cuni.cz",null,null,"Ministry of Health of the Czech Republic [00064203]","Supported by the Ministry of Health of the Czech Republic project for the conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic).",null,44,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1439-7595","1439-7609",null,"MOD RHEUMATOL","Mod. Rheumatol.","MAR",2014,24,2,null,null,null,null,366,371,null,"10.3109/14397595.2013.852848",null,6,"Rheumatology","Rheumatology","AC4IC","WOS:000332483500027"]
["J","Picha, D; Moravcova, L; Vanousova, D; Hercogova, J; Blechova, Z",null,null,null,"Picha, D.; Moravcova, L.; Vanousova, D.; Hercogova, J.; Blechova, Z.",null,null,"DNA persistence after treatment of Lyme borreliosis","FOLIA MICROBIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"POLYMERASE-CHAIN-REACTION; ANTIBIOTIC-THERAPY; BURGDORFERI DNA; SYNOVIAL-FLUID; DISEASE; ARTHRITIS; PCR; DIAGNOSIS; URINE; NEUROBORRELIOSIS","One hundred twenty-four patients-53 with neuroborreliosis, 48 with erythema migrans, and 23 with Lyme arthritis-were tested in a prospective study for the presence of the DNA of Borrelia burgdorferi sensu lato in plasma, cerebrospinal fluid (CSF), urine, and synovial fluid by nested polymerase chain reaction (PCR). Specific DNA was detected using five amplification systems simultaneously: three targeted chromosomal genes encoding 16S rDNA, flagellin, and p66; and two plasmid sequences of OspA and OspC. Patients were examined clinically and by PCR before and after treatment and again after 3 and 6 months. Before treatment, the specific DNA was detected in 78 patients (62.9 %). Forty-one neuroborreliosis patients were DNA-positive (77.4 %), with CSF positivity in 26 patients, urine in 25, and plasma in 16. Twenty-six erythema migrans patients were DNA-positive (54.2 %), with plasma positivity in 18 cases and urine in 14. Eleven Lyme arthritis cases (47.8 %) were DNA positive (six in urine, five in plasma, and four in synovial fluid). The frequency of PCR positives was comparable in CSF and urine, and it was lower by approximately 50 % in plasma. Specific DNA was also found in a significant number of patients in later testing periods: 48 patients after treatment, 29 patients after 3 months, and 6 patients after 6 months. The prolonged PCR positivity was not explainable by persistent infection according to the clinical manifestations of the disease. Possible explanations of the problem are discussed.","[Picha, D.; Moravcova, L.; Blechova, Z.] Charles Univ Prague, Hosp Na Bulovce, Sch Med 2, Clin Infect Dis 1, Prague 18081, Czech Republic; [Vanousova, D.; Hercogova, J.] Charles Univ Prague, Hosp Na Bulovce, Sch Med 2, Dermatol Clin, Prague 18081, Czech Republic","Picha, D (reprint author), Charles Univ Prague, Hosp Na Bulovce, Sch Med 2, Clin Infect Dis 1, Budinova 2, Prague 18081, Czech Republic.","dusan.picha@bulovka.cz",null,null,"Ministry of Health of Czech Republic [IGA NR/8293, NT/13467]","The study was supported by grants from the Ministry of Health of Czech Republic (IGA NR/8293 and NT/13467).",null,32,0,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632","1874-9356",null,"FOLIA MICROBIOL","Folia Microbiol.","MAR",2014,59,2,null,null,null,null,115,125,null,"10.1007/s12223-013-0272-4",null,11,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","AB9LO","WOS:000332115200004"]
["J","Bonthuis, M; van Stralen, KJ; Jager, KJ; Baiko, S; Jahnukainen, T; Laube, GF; Podracka, L; Seeman, T; Tyerman, K; Ulinski, T; Groothoff, JW; Schaefer, F; Verrina, E",null,null,null,"Bonthuis, Marjolein; van Stralen, Karlijn J.; Jager, Kitty J.; Baiko, Sergey; Jahnukainen, Timo; Laube, Guido F.; Podracka, Ludmila; Seeman, Tomas; Tyerman, Kay; Ulinski, Tim; Groothoff, Jaap W.; Schaefer, Franz; Verrina, Enrico",null,null,"Dyslipidaemia in children on renal replacement therapy","NEPHROLOGY DIALYSIS TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"children; dialysis; dyslipidaemia; renal replacement therapy; transplantation","CHRONIC KIDNEY-DISEASE; SERUM-LIPID LEVELS; TRANSPLANT RECIPIENTS; RISK-FACTORS; CARDIOVASCULAR RISK; PERITONEAL-DIALYSIS; INTERNATIONAL SURVEY; PEDIATRIC-PATIENTS; RANDOMIZED-TRIAL; BODY-COMPOSITION","Background. Information on lipid abnormalities in end-stage renal disease (ESRD) mainly originates from adult patients and small paediatric studies. We describe the prevalence of dyslipidaemia, and potential determinants associated with lipid measures in a large cohort of paediatric ESRD patients. Methods. In the ESPN/ERA-EDTA registry, lipid measurements were available for 976 patients aged 2-17 years from 19 different countries from the year 2000 onwards. Dyslipidaemia was defined as triglycerides >100 mg/dL (2-9 years) or >130 mg/dL (9-17 years), high-density lipoprotein (HDL) cholesterol <40 mg/dL or non-HDL cholesterol >145 mg/dL. Missing data were supplemented using multiple imputation. Results. The prevalence of dyslipidaemia was 85.1% in peritoneal dialysis (PD) patients, 76.1% in haemodialysis (HD) patients and 55.5% among renal allograft recipients. Both low and high body mass index (BMI) were associated with a less favourable lipid profile. Younger age was associated with a worse lipid profile among PD patients. HDL levels significantly improved after transplantation, whereas no significant improvements were found for triglyceride and non-HDL levels. In transplant recipients, use of cyclosporin was associated with significantly higher non-HDL and HDL levels than tacrolimus usage (P < 0.01). In transplant patients with eGFR < 29 mL/min/1.73 m(2), the mean triglyceride level was 137 mg/dL (99% confidence interval (CI): 119-159) compared with 102 mg/dL among those with eGFR >90 mL/min/1.73 m(2) (P < 0.0001). Conclusions. Dyslipidaemia is common among paediatric ESRD patients in Europe. Young age and PD treatment are associated with worse lipid profiles. Although lipid levels generally improve after transplantation, dyslipidaemia may persist due to decreased graft function, high BMI or to the use of certain immunosuppressants.","[Bonthuis, Marjolein; van Stralen, Karlijn J.; Jager, Kitty J.] Univ Amsterdam, Acad Med Ctr, Dept Med Informat, ESPN ERA EDTA Registry, NL-1105 AZ Amsterdam, Netherlands; [Baiko, Sergey] 2nd Childrens Hosp, Minsk, Byelarus; [Jahnukainen, Timo] Univ Helsinki, Childrens Hosp, Helsinki, Finland; [Laube, Guido F.] Univ Childrens Hosp, Dept Nephrol, Zurich, Switzerland; [Podracka, Ludmila] Safarik Univ, Fac Med, Kosice, Slovakia; [Seeman, Tomas] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Prague, Czech Republic; [Tyerman, Kay] Leeds Gen Infirm, Leeds, W Yorkshire, England; [Ulinski, Tim] Armand Trousseau Hosp, AP HP, Paris, France; [Ulinski, Tim] Univ Paris 06, Paris, France; [Groothoff, Jaap W.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat Nephrol, NL-1105 AZ Amsterdam, Netherlands; [Schaefer, Franz] Heidelberg Univ, Heidelberg, Germany; [Verrina, Enrico] Gaslini Childrens Hosp, Nephrol Dialysis & Transplantat Unit, Genoa, Italy","van Stralen, KJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Med Informat, ESPN ERA EDTA Registry, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.","k.j.vanstralen@amc.uva.nl",null,null,"European Renal Association; European Society of Paediatric Nephrology (ESPN); European Agency for Health and Consumers of the European Commission [ESPNFY_2013]; European Dialysis and Transplant Association (ERA-EDTA)","We thank the patients, their parents and the staff of all the dialysis and transplant units who have contributed data via their national registries and contact persons. We also thank P. Cochat, R. Coppo, D. Haffner, and J. Harambat for being members of the ESPN/ERA-EDTA Registry Committee, D. Shitza, R. Kramar, R. Oberbauer, A. Sukalo, K. van Hoeck, F. Collart, J. M. des Grottes, D. Pokrajac, D. Roussinov, D. Batinic, M. Lemac, J. Slavicek, K. Vondrak, J. Heaf, U. Toots, P. Finne, C. Gronhagen-Riska, C. Holmberg, C. Couchoud, M. Lasalle, E. Sahpazova, G. Gersdorf, C. Scholz, C. Barth, C. Scholz, B. Tonshoff, L. Plotznicki, G. A. Ioannidis, A. Kapogiannis, N. Printza, G. Reusz, S. Turi, L. Szabo, T. Szabo, E. Kis, Z.S. Gyorke, R. Palsson, V. Edvardsson, B. Gianolgio, T. de Palo, C. Pecoraro, S. Picca, S. Testa, E. Vidal, A. Jankauskiene, B. Punziene, V. Said-Conti, S. Pavicevic, T. Leivestad, A. Bjerre, A. Zurowska, I. Zagozdzon, C. Mota, M. Almeida, C. Afonso, G. Mircescu, L. Garneata, E. A. Molchanova, N. A. Tomilina, B. T. Bikbov, M. Kostic, A. Peco-Antic, D. Kruscic, S. Puric, B. Spasojevic-Dimitrijeva, G. Milosevski-Lomic, D. Paripovic, G. Kolvek, J. Buturovic-Ponikvar, G. Novljan, N. Battelino, A. Alonso Melgar and the Spanish Pediatric Registry, S. Schon, K. G. Prutz, B. Rippe, M. Herthelius, L. Backman, S. Rossi, E. Maurer, B. Schnarwyler, C. E. Kuenhi, A. Hoitsma, A. Hemke, and all centres participating in the RICHQ study, R. Topaloglu, O. Sollemezoglu, A. Duzova, D. Ivanov, the staff of the UK renal registry, S. Manish, T. Feest and C. Inward for contributing data to the ESPN/ERA-EDTA Registry. The ESPN/ERA-EDTA registry is funded by the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA), the European Society of Paediatric Nephrology (ESPN) and the European Agency for Health and Consumers of the European Commission (grant no. ESPNFY_2013).",null,58,0,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0931-0509","1460-2385",null,"NEPHROL DIAL TRANSPL","Nephrol. Dial. Transplant.","MAR",2014,29,3,null,null,null,null,594,603,null,"10.1093/ndt/gft429",null,11,"Transplantation; Urology & Nephrology","Transplantation; Urology & Nephrology","AC2YJ","WOS:000332381900020"]
["J","Stanik, J; Dusatkova, P; Cinek, O; Valentinova, L; Huckova, M; Skopkova, M; Dusatkova, L; Stanikova, D; Pura, M; Klimes, I; Lebl, J; Gasperikova, D; Pruhova, S",null,null,null,"Stanik, Juraj; Dusatkova, Petra; Cinek, Ondrej; Valentinova, Lucia; Huckova, Miroslava; Skopkova, Martina; Dusatkova, Lenka; Stanikova, Daniela; Pura, Mikulas; Klimes, Iwar; Lebl, Jan; Gasperikova, Daniela; Pruhova, Stepanka",null,null,"De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed","DIABETOLOGIA",null,null,"English","Article",null,null,null,null,null,"De novo mutations; Diabetes; GCK; HNF1A; HNF4A; MODY","HUMAN GLUCOKINASE GENE; DIAGNOSIS; YOUNG","MODY is mainly characterised by an early onset of diabetes and a positive family history of diabetes with an autosomal dominant mode of inheritance. However, de novo mutations have been reported anecdotally. The aim of this study was to systematically revisit a large collection of MODY patients to determine the minimum prevalence of de novo mutations in the most prevalent MODY genes (i.e. GCK, HNF1A, HNF4A). Analysis of 922 patients from two national MODY centres (Slovakia and the Czech Republic) identified 150 probands (16%) who came from pedigrees that did not fulfil the criterion of two generations with diabetes but did fulfil the remaining criteria. The GCK, HNF1A and HNF4A genes were analysed by direct sequencing. Mutations in GCK, HNF1A or HNF4A genes were detected in 58 of 150 individuals. Parents of 28 probands were unavailable for further analysis, and in 19 probands the mutation was inherited from an asymptomatic parent. In 11 probands the mutations arose de novo. In our cohort of MODY patients from two national centres the de novo mutations in GCK, HNF1A and HNF4A were present in 7.3% of the 150 families without a history of diabetes and 1.2% of all of the referrals for MODY testing. This is the largest collection of de novo MODY mutations to date, and our findings indicate a much higher frequency of de novo mutations than previously assumed. Therefore, genetic testing of MODY could be considered for carefully selected individuals without a family history of diabetes.","[Stanik, Juraj; Valentinova, Lucia; Huckova, Miroslava; Skopkova, Martina; Stanikova, Daniela; Klimes, Iwar; Gasperikova, Daniela] Slovak Acad Sci, Inst Expt Endocrinol, DIABGENE Lab, SK-83306 Bratislava, Slovakia; [Stanik, Juraj; Stanikova, Daniela] Comenius Univ, Fac Med, Dept Pediat 1, Bratislava, Slovakia; [Dusatkova, Petra; Cinek, Ondrej; Dusatkova, Lenka; Lebl, Jan; Pruhova, Stepanka] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Dusatkova, Petra; Cinek, Ondrej; Dusatkova, Lenka; Lebl, Jan; Pruhova, Stepanka] Univ Hosp Motol, Prague, Czech Republic; [Pura, Mikulas] Natl Inst Endocrinol & Diabetol, Lubochna, Slovakia; [Klimes, Iwar; Gasperikova, Daniela] Slovak Acad Sci, Ctr Mol Med, SK-83306 Bratislava, Slovakia","Gasperikova, D (reprint author), Slovak Acad Sci, Inst Expt Endocrinol, DIABGENE Lab, Vlarska 3, SK-83306 Bratislava, Slovakia.","daniela.gasperikova@savba.sk",null,null,"DIABGENE Laboratory [Transendogen/26240220051]; Research & Development Operational Programme; European Regional Development Fund; Ministry of Education, Science, Research and Sport of the Slovak Republic [2/0151/11]; Czech Ministry of Health [NT11402]; MH CZ-DRO, University Hospital Motol, Prague, the Czech Republic [00064203]","This work was supported by research grants of the DIABGENE Laboratory (Transendogen/26240220051) which is supported by the Research & Development Operational Programme and funded by the European Regional Development Fund and Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic (2/0151/11). This study was also supported by grants from the Czech Ministry of Health (NT11402 and MH CZ-DRO, University Hospital Motol, Prague, the Czech Republic 00064203).",null,10,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0012-186X","1432-0428",null,"DIABETOLOGIA","Diabetologia","MAR",2014,57,3,null,null,null,null,480,484,null,"10.1007/s00125-013-3119-2",null,5,"Endocrinology & Metabolism","Endocrinology & Metabolism","AB1NG","WOS:000331558400007"]
["J","Nartova, E; Kraus, J; Pavlik, E; Lukes, P; Katra, R; Plzak, J; Kolarova, L; Sterzl, I; Betka, J; Astl, J",null,null,null,"Nartova, Eva; Kraus, Jaroslav; Pavlik, Emil; Lukes, Petr; Katra, Rami; Plzak, Jan; Kolarova, Libuse; Sterzl, Ivan; Betka, Jan; Astl, Jaromir",null,null,"Presence of different genotypes of Helicobacter pylori in patients with chronic tonsillitis and sleep apnoea syndrome","EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"Helicobacter pylori; Tonsillar tissue; Sleep apnoea syndrome; Real-time PCR; Hybridisation probes","CHRONIC ADENOTONSILLITIS; ORAL CAVITY; COLONIZATION; INFECTION; CHILDREN; TISSUE; SEROPREVALENCE; ASSOCIATION; PLAY; IGA","Helicobacter pylori, a well-known gastric pathogen, has been detected in the oral cavity and oropharynx in tonsillar tissue. In our study, the presence of H. pylori in the tonsillar tissue of patients with chronic tonsillitis and sleep apnoea syndrome (SAS) was investigated. The aim was to detect and genotype H. pylori for a collection of data supporting the possible role of H. pylori in the aetiology of chronic tonsillitis and SAS. Helicobacter pylori was detected by real-time polymerase chain reaction (rt-PCR). 89 patients, 60 with a diagnosis of chronic tonsillitis and 29 with SAS, were tested. In the chronic tonsillitis group, Helicobacter was detected in 48 (80 %) specimens, cagA gene was detected in 12 samples (25 %) and 12 samples were negative. In SAS group, Helicobacter was found in 24 samples (82.76 %), cagA gene was detected in 5 (20.83 %) and 5 samples (17.24 %) were negative. Helicobacter pylori-specific immunoglobulins were tested by ELISA in the serum of 57 patients only with 41 (71.93 %) showing positive. Our results on H. pylori DNA detection and H. pylori seropositivity show 26.32 % discrepancy, slightly in favour of rt-PCR (15.79 % compared to 10.53 %). The H. pylori presence in tonsillar tissue does not depend on the type of oropharyngeal disease (p = 0.756). This study shows that oropharynx constitutes an extragastric reservoir of H. pylori infection which could serve as an aetiopathogenetic factor for chronic tonsillitis and tonsillar hyperplasia by SAS. No conclusion has yet been drawn about the mechanism of the process.","[Nartova, Eva; Lukes, Petr; Plzak, Jan; Betka, Jan] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Othorinolaryngol & Head & Neck Surg, Prague, Czech Republic; [Kraus, Jaroslav] Hosp Rudolph & Stephanie, Dept Othorinolaryngol, Beneov, Czech Republic; [Pavlik, Emil; Kolarova, Libuse] Charles Univ Prague, Gen Fac Hosp, Fac Med 1, Dept Microbiol & Immunol, Prague, Czech Republic; [Pavlik, Emil] Charles Univ Prague, Gen Fac Hosp, Fac Med 1, Inst Med Biochem & Lab Med, Prague, Czech Republic; [Katra, Rami] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept ENT, Prague, Czech Republic; [Sterzl, Ivan] Inst Endocrinol, Prague, Czech Republic; [Astl, Jaromir] Charles Univ Prague, Mil Univ Hosp, Fac Med 3, Dept ENT, Prague, Czech Republic","Nartova, E (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Othorinolaryngol & Head & Neck Surg, Prague, Czech Republic.","anave@volny.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NT11523]","This work was supported by Grant NT11523 of the Internal Grant Agency of the Ministry of Health of the Czech Republic.",null,36,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0937-4477","1434-4726",null,"EUR ARCH OTO-RHINO-L","Eur. Arch. Oto-Rhino-Laryn.","MAR",2014,271,3,null,null,null,null,607,613,null,"10.1007/s00405-013-2607-9",null,7,"Otorhinolaryngology","Otorhinolaryngology","AB3QU","WOS:000331706100028"]
["J","Gkalpakiotis, S; Arenberger, P; Gkalpakioti, P; Meluzinova, E; Chandran, D; Arenbergerova, M",null,null,null,"Gkalpakiotis, Spyridon; Arenberger, Petr; Gkalpakioti, Petra; Meluzinova, Eva; Chandran, Devika; Arenbergerova, Monika",null,null,"Management of psoriasis vulgaris and multiple sclerosis with fumaric acid","JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY",null,null,"English","Letter",null,null,null,null,null,null,"BG-12",null,"[Gkalpakiotis, Spyridon; Arenberger, Petr; Gkalpakioti, Petra; Chandran, Devika; Arenbergerova, Monika] Charles Univ Prague, Dept Dermatovenereol, Fac Med 3, Prague 10034 10, Czech Republic; Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Meluzinova, Eva] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague 10034 10, Czech Republic; Motol Univ Hosp, Prague, Czech Republic","Gkalpakiotis, S (reprint author), Charles Univ Prague, Dept Dermatovenereol, Fac Med 3, Srobarova 50, Prague 10034 10, Czech Republic.","spyros@centrum.cz",null,null,null,null,null,6,0,0,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0190-9622",null,null,"J AM ACAD DERMATOL","J. Am. Acad. Dermatol.","MAR",2014,70,3,null,null,null,null,"E60","E61",null,"10.1016/j.jaad.2013.10.031",null,3,"Dermatology","Dermatology","AB2FA","WOS:000331607400006"]
["J","Colombel, M; Heidenreich, A; Martinez-Pineiro, L; Babjuk, M; Korneyev, I; Surcel, C; Yakovlev, P; Colombo, R; Radziszewski, P; Witjes, F; Schipper, R; Mulders, P; Witjes, WPJ",null,null,null,"Colombel, Marc; Heidenreich, Axel; Martinez-Pineiro, Luis; Babjuk, Marko; Korneyev, Igor; Surcel, Cristian; Yakovlev, Pavel; Colombo, Renzo; Radziszewski, Piotr; Witjes, Fred; Schipper, Raymond; Mulders, Peter; Witjes, Wim P. J.",null,null,"Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: Overview and the Unmet Clinical Need for Alternative Adjuvant Therapy as Studied in the MAGNOLIA Trial","EUROPEAN UROLOGY",null,null,"English","Editorial Material",null,null,null,null,null,null,"TRANSITIONAL-CELL CARCINOMA; RADICAL CYSTECTOMY; SERIES",null,"[Colombel, Marc] Hop Edouard Herriot, Lyon, France; [Heidenreich, Axel] Univ Klinikum RWTH Aachen, Aachen, Germany; [Martinez-Pineiro, Luis] Hosp Univ Infanta Sofia, Madrid, Spain; [Babjuk, Marko] Charles Univ Prague, Hosp Motol, Prague, Czech Republic; [Babjuk, Marko] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Korneyev, Igor] Pavlov State Med Univ St Petersburg, St Petersburg, Russia; [Surcel, Cristian] Univ Med & Pharm Carol Davila, Bucharest, Romania; [Yakovlev, Pavel] Kiev Municipal Oncol Hosp, Kiev, Ukraine; [Colombo, Renzo] Univ Vita Salute San Raffaele Hosp, Milan, Italy; [Radziszewski, Piotr] Med Univ Warsaw, Warsaw, Poland; [Witjes, Fred; Mulders, Peter] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands; [Schipper, Raymond; Mulders, Peter; Witjes, Wim P. J.] EAU Res Fdn, Arnhem, Netherlands","Witjes, WPJ (reprint author), EAU Res Fdn, Mr EN van Kleffensstr 5, NL-6842 CV Arnhem, Netherlands.","w.witjes@curatrial.com",null,null,null,null,null,10,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838","1873-7560",null,"EUR UROL","Eur. Urol.","MAR",2014,65,3,null,null,null,null,509,511,null,"10.1016/j.eururo.2013.10.056",null,3,"Urology & Nephrology","Urology & Nephrology","302AC","WOS:000330572600005"]
["J","Brisset, S; Slamova, Z; Dusatkova, P; Briand-Suleau, A; Milcent, K; Metay, C; Simandlova, M; Sumnik, Z; Tosca, L; Goossens, M; Labrune, P; Zemankova, E; Lebl, J; Tachdjian, G; Sedlacek, Z",null,null,null,"Brisset, Sophie; Slamova, Zuzana; Dusatkova, Petra; Briand-Suleau, Audrey; Milcent, Karen; Metay, Corinne; Simandlova, Martina; Sumnik, Zdenek; Tosca, Lucie; Goossens, Michel; Labrune, Philippe; Zemankova, Elsa; Lebl, Jan; Tachdjian, Gerard; Sedlacek, Zdenek",null,null,"Anophthalmia, hearing loss, abnormal pituitary development and response to growth hormone therapy in three children with microdeletions of 14q22q23","MOLECULAR CYTOGENETICS",null,null,"English","Article",null,null,null,null,null,"Anophthalmia; 14q22q23 microdeletion; OTX2; Hearing loss; Pituitary; Growth hormone therapy","BMP4 GENE; MUTATIONS; ANOMALIES; DELETION; PHENOTYPE; EYE","Background: Microdeletions of 14q22q23 have been associated with eye abnormalities and pituitary defects. Other phenotypic features in deletion carriers including hearing loss and response to growth hormone therapy are less well recognized. We studied genotype and phenotype of three newly identified children with 14q22q23 deletions, two girls and one boy with bilateral anophthalmia, and compared them with previously published deletion patients and individuals with intragenic defects in genes residing in the region. Results: The three deletions were de novo and ranged in size between 5.8 and 8.9 Mb. All three children lacked one copy of the OTX2 gene and in one of them the deletion involved also the BMP4 gene. All three patients presented partial conductive hearing loss which tended to improve with age. Analysis of endocrine and growth phenotypes showed undetectable anterior pituitary, growth hormone deficiency and progressive growth retardation in all three patients. Growth hormone therapy led to partial catch-up growth in two of the three patients but just prevented further height loss in the third. Conclusions: The pituitary hypoplasia, growth hormone deficiency and growth retardation associated with 14q22q23 microdeletions are very remarkable, and the latter appears to have an atypical response to growth hormone therapy in some of the cases.","[Brisset, Sophie; Tosca, Lucie; Tachdjian, Gerard] Hop Antoine Beclere, AP HP, Serv Histol Embryol & Cytogenet, Clamart, France; [Slamova, Zuzana; Simandlova, Martina; Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic; [Slamova, Zuzana; Dusatkova, Petra; Simandlova, Martina; Sumnik, Zdenek; Sedlacek, Zdenek] Univ Hosp Motol, Prague, Czech Republic; [Dusatkova, Petra; Sumnik, Zdenek; Lebl, Jan] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague, Czech Republic; [Briand-Suleau, Audrey; Metay, Corinne; Goossens, Michel] Hop Henri Mondor, AP HP, Serv Biochim Genet, F-94010 Creteil, France; [Milcent, Karen; Labrune, Philippe] Hop Antoine Beclere, AP HP, Serv Pediat, Clamart, France; [Zemankova, Elsa] Genet & Pediat Ambulance, Benesov, Czech Republic; [Tosca, Lucie; Tachdjian, Gerard] INSERM, U935, Villejuif, France; [Brisset, Sophie; Milcent, Karen; Tosca, Lucie; Labrune, Philippe; Tachdjian, Gerard] Univ Paris 11, Fac Med Paris Sud, Le Kremlin Bicetre, France; [Briand-Suleau, Audrey; Metay, Corinne; Goossens, Michel] Univ Paris 12, INSERM, U955, Creteil, France","Sedlacek, Z (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic.","zdenek.sedlacek@lfmotol.cuni.cz",null,null,"Direction de l'Hospitalisation et de l'Organisation des Soins; Czech Ministry of Health [NT13692, DRO UH Motol 00064203];  [CZ.2.16/3.1.00/24022]","We thank the families for their cooperation. This work was supported by Direction de l'Hospitalisation et de l'Organisation des Soins, grants NT13692 and DRO UH Motol 00064203 from the Czech Ministry of Health, and CZ.2.16/3.1.00/24022.",null,17,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1755-8166",null,null,"MOL CYTOGENET","Mol. Cytogenet.","FEB 28",2014,7,null,null,null,null,null,null,null,17,"10.1186/1755-8166-7-17",null,7,"Genetics & Heredity","Genetics & Heredity","AD5CW","WOS:000333270100002"]
["J","Profant, O; Skoch, A; Balogova, Z; Tintera, J; Hlinka, J; Syka, J",null,null,null,"Profant, O.; Skoch, A.; Balogova, Z.; Tintera, J.; Hlinka, J.; Syka, J.",null,null,"DIFFUSION TENSOR IMAGING AND MR MORPHOMETRY OF THE CENTRAL AUDITORY PATHWAY AND AUDITORY CORTEX IN AGING","NEUROSCIENCE",null,null,"English","Article",null,null,null,null,null,"presbycusis; aging; auditory cortex; auditory pathway; MR morphometry; diffusion tensor imaging","AGE-RELATED-CHANGES; HUMAN CEREBRAL-CORTEX; SENSORINEURAL HEARING-LOSS; MAGNETIC-RESONANCE IMAGES; VOXEL-BASED MORPHOMETRY; WHITE-MATTER INTEGRITY; SURFACE RECONSTRUCTION; GEOMETRICALLY ACCURATE; INFERIOR COLLICULUS; SPEECH-PERCEPTION","Age-related hearing loss (presbycusis) is caused mainly by the hypofunction of the inner ear, but recent findings point also toward a central component of presbycusis. We used MR morphometry and diffusion tensor imaging (DTI) with a 3 T MR system with the aim to study the state of the central auditory system in a group of elderly subjects (> 65 years) with mild presbycusis, in a group of elderly subjects with expressed presbycusis and in young controls. Cortical reconstruction, volumetric segmentation and auditory pathway tractography were performed. Three parameters were evaluated by morphometry: the volume of the gray matter, the surface area of the gyrus and the thickness of the cortex. In all experimental groups the surface area and gray matter volume were larger on the left side in Heschl's gyrus and planum temporale and slightly larger in the gyrus frontalis superior, whereas they were larger on the right side in the primary visual cortex. Almost all of the measured parameters were significantly smaller in the elderly subjects in Heschl's gyrus, planum temporale and gyrus frontalis superior. Aging did not change the side asymmetry (laterality) of the gyri. In the central part of the auditory pathway above the inferior colliculus, a trend toward an effect of aging was present in the axial vector of the diffusion (L1) variable of DTI, with increased values observed in elderly subjects. A trend toward a decrease of L1 on the left side, which was more pronounced in the elderly groups, was observed. The effect of hearing loss was present in subjects with expressed presbycusis as a trend toward an increase of the radial vectors (L2L3) in the white matter under Heschl's gyrus. These results suggest that in addition to peripheral changes, changes in the central part of the auditory system in elderly subjects are also present; however, the extent of hearing loss does not play a significant role in the central changes. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.","[Profant, O.; Balogova, Z.; Syka, J.] Acad Sci Czech Republic, Inst Expt Med, Dept Auditory Neurosci, Prague, Czech Republic; [Skoch, A.; Tintera, J.] Inst Clin & Expt Med, MR Unit, Dept Diagnost & Intervent Radiol, Prague, Czech Republic; [Hlinka, J.] Acad Sci Czech Republic, Inst Comp Sci, Dept Nonlinear Dynam & Complex Syst, Prague, Czech Republic; [Profant, O.; Balogova, Z.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Univ Hosp Motol, Prague 15006 5, Czech Republic","Profant, O (reprint author), Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","profant@biomed.cas.cz","Hlinka, Jaroslav/E-1787-2013","Hlinka, Jaroslav/0000-0003-1402-1470"," [GACR P304/10/1872];  [GACR P304/12/G069];  [PRVOUK P27];  [GA13-23940S]","This research was supported by the grant GACR P304/10/1872, GACR P304/12/G069, PRVOUK P27 and Institutional Support 00023001IKEM of the Ministry of Health of the Czech Republic. Work by J. Hlinka was partially supported by the grant GA13-23940S.",null,87,0,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0306-4522","1873-7544",null,"NEUROSCIENCE","Neuroscience","FEB 28",2014,260,null,null,null,null,null,87,97,null,"10.1016/j.neuroscience.2013.12.010",null,11,"Neurosciences","Neurosciences & Neurology","302IM","WOS:000330598100008"]
["J","Pavlik, T; Majek, O; Buchler, T; Vyzula, R; Petera, J; Ryska, M; Ryska, A; Cibula, D; Babjuk, M; Abrahamova, J; Vorlicek, J; Muzik, J; Dusek, L",null,null,null,"Pavlik, Tomas; Majek, Ondrej; Buechler, Tomas; Vyzula, Rostislav; Petera, Jiri; Ryska, Miroslav; Ryska, Ales; Cibula, David; Babjuk, Marko; Abrahamova, Jitka; Vorlicek, Jiri; Muzik, Jan; Dusek, Ladislav",null,null,"Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008","CANCER EPIDEMIOLOGY",null,null,"English","Article",null,null,null,null,null,"Cancer; Population-based registry; Relative survival; Stage-specific analysis","COLORECTAL-CANCER; BREAST-CANCER; EARLY 21ST-CENTURY; DEATH CERTIFICATE; GERMANY; EUROCARE-4; MIGRATION; RATES; AGE","Background: The objective of this study was to assess trends in overall and in stage-specific 5-year relative survival rates of the Czech cancer patients between periods 2000-2004 and 2005-2008. Methods: All Czech cancer patients diagnosed between 1995 and 2008 were included in the analysis. Period analysis was employed to calculate 5-year relative survival for 21 cancers. Results: Significant improvements in crude 5-year relative survival for 14 of 21 assessed types of cancer, including the most frequent diagnoses, such as, colorectal, prostate, breast, lung, kidney, pancreatic, and bladder cancer and melanoma, were identified. Moreover, in case of colorectal, lung, and prostate cancer, improvement in stage-specific 5-year relative survival was confirmed as statistically significant for all clinical stages. No diagnosis showed significant decrease in the 5-year relative survival. However, the 5year relative survival remained poor in patients with metastatic cancers at diagnosis, particularly in case of liver, pancreatic, lung, and oesophageal cancer. Conclusions: The cancer-specific outcomes in the Czech Republic are improving. Nevertheless, despite the overall significant improvement in 5-year relative survival of most of the cancer diagnoses, the high proportion of patients primarily diagnosed with metastatic cancer still represents a substantial challenge for prevention and early detection. (C) 2013 Elsevier Ltd. All rights reserved.","[Pavlik, Tomas; Majek, Ondrej; Muzik, Jan; Dusek, Ladislav] Masaryk Univ, Inst Biostat & Anal, Brno 62500, Czech Republic; [Buechler, Tomas; Abrahamova, Jitka] Thomayer Hosp, Dept Oncol, Prague 14059, Czech Republic; [Buechler, Tomas; Abrahamova, Jitka] Thomayer Hosp, Fac Med 1, Prague 14059, Czech Republic; [Buechler, Tomas; Abrahamova, Jitka] Charles Univ Prague, Prague 14059, Czech Republic; [Vyzula, Rostislav; Vorlicek, Jiri] Masaryk Mem Canc Inst, Dept Complex Oncol Care, Brno 65653, Czech Republic; [Petera, Jiri] Univ Hosp Hradec Kralove, Dept Radiotherapy & Oncol, Hradec Kralove 50005, Czech Republic; [Ryska, Miroslav] Cent Mil Hosp, Dept Surg, Prague 16902, Czech Republic; [Ryska, Miroslav] Cent Mil Hosp, Fac Med 2, Prague 16902, Czech Republic; [Ryska, Miroslav] Charles Univ Prague, Prague 16902, Czech Republic; [Ryska, Ales] Charles Univ Prague, Fac Med, Fingerland Dept Pathol, Hradec Kralove 50005, Czech Republic; [Ryska, Ales] Univ Hosp Hradec Kralove, Hradec Kralove 50005, Czech Republic; [Cibula, David] Gen Univ Hosp, Gynaecol Oncol Ctr, Prague 12851, Czech Republic; [Cibula, David] Gen Univ Hosp, Fac Med 1, Prague 12851, Czech Republic; [Cibula, David] Charles Univ Prague, Prague 12851, Czech Republic; [Babjuk, Marko] Univ Hosp Motol, Dept Urol, Prague 15006, Czech Republic; [Babjuk, Marko] Univ Hosp Motol, Fac Med 2, Prague 15006, Czech Republic; [Babjuk, Marko] Charles Univ Prague, Prague 15006, Czech Republic","Dusek, L (reprint author), Masaryk Univ, Inst Biostat & Anal, Kamenice 3, Brno 62500, Czech Republic.","dusek@iba.muni.cz",null,null,"Masaryk University [MUNI/A/0828/2011]","This work was supported by Masaryk University [MUNI/A/0828/2011 to O.M.]. The funding body had no role in design, collection, analysis or interpretation of the data, writing of the manuscript or the decision to submit the manuscript for publication.",null,34,1,1,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","1877-7821","1877-783X",null,"CANCER EPIDEMIOL","Cancer Epidemiol.","FEB",2014,38,1,null,null,null,null,28,34,null,"10.1016/j.canep.2013.11.002",null,7,"Oncology; Public, Environmental & Occupational Health","Oncology; Public, Environmental & Occupational Health","AE5LF","WOS:000334029800005"]
["J","Fulin, P; Pokorny, D; Slouf, M; Vackova, T; Dybal, J; Sosna, A",null,null,null,"Fulin, P.; Pokorny, D.; Slouf, M.; Vackova, T.; Dybal, J.; Sosna, A.",null,null,"Effect of Sterilisation with Formaldehyde, Gamma Irradiation and Ethylene Oxide on the Properties of Polyethylene Joint Replacement Components","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"UHMWPE; sterilisation; ethylene oxide; gamma irradiation; oxidation; formaldehyde","MOLECULAR-WEIGHT POLYETHYLENE; PERIPROSTHETIC TISSUES; UHMWPE WEAR; RADIATION; OXIDATION","PURPOSE OF THE STUDY Each method of sterilisation has some effect on the structure and properties of UHMWPE and thus also on joint replacement longevity. This study was designed to compare, using objective methods of measurement, several kinds of sterilisation and to recommend the one which has the best prospect for making joint replacements last longer. MATERIAL AND METHODS Two groups of UHMWPE samples were tested. Group 1 included virgin GUR 1020 polyethylene, non-modified and non-sterilised (Meditech, Germany). Group 2 comprised of three sets of samples sterilised with formaldehyde, gamma irradiation and ethylene oxide, respectively. In both groups, physicochemical properties were assessed by infrared spectroscopy (IR), and the oxidation (OI) and trans-vinyl (VI) indices, which show the degree of oxidation of a material, were determined. Free-radical concentrations were measured by the method of electron spin resonance (ESR). The mechanical properties of each sample were studied using small punch tests (SPT) and testing microhardness (MH). Any change in mechanical properties can affect, to various degrees, the quality and longevity of a prosthetic joint. RESULTS The samples sterilised by gamma irradiation showed higher values of both the OI (0.37) and the VI index (0.038) than the other samples (OI, 0.02 to 0.05 and VI, 0). Also, the free-radical concentration was detectable only in the gamma-sterilised sample. Values obtained for mechanical properties were as follows: peak load in the range of 58.48 N (gamma irradiation) to 59.60 N (ethylene oxide); ultimate load in the range of 46.69 N (gamma irradiation) to 57.50 N (ethylene oxide); ultimate displacement in the range of 4.29 mm (gamma irradiation) to 4.58 mm (virgin polyethylene and formaldehyde); and work to failure in the range of 185.18 mJ (gamma irradiation) to 205.89 mJ (virgin polyethylene). Microhardness values were obtained in the following ranges: 41.2 to 44.6 MPa (virgin polyethylene); 40.2 to 44.1 MPa (formaldehyde); 46.1 to 49.3 MPa (gamma irradiation); and 40.3 to 44.2 MPa (ethylene oxide). DISCUSSION The samples sterilised with formaldehyde and ethylene oxide have mechanical properties very similar to virgin polyethylene, they are not damaged by oxidation and do not contain free radicals. Owing to these characteristics, the immediate and long-term oxidation stability of the three samples is higher. The sample sterilised by gamma irradiation showed the presence of free radicals and immediate and long-term oxidative degradation. This results in the deterioration of mechanical properties and the growth of crystallinity due to enhanced oxidation and leads to higher polyethylene microhardness. CONCLUSIONS Sterilisation with gamma irradiation results in oxidative degradation and mechanical property deterioration, which is one of the potential risks of a shorter life span of joint replacements. The use of ethylene oxide or formaldehyde does not change polymer properties nor has any effect on oxidation of materials. Therefore, a longer life expectancy of the joint replacements sterilised with ethylene oxide can be expected. The life span of their joint replacements is a key issue for the patients. Prosthetic joint loosening is painful and the patient often requires re-implantation. A higher number of re-implantations is associated with higher costs for the institution involved and, consequently, for the whole health care system. Although this study basically deals with chemical issues, it informs the surgeon of the latest developments leading to the improvement of implanted materials, which can increase the life expectancy of joint replacements and patients' satisfaction.","[Fulin, P.; Pokorny, D.; Sosna, A.] LF UK, Ortoped Klin 1 1, Prague 15006 5, Czech Republic; [Fulin, P.; Pokorny, D.; Sosna, A.] FN Motol, Prague 15006 5, Czech Republic; [Slouf, M.; Vackova, T.; Dybal, J.] Ustav Makromol Chem AV CR, Prague, Czech Republic","Fulin, P (reprint author), LF UK, Ortoped Klin 1 1, V Uvalu 84, Prague 15006 5, Czech Republic.","petrfulin@volny.cz","Dybal, Jiri/A-8290-2008","Dybal, Jiri/0000-0002-9148-3655",null,null,null,24,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2014,81,1,null,null,null,null,33,39,null,null,null,7,"Orthopedics","Orthopedics","AD0JW","WOS:000332921300003"]
["J","Veselka, J; Hajek, P; Tomasov, P; Tesar, D; Bruhova, H; Matejovic, M; Branny, M; Studencan, M; Zemanek, D",null,null,null,"Veselka, Josef; Hajek, Petr; Tomasov, Pavol; Tesar, David; Bruhova, Hana; Matejovic, Martin; Branny, Marian; Studencan, Martin; Zemanek, David",null,null,"Effect of Rosuvastatin Therapy on Troponin I Release Following Percutaneous Coronary Intervention in Nonemergency Patients (from the TIP 3 Study)","AMERICAN JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"PERIPROCEDURAL MYOCARDIAL-INFARCTION; STATIN THERAPY; ATORVASTATIN PRETREATMENT; RANDOMIZED-TRIAL; UNIVERSAL DEFINITION; OUTCOMES; IMPACT; ANGIOPLASTY; REDUCTION; IMPROVES","Several randomized studies have suggested that pretreatment with statins may reduce a periprocedural biomarker release in patients who underwent percutaneous coronary intervention (PCI); however, results remain controversial. The purpose of this study was to investigate the effect of a 1-day rosuvastatin therapy on troponin I release in patients who underwent nonemergency PCI. A total of 445 patients with angina pectoris were randomly assigned to therapy with rosuvastatin (20 mg 12 hours before coronary angiography + 20 mg immediately before PCI; rosuvastatin group, 220 patients) or PCI without statin therapy (control group, 225 patients). In patients taking statins (73%), rosuvastatin was added to their long-term statin therapy. The primary end point was the incidence of TnI microleak defined as TnI elevation >1.5 x upper limit of normal, and the secondary end point was the incidence of post-PCI TnI elevation >3 x upper limit of normal. The incidence of primary and secondary end point in the rosuvastatin versus control group was 13.6% versus 12% (p = 0.61) and 8.2% versus 7.1% (p = 0.67), respectively. Patients with C-reactive protein >= 2.0 mg/L had a decreased release of post-PCI TnI in the rosuvastatin group (0.032 [0.010 to 0.143] mu g/L vs 0.056 [0.018 to 0.241] mu g/L; p = 0.04). In conclusion, 1-day rosuvastatin therapy (20 mg twice a day) did not influence post-PCI TnI release in patients with angina. However, these results suggest that, in patients with an advanced inflammatory status, rosuvastatin loading therapy might have a cardioprotective effect. (C) 2014 Elsevier Inc. All rights reserved.","[Veselka, Josef; Hajek, Petr; Tomasov, Pavol; Tesar, David; Zemanek, David] Charles Univ Prague, Sch Med 2, Dept Cardiol, Univ Hosp Motol, Prague, Czech Republic; [Bruhova, Hana; Matejovic, Martin] Charles Univ Prague, Sch Med, Dept Med 1, Plzen, Czech Republic; [Bruhova, Hana; Matejovic, Martin] Teaching Hosp Pilsen, Plzen, Czech Republic; [Branny, Marian] Podlesi Hosp, Dept Cardiol, Trinec, Czech Republic; [Studencan, Martin] East Slovakia Inst Cardiovasc Dis, Dept Cardiol, Kosice, Slovakia","Veselka, J (reprint author), Charles Univ Prague, Sch Med 2, Dept Cardiol, Univ Hosp Motol, Prague, Czech Republic.","Josef.veselka@fnmotol.cz",null,null,"Ministry of Health, Prague, Czech Republic [00064203]","This study was supported by the project (Ministry of Health, Prague, Czech Republic) for conceptual development of research organization (00064203).",null,24,0,0,"EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC","BRIDGEWATER","685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA","0002-9149","1879-1913",null,"AM J CARDIOL","Am. J. Cardiol.","FEB 1",2014,113,3,null,null,null,null,446,451,null,"10.1016/j.amjcard.2013.10.026",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AA5TE","WOS:000331161700007"]
["J","Tmejova, K; Krejcova, L; Hynek, D; Adam, V; Babula, P; Trnkova, L; Stiborova, M; Eckschlager, T; Kizek, R",null,null,null,"Tmejova, Katerina; Krejcova, Ludmila; Hynek, David; Adam, Vojtech; Babula, Petr; Trnkova, Libuse; Stiborova, Marie; Eckschlager, Tomas; Kizek, Rene",null,null,"Electrochemical Study of Ellipticine Interaction with Single and Double Stranded Oligonucleotides","ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY",null,null,"English","Article",null,null,null,null,null,"Adsorptive transfer stripping technique; DNA; differential pulse voltammetry; ellipticine; hetero-nucleotides; intercalation; square wave voltammetry; cancer; therapy","ANTICANCER DRUG ELLIPTICINE; DNA ADDUCT FORMATION; PEROXIDASE-MEDIATED OXIDATION; SQUARE-WAVE VOLTAMMETRY; CELL-CYCLE ARREST; CANCER-CELLS; ELIMINATION VOLTAMMETRY; STRIPPING VOLTAMMETRY; ALKALOID ELLIPTICINE; AGENT ELLIPTICINE","Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) is an alkaloid that has been isolated from plants of an Apocynaceae family. It is one of the simplest naturally occurring alkaloids with a planar structure. Over the past decades, ellipticine became a very promising antitumor agent. Interaction with DNA is one of the most studied ellipticine effects on cell division. This phenomenon is not clearly explained so far. In our experiments we studied interaction of ellipticine with single-stranded and double-stranded oligonucleotides by electrochemical methods on mercury electrode. Differential pulse voltammetry was applied for ellipticine (Elli) and CA peak detection. Square wave voltammetry was applied for G peak detection. The effect of the interaction time and ellipticine concentrations on interactions of ellipticine with single-and double-stranded oligonucleotides was tested too.","[Tmejova, Katerina; Krejcova, Ludmila; Hynek, David; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Tmejova, Katerina; Krejcova, Ludmila; Hynek, David; Adam, Vojtech; Babula, Petr; Trnkova, Libuse; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Dept Chem, Fac Sci, CZ-61137 Brno, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz",null,null,"CYTORES GA CR [P301/10/0356]; CEITEC [CZ.1.05/1.1.00/02.0068]; project for conceptual development of research organization [00064203]","Financial support from CYTORES GA CR P301/10/0356, CEITEC CZ.1.05/1.1.00/02.0068 and the project for conceptual development of research organization 00064203 is highly acknowledged.",null,53,0,0,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","1871-5206","1875-5992",null,"ANTI-CANCER AGENT ME","Anti-Cancer Agents Med. Chem.","FEB",2014,14,2,null,null,null,null,331,340,null,null,null,10,"Oncology; Chemistry, Medicinal","Oncology; Pharmacology & Pharmacy","AB0DU","WOS:000331462800016"]
["J","Bontant, T; Sedlacek, P; Balduzzi, A; Gaspar, B; Cesaro, S; Einsele, H; Peters, C; Dalle, JH",null,null,null,"Bontant, T.; Sedlacke, P.; Balduzzi, A.; Gaspar, B.; Cesaro, S.; Einsele, H.; Peters, C.; Dalle, J-H",null,null,"Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the Inborn Errors, Infectious Diseases and Pediatric Diseases Working Parties of EBMT","BONE MARROW TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"pediatric; HSCT; CMV; prophylaxis; curative therapy; pre-emptive therapy","STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; REAL-TIME PCR; CYTOMEGALOVIRUS-INFECTION; PREEMPTIVE THERAPY; SOLID-ORGAN; RECIPIENTS; PREVENTION; GANCICLOVIR; PROPHYLAXIS","Human CMV infection is a frequent complication after HSC in children with remarkable morbidity and mortality. Antiviral drugs are relatively efficient but have numerous side effects. They are used as prophylactic, pre-emptive or therapeutic medicines. It is still a matter of debate which option is the best strategy. No uniform procedure has emerged regarding these three options, and new immunologic tools have raised more questions for physicians. To assess the current practice in the management of CMV infection, we sent a questionnaire to the EBMT centers performing hematopoietic SCT (HSCT) in children. Fifty-six out of 196 responded to the questionnaire (28.5%). Quantitative PCR was the most common monitoring tool (44/56). Only 4/56 centers use the pp65 antigenemia alone. All centers used pre-emptive strategy (56/56). 21/56 centers also used prophylactic measures, 13/21 after analysis of donor/receptor serologic status. Ganciclovir was the most common first-line agent for CMV disease (55/56). The most common dose and duration for induction treatment were 5 mg/kg bid (47/55) for 14 days (20/55). There is no uniform procedure for researching resistance strain, antiviral second-line therapy or cell therapy. A harmonization process should enable sound prospective trials to improve prevention, control and cure of CMV disease in children and adolescents.","[Bontant, T.; Dalle, J-H] Univ Paris 07, Hosp Robert Debre, Dept Hematol & Immunol, F-75935 Paris, France; [Sedlacke, P.] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Balduzzi, A.] Univ Milano Bicocca, Osped San Gerardo, Pediat Clin, Milan, Italy; [Gaspar, B.] UCL Inst Child Hlth, Mol Immunol Unit, Chair EBMT Inborn Error Working Party, London, England; [Cesaro, S.] Paediat Haematol Oncol Policlin GB Rossi, Chair EBMT Infect Dis Working Party, Verona, Italy; [Einsele, H.] Univ Hosp Wurzburg, Div Hematol, Dept Internal Med 2, Wurzburg, Germany; [Peters, C.] St Anna Childrens Hosp, Chair EBMT Paediat Dis Working Party, A-1090 Vienna, Austria","Dalle, JH (reprint author), Univ Paris 07, Hosp Robert Debre, Dept Hematol & Immunol, 48 Blvd Serurier,Paris Cedex 19, F-75935 Paris, France.","jhugues.dalle@gmail.com",null,null,null,null,null,35,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0268-3369","1476-5365",null,"BONE MARROW TRANSPL","Bone Marrow Transplant.","FEB",2014,49,2,null,null,null,null,276,279,null,"10.1038/bmt.2013.164",null,4,"Biophysics; Oncology; Hematology; Immunology; Transplantation","Biophysics; Oncology; Hematology; Immunology; Transplantation","AA6TB","WOS:000331229900022"]
["J","Papaemmanuil, E; Rapado, I; Li, YL; Potter, NE; Wedge, DC; Tubio, J; Alexandrov, LB; Van Loo, P; Cooke, SL; Marshall, J; Martincorena, I; Hinton, J; Gundem, G; van Delft, FW; Nik-Zainal, S; Jones, DR; Ramakrishna, M; Titley, I; Stebbings, L; Leroy, C; Menzies, A; Gamble, J; Robinson, B; Mudie, L; Raine, K; O'Meara, S; Teague, JW; Butler, AP; Cazzaniga, G; Biondi, A; Zuna, J; Kempski, H; Muschen, M; Ford, AM; Stratton, MR; Greaves, M; Campbell, PJ",null,null,null,"Papaemmanuil, Elli; Rapado, Inmaculada; Li, Yilong; Potter, Nicola E.; Wedge, David C.; Tubio, Jose; Alexandrov, Ludmil B.; Van Loo, Peter; Cooke, Susanna L.; Marshall, John; Martincorena, Inigo; Hinton, Jonathan; Gundem, Gunes; van Delft, Frederik W.; Nik-Zainal, Serena; Jones, David R.; Ramakrishna, Manasa; Titley, Ian; Stebbings, Lucy; Leroy, Catherine; Menzies, Andrew; Gamble, John; Robinson, Ben; Mudie, Laura; Raine, Keiran; O'Meara, Sarah; Teague, Jon W.; Butler, Adam P.; Cazzaniga, Giovanni; Biondi, Andrea; Zuna, Jan; Kempski, Helena; Muschen, Markus; Ford, Anthony M.; Stratton, Michael R.; Greaves, Mel; Campbell, Peter J.",null,null,"RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia","NATURE GENETICS",null,null,"English","Article",null,null,null,null,null,null,"CHROMOSOME TRANSLOCATIONS; MUTATIONAL PROCESSES; HUMAN CANCER; V(D)J RECOMBINATION; GENETIC ALTERATIONS; CHILDHOOD LEUKEMIA; PROSTATE-CANCER; CLONAL ORIGINS; DNA; GENOMES","The ETV6-RUNX1 fusion gene, found in 25% of childhood acute lymphoblastic leukemia ( ALL) cases, is acquired in utero but requires additional somatic mutations for overt leukemia. We used exome and low-coverage whole-genome sequencing to characterize secondary events associated with leukemic transformation. RAG-mediated deletions emerge as the dominant mutational process, characterized by recombination signal sequence motifs near breakpoints, incorporation of non-templated sequence at junctions, similar to 30-fold enrichment at promoters and enhancers of genes actively transcribed in B cell development and an unexpectedly high ratio of recurrent to non-recurrent structural variants. Single-cell tracking shows that this mechanism is active throughout leukemic evolution, with evidence of localized clustering and reiterated deletions. Integration of data on point mutations and rearrangements identifies ATF7IP and MGA as two new tumor-suppressor genes in ALL. Thus, a remarkably parsimonious mutational process transforms ETV6-RUNX1-positive lymphoblasts, targeting the promoters, enhancers and first exons of genes that normally regulate B cell differentiation.","[Papaemmanuil, Elli; Li, Yilong; Wedge, David C.; Tubio, Jose; Alexandrov, Ludmil B.; Van Loo, Peter; Cooke, Susanna L.; Marshall, John; Martincorena, Inigo; Hinton, Jonathan; Gundem, Gunes; Nik-Zainal, Serena; Jones, David R.; Ramakrishna, Manasa; Stebbings, Lucy; Leroy, Catherine; Menzies, Andrew; Gamble, John; Robinson, Ben; Mudie, Laura; Raine, Keiran; O'Meara, Sarah; Teague, Jon W.; Butler, Adam P.; Stratton, Michael R.; Campbell, Peter J.] Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, England; [Rapado, Inmaculada] Hosp Univ 12 Octubre, Madrid, Spain; [Potter, Nicola E.; van Delft, Frederik W.; Titley, Ian; Ford, Anthony M.; Greaves, Mel] Inst Canc Res, London SW3 6JB, England; [Van Loo, Peter] VIB, Dept Human Genet, Louvain, Belgium; [Van Loo, Peter] Univ Leuven, Louvain, Belgium; [van Delft, Frederik W.] Univ Newcastle, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England; [Cazzaniga, Giovanni; Biondi, Andrea] Hosp San Gerardo, Ctr Ric Tettamanti, Monza, Italy; [Zuna, Jan] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Zuna, Jan] Univ Hosp Motol, Prague, Czech Republic; [Kempski, Helena] Great Ormond St Hosp Sick Children, Camelia Botnar Labs, Mol Haematol & Canc Biol Unit, Paediat Malignancy Unit, London WC1N 3JH, England; [Kempski, Helena] UCL, Inst Child Hlth, London, England; [Muschen, Markus] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Campbell, Peter J.] Addenbrookes Natl Hlth Serv NHS Fdn Trust, Cambridge, England; [Campbell, Peter J.] Univ Cambridge, Dept Haematol, Cambridge, England","Campbell, PJ (reprint author), Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, England.","mel.greaves@icr.ac.uk; pc8@sanger.ac.uk",null,null,"Kay Kendall Leukaemia Fund (KKLF) [KKL407]; Leukemia and Lymphoma Research [11021]; Wellcome Trust [077012/Z/05/Z, WT100183MA]; Wellcome Trust Senior Clinical Research Fellowship [WT088340MA]; Research Foundation-Flanders (FWO); KKLF [KKL417]; University Hospital Motol [MH-CR DRO 00064203]","This work was supported by the Kay Kendall Leukaemia Fund (KKLF; grant reference KKL407), Leukemia and Lymphoma Research (grant reference 11021) and the Wellcome Trust (grant reference 077012/Z/05/Z). P.J.C. is personally funded through a Wellcome Trust Senior Clinical Research Fellowship (grant reference WT088340MA). P.V.L. is supported by a postdoctoral research fellowship from Research Foundation-Flanders (FWO). S.N.-Z. is a Wellcome Trust Intermediate Clinical Fellow (grant reference WT100183MA).F.W.v.D. is funded by KKLF (grant reference KKL417).J.Z. is supported by University Hospital Motol (grant MH-CR DRO 00064203).",null,56,2,2,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","1061-4036","1546-1718",null,"NAT GENET","Nature Genet.","FEB",2014,46,2,null,null,null,null,116,"+",null,"10.1038/ng.2874",null,13,"Genetics & Heredity","Genetics & Heredity","AA6KX","WOS:000331208300007"]
["J","Meissner, B; Bartram, T; Eckert, C; Trka, J; Panzer-Grumayer, R; Hermanova, I; Ellinghaus, E; Franke, A; Moricke, A; Schrauder, A; Teigler-Schlegel, A; Dorge, P; von Stackelberg, A; Basso, G; Bartram, CR; Kirschner-Schwabe, R; Bornhauser, B; Bourquin, JP; Cazzaniga, G; Hauer, J; Attarbaschi, A; Izraeli, S; Zaliova, M; Cario, G; Zimmermann, M; Avigad, S; Sokalska-Duhme, M; Metzler, M; Schrappe, M; Koehler, R; te Kronnie, G; Stanulla, M",null,null,null,"Meissner, Barbara; Bartram, Thies; Eckert, Cornelia; Trka, Jan; Panzer-Gruemayer, Renate; Hermanova, Ivana; Ellinghaus, Eva; Franke, Andre; Moericke, Anja; Schrauder, Andre; Teigler-Schlegel, Andrea; Doerge, Petra; von Stackelberg, Arend; Basso, Giuseppe; Bartram, Claus R.; Kirschner-Schwabe, Renate; Bornhaeuser, Beat; Bourquin, Jean-Pierre; Cazzaniga, Giovanni; Hauer, Julia; Attarbaschi, Andishe; Izraeli, Shai; Zaliova, Marketa; Cario, Gunnar; Zimmermann, Martin; Avigad, Smadar; Sokalska-Duhme, Magdalena; Metzler, Markus; Schrappe, Martin; Koehler, Rolf; te Kronnie, Geertruy; Stanulla, Martin",null,null,"Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia","HUMAN MOLECULAR GENETICS",null,null,"English","Article",null,null,null,null,null,null,"MINIMAL RESIDUAL DISEASE; MULTICENTER THERAPY TRIALS; V(D)J RECOMBINATION; CLINICAL-SIGNIFICANCE; GENE REARRANGEMENTS; AIEOP-BFM; T-CELL; PCR; CHILDREN; REPAIR","Acute lymphoblastic leukemia (ALL) accounts for similar to 25% of pediatric malignancies. Of interest, the incidence of ALL is observed similar to 20% higher in males relative to females. The mechanism behind the phenomenon of sex-specific differences is presently not understood. Employing genome-wide genetic aberration screening in 19 ALL samples, one of the most recurrent lesions identified was monoallelic deletion of the 5' region of SLX4IP. We characterized this deletion by conventional molecular genetic techniques and analyzed its interrelationships with biological and clinical characteristics using specimens and data from 993 pediatric patients enrolled into trial AIEOP-BFM ALL 2000. Deletion of SLX4IP was detected in similar to 30% of patients. Breakpoints within SLX4IP were defined to recurrent positions and revealed junctions with typical characteristics of illegitimate V(D) J-mediated recombination. In initial and validation analyses, SLX4IP deletions were significantly associated with male gender and ETV6/RUNX1-rearranged ALL (both overall P < 0.0001). For mechanistic validation, a second recurrent deletion affecting TAL1 and caused by the same molecular mechanism was analyzed in 1149 T-cell ALL patients. Validating a differential role by sex of illegitimate V(D) J-mediated recombination at the TAL1 locus, 128 out of 1149 T-cell ALL samples bore a deletion and males were significantly more often affected (P = 0.002). The repeatedly detected association of SLX4IP deletion with male sex and the extension of the sex bias to deletion of the TAL1 locus suggest that differential illegitimate V(D)J-mediated recombination events at specific loci may contribute to the consistent observation of higher incidence rates of childhood ALL in boys compared with girls.","[Meissner, Barbara; Bartram, Thies; Moericke, Anja; Schrauder, Andre; Doerge, Petra; Cario, Gunnar; Schrappe, Martin] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany; [Meissner, Barbara; Zaliova, Marketa; Zimmermann, Martin; Stanulla, Martin] Hannover Med Sch, D-30625 Hannover, Germany; [Eckert, Cornelia; von Stackelberg, Arend; Kirschner-Schwabe, Renate] Charite, Berlin, Germany; [Trka, Jan; Hermanova, Ivana; Zaliova, Marketa] Charles Univ Prague, Dept Pediat Hematol Oncol, Fac Med 2, Childhood Leukaemia Invest Prague CLIP, Prague, Czech Republic; [Panzer-Gruemayer, Renate; Attarbaschi, Andishe] St Anna Childrens Hosp, Dept Pediat, A-1090 Vienna, Austria; [Panzer-Gruemayer, Renate; Attarbaschi, Andishe] Med Univ Vienna, Childrens Canc Res Inst, Vienna, Austria; [Ellinghaus, Eva; Franke, Andre] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Teigler-Schlegel, Andrea] Univ Giessen, Oncogenet Lab, D-35390 Giessen, Germany; [Basso, Giuseppe; te Kronnie, Geertruy] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy; [Bartram, Claus R.; Koehler, Rolf] Heidelberg Univ, Dept Human Genet, Heidelberg, Germany; [Bornhaeuser, Beat; Bourquin, Jean-Pierre] Univ Childrens Hosp, Zurich, Switzerland; [Cazzaniga, Giovanni] Univ Milano Bicocca, M Tettamanti Res Ctr, Childrens Hosp, Monza, Italy; [Hauer, Julia] Univ Dusseldorf, Dept Pediat Oncol Hematol & Immunol, Dusseldorf, Germany; [Izraeli, Shai] Sheba Med Ctr Tel Hashomer, Ramat Gan, Israel; [Avigad, Smadar] Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel; [Sokalska-Duhme, Magdalena] Olga Childrens Hosp, Stuttgart, Germany; [Metzler, Markus] Univ Childrens Hosp Erlangen, Erlangen, Germany","Stanulla, M (reprint author), Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.","stanullla.martin@mh-hannover.de","Franke, Andre/B-2151-2010","Franke, Andre/0000-0003-1530-5811","Deutsche Jose Carreras Leukamie-Stiftung; Madeleine Schickedanz Kinderkrebs-Stiftung; Deutsche Krebshilfe; Israel Cancer Association; Fondazione Tettamanti (Monza); Fondazione Citta della Speranza; Fondazione Cariparo (Padova); St. Anna Kinderkrebs-forschung Austria","This work was supported by the Deutsche Jose Carreras Leukamie-Stiftung, the Madeleine Schickedanz Kinderkrebs-Stiftung, the Deutsche Krebshilfe, the Israel Cancer Association, Fondazione Tettamanti (Monza), Fondazione Citta della Speranza, Fondazione Cariparo (Padova) and St. Anna Kinderkrebs-forschung Austria.",null,45,0,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0964-6906","1460-2083",null,"HUM MOL GENET","Hum. Mol. Genet.","FEB 1",2014,23,3,null,null,null,null,590,601,null,"10.1093/hmg/ddt447",null,12,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","AA1FK","WOS:000330841700003"]
["J","Kriz, J; Relichova, Z",null,null,null,"Kriz, J.; Relichova, Z.",null,null,"Intermittent self-catheterization in tetraplegic patients: a 6-year experience gained in the spinal cord unit in Prague","SPINAL CORD",null,null,"English","Article",null,null,null,null,null,"spinal cord injury; tetraplegia; autonomic bladder; intermittent catheterization","INJURY","Objectives: To present a system of urological care for patients with cervical spinal cord injury (SCI) in the Spinal Cord Unit in Prague. Methods: Forty-one out of 412 patients hospitalized with acute SCI between 2007 and 2012 with motor complete SCI (AIS A, B) at the C4-C7 motor level and with sufficient follow-up duration were selected. Patients were trained using a male bladder catheterization model (37 with a transurethral catheter and 4 with a suprapubic catheter) to perform intermittent catheterization (IC) using an ergohand device, and were later encouraged to perform self-catheterization. Results: On the basis of the motor level of the SCI, 8 out of the 41 study patients were assigned to group 1 (C4), 11 to group 2 (C5), 15 to group 3 (C6) and 7 to group 4 (C7). All patients in group 1 had an indwelling urinary catheter. In group 2, 6 patients (54.6%) learned to perform IC, with 2 of them needing another person's assistance. In 5 patients (45.5%), suprapubic cystostomy was maintained (insufficient functional grip, severe autonomic dysreflexia, prompt reflex erection). Group 3 included 12 patients (80%) performing intermittent catheterization and 3 patients (20%) with suprapubic cystostomy (insufficient functional grip, post-bladder-surgery condition, cognitive impairment). In group 4, only 1 patient (14.3%) had an indwelling catheter due to severe abductor spasticity, whereas the remaining 6 (85.7%) learned to perform IC. Conclusions: These findings suggest that patients with cervical SCI below the C5 motor level are able to learn self-catheterization, which increases independence and decreases the risk of urinary infection and stone formation.","[Kriz, J.; Relichova, Z.] Univ Hosp Motol, Spinal Cord Unit, Prague 15000, Czech Republic","Kriz, J (reprint author), Univ Hosp Motol, Spinal Cord Unit, V Uvalu 84 Prague 5, Prague 15000, Czech Republic.","jiri.kriz@fnmotol.cz",null,null,"'Movement without Help' foundation","The study was supported by 'Movement without Help' foundation.",null,9,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1362-4393","1476-5624",null,"SPINAL CORD","Spinal Cord","FEB",2014,52,2,null,null,null,null,163,166,null,"10.1038/sc.2013.154",null,4,"Clinical Neurology; Rehabilitation","Neurosciences & Neurology; Rehabilitation","AA4RC","WOS:000331082700013"]
["J","Nagel, B; Janousek, J; Koestenberger, M; Maier, R; Sauseng, W; Strenger, V; Gamillscheg, A; Zartner, P",null,null,null,"Nagel, Bert; Janousek, Jan; Koestenberger, Martin; Maier, Robert; Sauseng, Werner; Strenger, Volker; Gamillscheg, Andreas; Zartner, Peter",null,null,"Remote Monitoring Leads to Early Recognition and Treatment of Critical Arrhythmias in Adults After Atrial Switch Operation for Transposition of the Great Arteries","CIRCULATION JOURNAL",null,null,"English","Article",null,null,null,null,null,"Arrhythmia; Cardiac resynchronization therapy; Congenital heart disease; Pacemaker","CARDIAC RESYNCHRONIZATION THERAPY; IMPLANTABLE ELECTRONIC DEVICES; CONGENITAL HEART-DISEASE; CARDIOVERTER-DEFIBRILLATOR PATIENTS; MUSTARD OPERATION; VENTRICULAR-ARRHYTHMIAS; EXPERT CONSENSUS; FAILURE; DEATH; TRIAL","Background: Adults with transposition of the great arteries (TGA) after atrial switch repair have an increased risk for arrhythmia and sudden cardiac death. We analyzed whether a remote monitoring (RM) system as part of an implantable cardiac device contributes to timely recognition and improved treatment of critical arrhythmias in these patients. Methods and Results: All consecutive TGA patients (n=11) requiring a pacemaker or cardiac resynchronization therapy with or without implantable cardioverter defibrillator between 2008 and 2011 were included. AM-detected arrhythmia, abnormality of device integrity and reaction time from event transmission until acknowledgement via email and clinical decision making were analyzed and compared to a control group (n=21). In 10 patients (91%) 17 arrhythmias were detected, 8 patients (80%) indicated no symptoms. In the RM group time interval from transmission to acknowledgement was 2.4 days (range, 0-4.5 days). Clinical decision-making was advanced by a mean of 77.5 days (range, 10-197 days) compared with conventional follow-up and identified adaption of anti-arrhythmic medication in 8, electrical cardioversion in 2, overdrive pacing in 1 and radiofrequency ablation in 2 patients. A coronary sinus lead fracture was identified in 1 patient followed by successful replacement. Conclusions: AM enables early detection of tachyarrhythmia followed by optimization of medical treatment and potentially life-saving anti-tachycardic intervention in adults after atrial repair of TGA.","[Nagel, Bert; Koestenberger, Martin; Sauseng, Werner; Strenger, Volker; Gamillscheg, Andreas] Med Univ Graz, Univ Childrens Hosp, Dept Pediat Cardiol, A-8036 Graz, Austria; [Maier, Robert] Med Univ Graz, Dept Internal Med, Div Cardiol, Grown Up Congenital Heart Dis Unit, A-8036 Graz, Austria; [Janousek, Jan] Univ Hosp Motol, Children Heart Ctr, Prague, Czech Republic; [Zartner, Peter] German Pediat Heart Ctr, Dept Pediat Cardiol, St Augustin, Germany","Nagel, B (reprint author), Med Univ Graz, Univ Childrens Hosp, Dept Pediat Cardiol, Auenbruggerpl 30, A-8036 Graz, Austria.","bert.nagel@klinikum-graz.at",null,null,"Ministry of Health, Czech Republic [00064203]","B.N.: none; J.J.: supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic); M.K., R.M., W.S., V.S., A.G., P.Z.: none. The authors declare that they have no conflict of interest.",null,33,0,0,"JAPANESE CIRCULATION SOC","TOYKO","18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN","1346-9843","1347-4820",null,"CIRC J","Circ. J.","FEB",2014,78,2,null,null,null,null,450,456,null,"10.1253/circj.CJ-13-0670",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","299UX","WOS:000330422300029"]
["J","Petruzelkova, L; Ananieva-Jordanova, R; Vcelakova, J; Vesely, Z; Stechova, K; Lebl, J; Dusatkova, P; Sumnik, Z; Coles, R; Powell, M; Furmaniak, J; Smith, BR; Kolouskova, S",null,null,null,"Petruzelkova, L.; Ananieva-Jordanova, R.; Vcelakova, J.; Vesely, Z.; Stechova, K.; Lebl, J.; Dusatkova, P.; Sumnik, Z.; Coles, R.; Powell, M.; Furmaniak, J.; Smith, B. Rees; Kolouskova, S.",null,null,"The dynamic changes of zinc transporter 8 autoantibodies in Czech children from the onset of Type 1 diabetes mellitus","DIABETIC MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"ANTIBODY STANDARDIZATION PROGRAM; GLUTAMIC-ACID DECARBOXYLASE; CLINICAL ONSET; ZNT8; DIAGNOSIS; ASSAY; AGE; CLASSIFICATION; SLC30A8; DECLINE","AimsThe prevalence of autoantibodies to zinc transporter8 (ZnT8) in Czech children at the onset of Type1 diabetes mellitus and dynamic changes in ZnT8 autoantibody levels during disease progression were studied. The value of ZnT8 autoantibody measurements in diagnosis of Type1 diabetes was assessed. MethodsSerum samples from 227 children with newly diagnosed Type1 diabetes and from 101 control children without diabetes were analysed in a retrospective cross-sectional study. One hundred and seventy-one samples from 116 of the patients with diabetes were analysed in a follow-up study at (median) intervals of 1, 3, 5 and 10years after onset of Type1 diabetes. ZnT8 autoantibodies were measured using a bridging enzyme-linked immunosorbent assay, while antibodies to glutamic acid decarboxylase, insulinoma antigen2 and insulin were measured by radioimmunoassays. ResultsZnT8 autoantibodies were detected in 163/227 (72%) of children at Type1 diabetes onset and in 1/101 (1%) of the control subjects. Sixteen out of 227 (7%) patients with Type1 diabetes were antibody negative based on three antibodies (glutamic acid decarboxylase, insulinoma antigen2 and insulin). This false-negative rate was reduced to 10/227 (4.4%) (P<0.05) after inclusion of ZnT8 autoantibody measurements. Of the children, 142/227 (63%) were positive for at least three antibodies and the most common combination was insulinoma antigen2, glutamic acid decarboxylase and ZnT8. ZnT8 autoantibody levels decreased over time after Type1 diabetes onset and the presence and level of ZnT8 autoantibodies correlated with IA-2 autoantibodies. ConclusionsA ZnT8 autoantibody enzyme-linked immunosorbent assay showed 72% disease sensitivity and 99% specificity at Type1 diabetes onset. Measurements of ZnT8 autoantibodies are important for Type1 diabetes diagnosis and should be included in the panel of autoantibodies tested at the onset of Type1 diabetes.","[Petruzelkova, L.; Vcelakova, J.; Vesely, Z.; Stechova, K.; Lebl, J.; Dusatkova, P.; Sumnik, Z.; Kolouskova, S.] Charles Univ Prague, Univ Hosp Motol, Dept Paediat, Prague, Czech Republic; [Petruzelkova, L.; Vcelakova, J.; Vesely, Z.; Stechova, K.; Lebl, J.; Dusatkova, P.; Sumnik, Z.; Kolouskova, S.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Ananieva-Jordanova, R.; Coles, R.; Powell, M.; Furmaniak, J.; Smith, B. Rees] FIRS Labs RSR Ltd, Cardiff, S Glam, Wales","Petruzelkova, L (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Paediat, Prague, Czech Republic.","LenkaPetruzelkova@gmail.com",null,null,"Ministry of Health, Czech Republic [00064203, IPL 699001]; RSR Ltd.","Supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 and IPL 699001 (Department of Paediatrics, University Hospital Motol, Prague, Czech Republic). The work was partially funded by RSR Ltd.",null,28,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0742-3071","1464-5491",null,"DIABETIC MED","Diabetic Med.","FEB",2014,31,2,null,null,null,null,165,171,null,"10.1111/dme.12308",null,7,"Endocrinology & Metabolism","Endocrinology & Metabolism","291DC","WOS:000329806900007"]
["J","Lukes, P; Pavlik, E; Potuznikova, B; Nartova, E; Foltynova, E; Plzak, J; Katra, R; Sterzl, I; Bartunkova, J; Betka, J; Astl, J",null,null,null,"Lukes, Petr; Pavlik, Emil; Potuznikova, Bela; Nartova, Eva; Foltynova, Eva; Plzak, Jan; Katra, Rami; Sterzl, Ivan; Bartunkova, Jirina; Betka, Jan; Astl, Jaromir",null,null,"Detection of Helicobacter pylori in oropharyngeal lymphatic tissue with real-time PCR and assessment of its carcinogenic potential","EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"Helicobacter pylori; Real-time PCR; Oropharynx; Oropharyngeal cancer; Sleep apnoea syndrome; Chronic tonsillitis","ORAL-CAVITY; CAGA GENE; INFECTION; RESPONSES; GENOTYPE; CANCER; EPIDEMIOLOGY; TRANSMISSION; PATHOGENESIS; TONSILLAR","Helicobacter pylori (HP) is considered a major gastric pathogen with oncogenic potential. The aim of this study was to determine whether HP is present in oropharyngeal lymphoid tissue and whether oropharyngeal HP strains carry virulence factor genes known to be involved in gastric carcinogenesis. The study included 104 subjects (41 patients with tonsillar carcinoma, 38 with chronic tonsillitis and 25 with obstructive sleep apnoea syndrome-OSAS). Detection of specific serum anti-HP antibodies was performed with an ELISA. The presence of HP in tissue was determined by culture and real-time PCR. Detection of virulence factors genes was also performed. Specific antibodies were found in 78.05 % of tumour cases, 34.21 % of chronic tonsillitis cases, and 72.0 % of OSAS cases. The presence of HP in the tissue was detected in 73.91 % of tonsillar tumours, 70.0 % of tonsillitis cases, and 69.23 % of OSAS specimens. The results of the virulence factor gene analysis showed the majority of the s1b (52.4 %) and m2 (59.5 %) alleles of vacA gene and limited abundance of cagA gene (12.5 %). Results confirm that HP may colonise oropharyngeal lymphoid tissue. Oropharyngeal HP colonisation was frequently found in the oropharyngeal cancer group and in patients with benign oropharyngeal diseases. A virulence factor gene analysis showed differences from the predominant strains most commonly found in the stomach. The strains obtained from the oropharynx differed primarily by the lower abundance of the cagA gene and carried the less virulent vacA gene allele combination.","[Lukes, Petr; Nartova, Eva; Foltynova, Eva; Plzak, Jan; Betka, Jan; Astl, Jaromir] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Prague 15006 5, Czech Republic; [Lukes, Petr; Nartova, Eva; Foltynova, Eva; Plzak, Jan; Betka, Jan; Astl, Jaromir] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Pavlik, Emil; Potuznikova, Bela; Sterzl, Ivan] Charles Univ Prague, Inst Microbiol & Immunol, Fac Med 1, Prague 15006 5, Czech Republic; [Pavlik, Emil; Potuznikova, Bela; Sterzl, Ivan] Gen Univ Hosp Prague, Prague, Czech Republic; [Plzak, Jan] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 15006 5, Czech Republic; [Katra, Rami] Charles Univ Prague, Dept Otorhinolaryngol, Fac Med 2, Prague 15006 5, Czech Republic; [Bartunkova, Jirina] Charles Univ Prague, Inst Immunol, Fac Med 2, Prague 15006 5, Czech Republic","Lukes, P (reprint author), Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.luk@gmail.com",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NT11523]","The research was supported by Grant NT11523 from the Internal Grant Agency of the Ministry of Health of the Czech Republic.",null,36,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0937-4477","1434-4726",null,"EUR ARCH OTO-RHINO-L","Eur. Arch. Oto-Rhino-Laryn.","FEB",2014,271,2,null,null,null,null,399,405,null,"10.1007/s00405-013-2574-1",null,7,"Otorhinolaryngology","Otorhinolaryngology","293TK","WOS:000329996400028"]
["J","Veselka, J; Krejci, J; Tomasov, P; Durdil, V; Riedlbauchova, L; Honek, J; Honek, T; Zemanek, D",null,null,null,"Veselka, Josef; Krejci, Jan; Tomasov, Pavol; Durdil, Vaclav; Riedlbauchova, Lucie; Honek, Jakub; Honek, Tomas; Zemanek, David",null,null,"Outcome of patients after alcohol septal ablation with permanent pacemaker implanted for periprocedural complete heart block","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Letter",null,null,null,null,null,"Hypertrophic cardiomyopathy; Ablation; Prognosis","CARDIOMYOPATHY",null,"[Veselka, Josef; Tomasov, Pavol; Durdil, Vaclav; Riedlbauchova, Lucie; Honek, Jakub; Zemanek, David] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Cardiol, Prague, Czech Republic; [Krejci, Jan; Honek, Tomas] Masaryk Univ, St Annes Hosp, Int Clin Res Ctr, Dept Internal Med Cardioangiol 1, Brno, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Cardiol, Prague, Czech Republic.","veselka.josef@seznam.cz",null,null,null,null,null,3,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273","1874-1754",null,"INT J CARDIOL","Int. J. Cardiol.","FEB 1",2014,171,2,null,null,null,null,"E37","E38",null,"10.1016/j.ijcard.2013.11.119",null,2,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","293ON","WOS:000329982200014"]
["J","Stovicek, J; Liskova, P; Lisy, J; Hlava, S; Keil, R",null,null,null,"Stovicek, Jan; Liskova, Petra; Lisy, Jiri; Hlava, Stepan; Keil, Radan",null,null,"Crohn's disease: Is there a place for neurological screening?","SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY",null,null,"English","Article",null,null,null,null,null,"Crohn's disease; demyelinating diseases; inflammatory bowel diseases; multiple sclerosis","INFLAMMATORY-BOWEL-DISEASE; FACTOR-ALPHA ANTAGONISTS; MULTIPLE-SCLEROSIS","Objective. Neurological complications of inflammatory bowel diseases (IBDs) are not rare but are under-diagnosed; some are probably immune-mediated. Several previous studies have suggested a higher incidence of demyelinating diseases such as multiple sclerosis in IBD patients. In this single-center, prospective, observational study, the authors focus on T2 focal white-matter lesions of the central nervous system on magnetic resonance imaging (MRI) in IBD patients that may be due to demyelination. Material and methods. A total of 70 patients with Crohn's disease were examined before beginning anti-TNF-alpha a therapy. These patients were treated with azathioprine, mesalazine or both. Patients were examined by a neurologist to detect possible signs of demyelinating disease, and patients underwent brain MRI (native T1, T2, and FLAIR sequences). Results. Thirty-seven patients (53%) exhibited abnormalities on neurological examination, and 26 patients (37%) displayed abnormalities on MRI. In seven cases, these MRI abnormalities (periventricular lesions) were suspected to be due to demyelination. Cerebral spinal fluid investigation (including polyclonal bands) was completely negative in five cases and was borderline in one case, and multiple sclerosis was confirmed in one case. Pathological MRI findings in 19 other patients were clinically nonsignificant; most were nonspecific sporadic lesions in white matter or mild atrophy. Conclusions. The results support previous data that the frequency of neurological findings in IBD patients is generally underestimated. With the extension of biological anti-TNF-alpha treatment for IBD, the possibility of a higher risk of developing multiple sclerosis should be considered.","[Stovicek, Jan; Hlava, Stepan; Keil, Radan] Charles Univ Prague, Fac Med 2, Clin Internal Med, Prague, Czech Republic; [Liskova, Petra] Charles Univ Prague, Fac Med 2, Neurol Clin, Prague, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Fac Med 2, Clin Radiol, Prague, Czech Republic","Stovicek, J (reprint author), Charles Univ Prague, Fac Med 2, Clin Internal Med, Prague, Czech Republic.","jan.stovicek@fnmotol.cz",null,null,"Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital Motol, Prague, Czech Republic [00064203]","The study was supported by Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203.",null,13,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0036-5521","1502-7708",null,"SCAND J GASTROENTERO","Scand. J. Gastroenterol.","FEB",2014,49,2,null,null,null,null,173,176,null,"10.3109/00365521.2013.867358",null,4,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","292AU","WOS:000329874800006"]
["J","Marciniak, R; Sheardova, K; Cermakova, P; Hudecek, D; Sumec, R; Hort, J",null,null,null,"Marciniak, Rafal; Sheardova, Katerina; Cermakova, Pavla; Hudecek, Daniel; Sumec, Rastislav; Hort, Jakub",null,null,"Effect of meditation on cognitive functions in context of aging and neurodegenerative diseases","FRONTIERS IN BEHAVIORAL NEUROSCIENCE",null,null,"English","Review",null,null,null,null,null,"meditation; cognition; dementia; aging; neurodegenerative diseases; Alzheimers disease; mild cognitive impairment; elderly","LONG-TERM MEDITATION; CEREBRAL-BLOOD-FLOW; VASCULAR RISK-FACTORS; GRAY-MATTER DENSITY; ALZHEIMERS-DISEASE; CORTICAL THICKNESS; TRANSCENDENTAL-MEDITATION; MEMORY LOSS; DEMENTIA; MINDFULNESS","Effect of different meditation practices on various aspects of mental and physical health is receiving growing attention. The present paper reviews evidence on the effects of several mediation practices on cognitive functions in the context of aging and neurodegenerative diseases. The effect of meditation in this area is still poorly explored. Seven studies were detected through the databases search, which explores the effect of meditation on attention, memory, executive functions, and other miscellaneous measures of cognition in a sample of older people and people suffering from neurodegenerative diseases. Overall, reviewed studies suggested a positive effect of meditation techniques, particularly in the area of attention, as well as memory, verbal fluency, and cognitive flexibility. These findings are discussed in the context of MRI studies suggesting structural correlates of the effects. Meditation can be a potentially suitable non-pharmacological intervention aimed at the prevention of cognitive decline in the elderly. However, the conclusions of these studies are limited by their methodological flaws and differences of various types of meditation techniques. Further research in this direction could help to verify the validity of the findings and clarify the problematic aspects.","[Marciniak, Rafal; Sheardova, Katerina; Cermakova, Pavla; Hudecek, Daniel; Sumec, Rastislav; Hort, Jakub] St Annes Univ, Hosp Brno, Int Clin Res Ctr, Brno 65691+, Czech Republic; [Cermakova, Pavla] Karolinska Inst, Alzheimers Dis Res Ctr, Dept Neurol Care Sci & Soc, Stockholm, Sweden; [Hort, Jakub] Charles Univ Prague, Fac Med 2, Dept Neurol, Memory Disorders Clin, Prague, Czech Republic","Marciniak, R (reprint author), St Annes Univ Hosp, Int Clin Res Ctr, Pekarska 53, Brno 65691+, Czech Republic.","marciniaq@gmail.com",null,null,null,null,null,78,0,0,"FRONTIERS RESEARCH FOUNDATION","LAUSANNE","PO BOX 110, LAUSANNE, 1015, SWITZERLAND","1662-5153",null,null,"FRONT BEHAV NEUROSCI","Front. Behav. Neurosci.","JAN 27",2014,8,null,null,null,null,null,null,null,17,"10.3389/fnbeh.2014.00017",null,9,"Behavioral Sciences; Neurosciences","Behavioral Sciences; Neurosciences & Neurology","301OM","WOS:000330541800001"]
["J","Urbanova, B; Tomek, A; Mikulik, R; Magerova, H; Horinek, D; Hort, J",null,null,null,"Urbanova, Barbora; Tomek, Ales; Mikulik, Robert; Magerova, Hana; Horinek, Daniel; Hort, Jakub",null,null,"Neurosonological examination: a non-invasive approach for the detection of cerebrovascular impairment in AD","FRONTIERS IN BEHAVIORAL NEUROSCIENCE",null,null,"English","Review",null,null,null,null,null,"Alzheimer's disease; carotid ultrasound; cerebrovascular reserve capacity; neurosonology; transcranial ultrasound","CEREBRAL-BLOOD-FLOW; TRANSCRANIAL DOPPLER ULTRASOUND; PATENT FORAMEN OVALE; INTIMA-MEDIA THICKNESS; MILD COGNITIVE IMPAIRMENT; CAROTID-ARTERY-DISEASE; TRANSESOPHAGEAL CONTRAST ECHOCARDIOGRAPHY; VASCULAR RISK-FACTORS; TO-LEFT SHUNTS; ALZHEIMERS-DISEASE","There has been a growing interest in vascular impairment associated with Alzheimer's disease (AD). This interest was stimulated by the findings of higher incidence of vascular risk factors in AD. Signs of vascular impairment were investigated notably in the field of imaging methods. Our aim was to explore ultrasonographic studies of extra- and intracranial vessels in patients with AD and mild cognitive impairment (MCI) and define implications for diagnosis, treatment, and prevention of the disease. The most frequently studied parameters with extracranial ultrasound are intima-media thickness in common carotid artery, carotid atherosclerosis, and total cerebral blood flow. The transcranial ultrasound concentrates mostly on flow velocities, pulsatility indices, cerebrovascular reserve capacity, and cerebral microembolization. Studies suggest that there is morphological and functional impairment of cerebral circulation in AD compared to healthy subjects. Ultrasound as a non-invasive method could be potentially useful in identifying individuals in a higher risk of progression of cognitive decline.","[Urbanova, Barbora; Tomek, Ales; Magerova, Hana; Hort, Jakub] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Neurol, Prague 15000 5, Czech Republic; [Mikulik, Robert] St Annes Univ Hosp, Int Clin Res Ctr, Dept Neurol, Brno, Czech Republic; [Horinek, Daniel] Charles Univ Prague, Cent Mil Hosp, Fac Med 1, Dept Neurosurg, Prague 15000 5, Czech Republic; [Horinek, Daniel; Hort, Jakub] St Annes Univ Hosp, Int Clin Res Ctr, Brno, Czech Republic","Urbanova, B (reprint author), Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Neurol, V Uvalu 84, Prague 15000 5, Czech Republic.","barbora.urbanova@gmail.com",null,null,"IGA MZ CR [NT/13319]; GAUK [347711]; project FNUSA-ICRC from the European Regional Development Fund [CZ.1.05/1.1.00/02.0123]","Supported by IGA MZ CR grant (No. NT/13319). Supported by GAUK grant (No 347711). Supported by the project FNUSA-ICRC (no. CZ.1.05/1.1.00/02.0123) from the European Regional Development Fund.",null,101,0,0,"FRONTIERS RESEARCH FOUNDATION","LAUSANNE","PO BOX 110, LAUSANNE, 1015, SWITZERLAND","1662-5153",null,null,"FRONT BEHAV NEUROSCI","Front. Behav. Neurosci.","JAN 21",2014,8,null,null,null,null,null,null,null,null,"10.3389/fnbeh.2014.00004",null,13,"Behavioral Sciences; Neurosciences","Behavioral Sciences; Neurosciences & Neurology","301DS","WOS:000330513600002"]
["J","Stary, J; Zimmermann, M; Campbell, M; Castillo, L; Dibar, E; Donska, S; Gonzalez, A; Izraeli, S; Janic, D; Jazbec, J; Konja, J; Kaiserova, E; Kowalczyk, J; Kovacs, G; Li, CK; Magyarosy, E; Popa, A; Stark, B; Jabali, Y; Trka, J; Hrusak, O; Riehm, H; Masera, G; Schrappe, M",null,null,null,"Stary, Jan; Zimmermann, Martin; Campbell, Myriam; Castillo, Luis; Dibar, Eduardo; Donska, Svetlana; Gonzalez, Alejandro; Izraeli, Shai; Janic, Dragana; Jazbec, Janez; Konja, Josip; Kaiserova, Emilia; Kowalczyk, Jerzy; Kovacs, Gabor; Li, Chi-Kong; Magyarosy, Edina; Popa, Alexander; Stark, Batia; Jabali, Yahia; Trka, Jan; Hrusak, Ondrej; Riehm, Hansjoerg; Masera, Giuseppe; Schrappe, Martin",null,null,"Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Intercontinental Trial ALL IC-BFM 2002","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"CHILDRENS ONCOLOGY GROUP; MINIMAL RESIDUAL DISEASE; REQUIRING PROLONGED OBSERVATION; AIEOP-BFM; CLINICAL-SIGNIFICANCE; PROGNOSTIC-FACTORS; T-CELL; RISK; SURVIVAL; THERAPY","Purpose From 2002 to 2007, the International Berlin-Frankfurt-Munster Study Group conducted a prospective randomized clinical trial (ALL IC-BFM 2002) for the management of childhood acute lymphoblastic leukemia (ALL) in 15 countries on three continents. The aim of this trial was to explore the impact of differential delayed intensification (DI) on outcome in all risk groups. Patients and Methods For this trial, 5,060 eligible patients were divided into three risk groups according to age, WBC, early treatment response, and unfavorable genetic aberrations. DI was randomized as follows: standard risk (SR), two 4-week intensive elements (protocol III) versus one 7-week protocol II; intermediate risk (IR), protocol III x 3 versus protocol II x 1; high risk (HR), protocol III x 3 versus either protocol II x 2 (Associazione Italiana Ematologia Oncologia Pediatrica [AIEOP] option), or 3 HR blocks plus single protocol II (Berlin-Frankfurt-Munster [BFM] option). Results At 5 years, the probabilities of event-free survival and survival were 74% ( 1%) and 82% (+/- 1%) for all 5,060 eligible patients, 81% and 90% for the SR (n = 1,564), 75% and 83% for the IR (n = 2,650), and 55% and 62% for the HR (n = 846) groups, respectively. No improvement was accomplished by more intense and/or prolonged DI. Conclusion The ALL IC-BFM 2002 trial is a good example of international collaboration in pediatric oncology. A wide platform of countries able to run randomized studies in ALL has been established. Although the alternative DI did not improve outcome compared with standard treatment and the overall results are worse than those achieved by longer established leukemia groups, the national results have generally improved. (C) 2013 by American Society of Clinical Oncology","[Stary, Jan; Trka, Jan; Hrusak, Ondrej] Charles Univ Prague, CZ-15006 Prague 5, Czech Republic; [Stary, Jan; Trka, Jan; Hrusak, Ondrej] Univ Hosp Motol, Prague, Czech Republic; [Jabali, Yahia] Reg Hosp, Ceske Budejovice, Czech Republic; [Zimmermann, Martin; Riehm, Hansjoerg] Hannover Med Sch, Hannover, Germany; [Schrappe, Martin] Univ Hosp Schleswig Holstein, Kiel, Germany; [Campbell, Myriam] Univ Chile, Roberto del Rio Hosp, Santiago, Chile; [Castillo, Luis] Hosp Pereira Rossell, Montevideo, Uruguay; [Dibar, Eduardo] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina; [Donska, Svetlana] Reg Oncol Hosp, Kiev, Ukraine; [Gonzalez, Alejandro] Inst Hematol & Immunol, Havana, Cuba; [Izraeli, Shai] Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr Israel, IL-52621 Tel Hashomer, Israel; [Stark, Batia] Tel Aviv Univ, Schneider Childrens Med Ctr Israel, Sackler Sch Med, IL-49100 Petah Tiqwa, Israel; [Janic, Dragana] Univ Belgrade, Univ Childrens Hosp, Belgrade, Serbia; [Jazbec, Janez] Univ Childrens Hosp, Ljubljana, Slovenia; [Konja, Josip] Univ Hosp Ctr Rebro, Zagreb, Croatia; [Kaiserova, Emilia] Univ Childrens Hosp, Bratislava, Slovakia; [Kowalczyk, Jerzy] Univ Lublin, Lublin, Poland; [Kovacs, Gabor; Magyarosy, Edina] Semmelweis Univ, H-1085 Budapest, Hungary; [Li, Chi-Kong] Chinese Univ Hong Kong, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Popa, Alexander] NN Blokhin Russian Canc Res Ctr, Moscow, Russia; [Masera, Giuseppe] Univ Milano Bicocca, Osped S Gerardo, Monza, Italy","Stary, J (reprint author), Charles Univ Prague, Dept Pediat Hematol Oncol, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","jan.stary@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic for Conceptual Development of Research Organization (University Hospital Motol, Prague, Czech Republic) [00064203]","Supported by Grant No. 00064203 from the Ministry of Health, Czech Republic for Conceptual Development of Research Organization (University Hospital Motol, Prague, Czech Republic).",null,45,1,1,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X","1527-7755",null,"J CLIN ONCOL","J. Clin. Oncol.","JAN 20",2014,32,3,null,null,null,null,174,"+",null,"10.1200/JCO.2013.48.6522",null,12,"Oncology","Oncology","302TN","WOS:000330627900004"]
["J","Yang, JJ; Park, TS; Lee, ST; Seo, JY; Oh, SH; Cho, EH; Strehl, S; Muhlegger, N; Dworzak, MN; Zuna, J; Pospisilova, D; Meyer, C; Marschalek, R; Kim, HJ; Kim, SH",null,null,null,"Yang, John Jeongseok; Park, Tae Sung; Lee, Seung-Tae; Seo, Ja-Young; Oh, Seung Hwan; Cho, Eun Hae; Strehl, Sabine; Muehlegger, Nora; Dworzak, Michael N.; Zuna, Jan; Pospisilova, Dagmar; Meyer, Claus; Marschalek, Rolf; Kim, Hee-Jin; Kim, Sun-Hee",null,null,"Molecular characterization and clinical impact of t(11;15)(q23;q14-15) MLL-CASC5 rearrangement","HAEMATOLOGICA",null,null,"English","Letter",null,null,null,null,null,"MLL; CASC5; hematologic malignancies; chromosome 3 abnormality; t(11;15)","ACUTE MYELOID-LEUKEMIA; GENE; MLL; AF15Q14",null,"[Yang, John Jeongseok] Kyung Hee Univ, Grad Sch, Dept Med, Seoul, South Korea; [Park, Tae Sung] Kyung Hee Univ, Sch Med, Dept Lab Med, Seoul, South Korea; [Lee, Seung-Tae; Seo, Ja-Young; Kim, Hee-Jin; Kim, Sun-Hee] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Lab Med & Genet, Seoul, South Korea; [Oh, Seung Hwan] Inje Univ, Coll Med, Dept Lab Med, Pusan, South Korea; [Cho, Eun Hae] Green Cross Genome, Yongin, South Korea; [Strehl, Sabine; Muehlegger, Nora; Dworzak, Michael N.] St Anna Kinderkrebsforsch eV, Childrens Canc Res Inst, Vienna, Austria; [Dworzak, Michael N.] Med Univ Vienna, Dept Pediat, St Anna Childrens Hosp, Vienna, Austria; [Zuna, Jan] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CLIP, Prague, Czech Republic; [Zuna, Jan] Univ Hosp Motol, Prague, Czech Republic; [Pospisilova, Dagmar] Palacky Univ, Fac Hosp, Dept Paediat, CR-77147 Olomouc, Czech Republic; [Meyer, Claus; Marschalek, Rolf] Goethe Univ Frankfurt, Diagnost Ctr Acute Leukemia, Inst Pharmaceut Biol, ZAFES, Frankfurt, Germany","Yang, JJ (reprint author), Kyung Hee Univ, Grad Sch, Dept Med, Seoul, South Korea.","153jesus@hanmail.net",null,null,null,null,null,15,0,0,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOLOGICA","Haematologica","JAN",2014,99,1,null,null,null,null,null,null,null,"10.3324/haematol.2013.095638",null,3,"Hematology","Hematology","AH1OL","WOS:000335890500004"]
["J","Fedorova, P; Srnec, R; Pencik, J; Schmid, P; Amler, E; Urbanova, L; Necas, A",null,null,null,"Fedorova, Petra; Srnec, Robert; Pencik, Jan; Schmid, Pavel; Amler, Evzen; Urbanova, Lucie; Necas, Alois",null,null,"Mechanical testing of newly developed biomaterial designed for intra-articular reinforcement of partially ruptured cranial cruciate ligament: ex vivo pig model","ACTA VETERINARIA BRNO",null,null,"English","Article",null,null,null,null,null,"Knee stabilization; stifle surgery; polycaprolactone nanofibre; polyester; synthetic material; biodegradable screw","ORTHOPEDIC SUTURE MATERIAL; EXTRAARTICULAR STABILIZATION; DEFICIENT STIFLES; LEADER LINE; DISEASE; RECONSTRUCTION; DOGS","The study deals with mechanical testing of newly developed material polyethylene terephtalate coated with polycaprolactone nanofibers in combination with biodagradable Hexalon ACL/PCL screws as a new possibility of intra-articular reinforcement of partially ruptured cranial cruciate ligament. Four groups of ex vivo models of pig stifle joints were prepared and tested: a model with intact CCL (group 1), a model with partial CCL rupture (group 2), a model with CCL rupture stabilized with 7 mm Mersilene strip (group 3), and a model with CCL rupture stabilized with 5 mm PET/PCL biomaterial strip (group 4). The models were loaded in the standing angle of 1000 and the maximum load (N) and the shift (mm) were monitored. The mean maximum peak power and the shift were 1266.0 +/- 146.9 N and 13.7 +/- 2.5 mm for group 1, and 1164.7 +/- 228.2 N and 1 6.8 +/- 3.3 mm for group 2, respectively. In all cases after reaching the maximum load, a tibial fracture occurred but never a CCL rupture. In groups 3 and 4, the initial fixation failure occurred in the mean values of 375.7 +/- 81.5 and 360.4 +/- 52.0 N, respectively, and with a bigger shift of 52.3 +/- 11.9 mm and 39.4 +/- 14.6 mm, respectively, compared to group 1. A critical point of failure was the anchoring in the bone. It can be concluded that the PET/PCL substitute in the ex vivo model has mechanically comparable properties with the clinically used Mersilene (R), and based on its proven ability to carry stem cells it could be appropriate for partially ruptured CCL protection.","[Fedorova, Petra; Urbanova, Lucie] Univ Vet & Pharmaceut Sci Brno, Fac Vet Med, Dept Surg & Orthopaed, Small Anim Clin, Brno 61242, Czech Republic; [Srnec, Robert; Necas, Alois] CEITEC Cent European Inst Technol, Brno, Czech Republic; [Pencik, Jan; Schmid, Pavel] Brno Univ Technol, Fac Civil Engn, Inst Bldg Testing, CS-61090 Brno, Czech Republic; [Amler, Evzen] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague, Czech Republic; [Amler, Evzen] Acad Sci Czech Republic, Vvi, Inst Expt Med, Lab Tissue Engn, Prague, Czech Republic","Fedorova, P (reprint author), Univ Vet & Pharmaceut Sci Brno, Fac Vet Med, Dept Surg & Orthopaed, Small Anim Clin, Palackeho Tr 1-3, Brno 61242, Czech Republic.","fedorovap@vfu.cz",null,null,"Ministry of Education, Youth and Sport of the Czech Republic [39/2012/FVL]; European Regional Development Fund [CZ.1.05/1.1.00/02.0068]","This study was supported by Ministry of Education, Youth and Sport of the Czech Republic (Research project IGA VFU No. 39/2012/FVL) and by the project \"CEITEC - Central European Institute of Technology\" (CZ.1.05/1.1.00/02.0068) from the European Regional Development Fund.",null,15,0,0,"VETERINARNI A FARMACEUTICKA UNIVERZITA BRNO","BRNO","PALACKEHO 1-3, BRNO CS-612 42, CZECH REPUBLIC","0001-7213","1801-7576",null,"ACTA VET BRNO","Acta Vet. BRNO",null,2014,83,1,null,null,null,null,55,60,null,"10.2754/avb201483010055",null,6,"Veterinary Sciences","Veterinary Sciences","AG1VQ","WOS:000335204700010"]
["J","Capkova, M; Sachova, J; Strnad, H; Kolar, M; Hroudova, M; Chovanec, M; Cada, Z; Steffl, M; Valach, J; Kastner, J; Vlcek, C; Smetana, K; Plzak, J",null,null,null,"Capkova, Marketa; Sachova, Jana; Strnad, Hynek; Kolar, Michal; Hroudova, Miluse; Chovanec, Martin; Cada, Zdenek; Steffl, Martin; Valach, Jaroslav; Kastner, Jan; Vlcek, Cestmir; Smetana, Karel, Jr.; Plzak, Jan",null,null,"Microarray Analysis of Serum mRNA in Patients with Head and Neck Squamous Cell Carcinoma at Whole-Genome Scale","BIOMED RESEARCH INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,null,"BREAST-CANCER PATIENTS; FREE NUCLEIC-ACIDS; CISPLATIN-RESISTANCE; DIFFERENTIAL EXPRESSION; STROMAL FIBROBLASTS; BH3-ONLY PROTEINS; REGULATED GENES; POOR-PROGNOSIS; PLASMA; MARKER","With the increasing demand for noninvasive approaches in monitoring head and neck cancer, circulating nucleic acids have been shown to be a promising tool. We focused on the global transcriptome of serumsamples of head and neck squamous cell carcinoma (HNSCC) patients in comparison with healthy individuals. We compared gene expression patterns of 36 samples. Twenty-four participants including 16 HNSCC patients (from 12 patients we obtained blood samples 1 year posttreatment) and 8 control subjects were recruited. The Illumina HumanWG-6 v3 Expression BeadChip was used to profile and identify the differences in serum mRNA transcriptomes. We found 159 genes to be significantly changed (Storey's.. value < 0.05) between normal and cancer serum specimens regardless of factors including p53 and B-cell lymphoma family members (Bcl-2, Bcl-XL). In contrast, there was no difference in gene expression between samples obtained before and after surgery in cancer patients. We suggest that microarray analysis of serum cRNA in patients with HNSCC should be suitable for refinement of early stage diagnosis of disease that can be important for development of new personalized strategies in diagnosis and treatment of tumours but is not suitable for monitoring further development of disease.","[Capkova, Marketa; Chovanec, Martin; Cada, Zdenek; Steffl, Martin; Kastner, Jan; Plzak, Jan] Charles Univ Prague, Univ Hosp Motol, Inst Postgrad Med, Dept Otorhinolaryngol Head & Neck Surg,Fac Med 1, Prague 15006 5, Czech Republic; [Capkova, Marketa; Sachova, Jana; Strnad, Hynek; Kolar, Michal; Hroudova, Miluse; Steffl, Martin; Vlcek, Cestmir] Acad Sci Czech Republic, Inst Mol Genet, Dept Genom & Bioinformat, CR-14220 Prague 4, Czech Republic; [Chovanec, Martin; Smetana, Karel, Jr.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 12800 2, Czech Republic; [Valach, Jaroslav] Charles Univ Prague, Dept Stomatol, Fac Med 1, Prague 12108 2, Czech Republic","Plzak, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Inst Postgrad Med, Dept Otorhinolaryngol Head & Neck Surg,Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.plzak@lf1.cuni.cz","Hroudova, Miluse/G-3829-2014","Hroudova, Miluse/0000-0001-6615-0149","Ministry of Health of the Czech Republic [NT13488, UNCE 204013, GAUK 291811, GAUK 60608, PRVOUK 27-1 OnkoKom, SVV264-510]","This work was supported by the Ministry of Health of the Czech Republic no. NT13488, UNCE 204013, GAUK 291811, GAUK 60608, PRVOUK 27-1 OnkoKom, and SVV264-510. Special thanks are due to Genomics and Bioinformatics Core Facility Center of Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, especially to Martina Chmelikova, for acquisition of microarray data, and to the Department of Immunology of Second Faculty of Medicine, Charles University in Prague, especially to Jitka Fucikova and Hana Ulcova, for serum samples processing.",null,64,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6133","2314-6141",null,"BIOMED RES INT","Biomed Res. Int.",null,2014,null,null,null,null,null,null,null,null,null,"10.1155/2014/408683",null,10,"Biotechnology & Applied Microbiology; Medicine, Research & Experimental","Biotechnology & Applied Microbiology; Research & Experimental Medicine","AG2HB","WOS:000335235800001"]
["J","Lukesova, E; Boucek, J; Rotnaglova, E; Salakova, M; Koslabova, E; Grega, M; Eckschlager, T; Rihova, B; Prochazka, B; Klozar, J; Tachezy, R",null,null,null,"Lukesova, E.; Boucek, J.; Rotnaglova, E.; Salakova, M.; Koslabova, E.; Grega, M.; Eckschlager, T.; Rihova, B.; Prochazka, B.; Klozar, J.; Tachezy, R.",null,null,"High Level of Tregs Is a Positive Prognostic Marker in Patients with HPV- Positive Oral and Oropharyngeal Squamous Cell Carcinomas","BIOMED RESEARCH INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,null,"REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; HUMAN-PAPILLOMAVIRUS; NECK-CANCER; NK CELLS; PERIPHERAL-BLOOD; CERVICAL-CANCER; HEAD; EXPRESSION; PREVALENCE","Background. Human papillomaviruses (HPVs) have been proved as one of the etiological factors of oropharyngeal squamous cell carcinoma (OPSCC). Patients with tumors of viral etiology have a lower recurrence rate and better prognosis. OPSCC is linked to an alteration in the immune system. Only a limited number of studies have correlated both the immunological parameters and HPV status with patient prognosis. The aim of this study was to determine whether HPV infection and the immunological status influence patient prognosis individually or in concurrence. Material and Methods. Sixty patients with oral and oropharyngeal carcinomas were enrolled. They were divided into HPV-positive and HPV-negative groups based on the expression of HPV 16 E6 mRNA. Basic lymphocyte subpopulations were determined in the peripheral blood by means of flow cytometry. Results. Significantly better disease-specific survival (DSS) was observed in patients with HPV-positive tumors. Nodal status, tumor grade, recurrence, and CD8+/Tregs ratio were identified as factors influencing DSS. A higher level of Tregs and a lower ratio of CD8/Tregs influenced overall survival (OS) independently of HPV status and age. Patients with HPV-positive tumors and high levels of Tregs survived significantly better than patients from the other groups. Conclusion. Better survival is associated with HPV positivity and elevated Tregs levels. Our data suggest that HPV infection and Tregs do not influence patient prognosis in concurrence.","[Lukesova, E.; Boucek, J.; Rotnaglova, E.; Koslabova, E.; Klozar, J.] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Prague 15006, Czech Republic; [Lukesova, E.; Salakova, M.; Koslabova, E.; Prochazka, B.; Tachezy, R.] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic; [Boucek, J.; Rihova, B.] Acad Sci Czech Republic, Inst Microbiol, Publ Res Inst, CR-14220 Prague, Czech Republic; [Grega, M.] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006, Czech Republic; [Eckschlager, T.] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15006, Czech Republic","Tachezy, R (reprint author), Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic.","rutach@uhkt.cz",null,null,"Grant Agency of the Ministry of Health of the Czech Republic [NT 12483, 11542]; Granting Agency of the Czech Republic [P304/12/2244]; Czech Republic, conceptual development of research organization; University Hospital Motol, Prague, Czech Republic [00064203, SVV 266513, UNCE 204013, PRVOUK 27-1]","The paper was supported by the Grant Agency of the Ministry of Health of the Czech Republic, Grant nos. NT 12483 and 11542 Ministry of Health; Granting Agency of the Czech Republic P304/12/2244, Czech Republic, conceptual development of research organization, University Hospital Motol, Prague, Czech Republic, 00064203; SVV 266513; UNCE 204013; and PRVOUK 27-1.",null,50,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6133","2314-6141",null,"BIOMED RES INT","Biomed Res. Int.",null,2014,null,null,null,null,null,null,null,null,303929,"10.1155/2014/303929",null,11,"Biotechnology & Applied Microbiology; Medicine, Research & Experimental","Biotechnology & Applied Microbiology; Research & Experimental Medicine","AG2GB","WOS:000335233200001"]
["J","Fik, Z; Astl, J; Zabrodsky, M; Lukes, P; Merunka, I; Betka, J; Chovanec, M",null,null,null,"Fik, Zdenek; Astl, Jaromir; Zabrodsky, Michal; Lukes, Petr; Merunka, Ilja; Betka, Jan; Chovanec, Martin",null,null,"Minimally Invasive Video-Assisted versus Minimally Invasive Nonendoscopic Thyroidectomy","BIOMED RESEARCH INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,null,"PRIMARY HYPERPARATHYROIDISM; PARATHYROID SURGERY; NECK DISSECTION; INCISION; CANCER; CARCINOMA; REVISION; NODULES; LENGTH","Minimally invasive video-assisted thyroidectomy (MIVAT) and minimally invasive nonendoscopic thyroidectomy (MINET) represent well accepted and reproducible techniques developed with the main goal to improve cosmetic outcome, accelerate healing, and increase patient's comfort following thyroid surgery. Between 2007 and 2011, a prospective nonrandomized study of patients undergoing minimally invasive thyroid surgery was performed to compare advantages and disadvantages of the two different techniques. There were no significant differences in the length of incision to perform surgical procedures. Mean duration of hemithyroidectomy was comparable in both groups, but it was more time consuming to perform total thyroidectomy by MIVAT. There were more patients undergoing MIVAT procedures without active drainage in the postoperative course and we also could see a trend for less pain in the same group. This was paralleled by statistically significant decreased administration of both opiates and nonopiate analgesics. We encountered two cases of recurrent laryngeal nerve palsies in the MIVAT group only. MIVAT and MINET represent safe and feasible alternative to conventional thyroid surgery in selected cases and this prospective study has shown minimal differences between these two techniques.","[Fik, Zdenek; Astl, Jaromir; Zabrodsky, Michal; Lukes, Petr; Betka, Jan; Chovanec, Martin] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague 15006 5, Czech Republic; [Fik, Zdenek; Astl, Jaromir; Zabrodsky, Michal; Lukes, Petr; Betka, Jan; Chovanec, Martin] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Fik, Zdenek] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Astl, Jaromir] Charles Univ Prague, Fac Med 3, Dept Otorhinolaryngol Head & Neck Surg, Mil Hosp, Prague 16900 6, Czech Republic; [Merunka, Ilja] Czech Tech Univ, Fac Elect Engn, Dept Electromagnet Field, Prague 16627 6, Czech Republic","Chovanec, M (reprint author), Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, V Uvalu 84, Prague 15006 5, Czech Republic.","martin.chovanec@lf1.cuni.cz",null,null,"Charles University [PRVOUK/LF1/P27]; Specific University Research (SVV UK) [266513]; UNCE [204013]; Ministry of Health of the Czech Republic IGA MZ CR [11542, 134 88]; European Regional Development Fund","The authors are grateful for funding by the Charles University, Projects PRVOUK/LF1/P27, Specific University Research (SVV UK) 266513 and UNCE 204013, the Ministry of Health of the Czech Republic IGA MZ CR 11542 and 134 88, and the European Regional Development Fund.",null,44,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6133","2314-6141",null,"BIOMED RES INT","Biomed Res. Int.",null,2014,null,null,null,null,null,null,null,null,null,"10.1155/2014/450170",null,7,"Biotechnology & Applied Microbiology; Medicine, Research & Experimental","Biotechnology & Applied Microbiology; Research & Experimental Medicine","AF5RJ","WOS:000334770300001"]
["S","Dostalova, T; Jelinkova, H; Sulc, J; Nemec, M; Buckova, M; Kasparova, M; Bradna, P",null,"Rechmann, P; Fried, D",null,"Dostalova, Tat'jana; Jelinkova, Helena; Sulc, Jan; Nemec, Michal; Buckova, Michaela; Kasparova, Magdalena; Bradna, Pavel",null,null,"Er:YAG laser delivery systems and sonic-activated bulk composite restoration: sculpturing and microleakage evaluation","LASERS IN DENTISTRY XX","Proceedings of SPIE",null,"English","Proceedings Paper","Conference on Lasers in Dentistry XX","FEB 02, 2014","San Francisco, CA","SPIE",null,"dentistry; Er:YAG laser; contact ablation; non-contact ablation; sonic activated composite","ASSISTED CAVITY PREPARATION; TOOTH STRUCTURE; ADHESION","The comparison of tissue quality and its restoration after contact, non-contact, and non-contact scanned Er:YAG (2940 nm) laser radiation ablation was evaluated. Laser setting for contact ablation was 250 mJ/pulse, pulse repetition rate 15 Hz, average power 3.75 W. For non-contact ablation these values were 600 mJ/pulse, 6 Hz, 3.6 W. All cavities were filled by sonic activated composite resin. Microleakage was assessed quantitatively by the degree of dye penetration. Cavity prepared by contact mode with sonic-activated composite filling protects microleakage formation.","[Dostalova, Tat'jana; Buckova, Michaela; Kasparova, Magdalena] Charles Univ Prague, Dept Stomatol, Fac Med 2, Prague 15006 5, Czech Republic","Dostalova, T (reprint author), Charles Univ Prague, Dept Stomatol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","tatjana.dostalova@fnmotol.cz",null,null,null,null,null,10,0,0,"SPIE-INT SOC OPTICAL ENGINEERING","BELLINGHAM","1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA","0277-786X",null,"978-0-8194-9842-7","PROC SPIE",null,null,2014,8929,null,null,null,null,null,null,null,null,"10.1117/12.2036771",null,8,"Biophysics; Dentistry, Oral Surgery & Medicine; Optics; Physics, Applied","Biophysics; Dentistry, Oral Surgery & Medicine; Optics; Physics","BA3LB","WOS:000334341900008"]
["J","Plzak, J; Macokova, P; Zabrodsky, M; Kastner, J; Lastuvka, P; Astl, J",null,null,null,"Plzak, Jan; Macokova, Pavla; Zabrodsky, Michal; Kastner, Jan; Lastuvka, Petr; Astl, Jaromir",null,null,"Influence of Radiofrequency Surgery on Architecture of the Palatine Tonsils","BIOMED RESEARCH INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,null,"HYPERTROPHY; REDUCTION; TONSILLOTOMY; HYPERPLASIA","Radiofrequency surgery is a widely used modern technique for submucosal volume reduction of the tonsils. So far there is very limited information on morphologic changes in the human tonsils after radiofrequency surgery. We performed histopathological study of tonsillectomy specimens after previous bipolar radiofrequency induced thermotherapy (RFITT). A total of 83 patients underwent bipolar RFITT for hypertrophy of palatine tonsils. Tonsil volume reduction was measured by 3D ultrasonography. Five patients subsequently underwent tonsillectomy. Profound histopathological examination was performed to determine the effect of RFITT on tonsillar architecture. All tonsillectomy specimens showed the intact epithelium, intact germinal centers, normal vascularization, and no evidence of increased fibrosis. No microscopic morphological changes in tonsillectomy specimens after bipolar RFITT were observed. RFITT is an effective submucosal volume reduction procedure for treatment of hypertrophic palatine tonsils with no destructive effect on microscopic tonsillar architecture and hence most probably no functional adverse effect.","[Plzak, Jan; Zabrodsky, Michal; Kastner, Jan; Lastuvka, Petr; Astl, Jaromir] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Prague 15006 5, Czech Republic; [Plzak, Jan; Zabrodsky, Michal; Kastner, Jan; Lastuvka, Petr; Astl, Jaromir] Fac Hosp Motol, Prague 15006 5, Czech Republic; [Macokova, Pavla] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic","Plzak, J (reprint author), Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Uvalu 84, Prague 15006 5, Czech Republic.","jan.plzak@lf1.cuni.cz",null,null,"PRVOUK [27]; UNCE [204013]; NT [13488]; SVV [266513]","This study was supported by PRVOUK 27, UNCE 204013, NT 13488, and SVV 266513.",null,13,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6133","2314-6141",null,"BIOMED RES INT","Biomed Res. Int.",null,2014,null,null,null,null,null,null,null,null,598257,"10.1155/2014/598257",null,4,"Biotechnology & Applied Microbiology; Medicine, Research & Experimental","Biotechnology & Applied Microbiology; Research & Experimental Medicine","AE3XK","WOS:000333911600001"]
["J","Vysata, O; Kukal, J; Valis, M; Pazdera, L; Hort, J; Prochazka, A",null,null,null,"Vysata, Oldrich; Kukal, Jaromir; Valis, Martin; Pazdera, Ladislav; Hort, Jakub; Prochazka, Ales",null,null,"Lag Synchronisation in the Human Brain: Evidence from 17,722 Healthy Subjects' EEG Analyses","NEUROQUANTOLOGY",null,null,"English","Article",null,null,null,null,null,"at least five keywords; separated by comma","CHAOTIC OSCILLATORS; PHASE; COHERENCE; MEG","The lag synchronisation of two different chaotic oscillators is a phenomenon that occurs when the signal from a lower frequency system is delayed with respect to a higher frequency system. The interaction among the multiple brain oscillators might produce lag synchronisation. In addition, phase differences between EEG channels might also reflect this \"time delay\" phenomenon. It has been suggested that the lag-synchronisation of chaotic oscillators depends on the direction of the delay differences between characteristic frequencies. The purpose of this study was to determine whether the direction of the phase difference between two electroencephalography (EEG) channels depends on the source of the characteristic frequency. The dependence of the phase shift on the mean frequency between two channels were examined in a group of 17,722 healthy truck drivers. The mean phase difference between two EEG channels was estimated using the Hilbert transform and compared with the difference in the characteristic frequency. The number of EEG segments with a phase delay from the electrode with a lower frequency to the electrode with a higher frequency was significantly higher than that moving in the opposite direction. The most significant direction of the phase delay was occipito-frontal. These results support the hypothesis that lag synchronisation occurs in the human brain as a result of phase differences that lead to \"time delays\" in the transfer of information from one part of the brain to another. However, this mechanism does not explain the dependence of phase differences on the frequencies between the electrodes. This work provides an alternative explanation for the phase shift between oscillations in different parts of the brain by the theory of nonlinear dynamical systems.","[Vysata, Oldrich; Valis, Martin] Charles Univ Prague, Fac Med, Dept Neurol, Hradec Kralove 50005, Czech Republic; [Kukal, Jaromir; Prochazka, Ales] Inst Chem Technol, Dept Comp & Control Engn, CR-16628 Prague, Czech Republic; [Pazdera, Ladislav] Neuroctr Caregrp, Rychnov Nad Kneznou, Czech Republic; [Hort, Jakub] Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Fac Med 2, Prague, Czech Republic; [Hort, Jakub] St Annes Univ Hosp, Int Clin Res Ctr, Univ Hosp Motol, Brno, Czech Republic","Vysata, O (reprint author), Charles Univ Prague, Fac Med, Dept Neurol, Sokolska 581, Hradec Kralove 50005, Czech Republic.","vysatao@gmail.com",null,null,null,null,null,16,0,0,"ANKA PUBLISHER","BORNOVA","116-11 SOK NO.10 K 2 D 2, BORNOVA, IZMIR 35050, TURKEY","1303-5150",null,null,"NEUROQUANTOLOGY","NeuroQuantology",null,2014,12,1,null,null,null,null,40,45,null,null,null,6,"Neurosciences","Neurosciences & Neurology","AE3TB","WOS:000333899200005"]
["J","Kriz, J; Rejchrt, M",null,null,null,"Kriz, J.; Rejchrt, M.",null,null,"Autonomic Dysreflexia - a Serious Complication of Spinal Cord Injury","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"spinal cord injury; autonomic dysreflexia; tetraplegia","INTERNATIONAL STANDARDS; CEREBRAL-HEMORRHAGE; BLOOD-PRESSURE; MANAGEMENT; MEN; NIFEDIPINE; BLADDER; PATIENT","Autonomic dysreflexia is a serious complication found in more than half of patients with spinal cord injury above the T6 level. In case of an autonomic system disorder, a trigger below the level of injury causes severe vasoconstriction with paroxysmal hypertension. Presenting symptoms include bradycardia, pounding headache, sweating and flushing above the level of lesion, and anxiety. However', AD can sometimes occur without symptoms. The causes of AD include bladder and bowel distension, urological surgeries as well as burning, pressure sores and fractures. Uncontrolled hypertension can lead to hemorrhagic stroke, retinal hemorrhage, respiratory or cardiac problems and even death. Management involves placing the patient in an upright position to take advantage of orthostatic reduction in blood pressure. As the first line of treatment, the cause of irritation has to immediately be eliminated; this usually leads to blood pressure stabilization. If hypertension continues, rapid onset antihypertensive drugs should be used.","[Kriz, J.] 2 LF UK & FN Motole, Spinalni Jednotka, Klin Rehabil & Telovychovneho Lekarstvi, Prague 15006 5, Czech Republic; [Rejchrt, M.] 2 LF UK & FN Motole, Urol Klin, Prague 15006 5, Czech Republic","Kriz, J (reprint author), 2 LF UK & FN Motole, Spinalni Jednotka, Klin Rehabil & Telovychovneho Lekarstvi, Prague 15006 5, Czech Republic.","jiri.kriz@fnmotol.cz",null,null,null,null,null,36,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,2,null,null,null,null,168,173,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AE0ND","WOS:000333662100004"]
["J","Kriz, J",null,null,null,"Kriz, Jiri",null,null,"Comment on article authors and Novak Ondrusova","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Editorial Material",null,null,null,null,null,null,"SPINAL-CORD-INJURY",null,"2 LF UK & FN Motole, Spinalni Jednotka, Klin Rehabil & Telovychovneho Lekarstvi, Prague 15006 5, Czech Republic","Kriz, J (reprint author), 2 LF UK & FN Motole, Spinalni Jednotka, Klin Rehabil & Telovychovneho Lekarstvi, Uvalu 84, Prague 15006 5, Czech Republic.","jiri.kriz@fnmotol.cz",null,null,null,null,null,6,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,2,null,null,null,null,179,179,null,null,null,1,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AE0ND","WOS:000333662100006"]
["J","Kriz, J; Hysperska, V",null,null,null,"Kriz, J.; Hysperska, V.",null,null,"Development of Neurological and Functional Clinical Picture after Spinal Cord Injury","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"spinal lesion; neurological classification; functional classification; compensation; recovery","RECOVERY; MULTICENTER; TETRAPLEGIA","Aim: To present neurological and functional outcome in patients one year after spinal cord injury (SCI). Patients and method: Patients with traumatic spinal cord lesion hospitalized at the Spinal Cord Unit in Prague from 2006 to 2012 were examined in regular intervals within one year after the injury. A total of 113 patients, 87 males and 26 females were included. Neurological examination according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) and functional assessment according to the Spinal Cord Independence Measure (SCIM) was performed. Results: Patients after complete lesion (74 patients) had the mean increase in the motor score of 3.45 +/- 5.88 points (+/- SD) and patients after incomplete lesion (39 patients) had the mean increase of 12.41 +/- 10.21 points, respectively. The sensory score increased by 7.14 +/- 10.07 points in patients with complete and by 8.46 +/- 16.23 points in patients with incomplete lesion. The mean increase in SCIM was 41.23 +/- 15.15 points in patients with motor complete lesion and by 55.04 +/- 26.30 points in patients with motor incomplete lesion. Comparing the 1st and 3rd functional assessment, at least one segment neurological level improvement was found in 48.72% of patients. In 29.73% patients, the initially complete lesion changed to an incomplete lesion (AIS A to AIS B-D), a change from AIS B to AIS C or D was found in 37.5% and a change from AIS C to ASI D in 92.31%. Conclusion: We identified a significant improvement in motor and sensory function in individuals one year after spinal cord injury. The neurological level of injury and the extent of injury may thus change with time. Improvement in functional abilities is even more obvious. The results should serve as a guidance for future therapeutic interventions.","[Kriz, J.; Hysperska, V.] 2 LF UK & FN Motole, Spinalni Jednotka, Klin RHB & TVL, Prague 15006 5, Czech Republic; [Kriz, J.] 3 LF UK & FNKV, Ortoped Traumatol Klin, Prague, Czech Republic","Kriz, J (reprint author), 2 LF UK & FN Motole, Spinalni Jednotka, Klin RHB & TVL, Uvalu 84, Prague 15006 5, Czech Republic.","jiri.kriz@fnmotol.cz",null,null,null,null,null,12,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,2,null,null,null,null,186,195,null,null,null,10,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AE0ND","WOS:000333662100008"]
["J","Ridzon, P; Ehler, E; Urban, P; Prochazka, B; Mazanec, R; Latta, J; Matulova, H; Otruba, P",null,null,null,"Ridzon, P.; Ehler, E.; Urban, P.; Prochazka, B.; Mazanec, R.; Latta, J.; Matulova, H.; Otruba, P.",null,null,"Normative Values of Nerve Conduction Studies of the Ulnar and Median Nerves Measured in a Standardized Way","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"nerve conduction studies; reference values; ulnar nerve; median nerve; sex differences; side differencies","ELBOW; NEUROPATHY; SEX","Objective: The objective of the study was to set normative values of conduction parameters of the median (NM) and ulnar nerves (NU) on a sufficiently large group of healthy volunteers using standardized methodology. The examination of NU focused on conduction across the elbow region. The differences in conduction parameters between males and females, dominant and non-dominant hands, right and left hands, and their dependence on age were also evaluated. Subjects and methods: A total of 227 healthy volunteers, mean age 39.4 years, were examined in five EMG laboratories in the Czech Republic. Results: NU: The amplitude of the compound motor action potential (CMAP) registered by a surface electrode from the abductor digiti minimi muscle (ADM) stimulated at the wrist, was 9.6 +/- 2.3 my; motor conduction velocity (MNCV) at the forearm was 60.4 +/- 5.2 mV; MNCV across the elbow 57.1 +/- 5.9 m/s. When registering from the first dorsal interosseus muscle (IDI) the amplitude of CMAP was 12.0 +/- 4.0 mV; MNCV was 59.7 +/- 4.7 m/s at the forearm, and 56.5 +/- 5.7 m/s across the elbow. Mean difference between MNCV at the forearm and across the elbow was 3.3 +/- 6.6 m/s when registering from ADM and 3.2 +/- 6.4 m/s when registering from IDI, sensory nerve conduction velocity (SNCV) was 55.8 +/- 4.8 m/s. MN: The mean amplitude of CMAP was 10.0 +/- 3.0 mV; MNCV at the forearm was 57.1 +/- 4.6 m/s; the mean amplitude of the sensory nerve action potential for digit II was 25.7 +/- 12.5 mu V; SNCV was 55.8 +/- 4.7 m/s. Conclusion: Owing to the standardized methodology and the large size of the examined group, the data from our study can be used as normative data for conduction studies of UN at the Guyon canal, the forearm, and across the elbow, as well as for the conduction studies of MN distally and at the forearm. Neither the differences in the measured parameters between males and females, dominant and non-dominant hands, and right and left hands, nor the decrease of MNCV with age were clinically significant.","[Ridzon, P.] Thomayerova Nemocnice, Neurol Oddeleni, Prague 14000 4, Czech Republic; [Ridzon, P.; Urban, P.] 1 LF UK & VFN, Klin Pracovniho Lekarstvi, Prague, Czech Republic; [Ehler, E.; Latta, J.] FZS UPa, Neurol Klin, Pardubice, Czech Republic; [Ehler, E.; Latta, J.] Pardubicke Krajska Nemocnice AS, Pardubice, Czech Republic; [Ehler, E.; Urban, P.] Statni Zdravotni Ustav, Prague, Czech Republic; [Mazanec, R.] 2 LF UK & FN Motole, Neurol Klin, Prague, Czech Republic; [Matulova, H.] LF UK & FN Hradec Kralove, Neurol Klin, Hradec Kralove, Czech Republic; [Otruba, P.] LF UP & FN Olomouc, Neurol Klin, Olomouc, Czech Republic","Ridzon, P (reprint author), Thomayerova Nemocnice, Neurol Oddeleni, Videnska 800, Prague 14000 4, Czech Republic.","petr.ridzon@ftn.cz",null,null,null,null,null,20,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,2,null,null,null,null,210,215,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AE0ND","WOS:000333662100011"]
["J","Strenkova, J; Vohanka, S; Haberlova, J; Junkerova, J; Mazanec, R; Mrazova, L; Parmova, O; Ridzon, P; Stanek, J; Siskova, D; Vondracek, P; Brabec, P; Snajdrova, L",null,null,null,"Strenkova, J.; Vohanka, S.; Haberlova, J.; Junkerova, J.; Mazanec, R.; Mrazova, L.; Parmova, O.; Ridzon, P.; Stanek, J.; Siskova, D.; Vondracek, P.; Brabec, P.; Snajdrova, L.",null,null,"REaDY - Czech Registry of Muscular Dystrophies","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"rare diseases; neuromuscular disorders; muscular dystrophies; clinical registries","ATTRIBUTE-VALUE DATABASES","Various forms of muscular dystrophies are mostly classified as rare diseases and rare diseases have received considerable attention from the European Union over the past few years. Based on the Council Recommendation of 8 June 2009 on an action in the field of rare diseases, the Czech government has embraced the National Action Plan on Rare Diseases, involving improvements in methodology of data collection on these diseases. The REaDY project (REgistry of muscular DYstrophy, http://ready.registry.cz) includes registries focusing on four types of neuromuscular disorders: Duchenne/Becker muscular dystrophy, spinal muscular atrophy, myotonic dystrophy, and facioscapulohumeral muscular dystrophy. As of 30th April 2013, REaDY registries contained data on 708 patients in total. Data from the REaDY project will lead to improvements in health care planning and predictions, including future estimates of financial costs, as well as costs and needs in the area of health technology (Health Technology Assessment, HTA). The costs are assessed from clinical data and from health care payers' data.","[Strenkova, J.; Brabec, P.; Snajdrova, L.] MU, Inst Biostat & Analyz, Brno 61137, Czech Republic; [Vohanka, S.; Mrazova, L.; Parmova, O.; Vondracek, P.] FN Brno, Brno, Czech Republic; [Haberlova, J.; Mazanec, R.] FN Motole, Prague, Czech Republic; [Junkerova, J.; Stanek, J.] FN Ostrava, Ostrava, Czech Republic; [Ridzon, P.; Siskova, D.] Thomayerova Nemocnice, Prague, Czech Republic","Snajdrova, L (reprint author), MU, Inst Biostat & Analyz, Kotlarska 2, Brno 61137, Czech Republic.","snajdrova@iba.muni.cz",null,null,null,null,null,5,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,2,null,null,null,null,230,234,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AE0ND","WOS:000333662100014"]
["J","Forgac, M; Uher, T; Zamecnik, J",null,null,null,"Forgac, M.; Uher, T.; Zamecnik, J.",null,null,"Nemaline Myopathy Associated with Monoclonal Gammopathy - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"nemaline myopathy; monoclonal gammopathy; muscle biopsy","ONSET ROD MYOPATHY; ADULT; DISEASE; HISTOCHEMISTRY; PATIENT; LIGHT","Nemaline (rod) myopathy is an uncommon muscle disease with a wide spectrum of phenotypes. Since 1966 until 2008, 71 patients with sporadic late-onset nemaline myopathy have been described. Among them, 12 had monoclonal gammopathy. This case report describes a 64-year-old man with IgG kappa monoclonal gammopathy of undetermined significance, who developed progressive muscle weakness and symmetric hypotrophy, mainly of the proximal limb muscles a year after diagnosis. Muscle biopsy and electron microscopy revealed the presence of numerous typical rod-shaped inclusions in muscle fibers and the diagnosis of nemaline myopathy was established. The patient did not respond to therapy with corticosteroids, application of IVIG had also been considered. The case report is supplemented with basic information related to sporadic late-onset nemaline myopathy.","[Forgac, M.; Uher, T.] 1 LF UK & VFN, Neurol Klin, Prague 12000 2, Czech Republic; [Zamecnik, J.] 2 LF UK & FN Motole, Ustav Patol & Mol Med, Prague, Czech Republic","Forgac, M (reprint author), 1 LF UK & VFN, Neurol Klin, Katerinska 30, Prague 12000 2, Czech Republic.","nnartin.forgac@vfn.cz",null,null,null,null,null,24,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,2,null,null,null,null,247,250,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AE0ND","WOS:000333662100018"]
["J","Navardauskaite, R; Dusatkova, P; Obermannova, B; Pfaeffle, RW; Blum, WF; Adukauskiene, D; Smetanina, N; Cinek, O; Verkauskiene, R; Lebl, J",null,null,null,"Navardauskaite, Ruta; Dusatkova, Petra; Obermannova, Barbora; Pfaeffle, Roland W.; Blum, Werner F.; Adukauskiene, Dalia; Smetanina, Natalija; Cinek, Ondrej; Verkauskiene, Rasa; Lebl, Jan",null,null,"High Prevalence of PROP1 Defects in Lithuania: Phenotypic Findings in an Ethnically Homogenous Cohort of Patients With Multiple Pituitary Hormone Deficiency","JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM",null,null,"English","Article",null,null,null,null,null,null,"MOLECULAR ANALYSIS; GENE-MUTATIONS; DELETION; GLAND; CHILDREN; MR; HEIGHT; HESX1; LHX3; HYPOPITUITARISM","Context: PROP1 gene mutations cause multiple pituitary hormone deficiency (MPHD). Objective: We sought to expand experience with PROP1 mutation carriers by studying a large cohort of Lithuanian patients. Patients and Methods: Sixty-seven MPHD patients were tested for PROP1 defects. Perinatal and postnatal data were obtained from medical records. Hormonal investigations, pituitary imaging, and GH therapy were provided in a single center in Kaunas, Lithuania. Results: A biallelic PROP1 gene mutation was found in 47 subjects (70.1%), of which 46 were homozygous for 296delGA. Positive finding rate among MPHD and population prevalence of PROP1 defects in Lithuania (15.8 per million) were the highest reported to date. Patients' birth lengths/weights were normal. Testicular retention was noted in 31% of boys. Median height SD scores declined over years 1-5: -1.56, -2.34, -3.43, -3.52, and -3.70. Mid-parental height predicted severity of growth retardation at diagnosis (r(2) = 0.30; P = .0001). Deficiencies of GH, TSH, ACTH, and FSH/LH were diagnosed in 44/44, 44/44, 19/44, and 22/44 subjects at median age of 5.5, 5.6, 13.1, and 15.0 years, respectively. Pituitary height ranged from 16.6mm(+20.2 SD) to 1.4mm (-15.5 SD) and declined with age (r(2) = 0.27, P = .001). GH replacement (dose 0.027 mg/kg/d) led to height velocities 12.2; 9.1; 6.9; 6.8; 6.7; 5.6; and 5.7 cm/y (medians) at years 1-7 and final height SD scores (17 patients) -0.98 +/- 1.77 (-1.04 +/- 1.41 below target height; P = .008 vs 0). Conclusions: High prevalence of PROP1 defects in Lithuania is due to 296delGA mutation, suggesting a founder effect.","[Navardauskaite, Ruta; Smetanina, Natalija; Verkauskiene, Rasa] Lithuanian Univ Hlth Sci, Inst Endocrinol, LT-50161 Kaunas, Lithuania; [Adukauskiene, Dalia] Lithuanian Univ Hlth Sci, Med Acad, LT-50161 Kaunas, Lithuania; [Dusatkova, Petra; Obermannova, Barbora; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 15006 5, Czech Republic; [Lebl, Jan] Univ Hosp Prague Motol, Prague 15006, Czech Republic; [Pfaeffle, Roland W.; Blum, Werner F.] Univ Leipzig, Univ Hosp Children & Adolescents, D-04317 Leipzig, Germany","Lebl, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat, 5 Uvalu 84, Prague 15006 5, Czech Republic.","jan.lebl@lfmotol.cuni.cz",null,null,"European Society of Pediatric Endocrinology; Czech Ministry of Health [NT13692]; University Hospital Motol, Prague, Czech Republic [MH CZ-DRO00064203/6001]","R.N. worked on the analyses and the manuscript in Prague with support of a clinical fellowship granted by the European Society of Pediatric Endocrinology. The study was supported by a grant (NT13692) from the Czech Ministry of Health and by MH CZ-DRO00064203/6001, University Hospital Motol, Prague, Czech Republic.",null,41,0,0,"ENDOCRINE SOC","WASHINGTON","2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA","0021-972X","1945-7197",null,"J CLIN ENDOCR METAB","J. Clin. Endocrinol. Metab.","JAN",2014,99,1,null,null,null,null,299,306,null,"10.1210/jc.2013-3090",null,8,"Endocrinology & Metabolism","Endocrinology & Metabolism","AD6WP","WOS:000333402200067"]
["J","Kasalicky, M; Dolezel, R; Vernerova, E; Haluzik, M",null,null,null,"Kasalicky, Mojmir; Dolezel, Radek; Vernerova, Eva; Haluzik, Martin",null,null,"Laparoscopic sleeve gastrectomy without over-sewing of the staple line is effective and safe","VIDEOSURGERY AND OTHER MINIINVASIVE TECHNIQUES",null,null,"English","Article",null,null,null,null,null,"morbid obesity; laparoscopic sleeve gastrectomy; diabetes; staple line","TYPE-2 DIABETES-MELLITUS; MORBID-OBESITY; METABOLIC SYNDROME; OPERATION; PARAMETERS; SURGERY; GHRELIN","Introduction: Laparoscopic sleeve gastrectomy (LSG) is a bariatric procedure with very good long-term weight-reducing and metabolic effects. Aim: Here we report 6 years' experience with LSG performed in morbidly obese patients by one surgical team focusing on the impact of the degree of sleeve restriction and safety of the procedure without over-sewing the staple line. Material and methods: From 2006 to 2012, 207 morbid obese patients with average age of 43.4 years and average body mass index 44.9 kg/m(2) underwent LSG without over-sewing the staple line. The complete 5- and 3-year follow-up is recorded in 59 and 117 patients with prospective data collection at 3, 6, 9, 12, 18, 24, 36, 42 and 60 months after LSG. Group 1 patients operated in 2006-2008 had smaller sleeve restriction. Group 2 patients operated in 2009-2012 had major sleeve restriction. All procedures were performed without over-sewing of the staple line. Results: The average %EBMIL (excess body mass index loss) in group 1 patients with minor sleeve restriction reached 54.1% and average %EWL (excess weight loss) was 50.8% while in group 2 with major sleeve restriction the average %EBMIL reached 69.7% and average %EWL was 66.8%. Final weight reduction was significantly higher in group 2 patients compared to group 1 patients with smaller sleeve restriction. Out of 49 patients with preoperatively diagnosed T2DM (type 2 diabetes mellitus) was completely resolved in 70.8%. Pre-operatively diagnosed hypertension normalized in 64.2%, improved in 23.2%, and remained unchanged in 12.6% of patients. Conclusions: Carefully performed LSG without over-sewing the staple line is feasible and safe. A better weight-reducing effect was present in patients with major sleeve restriction.","[Kasalicky, Mojmir; Dolezel, Radek; Vernerova, Eva] Charles Univ Prague, Fac Med 2, Prague 16902 6, Czech Republic; [Kasalicky, Mojmir; Dolezel, Radek; Vernerova, Eva] Cent Mil Hosp, Prague, Czech Republic; [Kasalicky, Mojmir] Trnava Univ, Fac Hlth Care & Social Work, Trnava, Slovakia; [Haluzik, Martin] Charles Univ Prague, Internal Dept Gen Fac Hosp 3, Fac Med 1, Prague 16902 6, Czech Republic","Kasalicky, M (reprint author), Charles Univ Prague, Fac Med 2, Vojenske Nemocnice 1200, Prague 16902 6, Czech Republic.","mojmir.kasalicky@uvn.cz",null,null," [RVO-VFN64165/2012];  [ZRO M01012]","Supported by RVO-VFN64165/2012; ZRO M01012.",null,26,0,0,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1895-4588",null,null,"VIDEOSURGERY MINIINV","Videosurgery Miniinvasive Tec.",null,2014,9,1,null,null,null,null,46,52,null,"10.5114/wiitm.2014.40387",null,7,"Surgery","Surgery","AE1KC","WOS:000333727200008"]
["J","Stolz, AJ; Harustiak, T; Simonek, J; Schutzner, J; Lischke, R",null,null,null,"Stolz, A. J.; Harustiak, T.; Simonek, J.; Schuetzner, J.; Lischke, R.",null,null,"Pneumonectomy for Non-Small Cell Lung Cancer : Predictors of Early Mortality and Morbidity","ACTA CHIRURGICA BELGICA",null,null,"English","Article",null,null,null,null,null,null,"BRONCHOPLEURAL FISTULA; RISK-FACTORS; INDUCTION CHEMOTHERAPY; RESECTION; COMPLICATIONS; THERAPY; IMPACT; CARCINOMA; INCREASE; STUMP","Background : The aim of this study was to determine independent risk factors affecting postoperative morbidity and mortality after pneumonectomy for non-small cell lung cancer (NSCLC). Methods : A review of 329 patients having pneumonectomy for NSCLC between January 1, 1998 and July 31, 2012 was undertaken. Factors affecting morbidity and mortality were analyzed by univariate and multivariate analyses. Results : The overall 30-day mortality rate was 5.1%. Smoking habits, chronic obstructive pulmonary disease (COPD) status, neoadjuvant therapy and obesity had no statistical influence on the short-term outcome. Coronary artery disease and respiratory failure were identified as risk factors for increased 30-day mortality (p < 0.01). Right pneumonectomy and presence of respiratory failure with mechanical ventilation increased the incidence of bronchopleural fistula (p < 0.01). Conclusions : Pneumonectomy for NSCLC carries an acceptable operative morbidity and mortality. Coronary artery disease, right pneumonectomy and respiratory failure adversely affect morbidity and mortality after this procedure.","[Stolz, A. J.; Harustiak, T.; Simonek, J.; Schuetzner, J.; Lischke, R.] Charles Univ Prague, Fac Med 1, Dept Surg 3, Univ Hosp Motol, Prague, Czech Republic","Stolz, AJ (reprint author), Charles Univ Prague, Fac Med 1, Dept Surg 3, Univ Hosp Motol, V Uvalu 84, Prague, Czech Republic.","stolz@seznam.cz",null,null,"Ministry of Health, Czech Republic [00064203]","Supporterd by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic).",null,19,0,0,"ACTA MEDICAL BELGICA","BRUSSELS","AVENUE CIRCULAIRE 138 A, B-1180 BRUSSELS, BELGIUM","0001-5458",null,null,"ACTA CHIR BELG","Acta Chir. Belg.","JAN-FEB",2014,114,1,null,null,null,null,25,30,null,null,null,6,"Surgery","Surgery","AD8EP","WOS:000333499600004"]
["J","Plzak, J; Zabrodsky, M; Lukes, P",null,null,null,"Plzak, Jan; Zabrodsky, Michal; Lukes, Petr",null,null,"Zenker's Diverticulum: Carbon Dioxide Laser Endoscopic Surgery","BIOMED RESEARCH INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,null,"SURGICAL-TREATMENT","Nowadays endoscopic diverticulotomy is the surgical approach of the first choice in treatment of Zenker's diverticulum. We report our experience with this procedure and try to sum up recent recommendations for management of surgery and postoperative care. Data of 34 patients with Zenker's diverticulum, treated by endoscopic carbon dioxide laser diverticulotomy at the Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic, were prospectively stored and followed in relatively short period from May 2009 to December 2013. The average length of diverticulum was 32 mm. The average duration of surgery was 32 min. The patients were fed via feeding tube for 6.1 days and antibiotics were administered for 7 days. Mean hospitalization time was 7.4 days. We observed one transient recurrent laryngeal nerve paralysis and no other serious complications. Recurrence rate was 3%. We recommend complete transection of the diverticular septum in one procedure, systemic antibiotic treatment and exclusion of transoral intake for minimally 5 days, and contrast oesophagogram before resumption of oral intake to exclude fistula. Open diverticulectomy should be reserved for cases with inadequate endoscopic exposure and for revision surgery for multiple recurrences from endoscopic diverticulotomies.","[Plzak, Jan; Zabrodsky, Michal; Lukes, Petr] Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Univ Hosp Motol, Prague 15006 5, Czech Republic","Plzak, J (reprint author), Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.plzak@lf1.cuni.cz",null,null,"Charles University in Prague [PRVOUK 27, NCE 204013, NT 13488]","This research is supported by Charles University in Prague Projects nos. PRVOUK 27 and UNCE 204013 and Grant no. NT 13488.",null,18,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6133","2314-6141",null,"BIOMED RES INT","Biomed Res. Int.",null,2014,null,null,null,null,null,null,null,null,516231,"10.1155/2014/516231",null,5,"Biotechnology & Applied Microbiology; Medicine, Research & Experimental","Biotechnology & Applied Microbiology; Research & Experimental Medicine","AD0AO","WOS:000332896400001"]
["J","Horak, M; Handl, M; Podskubka, A; Kana, R; Adler, J; Povysil, C",null,null,null,"Horak, M.; Handl, M.; Podskubka, A.; Kana, R.; Adler, J.; Povysil, C.",null,null,"Comparison of the Cellular Composition of Two Different Chondrocyte-Seeded Biomaterials and the Results of Their Transplantation in Humans","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"BOVINE ARTICULAR CHONDROCYTES; CARTILAGE DEFECTS; SUB-POPULATIONS; MATRIX; SCAFFOLDS; KNEE; IMPLANTATION; EXPRESSION; CELLS","Our study compares the histological and immunohistochemical cellular composition of two different chondrocyte-seeded biomaterials and the results of their transplantation. Our study cohort included 21 patients, comprising 19 men and two women with a mean age of 32 years, who were affected by single chondral lesions of the femoral condyles. These patients were enrolled in our study and treated with arthroscopic implantation of the tissue Hyalograft C and/or Brno culture. Brno culture bioengineered with a fibrin-based scaffold contains round cells showing features of differentiated chondrocytes expressing S-100 protein and a-smooth muscle actin. In contrast, in the case of Hyalograft C, the scaffold was made up of a fibrillar network composed of biomaterial fibres of the esters of hyaluronic acid and cells resembling fibroblasts and myofibroblasts and expressing only a-smooth muscle actin. The average size of the defects was 2.5 cm(2). Patients were evaluated using the standardized guidelines of the International Knee Documentation Committee. During the comparison of bioptic samples obtained from both patient cohorts, we did not observe any important differences in the histological makeup of the newly formed cartilage. This was predominantly composed of hyaline cartilage with small areas of fibrocartilage. The histological analysis of these two groups of homogeneous patients shows that this bioengineered approach, under proper indications, may offer favourable and stable clinical results over time, in spite of the different matrix and cellular composition of the two transplants used.","[Horak, M.] Homolka Hosp, Dept Radiol, Prague 15000 5, Czech Republic; [Handl, M.] Univ Hosp Motol, Dept Orthoped, Prague, Czech Republic; [Podskubka, A.] Teaching Hosp Na Bulovce, Dept Orthoped, Prague, Czech Republic; [Kana, R.] Gen Univ Hosp, Dept Otorhinolaryngol, Prague, Czech Republic; [Adler, J.] Univ Hosp Bohunice, Tissue Bank, Brno, Czech Republic; [Povysil, C.] Charles Univ Prague, Inst Pathol, Fac Med 1, Prague, Czech Republic; [Povysil, C.] Gen Univ Hosp, Prague, Czech Republic","Horak, M (reprint author), Homolka Hosp, Dept Radiol, Roentgenova 2, Prague 15000 5, Czech Republic.","martin.horak@homolka.cz",null,null," [PRVOUK- P27/LF1/1]","This work was supported by grant PRVOUK- P27/LF1/1.",null,23,0,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2014,60,1,null,null,null,null,1,9,null,null,null,9,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","AB9VI","WOS:000332143400001"]
["J","Tomasov, P; Minarik, M; Zemanek, D; Cadova, P; Homolova, S; Curila, K; Penicka, M; Benesova, L; Belsanova, B; Gregor, P; Veselka, J",null,null,null,"Tomasov, P.; Minarik, M.; Zemanek, D.; Cadova, P.; Homolova, S.; Curila, K.; Penicka, M.; Benesova, L.; Belsanova, B.; Gregor, P.; Veselka, J.",null,null,"Genetic Testing in the Management of Relatives of Patients with Hypertrophic Cardiomyopathy","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"BINDING PROTEIN-C; CARDIAC TROPONIN-T; DILATED CARDIOMYOPATHY; EUROPEAN-SOCIETY; MUTATIONS; ECHOCARDIOGRAPHY; OBSTRUCTION; CARDIOLOGY; POSITION; FEATURES","Hypertrophic cardiomyopathy is the most common genetic cardiac disease with vast genetic heterogeneity. First-degree relatives of patients with HCM are at 50% risk of inheriting the disease-causing mutation. Genetic testing is helpful in identifying the relatives harbouring the mutations. When genetic testing is not available, relatives need to be examined regularly. We tested a cohort of 99 unrelated patients with HCM for mutations in MYH7,MYBPC3, TNNI3 and TNNT2 genes. In families with identified pathogenic mutation, we performed genetic and clinical examination in relatives to study the influence of genetic testing on the management of the relatives and to study the usefulness of echocardiographic criteria for distinguishing relatives with positive and negative genotype. We identified 38 genetic variants in 47 patients (47 %). Fifteen of these variants in 21 patients (21 %) were pathogenic mutations. We per- formed genetic testing in 52 relatives (18 of them (35 %) yielding positive results). Genetic testing of one HCM patient allowed us to omit 2.45-5.15 future cardiologic examinations of the relatives. None of the studied echocardiographic criteria were significantly different between the relatives with positive and negative genotypes, with the exception of a combined echocardiographic score (genotype positive vs. genotype negative, 3.316 vs. -0.489, P = 0.01). As a conclusion, our study of HCM patients and their relatives confirmed the role of genetic testing in the management of the relatives and found only limited benefit of the proposed echocardiographic parameters in identifying disease-causing mutation carriers.","[Tomasov, P.; Zemanek, D.; Cadova, P.; Homolova, S.; Veselka, J.] Charles Univ Prague, Dept Cardiol, Fac Med 2, Prague 15006 5, Czech Republic; [Tomasov, P.; Zemanek, D.; Cadova, P.; Homolova, S.; Veselka, J.] Univ Hosp Motol, Prague, Czech Republic; [Minarik, M.; Benesova, L.; Belsanova, B.] Genomac Res Inst, Lab Mol Genet & Oncol, Prague, Czech Republic; [Curila, K.; Penicka, M.; Gregor, P.] Univ Hosp Kralovske Vinohrady, Dept Cardiol, Dept Internal Med 3, Prague, Czech Republic","Tomasov, P (reprint author), Charles Univ Prague, Dept Cardiol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","pavol.tomasov@fnmotol.cz",null,null,"Ministry of Health, Czech Republic [00064203]; Internal Grant Agency, Ministry of Health, Czech Republic [NT 11401-5, 9164/3]; Third Faculty of Medicine, Charles University in Prague, Czech Republic [UNCE 204010]","Supported by the project for conceptual development of research organization 00064203 (Ministry of Health, Czech Republic), grants NT 11401-5 and 9164/3 from the Internal Grant Agency, Ministry of Health, Czech Republic and grant UNCE 204010 from the Third Faculty of Medicine, Charles University in Prague, Czech Republic.",null,23,0,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2014,60,1,null,null,null,null,28,34,null,null,null,7,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","AB9VI","WOS:000332143400004"]
["J","Soukup, V; Duskova, J; Pesl, M; Capoun, O; Feherova, Z; Zamecnik, L; Hanus, T; Babjuk, M",null,null,null,"Soukup, V.; Duskova, J.; Pesl, M.; Capoun, O.; Feherova, Z.; Zamecnik, L.; Hanus, T.; Babjuk, M.",null,null,"The Prognostic Value of T1 Bladder Cancer Substaging: A Singlle Institution Retrospective Study","UROLOGIA INTERNATIONALIS",null,null,"English","Article",null,null,null,null,null,"T1 substaging; Urothelial carcinoma of the urinary bladder; Recurrence; Progression; Disease-specific survival; Overall survival","TRANSITIONAL-CELL-CARCINOMA; MUSCULARIS MUCOSAE INVASION; LAMINA PROPRIA INVASION; EORTC RISK TABLES; URINARY-BLADDER; NUCLEAR ACCUMULATION; EAU GUIDELINES; STAGE; PROGRESSION; DEPTH","Objective: To evaluate the prognostic value of the depth of lamina propria invasion in patients with T1 bladder cancer. Subjects and Methods: 200 patients were treated between the years 2002 and 2009. Tumours with depth of invasion above the muscularis nnucosae level were categorised as pT1a and those with depth of invasion up to or beyond the muscularis mucosae as pT1b. Results: Categorisation for pT1a and pT1b was performed in 176 of 200 patients (88%). In 10 patients a muscle-invasive tumour was found in retransurethral resection samples. 131 (79%) of 166 analysed patients had pT1a tumour and 35 (21%) had pT1b tumour. During the follow-up, in 101(61%) patients the tumour had recurred and in 27(16.3%) the tumour had progressed. Of all the investigated parameters, T1 substaging (p < 0.0001), grade (p = 0.0003) and the number of bacillus Calmette-Guerin instillations (p = 0.0490) were significant in predicting progression. The only significant factor for disease-specific survival was T1 substaging in univariable (p = 0.0008) and multivariable (hazard ratio 4.407) analysis. T1 substaging (p = 0.0149) and tumour multiplicity (p = 0.0448) have a statistically significant prognostic value with respect to overall survival. Conclusions: Deep invasion of the lamina propria is a significant adverse prognostic factor for tumour progression, disease-specific survival and overall survival. (C) 2014 S. Karger AG, Basel","[Soukup, V.; Pesl, M.; Capoun, O.; Feherova, Z.; Zamecnik, L.; Hanus, T.] Charles Univ Prague, Gen Teaching Hosp, Dept Urol, CZ-12808 Prague 2, Czech Republic; [Duskova, J.] Charles Univ Prague, Gen Teaching Hosp, Dept Pathol, CZ-12808 Prague 2, Czech Republic; [Soukup, V.] Charles Univ Prague, Fac Med 1, CZ-12808 Prague 2, Czech Republic; [Babjuk, M.] Charles Univ Prague, Hosp Motol, Dept Urol, CZ-12808 Prague 2, Czech Republic; [Babjuk, M.] Charles Univ Prague, Fac Med 2, CZ-12808 Prague 2, Czech Republic","Soukup, V (reprint author), Charles Univ Prague, Gen Teaching Hosp, Dept Urol, CZ-12808 Prague 2, Czech Republic.","viktor.soukup@seznam.cz",null,null,"TIP [CR FR-TI3/666]; IGA [NT/12205-5]","This study was supported by projects TIP CR FR-TI3/666 and IGA NT/12205-5.",null,29,0,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0042-1138","1423-0399",null,"UROL INT","Urol.Int.",null,2014,92,2,null,null,null,null,150,156,null,"10.1159/000355358",null,7,"Urology & Nephrology","Urology & Nephrology","AC4OK","WOS:000332500400005"]
["J","Stepan-Buksakowska, I; Szabo, N; Horinek, D; Toth, E; Hort, J; Warner, J; Charvat, F; Vecsei, L; Rocek, M; Kincses, ZT",null,null,null,"Stepan-Buksakowska, Irena; Szabo, Nikoletta; Horinek, Daniel; Toth, Eszter; Hort, Jakub; Warner, Joshua; Charvat, Frantisek; Vecsei, Laszlo; Rocek, Miloslav; Kincses, Zsigmond T.",null,null,"Cortical and Subcortical Atrophy in Alzheimer Disease Parallel Atrophy of Thalamus and Hippocampus","ALZHEIMER DISEASE & ASSOCIATED DISORDERS",null,null,"English","Article",null,null,null,null,null,"total brain atrophy; neuroimaging; Alzheimer disease; subcortical atrophy; regional atrophy","MILD COGNITIVE IMPAIRMENT; VOXEL-BASED MORPHOMETRY; TEMPORAL-LOBE ATROPHY; GRAY-MATTER LOSS; SHAPE-ANALYSIS; VOLUME; MRI; DIAGNOSIS; DEMENTIA; ROBUST","Brain atrophy is a key imaging hallmark of Alzheimer disease (AD). In this study, we carried out an integrative evaluation of AD-related atrophy. Twelve patients with AD and 13 healthy controls were enrolled. We conducted a cross-sectional analysis of total brain tissue volumes with SIENAX. Localized gray matter atrophy was identified with optimized voxel-wise morphometry (FSL-VBM), and subcortical atrophy was evaluated by active shape model implemented in FMRIB's Integrated Registration Segmentation Toolkit. SIENAX analysis demonstrated total brain atrophy in AD patients; voxel-based morphometry analysis showed atrophy in the bilateral mediotemporal regions and in the posterior brain regions. In addition, regarding the diminished volumes of thalami and hippocampi in AD patients, subsequent vertex analysis of the segmented structures indicated shrinkage of the bilateral anterior thalami and the left medial hippocampus. Interestingly, the volume of the thalami and hippocampi were highly correlated with the volume of the thalami and amygdalae on both sides in AD patients, but not in healthy controls. This complex structural information proved useful in the detailed interpretation of AD-related neurodegenerative process, as the multilevel approach showed both global and local atrophy on cortical and subcortical levels. Most importantly, our results raise the possibility that subcortical structure atrophy is not independent in AD patients.","[Hort, Jakub] Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol,Memory Disorders Clin, Prague 15006 5, Czech Republic; [Stepan-Buksakowska, Irena; Rocek, Miloslav] Charles Univ Prague, Dept Radiol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Horinek, Daniel] Charles Univ Prague, Dept Neurosurg, Fac Med 1, Univ Cent Mil Hosp, Prague 15006 5, Czech Republic; [Charvat, Frantisek] Univ Cent Mil Hosp, Dept Radiodiagnost, Prague 15006 5, Czech Republic; [Stepan-Buksakowska, Irena; Szabo, Nikoletta; Horinek, Daniel; Hort, Jakub; Kincses, Zsigmond T.] St Annes Univ Hosp, Int Clin Res Ctr, Brno, Czech Republic; [Szabo, Nikoletta; Toth, Eszter; Vecsei, Laszlo; Kincses, Zsigmond T.] Univ Szeged, Fac Med, Albert Szent Gyorgyi Clin Ctr, Dept Neurol,Hungarian Acad Sci, Szeged, Hungary; [Vecsei, Laszlo] Univ Szeged, Hungarian Acad Sci, Neurosci Res Grp, Szeged, Hungary; [Warner, Joshua] Mayo Clin, Dept Biomed Engn, Rochester, MN USA","Rocek, M (reprint author), Charles Univ Prague, Dept Radiol, Fac Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","miloslav.rocek@lfmotol.cuni.cz",null,null,"Ministry of Health's Departmental Research and Development Programme III [IGA NT 11536]; Ministry of Education [MSM 0021620816]; European Regional Development Fund-Project FNUSA-ICRC \"Neuroscience Research Group of the Hungarian Academy of Sciences and University of Szeged\" [CZ.1.05/1.1.00/02.0123]; OTKA [PD 104715]; Hungarian Academy of Sciences","Supported by IGA NT 11536 from Ministry of Health's Departmental Research and Development Programme III, Research Goal MSM 0021620816 from Ministry of Education, by European Regional Development Fund-Project FNUSA-ICRC (No.CZ.1.05/1.1.00/02.0123), \"Neuroscience Research Group of the Hungarian Academy of Sciences and University of Szeged\" and the OTKA PD 104715 grant. Z.T.K. was supported by the Bolyai Scholarship Programme of the Hungarian Academy of Sciences.",null,43,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0893-0341","1546-4156",null,"ALZ DIS ASSOC DIS","Alzheimer Dis. Assoc. Dis.","JAN-MAR",2014,28,1,null,null,null,null,65,72,null,"10.1097/WAD.0b013e318299d3d6",null,8,"Clinical Neurology; Pathology","Neurosciences & Neurology; Pathology","AB9CJ","WOS:000332086700010"]
["J","Vlcek, M; Landor, I; Horak, Z; Musil, V; Sosna, A; Jonas, D",null,null,null,"Vlcek, M.; Landor, I; Horak, Z.; Musil, V; Sosna, A.; Jonas, D.",null,null,"Mathematical modelling for the comparison of plate and intramedullary osteosynthesis stability in intraarticular distal radius fractures","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"mathematical modelling; distal radius fracture; locking plate osteosynthesis; intramedullary osteosynthesis; stability",null,"Background: A comparison between plate and intramedullary osteosynthesis techniques in terms of the biomechanical stability of distal radius fracture fixation. Methods: Mathematical modelling was used to simulate distal radius fractures, type Cl and type C2, and to compare the stability of osteosynthesis in both techniques under several wrist joint load conditions: axial compressive loading of the radius, bending loads in volar and dorsal flexion and radial and ulnar deviation, and axial torsional loading of the forearm. Results: For both type Cl and type C2 fractures, the stability of intramedullary osteosynthesis was comparable with plate osteosynthesis in dorsal flexion. Plate osteosynthesis proved to be more stable only in ulnar deviation. The intramedullary X-screw technique provided more stability when loads were applied in volar flexion, radial deviation, pronation and supination, and in axial loading of the radius. Conclusions: The result of mathematical simulations was comparable for both types of fracture. It showed a higher stability of intramedullary osteosynthesis. Although when lower force intensity was applied, both techniques were comparable (Fig. 8, Ref. 16). Text in PDF www.elis.sk.","[Vlcek, M.] Charles Univ Prague, Teaching Hosp Motol, Fac Med 2, Clin Orthopaed Surg 1,Dept Traumatol, CZ-15006 Prague 5, Czech Republic; [Landor, I; Sosna, A.] Charles Univ Prague, Teaching Hosp Motol, Fac Med 1, Clin Orthopaed Surg 1,Dept Traumatol, CZ-15006 Prague 5, Czech Republic; [Horak, Z.] Czech Tech Univ, Facul Mech Engn, Dept Mech Biomechan & Mech, Lab Biomech, Prague, Czech Republic; [Musil, V] Charles Univ Prague, Ctr Sci Informat, Fac Med 3, CZ-15006 Prague 5, Czech Republic","Landor, I (reprint author), Charles Univ Prague, Teaching Hosp Motol, Fac Med 1, Clin Orthopaed Surg 1,Dept Traumatol, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","dr.martinvlcek@gmail.com",null,null,null,null,null,4,0,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248","1336-0345",null,"BRATISL MED J","Bratisl. Med. J.",null,2014,115,2,null,null,null,null,107,111,null,"10.4149/BLL_2014_023",null,5,"Medicine, General & Internal","General & Internal Medicine","AB7SZ","WOS:000331992300012"]
["J","Leoncini, E; Ricciardi, W; Cadoni, G; Arzani, D; Petrelli, L; Paludetti, G; Brennan, P; Luce, D; Stucker, I; Matsuo, K; Talamini, R; La Vecchia, C; Olshan, AF; Winn, DM; Herrero, R; Franceschi, S; Castellsague, X; Muscat, J; Morgenstern, H; Zhang, ZF; Levi, F; Dal Maso, L; Kelsey, K; McClean, M; Vaughan, T; Lazarus, P; Purdue, MP; Hayes, RB; Chen, C; Schwartz, SM; Shangina, O; Koifman, S; Ahrens, W; Matos, E; Lagiou, P; Lissowska, J; Szeszenia-Dabrowska, N; Fernandez, L; Menezes, A; Agudo, A; Daudt, AW; Richiardi, L; Kjaerheim, K; Mates, D; Betka, J; Yu, GP; Schantz, S; Simonato, L; Brenner, H; Conway, DI; Macfarlane, TV; Thomson, P; Fabianova, E; Znaor, A; Rudnai, P; Healy, C; Boffetta, P; Chuang, SC; Lee, YCA; Hashibe, M; Boccia, S",null,null,null,"Leoncini, Emanuele; Ricciardi, Walter; Cadoni, Gabriella; Arzani, Dario; Petrelli, Livia; Paludetti, Gaetano; Brennan, Paul; Luce, Daniele; Stucker, Isabelle; Matsuo, Keitaro; Talamini, Renato; La Vecchia, Carlo; Olshan, Andrew F.; Winn, Deborah M.; Herrero, Rolando; Franceschi, Silvia; Castellsague, Xavier; Muscat, Joshua; Morgenstern, Hal; Zhang, Zuo-Feng; Levi, Fabio; Dal Maso, Luigino; Kelsey, Karl; McClean, Michael; Vaughan, Thomas L.; Lazarus, Philip; Purdue, Mark P.; Hayes, Richard B.; Chen, Chu; Schwartz, Stephen M.; Shangina, Oxana; Koifman, Sergio; Ahrens, Wolfgang; Matos, Elena; Lagiou, Pagona; Lissowska, Jolanta; Szeszenia-Dabrowska, Neonila; Fernandez, Leticia; Menezes, Ana; Agudo, Antonio; Daudt, Alexander W.; Richiardi, Lorenzo; Kjaerheim, Kristina; Mates, Dana; Betka, Jaroslav; Yu, Guo-Pei; Schantz, Stimson; Simonato, Lorenzo; Brenner, Hermann; Conway, David I.; Macfarlane, Tatiana V.; Thomson, Peter; Fabianova, Eleonora; Znaor, Ariana; Rudnai, Peter; Healy, Claire; Boffetta, Paolo; Chuang, Shu-Chun; Lee, Yuan-Chin Amy; Hashibe, Mia; Boccia, Stefania",null,null,"Adult height and head and neck cancer: a pooled analysis within the INHANCE Consortium","EUROPEAN JOURNAL OF EPIDEMIOLOGY",null,null,"English","Article",null,null,null,null,null,"Cancer; Height; Consortium; Head and neck neoplasms","BODY-MASS INDEX; INTERNATIONAL HEAD; EPIDEMIOLOGY CONSORTIUM; CARDIORESPIRATORY DISEASE; SECULAR TRENDS; RISK-FACTORS; LEG LENGTH; METAANALYSIS; COHORT; WOMEN","Several epidemiological studies have shown a positive association between adult height and cancer incidence. The only study conducted among women on mouth and pharynx cancer risk, however, reported an inverse association. This study aims to investigate the association between height and the risk of head and neck cancer (HNC) within a large international consortium of HNC. We analyzed pooled individual-level data from 24 case-control studies participating in the International Head and Neck Cancer Epidemiology Consortium. Odds ratios (ORs) and 95 % confidence intervals (CIs) were estimated separately for men and women for associations between height and HNC risk. Educational level, tobacco smoking, and alcohol consumption were included in all regression models. Stratified analyses by HNC subsites were performed. This project included 17,666 cases and 28,198 controls. We found an inverse association between height and HNC (adjusted OR per 10 cm height = 0.91, 95 % CI 0.86-0.95 for men; adjusted OR = 0.86, 95 % CI 0.79-0.93 for women). In men, the estimated OR did vary by educational level, smoking status, geographic area, and control source. No differences by subsites were detected. Adult height is inversely associated with HNC risk. As height can be considered a marker of childhood illness and low energy intake, the inverse association is consistent with prior studies showing that HNC occur more frequently among deprived individuals. Further studies designed to elucidate the mechanism of such association would be warranted.","[Leoncini, Emanuele; Ricciardi, Walter; Arzani, Dario; Boccia, Stefania] Univ Cattolica Sacro Cuore, Sect Hyg, Inst Publ Hlth, Rome, Italy; [Cadoni, Gabriella; Petrelli, Livia; Paludetti, Gaetano] Univ Cattolica Sacro Cuore, Inst Otorhinolaryngol, Rome, Italy; [Brennan, Paul; Herrero, Rolando; Franceschi, Silvia] Int Agcy Res Canc, F-69372 Lyon, France; [Luce, Daniele; Stucker, Isabelle] Ctr Res Epidemiol & Populat Hlth, INSERM, UMRS 1018, Villejuif, France; [Matsuo, Keitaro] Aichi Canc Ctr Res Inst, Nagoya, Aichi, Japan; [Talamini, Renato; Dal Maso, Luigino] Ctr Riferimento Oncol IRCCS, Aviano, Italy; [La Vecchia, Carlo] IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy; [La Vecchia, Carlo] Univ Milan, Milan, Italy; [Olshan, Andrew F.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Winn, Deborah M.; Purdue, Mark P.] NCI, NIH, Bethesda, MD 20892 USA; [Castellsague, Xavier] CIBER ESP, IDIBELL, ICO, Barcelona, Spain; [Muscat, Joshua; Lazarus, Philip] Penn State Coll Med, Hershey, PA USA; [Morgenstern, Hal] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA; [Morgenstern, Hal] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA; [Morgenstern, Hal] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Zhang, Zuo-Feng] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA; [Zhang, Zuo-Feng] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA; [Levi, Fabio] Univ Lausanne Hosp, Canc Epidemiol Unit, Inst Social & Prevent Med IUMSP, Lausanne, Switzerland; [Kelsey, Karl] Brown Univ, Providence, RI 02912 USA; [McClean, Michael] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Vaughan, Thomas L.; Chen, Chu; Schwartz, Stephen M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Hayes, Richard B.] NYU, Sch Med, Div Epidemiol, New York, NY USA; [Shangina, Oxana] Russian Acad Med Sci, Canc Res Ctr, Moscow, Russia; [Koifman, Sergio] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil; [Ahrens, Wolfgang] Leibniz Inst Prevent Res & Epidemiol BIPS, Bremen, Germany; [Ahrens, Wolfgang] Univ Bremen, Dept Math & Comp Sci, D-28359 Bremen, Germany; [Matos, Elena] Univ Buenos Aires, Inst Oncol Angel H Roffo, Buenos Aires, DF, Argentina; [Lagiou, Pagona] Univ Athens, Sch Med, GR-11527 Athens, Greece; [Lissowska, Jolanta] M Sklodowska Curie Mem Canc Ctr, Dept Canc Epidemiol & Prevent, Warsaw, Poland; [Lissowska, Jolanta] Inst Oncol, Warsaw, Poland; [Szeszenia-Dabrowska, Neonila] Inst Occupat Med, Lodz, Poland; [Fernandez, Leticia] Inst Oncol & Radiobiol, Havana, Cuba; [Menezes, Ana] Univ Fed Pelotas, Pelotas, Brazil; [Agudo, Antonio] IDIBELL, Catalan Inst Oncol ICO, Barcelona, Spain; [Daudt, Alexander W.] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Richiardi, Lorenzo] Univ Turin, Dept Med Sci, Turin, Italy; [Kjaerheim, Kristina] Canc Registry Norway, Oslo, Norway; [Mates, Dana] Natl Inst Publ Hlth, Bucharest, Romania; [Betka, Jaroslav] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Prague, Czech Republic; [Betka, Jaroslav] Univ Hosp Motol, Prague, Czech Republic; [Yu, Guo-Pei; Schantz, Stimson] New York Eye & Ear Infirm, New York, NY 10003 USA; [Simonato, Lorenzo] Univ Padua, Padua, Italy; [Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany; [Conway, David I.] Univ Glasgow, Sch Dent, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [Macfarlane, Tatiana V.] Univ Aberdeen, Sch Dent, Aberdeen, Scotland; [Thomson, Peter] Newcastle Univ, Sch Dent Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Fabianova, Eleonora] Reg Author Publ Hlth, Banska Bystrica, Slovakia; [Znaor, Ariana] Croatian Natl Canc Registry, Zagreb, Croatia; [Rudnai, Peter] Natl Inst Environm Hlth, Budapest, Hungary; [Healy, Claire] Univ Dublin Trinity Coll, Sch Dent Sci, Dublin 2, Ireland; [Boffetta, Paolo] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA; [Boffetta, Paolo] Int Prevent Res Inst, Lyon, France; [Chuang, Shu-Chun] Univ London Imperial Coll Sci Technol & Med, London, England; [Lee, Yuan-Chin Amy; Hashibe, Mia] Univ Utah, Sch Med, Dept Family & Prevent Med, Salt Lake City, UT 84112 USA; [Boccia, Stefania] IRCCS San Raffaele Pisana, Rome, Italy","Boccia, S (reprint author), Univ Cattolica Sacro Cuore, Sect Hyg, Inst Publ Hlth, Rome, Italy.","sboccia@rm.unicatt.it",null,null,"World Cancer Research Fund; European Commission INCO-COPERNICUS Program [IC15- CT98-0332]; French National Research Agency (ANR); French National Cancer Institute (INCA); French Agency for Food, Environmental and Occupational Health and Safety (ANSES); French Association for Research on Cancer (ARC); Fondation pour la Recherche Medicale (FRM); French Institute for Public Health Surveillance (InVS); Fondation de France; Ministry of Labour; Ministry of Health; Ministry of Science, Research and Arts Baden-Wurttemberg; Italian Association for Research on Cancer (AIRC); Italian League Against Cancer; Italian Ministry of Research; Italian Association for Research on Cancer (AIRC) [10068]; Italian Ministry of Education [PRIN 2009 X8YCBN]; AIRC (Italian Agency for Research on Cancer) [10491]; Swiss League against Cancer; Swiss Research against Cancer/Oncosuisse [KFS-700, OCS-1633]; European Community [QLK1-CT-2001-00182]; National Institutes of Health (NIH) US [R01CA078609, R01CA100679]; National Institute of Health (NIH) US [P50CA090388, R01DA011386, R03CA077954, T32CA009142, U01CA096134, R21ES011667, P01CA068384 K07CA104231, R01CA061188, R01CA048996, R01DE012609, P01CA068384, K07CA104231, R01DE013158]; Alper Research Program for Environmental Genomics of the UCLA Jonsson Comprehensive Cancer Center; NIH [R01CA051845, R01CA030022]; National Institute of Environmental Health Sciences [P30ES010126]; NCI, NIH, United States; National Institutes of Health (NCI) US; NIDCR; Fondo para la Investigacion Cientifica y Tecnologica (FONCYT) Argentina; IMIM (Barcelona); Fundaco de Amparo a Pesquisa no Estado de Sao Paulo (FAPESP) [01/01768-2]; European Commission [IC18-CT97-0222]; Ministry of Education, Science, Sports, Culture and Technology of Japan [17015052]; Ministry of Health, Labor and Welfare of Japan [H20-002]; Fondo de Investigaciones Sanitarias (FIS) of the Spanish Government [FIS 97/0024, FIS 97/0662, BAE 01/5013]; International Union Against Cancer (UICC); Yamagiwa-Yoshida Memorial International Cancer Study Grant; Fondazione Veronesi","The authors would like to thank all of the participants who took part in this research for providing us very insightful and constructive comments, which helped improve this manuscript. The individual studies were supported by the following grants: Central Europe study: World Cancer Research Fund and the European Commission INCO-COPERNICUS Program (IC15- CT98-0332). France study (2001-2007): French National Research Agency (ANR); French National Cancer Institute (INCA); French Agency for Food, Environmental and Occupational Health and Safety (ANSES); French Association for Research on Cancer (ARC); Fondation pour la Recherche Medicale (FRM); French Institute for Public Health Surveillance (InVS); Fondation de France; Ministry of Labour; Ministry of Health. Saarland study: Ministry of Science, Research and Arts Baden-Wurttemberg. Aviano study: Italian Association for Research on Cancer (AIRC), Italian League Against Cancer and Italian Ministry of Research. Milan study (1984-1989): Italian Association for Research on Cancer (AIRC). Milan study (2006-2009): Italian Association for Research on Cancer (AIRC, grant n. 10068) and Italian Ministry of Education (PRIN 2009 X8YCBN). Italy Multicenter study: Italian Association for Research on Cancer (AIRC), Italian League Against Cancer and Italian Ministry of Research. Rome study (2010-2013): AIRC (Italian Agency for Research on Cancer), n. 10491. Swiss study: Swiss League against Cancer and the Swiss Research against Cancer/Oncosuisse (KFS-700, OCS-1633). Western Europe study: European Community (5th Framework Programme) (QLK1-CT-2001-00182). Boston study: National Institutes of Health (NIH) US (R01CA078609, R01CA100679). Los Angeles study: National Institute of Health (NIH) US (P50CA090388, R01DA011386, R03CA077954, T32CA009142, U01CA096134, R21ES011667) and the Alper Research Program for Environmental Genomics of the UCLA Jonsson Comprehensive Cancer Center. MSKCC study: NIH (R01CA051845). New York Multicenter study: National Institutes of Health (NIH) US (P01CA068384 K07CA104231). North Carolina (1994-1997): National Institutes of Health (NIH) US (R01CA061188), and in part by a grant from the National Institute of Environmental Health Sciences (P30ES010126). Seattle-LEO study: NIH (R01CA030022). Seattle study: National Institutes of Health (NIH) US (R01CA048996, R01DE012609). Tampa study: National Institutes of Health (NIH) US (P01CA068384, K07CA104231, R01DE013158). US Multicenter study: The Intramural Program of the NCI, NIH, United States. Puerto Rico study: jointly funded by National Institutes of Health (NCI) US and NIDCR intramural programs. Latin America study: Fondo para la Investigacion Cientifica y Tecnologica (FONCYT) Argentina, IMIM (Barcelona), Fundaco de Amparo a Pesquisa no Estado de Sao Paulo (FAPESP) (No 01/01768-2), and European Commission (IC18-CT97-0222). Japan (1988-2000 and 2001-2005): Scientific Research grant from the Ministry of Education, Science, Sports, Culture and Technology of Japan (17015052) and grant for the Third-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare of Japan (H20-002). IARC Multicenter study: Fondo de Investigaciones Sanitarias (FIS) of the Spanish Government (FIS 97/0024, FIS 97/0662, BAE 01/5013), International Union Against Cancer (UICC), and Yamagiwa-Yoshida Memorial International Cancer Study Grant. The work of EL was supported by Fondazione Veronesi.",null,53,0,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0393-2990","1573-7284",null,"EUR J EPIDEMIOL","Eur. J. Epidemiol.","JAN",2014,29,1,null,null,null,null,35,48,null,"10.1007/s10654-013-9863-2",null,14,"Public, Environmental & Occupational Health","Public, Environmental & Occupational Health","AB2TO","WOS:000331645200004"]
["J","Bladen, CL; Thompson, R; Jackson, JM; Garland, C; Wegel, C; Ambrosini, A; Pisano, P; Walter, MC; Schreiber, O; Lusakowska, A; Jedrzejowska, M; Kostera-Pruszczyk, A; van der Pol, L; Wadman, RI; Gredal, O; Karaduman, A; Topaloglu, H; Yilmaz, O; Matyushenko, V; Rasic, VM; Kosac, A; Karcagi, V; Garami, M; Herczegfalvi, A; Monges, S; Moresco, A; Chertkoff, L; Chamova, T; Guergueltcheva, V; Butoianu, N; Craiu, D; Korngut, L; Campbell, C; Haberlova, J; Strenkova, J; Alejandro, M; Jimenez, A; Ortiz, GG; Enriquez, GVG; Rodrigues, M; Roxburgh, R; Dawkins, H; Youngs, L; Lahdetie, J; Angelkova, N; Saugier-Veber, P; Cuisset, JM; Bloetzer, C; Jeannet, PY; Klein, A; Nascimento, A; Tizzano, E; Salgado, D; Mercuri, E; Sejersen, T; Kirschner, J; Rafferty, K; Straub, V; Bushby, K; Verschuuren, J; Beroud, C; Lochmuller, H",null,null,null,"Bladen, Catherine L.; Thompson, Rachel; Jackson, Jacqueline M.; Garland, Connie; Wegel, Claire; Ambrosini, Anna; Pisano, Paolo; Walter, Maggie C.; Schreiber, Olivia; Lusakowska, Anna; Jedrzejowska, Maria; Kostera-Pruszczyk, Anna; van der Pol, Ludo; Wadman, Renske I.; Gredal, Ole; Karaduman, Ayse; Topaloglu, Haluk; Yilmaz, Oznur; Matyushenko, Vitaliy; Rasic, Vedrana Milic; Kosac, Ana; Karcagi, Veronika; Garami, Marta; Herczegfalvi, Agnes; Monges, Soledad; Moresco, Angelica; Chertkoff, Lilien; Chamova, Teodora; Guergueltcheva, Velina; Butoianu, Niculina; Craiu, Dana; Korngut, Lawrence; Campbell, Craig; Haberlova, Jana; Strenkova, Jana; Alejandro, Moises; Jimenez, Alatorre; Gabriel Ortiz, Genaro; Gonzalez Enriquez, Gracia Viviana; Rodrigues, Miriam; Roxburgh, Richard; Dawkins, Hugh; Youngs, Leanne; Lahdetie, Jaana; Angelkova, Natalija; Saugier-Veber, Pascal; Cuisset, Jean-Marie; Bloetzer, Clemens; Jeannet, Pierre-Yves; Klein, Andrea; Nascimento, Andres; Tizzano, Eduardo; Salgado, David; Mercuri, Eugenio; Sejersen, Thomas; Kirschner, Jan; Rafferty, Karen; Straub, Volker; Bushby, Kate; Verschuuren, Jan; Beroud, Christophe; Lochmueller, Hanns",null,null,"Mapping the differences in care for 5,000 Spinal Muscular Atrophy patients, a survey of 24 national registries in North America, Australasia and Europe","JOURNAL OF NEUROLOGY",null,null,"English","Article",null,null,null,null,null,"Spinal muscular atrophy; Rare disease; Disease registries; TREAT-NMD","SMN2 EXPRESSION; CHILDHOOD; SEVERITY; FREQUENCY; GENE","Spinal muscular atrophy (SMA) is an autosomal recessive genetic disorder characterised by the degeneration of motor neurons and progressive muscle weakness. It is caused by homozygous deletions in the survival motor neuron gene on chromosome 5. SMA shows a wide range of clinical severity, with SMA type I patients often dying before 2 years of age, whereas type III patients experience less severe clinical manifestations and can have a normal life span. Here, we describe the design, setup and utilisation of the TREAT-NMD national SMA patient registries characterised by a small, but fully standardised set of registry items and by genetic confirmation in all patients. We analyse a selection of clinical items from the SMA registries in order to provide a snapshot of the clinical data stratified by SMA subtype, and compare these results with published recommendations on standards of care. Our study included 5,068 SMA patients in 25 countries. A total of 615 patients were ventilated, either invasively (178) or non-invasively (437), 439 received tube feeding and 455 had had scoliosis surgery. Some of these interventions were not available to patients in all countries, but differences were also noted among high-income countries with comparable wealth and health care systems. This study provides the basis for further research, such as quality of life in ventilated SMA patients, and will inform clinical trial planning.","[Bladen, Catherine L.; Thompson, Rachel; Rafferty, Karen; Straub, Volker; Bushby, Kate; Lochmueller, Hanns] Inst Med Genet, MRC, Ctr Neuromuscular Dis Newcastle, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; [Jackson, Jacqueline M.; Garland, Connie; Wegel, Claire] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Ambrosini, Anna; Pisano, Paolo] Fdn Telethon, Assoc Italiana Pazienti Con Malattie Neuromuscola, I-20121 Milan, Italy; [Walter, Maggie C.; Schreiber, Olivia] Univ Munich, Friedrich Baur Inst, Dept Neurol, D-80336 Munich, Germany; [Lusakowska, Anna; Kostera-Pruszczyk, Anna] Med Univ Warsaw, Dept Neurol, PL-02970 Warsaw, Poland; [Jedrzejowska, Maria] Polish Acad Sci, Mossakowski Med Res Ctr, Neuromuscular Unit, PL-02106 Warsaw, Poland; [van der Pol, Ludo; Wadman, Renske I.] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Rudolf Magnus Inst Neurosci, Dept Neurol & Neurosurg, NL-3584 CX Utrecht, Netherlands; [Gredal, Ole] Rehabil Ctr Neuromuscular Dis, DK-8000 Aarhus C, Denmark; [Karaduman, Ayse; Topaloglu, Haluk; Yilmaz, Oznur] Univ Fac Hlth Sci, Dept Physiotherapy & Rehabil Hacettepe, TR-06100 Ankara, Turkey; [Matyushenko, Vitaliy] Fdn Children Spinal Muscular Atrophy, Kharkov, Ukraine; [Rasic, Vedrana Milic; Kosac, Ana] Clin Neurol & Psychiat Children & Youth, Belgrade 11000, Serbia; [Rasic, Vedrana Milic] Univ Belgrade, Fac Med, Belgrade, Serbia; [Karcagi, Veronika; Garami, Marta; Herczegfalvi, Agnes] NIEH, Dept Mol Genet, H-1097 Budapest, Hungary; [Monges, Soledad; Moresco, Angelica; Chertkoff, Lilien] Hosp Pediat JP Garrahan, Buenos Aires, DF, Argentina; [Chamova, Teodora; Guergueltcheva, Velina] Med Univ Sofia, Dept Neurol, Sofia, Bulgaria; [Butoianu, Niculina; Craiu, Dana] Hosp Al Obregia, Pediat Neurol Dept, Bucharest, Romania; [Korngut, Lawrence] Univ Calgary, Hlth Sci Ctr, Calgary, AB T2N 4N1, Canada; [Campbell, Craig] Univ Western Ontario, Shulich Sch Med, London, ON, Canada; [Campbell, Craig] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada; [Haberlova, Jana] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Strenkova, Jana] Masaryk Univ, Inst Biostat & Anal, Brno 62500, Czech Republic; [Alejandro, Moises; Gabriel Ortiz, Genaro; Gonzalez Enriquez, Gracia Viviana] Univ Guadalajara, CUCS, Guadalajara 44430, Jalisco, Mexico; [Jimenez, Alatorre; Rodrigues, Miriam; Roxburgh, Richard] Auckland City Hosp, Dept Neurol, Auckland 1142, New Zealand; [Dawkins, Hugh; Youngs, Leanne] Off Populat Hlth Genom, Dept Hlth, Perth, WA 6849, Australia; [Lahdetie, Jaana] Turku Univ, Cent Hosp, Turku 20521, Finland; [Angelkova, Natalija] Univ Hosp Children Dis, Dept Child Neurol, Skopje, Macedonia; [Saugier-Veber, Pascal; Cuisset, Jean-Marie] Fac Med & Pharm Rouen, Serv Genet, Genet Mol Lab, F-76183 Rouen, France; [Bloetzer, Clemens; Jeannet, Pierre-Yves] Univ Lausanne Hosp, Dept Med Chirurg Pediat DMCP, Paediat Neurol & Neurorehabil Unit, Lausanne, Switzerland; [Klein, Andrea] Univ Childrens Hosp, Dept Paediat Neurol, Zurich, Switzerland; [Nascimento, Andres] Hosp St Joan de Deu, Barcelona, Spain; [Tizzano, Eduardo] Hosp Santa Creu & Sant Pau, Barcelona, Spain; [Tizzano, Eduardo] CIBERER, Barcelona, Spain; [Salgado, David; Beroud, Christophe] Aix Marseille Univ, Fac Med La Timone, INSERM, UMR S910, F-13385 Marseille 05, France; [Salgado, David] Monash Univ, EMBL Australia, Australian Regenerat Med Inst, Melbourne, Vic 3004, Australia; [Mercuri, Eugenio] Univ Cattolica Sacro Cuore, Pediat Neurol Unit, Rome, Italy; [Sejersen, Thomas] Karolinska Inst, Stockholm, Sweden; [Kirschner, Jan] Univ Med Ctr, Dept Paediat Neurol & Muscle Disorders, Freiburg, Germany; [Verschuuren, Jan] Leiden Univ, Med Ctr, Dept Neurol, NL-2333 AA Leiden, Netherlands; [Beroud, Christophe] Hop Enfants, AP HM, Dept Med Genet, Marseille, France","Lochmuller, H (reprint author), Inst Med Genet, MRC, Ctr Neuromuscular Dis Newcastle, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.","catherine.bladen@ncl.ac.uk; hanns.lochmuller@ncl.ac.uk",null,null,"AFM [16104]; Jennifer Trust for Spinal Muscular Atrophy; EU [036825, VUL 317/2007]; German Ministry of Education and Research [01GM0302]; Italian Association of Patients with Neuromuscular Diseases (Italy); Neuromuscular Research Foundation Trust (New Zealand); Ministry of Science and Higher Education [641/N-TREAT/09/2010/0]; Ministry statutory grant to the Department of Neurology, Warsaw (Poland), KUKAS (Registry of Neuromuscular Disorders at Hacettepe); Association Francais contre les Myopathies; Princes Beatrix Spierfonds and the Spieren voor Spieren Foundation (the Netherlands); Association de la Suisse Romande et Italienne contre les Myopathies (ASRIM); Fondation Suisse de Recherche sur les Maladies Musculaires (FSRMM); Schweizerische Muskelgesellschaft (Switzerland); International Spinal Muscular Atrophy Patient Registry (Indiana University); Families of SMA (USA); Mexican Social Security Institute (IMSS); Instituto Jalisciense de Asistencia Social; Universidad de Guadalajara; Fundacion Hospitales San Javier; Rotary International, Fundacion Atrofia Muscular Espinal (FUNDAME Spain); GENAME Project (Hospital Sant Pau, Hospital Ramon y Cajal, Hospital La Fe, Hospital Virgen del Rocio, Hospital Sant Joan de Deu and Hospital Valle Hebron), Spain","The authors would like to acknowledge the families of those living with Spinal Muscular Atrophy who have been instrumental in the formation of the SMA national registries. We also acknowledge former and current members of the TREAT-NMD office at the Institute of Genetic Medicine in Newcastle, including Agata Mertyn, Stephen Lynn and Emma Heslop. We also acknowledge the members of the current TGDOC: Jan Verschuuren (Chair), Hugh Dawkins (Chair elect), Anna Ambrosini, Svetlana Artemieva, Alexander N. Baranov, Farhad Bayat, Christophe Beroud, Ria Broekgaarden, Filippo Buccella, Craig Campbell, Nick Catlin, Monica Ensini, Pat Furlong, Kevin Flanigan, Ole Gredal, Lauren Hache, Serap Inal, Jacqueline Jackson, Pierre-Yves Jeannet, Anna Kaminska, A. Ayse Karaduman, Veronika Karcagi, En Kimura, Janbernd Kirschner, Jaana Lahdetie, Hanns Lochmuller, Vitaliy Matyushenko, Vedrana Milic-Rasic, Violeta Mihaylova, Marie-Christine Ouillade, Ian Murphy, Miriam Rodrigues, Rosario dos Santos, Pascale Saugier-Veber, Inge Schwersenz, Thomas Sejersen, Rasha El Sherif, Eduardo Tizzano, Isabela Tudorache, Sylvie Tuffery-Giraud, Jen Wang, Simon Woods, W. Ludo van der Pol, Peter Van den Bergh, and Petr Vondracek. We acknowledge funding provided to the national SMA registries, including: AFM Grant No. 16104, Jennifer Trust for Spinal Muscular Atrophy (2012), TREAT-NMD: EU FP6 contract number 036825 (2007 to 2011), TREAT-NMD Operating Grant: (2012), VUL 317/2007 (Bulgaria), German Ministry of Education and Research, MD-NET # 01GM0302 (Germany), Italian Association of Patients with Neuromuscular Diseases (Italy), Neuromuscular Research Foundation Trust (New Zealand), Ministry of Science and Higher Education (641/N-TREAT/09/2010/0 and Ministry statutory grant to the Department of Neurology, Warsaw (Poland), KUKAS (Registry of Neuromuscular Disorders at Hacettepe) and Association Francais contre les Myopathies (AFM), Princes Beatrix Spierfonds and the Spieren voor Spieren Foundation (the Netherlands), Association de la Suisse Romande et Italienne contre les Myopathies (ASRIM), Fondation Suisse de Recherche sur les Maladies Musculaires (FSRMM) and Schweizerische Muskelgesellschaft (Switzerland), International Spinal Muscular Atrophy Patient Registry (Indiana University), which is supported by Families of SMA (USA), Mexican Social Security Institute (IMSS) and Instituto Jalisciense de Asistencia Social, Universidad de Guadalajara, Fundacion Hospitales San Javier, The Rotary International, Fundacion Atrofia Muscular Espinal (FUNDAME Spain), GENAME Project (Hospital Sant Pau, Hospital Ramon y Cajal, Hospital La Fe, Hospital Virgen del Rocio, Hospital Sant Joan de Deu and Hospital Valle Hebron), Spain.",null,18,0,0,"SPRINGER HEIDELBERG","HEIDELBERG","TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY","0340-5354","1432-1459",null,"J NEUROL","J. Neurol.","JAN",2014,261,1,null,null,null,null,152,163,null,"10.1007/s00415-013-7154-1",null,12,"Clinical Neurology","Neurosciences & Neurology","AA2ZK","WOS:000330962500017"]
["J","Kriz, J; Hakova, R; Hysperska, V; Hlinkova, Z; Lukas, R; Andel, R",null,null,null,"Kriz, J.; Hakova, R.; Hysperska, V.; Hlinkova, Z.; Lukas, R.; Andel, R.",null,null,"International Standards for Neurological Classification of Spinal Cord Injury - Revision 2013","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"spinal lesion; neurological classification; ASIA protocol",null,"International standards for neurological classification of spinal cord injury have been repeatedly revised since the first standards became available in 1982. The last revision, published in 2013, brought about important design and terminology changes to the data record form and some of the formulations. Also, the non-key muscle concept has been elaborated upon to distinguish between complete and incomplete motor lesion more precisely. The Czech version of the form and its distribution among health care professionals enables improved assessment of a neurological condition and its progression in SCI patients.","[Kriz, J.; Hakova, R.; Hysperska, V.; Hlinkova, Z.] RHB & TVL, LF UK & FN 2, Spinalni Jednotka Pri Klin, Prague 15006 5, Czech Republic; [Kriz, J.] 3 LF UK & FNKV, Ortoped Traumatol Klin, Prague, Czech Republic; [Lukas, R.] Krajska nemocnice Liberec, Traumactr, Liberec, Czech Republic; [Andel, R.] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Andel, R.] FN U Sv Anny & Brne, Mezinarodni Ctr Klin Vyzkumu, Brno, Czech Republic","Kriz, J (reprint author), RHB & TVL, LF UK & FN 2, Spinalni Jednotka Pri Klin, Motole Uvalu 84, Prague 15006 5, Czech Republic.","jiri.kriz@fnmotol.cz",null,null,null,null,null,3,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,1,null,null,null,null,77,81,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AA3RQ","WOS:000331010400011"]
["J","Ehler, E; Kopal, A; Mandysova, P; Vojtisek, P; Zamecnik, J",null,null,null,"Ehler, E.; Kopal, A.; Mandysova, P.; Vojtisek, P.; Zamecnik, J.",null,null,"Stiff-person Syndrome Associated with Myotonic Dystrophy Type 2-a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"English","Article",null,null,null,null,null,"co-contraction; GABAergic inhibition; immunoglobulins; myotonic dystrophy; stiff-person syndrome",null,"Stiff-person syndrome (SPS) is manifested by increased tone of the trunk muscles that gradually spreads to the limbs. The mechanism underlying this muscle hypertonia involves derangement of the inhibitory action of gamma-aminobutyric acid (GABA) at cortical and spinal levels with subsequent continuous motor unit activity. A co-contraction mechanism with a board-like abdomen and painful lumbar hyperlordosis plays an important role. Symptomatic treatment involves drugs that enhance inhibition (baclofen and benzodiazepines). Causal treatment focuses on immunosuppression (corticosteroids, intravenously administered immunoglobulins, and plasmapheresis). A combination of SPS and another genetic disease has not yet been described. We describe a case study of a 46-year-old man with gradual development of severe SPS whose electromyography (EMG) showed continuous motor unit activity as well as several myotonic discharges. Genetic testing was indicative of myotonic dystrophy type 2 (DM2).","[Ehler, E.; Kopal, A.; Mandysova, P.] Pardubice Reg Hosp, Dept Neurol, Pardubice 53203, Czech Republic; [Ehler, E.; Kopal, A.; Mandysova, P.; Vojtisek, P.] Univ Pardubice, Fac Hlth Studies, Pardubice, Czech Republic; [Vojtisek, P.] Pardubice Reg Hosp, Internal Dept, Pardubice 53203, Czech Republic; [Zamecnik, J.] Charles Univ Prague, Fac Med 2, Inst Pathol & Mol Med, Prague, Czech Republic; [Zamecnik, J.] Fac Hosp Motol, Prague, Czech Republic","Ehler, E (reprint author), Pardubice Reg Hosp, Dept Neurol, Kyjevska 44, Pardubice 53203, Czech Republic.","edvard.ehler@nemoc-nice-pardubice.cz",null,null,"Internal Grant Agency of the Ministry of Health [NT 13725-4/2012]","This study was supported by the Internal Grant Agency of the Ministry of Health, project NT 13725-4/2012.",null,13,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,1,null,null,null,null,104,108,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AA3RQ","WOS:000331010400017"]
["J","Raudenska, J; Javurkova, A; Kozak, J; Amlerova, J",null,null,null,"Raudenska, J.; Javurkova, A.; Kozak, J.; Amlerova, J.",null,null,"Neuropathic Pain Relief through Distraction Technique - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"chronic neuropathic pain; cognitive-behavioral therapy; distraction technique; relaxation training","ATTENTION","Distraction techniques are common behavioral interventions in terms of cognitive-behavioral therapy for pain management. Distraction techniques help patients to temporarily shift the focus of attention away from their pain and other unpleasant bodily sensations. They are frequently combined with other techniques. The case study describes a patient with chronic neuropathic pain due to a car accident who underwent a surgery but his back and leg pain persisted. A distraction technique in combination with relaxation training provided the patient with short-term pain relieve experience and helped him to cope with pain better.","[Raudenska, J.] 2 LF UK & FN Motole, Oddeleni Klin Psychol, Prague 15006 5, Czech Republic; [Javurkova, A.] FN Kralovske Vinohrady, Oddeleni Klin Psychol, Prague, Czech Republic; [Kozak, J.] 2 LF UK & FN Motole, Ctr Pro Lecbu & Vyzkum Bolestivych Stavu, Prague 15006 5, Czech Republic; [Amlerova, J.] 2 LF UK & FN Motole, Neurol Klin, Prague 15006 5, Czech Republic","Raudenska, J (reprint author), 2 LF UK & FN Motole, Oddeleni Klin Psychol, V Uvalu 84, Prague 15006 5, Czech Republic.","jaroslava.raudenska@fnmotol.cz",null,null,null,null,null,16,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,1,null,null,null,null,114,116,null,null,null,3,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AA3RQ","WOS:000331010400019"]
["J","Dudova, I; Kasparova, M; Markova, D; Zemankova, J; Beranova, S; Urbanek, T; Hrdlicka, M",null,null,null,"Dudova, Iva; Kasparova, Martina; Markova, Daniela; Zemankova, Jana; Beranova, Stepanka; Urbanek, Tomas; Hrdlicka, Michal",null,null,"Screening for autism in preterm children with extremely low and very low birth weight","NEUROPSYCHIATRIC DISEASE AND TREATMENT",null,null,"English","Article",null,null,null,null,null,"autism spectrum disorder; preterm children; screening; Autism Diagnostic Observation Schedule; prevalence","PERVASIVE DEVELOPMENTAL DISORDERS; SPECTRUM DISORDERS; MODIFIED CHECKLIST; INFANTS; TODDLERS; AGE; PREVALENCE; SYMPTOMS; GENETICS; RISK","Background: Studies of children with very low birth weight (VLBW, 1,000-1,500 g) and extremely low birth weight (ELBW, less than 1,000 g) indicate that this population seems to be at increased risk of autism spectrum disorder (ASD). Methods: Parents of 101 VLBW and ELBW children (age 2 years, corrected for prematurity) agreed to participate in the study and signed informed consents; however, parents of only 75 children (44 boys, 31 girls) completed the screening questionnaires. The screening battery included the Modified Checklist for Autism in Toddlers (M-CHAT), Communication and Symbolic Behavior Scales Developmental Profile Infant-Toddler Checklist (CSBS-DP-ITC), and the Infant/Toddler Sensory Profile (ITSP). Children with disabilities were excluded. All children who screened positive on any of the screening tools were subsequently invited for a detailed assessment. Results: Thirty-two children (42.7%) screened positive on at least one of the screening questionnaires. The screening tool with the most positive results was the CSBS-DP-ITC (26 positive screens), followed by the M-CHAT (19 positive screens) and the ITSP (11 positive screens). Of the 32 children who tested positive, 19 participated in the detailed follow-up assessment. A diagnosis of ASD was confirmed in eight of the 19 children. ASD prevalence, calculated from those 19 children and those with negative screening results (43 children), yielded a prevalence of 12.9% in the sample. The difference in frequency of positive screens between the tests was significant (P=0.011). In pair comparisons, ITSP was found to be significantly less positive than CSBS-DP-ITC (P=0.032). No significant differences were found between the M-CHAT and CSBS-DP-ITC or between the M-CHAT and ITSP. Conclusion: The results strongly support the hypothesis of an increased prevalence of autism in children with a birth weight less than 1,500 g.","[Dudova, Iva; Beranova, Stepanka; Hrdlicka, Michal] Charles Univ Prague, Fac Med 2, Dept Child Psychiat, Prague 15006, Czech Republic; [Dudova, Iva; Kasparova, Martina; Beranova, Stepanka; Hrdlicka, Michal] Univ Hosp Motol, Prague, Czech Republic; [Kasparova, Martina] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 15006, Czech Republic; [Markova, Daniela] Charles Univ Prague, Fac Med 1, Dept Pediat & Adolescent Med, Prague 15006, Czech Republic; [Markova, Daniela] Gen Univ Hosp, Prague, Czech Republic; [Zemankova, Jana] Charles Univ Prague, Fac Med, Dept Pediat, Kralove, Czech Republic; [Zemankova, Jana] Univ Hosp, Kralove, Czech Republic; [Urbanek, Tomas] Acad Sci Czech Republic, Inst Psychol, Brno, Czech Republic","Dudova, I (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Child Psychiat, V Uvalu 84, Prague 15006, Czech Republic.","iva.dudova@lfmotol.cuni.cz",null,null,"Ministry of Education, Youth and Sports, Czech Republic [COST LD11028]; Ministry of Health, Czech Republic (conceptual development of research organization, University Hospital Motol, Prague, Czech Republic) [00064203]; ESF (COST Action) [ESSEA BM1004]","This study was supported by the Ministry of Education, Youth and Sports, Czech Republic (research grant COST LD11028), the Ministry of Health, Czech Republic (conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203), and by the ESF (COST Action ESSEA BM1004). The authors would like to thank Thomas Secrest for his assistance with the English version of the manuscript.",null,31,0,0,"DOVE MEDICAL PRESS LTD","ALBANY","PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND","1176-6328","1178-2021",null,"NEUROPSYCH DIS TREAT","Neuropsychiatr. Dis. Treat.",null,2014,10,null,null,null,null,null,277,282,null,"10.2147/NDT.S57057",null,6,"Clinical Neurology; Psychiatry","Neurosciences & Neurology; Psychiatry","AA4QC","WOS:000331079900001"]
["J","Capkova, L; Koubkova, L; Kodet, R",null,null,null,"Capkova, L.; Koubkova, L.; Kodet, R.",null,null,"Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"carbonic anhydrase IX; CAIX; malignant mesothelioma; pleura; immunohistochemistry; immunocytochemistry","PLEURAL MESOTHELIOMA; THERAPY TARGET; LUNG-CANCER; HYPOXIA; CELL; MARKER; EFFUSIONS; PROGNOSIS; SURVIVAL; PROTEIN","Malignant mesothelioma is an aggressive tumor with a poor prognosis. Carbonic anhydrase IX (CAIX) is a membranously located metalloenzyme involved in pH homeostasis with influence on regulation of cell proliferation, oncogenesis and tumor progression. Much attention has been paid recently to carboanhydrases and their inhibitors as they offer an opportunity for both developing novel anticancer drugs, as well as diagnostic and prognostic tools. This study was designed to assess the expression of CAIX in malignant pleural and peritoneal mesotheliomas, their benign counterparts, and in pleural effusions from patients with malignant mesothelioma, metastatic carcinoma or a benign disease. Tissue blocks from 51 malignant mesotheliomas of pleura (47 cases; 41 epithelioid, 2 biphasic, 4 sarcomatoid) and peritoneum (4 cases; all epithelioid), 14 cases with normal or reactive pleural tissue, and 19 cell blocks were analyzed. CAIX expression was determined using immunohistochemistry and its membranous immunoreactivity was semiquantitatively evaluated. Specimens were divided into five subgroups according to the staining pattern and intensity. Overall, 92.2% (47/51) of mesotheliomas expressed CAIX. All epithelioid mesotheliomas showed CAIX positivity, which was predominantly strong and diffuse (73.3%, 33/45). Sarcomatoid mesotheliomas and sarcomatoid areas in biphasic mesotheliomas were negative. A strong diffuse staining was observed in all cases of normal mesothelia. In pleural effusions, CAIX expression was observed in malignant cells as well as in benign mesothelial cells. In conclusion, CAIX is expressed virtually in all mesotheliomas except for sarcomatoid subtype, and in benign mesothelia. There are probably more mechanisms of CAIX overexpression than hypoxia-induced in malignant mesothelioma, with the influence of other tissue specific transcription or growth factors depending on the type of the cell lineage. CAIX immunoreactivity is not a reliable diagnostic marker for distinguishing malignant cells from benign mesothelia in pleural effusions. Nevertheless, our data support the potential use of therapeutics targeting CAIX in patients with advanced mesothelioma.","[Capkova, L.; Kodet, R.] Univ Hosp Motol, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Capkova, L.; Kodet, R.] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; [Koubkova, L.] Univ Hosp Motol, Dept Pneumol, Prague 15006 5, Czech Republic","Capkova, L (reprint author), Univ Hosp Motol, Dept Pathol & Mol Med, V Uvalu 84, Prague 15006 5, Czech Republic.","linda.capkova@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic [00064203];  [OPPK CZ.2.16/3.1.00/24022]","The study was supported by the project of Ministry of Health, Czech Republic for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic) and by the project OPPK CZ.2.16/3.1.00/24022.",null,31,0,0,"VEDA, SLOVAK ACAD SCIENCES","BRATISLAVA","DUBRAVSKA CESTA 9, 842 34 BRATISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2014,61,2,null,null,null,null,161,169,null,"10.4149/neo_2014_031",null,9,"Oncology","Oncology","AA3QS","WOS:000331008000006"]
["J","Hort, J; Andel, R; Mokrisova, I; Gazova, I; Amlerova, J; Valis, M; Coulson, EJ; Harrison, J; Windisch, M; Laczo, J",null,null,null,"Hort, J.; Andel, R.; Mokrisova, I.; Gazova, I.; Amlerova, J.; Valis, M.; Coulson, E. J.; Harrison, J.; Windisch, M.; Laczo, J.",null,null,"Effect of Donepezil in Alzheimer Disease Can Be Measured by a Computerized Human Analog of the Morris Water Maze","NEURODEGENERATIVE DISEASES",null,null,"English","Article; Proceedings Paper","11th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD)","MAR 06-10, 2013","Florence, ITALY","Covance, GE Healthcare, Greenberg Family, Nutricia Adv Med Nutr, Pfizer & Janssen Alzheimers Alliance, Prothena",null,"Alzheimer disease; Donepezil; Morris water maze; Human analog of the Morris water maze; Spatial navigation","MILD COGNITIVE IMPAIRMENT; PROTEIN; MICE","Background: Drug development for Alzheimer disease (AD) is challenged by the success in animal models tested in the Morris water maze (MWM) and the subsequent failures to meet primary outcome measures in phase II or III clinical trials in patients. The human variant of MWM (hMWM) enables us to examine allocentric and egocentric navigation as in the MWM. Objective: It was the aim of this study to examine the utility of a computerized hMWM to assess the effects of donepezil in mild AD. Methods: Donepezil 5 mg/day was started after initial hMWM testing in the treated group (n = 12), and after 28 days, the dose was increased to 10 mg/day. The performance after 3 months was compared to that of a non-treated group (n = 12). Results: Donepezil stabilized or improved the spatial navigation performance after 3 months, especially in the allocentric delayed recall subtask (p = 0.014). Conclusions: The computerized hMWM has the potential to measure the effects of donepezil in mild AD. It is a sensitive cognitive outcome measure in AD clinical trials. (C) 2013 S. Karger AG, Basel","[Hort, J.; Andel, R.; Mokrisova, I.; Gazova, I.; Laczo, J.] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Hort, J.; Mokrisova, I.; Gazova, I.; Amlerova, J.; Laczo, J.] Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Fac Med 2, CZ-15006 Prague, Czech Republic; [Hort, J.; Mokrisova, I.; Gazova, I.; Amlerova, J.; Laczo, J.] Motol Univ Hosp, CZ-15006 Prague, Czech Republic; [Valis, M.] Charles Univ Prague, Dept Neurol, Hradec Kralove, Czech Republic; [Coulson, E. J.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia; [Andel, R.] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Harrison, J.] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England; [Harrison, J.] Metis Cognit Ltd, Kilmington, England; [Windisch, M.] NeuroScios GmbH St, St Radegund Graz, Austria","Hort, J (reprint author), Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Fac Med 2, CZ-15006 Prague, Czech Republic.","jakub.hort@fnmotol.cz","Coulson, Elizabeth/C-8766-2009",null,null,null,null,14,1,1,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1660-2854","1660-2862",null,"NEURODEGENER DIS","Neurodegener. Dis.",null,2014,13,"2014-03-02",null,null,null,null,192,196,null,"10.1159/000355517",null,5,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","304MY","WOS:000330752200036"]
["J","Tabernero, J; Van Cutsem, E; Lakomy, R; Prausova, J; Ruff, P; van Hazel, GA; Moiseyenko, VM; Ferry, DR; McKendrick, JJ; Soussan-Lazard, K; Chevalier, S; Allegra, CJ",null,null,null,"Tabernero, Josep; Van Cutsem, Eric; Lakomy, Radek; Prausova, Jana; Ruff, Paul; van Hazel, Guy A.; Moiseyenko, Vladimir M.; Ferry, David R.; McKendrick, Joseph J.; Soussan-Lazard, Karen; Chevalier, Soazig; Allegra, Carmen J.",null,null,"Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial","EUROPEAN JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"Aflibercept; VEGF Trap; Bevacizumab; Metastatic colorectal cancer; Performance status; Subgroup analysis","GROWTH-FACTORS; SOLID TUMORS","Purpose: The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen. In the present analysis, outcomes were evaluated in prespecified subgroups to assess the consistency of the treatment effect. Methods: Patients were randomised to receive FOLFIRI plus aflibercept or placebo every 2 weeks until disease progression or unacceptable toxicity occurred. Efficacy and safety outcomes were analysed with respect to demographic and baseline characteristics, and stratification factors (prior bevacizumab treatment and Eastern Cooperative Oncology Group performance status). Results: Median overall survival (OS, months [95.34% confidence interval (CI)]) for aflibercept versus placebo was 12.5 (10.8-15.5) versus 11.7 (9.8-13.8) in patients with prior bevacizumab treatment and 13.9 (12.7-15.6) versus 12.4 (11.2-13.5) in patients with no prior bevacizumab treatment. The p value for interaction was 0.5668, indicating there was no heterogeneity in these subgroups. For OS and progression-free survival (PFS), there was a significantly greater benefit (at the 2-sided 10% level) of treatment for patients with liver only metastases versus patients with no liver metastases/liver metastases with other organ involvement (p value for interaction: 0.0899 [OS]; 0.0076 [PFS]). There was no evidence of heterogeneity in treatment effect in any of the other subgroups examined. Conclusions: The benefits of aflibercept in combination with FOLFIRI in patients with mCRC previously treated with oxaliplatin were maintained across the specified patient subgroups, including in patients with or without prior bevacizumab treatment. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.","[Tabernero, Josep] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Barcelona 08035, Spain; [Tabernero, Josep] Univ Autonoma Barcelona, Inst Oncol VHIO, Barcelona 08035, Spain; [Van Cutsem, Eric] Univ Hosp Leuven, Louvain, Belgium; [Van Cutsem, Eric] Katholieke Univ Leuven, Louvain, Belgium; [Lakomy, Radek] Masaryk Mem Canc Inst, Brno, Czech Republic; [Prausova, Jana] Fak Nemocnice Motole, Prague, Czech Republic; [Ruff, Paul] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa; [van Hazel, Guy A.] Univ Western Australia, Nedlands, WA 6009, Australia; [Moiseyenko, Vladimir M.] Oncol Res Inst Na NN Petrov, St Petersburg, Russia; [Ferry, David R.] Russells Hall Hosp, Dudley, W Midlands, England; [McKendrick, Joseph J.] Monash Univ, Clayton, Vic 3800, Australia; [Soussan-Lazard, Karen; Chevalier, Soazig] Sanofi, Vitry Sur Seine, France; [Allegra, Carmen J.] Univ Florida, Gainesville, FL USA","Tabernero, J (reprint author), Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, P Vall dHebron 119-129, Barcelona 08035, Spain.","jtabernero@vhio.net","Moiseyenko, Vladimir/E-8892-2014","Moiseyenko, Vladimir/0000-0003-4807-7915","Sanofi; Regeneron Pharmaceuticals","This study was funded by Sanofi, in collaboration with Regeneron Pharmaceuticals. Employees of Sanofi were involved in the study design, the collection, analysis and interpretation of data, the writing of the manuscript and the decision to submit the manuscript for publication.",null,9,2,2,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0959-8049","1879-0852",null,"EUR J CANCER","Eur. J. Cancer","JAN",2014,50,2,null,null,null,null,320,331,null,"10.1016/j.ejca.2013.09.013",null,12,"Oncology","Oncology","293PV","WOS:000329986500008"]
["J","Sommerburg, O; Krulisova, V; Hammermann, J; Lindner, M; Stahl, M; Muckenthaler, M; Kohlmueller, D; Happich, M; Kulozik, AE; Votava, F; Balascakova, M; Skalicka, V; Stopsack, M; Gahr, M; Macek, M; Mall, MA; Hoffinann, GF",null,null,null,"Sommerburg, Olaf; Krulisova, Veronika; Hammermann, Jutta; Lindner, Martin; Stahl, Mirjam; Muckenthaler, Martina; Kohlmueller, Dirk; Happich, Margit; Kulozik, Andreas E.; Votava, Felix; Balascakova, Miroslava; Skalicka, Veronika; Stopsack, Marina; Gahr, Manfred; Macek, Milan, Jr.; Mall, Marcus A.; Hoffinann, Georg F.",null,null,"Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Article",null,null,null,null,null,"Cystic fibrosis; Newborn screening; Biochemical screening; Pancreatitis associated protein; Immunoreactive trypsinogen","NATIVE HUMAN COLON; DIAGNOSIS; PROTEIN; IMPLEMENTATION; GUIDELINES; SWEAT","Background: In recent years different IRT/PAP protocols have been evaluated, but the individual performance remains unclear. To optimize the IRT/PAP strategy we compared protocols from three regional CF newborn screening centers (Heidelberg, Dresden, and Prague). Methods: We evaluated the effect of elevating the IRT-cut-off from 50 to 65 mu g/l (similar to 97.5th to similar to 99.0th percentile), the need of a failsafe protocol (FS, lRT >= 99.9th percentile) and the relative performance using either two lRT-dependent PAP-cut-offs or one PAP-cut-off. Findings: Elevation of the IRT cut-off to 65 mu g/l (similar to 99.0th percentile) increased the PPV significantly (Dresden: 0.065 vs. 0.080, p <0.0001, Prague: 0.052 vs. 0.074, p <0.0001) without reducing sensitivity. All three IRT/PAP protocols showed a trend towards a higher sensitivity with FS than without and when using one PAP-cut-off instead of two IRT-dependent PAP-cut-offs. Conclusions: For best performance we suggest an IRT/PAP protocol with an lRT-cut-off close to the 99.0th percentile, FS, and a single PAP-cut-off. (C) 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Sommerburg, Olaf; Stahl, Mirjam; Muckenthaler, Martina; Happich, Margit; Kulozik, Andreas E.; Mall, Marcus A.] Heidelberg Univ, Div Paediat Pulmonol & Allergy, D-69120 Heidelberg, Germany; [Sommerburg, Olaf; Stahl, Mirjam; Muckenthaler, Martina; Happich, Margit; Kulozik, Andreas E.; Mall, Marcus A.] Heidelberg Univ, Cyst Fibrosis Ctr, Dept Paediat 3, D-69120 Heidelberg, Germany; [Sommerburg, Olaf; Stahl, Mirjam; Muckenthaler, Martina; Mall, Marcus A.; Hoffinann, Georg F.] Translat Lung Res Ctr Heidelberg TLRC, D-69120 Heidelberg, Germany; [Krulisova, Veronika; Balascakova, Miroslava; Macek, Milan, Jr.] Charles Univ Prague, Univ Hosp Motol, Dept Biol & Med Genet, CZ-15006 Prague 5, Czech Republic; [Krulisova, Veronika; Balascakova, Miroslava; Macek, Milan, Jr.] Charles Univ Prague, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Hammermann, Jutta; Gahr, Manfred] Univ Hosp Dresden, Dept Pediat, D-01307 Dresden, Germany; [Lindner, Martin; Kohlmueller, Dirk; Hoffinann, Georg F.] Heidelberg Univ, Childrens Hosp, Dept Paediat 1, Div Metab Dis, D-69120 Heidelberg, Germany; [Lindner, Martin; Kohlmueller, Dirk; Hoffinann, Georg F.] Heidelberg Univ, Childrens Hosp, Newborn Screening Ctr, Dept Paediat 1, D-69120 Heidelberg, Germany; [Votava, Felix] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Pediat, CZ-10034 Prague 10, Czech Republic; [Votava, Felix] Charles Univ Prague, Fac Med 3, CZ-10034 Prague 10, Czech Republic; [Skalicka, Veronika] Charles Univ Prague, Univ Hosp Motol, Dept Pediat, CZ-10006 Prague 5, Czech Republic; [Skalicka, Veronika] Charles Univ Prague, Fac Med 2, CZ-10006 Prague 5, Czech Republic; [Stopsack, Marina] Univ Hosp Dresden, Inst Clin Chem, D-01307 Dresden, Germany; [Stopsack, Marina] Univ Hosp Dresden, Lab Med, D-01307 Dresden, Germany; [Mall, Marcus A.] Heidelberg Univ, Dept Translat Pulmonol, D-69120 Heidelberg, Germany","Sommerburg, O (reprint author), Heidelberg Univ, Div Paediat Pulmonol & Allergy, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.","olaf.sommerburg@med.uni-heidelberg.de",null,null,"Dietmar-Hopp-Stiftung Walldorf GmbH; Deutsche Forschungsgemeinschaft [DFG MA 2081/4-1]; German Federal Ministry of Education and Research [BMBF 82DZL00401]; Czech Ministry of Health for conceptual development of research organization [00064203]; European Regional Development Fund Prague [CZ.2.16/3.1.00/24022OPPK]; Charles University Prague [PRVOUK UK2.LF, PRVOUK P31]","We gratefully thank all parents of newborns who participated in the study, all colleagues in participating obstetric and/or pediatric hospitals, Stephanie Hinz (Heidelberg) for technical assistance, Nadine Mutz (Heidelberg) for support in data management, and Gisela Haege (Heidelberg) for help in statistical analysis of the data. This study was sponsored by grants from the Dietmar-Hopp-Stiftung Walldorf GmbH (to O.S.), the Deutsche Forschungsgemeinschaft (DFG MA 2081/4-1 to M.A.M.), the German Federal Ministry of Education and Research (BMBF 82DZL00401), the Czech Ministry of Health for conceptual development of research organization (n. 00064203), the European Regional Development Fund Prague (CZ.2.16/3.1.00/24022OPPK to M.M.), and from Charles University Prague (PRVOUK UK2.LF to M.M. and PRVOUK P31 to F.V.).",null,21,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993","1873-5010",null,"J CYST FIBROS","J. Cyst. Fibros","JAN",2014,13,1,null,null,null,null,15,23,null,"10.1016/j.jcf.2013.06.003",null,9,"Respiratory System","Respiratory System","293DM","WOS:000329951600003"]
["J","Kerem, E; Viviani, L; Zolin, A; MacNeill, S; Hatziagorou, E; Ellemunter, H; Drevinek, P; Gulmans, V; Krivec, U; Olesen, H",null,null,null,"Kerem, Eitan; Viviani, Laura; Zolin, Anna; MacNeill, Stephanie; Hatziagorou, Elpis; Ellemunter, Helmut; Drevinek, Pavel; Gulmans, Vincent; Krivec, Uros; Olesen, Hanne",null,"ECFS Patient Registry Steering Grp","Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry","EUROPEAN RESPIRATORY JOURNAL",null,null,"English","Article",null,null,null,null,null,null,"PULMONARY-FUNCTION; PSEUDOMONAS-AERUGINOSA; CHILDREN; MUTATIONS; PHENOTYPE; MORTALITY; GENOTYPE; TRIAL","Pulmonary insufficiency is the main cause of death in cystic fibrosis (CF). We analysed forced expiratory volume in 1 s (FEV1) data of 14 732 patients registered in the European Cystic Fibrosis Society Patient Registry (ECFSPR) database in 2007. We used linear and logistic regressions to investigate associations between FEV1 % predicted and clinical outcomes. Body mass index (BMI), chronic infection by Pseudomonas aeruginosa, pancreatic status and CF-related diabetes (CFRD) showed a statistically significant (all p<0.0001) and clinically relevant effect on FEV1 % pred after adjusting for age. Patients with a lower BMI experience a six-fold increased odds ratio (95% CI 5.0-7.3) of having severe lung disease (FEV1 <40% pred) compared to patients with normal BMI. Being chronically infected with P. aeruginosa increases the odds ratio of severe lung disease by 2.4 (95% CI 2.0-2.7), and patients with pancreatic insufficiency experience a 2.0-fold increased odds ratio (95% CI 1.6-2.5) of severe lung disease compared to pancreatic sufficient patients. Patients with CFRD have a 1.8-fold increased odds ratio (95% CI 1.6-2.2) compared to patients not affected. These potential risk factors for pulmonary disease in patients with CF are to some degree preventable or treatable. We emphasise the importance of their early identification through frequent routine tests, the implementation of infection control measures, and a timely initiation of relevant therapies.","[Kerem, Eitan] Hadassah Hebrew Univ Hosp, Dept Pediat, IL-91240 Jerusalem, Israel; [Kerem, Eitan] Hadassah Hebrew Univ Hosp, CF Ctr, IL-91240 Jerusalem, Israel; [Viviani, Laura; Zolin, Anna] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy; [MacNeill, Stephanie] Univ London Imperial Coll Sci Technol & Med, Dept Occupat & Environm Med, Natl Heart & Lung Inst, London, England; [Hatziagorou, Elpis] Aristotle Univ Thessaloniki, Dept Paediat 3, CF Ctr, Hippokrat Hosp, GR-54006 Thessaloniki, Greece; [Ellemunter, Helmut] Med Univ Innsbruck, Dept Pediat, Cyst Fibrosis Ctr, Univ Klin Padiatrie 3, A-6020 Innsbruck, Austria; [Drevinek, Pavel] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic; [Drevinek, Pavel] Univ Hosp Motol, Prague, Czech Republic; [Drevinek, Pavel] Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Prague, Czech Republic; [Gulmans, Vincent] Dutch Cyst Fibrosis Fdn NCFS, Baarn, Netherlands; [Krivec, Uros] Univ Childrens Hosp, Unit Pulm Dis, Ljubljana, Slovenia; [Olesen, Hanne] Aarhus Univ Hosp, Dept Paediat, DK-8000 Aarhus, Denmark","Kerem, E (reprint author), Hadassah Hebrew Univ Hosp, Dept Pediat, Mt Scopus POB 24035, IL-91240 Jerusalem, Israel.","kerem@hadassah.org.il",null,null,"Chiesi Farmaceutici S.p.A.; IERFC (European Institute for Research in Cystic Fibrosis)","The ECFSPR is supported by an unrestricted grant from Chiesi Farmaceutici S.p.A. and from IERFC (European Institute for Research in Cystic Fibrosis). None of the funding sources had a role in study design; in the collection, analysis, and interpretation of data; in writing or reviewing the paper; nor in the decision to submit the paper for publication.",null,28,2,2,"EUROPEAN RESPIRATORY SOC JOURNALS LTD","SHEFFIELD","442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND","0903-1936","1399-3003",null,"EUR RESPIR J","Eur. Resp. J.","JAN",2014,43,1,null,null,null,null,125,133,null,"10.1183/09031936.00166412",null,9,"Respiratory System","Respiratory System","287ON","WOS:000329552200018"]
["J","Raudenska, M; Gumulec, J; Podlaha, O; Sztalmachova, M; Babula, P; Eckschlager, T; Adam, V; Kizekb, R; Masarik, M",null,null,null,"Raudenska, Martina; Gumulec, Jaromir; Podlaha, Ondrej; Sztalmachova, Marketa; Babula, Petr; Eckschlager, Tomas; Adam, Vojtech; Kizekb, Rene; Masarik, Michal",null,null,"Metallothionein polymorphisms in pathological processes","METALLOMICS",null,null,"English","Review",null,null,null,null,null,null,"METAL-RESPONSIVE ELEMENTS; SINGLE-NUCLEOTIDE POLYMORPHISMS; AMYOTROPHIC-LATERAL-SCLEROSIS; PROSTATE-SPECIFIC ANTIGEN; CENTRAL-NERVOUS-SYSTEM; OXIDATIVE STRESS; GENE-EXPRESSION; IIA GENE; MAMMALIAN METALLOTHIONEIN; TRANSCRIPTION FACTOR","Metallothioneins (MTs) are a class of metal-binding proteins characterized by a high cysteine content and low molecular weight. MTs play an important role in metal metabolism and protect cells against the toxic effects of radiation, alkylating agents and oxygen free radicals. The evidence that individual genetic characteristics of MTs play an important role in physiological and pathological processes associated with antioxidant defense and detoxification inspired targeted studies of genetic polymorphisms in a clinical context. In recent years, common MT polymorphisms were identified and associated with, particularly, western lifestyle diseases such as cancer, complications of atherosclerosis, and type 2 diabetes mellitus along with related complications. This review summarizes all evidence regarding MT polymorphisms of major human MTs (MT1, MT2, MT3 and MT4), their relation to pathological processes, and outlines specific applications of MTs as a set of genetic markers for certain pathologies.","[Raudenska, Martina; Gumulec, Jaromir; Sztalmachova, Marketa; Masarik, Michal] Masaryk Univ, Dept Pathol Physiol, Fac Med, CZ-62500 Brno, Czech Republic; [Raudenska, Martina; Gumulec, Jaromir; Adam, Vojtech; Kizekb, Rene; Masarik, Michal] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Podlaha, Ondrej] Harvard Univ, Dept Biostat & Computat Biol, Dana Farber Canc Inst, Sch Publ Hlth, Boston, MA 02115 USA; [Podlaha, Ondrej] Harvard Univ, Dept Biostat, Sch Publ Hlth, Boston, MA 02115 USA; [Sztalmachova, Marketa; Adam, Vojtech; Kizekb, Rene] Mendel Univ Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Babula, Petr] Univ Vet & Pharmaceut Sci, Dept Nat Drugs, Fac Pharm, CZ-61242 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Masarik, M (reprint author), Masaryk Univ, Dept Pathol Physiol, Fac Med, Kamenice 5, CZ-62500 Brno, Czech Republic.","masarik@med.muni.cz","Gumulec, Jaromir/D-7638-2012; Masarik, Michal/D-9920-2012; Raudenska, Martina/F-9187-2012","Gumulec, Jaromir/0000-0002-9658-3444; ","CEITEC [CZ.1.05/1.1.00/02.0068, doc CEITEC.02/2012]; project for conceptual development of research organization [00064203]","Financial support from CEITEC CZ.1.05/1.1.00/02.0068, doc CEITEC.02/2012 (JG), and project for conceptual development of research organization 00064203 is greatly acknowledged.",null,119,0,0,"ROYAL SOC CHEMISTRY","CAMBRIDGE","THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND","1756-5901","1756-591X",null,"METALLOMICS","Metallomics",null,2014,6,1,null,null,null,null,55,68,null,"10.1039/c3mt00132f",null,14,"Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","278LF","WOS:000328891100004"]
["J","Maly, J; Szarszoi, O; Netuka, I; Dorazilova, Z; Pirk, J",null,null,null,"Maly, Jiri; Szarszoi, Ondrej; Netuka, Ivan; Dorazilova, Zora; Pirk, Jan",null,null,"Fungal Infections Associated with Long-Term Mechanical Circulatory Support-Diagnosis and Management","JOURNAL OF CARDIAC SURGERY",null,null,"English","Review",null,null,null,null,null,null,"VENTRICULAR-ASSIST DEVICE; LINKED-IMMUNOSORBENT-ASSAY; CELL TRANSPLANT RECIPIENTS; BLOOD-STREAM INFECTIONS; REAL-TIME PCR; CLINICAL-PRACTICE GUIDELINES; CHAIN-REACTION ASSAY; INVASIVE ASPERGILLOSIS; STEM-CELL; RISK-FACTORS","Left ventricular assist devices (LVADs) are increasingly used as a treatment option for advanced heart failure. Fungal infections present a serious concern given the high association with major adverse events including death in this group of patients. The objective of this review is to summarize the incidence, risk factors, method for diagnosis, complication rate, and outcomes in patients with VADs who develop fungal infections. doi: 10.1111/jocs.12258 (J Card Surg 2014;29:95-100)","[Maly, Jiri; Szarszoi, Ondrej; Netuka, Ivan; Dorazilova, Zora; Pirk, Jan] Inst Clin & Expt Med, Dept Cardiovasc Surg, Prague 14021 4, Czech Republic; [Netuka, Ivan] Charles Univ Prague, Dept Surg 2, Dept Cardiovasc Surg, Fac Med 1, Prague, Czech Republic; [Maly, Jiri] Charles Univ Prague, Fac Med 2, Dept Cardiovasc Surg, Prague, Czech Republic","Netuka, I (reprint author), Inst Clin & Expt Med, Dept Cardiovasc Surg, Videnska 1958-9, Prague 14021 4, Czech Republic.","ivne@ikem.cz",null,null,null,null,null,80,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0886-0440","1540-8191",null,"J CARDIAC SURG","J. Card. Surg.","JAN",2014,29,1,null,null,null,null,95,100,null,"10.1111/jocs.12258",null,6,"Cardiac & Cardiovascular Systems; Surgery","Cardiovascular System & Cardiology; Surgery","284HO","WOS:000329307000015"]
["J","Zaliova, M; Zimmermannova, O; Dorge, P; Eckert, C; Moricke, A; Zimmermann, M; Stuchly, J; Teigler-Schlegel, A; Meissner, B; Koehler, R; Bartram, CR; Karawajew, L; Rhein, P; Zuna, J; Schrappe, M; Cario, G; Stanulla, M",null,null,null,"Zaliova, M.; Zimmermannova, O.; Doerge, P.; Eckert, C.; Moericke, A.; Zimmermann, M.; Stuchly, J.; Teigler-Schlegel, A.; Meissner, B.; Koehler, R.; Bartram, C. R.; Karawajew, L.; Rhein, P.; Zuna, J.; Schrappe, M.; Cario, G.; Stanulla, M.",null,null,"ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia","LEUKEMIA",null,null,"English","Letter",null,null,null,null,null,null,"BFM 2000 PROTOCOL; SUBTYPE",null,"[Zaliova, M.; Doerge, P.; Moericke, A.; Meissner, B.; Schrappe, M.; Cario, G.] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany; [Zaliova, M.; Zimmermannova, O.; Stuchly, J.; Zuna, J.] Charles Univ Prague, CLIP, Dept Pediat Hematol & Oncol, Fac Med 2, Prague, Czech Republic; [Zaliova, M.; Zimmermannova, O.; Stuchly, J.; Zuna, J.] Univ Hosp Motol, Prague, Czech Republic; [Eckert, C.; Karawajew, L.; Rhein, P.] Charite, Berlin, Germany; [Zaliova, M.; Zimmermann, M.; Stanulla, M.] Hannover Med Sch, D-30625 Hannover, Germany; [Teigler-Schlegel, A.] Univ Giessen, Oncogenet Lab, D-35390 Giessen, Germany; [Koehler, R.; Bartram, C. R.] Heidelberg Univ, Dept Human Genet, Heidelberg, Germany","Stanulla, M (reprint author), Hannover Med Sch, Carl Neuberg St 1, D-30625 Hannover, Germany.","stanulla.martin@mh-hannover.de",null,null,null,null,null,15,1,1,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924","1476-5551",null,"LEUKEMIA","Leukemia","JAN",2014,28,1,null,null,null,null,182,185,null,"10.1038/leu.2013.282",null,5,"Oncology; Hematology","Oncology; Hematology","286CD","WOS:000329441200020"]
["J","Aalbers, AM; van der Velden, VHJ; Yoshimi, A; Fischer, A; Noellke, P; Zwaan, CM; Baumann, I; Beverloo, HB; Dworzak, M; Hasle, H; Locatelli, F; De Moerloose, B; Gohring, G; Schmugge, M; Stary, J; Zecca, M; Langerak, AW; van Dongen, JJM; Pieters, R; Niemeyer, CM; van den Heuvel-Eibrink, MM",null,null,null,"Aalbers, A. M.; van der Velden, V. H. J.; Yoshimi, A.; Fischer, A.; Noellke, P.; Zwaan, C. M.; Baumann, I.; Beverloo, H. B.; Dworzak, M.; Hasle, H.; Locatelli, F.; De Moerloose, B.; Goehring, G.; Schmugge, M.; Stary, J.; Zecca, M.; Langerak, A. W.; van Dongen, J. J. M.; Pieters, R.; Niemeyer, C. M.; van den Heuvel-Eibrink, M. M.",null,null,"The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS","LEUKEMIA",null,null,"English","Letter",null,null,null,null,null,null,"ACQUIRED APLASTIC-ANEMIA; BONE-MARROW FAILURE; IMMUNOSUPPRESSIVE THERAPY; ANTITHYMOCYTE GLOBULIN; CHILDREN; CELLS; POPULATION; RABBIT; HORSE",null,"[Aalbers, A. M.; Zwaan, C. M.; Pieters, R.; van den Heuvel-Eibrink, M. M.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Aalbers, A. M.; van der Velden, V. H. J.; Langerak, A. W.; van Dongen, J. J. M.] Erasmus Univ, Dept Immunol, Med Ctr, Erasmus MC, NL-3000 DR Rotterdam, Netherlands; [Yoshimi, A.; Fischer, A.; Noellke, P.; Niemeyer, C. M.] Univ Freiburg, Div Pediat Hematol & Oncol, Dept Pediat & Adolescent Med, D-79106 Freiburg, Germany; [Baumann, I.] Boblingen Clin, Clin Ctr South West, Dept Pathol, Boblingen, Germany; [Beverloo, H. B.] Erasmus Univ, Dept Clin Genet, Erasmus MC, Med Ctr, NL-3000 DR Rotterdam, Netherlands; [Dworzak, M.] Med Univ Vienna, St Anna Childrens Hosp, Vienna, Austria; [Dworzak, M.] Med Univ Vienna, Childrens Canc Res Inst, Dept Pediat, Vienna, Austria; [Hasle, H.] Aarhus Univ, Hosp Skejby, Dept Pediat, Aarhus, Denmark; [Locatelli, F.] Univ Pavia, IRCCS Osped Bambino Gesu, Dept Pediat Hematol Oncol, Rome, Italy; [De Moerloose, B.] Ghent Univ Hosp, Dept Pediat Hematol Oncol, Ghent, Belgium; [Goehring, G.] Hannover Med Sch, Inst Cell & Mol Pathol, Hannover, Germany; [Schmugge, M.] Univ Childrens Hosp, Dept Hematol, Zurich, Switzerland; [Stary, J.] Charles Univ Prague, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Stary, J.] Univ Hosp Motol, Prague, Czech Republic; [Zecca, M.] Fdn IRCCS Policlin San Matteo, Pavia, Italy","Aalbers, AM (reprint author), Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl",null,null,null,null,null,16,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924","1476-5551",null,"LEUKEMIA","Leukemia","JAN",2014,28,1,null,null,null,null,189,192,null,"10.1038/leu.2013.195",null,5,"Oncology; Hematology","Oncology; Hematology","286CD","WOS:000329441200022"]
["J","Rygl, M; Vyhnanek, M; Kucera, A; Mixa, V; Kyncl, M; Snajdauf, J",null,null,null,"Rygl, Michal; Vyhnanek, M.; Kucera, A.; Mixa, V.; Kyncl, M.; Snajdauf, J.",null,null,"Technical innovation in minimally invasive repair of pectus excavatum","PEDIATRIC SURGERY INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"Pectus excavatum; Minimally invasive repair of pectus excavatum; Semiflexible thoracoscope; Wolkmann bone hook; Sternum elevating technique","NUSS PROCEDURE; CARDIAC PERFORATION; MEDIASTINAL DISSECTION; BAR DISPLACEMENT; COMPLICATIONS; THORACOSCOPY; EFFICACY; STERNUM","The aim of study was to introduce technical innovation of MIRPE which reduces the risk of cardiac injury. Modification of MIRPE method with semiflexible thoracoscope and sternum elevating technique has been used. Volkmann bone hook has been inserted percutaneously to the sternum. The hook elevates the sternum forward and enlarges the retrosternal space for safer passage of thoracoscopically guided introducer. Using semiflexible thoracoscope allows better view from various angles via one site of insertion. During the period 2005-2012, the MIRPE was performed on 29 girls and 151 boys; the mean age at the time of surgery was 15.9 years (range 13-18.7 years). The mean Haller index was 4.7 (range 2.7-20.5). The most common complication was pneumothorax (3.3 %) and the incidence of bar displacement was 2 %. The most serious complication was cardiac perforation when inserting Lorenz introducer. This occurred in a 16-year-old girl; she required urgent sternotomy with right atrial repair and recovered well. External elevation of sternum with the hook was used since this case. Subsequent 113 patients underwent surgery without any serious complications. Technical innovation using semiflexible thoracoscope and hook elevation of the sternum reduces the risk of cardiac injury. The hook opens the anterior mediastinum space effectively and makes the following dissection relatively safe and straightforward.","[Rygl, Michal; Vyhnanek, M.; Kucera, A.; Snajdauf, J.] Charles Univ Prague, Fac Med 2, Dept Pediat Surg, Prague 15000 5, Czech Republic; [Rygl, Michal; Vyhnanek, M.; Kucera, A.; Snajdauf, J.] Charles Univ Prague, Teaching Hosp Motol, Prague 15000 5, Czech Republic; [Mixa, V.] Charles Univ Prague, Fac Med 2, Dept Anaesthesia & Intens Care Med, Prague 15006 5, Czech Republic; [Mixa, V.; Kyncl, M.] Charles Univ Prague, Teaching Hosp Motol, Prague 15006 5, Czech Republic; [Kyncl, M.] Charles Univ Prague, Fac Med 2, Dept Imaging Methods, Prague 15006 5, Czech Republic","Rygl, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat Surg, V Uvalu 84, Prague 15000 5, Czech Republic.","mrygl@yahoo.com; martinvyh@gmail.com; alexandr.kucera@gmail.com; vmxa@volny.cz; Martin.Kyncl@fnmotol.cz; jiri.snajdauf@fnmotol.cz",null,null,null,null,null,20,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0179-0358","1437-9813",null,"PEDIATR SURG INT","Pediatr. Surg. Int.","JAN",2014,30,1,null,null,null,null,113,117,null,"10.1007/s00383-013-3435-0",null,5,"Pediatrics; Surgery","Pediatrics; Surgery","283HU","WOS:000329237900015"]
["J","Kraus, J; Nartova, E; Pavlik, E; Katra, R; Sterzl, I; Astl, J",null,null,null,"Kraus, Jaroslav; Nartova, Eva; Pavlik, Emil; Katra, Rami; Sterzl, Ivan; Astl, Jaromir",null,null,"Prevalence of Helicobacter pylori in adenotonsillar hypertrophy in children","ACTA OTO-LARYNGOLOGICA",null,null,"English","Article",null,null,null,null,null,"Adenoid; tonsils; PCR; pharynx","OTITIS-MEDIA; TISSUE; COLONIZATION; ASSOCIATION; TONSILLAR; EFFUSION; PCR","Conclusion: Our results encourage the notion that the pharynx could be an extragastric reservoir of Helicobacter pylori (HP). The study confirmed the presence of HP in adenotonsillar tissue in children. It could have importance in the pathophysiology of upper respiratory diseases. However, its precise role in these processes remains unclear and requires further studies. Objective: A prospective study was carried out to evaluate the presence of HP in tonsillar and adenoid tissue in children. The study focused on real-time PCR analyzing CagA and VacA genotypes of HP strains. Methods: A total of 37 consecutive pediatric patients with adenotonsillar hypertrophy indicated for surgery were observed in a prospective study. Adenoidectomy and/or tonsillectomy was performed in each patient; 49 specimens were taken, 32 from adenoids and 17 from tonsils. The presence of HP and its genotype were tested in all samples by real-time PCR analysis. Results: Of 49 samples analyzed, 48 were positive for the presence of HP (98%), so only 1 sample was negative. While the genotype VacAs1bm2 was definitely dominant in adenoid tissue, wider distribution was observed in tonsillar tissue. Cag(+) strains represented one-fifth of all samples (21%).","[Kraus, Jaroslav] Hosp Rudolf & Stefanie Benesov, Dept Otorhinolaryngol, Benesov 25630, Czech Republic; [Nartova, Eva; Astl, Jaromir] Charles Univ Prague, Fac Hosp Motol, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Prague, Czech Republic; [Pavlik, Emil] Charles Univ Prague, Fac Med 1, Inst Immunol & Microbiol, Prague, Czech Republic; [Pavlik, Emil] Gen Univ Hosp, Prague, Czech Republic; [Katra, Rami] Charles Univ Prague, Fac Med 2, Dept ENT, Prague, Czech Republic; [Sterzl, Ivan] Inst Endocrinol, Prague, Czech Republic; [Astl, Jaromir] Charles Univ Prague, Fac Med 3, Mil Hosp, Dept ENT, Prague, Czech Republic","Kraus, J (reprint author), Hosp Rudolf & Stefanie Benesov, ENT Dept, Machova 400, Benesov 25630, Czech Republic.","jarkraus@post.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NT-11523]","This study was supported by a grant (NT-11523) from the Internal Grant Agency of the Ministry of Health of the Czech Republic.",null,20,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0001-6489","1651-2251",null,"ACTA OTO-LARYNGOL","Acta Oto-Laryngol.","JAN",2014,134,1,null,null,null,null,88,92,null,"10.3109/00016489.2013.840924",null,5,"Otorhinolaryngology","Otorhinolaryngology","280VK","WOS:000329058700013"]
["J","Veselka, J",null,null,null,"Veselka, Josef",null,null,"Historical Milestones and Progress in the Research on Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy","CANADIAN JOURNAL OF CARDIOLOGY",null,null,"English","Review",null,null,null,null,null,null,"MYOCARDIAL CONTRAST ECHOCARDIOGRAPHY; SUDDEN CARDIAC DEATH; TRANSCORONARY ABLATION; REDUCTION THERAPY; PRACTICE GUIDELINES; GRADIENT REDUCTION; TASK-FORCE; FOLLOW-UP; MULTICENTER; STENOSIS","The first alcohol septal ablation was performed almost 20 years ago in 1994; since then it has become a widely used technique for the treatment of highly symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). It has been shown that postprocedural basal septal shrinking as a result of myocardial scarring is followed by a decrease in left ventricular (LV) obstruction, regression of LV hypertrophy within the first postprocedural year, improvement of diastolic function, and reduction of the degree of mitral regurgitation. All these changes are accompanied by significant symptom relief. Although there is only limited evidence of postprocedural long-term survival, all the studies presented here are consistent in the low incidence of sudden death and similar prognoses with an age-and sex-matched general population. Conversely, we still have to be aware that a certain knowledge gap exists with regard to postprocedural longterm outcome. Therefore, careful selection of patients for alcohol septal ablation is needed, and all patients should be treated in centres offering all therapeutic options.","[Veselka, Josef] Charles Univ Prague, Dept Cardiol, Sch Med 2, Prague, Czech Republic; [Veselka, Josef] Univ Hosp Motol, Prague, Czech Republic","Veselka, J (reprint author), Dept Cardiol, Vuvalu 84, Prague 15000 5, Czech Republic.","veselka.josef@seznam.cz",null,null,"Internal Grant Agency, Ministry of Health, Czech Republic [00064203, NT 11401-5]","J.V. is supported by the project for conceptual development of research organization 00064203 and Grant NT 11401-5 from the Internal Grant Agency, Ministry of Health, Czech Republic.",null,46,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0828-282X","1916-7075",null,"CAN J CARDIOL","Can. J. Cardiol.","JAN",2014,30,1,null,null,null,null,46,51,null,"10.1016/j.cjca.2013.10.001",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","281AQ","WOS:000329072300010"]
["J","Majer, F; Pelak, O; Kalina, T; Vlaskova, H; Dvorakova, L; Honzik, T; Palecek, T; Kuchynka, P; Masek, M; Zeman, J; Elleder, M; Sikora, J",null,null,null,"Majer, Filip; Pelak, Ondrej; Kalina, Tomas; Vlaskova, Hana; Dvorakova, Lenka; Honzik, Tomas; Palecek, Tomas; Kuchynka, Petr; Masek, Martin; Zeman, Jiri; Elleder, Milan; Sikora, Jakub",null,null,"Mosaic tissue distribution of the tandem duplication of LAMP2 exons 4 and 5 demonstrates the limits of Danon disease cellular and molecular diagnostics","JOURNAL OF INHERITED METABOLIC DISEASE",null,null,"English","Article",null,null,null,null,null,null,"MUTATION; GENE; CARDIOMYOPATHY; DEFICIENCY; AUTOPHAGY","Alu-mediated tandem duplication of exons 4 and 5 (g.15815_22218dup6404) is a novel mutation that has been detected in the LAMP2 gene (Xq24). This exon copy number variation was found in two brothers with the typical phenotype of Danon disease, including characteristic myocardial changes on magnetic resonance imaging. The 6.4 kb duplication was identified in both boys by a combination of exon dosage qPCR analyses and duplication breakpoint/junction mapping. The rearrangement results in a plethora of abnormal LAMP2 splicing variants and also in use of likely cryptic splice sites in the 3' terminus of LAMP2 gene. Although we found minute amounts of normal LAMP2B and LAMP2A mRNAs, no protein was detectable in peripheral blood leukocytes by flow cytometry in both brothers. Uniquely, the fraction of LAMP2-deficient granulocytes (0.06 %) assessed by flow cytometry in the patients' asymptomatic mother substantially differed from the random distribution of X-chromosome inactivation in her leukocytes. This discrepancy was later explained by molecular genetic methods as a consequence of mosaic distribution of the mutation in her somatic tissues. Altogether, we report a novel and mosaically distributed exon copy number rearrangement in the LAMP2 gene and comment on obstacles this genetic setup presents to the overall cellular and molecular diagnostic algorithm of Danon disease. Our observations of the mosaicism in the asymptomatic mother suggest that similarly affected females could be a potentially under-diagnosed Danon disease carrier group and that LAMP2 flow cytometry, because of its supreme sensitivity, can be an efficient method for pedigree screening.","[Majer, Filip; Vlaskova, Hana; Dvorakova, Lenka; Elleder, Milan; Sikora, Jakub] Charles Univ Prague, Inst Inherited Metab Disorders, Fac Med 1, Prague 12800 2, Czech Republic; [Majer, Filip; Vlaskova, Hana; Dvorakova, Lenka; Elleder, Milan; Sikora, Jakub] Gen Univ Hosp Prague, Prague 12800 2, Czech Republic; [Pelak, Ondrej; Kalina, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Childhood Leukaemia Invest Prague, Fac Med 2, Prague 12800 2, Czech Republic; [Pelak, Ondrej; Kalina, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Honzik, Tomas; Zeman, Jiri] Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague 12800 2, Czech Republic; [Honzik, Tomas; Palecek, Tomas; Kuchynka, Petr; Masek, Martin; Zeman, Jiri] Gen Univ Hosp, Prague, Czech Republic; [Palecek, Tomas; Kuchynka, Petr] Charles Univ Prague, Dept Med 2, Dept Cardiovasc Med, Fac Med Prague 1, Prague 12800 2, Czech Republic; [Masek, Martin] Charles Univ Prague, Dept Radiol, Fac Med 1, Prague 12800 2, Czech Republic","Sikora, J (reprint author), Charles Univ Prague, Inst Inherited Metab Disorders, Fac Med 1, Ke Karlovu 2, Prague 12800 2, Czech Republic.","jakub.sikora@lf1.cuni.cz",null,null,"MH CR [DRO 00064203, OPPK CZ.2.16/3.1.00/24022];  [0021620806];  [PRVOUK-P24/LF1/3];  [MH CZ-DRO VFN64165];  [PRVOUK-P35/LF1/5]","Milan Elleder, sadly deceased in September 2011 fundamentally contributed to the LAMP2 protein studies and thus to DD diagnosis in the family described in this manuscript. This work was primarily supported by Research Project no. 0021620806 and the PRVOUK-P24/LF1/3 and MH CZ-DRO VFN64165 projects. OP and TK are supported by MH CR, DRO 00064203 and OPPK CZ.2.16/3.1.00/24022 (University Hospital Motol, Prague, Czech Republic) projects. TP and PK are supported by the PRVOUK-P35/LF1/5 project.",null,20,0,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0141-8955","1573-2665",null,"J INHERIT METAB DIS","J. Inherit. Metab. Dis.","JAN",2014,37,1,null,null,null,null,117,124,null,"10.1007/s10545-013-9617-z",null,8,"Endocrinology & Metabolism; Genetics & Heredity","Endocrinology & Metabolism; Genetics & Heredity","281KN","WOS:000329100200015"]
["J","Sousa, SB; Jenkins, D; Chanudet, E; Tasseva, G; Ishida, M; Anderson, G; Docker, J; Ryten, M; Sa, J; Saraiva, JM; Barnicoat, A; Scott, R; Calder, A; Wattanasirichaigoon, D; Chrzanowska, K; Simandlova, M; Van Maldergem, L; Stanier, P; Beales, PL; Vance, JE; Moore, GE",null,null,null,"Sousa, Sergio B.; Jenkins, Dagan; Chanudet, Estelle; Tasseva, Guergana; Ishida, Miho; Anderson, Glenn; Docker, James; Ryten, Mina; Sa, Joaquim; Saraiva, Jorge M.; Barnicoat, Angela; Scott, Richard; Calder, Alistair; Wattanasirichaigoon, Duangrurdee; Chrzanowska, Krystyna; Simandlova, Martina; Van Maldergem, Lionel; Stanier, Philip; Beales, Philip L.; Vance, Jean E.; Moore, Gudrun E.",null,null,"Gain-of-function mutations in the phosphatidylserine synthase 1 (PTDSS1) gene cause Lenz-Majewski syndrome","NATURE GENETICS",null,null,"English","Article",null,null,null,null,null,null,"HAMSTER OVARY CELLS; HYPEROSTOTIC DWARFISM; CUTIS LAXA; PHOSPHATIDYLETHANOLAMINE; EXPRESSION; DYSPLASIA; BIOSYNTHESIS; ANOMALIES; PURIFICATION; INHIBITION","Lenz-Majewski syndrome (LMS) is a syndrome of intellectual disability and multiple congenital anomalies that features generalized craniotubular hyperostosis. By using whole-exome sequencing and selecting variants consistent with the predicted dominant de novo etiology of LMS, we identified causative heterozygous missense mutations in PTDSS1, which encodes phosphatidylserine synthase 1 (PSS1). PSS1 is one of two enzymes involved in the production of phosphatidylserine. Phosphatidylserine synthesis was increased in intact fibroblasts from affected individuals, and end-product inhibition of PSS1 by phosphatidylserine was markedly reduced. Therefore, these mutations cause a gain-of-function effect associated with regulatory dysfunction of PSS1. We have identified LMS as the first human disease, to our knowledge, caused by disrupted phosphatidylserine metabolism. Our results point to an unexplored link between phosphatidylserine synthesis and bone metabolism.","[Sousa, Sergio B.; Ishida, Miho; Moore, Gudrun E.] UCL, Inst Child Hlth, Clin & Mol Genet Unit, London, England; [Sousa, Sergio B.; Sa, Joaquim; Saraiva, Jorge M.] Ctr Hosp & Univ Coimbra, Hosp Pediat, Serv Genet Med, Coimbra, Portugal; [Jenkins, Dagan; Beales, Philip L.] UCL, Inst Child Hlth, Mol Med Unit, London, England; [Chanudet, Estelle; Beales, Philip L.] UCL, Inst Child Hlth, Ctr Translat GOSgene, London, England; [Tasseva, Guergana; Vance, Jean E.] Univ Alberta, Dept Med, Grp Mol & Cell Biol Lipids, Edmonton, AB, Canada; [Anderson, Glenn] Great Ormond St Hosp Sick Children, Dept Histopathol, London WC1N 3JH, England; [Docker, James; Stanier, Philip] UCL, Inst Child Hlth, Neural Dev Unit, London, England; [Ryten, Mina] UCL, Inst Neurol, Reta Lila Weston Inst, London, England; [Ryten, Mina] UCL, Inst Neurol, Dept Mol Neurosci, London, England; [Saraiva, Jorge M.] Univ Coimbra, Fac Med, Univ Clin Pediat, Coimbra, Portugal; [Barnicoat, Angela; Scott, Richard] Great Ormond St Hosp Sick Children, Clin Genet Dept, London, England; [Calder, Alistair] Great Ormond St Hosp Sick Children, Dept Radiol, London, England; [Wattanasirichaigoon, Duangrurdee] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pediat, Bangkok 10400, Thailand; [Chrzanowska, Krystyna] Childrens Mem Hlth Inst, Dept Med Genet, Warsaw, Poland; [Simandlova, Martina] Univ Hosp Motol & Second, Fac Med, Dept Biol & Med Genet, Prague, Czech Republic; [Van Maldergem, Lionel] Univ Franche Comte, Ctr Genet Humaine, F-25030 Besancon, France; [Van Maldergem, Lionel] Univ Franche Comte, Cutis Laxa Study Grp, F-25030 Besancon, France","Sousa, SB (reprint author), UCL, Inst Child Hlth, Clin & Mol Genet Unit, London, England.","sbsousa@chc.min-saude.pt","Stanier, Philip/C-1593-2008","Stanier, Philip/0000-0001-9340-8117","Lung GO Sequencing Project [HL-102923]; Women's Health Initiative (WHI) Sequencing Project [HL-102924]; Broad GO Sequencing Project [HL-102925]; Seattle GO Sequencing Project [HL-102926]; Heart GO Sequencing Project [HL-103010]; Fundacao para a Ciencia e Tecnologia [SFRH/BD/46778/2008]; Biomedical Research Centre of the National Institute for Health Research at Great Ormond Street Hospital for Children NHS Foundation Trust; UCL Institute of Child Health; Wellcome Trust; Faculty of Medicine at Ramathibodi Hospital; Czech research development grant [00064203]; Great Ormond Street Hospital Children's Charity (GOSHCC); WellBeing of Women; GOSHCC; UK Medical Research Council; National Science and Engineering Council of Canada","We are grateful to the individuals with LMS and their families for their participation in this study. We thank P. Clayton and R. Hennekam for their comments on the manuscript, A. Offiah for confirming the radiological diagnosis in subject 1 and W. Emmett for his valuable help in processing raw sequencing data. The authors would like to acknowledge D. Trabzuni and the UK Brain Expression Consortium, the Human Brain Transcriptome project at the Department of Neurobiology at the Yale University School of Medicine NHLBI for the use of data from their public database and the GO Exome Sequencing Project and its ongoing studies, which produced and provided exome variant calls for comparison, including the Lung GO Sequencing Project (HL-102923), the Women's Health Initiative (WHI) Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010). S. B. S. was supported by the Fundacao para a Ciencia e Tecnologia (SFRH/BD/46778/2008). The Centre for Translational Genomics-GOSgene is supported by the Biomedical Research Centre of the National Institute for Health Research at Great Ormond Street Hospital for Children NHS Foundation Trust and UCL Institute of Child Health. D.J. was supported by a Wellcome Trust ViP Award. D. W. is a recipient of Research Career Development Awards from the Faculty of Medicine at Ramathibodi Hospital. M. S. is supported by Czech research development grant 00064203. P. S. is supported by the Great Ormond Street Hospital Children's Charity (GOSHCC). The Fetal Growth and Development research team of G. E. M. is funded by WellBeing of Women, the Wellcome Trust, GOSHCC and the UK Medical Research Council. The research of J.E.V. is supported by the National Science and Engineering Council of Canada.",null,49,0,0,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","1061-4036","1546-1718",null,"NAT GENET","Nature Genet.","JAN",2014,46,1,null,null,null,null,70,"+",null,"10.1038/ng.2829",null,9,"Genetics & Heredity","Genetics & Heredity","281PM","WOS:000329113500016"]
["J","Janousek, J; Kubus, P",null,null,null,"Janousek, Jan; Kubus, Peter",null,null,"What's new in cardiac pacing in children?","CURRENT OPINION IN CARDIOLOGY",null,null,"English","Review",null,null,null,null,null,"cardiac pacing; cardiac resynchronization therapy; children; dyssynchrony; heart failure; implantable cardioverter-defibrillator; leads; pacemaker; sudden cardiac death","CONGENITAL HEART-DISEASE; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; LEFT-VENTRICULAR FUNCTION; ATRIOVENTRICULAR-BLOCK; PEDIATRIC-PATIENTS; RESYNCHRONIZATION THERAPY; LEAD EXTRACTION; YOUNG; SITE; CARDIOMYOPATHY","Purpose of reviewTo review and prioritize data on pediatric cardiac pacing published during the period of the last 18 months.Recent findingsNew approaches to preservation of ventricular function in pediatric pacing are based on recent publications confirming major influence of the ventricular pacing site on left ventricular (LV) function and synchrony. Current studies on epicardial vs. transvenous pacing continue to show survival superiority of endocardial leads. Long-term outcome of epicardial pacing may, however, be positively influenced by technical refinements. Recent amendments of the guidelines for cardiac resynchronization therapy (CRT) in adult idiopathic and ischemic cardiomyopathy are likely to influence CRT indications in children. Novel data give interesting insights into implantable cardioverter-defibrillator (ICD) lead survival as well as the use of ICDs in young patients with hypertrophic cardiomyopathy.SummaryPediatric cardiac pacing and ICD therapy is still a developing field likely to improve with technical refinements, proper lead placement and more specific therapy indications. The current review will give the reader information about recent developments and directions for the future.","[Janousek, Jan; Kubus, Peter] Univ Hosp Motol, Childrens Heart Ctr, Prague 15006, Czech Republic","Janousek, J (reprint author), Univ Hosp Motol, Childrens Heart Ctr, Vuvalu 84, Prague 15006, Czech Republic.","jan.janousek@lfmotol.cuni.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NT 12321-3/2011]; Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital Motol, Prague, Czech Republic [00064203]","The authors were supported by the grant of the Internal Grant Agency of the Ministry of Health of the Czech Republic NT 12321-3/2011 and by Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203.",null,30,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0268-4705","1531-7080",null,"CURR OPIN CARDIOL","Curr. Opin. Cardiol.","JAN",2014,29,1,null,null,null,null,76,82,null,"10.1097/HCO.0000000000000025",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","266BH","WOS:000327996800010"]
["J","Rieken, M; Xylinas, E; Kluth, L; Crivelli, JJ; Chrystal, J; Faison, T; Lotan, Y; Karakiewicz, PI; Holmang, S; Babjuk, M; Fajkovic, H; Seitz, C; Klatte, T; Pycha, A; Bachmann, A; Scherr, DS; Shariat, SF",null,null,null,"Rieken, Malte; Xylinas, Evanguelos; Kluth, Luis; Crivelli, Joseph J.; Chrystal, James; Faison, Talia; Lotan, Yair; Karakiewicz, Pierre I.; Holmang, Sten; Babjuk, Marek; Fajkovic, Harun; Seitz, Christian; Klatte, Tobias; Pycha, Armin; Bachmann, Alexander; Scherr, Douglas S.; Shariat, Shahrokh F.",null,null,"Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder","EUROPEAN UROLOGY",null,null,"English","Article",null,null,null,null,null,"TaG1 urothelial carcinoma of the bladder; Immediate postoperative; intravesical chemotherapy; Outcome assessment; Transurethral resection","IMMEDIATE POSTOPERATIVE INSTILLATION; EORTC RISK TABLES; TRANSURETHRAL RESECTION; EAU GUIDELINES; PROGRESSION; RECURRENCE; CHEMOTHERAPY; SURVEILLANCE; METAANALYSIS; PREVENTS","Background: Few studies have investigated the natural history of TaG1 urothelial carcinoma of the bladder (UCB). Objective: To assess the long-term outcomes of patients with TaG1 UCB and the impact of immediate postoperative instillation of chemotherapy (IPIC). Design, setting, and participants: A retrospective analysis of 1447 patients with TaG1 UCB treated between 1996 and 2007 at eight centers. Median follow-up was 67.2 mo (interquartile range: 67.9). Patients were stratified into three European Association of Urology (EAU) guidelines risk categories; high-risk patients (n = 11) were excluded. Intervention: Transurethral resection of the bladder with or without IPIC. Outcome measurements and statistical analysis: Univariable and multivariable Cox regression models addressed factors associated with disease recurrence, disease progression, death of disease, and any-cause death. Results and limitations: Of the 1436 patients, 601 (41.9%) and 835 (58.1%) were assigned to low-and intermediate-risk categories, respectively. The actuarial estimate of 5-yr recurrence-free survival was 56% (standard error: +/- 1). Advancing age (p = 0.04), tumor > 3 cm (p = 0.001), multiple tumors (p < 0.001), and recurrent tumors (p < 0.001) were independently associated with increased risk of disease recurrence, whereas IPIC was associated with decreased risk (p = 0.001). The actuarial estimate of 5-yr progression-free survival was 95% +/- 1. Advancing age (p < 0.001) and multiple tumors (p = 0.01) were independent risk factors for disease progression. Five-year cancer-specific survival was 98% +/- 1. Advancing age (p = 0.001) and previous recurrence (p = 0.04) were associated with increased risk, whereas female gender (p = 0.02) was associated with decreased risk of cancer-specific mortality. Compared with low-risk patients, intermediate-risk patients were at significantly higher risk of disease recurrence, disease progression, and cancer-specific mortality (all p < 0.01). Limitations include the retrospective design of the study and the lack of a central pathology review. Conclusions: TaG1 UCB patients experience heterogeneous risks of disease recurrence. We validated the EAU guidelines risk stratification in TaG1 UCB patients. IPIC was associated with a reduced risk of disease recurrence in patients with low-and intermediate-risk TaG1 UCB. (C) 2013 European Association of Urology. Published by Elsevier B. V. All rights reserved.","[Rieken, Malte; Xylinas, Evanguelos; Kluth, Luis; Crivelli, Joseph J.; Chrystal, James; Faison, Talia; Scherr, Douglas S.; Shariat, Shahrokh F.] New York Presbyterian Hosp, Dept Urol, Weill Cornell Med Coll, New York, NY USA; [Rieken, Malte; Bachmann, Alexander] Univ Basel Hosp, Dept Urol, CH-4031 Basel, Switzerland; [Xylinas, Evanguelos] Paris Descartes Univ, Cochin Hosp, APHP, Dept Urol, Paris, France; [Kluth, Luis] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Karakiewicz, Pierre I.] Univ Montreal, Dept Urol, Montreal, PQ, Canada; [Holmang, Sten] Sahlgrens Univ Hosp, Dept Urol, Gothenburg, Sweden; [Babjuk, Marek] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, Prague, Czech Republic; [Fajkovic, Harun; Seitz, Christian; Klatte, Tobias; Shariat, Shahrokh F.] Med Univ Vienna, Dept Urol, A-1090 Vienna, Austria; [Pycha, Armin] Cent Hosp Bolzano, Dept Urol, Bolzano, Italy","Shariat, SF (reprint author), Med Univ Vienna, Dept Urol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.","sfshariat@gmail.com",null,null,"Swiss National Science Foundation","Shahrokh F. Shariat certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Malte Rieken has received grant support from the Swiss National Science Foundation. Alexander Bachmann has been a consultant for American Medical Systems, Orion Pharma, Schering, Olympus, and Caris Life Sciences. Shahrokh F. Shariat has been on the advisory board for Ferring Pharmaceutics.",null,24,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838","1873-7560",null,"EUR UROL","Eur. Urol.","JAN",2014,65,1,null,null,null,null,201,209,null,"10.1016/j.eururo.2013.08.034",null,9,"Urology & Nephrology","Urology & Nephrology","262VR","WOS:000327766500037"]
["J","Pietrzak, A; Bartosinska, J; Dybiec, E; Chodorowska, G; Krasowska, D; Hercogova, J; Lotti, T",null,null,null,"Pietrzak, Aldona; Bartosinska, Joanna; Dybiec, Ewa; Chodorowska, Grazyna; Krasowska, Dorota; Hercogova, Jana; Lotti, Torello",null,null,"Hepato-Splenic and Lipid Profile Abnormalities - Do They Exist in Children Affected with Vitiligo?","ACTA DERMATOVENEROLOGICA CROATICA",null,null,"English","Article",null,null,null,null,null,"vitiligo; lipids; liver; spleen; melanocytes","ADIPOSE-TISSUE","Autoimmune disturbances and metabolic abnormalities observed in vitiligo, a disease of still unclear etiology, may provide evidence on the systemic nature of the disease. The aim of the study was to assess functional and morphological parameters of the liver and spleen, as well as the lipid profile in vitiligo-affected children, in order to ascertain whether any metabolic abnormalities or structural changes in these organs accompanied the course of vitiligo. The study included 34 patients with vitiligo hospitalized at the Department of Dermatology at the Medical University of Lublin and a control group of 35 healthy individuals, aged 7-15 years. Children with the active phase of vitiligo and at least 6 month history of vitiligo lesions were studied. Ultrasound examination of the liver and spleen enabled assessment of the size and parenchyma of the organs. Liver and spleen functions were assessed by means of the following additional examinations: blood test, transaminases, protein electrophoresis, lipid profile, autoantibodies, and HCV antibodies. The size of the liver was not significantly different in the vitiligo and control groups. The ultrasonographic pictures of the spleen revealed no abnormalities in organ size and structure. The concentration of HDL-cholesterol was significantly lower, whereas the concentration of LDL-cholesterol was significantly higher in patients with vitiligo than in healthy controls. The value of the LDL/HDL ratio was significantly higher in vitiligo patients. The results of our study indicate lipid disturbances in vitiligo-affected children. Since no structural and functional abnormalities in the liver and spleen were found, it seems likely that lipid disturbances in vitiligo may result from disturbed metabolic processes in the adipose tissue as well as from oxidative stress.","[Pietrzak, Aldona; Bartosinska, Joanna; Chodorowska, Grazyna; Krasowska, Dorota] Med Univ Lublin, Dept Dermatol Venereol & Paediat Dermatol, PL-20080 Lublin, Poland; [Dybiec, Ewa] Med Univ Lublin, Dept Paediat Radiol, PL-20080 Lublin, Poland; [Hercogova, Jana] Charles Univ Prague, Bulovka Univ Hosp, Fac Med 2, Dept Dermatol, Prague, Czech Republic; [Lotti, Torello] Univ Rome, Univ G Marconi, Rome, Italy; [Lotti, Torello] LifeCronos Inst Dermatol, Florence, Italy","Bartosinska, J (reprint author), Med Univ Lublin, Dept Dermatol Venereol & Paediat Dermatol, Radziwillowska 13 St, PL-20080 Lublin, Poland.","aldonkapietrzak@o2.pl",null,null,null,null,null,15,0,0,"CROATION DERMATOVENEROLOGICAL SOC","ZAGREB","ZAGREB UNIV HOSPITAL CTR, UNIV DEPT DERMATOLOGY & VENEROLOGY, SALATA 4, ZAGREB, 10000, CROATIA","1330-027X","1847-6538",null,"ACTA DERMATOVENER CR","Acta Dermatovenerol. Croat.",null,2014,22,1,null,null,null,null,19,25,null,null,null,7,"Dermatology","Dermatology","AI1UF","WOS:000336639800003",24813837]
["J","Stulik, J; Adamek, S; Barna, M; Kasprikova, N; Polanecky, O; Kryl, J",null,null,null,"Stulik, J.; Adamek, S.; Barna, M.; Kasprikova, N.; Polanecky, O.; Kryl, J.",null,null,"Axial Lumbar Interbody Fusion: Prospective Monocentric Study","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"AxiaLIF; lumbar spine; spinal fusion; axial lumbar fixation","BIOMECHANICAL EVALUATION; CLINICAL ARTICLE; FOLLOW-UP; L5-S1; COMPLICATIONS; FIXATION; SPONDYLOLISTHESIS; STABILIZATION; IMPLANT","PURPOSE OF THE STUDY The aim of this prospective study was to evaluate clinical and radiographic results in the patients who underwent L5-S1 fixation using the technique of percutaneous lumbar interbody fusion (AxiaLIF). MATERIAL The study comprised 23 patients, 11 women and 12 men, who ranged from age of 21 to 63 years, with an average of 48.2 years. In all patients surgical posterior stabilisation involving the L5-S1 segment had previously been done. The initial indications for surgery were L5-S1 spondylolisthesis in 20 and L5-S1 spondylosis and stenosis in three patients. METHODS The AxiaLIF technique for L5-S1 fixation was indicated in overweight patients and in those after repeated abdominal or retroperitoneal surgery. A suitable position and shape of the sacrum or lumbosacral junction was another criterion. The patients were evaluated between 26 and 56 months (average, 40.4 months) after primary surgery and, on the basis of CT and radiographic findings, bone union and lumbosacral junction stability were assessed. The clinical outcome was investigated using the ODI and VAS systems and the results were statistically analysed by the Wilcoxon test for paired samples with statistical significance set at a level of 0.05. RESULTS The average VAS value was 6.6 before surgery and, after surgery, 5.2 at three months, 4.2 at six months, 3.1 at one year, 2.9 at two years and 2.1 at three years (n=18). At two post-operative years, improvement in the VAS value by 56.1% was recorded. The average pre-operative ODI value was 25.1; the post-operative values were 17.0 at six months, 12.3 at one year, 10.6 at two years and 8.2 at three years (n=18). At two years after surgery the ODI value improved by 57.8%. To the question concerning their willingness to undergo, with acquired experience, surgery for the same diagnosis, 21 patients (91.3%) gave an affirmative answer. Neither screw breakage nor neurovascular damage or rectal injury was found. CT scans showed complete interbody bone fusion in 22 of the 23 patients (95.6%), In one patient the finding was not clear. Also, posterolateral fusion was achieved in all but one patients (95.6%). A stable L5-S1 segment was found in all patients at all follow-up intervals. The improvement in both VAS and ODI values was statistically significant. DISCUSSION In addition to indications usual in degenerative disc disease, overweight patients, those who had repeated trans- or retroperitoneal surgery in the L5-S1 region or who underwent long posterior fixation to stabilise the caudal margin of instrumentation are indicated for the AxiaLIF procedure. The clinical results of our study are in agreement with the conclusions of other studies and are similar to the outcomes of surgery using other types of fusion or dynamic stabilisation for this diagnosis. The high rate of fusion in our group is affected by use of a rigid transpedicular fixator together with posterolateral arthrodesis. On the other hand, no negative effects of only synthetic bone applied to interbody space were recorded. CONCLUSIONS The percutaneous axial pre-sacral approach to the L5-S1 interbody space with application of a double-treaded screw is another option for the management of this much strained segment. The technique is useful particularly when contraindications for conventional surgical procedures are present in patients with anatomical anomalies, in overweight patients or in those who have had repeated surgery in the region. Clinical outcomes and the success rate for L5-S1 bone fusion are comparable with conventional techniques. Complications are rare but their treatment is difficult.","[Stulik, J.; Barna, M.; Kryl, J.] Spondylochirurg Oddeleni FN Motol, Prague, Czech Republic; [Stulik, J.; Adamek, S.; Polanecky, O.; Kryl, J.] III Chirurg Klin 1 LF UK FN Motol, Prague, Czech Republic; [Kasprikova, N.] Ustav Biofyziky Informatiky 1 LF UK, Prague, Czech Republic","Stulik, J (reprint author), Spondylochirurg Oddeleni FN Motol, Chirurg Klin LF UK FN Motol 3 1, Ortoped Klin & Dospelych, 2 LF UK FN Motol,V Uvalu 84, Prague 15006, Czech Republic.","janstulik@spine.seznam.cz",null,null,null,null,null,18,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","JUN",2014,81,3,null,null,null,null,203,211,null,null,null,9,"Orthopedics","Orthopedics","AK5TW","WOS:000338490300004",24945389]
["J","Sebesta, P; Hach, J; St Tlusty, Z",null,null,null,"Sebesta, P.; Hach, J.; St Tlusty, Z.",null,null,"Middle-Third Clavicle Fracture with Ipsilateral Acromioclavicular Dislocation","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"clavicle fracture; acromioclavicular dislocation","JOINT","A rare case of a middle-third clavicle fracture concurrent with ipsilateral acromioclavicular dislocation in a 46-year-old women who had fallen off her bicycle is presented. The clavicular fracture was managed by locking plate osteosynthesis. The acromioclavicular joint was stabilised by traction osteorrhaphy that was removed at 7 weeks after the procedure. Both the radiographic and clinical outcomes were very good. The epidemiology, aetiology, diagnosis and therapy of this injury are discussed.","[Sebesta, P.; Hach, J.] Nemocnice Melnik, Ortoped Traumatol Oddeleni, Melnik 27601, Czech Republic; [St Tlusty, Z.] Nemocnice Melnik, Chirurg Oddeleni, Melnik 27601, Czech Republic; [Hach, J.] FN Motol, Ortoped Klin 1, Prague, Czech Republic","Sebesta, P (reprint author), Nemocnice Melnik, Ortoped Traumatol Oddeleni, Prazska 528, Melnik 27601, Czech Republic.","petr.sebesta@nemocnicemelnik.cz",null,null,null,null,null,14,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","JUN",2014,81,3,null,null,null,null,238,240,null,null,null,3,"Orthopedics","Orthopedics","AK5TW","WOS:000338490300009",24945394]
["J","Vojtech, Z; Malikova, H; Kramska, L; Anyz, J; Syrucek, M; Zamecnik, J; Liscak, R; Vladyka, V",null,null,null,"Vojtech, Zdenek; Malikova, Hana; Kramska, Lenka; Anyz, Jiri; Syrucek, Martin; Zamecnik, Josef; Liscak, Roman; Vladyka, Vilibald",null,null,"Long-term seizure outcome after stereotactic amygdalohippocampectomy","ACTA NEUROCHIRURGICA",null,null,"English","Article",null,null,null,null,null,"Stereotactic neurosurgery; Temporal lobe epilepsy; Epilepsy surgery; Hippocampal sclerosis","TEMPORAL-LOBE EPILEPSY; SURGICAL-TREATMENT; SURGERY; LOBECTOMY; RESECTION; RADIOSURGERY; EXTENT; MRI; AGE","The aim of the study was to evaluate the long-term seizure outcome and complications after stereotactic radiofrequency amygdalohippocampectomy (SAHE) performed for mesial temporal lobe epilepsy (MTLE). The article describes the cases of 61 patients who were treated at our institution during the period 2004-2010. Mean post-operative follow-up was 5.3 years. At the last postsurgical visit, 43 (70.5 %) patients were Engel Class I, six (9.8 %) Class II, nine (14.8 %) Class III and three (4.9 %) Class IV. The surgery was complicated by four intracranial haematomas. One of them caused acute hydrocephalus and was treated by shunting and resolved without sequelae. After SAHE, we performed open epilepsy surgery and re-thermo lesions in three and two patients, respectively (8.2 %). There were two cases of meningitis which required antibiotic treatment. In six patients psychiatric disorders developed and one of these committed suicide due to postoperative depression. Our results provide preliminary evidence for good long-term seizure outcomes after SAHE. SAHE could be an alternative therapy for MTLE.","[Vojtech, Zdenek] Na Homolce Hosp, Dept Neurol, Prague 150305, Czech Republic; [Kramska, Lenka] Na Homolce Hosp, Dept Psychol, Prague 150305, Czech Republic; [Malikova, Hana] Na Homolce Hosp, Dept Radiol, Prague 150305, Czech Republic; [Syrucek, Martin] Na Homolce Hosp, Dept Pathol, Prague 150305, Czech Republic; [Liscak, Roman; Vladyka, Vilibald] Na Homolce Hosp, Dept Stereotact & Radiat Neurosurg, Prague 150305, Czech Republic; [Anyz, Jiri] Czech Tech Univ, Fac Elect Engn, Dept Cybernet, CR-16635 Prague, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic","Vojtech, Z (reprint author), Na Homolce Hosp, Dept Neurol, Roentgenova 2, Prague 150305, Czech Republic.","zdenek.vojtech@homolka.cz",null,null,"MH CZ - DRO (Nemocnice Na Homolce - NNH) [00023884]","We are indebted to Petr Marusic, MD, PhD and Tomas Nezadal, MD, PhD for providing follow-up information about their patients and Mrs. Carey Vosecka, MA, LLB for help with English editing. Supported by MH CZ - DRO (Nemocnice Na Homolce - NNH, 00023884).",null,36,0,0,"SPRINGER WIEN","WIEN","SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA","0001-6268","0942-0940",null,"ACTA NEUROCHIR","Acta Neurochir.","AUG",2014,156,8,null,null,null,null,1529,1537,null,"10.1007/s00701-014-2126-5",null,9,"Clinical Neurology; Surgery","Neurosciences & Neurology; Surgery","AM3BA","WOS:000339724900017",24875613]
["J","Krhut, J; Mazanec, R; Seeman, P; Mann-Gow, T; Zvara, P",null,null,null,"Krhut, J.; Mazanec, R.; Seeman, P.; Mann-Gow, T.; Zvara, P.",null,null,"Lower urinary tract functions in a series of Charcot-Marie-Tooth neuropathy patients","ACTA NEUROLOGICA SCANDINAVICA",null,null,"English","Article",null,null,null,null,null,"bowel dysfunction; hereditary motor and sensory neuropathy; lower urinary tract dysfunction; questionnaire survey; sexual dysfunction","INTERNATIONAL CONSULTATION; THR124MET MUTATION; DISEASE; INCONTINENCE; HYPERPLASIA; DYSFUNCTION; SYMPTOMS; BLADDER; GENE","ObjectivesTo evaluate lower urinary tract (LUT), bowel, and sexual dysfunctions in a series of patients with Charcot-Marie-Tooth disease (CMT). Materials and MethodsA cohort of 58 patients and 54 healthy controls filled out the International Prostate Symptoms Score (IPSS) and the International Consultation on Incontinence Modular (ICIQ) Questionnaires to assess their symptoms and their impact on the patient's quality of life. ResultsOn the IPSS questionnaire, CMT patients reported a significantly higher score compared with the healthy controls in 7 of 8 questions. The ICIQ-male LUT symptoms questionnaire revealed a significantly higher score in 7 of 26 questions. In the ICIQ-female LUT questionnaire, a significantly higher score was observed in 13 of 24 questions. When assessing the bowel function in CMT patients using the ICIQ-bowel questionnaire, a significantly higher score in 30 of 40 questions was noted. No differences in sexual function were found in either group. ConclusionsThe occurrence of the LUT symptoms and bowel dysfunctions in CMT patients was significantly higher when compared with an age-matched control group. The symptoms were more frequent in female patients. The findings suggest that autonomic dysfunction should be evaluated and included in the diagnostic approach and care of CMT patients.","[Krhut, J.; Zvara, P.] Univ Ostrava, Dept Urol, Ostrava 70852, Czech Republic; [Mazanec, R.] Charles Univ Prague, Sch Med 2, Dept Neurol, Prague, Czech Republic; [Mazanec, R.; Seeman, P.] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Seeman, P.] Charles Univ Prague, Dept Pediat Neurol, Sch Med 2, Prague, Czech Republic; [Mann-Gow, T.; Zvara, P.] Univ Vermont, Dept Surg, Div Urol, Burlington, VT 05405 USA","Krhut, J (reprint author), Univ Ostrava, Dept Urol, 17 Listopadu 1790, Ostrava 70852, Czech Republic.","jan.krhut@fno.cz",null,null,null,null,null,18,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0001-6314","1600-0404",null,"ACTA NEUROL SCAND","Acta Neurol. Scand.","MAY",2014,129,5,null,null,null,null,319,324,null,"10.1111/ane.12176",null,6,"Clinical Neurology","Neurosciences & Neurology","AE1MD","WOS:000333732500008",23937377]
["J","Kutilek, P; Socha, V; Cakrt, O; Svoboda, Z",null,null,null,"Kutilek, Patrik; Socha, Vladimir; Cakrt, Ondrej; Svoboda, Zdenek",null,null,"Differences in evaluation methods of trunk sway using different MoCap systems","ACTA OF BIOENGINEERING AND BIOMECHANICS",null,null,"English","Article",null,null,null,null,null,"trunk; postural stability; camera system; orientation tracker; convex hull; confidence ellipse; pitch versus roll","PARKINSONS-DISEASE; POSTURAL STEADINESS; VESTIBULAR DEFICIT; GAIT TASKS; BALANCE; STABILITY; STANCE; RELIABILITY; NONFALLERS; THERAPY","The position of the trunk can be negatively influenced by many diseases. Several methods can be used for identifying defects in balance and coordination as a result of pathology of the musculoskeletal or nervous system. The aim of this article is to examine the relationship between the three methods used for analysis of trunk sway and compare two fundamentally different MoCap systems. We used a camera system and a 3DOF orientation tracker placed on subject's trunk, and measured inclination (roll) and flexion (pitch) during quiet stance. Ten healthy participants in the study were measured with eyes open and closed. The pitch versus roll plots of trunk were formed, and the area of the convex hull, area of confidence ellipse and total length of the trajectory of the pitch versus roll plot were calculated. The statistical analysis was performed and strong correlation between the area of the convex hull and area of the confidence ellipse was found. Also, the results show moderate correlation between the area of the confidence ellipse and total length of the trace, and moderate correlation between the area of the convex hull and total length of the trace. In general, the different MoCap systems show different areas and lengths but lead to the same conclusions. Statistical analysis of the participants with eyes open and eye closed did not show significant difference in the areas and total lengths of the pitch versus roll plots.","[Kutilek, Patrik; Socha, Vladimir; Cakrt, Ondrej] Czech Tech Univ, Fac Biomed Engn, Kladno 27201, Czech Republic; [Cakrt, Ondrej] Charles Univ Prague, Fac Med 2, Univ Hosp Motol, Prague, Czech Republic; [Svoboda, Zdenek] Palacky Univ Olomouc, Fac Phys Culture, Olomouc, Czech Republic","Socha, V (reprint author), Czech Tech Univ, Fac Biomed Engn, Sitna Sq 3105, Kladno 27201, Czech Republic.","vladimir.socha@fbmi.cvut.cz",null,null,"Charles University [VG20102015002 (2010-2015, MV0/VG)]; SGS CTU Prague [13/091/OHK4/1T/17]","This work was done at FBE CTU and Charles University in the framework of research program No. VG20102015002 (2010-2015, MV0/VG), and project SGS 13/091/OHK4/1T/17 CTU Prague. The authors would like to thank Andrej Madoran, B. A., for helping with translation of this work.",null,37,0,0,"WROCLAW UNIV TECHNOLOGY","WROCLAW","WROCLAW UNIV TECHNOLOGY, MECHANICAL DEPT, WYBRZEZE WYSPIANSKIEGO 27, WROCLAW, 50-370, POLAND","1509-409X",null,null,"ACTA BIOENG BIOMECH","Acta Bioeng. Biomech.",null,2014,16,2,null,null,null,null,85,94,null,"10.5277/abb140210",null,10,"Biophysics; Engineering, Biomedical","Biophysics; Engineering","AN1EG","WOS:000340324900010",25087580]
["J","Zieg, J",null,null,null,"Zieg, Jakub",null,null,"Evaluation and management of hyponatraemia in children","ACTA PAEDIATRICA",null,null,"English","Review",null,null,null,null,null,"Children; Hyponatraemia; Management; Renal salt-wasting syndrome; Syndrome of inappropriate antidiuretic hormone secretion","ANTIDIURETIC-HORMONE SECRETION; ANTI-DIURETIC HORMONE; URIC-ACID CLEARANCE; INAPPROPRIATE SECRETION; WATER RESTRICTION; PULMONARY-EDEMA; RESET OSMOSTAT; CEREBRAL EDEMA; PATHOPHYSIOLOGY; DIAGNOSIS","AimPaediatric hyponatraemia is usually caused by an excess of antidiuretic hormone and may lead to serious neurological complications. It is challenging for clinicians to differentiate between conditions causing excess water and salt loss. This review analyses individual causes of hyponatraemia and focuses on optimal diagnostic algorithms and treatment strategies. ConclusionCorrect evaluation of hyponatraemia requires proper understanding of the aetiology and appropriate management calls for a detailed history, physical examination and specific laboratory investigations.","[Zieg, Jakub] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Paediat, Prague, Czech Republic","Zieg, J (reprint author), Motol Univ Hosp, Dept Paediat, V Uvalu 84, Prague 15006 5, Czech Republic.","jakubzieg@hotmail.com",null,null,"project (Ministry of Health, Czech Republic) for conceptual development of research organisation (University Hospital Motol, Prague, Czech Republic) [00064203]","This work was supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organisation 00064203 (University Hospital Motol, Prague, Czech Republic). I thank Megan Shimota for her help with the preparation of the manuscript.",null,56,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0803-5253","1651-2227",null,"ACTA PAEDIATR","Acta Paediatr.","OCT",2014,103,10,null,null,null,null,1027,1034,null,"10.1111/apa.12705",null,8,"Pediatrics","Pediatrics","AQ4HD","WOS:000342753400014",24862500]
["J","Bukovjan, K; Toman, A; Kutlvasr, K; Marada, P; Kodet, R; Slama, P; Krikava, L",null,null,null,"Bukovjan, Karel; Toman, Ales; Kutlvasr, Karel; Marada, Petr; Kodet, Roman; Slama, Petr; Krikava, Libor",null,null,"Contents of chemical elements in tissues of European badger (Meles meles) affected by ovarian tumour - a case report","ACTA VETERINARIA BRNO",null,null,"English","Article",null,null,null,null,null,"Heavy metals; hazardous elements; cancerous tissue; ovary","METALLOTHIONEINS","Higher concentrations of chemical elements in animal tissues may be associated with tumours and may explain cancerogenity. In this study, selected chemical elements were measured in the liver, kidneys, muscles and tissues affected by tumour in a dead female European badger (Meles meles) with a metastatic ovarian carcinoma. Atomic absorption spectroscopy was used for the assessment of concentrations of arsenic, cadmium, chromium, copper, lead, and zinc. AMA 254 analyser was used for the assessment of mercury concentration. Concentrations of heavy metals such as As, Cr, Cu, Zn, Cd, Pb, and total Hg amounted to 0.031, 0.16, 7.74, 44.54, 0.67, 0.67, and 0.36 mg.kg(-1) in the tumour tissue. This is the first detection of ovarian tumour in a European badger (Meles meles) which was systematically examined for the presence of chemical elements.","[Bukovjan, Karel] Forestry & Game Management Res Inst, Strnady, Czech Republic; [Toman, Ales] Czech Univ Life Sci Prague, Dept Ecol, Prague, Czech Republic; [Kutlvasr, Karel; Krikava, Libor] Czech Univ Life Sci Prague, Dept Game Management & Wildlife Biol, Prague, Czech Republic; [Marada, Petr] Mendel Univ Brno, Dept Agr Food & Environm Engn, Brno, Czech Republic; [Kodet, Roman] Charles Univ Prague, Prague, Czech Republic; [Kodet, Roman] Univ Hosp Motol, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Slama, Petr] Mendel Univ Brno, Dept Anim Morphol Physiol & Genet, Brno, Czech Republic","Kutlvasr, K (reprint author), Czech Univ Life Sci, Dept Game Management & Wildlife Biol, Kamycka 129165 21, Prague 6, Czech Republic.","kutlvasr@fld.czu.cz",null,null,null,null,null,18,0,0,"VETERINARNI A FARMACEUTICKA UNIVERZITA BRNO","BRNO","PALACKEHO 1-3, BRNO CS-612 42, CZECH REPUBLIC","0001-7213","1801-7576",null,"ACTA VET BRNO","Acta Vet. BRNO",null,2014,83,2,null,null,null,null,139,143,null,"10.2754/avb201483020139",null,5,"Veterinary Sciences","Veterinary Sciences","AL4EV","WOS:000339086600012"]
["J","Veselka, J",null,null,null,"Veselka, Josef",null,null,"Pre-percutaneous coronary intervention statin therapy: Is it necessary?","AMERICAN HEART JOURNAL",null,null,"English","Letter",null,null,null,null,null,null,null,null,"Charles Univ Prague, Univ Hosp Motol, Dept Cardiol, Sch Med 2, Prague, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Cardiol, Sch Med 2, Prague, Czech Republic.","veselka.josef@seznam.cz",null,null,null,null,null,6,0,0,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0002-8703","1097-5330",null,"AM HEART J","Am. Heart J.","AUG",2014,168,2,null,null,null,null,null,null,"168:e11","10.1016/j.ahj.2014.06.001",null,1,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AM9NG","WOS:000340207700003",25066564]
["J","Stepan-Buksakowska, IL; Accurso, JM; Diehn, FE; Huston, J; Kaufmann, TJ; Luetmer, PH; Wood, CP; Yang, X; Blezek, DJ; Carter, R; Hagen, C; Horinek, D; Hejcl, A; Rocek, M; Erickson, BJ",null,null,null,"Stepan-Buksakowska, I. L.; Accurso, J. M.; Diehn, F. E.; Huston, J.; Kaufmann, T. J.; Luetmer, P. H.; Wood, C. P.; Yang, X.; Blezek, D. J.; Carter, R.; Hagen, C.; Horinek, D.; Hejcl, A.; Rocek, M.; Erickson, B. J.",null,null,"Computer-Aided Diagnosis Improves Detection of Small Intracranial Aneurysms on MRA in a Clinical Setting","AMERICAN JOURNAL OF NEURORADIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"MAGNETIC-RESONANCE ANGIOGRAPHY; MULTIPLE ANEURYSMS; NATURAL-HISTORY; ACCURACY; IMAGES; PERFORMANCE; PREVALENCE; VALIDATION; OBSERVER; SINGLE","BACKGROUND AND PURPOSE: MRA is widely accepted as a noninvasive diagnostic tool for the detection of intracranial aneurysms, but detection is still a challenging task with rather low detection rates. Our aim was to examine the performance of a computer-aided diagnosis algorithm for detecting intracranial aneurysms on MRA in a clinical setting. MATERIALS AND METHODS: Aneurysm detectability was evaluated retrospectively in 48 subjects with and without computer-aided diagnosis by 6 readers using a clinical 3D viewing system. Aneurysms ranged from 1.1 to 6.0 mm (mean = 3.12 mm, median = 2.50 mm). We conducted a multireader, multicase, double-crossover design, free-response, observer-performance study on sets of images from different MRA scanners by using DSA as the reference standard. Jackknife alternative free-response operating characteristic curve analysis with the figure of merit was used. RESULTS: For all readers combined, the mean figure of merit improved from 0.655 to 0.759, indicating a change in the figure of merit attributable to computer-aided diagnosis of 0.10 (95% Cl, 0.03-0.18), which was statistically significant (F-1,F-47 = 7.00, P = .011). Five of the 6 radiologists had improved performance with computer-aided diagnosis, primarily due to increased sensitivity. CONCLUSIONS: In conditions similar to clinical practice, using computer-aided diagnosis significantly improved radiologists' detection of intracraniat DSA-confirmed aneurysms of <= 6 mm.","[Stepan-Buksakowska, I. L.; Diehn, F. E.; Huston, J.; Kaufmann, T. J.; Luetmer, P. H.; Wood, C. P.; Erickson, B. J.] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA; [Carter, R.; Hagen, C.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA; [Yang, X.; Blezek, D. J.] Mayo Clin, Dept Informat Serv, Rochester, MN 55905 USA; [Stepan-Buksakowska, I. L.; Horinek, D.; Hejcl, A.] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Stepan-Buksakowska, I. L.; Rocek, M.] Charles Univ Prague, Dept Radiol, Fac Med 2, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; [Accurso, J. M.] Mayo Clin, Dept Radiol, Jacksonville, FL 32224 USA; [Horinek, D.; Hejcl, A.] Masaryk Hosp, Dept Neurosurg, Usti Nad Labem, Czech Republic; [Horinek, D.] Cent Mil Hosp, Dept Neurosurg, Prague, Czech Republic","Erickson, BJ (reprint author), Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA.","bje@mayo.edu",null,null,"European Regional Development Fund; Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; European Social Fund; State Budget of the Czech Republic [CZ.1.07/2.3.00/20.0117]","This work was supported by European Regional Development Fund, Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123), the European Social Fund, and the State Budget of the Czech Republic, within the project Young Talent Incubator II (reg. no. CZ.1.07/2.3.00/20.0117).",null,33,0,0,"AMER SOC NEURORADIOLOGY","DENVILLE","PO BOX 3000, DENVILLE, NJ 07834-9349 USA","0195-6108","1936-959X",null,"AM J NEURORADIOL","Am. J. Neuroradiol.","OCT",2014,35,10,null,null,null,null,1897,1902,null,"10.3174/ajnr.A3996",null,6,"Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging","Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging","AQ5YY","WOS:000342885700010"]
["J","May, M; Brookman-May, S; Burger, M; Gilfrich, C; Fritsche, HM; Rink, M; Chun, F; Fisch, M; Roghmann, F; Noldus, J; Mayr, R; Pycha, A; Novotny, V; Wirth, M; Vallo, S; Haferkamp, A; Roigas, J; Brisuda, A; Stredele, R; Volkmer, B; Dechet, C; Schnabel, M; Denzinger, S; Stief, CG; Bastian, PJ; Aziz, A",null,null,null,"May, Matthias; Brookman-May, Sabine; Burger, Maximilian; Gilfrich, Christian; Fritsche, Hans-Martin; Rink, Michael; Chun, Felix; Fisch, Margit; Roghmann, Florian; Noldus, Joachim; Mayr, Roman; Pycha, Armin; Novotny, Vladimir; Wirth, Manfred; Vallo, Stefan; Haferkamp, Axel; Roigas, Jan; Brisuda, Antonin; Stredele, Regina; Volkmer, Bjoern; Dechet, Christopher; Schnabel, Marco; Denzinger, Stefan; Stief, Christian G.; Bastian, Patrick J.; Aziz, Atiqullah",null,null,"Concomitant Seminal Vesicle Invasion in pT4a Urothelial Carcinoma of the Bladder with Contiguous Prostatic Infiltration is an Adverse Prognosticator for Cancer-Specific Survival after Radical Cystectomy","ANNALS OF SURGICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"TRANSITIONAL-CELL-CARCINOMA; INVOLVEMENT","To evaluate the prognostic value of concomitant seminal vesicle invasion (cSVI) in patients with urothelial carcinoma of the bladder (UCB) and contiguous prostatic stromal infiltration in a large cystectomy series. A total of 385 patients with UCB and contiguous prostatic infiltration comprised our study. Patients were divided in two groups according to cSVI. Median follow-up was 36 months (interquartile range 11-74); the primary end point was cancer-specific mortality. The prognostic impact of cSVI was evaluated using multivariable Cox regression analysis. The predictive accuracy was assessed by a receiver operating characteristic analysis. A total of 229 patients (59.5 %) without cSVI comprised group A, and 156 patients (40.5 %) with cSVI comprised group B. Positive lymph nodes (63 vs. 44 %, p < 0.001) and positive surgical margins (34 % vs. 14 %, p < 0.001) were more common in patients with cSVI. The 5- and 10-year cancer-specific survival rates were 41 % and 32 % (group A) and 21 and 17 % (group B) (p < 0.001). In multivariable analysis, pathological nodal stage (hazard ratio [HR] 2.19, p < 0.001), soft tissue surgical margin (HR 1.57, p = 0.010), clinical tumor stage (HR 1.46, p = 0.010), adjuvant chemotherapy (HR 0.40, p < 0.001), and cSVI (HR 1.69, p < 0.001) independently impacted cancer-specific mortality. The c-indices of the multivariable models with and without inclusion of cSVI were 0.658 (95 % confidence interval 0.60-0.71) and 0.635 (95 % confidence interval 0.58-0.69), respectively, resulting in a predictive accuracy gain of 2.3 % (p = 0.002). In patients with UCB and prostatic stromal invasion, cSVI adversely affected cancer-specific survival compared to patients without cSVI. The inclusion of cSVI significantly improved the predictive accuracy of our multivariable model regarding survival.","[May, Matthias; Gilfrich, Christian] St Elisabeth Med Ctr Straubing, Dept Urol, Straubing, Germany; [Brookman-May, Sabine; Stief, Christian G.] Univ Munich, Dept Urol, Munich, Germany; [Burger, Maximilian; Fritsche, Hans-Martin; Schnabel, Marco; Denzinger, Stefan] Univ Regensburg, Caritas St Josef Med Ctr, Dept Urol, D-93053 Regensburg, Germany; [Rink, Michael; Chun, Felix; Fisch, Margit; Aziz, Atiqullah] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany; [Roghmann, Florian; Noldus, Joachim] Ruhr Univ Bochum, Marienhosp Herne, Dept Urol, Herne, Germany; [Mayr, Roman; Pycha, Armin] Gen Hosp Bolzano, Dept Urol, Bolzano, Italy; [Novotny, Vladimir; Wirth, Manfred] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Urol, D-01062 Dresden, Germany; [Vallo, Stefan; Haferkamp, Axel] Goethe Univ Frankfurt, Dept Urol, D-60054 Frankfurt, Germany; [Roigas, Jan] Vivantes Med Ctr Friedrichshain & Urban, Dept Urol, Berlin, Germany; [Brisuda, Antonin] Fac Med 2, Dept Urol, Prague, Czech Republic; [Brisuda, Antonin] Motol Univ Hosp, Prague, Czech Republic; [Stredele, Regina; Volkmer, Bjoern] Kassel Med Ctr, Dept Urol, Kassel, Germany; [Dechet, Christopher] Univ Utah, Huntsman Canc Inst, Div Urol, Salt Lake City, UT USA; [Bastian, Patrick J.] Paracelsus Med Ctr Golzheim, Dept Urol, Dusseldorf, Germany","Aziz, A (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany.","atiqullah.aziz@gmail.com",null,null,null,null,null,15,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1068-9265","1534-4681",null,"ANN SURG ONCOL","Ann. Surg. Oncol.","NOV",2014,21,12,null,null,null,null,4034,4040,null,"10.1245/s10434-014-3827-y",null,7,"Oncology; Surgery","Oncology; Surgery","AQ8OD","WOS:000343085600052",24895114]
["J","Tesfaye, H; Branova, R; Klapkova, E; Prusa, R; Janeckova, D; Riha, P; Sedlacek, P; Keslova, P; Malis, J",null,null,null,"Tesfaye, Hndie; Branova, Romana; Klapkova, Eva; Prusa, Richard; Janeckova, Daniela; Riha, Petr; Sedlacek, Petr; Keslova, Petra; Malis, Josef",null,null,"The importance of Therapeutic Drug Monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for Hematopoietic Stem Cell Transplantation (HSCT) in children","ANNALS OF TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"High-Dose Busulfan Target AUC; Pediatric HSCT; Limited Sampling Strategy TDM","BONE-MARROW-TRANSPLANTATION; GLUTATHIONE-S-TRANSFERASE; DAILY INTRAVENOUS BUSULFAN; HIGH-DOSE BUSULFAN; PEDIATRIC-PATIENTS; ADULT PATIENTS; IV BUSULFAN; PHASE-I; GENETIC POLYMORPHISMS; BU PHARMACOKINETICS","Background: Series of observations indicate PK/PD variability challenging the accuracy of the body-weight based busulfan (Bu) dosing schedule for (HSCT) conditioning therapy. The purpose of this communication is to describe the frequency of dose changes in initially body-weight-based fixed IV Bu dose and to emphasize the importance of TDM. Material/Methods: Sixty-two children (ages 2 months-18 years) were treated with IV busulfan doses based on body weight for myeloablation. TDM utilizing a limited sample strategy (trough concentration immediately before the 5th dose, followed by samples immediately after the end of the 2-h infusion peak, 4 h, and 6 h from initiation of the infusion) was performed in 46 of 62 subjects. Busulfan concentrations were determined by high-performance liquid chromatography (HPLC). AUC was calculated according to the trapezoidal rule. Results: We observed trough levels of 25-1244 mu g/L, peak levels of 849-4586 mu g/L, and AUC of 2225-12818 mu g/L.h following body weight-based high-dose busulfan. The doses were changed in 54% of cases. AUC in 5 of 9 patients with VOD were within target, in 3 patients AUC was higher, and in 1 patient AUC was lower. One of the 2 patients with neurotoxicity had higher AUC. Engraftment was 100%, but relapse occurred in 25% of cases. Conclusions: Our results demonstrate that even with IV busulfan, intra-individual PK/PD variability is challenging. Although AUC does not necessarily correspond with outcomes (due to the role of other factors the fact that doses were changed in 54% of cases underlines the importance of TDM.","[Tesfaye, Hndie; Branova, Romana; Klapkova, Eva; Prusa, Richard] Charles Univ Prague, Fac Hosp Motol, Dept Med Chem & Clin Biochem, Div Clin Pharmacol, Prague, Czech Republic; [Janeckova, Daniela; Riha, Petr; Sedlacek, Petr; Keslova, Petra; Malis, Josef] Charles Univ Prague, Fac Hosp Motol, Fac Med 2, Dept Paediat Hematol & Oncol, Prague, Czech Republic","Tesfaye, H (reprint author), Charles Univ Prague, Fac Hosp Motol, Dept Med Chem & Clin Biochem, Div Clin Pharmacol, Prague, Czech Republic.","hundie.tesfaye@medicon.cz",null,null,"Ministry of Health [00064203]; Faculty Hospital in Motol, Prague, Czech Republic","This study was supported as a part of the project of the Ministry of Health 00064203 for conceptual development of research organization and by the Faculty Hospital in Motol, Prague, Czech Republic.",null,65,0,0,"INT SCIENTIFIC LITERATURE, INC","SMITHTOWN","361 FOREST LANE, SMITHTOWN, NY 11787 USA","1425-9524",null,null,"ANN TRANSPL","Ann. Transpl.","MAY 9",2014,19,null,null,null,null,null,214,224,null,null,null,11,"Surgery; Transplantation","Surgery; Transplantation","AQ7ER","WOS:000342975900001",24811685]
["J","Zabrodsky, M; Lukes, P; Lukesova, E; Boucek, J; Plzak, J",null,null,null,"Zabrodsky, Michal; Lukes, Petr; Lukesova, Eva; Boucek, Jan; Plzak, Jan",null,null,"The Role of Narrow Band Imaging in the Detection of Recurrent Laryngeal and Hypopharyngeal Cancer after Curative Radiotherapy","BIOMED RESEARCH INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,null,"SQUAMOUS-CELL CARCINOMA; NECK-CANCER; ENDOSCOPIC EVALUATION; PHARYNGEAL CARCINOMA; RADIATION-THERAPY; TUMOR RECURRENCE; HEAD; RADIONECROSIS; SURVEILLANCE","Narrow band imaging is considered a significant improvement in the possibility of detecting early mucosal lesion of the upper aerodigestive tract. Early detection of mucosal neoplastic lesions is of utmost importance for patients survival. There is evidence that, especially in patients previously treated by means of curative radiotherapy or chemoradiotherapy, the early detection rate of recurrent disease is quite low. The aim of this study was to prove whether the videoendoscopy coupled with NBI might help detect recurrent or secondary tumors of the upper aerodigestive tract. 66 patients previously treated by means of RT or CRT with curative intent were enrolled in the study. All patients underwent transnasal flexible videoendoscopy with NBI mode under local anesthesia. When a suspicious lesion was identified in an ambulatory setting, its nature was proved histologically. Many of these changes were not identifiable by means of conventional white light (WL) endoscopy. The accuracy, sensitivity, specificity, and positive and negative predictive value of the method are very high (88%, 92%, 76%, 96%, and 91%, resp.). Results demonstrate that outpatient transnasal endoscopy with NBI is an excellent method for the follow-up of patients with carcinomas of the larynx and the hypopharynx primarily treated with radiotherapy.","[Zabrodsky, Michal; Lukes, Petr; Lukesova, Eva; Boucek, Jan; Plzak, Jan] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Prague 15006 5, Czech Republic","Zabrodsky, M (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, V Uvalu 84, Prague 15006 5, Czech Republic.","michal.zabrodsky@fnmotol.cz",null,null,"Charles University [PRVOUK/LF1/P27]; Specific University Research (SVV UK) [266513]; Ministry of Health of the Czech Republic, IGA MZ CR [11544]; UNCE [204013]","The authors are grateful for funding by Charles University, Projects PRVOUK/LF1/P27, Specific University Research (SVV UK) 266513, and UNCE 204013, and the Ministry of Health of the Czech Republic, IGA MZ CR no. 11544.",null,23,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6133","2314-6141",null,"BIOMED RES INT","Biomed Res. Int.",null,2014,null,null,null,null,null,null,null,null,175398,"10.1155/2014/175398",null,9,"Biotechnology & Applied Microbiology; Medicine, Research & Experimental","Biotechnology & Applied Microbiology; Research & Experimental Medicine","AL0ZG","WOS:000338855000001"]
["J","Lukes, P; Zabrodsky, M; Lukesova, E; Chovanec, M; Astl, J; Betka, JA; Plzak, J",null,null,null,"Lukes, Petr; Zabrodsky, Michal; Lukesova, Eva; Chovanec, Martin; Astl, Jaromir; Betka, Jaroslav A.; Plzak, Jan",null,null,"The Role of NBI HDTV Magnifying Endoscopy in the Prehistologic Diagnosis of Laryngeal Papillomatosis and Spinocellular Cancer","BIOMED RESEARCH INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,null,"ANGIOGENESIS","Narrow band imaging (NBI) HDTV (high definition television) magnifying endoscopy is considered to be superior for the accurate display of the microvascular patterns of superficial mucosal lesions. Observation of changes in intraepithelial papillary capillary loops (IPCL) can help distinguish benign from malignant lesions as part of an \"optical biopsy.\" However, IPCL changes in papillomas may be mistaken for spinocellular cancer (SCC). The aim of the study was to determine whether observing microvascular changes alone is sufficient for discriminating between laryngeal SCC and papillomatosis. An additional aim was to identify associated characteristics that could clarify the diagnosis. The study included 109 patients with a suspected laryngeal tumor or papilloma. HDTV NBI magnifying endoscopy was performed during direct laryngoscopy. It was possible to visualize IPCL changes in 82 out of 109 patients (75.2%). In 71 (86.6%) patients, the diagnosis was correctly determined. In 4 (4.9%) cases, the diagnosis of SCC was expressed on the basis of finding pathologic IPCL, but histology did not demonstrate malignancy. To achieve a correct diagnosis using HDTV NBI magnifying endoscopy, it is important not only to observe changes in the shape of IPCL but also to note possible papillary structures with central-axis capillaries typical of papillomatosis.","[Lukes, Petr] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague 15006 5, Czech Republic","Lukes, P (reprint author), Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.lukes@fnmotol.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NT11544]; MH CZ-DRO; University Hospital Motol, Prague, Czech Republic [00064203];  [PRVOUK P27];  [UNCE 204013];  [SVV 266513]","This paper was supported by Grants nos. NT11544 of the Internal Grant Agency of the Ministry of Health of the Czech Republic and by MH CZ-DRO, University Hospital Motol, Prague, Czech Republic, 00064203, PRVOUK P27, UNCE 204013, and SVV 266513.",null,16,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6133","2314-6141",null,"BIOMED RES INT","Biomed Res. Int.",null,2014,null,null,null,null,null,null,null,null,285486,"10.1155/2014/285486",null,7,"Biotechnology & Applied Microbiology; Medicine, Research & Experimental","Biotechnology & Applied Microbiology; Research & Experimental Medicine","AK0LC","WOS:000338103300001"]
["J","Lisy, J; Groh, D; Chovanec, M; Markova, M; Suchanek, V; Polaskova, P; Travnicek, M",null,null,null,"Lisy, J.; Groh, D.; Chovanec, M.; Markova, M.; Suchanek, V.; Polaskova, P.; Travnicek, M.",null,null,"Balloon Dilatation of Pediatric Subglottic Laryngeal Stenosis during the Artificial Apneic Pause: Experience in 5 Children","BIOMED RESEARCH INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,null,"DILATION; LARYNGOPLASTY","Introduction. Balloon dilatation is a method of choice for treatment of laryngeal stenosis in children. The aim of procedure in apneic pause is to avoid new insertion of tracheostomy cannula. Patients and Methods. The authors performed balloon dilatation of subglottic laryngeal strictures (SGS) in 5 children (3 girls and 2 boys) without tracheotomy. Two of them with traumatic and inflammatory SGS had a tracheal cannula removed in the past. The other 3 children with postintubation SGS had never had a tracheostomy before. The need for tracheostomy due to worsening stridor was imminent for all of them. Results. The total of seven laryngeal dilatations by balloon esophagoplasty catheter in apneic pause was performed in the 5 children. The procedure averted the need for tracheostomy placement in 4 of them (80%). Failure of dilatation in girl with traumatic stenosis and concomitant severe obstructive lung disease led to repeated tracheostomy. Conclusion. Balloon dilatation of laryngeal stricture could be done in the absence of tracheostomy in apneic pause. Dilatation averted threatening tracheostomy in all except one case. Early complication after the procedure seems to be a negative prognostic factor for the outcome of balloon dilatation.","[Lisy, J.; Suchanek, V.; Polaskova, P.] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Imaging Methods, Prague 15006, Czech Republic; [Groh, D.; Markova, M.] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Children ENT Dept, Prague 15006, Czech Republic; [Chovanec, M.] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Otorhinolaryngol & Head Neck Surg, Prague 15006, Czech Republic; [Travnicek, M.] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Anesthesiol, Prague 15006, Czech Republic","Lisy, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Imaging Methods, Prague 15006, Czech Republic.","jilisy@yahoo.com",null,null,null,null,null,9,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6133","2314-6141",null,"BIOMED RES INT","Biomed Res. Int.",null,2014,null,null,null,null,null,null,null,null,397295,"10.1155/2014/397295",null,4,null,null,"AJ6VQ","WOS:000337834800001"]
["J","Betka, J; Zverina, E; Balogova, Z; Profant, O; Skrivan, J; Kraus, J; Lisy, J; Syka, J; Chovanec, A",null,null,null,"Betka, Jan; Zverina, Eduard; Balogova, Zuzana; Profant, Oliver; Skrivan, Jiri; Kraus, Josef; Lisy, Jiri; Syka, Josef; Chovanec, Andmartin",null,null,"Complications of Microsurgery of Vestibular Schwannoma","BIOMED RESEARCH INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,null,"ACOUSTIC NEUROMA SURGERY; CEREBROSPINAL-FLUID LEAK; FACIAL-NERVE OUTCOMES; ANGLE TUMOR SURGERY; MIDDLE FOSSA APPROACH; TRANSLABYRINTHINE APPROACH; RETROSIGMOID APPROACH; HEARING PRESERVATION; CRANIAL FOSSA; SURGICAL-MANAGEMENT","Background. The aim of this study was to analyze complications of vestibular schwannoma (VS) microsurgery. Material and Methods. A retrospective study was performed in 333 patients with unilateral vestibular schwannoma indicated for surgical treatment between January 1997 and December 2012. Postoperative complications were assessed immediately after VS surgery as well as during outpatient followup. Results. In all 333 patients microsurgical vestibular schwannoma (Koos grade 1: 12, grade 2: 34, grade 3: 62, and grade 4: 225) removal was performed. The main neurological complication was facial nerve dysfunction. The intermediate and poor function (HB III-VI) was observed in 124 cases (45%) immediately after surgery and in 104 cases (33%) on the last followup. We encountered disordered vestibular compensation in 13%, permanent trigeminal nerve dysfunction in 1%, and transient lower cranial nerves (IX-XI) deficit in 6%. Nonneurological complications included CSF leakage in 63% (lateral/medial variant: 99/1%), headache in 9%, and intracerebral hemorrhage in 5%. We did not encounter any case of meningitis. Conclusions. Our study demonstrates that despite the benefits of advanced high-tech equipment, refined microsurgical instruments, and highly developed neuroimaging technologies, there are still various and significant complications associated with vestibular schwannomas microsurgery.","[Betka, Jan; Zverina, Eduard; Balogova, Zuzana; Profant, Oliver; Skrivan, Jiri; Chovanec, Andmartin] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Fac Hosp Motol, Prague 15006 5, Czech Republic; [Balogova, Zuzana; Profant, Oliver; Syka, Josef] Acad Sci Czech Republic, Dept Auditory Neurosci, Prague 14220 4, Czech Republic; [Kraus, Josef] Charles Univ Prague, Dept Pediat Neurol, Fac Med 2, Fac Hosp Motol, Prague 15006 5, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Dept Imaging Methods, Fac Med 2, Fac Hosp Motol, Prague 15006 5, Czech Republic","Betka, J (reprint author), Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Fac Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.betka@fnmotol.cz",null,null,"Ministry of Health of the Czech Republic (IGA MZ CR) [NT/11543-6 a NT/12459-5]; Charles University [PRVOUK/LF1/P27]; Specific University Research (SVV UK) [266513]; UNCE [204013]","The authors are grateful for funding by the Ministry of Health of the Czech Republic (IGA MZ CR NT/11543-6 a NT/124595) and Charles University (Projects PRVOUK/LF1/P27, Specific University Research (SVV UK) 266513, and UNCE 204013).",null,81,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6133","2314-6141",null,"BIOMED RES INT","Biomed Res. Int.",null,2014,null,null,null,null,null,null,null,null,315952,"10.1155/2014/315952",null,10,"Biotechnology & Applied Microbiology; Medicine, Research & Experimental","Biotechnology & Applied Microbiology; Research & Experimental Medicine","AJ1GT","WOS:000337404700001"]
["J","Boucek, J; Zabrodsky, M; Kuchar, M; Fanta, O; Skrivan, J; Betka, J",null,null,null,"Boucek, Jan; Zabrodsky, Michal; Kuchar, Martin; Fanta, Ondrej; Skrivan, Jiri; Betka, Jan",null,null,"A New Strategy for the Surgical Management of RLN Infiltrated by Well-Differentiated Thyroid Carcinoma","BIOMED RESEARCH INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,null,"RECURRENT LARYNGEAL NERVE; REGULATORY T-CELLS; PROGNOSTIC SCORING SYSTEM; NEEDLE-ASPIRATION BIOPSY; RETROSPECTIVE ANALYSIS; CANCER; RESECTION; EXTENSION; TRACHEA; MICROCARCINOMA","Well-differentiated thyroid carcinoma (WDTC) represents the most common endocrine malignancy. Despite excellent prognoses exceeding 90% in 10-year follow-up, there are clinically controversial issues. One of these is extrathyroidal tumour extension invading recurrent laryngeal nerve (RLN). The spread outside of the thyroid parenchyma and invasion to the surrounding structures, classified as always T4a, are the most important negative prognostic factor for the WDTC. Conversely, resection of the RLN leads to vocal cord paralysis with hoarseness, possible swallowing problems, and finally decreased quality of life. We propose a new algorithm for intraoperative management based on the MACIS classification, which would allow swift status evaluation pre/intraoperatively and consider a possibility to preserve the infiltrated RLN without compromising an oncological radicality. In the case of a preoperative vocal cord paralysis (VCP) and confirmation of the invasive carcinoma, a resection of the RLN and the nerve graft reconstruction are indicated. Preoperatively, unaffected vocal cord movement and intraoperatively detected RLN infiltration by the invasive WDTC require an individual assessment of the oncological risk by the proposed algorithm. Preservation of the infiltrated RLN is oncologically acceptable only in specific groups of patients of a younger age with a minor size of primary tumour.","[Boucek, Jan; Zabrodsky, Michal; Kuchar, Martin; Skrivan, Jiri; Betka, Jan] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague 15006, Czech Republic; [Boucek, Jan; Zabrodsky, Michal; Kuchar, Martin; Skrivan, Jiri; Betka, Jan] Univ Hosp Motol, Prague 15006, Czech Republic; [Fanta, Ondrej] Charles Univ Prague, Fac Phys Educ & Sport, Dept Anat & Biomech, Prague 15006, Czech Republic","Boucek, J (reprint author), Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, V Uvalu 84, Prague 15006, Czech Republic.","jboucek99@seznam.cz",null,null,"SVV [266513]; Prvouk [P27]; UNCE [204013];  [IGA MZ CR NT11542]","The work was supported by Grant no. IGA MZ CR NT11542 and by SVV 266513, Prvouk P27, and UNCE 204013.",null,40,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6133","2314-6141",null,"BIOMED RES INT","Biomed Res. Int.",null,2014,null,null,null,null,null,null,null,null,616521,"10.1155/2014/616521",null,6,"Biotechnology & Applied Microbiology; Medicine, Research & Experimental","Biotechnology & Applied Microbiology; Research & Experimental Medicine","AH7NZ","WOS:000336321600001"]
["J","Kasparova, M; Prochazka, A; Grajciarova, L; Yadollahi, M; Vysata, O; Dostalova, T",null,null,null,"Kasparova, Magdalena; Prochazka, Ales; Grajciarova, Lucie; Yadollahi, Mohammadreza; Vysata, Oldrich; Dostalova, Tat'jana",null,null,"Evaluation of dental morphometrics during the orthodontic treatment","BIOMEDICAL ENGINEERING ONLINE",null,null,"English","Article",null,null,null,null,null,"Orthodontic modelling; Geometric morphometrics; Digital models; Dental arch features; Digital signal processing; Regression analysis; Computational intelligence","OBJECTIVE GRADING SYSTEM; DIGITAL MODELS; PLASTER MODELS; RELIABILITY; ACCURACY; VALIDITY; CASTS; INDEX; SIZE; ARCH","Background: Diagnostic orthodontic and prosthetic procedures commence with an initial examination, during which a number of individual findings on occlusion or malocclusion are clarified. Nowadays we try to replace standard plaster casts by scanned objects and digital models. Method: Geometrically calibrated images aid in the comparison of several different steps of the treatment and show the variation of selected features belonging to individual biomedical objects. The methods used are based on geometric morphometrics, making a new approach to the evaluation of the variability of features. The study presents two different methods of measurement and shows their accuracy and reliability. Results: The experimental part of the present paper is devoted to the analysis of the dental arch objects of 24 patients before and after the treatment using the distances between the canines and premolars as the features important for diagnostic purposes. Our work proved the advantage of measuring digitalized orthodontic models over manual measuring of plaster casts, with statistically significant results and accuracy sufficient for dental practice. Conclusion: A new method of computer imaging and measurements of a dental stone cast provides information with the precision required for orthodontic treatment. The results obtained point to the reduction in the variance of the distances between the premolars and canines during the treatment, with a regression coefficient RC = 0.7 and confidence intervals close enough for dental practice. The ratio of these distances pointed to the nearly constant value of this measure close to 0.84 for the given set of 24 individuals.","[Kasparova, Magdalena; Dostalova, Tat'jana] Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague 15006 5, Czech Republic; [Prochazka, Ales; Grajciarova, Lucie; Yadollahi, Mohammadreza] Inst Chem Technol, Dept Comp & Control Engn, CR-16628 Prague 6, Czech Republic; [Vysata, Oldrich] Charles Univ Prague, Dept Neurol, Hradec Kralove 50005, Czech Republic","Prochazka, A (reprint author), Inst Chem Technol, Dept Comp & Control Engn, CR-16628 Prague 6, Czech Republic.","A.Prochazka@ieee.org",null,null,null,null,null,61,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1475-925X",null,null,"BIOMED ENG ONLINE","Biomed. Eng. Online","JUN 3",2014,13,null,null,null,null,null,null,null,68,"10.1186/1475-925X-13-68",null,13,"Engineering, Biomedical","Engineering","AJ0GF","WOS:000337327700001",24893983]
["J","Hrabeta, J; Stiborova, M; Adam, V; Kizek, R; Eckschlager, T",null,null,null,"Hrabeta, Jan; Stiborova, Marie; Adam, Vojtech; Kizek, Rene; Eckschlager, Tomas",null,null,"Histone deacetylase inhibitors in cancer therapy. A review","BIOMEDICAL PAPERS-OLOMOUC",null,null,"English","Review",null,null,null,null,null,"chromatin remodeling; histone acetylation; histone deacetylases; histone deacetylase inhibitors; combined treatment modalities; mechanisms of combined treatment","T-CELL LYMPHOMA; SUBEROYLANILIDE HYDROXAMIC ACID; VALPROIC ACID; PHASE-II; IN-VITRO; MULTIPLE-MYELOMA; PROSTATE-CANCER; COLON-CANCER; WALDENSTROM MACROGLOBULINEMIA; MYELODYSPLASTIC SYNDROMES","Background. Despite recent success toward discovery of more effective anticancer drugs, chemoresistance remains a major cause of treatment failure. There is emerging evidence that epigenetics plays a key role in the development of the resistance. Epigenetic regulators such as histone acetyltransferases (HATs) and histone deacetylases (HDACs) play an important role in gene expression. The latter are found to be commonly linked with many types of cancers and influence cancer development. Overall, histone acetylation is being investigated as a therapeutic target because of its importance in regulating gene expression. This review summarizes mechanisms of the anticancer effects of histone deacetylase (HDAC) inhibitors and the results of clinical studies. Results. Different HDAC inhibitors induce cancer cell death by different mechanisms that include changes in gene expression and alteration of both histone and non-histone proteins. Enhanced histone acetylation in tumors results in modification of expression of genes involved in cell signaling. Inhibition of HDACs causes changed expression in 2-10 % of genes involved in important biological processes. The results of experiments and clinical studies demonstrate that combination of HDAC inhibitors with some anticancer drugs have synergistic or additive effects. Conclusions. Even though many biological effects of HDAC inhibitors have been found, most of the mechanisms of their action remain unclear. In addition, their use in combination with other drugs and the combination regime need to be investigated. The discovery of predictive factors is also necessary. Finally, a key question is whether the pan-HDAC inhibitors or the selective inhibitors will be more efficient for different types of cancers.","[Hrabeta, Jan; Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, Prague, Czech Republic; [Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Brno, Czech Republic; [Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CS-61090 Brno, Czech Republic","Eckschlager, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic.","tomas.eckschlager@lfmotol.cuni.cz",null,null,"GACR [P301/10/0356]; MH CZ - DRO, University Hospital Motol, Prague, Czech Republic [00064203]; Charles University in Prague [UNCE 204025/2012]","Supported by GACR (grant P301/10/0356), by MH CZ - DRO, University Hospital Motol, Prague, Czech Republic 00064203 and Charles University in Prague (UNCE 204025/2012).",null,96,1,1,"PALACKY UNIV, MEDICAL FAC","OLOMOUC","CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC","1213-8118","1804-7521",null,"BIOMED PAP","Biomed. Pap-Olomouc",null,2014,158,2,null,null,null,null,161,169,null,"10.5507/bp.2013.085",null,9,"Engineering, Biomedical; Medicine, Research & Experimental","Engineering; Research & Experimental Medicine","AK7SO","WOS:000338628200001",24263215]
["J","Vavrinkova, B; Binder, T; Hadacova, I; Hrachovinova, I; Salaj, P; Hruda, M",null,null,null,"Vavrinkova, Blanka; Binder, Tomas; Hadacova, Ivana; Hrachovinova, Ingrid; Salaj, Peter; Hruda, Martin",null,null,"Does asymptomatic carriage of FV Leiden and FII prothrombin mutations in heterozygous configuration pose an increased risk of thrombembolic complications in the course of pregnancy, labor and puerperium?","BIOMEDICAL PAPERS-OLOMOUC",null,null,"English","Article",null,null,null,null,null,"FV Leiden mutation; FII prothrombin mutation; LMWH prophylaxis; severe late pregnancy complications; abruption of placenta; HELLP syndrome; severe preeclampsia; stillbirth; IUGR","FACTOR-V-LEIDEN; VENOUS THROMBOEMBOLISM; WOMEN","Objective. To evaluate the course of pregnancy and puerperium in asymptomatic carriers of FV Leiden and FII prothrombin mutation in heterozygous configuration in terms of risk of thrombembolic disease (TED) and late pregnancy complications. To evaluate whether global prophylactic LMWH administration during pregnancy benefits these women. Methods. We monitored the incidence of thrombembolic events and severe late pregnancy complications in 473 asymptomatic carriers of FV Leiden and FII prothrombin mutation in heterozygous configuration. In 253 women, preventive LMWH application was introduced already during pregnancy. In 220 women, the application of LMWH was commenced as late as on the delivery day. In both groups application of LMWH continued during the puerperium. Results. The incidence of TED in the whole group of carriers of thrombophylic mutations accounted for 0.19%. The incidence of severe late pregnancy complications was low - 2.5% compared with general population of pregnant women (6.4%). Conclusions. No direct causal relationship was established between asymptomatic carriage of Leiden and prothrombin mutation in heterozygous configuration and the occurrence of severe late pregnancy complications. There was no benefit from general LMWH prophylaxis started as early as pregnancy in these women and thus we consider it unnecessary.","[Vavrinkova, Blanka; Binder, Tomas; Hruda, Martin] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynaecol, Prague, Czech Republic; [Vavrinkova, Blanka; Binder, Tomas; Hruda, Martin] Teaching Hosp Motol, Prague, Czech Republic; [Hadacova, Ivana] Teaching Hosp Motol, Dept Hematol, Prague, Czech Republic; [Hrachovinova, Ingrid; Salaj, Peter] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic","Vavrinkova, B (reprint author), Charles Univ Prague, Fac Med 2, Dept Obstet & Gynaecol, Prague, Czech Republic.","blanka@vavrinkova.cz",null,null,null,null,null,12,0,0,"PALACKY UNIV, MEDICAL FAC","OLOMOUC","CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC","1213-8118","1804-7521",null,"BIOMED PAP","Biomed. Pap-Olomouc",null,2014,158,2,null,null,null,null,238,241,null,"10.5507/bp.2012.070",null,4,"Engineering, Biomedical; Medicine, Research & Experimental","Engineering; Research & Experimental Medicine","AK7SO","WOS:000338628200013",23128846]
["J","Votrubova, J; Juzlova, K; Smerhovsky, Z; Fialova, J; Gopfertova, D; Vojackova, N; Hercogova, J",null,null,null,"Votrubova, Jana; Juzlova, Katerina; Smerhovsky, Zdenek; Fialova, Jorga; Gopfertova, Dana; Vojackova, Nadezda; Hercogova, Jana",null,null,"Risk factors for comorbidities in Czech psoriatic patients: Results of a hospital-based case-control study","BIOMEDICAL PAPERS-OLOMOUC",null,null,"English","Article",null,null,null,null,null,"psoriasis; co-morbidities; risk factors; hospital-based case-control study","METABOLIC SYNDROME; DISEASE; PREVALENCE; PROFILE; SKIN","Background. Psoriasis is now known to be associated with multiple other diseases/comorbidities - including the metabolic syndrome, atherosclerosis and gastrointestinal diseases which are all significantly higher in psoriasis patients. Research results however are highly variable and the conclusions are ambiguous. As no similar study has been performed to date in Czech psoriatic patients, this study aimed at identifying risk factors and early stages of selected diseases/comorbidities in the patients. Methods and Results. The study was designed as a hospital-based case-control study. 131 patients with chronic plaque psoriasis formed the cases and 267 patients with other skin disorders formed the controls. A comparison was made of basic demographic and anthropometric indicators, metabolic parameters, the presence of specific antibodies (ASCA, AEP, p-ANCA, AGC, EMA, ARA, t-TG, AGA) and non-specific signs of gastrointestinal diseases. The chi squared, MWU tests and binary logistical model were used to evaluate the data. The results showed significant differences (P < 0.05) for the following parameters: blood pressure, waist circumference, weight, BMI values, leucocytes values, HDL cholesterol level, glycemia and gliadine antibody IgA level. All differences were to the detriment of psoriasis patients. In the binary logistical model the following parameters were associated with psoriasis: diastolic blood pressure, leucocyte value and glycemia. For all variables included in the logistical model P <= 0.001. Conclusions. The results were coherent and consistent with existing data. They indicate that psoriasis is interconnected with hypertension, higher BMI and a decreased level of HDL cholesterol. These parameters have been clearly demonstrated as risk factors for the development of cardiovascular diseases. Higher levels of gliadine IgA antibodies are one of the diagnostic markers of celiac disease. Higher values of leukocytes may be interpreted as a nonspecific indicator of gastrointestinal inflammatory diseases. The associations between psoriasis and diastolic blood pressure, BMI value and glycemia are statistically significant in the binary logistic regression model. Care for psoriatic patients should focus especially on secondary prevention of predisposing diseases.","[Votrubova, Jana; Juzlova, Katerina; Fialova, Jorga; Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatovenereol, Prague, Czech Republic; [Smerhovsky, Zdenek; Gopfertova, Dana] Charles Univ Prague, Fac Med 2, Dept Epidemiol, Prague, Czech Republic","Votrubova, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Dermatovenereol, Prague, Czech Republic.","jana-votrubova@seznam.cz",null,null,"Charles University Grant Agency [110410]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NT 13275/4]","The project was supported by the Charles University Grant Agency (Grant NO 110410) and the Internal Grant Agency of the Ministry of Health of the Czech Republic (Grant NT 13275/4).",null,30,0,0,"PALACKY UNIV, MEDICAL FAC","OLOMOUC","CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC","1213-8118","1804-7521",null,"BIOMED PAP","Biomed. Pap-Olomouc",null,2014,158,2,null,null,null,null,288,294,null,"10.5507/bp.2013.062",null,7,"Engineering, Biomedical; Medicine, Research & Experimental","Engineering; Research & Experimental Medicine","AK7SO","WOS:000338628200020",24077232]
["J","van der Veer, A; Zaliova, M; Mottadelli, F; De Lorenzo, P; te Kronnie, G; Harrison, CJ; Cave, H; Trka, J; Saha, V; Schrappe, M; Pieters, R; Biondi, A; Valsecchi, MG; Stanulla, M; den Boer, ML; Cazzaniga, G",null,null,null,"van der Veer, Arian; Zaliova, Marketa; Mottadelli, Federica; De Lorenzo, Paola; te Kronnie, Gertruuy; Harrison, Christine J.; Cave, Helene; Trka, Jan; Saha, Vaskar; Schrappe, Martin; Pieters, Rob; Biondi, Andrea; Valsecchi, Maria Grazia; Stanulla, Martin; den Boer, Monique L.; Cazzaniga, Giovanni",null,null,"IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL PRECURSOR; DELETIONS; CHILDREN; IKAROS; RECEPTOR; THERAPY; GENE; IDENTIFICATION; ADOLESCENTS","Childhood BCR-ABL1-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has an unfavorable outcome and shows high frequency of IKZF1 deletions. The prognostic value of IKZF1 deletions was evaluated in 2 cohorts of BCR-ABL1-positive BCP-ALL patients, before tyrosine kinase inhibitors (pre-TKI) and after introduction of imatinib (in the European Study for Philadelphia-Acute Lymphoblastic Leukemia [EsPhALL]). In 126/191 (66%) cases an IKZF1 deletion was detected. In the pre-TKI cohort, IKZF1-deleted patients had an unfavorable outcome compared with wild-type patients (4-year disease-free survival [DFS] of 30.0 +/- 6.8% vs 57.5 +/- 9.4%; P = .01). In the EsPhALL cohort, the IKZF1 deletions were associated with an unfavorable prognosis in patients stratified in the good-risk arm based on early clinical response (4-year DFS of 51.9 +/- 8.8% for IKZF1-deleted vs 78.6 +/- 13.9% for IKZF1 wild-type; P = .03), even when treated with imatinib (4-year DFS of 55.5 +/- 9.5% for IKZF1-deleted vs 75.0 +/- 21.7% for IKZF1 wild-type; P = .05). In conclusion, the highly unfavorable outcome for childhood BCR-ABL1-positive BCP-ALL with IKZF1 deletions, irrespective of imatinib exposure, underscores the need for alternative therapies. In contrast, good-risk patients with IKZF1 wild-type responded remarkably well to imatinib-containing regimens, providing a rationale to potentially avoid hematopoietic stem-cell transplantation in this subset of patients.","[van der Veer, Arian; Pieters, Rob; den Boer, Monique L.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat Oncol, Rotterdam, Netherlands; [Zaliova, Marketa; Schrappe, Martin; Stanulla, Martin] Univ Med Ctr Schleswig Holstein, Dept Pediat, Kiel, Germany; [Zaliova, Marketa; Trka, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Zaliova, Marketa; Trka, Jan] Univ Hosp Motol, Fac Med 2, Childhood Leukemia Invest Prague, Prague, Czech Republic; [Mottadelli, Federica; De Lorenzo, Paola; Biondi, Andrea; Cazzaniga, Giovanni] Univ Milano Bicocca, Pediat Clin, Ctr Ric Tettamanti, Mona, Italy; [De Lorenzo, Paola; Valsecchi, Maria Grazia] Univ Milano Bicocca, European Study Philadelphia Acute Lymphoblast Leu, Dept Hlth Sci, Monza, Italy; [te Kronnie, Gertruuy] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy; [Harrison, Christine J.] Newcastle Univ, Leukemia Res Cytogenet Grp, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Cave, Helene] Univ Paris Diderot, Hosp Robert Debre, Assitance Publ Hop Paris, Dept Genet, Paris, France; [Saha, Vaskar] Univ Manchester, Childrens Canc Grp, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Pieters, Rob; den Boer, Monique L.] Dutch Childhood Oncol Grp, The Hague, Netherlands","den Boer, ML (reprint author), Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.","m.l.denboer@erasmusmc.nl; gianni.cazzaniga@hsgerardo.org",null,null,"Dutch Cancer Society [EMCR 2007-3718]; Sophia Foundation for Scientific Research [658]; Pediatric Oncology Foundation Rotterdam; GACR Centre of Excellence [P302/12/G101]; Ministry of Health, Czech Republic [00064203]; University Hospital Motol, Prague, Czech Republic [UNCE204012]; Italian Association for Cancer Research; Italian Ministry of University and Research; Fondazione Cariplo; European Union under the European Network of Cancer Research in Children and Adolescents project [HEALTH-F2-2011-261474]","This work was supported by the Dutch Cancer Society (grant EMCR 2007-3718) (M.L.d.B. and R. P.); the Sophia Foundation for Scientific Research (grant 658) (A.v.d.V. and M.L.d.B.); the Pediatric Oncology Foundation Rotterdam (M.L.d.B. and R. P.); the GACR Centre of Excellence (grant P302/12/G101) (M.Z.); the project for conceptual development of research organization, Ministry of Health, Czech Republic (grant 00064203) (M.Z.); the University Hospital Motol, Prague, Czech Republic (grant UNCE204012) (M.Z.); the Italian Association for Cancer Research (G. C.); the Italian Ministry of University and Research (G. C.); and the Fondazione Cariplo (G. C.). The research leading to these results has received funding from the European Union's Seventh Framework Program(FP7/2007-2013) under the European Network of Cancer Research in Children and Adolescents project grant agreement HEALTH-F2-2011-261474 (M. G. V., G.t.K., G. C., and M.L.d.B.). These funding sources had no role in the collection, analysis, or interpretation of the results, or in writing the manuscript or the decision for submission of this manuscript.",null,33,2,2,"AMER SOC HEMATOLOGY","WASHINGTON","2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA","0006-4971","1528-0020",null,"BLOOD","Blood","MAR 13",2014,123,11,null,null,null,null,1691,1698,null,"10.1182/blood-2013-06-509794",null,8,"Hematology","Hematology","AH0YW","WOS:000335847700016",24366361]
["J","Aalbers, AM; van den Heuvel-Eibrink, MM; Baumann, I; Beverloo, HB; Driessen, GJ; Dworzak, M; Fischer, A; Gohring, G; Hasle, H; Locatelli, F; De Moerloose, B; Noellke, P; Schmugge, M; Stary, J; Yoshimi, A; Zecca, M; Zwaan, CM; van Dongen, JJM; Pieters, R; Niemeyer, CM; van der Velden, VHJ; Langerak, AW",null,null,null,"Aalbers, A. M.; van den Heuvel-Eibrink, M. M.; Baumann, I.; Beverloo, H. B.; Driessen, G. J.; Dworzak, M.; Fischer, A.; Goehring, G.; Hasle, H.; Locatelli, F.; De Moerloose, B.; Noellke, P.; Schmugge, M.; Stary, J.; Yoshimi, A.; Zecca, M.; Zwaan, C. M.; van Dongen, J. J. M.; Pieters, R.; Niemeyer, C. M.; van der Velden, V. H. J.; Langerak, A. W.",null,null,"T-cell receptor V beta skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS","BLOOD CANCER JOURNAL",null,null,"English","Article",null,null,null,null,null,null,"PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; RISK MYELODYSPLASTIC SYNDROME; ANTITHYMOCYTE GLOBULIN; BONE-MARROW; APLASTIC-ANEMIA; IMMUNOSUPPRESSIVE THERAPY; AUTOLOGOUS LYMPHOCYTES; CLINICAL-SIGNIFICANCE; CYCLOSPORINE-A; POPULATION","Immunosuppressive therapy (IST), consisting of antithymocyte globulin and cyclosporine A, is effective in refractory cytopenia of childhood (RCC), suggesting that, similar to low-grade myelodysplastic syndromes in adult patients, T lymphocytes are involved in suppressing hematopoiesis in a subset of RCC patients. However, the potential role of a T-cell-mediated pathophysiology in RCC remains poorly explored. In a cohort of 92 RCC patients, we prospectively assessed the frequency of T-cell receptor (TCR) b-chain variable (Vb) domain skewing in bone marrow and peripheral blood by heteroduplex PCR, and analyzed T-cell subsets in peripheral blood by flow cytometry. TCRVb skewing was present in 40% of RCC patients. TCRVb skewing did not correlate with bone marrow cellularity, karyotype, transfusion history, HLA-DR15 or the presence of a PNH clone. In 28 patients treated with IST, TCRVb skewing was not clearly related with treatment response. However, TCRVb skewing did correlate with a disturbed CD4(+)/ CD8(+) T-cell ratio, a reduction in naive CD8(+) T cells, an expansion of effector CD8(+) T cells and an increase in activated CD8(+) T cells (defined as HLA-DR+, CD57(+) or CD56(+)). These data suggest that T lymphocytes contribute to RCC pathogenesis in a proportion of patients, and provide a rationale for treatment with IST in selected patients with RCC.","[Aalbers, A. M.; van den Heuvel-Eibrink, M. M.; Zwaan, C. M.; Pieters, R.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Aalbers, A. M.; Driessen, G. J.; van Dongen, J. J. M.; van der Velden, V. H. J.; Langerak, A. W.] Erasmus Univ, Dept Immunol, Med Ctr, Erasmus MC, NL-3000 DR Rotterdam, Netherlands; [Baumann, I.] Boblingen Clin, Clin Ctr South West, Dept Pathol, Boblingen, Germany; [Beverloo, H. B.] Erasmus Univ, Dept Clin Genet, Med Ctr, Erasmus MC, NL-3000 DR Rotterdam, Netherlands; [Driessen, G. J.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat Infect Dis & Immunol, Rotterdam, Netherlands; [Dworzak, M.] Med Univ Vienna, St Anna Childrens Hosp, Dept Pediat, Vienna, Austria; [Dworzak, M.] Med Univ Vienna, Childrens Canc Res Inst, Vienna, Austria; [Fischer, A.; Noellke, P.; Yoshimi, A.; Niemeyer, C. M.] Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, D-79106 Freiburg, Germany; [Goehring, G.] Hannover Med Sch, Inst Cell & Mol Pathol, Hannover, Germany; [Hasle, H.] Aarhus Univ, Hosp Skejby, Dept Pediat, Aarhus, Denmark; [Locatelli, F.] Univ Pavia, IRCCS Osped Bambino Gesu, Dept Pediat Hematol Oncol, I-27100 Pavia, Italy; [De Moerloose, B.] Ghent Univ Hosp, Dept Pediat Hematol Oncol, Ghent, Belgium; [Schmugge, M.] Univ Childrens Hosp, Dept Hematol, Zurich, Switzerland; [Stary, J.] Charles Univ Prague, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Stary, J.] Univ Hosp Motol, Prague, Czech Republic; [Zecca, M.] Fdn IRCCS Policlin San Matteo, Pavia, Italy","Langerak, AW (reprint author), Erasmus MC, Dept Immunol, Dr Molewaterpl 50,Room Nb 1242b, NL-3015 GE Rotterdam, Netherlands.","a.langerak@erasmusmc.nl",null,null,"KiKa Foundation, Amstelveen, the Netherlands; Ministry of Health for conceptual development of research organization (University Hospital Motol, Prague, Czech Republic) [00064203]","AMA and this research were supported by the KiKa Foundation, Amstelveen, the Netherlands. In the Czech Republic, RCC diagnosis and treatment were supported by a grant of the Ministry of Health for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic). The authors acknowledge excellent technical support by research technicians from the Departments of Immunology and Pediatric Oncology/Hematology, Erasmus MC.",null,44,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","2044-5385",null,null,"BLOOD CANCER J","Blood Cancer J.","MAY",2014,4,null,null,null,null,null,null,null,"e209","10.1038/bcj.2014.28",null,7,"Oncology","Oncology","AI9DS","WOS:000337229900003",24786393]
["J","Weber, ML; Hsin, HY; Kalay, E; Brozkova, DS; Shimizu, T; Bayram, M; Deeley, K; Kuchler, EC; Forella, J; Ruff, TD; Trombetta, VM; Sencak, RC; Hummel, M; Briseno-Ruiz, J; Revu, SK; Granjeiro, JM; Antunes, LS; Antunes, LA; Abreu, FV; Costa, MC; Tannure, PN; Koruyucu, M; Patir, A; Poletta, FA; Mereb, JC; Castilla, EE; Orioli, LM; Marazita, ML; Ouyang, H; Jayaraman, T; Seymen, F; Vieira, AR",null,null,null,"Weber, Megan L.; Hsin, Hong-Yuan; Kalay, Ersan; Brozkova, Dana S.; Shimizu, Takehiko; Bayram, Merve; Deeley, Kathleen; Kuchler, Erika C.; Forella, Jessalyn; Ruff, Timothy D.; Trombetta, Vanessa M.; Sencak, Regina C.; Hummel, Michael; Briseno-Ruiz, Jessica; Revu, Shankar K.; Granjeiro, Jose M.; Antunes, Leonardo S.; Antunes, Livia A.; Abreu, Fernanda V.; Costa, Marcelo C.; Tannure, Patricia N.; Koruyucu, Mine; Patir, Asli; Poletta, Fernando A.; Mereb, Juan C.; Castilla, Eduardo E.; Orioli, Leda M.; Marazita, Mary L.; Ouyang, Hongjiao; Jayaraman, Thottala; Seymen, Figen; Vieira, Alexandre R.",null,null,"Role of estrogen related receptor beta (ESRRB) in DFN35B hearing impairment and dental decay","BMC MEDICAL GENETICS",null,null,"English","Article",null,null,null,null,null,"Dental caries; Deafness; Dental development; Ear development; Linkage disequilibrium; Genetics; Polymorphisms","GENOME-WIDE ASSOCIATION; HIGH CARIES EXPERIENCE; PERMANENT DENTITION; FAMILY; DFNB35; GENES; SCAN; PREVALENCE; EXPRESSION; MUTATIONS","Background: Congenital forms of hearing impairment can be caused by mutations in the estrogen related receptor beta (ESRRB) gene. Our initial linkage studies suggested the ESRRB locus is linked to high caries experience in humans. Methods: We tested for association between the ESRRB locus and dental caries in 1,731 subjects, if ESRRB was expressed in whole saliva, if ESRRB was associated with the microhardness of the dental enamel, and if ESRRB was expressed during enamel development of mice. Results: Two families with recessive ESRRB mutations and DFNB35 hearing impairment showed more extensive dental destruction by caries. Expression levels of ESRRB in whole saliva samples showed differences depending on sex and dental caries experience. Conclusions: The common etiology of dental caries and hearing impairment provides a venue to assist in the identification of individuals at risk to either condition and provides options for the development of new caries prevention strategies, if the associated ESRRB genetic variants are correlated with efficacy.","[Weber, Megan L.; Hsin, Hong-Yuan; Deeley, Kathleen; Kuchler, Erika C.; Forella, Jessalyn; Ruff, Timothy D.; Trombetta, Vanessa M.; Sencak, Regina C.; Hummel, Michael; Briseno-Ruiz, Jessica; Revu, Shankar K.; Marazita, Mary L.; Ouyang, Hongjiao; Jayaraman, Thottala; Vieira, Alexandre R.] Univ Pittsburgh, Sch Dent Med, Dept Oral Biol, Pittsburgh, PA 15261 USA; [Kalay, Ersan] Karadeniz Tech Univ, Sch Med, Dept Med Biol, Trabzon, Turkey; [Brozkova, Dana S.] Charles Univ 2, Univ Hosp Motol, Sch Med, DNA Lab Child Neurol, Prague, Czech Republic; [Shimizu, Takehiko] Nihon Univ, Sch Dent, Dept Pediat Dent, Matsudo, Chiba, Japan; [Bayram, Merve; Patir, Asli] Medipol Istanbul Univ, Dept Pedodont, Istanbul, Turkey; [Granjeiro, Jose M.] Univ Fed Fluminense, Clin Res Unit, Niteroi, RJ, Brazil; [Granjeiro, Jose M.] Qual & Technol INMETRO, Natl Inst Metrol, Duque De Caxias, RJ, Brazil; [Granjeiro, Jose M.; Antunes, Leonardo S.; Antunes, Livia A.; Abreu, Fernanda V.] Univ Fed Fluminense, Sch Dent, Dept Specif Format, Nova Friburgo, RJ, Brazil; [Costa, Marcelo C.] Univ Fed Rio de Janeiro, Dept Pediat Dent & Orthodont, BR-21941 Rio De Janeiro, RJ, Brazil; [Tannure, Patricia N.] Veiga Almeida Univ, Rio De Janeiro, RJ, Brazil; [Tannure, Patricia N.] Salgado Oliveira Univ, Sch Dent, Discipline Cariol, Niteroi, RJ, Brazil; [Koruyucu, Mine; Seymen, Figen] Istanbul Univ, Dept Pedodont, Istanbul, Turkey; [Poletta, Fernando A.; Castilla, Eduardo E.] CEMIC Ctr Med Educ & Clin Res, ECLAMC Lat Amer Collaborat Study Congenital Malf, Buenos Aires, DF, Argentina; [Poletta, Fernando A.; Castilla, Eduardo E.] Fundacao Oswaldo Cruz, INAGEMP CNPq Natl Inst Populat Med Genet, Dept Genet, ECLAMC, Rio De Janeiro, Brazil; [Mereb, Juan C.] ECLAMC, Hosp Area, El Bolson, RN, Argentina; [Orioli, Leda M.] Fed Univ Rio Janeiro, Inst Biol,ECLAMC, Ctr Hlth Sci,Dept Genet, INAGEMP CNPq Natl Inst Populat Med Genet, Rio De Janeiro, RJ, Brazil; [Ouyang, Hongjiao] Univ Pittsburgh, Sch Dent Med, Restorat Dent & Endodont, Dept Comprehens Care, Pittsburgh, PA USA; [Ouyang, Hongjiao] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA","Vieira, AR (reprint author), Univ Pittsburgh, Sch Dent Med, Dept Oral Biol, 3501 Terrace St,614 Salk Hall, Pittsburgh, PA 15261 USA.","arv11@pitt.edu",null,null,"NIH [R01-DE018914, R01-DE016148]; Czech Republic [IGA MHCZ NT14348]","We would like to thank the individuals that participated in this study for their support. We would also like to thank Eric Davis and Maggie Saludis for their contributions to the enamel microhardness portion of the study, Paula Noh for helping to optimize primers for sequencing, and Sarah Vinski for administrative support. This research is supported by NIH grants R01-DE018914 and R01-DE016148, and Czech Republic grant IGA MHCZ NT14348.",null,58,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2350",null,null,"BMC MED GENET","BMC Med. Genet.","JUL 15",2014,15,null,null,null,null,null,null,null,81,"10.1186/1471-2350-15-81",null,10,"Genetics & Heredity","Genetics & Heredity","AM0EZ","WOS:000339517900001",25023176]
["J","Stehlikova, K; Skalova, D; Zidkova, J; Mrazova, L; Vondracek, P; Mazanec, R; Vohanka, S; Haberlova, J; Hermanova, M; Zamecnik, J; Soucek, O; Oslejskova, H; Dvorackova, N; Solarova, P; Fajkusova, L",null,null,null,"Stehlikova, Kristyna; Skalova, Daniela; Zidkova, Jana; Mrazova, Lenka; Vondracek, Petr; Mazanec, Radim; Vohanka, Stanislav; Haberlova, Jana; Hermanova, Marketa; Zamecnik, Josef; Soucek, Ondrej; Oslejskova, Hana; Dvorackova, Nina; Solarova, Pavla; Fajkusova, Lenka",null,null,"Autosomal recessive limb-girdle muscular dystrophies in the Czech Republic","BMC NEUROLOGY",null,null,"English","Article",null,null,null,null,null,"Calpain-3; CAPN3; Limb girdle muscular dystrophy; LGMD2; Sequence capture","ACTIVATED CHLORIDE CHANNEL; LGMD2A PATIENTS; MESSENGER-RNA; MUTATION ANALYSIS; SKELETAL-MUSCLE; CALPAIN-3 GENE; PROTEIN GENE; LARGE COHORT; ANOCTAMIN 5; SPECTRUM","Background: Autosomal recessive limb-girdle muscular dystrophies (LGMD2) include a number of disorders with heterogeneous etiology that cause predominantly weakness and wasting of the shoulder and pelvic girdle muscles. In this study, we determined the frequency of LGMD subtypes within a cohort of Czech LGMD2 patients using mutational analysis of the CAPN3, FKRP, SGCA, and ANO5 genes. Methods: PCR-sequencing analysis; sequence capture and targeted resequencing. Results: Mutations of the CAPN3 gene are the most common cause of LGMD2, and mutations in this gene were identified in 71 patients in a set of 218 Czech probands with a suspicion of LGMD2. Totally, we detected 37 different mutations of which 12 have been described only in Czech LGMD2A patients. The mutation c.550delA is the most frequent among our LGMD2A probands and was detected in 47.1% of CAPN3 mutant alleles. The frequency of particular forms of LGMD2 was 32.6% for LGMD2A (71 probands), 4.1% for LGMD2I (9 probands), 2.8% for LGMD2D (6 probands), and 1.4% for LGMD2L (3 probands). Further, we present the first results of a new approach established in the Czech Republic for diagnosis of neuromuscular diseases: sequence capture and targeted resequencing. Using this approach, we identified patients with mutations in the DYSF and SGCB genes. Conclusions: We characterised a cohort of Czech LGMD2 patients on the basis of mutation analysis of genes associated with the most common forms of LGMD2 in the European population and subsequently compared the occurrence of particular forms of LGMD2 among countries on the basis of our results and published studies.","[Stehlikova, Kristyna; Skalova, Daniela; Zidkova, Jana; Fajkusova, Lenka] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, CZ-61300 Brno, Czech Republic; [Stehlikova, Kristyna; Skalova, Daniela; Zidkova, Jana; Fajkusova, Lenka] Masaryk Univ, Cent European Inst Technol, CZ-62500 Brno, Czech Republic; [Mrazova, Lenka] Univ Hosp Brno, Dept Child Neurol, CZ-61300 Brno, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Fac Med 2, Dept Neurol, CZ-15006 Prague, Czech Republic; [Mazanec, Radim; Haberlova, Jana; Zamecnik, Josef] Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Vohanka, Stanislav] Univ Hosp Brno, Dept Neurol, CZ-62500 Brno, Czech Republic; [Haberlova, Jana] Charles Univ Prague, Fac Med 2, Dept Child Neurol, CZ-15006 Prague, Czech Republic; [Hermanova, Marketa] Masaryk Univ, Fac Med, Dept Pathol Anat 1, CZ-65691 Brno, Czech Republic; [Hermanova, Marketa] St Annes Univ Hosp, CZ-65691 Brno, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, CZ-15006 Prague, Czech Republic; [Soucek, Ondrej] Univ Hosp Brno, Inst Pathol, CZ-62500 Brno, Czech Republic; [Dvorackova, Nina] Univ Hosp Ostrava, Dept Med Genet, CZ-70852 Ostrava, Czech Republic; [Solarova, Pavla] Univ Hosp Hradec Kralove, Dept Med Genet, CZ-50005 Ostrava, Czech Republic","Fajkusova, L (reprint author), Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Cernopolni 9, CZ-61300 Brno, Czech Republic.","lenka.fajkus@gmail.com",null,null,"Internal Grant Agency of the Czech Ministry of Health [NT/14574-3]; Czech Ministry of Education \"CEITEC-Central European Institute of Technology\" [CZ.1.05/1.1.00/02.0068]; SuPReMMe [CZ.1.07/2.3.00/20.0045]; Czech Ministry of Health for conceptual development of research organization (University Hospital Brno, Brno, Czech Republic) [65269705]; MH - DRO, University Hospital Motol, Prague, Czech Republic [00064203]","This work was funded by projects of the Internal Grant Agency of the Czech Ministry of Health (NT/14574-3), the Czech Ministry of Education \"CEITEC - Central European Institute of Technology\" (CZ.1.05/1.1.00/02.0068) and SuPReMMe (CZ.1.07/2.3.00/20.0045), and the Czech Ministry of Health for conceptual development of research organization 65269705 (University Hospital Brno, Brno, Czech Republic) and MH - DRO, University Hospital Motol, Prague, Czech Republic 00064203.",null,42,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2377",null,null,"BMC NEUROL","BMC Neurol.","AUG 19",2014,14,null,null,null,null,null,null,null,154,"10.1186/s12883-014-0154-7",null,9,"Clinical Neurology","Neurosciences & Neurology","AO9HI","WOS:000341666400001",25135358]
["J","Vlcek, M; Jaganjac, E; Pech, J; Jonas, D; Kebrle, R",null,null,null,"Vlcek, Martin; Jaganjac, Edib; Pech, Jan; Jonas, David; Kebrle, Radek",null,null,"Is minimally invasive application by intramedullary osteosynthesis in comparison with volar plating real benefit in the treatment of distal radius fractures?","BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES",null,null,"English","Article",null,null,null,null,null,"distal radius fracture; locking plate osteosynthesis; intramedullary osteosynthesis; complications","INTERNAL-FIXATION; NAIL; MANAGEMENT; SYSTEM","Purpose of the study: Can minimally invasive intramedullary osteosynthesis of distal radius fractures provide better therapeutic results than multidirectional locking plates? Retrospective study of 68 patients operated for distal radius fractures, 18 were treated with intramedullary X-screw (XSCR) fixation and so with the multidirectional angle-stable plate system (APTUS). The evaluation at 1-year follow-up included functional status of the wrist and hand, and radiographic findings In the XSCR group, the functional outcomes of the treated extremity did not achieve values comparable with those of the uninjured side in any of the parameters measured. The radiographic findings did not meet the requirements of successful healing due to failure to restore an anatomical volar tilt in 22.2% cases. In the APTUS group, comparable values of the injured and the uninjured side were achieved in radial deviation, ulnar deviation, pronation, supination and grip strength. The radiographic criteria of successful healing were met by all fractures treated by locking plate osteosynthesis. Implant migration associated with secondary displacement of bone fragments was recorded in 33.3 % of the XSCR patients and only in 4.0 % of the APTUS patients. The overall evaluation show that intramedullary osteosynthesis does not produce better treatment outcomes compared with plate osteosynthesis in indicated types of fractures. (C) 2014 Association of Basic Medical Sciences of FB&H. All rights reserved","[Vlcek, Martin; Jaganjac, Edib; Pech, Jan; Jonas, David] Teaching Hosp Motol, Clin Orthopaed Surg 1, Prague 15006 5, Czech Republic; [Kebrle, Radek] Inst Hand & Plast Surg Vysoke Nad Jizerou, Vysoke Nad Jizerou 51211, Czech Republic","Vlcek, M (reprint author), Teaching Hosp Motol, Clin Orthopaed Surg 1, Dept Traumathol, V Uvalu 84, Prague 15006 5, Czech Republic.","dr.martinvlcek@gmail.com",null,null,null,null,null,25,0,0,"ASSOC BASIC MEDICAL SCI FEDERATION BOSNIA & HERZEGOVINA SARAJEVO","CEKALUSA","UNIV SARAJEVO, MEDICAL FAC, CEKALUSA, SARAJEVO 90, BOSNIA & HERCEG","1512-8601","1840-4812",null,"BOSNIAN J BASIC MED","Bosnian J. Basic Med. Sci.","MAY",2014,14,2,null,null,null,null,81,88,null,null,null,8,"Medicine, Research & Experimental","Research & Experimental Medicine","AJ5ZP","WOS:000337769800005",24856379]
["J","Hytych, V; Pohnan, R; Taskova, A; Horazdovsky, P; Konopa, Z; Demes, R; Cermak, J; Vrabcova, A; Hoferka, P",null,null,null,"Hytych, V; Pohnan, R.; Taskova, A.; Horazdovsky, P.; Konopa, Z.; Demes, R.; Cermak, J.; Vrabcova, A.; Hoferka, P.",null,null,"Importance of histological verification of mediastinal lymphadenopathy in exact staging of non-small cell bronchogenic carcinoma","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"mediastinal lymphadenopathy; bronchogenic carcinoma; lung cancer","LUNG-CANCER; PROJECT","Background: Diagnostics and treatment of bronchogenic non-small cell lung carcinoma is a severe clinical problem. Radical surgery is the major treatment modality with the highest chance for a long-time survival. The aim of the study was to map metastasizing of bronchogenic non-small cell lung carcinoma into homolateral mediastinal lymph nodes and to assess the importance of histological verification of mediastinal lymphadenectomy for exact staging and treatment. Methods: Study of 29 patients with non-small cell lung carcinoma in stage IIIa, IIIb and IV (TNM classification) diagnosed from September 2006 to March 2007, with mediastinal lymph nodes invasion according to CT, and with subsequent mediastinal lymph node dissection during autopsy. Results: 50% of the right upper lobe tumors metastasized into group 1 nodes (N1-N4) and 50% into group 3 (N7). 66% of the right lower lobe tumors metastasized into group 3 nodes (N7) and 33.3% into group 1 (N1-4). 20.0% of the left upper lobe tumors metastasized into group 1 nodes (N1-4), 33.0% into group 2 (N5-6), 25.0% into group 3 (N7) and 16.7% into group 4 (N8-9). 23.5% of the left lower lobe tumors metastasized into group 1 nodes (N1-4), 23.5% into group 2 (N5-6), 23.5 % into group 4 (N8-9) and 29.5% into group 3 (N7). 27.6% of examined patients had false positivity of lymph node metastasis according to CT. Conclusion: Histological verification of suspect mediastinal lymph nodes via Endobronchial Ultrasound Biopsy (EBUS) or mediastinoscopy or thoracoscopy is crucial for determining the stage of the disease according to the TNM classification. False positivity of imaging methods in diagnostics of non-small cell brochogenic carcinoma can contraindicate up to quarter of potentially operable patients (Tab. 3, Ref. 11). Text in PDF www.elis.sk.","[Hytych, V; Taskova, A.; Horazdovsky, P.; Konopa, Z.; Demes, R.; Cermak, J.; Vrabcova, A.; Hoferka, P.] Thomayers Hosp, Dept Thorac Surg, CZ-14059 Prague 4, Czech Republic; [Pohnan, R.] Charles Univ Prague, Fac Mil Hosp, Cent Mil Hosp, Dept Surg,Fac Med 2, Prague, Czech Republic; [Pohnan, R.] Univ Def, Fac Mil Hlth Sci, Chair Field Surg, Hradec Kralove, Czech Republic","Hytych, V (reprint author), Thomayers Hosp, Dept Thorac Surg, Videnska 800, CZ-14059 Prague 4, Czech Republic.","vladislav.hytych@ftn.cz",null,null,null,null,null,9,0,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248","1336-0345",null,"BRATISL MED J","Bratisl. Med. J.",null,2014,115,9,null,null,null,null,585,587,null,"10.4149/BLL_2014_113",null,3,"Medicine, General & Internal","General & Internal Medicine","AQ8LZ","WOS:000343078300012",25318920]
["J","Skrivan, J; Cada, Z; Kluh, J; Boucek, J; Profant, O; Betka, J",null,null,null,"Skrivan, J.; Cada, Z.; Kluh, J.; Boucek, J.; Profant, O.; Betka, J.",null,null,"Revision operations after previous stapes surgery for persisting hearing loss","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"revision stapes surgery; otosclerosis","STAPEDECTOMY; OTOSCLEROSIS","Objectives: The aim of the study was to find out the reasons of the recurrent or persisting hearing loss after previous stapes surgery indicated for otosclerosis. Background: Revision stapes surgery is a relatively safe surgical method. Recurrent or persisting conductive hearing loss is commonly caused by prosthesis dislocation and adhesions in the oval window. Hearing loss is directly proportional to the number of previous operations. Method: Retrospective analysis of 48 patients after revision stapes surgery was done over a period of 4 years (2005-2008). Improvement of the hearing and the reasons of a previous surgery failure were studied. Results: Results were compared to the other studies. The main reason of the failed surgery was adhesions and dislocation of the prosthesis. The mean postoperative air-bone gap was 12.0 dB. A mean postoperative air-bone gap closure within 10 dB occurred in 24 cases (55.8 %), between 11-20 dB occurred in 11 cases (25.6 %) and above 20 dB in 8 cases (18.6 %). The original prosthesis was replaced with a new one in 41(95.3 %) cases. In 2 cases (4.7 %), previous prostheses were left in place and fixed by a ionomer glass cement to the long process of incus. Conclusion: Revision stapes surgery is a relatively safe surgical procedure allowing to improve hearing. The number of previous stapes surgery deteriorates hearing (p < 0.05) (Tab. 4, Ref. 20). Text in PDF www.elis.sk.","Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, CZ-15006 Prague 5, Czech Republic; Fac Hosp Motol, Postgrad Med Sch, Prague, Czech Republic","Cada, Z (reprint author), Charles Univ Prague, Fac Hosp Motol, Postgrad Med Sch, Dept Otorhinolaryngol & Head & Neck Surg,Fac Med, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","zdenek.cada@lf1.cuni.cz",null,null,"Charles University in Prague [260 510];  [IGA MZCR NT/11543-6]","This research was supported by the grants No. 260 510 of the Charles University in Prague and IGA MZCR NT/11543-6.",null,20,0,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248","1336-0345",null,"BRATISL MED J","Bratisl. Med. J.",null,2014,115,7,null,null,null,null,442,444,null,"10.4149/BLL_2014_087",null,3,"Medicine, General & Internal","General & Internal Medicine","AN8OL","WOS:000340863400011",25077369]
["J","Veselka, J; Krejci, J; Tomasov, P; Jahnlova, D; Honek, T; Januska, J; Branny, M; Zemanek, D",null,null,null,"Veselka, Josef; Krejci, Jan; Tomasov, Pavol; Jahnlova, Denisa; Honek, Tomas; Januska, Jaroslav; Branny, Marian; Zemanek, David",null,null,"Survival of Patients <= 50 Years of Age After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy","CANADIAN JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"MULTICENTER","Background: The long-term efficacy and safety of alcohol septal ablation (ASA) has recently been demonstrated. However, there is still debate about the outcome of younger patients who should be treated using myectomy, according to American College of Cardiology Foundation/American Heart Association guidelines. The aim of this study was to evaluate the long-term outcome of patients <= 50 years of age after ASA for hypertrophic obstructive cardiomyopathy (HOCM). Methods: We retrospectively evaluated consecutive, highly symptomatic patients aged <= 50 years with HOCM who underwent ASA. Results: Institutional databases of 3 cardiovascular centres identified 290 patients with HOCM who underwent ASA; 75 (26%) of them were aged <= 50 years at the time of their first ASA. Median duration of follow-up was 5.1 years (range, 0.1-15.4 years). Four patients (5%) died during the study period (438 patient-years; the annual mortality rate was 0.91%; 95% confidence interval [CI], 0.25-2.34%; the annual mortality rate combined with the first appropriate implantable cardioverter-defibrillator discharge was 1.43%; 95% CI, 0.52-3.10%). Survival free of all-cause mortality at 1, 5, and 10 years was 97% (95% CI, 89-99%), 94% (95% CI, 84-98%), and 94% (95% CI, 84-98%), respectively. Conclusions: Results of this first study focused on HOCM patients aged <= 50 years who underwent ASA suggest a low risk of all-cause death or appropriate implantable cardioverter-defibrillator discharge in the long-term follow-up.","[Veselka, Josef; Tomasov, Pavol; Jahnlova, Denisa; Zemanek, David] Charles Univ Prague, Dept Cardiol, Sch Med 2, Univ Hosp Motol, Prague 15000, Czech Republic; [Krejci, Jan; Honek, Tomas] Masaryk Univ, Dept Internal Med Cardioangiol 1, Int Clin Res Ctr, St Annes Univ Hosp, Brno, Czech Republic; [Januska, Jaroslav; Branny, Marian] Hosp Podlesi, Cardioctr Trinec, Trinec, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Dept Cardiol, Sch Med 2, Univ Hosp Motol, Prague 15000, Czech Republic.","veselka.josef@seznam.cz",null,null,"Project for Conceptual Development of Research Organization [00064203]; Internal Grant Agency, Ministry of Health, Czech Republic [NT 11401-5]; European Social Fund; State Budget of the Czech Republic e Project ICRC Human Bridge-Support of R&D teams through formation of new postdoctoral positions [CZ.1.07/2.3.00/30.0023]; European Regional Development Fund - Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; Agel A.S.: Familiar Hypertrophic Cardiomyopathy: Search for Causal Mutation, Correlation Genotype and Fenotype","This work was supported by the Project for Conceptual Development of Research Organization (00064203), by the Internal Grant Agency, Ministry of Health, Czech Republic (grant NT 11401-5), by the European Social Fund and the State Budget of the Czech Republic e Project ICRC Human Bridge-Support of R&D teams through formation of new postdoctoral positions (CZ.1.07/2.3.00/30.0023), by the European Regional Development Fund - Project FNUSA-ICRC (CZ.1.05/1.1.00/02.0123) and by Grant of Agel A.S.: Familiar Hypertrophic Cardiomyopathy: Search for Causal Mutation, Correlation Genotype and Fenotype.",null,21,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0828-282X","1916-7075",null,"CAN J CARDIOL","Can. J. Cardiol.","JUN",2014,30,6,null,null,null,null,634,638,null,"10.1016/j.cjca.2014.03.041",null,5,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AL6NT","WOS:000339250300008",24882534]
["J","Brenner, DR; Wozniak, MB; Feyt, C; Holcatova, I; Janout, V; Foretova, L; Fabianova, E; Shonova, O; Martinek, A; Ryska, M; Adamcakova, Z; Flaska, E; Moskal, A; Brennan, P; Scelo, G",null,null,null,"Brenner, Darren R.; Wozniak, Magdalena B.; Feyt, Clement; Holcatova, Ivana; Janout, Vladimir; Foretova, Lenka; Fabianova, Eleonora; Shonova, Olga; Martinek, Arnost; Ryska, Miroslav; Adamcakova, Zora; Flaska, Erik; Moskal, Aurelie; Brennan, Paul; Scelo, Ghislaine",null,null,"Physical activity and risk of pancreatic cancer in a central European multicenter case-control study","CANCER CAUSES & CONTROL",null,null,"English","Article",null,null,null,null,null,"Physical activity; Risk factor; Pancreatic cancer; Central European case-control study","LIFE-STYLE FACTORS; BODY-MASS INDEX; ABO BLOOD-GROUP; DIABETES-MELLITUS; ANTHROPOMETRIC FACTORS; PIPE SMOKING; MALE SMOKERS; COHORT; METAANALYSIS; CONSUMPTION","Findings from epidemiological studies examining physical activity in relation to pancreatic cancer risk have suggested decreased risks for physical activity; however, the results are inconsistent. The association between occupational and leisure-time physical activity and risk of pancreatic cancer was examined among 826 pancreatic cancer cases and 930 age-, sex- and center-matched controls from a large multicenter central European study in Czech Republic and Slovakia recruited between 2004 and 2012. Data on physical activity including type and dose (frequency, intensity, and duration) were examined using multivariable-adjusted logistic regression models. Occupational physical activity was not significantly associated with risk of pancreatic cancer [odds ratio (OR) 0.90, 95 % confidence interval (CI) 0.71-1.15]. A 35 % decrease in risk of pancreatic cancer was observed for regular leisure-time physical activity (OR 0.65, 95 % CI 0.52-0.87). The risk estimates were significant for low and moderate intensity of activity with the strongest protective effect among individuals who exercised during more than 40 weeks per year. The results for cumulated leisure-time physical activity assessed 1 year prior to diagnosis achieved the same level of risk reduction. In addition, stronger risk estimates for leisure-time physical activity were observed among women (men: OR 0.74, 95 % CI 0.54-1.01; women: OR 0.53, 95 % CI 0.37-0.75). The findings for female participants were stronger for intensity and frequency of leisure-time physical activity, in particular for light and moderate activity (OR 0.43, 95 % CI 0.25-0.75; and OR 0.57, 95 % CI 0.37-0.88, respectively). These results provide evidence for a decreased risk of pancreatic cancer associated with regular leisure-time physical activity.","[Brenner, Darren R.; Wozniak, Magdalena B.; Feyt, Clement; Moskal, Aurelie; Brennan, Paul; Scelo, Ghislaine] Int Agcy Res Canc, Genet Epidemiol Grp, F-69372 Lyon 08, France; [Brenner, Darren R.] Alberta Hlth Serv, Dept Populat Hlth Res, Canc Control Alberta, Calgary, AB, Canada; [Holcatova, Ivana] Charles Univ Prague, Inst Hyg & Epidemiol, Fac Med 1, Prague, Czech Republic; [Janout, Vladimir] Palacky Univ, Dept Prevent Med, Fac Med, CR-77147 Olomouc, Czech Republic; [Foretova, Lenka] Masaryk Mem Canc Inst, Dept Canc Epidemiol & Genet, Brno, Czech Republic; [Fabianova, Eleonora; Adamcakova, Zora] Reg Author Publ Hlth Banska Bystrica, Banska Bystrica, Slovakia; [Shonova, Olga] Reg Hosp, Dept Gastroenterol, Ceske Budejovice, Czech Republic; [Martinek, Arnost] Univ Ostrava, Fac Med, Dept Internal Med, CZ-70103 Ostrava, Czech Republic; [Ryska, Miroslav] Charles Univ Prague, Surg Clin, Fac Med 2, Prague, Czech Republic; [Ryska, Miroslav] Mil Univ Hosp, Prague, Czech Republic; [Flaska, Erik] Franklin D Roosevelt Univ Hosp, Surg Clin, Banska Bystrica, Slovakia","Scelo, G (reprint author), Int Agcy Res Canc, Genet Epidemiol Grp, 150 Cours Albert Thomas, F-69372 Lyon 08, France.","scelog@iarc.fr","Janout, Vladimir/M-5133-2014",null,"US National Cancer Institute at the National Institutes of Health [R03 CA123546-02]; Ministry of Health of the Czech Republic [NR 9029-4/2006, NR9422-3, NR9998-3, MH CZ-DRO-MMCI 00209805]; Ministry of Health of Slovakia [MZSR2007/17-RUVZBB-02]","This work was supported by a grant from the US National Cancer Institute at the National Institutes of Health (R03 CA123546-02); grants from the Ministry of Health of the Czech Republic (NR 9029-4/2006, NR9422-3, NR9998-3, MH CZ-DRO-MMCI 00209805); and a grant from the Ministry of Health of Slovakia (MZSR2007/17-RUVZBB-02).",null,43,0,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0957-5243","1573-7225",null,"CANCER CAUSE CONTROL","Cancer Causes Control","JUN",2014,25,6,null,null,null,null,669,681,null,"10.1007/s10552-014-0370-x",null,13,"Oncology; Public, Environmental & Occupational Health","Oncology; Public, Environmental & Occupational Health","AH3LA","WOS:000336023600003",24695987]
["J","Veselka, J; Lawrenz, T; Stellbrink, C; Zemanek, D; Branny, M; Januska, J; Sitar, J; Dimitrow, P; Krejci, J; Dabrowski, M; Mizera, S; Bartel, T; Kuhn, H",null,null,null,"Veselka, Josef; Lawrenz, Thorsten; Stellbrink, Christoph; Zemanek, David; Branny, Marian; Januska, Jaroslav; Sitar, Jan; Dimitrow, Pawel; Krejci, Jan; Dabrowski, Maciej; Mizera, Stanislav; Bartel, Thomas; Kuhn, Horst",null,null,"Early Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A European Multicenter and Multinational Study","CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS",null,null,"English","Article",null,null,null,null,null,"hypertrophic cardiomyopathy; alcohol septal ablation; cardiomyopathy","FOLLOW-UP; TRANSCORONARY ABLATION; MYOCARDIAL ABLATION; PREDICTORS; EXPERIENCE; SURVIVAL; THERAPY","Background: This study was designed to evaluate the outcomes of alcohol septal ablation (ASA) under multicenter and multinational conditions. Methods: Data for 459 patients (age 57 +/- 13 years) from nine European centers were prospectively collected and retrospectively analyzed. Results: ASA led to a significant reduction in outflow gradient (PG) and dyspnea [median of PG from 88 (58-123) mm Hg to 21 (11-41) mm Hg; median of NYHA class from 3 (2-3) to 1 (1-2); P < 0.01]. The incidence of 3-month major adverse events (death, electrical cardioversion for tachyarrhythmias, resuscitation) and mortality was 2.8% and 0.7%, respectively. Permanent pacemakers for post-ASA complete heart block were implanted in 43 patients (9%). Multivariate analysis identified higher amount of alcohol (however, in generally low-dose procedures), higher baseline left ventricular ejection fraction and higher age as independent predictors of PG decrease >= 50%. Conclusions: The results of the first European multicenter and multinational study demonstrate that real-world early outcomes of ASA patients are better than was reported in observations from the first decade after ASA introduction. (C) 2013 Wiley Periodicals, Inc.","[Veselka, Josef; Zemanek, David] Charles Univ Prague, Sch Med 2, Dept Cardiol, Prague, Czech Republic; [Veselka, Josef; Zemanek, David] Univ Hosp Motol, Prague, Czech Republic; [Lawrenz, Thorsten; Stellbrink, Christoph; Kuhn, Horst] Univ Witten Herdecke, Klinikum Bielefeld Mitte, Dept Cardiol & Internal Intens Care, Bielefeld, Germany; [Lawrenz, Thorsten; Stellbrink, Christoph; Kuhn, Horst] Univ Witten Herdecke, Dept Cardiol, Bielefeld, Germany; [Zemanek, David; Krejci, Jan] St Annes Univ Hosp, Int Clin Res Ctr, Dept Internal Med Cardioangiol 1, Brno, Czech Republic; [Branny, Marian; Januska, Jaroslav] Podlesi Hosp, Dept Cardiol, Trinec, Czech Republic; [Sitar, Jan] Dept Cardiol, Varna, Bulgaria; [Dimitrow, Pawel] Jagiellonian Univ, Coll Med, Dept Cardiol 2, Krakow, Poland; [Dabrowski, Maciej] Inst Cardiol, Dept Intervent Cardiol & Angiol, Warsaw, Poland; [Mizera, Stanislav] Natl Inst Cardiovasc Dis, Dept Cardiol, Bratislava, Slovakia; [Bartel, Thomas] Med Univ Innsbruck, Dept Internal Med 3, A-6020 Innsbruck, Austria","Veselka, J (reprint author), Charles Univ Prague, Sch Med 2, Dept Cardiol, Prague, Czech Republic.","veselka.josef@seznam.cz",null,null,"project for conceptual development of research organization [00064203]; Internal Grant Agency, Ministry of Health, Czech Republic [NT 11401-5]; European Social Fund; State Budget of the Czech Republic - Project ICRC Human Bridge -Support of R&D teams through formation of new postdoc positions [CZ.1.07/2.3.00/30.0023]; European Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]","Contract grant sponsor: project for conceptual development of research organization; Contract grant number: 00064203.Contract grant sponsor: Internal Grant Agency, Ministry of Health, Czech Republic; Contract grant number: NT 11401-5.Contract grant sponsor: European Social Fund and the State Budget of the Czech Republic - Project ICRC Human Bridge -Support of R&D teams through formation of new postdoc positions; Contract grant number: CZ.1.07/2.3.00/30.0023.Contract grant sponsor: European Regional Development Fund-Project FNUSA-ICRC; Contract grant number: CZ.1.05/1.1.00/02.0123.",null,29,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1522-1946","1522-726X",null,"CATHETER CARDIO INTE","Catheter. Cardiovasc. Interv.","JUL 1",2014,84,1,null,null,null,null,101,107,null,"10.1002/ccd.25236",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AJ8QA","WOS:000337970100021",24285605]
["J","Spacek, M; Veselka, J",null,null,null,"Spacek, Miloslav; Veselka, Josef",null,null,"Microembolization Following Balloon Deflation During Proximally Protected Carotid Artery Stenting-A Potential Focus of Procedure Improvement?","CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS",null,null,"English","Letter",null,null,null,null,null,null,"CEREBRAL PROTECTION; SYSTEM; SAFETY; TRIAL",null,"[Spacek, Miloslav; Veselka, Josef] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Cardiol,Ctr Cardiovasc, Prague, Czech Republic","Spacek, M (reprint author), Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Cardiol,Ctr Cardiovasc, Prague, Czech Republic.",null,null,null,null,null,null,6,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1522-1946","1522-726X",null,"CATHETER CARDIO INTE","Catheter. Cardiovasc. Interv.","JUN 1",2014,83,7,null,null,null,null,1185,1186,null,"10.1002/ccd.24969",null,2,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AH2LV","WOS:000335953900040",23613204]
["J","Rampichova, M; Buzgo, M; Chvojka, J; Prosecka, E; Kofronova, O; Amler, E",null,null,null,"Rampichova, Michala; Buzgo, Matej; Chvojka, Jiri; Prosecka, Eva; Kofronova, Olga; Amler, Evzen",null,null,"Cell penetration to nanofibrous scaffolds","CELL ADHESION & MIGRATION",null,null,"English","Article",null,null,null,null,null,"fibrous scaffold; mesenchymal stem cells; Forcespinning (R); cell penetration; electrospinning","TISSUE ENGINEERING APPLICATIONS; UNIAXIALLY ALIGNED ARRAYS; ELECTROSPUN NANOFIBERS; INFILTRATION; POROSITY; MESHES; FIBER","Cell infiltration is a critical parameter for the successful development of 3D matrices for tissue engineering. Application of electrospun nanofibers in tissue engineering has recently attracted much attention. Notwithstanding several of their advantages, small pore size and small thickness of the electrospun layer limit their application for development of 3D scaffolds. Several methods for the pore size and/or electrospun layer thickness increase have been recently developed. Nevertheless, tissue engineering still needs emerging of either novel nanofiber-enriched composites or new techniques for 3D nanofiber fabrication. Forcespinning (R) seems to be a promising alternative. The potential of the Forcespinning (R) method is illustrated in preliminary experiment with mesenchymal stem cells.","[Rampichova, Michala; Buzgo, Matej; Prosecka, Eva; Amler, Evzen] Acad Sci Czech Republic, Lab Tissue Engn, Inst Expt Med, Prague, Czech Republic; [Rampichova, Michala; Buzgo, Matej; Amler, Evzen] Czech Tech Univ, Univ Ctr Energy Efficient Bldg UCEEB, Kladno, Czech Republic; [Chvojka, Jiri] Tech Univ Liberec, Fac Text Engn, Dept Nonwoven Text, Liberec, Czech Republic; [Chvojka, Jiri] Tech Univ Liberec, Inst Nanomat, Liberec, Czech Republic; [Amler, Evzen] Charles Univ Prague, Inst Biophys, Fac Med 2, Prague, Czech Republic; [Kofronova, Olga] Acad Sci Czech Republic, Lab Mol Structure Characterizat, Inst Microbiol, Prague, Czech Republic; [Amler, Evzen] Czech Tech Univ, Fac Biomed Engn, Kladno, Czech Republic","Rampichova, M (reprint author), Acad Sci Czech Republic, Lab Tissue Engn, Inst Expt Med, Prague, Czech Republic.","m.rampichova@biomed.cas.cz","Kofronova, Olga/H-7239-2014; Rampichova, Michala/H-3121-2014",null,"Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Institutional Research Concept [RVO 61388971]; Ministry of Education Youth and Sports of the Czech Republic [IPv6]; Grant Agency of the Charles University [626012, 384311, 270513, 330611, 648112]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NT12156]","This study was supported by the Academy of Sciences of the Czech Republic, institutional research plans AV0Z50390703, AV0Z50390512, and the Institutional Research Concept RVO 61388971, The Ministry of Education Youth and Sports of the Czech Republic (project IPv6), The Grant Agency of the Charles University (grant No., 626012, 384311, 270513, 330611, 648112), and Internal Grant Agency of the Ministry of Health of the Czech Republic (grant No. NT12156).",null,23,0,0,"LANDES BIOSCIENCE","AUSTIN","1806 RIO GRANDE ST, AUSTIN, TX 78702 USA","1933-6918","1933-6926",null,"CELL ADHES MIGR","Celll Adhes. Migr.","JAN 1",2014,8,1,null,null,null,null,36,41,null,"10.4161/cam.27477",null,6,"Cell Biology","Cell Biology","AC3ZM","WOS:000332460300006",24429388]
["J","Brunnerova, R; Lebl, J",null,null,null,"Brunnerova, Renata; Lebl, Jan",null,null,"The occurrence of ocular diseases in patients with Turner syndrome","CENTRAL EUROPEAN JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,"Turner syndrome; 45, X karyotype; Chromosomal mosaicism; Refractive errors; Colour vision deficiency; Ptosis; Strabismus; Amblyopia; Epicanthus","DYSGENESIS","Turner syndrome is among the most common chromosomal aberrations. It is caused by a missing or anomaly of one X chromosome, alternatively a chromosomal mosaicism. It is often connected with a more frequent occurrence of some ocular diseases. In our study 81 girls and women with Turner syndrome from the age of 5 to 23 years old were examined. The occurrence of ocular diseases and their possible connection with karyotype was the main focus of our attention. Myopia had the highest incidence in these girls, further there were hyperopia, epicanthus, colour vision deficiency, amblyopia, strabismus and ptosis. The occurrence of colour vision deficiency was higher than in the general population where it differs in sexes. The occurrence of strabismus and ptosis was higher than in the general population. The total range of refractive errors was slightly higher than in the general population, with a different distribution according to karyotype. Hyperopia was recorded more often at the 45,X karyotype, namely 28 %, while for chromosomal mosaicism it was only in 18%. For myopia the ratio was reversed - chromosomal mosaicism in 31% and in 45,X karyotype in 26 %.In total, while comparing individual eye defects incidence in 45,X karyotype and chromosomal mosaicism, similar findings were recorded. These results were also assessed with the help of statistics.","[Brunnerova, Renata] Fac Hosp Kralovske Vinohrady, Dept Ophthalmol, Prague 10034 10, Czech Republic; [Lebl, Jan] Fac Hosp Motol, Dept Pediat, Prague 15000 5, Czech Republic","Brunnerova, R (reprint author), Fac Hosp Kralovske Vinohrady, Dept Ophthalmol, Prague 10034 10, Czech Republic.","brunner@fnkv.cz",null,null,null,null,null,30,0,0,"DE GRUYTER OPEN LTD","WARSAW","SOLIPSKA 14A-1, 02-482 WARSAW, POLAND","1895-1058","1644-3640",null,"CENT EUR J MED","Cent. Eur. J. Med.","OCT",2014,9,5,null,null,null,null,680,686,null,"10.2478/s11536-013-0323-x",null,7,"Medicine, General & Internal","General & Internal Medicine","AM5YW","WOS:000339938100013"]
["J","Musova, Z; Kaiserova, M; Kriegova, E; Fillerova, R; Vasovcak, P; Santava, A; Mensikova, K; Zumrova, A; Krepelova, A; Sedlacek, Z; Kanovsky, P",null,null,null,"Musova, Zuzana; Kaiserova, Michaela; Kriegova, Eva; Fillerova, Regina; Vasovcak, Peter; Santava, Alena; Mensikova, Katerina; Zumrova, Alena; Krepelova, Anna; Sedlacek, Zdenek; Kanovsky, Petr",null,null,"A Novel Frameshift Mutation in the AFG3L2 Gene in a Patient with Spinocerebellar Ataxia","CEREBELLUM",null,null,"English","Article",null,null,null,null,null,"SCA28; Spinocerebellar ataxia; AFG3L2; Frameshift mutation","HEREDITARY SPASTIC PARAPLEGIA; DOMINANT CEREBELLAR-ATAXIA; SLOW PROGRESSION; MITOCHONDRIA; TERMINATION; SCA28; SEQUENCE; NMD","Spinocerebellar ataxia type 28 (SCA28) is an autosomal dominant neurodegenerative disorder caused by missense AFG3L2 mutations. To examine the occurrence of SCA28 in the Czech Republic, we screened 288 unrelated ataxic patients with hereditary (N = 49) and sporadic or unknown (N = 239) form of ataxia for mutations in exons 15 and 16, the AFG3L2 mutation hotspots. A single significant variant, frameshift mutation c.1958dupT leading to a premature termination codon, was identified in a patient with slowly progressive speech and gait problems starting at the age of 68 years. Neurological examination showed cerebellar ataxia, mild Parkinsonian features with predominant bradykinesia, polyneuropathy of the lower limbs, and cognitive decline. However, other common SCA28 features like pyramidal tract signs (lower limb hyperreflexia, positive Babinski sign), ophthalmoparesis or ptosis were absent. The mutation was also found in a patient's unaffected daughter in whom a targeted examination at 53 years of age revealed mild imbalance signs. RNA analysis showed a decreased ratio of the transcript from the mutated AFG3L2 allele relative to the normal transcript in the peripheral lymphocytes of both patients. The ratio was increased by puromycin treatment, indicating that the mutated transcript can be degraded via nonsense-mediated RNA decay. The causal link between the mutation and the phenotype of the patient is currently unclear but a pathogenic mechanism based on AFG3L2 haploinsufficiency rather than the usual dominant-negative effect of missense AFG3L2 mutations reported in SCA28, cannot be excluded.","[Musova, Zuzana; Vasovcak, Peter; Krepelova, Anna; Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic; [Musova, Zuzana; Vasovcak, Peter; Zumrova, Alena; Krepelova, Anna; Sedlacek, Zdenek] Univ Hosp Motol, Prague, Czech Republic; [Kaiserova, Michaela; Mensikova, Katerina; Kanovsky, Petr] Palacky Univ, Dept Neurol, Fac Med & Dent, CR-77147 Olomouc, Czech Republic; [Kaiserova, Michaela; Kriegova, Eva; Fillerova, Regina; Santava, Alena; Mensikova, Katerina; Kanovsky, Petr] Univ Hosp, Olomouc, Czech Republic; [Kriegova, Eva; Fillerova, Regina] Palacky Univ, Dept Immunol, Fac Med & Dent, CR-77147 Olomouc, Czech Republic; [Santava, Alena] Palacky Univ, Dept Med Genet & Foetal Med, Fac Med & Dent, CR-77147 Olomouc, Czech Republic; [Zumrova, Alena] Charles Univ Prague, Dept Child Neurol, Fac Med 2, Prague, Czech Republic","Musova, Z (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic.","zuzana.musova@fnmotol.cz",null,null,"Ministry of Health of the Czech Republic [00064203]; Internal grant agency of Palacky University [IGA-LF_13_13];  [NT-12221]","We thank the patients for their participation in the study, two anonymous reviewers for very valuable comments and Michal Krupka, Ph.D., for his help with Western blot analysis. This work was supported by grant NT-12221 and grant for conceptual development of research organization University Hospital Motol 00064203 from the Ministry of Health of the Czech Republic, and by grant IGA-LF_13_13 from the Internal grant agency of Palacky University.",null,24,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1473-4222","1473-4230",null,"CEREBELLUM","Cerebellum","JUN",2014,13,3,null,null,null,null,331,337,null,"10.1007/s12311-013-0538-z",null,7,"Neurosciences","Neurosciences & Neurology","AG9LB","WOS:000335739600004",24272953]
["J","Urbanova, M; Vyhnalek, M; Nikolai, T; Michalec, J; Sheardova, K; Laczo, J; Hudecek, D; Hort, J",null,null,null,"Urbanova, M.; Vyhnalek, M.; Nikolai, T.; Michalec, J.; Sheardova, K.; Laczo, J.; Hudecek, D.; Hort, J.",null,null,"Validity of Enhanced Cued Recall Test in the Diagnosis of Alzheimer Dementia and Behavioral Variant of Frontotemporal Dementia","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"Alzheimer dementia; frontotemporal dementia; memory","DISEASE; IMPAIRMENT; CRITERIA","Introduction: Enhanced Cued Recall (ECR) memory test is especially valuable in screening for cognitive impairment in the elderly. ECR uses categorical cues during controlled encoding and recall; tests based on this paradigm are considered to be able to identify hippocampal memory impairment characterized by poor free recall with minimal effect of cueing, typical of Alzheimer's disease (AD). The test could aid in differentiating memory impairment in behavioural variant frontotemporal dementia (bvFTD) versus AD - despite the poor free recall bvFTD patients benefit considerably from cueing. Objective: To establish the validity of ECR in diagnosing memory impairment in AD and bvFTD. Methods: Thirty six patients with probable mild AD (MMSE 21.7 +/- 2.4), 15 with probable bvFTD (MMSE 23.8 +/- 2.4) and 45 healthy elderly (HE) (MMSE 28.96 +/- 1.17) underwent clinical and neuropsychological examination including ECR. Results: There was a statistically significant difference between all groups in all three ECR memory performance scores: free recall, total recall and cueing effect (p < 0.001). Free recall was the most effective score for discriminating dementias from healthy elderly (sensitivity 94% and specificity 100% for AD and sensitivity 80% and specificity 91% for bvFTD); total recall was most effective for differential diagnosis of both dementias (sensitivity 86% and specificity 87%). Conclusion: ECR is a highly sensitive and specific test for identification of memory impairment in AD and bvFTD, and can contribute to the differential diagnosis. We recommend it as highly useful test for clinical practice.","[Urbanova, M.; Vyhnalek, M.; Nikolai, T.; Sheardova, K.; Laczo, J.; Hudecek, D.; Hort, J.] FN Sv Anny Brne, Mezinarodni Centrum Klin Vyzkumu, Brno, Czech Republic; [Vyhnalek, M.; Nikolai, T.; Laczo, J.; Hort, J.] 2 LF UK, Neurol Klin, Kognitivni Centrum, Prague, Czech Republic; [Vyhnalek, M.; Nikolai, T.; Laczo, J.; Hort, J.] FN Motole, Prague, Czech Republic; [Michalec, J.] 1 LF UK, Psychiat Klin, Prague, Czech Republic; [Michalec, J.] VFN Praze, Prague, Czech Republic; [Sheardova, K.; Hudecek, D.] LF MU, Neurol Klin, Brno, Czech Republic; [Sheardova, K.; Hudecek, D.] FN Sv Anny Brne, Brno, Czech Republic","Urbanova, M (reprint author), Neurol Clin, LF UK 2, Uvalu 84, Prague 15006 5, Czech Republic.","martin.vyhnalek@fnmotol.cz",null,null,null,null,null,21,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,5,null,null,null,null,576,581,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AQ7TM","WOS:000343022100005"]
["J","Liba, Z; Hanzalova, J; Sebronova, V; Komarek, V",null,null,null,"Liba, Z.; Hanzalova, J.; Sebronova, V.; Komarek, V.",null,null,"Anti-N-Methyl-D-Aspartate Receptor Encephalitis","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"anti-NMDAR encephalitis; diagnosis; therapy",null,"N-methyl-D-aspartate encephalitis is a recently defined autoimmune disorder of the central nervous system. Neurological symptoms are associated with antibody-dependent internalization of NMDA receptors that leads to synapse disruption. Information about the disease, therapy and diagnosis are followed by clinical experience with our group of five patients.","[Liba, Z.; Sebronova, V.; Komarek, V.] 2 LF UK, Ustav Imunol Neurol Klin, Prague 15006 5, Czech Republic; [Hanzalova, J.] 2 LF UK, Likvorova Lab, Ustav Imunol Neurol Klin, Prague 15006 5, Czech Republic; FN Motole, Prague, Czech Republic","Liba, Z (reprint author), 2 LF UK, Klin Detske Neurol, Uvalu 84, Prague 15006 5, Czech Republic.","zuzana.liba@fnmotol.cz",null,null,null,null,null,10,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,5,null,null,null,null,624,630,null,null,null,7,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AQ7TM","WOS:000343022100014"]
["J","Libertinova, J; Meluzinova, E; Matoska, V; Zajac, M; Hyncicova, E; Tomek, A; Bojar, M",null,null,null,"Libertinova, J.; Meluzinova, E.; Matoska, V.; Zajac, M.; Hyncicova, E.; Tomek, A.; Bojar, M.",null,null,"Neutralising Antibodies and Myxovirus Resistance Protein A as a Marker of Biological Response to Interferon beta","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"interferon beta; multiple sclerosis; neutralizing antibodies; Myxovirus resistance protein A","MULTIPLE-SCLEROSIS; MS PATIENTS; THERAPY; BIOACTIVITY; BIOAVAILABILITY; DISAPPEARANCE","Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis. Patients treated with interferon beta may develop neutralizing antibodies that can reduce or abolish its efficacy. Interferon-inducible Myxovirus resistance protein A has been proven to be a sensitive marker of biological response to interferon beta. Neutralizing antibodies and the levels of Myxovirus resistance protein A mRNA are sensitive measures of biological response to interferon beta; their levels should be investigated in all interferon-treated patients.","[Libertinova, J.; Meluzinova, E.; Hyncicova, E.; Tomek, A.; Bojar, M.] 2 LF UK, Neurol Klin, Prague 15400 5, Czech Republic; [Libertinova, J.; Meluzinova, E.; Zajac, M.; Hyncicova, E.; Tomek, A.; Bojar, M.] FN Motole, Prague, Czech Republic; [Matoska, V.] Lab Mol Diagnost Nemocnice Homolce, Prague, Czech Republic; [Zajac, M.] 2 LF UK, Ustav Lekarske Mikrobiol, Prague 15400 5, Czech Republic","Libertinova, J (reprint author), 2 LF UK, Neurol Klin, Uvalu 84, Prague 15400 5, Czech Republic.","libertinova@gmail.com",null,null,null,null,null,21,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,5,null,null,null,null,638,641,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AQ7TM","WOS:000343022100016"]
["J","Kuzelova, H; Macek, M; Raboch, J; Ptacek, R",null,null,null,"Kuzelova, H.; Macek, M., Jr.; Raboch, J.; Ptacek, R.",null,null,"Genetic Variability in Attention Deficit Hyperactivity Disorder","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"attention deficit hyperactivity disorder; genetics; gene variant","GENOME-WIDE SCAN; DEFICIT/HYPERACTIVITY DISORDER; RECEPTOR GENE; SIB-PAIRS; ADHD; ASSOCIATION; LINKAGE; CHILDREN; LOCI; METHYLPHENIDATE","Attention deficit hyperactivity disorder (ADHD) is a common, probably highly genetically conditioned, neurobiological disorder. Heritability of ADHD symptoms is up to about 75%. However, the mechanism is still not fully understood. Attention is focused mainly on genes of the dopaminergic and serotonergic system as well as many other genes. The paper presents a summary of the most significant genetic associations with ADHD.","[Kuzelova, H.; Macek, M., Jr.] FN Motole, LF UK Praze 2, Prague, Czech Republic; [Kuzelova, H.; Raboch, J.; Ptacek, R.] LF UK & VFN, Psychiat Klin 1, Prague 12801 2, Czech Republic","Kuzelova, H (reprint author), LF UK & VFN, Psychiat Klin 1, Karlovu 11, Prague 12801 2, Czech Republic.","kuzelova.hana@email.cz",null,null,null,null,null,52,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,4,null,null,null,null,423,427,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AM2VV","WOS:000339709800003"]
["J","Cerman, J; Laczo, J; Vyhnalek, M; Vlcek, K; Lerch, O; Sheardova, K; Hort, J",null,null,null,"Cerman, J.; Laczo, J.; Vyhnalek, M.; Vlcek, K.; Lerch, O.; Sheardova, K.; Hort, J.",null,null,"Differences in Spatial Navigation Impairment in Neurodegenerative Dementias","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"Alzheimer's disease; frontotemporal lobar degeneration; dementia with Lewy bodies; spatial orientation","FRONTOTEMPORAL LOBAR DEGENERATION; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; LEWY BODIES; TOPOGRAPHICAL DISORIENTATION; FDG-PET; DIAGNOSIS; CRITERIA; ATROPHY; LOST","Impairment of multiple cognitive domains, including spatial navigation, leads to deterioration of self-sufficiency, a characteristic feature of patients with dementia. Spatial navigation is divided into three basic components that depend on different brain structures navigation using a close orientation cue (cued), starting position of the body (egocentric) and distant orientation cue (allocentric). The aim of the study was to compare differences in impairment of these spatial navigation components in patients with the most common types of neuro-degenerative dementias. In total, 78 patients with neurodegenerative dementias of various etiologies were divided into three groups: Alzheimer's disease (AD, n = 61), frontotemporal lobar degeneration (FTLD, n = 9) and dementia with Lewy bodies (DLB, n = 8). All subjects were examined in an experimental device called the Blue Velvet Arena that allows researchers to measure performance in each of the three navigation components. The results of the different tests were subsequently compared. In the cued navigation test, the FTLD group performed better than the AD (p = 0.03) and DLB (p = 0.006) groups. Furthermore, in the egocentric navigation test, the DLB group was outperformed by AD (p = 0.012) and FTLD (p = 0.012) groups. Finally, in the allocentric navigation test there were no differences among the groups (p = 0.069). Our results show that spatial navigation impairment may be least pronounced in FTLD patients and most pronounced in DLB patients. There are specific differences in spatial navigation impairment among patients with AD, FTLD and DLB that can be measured with the Blue Velvet Arena device.","[Cerman, J.; Laczo, J.; Vyhnalek, M.; Lerch, O.; Hort, J.] LF UK & FN Motole, Neurol Klin 2, Prague 15006 5, Czech Republic; [Laczo, J.; Sheardova, K.; Hort, J.] FN Sv Anny Brne, Klin Vyzkumu, Mezinarodni Ctr, ICRC, Brno, Czech Republic; [Vlcek, K.] Fyziol Ustav AV CR, Vvi, Oddeleni Neurofyziol Pameti, Prague, Czech Republic","Laczo, J (reprint author), LF UK & FN Motole, Neurol Klin 2, V Uvalu 84, Prague 15006 5, Czech Republic.","JanLaczo@seznam.cz","Vlcek, Kamil/B-9620-2012","Vlcek, Kamil/0000-0001-7152-3093",null,null,null,42,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,4,null,null,null,null,449,455,null,null,null,7,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AM2VV","WOS:000339709800007"]
["J","Brozkova, DS; Mazanec, R; Bohm, J; Vysata, O; Auer-Grumbach, M; Windpassinger, C; Neupauerova, J; Barankova, L; Nevsimalova, S; Seeman, P",null,null,null,"Brozkova, D. Safka; Mazanec, R.; Boehm, J.; Vysata, O.; Auer-Grumbach, M.; Windpassinger, Ch.; Neupauerova, J.; Barankova, L.; Nevsimalova, S.; Seeman, P.",null,null,"Hereditary Ulceromutilating Sensory Neuropathy - Clinical, Electrophysiological and Molecular Genetic Study of Three Families","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"hereditary sensory neuropathy; HSN1; CMT2B; RAB7 gene; SPTLC1 gene","SERINE PALMITOYLTRANSFERASE; TYPE-1; MUTATIONS; PROTEIN; SPTLC1","Aim: The goal was to clinically and electrophysiologically characterize two types of ulceromutilating hereditary neuropathy CMT2B and HSN1 in three Czech families where molecular genetic cause was confirmed. Patients: We describe three families, overall 16 affected patients, with hereditary sensory neuropathy. Methods: The diagnosis of sensory, predominantly axonal neuropathy was done on the basis of neurological and electrophysiological examination. Sequencing of the SPTLC1 and RAB7 genes was done in families A, B, C and 24 unrelated patients with clinical suspicion for HSN. Results: Hereditary sensory neuropathy type 1 (HSN1) caused by the p.C133Y mutation in the SPTLC1 gene was confirmed in family B and the Charcot-Marie-Tooth type 2B (CMT2B) caused by p.L129F and p.V162M mutations in the RAB7 gene was confirmed in families A and C. All three mutations have been previously described. DNA examination of 24 unrelated patients did not reveal the cause of their disease. Conclusion: As in other countries, ulceromutilating hereditary neuropathies CMT2B and HSN1 are rare in the Czech population. However, clinical manifestations are clearly recognizable if correctly obtained genealogical data family history is properly taken into account. The three families described here are the only known families with hereditary neuropathies caused by mutations in RAB7 and SPTLC1 in the Czech Republic. Clarification of the cause of ulceromutilating sensory neuropathy is crucial for genetic and clinical prognosis, including targeted genetic prevention, but possibly also for an L-serin therapy in SPTLC1 mutation patients to be tested in a clinical study (Boston, USA).","[Brozkova, D. Safka; Neupauerova, J.; Barankova, L.; Seeman, P.] 2 LF UK, Kliniky Detske Neurol, DNA Lab, Prague 15006 5, Czech Republic; [Brozkova, D. Safka; Neupauerova, J.; Barankova, L.; Seeman, P.] FN Motole, Prague, Czech Republic; [Mazanec, R.] Charles Univ, LF 2, Neurol Klin, Prague, Czech Republic; [Mazanec, R.] FN Motole, Prague, Czech Republic; [Boehm, J.; Nevsimalova, S.] 1 LF UK VFN, Neurol Klin, Prague, Czech Republic; [Vysata, O.] LF UK FN, Neurol Klin, Hradec Kralove, Czech Republic; [Auer-Grumbach, M.] Med Univ Vienna, Dept Orthopaed, Vienna, Austria; [Windpassinger, Ch.] Med Univ Graz, Inst Human Genet, Graz, Austria","Brozkova, DS (reprint author), 2 LF UK, Kliniky Detske Neurol, DNA Lab, Uvalu 84, Prague 15006 5, Czech Republic.","dana.brozkova@lf2.cuni.cz",null,null,null,null,null,15,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,4,null,null,null,null,479,486,null,null,null,8,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AM2VV","WOS:000339709800011"]
["J","Javurkova, A; Amlerova, J; Raudenska, J",null,null,null,"Javurkova, A.; Amlerova, J.; Raudenska, J.",null,null,"Long-term Observation of Cognitive, Emotional and Behavioral Changes in Patient with Multiple Sclerosis - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"multiple sclerosis; neuropsychologicalassessment; cognitive behavioral; therapy","QUALITY-OF-LIFE; THERAPY","The aim of the paper is to show cognitive, emotional and behavioural changes in a multiple sclerosis (MS) patient over eighteen years of observation. Case study documents maladaptation to MS diagnosis and prolonged maladaptive coping, diffusion and influence of affective components on inhibition of cognitive abilities and mental health status, the contribution of stress to development of pseudo-relapses\" of MS, psychosocial problems and quality of life. The diagnosis of MS was devastating for the patient herself and her family. Its unpredictable course complicated adjustment and created difficulties in planning for support. Effects of disease-related stress as well as a negative side-effect of treatment led to many psychosocial problems that impaired the patient's quality of life and affected compliance with treatment and rehabilitation. Repeated neuropsychological assessment was a part of a comprehensive diagnostic process and treatment of MS and, at the end of observation, in chronic-progressive phase of MS, was complemented with cognitive-behavioural therapy aimed at reducing burden of disease and improving the quality of life.","[Javurkova, A.] FN Kralovske Vinohrady, Oddeleni Klin Psychol, Prague, Czech Republic; [Amlerova, J.] 2 LF UK, Neurol Klin, Prague 15006 5, Czech Republic; [Amlerova, J.] FN Motole, Neurol Klin, Prague, Czech Republic; [Raudenska, J.] 2 LF UK, Oddeleni Klin Psychol, Prague 15006 5, Czech Republic; [Raudenska, J.] FN Motole, Oddeleni Klin Psychol, Prague, Czech Republic","Raudenska, J (reprint author), 2 LF UK, Oddeleni Klin Psychol, Uvalu 84, Prague 15006 5, Czech Republic.","jaroslava.raudenska@fnmotol.cz",null,null,null,null,null,10,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,4,null,null,null,null,501,504,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AM2VV","WOS:000339709800015"]
["J","Stepankova, H; Smolik, F; Vyhnalek, M; Nikolai, T; Horakova, K; Niederlova, M",null,null,null,"Stepankova, Hana; Smolik, Filip; Vyhnalek, Martin; Nikolai, Tomas; Horakova, Karolina; Niederlova, Marketa",null,null,"Propositional density in seniors' responses","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"psycholinguistics; aging; mild cognitive impairment; propositions","MILD COGNITIVE IMPAIRMENT; MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; EARLY-LIFE; LINGUISTIC ABILITY; IDEA DENSITY; NUN; LANGUAGE; RESERVE; OCCUPATION","Objectives. It has been shown that propositional density (PD), which roughly corresponds to the number of ideas expressed in a text of given length, is related to cognitive performance in the older age. The present study investigated differences in propositional density in oral language production between healthy seniors and patients with mild cognitive impairment (MCI). MCI is generally accepted as a prodromal stage of Alzheimer's disease (AD). Sample and setting. The sample included 33 MCI persons and 32 healthy controls (mean age 73 years). The groups were equivalent as for the age and education. As expected, there was a significant difference between Mini-Mental State Examination (MMSE) scores between the groups, with MMSE being a simplified measure of their cognitive status. Hypotheses. Lower PD was expected in MCI persons, as the task required recent past recall which is considered one of the early deficiencies in early AD and MCI due to AD. Statistical analysis. Mean PD across groups was compared using the independent samples t-test. Results. Mean propositional density in MCI persons was 48,74% (SD 5,78), and in healthy controls 53,06% (SD 4,56). The difference was statistically significant (p<0,001). Cohen's d 0,83 represents a large effect size for the group difference. Study limitations. The main limitation is the heterogeneity of the MCI group. Also, the detailed cognitive status of the healthy controls is unknown. Thus the group could include persons with some cognitive impairment which has not been detected yet.","[Stepankova, Hana; Smolik, Filip; Horakova, Karolina; Niederlova, Marketa] Univ Karlovy Praze, Filozoficka Fak, Prague, Czech Republic; [Stepankova, Hana; Horakova, Karolina] Psychiat Ctr Praha, Prague 18103 8, Czech Republic; [Vyhnalek, Martin; Nikolai, Tomas] Univ Karlovy Praze, Kognitivni Ctr, Neurol Klin, Lekarske Fak 2, Prague, Czech Republic; [Vyhnalek, Martin; Nikolai, Tomas] Fak Nemocnice Motole, Prague, Czech Republic; [Smolik, Filip] Psychol Ustav AV CR, Prague, Czech Republic; [Vyhnalek, Martin; Nikolai, Tomas] Fak Nemocnice Sv Anny Brne, Mezinarodni Ctr Klin Vyzkumu, Brno, Czech Republic","Stepankova, H (reprint author), Psychiat Ctr Praha, Ustavni 91, Prague 18103 8, Czech Republic.","hana.stepankova@centrum.cz","Stepankova, Hana/L-7413-2014","Stepankova, Hana/0000-0002-2332-0934",null,null,null,37,0,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X","1804-6436",null,"CESK PSYCHOL","Cesk. Psychol.",null,2014,58,4,null,null,null,null,317,325,null,null,null,9,"Psychology, Multidisciplinary","Psychology","AO6KV","WOS:000341461800001"]
["J","Kubus, P; Vit, P; Gebauer, RA; Materna, O; Janousek, J",null,null,null,"Kubus, Peter; Vit, Pavel; Gebauer, Roman A.; Materna, Ondrej; Janousek, Jan",null,null,"Electrophysiologic Profile and Results of Invasive Risk Stratification in Asymptomatic Children and Adolescents With the Wolff-Parkinson-White Electrocardiographic Pattern","CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"child; risk assessment; Wolff-Parkinson-White syndrome","ANTEROGRADE REFRACTORY PERIOD; VENTRICULAR PREEXCITATION; ATRIAL-FIBRILLATION; FOLLOW-UP; INTERMITTENT PREEXCITATION; ACCESSORY PATHWAY; CATHETER ABLATION; NATURAL-HISTORY; ISOPROTERENOL; PREDICT","Background Data on the results and clinical effect of an invasive risk stratification strategy in asymptomatic young patients with the Wolff-Parkinson-White electrocardiographic pattern are scarce. Methods and Results Eighty-five consecutive patients aged <18 years with a Wolff-Parkinson-White pattern and persistent preexcitation at maximum exercise undergoing invasive risk stratification were retrospectively studied. Adverse accessory pathway (AP) properties were defined according to currently consented criteria as any of the following: shortest preexcited RR interval during atrial fibrillation/rapid atrial pacing 250 ms (or antegrade effective refractory period 250 ms if shortest preexcited RR interval was not available) or inducible atrioventricular re-entrant tachycardia. Age at evaluation was median 14.9 years. Eighty-two patients had a structurally normal heart and 3 had hypertrophic cardiomyopathy. A single manifest AP was present in 80, 1 manifest and 1 concealed AP in 4, and 2 manifest APs in 1 patient. Adverse AP properties were present in 32 of 85 patients (37.6%) at baseline and in additional 16 of 44 (36.4%) after isoproterenol. Ablation was performed in 41 of these 48 patients. Ablation was deferred in the remaining 7 for pathway proximity to the atrioventricular node. In addition, 18 of the low-risk patients were ablated based on patient/parental decision. Conclusions Adverse AP properties at baseline were exhibited by 37.6% of the evaluated patients with an asymptomatic Wolff-Parkinson-White preexcitation persisting at peak exercise. Isoproterenol challenge yielded additional 36.4% of those tested at higher risk. Ablation was performed in a total of 69.4% of patients subjected to invasive risk stratification.","[Kubus, Peter; Materna, Ondrej; Janousek, Jan] Univ Hosp, Childrens Heart Ctr, Prague, Czech Republic; [Vit, Pavel] Childrens Univ Hosp Brno, Brno, Czech Republic; [Gebauer, Roman A.] Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, D-04109 Leipzig, Germany","Kubus, P (reprint author), Fak Nemocnice Motole, Detske Kardioctr, V Uvalu 84, Prague 15006, Czech Republic.","peter.kubus@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic and conceptual development of research organization, University Hospital Motol, Prague, Czech Republic [00064203]","This work was supported by Ministry of Health, Czech Republic and conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203.",null,26,1,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1941-3149","1941-3084",null,"CIRC-ARRHYTHMIA ELEC","Circ.-Arrhythmia Electrophysiol.","APR",2014,7,2,null,null,null,null,218,223,null,"10.1161/CIRCEP.113.000930",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AG1XO","WOS:000335209700008",24488978]
["J","Kelbich, P; Hejcl, A; Krulichova, IS; Prochazka, J; Hanuljakova, E; Peruthova, J; Koudelkova, M; Sames, M; Krejsek, J",null,null,null,"Kelbich, Petr; Hejcl, Ales; Krulichova, Iva Selke; Prochazka, Jan; Hanuljakova, Eva; Peruthova, Jitka; Koudelkova, Martina; Sames, Martin; Krejsek, Jan",null,null,"Coefficient of energy balance, a new parameter for basic investigation of the cerebrospinal fluid","CLINICAL CHEMISTRY AND LABORATORY MEDICINE",null,null,"English","Article",null,null,null,null,null,"coefficient of energy balance; CSF compartment; cytological picture of the CSF; energy relationships; inflammation in the CNS","GLUCOSE-UTILIZATION; ASEPTIC-MENINGITIS; OXIDATIVE BURST; DISTINGUISH; LYMPHOCYTES; BACTERIAL; MONOCYTES; MARKERS; LACTATE; CELL","Background: The concentrations of glucose and lactate in cerebrospinal fluid (CSF) provide important information about energy metabolism in the CSF compartment. To improve our understanding of this information we introduced a new parameter resulting from a formula for calculating the fictitious production of adenosine triphosphate, i.e., the coefficient of energy balance (KEB). Methods: We evaluated cytology, the concentrations of glucose and lactate and the KEB in the CSF of 948 patients, who were divided into five groups. For statistical analysis we used the Kruskal-Wallis test with post-hoc analysis using the Dunn method and multinomial regression analysis. We determined the specificities and sensitivities of the cytological pictures and the KEB. Results: A KEB>28.0 corresponded to normal energy metabolism in the CSF. A KEB<28.0 corresponded to an increased level of anaerobic metabolism in the CSF during inflammation in the CNS. A KEB<10.0 corresponded to a high level of anaerobic metabolism in the CSF during severe inflammation with an oxidative burst of professional phagocytes in the CNS. The KEB parameter increased the specificities of cytological examinations of the CSF in all cases. Conclusions: The KEB represents an equation for calculating the fictitious average number of ATP molecules produced in the CSF compartment from one molecule of glucose, and we used it successfully as a new parameter for evaluating energy metabolism status in the CSF.","[Kelbich, Petr; Peruthova, Jitka] Hosp Kadan, Dept Clin Biochem Haematol & Immunol, Kadan 43201, Czech Republic; [Kelbich, Petr; Krejsek, Jan] Charles Univ Prague, Fac Med Hradec Kralove, Dept Clin Immunol & Allergol, Hradec Kralove, Czech Republic; [Kelbich, Petr] Masaryk Hosp Usti Nad Labem, Dept Clin Biochem, Usti Nad Labem, Czech Republic; [Kelbich, Petr; Hanuljakova, Eva; Peruthova, Jitka; Koudelkova, Martina] Lab Liquorol & Neuroimmunol Topelex, Prague, Czech Republic; [Hejcl, Ales; Sames, Martin] Univ JE Purkyne, Masaryk Hosp Usti Nad Labem, Dept Neurosurg, Usti Nad Labem, Czech Republic; [Hejcl, Ales] St Annes Univ Hosp, Int Clin Res Ctr, Brno, Czech Republic; [Hejcl, Ales] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Hejcl, Ales] Charles Univ Prague, Fac Med 1, Cent Mil Hosp, Dept Neurosurg, Prague, Czech Republic; [Krulichova, Iva Selke] Charles Univ Prague, Fac Med Hradec Kralove, Inst Med Biophys, Hradec Kralove, Czech Republic; [Prochazka, Jan] Masaryk Hosp Usti Nad Labem, Dept Intens Care Med, Usti Nad Labem, Czech Republic; [Hanuljakova, Eva] Masaryk Hosp Usti Nad Labem, Dept Clin Biochem, Usti Nad Labem, Czech Republic; [Hanuljakova, Eva] Hosp Most, Dept Clin Biochem, Most, Czech Republic; [Peruthova, Jitka] Univ Pardubice, Fac Chem Technol, Pardubice, Czech Republic; [Sames, Martin] Charles Univ Prague, Fac Med 2, Dept Neurosurg, Prague, Czech Republic","Kelbich, P (reprint author), Hosp Kadan, Dept Clin Biochem Haematol & Immunol, Golovinova 1559, Kadan 43201, Czech Republic.","kelbich@nemkadan.cz",null,null,"Charles University in Prague, Faculty of Medicine in Hradec Kralove, Czech Republic [P37/09, P37/10]; European Regional Development Fund - Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; Ministry of Health of the Czech Republic [IGA NT 13883/4-2012]; Human Resources for Neurosciences in the Hradec Kralove Region [CZ.1.07/2.3.00/20.0274]; Human Resources for Neurosciences in the Usti Region [CZ.1.07/2.3.00/20.0274]; European social fund; state budget of the Czech Republic","We thank James Dutt for critical reading of the article. This work was supported by Charles University in Prague, Faculty of Medicine in Hradec Kralove, Czech Republic, the projects \"PRVOUK\" P37/09 and P37/10, by the European Regional Development Fund - Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123), by the Grant of the Ministry of Health of the Czech Republic IGA NT 13883/4-2012 and Human Resources for Neurosciences in the Hradec Kralove and Usti Regions, CZ.1.07/2.3.00/20.0274. This project is co-financed by the European social fund and the state budget of the Czech Republic.",null,40,0,0,"WALTER DE GRUYTER GMBH","BERLIN","GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY","1434-6621","1437-4331",null,"CLIN CHEM LAB MED","Clin. Chem. Lab. Med.","JUL",2014,52,7,null,null,null,null,1009,1017,null,"10.1515/cclm-2013-0953",null,9,"Medical Laboratory Technology","Medical Laboratory Technology","AL0YJ","WOS:000338852700019",24622789]
["J","Kayserova, J; Vcelakova, J; Stechova, K; Dudkova, E; Hromadkova, H; Sumnik, Z; Kolouskova, S; Spisek, R; Sediva, A",null,null,null,"Kayserova, Jana; Vcelakova, Jana; Stechova, Katerina; Dudkova, Eva; Hromadkova, Hana; Sumnik, Zdenek; Kolouskova, Stanislava; Spisek, Radek; Sediva, Anna",null,null,"Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients","CLINICAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Dendritic cell; Interferon-alpha; Type 1 diabetes","PERIPHERAL-BLOOD; INNATE IMMUNITY; T-CELLS; MICE; CROSSTALK; INDUCTION; MOLECULES; FREQUENCY; DISEASE; MOUSE","Objective: Dendritic cells (DCs) play an important role in pathogenesis of autoimmunity, including type 1 diabetes (T1D). In this study, we investigated DC subpopulations and their responses to TLR stimulation in T1D patients and their relatives. Methods: We analyzed the frequency of myeloid (mDCs) and plasmacytoid DCs (pDCs) in 97 T1D patients (69 onset, 28 long-term), 67 first-degree relatives, and 64 controls. We additionally tested the IFN-alpha production by pDCs upon stimulation with TLR 7, 8 and 9 agonists. Results: A lower number of mDCs and pDCs were found in T1D patients and their relatives. Of all the tested TLR ligands, only stimulation with CpG 2216 induced IFN-alpha production that was the highest in T1D relatives, except of autoantibody-negative relatives bearing the protective haplotypes. Conclusion: Our data demonstrate disturbances in DC number and function expressed most significantly in T1D relatives and point to a potential role of TLR9-induced IFN-alpha production in T1D development. (C) 2014 Elsevier Inc. All rights reserved.","[Kayserova, Jana; Dudkova, Eva; Hromadkova, Hana; Spisek, Radek; Sediva, Anna] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Immunol, Prague 15006, Czech Republic; [Vcelakova, Jana; Stechova, Katerina; Sumnik, Zdenek; Kolouskova, Stanislava] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat, Prague 15006, Czech Republic; [Spisek, Radek] Sotio As, Prague, Czech Republic","Sediva, A (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Immunol, V Uvalu 84, Prague 15006, Czech Republic.","jana.kayserova@lfmotol.cuni.cz; jana.vcelakova@lfmotol.cuni.cz; katerina.stechova@lfmotol.cuni.cz; eva.dudkova@fnmotol.cz; hana.hromadkova@lfmotol.cuni.cz; zdenek.sumnik@lfmotol.cuni.cz; stanislava.kolouskova@lfmotol.cuni.cz; spisek@sotio.com; anna.sediva@fnmotol.cz",null,null,"project GACR from the Grant Agency of Czech Republic [P302/10/1679]; project IGA from the Internal Grant Agency of Czech Ministry of Health [NT/11407-5]","The study was supported by the project GACR P302/10/1679 from the Grant Agency of Czech Republic and by the project IGA NT/11407-5 from the Internal Grant Agency of Czech Ministry of Health.",null,36,0,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1521-6616","1521-7035",null,"CLIN IMMUNOL","Clin. Immunol.","JUL",2014,153,1,null,null,null,null,49,55,null,"10.1016/j.clim.2014.03.018",null,7,"Immunology","Immunology","AJ8EQ","WOS:000337935900007",24709112]
["J","Riedlbauchova, L; Nedelka, T; Schlenker, J",null,null,null,"Riedlbauchova, Lucie; Nedelka, Tomas; Schlenker, Jakub",null,null,"Symptomatic arrhythmias due to syringomyelia-induced severe autonomic dysfunction","CLINICAL RESEARCH IN CARDIOLOGY",null,null,"English","Letter",null,null,null,null,null,null,"HEART-RATE-VARIABILITY; SPINAL-CORD-INJURY; FUNCTION-TESTS; NEUROPATHY","Syringomyelia is characterized by cavity formation in the spinal cord, most often at C2-Th9 level. Clinical manifestation reflects extent and localization of the spinal cord injury. Cases: 20-year old woman was admitted for recurrent rest-related presyncopes with sudden manifestation. Paroxysms of sinus bradycardia with SA and AV blocks were repeatedly documented during symptoms. There was normal echocardiographic finding, (para) infectious etiology was not proved. Character of the ECG findings raised suspicion on neurogenic cause. Autonomic nervous system testing demonstrated abnormalities reflecting predominant sympathetic dysfunction. Suspicion on incipient myelopathy was subsequently confirmed by MRI, which discovered syringomyelia at Th5 level as the only pathology. A 52-year old man with hypotrophic quadruparesis resulting from perinatal brain injury was sent for 2-years lasting symptoms (sudden palpitation, sweating, muscle tightness, shaking) with progressive worsening. Symptoms occurred in association with sudden increase of sinus rhythm rate and blood pressure that were provoked by minimal physical activity. Presence of significant autonomic dysregulation with baroreflex hyperreactivity in orthostatic test and symptomatic postural orthostatic tachycardia with verticalization-associated hypertension were proved. MRI revealed syringomyelia at C7 and Th7 level affecting sympathetic centers at these levels. Sympathetic fibers dysfunction at C-Th spinal level may cause significant autonomic dysfunction with arrhythmic manifestation.","[Riedlbauchova, Lucie] Charles Univ Prague, Motol Univ Hosp, Clin Cardiol, Dept Electrophysiol & Cardiac Pacing, Prague 15006, Czech Republic; [Riedlbauchova, Lucie; Nedelka, Tomas] Charles Univ Prague, Fac Med 2, Prague 15006, Czech Republic; [Nedelka, Tomas] Charles Univ Prague, Motol Univ Hosp, Neurol Clin, Dept Neurophysiol, Prague 15006, Czech Republic; [Nedelka, Tomas; Schlenker, Jakub] Czech Tech Univ, Fac Biomed Engn, CR-16635 Prague, Czech Republic","Riedlbauchova, L (reprint author), Charles Univ Prague, Motol Univ Hosp, Clin Cardiol, Dept Electrophysiol & Cardiac Pacing, V Uvalu 84, Prague 15006, Czech Republic.","lucie.riedlbauchova@fnmotol.cz",null,null,null,null,null,21,0,0,"SPRINGER HEIDELBERG","HEIDELBERG","TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY","1861-0684","1861-0692",null,"CLIN RES CARDIOL","Clin. Res. Cardiol.","OCT",2014,103,10,null,null,null,null,839,845,null,"10.1007/s00392-014-0725-z",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AP2NR","WOS:000341909800011",24847769]
["J","Lotti, T; D'Erme, AM; Hercogova, J",null,null,null,"Lotti, Torello; D'Erme, Angelo Massimiliano; Hercogova, Jana",null,null,"The role of neuropeptides in the control of regional immunity","CLINICS IN DERMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"NERVE GROWTH-FACTOR; CORTICOTROPIN-RELEASING HORMONE; PERMEABILITY BARRIER HOMEOSTASIS; MELANOCYTE-STIMULATING HORMONE; VASOACTIVE-INTESTINAL-PEPTIDE; DISCOID LUPUS-ERYTHEMATOSUS; GENE-RELATED PEPTIDE; HUMAN MAST-CELLS; ATOPIC-DERMATITIS; SUBSTANCE-P","Neuropeptides (NPs) and neurotransmitters are a heterogeneous group of soluble factors that make connections within the neuroendocrine and immune systems. NPs, including substance P (SP), vasoactive intestinal peptide (VIP), a melanocyte stimulating hormone (alpha-MSH), and calcitonin gene related peptide (CGRP), released by nerves that innervate the skin, can modulate the action of innate and adaptive skin immunity as well as the skin cells functions. Their role in several inflammatory skin diseases, such as atopic dermatitis, psoriasis, and vitiligo, and in the isotopic response has been reported. Further progress in understanding the various processes that modulate the interactions of the nervous and the skin immune system is essential to develop effective treatment for inflammatory skin conditions with neurogenic components and for understanding signs and symptoms in the isotopic response and, in general, in the control of global and regional immunity. (C) 2014 Elsevier Inc. All rights reserved.","[Lotti, Torello] Univ Rome G Marconi, Chair Dept Dermatol & Venereol, Rome, Italy; [D'Erme, Angelo Massimiliano] Univ Florence, Dept Surg & Translat Med, Div Dermatol, I-50121 Florence, Italy; [Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatol & Venereol, Prague, Czech Republic; [Hercogova, Jana] Bulovka Univ Hosp, Prague, Czech Republic","D'Erme, AM (reprint author), Univ Florence, Dept Surg & Translat Med, Div Dermatol, I-50121 Florence, Italy.","a.m.derme@gmail.com",null,null,null,null,null,98,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0738-081X","1879-1131",null,"CLIN DERMATOL","Clin. Dermatol.","SEP-OCT",2014,32,5,null,null,null,null,633,645,null,"10.1016/j.clindermato1.2014.04.011",null,13,"Dermatology","Dermatology","AO5RU","WOS:000341403800012",25160105]
["J","Bockenhauer, D; Zieg, J",null,null,null,"Bockenhauer, Detlef; Zieg, Jakub",null,null,"Electrolyte Disorders","CLINICS IN PERINATOLOGY",null,null,"English","Article",null,null,null,null,null,"Electrolyte disorders; Hyponatremia; Hypernatremia; Hypokalemia; Hyperkalemia; Newborn; Renal physiology","PLASMA POTASSIUM CONCENTRATION; PREMATURE-INFANTS; BARTTERS-SYNDROME; PRETERM INFANTS; SODIUM; HYPERKALEMIA; FLUID; TUBULOPATHIES; MANAGEMENT; NEWBORNS","Electrolyte disorders can result in life-threatening complications. The kidneys are tasked with maintaining electrolyte homoeostasis, yet the low glomerular filtration rate of neonatal kidneys, tubular immaturity, and high extrarenal fluid losses contribute to increased occurrence of electrolyte disorders in neonates. Understanding the physiologic basis of renal electrolyte handling is crucial in identifying underlying causes and initiation of proper treatment. This article reviews key aspects of renal physiology, the diagnostic workup of disorders of plasma sodium and potassium, and the appropriate treatment, in addition to inherited disorders associated with neonatal electrolyte disturbances that illuminate the physiology of renal electrolyte handling.","[Bockenhauer, Detlef] Great Ormond St Hosp Children NHS Fdn Trust, UCL Inst Child Hlth, Nephrol Unit, London WC1 3EH, England; [Zieg, Jakub] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 15006 5, Czech Republic; [Zieg, Jakub] Motol Univ Hosp, Prague 15006 5, Czech Republic","Bockenhauer, D (reprint author), Great Ormond St Hosp Children NHS Fdn Trust, UCL Inst Child Hlth, Nephrol Unit, 30 Guilford St, London WC1 3EH, England.","d.bockenhauer@ucl.ac.uk",null,null,null,null,null,56,0,0,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0095-5108","1557-9840",null,"CLIN PERINATOL","Clin. Perinatol.","SEP",2014,41,3,null,null,null,null,575,"+",null,"10.1016/j.clp.2014.05.007",null,17,"Obstetrics & Gynecology; Pediatrics","Obstetrics & Gynecology; Pediatrics","AP6IR","WOS:000342181400009",25155728]
["J","Zukic, D; Vlasak, A; Egger, J; Horinek, D; Nimsky, C; Kolb, A",null,null,null,"Zukic, Dzenan; Vlasak, Ales; Egger, Jan; Horinek, Daniel; Nimsky, Christopher; Kolb, Andreas",null,null,"Robust Detection and Segmentation for Diagnosis of Vertebral Diseases Using Routine MR Images","COMPUTER GRAPHICS FORUM",null,null,"English","Article",null,null,null,null,null,"MRI; segmentation; detection; diagnosis; spine; vertebrae; vertebra; inflation; efficient","SPINE IMAGES; LUMBAR SPINE; SPONDYLOLISTHESIS; FRACTURES; BODIES; MODEL; 3-D; CT","The diagnosis of certain spine pathologies, such as scoliosis, spondylolisthesis and vertebral fractures, is part of the daily clinical routine. Very frequently, magnetic resonance image data are used to diagnose these kinds of pathologies in order to avoid exposing patients to harmful radiation, like X-ray. We present a method which detects and segments all acquired vertebral bodies, with minimal user intervention. This allows an automatic diagnosis to detect scoliosis, spondylolisthesis and crushed vertebrae. Our approach consists of three major steps. First, vertebral centres are detected using a Viola-Jones like method, and then the vertebrae are segmented in a parallel manner, and finally, geometric diagnostic features are deduced in order to diagnose the three diseases. Our method was evaluated on 26 lumbar datasets containing 234 reference vertebrae. Vertebra detection has 7.1% false negatives and 1.3% false positives. The average Dice coefficient to manual reference is 79.3% and mean distance error is 1.76 mm. No severe case of the three illnesses was missed, and false alarms occurred rarely-0% for scoliosis, 3.9% for spondylolisthesis and 2.6% for vertebral fractures. The main advantages of our method are high speed, robust handling of a large variety of routine clinical images, and simple and minimal user interaction.","[Zukic, Dzenan; Kolb, Andreas] Univ Siegen, Comp Graph & Multimedia Syst Grp, D-57068 Siegen, Germany; [Vlasak, Ales] Univ Hosp Motol, Dept Neurosurg, Prague, Czech Republic; [Vlasak, Ales; Horinek, Daniel] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Egger, Jan; Nimsky, Christopher] Univ Hosp Giessen & Marburg, Dept Neurosurg, Marburg, Germany; [Horinek, Daniel] Jan Evangelista PurkyneUniv, Dept Neurosurg, Usti Nad Labem, Czech Republic","Zukic, D (reprint author), Univ Siegen, Comp Graph & Multimedia Syst Grp, D-57068 Siegen, Germany.","dzenanz@gmail.com; ales.vlasak@fnmotol.cz; egger@med.uni-marburg.de; horinek@med.uni-marburg.de; nimsky@med.uni-marburg.de; andreas.kolb@uni-siegen.de",null,null,"Australian Research Council [LP100200422]; European Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]","We are grateful to Ales Neubert from the University of Queensland, Brisbane, Australia, for providing datasets case_2 and case_10 and their manual segmentations. He received financial support from Australian Research Council's Linkage Projects funding scheme LP100200422. We are also grateful to Thomas Dukatz and Miriam Bauer from University Hospital Marburg for some of the manual segmentations. Ales Vlasak and Daniel Horinek were supported by European Regional Development Fund-Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123).",null,40,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0167-7055","1467-8659",null,"COMPUT GRAPH FORUM","Comput. Graph. Forum","SEP",2014,33,6,null,null,null,null,190,204,null,"10.1111/cgf.12343",null,15,"Computer Science, Software Engineering","Computer Science","AQ4WT","WOS:000342802200014"]
["J","Navratil, L; Navratil, V; Hajkova, S; Hlinakova, P; Dostalova, T; Vranova, J",null,null,null,"Navratil, Leos; Navratil, Vaclav; Hajkova, Simona; Hlinakova, Petra; Dostalova, Tatjana; Vranova, Jana",null,null,"Comprehensive treatment of temporomandibular joint disorders","CRANIO-THE JOURNAL OF CRANIOMANDIBULAR PRACTICE",null,null,"English","Article",null,null,null,null,null,"Jaw joint; Imbalance; Medical rehabilitation; Physiotherapy; Education","LEVEL LASER THERAPY; RAT MASSETER MUSCLE; PHYSICAL-THERAPY; MANUAL THERAPY; DOUBLE-BLIND; PAIN; EXERCISE","Aims: Changing lifestyles, decreasing physical activity, which is increasing the number of degenerative joint diseases of various etiology, and certain dental procedures are increasing the number of patients complaining of pain in their temporomandibular joints. The aim of the study was to assess the benefits of comprehensive physiotherapy sessions in order to decrease the number of temporomandibular joint problems, thereby improving the patient's quality of life. Methodology: An examination by a dentist determined each patient's treatment plan, which consisted of a medical exam, physical therapy and education. Each form of treatment was applied 10 times at intervals of 7-14 days. The main goal of the therapeutic physical education was to redress the muscle imbalance in the mandibular joint. This was achieved by restoring balance between the masticatory muscles, along with releasing the spastic shrouds found in the masticatory muscles. The aim of education was to teach the patient exercises focused on the temporomandibular joint and masticatory muscles. The intensity of the exercises and their composition were individually adjusted and adapted to their current state. Physical therapy consisted of the application of pulsed magnetic therapy, laser therapy, and non-invasive positive thermotherapy. Results: The above procedure was conducted on a therapeutic group of 24 patients (3 men and 20 women). In the course of therapy, there were no complications, and all patients adhered to the prescribed regime. None reported any side effects. The mean treatment duration was 123666 days. The outcome of the therapy was evaluated as described in the methodology, the degree of pain affecting the joint, and the opening ability of the mouth. In both parameters, there was a significant decline in patient pain. Conclusions: In a study devoted to tactics of rehabilitation treatment for temporomandibular joint disorders, the need for comprehensive long-term therapy, involving education, and learning proper chewing habits was made apparent for recovery and pain reduction. A priority in physical therapy, and combinations of pulsed magnetic therapy and hyperthermia-positive peloids, are also beneficial.","[Navratil, Leos; Navratil, Vaclav; Hajkova, Simona; Vranova, Jana] Czech Tech Univ, Fac Biomed Engn, Dept Med & Humanities, Kladno 27201, Czech Republic; [Navratil, Leos; Hajkova, Simona] Rehabil Ctr THERAP TILIA, Prague, Czech Republic; [Hlinakova, Petra; Dostalova, Tatjana] Charles Univ Prague, Fac Med 2, CR-11636 Prague 1, Czech Republic; [Hlinakova, Petra; Dostalova, Tatjana] Motol Univ Hosp, Dept Pediat Stomatol, Prague, Czech Republic","Navratil, L (reprint author), Czech Tech Univ, Sitna 3105, Kladno 27201, Czech Republic.","leos.navratil@fbmi.cvut.cz",null,null,"IGA of Ministry of Health of the Czech Republic [9902-4]","The study was supported by the IGA of Ministry of Health of the Czech Republic (no. 9902-4).",null,32,0,0,"MANEY PUBLISHING","LEEDS","STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND","0886-9634","2151-0903",null,"CRANIO","Cranio-J. Craniomandib. Pract.","JAN",2014,32,1,null,null,null,null,24,30,null,"10.1179/0886963413Z.0000000002",null,7,"Dentistry, Oral Surgery & Medicine","Dentistry, Oral Surgery & Medicine","AI7EQ","WOS:000337046600004",24660643]
["J","Klozar, J; Tachezy, R",null,null,null,"Klozar, Jan; Tachezy, Ruth",null,null,"What are the implications of human papillomavirus status in oropharyngeal tumors for clinical practice?","CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY",null,null,"English","Review",null,null,null,null,null,"human papillomavirus; oropharyngeal cancer; prognosis; survival","SQUAMOUS-CELL CARCINOMAS; NECK-CANCER; RISK-FACTOR; HEAD; HPV; PROGNOSIS; SURVIVAL; INVOLVEMENT; TRENDS; TRIALS","Purpose of reviewHuman papillomavirus (HPV) status itself is an important and very probably the strongest prognostic factor in head and neck cancer. Because of the prognostic advantage of patients with HPV-positive cancers, the issue of the quality of life of survivors has become increasingly important. The possibility of treatment de-escalation in patients with virally induced tumors is being considered. Many challenges have to be addressed in order to integrate HPV status in the routine decision-making in patients with oropharyngeal cancer. The present review discusses the standardization of detection methods suitable for clinical use and the differences in predictive parameters between patients with HPV-positive and HPV-negative tumors.Recent findingsThe gold standard for the identification of patients with oropharyngeal tumors etiologically linked to HPV infection is undoubtedly the detection of HPV 16 E6/E7 mRNA. The detection of a surrogate marker of active viral infection, p16ink4a, has a low sensitivity when used alone and must therefore be combined with the detection of HPV DNA or HPV-specific antibodies. The detailed knowledge of the importance of specific prognostic parameters is crucial in the choice of treatment. Nodal staging is probably much less important in HPV-positive cancers.SummaryIt is of great importance to implement standardized testing for the identification of patients with HPV-induced oropharyngeal tumors. The treatment decision models in HPV-positive tumors have to take into account the probably different prognostic value of nodal parameters. Before introducing treatment de-escalation in patients with virally induced tumors into clinical practice, more research and clinical studies are needed.","[Klozar, Jan] Charles Univ Prague, Motol Univ Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med, Prague, Czech Republic; [Tachezy, Ruth] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic","Klozar, J (reprint author), Motol Univ Hosp, V Uvalu 84, Prague 15006, Czech Republic.","jan.klozar@fnmotol.cz",null,null,"Granting Agency, Ministry of Health, Czech Republic [NT/12483]","Cited studies and this review were supported by Granting Agency, Ministry of Health, Czech Republic with grant number: NT/12483.",null,33,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1068-9508","1531-6998",null,"CURR OPIN OTOLARYNGO","Curr. Opin. Otolaryngol. Head Neck Surg.","APR",2014,22,2,null,null,null,null,90,94,null,"10.1097/MOO.0000000000000030",null,5,"Otorhinolaryngology","Otorhinolaryngology","AD5JB","WOS:000333287400002",24492854]
["J","Labikova, J; Vcelakova, J; Ulmannova, T; Petruzelkova, L; Kolouskova, S; Stechova, K",null,null,null,"Labikova, Jana; Vcelakova, Jana; Ulmannova, Tereza; Petruzelkova, Lenka; Kolouskova, Stanislava; Stechova, Katerina",null,null,"The cytokine production of peripheral blood mononuclear cells reflects the autoantibody profile of patients suffering from type 1 diabetes","CYTOKINE",null,null,"English","Article",null,null,null,null,null,"Autoantibodies; GAD65; IA2; IL17; Type 1 diabetes","AUTOREACTIVE T-CELLS; TH17 CELLS; FUNCTIONAL DEFECTS; REGULATORY CELLS; HIGH-RISK; MICE; MELLITUS; GAD65; IMMUNOLOGY; WORKSHOP","Type 1 diabetes (T1D) is an autoimmune disorder characterised by the immune-mediated destruction of insulin-producing pancreatic beta cells. The inflammatory process appears to be primarily mediated by pro-inflammatory Th1 lymphocytes, while the role Th17 cells in T1D is currently being investigated. T1D is characterised by the presence of autoantigen-specific autoantibodies. This study was conducted using patients with confirmed T1D and healthy control subjects. We examined the effect of the patient's autoantibody profile on peripheral blood mononuclear cell (PBMC) cytokine production following stimulation with the major diabetogenic autoantigens GAD65 and IA2. IFN-gamma and IL17 production was detected by ELISPOT and the ratio of basic cellular populations in PBMCs was measured by flow cytometry. We demonstrated a significant interaction between the patient's autoantibody profile and mode of stimulation. This suggests that autoantigen stimulation has a different effect on different groups of patients depending on their autoantibody profile. An increased production of IL17 was found in patients with high IA2 autoantibodies compared to patients with low levels of autoantibodies and healthy controls regardless of the mode of stimulation. The titre of IA2 autoantibodies positively correlates with the proportion of Tc lymphocytes and negatively correlates with the proportion of Th lymphocytes. Our results show that a patient's autoantibody profile reflects the type of cellular immune responses. It seems that the high titre of IA2 autoantibodies is related to increased production of IL17 and an increased proportion of Tc lymphocytes. This finding may be useful in designing immunointervention studies to prevent T1D. (C) 2014 Elsevier Ltd. All rights reserved.","[Labikova, Jana] Univ Hosp Motol, Dept Paediat, Prague 15006 5, Czech Republic; Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic","Labikova, J (reprint author), Univ Hosp Motol, Dept Paediat, V Uvalu 84, Prague 15006 5, Czech Republic.","jana.labik@seznam.cz; Jana.Vcelakova@fnmotol.cz; tulma@centrum.cz; lenkapetruzelkova@gmail.com; stanislava.kolouskova@lfmotol.cuni.cz; Katerinastechova@seznam.cz",null,null,"Ministry of Health, Czech Republic [00064203]; University Hospital Motol, Prague, Czech Republic; IPL [699 001]; IGA MZCR [NT/11407-5]; GACR [P302/10/1679]","This work was supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organisation 00064203 (University Hospital Motol, Prague, Czech Republic), IPL 699 001, IGA MZCR NT/11407-5 and GACR P302/10/1679.",null,26,0,0,"ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD","LONDON","24-28 OVAL RD, LONDON NW1 7DX, ENGLAND","1043-4666","1096-0023",null,"CYTOKINE","Cytokine","OCT",2014,69,2,null,null,null,null,189,195,null,"10.1016/j.cyto.2014.06.013",null,7,"Biochemistry & Molecular Biology; Cell Biology; Immunology","Biochemistry & Molecular Biology; Cell Biology; Immunology","AO6RB","WOS:000341478100004",24993165]
["J","Hrusak, O; Basso, G; Ratei, R; Gaipa, G; Luria, D; Mejstrikova, E; Karawajew, L; Buldini, B; Rozenthal, E; Bourquin, JP; Kalina, T; Sartor, M; Dworzak, MN",null,null,null,"Hrusak, Ondrej; Basso, Giuseppe; Ratei, Richard; Gaipa, Giuseppe; Luria, Drorit; Mejstrikova, Ester; Karawajew, Leonid; Buldini, Barbara; Rozenthal, Eti; Bourquin, Jean Pierre; Kalina, Tomas; Sartor, Mary; Dworzak, Michael N.",null,"AIEOP-BFM Flow Network","Flow Diagnostics Essential Code: A Simple and Brief Format for the Summary of Leukemia Phenotyping","CYTOMETRY PART B-CLINICAL CYTOMETRY",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; acute myeloid leukemia; cytometry; immunophenotyping; standardization; clinical reporting","CYTOMETRY","Background: Flow cytometry is a valuable part in the routine diagnostics of acute leukemia (AL). Although internationally recognized definitions of main AL subsets are available, there is currently no consensus format for the short summary of clinical flow cytometry reports. Since clinical reports are too long for most database purposes, there is a need for a standardized format of their short summaries. Methods: The Associazione Italiana Ematologia Oncologia Pediatrica-Berlin Frankfurt Muenster (AIEOP-BFM) Flow Network that encompasses reference diagnostics laboratories in Australia, Austria, Czechia, Germany, Israel, Italy, and Switzerland have designed a pro-forma for the summary of flow cytometry results in the diagnosis of leukemia. The process involved several meetings and other communications, during which the group established a consensus on the essentials that lead to the diagnostic conclusions in childhood AL. Results: The \"Flow Diagnostics Essential (FDE) Code\" is a result from an agreement within the AIEOP-BFM Flow Network. In a standardized format, it reports the extent of the infiltration by a malignant clone, followed by description antigen expression as strong, weak or negative, and a diagnostic conclusion. Conclusions: A consensus brief format (the \" FDE Code\") has been designed as a brief summary of the diagnostic immunophenotype of childhood AL. It is also applicable for the diagnostic investigation of other malignancies by flow cytometry. The FDE code may be included in the final clinical report and/or used in the setting of a multicenter clinical trial database. (C) 2013 International Clinical Cytometry Society","[Hrusak, Ondrej; Mejstrikova, Ester; Kalina, Tomas] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague, Czech Republic; [Hrusak, Ondrej; Mejstrikova, Ester; Kalina, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Basso, Giuseppe; Buldini, Barbara] Dipartimento Salute Donna & Bambino, Padua, Italy; [Ratei, Richard; Karawajew, Leonid] Charite Univ Med Berlin, Dept Pediat Oncol Hematol, Berlin, Germany; [Gaipa, Giuseppe] Lab Terapia Cellulare Stefano Verri, Monza, Italy; [Luria, Drorit] Schneider Childrens Med Ctr, Petah Tiqwa, Israel; [Rozenthal, Eti] Chaim Sheba Med Ctr, Inst Hematol, IL-52621 Tel Hashomer, Israel; [Bourquin, Jean Pierre] Univ Zurich, Univ Childrens Hosp, Div Oncol, Zurich, Switzerland; [Bourquin, Jean Pierre] Univ Zurich, Univ Childrens Hosp, Childrens Res Ctr, Zurich, Switzerland; [Sartor, Mary] Westmead Childrens Hosp, Dept Haematol, Sydney, NSW, Australia; [Dworzak, Michael N.] Med Univ Vienna, St Anna Childrens Hosp, Dept Pediat, Vienna, Austria; [Dworzak, Michael N.] Med Univ Vienna, Childrens Canc Res Inst, Vienna, Austria","Hrusak, O (reprint author), Dept Pediat Hematol & Oncol, CLIP Cytometry Lab, V Uvalu 84, Prague 15006 5, Czech Republic.","Ondrej.Hrusak@lfmotol.cuni.cz",null,null,"Czech Science Foundation (GACR) [P301/10/1877]","This work was supported by the Czech Science Foundation (GACR) P301/10/1877 (to authors OH, EM and TK).",null,9,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1552-4949","1552-4957",null,"CYTOM PART B-CLIN CY","Cytom. Part B-Clin. Cytom.","JUL",2014,86,4,null,null,null,null,288,291,null,"10.1002/cyto.b.21144",null,4,"Medical Laboratory Technology; Pathology","Medical Laboratory Technology; Pathology","AN4FZ","WOS:000340544300009",25057519]
["J","Tichy, M; Hercogova, J",null,null,null,"Tichy, Martin; Hercogova, Jana",null,null,"Manifestation of Crohn's disease in a young woman during the course of treatment for severe form of chronic plaque psoriasis with etanercept","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"Crohn's disease; paradoxical drug reaction (etanercept); psoriasis","JUVENILE IDIOPATHIC ARTHRITIS; THERAPY","With the growing number of patients with immune-modulated diseases treated with tumor necrosis factor (TNF) alpha inhibitors, we are more frequently encountering the occurrence of so-called paradoxical drug reactions. These are basically situations where during the course of the treatment of one disease, the manifestation of another with similar etiopathogenesis occurs, although under normal conditions this newly developed disease responds well to treatment with TNF alpha inhibitors and is indicated for this treatment. Skin reactions are most frequently recorded in the form of induced psoriasis and psoriasiform exanthems. A less common paradoxical reaction is the induction of Crohn's disease, which is most often described in association with the treatment of inflammatory joint diseases with etanercept. We present a case of induction of Crohn's disease during therapy with etanercept, where the primary disease being treated was psoriasis. In the literature, similar cases have only been described sporadically.","[Tichy, Martin] Palacky Univ, Dept Dermatol & Venereol, Fac Med & Dent, Olomouc 77520, Czech Republic; [Tichy, Martin] Univ Hosp, Olomouc 77520, Czech Republic; [Hercogova, Jana] Charles Univ Prague, Dept Dermatovenereol, Fac Med 2, Bulovka Hosp, Prague, Czech Republic","Tichy, M (reprint author), Palacky Univ, Dept Dermatol & Venereol, Fac Med & Dent, IP Pavlova 6, Olomouc 77520, Czech Republic.","tichy.martin.jun@fnol.cz",null,null,null,null,null,15,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296","1529-8019",null,"DERMATOL THER","Dermatol. Ther.","JUL-AUG",2014,27,4,null,null,null,null,211,214,null,"10.1111/dth.12119",null,4,"Dermatology","Dermatology","AN0MV","WOS:000340279600005",24548537]
["J","Juzlova, K; Votrubova, J; Kacerovska, D; Lukas, M; Bortlik, M; Rohacova, H; Nohynkova, E; Vojackova, N; Fialova, J; Hercogova, J",null,null,null,"Juzlova, Katerina; Votrubova, Jana; Kacerovska, Denisa; Lukas, Milan; Bortlik, Martin; Rohacova, Hana; Nohynkova, Eva; Vojackova, Nadezda; Fialova, Jorga; Hercogova, Jana",null,null,"Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"immunosuppression; skin manifestation; visceral leishmaniasis","LESIONS","Leishmaniasis is an infectious disease caused by parasitic flagellates of the genus Leishmania. The authors present a case of 44-year-old man with Crohn's disease treated successfully with infliximab. This case report shows rare visceral leishmaniasis with cutaneous symptoms in an immunocompromised patient. Skin manifestations may occur before or after the visceral infection and they are often diverse.","[Juzlova, Katerina; Votrubova, Jana; Vojackova, Nadezda; Fialova, Jorga; Hercogova, Jana] Charles Univ Prague, Dept Dermatovenereol, Fac Med 2, Prague 18081, Czech Republic; [Kacerovska, Denisa] Charles Univ Prague, Fac Med Pilsen, Dept Pathol, Prague 18081, Czech Republic; [Lukas, Milan; Bortlik, Martin] Charles Univ Prague, IBD Clin & Res Ctr, ISCARE As, Fac Med 1, Prague 18081, Czech Republic; [Rohacova, Hana] Charles Univ Prague, Bulovka Hosp, Dept Infect Dis, Fac Med 2, Prague 18081, Czech Republic; [Nohynkova, Eva] Charles Univ Prague, Dept Infect & Trop Dis, Fac Med 1, Prague 18081, Czech Republic; [Nohynkova, Eva] Hosp Bulovka, Prague, Czech Republic","Juzlova, K (reprint author), Charles Univ Prague, Dept Dermatovenereol, Fac Med 2, Budinova 2, Prague 18081, Czech Republic.","katerina.juzlova@gmail.com",null,null,"Internal Grant Agency- Ministry of Health of the Czech Republic [NT 14300-3]","The project was supported by Internal Grant Agency- Ministry of Health of the Czech Republic (Grant NT 14300-3).",null,15,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296","1529-8019",null,"DERMATOL THER","Dermatol. Ther.","MAY-JUN",2014,27,3,null,null,null,null,131,134,null,"10.1111/dth.12083",null,4,null,null,"AJ2WB","WOS:000337524100002",24903470]
["J","Secnikova, Z; Juzlova, K; Vojackova, N; Kazakov, DV; Hoskova, L; Fialova, J; Dzambova, M; Hercogova, J",null,null,null,"Secnikova, Zuzana; Juzlova, Katerina; Vojackova, Nadezda; Kazakov, Dmitry V.; Hoskova, Lenka; Fialova, Jorga; Dzambova, Martina; Hercogova, Jana",null,null,"The rare case of Alternaria alternata cutaneous and pulmonary infection in a heart transplant recipient treated by azole antifungals","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"Alternaria alternata; azole antifungals; heart transplantation","PHEOHYPHOMYCOSIS; INFECTORIA","We report a case of Alternaria alternata cutaneous and pulmonary infection in a 62-year-old man after heart transplantation treated by azole antifungals. Alternaria spp. belong to a group of opportunistic dematiaceous fungi with worldwide distribution. The cutaneous form of the infection in human is very rare and occurs predominantly among immunosuppressed patients. Therefore, diagnosis is often delayed or not reached at all. Appropriate treatment is not standardized and remains a matter of discussion. According to current studies, the best results are obtained with systemic azole antifungal therapy combined with surgical intervention.","[Secnikova, Zuzana; Juzlova, Katerina; Vojackova, Nadezda; Fialova, Jorga; Dzambova, Martina; Hercogova, Jana] Charles Univ Prague, Dermatovenereol Dept, Bulovka Hosp, Fac Med 2, Prague, Czech Republic; [Kazakov, Dmitry V.] Charles Univ Prague, Med Fac Hosp, Sikls Dept Pathol, Plzen, Czech Republic; [Hoskova, Lenka] Inst Clin & Expt Med, Dept Cardiol, Prague, Czech Republic","Secnikova, Z (reprint author), Charles Univ Prague, Dermatovenereol Dept, Bulovka Hosp, Fac Med 2, Prague, Czech Republic.","z.secnikova@gmail.com",null,null,"grant IGA of the Czech Ministry of Health [NT 14203]","This work was supported by the grant IGA of the Czech Ministry of Health No. NT 14203.",null,10,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296","1529-8019",null,"DERMATOL THER","Dermatol. Ther.","MAY-JUN",2014,27,3,null,null,null,null,140,143,null,"10.1111/dth.12096",null,4,null,null,"AJ2WB","WOS:000337524100004",24112410]
["J","Konkolova, R; Provaznikova, DH; Jirakova, A; Hercogova, J",null,null,null,"Konkolova, Radmila; Provaznikova, Doc Hana; Jirakova, Anna; Hercogova, Jana",null,null,"Can melanoma therapy change attitudes toward prevention and tanning?","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"melanoma; prevention; tanning","DIAGNOSIS","Malignant melanoma is the most lethal skin cancer whose incidence is increasing worldwide. Important is knowledge of risk factors, early diagnosis, long-term follow-up on confirmed melanoma cases and prevention. In this study, we tested melanoma patients' attitudes toward solar radiation and perception of the value of follow-up. The present cross-sectional epidemiological study was carried out in a group of patients diagnosed with stage I and II of malignant melanoma (n = 124). They were monitored for at least 1 year. The research was carried out by anonymous questionnaire. The results revealed that the respondents welcomed the opportunity of follow-up care. Its benefits were said to outweigh the inconvenience of repeated checkups. However, the esthetic importance of a suntan was still considered quite high. Substantial reserve was found in the use of sunscreen. The need for wide public education and the protection against excessive contact with solar radiation is evident. Regular monitoring seems to be just as important.","[Konkolova, Radmila; Jirakova, Anna; Hercogova, Jana] Charles Univ Prague, Dept Dermatol & Venereol, Fac Med 2, CR-18000 Prague, Czech Republic; [Konkolova, Radmila; Jirakova, Anna; Hercogova, Jana] Hosp Bulovka, Prague 18000, Czech Republic; [Provaznikova, Doc Hana] Charles Univ Prague, Dept Ctr Prevent Med, Div Hlth Children & Youth, Fac Med 3, CR-18000 Prague, Czech Republic","Jirakova, A (reprint author), Charles Univ Prague, Dept Dermatol & Venereol, Fac Med 2, CR-18000 Prague, Czech Republic.","annajirakova@seznam.cz",null,null,null,null,null,13,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296","1529-8019",null,"DERMATOL THER","Dermatol. Ther.","MAY-JUN",2014,27,3,null,null,null,null,156,158,null,"10.1111/dth.12100",null,3,null,null,"AJ2WB","WOS:000337524100008",24151966]
["J","Tichy, M; Urbanek, J; Sternbersky, J; Ditrichova, D; Hercogova, J",null,null,null,"Tichy, Martin; Urbanek, Jaroslav; Sternbersky, Jan; Ditrichova, Dagmar; Hercogova, Jana",null,null,"Life-threatening course of pemphigus vulgaris complicated by sepsis caused by azathioprine-induced bone marrow suppression, successfully managed with combination therapy","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"own experience; resistant form of pemphigus vulgaris; therapeutic possibilities","INTRAVENOUS IMMUNOGLOBULIN; RITUXIMAB; DIAGNOSIS; TRIAL","Severe forms of pemphigus vulgaris (PV) that are resistant to standard treatment present a life-threatening disease with a mortality of 5-10%. The treatment is usually individualized. The most popular procedures used today include intravenous applications of immunoglobulins and rituximab. Currently the common use of pulse corticosteroids, often in first-line treatment, is being neglected. This particular case documented the severity of the disease and also the need for combined and comprehensive care, in which corticosteroid pulse therapy still plays an important role.","[Tichy, Martin; Urbanek, Jaroslav; Sternbersky, Jan; Ditrichova, Dagmar] Palacky Univ, Fac Med & Dent, Dept Dermatol & Venereol, Olomouc 77520, Czech Republic; [Tichy, Martin; Urbanek, Jaroslav; Sternbersky, Jan; Ditrichova, Dagmar] Univ Hosp, Olomouc 77520, Czech Republic; [Hercogova, Jana] Charles Univ Prague, Dept Dermatovenereol, Fac Med 2, Bulovka Hosp, Prague, Czech Republic","Tichy, M (reprint author), Palacky Univ, Fac Med & Dent, Dept Dermatol & Venereol, IP Pavlova 6, Olomouc 77520, Czech Republic.","tichy.martin.jun@fnol.cz",null,null,null,null,null,14,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296","1529-8019",null,"DERMATOL THER","Dermatol. Ther.","MAY-JUN",2014,27,3,null,null,null,null,183,186,null,"10.1111/dth.12114",null,4,null,null,"AJ2WB","WOS:000337524100015",24283408]
["J","Dusatkova, P; Fang, MY; Pruhova, S; Gjesing, AP; Cinek, O; Hansen, T; Pedersen, OB; Xu, X; Lebl, J",null,null,null,"Dusatkova, Petra; Fang, Mingyan; Pruhova, Stepanka; Gjesing, Anette P.; Cinek, Ondrej; Hansen, Torben; Pedersen, Oluf B.; Xu, Xun; Lebl, Jan",null,null,"Lessons from whole-exome sequencing in MODYX families","DIABETES RESEARCH AND CLINICAL PRACTICE",null,null,"English","Article",null,null,null,null,null,"HNF1A; HNF1B; MODY; Whole-exome sequencing","HEPATOCYTE NUCLEAR FACTOR-1-BETA; MUTATIONS; YOUNG; GENE; DISEASE; ALPHA","We report the first results from whole-exome sequencing performed in families with Maturity-Onset Diabetes of the Young without a known genetic cause of diabetes (MODYX). This next generation sequencing technique pointed out that routine testing of MODY needs constant awareness and regular re-evaluation of both clinical criteria and primer sequences. (C) 2014 Elsevier Ireland Ltd. All rights reserved.","[Dusatkova, Petra; Pruhova, Stepanka; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-15006 Prague, Czech Republic; [Dusatkova, Petra; Pruhova, Stepanka; Cinek, Ondrej; Lebl, Jan] Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Fang, Mingyan; Xu, Xun] BGI Shenzen, Shenzhen 518083, Peoples R China; [Gjesing, Anette P.; Hansen, Torben; Pedersen, Oluf B.] Univ Copenhagen, Fac Hlth Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark; [Hansen, Torben] Univ Southern Denmark, Fac Hlth Sci, Odense, Denmark; [Pedersen, Oluf B.] Univ Copenhagen, Fac Hlth & Med Sci, Inst Biomed Sci, Copenhagen, Denmark; [Pedersen, Oluf B.] Aarhus Univ, Fac Hlth Sci, Aarhus, Denmark","Dusatkova, P (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-15006 Prague, Czech Republic.","petra.dusatkova@lfmotol.cuni.cz",null,null,"European Foundation for the Study of Diabetes (EFSD); Czech Ministry of Health [NT 11402]; Ministry of Health, Czech Republic [00064203/6001]","The study was supported by a European Foundation for the Study of Diabetes (EFSD), a grant from the Czech Ministry of Health (grant NT 11402) and by the project for conceptual development of research organization 00064203/6001 (Ministry of Health, Czech Republic).",null,13,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0168-8227","1872-8227",null,"DIABETES RES CLIN PR","Diabetes Res. Clin. Pract.","JUN",2014,104,3,null,null,null,null,"E72","E74",null,"10.1016/j.diabres.2014.03.008",null,3,"Endocrinology & Metabolism","Endocrinology & Metabolism","AK8YR","WOS:000338715200006",24698406]
["J","Czupryniak, L; Barkai, L; Bolgarska, S; Bronisz, A; Broz, J; Cypryk, K; Honka, M; Janez, A; Krnic, M; Lalic, N; Martinka, E; Rahelic, D; Roman, G; Tankova, T; Varkonyi, T; Wolnik, B; Zherdova, N",null,null,null,"Czupryniak, Leszek; Barkai, Laszlo; Bolgarska, Svetlana; Bronisz, Agata; Broz, Jan; Cypryk, Katarzyna; Honka, Marek; Janez, Andrej; Krnic, Mladen; Lalic, Nebojsa; Martinka, Emil; Rahelic, Dario; Roman, Gabriela; Tankova, Tsvetalina; Varkonyi, Tamas; Wolnik, Bogumil; Zherdova, Nadia",null,null,"Self-Monitoring of Blood Glucose in Diabetes: From Evidence to Clinical Reality in Central and Eastern Europe-Recommendations from the International Central-Eastern European Expert Group","DIABETES TECHNOLOGY & THERAPEUTICS",null,null,"English","Review",null,null,null,null,null,null,"ROSSO-IN-PRAXI; IMPROVES GLYCEMIC CONTROL; QUALITY-OF-LIFE; METABOLIC-CONTROL; RANDOMIZED-TRIAL; GLUCOMETABOLIC CONTROL; PARALLEL-GROUP; INSULIN; MELLITUS; MANAGEMENT","Self-monitoring of blood glucose (SMBG) is universally considered to be an integral part of type 1 diabetes management and crucial for optimizing the safety and efficacy of complex insulin regimens. This extends to type 2 diabetes patients on intensive insulin therapy, and there is also a growing body of evidence suggesting that structured SMBG is beneficial for all type 2 diabetes patients, regardless of therapy. However, access to SMBG can be limited in many countries in Central and Eastern Europe. A consensus group of diabetes experts from 10 countries in this region (with overlapping historical, political, and social environments)-Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia, Slovenia, and Ukraine-was formed to discuss the role of SMBG across the spectrum of patients with diabetes. The group considered SMBG to be an essential tool that should be accessible to all patients with diabetes, including those with non-insulin-treated type 2 diabetes. The current article summarizes the evidence put forward by the consensus group and provides their recommendations for the appropriate use of SMBG as part of individualized patient management. The ultimate goal of these evidence-based recommendations is to help patients and providers in Central and Eastern Europe to make optimal use of SMBG in order to maximize the efficacy and safety of glucose-lowering therapies, to prevent complications, and to empower the patient to play a more active role in the management of their diabetes.","[Czupryniak, Leszek] Med Univ Lodz, Internal Med & Diabetol Dept, PL-90153 Lodz, Poland; [Cypryk, Katarzyna] Med Univ Lodz, Dept Diabetol & Metab Dis, PL-90153 Lodz, Poland; [Barkai, Laszlo] Debrecen Univ Med, Med & Hlth Sci Ctr, Postgrad Inst Pediat, H-4012 Debrecen, Hungary; [Barkai, Laszlo] Univ Miskolc, Fac Hlth Care, Dept Theoret Hlth Sci, Miskolc, Hungary; [Bolgarska, Svetlana; Zherdova, Nadia] Natl Acad Med Sci, Dept Diabetol, Natl Med Acad Postgrad Educ, Inst Endocrinol & Metab, Kiev, Ukraine; [Bronisz, Agata] Nicholas Copernicus Univ, Dept Endocrinol & Diabetol, Torun, Poland; [Bronisz, Agata] Ludwik Rydygier Coll Med, Bydgoszcz, Poland; [Broz, Jan; Honka, Marek] Charles Univ Prague, Dept Internal Med, Fac Med 2, Prague, Czech Republic; [Broz, Jan; Honka, Marek] Fac Hosp Motol, Prague, Czech Republic; [Janez, Andrej] Univ Med Ctr, Dept Endocrinol Diabet & Metab Dis, Ljubljana, Slovenia; [Krnic, Mladen] Clin Hosp Ctr, Split, Croatia; [Lalic, Nebojsa] Univ Belgrade, Clin Ctr Serbia, Fac Med, Dept Endocrinol Diabet & Metab Dis, Belgrade, Serbia; [Martinka, Emil] Natl Inst Endocrinol & Diabetol, Lubochna, Slovakia; [Rahelic, Dario] Dubrava Univ Hosp, Dept Endocrinol Diabet & Metab Disorders, Zagreb, Croatia; [Roman, Gabriela] Iuliu Hatieganu Univ Med & Pharm, Clin Ctr Diabet, Cluj Napoca, Romania; [Tankova, Tsvetalina] Med Univ Sofia, Clin Ctr Endocrinol, Sofia, Bulgaria; [Varkonyi, Tamas] Univ Szeged, Dept Internal Med 1, Szeged, Hungary; [Wolnik, Bogumil] Med Univ Gdansk, Dept Hypertens & Diabetol, Gdansk, Poland","Czupryniak, L (reprint author), Med Univ Lodz, Barlicki Univ Hosp 1, Internal Med & Diabetol Dept, Ul Kopcinskiego 22, PL-90153 Lodz, Poland.","leszek.czupryniak@umed.lodz.pl",null,null,null,null,null,102,0,0,"MARY ANN LIEBERT, INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1520-9156","1557-8593",null,"DIABETES TECHNOL THE","Diabetes Technol. Ther.","JUL",2014,16,7,null,null,null,null,460,475,null,"10.1089/dia.2013.0302",null,16,"Endocrinology & Metabolism","Endocrinology & Metabolism","AK1PD","WOS:000338186100009",24716890]
["J","Cinek, O; Stene, LC; Kramna, L; Tapia, G; Oikarinen, S; Witso, E; Rasmussen, T; Torjesen, PA; Hyoty, H; Ronningen, KS",null,null,null,"Cinek, Ondrej; Stene, Lars C.; Kramna, Lenka; Tapia, German; Oikarinen, Sami; Witso, Elisabet; Rasmussen, Trond; Torjesen, Peter A.; Hyoty, Heikki; Ronningen, Kjersti S.",null,null,"Enterovirus RNA in longitudinal blood samples and risk of islet autoimmunity in children with a high genetic risk of type 1 diabetes: the MIDIA study","DIABETOLOGIA",null,null,"English","Article",null,null,null,null,null,"Autoimmunity; Enterovirus; Infancy; Longitudinal Study; RNA; RT-PCR; Virus-associated aetiology","DIFFERENT EUROPEAN POPULATIONS; BETA-CELL AUTOIMMUNITY; PERIPHERAL-BLOOD; MONONUCLEAR-CELLS; INFECTIONS; MELLITUS; STRAINS; VIRUSES; PCR","Aims/hypothesis Only a few longitudinal molecular studies of enterovirus and islet autoimmunity have been reported, and positive results seem to be limited to Finland. We aimed to investigate an association between enterovirus RNA in blood and islet autoimmunity in the MIDIA study from Norway, a country which largely shares environmental and economic features with Finland. Methods We analysed serial blood samples collected at ages 3, 6, and 9 months and then annually from 45 children who developed confirmed positivity for at least two autoantibodies (against insulin, GAD65 and IA-2) and 92 matched controls, all from a cohort of children with a single high-risk HLA-DQ-DR genotype. Enterovirus was tested in RNA extracted from frozen blood cell pellets, using real-time RT-PCR with stringent performance control. Results Out of 807 blood samples, 72 (8.9%) were positive for enterovirus. There was no association between enterovirus RNA and islet autoimmunity in samples obtained strictly before (7.6% cases, 10.0% controls, OR 0.75 [95% CI 0.36, 1.57]), or strictly after the first detection of islet autoantibodies (10.5% case, 5.8% controls, OR 2.00 [95% CI 0.64, 6.27]). However, there was a tendency towards a higher frequency of enterovirus detection in the first islet autoantibody-positive sample (15.8%) compared with the corresponding time point in matched controls (3.2%, OR 8.7 [95% CI 0.97, 77]). Neither of these results was changed by adjusting for potential confounders, restricting to various time intervals or employing various definitions of enterovirus positivity. Conclusions/interpretation Positivity for enterovirus RNA in blood did not predict the later induction of islet autoantibodies, but enterovirus tended to be detected more often at the islet autoantibody seroconversion stage.","[Cinek, Ondrej; Kramna, Lenka] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague 15006 5, Czech Republic; [Cinek, Ondrej; Kramna, Lenka] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Stene, Lars C.; Tapia, German; Witso, Elisabet; Rasmussen, Trond] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Oikarinen, Sami; Hyoty, Heikki] Univ Tampere, Dept Virol, FIN-33101 Tampere, Finland; [Torjesen, Peter A.] Oslo Univ Hosp, Hormone Lab, Oslo, Norway; [Hyoty, Heikki] Pirkanmaa Hosp Dist, Fimlab Labs, Tampere, Finland; [Ronningen, Kjersti S.] Oslo Univ Hosp, Dept Pediat Res, Oslo, Norway","Cinek, O (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat, V Uvalu 84, Prague 15006 5, Czech Republic.","Ondrej.Cinek@Lfmotol.cuni.cz",null,null,"Norwegian Organization for Health and Rehabilitation [2008/0182]; Ministry of Health of the Czech Republic [IGAMZ 11465-5]; Research Council of Norway [135893/330, 155300/320, 156477/730, 205086/F20, 166515/V50]; Norwegian Diabetes Association; Academy of Finland; Project for the Conceptual Development of Research Organisation (University Hospital Motol, Prague, Czech Republic) [00064203]; ISPAD","This study and the MIDIA project were funded by the Norwegian Organization for Health and Rehabilitation (2008/0182), the Ministry of Health of the Czech Republic (IGAMZ 11465-5), the Research Council of Norway (grants 135893/330, 155300/320, 156477/730, 205086/F20 and 166515/V50), the Norwegian Diabetes Association, the Academy of Finland (grant to HH) and the Project for the Conceptual Development of Research Organisation 00064203 (University Hospital Motol, Prague, Czech Republic). OC's sabbatical at HH's laboratory in 2012 was supported by an ISPAD Research Fellowship.",null,24,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0012-186X","1432-0428",null,"DIABETOLOGIA","Diabetologia","OCT",2014,57,10,null,null,null,null,2193,2200,null,"10.1007/s00125-014-3327-4",null,8,"Endocrinology & Metabolism","Endocrinology & Metabolism","AO9VZ","WOS:000341708900022",25047648]
["J","Poetsch, AR; Lipka, DB; Witte, T; Claus, R; Nollke, P; Zucknick, M; Olk-Batz, C; Fluhr, S; Dworzak, M; De Moerloose, B; Stary, J; Zecca, M; Hasle, H; Schmugge, M; van den Heuvel-Eibrink, MM; Locatelli, F; Niemeyer, CM; Flotho, C; Plass, C",null,null,null,"Poetsch, Anna R.; Lipka, Daniel B.; Witte, Tania; Claus, Rainer; Noellke, Peter; Zucknick, Manuela; Olk-Batz, Christiane; Fluhr, Silvia; Dworzak, Michael; De Moerloose, Barbara; Stary, Jan; Zecca, Marco; Hasle, Henrik; Schmugge, Markus; van den Heuvel-Eibrink, Marry M.; Locatelli, Franco; Niemeyer, Charlotte M.; Flotho, Christian; Plass, Christoph",null,null,"RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia","EPIGENETICS",null,null,"English","Article",null,null,null,null,null,"DNA methylation; JMML; RASA4; epigenetics; juvenile myelomonocytic leukemia","GTPASE-ACTIVATING PROTEINS; GAP1 FAMILY; MUTATIONS; CHILDHOOD; CHILDREN; PATHWAY; PTPN11; GENES; JMML","Aberrant DNA methylation at specific genetic loci is a key molecular feature of juvenile myelomonocytic leukemia (JMML) with poor prognosis. Using quantitative high-resolution mass spectrometry, we identified RASA4 isoform 2, which maps to chromosome 7 and encodes a member of the GAP1 family of GTPase-activating proteins for small G proteins, as a recurrent target of isoform-specific DNA hypermethylation in JMML (51% of 125 patients analyzed). RASA4 isoform 2 promoter methylation correlated with clinical parameters predicting poor prognosis (older age, elevated fetal hemoglobin), with higher risk of relapse after hematopoietic stem cell transplantation, and with PTPN11 mutation. The level of isoform 2 methylation increased in relapsed cases after transplantation. Interestingly, most JMML cases with monosomy 7 exhibited hypermethylation on the remaining RASA4 allele. The results corroborate the significance of epigenetic modifications in the phenotype of aggressive JMML.","[Poetsch, Anna R.; Lipka, Daniel B.; Witte, Tania; Claus, Rainer; Plass, Christoph] German Canc Res Ctr, Div Epigen & Canc Risk Factors C010, Heidelberg, Germany; [Noellke, Peter; Olk-Batz, Christiane; Fluhr, Silvia; Niemeyer, Charlotte M.; Flotho, Christian] Univ Med Ctr, Div Pediat Hematol Oncol, Freiburg, Germany; [Zucknick, Manuela] German Canc Res Ctr, Div Biostat, Heidelberg, Germany; [Dworzak, Michael] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Dworzak, Michael] Med Univ Vienna, Dept Pediat, Childrens Canc Res Inst, Vienna, Austria; [De Moerloose, Barbara] Ghent Univ Hosp, Dept Pediat Hematol Oncol, Ghent, Belgium; [Stary, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic; [Stary, Jan] Czech Pediat Hematol Working Grp CPH, Prague, Czech Republic; [Zecca, Marco] Policlin San Matteo, Fdn IRCCS, I-27100 Pavia, Italy; [Hasle, Henrik] Aarhus Univ, Hosp Skejby, Dept Pediat, Aarhus, Denmark; [Schmugge, Markus] Univ Childrens Hosp, Div Hematol, Zurich, Switzerland; [van den Heuvel-Eibrink, Marry M.] Erasmus MC, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [van den Heuvel-Eibrink, Marry M.] Dutch Childrens Oncol Grp, The Hague, Netherlands; [Locatelli, Franco] IRCCS Osped Bambino Gesu, Dept Pediat Hematol Oncol, Rome, Italy; [Locatelli, Franco] Univ Pavia, I-27100 Pavia, Italy; [Niemeyer, Charlotte M.; Flotho, Christian; Plass, Christoph] German Canc Consortium, Heidelberg, Germany","Flotho, C (reprint author), Univ Med Ctr, Div Pediat Hematol Oncol, Freiburg, Germany.","christian.flotho@uniklinik-freiburg.de",null,null,"Deutsche Forschungsgemeinschaft [FL 345/4-1, CRC 992-C05]","Grant support: Deutsche Forschungsgemeinschaft FL 345/4-1 (to CMN and CF), CRC 992-C05 (to CF).",null,23,0,0,"LANDES BIOSCIENCE","AUSTIN","1806 RIO GRANDE ST, AUSTIN, TX 78702 USA","1559-2294","1559-2308",null,"EPIGENETICS-US","Epigenetics","SEP",2014,9,9,null,null,null,null,1252,1260,null,"10.4161/epi.29941",null,9,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","AQ1TP","WOS:000342564500007",25147919]
["J","Harris, RA; Nagy-Szakal, D; Mir, SAV; Frank, E; Szigeti, R; Kaplan, JL; Bronsky, J; Opekun, A; Ferry, GD; Winter, H; Kellermayer, R",null,null,null,"Harris, R. Alan; Nagy-Szakal, Dorottya; Mir, Sabina A. V.; Frank, Eibe; Szigeti, Reka; Kaplan, Jess L.; Bronsky, Jiri; Opekun, Antone; Ferry, George D.; Winter, Harland; Kellermayer, Richard",null,null,"DNA methylation-associated colonic mucosal immune and defense responses in treatment-naive pediatric ulcerative colitis","EPIGENETICS",null,null,"English","Article",null,null,null,null,null,"Pediatric inflammatory bowel disease; ulcerative colitis; treatment-naive; epigenetics; DNA methylation; DNA expression; DNA methylome","INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; GENE-EXPRESSION; PREVALENCE; ONSET; SUSCEPTIBILITY; IDENTIFICATION; EPIDEMIOLOGY; MICROARRAYS; VALIDATION","Inflammatory bowel diseases (IBD) are emerging globally, indicating that environmental factors may be important in their pathogenesis. Colonic mucosal epigenetic changes, such as DNA methylation, can occur in response to the environment and have been implicated in IBD pathology. However, mucosal DNA methylation has not been examined in treatment-naive patients. We studied DNA methylation in untreated, left sided colonic biopsy specimens using the Infinium HumanMethylation450 BeadChip array. We analyzed 22 control (C) patients, 15 untreated Crohn's disease (CD) patients, and 9 untreated ulcerative colitis (UC) patients from two cohorts. Samples obtained at the time of clinical remission from two of the treatment-naive UC patients were also included into the analysis. UC-specific gene expression was interrogated in a subset of adjacent samples (5 C and 5 UC) using the Affymetrix GeneChip PrimeView Human Gene Expression Arrays. Only treatment-naive UC separated from control. One-hundred-and-20 genes with significant expression change in UC (>2-fold, P < 0.05) were associated with differentially methylated regions (DMRs). Epigenetically associated gene expression changes (including gene expression changes in the IFITM1, ITGB2, S100A9, SLPI, SAA1, and STAT3 genes) were linked to colonic mucosal immune and defense responses. These findings underscore the relationship between epigenetic changes and inflammation in pediatric treatment-naive UC and may have potential etiologic, diagnostic, and therapeutic relevance for IBD.","[Harris, R. Alan] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Nagy-Szakal, Dorottya; Mir, Sabina A. V.; Ferry, George D.; Kellermayer, Richard] Baylor Coll Med, Dept Pediat, USDA, ARS,Childrens Nutr Res Ctr,Texas Childrens Hosp, Houston, TX 77030 USA; [Frank, Eibe] Univ Waikato, Dept Comp Sci, Hamilton, New Zealand; [Szigeti, Reka] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Kaplan, Jess L.; Winter, Harland] MassGen Hosp Children, Dept Pediat, Boston, MA USA; [Bronsky, Jiri] Charles Univ Prague, Dept Pediat, Prague, Czech Republic; [Bronsky, Jiri] Univ Hosp Motol, Prague, Czech Republic; [Opekun, Antone] Baylor Coll Med, Dept Gastroenterol, Houston, TX 77030 USA","Kellermayer, R (reprint author), Baylor Coll Med, Dept Pediat, USDA, ARS,Childrens Nutr Res Ctr,Texas Childrens Hosp, Houston, TX 77030 USA.","kellerma@bcm.edu",null,null,"Broad Medical Research Program, the Broad Foundation [IBD-0252]; Child Health Research Career Development Agency of the Baylor College of Medicine (NIH) [5K12 HD041648]; Public Health Service grant [DK56338]; Karen and Brock Wagner family; Pediatric Inflammatory Bowel Disease Foundation","R. K. was supported in part by the Broad Medical Research Program, the Broad Foundation (IBD-0252); the Child Health Research Career Development Agency of the Baylor College of Medicine (NIH # 5K12 HD041648); a Public Health Service grant DK56338, funding the Texas Medical Center Digestive Diseases Center; and the Gutsy Kids Fund including philanthropic donation from the Karen and Brock Wagner family. H. S. W. was supported in part by a philanthropic donation from the Martin Schlaff Family. This project was also supported by the Pediatric Inflammatory Bowel Disease Foundation.",null,42,0,0,"LANDES BIOSCIENCE","AUSTIN","1806 RIO GRANDE ST, AUSTIN, TX 78702 USA","1559-2294","1559-2308",null,"EPIGENETICS-US","Epigenetics","AUG",2014,9,8,null,null,null,null,1131,1137,null,"10.4161/epi.29446",null,7,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","AO5CV","WOS:000341360600008",24937444]
["J","Amlerova, J; Cavanna, AE; Bradac, O; Javurkova, A; Raudenska, J; Marusic, P",null,null,null,"Amlerova, Jana; Cavanna, Andrea E.; Bradac, Ondrej; Javurkova, Alena; Raudenska, Jaroslava; Marusic, Petr",null,null,"Emotion recognition and social cognition in temporal lobe epilepsy and the effect of epilepsy surgery","EPILEPSY & BEHAVIOR",null,null,"English","Article",null,null,null,null,null,"Temporal lobe epilepsy; Emotion recognition; Social cognition; Epilepsy surgery; Seizures","FACIAL EMOTION; FEAR RECOGNITION; MIND; LOBECTOMY; AMYGDALA; DAMAGE; FACES; IMPACT; ONSET","The abilities to identify facial expression from another person's face and to attribute mental states to others refer to preserved function of the temporal lobes. In the present study, we set out to evaluate emotion recognition and social cognition in presurgical and postsurgical patients with unilateral refractory temporal lobe epilepsy (TLE). The aim of our study was to investigate the effects of TLE surgery and to identify the main risk factors for impairment in these functions. We recruited 30 patients with TLE for longitudinal data analysis (14 with right-sided and 16 with left-sided TLE) and 74 patients for cross-sectional data analysis (37 with right-sided and 37 with left-sided TLE) plus 20 healthy controls. Besides standard neuropsychological assessment, we administered an analog of the Ekman and Friesen test and the Faux Pas Test to assess emotion recognition and social cognition, respectively. Both emotion recognition and social cognition were impaired in the group of patients with TLE, irrespective of the focus side, compared with healthy controls. The performance in both tests was strongly dependent on the intelligence level. Beyond intelligence level, earlier age at epilepsy onset, longer disease duration, and history of early childhood brain injury predicted social cognition problems in patients with TLE. Epilepsy surgery within the temporal lobe seems to have neutral effect on patients' performances in both domains. However, there are a few individual patients who appear to be at risk of postoperative decline, even when seizure freedom is achieved following epilepsy surgery. (C) 2014 Elsevier Inc. All rights reserved.","[Amlerova, Jana; Marusic, Petr] Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Motol, Czech Republic; [Cavanna, Andrea E.] Univ Birmingham, Birmingham B15 2TT, W Midlands, England; [Cavanna, Andrea E.] UCL, Inst Neurol, London WC1E 6BT, England; [Cavanna, Andrea E.] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England; [Bradac, Ondrej] Charles Univ Prague, Dept Neurosurg, Fac Med 1, Cent Mil Hosp, Prague 15006 5, Motol, Czech Republic; [Javurkova, Alena; Raudenska, Jaroslava] Univ Hosp Motol, Dept Psychol, Prague, Czech Republic","Marusic, P (reprint author), Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","petr.marusic@fnmotol.cz",null,null," [IGA MZCR NT/11536-5]","This research was supported by grant project IGA MZCR NT/11536-5.",null,22,0,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1525-5050","1525-5069",null,"EPILEPSY BEHAV","Epilepsy Behav.","JUL",2014,36,null,null,null,null,null,86,89,null,"10.1016/j.yebeh.2014.05.001",null,4,"Behavioral Sciences; Clinical Neurology; Psychiatry","Behavioral Sciences; Neurosciences & Neurology; Psychiatry","AL4WW","WOS:000339136500018",24892754]
["J","Vydrova, R; Krsek, P; Kyncl, M; Jahodova, A; Dvorak, J; Komarek, V; Delalande, O; Tichy, M",null,null,null,"Vydrova, Rosa; Krsek, Pavel; Kyncl, Martin; Jahodova, Alena; Dvorak, Josef; Komarek, Vladimir; Delalande, Olivier; Tichy, Michal",null,null,"Peri-ictal headache due to epileptiform activity in a disconnected hemisphere","EPILEPTIC DISORDERS",null,null,"English","Article",null,null,null,null,null,"peri-ictal headache; hemispherotomy; AED withdrawal","CORTICAL SPREADING DEPRESSION","A 4-year-old girl with intractable epilepsy due to left-side hemispheric cortical dysplasia underwent a hemispherotomy. She was seizure-free after the surgery. EEG showed persistent abundant epileptiform activity over the left (disconnected) hemisphere, including ictal patterns that neither generalised nor had clinical correlates. Antiepileptic medication was completely withdrawn four years following the surgery. One week after the withdrawal, she developed episodes of intense left-sided hemicranias (ipsilateral to the surgery) with vomiting and photophobia that did not resemble her habitual seizures and were unresponsive to non-steroidal anti-inflammatory drugs. Video-EEG showed association of the headache attacks with ictal patterns over the disconnected hemisphere. Brain MRI revealed increased signal changes in the left hemisphere. Attacks responded promptly to i.v. midazolam and carbamazepine at a low dose. Mechanisms underlying peri-ictal headache originating in the disconnected hemisphere are discussed. [Published with video sequences]","[Vydrova, Rosa; Krsek, Pavel; Jahodova, Alena; Komarek, Vladimir] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Neurol, CZ-15006 Prague 5, Czech Republic; [Kyncl, Martin] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Radiol, CZ-15006 Prague 5, Czech Republic; [Dvorak, Josef; Tichy, Michal] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Neurosurg, CZ-15006 Prague 5, Czech Republic; [Delalande, Olivier] Fdn Ophtalmol Adolphe Rothschild, Paris, France","Krsek, P (reprint author), Charles Univ Prague, Motol Hosp, Med Sch 2, Dept Pediat Neurol,Motol Epilepsy Ctr, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","pavel.krsek@post.cz",null,null,"Ministry of Health, Czech Republic;  [IGA NT13357-4/2012]","This study was supported by grants IGA NT13357-4/2012 (Pavel Krsek) and by the Ministry of Health, Czech Republic; conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203 (Pavel Krsek).",null,8,0,0,"JOHN LIBBEY EUROTEXT LTD","MONTROUGE","127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE","1294-9361","1950-6945",null,"EPILEPTIC DISORD","Epileptic Disord.","JUN",2014,16,2,null,null,null,null,213,217,null,"10.1684/epd.2014.0653",null,5,null,null,"AJ4FY","WOS:000337629400009",24777063]
["J","Kovac, M; Vaskova, M; Petrackova, D; Pelkova, V; Mejstrikova, E; Kalina, T; Zaliova, M; Weiser, J; Stary, J; Hrusak, O",null,null,null,"Kovac, Martin; Vaskova, Martina; Petrackova, Denisa; Pelkova, Vendula; Mejstrikova, Ester; Kalina, Tomas; Zaliova, Marketa; Weiser, Jaroslav; Stary, Jan; Hrusak, Ondrej",null,null,"Cytokines, growth, and environment factors in bone marrow plasma of acute lymphoblastic leukemia pediatric patients","EUROPEAN CYTOKINE NETWORK",null,null,"English","Article",null,null,null,null,null,"pediatric acute lymphoblastic leukemia; bone marrow plasma; cytokine antibody array","ACUTE MYELOID-LEUKEMIA; TISSUE INHIBITOR; STROMAL CELLS; IN-VITRO; CHILDHOOD; SURVIVAL; GENE; HEMATOPOIESIS; EXPRESSION; MICROENVIRONMENT","Acute lymphoblastic leukemia (ALL) cells depend on the microenvironment of the host in vivo and do not survive in in vitro culture. Conversely, the suppression of non-malignant tissues is one of the leading characteristics of the course of ALL. Both the non-malignant suppression and malignant cell survival may be partly affected by soluble factors within the bone marrow (BM) environment. Here, we aimed to identify proteins in BM plasma of children with ALL that may contribute to ALL aggressiveness and/or the microenvironment-mediated survival of ALL cells. LBMp (leukemic bone marrow plasma) at the time of ALL diagnosis was compared to control plasma of bone marrow (CBMp) or peripheral blood (CPBp) using a cytokine antibody array. The cytokine antibody array enabled simultaneous detection of 79 proteins per sample. Candidate proteins exhibiting significantly different profiles were further analyzed and confirmed by ELISA. mRNAexpression of one of the candidate proteins (TIMP1) was studied using quantitative reverse transcriptase polymerase chain reaction (qRTPCR). The cytokine antibody array experiments identified 23 proteins that differed significantly (p<0.05); of these, two proteins (TIMP1 and LIF) withstood the Bonferroni correction. In contrast, little difference was observed between CBMp and CPBp. At the diagnosis of ALL, changes in the soluble microenvironment are detectable in BM plasma. These changes probably participate in the pathogenesis and/or result from the changes in the cell composition.","[Kovac, Martin; Vaskova, Martina; Pelkova, Vendula; Mejstrikova, Ester; Kalina, Tomas; Zaliova, Marketa; Hrusak, Ondrej] CLIP Childhood Leukemia Invest Prague, Prague, Czech Republic; [Kovac, Martin; Vaskova, Martina; Pelkova, Vendula; Mejstrikova, Ester; Kalina, Tomas; Zaliova, Marketa; Stary, Jan; Hrusak, Ondrej] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague, Czech Republic; [Kovac, Martin; Vaskova, Martina; Pelkova, Vendula; Mejstrikova, Ester; Kalina, Tomas; Zaliova, Marketa; Stary, Jan; Hrusak, Ondrej] Univ Hosp Motol, Prague, Czech Republic; [Petrackova, Denisa; Weiser, Jaroslav] Acad Sci Czech Republic, Inst Microbiol Vvi, Prague, Czech Republic","Hrusak, O (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague, Czech Republic.","ondrej.hrusak@lfmotol.cuni.cz","Weiser, jaroslav/I-2078-2013","Weiser, jaroslav/0000-0003-3541-4249","Charles University [GAUK 596912]; Center of Excellence UNCE [204012]; IGA MZCR [NR/9531-3]; MH CZ - DRO, University Hospital Motol, Prague, Czech Republic [00064203]","Financial support: this work was supported by grants from Charles University GAUK 596912, Center of Excellence UNCE 204012, IGA MZCR NR/9531-3, and supported by MH CZ - DRO, University Hospital Motol, Prague, Czech Republic 00064203. Conflict of interest: none.",null,31,0,0,"JOHN LIBBEY EUROTEXT LTD","MONTROUGE","127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE","1148-5493",null,null,"EUR CYTOKINE NETW","Eur. Cytokine Netw.","MAR",2014,25,1,null,null,null,null,8,13,null,"10.1684/ecn.2014.0348",null,6,"Biochemistry & Molecular Biology; Cell Biology; Immunology","Biochemistry & Molecular Biology; Cell Biology; Immunology","AO4RP","WOS:000341329400002",24998352]
["J","Veselka, J; Krejci, J; Tomasov, P; Zemanek, D",null,null,null,"Veselka, Josef; Krejci, Jan; Tomasov, Pavol; Zemanek, David",null,null,"Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population","EUROPEAN HEART JOURNAL",null,null,"English","Article",null,null,null,null,null,"Alcohol septal ablation; Prognosis; Hypertrophic cardiomyopathy","SUDDEN CARDIAC DEATH; FOLLOW-UP; RISK STRATIFICATION; AMERICAN-COLLEGE; MULTICENTER; EXPERIENCE; CARDIOLOGY; MYECTOMY; AGE","Aims We decided to determine the long-term survival of patients after alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) and compare this with the general population. Methods and results A total of 178 highly symptomatic, consecutive patients (58 +/- 12 years, 53% women) were treated by ASA between April 1998 and April 2013 and followed-up for 4.8 years (IQR 2.1-7.5). At baseline, 155 patients (87%) suffered from dyspnoea >= 3 class of NYHA; at the most recent examination, 87 patients (49%) and 23 patients (13%) reported dyspnoea of NYHA class 1 and >= 3, respectively. The left ventricular outflow gradient was significantly reduced (68 +/- 42 vs. 20 +/- 25 mmHg; P < 0.01). A total of 19 deaths (11%) occurred during 925 patient-years, which means an overall mortality rate of 2.1% per year. Survival free of all-cause mortality at 1, 5, and 10 years was 97% (95% CI, 93-99%), 92% (95% CI, 87-96%), and 82% (95% CI, 70-90%), respectively. This observed mortality was comparable to the expected survival for age- and sex-comparable general population (P = 0.34). According to multivariate analysis, the only independent predictor of all-cause mortality was age at ASA (hazard ratio 1.09, 95% CI 1.04-1.14; P < 0.01). Conclusions This study suggests that in patients with HOCM and important symptoms who underwent ASA, long-term survival after the procedure did not differ significantly from that of the general population.","[Veselka, Josef; Tomasov, Pavol; Zemanek, David] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Cardiol, Prague, Czech Republic; [Krejci, Jan] St Annes Univ Hosp, Int Clin Res Ctr, Dept Internal Med Cardioangiol 1, Brno, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Cardiol, Prague, Czech Republic.","veselka.josef@seznam.cz",null,null,"project for conceptual development of research organization [00064203]; Internal Grant Agency, Ministry of Health, Czech Republic [NT 11401-5]; European Social Fund; Czech Republic-Project ICRC Human Bridge-Support of RD teams [CZ.1.07/2.3.00/30.0023]; European Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]","This work was supported by the project for conceptual development of research organization (No. 00064203), by the Internal Grant Agency, Ministry of Health, Czech Republic (grant NT 11401-5), by European Social Fund and the State Budget of the Czech Republic-Project ICRC Human Bridge-Support of R&D teams through formation of new postdoc positions (no. CZ.1.07/2.3.00/30.0023) and by European Regional Development Fund-Project FNUSA-ICRC (no. CZ.1.05/1.1.00/02.0123).",null,30,0,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0195-668X","1522-9645",null,"EUR HEART J","Eur. Heart J.","AUG 7",2014,35,30,null,null,null,null,2040,"+",null,"10.1093/eurheartj/eht495",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AP7BK","WOS:000342232400013",24464834]
["J","Halvorsen, S; Atar, D; Yang, HQ; De Caterina, R; Erol, C; Garcia, D; Granger, CB; Hanna, M; Held, C; Husted, S; Hylek, EM; Jansky, P; Lopes, RD; Ruzyllo, W; Thomas, L; Wallentin, L",null,null,null,"Halvorsen, Sigrun; Atar, Dan; Yang, Hongqiu; De Caterina, Raffaele; Erol, Cetin; Garcia, David; Granger, Christopher B.; Hanna, Michael; Held, Claes; Husted, Steen; Hylek, Elaine M.; Jansky, Petr; Lopes, Renato D.; Ruzyllo, Witold; Thomas, Laine; Wallentin, Lars",null,null,"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","EUROPEAN HEART JOURNAL",null,null,"English","Article",null,null,null,null,null,"Atrial fibrillation; Age; Anticoagulants; Stroke; Bleeding; Apixaban","THROMBOEMBOLIC EVENTS; ORAL ANTICOAGULANTS; RISK; THERAPY; PREVALENCE; REDUCTION","Aims The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death, and bleeding. We evaluated these outcomes in relation to patient age. Methods and results A total of 18 201 patients with AF and a raised risk of stroke were randomized to warfarin or apixaban 5 mg b.d. with dose reduction to 2.5 mg b.d. or placebo in 831 patients with >= 2 of the following criteria: age >= 80 years, body weight <= 60 kg, or creatinine >= 133 mu mol/L. We used Cox models to compare outcomes in relation to patient age during 1.8 years median follow-up. Of the trial population, 30% were <65 years, 39% were 65 to <75, and 31% were >= 75 years. The rates of stroke, all-cause death, and major bleeding were higher in the older age groups (P < 0.001 for all). Apixaban was more effective than warfarin in preventing stroke and reducing mortality across all age groups, and associated with less major bleeding, less total bleeding, and less intracranial haemorrhage regardless of age (P interaction >0.11 for all). Results were also consistent for the 13% of patients >= 80 years. No significant interaction with apixaban dose was found with respect to treatment effect on major outcomes. Conclusion The benefits of apixaban vs. warfarin were consistent in patients with AF regardless of age. Owing to the higher risk at older age, the absolute benefits of apixaban were greater in the elderly.","[Halvorsen, Sigrun; Atar, Dan] Oslo Univ Hosp, Dept Cardiol B, N-0407 Oslo, Norway; [Atar, Dan] Univ Oslo, Inst Clin Med, N-0316 Oslo, Norway; [Yang, Hongqiu; Granger, Christopher B.; Lopes, Renato D.; Thomas, Laine] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [De Caterina, Raffaele] Univ G dAnnunzio, Pisa, Italy; [De Caterina, Raffaele] Fdn Toscana G Monasterio, Pisa, Italy; [Erol, Cetin] Ankara Univ, Fac Med, TR-06100 Ankara, Turkey; [Garcia, David] Univ Washington, Div Hematol, Seattle, WA 98195 USA; [Hanna, Michael] Bristol Myers Squibb Co, Princeton, NJ USA; [Held, Claes; Wallentin, Lars] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Held, Claes; Wallentin, Lars] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden; [Husted, Steen] Hosp Unit West, Dept Med, Herning Holstbro, Denmark; [Hylek, Elaine M.] Boston Univ, Med Ctr, Boston, MA USA; [Jansky, Petr] Univ Hosp Motol, Ctr Cardiovasc, Prague, Czech Republic; [Ruzyllo, Witold] Natl Inst Cardiol, Warsaw, Poland","Halvorsen, S (reprint author), Oslo Univ Hosp, Dept Cardiol B, N-0407 Oslo, Norway.","sigrun.h@online.no",null,null,"Bristol-Myers Squibb; Pfizer; University of Oslo","The ARISTOTLE trial was funded by Bristol-Myers Squibb and Pfizer. The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the article as written. Funding to pay the Open Access publication charges for this article was provided by the University of Oslo.",null,20,1,1,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0195-668X","1522-9645",null,"EUR HEART J","Eur. Heart J.","JUL",2014,35,28,null,null,null,null,1864,1872,null,"10.1093/eurheartj/ehu046",null,9,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AM7SI","WOS:000340068200011",24561548]
["J","Krizova, E; Byma, S",null,null,null,"Krizova, Eva; Byma, Svatopluk",null,null,"The integration of homoeopathy into Czech Health Care - A 10-year follow-up","EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE",null,null,"English","Article",null,null,null,null,null,"Homoeopathy; Primary care; New EU members; Ex-socialist countries; Czech Republic; Central and Eastern Europe","NATIONAL-SURVEY; COMPLEMENTARY; ACUPUNCTURE; ATTITUDES; HOSPITALS; MEDICINE; DOCTORS","Introduction: In Central Europe, homoeopathy has a long history although this was interrupted after World War 2 and renewed only after the liberalisation of society in 1989. This survey aimed to measure experience, practice and views of homoeopathy among Czech general physicians for the adult population and to compare the results with those of the 2001 survey. Methods: Identical original self-administered questionnaires were submitted to general physicians in 2001 and again in 2012. A convenience sample was used in 2012 whereas a random sample had been used in 2001. 1024 general physicians for the adult population who attended the 2012 Annual Conference of the Society of General Medicine received a questionnaire, and 419 replied (response rate=41%), while in 2001, 720 randomly selected members of the Society for General Medicine received a questionnaire, and 449 replied (response rate=62%). Differences in age and gender between the samples were corrected by weighted coefficients on the basis of direct demographic standardisation. Results: In 2012, approximately 1/4 of GPs 23% reported training in homoeopathy and 19% use homoeopathy in their clinical practice. The extent of homoeopathy is similar to other European countries with a tradition of homoeopathy. The effects of gender, age, location or religion turned out to be weak and inconsistent. No statistically significant changes in pivotal items were found between 2001 and 2012 samples. Conclusion: Homoeopathy has been firmly integrated into Czech primary health care and has remained so despite the worse economic conditions of the population and lack of public support. (C) 2013 Elsevier GmbH. All rights reserved.","[Krizova, Eva] Charles Univ Prague, Dept Med Eth & Humanities, Fac Med 2, Prague, Czech Republic; [Krizova, Eva] Charles Univ Prague, Protestant Theol Fac, Dept Pastoral & Social Care, Prague, Czech Republic; [Byma, Svatopluk] Charles Univ Prague, Fac Med, Inst Social Med, Hradec Kralove, Czech Republic","Krizova, E (reprint author), Karoliny Svetle 31, Prague 11000 1, Czech Republic.","evakriz@centrum.cz",null,null,"Internal Grant Agency of the Czech Ministry of Health [IGA MZ CR NO6647-2]","Yes, partially. The survey in 2001 was a part of a research project supported by the Internal Grant Agency of the Czech Ministry of Health (Ethical, sociological and philosophical aspects of unconventional medicine, Nr. IGA MZ CR NO6647-2), but the follow-up survey in 2012 was conducted without any financial support.",null,24,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1876-3820","1876-3839",null,"EUR J INTEGR MED","Eur. J. Integr. Med.","JUN",2014,6,3,null,null,null,null,277,285,null,"10.1016/j.eujim.2013.12.023",null,9,"Integrative & Complementary Medicine","Integrative & Complementary Medicine","AO4HA","WOS:000341296300005"]
["J","Hasenclever, D; Kurch, L; Mauz-Korholz, C; Elsner, A; Georgi, T; Wallace, H; Landman-Parker, J; Moryl-Bujakowska, A; Cepelova, M; Karlen, J; Fernandez-Teijeiro, AA; Attarbaschi, A; Fossa, A; Pears, J; Hraskova, A; Bergstrasser, E; Beishuizen, A; Uyttebroeck, A; Schomerus, E; Sabri, O; Korholz, D; Kluge, R",null,null,null,"Hasenclever, Dirk; Kurch, Lars; Mauz-Koerholz, Christine; Elsner, Andreas; Georgi, Thomas; Wallace, Hamish; Landman-Parker, Judith; Moryl-Bujakowska, Angelina; Cepelova, Michaela; Karlen, Jonas; Alvarez Fernandez-Teijeiro, Ana; Attarbaschi, Andishe; Fossa, Alexander; Pears, Jane; Hraskova, Andrea; Bergstraesser, Eva; Beishuizen, Auke; Uyttebroeck, Anne; Schomerus, Eckhard; Sabri, Osama; Koerholz, Dieter; Kluge, Regine",null,null,"qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma","EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING",null,null,"English","Article",null,null,null,null,null,"Lymphoma; Response; FDG-PET","POSITRON-EMISSION-TOMOGRAPHY; B-CELL LYMPHOMA; INTERNATIONAL HARMONIZATION PROJECT; STAGE HODGKINS LYMPHOMA; EVENT-FREE SURVIVAL; F-18-FDG PET; PROGNOSTIC VALUE; PREDICTIVE-VALUE; CLINICAL-TRIALS; FOLLOW-UP","Background Interim FDG-PET is used for treatment tailoring in lymphoma. Deauville response criteria consist of five ordinal categories based on visual comparison of residual tumor uptake to physiological reference uptakes. However, PET-response is a continuum and visual assessments can be distorted by optical illusions. Objectives With a novel semi-automatic quantification tool we eliminate optical illusions and extend the Deauville score to a continuous scale. Patients and methods SUVpeak of residual tumors and average uptake of the liver is measured with standardized volumes of interest. The qPET value is the quotient of these measurements. Deauville scores and qPET-values were determined in 898 pediatric Hodgkin's lymphoma patients after two OEPA chemotherapy cycles. Results Deauville categories translate to thresholds on the qPET scale: Categories 3, 4, 5 correspond to qPET values of 0.95, 1.3 and 2.0, respectively. The distribution of qPET values is unimodal with a peak representing metabolically normal responses and a tail of clearly abnormal outliers. In our patients, the peak is at qPET = 0.95 coinciding with the border between Deauville 2 and 3. qPET cut values of 1.3 or 2 (determined by fitting mixture models) select abnormal metabolic responses with high sensitivity, respectively, specificity. Conclusions qPET methodology provides semi-automatic quantification for interim FDG-PET response in lymphoma extending ordinal Deauville scoring to a continuous scale. Deauville categories correspond to certain qPET cut values. Thresholds between normal and abnormal response can be derived from the qPET-distribution without need for follow-up data. In our patients, qPET < 1.3 excludes abnormal response with high sensitivity.","[Hasenclever, Dirk] Univ Leipzig, IMISE, D-04109 Leipzig, Germany; [Kurch, Lars; Georgi, Thomas; Sabri, Osama; Kluge, Regine] Univ Hosp Leipzig, Dept Nucl Med, Leipzig, Germany; [Mauz-Koerholz, Christine; Koerholz, Dieter] Univ Hosp Halle, Dept Pediat, Halle, Germany; [Elsner, Andreas] Hermes Med Solut AB, Stockholm, Sweden; [Wallace, Hamish] Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland; [Landman-Parker, Judith] Hop Enfants Armand Trousseau, Paris, France; [Moryl-Bujakowska, Angelina] Jagiellonian Univ, Coll Med, Polish Amer Inst Pediat, Dept Pediat Oncol & Hematol, Krakow, Poland; [Cepelova, Michaela] Fac Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Karlen, Jonas] Karolinska Univ Hosp, Astrid Lindgrens Childrens Hosp, Pediat Canc Unit, Stockholm, Sweden; [Alvarez Fernandez-Teijeiro, Ana] Univ Hosp Virgen Macarena Avda, Dept Pediat Oncol & Hematol, Seville, Spain; [Attarbaschi, Andishe] Med Univ Vienna, St Anna Childrens Hosp, Dept Pediat Hematol & Oncol, Vienna, Austria; [Fossa, Alexander] Radiumhosp HF, Rikshosp, Dept Med Oncol & Radiotherapy, Oslo, Norway; [Hraskova, Andrea] Univ Childrens Hosp, Clin Pediat Oncol, Bratislava, Slovakia; [Bergstraesser, Eva] Univ Childrens Hosp, Dept Oncol, Zurich, Switzerland; [Beishuizen, Auke] MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Uyttebroeck, Anne] Univ Hosp Leuven, Dept Pediat Hematooncol, Leuven, Belgium; [Schomerus, Eckhard] Univ Odense OUH, HC Andersen Childrens Hosp, Dept Pediat Oncol & Hematol, Odense, Denmark","Kluge, R (reprint author), Univ Hosp Leipzig, Dept Nucl Med, Leipzig, Germany.","regine.kluge@medizin.uni-leipzig.de",null,null,"Deutsche Krebshilfe e. V. -Hermes Medical Solutions AB -Executive Agency for Health and Consumers (EAHC) -Peter-Escher-Stiftung.","The EURO-NET-trial received research support from Deutsche Krebshilfe e. V. -Hermes Medical Solutions AB -Executive Agency for Health and Consumers (EAHC) -Peter-Escher-Stiftung.",null,40,2,2,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1619-7070","1619-7089",null,"EUR J NUCL MED MOL I","Eur. J. Nucl. Med. Mol. Imaging","JUL",2014,41,7,null,null,null,null,1301,1308,null,"10.1007/s00259-014-2715-9",null,8,"Radiology, Nuclear Medicine & Medical Imaging","Radiology, Nuclear Medicine & Medical Imaging","AI9UR","WOS:000337286200005",24604592]
["J","Patockova, J; Sliva, J; Marhol, P; Crkovska, J; Stipek, S",null,null,null,"Patockova, Jitka; Sliva, Jiri; Marhol, Petr; Crkovska, Jirina; Stipek, Stanislav",null,null,"The influence of vitamin-rich diet on the extent of lipoperoxidation in brain of mice during an acute post-insulin hypoglycaemia","EUROPEAN JOURNAL OF PHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,"Lipoperoxidation; Vitamin C; Vitamin E; Hypoglycaemia Malondialdehyde; Superoxide dismutase; Glutathione peroxidase","OXIDATIVE STRESS; LIPID-PEROXIDATION; NEWBORN PIGLETS; RAT-BRAIN; ANTIOXIDANTS; ISCHEMIA; DAMAGE; ASSAY","Antioxidatives are widely used and recommended in common clinical praxis, even though they may have negative impact on our health under some circumstances (i.e. N-acetylcysteine, vitamin E, risk of lung cancer etc.). Our aim was to evaluate the role of exogenous scavengers in prevention of induced oxidative stress in rodents. Male ICR mice were used and acute hypoglycaemia was induced with insulin. The mice were randomized into eight experimental groups, either pretreated by vitamin C or vitamin E or combinations with respective vehicles. Total malondialdehyde (MDA), superoxide dismutase (SOD), and selenium-dependent glutathione peroxidase (GSHPx) activity were measured in brain tissue samples. ANOVA with a post-hoc Duncan or Turkey's tests were used for statistical evaluation. A statistically significant increase in brain MDA was observed after insulin-induced severe hypoglycaemia relative to normoglycaemia. Animals pretreated with vitamins, both in monotherapy and in combination (both P < 0.05), had significantly lower MDA values compared with animals without pretreatment. Importantly, significant differences were also observed after combination of vitamin C and E in GSHPx and SOD (both P < 0.05). (C) 2014 Elsevier B.V. All rights reserved.","[Patockova, Jitka; Sliva, Jiri] Charles Univ Prague, Fac Med 3, Dept Pharmacol, Prague 10000 10, Czech Republic; [Sliva, Jiri] Charles Univ Prague, Fac Med 2, Dept Pharmacol, Prague 10000 10, Czech Republic; [Marhol, Petr] Acad Sci Czech Republic, Inst Microbiol, Prague, Czech Republic; [Crkovska, Jirina; Stipek, Stanislav] Charles Univ Prague, Fac Med 1, Dept Chem, Prague 10000 10, Czech Republic","Sliva, J (reprint author), Charles Univ Prague, Fac Med 3, Dept Pharmacol, Ruska 87, Prague 10000 10, Czech Republic.","jiri.sliva@lf3.cuni.cz",null,null,"PRVOUK [P34]; VZ: MSM [0021620816]; Ministry of Education of the Czech Republic [LD13041]","This study was supported by research grants PRVOUK P34, VZ: MSM 0021620816, and the Ministry of Education of the Czech Republic, No, LD13041.",null,32,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0014-2999","1879-0712",null,"EUR J PHARMACOL","Eur. J. Pharmacol.","OCT 5",2014,740,null,null,null,null,null,641,644,null,"10.1016/j.ejphar.2014.06.015",null,4,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","AO2OH","WOS:000341163700078",24972242]
["J","Bruthans, J; Cifkova, R; Lanska, V; O'Flaherty, M; Critchley, JA; Holub, J; Jansky, P; Zvarova, J; Capewell, S",null,null,null,"Bruthans, Jan; Cifkova, Renata; Lanska, Vera; O'Flaherty, Martin; Critchley, Julia A.; Holub, Jiri; Jansky, Petr; Zvarova, Jana; Capewell, Simon",null,null,"Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007","EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"Coronary heart disease; coronary heart disease mortality; coronary heart disease risk factors; coronary heart disease management; Czech MONICA and Czech post-MONICA","ACUTE MYOCARDIAL-INFARCTION; RISK-FACTORS; LONGITUDINAL TRENDS; BLOOD-PRESSURE; DECREASE; THERAPY; HYPERTENSION; POPULATION; PREVENTION; FINLAND","Background: Coronary heart disease (CHD) mortality has declined substantially in the Czech Republic over the last two decades. Design: The purpose of this study was to determine what proportion of this CHD mortality decline could be associated with temporal trends in major CHD risk factors and what proportion with advances in medical and surgical treatments. Methods: The validated IMPACT mortality model was used to combine and analyse data on uptake and effectiveness of CHD management and risk factor trends in the Czech Republic in adults aged 25-74 years between 1985 and 2007. The main sources were official statistics, national quality of care registries, published trials and meta-analyses, and the Czech MONICA and Czech post-MONICA studies. Results: Between 1985 and 2007, age-adjusted CHD mortality rates in the Czech Republic decreased by 66.2% in men and 65.4% in women in the age group 25-74 years, representing 12,080 fewer CHD deaths in 2007. Changes in CHD risk factors explained approximately 52% of the total mortality decrease, and improvements in medical treatments approximately 43%. Increases in body mass index and in diabetes prevalence had a negative impact, increasing CHD mortality by approximately 1% and 5%, respectively. Conclusions: More than half of the very substantial fall in CHD mortality in the Czech Republic between 1985 and 2007 was attributable to reduction in major cardiovascular risk factors. Improvement in treatments accounted for approximately 43% of the total mortality decrease. These findings emphasize the value of primary prevention and evidence-based medical treatment.","[Bruthans, Jan; Cifkova, Renata] Inst Clin & Expt Med, Dept Prevent Cardiol, Prague 14021 4, Czech Republic; [Bruthans, Jan] Charles Univ Prague, Sch Med, Dept Med 2, Plzen, Czech Republic; [Cifkova, Renata] Thomayer Hosp, Ctr Cardiovasc Prevent, Prague, Czech Republic; [Cifkova, Renata] Charles Univ Prague, Sch Med 1, Prague, Czech Republic; [Cifkova, Renata] Charles Univ Prague, Sch Med 1, Dept Med 2, Prague, Czech Republic; [Cifkova, Renata] Int Clin Res Ctr Brno, Brno, Czech Republic; [Lanska, Vera] Inst Clin & Expt Med, Med Stat Unit, Prague 14021 4, Czech Republic; [O'Flaherty, Martin; Capewell, Simon] Univ Liverpool, Div Publ Hlth, Liverpool L69 3BX, Merseyside, England; [Critchley, Julia A.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Holub, Jiri] Inst Hlth Informat & Stat Czech Republ, Prague, Czech Republic; [Jansky, Petr] Charles Univ Prague, Sch Med 2, Dept Cardiovasc Surg, Prague, Czech Republic; [Jansky, Petr] Motol Univ Hosp, Prague, Czech Republic; [Zvarova, Jana] Acad Sci Czech Republic, Inst Comp Sci, Ctr Biomed Informat, Prague, Czech Republic","Bruthans, J (reprint author), Inst Clin & Expt Med, Dept Prevent Cardiol, Videnska 1958-9, Prague 14021 4, Czech Republic.","jan.bruthans@ikem.cz","Zvarova, Jana/B-5196-2014",null,"Krka Czech Republic s.r.o.; Servier Czech Republic s.r.o.","This work was supported by Krka Czech Republic s.r.o. and Servier Czech Republic s.r.o. (unrestricted research grants).",null,31,0,0,"SAGE PUBLICATIONS LTD","LONDON","1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND","2047-4873","2047-4881",null,"EUR J PREV CARDIOL","Eur. J. Prev. Cardiol.","JUL",2014,21,7,null,null,null,null,829,839,null,"10.1177/2047487312469476",null,11,null,null,"AJ3MW","WOS:000337571700005"]
["J","Midulla, F; Lombardi, E; Rottier, B; Lindblad, A; Grigg, J; Bohlin, K; Rusconi, F; Pohunek, P; Eber, E",null,null,null,"Midulla, Fabio; Lombardi, Enrico; Rottier, Bart; Lindblad, Anders; Grigg, Jonathan; Bohlin, Kajsa; Rusconi, Franca; Pohunek, Petr; Eber, Ernst",null,null,"Paediatrics in Barcelona","EUROPEAN RESPIRATORY JOURNAL",null,null,"English","Article",null,null,null,null,null,null,"LUNG CLEARANCE INDEX; RANDOMIZED CONTROLLED-TRIAL; ACTIVATING-FACTOR RECEPTOR; PRIMARY CILIARY DYSKINESIA; CYSTIC-FIBROSIS; PRETERM INFANTS; PRESCHOOL-CHILDREN; YOUNG-CHILDREN; FLEXIBLE BRONCHOSCOPY; RHINOVIRUS INFECTION","This update will describe the paediatric highlights from the 2013 European Respiratory Society (ERS) annual congress in Barcelona, Spain. Abstracts from the seven groups of the ERS Paediatric Assembly (Respiratory Physiology and Sleep, Asthma and Allergy, Cystic Fibrosis, Respiratory Infection and Immunology, Neonatology and Paediatric Intensive Care, Respiratory Epidemiology, and Bronchology) have been chosen by group officers and are presented in the context of current literature.","[Midulla, Fabio] Univ Roma La Sapienza, Dept Paediat, I-00185 Rome, Italy; [Lombardi, Enrico] Anna Meyer Childrens Univ Hosp, Dept Paediat, Florence, Italy; [Rottier, Bart] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp,GRIAC Res Inst, Dept Pediat Pulmonol & Allergol, Groningen, Netherlands; [Lindblad, Anders] Sahlgrens Univ Hosp, Queen Silvia Childrens Hosp, Dept Paediat, Gothenburg, Sweden; [Grigg, Jonathan] Queen Mary Univ London, Blizard Inst, London, England; [Bohlin, Kajsa] Karolinska Univ Hosp, Dept Neonatol, Stockholm, Sweden; [Bohlin, Kajsa] Karolinska Inst, Stockholm, Sweden; [Rusconi, Franca] Anna Meyer Childrens Univ Hosp, Epidemiol Unit, Florence, Italy; [Pohunek, Petr] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Pohunek, Petr] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Eber, Ernst] Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, A-8036 Graz, Austria","Eber, E (reprint author), Med Univ Graz, Univ Klin Kinder & Jugendheilkunde, Klin Abt Pulmonol & Allergol, Auenbruggerpl 34-2, A-8036 Graz, Austria.","ernst.eber@medunigraz.at",null,null,null,null,null,176,0,0,"EUROPEAN RESPIRATORY SOC JOURNALS LTD","SHEFFIELD","442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND","0903-1936","1399-3003",null,"EUR RESPIR J","Eur. Resp. J.","AUG",2014,44,2,null,null,null,null,457,474,null,"10.1183/09031936.00046414",null,18,"Respiratory System","Respiratory System","AM7AO","WOS:000340017300023",24833764]
["J","Bobek, V; Matkowski, R; Gurlich, R; Grabowski, K; Szelachowska, J; Lischke, R; Schutzner, J; Harustiak, T; Pazdro, A; Rzechonek, A; Kolostova, K",null,null,null,"Bobek, Vladimir; Matkowski, Rafal; Guerlich, Robert; Grabowski, Krzysztof; Szelachowska, Jolanta; Lischke, Robert; Schuetzner, Jan; Harustiak, Tomas; Pazdro, Alexandr; Rzechonek, Adam; Kolostova, Katarina",null,null,"Cultivation of circulating tumor cells in esophageal cancer","FOLIA HISTOCHEMICA ET CYTOBIOLOGICA",null,null,"English","Article",null,null,null,null,null,"esophageal cancer; circulating tumor cells; MetaCell (R); CTCs culture; gastrointestinal tumors","BREAST-CANCER; PERIPHERAL-BLOOD; MOLECULAR-DETECTION; CLINICAL-SIGNIFICANCE; COLORECTAL-CANCER; SURROGATE MARKER; PROSTATE-CANCER","The presence of circulating tumor cells (CTCs) in patients with metastatic carcinoma is generally associated with poor clinical outcome. There have been many investigations showing a possible use of CTCs as minimally invasive predictive and prognostic biomarker in cancer medicine. In this report a size-based method (MetaCell (R)) for quick and easy enrichment and cultivation of CTCs is presented to enable possible CTCs use in esophageal cancer (EC) management. In total, 43 patients with diagnosed EC, 20 with adenocarcinoma (AdenoCa) and 23 with squamous cell carcinoma (SCC), were enrolled into the adaptive prospective-like study. All the patients were candidates for surgery. The CTCs were detected in 27 patients (62.8%), with a higher rate in adenocarcinoma (75%) than SCC (52%). Finally, there were 26 patients with resectable tumors exhibiting CTCs-positivity in 69.2% and 17 patients with non-resectable tumors with 41.7% CTCs-positivity. Interestingly, in the patients undergoing neoadjuvant therapy, the CTCs were detected at time of surgery in 55.5% (10/18). The overall size-based filtration approach enabled to isolate viable CTCs and evaluate to their cytomorphological features by means of vital fluorescent staining. The CTCs were cultured in vitro for further downstream applications including immunohistochemical analysis. This is the first report of the successful culturing of esophageal cancer CTCs. The detection of CTCs presence could help in the future to guide timing of surgical treatment in EC patients.","[Bobek, Vladimir; Kolostova, Katarina] Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Prague 10034, Czech Republic; [Bobek, Vladimir; Rzechonek, Adam] Wroclaw Med Univ, Dept Histol & Embryol, Wroclaw, Poland; [Bobek, Vladimir; Lischke, Robert; Schuetzner, Jan; Harustiak, Tomas; Pazdro, Alexandr] Charles Univ Prague, Fac Med 1, Dept Surg 3, Prague, Czech Republic; [Bobek, Vladimir; Lischke, Robert; Schuetzner, Jan; Harustiak, Tomas; Pazdro, Alexandr] Univ Hosp Motol, Prague, Czech Republic; [Matkowski, Rafal] Wroclaw Med Univ, Lower Silesian Oncol Ctr, Div Surg Oncol, Wroclaw, Poland; [Matkowski, Rafal] Wroclaw Med Univ, Lower Silesian Oncol Ctr, Dept Oncol, Wroclaw, Poland; [Guerlich, Robert] Charles Univ Prague, Fac Med 3, Dept Surg, Prague, Czech Republic; [Guerlich, Robert] Charles Univ Prague, Fac Med 3, Dept Surg, Prague, Czech Republic; [Guerlich, Robert] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Grabowski, Krzysztof] Wroclaw Med Univ, Dept Gastrointestinal & Gen Surg, Wroclaw, Poland; [Szelachowska, Jolanta] Wroclaw Med Univ, Lower Silesian Oncol Ctr, Dept Oncol, Wroclaw, Poland","Bobek, V (reprint author), Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Srobarova St 50, Prague 10034, Czech Republic.","vbobek@centrum.cz",null,null,"League Against Cancer Prague, Czech Republic; Czech Ministry of Health: IGA [NT14439-3/2013]; Charles University in Prague [P27/2012]","This study was supported by Grant provided by the League Against Cancer Prague, Czech Republic (Grant with title: Sledovani hladiny CTC u vybranych nadoru gastrointestinalniho traktu) and grant of the Czech Ministry of Health: IGA NT14439-3/2013, and also supported by the research project P27/2012 awarded by the Charles University in Prague.",null,26,0,0,"VIA MEDICA","GDANSK","UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND","0239-8508","1897-5631",null,"FOLIA HISTOCHEM CYTO","Folia Histochem. Cytobiol.",null,2014,52,3,null,null,null,null,171,177,null,"10.5603/FHC.2014.0020",null,7,"Biochemistry & Molecular Biology; Cell Biology","Biochemistry & Molecular Biology; Cell Biology","AQ8EC","WOS:000343055500002",25308732]
["J","Creutzig, U; Zimmermann, M; Dworzak, MN; Gibson, B; Tamminga, R; Abrahamsson, J; Ha, SY; Hasle, H; Maschan, A; Bertrand, Y; Leverger, G; von Neuhoff, C; Razzouk, B; Rizzari, C; Smisek, P; Smith, OP; Stark, B; Reinhardt, D; Kaspers, GL",null,null,null,"Creutzig, Ursula; Zimmermann, Martin; Dworzak, Michael N.; Gibson, Brenda; Tamminga, Rienk; Abrahamsson, Jonas; Ha, Shau-Yin; Hasle, Henrik; Maschan, Alexey; Bertrand, Yves; Leverger, Guy; von Neuhoff, Christine; Razzouk, Bassem; Rizzari, Carmelo; Smisek, Petr; Smith, Owen P.; Stark, Batia; Reinhardt, Dirk; Kaspers, Gertjan L.",null,null,"The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01","HAEMATOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"ACUTE MYELOGENOUS LEUKEMIA; BFM STUDY-GROUP; INITIAL TREATMENT; FLOW-CYTOMETRY; CHILDREN; THERAPY; TRIAL; SURVIVAL; RECOMMENDATIONS; REMISSION","The prognostic significance of early response to treatment has not been reported in relapsed pediatric acute myeloid leukemia. In order to identify an early and easily applicable prognostic factor allowing subsequent treatment modifications, we assessed leukemic blast counts in the bone marrow by morphology on days 15 and 28 after first reinduction in 338 patients of the international Relapsed-AML2001/01 trial. Both day 15 and day 28 status was classified as good (<= 20% leukemic blasts) in 77% of patients. The correlation between day 15 and 28 blast percentages was significant, but not strong (Spearman correlation coefficient = 0.49, P<0.001). Survival probability decreased in a stepwise fashion along with rising blast counts at day 28. Patients with bone marrow blast counts at this time-point of <= 5%, 6-10%, 11-20% and >20% had 4-year probabilities of survival of 52%+/- 3% versus 36%+/- 10% versus 21%+/- 9% versus 14%+/- 4%, respectively, P<0.0001; this trend was not seen for day 15 results. Multivariate analysis showed that early treatment response at day 28 had the strongest prognostic significance, superseding even time to relapse (< or >= 12 months). In conclusion, an early response to treatment, measured on day 28, is a strong and independent prognostic factor potentially useful for treatment stratification in pediatric relapsed acute myeloid leukemia. This study was registered with ISRCTN code: 94206677.","[Creutzig, Ursula; Zimmermann, Martin; von Neuhoff, Christine; Reinhardt, Dirk] Hannover Med High Sch, BFM AML Grp, Hannover, Germany; [Dworzak, Michael N.] Med Univ Vienna, BFM AML Grp, St Anna Childrens Hosp, Vienna, Austria; [Dworzak, Michael N.] Med Univ Vienna, Childrens Canc Res Inst, Dept Pediat, Vienna, Austria; [Gibson, Brenda] Royal Hosp Sick Children, Dept Paediat Haematol, UK NCRI Childhood Leukaemia Grp, Glasgow G3 8SJ, Lanark, Scotland; [Tamminga, Rienk] Beatrix Childrens Hosp UMCG, Groningen, Netherlands; [Tamminga, Rienk; Kaspers, Gertjan L.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Abrahamsson, Jonas] Queen Silvias Childrens Hosp, Dept Pediat, NOPHO, Gothenburg, Sweden; [Ha, Shau-Yin] Queen Mary Hosp, Hong Kong Paediat Haematol & Oncol Study Grp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China; [Hasle, Henrik] NOPHO, Copenhagen, Denmark; [Hasle, Henrik] Aarhus Univ, Hosp Skejby, Dept Pediat, DK-8000 Aarhus C, Denmark; [Maschan, Alexey] Res Ctr Pediat Hematol Oncol & Immunol, Moscow, Russia; [Bertrand, Yves] FRALLE CLCG, Inst Hematol & Oncol Pediat, Lyon, France; [Leverger, Guy] FRALLE CLCG, Paris, France; [Leverger, Guy] Hop Enfants Armand Trousseau, Unit Oncohematol Pediat, Paris, France; [Razzouk, Bassem] St Judes Children Res Hosp, Memphis, TN USA; [Razzouk, Bassem] Peyton Manning Childrens Hosp St Vincent, Childrens Ctr Canc & Blood Dis, Indianapolis, IN USA; [Rizzari, Carmelo] Hosp S Gerardo, Dept Pediat, AIEOP, Monza, Italy; [Smisek, Petr] Charles Univ Prague, CPH, Dept Pediat Hematol & Oncol, Fac Med 2, CR-11636 Prague 1, Czech Republic; [Smisek, Petr] Charles Univ Prague, Univ Hosp Motol, CR-11636 Prague 1, Czech Republic; [Smith, Owen P.] Our Ladys Childrens Hosp, Dept Haematol & Oncol, UK CCLG, Dublin, Ireland; [Stark, Batia] Schneider Childrens Med Ctr Israel, Ctr Pediat Hematol Oncol, Petah Tiqwa, Israel; [Kaspers, Gertjan L.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands","Creutzig, U (reprint author), Hannover Med High Sch, BFM AML Grp, Hannover, Germany.","ursula@creutzig.de",null,null,null,null,null,18,1,1,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOLOGICA","Haematologica","SEP 1",2014,99,9,null,null,null,null,1472,1478,null,"10.3324/haematol.2014.104182",null,7,"Hematology","Hematology","AQ5GK","WOS:000342834900020",24763401]
["J","Pospisilova, D; Holub, D; Zidova, Z; Sulovska, L; Houda, J; Mihal, V; Hadacova, I; Radova, L; Dzubak, P; Hajduch, M; Divoky, V; Horvathova, M",null,null,null,"Pospisilova, Dagmar; Holub, Dusan; Zidova, Zuzana; Sulovska, Lucie; Houda, Jiri; Mihal, Vladimir; Hadacova, Ivana; Radova, Lenka; Dzubak, Petr; Hajduch, Marian; Divoky, Vladimir; Horvathova, Monika",null,null,"Hepcidin levels in Diamond-Blackfan anemia reflect erythropoietic activity and transfusion dependency","HAEMATOLOGICA",null,null,"English","Letter",null,null,null,null,null,"Diamond Blackfan anemia; hepcidin levels; erythropoietic activity; transfusion dependency","IRON; UPDATE",null,"[Pospisilova, Dagmar; Sulovska, Lucie; Houda, Jiri; Mihal, Vladimir] Palacky Univ, Fac Med & Dent, Dept Pediat, Olomouc, Czech Republic; [Pospisilova, Dagmar; Sulovska, Lucie; Houda, Jiri; Mihal, Vladimir] Univ Hosp Olomouc, Olomouc, Czech Republic; [Holub, Dusan; Dzubak, Petr; Hajduch, Marian] Palacky Univ, Fac Med, Inst Mol & Translat Med, CR-77147 Olomouc, Czech Republic; [Zidova, Zuzana; Divoky, Vladimir; Horvathova, Monika] Palacky Univ, Fac Med & Dent, Dept Biol, Olomouc, Czech Republic; [Hadacova, Ivana] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Radova, Lenka] Masaryk Univ, Cent European Inst Technol, Brno, Czech Republic","Horvathova, M (reprint author), Palacky Univ, Fac Med & Dent, Dept Biol, Olomouc, Czech Republic.","dagmar.pospisilova@fnol.cz; monika.horvathova@upol.cz","Hajduch, Marian/J-4015-2014",null,null,null,null,15,0,0,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOLOGICA","Haematologica","JUL 1",2014,99,7,null,null,null,null,null,null,null,"10.3324/haematol.2014.104034",null,4,"Hematology","Hematology","AQ5FY","WOS:000342833500008",24727814]
["J","Angelucci, E; Matthes-Martin, S; Baronciani, D; Bernaudin, F; Bonanomi, S; Cappellini, MD; Dalle, JH; Di Bartolomeo, P; de Heredia, CD; Dickerhoff, R; Giardini, C; Gluckman, E; Hussein, AA; Kamani, N; Minkov, M; Locatelli, F; Rocha, V; Sedlacek, P; Smiers, F; Thuret, I; Yaniv, I; Cavazzana, M; Peters, C",null,null,null,"Angelucci, Emanuele; Matthes-Martin, Susanne; Baronciani, Donatella; Bernaudin, Francoise; Bonanomi, Sonia; Cappellini, Maria Domenica; Dalle, Jean-Hugues; Di Bartolomeo, Paolo; Diaz de Heredia, Cristina; Dickerhoff, Roswitha; Giardini, Claudio; Gluckman, Eliane; Hussein, Ayad Achmed; Kamani, Naynesh; Minkov, Milen; Locatelli, Franco; Rocha, Vanderson; Sedlacek, Petr; Smiers, Frans; Thuret, Isabelle; Yaniv, Isaac; Cavazzana, Marina; Peters, Christina",null,"EBMT Inborn Error EBMT Paediat Wor","Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","HAEMATOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"BONE-MARROW-TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; IRON CHELATION-THERAPY; BETA-THALASSEMIA; PERIPHERAL-BLOOD; LONG-TERM; ALLOGENEIC TRANSPLANTATION; CONDITIONING REGIMEN; MIXED CHIMERISM; PREPARATIVE REGIMEN","Thalassemia major and sickle cell disease are the two most widely disseminated hereditary hemoglobinopathies in the world. The outlook for affected individuals has improved in recent years due to advances in medical management in the prevention and treatment of complications. However, hematopoietic stem cell transplantation is still the only available curative option. The use of hematopoietic stem cell transplantation has been increasing, and outcomes today have substantially improved compared with the past three decades. Current experience world-wide is that more than 90% of patients now survive hematopoietic stem cell transplantation and disease-free survival is around 80%. However, only a few controlled trials have been reported, and decisions on patient selection for hematopoietic stem cell transplantation and transplant management remain principally dependent on data from retrospective analyses and on the clinical experience of the transplant centers. This consensus document from the European Blood and Marrow Transplantation Inborn Error Working Party and the Paediatric Diseases Working Party aims to report new data and provide consensus-based recommendations on indications for hematopoietic stem cell transplantation and transplant management.","[Angelucci, Emanuele; Baronciani, Donatella] Osped Oncol Riferimento Reg Armando Businco, Cagliari, Italy; [Matthes-Martin, Susanne; Minkov, Milen; Peters, Christina] Med Univ, Dept Pediat, St Anna Childrens Hosp, Vienna, Austria; [Bernaudin, Francoise] CHI Creteil, Ctr Reference Drepanocytose, Creteil, France; [Bonanomi, Sonia] Hosp San Gerardo, Monza, Italy; [Cappellini, Maria Domenica] Policlin Hosp, IRCCS Fdn, Dipartimento Sci Clin & Comunita, Milan, Italy; [Dalle, Jean-Hugues] Hop Robert Debre, Serv Hematoimmunol, F-75019 Paris, France; [Di Bartolomeo, Paolo] Osped Civile, BMT Ctr, Pescara, Italy; [Diaz de Heredia, Cristina] Hop Maternoinfantil Val Hebron, Barcelona, Spain; [Dickerhoff, Roswitha] Univ Dusseldorf, Paediat Unit Haematol Oncol & Immunol, Dusseldorf, Germany; [Giardini, Claudio] Hematol & Stem Cell Transplant Ctr, Pesaro, Italy; [Gluckman, Eliane] Hop St Louis, Paris, France; [Hussein, Ayad Achmed] King Hussein Canc Ctr, Amman, Jordan; [Kamani, Naynesh] Childrens Natl Med Ctr, Div BMT Immunol, Washington, DC 20010 USA; [Locatelli, Franco] IRCCS Osped Pediat Bambino Gesu, Rome, Italy; [Rocha, Vanderson] Hop St Louis, Eurocord, Paris, France; [Sedlacek, Petr] Charles Univ Motol Prague, Sch Med 2, Dept Pediat Hematol & Oncol Teaching Hosp Motol, Prague, Czech Republic; [Smiers, Frans] Pediat Hematol Oncol & Bone Marrow Transplantat W, Leiden, Netherlands; [Thuret, Isabelle] Pediat Hop Enfants Timone, Serv Hematol, Marseille, France; [Yaniv, Isaac] Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel; [Cavazzana, Marina] INSERM, U768, Paris, France; [Cavazzana, Marina] Hop Univ Necker Enfants Malades, AP HP, Dept Biotherapie, Paris, France; [Cavazzana, Marina] Univ Paris 05, Sorbonne Paris Cite, IMAGINE Inst, Paris, France; [Cavazzana, Marina] AP HP, INSERM, CIC Biotherapie GHU Ouest, Paris, France","Peters, C (reprint author), Med Univ, Dept Pediat, St Anna Childrens Hosp, Vienna, Austria.","christina.peters@stanna.at",null,null,"Novartis Pharmaceuticals Corporation","Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. The authors would like to thank Nene Anadu, PhD, for medical editorial assistance with this manuscript.",null,100,1,1,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOLOGICA","Haematologica","MAY",2014,99,5,null,null,null,null,811,820,null,"10.3324/haematol.2013.099747",null,10,"Hematology","Hematology","AH6RD","WOS:000336257500008",24790059]
["J","Yoshimi, A; van den Heuvel-Eibrink, MM; Baumann, I; Schwarz, S; Simonitsch-Klupp, I; de Paepe, P; Campr, V; Kerndrup, GB; O'Sullivan, M; Devito, R; Leguit, R; Hernandez, M; Dworzak, M; de Moerloose, B; Stary, J; Hasle, H; Smith, OP; Zecca, M; Catala, A; Schmugge, M; Locatelli, F; Fuhrer, M; Fischer, A; Guderle, A; Nollke, P; Strahm, B; Niemeyer, CM",null,null,null,"Yoshimi, Ayami; van den Heuvel-Eibrink, Marry M.; Baumann, Irith; Schwarz, Stephan; Simonitsch-Klupp, Ingrid; de Paepe, Pascale; Campr, Vit; Kerndrup, Gitte Birk; O'Sullivan, Maureen; Devito, Rita; Leguit, Roos; Hernandez, Miguel; Dworzak, Michael; de Moerloose, Barbara; Stary, Jan; Hasle, Henrik; Smith, Owen P.; Zecca, Marco; Catala, Albert; Schmugge, Markus; Locatelli, Franco; Fuehrer, Monika; Fischer, Alexandra; Guderle, Anne; Noellke, Peter; Strahm, Brigitte; Niemeyer, Charlotte M.",null,null,"Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood","HAEMATOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"SEVERE APLASTIC-ANEMIA; ANTI-THYMOCYTE GLOBULIN; COLONY-STIMULATING FACTOR; MYELODYSPLASTIC-SYNDROME; MEDIATED INHIBITION; CYCLOSPORINE-A; PHASE-II; CHILDREN; MDS; PREDICTS","Refractory cytopenia of childhood is the most common subtype of myelodysplastic syndrome in children. In this study, we compared the outcome of immunosuppressive therapy using horse antithymocyte globulin (n=46) with that using rabbit antithymocyte globulin (n=49) in 95 patients with refractory cytopenia of childhood and hypocellular bone marrow. The response rate at 6 months was 74% for horse antithymocyte globulin and 53% for rabbit antithymocyte globulin (P=0.04). The inferior response in the rabbit antithymocyte globulin group resulted in lower 4-year transplantation-free (69% versus 46%; P=0.003) and failure-free (58% versus 48%; P=0.04) survival rates in this group compared with those in the horse antithymocyte globulin group. However, because of successful second-line hematopoietic stem cell transplantation, overall survival was comparable between groups (91% versus 85%; P=ns). The cumulative incidence of relapse (15% versus 9%; P=ns) and clonal evolution (12% versus 4%; P=ns) at 4 years was comparable between groups. Our results suggest that the outcome of immunosuppressive therapy with rabbit antithymocyte globulin is inferior to that of horse antithymocyte globulin. Although immunosuppressive therapy is an effective therapy in selected patients with refractory cytopenia of childhood, the long-term risk of relapse or clonal evolution remains.","[Yoshimi, Ayami; Fischer, Alexandra; Guderle, Anne; Noellke, Peter; Strahm, Brigitte; Niemeyer, Charlotte M.] Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, Freiburg, Germany; [van den Heuvel-Eibrink, Marry M.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Rotterdam, Netherlands; [van den Heuvel-Eibrink, Marry M.; Leguit, Roos] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Baumann, Irith] Boeblingen Hosp, Clin Ctr South West, Dept Pathol, Boblingen, Germany; [Schwarz, Stephan] Univ Med Ctr Erlangen, Dept Pathol, Erlangen, Germany; [Simonitsch-Klupp, Ingrid] Med Univ Vienna, Clin Inst Pathol, Vienna, Austria; [de Paepe, Pascale] Univ Hosp Ghent, Dept Pathol, Ghent, Belgium; [Campr, Vit] Univ Hosp Motol, Dept Pathol, Prague, Czech Republic; [Kerndrup, Gitte Birk] Vejle Hosp, Dept Pathol, Vejle, Denmark; [O'Sullivan, Maureen] Our Ladys Hosp Sick Children, Histol Lab, Dublin, Ireland; [Devito, Rita] Bambino Gesu Pediat Hosp, Dept Pathol, Rome, Italy; [Leguit, Roos] Univ Med Ctr Utrecht, Dept Pathol, The Hague, Netherlands; [Hernandez, Miguel] Hosp Univ La Fe, Dept Pathol, Valencia, Spain; [Dworzak, Michael] Med Univ Vienna, St Anna Childrens Hosp, Vienna, Austria; [Dworzak, Michael] Med Univ Vienna, Childrens Canc Res Inst, Dept Pediat, Vienna, Austria; [de Moerloose, Barbara] Ghent Univ Hosp, Dept Pediat Hematooncol, Ghent, Belgium; [Stary, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic; [Stary, Jan] Czech Pediat Hematol Working Grp, Prague, Czech Republic; [Hasle, Henrik] Aarhus Univ, Hosp Skejby, Dept Pediat, Aarhus, Denmark; [Smith, Owen P.] Our Ladys Hosp Sick Children, Dublin, Ireland; [Zecca, Marco] Fdn IRCCS Policlin San Matteo, Pavia, Italy; [Catala, Albert] Hosp St Joan de Deu, Dept Hematol, Barcelona, Spain; [Schmugge, Markus] Univ Childrens Hosp, Dept Hematol & Oncol, Zurich, Switzerland; [Locatelli, Franco] Bambino Gesu Pediat Hosp, Dept Pediat Hematol & Oncol, Rome, Italy; [Locatelli, Franco] Univ Pavia, I-27100 Pavia, Italy; [Fuehrer, Monika] Univ Munich, Children Hosp, Dr von Haunersches Kinderspital, D-81377 Munich, Germany","Yoshimi, A (reprint author), Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, Freiburg, Germany.","ayami.yoshimi@uniklinik-freiburg.de",null,null,"Parent Initiative for Children with Cancer, Freiburg (Fordervereins fur krebskranke Kinder e.V. Freiburg i.Br.); MH CZ-DRO, University Hospital Motol, Prague, Czech Republic [00064203]; AIRC (Associazione Italiana Ricerca sul Cancro) [5x1000]; Italian Ministry of University and Scientific Research (PRIN)","We thank the reference cytogeneticists (Brigitte Schlegelberger, M. D.; Gudrun Gohring, M. D.; Elisabeth Kromer, M. D.; Thomas Lion, M. D.; Nadine van Roy, M. D.; Kyra Michalova, M. D.; David Betts, M. D.; Laura Sainati, M. D.; Berna Beverloo, M. D.; Jose Cervera, M. D.; and Joelle Tchinda M. D.), colleagues of the Coordinating Study Center in Freiburg, Germany (Annamaria Cseh, M. D.; Mutlu Kartal, M. D.; Ingrid Furlan, M. D.; Axel Karow, M. D.; Marcin Wlodarski, M. D.; Shinsuke Hirabayashi, M. D.; Wilfried Truckenmueller; Regina Debray; Marco Teller; Ali-Riza Kaya), and all collaborators of the EWOG-MDS for contributing data to this study. This study was supported by a grant from the Parent Initiative for Children with Cancer, Freiburg (Fordervereins fur krebskranke Kinder e.V. Freiburg i.Br.) to the Coordinating Study Center in Freiburg, Germany; a grant from MH CZ-DRO, University Hospital Motol, Prague, Czech Republic 00064203 to JS; a grant from AIRC (Associazione Italiana Ricerca sul Cancro; Special Grant \"5x1000\") to FL; and a grant from the Italian Ministry of University and Scientific Research (PRIN-2010) to FL.",null,37,1,2,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOLOGICA","Haematologica","APR",2014,99,4,null,null,null,null,656,663,null,"10.3324/haematol.2013.095786",null,8,"Hematology","Hematology","AH6QQ","WOS:000336256100016",24162791]
["J","Teyssler, P; Kolostova, K; Bobek, V",null,null,null,"Teyssler, P.; Kolostova, K.; Bobek, V.",null,null,"Assessment of pain threshold in haemophilic patients","HAEMOPHILIA",null,null,"English","Article",null,null,null,null,null,null,"QUESTIONNAIRE; ARTHROPATHY; PEOPLE",null,"[Teyssler, P.; Kolostova, K.; Bobek, V.] Charles Univ Prague, Fac Med 3, Dept Tumor Biol, Prague 10097, Czech Republic; [Teyssler, P.] Charles Univ Prague, Fac Med 2, Clin Orthoped & Traumatol Children & Adults, Prague 10097, Czech Republic; [Teyssler, P.] Univ Hosp Motol, Prague, Czech Republic; [Bobek, V.] Charles Univ Prague, Fac Med 3, Dept Surg, Prague 10097, Czech Republic; [Bobek, V.] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic","Bobek, V (reprint author), Charles Univ Prague, Fac Med 3, Dept Tumor Biol, Ruska 87, Prague 10097, Czech Republic.","vbobek@centrum.cz",null,null,"Charles University in Prague, Third Faculty of Medicine, Prague, Czech Republic [P 27/2012]","This study was supported by research project P 27/2012 awarded by Charles University in Prague, Third Faculty of Medicine, Prague, Czech Republic.",null,16,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1351-8216","1365-2516",null,"HAEMOPHILIA","Haemophilia","MAR",2014,20,2,null,null,null,null,207,211,null,null,null,5,"Hematology","Hematology","AB0CO","WOS:000331459600027",24533950]
["J","Bahannan, AA; Slavicek, A; Cerny, L; Vokral, J; Valenta, Z; Lohynska, R; Chovanec, M; Betka, J",null,null,null,"Bahannan, Abdulrahman Ali; Slavicek, Ales; Cerny, Libor; Vokral, Jan; Valenta, Zdenek; Lohynska, Radka; Chovanec, Martin; Betka, Jan",null,null,"Effectiveness of transoral laser microsurgery for precancerous lesions and early glottic cancer guided by analysis of voice quality","HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK",null,null,"English","Article",null,null,null,null,null,"cordectomy; voice analysis; glottic cancer; precancerous lesion; larynx","LARYNGEAL CARCINOMAS; SURGERY; CO2-LASER; MANAGEMENT","BackgroundThe purpose of this study was to show our comparison of the quality of voice obtained after superficial transoral endoscopic cordectomies (types I, II, and III) according to the European Laryngological Society classification versus the more extended cordectomy (types IV and V) among patients with glottic precancerous lesions or early glottic cancer. MethodsSixty-two patients underwent vocal assessment after cordectomy (types I-V) for dysplasia, Tis, T1a, T1b, and T2 lesions. ResultsCordectomy (types I-III) had good vocal outcomes. Cordectomy (types IV-V) showed less favorable outcomes, p<.005 in common parameters of voice range profile and symmetry in stroboscopy after cordectomy (types IV-V), with significant voice handicap index. Recurrences were found in 4 patients with T1b and T2 cancer. Two cases were managed by a higher type of cordectomy, and the other 2 by total laryngectomy. ConclusionEffect of transoral laser microsurgery on quality of voice depends on the type of cordectomy and the site of the lesion. (c) 2013 Wiley Periodicals, Inc. Head Neck 36: 763-767, 2014","[Bahannan, Abdulrahman Ali; Slavicek, Ales; Chovanec, Martin; Betka, Jan] Charles Univ Prague, Univ Hosp Motol, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Prague, Czech Republic; [Cerny, Libor; Vokral, Jan] Charles Univ Prague, Gen Univ Hosp, Dept Phoniatr, Fac Med 1, Prague, Czech Republic; [Valenta, Zdenek] Inst Comp Sci AS CR, Dept Med Informat & Biostat, Prague, Czech Republic; [Lohynska, Radka] Univ Hosp Motol, Dept Radiotherapy & Oncol, Prague, Czech Republic","Bahannan, AA (reprint author), Hadhramout Univ Mukalla, Coll Med, Dept Otorhinolaryngol & Head & Neck Surg, POB 8435, Hadhramout, Yemen.","abahannan@gmail.com","Valenta, Zdenek/E-5094-2011","Valenta, Zdenek/0000-0001-7119-9764","UNCE [204013]; Internal Grant Agency of the Ministry of Health of Czech Republic [8430/3]; University Hospital Motol [9737]","Contract grant sponsor: This study was supported by the research project UNCE 204013, by the research project of the Internal Grant Agency of the Ministry of Health of Czech Republic no. 8430/3, and research project of the University Hospital Motol no. 9737.",null,18,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1043-3074","1097-0347",null,"HEAD NECK-J SCI SPEC","Head Neck-J. Sci. Spec. Head Neck","JUN",2014,36,6,null,null,null,null,763,767,null,"10.1002/hed.23368",null,5,"Otorhinolaryngology; Surgery","Otorhinolaryngology; Surgery","AH9VP","WOS:000336493200003",23616355]
["J","Kang, KT; Potts, JE; Radbill, AE; La Page, MJ; Papagiannis, J; Garnreiter, JM; Kubus, P; Kantoch, MJ; Von Bergen, NH; Fournier, A; Cote, JM; Paul, T; Anderson, CC; Cannon, BC; Miyake, CY; Blaufox, AD; Etheridge, SP; Sanatani, S",null,null,null,"Kang, Kristopher T.; Potts, James E.; Radbill, Andrew E.; La Page, Martin J.; Papagiannis, John; Garnreiter, Jason M.; Kubus, Petr; Kantoch, Michal J.; Von Bergen, Nicholas H.; Fournier, Anne; Cote, Jean-Marc; Paul, Thomas; Anderson, Charles C.; Cannon, Bryan C.; Miyake, Christina Y.; Blaufox, Andrew D.; Etheridge, Susan P.; Sanatani, Shubhayan",null,null,"Permanent junctional reciprocating tachycardia in children: A multicenter experience","HEART RHYTHM",null,null,"English","Article",null,null,null,null,null,"Permanent junctional reciprocating tachycardia; Antiarrhythmic medications ok; Catheter ablation; Pediatrics","CATHETER ABLATION; RADIOFREQUENCY ABLATION; FORM","BACKGROUND Permanent junctional reciprocating tachycardia (PJRT) is an uncommon form of supraventricular tachycardia in children. Treatment of this arrhythmia has been considered difficult because of a high medication failure rate and risk of cardiomyopathy. Outcomes in the current era of interventional treatment with catheter ablation have not been published. OBJECTIVE To describe the presentation and PJRT in children. METHODS This is a retrospective review of 194 pediatric patients with PJRT managed at 11 institutions between January 2000 and December 2010. RESULTS The median age at diagnosis was 3.2 months, including 110 infants (57%; aged <1 year). PJRT was incessant in 47%. The ratio of RP interval to cycle length was higher with incessant than with nonincessant tachycardia. Tachycardia-induced cardiomyopathy was observed in 18%. Antiarrhythmic medications were used for initial management in 76%, while catheter ablation was used initially in only 10%. Medications achieved complete resolution in 23% with clinical benefit in an additional 47%. Overall, 140 patients underwent 175 catheter ablation procedures with a success rate of 90%. There were complications in 9% with no major complications reported. Patients were followed for a median of 45.1 months. Regardless of treatment modality, normal sinus rhythm was present in 90% at last follow-up. Spontaneous resolution occurred in 12% of the patients. CONCLUSION PJRT in children is frequently incessant at the time of diagnosis and may be associated with tachycardia-induced cardiomyopathy. Antiarrhythmic medications result in complete control in few patients. Catheter ablation is effective, and serious complications are rare.","[Kang, Kristopher T.; Potts, James E.; Sanatani, Shubhayan] British Columbia Childrens Hosp, Dept Pediat, Div Cardiol, Vancouver, BC V6H 3V4, Canada; [Radbill, Andrew E.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [La Page, Martin J.] Univ Michigan, Ann Arbor, MI 48109 USA; [Papagiannis, John] Mitera Childrens Hosp, Athens, Greece; [Garnreiter, Jason M.; Etheridge, Susan P.] Primary Childrens Med Ctr, Salt Lake City, UT USA; [Kubus, Petr] Univ Hosp Motol, Childrens Heart Ctr, Prague, Czech Republic; [Kantoch, Michal J.] Stollery Childrens Hosp, Edmonton, AB, Canada; [Von Bergen, Nicholas H.] Univ Iowa, Childrens Hosp, Iowa City, IA USA; [Fournier, Anne] Univ Montreal, CHU Mere Enfant St Justine, Montreal, PQ, Canada; [Cote, Jean-Marc] CHUQ, Ctr Mere Enfant, Quebec City, PQ, Canada; [Paul, Thomas] Univ Gottingen, Univ Childrens Hosp, D-37073 Gottingen, Germany; [Anderson, Charles C.] Providence Sacred Heart Childrens Hosp, Spokane, WA USA; [Cannon, Bryan C.] Mayo Clin, Rochester, MN USA; [Miyake, Christina Y.] Lucile Packard Childrens Hosp, Palo Alto, CA USA; [Blaufox, Andrew D.] Steven & Alexandra Cohen Childrens Med Ctr New Yo, Lake Success, NY USA","Sanatani, S (reprint author), British Columbia Childrens Hosp, Dept Pediat, Div Cardiol, 4480 Oak St, Vancouver, BC V6H 3V4, Canada.","ssanatani@cw.bc.ca",null,null,"Rare Disease Foundation, Vancouver, Canada; MH CZ - DRO, University Hospital Motol, Prague, Czech Republic","This work was funded by a grant from the Rare Disease Foundation, Vancouver, Canada. Dr Kubus was supported by MH CZ - DRO, University Hospital Motol, Prague, Czech Republic.",null,15,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1547-5271","1556-3871",null,"HEART RHYTHM","Heart Rhythm","AUG",2014,11,8,null,null,null,null,1426,1432,null,"10.1016/j.hrthm.2014.04.033",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AO6CU","WOS:000341437200017",24769425]
["J","Taube, JR; Sperle, K; Banser, L; Seeman, P; Cavan, BCV; Garbern, JY; Hobson, GM",null,null,null,"Taube, Jennifer R.; Sperle, Karen; Banser, Linda; Seeman, Pavel; Cavan, Barbra Charina V.; Garbern, James Y.; Hobson, Grace M.",null,null,"PMD patient mutations reveal a long-distance intronic interaction that regulates PLP1/DM20 alternative splicing","HUMAN MOLECULAR GENETICS",null,null,"English","Article",null,null,null,null,null,null,"PELIZAEUS-MERZBACHER-DISEASE; AMINO-ACID SUBSTITUTIONS; RNA SECONDARY STRUCTURES; SPINAL MUSCULAR-ATROPHY; DM20 MESSENGER-RNA; PROTEOLIPID PROTEIN; WEB SERVER; GENE; EXON; ENHANCERS","Alternative splicing of the proteolipid protein 1 gene (PLP1) produces two forms, PLP1 and DM20, due to alternative use of 5' splice sites with the same acceptor site in intron 3. The PLP1 form predominates in central nervous system RNA. Mutations that reduce the ratio of PLP1 to DM20, whether mutant or normal protein is formed, result in the X-linked leukodystrophy Pelizaeus-Merzbacher disease (PMD). We investigated the ability of sequences throughout PLP1 intron 3 to regulate alternative splicing using a splicing minigene construct transfected into the oligodendrocyte cell line, Oli-neu. Our data reveal that the alternative splice of PLP1 is regulated by a long-distance interaction between two highly conserved elements that are separated by 581 bases within the 1071-base intron 3. Further, our data suggest that a base-pairing secondary structure forms between these two elements, and we demonstrate that mutations of either element designed to destabilize the secondary structure decreased the PLP1/DM20 ratio, while swap mutations designed to restore the structure brought the PLP1/DM20 ratio to near normal levels. Sequence analysis of intron 3 in families with clinical symptoms of PMD who did not have coding-region mutations revealed mutations that segregated with disease in three families. We showed that these patient mutations, which potentially destabilize the secondary structure, also reduced the PLP1/DM20 ratio. This is the first report of patient mutations causing disease by disruption of a long-distance intronic interaction controlling alternative splicing. This finding has important implications for molecular diagnostics of PMD.","[Taube, Jennifer R.; Sperle, Karen; Banser, Linda; Hobson, Grace M.] Alfred I duPont Hosp Children, Nemours Biomed Res, Wilmington, DE 19803 USA; [Seeman, Pavel] Charles Univ Prague, Dept Child Neurol, DNA Lab, Sch Med 2, Prague 15006 5, Czech Republic; [Seeman, Pavel] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Cavan, Barbra Charina V.] Cebu Inst Med, Dept Pediat, Cebu 6000, Philippines; [Garbern, James Y.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; [Hobson, Grace M.] Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA; [Hobson, Grace M.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pediat, Philadelphia, PA 19107 USA","Hobson, GM (reprint author), Alfred I duPont Hosp Children, Nemours Biomed Res, RC1-235,1701 Rockland Rd, Wilmington, DE 19803 USA.","ghobson@nemours.org",null,null,"National Institutes of Health [P20GM103464, R01N5058978]; Pelizaeus-Merzbacher Disease Foundation; Internal Grant Agency of Ministry of Health of the Czech Republic [NT14348]; Project for Conceptual Development of Research Organization [00064203]","This work was supported by National Institutes of Health (P20GM103464 and R01N5058978 to G.M.H.); the Pelizaeus-Merzbacher Disease Foundation (to G.M.H.); Internal Grant Agency of Ministry of Health of the Czech Republic (NT14348 to P. S.); and the Project for Conceptual Development of Research Organization (00064203 to P. S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the granting agencies and foundations.",null,60,0,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0964-6906","1460-2083",null,"HUM MOL GENET","Hum. Mol. Genet.","OCT 15",2014,23,20,null,null,null,null,5464,5478,null,"10.1093/hmg/ddu271",null,15,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","AQ9UO","WOS:000343202400014",24890387]
["J","Ballantyne, KN; Ralf, A; Aboukhalid, R; Achakzai, NM; Anjos, MJ; Ayub, Q; Balazic, J; Ballantyne, J; Ballard, DJ; Berger, B; Bobillo, C; Bouabdellah, M; Burri, H; Capal, T; Caratti, S; Cardenas, J; Cartault, F; Carvalho, EF; Carvalho, M; Cheng, BW; Coble, MD; Comas, D; Corach, D; D'Amato, ME; Davison, S; de Knijff, P; De Ungria, MCA; Decorte, R; Dobosz, T; Dupuy, BM; Elmrghni, S; Gliwinski, M; Gomes, SC; Grol, L; Haas, C; Hanson, E; Henke, J; Henke, L; Herrera-Rodriguez, F; Hill, CR; Holmlund, G; Honda, K; Immel, UD; Inokuchi, S; Jobling, MA; Kaddura, M; Kim, JS; Kim, SH; Kim, W; King, TE; Klausriegler, E; Kling, D; Kovacevic, L; Kovatsi, L; Krajewski, P; Kravchenko, S; Larmuseau, MHD; Lee, EY; Lessig, R; Livshits, LA; Marjanovic, D; Minarik, M; Mizuno, N; Moreira, H; Morling, N; Mukherjee, M; Munier, P; Nagaraju, J; Neuhuber, F; Nie, SJ; Nilasitsataporn, P; Nishi, T; Oh, HH; Olofsson, J; Onofri, V; Palo, JU; Pamjav, H; Parson, W; Petlach, M; Phillips, C; Ploski, R; Prasad, SPR; Primorac, D; Purnomo, GA; Purps, J; Rangel-Villalobos, H; Rebala, K; Rerkamnuaychoke, B; Gonzalez, DR; Robino, C; Roewer, L; Rosa, A; Sajantila, A; Sala, A; Salvador, JM; Sanz, P; Schmitt, C; Sharma, AK; Silva, DA; Shin, KJ; Sijen, T; Sirker, M; Sivakova, D; Skaro, V; Solano-Matamoros, C; Souto, L; Stenzl, V; Sudoyo, H; Syndercombe-Court, D; Tagliabracci, A; Taylor, D; Tillmar, A; Tsybovsky, IS; Tyler-Smith, C; van der Gaag, KJ; Vanek, D; Volgyi, A; Ward, D; Willemse, P; Yap, EPH; Yong, RYY; Pajnic, IZ; Kayser, M",null,null,null,"Ballantyne, Kaye N.; Ralf, Arwin; Aboukhalid, Rachid; Achakzai, Niaz M.; Anjos, Maria J.; Ayub, Qasim; Balazic, Joze; Ballantyne, Jack; Ballard, David J.; Berger, Burkhard; Bobillo, Cecilia; Bouabdellah, Mehdi; Burri, Helen; Capal, Tomas; Caratti, Stefano; Cardenas, Jorge; Cartault, Francois; Carvalho, Elizeu F.; Carvalho, Monica; Cheng, Baowen; Coble, Michael D.; Comas, David; Corach, Daniel; D'Amato, Maria E.; Davison, Sean; de Knijff, Peter; De Ungria, Maria Corazon A.; Decorte, Ronny; Dobosz, Tadeusz; Dupuy, Berit M.; Elmrghni, Samir; Gliwinski, Mateusz; Gomes, Sara C.; Grol, Laurens; Haas, Cordula; Hanson, Erin; Henke, Juergen; Henke, Lotte; Herrera-Rodriguez, Fabiola; Hill, Carolyn R.; Holmlund, Gunilla; Honda, Katsuya; Immel, Uta-Dorothee; Inokuchi, Shota; Jobling, Mark A.; Kaddura, Mahmoud; Kim, Jong S.; Kim, Soon H.; Kim, Wook; King, Turi E.; Klausriegler, Eva; Kling, Daniel; Kovacevic, Lejla; Kovatsi, Leda; Krajewski, Pawel; Kravchenko, Sergey; Larmuseau, Maarten H. D.; Lee, Eun Young; Lessig, Ruediger; Livshits, Ludmila A.; Marjanovic, Damir; Minarik, Marek; Mizuno, Natsuko; Moreira, Helena; Morling, Niels; Mukherjee, Meeta; Munier, Patrick; Nagaraju, Javaregowda; Neuhuber, Franz; Nie, Shengjie; Nilasitsataporn, Premlaphat; Nishi, Takeki; Oh, Hye H.; Olofsson, Jill; Onofri, Valerio; Palo, Jukka U.; Pamjav, Horolma; Parson, Walther; Petlach, Michal; Phillips, Christopher; Ploski, Rafal; Prasad, Samayamantri P. R.; Primorac, Dragan; Purnomo, Gludhug A.; Purps, Josephine; Rangel-Villalobos, Hector; Rebala, Krzysztof; Rerkamnuaychoke, Budsaba; Rey Gonzalez, Danel; Robino, Carlo; Roewer, Lutz; Rosa, Alexandra; Sajantila, Antti; Sala, Andrea; Salvador, Jazelyn M.; Sanz, Paula; Schmitt, Cornelia; Sharma, Anil K.; Silva, Dayse A.; Shin, Kyoung-Jin; Sijen, Titia; Sirker, Miriam; Sivakova, Daniela; Skaro, Vedrana; Solano-Matamoros, Carlos; Souto, Luis; Stenzl, Vlastimil; Sudoyo, Herawati; Syndercombe-Court, Denise; Tagliabracci, Adriano; Taylor, Duncan; Tillmar, Andreas; Tsybovsky, Iosif S.; Tyler-Smith, Chris; van der Gaag, Kristiaan J.; Vanek, Daniel; Volgyi, Antonia; Ward, Denise; Willemse, Patricia; Yap, Eric P. H.; Yong, Rita Y. Y.; Pajnic, Irena Zupanic; Kayser, Manfred",null,null,"Toward Male Individualization with Rapidly Mutating Y-Chromosomal Short Tandem Repeats","HUMAN MUTATION",null,null,"English","Article",null,null,null,null,null,"Y-chromosome; Y-STRs; haplotypes; RM Y-STRs; paternal lineage; forensic","FORENSIC ANALYSIS; STR HAPLOTYPES; POPULATIONS; RECOMMENDATIONS; DIVERSITY; DATABASE; HISTORY; UPDATE; ISFG","Relevant for various areas of human genetics, Y-chromosomal short tandem repeats (Y-STRs) are commonly used for testing close paternal relationships among individuals and populations, and for male lineage identification. However, even the widely used 17-loci Yfiler set cannot resolve individuals and populations completely. Here, 52 centers generated quality-controlled data of 13 rapidly mutating (RM) Y-STRs in 14,644 related and unrelated males from 111 worldwide populations. Strikingly, >99% of the 12,272 unrelated males were completely individualized. Haplotype diversity was extremely high (global: 0.9999985, regional: 0.99836-0.9999988). Haplotype sharing between populations was almost absent except for six (0.05%) of the 12,156 haplotypes. Haplotype sharing within populations was generally rare (0.8% nonunique haplotypes), significantly lower in urban (0.9%) than rural (2.1%) and highest in endogamous groups (14.3%). Analysis of molecular variance revealed 99.98% of variation within populations, 0.018% among populations within groups, and 0.002% among groups. Of the 2,372 newly and 156 previously typed male relative pairs, 29% were differentiated including 27% of the 2,378 father-son pairs. Relative to Yfiler, haplotype diversity was increased in 86% of the populations tested and overall male relative differentiation was raised by 23.5%. Our study demonstrates the value of RMY-STRs in identifying and separating unrelated and related males and provides a reference database. Published 2014 Wiley Periodicals, Inc.**","[Ballantyne, Kaye N.; Ralf, Arwin; Kayser, Manfred] Erasmus MC Univ, Med Ctr Rotterdam, Dept Forens Mol Biol, NL-3000 CA Rotterdam, Netherlands; [Ballantyne, Kaye N.] Victoria Police Forens Serv Dept, Off Chief Forens Scientist, Macleod, Vic, Australia; [Aboukhalid, Rachid; Bouabdellah, Mehdi] Mohammed V Agdal Univ, Fac Sci, Immunol & Biochem Lab, Forens Genet Unit, Rabat, Morocco; [Achakzai, Niaz M.] Univ Punjab, CEMB, Ctr Excellence Mol Biol, DNA Typing Lab, Lahore, Pakistan; [Anjos, Maria J.; Carvalho, Monica] Natl Inst Legal Med & Forens Sci IP, Forens Genet Serv, Coimbra, Portugal; [Ayub, Qasim; Tyler-Smith, Chris] Wellcome Trust Sanger Inst, Hinxton, South Cambridge, England; [Balazic, Joze; Pajnic, Irena Zupanic] Univ Ljubljana, Fac Med, Inst Forens Med, Ljubljana, Slovenia; [Ballantyne, Jack] Univ Cent Florida, Dept Chem, Orlando, FL 32816 USA; [Ballantyne, Jack; Hanson, Erin] Univ Cent Florida, Natl Ctr Forens Sci, Orlando, FL 32816 USA; [Ballard, David J.; Syndercombe-Court, Denise] Kings Coll London, Dept Forens & Analyt Sci, London WC2R 2LS, England; [Berger, Burkhard; Parson, Walther] Med Univ Innsbruck, Inst Legal Med, A-6020 Innsbruck, Austria; [Bobillo, Cecilia; Corach, Daniel; Sala, Andrea] Univ Buenos Aires, Fac Farm & Bioquim, Serv Huellas Digit Genet, Buenos Aires, DF, Argentina; [Bobillo, Cecilia; Corach, Daniel; Sala, Andrea] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina; [Burri, Helen; Haas, Cordula] Univ Zurich, Inst Legal Med, Zurich, Switzerland; [Capal, Tomas; Stenzl, Vlastimil] Inst Criminalist Prague, Dept Forens Genet, Prague, Czech Republic; [Caratti, Stefano; Robino, Carlo] Univ Turin, Dept Publ Hlth Sci & Pediat, Turin, Italy; [Cardenas, Jorge; Phillips, Christopher; Rey Gonzalez, Danel] Univ Santiago de Compostela, Inst Legal Med, Forens Genet Unit, Santiago De Compostela, Spain; [Cartault, Francois; Munier, Patrick] Site Ctr Hosp Felix Guyon, Serv Genet, St Denis, Reunion; [Carvalho, Elizeu F.; Silva, Dayse A.] Univ Estado Rio De Janeiro, Inst Biol, Dept Ecol, DNA Lab, Rio De Janeiro, Brazil; [Cheng, Baowen] Yunnan Prov Dept Publ Secur, Inst Forens Sci, Kunming, Peoples R China; [Coble, Michael D.; Hill, Carolyn R.] NIST, Appl Genet Grp, Gaithersburg, MD 20899 USA; [Comas, David; Sanz, Paula] Univ Pompeu Fabra, Inst Biol Evolut CSIC UPF, Dept Ciencies Expt & Salut, Barcelona, Spain; [D'Amato, Maria E.; Davison, Sean] Univ Western Cape, Dept Biotechnol, Forens DNA Lab, Cape Town, South Africa; [de Knijff, Peter; van der Gaag, Kristiaan J.; Willemse, Patricia] Leiden Univ, Dept Human Genet, Med Ctr, NL-2300 RA Leiden, Netherlands; [De Ungria, Maria Corazon A.; Salvador, Jazelyn M.] Univ Philippines, Nat Sci Res Inst, DNA Anal Lab, Quezon City 1101, Philippines; [Decorte, Ronny; Larmuseau, Maarten H. D.] Katholieke Univ Leuven, Dept Imaging & Pathol, Lab Forens Genet & Mol Archaeol, Leuven, Belgium; [Dobosz, Tadeusz] Wroclaw Med Univ, Dept Forens Med, Wroclaw, Poland; [Dupuy, Berit M.; Kling, Daniel] Norwegian Inst Publ Hlth, Dept Family Genet, Oslo, Norway; [Elmrghni, Samir; Kaddura, Mahmoud] Univ Benghazi, Fac Med, Dept Forens Med & Toxicol, Benghazi, Libya; [Gliwinski, Mateusz; Rebala, Krzysztof] Med Univ Gdansk, Dept Forens Med, Gdansk, Poland; [Gomes, Sara C.; Rosa, Alexandra] Univ Madeira, Human Genet Lab, Funchal, Portugal; [Grol, Laurens; Sijen, Titia] Netherlands Forens Inst, Dept Human Biol Traces R&D, The Hague, Netherlands; [Henke, Juergen; Henke, Lotte] Inst Blutgruppenforsch LGC GmbH, Cologne, Germany; [Herrera-Rodriguez, Fabiola] Poder Judicial, Dept Ciencias Forenses, Secc Bioquim, Unidad Genet Forense, San Joaquin De Flores, Heredia, Costa Rica; [Holmlund, Gunilla; Tillmar, Andreas] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Linkoping, Sweden; [Holmlund, Gunilla; Tillmar, Andreas] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, Linkoping, Sweden; [Honda, Katsuya; Nishi, Takeki] Univ Tsukuba, Fac Med, Dept Legal Med, Tsukuba, Ibaraki, Japan; [Immel, Uta-Dorothee; Lessig, Ruediger] Univ Halle Wittenberg, Inst Legal Med, D-06108 Halle, Germany; [Inokuchi, Shota; Mizuno, Natsuko] Natl Res Inst Police Sci, Kashiwa, Chiba 2770882, Japan; [Jobling, Mark A.; King, Turi E.] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; [Kim, Jong S.; Oh, Hye H.] Supreme Prosecutors Off, DNA Forens Div, Seoul, South Korea; [Kim, Soon H.] Natl Forens Serv, Eastern Dist Off, DNA Anal Lab, Gangwon Do, South Korea; [Kim, Wook] Dankook Univ, Dept Biol Sci, Cheonan, South Korea; [Klausriegler, Eva; Neuhuber, Franz] Salzburg Univ, Inst Legal Med, A-5020 Salzburg, Austria; [Kovacevic, Lejla; Marjanovic, Damir] Inst Genet Engn & Biotechnol, Sarajevo, Bosnia & Herceg; [Kovatsi, Leda] Aristotle Univ Thessaloniki, Sch Med, Lab Forens Med & Toxicol, GR-54006 Thessaloniki, Greece; [Krajewski, Pawel] Med Univ Warsaw, Ctr Biostruct, Dept Forens Med, Warsaw, Poland; [Kravchenko, Sergey; Livshits, Ludmila A.] NASU, Inst Mol Biol & Genet, Dept Human Genom, Kiev, Ukraine; [Lee, Eun Young; Shin, Kyoung-Jin] Yonsei Univ, Coll Med, Dept Forens Med, Seoul, South Korea; [Minarik, Marek; Petlach, Michal] Genomac Forens Inst, Prague, Czech Republic; [Moreira, Helena; Souto, Luis] Univ Aveiro, Dept Biol, Lab Genet Aplicada, P-3800 Aveiro, Portugal; [Morling, Niels; Olofsson, Jill] Univ Copenhagen, Fac Hlth & Med Sci, Dept Forens Med, Sect Forens Genet, Copenhagen, Denmark; [Mukherjee, Meeta; Sharma, Anil K.] Govt India, Minist Home Affairs, Directorate Forens Sci Serv, Cent Forens Sci Lab, Kolkata, India; [Nagaraju, Javaregowda; Prasad, Samayamantri P. R.] Ctr DNA Fingerprinting & Diagnost, Lab DNA Fingerprinting Serv, Hyderabad, Andhra Pradesh, India; [Nie, Shengjie] Kunming Med Univ, Sch Forens Med, Kunming, Peoples R China; [Nilasitsataporn, Premlaphat] Royal Thai Police, Off Forens Sci Police, Cent Sci Crime Detect Div, DNA & Biol Unit, Bangkok, Thailand; [Onofri, Valerio; Tagliabracci, Adriano] Univ Politecn Marche, Dept Biomed Sci & Publ Hlth, Sect Legal Med, Ancona, Italy; [Palo, Jukka U.; Sajantila, Antti] Univ Helsinki, Hjelt Inst, Dept Forens Med, Helsinki, Finland; [Pamjav, Horolma; Volgyi, Antonia] Minist Publ Adm & Justice, Network Forens Sci Inst, Inst Forens Med, DNA Lab, Budapest, Hungary; [Parson, Walther; Primorac, Dragan] Penn State Univ, Eberly Coll Sci, University Pk, PA 16802 USA; [Ploski, Rafal] Med Univ Warsaw, Ctr Biostruct, Dept Med Genet, Warsaw, Poland; [Primorac, Dragan] Univ New Haven, Henry C Lee Coll Criminal Justice & Forens Sci, West Haven, CT USA; [Primorac, Dragan] Univ Split, Sch Med, Split, Croatia; [Primorac, Dragan] Univ Osijek, Sch Med, Osijek, Croatia; [Purnomo, Gludhug A.; Sudoyo, Herawati] Eijkman Inst Mol Biol, Jakarta, Indonesia; [Purps, Josephine; Roewer, Lutz] Charite, Inst Legal Med & Forens Sci, D-13353 Berlin, Germany; [Rangel-Villalobos, Hector] Univ Guadalajara CUCienega UdeG, Inst Invest Genet Mol, Jalisco, Mexico; [Rerkamnuaychoke, Budsaba] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pathol, Bangkok 10400, Thailand; [Rosa, Alexandra] Univ Madeira, Ctr Life Sci, Med Sci Unit, Funchal, Portugal; [Sajantila, Antti] Univ N Texas, Hlth Sci Ctr, Dept Mol & Med Genet, Inst Appl Genet, Ft Worth, TX USA; [Schmitt, Cornelia; Sirker, Miriam] Univ Cologne, Fac Med, Inst Legal Med, D-50931 Cologne, Germany; [Sivakova, Daniela] Comenius Univ, Dept Anthropol, Bratislava, Slovakia; [Skaro, Vedrana] Genos Ltd, DNA Lab, Zagreb, Croatia; [Solano-Matamoros, Carlos] Univ Costa Rica, Fac Microbiol, San Jose, Costa Rica; [Taylor, Duncan] Forens Sci South Australia, Adelaide, SA, Australia; [Taylor, Duncan] Flinders Univ S Australia, Sch Biol Sci, Adelaide, SA 5001, Australia; [Tsybovsky, Iosif S.] State Comm Forens Expertises, Sci & Pract Ctr, Minsk, Byelarus; [Vanek, Daniel] Forens DNA Serv, Prague, Czech Republic; [Vanek, Daniel] Charles Univ Prague, Inst,Legal Med, Fac Med 2, Prague, Czech Republic; [Ward, Denise] Forens Sci South Australia, Adelaide, SA, Australia; [Yap, Eric P. H.; Yong, Rita Y. Y.] DSO Natl Labs, Def Med & Environm Res Inst, Singapore, Singapore","Kayser, M (reprint author), Erasmus MC Univ, Med Ctr Rotterdam, Dept Forens Mol Biol, POB 2040, NL-3000 CA Rotterdam, Netherlands.","m.kayser@erasmusmc.nl","Phillips, Christopher/E-4005-2012","Phillips, Christopher/0000-0002-9601-0128","Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) within the framework of the Forensic Genomics Consortium Netherlands (FGCN); Wellcome Trust [098051, 087576]; Leverhulme Trust [F/00 212/AM]; ALPKULTUR; Austrian Academy of Sciences' \"Alpine Research Programme\"; Spanish Government [CGL2010-14944/BOS]; UBACyT, Argentina [20020100100744]; PIP CONICET, Argentina [1220110100914]; FWO-Vlaanderen; National Natural Science Foundation of China [31100906, 81241136]; Medical Research Council of South Africa; National Research Foundation of South Africa; Philippine Council for Industry, Energy and Emerging Technology Research and Development (PCIEERD) of the Department of Science and Technology (DOST); Finnish Foundations' Professors Pool, Paulo Foundation","Contract grant sponsors: Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) within the framework of the Forensic Genomics Consortium Netherlands (FGCN); The Wellcome Trust (098051); The Wellcome Trust (087576); Leverhulme Trust (F/00 212/AM); ALPKULTUR and the Austrian Academy of Sciences' \"Alpine Research Programme\"; Spanish Government (CGL2010-14944/BOS); UBACyT 20020100100744 and PIP CONICET No1220110100914, Argentina; FWO-Vlaanderen; National Natural Science Foundation of China (31100906 and 81241136); Medical Research Council of South Africa and the National Research Foundation of South Africa; Philippine Council for Industry, Energy and Emerging Technology Research and Development (PCIEERD) of the Department of Science and Technology (DOST); Finnish Foundations' Professors Pool, Paulo Foundation.",null,34,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1059-7794","1098-1004",null,"HUM MUTAT","Hum. Mutat.","AUG",2014,35,8,null,null,null,null,1021,1032,null,"10.1002/humu.22599",null,12,"Genetics & Heredity","Genetics & Heredity","AL9AL","WOS:000339431600016",24917567]
["J","Harper, J; Geraedts, J; Borry, P; Cornel, MC; Dondorp, WJ; Gianaroli, L; Harton, G; Milachich, T; Kaariainen, H; Liebaers, I; Morris, M; Sequeiros, J; Sermon, K; Shenfield, F; Skirton, H; Soini, S; Spits, C; Veiga, A; Vermeesch, JR; Viville, S; de Wert, G; Macek, M",null,null,null,"Harper, Joyce; Geraedts, Joep; Borry, Pascal; Cornel, Martina C.; Dondorp, Wybo J.; Gianaroli, Luca; Harton, Gary; Milachich, Tanya; Kaariainen, Helena; Liebaers, Inge; Morris, Michael; Sequeiros, Jorge; Sermon, Karen; Shenfield, Francoise; Skirton, Heather; Soini, Sirpa; Spits, Claudia; Veiga, Anna; Vermeesch, Joris Robert; Viville, Stephane; de Wert, Guido; Macek, Milan, Jr.",null,"ESHG; ESHRE; EuroGentest2","Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy","HUMAN REPRODUCTION",null,null,"English","Article",null,null,null,null,null,"assisted reproduction technology; European Society of Human Genetics; European Society of Human Reproduction and Embryology; reproductive genetics; IVF","ESHRE PGD CONSORTIUM; EMBRYONIC STEM-CELLS; HUMAN PREIMPLANTATION EMBRYOS; IN-SITU HYBRIDIZATION; PRACTICE GUIDELINES; MALE-FERTILITY; CHROMOSOMAL-ABNORMALITIES; EPIGENETIC INHERITANCE; RECURRENT MISCARRIAGE; ANEUPLOID EMBRYOS","How has the interface between genetics and assisted reproduction technology (ART) evolved since 2005? The interface between ART and genetics has become more entwined as we increase our understanding about the genetics of infertility and we are able to perform more comprehensive genetic testing. In March 2005, a group of experts from the European Society of Human Genetics and European Society of Human Reproduction and Embryology met to discuss the interface between genetics and ART and published an extended background paper, recommendations and two Editorials. An interdisciplinary workshop was held, involving representatives of both professional societies and experts from the European Union Eurogentest2 Coordination Action Project. In March 2012, a group of experts from the European Society of Human Genetics, the European Society of Human Reproduction and Embryology and the EuroGentest2 Coordination Action Project met to discuss developments at the interface between clinical genetics and ART. As more genetic causes of reproductive failure are now recognized and an increasing number of patients undergo testing of their genome prior to conception, either in regular health care or in the context of direct-to-consumer testing, the need for genetic counselling and PGD may increase. Preimplantation genetic screening (PGS) thus far does not have evidence from RCTs to substantiate that the technique is both effective and efficient. Whole genome sequencing may create greater challenges both in the technological and interpretational domains, and requires further reflection about the ethics of genetic testing in ART and PGD/PGS. Diagnostic laboratories should be reporting their results according to internationally accepted accreditation standards (ISO 15189). Further studies are needed in order to address issues related to the impact of ART on epigenetic reprogramming of the early embryo. The legal landscape regarding assisted reproduction is evolving, but still remains very heterogeneous and often contradictory. The lack of legal harmonization and uneven access to infertility treatment and PGD/PGS fosters considerable cross-border reproductive care in Europe, and beyond. This continually evolving field requires communication between the clinical genetics and IVF teams and patients to ensure that they are fully informed and can make well-considered choices. Funding was received from ESHRE, ESHG and EuroGentest2 European Union Coordination Action project (FP7 - HEALTH-F4-2010-26146) to support attendance at this meeting.","[Harper, Joyce] UCL, Inst Womens Hlth, UCL Ctr PG&D, London WC1E 6HX, England; [Harper, Joyce] Ctr Reprod & Genet Hlth, London, England; [Geraedts, Joep] Maastricht Univ, Fac Hlth Med & Life Sci, Res Inst GROW, Dept Genet & Cell Biol, Maastricht, Netherlands; [Borry, Pascal] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Leuven, Belgium; [Cornel, Martina C.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Clin Genet, Amsterdam, Netherlands; [Dondorp, Wybo J.; de Wert, Guido] Maastricht Univ, Fac Hlth Med & Life Sci, Res Inst GROW, Dept Hlth Eth & Soc, Maastricht, Netherlands; [Gianaroli, Luca] SIS Me R, Reprod Med Unit, Bologna, Italy; [Harton, Gary] Univ Kent, Sch Biosci, Canterbury, Kent, England; [Harton, Gary] Reprogenetics, Livingston, NJ USA; [Milachich, Tanya] SAGBAL Hosp Dr Shterev, MC Reprod Hlth, Sofia, Bulgaria; [Kaariainen, Helena; Soini, Sirpa] Natl Inst Hlth & Welf THL, Helsinki, Finland; [Liebaers, Inge] Vrije Univ Brussel, Ctr Med Genet, Brussels, Belgium; [Morris, Michael] Synlab, Dept Mol Diagnost, Lausanne, Switzerland; [Sequeiros, Jorge] Univ Porto, ICBAS, P-4100 Oporto, Portugal; [Sequeiros, Jorge] Univ Porto, IBMC Inst Mol & Cell Biol, P-4100 Oporto, Portugal; [Sermon, Karen; Spits, Claudia] Vrije Univ Brussel, Dept Embryol & Genet, Brussels, Belgium; [Shenfield, Francoise] UCL, Inst Womens Hlth, Reprod Med Unit, London WC1E 6HX, England; [Skirton, Heather] Univ Plymouth, Fac Hlth Educ & Soc, Sch Nursing & Midwifery, Plymouth PL4 8AA, Devon, England; [Veiga, Anna] Inst Univ Dexeus, Reprod Med Serv, Barcelona, Spain; [Vermeesch, Joris Robert] Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium; [Viville, Stephane] CNRS, Inst Genet & Mol & Cellular Biol IGBMC, UMR 1704, Illkirch Graffenstaden, France; [Macek, Milan, Jr.] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Macek, Milan, Jr.] Univ Hosp Motol, Prague, Czech Republic","Harper, J (reprint author), UCL, Inst Womens Hlth, Ctr PG&D, 86-96 Chenies Mews, London WC1E 6HX, England.","joyce.harper@ucl.ac.uk","Spits, Claudia/J-1964-2014",null,"ESHRE; ESHG; EuroGentest2 European Union Coordination Action project [FP7 - HEALTH-F4-2010-26146]","Participation in the meeting from which this article arose was funded by ESHRE, ESHG and the EuroGentest2 European Union Coordination Action project (FP7 - HEALTH-F4-2010-26146).",null,115,1,1,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0268-1161","1460-2350",null,"HUM REPROD","Hum. Reprod.","AUG",2014,29,8,null,null,null,null,1603,"U24",null,"10.1093/humrep/deu130",null,10,"Obstetrics & Gynecology; Reproductive Biology","Obstetrics & Gynecology; Reproductive Biology","AM7TG","WOS:000340071000002",25006203]
["J","Truxova, I; Pokorna, K; Kloudova, K; Partlova, S; Spisek, R; Fucikova, J",null,null,null,"Truxova, Iva; Pokorna, Katerina; Kloudova, Kamila; Partlova, Simona; Spisek, Radek; Fucikova, Jitka",null,null,"Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs","IMMUNOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"Dendritic cell; Monocyte; Fast generation; Cancer immunotherapy; Vaccine","CYTOTOXIC T-CELLS; MELANOMA PATIENTS; HUMAN MONOCYTES; HELPER-CELLS; PHASE-I; MATURE; IL-12; VACCINATION; RESPONSES; PEPTIDE","Background: Dendritic cells (DCs) are professional antigen-presenting cells that are capable of inducing immune responses. DC-based vaccines are normally generated using a standard 5- to 7-day protocol. To shorten the DC-based vaccine production for use in cancer immunotherapy, we have developed a fast DC protocol by comparing standard DCs (Day 5 DCs) and fast DCs (Day 3 DCs). Methods: We tested the generation of Day 5 versus Day 3 DCs using CellGro media and subsequent activation by two activation stimuli: Poly (I:C) and LPS. We evaluated DC morphology, viability, phagocyte activity, cytokine production and ability to stimulate antigen-specific T cells. Results: Day 5 and Day 3 DCs exhibited similar phagocytic capacity. Poly (I:C)-activated Day 5 DCs expressed higher levels of the costimulatory and surface molecules CD80, CD86 and HLA-DR compared to Poly (I:C)-activated Day 3 DCs. Nevertheless, LPS-activated Day 5 and Day 3 DCs were phenotypically similar. Cytokine production was generally stronger when LPS was used as the maturation stimulus, and there were no significant differences between Day 5 and Day 3 DCs. Importantly, Day 5 and Day 3 DCs were able to generate comparable numbers of antigen-specific CD8(+) T cells. The number of Tregs induced by Day 5 and Day 3 DCs was also comparable. Conclusion: We identified monocyte-derived DCs generated in CellGro for 3 days and activated using Poly (I:C) similarly potent in most functional aspects as DCs produced by the standard 5 day protocol. These results provide the rationale for the evaluation of faster protocols for DC generation in clinical trials. (C) 2014 Elsevier B.V. All rights reserved.","[Truxova, Iva; Partlova, Simona; Spisek, Radek; Fucikova, Jitka] Charles Univ Prague, Inst Immunol, Fac Med 2, Prague 5, Czech Republic; [Truxova, Iva; Partlova, Simona; Spisek, Radek; Fucikova, Jitka] Univ Hosp Motol, Prague, Czech Republic; [Truxova, Iva; Pokorna, Katerina; Kloudova, Kamila; Partlova, Simona; Spisek, Radek; Fucikova, Jitka] Sotio, Prague, Czech Republic","Fucikova, J (reprint author), Charles Univ Prague, Inst Immunol, Fac Med 2, V Uvalu 84, Prague 5, Czech Republic.","jitka.fucikova@fnmotol.cz",null,null,"IGA [NT12402-5]","This project was supported by the research grant IGA NT12402-5.",null,43,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0165-2478","1879-0542",null,"IMMUNOL LETT","Immunol. Lett.","JUL",2014,160,1,null,null,null,null,39,49,null,"10.1016/j.imlet.2014.03.010",null,11,"Immunology","Immunology","AI8WR","WOS:000337208200006",24726860]
["J","Lenicek, M; Duricova, D; Hradsky, O; Dusatkova, P; Jiraskova, A; Lukas, M; Nachtigal, P; Vitek, L",null,null,null,"Lenicek, Martin; Duricova, Dana; Hradsky, Ondrej; Dusatkova, Petra; Jiraskova, Alena; Lukas, Milan; Nachtigal, Petr; Vitek, Libor",null,null,"The Relationship Between Serum Bilirubin and Crohn's Disease","INFLAMMATORY BOWEL DISEASES",null,null,"English","Article",null,null,null,null,null,"Crohn's disease; bilirubin; oxidative stress; bilirubin UDP-glucuronosyl transferase; Gilbert's syndrome","INFLAMMATORY-BOWEL-DISEASE; OXIDATIVE STRESS; HEME OXYGENASE-1; THERAPEUTIC APPLICATIONS; CARDIOVASCULAR-DISEASE; ANTIOXIDANT DEFENSES; LIPID-PEROXIDATION; GILBERT-SYNDROME; NADPH-OXIDASE; T-CELLS","Background: The oxidative stress is thought to play an important role in Crohn's disease (CD). As serum bilirubin represents the major endogenous antioxidant, this article aimed to evaluate in a clinical study, whether serum bilirubin levels and genes affecting its systemic concentrations are associated with CD. Methods: This exploratory case-control study was based on pediatric (n = 119) and adult (n = 504) patients with CD and 370 appropriate healthy control subjects. The (GT)(n) and (TA)(n) dinucleotide variations in heme oxygenase 1 (HMOX1) and bilirubin UDP-glucuronosyl transferase (UGT1A1) gene promoters were determined by fragment analysis. Serum bilirubin levels were compared in a subset of 90 cases and 229 controls, for whom biochemical data were available. Results: Substantially lower serum bilirubin levels were detected in patients with CD compared with controls (7.4 versus 12.1 mu mol/L, P < 10(-6)). Serum bilirubin levels were significantly lower in patients with CD within all UGT1A1*28 genotypes (P < 0.05). UGT1A1*28 homozygotes with wild-type NOD2 gene variant exhibited significant delay in CD manifestation (P = 0.004), while the protective effect of UGT1A1*28 homozygosity was lost in those patients with mutated NOD2 gene. No associations between CD risk and individual HMOX1 gene variants were observed. Conclusions: CD is associated with significantly low serum bilirubin levels, most likely as a result of increased oxidative stress accompanying this inflammatory disease. UGT1A1*28 allele homozygosity, responsible for higher bilirubin levels, seems to be an important modifier of CD manifestation.","[Lenicek, Martin; Jiraskova, Alena; Lukas, Milan; Vitek, Libor] Charles Univ Prague, Fac Med 1, Dept Med Biochem & Lab Diagnost, Prague 12808 2, Czech Republic; [Duricova, Dana; Lukas, Milan] ISCARE IVF Lighthouse, IBD Clin & Res Ctr, Prague, Czech Republic; [Hradsky, Ondrej; Dusatkova, Petra] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 12808 2, Czech Republic; [Nachtigal, Petr] Charles Univ Prague, Fac Pharm Hradec Kralove, Dept Biol & Med Sci, Prague 12808 2, Czech Republic; [Vitek, Libor] Charles Univ Prague, Fac Med 1, Dept Internal Med 4, Prague 12808 2, Czech Republic","Vitek, L (reprint author), Charles Univ Prague, Fac Med 1, Dept Internal Med 4, U Nemocnice 2, Prague 12808 2, Czech Republic.","vitek@cesnet.cz","Vitek, Libor/A-2645-2008",null,"Czech Ministry of Education [SVV 266516/2013, PRVOUK 4102280002]; Czech Ministry of Health [RVO VFN64165]","Supported by Grants SVV 266516/2013 and PRVOUK 4102280002 from the Czech Ministry of Education, and RVO VFN64165 from the Czech Ministry of Health.",null,34,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1078-0998","1536-4844",null,"INFLAMM BOWEL DIS","Inflamm. Bowel Dis.","MAR",2014,20,3,null,null,null,null,481,487,null,"10.1097/01.MIB.0000440817.84251.98",null,7,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","AG8ED","WOS:000335650700007",24407487]
["J","Bortlik, M; Duricova, D; Machkova, N; Kozeluhova, J; Kohout, P; Hrdlicka, L; Durilova, M; Mitrova, K; Hradsky, O; Bronsky, J; Malickova, K; Lukas, M",null,null,null,"Bortlik, Martin; Duricova, Dana; Machkova, Nadezda; Kozeluhova, Jana; Kohout, Pavel; Hrdlicka, Ludek; Durilova, Marianna; Mitrova, Katarina; Hradsky, Ondrej; Bronsky, Jiri; Malickova, Karin; Lukas, Milan",null,null,"Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children","INFLAMMATORY BOWEL DISEASES",null,null,"English","Article",null,null,null,null,null,"children; anti-TNF-alpha therapy; prenatal exposure; immune system; inflammatory bowel disease","THERAPY; INFECTIONS; INFLIXIMAB; CHILDHOOD; REGISTRY; NEWBORN; PATIENT; RISK","Background: Prenatal exposure to anti-tumor necrosis factor alpha (TNF-alpha) antibodies seems to be safe for fetal development. Data on long-term outcome of exposed children are missing. Our aim was to assess long-term postnatal development of children exposed to anti-TNF-alpha during pregnancy. Methods: Consecutive children aged >= 12 months exposed to anti-TNFs prenatally for maternal inflammatory bowel disease in 3 centers in the Czech Republic were enrolled. Data on psychomotor development, infections, antibiotics, vaccination, and allergy were retrospectively obtained from mothers, treating pediatricians, and children's vaccination cards. Furthermore, standardized laboratory tests on humoral and cellular immunity were performed. Results: Twenty-five children exposed to biologicals were included (median age, 34 mo; range, 14-70 mo). All children had normal growth, and all but 1 had normal psychomotor development. Majority (80%) experienced at least 1 infection (mainly respiratory), and 60% of infants received antibiotics, 32% of those within the first year of life. Vaccination was undertaken according to vaccination protocol to 23 infants (92%). Fifteen children also had tuberculosis vaccination without serious complication. Immunological investigation was performed with 17 children (68%). Cellular immunity was normal in all infants, and 7 children had mild decrease in IgA and/or IgG immunoglobulins without clinical significance. All children had a detectable serologic response to vaccination. Conclusions: Exposure to anti-TNF-alpha antibodies seems to be safe for growth and psychomotor development of children, although clinical significance of relatively high frequency of infections and antibiotic use among infants remains questionable because of the lack of a control group. Continuous follow-up of exposed children is absolutely warranted.","[Bortlik, Martin; Duricova, Dana; Machkova, Nadezda; Hrdlicka, Ludek; Lukas, Milan] Charles Univ Prague, ISCARE, IBD Clin & Res Ctr, Prague, Czech Republic; [Bortlik, Martin] Charles Univ Prague, Fac Med 1, Mil Hosp, Dept Internal Med, Prague, Czech Republic; [Kozeluhova, Jana] Univ Hosp Plzen, Dept Internal Med, Plzen, Czech Republic; [Kohout, Pavel] Thomayer Univ Hosp, Dept Internal Med, Prague, Czech Republic; [Durilova, Marianna; Mitrova, Katarina; Hradsky, Ondrej; Bronsky, Jiri] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Malickova, Karin; Lukas, Milan] Charles Univ Prague, Fac Med 1, Inst Med Biochem & Lab Diagnost, Prague, Czech Republic; [Malickova, Karin; Lukas, Milan] Gen Univ Hosp Prague, Prague, Czech Republic","Bortlik, M (reprint author), ISCARE As, IBD Clin & Res Ctr, Jankovcova 1569-2c, Prague 17000, Czech Republic.","mbortlik@seznam.cz",null,null," [IGA NT14300-3/2013]","Supported by the Grant IGA NT14300-3/2013.",null,15,1,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1078-0998","1536-4844",null,"INFLAMM BOWEL DIS","Inflamm. Bowel Dis.","MAR",2014,20,3,null,null,null,null,495,501,null,"10.1097/01.MIB.0000440984.86659.4f",null,7,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","AG8ED","WOS:000335650700009",24407486]
["J","de Ridder, L; Turner, D; Wilson, DC; Koletzko, S; Martin-de-Carpi, J; Fagerberg, UL; Spray, C; Sladek, M; Shaoul, R; Roma-Giannikou, E; Bronsky, J; Serban, DE; Cucchiara, S; Veres, G; Ruemmele, FM; Hojsak, I; Kolho, KL; Davies, IH; Aloi, M; Lionetti, P; Veereman-Wauters, G; Braegger, CP; Trindade, E; Wewer, AV; Hauer, A; Levine, A",null,null,null,"de Ridder, Lissy; Turner, Dan; Wilson, David C.; Koletzko, Sibylle; Martin-de-Carpi, Javier; Fagerberg, Ulrika L.; Spray, Christine; Sladek, Malgorzata; Shaoul, Ron; Roma-Giannikou, Eleftheria; Bronsky, Jiri; Serban, Daniela E.; Cucchiara, Salvatore; Veres, Gabor; Ruemmele, Frank M.; Hojsak, Iva; Kolho, Kaija L.; Davies, Ieuan H.; Aloi, Marina; Lionetti, Paolo; Veereman-Wauters, Gigi; Braegger, Christian P.; Trindade, Eunice; Wewer, Anne V.; Hauer, Almuthe; Levine, Arie",null,"Porto IBD Working Grp ESPGHAN","Malignancy and Mortality in Pediatric Patients with Inflammatory Bowel Disease: A Multinational Study from the Porto Pediatric IBD Group","INFLAMMATORY BOWEL DISEASES",null,null,"English","Article",null,null,null,null,null,"survey; mortality; pediatric inflammatory bowel disease; cancer","CROHNS-DISEASE; ULCERATIVE-COLITIS; COLORECTAL-CANCER; NATURAL-HISTORY; RISK; LYMPHOMA; REGISTRY; CHILDREN; ESPGHAN; ECCO","Background: The combination of the severity of pediatric-onset inflammatory bowel disease (IBD) phenotypes and the need for intense medical treatment may increase the risk of malignancy and mortality, but evidence regarding the extent of the problem is scarce. Therefore, the Porto Pediatric IBD working group of ESPGHAN conducted a multinational-based survey of cancer and mortality in pediatric IBD. Methods: A survey among pediatric gastroenterologists of 20 European countries and Israel on cancer and/or mortality in the pediatric patient population with IBD was undertaken. One representative from each country repeatedly contacted all pediatric gastroenterologists from each country for reporting retrospectively cancer and/or mortality of pediatric patients with IBD after IBD onset, during 2006-2011. Results: We identified 18 cases of cancers and/or 31 deaths in 44 children (26 males) who were diagnosed with IBD (ulcerative colitis, n = 21) at a median age of 10.0 years (inter quartile range, 3.0-14.0). Causes of mortality were infectious (n = 14), cancer (n = 5), uncontrolled disease activity of IBD (n = 4), procedure-related (n = 3), other non-IBD related diseases (n = 3), and unknown (n = 2). The most common malignancies were hematopoietic tumors (n = 11), of which 3 were hepatosplenic T-cell lymphoma and 3 Ebstein-Barr virus-associated lymphomas. Conclusions: Cancer and mortality in pediatric IBD are rare, but cumulative rates are not insignificant. Mortality is primarily related to infections, particularly in patients with 2 or more immunosuppressive agents, followed by cancer and uncontrolled disease. At least 6 lymphomas were likely treatment-associated by virtue of their phenotype.","[de Ridder, Lissy] Erasmus MC Sophia Childrens Hosp, Dept Pediat Gastroenterol, Rotterdam, Netherlands; [Turner, Dan] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Dept Pediat Gastroenterol, Jerusalem, Israel; [Wilson, David C.] Univ Edinburgh, Dept Pediat Gastroenterol Child Life & Hlth, Edinburgh, Midlothian, Scotland; [Koletzko, Sibylle] Univ Munich, Med Ctr, Dr v Hauner Childrens Hosp, Dept Pediat Gastroenterol, Munich, Germany; [Martin-de-Carpi, Javier] Hosp St Joan de Deu, Dept Pediat Gastroenterol, Unidad El Cuidado Integral Enfermedad Inflamatori, Secc Gastroenterol Hepatol & Nutr Pediat, Barcelona, Spain; [Fagerberg, Ulrika L.] Vastmanland Hosp, Dept Pediat Gastroenterol, Clin Res Ctr, Vasteras, Sweden; [Fagerberg, Ulrika L.] Karolinska Inst, Stockholm, Sweden; [Spray, Christine] Bristol Royal Hosp Children, Dept Pediat Gastroenterol, Bristol, Avon, England; [Sladek, Malgorzata] Jagiellonian Univ, Coll Med, Dept Pediat Gastroenterol & Nutr, Polish Amer Childrens Hosp, Krakow, Poland; [Shaoul, Ron] Bnai Zion Med Ctr, Dept Pediat, Pediat Day Care Unit, Haifa, Israel; [Roma-Giannikou, Eleftheria] Univ Athens, Dept Paediat 1, Athens, Greece; [Bronsky, Jiri] Charles Univ Prague, Fac Med 2, Dept Pediat Gastroenterol, Prague, Czech Republic; [Bronsky, Jiri] Univ Hosp Motol, Prague, Czech Republic; [Serban, Daniela E.] Iuliu Hatieganu Univ Med & Pharm, Dept Pediat Gastroenterol, Pediat Clin 2, Childrens Emergency Hosp, Cluj Napoca, Romania; [Cucchiara, Salvatore] Univ Roma La Sapienza, Pediat Gastroenterol & Liver Unit, I-00185 Rome, Italy; [Veres, Gabor] Semmelweis Univ, Dept Pediat Gastroenterol, H-1085 Budapest, Hungary; [Ruemmele, Frank M.] Univ Paris 05, Hop Necker Enfants Malad, APHP, Dept Pediat Gastroenterol,Sorbonne Paris Cite, Paris, France; [Hojsak, Iva] Univ Zagreb, Sch Med, Childrens Hosp Zagreb, Dept Pediat Gastroenterol,Referral Ctr Pediat Gas, Zagreb 41001, Croatia; [Kolho, Kaija L.] Univ Cent Hosp, Childrens Hosp, Dept Pediat Gastroenterol, Helsinki, Finland; [Kolho, Kaija L.] Univ Helsinki, Helsinki, Finland; [Davies, Ieuan H.] Univ Wales Hosp, Dept Pediat Gastroenterol, Cardiff CF4 4XW, S Glam, Wales; [Aloi, Marina] Univ Roma La Sapienza, Pediat Gastroenterol & Liver Unit, I-00185 Rome, Italy; [Lionetti, Paolo] Meyer Childrens Hosp, Florence, Italy; [Veereman-Wauters, Gigi] UZBrussels, Univ Hosp Brussels, Dept Pediat Gastroenterol & Nutr, Brussels, Belgium; [Braegger, Christian P.] Univ Childrens Hosp, Childrens Res Ctr, Div Gastroenterol & Nutr, Zurich, Switzerland; [Trindade, Eunice] Hosp Sao Joao, Pediat Gastroenterol Unit, Oporto, Portugal; [Wewer, Anne V.] Hvidovre Univ Hosp, Dept Paediat, DK-2650 Hvidovre, Denmark; [Hauer, Almuthe] Med Univ Graz, Graz, Austria; [Levine, Arie] Tel Aviv Univ, Wolfson Med Ctr, Dept Pediat Gastroenterol, IL-69978 Tel Aviv, Israel","de Ridder, L (reprint author), Erasmus MC Sophia Childrens Hosp, POB 2060, NL-3000 CB Rotterdam, Netherlands.","l.deridder@erasmusmc.nl",null,null,null,null,null,26,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1078-0998","1536-4844",null,"INFLAMM BOWEL DIS","Inflamm. Bowel Dis.","FEB",2014,20,2,null,null,null,null,291,300,null,"10.1097/01.MIB.0000439066.69340.3c",null,10,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","AH0DT","WOS:000335790000016",24374875]
["J","Tlaskal, T; Gebauer, R; Gilik, J; Tomek, V",null,null,null,"Tlaskal, Tomas; Gebauer, Roman; Gilik, Jiri; Tomek, Viktor",null,null,"Experience with the surgical treatment of atrioventricular septal defect with left ventricular outflow tract obstruction","INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY",null,null,"English","Article; Proceedings Paper","27th Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery","OCT 05-09, 2013","Vienna, AUSTRIA","European Assoc Cardio Thorac Surg",null,"Congenital heart disease; Atrioventricular septal defect; Left ventricular outflow tract obstruction; Surgical treatment; Reoperations; Long-term results","SUBAORTIC STENOSIS; ANATOMIC OBSERVATIONS; CANAL DEFECTS; REPAIR; VALVE","OBJECTIVES: We sought to determine the prevalence, morphology, surgical methods and results of surgery for left ventricular outflow tract obstruction (LVOTO) associated with atrioventricular septal defect (AVSD). METHODS: Correction of AVSD was performed in 615 patients. Twenty-three (3.7%) patients with LVOTO were identified. Sixteen (70%) of them had partial and 7 (30%) had complete AVSD. Surgery for AVSD was performed at a median of 0.6 years (mean 2.1 +/- 3.0 years), and surgery for LVOTO at a median of 3.4 years (mean 4.7 +/- 3.5 years). The point and period prevalence of LVOTO in AVSD were determined. Detailed morphological study, individualized repair of AVSD with LVOTO and long-term follow-up were performed. Early and long-term results were analysed. RESULTS: The point prevalence of LVOTO at the time of AVSD repair was 1.3%. The period prevalence of LVOTO was 3.7% in course of 8.3 +/- 6.0 (0-18.4) years and 191.4 patient-years following AVSD repair. Causes of LVOTO were fibromuscular membrane (n = 17), septal hypertrophy (n = 17), abnormal atrioventricular (AV) valve (n = 9), muscular bands (n = 3), fibrous strands (n = 4) and stenotic aortic valve (n = 2). Usually, a combination of several obstructive lesions was present. LVOTO was present at the time of AVSD repair in 8 patients (35%) and developed after repair in 15 (65%) patients. Membrane excision (n = 17), myectomy (n = 17), excision of abnormal AV valvar tissue (n = 8), excision of muscular bands and fibrous strands (n = 6), AV valve replacement (n = 2) and aortic valvotomy (n = 2) were required. There was 1 (4%) early and 1 (4%) late death. Six (29%) survivors required reoperation for recurrence of LVOTO at an average interval of 6.3 +/- 3.2 years after surgery. The actuarial survival at 1 and 10 years was 96 and 88%, respectively. The actuarial freedom from reoperation for LVOTO was 80, 40 and 20% at 6, 10 and 15 years after surgery, respectively. Eighteen (78%) patients remain in good condition at mean 6.0 +/- 5.5 years after surgery. CONCLUSIONS: The point prevalence of LVOTO at the time of AVSD repair was 1.3%, and period prevalence 3.7%. Fibromuscular membrane, septal hypertrophy and valvar attachments represent the most common causes of LVOTO. Usually, more structures are involved. The repair must be individualized. The presence of LVOTO increases the need for reoperation.","[Tlaskal, Tomas; Gebauer, Roman; Gilik, Jiri; Tomek, Viktor] Univ Hosp Motol, Childrens Heart Ctr, Prague 15006 5, Czech Republic","Tlaskal, T (reprint author), Univ Hosp Motol, Childrens Heart Ctr, Uvalu 84, Prague 15006 5, Czech Republic.","tomas.tlaskal@lfmotol.cuni.cz",null,null,null,null,null,25,0,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1569-9293","1569-9285",null,"INTERACT CARDIOV TH","Interact Cardiovasc. Thorac. Surg.","JUN",2014,18,6,null,null,null,null,789,795,null,"10.1093/icvts/ivu026",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AH9ZQ","WOS:000336505800021",24585256]
["J","Fucikova, J; Moserova, I; Truxova, I; Hermanova, I; Vancurova, I; Partlova, S; Fialova, A; Sojka, L; Cartron, PF; Houska, M; Rob, L; Bartunkova, J; Spisek, R",null,null,null,"Fucikova, Jitka; Moserova, Irena; Truxova, Iva; Hermanova, Ivana; Vancurova, Irena; Partlova, Simona; Fialova, Anna; Sojka, Ludek; Cartron, Pierre-Francois; Houska, Milan; Rob, Lukas; Bartunkova, Jirina; Spisek, Radek",null,null,"High hydrostatic pressure induces immunogenic cell death in human tumor cells","INTERNATIONAL JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"immunogenic cell death; high hydrostatic pressure; heat shock proteins; cancer immunotherapy; dendritic cells","DENDRITIC CELLS; PHOTODYNAMIC THERAPY; CALRETICULIN EXPOSURE; CANCER-THERAPY; ADAPTIVE IMMUNITY; OVARIAN-CANCER; ATP RELEASE; T-CELLS; CHEMOTHERAPY; APOPTOSIS","Recent studies have identified molecular events characteristic of immunogenic cell death (ICD), including surface exposure of calreticulin (CRT), the heat shock proteins HSP70 and HSP90, the release of high-mobility group box protein 1 (HMGB1) and the release of ATP from dying cells. We investigated the potential of high hydrostatic pressure (HHP) to induce ICD in human tumor cells. HHP induced the rapid expression of HSP70, HSP90 and CRT on the cell surface. HHP also induced the release of HMGB1 and ATP. The interaction of dendritic cells (DCs) with HHP-treated tumor cells led to a more rapid rate of DC phagocytosis, upregulation of CD83, CD86 and HLA-DR and the release of interleukin IL-6, IL-12p70 and TNF-alpha. DCs pulsed with tumor cells killed by HHP induced high numbers of tumor-specific T cells. DCs pulsed with HHP-treated tumor cells also induced the lowest number of regulatory T cells. In addition, we found that the key features of the endoplasmic reticulum stress-mediated apoptotic pathway, such as reactive oxygen species production, phosphorylation of the translation initiation factor eIF2 alpha and activation of caspase-8, were activated by HHP treatment. Therefore, HHP acts as a reliable and potent inducer of ICD in human tumor cells.","[Fucikova, Jitka; Fialova, Anna; Sojka, Ludek; Bartunkova, Jirina; Spisek, Radek] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague 5, Czech Republic; [Fucikova, Jitka; Hermanova, Ivana; Fialova, Anna; Sojka, Ludek; Rob, Lukas; Bartunkova, Jirina; Spisek, Radek] Charles Univ Prague, Univ Hosp Motol, Prague 5, Czech Republic; [Fucikova, Jitka; Moserova, Irena; Truxova, Iva; Vancurova, Irena; Partlova, Simona; Fialova, Anna; Sojka, Ludek; Bartunkova, Jirina; Spisek, Radek] Sotio, Prague, Czech Republic; [Hermanova, Ivana] Charles Univ Prague, Fac Med 2, Prague 5, Czech Republic; [Cartron, Pierre-Francois] Ctr Rech Cancerol Nantes Angers, INSERM, U892, Equipe Labellisee Ligue Natl Canc, Nantes, France; [Houska, Milan] Food Res Inst, Prague, Czech Republic; [Rob, Lukas] Charles Univ Prague, Fac Med 2, Dept Gynecol & Obstet, Prague 5, Czech Republic","Spisek, R (reprint author), Charles Univ Prague, Fac Med 2, Dept Immunol, V Uvalu 84, Prague 5, Czech Republic.","radek.spisek@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic [IGA NT12402-5, IGA NT1159]","Grant sponsor: Ministry of Health, Czech Republic; Grant number: IGA NT12402-5, IGA NT1159",null,50,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0020-7136","1097-0215",null,"INT J CANCER","Int. J. Cancer","SEP 1",2014,135,5,null,null,null,null,1165,1177,null,"10.1002/ijc.28766",null,13,"Oncology","Oncology","AJ3ZQ","WOS:000337608300017",24500981]
["J","Kensova, R; Hynek, D; Kynicky, J; Konecna, M; Eckschlager, T; Adam, V; Hubalek, J; Kizek, R",null,null,null,"Kensova, Renata; Hynek, David; Kynicky, Jindrich; Konecna, Marie; Eckschlager, Tomas; Adam, Vojtech; Hubalek, Jaromir; Kizek, Rene",null,null,"Determination of Metal Ions in the Plasma of Children with Tumour Diseases by Differential Pulse Voltammetry","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"Metals; Electrochemical Analysis; Plasma; EDTA; Interaction; Oncological Diseases","ATOMIC-ABSORPTION-SPECTROMETRY; CARBON-PASTE ELECTRODES; HEAVY-METALS; ELECTROCHEMICAL DETECTION; SPATIAL-DISTRIBUTION; BIOLOGICAL SAMPLES; BRDICKA REACTION; SILVER(I) IONS; FISH-TISSUES; METALLOTHIONEIN","The aim of this study was to investigate the interaction between lead ions and ethylenediaminetetraacetic acid (EDTA) in plasma. EDTA is widely used in medicine as anticoagulant agent. Understanding of the influence of EDTA on the electrochemical lead ions determination is very suitable for the determination of lead ions at patients with increased metals levels in body fluids. Further, the changes of metal ions levels (Zn, Cd, Pb and Cu) were monitored in the blood plasma of child patients treated for various oncological diseases. Electrochemical method differential pulse voltammetry with fully automated system and atomic absorption spectrometry was used for determination of the metal ions. It was found an increased amount of metal ions in the blood plasma of patients suffering from cancer disease in comparison with physiological values in healthy people. In these patients there was also found that they have higher levels of metallothionein and the ratio of GSH/GSSG was reduced. These results suggest that tumour diseases cause important changes in the level of ions.","[Kensova, Renata; Hynek, David; Konecna, Marie; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Kensova, Renata; Hynek, David; Konecna, Marie; Adam, Vojtech; Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Hynek, David; Kynicky, Jindrich; Konecna, Marie; Adam, Vojtech; Hubalek, Jaromir; Kizek, Rene] Mendel Univ Brno, Fac Agron, United Nat Environm Program, CZ-61300 Brno, Czech Republic; [Kynicky, Jindrich] Karel Englis Coll, CZ-60200 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Kensova, R (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz",null,null,"CEITEC [CZ.1.05/1.1.00/02.0068]; Lead and Cadmium Initiatives; United Nation Environment Program; project for conceptual development of research organization [00064203]","Financial support from CEITEC CZ.1.05/1.1.00/02.0068, Lead and Cadmium Initiatives, United Nation Environment Program and the project for conceptual development of research organization 00064203 is highly acknowledged.",null,75,0,0,"ESG","BELGRADE","BORIVOJA STEVANOVICA 25-7, BELGRADE, 11000, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","AUG",2014,9,8,null,null,null,null,4675,4691,null,null,null,17,"Electrochemistry","Electrochemistry","AK3JS","WOS:000338320000049"]
["J","Nechvatal, L; Petrosova, H; Grillova, L; Pospisilova, P; Mikalova, L; Strnadel, R; Kuklova, I; Kojanova, M; Kreidlova, M; Vanousova, D; Prochazka, P; Zakoucka, H; Krchnakova, A; Smajs, D",null,null,null,"Nechvatal, Lukas; Petrosova, Helena; Grillova, Linda; Pospisilova, Petra; Mikalova, Lenka; Strnadel, Radim; Kuklova, Ivana; Kojanova, Martina; Kreidlova, Miluse; Vanousova, Daniela; Prochazka, Premysl; Zakoucka, Hana; Krchnakova, Alena; Smajs, David",null,null,"Syphilis-causing strains belong to separate SS14-like or Nichols-like groups as defined by multilocus analysis of 19 Treponema pallidum strains","INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY",null,null,"English","Article",null,null,null,null,null,"Treponema pallidum; Syphilis; Yaws; Molecular typing; Multilocus analysis; SS14-like strains","COMPLETE GENOME SEQUENCE; REPEAT PROTEIN ARP; SUBSP PALLIDUM; MACROLIDE RESISTANCE; CONGENITAL-SYPHILIS; POSITIVE SELECTION; GENETIC DIVERSITY; MULTIPLE ALLELES; SSP PALLIDUM; TPRK GENE","Treponema pallidum strains are closely related at the genome level but cause distinct diseases. Subspecies pallidum (TPA) is the causative agent of syphilis, subspecies pertenue (TPE) causes yaws while subspecies endemicum (TEN) causes bejel (endemic syphilis). Compared to the majority of treponemal genomic regions, several chromosomal loci were found to be more diverse. To assess genetic variability in diverse genomic positions, we have selected (based on published genomic data) and sequenced five variable loci, TP0304, TP0346, TPO488, TP0515 and TP0558, in 19 reference Treponema pallidum strains including all T. pallidum subspecies (TPA, TPE and TEN). Results of this multilocus analysis divided syphilitic isolates into two groups: SS14-like and Nichols-like. The SS14-like group is comprised of SS14, Grady, Mexico A and Philadelphia 1 strains. The Nichols-like group consisted of strains Nichols, Bal 73-1, DAL-1, MN-3, Philadelphia 2, Haiti B and Madras. The TP0558 locus was selected for further studies because it clearly distinguished between the SS14- and Nichols-like groups and because the phylogenetic tree derived from the TP0558 locus showed the same clustering pattern as the tree constructed from whole genome sequences. In addition, TP0558 was shown as the only tested locus that evolved under negative selection within TPA strains. Sequencing of a short fragment (573 bp) of the TP0558 locus in a set of 25 clinical isolates from 22 patients collected in the Czech Republic during 2012-2013 revealed that clinical isolates follow the SS14- and Nichols-like distribution. (C) 2014 Elsevier GmbH. All rights reserved.","[Nechvatal, Lukas; Petrosova, Helena; Grillova, Linda; Pospisilova, Petra; Mikalova, Lenka; Smajs, David] Masaryk Univ, Fac Med, Dept Biol, Brno 62500, Czech Republic; [Strnadel, Radim] St Annes Fac Hosp Brno, Dept Dermatovenereol, Brno, Czech Republic; [Kuklova, Ivana; Kojanova, Martina] Charles Univ Prague, Fac Med 1, Dept Dermatol, Prague, Czech Republic; [Kreidlova, Miluse] Gen Univ Hosp, Inst Med Biochem, Prague, Czech Republic; [Kreidlova, Miluse] Gen Univ Hosp, Diagnost Lab, Prague, Czech Republic; [Kreidlova, Miluse] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Vanousova, Daniela] Charles Univ Prague, Bulovka Hosp, Fac Med 2, Dept Dermatovenerol, Prague, Czech Republic; [Prochazka, Premysl] Outpatient STI Clin Medictr, Prague, Czech Republic; [Zakoucka, Hana] Syphilis, Natl Reference Lab Diagnost, Prague, Czech Republic; [Zakoucka, Hana] Natl Inst Publ Hlth, Prague, Czech Republic; [Krchnakova, Alena] St Annes Hosp, Fac Med, Dept Med Microbiol, Brno, Czech Republic; [Krchnakova, Alena] Masaryk Univ, Brno 62500, Czech Republic","Smajs, D (reprint author), Masaryk Univ, Fac Med, Dept Biol, Kamenice 5,Bldg A6, Brno 62500, Czech Republic.","dsmajs@med.muni.cz",null,null,"Grant Agency of the Czech Republic [P302/12/0574]; Ministry of Health of the Czech Republic [NT11159-5/2010]","This work was supported by a grant from the Grant Agency of the Czech Republic (P302/12/0574) to D.S. and a grant from the Ministry of Health of the Czech Republic (NT11159-5/2010) to D.S.",null,59,1,1,"ELSEVIER GMBH, URBAN & FISCHER VERLAG","JENA","OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY","1438-4221","1618-0607",null,"INT J MED MICROBIOL","Int. J. Med. Microbiol.","JUL",2014,304,41795,null,null,null,null,645,653,null,"10.1016/j.ijmm.2014.04.007",null,9,"Microbiology; Virology","Microbiology; Virology","AM3TL","WOS:000339775600016",24841252]
["J","Urdzikova, LM; Ruzicka, J; LaBagnara, M; Karova, K; Kubinova, S; Jirakova, K; Murali, R; Sykova, E; Jhanwar-Uniyal, M; Jendelova, P",null,null,null,"Urdzikova, Lucia Machova; Ruzicka, Jiri; LaBagnara, Michael; Karova, Kristyna; Kubinova, Sarka; Jirakova, Klara; Murali, Raj; Sykova, Eva; Jhanwar-Uniyal, Meena; Jendelova, Pavla",null,null,"Human Mesenchymal Stem Cells Modulate Inflammatory Cytokines after Spinal Cord Injury in Rat","INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES",null,null,"English","Article",null,null,null,null,null,"mesenchymal stem cells; spinal cord injury; inflammatory cytokines","MARROW STROMAL CELLS; FUNCTIONAL RECOVERY; LUMBAR PUNCTURE; ADULT RATS; TRANSPLANTATION; TISSUE; PROMOTES; MODEL; MECHANISMS; CONTUSION","Transplantation of mesenchymal stem cells (MSC) improves functional recovery in experimental models of spinal cord injury (SCI); however, the mechanisms underlying this effect are not completely understood. We investigated the effect of intrathecal implantation of human MSC on functional recovery, astrogliosis and levels of inflammatory cytokines in rats using balloon-induced spinal cord compression lesions. Transplanted cells did not survive at the lesion site of the spinal cord; however, functional recovery was enhanced in the MSC-treated group as was confirmed by the Basso, Beattie, and Bresnahan (BBB) and the flat beam test. Morphometric analysis showed a significantly higher amount of remaining white matter in the cranial part of the lesioned spinal cords. Immunohistochemical analysis of the lesions indicated the rearrangement of the glial scar in MSC-treated animals. Real-time PCR analysis revealed an increased expression of Irf5, Mrc1, Fgf2, Gap43 and Gfap. Transplantation of MSCs into a lesioned spinal cord reduced TNF alpha, IL-4, IL-1 beta, IL-2, IL-6 and IL-12 and increased the levels of MIP-1 alpha and RANTES when compared to saline-treated controls. Intrathecal implantation of MSCs reduces the inflammatory reaction and apoptosis, improves functional recovery and modulates glial scar formation after SCI, regardless of cell survival. Therefore, repeated applications may prolong the beneficial effects induced by MSC application.","[Urdzikova, Lucia Machova; Ruzicka, Jiri; Karova, Kristyna; Kubinova, Sarka; Jirakova, Klara; Sykova, Eva; Jendelova, Pavla] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic; [Ruzicka, Jiri; Karova, Kristyna; Sykova, Eva; Jendelova, Pavla] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague 14220, Czech Republic; [LaBagnara, Michael; Murali, Raj; Jhanwar-Uniyal, Meena] New York Med Coll, Dept Neurosurg, Valhalla, NY 10595 USA","Jendelova, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220, Czech Republic.","urdzikl@saske.sk; j.ruzicka@biomed.cas.cz; m.labagnara@gmail.com; karova@biomed.cas.cz; sarka.k@biomed.cas.cz; jirakova@biomed.cas.cz; Raj_Murali@NYMC.edu; sykova@biomed.cas.cz; meena_jhanwar@NYMC.edu; jendel@biomed.cas.cz",null,null,"GACR (Grant Agency of Czech Republic) [13-15031P, 13-00939S, LH12024, GAUK521712, CZ.1.07/2.3.00/30.0018]; European Regional Development Fund [CZ.1.05/1.1.00/02.0109]","This study is supported by the grants, GACR (Grant Agency of Czech Republic) 13-15031P, 13-00939S, LH12024, GAUK521712, CZ.1.07/2.3.00/30.0018, and by the project \"Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University-BIOCEV\" (CZ.1.05/1.1.00/02.0109), from the European Regional Development Fund.",null,39,1,1,"MDPI AG","BASEL","POSTFACH, CH-4005 BASEL, SWITZERLAND","1422-0067",null,null,"INT J MOL SCI","Int. J. Mol. Sci.","JUL",2014,15,7,null,null,null,null,11275,11293,null,"10.3390/ijms150711275",null,19,"Chemistry, Multidisciplinary","Chemistry","AM7ID","WOS:000340038500006",24968269]
["J","Plencner, M; East, B; Tonar, Z; Otahal, M; Prosecka, E; Rampichova, M; Krejci, T; Litvinec, A; Buzgo, M; Mickova, A; Necas, A; Hoch, J; Amler, E",null,null,null,"Plencner, Martin; East, Barbora; Tonar, Zbynek; Otahal, Martin; Prosecka, Eva; Rampichova, Michala; Krejci, Tomas; Litvinec, Andrej; Buzgo, Matej; Mickova, Andrea; Necas, Alois; Hoch, Jiri; Amler, Evzen",null,null,"Abdominal closure reinforcement by using polypropylene mesh functionalized with poly-epsilon-caprolactone nanofibers and growth factors for prevention of incisional hernia formation","INTERNATIONAL JOURNAL OF NANOMEDICINE",null,null,"English","Article",null,null,null,null,null,"nanofibers; growth factors; surgical mesh; hernia regeneration; in vivo","POLYCAPROLACTONE SCAFFOLDS; FIBROUS SCAFFOLDS; FACTOR-BETA; REPAIR; COMPOSITE; ADHESION; COLLAGEN; DEPOSITION; MATRIX","Incisional hernia affects up to 20% of patients after abdominal surgery. Unlike other types of hernia, its prognosis is poor, and patients suffer from recurrence within 10 years of the operation. Currently used hernia-repair meshes do not guarantee success, but only extend the recurrence-free period by about 5 years. Most of them are nonresorbable, and these implants can lead to many complications that are in some cases life-threatening. Electrospun nanofibers of various polymers have been used as tissue scaffolds and have been explored extensively in the last decade, due to their low cost and good biocompatibility. Their architecture mimics the natural extracellular matrix. We tested a biodegradable polyester poly-epsilon-caprolactone in the form of nanofibers as a scaffold for fascia healing in an abdominal closure-reinforcement model for prevention of incisional hernia formation. Both in vitro tests and an experiment on a rabbit model showed promising results.","[Plencner, Martin; Prosecka, Eva; Mickova, Andrea; Amler, Evzen] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague, Czech Republic; [Plencner, Martin; Prosecka, Eva; Rampichova, Michala; Buzgo, Matej; Mickova, Andrea; Amler, Evzen] Acad Sci Czech Republic, Lab Tissue Engn, Prague 14240, Czech Republic; [East, Barbora; Krejci, Tomas; Hoch, Jiri] Charles Univ Prague, Fac Med 2, Dept Surg, Prague, Czech Republic; [Tonar, Zbynek] Charles Univ Prague, Fac Med Pilsen, Ctr Biomed, Plzen, Czech Republic; [Otahal, Martin] Charles Univ Prague, Fac Phys Educ & Sport, Dept Anat & Biomech, Prague, Czech Republic; [Rampichova, Michala; Buzgo, Matej; Mickova, Andrea] Czech Tech Univ, Univ Ctr Energy Efficient Bldg, Bustehrad, Czech Republic; [Litvinec, Andrej] Acad Sci Czech Republic, Inst Physiol, Dept Breeding & Zoohyg Lab Anim, Prague 14240, Czech Republic; [Necas, Alois] Univ Vet & Pharmaceut Sci Brno, Cent European Inst Technol, Fac Vet Med, Dept Surg & Orthoped,Small Anim Clin, Brno, Czech Republic; [Amler, Evzen] Czech Tech Univ, Fac Biomed Engn, Kladno, Czech Republic","Plencner, M (reprint author), Acad Sci Czech Republic, Inst Expt Med, 1083 Videnska, Prague 14240, Czech Republic.","martin.plencner@gmail.com","Necas, Alois/E-5058-2012",null,"Academy of Sciences of the Czech Republic (Institutional Research Concept) [RVO 68378041]; Ministry of Education, Youth and Sports of the Czech Republic (project IPv6); Grant Agency of Charles University [545313, 384311, 270513, 424213, 648112]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NT12156]; European Regional Development Fund [ED2.1.00/03.0076]; Central European Institute of Technology [CZ.1.05/1.1.00/02.0068]","This work was supported by the Academy of Sciences of the Czech Republic (Institutional Research Concept RVO 68378041), the Ministry of Education, Youth and Sports of the Czech Republic (project IPv6), the Grant Agency of Charles University (545313, 384311, 270513, 424213, 648112), and Internal Grant Agency of the Ministry of Health of the Czech Republic (NT12156). Histological quantification was supported by the European Regional Development Fund project ED2.1.00/03.0076, Central European Institute of Technology (CZ.1.05/1.1.00/02.0068), from the European Regional Development Fund. The authors would like to acknowledge O Kofronova and O Benada from the Laboratory of Molecular Structure Characterization, Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic, for scanning electron microscopy analyses.",null,44,0,0,"DOVE MEDICAL PRESS LTD","ALBANY","PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND","1178-2013",null,null,"INT J NANOMED","Int. J. Nanomed.",null,2014,9,null,null,null,null,null,3263,3277,null,"10.2147/IJN.S63095",null,15,"Nanoscience & Nanotechnology; Pharmacology & Pharmacy","Science & Technology - Other Topics; Pharmacology & Pharmacy","AK8EJ","WOS:000338659700001",25031534]
["J","Katra, R; Kabelka, Z; Jurovcik, M; Hradsky, O; Kraus, J; Pavlik, E; Nartova, E; Lukes, P; Astl, J",null,null,null,"Katra, R.; Kabelka, Z.; Jurovcik, M.; Hradsky, O.; Kraus, J.; Pavlik, E.; Nartova, E.; Lukes, P.; Astl, J.",null,null,"Pilot study: Association between Helicobacter pylori in adenoid hyperplasia and reflux episodes detected by multiple intraluminal impedance in children","INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"Laryngopharyngeal and gastroesophageal reflux; Adenoid hyperplasia; Helicobacter pylori; Multiple intraluminal impedance; PCR","GASTROESOPHAGEAL-REFLUX; CHRONIC ADENOTONSILLITIS; PHARYNGEAL REFLUX; OTITIS-MEDIA; INFECTION; PREVALENCE; DISORDERS; GUIDELINES; CHILDHOOD; GASTRITIS","Objectives: The aim of this pilot study was to investigate an association between laryngopharyngeal reflux detected by combined multiple intraluminal impedance and pH monitoring and Helicobacter pylori in adenoid hyperplasia detected with real time polymerase chain reaction (PCR). Methods: The study group consisted of 30 children (median age 5.34 years) with extraesophageal symptoms of gastroesophageal reflux disease with adenoid hyperplasia. All children underwent adenoidectomy with subsequent PCR detection of H. pylori DNA in the tissue and multiple intraluminal impedance and pH monitoring. The most proximal impedance sensor was located 1 cm caudal to the entrance of the oesophagus. Results: We found significant differences in the number of reflux episodes among patients with PCR positivity (median 35) and negativity (median 0) of H. pylori (p-value of Mann-Whitney U-test 0.0056). Patients with PCR positivity of H. pylori had significantly more reflux episodes reaching the upper oesophageal sphincter (p-value of Mann-Whitney U-test 0.023). The absence of reflux episode was the only independent factor for PCR negativity of H. pylori in the multiple logistic regression model. Conclusions: These results support the hypothesis that reflux episodes reaching the upper oesophageal sphincter may play an important role in the transmission of H. pylori into lymphoid tissue of the nasopharynx and thus may contribute to adenoid hyperplasia in children. (C) 2014 Elsevier Ireland Ltd. All rights reserved.","[Katra, R.; Kabelka, Z.; Jurovcik, M.] Charles Univ Prague, Dept ENT, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Hradsky, O.] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Kraus, J.] Hosp Rudolph & Stephanie, Dept Otorhinolaryngol, Benesov, Czech Republic; [Pavlik, E.] Charles Univ Prague, Dept Microbiol & Immunol, Gen Fac Hosp, Fac Med 1, Prague, Czech Republic; [Pavlik, E.] Charles Univ Prague, Inst Med Biochem & Lab Med, Gen Fac Hosp, Fac Med 1, Prague, Czech Republic; [Nartova, E.; Lukes, P.] Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Univ Hosp Motol, Fac Med 1, Prague, Czech Republic; [Astl, J.] Charles Univ Prague, Mil Univ Hosp, Fac Med 3, Dept ENT, Prague, Czech Republic","Katra, R (reprint author), Charles Univ Prague, Dept ENT, Fac Med 2, Univ Hosp Motol, Dvalu 84, Prague 15006 5, Czech Republic.","rami.katra@centrum.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NT11523]; Ministry of Health, Czech Republic [00064203]","This work was supported by Grant NT11523 of the Internal Grant Agency of the Ministry of Health of the Czech Republic and by the project (Ministry of Health, Czech Republic) for conceptual development of research organisation 00064203 (University Hospital Motol, Prague, Czech Republic).",null,45,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0165-5876","1872-8464",null,"INT J PEDIATR OTORHI","Int. J. Pediatr. Otorhinolaryngol.","AUG",2014,78,8,null,null,null,null,1243,1249,null,"10.1016/j.ijporl.2014.04.040",null,7,"Otorhinolaryngology; Pediatrics","Otorhinolaryngology; Pediatrics","AN0WN","WOS:000340304800008",24865809]
["J","Astl, J; Chovanec, M; Lukes, P; Katra, R; Dvorakova, M; Vlcek, P; Sykorova, P; Betka, J",null,null,null,"Astl, Jaromir; Chovanec, Martin; Lukes, Petr; Katra, Rami; Dvorakova, Marcela; Vlcek, Petr; Sykorova, Pavla; Betka, Jan",null,null,"Thyroid carcinoma surgery in children and adolescents - 15 years experience surgery of pediatric thyroid carcinoma","INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"Carcinoma; Child; Adolescent; Thyroidectomy; Neck dissection","MEDULLARY CARCINOMA; CANCER; CHILDHOOD; CHERNOBYL; RADIOIODINE; SURVIVAL; ACCIDENT; UKRAINE","Objectives: The purpose of this study is to evaluate the characteristics of thyroid gland surgery focusing on malignancies at the pediatric age with the main concern on treatment results and complications in extensive primary treatment. Methods: The records of all patients 18 years and younger with surgically treated thyroid diseases in the Prague Hospital, Motol, between 1991 and 2006 were retrospectively reviewed. Results: Thyroid surgery was performed on 148 pediatric patients (including 56 carcinomas). The youngest patient involved in the study was seven years old, the oldest patient 18 years old (mean 13.7 years). Most frequent histological cancer type was PTC (42 cases, 75%). Follicular cancer was diagnosed in five cases (8.9%) and medullar cancer in nine cases (16.1%). A prophylactic thyroidectomy was performed in three cases (5.4%) without clinical signs of thyroid tumor with diagnosed RET gene mutation. Conclusions: We consider total thyroidectomy with subsequent radioiodine ablation and TSH suppression as the basic approach in the treatment protocol of pediatric WDTC. The observed 100% recurrence-free and overall survival together with a low incidence of postoperative complications strongly supports the idea of a total thyroidectomy with selective neck dissection in the treatment of metastases of WDTC and MTC. (C) 2014 Elsevier Ireland Ltd. All rights reserved.","[Astl, Jaromir; Chovanec, Martin; Lukes, Petr; Betka, Jan] Charles Univ Hosp, Dept Otorhinolaryngol & Head & Neck Surg, IPVZ, Fac 1, Prague, Czech Republic; [Chovanec, Martin] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 16000 6, Czech Republic; [Katra, Rami] Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac 2, Prague 16000 6, Czech Republic; [Vlcek, Petr; Sykorova, Pavla] Charles Univ Prague, Dept Nucl Med, Prague 16000 6, Czech Republic; [Chovanec, Martin] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Hosp Motol, Fac Med 2, Prague 16000 6, Czech Republic; [Dvorakova, Marcela] Charles Univ Prague, Inst Endocrinol, Prague 16000 6, Czech Republic; [Astl, Jaromir] Charles Univ Prague, Dept Otorhinolaryngol, Fac Med 3, Prague 16000 6, Czech Republic; [Astl, Jaromir] Mil Fac Hosp, Prague, Czech Republic","Astl, J (reprint author), Charles Univ Prague, Dept Otorhinolaryngol, Fac Mil Hosp Stresovice, Fac Med 3, U Vojenske Nemocnice 1200, Prague 16000 6, Czech Republic.","jaromir.astl@seznam.cz",null,null,"Ministry of Health of Czech Republic [IGA NT 11455-5]","This work was supported by IGA NT 11455-5 Grant project Ministry of Health of Czech Republic.",null,20,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0165-5876","1872-8464",null,"INT J PEDIATR OTORHI","Int. J. Pediatr. Otorhinolaryngol.","JUL",2014,78,7,null,null,null,null,990,994,null,"10.1016/j.ijporl.2014.03.005",null,5,"Otorhinolaryngology; Pediatrics","Otorhinolaryngology; Pediatrics","AK7KV","WOS:000338608100005",24794415]
["J","Kautzner, J; Trc, T; Havlas, V",null,null,null,"Kautzner, Jakub; Trc, Tomas; Havlas, Vojtech",null,null,"Comparison of conservative against surgical treatment of anterior-superior iliac spine avulsion fractures in children and adolescents","INTERNATIONAL ORTHOPAEDICS",null,null,"English","Article",null,null,null,null,null,"Avulsion fracture; Anterior-superior iliac spine (ASIS); Apophyseal injury; Treatment strategy",null,"Avulsion fracture of the anterior-superior iliac spine is an uncommon injury. It is mostly seen in adolescent sprinters, distance runners and soccer players. Most cases are unilateral. We present a cohort of patients and the strategy for their treatment. During the period 2005-2012, we treated 23 (19 male, four female) patients with an average age of 15.1 years (4-17). Ten patients with minimally displaced fractures were treated conservatively, and 13 patients with greater fragment dislocation were treated surgically. All patients underwent the standardised rehabilitation protocol. We evaluated range of motion (ROM), X-ray six weeks and one year postoperatively, length of bed rest, return to activity and complication rates (infection, heterotopic ossification). All patients returned to sports at the preinjury level. Surgically treated patients showed faster recovery and better compliance with rehabilitation protocols. The time interval for X-ray union was comparable between groups, as was full recovery. There was no deep infection; however, there were five minor heterotopic ossifications, none of which required further treatment. We emphasise that the indication for surgical treatment is mainly determined by the grade of fragment displacement and the patient's sporting activity. Although long-term results were comparable between treatment methods, surgery carries the risk of higher complication rates and the need for osteosynthetic material extraction.","[Kautzner, Jakub; Trc, Tomas; Havlas, Vojtech] Charles Univ Prague, Fac Med 2, Dept Orthopaed & Traumatol, Prague 15006 5, Czech Republic","Havlas, V (reprint author), Charles Univ Prague, Fac Med 2, Dept Orthopaed & Traumatol, V Uvalu 84, Prague 15006 5, Czech Republic.","vojtech.havlas@seznam.cz",null,null,"Czech Research Institution [00064203]","Supported by Czech Research Institution Grant Project No. 00064203.",null,11,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0341-2695","1432-5195",null,"INT ORTHOP","Int. Orthop.","JUL",2014,38,7,null,null,null,null,1495,1498,null,"10.1007/s00264-014-2323-0",null,4,"Orthopedics","Orthopedics","AK5WA","WOS:000338496100023",24695975]
["J","Garg, AX; Devereaux, PJ; Yusuf, S; Cuerden, MS; Parikh, CR; Coca, SG; Walsh, M; Novick, R; Cook, RJ; Jain, AR; Pan, XB; Noiseux, N; Vik, K; Stolf, NA; Ritchie, A; Favaloro, RR; Parvathaneni, S; Whitlock, RP; Ou, YN; Lawrence, M; Lamy, A",null,null,null,"Garg, Amit X.; Devereaux, P. J.; Yusuf, Salim; Cuerden, Meaghan S.; Parikh, Chirag R.; Coca, Steven G.; Walsh, Michael; Novick, Richard; Cook, Richard J.; Jain, Anil R.; Pan, Xiangbin; Noiseux, Nicolas; Vik, Karel; Stolf, Noedir A.; Ritchie, Andrew; Favaloro, Roberto R.; Parvathaneni, Sirish; Whitlock, Richard P.; Ou, Yongning; Lawrence, Mitzi; Lamy, Andre",null,"CORONARY Investigators","Kidney Function After Off-Pump or On-Pump Coronary Artery Bypass Graft Surgery A Randomized Clinical Trial","JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION",null,null,"English","Article",null,null,null,null,null,null,"ACUTE-RENAL-FAILURE; CARDIAC-SURGERY; PERITUBULAR CAPILLARIES; INJURY; DISEASE; RISK; METAANALYSIS; NEPHROPATHY; INCREASES; DESIGN","IMPORTANCE Most acute kidney injury observed in the hospital is defined by sudden mild or moderate increases in the serum creatinine concentration, which may persist for several days. Such acute kidney injury is associated with lower long-term kidney function. However, it has not been demonstrated that an intervention that reduces the risk of such acute kidney injury better preserves long-term kidney function. OBJECTIVES To characterize the risk of acute kidney injury with an intervention in a randomized clinical trial and to determine if there is a difference between the 2 treatment groups in kidney function 1 year later. DESIGN, SETTING, AND PARTICIPANTS The Coronary Artery Bypass Grafting Surgery Off- or On-pump Revascularisation Study (CORONARY) enrolled 4752 patients undergoing first isolated coronary artery bypass graft (CABG) surgery at 79 sites in 19 countries. Patients were randomized to receive CABG surgery either with a beating-heart technique (off-pump) or with cardiopulmonary bypass (on-pump). From January 2010 to November 2011, 2932 patients (from 63 sites in 16 countries) from CORONARY were enrolled into a kidney function substudy to record serum creatinine concentrations during the postoperative period and at 1 year. The last 1-year serum creatinine concentration was recorded on January 18, 2013. MAIN OUTCOMES AND MEASURES Acute kidney injury within 30 days of surgery (>= 50% increase in serum creatinine concentration from prerandomization concentration) and loss of kidney function at 1 year (>= 20% loss in estimated glomerular filtration rate from prerandomization level). RESULTS Off-pump (n = 1472) vs on-pump (n = 1460) CABG surgery reduced the risk of acute kidney injury (17.5% vs 20.8%, respectively; relative risk, 0.83 [95% CI, 0.72-0.97], P = .01); however, there was no significant difference between the 2 groups in the loss of kidney function at 1 year (17.1% vs 15.3%, respectively; relative risk, 1.10 [95% CI, 0.95-1.29], P = .23). Results were consistent with multiple alternate continuous and categorical definitions of acute kidney injury or kidney function loss, and in the subgroup with baseline chronic kidney disease. CONCLUSIONS AND RELEVANCE Use of off-pump compared with on-pump CABG surgery reduced the risk of postoperative acute kidney injury, without evidence of better preserved kidney function with off-pump CABG surgery at 1 year. In this setting, an intervention that reduced the risk of mild to moderate acute kidney injury did not alter longer-term kidney function. Copyright 2014 American Medical Association. All rights reserved.","[Garg, Amit X.; Cuerden, Meaghan S.] Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada; [Garg, Amit X.] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada; [Garg, Amit X.; Devereaux, P. J.; Yusuf, Salim; Walsh, Michael; Whitlock, Richard P.; Lamy, Andre] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Devereaux, P. J.; Yusuf, Salim; Walsh, Michael; Whitlock, Richard P.; Ou, Yongning; Lawrence, Mitzi; Lamy, Andre] Populat Hlth Res Inst, Hamilton, ON, Canada; [Cuerden, Meaghan S.; Cook, Richard J.] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada; [Parikh, Chirag R.; Coca, Steven G.] Yale Univ, Sch Med, Nephrol Sect, New Haven, CT USA; [Novick, Richard] Univ Western Ontario, Div Cardiac Surg, London, ON, Canada; [Jain, Anil R.] SAL Hosp & Med Inst, Ahmadabad, India; [Pan, Xiangbin] Chinese Acad Med Sci, Peking Union Med Coll, Dept Cardiovasc Surg, Fuiwai Hosp, Beijing 100730, Peoples R China; [Noiseux, Nicolas] CHUM, Dept Cardiac Surg, Montreal, PQ, Canada; [Vik, Karel] Univ Hosp Motol, Prague, Czech Republic; [Stolf, Noedir A.] Hosp Clin Sao Paulo, Inst Coracao, Sao Paulo, Brazil; [Ritchie, Andrew] Essex Cardiothorac Ctr, Basildon, Essex, England; [Ritchie, Andrew] Anglia Ruskin Univ, Cambridge, Essex, England; [Favaloro, Roberto R.] Hosp Univ Fdn Favaloro, Dept Cardiovasc Surg, Buenos Aires, DF, Argentina; [Parvathaneni, Sirish] Mercy Hosp, Springfield, MO USA; [Whitlock, Richard P.; Lamy, Andre] McMaster Univ, Div Cardiac Surg, Hamilton, ON, Canada","Garg, AX (reprint author), London Hlth Sci Ctr, 800 Commissioners Rd E, London, ON N6A 4G5, Canada.","amit.garg@lhsc.on.ca",null,null,"Canadian Institutes of Health Research","The Coronary Artery Bypass Grafting Surgery Off- or On-pump Revascularisation Study (CORONARY) and this kidney function substudy were financially supported by grants from the Canadian Institutes of Health Research.",null,31,1,1,"AMER MEDICAL ASSOC","CHICAGO","330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA","0098-7484","1538-3598",null,"JAMA-J AM MED ASSOC","JAMA-J. Am. Med. Assoc.","JUN 4",2014,311,21,null,null,null,null,2191,2198,null,"10.1001/jama.2014.4952",null,8,"Medicine, General & Internal","General & Internal Medicine","AI2DU","WOS:000336668400020",24886787]
["J","Dvorak, CC; Hassan, A; Slatter, MA; Honig, M; Lankester, AC; Buckley, RH; Pulsipher, MA; Davis, JH; Gungor, T; Gabriel, M; Bleesing, JH; Bunin, N; Sedlacek, P; Connell, JA; Crawford, DF; Notarangelo, LD; Pai, SY; Hassid, J; Veys, P; Gennery, AR; Cowan, MJ",null,null,null,"Dvorak, Christopher C.; Hassan, Amel; Slatter, Mary A.; Hoenig, Manfred; Lankester, Arjan C.; Buckley, Rebecca H.; Pulsipher, Michael A.; Davis, Jeffrey H.; Guengoer, Tayfun; Gabriel, Melissa; Bleesing, Jacob H.; Bunin, Nancy; Sedlacek, Petr; Connell, James A.; Crawford, David F.; Notarangelo, Luigi D.; Pai, Sung-Yun; Hassid, Jake; Veys, Paul; Gennery, Andrew R.; Cowan, Morton J.",null,null,"Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency","JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Severe combined immunodeficiency; hematopoietic cell transplantation; sibling donors; unrelated donors; umbilical cord blood; conditioning; serotherapy","VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; COMBINED IMMUNE-DEFICIENCY; CORD BLOOD; B-CELLS; RECONSTITUTION; CHILDREN; ENGRAFTMENT; EXPERIENCE; CLEARANCE","Background: Patients with severe combined immunodeficiency disease who have matched sibling donors (MSDs) can proceed to hematopoietic cell transplantation (HCT) without conditioning chemotherapy. Objective: We sought to determine whether the results of HCT without chemotherapy-based conditioning from matched unrelated donors (URDs), either from volunteer adults or umbilical cord blood, are comparable with those from MSDs. Methods: We performed a multicenter survey of severe combined immunodeficiency transplantation centers in North America, Europe, and Australia to compile retrospective data on patients who have undergone unconditioned HCT from either URDs (n = 37) or MSDs (n = 66). Results: Most patients undergoing URD HCT (92%) achieved donor T-cell engraftment compared with 97% for those with MSDs; however, estimated 5-year overall and event-free survival were worse for URD recipients (71% and 60%, respectively) compared with MSD recipients (92% and 89%, respectively; P < .01 for both). URD recipients who received pre-HCT serotherapy had similar 5-year overall survival (100%) to MSD recipients. The incidences of grade II to IV acute and chronic graft-versus-host disease were higher in URD (50% and 39%, respectively) compared with MSD (22% and 5%, respectively) recipients (P < .01 for both). In the surviving patients there was no difference in T-cell reconstitution at the last follow-up between the URD and MSD recipients; however, MSD recipients were more likely to achieve B-cell reconstitution (72% vs 17%, P < .001). Conclusion: Unconditioned URD HCT achieves excellent rates of donor T-cell engraftment similar to that seen in MSD recipients, and reconstitution rates are adequate. However, only a minority will have myeloid and B-cell reconstitution, and attention must be paid to graft-versus-host disease prophylaxis. This approach might be safer in children ineligible for intense regimens to spare the potential complications of chemotherapy.","[Dvorak, Christopher C.; Hassid, Jake; Cowan, Morton J.] Univ Calif San Francisco, Benioff Childrens Hosp, Div Pediat Allergy Immunol & Blood & Marrow Trans, San Francisco, CA 94143 USA; [Hassan, Amel; Veys, Paul] UCL Inst Child Hlth, Mol Immunol Unit, Ctr Immunodeficiency, London, England; [Slatter, Mary A.; Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Hoenig, Manfred] Univ Med Ctr, Dept Pediat, Ulm, Germany; [Lankester, Arjan C.] Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RA Leiden, Netherlands; [Buckley, Rebecca H.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27706 USA; [Buckley, Rebecca H.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27706 USA; [Pulsipher, Michael A.] Univ Utah, Sch Med, Div Hematol & Hematol Malignancies, Primary Childrens Hosp,Hunstman Canc Inst, Salt Lake City, UT USA; [Davis, Jeffrey H.] British Columbia Childrens Hosp, Hematol Oncol BMT Program, Vancouver, WA USA; [Guengoer, Tayfun] Univ Childrens Hosp, Stem Cell Transplantat Dept, Zurich, Switzerland; [Gabriel, Melissa] Childrens Hosp Westmead, Dept Oncol, Sydney, NSW, Australia; [Bleesing, Jacob H.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Bunin, Nancy] Childrens Hosp Philadelphia, Dept Pediat, Div Oncol, Philadelphia, PA 19104 USA; [Sedlacek, Petr] Teaching Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Connell, James A.] Univ Michigan, Div Pediat Hematol Oncol, Ann Arbor, MI 48109 USA; [Crawford, David F.] Univ Oklahoma, Dept Pediat, Oklahoma City, OK USA; [Notarangelo, Luigi D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Notarangelo, Luigi D.] Harvard Univ, Sch Med, Childrens Hosp Boston, Manton Ctr Orphan Dis Res, Boston, MA USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Boston Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA","Dvorak, CC (reprint author), Univ Calif San Francisco, Benioff Childrens Hosp, Div Pediat Allergy Immunol & Blood & Marrow Trans, 505 Parnassus Ave,M 659, San Francisco, CA 94143 USA.","dvorakc@peds.ucsf.edu",null,null,"National Institute of Allergy and Infectious Diseases [1U54AI082973]; NIH Office of Rare Diseases Research, National Center for Advancing Translational Sciences","Data collection for this study was facilitated in part through the CIBMTR (U24-CA76518; principal investigator: M. M. Horowitz) and the Primary Immune Deficiency Treatment Consortium (PIDTC) Annual Scientific Workshop (R13 AI094943). The PIDTC is a part of the National Institutes of Health Rare Diseases Clinical Research Network with the DMCC at the University of South Florida. Funding and/or programmatic support for this project has been provided by grant no. 1U54AI082973 from the National Institute of Allergy and Infectious Diseases and the NIH Office of Rare Diseases Research, National Center for Advancing Translational Sciences. The views expressed are those of the authors and do not represent the position of the NIAID, ORDR/NCATS, NIH, or the US Government.",null,37,0,0,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0091-6749","1097-6825",null,"J ALLERGY CLIN IMMUN","J. Allergy Clin. Immunol.","OCT",2014,134,4,null,null,null,null,935,"U263",null,"10.1016/j.jaci.2014.06.021",null,24,"Allergy; Immunology","Allergy; Immunology","AQ9GC","WOS:000343155700023",25109802]
["J","Gathmann, B; Mahlaoui, N; Gerard, L; Oksenhendler, E; Warnatz, K; Schulze, I; Kindle, G; Kuijpers, TW; van Beem, RT; Guzman, D; Workman, S; Soler-Palacin, P; De Gracia, J; Witte, T; Schmidt, RE; Litzman, J; Hlavackova, E; Thon, V; Borte, M; Borte, S; Kumararatne, D; Kumararatne, D; Longhurst, H; Helbert, M; Szaflarska, A; Sediva, A; Belohradsky, BH; Jones, A; Baumann, U; Meyts, I; Kutukculer, N; Wagstrom, P; Galal, NM; Roesler, J; Farmaki, E; Zinovieva, N; Ciznar, P; Papadopoulou-Alataki, E; Bienemann, K; Velbri, S; Panahloo, Z; Grimbacher, B",null,null,null,"Gathmann, Benjamin; Mahlaoui, Nizar; Gerard, Laurence; Oksenhendler, Eric; Warnatz, Klaus; Schulze, Ilka; Kindle, Gerhard; Kuijpers, Taco W.; van Beem, Rachel T.; Guzman, David; Workman, Sarita; Soler-Palacin, Pere; De Gracia, Javier; Witte, Torsten; Schmidt, Reinhold E.; Litzman, Jiri; Hlavackova, Eva; Thon, Vojtech; Borte, Michael; Borte, Stephan; Kumararatne, Dinakantha; Feighery, Conleth; Longhurst, Hilary; Helbert, Matthew; Szaflarska, Anna; Sediva, Anna; Belohradsky, Bernd H.; Jones, Alison; Baumann, Ulrich; Meyts, Isabelle; Kutukculer, Necil; Wagstrom, Per; Galal, Nermeen Mouftah; Roesler, Joachim; Farmaki, Evangelia; Zinovieva, Natalia; Ciznar, Peter; Papadopoulou-Alataki, Efimia; Bienemann, Kirsten; Velbri, Sirje; Panahloo, Zoya; Grimbacher, Bodo",null,"CEREDIH; Dutch WID; European Soc Immunodeficiencies","Clinical picture and treatment of 2212 patients with common variable immunodeficiency","JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Common variable immunodeficiency; immunoglobulin replacement; patient self-reported outcomes; quality of life; primary antibody deficiency; autoimmunity; enteropathy; granulomas; lymphadenopathy; treatment","INTRAVENOUS IMMUNOGLOBULIN; B-CELL; INFECTIONS; DEFICIENCY; DISEASE; HYPOGAMMAGLOBULINEMIA; PHENOTYPES; TRIAL; IGM","Background: Common variable immunodeficiency (CVID) is an antibody deficiency with an equal sex distribution and a high variability in clinical presentation. The main features include respiratory tract infections and their associated complications, enteropathy, autoimmunity, and lymphoproliferative disorders. Objective: This study analyzes the clinical presentation, association between clinical features, and differences and effects of immunoglobulin treatment in Europe. Methods: Data on 2212 patients with CVID from 28 medical centers contributing to the European Society for Immunodeficiencies Database were analyzed retrospectively. Results: Early disease onset (< 10 years) was very frequent in our cohort (33.7%), especially in male subjects (39.8%). Male subjects with early-onset CVID were more prone to pneumonia and less prone to other complications suggesting a distinct disease entity. The diagnostic delay of CVID ranges between 4 and 5 years in many countries and is particularly high in subjects with early-onset CVID. Enteropathy, autoimmunity, granulomas, and splenomegaly formed a set of interrelated features, whereas bronchiectasis was not associated with any other clinical feature. Patient survival in this cohort was associated with age at onset and age at diagnosis only. There were different treatment strategies in Europe, with considerable differences in immunoglobulin dosing, ranging from 130 up to 750 mg/kg/mo. Patients with very low trough levels of less than 4 g/L had poor clinical outcomes, whereas higher trough levels were associated with a reduced frequency of serious bacterial infections. Conclusion: Patients with CVID are being managed differently throughout Europe, affecting various outcome measures. Clinically, CVID is a truly variable antibody deficiency syndrome.","[Gathmann, Benjamin; Warnatz, Klaus; Schulze, Ilka; Kindle, Gerhard; Grimbacher, Bodo] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, D-79108 Freiburg, Germany; [Gathmann, Benjamin; Warnatz, Klaus; Schulze, Ilka; Kindle, Gerhard; Grimbacher, Bodo] Univ Freiburg, D-79106 Freiburg, Germany; [Mahlaoui, Nizar] Hop Univ Necker Enfants Malad, AP HP, Serv Immunohematol Pediat, Paris, France; [Mahlaoui, Nizar] Hop Univ Necker Enfants Malad, AP HP, CEREDIH, Ctr Reference Deficits Immunitaires Hereditaires, Paris, France; [Mahlaoui, Nizar] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Gerard, Laurence; Oksenhendler, Eric] Hop St Louis, AP HP, Dept Clin Immunol, Paris, France; [Gerard, Laurence; Oksenhendler, Eric] Univ Paris Diderot, Sorbonne Paris Cite, EA3963, Paris, France; [Gerard, Laurence; Oksenhendler, Eric] CEREDIH, Paris, France; [Kuijpers, Taco W.] Dutch Working Party Immunodeficiencies WID, Amsterdam, Netherlands; [van Beem, Rachel T.] Sanquin Blood Supply Fdn, Dept Med, Amsterdam, Netherlands; [Guzman, David; Workman, Sarita; Grimbacher, Bodo] UCL Med Sch Royal Free Campus, London, England; [Guzman, David; Workman, Sarita; Grimbacher, Bodo] Royal Free Hosp NHS Fdn, London, England; [Soler-Palacin, Pere] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Vall dHebron Res Inst, Pediat Infect Dis & Immunodeficiencies Unit, E-08193 Barcelona, Spain; [De Gracia, Javier] UAB, Hosp Univ Vall dHebron, CIBER Enfermedades Resp CIBERES, Dept Pneumol, Barcelona, Spain; [Witte, Torsten; Schmidt, Reinhold E.] Hannover Med Sch, Clin Immunol & Rheumatol, Hannover, Germany; [Litzman, Jiri] Masaryk Univ, Fac Med, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Litzman, Jiri; Hlavackova, Eva] St Annes Univ Hosp, Brno, Czech Republic; [Thon, Vojtech] Masaryk Univ, Fac Med, Dept Clin Immunol & Allergy, Brno, Czech Republic; [Borte, Michael; Borte, Stephan] Univ Leipzig, Acad Teaching Hosp, Municipal Hosp St Georg, Childrens Hosp, Leipzig, Germany; [Kumararatne, Dinakantha] Cambridge Univ Hosp NHS Fdn Trust, Dept Clin Biochem & Immunol, Cambridge, England; [Feighery, Conleth] St Jamess Hosp Dublin, Dept Immunol, Dublin, Ireland; [Feighery, Conleth] Trinity Coll Dublin, Dublin, Ireland; [Longhurst, Hilary] Barts Hlth NHS Trust, Dept Immunol, London, England; [Helbert, Matthew] Cent Manchester & Manchester Childrens Univ Hosp, Manchester, Lancs, England; [Szaflarska, Anna] Children Univ Hosp, Krakow, Poland; [Sediva, Anna] Charles Univ Prague, Sch Med 2, Dept Immunol, Prague, Czech Republic; [Sediva, Anna] Univ Hosp Motol, Prague, Czech Republic; [Belohradsky, Bernd H.] Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; [Jones, Alison] Great Ormond St Hosp Sick Children, Inst Child Hlth, London WC1N 3JH, England; [Baumann, Ulrich] Hannover Med Sch, Immunol Unit, Hannover, Germany; [Meyts, Isabelle] Univ Hosp Gasthuisberg, Dept Pediat, Leuven, Belgium; [Kutukculer, Necil] Ege Univ, Fac Med, Dept Pediat Immunol, Izmir, Turkey; [Wagstrom, Per] Cty Hosp Ryhov Jonkoping, Dept Infect Dis, Jonkoping, Sweden; [Galal, Nermeen Mouftah] Cairo Univ, Cairo, Egypt; [Roesler, Joachim] Univ Hosp Dresden, Dept Pediat, Dresden, Germany; [Farmaki, Evangelia] Aristotle Univ Thessaloniki, Ippokrat Hosp, Dept Pediat 1, Pediat Immunol & Rheumatol Referral Ctr, GR-54006 Thessaloniki, Greece; [Zinovieva, Natalia] Res & Clin Ctr Pediat Hematol, Moscow, Russia; [Ciznar, Peter] Comenius Univ, Fac Med, Dept Pediat 1, Bratislava, Slovakia; [Ciznar, Peter] Children Univ Hosp, Bratislava, Slovakia; [Papadopoulou-Alataki, Efimia] Aristotle Univ Thessaloniki, Dept Pediat 4, Papageorgiou Hosp, GR-54006 Thessaloniki, Greece; [Bienemann, Kirsten] Univ Dusseldorf, Fac Med, Dusseldorf, Germany; [Velbri, Sirje] Tallinn Childrens Hosp, Tallinn, Estonia; [Panahloo, Zoya] CSL Behring, Dept Med Sci, Haywards Heath, W Sussex, England; [Borte, Stephan] Univ Leipzig, Translat Ctr Regenerat Med, D-04109 Leipzig, Germany","Grimbacher, B (reprint author), Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Engesserstr 4, D-79108 Freiburg, Germany.","bodo.grimbacher@uniklinik-freiburg.de","Soler-Palacin, Pere/N-2373-2014","Soler-Palacin, Pere/0000-0002-0346-5570","PPTA Europe; CSL Behring UK; German Federal Ministry of Education and Research [BMBF 01 EO 0803, BMBF 1315883]; DZIF project [TTU 04.802]; EU [HEALTH-F2-2008-201549]; German BMBF [01GM0896]; National Institute of Health Research of the UK, Cambridge Biomedical Centre; Great Ormond Street Hospital Children's Charity; Jeffrey Modell Foundation; Sanquin Blood Supply Foundation, Amsterdam, The Netherlands; French Ministry of Health; French association of patients with PID (IRIS); LFB; Baxter Biosciences; CSL Behring; Octapharma; Pfizer; Orphan Europe; Binding Site;  [DZIF TTU-IICH 07.801]","The European Society for Immunodeficiencies Database is sponsored by PPTA Europe (http://www.pptaglobal.org). CSL Behring UK provided support for this study by financing the statistical evaluation at Meridian HealthComms. This study was supported by the German Federal Ministry of Education and Research (BMBF 01 EO 0803) and the DZIF project TTU 04.802. Finally, the study was supported by EU grant HEALTH-F2-2008-201549 (EURO-PADnet). Sabine El-Helou entered data in some of the German centers. Her position was funded by German BMBF grant 01GM0896 (PID-NET). D. K. (Cambridge) was supported by National Institute of Health Research of the UK, Cambridge Biomedical Centre. Great Ormond Street Hospital Children's Charity part funded the post of Zoe Allwood's, who entered data at Great Ormond Street Hospital. S. B. was supported by funds from the German Federal Ministry of Education and Research (BMBF 1315883). T. W. and R. E. S. were funded by grant DZIF TTU-IICH 07.801: Genetic susceptibility and biomarkers of infection control. P. C. thanks the Jeffrey Modell Foundation for financial grant for support of the PID Register and Slovak National PID Database. The Dutch National Registry is supported by an unrestricted grant from Sanquin Blood Supply Foundation, Amsterdam, The Netherlands. CEREDIH is funded by the French Ministry of Health, and had received additional support from the French association of patients with PID (IRIS). CEREDIH receives educational grants from LFB, Baxter Biosciences, CSL Behring, Octapharma, Pfizer, Orphan Europe, and the Binding Site.",null,22,3,3,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0091-6749","1097-6825",null,"J ALLERGY CLIN IMMUN","J. Allergy Clin. Immunol.","JUL",2014,134,1,null,null,null,null,116,"+",null,"10.1016/j.jaci.2013.12.1077",null,22,"Allergy; Immunology","Allergy; Immunology","AL2BH","WOS:000338930300016",24582312]
["J","Kracker, S; Curtis, J; Ibrahim, MAA; Sediva, A; Salisbury, J; Campr, V; Debre, M; Edgar, JDM; Imai, K; Picard, C; Casanova, JL; Fischer, A; Nejentsev, S; Durandy, A",null,null,null,"Kracker, Sven; Curtis, James; Ibrahim, Mohammad A. A.; Sediva, Anna; Salisbury, Jon; Campr, Vit; Debre, Marianne; Edgar, J. David M.; Imai, Kohsuke; Picard, Capucine; Casanova, Jean-Laurent; Fischer, Alain; Nejentsev, Sergey; Durandy, Anne",null,null,"Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase delta syndrome","JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY",null,null,"English","Letter",null,null,null,null,null,null,"MAST-CELLS; PURIFICATION; DEFICIENCY",null,"[Kracker, Sven; Fischer, Alain; Durandy, Anne] Necker Childrens Hosp, Natl Inst Hlth & Med Res, Paris, France; [Kracker, Sven; Picard, Capucine; Casanova, Jean-Laurent; Fischer, Alain; Durandy, Anne] Descartes Sorbonne Paris Cite Univ Paris, Imagine Inst, Paris, France; [Curtis, James; Nejentsev, Sergey] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England; [Ibrahim, Mohammad A. A.] Kings Coll London, Kings Hlth Partners, Kings Coll Hosp NHS Fdn Trust, Div Allergy Asthma & Lung Biol,Dept Immunol Med,S, London WC2R 2LS, England; [Sediva, Anna] Univ Hosp Motol, Inst Immunol, Prague, Czech Republic; [Salisbury, Jon] Kings Coll London, Kings Hlth Partners, Kings Coll Hosp NHS Fdn Trust, Dept Histopathol,Sch Med, London WC2R 2LS, England; [Campr, Vit] Charles Univ Prague, Fac Med 2, Dept Pathol, Prague, Czech Republic; [Campr, Vit] Motol Univ Hosp, Prague, Czech Republic; [Debre, Marianne; Picard, Capucine; Fischer, Alain; Durandy, Anne] Necker Childrens Hosp, AP HP, Dept Immunol & Hematol, Paris, France; [Edgar, J. David M.] Queens Univ Belfast, Royal Hosp, Reg Immunol Serv, Belfast, Antrim, North Ireland; [Imai, Kohsuke] Natl Def Med Coll, Dept Pediat, Saitama, Japan; [Picard, Capucine; Durandy, Anne] Necker Childrens Hosp, AP HP, Ctr Primary Immunodeficiencies CEDI, Paris, France; [Picard, Capucine; Casanova, Jean-Laurent] Necker Med Sch, Necker Branch, Lab Human Genet Infect Dis, Paris, France; [Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, New York, NY 10021 USA","Kracker, S (reprint author), Necker Childrens Hosp, Natl Inst Hlth & Med Res, Paris, France.","sn262@cam.ac.uk; anne.durandy@inserm.fr",null,null,null,null,null,14,0,0,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0091-6749","1097-6825",null,"J ALLERGY CLIN IMMUN","J. Allergy Clin. Immunol.","JUL",2014,134,1,null,null,null,null,233,236,null,"10.1016/j.jaci.2014.02.020",null,8,"Allergy; Immunology","Allergy; Immunology","AL2BH","WOS:000338930300034",24698326]
["J","Kristofikova, Z; Ricny, J; Kolarova, M; Vyhnalek, M; Hort, J; Laczo, J; Sirova, J; Ripova, D",null,null,null,"Kristofikova, Zdena; Ricny, Jan; Kolarova, Michaela; Vyhnalek, Martin; Hort, Jakub; Laczo, Jan; Sirova, Jana; Ripova, Daniela",null,null,"Interactions between Amyloid-beta and Tau in Cerebrospinal Fluid of People with Mild Cognitive Impairment and Alzheimer's Disease","JOURNAL OF ALZHEIMERS DISEASE",null,null,"English","Article",null,null,null,null,null,"Amyloid-beta peptides; biomarker; cerebrospinal fluid; interactions; tau protein","APOLIPOPROTEIN-E EPSILON-4; A-BETA; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; PROTEIN; PEPTIDE; CSF; AGGREGATION; DEMENTIA","Background: Despite the physiological sequestration of amyloid-beta (A beta) peptides by various carriers, interactions between peptides and protein tau appear to be pathological and involved in the development of Alzheimer's disease (AD). A recent study reported increased A beta-tau interactions in the neurons of AD patients. Objective: We investigated the possibility that levels of A beta-tau complexes in cerebrospinal fluid could be a prospective biomarker of AD, with greater sensitivity and specificity than A beta(1-42), tau, or phospho-tau individually. Methods: By means of ELISA, we estimated levels of the complexes in 161 people (non-demented controls, people with mild cognitive impairment (MCI), probable AD or other types of dementia). Results: We found significant reductions in levels in people with MCI due to AD (down to 84.5%) or with AD (down to 80.5%) but not in other types of dementia. The sensitivity of the new biomarker to AD was 68.6%, the specificity 73.3% (compared to controls) or 59.1-66.1% (compared to other types of dementia). No significant correlations were observed between the complexes and the remaining biomarkers or between those and Mini-Mental State Examination score. Conclusion: We suppose that attenuated levels of complexes in cerebrospinal fluid reflect the accumulation of A beta bound to tau in AD neurons and that changes start many years before symptom onset, analogously to those in A beta(1-42), tau, or phospho-tau. Unfortunately, these complexes are not a significantly better biomarker of AD than current biomarkers.","[Kristofikova, Zdena; Ricny, Jan; Kolarova, Michaela; Sirova, Jana; Ripova, Daniela] Prague Psychiat Ctr, Prague 18103 8, Bohnice, Czech Republic; [Vyhnalek, Martin; Hort, Jakub; Laczo, Jan] Charles Univ Prague, Dept Neurol, Fac Med 2, Memory Disorders Clin, Prague, Czech Republic; [Vyhnalek, Martin; Hort, Jakub; Laczo, Jan] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic","Kristofikova, Z (reprint author), Prague Psychiat Ctr, Alzheimer Dis Ctr, Ustavni 91, Prague 18103 8, Bohnice, Czech Republic.","kristofikova@pcp.lf3.cuni.cz",null,null,"IGA MHCR [NT/11225-4]; MH CZ - DRO [00023752]","This study was supported by the IGA MHCR (NT/11225-4) and MH CZ - DRO (PCP, 00023752) projects.",null,40,0,0,"IOS PRESS","AMSTERDAM","NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS","1387-2877","1875-8908",null,"J ALZHEIMERS DIS","J. Alzheimers Dis.",null,2014,42,null,null,3,null,null,"S91","S98",null,"10.3233/JAD-132393",null,8,"Neurosciences","Neurosciences & Neurology","AO8HT","WOS:000341595800011",24670397]
["J","Vyhnalek, M; Nikolai, T; Andel, R; Nedelska, Z; Rubinova, E; Markova, H; Laczo, J; Bezdicek, O; Sheardova, K; Hort, J",null,null,null,"Vyhnalek, Martin; Nikolai, Tomas; Andel, Ross; Nedelska, Zuzana; Rubinova, Eva; Markova, Hana; Laczo, Jan; Bezdicek, Ondrej; Sheardova, Katerina; Hort, Jakub",null,null,"Neuropsychological Correlates of Hippocampal Atrophy in Memory Testing in Nondemented Older Adults","JOURNAL OF ALZHEIMERS DISEASE",null,null,"English","Article",null,null,null,null,null,"Amnestic mild cognitive impairment; episodic memory; hippocampus; MRI","MILD COGNITIVE IMPAIRMENT; PRECLINICAL ALZHEIMERS-DISEASE; ENCODING SPECIFICITY; DEPRESSIVE SYMPTOMS; AMNESTIC SYNDROME; EPISODIC MEMORY; VOLUMETRIC MRI; DEMENTIA; DIAGNOSIS; AD","Background and Objective: Cognitive deficits in older adults attributable to Alzheimer's disease (AD) pathology are featured early on by hippocampal impairment. Among tests used to evaluate memory, verbal memory tests with controlled encoding and cued recall are believed to be specific for hippocampal impairment. The objective of this study was to assess the relation between left and right hippocampal volumes and several frequently used memory tests. Methods: Fifty six nondemented older adults (30 with amnestic mild cognitive impairment and 26 cognitively healthy older adults) underwent neuropsychological testing including: 1) The Enhanced Cued Recall test (ECR), a memory test with controlled encoding and recall; 2) the Auditory Verbal Learning Test (AVLT), a verbal memory test without controlled encoding and with delayed recall; and 3) The Rey-Osterrieth Complex Figure test (ROCF), a visuospatial memory test-recall condition. 1.5T brain MRI scans were used to measure estimated total intracranial volume (eTIV) along with hippocampal right and left volumes, which were measured with quantitative volumetry using FreeSurfer package (version 4.4.0). Spearman partial correlation controlled for age was used to correct for non-normal score distribution and effect of age. Results: We found moderate correlations of hippocampal volumes with AVLT 1-5 scores, AVLT delayed recall, ECR free and total recall, and ROCF reproduction. Total recall in ECR using cued recall was not superior to any of the free recall tests. No correlation in any memory test was achieved with eTIV. Conclusion: Verbal memory tests, either with controlled encoding and cued delayed recall (ECR), or without it (AVLT), as well as nonverbal memory test with delayed recall (ROCF), equally reflect hippocampal atrophy in nondemented older adults.","[Vyhnalek, Martin; Nikolai, Tomas; Andel, Ross; Nedelska, Zuzana; Rubinova, Eva; Laczo, Jan; Sheardova, Katerina; Hort, Jakub] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Vyhnalek, Martin; Nikolai, Tomas; Nedelska, Zuzana; Laczo, Jan; Hort, Jakub] Charles Univ Prague, Memory Clin, Dept Neurol, Fac Med 2, Prague 15006 5, Czech Republic; [Vyhnalek, Martin; Nikolai, Tomas; Nedelska, Zuzana; Markova, Hana; Laczo, Jan; Hort, Jakub] Motol Univ Hosp, Prague, Czech Republic; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Bezdicek, Ondrej] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague 15006 5, Czech Republic; [Bezdicek, Ondrej] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague 15006 5, Czech Republic; [Bezdicek, Ondrej] Charles Univ Prague, Gen Univ Hosp Prague, Prague 15006 5, Czech Republic","Vyhnalek, M (reprint author), Charles Univ Prague, Memory Clin, Dept Neurol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","martin.vyhnalek@fnmotol.cz",null,null,"European Regional Development Fund [CZ.1.05/1.1.00/02.0123]; European Social Fund [CZ.1.07/2.3.00/20.0117]; Czech Ministry of Health [IGA NT 11225-4]; MH CZ - DRO; University Hospital Motol, Prague, Czech Republic [00064203]; Grant Agency of Charles University in Prague [624012]; National Center for Advancing Translational Sciences [UL1 TR000135]","Supported by the project FNUSA-ICRC (no. CZ.1.05/1.1.00/02.0123) from the European Regional Development Fund, by European Social Fund within the project Young Talent Incubator II (reg. no. CZ.1.07/2.3.00/20.0117), by Czech Ministry of Health IGA NT 11225-4 grant, by MH CZ - DRO, University Hospital Motol, Prague, Czech Republic 00064203, by Grant Agency of Charles University in Prague, Grant Number 624012 and by CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences.",null,67,0,0,"IOS PRESS","AMSTERDAM","NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS","1387-2877","1875-8908",null,"J ALZHEIMERS DIS","J. Alzheimers Dis.",null,2014,42,null,null,3,null,null,"S81","S90",null,"10.3233/JAD-132642",null,10,"Neurosciences","Neurosciences & Neurology","AO8HT","WOS:000341595800010",24670399]
["J","Kopecka, M; Kosek, D; Kukacka, Z; Rezabkova, L; Man, P; Novak, P; Obsil, T; Obsilova, V",null,null,null,"Kopecka, Miroslava; Kosek, Dalibor; Kukacka, Zdenek; Rezabkova, Lenka; Man, Petr; Novak, Petr; Obsil, Tomas; Obsilova, Veronika",null,null,"Role of the EF-hand-like Motif in the 14-3-3 Protein- mediated Activation of Yeast Neutral Trehalase Nth1","JOURNAL OF BIOLOGICAL CHEMISTRY",null,null,"English","Article",null,null,null,null,null,"Calcium; Enzyme Mechanisms; Mass Spectrometry (MS); Protein Cross-linking; Protein Structure; 14-3-3; Bmh; H; D Exchange; SAXS; Neutral Trehalase","SMALL-ANGLE SCATTERING; SACCHAROMYCES-CEREVISIAE; STRUCTURAL BASIS; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; GENE; PHOSPHORYLATION; 14-3-3-PROTEINS; BINDING; MACROMOLECULES","Background: The yeast neutral trehalase Nth1 is activated by the 14-3-3 protein binding. Results: The 14-3-3 protein induces a structural rearrangement of Nth1 with changes within the EF-hand like motif being essential for the activation process. Conclusion: The EF-hand-like motif-containing domain is crucial for the 14-3-3-dependent activation of Nth1. Significance: Structural basis of the mechanism of Nth1 activation. Trehalases hydrolyze the non-reducing disaccharide trehalose amassed by cells as a universal protectant and storage carbohydrate. Recently, it has been shown that the activity of neutral trehalase Nth1 from Saccharomyces cerevisiae is mediated by the 14-3-3 protein binding that modulates the structure of both the catalytic domain and the region containing the EF-hand-like motif, whose role in the activation of Nth1 is unclear. In this work, the structure of the Nth114-3-3 complex and the importance of the EF-hand-like motif were investigated using site-directed mutagenesis, hydrogen/deuterium exchange coupled to mass spectrometry, chemical cross-linking, and small angle x-ray scattering. The low resolution structural views of Nth1 alone and the Nth114-3-3 complex show that the 14-3-3 protein binding induces a significant structural rearrangement of the whole Nth1 molecule. The EF-hand-like motif-containing region forms a separate domain that interacts with both the 14-3-3 protein and the catalytic trehalase domain. The structural integrity of the EF-hand like motif is essential for the 14-3-3 protein-mediated activation of Nth1, and calcium binding, although not required for the activation, facilitates this process by affecting its structure. Our data suggest that the EF-hand like motif-containing domain functions as the intermediary through which the 14-3-3 protein modulates the function of the catalytic domain of Nth1.","[Kopecka, Miroslava; Kosek, Dalibor; Rezabkova, Lenka; Obsil, Tomas; Obsilova, Veronika] Acad Sci Czech Republic, Inst Physiol, Vvi, CR-14220 Prague, Czech Republic; [Kukacka, Zdenek; Man, Petr; Novak, Petr] Acad Sci Czech Republic, Inst Microbiol, Vvi, CR-14220 Prague, Czech Republic; [Kopecka, Miroslava] Charles Univ Prague, Fac Med 2, Prague 15006, Czech Republic; [Kosek, Dalibor; Rezabkova, Lenka; Obsil, Tomas] Charles Univ Prague, Dept Phys & Macromol Chem, Prague 12843, Czech Republic; [Kukacka, Zdenek; Man, Petr; Novak, Petr] Charles Univ Prague, Dept Biochem, Prague 12843, Czech Republic","Obsilova, V (reprint author), Acad Sci Czech Republic, Inst Physiol, Vvi, Videnska 1083, CR-14220 Prague, Czech Republic.","obsilova@biomed.cas.cz","Obsilova, Veronika/B-7116-2012; Obsil, Tomas/B-7142-2012; Man, Petr/H-2451-2014; Novak, Petr/F-9655-2014","Obsilova, Veronika/0000-0003-0851-7680; Novak, Petr/0000-0001-8688-529X","Czech Science Foundation [P207/11/0455]; Grant Agency of Charles University [644313, 800413]; Academy of Sciences of the Czech Republic Research Project of the Institute of Physiology [RVO: 67985823]; Academy of Sciences of the Czech Republic Research Project of the Institute of Microbiology [RVO: 61388971]; Academy of Sciences of the Czech Republic [OPPK CZ.2.16/3.1.00/24023]","This work was supported by Czech Science Foundation Project P207/11/0455; Grant Agency of Charles University Grants 644313 and 800413; and Academy of Sciences of the Czech Republic Research Projects RVO: 67985823 of the Institute of Physiology and RVO: 61388971 of the Institute of Microbiology. Access to MS facilities was supported by Academy of Sciences of the Czech Republic Project OPPK CZ.2.16/3.1.00/24023.",null,47,0,0,"AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA","0021-9258","1083-351X",null,"J BIOL CHEM","J. Biol. Chem.","MAY 16",2014,289,20,null,null,null,null,13948,13961,null,"10.1074/jbc.M113.544551",null,14,"Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","AH2XF","WOS:000335984600026",24713696]
["J","Klocperk, A; Grecova, J; Sismova, K; Kayserova, J; Fronkova, E; Sediva, A",null,null,null,"Klocperk, Adam; Grecova, Jarmila; Sismova, Kristyna; Kayserova, Jana; Fronkova, Eva; Sediva, Anna",null,null,"Helios Expression in T-regulatory Cells in Patients with di George Syndrome","JOURNAL OF CLINICAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"T-lymphocytes; Tregs; Immunodeficiency; Digeorge; Helios; Charge","22Q11.2 DELETION SYNDROME; DIGEORGE-SYNDROME; DISEASE; LYMPHOCYTES; CHILDREN; HUMANS; REGION","Syndrome diGeorge is associated amongst other clinical signs with various degrees of thymic dysplasia, related immunodeficiency and autoimmune disorders. Helios, a transcription factor from Ikaros family, has been proposed as a marker for thymus derived Tregs. We therefore examined Helios + Tregs in a cohort of patients with genetically proven diGeorge syndrome with typical T cell lymphopenia due to the thymic pathology. T cells, FoxP3+ Tregs and Helios + FoxP3+ Tregs were examined in 52 samples from 37 patients. One patient with diGeorge/CHARGE syndrome with total thymic aplasia was also included. Statistical analysis was performed using a linear regression comparison. Total absolute Tregs were significantly lower in diGeorge patients as compared to controls in all age groups (0-20 years) (p = 0.0016). The difference was more expressed in the first four years of age. Relative Treg numbers expressed as the percentage of Tregs in CD4+ T-cells, however, were not different in patients and controls in all age groups (p = 0.661), neither could we find any significant difference in the percentage of Helios + Tregs between patients and controls (p = 0.238). Helios + Tregs were still present in a patient with diGeorge/CHARGE syndrome with complete athymia 7 years after partially matched unrelated repeated T lymphocytes infusions. Our findings show that while there was a significant decrease in absolute numbers of Tregs in patients with diGeorge syndrome, the relative percentage of this population did not differ between patients and controls. Low absolute Tregs thus reflected typical T cells lymphopenia in patients. Helios expression was not affected in diGeorge syndrome.","[Klocperk, Adam; Grecova, Jarmila; Sismova, Kristyna; Kayserova, Jana; Fronkova, Eva; Sediva, Anna] Charles Univ Prague, Dept Immunol, Fac Med 2, Prague, Czech Republic; [Klocperk, Adam; Grecova, Jarmila; Sismova, Kristyna; Kayserova, Jana; Fronkova, Eva; Sediva, Anna] Univ Hosp Motol, Prague, Czech Republic","Klocperk, A (reprint author), Charles Univ Prague, Dept Immunol, Fac Med 2, Prague, Czech Republic.","adam.klocperk@fnmotol.cz",null,null,"Czech Ministry of Health [IGA MZ CR NT 13287-4/2012]","This research was financially supported by the IGA MZ CR NT 13287-4/2012 grant issued by the Czech Ministry of Health. We would like to thank MUDr. Tomas Kalina, PhD for valuable help with the analysis of flow-cytometric data.",null,26,0,0,"SPRINGER/PLENUM PUBLISHERS","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0271-9142","1573-2592",null,"J CLIN IMMUNOL","J. Clin. Immunol.","OCT",2014,34,7,null,null,null,null,864,870,null,"10.1007/s10875-014-0071-y",null,7,"Immunology","Immunology","AP6TZ","WOS:000342212000016",25008482]
["J","Mitrova, K; Karpisek, M; Durilova, M; Dragusin, LG; Nevoral, J; Bronsky, J",null,null,null,"Mitrova, Katarina; Karpisek, Michal; Durilova, Marianna; Dragusin, Lavinia Gabriela; Nevoral, Jiri; Bronsky, Jiri",null,null,"Development of High-Sensitive ELISA Method for Detection of Adipophilin Levels in Human Colostrum and Breast Milk","JOURNAL OF CLINICAL LABORATORY ANALYSIS",null,null,"English","Article",null,null,null,null,null,"adipophilin; ADRP; human breast milk; nutritional programming; ELISA","DIFFERENTIATION-RELATED PROTEIN; FAT GLOBULE-MEMBRANE; MAJOR PROTEINS; EXPRESSION; ACCUMULATION; ADIPONECTIN; METABOLISM; SECRETION; ALPHA; LIVER","Aim: To develop and validate high-sensitive (hs) ELISA method for detection of adipophilin (adipose differentiation-related protein, ADRP) in human breast milk (BM) and to analyze adipophilin levels in BM during 12 months of lactation. Methods: ADRP levels were determined using hsELISA method (Biovendor-Laboratory Medicine, Inc.) in colostrum (D0) and BM of 72 mothers was collected 1, 3, 6, and 12 months following delivery (M1, 3, 6, 12). Results: ADRP was detectable in BM up to 12 months of lactation. Mean levels at D0 were 1.98 +/- 0.12; M1, 2.83 +/- 0.21; M3, 2.39 +/- 0.17; M6, 2.57 +/- 0.16; and at M12 3.25 +/- 0.21 g/ml. Significantly higher levels of ADRP were found in M1 and M12 when compared to D0 and in M12 when compared to M3 (overall P = 0.0001). No significant correlation was seen between ADRP levels in BM and adiponectin, body weight of infants, their birth length, body weight gain during the first year of life, or BMI of mothers before pregnancy. Conclusions: We developed and validated hsELISA for detection of ADRP in human BM. ADRP was detectable in human BM during the whole 12 months of lactation period and its levels were intraindividually well-conserved. (C) 2014 Wiley Periodicals, Inc.","[Mitrova, Katarina; Durilova, Marianna; Nevoral, Jiri; Bronsky, Jiri] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague 15006 5, Czech Republic; [Mitrova, Katarina; Durilova, Marianna; Nevoral, Jiri; Bronsky, Jiri] Charles Univ Prague, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Karpisek, Michal] Univ Vet & Pharmaceut Sci, Fac Pharm, Dept Human Pharmacol & Toxicol, Brno, Czech Republic; [Dragusin, Lavinia Gabriela] Univ Bucharest, Fac Chem, Dept Chem Drugs & Cosmet, Bucharest, Romania; [Bronsky, Jiri] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, Prague 15006 5, Czech Republic","Bronsky, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat, V Uvalu 84, Prague 15006 5, Czech Republic.","bronsky@email.cz",null,null,"VZ MZO [64203/6001]","Grant sponsor: VZ MZO; Grant number: 64203/6001",null,27,0,0,"JOHN WILEY & SONS INC","HOBOKEN","111 RIVER ST, HOBOKEN, NJ 07030 USA","0887-8013","1098-2825",null,"J CLIN LAB ANAL","J. Clin. Lab. Anal.","JUL",2014,28,4,null,null,null,null,255,260,null,"10.1002/jcla.21675",null,6,"Medical Laboratory Technology","Medical Laboratory Technology","AM0QV","WOS:000339551900001",24577896]
["J","Grillova, L; Petrosova, H; Mikalova, L; Strnadel, R; Dastychova, E; Kuklova, I; Kojanova, M; Kreidlova, M; Vanousova, D; Hercogova, J; Prochazka, P; Zakoucka, H; Krchnakova, A; Vasku, V; Smajs, D",null,null,null,"Grillova, Linda; Petrosova, Helena; Mikalova, Lenka; Strnadel, Radim; Dastychova, Eliska; Kuklova, Ivana; Kojanova, Martina; Kreidlova, Miluse; Vanousova, Daniela; Hercogova, Jana; Prochazka, Premysl; Zakoucka, Hana; Krchnakova, Alena; Vasku, Vladimir; Smajs, David",null,null,"Molecular Typing of Treponema pallidum in the Czech Republic during 2011 to 2013: Increased Prevalence of Identified Genotypes and of Isolates with Macrolide Resistance","JOURNAL OF CLINICAL MICROBIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"23S RIBOSOMAL-RNA; AZITHROMYCIN RESISTANCE; CLINICAL ISOLATE; PRIMARY SYPHILIS; SUBSP PALLIDUM; POINT MUTATION; SAN-FRANCISCO; UNITED-STATES; STRAINS; CHINA","From January 2011 to December 2013, a total of 262 samples, from 188 patients suspected of having syphilis were tested for the presence of treponemal DNA by PCR amplification of five chromosomal loci, including the polA (TP0105), tmpC (TP0319), TP0136, TP0548, and 23S rRNA genes. Altogether, 146 samples from 103 patients were PCR positive for treponemal DNA. A set of 81 samples from 62 PCR-positive patients were typeable, and among them, nine different genotypes were identified. Compared to a previous study in the Czech Republic during 2004 to 2010, the number of genotypes detected among syphilis patients in a particular year increased to six in both 2012 and 2013, although they were not the same six. The proportion of macrolide-resistant clinical isolates in this 3-year study was 66.7%.","[Grillova, Linda; Petrosova, Helena; Mikalova, Lenka; Smajs, David] Masaryk Univ, Fac Med, Dept Biol, Brno, Czech Republic; [Strnadel, Radim; Dastychova, Eliska; Vasku, Vladimir] St Annes Fac Hosp Brno, Dept Dermatovenereol, Brno, Czech Republic; [Kuklova, Ivana; Kojanova, Martina] Charles Univ Prague, Dept Dermatol, Fac Med 1, Prague, Czech Republic; [Kreidlova, Miluse] Charles Univ Prague, Gen Univ Hosp, Inst Med Biochem & Lab Diagnost, Prague, Czech Republic; [Kreidlova, Miluse] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Vanousova, Daniela; Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatovenereol, Prague, Czech Republic; [Prochazka, Premysl] Outpatient STI Clin Medictr, Prague, Czech Republic; [Zakoucka, Hana] Natl Inst Publ Hlth, Natl Reference Lab Diagnost Syphilis, Prague, Czech Republic; [Krchnakova, Alena] St Annes Hosp, Fac Med, Dept Med Microbiol, Brno, Czech Republic; [Krchnakova, Alena] Masaryk Univ, Brno, Czech Republic","Smajs, D (reprint author), Masaryk Univ, Fac Med, Dept Biol, Brno, Czech Republic.","dsmajs@med.muni.cz",null,null,"Ministry of Health of the Czech Republic [NT11159-5/2010]; Grant Agency of the Czech Republic [310/07/0321]","This work was supported by the Ministry of Health of the Czech Republic (NT11159-5/2010 to D. S.) and the Grant Agency of the Czech Republic (310/07/0321 to D. S.).",null,36,0,0,"AMER SOC MICROBIOLOGY","WASHINGTON","1752 N ST NW, WASHINGTON, DC 20036-2904 USA","0095-1137","1098-660X",null,"J CLIN MICROBIOL","J. Clin. Microbiol.","OCT",2014,52,10,null,null,null,null,3693,3700,null,"10.1128/JCM.01292-14",null,8,"Microbiology","Microbiology","AP9AX","WOS:000342371700024",25100820]
["J","Viprey, VF; Gregory, WM; Corrias, MV; Tchirkov, A; Swerts, K; Vicha, A; Dallorso, S; Brock, P; Luksch, R; Valteau-Couanet, D; Papadakis, V; Laureys, G; Pearson, AD; Ladenstein, R; Burchill, SA",null,null,null,"Viprey, Virginie F.; Gregory, Walter M.; Corrias, Maria V.; Tchirkov, Andrei; Swerts, Katrien; Vicha, Ales; Dallorso, Sandro; Brock, Penelope; Luksch, Roberto; Valteau-Couanet, Dominique; Papadakis, Vassilios; Laureys, Genevieve; Pearson, Andrew D.; Ladenstein, Ruth; Burchill, Susan A.",null,null,"Neuroblastoma mRNAs Predict Outcome in Children With Stage 4 Neuroblastoma: AEuropean HR-NBL1/SIOPEN Study","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"MINIMAL RESIDUAL DISEASE; HIGH-RISK NEUROBLASTOMA; TIME RT-PCR; BONE-MARROW; TYROSINE-HYDROXYLASE; QRT-PCR; PROGNOSTIC INDICATOR; MOLECULAR-DETECTION; RANDOMIZED-TRIAL; ONCOLOGY GROUP","Purpose To evaluate the hypothesis that detection of neuroblastoma mRNAs by reverse transcriptase quantitative polymerase chain reaction (RTqPCR) in peripheral blood (PB) and bone marrow aspirates (BM) from children with stage 4 neuroblastoma are clinically useful biomarkers of risk. Methods RTqPCR for paired-like homeobox 2b (PHOX2B), tyrosine hydroxylase (TH), and doublecortin (DCX) mRNA in PB and BM of children enrolled onto the High-Risk Neuroblastoma Trial-1 of the European Society of Pediatric Oncology Neuroblastoma Group (HR-NBL1/SIOPEN) was performed at diagnosis and after induction therapy. Results High levels of TH, PHOX2B, or DCX mRNA in PB or BM at diagnosis strongly predicted for worse event-free survival (EFS) and overall survival (OS) in a cohort of 290 children. After induction therapy, high levels of these mRNAs predicted worse EFS and OS in BM but not in PB. Combinations of mRNAs in BM did not add to the predictive power of any single mRNA. However, in the original (n = 182) and validation (n = 137) PB cohorts, high TH (log(10)TH > 0.8) or high PHOX2B (log(10)PHOX2B > 0.28) identify 19% of children as ultrahigh risk, with 5-year EFS and OS rates of 0%; OS rate was 25% (95% CI, 16% to 36%) and EFS rate was 38% (95% CI, 28% to 49%) in the remaining children. The magnitude of reduction in mRNA level between diagnosis and postinduction therapy in BM or PB was not of additional predictive value. Conclusion High levels of TH and PHOX2B mRNA in PB at diagnosis objectively identify children with ultrahigh-risk disease who may benefit from novel treatment approaches. The level of TH, PHOX2B, and DCX mRNA in BM and/or PB at diagnosis might contribute to an algorithm to improve stratification of children for treatment.","[Viprey, Virginie F.; Burchill, Susan A.] Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England; [Gregory, Walter M.] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England; [Brock, Penelope] Great Ormond St Hosp Sick Children, London, England; [Pearson, Andrew D.] Royal Marsden Natl Hlth Serv Fdn Trust, Inst Canc Res, Sutton, Surrey, England; [Corrias, Maria V.; Dallorso, Sandro] Gaslini Inst, Genoa, Italy; [Luksch, Roberto] Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, I-20133 Milan, Italy; [Tchirkov, Andrei] Univ Auvergne, Ctr Hosp Univ Clermont Ferrand, Clermont Ferrand, France; [Tchirkov, Andrei] Univ Auvergne, Clermont Univ, Clermont Ferrand, France; [Valteau-Couanet, Dominique] Inst Gustave Roussy, Villejuif, France; [Swerts, Katrien; Laureys, Genevieve] Univ Hosp Ghent, Ghent, Belgium; [Vicha, Ales] Charles Univ Prague, Prague, Czech Republic; [Vicha, Ales] Univ Hosp Motol, Prague, Czech Republic; [Papadakis, Vassilios] Agia Sofia Childrens Hosp, Athens, Greece; [Ladenstein, Ruth] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria","Burchill, SA (reprint author), St James Univ Hosp, Childrens Canc Res Grp, Leeds Inst Canc & Pathol, Beckett St, Leeds LS9 7TF, W Yorkshire, England.","s.a.burchill@leeds.ac.uk","Corrias, Maria/E-4571-2011",null,null,null,null,34,0,0,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X","1527-7755",null,"J CLIN ONCOL","J. Clin. Oncol.","APR 1",2014,32,10,null,null,null,null,1074,"+",null,"10.1200/JCO.2013.53.3604",null,11,"Oncology","Oncology","AG0XF","WOS:000335138400017",24590653]
["J","Conway, S; Balfour-Lynn, IM; De Rijcke, K; Drevinek, P; Foweraker, J; Havermans, T; Heijerman, H; Lannefors, L; Lindblad, A; Macek, M; Madge, S; Moran, M; Morrison, L; Morton, A; Noordhoek, J; Sands, D; Vertommen, A; Peckham, D",null,null,null,"Conway, Steven; Balfour-Lynn, Ian M.; De Rijcke, Karleen; Drevinek, Pavel; Foweraker, Juliet; Havermans, Trudy; Heijerman, Harry; Lannefors, Louise; Lindblad, Anders; Macek, Milan; Madge, Sue; Moran, Maeve; Morrison, Lisa; Morton, Alison; Noordhoek, Jacquelien; Sands, Dorota; Vertommen, Anneke; Peckham, Daniel",null,null,"European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Review",null,null,null,null,null,"CF Centre; Multidisciplinary team; Continuing professional development","CHEST PHYSIOTHERAPY; TRANSITION PROGRAMS; LUNG-FUNCTION; LIFE CARE; CHILDREN; ADULTS; RECOMMENDATIONS; EXERCISE; MICROBIOLOGY; INCONTINENCE","A significant increase in life expectancy in successive birth cohorts of people with cystic fibrosis (CF) is a result of more effective treatment for the disease. It is also now widely recognized that outcomes for patients cared for in specialist CF Centres are better than for those who are not. Key to the effectiveness of the specialist CF Centre is the multidisciplinary team (MDT), which should include consultants, clinical nurse specialist, microbiologist, physiotherapist, dietitian, pharmacist, clinical psychologist, social worker, clinical geneticist and allied healthcare professionals, all of whom should be experienced in CF care. Members of the MDT are also expected to keep up to date with developments in CF through continued professional development, attendance at conferences, auditing and involvement in research. Specialists CF Centres should also network with other Centres both nationally and internationally, and feed Centre data to registries in order to further the understanding of the disease. This paper provides a framework for the specialist CF Centre, including the organisation of the Centre and the individual roles of MDT members, as well as highlighting the value of CF organisations and disease registries. (C) 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Conway, Steven] Leeds Teaching Hosp Trust, Paediat Unit, Leeds, W Yorkshire, England; [Conway, Steven] Leeds Teaching Hosp Trust, Adult CF Unit, Leeds, W Yorkshire, England; [Balfour-Lynn, Ian M.] Royal Brompton Hosp, London SW3 6LY, England; [Drevinek, Pavel] Charles Univ Prague, Fac Med 2, Dept Med Microbiol, Prague, Czech Republic; [Drevinek, Pavel] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Drevinek, Pavel] Univ Hosp Motol, Prague, Czech Republic; [Foweraker, Juliet] Papworth Hosp NHS Fdn Trust, Dept Microbiol, Cambridge, England; [Havermans, Trudy] Univ Hosp Leuven, Cyst Fibrosis Ctr, Leuven, Belgium; [Heijerman, Harry] HagaZiekenhuis, Dept Pulmonol & Cyst Fibrosis, The Hague, Netherlands; [Lannefors, Louise] Univ Copenhagen Hosp, Rigshosp, Copenhagen CF Ctr, DK-2100 Copenhagen, Denmark; [Lindblad, Anders] Queen Silvia Childrens Hosp, Gothenburg CF Ctr, Gothenburg, Sweden; [Macek, Milan] Univ Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Macek, Milan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Madge, Sue] Royal Brompton Hosp, Dept Resp Med, London SW3 6LY, England; [Moran, Maeve] St Vincents Univ Hosp, Dept Pharm, Natl Referral Ctr Adult Cyst Fibrosis, Dublin, Ireland; [Morrison, Lisa] Gartnavel Royal Hosp, West Scotland Adult CF Unit, Glasgow, Lanark, Scotland; [Morton, Alison] St James Hosp, Adult Cyst Fibrosis Unit, Leeds, W Yorkshire, England; [Sands, Dorota] Inst Mother & Child Hlth, Dept Pediat, Warsaw, Poland; [Vertommen, Anneke] Univ Hosp Leuven, Cyst Fibrosis Ctr, Leuven, Belgium; [Peckham, Daniel] St James Hosp, Adult Cyst Fibrosis Unit, Leeds, W Yorkshire, England","Conway, S (reprint author), Leeds Teaching Hosp Trust, Paediat Unit, Leeds, W Yorkshire, England.","steven.conway@doctors.net.uk",null,null,"Vertex","S. Conway, K. De Rijcke, P. Drevinek, J. Foweraker, T. Havermans, H. Heijerman, L. Lannefors, A. Lindblad, M. Macek, S. Madge, M. Moran, L. Morrison, A. Morton, J. Noordhoek, D. Sands, A. Vertommen, and D. Peckham have no conflicts of interest to report. I. M. Balfour-Lynn declares personal fees from Vertex, outside the submitted work.",null,85,2,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993","1873-5010",null,"J CYST FIBROS","J. Cyst. Fibros","MAY",2014,13,null,null,1,null,null,"S3","S22",null,"10.1016/j.jcf.2014.03.009",null,20,"Respiratory System","Respiratory System","AL0JV","WOS:000338814100002",24856776]
["J","Kolostova, K; Zhang, Y; Hoffman, RM; Bobek, V",null,null,null,"Kolostova, Katarina; Zhang, Yong; Hoffman, Robert M.; Bobek, Vladimir",null,null,"In Vitro Culture and Characterization of Human Lung Cancer Circulating Tumor Cells Isolated by Size Exclusion from an Orthotopic Nude-Mouse Model Expressing Fluorescent Protein","JOURNAL OF FLUORESCENCE",null,null,"English","Article",null,null,null,null,null,"Lung cancer; Orthotopic; Circulating tumor cells; CTC; In vitro culture; CTC; MetaCell; Filtration; Size; Fluorescence; RFP","METASTASIS; IMPACT","In the present study, we demonstrate an animal model and recently introduced size-based exclusion method for circulating tumor cells (CTCs) isolation. The methodology enables subsequent in vitro CTC-culture and characterization. Human lung cancer cell line H460, expressing red fluorescent protein (H460-RFP), was orthotopically implanted in nude mice. CTCs were isolated by a size-based filtration method and successfully cultured in vitro on the separating membrane (MetaCellA (R)), analyzed by means of time-lapse imaging. The cultured CTCs were heterogeneous in size and morphology even though they originated from a single tumor. The outer CTC-membranes were blebbing in general. Abnormal mitosis resulting in three daughter cells was frequently observed. The expression of RFP ensured that the CTCs originated from lung tumor. These readily isolatable, identifiable and cultivable CTCs can be used to characterize individual patient cancers and for screening of more effective treatment.","[Kolostova, Katarina; Bobek, Vladimir] Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Prague 10034, Czech Republic; [Zhang, Yong; Hoffman, Robert M.] AntiCancer Inc, San Diego, CA USA; [Hoffman, Robert M.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Bobek, Vladimir] Charles Univ Prague, Fac Med 1, Dept Surg 3, Prague, Czech Republic; [Bobek, Vladimir] Univ Hosp Motol, Prague, Czech Republic; [Bobek, Vladimir] Wroclaw Med Univ, Dept Histol & Embryol, Wroclaw, Poland","Bobek, V (reprint author), Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Srobarova 50, Prague 10034, Czech Republic.","vbobek@centrum.cz",null,null,"University Hospital Motol, Prague Czech Republic [000 64203]; Charles University in Prague [P 27/2012]","Supported by the research project conceptual development of research organization, University Hospital Motol, Prague Czech Republic, 000 64203 and Research project P 27/2012 awarded by Charles University in Prague",null,16,0,0,"SPRINGER/PLENUM PUBLISHERS","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1053-0509","1573-4994",null,"J FLUORESC","J. Fluoresc.","SEP",2014,24,5,null,null,null,null,1531,1536,null,"10.1007/s10895-014-1439-3",null,6,"Biochemical Research Methods; Chemistry, Analytical","Biochemistry & Molecular Biology; Chemistry","AP4QV","WOS:000342064100020",25141982]
["J","Lassuthova, P; Zaliova, M; Inoue, K; Haberlova, J; Sixtova, K; Sakmaryova, I; Paderova, K; Mazanec, R; Zamecnik, J; Siskova, D; Garbern, J; Seeman, P",null,null,null,"Lassuthova, Petra; Zaliova, Marketa; Inoue, Ken; Haberlova, Jana; Sixtova, Klara; Sakmaryova, Iva; Paderova, Katerina; Mazanec, Radim; Zamecnik, Josef; Siskova, Dana; Garbern, Jim; Seeman, Pavel",null,null,"Three New PLP1 Splicing Mutations Demonstrate Pathogenic and Phenotypic Diversity of Pelizaeus-Merzbacher Disease","JOURNAL OF CHILD NEUROLOGY",null,null,"English","Article",null,null,null,null,null,"Pelizaeus-Merzbacher disease; PLP1; splice-site mutations","PROTEOLIPID PROTEIN GENE; NERVOUS-SYSTEM; INFORMATION-THEORY; MYELIN; DM-20; DELETION; EXPRESSION; MOUSE; CELLS; NEUROPATHY","Pelizaeus-Merzbacher disease is a severe X-linked disorder of central myelination caused by mutations affecting the proteolipid protein gene. We describe 3 new PLP1 splicing mutations, their effect on splicing and associated phenotypes. Mutation c. 453_453+6del7insA affects the exon 3B donor splice site and disrupts the PLP1-transcript without affecting the DM20, was found in a patient with severe Pelizaeus-Merzbacher disease and in his female cousin with early-onset spastic paraparesis. Mutation c.191+1G>Acauses exon 2 skipping with a frame shift, is expected to result in a functionally null allele, and was found in a patient with mild Pelizaeus-Merzbacher disease and in his aunt with late-onset spastic paraparesis. Mutation c.696+1G>Autilizes a cryptic splice site in exon 5, causes partial exon 5 skipping and in-frame deletion, and was found in an isolated patient with a severe classical Pelizaeus-Merzbacher. PLP1 splice-site mutations express a variety of disease phenotypes mediated by different molecular pathogenic mechanisms.","[Lassuthova, Petra; Haberlova, Jana; Sakmaryova, Iva; Paderova, Katerina; Seeman, Pavel] Charles Univ Prague, Fac Med 2, Dept Paediat Neurol, Prague, Czech Republic; [Lassuthova, Petra; Zaliova, Marketa; Haberlova, Jana; Sakmaryova, Iva; Paderova, Katerina; Mazanec, Radim; Zamecnik, Josef; Seeman, Pavel] Univ Hosp Motol, Prague, Czech Republic; [Zaliova, Marketa] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Inoue, Ken] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan; [Sixtova, Klara; Siskova, Dana] Thomayers Hosp, Dept Paediat Neurol, Prague, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Garbern, Jim] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; [Garbern, Jim] Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI USA","Lassuthova, P (reprint author), Charles Univ Prague, V Uvalu 84, Prague, Czech Republic.","petra.lassuthova@gmail.com",null,null,"IGA MH CR NT [11521-4]; MH CZ-DRO, University Hospital Motol, Prague, Czech Republic [00064203]","The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by IGA MH CR NT 11521-4 and by MH CZ-DRO, University Hospital Motol, Prague, Czech Republic (00064203).",null,36,1,1,"SAGE PUBLICATIONS INC","THOUSAND OAKS","2455 TELLER RD, THOUSAND OAKS, CA 91320 USA","0883-0738","1708-8283",null,"J CHILD NEUROL","J. Child Neurol.","JUL",2014,29,7,null,null,null,null,924,931,null,"10.1177/0883073813492387",null,8,"Clinical Neurology; Pediatrics","Neurosciences & Neurology; Pediatrics","AM8ZY","WOS:000340170000007"]
["J","Ulmannova, T; Bartaskova, D; Spalova, I; Zoban, P; Vesely, Z; Stechova, K",null,null,null,"Ulmannova, Tereza; Bartaskova, Dagmar; Spalova, Ivana; Zoban, Petr; Vesely, Zdenek; Stechova, Katerina",null,null,"Maternal BMI and HDL as predictors of pregnancy outcome in women with type 1 diabetes","JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE",null,null,"English","Article",null,null,null,null,null,"BMI; HDL; preeclampsia; pregnancy outcome; type 1 diabetes","OBESITY; MACROSOMIA; SIZE","Objective: Diabetes in pregnancy is associated with increased risks of maternal as well as foetal complications. Methods: Retrospective data on 96 women and their 96 newborns were anonymously statistically analysed to assess pregnancies of type 1 diabetes (T1D) women managed in our hospital in past nine years. The outcomes of the neonates were divided into three categories according to the clinical status, presence of congenital abnormalities and infant's treatment. Results: We found out that the outcome of newborn infants associated with maternal HbA1c before gestation as well as during the whole course of pregnancy (p<0.02 for all). Surprisingly, neonatal outcome was strongly associated with the maternal BMI (p<0.05). In our model, a lowering of BMI by one grade led to an 18% increase in the chance that the newborn will have no health problems. We did not observe an important worsening of chronic diabetic complications in mothers; however, regarding maternal clinical status, we found that preeclampsia occurrence was strongly and independently connected to HDL level (p<0.01). Conclusion: Our data demonstrate that lower pregestational BMI could substantially improve T1D mothers' pregnancy outcome. Lower HDL levels in T1D mothers during pregnancy correlate with higher risk of preeclampsia development.","[Ulmannova, Tereza; Stechova, Katerina] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague 15006 5, Motol, Czech Republic; [Bartaskova, Dagmar] Charles Univ Prague, Fac Med 2, Dept Internal Med, Prague 15006 5, Motol, Czech Republic; [Spalova, Ivana; Zoban, Petr] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynaecol, Prague 15006 5, Motol, Czech Republic; [Vesely, Zdenek] Charles Univ Prague, Fac Med 2, Bioinformat Ctr, Prague 15006 5, Motol, Czech Republic; [Ulmannova, Tereza] Univ Hosp Motol, Prague 15006 5, Motol, Czech Republic","Ulmannova, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","tulma@centrum.cz",null,null,"Ministry of Health, Czech Republic [00064203]; (Department of Paediatrics, 2nd Faculty of Medicine, Prague, Czech Republic) [IPL 699 001]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NT/11 407-5]","This work is supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic), IPL 699 001 (Department of Paediatrics, 2nd Faculty of Medicine, Prague, Czech Republic) and Internal Grant Agency of the Ministry of Health of the Czech Republic (NT/11 407-5).",null,15,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","1476-7058","1476-4954",null,"J MATERN-FETAL NEO M","J. Matern.-Fetal Neonatal Med.","OCT",2014,27,15,null,null,null,null,1580,1583,null,"10.3109/14767058.2013.871252",null,4,"Obstetrics & Gynecology","Obstetrics & Gynecology","AP2TV","WOS:000341928900017",24298876]
["J","Stechova, K; Cerny, M; Brabec, R; Ulmannova, T; Bartaskova, D; Spalova, I; Zoban, P",null,null,null,"Stechova, Katerina; Cerny, Milos; Brabec, Radim; Ulmannova, Tereza; Bartaskova, Dagmar; Spalova, Ivana; Zoban, Petr",null,null,"Experience with real time continuous glucose monitoring in stabilising fluctuating glycaemia during intensive care of the preterm infant of a diabetic mother","JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE",null,null,"English","Article",null,null,null,null,null,"Diabetes mellitus; fetopathy; glucose administration; glycaemia measurement; hypoglycaemia; newborn of a diabetic mother","BORN","Objective: The newborns of diabetic mothers suffer from perinatal complications more frequently than the newborns of healthy women. Methods: We used for 7 days a real time continuous glucose monitoring system (RT-CGMS) to monitor glucose homeostasis and manage glucose administration in a premature newborn of a diabetic mother. Results: The boy was born at 35 +/- 5 gestational weeks with typical signs of diabetic fetopathy. RT-CGMS revealed 2 late hypoglycaemia episodes on the 2nd and 4th days. The sensor readings correlated well with glycaemia measured in the laboratory (r = 0.908, p = 0.005). To support conclusions of this case report, we attached the data of five other preterm newborns of diabetic mothers who were later successfully treated according to the RT-CGMS data as well. Conclusions: This approach allows timely response to glycaemia instability and is applicable even in preterm infants.","[Stechova, Katerina; Ulmannova, Tereza] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague 15006 5, Motol, Czech Republic; [Cerny, Milos; Brabec, Radim; Zoban, Petr] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynaecol, NICU, Prague 15006 5, Motol, Czech Republic; [Bartaskova, Dagmar] Charles Univ Prague, Fac Med 2, Dept Internal Med, Prague 15006 5, Motol, Czech Republic; [Spalova, Ivana] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynaecol, Prague 15006 5, Motol, Czech Republic; Motol Univ Hosp, Prague 15006 5, Motol, Czech Republic","Stechova, K (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","katerina.stechova@lfmotol.cuni.cz",null,null,"Project (Ministry of Health, Czech Republic) for Conceptual Development of Research, organisation (University Hospital Motol, Prague, Czech Republic) [00064203]","This study was supported by the Project (Ministry of Health, Czech Republic) for Conceptual Development of Research, organisation 00064203 (University Hospital Motol, Prague, Czech Republic). Dr. Stechova serves occasionally as a consultant of Medtronic comp. too.",null,7,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","1476-7058","1476-4954",null,"J MATERN-FETAL NEO M","J. Matern.-Fetal Neonatal Med.","SEP",2014,27,13,null,null,null,null,1389,1391,null,"10.3109/14767058.2013.858686",null,3,"Obstetrics & Gynecology","Obstetrics & Gynecology","AN2XH","WOS:000340448800022",24156750]
["J","Kotaska, K; Kolarova, J; Jedlickova, B; Cepova, J; Kotaska, J; Prusa, R",null,null,null,"Kotaska, Karel; Kolarova, Jitka; Jedlickova, Blanka; Cepova, Jana; Kotaska, Jan; Prusa, Richard",null,null,"LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A(2) IS INCREASED IN PATIENTS WITH IMPAIRED BONE DENSITY","JOURNAL OF MEDICAL BIOCHEMISTRY",null,null,"English","Article",null,null,null,null,null,"lipoprotein-associated phospholipase A(2); osteocalcin; bone metabolism","ACTIVATING-FACTOR ACETYLHYDROLASE; CARDIOVASCULAR-DISEASE; RISK; WOMEN","Background: Increased levels of lipoprotein-associated phospholipase A(2) are associated with atherosclerosis, and may contribute to cardiac disease. The aim of this study was to analyze serum levels of lipoprotein phospholipase A(2) (Lp-PLA(2)) in patients with impaired bone resorption and correlate the findings with markers of bone metabolism (osteocalcin) and other biochemical markers (cholesterol, low density lipoprotein, triacylglycerols). Methods: Serum Lp-PLA(2) was measured by a turbidimetric method in a group of currently treated 85 patients with impaired bone resorption and in a control group of 46 healthy individuals. Serum triacylglycerols was measured by the electrochemiluminescence immunoassay. Cholesterol, low density lipoprotein and triacylglycerols were measured by commercially available enzymatic assays. Bone density was investigated by dual energy X-ray densitometry performed on the lower spine and hips. Results: Concentrations of LP-PLA(2) were significantly elevated in the patients with bone resorption compared to the control group of healthy individuals (225 ng/mL vs. 192 ng/mL, p<0.001) with the highest difference in patients with a T score below -2.5 SD (227 vs. 192 ng/mL). Serum levels of Lp-PLA(2) also negatively correlated with decreased levels of serum osteocalcin in patients, and a significant difference in Lp-PLA(2) (p=0.02) levels was observed between the control group and group with low levels of osteocalcin. Elevated Lp-PLA(2) levels were significantly associated with the therapeutic procedures used, but not with age, gender and concentration of lipids. Conclusions: Lipoprotein-associated phospholipase A(2) seems to play an important role also in bone metabolism.","[Kotaska, Karel; Kolarova, Jitka; Jedlickova, Blanka; Cepova, Jana; Prusa, Richard] Charles Univ Prague, Fac Hosp Motol, Fac Med 2, Dept Med Chem & Clin Biochem, Prague 15006 5, Czech Republic; [Kotaska, Jan] Charles Univ Prague, Fac Hosp Motol, Fac Med 2, Dept Orthopaed, Prague 15006 5, Czech Republic","Kotaska, K (reprint author), Charles Univ Prague, Fac Hosp Motol, Fac Med 2, Dept Med Chem & Clin Biochem, U Uvalu 84, Prague 15006 5, Czech Republic.","kotaska@email.cz",null,null,"(Ministry of Health, Czech Republic) for Conceptual Development of Research Organization (University Hospital Motol, Prague, Czech Republic) [00064203]","Supported by the Project (Ministry of Health, Czech Republic) for Conceptual Development of Research Organization 00064203 (University Hospital Motol, Prague, Czech Republic).",null,15,0,0,"DE GRUYTER OPEN LTD","WARSAW","SOLIPSKA 14A-1, 02-482 WARSAW, POLAND","1452-8258","1452-8266",null,"J MED BIOCHEM","J. Med. Biochem.","OCT-DEC",2014,33,4,null,null,null,null,317,322,null,"10.2478/jomb-2014-0027",null,6,"Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","AN8OI","WOS:000340863100003"]
["J","Kriz, J; Andel, R; Hakova, R",null,null,null,"Kriz, Jiri; Andel, Ross; Hakova, Renata",null,null,"Delayed diagnosis of an unsuspected pelvic fracture in a patient with tetraplegia","JOURNAL OF SPINAL CORD MEDICINE",null,null,"English","Article",null,null,null,null,null,"Spinal cord injury; Patients with tetraplegia; Pelvic fracture; Osteporosis; Autonomic dysreflexia","SPINAL-CORD-INJURY; RISK","Study design: Case report. Context: In patients with a complete spinal cord injury (SCI) above T6 level, autonomic dysreflexia (AD) can be the only alerting sign of complications below the level of injury. A case report is presented of a patient with tetraplegia who progressively developed an AD syndrome after falling from a wheelchair. Initially, he was treated for symptomatic urinary tract infection and only later an unstable pelvic fracture was detected. Findings: A patient with chronic tetraplegia fell from his wheelchair while intoxicated. After the fall, he showed no signs of injury. Two days later, AD symptoms appeared while lying on his side or sitting. He presented to his community-based physician and received antibiotics for concomitant urinary tract infection. Because of persisting complaints, the patient was referred to the Spinal Cord Unit. Once the history of falling from the wheelchair was made known, symptoms of AD were suggestive of an internal injury. Radiography showed pelvic fracture and conservative treatment was administered. The fractures healed in 3 months, the therapeutic bed rest regimen was relaxed without trigerring AD symptoms. Conclusion: AD symptoms can suggest complications below the SCI level. Awareness and recognition of these symptoms are of utmost importance. However, etiology may be misleading. The role of a community-based general physician is to recognize the right moment when the need of a specialized assessment in a Spinal Cord Unit arises. In addition, patients should also be well informed about the most common possible complications from specialized SCI centers.","[Kriz, Jiri; Hakova, Renata] Univ Hosp Motol, Prague 5, Czech Republic; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Andel, Ross] St Annes Univ Hosp Brno, USA Int Clin Res Ctr, Brno, Czech Republic","Kriz, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Rehabil & Sports Med, Spinal Cord Unit, Prague 5, Czech Republic.","jiri.kriz@fnmotol.cz",null,null,"Movement without Help foundation","The study was partially supported by \"Movement without Help\" foundation.",null,5,0,0,"MANEY PUBLISHING","LEEDS","STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND","1079-0268","2045-7723",null,"J SPINAL CORD MED","J. Spinal Cord. Med.","JUL",2014,37,4,null,null,null,null,425,428,null,"10.1179/2045772313Y.0000000178",null,4,"Clinical Neurology","Neurosciences & Neurology","AQ1XJ","WOS:000342577700013",24621047]
["J","Hylek, EM; Held, C; Alexander, JH; Lopes, RD; De Caterina, R; Wojdyla, DM; Huber, K; Jansky, P; Steg, PG; Hanna, M; Thomas, L; Wallentin, L; Granger, CB",null,null,null,"Hylek, Elaine M.; Held, Claes; Alexander, John H.; Lopes, Renato D.; De Caterina, Raffaele; Wojdyla, Daniel M.; Huber, Kurt; Jansky, Petr; Steg, Philippe Gabriel; Hanna, Michael; Thomas, Laine; Wallentin, Lars; Granger, Christopher B.",null,null,"Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin","JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"atrial fibrillation; bleeding; factor Xa inhibitor","PROTHROMBIN COMPLEX CONCENTRATE; VITAMIN-K ANTAGONISTS; RISK-FACTORS; ANTITHROMBOTIC THERAPY; FACTOR VIIA; ANTICOAGULATION; HEMORRHAGE; STROKE; REVERSAL; TRIALS","Objectives This study sought to characterize major bleeding on the basis of the components of the major bleeding definition, to explore major bleeding by location, to define 30-day mortality after a major bleeding event, and to identify factors associated with major bleeding. Background Apixaban was shown to reduce the risk of major hemorrhage among patients with atrial fibrillation in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Methods All patients who received at least 1 dose of a study drug were included. Major bleeding was defined according to the criteria of the International Society on Thrombosis and Haemostasis. Factors associated with major hemorrhage were identified using a multivariable Cox model. Results The on-treatment safety population included 18,140 patients. The rate of major hemorrhage among patients in the apixaban group was 2.13% per year compared with 3.09% per year in the warfarin group (hazard ratio [HR] 0.69, 95% confidence interval [CI]: 0.60 to 0.80; p < 0.001). Compared with warfarin, major extracranial hemorrhage associated with apixaban led to reduced hospitalization, medical or surgical intervention, transfusion, or change in antithrombotic therapy. Major hemorrhage followed by mortality within 30 days occurred half as often in apixaban treated patients than in those receiving warfarin (HR 0.50, 95% CI: 0.33 to 0.74; p < 0.001). Older age, prior hemorrhage, prior stroke or transient ischemic attack, diabetes, lower creatinine clearance, decreased hematocrit, aspirin therapy, and nonsteroidal anti-inflammatory drugs were independently associated with an increased risk. Conclusions Apixaban, compared with warfarin, was associated with fewer intracranial hemorrhages, less adverse consequences following extracranial hemorrhage, and a 50% reduction in fatal consequences at 30 days in cases of major hemorrhage. (c) 2014 by the American College of Cardiology Foundation","[Hylek, Elaine M.] Boston Univ, Med Ctr, Boston, MA 02118 USA; [Held, Claes; Wallentin, Lars] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden; [Alexander, John H.; Lopes, Renato D.; Wojdyla, Daniel M.; Thomas, Laine; Granger, Christopher B.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [De Caterina, Raffaele] Univ G dAnnunzio, Chieti, Italy; [Huber, Kurt] Wilhelminen Hosp, Vienna, Austria; [Jansky, Petr] Motol Univ Hosp, Prague, Czech Republic; [Steg, Philippe Gabriel] Hop Bichat Claude Bernard, F-75877 Paris 18, France; [Hanna, Michael] Bristol Myers Squibb Co, Princeton, NJ USA","Hylek, EM (reprint author), Boston Univ, Sch Med, Boston Med Ctr, 801 Massa chusetts Ave,2nd Floor Suite, Boston, MA 02118 USA.","ehylek@bu.edu",null,null,"Bristol-Myers Squibb; Pfizer; Boehringer Ingelheim; AstraZeneca; Merck; GlaxoSmithKline; Roche; Regado Biosciences; Ortho-McNeil-Janssen Pharmaceuticals; PolyMedix; Bayer; Daiichi Sankyo; Sanofi-Aventis; Bristol-Myers Squibb/Pfizer; Servier; New York University School of Medicine; Otsuka; Merck Co; Evolva; Portola; Athera Biotechnologies; Hoffmann-La Roche; Novartis Pharmaceutical Company; Lilly; Takeda","The ARISTOTLE trial was supported by Bristol-Myers Squibb and Pfizer. Dr. Hylek is a consultant with, receives travel support from, and is an adjudication committee member with Bristol-Myers Squibb, Daiichi Sankyo, Merck, Ortho-McNeil, Johnson & Johnson, and Pfizer; and has received lecture fees from Boehringer Ingelheim. Dr. Held has received grants from AstraZeneca, Merck, GlaxoSmithKline, Roche, and Bristol-Myers Squibb; is on the membership advisory board for AstraZeneca; and has received honoraria from AstraZeneca. Dr. Alexander has received grants from Bristol-Myers Squibb, Merck, and Regado Biosciences; travel support from Bristol-Myers Squibb; and consulting fees from Bristol- Myers Squibb, Pfizer, Merck, AstraZeneca, Boehringer Ingelheim, Ortho-McNeil-Janssen Pharmaceuticals, PolyMedix, Regado Biosciences, Bayer, and Daiichi Sankyo. Dr. Lopes has received grants from Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo; and consulting fees from Bristol-Myers Squibb, Pfizer, Bayer, and Janssen Research & Development, LLC. Dr. De Caterina is a steering committee member, a national coordinator for Italy, coauthor of the APPRAISE-2, ARISTOTLE, AVERROES studies, and coauthor of European Society of Cardiology Guidelines on Atrial Fibrillation; and has received fees, honoraria, and research funding from Sanofi-Aventis, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo. Dr. Huber has received lecture fees from AstraZeneca, Bristol-Myers Squibb/Pfizer, Boehringer Ingelheim, Bayer, Daiichi Sankyo, and Sanofi-Aventis. Dr. Steg has received travel support from Bristol-Myers Squibb; is on the membership boards of Bayer, BristolMyers Squibb/Pfizer, AstraZeneca, and Boehringer Ingelheim; has received consulting fees from Bristol-Myers Squibb, Eisai, Ablynx, Amarin, Astellas, Eli Lilly, Medtronic, Novartis, Roche, Servier, The Medicines Company, Sanofi, and AstraZeneca; grants from Servier, Sanofi, and New York University School of Medicine; and lecture fees from Pfizer, Amgen, Otsuka, and Aterovax. Dr. Hanna is an employee of Bristol-Myers Squibb and receives stock as part of compensation. Dr. Wallentin has received grants from AstraZeneca, Merck, Boehringer Ingelheim, Bristol-Squibb/Pfizer, and GlaxoSmithKline; consulting fees from Merck & Co, Regado Biosciences, Evolva, Portola, C. S. L. Behring, Athera Biotechnologies, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, and Bristol-Myers Squibb/Pfizer; lecture fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Merck & Co; honoraria from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Merck & Co; and travel support from AstraZeneca and Bristol- Myers Squibb/Pfizer. Dr. Granger has received grants from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic Foundation, Merck & Co, Pfizer, Sanofi-Aventis, Takeda, and The Medicines Company; and consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, Novartis Pharmaceutical Company, Lilly, Pfizer, Sanofi-Aventis, Takeda, The Medicines Company, and AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.",null,27,2,2,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0735-1097","1558-3597",null,"J AM COLL CARDIOL","J. Am. Coll. Cardiol.","MAY 27",2014,63,20,null,null,null,null,2141,2147,null,"10.1016/j.jacc.2014.02.549",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AH8GA","WOS:000336372700015",24657685]
["J","Chvatal, A",null,null,null,"Chvatal, Alexandr",null,null,"Jiri Prochaska (1749-1820): Part 1: A Significant Czech Anatomist, Physiologist and Neuroscientist of the Eighteenth Century","JOURNAL OF THE HISTORY OF THE NEUROSCIENCES",null,null,"English","Article",null,null,null,null,null,"physiology; Jiri Prochaska; eighteenth century; anatomy; Vienna; Prague",null,"Jiri (George) Prochaska (1749-1820), a Czech anatomist, physiologist, and neuroscientist of the eighteenth century, ranks among the major figures of Czech and European cultural history. The works of Jiri Prochaska, due to historical circumstances, were published mostly in Latin and only some in German. However, given that only one treatise was partially translated into English, the results of his extensive research activities are currently unavailable to the international scientific community. The achievements of Jiri Prochaska undoubtedly belong to the major intellectual heritage of European science and certainly deserve attention as such, although his research reflected the time in which he lived and therefore has been reevaluated by later researchers. Undoubtedly, it is our duty not only to remember the work and legacy of Jiri Prochaska, which significantly influenced the development of our knowledge, but also to try to critically assess his contribution in terms of today. This article surveys the important biographical events of Jiri Prochaska's life, taking into account the significance of his research.","[Chvatal, Alexandr] Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Prague 14220 4, Krc, Czech Republic; [Chvatal, Alexandr] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic","Chvatal, A (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Krc, Czech Republic.","chvatal@biomed.cas.cz",null,null,null,null,null,41,0,0,"TAYLOR & FRANCIS INC","PHILADELPHIA","530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA","0964-704X","1744-5213",null,"J HIST NEUROSCI","J. Hist. Neurosci.","OCT 2",2014,23,4,null,null,null,null,367,376,null,"10.1080/0964704X.2014.881310",null,10,"History & Philosophy Of Science; Neurosciences","History & Philosophy of Science; Neurosciences & Neurology","AR0CV","WOS:000343234400003",25055079]
["J","Schwabova, J; Maly, T; Laczo, J; Zumrova, A; Komarek, V; Musova, Z; Zahalka, F",null,null,null,"Schwabova, J.; Maly, T.; Laczo, J.; Zumrova, A.; Komarek, V.; Musova, Z.; Zahalka, F.",null,null,"Application of a Scale for the Assessment and Rating of Ataxia (SARA) in Friedreich's ataxia patients according to posturography is limited","JOURNAL OF THE NEUROLOGICAL SCIENCES",null,null,"English","Article",null,null,null,null,null,"Friedreich's ataxia; Autosomal dominant spinocerebellar ataxia; SARA; FARS; Clinical rating scale; Posturography","RELIABILITY; DEFICITS; REPEAT","Background: A scale for the Assessment and Rating of Ataxia (SARA) was developed for evaluation of autosomal dominant cerebellar ataxias (ADCA) and was also recommended for clinical trials of Friedreich's ataxia patients (FRDA). FRDA, unlike ADCA, is characterized as being a sensory type of ataxia for which the disease-specific Friedreich ataxia rating scale (FARS) was developed. The objective of this study was to determine whether SARA and FARS scores are associated with posturographic parameters in FRDA patients. Method: Adult patients with genetically confirmed FRDA (n = 11) and ADCA (n = 13) were evaluated by SARA, FARS and posturography. Results: FRDA patients' postural stability parameters, in stance with visual control, correlated with balance impairment in FARS (r = 0.622; p < 0.05) and SARA (r = 0.735; p < 0.05). Without visual control, only FARS correlated with balance impairment (r = 0.732; p < 0.05). Conclusion: The SARA, in FRDA patients, correlates with stance with visual control but not without visual control which emphasizes sensory ataxia. This suggests that application of the SARA in Friedreich's ataxia patients according to posturography is possible but presumably limited and FARS, although being a more time consuming scale, may have advantages over SARA in FRDA patients. (C) 2014 Elsevier B.V. All rights reserved.","[Schwabova, J.; Maly, T.] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague 150065, Czech Republic; [Schwabova, J.; Laczo, J.; Musova, Z.] Motol Univ Hosp, Prague 515006 5, Czech Republic; [Schwabova, J.; Zumrova, A.; Komarek, V.] Charles Univ Prague, Fac Med 2, Dept Paediat Neurol, Prague 15006 5, Czech Republic; [Maly, T.; Zahalka, F.] Charles Univ Prague, Fac Phys Educ & Sport, Res Sport Ctr, Prague 16252 6, Czech Republic; [Laczo, J.] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno 65691, Czech Republic; [Musova, Z.] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 15006 5, Czech Republic","Schwabova, J (reprint author), Charles Univ Prague, Fac Med, Dept Neurol, V Uvalu 84, Prague 15006 5, Czech Republic.","schwabova@gmail.com",null,null,"MH CZ-DRO, University Hospital Motol, Prague, Czech Republic [00064203]; MSM [0021620864]; GACR [P407/11/P784]; PRVOUK [P38]; European Regional Development Fund Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; project ICRC-ERA-HumanBridge [316345]; Laboratory Research Grant [2/2012 (699002)]","We would like to thank the patients who participated in this study and their families. This study was supported by MH CZ-DRO, University Hospital Motol, Prague, Czech Republic 00064203; MSM 0021620864; GACR P407/11/P784; PRVOUK P38; the European Regional Development Fund Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123) and by project ICRC-ERA-HumanBridge (no. 316345). Institutional Support of Laboratory Research Grant No. 2/2012 (699002).",null,20,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0022-510X","1878-5883",null,"J NEUROL SCI","J. Neurol. Sci.","JUN 15",2014,341,41671,null,null,null,null,64,67,null,"10.1016/j.jns.2014.04.001",null,4,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","AI9OP","WOS:000337262200014",24768059]
["J","Ruffini, E; Detterbeck, F; Van Raemdonck, D; Rocco, G; Thomas, P; Weder, W; Brunelli, A; Guerrera, F; Keshavjee, S; Altorki, N; Schutzner, J; Arame, A; Spaggiari, L; Lim, E; Toker, A; Venuta, F",null,null,null,"Ruffini, Enrico; Detterbeck, Frank; Van Raemdonck, Dirk; Rocco, Gaetano; Thomas, Pascal; Weder, Walter; Brunelli, Alessandro; Guerrera, Francesco; Keshavjee, Shaf; Altorki, Nasser; Schuetzner, Jan; Arame, Alex; Spaggiari, Lorenzo; Lim, Eric; Toker, Alper; Venuta, Federico",null,"European Soc Thoracic Surg Thymic","Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database","JOURNAL OF THORACIC ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"Thymic carcinoma; Staging; Prognostic factors; Thymic tumors; Surgery","SINGLE INSTITUTION; PREDICT PROGNOSIS; STAGING SYSTEM; MASAOKA STAGE; TUMORS; MULTICENTER; EXPERIENCE; RESECTION; SURVIVAL; OUTCOMES","Introduction: Thymic carcinoma is a rare and aggressive thymic neoplasm. The European Society of Thoracic Surgeons developed a retrospective database collecting patients undergoing resection for thymic tumors from 1990 to 2010. Methods: Of 2265 patients with thymic tumors, there were 229 thymic carcinomas. Clinicopathological characteristics were analyzed including age, associated paraneoplastic diseases, stage (Masaoka-Koga), World Health Organization histologic subtypes, type of resection (total/subtotal/biopsy/no resection), tumor size, pre/postoperative treatments, and recurrence. Outcome measures included overall survival (OS), freedom from recurrence, and cumulative incidence of recurrence. Results: A complete resection was achieved in 140 patients (69%). Recurrence occurred in 54 patients (28%). Five- and 10-year OS rates were 0.61 and 0.37. Five- and 10-year freedom from recurrence rates were 0.60 and 0.43. Cumulative incidence of recurrence was 0.21 (3 yr), 0.27 (5 yr), and 0.32 (10 yr). Survival was better after surgical resection versus biopsy/no resection (p < 0.001), after complete resection versus subtotal resection (p < 0.001), and when using Masaoka-Koga system (stages I-II versus III versus IV) (p < 0.001). The use of multidisciplinary treatments resulted in a survival advantage which was significant in the surgery + radiotherapy group (p = 0.02). Incomplete resection (p < 0.0001) and advanced stage (Masaoka-Koga III-IV) (p = 0.02) had a negative impact on OS at multivariable analysis. Administration of adjuvant radiotherapy was beneficial in increasing OS (p = 0.02). Conclusions: The results of our study indicate that patients with thymic carcinoma should undertake surgical resection whenever possible; a complete resection and early Masaoka-Koga stage are independent predictors of improved survival; our results also suggest that postoperative radiotherapy is beneficial in improving survival.","[Ruffini, Enrico; Guerrera, Francesco] Univ Turin, Dept Surg, Thorac Surg Sect, I-10126 Turin, Italy; [Detterbeck, Frank] Yale Univ, Thorac Surg Sect, New Haven, CT USA; [Van Raemdonck, Dirk] Univ Hosp Leuven, Dept Thorac Surg, Louvain, Belgium; [Rocco, Gaetano] Pascale Fdn, Natl Canc Inst, Dept Thorac Surg, Naples, Italy; [Thomas, Pascal] Aix Marseille Univ, Dept Thorac Surg, Marseille, France; [Weder, Walter] Univ Zurich Hosp, Dept Thorac Surg, CH-8091 Zurich, Switzerland; [Brunelli, Alessandro] St James Univ Hosp, Div Thorac Surg, Leeds LS9 7TF, W Yorkshire, England; [Keshavjee, Shaf] Univ Toronto, Toronto Gen Hosp, Dept Thorac Surg, Toronto, ON M5G 1L7, Canada; [Altorki, Nasser] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Thorac Surg, New York, NY USA; [Schuetzner, Jan] Charles Univ Prague, Dept Surg 3, Fac Med 1, Prague, Czech Republic; [Schuetzner, Jan] Univ Hosp Motol, Prague, Czech Republic; [Arame, Alex] Hop Europeen Georges Pompidou, Dept Thorac Surg, Paris, France; [Arame, Alex] Hop Laennec, F-75340 Paris, France; [Spaggiari, Lorenzo] European Inst Oncol, Dept Thorac Surg, Milan, Italy; [Lim, Eric] Royal Brompton & Harefield NHS Fdn Trust, Dept Thorac Surg, London, England; [Lim, Eric] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Div, London, England; [Toker, Alper] Istanbul Univ, Istanbul Med Sch, Dept Thorac Surg, Istanbul, Turkey; [Venuta, Federico] Univ Roma La Sapienza, Dept Thorac Surg, Policlin Umberto I, Fdn Eleonora Lorilard Spencer Cenci, I-00185 Rome, Italy","Ruffini, E (reprint author), Univ Turin, 3 Via Genova, I-10126 Turin, Italy.","enrico.ruffini@unito.it","Spaggiari, Lorenzo/G-7915-2012; Guerrera, Francesco/M-9391-2014","Guerrera, Francesco/0000-0002-4125-4379",null,null,null,30,1,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1556-0864","1556-1380",null,"J THORAC ONCOL","J. Thorac. Oncol.","APR",2014,9,4,null,null,null,null,541,548,null,"10.1097/JTO.0000000000000128",null,8,"Oncology; Respiratory System","Oncology; Respiratory System","AD3MO","WOS:000333145300021",24736078]
["J","Malik, J; Kudlicka, J; Novakova, L; Adamec, J; Malikova, H; Kavan, J",null,null,null,"Malik, Jan; Kudlicka, Jaroslav; Novakova, Ludmila; Adamec, Josef; Malikova, Hana; Kavan, Jan",null,null,"Surveillance of arteriovenous accesses with the use of duplex Doppler ultrasonography","JOURNAL OF VASCULAR ACCESS",null,null,"English","Article",null,null,null,null,null,"Duplex Doppler ultrasonography; Stenosis; Surveillance; Vascular access","BALLOON ANGIOPLASTY FAILS; VASCULAR ACCESS; BLOOD-FLOW; ULTRASOUND SURVEILLANCE; STENOSIS SURVEILLANCE; HEMODIALYSIS-PATIENTS; PTFE GRAFTS; THROMBOSIS; PATENCY; MANAGEMENT","Stenosis is the most frequent vascular access complication and is responsible for access thrombosis and thus long-term patency limitation. Regular arteriovenous graft (WAVG) examination by ultrasonography and preemptive balloon angioplasty prolong AVG cumulative patency according to some, but by far not all trials. This was why the routine use of ultrasound surveillance is not recommended recently. In this review we show huge differences in the definition of stenosis significance among the trials and other probable factors, which may have caused the contradiction of the results. Without precise definition of stenosis significance, many AVGs have been undergoing unnecessary balloon interventions with high morbidity, high cost and low benefit.","[Malik, Jan; Kudlicka, Jaroslav] Charles Univ Prague, Fac Med 1, Dept Internal Med 3, Prague, Czech Republic; [Novakova, Ludmila; Adamec, Josef] Czech Tech Univ, Fac Mech Engn, Dept Fluid Dynam & Power Engn, Prague, Czech Republic; [Malikova, Hana] Charles Univ Prague, Fac Med 2, Dept Anat, Prague, Czech Republic; [Kavan, Jan] Charles Univ Prague, Fac Med 1, Dept Radiol, Prague, Czech Republic","Malik, J (reprint author), Gen Univ Hosp Prague, Dept Internal Med 3, U Nemocnice 1, Prague 12808 2, Czech Republic.","malik.jan@vfn.cz",null,null,"Internal Grant Agency, Ministry of Health, Czech Republic [NT 14160/3]; Charles University [PRVOUK-P35/LF1/5]","Grant No. NT 14160/3 of the Internal Grant Agency, Ministry of Health, Czech Republic and Research project of Charles University PRVOUK-P35/LF1/5.",null,34,0,0,"WICHTIG EDITORE","MILAN","72/74 VIA FRIULI, 20135 MILAN, ITALY","1129-7298","1724-6032",null,"J VASC ACCESS","J. Vasc. Access",null,2014,15,null,null,7,null,null,"S28","S32",null,"10.5301/jva.5000240",null,5,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","AP7OF","WOS:000342265900006",24817451]
["J","van Stralen, KJ; Borzych-Duzalka, D; Hataya, H; Kennedy, SE; Jager, KJ; Verrina, E; Inward, C; Ronnholm, K; Vondrak, K; Warady, BA; Zurowska, AM; Schaefer, F; Cochat, P",null,null,null,"van Stralen, Karlijn J.; Borzych-Duzalka, Dagmara; Hataya, Hiroshi; Kennedy, Sean E.; Jager, Kitty J.; Verrina, Enrico; Inward, Carol; Ronnholm, Kai; Vondrak, Karel; Warady, Bradley A.; Zurowska, Aleksandra M.; Schaefer, Franz; Cochat, Pierre",null,"ESPN ERA-EDTA ANZDATA","Survival and clinical outcomes of children starting renal replacement therapy in the neonatal period","KIDNEY INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"end-stage renal disease; ethics; neonate; peritoneal dialysis; renal replacement therapy","CHRONIC KIDNEY-DISEASE; PEDIATRIC NEPHROLOGY; PERITONEAL-DIALYSIS; BLOOD-PRESSURE; INFANTS; FAILURE; MANAGEMENT; TRANSPLANTATION; ATTITUDES; LIFE","End-stage renal disease requiring renal replacement therapy (RRT) during the neonatal period is a very rare condition, and little information is available regarding long-term RRT and outcomes. To gain more information, we performed a collaborative study on patient characteristics and treatment outcomes in children who started RRT as neonates during their first month of life between 2000 and 2011 who were prospectively registered in the ESPN/ERA-EDTA, the IPPN (since 2007), the Japanese registry, or the Australian and New Zealand Dialysis and Transplant (ANZDATA) registry. During the first month of life, 264 patients from 32 countries started RRT and were followed for a median of 29 months (interquartile range 11-60 months). Most neonates (242) started on peritoneal dialysis, 21 started on hemodialysis, and 1 patient with a transplant. The most important causes of renal failure were congenital anomalies of the kidney and urinary tract in 141, cystic kidneys in 35, and cortical necrosis in 30. Within 2 years after the start of RRT, 69 children changed dialysis modality and 53 received a renal transplant. After a median of 7 months, 45 children had died, mainly because of infection, resulting in an estimated 2-year survival of 81%, and 5-year survival of 76%. Growth retardation (63%), anemia (55%), and hypertension (57%) were still major problems after 2 years. Thus, relatively good medium-term patient survival may be achieved with RRT started during the neonatal period, but specific therapeutic challenges continue to exist in this age group.","[van Stralen, Karlijn J.; Jager, Kitty J.] Univ Amsterdam, Acad Med Ctr, ESPN ERA EDTA Registry, NL-1100 DE Amsterdam, Netherlands; [Borzych-Duzalka, Dagmara; Zurowska, Aleksandra M.] Med Univ Gdansk, Dept Pediat Nephrol & Hypertens, Gdansk, Poland; [Borzych-Duzalka, Dagmara] Heidelberg Univ, Ctr Pediat & Adolescent Med, Heidelberg, Germany; [Hataya, Hiroshi] Tokyo Metropolitan Childrens Med Ctr, Tokyo, Japan; [Kennedy, Sean E.] Univ New S Wales, UNSW Med, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Verrina, Enrico] Ist Giannina Gaslini, I-16148 Genoa, Italy; [Inward, Carol] Bristol Royal Hosp Children, Bristol, Avon, England; [Ronnholm, Kai] Univ Helsinki, Childrens Hosp, Helsinki, Finland; [Vondrak, Karel] Univ Hosp Prague Motol, Prague, Czech Republic; [Warady, Bradley A.] Childrens Mercy Hosp, Kansas City, MO 64108 USA; [Cochat, Pierre] Hosp Civils Lyon, Ctr Reference Malad Renales Rares, Lyon, France; [Cochat, Pierre] Univ Lyon 1, F-69365 Lyon, France","van Stralen, KJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Med Informat, ESPN ERA EDTA Registry, POB 22700, NL-1100 DE Amsterdam, Netherlands.","K.J.vanStralen@amc.uva.nl",null,null,"ERA-EDTA; ESPN; European Council [ESPN_FY2013]; International Society for Peritoneal Dialysis; Baxter Health Care; Fresenius Medical Care; Ipsen; Pfizer; IBM; Australian Organ and Tissue Authority, Kidney Health Australia; New Zealand Ministry of Health","We thank all patients, families, physicians, and centers who contributed to the ESPN/ERA-EDTA Registry, the IPPN registry, the Japanese registry, and the ANZDATA. The ESPN/ERA-EDTA registry is funded by the ERA-EDTA, the ESPN, and the European Council (ESPN_FY2013). The IPPN has received support from the International Society for Peritoneal Dialysis, Baxter Health Care, Fresenius Medical Care, Ipsen, Pfizer, and IBM, whereas the ANZDATA is funded by the Australian Organ and Tissue Authority, Kidney Health Australia, and the New Zealand Ministry of Health.",null,33,3,3,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","0085-2538","1523-1755",null,"KIDNEY INT","Kidney Int.","JUL",2014,86,1,null,null,null,null,168,174,null,"10.1038/ki.2013.561",null,7,"Urology & Nephrology","Urology & Nephrology","AK7IJ","WOS:000338601700025",24499775]
["J","Coenen, EA; Zwaan, CM; Stary, J; Baruchel, A; de Haas, V; Stam, RW; Reinhardt, D; Kaspers, GJL; Arentsen-Peters, STCJM; Meyer, C; Marschalek, R; Nigro, LL; Dworzak, M; Pieters, R; van den Heuvel-Eibrinkt, MM",null,null,null,"Coenen, E. A.; Zwaan, C. M.; Stary, J.; Baruchel, A.; de Haas, V.; Stam, R. W.; Reinhardt, D.; Kaspers, G. J. L.; Arentsen-Peters, S. T. C. J. M.; Meyer, C.; Marschalek, R.; Nigro, L. L.; Dworzak, M.; Pieters, R.; van den Heuvel-Eibrinkt, M. M.",null,null,"Unique BHLHB3 overexpression in pediatric acute myeloid leukemia with t(6;11)(q27;q23)","LEUKEMIA",null,null,"English","Letter",null,null,null,null,null,null,"TRANSCRIPTION FACTOR DEC2; BREAST-CANCER CELLS; LOOP; EXPRESSION; TARGET; GENE",null,"[Coenen, E. A.; Zwaan, C. M.; Stam, R. W.; Arentsen-Peters, S. T. C. J. M.; Pieters, R.; van den Heuvel-Eibrinkt, M. M.] Sophia Childrens Univ Hosp, Erasmus MC, Rotterdam, Netherlands; [Zwaan, C. M.; de Haas, V.; Pieters, R.; van den Heuvel-Eibrinkt, M. M.] DCOG, The Hague, Netherlands; [Stary, J.] Charles Univ Prague, Prague, Czech Republic; [Stary, J.] Univ Hosp Motol, Prague, Czech Republic; [Baruchel, A.] Hop Robert Debre, AP HP, F-75019 Paris, France; [Baruchel, A.] Univ ParisDiderot, Paris, France; [Reinhardt, D.] AML BFM Study Grp, Hannover, Germany; [Kaspers, G. J. L.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Marschalek, R.] ZAFES, DCAL, Inst Pharmaceut Biol, Frankfurt, Germany; [Nigro, L. L.] Azienda Policlin, Ctr Pediat Hematol Oncol, Catania, Italy; [Dworzak, M.] Med Univ Vienna, St Anna Childrens Hosp, Vienna, Austria; [Dworzak, M.] Med Univ Vienna, Childrens Canc Res Inst, Dept Pediat, Vienna, Austria","Coenen, EA (reprint author), Sophia Childrens Univ Hosp, Erasmus MC, Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl",null,null,null,null,null,22,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924","1476-5551",null,"LEUKEMIA","Leukemia","JUL",2014,28,7,null,null,null,null,1564,1568,null,"10.1038/leu.2014.82",null,5,"Oncology; Hematology","Oncology; Hematology","AM2UE","WOS:000339705500028",24561520]
["J","Emmrich, S; Katsman-Kuipers, JE; Henke, K; Khatib, ME; Jammal, R; Engeland, F; Dasci, F; Zwaan, CM; den Boer, ML; Verboon, L; Stary, J; Baruchel, A; de Haas, V; Danen-van Oorschot, AA; Fornerod, M; Pieters, R; Reinhardt, D; Klusmann, JH; van den Heuvel-Eibrink, MM",null,null,null,"Emmrich, S.; Katsman-Kuipers, J. E.; Henke, K.; Khatib, M. E.; Jammal, R.; Engeland, F.; Dasci, F.; Zwaan, C. M.; den Boer, M. L.; Verboon, L.; Stary, J.; Baruchel, A.; de Haas, V.; Danen-van Oorschot, A. A.; Fornerod, M.; Pieters, R.; Reinhardt, D.; Klusmann, J. H.; van den Heuvel-Eibrink, M. M.",null,null,"miR-9 is a tumor suppressor in pediatric AML with t(8;21)","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"microRNA; AML1-ETO; t(8;21); miR-9; LIN28B; HMGA2","ACUTE MYELOID-LEUKEMIA; INTERNATIONAL EXPERT PANEL; GENETIC-HETEROGENEITY; ABERRANT EXPRESSION; UP-REGULATION; MICRORNA; LET-7; HMGA2; DIFFERENTIATION; CELLS","MicroRNAs (miRNAs) play a pivotal role in the regulation of hematopoiesis and development of leukemia. Great interest emerged in modulating miRNA expression for therapeutic purposes. In order to identify miRNAs, which specifically suppress leukemic growth of acute myeloid leukemia (AML) with t(8; 21), inv(16) or mixed lineage leukemia (MLL) rearrangement by inducing differentiation, we conducted a miRNA expression profiling in a cohort of 90 cytogenetically characterized, de novo pediatric AML cases. Four miRNAs, specifically downregulated in MLL-rearranged, t(8; 21) or inv(16) AMLs, were characterized by their tumor-suppressive properties in cell lines representing those respective cytogenetic groups. Among those, forced expression of miR-9 reduced leukemic growth and induced monocytic differentiation of t(8; 21) AML cell lines in vitro and in vivo. The tumor-suppressive functions of miR-9 were specifically restricted to AML cell lines and primary leukemic blasts with t(8; 21). On the other hand, these functions were not evident in AML blasts from patients with MLL rearrangements. We showed that miR-9 exerts its effects through the cooperation with let-7 to repress the oncogenic LIN28B/HMGA2 axis. Thus, miR-9 is a tumor suppressor-miR which acts in a stringent cell contextdependent manner.","[Emmrich, S.; Henke, K.; Khatib, M. E.; Jammal, R.; Engeland, F.; Dasci, F.; Reinhardt, D.; Klusmann, J. H.] Hannover Med Sch, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany; [Katsman-Kuipers, J. E.; Zwaan, C. M.; den Boer, M. L.; Verboon, L.; Danen-van Oorschot, A. A.; Fornerod, M.; Pieters, R.; van den Heuvel-Eibrink, M. M.] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands; [Stary, J.] Charles Univ Prague, Prague, Czech Republic; [Stary, J.] Univ Hosp Motol, Prague, Czech Republic; [Baruchel, A.] St Louis Hosp, Paris, France; [de Haas, V.] Dutch Childhood Oncol Grp, The Hague, Netherlands","Klusmann, JH (reprint author), Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.","klusmann.jan-henning@mh-hannover.de; m.vandenheuvel@erasmusmc.nl",null,null,"Hannover Biomedical Research School; Children Cancer Free Foundation [49]; German Research Foundation (DFG) [KL-2374/2-1]; DFG; KIKA","The authors would like to thank J Schoening for general lab support; Drs. K Weber and B Fehse for providing plasmids. SE, FE, RJ and KH were supported by the Hannover Biomedical Research School. JEK-K, LV and AAD-vO were supported by the Children Cancer Free Foundation (KIKA, project 49). JHK is a fellow of the Emmy Noether-Programme from the German Research Foundation (DFG; KL-2374/2-1). This work was supported by grants to JHK from the DFG (KL-2374/2-1) and to JEK, CMZ and MMvdH-E from KIKA (project 49).",null,53,1,1,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924","1476-5551",null,"LEUKEMIA","Leukemia","MAY",2014,28,5,null,null,null,null,1022,1032,null,"10.1038/leu.2013.357",null,11,"Oncology; Hematology","Oncology; Hematology","AI2BJ","WOS:000336661500006",24270738]
["J","Kortum, F; Abdollahpour, H; Alawi, M; Korenke, G; Seemanova, E; Tinschert, S; Zenker, M; Rosenberger, G; Kutsche, K",null,null,null,"Kortuem, F.; Abdollahpour, H.; Alawi, M.; Korenke, G. C.; Seemanova, E.; Tinschert, S.; Zenker, M.; Rosenberger, G.; Kutsche, K.",null,null,"Exome sequencing for identification of disease genes for rare syndromes. Experiences from Hamburg","MEDIZINISCHE GENETIK",null,null,"German","Article",null,null,null,null,null,"High-throughput nucleotide sequencing; Exome; Variant prioritization; Mendelian disorder; Molecular diagnostics","ENCODING DELTA(1)-PYRROLINE-5-CARBOXYLATE SYNTHASE; SOMATIC ACTIVATING MUTATIONS; CAUSE COSTELLO-SYNDROME; PROTEIN COMPLEX; INTELLECTUAL DISABILITY; PHENOTYPIC SPECTRUM; TRANS-GOLGI; DISCOVERY; GERMLINE; GENETICS","Whole exome sequencing (WES) is the state-of-the-art method for identification of pathogenic mutations in patients with a Mendelian disorder. WES comprehensively covers the coding sequence of the genome and is a fast and cost-effective technique. As most of the technical difficulties have been overcome for WES, the major issue is data processing and analysis to find the pathogenic sequence variation among tens of thousands of sequence changes. Bioinformatic analysis pipelines for filtering sequence variants have to be adapted according to the patients and family members examined by WES and the most likely inheritance pattern underlying the disease. Based on 4 cases, different variant prioritization strategies which led to identification of the most likely causative changes in the index patients are described.","[Kortuem, F.; Abdollahpour, H.; Rosenberger, G.; Kutsche, K.] Univ Klinikum Hamburg Eppendorf, Inst Humangenet, D-20246 Hamburg, Germany; [Alawi, M.] Univ Klinikum Hamburg Eppendorf, Bioinformat Serv Facil, D-20246 Hamburg, Germany; [Alawi, M.] Heinrich Pette Inst, Leibniz Inst Expt Virol, Hamburg, Germany; [Korenke, G. C.] Klinikum Oldenburg, Zentrum Kinder & Jugendmed, Oldenburg, Germany; [Seemanova, E.] Charles Univ Prague, Univ Hosp Motol, Inst Biol & Med Genet, Dept Clin Genet,Med Sch 2, Prague, Czech Republic; [Tinschert, S.] Med Univ Innsbruck, Dept Med Genet Mol & Klin Pharmakol, Sekt Humangenet, Innsbruck, Austria; [Tinschert, S.] Tech Univ Dresden, Inst Klin Genet, Med Fak Carl Gustav Carus, Dresden, Germany; [Zenker, M.] Univ Magdeburg, Inst Humangenet, D-39106 Magdeburg, Germany","Rosenberger, G (reprint author), Univ Klinikum Hamburg Eppendorf, Inst Humangenet, Martinistr 52, D-20246 Hamburg, Germany.","rosenberger@uke.de; kkutsche@uke.de",null,null,null,null,null,39,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1863-5490",null,null,"MED GENET-BERLIN","Med. Genet.","JUN",2014,26,2,null,null,null,null,246,254,null,"10.1007/s11825-014-0446-8",null,9,"Genetics & Heredity","Genetics & Heredity","AM5HD","WOS:000339886900004"]
["S","Jiruska, P; de Curtis, M; Jefferys, JGR",null,"Jiruska, P; DeCurtis, M; Jefferys, JGR",null,"Jiruska, Premysl; de Curtis, Marco; Jefferys, John G. R.",null,null,"Modern Concepts of Focal Epileptic Networks","MODERN CONCEPTS OF FOCAL EPILEPTIC NETWORKS","International Review of Neurobiology",null,"English","Review; Book Chapter",null,null,null,null,null,null,"TEMPORAL-LOBE EPILEPSY; BRAIN NETWORKS; INHIBITION; EPILEPTOGENESIS; EXCITABILITY; HYPOTHESIS; CHANNELS; CORTEX",null,"[Jiruska, Premysl] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Prague, Czech Republic; [Jiruska, Premysl] Charles Univ Prague, Motol Univ Hosp, Dept Neurol, Fac Med 2, Prague, Czech Republic; [de Curtis, Marco] Ist Neurol C Besta, Fdn IRCCS, Dept Epileptol & Expt Neurophysiol, Milan, Italy; [Jefferys, John G. R.] Univ Birmingham, Sch Clin & Expt Med, Neuronal Networks Grp, Birmingham, W Midlands, England; [Jefferys, John G. R.] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England","Jiruska, P (reprint author), Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Prague, Czech Republic.","jiruskapremysl@gmail.com",null,null,null,null,null,34,0,0,"ELSEVIER ACADEMIC PRESS INC","SAN DIEGO","525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA","0074-7742",null,"978-0-12-418693-4","INT REV NEUROBIOL","Int. Rev. Neurobiol.",null,2014,114,null,null,null,null,null,1,7,null,"10.1016/B978-0-12-418693-4.00001-7",null,7,"Neurosciences","Neurosciences & Neurology","BB0MO","WOS:000340439500001",25078496]
["S","Blauwblomme, T; Jiruska, P; Huberfeld, G",null,"Jiruska, P; DeCurtis, M; Jefferys, JGR",null,"Blauwblomme, Thomas; Jiruska, Premysl; Huberfeld, Gilles",null,null,"Mechanisms of Ictogenesis","MODERN CONCEPTS OF FOCAL EPILEPTIC NETWORKS","International Review of Neurobiology",null,"English","Review; Book Chapter",null,null,null,null,null,null,"TEMPORAL-LOBE EPILEPSY; HIGH-FREQUENCY OSCILLATIONS; RAT HIPPOCAMPAL SLICES; CA1 PYRAMIDAL CELLS; HUMAN EPILEPTOGENIC HIPPOCAMPUS; SEIZURE-LIKE ACTIVITY; CEREBRAL-BLOOD-FLOW; LOW-CALCIUM MODEL; SYSTEM IN-VITRO; EPILEPTIFORM ACTIVITY","Epilepsy is a paroxysmal condition characterized by repeated transient seizures separated by longer interictal periods. lctogenesis describes the processes of transition from the interictal state to a seizure. The processes include a preictal state, with specific clinical signs and a distinct electrophysiology which may provide opportunities to anticipate, or even prevent, seizures. Biological mechanisms of ictogenesis remain poorly understood and may vary between conditions/syndromes. We review here ictogenic processes including the involvement of pyramidal cells, interneurons and astrocytes, GABAergic and glutamatergic signaling, and ionic perturbations. Our review suggests that specific excitatory influences at the transition to an ictal event include (1) GABA receptor activation with a neuronal Cl- load and (2) a transient increase in external K+.","[Blauwblomme, Thomas] Hop Necker Enfants Malad, APHP, Neurosurg Unit, Paris, France; [Blauwblomme, Thomas] Univ Paris 05, Paris, France; [Blauwblomme, Thomas; Huberfeld, Gilles] INSERM, Infantile Epilepsies & Brain Plast U1129, Paris, France; [Blauwblomme, Thomas; Huberfeld, Gilles] Univ Paris 05, PRES Sorbonne Paris Cite, Paris, France; [Blauwblomme, Thomas; Huberfeld, Gilles] CEA, Gif Sur Yvette, France; [Jiruska, Premysl] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Prague, Czech Republic; [Jiruska, Premysl] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Neurol, Prague, Czech Republic; [Huberfeld, Gilles] CHU Pitie Salpetriere, APHP, Dept Clin Neurophysiol, Paris, France; [Huberfeld, Gilles] Univ Paris 06, Paris, France","Huberfeld, G (reprint author), INSERM, Infantile Epilepsies & Brain Plast U1129, Paris, France.","gilles.huberfeld@upmc.fr",null,null,null,null,null,176,0,0,"ELSEVIER ACADEMIC PRESS INC","SAN DIEGO","525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA","0074-7742",null,"978-0-12-418693-4","INT REV NEUROBIOL","Int. Rev. Neurobiol.",null,2014,114,null,null,null,null,null,155,185,null,"10.1016/B978-0-12-418693-4.00007-8",null,31,"Neurosciences","Neurosciences & Neurology","BB0MO","WOS:000340439500007",25078502]
["S","Martinkovic, L; Hecimovic, H; Sulc, V; Marecek, R; Marusic, P",null,"Jiruska, P; DeCurtis, M; Jefferys, JGR",null,"Martinkovic, Lukas; Hecimovic, Hrvoje; Sulc, Vlastimil; Marecek, Radek; Marusic, Petr",null,null,"Modern Techniques of Epileptic Focus Localization","MODERN CONCEPTS OF FOCAL EPILEPTIC NETWORKS","International Review of Neurobiology",null,"English","Review; Book Chapter",null,null,null,null,null,null,"TEMPORAL-LOBE EPILEPSY; POSITRON-EMISSION-TOMOGRAPHY; VOXEL-BASED MORPHOMETRY; GENERALIZED TONICCLONIC SEIZURES; INDEPENDENT COMPONENT ANALYSIS; HIGH-FREQUENCY OSCILLATIONS; FOCAL CORTICAL DYSPLASIA; COMPLEX PARTIAL SEIZURES; 5-HT1A RECEPTOR-BINDING; EEG-CORRELATED FMRI","A clear concept of epileptic zones remains of high clinical relevance in presurgical evaluation of refractory epilepsy patients and in resection planning. Recent advances in understanding how each of the epileptic zones is functionally organized strengthened the importance of the network concept. It has been shown that neuronal networks underlying the individual epileptic zone may involve multiple brain structures with complex interactions between them. The network concept has impact not only for better understanding of pathophysiology of partial epilepsy but also for clinical practice, particularly for epilepsy surgery. This review examines recent reports on the use of advanced imaging techniques which enable to map the epileptic zones and their structural and functional organization. Magnetic resonance postprocessing substantially improved the accuracy in detection of the epileptogenic lesions. The seizure-onset zone is primarily determined by electrophysiology but can also be localized using single photon emission computed tomography. The functional deficit zone is commonly assessed by a number of tests including methods of functional neuroimaging (positron emission tomography) which can delineate hypometabolic cortical areas and subcortical structures. Hemodynamic fluctuations associated with interictal epileptiform discharges can be detected by novel functional magnetic resonance technique which is nowadays widely used for the irritative zone localization. These techniques open new prospect for epilepsy surgery in patients who were previously considered as not suitable candidates of surgical treatment.","[Martinkovic, Lukas; Sulc, Vlastimil; Marusic, Petr] Charles Univ Prague, Dept Neurol, Motol Univ Hosp, Fac Med 2, Prague, Czech Republic; [Hecimovic, Hrvoje] Univ Hosp, Dept Neurol, Zagreb Epilepsy Ctr, Zagreb, Croatia; [Marecek, Radek] Masaryk Univ, CEITEC Cent European Inst Technol, Brno, Czech Republic; [Marecek, Radek] Masaryk Univ, Brno Epilepsy Ctr, Dept Neurol, St Annes Univ Hosp, Brno, Czech Republic; [Marecek, Radek] Masaryk Univ, Fac Med, Brno, Czech Republic","Marusic, P (reprint author), Charles Univ Prague, Dept Neurol, Motol Univ Hosp, Fac Med 2, Prague, Czech Republic.","petr.marusic@fnmotol.cz",null,null,null,null,null,120,0,0,"ELSEVIER ACADEMIC PRESS INC","SAN DIEGO","525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA","0074-7742",null,"978-0-12-418693-4","INT REV NEUROBIOL","Int. Rev. Neurobiol.",null,2014,114,null,null,null,null,null,245,278,null,"10.1016/B978-0-12-418693-4.00010-8",null,34,"Neurosciences","Neurosciences & Neurology","BB0MO","WOS:000340439500010",25078505]
["J","Drabova, J; Trkova, M; Hancarova, M; Novotna, D; Hejtmankova, M; Havlovicova, M; Sedlacek, Z",null,null,null,"Drabova, Jana; Trkova, Marie; Hancarova, Miroslava; Novotna, Drahuse; Hejtmankova, Michaela; Havlovicova, Marketa; Sedlacek, Zdenek",null,null,"A 15 Mb large paracentric chromosome 21 inversion identified in Czech population through a pair of flanking duplications","MOLECULAR CYTOGENETICS",null,null,"English","Article",null,null,null,null,null,"Inversion; Duplication; USP25; SNP arrays; Founder effect","HUMAN GENOME; PERICENTRIC INVERSIONS; SEGREGATION ANALYSIS; POLYMORPHISM; ORIGIN; RECOMBINATION; PHENOTYPE; VARIANTS; CLUSTERS; DATABASE","Background: Inversions are balanced structural chromosome rearrangements, which can influence gene expression and the risk of unbalanced chromosome constitution in offspring. Many examples of inversion polymorphisms exist in human, affecting both heterochromatic regions and euchromatin. Results: We describe a novel, 15 Mb long paracentric inversion, inv(21)(q21.1q22.11), affecting more than a third of human 21q. Despite of its length, the inversion cannot be detected using karyotyping due to similar band patterns on the normal and inverted chromosomes, and is therefore likely to escape attention. Its identification was aided by the repeated observation of the same pair of 150 kb long duplications present in cis on chromosome 21 in three Czech families subjected to microarray analysis. The finding prompted us to hypothesise that this co-occurrence of two remote duplications could be associated with an inversion of the intervening segment, and this speculation turned out to be right. The inversion was confirmed in a series of FISH experiments which also showed that the second copy of each of the duplications was always located at the opposite end of the inversion. The presence of the same pair of duplications in additional individuals reported in public databases indicates that the inversion may also be present in other populations. Three out of the total of about 4000 chromosomes 21 examined in our sample carried the duplications and were inverted, corresponding to carrier frequency of about 1/660. Although the breakpoints affect protein-coding genes, the occurrence of the inversion in normal parents and siblings of our patients and the occurrence of the duplications in unaffected controls in databases indicate that this rare variant is rather non-pathogenic. The inverted segment carried an identical shared haplotype in the three families studied. The haplotypes, however, diverged very rapidly in the flanking regions, possibly pointing to an ancient founder event at the origin of the inversion. Conclusions: The identification of inv(21)(q21.1q22.11) supports the notion that paracentric inversions are the most common form of chromosomal variation and that some of them may still remain undetected.","[Drabova, Jana; Hancarova, Miroslava; Novotna, Drahuse; Havlovicova, Marketa; Sedlacek, Zdenek] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Drabova, Jana; Hancarova, Miroslava; Novotna, Drahuse; Havlovicova, Marketa; Sedlacek, Zdenek] Univ Hosp Motol, Prague, Czech Republic; [Trkova, Marie; Hejtmankova, Michaela] Gennet, Prague, Czech Republic","Sedlacek, Z (reprint author), Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic.","zdenek.sedlacek@lfmotol.cuni.cz",null,null,"European Commission [CHERISH 223692, COST BM1004, CZ.2.16/3.1.00/24022]; Czech Ministry of Health [NT/14200, DRO UH Motol 00064203, LD11028]; Czech Ministry of Education [NT/14200, DRO UH Motol 00064203, LD11028]","We thank the families of the patients for their cooperation, and Tereza Jancuskova and Sona Pekova for the preparation of FISH probes. The study was supported by grants CHERISH 223692, COST BM1004 and CZ.2.16/3.1.00/24022 from the European Commission, and NT/14200, DRO UH Motol 00064203 and LD11028 from the Czech Ministries of Health and Education.",null,28,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1755-8166",null,null,"MOL CYTOGENET","Mol. Cytogenet.","AUG 19",2014,7,null,null,null,null,null,null,null,51,"10.1186/1755-8166-7-51",null,8,"Genetics & Heredity","Genetics & Heredity","AO7CD","WOS:000341508700001"]
["J","Amler, E; Filova, E; Buzgo, M; Prosecka, E; Rampichova, M; Necas, A; Nooeaid, P; Boccaccini, AR",null,null,null,"Amler, Evzen; Filova, Eva; Buzgo, Matej; Prosecka, Eva; Rampichova, Michala; Necas, Alois; Nooeaid, Patcharakamon; Boccaccini, Aldo R.",null,null,"Functionalized nanofibers as drug-delivery systems for osteochondral regeneration","NANOMEDICINE",null,null,"English","Review",null,null,null,null,null,"bone; cartilage; drug delivery; electrospinning; liposome; nanofiber","MESENCHYMAL STEM-CELLS; BONE MORPHOGENETIC PROTEIN-2; AUTOLOGOUS CHONDROCYTE IMPLANTATION; TISSUE ENGINEERING APPLICATIONS; BMP-INDUCED OSTEOGENESIS; GROWTH-FACTOR DELIVERY; CONTROLLED-RELEASE; ELECTROSPUN NANOFIBERS; COMPOSITE SCAFFOLD; CARTILAGE REPAIR","A wide range of drug-delivery systems are currently attracting the attention of researchers. Nanofibers are very interesting carriers for drug delivery. This is because nanofibers are versatile, flexible, nanobiomimetic and similar to extracellular matrix components, possible to be functionalized both on their surface as well as in their core, and also because they can be produced easily and cost effectively. There have been increasing attempts to use nanofibers in the construction of a range of tissues, including cartilage and bone. Nanofibers have also been favorably engaged as a drug-delivery system in cell-free scaffolds. This short overview is devoted to current applications and to further perspectives of nanofibers as drug-delivery devices in the field of cartilage and bone regeneration, and also in osteochondral reconstruction.","[Amler, Evzen; Prosecka, Eva] Charles Univ Prague, Dept Biophys, Fac Med 2, Prague 15006, Czech Republic; [Amler, Evzen; Filova, Eva; Buzgo, Matej; Prosecka, Eva; Rampichova, Michala] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic; [Amler, Evzen] Nanoprogres Zspo, Pardubice 53009, Czech Republic; [Filova, Eva] Czech Tech Univ, Inst Biomed Engn, Kladno 27201, Czech Republic; [Buzgo, Matej; Rampichova, Michala] Univ Ctr Energy Efficient Bldg, Bustehrad 27343, Czech Republic; [Necas, Alois] Univ Vet & Pharmaceut Sci Brno, CEITEC Cent European Inst Technol, Brno, Czech Republic; [Nooeaid, Patcharakamon; Boccaccini, Aldo R.] Univ Erlangen Nurnberg, Inst Biomat, Dept Mat Sci & Engn, D-91058 Erlangen, Germany","Amler, E (reprint author), Charles Univ Prague, Dept Biophys, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","amler@lfmotol.cuni.cz","Boccaccini, Aldo/C-7905-2013",null,"Academy of Sciences of the Czech Republic [AV0Z50390703]; Ministry of Health of the Czech Republic [NT12156]; project 'CEITEC - Central European Institute of Technology' from the European Regional Development Fund [CZ.1.05/1.1.00/02.0068]; GAUK [626012, 384311, 545313, 424213, 270513, ESF CZ.1.07/2.3.00/20.0092]; UCEEB","The authors gratefully acknowledge funding from the Academy of Sciences of the Czech Republic (Institutional Research Plan AV0Z50390703), from the Ministry of Health of the Czech Republic (grant no. NT12156), by the project 'CEITEC - Central European Institute of Technology' (CZ.1.05/1.1.00/02.0068) from the European Regional Development Fund and GAUK (student grant nos. 626012, 384311, 545313, 424213, 270513, ESF CZ.1.07/2.3.00/20.0092), and from UCEEB support IPv6, which have provided support for some of the work discussed here. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in, or in financial conflict with, the subject matter or materials discussed in the manuscript (apart from those disclosed).",null,90,0,0,"FUTURE MEDICINE LTD","LONDON","UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND","1743-5889","1748-6963",null,"NANOMEDICINE-UK","Nanomedicine","MAY",2014,9,7,null,null,null,null,1083,1094,null,"10.2217/NNM.14.57",null,12,"Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology","Biotechnology & Applied Microbiology; Science & Technology - Other Topics","AK9YF","WOS:000338783800018",24978465]
["J","Ripke, S; Neale, BM; Corvin, A; Walters, JTR; Farh, KH; Holmans, PA; Lee, P; Bulik-Sullivan, B; Collier, DA; Huang, HL; Pers, TH; Agartz, I; Agerbo, E; Albus, M; Alexander, M; Amin, F; Bacanu, SA; Begemann, M; Belliveau, RA; Bene, J; Bergen, SE; Bevilacqua, E; Bigdeli, TB; Black, DW; Bruggeman, R; Buccola, NG; Buckner, RL; Byerley, W; Cahn, W; Cai, GQ; Campion, D; Cantor, RM; Carr, VJ; Carrera, N; Catts, SV; Chambert, KD; Chan, RCK; Chen, RYL; Chen, EYH; Cheng, W; Cheung, EFC; Chong, SA; Cloninger, CR; Cohen, D; Cohen, N; Cormican, P; Craddock, N; Crowley, JJ; Curtis, D; Davidson, M; Davis, KL; Degenhardt, F; Del Favero, J; Demontis, D; Dikeos, D; Dinan, T; Djurovic, S; Donohoe, G; Drapeau, E; Duan, J; Dudbridge, F; Durmishi, N; Eichhammer, P; Eriksson, J; Escott-Price, V; Essioux, L; Fanous, AH; Farrell, MS; Frank, J; Franke, L; Freedman, R; Freimer, NB; Friedl, M; Friedman, JI; Fromer, M; Genovese, G; Georgieva, L; Giegling, I; Giusti-Rodriguez, P; Godard, S; Goldstein, JI; Golimbet, V; Gopal, S; Gratten, J; de Haan, L; Hammer, C; Hamshere, ML; Hansen, M; Hansen, T; Haroutunian, V; Hartmann, AM; Henskens, FA; Herms, S; Hirschhorn, JN; Hoffmann, P; Hofman, A; Hollegaard, MV; Hougaard, DM; Ikeda, M; Joa, I; Julia, A; Kahn, RS; Kalaydjieva, L; Karachanak-Yankova, S; Karjalainen, J; Kavanagh, D; Keller, MC; Kennedy, JL; Khrunin, A; Kim, Y; Klovins, J; Knowles, JA; Konte, B; Kucinskas, V; Kucinskiene, ZA; Kuzelova-Ptackova, H; Kahler, AK; Laurent, C; Keong, JLC; Lee, SH; Legge, SE; Lerer, B; Li, MX; Li, T; Liang, KY; Lieberman, J; Limborska, S; Loughland, CM; Lubinski, J; Lonnqvist, J; Macek, M; Magnusson, PKE; Maher, BS; Maier, W; Mallet, J; Marsal, S; Mattheisen, M; Mattingsdal, M; McCarley, RW; McDonald, C; McIntosh, AM; Meier, S; Meijer, CJ; Melegh, B; Melle, I; Mesholam-Gately, RI; Metspalu, A; Michie, PT; Milani, L; Milanova, V; Mokrab, Y; Morris, DW; Mors, O; Murphy, KC; Murray, RM; Myin-Germeys, I; Muller-Myhsok, B; Nelis, M; Nenadic, I; Nertney, DA; Nestadt, G; Nicodemus, KK; Nikitina-Zake, L; Nisenbaum, L; Nordin, A; O'Callaghan, E; O'Dushlaine, C; O'Neill, FA; Oh, SY; Olincy, A; Olsen, L; Van Os, J; Pantelis, C; Papadimitriou, GN; Papiol, S; Parkhomenko, E; Pato, MT; Paunio, T; Pejovic-Milovancevic, M; Perkins, DO; Pietilainen, O; Pimm, J; Pocklington, AJ; Powell, J; Price, A; Pulver, AE; Purcell, SM; Quested, D; Rasmussen, HB; Reichenberg, A; Reimers, MA; Richards, AL; Roffman, JL; Roussos, P; Ruderfer, DM; Salomaa, V; Sanders, AR; Schall, U; Schubert, CR; Schulze, TG; Schwab, SG; Scolnick, EM; Scott, RJ; Seidman, LJ; Shi, JX; Sigurdsson, E; Silagadze, T; Silverman, JM; Sim, K; Slominsky, P; Smoller, JW; So, HC; Spencer, CCA; Stahl, EA; Stefansson, H; Steinberg, S; Stogmann, E; Straub, RE; Strengman, E; Strohmaier, J; Stroup, TS; Subramaniam, M; Suvisaari, J; Svrakic, DM; Szatkiewicz, JP; Soderman, E; Thirumalai, S; Toncheva, D; Tosato, S; Veijola, J; Waddington, J; Walsh, D; Wang, D; Wang, Q; Webb, BT; Weiser, M; Wildenauer, DB; Williams, NM; Williams, S; Witt, SH; Wolen, AR; Wong, EHM; Wormley, BK; Xi, HS; Zai, CC; Zheng, XB; Zimprich, F; Wray, NR; Stefansson, K; Visscher, PM; Adolfsson, R; Andreassen, OA; Blackwood, DHR; Bramon, E; Buxbaum, JD; Borglum, AD; Cichon, S; Darvasi, A; Domenici, E; Ehrenreich, H; Esko, T; Gejman, PV; Gill, M; Gurling, H; Hultman, CM; Iwata, N; Jablensky, AV; Jonsson, EG; Kendler, KS; Kirov, G; Knight, J; Lencz, T; Levinson, DF; Li, QQS; Liu, JJ; Malhotra, AK; McCarroll, SA; McQuillin, A; Moran, JL; Mortensen, PB; Mowry, BJ; Nothen, MM; Ophoff, RA; Owen, MJ; Palotie, A; Pato, CN; Petryshen, TL; Posthuma, D; Rietschel, M; Riley, BP; Rujescu, D; Sham, PC; Sklar, P; St Clair, D; Weinberger, DR; Wendland, JR; Werge, T; Daly, MJ; Sullivan, PF; O'Donovan, MC",null,null,null,"Ripke, Stephan; Neale, Benjamin M.; Corvin, Aiden; Walters, James T. R.; Farh, Kai-How; Holmans, Peter A.; Lee, Phil; Bulik-Sullivan, Brendan; Collier, David A.; Huang, Hailiang; Pers, Tune H.; Agartz, Ingrid; Agerbo, Esben; Albus, Margot; Alexander, Madeline; Amin, Farooq; Bacanu, Silviu A.; Begemann, Martin; Belliveau, Richard A., Jr.; Bene, Judit; Bergen, Sarah E.; Bevilacqua, Elizabeth; Bigdeli, Tim B.; Black, Donald W.; Bruggeman, Richard; Buccola, Nancy G.; Buckner, Randy L.; Byerley, William; Cahn, Wiepke; Cai, Guiqing; Campion, Dominique; Cantor, Rita M.; Carr, Vaughan J.; Carrera, Noa; Catts, Stanley V.; Chambert, Kimberly D.; Chan, Raymond C. K.; Chen, Ronald Y. L.; Chen, Eric Y. H.; Cheng, Wei; Cheung, Eric F. C.; Chong, Siow Ann; Cloninger, C. Robert; Cohen, David; Cohen, Nadine; Cormican, Paul; Craddock, Nick; Crowley, James J.; Curtis, David; Davidson, Michael; Davis, Kenneth L.; Degenhardt, Franziska; Del Favero, Jurgen; Demontis, Ditte; Dikeos, Dimitris; Dinan, Timothy; Djurovic, Srdjan; Donohoe, Gary; Drapeau, Elodie; Duan, Jubao; Dudbridge, Frank; Durmishi, Naser; Eichhammer, Peter; Eriksson, Johan; Escott-Price, Valentina; Essioux, Laurent; Fanous, Ayman H.; Farrell, Martilias S.; Frank, Josef; Franke, Lude; Freedman, Robert; Freimer, Nelson B.; Friedl, Marion; Friedman, Joseph I.; Fromer, Menachem; Genovese, Giulio; Georgieva, Lyudmila; Giegling, Ina; Giusti-Rodriguez, Paola; Godard, Stephanie; Goldstein, Jacqueline I.; Golimbet, Vera; Gopal, Srihari; Gratten, Jacob; de Haan, Lieuwe; Hammer, Christian; Hamshere, Marian L.; Hansen, Mark; Hansen, Thomas; Haroutunian, Vahram; Hartmann, Annette M.; Henskens, Frans A.; Herms, Stefan; Hirschhorn, Joel N.; Hoffmann, Per; Hofman, Andrea; Hollegaard, Mads V.; Hougaard, David M.; Ikeda, Masashi; Joa, Inge; Julia, Antonio; Kahn, Rene S.; Kalaydjieva, Luba; Karachanak-Yankova, Sena; Karjalainen, Juha; Kavanagh, David; Keller, Matthew C.; Kennedy, James L.; Khrunin, Andrey; Kim, Yunjung; Klovins, Janis; Knowles, James A.; Konte, Bettina; Kucinskas, Vaidutis; Kucinskiene, Zita Ausrele; Kuzelova-Ptackova, Hana; Kahler, Anna K.; Laurent, Claudine; Keong, Jimmy Lee Chee; Lee, S. Hong; Legge, Sophie E.; Lerer, Bernard; Li, Miaoxin; Li, Tao; Liang, Kung-Yee; Lieberman, Jeffrey; Limborska, Svetlana; Loughland, Carmel M.; Lubinski, Jan; Lonnqvist, Jouko; Macek, Milan, Jr.; Magnusson, Patrik K. E.; Maher, Brion S.; Maier, Wolfgang; Mallet, Jacques; Marsal, Sara; Mattheisen, Manuel; Mattingsdal, Morten; McCarley, Robert W.; McDonald, Colm; McIntosh, Andrew M.; Meier, Sandra; Meijer, Carin J.; Melegh, Bela; Melle, Ingrid; Mesholam-Gately, Raquelle I.; Metspalu, Andres; Michie, Patricia T.; Milani, Lili; Milanova, Vihra; Mokrab, Younes; Morris, Derek W.; Mors, Ole; Murphy, Kieran C.; Murray, Robin M.; Myin-Germeys, Inez; Mueller-Myhsok, Bertram; Nelis, Mari; Nenadic, Igor; Nertney, Deborah A.; Nestadt, Gerald; Nicodemus, Kristin K.; Nikitina-Zake, Liene; Nisenbaum, Laura; Nordin, Annelie; O'Callaghan, Eadbhard; O'Dushlaine, Colm; O'Neill, F. Anthony; Oh, Sang-Yun; Olincy, Ann; Olsen, Line; Van Os, Jim; Pantelis, Christos; Papadimitriou, George N.; Papiol, Sergi; Parkhomenko, Elena; Pato, Michele T.; Paunio, Tiina; Pejovic-Milovancevic, Milica; Perkins, Diana O.; Pietilainen, Olli; Pimm, Jonathan; Pocklington, Andrew J.; Powell, John; Price, Alkes; Pulver, Ann E.; Purcell, Shaun M.; Quested, Digby; Rasmussen, Henrik B.; Reichenberg, Abraham; Reimers, Mark A.; Richards, Alexander L.; Roffman, Joshua L.; Roussos, Panos; Ruderfer, Douglas M.; Salomaa, Veikko; Sanders, Alan R.; Schall, Ulrich; Schubert, Christian R.; Schulze, Thomas G.; Schwab, Sibylle G.; Scolnick, Edward M.; Scott, Rodney J.; Seidman, Larry J.; Shi, Jianxin; Sigurdsson, Engilbert; Silagadze, Teimuraz; Silverman, Jeremy M.; Sim, Kang; Slominsky, Petr; Smoller, Jordan W.; So, Hon-Cheong; Spencer, Chris C. A.; Stahl, Eli A.; Stefansson, Hreinn; Steinberg, Stacy; Stogmann, Elisabeth; Straub, Richard E.; Strengman, Eric; Strohmaier, Jana; Stroup, T. Scott; Subramaniam, Mythily; Suvisaari, Jaana; Svrakic, Dragan M.; Szatkiewicz, Jin P.; Soderman, Erik; Thirumalai, Srinivas; Toncheva, Draga; Tosato, Sarah; Veijola, Juha; Waddington, John; Walsh, Dermot; Wang, Dai; Wang, Qiang; Webb, Bradley T.; Weiser, Mark; Wildenauer, Dieter B.; Williams, Nigel M.; Williams, Stephanie; Witt, Stephanie H.; Wolen, Aaron R.; Wong, Emily H. M.; Wormley, Brandon K.; Xi, Hualin Simon; Zai, Clement C.; Zheng, Xuebin; Zimprich, Fritz; Wray, Naomi R.; Stefansson, Kari; Visscher, Peter M.; Adolfsson, Rolf; Andreassen, Ole A.; Blackwood, Douglas H. R.; Bramon, Elvira; Buxbaum, Joseph D.; Borglum, Anders D.; Cichon, Sven; Darvasi, Ariel; Domenici, Enrico; Ehrenreich, Hannelore; Esko, Tonu; Gejman, Pablo V.; Gill, Michael; Gurling, Hugh; Hultman, Christina M.; Iwata, Nakao; Jablensky, Assen V.; Jonsson, Erik G.; Kendler, Kenneth S.; Kirov, George; Knight, Jo; Lencz, Todd; Levinson, Douglas F.; Li, Qingqin S.; Liu, Jianjun; Malhotra, Anil K.; McCarroll, Steven A.; McQuillin, Andrew; Moran, Jennifer L.; Mortensen, Preben B.; Mowry, Bryan J.; Noethen, Markus M.; Ophoff, Roel A.; Owen, Michael J.; Palotie, Aarno; Pato, Carlos N.; Petryshen, Tracey L.; Posthuma, Danielle; Rietschel, Marcella; Riley, Brien P.; Rujescu, Dan; Sham, Pak C.; Sklar, Pamela; St Clair, David; Weinberger, Daniel R.; Wendland, Jens R.; Werge, Thomas; Daly, Mark J.; Sullivan, Patrick F.; O'Donovan, Michael C.",null,"Psychiat Genomics Consortium; Psychosis Endophenotypes Int Conso; Wellcome Trust Case-Control Consor","Biological insights from 108 schizophrenia-associated genetic loci","NATURE",null,null,"English","Article",null,null,null,null,null,null,"GENOME-WIDE ASSOCIATION; COMMON VARIANTS; PSYCHIATRIC-DISORDERS; BIPOLAR DISORDER; CONFERRING RISK; DISEASE; IDENTIFICATION; METAANALYSIS; MUTATIONS; FRAMEWORK","Schizophrenia is a highly heritable disorder. Genetic risk is conferred by a large number of alleles, including common alleles of small effect that might be detected by genome-wide association studies. Here we report a multi-stage schizophrenia genome-wide association study of up to 36,989 cases and 113,075 controls. We identify 128 independent associations spanning 108 conservatively defined loci that meet genome-wide significance, 83 of which have not been previously reported. Associations were enriched among genes expressed in brain, providing biological plausibility for the findings. Many findings have the potential to provide entirely new insights into aetiology, but associations at DRD2 and several genes involved in glutamatergic neurotransmission highlight molecules of known and potential therapeutic relevance to schizophrenia, and are consistent with leading pathophysiological hypotheses. Independent of genes expressed in brain, associations were enriched among genes expressed in tissues that have important roles in immunity, providing support for the speculated link between the immune system and schizophrenia.",{"$cut":{"chars":24131,"head":"[Ripke, Stephan; Neale, Benjamin M.; Farh, Kai-How; Lee, Phil; Bulik-Sullivan, Brendan; Huang, Hailiang; Fromer, Menachem; Goldstein, Jacqueline I.; Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA; [Ripke, Stephan; Neale, Benjamin M.; Lee, Phil; Bulik-Sullivan, Brendan; Belliveau, Richard A., Jr.; Bergen, Sarah E.; Bevilacqua, Elizabeth; Chambert, Kimberly D.; Fromer, Menachem; Genovese, Giulio; O'Dushlaine, Colm; Scolnick, Edward M.; Smoller, Jordan W.; McCarroll, Steven A.; Moran, Jennifer L.; Palotie, Aarno; Petryshen, Tracey L.; Daly, Mark J.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA; [Neale, Benjamin M.; Huang, Hailiang; Pers, Tune H.; Goldstein, Jacqueline I.; Hirschhorn, Joel N.; Price, Alkes; Stahl, Eli A.; Esko, Tonu; Daly, Mark J.] Broad Inst MIT & Harvard, Med & Populat Genet Program, Cambridge, MA 02142 USA; [Neale, Benjamin M.; Lee, Phil; Fromer, Menachem; Smoller, Jordan W.; Palotie, Aarno] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA; [Corvin, Aiden; Cormican, Paul; Donohoe, Gary; Morris, Derek W.; Gill, Michael] Univ Ireland Trinity Coll, Dept Psychiat, Neuropsychiat Genet Res Grp, Dublin 8, Ireland; [Walters, James T. R.; Holmans, Peter A.; Carrera, Noa; Craddock, Nick; Escott-Price, Valentina; Georgieva, Lyudmila; Hamshere, Marian L.; Kavanagh, David; Legge, Sophie E.; Pocklington, Andrew J.; Richards, Alexander L.; Ruderfer, Douglas M.; Williams, Nigel M.; Kirov, George; Owen, Michael J.; O'Donovan, Michael C.] Cardiff Univ, Sch Med, MRC Ctr Neuropsychiat Genet & Genom, Inst Psychol Med & Clin Neurosci, Cardiff CF24 4HQ, S Glam, Wales; [Holmans, Peter A.; Craddock, Nick; Owen, Michael J.; O'Donovan, Michael C.] Cardiff Univ, Natl Ctr Mental Hlth, Cardiff CF24 4HQ, S Glam, Wales; [Collier, David A.; Mokrab, Younes] Eli Lilly & Co Ltd, Erl Wood Manor, Windlesham GU20 6PH, Surrey, England; [Collier, David A.] Kings Coll London, Inst Psychiat, Social Genet & Dev Psychiat Ctr, London SE5 8AF, England; [Pers, Tune H.] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark; [Pers, Tune H.; Hirschhorn, Joel N.; Esko, Tonu] Boston Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA; [Pers, Tune H.; Hirschhorn, Joel N.; Esko, Tonu] Boston Childrens Hosp, Ctr Basic & Translat Obes Res, Boston, MA 02115 USA; [Agartz, Ingrid; Soderman, Erik; Jonsson, Erik G.] Karolinska Inst, Psychiat Sect, Dept Clin Neurosci, SE-17176 Stockholm, Sweden; [Agartz, Ingrid] Diakonhjemmet Hosp, Dept Psychiat, N-0319 Oslo, Norway; [Agartz, Ingrid; Djurovic, Srdjan; Mattingsdal, Morten; Melle, Ingrid; Andreassen, Ole A.; Jonsson, Erik G.] Univ Oslo, Inst Clin Med, KG Jebsen Ctr Psychosis Res, NORMENT, N-0424 Oslo, Norway; [Agerbo, Esben; Mortensen, Preben B.] Aarhus Univ, CIRRAU, Ctr Integrat Register Based Res, DK-8210 Aarhus, Denmark; [Agerbo, Esben; Mortensen, Preben B.] Aarhus Univ, Natl Ctr Register Based Res, DK-8210 Aarhus, Denmark; [Agerbo, Esben; Demontis, Ditte; Hansen, Thomas; Mattheisen, Manuel; Mors, Ole; Olsen, Line; Rasmussen, Henrik B.; Borglum, Anders D.; Mortensen, Preben B.; Werge, Thomas] Lundbeck Fdn Initiat Integrat Psychiat Res, iPSYCH, Aarhus, Denmark; [Albus, Margot] State Mental Hosp, D-85540 Haar, Germany; [Alexander, Madeline; Laurent, Claudine; Levinson, Douglas F.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Amin, Farooq] Atlanta Vet Affairs Med Ctr, Dept Psychiat & Behav Sci, Atlanta, GA 30033 USA; [Amin, Farooq] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA; [Bacanu, Silviu A.; Bigdeli, Tim B.; Webb, Bradley T.; Wormley, Brandon K.] Virginia Commonwealth Univ, Dept Psychiat, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23298 USA; [Begemann, Martin; Hammer, Christian; Papiol, Sergi; Ehrenreich, Hannelore] Max Planck Inst Expt Med, D-37075 Gottingen, Germany; [Bene, Judit; Melegh, Bela] Univ Pecs, Dept Med Genet, H-7624 Pecs, Hungary; [Bene, Judit; Melegh, Bela] Univ Pecs, Szentagothai Res Ctr, H-7624 Pecs, Hungary; [Bergen, Sara"}},"O'Donovan, MC (reprint author), Cardiff Univ, Sch Med, MRC Ctr Neuropsychiat Genet & Genom, Inst Psychol Med & Clin Neurosci, Cardiff CF24 4HQ, S Glam, Wales.","odonovanmc@cardiff.ac.uk","Myin-Germeys, Inez /L-5106-2014; McDonald, Colm/C-1430-2009; McCarley, Robert/N-5562-2014",null,"US National Institute of Mental Health [U01 MH094421]","Core funding for the Psychiatric Genomics Consortium is from the US National Institute of Mental Health (U01 MH094421). We thank T. Lehner (NIMH). The work of the contributing groups was supported by numerous grants from governmental and charitable bodies as well as philanthropic donation. Details are provided in the Supplementary Notes. Membership of the Wellcome Trust Case Control Consortium and of the Psychosis Endophenotype International Consortium are provided in the Supplementary Notes.",null,50,12,12,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0028-0836","1476-4687",null,"NATURE","Nature","JUL 24",2014,511,7510,null,null,null,null,421,"+",null,"10.1038/nature13595",null,17,"Multidisciplinary Sciences","Science & Technology - Other Topics","AL7SO","WOS:000339335700037"]
["J","Northcott, PA; Lee, C; Zichner, T; Stutz, AM; Erkek, S; Kawauchi, D; Shih, DJH; Hovestadt, V; Zapatka, M; Sturm, D; Jones, DTW; Kool, M; Remke, M; Cavalli, FMG; Zuyderduyn, S; Bader, GD; VandenBerg, S; Esparza, LA; Ryzhova, M; Wang, W; Wittmann, A; Stark, S; Sieber, L; Seker-Cin, H; Linke, L; Kratochwil, F; Jager, N; Buchhalter, I; Imbusch, CD; Zipprich, G; Raeder, B; Schmidt, S; Diessl, N; Wolf, S; Wiemann, S; Brors, B; Lawerenz, C; Eils, J; Warnatz, HJ; Risch, T; Yaspo, ML; Weber, UD; Bartholomae, CC; von Kalle, C; Turanyi, E; Hauser, P; Sanden, E; Darabi, A; Siesjo, P; Sterba, J; Zitterbart, K; Sumerauer, D; van Sluis, P; Versteeg, R; Volckmann, R; Koster, J; Schuhmann, MU; Ebinger, M; Grimes, HL; Robinson, GW; Gajjar, A; Mynarek, M; von Hoff, K; Rutkowski, S; Pietsch, T; Scheurlen, W; Felsberg, J; Reifenberger, G; Kulozik, AE; von Deimling, A; Witt, O; Eils, R; Gilbertson, RJ; Korshunov, A; Taylor, MD; Lichter, P; Korbel, JO; Wechsler-Reya, RJ; Pfister, SM",null,null,null,"Northcott, Paul A.; Lee, Catherine; Zichner, Thomas; Stuetz, Adrian M.; Erkek, Serap; Kawauchi, Daisuke; Shih, David J. H.; Hovestadt, Volker; Zapatka, Marc; Sturm, Dominik; Jones, David T. W.; Kool, Marcel; Remke, Marc; Cavalli, Florence M. G.; Zuyderduyn, Scott; Bader, Gary D.; VandenBerg, Scott; Esparza, Lourdes Adriana; Ryzhova, Marina; Wang, Wei; Wittmann, Andrea; Stark, Sebastian; Sieber, Laura; Seker-Cin, Huriye; Linke, Linda; Kratochwil, Fabian; Jaeger, Natalie; Buchhalter, Ivo; Imbusch, Charles D.; Zipprich, Gideon; Raeder, Benjamin; Schmidt, Sabine; Diessl, Nicolle; Wolf, Stephan; Wiemann, Stefan; Brors, Benedikt; Lawerenz, Chris; Eils, Juergen; Warnatz, Hans-Joerg; Risch, Thomas; Yaspo, Marie-Laure; Weber, Ursula D.; Bartholomae, Cynthia C.; von Kalle, Christof; Turanyi, Eszter; Hauser, Peter; Sanden, Emma; Darabi, Anna; Siesjoe, Peter; Sterba, Jaroslav; Zitterbart, Karel; Sumerauer, David; van Sluis, Peter; Versteeg, Rogier; Volckmann, Richard; Koster, Jan; Schuhmann, Martin U.; Ebinger, Martin; Grimes, H. Leighton; Robinson, Giles W.; Gajjar, Amar; Mynarek, Martin; von Hoff, Katja; Rutkowski, Stefan; Pietsch, Torsten; Scheurlen, Wolfram; Felsberg, Joerg; Reifenberger, Guido; Kulozik, Andreas E.; von Deimling, Andreas; Witt, Olaf; Eils, Roland; Gilbertson, Richard J.; Korshunov, Andrey; Taylor, Michael D.; Lichter, Peter; Korbel, Jan O.; Wechsler-Reya, Robert J.; Pfister, Stefan M.",null,null,"Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma","NATURE",null,null,"English","Article",null,null,null,null,null,null,"ZINC-FINGER PROTEIN; T-CELL LYMPHOMAGENESIS; STEM-CELLS; SUPER-ENHANCERS; CANCER; MUTATIONS; GENOME; GENE; MYC; SUBGROUP","Medulloblastoma is a highly malignant paediatric brain tumour currently treated with a combination of surgery, radiation and chemotherapy, posing a considerable burden of toxicity to the developing child. Genomics has illuminated the extensive intertumoral heterogeneity of medulloblastoma, identifying four distinct molecular subgroups. Group 3 and group 4 subgroup medulloblastomas account for most paediatric cases; yet, oncogenic drivers for these subtypes remain largely unidentified. Here we describe a series of prevalent, highly disparate genomic structural variants, restricted to groups 3 and 4, resulting in specific and mutually exclusive activation of the growth factor independent 1 family proto-oncogenes, GFI1 and GFI1B. Somatic structural variants juxtapose GFI1 or GFI1B coding sequences proximal to active enhancer elements, including super-enhancers, instigating oncogenic activity. Our results, supported by evidence from mouse models, identify GFI1 and GFI1B as prominent medulloblastoma oncogenes and implicate 'enhancer hijacking' as an efficient mechanism driving oncogene activation in a childhood cancer.","[Northcott, Paul A.; Erkek, Serap; Kawauchi, Daisuke; Sturm, Dominik; Jones, David T. W.; Kool, Marcel; Wittmann, Andrea; Stark, Sebastian; Sieber, Laura; Seker-Cin, Huriye; Linke, Linda; Kratochwil, Fabian; Pfister, Stefan M.] German Canc Res Ctr, Div Pediat Neurooncol, D-69120 Heidelberg, Germany; [Lee, Catherine] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Lee, Catherine; Esparza, Lourdes Adriana; Wechsler-Reya, Robert J.] Sanford Burnham Med Res Inst, Tumor Initiat & Maintenance Program, La Jolla, CA 92037 USA; [Zichner, Thomas; Stuetz, Adrian M.; Erkek, Serap; Raeder, Benjamin; Korbel, Jan O.] European Mol Biol Lab EMBL, Genome Biol Unit, D-69117 Heidelberg, Germany; [Shih, David J. H.; Remke, Marc; Cavalli, Florence M. G.; Taylor, Michael D.] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada; [Hovestadt, Volker; Zapatka, Marc; Wang, Wei; Weber, Ursula D.; Lichter, Peter] German Canc Res Ctr, Div Mol Genet, D-69120 Heidelberg, Germany; [Zuyderduyn, Scott; Bader, Gary D.] Univ Toronto, Donnelly Ctr, Toronto, ON M5S 3E1, Canada; [VandenBerg, Scott] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Ryzhova, Marina] NN Burdenko Inst Neurosurg, Dept Neuropathol, Moscow 125047, Russia; [Jaeger, Natalie; Buchhalter, Ivo; Brors, Benedikt; Eils, Roland] German Canc Res Ctr, Div Theoret Bioinformat, D-69120 Heidelberg, Germany; [Imbusch, Charles D.; Zipprich, Gideon; Lawerenz, Chris; Eils, Juergen] German Canc Res Ctr, Data Management Facil, D-69120 Heidelberg, Germany; [Schmidt, Sabine; Diessl, Nicolle; Wolf, Stephan; Wiemann, Stefan] German Canc Res Ctr, Genom & Prote Core Facil, D-69120 Heidelberg, Germany; [Warnatz, Hans-Joerg; Risch, Thomas; Yaspo, Marie-Laure] Max Planck Inst Mol Genet, Dept Vertebrate Genom, D-14195 Berlin, Germany; [Bartholomae, Cynthia C.; von Kalle, Christof] German Canc Res Ctr, Div Translat Oncol, D-69120 Heidelberg, Germany; [Bartholomae, Cynthia C.; von Kalle, Christof] Natl Ctr Tumor Dis NCT, D-69120 Heidelberg, Germany; [von Kalle, Christof; Eils, Roland; Lichter, Peter] Heidelberg Ctr Personalised Oncol DKFZ HIPO, D-69120 Heidelberg, Germany; [Turanyi, Eszter] Semmelweis Univ SE, Dept Pathol & Expt Canc Res 1, H-1094 Budapest, Hungary; [Hauser, Peter] Semmelweis Univ, Dept Pediat 2, H-1094 Budapest, Hungary; [Sanden, Emma; Darabi, Anna; Siesjoe, Peter] Lund Univ, Div Neurosurg, Glioma Immunotherapy Grp, S-22100 Lund, Sweden; [Sanden, Emma; Darabi, Anna; Siesjoe, Peter] Lund Univ, Dept Clin Sci, S-22100 Lund, Sweden; [Sterba, Jaroslav; Zitterbart, Karel] Masaryk Univ, Dept Pediat Oncol, Brno 61300, Czech Republic; [Sterba, Jaroslav; Zitterbart, Karel] Univ Hosp, Brno 61300, Czech Republic; [Sumerauer, David] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague 15006, Czech Republic; [Sumerauer, David] Univ Hosp Motol, Prague 15006, Czech Republic; [van Sluis, Peter; Versteeg, Rogier; Volckmann, Richard; Koster, Jan] Univ Amsterdam, AMC, Dept Oncogen, NL-1105 AZ Amsterdam, Netherlands; [Schuhmann, Martin U.; Ebinger, Martin] Tubingen Univ Hosp, Dept Neurosurg, D-72076 Tubingen, Germany; [Grimes, H. Leighton] Cincinnati Childrens Hosp Med Ctr, Program Hematol Malignancies, Program Canc Pathol, Div Immunobiol,Div Expt Hematol & Pathol,Canc & B, Cincinnati, OH 45229 USA; [Robinson, Giles W.; Gilbertson, Richard J.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; [Robinson, Giles W.; Gajjar, Amar; Gilbertson, Richard J.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; Univ Med Ctr Hamburg Eppendorf, Dept Paediat Haematol & Oncol, D-20246 Hamburg, Germany; [Pietsch, Torsten] Univ Bonn, Dept Neuropathol, D-53105 Bonn, Germany; [Scheurlen, Wolfram] Nurnberg Childrens Hosp, Cnopfsche Kinderklin, D-90419 Nurnberg, Germany; [Felsberg, Joerg; Reifenberger, Guido] Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany; [Kulozik, Andreas E.; Witt, Olaf; Pfister, Stefan M.] Univ Heidelberg Hosp, Dept Pediat Oncol Hematol & Immunol, D-69120 Heidelberg, Germany; [von Deimling, Andreas; Korshunov, Andrey] Heidelberg Univ, Dept Neuropathol, D-69120 Heidelberg, Germany; [Taylor, Michael D.] Hosp Sick Children, Div Neurosurg, Toronto, ON M5G 1X8, Canada; [Korbel, Jan O.] European Bioinformat Inst EMBL EBI, EMBL, Saffron Walden CB10 1SD, Essex, England","Northcott, PA (reprint author), German Canc Res Ctr, Div Pediat Neurooncol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.","m.macleod@dkfz-heidelberg.de; korbel@embl.de; rwreya@sanfordburnham.org; s.pfister@dkfz-heidelberg.de","Wiemann, Stefan/E-4424-2013; Eils, Roland/B-6121-2009; Pfister, Stefan/F-6860-2013; Kool, Marcel/H-2541-2013","Wiemann, Stefan/0000-0003-4683-3174; Pfister, Stefan/0000-0002-5447-5322; ","PedBrain Tumor Project - German Cancer Aid [109252]; German Federal Ministry of Education and Research (BMBF) [01KU1201A, MedSys 0315416C, NGFNplus 01GS0883]; German Cancer Research Center-Heidelberg Center for Personalized Oncology (DKFZ-HIPO); EMBL International PhD Programme; Dutch Cancer Foundation KWF [2010-4713]; Dutch Cancer Foundation KIKA; US National Institutes of Health, National Center for Research Resources [P41 GM103504]; CancerSys grant MYC-NET (German Federal Ministry of Education and Research, BMBF) [0316076A]; European Commission [Health-F2-2010-260791]; Helmholtz Alliance PCCC [HA-305]; Hertie Foundation; DKFZ; California Institute for Regenerative Medicine [CIRM LA1-01747]; National Cancer Institute [5P30CA030199, R01 CA159859]; CureSearch for Children's Cancer Foundation","For technical support and expertise we thank: the DKFZ Genomics and Proteomics Core Facility; B. Haase, D. Pavlinic and B. Baying (EMBL Genomics Core Facility); M. Knopf (NCT Heidelberg); the Sanford-Burnham Animal Facility and Cell Imaging, Tissue & Histopathology Shared Resource; and the UCSD Flow Cytometry Core Facility. We also thank Active Motif for the preparation of histone ChIP libraries. This work was principally supported by the PedBrain Tumor Project contributing to the International Cancer Genome Consortium, funded by the German Cancer Aid (109252) and by the German Federal Ministry of Education and Research (BMBF, grants 01KU1201A, MedSys 0315416C and NGFNplus 01GS0883). Additional support came from the German Cancer Research Center-Heidelberg Center for Personalized Oncology (DKFZ-HIPO), the EMBL International PhD Programme (T.Z.), Dutch Cancer Foundations KWF (2010-4713) and KIKA (M.Ko.), the US National Institutes of Health, National Center for Research Resources (P41 GM103504; G.D.B.), the CancerSys grant MYC-NET (German Federal Ministry of Education and Research, BMBF, 0316076A), the European Commission (Health-F2-2010-260791), and the Helmholtz Alliance PCCC (grant number HA-305). PAN is a Roman Herzog Postdoctoral Fellow funded by the Hertie Foundation and the DKFZ. R.J.W.-R. is the recipient of a Research Leadership Award from the California Institute for Regenerative Medicine (CIRM LA1-01747) and obtained additional support from the National Cancer Institute (5P30CA030199 and R01 CA159859), and the CureSearch for Children's Cancer Foundation.",null,46,1,1,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0028-0836","1476-4687",null,"NATURE","Nature","JUL 24",2014,511,7510,null,null,null,null,428,"+",null,"10.1038/nature13379",null,19,"Multidisciplinary Sciences","Science & Technology - Other Topics","AL7SO","WOS:000339335700038",25043047]
["J","Ptacek, R; Kuzelova, H; Stefano, GB; Raboch, J; Kream, RM; Goetz, M",null,null,null,"Ptacek, Radek; Kuzelova, Hana; Stefano, George B.; Raboch, Jiri; Kream, Richard M.; Goetz, Michal",null,null,"ADHD and growth: questions still unanswered","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"ADHD; attention deficit hyperactivity disorder; growth changes; medication; stimulants","ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; STIMULANT MEDICATION; CHILDREN; METHYLPHENIDATE; HEIGHT; BOYS; WEIGHT","Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed childhood psychiatric disorders. It is manifested in every part of an affected child's behavior, with multiple symptomatology and heterogenous etiology. Published studies report that ADHD children may show changes in growth and development. Most of the studies on ADHD have been focused on connections between medication and growth changes and describe growth delays associated with medication. However, recent research results point to the low significance of the changes accompanying pharmacological treatment. Changes in growth may not only be a secondary effect of the treatment, but may also be specific characteristics of ADHD.","[Ptacek, Radek; Kuzelova, Hana; Stefano, George B.; Raboch, Jiri; Kream, Richard M.] Charles Univ Prague, Fac Med 1, Psychiat Clin, Ctr Cognit & Mol Neurosci, Prague 12801 2, Czech Republic; [Stefano, George B.; Kream, Richard M.] SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA; [Goetz, Michal] Charles Univ Prague, Fac Med 2, Dept Paediat Psychiat, Prague 12801 2, Czech Republic","Ptacek, R (reprint author), Charles Univ Prague, Fac Med 1, Psychiat Clin, Ctr Cognit & Mol Neurosci, Ke Karlovu 11, Prague 12801 2, Czech Republic.","ptacek@neuro.cz",null,null,"Charles University \"PRVOUK\" [P03, P26]","Supported by the Program of Charles University \"PRVOUK P03 and P26\".",null,47,0,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2014,35,1,null,null,null,null,1,6,null,null,null,6,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","AM8UO","WOS:000340153500001",24625909]
["J","Charvat, J; Svab, P; Havlin, J; Bilek, R; Zamrazil, V",null,null,null,"Charvat, Jiri; Svab, Premysl; Havlin, Jan; Bilek, Radovan; Zamrazil, Vaclav",null,null,"The significance of plasma adrenomedullin and calcitonin gene-related peptide concentration in patients with Type 2 diabetes mellitus who are treated for cardiovascular risk factors","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"adrenomedullin; CGRP; cardiovascular prognosis; cardiovascular risk factors; Type 2 diabetes mellitus","LONG-TERM TREATMENT; NITRIC-OXIDE; HEART-FAILURE; CGRP; EXPRESSION; RATS; CARDIOPROTECTION; NITROGLYCERIN; ARTERY; LEVEL","OBJECTIVES: To evaluate the significance of plasma adrenomedullin and calcitonin gene-related peptide (CGRP) concentration in patients with Type 2 diabetes mellitus who are treated for hypertension and dyslipidemia. METHOD: Plasma adrenomedullin and CGRP concentration, transthoracal echocardiography and ABPM were evaluated in 82 patients with Type 2 diabetes mellitus and 41 control subjects with no previous cardiovascular disease. All the subjects had casual blood pressure =140/90 mmHg or received antihypertensive medication, were treated by statin if LDL cholesterol was >= 3mmol/L, by fibrates if triacylglyceroles >= 2 mmol/L. RESULTS: The mean age was 61 +/- 6 in patients with diabetes mellitus and 61 +/- 5 years in control subjects (p=0.9). Plasma CGRP was 3.0 +/- 1.8 in patients with diabetes mellitus and 2.3 +/- 1.0 ng/ml in control subjects (p=0.09). Plasma adrenomedullin was 2.2 +/- 0.9 in patients with diabetes mellitus and 2.8 +/- 1.1 ng/ml in control subjects (p=0.01). In patients with diabetes mellitus mass index of the left ventricle was significantly higher and the parameters of diastolic function were more deteriorated. Plasma adrenomedullin and CGRP correlated significantly negatively with serum creatinine and positively with mean 24 hours arterial blood pressure in patients with diabetes mellitus but not in control subjects. Plasma adrenomedullin concentration in patients with diabetes mellitus treated for hypertension was significantly reduced. CONCLUSION: Despite concentration plasma adrenomedullin and CGRP modulation by cardioprotective treatment both neuropeptides remained involved in regulation of hemodynamic and metabolic parameters in patients with Type 2 diabetes mellitus. The low plasma of adrenomedullin in patients with Type 2 diabetic may be marker of the efficient intervention on cardiovascular risk factors.","[Charvat, Jiri; Svab, Premysl; Havlin, Jan] Charles Univ Prague, Fac Med 2, Dept Med, Prague 15006 5, Czech Republic; [Charvat, Jiri; Svab, Premysl; Havlin, Jan] Fac Hosp Prague Motol, Motol, Czech Republic","Charvat, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Med, Uvalu 84, Prague 15006 5, Czech Republic.","jiri.charvat@lfmotol.cuni.cz",null,null,null,null,null,23,0,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2014,35,2,null,null,null,null,154,158,null,null,null,5,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","AM8US","WOS:000340153900012",24878981]
["J","Sulc, V; Stykel, S; Hanson, DP; Brinkmann, BH; Jones, DT; Holmes, DR; Robb, RA; Senjem, ML; Mullan, BP; Watson, RE; Horinek, D; Cascino, GD; Wong-Kisiel, LC; Britton, JW; So, EL; Worrell, GA",null,null,null,"Sulc, Vlastimil; Stykel, Samantha; Hanson, Dennis P.; Brinkmann, Benjamin H.; Jones, David T.; Holmes, David R., III; Robb, Richard A.; Senjem, Matthew L.; Mullan, Brian P.; Watson, Robert E., Jr.; Horinek, Daniel; Cascino, Gregory D.; Wong-Kisiel, Lily C.; Britton, Jeffrey W.; So, Elson L.; Worrell, Gregory A.",null,null,"Statistical SPECT processing in MRI-negative epilepsy surgery","NEUROLOGY",null,null,"English","Article",null,null,null,null,null,null,"TEMPORAL-LOBE EPILEPSY; SUBTRACTION ICTAL SPECT; EXTRATEMPORAL EPILEPSY; NEOCORTICAL EPILEPSY; INTRACTABLE EPILEPSY; PROGNOSTIC-FACTORS; LOCALIZING VALUE; SEIZURE FOCUS; LOCALIZATION; PREDICTORS","Objective:To evaluate the benefit of statistical SPECT processing over traditional subtraction methods, we compared ictal-interictal SPECT analyzed by statistical parametric mapping (SPM) (ISAS), statistical ictal SPECT coregistered to MRI (STATISCOM), and subtraction ictal-interictal SPECT coregistered with MRI (SISCOM) in patients with MRI-negative focal temporal lobe epilepsy (nTLE) and extratemporal lobe epilepsy (nETLE).Methods:We retrospectively identified 49 consecutive cases of drug-resistant focal epilepsy that had a negative preoperative MRI and underwent interictal and ictal SPECT prior to resective epilepsy surgery. Interictal and ictal SPECT scans were analyzed using SISCOM, ISAS, and STATISCOM to create hyperperfusion and hypoperfusion maps for each patient. Reviewers blinded to clinical data and the SPECT analysis method marked the site of probable seizure origin and indicated their confidence in the localization.Results:In nTLE and nETLE, the hyperperfusions detected by STATISCOM (71% nTLE, 57% nETLE) and ISAS (67% nTLE, 53% nETLE) were more often colocalized with surgery resection site compared to SISCOM (38% nTLE, 36% nETLE). In nTLE, localization of the hyperperfusion to the region of surgery was associated with an excellent outcome for STATISCOM (p = 0.005) and ISAS (p = 0.027), but not in SISCOM (p = 0.071). This association was not present in nETLE for any method.Conclusion:In an unselected group of patients with normal MRI and focal epilepsy, SPM-based methods of SPECT processing showed better localization of SPECT hyperperfusion to surgical resection site and higher interobserver agreement compared to SISCOM. These results show the benefit of statistical SPECT processing methods and further highlight the challenge of nETLE.","[Sulc, Vlastimil; Brinkmann, Benjamin H.; Jones, David T.; Cascino, Gregory D.; Wong-Kisiel, Lily C.; Britton, Jeffrey W.; So, Elson L.; Worrell, Gregory A.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Senjem, Matthew L.; Mullan, Brian P.; Watson, Robert E., Jr.] Mayo Clin, Dept Radiol, Rochester, MN USA; [Stykel, Samantha; Hanson, Dennis P.; Holmes, David R., III; Robb, Richard A.] Mayo Clin, Dept Biomed Imaging Resource, Rochester, MN USA; [Sulc, Vlastimil; Horinek, Daniel] St Annes Univ Hosp, Int Clin Res Ctr, Brno, Czech Republic; [Sulc, Vlastimil] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague, Czech Republic; [Sulc, Vlastimil] Motol Univ Hosp, Prague, Czech Republic","Worrell, GA (reprint author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.","worrell.gregory@mayo.edu","Sulc, Vlastimil/J-5162-2014","Sulc, Vlastimil/0000-0002-2815-3442","Mayo CTSA [UL1TR000135]; NIH [R01-NS63039]; IGA MZCR [NT/11536-5]; European Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; European Social Fund within the project Young Talent Incubator II [CZ.1.07/2.3.00/20.0117]","Supported by a gift from Mr. and Mrs. David Hawk, Mayo CTSA grant number UL1TR000135, NIH R01-NS63039 (G. A. W.), IGA MZCR NT/11536-5, European Regional Development Fund-Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123), and the European Social Fund within the project Young Talent Incubator II (reg. no. CZ.1.07/2.3.00/20.0117).",null,33,1,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0028-3878","1526-632X",null,"NEUROLOGY","Neurology","MAR 18",2014,82,11,null,null,null,null,932,939,null,"10.1212/WNL.0000000000000209",null,8,"Clinical Neurology","Neurosciences & Neurology","AH6TB","WOS:000336262500010",24532274]
["J","Laczo, J; Andel, R; Vyhnalek, M; Vlcek, K; Nedelska, Z; Matoska, V; Gazova, I; Mokrisova, I; Sheardova, K; Hort, J",null,null,null,"Laczo, Jan; Andel, Ross; Vyhnalek, Martin; Vlcek, Kamil; Nedelska, Zuzana; Matoska, Vaclav; Gazova, Ivana; Mokrisova, Ivana; Sheardova, Katerina; Hort, Jakub",null,null,"APOE and Spatial Navigation in Amnestic MCI: Results From a Computer-Based Test","NEUROPSYCHOLOGY",null,null,"English","Article",null,null,null,null,null,"mild cognitive impairment; apolipoprotein E; hippocampus; Hidden Goal Task; neuropsychology","MILD COGNITIVE IMPAIRMENT; UNILATERAL TEMPORAL LOBECTOMY; MORRIS WATER MAZE; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; VIRTUAL-REALITY; HUMAN ANALOG; MEMORY; HIPPOCAMPAL; BRAIN","Objective: We investigated the association between APOE epsilon 4 status and spatial navigation in patients with amnestic mild cognitive impairment (aMCI) and assessed the role of hippocampal volume in this association. Method: Participants were 74 patients with clinically confirmed aMCI (33 APOE epsilon 4 noncarriers, 26 heterozygous, and 15 homozygous epsilon 4 carriers). Body-centered (egocentric) and world-centered (allocentric) spatial navigation in a computerized human analogue of the Morris Water Maze was assessed. Brain MRI with subsequent automated hippocampal volumetry was included. Results: Groups were similar in neuropsychological profile. Controlling for age, sex, education, and free memory recall, the APOE epsilon 4 carriers performed more poorly on all spatial navigation subtasks (ps < .05). APOE epsilon 4 homozygotes performed worse than heterozygotes (p = .021). Right hippocampal volume accounted for the differences in allocentric and delayed subtasks (ps > .05), but not in the egocentric subtask (p < .001). Conclusions: Using an easy-to-use, computer-based tool to assess spatial navigation, we found spatial navigation deficits to worsen in a dose-dependent manner as a function of APOE epsilon 4 status. This was at least partially due to differences in right hippocampal volume.","[Laczo, Jan; Vyhnalek, Martin; Nedelska, Zuzana; Gazova, Ivana; Mokrisova, Ivana; Hort, Jakub] Charles Univ Prague, CR-11636 Prague 1, Czech Republic; [Laczo, Jan; Vyhnalek, Martin; Nedelska, Zuzana; Gazova, Ivana; Mokrisova, Ivana; Hort, Jakub] Motol Univ Hosp, Prague, Czech Republic; [Laczo, Jan; Andel, Ross; Vyhnalek, Martin; Vlcek, Kamil; Nedelska, Zuzana; Gazova, Ivana; Mokrisova, Ivana; Sheardova, Katerina; Hort, Jakub] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Andel, Ross] Univ S Florida, Tampa, FL 33612 USA; [Vlcek, Kamil] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Matoska, Vaclav] Homolka Hosp, Prague, Czech Republic","Andel, R (reprint author), Univ S Florida, Sch Aging Studies, 13301 Bruce B Downs Blvd, Tampa, FL 33612 USA.","randel@usf.edu","Vlcek, Kamil/B-9620-2012","Vlcek, Kamil/0000-0001-7152-3093","Grant Agency of the Czech Republic [309/09/1053, 309/09/0286]; Grant Agency of Charles University in Prague [624012, 546113]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NT11225-4]; European Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; European Social Fund; State Budget of the Czech Republic; European Social Fund within the project Young Talent Incubator II [CZ.1.07/2.3.00/20.0117]; Ministry of Health, Czech Republic-conceptual development of research organization, University Hospital Motol, Prague, Czech Republic [00064203]; CTSA from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 TR000135];  [2/2012 (699002)];  [AV0Z50110509];  [RVO:67985823]","Dr. Laczo has consulted for Pfizer and holds shares of Polyhymnia-TS. He declares that he has no other competing interests. Dr. Hort has consulted for Pfizer, Janssen, Merck, Novartis, Elan, Zentiva, and Ipsen and holds shares of Polyhymnia-TS. He declares that he has no other competing interests. Other coauthors declare that they have no commercial or financial relationships that could be construed as a potential conflict of interest. This study was supported by Grant Agency of the Czech Republic Grants 309/09/1053 and 309/09/0286; Grant Agency of Charles University in Prague Grants 624012 and 546113; Internal Grant Agency of the Ministry of Health of the Czech Republic Grant NT11225-4; European Regional Development Fund-Project FNUSA-ICRC (CZ.1.05/1.1.00/02.0123); European Social Fund and the State Budget of the Czech Republic; European Social Fund within the project Young Talent Incubator II (reg. CZ.1.07/2.3.00/20.0117); Ministry of Health, Czech Republic-conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203; Institutional Support of Laboratory Research Grant 2/2012 (699002); research projects AV0Z50110509 and RVO:67985823. Zuzana Nedelska is currently appointed as a research fellow with the Departments of Neurology and Radiology Alzheimer's Disease Imaging Research Laboratory, Mayo Clinic Rochester, MN and is further supported by CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.",null,35,0,0,"AMER PSYCHOLOGICAL ASSOC","WASHINGTON","750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA","0894-4105","1931-1559",null,"NEUROPSYCHOLOGY","Neuropsychology","SEP",2014,28,5,null,null,null,null,676,684,null,"10.1037/neu0000072",null,9,"Psychology, Clinical; Neurosciences; Psychology","Psychology; Neurosciences & Neurology","AO4FO","WOS:000341291800002",24749727]
["J","Demlova, R; Mrkvicova, M; Sterba, J; Bernatikova, H; Stary, J; Sukova, M; Mikuskova, A; Chocholova, A; Mladosievicova, B; Soltysova, A; Behulova, D; Pilatova, K; Zdrazilova-Dubska, L; Valik, D",null,null,null,"Demlova, Regina; Mrkvicova, Martina; Sterba, Jaroslav; Bernatikova, Hana; Stary, Jan; Sukova, Martina; Mikuskova, Alena; Chocholova, Alica; Mladosievicova, Beata; Soltysova, Andrea; Behulova, Darina; Pilatova, Katerina; Zdrazilova-Dubska, Lenka; Valik, Dalibor",null,null,"Augmenting Clinical Interpretability of Thiopurine Methyltransferase Laboratory Evaluation","ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"Acute lymphoblastic leukemia; Compound heterozygote; Genotype-phenotype correlation; Rate-blanked pharmacophenotyping; Thiopurine methyltransferase","ACUTE LYMPHOBLASTIC-LEUKEMIA; INFLAMMATORY-BOWEL-DISEASE; IMPLEMENTATION CONSORTIUM GUIDELINES; S-METHYLTRANSFERASE; PHARMACOGENETICS; THERAPY; MERCAPTOPURINE; POLYMORPHISMS; GENOTYPE; GENE","Objective: Individuals with decreased thiopurine methyltransferase (TPMT) activity are at risk of adverse effects of thiopurine administration whereas its increased activity may inactivate drugs faster. We evaluated genotype-phenotype correlations in patients with suspected hematological malignancies and inflammatory bowel disease from our region based on findings of nonlinear TPMT enzyme kinetics previously unreported. Patients and Methods: The study group comprised 267 individuals. They were screened for the most common variants of low TPMT activity. TPMT activity was measured in erythrocytes using the HPLC rate-blanked method. Results: Thirty-three patients (12.4%) were heterozygous (26 were TPMT*1/*3A, 5 TPMT*1/*2, 2 TPMT*1/*3C) and 1 was a compound heterozygote (*2/*3A). Normal and low normal TPMT activities substantially overlapped in wildtype and heterozygous individuals, whereas high activities were found in 29 wild-type genotyped patients. Extreme and life-threatening toxicity was observed in the compound heterozygote patient. Conclusion: Activity measurement performed at diagnosis provides clinicians with information on immediate pharmacokinetic-related adverse events and/or hypermetabolism, and genotyping may indicate the rate of pharmacodynamic thioguanine nucleotide accumulation due to slower overall thiopurine metabolism. (C) 2014 S. Karger AG, Basel","[Demlova, Regina; Zdrazilova-Dubska, Lenka] Masaryk Univ, Sch Med, Dept Pharmacol, Brno, Czech Republic; [Mrkvicova, Martina; Pilatova, Katerina; Zdrazilova-Dubska, Lenka; Valik, Dalibor] Masaryk Mem Canc Inst, Dept Lab Med, CZ-65653 Brno, Czech Republic; [Demlova, Regina; Mrkvicova, Martina; Mikuskova, Alena; Pilatova, Katerina; Zdrazilova-Dubska, Lenka] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, CZ-65653 Brno, Czech Republic; [Sterba, Jaroslav; Bernatikova, Hana; Valik, Dalibor] Univ Hosp Brno, Dept Pediat Oncol, Brno, Czech Republic; [Mikuskova, Alena] Masaryk Univ, Sch Med, Dept Lab Methods, Brno, Czech Republic; [Stary, Jan; Sukova, Martina] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Stary, Jan; Sukova, Martina] Univ Hosp Motol, Prague, Czech Republic; [Chocholova, Alica] Childrens Univ Hosp, Dept Pediat Hematol & Oncol, Bone Marrow Transplantat Unit, Bratislava, Slovakia; [Mladosievicova, Beata] Comenius Univ, Sch Med, Inst Pathol Physiol, Bratislava, Slovakia; [Soltysova, Andrea] Comenius Univ, Fac Nat Sci, Dept Mol Biol, Bratislava, Slovakia; [Behulova, Darina] Childrens Univ Hosp, Dept Lab Med, Bratislava, Slovakia","Valik, D (reprint author), Masaryk Mem Canc Inst, Dept Lab Med, Zluty Kopec 7, CZ-65653 Brno, Czech Republic.","valik@mou.cz",null,null,"MH CZ-DRO (MMCI) [00209805, MUNI/A/0964/2012]; European Regional Development Fund (RECAMO) [CZ.1.05/2.1.00/03.0101]; ACIU [LM2011017]","This work was supported by MH CZ-DRO (MMCI, 00209805), MUNI/A/0964/2012, European Regional Development Fund (RECAMO; CZ.1.05/2.1.00/03.0101) and ACIU (LM2011017) projects. We thank Dr. Ladislav Dusek for his statistical advice. The corresponding author (D.V.) wishes to express his special thanks to Prof. John F. O'Brien, Mayo Clinic, Rochester, Minn., USA, who independently verified D.V.'s initial findings on nonlinear TPMT enzyme kinetics.",null,31,0,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0030-2414","1423-0232",null,"ONCOLOGY-BASEL","Oncology",null,2014,86,3,null,null,null,null,152,158,null,"10.1159/000357407",null,7,"Oncology","Oncology","AH2GK","WOS:000335939300004",24643197]
["J","Mahelkova, G; Ferrova, K; Pochop, P; Odehnal, M; Dotrelova, D",null,null,null,"Mahelkova, Gabriela; Ferrova, Kvetoslava; Pochop, Pavel; Odehnal, Milan; Dotrelova, Dagmar",null,null,"Corneal Confocal Microscopy for Vision Disturbance After an Epithelial Abrasion","OPTOMETRY AND VISION SCIENCE",null,null,"English","Article",null,null,null,null,null,"corneal confocal microscopy; healing of corneal epithelium; traumatic corneal abrasion; corneal basal epithelial cells; visual disturbance","OPTICAL COHERENCE TOMOGRAPHY; PHOTOTHERAPEUTIC KERATECTOMY","Purpose. To demonstrate the use of in vivo corneal confocal microscopy to reveal the reason for persistent disturbance of vision after a corneal abrasion. Case Report. A 49-year-old man presented with a decrease in visual acuity and monocular diplopia after a traumatic corneal abrasion. Anterior segment optical coherence tomography was not beneficial. In vivo corneal confocal microscopy showed abnormal folding in the basal epithelial layer of the cornea. Based on these findings, a therapeutic abrasion of the affected epithelium was performed. Visual acuity returned to 1.0 after therapeutic abrasion, and overall findings on the eye were within physiological limits. Control corneal confocal microscopic examination confirmed reparation of the structure of epithelial cell layers. Conclusions. The in vivo corneal confocal microscopy can reveal corneal pathologic abnormality even in cases where other methods are not beneficial. Alongside other modern methods, it may become an important tool to help locate pathologic abnormality accurately and choose the proper therapeutic strategy.","[Mahelkova, Gabriela; Ferrova, Kvetoslava; Pochop, Pavel; Odehnal, Milan; Dotrelova, Dagmar] Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, Prague 15006 5, Czech Republic; [Mahelkova, Gabriela; Ferrova, Kvetoslava; Pochop, Pavel; Odehnal, Milan; Dotrelova, Dagmar] Univ Hosp Motol, Prague, Czech Republic; [Mahelkova, Gabriela] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague 15006 5, Czech Republic","Mahelkova, G (reprint author), Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic.","gabriela.mahelkova@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic [00064203]; University Hospital Motol, Prague, Czech Republic;  [CZ.2.16/3.1.00/24022]","The study was supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic) and CZ.2.16/3.1.00/24022.",null,16,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1040-5488","1538-9235",null,"OPTOMETRY VISION SCI","Optom. Vis. Sci.","JAN",2014,91,1,null,null,null,null,"E18","E20",null,null,null,3,"Ophthalmology","Ophthalmology","AH6BH","WOS:000336215200004",24212189]
["J","Berankova, K; Uhlik, J; Honkova, L; Pohunek, P",null,null,null,"Berankova, Katarina; Uhlik, Jiri; Honkova, Lenka; Pohunek, Petr",null,null,"Structural changes in the bronchial mucosa of young children at risk of developing asthma","PEDIATRIC ALLERGY AND IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"NF-kappa B; neutrophils; asthma; allergen immunotherapy","BASEMENT-MEMBRANE; EOSINOPHILIC INFLAMMATION; AIRWAY; LUNG; CHILDHOOD; TENASCIN; TISSUE; CELLS","Background Allergen-specific immunotherapy (IT) is widely used to treat allergic diseases. The molecular mechanisms have not been clarified yet completely. The present work was undertaken to analyze the effect of IT in the activation of NF-kappa B. Methods Neutrophils from 15 pollen-allergic IT-treated patients, 10 untreated pollen-allergic patients, and 10 healthy donors were in vitro stimulated with LPS. NF-kappa B activation (p65/p52) was measured in their nuclear extracts by enzyme-linked immunosorbent assay (ELISA). I kappa B alpha phosphorylation, NF-kappa B-repressing factor (NRF) activation, and thromboxane A(2) (TXA(2)) and Interleukin-8 (IL-8) release were measured by ELISA. Results There was a positive correlation between the score of symptoms and NF-kappa B activation in human neutrophils. IT significantly decreased NF-kappa B activation levels in neutrophils compared with neutrophils from untreated patients. I kappa B alpha phosphorylation and NRF activation levels were, respectively, significantly lower and higher in neutrophils from IT-treated patients than from untreated patients. IL-8 and TXA(2) release were significantly lower in neutrophils from IT-treated patients than from untreated patients. Conclusions IT positive effects are at least in part mediated by the negative regulation of NF-kappa B activation in human neutrophils. These observations represent a novel view of neutrophils as possible cell target to treat IgE-dependent diseases through NF-kappa B downmodulation.","[Berankova, Katarina; Honkova, Lenka; Pohunek, Petr] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague 15006 5, Motol, Czech Republic; [Berankova, Katarina; Honkova, Lenka; Pohunek, Petr] Univ Hosp Motol, Prague, Czech Republic; [Uhlik, Jiri] Charles Univ Prague, Dept Histol & Embryol, Fac Med 2, Prague 15006 5, Motol, Czech Republic","Uhlik, J (reprint author), Charles Univ Prague, Dept Histol & Embryol, Fac Med 2, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","jiri.uhlik@lfmotol.cuni.cz",null,null,"GAUK [340911]; IGA MH CR [NT/11444]","Supported by GAUK 340911 and IGA MH CR NT/11444.",null,26,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0905-6157","1399-3038",null,"PEDIAT ALLERG IMM-UK","Pediatr. Allergy Immunol.","MAR",2014,25,2,null,null,"SI",null,136,142,null,"10.1111/pai.12145",null,7,"Allergy; Immunology; Pediatrics","Allergy; Immunology; Pediatrics","AD1BE","WOS:000332968000005",24028346]
["J","Forbes, TA; Watson, AR; Zurowska, A; Shroff, R; Bakkaloglu, S; Vondrak, K; Fischbach, M; Van de Walle, J; Ariceta, G; Edefonti, A; Aufricht, C; Jankauskiene, A; Holta, T; Ekim, M; Schmitt, CP; Stefanidis, C",null,null,null,"Forbes, Thomas A.; Watson, Alan R.; Zurowska, Aleksandra; Shroff, Rukshana; Bakkaloglu, Sevcan; Vondrak, Karel; Fischbach, Michel; Van de Walle, Johan; Ariceta, Gema; Edefonti, Alberto; Aufricht, Christoph; Jankauskiene, Augustina; Holta, Tuula; Ekim, Mesiha; Schmitt, Claus Peter; Stefanidis, Constantinos",null,"European Paediat Dialysis Working","Adherence to transition guidelines in European paediatric nephrology units","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Adolescence; Chronic kidney disease; Guidelines; Survey; Transition; Young adult","KIDNEY-TRANSPLANT RECIPIENTS; ADULT CARE; YOUNG-ADULTS; HEALTH-CARE; ADOLESCENTS; CONSENSUS; READINESS; BRAIN; TRIAL; YOUTH","There is increasing focus on the problems involved in the transition and transfer of young adult patients from paediatric to adult renal units. This situation was addressed by the 2011 International Pediatric Nephrology Association/International Society of Nephrology (IPNA/ISN) Consensus Statement on transition. We performed a survey of transition practices of 15 paediatric nephrology units across Europe 2 years after publication of the consensus statement. Two thirds of units were aware of the guidelines, and one third had integrated them into their transition practice. Forty-seven per cent of units transfer five or fewer patients with chronic kidney disease (CKD) stage 5 per year to a median of five adult centres, with higher numbers of CKD stages 2-4 patients. Seventy-three per cent of units were required by the hospital or government to transfer patients by a certain age. Eighty per cent of units commenced transition planning after the patient turned 15 years of age and usually within 1-2 years of the compulsory transfer age. Forty-seven per cent of units used a transition or transfer clinic. Prominent barriers to effective transition were patient and parent attachment to the paediatric unit and difficulty in allowing the young person to perform self-care. Whereas awareness of the consensus statement is suboptimal, it has had some impact on practice. Adult nephrologists receive transferred patients infrequently, and the process of transition is introduced too late by paediatricians. Government- and hospital-driven age-based transfer policies distract focus from the achievement of competencies in self care. Variable use of transition clinics, written patient information and support groups is probably due to economic and human-resource limitations. The consensus statement provides a standard for evolving and evaluating transition policies jointly agreed upon by paediatric and adult units.","[Forbes, Thomas A.; Watson, Alan R.] Nottingham Childrens Hosp, Childrens Renal & Urol Unit, Nottingham NG7 2UH, England; [Zurowska, Aleksandra] Gdansk Univ Hosp, Sch Med, Gdansk, Poland; [Shroff, Rukshana] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Bakkaloglu, Sevcan] Gazi Univ Hosp, Gazi, Turkey; [Vondrak, Karel] Univ Hosp Motol, Prague, Czech Republic; [Fischbach, Michel] Hosp Hautepierre, Strasbourg, France; [Van de Walle, Johan] Univ Hosp, Ghent, Belgium; [Ariceta, Gema] Hosp Cruces, Baracaldo, Vizcaya, Spain; [Edefonti, Alberto] Fdn IRCCS Policlin, Milan, Italy; [Aufricht, Christoph] Univ Hosp Pediat, Vienna, Austria; [Jankauskiene, Augustina] Vilnius Univ, Childrens Hosp, Vilnius, Lithuania; [Holta, Tuula] Univ Helsinki, Helsinki, Finland; [Ekim, Mesiha] Ankara Univ Hosp, Ankara, Turkey; [Schmitt, Claus Peter] Ctr Paediat & Adolescent Med, Heidelberg, Germany; [Stefanidis, Constantinos] Childrens Hosp, A&P Kyriakou, Athens, Greece","Watson, AR (reprint author), Nottingham Childrens Hosp, Childrens Renal & Urol Unit, QMC Campus,Derby Rd, Nottingham NG7 2UH, England.","judith.hayes@nuh.nhs.uk",null,null,null,null,null,35,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X","1432-198X",null,"PEDIATR NEPHROL","Pediatr. Nephrol.","SEP",2014,29,9,null,null,null,null,1617,1624,null,"10.1007/s00467-014-2809-4",null,8,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","AO5IM","WOS:000341377700017",24710747]
["J","Azukaitis, K; Loirat, C; Malina, M; Adomaitiene, I; Jankauskiene, A",null,null,null,"Azukaitis, Karolis; Loirat, Chantal; Malina, Michal; Adomaitiene, Irina; Jankauskiene, Augustina",null,null,"Macrovascular involvement in a child with atypical hemolytic uremic syndrome","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Atypical hemolytic uremic syndrome; Arterial stenoses; Fatal stroke; C3 gain-of-function mutation; Eculizumab","COMPLEMENT; ECULIZUMAB; PHENOTYPE; DISEASE; CELLS; AHUS","Atypical hemolytic uremic syndrome (aHUS) is a disorder of the complement system which leads to thrombotic microangiopathy. It is caused by either acquired or hereditary defects in the activation or regulation of the alternative complement pathway and is therefore considered to be a disease of local complement dysregulation in microvasculature with predominantly renal involvement. However, extrarenal manifestations are observed in approximately one-fifth of aHUS patients, with the myocardium and central nervous system (CNS) being involved most often. Additionally, there have been a few reports of aHUS with cerebral artery stenoses or periphereal gangrene, suggesting the possibility of 'macrovascular' involvement in aHUS. We present a child with early onset aHUS and a C3 gain-of-function mutation who developed cerebral artery stenoses, leading ultimately to death due to a massive stroke 9 days after successful renal transplantation under prophylactic eculizumab treatment. Similar cases described in the literature are also briefly summarized. The disease course in our patient with aHUS confirms that dysregulated complement activation can induce arterial steno-occlusive lesions in the absence of acute episodes of HUS. Further studies are required to document the frequency of such macrovascular complications and the role of eculizumab treatment in preventing their development and progression.","[Azukaitis, Karolis; Jankauskiene, Augustina] Vilnius State Univ, Vilnius, Lithuania; [Loirat, Chantal] Hop Robert Debre, AP HP, Serv Nephrol, F-75019 Paris, France; [Malina, Michal] Charles Univ Prague, Dept Paediat, Fac Med 2, Motol Univ Hosp, Prague, Czech Republic; [Adomaitiene, Irina; Jankauskiene, Augustina] Vilnius Univ Hosp, Santariskiu Klinikos, Childrens Hosp, LT-08406 Vilnius, Lithuania","Jankauskiene, A (reprint author), Vilnius Univ Hosp, Santariskiu Klinikos, Childrens Hosp, Santariskiu 4, LT-08406 Vilnius, Lithuania.","augustina.jankauskiene@mf.vu.lt",null,null,null,null,null,28,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X","1432-198X",null,"PEDIATR NEPHROL","Pediatr. Nephrol.","JUL",2014,29,7,null,null,null,null,1273,1277,null,"10.1007/s00467-013-2713-3",null,5,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","AH9BQ","WOS:000336434600020",24352218]
["J","Kocova, H; Dvorackova, O; Vondracek, P; Haberlova, J",null,null,null,"Kocova, Helena; Dvorackova, Olga; Vondracek, Petr; Haberlova, Jana",null,null,"Health-Related Quality of Life in Children and Adolescents With Spinal Muscular Atrophy in the Czech Republic","PEDIATRIC NEUROLOGY",null,null,"English","Article",null,null,null,null,null,"health-related quality of life; neuromuscular disorders; spinal muscular atrophy; Czech Republic","HISTORY","BACKGROUND: Spinal muscular atrophy is a rare hereditary neuromuscular disorder (with a prevalence of 1 per 30,000) that greatly debilitates patients and, in most cases, shortens their life expectancy. Although there is no causal therapy, improvements in symptomatic therapy have extended patients' life expectancy and increased their quality of life. Unfortunately, the advancements in care vary from country to country. To improve the care for children with spinal muscular atrophy in the Czech Republic, we created a survey to obtain the baseline information about their quality of life and compared the data with equivalent data from the United States. METHODS: We used the Pediatric Quality of Life Inventory 3.0 Neuromuscular Measurement Model, which is a health-related quality of life questionnaire specific to children with neuromuscular disorders. The survey was conducted on 35 children with genetically proven spinal muscular atrophy and their parents. RESULTS: Compared with the US data, the Czech data generally show a lower quality of life, mainly in the family resources part. The greatest score was achieved in the section about communication. Altogether, the parents' scores are lower than those of the children. CONCLUSION: In the Czech Republic, patients with spinal muscular atrophy and, especially their parents, have a significantly lower quality of life compared with US patients, mostly because of economic factors and a lack of social support. Our results reveal areas toward which improvement should be directed. The need for family support through social care as well as civic, patient, or organizational support is accentuated.","[Kocova, Helena; Dvorackova, Olga] Univ South Bohemia, Fac Hlth & Social Studies, Ceske Budejovice, Czech Republic; [Vondracek, Petr] Masaryk Univ, Fac Med, Brno, Czech Republic; [Haberlova, Jana] Charles Univ Prague, Sch Med 2, Dept Child Neurol, Prague 5, Czech Republic; [Haberlova, Jana] Fac Hosp, Prague 5, Czech Republic","Kocova, H (reprint author), Kolping Family Smecno, Zizkova 1, Ceske Budejovice 37001, Czech Republic.","helena.kocova@dumrodin.cz",null,null,null,null,null,19,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0887-8994","1873-5150",null,"PEDIATR NEUROL","Pediatr. Neurol.","JUN",2014,50,6,null,null,null,null,591,594,null,"10.1016/j.pediatrneurol.2014.01.037",null,4,"Clinical Neurology; Pediatrics","Neurosciences & Neurology; Pediatrics","AI1VQ","WOS:000336643700010",24679607]
["J","Quizon, A; Minic, P; Pohunek, P; Tal, A; Colin, AA",null,null,null,"Quizon, Annabelle; Minic, Pedrag; Pohunek, Petr; Tal, Asher; Colin, Andrew A.",null,null,"Obliterative Lower Airway Lesions in Childhood: Bronchoscopic Diagnosis and Clinical Spectrum","PEDIATRIC PULMONOLOGY",null,null,"English","Article",null,null,null,null,null,"bronchiolitis; bronchiolitis obliterans; bronchitis; bronchoscopy; obstructive airway disease","MIDDLE LOBE SYNDROME; PROPOSED UNIFYING MODEL; BRONCHITIS; CHILDREN; BRONCHIOLITIS; MYCOPLASMA; DISEASE","Previous reports have described structural airway abnormalities in children with non-cystic fibrosis chronic supportive lung disease as well as obliterative membranes in the major bronchi of cystic fibrosis patients. The putative paradigm proposed in the evolution of these membranes invokes intense inflammation resulting in granulation tissue and neovascularization with the formation of pyogenic granuloma and eventually fibrosis. Our series of four cases widens the spectrum of conditions that may be conducive to large airway obliteration to include non-suppurative chronic infections and possibly immunosuppression. Obliteration of lumina in proximal and distal airways was visualized on bronchoscopy, the latter by the use of the ultrathin bronchoscopes. An attempt at invasive intervention by transbronchial breaching of the obstruction was unsuccessful in three cases, and in one case, the obliterative process resolved spontaneously and without any radiologic trace, presumably by resorption or rupture or through development of collateral ventilation. This series highlights the use of bronchoscopy for diagnosis and occasionally for therapeutic intervention in hitherto little recognized obliterative airway lesions. These acquired obliterative lesions should be considered in the evaluation of patients with isolated non-resolving pulmonary infiltrates or other conditions in which bronchial and bronchiolar patency may be impaired. Pediatr Pulmonol. 2014; 49:E27-E34. (c) 2013 Wiley Periodicals, Inc.","[Quizon, Annabelle; Colin, Andrew A.] Univ Miami, Div Pediat Pulmonol, Miller Sch Med, Miami, FL 33156 USA; [Minic, Pedrag] Univ Belgrade, Fac Med, Belgrade, Serbia; [Minic, Pedrag] Mother & Child Hlth Inst Serbia, Belgrade, Serbia; [Pohunek, Petr] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Pohunek, Petr] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Tal, Asher] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Pediat, Soroka Univ Med Ctr, Beer Sheva, Israel","Quizon, A (reprint author), Univ Miami, Div Pediat Pulmonol, Miller Sch Med, 1580 NW 10th Ave, Miami, FL 33156 USA.","aquizon@med.miami.edu",null,null,"Ministry of Health, Czech Republic [00064203]","Petr Pohunek, MD, has been supported by the project (Ministry of Health, Czech Republic) for conceptual development and research organization 00064203.",null,18,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","8755-6863","1099-0496",null,"PEDIATR PULM","Pediatr. Pulmonol.","MAR",2014,49,3,null,null,null,null,"E27","E34",null,"10.1002/ppul.22775",null,8,"Pediatrics; Respiratory System","Pediatrics; Respiratory System","AA8ON","WOS:000331354900004",23460476]
["J","Vargova, L; Sykova, E",null,null,null,"Vargova, Lydia; Sykova, Eva",null,null,"Astrocytes and extracellular matrix in extrasynaptic volume transmission","PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES",null,null,"English","Review",null,null,null,null,null,"extracellular space; diffusion; tortuosity; astrocytes; extracellular matrix; volume fraction","CHONDROITIN SULFATE PROTEOGLYCANS; RAT SPINAL-CORD; DIFFUSION PARAMETERS; SPREADING DEPRESSION; ALZHEIMERS-DISEASE; WATER TRANSPORT; SPACE VOLUME; ANISOTROPIC DIFFUSION; CORPUS-CALLOSUM; TENASCIN-R","Volume transmission is a form of intercellular communication that does not require synapses; it is based on the diffusion of neuroactive substances across the brain extracellular space (ECS) and their binding to extrasynaptic high-affinity receptors on neurons or glia. Extracellular diffusion is restricted by the limited volume of the ECS, which is described by the ECS volume fraction a, and the presence of diffusion barriers, reflected by tortuosity l, that are created, for example, by fine astrocytic processes or extracellular matrix (ECM) molecules. Organized astrocytic processes, ECM scaffolds or myelin sheets channel the extracellular diffusion so that it is facilitated in a certain direction, i.e. anisotropic. The diffusion properties of the ECS are profoundly influenced by various processes such as the swelling and morphological rebuilding of astrocytes during either transient or persisting physiological or pathological states, or the remodelling of the ECM in tumorous or epileptogenic tissue, during Alzheimer's disease, after enzymatic treatment or in transgenic animals. The changing diffusion properties of the ECM influence neuron-glia interaction, learning abilities, the extent of neuronal damage and even cell migration. From a clinical point of view, diffusion parameter changes occurring during pathological states could be important for diagnosis, drug delivery and treatment.","[Vargova, Lydia; Sykova, Eva] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic; [Vargova, Lydia; Sykova, Eva] Inst Expt Med AS CR, Dept Neurosci, Prague, Czech Republic","Sykova, E (reprint author), Inst Expt Med AS CR, Dept Neurosci, Prague, Czech Republic.","sykova@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [13-11867S, P304-12-G069]","This study was supported by grant nos. 13-11867S and P304-12-G069 from the Grant Agency of the Czech Republic.",null,75,1,1,"ROYAL SOC","LONDON","6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND","0962-8436","1471-2970",null,"PHILOS T R SOC B","Philos. Trans. R. Soc. B-Biol. Sci.","OCT",2014,369,1654,null,null,"SI",null,null,null,20130608,"10.1098/rstb.2013.0608",null,8,"Biology","Life Sciences & Biomedicine - Other Topics","AP8VO","WOS:000342357600017",25225101]
["J","Spevacek, V; Pilarova, K; Koncekova, J; Koncek, O",null,null,null,"Spevacek, V.; Pilarova, K.; Koncekova, J.; Koncek, O.",null,null,"The influence of antioxidant THPC on the properties of polymer gel dosimeter","PHYSICS IN MEDICINE AND BIOLOGY",null,null,"English","Article",null,null,null,null,null,"gel dosimetry; polymer; overshot","RADIATION-DOSE DISTRIBUTIONS; OPTICAL COMPUTED-TOMOGRAPHY; ACRYLAMIDE; INTEGRITY","In order to decrease the negative influence of oxygen to the response of PAG dosimeters THPC has been added to the gel in the role of scavenger. Apart from the decreased influence of oxygen, THPC also influences other properties of gel dosimeters. This study examines these influences and their quantification. Previous studies have shown that increasing the concentration of THPC causes a decreasing response of the dosimeter (as measured in the relaxation rate R-2). Evaluation of the IR spectrum of gels irradiated by a variety of doses has shown that it is caused mostly by the changed structure of the arising polymer, not due to the decreased polymerization. THPC also changes the kinetics of the subsequent reactions in the gel after the end of irradiation. THPC has its influence also on the size of the dose response overshoot that happens in the areas of steep dose gradients. An easy model of action in the gel was suggested, which allows one to estimate the size and kinetics of the changed response of the dosimeter after the end of irradiation depending on the content of THPC, the size of the dose and the dose gradient.","[Spevacek, V.; Pilarova, K.] Czech Tech Univ, Fac Nucl Sci & Phys Engn, CR-11519 Prague 1, Czech Republic; [Koncekova, J.] Na Homolce Hosp, Dept Med Phys, Prague 15030 5, Czech Republic; [Koncek, O.] Univ Hosp Motol, Radiotherapeut Oncol Dept, Prague 15006 5, Czech Republic","Spevacek, V (reprint author), Czech Tech Univ, Fac Nucl Sci & Phys Engn, Brehova 7, CR-11519 Prague 1, Czech Republic.","vaclav.spevacek@fjfi.cvut.cz",null,null,null,null,null,22,0,0,"IOP PUBLISHING LTD","BRISTOL","TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND","0031-9155","1361-6560",null,"PHYS MED BIOL","Phys. Med. Biol.","SEP 7",2014,59,17,null,null,null,null,5141,5161,null,"10.1088/0031-9155/59/17/5141",null,21,"Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging","Engineering; Radiology, Nuclear Medicine & Medical Imaging","AO4RH","WOS:000341328200023",25138573]
["J","Koblihova, E; Mrazova, I; Vernerova, Z; Ryska, M",null,null,null,"Koblihova, E.; Mrazova, I.; Vernerova, Z.; Ryska, M.",null,null,"Acute Liver Failure Induced by Thioacetamide: Selection of Optimal Dosage in Wistar and Lewis Rats","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Acute liver failure; Thioacetamide; Wistar rats; Lewis rats","FULMINANT HEPATIC-FAILURE; FRACTIONATED PLASMA SEPARATION; ANIMAL-MODELS; INTRACRANIAL-PRESSURE; CARBON-TETRACHLORIDE; HYPERTENSIVE-RATS; INJURY; ENCEPHALOPATHY; HEPATOTOXICITY; RECEPTOR","Acute liver failure (ALF) is a clinical condition with very high mortality rate. Its pathophysiological background is still poorly understood, which necessitates a search for optimal experimental ALF models with features resembling those of the human disorder. Taking into consideration reproducibility of induction of ALF, adequate animal size, cost of animals, the required time gap between insult and death of animals (\"therapeutic window\"), potential risk to investigator and other aspects, administration of thioacetamide (TAA) in rats is currently most recommended. However, the fundamental details of this ALF model have not yet been evaluated. This prompted us to investigate, first, the course of ALF as induced by intraperitoneal TAA at doses increasing from 175 to 700 mg/kg BW per day. The animals' survival rate, plasma alanine and aspartate aminotransferase activities, and bilirubin and ammonia levels were determined over the follow-up period. Second, we examined whether Wistar and Lewis rats exhibit any differences in the course of ALF induced by different TAA doses. We found that the optimal dose for ALF induction in rats is 350 mg.kg(-1) i.p., given as a single injection. Wistar rats proved more susceptible to the development of TAA-induced ALF compared with Lewis rats. Collectively, our present findings provide a sound methodological background for experimental studies aimed at evaluation of pathophysiology and development of new approaches in the therapy of ALF.","[Koblihova, E.; Ryska, M.] Charles Univ & Cent Mil Hosp, Fac Med 2, Dept Surg, CZ-16902 Prague 6, Czech Republic; [Mrazova, I.; Vernerova, Z.] Inst Clin & Expt Med, Ctr Expt Med, Prague, Czech Republic; [Vernerova, Z.] Charles Univ Prague, Fac Med 3, Dept Pathol, Prague, Czech Republic","Koblihova, E (reprint author), Charles Univ & Cent Mil Hosp, Fac Med 2, Dept Surg, U Vojenske Nemocnice 1200, CZ-16902 Prague 6, Czech Republic.","eva.koblihova@uvn.cz",null,null,"Ministry of Health of the Czech Republic [00023001, MO 2012]; European Commission [CZ.2.16/3.1.00/22126]","This study was supported by Ministry of Health of the Czech Republic within the project for the development of research organization 00023001 (IKEM) and MO 2012 (CMH) - institutional support. The Center for Experimental Medicine (IKEM) received financial support from the European Commission within the Operational Program Prague-Competitiveness; project \"CEVKOON\" (#CZ.2.16/3.1.00/22126).",null,52,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408","1802-9973",null,"PHYSIOL RES","Physiol. Res.",null,2014,63,4,null,null,null,null,491,503,null,null,null,13,"Physiology","Physiology","AQ1UQ","WOS:000342568400010",24702498]
["J","Pokorny, M; Cervenka, L; Netuka, I; Pirk, J; Konarik, M; Maly, J",null,null,null,"Pokorny, M.; Cervenka, L.; Netuka, I.; Pirk, J.; Konarik, M.; Maly, J.",null,null,"Ventricular Assist Devices in Heart Failure: How to Support the Heart but Prevent Atrophy?","PHYSIOLOGICAL RESEARCH",null,null,"English","Review",null,null,null,null,null,"Ventricular assist devices; Cardiac; Heart; Atrophy; Mechanical unloading; Clenbuterol; Experimental models; Heterotopic heart transplantation","TRANSPLANTED RAT-HEART; FAILING HUMAN HEART; MYOCARDIAL RECOVERY; PROTEIN-SYNTHESIS; CARDIAC ATROPHY; ISCHEMIC CARDIOMYOPATHY; GENE-EXPRESSION; RODENT MODEL; CLENBUTEROL; HYPERTROPHY","Ventricular assist devices (VAD) have recently established themselves as an irreplaceable therapeutic modality of terminal heart failure. Because of the worldwide shortage of donors, ventricular assist devices play a key role in modern heart failure therapy. Some clinical data have revealed the possibility of cardiac recovery during VAD application. On the other hand, both clinical and experimental studies indicate the risk of the cardiac atrophy development, especially after prolonged mechanical unloading. Little is known about the specific mechanisms governing the unloading-induced cardiac atrophy and about the exact ultrastructural changes in cardiomyocytes, and even less is known about the ways in which possible therapeutical interventions may affect heart atrophy. One aim of this review was to present important aspects of the development of VAD-related cardiac atrophy in humans and we also review the most significant observations linking clinical data and those derived from studies using experimental models. The focus of this article was to review current methods applied to alleviate cardiac atrophy which follows mechanical unloading of the heart. Out of many pharmacological agents studied, only the selective beta2 agonist clenbuterol has been proved to have a significantly beneficial effect on unloading-induced atrophy. Mechanical means of atrophy alleviation also seem to be effective and promising.","[Pokorny, M.; Netuka, I.; Pirk, J.; Konarik, M.; Maly, J.] Inst Clin & Expt Med, Dept Cardiovasc Surg, Prague 14000 4, Czech Republic; [Cervenka, L.] Inst Clin & Expt Med, Ctr Med Expt, Prague 14000 4, Czech Republic; [Pokorny, M.; Cervenka, L.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Pokorny, M.; Cervenka, L.] Univ Hosp Motol, Prague, Czech Republic; [Netuka, I.] Charles Univ Prague, Dept Cardiovasc Surg, Fac Med & Surg 1, Dept Surg 2, Prague, Czech Republic","Pokorny, M (reprint author), Inst Clin & Expt Med, Dept Cardiovasc Surg, Videnska 1958-9, Prague 14000 4, Czech Republic.","mpok@ikem.cz",null,null,"Ministry of Health of the Czech Republic within the project for the development of research organization (IKEM) - institutional support [00023001]; European Commission within the Operational Program Prague-Competitiveness [CZ.2.16/3.1.00/22126]","This study was supported by project of the Ministry of Health of the Czech Republic within the project for the development of research organization 00023001 (IKEM) - institutional support. The Center for Experimental Medicine (IKEM) received financial support from the European Commission within the Operational Program Prague-Competitiveness; project \"CEVKOON\" (# CZ.2.16/3.1.00/22126).",null,60,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408","1802-9973",null,"PHYSIOL RES","Physiol. Res.",null,2014,63,2,null,null,null,null,147,156,null,null,null,10,"Physiology","Physiology","AH9KA","WOS:000336459800002",24779607]
["J","Urbanova, M; Dostalova, I; Trachta, P; Drapalova, J; Kavalkova, P; Haluzikova, D; Matoulek, M; Lacinova, Z; Mraz, M; Kasalicky, M; Haluzik, M",null,null,null,"Urbanova, M.; Dostalova, I.; Trachta, P.; Drapalova, J.; Kavalkova, P.; Haluzikova, D.; Matoulek, M.; Lacinova, Z.; Mraz, M.; Kasalicky, M.; Haluzik, M.",null,null,"Serum Concentrations and Subcutaneous Adipose Tissue mRNA Expression of Omentin in Morbid Obesity and Type 2 Diabetes Mellitus: the Effect of Very-Low-Calorie Diet, Physical Activity and Laparoscopic Sleeve Gastrectomy","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Omentin; Subcutaneous adipose tissue; Obesity; Laparoscopic sleeve gastrectomy; Very-low-calorie diet","INSULIN-RESISTANCE; METABOLIC SYNDROME; CARDIOMETABOLIC RISK; VISCERAL FAT; INFLAMMATION; OVERWEIGHT; ADIPOCYTOKINES; ENDOCRINE; PLASMA; WOMEN","Omentin is a novel adipokine with insulin-sensitizing effects expressed predominantly in visceral fat. We investigated serum omentin levels and its mRNA expression in subcutaneous adipose tissue (SCAT) of 11 women with type 2 diabetes mellitus (T2DM), 37 obese non-diabetic women (OB) and 26 healthy lean women (C) before and after various weight loss interventions: 2-week very-low-calorie diet (VLCD), 3-month regular exercise and laparoscopic sleeve gastrectomy (LSG). At baseline, both T2DM and OB groups had decreased serum omentin concentrations compared with C group while omentin mRNA expression in SCAT did not significantly differ among the groups. Neither VLCD nor exercise significantly affected serum omentin concentrations and its mRNA expression in SCAT of OB or T2DM group. LSG significantly increased serum omentin levels in OB group. In contrast, omentin mRNA expression in SCAT was significantly reduced after LSG. Baseline fasting serum omentin levels in a combined group of the studied subjects (C, OB, T2DM) negatively correlated with BMI, CRP, insulin, LDL-cholesterol, triglycerides and leptin and were positively related to HDLcholesterol. Reduced circulating omentin levels could play a role in the etiopathogenesis of obesity and T2DM. The increase in circulating omentin levels and the decrease in omentin mRNA expression in SCAT of obese women after LSG might contribute to surgery-induced metabolic improvements and sustained reduction of body weight.","[Urbanova, M.; Dostalova, I.; Trachta, P.; Drapalova, J.; Kavalkova, P.; Haluzikova, D.; Matoulek, M.; Lacinova, Z.; Mraz, M.; Haluzik, M.] Charles Univ Prague, Fac Med 1, Dept Med 3, Prague 12808 2, Czech Republic; [Urbanova, M.; Dostalova, I.; Trachta, P.; Drapalova, J.; Kavalkova, P.; Haluzikova, D.; Matoulek, M.; Lacinova, Z.; Mraz, M.; Haluzik, M.] Gen Univ Hosp, Prague 12808 2, Czech Republic; [Haluzikova, D.] Charles Univ Prague, Fac Med 1, Dept Sports Med, Prague 12808 2, Czech Republic; [Kasalicky, M.] Charles Univ Prague, Fac Med 2, Dept Surg, Prague 12808 2, Czech Republic; [Kasalicky, M.] Mil Univ Hosp, Prague, Czech Republic","Haluzik, M (reprint author), Charles Univ Prague, Fac Med 1, Dept Med 3, U Nemocnice 1, Prague 12808 2, Czech Republic.","mhalu@lf1.cuni.cz",null,null,"OP Prague Competitiveness [CZ.2.16/3.1.00/24012];  [RVO-VFN64165];  [SVV264503];  [IGANT13299-4]","Supported by RVO-VFN64165, SVV264503, IGANT13299-4 and project CZ.2.16/3.1.00/24012 from OP Prague Competitiveness.",null,34,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408","1802-9973",null,"PHYSIOL RES","Physiol. Res.",null,2014,63,2,null,null,null,null,207,218,null,null,null,12,"Physiology","Physiology","AH9KA","WOS:000336459800008",24397804]
["J","Zaloudikova, M; Herget, J; Vizek, M",null,null,null,"Zaloudikova, M.; Herget, J.; Vizek, M.",null,null,"The Contractile Response of Isolated Small Pulmonary Arteries Induced by Activated Macrophages","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Isolated pulmonary arteries; Reactive oxygen species; Macrophage","HYDROGEN-PEROXIDE; ALVEOLAR MACROPHAGES; CHRONIC HYPOXIA; SUBACUTE; LUNG","To test whether macrophages can play any role in hypoxic pulmonary vasoconstriction, we tested the in vitro response of rings from small pulmonary arteries to the activation of macrophages by FMLP, a substance stimulating predominantly membrane-bound NADPH oxidase. A small vessel myograph was used to measure the responses of rings from small pulmonary arteries (300-400 mu m) isolated from rat lungs. Rings from 5 rats were placed into both chambers of the myograph. The vessels were stabilized for 40 min and then normalized by automatic stretching to a wall tension equivalent to the intravascular pressure 30 mm Hg. At the start of each experiment, vessels were exposed to 80 mM K+ to obtain maximal contractile response, which was used to normalize subsequent contractile responses. 2x10(6) viable macrophages, obtained by peritoneal lavage, were added into one chamber, then 5 mu M FMLP was administrated to both chambers and the tension measurement was started. The hydrogen peroxide concentration produced by stimulated macrophages was measured luminometrically. The concentrations of H2O2 in specimens from chambers containing activated macrophages rose from 3.5 +/- 1.5 nM to 110 +/- 28 nM within 25 min of stimulation, while FMLP itself didn't increase the H2O2 concentration from the baseline value (4.5 +/- 3 nM) in samples from control chambers. After FMLP administration, the tension of the vessel rings in the presence of macrophages reached 0.23 +/- 0.07 of maximal contractile response, it did not change in controls. The addition of ROS scavenger 4-hydroxyTEMPO blocked the contractile response to the activation of macrophages. We conclude that the activation of macrophages stimulates the contraction of small pulmonary arteries and that this contraction is probably mediated by reactive oxygen species.","[Zaloudikova, M.; Vizek, M.] Charles Univ Prague, Fac Med 2, Dept Pathophysiol, Prague 15006, Czech Republic; [Herget, J.] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague 15006, Czech Republic","Zaloudikova, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Pathophysiol, Plzenska 130-221, Prague 15006, Czech Republic.","marie.zaloudikova@lfmotol.cuni.cz",null,null,"IGA [NT 13358-4]; GACR [13-01710S]","This study was partially supported by grants IGA NT 13358-4, GACR 13-01710S.",null,17,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408","1802-9973",null,"PHYSIOL RES","Physiol. Res.",null,2014,63,2,null,null,null,null,267,270,null,null,null,4,"Physiology","Physiology","AH9KA","WOS:000336459800015",24779609]
["J","Sheardova, K; Laczo, J; Vyhnalek, M; Andel, R; Mokrisova, I; Vlcek, K; Amlerova, J; Hort, J",null,null,null,"Sheardova, Katerina; Laczo, Jan; Vyhnalek, Martin; Andel, Ross; Mokrisova, Ivana; Vlcek, Kamil; Amlerova, Jana; Hort, Jakub",null,null,"Famous Landmark Identification in Amnestic Mild Cognitive Impairment and Alzheimer's Disease","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; EMOTION RECOGNITION; NATIONAL INSTITUTE; SEMANTIC MEMORY; FACE PERCEPTION; DEMENTIA; DEFICITS; RECOMMENDATIONS; CORTEX","Background: Identification of famous landmarks (FLI), famous faces (FFI) and recognition of facial emotions (FER) is affected early in the course of Alzheimer's disease (AD). FFI, FER and FLI may represent domain specific tasks relying on activation of distinct regions of the medial temporal lobe, which are affected successively during the course of AD. However, the data on FFI and FER in MCI are controversial and FLI domain remains almost unexplored. Objectives: To determine whether and how are these three specific domains impaired in head to head comparison of patients with amnestic MCI (aMCI) single domain (SD-aMCI) and multiple domain (MD-aMCI). We propose that FLI might be most reliable in differentiating SD-aMCI, which is considered to be an earlier stage of AD pathology spread out, from the controls. Patients and Methods: A total of 114 patients, 13 with single domain (SD-aMCI) and 30 with multiple domains (MD-aMCI), 29 with mild AD and 42 controls underwent standard neurological and neuropsychological evaluations as well as tests of FLI, FER and FFI. Results: Compared to the control group, AD subjects performed worse on FFI (p = 0.020), FER (p<0.001) and FLI (p<0.001), MD-aMCI group had significantly worse scores only on FLI (p = 0.002) and approached statistical significance on FER (0.053). SD-aMCI group performed significantly worse only on FLI (p = 0.028) compared to controls. Conclusions: Patients with SD-aMCI had an isolated impairment restricted to FLI, while patients with MD-aMCI showed impairment in FLI as well as in FER. Patients with mild dementia due to AD have more extensive impairment of higher visual perception. The results suggest that FLI testing may contribute to identification of patients at risk of AD. We hypothesize that clinical examination of all three domains might reflect the spread of the disease from transentorhinal cortex, over amygdala to fusiform gyrus.","[Sheardova, Katerina; Laczo, Jan; Vyhnalek, Martin; Andel, Ross; Mokrisova, Ivana; Hort, Jakub] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Laczo, Jan; Vyhnalek, Martin; Mokrisova, Ivana; Vlcek, Kamil; Amlerova, Jana; Hort, Jakub] Charles Univ Prague, Dept Neurol, Memory Clin, Fac Med 2, Prague, Czech Republic; [Laczo, Jan; Vyhnalek, Martin; Mokrisova, Ivana; Vlcek, Kamil; Amlerova, Jana; Hort, Jakub] Univ Hosp Motol, Prague, Czech Republic; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Vlcek, Kamil] Acad Sci Czech Republic, Inst Physiol, Dept Neurophysiol Memory, Prague, Czech Republic","Laczo, J (reprint author), St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic.","janlaczo@gmail.com","Vlcek, Kamil/B-9620-2012","Vlcek, Kamil/0000-0001-7152-3093","European Union Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; Grant Agency of Charles University [74308]; Ministry of Health, Czech Republic; Institutional Support of Laboratory Research Grant [2/2012 (699002)]; University Hospital Motol, Prague, Czech Republic [00064203]","Funding provided by the European Union Regional Development Fund-Project FNUSA-ICRC (CZ. 1.05/1.1.00/02.0123)-JH; Grant Agency of Charles University (74308)-IM; Ministry of Health, Czech Republic-conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203-JH; Institutional Support of Laboratory Research Grant No. 2/2012 (699002)-JH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,67,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","AUG 21",2014,9,8,null,null,null,null,null,null,"e105623","10.1371/journal.pone.0105623",null,8,"Multidisciplinary Sciences","Science & Technology - Other Topics","AO1WL","WOS:000341106100100",25144755]
["J","Malikova, J; Camats, N; Fernandez-Cancio, M; Heath, K; Gonzalez, I; Caimari, M; del Campo, M; Albisu, M; Kolouskova, S; Audi, L; Fluck, CE",null,null,null,"Malikova, Jana; Camats, Nuria; Fernandez-Cancio, Monica; Heath, Karen; Gonzalez, Isabel; Caimari, Maria; del Campo, Miguel; Albisu, Marian; Kolouskova, Stanislava; Audi, Laura; Flueck, Christa E.",null,null,"Human NR5A1/SF-1 Mutations Show Decreased Activity on BDNF (Brain-Derived Neurotrophic Factor), an Important Regulator of Energy Balance: Testing Impact of Novel SF-1 Mutations Beyond Steroidogenesis","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"ORPHAN NUCLEAR RECEPTOR; CHAIN-CLEAVAGE ENZYME; HORMONE-BETA-GENE; FACTOR-I SF-1; OVARIAN INSUFFICIENCY; SEX DEVELOPMENT; EXPRESSION; OBESITY; MOUSE; MICE","Context: Human NR5A1/SF-1 mutations cause 46,XY disorder of sex development (DSD) with broad phenotypic variability, and rarely cause adrenal insufficiency although SF-1 is an important transcription factor for many genes involved in steroidogenesis. In addition, the Sf-1 knockout mouse develops obesity with age. Obesity might be mediated through Sf-1 regulating activity of brain-derived neurotrophic factor (BDNF), an important regulator of energy balance in the ventromedial hypothalamus. Objective: To characterize novel SF-1 gene variants in 4 families, clinical, genetic and functional studies were performed with respect to steroidogenesis and energy balance. Patients: 5 patients with 46,XY DSD were found to harbor NR5A1/SF-1 mutations including 2 novel variations. One patient harboring a novel mutation also suffered from adrenal insufficiency. Methods: SF-1 mutations were studied in cell systems (HEK293, JEG3) for impact on transcription of genes involved in steroidogenesis (CYP11A1, CYP17A1, HSD3B2) and in energy balance (BDNF). BDNF regulation by SF-1 was studied by promoter assays (JEG3). Results: Two novel NR5A1/SF-1 mutations (Glu7Stop, His408Profs*159) were confirmed. Glu7Stop is the 4th reported SF-1 mutation causing DSD and adrenal insufficiency. In vitro studies revealed that transcription of the BDNF gene is regulated by SF-1, and that mutant SF-1 decreased BDNF promoter activation (similar to steroid enzyme promoters). However, clinical data from 16 subjects carrying SF-1 mutations showed normal birth weight and BMI. Conclusions: Glu7Stop and His408Profs*159 are novel SF-1 mutations identified in patients with 46,XY DSD and adrenal insufficiency (Glu7Stop). In vitro, SF-1 mutations affect not only steroidogenesis but also transcription of BDNF which is involved in energy balance. However, in contrast to mice, consequences on weight were not found in humans with SF-1 mutations.","[Malikova, Jana; Kolouskova, Stanislava] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Malikova, Jana; Kolouskova, Stanislava] Univ Hosp Motol, Prague, Czech Republic; [Malikova, Jana; Camats, Nuria; Flueck, Christa E.] Univ Childrens Hosp Bern, Dept Pediat, Bern, Switzerland; [Malikova, Jana; Camats, Nuria; Flueck, Christa E.] Univ Childrens Hosp Bern, Dept Clin Res, Bern, Switzerland; [Fernandez-Cancio, Monica; Albisu, Marian; Audi, Laura] Autonomous Univ Barcelona, CIBERER, Vall Hebron Res Inst VHIR, Barcelona, Spain; [Heath, Karen] Univ Autonoma Madrid, IdiPAZ, Inst Med & Mol Genet INGEMM, Hosp Univ La Paz, Madrid, Spain; [Gonzalez, Isabel] Univ Autonoma Madrid, IdiPAZ, Pediat Endocrinol Serv, Hosp Univ La Paz, Madrid, Spain; [Caimari, Maria] Son Espases Univ Hosp, Palma De Mallorca, Spain; [del Campo, Miguel] Hosp Valle De Hebron, Barcelona, Spain","Fluck, CE (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic.","christa.flueck@dkf.unibe.ch","Heath, Karen/K-7760-2014","Heath, Karen/0000-0002-5816-7044","Swiss National Science Foundation [320030-146127]; Instituto de Salud Carlos III, Madrid, Spain CIBERER [U-712]; AGAUR (University and Research Management and Evaluation Agency), Barcelona, Spain [2009SGR31]; ESPE (European Society of Pediatric Endocrinology); Novo Nordisk A/S","This work was supported by grants of the Swiss National Science Foundation (320030-146127) to CEF, the Instituto de Salud Carlos III, Madrid, Spain CIBERER U-712 to MFC and the AGAUR (University and Research Management and Evaluation Agency), Barcelona, Spain (2009SGR31) to LA, and by ESPE (European Society of Pediatric Endocrinology) Research Fellowship grants to JM and NC (sponsored by Novo Nordisk A/S). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,40,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","AUG 14",2014,9,8,null,null,null,null,null,null,"e104838","10.1371/journal.pone.0104838",null,9,"Multidisciplinary Sciences","Science & Technology - Other Topics","AO0QT","WOS:000341017000063",25122490]
["J","Adkins, I; Kamanova, J; Kocourkova, A; Svedova, M; Tomala, J; Janova, H; Masin, J; Chladkova, B; Bumba, L; Kovar, M; Ross, PJ; Tuckova, L; Spisek, R; Mills, KHG; Sebo, P",null,null,null,"Adkins, Irena; Kamanova, Jana; Kocourkova, Aneta; Svedova, Martina; Tomala, Jakub; Janova, Hana; Masin, Jiri; Chladkova, Barbora; Bumba, Ladislav; Kovar, Marek; Ross, Padraig J.; Tuckova, Ludmila; Spisek, Radek; Mills, Kingston H. G.; Sebo, Peter",null,null,"Bordetella Adenylate Cyclase Toxin Differentially Modulates Toll-Like Receptor-Stimulated Activation, Migration and T Cell Stimulatory Capacity of Dendritic Cells","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"RESPIRATORY-INFECTION; INTERLEUKIN-10 PRODUCTION; PROTECTIVE IMMUNITY; TH1/TH17 RESPONSE; IL-12 PRODUCTION; PERTUSSIS TOXIN; 3RD SIGNAL; INHIBITION; BINDING; MACROPHAGES","Adenylate cyclase toxin (CyaA) is a key virulence factor of the whooping cough agent Bordetella pertussis. The toxin targets CD11b-expressing phagocytes and delivers into their cytosol an adenylyl cyclase (AC) enzyme that subverts cellular signaling by increasing cAMP levels. In the present study, we analyzed the modulatory effects of CyaA on adhesive, migratory and antigen presenting properties of Toll-like receptor (TLR)-activated murine and human dendritic cells (DCs). cAMP signaling of CyaA enhanced TLR-induced dissolution of cell adhesive contacts and migration of DCs towards the lymph node-homing chemokines CCL19 and CCL21 in vitro. Moreover, we examined in detail the capacity of toxin-treated DCs to induce CD4(+) and CD8(+) T cell responses. Exposure to CyaA decreased the capacity of LPS-stimulated DCs to present soluble protein antigen to CD4(+) T cells independently of modulation of co-stimulatory molecules and cytokine production, and enhanced their capacity to promote CD4(+) CD25(+) Foxp3(+) T regulatory cells in vitro. In addition, CyaA decreased the capacity of LPS-stimulated DCs to induce CD8(+) T cell proliferation and limited the induction of IFN-gamma producing CD8(+) T cells while enhancing IL-10 and IL-17-production. These results indicate that through activation of cAMP signaling, the CyaA may be mobilizing DCs impaired in T cell stimulatory capacity and arrival of such DCs into draining lymph nodes may than contribute to delay and subversion of host immune responses during B. pertussis infection.","[Adkins, Irena; Kamanova, Jana; Svedova, Martina; Janova, Hana; Masin, Jiri; Bumba, Ladislav; Sebo, Peter] Acad Sci Czech Republic, Inst Microbiol, Lab Mol Biol Bacterial Pathogens, Prague, Czech Republic; [Tomala, Jakub; Kovar, Marek] Acad Sci Czech Republic, Inst Microbiol, Lab Tumor Immunol, Prague, Czech Republic; [Chladkova, Barbora; Tuckova, Ludmila] Acad Sci Czech Republic, Inst Microbiol, Lab Specif Cellular Immun, Prague, Czech Republic; [Kocourkova, Aneta; Spisek, Radek] Charles Univ Prague, Fac Med 2, Inst Immunol, Prague, Czech Republic; [Kocourkova, Aneta; Spisek, Radek] Univ Hosp Motol, Prague, Czech Republic; [Mills, Kingston H. G.] Univ Dublin Trinity Coll, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin 2, Ireland","Adkins, I (reprint author), Acad Sci Czech Republic, Inst Microbiol, Lab Mol Biol Bacterial Pathogens, Prague, Czech Republic.","adkins@sotio.com","Tomala, Jakub/J-6042-2014; Kovar, Marek/H-7793-2014; Bumba, Ladislav/H-2494-2014",null,"National Science Foundation of the Czech Republic [GA310/08/0447, GA310/09/P582, P301/11/0325]; Czech Ministry of Health [IGA NT12402-5]; Science Foundation Ireland [06/IN.1/B87]; Ministry of Education of Czech Republic; Charles University in Prague, Czech Republic [33779266]; FEBS short-term fellowship;  [1M0506]","This work was supported by the grant No. GA310/08/0447 (to PS), No. GA310/09/P582 (to IA) and No. P301/11/0325 (to MK) of the National Science Foundation of the Czech Republic, the Research center 1M0506, and by research grant IGA NT12402-5 from the Czech Ministry of Health. KM and PR are supported by a principal investigator grant (06/IN.1/B87) from Science Foundation Ireland. MS was a recipient of a stipend from the Ministry of Education of Czech Republic and of the support from the Specific Research Project No. 33779266 of the Charles University in Prague, Czech Republic. The support from a FEBS short-term fellowship granted to IA is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,57,1,1,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","AUG 1",2014,9,8,null,null,null,null,null,null,"e104064","10.1371/journal.pone.0104064",null,13,"Multidisciplinary Sciences","Science & Technology - Other Topics","AM4JL","WOS:000339819800123",25084094]
["J","Kunicka, T; Vaclavikova, R; Hlavac, V; Vrana, D; Pecha, V; Raus, K; Trnkova, M; Kubackova, K; Ambrus, M; Vodickova, L; Vodicka, P; Soucek, P",null,null,null,"Kunicka, Tereza; Vaclavikova, Radka; Hlavac, Viktor; Vrana, David; Pecha, Vaclav; Raus, Karel; Trnkova, Marketa; Kubackova, Katerina; Ambrus, Miloslav; Vodickova, Ludmila; Vodicka, Pavel; Soucek, Pavel",null,null,"Non-Coding Polymorphisms in Nucleotide Binding Domain 1 in ABCC1 Gene Associate with Transcript Level and Survival of Patients with Breast Cancer","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"MULTIDRUG-RESISTANCE PROTEIN-1; TRANSPORTER GENES; MRP1 GENE; EXPRESSION; CHEMOTHERAPY; CELLS; MRP1/ABCC1; MUTATIONS; CARCINOMA; SUBTYPES","Objectives: ATP-Binding Cassette (ABC) transporters may cause treatment failure by transporting of anticancer drugs outside of the tumor cells. Multidrug resistance-associated protein 1 coded by the ABCC1 gene has recently been suggested as a potential prognostic marker in breast cancer patients. This study aimed to explore tagged haplotype covering nucleotide binding domain 1 of ABCC1 in relation with corresponding transcript levels in tissues and clinical phenotype of breast cancer patients. Methods: The distribution of twelve ABCC1 polymorphisms was assessed by direct sequencing in peripheral blood DNA (n = 540). Results: Tumors from carriers of the wild type genotype in rs35623 or rs35628 exhibited significantly lower levels of ABCC1 transcript than those from carriers of the minor allele (p = 0.003 and p = 0.004, respectively). The ABCC1 transcript levels significantly increased in the order CT-GT>CC-GT>CC-GG for the predicted rs35626-rs4148351 diplotype. Chemotherapy-treated patients carrying the T allele in rs4148353 had longer disease-free survival than those with the GG genotype (p = 0.043). On the other hand, hormonal therapy-treated patients with the AA genotype in rs35628 had significantly longer disease-free survival than carriers of the G allele (p = 0.012). Conclusions: Taken together, our study shows that genetic variability in the nucleotide binding domain 1 has a significant impact on the ABCC1 transcript level in the target tissue and may modify survival of breast cancer patients.","[Kunicka, Tereza; Vaclavikova, Radka; Hlavac, Viktor; Vrana, David; Vodickova, Ludmila; Soucek, Pavel] Natl Inst Publ Hlth, Dept Toxicogen, Prague, Czech Republic; [Kunicka, Tereza; Hlavac, Viktor] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Vrana, David] Palacky Univ, Dept Oncol, Sch Med, CR-77147 Olomouc, Czech Republic; [Vrana, David] Teaching Hosp, Olomouc, Czech Republic; [Pecha, Vaclav; Raus, Karel] Inst Care Mother & Child, Prague, Czech Republic; [Trnkova, Marketa] Biolab Praha Ks, Prague, Czech Republic; [Kubackova, Katerina] Motol Univ Hosp, Dept Oncol, Prague, Czech Republic; [Ambrus, Miloslav] Fac Hosp Kralovske Vinohrady, Dept Radiotherapy & Oncol, Prague, Czech Republic; [Vodickova, Ludmila; Vodicka, Pavel] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Vodicka, Pavel] Charles Univ Prague, Fac Med 1, Inst Biol & Med Genet, Prague, Czech Republic","Soucek, P (reprint author), Natl Inst Publ Hlth, Dept Toxicogen, Prague, Czech Republic.","psoucek@szu.cz",null,null,"Internal Grant Agency of the Czech Ministry of Health [NT13679-4]; Czech Science Foundation [P303/12/G163]; Biolab Praha, k.s","This work was supported by grant of the Internal Grant Agency of the Czech Ministry of Health (www.mzcr.cz), no.: NT13679-4 and by the project of the Czech Science Foundation no.: P303/12/G163 (www.gacr.cz). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Biolab Praha, k.s provided support in the form of salary for author MT, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.",null,49,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","JUL 31",2014,9,7,null,null,null,null,null,null,"e101740","10.1371/journal.pone.0101740",null,13,"Multidisciplinary Sciences","Science & Technology - Other Topics","AM6EF","WOS:000339954800008",25078270]
["J","Prochazka, V; Pytlik, R; Janikova, A; Belada, D; Salek, D; Papajik, T; Campr, V; Furst, T; Furstova, J; Trneny, M",null,null,null,"Prochazka, Vit; Pytlik, Robert; Janikova, Andrea; Belada, David; Salek, David; Papajik, Tomas; Campr, Vit; Fuerst, Tomas; Furstova, Jana; Trneny, Marek",null,null,"A New Prognostic Score for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: The Prognostic Role of Blood Monocyte and Lymphocyte Counts Is Absent","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"NON-HODGKINS-LYMPHOMA; ABSOLUTE LYMPHOCYTE; PATIENTS OLDER; RITUXIMAB ERA; TRIAL; CHEMOTHERAPY; SURVIVAL; SUBTYPE; MARKER; IPI","Background: Absolute lymphocyte count (ALC) and absolute monocyte count (AMC) have been documented as independent predictors of survival in patients with newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL). Analysis of the prognostic impact of ALC and AMC in the context of International Prognostic Index (IPI) and other significant variables in elderly population treated in the R-CHOP regime has not been carried out yet. Methodology/Principal Findings: In this retrospective study, a cohort of 443 newly diagnosed DLBCL patients with age >= 60 was analyzed. All patients were treated with the R-CHOP therapy. An extensive statistical analysis was performed to identify risk factors of 3-year overall survival (OS). In multivariate analysis, only three predictors proved significant: Eastern Cooperative Oncology Group performance status (ECOG), age and bulky disease presence. These predictors were dichotomized (ECOG >= 1, age >= 70, bulk >= 7.5) to create a novel four-level score. This score predicted 3-year OS of 94.0%, 77.4%, 62.7% and 35.4% in the low-, low-intermediate, high-intermediate and high-risk groups, respectively (P<0.001). Further, a three-level score was tested which stratifies the population better (3-year OS: 91.9%, 67.2%, 36.2% in the low, intermediate and high-risk groups, respectively) but is more difficult to interpret. Both the 3- and 4-level scores were compared to standard scoring systems and, in our population, were shown to be superior in terms of patients risk stratification with respect to 3-year OS prediction. The results were successfully validated on an independent cohort of 162 patients of similar group characteristics. Conclusions: The prognostic role of baseline ALC, AMC or their ratio (LMR) was not confirmed in the multivariate context in elderly population with DLBCL treated with R-CHOP. The newly proposed age-specific index stratifies the elderly population into risk groups more precisely than the conventional IPI and its existing variants.","[Prochazka, Vit; Papajik, Tomas] Palacky Univ, Dept Hematooncol, Fac Med & Dent, CR-77147 Olomouc, Czech Republic; [Pytlik, Robert; Trneny, Marek] Charles Univ Prague, Internal Dept 1, Gen Hosp, Prague, Czech Republic; [Janikova, Andrea; Salek, David] Masaryk Univ, Dept Internal Med Hematooncol, Univ Hosp Brno, Brno, Czech Republic; [Janikova, Andrea; Salek, David] Masaryk Univ, Fac Med, Brno, Czech Republic; [Belada, David] Univ Hosp, Dept Med 2, Dept Hematol, Hradec Kralove, Czech Republic; [Belada, David] Fac Med, Hradec Kralove, Czech Republic; [Campr, Vit] Charles Univ Prague, Dept Pathol & Mol Med, Prague, Czech Republic; [Campr, Vit] Second Med Sch, Prague, Czech Republic; [Campr, Vit] Fac Hosp Motol, Prague, Czech Republic; [Fuerst, Tomas; Furstova, Jana] Palacky Univ, Dept Math Anal & Applicat Math, Fac Sci, CR-77147 Olomouc, Czech Republic","Furstova, J (reprint author), Palacky Univ, Dept Math Anal & Applicat Math, Fac Sci, CR-77147 Olomouc, Czech Republic.","jana.furstova@email.cz",null,null,"Czech Ministry of Health [MZCR IGA NT 12193]; Faculty of Medicine and Dentistry, Palacky University Olomouc [LF-2014-001]; J. W. Fulbright Commission","This work was supported by grants from Czech Ministry of Health (MZCR IGA NT 12193, http://www.mzcr.cz/) and Faculty of Medicine and Dentistry, Palacky University Olomouc (LF-2014-001, http://www.lf.upol.cz/). Tomas Furst and Jana Furstova gratefully acknowledge the support of the J. W. Fulbright Commission (http://www.fulbright.cz/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,25,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","JUL 24",2014,9,7,null,null,null,null,null,null,"e102594","10.1371/journal.pone.0102594",null,10,"Multidisciplinary Sciences","Science & Technology - Other Topics","AO5BG","WOS:000341354800028"]
["J","Gumulec, J; Masarik, M; Adam, V; Eckschlager, T; Provaznik, I; Kizek, R",null,null,null,"Gumulec, Jaromir; Masarik, Michal; Adam, Vojtech; Eckschlager, Tomas; Provaznik, Ivo; Kizek, Rene",null,null,"Serum and Tissue Zinc in Epithelial Malignancies: A Meta-Analysis","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"TRACE-ELEMENT CONCENTRATIONS; NEUTRON-ACTIVATION ANALYSIS; LUNG-CANCER PATIENTS; X-RAY-FLUORESCENCE; CU-ZN RATIO; BREAST-CANCER; HUMAN PROSTATE; COPPER/ZINC RATIO; VITAMIN-A; HEPATOCELLULAR-CARCINOMA","Background and Objectives: Current studies give us inconsistent results regarding the association of neoplasms and zinc(II) serum and tissues concentrations. The results of to-date studies using meta-analysis are summarized in this paper. Methods: Web of Science (Science citation index expanded), PubMed (Medline), Embase and CENTRAL were searched. Articles were reviewed by two evaluators; quality was assessed by Newcastle-Ottawa scale; meta-analysis was performed including meta-regression and publication bias analysis. Results: Analysis was performed on 114 case control, cohort and cross-sectional studies of 22737 participants. Decreased serum zinc level was found in patients with lung (effect size = -1.04), head and neck (effect size = -1.43), breast (effect size = -0.93), liver (effect size = -2.29), stomach (effect size = -1.59), and prostate (effect size = -1.36) cancers; elevation was not proven in any tumor. More specific zinc patterns are evident at tissue level, showing increase in breast cancer tissue (effect size = 1.80) and decrease in prostatic (effect size = -3.90), liver (effect size = -8.26), lung (effect size = -3.12), and thyroid cancer (effect size = -2.84). The rest of the included tumors brought ambiguous results, both in serum and tissue zinc levels across the studies. The association between zinc level and stage or grade of tumor has not been revealed by meta-regression. Conclusion: This study provides evidence on cancer-specific tissue zinc level alteration. Although serum zinc decrease was associated with most tumors mentioned herein, further - prospective - studies are needed.","[Gumulec, Jaromir; Masarik, Michal] Masaryk Univ, Fac Med, Dept Pathol Physiol, Brno, Czech Republic; [Gumulec, Jaromir; Masarik, Michal; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CS-61090 Brno, Czech Republic; [Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Provaznik, Ivo] Brno Univ Technol, Fac Elect Engn & Commun, Dept Biomed Engn, CS-61090 Brno, Czech Republic","Masarik, M (reprint author), Masaryk Univ, Fac Med, Dept Pathol Physiol, Brno, Czech Republic.","masarik@med.muni.cz","Gumulec, Jaromir/D-7638-2012; Masarik, Michal/D-9920-2012; Provaznik, Ivo/F-4121-2012","Gumulec, Jaromir/0000-0002-9658-3444; ","Central European Institute of Technology [CZ.1.05/1.1.00/02.0068]; Internal Grant Agency of Ministry of Health of the Czech Republic [IGA MH NT14337-3/2013]","Financial support from Central European Institute of Technology CZ.1.05/1.1.00/02.0068 and Internal Grant Agency of Ministry of Health of the Czech Republic (IGA MH NT14337-3/2013) is highly acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,127,1,1,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","JUN 18",2014,9,6,null,null,null,null,null,null,"e99790","10.1371/journal.pone.0099790",null,11,"Multidisciplinary Sciences","Science & Technology - Other Topics","AK6AC","WOS:000338508200042",24941118]
["J","Vaclavikova, E; Dvorakova, S; Skaba, R; Pos, L; Sykorova, V; Halkova, T; Vcelak, J; Bendlova, B",null,null,null,"Vaclavikova, Eliska; Dvorakova, Sarka; Skaba, Richard; Pos, Lucie; Sykorova, Vlasta; Halkova, Tereza; Vcelak, Josef; Bendlova, Bela",null,null,"RET Variants and Haplotype Analysis in a Cohort of Czech Patients with Hirschsprung Disease","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"MEDULLARY-THYROID CARCINOMA; SOUTHEASTERN CHINESE; PROTOONCOGENE; COMMON; MUTATIONS; ALLELES; 3'UTR; RISK; RARE","Hirschsprung disease (HSCR) is a congenital aganglionosis of myenteric and submucosal plexuses in variable length of the intestine. This study investigated the influence and a possible modifying function of RET proto-oncogene's single nucleotide polymorphisms (SNPs) and haplotypes in the development and phenotype of the disease in Czech patients. Genotyping of 14 SNPs was performed using TaqMan Genotyping Assays and direct sequencing. The frequencies of SNPs and generated haplotypes were statistically evaluated using chi-square test and the association with the risk of HSCR was estimated by odds ratio. SNP analysis revealed significant differences in frequencies of 11 polymorphic RET variants between 162 HSCR patients and 205 unaffected controls. Particularly variant alleles of rs1864410, rs2435357, rs2506004 (intron 1), rs1800858 (exon 2), rs1800861 (exon 13), and rs2565200 (intron 19) were strongly associated with increased risk of HSCR (p<0.00000) and were over-represented in males vs. females. Conversely, variant alleles of rs1800860, rs1799939 and rs1800863 (exons 7, 11, 15) had a protective role. The haploblock comprising variants in intron 1 and exon 2 was constructed. It represented a high risk of HSCR, however, the influence of other variants was also found after pruning from effect of this haploblock. Clustering patients according to genotype status in haploblock revealed a strong co-segregation with several SNPs and pointed out the differences between long and short form of HSCR. This study involved a large number of SNPs along the entire RET proto-oncogene with demonstration of their risk/protective role also in haplotype and diplotype analysis in the Czech population. The influence of some variant alleles on the aggressiveness of the disease and their role in gender manifestation differences was found. These data contribute to worldwide knowledge of the genetics of HSCR.","[Vaclavikova, Eliska; Dvorakova, Sarka; Sykorova, Vlasta; Halkova, Tereza; Vcelak, Josef; Bendlova, Bela] Res Inst Endocrinol, Dept Mol Endocrinol, CR-11694 Prague, Czech Republic; [Skaba, Richard; Pos, Lucie] Charles Univ Prague, Fac Med 2, Dept Paediat Surg, Prague, Czech Republic; [Skaba, Richard; Pos, Lucie] Hosp Motol, Prague, Czech Republic","Vaclavikova, E (reprint author), Res Inst Endocrinol, Dept Mol Endocrinol, CR-11694 Prague, Czech Republic.","evaclavikova@endo.cz",null,null,"IGA MH CR [NT13901-4]; GAUK [411611]; MH CZ","This work was supported by grant projects IGA MH CR NT13901-4, GAUK 411611 and MH CZ for conceptual development of research organisation 00023761 (Institute of Endocrinology, Prague, Czech Republic). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,19,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","JUN 4",2014,9,6,null,null,null,null,null,null,"e98957","10.1371/journal.pone.0098957",null,9,"Multidisciplinary Sciences","Science & Technology - Other Topics","AK4YO","WOS:000338430700102",24897126]
["J","Powell, AD; Saintot, PP; Gill, KK; Bharathan, A; Buck, SC; Morris, G; Jiruska, P; Jefferys, JGR",null,null,null,"Powell, Andrew D.; Saintot, Pierre-Philippe; Gill, Kalbinder K.; Bharathan, Ashtami; Buck, S. Caroline; Morris, Gareth; Jiruska, Premysl; Jefferys, John G. R.",null,null,"Reduced Gamma Oscillations in a Mouse Model of Intellectual Disability: A Role for Impaired Repetitive Neurotransmission?","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"LINKED MENTAL-RETARDATION; NETWORK OSCILLATIONS; IN-VITRO; SYNAPTIC PLASTICITY; GABAERGIC TRANSMISSION; PROTEIN OLIGOPHRENIN-1; COGNITIVE IMPAIRMENT; WORKING-MEMORY; VESICLE POOLS; HIPPOCAMPUS","Intellectual disability affects 2-3% of the population; mutations of the X-chromosome are a major cause of moderate to severe cases. The link between the molecular consequences of the mutation and impaired cognitive function remains unclear. Loss of function mutations of oligophrenin-1 (OPHN1) disrupt Rho-GTPase signalling. Here we demonstrate abnormal neurotransmission at CA3 synapses in hippocampal slices from Ophn1(-/y) mice, resulting from a substantial decrease in the readily releasable pool of vesicles. As a result, synaptic transmission fails at high frequencies required for oscillations associated with cognitive functions. Both spontaneous and KA-induced gamma oscillations were reduced in Ophn1(-/y) hippocampal slices. Spontaneous oscillations were rapidly rescued by inhibition of the downstream signalling pathway of oligophrenin-1. These findings suggest that the intellectual disability due to mutations of oligophrenin-1 results from a synaptopathy and consequent network malfunction, providing a plausible mechanism for the learning disabilities. Furthermore, they raise the prospect of drug treatments for affected individuals.","[Powell, Andrew D.; Saintot, Pierre-Philippe; Gill, Kalbinder K.; Bharathan, Ashtami; Buck, S. Caroline; Morris, Gareth; Jiruska, Premysl; Jefferys, John G. R.] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham, W Midlands, England; [Jiruska, Premysl] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Prague, Czech Republic; [Jiruska, Premysl] Charles Univ Prague, Dept Neurol, Sch Med 2, Prague, Czech Republic","Powell, AD (reprint author), Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham, W Midlands, England.","a.d.powell@bham.ac.uk",null,null,"Wellcome Trust [074771/Z/04/Z]; University of Birmingham Studentships","This work was supported by a Wellcome Trust grant to JGRJ (074771/Z/04/Z), and University of Birmingham Studentships to PPS, KKG, AB, SCB, and GM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,50,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","MAY 6",2014,9,5,null,null,null,null,null,null,"e95871","10.1371/journal.pone.0095871",null,10,"Multidisciplinary Sciences","Science & Technology - Other Topics","AJ9KS","WOS:000338029800036",24800744]
["J","Kuchar, M; Vankova, L; Petrokova, H; Cerny, J; Osicka, R; Pelak, O; Sipova, H; Schneider, B; Homola, J; Sebo, P; Kalina, T; Maly, P",null,null,null,"Kuchar, Milan; Vankova, Lucie; Petrokova, Hana; Cerny, Jiri; Osicka, Radim; Pelak, Ondrej; Sipova, Hana; Schneider, Bohdan; Homola, Jiri; Sebo, Peter; Kalina, Tomas; Maly, Petr",null,null,"Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells","PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS",null,null,"English","Article",null,null,null,null,null,"ribosome display; combinatorial library; psoriasis; engineered binding protein; protein scaffold; cytokine","STREPTOCOCCAL PROTEIN-G; HUMAN SERUM-ALBUMIN; MONOCLONAL-ANTIBODY; ENGINEERED PROTEINS; HIGH-AFFINITY; DOUBLE-BLIND; COMBINATORIAL LIBRARIES; AUTOIMMUNE INFLAMMATION; INTERFERON-GAMMA; PSORIASIS","Engineered combinatorial libraries derived from small protein scaffolds represent a powerful tool for generating novel binders with high affinity, required specificity and designed inhibitory function. This work was aimed to generate a collection of recombinant binders of human interleukin-23 receptor (IL-23R), which is a key element of proinflammatory IL-23-mediated signaling. A library of variants derived from the three-helix bundle scaffold of the albumin-binding domain (ABD) of streptococcal protein G and ribosome display were used to select for high-affinity binders of recombinant extracellular IL-23R. A collection of 34 IL-23R-binding proteins (called REX binders), corresponding to 18 different sequence variants, was used to identify a group of ligands that inhibited binding of the recombinant p19 subunit of IL-23, or the biologically active human IL-23 cytokine, to the recombinant IL-23R or soluble IL-23R-IgG chimera. The strongest competitors for IL-23R binding in ELISA were confirmed to recognize human IL-23R-IgG in surface plasmon resonance experiments, estimating the binding affinity in the sub- to nanomolar range. We further demonstrated that several REX variants bind to human leukemic cell lines K-562, THP-1 and Jurkat, and this binding correlated with IL-23R cell-surface expression. The REX125, REX009 and REX128 variants competed with the p19 protein for binding to THP-1 cells. Moreover, the presence of REX125, REX009 and REX115 variants significantly inhibited the IL-23-driven expansion of IL-17-producing primary human CD4(+) T-cells. Thus, we conclude that unique IL-23R antagonists derived from the ABD scaffold were generated that might be useful in designing novel anti-inflammatory biologicals. Proteins 2014; 82:975-989. (c) 2013 The Authors. Proteins: Structure, Function, and Bioinformatics Published by Wiley Periodicals, Inc.","[Kuchar, Milan; Vankova, Lucie; Petrokova, Hana; Sebo, Peter; Maly, Petr] Inst Biotechnol AS CR, Vvi, Lab Ligand Engn, Prague 14220 4, Czech Republic; [Cerny, Jiri; Schneider, Bohdan] Inst Biotechnol AS CR, Vvi, Lab Mol Recognit, Prague 14220 4, Czech Republic; [Osicka, Radim; Sebo, Peter] Inst Microbiol AS CR, Vvi, Prague 14220, Czech Republic; [Pelak, Ondrej; Kalina, Tomas] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Pelak, Ondrej; Kalina, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Sipova, Hana; Homola, Jiri] Inst Photon & Elect AS CR, Vvi, Prague 18251, Czech Republic","Maly, P (reprint author), Inst Biotechnol AS CR, Vvi, Videnska 1083, Prague 14220 4, Czech Republic.","petr.maly@img.cas.cz","Homola, Jiri/F-3683-2014; Cerny, Jiri/I-4733-2012; Kuchar, Milan/H-3029-2014; Schneider, Bohdan/D-2565-2009; Maly, Petr/H-5962-2014; Osicka, Radim/H-6776-2014; SEBO, Peter/F-7423-2011","Schneider, Bohdan/0000-0001-7855-3690; SEBO, Peter/0000-0002-9755-7715","Czech Science Foundation [P303/10/1849, P302/11/0580]; Institutional Research Concept [AV0Z50520701, RVO 86652036, RVO 61388971]; Motol Hospital Project [00064203]; UNCE [204012]; BIOCEV from the ERDF [CZ.1.05/1.1.00/02.0109]","Grant sponsor: Czech Science Foundation; Grant numbers: P303/10/1849 (to P. M.) and P302/11/0580 (to R.O.); Grant sponsor: Institutional Research Concept; Grant numbers: AV0Z50520701, RVO 86652036, and RVO 61388971; Grant sponsor: Motol Hospital Project (to T. K. and O.P.); Grant numbers: 00064203 and UNCE 204012. This study was supported by BIOCEV CZ.1.05/1.1.00/02.0109 from the ERDF.",null,41,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0887-3585","1097-0134",null,"PROTEINS","Proteins","JUN",2014,82,6,null,null,null,null,975,989,null,"10.1002/prot.24472",null,15,"Biochemistry & Molecular Biology; Biophysics","Biochemistry & Molecular Biology; Biophysics","AH2MJ","WOS:000335955300009",24549990]
["J","Solny, P; Zimak, J",null,null,null,"Solny, Pavel; Zimak, Jaroslav",null,null,"Research on radiation exposure from CT part of hybrid camera and diagnostic CT","RADIATION PHYSICS AND CHEMISTRY",null,null,"English","Article; Proceedings Paper","1st International Conference on Dosimetry and its Applications (ICDA)","JUN 23-28, 2013","Prague, CZECH REPUBLIC","Int Soc Radiat Phys, Czech Tech Univ, Fac Nucl Sci & Phys Engn, Int Radiat Phys Soc",null,"Effective dose; Nuclear medicine CT; Phantom measurement; TLD",null,"Research on radiation exposure from CT part of hybrid camera in seven different Departments of Nuclear Medicine (DNM) was conducted. Processed data and effective dose (E) estimations led to the idea of phantom verification and comparison of absorbed doses and software estimation. Anonymous data from about 100 examinations from each DNM was gathered. Acquired data was processed and utilized by dose estimation programs (ExPACT, ImPACT, ImpactDose) with respect to the type of examination and examination procedures. Individual effective doses were calculated using enlisted programs. Preserving the same procedure in dose estimation process allows us to compare the resulting E. Some differences and disproportions during dose estimation led to the idea of estimated E verification. Consequently, two different sets of about 100 of TLD 100H detectors were calibrated for measurement inside the Aldersnon RANDO Anthropomorphic Phantom. Standard examination protocols were examined using a 2 Slice CT- part of hybrid SPECT/CT. Moreover, phantom exposure from body examining protocol for 32 Slice and 64 Slice diagnostic CT scanner was also verified. Absorbed dose (D-T,D-R) measured using TLD detectors was compared with software estimation of equivalent dose H-T values, computed by E estimation software. Though, only limited number of cavities for detectors enabled measurement within the regions of lung, liver, thyroid and spleen-pancreas region, some basic comparison is possible. (C) 2014 Elsevier Ltd. All rights reserved.","[Solny, Pavel] Czech Tech Univ, Fac Nucl Sci & Phys Engn, CR-11519 Prague, Czech Republic; [Solny, Pavel; Zimak, Jaroslav] Charles Univ Prague, Fac Med 2, Motol Univ Hosp, CR-11636 Prague 1, Czech Republic","Solny, P (reprint author), Czech Tech Univ, Fac Nucl Sci & Phys Engn, CR-11519 Prague, Czech Republic.","solny@seznam.cz",null,null,null,null,null,7,0,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0969-806X",null,null,"RADIAT PHYS CHEM","Radiat. Phys. Chem.","NOV",2014,104,null,null,null,null,null,260,266,null,"10.1016/j.radphyschem.2014.05.044",null,7,"Chemistry, Physical; Nuclear Science & Technology; Physics, Atomic, Molecular & Chemical","Chemistry; Nuclear Science & Technology; Physics","AO6LM","WOS:000341463600054"]
["J","Chandak, P; Kessaris, N; Uwechue, RU; Abboudi, H; Hossain, M; Harris, F; Jones, K; Fronek, J",null,null,null,"Chandak, Pankaj; Kessaris, Nicos; Uwechue, Raphael Uzo; Abboudi, Hamid; Hossain, Mohammed; Harris, Fiona; Jones, Keith; Fronek, Jiri",null,null,"Successful Excision of a Suspected Mycotic Transplant Renal Artery Patch Aneurysm With Renal Allograft Autotransplantation","TRANSPLANTATION",null,null,"English","Letter",null,null,null,null,null,null,"KIDNEY-TRANSPLANTATION",null,"[Chandak, Pankaj; Kessaris, Nicos] Guys & St Thomas NHS Fdn Trust, Dept Nephrol & Renal Transplantat, London, England; [Uwechue, Raphael Uzo] Diana Princess Wales Hosp, Dept Gen Surg, Grimsby, Wales; [Abboudi, Hamid] Royal Sussex Cty Hosp, Dept Urol, Brighton BN2 5BE, E Sussex, England; [Hossain, Mohammed] St Georges Healthcare NHS Trust, St Georges Renal Transplant Unit, London, England; [Harris, Fiona] Epsom & St Helier Univ Hosp NHS Trust, Southwest Thames Renal & Transplantat Unit, Surrey, England; [Jones, Keith] St Georges Healthcare NHS Trust London, Vasc Inst, London, England; [Fronek, Jiri] Charles Univ Prague, Fac Med 2, Inst Clin & Expt Med, Transplant Surg Dept, Prague, Czech Republic","Kessaris, N (reprint author), Guys Hosp, Dept Nephrol & Renal Transplantat, 6th Floor,Borough Wing, London SE1 9RT, England.","Nicos.Kessaris@gstt.nhs.uk",null,null,null,null,null,5,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0041-1337","1534-6080",null,"TRANSPLANTATION","Transplantation","FEB 15",2014,97,3,null,null,null,null,"E25","E26",null,"10.1097/01.TP.0000438628.75848.9a",null,2,"Immunology; Surgery; Transplantation","Immunology; Surgery; Transplantation","AH0VK","WOS:000335838500006",24492430]
["J","Buchler, T; Bortlicek, Z; Poprach, A; Kubackova, K; Kiss, I; Zemanova, M; Fiala, O; Dusek, L; Vyzula, R; Melichar, B",null,null,null,"Buchler, Tomas; Bortlicek, Zbynek; Poprach, Alexandr; Kubackova, Katerina; Kiss, Igor; Zemanova, Milada; Fiala, Ondrej; Dusek, Ladislav; Vyzula, Rostislav; Melichar, Bohuslav",null,"Czech Renal Canc Cooperative Grp","Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis","UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS",null,null,"English","Article",null,null,null,null,null,"Everolimus; mTOR; Renal cell carcinoma; Tyrosine kinase inhibitors; Therapy","TRIAL","Objectives: The aim of the present study was to describe the efficacy and safety of everolimus in the treatment of metastatic renal cell carcinoma (mRCC) after administration of 1 vs. 2 prior tyrosine kinase inhibitors (TKIs). Patients and methods: A national renal information system database was used as the data source for the retrospective study. There were 483 patients who received everolimus as the second (n = 350) or the third (n = 112) targeted agent following TKIs. Results: Median progression-free survival (PFS) from the start of everolimus in the second or the third line of targeted therapy was 6.1 months for both subgroups (P = 0.863). Median total PFS from the start of the first targeted agent to progression on the third targeted agent for patients receiving 3 lines of therapy with TKI-TKI-everolimus (n = 112) and TKI-everolimus-TKI (n = 27) sequences was 28.3 months vs. 31.3 months, respectively (P = 0.16), and there was no significant difference in overall survival. PFS on everolimus was associated with PFS on previous TKIs in patients receiving 1 but not 2 previous TKIs. Only 13% of 352 patients starting targeted therapy for mRCC in 2010 had received 3 sequential targeted agents by the data cutoff in March 2013. Conclusion: PFS on everolimus correlated with PFS on TKIs in patients pretreated with 1 but not 2 TKIs. Everolimus can be deferred to the third line without loss of efficacy or increased toxicity. However, only a minority of patients with mRCC starting targeted treatment can be expected to receive third-line therapy. (C) 2014 Elsevier Inc. All rights reserved.","[Buchler, Tomas] Thomayer Hosp, Dept Oncol, Prague, Czech Republic; [Buchler, Tomas; Zemanova, Milada] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Bortlicek, Zbynek; Dusek, Ladislav] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic; [Poprach, Alexandr; Kiss, Igor; Vyzula, Rostislav] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic; [Kubackova, Katerina] Motol Univ Hosp, Dept Oncol, Prague, Czech Republic; [Kubackova, Katerina] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Zemanova, Milada] Gen Univ Hosp, Dept Oncol, Prague, Czech Republic; [Fiala, Ondrej] Univ Hosp, Dept Oncol, Plzen, Czech Republic; [Melichar, Bohuslav] Palacky Univ, Dept Oncol, Sch Med, CR-77147 Olomouc, Czech Republic; [Melichar, Bohuslav] Teaching Hosp, Olomouc, Czech Republic","Buchler, T (reprint author), Thomayer Hosp, Dept Oncol, Prague, Czech Republic.","tomas.buchler@ftn.cz",null,null,"Pfizer; Bayer; GSK; Roche; Novartis","T.B. and B.M. received honoraria for advisory boards and lectures from Novartis and Pfizer. K.K. received honoraria for advisory boards and lectures from Novartis. Other authors have declared no conflict of interest. The RENTS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, GSK, Roche, and Novartis).",null,17,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1078-1439","1873-2496",null,"UROL ONCOL-SEMIN ORI","Urol. Oncol.-Semin. Orig. Investig.","JUL",2014,32,5,null,null,null,null,569,575,null,"10.1016/j.urolonc.2013.12.007",null,7,"Oncology; Urology & Nephrology","Oncology; Urology & Nephrology","AK0GL","WOS:000338090800009",24629497]
["J","Klatte, T; Xylinas, E; Rieken, M; Roupret, M; Fajkovic, H; Seitz, C; Karakiewicz, PI; Lotan, Y; Babjuk, M; de Martino, M; Shariat, SF",null,null,null,"Klatte, Tobias; Xylinas, Evanguelos; Rieken, Malte; Roupret, Morgan; Fajkovic, Harun; Seitz, Christian; Karakiewicz, Pierre I.; Lotan, Yair; Babjuk, Marko; de Martino, Michela; Shariat, Shahrokh F.",null,null,"Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy","UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS",null,null,"English","Article",null,null,null,null,null,"ABO; Blood group; Blood type; Prognosis; Cystectomy; Biomarker","PANCREATIC-CANCER; BREAST-CANCER; SURVIVAL; ANTIGEN; DATABASE; TUMORS; STAGE; RISK; GENE","Objective: ABO blood type is an inherited characteristic that has been associated with the prognosis of several malignancies, but there is little evidence in urothelial carcinoma of the bladder (UCB). The purpose of this study was to evaluate the effect of ABO blood type on mortality in patients with UCB treated with radical cystectomy (RC). Methods: Multi-institutional data from 7,906 patients with UCB treated with RC between 1979 and 2012 were retrospectively analyzed. The effect of ABO blood type on UCB-related mortality was evaluated with univariable and multivariable competing-risks regression models. Results: ABO blood type was O in 3,728 (47%), A in 2,748 (35%), B in 888 (11%), and AB in 532 (7%) patients. Blood type B was associated with a greater likelihood of lymphovascular invasion (P = 0.010) and positive soft tissue margins (P = 0.008). The median follow-up was 41 months. The 5-year cumulative UCB-related mortality rates for blood type O, A, B, and AB were 29.5%, 30.5%, 33.2%, and 25.8%, respectively. In univariable competing-risks regression, patients with blood type B had worse UCB-related mortality than those with blood type O (P = 0.026) and AB (P = 0.020). In multivariable analysis, however, blood type lost its statistical significance. Conclusions: Among patients treated with RC, ABO blood type is associated with a statistically significant but clinically insignificant difference in UCB-related mortality. This association was not present in multivariable analysis. Our data therefore suggest no relevant association of ABO blood type with UCB-related prognosis. (C) 2014 Elsevier Inc. All rights reserved.","[Klatte, Tobias; Fajkovic, Harun; Seitz, Christian; de Martino, Michela; Shariat, Shahrokh F.] Med Univ Vienna, Vienna Gen Hosp, Dept Urol, Vienna, Austria; [Xylinas, Evanguelos; Rieken, Malte; Shariat, Shahrokh F.] Presbyterian Hosp, Weill Cornell Med Coll, Dept Urol, New York, NY USA; [Xylinas, Evanguelos] Paris Descartes Univ, Cochin Hosp, AP HP, Dept Urol, Paris, France; [Rieken, Malte] Univ Basel Hosp, Dept Urol, CH-4031 Basel, Switzerland; [Roupret, Morgan] Univ Paris 06, Inst Univ Cancerol GRC5, Fac Med Pierre & Marie Curie, Grp Hosp Pitie Salpetriere,AP HP,Dept Urol, Paris, France; [Karakiewicz, Pierre I.] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Babjuk, Marko] Hosp Motol, Fac Med 2, Dept Urol, Prague, Czech Republic","Shariat, SF (reprint author), Med Univ Vienna, Vienna Gen Hosp, Dept Urol, Vienna, Austria.","sfshariat@gmail.com",null,null,null,null,null,30,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1078-1439","1873-2496",null,"UROL ONCOL-SEMIN ORI","Urol. Oncol.-Semin. Orig. Investig.","JUL",2014,32,5,null,null,null,null,625,630,null,"10.1016/j.urolonc.2013.11.010",null,6,"Oncology; Urology & Nephrology","Oncology; Urology & Nephrology","AK0GL","WOS:000338090800017",24495451]
["J","Kutlvasr, K; Bukovjan, K; Kodet, R",null,null,null,"Kutlvasr, K.; Bukovjan, K.; Kodet, R.",null,null,"Bilateral low grade serous adenocarcinoma of the ovaries in a badger (Meles meles L.) and its association with a borderline serous ovarian tumour: a case report","VETERINARNI MEDICINA",null,null,"English","Article",null,null,null,null,null,"Meles meles; ovary; borderline serous tumour; low grade serous carcinoma; metastases","CLINICOPATHOLOGICAL ANALYSIS; CARCINOMAS; WT1","Here, we describe a case of a wild female badger (a sow) with disseminated serous adenocarcinoma of the ovary which corresponds to a group of low grade serous carcinomas of the ovary in humans. Beside grossly apparent dissemination of the disease we observed a scale of histological features classifiable as a precursor lesion - borderline serous tumour of the ovary with implant metastases at the peritoneum, and features of the borderline tumour transformation in the carcinoma. The latter features included invasion of some of the metastatic peritoneal implants into the adipose tissue of the mesentery, retroperitoneum, and in the muscle of diaphragm with lymphangioinvasion and with blood-borne metastatic disease in the lungs. The primary tumour and its metastases had a uniform cytological appearance without atypia of the tumour cells. Mitotic activity was exceptional. The proliferation activity as demonstrated by immunohistochemical investigation of Ki-67 protein expression (revealing all active phases of the cell cycle - G1, S, G2, M) showed a low proliferation activity of the tumour cells, comparable with findings in low grade carcinomas or borderline tumours of the ovaries in women. WT1 protein was expressed in the whole tumour cell population. All these features were diagnostic of serous carcinoma of the ovary with low grade malignant potential. Tumours of the ovaries in wildlife have been described previously but they are infrequent and are rarely classified histopathologically. This case report offers a parallel with serous carcinomas in human pathology including features of transformation from a precursor lesion of a borderline serous tumour into a serous low grade carcinoma.","[Kutlvasr, K.] Czech Univ Life Sci Prague, Dept Forest Protect & Game Management, Prague, Czech Republic; [Bukovjan, K.] Forestry & Game Management Res Inst, Jiloviste, Czech Republic; [Kodet, R.] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; [Kodet, R.] Univ Hosp, Prague, Czech Republic","Kodet, R (reprint author), Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, V Uvalu 84, Prague 15006 5, Czech Republic.","roman.kodet@fnmotol.cz",null,null,null,null,null,23,0,0,"CZECH ACADEMY AGRICULTURAL SCIENCES","PRAGUE","TESNOV 17, PRAGUE, 117 05, CZECH REPUBLIC","0375-8427",null,null,"VET MED-CZECH","Vet. Med.",null,2014,59,1,null,null,null,null,44,50,null,null,null,7,"Veterinary Sciences","Veterinary Sciences","AM1LZ","WOS:000339608900006"]
["J","Jirsa, M; Bronsky, J; Dvorakova, L; Sperl, J; Smajstrla, V; Horak, J; Nevoral, J; Hrebicek, M",null,null,null,"Jirsa, Milan; Bronsky, Jiri; Dvorakova, Lenka; Sperl, Jan; Smajstrla, Vit; Horak, Jiri; Nevoral, Jiri; Hrebicek, Martin",null,null,"ABCB4 mutations underlie hormonal cholestasis but not pediatric idiopathic gallstones","WORLD JOURNAL OF GASTROENTEROLOGY",null,null,"English","Article",null,null,null,null,null,"Idiopathic cholelithiasis; Intrahepatic cholestasis; Oral contraceptives; Low phospholipid-associated cholelithiasis; Gallbladder disease 1","SALT EXPORT PUMP; INTRAHEPATIC CHOLESTASIS; BILIARY-CIRRHOSIS; TRANSPORTER GENE; P-GLYCOPROTEIN; MDR3; PREGNANCY; ADULTS; CHOLELITHIASIS; DISEASE","AIM: To investigate the contribution of ABCB4 mutations to pediatric idiopathic gallstone disease and the potential of hormonal contraceptives to prompt clinical manifestations of multidrug resistance protein 3 deficiency. METHODS: Mutational analysis of ABCB4, screening for copy number variations by multiplex ligation-dependent probe amplification, genotyping for low expression allele c. 1331T > C of ABCB11 and genotyping for variation c. 55G > C in ABCG8 previously associated with cholesterol gallstones in adults was performed in 35 pediatric subjects with idiopathic gallstones who fulfilled the clinical criteria for low phospholipid-associated cholelithiasis syndrome (LPAC, OMIM #600803) and in 5 young females with suspected LPAC and their families (5 probands, 15 additional family members). The probands came to medical attention for contraceptive-associated intrahepatic cholestasis. RESULTS: A possibly pathogenic variant of ABCB4 was found only in one of the 35 pediatric subjects with idiopathic cholesterol gallstones whereas 15 members of the studied 5 LPAC kindreds were confirmed and another one was highly suspected to carry predictably pathogenic mutations in ABCB4. Among these 16, however, none developed gallstones in childhood. In 5 index patients, all young females carrying at least one pathogenic mutation in one allele of ABCB4, manifestation of LPAC as intrahepatic cholestasis with elevated serum activity of gamma-glutamyltransferase was induced by hormonal contraceptives. Variants ABCB11 c.1331T > C and ABCG8 c.55G > C were not significantly overrepresented in the 35 examined patients with suspect LPAC. CONCLUSION: Clinical criteria for LPAC syndrome caused by mutations in ABCB4 cannot be applied to pediatric patients with idiopathic gallstones. Sexual immaturity even prevents manifestation of LPAC. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.","[Jirsa, Milan] Inst Clin & Expt Med, Ctr Med Expt, Prague 14021, Czech Republic; [Jirsa, Milan] Charles Univ Prague, Fac Med 1, Inst Med Biochem & Lab Diagnost, Prague 12801, Czech Republic; [Horak, Jiri; Nevoral, Jiri] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 15006, Czech Republic; [Horak, Jiri; Nevoral, Jiri] Univ Hosp Motol, Prague 15006, Czech Republic; [Dvorakova, Lenka; Hrebicek, Martin] Charles Univ Prague, Fac Med 1, Inst Inherited Metab Disorders, Prague 12808, Czech Republic; [Dvorakova, Lenka; Hrebicek, Martin] Gen Univ Hosp Prague, Prague 12808, Czech Republic; [Sperl, Jan] Inst Clin & Expt Med, Dept Hepatogastroenterol, Prague 14021, Czech Republic; [Smajstrla, Vit] Bormed Private Hlth Ctr, Ostrava 72200, Czech Republic; [Horak, Jiri] Charles Univ Prague, Fac Med 3, Dept Internal Med 1, Prague 10034, Czech Republic","Jirsa, M (reprint author), Inst Clin & Expt Med, Ctr Med Expt, Videnska 1958-9, Prague 14021, Czech Republic.","milan.jirsa@ikem.cz",null,null,"Ministry of Health, Czech Republic [00023001]; IKEM, Prague, Czech Republic; MH CZ - DRO [VFN64165];  [PRVOUK-P24/LF1/3]","Supported by The project (Ministry of Health, Czech Republic) for development of research organization 00023001 (IKEM, Prague, Czech Republic) - Institutional support; PRVOUK-P24/LF1/3 and MH CZ - DRO VFN64165 to Dvorakova L and Hrebicek M",null,28,0,0,"BAISHIDENG PUBLISHING GROUP INC","PLEASANTON","8226 REGENCY DR, PLEASANTON, CA 94588 USA","1007-9327","2219-2840",null,"WORLD J GASTROENTERO","World J. Gastroenterol.","MAY 21",2014,20,19,null,null,null,null,5867,5874,null,"10.3748/wjg.v20.i19.5867",null,8,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","AH3TK","WOS:000336048200032",24914347]
["J","Chladek, P; Musalek, M; Zahradnik, P",null,null,null,"Chladek, P.; Musalek, M.; Zahradnik, P.",null,null,"Femoroacetabular Impingement Syndrome: First Experience with Surgical Treatment","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"femoroacetabular impingement syndrome; surgical treatment","HIP ARTHROSCOPY; PERIACETABULAR OSTEOTOMY; ACETABULAR IMPINGEMENT; OSTEOARTHRITIS; DISLOCATION; OUTCOMES; COMPLICATIONS; ARTHRITIS","PURPOSE OF THE STUDY Femoroacetabular impingement syndrome (FAI) represents a mechanical conflict between acetabulum and proximal part of the femur. This disorder may gradually result in the development of the hip osteoarthritis. FAI may be caused by an acetabular retroversion, rarely by coxa profunda or by asphericity of the femoral head and missing femoral head-neck offset respectively. However, a combination of both conditions is the most frequent. Before FAI treatment was adopted as a standard technique for hip preservation at our department, detailed cadaver studies of the vascular anatomy of the hip were performed and the relevant literature was reviewed. The aim of this study was to assess the efficiency of hip preserving surgery in relation to the technique used. We hypothesized that surgical intervention helped to alleviate pain and improve hip function. MATERIAL AND METHODS In the period from October 11, 2005 to June 30, 2012, a total of 168 patients (190 hips) had surgery for FAI. After we met exclusion criteria, 83 hips were treated by surgical hip dislocation (SHD) and 17 undergoing anterior minimally invasive surgery (AMIS). The minimum follow-up was 12 months, with an average of 3 years and 4 months, and a range of 12 months to 7 years and 8 months. The subjective evaluation by the patients and the functional hip assessment were based on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and the Non-Arthritic Hip Score (NAHS) questionnaires. To assess the efficiency of the techniques, the pre- and post-operative scores were compared in each group (SHD group, n=83; AMIS group, n=17). A comparison of pre- and post-operative data was also made for the groups joined together to evaluate the benefit of surgery as such in FAI treatment. The results were statistically analysed using the Wilcoxon test for paired samples; the level of significance was set at 0.05. RESULTS There was a statistically significant increase in the scores obtained after surgery, as compared with the pre-operative data, in the SHD and AMIS groups and in all patients evaluated together. Hip survival without the necessity of conversion to total hip replacement was 96.4% (80/83 hips) in the SHD group and 94.1% (16/17 hips) in the AMIS group. No serious complications were recorded. DISCUSSION The rate of failure in the surgical treatment of FAI syndrome in our patients was in accordance with the literature data, as was the number of the patients requiring conversion to total hip replacement. Also the other results were comparable with those of relevant studies. CONCLUSIONS Hip preservation surgery is an issue which has slowly been gaining consensus although opinions on it, including FAI surgical treatment, still vary. As FAI syndrome is a condition leading to degenerative changes in the hip, it is important to pay attention to a thorough diagnostic evaluation and a correct, though often long-term, therapy.","[Chladek, P.] Ortoped Klin UK 2 LF, Prague, Czech Republic; [Chladek, P.] FN Motol Detska Dospela Ortopedie & Traumatol, Prague, Czech Republic; [Musalek, M.] Katedra Zakladu Kinantropol Humanitnich FTVS UK P, Prague, Czech Republic; [Zahradnik, P.] Katedra Fyzioterapie FTVS UK Praha, Prague, Czech Republic","Chladek, P (reprint author), Ortoped Klin 2 LF UK, Uvalu 84, Prague 15000 5, Czech Republic.","chladek.ortopedie@gmail.com",null,null,null,null,null,37,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","OCT",2014,81,5,null,null,null,null,328,334,null,null,null,7,"Orthopedics","Orthopedics","AS1ND","WOS:000344046700005",25514341]
["J","Pech, J; Veigl, D; Hromadka, R; Dobias, J; Zatrapa, T",null,null,null,"Pech, J.; Veigl, D.; Hromadka, R.; Dobias, J.; Zatrapa, T.",null,null,"Shape-Memory Osteosynthesis for Trapeziometacarpal Joint Arthrodesis","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"rhizarthrosis; osteoarthritis; arthrodesis; shape-memory staple; trapeziometacarpal joint","CARPOMETACARPAL JOINT; BASAL JOINT; THUMB; OSTEOARTHRITIS; ARTHROPLASTY; ARTHRITIS; IMPLANT; HAND","PURPOSE OF THE STUDY Arthrodesis of the trapeziometacarpal joint is the method of choice in the treatment of degenerative arthritis of this joint. This procedure was indicated most frequently in middle-age patients doing hard manual labor. Methods for achieving a solid fusion of the trapeziometacarpal joint are known and often reported in the literature. Frequently, they are associated with some failure rate, particularly as concerns bone union. Our study presents a simple and effective method verified in cadaver specimens and then currently used at our department. MATERIAL AND METHODS The procedure for arthrodesis of the trapeziometacarpal joint was verified first in fixed wrist and hand specimens at the Institute of Anatomy, 1st Faculty of Medicine, Charles University in Prague. If the original shape of the basal thumb joint between the trapezium and the metacarpal is maintained, it allows for correct reduction and subsequent arthrodesis in a required position. In patients, surgical treatment included the use of implants, two DePuy shape-memory staples, which facilitate sufficient fragment compression and provide stable fixation. The staples were inserted in pre-drilled and gauged tunnels in the body of the trapezium and in the proximal metaphysis of the first metacarpal. RESULTS Between 2011 and 2014, the procedure was used in 14 patients diagnosed with primary arthritis of the trapeziometacarpal joint. The group comprised nine women and five men, the average age was 52 years and the range was 44 to 69 years. Surgery was most frequently carried out on the dominant upper extremity (85%); there was no bilateral surgery. The average follow-up was 18.3 months (range, 5 to 39 months). Solid fusion was recorded at 7 weeks after surgery in all patients except for the one still treated at the time of this paper submission. All patients were free of pain, ten reported satisfaction with grip strength and hand function, the rest would have preferred improvement in fine motor skills of the thumb. All of them found the cosmetic appearance of the hand satisfactory.. DISCUSSION The methods generally used for trapeziometacarpal joint arthrodesis are reported to carry some risk of pseudarthrosis development. A lot of modifications have been described, from conventional procedures using AO lag screws or Kirschner wires to up-to-date plate systems involving angle-stable fixation. Total fusion of the trapeziometacarpal joint is disputable in patients with rheumatoid arthritis from the technical point of view as well as the relevance of indication criteria. Some authors consider this procedure a contraindication for patients with rheumatoid arthritis. The use of joint replacement in treating trapeziometacarpal joint arthritis is another complex issue. CONCLUSIONS An arthrodesis of the trapeziometacarpal joint based on careful assessment of indication criteria proved to be a simple, effective and low-cost method of stable osteosynthesis that provided good conditions for solid fusion of the trapezium with the base of the first metacarpal. It allowed for sufficient abduction and opposition of the thumb, thus permitting satisfactory hand grip strength and full involvement in everyday life activities and occupations. It provided stability of the thumb, its painless movement and good cosmetic looks.","[Pech, J.; Veigl, D.; Hromadka, R.; Dobias, J.; Zatrapa, T.] I Ortoped Klin 1 LF UK, Prague 15006 5, Czech Republic; [Pech, J.; Veigl, D.; Hromadka, R.; Dobias, J.; Zatrapa, T.] FN Motol, Prague, Czech Republic; [Hromadka, R.] Lekarske Fak UK Praze 1, Anat Ustav, Prague, Czech Republic","Pech, J (reprint author), I Ortoped Klin 1 LF UK, Uvalu 84, Prague 15006 5, Czech Republic.","jan.pech@fnmotol.cz",null,null,null,null,null,20,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","OCT",2014,81,5,null,null,null,null,335,339,null,null,null,5,"Orthopedics","Orthopedics","AS1ND","WOS:000344046700006",25514342]
["J","Vlasak, A; Horinek, D; Sames, M",null,null,null,"Vlasak, Ales; Horinek, Daniel; Sames, Martin",null,null,"Radiographic changes after anterior cervical discectomy and their clinical impact","ACTA NEUROCHIRURGICA",null,null,"English","Letter",null,null,null,null,null,null,"INTERBODY FUSION; FOLLOW-UP; DISCECTOMY",null,"[Vlasak, Ales] Univ Hosp Motol, Dept Neurosurg, Prague, Czech Republic; [Vlasak, Ales; Horinek, Daniel] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Horinek, Daniel; Sames, Martin] Univ JE Purkyne, Masaryk Hosp, Dept Neurosurg, Usti Nad Labem, Czech Republic","Vlasak, A (reprint author), Univ Hosp Motol, Dept Neurosurg, Prague, Czech Republic.","ales.vlasak@fnmotol.cz",null,null,null,null,null,10,0,0,"SPRINGER WIEN","WIEN","SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA","0001-6268","0942-0940",null,"ACTA NEUROCHIR","Acta Neurochir.","NOV",2014,156,11,null,null,null,null,2153,2154,null,"10.1007/s00701-014-2110-0",null,2,"Clinical Neurology; Surgery","Neurosciences & Neurology; Surgery","AR9HP","WOS:000343884400017",24875611]
["J","Zoremba, N; Homola, A; Rossaint, R; Sykova, E",null,null,null,"Zoremba, Norbert; Homola, Ales; Rossaint, Rolf; Sykova, Eva",null,null,"Interstitial lactate, lactate/pyruvate and glucose in rat muscle before, during and in the recovery from global hypoxia","ACTA VETERINARIA SCANDINAVICA",null,null,"English","Article",null,null,null,null,null,"Hypoxia; Microdialysis; Muscle; Recovery; Lactate; Glucose; Metabolism","SEVERE HEAD-INJURY; LACTIC-ACIDOSIS; SKELETAL-MUSCLE; MICRODIALYSIS; BRAIN; TISSUE; METABOLISM","Background: Hypoxia results in an imbalance between oxygen supply and oxygen consumption. This study utilized microdialysis to monitor changes in the energy-related metabolites lactate, pyruvate and glucose in rat muscle before, during and after 30 minutes of transient global hypoxia. Hypoxia was induced in anaesthetised rats by reducing inspired oxygen to 6% O-2 in nitrogen. Results: Basal values for lactate, the lactate/pyruvate ratio and glucose were 0.72 +/- 0.04 mmol/l, 10.03 +/- 1.16 and 3.55 +/- 0.19 mmol/l (n = 10), respectively. Significant increases in lactate and the lactate/pyruvate ratio were found in the muscle after the induction of hypoxia. Maximum values of 2.26 +/- 0.37 mmol/l for lactate were reached during early reperfusion, while the lactate/pyruvate ratio reached maximum values of 35.84 +/- 7.81 at the end of hypoxia. Following recovery to ventilation with air, extracellular lactate levels and the lactate/pyruvate ratio returned to control levels within 30-40 minutes. Extracellular glucose levels showed no significant difference between hypoxia and control experiments. Conclusions: In our study, the complete post-hypoxic recovery of metabolite levels suggests that metabolic enzymes of the skeletal muscle and their related cellular components may be able to tolerate severe hypoxic periods without prolonged damage. The consumption of glucose in the muscle in relation to its delivery seems to be unaffected.","[Zoremba, Norbert; Rossaint, Rolf] Univ Hosp RWTH Aachen, Dept Anaesthesiol, D-52074 Aachen, Germany; [Homola, Ales; Sykova, Eva] Charles Univ Prague, Dept Neurosci, Prague 15006, Czech Republic; [Homola, Ales; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic","Zoremba, N (reprint author), Univ Hosp RWTH Aachen, Dept Anaesthesiol, Pauwelsstr 30, D-52074 Aachen, Germany.","nzoremba@ukaachen.de",null,null,"European Commission Marie Curie Training Site Programme [HPMT-CT-2000-00187]; Academy of Sciences of the Czech Republic [AV0Z50390512]; Ministry of Sport, Youth and Education of the Czech Republic [1M0021620803, LC544, GACR 309/09/1597]","This study was supported by the European Commission Marie Curie Training Site Programme HPMT-CT-2000-00187, by grant AV0Z50390512 from the Academy of Sciences of the Czech Republic and by grants 1M0021620803, LC544 and GACR 309/09/1597 from the Ministry of Sport, Youth and Education of the Czech Republic.",null,21,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","0044-605X","1751-0147",null,"ACTA VET SCAND","Acta Vet. Scand.","NOV 13",2014,56,null,null,null,null,null,null,null,72,"10.1186/s13028-014-0072-0",null,5,"Veterinary Sciences","Veterinary Sciences","AT4DE","WOS:000344889000001"]
["J","Magerova, H; Vyhnalek, M; Laczo, J; Andel, R; Rektorova, I; Kadlecova, A; Bojar, M; Hort, J",null,null,null,"Magerova, Hana; Vyhnalek, Martin; Laczo, Jan; Andel, Ross; Rektorova, Irena; Kadlecova, Alexandra; Bojar, Martin; Hort, Jakub",null,null,"Odor Identification in Frontotemporal Lobar Degeneration Subtypes","AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS",null,null,"English","Article",null,null,null,null,null,"odor identification; behavioral variant frontotemporal dementia; primary nonfluent aphasia; semantic dementia; progressive supranuclear palsy; cognitive status","PROGRESSIVE SUPRANUCLEAR PALSY; IDIOPATHIC PARKINSONS-DISEASE; MILD COGNITIVE IMPAIRMENT; HUMAN OLFACTORY CORTEX; ALZHEIMERS-DISEASE; NONFLUENT APHASIA; SEMANTIC DEMENTIA; EARLY-DIAGNOSIS; PICKS-DISEASE; ATROPHY","Odor identification impairment is a feature of several neurodegenerative disorders. Although neurodegenerative changes in the frontotemporal lobar degeneration (FTLD) subtypes involve areas important for olfactory processing, data on olfactory function in these patients are limited. An 18-item, multiple-choice odor identification test developed at our memory clinic, the Motol Hospital smell test, was administered to 9 patients with behavioral variant frontotemporal dementia, 13 patients with the language variants, primary nonfluent aphasia (n = 7) and semantic dementia (n = 6), and 8 patients with progressive supranuclear palsy. Compared to the control group (n = 15), all FTLD subgroups showed significant impairment of odor identification (P < .05). The differences between the FTLD subgroups were not significant. No correlation between odor identification and neuropsychological tests results was found. Our data suggest that odor identification impairment is a symptom common to FTLD syndromes, and it seems to be based on olfactory structure damage rather than cognitive decline.","[Magerova, Hana; Vyhnalek, Martin; Laczo, Jan; Kadlecova, Alexandra; Bojar, Martin; Hort, Jakub] Charles Univ Prague, Fac Med 2, Memory Clin, Dept Neurol, Prague 15006, Czech Republic; [Magerova, Hana; Vyhnalek, Martin; Laczo, Jan; Kadlecova, Alexandra; Bojar, Martin; Hort, Jakub] Charles Univ Prague, Motol Univ Hosp, Prague 15006, Czech Republic; [Vyhnalek, Martin; Laczo, Jan; Hort, Jakub] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Rektorova, Irena] Masaryk Univ, Sch Med, Dept Neurol 1, Brno, Czech Republic; [Rektorova, Irena] Masaryk Univ, St Annes Hosp, Brno, Czech Republic; [Rektorova, Irena] Masaryk Univ, CEITEC, Appl Neurosci Res Grp, Brno, Czech Republic","Magerova, H (reprint author), Charles Univ Prague, Fac Med 2, Memory Clin, Dept Neurol, V Uvalu 84, Prague 15006, Czech Republic.","magerova.hana@gmail.com",null,null,"European Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; Grant Agency of the Czech Republic [309/09/1053]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NT 11225-4]; NT 11225-4); Institutional Support of Laboratory Research [2/2012 (699002)]; Ministry of Health, Czech Republic; University Hospital Motol, Prague, Czech Republic [00064203]; Grant Agency of Charles University [74308, 98509]","The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the European Regional Development Fund-Project FNUSA-ICRC (grant number CZ.1.05/1.1.00/02.0123); Grant Agency of the Czech Republic (grant number 309/09/1053); Internal Grant Agency of the Ministry of Health of the Czech Republic (grant number NT 11225-4); Institutional Support of Laboratory Research Grant No. 2/2012 (699002); Ministry of Health, Czech Republic-conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203; and Grant Agency of Charles University (grant numbers 74308 and 98509).",null,55,0,0,"SAGE PUBLICATIONS INC","THOUSAND OAKS","2455 TELLER RD, THOUSAND OAKS, CA 91320 USA","1533-3175","1938-2731",null,"AM J ALZHEIMERS DIS","Am. J. Alzheimers Dis. Other Dement.","DEC",2014,29,8,null,null,null,null,762,768,null,"10.1177/1533317514539033",null,7,"Geriatrics & Gerontology; Clinical Neurology","Geriatrics & Gerontology; Neurosciences & Neurology","AU0SR","WOS:000345335300017",24939002]
["J","Havlin, J; Matousovic, K; Schuck, O",null,null,null,"Havlin, Jan; Matousovic, Karel; Schueck, Otto",null,null,"A \"Lingering Mystery\" of Postdialysis Serum Bicarbonate Concentration","AMERICAN JOURNAL OF KIDNEY DISEASES",null,null,"English","Letter",null,null,null,null,null,null,"HEMODIALYSIS",null,"[Havlin, Jan; Matousovic, Karel; Schueck, Otto] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Havlin, Jan; Matousovic, Karel; Schueck, Otto] Fac Hosp, Prague, Czech Republic; [Havlin, Jan] B Braun Avitum Praha Nusle Dialysis Ctr, Prague, Czech Republic","Havlin, J (reprint author), Charles Univ Prague, Fac Med 2, Prague, Czech Republic.",null,null,null,null,null,null,5,1,1,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0272-6386","1523-6838",null,"AM J KIDNEY DIS","Am. J. Kidney Dis.","DEC",2014,64,6,null,null,null,null,1000,1001,null,"10.1053/j.ajkd.2014.09.010",null,4,"Urology & Nephrology","Urology & Nephrology","AU1TZ","WOS:000345404200025",25453838]
["J","Krutova, M; Nyc, O; Kuijper, EJ; Geigerova, L; Matejkova, J; Bergerova, T; Arvand, M",null,null,null,"Krutova, Marcela; Nyc, Otakar; Kuijper, Ed J.; Geigerova, Lenka; Matejkova, Jana; Bergerova, Tamara; Arvand, Mardjan",null,null,"A case of imported Clostridium difficile PCR-ribotype 027 infection within the Czech Republic which has a high prevalence of C-difficile ribotype 176","ANAEROBE",null,null,"English","Article",null,null,null,null,null,"Clostridium difficile; PCR ribotype 027; PCR ribotype 176; MLVA; Capillary electrophoresis; C. difficile infection","EMERGENCE; POLAND","The first case of Clostridium difficile RT027 infection in the Czech Republic (CZ) was identified. The patient had been hospitalised in Germany prior to moving to CZ. Multiple-Locus Variable number tandem repeat Analysis revealed a genetic relatedness between the patient's isolate and RT027 isolate collected in the German hospital. (C) 2014 Elsevier Ltd. All rights reserved.","[Krutova, Marcela; Nyc, Otakar; Matejkova, Jana] Charles Univ Prague, Fac Med 2, Dept Med Microbiol, Prague 15006 5, Czech Republic; [Krutova, Marcela; Nyc, Otakar; Matejkova, Jana] Motol Univ Hosp, Prague 15006 5, Czech Republic; [Krutova, Marcela] Charles Univ Prague, Fac Med 2, Dept Paediat Neurol, Prague 15006 5, Czech Republic; [Arvand, Mardjan] Ctr Hlth Protect, Hesse State Hlth Off, Dillenburg, Germany; [Kuijper, Ed J.] Leiden Univ, Med Ctr, Leiden, Netherlands; [Geigerova, Lenka; Bergerova, Tamara] Charles Univ Prague, Fac Med, Dept Microbiol, Prague 15006 5, Czech Republic; [Geigerova, Lenka; Bergerova, Tamara] Univ Hosp Plzen, Plzen, Czech Republic","Krutova, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Med Microbiol, V Uvalu 84, Prague 15006 5, Czech Republic.","marcela.krutova@seznam.cz",null,null,"DRO, University Hospital Motol, Prague, Czech Republic [MH CZ IGA NT14209 - 3, 00064203]","Supported by: MH CZ IGA NT14209 - 3 and DRO, University Hospital Motol, Prague, Czech Republic 00064203.",null,10,0,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","1075-9964","1095-8274",null,"ANAEROBE","Anaerobe","DEC",2014,30,null,null,null,null,null,153,155,null,"10.1016/j.anaerobe.2014.09.020",null,3,"Microbiology","Microbiology","AY7XE","WOS:000347768400027",25300750]
["J","Spenerova, M; Dzubak, P; Srovnal, J; Radova, L; Burianova, R; Konecny, P; Salkova, S; Novak, Z; Pospisilova, D; Stary, J; Blazek, B; Hak, J; Votava, T; Timr, P; Kaiserova, E; Bubanska, E; Mihal, V; Hajduch, M",null,null,null,"Spenerova, Michaela; Dzubak, Petr; Srovnal, Josef; Radova, Lenka; Burianova, Renata; Konecny, Petr; Salkova, Sona; Novak, Zbynek; Pospisilova, Dagmar; Stary, Jan; Blazek, Bohumir; Hak, Jiri; Votava, Tomas; Timr, Pavel; Kaiserova, Emilia; Bubanska, Eva; Mihal, Vladimir; Hajduch, Marian",null,null,"Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia","BIOMEDICAL PAPERS-OLOMOUC",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; glucocorticoids; prednisone; prednisolone; dexamethasone; drug resistance; MTT assay","CHILDREN","Introduction. Glucocorticoids, particularly prednisone/prednisolone and dexamethasone, play a prominent role in the treatment of pediatric patients with acute lymphoblastic leukemia due to their ability to induce apoptosis in susceptible cells. Current therapeutic protocols use prednisone for both the prophase and the induction phase of the therapy because the greater antileukemic activity of dexamethasone is compromised by its high frequency of serious adverse reactions. Aim. To compare, for the first time, the in vitro antileukemic activity of prednisolone alone to that of a combination of prednisolone and dexamethasone using dexamethasone at a very low and presumably safe dosage (1/50 w/w). Methods. Lymphoblasts were isolated from bone marrow and/or blood samples from children with newly diagnosed acute lymphoblastic leukemia. The cytotoxic activity of prednisolone, dexamethasone and the prednisolone/dexamethasone combination against isolated leukemia cells was analyzed using the MTT cytotoxicity assay. Results. We observed differences in the in vitro antileukemic activity of prednisolone and dexamethasone in 21% of the tested patients. 3% of the children were prednisolone sensitive but dexamethasone resistant, while 18% were prednisolone resistant and dexamethasone sensitive. 32% were sensitive to both glucocorticoids and 18% were resistant to both. Cells from patients with good in vivo responses to prednisone monotherapy were more responsive to prednisolone in vitro than were cells from patients with poor prednisone responses (P<0.07). Importantly, we demonstrated that the use of even a minimal dose (1/50 w/w) of dexamethasone with prednisolone dramatically increases the in vitro anti-leukemic activity of prednisolone (P<0.0006). Conclusion. The high inter-individual variability of acute lymphoblastic leukemia responses to glucocorticoids suggest that either patients should be selected for prednisone or dexamethasone treatment on the basis of predictive biomarkers or that prednisone should be used directly in combination with a very low and safe dose of dexamethasone to potentiate its antileukemic activity. The latter option is likely to be cheaper and more efficient, and therefore warrants further clinical investigation to assess its efficacy and safety in treating childhood acute lymphoblastic leukemia.","[Spenerova, Michaela; Dzubak, Petr; Srovnal, Josef; Radova, Lenka; Burianova, Renata; Konecny, Petr; Salkova, Sona; Mihal, Vladimir; Hajduch, Marian] Palacky Univ Olomouc, Fac Med & Dent, Inst Mol & Translat Med, Expt Med Lab, Olomouc, Czech Republic; [Spenerova, Michaela; Dzubak, Petr; Srovnal, Josef; Radova, Lenka; Burianova, Renata; Konecny, Petr; Salkova, Sona; Novak, Zbynek; Pospisilova, Dagmar; Mihal, Vladimir; Hajduch, Marian] Univ Hosp Olomouc, Olomouc, Czech Republic; [Spenerova, Michaela; Dzubak, Petr; Srovnal, Josef; Novak, Zbynek; Pospisilova, Dagmar; Mihal, Vladimir] Palacky Univ Olomouc, Fac Med & Dent, Dept Pediat, Olomouc, Czech Republic; [Stary, Jan] Univ Hosp Motol, Dept Pediat Haematol & Oncol, Prague, Czech Republic; [Blazek, Bohumir] Univ Hosp, Dept Pediat, Ostrava, Czech Republic; [Spenerova, Michaela; Dzubak, Petr; Hak, Jiri] Univ Hosp, Dept Pediat, Hradec Kralove, Czech Republic; [Votava, Tomas] Fac Hosp, Dept Pediat, Plzen, Czech Republic; [Timr, Pavel] Hosp Ceske Budejovice, Dept Pediat, Ceske Budejovice, Czech Republic; [Kaiserova, Emilia] Univ Hosp, Dept Pediat Oncol, Bratislava, Slovakia; [Bubanska, Eva] Childrens Med Univ Dept, Dept Pediat Oncol & Hematol, Banska Bystrica, Slovakia","Hajduch, M (reprint author), Palacky Univ Olomouc, Fac Med & Dent, Inst Mol & Translat Med, Expt Med Lab, Olomouc, Czech Republic.","marian.hajduch@fnol.cz","Hajduch, Marian/J-4015-2014",null,"Internal Grant Agency of the Czech Ministry of Health [IGA NS 9939]; Palacky University [IGA UP LF_2011_018]; Operational Program Research and Development for Innovations [CZ.1.05/2.1.00/01.0030]","This study was performed as a collaborative enterprise involving staff from the Pediatric Onco-Hematology Centers of the Czech and Slovak Republics - specifically, those in Prague, Olomouc, Ostrava, Plzen, Hradec Kralove, Ceske Budejovice, Bratislava and Banska Bystrica. Financial support was provided by grants from the Internal Grant Agency of the Czech Ministry of Health (grant No. IGA NS 9939) and Palacky University (IGA UP LF_2011_018). The infrastructural part of the project (the Institute of Molecular and Translational Medicine) was supported by the Operational Program Research and Development for Innovations (project CZ.1.05/2.1.00/01.0030).",null,18,0,0,"PALACKY UNIV, MEDICAL FAC","OLOMOUC","CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC","1213-8118","1804-7521",null,"BIOMED PAP","Biomed. Pap-Olomouc",null,2014,158,3,null,null,null,null,422,427,null,"10.5507/bp.2012.059",null,6,"Engineering, Biomedical; Medicine, Research & Experimental","Engineering; Research & Experimental Medicine","AU1RR","WOS:000345398500014",23128824]
["J","Vranova, J; Arenbergerova, M; Arenberger, P; Vrana, A; Zivcak, J; Kolarova, H; Rosina, J",null,null,null,"Vranova, Jana; Arenbergerova, Monika; Arenberger, Petr; Vrana, Antonin; Zivcak, Jozef; Kolarova, Hana; Rosina, Jozef",null,null,"Malignant melanoma in the Czech Republic: Incidence and mortality according to sex, age and disease stage","BIOMEDICAL PAPERS-OLOMOUC",null,null,"English","Article",null,null,null,null,null,"incidence; mortality; cutaneous melanoma; prevention campaign; risk factors; estimated annual percentage change; biomedical engineering","SKIN-CANCER INCIDENCE; TRENDS; PREVENTION; EUROPE; EPIDEMIOLOGY; PROTECTION; CHILDREN; SUNBEDS; POLICY","Background. The Czech Republic has reported one of the highest incidence rates of cutaneous melanoma (CM) in Europe and the rate continues to rise. Our study undertook a detailed investigation of the incidence and mortality of melanoma relative to sex, age and disease stage. The main goals were to elucidate the causes of the rising trends and explain the differences in development relative to sex, age and disease stage. Methods and Results. The estimated annual percentage change (EAPC) using the Joinpoint Regression Model was calculated separately for men and women for all age categories and for all T stages of TNM classification. The EAPC for women was slightly higher than for men. This was only found in melanomas thinner than 1 mm (T1). For all other stages (T2, T3 and T4) the situation was worse in men. A higher incidence rate of CM and the higher value of EAPC were found for women in younger age categories (up to 49 years). In the next age category, from 50 to 59 years, the incidence of CM was comparable in both sexes as well as the EAPC. In the older age categories, i.e. 60 years and older, a significant increase was found predominantly in men. The mortality rates were only comparable between men and women in the 20 to 29 year age group. In all other categories there was a higher mortality for men. Conclusions. The number of melanoma cases in the Czech Republic is increasing faster than any other cancer. Despite improved survival rates, the death rate from CM continues to climb as a result of exponential increases in incidence. Thus primary and secondary prevention campaigns are essential for future reductions in CM incidence and mortality in the Czech Republic.","[Vranova, Jana; Rosina, Jozef] Charles Univ Prague, Fac Med 3, Dept Med Biophys & Med Informat, Prague, Czech Republic; [Arenbergerova, Monika; Arenberger, Petr] Charles Univ Prague, Fac Med 3, Dept Dermatovenerol, Prague, Czech Republic; [Vrana, Antonin] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Zivcak, Jozef] Tech Univ Kosice, Fac Mech Engn, Dept Biomed Engn Automat & Measurement, Kosice, Slovakia; [Kolarova, Hana] Palacky Univ, Inst Mol & Translat Med, Fac Med & Dent, Dept Med Biophys, CR-77147 Olomouc, Czech Republic; [Rosina, Jozef] Czech Tech Univ, Fac Biomed Engn, Kladno, Czech Republic","Vranova, J (reprint author), Charles Univ Prague, Fac Med 3, Dept Med Biophys & Med Informat, Prague, Czech Republic.","jana.vranova@lf3.cuni.cz",null,null," [CZ.1.05/2.1.00/01.0030]","This work was supported by the grant project CZ.1.05/2.1.00/01.0030.",null,31,0,0,"PALACKY UNIV, MEDICAL FAC","OLOMOUC","CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC","1213-8118","1804-7521",null,"BIOMED PAP","Biomed. Pap-Olomouc",null,2014,158,3,null,null,null,null,438,446,null,"10.5507/bp.2012.081",null,9,"Engineering, Biomedical; Medicine, Research & Experimental","Engineering; Research & Experimental Medicine","AU1RR","WOS:000345398500017",23128825]
["J","Pochop, P; Darsova, D; Uhlik, J; Lestak, J; Kukacka, J; Kodetova, D; Klapkova, E; Malis, J; Vajner, L",null,null,null,"Pochop, Pavel; Darsova, Denisa; Uhlik, Jiri; Lestak, Jan; Kukacka, Jiri; Kodetova, Daniela; Klapkova, Eva; Malis, Josef; Vajner, Ludek",null,null,"Retinal toxicity after repeated intravitreal carboplatin injection into rabbit eyes","BIOMEDICAL PAPERS-OLOMOUC",null,null,"English","Article",null,null,null,null,null,"carboplatin concentration; electroretinogram; intravitreal seeding; local treatment; rabbit; retinoblastoma","RETINOBLASTOMA; CHEMOTHERAPY; PHARMACOKINETICS; ERG","Background. The aim of this study was to assess retinal toxicity in a rabbit model after carboplatin delivered as repeated transcorneal intravitreal injection, in order to determine the highest possible safe dose for use in human retinoblastoma \"seeding\" tumor chemotherapy. Methods and Results. We used six albino rabbits in an in vivo experiment and injected 0.008 mg of carboplatin intra-vitreally (iv) 4 times at two-week intervals. 0.08 mL saline was injected into the left eye. We recorded electroretinograms (ERGs) before the first carboplatin injection and after the fourth injection. Platinum concentration was measured 1 h after the fifth additional injection. We found reduced dark-adapted b-wave amplitudes and, light-adapted b-wave and a-wave amplitudes. The differences between right and left eyes was significant but we found no histopathologic retinal changes. Conclusions. 0.008 mg of carboplatin is probably the highest possible safe dose for the treatment of retinoblastoma patients. Questionable is direct extrapolation of retinal toxicity from the rabbit eye model to the human eye.","[Pochop, Pavel; Darsova, Denisa] Charles Univ Prague, Fac Med 2, Dept Ophthalmol Children & Adults, CR-11636 Prague 1, Czech Republic; [Uhlik, Jiri; Vajner, Ludek] Charles Univ Prague, Fac Med 2, Dept Histol & Embryol, CR-11636 Prague 1, Czech Republic; [Kukacka, Jiri; Klapkova, Eva] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, CR-11636 Prague 1, Czech Republic; [Kodetova, Daniela] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, CR-11636 Prague 1, Czech Republic; [Malis, Josef] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CR-11636 Prague 1, Czech Republic; [Lestak, Jan] Clin Jan Lestak, Dept Ophthalmol, Prague, Czech Republic","Pochop, P (reprint author), Charles Univ Prague, Fac Med 2, Dept Ophthalmol Children & Adults, CR-11636 Prague 1, Czech Republic.","pavel.pochop@gmail.com",null,null,null,null,null,16,1,1,"PALACKY UNIV, MEDICAL FAC","OLOMOUC","CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC","1213-8118","1804-7521",null,"BIOMED PAP","Biomed. Pap-Olomouc",null,2014,158,4,null,null,null,null,552,556,null,"10.5507/bp.2012.106",null,5,"Engineering, Biomedical; Medicine, Research & Experimental","Engineering; Research & Experimental Medicine","AX8QH","WOS:000347173200009"]
["J","Ivica, J; Wilhelm, J",null,null,null,"Ivica, Josko; Wilhelm, Jiri",null,null,"Lipophilic fluorescent products of free radicals","BIOMEDICAL PAPERS-OLOMOUC",null,null,"English","Article",null,null,null,null,null,"lipofuscin-like pigments; lipid peroxidation; free radicals; fluorescence","LIPOFUSCIN-LIKE PIGMENTS; LOW-DENSITY-LIPOPROTEIN; BODY-GAMMA-IRRADIATION; LIPOXIDATION END-PRODUCTS; LIPID-PEROXIDATION; OXIDATIVE STRESS; RAT-LIVER; MITOCHONDRIAL DYSFUNCTION; ALZHEIMERS-DISEASE; AMINO-ACIDS","Background. Fluorescent pigments are the end-products of reactions involving free radical attack on biological molecules and can be formed, for example, in reactions between lipid peroxidation products, mainly unsaturated aldehydes, with free amino groups. Their characteristic emission maximum was found to be at 420-470 nm after being excited at 340-390 nm. The mechanism of their formation and chemical identity has been revealed in many in vitro studies, in which reactive aldehydes were incubated with amino group-containing molecules. Owing to their intrinsic fluorescent properties and molecular stability these products are easily measured by means of spectrofluorimetry and are used as biomarkers of oxidative stress caused by various triggers. It has been found that the fluorescent products are formed in excess in conditions linked with increased free radical production, such as atherosclerosis, Alzheimer's disease and multiple sclerosis. Methods. We searched the literature using \"MEDLINE\" and \"Web of Science\" in order to get an overview of the state of knowledge about fluorescent products of free radicals, that is, their analysis from in vitro studies, animal and human studies and their use as markers of oxidative damage. Conclusions. Although their chemical structure may not have been elucidated, the fluorophores formed in this way have found application as markers of oxidative stress in many animal and human studies. In vitro experiments using model reactions have given some clues as to how certain fluorescent pigments arise during oxidative reactions in vivo. Advances in analytical techniques should lead the chemical characterization of pigments of different origin to completeness.","[Ivica, Josko] Charles Univ Prague, Fac Med 2, Dept Med Chem & Clin Biochem, Prague, Czech Republic; [Ivica, Josko] Motol Hosp, Prague, Czech Republic; [Ivica, Josko; Wilhelm, Jiri] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic","Ivica, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Med Chem & Clin Biochem, Prague, Czech Republic.","josko.ivica@gmail.com",null,null,"Grant Agency of Czech Republic (GACR) [P303/11/0298]","This study was supported by grant No. P303/11/0298 of Grant Agency of Czech Republic (GACR).",null,84,0,0,"PALACKY UNIV, MEDICAL FAC","OLOMOUC","CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC","1213-8118","1804-7521",null,"BIOMED PAP","Biomed. Pap-Olomouc",null,2014,158,3,null,null,null,null,365,372,null,"10.5507/bp.2012.112",null,8,"Engineering, Biomedical; Medicine, Research & Experimental","Engineering; Research & Experimental Medicine","AU1RR","WOS:000345398500006",23446206]
["J","Vesely, S; Jarolim, L; Duskova, K; Schmidt, M; Dusek, P; Babjuk, M",null,null,null,"Vesely, Stepan; Jarolim, Ladislav; Duskova, Katerina; Schmidt, Marek; Dusek, Pavel; Babjuk, Marko",null,null,"The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy","BMC UROLOGY",null,null,"English","Article",null,null,null,null,null,"Prostate specific antigen; Radical prostatectomy; Surgical margins; Adjuvant radiotherapy","RETROPUBIC PROSTATECTOMY; PROGNOSTIC-SIGNIFICANCE; ADJUVANT RADIOTHERAPY; FOLLOW-UP; CANCER; PROGRESSION; RECURRENCE; TRIAL; PREDICTS; SURVIVAL","Background: It is well recognized that the presence of positive surgical margins (PSM) after radical prostatectomy (RP) adversely affects cancer specific outcomes and recent evidence from randomized trials supports the use of adjuvant radiotherapy in these cases. However, not all of the patients with PSM develop disease recurrence and the policy of adjuvant radiation could result in considerable over-treatment. We investigated the ability of early postoperative prostate specific antigen (PSA) and PSA decline rates to stratify the risk of disease progression during the first weeks after the surgery thereby allowing adequate time for planning eventual adjuvant therapy. Methods: We studied 116 consecutive patients with the finding of PSM after RP for localized prostate cancer between 2001 and 2012. No patients were treated with radiation or hormonal therapy. An intensive postoperative PSA monitoring using ultrasensitive assay started first at day 14 after the surgery, then at day 30, 60, 90 and 180, and subsequently in 3 monthly intervals. Biochemical recurrence (BCR) presented the failure of surgical treatment and it was defined as PSA >= 0.2 ng/ml. The ability of PSA decline parameters to predict BCR was assessed using Cox regression model and area under the curve (AUC) calculation. Results: Overall 55 (47%) patients experienced BCR during median follow-up of 31.4 months (range 6-69). Preoperative PSA, pathologic Gleason sum and pathologic grade failed to reveal any association with observation of BCR. Postoperative PSA levels achieved significant predictive accuracy already on day 30 (AUC 0.74). PSA > 0.073 ng/ml at day 30 increased significantly the risk of BCR (HR 4.35, p < 0.001). Predictive accuracy was significantly exceeded on day 60 (AUC 0.84; p < 0.001), while further enhancements on day 90 (AUC 0.84) and 180 (AUC 0.91) were not significant. Conclusions: The level of ultrasensitive PSA yields valuable information about the prostatectomy outcome already at the first month after the surgery and should aid risk stratification in patients with PSM. Patients not likely to experience subsequent disease progression may be spared the toxicity of immediate adjuvant radiotherapy.","[Vesely, Stepan; Jarolim, Ladislav; Duskova, Katerina; Schmidt, Marek; Dusek, Pavel; Babjuk, Marko] Charles Univ Prague, Dept Urol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic","Vesely, S (reprint author), Charles Univ Prague, Dept Urol, Fac Med 2, Univ Hosp Motol, Uvalu 84, Prague 15006 5, Czech Republic.","stepan.vesely@fnmotol.cz",null,null,"project (Ministry of Health, Czech Republic) for conceptual development of research organization (University Hospital Motol, Prague, Czech Republic) [00064203]","Supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic).",null,25,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2490",null,null,"BMC UROL","BMC Urol.","OCT 2",2014,14,null,null,null,null,null,null,null,79,"10.1186/1471-2490-14-79",null,6,"Urology & Nephrology","Urology & Nephrology","AU2QU","WOS:000345463700001",25277310]
["J","van Gestel, JPJ; Bierings, MB; Dauger, S; Dalle, JH; Pavlicek, P; Sedlacek, P; Monteiro, LM; Lankester, A; Bollen, CW",null,null,null,"van Gestel, J. P. J.; Bierings, M. B.; Dauger, S.; Dalle, J-H; Pavlicek, P.; Sedlacek, P.; Monteiro, L. M.; Lankester, A.; Bollen, C. W.",null,null,"Outcome of invasive mechanical ventilation after pediatric allogeneic hematopoietic SCT: results from a prospective, multicenter registry","BONE MARROW TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,null,"STEM-CELL TRANSPLANTATION; INTENSIVE-CARE-UNIT; ACUTE RESPIRATORY-FAILURE; BONE-MARROW-TRANSPLANTATION; CHILDREN REQUIRING ADMISSION; RENAL REPLACEMENT THERAPY; CRITICALLY-ILL CHILDREN; HEMATOLOGY PATIENTS; CANCER-PATIENTS; NONINVASIVE VENTILATION","Exact data on prognosis of children receiving invasive mechanical ventilation (IMV) after allogeneic hematopoietic SCT (HSCT) is lacking. We therefore started a prospective registry in four European university HSCT centers (Leiden, Paris, Prague and Utrecht) and their pediatric intensive care units (PICUs). The registry started in January 2009. In January 2013, the four centers together had treated a total of 83 admissions with IMV. The case fatality rate in these patients was 52%. Mortality 6 months after PICU discharge was 45%. There were significant differences between centers in the proportion of children who received IMV after HSCT (6-23%, P < 0.01), in severity of disease on admission to PICU (predicted mortality 14-37%, P < 0.01), in applying noninvasive ventilation before IMV (3-75% of admissions, P < 0.01) and in the use of renal replacement therapy (RRT) (8-58% of admissions, P < 0.01). Severe impairment in oxygenation, use of RRT and CMV viremia were independent predictors of mortality. Our study shows that mortality in children receiving IMV after HSCT remains high, but has clearly improved compared with older studies. Patient selection and treatment in PICU differed significantly between centers, which underscores the need to standardize and optimize the PICU admission criteria, ventilatory strategies and therapies applied in PICU.","[van Gestel, J. P. J.; Bollen, C. W.] Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Pediat Intens Care Unit, NL-3508 AB Utrecht, Netherlands; [Bierings, M. B.] Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Dept Pediat Hematol Immunol & Bone Marrow Transpl, NL-3508 AB Utrecht, Netherlands; [Dauger, S.] Robert Debre Hosp, AP HP, Pediat Intens Care Unit, Paris, France; [Dauger, S.] Univ Paris 07, Paris, France; [Dalle, J-H] Robert Debre Hosp, AP HP, Dept Pediat Hematol Immunol & Bone Marrow Transpl, Paris, France; [Dalle, J-H] Univ Paris 07, Paris, France; [Pavlicek, P.] Charles Univ Prague, Hosp Motol, Pediat Intens Care Unit, Prague, Czech Republic; [Sedlacek, P.] Charles Univ Prague, Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Monteiro, L. M.] Leiden Univ, Med Ctr, Pediat Intens Care Unit, Leiden, Netherlands; [Lankester, A.] Leiden Univ, Med Ctr, Dept Pediat Hematol Immunol & Bone Marrow Transpl, Leiden, Netherlands","van Gestel, JPJ (reprint author), Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Pediat Intens Care Unit, POB 85090, NL-3508 AB Utrecht, Netherlands.","j.vangestel@umcutrecht.nl",null,null,null,null,null,37,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0268-3369","1476-5365",null,"BONE MARROW TRANSPL","Bone Marrow Transplant.","OCT",2014,49,10,null,null,null,null,1287,1292,null,"10.1038/bmt.2014.147",null,6,"Biophysics; Oncology; Hematology; Immunology; Transplantation","Biophysics; Oncology; Hematology; Immunology; Transplantation","AR5ZC","WOS:000343660300007",25068426]
["J","Mares, P; Ticha, K; Mikulecka, A",null,null,null,"Mares, Pavel; Ticha, Katerina; Mikulecka, Anna",null,null,"Anticonvulsant and behavioral effects of muscimol in immature rats","BRAIN RESEARCH",null,null,"English","Article",null,null,null,null,null,"Pentetrazol-induced seizures; Cortical afterdischarges; Motor activities; Ontogeny; Muscimol; Rat","CORTICAL EPILEPTIC AFTERDISCHARGES; MESENCEPHALIC LOCOMOTOR REGION; RECEPTOR AGONIST MUSCIMOL; INDUCED SEIZURES; GABA; BRAIN; ONTOGENY; ACID","Potentiation of GABAergic inhibition is a mechanism of action of many antiepileptic drugs. The potential use of an agonist of GABA-A receptors, muscimol, as an antiepileptic drug was studied in immature rats by assessing anticonvulsant activity and side effects on motor activities. Anticonvulsant action was tested in two models of seizures (pentetrazol-induced convulsions and cortical epileptic afterdischarges). Off target effect on motor performance was assessed in a battery of tests and in the open field in three age groups (12-, 18- and 25-day-old rats). Muscimol was administered in doses from 0.1 to 1 mg/kg i.p. Only the 1 mg/kg dose exhibited marked anticonvulsant effect against pentetrazol-induced convulsions in 12- and 18-day-old rats, proconvulsant effect was observed in the second model in 18- and 25-day-old rats as prolongation of afterdischarges. Even the 0.5 mg/kg dose suppressed spontaneous locomotion and heavily compromised motor performance. The effect on motor activity was marked in the youngest group and decreased with age. Due to the low anticonvulsant potency and serious side effects, systemic administration of a competitive agonist of GABA(A) receptors in immature animals is not a promising strategy for new anticonvulsants. (C) 2014 Elsevier B.V. All rights reserved.","[Mares, Pavel; Ticha, Katerina; Mikulecka, Anna] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, CR-14220 Prague 4, Czech Republic; [Ticha, Katerina] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Mares, P (reprint author), Acad Sci Czech Republic, Inst Physiol, Videnska 1083, CR-14220 Prague 4, Czech Republic.","maresp@biomed.cas.cz",null,null,"Grant Agency of Charles University [92310]; Grant Agency of Czech Republic [P304/10/1274]; Academy of Sciences of Czech Republic [RVO 67985828]","This study was supported by a grant No. 92310 of the Grant Agency of Charles University, grant No. P304/10/1274 of the Grant Agency of Czech Republic and a project RVO 67985828 of the Academy of Sciences of Czech Republic.",null,35,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0006-8993","1872-6240",null,"BRAIN RES","Brain Res.","SEP 25",2014,1582,null,null,null,null,null,227,236,null,"10.1016/j.brainres.2014.07.038",null,10,"Neurosciences","Neurosciences & Neurology","AR1PM","WOS:000343357100022",25084038]
["J","Melichercik, P; Klapkova, E; Landor, I; Judl, T; Sibek, M; Jahoda, D",null,null,null,"Melichercik, P.; Klapkova, E.; Landor, I; Judl, T.; Sibek, M.; Jahoda, D.",null,null,"The effect of Vancomycin degradation products in the topical treatment of osteomyelitis","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"osteomyelitis; resistant bacterial infection; local antibiotic carriers; crystalline degradation products of Vancomycin","RESISTANT STAPHYLOCOCCUS-AUREUS; CLINICAL-USE; BONE; REVISION","Background: The topical application of Vancomycin is increasingly being used in orthopedics because of the development of methicillin resistant bacteria. Consequently, resistance to Vancomycin has recently been on the rise. One possible explanation for this phenomenon could be the thermal degradation of Vancomycin to antibacterially inactive crystalline degradation products (CDP-1s). The aim of our in vitro experiment was to compare the creation and elution characteristics of CDP-1s and the active form of Vancomycin (factor B) released from bone grafts. Methods: CDP-1s and the factor B released from bone grafts into the buffer solution were measured using the high-performance liquid chromatography method at progressive intervals. Results: The factor B was released from bone grafts at the highest levels, typically on the first day (618.8 mg/L). CDP-1 levels kept increasing until the end of measurement on day 15, when the concentration of CDP-1s (1280.7 mg/L) was much higher compared to that of factor B (217.5 mg/L). Conclusions: We confirmed the tendency of Vancomycin to convert to antimicrobially ineffective CDP-1s. Although Vancomycin is decomposed into crystalline degradation products, its active forms are released from bone grafts in sufficient concentration for more than two keks (Tab. 3, Fig. 1, Ref. 15). Text in PDF www.elis.sk.","[Melichercik, P.; Landor, I; Judl, T.; Sibek, M.; Jahoda, D.] Charles Univ Prague, Fac Med 1, Dept Orthopaed, CZ-15006 Prague 5, Czech Republic; [Melichercik, P.; Klapkova, E.; Landor, I; Judl, T.; Sibek, M.; Jahoda, D.] Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic; [Klapkova, E.] Charles Univ Prague, Fac Med 2, Dept Med Chem & Biochem, CZ-15006 Prague 5, Czech Republic","Melichercik, P (reprint author), Charles Univ Prague, Fac Med 1, Dept Orthopaed, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","pmeliche@seznam.cz",null,null,"Ministry of Health of the Czech Republic [00064203]; Motol University Hospital, Prague, Czech Republic; Internal Grant Agency of Ministry of Health of the Czech Republic [9777, NT/14218]","This work was supported by institutional grant No. 00064203 from the Ministry of Health of the Czech Republic for the conceptual development of research organizations (Motol University Hospital, Prague, Czech Republic), Internal Grant of the Motol University Hospital, Prague, Czech Republic, \"Modern Therapy\" for the project Local treatment of osteomyelitis with antimicrobial peptides released from local carriers used in orthopaedics\", No. 9777 and grant No. NT/14218 from the Internal Grant Agency of Ministry of Health of the Czech Republic.",null,15,0,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248","1336-0345",null,"BRATISL MED J","Bratisl. Med. J.",null,2014,115,12,null,null,null,null,796,799,null,"10.4149/BLL_2014_154",null,4,"Medicine, General & Internal","General & Internal Medicine","AZ5EU","WOS:000348244100013",25520231]
["J","Polanecky, O; Adamek, S; Sedy, J; Skorepa, J; Hladik, P; Smejkal, M; Pafko, P; Lischke, R",null,null,null,"Polanecky, O.; Adamek, S.; Sedy, J.; Skorepa, J.; Hladik, P.; Smejkal, M.; Pafko, P.; Lischke, R.",null,null,"Postoperative rectal anastomotic complications","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"rectum; anastomosis; complication; human","COLORECTAL SURGERY; INTESTINAL ANASTOMOSES; COLLAGEN-SYNTHESIS; BOWEL PREPARATION; RANDOMIZED-TRIAL; LEAKAGE; COLON","Colorectal cancer represents the most common tumour of the gastrointestinal tract and the second most common tumour in men as well as women. The trend of increasing incidence of colorectal cancer is alerting. We undertook a retrospective study on 588 patients with rectal cancer and operated by rectal resection with anastomosis between the years 2002-2012. In our sample, we observed 54 (9.2 %) cases of anastomosis insufficiencies requiring reoperation. Out of 54 insufficient anastomoses, 36 (66 %) were in the lower two thirds of the rectum and only 18 (34 %) in the oral one. Although we have observed similar occurrences of anastomosis insufficiency in both groups - classical vs. staple suture (9.5 % and 9.0 %, respectively), the majority of stapler anastomoses (94 %) were made in the aboral part of the rectum. However, we can state that a majority of authors prefer the staple anastomosis as the one with lowest risk, mainly in the distal region of anastomosis. The high ligation of inferior mesenteric artery was performed in 182 (31 %) patients; out of these, we observed anastomosis insufficiency in 12 cases (22 %), which is exactly similar to that in the group of patients without high ligation of the inferior mesenteric artery. We did not observe the use of antibiotics in therapeutical doses as a positive factor for anastomosis insufficiencies, and neither was oncological therapy observed as a risk factor. In our group of patients we agreed that age, level of anastomosis and corticosteroids are high-risk factors. The purpose of these reports, is for the sake of future to share and reference our experiences with cases of rectal and rectosigmoideal resection over the last 11 years. We consider it important to reference our results, especially the risk factors regarding the healing of rectal anastomosis, because anastomotic healing is a surgical problem with potentially deadly consequences for patients (Tab. 4, Ref. 24). Text in PDF www.elis.sk.","[Polanecky, O.; Adamek, S.; Skorepa, J.; Hladik, P.; Smejkal, M.; Pafko, P.; Lischke, R.] First Fac Med, Dept Surg 3, CZ-15006 Prague 5, Czech Republic; [Polanecky, O.; Adamek, S.; Skorepa, J.; Hladik, P.; Smejkal, M.; Pafko, P.; Lischke, R.] Teaching Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Sedy, J.] ASCR, Inst Physiol, Prague, Czech Republic","Adamek, S (reprint author), First Fac Med, Dept Surg 3, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","sadamek@post.cz",null,null,"Ministry of Health, Czech Republic [00064203]","Supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic).",null,23,0,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248","1336-0345",null,"BRATISL MED J","Bratisl. Med. J.",null,2014,115,12,null,null,null,null,781,785,null,"10.4149/BLL_2014_151",null,5,"Medicine, General & Internal","General & Internal Medicine","AZ5EU","WOS:000348244100010",25520228]
["J","Bartelheim, K; Sumerauer, D; Behrends, U; Kodetova, D; Kucera, F; Leuschner, I; Neumayer, P; Oyen, F; Rube, C; Siebert, R; Schneppenheim, R; Seeringer, A; Vasovcak, P; Fruhwald, MC",null,null,null,"Bartelheim, Kerstin; Sumerauer, David; Behrends, Uta; Kodetova, Daniela; Kucera, Filip; Leuschner, Ivo; Neumayer, Petra; Oyen, Florian; Ruebe, Christian; Siebert, Reiner; Schneppenheim, Reinhard; Seeringer, Angela; Vasovcak, Peter; Fruehwald, Michael C.",null,null,"Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB)","CANCER GENETICS",null,null,"English","Article",null,null,null,null,null,"Rhabdoid tumor; heart; SMARCB1; EU-RHAB; intensive multimodal therapy","IMMUNOHISTOCHEMICAL ANALYSIS; HSNF5/INI1; INFANT; CHILDREN; THERAPY; GROWTH; CANCER","Rhabdoid tumors are rare but highly aggressive malignancies of infancy and early childhood with a generally unfavorable prognosis. Despite a wide variety of anatomic locations rhabdoid tumors share mutational inactivation of the SWI/SNF (SWItch/Sucrose NonFermentable) core component gene SMARCB1 (also known as INI1, hSNF5 or BAF47) in chromosome 22. As this inactivation usually results in loss of SMARCB1 expression, detectable by an antibody against the SMARCB1 protein, the accurate diagnosis of a rhabdoid tumor may be more distinctly and frequently made. Several reports on rhabdoid tumors presenting in various anatomic sites outside the kidneys and CNS are on record. We report two cases of rhabdoid tumors originating in the heart (cardiac tissue), which were entered into the European Rhabdoid Registry (EU-RHAB). The first case presented with intracardial and -cranial lesions as well as malignant ascites, while the second patient demonstrated an isolated cardiac tumor. This induced a different therapeutic approach and subsequently different clinical course (death 7 weeks after diagnosis in patient 1). Patient 2 presented with a bifocal intracardial tumor without metastases and remains in complete remission for 46 months since diagnosis following multimodal therapy. The second case demonstrates that even in a potentially futile clinical situation early and accurate diagnosis followed by prompt and intensive multimodal therapy may offer prolonged survival, potential cure and improved quality of life.","[Bartelheim, Kerstin; Neumayer, Petra; Seeringer, Angela; Fruehwald, Michael C.] Childrens Hosp Augsburg, Swabian Childrens Canc Ctr, Augsburg, Germany; [Sumerauer, David] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Behrends, Uta] Univ Technol, Childrens Hosp Schwabing, Dept Pediat Hematol & Oncol, Munich, Germany; [Kodetova, Daniela] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Pathol & Mol Med, Prague, Czech Republic; [Kucera, Filip] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Kucera, Filip] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Leuschner, Ivo] Univ Kiel, Dept Pediat Pathol, Kiel Pediat Tumor Registry, Kiel, Germany; [Oyen, Florian; Schneppenheim, Reinhard] Univ Med Ctr Hamburg Eppendorf, Dept Paediat Haematol & Oncol, Hamburg, Germany; [Ruebe, Christian] Univ Saarland, Dept Radiol, Homburg Saar, Germany; [Siebert, Reiner] Univ Kiel, Inst Human Genet, Kiel, Germany; [Siebert, Reiner] Univ Hosp Schleswig Holstein, Kiel, Germany; [Vasovcak, Peter] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Fruehwald, Michael C.] Univ Childrens Hosp Munster, Dept Pediat Hematol & Oncol, Munster, Germany","Fruhwald, MC (reprint author), Childrens Hosp Augsburg, Swabian Childrens Canc Ctr, Augsburg, Germany.","Michael.Fruehwald@klinikum-augsburg.de",null,null,"Deutsche Kinderkrebsstiftung; Gesellschaft fur Kinderkrebsforschung - GKKF; parent organization \"Horizonte\", Weseke, Germany; Project for Conceptual Development of Research Organization [00064203]; \"KinderKrebsInitiative\" Buchholz/Holm-Seppensen, Germany; \"Foerdergemeinschaft Kinderkrebszentrum Hamburg e.V.\", Germany","The European Registry for Rhabdoid Tumors (EU-RHAB) is supported by the \"Deutsche Kinderkrebsstiftung\", the \"Gesellschaft fur Kinderkrebsforschung - GKKF\" and the parent organization \"Horizonte\", Weseke, Germany. Participation of University Hospital Motol is supported by the \"Project for Conceptual Development of Research Organization 00064203\". The research for R. Siebert und pediatric tumors is supported by the \"KinderKrebsInitiative\" Buchholz/Holm-Seppensen, Germany. Financial support for the molecular genetic diagnostics reference laboratory of R. Schneppenheim is provided by the \"Foerdergemeinschaft Kinderkrebszentrum Hamburg e.V.\", Germany.",null,23,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","2210-7762","2210-7770",null,"CANCER GENET-NY","Cancer Genet.","SEP",2014,207,9,null,null,"SI",null,379,383,null,"10.1016/j.cancergen.2014.04.005",null,5,"Oncology; Genetics & Heredity","Oncology; Genetics & Heredity","AX3DB","WOS:000346819600007",24972932]
["J","Koci, Z; Turnovcova, K; Dubsky, M; Baranovicova, L; Holan, V; Chudickova, M; Sykova, E; Kubinova, S",null,null,null,"Koci, Zuzana; Turnovcova, Karolina; Dubsky, Michal; Baranovicova, Lenka; Holan, Vladimir; Chudickova, Milada; Sykova, Eva; Kubinova, Sarka",null,null,"Characterization of human adipose tissue-derived stromal cells isolated from diabetic patient's distal limbs with critical ischemia","CELL BIOCHEMISTRY AND FUNCTION",null,null,"English","Article",null,null,null,null,null,"adipose tissue; cell therapy; diabetes; differentiation; flow cytometry; mesenchymal stem cells","MESENCHYMAL STEM-CELLS; BONE-MARROW; REGENERATIVE MEDICINE; INTERNATIONAL-SOCIETY; MARKERS; FIBROBLASTS; INCREASES; STATEMENT; BLOOD; MODEL","Adipose tissue is an abundant source of autologous adult stem cells that may bring new therapeutic perspectives on the treatment of diabetes and its complications. It is unclear whether adipose tissue-derived stromal cells (ASCs) of diabetic patients, constantly influenced by hyperglycaemia, have the same properties as non-diabetic controls. As an alternative source of ASCs, adipose tissue from distal limbs of diabetic patients with critical ischemia was isolated. ASCs were characterized in terms of cell surface markers, multilineage differentiation and the expression of vascular endothelial growth factor (VEGFA), chemokine-related genes and compared with non-diabetic controls. Flow cytometry analysis confirmed mesenchymal phenotypes in both diabetic and non-diabetic ASCs. Nevertheless, 40% of diabetic and 20% of non-diabetic ASC samples displayed high expressions of fibroblast marker, which inversely correlated with the expression of CD105. In diabetic patients, significantly decreased expression of VEGFA and chemokine receptor CXCR4 was found in fibroblast-positive ASCs, compared with their fibroblast-negative counterparts. Reduced osteogenic differentiation and the downregulation of chemokine CXCL12 were found in fibroblast-negative diabetic ASCs. Both diabetic and non-diabetic ASCs were differentiated into adipocytes and chondrocytes and did not reveal islet-like cell differentiation. According to this study, adipose tissue from distal limbs of diabetic patients is not satisfactory as an autologous ASC source. Copyright (c) 2014 John Wiley & Sons, Ltd. SIGNIFICANCE OF THE STUDYHyperglycaemic milieu as well as other metabolic disorders linked to diabetes may have an influence on endogenous stem cell properties. The present study investigated the feasibility of autologous stem cell therapy in diabetic patients. ASCs isolated from the ischemic limb of diabetic patients were found to be less potent when compared phenotypically and functionally to control non-diabetic counterparts with no signs of limb ischemia. High expression of fibroblast markers associated with reduced expression of VEGFA as well as reduced osteogenic differentiation may have an impact on the effectiveness of autologous cell therapies in diabetic patients.","[Koci, Zuzana; Turnovcova, Karolina; Baranovicova, Lenka; Holan, Vladimir; Chudickova, Milada; Sykova, Eva; Kubinova, Sarka] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Prague, Czech Republic; [Koci, Zuzana; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Dubsky, Michal] Inst Clin & Expt Med, Ctr Diabet, Prague, Czech Republic","Koci, Z (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Prague, Czech Republic.","zuzana.koci@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [P304/11/0653, P304-14-03540S, 14-14961S, LO1309]; PU I programme and BIOCEV CZ [1.05/1.1.00/02.0109]; European Regional Development Fund","We would like to thank Prof. Antonin Sosna, Prof. Assoc. Vojtech Havlas and Dr. Kacirkova for providing the control non-diabetic samples from adipose tissue.This work was supported by the Grant Agency of the Czech Republic: P304/11/0653, P304-14-03540S, 14-14961S, LO1309 of the MEYS of the CR under the NPU I programme and BIOCEV CZ. 1.05/1.1.00/02.0109), from the European Regional Development Fund.",null,40,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0263-6484","1099-0844",null,"CELL BIOCHEM FUNCT","Cell Biochem. Funct.","OCT",2014,32,7,null,null,null,null,597,604,null,"10.1002/cbf.3056",null,8,"Biochemistry & Molecular Biology; Cell Biology","Biochemistry & Molecular Biology; Cell Biology","AR8AW","WOS:000343798900007",25251698]
["J","Lukas, R; Stulik, J; Sram, J; Pazour, J; Kriz, J; Nesnidal, P",null,null,null,"Lukas, R.; Stulik, J.; Sram, J.; Pazour, J.; Kriz, J.; Nesnidal, P.",null,null,"The Effect of Suboptimal Surgical Treatment of Spinal Fractures on the Course of Spinal Cord Injury","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"spinal cord injury; spinal cord decompression; spinal fracture reduction; spine stabilization","PEDICLE SCREW PLACEMENT; POSTTRAUMATIC SYRINGOMYELIA; ACCURACY; CLASSIFICATION; INTERVENTION","Introduction: Right surgical strategy, optimal timing and correct surgical technique are crucial for the quality of treatment of spinal fractures associated with neurological deficit. Failure of any of these parts of treatment has an immensely negative effect on subsequent patient care. In many cases, the quality of technical performance of the surgery is controversial. It is desirable to improve the use of spinal implants to achieve undisturbed course of subacute and chronic phases of treatment Material and methods: Retrospective analysis of the quality of primary surgical treatment of patients with posttraumatic spinal cord injury treated at the Spinal Unit of the Regional Hospital Liberec between 2003 and 2012 and at the Spinal Unit of the University Hospital Motol in Prague between 2004 and 2012. Results: Incorrect surgical treatment was delivered in 191 of 775 cases (24.6%). Wrong fracture reduction was preformed in 111 cases (58.1%). Incorrect pedicle screw insertion was found in 78 cases, followed by insufficient decompression of the spinal channel in 52 cases. A revision surgery with complete reinstrumentation was required in 85 patients (44.5%). We identified no development in the number of suboptimally treated patients over the analyzed years. The length of hospital stay in suboptimally treated patients was prolonged by the mean of 9.58 days. Conclusion: The authors recommend strict compliance with the surgical technique and rigorous post-operative X-ray follow ups. This field could further be improved with high-quality spinal surgery educational system.","[Lukas, R.; Sram, J.; Pazour, J.] Krajska Nemocnice Liberec As, Traumacentrum, Liberec 46063, Czech Republic; [Stulik, J.; Kriz, J.] LF UK FN Motole, Spinalni Jednotka Pri, Klin Rehabil & Telovychovneho Lekarstvi, Prague, Czech Republic; [Nesnidal, P.] FN Motole, Spondylochirurg Oddeleni, Prague, Czech Republic","Lukas, R (reprint author), Krajska Nemocnice Liberec As, Traumacentrum, Husova 10, Liberec 46063, Czech Republic.","richard.lukas@nemlib.cz",null,null,null,null,null,25,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,6,null,null,null,null,734,740,null,null,null,7,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AW4CO","WOS:000346229200009"]
["J","Sramek, M; Ruzickova, T; Kesnerova, P; Kadlecova, P; Mikulik, R",null,null,null,"Sramek, M.; Ruzickova, T.; Kesnerova, P.; Kadlecova, P.; Mikulik, R.",null,null,"Reducing the Door-to-needle Interval, Experience from the Stroke Centre in Kladno","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"stroke; reducing DTN; increasing efficacy of IVT","ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; THROMBOLYSIS; MANAGEMENT; GUIDELINES; MINUTES","Aim: To analyze the effectiveness of interventions intended to reduce door-to-needle time (DNT) for patients treated with intravenous thrombolysis (IVT), considering that DNT is the only parameter we can influence to improve the efficacy of IVT. Material and methods: The data were collected from the Stroke Centre of the Kladno Regional Hospital over the period 07/2011 to 06/2013. Interventions intended to reduce the DNT have been implemented in 05/2012 and include: well-developed cooperation with the emergency medical service, improved coordination of care within the hospital, administration of IVT immediately after CT in selected patients. DNTs in the target group (patients treated after implementation of the interventions) were compared to the DNTs in a historical control group (patients treated with thrombolysis from 7/2011 to 4/2012). Multiple logistic regression analysis was used for adjusting the baseline characteristics of the patients. Results: The target group showed clinically crucial shortening of DNT from 65 min to 45 min (p = 0.001), a slight reduction of the median onset-to-treatment time (OTT) from 144 min to 130 min (p = 0.66) and a slight decrease in symptomatic intracranial hemorrhage (SICH) compared to the control group from 4.40% to 3.70% (OR 0.90, 95% CI: 0.11-7.03). We did not detect any SICH in the group of patients who were treated even though the complete laboratory results were not known (n = 17). Patients treated during working hours had a 6.8-times higher chance of treatment initiation within 60 min compared to patients treated during \"on call\" hours (OR 6.78, 95% CI: 2.34-19.64). Conclusions: The interventions implemented to reduce DNT were highly effective and safe. IVT administration without complete laboratory results in selected patients was safe and significantly contributed to reducing the median DNT of the entire group.","[Sramek, M.] Nemocnice Horovice, Neurol Oddeleni, Horovice 26831, Czech Republic; [Sramek, M.; Ruzickova, T.; Kesnerova, P.] LF UK FN Motole, Neurol Klin 2, Prague, Czech Republic; [Ruzickova, T.; Kesnerova, P.] Oblastni Nemocnice Kladno As, Neurol Oddeleni, Kladno, Czech Republic; [Kadlecova, P.; Mikulik, R.] LF MU FN Sv Anny Brne, Neurol Klin, Brno, Czech Republic; [Mikulik, R.] FN U Sv Anny Brne, Mezinarodni Centrum Klin Vyzkumu ICRC, Brne, Czech Republic","Sramek, M (reprint author), Nemocnice Horovice, K Nemocnici 1106, Horovice 26831, Czech Republic.","martin.sramek@gmail.com",null,null,null,null,null,14,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2014,77,6,null,null,null,null,747,752,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AW4CO","WOS:000346229200011"]
["J","Kubus, P; Materna, O; Tax, P; Tomek, V; Janousek, J",null,null,null,"Kubus, Peter; Materna, Ondrej; Tax, Petr; Tomek, Viktor; Janousek, Jan",null,null,"Successful Permanent Resynchronization for Failing Right Ventricle After Repair of Tetralogy of Fallot","CIRCULATION",null,null,"English","Editorial Material",null,null,null,null,null,null,null,null,"[Kubus, Peter; Materna, Ondrej; Tax, Petr; Tomek, Viktor; Janousek, Jan] Motol Univ Hosp, Childrens Heart Ctr, Prague, Czech Republic","Kubus, P (reprint author), FN Motole, Detske Kardioctr, V Uvalu 84, Prague 15006, Czech Republic.","peter.kubus@fnmotol.cz",null,null,null,null,null,4,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322","1524-4539",null,"CIRCULATION","Circulation","NOV 25",2014,130,22,null,null,null,null,"E186","E190",null,"10.1161/CIRCULATIONAHA.114.012205",null,5,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","Cardiovascular System & Cardiology","AU3MJ","WOS:000345517100001",25421048]
["J","Sediva, A; Chapel, H; Gardulf, A",null,null,null,"Sediva, A.; Chapel, H.; Gardulf, A.",null,"European Soc Immunodeficiencies","Europe Immunoglobulin Map","CLINICAL AND EXPERIMENTAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,null,null,null,"[Sediva, A.] Charles Univ Prague, Motol Univ Hosp, Dept Immunol, Prague, Czech Republic; [Sediva, A.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Chapel, H.] Univ Oxford, Nuffield Dept Med, Primary Immunodeficiency Unit, Oxford, England; [Gardulf, A.] Karolinska Inst, Div Clin Immunol, Dept Lab Med, Karolinska Univ Hosp, Stockholm, Sweden","Sediva, A (reprint author), Charles Univ Prague, Motol Univ Hosp, Dept Immunol, Prague, Czech Republic.","anna.sediva@fnmotol.cz",null,null,"CSL Behring; Baxter; Octapharma; Biotest; LFB","A. S. has received consultancy fees from CSL Behring, Baxter and Octapharma. H. C. has received consultancy fees from Biotest, Baxter and LFB. A. G. has collaborated with CSL Behring, Baxter and Octapharma for advisory boards, but received no direct funding.",null,3,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0009-9104","1365-2249",null,"CLIN EXP IMMUNOL","Clin. Exp. Immunol.","DEC",2014,178,null,null,1,"SI",null,141,143,null,"10.1111/cei.12546",null,3,"Immunology","Immunology","AX5OQ","WOS:000346976700058",25546797]
["J","Sporkova, A; Jichova, S; Huskova, Z; Kopkan, L; Nishiyama, A; Hwang, SH; Hammock, BD; Imig, JD; Kompanowska-Jezierska, E; Sadowski, J; Kramer, HJ; Cervenka, L",null,null,null,"Sporkova, Alexandra; Jichova, Sarka; Huskova, Zuzana; Kopkan, Libor; Nishiyama, Akira; Hwang, Sung H.; Hammock, Bruce D.; Imig, John D.; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz; Kramer, Herbert J.; Cervenka, Ludek",null,null,"Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: Studies in Cyp1a1-Ren-2 transgenic rats","CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"angiotensin-II; cytochrome P-450 epoxygenase; eicosanoids; epoxyeicosatrienoic acids; hypertension; soluble epoxide hydrolase","SPONTANEOUSLY HYPERTENSIVE-RATS; RENIN-ANGIOTENSIN SYSTEM; BLOOD-PRESSURE RESEARCH; END-ORGAN DAMAGE; II LEVELS; CYTOCHROME-P-450 METABOLITES; ARACHIDONIC-ACID; RENAL-FUNCTION; NITRIC-OXIDE; NATRIURESIS","Recent studies have shown that the long-term antihypertensive action of soluble epoxide hydrolase inhibition (sEH) in angiotensin-II (AngII)-dependent hypertension might be mediated by the suppression of intrarenal AngII levels. To test this hypothesis, we examined the effects of acute (2 days) and chronic (14 days) sEH inhibition on blood pressure (BP) in transgenic rats with inducible AngII-dependent hypertension. AngII-dependent malignant hypertension was induced by 10 days' dietary administration of indole-3-carbinol (I3C), a natural xenobiotic that activates the mouse renin gene in Cyp1a1-Ren-2 transgenic rats. BP was monitored by radiotelemetry. Acute and chronic sEH inhibition was achieved using cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid, given at doses of 0.3, 3, 13, 26, 60 and 130 mg/L in drinking water. At the end of experiments, renal concentrations of epoxyeicosatrienoic acids, their inactive metabolites dihydroxyeicosatrienoic acids and AngII were measured. Acute BP-lowering effects of sEH inhibition in I3C-induced rats was associated with a marked increase in renal epoxyeicosatrienoic acids to dihydroxyeicosatrienoic acids ratio and acute natriuresis. Chronic treatment with cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid in I3C-induced rats elicited dose-dependent persistent BP lowering associated with a significant reduction of plasma and kidney AngII levels. Our findings show that the acute BP-lowering effect of sEH inhibition in I3C-induced Cyp1a1-Ren-2 transgenic rats is mediated by a substantial increase in intrarenal epoxyeicosatrienoic acids and their natriuretic action without altering intrarenal renin-angiotensin system activity. Long-term antihypertensive action of cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid in I3C-induced Cyp1a1-Ren-2 transgenic rats is mediated mostly by suppression of intrarenal AngII concentration.","[Sporkova, Alexandra; Jichova, Sarka; Huskova, Zuzana; Kopkan, Libor; Cervenka, Ludek] Ctr Med Expt, Inst Clin & Expt Med, CZ-14000 Prague 4, Czech Republic; [Jichova, Sarka] Kagawa Univ, Dept Physiol, Kagawa, Japan; [Nishiyama, Akira] Kagawa Univ, Dept Pharmacol, Kagawa, Japan; [Hwang, Sung H.; Hammock, Bruce D.] Univ Calif Davis, UCD Comprehens Canc Ctr, Dept Entomol, Davis, CA 95616 USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz] Polish Acad Sci, M Mossakowski Med Res Ctr, Dept Renal & Body Fluid Physiol, Warsaw, Poland; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, Bonn, Germany; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Cervenka, L (reprint author), Ctr Med Expt, Inst Clin & Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz",null,null,"Internal Grant Agency of the Ministry of Health [NT/12171-5]; European Commission [IRG 247847, CZ.2.16/3.1.00/28025]; Ministry of Health of the Czech Republic [00023001]; Grant Agency of Charles University [266213]; NIH [HL59699, DK38226]; NIEHS [R01 ES02710, R01 ES013933, P42 ES013933]; West Coast Center [U24 DK097154]; EicOsis","This study was principally supported by grant No. NT/12171-5 awarded by the Internal Grant Agency of the Ministry of Health to ZH. AS was supported by a Marie Curie Fellowship from the European Commission Program PEOPLE (IRG 247847). The Institute for Clinical and Experimental Medicine (IKEM) is a recipient of the project of the Ministry of Health of the Czech Republic for the development of research organization 00023001 (institutional support). SJ is supported the Grant Agency of Charles University No. 266213. The Center for Experimental Medicine (IKEM) received financial support from the European Commission within the Operational Program Prague-Competitiveness; project \"Rozvoj infraskruktury PEM\" (#CZ.2.16/3.1.00/28025). JDI was supported by NIH grants HL59699 and DK38226. SHH was supported by a fellowship from the NIEHS Supported Basic Research Program. Partial support was provided by NIEHS Grant R01 ES02710, R01 ES013933 and P42 ES013933, and by West Coast Center U24 DK097154 awarded to BDH. BDH is a George and Judy Marcus Senior Fellow of the American Asthma Foundation. BDH was funded by EicOsis to develop soluble epoxide hydrolase inhibitors for treating inflammatory and neuropathic pain. The other authors declare no potential conflict of interest.",null,47,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1440-1681",null,null,"CLIN EXP PHARMACOL P","Clin. Exp. Pharmacol. Physiol.","DEC",2014,41,12,null,null,null,null,1003,1013,null,"10.1111/1440-1681.12310",null,11,"Pharmacology & Pharmacy; Physiology","Pharmacology & Pharmacy; Physiology","AX1SR","WOS:000346726900008",25224811]
["J","Sediva, A; Horvath, R; Manasek, V; Gregorova, A; Plevova, P; Horackova, M; Tesarova, M; Toplak, N; Debeljak, M",null,null,null,"Sediva, A.; Horvath, R.; Manasek, V.; Gregorova, A.; Plevova, P.; Horackova, M.; Tesarova, M.; Toplak, N.; Debeljak, M.",null,null,"Cluster of patients with Familial Mediterranean fever and heterozygous carriers of mutations in MEFV gene in the Czech Republic","CLINICAL GENETICS",null,null,"English","Article",null,null,null,null,null,"amyloidosis; autoinflammatory syndromes; colchicine; Familial Mediterranean fever; MEFV gene","DISEASE","Familial Mediterranean fever (FMF) is a well-described monogenic autosomal recessive disorder with highest occurrence in the Mediterranean region. In this article, we describe the experience of a center in the Czech Republic that follows four families with members bearing mutations in MEFV gene without provable ancestry from the Mediterranean region. We also discuss the clinical picture of the heterozygous variants that were present in our cohort. The typical clinical presentation in heterozygotes corresponds to data described in the international literature. The possibility of combination of mutations and/or polymorphisms in different genes and epigenetic or environmental influences on the clinical symptoms are taken into account.","[Sediva, A.; Horvath, R.] Charles Univ Prague, Dept Immunol, Sch Med 2, Fac Hosp Motol, Prague 15006, Czech Republic; [Manasek, V.] Hosp Novy Jicin, Complex Ctr Oncol, Novy Jicin, Czech Republic; [Gregorova, A.; Plevova, P.] Univ Hosp Ostrava, Dept Med Genet, Ostrava, Czech Republic; [Horackova, M.] Charles Univ Prague, Fac Hosp Motol, Sch Med 2, Dept Internal Med, Prague 15006, Czech Republic; [Tesarova, M.] Charles Univ Prague, Fac Med 1, Dept Paediat & Adolescent Med, Prague 15006, Czech Republic; [Tesarova, M.] Gen Univ Hosp Prague, Prague, Czech Republic; [Toplak, N.; Debeljak, M.] Univ Med Ctr Ljubljana, Univ Childrens Hosp, Mol Genet Lab, Ljubljana, Slovenia; [Toplak, N.; Debeljak, M.] Univ Med Ctr Ljubljana, Univ Childrens Hosp, Dept Allergol Rheumatol & Clin Immunol, Ljubljana, Slovenia","Sediva, A (reprint author), Charles Univ Prague, Dept Immunol, Sch Med 2, Fac Hosp Motol, V Uvalu 84, Prague 15006, Czech Republic.","anna.sediva@lfmotol.cuni.cz",null,null,"MZ CR - RVO, FN Motol [00064203]; Slovenian Research Agency [J3-4150, P3-0343]","We would like to thank all our patients participating in the study. We would also like to thank Adam Klocperk for administrative help with this manuscript. This project was supported by MZ CR - RVO, FN Motol 00064203, and Slovenian Research Agency grants J3-4150 and P3-0343.",null,8,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0009-9163","1399-0004",null,"CLIN GENET","Clin. Genet.","DEC",2014,86,6,null,null,null,null,564,569,null,"10.1111/cge.12323",null,6,"Genetics & Heredity","Genetics & Heredity","AU1EN","WOS:000345363900010",24251727]
["J","Hradsky, O; Ohem, J; Mitrova, K; Durilova, M; Kotalova, R; Nevoral, J; Kolho, KL; Bronsky, J",null,null,null,"Hradsky, Ondrej; Ohem, Jan; Mitrova, Katarina; Durilova, Marianna; Kotalova, Radana; Nevoral, Jiri; Kolho, Kaija-Leena; Bronsky, Jiri",null,null,"Fecal Calprotectin Levels in Children is more tightly Associated with Histological than with Macroscopic Endoscopy Findings","CLINICAL LABORATORY",null,null,"English","Article",null,null,null,null,null,"Calprotectin; Crohn's disease; ulcerative colitis; inflammatory bowel disease; pathology; endoscopy; microscopic colitis","INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; INTESTINAL INFLAMMATION; DIAGNOSTIC-ACCURACY; CHRONIC-DIARRHEA; ULCERATIVE-COLITIS; PEDIATRIC-PATIENTS; RELAPSE; MARKER; PROTEIN","Background: Children with suspected bowel inflammation require an invasive endoscopic procedure, which is usually performed under general anesthesia. To improve the selection of candidates for endoscopy, fecal calprotectin level has been proposed as a noninvasive marker of intestinal inflammation. In the future, home testing is a likely option. Thus, the aim of this study was to affirm the association between bedside-measured fecal calprotectin concentration and histological and endoscopic findings in a panel of patients with suspected chronic bowel inflammation. Methods: Stool samples and microscopic and macroscopic findings from 41 patients, who underwent ileocolonoscopy for suspicion of bowel inflammation, were consecutively obtained between April 2009 and December 2010. Stool samples were analyzed using the bedside fecal calprotectin enzyme-linked immunosorbent assay (Quantum Blue; Buhlmann, Laboratories AG, Switzerland). Results: Fecal calprotectin levels were elevated in 18 children with bowel inflammation on endoscopy (median at the upper limit of undiluted samples, 300 mu g/g) compared with 23 children without bowel inflammation (median, 105 mu g/g; p < 0.00097). Similarly, the fecal calprotectin level was elevated in 25 children with positive histological findings as assessed by a pathologist (median, 300 mu g/g) compared with 16 children without histological inflammation (median, 73 mu g/g; p < 0.000014). Based on the optimal area under the curve, we calculated the cutoff fecal calprotectin level for bowel inflammation on endoscopy as 167 mu g/g (area under the curve, 0.86; 95% confidence interval (CI), 0.81 - 0.92) and on histological examination as 280 mu g/g (area under the curve, 0.78; 95% CI, 0.70 0.86). Fecal calprotectin level was more sensitive than endoscopy for diagnosis of microscopic bowel inflammation (p = 0.000014). Conclusions: Our results clearly show that even the bedside test for fecal calprotectin level, using the optimal cutoff value, is feasible enough in determining candidates for an endoscopic procedure in order to confirm bowel inflammation and is more tightly associated with histological findings than with endoscopic findings. Thus, the calprotectin level reflects histological activity, even in cases with normal endoscopic findings. The bedside test described herein is a sufficient screening method for this purpose.","[Hradsky, Ondrej; Ohem, Jan; Mitrova, Katarina; Durilova, Marianna; Kotalova, Radana; Nevoral, Jiri; Bronsky, Jiri] Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Hradsky, Ondrej; Ohem, Jan; Mitrova, Katarina; Durilova, Marianna; Kotalova, Radana; Nevoral, Jiri; Bronsky, Jiri] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Kolho, Kaija-Leena] Univ Helsinki, Hosp Children & Adolescents, Dept Gastroenterol, FIN-00290 Helsinki, Finland","Bronsky, J (reprint author), Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","jiri.bronsky@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic [00064203/6001]","This study was supported by the project of the Ministry of Health, Czech Republic, for conceptual development of research organizations (No. 00064203/6001; University Hospital Motol, Prague, Czech Republic).",null,40,0,0,"CLIN LAB PUBL","HEIDELBERG","IM BREITSPIEL 15, HEIDELBERG, D-69126, GERMANY","1433-6510",null,null,"CLIN LAB","Clin. Lab.",null,2014,60,12,null,null,null,null,1993,2000,null,"10.7754/Clin.Lab.2014.140203",null,8,"Medical Laboratory Technology","Medical Laboratory Technology","AY6HI","WOS:000347667300006"]
["J","Vicha, A; Taieb, D; Pacak, K",null,null,null,"Vicha, Ales; Taieb, David; Pacak, Karel",null,null,"Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma","ENDOCRINE-RELATED CANCER",null,null,"English","Review",null,null,null,null,null,"SDHx; glycolysis; Warburg effect; reactive oxygen species; succinate dehydrogenase; pheochromocytoma; paraganglioma; renal cell carcinoma; gastrointestinal stromal tumor; hypoxia; pseudohypoxia","HYPOXIA-INDUCIBLE FACTOR-1; POSITRON-EMISSION-TOMOGRAPHY; HIF PROLYL HYDROXYLASES; COMPLEX-II DEFICIENCY; GERM-LINE MUTATIONS; PYRUVATE-KINASE M2; SUCCINATE-DEHYDROGENASE; SPORADIC PHEOCHROMOCYTOMA; HEREDITARY PARAGANGLIOMA; GENE-MUTATIONS","Warburg's metabolic hypothesis is based on the assumption that a cancer cell's respiration must be under attack, leading to its damage, in order to obtain increased glycolysis. Although this may not apply to all cancers, there is some evidence proving that primarily abnormally functioning mitochondrial complexes are indeed related to cancer development. Thus, mutations in complex II (succinate dehydrogenase (SDH)) lead to the formation of pheochromocytoma (PHEO)/paraganglioma (PGL). Mutations in one of the SDH genes (SDHx mutations) lead to succinate accumulation associated with very low fumarate levels, increased glutaminolysis, the generation of reactive oxygen species, and pseudohypoxia. This results in significant changes in signaling pathways (many of them dependent on the stabilization of hypoxia-inducible factor), including oxidative phosphorylation, glycolysis, specific expression profiles, as well as genomic instability and increased mutability resulting in tumor development. Although there is currently no very effective therapy for SDHx-related metastatic PHEOs/PGLs, targeting their fundamental metabolic abnormalities may provide a unique opportunity for the development of novel and more effective forms of therapy for these tumors.","[Vicha, Ales] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Vicha, Ales] Univ Hosp Motol, Prague, Czech Republic; [Taieb, David] CHU Timone, CERIMED, Serv Cent Biophys & Med Nucl, Marseille, France; [Taieb, David] Ctr Rech Cancerol Marseille, Dept Mol Oncol, Marseille, France; [Pacak, Karel] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD 20892 USA","Pacak, K (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bldg 10,CRC,1-East,Room 1-3140,10 Ctr Dr,MSC 1109, Bethesda, MD 20892 USA.","karel@mail.nih.gov",null,null,"Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Neurological Disorders and Stroke at the National Institutes of Health; MH CZ - DRO, University Hospital Motol, Prague, Czech Republic [00064203]","This work was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, and by MH CZ - DRO, University Hospital Motol, Prague, Czech Republic 00064203.",null,213,1,1,"BIOSCIENTIFICA LTD","BRISTOL","EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND","1351-0088","1479-6821",null,"ENDOCR-RELAT CANCER","Endocr.-Relat. Cancer","JUN",2014,21,3,null,null,null,null,"R261","R277",null,"10.1530/ERC-13-0398",null,17,"Oncology; Endocrinology & Metabolism","Oncology; Endocrinology & Metabolism","AT2TA","WOS:000344787700017",24500761]
["J","Drevinek, P",null,null,null,"Drevinek, P.",null,null,"Burkholderla cepacla complex: epidemiology and diagnosis of infection in patients with cystic fibrosis","EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"Burkholderia cepacla complex; cystic fibrosis; epidemic strain; pathogenesis of the infection","PSEUDOMONAS-CEPACIA; PCR DETECTION; SP-NOV; CENOCEPACIA; IDENTIFICATION; MULTIVORANS; DIVERSITY; GENOMOVARS; GENOME; SPUTUM","Bacteria of the Burkhoideria cepacia complex are the cause of severe lung infections primarily in patients with cystic fibrosis (CF). The risk of epidemic spread of the pathogen in the community of CF patients was the reason for implementing strict isolation measures and icientifyina the bacterium as early as possible. This re- view article features the taxonomy of the Burkholaena cepacia complex, possibilities for the laboratory diagnosis of all representatives of this complex, and epidemiological situation in the communities of CE patients in the Czech Republic and in the world.","[Drevinek, P.] Charles Univ Prague, Lekarske Fak, Ustav Lekarske Mikrobiol 2, CR-11636 Prague 1, Czech Republic; [Drevinek, P.] Fak Nemocnice Motole, Prague, Czech Republic","Drevinek, P (reprint author), LF, Ustav Lekarske Mikrobiol UK 2, V Uvalu 84, Prague 15006 5, Czech Republic.","pavel.drevinek@Lfmotol.cuni.cz",null,null,null,null,null,44,0,0,"CESKA LEKARSKA SPOLECNOST J  EV  PURKYNE","PRAGUE","SOKOLSKA 31, PRAGUE, 00000, CZECH REPUBLIC","1210-7913",null,null,"EPIDEMIOL MIKROBI IM","Epidemiol. Mikrobiol. Imunol.",null,2014,63,1,null,null,null,null,18,26,null,null,null,9,"Immunology; Microbiology","Immunology; Microbiology","AR5PB","WOS:000343635100004",24730990]
["J","Krutova, M; Matejkova, J; Zajac, M; Hubacek, P; Nyc, O",null,null,null,"Krutova, M.; Matejkova, J.; Zajac, M.; Hubacek, P.; Nyc, O.",null,null,"Diagnosis of Clostridium difficile infections: Comparative study of two immuno enzyme assays with confirmation by PCR and culture followed by PCR ribotyping","EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"Clostridium difficile; ribotyping; glutamate dehydrogenase; toxins A/B; Quik Chek Complete; Liaison","REAL-TIME PCR; POLYMERASE-CHAIN-REACTION; DIARRHEAL STOOLS; RAPID DETECTION; EMERGENCE; SAMPLES; TOXIN","Study objective: Comparison of two commercially available tests for the detection of Clostridium difficile Glutamate Dehydrogenase (GDH) and toxins A and B for their sensitivity and specificity. Material and methods: Eighty-six stool samples from patients hospitalised in the Motol University Hospital were analysed. GDH and toxins A and B were assayed in parallel by two tests: C. difficile Quik Chek Complete (R) (Techlab, USA) and Liaison (R) C. difficile GDH and Toxins A alpha B (DiaSorin, USA). From the stool samples, nucleic acids were also isolated using the UltraClean (R) Fecal DNA kit (MoBio Laboratories, USA). The commercially available C. difficile Elite MGB (R) kit (Nanogen, Italy) was used for the polymerase chain reaction (PCR). Anaerobic culture on C. difficile selective medium (Oxoid) was performed for all positive samples at least in one test. Pure isolates were characterized by PCR ribotyping. Results: Thirty-six (42%) samples were GDH negative and toxin A/B negative by both tests. Twenty (23%) samples wereGDH positive and toxin A/B positive by both tests. Nine (10%) samples were GDH positive and toxin negative by both tests, but were positive by PCR. Eleven (13%) samples that were GDH positive and toxin negative by both tests remained negative by PCR. Six (7%) samples only were GDH positive and toxin positive by the Liaison (R) test alone. Four (5%) samples were GDH-positive by the Liaison (R) test alone. Culture failure was observed in 11 (13%) samples, of which seven were positive by PCR. PCR was inhibited in five (6%) samples. The following toxigenic ribotypes: AI-3, 001, 002, 012,014, 017, 020, 049, 054, 078, 176, 203, AND 413 and non-toxigenic ribotypes: AI-34, AI-61, 010, 485, 495, AND 596 were identified. Conclusion: The Liaison (R) test had seven percent higher sensitivity for the detection of toxins A/B. The two-step protocol of the tests is also cost-saving. The savings can be used e. g. for incorporating the PCR techniques into the diagnostic algorithm of the laboratory.","Charles Univ Prague, Lekarska Fak 2, Ustav Lekarske Mikrobiol, CR-11636 Prague 1, Czech Republic; Fak Nemocnice Motole, Prague, Czech Republic","Krutova, M (reprint author), LF UK, Ustav Lekarske Mikrobiol 2, 5 Uvalu 84, Prague 15006 5, Czech Republic.","marcela.krutova@seznam.cz",null,null,null,null,null,20,0,0,"CESKA LEKARSKA SPOLECNOST J  EV  PURKYNE","PRAGUE","SOKOLSKA 31, PRAGUE, 00000, CZECH REPUBLIC","1210-7913",null,null,"EPIDEMIOL MIKROBI IM","Epidemiol. Mikrobiol. Imunol.",null,2014,63,2,null,null,null,null,99,102,null,null,null,4,"Immunology; Microbiology","Immunology; Microbiology","AR5PD","WOS:000343635300005",25025672]
["J","Chrenkova, V; Hubacek, P; Sedlacek, P; Riha, P; Kodetova, D; Bebrova, E",null,null,null,"Chrenkova, V; Hubacek, P.; Sedlacek, P.; Riha, P.; Kodetova, D.; Bebrova, E.",null,null,"Post-mortem analysis of Candida albicans breakthrough infection during echinocandin treatment in haematopoietic stem cell transplant recipient","EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE",null,null,"English","Article",null,null,null,null,null,"invasive candida dinase; haematopoietic stem cell transplant; echinocandin resistance","INVASIVE FUNGAL-INFECTIONS; MINIMAL RESIDUAL DISEASE; ANTIFUNGAL THERAPY; ACUTE-LEUKEMIA; SUSCEPTIBILITY; MICAFUNGIN; RESISTANCE; FKS1; TIME; SUBSTITUTIONS","We present case of a girl deceased due to Candida albicans breakthrough invasive infection during the echinocandin treatment after undergoing allogeneic haematopoietic stem cell transplant for relaps of acute myeloid leukaemia. Candida albicans generally susceptible to all antifungal drugs wasn't considered for potential resistance and conventional blood culture positivity was too late to reveal the resistance to echinocandins. Due to severe organ toxicities (liver, kidneys) she received echinocandin as an antifungal prophylaxis, no change was made for the treatment of Candida albicans infection. Later, the molecular analysis proved the mutation S645P known as being responsible for the echinocandin resistance. The post mortem analysis of fungal burden in autopsy samples showed very high levels of Candida DNA in gut, liver, spleen and kidneys.","[Chrenkova, V; Hubacek, P.; Bebrova, E.] Charles Univ Prague, Fac Med 2, Dept Med Microbiol, CR-11636 Prague 1, Czech Republic; [Chrenkova, V; Hubacek, P.; Sedlacek, P.; Riha, P.; Kodetova, D.; Bebrova, E.] Motol Univ Hosp, Prague, Czech Republic; [Hubacek, P.; Sedlacek, P.; Riha, P.] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CR-11636 Prague 1, Czech Republic; [Kodetova, D.] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, CR-11636 Prague 1, Czech Republic","Chrenkova, V (reprint author), Ustav Lekarske Mikrobiol FN Motole, 5 Uvalu 84, Prague 15006 5, Czech Republic.","vanda.chrenkova@fnmotol.cz",null,null,"MH CZ - DRO, University Hospital Motol, Prague, Czech Republic [00064203]","Supported by MH CZ - DRO, University Hospital Motol, Prague, Czech Republic 00064203.",null,28,0,0,"CESKA LEKARSKA SPOLECNOST J  EV  PURKYNE","PRAGUE","SOKOLSKA 31, PRAGUE, 00000, CZECH REPUBLIC","1210-7913",null,null,"EPIDEMIOL MIKROBI IM","Epidemiol. Mikrobiol. Imunol.",null,2014,63,2,null,null,null,null,121,124,null,null,null,4,"Immunology; Microbiology","Immunology; Microbiology","AR5PD","WOS:000343635300010",25025677]
["J","Cho, JR; Koo, DL; Joo, EY; Seo, DW; Hong, SC; Jiruska, P; Hong, SB",null,null,null,"Cho, Jounhong Ryan; Koo, Dae Lim; Joo, Eun Yeon; Seo, Dae Won; Hong, Seung-Chyul; Jiruska, Premysl; Hong, Seung Bong",null,null,"Resection of individually identified high-rate high-frequency oscillations region is associated with favorable outcome in neocortical epilepsy","EPILEPSIA",null,null,"English","Article",null,null,null,null,null,"Epilepsy surgery; High-frequency oscillations; Neocortical epilepsy; Surgical outcome; Automated detection","TEMPORAL-LOBE; PRESURGICAL EVALUATION; FOCAL EPILEPSY; FAST RIPPLES; 80-500 HZ; MACROELECTRODES; RECORDINGS; SPIKES; EXTENT; SLEEP","ObjectivesHigh-frequency oscillations (HFOs) represent a novel electrophysiologic marker of endogenous epileptogenicity. Clinically, this propensity can be utilized to more accurately delineate the resection margin before epilepsy surgery. Currently, prospective application of HFOs is limited because of a lack of an exact quantitative measure to reliably identify HFO-generating areas necessary to include in the resection. Here, we evaluated the potential of a patient-individualized approach of identifying high-rate HFO regions to plan the neocortical resection. MethodsFifteen patients with neocortical seizure-onset zones (SOZs) underwent intracranial electroencephalographic monitoring. To identify interictal HFOs, we applied an automated, hypersensitive HFO-detection algorithm followed by post hoc processing steps to reject false detections. The spatial relationship between HFO distribution and the SOZ was evaluated. To address high interpatient variability in HFO properties, we evaluated the high-rate HFO region, an unbiased statistical parameter, in each patient. The relationship between resection of the high-rate HFO region and postoperative outcome was examined. ResultsGrouped data demonstrated that the rate of ripple (60-200Hz) and fast ripple (200-500Hz) was increased in the SOZ (both p<0.01). Intrapatient analysis of the HFO distribution localized the SOZ in 11 patients. High-rate HFO regions were determined in all patients by an individually adjusted threshold. Resection of high-rate HFO regions was significantly associated with a seizure-free outcome (p<0.01). The extent/ratio of SOZ or spiking region resection did not differ between seizure-free and seizure-persistent groups. SignificanceIntrapatient analysis of high-rate HFOs provides more detailed description of HFO-generating areas and can mark the areas of clinically significant epileptogenicitya crucial component of the neocortical epileptic network that should be removed to achieve a good outcome. Validating and adopting an unbiased quantitative HFO parameter has the potential to propel wider and prospective utilization of HFOs in the surgical treatment of neocortical epilepsy and to improve its outcome.","[Cho, Jounhong Ryan; Koo, Dae Lim; Joo, Eun Yeon; Seo, Dae Won; Hong, Seung Bong] Sungkyunkwan Univ Sch Med, Dept Neurol, Samsung Med Ctr, Seoul 135710, South Korea; [Cho, Jounhong Ryan; Hong, Seung Bong] Samsung Biomed Res Inst, Seoul, South Korea; [Cho, Jounhong Ryan] CALTECH, Div Computat & Neural Syst, Pasadena, CA 91125 USA; [Koo, Dae Lim] Seoul Natl Univ Boramae Hosp, Dept Neurol, Seoul, South Korea; [Hong, Seung-Chyul] Sungkyunkwan Univ Sch Med, Dept Neurosurg, Samsung Med Ctr, Seoul 135710, South Korea; [Jiruska, Premysl] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Prague, Czech Republic; [Jiruska, Premysl] Charles Univ Prague, Dept Neurol, Sch Med 2, Univ Hosp Motol Prague, Prague, Czech Republic","Hong, SB (reprint author), Sungkyunkwan Univ Sch Med, Dept Neurol, Samsung Med Ctr, 50 Irwon Dong, Seoul 135710, South Korea.","sbhong@skku.edu",null,null,"Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A110097]; Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI10C2020]; Neuron Fund for Support of Science (Czech Republic) [2012/10]; Ministry of Health of the Czech Republic [IGA NT/14489-3]","The authors are indebted to the patients who participated in this study, and appreciate the staff of the epilepsy monitoring unit of Samsung Medical Center for their assistance. We thank Sun Hwa Kim and Jeong Sik Kim for their help on 3D reconstructed MRI images. This work was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A110097; to S. B. H.); a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020; to S. B. H.); and grants from Neuron Fund for Support of Science (Czech Republic, 2012/10; to P.J.) and the Ministry of Health of the Czech Republic (IGA NT/14489-3; to P.J).",null,40,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0013-9580","1528-1167",null,"EPILEPSIA","Epilepsia","NOV",2014,55,11,null,null,null,null,1872,1883,null,"10.1111/epi.12808",null,12,"Clinical Neurology","Neurosciences & Neurology","AT9DE","WOS:000345227400030",25266626]
["J","Rehulka, P; Dolezalova, I; Janousova, E; Tomasek, M; Marusic, P; Brazdil, M; Kuba, R",null,null,null,"Rehulka, Pavel; Dolezalova, Irena; Janousova, Eva; Tomasek, Martin; Marusic, Petr; Brazdil, Milan; Kuba, Robert",null,null,"Ictal and postictal semiology in patients with bilateral temporal lobe epilepsy","EPILEPSY & BEHAVIOR",null,null,"English","Article",null,null,null,null,null,"Epilepsy; Bitemporal; Bilateral temporal lobe epilepsy; Invasive EEG; Semiology; Postictal unresponsiveness","COMPLEX PARTIAL SEIZURES; BITEMPORAL EPILEPTIFORM ABNORMALITIES; VAGAL NERVE-STIMULATION; DEPTH ELECTROENCEPHALOGRAPHY; PROGNOSTIC-SIGNIFICANCE; LATERALIZING VALUE; SURGICAL-TREATMENT; PROPAGATION TIME; LOBECTOMY; SPREAD","Bilateral temporal lobe epilepsy is characterized by evidence of seizure onset independently in both temporal lobes. Themain aim of the present study was to determine whether patients with evidence of independent bilateral temporal lobe epilepsy (biTLE) can be identified noninvasively on the basis of seizure semiology analysis. Thirteen patients with biTLE, as defined by invasive EEG, were matched with 13 patients with unilateral temporal lobe epilepsy (uniTLE). In all 26 patients, the frequency of predefined clusters of ictal and periictal signs were evaluated: ictal motor signs (IMSs), periictalmotor signs (PIMSs), periictal vegetative signs (PIVSs), the frequency of early oroalimentary automatisms (EOAs), and the duration of postictal unresponsiveness (PU). Some other noninvasive and clinical data were also evaluated. A lower frequency of IMSs was noted in the group with biTLE (patients = 46.2%, seizures = 20.7%) than in the group with uniTLE (patients = 92.3%, seizures = 61.0%) (p = 0.030; p < 0.001, respectively). The individual IMS average per seizure was significantly lower in the group with biTLE (0.14; range = 0-1.0) than in the group with uniTLE (0.80; range = 0-2.6) (p = 0.003). Postictal unresponsiveness was longer than 5 min in more patients (75.0%) and seizures (42.9%) in the group with biTLE than in the groupwith uniTLE (patients = 30.8%, seizures= 18.6%) (p= 0.047; p= 0.002). The frequency of EOAs, PIMSs, PIVSs, and other clinical data did not differ significantly. There is a lower frequency of ictal motor signs and longer duration of postictal unresponsiveness in patients with biTLE. (C) 2014 Elsevier Inc. All rights reserved.","[Rehulka, Pavel; Dolezalova, Irena; Brazdil, Milan; Kuba, Robert] St Annes Univ Hosp, Dept Neurol 1, Brno Epilepsy Ctr, Brno 65691, Czech Republic; [Rehulka, Pavel; Dolezalova, Irena; Brazdil, Milan; Kuba, Robert] Masaryk Univ, Fac Med, Brno 65691, Czech Republic; [Rehulka, Pavel; Dolezalova, Irena; Brazdil, Milan; Kuba, Robert] Masaryk Univ, Cent European Inst Technol CEITEC, Behav & Social Neurosci Res Grp, Brno 65691, Czech Republic; [Janousova, Eva] Masaryk Univ, Inst Biostat & Anal, Brno 65691, Czech Republic; [Tomasek, Martin; Marusic, Petr] Charles Univ Prague, Fac Med 2, Dept Neurol, Motol Univ Hosp, Prague, Czech Republic","Rehulka, P (reprint author), St Annes Univ Hosp, Dept Neurol 1, Brno Epilepsy Ctr, Pekarska 53, Brno 65691, Czech Republic.","rehulka.pavel@fnusa.cz",null,null,"CEITEC - Central European Institute of Technology from the European Regional Development Fund [CZ.1.05/1.1.00/02.0068]","This study was supported by the \"CEITEC - Central European Institute of Technology\" project (CZ.1.05/1.1.00/02.0068) from the European Regional Development Fund.",null,42,0,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1525-5050","1525-5069",null,"EPILEPSY BEHAV","Epilepsy Behav.","DEC",2014,41,null,null,null,null,null,40,46,null,"10.1016/j.yebeh.2014.09.033",null,7,"Behavioral Sciences; Clinical Neurology; Psychiatry","Behavioral Sciences; Neurosciences & Neurology; Psychiatry","AW3LH","WOS:000346187700010",25282104]
["J","Kubus, P; Vit, P; Gebauer, RA; Zaoral, L; Peichl, P; Fiala, M; Janousek, J",null,null,null,"Kubus, Peter; Vit, Pavel; Gebauer, Roman A.; Zaoral, Libor; Peichl, Petr; Fiala, Martin; Janousek, Jan",null,null,"Long-term results of paediatric radiofrequency catheter ablation: a population-based study","EUROPACE",null,null,"English","Article",null,null,null,null,null,"Radiofrequency ablation; Children; Tachycardia; Congenital heart disease; Paediatric","NODAL REENTRANT TACHYCARDIA; CONGENITAL HEART-DISEASE; ACCESSORY PATHWAYS; SUPRAVENTRICULAR TACHYCARDIA; WORKING GROUP; YOUNG-ADULTS; CHILDREN; CRYOABLATION; EXPERIENCE; SYSTEM","Aims We aimed to evaluate long-term utilization and results of paediatric radiofrequency catheter ablation (RFCA) in a population-based study. Methods and results Data from all three centres performing paediatric RFCA for the whole population of the Czech Republic between 1993 and 2010 were retrospectively reviewed. A total of 708 ablation procedures in 633 consecutive patients,18 years for 716 different substrates were tracked, with accessory pathways = 439 (61.3%) and atrioventricular nodal reentry tachycardia (AVNRT) = 205 (28.6%) being most frequent. Incidence of RFCA reached 0.049 per 1000 children,18 years of age in the recent era (2006-10). Indications included patient preference (68.0%), drug refractoriness (15.5%), asymptomatic Wolff-Parkinson-White pre-excitation (8.4%), and malignant arrhythmia (6.1%). Median follow-up was 13.7 (interquartile range 5.7-21.5) months. Overall acute/long-term success of the primary procedure was 89.1/77.2% (accessory pathways 87.2/77.7%, AVNRT98.5/84.4%). Re-ablation was performed in 73 of 163 substrates after a primary unsuccessful ablation resulting in a long-term cumulative efficacy of 96.3%. Between 1993-2005 and 2006-10, procedure/fluoroscopy time decreased from median 154/24 to 105/14 min. (P < 0.001 for both). Serious complications occurred in nine patients (1.4%). Conclusion This population-based study could replicate data from previous single-or multi-centre reports confirming RFCA as a safe method of arrhythmia treatment in children with long-term cumulative efficacy exceeding 90% and significant decrease in the procedure and fluoroscopy time during the study period. The need for RFCA can be estimated at similar to 0.05/1000 children <18 years using current indication criteria.","[Kubus, Peter; Janousek, Jan] Univ Hosp Motol, Childrens Heart Ctr, Prague 15006, Czech Republic; [Vit, Pavel; Zaoral, Libor] Childrens Univ Hosp, Brno 62500, Czech Republic; [Gebauer, Roman A.] Univ Leipzig, Ctr Heart, Dept Paediat Cardiol, D-04289 Leipzig, Germany; [Peichl, Petr] Inst Clin & Expt Med, Dept Cardiol, Prague 14021, Czech Republic; [Fiala, Martin] Univ Hosp Brno, Dept Cardiol, Brno 65691, Czech Republic","Kubus, P (reprint author), Univ Hosp Motol, Childrens Heart Ctr, V Uvalu 84, Prague 15006, Czech Republic.","peter.kubus@fnmotol.cz",null,null,"Ministry of Health, Czech Republic [00064203]","This study was supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic).",null,32,1,1,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1099-5129","1532-2092",null,"EUROPACE","Europace","DEC",2014,16,12,null,null,null,null,1808,1813,null,"10.1093/europace/euu087",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AX7OL","WOS:000347104900022",24846163]
["J","Spacek, M; Fiedler, J; Suchanek, V; Veselka, J",null,null,null,"Spacek, Miloslav; Fiedler, Jiri; Suchanek, Vojtech; Veselka, Josef",null,null,"Echocardiographic detection of myocardial crypts in hypertrophic cardiomyopathy: a first report in phenotype-positive patient","EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING",null,null,"English","Editorial Material",null,null,null,null,null,null,null,null,"[Spacek, Miloslav; Fiedler, Jiri; Veselka, Josef] Charles Univ Prague, Cardiovasc Ctr, Dept Cardiol, Sch Med 2,Univ Hosp Motol, Prague 15000 5, Czech Republic; [Suchanek, Vojtech] Univ Hosp Motol, Dept Imaging Tech, Prague, Czech Republic","Spacek, M (reprint author), Charles Univ Prague, Cardiovasc Ctr, Dept Cardiol, Sch Med 2,Univ Hosp Motol, V Uvalu 84, Prague 15000 5, Czech Republic.","mildaspacek@gmail.com",null,null,null,null,null,0,0,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","2047-2404","2047-2412",null,"EUR HEART J-CARD IMG","Eur. Heart J.-Cardiovasc. Imaging","OCT",2014,15,10,null,null,null,null,1180,1180,null,"10.1093/ehjci/jeu087",null,1,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AT8NB","WOS:000345188700018",24866903]
["J","Horak, P; Peppard, J; Sykora, J; Gala, TM",null,null,null,"Horak, Petr; Peppard, Joan; Sykora, Juraj; Gala, Tajda Miharija",null,null,"EAHP survey and European Statements of Hospital Pharmacy - can we achieve a perfect match?","EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE",null,null,"English","Article",null,null,null,null,null,null,null,"The European Summit on Hospital Pharmacy 'examined and determined' what the role of hospital pharmacy practice should be in today's Europe, and the Statements were agreed by hospital pharmacists and external stakeholders. However, their implementation is challenging. The 2014 European Association of Hospital Pharmacists (EAHP) General Assembly dedicated considerable time to determining the most difficult and important issues. For 20 years the EAHP Survey has been the main tool to identify the state-of-art of the profession throughout Europe, but it is now time to re-think survey procedures so that it will provide EAHP and its members with quicker and more relevant feedback and information. Therefore, a new model with a 3-year cycle has been developed and approved by the General Assembly. A set of questions that can be properly evaluated should be devised and a benchmarking tool built. Many other issues also need to be resolved in the next few months.","[Horak, Petr; Peppard, Joan; Sykora, Juraj; Gala, Tajda Miharija] European Assoc Hosp Pharmacists, B-1040 Brussels, Belgium; [Horak, Petr] Univ Hosp Motol, Prague, Czech Republic; [Peppard, Joan] Midland Reg Hosp Tullamore, Tullamore, Ireland; [Sykora, Juraj] Natl Canc Inst, Pharm Dept SZU, Bratislava, Slovakia; [Gala, Tajda Miharija] Univ Med Ctr Ljubljana, Pharm Dept, Ljubljana, Slovenia","Horak, P (reprint author), European Assoc Hosp Pharmacists, Rue Abbe Cuypers 3, B-1040 Brussels, Belgium.","horak@hospitalpharmacy.cz",null,null,null,null,null,0,0,0,"BMJ PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","2047-9956","2047-9964",null,"EUR J HOSP PHARM-S P","Eur. J. Hosp. Pharm.-Sci. Pract.","OCT",2014,21,5,null,null,null,null,291,293,null,"10.1136/ejhpharm-2014-000541",null,3,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","AW2RT","WOS:000346137200013"]
["J","Bobek, V; Kolostova, K; Kucera, E",null,null,null,"Bobek, Vladimir; Kolostova, Katarina; Kucera, Eduard",null,null,"Circulating endometrial cells in peripheral blood","EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY",null,null,"English","Article",null,null,null,null,null,"Endometriosis; CEC; Circulating endometrial cells; Cultivation; Meta Cell; Biomarker","GROWTH-FACTORS; TUMOR-CELLS; BIOMARKERS; CANCER; WOMEN; DIAGNOSIS; MELANOMA; RISK","Objectives: Endometriosis is a common disorder amongst women of reproductive age. Despite extensive research, no reliable blood tests currently exist for the diagnosis of endometriosis Study design: We report several new approaches enabling study of cell specific characteristic of endometrial cells, introducing enrichment and culturing of viable circulating endometrial cells (CECs) isolated from peripheral blood (PB) and peritoneal endometrial cells (PECs) from peritoneal washing (PW). Size-based enrichment method (MetaCell (R), Czech Republic) has been used for the filtration of PB and PW in patients with diagnosed endometriosis. Results: The PECs were found in the PW in all of the tested patients (n = 17), but CECs) only in 23.5% (4/17) cases. Their endometrial origin has been proved by immunohistochemistry. PECs were successfully cultured in vitro directly on the separating membrane (9/17) exhibiting both endometrial cell phenotypes: stromal and glandular within the culture. CECs were successfully cultured in the two of the four positive cases, but in none of them confluence has been reached. The occurrence in CECs in PB is clear and very specific evidence of an active endometrial disease. Conclusions: We demonstrated efficient, quick and user friendly endometrial cells capture platform based on a cell size. Furthermore, we demonstrated an ability to culture the captured cells, a critical requirement for post-isolation cellular analysis directed to better understanding of endometriosis pathogenesis. (C) 2014 Elsevier Ireland Ltd. All rights reserved.","[Bobek, Vladimir; Kolostova, Katarina] Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Prague 10034, Czech Republic; [Bobek, Vladimir] Wroclaw Med Univ, Dept Histol & Embryol, Wroclaw, Poland; [Bobek, Vladimir] Charles Univ Prague, Fac Med 1, Dept Surg 3, Prague, Czech Republic; [Bobek, Vladimir] Univ Hosp Motol, Prague, Czech Republic; [Kolostova, Katarina] Charles Univ Prague, Fac Med 3, Dept Tumor Biol, Prague 10097, Czech Republic; [Kucera, Eduard] Charles Univ Prague, Fac Med 3, Dept Gynecol & Obstet 3, Prague 10097, Czech Republic; [Kucera, Eduard] Univ Hosp Kralovske Vinohrady, Prague 10097, Czech Republic","Bobek, V (reprint author), Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Srobarova 50, Prague 10034, Czech Republic.","vbobek@centrum.cz",null,null,"Charles University in Prague, 3rd Faculty of Medicine, Prague, Czech Republic [P 27/2012]; Czech Ministry of Health [IGA NT14441-3/2013]","This study was supported by the Research project P 27/2012 awarded by Charles University in Prague, 3rd Faculty of Medicine, Prague, Czech Republic and grant of the Czech Ministry of Health: IGA NT14441-3/2013.",null,24,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0301-2115","1872-7654",null,"EUR J OBSTET GYN R B","Eur. J. Obstet. Gynecol. Reprod. Biol.","OCT",2014,181,null,null,null,null,null,267,274,null,"10.1016/j.ejogrb.2014.07.037",null,8,"Obstetrics & Gynecology; Reproductive Biology","Obstetrics & Gynecology; Reproductive Biology","AS0EW","WOS:000343952000048",25195200]
["J","Witjes, JA; Babjuk, M; Gontero, P; Jacqmin, D; Karl, A; Kruck, S; Mariappan, P; Redorta, JP; Stenzl, A; van Velthoven, R; Zaak, D",null,null,null,"Witjes, J. Alfred; Babjuk, Marek; Gontero, Paolo; Jacqmin, Didier; Karl, Alexander; Kruck, Stephan; Mariappan, Paramananthan; Redorta, Juan Palou; Stenzl, Arnulf; van Velthoven, Roland; Zaak, Dirk",null,null,"Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations","EUROPEAN UROLOGY",null,null,"English","Review",null,null,null,null,null,"Cost effectiveness; Fluorescence cystoscopy; Hexaminolevulinate; Bladder cancer; Quality-adjusted life-years; Recurrence","INVASIVE BLADDER-CANCER; FLUORESCENCE CYSTOSCOPY; TRANSURETHRAL RESECTION; PHOTODYNAMIC DIAGNOSIS; FOLLOW-UP; UROTHELIAL CARCINOMA; FLEXIBLE CYSTOSCOPY; CALMETTE-GUERIN; URINARY-TRACT; METAANALYSIS","Context: Non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence risk, partly because of the persistence of lesions following transurethral resection of bladder tumour (TURBT) due to the presence of multiple lesions and the difficulty in identifying the exact extent and location of tumours using standard white-light cystoscopy (WLC). Hexaminolevulinate (HAL) is an optical-imaging agent used with blue-light cystoscopy (BLC) in NMIBC diagnosis. Increasing evidence from long-term follow-up confirms the benefits of BLC over WLC in terms of increased detection and reduced recurrence rates. Objective: To provide updated expert guidance on the optimal use of HAL-guided cystoscopy in clinical practice to improve management of patients with NMIBC, based on a review of the most recent data on clinical and cost effectiveness and expert input. Evidence acquisition: PubMed and conference searches, supplemented by personal experience. Evidence synthesis: Based on published data, it is recommended that BLC be used for all patients at initial TURBT to increase lesion detection and improve resection quality, thereby reducing recurrence and improving outcomes for patients. BLC is particularly useful in patients with abnormal urine cytology but no evidence of lesions on WLC, as it can detect carcinoma in situ that is difficult to visualise on WLC. In addition, personal experience of the authors indicates that HAL-guided BLC can be used as part of routine inpatient cystoscopic assessment following initial TURBT to confirm the efficacy of treatment and to identify any previously missed or recurrent tumours. Health economic modelling indicates that the use of HAL to assist primary TURBT is no more expensive than WLC alone and will result in improved quality-adjusted life-years and reduced costs over time. Conclusions: HAL-guided BLC is a clinically effective and cost-effective tool for improving NMIBC detection and management, thereby reducing the burden of disease for patients and the health care system. Patient summary: Blue-light cystoscopy (BLC) helps the urologist identify bladder tumours that may be difficult to see using standard white-light cystoscopy (WLC). As a result, the amount of tumour that is surgically removed is increased, and the risk of tumour recurrence is reduced. Although use of BLC means that the initial operation costs more than it would if only WLC were used, over time the total costs of managing bladder cancer are reduced because patients do not need as many additional operations for recurrent tumours. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.","[Witjes, J. Alfred] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6500 HB Nijmegen, Netherlands; [Babjuk, Marek] Charles Univ Prague, Motol Hosp, Dept Urol, Fac Med 2, Prague, Czech Republic; [Gontero, Paolo] Univ Turin, San Giovanni Battista Hosp, Dept Urol, Turin, Italy; [Jacqmin, Didier] Strasbourg Univ Hosp, Dept Urol, Strasbourg, France; [Karl, Alexander] Univ Munich, Dept Urol, Munich, Germany; [Kruck, Stephan; Stenzl, Arnulf] Univ Tubingen, Dept Urol, Tubingen, Germany; [Mariappan, Paramananthan] Western Gen Hosp, Dept Urol, Edinburgh EH4 2XU, Midlothian, Scotland; [Redorta, Juan Palou] Puigvert Fdn, Dept Urol, Urol Oncol Unit, Barcelona, Spain; [van Velthoven, Roland] Inst Jules Bordet, Dept Urol, B-1000 Brussels, Belgium; [Zaak, Dirk] Traunstein Hosp, Dept Urol, Traunstein, Germany","Witjes, JA (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Urol, POB 9101, NL-6500 HB Nijmegen, Netherlands.","fred.witjes@radboudumc.nl",null,null,"Ipsen SA","All authors were offered financial support from Ipsen SA to attend the initial expert-group meeting. Ipsen SA provided financial support for editorial assistance in manuscript preparation. The authors retained editorial control over the content.",null,48,1,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838","1873-7560",null,"EUR UROL","Eur. Urol.","NOV",2014,66,5,null,null,null,null,863,871,null,"10.1016/j.eururo.2014.06.037",null,9,"Urology & Nephrology","Urology & Nephrology","AT1KY","WOS:000344693500022"]
["J","Lukas, J; Drabek, J; Dudesek, B; Vazan, P; Stranska, J; Jancik, S; Mackova, M; Syrucek, M; Lukas, D; Duskova, J; Dundr, P; Hintnausova, B; Jiskra, J",null,null,null,"Lukas, J.; Drabek, J.; Dudesek, B.; Vazan, P.; Stranska, J.; Jancik, S.; Mackova, M.; Syrucek, M.; Lukas, D.; Duskova, J.; Dundr, P.; Hintnausova, B.; Jiskra, J.",null,null,"Correlation among the BRAF Gene Mutation Status, Clinicopathological Features of Primary Tumour, and Lymph Node Metastasizing of Papillary Thyroid Carcinoma","EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES",null,null,"English","Article",null,null,null,null,null,"papillary carcinoma; BRAF(V600E) mutation; clinical and pathological parameters; neck node metastases","BRAF(V600E) MUTATION; V600E MUTATION; CLINICAL-IMPLICATIONS; DIAGNOSTIC-ACCURACY; PROGNOSTIC-FACTORS; CANCER; SPECIMENS; MELANOMA","Background: Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumour. A common mutation of papillary thyroid carcinoma (PTC) is the somatic mutation of the BRAF(V600E) gene. Aim: The aim was to 1) determine the association of lymph node metastases of PTC with the BRAF gene mutation of primary tumour; 2) evaluate association of the BRAF mutation in the primary tumour with clinicopathological parameters; 3) examine the extent of genetic heterogeneity by monitoring the BRAF mutation in multicentric tumours. Subjects and methods: Retrospective analysis of the BRAF(V600E) mutation in PTC and PTC neck lymph node metastases in 156 patients operated from 2003 to 2012 in Prague and Zlin, the Czech Republic, using a qPCR assay. The results were correlated with clinicopathological factors. Results: DNA was successfully extracted from 137 samples. The BRAF(V600E) mutation was detected in 78 cases (56.9 %). The patients with BRAF p.Val600Glu mutation of primary tumour had only non-significantly higher risk of cervical lymph node metastases [OR = 2.39 (95 %) CI 1.00-5.75, p = 0.052]. In the classic papillary variant, the BRAF(V600E) mutation was found significantly more often than in other PTC subtypes (p = 0.022). We did not confirm any significant association between the BRAF(V600E) mutation and other clinicopathological findings. Conclusion: Except for the higher prevalence in papillary variant of PTC, BRAF p.Val600Glu mutation was not associated with other prognostic clinicopathological factors of PTC. BRAF mutation cannot be regarded as a reliable marker of node metastases in patients with PTC.","[Lukas, J.] Nemocnice Na Homolce, Dept Otolaryngol Head & Neck Surg, Prague 15030 5, Czech Republic; [Lukas, J.] Charles Univ Prague, Fac Med, Dept Otolaryngol, Plzen, Czech Republic; [Drabek, J.; Stranska, J.; Jancik, S.] Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Expt Med Lab, CR-77147 Olomouc, Czech Republic; [Dudesek, B.] Atlas Hosp, Dept Surg, Zlin, Czech Republic; [Vazan, P.] Biopsy & Cytol Lab JA Bata, Zlin, Czech Republic; [Mackova, M.] Charles Univ Prague, Fac Med 2, Dept Nucl Med & Endocrinol, Prague, Czech Republic; [Syrucek, M.] Nemocnice Na Homolce, Dept Pathol, Prague 15030 5, Czech Republic; [Lukas, D.] Charles Univ Prague, Fac Med 3, Surg Clin, Prague, Czech Republic; [Lukas, D.] Fac Hosp Kralovske Vinohrady, Prague, Czech Republic; [Duskova, J.; Dundr, P.] Charles Univ Prague, Fac Med 1, Inst Pathol, Prague, Czech Republic; [Hintnausova, B.] Nemocnice Na Homolce, Dept Endocrinol, Prague 15030 5, Czech Republic; [Jiskra, J.] Charles Univ Prague, Dept Endocrinol, Dept Med 3, CR-11636 Prague 1, Czech Republic; [Jiskra, J.] Charles Univ Prague, Metab Fac Med 1, CR-11636 Prague 1, Czech Republic; [Jiskra, J.] Gen Univ Hosp Prague, Prague, Czech Republic","Lukas, J (reprint author), Nemocnice Na Homolce, Dept Otolaryngol Head & Neck Surg, Roentgenova 2, Prague 15030 5, Czech Republic.","jluk@seznam.cz",null,null," [LM2010004];  [CZ.1.07/2.3.00/30.0041];  [CZ.1.05/2.1.00/01.0030]","Project was partially supported by grants LM2010004, CZ.1.07/2.3.00/30.0041, and CZ.1.05/2.1.00/01.0030.",null,37,0,0,"JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH","STUTTGART","RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY","0947-7349","1439-3646",null,"EXP CLIN ENDOCR DIAB","Exp. Clin. Endocrinol. Diabet.","MAY",2014,122,5,null,null,null,null,268,272,null,"10.1055/s-0034-1372624",null,5,"Endocrinology & Metabolism","Endocrinology & Metabolism","AW4RJ","WOS:000346268000003",24839220]
["J","Fik, Z; Dvorankova, B; Kodet, O; Boucek, J; Betka, JA; Betka, J; Andre, S; Gabius, HJ; Snajdr, P; Smetana, K; Chovanec, M",null,null,null,"Fik, Z.; Dvorankova, B.; Kodet, O.; Boucek, J.; Betka, J. A.; Betka, J.; Andre, S.; Gabius, H. -J.; Snajdr, P.; Smetana, K., Jr.; Chovanec, M.",null,null,"Towards Dissecting Molecular Routes of Intercellular Communication in the Tumour Microenvironment: Phenotypic Plasticity of Stem Cell-Associated Markers in Co-culture (Carcinoma Cell/Fibroblast) Systems","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,"cancer-associated fibroblasts; cancer stem cell; CD44; galectin; side population; tumour stroma","NECK SQUAMOUS CANCER; REGULATORY GALECTINS; STROMAL FIBROBLASTS; HUMAN KERATINOCYTES; NUCLEAR PRESENCE; SIDE POPULATION; SUGAR CODE; IN-VITRO; HEAD; IDENTIFICATION","Increasing evidence attributes tumour fates to a small population of cells (cancer stem cells) capable of surviving therapeutic interventions. Investigation of their characteristics, especially in cross-talk with other cell types of the tumour microenvironment, can pave the way to innovative therapeutic concepts. The central issue of this study was to evaluate the impact of stroma on tumour cells with stem cell-like features in a squamous cell carcinoma model (FaDu). Six different types of experimental conditions were tested using distinct compositions of the culture system, and both morphologic and molecular features of the tumour cells were analysed. In detail, FaDu cells alone were used as a control, compared to tumour cells from co-culture, with squamous cell cancer-derived stromal fibroblasts or normal skin human fibroblasts, both in the direct and indirect (insert) systems, adding analysis of side population cells of FaDu culture. Measurements were taken on days 2, 7 and 9 of culture and immediately after preparation in the case of the side population. A panel of antibodies against keratins 8, 10, 19, stem cell markers CD29, CD44, CD 133, as well as biotinylated adhesion/growth-regulatory galectin 1 served as a toolbox for phenotypic characterization. Co-culture with fibroblasts prepared from tumour stroma and with dermal fibroblasts affected marker presentation, maintaining an undifferentiated stage phenotypically related to stem cells. Side-population cells showed close relationship to cancer stem cells in these characteristics. In conclusion, normal and tumour stromal fibroblasts are capable of shifting the marker expression profile of Fa Du cells to a stem-cell-like phenotypic pattern in co-culture.","[Fik, Z.; Dvorankova, B.; Kodet, O.; Snajdr, P.; Smetana, K., Jr.; Chovanec, M.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 15006 5, Czech Republic; [Fik, Z.; Boucek, J.; Betka, J. A.; Betka, J.; Chovanec, M.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague 15006 5, Czech Republic; [Fik, Z.; Boucek, J.; Betka, J. A.; Betka, J.; Chovanec, M.] Charles Univ Prague, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Kodet, O.] Charles Univ Prague, Fac Med 1, Dept Dermatol & Venereol, Prague 15006 5, Czech Republic; [Kodet, O.] Charles Univ Prague, Gen Univ Hosp, Prague 15006 5, Czech Republic; [Boucek, J.; Betka, J. A.] Acad Sci Czech Republic, Inst Microbiol, Dept Immunol & Gnotobiol, Vvi, Prague, Czech Republic; [Andre, S.; Gabius, H. -J.] Univ Munich, Fac Vet Med, Inst Physiol Chem, Munich, Germany","Chovanec, M (reprint author), Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, V Uvalu 84, Prague 15006 5, Czech Republic.","Martin.Chovanec@lf1.cuni.cz",null,null,"Charles University in Prague [GAUK 291811, PRVOUK/LF1/P27]; Specific University Research; Ministry of Health of the Czech Republic [IGA MZ CR 11542, 134 88]; BIOCEV (\"Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University in Vestec\" [CZ.1.05/1.1.00/02.0109]; European Regional Development Fund; Verein zur Forderung des biologisch-technologischen Fortschritts in der Medizin e.V.; EC (ITN network GLYCOPHARM) [317297]; UNCE [204013]","The project was supported by Charles University in Prague, projects Nos. GAUK 291811, PRVOUK/LF1/P27, Specific University Research and UNCE 204013, by the Ministry of Health of the Czech Republic IGA MZ CR 11542 and 134 88, and the project BIOCEV (\"Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University in Vestec\" (CZ.1.05/1.1.00/02.0109), the European Regional Development Fund, the Verein zur Forderung des biologisch-technologischen Fortschritts in der Medizin e.V. and by the EC (ITN network GLYCOPHARM, contract No. 317297).",null,55,0,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2014,60,5,null,null,null,null,205,212,null,null,null,8,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","AW4EN","WOS:000346234100001"]
["J","Krutova, M; Matejkova, J; Nyc, O",null,null,null,"Krutova, Marcela; Matejkova, Jana; Nyc, Otakar",null,null,"C-difficile ribotype 027 or 176?","FOLIA MICROBIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"TOXIN PRODUCTION; NORTH-AMERICA; DISEASE; EUROPE","Clostridium difficile is a major nosocomial pathogen of present times. The analysis of 624 C. difficile strains from 11 hospitals in the Czech Republic in 2013 revealed that 40 % of isolates belonged to ribotype 176. These results suggest that the incidence of CDI (C. difficile infection) in the Czech Republic has increased probably in connection with C. difficile ribotype 176. The molecular systems Xpert C. difficile Epi assay (Cepheid Inc., Sunnyvale, CA) diagnoses toxigenic strains and supports C. difficile ribotype 027 determination based on three specific target places in the toxigenic C. difficile genome. Twenty-nine strains cultivated from stool specimens were evaluated by the Xpert systems as presumed C. difficile PCR ribotype 027 were confirmed as a C. difficile ribotype 176 based on ribotyping. A further 120 C. difficile strains of ribotype 176 were examined for the presence of genes tcdB, cdtB and deletion in position 117 in the tcdC gene. Our experience shows that due to the correspondence of the target places, C. difficile ribotype 176 may be interpreted as ribotype 027 by Xpert C. difficile Epi assay (Cepheid Inc., Sunnyvale, CA). Further molecular analysis as ribotyping based on capillary electrophoresis is needed to differentiate between C. difficile ribotypes 027 and 176 for appropriate epidemiological situation control on local and national levels.","[Krutova, Marcela; Matejkova, Jana; Nyc, Otakar] Charles Univ Prague, Dept Paediat Neurol, Fac Med 2, Prague 15006 5, Czech Republic; [Krutova, Marcela; Matejkova, Jana; Nyc, Otakar] Motol Univ Hosp, Prague 15006 5, Czech Republic; [Krutova, Marcela] Charles Univ Prague, Dept Paediat Neurol, Fac Med 2, DNA Lab, Prague 15006 5, Czech Republic","Krutova, M (reprint author), Charles Univ Prague, Dept Paediat Neurol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","marcela.krutova@seznam.cz",null,null,"Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital in Motol, Prague, Czech Republic [00064203]; MH CZ IGA [NT/14209 - 3]","We would like to thank the European C. difficile infection surveillance network for their professional support. This work was supported by Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital in Motol, Prague, Czech Republic 00064203 and MH CZ IGA NT/14209 - 3. We would like to thank Jamie Byrne for the English revision of this text.",null,29,0,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632","1874-9356",null,"FOLIA MICROBIOL","Folia Microbiol.","NOV",2014,59,6,null,null,null,null,523,526,null,"10.1007/s12223-014-0323-5",null,4,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","AR8GB","WOS:000343812600010",24970104]
["J","Robova, H; Halaska, MJ; Pluta, M; Skapa, P; Matecha, J; Lisy, J; Rob, L",null,null,null,"Robova, Helena; Halaska, Michael J.; Pluta, Marek; Skapa, Petr; Matecha, Jan; Lisy, Jiri; Rob, Lukas",null,null,"Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer","GYNECOLOGIC ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"Fertility-sparing surgery; Neoadjuvant chemotherapy; Trachelectomy; Pregnancy outcome; Fertility outcome; Cervical cancer","SQUAMOUS-CELL CARCINOMA; RADICAL TRACHELECTOMY; TRIAL; WOMEN","Objective. 28 women under 35 years with early-stage cervical cancer and strong desire for fertility preservation that do not fulfil standard criteria for fertility-sparing surgery (tumour larger than 2 cm or with deep of infiltration more than half of stroma) were included in prospective study. Methods. Dose-dense neoadjuvant chemotherapy (NAC) was performed on all 28 patients in 10-day intervals: cisplatin plus ifosfamide in squamous cell cancer (15 women-53.6%) or cisplatin plus doxorubicin in adenocarcinoma (13 women-46.3%). Patients underwent laparoscopic lymphadenectomy and vaginal simple trachelectomy after NAC. Patients with positive lymph nodes or inadequate free surgical margins underwent radical hysterectomy. Results. No residual disease was found in 6 women (21.4%), microscopic disease was observed in 11 women (39.3%) and macroscopic tumour in was observed in 11 women (39.3%). Ten women (35.7%) lost fertility. Four women (20%) after fertility-sparing surgery recurred, two died of the disease (10%). Fertility was spared in 20 (71.4%) women and 10 of them became pregnant (50%). Eight women delivered ten babies (6 term and four preterm deliveries). There were two miscarriages in second trimester (in one woman) and one in first trimester. One woman underwent four unsuccessful cycles of IVF, one failed to become pregnant and one recurred too early. Two women underwent chemoradiotherapy for recurrence and lost chance for pregnancy. Conclusions. Downstaging by NAC in IB1 and IB2 cervical cancer before fertility-sparing surgery is still an experimental procedure, but shows some promise. Long-term results in relation to oncological outcome for this concept are still needed. (C) 2014 Elsevier Inc. All rights reserved.","[Robova, Helena; Halaska, Michael J.; Pluta, Marek; Matecha, Jan; Rob, Lukas] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, Prague 15000 5, Czech Republic; [Skapa, Petr] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15000 5, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Fac Med 2, Dept Radiol, Prague 15000 5, Czech Republic","Rob, L (reprint author), Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, V Uvalu 84, Prague 15000 5, Czech Republic.","lukas.rob@lfmotol.cuni.cz",null,null," [MZ CR NT 13166]","This work is supported by grant MZ CR NT 13166.",null,16,0,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0090-8258","1095-6859",null,"GYNECOL ONCOL","Gynecol. Oncol.","NOV",2014,135,2,null,null,null,null,213,216,null,"10.1016/j.ygyno.2014.08.021",null,4,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","AU4TW","WOS:000345605200008",25159484]
["J","Valerio, DG; Katsman-Kuipers, JE; Jansen, JH; Verboon, LJ; de Haas, V; Stary, J; Baruchel, A; Zimmermann, M; Pieters, R; Reinhardt, D; van den Heuvel-Eibrink, MM; Zwaan, CM",null,null,null,"Valerio, Daria G.; Katsman-Kuipers, Jenny E.; Jansen, Joop H.; Verboon, Lonneke J.; de Haas, Valerie; Stary, Jan; Baruchel, Andre; Zimmermann, Martin; Pieters, Rob; Reinhardt, Dirk; van den Heuvel-Eibrink, Marry M.; Zwaan, C. Michel",null,null,"Mapping epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia","HAEMATOLOGICA",null,null,"English","Letter",null,null,null,null,null,"pediatric acute myeloid leukemia; IDH; DNMT3A; TET2","IDH2 MUTATIONS; TET2; AML; MALIGNANCIES; DNMT3A; ASXL1; EZH2",null,"[Valerio, Daria G.; Katsman-Kuipers, Jenny E.; Verboon, Lonneke J.; Pieters, Rob; van den Heuvel-Eibrink, Marry M.; Zwaan, C. Michel] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol, Rotterdam, Netherlands; [Jansen, Joop H.] Radboud UMC, Dept Hematol, Nijmegen, Netherlands; [de Haas, Valerie] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Stary, Jan] Charles Univ Prague, Sch Med 1, Prague, Czech Republic; [Baruchel, Andre] Hop Robert Debre, AP HP, F-75019 Paris, France; [Baruchel, Andre] Univ Paris Diderot, Paris, France; [Zimmermann, Martin; Reinhardt, Dirk] Med High Sch, Dept Pediat Oncol Hematol, AML BFM Study Grp, Hannover, Germany","Zwaan, CM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol, Rotterdam, Netherlands.","c.m.zwaan@erasmusmc.nl",null,null,null,null,null,15,0,0,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOLOGICA","Haematologica","AUG 1",2014,99,8,null,null,null,null,"E130","E132",null,"10.3324/haematol.2013.094565",null,3,"Hematology","Hematology","AQ5GF","WOS:000342834300002",24816242]
["J","Materna, O; Kubus, P; Janousek, J",null,null,null,"Materna, Ondrej; Kubus, Peter; Janousek, Jan",null,null,"Right ventricular resynchronization in a child with hypoplastic left heart syndrome","HEART RHYTHM",null,null,"English","Article",null,null,null,null,null,"Child; Hypoplastic Left heart syndrome; Single ventricle; Resynchronization; Right bundle branch block","THERAPY",null,"[Materna, Ondrej; Kubus, Peter; Janousek, Jan] Motol Univ Hosp, Childrens Heart Ctr, Prague, Czech Republic","Materna, O (reprint author), FN Motole, Detske Kardioctr, Uvalu 84, Prague 15006, Czech Republic.","ondrej.materna@fnmotol.cz",null,null,"Ministry of Health, Czech Republic-Conceptual Development of Research Organization, Motol University Hospital, Prague, Czech Republic [00064203]","This work was supported by the research grant from the Ministry of Health, Czech Republic-Conceptual Development of Research Organization, Motol University Hospital, Prague, Czech Republic (grant no. 00064203).",null,5,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1547-5271","1556-3871",null,"HEART RHYTHM","Heart Rhythm","DEC",2014,11,12,null,null,null,null,2303,2305,null,"10.1016/j.hrthm.2014.09.001",null,3,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AU1SM","WOS:000345400500028",25194900]
["J","Malikova, J; Fluck, CE",null,null,null,"Malikova, Jana; Flueck, Christa E.",null,null,"Novel Insight into Etiology, Diagnosis and Management of Primary Adrenal Insufficiency","HORMONE RESEARCH IN PAEDIATRICS",null,null,"English","Review",null,null,null,null,null,"Primary adrenal insufficiency; Steroid biosynthesis; Familial glucocorticoid deficiency; Hypocortisolism; Addison's disease; ACTH resistance","FAMILIAL GLUCOCORTICOID DEFICIENCY; MODIFIED-RELEASE HYDROCORTISONE; GENOTYPE-PHENOTYPE CORRELATIONS; P450 OXIDOREDUCTASE DEFICIENCY; CORTISONE-REDUCTASE DEFICIENCY; KILLER-CELL DEFICIENCY; PCNA-BINDING DOMAIN; REPLACEMENT THERAPY; GROWTH-RETARDATION; MASS-SPECTROMETRY","Primary adrenal insufficiency (PAI) is a rare condition in childhood which is either inherited (mostly) or acquired. It is characterized by glucocorticoid and maybe mineralocorticoid deficiency. The most common form in children is 21-hydroxylase deficiency, which belongs to the steroid biosynthetic defects causing PAI. Newer forms of complex defects of steroid biosynthesis are P450 oxidoreductase deficiency and (apparent) cortisone reductase deficiency. Other forms of PAI include metabolic disorders, autoimmune disorders and adrenal dysgenesis, e.g. the IMAGe syndrome, for which the underlying genetic defect has been recently identified. Newer work has also expanded the genetic causes underlying isolated, familial glucocorticoid deficiency (FGD). Mild mutations of CYP11A1 or StAR have been identified in patients with FGD. MCM4 mutations were found in a variant of FGD in an Irish travelling community manifesting with PAI, short stature, microcephaly and recurrent infections. Finally, mutations in genes involved in the detoxification of reactive oxygen species were identified in patients with unsolved FGD. Most mutations were found in the enzyme nicotinamide nucleotide transhydrogenase, which uses the mitochondrial proton pump gradient to produce NADPH. NADPH is essential in maintaining high levels of reduced forms of antioxidant enzymes for the reduction of hydrogen peroxide. Similarly, mutations in the gene for TXNRD2 involved in this system were found in FGD patients, suggesting that the adrenal cortex is particularly susceptible to oxidative stress. (C) 2014 S. Karger AG, Basel.","[Malikova, Jana] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague, Czech Republic; [Malikova, Jana] Univ Hosp Motol, Prague, Czech Republic; [Malikova, Jana; Flueck, Christa E.] Univ Childrens Hosp Bern, Div Pediat Endocrinol & Diabetol, Dept Pediat, Bern, Switzerland; [Malikova, Jana; Flueck, Christa E.] Univ Childrens Hosp Bern, Dept Clin Res, Bern, Switzerland","Fluck, CE (reprint author), Univ Childrens Hosp Bern, Freiburgstr 15-C845, CH-3010 Bern, Switzerland.","christa.flueck@dkf.unibe.ch",null,null,"Swiss National Science Foundation [320030-146127]; European Society for Paediatric Endocrinology","We thank Dr. Chantal Cripe-Mamie for proofreading the manuscript. This work has been supported by a grant from the Swiss National Science Foundation (320030-146127) to C.E.F. and by a short-term research fellowship grant of the European Society for Paediatric Endocrinology to J.M.",null,61,0,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1663-2818","1663-2826",null,"HORM RES PAEDIAT","Horm. Res. Paediatr.",null,2014,82,3,null,null,null,null,145,157,null,"10.1159/000363107",null,13,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","AU2LA","WOS:000345448500002",25096886]
["J","Konecna, R; Nguyen, HV; Stanisavljevic, M; Blazkova, I; Krizkova, S; Vaculovicova, M; Stiborova, M; Eckschlager, T; Zitka, O; Adam, V; Kizek, R",null,null,null,"Konecna, Romana; Hoai Viet Nguyen; Stanisavljevic, Maja; Blazkova, Iva; Krizkova, Sona; Vaculovicova, Marketa; Stiborova, Marie; Eckschlager, Tomas; Zitka, Ondrej; Adam, Vojtech; Kizek, Rene",null,null,"Doxorubicin Encapsulation Investigated by Capillary Electrophoresis with Laser-Induced Fluorescence Detection","CHROMATOGRAPHIA",null,null,"English","Article",null,null,null,null,null,"Capillary electrophoresis; Fluorescence; Drug delivery; Doxorubicin; Apoferritin","DRUG-DELIVERY; ELECTROCHEMICAL-BEHAVIOR; RAT PLASMA; APOFERRITIN; PHARMACOKINETICS; QUANTIFICATION; ANTHRACYCLINES; NANOPARTICLES; DAUNORUBICIN; THERAPY","Doxorubicin (DOX) belongs to the group of anthracycline antibiotics with very effective anticancer properties. On the other hand, the cardiotoxic effects limit its application over the maximum cumulative dose. To overcome this obstacle, encapsulation of this drug into the protective nanotransporter such as apoferritin is beneficial. In this study, fluorescent behavior of DOX in various solvents was determined by fluorescence spectrometry, demonstrating the fluorescence quenching effect of water, which is often used as a solvent. It was found that by increasing the amount of the organic phase in the DOX solvent the dynamic quenching is significantly suppressed. Ethanol, acetonitrile and dimethyl sulfoxide were tested and the best linearity of the calibration curve was obtained when above 50 % of the solvent was present in the binary mixture with water. Moreover, pH influence on the DOX fluorescence was also observed within the range of 4-10. Two times higher fluorescence intensity was observed at pH 4 compared to pH 10. Further, the DOX behavior in capillary electrophoresis (CE) was investigated. Electrophoretic mobilities (CE) in various pH of the background electrolyte were determined within the range from 16.3 to -13.3 x 10 (-9) m(-2) V-1 s(-1). Finally, CE was also used to monitor the encapsulation of DOX into the cavity of apoferritin as well as the pH-triggered release.","[Konecna, Romana; Hoai Viet Nguyen; Stanisavljevic, Maja; Blazkova, Iva; Zitka, Ondrej; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Brno 61300, Czech Republic; [Krizkova, Sona; Vaculovicova, Marketa; Zitka, Ondrej; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, Brno 61600, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12840 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague 15006 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Kizek, Rene] Mendel Univ Brno, Cent European Inst Technol, Brno 61300, Czech Republic; [Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Brno 61300, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Cent European Inst Technol, Zemedelska 1, Brno 61300, Czech Republic.","kizek@sci.muni.cz","Stiborova, Marie/A-5982-2015","Stiborova, Marie/0000-0001-5430-4403","GA CR CYTORES [P301/10/0356]","The financial support from GA CR CYTORES P301/10/0356 is highly acknowledged.",null,23,0,0,"SPRINGER HEIDELBERG","HEIDELBERG","TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY","0009-5893","1612-1112",null,"CHROMATOGRAPHIA","Chromatographia","NOV",2014,77,"21-22",null,null,null,null,1469,1476,null,"10.1007/s10337-014-2733-6",null,8,"Biochemical Research Methods; Chemistry, Analytical","Biochemistry & Molecular Biology; Chemistry","AT5TK","WOS:000345004800008"]
["J","Uhlik, J; Simunkova, P; Zaloudikova, M; Partlova, S; Jarkovsky, J; Vajner, L",null,null,null,"Uhlik, Jiri; Simunkova, Petra; Zaloudikova, Marie; Partlova, Simona; Jarkovsky, Jiri; Vajner, Ludek",null,null,"Airway Wall Remodeling in Young and Adult Rats with Experimentally Provoked Bronchial Asthma","INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Brown Norway rats; Ovalbumin; Morphometry; Eosinophils; Goblet cells; Basement membrane","BROWN-NORWAY RATS; SMOOTH-MUSCLE; SUBEPITHELIAL FIBROSIS; TRACHEAL EPITHELIUM; STRUCTURAL-CHANGES; ALLERGEN EXPOSURE; SECRETORY-CELLS; GROWTH-FACTORS; GOBLET CELLS; INFLAMMATION","Background: Airway wall remodeling is a typical finding in patients suffering from bronchial asthma. While morphological changes have been thoroughly described in adults, less is known about such changes in children because of the limited accessibility of relevant material. To overcome this constraint, animal asthma models may be used instead of human specimens. This study examined rats with artificially stimulated chronic asthma-like symptoms. Methods: Brown Norway rats of two age categories (young and adult) were sensitized by ovalbumin (OA), and their intrapulmonary airways (IA) were studied using morphometric and histochemical methods. Results: OA administration induced a significant increase in lung resistance in young animals but not in adults. The total IA wall area was significantly increased in both young and adult OA rats. In young animals, thickening of the adventitia played a more crucial role in this increase than it did in adults, in which the mucosa and the submucosa participated to a higher degree. The IA walls of young OA rats had significantly higher levels of infiltrating eosinophils than those of adult OA animals. The multiplication of goblet cells was more pronounced in adult rats, which was associated with a tendency to produce a higher proportion of acidic glycoconjugates. Conclusions: OA stimulation affected the IA of young rats differently than those of adult animals. Changes in the outer IA layer of young rats can be triggered by activated eosinophils; however, stimulated airway epithelium can be a source of factors that influence the inner IA layers in adult rats. (C) 2014 S. Karger AG, Basel","[Uhlik, Jiri; Vajner, Ludek] Charles Univ Prague, Fac Med 2, Dept Histol & Embryol, CZ-15006 Prague 5, Czech Republic; [Simunkova, Petra] Charles Univ Prague, Fac Med 2, Dept Paediat, CZ-15006 Prague 5, Czech Republic; [Zaloudikova, Marie] Charles Univ Prague, Fac Med 2, Dept Pathophysiol, CZ-15006 Prague 5, Czech Republic; [Partlova, Simona] Charles Univ Prague, Fac Med 2, Dept Immunol, CZ-15006 Prague 5, Czech Republic; [Jarkovsky, Jiri] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic","Uhlik, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Histol & Embryol, Uvalu 84, CZ-15006 Prague 5, Czech Republic.","jiri.uhlik@lfmotol.cuni.cz",null,null,"Internal Grant Agency of the Ministry of Health, Czech Republic [NT-11459]","This work was supported by a grant from the Internal Grant Agency of the Ministry of Health, Czech Republic (No. NT-11459).",null,57,0,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1018-2438","1423-0097",null,"INT ARCH ALLERGY IMM","Int. Arch. Allergy Immunol.",null,2014,164,4,null,null,null,null,289,300,null,"10.1159/000366278",null,12,"Allergy; Immunology","Allergy; Immunology","AR5HB","WOS:000343614500005",25228052]
["J","Veselka, J; Spacek, M; Hajek, P; Horvath, M; Stechovsky, C; Zimolova, P",null,null,null,"Veselka, Josef; Spacek, Miloslav; Hajek, Petr; Horvath, Martin; Stechovsky, Cyril; Zimolova, Petra",null,null,"Impact of single versus double vessel carotid disease on long-term survival in patients treated with carotid stenting","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Letter",null,null,null,null,null,"Carotid stenting; Survival; Atherosclerosis",null,null,"[Veselka, Josef; Spacek, Miloslav; Hajek, Petr; Horvath, Martin; Stechovsky, Cyril; Zimolova, Petra] Charles Univ Prague, Dept Cardiol, Motol Univ Hosp, Sch Med 2, Prague 15000 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Dept Cardiol, Motol Univ Hosp, Sch Med 2, V Uvalu 84, Prague 15000 5, Czech Republic.","veselka.josef@seznam.cz",null,null,null,null,null,3,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273","1874-1754",null,"INT J CARDIOL","Int. J. Cardiol.","OCT 20",2014,176,3,null,null,null,null,1299,1300,null,"10.1016/j.ijcard.2014.07.165",null,2,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AR9KT","WOS:000343893300204",25127969]
["J","Honek, J; Sramek, M; Sefc, L; Januska, J; Fiedler, J; Horvath, M; Tomek, A; Novotny, S; Honek, T; Veselka, J",null,null,null,"Honek, Jakub; Sramek, Martin; Sefc, Ludek; Januska, Jaroslav; Fiedler, Jiri; Horvath, Martin; Tomek, Ales; Novotny, Stepan; Honek, Tomas; Veselka, Josef",null,null,"Effect of conservative dive profiles on the occurrence of venous and arterial bubbles in divers with a patent foramen ovale: A pilot study","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Letter",null,null,null,null,null,"Patent foramen ovale; Decompression sickness; Paradoxical embolism; Conservative dive profile","TO-LEFT SHUNT; CLOSURE",null,"[Honek, Jakub; Fiedler, Jiri; Horvath, Martin; Honek, Tomas; Veselka, Josef] Charles Univ Prague, Fac Med 2, Dept Cardiol, Prague, Czech Republic; [Honek, Jakub; Sramek, Martin; Fiedler, Jiri; Horvath, Martin; Tomek, Ales; Honek, Tomas; Veselka, Josef] Motol Univ Hosp, Prague, Czech Republic; [Honek, Jakub; Sramek, Martin; Sefc, Ludek] Charles Univ Prague, Fac Med 1, Inst Pathol Physiol, Prague, Czech Republic; [Sramek, Martin; Tomek, Ales] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague, Czech Republic; [Januska, Jaroslav] Hosp Podlesi, Cardioctr, Trinec, Czech Republic; [Novotny, Stepan] Kladno Reg Hosp, Hyperbar Chamber, Kladno, Czech Republic","Veselka, J (reprint author), Univ Hosp Motol, Dept Cardiol, V Uvalu 84, Prague 15006 5, Czech Republic.","veselka.josef@seznam.cz",null,null,null,null,null,6,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273","1874-1754",null,"INT J CARDIOL","Int. J. Cardiol.","OCT 20",2014,176,3,null,null,null,null,1001,1002,null,"10.1016/j.ijcard.2014.04.218",null,2,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","AR9KT","WOS:000343893300092",25168097]
["J","Im, TS; Chun, EJ; Lee, MS; Adla, T; Kim, JA; Choi, SI",null,null,null,"Im, Tae Seong; Chun, Eun Ju; Lee, Min Su; Adla, Theodor; Kim, Jeong A.; Choi, Sang Il",null,null,"Grade-response relationship between blood pressure and severity of coronary atherosclerosis in asymptomatic adults: assessment with coronary CT angiography","INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING",null,null,"English","Article",null,null,null,null,null,"Subclinical coronary atherosclerosis; Hypertension; Coronary CT angiography","COMPUTED-TOMOGRAPHY ANGIOGRAPHY; HEINZ NIXDORF RECALL; RISK STRATIFICATION; HYPERTENSION; MORTALITY; MEN; QUANTIFICATION; METAANALYSIS; INDIVIDUALS; DISEASE","Hypertension is known to be a strong risk factor for coronary atherosclerosis. We aimed to investigate the prevalence, severity, and plaque characteristics of coronary atherosclerosis according to grade of blood pressure (BP) using coronary CT angiography (CCTA) in asymptomatic adults. We enrolled 8,238 asymptomatic subjects who underwent coronary artery calcium scoring (CACS) and CCTA for health screening purposes. Subjects were classified according to JNC 7 guidelines (normal, systolic BP/diastolic BP < 120/80; pre-hypertension [PH], 120-139/80-89; hypertension stage 1 [H1], 140-159/90-99; hypertension stage 2 [H2], > 160/100). Isolated systolic hypertension (ISH; systolic BP > 140, diastolic BP < 80) was additionally categorized. With CCTA, the presence of plaques, severity of stenosis, and plaque types were assessed. Using multiple logistic regression analysis, the adjusted odds ratios (AORs) for plaque, obstructive coronary artery disease (CAD) (luminal stenosis a parts per thousand yen50 %), non-calcified plaque (NCP), and CACS > 100 were assessed according to BP grade. After adjustment for clinical risk factors, the risk of subclinical atherosclerosis, NCP, and CACS > 100 gradually increased from PH stage (all P values for trend < 0.05), while the risk of obstructive CAD increased from the H1 stage (AORs of H1 and H2: 1.70 and 2.33, respectively). In the ISH group, the AOR of subclinical atherosclerosis (1.64) was higher than in the H1 group (1.55), while the AOR of obstructive CAD (2.58) was higher than in the H2 group (2.33). Therefore, our study strongly suggests that coronary atherosclerosis in asymptomatic adults shows a grade-response relationship according to hypertension grade.","[Im, Tae Seong; Chun, Eun Ju; Lee, Min Su; Choi, Sang Il] Seoul Natl Univ, Dept Radiol, Bundang Hosp, Gyeonggido 436707, South Korea; [Chun, Eun Ju] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Cardiovasc Ctr, Gyeonggido 436707, South Korea; [Adla, Theodor] Motol Univ Hosp, Dept Imaging Tech, Prague, Czech Republic; [Kim, Jeong A.] Inje Univ, Ilsan Paik Hosp, Dept Radiol, Gyeonggido 411706, South Korea","Chun, EJ (reprint author), Seoul Natl Univ, Dept Radiol, Bundang Hosp, Gyeonggido 436707, South Korea.","drejchun@hanmail.net",null,null,null,null,null,23,0,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","1569-5794","1573-0743",null,"INT J CARDIOVAS IMAG","Int. J. Cardiovasc. Imaging","DEC",2014,30,null,null,2,"SI",null,105,112,null,"10.1007/s10554-014-0522-9",null,8,"Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging","Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging","AT7DQ","WOS:000345097400004",25178841]
["J","Cegan, M; Kolostova, K; Matkowski, R; Broul, M; Schraml, J; Fiutowski, M; Bobek, V",null,null,null,"Cegan, Martin; Kolostova, Katarina; Matkowski, Rafal; Broul, Marek; Schraml, Jan; Fiutowski, Marek; Bobek, Vladimir",null,null,"In vitro culturing of viable circulating tumor cells of urinary bladder cancer","INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY",null,null,"English","Article",null,null,null,null,null,"Urinary bladder cancer; circulating tumor cells; CTC; MetaCell; urothelial tumors","RADICAL CYSTECTOMY; CARCINOMA; MARKERS","Objective: Approximately one third of patients diagnosed with muscle-invasive urinary bladder cancer (UBC) have undetected metastases at the time of treatment of the primary tumor. Currently there are no reliable specific serum markers for monitoring and evaluating risk profiles of urothelial cancers. Several studies suggest that detection of circulating tumor cells (CTCs) may correlate with the disease status and prognosis at baseline and early in the treatment of cancers. In this study a new way of isolation and in vitro cultivation of CTCs of urinary bladder cancer was introduced. Materials and methods: Peripheral blood (PB) samples from 53 patients who had undergone urological procedure were evaluated using the MetaCell device (MetaCell s.r.o., Ostrava, Czech Republic). The patients enrolled in the study were both oncological patients with UBC and non-oncological patients with inflammation (14 patients). The sensitivity and quantification of CTCs were evaluated. The separated CTCs were cultured in vitro. Results: 39 patients with confirmed UBC were enrolled in the study. CTCs were detected in 25 (64%) patients, and most of these patients had between 6 and 10 cells. The separated CTCs were successfully cultured in vitro. Conclusion: CTCs were detected in a higher percentage of patients than in other studies. This paper describes the first successful culturing of human UBC cells. The MetaCell approach used in this study enabled the capture of viable intact virgin CTCs (virgin CTC) suitable for next in vitro culturing, single cell analysis or drug testing.","[Cegan, Martin] Masaryks Hosp Usti Nad Labem, Krajska Zdravotni As, Dept Pathol, Usti Nad Labem, Czech Republic; [Kolostova, Katarina; Bobek, Vladimir] Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Prague 10097, Czech Republic; [Matkowski, Rafal] Wroclaw Med Univ, Dept Oncol, PL-50367 Wroclaw, Poland; [Matkowski, Rafal] Wroclaw Med Univ, Div Surg Oncol, PL-50367 Wroclaw, Poland; [Matkowski, Rafal] Lower Silesian Oncol Ctr, PL-53413 Wroclaw, Poland; [Broul, Marek; Schraml, Jan] Masaryks Hosp Usti Nad Labem, Krajska Zdravotni As, Dept Urol, Usti Nad Labem, Czech Republic; [Broul, Marek; Schraml, Jan] Masaryks Hosp Usti Nad Labem, Krajska Zdravotni As, Ctr Robot Surg, Usti Nad Labem, Czech Republic; [Fiutowski, Marek] Reg Specialist Hosp, Dept Urol, PL-51318 Wroclaw, Poland; [Bobek, Vladimir] Wroclaw Med Univ, Dept Histol & Embryol, PL-50368 Wroclaw, Poland; [Bobek, Vladimir] Charles Univ Prague, Fac Med 1, Dept Surg 3, Prague 10500, Czech Republic; [Bobek, Vladimir] Univ Hosp Motol, Prague 10500, Czech Republic","Bobek, V (reprint author), Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Srobarova 50, Prague 10034, Czech Republic.","vbobek@centrum.cz",null,null,"Charles University in Prague [P 27/2012]; Wroclaw Medical University [ST-843]","Supported by research project no. P 27/2012 awarded by Charles University in Prague and by research project no. ST-843 awarded by Wroclaw Medical University.",null,16,0,0,"E-CENTURY PUBLISHING CORP","MADISON","40 WHITE OAKS LN, MADISON, WI 53711 USA","1936-2625",null,null,"INT J CLIN EXP PATHO","Int. J. Clin. Exp. Pathol.",null,2014,7,10,null,null,null,null,7164,7171,null,null,null,8,"Oncology; Pathology","Oncology; Pathology","AT7RU","WOS:000345135900094",25400813]
["J","Stiborova, M; Poljakova, J; Mrizova, I; Borek-Dohalska, L; Eckschlager, T; Adam, V; Kizek, R; Frei, E",null,null,null,"Stiborova, Marie; Poljakova, Jitka; Mrizova, Iveta; Borek-Dohalska, Lucie; Eckschlager, Tomas; Adam, Vojtech; Kizek, Rene; Frei, Eva",null,null,"Expression Levels of Enzymes Metabolizing an Anticancer Drug Ellipticine Determined by Electromigration Assays Influence its Cytotoxicity to Cancer Cells - A Comparative Study","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"Ellipticine; Cancer Cells; Cytotoxicity; Cytochromes P450; Peroxidases; Protein Expression; Western Blotting; Metabolism; DNA Adducts","DNA ADDUCT FORMATION; CYTOCHROMES P450 1A1; ALKALOID ELLIPTICINE; NEUROBLASTOMA-CELLS; AGENT ELLIPTICINE; COVALENT BINDING; RAT-LIVER; SUDAN-I; ACTIVATION; 13-HYDROXYELLIPTICINE","The antineoplastic alkaloid ellipticine is a prodrug, of which the pharmacological efficiency is dependent on its cytochrome P450 (CYP)- and/or peroxidase-mediated activation to 12-hydroxy- and 13-hydroxyellipticine, which are both the metabolites forming DNA adducts in target tissues. Using the method of Western blotting, the expression of CYP1A1, 1B1, 3A4, lactoperoxidase, thyroid peroxidase, cyclooxygenase-1 and cytochrome b(5), the enzymes that catalyze and/or influence ellipticine metabolism, was investigated in several cancer cells sensitive to ellipticine (HL-60 promyelocytic leukemia and T-cell leukemia CCRF-CEM cells, glioblastoma U87MG cells, thyroid cancer BHT-101, B-CPAP and 8505-C cells, neuroblastoma UKF-NB-3 and UKF-NB-4 cell lines and breast adenocarcinoma MCF-7 cells). The findings summarized from several former studies reviewed in this study, together with new results indicate that, depending on individual cells, cytotoxicity of ellipticine, which is mediated by formation of covalent DNA adducts to these cancer cells, is influenced by expression levels of these CYP and peroxidase enzymes in the tested cancer cells. Furthermore, a potency of ellipticine to induce the enzymes dictating activation of ellipticine to form DNA adducts in studied cancer cells determines an increase in cytotoxicity of ellipticine to these tumor cells.","[Stiborova, Marie; Poljakova, Jitka; Mrizova, Iveta; Borek-Dohalska, Lucie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Frei, Eva] German Canc Res Ctr, Natl Ctr Tumor Dis, Div Prevent Oncol, D-69120 Heidelberg, Germany","Stiborova, M (reprint author), Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, CZ-12840 Prague 2, Czech Republic.","stiborov@natur.cuni.cz","Stiborova, Marie/A-5982-2015","Stiborova, Marie/0000-0001-5430-4403","GACR [P301/10/0356]; Charles University in Prague [UNCE 204025/2012]","Financial support from GACR (grant P301/10/0356) and Charles University in Prague (UNCE 204025/2012) is highly acknowledged.",null,38,1,1,"ESG","BELGRADE","BORIVOJA STEVANOVICA 25-7, BELGRADE, 11000, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","OCT",2014,9,10,null,null,null,null,5675,5689,null,null,null,15,"Electrochemistry","Electrochemistry","AT9QP","WOS:000345261700024"]
["J","Novotna, B; Koblizek, V; Zatloukal, J; Plutinsky, M; Hejduk, K; Zbozinkova, Z; Jarkovsky, J; Sobotik, O; Dvorak, T; Safranek, P",null,null,null,"Novotna, Barbora; Koblizek, Vladimir; Zatloukal, Jaromir; Plutinsky, Marek; Hejduk, Karel; Zbozinkova, Zuzana; Jarkovsky, Jiri; Sobotik, Ondrej; Dvorak, Tomas; Safranek, Petr",null,null,"Czech multicenter research database of severe COPD","INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE",null,null,"English","Article",null,null,null,null,null,"phenotypes; comorbidities; exacerbations; all-cause mortality; prospective study","OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; HEALTH-STATUS; COMORBIDITIES; GUIDELINES; PHENOTYPES; MORTALITY; DIAGNOSIS; SCORES","Purpose: Chronic obstructive pulmonary disease (COPD) has been recognized as a heterogeneous, multiple organ system-affecting disorder. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) places emphasis on symptom and exacerbation management. The aim of this study is examine the course of COPD and its impact on morbidity and all-cause mortality of patients, with respect to individual phenotypes and GOLD categories. This study will also evaluate COPD real-life patient care in the Czech Republic. Patients and methods: The Czech Multicentre Research Database of COPD is projected to last for 5 years, with the aim of enrolling 1,000 patients. This is a multicenter, observational, and prospective study of patients with severe COPD (post-bronchodilator forced expiratory volume in 1 second <= 60%). Every consecutive patient, who fulfils the inclusion criteria, is asked to participate in the study. Patient recruitment is done on the basis of signed informed consent. The study was approved by the Multicentre Ethical Committee in Brno, Czech Republic. Results: The objective of this paper was to outline the methodology of this study. Conclusion: The establishment of the database is a useful step in improving care for COPD subjects. Additionally, it will serve as a source of data elucidating the natural course of COPD, comorbidities, and overall impact on the patients. Moreover, it will provide information on the diverse course of the COPD syndrome in the Czech Republic.","[Novotna, Barbora; Koblizek, Vladimir] Charles Univ Prague, Fac Med Hradec Kralove, Univ Hosp Hradec Kralove, Dept Pneumol, Hradec Kralove 50005, Czech Republic; [Zatloukal, Jaromir] Palacky Univ, Univ Hosp, Dept Pulmonol, CR-77147 Olomouc, Czech Republic; [Plutinsky, Marek] Masaryk Univ, Univ Hosp, Dept Pulmonol, Brno, Czech Republic; [Hejduk, Karel; Zbozinkova, Zuzana; Jarkovsky, Jiri] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic; [Sobotik, Ondrej] Charles Univ Prague, Univ Hosp Motol, Dept Pulmonol, Prague, Czech Republic; [Dvorak, Tomas] Hosp Bulovka, Dept Pulmonol, Prague, Czech Republic; [Safranek, Petr] Charles Univ Prague, Univ Hosp, Dept Pulmonol, Plzen, Czech Republic","Koblizek, V (reprint author), Charles Univ Prague, Fac Med Hradec Kralove, Univ Hosp Hradec Kralove, Dept Pneumol, Sokolska 581, Hradec Kralove 50005, Czech Republic.","vladimir.koblizek@fnhk.cz",null,null,"Czech Pneumological and Phthiseological Society; Czech Multicentre Research Database of COPD via AstraZeneca; Czech Multicentre Research Database of COPD via Boehringer Ingelheim; Czech Multicentre Research Database of COPD via GlaxoSmithKline; Czech Multicentre Research Database of COPD via Medicom International s.r.o.; Czech Multicentre Research Database of COPD via Novartis; Czech Multicentre Research Database of COPD via Pfizer; Czech Multicentre Research Database of COPD via Takeda; Czech Ministry of Health [15/14/NAP]; MH CZ - DRO (UHHK) [00179906]; MH CZ [NT13531-3/2013]","The authors would like to thank the Czech Pneumological and Phthiseological Society for their ongoing support, namely, Professor V Kolek (The President of the Czech Pneumological and Phthiseological Society), Professor M Marel (The Scientific Secretary of the Czech Pneumological and Phthiseological Society), and Associate Professor L Dusek (The Director of Institute of Biostatistics and Analyses, Masaryk University) for their indispensable assistance with initialization of this project.The Czech Multicentre Research Database of COPD has been given funding via unrestricted grants from the following companies: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Medicom International s.r.o., Novartis, Pfizer, and Takeda.The Czech Multicentre Research Database of COPD is supported by a grant from the Czech Ministry of Health (grant number 15/14/NAP, The incidence of A1AT deficiency in patients with a severe form of COPD). Additionally, this project is supported by MH CZ - DRO (UHHK, 00179906) and by MH CZ NT13531-3/2013.",null,43,0,0,"DOVE MEDICAL PRESS LTD","ALBANY","PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND","1178-2005",null,null,"INT J CHRONIC OBSTR","Int. J. Chronic Obstr. Pulm. Dis.",null,2014,9,null,null,null,null,null,1265,1274,null,"10.2147/COPD.S71828",null,10,"Respiratory System","Respiratory System","AT4QR","WOS:000344926200001",25419124]
["J","Tomek, A; Urbanova, B; Hort, J",null,null,null,"Tomek, Ales; Urbanova, Barbora; Hort, Jakub",null,null,"Utility of Transcranial Ultrasound in Predicting Alzheimer's Disease Risk","JOURNAL OF ALZHEIMERS DISEASE",null,null,"English","Review",null,null,null,null,null,"Alzheimer's disease; breath-holding test; cerebrovascular reserve capacity; transcranial doppler sonography; transcranial color coded duplex ultrasonography; minimal cognitive impairment","CEREBRAL-BLOOD-FLOW; MILD COGNITIVE IMPAIRMENT; ASYMPTOMATIC CAROTID STENOSIS; DOPPLER PULSATILITY INDEX; VASCULAR DEMENTIA; CEREBROVASCULAR REACTIVITY; VASOMOTOR REACTIVITY; ARTERY-DISEASE; AUTOREGULATION; VELOCITY","Alzheimer's disease (AD) is a progressive, neurodegenerative disease characterized by an increasing incidence. One of the pathologic processes that underlie this disorder is impairment of brain microvasculature. Transcranial ultrasound is a non-invasive examination of cerebral blood flow that can be employed as a simple and useful screening tool for assessing the vascular status of brain circulation in preclinical and clinical stages of AD. The objective of this review is to explore the utility of using a transcranial ultrasound to diagnose AD. With transcranial ultrasound, the most frequently studied parameters are cerebral blood flow velocities and pulsatility indices, cerebrovascular reserve capacity, and cerebral microembolization. On the basis of current knowledge, we recommend using as a transcranial Doppler sonography screening method of choice the assessment of cerebrovascular reserve capacity with breath-holding test.","[Tomek, Ales] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague 15018 5, Czech Republic; [Tomek, Ales] Motol Univ Hosp, Prague 15018 5, Czech Republic","Tomek, A (reprint author), Charles Univ Prague, Dept Neurol, Fac Med 2, V Uvalu 84, Prague 15018 5, Czech Republic.","ales.tomek@fnmotol.cz",null,null,"Grant Agency of Ministry of Health of Czech Republic (IGA) [NT/13319]","The authors of the article were supported by the Grant Agency of Ministry of Health of Czech Republic (IGA No. NT/13319).",null,66,0,0,"IOS PRESS","AMSTERDAM","NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS","1387-2877","1875-8908",null,"J ALZHEIMERS DIS","J. Alzheimers Dis.",null,2014,42,null,null,4,null,null,"S365","S374",null,"10.3233/JAD-141803",null,10,"Neurosciences","Neurosciences & Neurology","AR9KQ","WOS:000343893000005",25298200]
["J","Rubinova, E; Nikolai, T; Markova, H; Siffelova, K; Laczo, J; Hort, J; Vyhnalek, M",null,null,null,"Rubinova, Eva; Nikolai, Tomas; Markova, Hana; Siffelova, Kamila; Laczo, Jan; Hort, Jakub; Vyhnalek, Martin",null,null,"Clock Drawing Test and the diagnosis of amnestic mild cognitive impairment: Can more detailed scoring systems do the work?","JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY",null,null,"English","Article",null,null,null,null,null,"Clock Drawing Test; Amnestic mild cognitive impairment; Neuropsychology; Mini-Mental State Examination; Combination of scores","SCREENING TOOL; ALZHEIMERS-DISEASE; DEMENTIA; ACCURACY; VALIDITY","Introduction: The Clock Drawing Test is a frequently used cognitive screening test with several scoring systems in elderly populations. We compare simple and complex scoring systems and evaluate the usefulness of the combination of the Clock Drawing Test with the Mini-Mental State Examination to detect patients with mild cognitive impairment. Method: Patients with amnestic mild cognitive impairment (n = 48) and age- and education-matched controls (n = 48) underwent neuropsychological examinations, including the Clock Drawing Test and the Mini-Mental State Examination. Clock drawings were scored by three blinded raters using one simple (6-point scale) and two complex (17- and 18-point scales) systems. The sensitivity and specificity of these scoring systems used alone and in combination with the Mini-Mental State Examination were determined. Results: Complex scoring systems, but not the simple scoring system, were significant predictors of the amnestic mild cognitive impairment diagnosis in logistic regression analysis. At equal levels of sensitivity (87.5%), the Mini-Mental State Examination showed higher specificity (31.3%, compared with 12.5% for the 17-point Clock Drawing Test scoring scale). The combination of Clock Drawing Test and Mini-Mental State Examination scores increased the area under the curve (0.72; p < .001) and increased specificity (43.8%), but did not increase sensitivity, which remained high (85.4%). Conclusions: A simple 6-point scoring system for the Clock Drawing Test did not differentiate between healthy elderly and patients with amnestic mild cognitive impairment in our sample. Complex scoring systems were slightly more efficient, yet still were characterized by high rates of false-positive results. We found psychometric improvement using combined scores from the Mini-Mental State Examination and the Clock Drawing Test when complex scoring systems were used. The results of this study support the benefit of using combined scores from simple methods.","[Rubinova, Eva; Nikolai, Tomas; Markova, Hana; Laczo, Jan; Hort, Jakub; Vyhnalek, Martin] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno 65691, Czech Republic; [Nikolai, Tomas; Laczo, Jan; Hort, Jakub; Vyhnalek, Martin] Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Fac Med 2, Prague, Czech Republic; [Nikolai, Tomas; Laczo, Jan; Hort, Jakub; Vyhnalek, Martin] Motol Univ Hosp, Prague, Czech Republic; [Siffelova, Kamila] Charles Univ Prague, Dept Psychol, Fac Arts, Prague, Czech Republic","Rubinova, E (reprint author), St Annes Univ Hosp Brno, Int Clin Res Ctr, Pekarska 53, Brno 65691, Czech Republic.","eva.rubinova@gmail.com",null,null,"European Regional Development Fund project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; Charles University in Prague, Faculty of Arts [VG137]; Ministry of Health, Czech Republic-Conceptual Development of Research Organization, University Hospital Motol, Prague, Czech Republic [00064203]","The research was supported by the European Regional Development Fund project FNUSA-ICRC [grant number CZ.1.05/1.1.00/02.0123]; Charles University in Prague, Faculty of Arts, internal grants 2012 [grant number VG137]; and Ministry of Health, Czech Republic-Conceptual Development of Research Organization, University Hospital Motol, Prague, Czech Republic [grant number 00064203]. All authors reported no financial interests or potential conflicts of interest.",null,27,0,0,"TAYLOR & FRANCIS INC","PHILADELPHIA","530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA","1380-3395","1744-411X",null,"J CLIN EXP NEUROPSYC","J. Clin. Exp. Neuropsychol.","NOV 26",2014,36,10,null,null,null,null,1076,1083,null,"10.1080/13803395.2014.977233",null,8,"Psychology, Clinical; Clinical Neurology; Psychology","Psychology; Neurosciences & Neurology","AX3MB","WOS:000346842300007",25486502]
["J","Ruemmele, FM; Veres, G; Kolho, KL; Griffiths, A; Levine, A; Escher, JC; Dias, JA; Barabino, A; Braegger, CP; Bronsky, J; Buderus, S; Martin-de-Carpi, J; De Ridder, L; Fagerberg, UL; Hugot, JP; Kierkus, J; Kolacek, S; Koletzkou, S; Lionetti, P; Miele, E; Lopez, VMN; Paerregaard, A; Russell, RK; Serban, DE; Shaoul, R; Van Rheenen, P; Veereman, G; Weiss, B; Wilson, D; Dignass, A; Eliakim, A; Winter, H; Turner, D",null,null,null,"Ruemmele, F. M.; Veres, G.; Kolho, K. L.; Griffiths, A.; Levine, A.; Escher, J. C.; Dias, J. Amil; Barabino, A.; Braegger, C. P.; Bronsky, J.; Buderus, S.; Martin-de-Carpi, J.; De Ridder, L.; Fagerberg, U. L.; Hugot, J. P.; Kierkus, J.; Kolacek, S.; Koletzkou, S.; Lionetti, P.; Miele, E.; Navas Lopez, V. M.; Paerregaard, A.; Russell, R. K.; Serban, D. E.; Shaoul, R.; Van Rheenen, P.; Veereman, G.; Weiss, B.; Wilson, D.; Dignass, A.; Eliakim, A.; Winter, H.; Turner, D.",null,null,"Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease","JOURNAL OF CROHNS & COLITIS",null,null,"English","Article",null,null,null,null,null,"Pediatric; Crohn's disease; Guidelines; Medical therapy","INFLAMMATORY-BOWEL-DISEASE; RANDOMIZED-CONTROLLED-TRIAL; SINGLE-CENTER COHORT; EXCLUSIVE ENTERAL NUTRITION; POPULATION-BASED COHORT; TERM-FOLLOW-UP; PLACEBO-CONTROLLED TRIALS; NONMELANOMA SKIN CANCERS; NEWLY-DIAGNOSED CHILDREN; DEVELOP REGISTRY DATA","Children and adolescents with Crohn's disease (CD) present often with a more complicated disease course compared to adult patients. In addition, the potential impact of CD on growth, pubertal and emotional development of patients underlines the need for a specific management strategy of pediatric-onset CD. To develop the first evidenced based and consensus driven guidelines for pediatric-onset CD an expert panel of 33 IBD specialists was formed after an open call within the European Crohn's and Colitis Organisation and the European Society of Pediatric Gastroenterolog, Hepatology and Nutrition. The aim was to base on a thorough review of existing evidence a state of the art guidance on the medical treatment and long term management of children and adolescents with CD, with individualized treatment algorithms based on a benefit-risk analysis according to different clinical scenarios. In children and adolescents who did not have finished their growth, exclusive enteral nutrition (EEN) is the induction therapy of first choice due to its excellent safety profile, preferable over corticosteroids, which are equipotential to induce remission. The majority of patients with pediatric-onset CD require immunomodulator based maintenance therapy. The experts discuss several factors potentially predictive for poor disease outcome (such as severe perianal fistulizing disease, severe stricturing/penetrating disease, severe growth retardation, panenteric disease, persistent severe disease despite adequate induction therapy), which may incite to an anti-TNF-based top down approach. These guidelines are intended to give practical (whenever possible evidence-based) answers to (pediatric) gastroenterologists who take care of children and adolescents with CD; they are not meant to be a rule or legal standard, since many different clinical scenario exist requiring treatment strategies not covered by or different from these guidelines. (C) 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.","[Ruemmele, F. M.] Hop Necker Enfants Malad, AP HP, Dept Paediat Gastroenterol, F-75015 Paris, France; [Ruemmele, F. M.] Univ Paris 05, Sorbonne Paris Cite, F-75006 Paris, France; [Ruemmele, F. M.] INSERM, U989, Inst IMAGINE, F-75015 Paris, France; [Veres, G.] Semmelweis Univ, Dept Paediat 1, H-1083 Budapest, Hungary; [Kolho, K. L.] Univ Helsinki, Dept Gastroenterol, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland; [Griffiths, A.] Univ Toronto, Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1X8, Canada; [Levine, A.] Tel Aviv Univ, Paediat Gastroenterol & Nutr Unit, Edith Wolfson Med Ctr, IL-58100 Holon, Israel; [Escher, J. C.] Erasmus MC, Dept Paediat Gastroenterol, NL-3015 CN Rotterdam, Netherlands; [Dias, J. Amil] Hosp Sao Joao, Unit Paediat Gastroenterol, P-4202451 Oporto, Portugal; [Barabino, A.] Ist Giannina Gaslini, Gastroenterol & Endoscopy Unit, I-16148 Genoa, Italy; [Braegger, C. P.] Univ Childrens Hosp Zurich, Div Gastroenterol & Nutr, CH-8032 Zurich, Switzerland; [Braegger, C. P.] Univ Childrens Hosp Zurich, Childrens Res Ctr, CH-8032 Zurich, Switzerland; [Bronsky, J.] Univ Hosp Motol, Dept Pediat, Prague 15006, Czech Republic; [Buderus, S.] St Marien Hosp, Dept Paediat, D-53115 Bonn, Germany; [Martin-de-Carpi, J.] Hosp St Joan de Deu, Dept Paediat Gastroenterolgoy Hepatol & Nutr, Barcelona 08950, Spain; [De Ridder, L.] Erasmus MC, Dept Paediat Gastroenterol, NL-3015 CN Rotterdam, Netherlands; [Fagerberg, U. L.] Karolinska Inst, Vastmanland Hosp, Clin Res Ctr, Dept Pediat, S-72189 Stockholm, Sweden; [Hugot, J. P.] Hop Robert Debre, AP HP, Dept Gastroenterol & Nutr, F-75019 Paris, France; [Hugot, J. P.] Univ Paris Diderot, Sorbonne Paris Cite, F-75018 Paris, France; [Kierkus, J.] Inst Pomn Ctr Zdrowia Dziecka, Dept Gastroenterol Hepatol & Feeding Disorders, PL-04730 Warsaw, Poland; [Kolacek, S.] Univ Zagreb, Sch Med, Childrens Hosp, Dept Paediat Gastroenterol, Zagreb 10000, Croatia; [Koletzkou, S.] Dr von Hauner Childrens Hosp, Dept Paediat Gastroenterol, D-80337 Munich, Germany; [Lionetti, P.] Meyer Childrens Hosp, Dept Gastroenterol & Nutr, I-50139 Florence, Italy; [Miele, E.] Univ Naples Federico II, Paediat Sect, Dept Translat Med Sci, I-80131 Naples, Italy; [Navas Lopez, V. M.] Hosp Materno Infantil, Paediat Gastroenterol & Nutr Unit, Malaga 29009, Spain; [Paerregaard, A.] Hvidovre Univ Hosp, Dept Paediat 460, DK-2650 Hvidovre, Denmark; [Russell, R. K.] Yorkhill Hosp, Dept Paediat Gastroenterol, Glasgow G3 8SJ, Lanark, Scotland; [Serban, D. E.] Iuliu Hatieganu Univ Med & Pharm, Emergency Childrens Hosp, Dept Paediat 2, Cluj Napoca 400177, Romania; [Shaoul, R.] Rambam Hlth Care Campus, Rappaport Fac Med, Dept Pediat Gastroenterol & Nutr, IL-31096 Haifa, Israel; [Van Rheenen, P.] Univ Groningen, Univ Med Ctr Groningen, Dept Paediat Gastroenterol Hepatol & Nutr, NL-9700 RB Groningen, Netherlands; [Veereman, G.] Childrens Univ Hosp, Dept Paediat Gastroenterol & Nutr, B-1090 Brussels, Belgium; [Weiss, B.] Edmond & Lily Safra Childrens Hosp, Sheba Med Ctr, Paediat Gastroenterol & Nutr Unit, Tel Hashomer, Israel; [Wilson, D.] Royal Hosp Sick Children, Child Life & Hlth, Edinburgh EH9 1LF, Midlothian, Scotland; [Dignass, A.] Mass Gen Hosp Children, Div Pediat Gastroenterol Hepatol & Nutr, Boston, MA 02114 USA; [Eliakim, A.] Hebrew Univ Jerusalem, Pediat Gastroenterol Unit, Shaare Zedek Med Ctr, IL-91905 Jerusalem, Israel; [Winter, H.] Agaplesion Markus Hosp, Dept Med 1, D-60431 Frankfurt, Germany; [Turner, D.] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel","Ruemmele, FM (reprint author), Univ Paris 05, Hop Necker Enfants Malad, INSERM, Sorbonne Paris Cite,U989, 149 Rue Sevres, F-75015 Paris, France.","frank.ruemmele@nck.aphp.fr",null,null,null,null,null,284,2,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1873-9946","1876-4479",null,"J CROHNS COLITIS","J. Crohns Colitis","OCT 1",2014,8,10,null,null,null,null,1179,1207,null,"10.1016/j.crohns.2014.04.005",null,29,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","AS2RU","WOS:000344128100004",24909831]
["J","McDaniel, D; Fritz, K; Machovcova, A; Bernardy, J",null,null,null,"McDaniel, David; Fritz, Klaus; Machovcova, Alena; Bernardy, Jan",null,null,"A Focused Monopolar Radiofrequency Causes Apoptosis: A Porcine Model","JOURNAL OF DRUGS IN DERMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ADIPOSE-TISSUE; FAT; OBESITY; CELLS","Background: The purpose of this study was to demonstrate the effect of monopolar, focused radiofrequency (RF) with embedded cooling on subcutaneous skin structures. Specifically, the study was to prove that the monopolar RF with cooling can selectively heat fat, causing disintegration of adipocytes and programmed cell death (apoptosis) of the subcutaneous fat cells. Methods: A non-invasive monopolar RF device with cooling (Exilis Elite, BTL Industries, Framingham, MA) was used to reduce abdominal fat in a porcine model. The study was done on 3 Vietnamese pigs in a certified veterinary facility. The treatment was delivered to an area the size of 20 x 10cm. The treatment duration was 11 minutes, 30 seconds. Biopsy samples were taken before the first treatment, 1 hour post each treatment, as well as 8 and 20 hours post each treatment. Programmed cell death (apoptosis) was monitored using the TUNEL method. The temperature was measured on the skin surface by an infrared thermal imager and built-in IR thermometer, and by an internal probe inserted into various depths of the subcutaneous layer. The internal probe placement was monitored by diagnostic ultrasound examination. Results: The temperature in the treated adipose tissue was higher compared to the skin surface temperature. The average temperature gradient observed was 3.1 degrees C. Due to the temperature gradient the skin surface remained intact, while subcutaneous layers showed significant changes. The TUNEL method proved large-scale apoptosis of fat cells after each treatment. The apoptotic index increased from 7% before the first treatment to an average of 53.4%, 39.6%, 40.2%, and 44.7% respectively for each treatment. In the three-month follow up the apoptotic index dropped back to 11.7%. Histology, blood biochemistry and hematology samples showed mild to no signs of inflammation in the treated area. Conclusion: The study has shown that use of monopolar, focused radiofrequency can induce substantial apoptotic process in a porcine model. The data suggests that the monopolar, focused radiofrequency device can be used for reduction of fat and body shaping.","[McDaniel, David] McDaniel Inst Antiaging Res, Virginia Beach, VA 23454 USA; [Fritz, Klaus] Dermatol & Laser Ctr Landau, Landau, Germany; [Fritz, Klaus] Univ Osnabruck, Dept Hlth Sci, D-49069 Osnabruck, Germany; [Machovcova, Alena] Univ Hosp Motol, Dept Dermatol & Venereol, Prague, Czech Republic; [Machovcova, Alena] Charles Univ Prague, Dept Occupat Med, Fac Med 1, Prague, Czech Republic; [Bernardy, Jan] Vet Res Inst, CS-62132 Brno, Czech Republic","McDaniel, D (reprint author), McDaniel Inst Antiaging Res, Virginia Beach, VA 23454 USA.","dhm@drmcdaniel.com",null,null,null,null,null,9,0,0,"JOURNAL OF DRUGS IN DERMATOLOGY","NEW YORK","377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA","1545-9616",null,null,"J DRUGS DERMATOL","J. Drugs Dermatol.","NOV",2014,13,11,null,null,null,null,1336,1340,null,null,null,5,"Dermatology","Dermatology","AT5IJ","WOS:000344976800008",25607699]
["J","Davies, KA; Longshaw, CM; Davis, GL; Bouza, E; Barbut, F; Barna, Z; Delmee, M; Fitzpatrick, F; Ivanova, K; Kuijper, E; Macovei, IS; Mentula, S; Mastrantonio, P; von Muller, L; Oleastro, M; Petinaki, E; Pituch, H; Noren, T; Novakova, E; Nyc, O; Rupnik, M; Schmid, D; Wilcox, MH",null,null,null,"Davies, Kerrie A.; Longshaw, Christopher M.; Davis, Georgina L.; Bouza, Emilio; Barbut, Frederic; Barna, Zsuzsanna; Delmee, Michel; Fitzpatrick, Fidelma; Ivanova, Kate; Kuijper, Ed; Macovei, Ioana S.; Mentula, Silja; Mastrantonio, Paola; von Mueller, Lutz; Oleastro, Monica; Petinaki, Efthymia; Pituch, Hanna; Noren, Torbjorn; Novakova, Elena; Nyc, Otakar; Rupnik, Maja; Schmid, Daniela; Wilcox, Mark H.",null,null,"Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID)","LANCET INFECTIOUS DISEASES",null,null,"English","Article",null,null,null,null,null,null,"CHANGING EPIDEMIOLOGY; ECONOMIC BURDEN; IMPACT; RATES","Background Variations in testing for Clostridium difficile infection can hinder patients' care, increase the risk of transmission, and skew epidemiological data. We aimed to measure the underdiagnosis of C difficile infection across Europe. Methods We did a questionnaire-based study at 482 participating hospitals across 20 European countries. Hospitals were questioned about their methods and testing policy for C difficile infection during the periods September, 2011, to August, 2012, and September, 2012, to August, 2013. On one day in winter, 2012-13 (December, 2012, or January, 2013), and summer, 2013 (July or August), every hospital sent all diarrhoeal samples submitted to their microbiology laboratory to a national coordinating laboratory for standardised testing of C difficile infection. Our primary outcome measures were the rates of testing for and cases of C difficile infection per 10 000 patient bed-days. Results of local and national C difficile infection testing were compared with each other. If the result was positive at the national laboratory but negative at the local hospital, the result was classified as undiagnosed C difficile infection. We compared differences in proportions with the Mann-Whitney test, or McNemar's test if data were matched. Findings During the study period, participating hospitals reported a mean of 65.8 tests (country range 4. 6-223.3) for C difficile infection per 10 000 patient-bed days and a mean of 7.0 cases (country range 0.7-28.7) of C difficile infection per 10 000 patient-bed days. Only two-fifths of hospitals reported using optimum methods for testing of C difficile infection (defined by European guidelines), although the number of participating hospitals using optimum methods increased during the study period, from 152 (32%) of 468 in 2011-12 to 205 (48%) of 428 in 2012-13. Across all 482 European hospitals on the two sampling days, 148 (23%) of 641 samples positive for C difficile infection (as determined by the national laboratory) were not diagnosed by participating hospitals because of an absence of clinical suspicion, equating to about 74 missed diagnoses per day. Interpretation A wide variety of testing strategies for C difficile infection are used across Europe. Absence of clinical suspicion and suboptimum laboratory diagnostic methods mean that an estimated 40 000 inpatients with C difficile infection are potentially undiagnosed every year in 482 European hospitals.","[Davies, Kerrie A.; Davis, Georgina L.; Wilcox, Mark H.] Univ Leeds, EUCLID European Coordinators, Leeds, W Yorkshire, England; [Longshaw, Christopher M.] Astellas Pharma Europe, Chertsey, England; [Bouza, Emilio] Univ Gregorio Maranon, Gen Hosp, Microbiol Clin E Infecc, Catedrat Jefe Serv, Madrid, Spain; [Barbut, Frederic] Univ Paris 06, Natl Reference Lab Clostridium Difficile, Paris, France; [Barna, Zsuzsanna] Natl Ctr Epidemiol, Dept Bacteriol, Budapest, Hungary; [Delmee, Michel] Catholic Univ Louvain, IREC, B-1200 Brussels, Belgium; [Fitzpatrick, Fidelma] Hlth Protect Surveillance Ctr, Dublin, Ireland; [Fitzpatrick, Fidelma] Beaumont Hosp, Dublin 9, Ireland; [Ivanova, Kate] Natl Ctr Infect & Parasit Dis, Sofia, Bulgaria; [Kuijper, Ed] Leiden Univ, Med Ctr, Dept Med Microbiol, Leiden, Netherlands; [Macovei, Ioana S.] Cantacuzino Natl Inst Res & Dev Microbiol & Immun, Bucharest, Romania; [Mentula, Silja] Natl Inst Hlth & Welf THL, Bacteriol Unit, Helsinki, Finland; [Mastrantonio, Paola] Ist Super Sanita, Dept Infect Dis, I-00161 Rome, Italy; [von Mueller, Lutz] Univ Saarland, Med Ctr, Inst Med Microbiol & Hyg, Homburg, Germany; [Oleastro, Monica] Natl Inst Hlth Dr Ricardo Jorge, Dept Infect Dis, Lisbon, Portugal; [Petinaki, Efthymia] Univ Thessalia, Univ Hosp, Sch Med, Larisa, Greece; [Pituch, Hanna] Med Univ Warsaw, Dept Med Microbiol, Warsaw, Poland; [Noren, Torbjorn] Orebro Univ Hosp, Orebro, Sweden; [Novakova, Elena] Comenius Univ, Jessenius Fac Med Martin, Martin, TN, Slovakia; [Nyc, Otakar] Univ Hosp Motol, Dept Med Microbiol, Prague, Czech Republic; [Rupnik, Maja] Univ Maribor, Fac Med, SLO-2000 Maribor, Slovenia; [Rupnik, Maja] Natl Lab Hlth Environm & Food NLZOH, Maribor, Slovenia; [Schmid, Daniela] Austrian Agcy Hlth & Food Safety, Inst Med Microbiol & Hyg, Vienna, Austria","Wilcox, MH (reprint author), Leeds Teaching Hosp NHS Trust, Dept Microbiol, Leeds LS1 3EX, W Yorkshire, England.","mark.wilcox@leedsth.nhs.uk",null,null,"Astellas Pharmaceuticals Europe","Astellas Pharmaceuticals Europe.",null,30,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1473-3099","1474-4457",null,"LANCET INFECT DIS","Lancet Infect. Dis.","DEC",2014,14,12,null,null,null,null,1208,1219,null,"10.1016/S1473-3099(14)70991-0",null,12,"Infectious Diseases","Infectious Diseases","AU6NS","WOS:000345720200033",25455988]
["J","McKone, EF; Borowitz, D; Drevinek, P; Griese, M; Konstan, MW; Wainwright, C; Ratjen, F; Sermet-Gaudelus, I; Plant, B; Munck, A; Jiang, Y; Gilmartin, G; Davies, JC",null,null,null,"McKone, Edward F.; Borowitz, Drucy; Drevinek, Pavel; Griese, Matthias; Konstan, Michael W.; Wainwright, Claire; Ratjen, Felix; Sermet-Gaudelus, Isabelle; Plant, Barry; Munck, Anne; Jiang, Ying; Gilmartin, Geoffrey; Davies, Jane C.",null,"VX08 770 105 PERSIST Study Grp","Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","LANCET RESPIRATORY MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"QUALITY-OF-LIFE; PULMONARY EXACERBATIONS; CFTR POTENTIATOR; INHALED TOBRAMYCIN; CONTROLLED-TRIAL; G551D MUTATION; DORNASE ALPHA; CLINICAL-USE; DECLINE; VX-770","Background Ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, is approved for the treatment of patients with cystic fibrosis aged 6 years or older with Gly551Asp-CFTR. We assessed the safety and efficacy of ivacaftor during 96 weeks of PERSIST in patients with cystic fibrosis who completed a previous 48-week, placebo-controlled trial of the drug (STRIVE or ENVISION). Methods In this phase 3, open-label extension study, patients received ivacaftor 150 mg every 12 h in addition to their prescribed cystic fibrosis therapies. Patients who received placebo in their previous study initiated ivacaftor in this extension study. Patients were eligible if they had a Gly551Asp-CFTR mutation on at least one allele. The primary objective was to assess the long-term safety profile of ivacaftor as assessed by adverse events, clinical laboratory assessments, electrocardiograms, vital signs, and physical examination; secondary measures included change in forced expiratory volume in one second (FEV1), weight, and pulmonary exacerbations. This study is registered with ClinicalTrials.gov, number NCT01117012 and EudraCT, number 2009-012997-11. Findings Between July 8, 2010, and April 8, 2013, 144 adolescents/adults (>= 12 years) from STRIVE and 48 children (6-11 years) from ENVISION were enrolled. Across both trials, 38 (20%) patients had a serious adverse event during the first 48 weeks and 44(23%) during the subsequent 48 weeks. Two adults (1%) and one child (<1%) discontinued because of adverse events. The most common adverse events were pulmonary exacerbation, cough, and upper respiratory tract infection. Patients previously treated with ivacaftor had sustained improvements in FEV1, weight, and rate of pulmonary exacerbations for up to 144 weeks of treatment. Among adolescents/adults and children who previously received ivacaftor, absolute change FEV1 at week 96 (144 weeks ivacaftor) was 9.4 and 10.3% points and absolute increase in weight was 4.1 kg and 14.8 kg, respectively. For adolescents/adults only, the pulmonary exacerbation rate remained suppressed compared with that of patients who received placebo in the placebo-controlled study. Interpretation At 144 weeks of treatment, ivacaftor was well tolerated, with no new safety concerns. Ivacaftor also provided durable effects for 144 weeks in patients who had received active treatment in the placebo-controlled study. Those patients who previously received placebo had improvements comparable to those of patients treated with ivacaftor in the placebo-controlled study.","[McKone, Edward F.] St Vincents Univ Hosp, Dublin 4, Ireland; [McKone, Edward F.] Univ Coll Dublin, Sch Med, Dublin 2, Ireland; [Borowitz, Drucy] SUNY Buffalo, Buffalo, NY 14260 USA; [Drevinek, Pavel] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Drevinek, Pavel] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Griese, Matthias] Hauner Childrens Hosp, Munich, Germany; [Griese, Matthias] Univ Munich, Munich, Germany; [Konstan, Michael W.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Konstan, Michael W.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Wainwright, Claire] Univ Queensland, Royal Childrens Hosp, Brisbane, Qld, Australia; [Wainwright, Claire] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Ratjen, Felix] Hosp Sick Children, Dept Pediat, Div Resp Med, Toronto, ON M5G 1X8, Canada; [Ratjen, Felix] Univ Toronto, Toronto, ON, Canada; [Sermet-Gaudelus, Isabelle] Univ Paris 04, AP HP, INSERM, U1151, Paris, France; [Plant, Barry] Natl Univ Ireland Univ Coll Cork, Cork Univ Hosp, Cork, Ireland; [Munck, Anne] Univ Paris 07, Hop Robert Debre, AP HP, CF Ctr, Paris, France; [Jiang, Ying; Gilmartin, Geoffrey] Vertex Pharmaceut Inc, Boston, MA USA; [Davies, Jane C.] Royal Brompton Hosp, London SW3 6LY, England","McKone, EF (reprint author), St Vincents Univ Hosp, Natl Referral Ctr Adult Cyst Fibrosis, Dublin 4, Ireland.","e.mckone@svuh.ie",null,null,"Vertex Pharmaceuticals Inc.","Vertex Pharmaceuticals Inc.",null,29,0,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","2213-2600",null,null,"LANCET RESP MED","Lancet Resp. Med.","NOV",2014,2,11,null,null,null,null,902,910,null,"10.1016/52213-2600(14)70218-8",null,9,"Respiratory System","Respiratory System","AT4KY","WOS:000344909400016",25311995]
["J","Hlavac, V; Brynychova, V; Vaclavikova, R; Ehrlichova, M; Vrana, D; Pecha, V; Trnkova, M; Kodet, R; Mrhalova, M; Kubackova, K; Gatek, J; Vazan, P; Soucek, P",null,null,null,"Hlavac, Viktor; Brynychova, Veronika; Vaclavikova, Radka; Ehrlichova, Marie; Vrana, David; Pecha, Vaclav; Trnkova, Marketa; Kodet, Roman; Mrhalova, Marcela; Kubackova, Katerina; Gatek, Jiri; Vazan, Petr; Soucek, Pavel",null,null,"The Role of Cytochromes P450 and Aldo-Keto Reductases in Prognosis of Breast Carcinoma Patients","MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"ESTROGEN-RECEPTOR-ALPHA; HUMAN LIVER-MICROSOMES; CARBONYL REDUCTASE; METABOLIZING-ENZYMES; CANCER PATIENTS; EXPRESSION; GENES; TUMOR; CYCLOPHOSPHAMIDE; ACTIVATION","Metabolism of anticancer drugs affects their antitumor effects. This study has investigated the associations of gene expression of enzymes metabolizing anticancer drugs with therapy response and survival of breast carcinoma patients. Gene expression of 13 aldo-keto reductases (AKRs), carbonyl reductase 1, and 10 cytochromes P450 (CYPs) was assessed using quantitative real-time polymerase chain reaction in tumors and paired adjacent nonneoplastic tissues from 68 posttreatment breast carcinoma patients. Eleven candidate genes were then evaluated in an independent series of 50 pretreatment patients. Protein expression of the most significant genes was confirmed by immunoblotting. AKR1A1 was significantly overexpressed and AKR1C1-4, KCNAB1, CYP2C19, CYP3A4, and CYP3A5 downregulated in tumors compared with control nonneoplastic tissues after correction for multiple testing. Significant association of CYP2B6 transcript levels in tumors with expression of hormonal receptors was found in the posttreatment set and replicated in the pretreatment set of patients. Significantly higher intratumoral levels of AKR1C1, AKR1C2, or CYP2W1 were found in responders to neoadjuvant chemotherapy compared with nonresponders. Patients with high AKR7A3 or CYP2B6 levels in the pretreatment set had significantly longer disease-free survival than patients with low levels. Protein products of AKR1C1, AKR1C2, AKR7A3, CYP3A4, and carbonyl reductase (CBR1) were found in tumors and those of AKR1C1, AKR7A3, and CBR1 correlated with their transcript levels. Small interfering RNA-directed knockdown of AKR1C2 or vector-mediated upregulation of CYP3A4 in MDA-MB-231 model cell line had no effect on cell proliferation after paclitaxel treatment in vitro. Prognostic and predictive roles of drug-metabolizing enzymes strikingly differ between posttreatment and pretreatment breast carcinoma patients. Mechanisms of action of AKR1C2, AKR7A3, CYP2B6, CYP3A4, and CBR1 should continue to be further followed in breast carcinoma patients and models.","[Hlavac, Viktor; Brynychova, Veronika; Vaclavikova, Radka; Ehrlichova, Marie; Vrana, David; Soucek, Pavel] Natl Inst Publ Hlth, Toxicogen Unit, Prague 10042, Czech Republic; [Hlavac, Viktor; Brynychova, Veronika; Ehrlichova, Marie] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Vrana, David] Palacky Univ, Dept Oncol, Sch Med, CR-77147 Olomouc, Czech Republic; [Vrana, David] Teaching Hosp, Olomouc, Czech Republic; [Pecha, Vaclav] Inst Care Mother & Child, Zlin, Czech Republic; [Trnkova, Marketa] Biolab Praha Ltd, Zlin, Czech Republic; [Kodet, Roman; Mrhalova, Marcela] Univ Hosp Motol, Dept Pathol & Mol Med, Prague, Czech Republic; [Kubackova, Katerina] Univ Hosp Motol, Dept Oncol, Prague, Czech Republic; [Gatek, Jiri] Hosp Atlas, Dept Surg, Zlin, Czech Republic; [Gatek, Jiri] Tomas Bata Univ, Zlin, Czech Republic; [Vazan, Petr] VELAB Ltd, Dept Pathol, Zlin, Czech Republic","Soucek, P (reprint author), Natl Inst Publ Hlth, Toxicogen Unit, Dept Toxicol & Safety, Srobarova 48, Prague 10042, Czech Republic.","psoucek@szu.cz",null,null,"Czech Science Foundation [13-25222J]; Internal Grant Agency of the Czech Ministry of Health [NT/14055-3]","This work was supported by the grants of the Czech Science Foundation No. 13-25222J and the Internal Grant Agency of the Czech Ministry of Health No. NT/14055-3.",null,43,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA","0025-7974","1536-5964",null,"MEDICINE","Medicine (Baltimore)","DEC",2014,93,28,null,null,null,null,null,null,null,"10.1097/MD.0000000000000255",null,12,"Medicine, General & Internal","General & Internal Medicine","AX2GS","WOS:000346762200020",25526449]
["J","Lizcova, L; Zemanova, Z; Lhotska, H; Zuna, J; Hovorkova, L; Mejstrikova, E; Malinova, E; Rabasova, J; Raska, I; Sramkova, L; Stary, J; Michalova, K",null,null,null,"Lizcova, Libuse; Zemanova, Zuzana; Lhotska, Halka; Zuna, Jan; Hovorkova, Lenka; Mejstrikova, Ester; Malinova, Eva; Rabasova, Jana; Raska, Ivan; Sramkova, Lucie; Stary, Jan; Michalova, Kyra",null,null,"An unusual case of high hyperdiploid childhood ALL with cryptic BCR/ABL1 rearrangement","MOLECULAR CYTOGENETICS",null,null,"English","Article",null,null,null,null,null,"High-hyperdiploid childhood ALL; Ph-negative childhood ALL; BCR/ABL1 fusion; FISH; CGH-SNP array","ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMERASE-CHAIN-REACTION; RESIDUAL DISEASE DETECTION; IN-SITU HYBRIDIZATION; CANCER PROGRAM; GENE; PATTERNS; EUROPE","Background: Both high hyperdiploidy (HeH) and the translocation t(9;22)(q34;q11) are recurrent abnormalities in childhood B-cell acute lymphoblastic leukemia (ALL) and both are used in current classification to define different genetic and prognostic subtypes of the disease. The coexistence of these two primary genetic aberrations within the same clone is very rare in children with ALL. Here we report a new case of a 17-year-old girl with newly diagnosed ALL and uncommon cytogenetic and clinical finding combining high hyperdiploidy and a cryptic BCR/ABL1 fusion and an inherited Charcot-Marie-Tooth neuropathy detected during the induction treatment. Results: High hyperdiploid karyotype 51,XX,+X,+4,+14,+17,+21 without apparent structural aberrations was detected by conventional cytogenetic analysis and multicolor FISH. A cryptic BCR/ABL1 fusion, which was caused by the insertion of part of the ABL1 gene into the 22q11 region, was proved in HeH clone by FISH, RT-PCR and CGH-SNP array. In addition, an abnormal FISH pattern previously described as the deletion of the 3'BCR region in some BCR/ABL1 positive cases was not proved in our patient. Conclusion: A novel case of extremely rare childhood ALL, characterized by HeH and a cryptic BCR/ABL1 fusion, is presented and to the best of our knowledge described for the first time. The insertion of ABL1 into the BCR region in malignant cells is supposed. Clearly, further studies are needed to determine the genetic consequences and prognostic implications of these unusual cases.","[Lizcova, Libuse; Zemanova, Zuzana; Lhotska, Halka; Malinova, Eva; Michalova, Kyra] Charles Univ Prague, Inst Med Biochem & Lab Diagnost, Ctr Oncocytogenet, Gen Univ Hosp Prague, Prague, Czech Republic; [Lizcova, Libuse; Zemanova, Zuzana; Lhotska, Halka; Malinova, Eva; Michalova, Kyra] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Zuna, Jan; Hovorkova, Lenka] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CLIP Childhood Leukaemia Investigat Prague, Prague, Czech Republic; [Mejstrikova, Ester; Rabasova, Jana] Fac Hosp Hradec Kralove, Dept Med Genet, Hradec Kralove, Czech Republic; [Raska, Ivan] Charles Univ Prague, Fac Med 1, Inst Cellular Biol & Pathol, Prague, Czech Republic; [Sramkova, Lucie; Stary, Jan] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Sramkova, Lucie; Stary, Jan] Univ Hosp Motol, Prague, Czech Republic","Lizcova, L (reprint author), Charles Univ Prague, Inst Med Biochem & Lab Diagnost, Ctr Oncocytogenet, Gen Univ Hosp Prague, Prague, Czech Republic.","libuse.lizcova@vfn.cz",null,null,"Czech Ministry of Health [RVO-VFN64165]; IGA [NT14350-3]; Czech Science Foundation [GACR-P302/12/G157]","This work was supported by grants from the Czech Ministry of Health RVO-VFN64165, and IGA NT14350-3 and the Czech Science Foundation GACR-P302/12/G157.",null,18,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1755-8166",null,null,"MOL CYTOGENET","Mol. Cytogenet.","OCT 24",2014,7,null,null,null,null,null,null,null,72,"10.1186/s13039-014-0072-9",null,5,"Genetics & Heredity","Genetics & Heredity","AS2OM","WOS:000344119500001",25360156]
["J","Scelo, G; Riazalhosseini, Y; Greger, L; Letourneau, L; Gonzalez-Porta, M; Wozniak, MB; Bourgey, M; Harnden, P; Egevad, L; Jackson, SM; Karimzadeh, M; Arseneault, M; Lepage, P; How-Kit, A; Daunay, A; Renault, V; Blanche, H; Tubacher, E; Sehmoun, J; Viksna, J; Celms, E; Opmanis, M; Zarins, A; Vasudev, NS; Seywright, M; Abedi-Ardekani, B; Carreira, C; Selby, PJ; Cartledge, JJ; Byrnes, G; Zavadil, J; Su, J; Holcatova, I; Brisuda, A; Zaridze, D; Moukeria, A; Foretova, L; Navratilova, M; Mates, D; Jinga, V; Artemov, A; Nedoluzhko, A; Mazur, A; Rastorguev, S; Boulygina, E; Heath, S; Gut, M; Bihoreau, MT; Lechner, D; Foglio, M; Gut, IG; Skryabin, K; Prokhortchouk, E; Cambon-Thomsen, A; Rung, J; Bourque, G; Brennan, P; Tost, J; Banks, RE; Brazma, A; Lathrop, GM",null,null,null,"Scelo, Ghislaine; Riazalhosseini, Yasser; Greger, Liliana; Letourneau, Louis; Gonzalez-Porta, Mar; Wozniak, Magdalena B.; Bourgey, Mathieu; Harnden, Patricia; Egevad, Lars; Jackson, Sharon M.; Karimzadeh, Mehran; Arseneault, Madeleine; Lepage, Pierre; How-Kit, Alexandre; Daunay, Antoine; Renault, Victor; Blanche, Helene; Tubacher, Emmanuel; Sehmoun, Jeremy; Viksna, Juris; Celms, Edgars; Opmanis, Martins; Zarins, Andris; Vasudev, Naveen S.; Seywright, Morag; Abedi-Ardekani, Behnoush; Carreira, Christine; Selby, Peter J.; Cartledge, Jon J.; Byrnes, Graham; Zavadil, Jiri; Su, Jing; Holcatova, Ivana; Brisuda, Antonin; Zaridze, David; Moukeria, Anush; Foretova, Lenka; Navratilova, Marie; Mates, Dana; Jinga, Viorel; Artemov, Artem; Nedoluzhko, Artem; Mazur, Alexander; Rastorguev, Sergey; Boulygina, Eugenia; Heath, Simon; Gut, Marta; Bihoreau, Marie-Therese; Lechner, Doris; Foglio, Mario; Gut, Ivo G.; Skryabin, Konstantin; Prokhortchouk, Egor; Cambon-Thomsen, Anne; Rung, Johan; Bourque, Guillaume; Brennan, Paul; Tost, Joerg; Banks, Rosamonde E.; Brazma, Alvis; Lathrop, G. Mark",null,null,"Variation in genomic landscape of clear cell renal cell carcinoma across Europe","NATURE COMMUNICATIONS",null,null,"English","Article",null,null,null,null,null,null,"SOMATIC MUTATIONS; KIDNEY CANCER; PROGNOSTIC-SIGNIFICANCE; ARISTOLOCHIC ACID; WIDE ASSOCIATION; GENE ALTERATIONS; SEQUENCING DATA; RNA-SEQ; NEPHROPATHY; EXPRESSION","The incidence of renal cell carcinoma (RCC) is increasing worldwide, and its prevalence is particularly high in some parts of Central Europe. Here we undertake whole-genome and transcriptome sequencing of clear cell RCC (ccRCC), the most common form of the disease, in patients from four different European countries with contrasting disease incidence to explore the underlying genomic architecture of RCC. Our findings support previous reports on frequent aberrations in the epigenetic machinery and PI3K/mTOR signalling, and uncover novel pathways and genes affected by recurrent mutations and abnormal transcriptome patterns including focal adhesion, components of extracellular matrix (ECM) and genes encoding FAT cadherins. Furthermore, a large majority of patients from Romania have an unexpected high frequency of A:T>T:A transversions, consistent with exposure to aristolochic acid (AA). These results show that the processes underlying ccRCC tumorigenesis may vary in different populations and suggest that AA may be an important ccRCC carcinogen in Romania, a finding with major public health implications.","[Scelo, Ghislaine; Wozniak, Magdalena B.; Abedi-Ardekani, Behnoush; Carreira, Christine; Byrnes, Graham; Zavadil, Jiri; Brennan, Paul] IARC, F-69008 Lyon, France; [Riazalhosseini, Yasser; Karimzadeh, Mehran; Arseneault, Madeleine; Bourque, Guillaume; Lathrop, G. Mark] McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada; [Riazalhosseini, Yasser; Letourneau, Louis; Bourgey, Mathieu; Karimzadeh, Mehran; Arseneault, Madeleine; Lepage, Pierre; Bourque, Guillaume; Lathrop, G. Mark] McGill Univ, Montreal, PQ H3A 0G1, Canada; [Riazalhosseini, Yasser; Letourneau, Louis; Bourgey, Mathieu; Karimzadeh, Mehran; Arseneault, Madeleine; Lepage, Pierre; Bourque, Guillaume; Lathrop, G. Mark] Genome Quebec Innovat Ctr, Montreal, PQ H3A 0G1, Canada; [Greger, Liliana; Gonzalez-Porta, Mar; Su, Jing; Rung, Johan; Brazma, Alvis] EMBL EBI, European Bioinformat Inst, European Mol Biol Lab, Hinxton CB10 1SD, Cambs, England; [Harnden, Patricia; Jackson, Sharon M.; Vasudev, Naveen S.; Selby, Peter J.; Banks, Rosamonde E.] Univ Leeds, St Jamess Univ Hosp, Leeds Inst Canc & Pathol, Leeds LS9 7TF, W Yorkshire, England; [Egevad, Lars] Karolinska Inst, Dept Pathol, SE-17177 Stockholm, Sweden; [How-Kit, Alexandre; Daunay, Antoine; Renault, Victor; Blanche, Helene; Tubacher, Emmanuel; Sehmoun, Jeremy; Lathrop, G. Mark] Fdn Jean Dausset, Ctr Etude Polymorphisme Humain, F-75010 Paris, France; [Viksna, Juris; Celms, Edgars; Opmanis, Martins; Zarins, Andris] Univ Latvia, Inst Math & Comp Sci, LV-1459 Riga, Latvia; [Seywright, Morag] Beatson Inst Canc Res, Dept Pathol, Glasgow G61 1BD, Lanark, Scotland; [Cartledge, Jon J.] St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Pyrah Dept Urol, Leeds LS9 7TF, W Yorkshire, England; [Holcatova, Ivana] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague 12800, Czech Republic; [Brisuda, Antonin] Univ Hosp Motol, Prague 15006, Czech Republic; [Zaridze, David; Moukeria, Anush] Russian NN Blokhin Canc Res Ctr, Moscow 115478, Russia; [Foretova, Lenka; Navratilova, Marie] Masaryk Mem Canc Inst, Dept Canc Epidemiol & Genet, Brno 65653, Czech Republic; [Foretova, Lenka; Navratilova, Marie] MF MU, Brno 65653, Czech Republic; [Mates, Dana] Natl Inst Publ Hlth, Bucharest 050463, Romania; [Jinga, Viorel] Carol Davila Univ Med & Pharm, Burghele Hosp, Bucharest 050659, Romania; [Artemov, Artem; Mazur, Alexander; Skryabin, Konstantin; Prokhortchouk, Egor] Russian Acad Sci, Ctr Bioengn, Moscow 117312, Russia; [Nedoluzhko, Artem; Rastorguev, Sergey; Boulygina, Eugenia; Skryabin, Konstantin; Prokhortchouk, Egor] Kurchatov Inst, Natl Res Ctr, Moscow 123182, Russia; [Heath, Simon; Gut, Marta; Gut, Ivo G.] Ctr Nacl Anal Genom, Barcelona 08028, Spain; [Bihoreau, Marie-Therese; Lechner, Doris; Foglio, Mario; Tost, Joerg; Lathrop, G. Mark] CEA, Inst Genom, Ctr Natl Genotypage, F-91000 Evry, France; [Cambon-Thomsen, Anne] Univ Toulouse 3, INSERM, F-31000 Toulouse, France","Lathrop, GM (reprint author), McGill Univ, Dept Human Genet, 1205 Dr Penfield Ave, Montreal, PQ H3A 1B1, Canada.","tania.abouyounes@mail.mcgill.ca",null,null,"EU [241669]; Genome Quebec, le Ministere de l'Enseignement superieur, de la Recherche, de la Science et de la Technologie (MESRST) Quebec; McGill University; Cancer Research UK Centre; MH CZ-DRO (MMCI) [00209805]; RECAMO, Brno, Czech Republic [CZ.1.05/2.1.00/03.0101]; Compute Canada","This study was supported by the EU FP7 under grant agreement number 241669 (the CAGEKID project, http://www.cng.fr/cagekid) and a grant from Genome Quebec, le Ministere de l'Enseignement superieur, de la Recherche, de la Science et de la Technologie (MESRST) Quebec and McGill University. We also acknowledge the support of Cancer Research UK Centre and ECMC infrastructure funding in Leeds, and are grateful to the sample processing, urology, pathology and oncology clinical teams at St James's University Hospital, Leeds. This work was also supported in part by MH CZ-DRO (MMCI, 00209805) and RECAMO, CZ.1.05/2.1.00/03.0101, Brno, Czech Republic. We are grateful to the patients for consenting to take part in this study. We thank Eamonn Maher and Joerg Hoheisel for valuable advice on the project. This research was enabled in part by support provided by Compute Canada.",null,70,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","2041-1723",null,null,"NAT COMMUN","Nat. Commun.","OCT",2014,5,null,null,null,null,null,null,null,5135,"10.1038/ncomms6135",null,13,"Multidisciplinary Sciences","Science & Technology - Other Topics","AS0PQ","WOS:000343980300009",25351205]
["J","Mannil, M; Solari, A; Leha, A; Pelayo-Negro, AL; Berciano, J; Schlotter-Weigel, B; Walter, MC; Rautenstrauss, B; Schnizer, TJ; Schenone, A; Seeman, P; Kadian, C; Schreiber, O; Angarita, NG; Fabrizi, GM; Gemignani, F; Padua, L; Santoro, L; Quattrone, A; Vita, G; Calabrese, D; Young, P; Laura, M; Haberlova, J; Mazanec, R; Paulus, W; Beissbarth, T; Shy, ME; Reilly, MM; Pareyson, D; Sereda, MW",null,null,null,"Mannil, Manoj; Solari, Alessandra; Leha, Andreas; Pelayo-Negro, Ana L.; Berciano, Jose; Schlotter-Weigel, Beate; Walter, Maggie C.; Rautenstrauss, Bernd; Schnizer, Tuuli J.; Schenone, Angelo; Seeman, Pavel; Kadian, Chandini; Schreiber, Olivia; Angarita, Natalia G.; Fabrizi, Gian Maria; Gemignani, Franco; Padua, Luca; Santoro, Lucio; Quattrone, Aldo; Vita, Giuseppe; Calabrese, Daniela; Young, Peter; Laura, Matilde; Haberlova, Jana; Mazanec, Radim; Paulus, Walter; Beissbarth, Tim; Shy, Michael E.; Reilly, Mary M.; Pareyson, Davide; Sereda, Michael W.",null,"CMT-TRIAAL CMT-TRAUK Grp","Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients","NEUROMUSCULAR DISORDERS",null,null,"English","Article",null,null,null,null,null,"Charcot-Marie-Tooth; CMT1A; HMSN; Secondary clinical outcome measures; CMTNS; Score generation","R-PACKAGE; 1A; RELIABILITY; DUPLICATION; CHROMOSOME-17; VARIABILITY; VALIDATION; TYPE-1A","This study evaluates primary and secondary clinical outcome measures in Charcot-Marie-Tooth disease type 1A (CMT1A) with regard to their contribution towards discrimination of disease severity. The nine components of the composite Charcot-Marie-Tooth disease Neuropathy Score and six additional secondary clinical outcome measures were assessed in 479 adult patients with genetically proven CMT1A and 126 healthy controls. Using hierarchical clustering, we identified four significant clusters of patients according to clinical severity. We then tested the impact of each of the CMTNS components and of the secondary clinical parameters with regard to their power to differentiate these four clusters. The CMTNS components ulnar sensory nerve action potential (SNAP), pin sensibility, vibration and strength of arms did not increase the discriminant value of the remaining five CMTNS components (Ulnar compound motor action potential [CMAP], leg motor symptoms, arm motor symptoms, leg strength and sensory symptoms). However, three of the six additional clinical outcome measures the 10 m-timed walking test (T10MW), 9 hole-peg test (9HPT), and foot dorsal flexion dynamometry further improved discrimination between severely and mildly affected patients. From these findings, we identified three different composite measures as score hypotheses and compared their discriminant power with that of the CMTNS. A composite of eight components CMAP, Motor symptoms legs, Motor symptoms arms, Strength of Legs, Sensory symptoms), displayed the strongest power to discriminate between the clusters. As a conclusion, five items from the CMTNS and three secondary clinical outcome measures improve the clinical assessment of patients with CMT1A significantly and are beneficial for upcoming clinical and therapeutic trials. (C) 2014 Elsevier B.V. All rights reserved.","[Paulus, Walter; Sereda, Michael W.] Univ Med Ctr Gottingen, Dept Clin Neurophysiol, Gottingen, Germany; [Solari, Alessandra] IRCCS Fdn, C Besta Neurol Inst, Unit Neuroepidemiol, Milan, Italy; [Leha, Andreas; Beissbarth, Tim] Univ Med Ctr Groningen, Dept Med Stat, Gottingen, Germany; [Pelayo-Negro, Ana L.; Berciano, Jose] Univ Hosp Marques de Valdecilla IDIVAL, Serv Neurol, UC, Santander, Spain; [Pelayo-Negro, Ana L.; Berciano, Jose] CIBERNED, Santander, Spain; [Schlotter-Weigel, Beate; Walter, Maggie C.; Schreiber, Olivia; Angarita, Natalia G.] Univ Munich, Dept Neurol, Friedrich Baur Inst, Munich, Germany; [Rautenstrauss, Bernd] Med Genet Zentrum, Munich, Germany; [Schenone, Angelo] Univ Genoa, Dept Neurol Ophthalmol & Genet, Genoa, Italy; [Schenone, Angelo] IRRCS San Martino IST, Genoa, Italy; [Seeman, Pavel; Haberlova, Jana; Mazanec, Radim] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Seeman, Pavel; Haberlova, Jana; Mazanec, Radim] Univ Hosp Motol, Prague, Czech Republic; [Kadian, Chandini] Univ Zurich, Dept Biochem, Zurich, Switzerland; [Fabrizi, Gian Maria] Univ Verona, Dept Neurol Neuropsychol Morphol & Motor Sci, I-37100 Verona, Italy; [Gemignani, Franco] Univ Parma, Dept Neurosci, I-43100 Parma, Italy; [Padua, Luca] Univ Cattolica Sacro Cuore, Dept Neurosci, I-00168 Rome, Italy; [Padua, Luca] Univ Cattolica Sacro Cuore, Don Gnocchi Fdn, I-00168 Rome, Italy; [Santoro, Lucio] Dept Neurol Sci, Naples, Italy; [Quattrone, Aldo] Magna Graecia Univ Catanzaro, Neurol Clin, Catanzaro, Italy; [Quattrone, Aldo] CNR, Neuroimaging Res Unit, Catanzaro, Italy; [Vita, Giuseppe] Univ Messina, Dept Neurosci, Messina, Italy; [Vita, Giuseppe] Fdn Aurora Onlus, Clin Ctr NEMO SUD, Messina, Italy; [Calabrese, Daniela; Pareyson, Davide] IRCCS Fdn, C Besta Neurol Inst, Clin Cent & Peripheral Degenerat Neuropathies Uni, Dept Clin Neurosci, Milan, Italy; [Young, Peter] Univ Munster, Dept Sleep Med & Neuromuscular Disorders, D-48149 Munster, Germany; [Laura, Matilde; Reilly, Mary M.] Natl Hosp Neurol, UCL Inst Neurol, MRC, Ctr Neuromuscular Dis, London WC1N 3BG, England; [Mannil, Manoj; Schnizer, Tuuli J.; Sereda, Michael W.] Max Planck Inst Expt Med, Dept Neurogenet, Res Grp Mol & Translat Neurol, D-37075 Gottingen, Germany; [Shy, Michael E.] Univ Iowa, Dept Neurol, Carver Coll Med, Iowa City, IA 52242 USA","Pareyson, D (reprint author), IRCCS Fdn, C Besta Neurol Inst, Clin Cent & Peripheral Degenerat Neuropathies Uni, Dept Clin Neurosci, Milan, Italy.","davide.pareyson@istituto-besta.it; sereda@em.mpg.de","Paulus, Walter/A-3544-2009","Paulus, Walter/0000-0001-5549-8377",null,null,null,30,0,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0960-8966","1873-2364",null,"NEUROMUSCULAR DISORD","Neuromusc. Disord.","NOV",2014,24,11,null,null,null,null,1003,1017,null,"10.1016/j.nmd.2014.06.431",null,15,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","AU6TC","WOS:000345733600011",25085517]
["J","Dudova, I; Markova, D; Kasparova, M; Zemankova, J; Beranova, S; Urbanek, T; Hrdlicka, M",null,null,null,"Dudova, Iva; Markova, Daniela; Kasparova, Martina; Zemankova, Jana; Beranova, Stepanka; Urbanek, Tomas; Hrdlicka, Michal",null,null,"Comparison of three screening tests for autism in preterm children with birth weights less than 1,500 grams","NEUROPSYCHIATRIC DISEASE AND TREATMENT",null,null,"English","Article",null,null,null,null,null,"autism spectrum disorders; preterm children; screening; Modified Checklist for Autism in Toddlers; Communication and Symbolic Behavior Scales Developmental Profile Infant-Toddler Checklist; Infant/Toddler Sensory Profile","SPECTRUM DISORDERS; MODIFIED CHECKLIST; INFANTS; AGE; PREVALENCE; TODDLERS; OUTCOMES; RISK; BORN","Background: Preterm children seem to be at increased risk for autism spectrum disorders (ASD). Methods: Parents of 157 children with birth weights less than 1,500 g (age 2 years, corrected for prematurity; 88 boys, 69 girls) completed screening questionnaires. The screening battery included the Modified Checklist for Autism in Toddlers (M-CHAT), Communication and Symbolic Behavior Scales Developmental Profile Infant-Toddler Checklist (CSBS-DP-ITC), and the Infant/Toddler Sensory Profile (ITSP). Children with disabilities were excluded. All children who screened positive on any of the screening tools were subsequently assessed by clinical examination including the Autism Diagnostic Observation Schedule. Results: Fifty-six children (35.7%) screened positive on at least one of the parental screening questionnaires. Of the 56 children who tested positive, 33 participated in the detailed clinical follow-up assessment. A diagnosis of ASD was confirmed in 13 of the 33 children. The ASD prevalence was 9.7% of the sample. Analysis of children with and without an ASD diagnosis found significant differences relative to gestational age (26.9 weeks vs 28.3 weeks, P=0.033) and length of the stay in hospital (89.5 days vs 75.4 days, P=0.042). The screening tool with the most positive results was CSBS-DP-ITC (42 positive screens [PS]), followed by M-CHAT (28 PS), and ITSP (22 PS). Differences in the frequency of PS among the tests were significant (P=0.008). CSBS-DP-ITC had the highest sensitivity (0.846), followed by M-CHAT (0.692) and ITSP (0.462). Conclusion: Our results indicate a higher prevalence of autism in children with birth weights <1,500 g at 2 years of age compared to the general population prevalence. The ASD diagnosis was associated with shorter gestation times and longer hospital stays. Our findings support the simultaneous use of more than one screening tests in order to increase screening sensitivity.","[Dudova, Iva; Beranova, Stepanka; Hrdlicka, Michal] Charles Univ Prague, Fac Med 2, Dept Child Psychiat, Prague 15006, Czech Republic; [Dudova, Iva; Kasparova, Martina; Beranova, Stepanka; Hrdlicka, Michal] Univ Hosp Motol, Prague, Czech Republic; [Markova, Daniela] Charles Univ Prague, Fac Med 1, Dept Pediat & Adolescent Med, Prague, Czech Republic; [Markova, Daniela] Gen Univ Hosp, Prague, Czech Republic; [Kasparova, Martina] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 15006, Czech Republic; [Zemankova, Jana] Charles Univ Prague, Fac Med, Dept Pediat, Hradec Kralove, Czech Republic; [Zemankova, Jana] Univ Hosp, Hradec Kralove, Czech Republic; [Urbanek, Tomas] Acad Sci, Inst Psychol, Brno, Czech Republic","Dudova, I (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Child Psychiat, V Uvalu 84, Prague 15006, Czech Republic.","iva.dudova@lfmotol.cuni.cz","Urbanek, Tomas/G-9427-2014","Urbanek, Tomas/0000-0002-8807-4869","Ministry of Education, Youth and Sports, Czech Republic [COST LD11028]; Ministry of Health, Czech Republic [IGA NT/14200]; ESF (COST Action ) [ESSEA BM1004]; conceptual development of research organization, University Hospital Motol, Prague, Czech Republic [00064203]","This work was supported by the Ministry of Education, Youth and Sports, Czech Republic (research grant COST LD11028), by the Ministry of Health, Czech Republic (research grant IGA NT/14200 and conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203), and by the ESF (COST Action ESSEA BM1004). The authors would like to thank Thomas Secrest for his assistance with the English version of the manuscript.",null,39,0,0,"DOVE MEDICAL PRESS LTD","ALBANY","PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND","1178-2021",null,null,"NEUROPSYCH DIS TREAT","Neuropsychiatr. Dis. Treat.",null,2014,10,null,null,null,null,null,2201,2208,null,"10.2147/NDT.S72921",null,8,"Clinical Neurology; Psychiatry","Neurosciences & Neurology; Psychiatry","AT4SC","WOS:000344930800001",25484588]
["J","Bloy, N; Pol, J; Aranda, F; Eggermont, A; Cremer, I; Fridman, WH; Fucikova, J; Galon, J; Tartour, E; Spisek, R; Dhodapkar, MV; Zitvogel, L; Kroemer, G; Galluzzi, L",null,null,null,"Bloy, Norma; Pol, Jonathan; Aranda, Fernando; Eggermont, Alexander; Cremer, Isabelle; Fridman, Wolf Herve; Fucikova, Jitka; Galon, Jerome; Tartour, Eric; Spisek, Radek; Dhodapkar, Madhav V.; Zitvogel, Laurence; Kroemer, Guido; Galluzzi, Lorenzo",null,null,"Trial watch: Dendritic cell-based anticancer therapy","ONCOIMMUNOLOGY",null,null,"English","Review",null,null,null,null,null,"antigen cross-presentation; autophagy; DC-based vaccination; immunogenic cell death; regulatory T cells; Toll-like receptor agonists","ANTIGEN-PRESENTING CELLS; INDUCED KILLER-CELLS; ANTITUMOR IMMUNE-RESPONSES; CYTOTOXIC T-LYMPHOCYTES; ADVANCED MELANOMA PATIENTS; RESISTANT PROSTATE-CANCER; COLONY-STIMULATING FACTOR; APOPTOTIC TUMOR-CELLS; IN-VIVO IMMUNIZATION; DC-SIGN","The use of patient-derived dendritic cells (DCs) as a means to elicit therapeutically relevant immune responses in cancer patients has been extensively investigated throughout the past decade. In this context, DCs are generally expanded, exposed to autologous tumor cell lysates or loaded with specific tumor-associated antigens (TAAs), and then reintroduced into patients, often in combination with one or more immunostimulatory agents. As an alternative, TAAs are targeted to DCs in vivo by means of monoclonal antibodies, carbohydrate moieties or viral vectors specific for DC receptors. All these approaches have been shown to (re) activate tumor-specific immune responses in mice, often mediating robust therapeutic effects. In 2010, the first DC-based preparation (sipuleucel-T, also known as Provenge((R))) has been approved by the US Food and Drug Administration (FDA) for use in humans. Reflecting the central position occupied by DCs in the regulation of immunological tolerance and adaptive immunity, the interest in harnessing them for the development of novel immunotherapeutic anticancer regimens remains high. Here, we summarize recent advances in the preclinical and clinical development of DC-based anticancer therapeutics.","[Bloy, Norma; Pol, Jonathan; Aranda, Fernando; Eggermont, Alexander; Galluzzi, Lorenzo] Gustave Roussy Canc Campus, Villejuif, France; [Bloy, Norma; Pol, Jonathan; Aranda, Fernando; Cremer, Isabelle; Fridman, Wolf Herve; Galon, Jerome; Kroemer, Guido; Galluzzi, Lorenzo] INSERM, U1138, Paris, France; [Bloy, Norma; Pol, Jonathan; Aranda, Fernando; Kroemer, Guido; Galluzzi, Lorenzo] Ctr Rech Cordeliers, Equipe Labellisee Ligue Natl Canc 11, Paris, France; [Bloy, Norma] Univ Paris 11, Orsay, France; [Fridman, Wolf Herve] Ctr Rech Cordeliers, Equipe 13, Paris, France; [Fridman, Wolf Herve; Galon, Jerome] Univ Paris 06, Paris, France; [Fucikova, Jitka; Spisek, Radek] Charles Univ Prague, Sch Med 2, Dept Immunol, Prague, Czech Republic; [Fucikova, Jitka; Spisek, Radek] Univ Hosp Motol, Prague, Czech Republic; [Fucikova, Jitka; Spisek, Radek] Sotio As, Prague, Czech Republic; [Galon, Jerome] Ctr Rech Cordeliers, Lab Integrat Canc Immunol, Paris, France; [Galon, Jerome; Tartour, Eric; Kroemer, Guido; Galluzzi, Lorenzo] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Tartour, Eric] INSERM, U970, Paris, France; [Tartour, Eric; Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France; [Dhodapkar, Madhav V.] Yale Univ, Dept Med Immunobiol, New Haven, CT USA; [Zitvogel, Laurence] Yale Univ, Yale Canc Ctr, New Haven, CT USA; [Kroemer, Guido] INSERM, U1015, CICBT507, Villejuif, France; [Kroemer, Guido] Gustave Roussy Canc Campus, Metabol & Cell Biol Platforms, Villejuif, France","Kroemer, G (reprint author), INSERM, U1138, Paris, France.","kroemer@orange.fr; deadoc@vodafone.it",null,null,"Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-deFrance; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche M edicale (FRM); European Commission (ArtForce); European Research Council (ERC); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI)","Authors are supported by Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-deFrance; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche M edicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).",null,348,0,0,"LANDES BIOSCIENCE","AUSTIN","1806 RIO GRANDE ST, AUSTIN, TX 78702 USA","2162-4011","2162-402X",null,"ONCOIMMUNOLOGY","OncoImmunology",null,2014,3,11,null,null,null,null,null,null,"e963424","10.4161/21624011.2014.963424",null,16,"Oncology; Immunology","Oncology; Immunology","AX4TC","WOS:000346923100008"]
["J","Kepp, O; Senovilla, L; Vitale, I; Vacchelli, E; Adjemian, S; Agostinis, P; Apetoh, L; Aranda, F; Barnaba, V; Bloy, N; Bracci, L; Breckpot, K; Brough, D; Buque, A; Castro, MG; Cirone, M; Colombo, MI; Cremer, I; Demaria, S; Dini, L; Eliopoulos, AG; Faggioni, A; Formenti, SC; Fucikova, J; Gabriele, L; Gaipl, US; Galon, J; Garg, A; Ghiringhelli, F; Giese, NA; Guo, ZS; Hemminki, A; Herrmann, M; Hodge, JW; Holdenrieder, S; Honeychurch, J; Hu, HM; Huang, X; Illidge, TM; Kono, K; Korbelik, M; Krysko, DV; Loi, S; Lowenstein, PR; Lugli, E; Ma, YT; Madeo, F; Manfredi, AA; Martins, I; Mavilio, D; Menger, L; Merendino, N; Michaud, M; Mignot, G; Mossman, KL; Multhoff, G; Oehler, R; Palombo, F; Panaretakis, T; Pol, J; Proietti, E; Ricci, JE; Riganti, C; Rovere-Querini, P; Rubartelli, A; Sistigu, A; Smyth, MJ; Sonnemann, J; Spisek, R; Stagg, J; Sukkurwala, AQ; Tartour, E; Thorburn, A; Thorne, SH; Vandenabeele, P; Velotti, F; Workenhe, ST; Yang, HN; Zong, WX; Zitvogel, L; Kroemer, G; Galluzzi, L",null,null,null,"Kepp, Oliver; Senovilla, Laura; Vitale, Ilio; Vacchelli, Erika; Adjemian, Sandy; Agostinis, Patrizia; Apetoh, Lionel; Aranda, Fernando; Barnaba, Vincenzo; Bloy, Norma; Bracci, Laura; Breckpot, Karine; Brough, David; Buque, Aitziber; Castro, Maria G.; Cirone, Mara; Colombo, Maria I.; Cremer, Isabelle; Demaria, Sandra; Dini, Luciana; Eliopoulos, Aristides G.; Faggioni, Alberto; Formenti, Silvia C.; Fucikova, Jitka; Gabriele, Lucia; Gaipl, Udo S.; Galon, Jerome; Garg, Abhishek; Ghiringhelli, Francois; Giese, Nathalia A.; Guo, Zong Sheng; Hemminki, Akseli; Herrmann, Martin; Hodge, James W.; Holdenrieder, Stefan; Honeychurch, Jamie; Hu, Hong-Min; Huang, Xing; Illidge, Tim M.; Kono, Koji; Korbelik, Mladen; Krysko, Dmitri V.; Loi, Sherene; Lowenstein, Pedro R.; Lugli, Enrico; Ma, Yuting; Madeo, Frank; Manfredi, Angelo A.; Martins, Isabelle; Mavilio, Domenico; Menger, Laurie; Merendino, Nicolo; Michaud, Michael; Mignot, Gregoire; Mossman, Karen L.; Multhoff, Gabriele; Oehler, Rudolf; Palombo, Fabio; Panaretakis, Theocharis; Pol, Jonathan; Proietti, Enrico; Ricci, Jean-Ehrland; Riganti, Chiara; Rovere-Querini, Patrizia; Rubartelli, Anna; Sistigu, Antonella; Smyth, Mark J.; Sonnemann, Juergen; Spisek, Radek; Stagg, John; Sukkurwala, Abdul Qader; Tartour, Eric; Thorburn, Andrew; Thorne, Stephen H.; Vandenabeele, Peter; Velotti, Francesca; Workenhe, Samuel T.; Yang, Haining; Zong, Wei-Xing; Zitvogel, Laurence; Kroemer, Guido; Galluzzi, Lorenzo",null,null,"Consensus guidelines for the detection of immunogenic cell death","ONCOIMMUNOLOGY",null,null,"English","Review",null,null,null,null,null,"ATP release; autophagy; calreticulin; endoplasmic reticulum stress; HMGB1; immunotherapy","MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; HEAT-SHOCK PROTEINS; GROUP BOX-1 PROTEIN; APOPTOTIC CALRETICULIN EXPOSURE; MOLECULAR-PATTERN MOLECULES; ANTICANCER IMMUNE-RESPONSES; FLOW-CYTOMETRIC DETECTION; HUMAN TUMOR-CELLS; FIND-ME SIGNAL; NECROTIC CELLS","Apoptotic cells have long been considered as intrinsically tolerogenic or unable to elicit immune responses specific for dead cell-associated antigens. However, multiple stimuli can trigger a functionally peculiar type of apoptotic demise that does not go unnoticed by the adaptive arm of the immune system, which we named \"immunogenic cell death\" (ICD). ICD is preceded or accompanied by the emission of a series of immunostimulatory damage-associated molecular patterns (DAMPs) in a precise spatiotemporal configuration. Several anticancer agents that have been successfully employed in the clinic for decades, including various chemotherapeutics and radiotherapy, can elicit ICD. Moreover, defects in the components that underlie the capacity of the immune system to perceive cell death as immunogenic negatively influence disease outcome among cancer patients treated with ICD inducers. Thus, ICD has profound clinical and therapeutic implications. Unfortunately, the gold-standard approach to detect ICD relies on vaccination experiments involving immunocompetent murine models and syngeneic cancer cells, an approach that is incompatible with large screening campaigns. Here, we outline strategies conceived to detect surrogate markers of ICD in vitro and to screen large chemical libraries for putative ICD inducers, based on a high-content, high-throughput platform that we recently developed. Such a platform allows for the detection of multiple DAMPs, like cell surface-exposed calreticulin, extracellular ATP and high mobility group box 1 (HMGB1), and/or the processes that underlie their emission, such as endoplasmic reticulum stress, autophagy and necrotic plasma membrane permeabilization. We surmise that this technology will facilitate the development of next-generation anticancer regimens, which kill malignant cells and simultaneously convert them into a cancer-specific therapeutic vaccine.","[Kepp, Oliver; Vacchelli, Erika; Adjemian, Sandy; Aranda, Fernando; Bloy, Norma; Buque, Aitziber; Huang, Xing; Ma, Yuting; Menger, Laurie; Michaud, Michael; Pol, Jonathan; Sukkurwala, Abdul Qader; Kroemer, Guido; Galluzzi, Lorenzo] Ctr Rech Cordeliers, Ligue Natl Canc, Equipe 11, Paris, France; [Kepp, Oliver; Senovilla, Laura; Vacchelli, Erika; Adjemian, Sandy; Aranda, Fernando; Bloy, Norma; Buque, Aitziber; Cremer, Isabelle; Galon, Jerome; Huang, Xing; Ma, Yuting; Menger, Laurie; Michaud, Michael; Pol, Jonathan; Sukkurwala, Abdul Qader; Kroemer, Guido; Galluzzi, Lorenzo] INSERM, U1138, Paris, France; [Kepp, Oliver; Senovilla, Laura; Huang, Xing; Kroemer, Guido] Metabol Platform, Villejuif, France; [Kepp, Oliver; Senovilla, Laura; Huang, Xing; Kroemer, Guido] Cell Biol Platform, Villejuif, France; [Senovilla, Laura; Zitvogel, Laurence] INSERM, U1015, Villejuif, France; [Vitale, Ilio; Sistigu, Antonella] Regina Elena Inst Canc Res, Rome, Italy; [Adjemian, Sandy] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Mol Cell Biol Lab, Sao Paulo, Brazil; [Agostinis, Patrizia; Garg, Abhishek] Univ Leuven, Dept Cellular & Mol Med, Cell Death Res & Therapy, Leuven, Belgium; [Apetoh, Lionel; Ghiringhelli, Francois] INSERM, UMR866, Dijon, France; [Apetoh, Lionel; Ghiringhelli, Francois] Ctr Georges Francois Leclerc, Dijon, France; [Apetoh, Lionel; Ghiringhelli, Francois] Univ Bourgogne, Dijon, France; [Barnaba, Vincenzo; Palombo, Fabio] Univ Roma La Sapienza, Dept Internal Med & Med Sci, I-00185 Rome, Italy; [Barnaba, Vincenzo; Palombo, Fabio] Fdn Cenci Bolognetti, Ist Pasteur, Rome, Italy; [Bracci, Laura; Gabriele, Lucia; Proietti, Enrico] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Breckpot, Karine] Free Univ Brussels, Dept Biomed Sci Med Sch, Lab Mol & Cellular Therapy, Jette, Belgium; [Brough, David] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Castro, Maria G.; Lowenstein, Pedro R.] Univ Michigan, Sch Med, Dept Neurosurg & Cell & Dev Biol, Ann Arbor, MI 48109 USA; [Cirone, Mara; Faggioni, Alberto] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy; [Colombo, Maria I.] Univ Nacl Cuyo, Inst Histol & Embriol IHEM, Fac Ciencias Med, CONICET,Lab Biol Celular & Mol, RA-5500 Mendoza, Argentina; [Cremer, Isabelle; Galon, Jerome] Univ Paris 06, Paris, France; [Cremer, Isabelle] Ctr Rech Cordeliers, Equipe 13, Paris, France; [Demaria, Sandra] NYU, Sch Med, Dept Pathol, New York, NY USA; [Dini, Luciana] Univ Salento, Dept Biol & Environm Sci & Technol DiSTeBA, Lecce, Italy; [Eliopoulos, Aristides G.] Univ Crete, Sch Med, Div Basic Sci, Mol & Cellular Biol Lab, Iraklion, Greece; [Eliopoulos, Aristides G.] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion, Greece; [Formenti, Silvia C.] NYU, Sch Med, Dept Radiat Oncol, New York, NY USA; [Formenti, Silvia C.] Langone Med Ctr, New York, NY USA; [Fucikova, Jitka; Spisek, Radek] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague, Czech Republic; [Fucikova, Jitka; Spisek, Radek] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Fucikova, Jitka; Spisek, Radek] Sotio, Prague, Czech Republic; [Gaipl, Udo S.] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Radiat Oncol, D-91054 Erlangen, Germany; [Galon, Jerome; Kroemer, Guido; Galluzzi, Lorenzo] Univ Paris 05, Univ Paris Descartes, Sorbonne Paris Cite, Paris, France; [Galon, Jerome] Ctr Rech Cordeliers, Lab Integrat Canc Immunol, Paris, France; [Giese, Nathalia A.] Univ Heidelberg Hosp, European Pancreas Ctr, Dept Surg, Heidelberg, Germany; [Guo, Zong Sheng; Thorne, Stephen H.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Hemminki, Akseli] Univ Helsinki, Transplantat Lab, Canc Gene Therapy Grp, Haartman Inst, Helsinki, Finland; [Herrmann, Martin] Univ Erlangen Nurnberg, Dept Internal Med 3, D-91054 Erlangen, Germany; [Hodge, James W.] NCI, Tumor Immunol & Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Holdenrieder, Stefan] Univ Hosp Bonn, Inst Clin Chem & Clin Pharmacol, Bonn, Germany; [Honeychurch, Jamie; Illidge, Tim M.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Inst Canc Studies, Fac Med & Human Sci, Manchester, Lancs, England; [Hu, Hong-Min] Southeast Univ, Affiliated Hosp 2, Canc Res & Biotherapy Ctr, Nanjing, Jiangsu, Peoples R China; [Hu, Hong-Min] Providence Portland Med Ctr, Earle A Chiles Res Inst, Lab Canc Immunobiol, Portland, OR USA; [Kono, Koji] Natl Univ Singapore, Dept Surg, Singapore 117548, Singapore; [Kono, Koji] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Korbelik, Mladen] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; [Krysko, Dmitri V.; Vandenabeele, Peter] VIB Inflammat Res Ctr, Ghent, Belgium; [Krysko, Dmitri V.; Vandenabeele, Peter] Univ Ghent, Dept Biomed Mol Biol, B-9000 Ghent, Belgium; [Loi, Sherene] Peter MacCallum Canc Ctr, Div Canc Med, East Melbourne, Vic, Australia; [Loi, Sherene] Peter MacCallum Canc Ctr, Div Res, East Melbourne, Vic, Australia; [Lugli, Enrico; Mavilio, Domenico] Humanitas Clin & Res Ctr, Unit Clin & Expt Immunol, Milan, Italy; [Lugli, Enrico; Mavilio, Domenico] Univ Milan, Dept Med Biotechnol & Translat Med, Rozzano, Italy; [Madeo, Frank] Graz Univ, Inst Mol Biosci, Graz, Austria; [Manfredi, Angelo A.; Rovere-Querini, Patrizia] Univ Vita Salute San Raffaele, Milan, Italy; [Manfredi, Angelo A.; Rovere-Querini, Patrizia] Ist Sci San Raffaele, I-20132 Milan, Italy; [Martins, Isabelle] INSERM, U1030, Villejuif, France; [Martins, Isabelle] Univ Paris 11, Fac Med, Le Kremlin Bicetre, France; [Menger, Laurie] UCL, Dept Res Haematol, Canc Immunol Unit, Inst Canc, London, England; [Merendino, Nicolo; Velotti, Francesca] Univ Tuscia, Dept Ecol & Biol Sci DEB, Viterbo, Italy; [Mossman, Karen L.; Workenhe, Samuel T.] McMaster Immunol Res Ctr, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Mossman, Karen L.; Workenhe, Samuel T.] McMaster Univ, Inst Infect Dis Res, Hamilton, ON, Canada; [Multhoff, Gabriele] Tech Univ Munich, Klinikum Rechts Isar, Dept Radiat Oncol, D-80290 Munich, Germany; [Oehler, Rudolf] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria; [Panaretakis, Theocharis] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Ricci, Jean-Ehrland] INSERM, U1065, Nice, France; [Ricci, Jean-Ehrland] Ctr Mediterran Med Mol C3M, Equipe Controle Metabol Morts Cellulaires, Nice, France; [Ricci, Jean-Ehrland] Univ Nice Sophia Antipolis, Fac Med, F-06189 Nice, France; [Ricci, Jean-Ehrland] Ctr Hosp Univ Nice, Nice, France; [Riganti, Chiara] Univ Turin, Dept Oncol, Turin, Italy; [Riganti, Chiara] Univ Turin, Subalpine Ctr Res & Expt Med CeRMS, Turin, Italy; [Rubartelli, Anna] Azienda Osped Univ San Martino, Ist Nazl Ric Cancro, Cell Biol Unit, Genoa, Italy; [Smyth, Mark J.] QIMR Berghofer Med Res Inst, Immunol Canc & Infect Lab, Herston, Qld, Australia; [Smyth, Mark J.] Univ Queensland, Sch Med, Herston, Qld, Australia; [Sonnemann, Juergen] Jena Univ Hosp, Childrens Clin, Dept Pediat Haematol & Oncol, Jena, Germany; [Stagg, John] Univ Montreal, Fac Pharm, Ctr Rech, Ctr Hosp, Montreal, PQ H3C 3J7, Canada; [Sukkurwala, Abdul Qader] Dow Univ Hlth Sci, Dow Int Med Coll, Dept Pathol, Karachi, Pakistan; [Tartour, Eric] INSERM, U970, Paris, France; [Tartour, Eric; Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France; [Thorburn, Andrew] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO USA; [Vandenabeele, Peter] Univ Ghent, Methusalem Program, B-9000 Ghent, Belgium; [Yang, Haining] Univ Hawaii Canc Ctr, Honolulu, HI USA; [Zong, Wei-Xing] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; [Zitvogel, Laurence] Ctr Invest Clin Biotherapie 507 CICBT507, Villejuif, France","Galluzzi, L (reprint author), Ctr Rech Cordeliers, Ligue Natl Canc, Equipe 11, Paris, France.","deadoc@vodafone.it",null,null,"Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); European Commission (ArtForce); European Research Council (ERC); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI)","GL and LG are supported by the Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).",null,288,0,0,"LANDES BIOSCIENCE","AUSTIN","1806 RIO GRANDE ST, AUSTIN, TX 78702 USA","2162-4011","2162-402X",null,"ONCOIMMUNOLOGY","OncoImmunology",null,2014,3,9,null,null,null,null,null,null,"e955691","10.4161/21624011.2014.955691",null,19,"Oncology; Immunology","Oncology; Immunology","AX4SU","WOS:000346922400019"]
["J","Adkins, I; Fucikova, J; Garg, AD; Agostinis, P; Spisek, R",null,null,null,"Adkins, Irena; Fucikova, Jitka; Garg, Abhishek D.; Agostinis, Patrizia; Spisek, Radek",null,null,"Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy","ONCOIMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"cancer immunotherapy; high hydrostatic pressure; hyperthermia; immunogenic cell death; ionizing irradiation; photodynamic therapy with hypericin","HIGH HYDROSTATIC-PRESSURE; REGULATORY T-CELLS; ANTICANCER IMMUNE-RESPONSES; DISTANT UNTREATED TUMORS; PHOTODYNAMIC-THERAPY; ANTITUMOR IMMUNITY; DENDRITIC CELLS; ER STRESS; CALRETICULIN EXPOSURE; INTRACELLULAR HYPERTHERMIA","The concept of immunogenic cancer cell death (ICD), as originally observed during the treatment with several chemotherapeutics or ionizing irradiation, has revolutionized the view on the development of new anticancer therapies. ICD is defined by endoplasmic reticulum (ER) stress response, reactive oxygen species (ROS) generation, emission of danger-associated molecular patterns and induction of antitumor immunity. Here we describe known and emerging cancer cell death-inducing physical modalities, such as ionizing irradiation, ultraviolet C light, Photodynamic Therapy (PDT) with Hypericin, high hydrostatic pressure (HHP) and hyperthermia (HT), which have been shown to elicit effective antitumor immunity. We discuss the evidence of ICD induced by these modalities in cancer patients together with their applicability in immunotherapeutic protocols and anticancer vaccine development.","[Adkins, Irena; Fucikova, Jitka; Spisek, Radek] Sotio, Prague, Czech Republic; [Adkins, Irena; Fucikova, Jitka; Spisek, Radek] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague, Czech Republic; [Adkins, Irena; Fucikova, Jitka; Spisek, Radek] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Garg, Abhishek D.; Agostinis, Patrizia] Univ Leuven KU Leuven, Dept Mol & Cell Biol, Cell Death Res & Therapy CDRT Unit, Leuven, Belgium","Adkins, I (reprint author), Sotio, Prague, Czech Republic.","adkins@sotio.com; spisek@sotio.com",null,null,"Ministry of Health of the Czech Republic [IGA NT12402-5, IGA NT1159]; FWO post-doctoral fellowship; FWO [G0584.12N, K202313N]; KU Leuven [GOA/11/2009]; Interuniversity Attraction Poles Programme [IAP7/32]; Belgian State","This work was supported by research grants IGA NT12402-5 and IGA NT1159 provided by the Ministry of Health of the Czech Republic. A.D.G. is supported by a FWO post-doctoral fellowship. Research in the lab of P.A. is supported by FWO (G0584.12N and K202313N), GOA/11/2009 grant of the KU Leuven and IAP7/32, funded by the Interuniversity Attraction Poles Programme, initiated by the Belgian State.",null,125,0,0,"LANDES BIOSCIENCE","AUSTIN","1806 RIO GRANDE ST, AUSTIN, TX 78702 USA","2162-4011","2162-402X",null,"ONCOIMMUNOLOGY","OncoImmunology",null,2014,3,12,null,null,null,null,null,null,"e968434","10.4161/21624011.2014.968434",null,12,"Oncology; Immunology","Oncology; Immunology","AY6MH","WOS:000347679800010"]
["J","Honkova, L; Uhlik, J; Berankova, K; Svobodova, T; Pohunek, P",null,null,null,"Honkova, Lenka; Uhlik, Jiri; Berankova, Katarina; Svobodova, Tamara; Pohunek, Petr",null,null,"Epithelial basement membrane thickening is related to TGF-Beta 1 expression in children with chronic respiratory diseases","PEDIATRIC ALLERGY AND IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"asthma; cystic fibrosis; primary ciliary dyskinesia; remodelling; TGF-1","GROWTH-FACTOR-BETA; PRIMARY CILIARY DYSKINESIA; CYSTIC-FIBROSIS; EXTRACELLULAR-MATRIX; EOSINOPHILIC INFLAMMATION; TGF-BETA; ASTHMA; CELLS; DIAGNOSIS; BIOPSIES","BackgroundThe complex structural changes of bronchial mucosa, known as remodelling, have been considered unique and typical for asthma. However, similar changes were recently found in other chronic respiratory diseases. The aim of this study was to compare basement membrane (BM) thickness and the number of transforming growth factor beta 1 (TGF-1) positive epithelial cells in children with asthma, cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and healthy controls. MethodsA total of 58 children (11.13.9yr, 55% males) were enrolled in this cross-sectional study. Endobronchial biopsy was performed in 27 children with asthma, 12 with CF, 12 with PCD and in 7 control patients. We studied the samples using light microscopy to assess BM width, the number of TGF-1 positive epithelial cells and their correlation. ResultsWe found increased BM thickness (6.65 +/- 1.22m vs. 2.93 +/- 0.75m, p<0.01) and a higher number of TGF-1 positive epithelial cells (61.39 +/- 19.03 vs. 21.57 +/- 12.58, p<0.01) in children with chronic respiratory diseases compared to controls. There was no difference in these parameters between asthma, CF and PCD. A positive correlation between BM thickness and the number of TGF-1 positive cells was observed in all groups including controls (r=0.84, p<0.01). ConclusionsIncreased BM thickness and number of TGF-1 positive epithelial cells were found in children with asthma, CF and PCD. The number of TGF-1 positive cells correlated positively with the BM thickness in all groups. We suggest that this might be a common generic feature of bronchial remodelling in chronic respiratory diseases.","[Honkova, Lenka; Berankova, Katarina; Svobodova, Tamara; Pohunek, Petr] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Honkova, Lenka; Berankova, Katarina; Svobodova, Tamara; Pohunek, Petr] Motol Univ Hosp, Prague 15006 5, Czech Republic; [Uhlik, Jiri] Charles Univ Prague, Fac Med 2, Dept Histol & Embryol, Prague, Czech Republic","Pohunek, P (reprint author), Motol Univ Hosp, Dept Paediat, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.pohunek@LFMotol.cuni.cz",null,null,"Ministry of Health, Czech Republic [IGA MZ NT/11444]; Charles University in Prague, Czech Republic [GAUK 360213]","The study was supported by following research grants: IGA MZ NT/11444 (Ministry of Health, Czech Republic) and GAUK 360213 (Charles University in Prague, Czech Republic).",null,29,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0905-6157","1399-3038",null,"PEDIAT ALLERG IMM-UK","Pediatr. Allergy Immunol.","OCT",2014,25,6,null,null,null,null,593,599,null,"10.1111/pai.12275",null,7,"Allergy; Immunology; Pediatrics","Allergy; Immunology; Pediatrics","AT3YS","WOS:000344872400011",25201521]
["J","Mazurek, H; Chiron, R; Kucerova, T; Geidel, C; Bolbas, K; Chuchalin, A; Blanco-Aparicio, M; Santoro, D; Varoli, G; Zibellini, M; Cicirello, HG; Antipkin, YG",null,null,null,"Mazurek, Henryk; Chiron, Raphael; Kucerova, Tereza; Geidel, Christian; Bolbas, Katalin; Chuchalin, Alexander; Blanco-Aparicio, Marina; Santoro, Debora; Varoli, Guido; Zibellini, Marco; Cicirello, Helen G.; Antipkin, Yuriy G.",null,null,"Long-Term Efficacy and Safety of Aerosolized Tobramycin 300 mg/4 ml in Cystic Fibrosis","PEDIATRIC PULMONOLOGY",null,null,"English","Article",null,null,null,null,null,"Pseudomonas aeruginosa; nebulization; long-term; FEV1; cystic fibrosis; tobramycin susceptibility","INHALED AZTREONAM LYSINE; PSEUDOMONAS-AERUGINOSA; NEBULIZED TOBRAMYCIN; LUNG; SUSCEPTIBILITY; ANTIBIOTICS; INFECTION; DRUG; BRAMITOB((R)); MANAGEMENT","IntroductionAerosolized tobramycin is a standard of care for chronic Pseudomonas aeruginosa (Pa) infection in patients with cystic fibrosis (CF). ObjectivesThe long-term safety and efficacy of intermittent (28-day on/off cycles) inhaled tobramycin nebulization solution 300mg/4ml (TNS4, Bramitob (R)/Bethkis (R)) was assessed over 56 weeks in CF patients aged 6 years having baseline 1sec forced expiratory volume (FEV1) 40-80% predicted. MethodsPatients were initially randomized in an 8-week open-label trial (core phase) to compare TNS4 (N=159) and tobramycin 300mg/5ml (TNS5, TOBI (R)) (N=165). A subset of patients continued in a 48-week, single-arm extension receiving TNS4 only. The primary endpoint of the core phase was to demonstrate the non-inferiority of TNS4 compared to TNS5 in terms of absolute change from baseline to week 4 in FEV1 % predicted. The assessment of long-term safety was the primary purpose of the extension phase. Throughout all phases of the study, microbiological assessments, adverse events, and audiometry findings were also evaluated. ResultsIn the core phase (N=321), FEV1 (% predicted) increased from baseline (absolute change) following a single on-treatment cycle for both TNS4 (7.0%) and TNS5 (7.5%) and the non-inferiority between treatments was met [difference between treatments of -0.5 (95% CI: -2.6; 1.6)]. These improvements were maintained throughout the extension phase (N=209), ranging throughout the study between 5.1% (95% CI: 3.2; 6.9) and 8.1% (95% CI: 6.8; 9.4) compared to baseline. Pa sputum count reductions ranged between 0.6 (95% CI: 0.2; 0.9) to 2.3 (95% CI: 2.0; 2.6) log(10) CFU/g throughout the 56 weeks. No remarkable safety issues were identified throughout both study phases, with similar percentages of patients reporting adverse events in the two treatment groups during the 8-week core phase [TNS4 (31.4%); TNS5 (28.0%)]. ConclusionsOverall, TNS4 demonstrated short-term clinical benefits similar to TNS5 which were maintained during the long-term use of TNS4 and was also associated with a favorable tolerability profile. Pediatr Pulmonol. 2014; 49:1076-1089. (c) 2014 Wiley Periodicals, Inc.","[Mazurek, Henryk] Inst Gruzlicy & Chorob Pluc, Oddzial Terenowy Jana & Ireny Rudnikow Rabce Zdro, Klin Pneumonol & Mukowiscydozy, PL-34700 Rabka Zdroj, Poland; [Chiron, Raphael] Hop Arnaud Villeneuve, Ctr Malad Resp, Montpellier, France; [Kucerova, Tereza] Ctr Pro Cystickou Fibrosu, Pediat Klin, Fak Nemocnice Motole, Prague, Czech Republic; [Geidel, Christian] Univ Giessen, Mukovizidose Zentrum, Zentrum Kinderheilkunde & Jugendmed, D-35390 Giessen, Germany; [Bolbas, Katalin] Kaposi Mor Oktatokorhaz, Gyermekpulmonol Reszleg, Mosdos, Hungary; [Chuchalin, Alexander] Roszdrav Lab Cyst Fibrosis, Fed State Inst, Sci Res Pulmonol Inst, Moscow, Russia; [Blanco-Aparicio, Marina] Complejo Hosp Univ La Coruna, Serv Neumol, La Coruna, Spain; [Santoro, Debora; Varoli, Guido; Zibellini, Marco] Chiesi Farmaceut SpA, Corp Clin Dev, Parma, Italy; [Cicirello, Helen G.] Chiesi Pharmaceut Inc, Rockville, MD USA; [Antipkin, Yuriy G.] Inst Pediat Obstet & Gynecol, Dept Resp Dis & Ecol Problems Childrens Hlth, Kiev, Ukraine","Mazurek, H (reprint author), Inst Gruzlicy & Chorob Pluc, Oddzial Terenowy Jana & Ireny Rudnikow Rabce Zdro, Klin Pneumonol & Mukowiscydozy, Ul Prof Jana Rudnika 3B, PL-34700 Rabka Zdroj, Poland.","hmazurek@zpigichp.edu.pl",null,null,null,null,null,36,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","8755-6863","1099-0496",null,"PEDIATR PULM","Pediatr. Pulmonol.","NOV",2014,49,11,null,null,null,null,1076,1089,null,"10.1002/ppul.22989",null,14,"Pediatrics; Respiratory System","Pediatrics; Respiratory System","AS3KE","WOS:000344175400005",24464974]
["J","Moorthy, LN; Roy, E; Kurra, V; Peterson, MGE; Hassett, AL; Lehman, TJA; Scot, C; El-Ghoneimy, D; Saad, S; El Feky, R; Al-Mayouf, S; Dolezalova, P; Malcova, H; Herlin, T; Nielsen, S; Wulffraat, N; van Royen, A; Marks, SD; Belot, A; Brunner, J; Huemer, C; Foeldvari, I; Horneff, G; Saurenman, T; Schroeder, S; Pratsidou-Gertsi, P; Trachana, M; Uziel, Y; Aggarwal, A; Constantin, T; Cimaz, R; Giani, T; Cantarini, L; Falcini, F; Manzoni, SM; Ravelli, A; Rigante, D; Zulian, F; Miyamae, T; Yokota, S; Sato, J; Magalhaes, CS; Len, CA; Appenzeller, S; Knupp, SO; Rodrigues, MC; Sztajnbok, F; de Almeida, RG; de Jesus, AA; Campos, LMD; Silva, C; Lazar, C; Susic, G; Avcin, T; Cuttica, R; Burgos-Vargas, R; Faugier, E; Anton, J; Modesto, C; Vazquez, L; Barillas, L; Barinstein, L; Sterba, G; Maldonado, I; Ozen, S; Kasapcopur, O; Demirkaya, E; Benseler, S",null,null,null,"Moorthy, Lakshmi Nandini; Roy, Elizabeth; Kurra, Vamsi; Peterson, Margaret G. E.; Hassett, Afton L.; Lehman, Thomas J. A.; Scot, Christiaan; El-Ghoneimy, Dalia; Saad, Shereen; El Feky, Reem; Al-Mayouf, Sulaiman; Dolezalova, Pavla; Malcova, Hana; Herlin, Troels; Nielsen, Susan; Wulffraat, Nico; van Royen, Annet; Marks, Stephen D.; Belot, Alexandre; Brunner, Jurgen; Huemer, Christian; Foeldvari, Ivan; Horneff, Gerd; Saurenman, Traudel; Schroeder, Silke; Pratsidou-Gertsi, Polyxeni; Trachana, Maria; Uziel, Yosef; Aggarwal, Amita; Constantin, Tamas; Cimaz, Rolando; Giani, Theresa; Cantarini, Luca; Falcini, Fernanda; Manzoni, Silvia Magni; Ravelli, Angelo; Rigante, Donato; Zulian, Fracnceso; Miyamae, Takako; Yokota, Shumpei; Sato, Juliana; Magalhaes, Claudia S.; Len, Claudio A.; Appenzeller, Simone; Knupp, Sheila Oliveira; Rodrigues, Marta Cristine; Sztajnbok, Flavio; de Almeida, Rozana Gasparello; de Jesus, Adriana Almeida; de Arruda Campos, Lucia Maria; Silva, Clovis; Lazar, Calin; Susic, Gordana; Avcin, Tadej; Cuttica, Ruben; Burgos-Vargas, Ruben; Faugier, Enrique; Anton, Jordi; Modesto, Consuelo; Vazquez, Liza; Barillas, Lilliana; Barinstein, Laura; Sterba, Gary; Maldonado, Irama; Ozen, Seza; Kasapcopur, Ozgur; Demirkaya, Erkan; Benseler, Susa",null,"Collaborative Grp","Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration","PEDIATRIC RHEUMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"CROSS-CULTURAL ADAPTATION; GENERIC CORE SCALES; LUPUS-ERYTHEMATOSUS; RELIABILITY; VALIDATION; VALIDITY; CHILDREN; SMILEY","Background: Rheumatic diseases in children are associated with significant morbidity and poor health-related quality of life (HRQOL). There is no health-related quality of life (HRQOL) scale available specifically for children with less common rheumatic diseases. These diseases share several features with systemic lupus erythematosus (SLE) such as their chronic episodic nature, multi-systemic involvement, and the need for immunosuppressive medications. HRQOL scale developed for pediatric SLE will likely be applicable to children with systemic inflammatory diseases. Findings: We adapted Simple Measure of Impact of Lupus Erythematosus in Youngsters (SMILEY (c)) to Simple Measure of Impact of Illness in Youngsters (SMILY (c)-Illness) and had it reviewed by pediatric rheumatologists for its appropriateness and cultural suitability. We tested SMILY (c)-Illness in patients with inflammatory rheumatic diseases and then translated it into 28 languages. Nineteen children (79% female, n= 15) and 17 parents participated. The mean age was 12 +/- 4 years, with median disease duration of 21 months (1-172 months). We translated SMILY (c)-Illness into the following 28 languages: Danish, Dutch, French (France), English (UK), German (Germany), German (Austria), German (Switzerland), Hebrew, Italian, Portuguese (Brazil), Slovene, Spanish (USA and Puerto Rico), Spanish (Spain), Spanish (Argentina), Spanish (Mexico), Spanish (Venezuela), Turkish, Afrikaans, Arabic (Saudi Arabia), Arabic (Egypt), Czech, Greek, Hindi, Hungarian, Japanese, Romanian, Serbian and Xhosa. Conclusion: SMILY (c)-Illness is a brief, easy to administer and score HRQOL scale for children with systemic rheumatic diseases. It is suitable for use across different age groups and literacy levels. SMILY (c)-Illness with its available translations may be used as useful adjuncts to clinical practice and research.","[Moorthy, Lakshmi Nandini] Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA; [Roy, Elizabeth; Kurra, Vamsi] Rutgers State Univ, Child Hlth Inst New Jersey, New Brunswick, NJ 08901 USA; [Peterson, Margaret G. E.; Lehman, Thomas J. A.] Hosp Special Surg, New York, NY 10021 USA; [Hassett, Afton L.] Univ Michigan, Ann Arbor, MI 48109 USA; [Scot, Christiaan] Red Cross War Mem Childrens Hosp, Cape Town, South Africa; [El-Ghoneimy, Dalia] Ain Shams Univ, Pediat Allergy Immunol & Rheumatol Unit, Cairo, Egypt; [Saad, Shereen; El Feky, Reem] Ain Shams Univ, Pediat Rheumatol Pediat Allergy Immunol & Rheum, Cairo, Egypt; [Al-Mayouf, Sulaiman] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia; [Dolezalova, Pavla] Charles Univ Prague, Prague, Czech Republic; [Dolezalova, Pavla] Gen Univ Hosp, Prague, Czech Republic; [Malcova, Hana] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Herlin, Troels] Aarhus Univ, Hosp Skejby, Aarhus, Denmark; [Nielsen, Susan] Rigshosp, Juliane Marie Ctr, DK-2100 Copenhagen, Denmark; [Wulffraat, Nico] Univ Med Ctr, Dept Pediat Immunol, Utrecht, Netherlands; [van Royen, Annet] Wilhelmina Childrens Hosp, Utrecht, Netherlands; [Marks, Stephen D.] Great Ormond St Hosp Sick Children, Children NHS Fdn Trust, Renal Unit, London, England; [Belot, Alexandre] Lyon Univ, Hosp Civils Lyon, Rheumatol & Dermatol Dept, Lyon, France; [Brunner, Jurgen] Med Univ Innsbruck, A-6020 Innsbruck, Austria; [Huemer, Christian] Prim Univ Doz, Bregenz, Austria; [Foeldvari, Ivan] Hamburg Ctr Pediat & Adolescence Rheumatol, Hamburg, Germany; [Horneff, Gerd] Asklepios Clin Sankt, Augustin, Germany; [Saurenman, Traudel; Schroeder, Silke] Univ Zurich, Childrens Hosp, Zurich, Switzerland; [Pratsidou-Gertsi, Polyxeni; Trachana, Maria] Aristotle Univ Thessaloniki, Pediat Immunol & Rheumatol Referral Ctr, GR-54006 Thessaloniki, Greece; [Uziel, Yosef] Israel Meir Hosp, Kefar Sava, Israel; [Aggarwal, Amita] Sanjay Gandhi Postgrad Inst Med Sci, Lucknow, Uttar Pradesh, India; [Constantin, Tamas] Semmelweis Univ, H-1085 Budapest, Hungary; [Cimaz, Rolando; Giani, Theresa] Anna Meyer Hosp, Florence, Italy; [Cantarini, Luca] Univ Siena, Res Ctr System Autoimmune & Autoinflammatory Dis, I-53100 Siena, Italy; [Falcini, Fernanda] Univ Florence, Florence, Italy; [Manzoni, Silvia Magni] Osped Pediat Bambino Gesu, IRCCS, Pediat Rheumatol Unit, Rome, Italy; [Ravelli, Angelo] Univ Genoa Pediat II Reumatol, Ist G Gaslini EULAR, Ctr Excellence Rheumatol, Genoa, Italy; [Rigante, Donato] Univ Cattolica Sacro Cuore, Inst Pediat, Rome, Italy; [Zulian, Fracnceso] Univ Padua, Dept Pediat, Pediat Rheumatol Unit, Padua, Italy; [Miyamae, Takako; Yokota, Shumpei] Yokohama City Univ, Sch Med, Yokohama, Kanagawa 232, Japan; [Sato, Juliana; Magalhaes, Claudia S.] Univ Estadual Paulista, UNESP, Botucatu, SP, Brazil; [Len, Claudio A.] Univ Fed Sao Paulo, Dept Pediat, Sao Paulo, Brazil; [Appenzeller, Simone] Univ Estadual Campinas, Dept Med, Campinas, SP, Brazil; [Knupp, Sheila Oliveira; Rodrigues, Marta Cristine] Univ Fed Rio de Janeiro, Dept Pediat, Rio De Janeiro, Brazil; [Sztajnbok, Flavio; de Almeida, Rozana Gasparello] Univ Estado do, Adolescent Hlth Care Unit, Div Pediat Rheumatol, Rio De Janeiro, Brazil; [de Jesus, Adriana Almeida; de Arruda Campos, Lucia Maria] Univ Sao Paulo, Fac Med, Childrens Inst, Dept Pediat,Pediat Rheumatol Unit, Sao Paulo, Brazil; [Silva, Clovis] Childrens Inst, Pediat Rheumatol Unit, Sao Paulo, Brazil; [Lazar, Calin] Clin Pediat I, Cluj Napoca, Romania; [Susic, Gordana] Inst Rheumatol, Belgrade, Serbia; [Avcin, Tadej] Univ Childrens Hosp, Univ Med Ctr Ljubljana, Ljubljana, Slovenia; [Cuttica, Ruben] Head Rheumatol Hosp Pedro Elizalde, Buenos Aires, DF, Argentina; [Burgos-Vargas, Ruben] Hosp Gen Mexico City, Mexico City, DF, Mexico; [Faugier, Enrique] Hosp Infantil Mexico Fed Gomez, Mexico City, DF, Mexico; [Anton, Jordi] Hosp San Juan Dios, Barcelona, Spain; [Modesto, Consuelo] Hosp Univ Valle Hebron, Barcelona, Spain; [Barinstein, Laura] Mt Sinai Med Ctr, New York, NY 10029 USA; [Sterba, Gary] Mt Sinai Med Ctr, Miami Beach, FL 33140 USA; [Maldonado, Irama] Complejo Hosp Univ Ruiz & Paez, Bolivar, Venezuela; [Ozen, Seza] Hacettepe Univ, Dept Pediat, Ankara, Turkey; [Kasapcopur, Ozgur] Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey; [Demirkaya, Erkan] FMF Arthrit Vasculitis & Orphan Dis Res Ctr, Inst Hlth Sci, Ankara, Turkey; [Benseler, Susa] Univ Calgary, Dept Pediat, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 1N4, Canada","Moorthy, LN (reprint author), Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA.","moorthln@rwjms.rutgers.edu",null,null,null,null,null,10,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1546-0096",null,null,"PEDIATR RHEUMATOL","Pediatr. Rheumatol.","NOV 25",2014,12,null,null,null,null,null,null,null,49,"10.1186/1546-0096-12-49",null,6,"Pediatrics; Rheumatology","Pediatrics; Rheumatology","AW8OB","WOS:000346520700001"]
["J","Cooper, DN; Brand, A; Dolzan, V; Fortina, P; Innocenti, F; Lee, MTM; Macek, M; Al-Mulla, F; Prainsack, B; Squassina, A; Vayena, E; Vozikis, A; Williams, MS; Patrinos, GP",null,null,null,"Cooper, David N.; Brand, Angela; Dolzan, Vita; Fortina, Paolo; Innocenti, Federico; Lee, Ming Ta Michael; Macek, Milan, Jr.; Al-Mulla, Fahd; Prainsack, Barbara; Squassina, Alessio; Vayena, Effy; Vozikis, Athanassios; Williams, Marc S.; Patrinos, George P.",null,null,"Bridging genomics research between developed and developing countries: the Genomic Medicine Alliance","PERSONALIZED MEDICINE",null,null,"English","Article",null,null,null,null,null,"economic evaluation in genomic medicine; ethics in genomics; genethics; genetics education; genome informatics; genome literacy; genomic medicine; pharmacogenomics; public health genomics; whole-genome sequencing","TO-CONSUMER GENOMICS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; HEALTH; CHALLENGES; DATABASES; GENETICS","The Genomic Medicine Alliance is a global academic research network that aims to establish and strengthen collaborative ties between the various genomic medicine stakeholders. Its focus lies on the translation of scientific research findings into clinical practice. It brings together experts from disciplines including genome informatics, pharmacogenomics, public health genomics, ethics in genomics and health economics, and it is supervised by a 14-member International Scientific Advisory Committee comprising internationally renowned scientists. The Alliance's official journal, Public Health Genomics, offers members a highly respected publication forum for their original research findings. In the short-to-medium term, the Genomic Medicine Alliance hopes to harmonize research activities between developed and developing countries and to organize educational activities in the field of genomic medicine.","[Cooper, David N.] Cardiff Univ, Sch Med, Inst Med Genet, Cardiff CF10 3AX, S Glam, Wales; [Brand, Angela] Univ Maastricht, Inst Publ Hlth Genom, Maastricht, Netherlands; [Dolzan, Vita] Univ Ljubljana, Sch Med, Ljubljana, Slovenia; [Fortina, Paolo] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Innocenti, Federico] Univ N Carolina, Inst Pharmacogenom & Individualized Therapy, Chapel Hill, NC USA; [Lee, Ming Ta Michael] RIKEN, Ctr Integrat Med Sci, Lab Int Alliance Genom Res, Yokohama, Kanagawa, Japan; [Macek, Milan, Jr.] Charles Univ Prague, Prague, Czech Republic; [Macek, Milan, Jr.] Fac Hosp Motol, Inst Biol & Med Genet, Prague, Czech Republic; [Al-Mulla, Fahd] Kuwait Univ, Mol Pathol Unit, Safat, Kuwait; [Prainsack, Barbara] Kings Coll London, Dept Social Sci Hlth & Med, London WC2R 2LS, England; [Squassina, Alessio] Univ Cagliari, Sch Med, Dept Biomed Sci, Cagliari, Italy; [Vayena, Effy] Univ Zurich, Inst Biomed Eth, Zurich, Switzerland; [Vozikis, Athanassios] Univ Piraeus, Dept Econ, Piraeus, Greece; [Williams, Marc S.] Geisinger Hlth Syst, Genom Med Inst, Danville, PA USA; [Patrinos, George P.] Univ Patras, Sch Hlth Sci, Dept Pharm, GR-26504 Patras, Greece","Patrinos, GP (reprint author), Univ Patras, Sch Hlth Sci, Dept Pharm, Univ Campus, GR-26504 Patras, Greece.","gpatrinos@upatras.gr",null,null,null,null,null,28,2,2,"FUTURE MEDICINE LTD","LONDON","UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND","1741-0541","1744-828X",null,"PERS MED","Pers. Med.",null,2014,11,7,null,null,"SI",null,615,623,null,"10.2217/pme.14.59",null,9,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","AT4SG","WOS:000344931400002"]
["J","Hromadnikova, I; Kotlabova, K; Hympanova, L; Doucha, J; Krofta, L",null,null,null,"Hromadnikova, Ilona; Kotlabova, Katerina; Hympanova, Lucie; Doucha, Jindrich; Krofta, Ladislav",null,null,"First Trimester Screening of Circulating C19MC microRNAs Can Predict Subsequent Onset of Gestational Hypertension","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"PLACENTA-SPECIFIC MICRORNAS; INTRAUTERINE GROWTH RESTRICTION; HUMAN CHORIONIC-GONADOTROPIN; FREE FETAL DNA; MATERNAL PLASMA; PRENATAL-DIAGNOSIS; PREGNANT-WOMEN; HYPERMETHYLATED RASSF1A; ANGIOGENIC FACTORS; PREECLAMPSIA","Objective: The objective of the study was to evaluate risk assessment for gestational hypertension based on the profile of circulating placental specific C19MC microRNAs in early pregnancy. Study design: The prospective longitudinal cohort study of women enrolled at first trimester screening at 10 to 13 weeks was carried out (n=267). Relative quantification of placental specific C19MC microRNAs (miR-516-5p, miR-517*, miR-518b, miR-520a*, miR-520h, miR-525 and miR-526a) was determined in 28 normal pregnancies and 18 pregnancies which developed gestational hypertension using real-time PCR and a comparative Ct method relative to synthetic C. elegans microRNA (cel-miR-39). Results: Increased extracellular C19MC microRNA plasmatic levels (miR-516-5p, p<0.001; miR-517*, p-0.007; miR-520h, p<0.001; miR-518b, p=0.002) were detected in patients destined to develop gestational hypertension. MiR-520h had the best predictive performance with a PPV of 84.6% at a 7.1% false positive rate. The combination of miR-520h and miR-518b was able to predict 82.6% of women at the same false positive rate. The overall predictive capacity of single miR-518b (73.3% at 14.3% FPR), miR-516-5p (70.6% at 17.9% FPR) and miR-517* (57.9% at 28.6% FPR) biomarkers was lower. Conclusion: The study brought interesting finding that the up-regulation of miR516-5p, miR-517*, miR-520h and miR-518b is associated with a risk of later development of gestational hypertension. First trimester screening of extracellular miR-520h alone or in combination with miR-518b identified a significant proportion of women with subsequent gestational hypertension.","[Hromadnikova, Ilona; Kotlabova, Katerina; Hympanova, Lucie] Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Prague 10000, Czech Republic; [Hympanova, Lucie; Krofta, Ladislav] Charles Univ Prague, Fac Med 3, Inst Care Mother & Child, Prague 14700, Czech Republic; [Doucha, Jindrich] Charles Univ Prague, Fac Med 2, Clin Obstet & Gynecol, Prague 15006, Czech Republic","Hromadnikova, I (reprint author), Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Ruska 87, Prague 10000, Czech Republic.","Ilona.Hromadnikova@lf3.cuni.cz",null,null,"Grant Agency of Czech Republic [304/12/1352]; Charles University research program [PRVOUK P32]","The work was exclusively supported by the Grant Agency of Czech Republic (no. 304/12/1352) and partially supported by the Charles University research program PRVOUK P32 (www.gacr.cz) (IH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,73,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","DEC 15",2014,9,12,null,null,null,null,null,null,"e113735","10.1371/journal.pone.0113735",null,18,"Multidisciplinary Sciences","Science & Technology - Other Topics","AW9WY","WOS:000346607100007",25502889]
["J","Petrovova, M; Tkadlec, J; Dvoracek, L; Streitova, E; Licha, I",null,null,null,"Petrovova, Miroslava; Tkadlec, Jan; Dvoracek, Lukas; Streitova, Eliska; Licha, Irena",null,null,"NAD(P)H-Hydrate Dehydratase- A Metabolic Repair Enzyme and Its Role in Bacillus subtilis Stress Adaptation","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"TRANSCRIPTION FACTOR; REGULATORY NETWORK; SIGMA-B; GENES; DEHYDROGENASE; BIOSYNTHESIS; ACTIVATION; PROTEOMICS; RESPONSES; REGULON","Background: One of the strategies for survival stress conditions in bacteria is a regulatory adaptive system called general stress response (GSR), which is dependent on the SigB transcription factor in Bacillus sp. The GSR is one of the largest regulon in Bacillus sp., including about 100 genes; however, most of the genes that show changes in expression during various stresses have not yet been characterized or assigned a biochemical function for the encoded proteins. Previously, we characterized the Bacillus subtilis168 osmosensitive mutant, defective in the yxkO gene (encoding a putative ribokinase), which was recently assigned in vitro as an ADP/ATP-dependent NAD(P) H-hydrate dehydratase and was demonstrated to belong to the SigB operon. Methods and Results: We show the impact of YxkO on the activity of SigB-dependent Pctc promoter and adaptation to osmotic and ethanol stress and potassium limitation respectively. Using a 2DE approach, we compare the proteomes of WT and mutant strains grown under conditions of osmotic and ethanol stress. Both stresses led to changes in the protein level of enzymes that are involved in motility (flagellin), citrate cycle (isocitrate dehydrogenase, malate dehydrogenase), glycolysis (phosphoglycerate kinase), and decomposition of Amadori products (fructosamine-6-phosphate deglycase). Glutamine synthetase revealed a different pattern after osmotic stress. The patterns of enzymes for branched amino acid metabolism and cell wall synthesis (L-alanine dehydrogenase, aspartate-semialdehyde dehydrogenase, ketol-acid reductoisomerase) were altered after ethanol stress. Conclusion: We performed the first characterization of a Bacillus subtilis168 knock-out mutant in the yxkO gene that encodes a metabolite repair enzyme. We show that such enzymes could play a significant role in the survival of stressed cells.","[Petrovova, Miroslava; Tkadlec, Jan; Dvoracek, Lukas; Streitova, Eliska; Licha, Irena] Charles Univ Prague, Fac Sci, Dept Genet & Microbiol, Prague, Czech Republic; [Tkadlec, Jan; Streitova, Eliska] Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Prague, Czech Republic","Licha, I (reprint author), Charles Univ Prague, Fac Sci, Dept Genet & Microbiol, Prague, Czech Republic.","licha@natur.cuni.cz",null,null,"Ministry of Education, Youth and Sports of the Czech Republic [LC06066]; Charles University by project of Specific University Research [SVV-2014-260081]","The study was supported by projects of Ministry of Education, Youth and Sports of the Czech Republic (LC06066) and by the Charles University by project of Specific University Research (SVV-2014-260081). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,38,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","NOV 13",2014,9,11,null,null,null,null,null,null,"e112590","10.1371/journal.pone.0112590",null,10,"Multidisciplinary Sciences","Science & Technology - Other Topics","AY6YT","WOS:000347709300076"]
["J","Fronkova, E; Klocperk, A; Svaton, M; Novakova, M; Kotrova, M; Kayserova, J; Kallna, T; Keslova, P; Votava, F; Vinohradska, H; Freiberger, T; Mejstrikova, E; Trka, J; Sediva, A",null,null,null,"Fronkova, Eva; Klocperk, Adam; Svaton, Mlchael; Novakova, Michaela; Kotrova, Mlchaela; Kayserova, Jana; Kallna, Tomas; Keslova, Petra; Votava, Felix; Vinohradska, Hana; Freiberger, Tomas; Mejstrikova, Ester; Trka, Jan; Sediva, Anna",null,null,"The TREC/KREC Assay for the Diagnosis and Monitoring of Patients with DiGeorge Syndrome","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"T-CELL-RECEPTOR; MINIMAL RESIDUAL DISEASE; DELETION SYNDROME; EXCISION CIRCLES; THYMIC OUTPUT; IMMUNODEFICIENCY; TRANSPLANTATION; PROLIFERATION; REPERTOIRES; CHILDREN","DiGeorge syndrome (DGS) presents with a wide spectrum of thymic pathologies. Nationwide neonatal screening programs of lymphocyte production using T-cell recombination excision circles (TREC) have repeatedly identified patients with DGS. We tested what proportion of DGS patients could be identified at birth by combined TREC and kappa-deleting element recombination circle (KREC) screening. Furthermore, we followed TREC/KREC levels in peripheral blood (PB) to monitor postnatal changes in lymphocyte production. Methods: TREC/KREC copies were assessed by quantitative PCR (qPCR) and were related to the albumin control gene in dry blood spots (DBSs) from control (n=56), severe immunodeficiency syndrome (SCID, n=10) and DGS (n=13) newborns. PB was evaluated in DGS children (n=32), in diagnostic samples from SCID babies (n=5) and in 91 controls. Results: All but one DGS patient had TREC levels in the normal range at birth, albeit quantitative TREC values were significantly lower in the DGS cohort. One patient had slightly reduced KREC at birth. Postnatal DGS samples revealed reduced TREC numbers in 5 of 32 (16%) patients, whereas KREC copy numbers were similar to controls. Both TREC and KREC levels showed a more pronounced decrease with age in DGS patients than in controls (p<0.0001 for both in a linear model). DGS patients had higher percentages of NK cells at the expense of T cells (p<0.0001). The patients with reduced TREC levels had repeated infections in infancy and developed allergy and/or autoimmunity, but they were not strikingly different from other patients. In 12 DGS patients with paired DBS and blood samples, the TREC/KREC levels were mostly stable or increased and showed similar kinetics in respective patients. Conclusions: The combined TREC/KREC approach with correction via control gene identified 1 of 13 (8%) of DiGeorge syndrome patients at birth in our cohort. The majority of patients had TREC/KREC levels in the normal range.","[Fronkova, Eva; Svaton, Mlchael; Novakova, Michaela; Kotrova, Mlchaela; Kallna, Tomas; Keslova, Petra; Mejstrikova, Ester; Trka, Jan] Charles Univ Prague, Sch Med 2, Dept Paediat Haematol Oncol, CLIP, Prague, Czech Republic; [Fronkova, Eva; Klocperk, Adam; Svaton, Mlchael; Novakova, Michaela; Kotrova, Mlchaela; Kayserova, Jana; Kallna, Tomas; Keslova, Petra; Mejstrikova, Ester; Trka, Jan; Sediva, Anna] Charles Univ Prague, Sch Med 2, Dept Immunol, Prague, Czech Republic; [Klocperk, Adam; Kayserova, Jana; Sediva, Anna] Univ Hosp Motol, Prague, Czech Republic; [Votava, Felix] Charles Univ Prague, Sch Med 3, Dept Pediat, Prague, Czech Republic; [Votava, Felix] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Vinohradska, Hana] Masaryk Univ, Fac Med, Children Hosp, Dept Clin Biochem, Brno, Czech Republic; [Freiberger, Tomas] Masaryk Univ, Dept Clin Immunol & Allergol, Fac Med, Brno, Czech Republic; [Freiberger, Tomas] Cent European Inst Technol, Brno, Czech Republic; [Freiberger, Tomas] Ctr Cardiovasc Surg & Transplantat, Mol Genet Lab, Brno, Czech Republic","Sediva, A (reprint author), Charles Univ Prague, Sch Med 2, Dept Immunol, Prague, Czech Republic.","anna.sediva@fnmotol.cz",null,null,"Czech Science Foundation (GACR) Centre of Excellence [P302/12/G101]; Internal Grant Agency of the Ministry of Health of the Czech Republic [IGA MZCR NT/13287-4/2012]; Ministry of Health of the Czech Republic (MH CZ-DRO), University Hospital Motol, Prague, Czech Republic [00064203]; L'Oreal for Women in Science Fellowship; Science Development Program at Charles University in Prague, PRVOUK [P31]","Funding: Support was provided by the Czech Science Foundation (GACR) Centre of Excellence, P302/12/G101, http://www.gacr.cz/en/, (EF, JT); Internal Grant Agency of the Ministry of Health of the Czech Republic, IGA MZCR NT/13287-4/2012, http://iga.mzcr.cz/publicWeb/ (AS); Ministry of Health of the Czech Republic (MH CZ-DRO), University Hospital Motol, Prague, Czech Republic, 00064203, http://www.mzcr.cz/ (AS); L'Oreal for Women in Science Fellowship in 2013, http://www.prozenyvevede.cz (EF); Science Development Program at Charles University in Prague, PRVOUK P31. http://ips.fsv.cuni.cz/IPSENG-53.html (FV). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,25,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","DEC 8",2014,9,12,null,null,null,null,null,null,"e114514","10.1371/journal.pone.0114514",null,13,"Multidisciplinary Sciences","Science & Technology - Other Topics","AX4MX","WOS:000346907600065",25485546]
["J","Forostyak, S; Homola, A; Turnovcova, K; Svitil, P; Jendelova, P; Sykova, E",null,null,null,"Forostyak, Serhiy; Homola, Ales; Turnovcova, Karolina; Svitil, Pavel; Jendelova, Pavla; Sykova, Eva",null,null,"Intrathecal Delivery of Mesenchymal Stromal Cells Protects the Structure of Altered Perineuronal Nets in SOD1 Rats and Amends the Course of ALS","STEM CELLS",null,null,"English","Article",null,null,null,null,null,"Neurodegeneration; Stem cells; Extracellular matrix; Proteoglycans; Preclinical trials","AMYOTROPHIC-LATERAL-SCLEROSIS; EMBRYONIC STEM-CELLS; SPINAL-CORD-INJURY; TRANSGENIC MOUSE MODEL; CENTRAL-NERVOUS-SYSTEM; MOTOR-NEURON DISEASE; EXTRACELLULAR-MATRIX; FUNCTIONAL RECOVERY; CHONDROITINASE ABC; MICROGLIAL ACTIVATION","Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder resulting in a lethal outcome. We studied changes in ventral horn perineuronal nets (PNNs) of superoxide dismutase 1 (SOD1) rats during the normal disease course and after the intrathecal application (5 x 10(5) cells) of human bone marrow mesenchymal stromal cells (MSCs) postsymptom manifestation. We found that MSCs ameliorated disease progression, significantly improved motor activity, and prolonged survival. For the first time, we report that SOD1 rats have an abnormal disorganized PNN structure around the spinal motoneurons and give different expression profiles of chondroitin sulfate proteoglycans (CSPGs), such as versican, aggrecan, and phosphacan, but not link protein-1. Additionally, SOD1 rats had different profiles for CSPG gene expression (Versican, Hapln1, Neurocan, and Tenascin-R), whereas Aggrecan and Brevican profiles remained unchanged. The application of MSCs preserved PNN structure, accompanied by better survival of motorneurons. We measured the concentration of cytokines (IL-1, MCP-1, TNF-, GM-CSF, IL-4, and IFN-) in the rats' cerebrospinal fluid and found significantly higher concentrations of IL-1 and MCP-1. Our results show that PNN and cytokine homeostasis are altered in the SOD1 rat model of ALS. These changes could potentially serve as biological markers for the diagnosis, assessment of treatment efficacy, and prognosis of ALS. We also show that the administration of human MSCs is a safe procedure that delays the loss of motor function and increases the overall survival of symptomatic ALS animals, by remodeling the recipients' pattern of gene expression and having neuroprotective and immunomodulatory effects. Stem Cells2014;32:3163-3172","[Forostyak, Serhiy; Homola, Ales; Turnovcova, Karolina; Svitil, Pavel; Jendelova, Pavla; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Forostyak, Serhiy; Homola, Ales; Turnovcova, Karolina; Svitil, Pavel; Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Med Fac 2, Dept Neurosci, Prague, Czech Republic","Forostyak, S (reprint author), AS CR, Dept Neurosci, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","serhiy.forostyak@biomed.cas.cz",null,null," [GACR 14-10504P];  [304/11/0189];  [P304/12/G069];  [MSMT CZ.1.07/2.3.00/30.0018]","This study was supported by the Grants GACR 14-10504P, 304/11/0189, P304/12/G069 and MSMT CZ.1.07/2.3.00/30.0018. We thank James Dutt and Elisa Brann for critical reading of the manuscript.",null,70,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1066-5099","1549-4918",null,"STEM CELLS","Stem Cells","DEC",2014,32,12,null,null,null,null,3163,3172,null,"10.1002/stem.1812",null,10,"Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology","Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology","AU4PL","WOS:000345593700012",25113670]
["J","Malikova, H; Kramska, L; Vojtech, Z; Liscak, R; Sroubek, J; Lukavsky, J; Druga, R",null,null,null,"Malikova, Hana; Kramska, Lenka; Vojtech, Zdenek; Liscak, Roman; Sroubek, Jan; Lukavsky, Jiri; Druga, Rastislav",null,null,"Different Surgical Approaches for Mesial Temporal Epilepsy: Resection Extent, Seizure, and Neuropsychological Outcomes","STEREOTACTIC AND FUNCTIONAL NEUROSURGERY",null,null,"English","Article",null,null,null,null,null,"Epilepsy surgery; Temporal lobe epilepsy; Memory; Outcome; MRI volumetry; Amygdalohippocampectomy","STEREOTACTIC RADIOFREQUENCY AMYGDALOHIPPOCAMPECTOMY; LOBE EPILEPSY; INTRINSIC CONNECTIONS; SURGERY; RADIOSURGERY; METAANALYSIS; REDUCTION; MEMORY","Background: Surgical therapy of intractable mesial temporal lobe epilepsy (MTLE) is an effective and well-established treatment. Objectives: We compared two different surgical approaches, standard microsurgical anterior temporal resection (ATL) and stereotactic radiofrequency amygdalohippocampectomy (SAHE) for MTLE, with respect to the extent of resection or destruction, clinical outcomes, and complications. Material and Methods: 75 MTLE patients were included: 41 treated by SAHE (11 right sided, 30 left sided) and 34 treated by ATL (21 right sided, 13 left sided). Results: SAHE and ATL seizure control were comparable (Engel I in 75.6 and 76.5% 2 years after surgery and 79.3 and 76.5% 5 years after procedures, respectively). The neuropsychological results of SAHE patients were better than in ATL. In SAHE patients, no memory deficit was found. Hippocampal (60.6 +/- 18.7%) and amygdalar (50.3 +/- 21.9%) volume reduction by SAHE was significantly lower than by ATL (86.0 +/- 12.7% and 80.2 +/- 20.9%, respectively). The overall rate of surgical nonsilent complications without permanent neurological deficit after ATL was 11.8%, and another 8.8% silent infarctions were found on MRI. The rate of clinically manifest complications after SAHE was 4.9%. The rate of visual field defects after SAHE was expectably less frequent than after ATL. Conclusion: Seizure control by SAHE was comparable to ATL. However, SAHE was safer with better neuropsychological results. (C) 2014 S. Karger AG, Basel","[Malikova, Hana] Na Homolce Hosp, Epilepsy Ctr, Dept Radiol, CZ-15000 Prague 5, Czech Republic; [Kramska, Lenka] Na Homolce Hosp, Epilepsy Ctr, Dept Clin Psychol, CZ-15000 Prague 5, Czech Republic; [Vojtech, Zdenek] Na Homolce Hosp, Epilepsy Ctr, Dept Neurol, CZ-15000 Prague 5, Czech Republic; [Liscak, Roman] Na Homolce Hosp, Epilepsy Ctr, Dept Radiat & Stereotact Neurosurg, CZ-15000 Prague 5, Czech Republic; [Sroubek, Jan] Na Homolce Hosp, Epilepsy Ctr, Dept Neurosurg, CZ-15000 Prague 5, Czech Republic; [Malikova, Hana; Druga, Rastislav] Charles Univ Prague, Fac Med 2, Inst Anat, Prague, Czech Republic; [Vojtech, Zdenek] Charles Univ Prague, Fac Med 3, Dept Neurol, Prague, Czech Republic; [Lukavsky, Jiri] Acad Sci Czech Republic, Inst Psychol, Prague, Czech Republic","Malikova, H (reprint author), Na Homolce Hosp, Dept Radiol, Roentgenova 2, CZ-15000 Prague 5, Czech Republic.","hana.malikova@homolka.cz",null,null,"Ministry of Health, Czech Republic - conceptual development of research organization (Nemocnice Na Homolce) [00023884]; Academy of Sciences of the Czech Republic [RVO 68081740]","The study was supported by the Ministry of Health, Czech Republic - conceptual development of research organization (Nemocnice Na Homolce, 00023884). The work of J.L. was supported by the grant No. RVO 68081740 of the Academy of Sciences of the Czech Republic.",null,31,0,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1011-6125","1423-0372",null,"STEREOT FUNCT NEUROS","Stereotact. Funct. Neurosurg.",null,2014,92,6,null,null,null,null,372,380,null,"10.1159/000366003",null,9,"Neurosciences; Neuroimaging; Surgery","Neurosciences & Neurology; Surgery","AW4UT","WOS:000346276500006",25359168]
["J","Vickova, M; Hancarova, M; Drabova, J; Slamova, Z; Koudova, M; Alanova, R; Mannik, K; Kurg, A; Sedlacek, Z",null,null,null,"Vickova, Marketa; Hancarova, Miroslava; Drabova, Jana; Slamova, Zuzana; Koudova, Monika; Alanova, Renata; Mannik, Katrin; Kurg, Ants; Sedlacek, Zdenek",null,null,"Monozygotic Twins with 17q21.31 Microdeletion Syndrome","TWIN RESEARCH AND HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"17q21.31 microdeletion syndrome; monozygotic twins; CNV; epigenetics","EPIGENETIC DIFFERENCES; INVERSION POLYMORPHISM; COMMON INVERSION; DNA METHYLATION; KANSL1 CAUSE; DISCORDANT; MUTATIONS; PHENOTYPE; GENE","Chromosome 17q21.31 microdeletion syndrome is a genomic disorder caused by a recurrent 600 kb long deletion. The deletion affects the region of a common inversion present in about 20% of Europeans. The inversion is associated with the H2 haplotype carrying additional low-copy repeats susceptible to non-allelic homologous recombination, and this haplotype is prone to deletion. No instances of 17q21.31 deletions inherited from an affected parent have been reported, and the deletions always affected a parental chromosome with the H2 haplotype. The syndrome is characterized clinically by intellectual disability, hypotonia, friendly behavior and specific facial dysmorphism with long face, large tubular or pear-shaped nose and bulbous nasal tip. We present monozygotic twin sisters showing the typical clinical picture of the syndrome. The phenotype of the sisters was very similar, with a slightly more severe presentation in Twin B. The 17q21.31 microdeletion was confirmed in both patients but in neither of their parents. Potential copy number differences between the genomes of the twins were subsequently searched using high-resolution single nucleotide polymorphism (SNP) and comparative genome hybridisation (CGH) arrays. However, these analyses identified no additional aberrations or genomic differences that could potentially be responsible for the subtle phenotypic differences. These could possibly be related to the more severe perinatal history of Twin B, or to the variable expressivity of the disorder. In accord with the expectations, one of the parents (the mother) was shown to carry the H2 haplotype, and the maternal allele of chromosome 17q21.31 was missing in the twins.","[Vickova, Marketa; Hancarova, Miroslava; Drabova, Jana; Slamova, Zuzana; Koudova, Monika; Alanova, Renata; Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague 15000 5, Czech Republic; [Vickova, Marketa; Hancarova, Miroslava; Drabova, Jana; Slamova, Zuzana; Koudova, Monika; Alanova, Renata; Sedlacek, Zdenek] Univ Hosp Motol, Prague 15000 5, Czech Republic; [Mannik, Katrin; Kurg, Ants] Univ Tartu, Inst Mol & Cell Biol, EE-50090 Tartu, Estonia","Hancarova, M (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Plzenska 130-221, Prague 15000 5, Czech Republic.","miroslava.hancarova@lfmotol.cuni.cz",null,null,"European Commission [CHERISH 223692, CZ.2.16/3.1.00/24022]; Czech Ministry of Health [DRO UH Motol 00064203, NT/14200]; Estonian Ministry of Education and Research [SF0180027s10]","We thank the family of the patients for cooperation. Supported by grants CHERISH 223692 and CZ.2.16/3.1.00/24022 from the European Commission, DRO UH Motol 00064203 and NT/14200 from the Czech Ministry of Health, and SF0180027s10 from the Estonian Ministry of Education and Research.",null,26,0,0,"CAMBRIDGE UNIV PRESS","NEW YORK","32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA","1832-4274","1839-2628",null,"TWIN RES HUM GENET","Twin Res. Hum. Genet.","OCT",2014,17,5,null,null,"SI",null,405,410,null,"10.1017/thg.2014.29",null,6,"Genetics & Heredity; Obstetrics & Gynecology","Genetics & Heredity; Obstetrics & Gynecology","AS0JS","WOS:000343964200008"]
["J","Rieken, M; Xylinas, E; Kluth, L; Crivelli, JJ; Chrystal, J; Faison, T; Lotan, Y; Karakiewicz, PI; Sun, M; Fajkovic, H; Babjuk, M; Bachmann, A; Scherr, DS; Shariat, SF",null,null,null,"Rieken, Malte; Xylinas, Evanguelos; Kluth, Luis; Crivelli, Joseph J.; Chrystal, James; Faison, Talia; Lotan, Yair; Karakiewicz, Pierre I.; Sun, Maxine; Fajkovic, Harun; Babjuk, Marek; Bachmann, Alexander; Scherr, Douglas S.; Shariat, Shahrokh F.",null,null,"Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma","UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS",null,null,"English","Article",null,null,null,null,null,"Metformin; Diabetes mellitus; Bladder cancer; Radical cystectomy; Outcomes","BLADDER-CANCER; RISK; RECURRENCE; SURVIVAL; COHORT; THIAZOLIDINEDIONES; METAANALYSIS; MORTALITY; INVASION","Objectives: Evidence suggests a positive effect of metfoimin on cancer incidence and outcome. To date, the effect of metfoimin use on prognosis in urothelial carcinoma of the bladder (UCB) remains uninvestigated. We tested the hypothesis that metformin use affects oncologic outcomes of patients treated with radical cystectomy for UCB. Methods and materials: We retrospectively evaluated 1,502 patients treated at 4 institutions with radical cystectomy and pelvic lymphadenectomy without neoadjuvant therapy. Cox regression models addressed the association of diabetes mellitus (DM) and metformin use with disease recurrence, cancer-specific mortality, and any-cause mortality. Results: A total of 200 patients (13.3%) had DM, 80 patients (5.3%) used metformin. Within a median follow-up of 34 months, 509 patients (33.9%) experienced disease recurrence, 402 patients (26.8%) died of UCB, and 551 patients (36.7%) died from any cause. In univariable Cox regression analyses, DM without metfonnin use was associated with increased risk of disease recurrence (hazard ratio RIR]: 1.40, 95% confidence interval ICII 1.05 1.87, P = 0.02), cancer-specilic mortality (HR: 1.60, 95% CI 1.17 2.17, P = 0.003), and any-cause mortality (HR: 1.55, 95% CI 1.18 2.03, P = 0.002), whereas mettOrmin use was associated with decreased risk of disease recurrence (IIR: 0.61. 95% CI 0.37 0.98, P = 0.04), cancer-specific mortality (11R: 0.56, 95% CI 0.33 0.97, P = 0.04), and any-cause mortality (IIR: 0.54, 95% CI 0.33 0.88, P = 0.01). In multivariable Cox regression analyses, DM treated without metformin use remained associated with worse cancer-specific mortality (HR: 1.53, 95% CI 1.12-2.09, P = 0.007) and any-cause mortality (HR: 1.52, 95% CI 1.16-2.00, P = 0.003) but not disease recurrence. Conclusions: Diabetic patients who do not use metformin appear to be at higher risk of cancer-specific and any-cause mortality than patients without DM. It remains unclear, whether the severity of DM in this group of patients or the use of metformin itself affects outcomes of UCB. The mechanisms behind the effect of DM on patients with UCB and the potential protective effect of metformin need further elucidation. (C) 2014 Elsevier Inc. All rights reserved.","[Rieken, Malte; Xylinas, Evanguelos; Kluth, Luis; Crivelli, Joseph J.; Chrystal, James; Faison, Talia; Scherr, Douglas S.; Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Urol, New York, NY 10065 USA; [Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Med Oncol, New York, NY USA; [Rieken, Malte; Bachmann, Alexander] Univ Basel Hosp, Dept Urol, CH-4031 Basel, Switzerland; [Xylinas, Evanguelos] Paris Descartes Univ, Cochin Hosp, APHP, Dept Urol, Paris, France; [Kluth, Luis] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Karakiewicz, Pierre I.; Sun, Maxine] Univ Montreal, Dept Urol, Montreal, PQ, Canada; [Fajkovic, Harun] Med Univ Vienna, Dept Urol, Vienna, Austria; [Babjuk, Marek] Charles Univ Prague, Hosp Motol, Dept Urol, Fac Med 2, Prague, Czech Republic; [Shariat, Shahrokh F.] Med Univ Vienna, Dept Urol, Vienna, Austria","Shariat, SF (reprint author), New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Urol, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,null,null,null,29,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1078-1439","1873-2496",null,"UROL ONCOL-SEMIN ORI","Urol. Oncol.-Semin. Orig. Investig.","JAN",2014,32,1,null,null,null,null,null,null,null,"10.1016/j.urolonc.2013.07.006",null,8,"Oncology; Urology & Nephrology","Oncology; Urology & Nephrology","AX9SW","WOS:000347243300098"]
["J","Vesela, P; Tonar, Z; Salek, D; Vokurka, S; Trneny, M; Kodet, R; Moulis, M; Kasparova, P; Vernerova, Z; Velenska, Z; Stritesky, J; Michal, M; Boudova, L",null,null,null,"Vesela, Pavla; Tonar, Zbynek; Salek, David; Vokurka, Samuel; Trneny, Marek; Kodet, Roman; Moulis, Mojmir; Kasparova, Petra; Vernerova, Zdenka; Velenska, Zuzana; Stritesky, Jan; Michal, Michal; Boudova, Ludmila",null,null,"Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases","VIRCHOWS ARCHIV",null,null,"English","Article",null,null,null,null,null,"Angiogenesis; Mantle cell lymphoma; Mantle cell lymphoma international prognostic index; Microvessel density; Prognosis; Proliferative activity","BONE-MARROW ANGIOGENESIS; EUROPEAN-MCL-NETWORK; FOLLICULAR LYMPHOMA; PROLIFERATION INDEX; RANDOMIZED-TRIALS; MULTIPLE-MYELOMA; IMMUNOCHEMOTHERAPY; EXPRESSION; RITUXIMAB; MIPI","The clinical course and therapy of mantle cell lymphoma (MCL) are heterogeneous and often unsatisfactory. Prognostic factors are needed to stratify the patients. Microvessel density (MVD) has prognostic significance in some malignancies. There is little information about the vasculature of MCL, although some antiangiogenic drugs are in use. We studied MVD using systematic uniform random sampling and unbiased counting frames in immunohistochemical reactions with anti-CD34 antibody in pre-therapeutic extramedullary MCL samples of 177 patients. We analyzed the relationship of MVD to overall survival (OS) and progression-free survival (PFS), as well as to proliferative activity (Ki-67), mantle cell lymphoma prognostic index (MIPI), morphological variant, pattern of growth, and localization. MVD varied widely: range 54.6-503.6 vessels/mm(2), median 158.2 vessels/mm(2). Higher MVD was associated with bone marrow infiltration at the time of diagnosis (P = 0.001). High MVD was associated with significantly worse OS (P = 0.04) only in patients treated with non-intensive (conventional) therapy. MVD correlated positively with MIPI scores but not with the proliferation, morphological variant, growth pattern, or localization. Univariate analysis identified a prognostic influence of morphological variant, MIPI, and proliferative activity on OS and PFS and a prognostic influence of bone marrow infiltration at the time of diagnosis on PFS. Multivariate analysis showed prognostic influence of MIPI and proliferative activity on OS and PFS only. In conclusion, this is the first clinicopathological study of MVD of MCL with long-term follow-up showing negative prognostic trends of high MVD in MCL and positive correlation of MVD and MIPI.","[Vesela, Pavla; Michal, Michal; Boudova, Ludmila] Charles Univ Prague, Sikls Dept Pathol, Fac Med Pilsen, Plzen 30460, Czech Republic; [Vesela, Pavla; Michal, Michal; Boudova, Ludmila] Univ Hosp Plzen, Plzen 30460, Czech Republic; [Tonar, Zbynek] Charles Univ Prague, Biomed Ctr, Fac Med Pilsen, Plzen, Czech Republic; [Salek, David] Univ Hosp, Dept Internal Med Hematol & Oncol, Brno, Czech Republic; [Salek, David] Masaryk Univ, Brno, Czech Republic; [Vokurka, Samuel] Charles Univ Prague, Dept Hematooncol, Fac Med Pilsen, Plzen, Czech Republic; [Vokurka, Samuel] Univ Hosp, Plzen, Czech Republic; [Trneny, Marek] Charles Univ Prague, Dept Med 1, Prague, Czech Republic; [Trneny, Marek; Velenska, Zuzana; Stritesky, Jan] Gen Univ Hosp, Prague, Czech Republic; [Kodet, Roman] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Kodet, Roman] Fac Hosp Motol, Prague, Czech Republic; [Moulis, Mojmir] Masaryk Univ, Dept Pathol, Brno, Czech Republic; [Moulis, Mojmir] Univ Hosp, Brno, Czech Republic; [Kasparova, Petra] Charles Univ Prague, Fac Med, Fingerland Dept Pathol, Hradec Kralove, Czech Republic; [Kasparova, Petra] Charles Univ Prague, Fac Hosp, Hradec Kralove, Czech Republic; [Vernerova, Zdenka] Charles Univ Prague, Fac Med 3, Dept Pathol, Prague, Czech Republic; [Velenska, Zuzana; Stritesky, Jan] Charles Univ Prague, Inst Pathol, Fac Med 1, Prague, Czech Republic","Boudova, L (reprint author), Charles Univ Prague, Sikls Dept Pathol, Fac Med Pilsen, Alej Svobody 80, Plzen 30460, Czech Republic.","boudova@medima.cz",null,null,"Ministry of Education and Youth of the Czech Republic [MSM0021620819]; Charles University in Prague [P36]; Internal Grant Agency of the Ministry of Health of the Czech Republic [IGA MZ CR NT 12193-5]","The help of many participating physicians and data managers providing clinical information and pathological specimens is greatly acknowledged. This study was supported in part by research grants of the Ministry of Education and Youth of the Czech Republic MSM0021620819 (LB), by the Charles University in Prague, Project No. P36 (ZT), and by the grant of the Internal Grant Agency of the Ministry of Health of the Czech Republic IGA MZ CR NT 12193-5 (LB, PV, DS, MT, on behalf of CLSG).",null,41,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0945-6317","1432-2307",null,"VIRCHOWS ARCH","Virchows Arch.","NOV",2014,465,5,null,null,null,null,587,597,null,"10.1007/s00428-014-1632-4",null,11,"Pathology","Pathology","AS6WD","WOS:000344399200011",25048573]
["J","Bobek, V; Gurlich, R; Eliasova, P; Kolostova, K",null,null,null,"Bobek, Vladimir; Gurlich, Robert; Eliasova, Petra; Kolostova, Katarina",null,null,"Circulating tumor cells in pancreatic cancer patients: Enrichment and cultivation","WORLD JOURNAL OF GASTROENTEROLOGY",null,null,"English","Article",null,null,null,null,null,"Pancreatic cancer; Circulating tumor cells; Biomarker; Cultivation","METASTATIC BREAST-CANCER; PROGNOSTIC VALUE; DIAGNOSIS; METAANALYSIS; CHALLENGES; MANAGEMENT; SURVIVAL; EPCAM","AIM: To investigate the feasibility of separation and cultivation of circulating tumor cells (CTCs) in pancreatic cancer (PaC) using a filtration device. METHODS: In total, 24 PaC patients who were candidates for surgical treatment were enrolled into the study. Peripheral blood samples were collected before an indicated surgery. For each patient, approximately 8 mL of venous blood was drawn from the antecubital veins. A new size-based separation MetaCell (R) technology was used for enrichment and cultivation of CTCs in vitro. (Separated CTCs were cultured on a membrane in FBS enriched RPMI media and observed by inverted microscope. The cultured cells were analyzed by means of histochemistry and immunohistochemistry using the specific antibodies to identify the cell origin. RESULTS: CTCs were detected in 16 patients (66.7%) of the 24 evaluable patients. The CTC positivity did not reflect the disease stage, tumor size, or lymph node involvement. The same percentage of CTC positivity was observed in the metastatic and non-metastatic patients (66.7% vs 66.7%). We report a successful isolation of CTCs in PaC patients capturing proliferating cells. The cells were captured by a capillary action driven size-based filtration approach that enabled cells cultures from the viable CTCs to be unaffected by any antibodies or lysing solutions. The captured cancer cells displayed plasticity which enabled some cells to invade the separating membrane. Further, the cancer cells in the \"bottom fraction\", may represent a more invasive CTC-fraction. The CTCs were cultured in vitro for further downstream applications. CONCLUSION: The presented size-based filtration method enables culture of CTCs in vitro for possible downstream applications. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.","[Bobek, Vladimir; Kolostova, Katarina] Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Prague 10034, Czech Republic; [Bobek, Vladimir] Wroclaw Med Univ, Dept Histol & Embryol, PL-50367 Wroclaw, Poland; [Bobek, Vladimir] Charles Univ Prague, Fac Med 1, Dept Surg 3, Prague 10034, Czech Republic; [Bobek, Vladimir] Univ Hosp Motol, Prague 10034, Czech Republic; [Gurlich, Robert; Eliasova, Petra] Univ Hosp Kralovske Vinohrady, Dept Surg, Prague 0034, Czech Republic","Bobek, V (reprint author), Univ Hosp Kralovske Vinohrady, Dept Lab Genet, Srobarova 50, Prague 10034, Czech Republic.","vbobek@centrum.cz",null,null,"Research project \"CTC in gastrointestinal cancer \"awarded by League Against Cancer Prague, Czech Republic; Czech Ministry of Health [IGA NT14439-3/2013]; Ministry of Helath Czech Republic, conceptual development of research organization, University Hospital Motol, Prague Czech Republic [000 64203]","Supported by Research project \"CTC in gastrointestinal cancer \"awarded by League Against Cancer Prague, Czech Republic and grant of the Czech Ministry of Health, No. IGA NT14439-3/2013; and by the projects by Ministry of Helath Czech Republic, conceptual development of research organization, University Hospital Motol, Prague Czech Republic, No. 000 64203",null,26,0,0,"BAISHIDENG PUBLISHING GROUP INC","PLEASANTON","8226 REGENCY DR, PLEASANTON, CA 94588 USA","1007-9327","2219-2840",null,"WORLD J GASTROENTERO","World J. Gastroenterol.","DEC 7",2014,20,45,null,null,null,null,17163,17170,null,"10.3748/wjg.v20.i45.17163",null,8,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","AW1LK","WOS:000346050700038",25493031]

{"sheet":"ARCHIV - WOS 2009-2013","index":2,"n_rows":1545,"n_cols":63,"rows_kept":1545,"cut":false,"hidden":false,"merged":[]}
["Počet z DT",null,null,null,"PT","AU","BA","BE","GP","AF","BF","CA","TI","SO","SE","BS","LA","DT","CT","CY","CL","SP","HO","DE","ID","AB","C1","RP","EM","RI","OI","FU","FX","CR","NR","TC","Z9","PU","PI","PA","SN","EI","BN","J9","JI","PD","PY","VL","IS","PN","SU","SI","MA","BP","EP","AR","DI","D2","PG","WC","SC","GA","UT"]
["PY","DT","Celkem",null,"J","Connolly, SJ; Ezekowitz, MD; Yusuf, S; Eikelboom, J; Oldgren, J; Parekh, A; Pogue, J; Reilly, PA; Themeles, E; Varrone, J; Wang, S; Alings, M; Xavier, D; Zhu, J; Diaz, R; Lewis, BS; Darius, H; Diener, HC; Joyner, CD; Wallentin, L",null,null,null,"Connolly, Stuart J.; Ezekowitz, Michael D.; Yusuf, Salim; Eikelboom, John; Oldgren, Jonas; Parekh, Amit; Pogue, Janice; Reilly, Paul A.; Themeles, Ellison; Varrone, Jeanne; Wang, Susan; Alings, Marco; Xavier, Denis; Zhu, Jun; Diaz, Rafael; Lewis, Basil S.; Darius, Harald; Diener, Hans-Christoph; Joyner, Campbell D.; Wallentin, Lars",null,"RE-LY Steering Comm & Investigator","Dabigatran versus Warfarin in Patients with Atrial Fibrillation.","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"NON-INFERIORITY TRIAL; ANTITHROMBOTIC THERAPY; ANTICOAGULANT-THERAPY; ORAL ANTICOAGULANT; PREVENT STROKE; ASPIRIN; THROMBOEMBOLISM; METAANALYSIS; CLOPIDOGREL; ETEXILATE","Background: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. Methods: In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran -- 110 mg or 150 mg twice daily -- or, in an unblinded fashion, adjusted-dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism. Results: Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.91; 95% confidence interval [CI], 0.74 to 1.11; P<0.001 for noninferiority) and 1.11% per year in the group that received 150 mg of dabigatran (relative risk, 0.66; 95% CI, 0.53 to 0.82; P<0.001 for superiority). The rate of major bleeding was 3.36% per year in the warfarin group, as compared with 2.71% per year in the group receiving 110 mg of dabigatran (P=0.003) and 3.11% per year in the group receiving 150 mg of dabigatran (P=0.31). The rate of hemorrhagic stroke was 0.38% per year in the warfarin group, as compared with 0.12% per year with 110 mg of dabigatran (P<0.001) and 0.10% per year with 150 mg of dabigatran (P<0.001). The mortality rate was 4.13% per year in the warfarin group, as compared with 3.75% per year with 110 mg of dabigatran (P=0.13) and 3.64% per year with 150 mg of dabigatran (P=0.051). Conclusions: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. (ClinicalTrials.gov number, NCT00262600.) N Engl J Med 2009;361:1139-51.","[Connolly, Stuart J.; Yusuf, Salim; Eikelboom, John; Pogue, Janice; Themeles, Ellison] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; [Connolly, Stuart J.; Yusuf, Salim; Eikelboom, John; Pogue, Janice; Themeles, Ellison] Hamilton Hlth Sci, Hamilton, ON, Canada; [Ezekowitz, Michael D.; Parekh, Amit] Lankenau Inst Med Res, Wynnewood, PA USA; [Ezekowitz, Michael D.; Parekh, Amit] Ctr Heart, Wynnewood, PA USA; [Oldgren, Jonas; Wallentin, Lars] Uppsala Clin Res Ctr, Uppsala, Sweden; [Reilly, Paul A.; Varrone, Jeanne; Wang, Susan] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; [Alings, Marco] Working Grp Cardiovasc Res Netherlands, Utrecht, Netherlands; [Xavier, Denis] St Johns Natl Acad Hlth Sci, Bangalore, Karnataka, India; [Zhu, Jun] FuWai Hosp, Beijing, Peoples R China; [Diaz, Rafael] Estudios Clin Latinoamer, Rosario, Santa Fe, Argentina; [Lewis, Basil S.] Lady Davies Carmel Med Ctr, Haifa, Israel; [Darius, Harald] Vivantes Klinikum Neukolln, Berlin, Germany; [Diener, Hans-Christoph] Univ Duisburg Essen, Essen, Germany; [Joyner, Campbell D.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada","Connolly, SJ (reprint author), McMaster Univ, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.","connostu@phri.ca","Tanne, David/F-2560-2010; Davis, Stephen/L-5260-2013","Tanne, David/0000-0002-6699-2220; Davis, Stephen/0000-0003-0962-2300","Boehringer Ingelheim","Supported by a grant from Boehringer Ingelheim.","Birman-Deych E, 2006, STROKE, V37, P1070, DOI 10.1161/01.STR.0000208294.46968.a4; Bousser MG, 2008, LANCET, V372, P2022; Bousser MG, 2008, LANCET, V371, P315; Connolly S, 2006, LANCET, V367, P1903; Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301; Connolly SJ, 2008, CIRCULATION, V118, P2029, DOI 10.1161/CIRCULATIONAHA.107.750000; Deiner HC, 2006, CEREBROVASC DIS, V21, P279, DOI DOI 10.1159/000091265; Eriksson BI, 2007, LANCET, V370, P2004; Eriksson BI, 2007, LANCET, V370, P949, DOI 10.1016/S0140-6736(07)61445-7; Ezekowitz MD, 2007, AM J CARDIOL, V100, P1419, DOI 10.1016/j.amjcard.2007.06.034; Ezekowitz MD, 2009, AM HEART J, V157, P805, DOI 10.1016/j.ahj.2009.02.005; Fuster V, 2006, J AM COLL CARDIOL, V48, P854, DOI 10.1016/j.jacc.2006.07.009; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Hart RG, 2007, ANN INTERN MED, V146, P857; Hart RG, 1999, ANN INTERN MED, V131, P492; Hurlen M, 2002, NEW ENGL J MED, V347, P969, DOI 10.1056/NEJMoa020496; Hylek EM, 2007, CIRCULATION, V115, P2689, DOI 10.1161/CIRCULATIONHA.106.653048; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; Stangier J, 2008, CLIN PHARMACOKINET, V47, P285, DOI 10.2165/00003088-200847050-00001",19,2018,2091,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","SEP 17",2009,361,12,null,null,null,null,1139,1151,null,"10.1056/NEJMoa0905561",null,13,"Medicine, General & Internal","General & Internal Medicine","494QA","WOS:000269828000005"]
[2009,"Article",258,null,"J","Pfeffer, MA; Burdmann, EA; Chen, CY; Cooper, ME; de Zeeuw, D; Eckardt, KU; Feyzi, JM; Ivanovich, P; Kewalramani, R; Levey, AS; Lewis, EF; McGill, JB; McMurray, JJV; Parfrey, P; Parving, HH; Remuzzi, G; Singh, AK; Solomon, SD; Toto, R",null,null,null,"Pfeffer, Marc A.; Burdmann, Emmanuel A.; Chen, Chao-Yin; Cooper, Mark E.; de Zeeuw, Dick; Eckardt, Kai-Uwe; Feyzi, Jan M.; Ivanovich, Peter; Kewalramani, Reshma; Levey, Andrew S.; Lewis, Eldrin F.; McGill, Janet B.; McMurray, John J. V.; Parfrey, Patrick; Parving, Hans-Henrik; Remuzzi, Giuseppe; Singh, Ajay K.; Solomon, Scott D.; Toto, Robert",null,"TREAT Investigators","A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"STAGE RENAL-DISEASE; ERYTHROPOIESIS-STIMULATING AGENTS; RECOMBINANT HUMAN ERYTHROPOIETIN; RANDOMIZED-TRIALS; CARDIOVASCULAR-DISEASE; HEMODIALYSIS-PATIENTS; ANEMIA CORRECTION; CLINICAL-TRIALS; EPOETIN-ALPHA; RISK-FACTOR","BACKGROUND Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested. METHODS In this study involving 4038 patients with diabetes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with rescue darbepoetin alfa when the hemoglobin level was less than 9.0 g per deciliter. The primary end points were the composite outcomes of death or a cardiovascular event (nonfatal myocardial infarction, congestive heart failure, stroke, or hospitalization for myocardial ischemia) and of death or end-stage renal disease. RESULTS Death or a cardiovascular event occurred in 632 patients assigned to darbepoetin alfa and 602 patients assigned to placebo ( hazard ratio for darbepoetin alfa vs. placebo, 1.05; 95% confidence interval [CI], 0.94 to 1.17; P = 0.41). Death or end-stage renal disease occurred in 652 patients assigned to darbepoetin alfa and 618 patients assigned to placebo ( hazard ratio, 1.06; 95% CI, 0.95 to 1.19; P = 0.29). Fatal or nonfatal stroke occurred in 101 patients assigned to darbepoetin alfa and 53 patients assigned to placebo ( hazard ratio, 1.92; 95% CI, 1.38 to 2.68; P<0.001). Red-cell transfusions were administered to 297 patients assigned to darbepoetin alfa and 496 patients assigned to placebo (P<0.001). There was only a modest improvement in patient-reported fatigue in the darbepoetin alfa group as compared with the placebo group. CONCLUSIONS The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes ( either death or a cardiovascular event or death or a renal event) and was associated with an increased risk of stroke. For many persons involved in clinical decision making, this risk will outweigh the potential benefits. (ClinicalTrials.gov number, NCT00093015.)","[Pfeffer, Marc A.] Harvard Univ, Div Cardiovasc, Brigham & Womens Hosp, Dept Med,Med Sch, Boston, MA 02115 USA; [Levey, Andrew S.] Tufts Med Ctr, Div Nephrol, Boston, MA USA; [Burdmann, Emmanuel A.] Hosp Base, Fac Med Sao Jose Rio Preto, Sao Jose Do Rio Preto, Brazil; [Chen, Chao-Yin; Kewalramani, Reshma] Amgen Inc, Global Biostat & Epidemiol & Global Clin Dev, Thousand Oaks, CA USA; [Cooper, Mark E.] Baker Heart Res Inst, Melbourne, Vic, Australia; [de Zeeuw, Dick] Univ Groningen, Univ Med Ctr Groningen, Div Clin Pharmacol, NL-9713 AV Groningen, Netherlands; [Eckardt, Kai-Uwe] Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Erlangen, Germany; [Feyzi, Jan M.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA; [Ivanovich, Peter] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA; [McGill, Janet B.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63130 USA; [McMurray, John J. V.] British Heart Fdn Glasgow Cardiovasc Res Ctr, Dept Cardiol, Glasgow, Lanark, Scotland; [Parfrey, Patrick] Hlth Sci Ctr, Div Nephrol, St John, NF, Canada; [Parving, Hans-Henrik] Univ Copenhagen, Rigshosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark; [Parving, Hans-Henrik] Aarhus Univ, Fac Hlth Sci, Aarhus, Denmark; [Remuzzi, Giuseppe] Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy; [Toto, Robert] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA","Pfeffer, MA (reprint author), Harvard Univ, Div Cardiovasc, Brigham & Womens Hosp, Dept Med,Med Sch, 75 Francis St, Boston, MA 02115 USA.","mpfeffer@rics.bwh.harvard.edu","Cooper, Mark/E-8680-2010; Johnson, David/F-2897-2011; Burdmann, Emmanuel/B-7023-2009; de Jesus Falcao Pestana Vasconcelos, Manuel/E-9226-2013; 5, INCT/H-4505-2013; Diabetes, Inct/I-2186-2013; Solomon, Scott/I-5789-2013; de Zeeuw, Dick/E-9080-2014","Johnson, David/0000-0001-5491-3460; ","Amgen; Baxter; Celladon; Novartis; Sanofi-Aventis; Roche; Robert Wood Johnson Foundation; Boehringer Ingelheim; BMS; AstraZeneca; Cytokinetics; Hoffmann-La Roche; Pfizer; Scios; GlaxoSmithKline; Johnson & Johnson; AMAG Pharmaceuticals; Watson; Reata; Abbott","Supported by Amgen, which provided independent statistical support through a contract with the board of regents for the University of Wisconsin System for data analysis for the TREAT Data and Safety Monitoring Committee as well as for the study.Dr. Pfeffer reports receiving consulting fees from Abbott, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Centocor, CVRx, Genentech, Cytokinetics, Daiichi Sankyo, Genzyme, Medtronic, Novartis, Roche, Sanofi-Aventis, Servier, and VIA Pharmaceutics and grant support from Amgen, Baxter, Celladon, Novartis, and Sanofi-Aventis, and being named coinventor on a patent for the use of inhibitors of the renin-angiotensin system in selected survivors of myocardial infarction; Dr. Burdmann, receiving consulting fees from Amgen and Sigma Pharma and grant support from Amgen and Roche; Drs. Chen and Kewalramani, being employees of and owning stock in Amgen; Dr. Cooper, receiving consulting fees from Amgen; Dr. de Zeeuw, receiving consulting fees from Amgen and Novartis and lecture fees from Amgen; Dr. Eckardt, receiving consulting fees from Amgen, Ortho Biotech, Roche, Affymax, Stada, and Sandoz-Hexal and lecture fees from Amgen, Ortho Biotech, and Roche; Dr. Ivanovich, receiving consulting fees from Amgen, Baxter, Biogen, and Reata; Dr. Levey, receiving grant support from Amgen; Dr. Lewis, receiving consulting fees from Amgen and grant support from Amgen and the Robert Wood Johnson Foundation; Dr. McGill, receiving consulting fees from Amgen and Boehringer Ingelheim, lecture fees from Novartis, and grant support from Novartis and Boehringer Ingelheim; Dr. McMurray, receiving consulting fees from Menarini, Bristol- Myers Squibb, Roche, Novocardia, Boehringer Ingelheim, Novartis, BioMerieux, and Boston Scientific, lecture fees from AstraZeneca, Solvay, Takeda, Novartis, BMS Sanofi, and Vox Media, and grant support from BMS, Novartis, Amgen, AstraZeneca, Cytokinetics, Hoffmann-La Roche, Pfizer, Scios, and GlaxoSmithKline; Dr. Parfrey, receiving consulting and lecture fees from Amgen and lecture fees from Ortho Biotech; Dr. Parving, receiving consulting fees from Amgen and Novartis and lecture fees from Novartis; Dr. Singh, receiving consulting fees from Johnson & Johnson and Watson, lecture fees from Johnson & Johnson, Amgen, and Watson, and grant support from Johnson & Johnson, Amgen, Roche, AMAG Pharmaceuticals, and Watson; Dr. Solomon, receiving grant support from Amgen; and Dr. Toto, receiving consulting and lecture fees from Amgen and grant support from Novartis, Reata, and Abbott. No other potential conflict of interest relevant to this article was reported.","BAIGENT C, 2005, LANCET, V366, P1358; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Baigent C, 2008, LANCET, V371, P2084; Bohlius J, 2009, LANCET, V373, P1532, DOI 10.1016/S0140-6736(09)60502-X; Bohlius J, 2009, LANCET, V374, P28; Booth GL, 2006, LANCET, V368, P29, DOI 10.1016/S0140-6736(06)68967-8; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Califf RM, 2002, CIRCULATION, V106, P1015, DOI 10.1161/01.CIR.0000023260.78078.BB; LAUPACIS A, 1990, BRIT MED J, V300, P573; DeMets DL, 1999, LANCET, V354, P1983, DOI 10.1016/S0140-6736(99)03464-9; DUREKE TB, 2006, NEW ENGL J MED, V355, P2071; EHRENREICH H, 2009, STROKE          1015; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992; Foley RN, 1996, AM J KIDNEY DIS, V28, P53, DOI 10.1016/S0272-6386(96)90130-4; *FOOD DRUG ADM, FDA BLOCK BOX WARN A; Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245; Keane WF, 2003, KIDNEY INT, V63, P1499, DOI 10.1046/j.1523-1755.2003.00885.x; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Leyland-Jones B, 2005, J CLIN ONCOL, V23, P5960, DOI 10.1200/JCO.2005.06.150; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P121, DOI 10.1093/ndt/gfg458; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P1666, DOI 10.1093/ndt/gfh314; Mozzicato P, 2007, DRUG SAFETY, V30, P617, DOI 10.2165/00002018-200730070-00009; Parfrey PS, 2005, J AM SOC NEPHROL, V16, P2180, DOI 10.1681/ASN.2004121039; Pfeffer MA, 2009, AM J KIDNEY DIS, V54, P59, DOI 10.1053/j.ajkd.2009.04.008; Pfeffer Marc A, 2005, Rev Cardiovasc Med, V6 Suppl 3, pS35; Pfeffer MA, 2008, AM J KIDNEY DIS, V51, P366, DOI 10.1053/j.ajkd.2008.01.003; Pfeffer MA, 2007, NEW ENGL J MED, V356, P959, DOI 10.1056/NEJMc066568; Phrommintikul A, 2007, LANCET, V369, P381, DOI 10.1016/S0140-6736(07)60194-9; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Strippoli GF, 2006, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003967.P1B; STRIPPOLI GFM, 2007, LANCET, V369, P349; Tonelli M, 2005, CIRCULATION, V112, P171, DOI 10.1161/CIRCULATIONAHA.104.517565; Tong PCY, 2006, DIABETES CARE, V29, P2439, DOI 10.2337/dc06-0887; Turnbull F, 2005, ARCH INTERN MED, V165, P1410; Vlagopoulos PT, 2005, J AM SOC NEPHROL, V16, P3403, DOI 10.1681/ASN.2005030226",36,550,563,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","NOV 19",2009,361,21,null,null,null,null,2019,2032,null,"10.1056/NEJMoa0907845",null,14,"Medicine, General & Internal","General & Internal Medicine","521DA","WOS:000271898600007"]
[null,"Article; Proceedings Paper",7,null,"J","Wuhl, E; Trivelli, A; Picca, S; Litwin, M; Peco-Antic, A; Zurowska, A; Testa, S; Jankauskiene, A; Emre, S; Caldas-Afonso, A; Anarat, A; Niaudet, P; Mir, S; Bakkaloglu, A; Enke, B; Montini, G; Wingen, AM; Sallay, P; Jeck, N; Berg, U; Caliskan, S; Wygoda, S; Hohbach-Hohenfellner, K; Dusek, J; Urasinski, T; Arbeiter, K; Neuhaus, T; Gellermann, J; Drozdz, D; Fischbach, M; Moller, K; Wigger, M; Peruzzi, L; Mehls, O; Schaefer, F",null,null,null,"Wuehl, Elke; Trivelli, Antonella; Picca, Stefano; Litwin, Mieczyslaw; Peco-Antic, Amira; Zurowska, Aleksandra; Testa, Sara; Jankauskiene, Augustina; Emre, Sevinc; Caldas-Afonso, Alberto; Anarat, Ali; Niaudet, Patrick; Mir, Sevgi; Bakkaloglu, Aysin; Enke, Barbara; Montini, Giovanni; Wingen, Ann-Margret; Sallay, Peter; Jeck, Nikola; Berg, Ulla; Caliskan, Salim; Wygoda, Simone; Hohbach-Hohenfellner, Katharina; Dusek, Jiri; Urasinski, Tomasz; Arbeiter, Klaus; Neuhaus, Thomas; Gellermann, Jutta; Drozdz, Dorota; Fischbach, Michel; Moeller, Kristina; Wigger, Marianne; Peruzzi, Licia; Mehls, Otto; Schaefer, Franz",null,null,"Strict Blood-Pressure Control and Progression of Renal Failure in Children","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"CONVERTING-ENZYME INHIBITOR; RANDOMIZED CONTROLLED-TRIAL; GLOMERULAR-FILTRATION-RATE; KIDNEY-DISEASE; FOLLOW-UP; RAMIPRIL; INSUFFICIENCY; PROTEINURIA; HYPERTENSION; NEPHROPATHY","Background Although inhibition of the renin-angiotensin system delays the progression of renal failure in adults with chronic kidney disease, the blood-pressure target for optimal renal protection is controversial. We assessed the long-term renoprotective effect of intensified blood-pressure control among children who were receiving a fixed high dose of an angiotensin-converting-enzyme (ACE) inhibitor. Methods After a 6-month run-in period, 385 children, 3 to 18 years of age, with chronic kidney disease (glomerular filtration rate of 15 to 80 ml per minute per 1.73 m(2) of body-surface area) received ramipril at a dose of 6 mg per square meter of body-surface area per day. Patients were randomly assigned to intensified blood-pressure control (with a target 24-hour mean arterial pressure below the 50th percentile) or conventional blood-pressure control (mean arterial pressure in the 50th to 95th percentile), achieved by the addition of antihypertensive therapy that does not target the renin-angiotensin system; patients were followed for 5 years. The primary end point was the time to a decline of 50% in the glomerular filtration rate or progression to end-stage renal disease. Secondary end points included changes in blood pressure, glomerular filtration rate, and urinary protein excretion. Results A total of 29.9% of the patients in the group that received intensified blood-pressure control reached the primary end point, as assessed by means of a Kaplan-Meier analysis, as compared with 41.7% in the group that received conventional blood-pressure control (hazard ratio, 0.65; confidence interval, 0.44 to 0.94; P = 0.02). The two groups did not differ significantly with respect to the type or incidence of adverse events or the cumulative rates of withdrawal from the study (28.0% vs. 26.5%). Proteinuria gradually rebounded during ongoing ACE inhibition after an initial 50% decrease, despite persistently good blood-pressure control. Achievement of blood-pressure targets and a decrease in proteinuria were significant independent predictors of delayed progression of renal disease. Conclusions Intensified blood-pressure control, with target 24-hour blood-pressure levels in the low range of normal, confers a substantial benefit with respect to renal function among children with chronic kidney disease. Reappearance of proteinuria after initial successful pharmacologic blood-pressure control is common among children who are receiving long-term ACE inhibition. (ClinicalTrials.gov number, NCT00221845.)","[Wuehl, Elke; Mehls, Otto; Schaefer, Franz] Univ Heidelberg, Ctr Pediat & Adolescent Med, Div Pediat Nephrol, D-69120 Heidelberg, Germany; [Enke, Barbara] Childrens Hosp, Hannover Med Sch, Hannover, Germany; [Wingen, Ann-Margret] Univ Childrens Hosp Essen, Essen, Germany; [Jeck, Nikola] Univ Marburg, Dept Pediat, Marburg, Germany; [Wygoda, Simone] Urban Hosp St Georg, Leipzig, Germany; [Hohbach-Hohenfellner, Katharina] Univ Childrens Hosp, Mainz, Germany; [Gellermann, Jutta] Charite Childrens Hosp, Berlin, Germany; [Moeller, Kristina] Univ Childrens Hosp Hamburg Eppendorf, Hamburg, Germany; [Wigger, Marianne] Univ Childrens Hosp, Rostock, Germany; [Trivelli, Antonella] G Gaslini, Genoa, Italy; [Picca, Stefano] Osped Pediat Bambino Gesu, Rome, Italy; [Testa, Sara] Policlin Mangiagalli, Ist Ricovero & Cura, Carattere Sci Osp Maggiore, Milan, Italy; [Montini, Giovanni] Univ Padua, Azienda Osped, Padua, Italy; [Peruzzi, Licia] Osped Infantile Regina Margherita, Turin, Italy; [Litwin, Mieczyslaw] Childrens Mem Hlth Hosp, Warsaw, Poland; [Zurowska, Aleksandra] Med Univ Gdansk, Dept Pediat & Adolescent Nephrol & Hypertens, Gdansk, Poland; [Urasinski, Tomasz] Pomeranian Acad Med, Szczecin, Poland; [Drozdz, Dorota] Jagiellonian Univ, Coll Med, Polish Amer Childrens Hosp, Krakow, Poland; [Peco-Antic, Amira] Univ Childrens Hosp, Belgrade, Serbia; [Jankauskiene, Augustina] Vilnius State Univ, Childrens Hosp, Vilnius, Lithuania; [Emre, Sevinc] Univ Istanbul, Istanbul Fac Med, Istanbul, Turkey; [Anarat, Ali] Cukurova Univ, Sch Med, Adana, Turkey; [Mir, Sevgi] Ege Univ, Fac Med, Dept Pediat, Izmir, Turkey; [Bakkaloglu, Aysin] Hacettepe Univ, Fac Med, TR-06100 Ankara, Turkey; [Caliskan, Salim] Istanbul Univ, Cerrahpasa Med Fac, Istanbul, Turkey; [Niaudet, Patrick] Hop Necker Enfants Malad, Paris, France; [Caldas-Afonso, Alberto] Hosp Sao Joao, Oporto, Portugal; [Fischbach, Michel] Hop Univ Strasbourg, Strasbourg, France; [Sallay, Peter] Semmelweis Univ Budapest, Dept Pediat 1, Budapest, Hungary; [Berg, Ulla] Huddinge Univ Hosp, Karolinska Inst, Stockholm, Sweden; [Dusek, Jiri] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Arbeiter, Klaus] Univ Childrens Hosp, Vienna, Austria; [Neuhaus, Thomas] Univ Childrens Hosp, Zurich, Switzerland","Schaefer, F (reprint author), Univ Heidelberg, Ctr Pediat & Adolescent Med, Div Pediat Nephrol, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.","franz.schaefer@med.uni-heidelberg.de","Schaefer, Franz/G-4365-2010; Litwin, Mieczyslaw/C-3868-2012",null,"Boehringer Ingelheim Stiftung; European Commission [QLRT-2001-00908]; Kuratorium fur Dialyse und Nierentransplantation, Neu-Isenburg; Baxter Extramural Grant Program","Supported by grants from the Boehringer Ingelheim Stiftung; the European Commission (Fifth Framework Programme, QLRT-2001-00908); Kuratorium fur Dialyse und Nierentransplantation, Neu-Isenburg; and the Baxter Extramural Grant Program.",null,33,161,161,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","OCT 22",2009,361,17,null,null,null,null,1639,1650,null,null,null,12,"Medicine, General & Internal","General & Internal Medicine","508YW","WOS:000270977400006"]
[null,"Editorial Material",2,null,"J","Patterson, CC; Dahquist, GG; Gyurus, E; Green, A; Soltesz, G",null,null,null,"Patterson, Christopher C.; Dahquist, Gisela G.; Gyurus, Eva; Green, Anders; Soltesz, Gyula",null,"EURODIAB Study Grp","Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study","LANCET",null,null,"English","Article",null,null,null,null,null,null,"AGED LESS-THAN-15 YEARS; INCREASED RISK; MISSING LINK; YOUNG-ADULTS; ONSET; CHILDREN; MELLITUS; PERIOD; HYPOTHESIS; EPIDEMIOLOGY","Background The incidence of type 1 diabetes in children younger than 15 years is increasing. Prediction of future incidence of this disease will enable adequate fund allocation for delivery of care to be planned. We aimed to establish 15-year incidence trends for childhood type 1 diabetes in European centres, and thereby predict the future burden of childhood diabetes in Europe. Methods 20 population-based EURODIAB registers in 17 countries registered 29311 new cases of type 1 diabetes, diagnosed in children before their 15th birthday during a 15-year period, 1989-2003. Age-specific log linear rates of increase were estimated in five geographical regions, and used in conjunction with published incidence rates and population projections to predict numbers of new cases throughout Europe in 2005, 2010, 2015, and 2020. Findings Ascertainment was better than 90% in most registers. All but two registers showed significant yearly increases in incidence, ranging from 0.6% to 9.3%. The overall annual increase was 3.9% (95% Cl 3.6-4.2), and the increases in the age groups 0-4 years, 5-9 years, and 10-14 years were 5.4% (4.8-6.1), 4.3% (3.8-4.8), and 2.9% (2.5-3.3), respectively. The number of new cases in Europe in 2005 is estimated as 15000, divided between the 0-4 year, 5-9 year, and 10-14 year age-groups in the ratio 24%, 35%, and 41%, respectively. In 2020, the predicted number of new cases is 24400, with a doubling in numbers in children younger than 5 years and a more even distribution across age-groups than at present (29%, 37%, and 34%, respectively). Prevalence under age 15 years is predicted to rise from 94 000 in 2005, to 160 000 in 2020. Interpretation If present trends continue, doubling of new cases of type 1 diabetes in European children younger than 5 years is predicted between 2005 and 2020, and prevalent cases younger than 15 years will rise by 70%. Adequate health-care resources to meet these children's needs should be made available.","[Patterson, Christopher C.] Queens Univ Belfast, Ctr Publ Hlth, Epidemiol Res Grp, Belfast BT12 6BJ, Antrim, North Ireland; [Dahquist, Gisela G.] Umea Univ, Dept Clin Sci, Umea, Sweden; [Gyurus, Eva; Soltesz, Gyula] Univ Pecs, Fac Med, Dept Paediat, Pecs, Hungary; [Green, Anders] Univ So Denmark, Inst Publ Hlth, Dept Epidemiol, Odense, Denmark; [Green, Anders] S Odense Univ Hosp, Ctr Natl Clin Database, Odense, Denmark","Patterson, CC (reprint author), Queens Univ Belfast, Ctr Publ Hlth, Epidemiol Res Grp, Mulhouse Bldg,Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.","c.patterson@qub.ac.uk","Polanska, Joanna/A-5271-2008; Polanska, Joanna/H-4513-2013","Polanska, Joanna/0000-0001-8004-9864","Czech Ministry of Eduction [MSM 0021620814]; Finnish National Institute for Health and Welfare; German Paediatric Surveillance Unit, Dusseldorf University and DPV Science Initiative, Ulm University; Hungarian Childhood Diabetes Epidemiology Group; Northern Ireland Childhood Diabetes Group, Bart's-Oxford study group; Yorkshire Paediatric Diabetes Specialist Interest Group; Health Quality Information Partnership, Department of Health, England; Swedish Research Council [07531]; European Community [MR4*/029/UK, BMH1-CT92-0043, BMH4-CT96-0577, IC20-CT96-0070]","We thank Gerda Brutti, who was administrator for the EURODIAB study group during its first decade, the Austrian Diabetes Incidence Study Group, the Czech Childhood Diabetes Register (supported by Czech Ministry of Eduction grant MSM 0021620814), the Finnish National Institute for Health and Welfare, the German Paediatric Surveillance Unit, Dusseldorf University and DPV Science Initiative, Ulm University, the Hungarian Childhood Diabetes Epidemiology Group, the Northern Ireland Childhood Diabetes Group, Bart's-Oxford study group (register funded by Diabetes UK), the Yorkshire Paediatric Diabetes Specialist Interest Group (register funded by the Health Quality Information Partnership, Department of Health, England), and the Swedish Childhood Diabetes Study Group (register funded by the Swedish Research Council, Project number 07531). The collaboration was supported in part by European Community Concerted Action Program grants (MR4*/029/UK, BMH1-CT92-0043, BMH4-CT96-0577, and IC20-CT96-0070).","Aamodt G, 2007, DIABETES CARE, V30, P884, DOI 10.2337/dc06-1568; [Anonymous], 2010, WORLD POPULATION PRO; Bishop YMM, 1974, DISCRETE MULTIVARIAT; Bruno G, 2001, DIABETOLOGIA, V44, P22, DOI 10.1007/s001250051575; Cardwell CR, 2008, DIABETOLOGIA, V51, P726, DOI 10.1007/s00125-008-0941-z; CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406; Dahlquist G, 2006, DIABETOLOGIA, V49, P20, DOI 10.1007/s00125-005-0076-4; Bessaoud K, 2006, DIABETIC MED, V23, P857, DOI 10.1111/j.1464-5491.2006.01925.x; Green A, 2000, LANCET, V355, P873; Dahlquist G, 2002, DIABETES CARE, V25, P1755; *EUROSTAT, EUROSTAT EST 2005 PO; Feltbower RG, 2003, DIABETIC MED, V20, P437, DOI 10.1046/j.1464-5491.2003.00960.x; Gale EAM, 2002, DIABETOLOGIA, V45, P588, DOI 10.1007/s00125-002-0801-1; Green A, 2001, DIABETOLOGIA, V44, pB3, DOI 10.1007/PL00002950; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; Hermann R, 2003, DIABETOLOGIA, V46, P420, DOI 10.1007/s00125-003-1045-4; Joner G, 2004, DIABETES CARE, V27, P1618, DOI 10.2337/diacare.27.7.1618; Kaufman FR, 2007, PEDIATR DIABETES, V8, P4, DOI 10.1111/j.1399-5448.2007.00327.x; Kyvik KO, 2004, DIABETOLOGIA, V47, P377, DOI 10.1007/s00125-004-1331-9; McKinney PA, 2000, DIABETIC MED, V17, P236, DOI 10.1046/j.1464-5491.2000.00220.x; MOLTCHANOVA E, 2005, STAT MED, V25, P2989; Patterson CC, 2001, DIABETOLOGIA, V44, pB9, DOI 10.1007/PL00002961; Pundziute-Lycka A, 2002, DIABETOLOGIA, V45, P783, DOI 10.1007/s00125-002-0845-2; Pundziute-Lycka A, 2004, ACTA PAEDIATR, V93, P1519, DOI 10.1080/08035250410026680; SCHOBER E, 2008, EUR J PEDIATR, V67, P293; SOLTESZ G, 2006, DIABETES ATLAS, P153; Soltesz G, 2007, PEDIATR DIABETES, V8, P6, DOI 10.1111/j.1399-5448.2007.00280.x; Svensson J, 2002, DIABETES CARE, V25, P2197, DOI 10.2337/diacare.25.12.2197; SHAMOON H, 1993, NEW ENGL J MED, V329, P977; Weets I, 2002, DIABETES CARE, V25, P840, DOI 10.2337/diacare.25.5.840; Wilkin TJ, 2001, DIABETOLOGIA, V44, P914, DOI 10.1007/s001250100548",31,382,399,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0140-6736",null,null,"LANCET","Lancet","JUN 13",2009,373,9680,null,null,null,null,2027,2033,null,"10.1016/S0140-6736(09)60568-7",null,7,"Medicine, General & Internal","General & Internal Medicine","459DJ","WOS:000267080100029"]
[null,"Letter",4,null,"J","Esparza-Gordillo, J; Weidinger, S; Folster-Holst, R; Bauerfeind, A; Ruschendorf, F; Patone, G; Rohde, K; Marenholz, I; Schulz, F; Kerscher, T; Hubner, N; Wahn, U; Schreiber, S; Franke, A; Vogler, R; Heath, S; Baurecht, H; Novak, N; Rodriguez, E; Illig, T; Lee-Kirsch, MA; Ciechanowicz, A; Kurek, M; Piskackova, T; Macek, M; Lee, YA; Ruether, A",null,null,null,"Esparza-Gordillo, Jorge; Weidinger, Stephan; Foelster-Holst, Regina; Bauerfeind, Anja; Ruschendorf, Franz; Patone, Giannino; Rohde, Klaus; Marenholz, Ingo; Schulz, Florian; Kerscher, Tamara; Hubner, Norbert; Wahn, Ulrich; Schreiber, Stefan; Franke, Andre; Vogler, Rainer; Heath, Simon; Baurecht, Hansjoerg; Novak, Natalija; Rodriguez, Elke; Illig, Thomas; Lee-Kirsch, Min-Ae; Ciechanowicz, Andrzej; Kurek, Michael; Piskackova, Tereza; Macek, Milan; Lee, Young-Ae; Ruether, Andreas",null,null,"A common variant on chromosome 11q13 is associated with atopic dermatitis","NATURE GENETICS",null,null,"English","Article",null,null,null,null,null,null,"GENOME-WIDE ASSOCIATION; CROHNS-DISEASE; FILAGGRIN MUTATIONS; ULCERATIVE-COLITIS; COMPLEX; ASTHMA; ECZEMA; GENES; EXPRESSION; CHILDREN","We conducted a genome-wide association study in 939 individuals with atopic dermatitis and 975 controls as well as 270 complete nuclear families with two affected siblings. SNPs consistently associated with atopic dermatitis in both discovery sets were then investigated in two additional independent replication sets totalling 2,637 cases and 3,957 controls. Highly significant association was found with allele A of rs7927894 on chromosome 11q13.5, located 38 kb downstream of C11orf30 (P(combined) = 7.6 x 10(-10)). Approximately 13% of individuals of European origin are homozygous for rs7927894[A], and their risk of developing atopic dermatitis is 1.47 times that of noncarriers.","[Esparza-Gordillo, Jorge; Marenholz, Ingo; Schulz, Florian; Kerscher, Tamara; Wahn, Ulrich; Lee, Young-Ae] Charite Univ Med Berlin, D-13353 Berlin, Germany; [Esparza-Gordillo, Jorge; Bauerfeind, Anja; Ruschendorf, Franz; Patone, Giannino; Rohde, Klaus; Marenholz, Ingo; Schulz, Florian; Kerscher, Tamara; Hubner, Norbert; Lee, Young-Ae] Max Delbruck Ctr Mol Med, Berlin, Germany; [Weidinger, Stephan; Rodriguez, Elke] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Weidinger, Stephan; Baurecht, Hansjoerg; Rodriguez, Elke] Tech Univ Munich, Ctr Allergy & Environm, ZAUM, Munich, Germany; [Weidinger, Stephan; Baurecht, Hansjoerg; Rodriguez, Elke] Tech Univ Munich, Helmholtz Zentrum Munich, Div Environm Dermatol & Allergy, Munich, Germany; [Foelster-Holst, Regina] Univ Hosp Schleswig Holstein, Clin Dermatol Venerol & Allergol, Kiel, Germany; [Franke, Andre; Ruether, Andreas] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Schreiber, Stefan; Vogler, Rainer] Univ Kiel, POPGEN Biobank Project, Kiel, Germany; [Heath, Simon] Ctr Natl Genotypage, Evry, France; [Baurecht, Hansjoerg] Tech Univ Munich, IMSE, Munich, Germany; [Novak, Natalija] Univ Bonn, Dept Dermatol & Allergy, D-5300 Bonn, Germany; [Lee-Kirsch, Min-Ae] German Res Ctr Environm Hlth, Helmholtz Zentrum Munich, Dept Epidemiol, Neuherberg, Germany; [Lee-Kirsch, Min-Ae] Tech Univ Dresden, Klin Kinder & Jugendmed, Dresden, Germany; [Ciechanowicz, Andrzej] Pomeranian Med Univ, Dept Lab Diagnost & Mol Med, Szczecin, Poland; [Kurek, Michael] Pomeranian Med Univ, Dept Clin Allergol, Szczecin, Poland; [Piskackova, Tereza; Macek, Milan] Charles Univ Prague, Med Sch & Fac 2, Dept Biol & Med Genet, Prague, Czech Republic","Lee, YA (reprint author), Charite Univ Med Berlin, D-13353 Berlin, Germany.","yolee@mdc-berlin.de","Schreiber, Stefan/B-6748-2008; Folster-Holst, Regina/A-9560-2010; Weidinger, Stephan/C-8461-2011; Franke, Andre/B-2151-2010; Heath, Simon/J-4138-2012; Baurecht, Hansjoerg/C-4035-2013; Rodriguez, Elke/C-4259-2013","Franke, Andre/0000-0003-1530-5811; ","German Ministry of Education and Research (BMBF) through the Clinical Research Group for Allergy at Charite Berlin; National Genome Research Network (NGFN); PopGen biobank and infrastructure support through the DFG cluster of excellence \"Inflammation at Interfaces'; EMBO long-term fellowship [522-2006]; Marie Curie EIF fellowship [039868]; German Research Council [DFG NO454/1-4, NO454/2-4, NO454/5-2, SFB704 TPA4]; BONFOR grants of the University of Bonn; University Hospital Rechts der Isar [KKF-07/04, KKF-27/05]; Technische Universitat Munchen; Wilhelm-Vaillant-Stiftung and a Heisenberg fellowship [DFG WE 2678/4-1]; German Research Council;  [VZFNM00064203]","We thank all subjects with eczema, families and physicians for their participation. We thank I. v. Gwinner-Buhring, F. Kussebi, C. Ockeloen, T. Schilling and I. Schulz for subject evaluation. We are grateful to C. Flachmeier, S. Kolberg, M. Schwarz, I. Szangolies, S. Blachut, G. Born, S. Schmidt, C. v. d. Lancken, T. Henke, B. Fedders and T. Wesse for technical assistance, and to M. Wittig for database management. We thank L. Ghys and M. De Longueville (UCB Pharma) and the following EPAAC and ETAC investigators for providing case samples: O. Rybnicek (Brno, Czech Republic), J. Chladkova, T. Chyba (Hradec Kralove, Czech Republic), F. Kopriva (Olomouc, Czech Republic), O. S. kopkova, V. Balcarek (Ostrava, Czech Republic), H. Honomichlova, P. Honomichlova-Houdkova, P. Honomichl (Plzen Lochotin, Czech Republic), M. Spicakova, S. Kynclova, V. Petru, A. Carbolova, K. Kopecka, P. Pohunek, T. Svobodova, V. S. picak, K. Kopecka, M. Maltulka (Praha, Czech Republic), M. Kaczmarski, B. Cudowska, J. Wasilewska, E. Matuszfewska (Bialystok, Poland), T. Malaczynska, B. Klajna-Kraluk (Gdansk, Poland), J. Sokalska, E. Masnica-Wasylkowska, I. Biegun-Awramineko, M. Chlon (Gliwice Poland), T. Latos, E. Pomaranska, G. Gaszczyk, B. Makuch, J. Stanisz, J. Bokiej (Karpacz, Poland), G. Lis, E. Cichocka-Jarosz, I. Glodzik, T. Szczerbinski (Krakow, Poland), D. Chlebna-Sokol, A. Stanczyk, J. Wlazlowski, I. Ligenza, B. Kamer, K. Pyziak, R. Pasowska, J. Zwaigzne-Raczynska (Lodz, Poland), A. Emeryk, H. Milanowska, G. Zywicka, M. Bartkowiak-Emeryk, E. Chojna (Lublin, Poland), A. Swiatly, A. SzczawinskaPoplonyk, M. Kulesza-Kazecka, J. Alkiewicz, A. Breborowicz (Poznan, Poland), R. Kurzawa, A. Wojcik, U. Jedrys-Klucjasz, E. Urbanek-Jozwik (Rabka Zdroj, Poland), L. Dymek, A. Dymek, A. Bozek (Strzelce opolskie, Poland), D. Chmielewska-Szewczyk, J. Lange, J. Peradzynska, M. Kulus, E. Najberg, E. Nowicka, A. Chrupek (Warszawa, Poland), A. Boznanski, E. Willak-Janc, A. Latkowska, E. Sikorska, M. T. Jarlinska (Wroclaw, Poland). The study was funded by the German Ministry of Education and Research (BMBF) through the Clinical Research Group for Allergy at Charite Berlin, the National Genome Research Network (NGFN), by the PopGen biobank and infrastructure support through the DFG cluster of excellence \"Inflammation at Interfaces''. This work was supported by an EMBO long-term fellowship (522-2006) and by a Marie Curie EIF fellowship (039868) to J. E. G. N. N. was supported by grants from the German Research Council (DFG NO454/1-4, NO454/2-4, NO454/5-2, SFB704 TPA4) and BONFOR grants of the University of Bonn. S. W. was supported by research grants KKF-07/04 and KKF-27/05 of the University Hospital Rechts der Isar, Technische Universitat Munchen, a grant from the Wilhelm-Vaillant-Stiftung and a Heisenberg fellowship (DFG WE 2678/4-1) from the German Research Council. M. M. was supported by research grant VZFNM00064203.",null,30,100,101,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","1061-4036",null,null,"NAT GENET","Nature Genet.","MAY",2009,41,5,null,null,null,null,596,601,null,"10.1038/ng.347",null,6,"Genetics & Heredity","Genetics & Heredity","438SL","WOS:000265575600022"]
[null,"Proceedings Paper",3,null,"J","Verdecchia, P; Sleight, P; Mancia, G; Fagard, R; Trimarco, B; Schmieder, RE; Kim, JH; Jennings, G; Jansky, P; Chen, JH; Liu, LS; Gao, P; Probstfield, J; Teo, K; Yusuf, S",null,null,null,"Verdecchia, Paolo; Sleight, Peter; Mancia, Giuseppe; Fagard, Robert; Trimarco, Bruno; Schmieder, Roland E.; Kim, Jae-Hyung; Jennings, Garry; Jansky, Petr; Chen, Jyh-Hong; Liu, Lisheng; Gao, Peggy; Probstfield, Jeffrey; Teo, Koon; Yusuf, Salim",null,"ONTARGET TRANSCEND Investigators","Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease","CIRCULATION",null,null,"English","Article",null,null,null,null,null,"angiotensin; electrocardiography; epidemiology; hypertrophy; prognosis","ESSENTIAL-HYPERTENSION; ARTERIAL-HYPERTENSION; CARDIAC-HYPERTROPHY; AT(2) RECEPTORS; BLOOD-PRESSURE; SERIAL CHANGES; MASS; REGRESSION; REDUCTION; EVENTS","Background-Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown. Methods and Results-In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of ACE inhibitors were randomly assigned to ramipril, telmisartan, or their combination (n=23 165). In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND), patients intolerant of ACE inhibitors were randomized to telmisartan or placebo (n=5343). Prevalence of LVH at entry in TRANSCEND was 12.7%. It was reduced by telmisartan (10.5% and 9.9% after 2 and 5 years) compared with placebo (12.7% and 12.8% after 2 and 5 years) (overall odds ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91; P=0.0017). New-onset LVH occurred less frequently with telmisartan compared with placebo (overall odds ratio, 0.63; 95% CI, 0.51 to 0.79; P=0.0001). LVH regression was similar in the 2 groups. In ONTARGET, prevalence of LVH at entry was 12.4%. At follow-up, it occurred slightly less frequently with telmisartan (odds ratio, 0.92; 95% CI, 0.83 to 1.01; P=0.07) and the combination (odds ratio, 0.93; 95% CI, 0.84 to 1.02; P=0.12) than with ramipril, but differences between the groups were not significant. New-onset LVH was associated with a higher risk of primary outcome during follow-up (hazard ratio, 1.77; 95% CI, 1.50 to 2.07). Conclusions-In patients at high vascular risk, telmisartan is more effective than placebo in reducing LVH. New-onset LVH is reduced by 37%. The effect of combination of the 2 drugs on LVH is similar to that of ramipril alone. (Circulation. 2009;120:1380-1389.)","[Verdecchia, Paolo; Sleight, Peter; Teo, Koon; Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L2X2, Canada; [Verdecchia, Paolo] Hosp S Maria Misericordia, Clin Res Unit Prevent Cardiol, Perugia, Italy; [Sleight, Peter] John Radcliffe Hosp, Oxford OX3 9DU, England; [Mancia, Giuseppe] Univ Milano Bicocca, Milan, Italy; [Fagard, Robert] Catholic Univ Leuven, Hypertens Unit, Louvain, Belgium; [Trimarco, Bruno] Univ Naples Federico 2, Dept Clin Med & Cardiovasc & Immunol Sci, Naples, Italy; [Schmieder, Roland E.] Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Erlangen, Germany; [Kim, Jae-Hyung] Catholic Univ Korea, St Pauls Hosp, Dept Cardiol, Div Cardiol, Seoul, South Korea; [Jennings, Garry] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia; [Jansky, Petr] Univ Hosp Motol, Dept Cardiovasc Surg, Prague, Czech Republic; [Chen, Jyh-Hong] Natl Cheng Kung Univ, Coll Med, Div Cardiol, Dept Med, Tainan 70101, Taiwan; [Liu, Lisheng] Chinese Acad Med Sci, Fu Wai Hosp, Dept Hypertens, Beijing 100037, Peoples R China; [Probstfield, Jeffrey] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA","Verdecchia, P (reprint author), McMaster Univ, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L2X2, Canada.","verdec@tin.it","Jennings, Garry/B-3914-2009",null,"Boehringer-Ingelheim","This study was supported by Boehringer-Ingelheim.",null,37,40,42,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322",null,null,"CIRCULATION","Circulation","OCT 6",2009,120,14,null,null,null,null,1380,1389,null,"10.1161/CIRCULATIONAHA.109.865774",null,10,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","Cardiovascular System & Cardiology","502VQ","WOS:000270488800007"]
[null,"Review",17,null,"J","Bartlett, JR; Friedman, KJ; Ling, SC; Pace, RG; Bell, SC; Bourke, B; Castaldo, G; Castellani, C; Cipolli, M; Colombo, C; Colombo, JL; Debray, D; Fernandez, A; Lacaille, F; Macek, M; Rowland, M; Salvatore, F; Taylor, CJ; Wainwright, C; Wilschanski, M; Zemkova, D; Hannah, WB; Phillips, MJ; Corey, M; Zielenski, J; Dorfman, R; Wang, YF; Zou, F; Silverman, LM; Drumm, ML; Wright, FA; Lange, EM; Durie, PR; Knowles, MR",null,null,null,"Bartlett, Jaclyn R.; Friedman, Kenneth J.; Ling, Simon C.; Pace, Rhonda G.; Bell, Scott C.; Bourke, Billy; Castaldo, Giuseppe; Castellani, Carlo; Cipolli, Marco; Colombo, Carla; Colombo, John L.; Debray, Dominique; Fernandez, Adriana; Lacaille, Florence; Macek, Milan, Jr.; Rowland, Marion; Salvatore, Francesco; Taylor, Christopher J.; Wainwright, Claire; Wilschanski, Michael; Zemkova, Dana; Hannah, William B.; Phillips, M. James; Corey, Mary; Zielenski, Julian; Dorfman, Ruslan; Wang, Yunfei; Zou, Fei; Silverman, Lawrence M.; Drumm, Mitchell L.; Wright, Fred A.; Lange, Ethan M.; Durie, Peter R.; Knowles, Michael R.",null,"Gene Modifier Study Grp","Genetic Modifiers of Liver Disease in Cystic Fibrosis","JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION",null,null,"English","Article",null,null,null,null,null,null,"TRANSMEMBRANE CONDUCTANCE REGULATOR; ALPHA-1-ANTITRYPSIN DEFICIENCY; LUNG-DISEASE; RISK-FACTORS; ALPHA(1)-ANTITRYPSIN DEFICIENCY; SEVERITY; EPIDEMIOLOGY; ASSOCIATION; EXPRESSION; CIRRHOSIS","Context A subset (approximate to 3%-5%) of patients with cystic fibrosis (CF) develops severe liver disease with portal hypertension. Objective To assess whether any of 9 polymorphisms in 5 candidate genes (alpha(1)-antitrypsin or alpha(1)-antiprotease [SERPINA1], angiotensin-converting enzyme [ACE], glutathione S-transferase [GSTP1], mannose-binding lectin 2 [MBL2], and transforming growth factor beta 1 [TGFB1]) are associated with severe liver disease in patients with CF. Design, Setting, and Participants Two-stage case-control study enrolling patients with CF and severe liver disease with portal hypertension (CFLD) from 63 CF centers in the United States as well as 32 in Canada and 18 outside of North America, with the University of North Carolina at Chapel Hill as the coordinating site. In the initial study, 124 patients with CFLD (enrolled January 1999-December 2004) and 843 control patients without CFLD were studied by genotyping 9 polymorphisms in 5 genes previously studied as modifiers of liver disease in CF. In the second stage, the SERPINA1 Z allele and TGFB1 codon 10 genotype were tested in an additional 136 patients with CFLD (enrolled January 2005-February 2007) and 1088 with no CFLD. Main Outcome Measures Differences in distribution of genotypes in patients with CFLD vs patients without CFLD. Results The initial study showed CFLD to be associated with the SERPINA1 Z allele (odds ratio [OR], 4.72; 95% confidence interval [CI], 2.31-9.61; P = 3.3 x 10(-6)) and with TGFB1 codon 10 CC genotype (OR, 1.53; 95% CI, 1.16-2.03; P = 2.8 x 10(-3)). In the replication study, CFLD was associated with the SERPINA1 Z allele (OR, 3.42; 95% CI, 1.54-7.59; P = 1.4 x 10(-3)) but not with TGFB1 codon 10. A combined analysis of the initial and replication studies by logistic regression showed CFLD to be associated with SERPINA1 Z allele (OR, 5.04; 95% CI, 2.88-8.83; P = 1.5 x 10(-8)). Conclusions The SERPINA1 Z allele is a risk factor for liver disease in CF. Patients who carry the Z allele are at greater risk (OR, approximate to 5) of developing severe liver disease with portal hypertension. JAMA. 2009;302(10):1076-1083","[Bartlett, Jaclyn R.; Pace, Rhonda G.; Hannah, William B.; Knowles, Michael R.] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; [Wang, Yunfei; Lange, Ethan M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Wang, Yunfei; Zou, Fei; Wright, Fred A.; Lange, Ethan M.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Wang, Yunfei; Zou, Fei; Wright, Fred A.; Lange, Ethan M.] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA; [Friedman, Kenneth J.] Lab Corp Amer, Ctr Mol Biol & Pathol, Res Triangle Pk, NC USA; [Ling, Simon C.; Durie, Peter R.] Hosp Sick Children, Div Gastroenterol Hepatol & Nutr, Toronto, ON M5G 1X8, Canada; [Ling, Simon C.; Corey, Mary; Durie, Peter R.] Univ Toronto, Toronto, ON, Canada; [Bell, Scott C.] Prince Charles Hosp, Adult Cyst Fibrosis Ctr, Chermside, Qld, Australia; [Bourke, Billy; Rowland, Marion] Our Ladys Childrens Hosp, Childrens Res Ctr, Crumlin, Ireland; [Rowland, Marion] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland; [Castaldo, Giuseppe; Salvatore, Francesco] Univ Naples Federico 2, CEINGE Adv Biotechnol, Naples, Italy; [Castaldo, Giuseppe; Salvatore, Francesco] Univ Naples Federico 2, Dept Biochem & Med Biotechnol, Naples, Italy; [Castellani, Carlo; Cipolli, Marco] Azienda Osped Verona, Cyst Fibrosis Ctr, Verona, Italy; [Colombo, Carla] Univ Milan, CF Ctr, Fdn IRCCS Osped Maggiore Policlin, Milan, Italy; [Colombo, John L.] Univ Nebraska Med Ctr, Dept Pediat, Pulm Sect, Omaha, NE USA; [Debray, Dominique] Ctr Hosp Univ Bicetre, Serv Hepatol Pediat, Le Kremlin Bicetre, France; [Fernandez, Adriana] La Plata Childrens Hosp, Cyst Fibrosis Ctr, Buenos Aires, DF, Argentina; [Lacaille, Florence] Hop Necker Enfants Malad, Pediat Hepatogastroenterol Nutr Unit, Paris, France; [Macek, Milan, Jr.] Charles Univ Prague, Dept Biol, Prague, Czech Republic; [Macek, Milan, Jr.] Charles Univ Prague, Dept Med Genet, Prague, Czech Republic; [Zemkova, Dana] Charles Univ Prague, Dept Pediat, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; [Taylor, Christopher J.] Univ Sheffield, Acad Unit Child Hlth, Dept Paediat Gastroenterol, Sheffield, S Yorkshire, England; [Wainwright, Claire] Royal Childrens Hosp, Queensland Childrens Resp Ctr, Brisbane, Qld, Australia; [Wilschanski, Michael] Hadassah Med Org, Dept Pediat Gastroenterol, Jerusalem, Israel; [Silverman, Lawrence M.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Drumm, Mitchell L.] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Drumm, Mitchell L.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA","Knowles, MR (reprint author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, 7019 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.","knowles@med.unc.edu","Bell, Scott/A-7241-2011; Repetto, Gabriela/C-7833-2012; Lewindon, Peter/E-9196-2014","Bell, Scott/0000-0001-8651-7139; Lewindon, Peter/0000-0002-9502-3090","Cystic Fibrosis Foundation [SILVER0Z00, KNOWLE00A0, DRUMM04P0, DRUMM0A00]; National Institutes of Health [NIH R01GM074175, NIH/NIDDK DK066368, CTRC RR00046, CTSA UL1RR025747]; Prince Charles Hospital Foundation; OWHC/CIHR Fellowship; Czech Ministry of Health [VZFNM00064203, NS9488/3]; MIUR, Rome, Italy; Regione Campania, Italy; Health Research Board Grant [RFRD-05-07]; Genome Canada through the Ontario Genomics Institute [2004-OGI-3-05]; Lloyd Carr-Harris Foundation; Canadian Cystic Fibrosis Foundation","This study was supported by grants from the Cystic Fibrosis Foundation (SILVER0Z00, KNOWLE00A0, DRUMM04P0, DRUMM0A00); the National Institutes of Health (NIH R01GM074175, NIH/NIDDK DK066368, CTRC RR00046, CTSA UL1RR025747); the Prince Charles Hospital Foundation; the OWHC/CIHR Fellowship; the Czech Ministry of Health (VZFNM00064203, NS9488/3); MIUR, Rome, Italy, and Regione Campania, Italy; a Fellowship in Rare Diseases from The Health Research Board Grant (RFRD-05-07); Genome Canada through the Ontario Genomics Institute (2004-OGI-3-05); the Lloyd Carr-Harris Foundation; and the Canadian Cystic Fibrosis Foundation.",null,41,62,63,"AMER MEDICAL ASSOC","CHICAGO","515 N STATE ST, CHICAGO, IL 60610-0946 USA","0098-7484",null,null,"JAMA-J AM MED ASSOC","JAMA-J. Am. Med. Assoc.","SEP 9",2009,302,10,null,null,null,null,1076,1083,null,null,null,8,"Medicine, General & Internal","General & Internal Medicine","491XH","WOS:000269616200025"]
["2009 Celkem",null,291,null,"J","Krsek, P; Maton, B; Jayakar, P; Dean, P; Korman, B; Rey, G; Dunoyer, C; Pacheco-Jacome, E; Morrison, G; Ragheb, J; Vinters, HV; Resnick, T; Duchowny, M",null,null,null,"Krsek, P.; Maton, B.; Jayakar, P.; Dean, P.; Korman, B.; Rey, G.; Dunoyer, C.; Pacheco-Jacome, E.; Morrison, G.; Ragheb, J.; Vinters, H. V.; Resnick, T.; Duchowny, M.",null,null,"Incomplete resection of focal cortical dysplasia is the main predictor of poor postsurgical outcome","NEUROLOGY",null,null,"English","Article",null,null,null,null,null,null,"PEDIATRIC EPILEPSY SURGERY; SURGICAL-TREATMENT; INTRACTABLE EPILEPSY; INTRINSIC EPILEPTOGENICITY; CHILDREN; MALFORMATIONS; LESIONS; EEG; CLASSIFICATION; SUBTYPES","Background: Focal cortical dysplasia (FCD) is recognized as the major cause of focal intractable epilepsy in childhood. Various factors influencing postsurgical seizure outcome in pediatric patients with FCD have been reported. Objective: To analyze different variables in relation to seizure outcome in order to identify prognostic factors for selection of pediatric patients with FCD for epilepsy surgery. Methods: A cohort of 149 patients with histologically confirmed mild malformations of cortical development or FCD with at least 2 years of postoperative follow-up was retrospectively studied; 113 subjects had at least 5 years of postoperative follow-up. Twenty-eight clinical, EEG, MRI, neuropsychological, surgical, and histopathologic parameters were evaluated. Results: The only significant predictor of surgical success was completeness of surgical resection, defined as complete removal of the structural MRI lesion (if present) and the cortical region exhibiting prominent ictal and interictal abnormalities on intracranial EEG. Unfavorable surgical outcomes are mostly caused by overlap of dysplastic and eloquent cortical regions. There were nonsignificant trends toward better outcomes in patients with normal intelligence, after hemispherectomy and with FCD type II. Other factors such as age at seizure onset, duration of epilepsy, seizure frequency, associated pathologies including hippocampal sclerosis, extent of EEG and MRI abnormalities, as well as extent and localization of resections did not influence outcome. Twenty-five percent of patients changed Engel's class of seizure outcome after the second postoperative year. Conclusions: The ability to define and fully excise the entire region of dysplastic cortex is the most powerful variable influencing outcome in pediatric patients with focal cortical dysplasia. Neurology (R) 2009;72:217-223","[Krsek, P.] Charles Univ Prague, Sch Med 2, Motol Univ Hosp, Dept Pediat Neurol, CZ-15006 Prague 5, Czech Republic; [Maton, B.; Jayakar, P.; Dean, P.; Dunoyer, C.; Resnick, T.; Duchowny, M.] Miami Childrens Hosp, Inst Brain, Dept Neurol, Miami, FL USA; [Maton, B.; Jayakar, P.; Dean, P.; Dunoyer, C.; Resnick, T.; Duchowny, M.] Miami Childrens Hosp, Inst Brain, Comprehens Epilepsy Program, Miami, FL USA; [Korman, B.; Rey, G.] Miami Childrens Hosp, Inst Brain, Neuropsychol Sect, Miami, FL USA; [Pacheco-Jacome, E.] Miami Childrens Hosp, Inst Brain, Dept Radiol, Miami, FL USA; [Morrison, G.; Ragheb, J.] Miami Childrens Hosp, Inst Brain, Dept Neurol Surg, Miami, FL USA; [Resnick, T.; Duchowny, M.] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA","Krsek, P (reprint author), Charles Univ Prague, Sch Med 2, Motol Univ Hosp, Dept Pediat Neurol, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","pavel.krsek@post.cz",null,null," [IGA NR/8843-4];  [VZ MZO 00064203]","Supported by grant IGA NR/8843-4 and VZ MZO 00064203.",null,30,71,75,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0028-3878",null,null,"NEUROLOGY","Neurology","JAN 20",2009,72,3,null,null,null,null,217,223,null,"10.1212/01.wnl.0000334365.22854.d3",null,7,"Clinical Neurology","Neurosciences & Neurology","396XE","WOS:000262624300005"]
[2010,"Article",254,null,"J","Kubinova, S; Horak, D; Sykova, E",null,null,null,"Kubinova, Sarka; Horak, Daniel; Sykova, Eva",null,null,"Cholesterol-modified superporous poly(2-hydroxyethyl methacrylate) scaffolds for tissue engineering","BIOMATERIALS",null,null,"English","Article",null,null,null,null,null,"Cell adhesion; Cell viability; Hydrogel; PolyHEMA; Porosity","MESENCHYMAL STEM-CELLS; POROUS HYDROGELS; PORE-SIZE; ADHESION; BONE; SURFACE; ADSORPTION; BEHAVIOR; ENERGY; FILMS","Modifications of poly(2-hydroxyethyl methacrylate) (PHEMA) with cholesterol and laminin have been developed to design scaffolds that promote cell-surface interaction. Cholesterol-modified superporous PHEMA scaffolds have been prepared by the bulk radical copolymerization of 2-hydroxyethyl methacrylate (HEMA), cholesterol methacrylate (CHLMA) and the cross-linking agent ethylene dimethacrylate (EDMA) in the presence of ammonium oxalate crystals to introduce interconnected superpores in the matrix. With the aim of immobilizing laminin (LN), carboxyl groups were also introduced to the scaffold by the copolymerization of the above monomers with 2-[(methoxycarbonyl)methoxy]ethyl methacrylate (MCMEMA). Subsequently, the MCMEMA moiety in the resulting hydrogel was hydrolyzed to 12(methacryloyloxy)ethoxy]acetic acid (MOEAA), and laminin was immobilized via carbodiimide and N-hydroxysulfosuccinimide chemistry. The attachment, viability and morphology of mesenchymal stem cells (MSCs) were evaluated on both nonporous and superporous laminin-modified as well as laminin-unmodified PHEMA and poly(2-hydroxyethyl methacrylate-co-cholesterol methacrylate) P(HEMA-CHLMA) hydrogels. Neat PHEMA and laminin-modified PHEMA (LN-PHEMA) scaffolds facilitated MSC attachment, but did not support cell spreading and proliferation: the viability of the attached cells decreased with time of cultivation. In contrast, MSCs spread and proliferated on P(HEMA-CHLMA) and LN-P(HEMA-CHLMA) hydrogels. (C) 2009 Elsevier Ltd. All rights reserved.","[Horak, Daniel] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Kubinova, Sarka; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Horak, Daniel; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic","Horak, D (reprint author), Acad Sci Czech Republic, Inst Macromol Chem, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic.","horak@imc.cas.cz",null,null,"EU [LSHM-CT-2007-037862]; Academy of Sciences of the Czech Republic [KAN200520804]","Financial support of the EU grant Artemis (LSHM-CT-2007-037862) and the Academy of Sciences of the Czech Republic (KAN200520804) is gratefully acknowledged.",null,35,21,21,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0142-9612",null,null,"BIOMATERIALS","Biomaterials","SEP",2009,30,27,null,null,null,null,4601,4609,null,"10.1016/j.biomaterials.2009.05.007",null,9,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","488DX","WOS:000269330400019"]
[null,"Article; Proceedings Paper",8,null,"J","Loh, ML; Sakai, DS; Flotho, C; Kang, M; Fliegauf, M; Archambeault, S; Mullighan, CG; Chen, L; Bergstraesser, E; Bueso-Ramos, CE; Emanuel, PD; Hasle, H; Issa, JP; van den Heuvel-Eibrink, MM; Locatelli, F; Stary, J; Trebo, M; Wlodarski, M; Zecca, M; Shannon, KM; Niemeyer, CM",null,null,null,"Loh, Mignon L.; Sakai, Debbie S.; Flotho, Christian; Kang, Michelle; Fliegauf, Manfred; Archambeault, Sophie; Mullighan, Charles G.; Chen, Leslie; Bergstraesser, Eva; Bueso-Ramos, Carlos E.; Emanuel, Peter D.; Hasle, Henrik; Issa, Jean-Pierre; van den Heuvel-Eibrink, Marry M.; Locatelli, Franco; Stary, Jan; Trebo, Monica; Wlodarski, Marcin; Zecca, Marco; Shannon, Kevin M.; Niemeyer, Charlotte M.",null,null,"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"ACQUIRED UNIPARENTAL DISOMY; C-CBL; LYMPHOBLASTIC-LEUKEMIA; MYELOID MALIGNANCIES; LIGASE ACTIVITY; ACTIVATION; PTPN11; GROWTH; RAS; NEUROFIBROMATOSIS","Juvenile myelomonocytic leukemia is an aggressive myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Seventy-five percent of patients harbor mutations in the NF1, NRAS, KRAS, or PTPN11 genes, which encode components of Ras signaling networks. Using single nucleotide polymorphism arrays, we identified a region of 11q isodisomy that contains the CBL gene in several JMML samples, and subsequently identified CBL mutations in 27 of 159 JMML samples. Thirteen of these mutations alter codon Y371. In this report, we also demonstrate that CBL and RAS/PTPN11 mutations were mutually exclusive in these patients. Moreover, the exclusivity of CBL mutations with respect to other Ras pathway-associated mutations indicates that CBL may have a role in deregulating this key pathway in JMML. (Blood. 2009; 114: 1859-1863)","[Loh, Mignon L.; Sakai, Debbie S.; Kang, Michelle; Archambeault, Sophie; Chen, Leslie; Shannon, Kevin M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Loh, Mignon L.; Sakai, Debbie S.; Kang, Michelle; Archambeault, Sophie; Chen, Leslie; Shannon, Kevin M.] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; [Flotho, Christian; Fliegauf, Manfred; Wlodarski, Marcin; Niemeyer, Charlotte M.] Univ Freiburg, Dept Pediat & Adolescent Med, Freiburg, Germany; [Mullighan, Charles G.] St Jude Childrens Hosp, Dept Pathol, Memphis, TN 38105 USA; [Bergstraesser, Eva; Issa, Jean-Pierre] Univ Childrens Hosp, Dept Hematol & Oncol, Zurich, Switzerland; [Bueso-Ramos, Carlos E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Emanuel, Peter D.] Univ Arkansas, Ctr Comprehens Canc, Little Rock, AR 72204 USA; [Hasle, Henrik] Aarhus Univ Hosp, Dept Pediat, Skejby, Denmark; [van den Heuvel-Eibrink, Marry M.] Sophia Childrens Univ Hosp, Erasmus MC, Dutch Childrens Oncol Grp, Rotterdam, Netherlands; [Locatelli, Franco; Zecca, Marco] Univ Pavia, Fdn IRCCS, Policlin San Matteo, I-27100 Pavia, Italy; [Stary, Jan] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Trebo, Monica] St Anna Childrens Hosp, Vienna, Austria","Loh, ML (reprint author), 513 ParnassusAve,HSE-302,Box 0519, San Francisco, CA 94143 USA.","lohm@peds.ucsf.edu","Mullighan, Charles/H-3253-2011","Mullighan, Charles/0000-0002-1871-1850","National Institutes of Health [CA113557, CA108631, CA104282, CA72614, CA95621]; California Institute of Regenerative Medicine [T1-00002]; V Foundation for Cancer Research; Frank A. Campini Foundation [LLS 6059-09]; Deutsche Kinderkrebsstiftung; Deutsche Forschungsgemeinschaft","This work was supported in part by the National Institutes of Health (grants CA113557, M. L. L.; CA108631, M. L. L., K. M. S., L. C.; CA104282, M. L. L., K. M. S.; CA72614, K. M. S.; CA95621, M. L. L., M. K., P. D. E., K. M. S.), California Institute of Regenerative Medicine (T1-00002; D. S. S.), V Foundation for Cancer Research (M. L. L., K. M. S.), the Frank A. Campini Foundation (M. L. L., K. M. S.), LLS 6059-09 (M. L. L.), the American Lebanese Syrian Associated Charities (C. G. M.), the Deutsche Kinderkrebsstiftung (C. M. N., C. F.), the Deutsche Forschungsgemeinschaft",null,32,100,104,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","AUG 27",2009,114,9,null,null,null,null,1859,1863,null,"10.1182/blood-2009-01-198416",null,5,"Hematology","Hematology","488WI","WOS:000269380600022"]
[null,"Editorial Material",7,null,"J","Balgobind, BV; Raimondi, SC; Harbott, J; Zimmermann, M; Alonzo, TA; Auvrignon, A; Beverloo, HB; Chang, M; Creutzig, U; Dworzak, MN; Forestier, E; Gibson, B; Hasle, H; Harrison, CJ; Heerema, NA; Kaspers, GJL; Leszl, A; Litvinko, N; Lo Nigro, L; Morimoto, A; Perot, C; Pieters, R; Reinhardt, D; Rubnitz, JE; Smith, FO; Stary, J; Stasevich, I; Strehl, S; Taga, T; Tomizawa, D; Webb, D; Zemanova, Z; Zwaan, CM; van den Heuvel-Eibrink, MM",null,null,null,"Balgobind, Brian V.; Raimondi, Susana C.; Harbott, Jochen; Zimmermann, Martin; Alonzo, Todd A.; Auvrignon, Anne; Beverloo, H. Berna; Chang, Myron; Creutzig, Ursula; Dworzak, Michael N.; Forestier, Erik; Gibson, Brenda; Hasle, Henrik; Harrison, Christine J.; Heerema, Nyla A.; Kaspers, Gertjan J. L.; Leszl, Anna; Litvinko, Nathalia; Lo Nigro, Luca; Morimoto, Akira; Perot, Christine; Pieters, Rob; Reinhardt, Dirk; Rubnitz, Jeffrey E.; Smith, Franklin O.; Stary, Jan; Stasevich, Irina; Strehl, Sabine; Taga, Takashi; Tomizawa, Daisuke; Webb, David; Zemanova, Zuzana; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.",null,null,"Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; CHILDRENS-ONCOLOGY-GROUP; AML TRIALS; CHROMOSOMAL-ABNORMALITIES; GROUP-B; CANCER; MLL; MULTICENTER; ADOLESCENTS","Translocations involving chromosome 11q23 frequently occur in pediatric acute myeloid leukemia (AML) and are associated with poor prognosis. In most cases, the MLL gene is involved, and more than 50 translocation partners have been described. Clinical outcome data of the 11q23-rearranged subgroups are scarce because most 11q23 series are too small for meaningful analysis of subgroups, although some studies suggest that patients with t(9;11)(p22;q23) have a more favorable prognosis. We retrospectively collected outcome data of 756 children with 11q23- or MLL-rearranged AML from 11 collaborative groups to identify differences in outcome based on translocation partners. All karyotypes were centrally reviewed before assigning patients to subgroups. The event-free survival of 11q23/MLL-rearranged pediatric AML at 5 years from diagnosis was 44%(+/- 5%), with large differences across subgroups (11% +/- 5% to 92% +/- 5%). Multivariate analysis identified the following subgroups as independent prognostic predictors: t(1;11)(q21;q23) (hazard ratio [HR] = 0.1, P = .004); t(6;11)(q27;q23) (HR = 2.2, P < .001); t(10;11)(p12;q23) (HR = 1.5, P = .005); and t(10;11)(p11.2;q23) (HR = 2.5, P = .005). We could not confirm the favorable prognosis of the t( 9; 11)( p22; q23) subgroup. We identified large differences in outcome within 11q23/MLL-rearranged pediatric AML and novel subgroups based on translocation partners that independently predict clinical outcome. Screening for these translocation partners is needed for accurate treatment stratification at diagnosis. (Blood. 2009; 114: 2489-2496)","[Balgobind, Brian V.; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.] Erasmus MC, Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3000 CB Rotterdam, Netherlands; [Raimondi, Susana C.; Rubnitz, Jeffrey E.] St Jude Childrens Hosp, Memphis, TN 38105 USA; [Raimondi, Susana C.; Alonzo, Todd A.; Heerema, Nyla A.; Smith, Franklin O.] Childrens Oncol Grp, Arcadia, CA USA; [Harbott, Jochen] Univ Giessen, Acute Myeloid Leukemia Berlin Frankfurt Munster S, Dept Pediat Hematol & Oncol, Giessen, Germany; [Zimmermann, Martin; Reinhardt, Dirk] Hannover Med Sch, Acute Myeloid Leukemia Berlin Frankfurt Munster S, D-3000 Hannover, Germany; [Auvrignon, Anne; Perot, Christine] Hop Trousseau, F-75571 Paris, France; [Beverloo, H. Berna] Dutch Working Grp Hematooncol Genome Diagnost, Dutch Childhood Oncol Grp, The Hague, Netherlands; [Beverloo, H. Berna] Erasmus MC, Dept Clin Genet, NL-3000 CB Rotterdam, Netherlands; [Chang, Myron] Ctr Data, Childrens Oncol Grp, Gainesville, FL USA; [Creutzig, Ursula] Univ Hosp, Acute Myeloid Leukemia Berlin Frankfurt Munster S, Munster, Germany; [Dworzak, Michael N.; Strehl, Sabine] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Forestier, Erik] Umea Univ Hosp, Nord Soc Pediat Hematol & Oncol, Dept Clin Sci, S-90185 Umea, Sweden; [Gibson, Brenda] Royal Hosp Sick Children, Dept Pediat Oncol Hematol, Glasgow G3 8SJ, Lanark, Scotland; [Hasle, Henrik] Aarhus Univ, Nord Soc Pediat Hematol & Oncol, Dept Pediat, Hosp Skejby, Aarhus, Denmark; [Harrison, Christine J.] Univ Newcastle, No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England; [Heerema, Nyla A.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Kaspers, Gertjan J. L.; Webb, David] Berlin Frankfurt Munster Study Grp, Acute Myeloid Leukemia Comm 1, Frankfurt, Germany; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands; [Leszl, Anna] Univ Padua, Pediat Clin, Italian Assoc Pediat Hematol Oncol, Padua, Italy; [Litvinko, Nathalia; Stasevich, Irina] Res Ctr Pediat Oncol & Hematol, Minsk, Byelarus; [Lo Nigro, Luca] Univ Catania, Pediat Clin, Italian Assoc Pediat Hematol Oncol, Catania, Italy; [Morimoto, Akira; Taga, Takashi; Tomizawa, Daisuke] Japanese Pediat Leukemia Lymphoma Study Grp, Tokyo, Japan; [Morimoto, Akira] Jichi Med Univ, Dept Pediat, Jichi, Tochigi, Japan; [Smith, Franklin O.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Smith, Franklin O.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Stary, Jan] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Taga, Takashi] Shiga Univ Med Sci, Dept Pediat, Shiga, Japan; [Tomizawa, Daisuke] Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Tokyo, Japan; [Webb, David] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Zemanova, Zuzana] Charles Univ Prague, Ctr Oncocytogenet, Gen Univ Hosp, Prague, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Fac Med 1, Prague, Czech Republic","van den Heuvel-Eibrink, MM (reprint author), Erasmus MC, Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rm Sp 2456,Dr Molewaterpl 60,POB 2060, NL-3000 CB Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","International Pediatric AML Group of the I-Berlin-Frankfurt-Munster Study Group-SG; American Lebanese Syrian Associated Charities; Czech Ministry of Education [MSM0021620813]; Children's Oncology Group Chair's [U10 CA98543]; COG Statistics Data Center [U10 CA98413]; Swedish Children's Cancer Foundation; NWO Netherlands Organization for Scientific Research; Foundation Childhood Oncology Center Rotterdam","This work was supported by the International Pediatric AML Group of the I-Berlin-Frankfurt-Munster Study Group-SG, which is chaired by Prof. Gertjan J. L. Kaspers (1999-2007) and Dr David Webb (2007-present). This work was further supported in part by the American Lebanese Syrian Associated Charities, the Czech Ministry of Education (MSM0021620813), Children's Oncology Group Chair's Grant U10 CA98543, COG Statistics & Data Center Grant U10 CA98413, and the Swedish Children's Cancer Foundation. The project of B. V. B. is funded by the NWO Netherlands Organization for Scientific Research and the Foundation Childhood Oncology Center Rotterdam.",null,33,89,96,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","SEP 17",2009,114,12,null,null,null,null,2489,2496,null,"10.1182/blood-2009-04-215152",null,8,"Hematology","Hematology","495WD","WOS:000269925000017"]
[null,"Letter",13,null,"J","Pytlik, R; Stehlik, D; Soukup, T; Kalbacova, M; Rypacek, F; Trc, T; Mulinkova, K; Michnova, P; Kideryova, L; Zivny, J; Klener, P; Vesela, R; Trneny, M; Klener, P",null,null,null,"Pytlik, Robert; Stehlik, David; Soukup, Tomas; Kalbacova, Marie; Rypacek, Frantisek; Trc, Tomas; Mulinkova, Katarina; Michnova, Petra; Kideryova, Linda; Zivny, Jan; Klener, Pavel, Jr.; Vesela, Romana; Trneny, Marek; Klener, Pavel",null,null,"The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering","BIOMATERIALS",null,null,"English","Article",null,null,null,null,null,"Tissue engineering; Multipotent mesenchymal stromal cells; Human serum; Expansion; Differentiation; Orthopedic surgery","MARROW-DERIVED STEM; FETAL CALF SERUM; IN-VITRO; PROGENITOR CELLS; SCALE EXPANSION; DIFFERENTIATION; CULTURE; GROWTH; TRANSPLANTATION; PROLIFERATION","Clinical application of human multipotent mesenchymal stromal cells (hMSCs) requires their expansion to be safe and rapid. We aimed to develop an expansion protocol which would avoid xenogeneic proteins, including fetal calf serum (FCS), and which would shorten the cultivation time and avoid multiple passaging. First, we have compared research-grade alpha-MEM medium with clinical grade CellGro (TM) for Hematopoietic Cells' Medium. When FCS was used for supplementation and non-adherent cells were discarded, both media were comparable. Both media were comparable also when pooled human serum (hS) was used instead of FCS, but the numbers of hMSCs were lower when non-adherent cells were discarded. However, significantly more hMSCs were obtained both in alpha-MEM and in CellGro (TM) supplemented with hS when the non-adherent cells were left in the culture. Furthermore, addition of recombinant cytokines and other supplements (EGF, PDGF-BB, M-CSF, FGF-2, dexamethasone, insulin and ascorbic acid) to the CellGro (TM) Co-culture system with hS led to 40-fold increase of hMSCs' yield after two weeks of cultivation compared to alpha-MEM with FCS. The hMSCs expanded in the described co-culture system retain their osteogenic, adipogenic and chondrogenic differentiation potential in vitro and produce bone-like mineralized tissue when propagated on 3D polylactide scaffolds in immunodeficient mice. Our protocol thus allows for very effective one-step, xenogeneic protein-free expansion of hMSCs, which can be easily transferred into good manufacturing practice (GMP) conditions for large-scale, clinical-grade production of hMSCs for purposes of tissue engineering. (c) 2009 Elsevier Ltd. All rights reserved.","[Pytlik, Robert; Michnova, Petra; Kideryova, Linda; Klener, Pavel, Jr.; Vesela, Romana; Trneny, Marek; Klener, Pavel] Charles Univ Prague, Fac Med 1, Dept Med 1, Prague 12808 2, Czech Republic; [Stehlik, David; Trc, Tomas] Charles Univ Prague, Fac Med 2, Dept Children & Adult Orthoped Surg, Prague 12808 2, Czech Republic; [Soukup, Tomas] Charles Univ Prague, Fac Med, Inst Histol & Embryol, Hradec Kralove, Czech Republic; [Kalbacova, Marie] Charles Univ Prague, Fac Med 1, Inst Inherited Metab Disorders, Prague 12808 2, Czech Republic; [Rypacek, Frantisek; Mulinkova, Katarina] Acad Sci Czech Republic, Inst Macromol Chem, Prague, Czech Republic; [Zivny, Jan; Klener, Pavel, Jr.] Charles Univ Prague, Fac Med 1, Inst Pathol Physiol, Prague 12808 2, Czech Republic","Pytlik, R (reprint author), Charles Univ Prague, Fac Med 1, Dept Med 1, U Nemocnice 2, Prague 12808 2, Czech Republic.","pytlikr@seznam.cz",null,null,null,null,null,54,22,25,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0142-9612",null,null,"BIOMATERIALS","Biomaterials","JUL",2009,30,20,null,null,null,null,3415,3427,null,"10.1016/j.biomaterials.2009.03.001",null,13,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","455FR","WOS:000266744100007"]
[null,"Review",27,null,"J","Jelinkova, H; Sulc, J; Dostalova, T; Koranda, P; Nemec, M; Hofmanova, P",null,null,null,"Jelinkova, H.; Sulc, J.; Dostalova, T.; Koranda, P.; Nemec, M.; Hofmanova, P.",null,null,"Bracket debonding by mid-infrared laser radiation","LASER PHYSICS LETTERS",null,null,"English","Article",null,null,null,null,null,"bracket debonding; infrared lasers; Tm:YAG 1.997 mu m laser; Nd:YAG 1.444 mu m laser; GaAs laser diode","ER-YAG LASER; CARBON-DIOXIDE LASER; CERAMIC BRACKETS; BOND STRENGTH; ORTHODONTIC BRACKETS; REMOVAL; SHEAR; DENTIN; ABLATION; INVITRO","The purpose of the study was to determine the proper laser radiation for ceramic bracket debonding and the investigation of the tooth root temperature injury. The debonding was investigated by diode-pumped continuously running Tm:YAP and Nd:YAG lasers, and by GaAs laser diode generating radiation with the wavelengths 1.997 mu m, 1.444 mu m, and 0.808 mu m, respectively. The possibility of brackets removal by laser radiation was investigated together with the tooth and, it specifically, root temperature rise. From the results it follows that continuously running diode pumped Tm:YAG or Nd:YAG laser generating wavelengths 1.997 mu m or 1.444 mu m, respectively, having the output power 1 W can be good candidates for ceramic brackets debonding.","[Jelinkova, H.; Sulc, J.; Koranda, P.; Nemec, M.] Czech Tech Univ, Fac Nucl Sci & Phys Engn, CR-11519 Prague 1, Czech Republic; [Dostalova, T.; Hofmanova, P.] Charles Univ Prague, Sch Med 2, Dept Pediat Stomatol, Prague 15006 5, Czech Republic","Jelinkova, H (reprint author), Czech Tech Univ, Fac Nucl Sci & Phys Engn, Brehova 7, CR-11519 Prague 1, Czech Republic.","helena.jelinkova@fjfi.cvut.cz",null,null,"Czech Ministry of Education [MSM6840770022]","This research has been supported by the Grant of the Czech Ministry of Education No. MSM6840770022 \"Laser systems, radiation and modern optical applications\". The authors wish to thank their colleagues Jan Adamek and Jan Siegl from The Department of Materials, FNSPE CVUT Prague, for the provided Scanning Electron Microscopy measurements as well as to Jaroslav Racek from 1st Medical Faculty, Department of Stomatology, Charles University Prague for bracketing of tooth samples.",null,33,7,7,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","1612-2011",null,null,"LASER PHYS LETT","Laser Phys. Lett.","MAR",2009,6,3,null,null,null,null,222,228,null,"10.1002/lapl.200810117",null,7,"Instruments & Instrumentation","Instruments & Instrumentation","421OZ","WOS:000264369500008"]
["2010 Celkem",null,309,null,"J","Meyer, C; Kowarz, E; Hofmann, J; Renneville, A; Zuna, J; Trka, J; Ben Abdelali, R; Macintyre, E; De Braekeleer, E; De Braekeleer, M; Delabesse, E; de Oliveira, MP; Cave, H; Clappier, E; van Dongen, JJM; Balgobind, BV; van den Heuvel-Eibrink, MM; Beverloo, HB; Panzer-Grumayer, R; Teigler-Schlegel, A; Harbott, J; Kjeldsen, E; Schnittger, S; Koehl, U; Gruhn, B; Heidenreich, O; Chan, LC; Yip, SF; Krzywinski, M; Eckert, C; Moricke, A; Schrappe, M; Alonso, CN; Schafer, BW; Krauter, J; Lee, DA; zur Stadt, U; Kronnie, GT; Sutton, R; Izraeli, S; Trakhtenbrot, L; Lo Nigro, L; Tsaur, G; Fechina, L; Szczepanski, T; Strehl, S; Ilencikova, D; Molkentin, M; Burmeister, T; Dingermann, T; Klingebiel, T; Marschalek, R",null,null,null,"Meyer, C.; Kowarz, E.; Hofmann, J.; Renneville, A.; Zuna, J.; Trka, J.; Ben Abdelali, R.; Macintyre, E.; De Braekeleer, E.; De Braekeleer, M.; Delabesse, E.; de Oliveira, M. P.; Cave, H.; Clappier, E.; van Dongen, J. J. M.; Balgobind, B. V.; van den Heuvel-Eibrink, M. M.; Beverloo, H. B.; Panzer-Gruemayer, R.; Teigler-Schlegel, A.; Harbott, J.; Kjeldsen, E.; Schnittger, S.; Koehl, U.; Gruhn, B.; Heidenreich, O.; Chan, L. C.; Yip, S. F.; Krzywinski, M.; Eckert, C.; Moericke, A.; Schrappe, M.; Alonso, C. N.; Schaefer, B. W.; Krauter, J.; Lee, D. A.; zur Stadt, U.; Kronnie, G. Te; Sutton, R.; Izraeli, S.; Trakhtenbrot, L.; Lo Nigro, L.; Tsaur, G.; Fechina, L.; Szczepanski, T.; Strehl, S.; Ilencikova, D.; Molkentin, M.; Burmeister, T.; Dingermann, T.; Klingebiel, T.; Marschalek, R.",null,null,"New insights to the MLL recombinome of acute leukemias","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"MLL; translocations partner genes; acute leukemia; ALL; AML","ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHROMOSOMAL BREAKPOINT SEQUENCES; PARTIAL TANDEM DUPLICATION; MINIMAL-RESIDUAL-DISEASE; HISTONE METHYLATION; PARTNER GENES; PROTEIN; TRANSLOCATIONS; IDENTIFICATION","Chromosomal rearrangements of the human MLL gene are associated with high-risk pediatric, adult and therapy-associated acute leukemias. These patients need to be identified, treated appropriately and minimal residual disease was monitored by quantitative PCR techniques. Genomic DNA was isolated from individual acute leukemia patients to identify and characterize chromosomal rearrangements involving the human MLL gene. A total of 760 MLL-rearranged biopsy samples obtained from 384 pediatric and 376 adult leukemia patients were characterized at the molecular level. The distribution of MLL breakpoints for clinical subtypes (acute lymphoblastic leukemia, acute myeloid leukemia, pediatric and adult) and fused translocation partner genes (TPGs) will be presented, including novel MLL fusion genes. Combined data of our study and recently published data revealed 104 different MLL rearrangements of which 64 TPGs are now characterized on the molecular level. Nine TPGs seem to be predominantly involved in genetic recombinations of MLL: AFF1/AF4, MLLT3/AF9, MLLT1/ENL, MLLT10/AF10, MLLT4/AF6, ELL, EPS15/AF1P, MLLT6/AF17 and SEPT6, respectively. Moreover, we describe for the first time the genetic network of reciprocal MLL gene fusions deriving from complex rearrangements. Leukemia (2009) 23, 1490-1499; doi:10.1038/leu.2009.33; published online 5 March 2009","[Meyer, C.; Kowarz, E.; Hofmann, J.; Dingermann, T.; Marschalek, R.] Univ Frankfurt, Diagnost Ctr Acute Leukemia, Inst Pharmaceut Biol, ZAFES, D-60438 Frankfurt, Germany; [Renneville, A.] CHU Lille, Dept Hematol, Biol & Pathol Ctr, F-59037 Lille, France; [Renneville, A.] INSERM, Team 3, U837, F-59045 Lille, France; [Zuna, J.; Trka, J.] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol Oncol, CLIP, Prague, Czech Republic; [Ben Abdelali, R.; Macintyre, E.] Univ Paris 05, AP HP Necker, Paris, France; [De Braekeleer, E.; De Braekeleer, M.] Univ Bretagne Occidentale, Fac Med & Sci Sante, Lab Histol Embryol & Cytogenet, Brest, France; [De Braekeleer, E.; De Braekeleer, M.] INSERM, U613, Brest, France; [Delabesse, E.] CHU Purpan, Hematol Lab, Toulouse, France; [de Oliveira, M. P.] Inst Nacl Canc Rio de Janeiro, Res Ctr, Pediat Hematol Oncol Program, Rio De Janeiro, Brazil; [Cave, H.; Clappier, E.] Hop Robert Debre, Dept Genet, F-75019 Paris, France; [van Dongen, J. J. M.] Sophia Childrens Univ Hosp, Dept Immunol, Erasmus MC, Rotterdam, Netherlands; [Balgobind, B. V.; van den Heuvel-Eibrink, M. M.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Beverloo, H. B.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands; [Panzer-Gruemayer, R.; Strehl, S.] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Teigler-Schlegel, A.; Harbott, J.] Childrens Univ Hosp, Dept Pediat Hematol & Oncol, Giessen, Germany; [Kjeldsen, E.] Aarhus Univ, Cancercytogenet Lab, Aarhus, Denmark; [Schnittger, S.] MLL Munich Leukemia Lab, Munich, Germany; [Koehl, U.; Klingebiel, T.] Univ Frankfurt, Dept Pediat Hematol & Oncol, Frankfurt, Germany; [Gruhn, B.] Univ Jena, Dept Pediat, Jena, Germany; [Heidenreich, O.] Univ Newcastle, No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England; [Chan, L. C.; Yip, S. F.] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Krzywinski, M.] Canadas Michael Smith Genome Sci Ctr, Vancouver, BC, Canada; [Eckert, C.] Charite, Dept Pediat Oncol & Hematol, CVK, D-13353 Berlin, Germany; [Moericke, A.; Schrappe, M.] Univ Schleswig Holstein, Dept Paediat, Kiel, Germany; [Alonso, C. N.] Hosp Nacl Pediatria Prof Dr JP Garrahan, Serv Hematooncol, Buenos Aires, DF, Argentina; [Schaefer, B. W.] Univ Childrens Hosp, Dept Oncol, Zurich, Switzerland; [Krauter, J.] Hannover Med Sch, Clin Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany; [Lee, D. A.] Univ Texas MD Anderson Canc Ctr, Cell Therapy Sect, Div Pediat, Houston, TX 77030 USA; [zur Stadt, U.] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany; [Kronnie, G. Te] Univ Padua, Dept Paediat & Oncohematol, Padua, Italy; [Sutton, R.] Sydney Childrens Hosp, Childrens Canc Inst, Sydney, NSW, Australia; [Izraeli, S.; Trakhtenbrot, L.] Chaim Sheba Med Ctr, Dept Pediat Hematooncol, Tel Aviv, Israel; [Izraeli, S.; Trakhtenbrot, L.] Canc Res Ctr, Tel Aviv, Israel; [Izraeli, S.; Trakhtenbrot, L.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Lo Nigro, L.] Univ Catania, Ctr Pediat Hematol Oncol, Catania, Italy; [Tsaur, G.; Fechina, L.] Reg Children Hosp 1, Pediat Oncol & Hematol Ctr, Res Inst Med Cell Technol, Ekaterinburg, Russia; [Szczepanski, T.] Med Univ Silesia, Dept Pediat Hematol & Oncol, Zabrze, Poland; [Ilencikova, D.] Natl Canc Hosp, Dept Clin Genet, Bratislava, Slovakia; [Molkentin, M.; Burmeister, T.] Charite, CBF, Fac Med 3, D-13353 Berlin, Germany","Marschalek, R (reprint author), Univ Frankfurt, Diagnost Ctr Acute Leukemia, Inst Pharmaceut Biol, ZAFES, Max von Laue Str 9, D-60438 Frankfurt, Germany.","Rolf.Marschalek@em.uni-frankfurt.de","Schrappe, Martin/A-8109-2010; Marschalek, Rolf/D-3404-2011; Inca, Inct/K-2204-2013; Tang, Macy/B-9798-2014",null,"Deutsche Krebshilfe [107819]; German Jose Carreras Leukemia foundation [R06/22]; Polish Ministry of Science and Higher Education [2 P054 095 30]","This work was made possible by and conducted within the framework of the International BFM Study Group. This study was supported by grant 107819 from the Deutsche Krebshilfe to RM, TD and TK; supported by grant R06/22 from the German Jose Carreras Leukemia foundation to TB and supported by grant 2 P054 095 30 from the Polish Ministry of Science and Higher Education to TS.",null,42,159,166,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","AUG",2009,23,8,null,null,null,null,1490,1499,null,"10.1038/leu.2009.33",null,10,"Oncology; Hematology","Oncology; Hematology","482CR","WOS:000268862000017"]
[2011,"Article",248,null,"J","Hollink, IHIM; van den Heuvel-Eibrink, MM; Zimmermann, M; Balgobind, BV; Arentsen-Peters, STCJM; Alders, M; Willasch, A; Kaspers, GJL; Trka, J; Baruchel, A; de Graaf, SSN; Creutzig, U; Pieters, R; Reinhardt, D; Zwaan, CM",null,null,null,"Hollink, Iris H. I. M.; van den Heuvel-Eibrink, Marry M.; Zimmermann, Martin; Balgobind, Brian V.; Arentsen-Peters, Susan T. C. J. M.; Alders, Marielle; Willasch, Andre; Kaspers, Gertjan J. L.; Trka, Jan; Baruchel, Andre; de Graaf, Siebold S. N.; Creutzig, Ursula; Pieters, Rob; Reinhardt, Dirk; Zwaan, C. Michel",null,null,"Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"WT1 GENE; NORMAL KARYOTYPE; NUCLEOPHOSMIN MUTATIONS; TANDEM DUPLICATION; TREATMENT STRATEGY; TUMOR-SUPPRESSOR; DRUG-RESISTANCE; PEDIATRIC AML; TRIALS; FLT3","Wilms tumor 1 (WT1) mutations have recently been identified in approximately 10% of adult acute myeloid leukemia (AML) with normal cytogenetics (CN-AML) and are associated with poor outcome. Using array-based comparative genome hybridization in pediatric CN-AML samples, we detected a WT1 deletion in one sample. The other WT1 allele was mutated. This prompted us to further investigate the role of WT1 aberrations in childhood AML. Mutations were found in 35 of 298 (12%) diagnostic pediatric AML samples. In 19 of 35 (54%) samples, more than one WT1 aberration was found: 15 samples had 2 different mutations, 2 had a homozygous mutation, and 2 had a mutation plus a WT1 deletion. WT1 mutations clustered significantly in the CN-AML subgroup (22%; P < .001) and were associated with FLT3/ITD (43 vs 17%; P < .001). WT1 mutations conferred an independent poor prognostic significance (WT1 mutated vs wildtype patients: 5-year probability of overall survival [pOS] 35% vs 66%, P = .002; probability of event-free survival 22% vs 46%, P < .001; and cumulative incidence of relapse or regression 70% vs 44%, P < .001). Patients with both a WT1 mutation and a FLT3/ITD had a dismal prognosis (5-year pOS 21%). WT1 mutations occur at a significant rate in childhood AML and are a novel independent poor prognostic marker. (Blood. 2009; 113: 5951-5960)","[Hollink, Iris H. I. M.; van den Heuvel-Eibrink, Marry M.; Balgobind, Brian V.; Arentsen-Peters, Susan T. C. J. M.; Pieters, Rob; Zwaan, C. Michel] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands; [Zimmermann, Martin; Reinhardt, Dirk] Med High Sch, Dept Pediat Oncol Hematol, AML BFM Study Grp, Hannover, Germany; [Alders, Marielle] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Willasch, Andre] Univ Childrens Hosp Frankfurt, Dept Hematol & Oncol, Frankfurt, Germany; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands; [Trka, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Baruchel, Andre] St Louis Hosp, Paris, France; [de Graaf, Siebold S. N.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat Oncol Hematol, NL-6525 ED Nijmegen, Netherlands; [Creutzig, Ursula] Univ Childrens Hosp, AML BFM Study Grp, Munster, Germany","Zwaan, CM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol & Hematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.","c.m.zwaan@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Pediatric Oncology Foundation Rotterdam (KOCR); The Netherlands Organization for Scientific Research (NWO; Deutsche Krebshilfe","I. H. I. M. H. was funded by the Pediatric Oncology Foundation Rotterdam (KOCR), B. V. B. was funded by The Netherlands Organization for Scientific Research (NWO), and D. R. was funded by the Deutsche Krebshilfe.",null,33,49,50,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","JUN 4",2009,113,23,null,null,null,null,5951,5960,null,"10.1182/blood-2008-09-177949",null,10,"Hematology","Hematology","454BH","WOS:000266656100038"]
[null,"Article; Proceedings Paper",6,null,"J","Giaccone, G; Zatloukal, P; Roubec, J; Floor, K; Musil, J; Kuta, M; van Klaveren, RJ; Chaudhary, S; Gunther, A; Shamsili, S",null,null,null,"Giaccone, Giuseppe; Zatloukal, Petr; Roubec, Jaromir; Floor, Karijn; Musil, Jaromir; Kuta, Milan; van Klaveren, Rob J.; Chaudhary, Subhash; Gunther, Adrie; Shamsili, Setareh",null,null,"Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non-Small-Cell Lung Cancer","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Article; Proceedings Paper","International Conference of the American-Association-for-Cancer-Research/National-Cancer-Institute/European-Organisation-for-Research-and-Treatment-of-Cancer","OCT 22-26, 2007","San Francisco, CA","Amer Assoc Canc Res, NCI, European Org Res & Treatment Canc",null,null,"ANTI-APOPTOSIS GENE; ANTIAPOPTOSIS GENE; PROGNOSTIC-FACTORS; EXPRESSION; CHEMOTHERAPY; DOCETAXEL; CARCINOMA; NEUROBLASTOMA; THERAPY; MARKER","Purpose To evaluate the antitumor activity and safety of YM155, a novel, small-molecule suppressor of survivin, as single-agent therapy in patients with previously treated, advanced non-small-cell lung cancer (NSCLC). Patients and Methods Patients with stage IIIb/IV NSCLC who had experienced treatment failure during one or two prior chemotherapy regimens (at least one of which was platinum based) received YM155 as a continuous intravenous infusion (4.8 mg/m(2)/d) over 168 hours followed by observation for 14 days in 21-day treatment cycles. The primary end point was objective tumor response rate (ORR). Secondary end points included duration of stable disease (SD), progression-free survival (PFS), overall survival (OS), safety and pharmacokinetic profiles, and pharmacodynamic evaluations. Results Thirty-seven patients received YM155. Two patients achieved a confirmed partial response, with an ORR of 5.4% (95% CI, 0.7% to 18.2%). An additional 14 patients (37.8%) achieved SD resulting in a disease control rate of 43.2% (95% CI, 27.1% to 60.5%). Median duration of PFS was 1.7 months (95% CI, 1.3 to 2.8 months). Median duration of OS was 6.6 months (95% CI, 4 to 12.2 months), with a 1-year survival rate of 35.1%. Treatment with YM155 was well tolerated with the majority of treatment discontinuations not treatment related. Conclusion YM155 exhibited modest single-agent activity in patients with refractory, advanced NSCLC. A favorable safety/tolerability profile was reported. Further evaluation of YM155 in combination with chemotherapy and other targeted agents may be warranted. J Clin Oncol 27:4481-4486. (C) 2009 by American Society of Clinical Oncology","Vrije Univ Med Ctr, Amsterdam, Netherlands; Erasmus MC, Rotterdam, Netherlands; Astellas Pharma Europe BV, Leiderdorp, Netherlands; Charles Univ Prague, Fac Med 3, Prague, Czech Republic; Teaching Hosp Bulovka, Prague, Czech Republic; Charles Univ Prague, Fac Med 2, Prague, Czech Republic; Teaching Hosp Motol, Prague, Czech Republic; Teaching Hosp Ostrava Poruba, Ostrava, Czech Republic; Nemocnice Chomutov, Chomutov, Czech Republic; Onkol Ctr JG Mendla, Novy Jicin, Czech Republic","Giaccone, G (reprint author), NCI, Med Oncol Branch, 10 Ctr Dr, Bethesda, MD 20892 USA.","giacconeg@mail.nih.gov",null,null,null,null,null,35,78,81,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,null,"J CLIN ONCOL","J. Clin. Oncol.","SEP 20",2009,27,27,null,null,null,null,4481,4486,null,"10.1200/JCO.2008.21.1862",null,6,"Oncology","Oncology","496ZO","WOS:000270019900009"]
[null,"Editorial Material",4,null,"J","Qasim, W; Cavazzana-Calvo, M; Davies, EG; Davis, J; Duval, M; Eames, G; Farinha, N; Filopovich, A; Fischer, A; Friedrich, W; Gennery, A; Heilmann, C; Landais, P; Horwitz, M; Porta, F; Sedlacek, P; Seger, R; Slatten, M; Teague, L; Eapen, M; Veys, P",null,null,null,"Qasim, Waseem; Cavazzana-Calvo, Marina; Davies, E. Graham; Davis, Jeffery; Duval, Michel; Eames, Gretchen; Farinha, Nuno; Filopovich, Alexandra; Fischer, Alain; Friedrich, Wilhelm; Gennery, Andrew; Heilmann, Carsten; Landais, Paul; Horwitz, Mitchell; Porta, Fulvio; Sedlacek, Petr; Seger, Reinhard; Slatten, Mary; Teague, Lochie; Eapen, Mary; Veys, Paul",null,null,"Allogeneic Hematopoietic Stem-Cell Transplantation for Leukocyte Adhesion Deficiency","PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"leukocyte adhesion deficiency; stem-cell transplantation; reduced-intensity conditioning","BONE-MARROW-TRANSPLANTATION; INTENSITY-CONDITIONING REGIMEN; DISEASE PHENOTYPE; UNRELATED DONOR; 6-YEAR-OLD BOY; REVERSION; IMMUNODEFICIENCY; SURVIVAL; TYPE-1","OBJECTIVES. Leukocyte adhesion deficiency is a rare primary immune disorder caused by defects of the CD18 beta-integrin molecule on immune cells. The condition usually presents in early infancy and is characterized by deep tissue infections, leukocytosis with impaired formation of pus, and delayed wound healing. Allogeneic hematopoietic stem-cell transplantation offers the possibility of curative therapy, and with patient numbers at any individual center being limited, we surveyed the transplant experience at 14 centers worldwide. METHODS. The course of 36 children with a confirmed diagnosis of leukocyte adhesion deficiency who underwent hematopoietic stem-cell transplantation between 1993 and 2007 was retrospectively analyzed. Data were collected by the registries of the European Society for Immunodeficiencies/European Group for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research. RESULTS. At a median follow-up of 62 months (extending to 14 years), the overall survival rate was 75%. Myeloablative conditioning regimens were used in 28 patients, and reduced-intensity conditioning in 8 patients, with no deaths in this subgroup. Survival rates after matched family donor and unrelated donor transplants were similar, with 11 of 14 matched family donor and 12 of 14 unrelated donor recipients alive; mortality was greatest after haploidentical transplants, after which 4 of 8 children did not survive. Twenty-seven transplant recipients were alive, with full donor engraftment in 17 cases, mixed multilineage chimerism in 7 patients, and mononuclear cell-restricted chimerism in an additional 3 cases. CONCLUSIONS. Hematopoietic stem-cell transplantation offers long-term benefit in leukocyte adhesion deficiency and should be considered as an early therapeutic option if a suitable HLA-matched stem-cell donation is available. Reduced-intensity conditioning was particularly safe, and mixed-donor chimerism seems sufficient to prevent significant symptoms, although careful long-term monitoring will be required for these patients. Pediatrics 2009; 123: 836-840","[Qasim, Waseem; Davies, E. Graham; Veys, Paul] Great Ormond St Hosp Sick Children, Dept Immunol, London WC1N 1EH, England; [Cavazzana-Calvo, Marina; Fischer, Alain; Landais, Paul] Hop Necker Enfants Malad, Dept Immunol, Paris, France; [Davis, Jeffery] British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC V6H 3V4, Canada; [Duval, Michel] Hop St Justine, Serv Hematooncol, Montreal, PQ H3T 1C5, Canada; [Eames, Gretchen] Cook Childrens Med Ctr, Dept Blood & Marrow Transplantat, Ft Worth, TX USA; [Farinha, Nuno] Hosp Sao Joao, Hematol & Oncol Unit, Oporto, Portugal; [Filopovich, Alexandra] Cincinnati Childrens Hosp Med Ctr, Dept Immunol, Cincinnati, OH USA; [Friedrich, Wilhelm] Univ Ulm, Dept Blood & Marrow Transplantat, Ulm, Germany; [Gennery, Andrew; Slatten, Mary] Newcastle Gen Hosp, Dept Immunol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Heilmann, Carsten] Rigshosp, Dept Blood & Marrow Transplantat, DK-2100 Copenhagen, Denmark; [Horwitz, Mitchell] Duke Univ, Med Ctr, Div Cellular Therapy, Durham, NC USA; [Porta, Fulvio] Univ Brescia, Pediat Clin, Brescia, Italy; [Sedlacek, Petr] Univ Hosp Motol, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Seger, Reinhard] Univ Hosp Childrens, Div Immunol Hematol & Oncol, Zurich, Switzerland; [Teague, Lochie] Starship Childrens Hosp, Auckland, New Zealand; [Eapen, Mary] Med Coll Wisconsin, Ctr Int Blood, Milwaukee, WI 53226 USA; [Eapen, Mary] Med Coll Wisconsin, Marrow Transplant Res Stat Ctr, Milwaukee, WI 53226 USA","Qasim, W (reprint author), Great Ormond St Hosp Sick Children, Dept Immunol, 30 Guilford St, London WC1N 1EH, England.","w.qasim@ich.ucl.ac.uk","QASIM, WASEEM/B-3036-2009",null,"Registries of the European Society for Immunodeficiencies/European Group for Blood and Marrow Transplantation; Public Health Service [U24-CA76518-10]; National Cancer Institute; National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute","We are grateful for assistance from the Registries of the European Society for Immunodeficiencies/European Group for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research. Dr Qasim was supported by the Leukemia Research Fund. Support from Public Health Service grant U24-CA76518-10 from the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute is also acknowledged.",null,23,29,29,"AMER ACAD PEDIATRICS","ELK GROVE VILLAGE","141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA","0031-4005",null,null,"PEDIATRICS","Pediatrics","MAR",2009,123,3,null,null,null,null,836,840,null,"10.1542/peds.2008-1191",null,5,"Pediatrics","Pediatrics","413XH","WOS:000263825500016"]
[null,"Letter",14,null,"J","Lurz, P; Puranik, R; Nordmeyer, J; Muthurangu, V; Hansen, MS; Schievano, S; Marek, J; Bonhoeffer, P; Taylor, AM",null,null,null,"Lurz, Philipp; Puranik, Rajesh; Nordmeyer, Johannes; Muthurangu, Vivek; Hansen, Michael S.; Schievano, Silvia; Marek, Jan; Bonhoeffer, Philipp; Taylor, Andrew M.",null,null,"Improvement in left ventricular filling properties after relief of right ventricle to pulmonary artery conduit obstruction: contribution of septal motion and interventricular mechanical delay","EUROPEAN HEART JOURNAL",null,null,"English","Article",null,null,null,null,null,"Ventricular interaction; Interventricular mechanical delay; Right ventricle to pulmonary artery conduit; Septal motion; Congenital heart disease","PRESSURE-OVERLOAD; HYPERTENSION; DYSFUNCTION; ASYNCHRONY; TETRALOGY; FALLOT; REPAIR","To investigate the impact of relief of right ventricle (RV) to pulmonary artery (PA) conduit obstruction on septal motion and ventricular interaction and its functional implications for left ventricular (LV) filling properties. In 20 consecutive patients with congenital heart disease and RV to PA conduit obstruction, the following were prospectively assessed before and after percutaneous pulmonary valve implantation (PPVI): the septal curvature and LV volumes throughout the cardiac cycle by magnetic resonance imaging; RV to LV mechanical delay by 2D-echocardiographic strain imaging; and objective exercise capacity. Percutaneous pulmonary valve implantation led to a reduction in RV to LV mechanical delay (127.9 +/- 50.9 vs. 37.7 +/- 35.6 ms; P < 0.001) and less LV septal bowing in early LV diastole (septal curvature: -0.11 +/- 0.11 vs. 0.07 +/- 0.13 cm(-1); P < 0.001). Early LV diastolic filling (first one-third of diastole) increased significantly (17.5 +/- 9.4 to 30.4 +/- 9.4 mL/m(2); P < 0.001). The increase in early LV diastolic filling correlated with the reduction in RV to LV mechanical delay (r = -0.68; P = 0.001) and change in septal curvature (r = 0.71; P < 0.001). In addition, the improvement in peak oxygen uptake (56.0 +/- 16.0 vs. 64.1 +/- 13.7% of predicted; P < 0.001) was associated with the increase in early LV diastolic filling (r = 0.69; P = 0.001). Relief of RV to PA conduit obstruction significantly improves early LV filling properties. This is attributed to more favourable septal motion and reduction in interventricular mechanical delay.","[Lurz, Philipp; Puranik, Rajesh; Nordmeyer, Johannes; Muthurangu, Vivek; Hansen, Michael S.; Schievano, Silvia; Marek, Jan; Bonhoeffer, Philipp; Taylor, Andrew M.] UCL, Inst Child Hlth, Cardiac Unit, London WC1N 3JH, England; [Lurz, Philipp; Puranik, Rajesh; Nordmeyer, Johannes; Muthurangu, Vivek; Hansen, Michael S.; Schievano, Silvia; Marek, Jan; Bonhoeffer, Philipp; Taylor, Andrew M.] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Lurz, Philipp; Nordmeyer, Johannes; Bonhoeffer, Philipp] Heart Hosp, NHS Trust, London, England","Lurz, P (reprint author), UCL, Inst Child Hlth, Cardiac Unit, Great Ormond St, London WC1N 3JH, England.","philipp.lurz@gmx.de","Taylor, Andrew/C-4311-2008; Schievano, Silvia/B-6803-2009",null,"European Union; Neil Hamilton Fairley NHMRC/NHF of Australia Postdoctoral Fellowship; British Heart Cardiovascular Initiative [CI/05/010]; Higher Education Funding Council for England (HEFCE)","P. L. is funded by the European Union (Health-e-Child Initiative); R. P. is funded by the Neil Hamilton Fairley NHMRC/NHF of Australia Postdoctoral Fellowship; V. M., M. S. H., and A. M. T. are funded by the British Heart Cardiovascular Initiative; Grant Number: CI/05/010. A. M. T. is funded by the Higher Education Funding Council for England (HEFCE).","Baker AE, 1998, AM J PHYSIOL-HEART C, V275, pH476; BELENKIE I, 1988, CIRCULATION, V78, P761; BEYAR R, 1993, AM J PHYSIOL, V265, pH2044; Chow PC, 2008, AM J CARDIOL, V101, P874, DOI 10.1016/j.amjcard.2007.11.033; Coats L, 2006, CIRCULATION, V113, P2037, DOI 10.1061/CIRCULATIONAHA.105.591438; Gan CTJ, 2006, AM J PHYSIOL-HEART C, V290, pH1528, DOI 10.1152/ajpheart.01031.2005; Ghai A, 2002, J AM COLL CARDIOL, V40, P1675, DOI 10.1016/S0735-1097(02)02344-6; Gurudevan SV, 2007, J AM COLL CARDIOL, V49, P1334, DOI 10.1016/j.jacc.2007.01.028; Lopez-Candales A, 2005, AM J CARDIOL, V96, P602, DOI 10.1016/j.amjcard.2005.04.028; Lopez-Candales Angel, 2005, Cardiovasc Ultrasound, V3, P23, DOI 10.1186/1476-7120-3-23; LOUIE EK, 1986, J AM COLL CARDIOL, V8, P1298; Lurz P, 2008, CIRCULATION, V117, P1964, DOI 10.1161/CIRCULATIONAHA.107.735779; Mahmud E, 2002, J AM COLL CARDIOL, V40, P318, DOI 10.1016/S0735-1097(02)01959-9; Marcus JT, 2008, J AM COLL CARDIOL, V51, P750, DOI 10.1016/j.jacc.2007.10.041; Norton JM, 2001, ADV PHYSIOL EDUC, V25, P53; Oosterhof T, 2006, EUR HEART J, V27, P1478, DOI 10.1093/eurheartj/ehl033; Roeleveld RJ, 2005, RADIOLOGY, V234, P710, DOI 10.1148/radiol.2343040151; STOJNIC BB, 1992, BRIT HEART J, V68, P16; Tweddell JS, 2000, CIRCULATION, V102, P130; Vonk-Noordegraaf A, 2005, CHEST, V128, p628S, DOI 10.1378/chest.128.6_suppl.628S",20,22,25,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0195-668X",null,null,"EUR HEART J","Eur. Heart J.","SEP",2009,30,18,null,null,null,null,2266,2274,null,"10.1093/eurheartj/ehp258",null,9,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","496DL","WOS:000269949200023"]
[null,"News Item",1,null,"J","Gebauer, RA; Tomek, V; Salameh, A; Marek, J; Chaloupecky, V; Gebauer, R; Matejka, T; Vojtovic, P; Janousek, J",null,null,null,"Gebauer, Roman A.; Tomek, Viktor; Salameh, Aida; Marek, Jan; Chaloupecky, Vaclav; Gebauer, Roman; Matejka, Tomas; Vojtovic, Pavel; Janousek, Jan",null,null,"Predictors of left ventricular remodelling and failure in right ventricular pacing in the young","EUROPEAN HEART JOURNAL",null,null,"English","Article",null,null,null,null,null,"Permanent cardiac pacing; Heart failure; Cardiac resynchronization therapy; Congenital heart disease; Children","COMPLETE ATRIOVENTRICULAR-BLOCK; CONGENITAL HEART-DISEASE; DILATED CARDIOMYOPATHY; RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION; CHILDREN; DYSFUNCTION; EXPERIENCE; PACEMAKER; ATRIAL","To identify risk factors for left ventricular (LV) dysfunction in right ventricular (RV) pacing in the young. Left ventricular function was evaluated in 82 paediatric patients with either non-surgical (n = 41) or surgical (n= 41) complete atrioventricular block who have been 100% RV paced for a mean period of 7.4 years. Left ventricular shortening fraction (SF) decreased from a median (range) of 39 (24-62)% prior to implantation to 32 (8-49)% at last follow-up (P < 0.05). Prevalence of a combination of LV dilatation (LV end-diastolic diameter >+2z-values) and dysfunction (SF < 0.26) was found to increase from 1.3% prior to pacemaker implantation to 13.4% (11/82 patients) at last follow-up (P = 0.01). Ten of these 11 patients had progressive LV remodelling and 8 of 11 were symptomatic. The only significant risk factor for the development of LV dilatation and dysfunction was the presence of epicardial RV free wall pacing (OR = 14.3, P < 0.001). Other pre-implantation demographic, diagnostic, and haemodynamic factors including block aetiology, pacing variables, and pacing duration did not show independent significance. Right ventricular pacing leads to pathologic LV remodelling in a significant proportion of paediatric patients. The major independent risk factor is the presence of epicardial RV free wall pacing, which should be avoided whenever possible.","[Salameh, Aida; Janousek, Jan] Univ Leipzig, Dept Pediat Cardiol, Ctr Heart, D-04289 Leipzig, Germany; [Gebauer, Roman A.; Tomek, Viktor; Chaloupecky, Vaclav; Gebauer, Roman; Matejka, Tomas; Vojtovic, Pavel] Univ Hosp Motol, Kardioctr & Cardiovasc Res Ctr, Prague, Czech Republic; [Marek, Jan] Great Ormond St Hosp Sick Children, Dept Pediat Cardiol, London, England","Janousek, J (reprint author), Univ Leipzig, Dept Pediat Cardiol, Ctr Heart, Strumpellstr 39, D-04289 Leipzig, Germany.","jan.janousek@medizin.uni-leipzig.de",null,null,"Ministry of Health, Czech Republic [NR/9472-3]","Funding for this work was provided by the Ministry of Health, Czech Republic (Grant NR/9472-3 to R. A. G.). Funding to pay the Open Access publication charges for this article was provided by the institutional research budget of the Heart Center of the University of Leipzig, Germany.",null,22,20,23,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0195-668X",null,null,"EUR HEART J","Eur. Heart J.","MAY",2009,30,9,null,null,null,null,1097,1104,null,"10.1093/eurheartj/ehp060",null,8,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","441AD","WOS:000265740200015"]
[null,"Proceedings Paper",1,null,"J","Barbato, A; Frischer, T; Kuehni, CE; Snijders, D; Azevedo, I; Baktai, G; Bartoloni, L; Eber, E; Escribano, A; Haarman, E; Hesselmar, B; Hogg, C; Jorissen, M; Lucas, J; Nielsen, KG; O'Callaghan, C; Omran, H; Pohunek, P; Strippoli, MPF; Bush, A",null,null,null,"Barbato, A.; Frischer, T.; Kuehni, C. E.; Snijders, D.; Azevedo, I.; Baktai, G.; Bartoloni, L.; Eber, E.; Escribano, A.; Haarman, E.; Hesselmar, B.; Hogg, C.; Jorissen, M.; Lucas, J.; Nielsen, K. G.; O'Callaghan, C.; Omran, H.; Pohunek, P.; Strippoli, M-P. F.; Bush, A.",null,null,"Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children","EUROPEAN RESPIRATORY JOURNAL",null,null,"English","Review",null,null,null,null,null,"Consensus statement; diagnosis; primary ciliary dyskinesia; treatment","LINKED RETINITIS-PIGMENTOSA; CONGENITAL HEART-DISEASE; RECOMBINANT HUMAN DNASE; SITUS-INVERSUS TOTALIS; OUTER DYNEIN ARM; KARTAGENERS-SYNDROME; CYSTIC-FIBROSIS; MUCOCILIARY CLEARANCE; IMMOTILE-CILIA; LUNG TRANSPLANTATION","Primary ciliary dyskinesia (PCD) is associated with abnormal ciliary structure and function, which results in retention of mucus and bacteria in the respiratory tract, leading to chronic oto-sino-pulmonary disease, situs abnormalities and abnormal sperm motility. The diagnosis of PCD requires the presence of the characteristic clinical phenotype and either specific ultrastructural ciliary defects identified by transmission electron microscopy or evidence of abnormal ciliary function. Although the management of children affected with PCD remains uncertain and evidence is limited, it remains important to follow-up these patients with an adequate and shared care system in order to prevent future lung damage. This European Respiratory Society consensus statement on the management of children with PCD formulates recommendations regarding diagnostic and therapeutic approaches in order to permit a more accurate approach in these patients. Large well-designed randomised controlled trials, with clear description of patients, are required in order to improve these recommendations on diagnostic and treatment approaches in this disease.","[Barbato, A.] Univ Padua, Dept Paediat, Paediat Pulmonol Unit, I-35128 Padua, Italy; [Frischer, T.] Univ Vienna, Dept Paediat, Vienna, Austria; [Eber, E.] Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria; [Kuehni, C. E.; Strippoli, M-P. F.] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [Bartoloni, L.] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland; [Azevedo, I.] Hosp Sao Joao, Dept Paediat, Oporto, Portugal; [Baktai, G.] Paediat Inst Svabhegy, Budapest, Hungary; [Escribano, A.] Univ Valencia, Dept Paediat, Paediat Pulmonol Unit, Clin Univ Hosp, Valencia, Spain; [Haarman, E.] Emma Childrens Hosp, Acad Med Ctr, Dept Paediat & Neonatol, Amsterdam, Netherlands; [Hesselmar, B.] Gothenburg Univ, Dept Paediat, Inst Clin Sci, Sahlgrenska Acad, Gothenburg, Sweden; [Hogg, C.; Bush, A.] Royal Brompton Hosp, Dept Paediat Resp Med, London SW3 6LY, England; [Lucas, J.] Southampton Univ Hosp NHS Trust, Southampton, Hants, England; [O'Callaghan, C.] Univ Leicester, Div Paediat, Dept Infect Immun & Inflammat, Leicester, Leics, England; [O'Callaghan, C.] Leicester Childrens Hosp, Leicester, Leics, England; [Jorissen, M.] Univ Hosp Leuven, Dept Ear Nose & Throat, Louvain, Belgium; [Nielsen, K. G.] Rigshosp, Copenhagen Univ Hosp, Paediat Pulm Serv, DK-2100 Copenhagen, Denmark; [Nielsen, K. G.] Rigshosp, Copenhagen Univ Hosp, Cyst Fibrosis Ctr, Dept Paediat,Clin 1,Juliane Marie Ctr, DK-2100 Copenhagen, Denmark; [Omran, H.] Univ Hosp Freiburg, Dept Paediat & Adolescent Med, Freiburg, Germany; [Pohunek, P.] Univ Hosp Motol, Dept Paediat, Prague, Czech Republic; [Pohunek, P.] Charles Univ Prague, Sch Med 2, Prague, Czech Republic","Barbato, A (reprint author), Univ Padua, Dept Paediat, Paediat Pulmonol Unit, Via Giustiniani 3, I-35128 Padua, Italy.","barbato@pediatria.unipd.it","Eber, Ernst/B-6381-2012; Lucas, Jane/C-3620-2013; Bartoloni, Lucia/I-2504-2013; Strippoli, Marie-Pierre/K-8164-2013","Strippoli, Marie-Pierre/0000-0003-3053-484X",null,null,null,115,97,100,"EUROPEAN RESPIRATORY SOC JOURNALS LTD","SHEFFIELD","442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND","0903-1936",null,null,"EUR RESPIR J","Eur. Resp. J.","DEC",2009,34,6,null,null,null,null,1264,1276,null,"10.1183/09031936.00176608",null,13,"Respiratory System","Respiratory System","530XD","WOS:000272625000005"]
[null,"Review",13,null,"J","O'Brien, JT; McKeith, IG; Walker, Z; Tatsch, K; Booij, J; Darcourt, J; Marquardt, M; Reininger, C",null,null,null,"O'Brien, John T.; McKeith, Ian G.; Walker, Zuzana; Tatsch, Klaus; Booij, Jan; Darcourt, Jacques; Marquardt, Moritz; Reininger, Cornelia",null,null,"Diagnostic accuracy of I-123-FP-CIT SPECT in possible dementia with Lewy bodies","BRITISH JOURNAL OF PSYCHIATRY",null,null,"English","Article",null,null,null,null,null,null,"ALZHEIMERS-DISEASE; MYOCARDIAL SCINTIGRAPHY; DIFFERENTIAL-DIAGNOSIS; INTERNATIONAL WORKSHOP; PARKINSONS-DISEASE; CLINICAL-DIAGNOSIS; TASK-FORCE; CRITERIA; SCALE; CONSORTIUM","Background I-123-FP-CIT SPECT (single photon emission computed tomography) can help in the differential diagnosis of probable dementia with Lewy bodies (Lewy body dementia) and Alzheimer's disease. Aims our aim was to determine the accuracy of I-123-FP-CIT SPECT in diagnosing people with possible dementia with Lewy bodies. Method We undertook a 12-month follow-up of 325 individuals with probable or possible Lewy body or non-Lewy body dementia who had previously undergone I-123-FP-CIT SPECT. A consensus panel, masked to SPECT findings, established diagnosis at 12 months in 264 people. Results Of 44 people with possible dementia with Lewy bodies at baseline, at follow-up the diagnosis for 19 people was probable dementia with Lewy bodies (43%), in 7 people non-Lewy body dementia (16%) and for 18 individuals it remained possible dementia with Lewy bodies (41%). Of the 19 who at follow-up were diagnosed with probable dementia with Lewy bodies, 12 had abnormal scans at baseline (sensitivity 63%); all 7 individuals with a possible diagnosis who were diagnosed as having Alzheimer's disease at follow-up had normal scans (specificity 100%). Conclusions our findings confirm the diagnostic accuracy of I-123-FP-CIT SPECT in distinguishing Lewy body from non-Lewy body dementia and also suggest a clinically useful role in diagnostically uncertain cases, as an abnormal scan in a person with possible dementia with Lewy bodies is strongly suggestive of dementia with Lewy bodies.","[O'Brien, John T.; McKeith, Ian G.] Univ Newcastle, Inst Ageing & Hlth, Newcastle Upon Tyne, Tyne & Wear, England; [Walker, Zuzana] UCL, Dept Mental Hlth Sci, London WC1E 6BT, England; [Tatsch, Klaus] Ludwig Maximilians Univ Hosp, Dept Nucl Med, Munich, Germany; [Booij, Jan] Univ Amsterdam, Acad Med Ctr, Dept Nucl Med, NL-1105 AZ Amsterdam, Netherlands; [Darcourt, Jacques] Univ Nice Sophia Antipolis, Fac Med, Dept Nucl Med, Nice, France; [Marquardt, Moritz; Reininger, Cornelia] GE Healthcare, Clin Res & Dev, Munich, Germany","O'Brien, JT (reprint author), Newcastle Gen Hosp, Wolfson Res Ctr, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.","j.t.o'brien@ncl.ac.uk",null,null,"GE Healthcare","The sponsor (GE Healthcare) financially supported the collection, analysis and interpretation of data. The study was initiated by the principal investigators who drafted and approved the manuscript. The first author had full access to all the data in the study and wrote and approved the manuscript.","ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; Barber R, 1999, NEUROLOGY, V52, P1153; Booij J, 1999, J NUCL MED, V40, P753; Booij J, 1998, J NUCL MED, V39, P1879; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308; Fahn S., 1987, RECENT DEV PARKINSON, P153; Firbank MJ, 2007, PSYCHIAT RES-NEUROIM, V155, P135, DOI 10.1016/j.pscychresns.2007.01.001; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gilman S, 2004, ANN NEUROL, V55, P774, DOI 10.1002/ana.20088; Hampel H, 2004, ARCH GEN PSYCHIAT, V61, P95, DOI 10.1001/archpsyc.61.1.95; Hanyu H, 2006, EUR J NUCL MED MOL I, V33, P248, DOI 10.1007/s00259-005-1921-x; Hoehn MM, 1998, NEUROLOGY, V50, P318; Hu XS, 2000, NEUROLOGY, V55, P1575; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; HUPPERT FA, 1995, BRIT J CLIN PSYCHOL, V34, P529; Kantarci K, 2004, NEUROLOGY, V63, P1393; Litvan I, 2003, MOVEMENT DISORD, V18, P467, DOI 10.1002/mds.10459; Lobotesis K, 2001, NEUROLOGY, V56, P643; McKeith I, 2007, LANCET NEUROL, V6, P305, DOI 10.1016/S1474-4422(07)70057-1; McKeith IG, 2000, NEUROLOGY, V54, P1050; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; McKeith IG, 1996, NEUROLOGY, V47, P1113; MCKHANN G, 1984, NEUROLOGY, V34, P939; O'Brien JT, 2004, ARCH NEUROL-CHICAGO, V61, P919, DOI 10.1001/archneur.61.6.919; Piggott MA, 1999, BRAIN, V122, P1449, DOI 10.1093/brain/122.8.1449; ROMAN GC, 1993, NEUROLOGY, V43, P250; Soret M, 2006, EUR J NUCL MED MOL I, V33, P1062, DOI 10.1007/s00259-005-0003-4; Walker MP, 2000, BRIT J PSYCHIAT, V177, P252, DOI 10.1192/bjp.177.3.252; Walker Z, 2007, J NEUROL NEUROSUR PS, V78, P1176, DOI 10.1136/jnnp.2006.110122; Walker Z, 2002, J NEUROL NEUROSUR PS, V73, P134, DOI 10.1136/jnnp.73.2.134; Warrington E K, 1991, Cortex, V27, P370; Yoshita M, 2001, J NEUROL NEUROSUR PS, V71, P583, DOI 10.1136/jnnp.71.5.583",32,44,44,"ROYAL COLLEGE OF PSYCHIATRISTS","LONDON","BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND","0007-1250",null,null,"BRIT J PSYCHIAT","Br. J. Psychiatry","JAN",2009,194,1,null,null,null,null,34,39,null,"10.1192/bjp.bp.108.052050",null,6,"Psychiatry","Psychiatry","404FS","WOS:000263137000006"]
["2011 Celkem",null,287,null,"J","van der Linden, MH; Valsecchi, MG; De Lorenzo, P; Moricke, A; Janka, G; Leblanc, TM; Felice, M; Biondi, A; Campbell, M; Hann, I; Rubnitz, JE; Stary, J; Szczepanski, T; Vora, A; Ferster, A; Hovi, L; Silverman, LB; Pieters, R",null,null,null,"van der Linden, Marieke H.; Valsecchi, Maria Grazia; De Lorenzo, Paola; Moericke, Anja; Janka, Gritta; Leblanc, Thierry M.; Felice, Maria; Biondi, Andrea; Campbell, Myriam; Hann, Ian; Rubnitz, Jeffrey E.; Stary, Jan; Szczepanski, Tomasz; Vora, Ajay; Ferster, Alina; Hovi, Liisa; Silverman, Lewis B.; Pieters, Rob",null,null,"Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"ONCOLOGY-GROUP; PROGNOSTIC-FACTORS; INFANTS; EXPERIENCE; THERAPY; TRIAL","Acute lymphoblastic leukemia (ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal, no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of MLL rearrangements and CD10-negative B-lineage ALL compared with older infants. Induction failure rate was 13% and not significantly different from that in older infants (7%, P = .14), but relapse rate was significantly higher in congenital ALL patients (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3], P < .001). Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20% (SE 9.1%). Early death in complete remission and treatment delays resulting from toxicity were not different. The survival of 17% after last follow-up, combined with a toxicity profile comparable with that in older infants, justifies treating congenital ALL with curative intent. This trial was registered at www.clinicaltrials.gov as no. NCT 00015873, and at www.controlled-trials.com as no. ISRCTN24251487. (Blood. 2009; 114: 3764-3768)","[Pieters, Rob] Erasmus MC Sophia Childrens Hosp, Dept Paediat Oncol & Haematol, NL-3015 GJ Rotterdam, Netherlands; [Valsecchi, Maria Grazia; De Lorenzo, Paola] Univ Milano Bicocca, Dept Clin Med & Prevent, Milan, Italy; [Moericke, Anja] Univ Med Ctr Schleswig Holstein, Kiel, Germany; [Janka, Gritta] Univ Hosp Hamburg Eppendorf, Cooperat Study Grp Treatment ALL, Hamburg, Germany; [Leblanc, Thierry M.] Hop St Louis, French ALL Grp, Paris, France; [Felice, Maria] Argentina Hosp Pediat, Buenos Aires, DF, Argentina; [Biondi, Andrea] Univ Milano Bicocca, Assoc Italiana Ematol Oncol Pediat, Monza, Italy; [Campbell, Myriam] Hosp Roberto Del Rio, Programa Infantil Nacl Drogas Antineplasicas, Santiago, Chile; [Hann, Ian] Great Ormond St Hosp Sick Children, UK Childrens Canc Study Grp, London WC1N 3JH, England; [Rubnitz, Jeffrey E.] St Jude Childrens Hosp, Memphis, TN 38105 USA; [Stary, Jan] Charles Univ Prague, Czech Paediat Haematol, Univ Hosp Motol, Prague, Czech Republic; [Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Szczepanski, Tomasz] Med Univ Silesia, Polish Paediat Leukemia & Lymphoma Study Grp, Zabrze, Poland; [Vora, Ajay] Sheffield Childrens Hosp, Sheffield, S Yorkshire, England; [Ferster, Alina] Hop Univ Enfants Reine Fabiola, Childrens Leukemia Grp, Brussels, Belgium; [Hovi, Liisa] Univ Helsinki, Nord Soc Paediat Haematol & Oncol, Helsinki, Finland; [Silverman, Lewis B.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Pieters, Rob] Dutch Childhood Oncol Grp, The Hague, Netherlands","Pieters, R (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Paediat Oncol & Haematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.","rob.pieters@erasmusmc.nl",null,null,"KiKa; Associazione Italiana Ricerca sul Cancro Regional [Cod 1105]; Fondazione Tettamanti and Comitato MM Verga; Polish Ministry of Science and Higher Education [2 P054 095 30]; Czech Ministry of Education [MSM0021620813]; Deutsche Krebshilfe","M. H. v. d. L. is supported by KiKa. The many participating institutes of all study groups are acknowledged for their support. This study in Associazione Italiana Ematologia Oncologia Pediatrica is partially supported by Associazione Italiana Ricerca sul Cancro Regional Grant Cod 1105 (to A. B. and M. G. V.). The international study operating center was partially supported by Fondazione Tettamanti and Comitato MM Verga (to M. G. V. and P. D. L.). T. S. was supported by the Polish Ministry of Science and Higher Education (grant 2 P054 095 30). Czech Paediatric Haematology was supported by the Czech Ministry of Education (grant MSM0021620813). Berlin-Frankfurt-Munster Germany was supported by Deutsche Krebshilfe.",null,20,16,16,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","OCT 29",2009,114,18,null,null,null,null,3764,3768,null,"10.1182/blood-2009-02-204214",null,5,"Hematology","Hematology","512RO","WOS:000271268100010"]
[2012,"Article",322,null,"J","Lurbe, E; Cifkova, R; Cruickshank, JK; Dillon, MJ; Ferreira, I; Invitti, C; Kuznetsovah, T; Laurent, S; Mancia, G; Morales-Olivas, F; Rascher, W; Redon, J; Schaefer, F; Seeman, T; Stergiou, G; Wuhl, E; Zanchetti, A",null,null,null,"Lurbe, Empar; Cifkova, Renata; Cruickshank, J. Kennedy; Dillon, Michael J.; Ferreira, Isabel; Invitti, Cecilia; Kuznetsovah, Tatiana; Laurent, Stephane; Mancia, Giuseppe; Morales-Olivas, Francisco; Rascher, Wolfgang; Redon, Josep; Schaefer, Franz; Seeman, Tomas; Stergiou, George; Wuehl, Elke; Zanchetti, Alberto",null,null,"Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension","JOURNAL OF HYPERTENSION",null,null,"English","Review",null,null,null,null,null,"adolescents; children; European; management of high blood pressure; recommendations; society of hypertension","LEFT-VENTRICULAR HYPERTROPHY; INTIMA-MEDIA THICKNESS; TARGET-ORGAN DAMAGE; ANGIOTENSIN RECEPTOR BLOCKER; CARDIOVASCULAR RISK-FACTORS; PLACEBO-CONTROLLED TRIAL; WHITE COAT HYPERTENSION; CHRONIC KIDNEY-DISEASES; CORONARY-HEART-DISEASE; CHRONIC-RENAL-FAILURE","Hypertension in children and adolescents has gained ground in cardiovascular medicine, thanks to the progress made in several areas of pathophysiological and clinical research. These guidelines represent a consensus among specialists involved in the detection and control of high blood pressure in children and adolescents. The guidelines synthesize a considerable amount of scientific data and clinical experience and represent best clinical wisdom upon which physicians, nurses and families should base their decisions. They call attention to the burden of hypertension in children and adolescents, and its contribution to the current epidemic of cardiovascular disease, these guidelines should encourage public policy makers, to develop a global effort to improve identification and treatment of high blood pressure among children and adolescents. J Hypertens 27: 1719-1742 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Lurbe, Empar] Univ Valencia, Consorcio Hosp Gen, Dept Pediat, Valencia 46014, Spain; [Lurbe, Empar; Redon, Josep] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CB06 03, Madrid, Spain; [Cifkova, Renata] Inst Clin & Expt Med, Dept Prevent Cardiol, Prague, Czech Republic; [Cruickshank, J. Kennedy] Univ Manchester, Div Cardiovasc & Endocrine Sci, Manchester Royal Infirm, Cardiovasc Res Grp, Manchester, Lancs, England; [Dillon, Michael J.] UCL Inst Child Hlth, Nephrourol Unit, London, England; [Ferreira, Isabel] Maastricht Univ, Med Ctr, CAPHRI, CARIM,Dept Internal Med Clin Epidemiol & Med Tech, Maastricht, Netherlands; [Invitti, Cecilia] IRCCS, Ist Auxolog Italiano, Unit Metab Dis & Diabet, Milan, Italy; [Kuznetsovah, Tatiana] Univ Leuven, Lab Hypertens, Louvain, Belgium; [Laurent, Stephane] Hop Europeen, Dept Pharmacol, Paris, France; [Mancia, Giuseppe] Univ Milano Bicocca, Osped San Gerardo, Milan, Italy; [Morales-Olivas, Francisco] Univ Valencia, Dept Pharmacol, Valencia, Spain; [Rascher, Wolfgang] Univ Klinikum, Kinder & Judendklin, Erlangen, Germany; [Redon, Josep] Univ Valencia, Hosp Clin, Dept Internal Med, Valencia, Spain; [Schaefer, Franz; Wuehl, Elke] Univ Heidelberg, Ctr Pediat & Adolescent Med, Div Pediat Nephrol, Heidelberg, Germany; [Seeman, Tomas] Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Stergiou, George] Third Univ, Sotiria Hosp, Dept Med, Hypertens Ctr, Athens, Greece; [Zanchetti, Alberto] Univ Milan, Ctr Interuniv Fisiol Clin & Ipertens, Milan, Italy; [Zanchetti, Alberto] Ist Auxol Italiano, Milan, Italy","Lurbe, E (reprint author), Univ Valencia, Consorcio Hosp Gen, Dept Pediat, Avda Tres Cruces S-N, Valencia 46014, Spain.","empar.lurbe@uv.es","Schaefer, Franz/G-4365-2010; Kuznetsova, Tatiana/I-6882-2013","Kuznetsova, Tatiana/0000-0003-3564-7405",null,null,null,173,170,185,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,null,"J HYPERTENS","J. Hypertens.","SEP",2009,27,9,null,null,null,null,1719,1742,null,"10.1097/HJH.0b013e32832f4f6b",null,24,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","491AP","WOS:000269549500001"]
[null,"Article; Proceedings Paper",2,null,"J","Nelis, M; Esko, T; Magi, R; Zimprich, F; Zimprich, A; Toncheva, D; Karachanak, S; Piskackova, T; Balascak, I; Peltonen, L; Jakkula, E; Rehnstrom, K; Lathrop, M; Heath, S; Galan, P; Schreiber, S; Meitinger, T; Pfeufer, A; Wichmann, HE; Melegh, B; Polgar, N; Toniolo, D; Gasparini, P; D'Adamo, P; Klovins, J; Nikitina-Zake, L; Kucinskas, V; Kasnauskiene, J; Lubinski, J; Debniak, T; Limborska, S; Khrunin, A; Estivill, X; Rabionet, R; Marsal, S; Julia, A; Antonarakis, SE; Deutsch, S; Borel, C; Attar, H; Gagnebin, M; Macek, M; Krawczak, M; Remm, M; Metspalu, A",null,null,null,"Nelis, Mari; Esko, Tonu; Magi, Reedik; Zimprich, Fritz; Zimprich, Alexander; Toncheva, Draga; Karachanak, Sena; Piskackova, Tereza; Balascak, Ivan; Peltonen, Leena; Jakkula, Eveliina; Rehnstrom, Karola; Lathrop, Mark; Heath, Simon; Galan, Pilar; Schreiber, Stefan; Meitinger, Thomas; Pfeufer, Arne; Wichmann, H-Erich; Melegh, Bela; Polgar, Noemi; Toniolo, Daniela; Gasparini, Paolo; D'Adamo, Pio; Klovins, Janis; Nikitina-Zake, Liene; Kucinskas, Vaidutis; Kasnauskiene, Jurate; Lubinski, Jan; Debniak, Tadeusz; Limborska, Svetlana; Khrunin, Andrey; Estivill, Xavier; Rabionet, Raquel; Marsal, Sara; Julia, Antonio; Antonarakis, Stylianos E.; Deutsch, Samuel; Borel, Christelle; Attar, Homa; Gagnebin, Maryline; Macek, Milan; Krawczak, Michael; Remm, Maido; Metspalu, Andres",null,null,"Genetic Structure of Europeans: A View from the North-East","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,null,"Using principal component (PC) analysis, we studied the genetic constitution of 3,112 individuals from Europe as portrayed by more than 270,000 single nucleotide polymorphisms (SNPs) genotyped with the Illumina Infinium platform. In cohorts where the sample size was >100, one hundred randomly chosen samples were used for analysis to minimize the sample size effect, resulting in a total of 1,564 samples. This analysis revealed that the genetic structure of the European population correlates closely with geography. The first two PCs highlight the genetic diversity corresponding to the northwest to southeast gradient and position the populations according to their approximate geographic origin. The resulting genetic map forms a triangular structure with a) Finland, b) the Baltic region, Poland and Western Russia, and c) Italy as its vertexes, and with d) Central- and Western Europe in its centre. Inter- and intra- population genetic differences were quantified by the inflation factor lambda (lambda) (ranging from 1.00 to 4.21), fixation index (F(st)) (ranging from 0.000 to 0.023), and by the number of markers exhibiting significant allele frequency differences in pair-wise population comparisons. The estimated lambda was used to assess the real diminishing impact to association statistics when two distinct populations are merged directly in an analysis. When the PC analysis was confined to the 1,019 Estonian individuals (0.1% of the Estonian population), a fine structure emerged that correlated with the geography of individual counties. With at least two cohorts available from several countries, genetic substructures were investigated in Czech, Finnish, German, Estonian and Italian populations. Together with previously published data, our results allow the creation of a comprehensive European genetic map that will greatly facilitate inter-population genetic studies including genome wide association studies (GWAS).",null,"Nelis, M (reprint author), Univ Tartu, Inst Mol & Cell Biol, Ulikooli 18, EE-50090 Tartu, Estonia.","andres@ebc.ee","Krawczak, Michael/A-8964-2010; Schreiber, Stefan/B-6748-2008; Klovins, Janis/C-5695-2011; Estivill, Xavier/E-2957-2012; Heath, Simon/J-4138-2012; Polgar, Noemi/B-3948-2013; Pfeufer, Arne/B-6634-2013; rabionet, raquel/A-7407-2009; rabionet, raquel/C-8379-2009; d'Adamo, Pio/G-4064-2011","rabionet, raquel/0000-0001-5006-8140; rabionet, raquel/0000-0001-5006-8140; d'Adamo, Pio/0000-0001-9367-4909",null,null,"Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409; Barbujani G, 2004, ANNU REV GENOM HUM G, V5, P119, DOI 10.1146/annurev.genom.5.061903.180021; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bauchet M, 2007, AM J HUM GENET, V80, P948, DOI 10.1086/513477; Bersaglieri T, 2004, AM J HUM GENET, V74, P1111, DOI 10.1086/421051; Burton PR, 2009, INT J EPIDEMIOL, V38, P263, DOI 10.1093/ije/dyn147; Chikhi L, 2002, P NATL ACAD SCI USA, V99, P11008, DOI 10.1073/pnas.162158799; de Bakker PIW, 2008, HUM MOL GENET, V17, pR122, DOI 10.1093/hmg/ddn288; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Heath SC, 2008, EUR J HUM GENET, V16, P1413, DOI 10.1038/ejhg.2008.210; Jakkula E, 2008, AM J HUM GENET, V83, P787, DOI 10.1016/j.ajhg.2008.11.005; Jakobsson M, 2008, NATURE, V451, P998, DOI 10.1038/nature06742; Krawczak M, 2006, COMMUNITY GENET, V9, P55, DOI 10.1159/000090694; Lao O, 2008, CURR BIOL, V18, P1241, DOI 10.1016/j.cub.2008.07.049; Li QZ, 2008, GENET EPIDEMIOL, V32, P215, DOI 10.1002/gepi.20296; Lowel H, 2005, GESUNDHEITSWESEN, V67, pS13, DOI 10.1055/s-2005-858234; Manni F, 2004, HUM BIOL, V76, P173, DOI 10.1353/hub.2004.0034; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; MENOZZI P, 1978, SCIENCE, V201, P786, DOI 10.1126/science.356262; Novembre J, 2008, NATURE, V456, P98, DOI 10.1038/nature07331; Price AL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0030236; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Pritchard JK, 2000, GENETICS, V155, P945; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Roewer L, 2005, HUM GENET, V116, P279, DOI 10.1007/s00439-004-1201-z; Salmela E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003519; Service S, 2006, NAT GENET, V38, P556, DOI 10.1038/ng1770; Simoni L, 2000, AM J HUM GENET, V66, P262, DOI 10.1086/302706; Steffens M, 2006, HUM HERED, V62, P20, DOI 10.1159/000095850; Tian C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040004; Torroni A, 2006, TRENDS GENET, V22, P339, DOI 10.1016/j.tig.2006.04.001; Varilo T, 2000, EUR J HUM GENET, V8, P604, DOI 10.1038/sj.ejhg.5200482; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Wichmann HE, 2005, GESUNDHEITSWESEN, V67, pS26, DOI 10.1055/s-2005-858226; Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120",35,96,97,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA","1932-6203",null,null,"PLOS ONE","PLoS One","MAY 8",2009,4,5,null,null,null,null,null,null,"e5472","10.1371/journal.pone.0005472",null,10,"Multidisciplinary Sciences","Science & Technology - Other Topics","443TN","WOS:000265933800011"]
[null,"Editorial Material",6,null,"J","Eiselleova, L; Matulka, K; Kriz, V; Kunova, M; Schmidtova, Z; Neradil, J; Tichy, B; Dvorakova, D; Pospisilova, S; Hampl, A; Dvorak, P",null,null,null,"Eiselleova, Livia; Matulka, Kamil; Kriz, Vitezslav; Kunova, Michaela; Schmidtova, Zuzana; Neradil, Jakub; Tichy, Boris; Dvorakova, Dana; Pospisilova, Sarka; Hampl, Ales; Dvorak, Petr",null,null,"A Complex Role for FGF-2 in Self-Renewal, Survival, and Adhesion of Human Embryonic Stem Cells","STEM CELLS",null,null,"English","Article",null,null,null,null,null,"Fibroblast growth factor-2; Human ESCs; Self-renewal; Cell survival; Adhesion","FIBROBLAST-GROWTH-FACTOR; CULTURE-CONDITIONS; GENE-EXPRESSION; HUMAN ESCS; MOUSE; DIFFERENTIATION; PROLIFERATION; IMPLANTATION; RECEPTOR; FORMS","The transcription program that is responsible for the pluripotency of human ESCs (hESCs) is believed to be comaintained by exogenous fibroblast growth factor-2 (FGF-2), which activates FGF receptors (FGFRs) and stimulates the mitogen-activated protein kinase (MAPK) pathway. However, the same pathway is stimulated by insulin receptors, insulin-like growth factor 1 receptors, and epidermal growth factor receptors. This mechanism is further complicated by intracrine FGF signals. Thus, the molecular mechanisms by which FGF-2 promotes the undifferentiated growth of hESCs are unclear. Here we show that, in undifferentiated hESCs, exogenous FGF-2 stimulated the expression of stem cell genes while suppressing cell death and apoptosis genes. Inhibition of autocrine FGF signaling caused upregulation of differentiation-related genes and downregulation of stem cell genes. Thus, exogenous FGF-2 reinforced the pluripotency maintenance program of intracrine FGF-2 signaling. Consistent with this hypothesis, expression of endogenous FGF-2 decreased during hESC differentiation and FGF-2 knockdown-induced hESC differentiation. In addition, FGF-2 signaling via FGFR2 activated MAPK kinase/extracellular signal-regulated kinase and AKT kinases, protected hESC from stress-induced cell death, and increased hESC adhesion and cloning efficiency. This stimulation of self-renewal, cell survival, and adhesion by exogenous and endogenous FGF-2 may synergize to maintain the undifferentiated growth of hESCs. STEM CELLS 2009;27:1847-1857","[Eiselleova, Livia; Matulka, Kamil; Kriz, Vitezslav; Kunova, Michaela; Schmidtova, Zuzana; Neradil, Jakub; Hampl, Ales; Dvorak, Petr] Masaryk Univ, Fac Med, Dept Biol, Brno 62500, Czech Republic; [Eiselleova, Livia; Matulka, Kamil; Kunova, Michaela; Hampl, Ales; Dvorak, Petr] Masaryk Univ, Fac Med, Ctr Chem Genet, Brno 62500, Czech Republic; [Tichy, Boris; Dvorakova, Dana; Pospisilova, Sarka] Masaryk Univ, Univ Hosp Brno, Dept Internal Med Hematooncol, Brno 62500, Czech Republic; [Hampl, Ales; Dvorak, Petr] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Embryol, Prague, Czech Republic; [Hampl, Ales; Dvorak, Petr] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Dvorak, P (reprint author), Masaryk Univ, Fac Med, Dept Biol, Kamenice 5,Bldg A6, Brno 62500, Czech Republic.","pdvorak@med.muni.cz","Vopenkova, Katerina/C-7133-2012; Tichy, Boris/C-1314-2009; Pospisilova, Sarka/D-7200-2012; Dvorak, Petr/G-2509-2013","Tichy, Boris/0000-0001-9252-7974; Dvorak, Petr/0000-0002-3229-140X","Ministry of Education, Youth, and Sport of the Czech Republic [MSM0021622430, LC06077, 1M0538]; Academy of Sciences of the Czech Republic [AV0Z50390512, AV0Z50390703]; European Commission Framework Programme 6 [LSHG-CT-2006-018739]","We thank Peter W. Andrews of the University of Sheffield, Sheffield, U. K., for sorted SSEA3-positive hESCs and Outi Hovatta of the Karolinska Institutet, Huddinge, Sweden, for the HS237 hESC line. This study was supported by the Ministry of Education, Youth, and Sport of the Czech Republic (MSM0021622430, LC06077, 1M0538), the Academy of Sciences of the Czech Republic (AV0Z50390512, AV0Z50390703), and European Commission Framework Programme 6 (contract LSHG-CT-2006-018739) funding.",null,46,65,66,"ALPHAMED PRESS","DURHAM","318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA","1066-5099",null,null,"STEM CELLS","Stem Cells","AUG",2009,27,8,null,null,null,null,1847,1857,null,"10.1002/stem.128",null,11,"Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology","Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology","497HZ","WOS:000270050900016"]
[null,"Letter",11,null,"J","Weerkamp, F; Dekking, E; Ng, YY; van der Velden, VHJ; Wai, H; Bottcher, S; Bruggemann, M; van der Sluijs, AJ; Koning, A; Boeckx, N; Van Poecke, N; Lucio, P; Mendonca, A; Sedek, L; Szczepanski, T; Kalina, T; Kovac, M; Hoogeveen, PG; Flores-Montero, J; Orfao, A; Macintyre, E; Lhermitte, L; Chen, R; Brouwer-De Cock, KAJ; van der Linden, A; Noordijk, AL; Comans-Bitter, WM; Staal, FJT; van Dongen, JJM",null,null,null,"Weerkamp, F.; Dekking, E.; Ng, Y. Y.; van der Velden, V. H. J.; Wai, H.; Boettcher, S.; Brueggemann, M.; van der Sluijs, A. J.; Koning, A.; Boeckx, N.; Van Poecke, N.; Lucio, P.; Mendonca, A.; Sedek, L.; Szczepanski, T.; Kalina, T.; Kovac, M.; Hoogeveen, P. G.; Flores-Montero, J.; Orfao, A.; Macintyre, E.; Lhermitte, L.; Chen, R.; Brouwer-De Cock, K. A. J.; van der Linden, A.; Noordijk, A. L.; Comans-Bitter, W. M.; Staal, F. J. T.; van Dongen, J. J. M.",null,"EuroFlow Consortium EU-FP6 LSHB-","Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"BCR-ABL protein; t(9;22); CML; precursor-B-ALL; immunobead; flow cytometry","CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMERASE-CHAIN-REACTION; RESIDUAL DISEASE DETECTION; PHILADELPHIA-CHROMOSOME; C-ABL; TYROSINE KINASE; ANTIBODY RECOGNITION; GENE TRANSCRIPTS","BCR-ABL fusion proteins show increased signaling through their ABL tyrosine kinase domain, which can be blocked by specific inhibitors, thereby providing effective treatment. This makes detection of BCR-ABL aberrations of utmost importance for diagnosis, classification and treatment of leukemia patients. BCR-ABL aberrations are currently detected by karyotyping, fluorescence in situ hybridization (FISH) or PCR techniques, which are time consuming and require specialized facilities. We developed a simple flow cytometric immunobead assay for detection of BCR-ABL fusion proteins in cell lysates, using a bead-bound anti-BCR catching antibody and a fluorochrome-conjugated anti-ABL detection antibody. We noticed protein stability problems in lysates caused by proteases from mature myeloid cells. This problem could largely be solved by adding protease inhibitors in several steps of the immunobead assay. Testing of 145 patient samples showed fully concordant results between the BCR-ABL immunobead assay and reverse transcriptase PCR of fusion gene transcripts. Dilution experiments with BCR-ABL positive cell lines revealed sensitivities of at least 1%. We conclude that the BCR-ABL immunobead assay detects all types of BCR-ABL proteins in leukemic cells with high specificity and sensitivity. The assay does not need specialized laboratory facilities other than a flow cytometer, provides results within similar to 4 h, and can be run in parallel to routine immunophenotyping. Leukemia (2009) 23, 1106-1117; doi: 10.1038/leu.2009.93; published online 23 April 2009","[van Dongen, J. J. M.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, NL-3015 GE Rotterdam, Netherlands; [Weerkamp, F.; Dekking, E.; Ng, Y. Y.; Brouwer-De Cock, K. A. J.; van der Linden, A.; Noordijk, A. L.] Dynomics, Rotterdam, Netherlands; [Wai, H.; Chen, R.] BD Biosci, San Jose, CA USA; [Boettcher, S.; Brueggemann, M.] Univ Klin Schleswig Holstein, Dept Med 2, Kiel, Germany; [van der Sluijs, A. J.; Koning, A.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Boeckx, N.; Van Poecke, N.] Univ Hosp Leuven, Dept Lab Med, Louvain, Belgium; [Lucio, P.; Mendonca, A.] Inst Portugues Oncol Francisco Gentil, Dept Hematol, Lisbon, Portugal; [Sedek, L.; Szczepanski, T.] Med Univ Silesia, Dept Pediat Hematol & Oncol, Zabrze, Poland; [Kalina, T.; Kovac, M.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Flores-Montero, J.; Orfao, A.] Univ Salamanca, Dept Med, Canc Res Ctr, IBMCC CSIC USAL, E-37008 Salamanca, Spain; [Flores-Montero, J.; Orfao, A.] Univ Salamanca, Cytometry Serv, E-37008 Salamanca, Spain; [Macintyre, E.; Lhermitte, L.] Hop Necker Enfants Malad, Dept Hematol, Paris, France","van Dongen, JJM (reprint author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.","j.j.m.vandongen@erasmusmc.nl","Kalina, Tomas/C-1078-2009; 2009, Secribsal/A-1266-2012; Bruggemann, Monika/M-8150-2013","Bruggemann, Monika/0000-0001-5514-5010","European Commission through the STREP [LSHB-CT-2006-018708]; Fondo de Investigaciones Sanitarias (FIS) [EST-08-90881]; Instituto de Salud Carlos III (Ministerio de Ciencia e Innovacion, Madrid, Spain)","This study was supported by the European Commission through the STREP grant EU-FP6, LSHB-CT-2006-018708, entitled Euro-Flow, 'Flow cytometry for fast and sensitive diagnosis and follow-up of haematological malignancies'. Work carried out at Salamanca was supported in part by a grant (EST-08-90881) from the Fondo de Investigaciones Sanitarias (FIS) of the Instituto de Salud Carlos III (Ministerio de Ciencia e Innovacion, Madrid, Spain).",null,45,28,28,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","JUN",2009,23,6,null,null,null,null,1106,1117,null,"10.1038/leu.2009.93",null,12,"Oncology; Hematology","Oncology; Hematology","456DQ","WOS:000266820700011"]
[null,"Review",31,null,"J","Eckerle, S; Brune, V; Doring, C; Tiacci, E; Bohle, V; Sundstrom, C; Kodet, R; Paulli, M; Falini, B; Klapper, W; Chaubert, AB; Willenbrock, K; Metzler, D; Brauninger, A; Kuppers, R; Hansmann, ML",null,null,null,"Eckerle, S.; Brune, V.; Doering, C.; Tiacci, E.; Bohle, V.; Sundstrom, C.; Kodet, R.; Paulli, M.; Falini, B.; Klapper, W.; Chaubert, A. B.; Willenbrock, K.; Metzler, D.; Braeuninger, A.; Kueppers, R.; Hansmann, M. -L",null,null,"Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"anaplastic large cell lymphoma; Hodgkin lymphoma; gene expression profiling; lymphoma pathogenesis","NF-KAPPA-B; REED-STERNBERG CELLS; T-CELL; CLASSICAL HODGKIN; MOLECULAR-BIOLOGY; CDNA ARRAYS; DISEASE; TRANSCRIPTION; PROMOTER; FEATURES","Anaplastic large cell lymphoma (ALCL) is a main type of T-cell lymphomas and comprises three distinct entities: systemic anaplastic lymphoma kinase (ALK) positive, systemic ALK(-) and cutaneous ALK(-) ALCL (cALCL). Little is known about their pathogenesis and their cellular origin, and morphological and immunophenotypical overlap exists between ALK(-) ALCL and classical Hodgkin lymphoma (cHL). We conducted gene expression profiling of microdissected lymphoma cells of five ALK(+) and four ALK(-) systemic ALCL, seven cALCL and sixteen cHL, and of eight subsets of normal T and NK cells. The analysis supports a derivation of ALCL from activated T cells, but the lymphoma cells acquired a gene expression pattern hampering an assignment to a CD4(+), CD8(+) or CD30(+) T-cell origin. Indeed, ALCL display a down-modulation of many T-cell characteristic molecules. All ALCL types show significant expression of NF kappa B target genes and upregulation of genes involved in oncogenesis (e. g. EZH2). Surprisingly, few genes are differentially expressed between systemic and cALCL despite their different clinical behaviour, and between ALK(-) ALCL and cHL despite their different cellular origin. ALK(+) ALCL are characterized by expression of genes regulated by pathways constitutively activated by ALK. This study provides multiple novel insights into the molecular biology and pathogenesis of ALCL. Leukemia (2009) 23, 2129-2138; doi: 10.1038/leu.2009.161; published online 6 August 2009","[Eckerle, S.; Brune, V.; Tiacci, E.; Bohle, V.; Kueppers, R.] Univ Duisburg Essen, Inst Cell Biol Canc Res, Sch Med, D-45122 Essen, Germany; [Eckerle, S.; Brune, V.; Doering, C.; Willenbrock, K.; Braeuninger, A.; Hansmann, M. -L] Goethe Univ Frankfurt, Senckenberg Inst Pathol, Sch Med, Frankfurt, Germany; [Doering, C.; Metzler, D.] Goethe Univ Frankfurt, Inst Informat, Frankfurt, Germany; [Sundstrom, C.] Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden; [Kodet, R.] Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Paulli, M.] Univ Pavia, Policlin San Matteo, Inst Pathol Anat, I-27100 Pavia, Italy; [Falini, B.] Univ Perugia, Inst Hematol, I-06100 Perugia, Italy; [Klapper, W.] Univ Hosp Schleswig Holstein, Haematopathol Sect, Inst Pathol, Kiel, Germany; [Chaubert, A. B.] CHU Vaudois, Inst Pathol, CH-1011 Lausanne, Switzerland; [Braeuninger, A.] Univ Munster, Inst Pathol, Munster, Germany; [Klapper, W.] Univ Hosp Schleswig Holstein, Lymph Node Registry, Kiel, Germany","Kuppers, R (reprint author), Univ Duisburg Essen, Inst Cell Biol Canc Res, Sch Med, Virchowstr 173, D-45122 Essen, Germany.","ralf.kueppers@uk-essen.de","Klapper, Wolfram/D-2516-2010",null,"Deutsche Forschungsgemeinschaft [KU1315/5-2, BR1238/6-2 and 6-3, WI2015/1-1]; Deutsche Krebshilfe and the Associazione Italiana per la Ricerca sul Cancro (AIRC); German Jose Carreras Leukemia Foundation [F 05/01]","We highly appreciate the excellent technical assistance of Ralf Lieberz, Nicole Dieckert, Yvonne Michel, Ingrid Kremser and Klaus Lennartz. We thank Dr Detlef Gussow and Melanie Kuhnl from Merck KGaA, Darmstadt, Germany for the opportunity to scan the Affymetrix arrays in their laboratory. This work was supported by grants from the Deutsche Forschungsgemeinschaft (KU1315/5-2, BR1238/6-2 and 6-3 and WI2015/1-1), the Deutsche Krebshilfe and the Associazione Italiana per la Ricerca sul Cancro (AIRC). Enrico Tiacci was recipient of a fellowship (F 05/01) granted by the German Jose Carreras Leukemia Foundation.",null,43,26,28,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","NOV",2009,23,11,null,null,null,null,2129,2138,null,"10.1038/leu.2009.161",null,10,"Oncology; Hematology","Oncology; Hematology","518BV","WOS:000271666000021"]
["2012 Celkem",null,372,null,"J","Willasch, AM; Gruhn, B; Coliva, T; Kalinova, M; Schneider, G; Kreyenberg, H; Steinbach, D; Weber, G; Hollink, I; Zwaan, CM; Biondi, A; van der Velden, VHJ; Reinhardt, D; Cazzaniga, G; Bader, P; Trka, J",null,null,null,"Willasch, A. M.; Gruhn, B.; Coliva, T.; Kalinova, M.; Schneider, G.; Kreyenberg, H.; Steinbach, D.; Weber, G.; Hollink, Ihim; Zwaan, C. M.; Biondi, A.; van der Velden, V. H. J.; Reinhardt, D.; Cazzaniga, G.; Bader, P.; Trka, J.",null,"European Study Grp WT1 Expression","Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"WT1 expression; minimal residual disease; real-time PCR; childhood AML; WT1 gene mutations; standardized approach","ACUTE MYELOID-LEUKEMIA; RT-PCR ANALYSIS; POLYMERASE-CHAIN-REACTION; QUALITY-CONTROL PROGRAM; MYELODYSPLASTIC SYNDROMES; PROGNOSTIC IMPLICATIONS; CANCER PROGRAM; BONE-MARROW; EXPRESSION; TRANSCRIPTS","A standardized, sensitive and universal method for minimal residual disease (MRD) detection in acute myeloid leukemia (AML) is still pending. Although hyperexpression of Wilms' tumor (WT1) gene transcript has been frequently proposed as an MRD marker in AML, wide comparability of the various methods used for evaluating WT1 expression has not been given. We established and standardized a multicenter approach for quantifying WT1 expression by quantitative reverse transcriptase PCR (qRT-PCR), on the basis of a primer/probe set combination at exons 6 and 7. In a series of quality-control rounds, we analyzed 69 childhood AML samples and 47 normal bone marrow (BM) samples from 4 participating centers. Differences in the individual WT1 expressions levels ranged within < 0.5 log of the mean in 82% of the cases. In AML samples, the median WT1/1E + 04 Abelson (ABL) expression was 3.5E + 03 compared with that of 2.3E + 01 in healthy BM samples. As 11.5% of childhood AML samples in this cohort harbored WT1 mutations in exon 7, the effect of mutations on WT1 expression has been investigated, showing that mutated cases expressed significantly higher WT1 levels than wild-type cases. Hence, our approach showed high reproducibility and applicability, even in patients with WT1 mutations; therefore, it can be widely used for the quantitation of WT1 expression in future clinical trials. Leukemia (2009) 23, 1472-1479; doi:10.1038/leu.2009.51; published online 26 March 2009","[Willasch, A. M.; Kreyenberg, H.; Weber, G.; Bader, P.] Univ Frankfurt, Dept Pediat Hematol Oncol & Hemostaseol, Hosp Children & Adolescents 3, D-60590 Frankfurt, Germany; [Gruhn, B.] Schiller Univ Jena, Dept Pediat Hematol & Oncol, Univ Childrens Hosp, Jena, Germany; [Coliva, T.; Biondi, A.; Cazzaniga, G.] Univ Milan, Dept Pediat Hematol & Oncol, Bicocca Clin Pediat, Osped San Gerardo, Monza, Italy; [Kalinova, M.; Trka, J.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Kalinova, M.; Trka, J.] Univ Childrens Hosp, Prague, Czech Republic; [Schneider, G.] Univ Frankfurt, Dept Comp Sci & Math, Frankfurt, Germany; [Steinbach, D.] Univ Ulm, Univ Childrens Hosp, Dept Pediat Hematol & Oncol, Ulm, Germany; [Hollink, Ihim; Zwaan, C. M.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Hematol & Oncol, Rotterdam, Netherlands; [van der Velden, V. H. J.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Reinhardt, D.] Med High Sch, Dept Pediat Oncol & Hematol, AML BFM Study Grp, Hannover, Germany","Willasch, AM (reprint author), Univ Frankfurt, Dept Pediat Hematol Oncol & Hemostaseol, Hosp Children & Adolescents 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.","andre.willasch@kgu.de","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Deutsche Jose Carreras Leukamie Stiftung [DJCLS R04/09]; Munich, Germany; Czech Ministry of Education [0021620813]; Prague, Czech Republic; 'Fondazione Tettamanti, Fondazione Cariplo and AIRC', Italy; KOCR Foundation","This work was supported by the 'Deutsche Jose Carreras Leukamie Stiftung e. V. (DJCLS R04/09)', Munich, Germany (PB, HK, AMW), by the 'Research Project of the Czech Ministry of Education (No. 0021620813)', Prague, Czech Republic (JT, MK), by the 'Fondazione Tettamanti, Fondazione Cariplo and AIRC', Italy (AB, GC) and by the 'KOCR Foundation', Rotterdam, The Netherlands (IHIMH, CMZ). We thank Vida Meyer (Frankfurt), Nadine Pfaffendorf (Jena), Vincenzo Rossi (Monza) and Patricia Hoogeveen (Rotterdam) for their excellent technical assistance.",null,35,27,27,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","AUG",2009,23,8,null,null,null,null,1472,1479,null,"10.1038/leu.2009.51",null,8,"Oncology; Hematology","Oncology; Hematology","482CR","WOS:000268862000015"]
[2013,"Article",235,null,"J","Rubio-Cabezas, O; Minton, JAL; Caswell, R; Shield, JP; Deiss, D; Sumnik, Z; Cayssials, A; Herr, M; Loew, A; Lewis, V; Ellard, S; Hattersley, AT",null,null,null,"Rubio-Cabezas, Oscar; Minton, Jayne A. L.; Caswell, Richard; Shield, Julian P.; Deiss, Dorothee; Sumnik, Zdenek; Cayssials, Amely; Herr, Mathias; Loew, Anja; Lewis, Vaughan; Ellard, Sian; Hattersley, Andrew T.",null,null,"Clinical Heterogeneity in Patients With FOXP3 Mutations Presenting With Permanent Neonatal Diabetes","DIABETES CARE",null,null,"English","Article",null,null,null,null,null,null,"X-LINKED SYNDROME; REGULATORY T-CELLS; IMMUNE DYSREGULATION; SYNDROME IPEX; SWISS-MODEL; POLYENDOCRINOPATHY; ENTEROPATHY; MELLITUS; PROTEIN; IMMUNODYSREGULATION","OBJECTIVE - Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is caused by FOXP3 mutations. We aimed to determine the prevalence, genetics, and clinical phenotype of FOXP3 mutations in a large cohort with permanent neonatal diabetes (PNDM). RESEARCH DESIGN AND METHODS - The 11 coding exons and the polyadenylation region of FOXP3 Were sequenced in 26 male subjects with diabetes diagnosed before 6 months of age in whom common genetic causes of PNDM had been excluded. Ten subjects had at least one additional immune-related disorder, and the remaining 16 had isolated diabetes. RESULTS - We identified four hemizygous FOXP3 Mutations in 6 of 10 patients with associated immune-related disorders and in 0 of 16 patients with isolated diabetes (P = 0.002). Three patients with two novel mutations (R337Q and P339A) and the previously reported L76QfsX53 developed classic IPEX syndrome and died within the First, 13 months. The novel mutation V408M was found in three patients from two unrelated families and had a mild phenotype with hypothyroidism and autoimmune enteropathy (it = 2) or nephrotic syndrome (n = 1) and survival to 12-15 years. CONCLUSIONS - FOXP3 mutations result in similar to 4% of cases of male patients with permanent diabetes diagnosed before 6 months. Patients not only have classic IPEX syndrome but, unexpectedly. may have a more benign phenotype. FOXP3 sequencing should be performed in any male patient with the diagnosis of diabetes in the first 6 months who develops other possible autoimmune-associated conditions, even in the absence of full IPEX syndrome.","[Rubio-Cabezas, Oscar; Minton, Jayne A. L.; Ellard, Sian; Hattersley, Andrew T.] Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England; [Rubio-Cabezas, Oscar] Hosp Infantil Univ Nino Jesus, Dept Endocrinol, Madrid, Spain; [Caswell, Richard] Cardiff Univ, Sch Biosci, Cardiff, S Glam, Wales; [Shield, Julian P.] Bristol Royal Hosp Children, Dept Pediat Endocrinol, Bristol, Avon, England; [Deiss, Dorothee; Herr, Mathias] Virchow Childrens Hosp, Dept Pediat Diabetol & Endocrinol, Berlin, Germany; [Sumnik, Zdenek] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Cayssials, Amely] Hosp Italiano Buenos Aires, Dept Pediat, Buenos Aires, DF, Argentina; [Herr, Mathias] DRK Kliniken Berlin Westend, Klin Kinder & Jugendmed, Berlin, Germany; [Loew, Anja] Kinderklin Dritter Orden, Munich, Germany; [Lewis, Vaughan] Royal Devon & Exeter Fdn Trust, Dept Pediat, Exeter, Devon, England","Hattersley, AT (reprint author), Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter, Devon, England.","andrew.hattersley@pms.ac.uk","Hamilton-Shield, Julian/D-6297-2014",null,"Wellcome Trust [067463/Z/2/Z]; \"Instituto de Salud Carlos III\" [FIS CM06/00013]; Czech Ministry of Education [021620819]; Czech Ministry of Health [64203]","No potential conflicts of interest relevant to this article were reported. We thank Andrew Parrish for his technical assistance. We also thank Olga Kordonouri for tier clinical input and help with the writing of the manuscript.",null,26,24,26,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0149-5992",null,null,"DIABETES CARE","Diabetes Care","JAN",2009,32,1,null,null,null,null,111,116,null,"10.2337/dc08-1188",null,6,"Endocrinology & Metabolism","Endocrinology & Metabolism","390UA","WOS:000262188000023"]
[null,"Article; Proceedings Paper",2,null,"J","Goubau, C; Wilschanski, M; Skalicka, V; Lebecque, P; Southern, KW; Sermet, I; Munck, A; Derichs, N; Middleton, PG; Hjelte, L; Padoan, R; Vasar, M; De Boeck, K",null,null,null,"Goubau, C.; Wilschanski, M.; Skalicka, V.; Lebecque, P.; Southern, K. W.; Sermet, I.; Munck, A.; Derichs, N.; Middleton, P. G.; Hjelte, L.; Padoan, R.; Vasar, M.; De Boeck, K.",null,null,"Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis","THORAX",null,null,"English","Article; Proceedings Paper","8th International Congress on Pediatric Pulmonolgy","MAR 29-31, 2008","Nice, FRANCE",null,null,null,"NASAL POTENTIAL DIFFERENCE; TRANSMEMBRANE REGULATOR GENE; PULMONARY-FUNCTION; CLINICAL-TRIALS; MUTATIONS; DISEASE; CONSENSUS; EXACERBATIONS; GUIDELINES; MANAGEMENT","Background: In patients with symptoms suggestive of cystic fibrosis (CF) and intermediate sweat chloride values (30-60 mmol/l), extensive CFTR gene mutation analysis and nasal potential difference (NPD) measurement are used as additional diagnostic tests and a positive result in either test provides evidence of CFTR dysfunction. To define the phenotype of such patients and confirm the validity of grouping them, patients with intermediate sweat chloride values in whom either additional CF diagnostic test was abnormal were compared with subjects in whom this was not the case and patients with classic CF. Methods: The phenotypic features of four groups were compared: 59 patients with CFTR dysfunction, 46 with an intermediate sweat chloride concentration but no evidence of CFTR dysfunction (CF unlikely), 103 patients with CF and pancreatic sufficiency (CF-PS) and 62 with CF and pancreatic insufficiency (CF-PI). Results: The CFTR dysfunction group had more lower respiratory tract infections (p = 0.01), more isolation of CF pathogens (p<0.001) and clubbing (p = 0.001) than the CF unlikely group, but less frequent respiratory tract infections with CF pathogens than the CF-PS group (p = 0.05). Patients in the CF-PS group had a milder phenotype than those with PI. Many features showed stepwise changes through the patient groups. Conclusion: Patients with intermediate sweat chloride values and two CFTR mutations or an abnormal NPD measurement have a CF-like phenotype compatible with CFTR dysfunction and, as a group, differ phenotypically from patients with intermediate sweat chloride values in whom further CF diagnostic tests are normal as well as from CF-PS and CF-PI patients.","[Goubau, C.; De Boeck, K.] Univ Louvain, Dept Paediat, Louvain, Belgium; [Wilschanski, M.] Hadassah Med Org, Dept Paediat Gastroenterol, Jerusalem, Israel; [Skalicka, V.] Fac Hosp Motol, Dept Paediat, Prague, Czech Republic; [Lebecque, P.] Univ Catholique Louvain, Clin St Luc, B-1200 Brussels, Belgium; [Southern, K. W.] Royal Liverpool Childrens Hosp, Liverpool L7 7DG, Merseyside, England; [Sermet, I.] Hop Necker Enfants Malad, Paris, France; [Munck, A.] Hop Robert Debre, F-75019 Paris, France; [Derichs, N.] Hannover Med Sch, Dept Paediat, D-30623 Hannover, Germany; [Middleton, P. G.] Westmead Hosp, Ludwig Engel Ctr Resp Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia; [Middleton, P. G.] Univ Sydney, Westmead, NSW 2145, Australia; [Hjelte, L.] Karolinska Univ, Huddinge Hosp, Stockholm CF Ctr, Karolinska Inst, Stockholm, Sweden; [Padoan, R.] Osped Bambini Brescia, CF Ctr, Brescia, Italy; [Vasar, M.] Tartu Univ Clin, Childrens Clin, Tartu, Estonia","De Boeck, K (reprint author), Katholieke Univ Leuven Hosp, Dept Paediat, Herestr 49, B-3000 Louvain, Belgium.","christiane.deboeck@uzleuven.be",null,null,null,null,null,41,23,23,"B M J PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","0040-6376",null,null,"THORAX","Thorax","AUG",2009,64,8,null,null,null,null,683,691,null,"10.1136/thx.2008.104752",null,9,"Respiratory System","Respiratory System","476AB","WOS:000268408000011"]
[null,"Editorial Material",8,null,"J","Zaliova, M; Fronkova, E; Krejcikova, K; Muzikova, K; Mejstrikova, E; Stary, J; Trka, J; Zuna, J",null,null,null,"Zaliova, M.; Fronkova, E.; Krejcikova, K.; Muzikova, K.; Mejstrikova, E.; Stary, J.; Trka, J.; Zuna, J.",null,null,"Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukaemia; BCR/ABL; Ig/TCR; minimal residual disease; relapse","ACUTE LYMPHOBLASTIC-LEUKEMIA; TIME QUANTITATIVE PCR; POLYMERASE-CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA; EXTREMELY POOR-PROGNOSIS; PHILADELPHIA-CHROMOSOME; GENE REARRANGEMENTS; MOLECULAR RESPONSE; CONCERTED ACTION; MESSENGER-RNA","Minimal residual disease (MRD) monitoring is an essential tool for risk group stratification in current treatment protocols for childhood acute lymphoblastic leukaemia (ALL). Although quantitative detection of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements is currently considered to be the standard method, leukaemia fusion genes provide other possible targets for MRD follow-up, as already demonstrated in TEL/AML1-positive ALLs. We analysed and compared MRD levels quantified by BCR/ABL transcript detection and by the standard Ig/TCR-based method in 218 bone marrow specimens from 17 children with BCR/ABL-positive ALL. We found only a limited overall correlation of MRD levels as assessed by the two methods (correlation coefficient R(2) = 0.64). The correlation varied among patients from excellent (R(2) = 0.99) to very poor (R(2) = 0.17). Despite identical sensitivity of the approaches, 20% of the samples were negative by the Ig/TCR approach whereas positive by the BCR/ABL method. We show that multilineage involvement is at least partly responsible for the discrepancy. Moreover, our data demonstrate that BCR/ABL monitoring enables better and earlier prediction of relapse compared to the standard Ig/TCR methodology. We conclude that BCR/ABL-based MRD monitoring of childhood ALL is a clinically relevant tool and should be performed in parallel with the standard Ig/TCR follow-up. Leukemia (2009) 23, 944-951; doi:10.1038/leu.2008.386; published online 22 January 2009","[Zuna, J.] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CLIP, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Zuna, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CLIP, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.zuna@lfmotol.cuni.cz",null,null," [MSM0021620813];  [MZO00064203];  [NS10004]","This work was supported by grants MSM0021620813, MZO00064203 and NS10004. We acknowledge all participating centres within the Czech Paediatric Haematology Working Group (CPH) for clinical management and sample collection.",null,47,10,10,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","MAY",2009,23,5,null,null,null,null,944,951,null,"10.1038/leu.2008.386",null,8,"Oncology; Hematology","Oncology; Hematology","444UO","WOS:000266006100017"]
[null,"Letter",17,null,"J","Krsek, P; Pieper, T; Karlmeier, A; Hildebrandt, M; Kolodziejczyk, D; Winkler, P; Pauli, E; Blumcke, I; Holthausen, H",null,null,null,"Krsek, Pavel; Pieper, Tom; Karlmeier, Anja; Hildebrandt, Michelle; Kolodziejczyk, Dieter; Winkler, Peter; Pauli, Elisabeth; Bluemcke, Ingmar; Holthausen, Hans",null,null,"Different presurgical characteristics and seizure outcomes in children with focal cortical dysplasia type I or II","EPILEPSIA",null,null,"English","Article",null,null,null,null,null,"Epilepsy surgery; Cortical malformation; MRI; EEG; Neuropsychology; Seizure outcome","NEURONAL MIGRATION DISORDERS; PEDIATRIC EPILEPSY SURGERY; DUAL PATHOLOGY; INTRACTABLE EPILEPSY; CLINICAL CORRELATIONS; MALFORMATIONS; CLASSIFICATION; FEATURES; SUBTYPES; ABNORMALITIES","Cortical dysplasia (FCD) is a frequent cause of epilepsy in childhood. Two major pathological variants are distinguished, FCD type I and II. The aim of the study was to characterize differences between FCD type I and II with respect to imaging and EEG findings, clinical and neuropsychological presentations, and surgical outcome. Forty children with refractory epilepsy and histopathologically confirmed FCD were retrospectively analyzed. FCD type I was identified in 24 and FCD type II in 16 patients. Characteristic MRI abnormalities in FCD type I included subtle white matter signal changes and regional reduction of the white matter volume. Typical MRI findings in FCD type II were increased cortical thickness, transmantle sign, gray-white matter junction blurring, fluid-attenuated inversion recovery (FLAIR) and proton density (PD) gray matter signal changes as well as T1w, and PD white matter signal changes. Continuous EEG slowing was significantly more common in patients with FCD type I. Children with FCD type I presented with lower levels of intelligence and were suffering more often from maladaptive behavior and behavioral disorders. Surgical outcome was significantly worse in the FCD type I group (seizure freedom was achieved in 21% FCD type I patients and in 75% FCD type II subjects, p < 0.001). Clinically important differences were found in children with distinct histopathological subtypes of FCD. Due to prominent neuropsychological deficits and worse seizure outcome, treatment strategies in FCD type I are more challenging than previously reported and these children should be recognized and specifically addressed within the incoherent group of patients with malformative brain disorders.","[Krsek, Pavel] Charles Univ Prague, Sch Med 2, Dept Pediat Neurol, Motol Hosp, Prague 15006 5, Czech Republic; [Pieper, Tom; Karlmeier, Anja; Holthausen, Hans] Behandlungszentrum Vogtareuth, Neuropediat Clin, Epilepsy Ctr Children, Vogtareuth, Germany; [Pieper, Tom; Karlmeier, Anja; Holthausen, Hans] Behandlungszentrum Vogtareuth, Clin Neurorehabil, Vogtareuth, Germany; [Hildebrandt, Michelle; Bluemcke, Ingmar] Univ Hosp Erlangen, Ctr Epilepsy Surg, Dept Neuropathol & Neuropathol Reference, Erlangen, Germany; [Kolodziejczyk, Dieter] Behandlungszentrum Vogtareuth, Clin Neurosurg & Neuroradiol, Vogtareuth, Germany; [Winkler, Peter] Olga Hosp, Dept Radiol, Stuttgart, Germany; [Pauli, Elisabeth] Univ Hosp Erlangen, Dept Neurol, Epilepsy Ctr, Erlangen, Germany","Krsek, P (reprint author), Charles Univ Prague, Sch Med 2, Dept Pediat Neurol, Motol Univ Hosp, V Uvalu 84, Prague 15006 5, Czech Republic.","pavel.krsek@post.cz","shengkun, yu/B-8440-2012",null,"IGA [NR/8843-4]; FNM [00000064203]; German Research Council [DFG Bl 421/1-2]; European Community [LSHM-CT-2006-037315]; ELAN; FAU Erlangen-Nurernberg","Conflict of interest: We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. All authors report no conflict of interest.",null,58,46,50,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0013-9580",null,null,"EPILEPSIA","Epilepsia","JAN",2009,50,1,null,null,null,null,125,137,null,"10.1111/j.1528-1167.2008.01682.x",null,13,"Clinical Neurology","Neurosciences & Neurology","391HN","WOS:000262224500012"]
[null,"Proceedings Paper",1,null,"J","Joshi, S; Sedivy, V; Hodyc, D; Herget, J; Gurney, AM",null,null,null,"Joshi, Shreena; Sedivy, Vojtech; Hodyc, Daniel; Herget, Jan; Gurney, Alison M.",null,null,"KCNQ Modulators Reveal a Key Role for KCNQ Potassium Channels in Regulating the Tone of Rat Pulmonary Artery Smooth Muscle","JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS",null,null,"English","Article",null,null,null,null,null,null,"LINOPIRDINE DUP 996; INNER HAIR-CELLS; K+ CHANNELS; SENSORY NEURONS; K(V)7 CHANNELS; VASCULAR-TONE; CURRENTS; MYOCYTES; VASOCONSTRICTION; HYPERTENSION","Potassium channels are central to the regulation of pulmonary vascular tone. The smooth muscle cells of pulmonary artery display a background K(+) conductance with biophysical properties resembling those of KCNQ (K(V)7) potassium channels. Therefore, we investigated the expression and functional role of KCNQ channels in pulmonary artery. The effects of selective KCNQ channel modulators were investigated on K(+) current and membrane potential in isolated pulmonary artery smooth muscle cells (PASMCs), on the tension developed by intact pulmonary arteries, and on pulmonary arterial pressure in isolated perfused lungs and in vivo. The KCNQ channel blockers, linopirdine and XE991 [10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone], inhibited the noninactivating background K(+) conductance in PASMCs and caused depolarization, vasoconstriction, and raised pulmonary arterial pressure without constricting several systemic arteries or raising systemic pressure. The KCNQ channel openers, retigabine and flupirtine, had the opposite effects. PASMCs were found to express KCNQ4 mRNA, at higher levels than mesenteric artery, along with smaller amounts of KCNQ1 and 5. It is concluded that KCNQ channels, most probably KCNQ4, make an important contribution to the regulation of pulmonary vascular tone, with a greater contribution in pulmonary compared with systemic vessels. The pulmonary vasoconstrictor effect of KCNQ blockers is a potentially serious side effect, but the pulmonary vasodilator effect of the openers may be useful in the treatment of pulmonary hypertension.","[Gurney, Alison M.] Univ Manchester, Fac Life Sci, Core Technol Facil, Manchester M13 9NT, Lancs, England; [Sedivy, Vojtech; Hodyc, Daniel; Herget, Jan] Charles Univ Prague, Fac Med 2, Cardiovasc Res Ctr, Prague, Czech Republic; [Sedivy, Vojtech; Hodyc, Daniel; Herget, Jan] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Gurney, AM (reprint author), Univ Manchester, Fac Life Sci, Core Technol Facil, Floor 2,46 Grafton St, Manchester M13 9NT, Lancs, England.","alison.gurney@manchester.ac.uk","Herget, Jan/I-6313-2012",null,"Biotechnology and Biological Sciences Research Council [BBS/B/11761/2]; Tenovus Scotland; Leonardo da Vinci Programme; Grant Agency of Charles University [2419/2007]; Centre for Cardiovascular Research [MSMT 1M 0510]; Czech Science Foundation [305/08/0108]","This work was supported by the Biotechnology and Biological Sciences Research Council [Grant BBS/B/11761/2]; Tenovus Scotland; Leonardo da Vinci Programme; the Grant Agency of Charles University [Grant 2419/2007]; the Centre for Cardiovascular Research [Grant MSMT 1M 0510]; and the Czech Science Foundation [Grant 305/08/0108].",null,42,34,36,"AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA","0022-3565",null,null,"J PHARMACOL EXP THER","J. Pharmacol. Exp. Ther.","APR",2009,329,1,null,null,null,null,368,376,null,"10.1124/jpet.108.147785",null,9,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","426KW","WOS:000264708200041"]
[null,"Review",21,null,"J","van der Stoep, N; van Paridon, CDM; Janssens, T; Krenkova, P; Stambergova, A; Macek, M; Matthijs, G; Bakker, E",null,null,null,"van der Stoep, Nienke; van Paridon, Chantal D. M.; Janssens, Tom; Krenkova, Petra; Stambergova, Alexandra; Macek, Milan; Matthijs, Gert; Bakker, Egbert",null,null,"Diagnostic Guidelines for High-Resolution Melting Curve (HRM) Analysis: An Interlaboratory Validation of BRCA1 Mutation Scanning Using the 96-Well LightScanner (TM)","HUMAN MUTATION",null,null,"English","Article",null,null,null,null,null,"high-resolution melting curve analysis; HRM; BRCA1; diagnostic validation","GRADIENT GEL-ELECTROPHORESIS; EARLY-ONSET BREAST; SENSITIVE DETECTION; OVARIAN-CANCER; VARIANTS; FAMILIES; CARRIERS; DHPLC; GENE","Genetic analysis of BRCA1 by sequencing is often preceded by a scanning method like denaturing gradient gel electrophoresis (DGGE), protein truncation test (PTT) or DHPLC. High-resolution melting curve (HRM) analysis is a promising and economical method for high-throughput Mutation scanning. The EuroGentest network (www.eurogentest.org) aims to assist with the introduction of novel technologies in the diagnostic setting. Therefore, we have performed a thorough and high, standard interlaboratory evaluation and validation of HRM, in collaboration with Idaho Technology, the manufacturer of the LightScanner (TM) (LS). Through this detailed study of 170 variants, we have generated guidelines for easy setup and implementation of HRM as a scanning technique for new genes, which are adaptable to the quality system of an individual diagnostic laboratory. This validation study includes the description of a BRCA1-specific mutation screening test using the 96-well LS. This assay comprises 40 amplicons and was evaluated using a statistically significant elaborate panel of variants and control DNA samples. All heterozygous variants were detected. Moreover, genotype analysis for nine common polymorphisms created a fast screening and detection method for these frequently occurring nonpathogenic variants. A blind study using a total of 28 patient-derived DNA samples resulted also in 100% detection and showed an average specificity of 98%, indicating a low incidence of false positives (FPs). Hum Mutat 30, 899-909, 2009. (C) 2009 Wiley-Liss, Inc.","[van der Stoep, Nienke; van Paridon, Chantal D. M.; Bakker, Egbert] Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands; [Krenkova, Petra; Stambergova, Alexandra; Macek, Milan] Charles Univ Prague, Inst Biol & Med Genet, Prague, Czech Republic; [Janssens, Tom; Matthijs, Gert] Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium","van der Stoep, N (reprint author), Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands.","nvdstoep@lumc.nl","Bakker, Egbert/D-3525-2009",null,"EU [FP6-512148]; VZFNM [00064203/6112]","This study was funded through EuroGentest Network of Excellence Project 2005-EU Contract no. FP6-512148 (http:/www.eurogentest.org/). P.K. and P.N. were supported by VZFNM 00064203/6112/. We thank the research team from Idaho Technology (Salt Lake City, Utah, USA), in particular Dr. Deepika del Silva, and BIOKE (Leiden, Netherlands), for their Outstanding help, technical improvements, and advice during the entire evaluation project.",null,22,57,57,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1059-7794",null,null,"HUM MUTAT","Hum. Mutat.","JUN",2009,30,6,null,null,null,null,899,909,null,"10.1002/humu.21004",null,11,"Genetics & Heredity","Genetics & Heredity","466BJ","WOS:000267635100007"]
[null,"Review; Book Chapter",1,null,"J","Funa, NS; Kriz, V; Zang, G; Calounova, G; Akerblom, B; Mares, J; Larsson, E; Sun, Y; Betsholtz, C; Welsh, M",null,null,null,"Funa, Nina S.; Kriz, Vitezslav; Zang, Guangxiang; Calounova, Gabriela; Akerblom, Bjoern; Mares, Jaroslav; Larsson, Erik; Sun, Ying; Betsholtz, Christer; Welsh, Michael",null,null,"Dysfunctional Microvasculature as a Consequence of Shb Gene Inactivation Causes Impaired Tumor Growth","CANCER RESEARCH",null,null,"English","Article",null,null,null,null,null,null,"ENDOTHELIAL-CELL APOPTOSIS; BLOOD-VESSEL FORMATION; FOCAL ADHESION KINASE; NEURAL STEM-CELLS; ADAPTER PROTEIN; VASCULAR-PERMEABILITY; VE-CADHERIN; RHO-KINASE; ANGIOGENESIS; DIFFERENTIATION","Shb (Src homology 2 protein B) is an adapter protein downstream of the vascular endothelial growth factor receptor receptor-2 (VEGFR-2). Previous experiments have suggested a role for Shb in endothelial cell function. Recently, the Shb gene was inactivated and Shb null mice were obtained on a mixed genetic background, but not on C57B16 mice. The present study was performed to address endothelial function in the Shb knockout mouse and its relevance for tumor angiogenesis. Tumor growth was retarded in Shb mutant mice, and this correlated with decreased angiogenesis both in tumors and in Matrigel plugs. Shb null mice display an abnormal endothelial ultrastructure in liver sinusoids and heart capillaries with cytoplasmic extensions projecting toward the lumen. Shb null heart VE-cadherin staining was less distinct than that of control heart, exhibiting in the former case a wavy and punctuate pattern. Experiments on isolated endothelial cells suggest that these changes could partly reflect cytoskeletal abnormalities. Vascular permeability was increased in Shb null mice in heart, kidney, and skin, whereas VEGF-stimulated vascular permeability was reduced in Shb null mice. It is concluded that Shb plays an important role in maintaining a functional vasculature in adult mice, and that interference with Shb signaling may provide novel means to regulate tumor angiogenesis. [Cancer Res 2009;69(5):2141-8]","[Funa, Nina S.; Zang, Guangxiang; Calounova, Gabriela; Akerblom, Bjoern; Welsh, Michael] Uppsala Univ, Dept Med Cell Biol, S-75123 Uppsala, Sweden; [Larsson, Erik] Uppsala Univ, Dept Genet & Pathol, S-75123 Uppsala, Sweden; [Kriz, Vitezslav] Masaryk Univ, Dept Biol, Brno, Czech Republic; [Zang, Guangxiang] Jilin Univ, Sch Stomatol, Dept Pathol, Changchun, Peoples R China; [Calounova, Gabriela; Mares, Jaroslav] Charles Univ Prague, Dept Med Genet, Prague, Czech Republic; [Sun, Ying; Betsholtz, Christer] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden","Welsh, M (reprint author), Uppsala Univ, Dept Med Cell Biol, Box 571,Husargatan 3, S-75123 Uppsala, Sweden.","Michael.welsh@mcb.uu.se",null,null,"Juvenile Diabetes Research Foundation International; Swedish Cancer Foundation; Swedish Research Council; Swedish Diabetes Association; Wallenberg Foundation; Family Ernfors Fund","We thank Drs. Laura Benjamin, Sara Weis David Millstone, Orian Kallskog, and Lena Claesson-Welsh for helpful advice. The technical assistance by Anders Ahlander, Barbro Einarsson, Irja Johansson, Britta Isaksson, Ing-Marie Morsare, and Eva Tornelius is gratefully acknowledged.",null,49,11,11,"AMER ASSOC CANCER RESEARCH","PHILADELPHIA","615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA","0008-5472",null,null,"CANCER RES","Cancer Res.","MAR 1",2009,69,5,null,null,null,null,2141,2148,null,"10.1158/0008-5472.CAN-08-3797",null,8,"Oncology","Oncology","415ML","WOS:000263937800058"]
["2013 Celkem",null,285,null,"J","Marre, M; Shaw, J; Brandle, M; Bebakar, WMW; Kamaruddin, NA; Strand, J; Zdravkovic, M; Le Thi, TD; Colagiuri, S",null,null,null,"Marre, M.; Shaw, J.; Braendle, M.; Bebakar, W. M. W.; Kamaruddin, N. A.; Strand, J.; Zdravkovic, M.; Le Thi, T. D.; Colagiuri, S.",null,"LEAD-1 Su Study Grp","Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","DIABETIC MEDICINE",null,null,"English","Article",null,null,null,null,null,"dipeptidyl peptidase-4; glucagon-like peptide-1 receptor agonist; incretin; insulinotropic; thiazolidinedione","GLUCAGON-LIKE PEPTIDE-1; BETA-CELL FUNCTION; METFORMIN; MELLITUS; SAFETY; HYPERGLYCEMIA; GLIMEPIRIDE; REDUCTION; EXENDIN-4; EFFICACY","To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes. In total, 1041 adults (mean +/- sd), age 56 +/- 10 years, weight 82 +/- 17 kg and glycated haemoglobin (HbA(1c)) 8.4 +/- 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study. Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA(1c) from baseline, (-1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (-0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride. Liraglutide 0.6 mg was less effective (-0.6%, baseline 8.4%). Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l). Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [-2.5 to -2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (-0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (-1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l). Changes in body weight with liraglutide 1.8 mg (-0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (-0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg). Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%). Liraglutide added to glimepiride was well tolerated and provided improved glycaemic control and favourable weight profile. Diabet. Med. 26, 268-278 (2009).","[Marre, M.] Grp Hosp Bichat Claude Bernard, Serv Endocrinol Diabetol Nutr, F-75722 Paris 18, France; [Shaw, J.] Int Diabet Inst, Melbourne, Vic, Australia; [Braendle, M.] Kantonsspital St Gallen, Div Endocrinol Diabet & Osteol, St Gallen, Switzerland; [Bebakar, W. M. W.] Hosp Univ Sains, Dept Med, Kelantan, Malaysia; [Kamaruddin, N. A.] Univ Kebangsaan Malaysia, Dept Med, Kuala Lumpur, Malaysia; [Strand, J.] Oulun Diakonissalaitos, Oulu, Finland; [Zdravkovic, M.; Le Thi, T. D.] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; [Colagiuri, S.] Univ Sydney, Inst Obes Nutr & Exercise, Sydney, NSW 2006, Australia","Marre, M (reprint author), Grp Hosp Bichat Claude Bernard, Serv Endocrinol Diabetol Nutr, 46 Rue Henri Huchard, F-75722 Paris 18, France.","michel.marre@bch.ap-hop-paris.fr","Shaw, Jonathan/E-7388-2010","Shaw, Jonathan/0000-0002-6187-2203",null,null,"Agerso H, 2002, DIABETOLOGIA, V45, P195, DOI 10.1007/s00125-001-0719-z; American Association of Clinical Endocrinologists, 2007, ENDOCR PRACT S1, V13, P1; American Diabetes Association, 2008, DIABETES CARE S1, V31, pS12, DOI DOI 10.2337/DC08-S012; BLONDE L, 2008, CAN J DIABETES, V32; Buse JB, 2004, DIABETES CARE, V27, P2628, DOI 10.2337/diacare.27.11.2628; Degn KB, 2004, DIABETES, V53, P1187, DOI 10.2337/diabetes.53.5.1187; Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5; Egan JM, 2003, AM J PHYSIOL-ENDOC M, V284, pE1072, DOI 10.1152/ajpendo.00315.2002; Garber A, 2009, LANCET, V373, P473, DOI 10.1016/S0140-6736(08)61246-5; Green J, 2007, INT J CLIN PRACT, V61, P3, DOI 10.1111/j.1742-1241.2007.01438.x; Hermansen K, 2007, DIABETES OBES METAB, V9, P733, DOI 10.1111/j.1463-1326.2007.00744.x; Holst JJ, 2007, PHYSIOL REV, V87, P1409, DOI 10.1152/physrev.00034.2006; International Diabetes Federation, 2005, GLOB GUID TYP 2 DIAB; Knudsen LB, 2000, J MED CHEM, V43, P1664, DOI 10.1021/jm9909645; Mari A, 2007, DIABETES CARE, V30, P2032, DOI 10.2337/dc07-0310; Nathan DM, 2006, DIABETES CARE, V29, P1963, DOI 10.2337/dc06-9912; Nauck M, 2009, DIABETES CARE, V32, P84, DOI 10.2337/dc08-1355; Russell-Jones D, 2008, DIABETOLOGIA, V51, pS68; RUSSELLJONES D, 2008, DIABETES, V57, pP536; Vilsboll T, 2007, DIABETES CARE, V30, P1608, DOI 10.2337/dc06-2593; Vilsboll T, 2008, DIABETIC MED, V25, P152, DOI 10.1111/j.1464-5491.2007.02333.x; Zinman B, 2008, DIABETOLOGIA, V51, pS359",22,295,325,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0742-3071",null,null,"DIABETIC MED","Diabetic Med.","MAR",2009,26,3,null,null,null,null,268,278,null,"10.1111/j.1464-5491.2009.02666.x",null,11,"Endocrinology & Metabolism","Endocrinology & Metabolism","418QQ","WOS:000264163800011"]
["(prázdné)","(prázdné)",null,null,"J","Botev, R; Mallie, JP; Couchoud, C; Schuck, O; Fauvel, JP; Wetzels, JFM; Lee, N; De Santo, NG; Cirillo, M",null,null,null,"Botev, Rossini; Mallie, Jean-Pierre; Couchoud, Cecile; Schueck, Otto; Fauvel, Jean-Pierre; Wetzels, Jack F. M.; Lee, Nelson; De Santo, Natale G.; Cirillo, Massimo",null,null,"Estimating Glomerular Filtration Rate: Cockcroft-Gault and Modification of Diet in Renal Disease Formulas Compared to Renal Inulin Clearance","CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,null,"SERUM CREATININE ASSAY; CYSTATIN-C; PREDICTION EQUATION; SURFACE-AREA; TRANSPLANTATION; GFR; MARKER; MDRD; IOTHALAMATE; CALIBRATION","Background and objectives: Evaluation of renal function by estimation of the glomerular filtration rate (GFR) is very important for the diagnosis and treatment of patients with chronic kidney disease (CKD). The Cockcroft-Gault (CG) and Modification of Diet in Renal Disease (MDRD) formulas are the most commonly used estimations. Design, setting, participants, & measurements: Estimated GFR values by each formula were compared with measured GFR (mGFR) by renal inulin clearance in 2208 European adults (46% women, 1.4% Caribbean blacks), with and without CKD, and mean mGFR 72.4 +/- 39.0 (range 2.2 to 177.2) ml/min/1.73 m(2). Results: Overall, the CG and MDRD formulas showed bias (mean difference) -3.5 ml/min/1.73 m(2) (5.3%), P < 0.001, and -9.8 ml/min/1.73 m(2) (-6.4%), P < 0.001; precision (SD of bias) 21.5 ml/min/1.73 m(2) (43.1%) and 20.0 ml/min/1.73 m(2) (33.0%); limits of agreement (2 SD by Bland-Altman method) 39.5 to -46.5 (range 86.0) ml/min/1.73 m(2) and 30.2 to -49.8 (range 80.0) ml/min/1.73 m(2); and accuracy within +/- 30% of mGFR 70.8 and 69.0%, respectively. Both formulas showed a trend for decreasing accuracy with lower mGFR levels. According to the Kidney Disease Outcomes Quality Initiative (K/DOQI)-CKD classification's five GFR groups, the CG and MDRD formulas properly assigned 61.6 and 57.1%, of the entire population and had a range of positive predictive values 42.6 to 81.8% and 39.6 to 85.2% and of negative predictive values 81.7 to 96.6% and 76.4 to 97.5%, respectively. Conclusions: The CG and MDRD formulas had some limitations for proper GFR estimation and K/DOQI-CKD classification by GFR levels alone. Clin J Am Soc Nephrol 4: 899-906, 2009. doi: 10.2215/CJN.05371008","[Botev, Rossini] Hawaii Permanente Med Grp, Dept Nephrol, Honolulu, HI 96819 USA; [Mallie, Jean-Pierre] Nancy Univ, Fac Med, Nancy, France; [Couchoud, Cecile] Agence Biomed, Coordinat French ESRD Registry REIN, La Plaine St Denis, France; [Schueck, Otto] Charles Univ Prague, Internal Clin, Fac Med 2, Prague, Czech Republic; [Fauvel, Jean-Pierre] Hop Edouard Herriot, Dept Nephrol, Lyon, France; [Wetzels, Jack F. M.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Lee, Nelson] Genentech Inc, Dept Clin Data Management, San Francisco, CA USA; [De Santo, Natale G.; Cirillo, Massimo] Univ Naples 2, Nephrol Unit, Naples, Italy","Botev, R (reprint author), Hawaii Permanente Med Grp, Dept Nephrol, 3288 Moanalua Rd, Honolulu, HI 96819 USA.","rossini.c.botek@kp.org","Wetzels, Jack/A-1720-2014",null,null,null,null,38,53,55,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1555-9041",null,null,"CLIN J AM SOC NEPHRO","Clin. J. Am. Soc. Nephrol.","MAY",2009,4,5,null,null,null,null,899,906,null,"10.2215/CJN.05371008",null,8,"Urology & Nephrology","Urology & Nephrology","441CC","WOS:000265745900005"]
["(prázdné) Celkem",null,null,null,"J","Cmejla, R; Cmejlova, J; Handrkova, H; Petrak, J; Petrtylova, K; Mihal, V; Stary, J; Cerna, Z; Jabali, Y; Pospisilova, D",null,null,null,"Cmejla, Radek; Cmejlova, Jana; Handrkova, Helena; Petrak, Jiri; Petrtylova, Kvetoslava; Mihal, Vladimir; Stary, Jan; Cerna, Zdena; Jabali, Yahia; Pospisilova, Dagmar",null,null,"Identification of Mutations in the Ribosomal Protein L5 (RPL5) and Ribosomal Protein L11 (RPL11) Genes in Czech Patients With Diamond-Blackfan Anemia","HUMAN MUTATION",null,null,"English","Article",null,null,null,null,null,"ribosomal protein L5; RPL5; ribosomal protein L11; RPL11; ribosomal protein L23; RPL23; Diamond-Blackfan anemia; DBA","ADENOSINE-DEAMINASE ACTIVITY; INHIBITION; P53; RNA; UBIQUITINATION; ACTIVATION; SUBUNITS; PATHWAY; MDM2; S19","Diamond-Blackfan anemia (DBA) is a congenital red blood cell aplasia that is usually diagnosed during early infancy. Apart from defects in red blood cell maturation, the disorder is also associated with various physical anomalies in 40% of patients. Mutations in the ribosomal protein (RP) S19 are found in 25% of patients, while mutations in other proteins of the small ribosomal subunit-RPS17 and RPS24-have been found in a fraction of patients. Recently, mutations in RPL5, RPL11, and RPL35a of the large ribosomal subunit have also been reported in several DBA patients. Here, we present the identification of mutations in the RPL5 and RPL11 genes in patients from the Czech DBA Registry. Mutations in RPL5 were identified in eight patients from 6 out of 28 families (21.4%), and mutations in RPL11 in two patients from 2 out of 28 families (7.1%). Interestingly, all 10 patients with either an RPL5 or RPL11 mutation exhibited one or more physical anomalies; specifically, thumb anomalies (flat thenar) were always present, while no such anomaly was observed in seven patients with an RPS19 mutation. Moreover, 9 out of 10 patients with either an RPL5 or RPL11 mutation were born small for gestational age (SGA) compared to 3 out of 7 patients froth the RPS19-mutated group. These observations may suggest that mutations, at least in RPL5, seem to generally have more profound impact on fetal development than mutations in RPS19. Since RPL5 and RPL11, together with RPL23, are also involved in the MDM2-mediated p53 pathway regulation, we also screened the RPL23 gene for mutations; however, no mutations were identified. Hum Mutat 30, 321-327, 2009. (C) 2009 Wiley-Liss, Inc.","[Cmejla, Radek; Cmejlova, Jana; Handrkova, Helena; Petrak, Jiri] Inst Hematol & Blood Transfus, Dept Cell Physiol, CR-12820 Prague, Czech Republic; [Petrtylova, Kvetoslava] Univ Hosp Motol, Dept Hematol, Prague, Czech Republic; [Mihal, Vladimir] Palacky Univ, Dept Pediat, CR-77147 Olomouc, Czech Republic; [Stary, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague, Czech Republic; [Cerna, Zdena] Charles Univ Hosp, Dept Pediat, Plzen, Czech Republic; [Jabali, Yahia] Reg Hosp Ceske Budejovice, Dept Pediat, Ceske Budejovice, Czech Republic; [Petrak, Jiri] Charles Univ Prague, Dept Pathol Physiol, Fac Med 1, Prague, Czech Republic","Cmejla, R (reprint author), Inst Hematol & Blood Transfus, Dept Cell Physiol, U Nemocnice 1, CR-12820 Prague, Czech Republic.","racm@centrum.cz; pospisid@fnol.cz",null,null,"Ministry of Health [00023736]; Grant Agency of Charles University [25792892807]; Ministry of Education, Czech Republic [MSMT LC06044, MSM 6198959205]","We thank Dr. David Hardekopf for reading the manuscript. This work was supported by the Ministry of Health (00023736 to R.C.); the Grant Agency of Charles University (25792892807 to H.H.); and the Ministry of Education, Czech Republic (MSMT LC06044 to R.C. and J.P.; MSM 6198959205 D.P.).",null,25,38,41,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1059-7794",null,null,"HUM MUTAT","Hum. Mutat.","MAR",2009,30,3,null,null,null,null,321,327,null,"10.1002/humu.20874",null,7,"Genetics & Heredity","Genetics & Heredity","416NB","WOS:000264011700007"]
["Celkový součet",null,1544,null,"J","Azad, AK; Rauh, R; Vermeulen, F; Jaspers, M; Korbmacher, J; Boissier, B; Bassinet, L; Fichou, Y; des Georges, M; Stanke, F; De Boeck, K; Dupont, L; Balascakova, M; Hjelte, L; Lebecque, P; Radojkovic, D; Castellani, C; Schwartz, M; Stuhrmann, M; Schwarz, M; Skalicka, V; de Monestrol, I; Girodon, E; Ferec, C; Claustres, M; Tummler, B; Cassiman, JJ; Korbmacher, C; Cuppens, H",null,null,null,"Azad, Abul Kalam; Rauh, Robert; Vermeulen, Francois; Jaspers, Martine; Korbmacher, Judit; Boissier, Brigitte; Bassinet, Laurence; Fichou, Yann; des Georges, Marie; Stanke, Frauke; De Boeck, Kris; Dupont, Lieven; Balascakova, Miroslava; Hjelte, Lena; Lebecque, Patrick; Radojkovic, Dragica; Castellani, Carlo; Schwartz, Marianne; Stuhrmann, Manfred; Schwarz, Martin; Skalicka, Veronika; de Monestrol, Isabelle; Girodon, Emmanuelle; Ferec, Claude; Claustres, Mireille; Tuemmler, Burkhard; Cassiman, Jean-Jacques; Korbmacher, Christoph; Cuppens, Harry",null,null,"Mutations in the Amiloride-Sensitive Epithelial Sodium Channel in Patients With Cystic Fibrosis-Like Disease","HUMAN MUTATION",null,null,"English","Article",null,null,null,null,null,"CF; CFTR; ENaC; SCNN1A","TRANSMEMBRANE CONDUCTANCE REGULATOR; BETA-SUBUNIT; PSEUDOHYPOALDOSTERONISM TYPE-1; CONGENITAL ABSENCE; LIDDLES SYNDROME; CFTR MUTATIONS; ALPHA-SUBUNIT; LUNG-DISEASE; VAS-DEFERENS; NA+ CHANNEL","We investigated whether mutations in the genes that code for the different subunits of the amiloride-sensitive epithelial sodium channel (ENaC) might result in cystic fibrosis (CF)-like disease. In a small fraction of the patients, the disease could be potentially explained by an ENaC mutation by a Mendelian mechanism, such as p.V114I and p.F61L in SCNN1A. More importantly, a more than three-fold significant increase in incidence of several rare ENaC polymorphisms was found in the patient group (30% vs. 9% in controls), indicating an involvement of ENaC in some patients by a polygenetic mechanism. Specifically, a significantly higher number of patients carried c.-55+5G > C or p.W493R in SCNN1A in the heterozygous state, with odds ratios (ORs) of 13.5 and 2.7, respectively. The p.W493R-SCNN1A polymorphism was even found to result in a four-fold more active ENaC channel when heterologously expressed in Xenopus laevis oocytes. About I in 975 individuals in the general population will be heterozygous for the hyperactive p.W493R-SCNN1A mutation and a cystic fibrosis transmembrane conductance regulator (CFTR) gene that results in very low amounts (0-10%) functional CFTR. These ENaC/CFTR genotypes may play a hitherto unrecognized role in lung diseases. Hum Mutat 30:1093-1103, 2009. (C) 2009 Wiley-Liss, Inc.","[Azad, Abul Kalam; Jaspers, Martine; Radojkovic, Dragica; Cassiman, Jean-Jacques; Cuppens, Harry] Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; [Rauh, Robert; Korbmacher, Judit; Korbmacher, Christoph] Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol, Erlangen, Germany; [Vermeulen, Francois; De Boeck, Kris] Univ Hosp Gasthuisberg, Dept Pediat, Louvain, Belgium; [Boissier, Brigitte; Bassinet, Laurence; Girodon, Emmanuelle] Hop Henri Mondor, Serv Biochim & Genet, F-94010 Creteil, France; [Fichou, Yann; Ferec, Claude] CHU Brest, Lab Genet Mol & Histocompatibil, F-29285 Brest, France; [des Georges, Marie; Claustres, Mireille] IURC, CHU Montpellier, Genet Mol Lab, Montpellier, France; [Stanke, Frauke; Tuemmler, Burkhard] Hannover Med Sch, Klin Forschergrp, D-30623 Hannover, Germany; [Dupont, Lieven] Univ Hosp Gasthuisberg, Dept Pulmonol, Louvain, Belgium; [Balascakova, Miroslava; Skalicka, Veronika] Charles Univ Prague, Sch Med, Inst Biol & Med Genet, Pneumol Clin, Prague, Czech Republic; [Balascakova, Miroslava; Skalicka, Veronika] Charles Univ Prague, Sch Med, Pediat Clin, Prague, Czech Republic; [Balascakova, Miroslava; Skalicka, Veronika] Univ Hosp Motol, Prague, Czech Republic; [Hjelte, Lena; de Monestrol, Isabelle] Karolinska Univ Hosp, Stockholm Cyst Fibrosis CF Ctr, Huddinge, Sweden; [Lebecque, Patrick] Univ Catholique Louvain, Clin St Luc, Pediat Pulmonol & Cyst Fibrosis Unit, B-1200 Brussels, Belgium; [Castellani, Carlo] Azienda Osped Verona, Cyst Fibrosis Ctr, Verona, Italy; [Schwarz, Martin] Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark; [Stuhrmann, Manfred] Hannover Med Sch, Inst Humangenet, D-30623 Hannover, Germany; [Schwarz, Martin] Royal Manchester Childrens Hosp, Mol Genet Lab, Manchester M27 1HA, Lancs, England","Cuppens, H (reprint author), Katholieke Univ Leuven, Ctr Human Genet, Gasthuisberg O&N1 602,Herestr 49, B-3000 Louvain, Belgium.","harry.cuppens@med.kuleuven.be","de Monestrol, Isabelle/C-6238-2013; LABO, U827/A-8632-2008; Rauh, Robert/F-4129-2014","Rauh, Robert/0000-0002-9406-3939","Alphonse and Jean Forton Fund-Koning Boudewijn Stichting [2005 04 R7 115 130]; Het Fonds voor Wetenschappelijk Onderzoek Vlaanderen [G.0521.06, 1.5.111.07]; Interuniversity Attraction Poles [IAP P6/05]; EU [QLG1-CT-2001-01005-CFPRONET]; Vaincre La Mucoviscidose [RC0532]; Deutsche Forschungsgemeinschaft [SFB 423, TP A12]; Katholieke Universiteit Leuven, Belgium [1110];  [VZFNM 00064203];  [NR/9488-3]","These investigations were realized by grants from the Alphonse and Jean Forton Fund-Koning Boudewijn Stichting (2005 04 R7 115 130); Het Fonds voor Wetenschappelijk Onderzoek Vlaanderen (G.0521.06 and 1.5.111.07), the Interuniversity Attraction Poles (IAP P6/05); the EU grant (QLG1-CT-2001-01005-CFPRONET), the Vaincre La Mucoviscidose (RC0532), and the Deutsche Forschungsgemeinschaft (SFB 423, TP A12). A.K.A. is a recipient of a doctoral fellowship award from the Interfaculty Council for Development Cooperation (1110) of the Katholieke Universiteit Leuven, Belgium. J.J.C. holds the Arthur Bax and Anna Vanluffelen Chair of Human Genetics, KU Leuven, Belgium. We thank Steffen Fieuws for his advice in statistical analysis and Dieter Gruenert for providing the 16HBE14o- cell line. We also acknowledge Milan Macek, Jr., Vera Vavrova, Libor Fila, and Daniela Zemkova for their assistance in clinical data collection and support. They were supported by grants VZFNM 00064203 and NR/9488-3.",null,37,31,37,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1059-7794",null,null,"HUM MUTAT","Hum. Mutat.","JUL",2009,30,7,null,null,null,null,1093,1103,null,"10.1002/humu.21011",null,11,"Genetics & Heredity","Genetics & Heredity","468CQ","WOS:000267791700009"]
[null,null,null,null,"J","Janousek, J; Gebauer, RA; Abdul-Khaliq, H; Turner, M; Kornyei, L; Grollmuss, O; Rosenthal, E; Villain, E; Fruh, A; Paul, T; Blom, NA; Happonen, JM; Bauersfeld, U; Jacobsen, JR; van den Heuvel, F; Delhaas, T; Papagiannis, J; Trigo, C",null,null,null,"Janousek, J.; Gebauer, R. A.; Abdul-Khaliq, H.; Turner, M.; Kornyei, L.; Grollmuss, O.; Rosenthal, E.; Villain, E.; Frueh, A.; Paul, T.; Blom, N. A.; Happonen, J-M; Bauersfeld, U.; Jacobsen, J. R.; van den Heuvel, F.; Delhaas, T.; Papagiannis, J.; Trigo, C.",null,"Assoc European Paediat Cardiology","Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates","HEART",null,null,"English","Article",null,null,null,null,null,null,"RESYNCHRONIZATION THERAPY; DILATED CARDIOMYOPATHY; VENTRICULAR DYSFUNCTION; ATRIOVENTRICULAR-BLOCK; YOUNG-PATIENTS; FAILURE; ATRIAL; TRANSPOSITION; REGURGITATION; PACEMAKER","Background: Cardiac resynchronisation therapy (CRT) is increasingly used in children in a variety of anatomical and pathophysiological conditions, but published data are scarce. Objective: To record current practice and results of CRT in paediatric and congenital heart disease. Design: Retrospective multicentre European survey. Setting: Paediatric cardiology and cardiac surgery centres. Patients: One hundred and nine patients aged 0.24-73.8 (median 16.9) years with structural congenital heart disease (n=87), congenital atrioventricular block (n=12) and dilated cardiomyopathy (n=10) with systemic left (n=69), right (n=36) or single (n=4) ventricular dysfunction and ventricular dyssynchrony during sinus rhythm (n=25) or associated with pacing (n=84). Interventions: CRT for a median period of 7.5 months (concurrent cardiac surgery in 16/109). Main outcome measures: Functional improvement and echocardiographic change in systemic ventricular function. Results: The z score of the systemic ventricular end-diastolic dimension decreased by median 1.1 (p < 0.001). Ejection fraction (EF) or fractional area of change increased by a mean (SD) of 11.5 (14.3)% (p < 0.001) and New York Heart Association (NYHA) class improved by median 1.0 grade (p < 0.001). Non-response to CRT (18.5%) was multivariably predicted by the presence of primary dilated cardiomyopathy (p=0.002) and poor NYHA class (p=0.003). Presence of a systemic left ventricle was the strongest multivariable predictor of improvement in EF/fractional area of change (p < 0.001). Results were independent of the number of patients treated in each contributing centre. Conclusion: Heart failure associated with ventricular pacing is the largest indication for CRT in paediatric and congenital heart disease. CRT efficacy varies widely with the underlying anatomical and pathophysiological substrate.","[Janousek, J.; Grollmuss, O.] Univ Leipzig, Dept Paediat Cardiol, Ctr Heart, D-04289 Leipzig, Germany; [Gebauer, R. A.] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Gebauer, R. A.] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Abdul-Khaliq, H.] German Heart Ctr Berlin, Berlin, Germany; [Turner, M.] Bristol Royal Infirm & Gen Hosp, Bristol, Avon, England; [Turner, M.] Univ Bristol, Bristol, Avon, England; [Kornyei, L.] Hungarian Paediat Heart Ctr, Budapest, Hungary; [Rosenthal, E.] Guys & St Thomas Trust, Evelina Childrens Hosp, London, England; [Villain, E.] Hop Necker Enfants Malad, Dept Pediat Cardiol, Paris, France; [Frueh, A.] Univ Oslo, Rikshosp, Univ Hosp, Paediat Care Unit, N-0027 Oslo, Norway; [Paul, T.] Univ Hosp, Dept Paediat Cardiol & Intens Care, Gottingen, Germany; [Blom, N. A.] Leiden Univ, Dept Paediat Cardiol, Med Ctr, Leiden, Netherlands; [Happonen, J-M] Univ Helsinki, Cent Hosp, Dept Paediat, Div Paediat Cardiol, Helsinki, Finland; [Bauersfeld, U.] Univ Childrens Hosp Zurich, Div Paediat Cardiol, Zurich, Switzerland; [Jacobsen, J. R.] Rigshosp, Dept Paediat, DK-2100 Copenhagen, Denmark; [van den Heuvel, F.] Univ Groningen, Univ Med Ctr Groningen, Div Paediat Cardiol, Beatrix Childrens Hosp, Groningen, Netherlands; [Delhaas, T.] AZ Maastricht, Div Paediat Cardiol, Maastricht, Netherlands; [Papagiannis, J.] Onassis Cardiac Surg Ctr, Dept Paediat Cardiol, Athens, Greece; [Trigo, C.] Hosp Santa Maria, Serv Cardiol Pediat, Lisbon, Portugal","Janousek, J (reprint author), Univ Leipzig, Dept Paediat Cardiol, Ctr Heart, Strumpellstr 39, D-04289 Leipzig, Germany.","jan.janousek@medizin.uni-leipzig.de","Rosenthal, Eric/I-7469-2012","Rosenthal, Eric/0000-0003-3030-9749","Ministry of Health, Czech Republic [NR/9472- 3]; University Hospital Motol, Prague, Czech Republic [64203]","Ministry of Health, Czech Republic (grant NR/9472- 3 to RAG) and University Hospital Motol, Prague, Czech Republic (research project No 64203 to RAG).",null,23,38,38,"B M J PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","1355-6037",null,null,"HEART","Heart","JUL 15",2009,95,14,null,null,null,null,1165,1171,null,"10.1136/hrt.2008.160465",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","463OQ","WOS:000267441900008"]
[null,null,null,null,"J","Rasmussen, T; Stene, LC; Samuelsen, SO; Cinek, O; Wetlesen, T; Torjesen, PA; Ronningen, KS",null,null,null,"Rasmussen, Trond; Stene, Lars C.; Samuelsen, Sven O.; Cinek, Ondrej; Wetlesen, Turid; Torjesen, Peter A.; Ronningen, Kjersti S.",null,null,"Maternal BMI Before Pregnancy, Maternal Weight Gain During Pregnancy, and Risk of Persistent Positivity for Multiple Diabetes-Associated Autoantibodies in Children With the High-Risk HLA Genotype The MIDIA study","DIABETES CARE",null,null,"English","Article",null,null,null,null,null,null,"BODY-MASS INDEX; TYPE-1; COHORT; TRENDS; AGE","OBJECTIVE - To assess whether maternal BMI before pregnancy and weight gain during pregnancy predicted the risk of islet autoimmunity in genetically susceptible children. RESEARCH DESIGH AHD METHODS - Of 46,939 newborns screened for the high-risk HLA genotype DR4-DQ8/DR3-DQ2, 1,003 were positive and 885 were followed with serial blood samples tested for autoantibodies to insulin, GAD, and insulinoma-associated protein 2 (IA2). The end point was defined as repeated positivity for two or three autoantibodies or the onset of type I diabetes (islet autoimmunity). RESULTS - Thirty-six children developed islet autoimmunity, of whom 10 developed type I diabetes. Both maternal BMI >= 30 kg/m(2) before pregnancy and maternal weight gain >= 15 kg predicted the increased risk of islet autoimmunity (hazard ratio [HR] 2.5, P = 0.023, and HR 2.5, P = 0.015, respectively), independent of maternal diabetes. CONCLUSIONS - Maternal weight may predict risk of islet autoimmunity in offspring with a high genetic susceptibility for type I diabetes.","[Rasmussen, Trond; Stene, Lars C.; Samuelsen, Sven O.; Wetlesen, Turid; Ronningen, Kjersti S.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Samuelsen, Sven O.] Univ Oslo, Dept Math, Oslo, Norway; [Cinek, Ondrej] Motol Univ Hosp, Dept Pediat, Prague, Czech Republic; [Torjesen, Peter A.] Univ Oslo, Aker Univ Hosp, Hormone Lab, Oslo, Norway","Rasmussen, T (reprint author), Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway.","trond.rasmussen@fhi.no",null,null,"Research Council of Norway [135893/330, 155300/320, 156477/730, 166515/V50]; Norwegian Diabetes Association, the Children With Diabetes Foundation [Food-CT-2005-016320]","This study was funded by the Research Council of Norway (grants 135893/330, 155300/320, 156477/730, and 166515/V50), the Norwegian Diabetes Association, the Children With Diabetes Foundation (Denver, CO), and NewGeneris (grant Food-CT-2005-016320).",null,12,17,17,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0149-5992",null,null,"DIABETES CARE","Diabetes Care","OCT",2009,32,10,null,null,null,null,1904,1906,null,"10.2337/dc09-0663",null,3,"Endocrinology & Metabolism","Endocrinology & Metabolism","509HE","WOS:000271004900027"]
[null,null,null,null,"J","Burgelova, M; Vanourkova, Z; Thumova, M; Dvorak, P; Opocensky, M; Kramer, HJ; Zelizko, M; Maly, J; Bader, M; Cervenka, L",null,null,null,"Buergelova, Marcela; Vanourkova, Zdenka; Thumova, Monika; Dvorak, Pavel; Opocensky, Martin; Kramer, Herbert J.; Zelizko, Michal; Maly, Jan; Bader, Michael; Cervenka, Ludek",null,null,"Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension","JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"angiotensin II; angiotensin-(1-7); angiotensin-converting enzyme 2; renal function; renin-angiotensin system; two-kidney one-clip Goldblatt hypertension","ANGIOTENSIN-(1-7)-PRODUCING FUSION PROTEIN; RENAL FUNCTIONAL-RESPONSES; REN-2 TRANSGENIC RATS; BLOOD-PRESSURE; II LEVELS; INTRARENAL INFUSION; KIDNEY-DISEASE; NITRIC-OXIDE; EXPRESSION; BLOCKADE","Objective Recent studies have shown that the heptapeptide angiotensin-(1-7) [Ang-(1-7)] exerts important vasoactive actions and can act as an endogenous physiological antagonist of angiotensin II (Ang II) within the renin-angiotensin system (RAS). The present study was performed to evaluate the effects, first, of chronic increases of Ang-(1-7) levels, second, of [7-D-Ala], an Ang-(1-7) receptor antagonist, and, third, of an angiotensin-converting enzyme 2 (ACE2) inhibitor on the course of hypertension and of renal function of the nonclipped kidney in two-kidney, one-clip (2K1C) Goldblatt hypertensive rats. Methods Blood pressure (BP) was monitored by radiotelemetry. Elevation of the effect of circulating Ang-(1-7) levels was achieved either by chronic subcutaneous infusion of Ang-(1-7) through osmotic minipumps or by employing transgenic rats that express an Ang-(1-7)-producing fusion protein [Ang-(1-7) TGR+/+] (and its control Ang-(1-7) TGR-/-). [7-D-Ala] was also infused subcutaneously and the ACE2 inhibitor was administrated in drinking water. On day 25 after clipping, rats were anesthetized and renal function was evaluated. Results Chronic infusion of Ang-(1-7) did not modify the course of 2K1C hypertension and did not alter renal function as compared with saline vehicle-infused 2K1C rats. Chronic infusion of [7-D-Ala] or treatment with the ACE2 inhibitor worsened the course of hypertension and elicited decreases in renal hemodynamics. [Ang-(1-7) TGR+/+] and [Ang-(1-7) TGR-/-] rats exhibited a similar course of hypertension. Conclusion The present data support the notion that Ang(1-7) serves as an important endogenous vasodilator and natriuretic agent and its deficiency might contribute to the acceleration of 2K1C Goldblatt hypertension. J Hypertens 27: 1988-2000 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Vanourkova, Zdenka; Thumova, Monika; Dvorak, Pavel; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Buergelova, Marcela; Opocensky, Martin; Maly, Jan] Transplant Ctr, Dept Nephrol, Prague, Czech Republic; [Vanourkova, Zdenka; Thumova, Monika; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Med Policlin, Dept Med, Nephrol Sect, D-5300 Bonn, Germany; [Zelizko, Michal] Inst Clin & Expt Med, Dept Cardiol, CZ-14000 Prague 4, Czech Republic; [Bader, Michael] Max Delbruck Ctr Mol Med, Berlin, Germany; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Cervenka, L (reprint author), Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz",null,null,"Grant Agency of Academy of Science of Czech Republic [IAA 511-700-701]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Czech Science Foundation [305/08/J006]; German Research Foundation (Deutsche Forschungsgemeinschaft) [Kra 433/14-2, 436 TSE 113/50/0-1]","This study was supported by grant No. IAA 511-700-701 awarded to M. B. by the Grant Agency of Academy of Science of Czech Republic (GAAV). Z. V. is partly supported from the Center for Cardiovascular Research (1M6798582302). L. C. is supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001) and by a grant awarded by the Czech Science Foundation (GAC. R) No. 305/08/J006. H. J. Kramer is supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn (Kra 433/14-2 and 436 TSE 113/50/0-1).",null,43,21,24,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,null,"J HYPERTENS","J. Hypertens.","OCT",2009,27,10,null,null,null,null,1988,2000,null,"10.1097/HJH.0b013e32832f0d06",null,13,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","503NM","WOS:000270543300012"]
[null,null,null,null,"J","Babic, M; Horak, D; Jendelova, P; Glogarova, K; Herynek, V; Trchova, M; Likavcanova, K; Lesny, P; Pollert, E; Hajek, M; Sykova, E",null,null,null,"Babic, Michal; Horak, Daniel; Jendelova, Pavla; Glogarova, Katerina; Herynek, Vit; Trchova, Miroslava; Likavcanova, Katarina; Lesny, Petr; Pollert, Emil; Hajek, Milan; Sykova, Eva",null,null,"Poly(N,N-dimethylacrylamide)-Coated Maghemite Nanoparticles for Stem Cell Labeling","BIOCONJUGATE CHEMISTRY",null,null,"English","Article",null,null,null,null,null,null,"IRON-OXIDE NANOPARTICLES; IN-VIVO; SUPERPARAMAGNETIC NANOPARTICLES; MIGRATION; TRANSFECTION; PROGENITOR; PARTICLES; TRACKING; AGENT; VITRO","Maghemite (gamma-Fe(2)O(3)) nanoparticles were obtained by the coprecipitation of Fe(II) and Fe (III) salts with ammonium hydroxide followed by oxidation with sodium hypochlorite. Solution radical polymerization of N,N-dimethylacrylamide (DMAAm) in the presence of maghemite nanoparticles yielded poly(N,N-dimethylacrylamide) (PDMAAm)-coated maghemite nanoparticles. The presence of PDMAAm on the maghemite particle surface was confirmed by elemental analysis and ATR FTIR spectroscopy. Other methods of nanoparticle characterization involved scanning and transmission electron microscopy, atomic adsorption spectroscopy (AAS), and dynamic light scattering (DLS). The conversion of DMAAm during polymerization and the molecular weight of PDMAAm bound to maghemite were determined by using gas and size-exclusion chromatography, respectively. The effect of ionic 4,4'-azobis(4-cyanovaleric acid) (ACVA) initiator on nanoparticle morphology was elucidated. The nanoparticles exhibited long-term colloidal stability in water or physiological buffer. Rat and human bone marrow mesenchymal stem cells (MSCs) were labeled with uncoated and PDMAAm-coated maghemite nanoparticles and with Endorem as a control. Uptake of the nanoparticles was evaluated by Prussian Blue staining, transmission electron microscopy, T(2)-MR relaxometry, and iron content analysis. Significant differences in labeling efficiency were found for human and rat cells. PDMAAm-modified nanoparticles demonstrated a higher efficiency of intracellular uptake into human cells in comparison with that of dextran-modified (Endorem) and unmodified nanoparticles. In gelatin, even a small number of labeled cells changed the contrast in MR images. PDMAAm-coated nanoparticles provided the highest T(2) relaxivity of all the investigated particles. In vivo MR imaging of PDMAAm-modified iron oxide-labeled rMSCs implanted in a rat brain confirmed their better resolution compared with Endorem-labeled cells.","[Babic, Michal; Horak, Daniel; Trchova, Miroslava] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Babic, Michal; Horak, Daniel; Jendelova, Pavla; Herynek, Vit; Lesny, Petr; Hajek, Milan; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Jendelova, Pavla; Glogarova, Katerina; Likavcanova, Katarina; Lesny, Petr; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Herynek, Vit; Hajek, Milan] Inst Clin & Expt Med, Prague 14021 4, Czech Republic; [Pollert, Emil] Acad Sci Czech Republic, Inst Phys, Prague 16253 6, Czech Republic","Horak, D (reprint author), Acad Sci Czech Republic, Inst Macromol Chem, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic.","horak@imc.cas.cz","Babic, Michal/B-7075-2013",null,"Center for Cell Therapy and Tissue Repair [1M0538]; Grant Agency of AS CR [KAN201110651, KAN200200651]; Grant Agency of the Czech Republic [203/09/1242]; EC-FP6 project DiMI [LSHB-CT-2005-512146]","The financial support of the Center for Cell Therapy and Tissue Repair No. 1M0538, the Grant Agency of AS CR (grants KAN201110651 and KAN200200651), the Grant Agency of the Czech Republic (203/09/1242) and the EC-FP6 project DiMI (LSHB-CT-2005-512146) is gratefully acknowledged.",null,28,28,29,"AMER CHEMICAL SOC","WASHINGTON","1155 16TH ST, NW, WASHINGTON, DC 20036 USA","1043-1802",null,null,"BIOCONJUGATE CHEM","Bioconjugate Chem.","FEB",2009,20,2,null,null,null,null,283,294,null,"10.1021/bc800373x",null,12,"Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic","Biochemistry & Molecular Biology; Chemistry","409TP","WOS:000263529000015"]
[null,null,null,null,"J","Poljakova, J; Eckschlager, T; Hrabeta, J; Hrebackova, J; Smutny, S; Frei, E; Martinek, V; Kizek, R; Stiborova, M",null,null,null,"Poljakova, Jitka; Eckschlager, Tomas; Hrabeta, Jan; Hrebackova, Jana; Smutny, Svatopluk; Frei, Eva; Martinek, Vaclav; Kizek, Rene; Stiborova, Marie",null,null,"The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells","BIOCHEMICAL PHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,"Ellipticine; Anticancer drug; Neuroblastoma; Cytotoxicity; DNA adduct","ENVIRONMENTAL-POLLUTANT 3-NITROBENZANTHRONE; HUMAN CYTOCHROME-P450 ENZYMES; CARCINOGEN ARISTOLOCHIC ACID; PROSTAGLANDIN-H SYNTHASE; HUMAN METABOLITE; CYCLE ARREST; CANCER-CELLS; DEOXYGUANOSINE ADDUCTS; LIVER-MICROSOMES; IN-VIVO","Ellipticine is an antineoplastic agent, whose mode of action is based mainly on DNA intercalation, inhibition of topoisomerase 11 and formation of covalent DNA adducts mediated by cytochromes P450 and peroxidases. Here, the molecular mechanism of DNA-mediated ellipticine action in human neuroblastoma IMR-32, UKF-NB-3 and UKF-NB-4 cancer cell lines was investigated. Treatment of neuroblastoma cells with ellipticine resulted in apoptosis induction, which was verified by the appearance of DNA fragmentation, and in inhibition of cell growth. These effects were associated with formation of two covalent ellipticine-derived DNA adducts, identical to those formed by the cytochrome P450- and peroxidase-mediated ellipticine metabolites, 13-hydroxy- and 12-hydroxyellipticine. The expression of these enzymes at mRNA and protein levels and their ability to generate ellipticine-DNA adducts in neuroblastoma cells were proven, using the real-time polymerase chain reaction, Western blotting analyses and by analyzing ellipticine-DNA adducts in incubations of this drug with neuroblastoma S9 fractions, enzyme cofactors and DNA. The levels of DNA adducts correlated with toxicity of ellipticine to IMR-32 and UKF-NB-4 cells, but not with that to UKF-NB-3 cells. In addition, hypoxic cell culture conditions resulted in a decrease in ellipticine toxicity to IMR-32 and UKF-NB-4 cells and this correlated with lower levels of DNA adducts. Both these cell lines accumulated in S phase, suggesting that ellipticine-DNA adducts interfere with DNA replication. The results demonstrate that among the multiple modes of ellipticine antitumor action, formation of covalent DNA adducts by ellipticine is the predominant mechanism of cytotoxicity to IMR-32 and UKF-NB-4 neuroblastoma cells. (C) 2009 Elsevier Inc. All rights reserved.","[Poljakova, Jitka; Martinek, Vaclav; Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12840 2, Czech Republic; [Eckschlager, Tomas; Hrabeta, Jan; Hrebackova, Jana] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Eckschlager, Tomas; Hrabeta, Jan; Hrebackova, Jana; Smutny, Svatopluk] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Smutny, Svatopluk] Charles Univ Prague, Sch Med 2, Dept Surg 1, Prague 15006 5, Czech Republic; [Frei, Eva] German Canc Res Ctr, Div Mol Toxicol, D-69120 Heidelberg, Germany; [Kizek, Rene] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, Brno 61300, Czech Republic","Stiborova, M (reprint author), Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, Prague 12840 2, Czech Republic.","stiborov@natur.cuni.cz","Kizek, Rene/D-7748-2012; Martinek, Vaclav/E-6710-2011","Martinek, Vaclav/0000-0003-3321-4526","Grant Agency of the Czech Republic [203/06/0329]; Internal Grant Agency of Ministry of Health of the Czech Republic [NR9522-3/2007]; Ministry of Education of the Czech Republic [MSM0021620813, 1M0505]","The work was supported by the Grant Agency of the Czech Republic (grant 203/06/0329), Internal Grant Agency of Ministry of Health of the Czech Republic (grant NR9522-3/2007) and Ministry of Education of the Czech Republic (grants MSM0021620813 and 1M0505). Fruitful help of Dr. A. Vicha, M.D. (Department of Pediatric Hematology and Oncology, 2nd Medical School, Charles University and University Hospital Motol, Prague, Czech Republic) is gratefully acknowledged. We thank Prof.J. Cinatljr. U. W. Goethe University, Frankfurt, Germany) for providing cell lines.",null,55,32,32,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0006-2952",null,null,"BIOCHEM PHARMACOL","Biochem. Pharmacol.","MAY 1",2009,77,9,null,null,null,null,1466,1479,null,"10.1016/j.bcp.2009.01.021",null,14,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","433IH","WOS:000265197000003"]
[null,null,null,null,"J","Dequeker, E; Stuhrmann, M; Morris, MA; Casals, T; Castellani, C; Claustres, M; Cuppens, H; Des Georges, M; Ferec, C; Macek, M; Pignatti, PF; Scheffer, H; Schwartz, M; Witt, M; Schwarz, M; Girodon, E",null,null,null,"Dequeker, Els; Stuhrmann, Manfred; Morris, Michael A.; Casals, Teresa; Castellani, Carlo; Claustres, Mireille; Cuppens, Harry; des Georges, Marie; Ferec, Claude; Macek, Milan; Pignatti, Pier-Franco; Scheffer, Hans; Schwartz, Marianne; Witt, Michal; Schwarz, Martin; Girodon, Emmanuelle",null,null,"Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders - updated European recommendations","EUROPEAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"guidelines; recommendations; genetic testing; cystic fibrosis; CFTR; CFTR-related disorders","TRANSMEMBRANE CONDUCTANCE REGULATOR; FETAL ECHOGENIC BOWEL; CONGENITAL ABSENCE; VAS-DEFERENS; UNIPARENTAL DISOMY; DISSEMINATED BRONCHIECTASIS; OBSTRUCTIVE AZOOSPERMIA; GENOMIC REARRANGEMENTS; BAYESIAN-ANALYSIS; RISK-ASSESSMENT","The increasing number of laboratories offering molecular genetic analysis of the CFTR gene and the growing use of commercial kits strengthen the need for an update of previous best practice guidelines (published in 2000). The importance of organizing regional or national laboratory networks, to provide both primary and comprehensive CFTR mutation screening, is stressed. Current guidelines focus on strategies for dealing with increasingly complex situations of CFTR testing. Diagnostic flow charts now include testing in CFTR-related disorders and in fetal bowel anomalies. Emphasis is also placed on the need to consider ethnic or geographic origins of patients and individuals, on basic principles of risk calculation and on the importance of providing accurate laboratory reports. Finally, classification of CFTR mutations is reviewed, with regard to their relevance to pathogenicity and to genetic counselling.","[Girodon, Emmanuelle] Grp Hosp Henri Mondor Albert Chenevier, APHP, Serv Biochim & Genet, F-94010 Creteil, France; [Dequeker, Els; Cuppens, Harry] Ctr Human Genet, Kuleuven, Belgium; [Stuhrmann, Manfred] Hannover Med Sch, Inst Humangenet, D-30623 Hannover, Germany; [Morris, Michael A.] Univ Hosp, Serv Med Genet, Lab Diagnost Mol, Geneva, Switzerland; [Casals, Teresa] IDIBELL, Ctr Genet Medica & Mol, Barcelona, Spain; [Castellani, Carlo] Osped Civile, Cyst Fibrosis Ctr, I-37126 Verona, Italy; [Claustres, Mireille; des Georges, Marie] CHU Montpellier, Serv Genet Mol, Montpellier, France; [Claustres, Mireille; des Georges, Marie] INSERM, U827, Montpellier, France; [Ferec, Claude] Genet Mol Lab, Brest, France; [Macek, Milan] Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Macek, Milan] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Pignatti, Pier-Franco] Univ Verona, Sect Biol & Genet, I-37100 Verona, Italy; [Scheffer, Hans] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands; [Schwartz, Marianne] Mol Genet Lab, Copenhagen, Denmark; [Witt, Michal] Polish Acad Sci, Inst Human Genet, Dept Mol & Clin Genet, PL-60479 Poznan, Poland; [Schwarz, Martin] St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England","Girodon, E (reprint author), Grp Hosp Henri Mondor Albert Chenevier, APHP, Serv Biochim & Genet, 51 Av Marechal de Lattre de Tassigny, F-94010 Creteil, France.","emmanuelle.girodon@inserm.fr","Scheffer, Hans/E-4644-2012; Casals, Teresa/K-4587-2012; LABO, U827/A-8632-2008","Casals, Teresa/0000-0001-6078-2823; ","EU project EuroGentest [FP6-512148]; European Cystic Fibrosis Network","This study was supported and performed within the framework of the EU project EuroGentest (FP6-512148) and the European Cystic Fibrosis Network.",null,81,68,70,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,null,"EUR J HUM GENET","Eur. J. Hum. Genet.","JAN",2009,17,1,null,null,null,null,51,65,null,"10.1038/ejhg.2008.136",null,15,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","382EU","WOS:000261588800008"]
[null,null,null,null,"J","Huska, D; Hubalek, J; Adam, V; Vajtr, D; Horna, A; Trnkova, L; Havel, L; Kizek, R",null,null,null,"Huska, Dalibor; Hubalek, Jaromir; Adam, Vojtech; Vajtr, David; Horna, Ales; Trnkova, Libuse; Havel, Ladislav; Kizek, Rene",null,null,"Automated nucleic acids isolation using paramagnetic microparticles coupled with electrochemical detection","TALANTA",null,null,"English","Article",null,null,null,null,null,"mRNA; Isolation; Magnetic particle and bead; Cyclic voltammetry; Square wave voltammetry; Brain tissue; Maize plants; Cadmium","TRAUMATIC BRAIN-INJURY; ELIMINATION VOLTAMMETRY; MAGNETIC PARTICLES; DNA HYBRIDIZATION; OSZILLOGRAPHISCHE POLAROGRAPHIE; CARBON ELECTRODES; GENOMIC DNA; NANOPARTICLES; EXTRACTION; OLIGONUCLEOTIDES","Easy, efficient and low demanding separation of mRNA from biological material is needed to study gene expression and to use in chip technologies. It is common knowledge that each mRNA molecule contains sequence of 25 adenines. This feature can be used for binding mRNA on the surface of the particles coated by thymine chains. The present work reports on suggesting and optimizing of mRNA separation and detection from biological material via paramagnetic microparticles coupled with electrochemical detection. Primarily we optimized cyclic and square wave voltammetric conditions to detect poly(A),which was used as standard to mimic behaviour of mRNA. Under the optimized square wave voltammetric conditions (frequency 280 Hz, accumulation time 200 s, supporting electrolyte and its temperature: acetate buffer 4.6 and 35 degrees C) we estimated detection limit down to 1 ng of poly(A) per ml. To enhance effectiveness and repeatability of isolation of nucleic acid automated approach for rinsing and hybridizing was proposed. We optimized the whole procedure and experimental conditions. Using automated way of isolation and under optimized conditions the yield of poly(A) (isolated concentration of poly(A)/given concentration of poly(A)*100) was approximately 75%. The suggested and optimized method for poly(A) isolation and detection was utilized for the analysis of brain tissues of patients with traumatic brain injury. The total amount of isolated mRNA varied from 40 to 760 g of mRNA per g of brain tissue. The isolation of mRNA from six samples per run was not longer than 2.5 h. Moreover, we applied the optimized procedure on fully automated pipetting instrument to isolate mRNA. The instrument was successfully tested on the analysis of extracts from roots of maize plants treated with cadmium(II) ions. (C) 2009 Elsevier B.V. All rights reserved.","[Huska, Dalibor; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Huska, Dalibor; Havel, Ladislav] Mendel Univ Agr & Forestry Brno, Dept Plant Biol, CZ-61300 Brno, Czech Republic; [Hubalek, Jaromir] Brno Univ Technol, Fac Elect Engn & Commun, Dept Microelect, CZ-60200 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic; [Vajtr, David] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, CZ-15006 Prague 5, Czech Republic; [Horna, Ales] Tomas Bata Univ, Fac Technol, CZ-76272 Zlin, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CZ-61137 Brno, Czech Republic","Kizek, R (reprint author), Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Havel, Ladislav/C-8954-2012; Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Horna, Ales/H-6388-2012","Havel, Ladislav/0000-0003-3378-2785; ","GACR [102/08/1546, KAN208130801]","Financial support from the grant GACR 102/08/1546 and KAN208130801 is highly acknowledged.",null,51,34,34,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0039-9140",null,null,"TALANTA","Talanta","JUL 15",2009,79,2,null,null,null,null,402,411,null,"10.1016/j.talanta.2009.04.007",null,10,"Chemistry, Analytical","Chemistry","473OK","WOS:000268216900046"]
[null,null,null,null,"J","Simko, F; Pechanova, O; Pelouch, V; Krajcirovicova, K; Mullerova, M; Bednarova, K; Adamcova, M; Paulis, L",null,null,null,"Simko, Fedor; Pechanova, Olga; Pelouch, Vaclav; Krajcirovicova, Kristina; Mullerova, Martina; Bednarova, Kristina; Adamcova, Michaela; Paulis, Ludovit",null,null,"Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats","JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"captopril; fibrosis; melatonin; myocardial hypertrophy; simvastatin; spironolactone","NAME-INDUCED HYPERTENSION; VASCULAR REACTIVITY; NITRIC-OXIDE; HYPERTROPHY; REGRESSION; HEART; ANGIOTENSIN; PREVENTION; FIBROSIS; STATINS","Objective Melatonin was shown to reduce blood pressure, oxidative load and to increase nitric oxide bioavailability predisposing melatonin to have antiremodelling potential. Design The aim of this study was to show whether melatonin can reverse left ventricular remodelling in spontaneously hypertensive rats (SHR) and to compare this potential protective effect with captopril, spironolactone, or simvastatin. Methods Six groups of 3-month old rats (eight per group) were treated for 5 weeks: control untreated Wistar rats, control SHR, SHR plus melatonin (10 mg/kg per 24 h), SHR plus captopril (100 mg/kg per 24 h), SHR plus spironolactone (200 mg/kg per 24 h) and SHR plus simvastatin (10 mg/kg per 24 h). Their systolic blood pressure (SBP) was measured by the tail-cuff method. The relative weights of the left ventricle, nitric oxide synthase (NOS) activity, endothelial NOS and nuclear factor kappa B (NF-kappa B) protein expression, conjugated dienes concentration, level of collagenous proteins and hydroxyproline were measured. Results SBP was reduced by all drugs investigated but most prominently by captopril in SHR. The activity of NOS and endothelial NOS expression increased in the left ventricles of SHR compared with controls. Melatonin and spironolactone further increased NOS expression. Left ventricular oxidative load, estimated by NF-kappa B expression and conjugated dienes concentration, increased in SHR. Only melatonin reduced NF-kappa B expression and decreased conjugated diens concentration. Only captopril reduced left ventricular hypertrophy in SHR, whereas melatonin reduced collagenous protein concentration and hydroxyproline content in the left ventricle. Conclusion It is concluded that although melatonin, in comparison with captopril, did not reverse left ventricle hypertrophy, it reversed left ventricular fibrosis. This protection by melatonin may be caused by its prominent antioxidative effect. J Hypertens 27 (suppl 6): S5-S10 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Simko, Fedor; Krajcirovicova, Kristina; Mullerova, Martina; Bednarova, Kristina; Paulis, Ludovit] Comenius Univ, Dept Pathophysiol, Sch Med, Bratislava 81108, Slovakia; [Simko, Fedor] Comenius Univ, Clin Med 3, Sch Med, Bratislava 81108, Slovakia; [Pechanova, Olga; Paulis, Ludovit] Slovak Acad Sci, Inst Normal & Pathol Physiol, Bratislava, Slovakia; [Pechanova, Olga] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Pechanova, Olga] Acad Sci Czech Republic, Cardiovasc Res Ctr, Prague, Czech Republic; [Pelouch, Vaclav] Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Hradec Kralove, Czech Republic; [Adamcova, Michaela] Charles Univ Prague, Sch Med, Dept Physiol, Hradec Kralove, Czech Republic","Simko, F (reprint author), Comenius Univ, Dept Pathophysiol, Sch Med, Sasinkova 4, Bratislava 81108, Slovakia.","fedor.simko@fmed.uniba.sk",null,null,"VEGA [1/0187/09, 2/0178/09, APVV-0538-07, MSM0021620820]","This study is supported by research grants of VEGA no. 1/0187/09 and no. 2/0178/09, APVV-0538-07 and MSM0021620820.",null,30,20,20,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,null,"J HYPERTENS","J. Hypertens.","AUG",2009,27,null,null,null,null,null,"S5","S10",null,"10.1097/01.hjh.0000358830.95439.e8",null,6,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","491AO","WOS:000269549400002"]
[null,null,null,null,"J","Polakova, V; Pardini, B; Naccarati, A; Landi, S; Slyskova, J; Novotny, J; Vodickova, L; Bermejo, JL; Hanova, M; Smerhovsky, Z; Tulupova, E; Kumar, R; Hemminki, K; Vodicka, P",null,null,null,"Polakova, V.; Pardini, B.; Naccarati, A.; Landi, S.; Slyskova, J.; Novotny, J.; Vodickova, L.; Bermejo, J. L.; Hanova, M.; Smerhovsky, Z.; Tulupova, E.; Kumar, R.; Hemminki, K.; Vodicka, P.",null,null,"Genotype and Haplotype Analysis of Cell Cycle Genes in Sporadic Colorectal Cancer in the Czech Republic","HUMAN MUTATION",null,null,"English","Article",null,null,null,null,null,"TP53; CDKN1A; CDKN2A; genetic polymorphisms; haplotype analysis; colorectal cancer susceptibility; CRC","WIDE ASSOCIATION SCAN; INCREASED RISK; P53 GENOTYPES; BREAST-CANCER; LUNG-CANCER; POLYMORPHISMS; SUSCEPTIBILITY; TP53; GENOME; ADENOCARCINOMAS","The Czech Republic has one of the highest incidences of colorectal cancer (CRC) in the world. To assess the role of genetic variants on the disease, we genotyped polymorphisms in the TP53 (rs17878362: A(1)>A(2), rs1042522:G>C, rs12947788: C>T, and rs17884306:G>A), CDKN1A (rs1801270: C>A and rs1059234:C>T), and CDKN2A (rs3731249:G>A, rs11515:C>G, and rs3088440: C>T) genes in 614 hospital-based CRC cases and 614 matched controls from the country. Despite the tendency toward differential distribution of variant allele frequencies for some polymorphisms, none was significantly associated with CRC risk. We observed differential distribution of major haplotypes arising from four polymorphisms ill the TP53 gene between cases and controls (global P<0.0001). The two most common haplotypes, A(1)GCG and A(2)CCG, were present in 81% of the cases compared to 71% of the controls. In comparison to the most common haplotype (A(1)GCG), the haplotype A2CCG was associated with an increased risk (odds ratio (OR], 1.40; 95% confidence interval [CI], 1.07-1.82), while the four other haplotypes A(1)CCG (OR, 0.60; 95% CI, 0.45-0.79), A(2)GCG (OR, 0.53; 95% CI, 0.35-0.81), A(1)GTG (OR, 0.31; 95% CI, 0.15-0.64), and A(1)GCA (OR, 0.19; 95% CI, 0.07-0.51) were associated with a decreased risk. The effect of haplotypes in the TP53 gene was similar in colon (global P < 0.000 1) and rectal cancers (P = 0.006). No association with the disease was observed with haplotypes of the CDKN1A and CDKN2A polymorphisms. The results from this study suggest that prevalent haplotypes within the TP53 gene may modulate CRC risks in the population. Hum Mutat 30, 661-668, 2009. (C) 2009 Wiley-Liss, Inc.","[Polakova, V.; Pardini, B.; Naccarati, A.; Slyskova, J.; Vodickova, L.; Hanova, M.; Vodicka, P.] Acad Sci Czech Republic, Inst Expt Med, Prague 14200 4, Czech Republic; [Polakova, V.] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Novotny, J.] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Landi, S.] Univ Pisa, Dept Biol, Pisa, Italy; [Vodickova, L.; Smerhovsky, Z.] Natl Inst Publ Hlth, Prague, Czech Republic; [Bermejo, J. L.; Kumar, R.; Hemminki, K.] German Canc Res Ctr, D-6900 Heidelberg, Germany","Vodicka, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14200 4, Czech Republic.","pvodicka@biomed.cas.cz",null,null,"Czech Republic [GACR 310/07/1430, AVOZ 50390703, AVOZ 50390512, GAUK 96908/8/2008]; BMBF","Contract grant sponsor: Czech Republic; Grant numbers: GACR 310/07/1430, AVOZ 50390703; AVOZ 50390512; and GAUK 96908/8/2008, Contract grant sponsor BMBF for NGFN+.",null,51,18,19,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1059-7794",null,null,"HUM MUTAT","Hum. Mutat.","APR",2009,30,4,null,null,null,null,661,668,null,"10.1002/humu.20931",null,8,"Genetics & Heredity","Genetics & Heredity","430RO","WOS:000265006400021"]
[null,null,null,null,"J","Paulis, L; Pechanova, O; Zicha, J; Krajcirovicova, K; Barta, A; Pelouch, V; Adamcova, M; Simko, F",null,null,null,"Paulis, Ludovit; Pechanova, Olga; Zicha, Josef; Krajcirovicova, Kristina; Barta, Andrej; Pelouch, Vaclav; Adamcova, Michaela; Simko, Fedor",null,null,"Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of N(G)-nitro-L-arginine-methyl ester hypertensive rats","JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"collagen; fibrosis; hydroxyproline; hypertension; hypertrophy; melatonin; N(G)-nitro-L-arginine-methyl ester; nitric oxide","NAME-INDUCED HYPERTENSION; BLOOD-PRESSURE; HEART; CARDIOMYOPATHY; EXPRESSION; REGRESSION; AORTA; CAPTOPRIL; BRAIN; OXIDE","Objective Melatonin was shown to reduce blood pressure, enhance nitric oxide availability and scavenge free radicals. There is, however, a shortage of data with respect to the effect of melatonin on pathological left ventricular remodelling associated with haemodynamic overload. Design We investigated whether melatonin was able to prevent left ventricular hypertrophy (LVH) and fibrosis associated with N(G)-nitro-L-arginine-methyl ester (L-NAME)induced hypertension. Methods Four groups of male Wistar rats were investigated: control, L-NAME (50 mg/kg per day), melatonin (10 mg/kg per day) and L-NAME plus melatonin. Blood pressure was measured non-invasively each week. After 5 weeks of treatment the animals were killed and nitric oxide synthase (NOS) activity, endothelial and inducible NOS expression, the level of collagenous proteins, hydroxyproline and conjugated dienes in the left ventricle were determined. Results The administration of L-NAME inhibited NOS activity, increased conjugated dienes concentration, elevated blood pressure and induced LVH and fibrosis (indicated by increased collagenous proteins and hydroxyproline levels). The addition of melatonin to L-NAME treatment failed to prevent the attenuation of NOS activity and the development of LVH and prevented hypertension only partly. The administration of melatonin, however, completely prevented the increase in conjugated dienes concentration and the development of left ventricular fibrosis. NOS expression was not different among experimental groups. Conclusion Melatonin prevented the development of left ventricular fibrosis and the increase in oxidative load in rats with L-NAME-induced hypertension. The antifibrotic effect of melatonin seems to be independent of its effects on NOS activity and might be linked to its antioxidant properties. J Hypertens 27 (suppl 6):S11-S16 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Paulis, Ludovit] Charite, Cardiovasc Res Ctr, D-10115 Berlin, Germany; [Paulis, Ludovit; Krajcirovicova, Kristina; Simko, Fedor] Comenius Univ, Sch Med, Dept Pathophysiol, Bratislava, Slovakia; [Paulis, Ludovit; Pechanova, Olga; Barta, Andrej] Slovak Acad Sci, Inst Normal & Pathol Physiol, Bratislava, Slovakia; [Paulis, Ludovit; Pechanova, Olga; Barta, Andrej] Slovak Acad Sci, Ctr Excellence Cardiovasc Res, Bratislava, Slovakia; [Pechanova, Olga; Zicha, Josef] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Pechanova, Olga; Zicha, Josef] Acad Sci Czech Republic, Cardiovasc Res Ctr, Prague, Czech Republic; [Pelouch, Vaclav] Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Prague, Czech Republic; [Adamcova, Michaela] Charles Univ Prague, Sch Med, Dept Physiol, Hradec Kralove, Czech Republic; [Simko, Fedor] Comenius Univ, Sch Med, Clin Med 3, Bratislava, Slovakia","Paulis, L (reprint author), Charite, Cardiovasc Res Ctr, Hess Str 3-4, D-10115 Berlin, Germany.","ludo@lfuk.sk","Zicha, Josef/B-1349-2012","Zicha, Josef/0000-0001-6051-6541","VEGA [1/0187/09, 2/0178/09]; APVV [0538-07]; Marie Curie Intra European Fellowship COME-in-CARE [PIEF-GA-2009-237834];  [MSM0021620820]","This work was partly supported by VEGA grants no. 1/0187/09 and no. 2/0178/09, APVV grant 0538-07, the research project MSM0021620820 and by a Marie Curie Intra European Fellowship COME-in-CARE, PIEF-GA-2009-237834 within the 7th European Community Framework Programme.",null,31,18,18,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,null,"J HYPERTENS","J. Hypertens.","AUG",2009,27,null,null,null,null,null,"S11","S16",null,"10.1097/01.hjh.0000358831.33558.97",null,6,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","491AO","WOS:000269549400003"]
[null,null,null,null,"J","Salameh, A; Krautblatter, S; Karl, S; Blanke, K; Gomez, DR; Dhein, S; Pfeiffer, D; Janousek, J",null,null,null,"Salameh, A.; Krautblatter, S.; Karl, S.; Blanke, K.; Gomez, D. Rojas; Dhein, S.; Pfeiffer, D.; Janousek, J.",null,null,"The signal transduction cascade regulating the expression of the gap junction protein connexin43 by beta-adrenoceptors","BRITISH JOURNAL OF PHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,"Cx43; cardiomyocytes; beta-adrenoceptor; isoprenaline; MAPK; congestive heart failure; hypertrophic cardiomyopathy; human cardiac biopsy","ELEMENT-BINDING-PROTEIN; CARDIAC MYOCYTES; HYPERTROPHIC CARDIOMYOPATHY; INTERCELLULAR COMMUNICATION; VENTRICULAR CARDIOMYOCYTES; ADRENERGIC STIMULATION; CONDUCTION-VELOCITY; RAT CARDIOMYOCYTES; KINASE-A; ACTIVATION","Background and purpose: In mammalian heart, connexin43 (Cx43) represents the predominant connexin in the working myocardium. As the beta-adrenoceptor is involved in many cardiac diseases, we wanted to clarify the pathway by which beta-adrenoceptor stimulation may control Cx43 expression. Experimental approach: Cultured neonatal rat cardiomyocytes were stimulated with isoprenaline. Cx43 expression as well as activation of p38 mitogen-activated protein kinase (MAPK), p42/44 MAPK, JUN NH(2)-terminalkinase (JNK) and nuclear translocation of the transcription factors activator protein 1 (AP1) and CRE-binding protein (CREB) were investigated. Additionally, we assessed Cx43 expression and distribution in left ventricular biopsies from patients without any significant heart disease, and from patients with either congestive heart failure [dilated cardiomyopathy (DCM)] or hypertrophic cardiomyopathy (HCM). Key results: Isoprenaline exposure caused about twofold up-regulation of Cx43 protein with a pEC(50) of 7.92 +/- 0.11, which was inhibited by propranolol, SB203580 (4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl)-1H-imidazole) (p38 inhibitor), PD98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one) (MAPK 1 kinase inhibitor) (Alexis Biochemicals, San Diego, CA, USA) or cyclosporin A. Similar findings were obtained for Cx43 mRNA. Furthermore, Cx43 up-regulation was accompanied by phosphorylation of p38, p42/44 and JNK, and by translocation of AP1 and CREB to the nucleus. Analysis of Cx43 protein and mRNA in ventricular biopsies revealed that in patients with DCM, Cx43 content was significantly lower, and in patients with HCM, Cx43 content was significantly higher, relative to patients without any cardiomyopathy. More importantly, Cx43 distribution also changed with more Cx43 being localized at the lateral border of the cardiomyocytes. Conclusion and implication: beta-adrenoceptor stimulation up-regulated cardiac Cx43 expression via a protein kinase A and MAPK-regulated pathway, possibly involving AP1 and CREB. Cardiomyopathy altered Cx43 expression and distribution. British Journal of Pharmacology (2009) 158, 198-208; doi:10.1111/j.1476-5381.2009.00344.x","[Salameh, A.; Karl, S.; Blanke, K.; Janousek, J.] Univ Leipzig, Dept Paediat Cardiol, Ctr Heart, D-04289 Leipzig, Germany; [Krautblatter, S.] Univ Wurzburg, Inst Physiol, D-8700 Wurzburg, Germany; [Gomez, D. Rojas; Dhein, S.] Univ Leipzig, Clin Cardiac Surg, Ctr Heart, D-04289 Leipzig, Germany; [Pfeiffer, D.] Univ Leipzig, Clin Cardiol & Angiol, D-04289 Leipzig, Germany","Salameh, A (reprint author), Univ Leipzig, Dept Paediat Cardiol, Ctr Heart, Strumpellstr 39, D-04289 Leipzig, Germany.","aida.salameh@med.uni-leipzig.de",null,null,null,null,"Aggeli IKS, 2006, CELL SIGNAL, V18, P1801, DOI 10.1016/j.cellsig.2006.02.001; Bailey J, 2002, J CLIN ENDOCR METAB, V87, P1717, DOI 10.1210/jc.87.4.1717; BARTHEL F, 1995, J NEUROCHEM, V64, P41; Beardslee MA, 1998, CIRC RES, V83, P629; BOUTILLIER AL, 1992, J BIOL CHEM, V267, P23520; Darrow BJ, 1996, CIRC RES, V79, P174; de Boer TP, 2007, CIRC J, V71, P973, DOI 10.1253/circj.71.973; Dupont E, 2001, J MOL CELL CARDIOL, V33, P359, DOI 10.1006/jmcc.2000.1308; Echetebu CO, 1999, MOL HUM REPROD, V5, P757, DOI 10.1093/molehr/5.8.757; Engh RA, 1996, J BIOL CHEM, V271, P26157; Fan GC, 2006, CIRC RES, V99, P1233, DOI 10.1161/01.RES.0000251074.19348.af; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Glover D, 2003, INT J RADIAT BIOL, V79, P955, DOI 10.1080/09553000310001632895; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Goldspink PH, 1996, CELL TISSUE RES, V285, P379, DOI 10.1007/s004410050653; Kaprielian RR, 1998, CIRCULATION, V97, P651; Kostin S, 2004, CARDIOVASC RES, V62, P426, DOI 10.1016/j.cardiores.2003.12.010; Kostin S, 2003, MOL CELL BIOCHEM, V242, P135, DOI 10.1023/A:1021154115673; Krishnamurthy P, 2007, HYPERTENSION, V49, P865, DOI 10.1161/01.HYP.0000258703.36986.13; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Markou T, 2004, J MOL CELL CARDIOL, V37, P1001, DOI 10.1016/j.yjmcc.2004.08.002; Muller FU, 2001, CARDIOVASC RES, V52, P95, DOI 10.1016/S0008-6363(01)00361-3; Polontchouk L, 2001, J AM COLL CARDIOL, V38, P883, DOI 10.1016/S0735-1097(01)01443-7; Ponicke K, 2002, J PHARMACOL EXP THER, V301, P71, DOI 10.1124/jpet.301.1.71; Ponicke K, 1999, N-S ARCH PHARMACOL, V360, P301, DOI 10.1007/s002109900077; Ripplinger CM, 2007, CIRC RES, V101, P1049, DOI 10.1161/CIRCRESAHA.107.161240; Salameh A, 2006, FASEB J, V20, P365, DOI 10.1096/fj.05-4871fje; Salameh A, 2005, BBA-BIOMEMBRANES, V1719, P36, DOI 10.1016/j.bbamem.2005.09.007; Salameh A, 2003, N-S ARCH PHARMACOL, V368, P33, DOI 10.1007/s00210-003-0760-1; Salameh A, 2004, EUR J PHARMACOL, V503, P9, DOI 10.1016/j.ejphar.2004.09.024; Schafer M, 2001, J AM COLL CARDIOL, V37, P300, DOI 10.1016/S0735-1097(00)01065-2; Sepp R, 1996, HEART, V76, P412, DOI 10.1136/hrt.76.5.412; Taimor G, 2004, AM J PHYSIOL-HEART C, V286, pH2369, DOI 10.1152/ajpheart.00741.2003; Takemoto Y, 1999, J MOL CELL CARDIOL, V31, P2017, DOI 10.1006/jmcc.1999.1033; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; Zhang GX, 2005, CARDIOVASC RES, V65, P230, DOI 10.1016/j.cardiones.2004.08.013; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760",38,21,24,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0007-1188",null,null,"BRIT J PHARMACOL","Br. J. Pharmacol.","SEP",2009,158,1,null,null,null,null,198,208,null,"10.1111/j.1476-5381.2009.00344.x",null,11,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","487YN","WOS:000269315700020"]
[null,null,null,null,"J","Hothi, DK; Rees, L; Marek, J; Burton, J; McIntyre, CW",null,null,null,"Hothi, Daljit K.; Rees, Lesley; Marek, Jan; Burton, James; McIntyre, Christopher W.",null,null,"Pediatric Myocardial Stunning Underscores the Cardiac Toxicity of Conventional Hemodialysis Treatments","CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,null,"CHRONIC-RENAL-FAILURE; LEFT-VENTRICULAR DYSFUNCTION; DISEASE; CHILDREN; DIALYSIS; INSUFFICIENCY; MORTALITY; TROPONIN; DAMAGE; FLOW","Background and objective: In adults, hemodialysis (HD)-induced ischemia causes reversible myocardial dysfunction (myocardial stunning) that is progressive with raised attendant mortality. Children share an increased risk for death from a spectrum of uremia-related cardiovascular abnormalities but in the absence of significant classical atheromatous coronary artery disease; therefore, we elected to assess children who were on HD for the occurrence of myocardial stunning to investigate the relative importance of characteristic uremic cardiovascular abnormalities in the development of ischemic cardiac injury. Design, setting, participants, & measurements: We included all single-center long-term HD patients (n = 12; range 2 to 17 yr), excluding those with structural cardiac disease. Patients underwent conventional thrice-weekly HD for 4 h using high-flux membranes. We measured regional left ventricle wall motion using serial echocardiography (before HD, during HD, and 15 min after HD). Significant stunning was defined as a 20% reduction in regional wall motion (RRWM) in two or more segments and hyperkinesis as an either >20 or >50% increase in shortening fraction (SF). Results: Eleven of 12 patients developed myocardial stunning with varying degrees of compensatory hyperkinesis in unaffected segments, maintaining left ventricular ejection fraction throughout HD. The mean segmental %SF([Overall]) and %SF([RRWM]) fell during HD (2.19 to 1.77 and 2.72 to 1.37, respectively). Intradialytic BP reduction was significantly associated with mean segmental %SF([RRWM]*). Conclusions: Children who receive conventional HD experience myocardial stunning. These data, in combination with previous adult studies of intradialytic myocardial blood flow, suggest a characteristic cardiovascular phenotype in HD patients that predisposes to significant demand ischemia.","[Burton, James; McIntyre, Christopher W.] Derby City Gen Hosp, Dept Renal Med, Derby DE22 3NE, England; [Hothi, Daljit K.; Rees, Lesley] Great Ormond St Hosp Sick Children, Dept Nephrourol, London WC1N 3JH, England; [Marek, Jan] Great Ormond St Hosp Sick Children, Dept Pediat Cardiol, London WC1N 3JH, England; [McIntyre, Christopher W.] Univ Nottingham, Sch Grad Entry Med & Hlth, Nottingham NG7 2RD, England","McIntyre, CW (reprint author), Derby City Gen Hosp, Dept Renal Med, Uttoxeter Rd, Derby DE22 3NE, England.","chris.mcintyre@nottingham.ac.uk","Rees, Lesley/C-5027-2008",null,"Kids Kidney Research UK","This study was funded by Kids Kidney Research UK.","Bosch J G, 1995, J Am Soc Echocardiogr, V8, P810, DOI 10.1016/S0894-7317(05)80005-7; BRAUNWALD E, 1982, CIRCULATION, V66, P1146; BURTON JO, 2007, ANN M AM SOC NEPHR S; BURTON JO, 2008, RENAL FAILURE, V30, P1; Calabro P, 2003, CIRCULATION, V108, P1930, DOI 10.1161/01.CIR.0000096055.62724.C5; Chade AR, 2006, KIDNEY INT, V69, P266, DOI 10.1038/sj.ki.5000031; Chinali M, 2007, J AM SOC NEPHROL, V18, P593, DOI 10.1681/ASN.2006070691; Conlon PJ, 1998, CLIN NEPHROL, V49, P236; Dasselaar JJ, 2009, NEPHROL DIAL TRANSPL, V24, P604, DOI 10.1093/ndt/gfn501; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; De Lima JJG, 2003, HYPERTENSION, V42, P263, DOI 10.1161/01.HYP.0000087889.60760.87; Douglas PS, 2008, CIRCULATION, V117, P1478, DOI 10.1161/CIRCULATIONAHA.107.189097; Foley RN, 2000, J AM SOC NEPHROL, V11, P912; Foley R N, 1998, J Am Soc Nephrol, V9, pS16; Freedman BI, 2006, ADV CHRONIC KIDNEY D, V13, P105, DOI 10.1053/j.ackd.2006.01.001; Hausberg M, 2002, CIRCULATION, V106, P1974, DOI 10.1161/01.CIR.0000034043.16664.96; Hothi DK, 2008, PEDIATR NEPHROL, V23, P813, DOI 10.1007/s00467-007-0724-7; Kari JA, 1997, KIDNEY INT, V52, P468, DOI 10.1038/ki.1997.354; Lipshultz SE, 2003, PEDIATRICS, V112, P79, DOI 10.1542/peds.112.1.79; London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414; McIntyre CW, 2008, CLIN J AM SOC NEPHRO, V3, P19, DOI 10.2215/CJN.03170707; Mitsnefes MM, 2004, KIDNEY INT, V65, P1461, DOI 10.1111/j.1523-1755.2004.00525.x; Petix NR, 2005, J NUCL CARDIOL, V12, P20, DOI 10.1016/j.nuclcard.2004.09.017; Selby NM, 2006, CLIN J AM SOC NEPHRO, V1, P1216, DOI 10.2215/CJN.02010606; Selby NM, 2006, AM J KIDNEY DIS, V47, P830, DOI 10.1053/j.ajkd.2006.01.012; Shoji T, 2004, KIDNEY INT, V66, P1212, DOI 10.1111/j.1523-1755.2004.00812.x; Shroff RC, 2007, J AM SOC NEPHROL, V18, P2996, DOI 10.1681/ASN.2006121397; Stewart GA, 2004, CLIN PHYSIOL FUNCT I, V24, P387, DOI 10.1111/j.1475-097X.2004.00583.x; Tarakcioglu M, 2002, INT J CLIN PRACT, V56, P328; Wayand D, 2000, CLIN CHEM, V46, P1345; WEBER KT, 1991, CIRCULATION, V83, P1849; Wijns W, 1998, NEW ENGL J MED, V339, P173; Wittstein Ilan S, 2008, Curr Heart Fail Rep, V5, P61, DOI 10.1007/s11897-008-0011-3",33,22,22,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1555-9041",null,null,"CLIN J AM SOC NEPHRO","Clin. J. Am. Soc. Nephrol.","APR",2009,4,4,null,null,null,null,790,797,null,"10.2215/CJN.05921108",null,8,"Urology & Nephrology","Urology & Nephrology","429RN","WOS:000264937900020"]
[null,null,null,null,"J","Bartunkova, J; Kayserova, J; Shoenfeld, Y",null,null,null,"Bartunkova, Jirina; Kayserova, Jana; Shoenfeld, Yehuda",null,null,"Allergy and autoimmunity: Parallels and dissimilarity The Yin and Yang of Immunopathology","AUTOIMMUNITY REVIEWS",null,null,"English","Article",null,null,null,null,null,"Autoimmune disease; Allergy; HLA; Cytokines; Autoantigens","SYSTEMIC-LUPUS-ERYTHEMATOSUS; ATOPIC-DERMATITIS; IMMUNOGLOBULIN-E; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; SJOGRENS-SYNDROME; DISEASES; ASTHMA; IGE; CHILDREN","The etiopathogenesis of allergy and autoimmune diseases is caused by genetic and acquired (environmental) factors, which might be common to both immmunopathologies. Genetic factors play an important role in the development and process of immunopathological diseases. Several studies suggest a close relation between gene polymorphism of HLA and cytokines and development of autoimmunity and allergy. Certain gene polymorphisms act as risk or as protective factors. The infection also plays an important role in the induction of allergy and autoimmunity - as a trigger or as a protective factor. Moreover, similar clinical manifestations of both immunopathologies could result in diagnostic problems. This review summarizes the linkage of mechanisms of etiopathogenesis, clinical manifestations and therapeutic strategy between allergic and autoimmune diseases. (C) 2008 Elsevier B.V. All rights reserved.","[Bartunkova, Jirina; Kayserova, Jana] Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Shoenfeld, Yehuda] Tel Aviv Univ, Ctr Autoimmune Dis, Dept Med B, Sheba Med Ctr, IL-52621 Tel Hashomer, Israel","Bartunkova, J (reprint author), Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","jirina.bartunkova@lfmotol.cuni.cz",null,null,null,null,null,40,4,5,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1568-9972",null,null,"AUTOIMMUN REV","Autoimmun. Rev.","FEB",2009,8,4,null,null,null,null,302,308,null,"10.1016/j.autrev.2008.09.004",null,7,"Immunology","Immunology","419JL","WOS:000264215500005"]
[null,null,null,null,"J","Jarolim, L; Sedy, J; Schmidt, M; Nanka, O; Foltan, R; Kawaciuk, I",null,null,null,"Jarolim, Ladislav; Sedy, Jiri; Schmidt, Marek; Nanka, Ondrej; Foltan, Rene; Kawaciuk, Ivan",null,null,"Gender Reassignment Surgery in Male-to-Female Transsexualism: A Retrospective 3-Month Follow-up Study with Anatomical Remarks","JOURNAL OF SEXUAL MEDICINE",null,null,"English","Article",null,null,null,null,null,"Male-To-Female Transsexualism; Sex Reassignment Surgery; Anatomy","SEX-REASSIGNMENT; DORSALIS PENIS/CLITORIDIS; VAGINOPLASTY; PROSTATE; CLITOROPLASTY; COMPLICATIONS; NEOCLITORIS; CONVERSION; DISORDERS; CARCINOMA","Greater acceptance of sexual minorities has enabled people with transsexualism access to adequate treatment and social integration. Gender reassignment surgery is a complex phase in the care of transsexual patients. In response to a greater volume of patients, surgical techniques have evolved and the outcome in patients with male-to-female transsexualism is now a very accurate imitation of female genitalia, enabling sexual intercourse with orgasm. To evaluate the results of surgical reassignment of genitalia in male-to-female transsexuals. A retrospective 3-month follow-up study of patients' opinions following gender reassignment surgery in 129 patients having a primary procedure (eight of whom had later sigmoideocolpoplasty) and five patients undergoing reoperation following an initial unsuccessful procedure at other units. All patients were male transsexuals. The surgical techniques are described in detail. Sexual functions and complications 3 months after surgery. All patients were satisfied with the first phase operation. Thirteen patients (9.7%) underwent successful sigmoideocolpoplasty. Main complications were as follows: rectal lesions developing during preparation of the vaginal canal (1.5%); bleeding from the stump of the shortened urethra in the first 48 hours postoperatively requiring secondary suturing (4.5%); temporary urinary retention requiring repeated insertion of urinary catheters for up to 6 days (5.2%); and healing of the suture between the perineum and the posterior aspect of the vaginal introitus healing by secondary intention (5.2%). The neoclitoris had erogenous sensitivity in 93.9% of patients and 65.3% reached orgasm in the first 3 months. Surgical conversion of the genitalia is a safe and important phase of the treatment of male-to-female transsexuals. Jarolim L, Sedy J, Schmidt M, Nanka O, Foltan R, and Kawaciuk I. Gender reassignment surgery in male-to-female transsexualism: A retrospective 3-month follow-up study with anatomical remarks. J Sex Med 2009;6:1635-1644.","[Jarolim, Ladislav; Schmidt, Marek; Kawaciuk, Ivan] Charles Univ Prague, Dept Urol, Fac Med 2, Prague, Czech Republic; [Sedy, Jiri] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Nanka, Ondrej] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Sedy, Jiri] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Jarolim, Ladislav; Schmidt, Marek; Kawaciuk, Ivan] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic","Jarolim, L (reprint author), Charles Univ Prague, Dept Urol, Fac Med 2, Prague, Czech Republic.","ladislav.jarolim@lfmotol.cuni.cz",null,null,"Ministry of Education, Youth and Sport of The Czech Republic [VZ 0021620806]","This study was supported by a grant from the Ministry of Education, Youth and Sport of The Czech Republic VZ 0021620806.",null,41,6,6,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1743-6095",null,null,"J SEX MED","J. Sex. Med.","JUN",2009,6,6,null,null,null,null,1635,1644,null,"10.1111/j.1743-6109.2009.01245.x",null,10,"Urology & Nephrology","Urology & Nephrology","451JA","WOS:000266465300015"]
[null,null,null,null,"J","Zamecnik, J; Vesely, D; Jakubicka, B; Cibula, A; Pitha, J; Schutzner, J; Mazanec, R",null,null,null,"Zamecnik, Josef; Vesely, Dan; Jakubicka, Branislav; Cibula, Adrian; Pitha, Jiri; Schutzner, Jan; Mazanec, Radim",null,null,"Atrophy of type II fibres in myasthenia gravis muscle in thymectomized patients: steroid-induced change with prognostic impact","JOURNAL OF CELLULAR AND MOLECULAR MEDICINE",null,null,"English","Article",null,null,null,null,null,"Myasthenia gravis; muscle atrophy; corticosteroids; prognosis; morphometry","HISTOGRAPHIC ANALYSIS; MYOPATHY; EXPRESSION; BIOPSIES; THYMOMA","Selective atrophy of type II muscle fibres has been long recognized as an enigmatic but consistent feature of myasthenia gravis (MG) muscle; however, the pathophysiology and the mechanism of that change have remained obscure. In the present study, the results of histomorphometric analysis performed on muscle biopsies from 207 thymectomized seropositive MG patients were correlated with clinical features of MG to demonstrate possible pathophysiological associations and potential prognostic impact. The atrophy of type II fibres was verified in 35 cases (16.9%), being more pronounced in fibres of IIB subtype. It was neither significantly associated with the duration and severity of MG nor with the age of the patients. On the other hand, we demonstrated that the atrophy associated with long-term treatment with corticosteroids, and correlated with increasing doses. Thus, we suppose that the atrophy of type II muscle fibres in seropositive MG is steroid induced rather than MG-associated event. Although the MG patients with atrophy of type II fibres did not differ from the remaining MG cases in terms of improvement in the disease during the follow-up period, our analysis provides clear evidence that they presented a significantly slower tendency to reach an asymptomatic state after thymectomy. Therefore, the steroid-induced atrophy of type II fibres in MG muscle might be considered to be an unfavourable prognostic factor.","[Zamecnik, Josef; Vesely, Dan; Jakubicka, Branislav; Cibula, Adrian] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 15006, Czech Republic; [Zamecnik, Josef; Vesely, Dan; Jakubicka, Branislav; Cibula, Adrian; Schutzner, Jan; Mazanec, Radim] Univ Hosp Motol, Prague, Czech Republic; [Vesely, Dan] Charles Univ Prague, Dept Infect Dis 1, Fac Med 2, CR-11636 Prague 1, Czech Republic; [Vesely, Dan] Univ Hosp Bulovka, Bulovka, Czech Republic; [Pitha, Jiri] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague 15006, Czech Republic; [Pitha, Jiri] Charles Univ Prague, Dept Neurol, Fac Med 3, Prague 15006, Czech Republic; [Schutzner, Jan] Charles Univ Prague, Dept Surg 3, Fac Med 1, CR-11636 Prague 1, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague 15006, Czech Republic","Zamecnik, J (reprint author), Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","josef.zamecnik@lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic [IGA MZCR NR/8924-3, VZ FNM 00064203]","The study was supported by the Grant of Ministry of Health of the Czech Republic No. IGA MZCR NR/8924-3 and by the Research Project No. VZ FNM 00064203.",null,35,2,2,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1582-1838",null,null,"J CELL MOL MED","J. Cell. Mol. Med.","AUG",2009,13,"8B",null,null,null,null,2008,2018,null,"10.1111/j.1582-4934.2008.00431.x",null,11,"Cell Biology; Medicine, Research & Experimental","Cell Biology; Research & Experimental Medicine","525CN","WOS:000272190800036"]
[null,null,null,null,"J","Svehlik, M; Zwick, EB; Steinwender, G; Linhart, WE; Schwingenschuh, P; Katschnig, P; Ott, E; Enzinger, C",null,null,null,"Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhardt; Linhart, Wolfgang E.; Schwingenschuh, Petra; Katschnig, Petra; Ott, Erwin; Enzinger, Christian",null,null,"Gait Analysis in Patients With Parkinson's Disease Off Dopaminergic Therapy","ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION",null,null,"English","Article",null,null,null,null,null,"Biomechanics; Levodopa; Neurologic gait disorders; Parkinson Disease; Rehabilitation","BASAL GANGLIA; WALKING; BIOMECHANICS; PARAMETERS","Objective: To compare time-distance, kinematic, and kinetic gait parameters in patients with idiopathic Parkinson's disease (PD) off dopaminergic therapy with a group of healthy control subjects. Design: A group-comparison study. Setting: Gait analysis laboratory. Participants: Patients with PD (n=20) and healthy age-matched controls (n=20). Interventions: Not applicable. Main Outcome Measures: Time-distance, kinematic, and kinetic gait variables. Results: PD patients walked slower with shorter stride-length, comparable cadence, and longer double support times. Kinematics showed a reduction of the range of motion in the hip, knee, and ankle joints. Maximum hip extension and the ankle plantar flexion were significantly reduced. Kinetic gait parameters showed reduced push-off ankle power and lift-off hip power generation. Strong correlations between these important body advancement mechanisms and the walking velocity were observed. Conclusions: In addition to previously described dysfunctional kinematics, abnormal kinetic parameters play an important role in the characterization of gait in PD patients off therapy. Hence, these parameters could be used to document treatment effects of parkinsonian gait disorders.","[Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhardt; Linhart, Wolfgang E.] Med Univ Graz, Dept Paediat Surg, Paediat Orthopaed Unit, A-8036 Graz, Austria; [Schwingenschuh, Petra; Katschnig, Petra; Ott, Erwin] Med Univ Graz, Dept Neurol, A-8036 Graz, Austria; [Svehlik, Martin] Charles Univ Prague, Sch Med 2, Dept Children & Adult Orthopaed & Traumatol, Prague, Czech Republic","Svehlik, M (reprint author), Med Univ Graz, Dept Paediat Surg, Paediat Orthopaed Unit, Auenbruggerpl 34, A-8036 Graz, Austria.","martin.spejlik@seznam.cz","Schwingenschuh, Petra/J-7887-2012",null,null,null,null,28,9,9,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0003-9993",null,null,"ARCH PHYS MED REHAB","Arch. Phys. Med. Rehabil.","NOV",2009,90,11,null,null,null,null,1880,1886,null,"10.1016/j.apmr.2009.06.017",null,7,"Rehabilitation; Sport Sciences","Rehabilitation; Sport Sciences","520XC","WOS:000271881900010"]
[null,null,null,null,"J","Eckschlager, T; Adam, V; Hrabeta, J; Figova, K; Kizek, R",null,null,null,"Eckschlager, Tomas; Adam, Vojtech; Hrabeta, Jan; Figova, Katarina; Kizek, Rene",null,null,"Metallothioneins and Cancer","CURRENT PROTEIN & PEPTIDE SCIENCE",null,null,"English","Review",null,null,null,null,null,"Metallothioneins; cancer marker; cancer cell chemoresistance; detection","CAPILLARY-ZONE-ELECTROPHORESIS; PERFORMANCE LIQUID-CHROMATOGRAPHY; CURRENT STRIPPING CHRONOPOTENTIOMETRY; DIFFERENTIAL-PULSE POLAROGRAPHY; MASS-SPECTROMETRIC DETECTION; BIOINORGANIC SPECIATION ANALYSIS; CURVE RESOLUTION ANALYSIS; MESSENGER-RNA EXPRESSION; MERCURY SATURATION ASSAY; KI-67 ANTIGEN-EXPRESSION","Metallothioneins (MTs) are low molecular, cysteine-rich proteins that have naturally-occurring Zn2+ in both clusters. They may serve as a reservoir of metals for synthesis of apoenzymes and zinc-finger transcription regulators. MTs are also involved with several important proteins e. g. p53, NF-kappa B, PKCl, and GTPase Rab3A. New biological roles for these proteins have been identified including those needed in the carcinogenic process. However, their use as a predictive marker remains controversial. Several reports have disclosed MTs expression as a prognostic factor for tumor progression and drug resistance in a variety of malignancies particularly breast, prostatic, ovarial, head and neck, non-small cell lung cancer, melanoma, and soft tissue sarcoma. The role of MTs as a tumor disease marker or as a cause of resistance in cancer treatment is reviewed and discussed. Moreover, we describe some analytical methods that were developed to detect MTs.","[Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Eckschlager, Tomas; Hrabeta, Jan; Figova, Katarina] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012",null,"Grant Agency of the Czech Academy of Sciences [GA AV IAAA401990701]; Ministry of Education, Youth and Sports [MSM 0021620813]","The financial support from the Grant Agency of the Czech Academy of Sciences (grant no. GA AV IAAA401990701) and from the Ministry of Education, Youth and Sports (grant no. MSM 0021620813) is greatly acknowledged.",null,235,72,75,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","1389-2037","1875-5550",null,"CURR PROTEIN PEPT SC","Curr. Protein Pept. Sci.","AUG",2009,10,4,null,null,null,null,360,375,null,null,null,16,"Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","482VS","WOS:000268918200004"]
[null,null,null,null,"J","Hajek, M; Krsek, P; Dezortova, M; Marusic, P; Zamecnik, J; Kyncl, M; Tomasek, M; Krijtova, H; Komarek, V",null,null,null,"Hajek, Milan; Krsek, Pavel; Dezortova, Monika; Marusic, Petr; Zamecnik, Josef; Kyncl, Martin; Tomasek, Martin; Krijtova, Hana; Komarek, Vladimir",null,null,"H-1 MR spectroscopy in histopathological subgroups of mesial temporal lobe epilepsy","EUROPEAN RADIOLOGY",null,null,"English","Article",null,null,null,null,null,"MR spectroscopy; Temporal lobe epilepsy; Hippocampus; Malformations of cortical development; Treatment outcome","MAGNETIC-RESONANCE-SPECTROSCOPY; HIPPOCAMPAL SCLEROSIS; DUAL PATHOLOGY; LATERALIZATION; LOBECTOMY; SPECTRA; SURGERY; P-31; ABNORMALITIES; DYSFUNCTION","The aim of the study was to analyze the lateralizing value of proton magnetic resonance spectroscopy (H-1 MRS) in histopathologically different subgroups of mesial temporal lobe epilepsies (MTLE) and to correlate results with clinical, MRI and seizure outcome data. A group of 35 patients who underwent resective epilepsy surgery was retrospectively studied. Hippocampal H-1 MR spectra were evaluated. Metabolite concentrations were obtained using LCModel and NAA/Cr, NAA/Cho, NAA/(Cr+Cho), Cho/Cr ratios and coefficients of asymmetry were calculated. MRI correctly lateralized 89% of subjects and H-1 MRS 83%. MRI together with H-1 MRS correctly lateralized 100% of patients. Nineteen subjects had \"classical\" hippocampal sclerosis (HS), whereas the remaining 16 patients had \"mild\" HS. Nineteen patients had histopathologically proven malformation of cortical development (MCD) in the temporal pole; 16 subjects had only HS. No difference in H-1 MRS findings was found between patients in different histopathological subgroups of MTLE. Our results support the hypothesis that H-1 MRS abnormalities do not directly reflect histopathological changes in MTLE patients. Subjects with non-lateralized H-1 MRS abnormalities did not have a worse postoperative seizure outcome. We found no significant impact of contralateral H-1 MRS abnormality on post-surgical seizure outcome.","[Krsek, Pavel; Komarek, Vladimir] Charles Univ Prague, Sch Med 2, Motol Hosp, Dept Pediat Neurol, Prague 15006 5, Czech Republic; [Hajek, Milan; Dezortova, Monika] Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, MR Unit, Prague, Czech Republic; [Marusic, Petr; Tomasek, Martin; Krijtova, Hana] Charles Univ Prague, Sch Med 2, Motol Hosp, Dept Neurol, Prague 15006 5, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Sch Med 2, Motol Hosp, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Kyncl, Martin] Charles Univ Prague, Sch Med 2, Motol Hosp, Dept Radiol, Prague 15006 5, Czech Republic","Krsek, P (reprint author), Charles Univ Prague, Sch Med 2, Motol Hosp, Dept Pediat Neurol, V Uvalu 84, Prague 15006 5, Czech Republic.","pavel.krsek@post.cz",null,null,"GACR [309/02/D076]; IGA [NR/8843-4, 00000064203, MZ0IKEM2005]","Supported by grants GACR no. 309/02/D076 and IGA no. NR/8843-4 and Research Projects nos. 00000064203 and MZ0IKEM2005.",null,41,8,11,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0938-7994",null,null,"EUR RADIOL","Eur. Radiol.","FEB",2009,19,2,null,null,null,null,400,408,null,"10.1007/s00330-008-1156-x",null,9,"Radiology, Nuclear Medicine & Medical Imaging","Radiology, Nuclear Medicine & Medical Imaging","396GA","WOS:000262579000017"]
[null,null,null,null,"J","Kideryova, L; Lacina, L; Dvorankova, B; Stork, J; Cada, Z; Szabo, P; Andre, S; Kaltner, H; Gabius, HJ; Smetana, K",null,null,null,"Kideryova, L.; Lacina, L.; Dvorankova, B.; Stork, J.; Cada, Z.; Szabo, P.; Andre, S.; Kaltner, H.; Gabius, H. -J.; Smetana, K., Jr.",null,null,"Phenotypic characterization of human keratinocytes in coculture reveals differential effects of fibroblasts from benign fibrous histiocytoma (dermatofibroma) as compared to cells from its malignant form and to normal fibroblasts","JOURNAL OF DERMATOLOGICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"Benign fibrous histiocytoma; Fibroblasts; Galectin; Keratin; Nucleostemin","STEM-CELLS; IN-VITRO; OVERLYING DERMATOFIBROMA; STROMAL FIBROBLASTS; MAMMALIAN LECTINS; EPIDERMAL-CELLS; HAIR FOLLICLE; EXPRESSION; CARCINOMA; GALECTIN-1","Background: Benign and malignant fibrous histiocytoma present with a considerable difference concerning cellular organization in their vicinity. Objective: Normally appearing epithelium covers the malignant form in contrast to hyperplastic epidermis for benign tumors. It is an open question as to whether the tumor-associated fibroblasts are capable to affect phenotypic features of normal keratinocytes, prompting this comparative analysis. Methods: Fibroblasts were isolated from benign and malignant fibrous histiocytomas, respectively, and also from normal dermis. The resulting cell populations were thoroughly characterized immunocytochemically using a large panel of antibodies. The three fibroblast preparations were cocultured with normal interfollicular keratinocytes. Their phenotype was characterized for distinct properties including differentiation and proliferation. Results: Fibroblasts prepared from both tumor types were phenotypically practically identical with normal dermal fibroblasts. Their activities on keratinocytes were different. Cells prepared from benign fibrous histiocytoma were capable to effect strong expression of keratin 19 and production of a galectin-1-rich extracellular matrix. Fibroblasts isolated from malignant fibrous histiocytoma led to a phenotype very similar to that when keratinocytes were cocultured with normal dermal fibroblasts. Conclusion: Fibroblasts prepared from benign fibrous histiocytoma were biologically active on keratinocytes in a particular manner. Our results on fibroblast activity are suggested to be relevant for morphologic differences observed in vivo between normal epidermis and epidermis adjacent to the Studied tumor types. (C) 2009 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.","[Lacina, L.; Dvorankova, B.; Cada, Z.; Szabo, P.; Smetana, K., Jr.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Kideryova, L.] Charles Univ Prague, Fac Med 1, Dept Internal Med 1, Prague 12800 2, Czech Republic; [Lacina, L.; Dvorankova, B.; Smetana, K., Jr.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 12800 2, Czech Republic; [Lacina, L.; Stork, J.] Charles Univ Prague, Fac Med 1, Dept Dermatovenereol, Prague 12800 2, Czech Republic; [Cada, Z.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague 12800 2, Czech Republic; [Andre, S.; Kaltner, H.; Gabius, H. -J.] Univ Munich, Fac Vet Med, Inst Physiol Chem, Munich, Germany","Smetana, K (reprint author), Charles Univ Prague, Fac Med 1, Inst Anat, Nemocnice 3, Prague 12800 2, Czech Republic.","Karel.Smetana@lf1.cuni.cz",null,null,"Ministry of Education, Youth and Sports of the Czech Republic [MSM 0021620806, 1M0538]; EC Marie Curie Research Training Network [2005-019561]","Authors are grateful to Mrs. Iva BurdovA for excellent technical assistance. This study was supported by the Ministry of Education, Youth and Sports of the Czech Republic, Project Nos. MSM 0021620806 and 1M0538 as well as an EC Marie Curie Research Training Network (Contract No. 2005-019561).",null,49,2,3,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0923-1811",null,null,"J DERMATOL SCI","J. Dermatol. Sci.","JUL",2009,55,1,null,null,null,null,18,26,null,"10.1016/j.jdermsci.2009.03.009",null,9,"Dermatology","Dermatology","459FJ","WOS:000267086100003"]
[null,null,null,null,"J","Pluta, M; Rob, L; Charvat, M; Chmel, R; Halaska, M; Skapa, P; Robova, H",null,null,null,"Pluta, Marek; Rob, Lukas; Charvat, Martin; Chmel, Roman; Halaska, Michael, Jr.; Skapa, Petr; Robova, Helena",null,null,"Less radical surgery than radical hysterectomy in early stage cervical cancer - A pilot study","GYNECOLOGIC ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"Sentinel lymph node; Early cervical cancer IB1; Laparoscopical lymphadenectomy; Conservative surgery; Parametrectomy; Morbidity","SENTINEL NODE IDENTIFICATION; PARAMETRIAL INVOLVEMENT; PELVIC LYMPHADENECTOMY; SURGICAL-TREATMENT; LYMPH-NODES; IB-IIA; PARAMETRECTOMY; TRACHELECTOMY; DYSFUNCTION; MANAGEMENT","Objective. The purpose of this pilot study was to evaluate the feasibility and safety of a less radical Surgery: laparoscopic lymphadenectomy followed by a simple vaginal hysterectomy in sentinel lymph node (SLN) negative early cervical cancer patients. Treatment-associated morbidity and oncological outcome were evaluated. Patients and methods. From December 2000 to September 2007, 60 patients (50 squamous and 10 adenocarcinoma patients) in stages 3-IA1, 11-IA2 and 46-IB1 with median age of 44.6 years (range 3364 years) were enrolled. Patients were selected based on favorable cervical tumors (IA1 with lymph-vascular space invasion [LVSI], IA2 and IB1 with tumor size less than 20 mm and less than half of stromal invasion). All patients underwent laparoscopic SLN identification using frozen section (FS). Negative SLN patients underwent complete pelvic laparoscopic lymphadenectomy and vaginal hysterectomy. FS positive patients underwent radical hysterectomy with low paraaortic lymphadenectomy. Results. The average number of sentinel nodes per side was 1.4 with detection rate per side of 95%. The average number of removed nodes was 23.2. Five patients (8.3%) were SLN positive. There were two false negative FS results (both were micrometastases in SLN). Median follow-up was 47 months (range 12-92). There were no recurrences in 55 SLN negative patients and in 5 SLN positive patients. Conclusion. Lymphatic mapping and SLN identification improved safety in less radical surgery in early stage cervical cancer. This preliminary study showed that it is both feasible and safe to reduce the radicality of parametrial resection for small tumor volume in SLN negative patients. Results also indicated that treatment-associated morbidity is low. (C) 2009 Elsevier Inc. All rights reserved.","[Pluta, Marek; Rob, Lukas; Charvat, Martin; Chmel, Roman; Halaska, Michael, Jr.; Robova, Helena] Charles Univ Prague, Dept Gynecol & Obstet, Div Oncogynecol, Fac Med 2, Prague 15006 5, Czech Republic; [Skapa, Petr] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 15006 5, Czech Republic","Rob, L (reprint author), Fac Hosp Motol, Dept Gynecol & Obstet, Fac Med 2, Uvalu 84, Prague 15000 5, Czech Republic.","lukas.rob@lfmotol.cuni.cz",null,null,"IGA [MZCR NS99144]","This work is supported by grant IGA MZCR NS99144.",null,30,38,40,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0090-8258",null,null,"GYNECOL ONCOL","Gynecol. Oncol.","MAY",2009,113,2,null,null,null,null,181,184,null,"10.1016/j.ygyno.2009.02.005",null,4,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","436GJ","WOS:000265400400007"]
[null,null,null,null,"J","Erbanova, M; Thumova, M; Huskova, Z; Vaneckova, I; Vanourkova, Z; Mullins, JJ; Kramer, HJ; Burgelova, M; Rakusan, D; Cervenka, L",null,null,null,"Erbanova, Michaela; Thumova, Monika; Huskova, Zuzana; Vaneckova, Ivana; Vanourkova, Zdenka; Mullins, John J.; Kramer, Herbert J.; Buergelova, Marcela; Rakusan, Dan; Cervenka, Ludek",null,null,"Impairment of the autoregulation of renal hemodynamics and of the pressure-natriuresis relationship precedes the development of hypertension in Cyp1a1-Ren-2 transgenic rats","JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"angiotensin II levels; autoregulation; glomerular filtration rate; hypertension; inducible transgenic renin gene rats; renal blood flow; renin-angiotensin system; sodium excretion","RENIN-ANGIOTENSIN SYSTEM; AT(1) RECEPTOR BLOCKADE; ONE-CLIP HYPERTENSION; SALT-SENSITIVE RATS; II-INFUSED RATS; AT(2) RECEPTOR; ARTERIAL-PRESSURE; BLOOD-FLOW; KIDNEY; MICE","Objective The present study was performed to characterize the autoregulatory efficiency of renal blood flow and glomerular filtration rate and the pressure-natriuresis relationship in transgenic rats with inducible angiotensin II (ANG II)-dependent hypertension (Cyp1a1-Ren-2 rats). Methods The renin gene was induced in Cyp1a1-Ren-2 rats through dietary administration of the natural xenobiotic indole-3-carbinol (13C, 0.3%) for 12 and 24 h, respectively. Noninduced rats served as controls. Anesthetized rats were prepared for renal function studies and an aortic clamp was placed above the junction of the left renal artery to regulate the level of renal arterial pressure. Plasma renin activity, ANG II and aldosterone levels were measured at the end of the experiment by radioimmunoassay. Results Administration of 13C resulted in progressive increases in plasma renin activity and plasma and kidney ANG II levels; however, it did not significantly alter aldosterone levels as compared with those in noninduced rats. 13C induction for 12h did not cause significant changes in blood pressure as compared with those in noninduced rats. 13C induction for 24 h elicited a significant rise in blood pressure. Twelve-hour 13C induction caused an impairment of the autoregulatory efficiency of renal blood flow and glomerular filtration rate and of the pressure-natriuresis relationship as compared with that in noninduced rats. In addition, 24 h 13C induction of the renin gene resulted in a marked reduction in renal blood flow and glomerular filtration rate and a further impairment of the pressure-natriuresis mechanism as compared with that in noninduced rats. Conclusion Our findings indicate that an impairment of the pressure-natriuresis mechanism precedes the development of ANG II-dependent hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens 27:575-586 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Erbanova, Michaela; Thumova, Monika; Huskova, Zuzana; Vaneckova, Ivana; Vanourkova, Zdenka; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Erbanova, Michaela; Thumova, Monika; Huskova, Zuzana; Vaneckova, Ivana; Vanourkova, Zdenka; Rakusan, Dan; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Mullins, John J.] Univ Edinburgh, Sch Med, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland; [Kramer, Herbert J.] Univ Bonn, Nephrol Sect, Dept Med, D-5300 Bonn, Germany; [Buergelova, Marcela] Thomayer Teaching Hosp, Dept Nephrol, Transplant Ctr, Inst Clin & Expt Med, Prague, Czech Republic; [Rakusan, Dan] Thomayer Teaching Hosp, Dept Internal Med, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Cervenka, L (reprint author), Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz","Vaneckova, Ivana/B-5543-2012",null,"Czech Republic (GACR) [305/07/0167]; Center for Cardiovascular Research [IM6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Agency of Academy of Science of Czech Republic [. IAA-11-700-701]; German Research Foundation (Deutsche forschungsgemeinschaft) [Kra 433/14-2, 436 TSE 113/50/0-1]","The present study was Supported by grant No. 305/07/0167 awarded to I.V. by the Grant Agency of Czech Republic (GACR). M.E. and Z.H. are partly supported from the Center for Cardiovascular Research (IM6798582302). L.C. is Supported by the institutional financial Support of the Institute for Clinical and Experimental Medicine (MZO 00023001). M.B. is supported by grant No. IAA-11-700-701 awarded to M.B. by the Grant Agency of Academy of Science of Czech Republic (GAAV). H.J. Kramer is Supported by grants from the German Research Foundation (Deutsche forschungsgemeinschaft), Bonn (Kra 433/14-2 and 436 TSE 113/50/0-1).",null,40,12,12,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,null,"J HYPERTENS","J. Hypertens.","MAR",2009,27,3,null,null,null,null,575,586,null,"10.1097/HJH.0b013e32831cbd5a",null,12,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","432QM","WOS:000265149200019"]
[null,null,null,null,"J","Duricova, D; Pedersen, N; Lenicek, M; Hradsky, O; Bronsky, J; Adamcova, M; Elkjaer, M; Andersen, PS; Vitek, L; Larsen, K; Lukas, M; Nevoral, J; Wewer, V; Munkholm, P",null,null,null,"Duricova, D.; Pedersen, N.; Lenicek, M.; Hradsky, O.; Bronsky, J.; Adamcova, M.; Elkjaer, M.; Andersen, P. S.; Vitek, L.; Larsen, K.; Lukas, M.; Nevoral, J.; Wewer, V.; Munkholm, P.",null,null,"Infliximab dependency in children with Crohn's disease","ALIMENTARY PHARMACOLOGY & THERAPEUTICS",null,null,"English","Article",null,null,null,null,null,null,"INFLAMMATORY-BOWEL-DISEASE; EVIDENCE BASED CONSENSUS; MAINTENANCE INFLIXIMAB; PEDIATRIC-PATIENTS; NATURAL-HISTORY; FOLLOW-UP; THERAPY; COHORT; GENE; NOD2/CARD15",null,"[Pedersen, N.; Elkjaer, M.; Munkholm, P.] Univ Copenhagen, Herlev Hosp, Med Sect, Gastrointestinal Unit, DK-2730 Herlev, Denmark; [Lenicek, M.; Vitek, L.] Charles Univ Prague, Inst Clin Biochem, Prague, Czech Republic; [Lenicek, M.; Vitek, L.] Charles Univ Prague, Diagnost Lab, Fac Med 1, Prague, Czech Republic; [Hradsky, O.; Bronsky, J.; Nevoral, J.] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Hradsky, O.; Bronsky, J.; Nevoral, J.] Univ Hosp Motol Prague, Prague, Czech Republic; [Larsen, K.] Univ Copenhagen, Hvidovre Hosp, Dept Stat Unit, DK-2650 Hvidovre, Denmark; [Lukas, M.] Charles Univ Prague, IBD Ctr, ISCARE IVF As, Prague, Czech Republic; [Wewer, V.] Univ Copenhagen, Hvidovre Hosp, Dept Paediat, DK-2650 Hvidovre, Denmark; [Duricova, D.; Vitek, L.] Charles Univ Prague, Dept Internal Med 4, Fac Med 1, Prague, Czech Republic; [Adamcova, M.] Charles Univ Prague, Dept Paediat, Hosp Fac Med 1, Prague, Czech Republic; [Andersen, P. S.] State Serum Inst, Dept Clin Biochem, Copenhagen, Denmark","Munkholm, P (reprint author), Herlev Univ Hosp, Dept Med Gastroenterol, Herlev Ringvej 75, DK-2730 Herlev, Denmark.","pia_munkholm@mail.dk","Vitek, Libor/A-2645-2008",null,null,null,null,37,7,8,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0269-2813",null,null,"ALIMENT PHARM THER","Aliment. Pharmacol. Ther.","APR 1",2009,29,7,null,null,null,null,792,799,null,"10.1111/j.1365-2036.2009.03926.x",null,8,"Gastroenterology & Hepatology; Pharmacology & Pharmacy","Gastroenterology & Hepatology; Pharmacology & Pharmacy","415BI","WOS:000263908900011"]
[null,null,null,null,"J","Mraz, M; Bartlova, M; Lacinova, Z; Michalsky, D; Kasalicky, M; Haluzikova, D; Matoulek, M; Dostalova, I; Humenanska, V; Haluzik, M",null,null,null,"Mraz, M.; Bartlova, M.; Lacinova, Z.; Michalsky, D.; Kasalicky, M.; Haluzikova, D.; Matoulek, M.; Dostalova, I.; Humenanska, V.; Haluzik, M.",null,null,"Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity","CLINICAL ENDOCRINOLOGY",null,null,"English","Article",null,null,null,null,null,null,"BETA-CELL FUNCTION; PPAR-ALPHA; INSULIN-RESISTANCE; METABOLIC SYNDROME; ADIPOSE-TISSUE; FIBROBLAST-GROWTH-FACTOR-21; FGF-21; HOMEOSTASIS; ADIPONECTIN; HORMONES","Objective Fibroblast growth factor-21 (FGF21) is a novel endocrine and paracrine regulator of metabolic homeostasis. The aim of our study was to measure its serum concentrations in patients with obesity, obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C), and to assess the changes of its circulating levels and mRNA expression after dietary and pharmacological interventions. Design We measured biochemical parameters, serum FGF21, adiponectin, leptin and insulin levels by commercial ELISA and RIA kits, and mRNA expression in the liver, subcutaneous and visceral fat by RT PCR in 26 obese patients, 11 T2DM patients and 32 control subjects. The interventions were acute hyperinsulinaemia during isoglycaemic-hyperinsulinaemic clamp, very low calorie diet (VLCD) and 3 months treatment with PPAR-alpha agonist fenofibrate. Results Baseline serum FGF21 levels were significantly higher in both obese and T2DM patients relative to healthy controls. FGF21 levels in obesity did not significantly differ from T2DM group. Both 3 weeks of VLCD and 3 months of fenofibrate treatment significantly increased FGF21 levels. FGF21 mRNA expression in visceral fat was twofold higher in obesity relative to C group, while it did not differ in subcutaneous fat. VLCD significantly increased FGF21 mRNA expression in subcutaneous fat of obesity. 3-h hyperinsulinaemia during the clamp increased FGF21 levels in T2DM but not in C group. Conclusion An increase in FGF21 levels after VLCD and fenofibrate treatment may contribute to positive metabolic effect of these interventions and suggests the possibility of direct positive metabolic effects of FGF21 in humans.","[Mraz, M.; Bartlova, M.; Lacinova, Z.; Matoulek, M.; Dostalova, I.; Haluzik, M.] First Fac Med, Dept Med 3, Prague 12808 2, Czech Republic; [Michalsky, D.; Kasalicky, M.] First Fac Med, Dept Surg, Prague 12808 2, Czech Republic; [Haluzikova, D.] First Fac Med, Dept Sports Med, Prague 12808 2, Czech Republic; Gen Univ Hosp, Prague 12808 2, Czech Republic; [Humenanska, V.] Bio Vendor, Brno, Czech Republic","Haluzik, M (reprint author), First Fac Med, Dept Med 3, U Nemocnice 1, Prague 12808 2, Czech Republic.","mhalu@lf1.cuni.cz",null,null," [MZ0VFN2005];  [IGA 8302-5]","Supported by MZ0VFN2005 and IGA 8302-5 to MH.","Anderlova K, 2007, PHYSIOL RES, V56, P579; Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Chen WW, 2008, EXP CLIN ENDOCR DIAB, V116, P65, DOI 10.1055/s-2007-985148; Dolinkova M, 2008, MOL CELL ENDOCRINOL, V291, P63, DOI 10.1016/j.mce.2008.05.001; Dostalova I, 2008, J CLIN ENDOCR METAB, V93, P3627, DOI 10.1210/jc.2008-0746; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fu XB, 2004, WORLD J GASTROENTERO, V10, P3590; Haluzik M, 2006, CURR OPIN INVESTIG D, V7, P306; Havel PJ, 2002, CURR OPIN LIPIDOL, V13, P51, DOI 10.1097/00041433-200202000-00008; Housa D, 2006, PHYSIOL RES, V55, P233; Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Kharitonenkov A, 2008, BIODRUGS, V22, P37; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kharitonenkov A, 2007, ENDOCRINOLOGY, V148, P774, DOI 10.1210/en.2006-1168; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Lundasen T, 2007, BIOCHEM BIOPH RES CO, V360, P437, DOI 10.1016/j.bbrc.2007.06.068; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Moyers JS, 2007, J CELL PHYSIOL, V210, P1, DOI 10.1002/jep.20847; Muise ES, 2008, MOL PHARMACOL, V74, P403, DOI 10.1124/mol.108.044826; Nishimura T, 2000, BBA-GENE STRUCT EXPR, V1492, P203, DOI 10.1016/S0167-4781(00)00067-1; Tomlinson E, 2002, ENDOCRINOLOGY, V143, P1741, DOI 10.1210/en.143.5.1741; Trujillo ME, 2005, J INTERN MED, V257, P167, DOI 10.1111/j.1365-2796.2004.01426.x; Wente W, 2006, DIABETES, V55, P2470, DOI 10.2337/db05-1435; Zhang X, 2008, DIABETES, V57, P1246, DOI 10.2337/db07-1476; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0",27,57,61,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0300-0664","1365-2265",null,"CLIN ENDOCRINOL","Clin. Endocrinol.","SEP",2009,71,3,null,null,null,null,369,375,null,"10.1111/j.1365-2265.2008.03502.x",null,7,"Endocrinology & Metabolism","Endocrinology & Metabolism","482XN","WOS:000268924000010"]
[null,null,null,null,"J","Tachezy, R; Klozar, J; Rubenstein, L; Smith, E; Salakova, M; Smahelova, J; Ludvikova, V; Rotnaglova, E; Kodet, R; Hamsikova, E",null,null,null,"Tachezy, Ruth; Klozar, Jan; Rubenstein, Linda; Smith, Elaine; Salakova, Martina; Smahelova, Jana; Ludvikova, Viera; Rotnaglova, Elika; Kodet, Roman; Hamsikova, Eva",null,null,"Demographic and Risk Factors in Patients With Head and Neck Tumors","JOURNAL OF MEDICAL VIROLOGY",null,null,"English","Article",null,null,null,null,null,"HPV; PCR; oral cancer; oropharyngeal cancer; antibodies; ELISA","HUMAN-PAPILLOMAVIRUS INFECTION; CERVICAL-CANCER PATIENTS; ORAL-CANCER; FOLLOW-UP; OROPHARYNGEAL CANCER; CARCINOMA PATIENTS; PROGNOSTIC-FACTOR; IMMUNE-RESPONSE; SEXUAL-BEHAVIOR; ANTIBODIES","The association between human papillomavirus (HPV) infection and the development of head and neck cancer has been documented recently. In this study on 86 head and neck cancer patients and 124 controls, data regarding demographics, behavioral risk factors, and risks related to HPV exposure were collected. HPV detection was carried out using polymerase chain reaction in the tumors and in oral exfoliated cells, and HPV typing by a reverse line blot assay specific for 37 HPV types. Sera were tested by an enzyme-linked immunosorbent assay specific for HPV proteins. Head and neck cancer cases report significantly more oral-anal contact (P=0.02) and tobacco and alcohol use than controls (P=0.001; P=0.02, respectively). High-risk HPV DNA was detected in 43% of oral washings of cases and 4% of controls (P<0.0001). The association between the presence of high-risk HPV DNA in oral exfoliated cells and in tumor tissues was statistically significant (adjusted P<0.0001). The prevalence of HPV-specific antibodies was significantly higher in cases than in controls (adjusted P<0.0001). These results provide epidemiological and immunological evidence for HR HPV as a strong risk factor (OR = 44.3, P<0.0001) for head and neck cancer, even after controlling for age, tobacco and alcohol use. The detection of high-risk HPV DNA in oral exfoliated cells and HPV-specific antibodies in serum can be considered as clinically relevant surrogate markers for the presence of a HPV-associated head and neck cancer, with a high sensitivity (83%) and specificity (88%). J. Med. Virol. 81:878-887,2009. (C) 2009 Wiley-Liss, Inc.","[Tachezy, Ruth; Salakova, Martina; Smahelova, Jana; Ludvikova, Viera; Hamsikova, Eva] Inst Hematol & Blood Transfus, Dept Expt Virol, Prague, Czech Republic; [Klozar, Jan; Rotnaglova, Elika] Charles Univ Prague, Fac Med 1, Dept Otolaryngol Head & Neck Surg, Prague, Czech Republic; [Rubenstein, Linda; Smith, Elaine] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; [Kodet, Roman] Charles Univ Prague, Fac Med 2, Inst Pathol & Mol Biol, Prague, Czech Republic","Tachezy, R (reprint author), Inst Haematol & Blood Transfus U Nemocnice 1, Dept Expt Virol, Prague 12820 2, Czech Republic.","rutach@uhkt.cz",null,null,"Ministry of Health, Czech Republic [NR/8852-3, NR/9466-3]; NIH FIRCA [1R03TW001500-01]","Ministry of Health, Czech Republic; Grant numbers: NR/8852-3, NR/9466-3; Grant sponsor: NIH FIRCA; Grant number: 1R03TW001500-01.",null,47,36,39,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","0146-6615",null,null,"J MED VIROL","J. Med. Virol.","MAY",2009,81,5,null,null,null,null,878,887,null,"10.1002/jmv.21470",null,10,"Virology","Virology","429FR","WOS:000264906800016"]
[null,null,null,null,"J","Mayell, SJ; Munck, A; Craig, JV; Sermet, I; Brownlee, KG; Schwarz, MJ; Castellani, C; Southern, KW",null,null,null,"Mayell, S. J.; Munck, A.; Craig, J. V.; Sermet, I.; Brownlee, K. G.; Schwarz, M. J.; Castellani, C.; Southern, K. W.",null,"European Cystic Fibrosis Soc","A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis","Journal of Cystic Fibrosis",null,null,"English","Article",null,null,null,null,null,"Cystic fibrosis; Neonatal screening; Management; Sweat test; Gene analysis","IMMUNOREACTIVE TRYPSINOGEN; MUTATION ANALYSIS","Screening newborns for cystic fibrosis (CF) is considered to be an ethical undertaking in regions with a significant incidence of the condition. Current screening protocols result in recognition of infants with an equivocal diagnosis. A survey of European practice suggested inconsistencies in the evaluation and management of these infants. We have undertaken a consensus process using a modified Delphi method. This has enabled input of CF specialists from a wide geographical area to a rigorous process that has provided a clear pathway to a consensus statement. A core group produced 21 statements, which were modified over a series of three rounds (including a meeting arranged at the European CF Conference). A final document of 19 statements was produced, all of which achieved a satisfactory level of consensus. The statements cover four themes; sweat testing, further assessments and investigations, review arrangements and database. This consensus document will provide guidance to CF specialists with established screening programmes and those who are in the process of implementing newborn screening in their region. Crown Copyright (C) 2008 Published by Elsevier B.V on behalf of European Cystic Fibrosis Society. All rights reserved.","[Southern, K. W.] Univ Liverpool, Royal Liverpool Childrens Hosp, Inst Child Hlth, Liverpool L12 2AP, Merseyside, England; [Munck, A.] Hop Robert Debre, AP HP, F-75019 Paris, France; [Sermet, I.] Hop Necker Enfants Malad, Paris, France; [Munck, A.] AFDPHE, Paris, France; [Brownlee, K. G.] St James Univ Hosp, Reg CF Unit, Leeds LS9 7TF, W Yorkshire, England; [Schwarz, M. J.] St Marys Hosp, Reg Mol Genet Serv, Manchester M13 0JH, Lancs, England; [Castellani, C.] Azienda Osped, Cyst Fibrosis Ctr, Verona, Italy","Southern, KW (reprint author), Univ Liverpool, Royal Liverpool Childrens Hosp, Inst Child Hlth, Eaton Rd, Liverpool L12 2AP, Merseyside, England.","kwsouth@liv.ac.uk",null,null,null,null,"Castellani C, 2005, AM J MED GENET A, V135A, P142, DOI 10.1002/ajmg.a.30470; Castellani C, 2008, J CYST FIBROS, V7, P179, DOI 10.1016/j.jcf.2008.03.009; CROSSLEY JR, 1979, LANCET, V1, P472; Cuppens H, 1998, J CLIN INVEST, V101, P487, DOI 10.1172/JCI639; Eng W, 2005, PEDIATR PULM, V40, P64, DOI 10.1002/ppul.20235; FARRELL MP, 2008, J CYST FIBROS, V7, P262; Groman JD, 2004, AM J HUM GENET, V74, P176, DOI 10.1086/381001; LeGrys VA, 2007, J PEDIATR, V151, P85, DOI 10.1016/j.jpeds.2007.03.002; Massie RJ, 2000, J PEDIATR, V137, P214, DOI 10.1067/mpd.2000.107162; MERELLE ME, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001402; Murphy MK, 1998, HEALTH TECHNOL ASSES, V2, pi; Parad RB, 2005, J PEDIATR, V147, pS69, DOI 10.1016/j.jpeds.2005.08.015; Peckham D, 2006, J CYST FIBROS, V5, P63, DOI 10.1016/j.jcf2005.09.009; Roussey M, 2007, J INHERIT METAB DIS, V30, P613, DOI 10.1007/s10545-007-0633-8; Southern KW, 2007, J CYST FIBROS, V6, P57, DOI 10.1016/j.jcf.2006.05.008; Southern KW, 2004, J ROY SOC MED, V97, P57",16,38,38,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","JAN",2009,8,1,null,null,null,null,71,78,null,"10.1016/j.jcf.2008.09.005",null,8,"Respiratory System","Respiratory System","395WI","WOS:000262553800014"]
[null,null,null,null,"J","Morfin, F; Dupuis-Girod, S; Frobert, E; Mundweiler, S; Carrington, D; Sedlacek, P; Bierings, M; Cetkovsky, P; Kroes, ACM; van Tol, MJD; Thouvenot, D",null,null,null,"Morfin, Florence; Dupuis-Girod, Sophie; Frobert, Emilie; Mundweiler, Stephanie; Carrington, David; Sedlacek, Petr; Bierings, Marc; Cetkovsky, Petr; Kroes, Aloys C. M.; van Tol, Maarten J. D.; Thouvenot, Danielle",null,null,"Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone","ANTIVIRAL THERAPY",null,null,"English","Article",null,null,null,null,null,null,"BONE-MARROW-TRANSPLANTATION; SPECTRUM ANTIVIRAL ACTIVITY; HEMORRHAGIC CYSTITIS; INFECTIONS; RECIPIENTS; THERAPY; REPLICATION; DRUGS; 1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE; NUCLEOSIDE","Background: We have previously reported that human adenovirus (HAdV) reference strains clearly show species-dependent resistance to ribavirin, whereas different species of HAdV are equally sensitive to cidofovir. All the serotypes tested were susceptible to cidofovir, whereas only serotypes from species C were sensitive to ribavirin. Here, we aimed to extend these investigations to clinical isolates. Methods: In vitro, we tested 126 isolates obtained from 65 patients included in a European survey of HAdV infection. Results: Among the 126 isolates tested, all presented cidofovir 50% inhibitory concentration (IC(50)) in the same range as the HAdV 5 reference strain. Regarding ribavirin, all isolates from species C (79 tested) showed an IC(50) comparable with previously reported results for reference strains; however, 24/32, 2/6 and 3/3 tested isolates from species A, B and D, respectively, were shown to have a ribavirin IC(50) comparable with the HAdV 5 reference strain (species Q, contrary to previous observations for reference strains of the same species. Among patients who were treated with cidofovir for disseminated HAdV infection, >= 4 sequential isolates could be obtained from 9 patients; no variation in cidofovir susceptibility could be detected. Conclusions: Cidofovir is active in vitro in all HAdV clinical isolates. Ribavirin was revealed to be active on most HAdV isolates from species A, B and D, and in all isolates from species C. Finally, no resistance to cidofovir became apparent in sequential isolates obtained from treated patients.","[Morfin, Florence; Frobert, Emilie; Mundweiler, Stephanie; Thouvenot, Danielle] Univ Lyon 1, Lab Virol & Pathogenese Humaine, CNRS, FRE 3011, F-69365 Lyon, France; [Morfin, Florence; Mundweiler, Stephanie; Thouvenot, Danielle] Hosp Civils Lyon, Ctr Biol & Pathol Est, Virol Lab, Lyon, France; [Dupuis-Girod, Sophie] Hosp Civils Lyon, Hop Debrousse, Hematol & Bone Marrow Transplantat Unit, Lyon, France; [Dupuis-Girod, Sophie] Hosp Civils Lyon, Genet Unit, Hop Hotel Dieu, Lyon, France; [Carrington, David] Reg Virus Lab, Bristol, Avon, England; [Sedlacek, Petr] Motol Univ Hosp, Dept Pediat, Prague, Czech Republic; [Bierings, Marc] Wilhelmina Kinderziekenhuis Hematol, Utrecht, Netherlands; [Cetkovsky, Petr] UHKT, Inst Hematol & Blood Transfus, Prague, Czech Republic; [Kroes, Aloys C. M.] Leiden Univ, Med Ctr, Dept Med Microbiol, Leiden, Netherlands; [van Tol, Maarten J. D.] Leiden Univ, Med Ctr, Dept Pediat, Leiden, Netherlands","Morfin, F (reprint author), Univ Lyon 1, Lab Virol & Pathogenese Humaine, CNRS, FRE 3011, F-69365 Lyon, France.","florence.morfin-sherpa@chu-lyon.fr",null,null,"European funding EC [QLK2-CT-2002-01432]","This work has received European funding (EC project QLK2-CT-2002-01432).",null,33,15,16,"INT MEDICAL PRESS LTD","LONDON","2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND","1359-6535",null,null,"ANTIVIR THER","Antivir. Ther.",null,2009,14,1,null,null,null,null,55,61,null,null,null,7,"Infectious Diseases; Pharmacology & Pharmacy; Virology","Infectious Diseases; Pharmacology & Pharmacy; Virology","413RC","WOS:000263809200006"]
[null,null,null,null,"J","Gimpel, C; Wuhl, E; Arbeiter, K; Drozdz, D; Trivelli, A; Charbit, M; Gellermann, J; Dusek, J; Jankauskiene, A; Emre, S; Schaefer, F",null,null,null,"Gimpel, Charlotte; Wuehl, Elke; Arbeiter, Klaus; Drozdz, Dorota; Trivelli, Antonella; Charbit, Marina; Gellermann, Jutta; Dusek, Jiri; Jankauskiene, Augustina; Emre, Sevinc; Schaefer, Franz",null,"ESCAPE Trial Grp","Superior consistency of ambulatory blood pressure monitoring in children: implications for clinical trials","JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"adolescents; ambulatory blood pressure measurement; antihypertensive drugs; children; clinical trial; hypertension","CHRONIC-RENAL-FAILURE; MASKED HYPERTENSION; MASS INDEX; ADOLESCENTS; HOME; EFFICACY; OFFICE; REPRODUCIBILITY; INFANTS; HEALTHY","Background Casual office blood pressure (CBP) measurements are still standard in antihypertensive drug trials. In pediatric hypertensive trials, ethical considerations, very low disease prevalence and the marked impact of white-coat hypertension create the need for very sensitive and reproducible techniques of BP assessment. We hypothesized that ambulatory BP monitoring (ABPM) may identify treatment effects more sensitively than CBP and thereby reduce sample sizes required in pediatric antihypertensive trials. Methods Standard deviations (SDs) were used to assess population variability of CBP and ABPM at baseline and after 6 months standardized antihypertensive treatment from a trial investigating the BP-lowering effect of ramipril in children with chronic kidney disease. Results In 157 hypertensive children, ramipril had a similar mean BP-lowering effect on clinic and ambulatory 24-h BP for systolic (-10 vs. -11 mm Hg, P = NS) and diastolic values (-9 vs. -11 mm Hg, P = NS). However, the SDs of the CBP responses were up to 39% larger than those of ABPM (SBP 15.5 vs. 9.4; DBP 13.8 vs. 8.8; both P< 0.0001). Using power analysis, we demonstrate that, depending on the magnitude of the expected antihypertensive effect and trial design, the utilization of ABPM in antihypertensive drug efficacy studies allows reduction of sample sizes by 57-75%. This reduction of cohort size with ABPM is substantially greater than previously observed for adults. Conclusion The primary use of ABPM can substantially reduce the number of children put at potential risk in blinded antihypertensive drug trials by up to three quarters. J Hypertens 27:1568-1574 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.","[Gimpel, Charlotte; Wuehl, Elke; Schaefer, Franz] Univ Heidelberg Hosp, Div Pediat Nephrol, Ctr Pediat & Adolescent Med, D-69120 Heidelberg, Germany; [Arbeiter, Klaus] Univ Childrens Hosp, Vienna, Austria; [Drozdz, Dorota] Jagiellonian Univ, Dialysis Unit, Polish Amer Childrens Hosp, Coll Med, Krakow, Poland; [Trivelli, Antonella] G Gaslini Inst Children, Genoa, Italy; [Charbit, Marina] Hop Necker Enfants Malad, Paris, France; [Gellermann, Jutta] Univ Childrens Hosp, Charite, Berlin, Germany; [Dusek, Jiri] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Jankauskiene, Augustina] Vilnius State Univ, Childrens Hosp, Vilnius, Lithuania; [Emre, Sevinc] Univ Istanbul, Istanbul Fac Med, Istanbul, Turkey","Schaefer, F (reprint author), Univ Heidelberg Hosp, Div Pediat Nephrol, Ctr Pediat & Adolescent Med, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.","franz.schaefer@med.uni-heidelberg.de","Schaefer, Franz/G-4365-2010; Litwin, Mieczyslaw/C-3868-2012",null,"European Commission [QLG1-CT- 2002-00908]; Boehringer Ingelheim Stiftung; Baxter Extramural; Aventis Pharma","Support for this study was obtained from the (5th Framework Programme (QLG1-CT- 2002-00908), the Boehringer Ingelheim Stiftung, the Baxter Extramural Grant Program and Aventis Pharma.",null,33,15,15,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,null,"J HYPERTENS","J. Hypertens.","AUG",2009,27,8,null,null,null,null,1568,1574,null,"10.1097/HJH.0b013e32832cb2a8",null,7,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","481JD","WOS:000268803900011"]
[null,null,null,null,"J","Kanovsky, P; Bares, M; Severa, S; Richardson, A",null,null,null,"Kanovsky, Petr; Bares, Martin; Severa, Stanislav; Richardson, Alan",null,"Dysport Paediat Limb Spasticity St","Long-term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy","DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY",null,null,"English","Article",null,null,null,null,null,null,"DOUBLE-BLIND; GAIT; CONTRACTURES; MANAGEMENT; SURGERY","In this study, we compared the long-term efficacy and tolerability of two dosage regimens of the potent botulinum toxin type A (BoNT-A; Dysport; Ipsen Ltd, Slough, UK) in children with cerebral palsy (CP) and lower-limb spasticity. Children aged 1 to 8 years with diplegic CP who were able to walk (aided or unaided) were randomized (1:1) to 30 LD(50) units/kg total body weight of BoNT-A (injected into gastrocnemius muscles) every 4 months or once yearly for 2 years in this multicentre, assessor-blinded, parallel-group study. In the 4-monthly group (n=110, 39 males, 71 females), mean age was 3 years 8 months (SD 1y 6mo, range 1-8y). In the yearly group (n=104, 47 males, 57 females), mean age was 4 years 4 months (SD 1y 6mo, range 2-8y). Both treatment groups had similar baseline Gross Motor Function Measure scores. At month 28 (primary endpoint; intention-to-treat group), median maximum passive ankle dorsiflexion was 12.00 degrees in the 4-monthly and 11.00 degrees in the yearly group. Between-group difference of 1.67 degrees was not statistically significant (p=0.055). Other efficacy endpoints showed no significant difference between the regimens. The results of the study do not allow a clear conclusion of the preferred injection regimen.","[Kanovsky, Petr; Bares, Martin] Masaryk Univ, St Anne Univ Hosp, Dept Neurol 1, Brno, Czech Republic; [Severa, Stanislav] Reg Hosp, Dept Child Neurol, Nove Mesto Na Morave, Czech Republic; [Richardson, Alan] Ipsen Ltd, Slough, Berks, England","Kanovsky, P (reprint author), Palacky Univ, Univ Hosp, Dept Neurol, Ip Pavlova 6, CZ-77520 Olomouc, Czech Republic.","petr.kanovsky@fnol.cz","Bares, Martin/E-3700-2012",null,null,null,"ALBRIGHT AL, 1995, CNS DRUGS, V4, P17, DOI 10.2165/00023210-199504010-00003; BAKER R, 2000, GAIT POSTURE, V12, P64; Baker R, 2002, DEV MED CHILD NEUROL, V44, P666; Barry MJ, 1996, J CHILD NEUROL, V11, pS51; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; Boyd R, 1997, EUR J NEUROL, V4, pS15; COSGROVE AP, 1994, DEV MED CHILD NEUROL, V36, P379; Gage JR, 1991, CLIN DEV MED; Gooch JL, 2004, ARCH PHYS MED REHAB, V85, P1121, DOI 10.1016/j.apmr.2003.09.032; Graham HK, 2000, GAIT POSTURE, V11, P67, DOI 10.1016/S0966-6362(99)00054-5; HAGBERG B, 1993, RECENT ADV PAEDIATRI, V11, P67; Hagglund G, 2005, J PEDIATR ORTHOP B, V14, P269; HERRMANN J, 2000, ANN M AM AC CER PALS; Johnson DC, 1997, J PEDIATR ORTHOPED, V17, P392, DOI 10.1097/00004694-199705000-00022; Kanovsky P, 2004, CESK SLOV NEUROL N, V67, P16; Kessler KR, 1999, J NEUROL, V246, P265, DOI 10.1007/s004150050345; Mall V, 2006, DEV MED CHILD NEUROL, V48, P10, DOI 10.1017/S0012162206000041; Molenaers G, 2006, J BONE JOINT SURG AM, V88A, P161, DOI 10.2106/JBJS.C.01497; Molenberghs G, 2007, J ROY STAT SOC A STA, V170, P861, DOI 10.1111/j.1467-985X.2007.00504.x; Morton RE, 2006, DEV MED CHILD NEUROL, V48, P555, DOI 10.1017/S0012162206001174; Morton RE, 2004, ARCH DIS CHILD, V89, P1133, DOI 10.1136/adc.2003.044560; NORLIN R, 1986, J PEDIATR ORTHOPED, V6, P674; Ruiz Francis J, 2004, Eur J Health Econ, V5, P227, DOI 10.1007/s10198-004-0224-7; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.2307/2335876; Ubhi T, 2000, ARCH DIS CHILD, V83, P481, DOI 10.1136/adc.83.6.481; Watkins B, 1995, PEDIAT PHYS THER, V7, P3; Young R R, 1994, Neurology, V44, pS12",27,11,14,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0012-1622",null,null,"DEV MED CHILD NEUROL","Dev. Med. Child Neurol.","JUN",2009,51,6,null,null,null,null,436,445,null,"10.1111/j.1469-8749.2008.03264.x",null,10,"Clinical Neurology; Pediatrics","Neurosciences & Neurology; Pediatrics","443TS","WOS:000265934300007"]
[null,null,null,null,"J","Dhir, V; Reisch, N; Bleicken, CM; Lebl, J; Kamrath, C; Schwarz, HP; Grotzinger, J; Sippell, WG; Riepe, FG; Arlt, W; Krone, N",null,null,null,"Dhir, Vivek; Reisch, Nicole; Bleicken, Caroline M.; Lebl, Jan; Kamrath, Clemens; Schwarz, Hans-Peter; Groetzinger, Joachim; Sippell, Wolfgang G.; Riepe, Felix G.; Arlt, Wiebke; Krone, Nils",null,null,"Steroid 17 alpha-Hydroxylase Deficiency: Functional Characterization of Four Mutations (A174E, V178D, R440C, L465P) in the CYP17A1 Gene","JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM",null,null,"English","Article",null,null,null,null,null,null,"GENOTYPE-PHENOTYPE CORRELATIONS; ISOLATED 17,20-LYASE DEFICIENCY; CONGENITAL ADRENAL-HYPERPLASIA; DIFFERENTIAL INHIBITION; P450 OXIDOREDUCTASE; CYTOCHROME P450C17; POINT MUTATION; IDENTIFICATION; ALDOSTERONE; FEMALE","Context: Steroid 17 alpha-hydroxylase (CYP17A1, alias P450c17) deficiency (17OHD) is a rare form of congenital adrenal hyperplasia. The CYP17A1 enzyme catalyzes two distinct reactions, 17 alpha-hydroxylase and 17,20-lyase activities. Objective: The aim of the study was to analyze the structural and functional consequences of three novel (A174E, V178D, and L465P) and one previously reported (R440C) CYP17A1 mutation found in three patients clinically and biochemically presenting with 17OHD. Patients and Methods: Two patients suffering from 46, XY disordered sex development presented at ages 5.5 and 8.8 yr, respectively, with tall stature and hypertension. Mutation analysis revealed compound heterozygous CYP17A1 mutations (A174E/K388X; V178D/R440C). The third patient (46, XX) presented with primary amenorrhea and hypertension at age 15 yr. She was homozygous for the novel L465P mutation. Functional studies employing a yeast microsomal expression system compared wild-type and mutant CYP17A1 both with regard to 17 alpha-hydroxylase and 17,20-lyase activity. Mutants were examined in a computational three-dimensional model of the CYP17A1 protein. Results: The activity assays showed that all three mutants retain only 0-7% of both 17 alpha-hydroxylase and 17,20-lyase activity relative to CYP17A1 wild-type activity, corresponding to the in vivo situation. Enzyme kinetic studies proved the impairment of both reactions, respectively. Computer-based three-dimensional model analysis of CYP17A1 using CYP2B4 as template showed that three of the mutations had no direct effect on the active center, whereas one affects the heme coordination. Conclusion: The functional studies revealed that the described missense mutations result in severe 17OHD. Our data are important to predict the phenotypic expressions and provide important information for patient management and genetic counseling. (J Clin Endocrinol Metab 94: 3058-3064, 2009)","[Krone, Nils] Univ Birmingham, Ctr Endocrinol Diabet & Metab, Sch Clin & Expt Med, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England; [Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 11000, Czech Republic; [Kamrath, Clemens] Zentrum Kinderheilkunde I, Zentrum Kinder & Jugendmed, D-60596 Frankfurt, Germany; [Schwarz, Hans-Peter] Univ Hosp Munich, von Haunersches Kinderspital, Dept Endocrinol, D-80337 Munich, Germany; [Groetzinger, Joachim] Univ Kiel, Inst Biochem, D-24118 Kiel, Germany; [Sippell, Wolfgang G.; Riepe, Felix G.] Univ Hosp Schleswig Holstein, Dept Pediat, Div Pediat Endocrinol & Diabet, D-24105 Kiel, Germany","Krone, N (reprint author), Univ Birmingham, Ctr Endocrinol Diabet & Metab, Sch Clin & Expt Med, Inst Biomed Res, Wolfson Dr, Birmingham B15 2TT, W Midlands, England.","n.p.krone@bham.ac.uk","Arlt, Wiebke/B-6310-2009","Arlt, Wiebke/0000-0001-5106-9719","Deutsche Forschungsgemeinschaft [AL203-9, KR 3363/1-1]; European Community's Seventh Framework Program [PIEFGA2008- 221058]; Medical Research Council UK [G116/172]; Wellcome Trust [GR079865MA]","This work was supported by the Deutsche Forschungsgemeinschaft (Grant AL203-9 to W. A.; Grant KR 3363/1-1 to N. K.), the European Community's Seventh Framework Program (Marie Curie Intra-European Fellowship for Career Development under grant agreement PIEFGA2008- 221058 to N. R.), the Medical Research Council UK (Senior Clinical Fellowship G116/172 to W. A.), and the Wellcome Trust (Clinician Scientist Fellowship GR079865MA to N. K.).",null,33,10,10,"ENDOCRINE SOC","CHEVY CHASE","8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA","0021-972X","1945-7197",null,"J CLIN ENDOCR METAB","J. Clin. Endocrinol. Metab.","AUG",2009,94,8,null,null,null,null,3058,3064,null,"10.1210/jc.2009-0172",null,7,"Endocrinology & Metabolism","Endocrinology & Metabolism","479UW","WOS:000268687700058"]
[null,null,null,null,"J","Sobotkova, A; Masova-Chrastinova, L; Suttnar, J; Stikarova, J; Majek, P; Reicheltova, Z; Kotlin, R; Weisel, JW; Maly, M; Dyr, JE",null,null,null,"Sobotkova, Alzbeta; Masova-Chrastinova, Leona; Suttnar, Jiri; Stikarova, Jana; Majek, Pavel; Reicheltova, Zuzana; Kotlin, Roman; Weisel, John W.; Maly, Martin; Dyr, Jan E.",null,null,"Antioxidants change platelet responses to various stimulating events","FREE RADICAL BIOLOGY AND MEDICINE",null,null,"English","Article",null,null,null,null,null,"Platelet; Adhesion; Aggregation; Resveratrol; Trolox; Free radicals","PERFORMANCE LIQUID-CHROMATOGRAPHY; BLOOD-PLATELETS; VITAMIN-E; HYDROGEN-PEROXIDE; WHOLE-BLOOD; DIABETIC-PATIENTS; FLOW CONDITIONS; AGGREGATION; RESVERATROL; ACTIVATION","The role of platelets in hemostasis may be influenced by alteration of the platelet redox state-the presence of antioxidants and the formation of reactive oxygen and nitrogen species. We investigated the effects of two antioxidants, resveratrol and trolox, on platelet activation. Trolox and resveratrol inhibited aggregation of washed platelets and platelet-rich plasma activated by ADP, collagen, and thrombin receptor-activating peptide. Resveratrol was a more effective agent in reducing platelet static and dynamic adhesion in comparison with trolox. The antioxidant capacity of resveratrol was, however, the same as that of trolox. After incubation of platelets with antioxidants, the resveratrol intraplatelet concentration was about five times lower than the intracellular concentration of trolox. Although both antioxidants comparably lowered hydroxyl radical and malondialdehyde production in platelets stimulated with collagen, TxB(2) levels were decreased by resveratrol much more effectively than by trolox. Cyclooxygenase I was inhibited by resveratrol and not by trolox. Our data indicate that antioxidants, apart from nonspecific redox or radical-quenching mechanisms, inhibit platelet activation also by specific interaction with target proteins. The results also show the importance Of Studying platelet activation under conditions of real blood flow in contact with reactive surfaces, e.g., using dynamic adhesion experiments. (C) 2009 Elsevier Inc. All rights reserved.","[Sobotkova, Alzbeta; Masova-Chrastinova, Leona; Suttnar, Jiri; Stikarova, Jana; Majek, Pavel; Reicheltova, Zuzana; Kotlin, Roman; Dyr, Jan E.] Inst Hematol & Blood Transfus, Prague 12800 2, Czech Republic; [Weisel, John W.] Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; [Maly, Martin] Motol Univ Hosp, Dept Cardiol, Prague 15006 5, Czech Republic","Masova-Chrastinova, L (reprint author), Inst Hematol & Blood Transfus, U Nemocnice 1, Prague 12800 2, Czech Republic.","leona.chrastinova@uhkt.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health, Czech Republic [NS10633-3/2009, MZ 02373601]; Academy of Sciences, Czech Republic [KAN200670701]","This study was supported by Grants NS10633-3/2009 and MZ 02373601 from the Ministry of Health, Czech Republic, and by Grant KAN200670701 from the Academy of Sciences, Czech Republic.",null,43,13,13,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0891-5849",null,null,"FREE RADICAL BIO MED","Free Radic. Biol. Med.","DEC 15",2009,47,12,null,null,null,null,1707,1714,null,"10.1016/j.freeradbiomed.2009.09.015",null,8,"Biochemistry & Molecular Biology; Endocrinology & Metabolism","Biochemistry & Molecular Biology; Endocrinology & Metabolism","528II","WOS:000272436900002"]
[null,null,null,null,"J","Pinskerova, V; Samuelson, KM; Stammers, J; Maruthainar, K; Sosna, A; Freeman, MAR",null,null,null,"Pinskerova, V.; Samuelson, K. M.; Stammers, J.; Maruthainar, K.; Sosna, A.; Freeman, M. A. R.",null,null,"The knee in full flexion AN ANATOMICAL STUDY","JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME",null,null,"English","Article",null,null,null,null,null,null,"LIVING KNEE; MOVEMENT; KINEMATICS; JOINT; MRI","There has been only one limited report dating from 1941 using dissection which has described the tibiofemoral joint between 120 degrees and 160 degrees of flexion despite the relevance of this arc to total knee replacement. We now provide a full description having examined one living and eight cadaver knees using MRI, dissection and previously published cryosections in one knee. In the range of flexion from 120 degrees to 160 degrees the flexion facet centre of the medial femoral condyle moves back 5 mm and rises up on to the posterior horn of the medial meniscus. At 160 degrees the posterior horn is compressed in a synovial recess between the femoral cortex and the tibia. This limits flexion. The lateral femoral condyle also rolls back with the posterior horn of the lateral meniscus moving with the condyle. Both move down over the posterior tibia at 160 degrees of flexion. Neither the events between 120 degrees and 160 degrees nor the anatomy at 160 degrees could result from a continuation of the kinematics up to 120 degrees. Therefore hyperflexion is a separate arc. The anatomical and functional features of this arc suggest that it would be difficult to design an implant for total knee replacement giving physiological movement from 0 degrees to 160 degrees.","[Pinskerova, V.; Sosna, A.; Freeman, M. A. R.] Charles Univ Prague, Orthopaed Clin 1, Fac Hosp Motol, Prague 5, Czech Republic","Maruthainar, K (reprint author), Royal Natl Orthopaed & Royal Free Hosp Rotat, Dept Trauma & Orthopaed, Ctr Biomed Engn, Brockley Hill, Stanmore HA7 4LP, Middx, England.","kunalan@gmail.com",null,null,null,null,null,14,10,10,"BRITISH EDITORIAL SOC BONE JOINT SURGERY","LONDON","22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND","0301-620X",null,null,"J BONE JOINT SURG BR","J. Bone Joint Surg.-Br. Vol.","JUN",2009,"91B",6,null,null,null,null,830,834,null,"10.1302/0301-620X.91B6.22319",null,5,"Orthopedics; Surgery","Orthopedics; Surgery","458PF","WOS:000267035300023"]
[null,null,null,null,"J","Sochorova, K; Budinsky, V; Rozkova, D; Tobiasova, Z; Dusilova-Sulkova, S; Spisek, R; Bartunkova, J",null,null,null,"Sochorova, Klara; Budinsky, Vit; Rozkova, Daniela; Tobiasova, Zuzana; Dusilova-Sulkova, Sylvie; Spisek, Radek; Bartunkova, Jirina",null,null,"Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells","CLINICAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Immunomodulatory effect; Vitamin D; VDR activators; Paricalcitol; Calcitriol; Dendritic cell; Chronic kidney disease","VITAMIN-D-RECEPTOR; CHRONIC KIDNEY-DISEASE; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; SECONDARY HYPERPARATHYROIDISM; UREMIC RATS; EXPRESSION; IMMUNITY; ATHEROSCLEROSIS; DIFFERENTIATION; CALCIFICATION","Paricalcitol (19-nor-1,25/OH(2)/D(2)), a second generation vitamin D receptor (VDR) activator, is a synthetic analogue of vitamin D3. In contrast to calcitriol, paricalcitol has a reduced effect on intestinal calcium resorption thus avoiding undesirable hypercalcemia. Information about immunomodulatory activity of paricalcitol is scarce. In this study we show that, in all investigated aspects, paricalcitol retains significant immunomodulatory activity, comparable to calcitriol. Both VDR agonists impaired differentiation of immature dendritic cells (DCs) from monocytes. The presence of VDR agonists during DC differentiation abolished their capacity to be activated and, despite potent Toll-like receptor mediated stimulation, VDR agonist-treated DCs remained in the immature state. In accordance with these findings, VDR-treated DCs produced no bioactive IL-12 and had a significantly decreased capacity to induce antigen-specific Tcells while the capacity to induce functional Tregs remained unchanged when compared to control DCs. As DCs and Tcells play an important role in the pathogenesis of atherosclerosis, in end-stage renal disease patients, paricalcitol should be a VDR agonist of choice for the reduction of the risk of atherosclerosis due to its immunomodulatory effect proven in this study and known limited hypercalcemic effect. The immunomodulatory potency of paricalcitol makes it a drug of interest in the therapy of chronic immune-mediated inflammatory diseases. (C) 2009 Elsevier Inc. All rights reserved.","[Sochorova, Klara; Budinsky, Vit; Rozkova, Daniela; Tobiasova, Zuzana; Spisek, Radek; Bartunkova, Jirina] Charles Univ Prague, Inst Immunol, Fac Med 2, Prague 15006, Czech Republic; [Sochorova, Klara; Budinsky, Vit; Rozkova, Daniela; Tobiasova, Zuzana; Spisek, Radek; Bartunkova, Jirina] Univ Hosp Motol, Prague 15006, Czech Republic; [Dusilova-Sulkova, Sylvie] Charles Univ Prague, Dept Gerontol & Metab, Fac Med, Prague 15006, Czech Republic; [Dusilova-Sulkova, Sylvie] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic","Bartunkova, J (reprint author), Charles Univ Prague, Inst Immunol, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","jirina.bartunkova@lfmotol.cuni.cz","Spisek, Radek/E-6724-2011",null,"The Czech Ministry of Education [MSM 0021620812, MSM 0021620819]; Charles University [GAUK 7588/2007]","Supported by research grants MSM 0021620812 and MSM 0021620819 from The Czech Ministry of Education and GAUK 7588/2007 from Charles University.",null,32,20,23,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1521-6616",null,null,"CLIN IMMUNOL","Clin. Immunol.","OCT",2009,133,1,null,null,null,null,69,77,null,"10.1016/j.clim.2009.06.011",null,9,"Immunology","Immunology","500IN","WOS:000270292400008"]
[null,null,null,null,"J","Turnovcova, K; Ruzickova, K; Vanecek, V; Sykova, E; Jendelova, P",null,null,null,"Turnovcova, Karolina; Ruzickova, Katerina; Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla",null,null,"Properties and growth of human bone marrow mesenchymal stromal cells cultivated in different media","CYTOTHERAPY",null,null,"English","Article",null,null,null,null,null,"cell cycle; cell differentiation; cell-surface antigens; clinical trials; colony-forming units; population doubling time","FETAL CALF SERUM; IN-VITRO EXPANSION; STEM-CELLS; ANIMAL SERUM; THERAPY; ANTIBODIES; PROLIFERATION; DETERMINANT; SUBSTITUTE; EXPRESSION","Background aims Human mesenchymal stromal cells (hMSC) are a promising tool for future clinical application, but their use requires rapid cell expansion in media suitable for clinical use. Therefore, we tested the influence of several culture media on colony formation, population doubling (PD) time, cell cycle and surface marker expression. Methods hMSC isolated from human bone marrow (BM) obtained from healthy donors were seeded and expanded in different culture media: alpha-minimum essential medium (MEM) supplemented with 2.5%, 5%, 10% or 20% fetal bovine serum (FBS), 5% or 10% human cord blood serum (hCBS), 5% or 10% human blood serum from AB adult donors (hABS), or mesenchymal stem cell growth medium (MSCGM (TM)). The number, diameter and total area of the colonies formed and PD time were determined, and the cell cycle and 16 surface markers were analyzed. Results Colony-forming efficiency was best in alpha-MEM/hCBS and alpha-MEM/hABS, good in MSCGM and worst in alpha-MEM/FBS. The shortest PD time was achieved in media enriched with human sera or MSCGM, while the time was increased in alpha-MEM/FBS. The largest proliferating fraction was seen in MSCGM followed by media enriched with human sera; the fraction was smallest in alpha-MEM/FBS. Staining for CD34, CD45, CD235a and CD271 was negative, while that for CD29, CD44, CD73, CD90, CD105 and human leukocyte antigen (HLA)-A, -B, -C was positive in all media tested. Media with human serum did not adversely affect the differentiation potential of hMSC, and differentiation into osteoblasts was enhanced. Conclusions The choice of serum influences hMSC expansion and cell properties; alpha-MEM supplemented with hABS seems to be a promising candidate for clinical use.","[Turnovcova, Karolina; Ruzickova, Katerina; Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Turnovcova, Karolina; Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic; [Turnovcova, Karolina; Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague, Czech Republic","Jendelova, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","jendel@biomed.cas.cz",null,null,"EC FP6 projects RESCUE [LSHB-CT2005- 518233]; ENINET [LSHM-CT-2005-019063];  [AV0Z50390703];  [1M0538];  [LC554];  [309/08/H079]","We thank Jarmila Kasparova for technical assistance, James Dutt for critical reading of the manuscript and Marie Hladikova for statistical analysis. This study was supported by the grants AV0Z50390703, 1M0538, LC554, 309/08/H079 and the EC FP6 projects RESCUE (LSHB-CT2005- 518233) and ENINET (LSHM-CT-2005-019063).",null,39,20,22,"TAYLOR & FRANCIS AS","OSLO","KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY","1465-3249",null,null,"CYTOTHERAPY","Cytotherapy",null,2009,11,7,null,null,null,null,874,885,null,"10.3109/14653240903188947",null,12,"Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental","Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine","523AS","WOS:000272043100008"]
[null,null,null,null,"J","Benesova, J; Hock, M; Butenko, O; Prajerova, I; Anderova, M; Chvatal, A",null,null,null,"Benesova, Jana; Hock, Miroslav; Butenko, Olena; Prajerova, Iva; Anderova, Miroslava; Chvatal, Alexander",null,null,"Quantification of Astrocyte Volume Changes During Ischemia In Situ Reveals Two Populations of Astrocytes in the Cortex of GFAP/EGFP Mice","JOURNAL OF NEUROSCIENCE RESEARCH",null,null,"English","Article",null,null,null,null,null,"Indexing terms: ischemia; volume regulation; astrocyte processes; acidification; patch-clamp","CENTRAL-NERVOUS-SYSTEM; K+-CL-COTRANSPORTER; 3-DIMENSIONAL CONFOCAL MORPHOMETRY; MIDDLE-CEREBRAL-ARTERY; CELL-VOLUME; AMINO-ACIDS; GLUTAMATE TRANSPORTERS; CULTURED ASTROCYTES; REACTIVE ASTROCYTES; BRAIN-CELLS","Energy depletion during ischemia leads to disturbed ionic homeostasis and accumulation of neuroactive substances in the extracellular space, subsequently leading to volume changes in astrocytes. Confocal microscopy combined with 3D reconstruction was used to quantify ischemia-induced astrocyte volume changes in cortical slices of GFAP/EGFP transgenic mice. Twenty-minutes of oxygen-glucose deprivation (OGD) or oxygen-glucose deprivation combined with acidification (OGD(pH) (6.8)) revealed the presence of two distinct astrocytic populations, the first showing a large volume increase (HR astrocytes) and the second displaying a small volume increase (LR astrocytes). In addition, changes in resting membrane potential (V(m)), measured by the patch-clamp technique, supported the existence of two astrocytic populations responding differently to ischemia. Although one group markedly depolarized during OGD or OGD(pH) (6.8), only small changes in V(m) toward more negative values were observed in the second group. Conversely, acidification (ACF(pH) (6.8)) led to a uniform volume decrease in all astrocytes, accompanied by only a small depolarization. Interestingly, two differently responding populations were not detected during acidification. Differences in the expression of inwardly rectifying potassium channels (Kir4.1), glial fibrillary acidic protein (GFAP), and taurine levels in cortical astrocytes were detected using immunohistochemical methods. We conclude that two distinct populations of astrocytes are present in the cortex of GFAP/EGFP mice, based on volume and V(m) changes during exposure to OGD or OGD(pH) (6.8). Immunohistochemical analysis suggests that-the diverse expression of Kir4.1 channels and GFAP as well as differences in the accumulation of taurine might contribute to the distinct ability of astrocytes to regulate their volume. (C) 2008 Wiley-Liss, Inc.","[Benesova, Jana; Butenko, Olena; Prajerova, Iva; Anderova, Miroslava; Chvatal, Alexander] Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Neurobiol Lab, Prague 14220 4, Czech Republic; [Benesova, Jana; Butenko, Olena; Prajerova, Iva; Chvatal, Alexander] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Hock, Miroslav] Acad Sci Czech Republic, Inst Physiol, Dept Epithelial Physiol, Prague, Czech Republic; [Anderova, Miroslava; Chvatal, Alexander] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Chvatal, A (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Neurobiol Lab, Videnska 1083, Prague 14220 4, Czech Republic.","anderova@biomed.cas.cz","Hock, Miroslav/A-6737-2012",null,"Grant Agency of the Czech Republic [305/06/1316, 305/06/1464]; Academy of Sciences of the Czech Republic [AVOZ50390512]; Ministry of Education, Youth and Sports of the Czech Republic [LC554]","Grant Agency of the Czech Republic: Contract grant number: 305/06/1316; Contract grant number: 305/06/1464; Contract grant sponsor: Academy of Sciences of the Czech Republic; Contract grant number: AVOZ50390512; Contract grant sponsor: Ministry of Education, Youth and Sports of the Czech Republic: Contract grant number: LC554.",null,75,20,21,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","0360-4012",null,null,"J NEUROSCI RES","J. Neurosci. Res.","JAN",2009,87,1,null,null,null,null,96,111,null,"10.1002/jnr.21828",null,16,"Neurosciences","Neurosciences & Neurology","397QX","WOS:000262678300011"]
[null,null,null,null,"J","Lastovicka, J; Budinsky, V; Spisek, R; Barunkova, J",null,null,null,"Lastovicka, J.; Budinsky, V.; Spisek, R.; Barunkova, J.",null,null,"Assessment of lymphocyte proliferation: CFSE kills dividing cells and modulates expression of activation markers","CELLULAR IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"(3)H-thymidine incorporation; CSFE staining; Expression of activation markers; Immunodeficiencies","DIACETATE SUCCINIMIDYL ESTER; FLOW CYTOMETRIC ANALYSIS; FLUORESCENT DYES; T-CELLS; IN-VIVO; CD69 EXPRESSION; MIGRATION; KINETICS; DIVISION","The measurement of cell proliferation after mitogenic stimulation is an important parameter used in diagnosis of immunodeficiencies in clinical laboratory as well as in various fields of lymphocyte research. Recent methods try to overcome the radioactive assay using tritiated thymidine ((3)H) by flow-cytometric methods using different fluorochromes such as CFSE or even to substitute these direct methods by tracing the expression of cell-membrane activation markers associated with various steps of proliferation cycle. In our study we compared the (3)H assay with CFSE-staining method and expression of activation markers (CD69, HLA-DR, CD25, CD27, CD71, CD152, CD134 and CD195) on a sample of 128 consecutive patients and healthy controls evaluated in clinical laboratory. We also tested various concentrations of USE and its impact on proliferation activity and expression of activation markers. We found that CFSE in concentration from 37 nM to 10 mu M decreases the proliferative capacity (expressed in cpm 3 H assay) due to the decreased viability of proliferating cells (measured as 7-AAD+) in concentration-dependent manner. Moreover, CFSE substantially modulates the expression of activation molecules (decreasing CD69, HLA-DR, CD25 the majority of examinated molecules). We found a good correlation between CFSE-staining method with (3)H assay, if CFSE low population is gated on CD3+ population (correlation coefficient 0.801), but only in samples with stimulation index (SI) higher then 25. In poorly proliferating samples (SI <= 25) no correlation was found due to several false positive results in USE test. Statistically significant correlation between proliferation assessed as 3 H-thymidine incorporation and expression of activation markers was found in the case of CD25, CD27, CD38, CD152, CD71, still only in samples with higher proliferation activity (SI > 25). No correlation was found with CD134, CD195, HLA-DR and CD69. We conclude that standard assay with (3)H-thymidine incorporation is unreplaceable assay in diagnosis of severe cellular immunodeficiencies as CFSE assay have high proportion of false positive results. Researchers tracing cell-membrane bound molecules on dividing cells stained by CFSE must take into account that USE may substantially modulate the expression of these markers and decrease the viability of stained cells. (C) 2009 Elsevier Inc. All rights reserved.","[Lastovicka, J.] Charles Univ Prague, Sch Med 2, Inst Immunol, Prague 15006 5, Czech Republic; Charles Univ Prague, Univ Hosp Motol, Prague 15006 5, Czech Republic","Lastovicka, J (reprint author), Charles Univ Prague, Sch Med 2, Inst Immunol, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.lastovicka@lfmotol.cuni.cz","Spisek, Radek/E-6724-2011",null,"VZ MSM [002162 0812]","This work was supported by the research project VZ MSM 002162 0812.",null,22,18,19,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0008-8749",null,null,"CELL IMMUNOL","Cell. Immunol.",null,2009,256,41671,null,null,null,null,79,85,null,"10.1016/j.cellimm.2009.01.007",null,7,"Cell Biology; Immunology","Cell Biology; Immunology","426IH","WOS:000264700700011"]
[null,null,null,null,"J","Norambuena, PA; Copeland, JA; Krenkova, P; Stambergova, A; Macek, M",null,null,null,"Norambuena, Patricia A.; Copeland, Joshua A.; Krenkova, Petra; Stambergova, Alexandra; Macek, Milan, Jr.",null,null,"Diagnostic method validation: High resolution melting (HRM) of small amplicons genotyping for the most common variants in the MTHFR gene","CLINICAL BIOCHEMISTRY",null,null,"English","Article",null,null,null,null,null,"DNA diagnostics; Genotyping; High resolution melting (HRM); Diagnostic validation; Methylenetetrahydrofolate reductase gene (MTHFR); Organization for Economic Cooperation and Development (OECD) guidelines; Small amplicons","SINGLE-NUCLEOTIDE POLYMORPHISMS; METHYLENETETRAHYDROFOLATE REDUCTASE; VASCULAR-DISEASE; RISK-FACTOR; CFTR GENE; MUTATION; DNA; CANCER; IDENTIFICATION; SYSTEM","Objectives: According to OECD guidelines methods implemented in a diagnostic laboratory should be properly validated prior their implementation. For this purpose we selected genotyping by High Resolution Melting (HRM) of small amplicons using common variants in MTHFR as a model. Design and methods: We selected previously typed samples on which selected analytical validation-related parameters relevant to DNA diagnostics - specificity, sensitivity, precision, robustness and ability to perform reliable calls were evaluated. Results: Correct genotype was assigned in 375/381 (98.4%) for c.677 C>T (rs1801133: C>T; p.A222 V) and in 102/104 (98.1%) for c.1298 A>C (rs1801131: A>C; p.E429A) of all cases. Low analytical failure rate and very high specificity/sensitivity were achieved. Similarly, precision and robustness were consistent. Conclusions: We have successfully validated HRM of small amplicons using common MTHFR variants as a model. We proved that this technique is highly reliable for routine diagnostics and our diagnostic validation strategy can serve as a model for other applications. (C) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","[Macek, Milan, Jr.] Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague 15006 5, Czech Republic","Macek, M (reprint author), Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Uvalu 84, Prague 15006 5, Czech Republic.","patynorambuena@gmail.com; milan.macek.jr@lfmotol.cuni.cz",null,null,"VZFNM [00064203(6112)]; IGA [NR9448-3]; Czech Ministry of Health and EuroGentest [FP6-512148]","We thank I. Anguelovd, M. Fialova A. Nestorovic and E. Raugova for sample preparation and technical assistance. We acknowledge helpful consultations with Dr. N. van der Stoep (Leiden University Medical Centre) and Dr. M. Morris (Geneva University Hospital). Supported by VZFNM 00064203(6112) and IGA NR9448-3 from the Czech Ministry of Health and EuroGentest (FP6-512148).",null,39,21,23,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0009-9120",null,null,"CLIN BIOCHEM","Clin. Biochem.","AUG",2009,42,12,null,null,null,null,1308,1316,null,"10.1016/j.clinbiochem.2009.04.015",null,9,"Medical Laboratory Technology","Medical Laboratory Technology","478YS","WOS:000268625300015"]
[null,null,null,null,"J","Hejcl, A; Lesny, P; Pradny, M; Sedy, J; Zamecnik, J; Jendelova, P; Michalek, J; Sykova, E",null,null,null,"Hejcl, A.; Lesny, P.; Pradny, M.; Sedy, J.; Zamecnik, J.; Jendelova, P.; Michalek, J.; Sykova, E.",null,null,"Macroporous hydrogels based on 2-hydroxyethyl methacrylate. Part 6: 3D hydrogels with positive and negative surface charges and polyelectrolyte complexes in spinal cord injury repair","JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"MULTILAYER FILMS; AXONAL GROWTH; CELL-ADHESION; RAT-BRAIN; PROTEIN; TRANSPLANTATION; BIOMATERIALS; COPOLYMERS; POLYMER","Macroporous hydrogels are artificial biomaterials commonly used in tissue engineering, including central nervous system (CNS) repair. Their physical properties may be modified to improve their adhesion properties and promote tissue regeneration. We implanted four types of hydrogels based on 2-hydroxyethyl methacrylate ( HEMA) with different surface charges inside a spinal cord hemisection cavity at the Th8 level in rats. The spinal cords were processed 1 and 6 months after implantation and histologically evaluated. Connective tissue deposition was most abundant in the hydrogels with positively-charged functional groups. Axonal regeneration was promoted in hydrogels carrying charged functional groups; hydrogels with positively charged functional groups showed increased axonal ingrowth into the central parts of the implant. Few astrocytes grew into the hydrogels. Our study shows that HEMA-based hydrogels carrying charged functional groups improve axonal ingrowth inside the implants compared to implants without any charge. Further, positively charged functional groups promote connective tissue infiltration and extended axonal regeneration inside a hydrogel bridge.","[Hejcl, A.; Lesny, P.; Sedy, J.; Jendelova, P.; Sykova, E.] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Hejcl, A.; Lesny, P.; Pradny, M.; Sedy, J.; Jendelova, P.; Michalek, J.; Sykova, E.] Charles Univ Prague, Dept Neurosci, Fac Hosp Motol, Fac Med 2, Prague, Czech Republic; [Hejcl, A.; Lesny, P.; Pradny, M.; Sedy, J.; Jendelova, P.; Michalek, J.; Sykova, E.] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Hosp Motol, Fac Med 2, Prague, Czech Republic; [Pradny, M.; Michalek, J.] Acad Sci Czech Republic, Inst Macromol Chem, Prague 14220 4, Czech Republic; [Zamecnik, J.] Charles Univ Prague, Dept Pathol & Mol Med, Fac Hosp Motol, Fac Med 2, Prague, Czech Republic; [Hejcl, A.] Masaryk Hosp, Dept Neurosurg, Usti Nad Labem, Czech Republic","Hejcl, A (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","ales.hejcl@mnul.cz","Michalek, Jiri/D-7251-2013",null,"Academy of Sciences of the Czech Republic [AVOZ50390703]; Ministry of Education of the Czech Republic [1M0538]; Grant agency of the Czech Academy of Science [GAAV IAA500390902]; Ministry of Health of the Czech Republic [1A8697-5]; EC FP6 project RESCUE [LSHB-CT-2005-518233]","We thank James Dutt for reading of the manuscript. This work was supported by the following grants: AVOZ50390703 from the Academy of Sciences of the Czech Republic, 1M0538 from the Ministry of Education of the Czech Republic, GAAV IAA500390902 from the Grant agency of the Czech Academy of Science, 1A8697-5 from the Ministry of Health of the Czech Republic, and the EC FP6 project RESCUE (LSHB-CT-2005-518233).",null,31,19,22,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0957-4530",null,null,"J MATER SCI-MATER M","J. Mater. Sci.-Mater. Med.","JUL",2009,20,7,null,null,null,null,1571,1577,null,"10.1007/s10856-009-3714-4",null,7,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","472BD","WOS:000268103200020"]
[null,null,null,null,"J","Hubacek, P; Muzikova, K; Hrdlickova, A; Cinek, O; Hyncicova, K; Hrstkova, H; Sedlacek, P; Stary, J",null,null,null,"Hubacek, Petr; Muzikova, Katerina; Hrdlickova, Alena; Cinek, Ondrej; Hyncicova, Katerina; Hrstkova, Hana; Sedlacek, Petr; Stary, Jan",null,null,"Prevalence of HHV-6 Integrated Chromosomally Among Children Treated for Acute Lymphoblastic or Myeloid Leukemia in the Czech Republic","JOURNAL OF MEDICAL VIROLOGY",null,null,"English","Article",null,null,null,null,null,"human herpesvirus 6; leukemia; chromosomal integration","HUMAN-HERPESVIRUS 6; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; PERIPHERAL-BLOOD LEUKOCYTES; HUMAN-HERPESVIRUS-6 INFECTION; LABORATORY DIAGNOSIS; DNA; ENCEPHALITIS; ENCEPHALOPATHY; DISEASE","Chromosomal integration of human herpesvirus 6 (HHV-6) is a novel situation found in a small percentage of individuals. While active HHV-6 infection is treatable using antivirals, the abnormally high level of HHV-6 DNA found in chromosomal integration of HHV-6 (Cl-HHV-6) is not affected by such drugs. Stored DNA samples taken originally for detection of fusion genes and minimal residual disease from 339 pediatric patients treated for leukemia in the Czech Republic between the years 1995-2007 were tested retrospectively. Using real-time quantitative PCR technology, the quantity of HHV-6 DNA detected was normalized to 100,000 human genome equivalents as assessed by quantitation of the albumin gene. HHV-6 DNA was detected in 107 samples from 91 patients (26.8%). In the majority of samples (99) only a minute level of normalized viral copies (NVCs) (median 1.84 NVCs) was detected. A high viral load of approximately 100,000 NVCs was detected in 5 patients (1.5%; median 140,150 NVCs), in all of whom were confirmed subsequently Cl-HHV-6 by a detection of HHV-6 DNA in hair follicles or in the nails. In all but one patient with HHV-6 variant B, variant A of the virus was detected. None of the patients with Cl-HHV-6 had complications attributable to HHV-6 infection. The prevalence of CI-HHV-6 in childhood leukemia does not differ from that published for other patients or healthy populations. Where high levels of HHV-6 DNA are present, Cl-HHV-6 should be confirmed as soon as possible so that potentially toxic but ineffective antiviral treatment can be stopped. J. Med. Virol. 81:258263, 2009. (c) 2008 Wiley-Liss, Inc.","[Hubacek, Petr; Muzikova, Katerina; Sedlacek, Petr; Stary, Jan] Motol Univ Hosp, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Hrdlickova, Alena; Cinek, Ondrej; Hyncicova, Katerina] Motol Univ Hosp, Dept Paediat, CZ-15006 Prague, Czech Republic; [Hrstkova, Hana] Brno Univ Hosp, Dept Paediat 1, Brno, Czech Republic","Hubacek, P (reprint author), Motol Univ Hosp, Dept Paediat Haematol & Oncol, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","petr.hubacek@lfmotol.cuni.cz",null,null,"Czech Ministry of Health [FNM00064203]; Czech Ministry of Education [MSMT0021620813]","Czech Ministry of Health; Grant number: FNM00064203; Grant sponsor: Czech Ministry of Education; Grant number: MSMT0021620813.",null,34,21,21,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","0146-6615",null,null,"J MED VIROL","J. Med. Virol.","FEB",2009,81,2,null,null,null,null,258,263,null,"10.1002/jmv.21371",null,6,"Virology","Virology","389LX","WOS:000262095300008"]
[null,null,null,null,"J","Musova, Z; Mazanec, R; Krepelova, A; Ehler, E; Vales, J; Jaklova, R; Prochazka, T; Koukal, P; Marikova, T; Kraus, J; Havlovicova, M; Sedlacek, Z",null,null,null,"Musova, Zuzana; Mazanec, Radim; Krepelova, Anna; Ehler, Edvard; Vales, Jiri; Jaklova, Radka; Prochazka, Tomas; Koukal, Petr; Marikova, Tatana; Kraus, Josef; Havlovicova, Marketa; Sedlacek, Zdenek",null,null,"Highly Unstable Sequence Interruptions of the CTG Repeat in the Myotonic Dystrophy Gene","AMERICAN JOURNAL OF MEDICAL GENETICS PART A",null,null,"English","Article",null,null,null,null,null,"myotonic dystrophy; CTG repeat; interruptions; DMPK gene","SPINOCEREBELLAR ATAXIA; TRINUCLEOTIDE REPEATS; FRIEDREICH ATAXIA; CAA INTERRUPTIONS; TRIPLET REPEAT; CGG REPEATS; INSTABILITY; EXPANSION; ALLELES; TYPE-1","Myotonic dystrophy type I is caused by the expansion of a CTG repeat in the 3' UTR of the DMPK gene. A length exceeding 50 CTG triplets is pathogenic. Intermediate alleles with 35-49 triplets are not disease-causing but show instability in intergenerational transmissions. We report on the identification of multiple patients with different patterns of CCG and CTC interruptions in the DMPKCTG repeat tract that display unique intergenerational instability. In patients bearing interrupted expanded alleles, the location of the interruptions changed dramatically between generations and the repeats tended to contract. The phenotype for these patients corresponded to the classical form of the disease, but in some cases without muscular dystrophy and possibly with a later onset than expected. Symptomatic patients bearing interrupted intermediate length repeat tracts were also identified, although the role of the interruptions in their phenotype remains unclear. The identification of interruptions in the DMPK repeat has important consequences for molecular genetic testing where they can lead to false negative conclusions. (C) 2009 Wiley-Liss, Inc.","[Musova, Zuzana; Krepelova, Anna; Marikova, Tatana; Havlovicova, Marketa; Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, Prague 15006 5, Czech Republic; [Musova, Zuzana; Mazanec, Radim; Krepelova, Anna; Marikova, Tatana; Kraus, Josef; Havlovicova, Marketa; Sedlacek, Zdenek] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Dept Neurol, Sch Med 2, Prague 15006 5, Czech Republic; [Ehler, Edvard] Reg Hosp Pardubice, Dept Neurol, Pardubice, Czech Republic; [Vales, Jiri] Univ Hosp Plzen, Dept Neurol, Plzen, Czech Republic; [Jaklova, Radka] Univ Hosp Plzen, Dept Med Genet, Plzen, Czech Republic; [Prochazka, Tomas] Na Homolce Hosp, Dept Neurol, Prague, Czech Republic; [Koukal, Petr] EMG Lab, Ceska Lipa, Czech Republic; [Kraus, Josef] Charles Univ Prague, Dept Child Neurol, Sch Med 2, Prague 15006 5, Czech Republic","Musova, Z (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","zuzana.musova@lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic [MZ000064203]","We thank an anonymous reviewer for helpful comments. The work was supported by grant MZ000064203 from the Ministry of Health of the Czech Republic.",null,40,31,34,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1552-4825",null,null,"AM J MED GENET A","Am. J. Med. Genet. A","JUL",2009,"149A",7,null,null,null,null,1365,1374,null,"10.1002/ajmg.a.32987",null,10,"Genetics & Heredity","Genetics & Heredity","467VA","WOS:000267770000001"]
[null,null,null,null,"J","Laczo, J; Vlcek, K; Vyhnalek, M; Vajnerova, O; Ort, M; Holmerova, I; Tolar, M; Andel, R; Bojar, M; Hort, J",null,null,null,"Laczo, Jan; Vlcek, Kamil; Vyhnalek, Martin; Vajnerova, Olga; Ort, Michael; Holmerova, Iva; Tolar, Martin; Andel, Ross; Bojar, Martin; Hort, Jakub",null,null,"Spatial navigation testing discriminates two types of amnestic mild cognitive impairment","BEHAVIOURAL BRAIN RESEARCH",null,null,"English","Article",null,null,null,null,null,"Morris Water Maze; Spatial navigation; Humans; Hippocampus; Memory; Frontal lobe; Mild cognitive impairment; Alzheimer's disease","ALZHEIMERS-DISEASE; TOPOGRAPHICAL DISORIENTATION; HIPPOCAMPAL-LESIONS; PREFRONTAL CORTEX; EXPLICIT MEMORY; HUMANS; DEMENTIA; DEFICITS; TASK; RATS","The hippocampus is essential for consolidation of declarative information and spatial navigation. Alzheimer's disease (AD) diagnosis tends to be preceded by a long prodromal period and mild cognitive impairment (MCI). Our goal was to test whether amnestic MCI comprises two different subgroups, with hippocampal and non-hippocampal memory impairment, that vary with respect to spatial navigation ability. A total of 52 patients were classified into two subgroups: non-amnestic MCI (naMCI) (n = 10) and amnestic MCI (aMCI) (n = 42). The aMCI subgroup was further stratified into memory impairment of hippocampal type-hippocampal aMCI (HaMCI) (n = 10) (potential preclinical AD) and isolated retrieval impairment-non-hippocampal (NHaMCI) (n = 32). Results were compared to control (n = 28) and AD (n = 21) groups. We used the Hidden Goal Task, a human analogue of the Morris Water Maze, to examine spatial navigation either dependent (egocentric) or independent of individual's position (allocentric). Overall, the HaMCI group performed poorer on spatial navigation than the NHaMCI group, especially in the latter trials when the HaMCI group exhibited limited capacity to learn and the NHaMCI group exhibited a learning effect. Finally, the HaMCI group performed almost identically as the AD group. Spatial navigation deficit is particularly pronounced in individuals with hippocampus-related memory impairment and may signal preclinical AD. (C) 2009 Elsevier B.V. All rights reserved.","[Laczo, Jan; Vyhnalek, Martin; Ort, Michael; Bojar, Martin; Hort, Jakub] Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Sch Med 2, Prague 15006 5, Czech Republic; [Vlcek, Kamil] Acad Sci Czech Republic, Inst Physiol, Dept Neurophysiol Memory & Computat Neurosci, Prague, Czech Republic; [Vajnerova, Olga] Charles Univ Prague, Inst Physiol, Sch Med 2, Prague 15006 5, Czech Republic; [Ort, Michael] Charles Univ Prague, Dept Psychiat, Sch Med 1, Prague 15006 5, Czech Republic; [Holmerova, Iva] Ctr Gerontol, Prague, Czech Republic; [Tolar, Martin] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Andel, Ross] Univ S Florida, Florida Alzheimers Dis Res Ctr, Tampa, FL USA","Laczo, J (reprint author), Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","JanLaczo@seznam.cz","Vlcek, Kamil/B-9620-2012","Vlcek, Kamil/0000-0001-7152-3093","Czech Republic [309/09/1053, 309/09/0286]; Ministry of Education Youth and Sports of the Czech Republic [IM0517, LC554, AVOZ50110509]","Supported by the Grant Agency of the Czech Republic Grants 309/09/1053 and 309/09/0286, Ministry of Education Youth and Sports of the Czech Republic Grants IM0517 and LC554, and research project AVOZ50110509.",null,57,29,31,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0166-4328",null,null,"BEHAV BRAIN RES","Behav. Brain Res.","SEP 14",2009,202,2,null,null,null,null,252,259,null,"10.1016/j.bbr.2009.03.041",null,8,"Behavioral Sciences; Neurosciences","Behavioral Sciences; Neurosciences & Neurology","458HK","WOS:000267006300015"]
[null,null,null,null,"J","Vajtr, D; Benada, O; Kukacka, J; Prusa, R; Houstava, L; Toupalik, P; Kizek, R",null,null,null,"Vajtr, D.; Benada, O.; Kukacka, J.; Prusa, R.; Houstava, L.; Toupalik, P.; Kizek, R.",null,null,"Correlation of Ultrastructural Changes of Endothelial Cells and Astrocytes Occurring during Blood Brain Barrier Damage after Traumatic Brain Injury with Biochemical Markers of Blood Brain Barrier Leakage and Inflammatory Response","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Blood brain barrier; Expansive contusion; Metalloproteinases; S-100B protein; Interleukin-6","NEURON-SPECIFIC-ENOLASE; SEVERE HEAD-INJURY; S-100B PROTEIN; CONTUSION; TOMOGRAPHY; RELEASE; RAT","Focal cerebral contusion can be dynamic and expansive. It has been proved that subsequent expansive contusion is caused by brain parenchyma damage, especially BBB damage. We investigated a group of patients with traumatic brain injury. The patients (n=18) were divided into group I (n=7) of patients submitted to neurosurgery due to expansive contusion, and group II (n=11) of patients without surgery. Serum concentrations of NSE and S-100B protein were measured by electrochemiluminescence immunoassay, interleukin-6 (IL-6) was measured by chemiluminescent sequential immunometric assay and matrix metalloproteinases (MMP-9, MMP-2) were measured by immunoassays. Cortical biopsy specimens of brain were investigated by electron microscopy in patients with trauma brain injury submitted to neurosurgery. Biochemical investigation from first day up to third day after traumatic brain injury proved increased values of IL-6 (302.2 +/- 119.9 vs. 59.6 +/- 11.9 ng/l, p<0.02) and S-100B protein (3.064 +/- 1.064 vs. 0.649 +/- 0.182 mu g/l, p<0.05) in patients with expansive lesion compared to patients without expansive contusion. Significantly higher levels of MMP-9 (150.4 +/- 28.46 vs. 74.11 +/- 13.16 ng/l, p<0.05) and of MMP- 2 (814.5 +/- 126.3 vs. 523.1 +/- 25.28 ng/l, p<0.05) were found during first 3 days after admission in group I compared to group II. MMP- 9 has also elevated in group II from lower values after admission (74.11 +/- 13.16 ng/l) up to high levels on the 10th day of hospitalization (225.1 +/- 49.35 ng/l). Ultrastructural investigation of endothelial cells and surrounded tissue revealed perivascular hemorrhage, increased pinocytic activity of endothelial cells, and cytotoxic edema of astroglial cells. Multivesical bodies were disclosed inside the endothelial cells. Higher levels of serum protein S-100B and IL-6 correlated with ultrastructural changes of endothelial cells, and with inflammatory response following TBI, respectively.","[Vajtr, D.; Kukacka, J.; Prusa, R.] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, Prague 15006 5, Czech Republic; [Vajtr, D.; Kukacka, J.; Prusa, R.] Univ Hosp Motol, Prague, Czech Republic; [Benada, O.] Acad Sci Czech Republic, Inst Microbiol, Prague, Czech Republic; [Vajtr, D.] Charles Univ Prague, Fac Med 1, Dept Forens Med & Toxicol, Prague 15006 5, Czech Republic; [Houstava, L.] Charles Univ Prague, Fac Med 3, Dept Neurosurg, Prague 15006 5, Czech Republic; [Toupalik, P.] Charles Univ Prague, Fac Med 2, Dept Forens Med, Prague 15006 5, Czech Republic; [Kizek, R.] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Brno, Czech Republic","Vajtr, D (reprint author), Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, V Uvalu 84, Prague 15006 5, Czech Republic.","vajtr.david.1LFUK@seznam.cz","Kizek, Rene/D-7748-2012; Kukacka, Jiri/C-4770-2013",null,"IGA CR [NR/8793-3/2006]; Institutional Scientific Project [AV0Z50200510]","We thank M. Elleder for expert assistance. Our work was supported by IGA CR, reg. no. NR/8793-3/2006 and Institutional Scientific Project AV0Z50200510.",null,21,20,23,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,2,null,null,null,null,263,268,null,null,null,6,"Physiology","Physiology","442PM","WOS:000265853100013"]
[null,null,null,null,"J","Halaska, MJ; Pentheroudakis, G; Strnad, P; Stankusova, H; Chod, J; Robova, H; Petruzelka, L; Rob, L; Pavlidis, N",null,null,null,"Halaska, Michael J.; Pentheroudakis, George; Strnad, Pavel; Stankusova, Hana; Chod, Jiri; Robova, Helena; Petruzelka, Lubos; Rob, Lukas; Pavlidis, Nicholas",null,null,"Presentation, Management and Outcome of 32 Patients with Pregnancy-Associated Breast Cancer: A Matched Controlled Study","BREAST JOURNAL",null,null,"English","Article",null,null,null,null,null,"breast cancer; chemotherapy; outcome; pregnancy; pregnancy-associated breast cancer; prognosis","IN-UTERO; CHEMOTHERAPY; CARCINOMA; PROGNOSIS; WOMEN","Pregnancy-associated breast cancer (PABC) is a rare and challenging problem. We sought to describe epidemiology, management and outcome of women in whom breast cancer was diagnosed during pregnancy or within one year after delivery. Thirty-two women with PABC were referred to two European Union oncology centers between 1995 and 2007, 16 during pregnancy and 16 within 1 year after delivery. Data concerning diagnosis, management, delivery and fetal and maternal outcome were recorded. A group of 32 patients (matched controls) presenting with nonpregnancy-associated breast cancer (non-PABC) was matched for age at diagnosis, tumor size and stage to each PABC patient. Differences in outcome between the PABC and non-PABC groups were then assessed. Histological features were similar in both groups, except that estrogen receptor-negative tumors were more common in the PABC group. Three patients received chemotherapy and two others underwent surgery during pregnancy, with no excess toxicity or severe maternal/fetal adverse effects. All children in the PABC group were healthy, except for one exposed to epirubicin in utero and born with rectal atresia. Overall survival was similar in PABC and non-PABC patients (p = 0.449). The subgroup of patients with breast cancer diagnosed within one year after delivery showed a shorter time to relapse than controls or patients with gestational cancer (p = 0.0178). PABC is a special situation, necessitating individualized, multi-disciplinary management. Prognosis is similar for women with nongestational cancer matched for age and stage though poorer outcome postpartum should be further investigated.","[Halaska, Michael J.; Strnad, Pavel; Chod, Jiri; Robova, Helena; Rob, Lukas] Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 1, Prague 15000 5, Czech Republic; [Pentheroudakis, George; Pavlidis, Nicholas] Ioannina Univ Hosp, Dept Med Oncol, Ioannina, Greece; [Stankusova, Hana] FN Motol, Dept Radiat & Oncol, Prague, Czech Republic; [Petruzelka, Lubos] Charles Univ Prague, Dept Oncol, Fac Med 1, Prague 15000 5, Czech Republic","Halaska, MJ (reprint author), Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 1, Prague Uvalu 84, Prague 15000 5, Czech Republic.","mhalaska@centrum.cz",null,null,"Ministry of Health of the Czech Republic [9455-3]","The work was supported by a grant from the Ministry of Health of the Czech Republic, IGA MZ NR 9455-3. Thanks for the co-operation of DTC, Prague.",null,31,18,20,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1075-122X",null,null,"BREAST J","Breast J.","SEP-OCT",2009,15,5,null,null,null,null,461,467,null,"10.1111/j.1524-4741.2009.00760.x",null,7,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","487IP","WOS:000269265800003"]
[null,null,null,null,"J","Cada, Z; Smetana, K; Lacina, L; Plzakova, Z; Stork, J; Kaltner, H; Russwurm, R; Lensch, M; Andre, S; Gabius, HJ",null,null,null,"Cada, Z.; Smetana, K., Jr.; Lacina, L.; Plzakova, Z.; Stork, J.; Kaltner, H.; Russwurm, R.; Lensch, M.; Andre, S.; Gabius, H. -J.",null,null,"Immunohistochemical Fingerprinting of the Network of Seven Adhesion/Growth-Regulatory Lectins in Human Skin and Detection of Distinct Tumour-Associated Alterations","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,"apoptosis; galectin; glycohistochemistry; glycoprotein; integrin; stroma; sugar code","NECK SQUAMOUS-CELL; GALECTIN-7 P53-INDUCED GENE-1; HUMAN NEUROBLASTOMA-CELLS; ENTEROCYTE-LIKE CELLS; ENDOGENOUS LECTINS; IN-VITRO; RT-PCR/IMMUNOHISTOCHEMISTRY; HYPOPHARYNGEAL CANCER; EXTRACELLULAR-MATRIX; PROGNOSTIC RELEVANCE","Glycans of natural glycoconjugates are considered as a source of biological information relevant to cell adhesion or growth. Sugar-based messages are decoded and translated into responses by endogenous lectins. This mechanism assigns a functional dimension to tumour-associated changes of glycosylation. Consequently, it calls for mapping the lectin presence in tumours. Such an analysis has so far commonly been performed with the scope to determine expression of a few distinct proteins, e.g. from the effector family of galectins with focus on galectins-1 and -3. Due to the emerging evidence for functional divergence among galectins it is timely to address the challenge to evaluate their presence beyond these few family members. Having raised a panel of non-cross-reactive antibodies against seven human galectins covering all three subfamilies, we describe their expression profiles in human skin. Comparison of normal and malignant tissues enabled us to define galectin-type-dependent alterations, arguing in favour of distinct functionalities. It is concluded that comprehensive monitoring performed to define the different aspects of the galectin network, as documented in this pilot study, is advisable for future histopathologic studies aimed at delineating clinical correlations.","[Cada, Z.; Smetana, K., Jr.; Lacina, L.; Plzakova, Z.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Cada, Z.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Prague 12800 2, Czech Republic; [Lacina, L.; Stork, J.] Charles Univ Prague, Fac Med 1, Dept Dermatovenerol, Prague 12800 2, Czech Republic; [Smetana, K., Jr.; Lacina, L.; Plzakova, Z.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 12800 2, Czech Republic; [Kaltner, H.; Russwurm, R.; Lensch, M.; Andre, S.; Gabius, H. -J.] Univ Munich, Inst Physiol Chem, Fac Vet Med, D-8000 Munich, Germany","Smetana, K (reprint author), Charles Univ Prague, Fac Med 1, Inst Anat, Nemocnice 3, Prague 12800 2, Czech Republic.","karel.smetana@lfl.cuni.cz",null,null,"Ministry of Education, Youth and Sports of the Czech Republic [MSM 0021620806]; Mizutani Foundation for Glycoscience (Tokyo, Japan); EC Marie Curie Research Training Network [HRTN-CT-2005-019561]","This study was supported by the Ministry of Education, Youth and Sports of the Czech Republic (project No. MSM 0021620806), the Mizutani Foundation for Glycoscience (Tokyo, Japan) and an EC Marie Curie Research Training Network grant (contract No. HRTN-CT-2005-019561).",null,67,21,21,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2009,55,4,null,null,null,null,145,152,null,null,null,8,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","488SD","WOS:000269369200005"]
[null,null,null,null,"J","Veselka, J; Zemanek, D; Tomasov, P; Duchonova, R; Linhartova, K",null,null,null,"Veselka, Josef; Zemanek, David; Tomasov, Pavol; Duchonova, Radka; Linhartova, Katerina",null,null,"Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective","HEART AND VESSELS",null,null,"English","Article",null,null,null,null,null,"Hypertrophic cardiomyopathy; Ablation; Therapy; Obstruction","MYECTOMY; IMPROVEMENT; EXPERIENCE; SURGERY","Echo-guided alcohol septal ablation (ASA) is an alternative treatment for highly symptomatic patients with obstructive hypertrophic cardiomyopathy (HOCM). Previous reports suggest that a low dose of alcohol (1.5-2 ml) is as effective as the classic dose (2-4 ml) used in the past. Because a larger infarct might be associated with a potential long-term risk, in this pilot study we wanted to determine whether an ultra-low dose of alcohol (1 ml) would be effective in the mid-term follow-up. Seventy patients (55 +/- 13 years, range 24-81 years, septum thickness < 31 mm) with a highly symptomatic HOCM receiving maximum medical therapy were enrolled. Thirty-five consecutive patients (group I) have been treated with an ultra-low alcohol dose (1.0 +/- 0.1 ml) and compared with a control group II of 35 patients treated by the same medical team using the classic alcohol dose (2.5 +/- 0.8 ml) in the past. At 6-month follow-up, both groups of patients improved in dyspnea (2.9 +/- 0.6 vs 1.5 +/- 0.5 New York Heart Association [NYHA] class for group I; P < 0.01, and 2.5 +/- 0.7 vs 1.4 +/- 0.4 NYHA class for group II; P < 0.01) and angina (2.1 +/- 1 vs 0.6 +/- 0.8 Canadian Cardiovascular Society [CCS] class for group I; P < 0.01, and 2.1 +/- 0.9 vs 0.7 +/- 0.7 CCS class for group II; P < 0.01). There was a significant decrease in left ventricular (LV) ejection fraction (P < 0.05), septum thickness (P < 0.01), and LV outflow gradient (P < 0.01) in both groups of patients. However, there was no significant difference with regard to the extent of symptomatic or echocardiographic changes and complications between both groups. These results suggest that the ultra-low dose of alcohol (1 ml) is still effective in the treatment of the majority of HOCM patients without extreme septum hypertrophy (< 31 mm).","[Veselka, Josef; Zemanek, David; Tomasov, Pavol; Duchonova, Radka; Linhartova, Katerina] Univ Hosp Motol, Ctr Cardiovasc, Dept Cardiol, Prague 15000 5, Czech Republic","Veselka, J (reprint author), Univ Hosp Motol, Ctr Cardiovasc, Dept Cardiol, Vuvalu 84, Prague 15000 5, Czech Republic.","veselka.josef@seznam.cz",null,null,"Ministry of Health of the Czech Republic [00064203]","The study was supported by grant 00064203 from the Ministry of Health of the Czech Republic.",null,23,23,25,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0910-8327",null,null,"HEART VESSELS","Heart Vessels","JAN",2009,24,1,null,null,null,null,27,31,null,"10.1007/s00380-008-1083-4",null,5,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","Cardiovascular System & Cardiology","397XZ","WOS:000262697000005"]
[null,null,null,null,"J","Krizkova, S; Fabrik, I; Adam, V; Hrabeta, P; Eckschlager, T; Kizek, R",null,null,null,"Krizkova, S.; Fabrik, I; Adam, V; Hrabeta, P.; Eckschlager, T.; Kizek, R.",null,null,"Metallothionein - a promising tool for cancer diagnostics","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Review",null,null,null,null,null,"cancer; tumour; metallothionein; marker; blood serum","FACTOR-KAPPA-B; METAL-COMPOUNDS; TRACE-ELEMENTS; ZINC; ACTIVATION; EXPRESSION; PROTEIN; CELLS; CARCINOGENESIS; INHIBITION","The latest research outcomes indicate that metallothionein (MT) levels in peripheral blood and serum from cancer patients can provide many interesting information about type or clinical stage of the disease, or response to therapy. MT plays a key role in transport of essential heavy metals, detoxification of toxic metals and protection of cells against oxidation stress. Serum MT levels of cancer patients are three times higher than control patients (0.5 mu M). The elevated MT levels in cancer cells are probably related to their increased proliferation and protection against apoptosis. Automated electrochemical detection of MT allows its serial analysis in a very small volume with excellent sensitivity, reliability and reproducibility and therefore it can be considered as a new tool for cancer diagnosis (Fig. 4, Ref. 55). Full Text (Free, PDF) www.bmj.sk.","[Krizkova, S.; Kizek, R.] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Fabrik, I] Masaryk Univ, Fac Sci, Dept Biochem, CS-61137 Brno, Czech Republic; [Adam, V] Mendel Univ Agr & Forestry Brno, Dept Anim Nutr & Forage Prod, Fac Agron, Brno, Czech Republic; [Hrabeta, P.; Eckschlager, T.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague, Czech Republic; [Hrabeta, P.; Eckschlager, T.] Univ Hosp Motol, Prague, Czech Republic","Kizek, R (reprint author), Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Krizkova, Sona/E-9617-2012",null,"Grant Agency of Charles University [7926/2007]; Ministry of Education, Youth and Sports of the Czech Republic [MSM0021620813]; Grant Agency of the Academy of Sciences of the Czech Republic [GA AV IAA401990701]","The authors wish to express theirs thanks to the Grant Agency of Charles University (grant 7926/2007), to Ministry of Education, Youth and Sports of the Czech Republic (grant MSM0021620813) and to the Grant Agency of the Academy of Sciences of the Czech Republic (GA AV IAA401990701) for financial support.",null,55,42,42,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248",null,null,"BRATISL MED J","Bratisl. Med. J.",null,2009,110,2,null,null,null,null,93,97,null,null,null,5,"Medicine, General & Internal","General & Internal Medicine","418PB","WOS:000264159400006"]
[null,null,null,null,"J","Krizkova, S; Adam, V; Eckschlager, T; Kizek, R",null,null,null,"Krizkova, Sona; Adam, Vojtech; Eckschlager, Tomas; Kizek, Rene",null,null,"Using of chicken antibodies for metallothionein detection in human blood serum and cadmium-treated tumour cell lines after dot- and electroblotting","ELECTROPHORESIS",null,null,"English","Article",null,null,null,null,null,"Cancer cell lines; Differential pulse voltammetry-Brdicka reaction; Dot immunobinding assay; Metallothionein; Western blot","PERFORMANCE LIQUID-CHROMATOGRAPHY; TRANSFER STRIPPING TECHNIQUE; IMMUNOSORBENT-ASSAY ELISA; MESSENGER-RNA EXPRESSION; MERCURY SATURATION ASSAY; CAPILLARY-ELECTROPHORESIS; BRDICKA REACTION; ELECTROCHEMICAL DETECTION; MASS-SPECTROMETRY; EISENIA-FOETIDA","Metallothionein (MT) is a low-molecular mass protein playing an essential role in homeostasis of heavy metal ions. Its relation with formation and progression of a tumour disease is discussed in this article. Here, we propose a new methodological approach for visualization of MT on PVDF membranes after dot- and electroblotting by using a commercial mouse monoclonal antibody E9 and polyclonal chicken antibodies. The optimized procedure was as follows. We dotted 1 mu m sample volume on PVDF membrane and let it to dry. Then, we blocked the membrane surface with 2% BSA in PBS for 30 min After that, the membrane was incubated in chicken primary antibody (diluted 1:500), washed, and incubated in rabbit-anti-chicken secondary antibody conjugated with horseradish peroxidase. To visualize the interaction, we used 3-aminoethyl-9-carbazole. Under these conditions, we estimated detection limit as 3 pa of NIT per 1 mu L. The optimal approach was further utilized for detection of MT level in two human fibroblast cell lines and in blood serum obtained from children with medulloblastoma. The results were in good agreement with differential pulse voltammetry-Brdicka reaction.","[Krizkova, Sona; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Dept Anim Nutr & Forage Prod, Fac Agron, CZ-61300 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CR-11636 Prague, Czech Republic","Kizek, R (reprint author), Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Krizkova, Sona/E-9617-2012",null,null,null,null,89,30,30,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","0173-0835",null,null,"ELECTROPHORESIS","Electrophoresis","NOV",2009,30,21,null,null,null,null,3726,3735,null,"10.1002/elps.200900201",null,10,"Biochemical Research Methods; Chemistry, Analytical","Biochemistry & Molecular Biology; Chemistry","524EG","WOS:000272126000011"]
[null,null,null,null,"J","Vasakova, M; Sterclova, M; Kolesar, L; Slavcev, A; Pohunek, P; Sulc, J; Skibova, J; Striz, I",null,null,null,"Vasakova, M.; Sterclova, M.; Kolesar, L.; Slavcev, A.; Pohunek, P.; Sulc, J.; Skibova, J.; Striz, I.",null,null,"Bronchoalveolar Lavage Fluid Cellular Characteristics, Functional Parameters and Cytokine and Chemokine Levels in Interstitial Lung Diseases","SCANDINAVIAN JOURNAL OF IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,null,"IDIOPATHIC PULMONARY-FIBROSIS; EXPERIMENTAL HYPERSENSITIVITY PNEUMONITIS; ENDOTHELIAL GROWTH-FACTOR; ALVEOLAR MACROPHAGES; ANGIOGENIC ACTIVITY; CC-CHEMOKINE; SARCOIDOSIS; EXPRESSION; CCL18; IL-8","Idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP) and sarcoidosis belong to interstitial lung diseases (ILD) where an imbalance of regulatory, profibrotic and antifibrotic cytokines is hypothesized. The relationship of bronchoalveolar lavage (BAL) fluid (BALF) cytokines, BALF cell profile and ILD course is supposed. The aim of our study was to correlate BALF cytokine and chemokine levels with BALF cellular characteristics and lung function parameters in different ILD. Twenty-two sarcoidosis, seven IPF and 11 HP patients underwent lung function tests and BAL. The BALF differential cell counts and superficial cell markers were characterized, and MCP-1, MIP-1 alpha, MIP-1 beta, RANTES, epithelial neutrophil-activating protein (ENA)-78, FGF, G-CSF, GM-CSF, IFN-gamma, interleukin (IL)-1 alpha, IL-1RA, IL-1 beta, -2 beta, -4 beta, -5 beta, -6 beta, -8 beta, -10 beta, -17 beta, tumour necrosis factor (TNF)-alpha, thromobopoietin (Tpo) and vascular endothelial growth factor (VEGF) values measured. The BALF VEGF values were highest in sarcoidosis (P = 0.0526). IL-1RA values were higher in IPF and HP compared with sarcoidosis (P = 0.0334). IL-8/ENA-78 ratio positively correlated with BALF neutrophil counts in IPF (r = 0.89, P = 0.04). Vital capacity and TL(CO) values positively correlated with VEGF and negatively with IL-8 BALF levels in all ILDs but the correlations were most significant in sarcoidosis group. We suppose that VEGF plays a role in ILDs' early phases and has rather angiogenic than profibrotic effect. On the contrary, IL-8 is probably upregulated in advanced ILDs with prominent fibrosis and marked lung functions decline. We state that BALF VEGF, IL-8 and ENA-78 levels and IL-8/ENA-78 ratio could become useful markers of ILDs' phase, activity and prognosis. They might also be helpful in treatment modality choice.","[Vasakova, M.; Sterclova, M.] Charles Univ Prague, Dept Resp Dis, Sch Med 1, Univ Thomayer Hosp Prague, Prague 14059 4, Czech Republic; [Kolesar, L.; Slavcev, A.; Striz, I.] Inst Clin & Expt Med, Dept Immunol, Prague, Czech Republic; [Pohunek, P.; Sulc, J.] Charles Univ Prague, Dept Pediat, Sch Med 2, Univ Hosp Motol, Prague 14059 4, Czech Republic; [Skibova, J.] Inst Clin & Expt Med, Med Stat Unit, Prague, Czech Republic","Vasakova, M (reprint author), Charles Univ Prague, Dept Resp Dis, Sch Med 1, Univ Thomayer Hosp Prague, Videnska 800, Prague 14059 4, Czech Republic.","martina.vasakova@ftn.cz",null,null,"MHCR [9131-3/2007]","The study was supported with grant MHCR 9131-3/2007.",null,28,21,24,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-9475",null,null,"SCAND J IMMUNOL","Scand. J. Immunol.","MAR",2009,69,3,null,null,null,null,268,274,null,"10.1111/j.1365-3083.2008.02222.x",null,7,"Immunology","Immunology","405XR","WOS:000263258000011"]
[null,null,null,null,"J","Szabo, P; Dam, TK; Smetana, K; Dvorankova, B; Kurbler, D; Brewer, CF; Gabius, HJ",null,null,null,"Szabo, P.; Dam, T. K.; Smetana, K., Jr.; Dvorankova, B.; Kuerbler, D.; Brewer, C. F.; Gabius, H. -J.",null,null,"Phosphorylated Human Lectin Galectin-3: Analysis of Ligand Binding by Histochemical Monitoring of Normal/Malignant Squamous Epithelia and by Isothermal Titration Calorimetry","ANATOMIA HISTOLOGIA EMBRYOLOGIA",null,null,"English","Article",null,null,null,null,null,null,"TUMOR-CELL LINES; ENDOGENOUS LECTINS; GANGLIOSIDE GM(1); MAMMALIAN LECTINS; CARCINOMA CELLS; N-GLYCAN; IN-VIVO; EXPRESSION; SITES; DIFFERENTIATION","The human lectin galectin-3 is a multifunctional effector with special functions in regulation of adhesion and apoptosis. Its unique trimodular organization includes the 12-residue N-terminal sequence, a substrate for protein kinase CK1-dependent phosphorylation. As a step towards elucidating its significance, we prepared phosphorylated galectin-3, labelled it and used it as a tool in histochemistry. We monitored normal and malignant squamous epithelia. Binding was suprabasal with obvious positive correlation to the degree of differentiation and negative correlation to proliferation. The staining pattern resembled that obtained with the unmodified lectin. Basal cell carcinomas were invariably negative. The epidermal positivity profile was akin to distribution of the desmosomal protein desmoglein, as also seen with keratinocytes in vitro. In all cases, binding was inhibitable by the presence of lactose, prompting further investigation of the activity of the lectin site by a sensitive biochemical method, i.e. isothermal titration calorimetry. The overall affinity and the individual enthalpic and entropic contributions were determined. No effect of phosphorylation was revealed. This strategic combination of histo- and biochemical techniques applied to an endogenous effector after its processing by a protein kinase thus enabled a detailed monitoring of the binding properties of the post-translationally modified lectin. It underscores the value of using endogenous lectins as a histochemical tool. The documented approach has merit for applications beyond lectinology.","[Kuerbler, D.] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Szabo, P.; Smetana, K., Jr.; Dvorankova, B.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Dam, T. K.; Brewer, C. F.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA; [Dam, T. K.; Brewer, C. F.] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; [Smetana, K., Jr.; Dvorankova, B.] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague, Czech Republic; [Gabius, H. -J.] Univ Munich, Fac Vet Med, Inst Physiol Chem, D-80539 Munich, Germany","Kurbler, D (reprint author), German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.","d.kuebler@dkfz.de",null,null,"Ministry of Education, Youth and Sport of the Czech Republic [MSM 002160806, 1M0021620803]; Agency of the Ministry of Health of the Czech Republic [NR-9049-3]; EC Marie Curie Research Training Network [MRTN-CT-2005-019561]","This study was supported by the Ministry of Education, Youth and Sport of the Czech Republic, project no. MSM 002160806 and no. 1M0021620803, by the Grant Agency of the Ministry of Health of the Czech Republic, project no. NR-9049-3, an EC Marie Curie Research Training Network grant (contract no. MRTN-CT-2005-019561) and by the research initiative LMU excellent. Authors are grateful to Drs Jan Plzak, Martin Chovanec and Lukas Lacina for providing tumour samples and to Eva Vancova, Iva Burdova and Vit Hajduch for excellent technical assistance.",null,62,18,18,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0340-2096",null,null,"ANAT HISTOL EMBRYOL","Anat. Histol. Embryol.","FEB",2009,38,1,null,null,null,null,68,75,null,"10.1111/j.1439-0264.2008.00899.x",null,8,"Anatomy & Morphology; Veterinary Sciences","Anatomy & Morphology; Veterinary Sciences","394MP","WOS:000262451100011"]
[null,null,null,null,"J","Veselka, J; Zemanek, D; Hajek, P; Maly, M; Adlova, R; Martinkovicova, L; Tesar, D",null,null,null,"Veselka, Josef; Zemanek, David; Hajek, Petr; Maly, Martin; Adlova, Radka; Martinkovicova, Lucie; Tesar, David",null,null,"Effect of Two-Day Atorvastatin Pretreatment on the Incidence of Periprocedural Myocardial Infarction Following Elective Percutaneous Coronary Intervention: A Single-Center, Prospective, and Randomized Study","AMERICAN JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"PREPROCEDURAL STATIN THERAPY; INJURY; EXTENT; TRIAL","Both randomized and observational studies have suggested that pretreatment with statins may reduce the incidence of periprocedural myocardial infarction (PMI) in patients with stable angina during elective percutaneous coronary intervention (PCI). The purpose of this randomized study (Clinical Trial Registration No. NCT00469326) was to investigate the effect of 2-day atorvastatin therapy on the incidence of PMI in patients with stable angina pectoris undergoing elective PCI. A total of 200 patients with stable angina pectoris who were not taking statins and who had been referred for PCI were enrolled and randomized (ratio 1:1) to a 2-day pretreatment regimen with atorvastatin 80 mg/day and subsequent PCI or immediate PCI. The serum concentration of creatine kinase-MB mass and troponin I were measured before and 16 to 24 hours after PCI. The incidence of PMI was assessed using established criteria. Of the patients, 10% in the atorvastatin group and 12% in the control group had a postprocedural creatine kinase-MB mass elevation >= 3 times the upper limit of normal (p = 0.65). The incidence of PMI as determined by the postinterventional release of troponin I >= 3 times the upper limit of normal was 17% in the atorvastatin group and 16% in the control group (p = 0.85). The median creatine kinase-MB mass peak after PCI was 1.46 ng/ml (interquartile range 0.83 to 2.52) in the atorvastatin group and 1.40 ng/ml (inter-quartile range 0.90 to 2.54) in the control group (p = 0.70). The median peak troponin I level after PCI was 0.100 ng/ml (0.096 to 0.385) in the atorvastatin group and 0.100 ng/ml (0.60 to 0.262) in the control group (p = 0.54). On multivariate analysis, the only independent predictor of PMI was patient age (odds ratio 1.09, 95% confidence interval 1.025 to 1.159, p = 0.006). In conclusion, in the present study 2-day pre-PCI therapy with atorvastatin did not reduce the occurrence of PMI in patients with stable angina pectoris undergoing elective PCI. (c) 2009 Elsevier Inc. All rights reserved. (Am J Cardiol 2009;104:630-633)","[Veselka, Josef; Zemanek, David; Hajek, Petr; Maly, Martin; Adlova, Radka; Martinkovicova, Lucie; Tesar, David] Charles Univ Prague, Dept Cardiol, Ctr Cardiovasc, Univ Hosp,Motol Med Sch 1, Prague, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Dept Cardiol, Ctr Cardiovasc, Univ Hosp,Motol Med Sch 1, Prague, Czech Republic.","veselka.josef@seznam.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health of the Czech Republic, Prague, Czech Republic [00064203]","This work was supported by Grant 00064203 from the Ministry of Health of the Czech Republic, Prague, Czech Republic.",null,13,15,18,"EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC","BRIDGEWATER","685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA","0002-9149",null,null,"AM J CARDIOL","Am. J. Cardiol.","SEP 1",2009,104,5,null,null,null,null,630,633,null,"10.1016/j.amjcard.2009.04.048",null,4,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","493RW","WOS:000269756600003"]
[null,null,null,null,"J","Castellani, C; Southern, KW; Brownlee, K; Roelse, JD; Duff, A; Farrell, M; Mehta, A; Munck, A; Pollitt, R; Sermet-Gaudelus, I; Wilcken, B; Ballmann, M; Corbetta, C; de Monestrol, I; Farrell, P; Feilcke, M; Ferec, C; Gartner, S; Gaskin, K; Hammermann, J; Kashirskaya, N; Loeber, G; Macek, M; Mehta, G; Reiman, A; Rizzotti, P; Sammon, A; Sands, D; Smyth, A; Sommerburg, O; Torresani, T; Travert, G; Vernooij, A; Elborn, S",null,null,null,"Castellani, Carlo; Southern, Kevin W.; Brownlee, Keith; Roelse, Jeannette Dankert; Duff, Alistair; Farrell, Michael; Mehta, Anil; Munck, Anne; Pollitt, Rodney; Sermet-Gaudelus, Isabelle; Wilcken, Bridget; Ballmann, Manfred; Corbetta, Carlo; de Monestrol, Isabelle; Farrell, Philip; Feilcke, Maria; Ferec, Claude; Gartner, Silvia; Gaskin, Kevin; Hammermann, Jutta; Kashirskaya, Nataliya; Loeber, Gerard; Macek, Milan, Jr.; Mehta, Gita; Reiman, Andreas; Rizzotti, Paolo; Sammon, Alec; Sands, Dorota; Smyth, Alan; Sommerburg, Olaf; Torresani, Toni; Travert, Georges; Vernooij, Annette; Elborn, Stuart",null,null,"European best practice guidelines for cystic fibrosis neonatal screening","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Review",null,null,null,null,null,"Cystic fibrosis; Neonatal screening; Diagnosis; Immunoreactive trypsinogen; Sweat test","DRIED-BLOOD SPOT; IMMUNOREACTIVE TRYPSINOGEN LEVELS; AGE-RELATED ALTERATIONS; DIRECT GENE ANALYSIS; DELAYED DIAGNOSIS; YOUNG-CHILDREN; CATIONIC TRYPSINOGEN; PRENATAL-CARE; SWEAT-TEST; NEWBORN","There is wide agreement on the benefits of NBS for CF in terms of lowered disease severity, decreased burden of care, and reduced costs. Risks are mainly associated with disclosure of carrier status and diagnostic uncertainty. When starting a NBS programme for CF it is important to take precautions in order to minimise avoidable risks and maximise benefits. In Europe more than 25 screening programmes have been developed.. with quite marked variation in protocol design. However, given the wide geographic, ethnic, and economic variations, complete harmonisation of protocols is not appropriate. There is little evidence to Support the use of IRT alone as a second tier, without involving DNA mutation analysis. However, if IRT/DNA testing does not lead to the desired specificity/sensitivity ratio in a population, a screening programme based on IRT/IRT may be used. Sweat chloride concentration remains the gold standard for discriminating between NBS false and true positives, but age-related changes in sweat chloride should be taken into account. CF phenotypes associated with less severe disease often have intermediate or normal sweat chloride concentrations. Programmes should include arrangements for counselling and management of infants where the diagnosis is not clear-cut. All newborns identified by NBS should be managed according to internationally accepted guidelines. CF centre care and the availability of necessary medication are essential prerequisites before the introduction of NBS Programmes. Clear explanation to families of the process of screening and of implications of normal and abnormal results is central to the success of CF NBS programmes. Effective communication is especially important when parents are told that their child is affected or is a carrier. When establishing a NBS programme for CF, attention should be given to ensuring timely and appropriate processing of results, to minimise potential stress for families. (C) 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Castellani, Carlo] Verona Cyst Fibrosis Ctr, I-37126 Verona, Italy; [Southern, Kevin W.] Univ Liverpool, Liverpool L69 3BX, Merseyside, England; [Brownlee, Keith; Duff, Alistair] St James Univ Hosp, Leeds Reg Cyst Fibrosis Unit, Leeds, W Yorkshire, England; [Roelse, Jeannette Dankert] Atrium Med Centrum Heerlen, Heerlen, Netherlands; [Farrell, Michael] Med Coll Wisconsin, Milwaukee, WI USA; [Mehta, Anil] Univ Dundee, Div Maternal & Child Hlth Sci, Dundee DD1 4HN, Scotland; [Munck, Anne] AP HP, Robert Debre Cyst Fibrosis Ctr, Paris, France; [Pollitt, Rodney] Sheffield Childrens Hosp, Sheffield, S Yorkshire, England; [Wilcken, Bridget] Hop Necker Enfants Malad, INSERM, U465, Ctr Ressources & Competence Mucoviscidose, Paris, France; [Mehta, Anil; Gaskin, Kevin] Childrens Hosp Westmead, Sydney, NSW, Australia; [Ballmann, Manfred] Hannover Med Sch, Dept Paediat, Hannover, Germany; [Corbetta, Carlo] Osped Bambini V Buzzi, Milan AO ICP, Milan, Italy; [de Monestrol, Isabelle] Karolinska Univ, Huddinge Hosp, Stockholm CF Ctr, Stockholm, Sweden; [Farrell, Philip] Univ Wisconsin, Madison, WI 53706 USA; [Feilcke, Maria] Munich Cyst Fibrosis Ctr, Munich, Germany; [Ferec, Claude] Univ Bretagne Occidentale, Ctr Hosp Univ Brest, F-29269 Brest, France; [Gartner, Silvia] Hosp Vall de Hebron, Unidad Fibrosis Quist, Barcelona, Spain; [Hammermann, Jutta] Dresden Cyst Fibrosis Ctr, Dresden, Germany; [Kashirskaya, Nataliya] Moscow Cyst Fibrosis Ctr, Moscow, Russia; [Loeber, Gerard] Natl Inst Publ Hlth, Int Soc Neonatal Screening, Bilthoven, Netherlands; [Macek, Milan, Jr.] Charles Univ Prague 2, Sch Med, Dept Biol & Med Genet, Prague, Czech Republic; [Rizzotti, Paolo] Verona Hosp, Cent Lab, Verona, Italy; [Sands, Dorota] Cyst Fibrosis Ctr, Inst Mother & Child, Warsaw, Poland; [Smyth, Alan] Univ Nottingham, Div Child Hlth, Nottingham NG7 2RD, England; [Sommerburg, Olaf] Heidelberg Cyst Fibrosis Ctr, Heidelberg, Germany; [Torresani, Toni] Univ Childrens Hosp Zurich, Swiss Neonatal Screening Lab, Zurich, Switzerland; [Travert, Georges] Caen Univ Hosp, Neonatal Screening Ctr Normandy, Caen, France; [Elborn, Stuart] Belfast Cyst Fibrosis Ctr, Belfast, Antrim, North Ireland","Castellani, C (reprint author), Verona Cyst Fibrosis Ctr, Piazzale Stefani 1, I-37126 Verona, Italy.","carlo.castellani@azosp.vr.it","de Monestrol, Isabelle/C-6238-2013",null,"EuroCareCF [LSHM-CT-2005-018932]; International Society for Neonatal Screening; European Molecular Genetics Quality Network and EuroGentest","The organisers of the Consensus Conference would like to acknowledge support from EuroCareCF (LSHM-CT-2005-018932), the International Society for Neonatal Screening, the European Molecular Genetics Quality Network and EuroGentest. We also want to thank all CF organisations and commercial companies which supported the meeting: US CF Foundation, Mukoviszidose-ev, Vaincre la Mucoviscidose, Chiesi Farmaceutici, Wescor, Abbott Diagnostics, PerkinElmer, Innogenetics, Whatman, Nuclear Laser Medicine. Milan Macek was supported by grant VZFNM00064203.",null,126,56,57,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","MAY",2009,8,3,null,null,null,null,153,173,null,"10.1016/j.jcf.2009.01.004",null,21,"Respiratory System","Respiratory System","451HQ","WOS:000266461700001"]
[null,null,null,null,"J","Amant, F; Van Calsteren, K; Halaska, MJ; Beijnen, J; Lagae, L; Hanssens, M; Heyns, L; Lannoo, L; Ottevanger, NP; Bogaert, WV; Ungar, L; Vergote, I; du Bois, A",null,null,null,"Amant, Frederic; Van Calsteren, Kristel; Halaska, Michael J.; Beijnen, Jos; Lagae, Lieven; Hanssens, Myriam; Heyns, Liesbeth; Lannoo, Lore; Ottevanger, Nelleke P.; Bogaert, Walter Vanden; Ungar, Laszlo; Vergote, Ignace; du Bois, Andreas",null,null,"Gynecologic Cancers in Pregnancy: Guidelines of an International Consensus Meeting","INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER",null,null,"English","Review",null,null,null,null,null,"Cancer; Pregnancy; Gynecologic; Cervical; Ovarian; Chemotherapy; Vulvar; Neonatal; Offspring; Cognitive","OF-THE-LITERATURE; ENDODERMAL SINUS TUMOR; PELVIC LYMPH-NODES; CERVICAL INTRAEPITHELIAL NEOPLASIA; METASTATIC BREAST-CANCER; SQUAMOUS-CELL CARCINOMA; EPITHELIAL OVARIAN-CARCINOMA; CLINICAL-PRACTICE GUIDELINES; TERM-FOLLOW-UP; NEOADJUVANT CHEMOTHERAPY","Background: Gynecologic cancer during pregnancy is a special challenge because cancer or its treatment may affect not only the pregnant women in general but directly involve the reproductive tract and fetus. Currently, there are no guidelines on how to deal with this special coincidence. Methods: An international consensus meeting on staging and treatment of gynecological malignancies during pregnancy was organised including a systematic literature search, and interpretation followed by a physical meeting of all participants with intensive discussion. In the absence of large trials and randomized studies, recommendations were based on available literature data and personal experience thus representing a low but best achievable level of evidence. Findings: Randomized trials and prospective Studies on cancer treatment during pregnancy are lacking. Gynecological cancer during pregnancy is a demanding problem, and multidisciplinary expertise should be available. Counseling both parents on the maternal prognosis and fetal risk is needed. When there is a firm desire to continue the pregnancy, gynecological cancer can be treated in selected cases. The staging and treatment should follow the standard approach as much as possible. Guidelines for safe pelvic surgery during pregnancy are presented. Mainly in cervical and ovarian cancer, chemotherapy and an alternative surgical approach need to be considered. Administration of chemotherapy during the second or third trimester may probably not increase the incidence of congenital malformations. Until now, the long-term Outcome of children in utero exposed to oncological treatment modalities is poorly documented, but preterm birth oil its own is associated with cognitive impairment. Delivery should be postponed preferably until after a gestational age of 35 weeks. Interpretation: Further research including international registries for gynecologic cancer in pregnancy is urgently needed. The gathering of both available literature and personal experience allowed only suggesting models for treatment of gynecologic cancer in pregnancy.","[Amant, Frederic] Katholieke Univ Leuven, Div Gynaecol Oncol, Dept Obstet & Gynaecol, UZ Gasthuisberg,Leuven Canc Inst LKI, B-3000 Louvain, Belgium; [Halaska, Michael J.] Charles Univ Prague, Div Oncogynaecol, Dept Obstet & Gynaecol, Fac Med 2, Prague, Czech Republic; [Beijnen, Jos] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands; [Ottevanger, Nelleke P.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands; [Ungar, Laszlo] Natl Canc Inst, Budapest, Hungary; [du Bois, Andreas] Dr Horst Schmidt Klin, Dept Gynaecol & Gynaecol Oncol, Wiesbaden, Germany","Amant, F (reprint author), Katholieke Univ Leuven, Div Gynaecol Oncol, Dept Obstet & Gynaecol, UZ Gasthuisberg,Leuven Canc Inst LKI, Herestr 49, B-3000 Louvain, Belgium.","Frederic.amant@uz.kuleuven.ac.be",null,null,"UCB chair","Frederic Amant is clinical researcher for Research Foundation-Flanders (F.WO.); Kristel Van Calsteren is aspirant for Research Foundation-flanders (F.W.O.). Lieven Lagae is holderofthe UCB chair in Cognitive dysfunctions in Childhood.",null,158,39,42,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X","1525-1438",null,"INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","MAY",2009,19,null,null,1,null,null,"S1","S12",null,"10.1111/IGC.0b013e3181a1d0ec",null,12,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","457ZG","WOS:000266976900001"]
[null,null,null,null,"J","Topinka, J; Milcova, A; Libalova, H; Novakova, Z; Rossner, P; Balascak, I; Sram, RJ",null,null,null,"Topinka, J.; Milcova, A.; Libalova, H.; Novakova, Z.; Rossner, P., Jr.; Balascak, I.; Sram, R. J.",null,null,"Biomarkers of exposure to tobacco smoke and environmental pollutants in mothers and their transplacental transfer to the foetus. Part I: Bulky DNA adducts","MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS",null,null,"English","Article",null,null,null,null,null,"Air pollution; DNA adducts; PAHs; Complex mixtures; Placenta; Tobacco smoke","POLYCYCLIC AROMATIC-HYDROCARBONS; HUMAN-PLACENTA; AIR-POLLUTION; CHILDRENS HEALTH; FETAL-GROWTH; TISSUES; WOMEN; RADIOIMMUNOASSAY; SUSCEPTIBILITY; POPULATION","(32)P-postlabelling and PAH-ELISA using the antiserum #29 were employed to analyze DNA adducts in venous and umbilical cord blood and the placenta of 79 mothers giving birth to 80 living babies in Prague (Czech Republic) Ambient air exposure was measured by stationary measurements of basic air Pollutants (PM2.5. c-PAHs) during the entire pregnancy Tobacco smoke exposure was assessed by questionnaire data and by plasma cotinine levels The total DNA adduct levels in the lymphocytes of mothers and newborns were elevated by 30-40%(p < 0.001)compared with the placenta B[a]P-like DNA adduct(adduct with the identical chromatographic mobility on TLC as major BPDE derived DNA adduct) levels were elevated in the blood of mothers compared with the placenta and the blood of newborns(p < 0.05 and p < 0.01) In tobacco smoke-exposed mothers, higher DNA adduct levels in the blood of mothers and newborns compared with the placenta were found (p < 0.001), whereas the total and B[a]P-like adduct levels were comparable in the blood of mothers and newborns B[a]P-like adducts were elevated in the blood of mothers unexposed to tobacco smoke compared with that of corresponding newborns and the placenta (p < 0.01) Total and B[a]P-like DNA adducts were increased in the placenta of tobacco smoke-exposed compared with unexposed mothers (p < 0.001 and p < 0.01). In lymphocytes of tobacco smoke-exposed mothers, the comparison of total adduct levels (1.18 +/- 0.67 vs. 0.92 +/- 0.28)and B[a]P-like DNA adducts (0.22 +/- 0.12 adducts/10(8) nucleotides vs 0.15 +/- 0.06 adducts/10(8) nucleotides) with newborns indicated a 30-40% increase of adducts in mothers. Almost equal PAH-DNA adduct levels were detected by anti-BPDE-DNA ELISA in the placenta of tobacco smoke-exposed and unexposed mothers Our results suggest a protective effect of the placental barrier against the genotoxic effect of some tobacco smoke components between the circulation of mother and child We found a correlation between adduct levels in the blood of mothers and newborns (C) 2009 Elsevier B.V. All rights reserved","[Topinka, J.; Milcova, A.; Libalova, H.; Novakova, Z.; Rossner, P., Jr.; Sram, R. J.] AS CR VVI, Lab Genet Ecotoxicol, Inst Expt Med, Prague 14220 4, Czech Republic; [Balascak, I.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Topinka, J (reprint author), AS CR VVI, Lab Genet Ecotoxicol, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.",null,null,null,"Czech Ministry of the Education [2B06088]; Academy of Sciences of the Czech Republic [AVOZ50390512]","We thank the gynecological staff of the University Hospital in Prague-Motol. The study was supported by the Czech Ministry of the Education (grant number 2B06088) and by the Academy of Sciences of the Czech Republic (grant number AVOZ50390512).",null,35,31,33,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0027-5107",null,null,"MUTAT RES-FUND MOL M","Mutat. Res.-Fundam. Mol. Mech. Mutagen.","OCT 2",2009,669,41671,null,null,null,null,13,19,null,"10.1016/j.mrfmmm.2009.04.011",null,7,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","510CO","WOS:000271065800003"]
[null,null,null,null,"J","Pitzen, TR; Chrobok, J; Stulik, J; Ruffing, S; Drumm, J; Sova, L; Kucera, R; Vyskocil, T; Steudel, WI",null,null,null,"Pitzen, Tobias R.; Chrobok, Jiri; Stulik, Jan; Ruffing, Sabine; Drumm, Joerg; Sova, Laurentius; Kucera, Roman; Vyskocil, Tomas; Steudel, Wolf Ingo",null,null,"Implant Complications, Fusion, Loss of Lordosis, and Outcome After Anterior Cervical Plating With Dynamic or Rigid Plates Two-Year Results of a Multi-Centric, Randomized, Controlled Study","SPINE",null,null,"English","Article",null,null,null,null,null,"cervical spine; surgery; randomized controlled study; implants; complications","INTERBODY FUSION; FOLLOW-UP; SPINE; STABILIZATION; FIXATION; REMOVAL; BONE","Study Design. Prospective, controlled, randomized, multicenter study. Objective. To analyze implant complications and speed. Summary of Background Data. Rigid plate designs, in which the screws are locked to the plate, are in common use and thought to provide more fixation than dynamic designs, in which the screws may glide when the graft is settling. The aim of the study is to analyze (1) implant complications, (2) speed of fusion, (3) loss of lordosis, and (4) clinical outcome in both types of plates. Methods. One hundred thirty-two patients were included and assigned by randomization to one of the groups in which they received a routine anterior cervical discectomy and autograft fusion with either a dynamic plate (ABC, study group) or a rigid plate (CSLP, control group). At discharge, after 3 and 6 months and finally after 2 years, implant complications, segmental mobility, absence of radiolucencies, absence of bone sclerosis, evidence of bridging trabecular bone, loss of lordosis, Visual Analog Scale (VAS) and Neck Disability Score were recorded. All radiographic measurements were performed by an independent radiologist. Results. There have been 4 patients with implant complications within the control group and no implant complications within the study group, P = 0.045. Mean segmental mobility before discharge for the study group was 1.7 mm, 1.4 mm after 3 months, 0.8 mm after 6 months, and 0.4 mm after 2 years. For the control group, these values were 1.0, 1.8, 1.6, and 0.5 mm. The difference at 6 months between both groups was significant (P = 0.024). Neither absence of radiolucencies, nor absence of sclerosis, nor evidence of bridging bone showed significant differences between the 2 groups through the postoperative follow-up (P > 0.05). The loss of segmental lordosis for the study group with respect to intraoperative radiograph was 1.3 at discharge and 4.3 after 2 years. For the controlgroup, these values were 0.9, 0.7. The difference at 2 years was significant (P = 0.003). Clinical postoperative outcome (VAS and ODI) was not different between the 2 groups through the postoperative follow-up (P > 0.05). Conclusion. Dynamic cervical plate designs provide less implant complications (no patient) compared with rigid plate designs (4 patients). Speed of fusion was faster in the presence of a dynamic plate. However, loss of segmental lordosis is significantly higher if dynamic plates are used, which did not result in differences regarding clinical outcome between dynamic and constrained plates after 2 years. Thus, dynamic plates should be considered to be the preferred treatment option because of the lower risk for implant failure-related revision surgery.","[Pitzen, Tobias R.] SRH Waldklinikum Gera gGmbH, D-07548 Gera, Germany; [Chrobok, Jiri; Kucera, Roman] Homolka Hosp, Prague, Czech Republic; [Stulik, Jan; Vyskocil, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Ruffing, Sabine] Bundesknappschaftsklin Puttlingen, Puttlingen, Germany; [Drumm, Joerg; Steudel, Wolf Ingo] Univ Saarland, Dept Neurosurg, D-6650 Homburg, Germany; [Sova, Laurentius] Bundeswehrkrankenhaus Ulm, Dept Neurosurg, Ulm, Germany","Pitzen, TR (reprint author), SRH Waldklinikum Gera gGmbH, Str Friedens 122, D-07548 Gera, Germany.","pitzen@t-online.de",null,null,null,null,null,23,27,33,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0362-2436",null,null,"SPINE","SPINE","APR 1",2009,34,7,null,null,null,null,641,646,null,"10.1097/BRS.0b013e318198ce10",null,6,"Clinical Neurology; Orthopedics","Neurosciences & Neurology; Orthopedics","440CX","WOS:000265677500001"]
[null,null,null,null,"J","Krepela, E; Dankova, P; Moravcikova, E; Krepelova, A; Prochazka, J; Cermak, J; Schutzner, J; Zatloukal, P; Benkova, K",null,null,null,"Krepela, Evzen; Dankova, Petra; Moravcikova, Erika; Krepelova, Anna; Prochazka, Jan; Cermak, Jan; Schutzner, Jan; Zatloukal, Petr; Benkova, Kamila",null,null,"Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma","INTERNATIONAL JOURNAL OF ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"non-small cell lung carcinoma; survivin; hepatitis B X-interacting protein; X-chromosome-linked inhibitor of apoptosis protein; expression; apoptosis","X-LINKED INHIBITOR; NF-KAPPA-B; HUMAN CANCER-CELLS; GENE-EXPRESSION; RADIATION SENSITIZATION; PRECLINICAL MODELS; ENDOTHELIAL-CELLS; UBIQUITIN LIGASE; CASPASE ACTIVITY; SMAC MIMETICS","Members of the inhibitor of apoptosis protein (IAP) family, survivin and X-chromosome-linked IAP (XIAP), contribute to apoptosis resistance of cancer cells, and in increase in their expression may elevate the apoptotic threshold of malignant tumours during their growth and progression. In the present study, we investigated the expression status of survivin and its interactants hepatitis B X-interacting protein (HBXIP) and XIAP in non-small cell lung carcinoma (NSCLC) cell lines and NSCLC tumours and matched lungs from surgically treated patients in relation to their clinicopathological data. The expression of survivin, HBXIP and XIAP mRNAs was quantitated by real-time RT-PCR. The expression of survivin and XIAP proteins was analysed by Western blotting and ELISA. Survivin mRNA and protein levels were highly upregulated in NSCLC cells and tissues as compared to the lungs. In fact, the levels of survivin mRNA and protein in the tumours were more than 10-fold higher in 96 (64%) and 72 (82%) of the 150 and 88 examined NSCLC patients, respectively. The expression of survivin mRNA was higher in squamous cell lung carcinomas than in tune, adenocarcinomas (LACs; P=0.003) and in less-differentiated tumours than in well-differentiated ones (P=0.007). The level of survivin protein was higher in stage IB and stage II+III tumours (P=0.049 and P=0.044), than in stage IA tumours. The BIRC5 promoter polymorphism at nucleotide -31 did not influence the expression of survivin mRNA and protein in NSCLC cells and tumours. HBXIP mRNA was abundantly expressed in NSCLC cell lines and NSCLC tumours and lungs, while its level was comparable in the tumours and lungs. The expression of XIAP mRNA in NSCLC cell lines and NSCLC tumours and lungs was not significantly different. However, the expression of XIAP protein was higher in NSCLC tumours, particularly in LACs, as compared to the lungs (P=0.017 and P=0.004). In conclusion, the overexpression of survivin in the majority of NSCLCs together with the abundant or upregulated expression of HBXIP and XIAP suggest that tumours are endowed with resistance against a variety of apoptosis-inducing conditions.","[Krepela, Evzen; Zatloukal, Petr] Univ Hosp Bulovka, Dept Pneumol & Thorac Surg, Div Pneumol, Prague 18081 8, Czech Republic; [Cermak, Jan] Univ Hosp Bulovka, Div Surg, Prague 18081 8, Czech Republic; [Krepela, Evzen; Dankova, Petra; Moravcikova, Erika; Prochazka, Jan] Univ Hosp Bulovka, Labs Mol & Cell Biol, Prague 18081 8, Czech Republic; [Benkova, Kamila] Univ Hosp Bulovka, Dept Pathol, Prague 18081 8, Czech Republic; [Krepelova, Anna] Univ Hosp Motol, Fac Med 2, Inst Biol & Med Genet, Prague, Czech Republic; [Schutzner, Jan] Univ Hosp Motol, Fac Med 1, Dept Surg 3, Prague, Czech Republic","Krepela, E (reprint author), Univ Hosp Bulovka, Dept Pneumol & Thorac Surg, Div Pneumol, Budinova 2, Prague 18081 8, Czech Republic.","krepelae@fnb.cz",null,null,"Ministry of Health, Czech Republic [NR/7860-5, MZO 00064211]","This work was supported by a grant (no. NR/7860-5) and an institutional research project (no. MZO 00064211) from the Ministry of Health, Czech Republic.",null,89,25,30,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1019-6439","1791-2423",null,"INT J ONCOL","Int. J. Oncol.","DEC",2009,35,6,null,null,null,null,1449,1462,null,"10.3892/ijo_00000464",null,14,"Oncology","Oncology","518QQ","WOS:000271708600026"]
[null,null,null,null,"J","Krizkova, S; Blahova, P; Nakielna, J; Fabrik, I; Adam, V; Eckschlager, T; Beklova, M; Svobodova, Z; Horak, V; Kizek, R",null,null,null,"Krizkova, Sona; Blahova, Pavlina; Nakielna, Johana; Fabrik, Ivo; Adam, Vojtech; Eckschlager, Tomas; Beklova, Miroslava; Svobodova, Zdenka; Horak, Vratislav; Kizek, Rene",null,null,"Comparison of Metallothionein Detection by Using Brdicka Reaction and Enzyme-Linked Immunosorbent Assay Employing Chicken Yolk Antibodies","ELECTROANALYSIS",null,null,"English","Article",null,null,null,null,null,"Metallothionein; Differential pulse voltammetry; ELISA; Chicken yolk antibodies; Human blood serum; Immunoassays; Antibodies","PERFORMANCE LIQUID-CHROMATOGRAPHY; CADMIUM-INDUCED METALLOTHIONEIN; MESSENGER-RNA EXPRESSION; MERCURY SATURATION ASSAY; CAPILLARY-ELECTROPHORESIS; ELECTROCHEMICAL TECHNIQUES; ZINC SUPPLEMENTATION; SPECIATION ANALYSIS; MASS-SPECTROMETRY; FISH-TISSUES","In this Study, two methods for metallothioneins (MT) determination in a biological sample were compared. Particularly, twenty five human and nine pig blood serum samples and liver and kidney samples from thirty five carps (Cyprinus carpio) were analyzed by enzyme-linked immunosorbent assay and differential pulse voltammetry Brdicka's reaction. The results obtained by these two methods were in good agreement. For commercially available NIT standard the correlation coefficient between the single concentrations signal height was 0.99. In biological samples the correlation coefficients were 0.90 for fish liver and kidney samples, 0.91 for pig blood serum and 0.93 for human blood serum.","[Krizkova, Sona; Blahova, Pavlina; Nakielna, Johana; Fabrik, Ivo; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague, Czech Republic; [Beklova, Miroslava] Univ Vet & Pharmaceut Sci, Dept Vet Ecol & Environm Protect, CZ-61242 Brno, Czech Republic; [Svobodova, Zdenka] Univ Vet & Pharmaceut Sci, Fac Vet Hyg & Ecol, Dept Vet Publ Hlth & Toxicol, CZ-61242 Brno, Czech Republic; [Svobodova, Zdenka] Univ S Bohemia Ceske Budejovice, Res Inst Fish Culture & Hydrobiol, CZ-38925 Vodnany, Czech Republic; [Horak, Vratislav] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Dept Anim Embryol Cell & Tissue Differentitat, Lab Tumour Biol,Vvi, CZ-27721 Libechov, Czech Republic","Kizek, R (reprint author), Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Krizkova, Sona/E-9617-2012; BEKLOVA, Miroslava/F-5477-2012",null,"INCHEMBIOL [MSM 0021622412, MSM 6215712402, MSM 0021620813, GAAV IAA401990701]","Financial support from INCHEMBIOL MSM 0021622412, MSM 6215712402, MSM 0021620813, GAAV IAA401990701 and Ligra. proti rakovine Prague is highly acknowledged. Moreover, the authors express their thanks to Veronika Kohoutkova for English correction.",null,92,28,28,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","1040-0397",null,null,"ELECTROANAL","Electroanalysis","DEC",2009,21,23,null,null,null,null,2575,2583,null,"10.1002/elan.200900243",null,9,"Chemistry, Analytical; Electrochemistry","Chemistry; Electrochemistry","532HW","WOS:000272738800010"]
[null,null,null,null,"J","Dostalova, I; Roubicek, T; Bartlova, M; Mraz, M; Lacinova, Z; Haluzikova, D; Kavalkova, P; Matoulek, M; Kasalicky, M; Haluzik, M",null,null,null,"Dostalova, Ivana; Roubicek, Tomas; Bartlova, Marketa; Mraz, Milos; Lacinova, Zdena; Haluzikova, Denisa; Kavalkova, Petra; Matoulek, Martin; Kasalicky, Mojmir; Haluzik, Martin",null,null,"Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet","EUROPEAN JOURNAL OF ENDOCRINOLOGY",null,null,"English","Article",null,null,null,null,null,null,"TGF-BETA SUPERFAMILY; INSULIN-RESISTANCE; GENE-EXPRESSION; ADIPOSE-TISSUE; MEMBER; MIC-1; ACTIVATION; ANOREXIA; PROFILE; PLASMA","Objective: Macrophage inhibitory cytokine-1 (MIC-1) is a novel regulator of energy homeostasis. We explored whether alterations in MIC-1 levels contribute to metabolic disturbances in patients with obesity and/or obesity and type 2 diabetes mellitus (T2DM). Design: We measured serum MIC-1 levels and its mRNA expression in subcutaneous and visceral adipose tissue of 17 obese nondiabetic women, 14 obese women with T2DM and 23 healthy lean women. We also explored the relationship of MIC-1. with anthropometric and biochemical parameters and studied the influence of 2-week very low calorie diet (VLCD) on serum MIC-I levels. Methods: Serum MIC-1. levels were measured by ELISA and its mRNA expression was determined by RT-PCR. Results: Both obese and T2DM group had significantly elevated serum MIC-1 levels relative to controls. T2DM group had significantly higher serum MIC-1 levels relative to obese group. Serum MIC-1 positively correlated with body weight, body fat, and serum levels of triglycerides. glucose, HbAlc, and C-reactive protein and it was inversely related to serum high-density lipoprotein cholesterol. Fat mRNA MIC-1 expression did not significantly differ between lean and obese women but it was significantly higher in subcutaneous than in visceral fat in both groups. VLCD significantly increased serum MIC-1 levels in obese but not T2DM group. Conclusion: Elevated MIC-1. levels in patients with obesity are further increased by the presence of T2DM. We suggest that in contrast to patients with cancer cachexia, increased MIC-1. levels in obese patients and diabetic patients do not induce weight loss.","[Dostalova, Ivana; Roubicek, Tomas; Bartlova, Marketa; Mraz, Milos; Lacinova, Zdena; Haluzikova, Denisa; Kavalkova, Petra; Matoulek, Martin; Haluzik, Martin] Charles Univ Prague, Dept Med 1, Fac Med 1, Prague 12800 2, Czech Republic; [Haluzikova, Denisa] Charles Univ Prague, Dept Sports Med, Fac Med 1, Prague 12800 2, Czech Republic; [Kasalicky, Mojmir] Charles Univ Prague, Dept Surg, Fac Med 1, Prague 12800 2, Czech Republic; Gen Univ Hosp, Prague 12800 2, Czech Republic","Haluzik, M (reprint author), Charles Univ Prague, Dept Med 1, Fac Med 1, Nemocnice 1, Prague 12800 2, Czech Republic.","mhalu@lf1.cuni.cz",null,null,"MZOVFN2005","This work was supported by MZOVFN2005.",null,26,22,24,"BIOSCIENTIFICA LTD","BRISTOL","EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND","0804-4643",null,null,"EUR J ENDOCRINOL","Eur. J. Endocrinol.","SEP",2009,161,3,null,null,null,null,397,404,null,"10.1530/EJE-09-0417",null,8,"Endocrinology & Metabolism","Endocrinology & Metabolism","534ZA","WOS:000272934900004"]
[null,null,null,null,"J","Rossner, P; Milcova, A; Libalova, H; Novakova, Z; Topinka, J; Balascak, I; Sram, RJ",null,null,null,"Rossner, P., Jr.; Milcova, A.; Libalova, H.; Novakova, Z.; Topinka, J.; Balascak, I.; Sram, R. J.",null,null,"Biomarkers of exposure to tobacco smoke and environmental pollutants in mothers and their transplacental transfer to the foetus. Part II. Oxidative damage","MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS",null,null,"English","Article",null,null,null,null,null,"Air pollution; Oxidative stress; Newborns; Mothers","AMBIENT AIR-POLLUTION; OF-THE-LITERATURE; DNA-DAMAGE; GESTATIONAL-AGE; CORD BLOOD; IN-VIVO; STRESS; PLASMA; PREGNANCY; HEALTHY","Oxidative damage to macromolecules may have numerous negative health consequences. We measured oxidative damage to DNA, proteins and lipids in 80 newborns and 79 mothers, analyzed the effect of mother's tobacco smoke exposure on oxidative stress, and assessed correlations between oxidative stress markers and bulky and PAH (polycyclic aromatic hydrocarbons)-specific DNA adducts. Mean levels (+/-S.D.) of 8-oxodeoxyguanosine (8-oxodG) per 10(5) dG in the placenta were 2.85 +/- 0.78; we did not see a difference between 8-oxodG levels in newborns born to mothers exposed and unexposed to tobacco smoke. Protein carbonyl levels. a marker of protein oxidation, were comparable in the umbilical cord and in maternal venous blood plasma (17.4 +/- 3.2 and 17.6 +/- 4.2 nmol/ml plasma in newborns and mothers, respectively, p = 0.66). Lipid peroxidation measured as levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP) in plasma was significantly higher in newborns than in mothers (362 +/- 129 and 252 +/- 130 pg/ml in newborns and mothers, respectively, p < 0.001) We did not find any effect of tobacco smoke exposure on either biomarker in any group. Levels of both protein carbonyls and 15-F(2t)-IsoP in cord blood significantly correlated with those in maternal plasma (p < 0.001). 8-oxodG levels positively correlated with plasma carbonyls in cord plasma, as well as with cotinine levels (marker of tobacco smoke exposure) in maternal plasma. 8-oxodG levels also correlated with bulky DNA adducts in lymphocyte DNA of newborns and mothers and with PAH-DNA adducts in the placenta. Our results showed higher lipid peroxidation in newborns than in mothers, close correlation of analyzed oxidative stress markers between newborns and mothers, and a relationship between oxidative stress and induction of DNA adducts. (C) 2009 Elsevier B.V. All rights reserved","[Rossner, P., Jr.; Milcova, A.; Libalova, H.; Novakova, Z.; Topinka, J.; Sram, R. J.] AS CR VVI, Lab Genet Ecotoxicol, Inst Expt Med, Prague 14220 4, Czech Republic; [Balascak, I.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Rossner, P (reprint author), AS CR VVI, Lab Genet Ecotoxicol, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","prossner@biomedcas.cz",null,null,"Czech Ministry of the Education [21306088]; Academy of Sciences of the Czech Republic [AVOZ50390512]","We thank the gynecological staff of the University Hospital in Prague-Motol. The study was supported by Czech Ministry of the Education (grant number 21306088) and by Academy of Sciences of the Czech Republic (grant number AVOZ50390512).",null,45,23,23,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0027-5107",null,null,"MUTAT RES-FUND MOL M","Mutat. Res.-Fundam. Mol. Mech. Mutagen.","OCT 2",2009,669,41671,null,null,null,null,20,26,null,"10.1016/j.mrfmmm.2009.04.010",null,7,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","510CO","WOS:000271065800004"]
[null,null,null,null,"J","Hilgert, N; Huentelman, MJ; Thorburn, AQ; Fransen, E; Dieltjens, N; Mueller-Malesinska, M; Pollak, A; Skorka, A; Waligora, J; Ploski, R; Castorina, P; Primignani, P; Ambrosetti, U; Murgia, A; Orzan, E; Pandya, A; Arnos, K; Norris, V; Seeman, P; Janousek, P; Feldmann, D; Marlin, S; Denoyelle, F; Nishimura, CJ; Janecke, A; Nekahm-Heis, D; Martini, A; Mennucci, E; Toth, T; Sziklai, I; del Castillo, I; Moreno, F; Petersen, MB; Iliadou, V; Tekin, M; Incesulu, A; Nowakowska, E; Bal, J; de Heyning, PV; Roux, AF; Blanchet, C; Goizet, C; Lancelot, G; Fialho, G; Caria, H; Liu, XZ; Xiaomei, OY; Govaerts, P; Gronskov, K; Hostmark, K; Frei, K; Dhooge, I; Vlaeminck, S; Kunstmann, E; Van Laer, L; Smith, RJH; Van Camp, G",null,null,null,"Hilgert, Nele; Huentelman, Matthew J.; Thorburn, Ashley Q.; Fransen, Erik; Dieltjens, Nele; Mueller-Malesinska, Malgorzata; Pollak, Agnieszka; Skorka, Agata; Waligora, Jaroslaw; Ploski, Rafal; Castorina, Pierangela; Primignani, Paola; Ambrosetti, Umberto; Murgia, Alessandra; Orzan, Eva; Pandya, Arti; Arnos, Kathleen; Norris, Virginia; Seeman, Pavel; Janousek, Petr; Feldmann, Delphine; Marlin, Sandrine; Denoyelle, Francoise; Nishimura, Carla J.; Janecke, Andreas; Nekahm-Heis, Doris; Martini, Alessandro; Mennucci, Elena; Toth, Timea; Sziklai, Istvan; del Castillo, Ignacio; Moreno, Felipe; Petersen, Michael B.; Iliadou, Vasiliki; Tekin, Mustafa; Incesulu, Armagan; Nowakowska, Ewa; Bal, Jerzy; de Heyning, Paul Van; Roux, Anne-Francoise; Blanchet, Catherine; Goizet, Cyril; Lancelot, Guenaelle; Fialho, Graca; Caria, Helena; Liu, Xue Zhong; Xiaomei, Ouyang; Govaerts, Paul; Gronskov, Karen; Hostmark, Karianne; Frei, Klemens; Dhooge, Ingeborg; Vlaeminck, Stephen; Kunstmann, Erdmute; Van Laer, Lut; Smith, Richard J. H.; Van Camp, Guy",null,null,"Phenotypic variability of patients homozygous for the GJB2 mutation 35delG cannot be explained by the influence of one major modifier gene","EUROPEAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"hereditary hearing loss; connexin 26; 35delG; association study; modifier gene","GENOME-WIDE ASSOCIATION; HEARING-LOSS; DISEASE; DNA; IDENTIFICATION","Hereditary hearing loss (HL) is a very heterogeneous trait, with 46 gene identifications for non-syndromic HL. Mutations in GJB2 cause up to half of all cases of severe-to-profound congenital autosomal recessive non-syndromic HL, with 35delG being the most frequent mutation in Caucasians. Although a genotype-phenotype correlation has been established for most GJB2 genotypes, the HL of 35delG homozygous patients is mild to profound. We hypothesise that this phenotypic variability is at least partly caused by the influence of modifier genes. By performing a whole-genome association (WGA) study on 35delG homozygotes, we sought to identify modifier genes. The association study was performed by comparing the genotypes of mild/moderate cases and profound cases. The first analysis included a pooling-based WGA study of a first set of 255 samples by using both the Illumina 550K and Affymetrix 500K chips. This analysis resulted in a ranking of all analysed single-nucleotide polymorphisms (SNPs) according to their P-values. The top 250 most significantly associated SNPs were genotyped individually in the same sample set. All 192 SNPs that still had significant P-values were genotyped in a second independent set of 297 samples for replication. The significant P-values were replicated in nine SNPs, with combined P-values between 3 x 10(-3) and 1 x 10(-4). This study suggests that the phenotypic variability in 35delG homozygous patients cannot be explained by the effect of one major modifier gene. Significantly associated SNPs may reflect a small modifying effect on the phenotype. Increasing the power of the study will be of greatest importance to confirm these results.","[Hilgert, Nele; Fransen, Erik; Dieltjens, Nele; Van Laer, Lut; Van Camp, Guy] Univ Antwerp, Dept Med Genet, B-2610 Antwerp, Belgium; [Huentelman, Matthew J.; Thorburn, Ashley Q.] Translat Genom Res Inst, Phoenix, AZ USA; [Mueller-Malesinska, Malgorzata; Pollak, Agnieszka; Skorka, Agata] Inst Physiol & Pathol Hearing, Warsaw, Poland; [Waligora, Jaroslaw] Med Univ Warsaw, Dept Diabetol Newborn Pathol & Birth Defects, Warsaw, Poland; [Ploski, Rafal] Med Univ Warsaw, Dept Med Genet, Warsaw, Poland; [Castorina, Pierangela] Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, UO Audiol, Milan, Italy; [Primignani, Paola] Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, Med Genet Lab, Milan, Italy; [Ambrosetti, Umberto] Univ Milan, Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, ENT & Ophthalmol Dept,UO Audiol, Milan, Italy; [Murgia, Alessandra] Univ Padua, Dept Pediat, Rare Dis Ctr, Padua, Italy; [Orzan, Eva] Univ Hosp Padova, Pediat Audiol Unit, Dept Otolaryngol & Otosurgery, Padua, Italy; [Pandya, Arti] Virginia USA Commonwealth Univ, Sch Med, Dept Human Genet, Richmond, VA USA; [Arnos, Kathleen; Norris, Virginia] Gallaudet Univ, Dept Biol, Washington, DC 20002 USA; [Seeman, Pavel] Charles Univ Prague, Dept Child Neurol, DNA Lab, Sch Med 2, Prague, Czech Republic; [Janousek, Petr] Charles Univ Prague, Dept Child ENT, Sch Med 2, Prague, Czech Republic; [Janousek, Petr] Univ Hosp Motol, Prague, Czech Republic; [Feldmann, Delphine] Hop Enfants Armand Trousseau, AP HP, Serv Biochim & Biol Mol, Paris, France; [Marlin, Sandrine] Hop Enfants Armand Trousseau, AP HP, Unite Genet Med, Paris, France; [Denoyelle, Francoise] Hop Enfants Armand Trousseau, AP HP, Serv ORL & Chirurg Cervico Faciale, Paris, France; [Denoyelle, Francoise] UPMC Paris 06, Paris, France; [Nishimura, Carla J.; Smith, Richard J. H.] Univ Iowa, Dept Otolaryngol & Interdept PhD Program Genet, Iowa City, IA USA; [Janecke, Andreas] Innsbruck Med Univ, Div Clin Genet, Innsbruck, Austria; [Nekahm-Heis, Doris] Innsbruck Med Univ, Clin Dept Hearing Voice & Speech Disorders, Innsbruck, Austria; [Martini, Alessandro; Mennucci, Elena] Univ Hosp, Audiol & ENT Dept, Ferrara, Italy; [Toth, Timea; Sziklai, Istvan] Debrecen Univ Med, Dept Otolaryngol, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary; [del Castillo, Ignacio; Moreno, Felipe] Hosp Ramon & Cajal, Unidad Genet Mol, E-28034 Madrid, Spain; [del Castillo, Ignacio; Moreno, Felipe] CIBERER, Madrid, Spain; [Petersen, Michael B.] Aghia Sophia Childrens Hosp, Dept Genet, Inst Child Hlth, Athens, Greece; [Iliadou, Vasiliki] Aristotle Univ Thessaloniki, Dept Psychoacoust Neurootol, AHEPA Hosp, Psychiat Clin 3, GR-54006 Thessaloniki, Greece; [Tekin, Mustafa] Ankara Univ, Sch Med, Div Pediat Mol Genet, TR-06100 Ankara, Turkey; [Incesulu, Armagan] Eskisehir Osmangazi Univ, Dept Otolaryngol Head & Neck Surg, Eskisehir, Turkey; [Nowakowska, Ewa] Inst Mother & Child Hlth, Dept Audiol & Laryngol, Warsaw, Poland; [Bal, Jerzy] Inst Mother & Child Hlth, Dept Med Genet, Warsaw, Poland; [de Heyning, Paul Van] Univ Antwerp, Dept Otorhinolaryngol, Univ Antwerp Hosp, B-2020 Antwerp, Belgium; [Roux, Anne-Francoise] CHU Montpellier, Genet Mol Lab, Montpellier, France; [Blanchet, Catherine] Hop Montpellier, ENT Dept, Sensory Genet Dis Natl Reference Ctr, Montpellier, France; [Goizet, Cyril] Univ Victor Segalen Bordeaux 2, Lab Genet Humaine Dev & Canc, Bordeaux, France; [Lancelot, Guenaelle] CHU Pellegrin, Genet Mol Lab, Bordeaux, France; [Fialho, Graca; Caria, Helena] Univ Lisbon, Fac Sci, Ctr Biodivers Funct & Integrat Genom, P-1699 Lisbon, Portugal; [Liu, Xue Zhong; Xiaomei, Ouyang] Univ Miami, Dept Otolaryngol, Miami, FL USA; [Govaerts, Paul] Eargroup, Antwerp, Belgium; [Gronskov, Karen] Kennedy Ctr, Med Genet Lab, Glostrup, Denmark; [Hostmark, Karianne] Bispebjerg Hosp, Dept Audiol, DK-2400 Copenhagen, Denmark; [Frei, Klemens] Med Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria; [Dhooge, Ingeborg; Vlaeminck, Stephen] Univ Ziekenhuis Gent, Klin Audiol, Ghent, Belgium; [Kunstmann, Erdmute] Univ Wurzburg, Dept Human Genet, Wurzburg, Germany","Van Camp, G (reprint author), Univ Antwerp, Dept Med Genet, Campus Drie Eiken,Univ Pl 1, B-2610 Antwerp, Belgium.","guy.vancamp@ua.ac.be","Iliadou, Vasiliki Maria/F-3164-2011; del Castillo, Ignacio/B-4314-2013; Van Camp, Guy/F-3386-2013; LABO, U827/A-8632-2008","Iliadou, Vasiliki Maria/0000-0002-1122-5104; del Castillo, Ignacio/0000-0003-1188-3665; Van Camp, Guy/0000-0001-5105-9000; ","EUROHEAR [LSHG-CT2004-512063]; Fund for Scientific Research Flanders (FWO-F) [G. 0138.07]; MNiSW [0711/ P01/ 2006/ 31]; Oticon Foundation; National Institutes of Health [DC02842]","We are very grateful to all patients who cooperated in this study. This study was supported in part by grants from EUROHEAR (LSHG-CT2004-512063), the Fund for Scientific Research Flanders (FWO-F, Grant G. 0138.07), the MNiSW Grant 0711/ P01/ 2006/ 31, the Oticon Foundation (Denmark, MBP) and the National Institutes of Health (NIDCD DC02842 to RJHS). Nele Hilgert is a fellow of the Fund for Scientific Research Flanders (FWO-F).",null,21,18,19,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,null,"EUR J HUM GENET","Eur. J. Hum. Genet.","APR",2009,17,4,null,null,null,null,517,524,null,"10.1038/ejhg.2008.201",null,8,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","421JJ","WOS:000264354900015"]
[null,null,null,null,"J","Martin, RCG; Robbins, K; Tomalty, D; O'Hara, R; Bosnjakovic, P; Padr, R; Rocek, M; Slauf, F; Scupchenko, A; Tatum, C",null,null,null,"Martin, Robert C. G.; Robbins, Ken; Tomalty, Dana; O'Hara, Ryan; Bosnjakovic, Petar; Padr, Radek; Rocek, Miloslav; Slauf, Frantisek; Scupchenko, Alexander; Tatum, Cliff",null,null,"Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report","WORLD JOURNAL OF SURGICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ELUTING BEADS; ARTERIAL CHEMOEMBOLIZATION; HEPATOCELLULAR-CARCINOMA; SYSTEMIC CHEMOTHERAPY; SOLID TUMORS; MICROSPHERES; CRITERIA; MANAGEMENT; INFUSION","Background: Following failure of standard systemic chemotherapy, the role of hepatic transarterial therapy for colorectal hepatic metastasis continues to evolve as the experience with this technique matures. The aim of this study to gain a better understanding of the value of drug eluting bead therapy when administered to patients with unresectable colorectal hepatic metastasis. Methods: This was an open-label, multi-center, single arm study, of unresectable colorectal hepatic metastasis patients who had failed standard therapy from 10/2006-10/2008. Patients received repeat embolizations with Irinotecan loaded beads(max 100 mg per embolization) per treating physician's discretion. Results: Fifty-five patients underwent 99 treatments using Irinotecan drug eluting beads. The median number of total treatments per patient was 2(range of 1-5). Median length of hospital stay was 23 hours(range 23 hours - 10 days). There were 30(30%) sessions associated with adverse reactions during or after the treatment. The median disease free and overall survival from the time of first treatment was 247 days and 343 days. Six patients(10%) were downstaged from their original disease status. Of these, four were treated with surgery and two with RFA. Neither number of liver lesions, size of liver lesions or extent of liver replacement(<= 25% vs >25%) were predictors of overall survival. Only the presence of extrahepatic disease(p = 0,001), extent of prior chemotherapy (failed 1(st) and 2(nd) line vs > 2 line failure)(p = 0,007) were predictors of overall survival in multivariate analysis. Conclusion: Chemoembolization using Irinotecan loaded beads was safe and effective in the treatment of patients as demonstrated by a minimal complication rate and acceptable tumor response.","[Martin, Robert C. G.] Univ Louisville, Sch Med, Div Surg Oncol, Louisville, KY 40292 USA; [Robbins, Ken] Baptist Hlth, Little Rock, AR USA; [Tomalty, Dana] Huntsville Dist Mem Hosp, Huntsville, AL USA; [O'Hara, Ryan] Radiol & Imaging Consultants, PC, Inst Minimally Invas Therapy, Colorado Springs, CO USA; [Bosnjakovic, Petar] Clin Ctr Nis, Inst Radiol, Nish, Serbia; [Padr, Radek] Univ Hosp Motol, Dept Radiol, Prague, Czech Republic; [Padr, Radek] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Padr, Radek] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Rocek, Miloslav; Slauf, Frantisek] Inst Clin & Intervent Radiol IKEM, Dept Diagnost & Intervent Radiol, Prague 14000 4, Czech Republic; [Scupchenko, Alexander] Reg Oncol Dispenser, Samara, Russia; [Tatum, Cliff] Norton Radiol, Louisville, KY USA","Martin, RCG (reprint author), Univ Louisville, Sch Med, Div Surg Oncol, Louisville, KY 40292 USA.","Robert.Martin@louisville.edu; radonc@yahoo.com; Dtomalty@mac.com; rohara@yahoo.com; petarbos1@eunet.yu; padr.radek1@post.cz; miloslav.rocek1@post.cz; slauf.f1@seznam.cz; Scup_chen@mail.ru; cmtj@aol.com",null,null,"Unrestricted Education; Biocompatibles","Research Support: Unrestricted Education Grant: Biocompatibles",null,30,31,33,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1477-7819",null,null,"WORLD J SURG ONCOL","World J. Surg. Oncol.","NOV 3",2009,7,null,null,null,null,null,null,null,80,"10.1186/1477-7819-7-80",null,12,"Oncology; Surgery","Oncology; Surgery","526ON","WOS:000272300700001"]
[null,null,null,null,"J","Havrdova, E; Zivadinov, R; Krasensky, J; Dwyer, MG; Novakova, I; Dolezal, O; Ticha, V; Dusek, L; Houzvickova, E; Cox, JL; Bergsland, N; Hussein, S; Svobodnik, A; Seidl, Z; Vaneckova, M; Horakova, D",null,null,null,"Havrdova, E.; Zivadinov, R.; Krasensky, J.; Dwyer, M. G.; Novakova, I.; Dolezal, O.; Ticha, V.; Dusek, L.; Houzvickova, E.; Cox, J. L.; Bergsland, N.; Hussein, S.; Svobodnik, A.; Seidl, Z.; Vaneckova, M.; Horakova, D.",null,null,"Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis","MULTIPLE SCLEROSIS",null,null,"English","Article",null,null,null,null,null,"azathioprine; beta-interferon; corticosteroids; disease modifying therapies; placebo-controlled","RELAPSING-REMITTING MS; PLACEBO-CONTROLLED TRIAL; BRAIN ATROPHY; DOUBLE-BLIND; THERAPY; DISEASE; MRI; GUIDELINES; EFFICACY; METHYLPREDNISOLONE","Background Studies evaluating interferon beta (IFN beta) for multiple sclerosis (MS) showed only partial efficacy. In many patients, IFN beta does not halt relapses or disability progression. One strategy to potentially enhance efficacy is to combine IFN beta with classical immunosuppressive agents, such as azathioprine (AZA) or corticosteroids, commonly used for other autoimmune disorders. Objective The Avonex-Steroids-Azathioprine study was placebo-controlled trial and evaluated efficacy of IFN beta-1a alone and combined with low-dose AZA alone or low-dose AZA and low-dose corticosteroids as initial therapy. Methods A total of 181 patients with relapsing-remitting MS (RRMS) were randomized to receive IFN beta-1a 30 mu g intramuscularly (IM) once weekly, IFN beta-1a 30 mu g IM once weekly plus AZA 50 mg orally once daily, or IFN beta-1a 30 mu g IM once weekly plus AZA 50 mg orally once daily plus prednisone 10 mg orally every other day. The primary end point was annualized relapse rate (ARR) at 2 years. Patients were eligible for enrollment in a 3-year extension. Results At 2 years, adjusted ARR was 1.05 for IFN beta-1a, 0.91 for IFN beta-1a plus AZA, and 0.73 for combination. The cumulative probability of sustained disability progression was 16.8% for IFN beta-1a, 20.7% for IFN beta-1a plus AZA, and 17.5% for combination. There were no statistically significant differences among groups for either measure at 2 and 5 years. Percent T2 lesion volume change at 2 years was significantly lower for combination (+14.5%) versus IFN beta-1a alone (+30.3%, P < 0.05). Groups had similar safety profiles. Conclusion In IFN beta-naive patients with early active RRMS, combination treatment did not show superiority over IFN beta-1a monotherapy. Multiple Sclerosis 2009; 15: 965-976. http://msj.sagepub.com","[Havrdova, E.] Charles Univ Prague, Dept Neurol, Sch Med 1, Fac Med 1, Prague 12808 2, Czech Republic; [Zivadinov, R.; Dwyer, M. G.; Cox, J. L.; Bergsland, N.; Hussein, S.] SUNY Buffalo, Dept Neurol, Buffalo Neuroimaging Anal Ctr, Buffalo, NY 14260 USA; [Krasensky, J.; Seidl, Z.; Vaneckova, M.] Charles Univ Prague, Dept Radiol, Fac Med 1, Prague 12808 2, Czech Republic; [Dusek, L.; Svobodnik, A.] Masaryk Univ, Fac Med, Ctr Biostat & Anal, Brno, Czech Republic; [Dusek, L.; Svobodnik, A.] Masaryk Univ, Fac Sci, Brno, Czech Republic; [Houzvickova, E.] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague 12808 2, Czech Republic","Havrdova, E (reprint author), Charles Univ Prague, Dept Neurol, Sch Med 1, Fac Med 1, Katerinska 30, Prague 12808 2, Czech Republic.","eva.havrdova@gmail.com","Horakova, Dana/D-4649-2011; Dusek, Ladislav/G-8794-2013",null,"Czech Ministry of Education [MSM 0021620849]","The authors thank the subjects who participated in this study. MRI acquisition and analysis was supported by Biogen Idec. EH, DH, OD, ZS, JK, and MV acknowledge financial support from the Czech Ministry of Education (research program MSM 0021620849). Sabrina Maurer and Matthew Hasson, Scientific Connexions, Newtown, Pennsylvania, USA assisted in the first draft of this paper and provided technical and editorial support during the preparation for submission; funding for these activities was provided by Biogen Idec.",null,42,29,29,"SAGE PUBLICATIONS LTD","LONDON","1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND","1352-4585",null,null,"MULT SCLER","Mult. Scler.","AUG",2009,15,8,null,null,null,null,965,976,null,"10.1177/1352458509105229",null,12,"Clinical Neurology","Neurosciences & Neurology","481IC","WOS:000268800000012"]
[null,null,null,null,"J","Lapcikova, M; Slouf, M; Dybal, J; Zolotarevova, E; Entlicher, G; Pokorny, D; Gallo, J; Sosna, A",null,null,null,"Lapcikova, Monika; Slouf, Miroslav; Dybal, Jiri; Zolotarevova, Eva; Entlicher, Gustav; Pokorny, David; Gallo, Jiri; Sosna, Antonin",null,null,"Nanometer size wear debris generated from ultra high molecular weight polyethylene in vivo","WEAR",null,null,"English","Article",null,null,null,null,null,"Ultra high molecular weight polyethylene; Nanometer size wear debris; Morphology of wear particles; Total hip replacement","UHMWPE WEAR; PERIPROSTHETIC TISSUES; PARTICLES; HIP; ARTHROPLASTIES; QUANTIFICATION; PROSTHESES; NUMBER; VITRO","Ultra high molecular weight polyethylene (UHMWPE) wear debris is a major cause of long-term failure of total hip replacements. UHMWPE wear particle sizes range from submicron to several millimeters, but the particles below 10 mu m exhibit the highest biological activity. Some in vitro wear particles, produced in joint simulators. were shown to be smaller than 0.2 mu m and recently even in vitro particles as small as several tens of nanometers have been detected. This study brings the first evidence that nano-sized wear particles with sizes below 0.05 mu m are produced in vivo. UHMWPE wear nanoparticles were revealed by high-resolution, field emission gun scanning electron microscopy (FEGSEM) in the periprosthetic tissues of two different patients. Purity of the isolated wear nanoparticles was confirmed by energy-dispersive analysis of X-rays (EDS) and infrared spectroscopy (IR). Morphology of wear nanoparticles was determined by image analysis of FEGSEM micrographs. The average equivalent diameters of wear particles in the first and the second patient were 18.5 and 21.2 nm, respectively. Nanoscale wear debris could only be reliably detected if the isolation protocol included intensive sonication and if higher-than-usual magnifications were employed during FEGSEM analysis. (C) 2008 Elsevier B.V. All rights reserved.","[Lapcikova, Monika; Slouf, Miroslav; Dybal, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, Prague 16206 6, Czech Republic; [Zolotarevova, Eva; Entlicher, Gustav] Charles Univ Prague, Fac Sci, Prague 12840 2, Czech Republic; [Pokorny, David; Sosna, Antonin] Fac Hosp Motol, Orthopaed Clin, Prague 15606 5, Czech Republic; [Gallo, Jiri] Palacky Univ, Fac Med & Dent, Dept Orthopaed, Olomouc 77520 6, Czech Republic","Slouf, M (reprint author), Acad Sci Czech Republic, Inst Macromol Chem, Heyrovskeho Namesti 2, Prague 16206 6, Czech Republic.","slouf@imc.cas.cz","Slouf, Miroslav/F-6311-2012; Dybal, Jiri/A-8290-2008","Slouf, Miroslav/0000-0003-1528-802X; Dybal, Jiri/0000-0002-9148-3655","Ministry of Education, Youth and Sports of the Czech Republic [2B06096]","Financial support through grant 2B06096 (Ministry of Education, Youth and Sports of the Czech Republic) is gratefully acknowledged.",null,20,19,20,"ELSEVIER SCIENCE SA","LAUSANNE","PO BOX 564, 1001 LAUSANNE, SWITZERLAND","0043-1648",null,null,"WEAR","Wear","JAN 5",2009,266,41671,null,null,null,null,349,355,null,"10.1016/j.wear.2008.06.005",null,7,"Engineering, Mechanical; Materials Science, Multidisciplinary","Engineering; Materials Science","381LY","WOS:000261538800041"]
[null,null,null,null,"J","Druga, R",null,null,null,"Druga, R.",null,null,"Neocortical Inhibitory System","FOLIA BIOLOGICA",null,null,"English","Review",null,null,null,null,null,"cortical interneurons; GABAergic neurons; calcium-binding proteins; neuropeptides","CALCIUM-BINDING PROTEINS; LOCAL-CIRCUIT NEURONS; MEDIAL PREFRONTAL CORTEX; RAT VISUAL-CORTEX; DIAPHORASE-POSITIVE NEURONS; HUMAN TEMPORAL NEOCORTEX; PARVALBUMIN-IMMUNOREACTIVE NEURONS; PRIMARY SOMATOSENSORY CORTEX; GLUTAMIC-ACID DECARBOXYLASE; CENTRAL AUDITORY-SYSTEM","The neocortex contains two neuron types, excitatory (glutamatergic) pyramidal cells and inhibitory nonpyramidal (GABAergic) cells. GABAergic, inhibitory interneurons are morphologically distinct from excitatory pyramidal cells and account for 20-25 % of all neocortical neurons. Recent studies discovered that besides morphological features, inhibitory interneurons are molecularly and physiologically heterogenous and differ significantly in arrangement and terminations of their axonal endings. In neocortical interneurons, GABA is also co-localized with calcium-binding proteins (parvalbumin, calbindin, calretinin), with neuropeptides and nitric oxide synthase. Axons of GABAergic neurons target distinct domains of pyramidal neurons. Double-bouquet, Martinotti and neurogliaform cells (CB-IR, CR-IR) target distal dendrites of pyramidal neurons and probably regulate the vertical integration of synaptic input along the dendritic tree of pyramids. Basket cells (PV-IR) innervate soma and proximal dendrites, and Chandelier cells (PV-IR) exhibit synaptic contacts on the axon initial segment of pyramidal neurons. GABAergic neocortical interneurons are interconnected by gap junctions. Most often coupling is bidirectional and occurs between interneurons of the same type. Cortical pyramidal neurons derive from the dorsal telencephalon while the majority of interneurons derive from the ganglionic eminences of the ventral telencephalon, and tangentially migrate into cortex. Adult mammalian neurogenesis is not restricted to the hippocampus, but a small number of the new neurons is also generated in the neocortex. New cortical neurons are GABAergic and co-express calbindin and calretinin. Quantitative analysis of selected areas of the neocortex (neuropsychiatric diseases, models of epilepsy, aging) demonstrate a decrease in density of PV-IR and CB-IR neurons but not CR-IR neurons.","[Druga, R.] Charles Univ Prague, Inst Anat, Fac Med 2, Prague 12800 2, Czech Republic; [Druga, R.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 12800 2, Czech Republic","Druga, R (reprint author), Charles Univ Prague, Inst Anat, Fac Med 2, Unemocnice 3, Prague 12800 2, Czech Republic.","rastislav.druga@lfl.cuni.cz",null,null,"Grant Agency of the Czech Republic [309/07/1336, 304/07/1137]; Czech Ministry of Education, Youth and Sports [LC 554]","This work was supported by the Grant Agency of the Czech Republic, grants Nos. 309/07/1336 and 304/07/1137, and by project of the Czech Ministry of Education, Youth and Sports LC 554.",null,133,29,29,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2009,55,6,null,null,null,null,201,217,null,null,null,17,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","549HX","WOS:000274039700002"]
[null,null,null,null,"J","Seeman, T",null,null,null,"Seeman, Tomas",null,null,"Hypertension after renal transplantation","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Hypertension; Children; Renal transplantation; Graft function; Graft survival; Blood pressure control; Angiotensin-converting enzyme inhibitors","AMBULATORY BLOOD-PRESSURE; LEFT-VENTRICULAR MASS; ARTERIAL-HYPERTENSION; ALLOGRAFT SURVIVAL; KIDNEY-TRANSPLANTATION; GRAFT-SURVIVAL; CYCLOSPORINE MICROEMULSION; CARDIOVASCULAR-DISEASE; PEDIATRIC-PATIENTS; NATIVE KIDNEYS","Hypertension is a common and serious complication after renal transplantation. It is an important risk factor for graft loss and morbidity and mortality of transplanted children. The etiology of posttransplant hypertension is multifactorial: native kidneys, immunosuppressive therapy, renal-graft artery stenosis, and chronic allograft nephropathy are the most common causes. Blood pressure (BP) in transplanted children should be measured not only by casual BP (CBP) measurement but also regularly by ambulatory BP monitoring (ABPM). The prevalence of posttransplant hypertension ranges between 60% and 90% depending on the method of BP measurement and definition. Left ventricular hypertrophy is a frequent type of end-organ damage in hypertensive children after transplantation (50-80%). All classes of antihypertensive drugs can be used in the treatment of posttransplant hypertension. Hypertension control in transplanted children is poor; only 20-50% of treated children reach normal BP. The reason for this poor control seems to be inadequate antihypertensive therapy, which can be improved by increasing the number of antihypertensive drugs. Improved hypertension control leads to improved long-term graft and patient survival in adults. In children, there is a great potential for antihypertensive treatment that could also result in improved graft and patient survival.","[Seeman, Tomas] Charles Univ Prague, Dept Pediat, Sch Med 2, Prague 15006, Czech Republic; [Seeman, Tomas] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Transplantat Ctr Univ, Prague 15006, Czech Republic","Seeman, T (reprint author), Charles Univ Prague, Dept Pediat, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic.","tomas.seeman@lfmotol.cuni.cz","Seeman, Tomas/H-3032-2013",null,null,null,null,90,15,17,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","MAY",2009,24,5,null,null,null,null,959,972,null,"10.1007/s00467-007-0627-7",null,14,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","423ZQ","WOS:000264535700005"]
[null,null,null,null,"J","Robova, H; Charvat, M; Strnad, P; Hrehorcak, M; Taborska, K; Skapa, P; Rob, L",null,null,null,"Robova, Helena; Charvat, Martin; Strnad, Pavel; Hrehorcak, Martin; Taborska, Katerina; Skapa, Petr; Rob, Lukas",null,null,"Lymphatic Mapping in Endometrial Cancer Comparison of Hysteroscopic and Subserosal Injection and the Distribution of Sentinel Lymph Nodes","INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER",null,null,"English","Article",null,null,null,null,null,"Endometrial cancer; Sentinel lymph node; Hysteroscopy; Subserosal injection","SENTINEL NODE BIOPSY; WOMEN; LYMPHADENECTOMY; BLUE","Introduction: Endometrial cancer incidence increases over the age of 65 and lymphadenectomy in these women is a morbid procedure. Sentinel lymph node (SLN) should avoid extensive lymphadenectomy in node negative patients. The aim of this prospective study is to determine the feasibility and usefulness of lymphatic mapping and SLN identification in the management of endometrial cancer. Methods: From January 2004 to December 2007 101 women with endometrial cancer participated in the study. We injected (99)Tc hysteroscopically, peritumorally 2 hours before laparotomy in 24 women. We applied (99)Tc and blue dye subserously after laparotomy and before adhesiolysis in 67 women. Ten patients with metastatic disease in ovary, omentum, peritoneum, and bulky nodes were excluded from analysis. Results: We detected SLN in 12 women (50%) in hysteroscopic group and ill 49 women (73.1%) in subserous group. We identified 133 SLNs in 61 women. We found 20 SLNs (15.0%) in supraobturator region, 78 (58.6%) in external iliac area, 11 (8.3%) in paraaortal area, 13 (9.8%) on common iliac artery, 8 (6.0%) in medial part of lateral parametrium, and 3 (2.3%) in presacral area. Conclusions: Sentinel lymph node identification is a new strategy that can be used to examine nodal status with a high successful rate in breast, cervical, and vulvar cancer. Results in endometrial cancer are not as successful, however. In the future, it will be necessary to find optimal timing, the best route of application, and the \"right\" size of the (99m)Tc particles. Subserous application seems to be superior to hysteroscopic application.","[Robova, Helena; Charvat, Martin; Strnad, Pavel; Hrehorcak, Martin; Rob, Lukas] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynaecol, Div Gynaecol Oncol, Prague, Czech Republic; [Taborska, Katerina] Charles Univ Prague, Fac Med 2, Dept Endocrinol, Prague, Czech Republic; [Taborska, Katerina] Charles Univ Prague, Fac Med 2, Dept Nucl Med, Prague, Czech Republic; [Skapa, Petr] Charles Univ Prague, Fac Med 2, Dept Pathol Anat, Prague, Czech Republic; [Skapa, Petr] Charles Univ Prague, Fac Med 2, Dept Mol Med, Prague, Czech Republic","Rob, L (reprint author), Fac Hosp Motol, Dept Obstet & Gynaecol, Vuvalu 84, Prague 15000 5, Czech Republic.","lukas.rob@ifmotol.cuni.cz",null,null,"IGA MZ [CR NR-8873-3]","This work is supported by grant IGA MZ CR NR-8873-3.",null,19,13,17,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X",null,null,"INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","APR",2009,19,3,null,null,null,null,391,394,null,"10.1111/IGC.0b013e3181a1c0b1",null,4,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","457ZE","WOS:000266976600016"]
[null,null,null,null,"J","Obermannova, B; Banghova, K; Sumnik, Z; Dvorakova, HM; Betka, J; Fencl, F; Kolouskova, S; Cinek, O; Lebl, J",null,null,null,"Obermannova, Barbora; Banghova, Karolina; Sumnik, Zdenek; Dvorakova, Hana M.; Betka, Jan; Fencl, Filip; Kolouskova, Stanislava; Cinek, Ondrej; Lebl, Jan",null,null,"Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene","EUROPEAN JOURNAL OF PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"Primary hyperparathyroidism; Hypercalcaemia; Newborn; Parathyroidectomy; Bisphosphonates","CALCIUM-SENSING RECEPTOR; BENIGN HYPOCALCIURIC HYPERCALCEMIA; AUTOSOMAL-DOMINANT HYPOCALCEMIA; FUNCTIONAL-CHARACTERIZATION; POLYMORPHISMS","We present a male patient with neonatal severe primary hyperparathyroidism, whose manifestation was exceptionally serious for the heterozygous inactivating mutation he carried in the CASR gene. The patient presented soon after birth with respiratory distress requiring long-term mechanical ventilation, bone and chest deformities, feeding problems, and hypotonia. He had hypercalcaemia, hypophosphataemia, and hyperparathyroidism. There was no known history of calcium metabolism disorders in the family. As the impact on calcaemia of a rescue therapy with bisphosphonates was only transient, a subtotal and subsequently total parathyroidectomy were performed in the fourth month of life. Afterwards his clinical status improved and the fractures healed, but his neuropsychological development is delayed due to cerebral atrophy. Genetic analysis revealed a heterozygous missense CASR mutation R185Q, and an approximately equal expression of the mutated and wild-type RNA in the parathyroid tissue. The mother of the child was homozygous for the wild-type allele; the father is unknown. In conclusion, this patient demonstrates how serious neonatal hyperparathyroidism can be when caused by a heterozygous mutation. This may be attributable to a combination of dominant-negative action of the mutant allele with an intrauterine foetal hyperparathyroidism developed in the mother's normocalcaemic environment, further aggravated by a putative maternal vitamin D deficiency during pregnancy.","[Obermannova, Barbora] Univ Hosp Motol, Dept Paediat, Prague 15006, Czech Republic; [Dvorakova, Hana M.] Charles Univ Prague, Fac Med 2, Dept Neonatol, Prague, Czech Republic; [Betka, Jan] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol, Prague, Czech Republic; [Obermannova, Barbora; Banghova, Karolina; Sumnik, Zdenek; Fencl, Filip; Kolouskova, Stanislava; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic","Obermannova, B (reprint author), Univ Hosp Motol, Dept Paediat, Uvalu 84, Prague 15006, Czech Republic.","obermannova@seznam.cz",null,null,"Czech Ministry of Education [MSM0021620814, MSM0021620819]; Czech Ministry of Health [MZ000064203]","The study was supported by an institutional grant from the Czech Ministry of Education ( grants MSM0021620814 and MSM0021620819), and by the Czech Ministry of Health ( grants MZ000064203). Drs. M. Mrhalova and L. Krskova, Institute of Pathology, Motol University Hospital, Prague, are acknowledged for assistance with the RNA analysis.",null,18,11,12,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,null,"EUR J PEDIATR","Eur. J. Pediatr.","MAY",2009,168,5,null,null,null,null,569,573,null,"10.1007/s00431-008-0794-y",null,5,"Pediatrics","Pediatrics","420WY","WOS:000264321100009"]
[null,null,null,null,"J","Malina, M; Cinek, O; Janda, J; Seeman, T",null,null,null,"Malina, Michal; Cinek, Ondrej; Janda, Jan; Seeman, Tomas",null,null,"Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Actin cytoskeleton; Cyclosporine; NPHS2 gene; Proteinuria; Steroid-resistant nephrotic syndrome","ALPORT-SYNDROME; WT1","Autosomal recessive steroid-resistant nephrotic syndrome (NS) is a rare, genetically determined nephropathy caused mainly by a mutation in the NPHS2 gene. This type of NS is usually resistant to other immunosuppressive therapy as well, but a few cases of cyclosporine A-induced partial remission of inherited NS have been reported. We present a boy that developed NS at the age of 18 months. There was no decrease of proteinuria on standard prednisolone therapy, and a diagnosis of steroid-resistant NS was established. However, the proteinuria decreased significantly following the initiation of cyclosporine A therapy (from 1280 to 380 mg/m(2) per day) without any negative effects on renal function (stable glomerular filtration rate 130-150 ml/min per 1.73 m(2)). The molecular genetic test revealed a homozygous R138Q mutation in the NPHS2 gene. Our case demonstrates that cyclosporine A can induce partial remission in patients with genetic forms of NS without influencing the glomerular filtration rate. However, its long-term effect and safety in children with hereditary forms of nephrotic syndrome have yet to be investigated.","[Malina, Michal; Cinek, Ondrej; Janda, Jan; Seeman, Tomas] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague 15006 5, Czech Republic","Malina, M (reprint author), Charles Univ Prague, Dept Pediat, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","michal.malina@lfmotol.cuni.cz",null,null,"Ministry of Health and Education of the Czech Republic [VZ MZ CR Nr. 0006420301, MSMT CR Nr. 0021620819]","We would like to thank to Dr. M. Konecna from the Pediatric Department of Trinec hospital for the initial diagnosis and long- term follow- up of the patient and Dr. T. Sulakova from Faculty of Health studies, Teaching Hospital Ostrava for performing renal biopsy. This study was supported by grants of the Ministry of Health and Education of the Czech Republic VZ MZ CR Nr. 0006420301 and MSMT CR Nr. 0021620819.",null,11,11,11,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","OCT",2009,24,10,null,null,null,null,2051,2053,null,"10.1007/s00467-009-1211-0",null,3,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","487XX","WOS:000269312900021"]
[null,null,null,null,"J","Horvath, R; Budinsky, V; Kayserova, J; Kalina, T; Formankova, R; Stary, J; Bartunkova, J; Sedlacek, P; Spisek, R",null,null,null,"Horvath, Rudolf; Budinsky, Vit; Kayserova, Jana; Kalina, Tomas; Formankova, Renata; Stary, Jan; Bartunkova, Jirina; Sedlacek, Petr; Spisek, Radek",null,null,"Kinetics of dendritic cells reconstitution and costimulatory molecules expression after myeloablative allogeneic haematopoetic stem cell transplantation: Implications for the development of acute graft-versus host disease","CLINICAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Dendritic cell; Acute GVHD; Corticosteroids; BMT; HSCT","ANTIGEN-PRESENTING CELLS; PERIPHERAL-BLOOD; LANGERHANS CELLS; STEADY-STATE; T-CELLS; IN-VIVO; DIFFERENTIATION; GVHD; GENERATION; MATURATION","Allogeneic hematopoetic stem cell transplantation (HSCT) represents a unique opportunity to monitor the kinetics of reconstitution of dendritic cells (DCs) and their dynamics in distinct pathologies. We analyzed DCs reconstitution after myeloablative HSCT We separately analyzed patients with acute GVHD. DCs were monitored from the earliest phase of hematopoetic reconstitution until day + 365. Both myeloid DCs and plasmacytoid DCs appeared at earliest stages after engraftment and relative numbers within white blood cells compartment peaked between days 19-25 after HSCT Their proportion then gradually declined and absolute numbers of both DC subsets remained lower than in controls during the whole follow-up. Patients with acute GVHD had significantly tower numbers of circulating DCs. Decrease in DC counts preceded onset of clinical symptoms by at least 24 h and was independent of corticosteroids administration. This study reveals quantification of plasmacytoid and myeloid DCs as a potential biomarker for the prediction of acute GVHD development. (C) 2008 Published by Elsevier Inc.","[Horvath, Rudolf; Budinsky, Vit; Kayserova, Jana; Bartunkova, Jirina; Spisek, Radek] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Inst Immunol, Prague 5, Czech Republic; [Kalina, Tomas; Formankova, Renata; Stary, Jan; Sedlacek, Petr] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 5, Czech Republic","Spisek, R (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Inst Immunol, V Uvalu 84, Prague 5, Czech Republic.","radek.spisek@lfmotol.cuni.cz","Kalina, Tomas/C-1078-2009; Spisek, Radek/E-6724-2011",null,"Czech Ministry of Education [MSM 0021620812]; GACR [310/08/0838]; MZ [CR 00064203]","This study was supported by project MSM 0021620812 from The Czech Ministry of Education, grant GACR 310/08/0838 and by MZ CR 00064203.",null,43,9,9,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1521-6616",null,null,"CLIN IMMUNOL","Clin. Immunol.","APR",2009,131,1,null,null,null,null,60,69,null,"10.1016/j.clim.2008.10.009",null,10,"Immunology","Immunology","428GC","WOS:000264835000007"]
[null,null,null,null,"J","Ryska, M; Laszikova, E; Pantoflicek, T; Ryska, O; Prazak, J; Koblihova, E",null,null,null,"Ryska, M.; Laszikova, E.; Pantoflicek, T.; Ryska, O.; Prazak, J.; Koblihova, E.",null,null,"Fractionated Plasma Separation and Adsorption Significantly Decreases Intracranial Pressure in Acute Liver Failure: Experimental Study","EUROPEAN SURGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Acute liver failure; Experimental treatment; Fractionated plasma separation and absorption","FULMINANT HEPATIC-FAILURE; ALBUMIN DIALYSIS; EXTRACORPOREAL SYSTEM; SUPPORT; PROMETHEUS(R); BRAIN; TRANSPLANTATION; MANAGEMENT; DEVICES; MODEL","Background: The aim of the study was to determine the influence of fractionated plasma separation and absorption (FPSA) on intracranial pressure (ICP) in acute liver failure (ALF). Methods: A surgical model of ALF in pigs (35-40 kg) was used. We compared laboratory data and haemodynamic parameters from the ALF control group to the ALF group treated by Prometheus using ANOVA with repeated measures and grouping factors, by calculating the area under the curve, and by the Mann-Whitney rank test. Results: Bilirubin levels differed significantly in favour of the FPSA treatment group: after 6 h 12.81 +/- 6.54 versus 29.84 +/- 9.99, after 9 h 11.94 +/- 4.14 versus 29.95 +/- 12.36 (p < 0.01) and after 12 h 13.88 +/- 6.31 versus 26.10 +/- 12.23 mmol/l (p < 0.05). ICP values differed significantly in favour of the FPSA treatment group: after 9 h 19.1 +/- 4.09 versus 24.1 +/- 2.85 (p < 0.01), after 10 h 21.9 +/- 3.63 versus 25.1 +/- 2.19, after 11 h 22.5 +/- 3.98 versus 26.3 +/- 3.50, and after 12 h 24.0 +/- 4.66 versus 29.8 +/- 5.88 mm Hg (p < 0.05). Conclusion: The authors demonstrated that a significant decrease in ICP was found in pigs with ALF following treatment by FPSA. Copyright (c) 2009 S. Karger AG, Basel","[Ryska, M.; Pantoflicek, T.; Koblihova, E.] Charles Univ Prague, Sch Med 2, Dept Surg, CZ-16000 Prague 6, Czech Republic; [Prazak, J.] Charles Univ Prague, Sch Med 2, Dept Anaesthesiol Resuscitat & Intens Care, CZ-16000 Prague, Czech Republic; [Ryska, M.; Laszikova, E.; Pantoflicek, T.; Koblihova, E.] Charles Univ Prague, Sch Med 2, Ctr Cell Therapy & Tissue Repair, CZ-16000 Prague 6, Czech Republic; [Laszikova, E.] Cent Mil Hosp, Dept Anaesthesiol & Resuscitat, Prague, Czech Republic; [Ryska, O.] Charles Univ Prague, Sch Med 1, Dept Surg, CZ-16000 Prague 6, Czech Republic","Ryska, M (reprint author), Charles Univ Prague, Sch Med 2, Dept Surg, U Vojenske Nem 1200, CZ-16000 Prague 6, Czech Republic.","miroslav.ryska@uvn.cz",null,null,"Czech Ministry of Health [CEZ: L17/98: 00023001, S9140]","This study was supported by the Research Centre (LN00A065), funded by grants from the Czech Ministry of Health CEZ: L17/98: 00023001 and S9140.",null,24,7,8,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0014-312X",null,null,"EUR SURG RES","Eur. Surg. Res.",null,2009,42,4,null,null,null,null,230,235,null,"10.1159/000208790",null,6,"Surgery","Surgery","432KH","WOS:000265131400005"]
[null,null,null,null,"J","Chovanec, M; Novotna, J; Wilhelm, J; Hampl, V; Vizek, M; Herget, J",null,null,null,"Chovanec, M.; Novotna, J.; Wilhelm, J.; Hampl, V.; Vizek, M.; Herget, J.",null,null,"Hypercapnia Attenuates Hypoxic Pulmonary Hypertension by Inhibiting Lung Radical Injury","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Chronic hypoxia; Chronic hypercapnia; Pulmonary hypertension; Hypoxic lung injury","CARBON-DIOXIDE; NEWBORN RAT; DAMAGE; PEROXYNITRITE; ERYTHROCYTES; REPERFUSION","Chronic lung hypoxia results in hypoxic pulmonary hypertension. Concomitant chronic hypercapnia partly inhibits the effect of hypoxia on pulmonary vasculature. Adult male rats exposed to 3 weeks hypoxia (Fi(02)=0.1) combined with hypercapnia (Fi(C02)=0.04-0.05) had lower pulmonary arterial blood pressure, increased weight of the right heart ventricle, and less pronounced structural remodeling of the peripheral pulmonary arteries compared with rats exposed only to chronic hypoxia (Fi(02)=0.1). According to our hypothesis, hypoxic pulmonary hypertension is triggered by hypoxic injury to the walls of the peripheral pulmonary arteries. Hypercapnia inhibits release of both oxygen radicals and nitric oxide at the beginning of exposure to the hypoxic environment. The plasma concentration of nitrotyrosine, the marker of peroxynitrite activity, is lower in hypoxic rats exposed to hypercapnia than in those exposed to hypoxia alone. Hypercapnia blunts hypoxia-induced collagenolysis in the walls of prealveolar pulmonary arteries. We conclude that hypercapnia inhibits the development of hypoxic pulmonary hypertension by the inhibition of radical injury to the walls of peripheral pulmonary arteries.","[Chovanec, M.; Hampl, V.; Herget, J.] Charles Univ Prague, Dept Physiol, Sch Med 2, Prague 15000 5, Czech Republic; [Vizek, M.] Charles Univ Prague, Dept Pathophysiol, Sch Med 2, Prague 15000 5, Czech Republic; [Novotna, J.; Wilhelm, J.] Charles Univ Prague, Dept Biochem, Sch Med 2, Prague 15000 5, Czech Republic; [Chovanec, M.; Novotna, J.; Wilhelm, J.; Hampl, V.; Vizek, M.; Herget, J.] Cardiovasc Res Ctr, Prague, Czech Republic; [Chovanec, M.] Na Homolce Hosp, Dept Cardiol, Prague, Czech Republic","Chovanec, M (reprint author), Charles Univ Prague, Dept Physiol, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic.","milan.chovanec@lfmotol.cuni.cz","Wilhelm, Jiri/C-6252-2012; Herget, Jan/I-6313-2012; Hampl, Vaclav/A-2732-2009","Hampl, Vaclav/0000-0001-5776-4624","GACR [305/05/08/108]; GAUK [78007]; Cardiovascular Research Center [1M510]","Supported by grants GACR 305/05/08/108 and GAUK 78007 as well as by Cardiovascular Research Center 1M510. Preliminary report of the part of results was presented at the Experimental Biology Meeting 2009, New Orleans, USA and Meeting of the Czech Physiological Society, 2001 and 2002, Prague, Czech Republic. We would like to thank to our lab assistants: Ms Olga Hnilickova and Pavlina Smolkova for assisting experiments and Ms Elizabeth \"Liz\" Coling help with the manuscript preparation.",null,38,7,7,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,null,null,2,null,null,"S79","S85",null,null,null,7,"Physiology","Physiology","542ZC","WOS:000273537200008"]
[null,null,null,null,"J","Krskova, L; Kalinova, M; Brizova, H; Mrhalova, M; Sumerauer, D; Kodet, R",null,null,null,"Krskova, Lenka; Kalinova, Marketa; Brizova, Helena; Mrhalova, Marcela; Sumerauer, David; Kodet, Roman",null,null,"Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma","CANCER GENETICS AND CYTOGENETICS",null,null,"English","Article",null,null,null,null,null,null,"SYT-SSX; PROLIFERATIVE ACTIVITY; TUMOR-TYPE; APOPTOSIS; PROTEIN; FUSION; OVEREXPRESSION; PROGNOSIS; CELLS; TRANSLOCATION","Synovial sarcoma (SS) is a highly aggressive soft tissue sarcoma that causes death in more than half of the affected patients. An immunohistochemical and molecular study of the BCL2, MKI67, and CCND1 genes (expressing the BCL2, KI-67, and cyclin D1 proteins, respectively) was performed to determine the expression profiles in correlation with mRNA levels, and to assess the possible utility of these genes as a potential target for the treatment. Cyclin D1 staining was identified in 18 of 30 cases (60%), and CCND1 mRNA was overexpressed in 15 of 32 cases (47%). KI-67 nuclear immunoreactivity was found in 14 of 29 cases (48%), and MKI67 mRNA was overexpressed in 12 of 32 cases (37.5%). The high level of MKI67 mRNA was observed predominantly in monophasic SS. BCL2, a negative regulator of apoptosis, was expressed in all 32 cases. The intensity of the BCL2 protein expression correlated well with the mRNA level (P < 0.0001). The high level of BCL2 mRNA correlated with a high level of CCND1 mRNA, but not with MKI67 mRNA level. Despite advances in therapy of sarcomas, the prognosis of patients with SS remains unfavorable, and a search for an improved therapy approach remains necessary. The strong immunopositivity of BCL2 in SS correlates well with a high level of BCL2 mRNA. Treatment with antisense BCL2 (G3139) may therefore represent an appropriate alternative therapy for patients with BCL2-positive synovial sarcomas. (C) 2009 Elsevier Inc. All rights reserved.","[Krskova, Lenka; Kalinova, Marketa; Brizova, Helena; Mrhalova, Marcela; Kodet, Roman] Charles Univ Prague, Dept Pathol & Mol Med, Sch Med 2, Prague 15006, Czech Republic; [Krskova, Lenka; Kalinova, Marketa; Brizova, Helena; Mrhalova, Marcela; Sumerauer, David; Kodet, Roman] Fac Hosp Motol, Prague 15006, Czech Republic; [Sumerauer, David] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague 15006, Czech Republic","Krskova, L (reprint author), Charles Univ Prague, Dept Pathol & Mol Med, Sch Med 2, Uvalu 84, Prague 15006, Czech Republic.","lenka.krskova@lfmotol.cuni.cz",null,null,"Grant Agency of Charles University GAUK [200 052 (63/2005/C)]; Internal Grant of Faculty Hospital Moto [IGFNM 9756]; Research Project of the Ministry of Education [MSM 0021620813]; Research Project of the Ministry of Health of Czech Republic [FNM MZO 00064203]","This study was supported by the Grant Agency of Charles University GAUK 200 052 (63/2005/C), Internal Grant of Faculty Hospital Moto IGFNM 9756, the Research Project of the Ministry of Education MSM 0021620813, and the Research Project of the Ministry of Health of Czech Republic FNM MZO 00064203.",null,34,4,6,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,null,"CANCER GENET CYTOGEN","Cancer Genet. Cytogenet.","AUG",2009,193,1,null,null,null,null,1,8,null,"10.1016/j.cancergencyto.2009.03.008",null,8,"Oncology; Genetics & Heredity","Oncology; Genetics & Heredity","482XC","WOS:000268922900001"]
[null,null,null,null,"J","Prochazkova, K; Pavlikova, K; Minarik, M; Sumerauer, D; Kodet, R; Sedlacek, Z",null,null,null,"Prochazkova, Kamila; Pavlikova, Kristyna; Minarik, Marek; Sumerauer, David; Kodet, Roman; Sedlacek, Zdenek",null,null,"Somatic TP53 Mutation Mosaicism in a Patient With Li-Fraumeni Syndrome","AMERICAN JOURNAL OF MEDICAL GENETICS PART A",null,null,"English","Article",null,null,null,null,null,"cancer predisposition; TP53 mutation; Li-Fraumeni syndrome; somatic mosaicism; allelic imbalance; de novo mutation","GERMLINE P53 MUTATIONS; NEUROFIBROMATOSIS TYPE-1; FAMILIAL SYNDROME; BREAST-CANCER; GENE; ELECTROPHORESIS; NEOPLASMS; SARCOMAS; TUMORS","We present a girl who developed adrenocortical adenoma at the age of I year and osteosarcoma at the age of 5 years. There was no history of cancer in her parents and their relatives. However, both tumors were typical for the Li-Fraumeni syndrome (LFS), and the patient met criteria for germline TP53 mutation testing. A mutation in codon 282 (Arg282Trp) was identified in her blood lymphocyte genomic DNA. The substitution was found in neither of her parents, which indicated a possibility of a de novo mutation. Unexpectedly, sequencing of the DNA of the patient repeatedly showed allelic imbalance in favor of the normal allele. This observation prompted us to investigate the putative somatic mosaicism in the patient consisting of normal cells and cells heterozygous for the mutation. The imbalance was also examined in two other non-invasively sampled tissues, buccal cells, and cells from the urine sediment, and sequencing was confirmed with two other independent methods. While the findings in blood and the urine sediment were similar, in buccal cells both alleles were present in equal amounts. The allele ratio in lymphocytes was consistent with a mosaic where about 2/3 of cells carried two normal alleles and only 1/3 was heterozygous for the mutation. Despite the mosaicism the girl developed two early childhood tumors of mesodermal origin, and her phenotype was thus not milder than that of other germline TP53 mutation carriers. To our knowledge this is the first description of somatic mosaicism for a de novo TP53 mutation in LFS. (c) 2008 Wiley-Liss, Inc.","[Prochazkova, Kamila; Pavlikova, Kristyna; Sedlacek, Zdenek] Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague 15006 5, Czech Republic; [Prochazkova, Kamila; Pavlikova, Kristyna; Sumerauer, David; Kodet, Roman; Sedlacek, Zdenek] Univ Hosp Motol, Prague, Czech Republic; [Minarik, Marek] Genomac Int, Lab Mol Genet & Oncol, Prague, Czech Republic; [Sumerauer, David] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Kodet, Roman] Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic","Sedlacek, Z (reprint author), Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, V Uvalu 84, Prague 15006 5, Czech Republic.","zdenek.sedlacek@lfmotol.cuni.cz","Minarik, Marek/B-5995-2009",null,"Ministry of Education of the Czech Republic [MSM0021620813]; Ministry of Health of the Czech Republic [MZ000064203]","We thank Dr. Drahuse Novotna for karyotyping of the patient. The work was supported by grants MSM0021620813 (Ministry of Education of the Czech Republic) and MZ000064203 (Ministry of Health of the Czech Republic).",null,25,5,5,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1552-4825",null,null,"AM J MED GENET A","Am. J. Med. Genet. A","FEB",2009,"149A",2,null,null,null,null,206,211,null,"10.1002/ajmg.a.32574",null,6,"Genetics & Heredity","Genetics & Heredity","408KH","WOS:000263433400011"]
[null,null,null,null,"J","Schejbalova, A; Havlas, V; Trc, T",null,null,null,"Schejbalova, Alena; Havlas, Vojtech; Trc, Tomas",null,null,"Irreducible dislocation of the hip in cerebral palsy patients treated by Schanz proximal femoral valgus osteotomy","INTERNATIONAL ORTHOPAEDICS",null,null,"English","Article",null,null,null,null,null,null,"HEAD RESECTION; UNSTABLE HIPS; PAINFUL HIP; CHILDREN; ARTHRODESIS; REPLACEMENT; SUBLUXATION","Palliative Schanz proximal femoral valgus osteotomy is considered a common option for treatment of irreducible hip dislocation in cerebral palsy. From 1992 to 2005, Schanz osteotomy was indicated on 55 occasions in 35 nonambulatory patients with the quadriplegic form of cerebral palsy aged 9-18. Postoperatively, the main emphasis focussed on clinical presentation, improvement of hip range of motion, and pain relief. X-rays were carried out at three, six, and 12 months postoperatively with subsequent average follow up 98 +/- 4.5 months. In all patients, the range of hip abduction and flexion increased. In 54 (98.2%) cases painful symptoms significantly improved. One patient (1.8%) had a subsequent femoral head excision because of persistent hip pain. Transient hip pain persisted in four patients (7.3%). Schanz valgus osteotomy improves the hip range of motion, relieves pain, and facilitates care of the patient. Schanz femoral osteotomy is a less invasive method compared to proximal femoral excision and should preferably be used in older children with neurogenic hip dislocation in whom reconstructive surgery is not indicated.","[Schejbalova, Alena; Havlas, Vojtech; Trc, Tomas] Charles Univ Prague, Dept Orthopaed Surg, Sch Med 2, Prague 15006 5, Czech Republic; [Havlas, Vojtech] Dumfries & Galloway Royal Infirm, Dept Orthopaed Surg, Dumfries, Scotland","Havlas, V (reprint author), Charles Univ Prague, Dept Orthopaed Surg, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","vojtech.havlas@seznam.cz",null,null,"IGA MZ NR [8333-3]","The work was supported by grant IGA MZ NR 8333-3.",null,25,4,4,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0341-2695",null,null,"INT ORTHOP","Int. Orthop.","DEC",2009,33,6,null,null,null,null,1713,1717,null,"10.1007/s00264-008-0676-y",null,5,"Orthopedics","Orthopedics","524WE","WOS:000272174300040"]
[null,null,null,null,"J","Krenkova, P; Norambuena, P; Stambergova, A; Macek, M",null,null,null,"Krenkova, P.; Norambuena, P.; Stambergova, A.; Macek, M., Jr.",null,null,"Evaluation of High-Resolution Melting (HRM) for Mutation Scanning of Selected Exons of the CFTR Gene","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,"CFTR; high-resolution melting; HRM; mutation detection","PERFORMANCE LIQUID-CHROMATOGRAPHY; GRADIENT GEL-ELECTROPHORESIS; DNA; POLYMORPHISMS; SENSITIVITY; SEQUENCE","Hereby we present evaluation of high-resolution melting for mutation scanning applied to the cystic fibrosis transmembrane conductance regulator gene. High resolution melting was used for mutation scanning of selected samples derived from cystic fibrosis patients with a known cystic fibrosis transmembrane conductance regulator genotype. We tested 19 different disease-causing cystic fibrosis transmembrane conductance regulator mutant genotypes located within six exons of the cystic fibrosis transmembrane conductance regulator gene (4, 7, 10, 11, 14b and 22). Normalized melting curves of tested samples were compared to sequenced-verified wildtype samples. Determined mutations are as follows: p.F508del, p.1507del, p.G551D, p.R347P, c.17171-1G>A, c.621+1G>T, p.V122X, p.I336K, p.R553X, c.2789+5G>A, c.574delA, c.1811+1G>C, p.L1335F, p.L1335P, p.L1324P and p.M470V and represent minimally 76.5 % of all cystic fibrosis alleles detected in the Czech cystic fibrosis population. All analysed samples with mutant genotypes were unambiguously distinguished from wild-type samples. High-resolution melting analysis enabled reliable detection of all single-nucleotide polymorphism classes and 1- or 3- base pair deletions. We examined the specificity, sensitivity and precision of this methodology. High-resolution melting analysis is an economical, sensitive and specific close-tube method and has a high utility for the detection of unknown mutations in cystic fibrosis DNA diagnostics.","[Krenkova, P.] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; Univ Hosp Motol, Dept Biol & Med Genet, Cyst Fibrosis Ctr, Prague 15006 5, Czech Republic","Krenkova, P (reprint author), Charles Univ Prague, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","petra.krenkova@email.cz",null,null,"EuroGentest [FP6-512145];  [VZFNM00064203];  [NR-9448-3/2007]","This study was supported by VZFNM00064203, EuroGentest (FP6-512145) and NR-9448-3/2007.",null,23,4,4,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2009,55,6,null,null,null,null,238,242,null,null,null,5,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","549HX","WOS:000274039700006"]
[null,null,null,null,"J","Herynek, V; Ruzickova, K; Jendelova, P; Sykova, E; Hajek, M",null,null,null,"Herynek, Vit; Ruzickova, Katerina; Jendelova, Pavla; Sykova, Eva; Hajek, Milan",null,null,"Metabolic changes in the rat brain after a photochemical lesion treated by stem cell transplantation assessed by 1H MRS","MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE",null,null,"English","Article",null,null,null,null,null,"Mesenchymal stem cell transplantation; Magnetic resonance spectroscopy; Rats; Wistar","MARROW STROMAL CELLS; CENTRAL-NERVOUS-SYSTEM; OLIGODENDROCYTE PRECURSOR CELLS; MAGNETIC-RESONANCE TRACKING; IRON-OXIDE NANOPARTICLES; SPINAL-CORD-INJURY; BONE-MARROW; N-ACETYLASPARTATE; CONTRAST AGENT; GROWTH-FACTOR","Metabolite changes in an experimental lesion in the rat cortex and in the contralateral hemisphere after the intravenous administration of mesenchymal stem cells (MSCs) were assessed by proton MR spectroscopy to verify the impact of the cell treatment on the brain tissue. Wistar rats with a photochemical cortical lesion and transplanted MSCs or sham transplanted rats were examined. Proton spectra were obtained from the lesion and from the contralateral cortex. Magnetic resonance spectroscopy revealed a gradual recovery of the damaged tissue; however, we found no significant differences in metabolite concentrations in the lesioned hemisphere between treated and untreated animals. Higher concentrations of glutamate and N-acetyl aspartate were found in the contralateral hemisphere in cell-treated animals compared to untreated ones. Lesioned animals showed neurogenesis in the contralateral hemisphere; the number of newly generated cells in stem cell-treated animals was 50% higher than those observed in untreated animals. No direct impact of cell transplantation was observed in the lesion. However, changes in the contralateral hemisphere suggest that the transplanted MSCs might stimulate repair processes and plasticity resulting in the generation of newborn cells, which might enable the faster adoption of the damaged tissue's function by healthy tissue.","[Herynek, Vit; Hajek, Milan] Inst Clin & Expt Med, MR Unit, Dept Radiodiagnost & Intervent Radiol, Prague 14021, Czech Republic; [Herynek, Vit; Ruzickova, Katerina; Jendelova, Pavla; Sykova, Eva; Hajek, Milan] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006, Czech Republic; [Ruzickova, Katerina; Jendelova, Pavla; Sykova, Eva] Inst Expt Med ASCR, Prague 14220, Czech Republic; [Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague 15006, Czech Republic","Herynek, V (reprint author), Inst Clin & Expt Med, MR Unit, Dept Radiodiagnost & Intervent Radiol, Videnska 1958-9, Prague 14021, Czech Republic.","vit.herynek@medicon.cz",null,null,"Academy of Sciences of the Czech Republic [AV0Z50390703, KAN201110651]; Ministry of Education, Youth and Sports of the Czech Republic [1M0538, LC554]; Ministry of Health of the Czech Republic [MZ01IKEM2005]; National Grant Agency of the Czech Republic [GACR 309/06/1594]; EC-FP6 [LSHB-CT-2005-512146]","This work was supported by grants from the Academy of Sciences of the Czech Republic AV0Z50390703, KAN201110651, the Ministry of Education, Youth and Sports of the Czech Republic 1M0538, LC554, the Ministry of Health of the Czech Republic MZ01IKEM2005, the National Grant Agency of the Czech Republic GACR 309/06/1594 and the EC-FP6 project DiMI: LSHB-CT-2005-512146.",null,43,3,4,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0968-5243",null,null,"MAGN RESON MATER PHY","Magn. Reson. Mat. Phys. Biol. Med.","AUG",2009,22,4,null,null,null,null,211,220,null,"10.1007/s10334-009-0166-2",null,10,"Radiology, Nuclear Medicine & Medical Imaging","Radiology, Nuclear Medicine & Medical Imaging","482QM","WOS:000268903800002"]
[null,null,null,null,"J","Koutek, J; Kocourkova, J; Hladikova, M; Hrdlicka, M",null,null,null,"Koutek, Jiri; Kocourkova, Jana; Hladikova, Marie; Hrdlicka, Michal",null,null,"Suicidal behavior in children and adolescents: Does a history of trauma predict less severe suicidal attempts?","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"suicidal attempt; child; adolescent; risk factor; intensity of suicidal intent; somatic severity","CHILDHOOD TRAUMA; RISK-FACTORS; ADULTS; DEPRESSION; ABUSE","OBJECTIVES: The aim of this study was to identify risk factors and possible predictors of severity of suicidal behavior of children and adolescents. METHODS: Seventy-seven patients (15 boys and 62 girls) aged 15.5 +/- 1.6 years on average, hospitalized due to a suicidal attempt in the department of pediatric psychiatry, were examined. Structured interviews with patients and their parents were used to clinically assess circumstances of suicidal behavior, relevant risk factors and severity of suicidal behavior. RESULTS: The results indicated that patients with any previous traumatic experience tended to have somatically less severe suicidal attempts (p = 0.050). Intensity of suicidal intent was associated with a history of depression (p = 0.014) and anxiety disorders (p = 0.004), and the current stress from a mental disorder (p = 0.014). Somatic severity of suicidal behavior was significantly associated with intensity of suicidal intent (p = 0.014). A history of any trauma (previous traumatic experience predicted less severe suicidal behavior, p = 0.053) and the current stress from sexual problems (p = 0.067) were identified as predictors of somatic severity of suicidality. These two predictors showed only a trend level of significance. The only significant predictor of intensity of suicidal intent was the current stress from a mental illness (p = 0.017). CONCLUSIONS: Several risk factors of somatic severity of suicidal behavior and intensity of suicidal intent were described. The most important finding of the study was the association between a history of psychological trauma and a tendency to have less somatically severe suicidal behavior.","[Koutek, Jiri; Kocourkova, Jana; Hrdlicka, Michal] Charles Univ Prague, Fac Med 2, Dept Pediat Psychiat, Prague 15006, Czech Republic; [Hladikova, Marie] Charles Univ Prague, Fac Med 2, Dept Med Informat, Prague 15006, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 1, Prague 12108, Czech Republic","Koutek, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat Psychiat, Uvalu 84, Prague 15006, Czech Republic.","jiri.koutek@lfmotol.cuni.cz",null,null," [MSM 0021620849]","The study was supported by grant MSM 0021620849.",null,28,3,3,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.","MAR",2009,30,1,null,null,null,null,99,106,null,null,null,8,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","436PR","WOS:000265426800021"]
[null,null,null,null,"J","Eckschlager, T; Radvanska, J; Slaby, K; Prusa, R; Hochova, I; Radvansky, J",null,null,null,"Eckschlager, T.; Radvanska, J.; Slaby, K.; Prusa, R.; Hochova, I.; Radvansky, J.",null,null,"Changes of blood count, lymphocyte subpopulations and immunoglobulin levels in nephroblastoma long term survivors","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"nephroblastoma long-term survivors; blood count; lymphocyte subpopulations; immunoglobulin G, A, M serum levels","WILMS-TUMOR; HODGKINS-DISEASE; CANCER; CHILDHOOD","The aim of this study was to investigate the frequency of blood count, lymphocyte subpopulations, and immunoglobulin levels alterations in a group of healthy nephroblastoma long-term survivors. The group included 122 nephroblastoma long-term survivors who were at least five years post anticancer therapy and free of any sign of recurrence. The proportion of lumphocyte subpopulations was analyzed by flow cytometry using antibodies anti CD45 FITC/CD14 PE, anti CD3 FITC/CD16+CD56 PE. anti CD4 FITC/CD8 PE and anti CD20 FITC. Immunoglobulin G, A, and M levels were evaluated by immunoturbidimetry. Total blood Count was, also examined. The Occurrence of decreased immunoglobulin levels, leukocytes, lymphocytes, and granulocytes count, proportion of T lymphocytes and their CD4+ subpopulation are not frequent. The most frequently decreased lymphocyte subpopulation was CD8 (15.5%). The most frequent abnormal findings were increased proportion of NK cells (38.5%), B lymphocytes (38,52%), decreased number of erythrocytes (25.2%), hemoglobin levels (41.7%) and hematocrit (13.9%). The only significant differences between results of immunological examination and course of the disease were more frequently decreased proportion of CD4+ lymphocytes ill recurrent disease Survivors and lower IgA levels in survivors after radiotherapy. We found decreased at least one immunological parameter in one fifth of the Survivors. The most frequently altered parameter was hemoglobin, which was decreased in 41.7% of survivors. Decraesed hemoglobin may worsen quality of survivors' life.","[Eckschlager, T.; Radvanska, J.] 2nd Med Sch & Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Slaby, K.; Radvansky, J.] 2nd Med Sch & Univ Hosp Motol, Dept Sport Med, Prague, Czech Republic; [Prusa, R.] 2nd Med Sch & Univ Hosp Motol, Dept Clin Biochem & Pathobiochem, Prague, Czech Republic; [Hochova, I.] 2nd Med Sch & Univ Hosp Motol, Dept Clin Hematol, Prague, Czech Republic","Eckschlager, T (reprint author), 2nd Med Sch & Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic.","eckschlagertomas@yahoo.com",null,null,"IGA [NR/87/96-3]; MSMT [0021620813]","This work Was Supported by the grants IGA NR/87/96-3 and MSMT No 0021620813.",null,13,3,3,"VEDA, SLOVAK ACAD SCIENCES","BRATISLAVA","DUBRAVSKA CESTA 9, 842 34 BRATISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2009,56,1,null,null,null,null,9,12,null,null,null,4,"Oncology","Oncology","396TN","WOS:000262614200002"]
[null,null,null,null,"J","Zaloudikova, M; Vizek, M; Herget, J",null,null,null,"Zaloudikova, M.; Vizek, M.; Herget, J.",null,null,"Hyperoxia Blunts Acute Hypoxia- and PGF(2a)-Induced Pulmonary Vasoconstriction in Chronically Hypoxic Rats","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Hypoxia; Hyperoxia; Isolated pulmonary arteries; Hypoxic pulmonary vasoconstriction","CA2+ SENSITIZATION; SMOOTH-MUSCLE; MECHANISM; ARTERIES; CALCIUM; LUNGS; HYPERTENSION; INJURY","We investigated the influence of oxygenation of in vitro lung preparation on the pulmonary vascular reactivity. Small pulmonary vessels isolated from adult male Wistar rats exposed for 4 days to hypoxia (F-iO2 = 0.1, group CH) were compared with those of normoxic controls (group N). The bath in the chamber of small vessel myograph was saturated with gas mixture containing either 21 % or 95 % of O-2 with 5 % CO2 and we measured the reactions of vessels to acute hypoxic challenge with 0 % O-2 or to PGF(2 alpha). We did not observe any difference of the contractile responses between both groups when the normoxic conditions were set in the bath. When the bath oxygenation was increased to 95 % O-2, the contractions induced by hypoxic challenge and PGF(2 alpha) decreased in chronically hypoxic rats and did not change in normoxic controls. We hypothesize that reduced reactivity of vessels from hypoxic rats in hyperoxia results from the effect of chronic hypoxia on Ca2+ signaling in the vascular smooth muscle, which is modulated by increased free radical production during the exposure to chronic hypoxia and further hyperoxia.","[Zaloudikova, M.; Vizek, M.] Charles Univ Prague, Dept Pathophysiol, Fac Med 2, Prague 15006 5, Czech Republic; [Herget, J.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague 15006, Czech Republic; [Zaloudikova, M.; Vizek, M.; Herget, J.] Cardiovasc Res Ctr, Prague, Czech Republic","Zaloudikova, M (reprint author), Charles Univ Prague, Dept Pathophysiol, Fac Med 2, Plzenska 130-221, Prague 15006 5, Czech Republic.","marie.zaloudikova@lfmotol.cuni.cz","Herget, Jan/I-6313-2012",null,"GACR [305/06/P385, 305/05/08/108, 1M510]","This study was partially supported by grants GACR 305/06/P385, GACR 305/05/08/108, Center 1M510.",null,20,3,3,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,6,null,null,null,null,917,920,null,null,null,4,"Physiology","Physiology","539YP","WOS:000273296600018"]
[null,null,null,null,"J","Rygl, M; Novotna, J; Herget, J; Skaba, R; Snajdauf, J",null,null,null,"Rygl, M.; Novotna, J.; Herget, J.; Skaba, R.; Snajdauf, J.",null,null,"Parameters of Healing in Approximative Intestinal Anastomosis","EUROPEAN JOURNAL OF PEDIATRIC SURGERY",null,null,"English","Article",null,null,null,null,null,"approximative anastomosis; matrix metalloproteinase; anastomotic strength; extremely low birth weight neonates","NECROTIZING ENTEROCOLITIS; MATRIX METALLOPROTEINASES; PERITONEAL DRAINAGE; GASTROINTESTINAL-TRACT; COLONIC ANASTOMOSES; BREAKING STRENGTH; SUTURE TECHNIQUE; SMALL-BOWEL; LAPAROTOMY; RAT","Introduction: The restoration of bowel continuity using multiple classic anastomoses is mostly impossible in unstable critically ill extremely low birth weight neonates. The parameters of healing of approximative anastomoses in which integrity and continuity of bowel is achieved with limited number of stitches were evaluated in an experimental study. Material and Methods: Small bowel anastomoses were performed in twenty-two adult male rats. An approximative ileo-ileal anastomosis was performed with five seromuscular-interrupted sutures only; in the control group the anastomosis was performed with the conventional technique of interrupted sutures. The mechanical and biochemical parameters were compared. Results: All anastomoses in both groups healed well without obstruction. The mean operating time needed for an approximative anastomosis was shorter (16 +/- 7.1 min versus 23.6 +/- 6.2 min, p = 0.016). The strength of the approximative anastomoses on the 1st day after surgery was 55 +/- 15 torr; the strength of the conventional anastomoses was 55 +/- 42 torr. The strength of the approximative anastomoses after 7 days was 249 +/- 39 torr; the strength of the conventional anastomoses was 218 23 torr(p = 0.118). The activity of the collagenolytic enzymes matrix metalloproteinase-2 and matrix metalloproteinase-9 in the anastomotic area was significantly increased compared with the activity in samples of non-operated bowel. There was no significant difference in collagenolytic activity between both types of anastomoses. Conclusion: The approximative anastomosis is a time-saving alternative to conventional anastomoses with a comparable Course of anastomotic healing, anastomotic strength, and changes in collagen metabolism.","[Rygl, M.; Skaba, R.; Snajdauf, J.] Charles Univ Prague, Sch Med 2, Dept Pediat Surg, Prague 15006, Czech Republic; [Novotna, J.] Charles Univ Prague, Sch Med 2, Dept Med Chem & Biochem, Prague 15006, Czech Republic; [Herget, J.] Charles Univ Prague, Sch Med 2, Dept Physiol, Prague 15006, Czech Republic","Rygl, M (reprint author), Charles Univ Prague, Sch Med 2, Dept Pediat Surg, V Uvalu 84, Prague 15006, Czech Republic.","mrygl@yahoo.com","Herget, Jan/I-6313-2012",null,"FNM MZO [00064203/6309]","Supported by Research Project FNM MZO 00064203/6309.",null,27,1,3,"GEORG THIEME VERLAG KG","STUTTGART","RUDIGERSTR 14, D-70469 STUTTGART, GERMANY","0939-7248",null,null,"EUR J PEDIATR SURG","Eur. J. Pediatr. Surg.","FEB",2009,19,1,null,null,null,null,25,29,null,"10.1055/s-2008-1039010",null,5,"Pediatrics; Surgery","Pediatrics; Surgery","417FN","WOS:000264062000006"]
[null,null,null,null,"J","Hanus, M; Trc, T; Handl, M",null,null,null,"Hanus, M.; Trc, T.; Handl, M.",null,null,"Method of Functional Treatment of Distal Radius Fractures","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"distal radius fracture; functional treatment; Sarmiento's method",null,"PURPOSE OF THE STUDY To present the method of functional treatment of distal radius fractures, and to evaluate its results in a group of 57 patients. MATERIAL The method described here was used to treat a Colles' fracture in 57 patients between 2001 and 2005. The average age of patients at the time of injury was 62 years (range, 19 to 82). The minimal interval between the end of treatment and the evaluation of the patient group was one year. METHODS The presented method is based on the principles of functional treatment of wrist fractures, as advocated by Sarmiento et al. When the patient has been indicated for this treatment, the arm is immobilised in a classic rigid cast. This cast is changed three weeks after application for a cast permitting full palmar flexion and full ulnar deviation. The cast is removed when callus formation is detected and the fracture site is free of pain. During this treatment, much attention is paid to skin condition, with an emphasis on preventing the development of Sudeck's algoneurodystrophy. RESULTS This method of functional treatment resulted in complete fracture healing in all patients. None of them required hospitalization. The total period of immobilization was on average 45 days, ranging from 41 to 57 days. On subjective evaluation the patients regarded both the course and the result of treatment as good. DISCUSSION In this paper the authors address the permanent conflict between concepts of surgical and conservative therapy. Their results fully support the fact that the freedom of motion of all joints for a greater part of treatment is necessary for healing as well as prevention of a subsequent restriction of the range of motion. They also provide evidence that this modified method facilitates healing without complications. The patients were satisfied with the outcome of treatment; there was no poor result reported. CONCLUSIONS The method of functional treatment for distal radius fractures is an effective procedure allowing for good bone healing with a minimum of complications. In addition, the treatment can almost exclusively be carried out in an out-patient department. The mechanism promoting the process of osteogenesis in its course is not known yet. However, it has to be mentioned that the method is time-consuming for both the physician and the patient.","[Hanus, M.] LF UK, Ortoped Klin 2, Prague 15006 5, Czech Republic; FN Motol Detska & Dospela Ortopedie & Traumatol, Prague, Czech Republic","Hanus, M (reprint author), LF UK, Ortoped Klin 2, Uvalu 84, Prague 15006 5, Czech Republic.","Mar.doc@seznam.cz",null,null,null,null,null,18,2,2,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2009,76,2,null,null,null,null,116,120,null,null,null,5,"Orthopedics","Orthopedics","439ZY","WOS:000265668600007"]
[null,null,null,null,"J","Svojgr, K; Burjanivova, T; Vaskova, M; Kalina, T; Stary, J; Trka, J; Zuna, J",null,null,null,"Svojgr, Karel; Burjanivova, Tatiana; Vaskova, Martina; Kalina, Tomas; Stary, Jan; Trka, Jan; Zuna, Jan",null,null,"Adaptor molecules expression in normal lymphopoiesis and in childhood leukemia","IMMUNOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"Acute lymphoblastic leukemia; Prognosis; Childhood; PAG; LAT; NTAL; LIME","T-CELL-ACTIVATION; B-LYMPHOCYTES; MEMBRANE MICRODOMAINS; ENRICHED MICRODOMAINS; PROTEIN; LAT; DIFFERENTIATION; LIME; PAG; SINGLE","Transmembrane adaptor proteins are key mediators of antigen receptor signaling in lymphocytes. By influencing proliferation and differentiation, these molecules might play a role in ethiopathogenesis of acute lymphoblastic leukemia (ALL). The aim of this study was to characterize expression of PAG, LAT, NTAL and LIME adaptors at the mRNA and protein levels in normal B- and T-precursors. Moreover, diagnostic samples of childhood ALL cases were analyzed. During normal lymphocyte development, some adaptors show significant dynamics (gradual decrease of NTAL and increase of LAT and LIME during the T-cell maturation, decrease of PAG in B-precursors, high levels of LIME in peripheral B-lymphocytes). Analysis of childhood ALL samples revealed that in B-cell precursor ALL, the TEL/AML1 subgroup have unique adaptor profile compared to other leukemias. Moreover, NTAL expression separates T lineage leukemias into two subgroups with good and poor response to initial prednisone therapy showing prognostic impact of this molecule in T-ALL (C) 2009 Elsevier B.V. All rights reserved.","[Svojgr, Karel] Charles Univ Prague, CLIP, Sch Med 2, Dept Pediat Hematol & Oncol,Fac Med 2, Prague 15006 5, Czech Republic","Svojgr, K (reprint author), Charles Univ Prague, CLIP, Sch Med 2, Dept Pediat Hematol & Oncol,Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic.","karel.svojgr@lfmotol.cuni.cz","Kalina, Tomas/C-1078-2009",null,"GAUK [7356/2007]; MSMT [21620813, 2B06064]; IGA [NR9108-3]","We appreciate collaboration of all the Czech Pediatric Hematology Working Group (CPH) centers for providing diagnostic material and data. We would like to thank to Karel Drbal for valuable discussion and to Pavel Semerak for technical assistance. This study was supported by grants GAUK 7356/2007, MSMT 21620813, MSMT 2B06064 and IGA NR9108-3.",null,33,2,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0165-2478",null,null,"IMMUNOL LETT","Immunol. Lett.","FEB 21",2009,122,2,null,null,null,null,185,192,null,"10.1016/j.imlet.2008.12.008",null,8,"Immunology","Immunology","432JM","WOS:000265129300019"]
[null,null,null,null,"J","Dudova, I; Hrdlicka, M",null,null,null,"Dudova, Iva; Hrdlicka, Michal",null,null,"The importance of olfactory functions in psychiatry","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"olfaction; neuropsychiatry; neurodegenerative disorders; schizophrenia; autism","ALZHEIMERS-DISEASE; PARKINSON-DISEASE; IDENTIFICATION; DIAGNOSIS; DISORDER; AUTISM","Authors deal with experimental and clinical utilization of olfaction examination in neuropsychiatric disorders. They mention briefly the importance of olfaction and the anatomy of olfactory track and olfactory brain centers. They explain methods of olfaction examination, especially the most frequent used tests - UPSIT and Sniffin 'Sticks. The olfaction disorders are one of the early symptoms of some serious neurodegenerative disorders. In the case of Parkinson and Alzheimer diseases, the olfaction examination is included in recommended procedures of differential diagnostics judgment. The most explored psychiatric disorder associated with olfaction disorders is schizophrenia. The changes in olfactory threshold measurement, olfactory identification and discrimination, and olfactory memory were described. The results of several studies in autistic patients proved the deficit in olfactory functions and suggested the possibility to utilize the screening examination of olfactory functions as a bio-behavioral marker of autistic spectrum disorders.","[Dudova, Iva; Hrdlicka, Michal] FN Motol, Detska Psychiat Klinika UK 2LF, Prague, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Lekarska Fak 1, Prague, Czech Republic","Dudova, I (reprint author), Detska Psychiat Klinika FN Motole, Uvalu 84, Prague 15006, Czech Republic.","iva.dudova@lfmotol.cuni.cz",null,null,null,null,null,25,2,2,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2009,53,1,null,null,null,null,34,39,null,null,null,6,"Psychology, Multidisciplinary","Psychology","414UN","WOS:000263890800003"]
[null,null,null,null,"J","Lassuthova, P; Barankova, L; Kraus, J; Marikova, T; Seeman, P",null,null,null,"Lassuthova, Petra; Barankova, Lucia; Kraus, Josef; Marikova, Tat'ana; Seeman, Pavel",null,null,"Emery-Dreifuss Muscular Dystrophy: A Novel Mutation in the LMNA Gene","PEDIATRIC NEUROLOGY",null,null,"English","Article",null,null,null,null,null,null,"LAMIN A/C GENE; SUDDEN-DEATH","Described here is the phenotypical expression of a novel LMNA mutation c.1157 G>T in a Czech patient with an early-onset form of Emery-Dreifuss muscular dystrophy. The mutation predicts aberrant splicing. Now 21 years old, the patient has had slowly progressing muscle dystrophy since the age of one and early contractures of elbows. He is the only family member affected. Even though the dystrophy typically affects the heart as well, in the present case these signs are not yet expressed. (C) 2009 by Elsevier Inc. All rights reserved.","[Lassuthova, Petra; Kraus, Josef; Seeman, Pavel] Charles Univ Prague, Dept Child Neurol, Sch Med 2, Prague 15006 5, Czech Republic; [Barankova, Lucia] Charles Univ Prague, Sch Med 2, Dept Neurol, Prague 15006 5, Czech Republic; [Marikova, Tat'ana] Charles Univ Prague, Sch Med 2, Inst Biol & Med Genet, Prague 15006 5, Czech Republic","Lassuthova, P (reprint author), Charles Univ Prague, Dept Child Neurol, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","petra.lassuthova@gmail.com",null,null,"Czech Republic Ministry of Health [8330-3]","This study was supported by a grant from the Czech Republic Ministry of Health (Internal Grant Agency of Ministry of Health of Czech Republic NR 8330-3).",null,14,1,2,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0887-8994",null,null,"PEDIATR NEUROL","Pediatr. Neurol.","AUG",2009,41,2,null,null,null,null,127,130,null,"10.1016/j.pediatrneurol.2009.03.009",null,4,"Clinical Neurology; Pediatrics","Neurosciences & Neurology; Pediatrics","473ME","WOS:000268210200010"]
[null,null,null,null,"J","Mazanec, R; Horacek, O; Kobesova, A; Smetana, R",null,null,null,"Mazanec, R.; Horacek, O.; Kobesova, A.; Smetana, R.",null,null,"Hereditary Neuropathy","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"hereditary neuropathy; Charcot-Marie-Tooth; pes cavus; electromyography; molecular genetics","MARIE-TOOTH-DISEASE; MUSCULAR-ATROPHY SYNDROME; SENSORY NEUROPATHY; CENTRAL CONDUCTION; ASCORBIC-ACID; NERVE BIOPSY; MOUSE MODEL; MUTATIONS; GENE; MOTOR","Hereditary neuropathy is a clinically and genetically heterogeneous group of diseases which most often represent a hereditary neuromuscular disorder. The prevalence is approximately 17-40 per 100,000. The most frequent form is called Charcot-Marie-Tooth disease (CMT) or hereditary motor and sensitive neuropathy (HMSN). In most cases, the clinical symptoms appear in the 1(st) and 2(nd) decade and include atrophy and weakness of lower limb muscles (peroneal atrophy), the pes cavus deformity of the foot with a shortened Achilles tendon, areflexia in the lower limbs and the stocking type sensory disorder. The basic classification of hereditary neuropathies is based on electrophysiological studies which classify CMT disease into two basic types. Type no. 1 - demyelinisation - with the n. medianus motor fibre conduction velocity at forearm below 38 m/s, and type no. 2 - axonal - with a velocity above 38 m/s. Molecular geneticists have so far identified causal mutations in 40 genes and have made a major contribution to molecular genetic classification of CMT disease and to the understanding of pathogenesis of the most frequent forms of hereditary neuropathies. Heredity involves all types of monogenic Mendelian inheritance: autosomal dominant, autosomal recessive and gonosomal dominant. Because causal therapy does not exist, current therapeutic approach is based on rehabilitation, prosthetic and orthopedic treatment. In a vast majority of cases, the prognosis of patients is good as this condition does not impair their standard life expectancy, even though it has a major impact on the patients' quality of life.","[Mazanec, R.] LF UK FN Motole, Neurol Klin 2, Prague 15006 5, Czech Republic; [Horacek, O.; Kobesova, A.] LF UK FN Motole, Rehabilitacni Klin 2, Prague 15006 5, Czech Republic; [Smetana, R.] LF UK FN Motole, Il Ortoped Klin 2, Prague 15006 5, Czech Republic","Mazanec, R (reprint author), LF UK FN Motole, Neurol Klin 2, V Uvalu 84, Prague 15006 5, Czech Republic.","radim.mazanec@email.cz","Rastelli, Marcio/B-8034-2011",null,null,null,"Antonellis A, 2003, AM J HUM GENET, V72, P1293, DOI 10.1086/375039; Auer-Grumbach M, 2000, NEUROLOGY, V54, P45; Auer-Grumbach M, 2000, NEUROLOGY, V55, P1552; Baxter RV, 2002, NAT GENET, V30, P21, DOI 10.1038/ng796; BERGOFFEN J, 1993, AM J HUM GENET, V52, P312; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Bernard R, 2006, NEUROMOL MED, V8, P87, DOI 10.1385/NMM:8:1-2:87; Boerkoel CF, 2002, ANN NEUROL, V51, P190, DOI 10.1002/ana.10089; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; Charcot JM, 1886, REV MED-PARIS, V6, P97; DAVIS CJF, 1978, J GENET HUM, V26, P311; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; Dubourg O, 2006, NEUROMOL MED, V8, P75, DOI 10.1385/NMM:8:1-2:75; DWYER FC, 1975, CLIN ORTHOP RELAT R, P254; DYCK PJ, 1989, NEUROLOGY, V39, P1302; DYCK PJ, 1993, PERIPHERAL NEUROPATH, V3, P1094; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; Fontes M, 2004, M S-MED SCI, V20, P843, DOI 10.1051/medsci/20042010843; Gravel C, 1997, NAT MED, V3, P765, DOI 10.1038/nm0797-765; HARDING AE, 1980, J NEUROL SCI, V45, P337, DOI 10.1016/0022-510X(80)90177-X; HARDING AE, 1980, J MED GENET, V17, P329, DOI 10.1136/jmg.17.5.329; HAYASAKA K, 1993, NAT GENET, V5, P31, DOI 10.1038/ng0993-31; Horacek O, 2007, SPINE, V32, P2502; Jordanova A, 2003, BRAIN, V126, P590, DOI 10.1093/brain/awg059; Kaya F, 2008, MUSCLE NERVE, V38, P1052, DOI 10.1002/mus.21071; KOBESOVA A, 2007, POSTGRADUALNI MED, V9, P139; KOBESOVA A, 2004, REHABIL FYZ LEK, V4, P169; Kobesova A, 2008, CESK SLOV NEUROL N, V71, P277; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MADRID R, 1977, J NEUROL SCI, V32, P91, DOI 10.1016/0022-510X(77)90042-9; Massicote C., 2004, NEUROSCIENCE MOL MED, P401; Mersiyanova IV, 2000, AM J HUM GENET, V67, P37, DOI 10.1086/302962; Mikesova E, 2005, NEUROMUSCULAR DISORD, V15, P764, DOI 10.1016/j.nmd.2005.08.001; Nicholson G, 1996, J NEUROL NEUROSUR PS, V61, P43, DOI 10.1136/jnnp.61.1.43; Passage E, 2004, NAT MED, V10, P396, DOI 10.1038/nm1023; Perea J, 2001, HUM MOL GENET, V10, P1007, DOI 10.1093/hmg/10.10.1007; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Schejbalova A, 1993, Cesk Pediatr, V48, P701; SEEMAN P, 2007, ANAL GENU PRO LAMIN; Seeman P, 2004, CESK SLOV NEUROL N, V67, P321; Seeman P, 1999, ANN NY ACAD SCI, V883, P485, DOI 10.1111/j.1749-6632.1999.tb08617.x; Seeman P, 2001, INT J MOL MED, V8, P461; Sereda MW, 2003, NAT MED, V9, P1533, DOI 10.1038/nm957; SHAPIRO BE, 2006, PERIPHERAL NERVE DIS, P743; Shy ME, 2005, NEUROLOGY, V64, P1209; Shy ME, 2004, BRAIN, V127, P371, DOI 10.1093/brain/awh048; Silander K, 1998, HUM MUTAT, V12, P59, DOI 10.1002/(SICI)1098-1004(1998)12:1<59::AID-HUMU9>3.0.CO;2-A; SMETANA P, 2008, POSTGRADUALNI MED, V10, P880; Street VA, 2003, NEUROLOGY, V60, P22; Tooth HH, 1886, PERONEAL TYPE PROGR; Verhoeven K, 2003, AM J HUM GENET, V72, P722, DOI 10.1086/367847; Warner LE, 1998, NAT GENET, V18, P382, DOI 10.1038/ng0498-382; Zhang XB, 2008, BRAIN, V131, P1990, DOI 10.1093/brain/awn114; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341",54,1,1,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,1,null,null,null,null,5,16,null,null,null,12,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","413EB","WOS:000263774600001"]
[null,null,null,null,"J","Chlumsky, J; Havlin, J",null,null,null,"Chlumsky, Jaromir; Havlin, Jan",null,null,"Spontaneous jugular vein thrombosis","ACTA CARDIOLOGICA",null,null,"English","Article",null,null,null,null,null,"Spontaneous jugular vein thrombosis; anticoagulation treatment","CATHETER","Jugular vein thrombosis (JVT) is usually secondary to central venous catheterisation, distant malignancy, hypercoagulable state or ovarian hyperstimulation syndrome. Spontaneous internal JVT is an extremely rare entity. A 61-year-old man presented with swelling of the right side of his face. An ultrasonographic scan showed thrombosis of the right jugular vein. Clinical tests, including oncomarkers, X-ray, CT scan and abdominal ultrasonography, searching for malignancy, were negative. The patient was heparinized immediately using LMWH and then underwent warfarin anticoagulation therapy for 6 months. One year later the patient was in good clinical condition with no malignancy diagnosed. Aetiology and the treatment of spontaneous JVT are discussed.","[Chlumsky, Jaromir] Charles Univ Prague, Univ Hosp Motol, Dept Med, Prague 15000 5, Czech Republic","Chlumsky, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Med, Uvalu 84, Prague 15000 5, Czech Republic.","jaromirchlumsky@seznam.cz",null,null,null,null,null,16,0,0,"ACTA CARDIOLOGICA","BRUSSELS","AVENUE CIRCULAIRE 138A, 1180 BRUSSELS, BELGIUM","0001-5385",null,null,"ACTA CARDIOL","Acta Cardiol.","OCT",2009,64,5,null,null,null,null,689,691,null,"10.2143/AC.64.5.2042704",null,3,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","524ZU","WOS:000272183700020"]
[null,null,null,null,"J","Kocourkova, J; Koutek, J; Hrdlicka, M",null,null,null,"Kocourkova, Jana; Koutek, Jiri; Hrdlicka, Michal",null,null,"Self-harm in adolescence: a girl who swallowed needles","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"self-harm; adolescence; therapy","PERSONALITY; BEHAVIORS; STRESS; INJURY","Self-harm represents a serious and pathological behavior that occurs most notably during adolescent years and currently seems to be a problem that is on the increase. Self-harm is a self destructive behavior which most frequently takes the form of cutting and burning. Relative to suicidal behavior, self-harm, in and of itself, is not intended to be lethal and tends to be repeated and addictive. However, in cases of self-harm the risk of suicidal behavior cannot be ignored. This presentation is a case study of a girl who engaged in an unusual form of self-harm, by swallowing needles.","[Kocourkova, Jana; Koutek, Jiri; Hrdlicka, Michal] Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Prague 15006, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 1, Prague 15006, Czech Republic","Kocourkova, J (reprint author), Charles Univ Prague, Dept Child Psychiat, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","jana.kocourkova@lfmotol.cuni.cz",null,null,"MSM [0021620849]","Supported by grant MSM 0021620849.",null,16,0,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2009,30,6,null,null,null,null,705,708,null,null,null,4,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","565CK","WOS:000275266400005"]
[null,null,null,null,"J","Wilhelm, J; Vytasek, R; Ostadalova, I; Vajner, L",null,null,null,"Wilhelm, Jiri; Vytasek, Richard; Ostadalova, Ivana; Vajner, Ludek",null,null,"Evaluation of different methods detecting intracellular generation of free radicals","MOLECULAR AND CELLULAR BIOCHEMISTRY",null,null,"English","Article",null,null,null,null,null,"Reactive oxygen species; Fluorescent probes; Autofluorescence; Cellular ageing; Tissue thin sections","NADPH OXIDASE ACTIVITY; OXIDATIVE STRESS; SUPEROXIDE-PRODUCTION; DIHYDRORHODAMINE 123; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE; CARDIAC MYOCYTES; IN-VITRO; HYDROETHIDINE","Reactive oxygen species (ROS) play several biological roles. We investigated the applicability of fluorescent probes for their detection (i) in rabbit lens epithelial cells during ageing in culture, and (ii) in thin sections of rat heart. We used dihydroethidium (DHE), dichlorofluorescin (DCFH), and dihydrorhodamine 123 (DHR) together with detection of autofluorescence both in cells and in chloroform extracts. Superoxide production was confirmed by a specific histochemical method using Mn(2+). All methods demonstrated higher production of ROS in older cells. All probes revealed different sites of ROS production in young and old cells and could be used for investigation of ROS generation during cell ageing. In the thin sections of rat heart DCFH was not suitable for intracellular ROS detection. The results indicate that the potential of fluorescent dyes in ROS detection is not usually fully exploited, and that blue autofluorescence is associated with oxidative damage.","[Wilhelm, Jiri; Vytasek, Richard] Charles Univ Prague, Dept Med Chem & Biochem, Cardiovasc Res Ctr, Sch Med 2, Prague 15000 5, Czech Republic; [Ostadalova, Ivana] Acad Sci Czech Republic, Inst Physiol, Cardiovasc Res Ctr, CR-14220 Prague 4, Czech Republic; [Vajner, Ludek] Charles Univ Prague, Dept Histol & Embryol, Sch Med 2, Prague 15000 5, Czech Republic","Wilhelm, J (reprint author), Charles Univ Prague, Dept Med Chem & Biochem, Cardiovasc Res Ctr, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic.","jiri.wilhelm@lfmotol.cuni.cz","Wilhelm, Jiri/C-6252-2012; Vajner, Ludek/C-5823-2014; Vytasek, Richard/C-7571-2014",null,"Grant Agency of the Czech Republic [305/08/0108]; Czech Ministry of Education, Youth and Physical Education [1MO510]; AV OZ [50110509]","This study was supported by grant No. 305/08/0108 from the Grant Agency of the Czech Republic, a grant of Czech Ministry of Education, Youth and Physical Education No. 1MO510 and grant AV OZ No. 50110509.",null,26,14,14,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0300-8177",null,null,"MOL CELL BIOCHEM","Mol. Cell. Biochem.","AUG",2009,328,41671,null,null,null,null,167,176,null,"10.1007/s11010-009-0086-5",null,10,"Cell Biology","Cell Biology","465MX","WOS:000267592600020"]
[null,null,null,null,"J","Hubacek, P; Keslova, P; Formankova, R; Pochop, P; Cinek, O; Zajac, M; Lochmanova, J; Stary, J; Sedlacek, P",null,null,null,"Hubacek, Petr; Keslova, Petra; Formankova, Renata; Pochop, Pavel; Cinek, Ondrej; Zajac, Miroslav; Lochmanova, Jana; Stary, Jan; Sedlacek, Petr",null,null,"Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet","PEDIATRIC TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"cytomegalovirus; transplantation; ganciclovir resistance; cidofovir; foscarnet","PHARMACOKINETIC PROPERTIES; IMMUNOCOMPROMISED PATIENTS; ANTIVIRAL ACTIVITY; THERAPEUTIC USE; GANCICLOVIR; INFECTION","We report an 18-yr-old female patient with repeated CMV reactivations after HSCT treated by several pre-emptive courses of virostatic therapy. Seven months after HSCT, she developed CMV encephalitis/retinitis. Initial therapy with GCV and hyperimmune globulin failed, and later on GCV-resistant strain was detected. Continual increase of CMV DNA in peripheral blood led us to combined therapy with CDV and FCV, which was successful and free of severe renal toxicity. To our best knowlegde, this is the first reported case of successful CMV treatment with a combination of CDV and FCV.","[Hubacek, Petr; Keslova, Petra; Formankova, Renata; Stary, Jan; Sedlacek, Petr] Charles Univ Prague, Dept Paediat Haematol & Oncol, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic; [Pochop, Pavel] Charles Univ Prague, Dept Ophthalmol Children & Adults, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague, Czech Republic; [Cinek, Ondrej] Charles Univ Prague, Dept Paediat, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic; [Zajac, Miroslav] Charles Univ Prague, Dept Microbiol, Sch Med 2, Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic; [Lochmanova, Jana] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Dept Internal Med, Brno, Czech Republic; [Lochmanova, Jana] Masaryk Univ, Brno, Czech Republic","Sedlacek, P (reprint author), Charles Univ Prague, Dept Paediat Haematol & Oncol, Sch Med 2, Motol Univ Hosp, Uvalu 84, CZ-15006 Prague 5, Czech Republic.","petr.hubacek@lfmotol.cuni.cz",null,null,null,null,null,7,7,8,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1397-3142",null,null,"PEDIATR TRANSPLANT","Pediatr. Transplant.","NOV",2009,13,7,null,null,null,null,919,922,null,"10.1111/j.1399-3046.2008.01070.x",null,4,"Pediatrics; Transplantation","Pediatrics; Transplantation","505CS","WOS:000270666600022"]
[null,null,null,null,"J","Sedy, J; Zicha, J; Kunes, J; Jendelova, P; Sykova, E",null,null,null,"Sedy, J.; Zicha, J.; Kunes, J.; Jendelova, P.; Sykova, E.",null,null,"Rapid but not Slow Spinal Cord Compression Elicits Neurogenic Pulmonary Edema in the Rat","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Neurogenic pulmonary edema; Rat; Spinal cord injury; Blood pressure; Heart rate","STEM-CELLS; INJURY; MODEL; PERMEABILITY; ISOFLURANE; PROMOTES; REPAIR","The development of neurogenic pulmonary edema (NPE) can be elicited by an immediate epidural balloon compression of the thoracic spinal cord. To evaluate whether a slower balloon inflation could prevent NPE development, we examined the extent of NPE in animals lesioned with a rapid (5 mu l - 5 mu l - 5 mu l) or slow rate (3 mu l - 2 mu l - 2 mu l - 2 mu l - 2 mu l - 2 mu l - 2 mu l) of balloon inflation. These groups were compared with the NPE model ( immediate inflation to 15 mu l) and with healthy controls. Slow balloon inflation prevented NPE development, whereas the pulmonary index and histology revealed a massive pulmonary edema in the group with a rapid rate of balloon inflation. Pulmonary edema was preceded by a considerable decrease in heart rate during the inflation procedure. Moreover, rapid inflation of balloon in spinal channel to either 5 mu l or 10 mu l did not cause NPE. Thus, a slow rate of balloon inflation in the thoracic epidural space prevents the development of neurogenic pulmonary edema, most likely due to the better adaptation of the organism to acute circulatory changes (rapid elevation of systemic blood pressure accompanied by profound heart rate reduction) during the longer balloon inflation period. It should be noted that spinal cord transection at the same level did not cause neurogenic pulmonary edema.","[Sedy, J.; Jendelova, P.; Sykova, E.] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Sedy, J.; Jendelova, P.; Sykova, E.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Sedy, J.; Jendelova, P.; Sykova, E.] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Sedy, J.; Zicha, J.; Kunes, J.] Acad Sci Czech Republic, Inst Physiol, CR-14220 Prague 4, Czech Republic; [Kunes, J.] Cardiovasc Res Ctr, Prague, Czech Republic","Sedy, J (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","jirisedy@hotmail.com","Zicha, Josef/B-1349-2012; Kunes, Jaroslav/B-7079-2012","Zicha, Josef/0000-0001-6051-6541; ","EC [LSHB-CT-2005-518233];  [AV0Z50390512];  [AV0Z50110509];  [1M0538];  [LC554];  [GACR309/06/1246];  [IGA MZ 1A8697-5];  [IGA MZ NR/8339-3];  [1M0510]","We thank Dominika Duskov~ and Iva Nahodilov~ for their excellent technical assistance. We thank James Dutt for critical reading of the manuscript. We acknowledge the support provided by the grants AV0Z50390512, AV0Z50110509, 1M0538, LC554, GACR309/06/1246, IGA MZ 1A8697-5, IGA MZ NR/8339-3, 1M0510 and the EC FP6 project RESCUE (LSHB-CT-2005-518233).",null,24,6,8,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,2,null,null,null,null,269,277,null,null,null,9,"Physiology","Physiology","442PM","WOS:000265853100014"]
[null,null,null,null,"J","Sedy, J; Zicha, J; Kunes, J; Sykova, E",null,null,null,"Sedy, Jiri; Zicha, Josef; Kunes, Jaroslav; Sykova, Eva",null,null,"Atropine may prevent the development of neurogenic pulmonary edema","MEDICAL HYPOTHESES",null,null,"English","Article",null,null,null,null,null,null,"SPINAL-CORD-INJURY; MODEL; COMPLICATIONS; RAT","Neurogenic pulmonary edema is an acute life-threatening complication of central nervous system injury. We introduce a hypothesis that early i.v. administration of high-dose atropine can prevent neurogenic pulmonary edema development on the basis of the prevention of baroreflex-induced bradycardia, which was recognized as a major factor in neurogenic pulmonary edema formation. To validate this hypothesis, a clinical trial in patients suffering from subarachnoid haemorrhage should be performed, with atropine administered i.v. immediately after the maintenance of the living functions, intubation and ability to monitor patient. (C) 2009 Elsevier Ltd. All rights reserved.","[Sedy, Jiri; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Sedy, Jiri; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Sedy, Jiri; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Sedy, Jiri] Charles Univ Prague, Fac Med 1, Inst Dent Res, Prague, Czech Republic; [Sedy, Jiri] Gen Univ Hosp, Prague, Czech Republic; [Sedy, Jiri; Zicha, Josef; Kunes, Jaroslav] Acad Sci Czech Republic, Inst Physiol, CR-14220 Prague, Czech Republic; [Zicha, Josef; Kunes, Jaroslav] Charles Univ Prague, Fac Med 2, Cardiovasc Res Ctr, Prague, Czech Republic","Sedy, J (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","jirisedy@hotmail.com","Zicha, Josef/B-1349-2012; Kunes, Jaroslav/B-7079-2012","Zicha, Josef/0000-0001-6051-6541; ","EC [LSHB-CT-2005-518233];  [AVOZ50390512];  [1M0021620803];  [GACR309/06/1246];  [1A8697-5];  [AVOZ50110509];  [IM0510];  [IM0538 AVOZ50390703];  [LC554];  [GACR309/09/1430];  [IGA MZ 1A8697-5]","We thank to James Dutt for critical reading of the manuscript. We acknowledge the support provided by the Grants AVOZ50390512, 1M0021620803, GACR309/06/1246, 1A8697-5, EC FP6 project RESCUE (LSHB-CT-2005-518233), AVOZ50110509, IM0510, IM0538 AVOZ50390703, LC554, GACR309/09/1430, and IGA MZ 1A8697-5.",null,17,5,8,"CHURCHILL LIVINGSTONE","EDINBURGH","JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND","0306-9877",null,null,"MED HYPOTHESES","Med. Hypotheses","JUL",2009,73,1,null,null,null,null,42,44,null,"10.1016/j.mehy.2008.12.051",null,3,"Medicine, Research & Experimental","Research & Experimental Medicine","452ZG","WOS:000266579100013"]
[null,null,null,null,"J","Snajdauf, J; Rygl, M; Petru, O; Kalousova, J; Kuklova, P; Mixa, V; Keil, R; Hribal, Z",null,null,null,"Snajdauf, J.; Rygl, M.; Petru, O.; Kalousova, J.; Kuklova, P.; Mixa, V.; Keil, R.; Hribal, Z.",null,null,"Duodenum-Sparing Technique of Head Resection in Solid Pseudopapillary Tumor of the Pancreas in Children","EUROPEAN JOURNAL OF PEDIATRIC SURGERY",null,null,"English","Article",null,null,null,null,null,"solid pseudopapillary tumor of the pancreas; duodenum-sparing technique; pancreatic surgery in children","PRESERVING RESECTION; PAPILLARY; NEOPLASM; PANCREATICODUODENECTOMY; LESIONS","Aim of study: Aim of the Study was to assess the complications and long-term results in children operated on for solid pseudopapillary tumor of the pancreas (SPTP) between 1993-2008 at the authors' institution with a focus on a novel duodenum-sparing technique to treat tumors Of the head of the pancreas. Methods: Retrospective analysis was performed of patient data including demographics, diagnostic measures, the operative technique focusing on tumor of the head of the pancreas, complications and long-term results. Results: There were 13 patients (12 girls and one boy) with an average age of 14 years (9-17.5 years) at operation. In 7 patients the tumor was localized in the head of the pancreas, in 4 patients in the tail, and in 2 patients both the body and tail were involved. Patients with body and tail involvement underwent distal pancreatic resection. In 6 patients with head involvement a duodenum-sparing resection of the head and end-to-end anastomosis of the excluded jejunal loop either to the corpus or tail of the pancreas were performed. One girl underwent a modified Whipple operation. She developed a biliary fistula which closed after three weeks with endoscopic stenting. One patient with head resection developed a biliary fistula which closed after two weeks of stenting. One patient who underwent resection of the pancreatic head complained of recurrent abdominal pain one year postoperatively. All patients are alive without tumor recurrence at 6 months to 16 years after operation. Conclusion: SPTP is a rare pancreatic tumor with a low degree of malignancy. No perioperative chemotherapy is necessary. Therefore duodenal resection in cases of SPTP in the head of the gland seems too invasive and mutilating. The authors consider the duodenum-sparing technique to be more appropriate for the developing organism of a child. Favorable short and long-term results support this opinion.","[Snajdauf, J.] Charles Univ Prague, Inst Postraguate Med, Sch Med 2, Dept Pediat Surg, Prague 15000, Czech Republic; [Rygl, M.; Petru, O.; Kalousova, J.; Kuklova, P.; Mixa, V.; Keil, R.; Hribal, Z.] Charles Univ Prague, Fac Med 2, Prague 15000, Czech Republic; [Rygl, M.; Petru, O.; Kalousova, J.; Kuklova, P.; Mixa, V.; Keil, R.; Hribal, Z.] Charles Univ Prague, Teaching Hosp Motol, Prague 15000, Czech Republic","Snajdauf, J (reprint author), Charles Univ Prague, Inst Postraguate Med, Sch Med 2, Dept Pediat Surg, Uvalu 84, Prague 15000, Czech Republic.","jiri.snajdauf@fnmotol.cz",null,null,null,null,null,20,4,6,"GEORG THIEME VERLAG KG","STUTTGART","RUDIGERSTR 14, D-70469 STUTTGART, GERMANY","0939-7248",null,null,"EUR J PEDIATR SURG","Eur. J. Pediatr. Surg.","DEC",2009,19,6,null,null,null,null,354,357,null,"10.1055/s-0029-1237729",null,4,"Pediatrics; Surgery","Pediatrics; Surgery","538UD","WOS:000273208600003"]
[null,null,null,null,"J","Sedy, J; Zicha, J; Kunes, J; Hejcl, A; Sykova, E",null,null,null,"Sedy, Jiri; Zicha, Josef; Kunes, Jaroslav; Hejcl, Ales; Sykova, Eva",null,null,"The role of nitric oxide in the development of neurogenic pulmonary edema in spinal cord-injured rats: the effect of preventive interventions","AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"blood pressure; heart rate; atropine","HEART-RATE; ISOFLURANE; MODEL; BAROREFLEX; RABBITS; REFLEX; SEVOFLURANE; INHIBITION; MECHANISMS","Sedy J, Zicha J, Kunes. J, Hejc. l A, Sykova E. The role of nitric oxide in the development of neurogenic pulmonary edema in spinal cord-injured rats: the effect of preventive interventions. Am J Physiol Regul Integr Comp Physiol 297: R1111-R1117, 2009. First published August 12, 2009; doi: 10.1152/ajpregu.00251.2009.-Neurogenic pulmonary edema (NPE) is an acute life-threatening complication following an injury of the spinal cord or brain, which is associated with sympathetic hyperactivity. The role of nitric oxide (NO) in NPE development in rats subjected to balloon compression of the spinal cord has not yet been examined. We, therefore, pretreated Wistar rats with the NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) either acutely (just before the injury) or chronically (for 4 wk prior to the injury). Acute (but not chronic) L-NAME administration enhanced NPE severity in rats anesthetized with 1.5% isoflurane, leading to the death of 83% of the animals within 10 min after injury. Pretreatment with either the ganglionic blocker pentolinium (to reduce blood pressure rise) or the muscarinic receptor blocker atropine (to lessen heart rate decrease) prevented or attenuated NPE development in these rats. We did not observe any therapeutic effects of atropine administered 2 min after spinal cord compression. Our data indicate that NPE development is dependent upon a marked decrease of heart rate under the conditions of high blood pressure elicited by the activation of the sympathetic nervous system. These hemodynamic alterations are especially pronounced in rats subjected to acute NO synthase inhibition. In conclusion, nitric oxide has a partial protective effect on NPE development because it attenuates sympathetic vasoconstriction and consequent baroreflex-induced bradycardia following spinal cord injury.","[Sedy, Jiri; Hejcl, Ales; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Sedy, Jiri; Zicha, Josef; Kunes, Jaroslav] Acad Sci Czech Republic, Inst Physiol, CR-14220 Prague 4, Czech Republic; [Sedy, Jiri] Charles Univ Prague, Inst Dent Res, Fac Med 1, Prague, Czech Republic; [Sedy, Jiri] Gen Univ Hosp, Prague, Czech Republic; [Zicha, Josef; Kunes, Jaroslav] Cardiovasc Res Ctr, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic","Sedy, J (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","jirisedy@hotmail.com","Zicha, Josef/B-1349-2012; Kunes, Jaroslav/B-7079-2012","Zicha, Josef/0000-0001-6051-6541; ","Ministry of Education of the Czech Republic [AV0Z50390512, AV0Z50110509, 1M0538, LC554, 1M0510]; Grant Agency of the Czech Republic [GACR309/06/1246, GACR 305/08/0139]; Czech Ministry of Health [IGA MZ 1A8697-5, IGA MZ NR/8339-3]; Internal Agency of the Academy of the Czech Republic [IAA 500390902]; European Comission [LSHB-CT-2005-518233]","We acknowledge the support provided by the Grants AV0Z50390512, AV0Z50110509, 1M0538, LC554, and 1M0510 by the Ministry of Education of the Czech Republic, Grants GACR309/06/1246 and GACR 305/08/0139 by Grant Agency of the Czech Republic, Grants IGA MZ 1A8697-5 and IGA MZ NR/8339-3 by Czech Ministry of Health, Grant IAA 500390902 by Internal Agency of the Academy of the Czech Republic and the European Comission FP6 project RESCUE (LSHB-CT-2005-518233).",null,27,5,5,"AMER PHYSIOLOGICAL SOC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","0363-6119",null,null,"AM J PHYSIOL-REG I","Am. J. Physiol.-Regul. Integr. Comp. Physiol.","OCT",2009,297,4,null,null,null,null,"R1111","R1117",null,"10.1152/ajpregu.00251.2009",null,7,"Physiology","Physiology","498YY","WOS:000270184100023"]
[null,null,null,null,"J","Stejskalova, E; Malis, J; Snajdauf, J; Pycha, K; Urbankova, H; Bajciova, V; Stary, J; Kodet, R; Jarosova, M",null,null,null,"Stejskalova, Eva; Malis, Josef; Snajdauf, Jiri; Pycha, Karel; Urbankova, Helena; Bajciova, Viera; Stary, Jan; Kodet, Roman; Jarosova, Marie",null,null,"Cytogenetic and array comparative genomic hybridization analysis of a series of hepatoblastomas","CANCER GENETICS AND CYTOGENETICS",null,null,"English","Article",null,null,null,null,null,null,"IN-SITU HYBRIDIZATION; GENETIC ALTERATIONS; ABNORMALITIES; ABERRATIONS; 1Q; RHABDOMYOSARCOMA; REARRANGEMENTS; TRANSLOCATION; MICROARRAYS; REGION","Hepatoblastoma is the most common primary hepatic tumor in children, and only a limited number of detailed karyotypic analyses have been reported to date. In the present study, cytogenetic abnormalities were identified in nine cases of hepatoblastoma from a single institution. Among characteristic chromosomal changes detected were simple numerical aberrations, structural alterations of chromosomes 1, 2, and 8, and the recurrent unbalanced rearrangements der(4)t(1;4)(q25.2;q35.1) and der(6)t(1;6)(q21;q26). Array comparative genomic hybridization was applied in four of the cases. The combined cytogenetic, molecular cytogenetic, and histopathologic analyses are presented here, together with clinical data. The results substantially confirm previous findings of aberrations involving chromosomal loci on 1q, 2 or 2q, 4q, 6q, 8 or 8q, and 20 as significant in the development and clinical course of this disease. (C) 2009 Elsevier Inc. All rights reserved.","[Stejskalova, Eva; Malis, Josef; Stary, Jan] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Snajdauf, Jiri; Pycha, Karel] Univ Hosp Motol, Dept Pediat Surg, Prague 15006 5, Czech Republic; [Urbankova, Helena; Jarosova, Marie] Palacky Univ Hosp, Dept Hematooncol, Olomouc, Czech Republic; [Bajciova, Viera] Univ Hosp Brno, Dept Pediat Oncol, Brno, Czech Republic; [Kodet, Roman] Univ Hosp Motol, Inst Pathol & Mol Med, Prague 15006 5, Czech Republic","Stejskalova, E (reprint author), Univ Hosp Motol, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006 5, Czech Republic.","eva.stejskalova@lfmotol.cuni.cz",null,null,"Ministry of Health [IGA MZ NR/9050-3]","The authors thank Mrs. H. Mendlova, D. Honsova, J. Sulcova, and J. Balcarkova for their invaluable technical assistance. This work was supported by a grant from the internal grant agency of the Ministry of Health (IGA MZ NR/9050-3).",null,26,4,5,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,null,"CANCER GENET CYTOGEN","Cancer Genet. Cytogenet.","OCT 15",2009,194,2,null,null,null,null,82,87,null,"10.1016/j.cancergencyto.2009.06.001",null,6,"Oncology; Genetics & Heredity","Oncology; Genetics & Heredity","504AO","WOS:000270585200003"]
[null,null,null,null,"J","Dusatkova, P; Hradsky, O; Lenicek, M; Bronsky, J; Nevoral, J; Kotalova, R; Bajerova, K; Vitek, L; Lukas, M; Cinek, O",null,null,null,"Dusatkova, Petra; Hradsky, Ondrej; Lenicek, Martin; Bronsky, Jiri; Nevoral, Jiri; Kotalova, Radana; Bajerova, Katerina; Vitek, Libor; Lukas, Milan; Cinek, Ondrej",null,null,"Association of IL23R p.381Gln and ATG16L1 p.197Ala With Crohn Disease in the Czech Population","JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION",null,null,"English","Article",null,null,null,null,null,"Age at onset; ATG16L1; Crohn disease; Genetic association; IL23R","INFLAMMATORY-BOWEL-DISEASE; GENOME-WIDE ASSOCIATION; ITALIAN POPULATION; SUSCEPTIBILITY; GENE; VARIANT; EXPRESSION; PHENOTYPE; AUTOPHAGY; CELLS","Objectives: An association of variants in the genes encoding the interleukin 23 receptor (IL23R, p.Arg381Gln, rs11209026), and the autophagy-related gene 16-like 1 (ATG16L1, p.Ala197Thr, rs2241880) with Crohn disease (CD) was identified by whole genome association studies, and subsequently confirmed by other works. The aim of this study was to assess this association in the Czech population. Subjects and Methods: In a case-control study 333 patients with CD (137 paediatric and 196 adult-onset) and 499 unrelated healthy controls were genotyped using TaqMan SNP assays. Results: The IL23R p.381Gln allele was protective against CD in the Czech population (allelic frequency 3.2% in patients vs 5.5% in control subjects; OR 0.56, 95% CI 0.33-0.93, P=0.02). ATG16L1 p.197Ala allele conferred increased risk of CD (allelic frequency 60% in patients vs 51% in controls; OR 1.25, 95% CI 1.02-1.52, P=0.03). There was no appreciable difference in the effect of the associated alleles across the strata of CARD15-conferred risk. The IL23R and ATG16L1 variants did not influence the age at diagnosis, and in the genotype-phenotype analysis, the only detected association was a weak one between IL23R p.381Gln and involvement of the upper gastrointestinal tract (uncorrected P=0.031). Conclusions: We confirmed the role of IL23R and ATG16L1 in the CD susceptibility in the Czech population, and found a weak protective effect of IL23R p.381Gln against upper gastrointestinal tract involvement. JPGN 49:405-410, 2009.","[Dusatkova, Petra; Hradsky, Ondrej; Bronsky, Jiri; Nevoral, Jiri; Kotalova, Radana; Cinek, Ondrej] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Dusatkova, Petra; Hradsky, Ondrej; Bronsky, Jiri; Nevoral, Jiri; Kotalova, Radana; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, CZ-15006 Prague, Czech Republic; [Lenicek, Martin; Vitek, Libor] Charles Univ Prague, Inst Clin Biochem, CZ-15006 Prague, Czech Republic; [Lenicek, Martin; Vitek, Libor] Charles Univ Prague, Diagnost Lab, Fac Med 1, CZ-15006 Prague, Czech Republic; [Bajerova, Katerina] Fac Hosp, Pediat Internal Med Clin 1, Brno, Czech Republic; [Lukas, Milan] Charles Univ Prague, Fac Med 1, Dept Internal Med 4, CZ-15006 Prague, Czech Republic","Cinek, O (reprint author), Charles Univ Prague, Dept Pediat, Univ Hosp Motol, V Uvalu 84, CZ-15006 Prague, Czech Republic.","Ondrej.Cinek@Lfmotol.cuni.cz","Vitek, Libor/A-2645-2008",null,"Czech Ministry of Health [MZ00064203]; University Hospital Motol; Charles University in Prague [GAUK 7660/2007]","This study was supported by grants from the Czech Ministry of Health (MZ00064203), the University Hospital Motol, and the grant agency of the Charles University in Prague (GAUK 7660/2007).",null,28,4,5,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0277-2116",null,null,"J PEDIATR GASTR NUTR","J. Pediatr. Gastroenterol. Nutr.","OCT",2009,49,4,null,null,null,null,405,410,null,null,null,6,"Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","502PU","WOS:000270473200006"]
[null,null,null,null,"J","Seeman, T; Dusek, J; Vondrak, K; Spatenka, J; Feber, J",null,null,null,"Seeman, Tomas; Dusek, Jiri; Vondrak, Karel; Spatenka, Jaroslav; Feber, Janusz",null,null,"Profiling proteinuria in children after renal transplantation","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Tubular proteinuria; Glomerular proteinuria; Renal transplantation; Children; Albuminuria; Alpha-1-microglobulin","KIDNEY-TRANSPLANTATION; RECIPIENTS; SURVIVAL; HISTOPATHOLOGY; ADOLESCENTS; EXCRETION; SIROLIMUS; BLOCKADE; DISEASES; ALBUMIN","Proteinuria is a common complication after renal transplantation (RTx). In adults, tubular proteinuria prevails and is associated with impaired graft survival. In the absence of studies on proteinuria profiling in transplanted children, we aimed at analyzing the types of proteinuria in transplanted children. Fifty-three children (11.8 years) were analyzed in a cross-sectional study. Morning urine was tested for total protein (PROT), albumin (ALB) and alpha-1-microglobulin (AMG). The type of proteinuria was assessed by the alpha-1-microglobulin/albumin algorithm (AAA): [AAA = AMG x 100/(AMG+ALB]. Median PROT, ALB, and AMG (in mg/mmol creatinine) were 20.0, 3.8, and 4.9, respectively. Pathological total proteinuria (> 22 mg protein/mmol creatinine) was found in 47% of children (25/53). Only 20% of patients with pathological total proteinuria (5/25) had glomerular proteinuria, whereas 80% (20/25) had tubular proteinuria. Three of five children with glomerular proteinuria had chronic allograft nephropathy. Both AMG and albuminuria negatively correlated with the estimated glomerular filtration rate (eGFR) (p = 0.021 and 0.003, respectively). In conclusion, tubular proteinuria was present in 80% of children post-RTx and may be associated with impaired graft function; glomerular proteinuria is associated mainly with chronic allograft nephropathy.","[Seeman, Tomas; Dusek, Jiri; Vondrak, Karel; Spatenka, Jaroslav] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Fac Med 2, Prague 15006, Czech Republic; [Seeman, Tomas; Dusek, Jiri; Vondrak, Karel; Spatenka, Jaroslav] Charles Univ Prague, Transplantat Ctr, Univ Hosp Motol, Fac Med 2, Prague 15006, Czech Republic; [Feber, Janusz] Childrens Hosp Eastern Ontario, Div Pediat Nephrol, Ottawa, ON K1H 8L1, Canada","Seeman, T (reprint author), Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","tomas.seeman@lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic [NR/9524-3]; VZ MSMT [0021620819]","This study was supported by grant IGA of the Ministry of Health of the Czech Republic, reg. No NR/9524-3, and grant VZ MSMT reg. No. 0021620819.",null,25,4,4,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","DEC",2009,24,12,null,null,null,null,2439,2444,null,"10.1007/s00467-009-1275-x",null,6,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","512WV","WOS:000271283400021"]
[null,null,null,null,"J","Chladek, P; Trc, T; Schejbalova, A; Rehacek, V",null,null,null,"Chladek, P.; Trc, T.; Schejbalova, A.; Rehacek, V.",null,null,"Bernese Periacetabular Osteotomy (Ganz Procedure). First Experience","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"acetabular dysplasia; Bernese periacetabular osteotomy; Ganz procedure","ANTERIOR FEMOROACETABULAR IMPINGEMENT; HIP-DYSPLASIA; COMPLICATIONS; EXPOSURE; SURGERY","PURPOSE OF THE STUDY Developmental dysplasia of the hip (DDH), treated either conservatively or surgically, may result in a dysplastic acetabulum. To treat this after bone maturation is completed, Bernese periacetabular osteotomy, also known as the Ganz procedure, has recently been used as the method of choice at our department. The evaluation of the first results is presented here. MATERIAL AND METHODS The group evaluated comprised 25 hips (21 female and 4 male) in 22 patients. Nineteen hips were treated for residual dysplasia of the acetabulum due to DDH, and six for a spastic hip. The average age was 26 years (range, 12 to 44) and 14 right and 11 left hips were involved On pre- and post-operative radiographs the AC index, Wiberg lateral CE angle, Wagner index, improvement in Shenton's line, and lateralisation and anteversion of the acetabulum were compared. Bernese periacetabular osteotomy is an extensive surgical procedure requiring special instrumentation. It may be associated with serious complications and has a relatively long learning curve. RESULTS The average follow-up was 18 months (range, 2 to 36). The average duration of surgery was 2 hours and 44 min (range, 2 to 31/2 h). The average values improved in the AC index by 24 degrees, lateral CE angle by 29 degrees and Wagner index by 18%. Shenton's line was corrected by surgery in 20 hips and lateral migration in 16 hips. In two hips lateralisation did not changed. Two serious complications were recorded: para-articular ossification requiring excision and concomitant acetabular trimming, and great intra-operative blood loss. DISCUSSION Various mechanisms of damage to the hip are discussed and the methods of treatment outlined, together with prerequisites for successful surgery. Potential complications and their treatment are mentioned. CONCLUSIONS Bernese periacetabular osteotomy makes the range of roofing procedures for hip joint treatment wider. These, as well as hip joint reduction techniques, should be performed in major specialized centres.","FN Motol Detska & Dospela Ortoped & Traumatol, Prague, Czech Republic; [Chladek, P.] LF UK, Ortoped Klin 2, Prague 15000 5, Czech Republic","Chladek, P (reprint author), LF UK, Ortoped Klin 2, Uvalu 84, Prague 15000 5, Czech Republic.","petr.chladek@fnmotol.cz",null,null,null,null,null,48,4,4,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","AUG",2009,76,4,null,null,null,null,295,301,null,null,null,7,"Orthopedics","Orthopedics","492VV","WOS:000269691300005"]
[null,null,null,null,"J","Stastny, E; Trc, T; Handl, M; Frydl, J",null,null,null,"Stastny, E.; Trc, T.; Handl, M.; Frydl, J.",null,null,"Cementless Total Hip Replacement Type SF: Mid-Term Results","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"cementless total hip arthroplasty; porous coating of the prosthesis; press-fit fixation; secondary fixation","EXPERIENCE; FIXATION; SOCKETS; BONE","PURPOSE OF THE STUDY The authors evaluate the mid-term results and their experience with the cementless total hip replacement Beznoska type S.F. \"Slavik, Fencl\" in a group of 40 patients. MATERIAL During 2002, a total of 46 patients underwent implantation of a cementless total hip replacement (THR) type S.F. Six patients failed to come to the final follow-up at 5 years after surgery. Coxarthritis was the indication for primary surgery in the majority of the patients. The average age of the group, which comprised 20 men and 20 women, was 63 (50-75) years. METHODS At the end of 2007, 40 patients were evaluated at an average follow-up of 62.5 months. The patients' age, gender, body mass index, physical activity, diagnosis on which indication for surgery was based, size of each cementless component and intra- and post-operative complications were recorded. The objective outcome was assessed using the Harris Hip Score (HHS), signs of secondary stability were evaluated on radiographs at 3, 6 and 12 months, then at 3 and 5 years after the primary THR. RESULTS The primary fixation of all components was always good. In the post-operative period there was no THR dislocation and no loosening of the polyethylene acetabular liner from the titanium shell. One patient suffered a periprosthetic fracture following a fall. At 5-year follow-up, no evidence of acetabular loosening was found one patient required polyethylene liner exchange for excessive wear. Thirty-eight stems were evaluated as stable, with three stems showing ingrowth of a fibrous intermediate layer. Only one femoral component was assessed as unstable with a suspected late haematogenous infection. The mean HHS value was 45.6 before THR and 90.3 at 5 years after the primary surgery. The results were excellent in 24, very good in 12, fair in two and poor in two patients. DISCUSSION If the correct surgical procedure is observed, a perfect press-fit fixation of both components can always be achieved. The S.F. type implant can also be used for a dysplastic acetabulum in this case a deeper reaming of the acetabular bed in preferred to acetabular augmentation (acetabuloplasty). The excessive polyethylene wear in one patient can be accounted for by the patient's overdone daily exercise the imperfect secondary osteointegration of three stems was probably due to the selection of a smaller femoral component than it was appropriate. When an undersized stem is used, insufficient implant osteointegration and a higher incidence of pain symptoms should be expected. The findings of signs of stress shielding were in accordance with those reported in the literature. CONCLUSIONS The mid-term clinical results and evidence of good osteointegration of both components five years after primary implantation of the THR type S.F. in 40 patients are very satisfactory. This group of patients will be followed up for another 5 years and evaluated.","[Stastny, E.] FN Motol, LF UK, Ortoped Klin Deti & Dospelych 2, Prague 15018 5, Czech Republic","Stastny, E (reprint author), FN Motol, LF UK, Ortoped Klin Deti & Dospelych 2, Uvalu 84, Prague 15018 5, Czech Republic.","stastnyed@seznam.cz",null,null,null,null,null,27,1,4,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2009,76,6,null,null,null,null,487,494,null,null,null,8,"Orthopedics","Orthopedics","539FC","WOS:000273238000006"]
[null,null,null,null,"J","Balascakova, M; Holubova, A; Skalicka, V; Zemkova, D; Kracmar, P; Gonsorcikova, L; Camajova, J; Piskackova, T; Lebl, J; Drevinek, P; Gregor, V; Vavrova, V; Votava, F; Macek, M",null,null,null,"Balascakova, Miroslava; Holubova, Andrea; Skalicka, Veronika; Zemkova, Dana; Kracmar, Petr; Gonsorcikova, Lucie; Camajova, Jana; Piskackova, Tereza; Lebl, Jan; Drevinek, Pavel; Gregor, Vladimir; Vavrova, Vera; Votava, Felix; Macek, Milan, Jr.",null,null,"Pilot newborn screening project for cystic fibrosis in the Czech Republic: Defining role of the delay in its symptomatic diagnosis and influence of ultrasound-based prenatal diagnosis on the incidence of the disease","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Article",null,null,null,null,null,"CF carriers; CFTR gene; Cystic fibrosis (OMIM 219700); Decentralisation of health care; DNA testing; Incidence; Immunoreactive trypsinogen; Newborn screening; Prenatal diagnosis",null,"The objective need for cystic fibrosis (CF) newborn screening (NBS) in the Czech Republic has recently been substantiated by a significant delay of its symptomatic diagnosis. This trend most likely resulted from the process of decentralisation of health care which led to the deterioration of care for patients who need specialised approaches. Applied newborn screening model (IRT/DNA/IRT) was efficacious enough to detect CF cases with median age at diagnosis of 37 days. The incidence of CF (I in 6946 live births) ascertained in this project was lower than that established previously by epidemiological studies (1 in 2700-1 in 3300). However, adjustment far broadly applied ultrasound-based prenatal diagnosis (PND) in the 2nd trimester of pregnancy, that was performed within the period of the project (1/2/2005-2/11/2006), rendered an incidence estimate of I in 4023. This value is closer to that observed in other CF NBS programmes and reflects influence of PND on the incidence of CF. (C) 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Balascakova, Miroslava; Holubova, Andrea; Camajova, Jana; Piskackova, Tereza; Macek, Milan, Jr.] Charles Univ Prague, Dept Biol & Med Genet, Cyst Fibrosis Ctr, Sch Med 2, CZ-15606 Prague 5, Czech Republic; [Balascakova, Miroslava; Holubova, Andrea; Skalicka, Veronika; Zemkova, Dana; Gonsorcikova, Lucie; Camajova, Jana; Piskackova, Tereza; Lebl, Jan; Drevinek, Pavel; Vavrova, Vera; Macek, Milan, Jr.] Charles Univ Prague, Fac Hosp Motol, CZ-15606 Prague, Czech Republic; [Skalicka, Veronika; Zemkova, Dana; Gonsorcikova, Lucie; Lebl, Jan; Drevinek, Pavel; Vavrova, Vera] Charles Univ Prague, Dept Paediat, Cyst Fibrosis Ctr, Sch Med 2, CZ-15606 Prague 5, Czech Republic; [Gregor, Vladimir] Charles Univ Prague, Dept Med Genet, Fac Thomayer Hosp, CZ-15606 Prague 5, Czech Republic; [Kracmar, Petr; Votava, Felix] Charles Univ Prague, Dept Paediat, Med Sch 3, CZ-15606 Prague 5, Czech Republic; [Kracmar, Petr; Votava, Felix] Charles Univ Prague, Fac Hosp Kralovske Vinohrady, CZ-15606 Prague 5, Czech Republic","Macek, M (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Cyst Fibrosis Ctr, Sch Med 2, V Uvalu 84, CZ-15606 Prague 5, Czech Republic.","Milan.Macek.Jr@LFmotol.cuni.cz",null,null,"IGA Czech Ministry of Health [MSM0021620814, VZFNMOO064203]","Supported by IGA Czech Ministry of Health 9986-3, MSM0021620814 and VZFNMOO064203.",null,20,3,3,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","MAY",2009,8,3,null,null,null,null,224,227,null,"10.1016/j.jcf.2009.01.002",null,4,"Respiratory System","Respiratory System","451HQ","WOS:000266461700010"]
[null,null,null,null,"J","Vymazal, T; Horacek, M; Durpekt, R; Hladikova, M; Cvachovec, K",null,null,null,"Vymazal, Tomas; Horacek, Michal; Durpekt, Radim; Hladikova, Marie; Cvachovec, Karel",null,null,"Is Allogeneic Blood Transfusion a Risk Factor for Sternal Dehiscence Following Cardiac Surgery? A Prospective Observational Study","INTERNATIONAL HEART JOURNAL",null,null,"English","Article",null,null,null,null,null,"Sternal dehiscence; Immune modulation; Blood transfusion; Cardiac surgery","BYPASS GRAFT-SURGERY; RED-CELLS; ANEMIA; LENGTH; MORBIDITY; MORTALITY; STORAGE","Sternal dehiscence following cardiac Surgery has a multifactorial etiology. Significant risk factors contributing to sternal dehiscence include chronic obstructive pulmonary disease (COPD), obesity, or re-exploration due to bleeding or pericardial tamponade. We have focused on the role of allogeneic blood transfusion as a factor leading to the poor healing of surgical wounds. A prospective Observational study of 1553 elective and emergency cardiac surgery patients was performed between January 2003 and June 2007. All of the patients enrolled in this Study underwent median sternotomy. We studied the relationship between sternal dehiscence following cardiac Surgery and the total number of packed red blood cells transfused. The incidence of sternal dehiscence in the study group was 3.4%. Diabetic patients did not have a higher incidence Of Wound dehiscence. Although COPD,(2)) obesity,(2)) and re-exploration(4)) contributed to sternal dehiscence, the number of allogeneic blood transfusions during the perioperative period was an important independent risk factor for sternal dehiscence. Patients with sternal dehiscence received an average of 7.6 transfusion units (TU) of allogeneic blood versus 1.6 TU of allogeneic blood in the group without sternal dehiscence (P < 0.00005). The dehiscence affected patients without any other significant risk factor who received 6 or more TU, or patients with at least one significant risk factor who received 4 of more TU of allogeneic blood. According to our results, the total amount of allogeneic blood transfused is an important risk factor contributing to sternal dehiscence. Regardless of other risk preconditions, the transfusion of 6 or more TU Could result in sternal dehiscence following cardiac surgery. (Int Heart J 2009; 50: 601-608)","[Vymazal, Tomas; Horacek, Michal; Cvachovec, Karel] Univ Hosp Motol, Dept Anesthesiol & Intens Care Med, Prague 15006 5, Czech Republic; [Durpekt, Radim] Univ Hosp Motol, Dept Cardiovasc Surg, Prague 15006 5, Czech Republic; [Hladikova, Marie] Charles Univ Prague, Fac Med 2, Dept Med Informat, Prague, Czech Republic","Vymazal, T (reprint author), Univ Hosp Motol, Dept Anesthesiol & Intens Care Med, Prague 15006 5, Czech Republic.",null,null,null,null,null,null,20,2,2,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","1349-2365",null,null,"INT HEART J","Int. Heart J.","SEP",2009,50,5,null,null,null,null,601,607,null,null,null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","513EB","WOS:000271304100006"]
[null,null,null,null,"J","Seeman, T; Malikova, M; Blahova, K; Seemanova, E",null,null,null,"Seeman, Tomas; Malikova, Marcela; Blahova, Kveta; Seemanova, Eva",null,null,"Polycystic kidney and hepatic disease with mental retardation and hand anomalies in three siblings","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Autosomal recessive inheritance; Facial dysmorphy; Hand anomalies; Hepatic fibrosis; Mental retardation; Polycystic kidneys; Proximal implanted thumbs","FIBROSIS; ARPKD","A family with three children affected with congenital polycystic kidneys, hepatic fibrosis, mental retardation, minor anomalies of the hands, and dysmorphic facial features is reported. All children progressed to chronic renal failure. Linkage to the locus for autosomal recessive polycystic kidney disease was excluded by haplotype analysis. The family is endogamic, and the affected siblings are of both sexes, which is in agreement with an autosomal recessive determination of this syndrome. A similar syndrome was reported in 1990 by Labrune et al. [J Pediatr Gastroenterol Nutr (1990) 10:540-543]. Our report provides further evidence for the etiological heterogeneity of polycystic kidney with hepatic fibrosis. The syndrome reported here should be considered in the differential diagnosis of the early manifestation of polycystic kidneys. Mental retardation and hand anomalies are the hallmarks for the differential diagnosis of this syndrome.","[Seeman, Tomas; Blahova, Kveta] Charles Univ Prague, Dept Pediat, Sch Med 2, Univ Hosp Motol, Prague 15006, Czech Republic; [Malikova, Marcela; Seemanova, Eva] Charles Univ Prague, Dept Clin Genet, Sch Med 2, Univ Hosp Motol,Inst Biol & Med Genet, Prague 15006, Czech Republic","Seeman, T (reprint author), Charles Univ Prague, Dept Pediat, Sch Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006, Czech Republic.","tomas.seeman@lfmotol.cuni.cz",null,null,"VZ MZ CR [0006420301]; VZ MSMT CR [0021620819]; IGA [NR9457-3]","We thank Prof. Klaus Zerres and Dr. Carsten Bergmann from the Aachen University of Technology for haplotype analysis of the ARPKD, Dr. Karel Vondrak for providing clinical data and Dr. Pavel Dvorak for technical support. Supported by grant VZ MZ CR 0006420301, VZ MSMT CR 0021620819 and IGA NR9457-3.",null,10,2,2,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","JUL",2009,24,7,null,null,null,null,1409,1412,null,"10.1007/s00467-008-1049-x",null,4,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","451XN","WOS:000266504300020"]
[null,null,null,null,"J","Mahelkova, G; Bacakova, L; Korynta, J; Vajner, L; Vytasek, R",null,null,null,"Mahelkova, G.; Bacakova, L.; Korynta, J.; Vajner, L.; Vytasek, R.",null,null,"Effect of Culture Substrate and Culture Conditions on Lens Epithelial Cell Proliferation and alpha-smooth Muscle Actin Expression","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,"alpha-smooth muscle actin; cell proliferation; culture substrates; lens epithelial cells","POSTERIOR CAPSULE OPACIFICATION; GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; CATARACT; TRANSDIFFERENTIATION; ADHESION; DIFFERENTIATION; INDUCTION; MIGRATION; CYTOKINES","The most common complication following cataract surgery is posterior capsule opacification. This results from migration, proliferation and transdifferentiation of residual lens epithelial cells (LECs). We studied the effect of several culture substrates and culture conditions on LEC proliferation and alpha-smooth muscle actin (alpha-SMA) expression. We used primary and secondary cultures of porcine LECs cultivated on collagen I, collagen IV, microscopic glass slides, and uncoated plastic dishes. We studied the cell proliferation and expression of alpha-SMA and alpha-, beta-, and gamma-crystallins. The effect of the medium exchange protocol was studied using the TOTL-86 rabbit epithelial lens cell line. There was no difference in growth characteristics of primary cultures on different substrates. In secondary cultures, LECs adhered better to collagen-coated surfaces. The culture substrate influenced LEC proliferation and alpha-SMA expression. The proliferation was greater when the medium was changed than when extra medium was added on the 4(th) day. The cells did not synthesize alpha-, beta- or gamma-crystallin. The culture substrate influences the adhesion ability, proliferation and alpha-SMA expression in lens epithelial cells. In addition, it is necessary to consider the effects of the medium exchange protocol, serum supplementation, cell density and other cell culture conditions in lens epithelial cell experiments.","[Mahelkova, G.] Charles Univ Prague, Fac Med 2, Inst Physiol, Prague 15000 5, Czech Republic; [Mahelkova, G.] Charles Univ Prague, Fac Med 2, Clin Ophthalmol, Prague 15000 5, Czech Republic; [Vajner, L.] Charles Univ Prague, Fac Med 2, Inst Histol & Embryol, Prague 15000 5, Czech Republic; [Vytasek, R.] Charles Univ Prague, Fac Med 2, Inst Med Chem & Biochem, Prague 15000 5, Czech Republic; [Bacakova, L.] Acad Sci Czech Republic, Inst Physiol, Dept Growth & Differentiat Cell Populat, Prague, Czech Republic; [Korynta, J.] Univ Edinburgh, Edinburgh, Midlothian, Scotland","Mahelkova, G (reprint author), Charles Univ Prague, Fac Med 2, Inst Physiol, Plzenska 221, Prague 15000 5, Czech Republic.","gabriela.czakoova@post.cz","Bacakova, Lucie/C-2664-2012; Vajner, Ludek/C-5823-2014; Vytasek, Richard/C-7571-2014",null,"Charles University in Prague, Czech Republic [51/2001/C/2.LF]; Agency of the Czech Republic [305/08/0108]; Academy of Sciences of the Czech Republic [1QS500110564]","This work was supported by grant No. 51/2001/C/2.LF of Charles University in Prague, Czech Republic, grant No. 305/08/0108 of the Grant Agency of the Czech Republic and grant No. 1QS500110564 of the Academy of Sciences of the Czech Republic.",null,41,2,2,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2009,55,2,null,null,null,null,66,76,null,null,null,11,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","441JM","WOS:000265765100006"]
[null,null,null,null,"J","Kucera, A; Pycha, K; Pajer, P; Spisek, R; Skaba, R",null,null,null,"Kucera, A.; Pycha, K.; Pajer, P.; Spisek, R.; Skaba, R.",null,null,"Dendritic Cell-Based Immunotherapy Induces Transient Clinical Response in Advanced Rat Fibrosarcoma - Comparison with Preventive Anti-tumour Vaccination","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,"dendritic cells; immunotherapy; cancer immunotherapy; chemotherapy","DYING TUMOR-CELLS; CANCER-IMMUNOTHERAPY; T-CELLS; CHEMOTHERAPY; EXPOSURE; IMMUNITY; IMMUNOSURVEILLANCE; IMMUNOPREVENTION; INDUCTION; VACCINES","In this study we present the models of preventive and therapeutic vaccination of sarcoma-bearing rats with dendritic cells that present tumour antigens from killed tumour cells. We present the characteristics of dendritic cell-based vaccine and its capacity to induce anti-tumour immune response both in vitro and in vivo. We show that preventive vaccination efficiently prevents tumour growth. On the other hand, vaccination of rats with established tumours did not lead to eradication of the tumours. Despite the induction of a vigorous immune response after administration of dendritic cell-based vaccine and transient decrease in tumour progression, tumours eventually resumed their growth and animals vaccinated with dendritic cells succumbed to cancer. In both settings, preventive and therapeutic, dendritic cell-based vaccination induced a vigorous tumour-specific T-cell response. These results argue for the timing of cancer immunotherapy to the stages of low tumour load. Immunotherapy initiated at the stage of minimal residual disease, after reduction of tumour load by other modalities, will have much better chance to offer a clinical benefit to cancer patients than the immunotherapy at the stage of metastatic disease.","[Spisek, R.] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague 15006, Czech Republic; [Kucera, A.; Pycha, K.; Skaba, R.] Charles Univ Prague, Fac Med 2, Dept Paediat Surg, Prague 15006, Czech Republic; [Kucera, A.; Pycha, K.; Skaba, R.] Univ Hosp Motol, Dept Paediat Surg, Prague, Czech Republic; [Spisek, R.] Univ Hosp Motol, Dept Immunol, Prague, Czech Republic; [Pajer, P.] Acad Sci Czech Republic, Inst Mol Genet, Dept Mol Virol, Prague, Czech Republic","Spisek, R (reprint author), Charles Univ Prague, Fac Med 2, Dept Immunol, V Uvalu 84, Prague 15006, Czech Republic.","radek.spisek@lfmotol.cuni.cz","Spisek, Radek/E-6724-2011",null,"The Ministry of Education, Youth and Sports of the Czech Republic [MSM0021620812]","This study was supported by research grant MSM0021620812 from The Ministry of Education, Youth and Sports of the Czech Republic.",null,26,1,2,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2009,55,4,null,null,null,null,119,125,null,null,null,7,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","488SD","WOS:000269369200001"]
[null,null,null,null,"J","Stechova, K; Spalova, I; Durilova, M; Bartaskova, D; Cerny, M; Cerna, M; Pithova, P; Chudoba, D; Stavikova, V; Ulmannova, T; Faresjo, M",null,null,null,"Stechova, K.; Spalova, I.; Durilova, M.; Bartaskova, D.; Cerny, M.; Cerna, M.; Pithova, P.; Chudoba, D.; Stavikova, V.; Ulmannova, T.; Faresjo, M.",null,null,"Influence of Maternal Hyperglycaemia on Cord Blood Mononuclear Cells in Response to Diabetes-associated Autoantigens","SCANDINAVIAN JOURNAL OF IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,null,"T-CELLS; MOTHERS; PREGNANCY; CHILDREN; NEWBORNS; MELLITUS; FATHERS; RISK","Perfect maternal diabetes compensation is crucial for the outcome of the baby. However, little is known how hyperglycaemia influences the specific immune response. Furthermore, babies of type 1 diabetes (T1D) mothers have less risk of development T1D than babies with a T1D father. This study aimed to analyze the effect of maternal hyperglycaemia on newborns with focus on the response to diabetes-associated autoantigens. Populations: (1) Newborns of T1D mothers split into groups according to maternal diabetes compensation during the 3rd trimester: perfect (n = 15) or acceptable (n = 25) compensation. (2) newborns with T1D father (n = 12) (3) newborns with a mother treated for either gestational or type 2 diabetes (n = 10) (4) control newborns (n = 25). Spontaneous as well as diabetes-associated autoantigen-stimulated production of 23 cytokines and chemokines were tested using protein microarray. In addition, the influence of glucose on cytokine and chemokine responsiveness was analyzed in vitro. The study groups differed in their spontaneous as well as stimulated cytokine and chemokine spectra. A prominent Th1 response (high IFN-gamma) from autoantigen stimulation was observed especially in babies of T1D fathers (P = 0.001) and also in mothers with perfect diabetes compensation during the 3rd trimester (P = 0.016) in comparison with control newborns. By contrast, cord blood mononuclear cells cultivated in vitro in high glucose concentration decreased the diabetogenic stimulated Th1 cytokine response. Maternal 'sweet' as well as 'autoimmune environment' may both lead to lower occurrence of T1D within their offspring. Further studies will reveal the exact immunological mechanism of this observation.","[Stechova, K.] Univ Hosp Motol, Dept Paediat, Lab Autoimmune Dis, Prague 15006 5, Czech Republic; [Stechova, K.; Durilova, M.; Stavikova, V.; Ulmannova, T.] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic; [Spalova, I.] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynaecol, Prague, Czech Republic; [Bartaskova, D.; Pithova, P.] Charles Univ Prague, Fac Med 2, Dept Internal Med, Prague, Czech Republic; [Cerny, M.] Charles Univ Prague, Fac Med 2, Neonatal Intens Care Unit, Prague, Czech Republic; [Chudoba, D.] Charles Univ Prague, Fac Med 2, Dept Biol & Genet, Prague, Czech Republic; [Cerna, M.] Inst Care Mother & Child, Prague, Czech Republic; [Faresjo, M.] Linkoping Univ, Fac Hlth Sci, Div Paediat, Linkoping, Sweden; [Faresjo, M.] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Diabet Res Ctr, Linkoping, Sweden; [Faresjo, M.] Jonkoping Univ, Sch Hlth Sci, Dept Nat Sci & Biomed, Jonkoping, Sweden","Stechova, K (reprint author), Univ Hosp Motol, Dept Paediat, Lab Autoimmune Dis, V Uvalu 84, Prague 15006 5, Czech Republic.","info@labao.cz",null,null,"Research Project of University Hospital Motol [00064203-6207]","This project was supported by Research Project of University Hospital Motol No. 00064203-6207.",null,19,1,1,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-9475",null,null,"SCAND J IMMUNOL","Scand. J. Immunol.","AUG",2009,70,2,null,null,null,null,149,158,null,"10.1111/j.1365-3083.2009.02282.x",null,10,"Immunology","Immunology","471MJ","WOS:000268061600010"]
[null,null,null,null,"J","Szabo, M; Peliskova, P; Kvapil, M; Matous, M",null,null,null,"Szabo, Marcela; Peliskova, Pavlina; Kvapil, Milan; Matous, Milos",null,null,"Positive effect of long-term tailored physical activity therapy on diabetes mellitus management in an obese type 2 diabetic patient","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"obese type 2 diabetic; individualized physical activity; withdrawal insulin therapy; insulin sensitisers; control of diabetes; weight loss","CARDIORESPIRATORY FITNESS; MEN; EXERCISE; MORTALITY; DIAMETER","The case history of a 44-year-old, severely obese Caucasian man with serious decompensation of diabetes and subsequent withdrawal of high-dose insulin is reported. Insulin was withdrawn after 5 years of continuous therapy and the patient was treated for 6 months with diet, individualized physical therapy and oral antidiabetic drugs from the group of insulin sensitizers. Six months later, oral antidiabetics were discontinued for low blood glucose levels, and the treatment was limited to therapeutic life style changes. After insulin withdrawal, the patient's condition markedly improved: he showed better diabetes control, decrease in insulin resistance, weight loss, reduced BMI, reduced waist circumference, sagittal abdominal diameter and body fat, increased fitness level, normalized blood pressure and decreased heart rate at rest.","[Szabo, Marcela; Peliskova, Pavlina; Kvapil, Milan] Charles Univ Prague, Univ Hosp Motol, Dept Med, Sch Med 2, Prague 15006 6, Czech Republic; [Matous, Milos] Charles Univ Prague, Univ Hosp Motol, Dept Rehabil & Sport Med, Sch Med 2, Prague 15006 6, Czech Republic","Szabo, M (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Med, Sch Med 2, Uvalu 84, Prague 15006 6, Czech Republic.","mszabo@seznam.cz",null,null,"IGA of Czech Republic [NR/8975-3/2006]","Grant of IGA of Czech Republic N. NR/8975-3/2006 supports this study",null,8,1,1,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.","MAR",2009,30,1,null,null,null,null,22,24,null,null,null,3,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","436PR","WOS:000265426800008"]
[null,null,null,null,"J","Lassuthova, P; Barankova, L; Haberlova, J; Mazanec, R; Wallace, A; Huehne, K; Rautenstrauss, B; Seeman, P",null,null,null,"Lassuthova, Petra; Barankova, Lucia; Haberlova, Jana; Mazanec, Radim; Wallace, Andrew; Huehne, Kathrin; Rautenstrauss, Bernd; Seeman, Pavel",null,null,"Mutations in the LMNA gene do not cause axonal CMT in Czech patients","JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"autosomal recessive Charcot-Marie-Tooth disease; HMSN II; Lamin A/C; MLPA; mutation","CHARCOT-MARIE-TOOTH; LAMIN A/C GENE; MUSCULAR-DYSTROPHY; HEREDITARY MOTOR; DISEASE MAPS; NEUROPATHY; FAMILIES; TYPE-2; LOCUS; FORM","The LMNA gene was sequenced in 98 Czech patients from 94 unrelated families with early-onset axonal Charcot-Marie-Tooth (CMT) disease consistent with both autosomal recessive inheritance and sporadic cases. Biallelic pathogenic mutations were not found in any patient in this group. One patient carried the c.1870C>T mutation that is predicted to result in the amino-acid substitution, p. Arg624Cys, on one allele, but the second causative mutation was not detected. LMNA mutation is not likely to be associated with the disease in this family. To exclude larger deletions/duplications in the LMNA gene not detectable by sequencing, 48 patients from this group were also analyzed with multiplex ligation-dependent probe amplification. No rearrangements in the LMNA gene were detected. We conclude that mutations in the LMNA gene are absent from a large group of Czech patients with axonal autosomal recessive CMT disease. Consequently, LMNA mutation screening does not seem to be relevant for axonal CMT DNA diagnostics. A similar situation may apply to other European populations. Journal of Human Genetics (2009) 54, 365-368; doi:10.1038/jhg.2009.43; published online 8 May 2009","[Lassuthova, Petra; Haberlova, Jana; Seeman, Pavel] Charles Univ Prague, Dept Child Neurol, DNA Lab, Sch Med 2, Prague 15006 5, Czech Republic; [Barankova, Lucia; Mazanec, Radim] Charles Univ Prague, Dept Neurol, Sch Med 2, Prague 15006 5, Czech Republic; [Wallace, Andrew] St Marys Hosp, Dept Med Genet, NGRL Manchester, Manchester M13 0JH, Lancs, England; [Huehne, Kathrin; Rautenstrauss, Bernd] Univ Erlangen Nurnberg, Inst Human Genet, D-8520 Erlangen, Germany; [Rautenstrauss, Bernd] MGZ Med Genet Zentrum, Munich, Germany","Lassuthova, P (reprint author), Charles Univ Prague, Dept Child Neurol, DNA Lab, Sch Med 2, Uvalu 84, Prague 15006 5, Czech Republic.","petra.lassuthova@gmail.com",null,null,"Czech Ministry of Health [NR 8330-3]","This study was supported by the Czech Ministry of Health (Grant IGA NR 8330-3). We thank our patients and their families for their participation.",null,22,0,0,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","1434-5161",null,null,"J HUM GENET","J. Hum. Genet.","JUN",2009,54,6,null,null,null,null,365,368,null,"10.1038/jhg.2009.43",null,4,"Genetics & Heredity","Genetics & Heredity","474VP","WOS:000268312700010"]
[null,null,null,null,"J","Cakrt, O; Kolar, P; Cerny, R; Funda, T; Jerabek, J",null,null,null,"Cakrt, O.; Kolar, P.; Cerny, R.; Funda, T.; Jerabek, J.",null,null,"Electrotactile Stimulation of the Tongue: a New Option in the Rehabilitation of Postural Stability - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"biofeedback; postural balance; rehabilitation; cerebellar syndrome","SUBSTITUTION; BALANCE","A completely new technique in the rehabilitation of patients suffering from balance disorders is the use of biological feedback by way of electrotactile stimulation - the BrainPort (R) system. Thanks to electrotactile stimulation of the tongue, the patient is informed of the actual position of his head. The principle part of the equipment is an accelerometer, which transmits information concerning changes in head positions to electrical impulses, which the patient feels on their tongue. The technique is predominantly used in peripheral disorders of the labyrinth where satisfactory compensation has not been achieved with standard processes. The technique is also promising in patients with central stability disorders. This paper demonstrates the promising effect of this rehabilitative approach in patients with palleocerebellar disorders.","[Cakrt, O.; Kolar, P.] LF UK & FN Motole, Klin Rehabil & Telovychovneho Lekarstvi 2, Prague 15006, Czech Republic; [Cerny, R.; Jerabek, J.] LF UK & FN Motole, Neurol Klin Dospelych 2, Prague 15006, Czech Republic; [Funda, T.; Jerabek, J.] LF UK Praze, CVUT FBMI, Spolecne Pracoviste Biomed Inzenyrstvi FBMI, Prague, Czech Republic","Cakrt, O (reprint author), LF UK & FN Motole, Klin Rehabil & Telovychovneho Lekarstvi 2, Uvalu 84,5 Motol, Prague 15006, Czech Republic.","ondrej.cakrt@lfmotol.cuni.cz",null,null,null,null,null,10,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,4,null,null,null,null,364,367,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","486HZ","WOS:000269188200011"]
[null,null,null,null,"J","Hoza, D; Lastovka, M; Bojar, M; Cerny, R; Sturm, D; Kraus, J; Liby, P; Tichy, M",null,null,null,"Hoza, D.; Lastovka, M.; Bojar, M.; Cerny, R.; Sturm, D.; Kraus, J.; Liby, P.; Tichy, M.",null,null,"An Improvement in Smooth Pursuit Eye Movements and Phonation Following Selective Dorsal Rhizotomy","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"rhizotomy; spasticity; ocular pursuit","SPASTIC CEREBRAL-PALSY; POSTERIOR RHIZOTOMY; CHILDREN; PERFORMANCE","Backgrounds: Selective dorsal rhizotomy (SDR) represents a standard therapeutic technique for the treatment of spasticity. Besides reducing spasticity of the lower limbs, an improvement in motor skills of the upper limbs and an improvement in speech and eye movements have also been repeatedly documented in literature. Aim: The objective of this study was to objectify the improvement in phonation and eye tracking. Methods: Eight patients underwent videooculographic testing and 1 1 underwent acoustic speech analysis. The measured parameters were a deviation from basic frequency, shimmer, jitter and phonation index in the acoustic speech analysis and a correlation coefficient of the horizontal stimulus upon videooculography. Results: Seven of the eleven patients demonstrated an improvement in acoustic parameters; four subjects reported an improvement in eye tracking. Conclusion: Improvement in phonation and eye tracking following selective dorsal rhizotomy was objectified by testing techniques. The described suprasegmental effects of SDR can be explained by a possibly reduced response of the pathologic polysynaptic due to deafferentation, which developed following selective dorsal rhizotomy.","[Hoza, D.; Liby, P.; Tichy, M.] Neurochirurg Oddeleni FN Motole, Prague 15006, Czech Republic; [Lastovka, M.] LF UK & VFN Praze, Foniatr Klin 1, Prague, Czech Republic; [Bojar, M.; Cerny, R.; Sturm, D.] LF UK & FN Motole, Neurol Klin 2, Prague, Czech Republic; [Kraus, J.] LF UK & FN Motole, Klin Detske Neurol 2, Prague, Czech Republic","Hoza, D (reprint author), Neurochirurg Oddeleni FN Motole, Uvalu 84,5 Motol, Prague 15006, Czech Republic.","david.hoza@yahoo.de",null,null,null,null,null,18,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,4,null,null,null,null,378,382,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","486HZ","WOS:000269188200014"]
[null,null,null,null,"J","Tejral, G; Kolacna, L; Schoner, W; Amler, E",null,null,null,"Tejral, G.; Kolacna, L.; Schoner, W.; Amler, E.",null,null,"The pi-Helix Formation between Asp(369) and Thr(375) as a Key Factor in E-1-E-2 Conformational Change of Na+/K+-ATPase","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Computer modeling; Molecular dynamics simulations; Molecular structure; Na+/K+-ATPase; E-1/E-2 conformation","PROTEIN SECONDARY STRUCTURE; NA,K-ATPASE ALPHA-SUBUNIT; CALCIUM-PUMP; BINDING-SITE; 3-DIMENSIONAL STRUCTURE; SARCOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FOLD RECOGNITION; H-4-H-5 LOOP","Molecular modeling of the H-4-H-5-loop of the alpha(2) isoform of Na+/K+-ATPase in the E-1 and E-2 conformations revealed that twisting of the nucleotide (N) domain toward the phosphorylation (P) domain is connected with the formation of a short pi-helix between Asp(369) and Thr(375). This conformational change close to the hinge region between the N-domain and the P-domain could be an important event leading to a bending of the N-domain by 64.7 degrees and to a shortening of the distance between the ATP binding site and the phosphorylation site (Asp(369)) by 1.22 nm from 3.22 nm to 2.00 nm. It is hypothesized that this shortening mechanism is involved in the Na+-dependent formation of the Asp(369) phospho-intermediate as part of the overall Na+/K+-ATPase activity.","[Tejral, G.; Kolacna, L.; Amler, E.] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague 15006 5, Czech Republic; [Tejral, G.; Kolacna, L.; Amler, E.] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Prague, Czech Republic; [Tejral, G.; Amler, E.] Charles Univ Prague, Fac Med 2, Cardiovasc Res Ctr, Prague 15006 5, Czech Republic; [Schoner, W.] Univ Giessen, Inst Biochem & Endocrinol, Giessen, Germany","Amler, E (reprint author), Charles Univ Prague, Fac Med 2, Inst Biophys, Uvalu 84, Prague 15006 5, Czech Republic.","evzen.amler@lfmotol.cuni.cz",null,null,"AS CR [1ET400110403, IAA500390702]; Ministry of Education, Youth and Sport of the Czech Republic [1M0510, 1M6798582302]; NPV II [2B06130]; AV0 - ASCR Institutional research [AV0Z50390512, AV0Z50390703]; Czech Science Foundation [GA202/09/1151]; EU [214539]","This work was supported by the Grant Agency of AS CR grants No. 1ET400110403 and IAA500390702, the Ministry of Education, Youth and Sport of the Czech Republic grants No. 1M0510 (1M6798582302) and NPV II 2B06130, AV0 - ASCR Institutional research plans AV0Z50390512 and AV0Z50390703 and by Czech Science Foundation grant No. GA202/09/1151, EU project BIOSCENT ID number 214539.",null,45,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,4,null,null,null,null,583,589,null,null,null,7,"Physiology","Physiology","507ME","WOS:000270857000014"]
[null,null,null,null,"J","Picha, D; Moravcova, L; Rusina, R",null,null,null,"Picha, D.; Moravcova, L.; Rusina, R.",null,null,"S-100 Protein and Neuron Specific Enolasis in the Clinical Diagnostics of Brain Impairment","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"neuron-specific enolase; S-100 protein","MYELIN BASIC-PROTEIN; CEREBROSPINAL-FLUID; SERUM-LEVELS; ACIDIC PROTEIN; S100B; INJURY; NEUROFILAMENT; SCLEROSIS; DYNAMICS; DISEASE","Within a group of 28 patients with clinically manifested CNS affection, the concentration of S-100 protein and neuron specific enolasis in the serum and in the cerebrospinal fluid was monitored using commercial sets, The concentrations of neuron specific enolasis in the serum corresponded to normal serum values, in the cerebrospinal fluid a pathologically increased value was identified only once. With the S-100 protein, abnormally increased values were recorded three times in the serum while in the cerebrospinal fluid all the measured values except for two were pathologically increased. The correlation of levels of the examined neuropeptides with the clinical condition of patients with nerve lesion has not been proved.","[Picha, D.; Moravcova, L.] 2 LF UK, Infekcini Klin 1, Prague 18081 8, Czech Republic; [Picha, D.; Moravcova, L.] FN Na Bulovce, Prague, Czech Republic; [Rusina, R.] Neurol Klin IPVZ, Prague, Czech Republic; [Rusina, R.] FTNsP, Prague, Czech Republic","Picha, D (reprint author), 2 LF UK, Infekcini Klin 1, Budinova 2, Prague 18081 8, Czech Republic.","dusan.picha@fnb.cz",null,null,null,null,null,18,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,3,null,null,null,null,274,278,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","459JD","WOS:000267097100013"]
[null,null,null,null,"J","Kalina, T; Stuchly, J; Janda, A; Hrusak, O; Ruzickova, S; Sediva, A; Litzman, J; Vlkova, M",null,null,null,"Kalina, Tomas; Stuchly, Jan; Janda, Ales; Hrusak, Ondrej; Ruzickova, Sarka; Sediva, Anna; Litzman, Jiri; Vlkova, Marcela",null,null,"Profiling of Polychromatic Flow Cytometry Data on B-Cells Reveals Patients' Clusters in Common Variable Immunodeficiency","CYTOMETRY PART A",null,null,"English","Article",null,null,null,null,null,"B-lymphocyte subsets; common variable immunodeficiency; flow cytometry; probability binning; B-lymphocyte profiling","CLASSIFICATION; SUBGROUPS; PACKAGE; DISEASE; CD27","The aim of this study was to find an objective computational approach for phenotype analysis of common variable immunodeficiency (CVID) patients that describes all differences in the six-color space and to form groups of patients using computational methods. CVID is a heterogeneous primary immunodeficiency disorder where molecular defect is recognized in <10% of the cases and is unknown in the majority of patients. The current CVID classification, EUROClass, is based on quantification of selected B-cell subsets. Using six-color polychromatic flow cytometry, we analyzed B-cell phenotypes in a cohort of 48 CVID patients and 49 healthy donors. We used a \"probability binning\" algorithm to create 1,024 bins (each bin is a six-color gate) that covered the cells' distribution within the entire B-cell compartment. A matrix file recording cellular content in all the bins was made. The hierarchical clustering of the individual samples was analyzed using a Pearson correlation of the bins' values. The Cut tree algorithm found 12 clusters. In six clusters, healthy individuals predominated; in one cluster, smB+CD21low (CVID patients by EUROClass) cells prevailed; in one cluster, smB-CD21norm cells prevailed; in one cluster, smB+CD21low cells prevailed; the remaining cluster was mixed. The overall reproducibility of probability binning clustering was confirmed by matching of replicates to the original cohort using the similarity matrix of the Pearson correlation, 15 replicates matched the same individual, three replicates matched a different individual within the same cluster, and three replicates matched to a different cluster. We were able to define B-cell subsets over- or under-represented in a particular cluster and display them back in the flow cytometry software. We describe a new analytical approach that enables a search in an objective computational environment for patient cohorts that are defined by similar B-cell profiles and thus contribute to the description of differences between CVID patient groups. (C) 2009 International Society for Advancement of Cytometry","[Kalina, Tomas; Stuchly, Jan; Janda, Ales; Hrusak, Ondrej] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Kalina, Tomas; Stuchly, Jan; Janda, Ales; Hrusak, Ondrej; Sediva, Anna] Univ Hosp Motol, Prague, Czech Republic; [Kalina, Tomas; Stuchly, Jan; Janda, Ales; Hrusak, Ondrej] CLIP, Prague, Czech Republic; [Stuchly, Jan] Charles Univ Prague, Fac Math & Phys, Dept Numer Math, Prague, Czech Republic; [Ruzickova, Sarka] Acad Sci Czech Republic, Inst Biotechnol, Lab Diagnost Autoimmune Dis, PRI, Prague, Czech Republic; [Sediva, Anna] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague 15006 5, Czech Republic; [Litzman, Jiri; Vlkova, Marcela] St Annes Fac Hosp, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Litzman, Jiri; Vlkova, Marcela] Masaryk Univ, Fac Med, Brno, Czech Republic","Kalina, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006 5, Czech Republic.","tomas.kalina@lfmotol.cuni.cz","Litzman, Jiri/E-2746-2012",null,"Czech Ministry of Health [NR/9198-3]","Grant sponsor: Czech Ministry of Health; Grant number: NR/9198-3.",null,19,16,16,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1552-4922","1552-4930",null,"CYTOM PART A","Cytom. Part A","NOV",2009,"75A",11,null,null,null,null,902,909,null,"10.1002/cyto.a.20801",null,8,"Biochemical Research Methods; Cell Biology","Biochemistry & Molecular Biology; Cell Biology","515UN","WOS:000271498500003"]
[null,null,null,null,"J","Hyrsl, L; Zavada, J; Zavadova, Z; Kawaciuk, I; Vesely, S; Skapa, P",null,null,null,"Hyrsl, L.; Zavada, J.; Zavadova, Z.; Kawaciuk, I.; Vesely, S.; Skapa, P.",null,null,"Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"Carbonic anhydrase IX; diagnostic antigen; transitional cell carcinoma","HYPOXIA; IDENTIFICATION; CANCER; SERUM","We investigated the expression of cell-associated CAIX protein in histological sections of the transitional cell carcinoma (TCC) of the urinary tract and of the soluble form of CAIX (s-CAIX) shed by the tumor into the serum and urine of TCC patients. A total of 23 patients with histologically confirmed TCC or squamous cell carcinoma (SCC) were enrolled in the pilot study. Sixteen healthy individuals served as controls. Membrane-bound CAIX was present in the tumor cells near the endoluminal surface. Necrosis was observed in only 4 samples. Using Western blots, s-CAIX concentrated from urine was visualized as a double band at 50 and 54 kDa. In most cases, the presence of s-CAIX in the urine correlated with CAIX expression in the tumor. On the other hand, s-CAIX did not exceed the normal level in the serum of TCC patients. Urine from patients with TCC of the urinary bladder and renal pelvis contained s-CAIX, allowing the detection of tumors in approximately 70% of the patients. Moreover, two additional patients with suspected, but unconfirmed bladder tumor, with s-CAIX detected in urine, developed tumors identified as TCC within six months. We suggest that after a simple, rapid and sensitive test, monitoring s-CAIX levels in urine will be developed, it may be useful for early detection of relapse in patients following transurethral tumor resection.","[Hyrsl, L.; Kawaciuk, I.; Vesely, S.] Charles Univ Prague, Dept Urol, Fac Med 2, Prague, Czech Republic; [Zavada, J.; Zavadova, Z.] Acad Sci Czech Republic, Inst Organ Chem & Biochem, Prague, Czech Republic; [Skapa, P.] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Hyrsl, L.; Kawaciuk, I.; Vesely, S.; Skapa, P.] Hosp Motol, Prague, Czech Republic","Hyrsl, L (reprint author), Charles Univ Prague, Dept Urol, Fac Med 2, Prague, Czech Republic.","lhyrsl@volny.cz",null,null,"Bayer Diagnostics, USA","This research was supported by Bayer Diagnostics, USA. The authors thank Hillary Hoffman for language correction.",null,13,14,14,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2009,56,4,null,null,null,null,298,302,null,"10.4149/neo_2009_04_298",null,5,"Oncology","Oncology","522IM","WOS:000271991100004"]
[null,null,null,null,"J","Kolar, P; Neuwirth, J; Sanda, J; Suchanek, V; Svata, Z; Volejnik, J; Pivec, M",null,null,null,"Kolar, P.; Neuwirth, J.; Sanda, J.; Suchanek, V.; Svata, Z.; Volejnik, J.; Pivec, M.",null,null,"Analysis of Diaphragm Movement during Tidal Breathing and during its Activation while Breath Holding Using MRI Synchronized with Spirometry","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Diaphragm fiction; Magnetic resonance Paging; Thorax; Posture","OBSTRUCTIVE PULMONARY-DISEASE; CHEST-WALL; MOTION; FLUOROSCOPY; EMPHYSEMA","Using magnetic resonance imaging (MRI) in conjunction with synchronized spirometry we analyzed and compared diaphragm movement during tidal breathing and voluntary movement of the diaphragm while breath holding. Breathing cycles of 16 healthy subjects were examined using a dynamic sequence (77 slices in sagittal plane during 20 s, 1NSA, 240x256, TR4.48, TE2.24, FA90, TSE1, FOV 328). The amplitude of movement of the apex and dorsal costophrenic angle of the diaphragm were measured for two test conditions: tidal breathing and voluntary breath holding. The maximal inferior and superior positions of the diaphragm were subtracted from the corresponding positions during voluntary movements while breath holding. The average amplitude of inferio-superior movement of the diaphragm apex during tidal breathing was 27.3 +/- 10.2 mm (mean +/- SD), and during voluntary movement while breath holding was 32.5 +/- 16.2 mm. Movement of the costophrenic angle was 39 +/- 17.6 mm during tidal breathing and 45.5 +/- 21.2 mm during voluntary movement while breath holding. The inferior position of the diaphragm was lower in 11 of 16 subjects (68.75 %) and identical in 2 of 16 (12.5 %) subjects during voluntary movement compared to the breath holding. Pearson's correlation coefficient was used to demonstrate that movement of the costophrenic angle and apex of the diaphragm had a linear relationship in both examined situations (r=0.876). A correlation was found between the amplitude of diaphragm movement during tidal breathing and lung volume (r=0.876). The amplitude of movement of the diaphragm with or without breathing showed no correlation to each other (r=0.074). The movement during tidal breathing shows a correlation with the changes in lung volumes. Dynamic MRI demonstrated that individuals are capable of moving their diaphragm voluntarily, but the amplitude of movement differs from person to person. In this study, the movements of the diaphragm apex and the costophrenic angle were synchronous during voluntary movement of the diaphragm while breath holding. Although the sample is small, this study confirms that the function of the diaphragm is not only respiratory but also postural and can be voluntarily controlled.","[Kolar, P.; Pivec, M.] Charles Univ Prague, Fac Med 2, Dept Rehabil, Prague 5, Motol, Czech Republic; [Kolar, P.; Neuwirth, J.; Sanda, J.; Suchanek, V.; Svata, Z.; Pivec, M.] Univ Hosp Motol, Prague, Czech Republic; [Neuwirth, J.; Sanda, J.; Suchanek, V.; Svata, Z.] Charles Univ Prague, Fac Med 2, Dept Imaging Methods, Prague 5, Motol, Czech Republic; [Volejnik, J.] Kurka Med SRO, Prague, Czech Republic","Kolar, P (reprint author), Charles Univ Prague, Fac Med 2, Dept Rehabil, Prague 5, Motol, Czech Republic.","pavel.kolar@fnmotol.cz",null,null,null,null,null,21,12,13,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,3,null,null,null,null,383,392,null,null,null,10,"Physiology","Physiology","472JC","WOS:000268125600009"]
[null,null,null,null,"J","Vasovcak, P; Puchmajerova, A; Roubalik, J; Krepelova, A",null,null,null,"Vasovcak, Peter; Puchmajerova, Alena; Roubalik, Jan; Krepelova, Anna",null,null,"Mutations in STK11 gene in Czech Peutz-Jeghers patients","BMC MEDICAL GENETICS",null,null,"English","Article",null,null,null,null,null,null,"SEX-CORD TUMOR; MUCOCUTANEOUS PIGMENTATION; GASTRIC ADENOCARCINOMA; GERMLINE MUTATION; CANCER; LINKAGE; LOCUS; RISK; LKB1; CARCINOMA","Background: Peutz-Jeghers syndrome (PJS) is an autosomal dominant hereditary disease characterized by mucocutaneous pigmentation and gastrointestinal hamartomatous polyposis. The germline mutations in the serine/threonine kinase 11 (STK11) gene have been shown to be associated with the disease. Individuals with PJS are at increased risk for development of various neoplasms. The aim of the present study was to characterize the genotype and phenotype of Czech patients with PJS. Methods: We examined genomic DNA of 8 individuals from five Czech families by sequencing analysis of STK11 gene, covering its promotor region, the entire coding region and the splice-site boundaries, and by multiplex ligation-dependent probe amplification (MLPA) assay designed for the identification of large exonic deletions or duplications of STK11 gene. Results: We found pathogenic mutations in STK11 gene in two families fulfilling the diagnostic criteria of PJS and in one of three sporadic cases not complying with the criteria. The patient with the frameshift mutation in STK11 gene developed aggressive gastric cancer. No other studied proband has developed a carcinoma so far. Conclusion: Our results showed that a germline mutation of STK11 gene can be found not only in probands fulfilling the PJS diagnostic criteria, but also in some sporadic cases not complying with the criteria. Moreover, we observed a new case of aggressive gastric cancer in a young patient with a frameshift mutation of STK11 gene.","[Vasovcak, Peter; Puchmajerova, Alena; Krepelova, Anna] Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Roubalik, Jan] Bata Hosp, Digest Endoscopy Ctr, Zlin, Czech Republic","Vasovcak, P (reprint author), Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague, Czech Republic.","pevas78@hotmail.com; alena.puchmajerova@lfmotol.cuni.cz; roubalik@bnzlin.cz; anna.krepelova@fnmotol.cz",null,null,null,null,null,44,5,5,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2350",null,null,"BMC MED GENET","BMC Med. Genet.","JUL 19",2009,10,null,null,null,null,null,null,null,69,"10.1186/1471-2350-10-69",null,8,"Genetics & Heredity","Genetics & Heredity","491FK","WOS:000269563000001"]
[null,null,null,null,"J","Nevoral, J; Rada, V; Vlkova, E; Blahova, K; Bronsky, J; Bubakova, D; Killer, J",null,null,null,"Nevoral, J.; Rada, V.; Vlkova, E.; Blahova, K.; Bronsky, J.; Bubakova, D.; Killer, J.",null,null,"Intestinal microbiota in exclusively breast-fed infants with blood-streaked stools","FOLIA MICROBIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"BOVINE BETA-LACTOGLOBULIN; GERM-FREE; IMMUNODEFICIENT MICE; ALLERGIC COLITIS; MUCOSAL IMMUNITY; HUMAN-MILK; MICROFLORA; CHILDREN; IMMUNOCOMPETENT; INFLAMMATION","Intestinal microbiota in exclusively breast-fed infants with blood-streaked stools and in healthy exclusively breast-fed babies was compared. Total anaerobes, bifidobacteria, lactobacilli, coliform bacteria, enterococci and clostridia were quantified by cultivation methods in feces of 17 full-term exclusively breastfed patients (aged 16.3 +/- 7.4 weeks) with blood-streaked stools and in the control group of 22 healthy fullterm exclusively breast-fed infants (13.7 +/- 6.4 weeks). Specific fluorescence in situ hybridization kits for Bifidobacterium spp. were used for the quantitative detection of bifidobacteria in samples. Control samples had significantly (p < 0.05) higher counts of total anaerobes. Bifidobacteria were not detected in patients' samples in 65 % and in controls in 36 % (p < 0.01). Bifidobacteria counts were also significantly higher in the control group (p < 0.01). Furthermore, clostridia strains were detected only in feces from bifidobacteria-negative infants reaching counts > 8 log CFU/g. Lactobacilli were not detected in 65 % patients and in 45 % control samples. However, this difference was not significant as well as the difference in lactobacilli counts. Eosinophilia was observed in 35 % of patients, low IgA concentration in 71 % and also low IgG concentration in 71 %. pANCA positivity was found in 53 % of patients. In conclusion a significant low proportion of bifidobacterial microbiota in patients with blood-streaked stools was shown in comparison with controls.","[Nevoral, J.; Blahova, K.; Bronsky, J.] Charles Univ Prague, Sch Med 2, Dept Pediat, Prague 15006, Czech Republic; [Nevoral, J.; Blahova, K.; Bronsky, J.] Univ Hosp Motol, Prague 15006, Czech Republic; [Rada, V.; Vlkova, E.; Killer, J.] Czech Univ Life Sci Prague, Dept Microbiol Nutr & Dietet, Prague, Czech Republic; [Bubakova, D.] Ctr Hlth, Prague 10, Czech Republic","Nevoral, J (reprint author), Charles Univ Prague, Sch Med 2, Dept Pediat, Prague 15006, Czech Republic.","jiri.nevoral@seznam.cz",null,null,"Ministry of Health of Czech Republic [IGA MZ NR/8310-5]; Agency of Ministry of Education, Youth and Sports of Czech Republic, [MSM 604 607 0901];  [VZ 64203/6903]","The work was supported by grant IGA MZ NR/8310-5 from the Ministry of Health of Czech Republic and grant no. MSM 604 607 0901 of the Grant Agency of Ministry of Education, Youth and Sports of Czech Republic, VZ 64203/6903.",null,26,4,5,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632",null,null,"FOLIA MICROBIOL","Folia Microbiol.","MAR",2009,54,2,null,null,null,null,167,171,null,"10.1007/s12223-009-0026-5",null,5,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","442HS","WOS:000265832900014"]
[null,null,null,null,"J","Fencl, F; Janda, J; Blahova, K; Hribal, Z; Stekrova, J; Puchmajerova, A; Seeman, T",null,null,null,"Fencl, Filip; Janda, Jan; Blahova, Kveta; Hribal, Zdenek; Stekrova, Jitka; Puchmajerova, Alena; Seeman, Tomas",null,null,"Genotype-phenotype correlation in children with autosomal dominant polycystic kidney disease","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Autosomal dominant polycystic kidney disease; PKD1 gene; PKD2 gene; Renal function; Ultrasound; Blood pressure; Hypertension; Children","RENAL-DISEASE; CLINICAL-FEATURES; BLOOD-PRESSURE; IN-UTERO; PKD2; PROGNOSIS; GENE; ADOLESCENTS; PROGRESSION; CHILDHOOD","Adults with autosomal dominant polycystic kidney disease (ADPKD) and PKD1 mutations have a more severe disease than do patients with PKD2 mutations. The aim of this study was to compare phenotypes between children with mutations in the PKD1/PKD2 genes. Fifty PKD1 children and ten PKD2 children were investigated. Their mean age was similar (8.6 +/- 5.4 years and 8.9 +/- 5.6 years). Renal ultrasound was performed, and office blood pressure (BP), ambulatory BP, creatinine clearance and proteinuria were measured. The PKD1 children had, in comparison with those with PKD2, significantly greater total of renal cysts (13.3 +/- 12.5 vs 3.0 +/- 2.1, P = 0.004), larger kidneys [right/left kidney length 0.89 +/- 1.22 standard deviation score (SDS) vs 0.17 +/- 1.03 SDS, P = 0.045, and 1.19 +/- 1.42 SDS vs 0.12 +/- 1.09 SDS, P = 0.014, successively] and higher ambulatory day-time and night-time systolic BP (day-time/night-time BP index 0.93 +/- 0.10 vs 0.86 +/- 0.05, P = 0.021 and 0.94 +/- 0.07 vs 0.89 +/- 0.04, P = 0.037, successively). There were no significant differences in office BP, creatinine clearance or proteinuria. Prenatal renal cysts (14%), hypertension defined by ambulatory BP (27%) and enlarged kidneys (32%) were observed only in the PKD1 children. This is the first study on genotype-phenotype correlation in children with ADPKD. PKD1 children have more and larger renal cysts, larger kidneys and higher ambulatory BP than do PKD2 children. Renal cysts and enlarged kidneys detected prenatally are highly specific for children with PKD1.","[Fencl, Filip; Janda, Jan; Blahova, Kveta; Seeman, Tomas] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Paediat, Prague 15006, Czech Republic; [Hribal, Zdenek] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Imaging Methods, Prague 15006, Czech Republic; [Stekrova, Jitka; Puchmajerova, Alena] Charles Univ Prague, Inst Biol, Prague 15006, Czech Republic; [Stekrova, Jitka] Charles Univ Prague, Dept Med Genet, Fac Med 1, Prague 15006, Czech Republic; [Puchmajerova, Alena] Charles Univ Prague, Dept Med Genet, Fac Med 2, Prague 15006, Czech Republic","Fencl, F (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Paediat, Uvalu 84, Prague 15006, Czech Republic.","filipfencl@seznam.cz","Seeman, Tomas/H-3032-2013",null,"VZ MZ [CR 00064203]; MSMT [CR 0021620819]; IGA [MZ CR NR/9427-3]","This study was supported by grants VZ MZ CR 00064203, MSMT CR 0021620819 and IGA MZ CR NR/9427-3. We thank all paediatric nephrologists for referring children with polycystic kidney diseases to our centre, and we wish to thank Dr. J. Zidovska, Dr. J. Reiterova, Dr. M. Koudova, Dr. I. Grochova and Dr. F. Losan for information about the families. We are grateful to the families for their cooperation.",null,33,3,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","MAY",2009,24,5,null,null,null,null,983,989,null,"10.1007/s00467-008-1090-9",null,7,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","423ZQ","WOS:000264535700007"]
[null,null,null,null,"J","Zuna, J; Burjanivova, T; Mejstrikova, E; Zemanova, Z; Muzikova, K; Meyer, C; Horsley, SW; Kearney, L; Colman, S; Ptoszkova, H; Marschalek, R; Hrusak, O; Stary, J; Greaves, M; Trka, J",null,null,null,"Zuna, Jan; Burjanivova, Tatiana; Mejstrikova, Ester; Zemanova, Zuzana; Muzikova, Katerina; Meyer, Claus; Horsley, Sharon W.; Kearney, Lyndal; Colman, Susan; Ptoszkova, Hana; Marschalek, Rolf; Hrusak, Ondrej; Stary, Jan; Greaves, Mel; Trka, Jan",null,null,"Covert Preleukemia Driven by MLL Gene Fusion","GENES CHROMOSOMES & CANCER",null,null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; CLONAL EXPANSION; INFANT LEUKEMIA; REARRANGEMENT; INV(11)(Q21Q23); IDENTIFICATION; CHILDHOOD","Acute leukemia is considered to be a two- or multiple-step process. Although there is a considerable knowledge regarding the character of the \"first hit,\" the nature of the \"second hit\" remains unanswered in most of the cases including leukemias with MLL gene rearrangement. We demonstrate here a striking sequence of events, which include a covert, protracted preleukemic phase characterized by a dominant MLL/FOXO3A clone with intact myeloid differentiation and the subsequent acquisition of a secondary genetic abnormality, leading to overt lymphoblastic leukemia. Backtracking of the secondary acute lymphoblastic leukemia (sALL) with the MLL rearrangement showed no blasts in the bone marrow (BM) during the protracted preleukemic phase. However, at the same time (more than 1 year before the sALL diagnosis) the MLL/FOXO3A was present in up to 90% of BM cells including myeloid lineage, suggesting that the fusion arose in a multipotent progenitor. To identify potential \"second hit\" precipitating sALL we compared DNA in preleukemic versus fully leukemic samples. The analysis revealed a 10 Mb gain on 19q13.32 in the sALL, absent in the preleukemic specimen. These data provide insight into the dynamics of leukemogenesis in secondary leukemia with MILL rearrangement. (C) 2008 Wiley-Liss, Inc.","[Zuna, Jan; Burjanivova, Tatiana; Mejstrikova, Ester; Muzikova, Katerina; Hrusak, Ondrej; Trka, Jan] Charles Univ Prague, Sch Med 2, Dept Paediat Haematol & Oncol, CLIP, Prague 15006 5, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Sch Med 1, Inst Clin Biochem, Ctr Oncocytogenet, Prague 15006 5, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Sch Med 1, Diagnost Lab, Prague 15006 5, Czech Republic; [Meyer, Claus; Marschalek, Rolf] Goethe Univ Frankfurt, DCLA, Inst Pharmaceut Biol, Frankfurt, Main, Germany; [Horsley, Sharon W.; Kearney, Lyndal; Colman, Susan; Greaves, Mel] Inst Canc Res, Sect Haematooncol, London SW3 6JB, England; [Ptoszkova, Hana] Univ Ostrava, Univ Hosp Ostrava, Dept Paediat, Ostrava, Czech Republic","Zuna, J (reprint author), Charles Univ Prague, Sch Med 2, Dept Paediat Haematol & Oncol, CLIP, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.zuna@lfmotol.cuni.cz","Marschalek, Rolf/D-3404-2011",null,"MSMT CR [21620813]; IGA-MZ [NR/8269-3]","Supported by: MSMT CR, Grant number 21620813; IGA-MZ, Grant number: NR/8269-3; Leukaemia Research (UK).",null,35,3,3,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1045-2257",null,null,"GENE CHROMOSOME CANC","Gene Chromosomes Cancer","JAN",2009,48,1,null,null,null,null,98,107,null,"10.1002/gcc.20622",null,10,"Oncology; Genetics & Heredity","Oncology; Genetics & Heredity","380IU","WOS:000261460200008"]
[null,null,null,null,"J","Maly, M; Hrachovinova, I; Tomasov, P; Salaj, P; Hajek, P; Veselka, J",null,null,null,"Maly, Martin; Hrachovinova, Ingrid; Tomasov, Pavol; Salaj, Peter; Hajek, Petr; Veselka, Josef",null,null,"Patients with acute coronary syndromes have low tissue factor activity and microparticle count, but normal concentration of tissue factor antigen in platelet free plasma - a pilot study","EUROPEAN JOURNAL OF HAEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"tissue factor; microparticles; platelets; acute coronary syndrome","FACTOR PATHWAY INHIBITOR; HUMAN ATHEROSCLEROTIC PLAQUES; SHED MEMBRANE MICROPARTICLES; MYOCARDIAL-INFARCTION; P-SELECTIN; BLOOD; COAGULATION; HEMOSTASIS","Tissue factor (TF) is a main initiator of coagulation cascade. Its determination in conditions of acute coronary syndrome is logistically difficult. Hence, in our study, the activity and the concentration of TF and the count of microparticles in the platelet free plasma (PFP) were determined. Blood was drawn from both coronary sinus and femoral vein circulation in a cohort of 40 patients. TF activity was measured by activation of factor X in the presence of factor VIIa, whereas microparticles were detected using flow cytometry. TF antigen concentrations were determined using the ELISA test. TF activity in the stable angina subgroup was not significantly different from the control group (18.12 +/- 3.35 mOD/min vs. 17.72 +/- 4.05 mOD/min, respectively), but it was significantly lower in the unstable angina (7.62 +/- 4.19 mOD/min) and myocardial infarction (MI) (3.56 +/- 3.85 mOD/min) subgroups (P < 0.05). Results from the coronary sinus and femoral vein circulations were not significantly different. The count of microparticles decreased according to the severity of the acute coronary syndrome: control group, 520 +/- 172; stable angina subgroup, 532 +/- 167; unstable angina subgroup, 392 +/- 142; and MI subgroup, 165 +/- 30 (P < 0.05). There were no significant differences in concentrations of TF antigen in four subgroups. These results suggest that the procoagulant TF-bearing microparticles could be recruited from PFP by interaction with platelets and blood cells in the conditions of acute coronary syndrome.","[Maly, Martin; Tomasov, Pavol; Hajek, Petr; Veselka, Josef] Univ Hosp Motol, Dept Cardiol, Fac Med 1, Prague 15006 5, Czech Republic; [Hrachovinova, Ingrid; Salaj, Peter] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic","Maly, M (reprint author), Univ Hosp Motol, Dept Cardiol, Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic.","martin.maly@fnmotol.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health of Czech Republic [00064203]","Supported by the grant from the Ministry of Health of Czech Republic No. 00064203.",null,18,2,3,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0902-4441","1600-0609",null,"EUR J HAEMATOL","Eur. J. Haematol.","FEB",2009,82,2,null,null,null,null,148,153,null,"10.1111/j.1600-0609.2008.01175.x",null,6,"Hematology","Hematology","393CA","WOS:000262347300009"]
[null,null,null,null,"J","Kotalova, R; Jirsa, M; Vavrova, V; Vrabelova-Pouchla, S; Macek, M",null,null,null,"Kotalova, Radana; Jirsa, Milan; Vavrova, Vera; Vrabelova-Pouchla, Slavka; Macek, Milan, Jr.",null,null,"Wilson disease as a cause of liver injury in cystic fibrosis","Journal of Cystic Fibrosis",null,null,"English","Article",null,null,null,null,null,"Cystic fibrosis; Wilson disease; Liver disease; Cholestasis; Jaundice","DIAGNOSIS; ATP7B; GENE","Cystic fibrosis-related liver disease affects approximately one third of all patients with cystic fibrosis. Initial signs of other liver diseases including the genetically determined disorders of the liver co-inherited with cystic fibrosis may be obscured by or ascribed to cystic fibrosis-related liver disease. We report a patient shown to suffer simultaneously from cystic fibrosis and hepatic Wilson disease. Our case documents that in patients with cystic fibrosis presenting with liver disease, when unusual clinical and/or laboratory abnormalities appear and fail to respond to standard therapy, a second disease, including rare inherited metabolic disorders such as the hepatic form of Wilson disease or alpha(1)-antitrypsin deficiency, should be suspected. (c) 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Kotalova, Radana] Charles Univ Prague, Sch Med 2, Dept Pediat, Prague 15006 5, Czech Republic; [Kotalova, Radana; Macek, Milan, Jr.] Fac Hosp Motol, Prague 15006 5, Czech Republic; [Macek, Milan, Jr.] Charles Univ Prague, Sch Med 2, Dept Biol & Med Genet, Prague 15006 5, Czech Republic; [Jirsa, Milan] Inst Clin & Expt Med, Prague, Czech Republic; [Vavrova, Vera; Vrabelova-Pouchla, Slavka] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Brno, Czech Republic","Kotalova, R (reprint author), Charles Univ Prague, Sch Med 2, Dept Pediat, V Uvalu 84, Prague 15006 5, Czech Republic.","radana.kotalova@scznam.cz",null,null,"Institute of Clinical and Experimental Medicine [MZO:00023001]; Ministry of Health of the Czech Republic [VZ FNM 00064203(6112), IGA 9488-3]","We thank A. S. Knisely, M.D., King's College Hospital, London, UK, for comments. MJ was supported by the Institute of Clinical and Experimental Medicine, MZO:00023001, MM was supported by VZ FNM 00064203(6112) and IGA 9488-3 from the Ministry of Health of the Czech Republic.",null,8,2,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","JAN",2009,8,1,null,null,null,null,63,65,null,"10.1016/j.jcf.2008.09.003",null,3,"Respiratory System","Respiratory System","395WI","WOS:000262553800012"]
[null,null,null,null,"J","Stechova, K; Pomahacova, R; Hrabak, J; Durilova, M; Sykora, J; Chudoba, D; Stavikova, V; Flajsmanova, K; Varvarovska, J",null,null,null,"Stechova, K.; Pomahacova, R.; Hrabak, J.; Durilova, M.; Sykora, J.; Chudoba, D.; Stavikova, V.; Flajsmanova, K.; Varvarovska, J.",null,null,"Reactivity to Helicobacter pylori Antigens in Patients Suffering from Thyroid Gland Autoimmunity","EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES",null,null,"English","Article",null,null,null,null,null,"Helicobacter pylori; autoimmune thyroiditis; cytokine; chemokine","DC-SIGN; DIABETES-MELLITUS; LEWIS-X; INFECTION; DISEASE; CHILDREN; CELLS; LIPOPOLYSACCHARIDE; POPULATION; ANTIBODIES","The role of infection in autoimmunity is widely discussed. In this Study we concentrated on relationship between Helicobacter pylori as a very important gastroduodenal pathogen and autoimmune thyroiditis (AT). Forty seven AT patients and 34 healthy controls were enrolled. They were split into: THP (H. pylori positive patients, n = 17), THN (H. pylori negative patients, n = 30), CP (H. pylori positive controls, n = 17) and CN groups (H.pylori negative controls, n=17). By protein microarray we analysed production of 23 cytokines and chemokines prior and post stimulation with H.pylori lysate and its lipopolysacharide (LPS). Reactivity to lysate as well as to bacterial LPS differed within groups. The lowest basal cytokine and chemokine production was observed in CN group but these subjects reacted significantly to specific stimulation by increasing IFN-gamma (in comparison with THP p=0.01 for LPS and p=0.004 for H. pylori lysate) and TGFbeta production (p=0.015 for LIPS). In contrast, IL-10 and IL-5 were decreased in this group. In CP, THN and THP groups, we observed in general higher chemokine response. THP group increased proinflammatory IL-6 after specific stimulation as well (in comparison with CP p < 0.0001 for LPS stimulation). We observed different \"reactivity pattern\" to H. pylori within groups with low basal cytokine and chemokine production in healthy H.pylori negative controls but with clear specific response in IFN-gamma and TGF-beta production in this group. Adequate immune reaction which is joined to appropriate immunoregulation leads to prevention of the chronic infection and on the other hand may prevent the development of \"connected\" diseases such as autoimmune.","[Stechova, K.] Univ Hosp Motol, Dept Paediat, Lab Autoimmune Dis, Prague 15006 5, Motol, Czech Republic; [Stechova, K.; Durilova, M.; Stavikova, V.; Flajsmanova, K.] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic; [Pomahacova, R.; Sykora, J.; Varvarovska, J.] Charles Univ Prague, Fac Med Plzen, Dept Paediat, Prague, Czech Republic; [Hrabak, J.] Charles Univ Prague, Fac Med Plzen, Dept Microbiol, Prague, Czech Republic; [Chudoba, D.] Charles Univ Prague, Fac Med 2, Dept Biol & Genet, Prague, Czech Republic","Stechova, K (reprint author), Univ Hosp Motol, Dept Paediat, Lab Autoimmune Dis, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","info@labao.cz",null,null,"Grant Agency of Ministry of Health IGA MZCR [NR 8887-3]","This project was supported by the project of internal Grant Agency of Ministry of Health IGA MZCR No NR 8887-3.",null,35,1,1,"JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH","STUTTGART","RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY","0947-7349",null,null,"EXP CLIN ENDOCR DIAB","Exp. Clin. Endocrinol. Diabet.","SEP",2009,117,8,null,null,null,null,423,431,null,"10.1055/s-0029-1214385",null,9,"Endocrinology & Metabolism","Endocrinology & Metabolism","505GM","WOS:000270680100011"]
[null,null,null,null,"J","Haberlova, J; Claeys, KG; De Jonghe, P; Seeman, P",null,null,null,"Haberlova, J.; Claeys, K. G.; De Jonghe, P.; Seeman, P.",null,null,"Cranial nerves palsy as an initial feature of an early onset distal hereditary motor neuropathy - A new distal hereditary motor neuropathy phenotype","NEUROMUSCULAR DISORDERS",null,null,"English","Article",null,null,null,null,null,"Distal hereditary motor neuropathy; Cranial nerve palsy; Slow progression; Autosomal dominant inheritance","MUSCULAR-ATROPHY; PARALYSIS","Distal hereditary motor neuropathy is a heterogeneous group of disorders characterised by a pure motor axonal neuropathy. It is occasionally associated with additional signs such as facial weakness, vocal cord paralysis, weakness of the diaphragm, and pyramidal signs. Although predominantly the inheritance is autosomal dominant, all types of inheritance have been described. Here we report a Czech family with cranial nerves palsy as an initial feature of a non progressive infantile onset dominant distal hereditary motor neuropathy. This family may represent a new subtype of distal hereditary motor neuropathy. (C) 2009 Elsevier B.V. All rights reserved.","[Haberlova, J.; Seeman, P.] Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague 15200 5, Czech Republic; [Claeys, K. G.] Grp Hosp Pitie Salpetriere, Inst Myol, F-75634 Paris, France; [De Jonghe, P.] Univ Antwerp VIB, Dept Mol Genet, Neurogenet Grp, B-2610 Antwerp, Belgium; [De Jonghe, P.] Univ Antwerp Hosp, Dept Neurol, Antwerp, Belgium","Haberlova, J (reprint author), Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague 15200 5, Czech Republic.","jana.haberlova@gmail.com",null,null,null,null,null,6,1,1,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0960-8966",null,null,"NEUROMUSCULAR DISORD","Neuromusc. Disord.","JUN",2009,19,6,null,null,null,null,427,428,null,"10.1016/j.nmd.2009.03.005",null,2,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","474SV","WOS:000268305200009"]
[null,null,null,null,"J","Blaha, M; Schwab, J; Vajnerova, O; Bednar, M; Padr, R; Bittner, P; Tichy, M",null,null,null,"Blaha, M.; Schwab, J.; Vajnerova, O.; Bednar, M.; Padr, R.; Bittner, P.; Tichy, M.",null,null,"Model of Closed Head Injury in Rats - Experimental Study","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"brain injury; intracranial pressure; animal models","INTRACRANIAL-PRESSURE","Objective: The objective of this study is to create a reproducible model of closed head injury in rats using the acceleration-deceleration mechanism, The model should result in increased intracranial pressure (ICP) and neurological deterioration animals, and generate graded brain injury. Material and method: In order to provoke cranial traumas we constructed an impactor with selectable weights and a mobile impact surface, Within the first pilot group of 40 rats, we tested only its basic setup. Afterwards, within the second group of 21 rats, we provoked an experimental cranial trauma using a weight of 400 grams dropped from a height ranging from 30 to 100 centimetres at a constant surface elasticity. Within the third control group of 15 rats, we measured physiological parameters including ICP. Results: According to the height of fall, four types of brain injuries were established - lethal, severe, moderate, and mild. With the lethal injury (45-100 cm), an immediate convulsions with subsequent death occurred in all the rats. A severe injury (40 cm) showed 50% mortality. Neurological deterioration and an average ICP of 9.3 +/- 3.76 mmHg was recorded in the surviving animals. A moderate brain injury (35 cm) resulted in lower mortality, the neurological deficit occurred in half of the survivors and ICP achieved 7.6 +/- 3.54 mmHg. Within the group of mild brain injury (30 cm), all animals survived without any neurological and behavioral deterioration with an ICP of 5.5 +/- 0.74 mmHg. The control group without any injury had an ICP of 2.9 +/- 0.81 mmHg. Conclusion: The described model of closed head injury in rats using a modified impactor with adjustable weights is suitable for both single-stage and two-stage experiments examining craniocerebral injuries. By simply changing the fall height of the impactor, reproducible severe, moderate, or mild brain injury can be created. The intracranial pressure elevation and the neurological deterioration correlate with these grades of brain injury.","[Blaha, M.; Schwab, J.; Tichy, M.] FN Motol, Neurochirurg Oddeleni, Prague 15006 5, Czech Republic; [Blaha, M.; Schwab, J.; Vajnerova, O.; Bittner, P.; Tichy, M.] LF UK, Ustav Fyziol, Prague, Czech Republic; [Bednar, M.] CLINICUM, Anesteziol Resuscitacni Oddeleni, Prague, Czech Republic; [Padr, R.] FN Motol, Klin Zobrazovacich Metod, Prague 15006 5, Czech Republic; [Padr, R.] 2 LF UK, Prague, Czech Republic","Blaha, M (reprint author), FN Motol, Neurochirurg Oddeleni, V Uvalu 84, Prague 15006 5, Czech Republic.","drmartinblaha@yahoo.com",null,null,null,null,null,18,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,3,null,null,null,null,235,241,null,null,null,7,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","459JD","WOS:000267097100005"]
[null,null,null,null,"J","Neuschlova, L; Sterbova, K; Zackova, J; Komarek, V",null,null,null,"Neuschlova, L.; Sterbova, K.; Zackova, J.; Komarek, V.",null,null,"Analysis of Psychological Profile and Video-EEG Monitoring in Sleep in Children with Developmental Dysphasia","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"dysphasia; electroencephalography","LANGUAGE IMPAIRMENT; EPILEPSY; SLI; COMORBIDITY; DISORDERS","Aim: We analyzed data from 37 children diagnosed with developmental dysphasia, who were referred for all-night video-EEG monitoring in order to detect epileptiform activity in sleep. Methods: We compared the results of a psychological evaluation in different groups of children, we focused on performance and verbal IQ and a vocabulary exam. Epileptiform discharges in sleep EEG were present in 12 children. Six of these children were included in an open prospective study of administering oral Diazepam for 6 to 8 months; these children were compared to six control subjects without discharges in the EEG and without medication. The aim was to verify the effect of a reduction in epileptiform activity on language development. Results: Comparison of the initial psychological evaluations showed a tendency towards worse scores in both verbal and nonverbal skills in patients with epileptiform EEG activity. This trend was not evident in the youngest category. In the six children with epileptiform activity who participated in our prospective study with oral Diazepam, we found a marked improvement in verbal skills, demonstrated as an increase in verbal IQ, only in one case. Conclusion: Our results do not support the hypothesis that children with developmental dysphasia and epileptiform EEG may benefit from antiepileptic treatment. However, our sample is not large enough for statistical evaluation. Our study may serve as a valuable source of information for further prospective studies in patients with developmental dysphasia.","[Neuschlova, L.; Sterbova, K.; Zackova, J.; Komarek, V.] UK 2 LF & FN Motol, Klin Detske Neurol, Prague 15000, Czech Republic","Komarek, V (reprint author), UK 2 LF & FN Motol, Klin Detske Neurol, Uvalu 84,5 Motol, Prague 15000, Czech Republic.","vladimir.komarek@lfmotol.cuni.cz",null,null,null,null,null,32,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,4,null,null,null,null,343,349,null,null,null,7,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","486HZ","WOS:000269188200008"]
[null,null,null,null,"J","Zamecnik, J; Pitha, J; Schutzner, J; Vesely, D; Jakubicka, B",null,null,null,"Zamecnik, J.; Pitha, J.; Schutzner, J.; Vesely, D.; Jakubicka, B.",null,null,"Myasthenia Gravis - a Critical Assessment of the Contribution of Muscle Biopsy Performed During Thymectomy","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"myasthenia gravis; muscle biopsy; thymectomy; prognosis","MITOCHONDRIA; MUSK","Objective: Surprisingly, structural changes outside the neuromuscular junctions were reported in limited series of myasthenia gravis (MG) muscles previously - mainly small collection of interstitial lymphocytes and atrophy of type II muscle fibers. However, the pathophysiological mechanisms remained unclear. We performed a systematic study on MG muscle biopsies to contribute to understanding of the association to MG and to demonstrate possible prognostic value. Methods: Sternothyroid muscle biopsies from 207 MG patients taken during thymectomy were analyzed histopathologically and by histochemistry and morphometry and correlated to the clinical features and the outcome of MG patients. Results: In 143 MG patients, no obvious pathological changes were observed in muscle biopsies. In 20 patients we observed an interstitial infiltration by mature naive CD45RA+Iymphocytes. The lymphocytic infiltration associated with the thymus pathology, mainly with thymoma. The morphometry disclosed selective atrophy of type II muscle fibers in 35 cases. The atrophy of type II muscle fibers was related to long-term corticosteroid treatment and the potential prognostic value could be demonstrated for its detection: the MG patients with type II fibers atrophy presented slower tendency to reach remission. Further, in 12 cases we demonstrated mild changes in mitochondrial metabolism, in 34 cases we disclosed angular atrophic fibers; no prognostic value was demonstrated for these changes. Conclusions: The previously reported histopathological changes in MG muscle are rare and mostly do not represent a feature of the MG, rather a consequence of the thymic disorder or of the long-term steroid therapy. The value of muscle biopsy performed during thymectomy for the particular MG patient remains controversial.","[Zamecnik, J.; Jakubicka, B.] UK 2 LF & FN Motole, Ustav Patol & Mol Mediciny, Prague 15006 5, Czech Republic; [Pitha, J.] UK 1 LF & VFN, Neurol Klin, Prague, Czech Republic; [Schutzner, J.] UK 1 LF & FN Motole, Chirurg Klin 3, Prague, Czech Republic; [Vesely, D.] UK 2 LF & FN Bulovka, Infekcni Klin 1, Prague, Czech Republic","Zamecnik, J (reprint author), UK 2 LF & FN Motole, Ustav Patol & Mol Mediciny, Uvalu 84, Prague 15006 5, Czech Republic.","josef.zamecnik@lfmotol.cuni.cz",null,null,null,null,null,23,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,2,null,null,null,null,147,154,null,null,null,8,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","436WJ","WOS:000265446500007"]
[null,null,null,null,"J","Vanek, D; Saskova, L; Koch, H",null,null,null,"Vanek, Daniel; Saskova, Lenka; Koch, Hubert",null,null,"Kinship and Y-Chromosome Analysis of 7th Century Human Remains: Novel DNA Extraction and Typing Procedure for Ancient Material","CROATIAN MEDICAL JOURNAL",null,null,"English","Article",null,null,null,null,null,null,"PCR; INHIBITOR; REMOVAL","Aim To develop novel DNA extraction and typing procedure for DNA identification of the 7th century human remains, determine the familiar relationship between the individuals, estimate the Y-chromosome haplogroup, and compare the Y-chromosome haplotype with the contemporary populations. Methods DNA from preserved femur samples was extracted using the modified silica-based extraction technique. Polymerase chain reaction amplification was performed using human identification kits MiniFiler, Identifiler, and Y-filer and also laboratory-developed and validated Y-chromosome short tandem repeat (STR) pentaplexes with short amplicons. Results For 244A, 244B, 244C samples, full autosomal DNA profiles ( 15 STR markers and Amelogenin) and for 244D, 244E, 244F samples, MiniFiler profiles were produced. Y-chromosome haplotypes consisting of up to 24 STR markers were determined and used to predict the Y-chromosome haplogroups and compare the resulting haplotypes with the current population. Samples 244A, 244B, 244C, and 244D belong to Y-chromosome haplogroup R1b and the samples 244E and 244F to haplogroup G2a. Comparison of ancient haplotypes with the current population yielded numerous close matches with genetic distance bellow 2. Conclusion Application of forensic genetics in archaeology enables retrieving new types of information and helps in data interpretation. The number of successfully typed autosomal and Y-STR loci from ancient specimens in this study is one of the largest published so far for aged samples.","[Vanek, Daniel; Saskova, Lenka] Forens DNA Serv, Prague 17000 7, Czech Republic; [Koch, Hubert] Bavarian State Dept Monuments & Sights, Regensburg, Germany","Vanek, D (reprint author), Forens DNA Serv, Janovskeho 18, Prague 17000 7, Czech Republic.","daniel.vanek@DNA.com.cz",null,null,"Bavarian State Department of Monuments and Sights; Ministry of Industry and Trade, Czech Republic [FI-IM3/115]","We acknowledge the assistance of Biologicals, namely Dr Martin Pospisek, in developing the HaR and DeX buffers used in the extraction protocol and quantitation chemistry. We also acknowledge the Prague Castle Administration, namely Dr Bravermanova, for providing the laboratory space for DNA extraction from the ancient material. This work was supported by the Bavarian State Department of Monuments and Sights and in part by Research Grant No. FI-IM3/115 from the Ministry of Industry and Trade, Czech Republic.","Alt K., 1998, DENT ANTHR FUNDAMENT; Athey T.W., 2005, J GENETIC GENEALOGY, V1, P1; Balaresque P, 2009, INT J LEGAL MED, V123, P15, DOI 10.1007/s00414-008-0253-3; Bouwrnan AS, 2008, J ARCHAEOL SCI, V35, P2580, DOI 10.1016/j.jas.2008.04.010; Butler JM, 2003, J FORENSIC SCI, V48, P1054; Butler JM, 2004, INT J LEGAL MED, V118, P178, DOI 10.1007/s00414-004-0436-5; Cipollaro M, 2005, J CELL PHYSIOL, V202, P315, DOI 10.1002/jcp.20116; Davoren J, 2007, CROAT MED J, V48, P478; Garcia-Bour J, 2004, AM J PHYS ANTHROPOL, V123, P361, DOI 10.1002/ajpa.10337; Gill P, 2001, CROAT MED J, V42, P229; Haak W, 2005, SCIENCE, V310, P1016, DOI 10.1126/science.1118725; HANDT O, 1994, EXPERIENTIA, V50, P524, DOI 10.1007/BF01921720; Hanson EK, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000688; HUCKENBECK W, DISTRIBUTION HUMAN D; Hummel S, 2000, Anthropol Anz, V58, P9; Kemp BM, 2006, J ARCHAEOL SCI, V33, P1680, DOI 10.1016/j.jas.2006.02.015; KOCH H, 2006, NIEDERBAYERISCHEN AR, V6, P191; KUBALEK P, 2008, ARCHAELOGY CENTRAL B, V1, P645; Lassen C, 2000, Anthropol Anz, V58, P1; Melchior L, 2008, AM J PHYS ANTHROPOL, V135, P206, DOI 10.1002/ajpa.20721; Riancho JA, 2003, FORENSIC SCI INT, V135, P232, DOI 10.1016/S0379-0738(03)00217-2; Scholz M, 1998, ANAL BIOCHEM, V259, P283, DOI 10.1006/abio.1998.2676; Schultes T, 1999, HUM GENET, V104, P164, DOI 10.1007/s004390050930; Schultes T, 2000, Anthropol Anz, V58, P37; Schultes T, 1997, Anthropol Anz, V55, P207; Shutler GG, 1999, J FORENSIC SCI, V44, P623; Taberlet P, 1996, NUCLEIC ACIDS RES, V24, P3189, DOI 10.1093/nar/24.16.3189; WIIK K, 2008, GENEALOGY, V4, P35; Yang DY, 2005, J ARCHAEOL SCI, V32, P331, DOI 10.1016/j.jas.2004.09.008",29,16,16,"MEDICINSKA NAKLADA","ZAGREB","VLASKA 69, HR-10000 ZAGREB, CROATIA","0353-9504",null,null,"CROAT MED J","Croat. Med. J.","JUN",2009,50,3,null,null,null,null,286,295,null,"10.3325/cmj.2009.50.286",null,10,"Medicine, General & Internal","General & Internal Medicine","452PM","WOS:000266553700007"]
[null,null,null,null,"J","Hubacek, P; Virgili, A; Ward, KN; Pohlreich, D; Keslova, P; Goldova, B; Markova, M; Zajac, M; Cinek, O; Nacheva, EP; Sedlacek, P; Cetkovsky, P",null,null,null,"Hubacek, Petr; Virgili, Anna; Ward, Katherine N.; Pohlreich, David; Keslova, Petra; Goldova, Barbora; Markova, Marketa; Zajac, Miroslav; Cinek, Ondrej; Nacheva, Elisabeth P.; Sedlacek, Petr; Cetkovsky, Petr",null,null,"HHV-6 DNA throughout the tissues of two stem cell transplant patients with chromosomally integrated HHV-6 and fatal CMV pneumonitis","BRITISH JOURNAL OF HAEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"human herpesvirus 6; cytomegalovirus; tissue; infection","HUMAN HERPESVIRUS-6; QUANTITATIVE-ANALYSIS; HUMAN-HERPESVIRUS-6; BLOOD; INFECTION; DISEASE; ASSAY; LOAD","Two patients with the characteristic high human herpesvirus 6 (HHV-6) DNA loads in peripheral blood caused by chromosomally integrated (CI) virus received a haematopoietic stem cell transplant (HSCT) from a donor without CI HHV-6. Both patients died in consequence of cytomegalovirus (CMV) pneumonitis. At autopsy, high amounts of CMV DNA were detected in lungs but at much lower levels in other organs. In contrast HHV-6 DNA was detected at high levels throughout the organs with the exception of donor-derived haematopoietic tissue. In individuals with chromosomal integration, HHV-6 DNA is found in every tissue of recipient origin indicating inheritance through the germ line.","[Hubacek, Petr; Keslova, Petra; Sedlacek, Petr] Charles Univ Prague, Motol Univ Hosp, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Hubacek, Petr; Keslova, Petra; Sedlacek, Petr] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague, Czech Republic; [Goldova, Barbora] Charles Univ Prague, Fac Med 1, Inst Pathol, CZ-15006 Prague 5, Czech Republic; [Pohlreich, David; Markova, Marketa; Cetkovsky, Petr] Inst Hematol & Blood Transfus, Prague, Czech Republic; [Ward, Katherine N.] Royal Free & Univ Coll Med Sch, Dept Infect, London, England; [Virgili, Anna; Nacheva, Elisabeth P.] Royal Free & Univ Coll Med Sch, Dept Acad Haematol, London, England; [Cinek, Ondrej] Fac Med 2, Dept Paediat, Prague, Czech Republic; [Zajac, Miroslav] Fac Med 2, Dept Med Microbiol, Prague, Czech Republic","Hubacek, P (reprint author), Charles Univ Prague, Motol Univ Hosp, Dept Paediat Haematol & Oncol, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","petr.hubacek@lfmotol.cuni.cz",null,null,"NIH Research through the University College London/University College London Hospitals Comprehensive Biomedical Research Centre; Leukaemia Research [05079, 05098];  [MZ 000064203];  [MSM 0021620813]","This work was supported by grants MZ 000064203 and MSM 0021620813. K. N. Ward acknowledges funding from the NIH Research through the University College London/University College London Hospitals Comprehensive Biomedical Research Centre and E. P. Nacheva acknowledges Leukaemia Research Fund grants 05079 and 05098.",null,14,14,14,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0007-1048",null,null,"BRIT J HAEMATOL","Br. J. Haematol.","MAY",2009,145,3,null,null,null,null,394,398,null,"10.1111/j.1365-2141.2009.07622.x",null,5,"Hematology","Hematology","430SP","WOS:000265009100014"]
[null,null,null,null,"J","Hrdlicka, M; Zedkova, I; Blatny, M; Urbanek, T",null,null,null,"Hrdlicka, Michal; Zedkova, Iveta; Blatny, Marek; Urbanek, Tomas",null,null,"Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"schizophrenia; antipsychotics; weight gain; adolescence","2ND-GENERATION ANTIPSYCHOTICS; ONSET SCHIZOPHRENIA; DRUG-TREATMENT; DOUBLE-BLIND; CHILDREN; RISPERIDONE; OLANZAPINE; TOLERABILITY; OBESITY; MEDICATIONS","OBJECTIVES: The aim of the study was to assess weight changes associated with certain atypical (AAP) and typical (TAP) antipsychotic drugs in patients with early-onset schizophrenia and other related psychotic disorders. METHODS: Our retrospective study included 109 patients (52 boys, 57 girls) with a mean age of 15.8 +/- 1.6 years. The patients were evaluated based to their medical records prior to starting therapy, and then after 1, 3, and 6 weeks of treatment. RESULTS: During the first week of treatment, the AAP group (n = 85; risperidone, olanzapine, ziprasidone, and clozapine) gained 1.5% of baseline weight whereas the TAP group (n = 24; haloperidol perphenazine, and sulpiride) gained only 0.2% (p = 0.049). Differences in relative changes between the two groups were not significant at weeks 3 and 6. Expressed as absolute values, patients in our sample gained an average of 3.4 kg (SD 3.2) on AAP and 2.0 kg (SD 3.9) on TAP during 6 weeks of treatment (p = 0.335). Only the risperidone, olanzapine, and clozapine groups had sufficient numbers of patients to allow a comparison at the endpoint of the study (week 6). The patients gained, on average, 3.6 kg (SD 2.6) on risperidone, 4.4 kg (SD 2.5) on olanzapine, and 2.1 kg (SD 4.0) on clozapine during the six weeks of treatment (p = 0.286). CONCLUSIONS: In our study, we did not find a difference in weight gain between the AAP and TAP groups, as large as has been described in the literature. It also seems plausible that the unique and variable weight changes associated with individual AAPs in the pediatric population are different from those observed in the adult population.","[Hrdlicka, Michal; Zedkova, Iveta] Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Prague 15006, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 1, Prague 12108, Czech Republic; [Blatny, Marek; Urbanek, Tomas] Acad Sci Czech Republic, Inst Psychol, Brno 60200, Czech Republic","Hrdlicka, M (reprint author), Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Uvalu 84, Prague 15006, Czech Republic.","michal.hrdlicka@lfmotol.cuni.cz",null,null,"Ministry of Education, Youth and Sports, Czech Republic [MSM 0021620849]; Academy of Sciences, Czech Republic [AV0Z70250504]","Supported by Ministry of Education, Youth and Sports, Czech Republic (research grant MSM 0021620849) and by Academy of Sciences, Czech Republic (research plan AV0Z70250504).",null,32,10,10,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.","FEB",2009,30,2,null,null,null,null,256,261,null,null,null,6,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","492MZ","WOS:000269663900013"]
[null,null,null,null,"J","Stulik, J; Klezl, Z; Sebesta, P; Kryl, J; Vyskocil, T",null,null,null,"Stulik, J.; Klezl, Z.; Sebesta, P.; Kryl, J.; Vyskocil, T.",null,null,"Occipitocervical Fixation: Long-Term Follow-up in Fifty-Seven Patients","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"occipitocervical fusion; occipitocervical fixation; occipitocervical instability","TRANSARTICULAR SCREW FIXATION; RHEUMATOID-ARTHRITIS; INTERNAL-FIXATION; POLYAXIAL SCREW; FUSION; STABILIZATION; ROD; INSTRUMENTATION; BONE; DISLOCATION","PURPOSE OF THE STUDY Occipitocervical fixation and spondylodesis is indicated in various cases of occipitocervical instability. The aim of this retrospective study was to evaluate the results of occipitocervical fixation at our institutions. MATERIAL Between 1997 and 2007, a total of 57 patients underwent occipitocervical fixation (OC) there were 25 men and 32 women, from four to 77 years of age, with an average of 58.7 years. The patients were allocated to two groups according to the method of OC fixation used: tying wires or cables (group 1) screw-rod or screw-plate systems (group 2). Indications for OC fixation included trauma in 15, rheumatoid arthritis (RA) in 28, destruction due to psoriasis in one, tumour in eight, and congenital anomalies of the cervico-cranial junction in five patients. In five patients with tumour, OC fixation was completed with a transoral or transmandibular procedure. The CO-T 1 or CO-T 2 segments were fixed in 22 patients, C0-C2 segments in 14, C0-C3 segments in six, C0-C4 segments in two, C0-C5 segments in eight and C0-C6 segments in five patients. METHODS In atlanto-occipital dislocation, comminuted fractures of the;atlas or similar injuries, C0-C1-C2 segments were fused in congenital anomaly, the CO-to-lower cervical spine was fixed, with C1 being avoided. The RA patients were treated by fixation of the CO to T1 or T2 segments. The atlas was fixed by the screw method of Goel, the C2 joint by that of Judet, or stable fusion of the two vertebrae was carried out by the Magerl transarticular technique. For the middle and lower cervical spine, lateral mass screw fixation by the Magerl method was used, and from C7 caudally the vertebrae were fixed transpedicularly. Occasionally, in small children in particular, a Ransford frame fixed with wires or cables was used. In principle, an extent of fixation as small as possible was employed. The patients were evaluated at a final follow-up ranging between 12 and 132 months after the primary surgery (average, 42.7 months). Indications for surgery and the method and extent of instrumentation were recorded. The evaluation included pain and neurological deficit assessment, radiographic evidence of the stability of fixation and bone union and intra-operative and early and late post-operative complications. RESULTS Of the 57 patients, bone fusion was the objective of surgery in 52. Further five patients died of associated injuries or serious medical complications shortly after the operation. Of the remaining 47, bone union was achieved in 44 patients (93.6%). Pseudoarthrosis developed in three patients who, however, because of a higher age and minimal complaints did not require revision surgery. In terms of bone union, there was no difference between a short (C0-C2) and a long (C0-CX or C-T) fixation. No differences among fixation materials were found. The differences in percent bone union after spondylodesis between the tying-wire and screw-rod fixation systems were not statistically significant (p>0.05). In the patients treated for RA, psoriasis or congenital anomaly, the Nurick scale score significantly improved at 2 years after surgery (p<0.05). In comparison with the others, the RA patients had a significantly higher number of complications (p<0.05). The patients treated for tumour showed a significant difference between the pre- and post-operative VAS values (p<0.05). DISCUSSION Of the patients with RA, psoriasis or congenital anomaly, 57.6% showed post-operative improvement in the Nurick scale score by 1-2 but never more than by 2. A decrease in pain intensity and neurological findings was recorded in 88.2% of the patients. This is in agreement with the results published in the international literature. In the patients treated for trauma, a high proportion (53.3%) had neurological deficit, which is unusually high for craniocervical injuries. This can be explained by the fact that OC fixation is used only in the most serious injuries. Of five patients with neurological deficit of Frankel grade A or B, three died and two required mechanical ventilation. Less serious neurological findings of Frankel grade C or D in three patients improved to a normal condition. CONCLUSIONS Rigid OC fixation is a very effective method for the treatment of craniocervical junction instability. The currently used implants allow us to achieve high stability and efficiency of bone union. Regardless of the instrumentation used, fusion is achieved in more than 90%, and clinical improvement in more than 80% of the patients.","[Stulik, J.] LF UK, Chirurg Klin 1 3, Spondylochirurg Oddeleni, FN Motol, Prague 15006 5, Czech Republic; [Stulik, J.] LF UK, Ortoped Klin Deti & Dospelych 2, Prague 15006 5, Czech Republic; [Klezl, Z.] Derbyshire Royal Infirm, Dept Trauma & Orthopaed, Derby DE1 2QY, England","Stulik, J (reprint author), LF UK, Chirurg Klin 1 3, Spondylochirurg Oddeleni, FN Motol, Uvalu 84, Prague 15006 5, Czech Republic.",null,null,null,null,null,null,37,7,7,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2009,76,6,null,null,null,null,479,486,null,null,null,8,"Orthopedics","Orthopedics","539FC","WOS:000273238000005"]
[null,null,null,null,"J","Seeman, T; Pohl, M; Misselwitz, J; John, U",null,null,null,"Seeman, Tomas; Pohl, Michael; Misselwitz, Joachim; John, Ulrike",null,null,"Angiotensin Receptor Blocker Reduces Proteinuria Independently of Blood Pressure in Children Already Treated with Angiotensin-Converting Enzyme Inhibitors","KIDNEY & BLOOD PRESSURE RESEARCH",null,null,"English","Article",null,null,null,null,null,"Angiotensin receptor blocker; Proteinuria; Chronic kidney disease; Angiotensin-converting enzyme inhibitors","NONDIABETIC RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; NEPHROPATHIES; COMBINATION; PROGRESSION; ADOLESCENTS; THERAPY","Background/Aims: Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) has higher antiproteinuric effects than single blockade in adults. In children, little is known on dual blockade of the renin-angiotensin system. The study investigates whether adding an ARB to proteinuric children already on ACEI reduces proteinuria. Methods: A total of 10 children (median age 13.3 years) with chronic kidney disease and persistent proteinuria despite maximal dose of ACEI were included. Losartan was given at an initial dose 0.8 mg/kg/day. Proteinuria, blood pressure (BP) and renal function (glomerular filtration rate) were measured. Results: Mean proteinuria decreased from 484 +/- 290 mg/mmol creatinine to 223 +/- 197 after 1-3 months of losartan treatment and remained stable at 234 +/- 153, 224 +/- 177 and 195 +/- 133 after 3-6, 6-12 months and at the last follow-up check (median 1.9 years, p < 0.05 for all visits vs. before treatment). The median percentage decrease in proteinuria was 66, 56, 44 and 66% during the study periods. No significant change in BP, glomerular filtration rate or serum potassium was observed. One child complained of rash, which led to discontinuation of losartan. Conclusion: Adding an ARB to current ACEI treatment can further reduce proteinuria in children with chronic kidney disease without affecting BP. Copyright (C) 2009 S. Karger AG, Basel","[Seeman, Tomas] Charles Univ Prague, Sch Med 2, Dept Pediat, Prague, Czech Republic; [Pohl, Michael; Misselwitz, Joachim; John, Ulrike] Univ Jena, Dept Pediat, Jena, Germany","Seeman, T (reprint author), Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Pediat, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","tomas.seeman@lfmotol.cuni.cz","Seeman, Tomas/H-3032-2013",null,"Ministry of Health and the Ministry of Education of the Czech Republic [VZ MZ 0006420301, MZOFNM2005, VZ MSMT 0021620819]","This study was supported by grants from the Ministry of Health and the Ministry of Education of the Czech Republic (VZ MZ 0006420301, MZOFNM2005 and VZ MSMT 0021620819).",null,21,5,5,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096",null,null,"KIDNEY BLOOD PRESS R","Kidney Blood Pressure Res.",null,2009,32,6,null,null,null,null,440,444,null,"10.1159/000266478",null,5,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","Physiology; Urology & Nephrology; Cardiovascular System & Cardiology","543CZ","WOS:000273548900008"]
[null,null,null,null,"J","Hajek, P; Alan, D; Vejvoda, J; Linhartova, K; Skapa, P; Hajsmannova, Z; Veselka, J",null,null,null,"Hajek, Petr; Alan, David; Vejvoda, Jiri; Linhartova, Katerina; Skapa, Petr; Hajsmannova, Zdenka; Veselka, Josef",null,null,"Treatment of a large left main coronary artery thrombus by aspiration thrombectomy","JOURNAL OF THROMBOSIS AND THROMBOLYSIS",null,null,"English","Article",null,null,null,null,null,"Left main coronary artery; Thrombus; Aspiration thrombectomy","ACUTE MYOCARDIAL-INFARCTION","A left main coronary artery thrombosis is a life-threatening condition demanding immediate therapeutic management. Traditional treatment options include thrombolysis, percutaneous coronary intervention (PCI) with stenting or cardiac bypass surgery. The number of reported cases in which aspiration thrombectomy has been used is limited. Indications for this therapeutic approach are determined by coronary anatomy, clinical stability, and hemodynamic condition of the patient. We present the case of an acute left main coronary artery thrombosis leading to progressive deterioration of left ventricle function that was successfully treated with aspiration thrombectomy.","[Hajek, Petr; Alan, David; Vejvoda, Jiri; Linhartova, Katerina; Veselka, Josef] Charles Univ Prague, Sch Med 1, Ctr Cardiovasc, Dept Cardiol, Prague 15006 5, Czech Republic; [Hajek, Petr; Alan, David; Vejvoda, Jiri; Linhartova, Katerina; Veselka, Josef] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Skapa, Petr] Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Hajsmannova, Zdenka] Charles Univ Prague, Dept Hematol, Inst Clin Biochem & Hematol, Fac Hosp, Plzen, Czech Republic; [Hajsmannova, Zdenka] Charles Univ Prague, Fac Med, Plzen, Czech Republic","Hajek, P (reprint author), Charles Univ Prague, Sch Med 1, Ctr Cardiovasc, Dept Cardiol, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.hajek@fnmotol.cz",null,null,"Ministry of Health of Czech Republic [00064203]","Supported by grant from the Ministry of Health of Czech Republic 00064203.",null,4,2,2,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0929-5305",null,null,"J THROMB THROMBOLYS","J. Thromb. Thrombolysis","APR",2009,27,3,null,null,null,null,352,354,null,"10.1007/s11239-008-0209-y",null,3,"Hematology; Peripheral Vascular Disease","Hematology; Cardiovascular System & Cardiology","428XV","WOS:000264886300015"]
[null,null,null,null,"J","Sliva, J; Dolezal, T; Sykora, D; Vosmanska, M; Krsiak, M",null,null,null,"Sliva, Jiri; Dolezal, Tomas; Sykora, David; Vosmanska, Magda; Krsiak, Miloslav",null,null,"Guaifenesin enhances the analgesic potency of ibuprofen, nimesulide and celecoxib in mice","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"ibuprofen; nimesulide; celecoxib; guaifenesin; pain; combination analgesics","PARACETAMOL; DONKEYS; ETHER; MOUSE","OBJECTIVES: Previously, we found that guaifenesin enhances analgesia induced by paracetamol. The aim of the present study was to determine whether guaifenesin is able to also increase analgesic activity in the non-steroid anti-inflammatory drugs ibuprofen, nimesulide and celecoxib. In addition we investigated the influence of guaifenesin on plasma levels of nimesulide. METHODS: A model of visceral pain consisting of intraperitoneal injection of acetic acid (writhing test) was used. Levels of nimesulide in plasma were measured by HPLC. All drugs were given orally and tested in mice. RESULTS: Guaifenesin alone did not produce any antinociceptive effect. Simultaneous administration of guaifenesin (200 mg/kg) and subanalgesic doses of ibuprofen (10 and 30 mg/kg), nimesulide (10 and 20 mg/kg) or celecoxib (I and 5 mg/kg) resulted in a significant antinociceptive effects. The plasma levels of nimesulide were significantly higher in combination with guaifenesin at 30, 60 and 90 min after oral administration in comparison to nimesulide monotherapy. CONCLUSION: The present results suggest that guaifenesin might enhance the analgesic activity of various non-steroidal anti-inflammatory drugs.","[Sliva, Jiri; Dolezal, Tomas; Krsiak, Miloslav] Charles Univ Prague, Fac Med 3, Dept Pharmacol, Prague 10000 10, Czech Republic; [Sliva, Jiri] Charles Univ Prague, Fac Med 2, Dept Pharmacol, Prague 10000 10, Czech Republic; [Sykora, David; Vosmanska, Magda] Fac Chem Engn, Dept Analyt Chem, Prague, Czech Republic","Sliva, J (reprint author), Charles Univ Prague, Fac Med 3, Dept Pharmacol, Ruska 87, Prague 10000 10, Czech Republic.","slivaj@seznam.cz","Sykora, David/D-2657-2009",null," [VZ: MSM0021620816]","This study was supported by research grants VZ: MSM0021620816. The authors would like to thank to Zentiva, a. s. for the ibuprofen and nimesulide, and Pfizer Ltd. for the celecoxib used in this study.",null,18,0,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2009,30,3,null,null,null,null,352,356,null,null,null,5,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","525FH","WOS:000272199300010"]
[null,null,null,null,"J","Ibrahim, I; Horacek, J; Bartos, A; Hajek, M; Ripova, D; Brunovsky, M; Tintera, J",null,null,null,"Ibrahim, Ibrahim; Horacek, Jiri; Bartos, Ales; Hajek, Milan; Ripova, Daniela; Brunovsky, Martin; Tintera, Jaroslav",null,null,"Combination of voxel based morphometry and diffusion tensor imaging in patients with Alzheimer's disease","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; voxel-based morphometry; diffusion tensor imaging; MRI; white matter; grey matter; fractional anisotropy; age","MILD COGNITIVE IMPAIRMENT; WHITE-MATTER DAMAGE; CORPUS-CALLOSUM; AGE; PROGRESSION; NETWORK; DYSFUNCTION; ANISOTROPY; BRAINS; VOLUME","OBJECTIVE: The aim of the study was to assess structural changes in gray matter (GM) volume and fractional anisotropy (FA) in patients with Alzheimer's disease (AD) compared to control subjects using Voxel-Based Morphometry (VBM). Fractional anisotropy in the corpus callosum of both groups was also calculated using ROI analysis. METHODS: Twenty-one patients and twenty-three control subjects underwent MRI examination using T1-weighted 3D MPRAGE sequence and diffusion spin-echo echo-planar imaging sequence in six directions. Structural MRI analyses for GM volume and FA were performed using an optimized VBM protocol implemented in SPM5. The influence of age and Mini-Mental State Examination (MMSE) was dealt with multiple regression analysis either for the whole group or for AD patients and controls separately. RESULTS: Patients showed significant reduction of GM volume mainly in the temporal lobes. In AD patients, no correlation was observed between GM volume and age or MMSE. FA was reduced in AD patients mainly in frontal and temporal lobes. In both groups no correlation was found between FA and age or MMSE. Patients with AD showed a significant decrease in FA and an increase in mean diffusivity (p < 0.0001) in the corpus callosum. CONCLUSIONS: In patients with AD we observed a significant reduction in FA values and GM volume; however, no correlation with age and MMSE was proven for both FA and GM for AD patients. This finding supports the hypothesis that morphological changes in patients with AD are not a continuous aging related process but represent qualitative changes.","[Ibrahim, Ibrahim; Hajek, Milan; Tintera, Jaroslav] Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, MR Unit, Prague 14021, Czech Republic; [Ibrahim, Ibrahim; Tintera, Jaroslav] Ctr Neuropsychiat Studies, Prague, Czech Republic; [Ibrahim, Ibrahim] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Horacek, Jiri; Bartos, Ales; Ripova, Daniela; Brunovsky, Martin] Prague Psychiat Ctr, Prague, Czech Republic; [Bartos, Ales] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Neurol, Fac Med 3, Prague, Czech Republic","Ibrahim, I (reprint author), Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, MR Unit, Videnska 1958-9, Prague 14021, Czech Republic.","ibib@medicon.cz",null,null,"Ministry of Health, Czech Republic [IGA IA8600, NR-8792-3]; Ministry of Education, Youth and Sports, Czech Republic [MZ0PCP2005, MZ0IKEM2005, 1M0517]","This work was supported by grants IGA IA8600 and NR-8792-3 from the Internal Grant Agency of the Ministry of Health, Czech Republic and projects MZ0PCP2005, MZ0IKEM2005 and 1M0517 from the Ministry of Education, Youth and Sports, Czech Republic.",null,38,12,12,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.","MAR",2009,30,1,null,null,null,null,39,45,null,null,null,7,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","436PR","WOS:000265426800011"]
[null,null,null,null,"J","Komrska, V; Pindurova, E; Blazek, B; Ptoszkova, H; Cerna, Z; Pospigilova, D; Zapletal, O",null,null,null,"Komrska, V.; Pindurova, E.; Blazek, B.; Ptoszkova, H.; Cerna, Z.; Pospigilova, D.; Zapletal, O.",null,null,"Use of recombinant factor VIII Advate in paediatric patients First steps in the Czech Republic","HAMOSTASEOLOGIE",null,null,"English","Article",null,null,null,null,null,null,null,null,"[Komrska, V.; Pindurova, E.] Univ Hosp Motol, Dept Paediat Haematol & Oncol, Prague 15006 5, Czech Republic; [Blazek, B.; Ptoszkova, H.] Univ Ostrava, Univ Hosp Ostrava, Children Dept, CZ-70852 Ostrava, Czech Republic; [Cerna, Z.] Univ Hosp, Children Dept, Plzen, Czech Republic; [Pospigilova, D.] Univ Hosp, Children Dept, Olomouc, Czech Republic; [Zapletal, O.] Univ Hosp, Dept Clin Haematol, Brno, Czech Republic","Komrska, V (reprint author), Univ Hosp Motol, Dept Paediat Haematol & Oncol, Uvalu 84, Prague 15006 5, Czech Republic.","vladimir.komrska@fnmotol.cz",null,null,null,null,null,0,0,0,"SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN","STUTTGART","HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY","0720-9355",null,null,"HAMOSTASEOLOGIE","Hamostaseologie","OCT",2009,29,null,null,1,null,null,"S47","S49",null,null,null,3,"Hematology","Hematology","525KK","WOS:000272214600014"]
[null,null,null,null,"J","Koudova, M; Seemanova, E; Zenker, M",null,null,null,"Koudova, Monika; Seemanova, Eva; Zenker, Martin",null,null,"Novel BRAF mutation in a patient with LEOPARD syndrome and normal intelligence","EUROPEAN JOURNAL OF MEDICAL GENETICS",null,null,"English","Article",null,null,null,null,null,"Noonan syndrome; LEOPARD syndrome; Cardio-facio-cutaneous syndrome; Mitogen-activated protein kinases; BRAF","FACIO-CUTANEOUS SYNDROME; NOONAN-SYNDROME; PHENOTYPIC SPECTRUM; COSTELLO-SYNDROME; GERMLINE KRAS; RAS PATHWAY; DISORDERS; SOS1","Noonan syndrome (NS) and related disorders are caused by mutations in various genes encoding molecules involved in the RAS-MAPK signalling cascade. There are strong genotype-phenotype correlations. BRAF is the major gene for cardio-facio-cutaneous syndrome (CFCS), and usually patients with a BRAF mutation have significant cognitive impairment. We report on a patient with LEOPARD syndrome and normal intelligence who was found to carry a novel sequence change in BRAF The mutation p.L245F was demonstrated to be de novo with no evidence of somatic mosaicism. This observation illustrates that the phenotypic spectrum caused by BRAF mutations is broader than previously assumed and that mental retardation is not necessarily associated. We speculate that the impact of p.L245F on BRAF protein function differs either qualitatively or quantitatively from those mutations associated with CFCS. (C) 2009 Elsevier Masson SAS. All rights reserved.","[Zenker, Martin] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Human Genet, D-91054 Erlangen, Germany; [Koudova, Monika; Seemanova, Eva] Charles Univ Prague, Univ Hosp Prague, Inst Biol & Med Genet, Prague, Czech Republic","Zenker, M (reprint author), Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Human Genet, Schwabachanlage 10, D-91054 Erlangen, Germany.","mzenker@humgenet.uni-erlangen.de",null,null,"German Research Foundation [ZE 524/4-1, IGA-NR 9457-3]","The authors wish to thank the patient and his family for their kind cooperation and Benedikt Quinger for skilful technical assistance. This work was supported by a grant from the German Research Foundation (DFG; ZE 524/4-1) to M.Z. and IGA-NR 9457-3 to E.S.",null,15,9,9,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1769-7212",null,null,"EUR J MED GENET","Eur. J. Med. Genet.","SEP-OCT",2009,52,5,null,null,null,null,337,340,null,"10.1016/j.ejmg.2009.04.006",null,4,"Genetics & Heredity","Genetics & Heredity","498GD","WOS:000270124300012"]
[null,null,null,null,"J","Finkova, A; Vazna, A; Hrachovina, O; Bendova, S; Prochazkova, K; Sedlacek, Z",null,null,null,"Finkova, Alena; Vazna, Alzbeta; Hrachovina, Ondrej; Bendova, Sarka; Prochazkova, Kamila; Sedlacek, Zdenek",null,null,"The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations","CANCER GENETICS AND CYTOGENETICS",null,null,"English","Article",null,null,null,null,null,null,"P53 GENE; BREAST-CANCER; CPG METHYLATION; TELOMERE LENGTH; HCHK2 MUTATIONS; BLOOD-CELLS; INDIVIDUALS; EPIMUTATION; CARCINOGENESIS; EXPRESSION","Germline TP53 mutations are found in only 70% of families with the Li-Fraumeni syndrome (LFS), and with an even lower frequency in families suggestive of LFS but not meeting clinical criteria of the syndrome. Despite intense efforts, to date, no other genes have been associated with the disorder in a significant number of TP53 mutation-negative families. A search for defects in TP53 other than heterozygous missense mutations showed that neither intron variants nor sequence variants in the TP53 promoter are frequent in LFS, and multiexon deletions have been found to be responsible for US only in several cases. Another cancer predisposition syndrome, hereditary non-polyposis colon cancer, has been associated with epigenetic silencing of one allele of the MLH1 or MSH2 genes. This prompted us to test the methylation of the TP53 gene promoter in a set of 14 families suggestive of LFS using bisulphite sequencing of three DNA fragments from the 5' region of the gene. We found no detectable methylation at any of the CG dinucleotides tested. Thus, epigenetic silencing of the TP53 promoter is not a frequent cause of the disorder in families suggestive of LFS but with no germline mutations in the coding part of the gene. (C) 2009 Elsevier Inc. All rights reserved.","[Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague 15006 5, Czech Republic","Sedlacek, Z (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, Vuvalu 84, Prague 15006 5, Czech Republic.","zdenek.sedlacek@lfmotol.cuni.cz",null,null," [MSM0021620813];  [MZO00064203]","This work was supported by grants MSM0021620813 and MZO00064203.",null,37,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,null,"CANCER GENET CYTOGEN","Cancer Genet. Cytogenet.","AUG",2009,193,1,null,null,null,null,63,66,null,"10.1016/j.cancergencyto.2009.04.014",null,4,"Oncology; Genetics & Heredity","Oncology; Genetics & Heredity","482XC","WOS:000268922900008"]
[null,null,null,null,"J","Cada, Z; Chovanec, M; Smetana, K; Betka, J; Lacina, L; Plzak, J; Kodet, R; Stork, J; Lensch, M; Kaltner, H; Andre, S; Gabius, HJ",null,null,null,"Cada, Z.; Chovanec, M.; Smetana, K., Jr.; Betka, J.; Lacina, L.; Plzak, J.; Kodet, R.; Stork, J.; Lensch, M.; Kaltner, H.; Andre, S.; Gabius, H-J.",null,null,"Galectin-7: will the lectin's activity establish clinical correlations in head and neck squamous cell and basal cell carcinomas?","HISTOLOGY AND HISTOPATHOLOGY",null,null,"English","Article",null,null,null,null,null,"Carcinoma; Collagen IV; Galectin; Keratinization; Lectin","MAMMALIAN LECTINS; P53-INDUCED GENE-1; ENDOGENOUS LECTINS; NUCLEAR PRESENCE; ANIMAL LECTINS; TUMOR-CELLS; EXPRESSION; CANCER; DIFFERENTIATION; PROGRESSION","The human lectin galectin-7 (Gal-7; p53-induced gene-1) has anti- and pro-malignant features in different in vitro models. We tried to clarify relation of its expression to cellular and clinical parameters in head and neck squamous and basal cell carcinomas. Using a non-cross-reactive antibody, immunohistochemical staining in squamous cell epithelia (epidermis, epithelium of oropharynx and larynx) (n = 57), squamous cell carcinomas (n = 47) and lymph node metastases (n = 25), as well as basal cell carcinomas (n = 10) were studied. This monitoring was flanked by processing to assess the level of differentiation (cytokeratins 10 and 14), proliferation (Ki67) and basal lamina formation (collagen IV). The results were correlated with clinical and pathological findings (grading, TNM-staging, extracapsular spread, angio- and lymphangioinvasion, perineural invasion, recurrence and survival). Gal-7 resides in all layers of epithelia with cytoplasmic and nuclear localization in normal specimens. Basal cell carcinomas were devoid of the Gal-7 respective signal. Squamous cell carcinomas were positive, presenting different staining profiles. Intense staining was predominantly found in squamous cell cancers with high degrees of differentiation and keratinization. Fittingly, poor level of differentiation (P = 0.0009), absence of keratinization (P = 0.0105) and significant discontinuity or absence of collagen IV expression in the peritumoral basal lamina (P = 0.0024) was found in Gal-7-negative tumors. Gal-7 presence was not related to gender, primary tumor site, T-stage, Nstage, clinical stage, extracapsular spread, angio- and lymphangioinvasion, perineural spread or treatment outcome at a statistically significant level. Immunohistochemical analysis revealed a positive correlation for differentiation and keratinization to Gal-7 presence in squamous cell carcinomas. Absence of Gal-7 expression was detected in basal cell carcinomas. These clinical data delineate Gal-7 influence on differentiation in vivo, without evidence for a role in dissemination reported for lymphoma.","[Chovanec, M.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Inst Anat, Prague 15006 5, Czech Republic; [Cada, Z.; Chovanec, M.; Betka, J.; Plzak, J.] Fac Hosp Motol, Dept Otorhinolaryngol Head & Neck Surg, Prague, Czech Republic; [Chovanec, M.; Smetana, K., Jr.; Plzak, J.] Fac Hosp Motol, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Lacina, L.; Stork, J.] Gen Teaching Hosp, Dept Dermatovenerol, Prague, Czech Republic; [Kodet, R.] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; [Kodet, R.] Fac Hosp Motol, Inst Pathol & Mol Med, Prague, Czech Republic; [Lensch, M.; Kaltner, H.; Andre, S.; Gabius, H-J.] Univ Munich, Inst Physiol Chem, Fac Vet Med, D-8000 Munich, Germany","Chovanec, M (reprint author), Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Inst Anat, Uvalu 84, Prague 15006 5, Czech Republic.","martin.chovanec@lf1.cuni.cz",null,null,"IGA MZ CR [NR 9049-3]; Ministry of Education, Youth and Sport of the Czech Republic [MSM 002160806]; GA CR [304/08/P175]; LMUexcellent and by an EC Marie Curie Research Training Network [MRTN-CT-2005-019561]","The study was supported by the IGA MZ CR, project No. NR 9049-3, by the Ministry of Education, Youth and Sport of the Czech Republic, project No. MSM 002160806, by the GA CR, project No 304/08/P175, by the research initiative LMUexcellent and by an EC Marie Curie Research Training Network grant (contract No. MRTN-CT-2005-019561). Authors are grateful to Dr. B. Friday and Prof. Dr. S. Namirha for valuable discussion, to Prof. Dr. D. Sedmera for critical reading as well as to Eva Vancovu and Vit Hajduch for excellent technical assistance.",null,40,12,13,"F HERNANDEZ","MURCIA","PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN","0213-3911",null,null,"HISTOL HISTOPATHOL","Histol. Histopath.","JAN",2009,24,1,null,null,null,null,41,48,null,null,null,8,"Cell Biology; Pathology","Cell Biology; Pathology","383TP","WOS:000261696700005"]
[null,null,null,null,"J","Camajova, J; Berwouts, S; Matthijs, G; Macek, M; Dequeker, E",null,null,null,"Camajova, Jana; Berwouts, Sarah; Matthijs, Gert; Macek, Milan, Jr.; Dequeker, Elisabeth",null,null,"Variability in the use of CE-marked assays for in vitro diagnostics of CFTR gene mutations in European genetic testing laboratories","EUROPEAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"cystic fibrosis; CE-marked IVD assays; validation; verification; mutation detection; variability","QUALITY-CONTROL","DNA diagnostics of genetic diseases increasingly shifts towards utilization of commercial assays. Cystic fibrosis (CF)-related DNA diagnostics were used as a model for a pilot survey of the variability in the utilization of qualitative CE-marked in vitro diagnostic (IVD) assays and the scale of their modification by end users. A structured questionnaire, developed in the context of the EuroGentest project, was distributed within the frame of the 2005 annual CF external quality assessment (EQA) scheme. Its aim was to evaluate the variability in the use of different CE-marked IVD assays in routine CF DNA diagnostics. Survey results were analysed and sequentially discussed with respective users and/or manufacturers. In total, 125 responses from EQA scheme participants were received. Almost half of the respondents modified manufacturer-recommended protocols. They also reported sporadic and/or recurrent problems with assay performance and genotyping of particular alleles. Nonetheless, only half of the respondents performed in-house verification before the implementation of the assay in clinical diagnostics and/or after modification of the recommended protocol. Results of this survey substantiate the importance of guidelines for proper verification of CE-marked IVD assays in DNA diagnostics, using CF as a model.","[Berwouts, Sarah; Matthijs, Gert; Dequeker, Elisabeth] Katholieke Univ Leuven, Ctr Human Genet, B-3000 Leuven, Belgium; [Camajova, Jana; Macek, Milan, Jr.] Charles Univ Prague, Dept Biol & Med Genet, Sch Med 2, Prague, Czech Republic; [Camajova, Jana; Macek, Milan, Jr.] Univ Hosp Motol, Prague, Czech Republic","Dequeker, E (reprint author), Katholieke Univ Leuven, Ctr Human Genet, Campus Gasthuisberg Herestr 49, B-3000 Leuven, Belgium.","els.dequeker@med.kuleuven.be",null,null,"EuroGentest [FP6-512148]; VZFNM [00064203/6112/]; EU","This work was supported by EuroGentest (FP6-512148), VZFNM 00064203/6112/ and EU CF Network. We are grateful to all laboratories that took part in the survey, including Drs A Corveleyn and F Le Calvez, who contributed to the development of the questionnaire. We appreciate the encouraging role of Professor J-J Cassiman. Input from Abbott Molecular, Innogenetics and Tepnel Diagnostics was helpful.",null,8,8,8,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,null,"EUR J HUM GENET","Eur. J. Hum. Genet.","APR",2009,17,4,null,null,null,null,537,540,null,"10.1038/ejhg.2008.209",null,4,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","421JJ","WOS:000264354900018"]
[null,null,null,null,"J","Szczurowska, E; Mares, P",null,null,null,"Szczurowska, Ewa; Mares, Pavel",null,null,"Controversial action of positive modulator of subtype 7 of metabotropic glutamate receptors AMN082 on cortical epileptic afterdischarges in immature rats","EUROPEAN JOURNAL OF PHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,"Cortical seizure; Ontogeny; Metabotropic glutamate receptor; Electrocorticogram; Convulsion; (Rat)","METHYL-D-ASPARTATE; AGONIST; ACTIVATION; SEIZURES; NUCLEUS; BRAIN; ACID; GABA","Some age-dependent epilepsies of infancy and childhood Cannot be Sufficiently treated with contemporaneous antiepileptics, therefore search for new mechanisms and new drugs active in pediatric patients is necessary. Possible anticonvulsant action of AMN082 (N,N'-dibenzhydryl-ethane-1,2-dihydrochloride). a positive allosteric modulator of metabotropic glutamate receptor subtype 7, was examined in a model of epileptic afterdischarges elicited in three age groups of immature rats ( 12, 18 and 25 days old) by electrical stimulation of sensorimotor cortex. AMN082 did not exhibit ail anticonvulsant action against spike-and-wave type of afterdischarges generated in thalamocortical system; on the contrary, moderate proconvulsant action Was found in 12- and 18-day-old rats (more marked prolongation of afterdischarges with repeated stimulations). On the other hand, AMN082 significantly shortened the second type of afterdischarges reflecting spread of epileptic activity into limbic system frequently recorded in 25-day-old rats. These contradictory results mean that AMN082 will not be a broad-spectrum anticonvulsant but it might be useful as a seizure-specific antiepileptic drug. (C) 2009 Elsevier B.V. All rights reserved","[Mares, Pavel] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, CZ-14220 Prague 4, Czech Republic; Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Mares, P (reprint author), Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.","maresp@biomed.cas.cz","Mares, Pavel/F-8903-2014",null,"Grant Agency of the Czech Republic [305/06/1188]; Academy of Sciences of the Czech Republic [AVOZ 50110905]","This Study Was Supported by a grant No. 305/06/1188 of the Grant Agency of the Czech Republic and by research project AVOZ 50110905 of the Academy of Sciences of the Czech Republic.",null,25,2,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0014-2999",null,null,"EUR J PHARMACOL","Eur. J. Pharmacol.","NOV 25",2009,623,41699,null,null,null,null,37,40,null,"10.1016/j.ejphar.2009.09.009",null,4,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","520NZ","WOS:000271853500006"]
[null,null,null,null,"J","Klima, J; Lacina, L; Dvorankova, B; Herrmann, D; Carnwath, JW; Niemann, H; Kaltner, H; Andre, S; Motlik, J; Gabius, HJ; Smetana, K",null,null,null,"Klima, J.; Lacina, L.; Dvorankova, B.; Herrmann, D.; Carnwath, J. W.; Niemann, H.; Kaltner, H.; Andre, S.; Motlik, J.; Gabius, H. -J.; Smetana, K., Jr.",null,null,"Differential Regulation of Galectin Expression/Reactivity during Wound Healing in Porcine Skin and in Cultures of Epidermal Cells with Functional Impact on Migration","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Epidermis; Keratinocytes; Lectin; Skin; Wound healing","HUMAN NEUROBLASTOMA-CELLS; ENDOGENOUS LECTINS; GANGLIOSIDE GM(1); EXPRESSION PROFILES; HUMAN KERATINOCYTES; MAMMALIAN LECTINS; TUMOR PROGRESSION; NUCLEAR PRESENCE; STEM-CELLS; N-GLYCAN","The glycophenotyping of mammalian cells with plant lectins maps aspects of the glycomic profile and disease-associated alterations. A salient step toward delineating their functional dimension is the detection of endogenous lectins. They can translate sugar-encoded changes into cellular responses. Among them, the members of the lectin family of galectins are emerging regulators of cell adhesion, migration and proliferation. Focusing on galectins-1, -3 and -7, we addressed the issue whether their expression is regulated during wound healing in porcine skin as model. A conspicuous upregulation is detected for galectin-1 in the dermis and a neoexpression in the epidermis, where an increased level of galectin-7 was also found. Applying biotinylated tissue lectins as probes, the signal intensities for accessible binding sites decreased, intimating an interaction of the cell lectin with reactive sites. In contrast, galectin-3 parameters remained rather constant. Of note, epidermal cells in culture also showed an increase in expression/presence of galectin-1, measured on the levels of mRNA and protein, in this case by Western blotting and quantitative immunocytochemistry. Used as matrix, galectin-1 conferred resistance to trypsin treatment to attached human keratinocytes and reduced migration into scratch-wound areas in vitro. This report thus presents new information on endogenous lectins in wound healing and differential regulation among the three tested cases.","[Klima, J.; Motlik, J.] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Libechov, Czech Republic; [Klima, J.; Lacina, L.; Dvorankova, B.; Motlik, J.; Smetana, K., Jr.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 12800 2, Czech Republic; [Lacina, L.; Dvorankova, B.; Smetana, K., Jr.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Lacina, L.] Charles Univ Prague, Fac Med 1, Dept Dermatovenerol, Prague 12800 2, Czech Republic; [Herrmann, D.; Carnwath, J. W.; Niemann, H.] Inst Farm Anim Genet FAL, Dept Biotechnol, Neustadt, Germany; [Kaltner, H.; Andre, S.; Gabius, H. -J.] Univ Munich, Inst Physiol Chem, Fac Vet Med, D-8000 Munich, Germany","Smetana, K (reprint author), Charles Univ Prague, Fac Med 1, Inst Anat, Nemocnice 3, Prague 12800 2, Czech Republic.","karel.smetana@lf1.cuni.cz",null,null,"Ministry of Education, Youth, and Sport of the Czech Republic [MSM0021620806, 1M0538]; EC [MRTN-CT-2005-019561]; LMUexcellent; German-Czech Collaboration in the Field of Agricultural Research [3/04]","This study was supported by the grants MSM0021620806 and 1M0538 from the Ministry of Education, Youth, and Sport of the Czech Republic, an EC grant (MRTN-CT-2005-019561) for a Marie Curie Research Training Network, the research initiative LMUexcellent and the German-Czech Collaboration in the Field of Agricultural Research (project no. 3/04). The authors are grateful to Eva Vancova, Iva Burdova and Vit Hajduch for their excellent technical assistance.",null,51,14,14,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,6,null,null,null,null,873,884,null,null,null,12,"Physiology","Physiology","539YP","WOS:000273296600012"]
[null,null,null,null,"J","Mahenthiralingam, E; Marchbank, A; Drevinek, P; Garaiova, I; Plummer, S",null,null,null,"Mahenthiralingam, Eshwar; Marchbank, Angela; Drevinek, Pavel; Garaiova, Iveta; Plummer, Sue",null,null,"Use of colony-based bacterial strain typing for tracking the fate of Lactobacillus strains during human consumption","BMC MICROBIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"CYSTIC-FIBROSIS; PROBIOTICS; DIFFERENTIATION; IDENTITY; LACTIS; PCR","Background: The Lactic Acid Bacteria (LAB) are important components of the healthy gut flora and have been used extensively as probiotics. Understanding the cultivable diversity of LAB before and after probiotic administration, and being able to track the fate of administered probiotic isolates during feeding are important parameters to consider in the design of clinical trials to assess probiotic efficacy. Several methods may be used to identify bacteria at the strain level, however, PCR-based methods such as Random Amplified Polymorphic DNA (RAPD) are particularly suited to rapid analysis. We examined the cultivable diversity of LAB in the human gut before and after feeding with two Lactobacillus strains, and also tracked the fate of these two administered strains using a RAPD technique. Results: A RAPD typing scheme was developed to genetically type LAB isolates from a wide range of species, and optimised for direct application to bacterial colony growth. A high-throughput strategy for fingerprinting the cultivable diversity of human faeces was developed and used to determine: (i) the initial cultivable LAB strain diversity in the human gut, and (ii) the fate of two Lactobacillus strains (Lactobacillus salivarius NCIMB 30211 and Lactobacillus acidophilus NCIMB 30156) contained within a capsule that was administered in a small-scale human feeding study. The L. salivarius strain was not cultivated from the faeces of any of the 12 volunteers prior to capsule administration, but appeared post-feeding in four. Strains matching the L. acidophilus NCIMB 30156 feeding strain were found in the faeces of three volunteers prior to consumption; after taking the Lactobacillus capsule, 10 of the 12 volunteers were culture positive for this strain. The appearance of both Lactobacillus strains during capsule consumption was statistically significant (p < 0.05). Conclusion: We have shown that genetic strain typing of the cultivable human gut microbiota can be evaluated using a high throughput RAPD technique based on single bacterial colonies. Validation of this strategy paves the way for future systematic studies on the fate and efficacy of bacterial probiotics during human clinical trials.","[Mahenthiralingam, Eshwar; Marchbank, Angela; Drevinek, Pavel] Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3TL, S Glam, Wales; [Drevinek, Pavel] 2nd Med Sch, Dept Paediat, Prague 15006, Czech Republic; [Garaiova, Iveta; Plummer, Sue] Obsidian Res Ltd, Port Talbot SA12 7BZ, Wales","Mahenthiralingam, E (reprint author), Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3TL, S Glam, Wales.","MahenthiralingamE@cardiff.ac.uk; MarchbankAM@cardiff.ac.uk; Pavel.drevinek@lfmotol.cuni.cz; ivetag@obsidianresearch.co.uk; suep@obsidianresearch.co.uk","Mahenthiralingam, Eshwar/D-3333-2009","Mahenthiralingam, Eshwar/0000-0001-9014-3790","Wellcome Trust [075586]","This work was supported by a grant from the HELP Wales Programme and Cultech Ltd. P. D. acknowledges salary funding from the Wellcome Trust (grant 075586). We thank: Catrin Thomas and Mark Weaver for technical assistance; Martin Day, Peter Vandamme, Julian Marchesi and Nigel Plummer for helpful discussions concerning the manuscript; and Peter Randerson for advice on the statistical analysis.","Baldwin A, 2005, J CLIN MICROBIOL, V43, P4665, DOI 10.1128/JCM.43.9.4665-4673.2005; Bartosch S, 2005, CLIN INFECT DIS, V40, P28, DOI 10.1086/426027; Cai H, 2007, MICROBIOL-SGM, V153, P2655, DOI 10.1099/mic.0.2007/006452-0; de las Rivas B, 2006, MICROBIOL-SGM, V152, P85, DOI 10.1099/mic.0.28482-0; DE MAN J. C., 1960, JOUR APPL BACT, V23, P130, DOI 10.1111/j.1365-2672.1960.tb00188.x; Frank DN, 2008, CURR OPIN GASTROEN, V24, P4; Hall TA., 1999, NUCL ACIDS S SER, V41, P95; Huys G, 2006, RES MICROBIOL, V157, P803, DOI 10.1016/j.resmic.2006.06.006; Mahenthiralingam E, 1996, J CLIN MICROBIOL, V34, P2914; Mahenthiralingam E, 1996, J CLIN MICROBIOL, V34, P1129; Maruo T, 2006, INT J FOOD MICROBIOL, V110, P69, DOI 10.1016/j.ijfoodmicro.2006.01.037; Parvez S, 2006, J APPL MICROBIOL, V100, P1171, DOI 10.1111/j.1365-2672.2006.02963.x; Pena JA, 2004, APPL ENVIRON MICROB, V70, P558, DOI 10.1128/AEM.70.1.558-568.2004; Reid G, 2008, INT DAIRY J, V18, P969, DOI 10.1016/j.idairyj.2007.11.025; Reid G, 2003, CLIN MICROBIOL REV, V16, P658, DOI 10.1128/CMR.16.4.658-672.2003; Schillinger U, 2003, CURR MICROBIOL, V47, P453, DOI 10.1007/s00284-003-4067-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vancanneyt M, 2006, APPL ENVIRON MICROB, V72, P5376, DOI 10.1128/AEM.00091-06; Yeung PSM, 2004, J APPL MICROBIOL, V97, P1095, DOI 10.1111/j.1365-2672.2004.02400.x; Yeung PSM, 2002, J DAIRY SCI, V85, P1039, DOI 10.3168/jds.S0022-0302(02)74164-7; REPORT JOINT FOOD AG",21,6,6,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2180",null,null,"BMC MICROBIOL","BMC Microbiol.","DEC 7",2009,9,null,null,null,null,null,null,null,251,"10.1186/1471-2180-9-251",null,15,"Microbiology","Microbiology","535YM","WOS:000273007900001"]
[null,null,null,null,"J","Tsenov, G; Redkozubova, O; Kubova, H; Mares, P",null,null,null,"Tsenov, Grygoryi; Redkozubova, Olga; Kubova, Hana; Mares, Pavel",null,null,"Effects of lamotrigine on cortically-elicited phenomena in adult rats: Differences between acute application and late consequences of early postnatal administration","BRAIN RESEARCH",null,null,"English","Article",null,null,null,null,null,"Lamotrigine; Early-life administration-cerebral cortex; Evoked potential; Epileptic afterdischarge-rat","ANTIEPILEPTIC DRUG LAMOTRIGINE; EPILEPTIC AFTERDISCHARGES; SEIZURE DEVELOPMENT; KINDLED SEIZURES; STIMULATION; GABAPENTIN; TIAGABINE; AMYGDALA; BRAIN; MODEL","Lamotrigine (LTG) is increasingly used in pediatric epileptology but there are no experimental data on delayed consequences of early life administration of LTG on epileptic phenomena. Therefore we used cortically induced epileptic phenomena to study these possible effects and compared the results with data on acute administration of LTG in adult rats. Naive adult rats as well as animals with a history of LTG administration in early postnatal period (daily from postnatal day 7 to 11 in a dose of 10 and/or 20 mg/kg i.p.) were implanted with cortical stimulation and recording electrodes. Cortical interhemispheric responses and epileptic afterdischarges (ADs) were elicited by stimulation of sensorimotor area in both groups. Acute administration of LTG (10 and/or 20 mg/kg i.p.) did not affect cortical interhemispheric evoked responses but increased thresholds for elicitation of movements elicited by stimulation, spike-and-wave ADs and accompanying clonic seizures. On the contrary, duration of ADs was increased. Animals injected with LTG postnatally exhibited increased thresholds for transition of ADs into a limbic type (mixed ADs), decreased incidence of the limbic type and suppression of recurrent ADs. Evoked responses exhibited a steeper input-output curve in a group receiving the 20 mg/kg dose of LTG during early development. Our results demonstrated a specific anticonvulsant effect as a delayed consequence of early-life administration of LTG; it differed from effects of acute administration of LTG to adult rats. (C) 2008 Elsevier B.V. All rights reserved.","[Tsenov, Grygoryi; Redkozubova, Olga; Kubova, Hana; Mares, Pavel] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, CZ-14220 Prague 4, Czech Republic; [Mares, Pavel] Charles Univ Prague, Fac Med 2, CZ-14220 Prague, Czech Republic; [Redkozubova, Olga] Moscow MV Lomonosov State Univ, Fac Biol, Moscow, Russia","Mares, P (reprint author), Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.","maresp@biomed.cas.cz","Kubova, Hana/C-4210-2012; Tsenov, Grygoriy/C-3897-2012; Mares, Pavel/F-8903-2014",null,"GlaxoSmithKline [Q1S501210509]; Academy of the Czech Republic [LC554, AV0Z5011009]","This study was supported by a grant from GlaxoSmithKline, a grant No.Q1S501210509 of the Grant Agency of the Academy of the Czech Republic and by research projects LC554 and AV0Z5011009.",null,35,5,5,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0006-8993",null,null,"BRAIN RES","Brain Res.","MAR 3",2009,1258,null,null,null,null,null,65,70,null,"10.1016/j.brainres.2008.12.054",null,6,"Neurosciences","Neurosciences & Neurology","423ZU","WOS:000264536100008"]
[null,null,null,null,"J","Zwick, EB; Svehlik, M; Steinwender, G; Linhart, WE",null,null,null,"Zwick, E. B.; Svehlik, M.; Steinwender, G.; Linhart, W. E.",null,null,"Short-term Effects of Botulinum Toxin A and Serial Casting on Triceps Surae Muscle Length and Equinus Gait in Children with Cerebral Palsy","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"English","Article",null,null,null,null,null,"cerebral palsy; botulinum toxin A; pes equinus; gait analysis","LOWER-LIMB SPASTICITY; DOUBLE-BLIND; GASTROCNEMIUS; MANAGEMENT; MULTICENTER; INJECTIONS; DISORDERS; EFFICACY; THERAPY; TRIAL","Aims: The aim of the study was to perform a comprehensive analysis of the short-term effects of a standardized high dose of BTX-A and serial casting on spastic equinus in children with cerebral palsy. A second goal was to evaluate this short-term effect on muscle lengths of the triceps surae. Materials and methodology: Prospective study on 10 children (17 limbs) with spastic cerebral palsy and equinus gait pattern. Three-dimensional kinematic and kinetic gait analysis with musculo-skeletal modelling was used to evaluate pre- and 10 weeks post-treatment results. The paired Student's T-test was used for data analysis. Results: Walking velocity and stride length did not change after BTX-A application. The maximal ankle angle at the end of single support increased (p = 0.045) which led to a change of the ankle angle slope quotient towards normal positive values (p = 0.001). Abnormal ankle power generation in the first part of single stance changed towards normal (p = 0.012). Notably, the ankle plantar-flexor power was not reduced 10 weeks after BTX-A injection (p = 0.486). No lengthening of the triceps surae muscles compared to the baseline assessment was found. Conclusions: Beneficial functional changes in ankle kinematics and kinetics after the application of BTX-A when combined with serial casting were demonstrated. The results of our study underline the possible differences in effect of BTX-A on intrafusal and extrafusal muscle fibres.","[Zwick, E. B.; Svehlik, M.; Steinwender, G.; Linhart, W. E.] Med Univ Graz, Dept Paediat Orthopaed, Dept Paediat Surg, A-8036 Graz, Austria; [Svehlik, M.] Charles Univ Prague, Dept Child & Adult Orthopaed & Traumatol, Sch Med 2, Prague, Czech Republic","Svehlik, M (reprint author), Med Univ Graz, Dept Paediat Orthopaed, Dept Paediat Surg, Auenbruggerpl 34, A-8036 Graz, Austria.","martin.spejlik@seznam.cz",null,null,null,null,null,34,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,6,null,null,null,null,553,558,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","529LW","WOS:000272519700008"]
[null,null,null,null,"J","Kopkan, L; Huskova, Z; Vanourkova, Z; Thumova, M; Skaroupkova, P; Maly, J; Kramer, HJ; Dvorak, P; Cervenka, L",null,null,null,"Kopkan, Libor; Huskova, Zuzana; Vanourkova, Zdenka; Thumova, Monika; Skaroupkova, Petra; Maly, Jan; Kramer, Herbert J.; Dvorak, Pavel; Cervenka, Ludek",null,null,"Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats","VASCULAR PHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,"Renin transgenic rats; Hypertension; Angiotensin II; Oxidative stress; Tempol; Apocynin","END-ORGAN DAMAGE; ENDOTHELIN RECEPTOR BLOCKADE; SALT-SENSITIVE HYPERTENSION; BLOOD-PRESSURE; NADPH OXIDASE; CARDIAC-HYPERTROPHY; NITRIC-OXIDE; ANG-II; RENAL-FUNCTION; PIVOTAL ROLE","Results of our previous studies have suggested that enhanced generation of superoxide (O(2)(-)) may contribute to the pathophysiology of hypertension in Ren-2 transgenic rats (TGR). The present study was performed to evaluate in TGR the effects of chronic treatment with the O(2)(-) scavenger tempol and the antioxidant apocynin on the development of hypertension. Systolic blood pressure (SBP) was monitored from 30 to 99 days of age in TGR and in normotensive Hannover Sprague-Dawley (HanSD) rats. At the end of the experiment, urinary protein and 8-isoprostane excretion were determined and angiotensin II (ANG II) and malondialdehyde (MDA) levels were measured in kidney and cardiac tissues. Cardiac hypertrophy was assessed as the ratio of left heart ventricle weight to tibia length (LVW/TL). Although tempol and apocynin treatment in TGR significantly decreased 8-isoprostane excretion and MAD tissue concentrations as compared with untreated TGR, it did not alter the course of SBP, LVW/TL ratio, proteinuria or ANG II levels that were enhanced as compared with HanSD rats. Our data suggest that the development of hypertension in TGR is clearly ANG II-dependent but the contribution of oxidative stress to the development of hypertension in this model appears to be negligible. (C) 2009 Elsevier Inc. All rights reserved.","[Kopkan, Libor; Huskova, Zuzana; Vanourkova, Zdenka; Thumova, Monika; Skaroupkova, Petra; Maly, Jan; Dvorak, Pavel; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14021 Prague 4, Czech Republic; [Kopkan, Libor; Huskova, Zuzana; Vanourkova, Zdenka; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Cervenka, L (reprint author), Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14021 Prague 4, Czech Republic.","luce@medicon.cz",null,null,"Institute for Clinical and Experimental Medicine [MZO 00023001]; Academy of Science of Czech Republic [KJB 502 030 801]; Czech Science Foundation [305/08/P053]; GACR [305/07/J006]; Center for Cardiovascular Research [1M6798582302]; German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn [Kra 433/14-2, 436 TSE 113/50/0-1]","This study was supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). L.K. is supported by grant no. KJB 502 030 801 awarded by the Grant Agency of the Academy of Science of Czech Republic. Z.H. is supported by grant no. 305/08/P053 awarded by the Czech Science Foundation (GAU). U. is supported by grant no. 305/07/J006 awarded by GACR. Z.V. is supported from the Center for Cardiovascular Research (1M6798582302). H.J. Kramer is supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn (Kra 433/14-2 and 436 TSE 113/50/0-1).",null,62,14,15,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1537-1891",null,null,"VASC PHARMACOL","Vasc. Pharmacol.","AUG-SEP",2009,51,41700,null,null,null,null,175,181,null,"10.1016/j.vph.2009.06.001",null,7,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","486EH","WOS:000269178100017"]
[null,null,null,null,"J","Cejka, C; Platenik, J; Buchal, R; Guryca, V; Sirc, J; Vejrazka, M; Crkovska, J; Ardan, T; Michalek, J; Brunova, B; Cejkova, J",null,null,null,"Cejka, Cestmir; Platenik, Jan; Buchal, Richard; Guryca, Vilem; Sirc, Jakub; Vejrazka, Martin; Crkovska, Jirina; Ardan, Taras; Michalek, Jiri; Brunova, Blanka; Cejkova, Jitka",null,null,"Effect of Two Different UVA Doses on the Rabbit Cornea and Lens","PHOTOCHEMISTRY AND PHOTOBIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"INDUCED LIPID-PEROXIDATION; MAS H-1-NMR SPECTROSCOPY; HUMAN SKIN FIBROBLASTS; SUPEROXIDE-DISMUTASE; GLUTATHIONE-PEROXIDASE; ALDEHYDE DEHYDROGENASE; PHOTOREFRACTIVE KERATECTOMY; ULTRAVIOLET-RADIATION; METABOLIC PROFILE; ACTION SPECTRUM","The aim of the present paper was to examine the irradiation effect of two doses of UVA rays (365 nm) on the rabbit cornea and lens. Corneas of anesthetized adult albino rabbits were irradiated with UVA rays for 5 days (daily dose 1.01 J cm(-2) in one group of rabbits and daily dose 2.02 J cm(-2) in the second group of animals). The third day after the last irradiation, the rabbits were killed, and their eyes were employed for spectrophotometrical, biochemical and immunohistochemical investigations. Normal eyes served as controls. Absorption spectra of the whole corneal centers were recorded over the UV-VIS (visible) spectral range. Levels of antioxidant and prooxidant enzymes, nitric oxide synthases and nitric oxide (indirectly measured as nitrate concentration) were investigated in the cornea. Malondialdehyde, a byproduct of lipid peroxidation, was examined in the cornea and lens. The results show that the staining for endothelial nitric oxide synthase was more pronounced in corneas irradiated with the higher UVA dose. Otherwise, UVA rays at either dose did not significantly change corneal light absorption properties and did not cause statistically significant metabolic changes in the cornea or lens. In conclusion, UVA rays at the employed doses did not evoke harmful effects in the cornea or lens.","[Cejka, Cestmir; Ardan, Taras; Cejkova, Jitka] Acad Sci Czech Republic, Inst Expt Med, Dept Eye Histochem & Pharmacol, Prague, Czech Republic; [Platenik, Jan; Buchal, Richard; Vejrazka, Martin; Crkovska, Jirina] Charles Univ Prague, Fac Med 1, Inst Med Biochem, CR-11636 Prague 1, Czech Republic; [Guryca, Vilem; Sirc, Jakub; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, Prague, Czech Republic; [Cejka, Cestmir; Brunova, Blanka] Charles Univ Prague, Fac Med 2, Dept Ophthalmol Children & Adults, CR-11636 Prague, Czech Republic","Cejkova, J (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Eye Histochem & Pharmacol, Prague, Czech Republic.","cejkova@biomed.cas.cz","Michalek, Jiri/D-7251-2013",null,"Czech Republic [47/2006/C/2.LF, 304/06/1379, AVOZ50390512]; Ministry of Education, Youth & Sports of the Czech Republic [MSM0021620807]","Supported by a grant from the Grant Agency of Charles University of the Czech Republic No. 47/2006/C/2.LF, by a grant from the Grant Agency of the Czech Republic No. 304/06/1379, by a grant from the Academy of Sciences of the Czech Republic AVOZ50390512 and in part by Research Plan No. MSM0021620807 from the Ministry of Education, Youth & Sports of the Czech Republic. The assistance of Mrs. Dana Domanyiova in the nitrate assay is acknowledged.",null,46,4,4,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0031-8655",null,null,"PHOTOCHEM PHOTOBIOL","Photochem. Photobiol.","MAY-JUN",2009,85,3,null,null,null,null,794,800,null,"10.1111/j.1751-1097.2008.00478.x",null,7,"Biochemistry & Molecular Biology; Biophysics","Biochemistry & Molecular Biology; Biophysics","436RB","WOS:000265431300020"]
[null,null,null,null,"J","Feber, J; Spatenka, J; Seeman, T; Matousovic, K; Zeman, L; Dusek, J; Moravek, J; Janda, J; Barrowman, NJ; Guerra, L; Leonard, M",null,null,null,"Feber, Janusz; Spatenka, Jaroslav; Seeman, Tomas; Matousovic, Karel; Zeman, Lubos; Dusek, Jiri; Moravek, Jiri; Janda, Jan; Barrowman, Nicholas J.; Guerra, Luis; Leonard, Michael",null,null,"Urinary tract infections in pediatric renal transplant recipients - a two center risk factors study","PEDIATRIC TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"pediatric renal transplantation; risk factors; pyelonephritis","KIDNEY-TRANSPLANTATION; VESICOURETERAL REFLUX; BLADDER DYSFUNCTION; CHILDREN; PYELONEPHRITIS; AUGMENTATION","UTI are common in renal Tx recipients and may significantly impact on the graft function. The aim of our study was to evaluate the prevalence, risk factors, and significance of UTI in Tx children. We performed a retrospective cross-sectional study of 76 Tx patients, median age at Tx was 13.4 yr. Twenty-one of 76 (28%) patients developed at least one UTI during the mean follow-up time of 3.3 +/- 2.0 yr post-Tx. The first UTI occurred at a median of 160 days post-Tx. The RR of having UTI was significantly higher in patients with the primary diagnosis of obstructive uropathy (RR = 2.6, 95th CI = 1.1-6.0, p = 0.032), history of PN pre Tx (RR = 2.7, 95th CI = 1.3-5.4, p = 0.009) and pre Tx VUR (RR = 2.2, 95th CI = 1.1-4.5, p = 0.045). These three factors also significantly decreased the infection-free survival time to the first UTI. Most UTI caused reversible acute allograft dysfunction, but the long-term graft function could not be reliably assessed with SCr. In conclusion, UTI occurred in 28% of pediatric Tx recipients, mostly during the first year post-Tx despite antibiotic prophylaxis. The diagnosis of obstructive uropathy, history of UTI and VUR prior to Tx were significant risk factors.","[Feber, Janusz] Childrens Hosp Eastern Ontario, Div Pediat Nephrol, Ottawa, ON K1H 8L1, Canada; [Spatenka, Jaroslav] Univ Hosp Motol, Transplant Ctr, Prague, Czech Republic; [Seeman, Tomas; Dusek, Jiri; Janda, Jan] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Matousovic, Karel] Univ Hosp Motol, Dept Internal Med, Prague, Czech Republic; [Zeman, Lubos; Moravek, Jiri] Univ Hosp Motol, Dept Pediat Surg, Prague, Czech Republic; [Barrowman, Nicholas J.] Childrens Hosp Eastern Ontario, Res Inst, Clin Res Unit, Ottawa, ON K1H 8L1, Canada; [Barrowman, Nicholas J.] Univ Ottawa, Ottawa, ON K1N 6N5, Canada; [Guerra, Luis; Leonard, Michael] Childrens Hosp Eastern Ontario, Div Pediat Urol, Ottawa, ON K1H 8L1, Canada","Feber, J (reprint author), Childrens Hosp Eastern Ontario, Div Nephrol, Dept Pediat, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.","jfeber@cheo.on.ca",null,null," [MSM 0021620810];  [MSM 0021620819]","We thank Stephanie Barnes for the revision of the manuscript. Grant support: research projects MSM 0021620810 and MSM 0021620819 (Czech Republic).",null,26,3,3,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1397-3142",null,null,"PEDIATR TRANSPLANT","Pediatr. Transplant.","NOV",2009,13,7,null,null,null,null,881,886,null,"10.1111/j.1399-3046.2008.01079.x",null,6,"Pediatrics; Transplantation","Pediatrics; Transplantation","505CS","WOS:000270666600016"]
[null,null,null,null,"J","Maly, MA; Hadacova, I; Hajek, P; Zemanek, D; Veselka, J",null,null,null,"Maly, Martin A.; Hadacova, Ivana; Hajek, Petr; Zemanek, David; Veselka, Josef",null,null,"High-residual platelet activity despite dual antiplatelet treatment associated with subacute stent thrombosis","CENTRAL EUROPEAN JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,"Resistance; Dual antiplatelet therapy; Stent thrombosis; Light transmittance aggregometry; Clopidogrel","STIMULATED PHOSPHOPROTEIN PHOSPHORYLATION; INCREASED RISK; CLOPIDOGREL RESISTANCE; CARDIOVASCULAR EVENTS; CORONARY; REACTIVITY; IMPLANTATION; THERAPY; ASPIRIN; ANTICOAGULATION","High-residual platelet activity despite the dual antiplatelet treatment with aspirin and clopidogrel is associated with major adverse cardiac events, including stent thrombosis. Acute and subacute stent thrombosis is rare, but presents itself with serious complications including high mortality and morbidity rates. Light transmittance aggregometry with specific agonists - arachidonic acid and 5-adenosin diphosphate - is still considered a standard for the assessment of platelet reactivity, besides novel methods like vasodilator-stimulated phosphoprotein phosphorylation. In our case study, we report the coincidence of high-residual platelet activity with subacute stent thrombosis despite the recommended doses of antiplatelet agents - aspirin and clopidogrel. Stent thrombosis was treated by aspiration thrombectomy, and antiplatelet treatment was modified by increasing the dose of aspirin and substituting clopidogrel with a firstgeneration thienopyridin - ticlopidin. The effect of the treatment was documented by reaching the optimal inhibition of platelet reactivity. In the 6- and 12-month follow-up, the patient presented no ischemic events.","[Maly, Martin A.; Hajek, Petr; Zemanek, David; Veselka, Josef] Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc, Fac Med 1, Prague 15000, Czech Republic; [Hadacova, Ivana] Univ Hosp Motol, Dept Hematol, Prague 15000, Czech Republic","Maly, MA (reprint author), Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc, Fac Med 1, Prague 15000, Czech Republic.","martin.maly@fnmotol.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health of Czech Republic [00064203]","Supported by the grant from the Ministry of Health of Czech Republic No 00064203.",null,26,1,1,"DE GRUYTER OPEN LTD","WARSAW","SOLIPSKA 14A-1, 02-482 WARSAW, POLAND","1895-1058","1644-3640",null,"CENT EUR J MED","Cent. Eur. J. Med.","MAR",2009,4,1,null,null,null,null,119,124,null,"10.2478/s11536-009-0007-8",null,6,"Medicine, General & Internal","General & Internal Medicine","406MP","WOS:000263299900018"]
[null,null,null,null,"J","Frisova, V; Kavalcova, L; Kyncl, M; Vlk, R; Kucera, A; Rocek, M",null,null,null,"Frisova, Veronika; Kavalcova, Lucie; Kyncl, Martin; Vlk, Radovan; Kucera, Alexandr; Rocek, Miloslav",null,null,"Congenital Gastric Outlet Obstruction by Pyloric Membrane: Prenatal and Postnatal Diagnosis and Management","FETAL DIAGNOSIS AND THERAPY",null,null,"English","Article",null,null,null,null,null,"Gastric outlet obstruction; Pyloric atresia; Polyhydramnios; Prenatal diagnosis; Ultrasonography; Fetal magnetic resonance imaging; Pyloroplasty","ATRESIA","Congenital gastric outlet obstruction is a rare condition representing only 1% of all gastrointestinal atresias. Prenatal diagnosis is uncommon and mostly confined to the third trimester of cases presenting a combination of polyhydramnios with dilated stomach. We report a case of congenital gastric outlet obstruction by pyloric membrane which was diagnosed prenatally in the third trimester by sonography and magnetic resonance imaging. The anomaly appeared to be isolated, thus a favorable outcome was expected. A baby girl weighing 3,430 g was delivered spontaneously at 36 weeks. Postnatal imaging methods confirmed the presence of a congenital gastric obstruction. 21 h after delivery, the baby underwent laparotomy, at which time a malrotation and pyloric membrane were found and resolved. The postoperative course was uneventful and the baby was discharged at the age of 18 days and remains well at controls. Copyright (C) 2009 S. Karger AG, Basel","[Frisova, Veronika; Kyncl, Martin; Rocek, Miloslav] Charles Univ Prague, Dept Imaging Methods, Fac Med 2, CZ-15006 Prague, Czech Republic; [Kavalcova, Lucie; Kucera, Alexandr] Charles Univ Prague, Dept Paediat Surg, Fac Med 2, CZ-15006 Prague, Czech Republic; [Vlk, Radovan] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, CZ-15006 Prague, Czech Republic; Fac Hosp Motol, Prague, Czech Republic","Frisova, V (reprint author), Charles Univ Prague, Dept Imaging Methods, Fac Med 2, Uvalu 84, CZ-15006 Prague, Czech Republic.","veronika.frisova@gmail.com",null,null,"MZO [0064203/6312, 0064203/6309, 0064203/6202]","Supported by grants of MZO 0064203/6312, 0064203/6309 and 0064203/6202.",null,6,0,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1015-3837",null,null,"FETAL DIAGN THER","Fetal Diagn. Ther.",null,2009,26,2,null,null,null,null,98,101,null,"10.1159/000242455",null,4,"Obstetrics & Gynecology","Obstetrics & Gynecology","506KY","WOS:000270774900008"]
[null,null,null,null,"J","Ryden, A; Stechova, K; Durilova, M; Faresjo, M",null,null,null,"Ryden, Anna; Stechova, Katerina; Durilova, Marianna; Faresjo, Maria",null,null,"Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes","DIABETES-METABOLISM RESEARCH AND REVIEWS",null,null,"English","Article",null,null,null,null,null,"Type 1 diabetes; high-risk children; T-helper cells; T-regulatory cells; cytokines; chemokines","MONOCYTE CHEMOATTRACTANT PROTEIN-1; GLUTAMIC-ACID DECARBOXYLASE; CHRONIC AUTOIMMUNE-DISEASE; BLOOD MONONUCLEAR-CELLS; IFN-GAMMA; HIGH-RISK; NOD MICE; T-CELLS; CYTOKINE PRODUCTION; REGULATORY-CELLS/","Background Type 1 diabetes (T1D) is all autoimmune disease dominated by loss of self-tolerance resulting in depletion of the beta-cells. This Study aims to confirm previous observations of a dominant T-helper (Th)1-like profile during the period close to onset of disease. Further, to follow the immune response from onset to 2 years duration, the Study focused on spontaneous as well as autoantigen-induced immune profile. Methods Peripheral blood mononuclear cells were collected 4 days and 1 and 2 years after diagnosis of T1D children, from healthy children carrying the human leukocyte antigen-risk genes and from high-risk children (ICA >= 20 IJDF units). Peripheral blood mononuclear cells were stimulated with glutamic acid decarboxylase (GAD(65)) and phytohaemagglutinin (PHA). Cytokines and chemokines were detected in cell-culture supernatants by protein microarray (naive T-cells; interleukin (IL)-7, Th1; interferon-gamma, turnout necrosis factor-beta, Th2; IL-5, Th3; transforming growth factor-beta, T-regulatory cell type 1; IL-10 and inflammatory cytokines; tumour necrosis factor-alpha, IL-6 and chemokines; monocyte chemoattractant protein-1, monokine upregulated by IFN-gamma) in relation to clinical outcome (C-peptide). Results High-risk children showed a dominant Th1-associated profile with high spontaneous and GAD(65)-induced secretion. The mitogen PHA instead induced a Th2-associated response exclusively in high-risk children. In contrast, newly diagnosed T1D children showed a pronounced Th3-associated cytokine profile as well as a burst of inflammatory cytokines and chemokines secreted both spontaneously and by GAD(65) and PHA stimulation. The immune response to GAD(65) and PHA, however, diminished with duration of disease. Conclusion A dominant Thl-associated immune profile was observed during the pre-diabetic phase. This Th1 dominance, however, diminished in favour of a temporary increase in a Th3-associated and inflammatory immune profile at the onset of disease. Copyright (C) 2009 John Wiley & Sons, Ltd.","[Ryden, Anna; Faresjo, Maria] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Res Ctr,Div Paediat & Diabet, S-58185 Linkoping, Sweden; [Stechova, Katerina; Durilova, Marianna] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Stechova, Katerina; Durilova, Marianna] Univ Hosp Motol, Prague, Czech Republic; [Faresjo, Maria] Jonkoping Univ, Sch Hlth Sci, Dept Nat Sci & Biomed, Jonkoping, Sweden","Faresjo, M (reprint author), Linkoping Univ, Fac Hlth Sci, Div Paediat, S-58185 Linkoping, Sweden.","maria.faresjo@liu.se",null,null,"Swedish Child Diabetes Foundation (Barndiabetesfonden); Schelin Foundation; Child Medicine Research Foundation; Research Project of the University Hospital Motol [00064203]","This project was generously supported by the Swedish Child Diabetes Foundation (Barndiabetesfonden), the Schelin Foundation, the Child Medicine Research Foundation and the Research Project of the University Hospital Motol (No. 00064203).",null,45,13,17,"JOHN WILEY & SONS LTD","CHICHESTER","THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND","1520-7552",null,null,"DIABETES-METAB RES","Diabetes-Metab. Res. Rev.","MAY",2009,25,4,null,null,null,null,335,343,null,"10.1002/dmrr.958",null,9,"Endocrinology & Metabolism","Endocrinology & Metabolism","449RH","WOS:000266347200008"]
[null,null,null,null,"J","Hubackova, M; Vaclavikova, R; Mrhalova, M; Kubackova, K; Kodet, R; Gut, I; Soucek, P",null,null,null,"Hubackova, Miluse; Vaclavikova, Radka; Mrhalova, Marcela; Kubackova, Katerina; Kodet, Roman; Gut, Ivan; Soucek, Pavel",null,null,"NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristcs of human mammary tumors","PHARMACOGENETICS AND GENOMICS",null,null,"English","Article",null,null,null,null,null,"breast cancer; immunohistochemistry; NQO1; polymorphism; transcript","BREAST-CANCER; NAD(P)H-QUINONE OXIDOREDUCTASE-1; C609T POLYMORPHISM; DT-DIAPHORASE; PROTEASOMAL DEGRADATION; PANCREATIC-CANCER; NQOI POLYMORPHISM; CLINICAL-RESPONSE; MITOMYCIN-C; P53","Objective The aim of this study was to further clarify the recently reported role of NAD(P)H:quinone oxidoreductase 1 (NQO1) as a strong prognostic and predictive factor in breast cancer. Methods NQO1 transcript levels were monitored in mammary tumors by real-time polymerase chain reaction. NQO1 protein levels were immunohistochemically determined in formalin-fixed paraffin-embedded tissues. NQO1 polymorphism (Pro187Ser, rs1800566) was also assessed. Evaluation (N=52) and validation (N=53) sets were analyzed subsequently. Results Carriers of variant NQO1-Ser allele had significantly more frequently NQO1-negative protein expression (P=0.001) in both sets. NQO1 transcript levels in samples with negative protein expression were significantly lower than in those with positive NQO1 protein expression (P=0.007) in both sets. Patients with stages 0/I/II had more often positive NQO1 protein expression than patients with stages III/IV (P=0.022) in the evaluation set. Significant association between NQO1 protein expression and TP53 protein status was also found (P=0.037). However, both associations were not replicated by analysis of the validation set. Analysis of both sets combined did not show significant association of NQO1 protein expression either with stage (P=0.231) or with TP53 protein status (P>0.999). Thus, the results observed in the evaluation set were effects of small sample size. Conclusion The role of NQO1 in human mammary gland carcinogenesis does not seem to be directly associated with classical clinico-pathological factors. Pharmacogenetics and Genomics 19:505-512 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.","[Hubackova, Miluse; Vaclavikova, Radka; Gut, Ivan; Soucek, Pavel] Natl Inst Publ Hlth, Lab Toxicogenom, Prague 10042 10, Czech Republic; [Hubackova, Miluse] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Mrhalova, Marcela; Kodet, Roman] Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Kubackova, Katerina] Charles Univ Prague, Sch Med 2, Dept Radiotherapy Oncol, Prague, Czech Republic; Hosp Motol, Prague, Czech Republic","Soucek, P (reprint author), Natl Inst Publ Hlth, Lab Toxicogenom, Srobarova 48, Prague 10042 10, Czech Republic.","psoucek@szu.cz",null,null,"Czech Ministry of Health [8563-5, 9426-3]; Agency of Charles University [94507]; Ministry of Health and Faculty Hospital [MZO 00064203/6704]","This work Was Supported by grants front Internal Grant Agency of the Czech Ministry of Health, no: 8563-5, 9426-3, a grant from the Grant Agency of Charles University, no: 94507 and Research Project of the Ministry of Health and Faculty Hospital no: MZO 00064203/6704.",null,24,5,5,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1744-6872",null,null,"PHARMACOGENET GENOM","Pharmacogenet. Genomics","JUL",2009,19,7,null,null,null,null,505,512,null,"10.1097/FPC.0b013e32832cf9cf",null,8,"Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy","Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy","465WD","WOS:000267619000003"]
[null,null,null,null,"J","Kalitova, P; Plzak, J; Kodet, R; Astl, J",null,null,null,"Kalitova, Petra; Plzak, Jan; Kodet, Roman; Astl, Jaromir",null,null,"Angiosarcoma of the thyroid","EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"Angiosarcoma; Thyroid gland; Total thyroidectomy; Immunohistochemistry; Fasciin; CD 31","EPITHELIOID ANGIOSARCOMA; GLAND; HEMANGIOSARCOMA","Hemangiosarcoma of the thyroid gland is a very rare entity. The therapy of this tumor is difficult because of its locally aggressive and destructive behavior with a high recurrence rate. We report a case of 60-year-old man with history of 1 month rapidly enlarging neck mass in the thyroid region. Ultrasound examination and CT scan showed resistance arising from the left thyroid lobe. FNAC revealed necrotic tumor mass without any cytological specification. Because of the clinical findings, a total thyroidectomy was indicated. The surgery was complicated by invasion of the tumor mass into the surrounding tissues. Therefore, only left side hemithyroidectomy was performed. Histopathology including histochemistry proved positive staining for Factor VIII, Fasciin, and CD31 in tumor cells. In this case, adjuvant oncological treatment was planned, but the patient died because of massive bleeding from the tumor mass. The histological diagnosis of thyroid hemangiosarcoma is mostly difficult. The treatment of the first choice is radical surgery. If the tumor cannot be treated by surgery, then radiotherapy, eventually chemotherapy is indicated. The prognosis is not favorable.","[Kalitova, Petra; Plzak, Jan; Astl, Jaromir] Charles Univ Prague, Fac Hosp Motol, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague 15006 5, Czech Republic; [Kalitova, Petra] Charles Univ Prague, Inst Physiol, Fac Med 1, Prague 15006 5, Czech Republic; [Plzak, Jan] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 15006 5, Czech Republic; [Plzak, Jan] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Kodet, Roman] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Fac Hosp Motol, Prague 15006 5, Czech Republic","Kalitova, P (reprint author), Charles Univ Prague, Fac Hosp Motol, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Uvalu 84, Prague 15006 5, Czech Republic.","petra.kalitova@lf1.cuni.cz",null,null,"IGA MZ CR [NR9049-3]","This study was supported by the IGA MZ CR No. NR9049-3. Many thanks to Daniel Drtik, M. D., from the ENT Department, Hospital Most, Czech Republic and Ivan Cech, M. D., from the Department of Radiology, Hospital Most, Czech Republic for providing CT imaging.",null,13,3,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0937-4477",null,null,"EUR ARCH OTO-RHINO-L","Eur. Arch. Oto-Rhino-Laryn.","JUN",2009,266,6,null,null,null,null,903,905,null,"10.1007/s00405-008-0820-8",null,3,"Otorhinolaryngology","Otorhinolaryngology","440FH","WOS:000265685700021"]
[null,null,null,null,"J","Klaboch, J; Opatrna, S; Matousovic, K; Sefrna, F; Havlin, J; Schuck, O",null,null,null,"Klaboch, Jan; Opatrna, Sylvie; Matousovic, Karel; Sefrna, Frantisek; Havlin, Jan; Schueck, Otto",null,null,"Acid-Base Balance in Peritoneal Dialysis Patients: A Stewart-Fencl Analysis","RENAL FAILURE",null,null,"English","Article",null,null,null,null,null,"acid-base balance; bicarbonate; icodextrin; lactate; peritoneal dialysis; Stewart principle","CAPD PATIENTS; METABOLIC-ACIDOSIS; HEMODIALYSIS-PATIENTS; BICARBONATE LEVELS; NUTRITIONAL-STATUS; PRACTICE PATTERNS; IMPACT; FLUID; BIOCOMPATIBILITY; ICODEXTRIN","Background. Evaluation of acid-base disorders using the Stewart-Fencl principle is based on assessment of independent factors: strong ion difference (SID) and the total concentration of non-volatile weak acids (Atot). This approach allows for a more detailed evaluation of the cause of acid-base imbalance than the conventional bicarbonate-centered approach based on the Henderson-Hasselbalch principle, which is a necessary yet insufficient condition to describe the state of the system. The aim of our study was to assess acid-base disorders in peritoneal dialysis (PD) patients using both of these principles. Methods. A total of 17 patients with chronic renal failure (10 men), aged 60.7 (22-84) years, treated by PD for 25.7 (1-147) months were examined. A control group included 17 healthy volunteers (HV) (8 males), with a mean age of 42.7 (22-77) years and normal renal function. Patients were treated with a solution containing bicarbonate (25 mmol/L) and lactate (15 mmol/L) as buffers; eleven of them used, during the nighttime dwell, a solution with icodextrin buffered by lactate at a concentration of 40 mmol/L. The following equations were employed for calculations of acid-base parameters according to the Stewart-Fencl principle. The first is SID = [Na(+)] + [K(+)] + 2[Ca(2+)] + 2[Mg(2+)] - [Cl(-)] - [UA(-)], where SID is the strong ion difference and [UA(-)] is the concentration of undetermined anions. For practical calculation of SID, the second equation, SID = [HCO(3)(-)] + [Alb(-)] + [Pi(-)], was used, where [Alb(-)] and [Pi(-)] are the charges carried by albumin and phosphates. The third is Atot, the total concentration of weak non-volatile acids, albumin [Alb] and phosphates [Pi]. Results. The capillary blood pH in PD group was 7.41 (7.27-7.48), [HCO(3)(-)] levels 23.7 (17.6-29.5) mmol/L, SID 36.3 (29.5-41.3) mmol/L, sodium-chloride difference 39.0 (31.0-44.0) mmol/L, [Pi] 1.60 (0.83-2.54) mmol/L, and [Alb] 39.7 (28.8-43.4) g/L (median, min-max). Bicarbonate in blood correlated positively with SID (Rho = 0.823; p < 0.001), with the sodium-chloride difference (Rho = 0.649; p < 0.01) and pH (Rho = 0.754; p < 0.001), and negatively with residual renal function (Rho = -0.517; p < 0.05). Moreover, the sodium-chloride difference was also found to correlate with SID (Rho = 0.653; p < 0.01). While the groups of PD and HV patients did not differ in median bicarbonate levels, significantly lower median value of SID were observed in PD patients, 36.3 vs. 39.3 mmol/L (p < 0.01); additionally, PD patients were shown to have significantly lower mean value of serum sodium levels, 138 vs. 141 mmol/L (p < 0.01), and serum chlorides levels, 100 vs. 104 mmol/L (p < 0.001). Despite the higher [UA(-)] levels in PD patients, 9.1 vs. 5.4 mmol/L (p < 0.001), this parameter was not found to correlate with bicarbonate levels. Conclusions. The results suggest that the decreased bicarbonate in PD patients results from a combination of decreased sodium-chloride difference and mildly increased unmeasured anions.","[Klaboch, Jan; Opatrna, Sylvie; Sefrna, Frantisek] Charles Univ Prague, Dept Med 1, Sch Med, Plzen 30460, Czech Republic; [Klaboch, Jan; Opatrna, Sylvie; Sefrna, Frantisek] Teaching Hosp, Plzen, Czech Republic; [Matousovic, Karel; Havlin, Jan; Schueck, Otto] Charles Univ Prague, Sch Med 2, Dept Med, Prague, Czech Republic; [Matousovic, Karel; Havlin, Jan; Schueck, Otto] Motol Univ Hosp, Prague, Czech Republic","Opatrna, S (reprint author), Charles Univ Prague, Sch Med, Dept Med, Alej Svobody 80, Plzen 30460, Czech Republic.","opatrna@fnplzen.cz",null,null,"Main Research Project [0021620819]","The study was supported by the Main Research Project No. MSM 0021620819.",null,47,1,1,"TAYLOR & FRANCIS INC","PHILADELPHIA","325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA","0886-022X",null,null,"RENAL FAILURE","Ren. Fail.",null,2009,31,8,null,null,null,null,625,632,null,"10.3109/08860220903134076",null,8,"Urology & Nephrology","Urology & Nephrology","509KK","WOS:000271015200001"]
[null,null,null,null,"J","Krijtova, H; Marusic, P",null,null,null,"Krijtova, H.; Marusic, P.",null,null,"Paroxysmal Kinesigenic Dyskinesia - a Case Report of a Young Woman with Alternating Hemidystonia","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"paroxysmal dyskinesia; alternating hemidystonia","FAMILIAL INFANTILE CONVULSIONS; CHOREOATHETOSIS; MUTATIONS; EPILEPSY; LINKAGE; PERFUSION; SEIZURES; THERAPY; GENES","Paroxysmal kinesigenic dyskinesia is a neurological disorder characterized by brief episodes of dystonia and choreathetosis triggered by sudden voluntary movement. The attacks typically last less than one minute and may occur even several times a day. Besides familiar idiopathic forms with autosomal dominant inheritance, sporadic cases may occur, or symptomatic forms may be associated with some CNS diseases and may manifest with the same type of paroxysms. At the beginning we review current knowledge on this disorder, including the historical development of the concept of paroxysmal dyskinesia. Then we present the case of a young woman who has suffered from sporadic idiopathic paroxysmal kinesigenic dyskinesia since she was 13 years old. Diagnosis was proved during video-EEG monitoring and her paroxysms can be characterised as alternating hemidystonia. She has been successfully treated with 300mg of lamotrigine per day.","[Krijtova, H.; Marusic, P.] LF & FN Motol, Neurol Klin UK 2, Prague 15006, Czech Republic","Krijtova, H (reprint author), LF & FN Motol, Neurol Klin UK 2, Uvalu 84,5 Motol, Prague 15006, Czech Republic.","hana.krijtova@fnmotol.cz",null,null,null,null,null,32,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,4,null,null,null,null,368,372,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","486HZ","WOS:000269188200012"]
[null,null,null,null,"J","Hummelova-Fanfrdlova, Z; Rektorova, I; Sheardova, K; Bartos, A; Linek, V; Ressner, P; Zapletalova, J; Vyhnalek, M; Hort, J",null,null,null,"Hummelova-Fanfrdlova, Zuzana; Rektorova, Irena; Sheardova, Katerina; Bartos, Ales; Linek, Vladimir; Ressner, Pavel; Zapletalova, Jana; Vyhnalek, Martin; Hort, Jakub",null,null,"Czech adaptation of Addenbrooke's Cognitive Examination","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"Addenbrooke's Cognitive Examination; dementia; Alzheimer disease; frontotemporal dementia","ALZHEIMERS-DISEASE; SPEAKING POPULATION; DEMENTIA; VALIDATION; BATTERY; SCALE","The goal of the study was to validate the quality of Czech adaptation of Addenbrooke's Cognitive Examination (ACE). ACE is a neuropsychological screening test battery serving for dementia detection and differentiation between dementia in Alzheimer disease and the frontotemporal dementia. The research sample consisted of 60 patients with diagnosis of probably dementia of Alzheimer type according DSM IV and NINCDS-ADRDA criteria. All patients passed neurological, basic biochemical, and morphological examinations. Psychological tests and scales including ACE were also administrated. The most expressive cognitive deficits in ACE were found in memory and verbal fluency subtests. The statistic procedures assessed good sensitivity of Czech adaptation of ACE: cut-off score 88 showed 100% sensitivity and that of 83 showed 96.6% sensitivity for dementia detection. The item test reliability assessed by Cronbach's alpha was 0.8. It can be stated that the Czech adaptation of Addenbrooke's Cognitive Examination represents not only a new useful test for cognitive deficits assessment but is also a sufficiently quality and sensitive test for dementia detection.","[Hummelova-Fanfrdlova, Zuzana] LF MU, Ustav Psychol & Somat, Brno 66243, Czech Republic; [Hummelova-Fanfrdlova, Zuzana; Rektorova, Irena; Sheardova, Katerina] FN & Sv Anny, Neurol Klin 1, Brno 65691, Czech Republic; [Bartos, Ales] UK 3 LF & FN Kralovske Vinohrady, Neurol Klin, Prague 10034, Czech Republic; [Linek, Vladimir] VFN, Prague 12000, Czech Republic; [Ressner, Pavel] FN Olomouc, Neurol Klin, Olomouc 77520, Czech Republic; [Zapletalova, Jana] Lekarska Fak UP, Ustav Lekarske Biofyz, Olomouc 77515, Czech Republic; [Vyhnalek, Martin; Hort, Jakub] Neurol Klin UK, LF & FN Motol 2, Prague 15018, Czech Republic; [Bartos, Ales] Psychiat Ctr Praha, AD Ctr, Prague 18103, Czech Republic","Hummelova-Fanfrdlova, Z (reprint author), LF MU, Ustav Psychol & Somat, Komenskeho Nam 2, Brno 66243, Czech Republic.","zuzana.fanfrdlova@fnusa.cz",null,null,null,null,null,19,15,15,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X","1804-6436",null,"CESK PSYCHOL","Cesk. Psychol.",null,2009,53,4,null,null,null,null,376,388,null,null,null,13,"Psychology, Multidisciplinary","Psychology","488YL","WOS:000269386200005"]
[null,null,null,null,"J","Kuba, R; Brazdil, M; Kalina, M; Prochazka, T; Hovorka, J; Nezadal, T; Hadac, J; Brozova, K; Sebronova, V; Komarek, V; Marusic, P; Oslejskova, H; Zarubova, J; Rektor, I",null,null,null,"Kuba, Robert; Brazdil, Milan; Kalina, Miroslav; Prochazka, Tomas; Hovorka, Jiri; Nezadal, Tomas; Hadac, Jan; Brozova, Klara; Sebronova, Vera; Komarek, Vladimir; Marusic, Petr; Oslejskova, Hana; Zarubova, Jana; Rektor, Ivan",null,null,"Vagus nerve stimulation: Longitudinal follow-up of patients treated for 5 years","SEIZURE-EUROPEAN JOURNAL OF EPILEPSY",null,null,"English","Article",null,null,null,null,null,"Vagus nerve stimulation; Efficacy; Long-term outcome; Complications","REFRACTORY EPILEPSY; PARTIAL SEIZURES; LONG-TERM; CLINICAL-EXPERIENCE; CHILDREN; THERAPY; TRIAL","We performed a retrospective, multicenter, open-label study to evaluate the efficacy Of vagus nerve stimulation (VNS) in all patients in the Czech Republic who have received this treatment for at least 5 years (n = 90). The mean last follow-up was 6.6 +/- 1.1 years (79 +/- 13 months). The median number of seizures among all patients decreased from 41.2 seizures/month in the prestimulation period to 14.9 seizures/month at 5 years follow-up visit. The mean percentage of seizure reduction was 55.9%. The responder rate in these patients is in concordance with the decrease of overall seizure frequency. At 1 year after beginning the stimulation, 44.4% of patients were responders; this percentage increased to 58.7% after 2 years. At the 5 years last follow-up 64.4% of patients were responders, 15.5% experienced >= 90% seizure reduction, and 5.5% were seizure-free. A separate analysis of patients younger than 16 years of age showed lower efficacy rates of VNS in comparison to the whole group. Complications and chronic adverse effects occurred in 13.3% of patients. VNS is an effective and safe method to refractory epilepsy in common clinical practice. (C) 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","[Kuba, Robert; Brazdil, Milan; Oslejskova, Hana; Rektor, Ivan] St Annes Univ Hosp, Dept Neurol 1, Brno Epilepsy Ctr, Brno 53, Pekarska, Czech Republic; [Kalina, Miroslav; Prochazka, Tomas] Homolce Hosp, Epilepsy Ctr, Prague, Czech Republic; [Hovorka, Jiri; Nezadal, Tomas] Charles Univ Prague, Frantisku Hosp, Neurol Epileptol & Neuropsychiat Dept, Sch Med 1, Prague 1, Czech Republic; [Hadac, Jan; Brozova, Klara; Zarubova, Jana] Thomayers Teaching Hosp, Ctr Epileptol & Epileptosurg, Prague, Czech Republic; [Sebronova, Vera; Komarek, Vladimir] Charles Univ Prague, Motol Hosp, Fac Med 2, Dept Pediat Neurol, CR-11636 Prague, Czech Republic; [Marusic, Petr] Charles Univ Prague, Motol Hosp, Fac Med 2, Dept Neurol, CR-11636 Prague 1, Czech Republic","Kuba, R (reprint author), St Annes Univ Hosp, Dept Neurol 1, Brno Epilepsy Ctr, Brno 53, Pekarska, Czech Republic.","robert.kuba@fnusa.cz; mbrazd@med.muni.cz; miroslav.kalina@homolka.cz; tomas.prochazka@homolka.cz; Hovorka@nnfp.cz; tumas@post.cz; hadac@cesnet.cz; klara.brozova@ftn.cz; vera.sebronova@lf2.cuni.cz; vladimir.komarek@lf2.cuni.cz; petr.marusic@lf2.cuni.cz; hoslej@fnbrno.cz; jana.zarubova@ftn.cz; irektor@med.muni.cz","Brazdil, Milan/D-6836-2012; Kuba, Robert/E-3274-2012",null,null,null,null,25,14,15,"W B SAUNDERS CO LTD","LONDON","32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND","1059-1311",null,null,"SEIZURE-EUR J EPILEP","Seizure","MAY",2009,18,4,null,null,null,null,269,274,null,"10.1016/j.seizure.2008.10.012",null,6,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","437CY","WOS:000265465000007"]
[null,null,null,null,"J","Vrana, D; Pikhart, H; Mohelnikova-Duchonova, B; Holcatova, I; Strnad, R; Slamova, A; Schejbalova, M; Ryska, M; Susova, S; Soucek, P",null,null,null,"Vrana, D.; Pikhart, H.; Mohelnikova-Duchonova, B.; Holcatova, I.; Strnad, R.; Slamova, A.; Schejbalova, M.; Ryska, M.; Susova, S.; Soucek, P.",null,null,"The association between glutathione S-transferase gene polymorphisms and pancreatic cancer in a central European Slavonic population","MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS",null,null,"English","Article",null,null,null,null,null,"Glutathione S-transferases; Pancreas; Cancer; Risk","RISK; ADENOCARCINOMA; GSTM1; METAANALYSIS; GSTT1","In the first case-control study on pancreatic cancer conducted on 253 cases and 403 controls in the Czech Republic we observed that the GSTP1-codon 105 Val variant allele and the GSTT1-null genotype were associated with an elevated risk for pancreatic cancer (OR = 1.38; 95%CI = 0.96-1.97 and OR = 1.56; 95%CI = 0.93-2.61, respectively). Combination of GSTT1-null and GSTP1-codon 105 Val variants further increased the risk for pancreatic cancer (OR = 2.50; 95%CI = 1.20-5.20). In conclusion, this study suggests population-specific associations of polymorphisms in key biotransformation genes with elevated risk for pancreatic cancer. (C) 2009 Elsevier B.V. All rights reserved.","[Vrana, D.; Mohelnikova-Duchonova, B.; Susova, S.; Soucek, P.] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042 10, Czech Republic; [Pikhart, H.] UCL, Int Inst Soc & Hlth, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; [Holcatova, I.; Slamova, A.; Schejbalova, M.] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, CR-11636 Prague, Czech Republic; [Strnad, R.; Ryska, M.] Charles Univ Prague, Fac Med 2, CR-11636 Prague 1, Czech Republic","Soucek, P (reprint author), Natl Inst Publ Hlth, Toxicogenom Unit, Srobarova 48, Prague 10042 10, Czech Republic.","psoucek@szu.cz","Pikhart, Hynek/E-3074-2010",null,"Ministry of Health Czech Republic [8563-5, 9422-3]","This work was supported by the Grant Agency of the Ministry of Health Czech Republic, grants No. 8563-5 and 9422-3.",null,17,12,12,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1383-5718",null,null,"MUTAT RES-GEN TOX EN","Mutat. Res. Genet. Toxicol. Environ. Mutagen.","NOV-DEC",2009,680,41671,null,null,null,null,78,81,null,"10.1016/j.mrgentox.2009.09.005",null,4,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","534DK","WOS:000272875500012"]
[null,null,null,null,"J","Brynda, E; Houska, M; Kysilka, J; Praadny, M; Lesny, P; Jendelovaa, P; Michaalek, J; Sykovaa, E",null,null,null,"Brynda, Eduard; Houska, Milan; Kysilka, Jiri; Pradny, Martin; Lesny, Petr; Jendelova, Pavla; Michalek, Jiri; Sykova, Eva",null,null,"Surface modification of hydrogels based on poly(2-hydroxyethyl methacrylate) with extracellular matrix proteins","JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"2-HYDROXYETHYL METHACRYLATE; COPOLYMERS; ADHESION; CHARGE","Infrared attenuated total reflection spectroscopy was used for in situ observation of the deposition of collagen I on poly(2-hydroxyethyl methacrylate-co-methacrylic acid, 2.9%) hydrogels and subsequent attachment of laminin or fibronectin on the collagen surface. While there was no adsorption of collagen dissolved in an acid solution on the hydrogel surface, it deposited on the surface at pH 6.5. The collagen layers with attached laminin or fibronectin were stable on hydrogel surface in physiological solution. The modification with collagen and particularly with collagen and laminin or fibronectin allowed the adhesion and growth of mesenchymal stromal cells and astrocytes on the hydrogel surface.","[Brynda, Eduard; Houska, Milan; Kysilka, Jiri; Pradny, Martin; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Brynda, Eduard; Pradny, Martin; Lesny, Petr; Jendelova, Pavla; Michalek, Jiri; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Lesny, Petr; Jendelova, Pavla; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic","Brynda, E (reprint author), Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic.","brynda@imc.cas.cz","Michalek, Jiri/D-7251-2013",null,"Academy of Sciences of the Czech Republic [AA400500507, KAN20670701, 1QS400500558, 309/06/1246, 1A8697-5, AVOZ503905703]","The study was supported by the Grant Agency of the Academy of Sciences of the Czech Republic (contract AA400500507), by the Academy of Sciences of the Czech Republic (contracts KAN20670701 and 1QS400500558), the Grant Agency of the Czech Republic (contract 309/06/1246), and grants 1A8697-5 and AVOZ503905703.",null,15,9,9,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0957-4530",null,null,"J MATER SCI-MATER M","J. Mater. Sci.-Mater. Med.","APR",2009,20,4,null,null,null,null,909,915,null,"10.1007/s10856-008-3625-9",null,7,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","411WK","WOS:000263683900009"]
[null,null,null,null,"J","Vaclavikova, E; Dvorakova, S; Sykorova, V; Bilek, R; Dvorakova, K; Vlcek, P; Skaba, R; Zelinka, T; Bendlova, B",null,null,null,"Vaclavikova, Eliska; Dvorakova, Sarka; Sykorova, Vlasta; Bilek, Radovan; Dvorakova, Katerina; Vlcek, Petr; Skaba, Richard; Zelinka, Tomas; Bendlova, Bela",null,null,"RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest","ENDOCRINE",null,null,"English","Article",null,null,null,null,null,"RET proto-oncogene; RET mutation; Medullary thyroid carcinoma; Hirschsprung's disease; Pheochromocytoma; Genetics","MEDULLARY-THYROID CARCINOMA; MULTIPLE ENDOCRINE NEOPLASIA; GERMLINE MUTATIONS; PRIMARY HYPERPARATHYROIDISM; PROPHYLACTIC THYROIDECTOMY; PROTOONCOGENE MUTATIONS; HIRSCHSPRUNGS-DISEASE; CLINICAL-PRACTICE; TYPE-2; PHEOCHROMOCYTOMA","Activating germline RET mutations are presented in patients with familial medullary thyroid carcinoma (FMTC) and multiple endocrine neoplasia (MEN) types 2A and 2B, whereas inactivating germline mutations in patients with Hirschsprung's disease (HSCR). The aim of this study was to evaluate genotype-phenotype correlations of the frequently discussed Tyr791Phe mutation in exon 13 of the RET proto-oncogene. Screening of three groups of patients was performed (276 families with medullary thyroid carcinoma (MTC), 122 families with HSCR, and 29 patients with pheochromocytoma). We found this mutation in 3 families with apparently sporadic MTC, 3 families with FMTC/MEN2, 1 patient with pheochromocytoma, and 3 families with HSCR. All gene mutation carriers have a silent polymorphism Leu769Leu in exon 13. In three families second germline mutations were detected: Cys620Phe (exon 10) in MEN2A family, Met918Thr (exon 16) in MEN2B family, and Ser649Leu (exon 11) in HSCR patient. Detection of the Tyr791Phe mutation in MEN2/MTC and also in HSCR families leads to the question whether this mutation has a dual character (gain-of-function as well as loss-of-function). A rare case of malignant pheochromocytoma in a patient with the Tyr791Phe mutation is presented. This study shows various clinical characteristics of the frequently discussed Tyr791Phe mutation.","[Vaclavikova, Eliska; Dvorakova, Sarka; Sykorova, Vlasta; Bendlova, Bela] Res Inst Endocrinol, Dept Mol Endocrinol, CR-11694 Prague 1, Czech Republic; [Bilek, Radovan] Res Inst Endocrinol, Dept Proteohormones & Biofactors, CR-11694 Prague, Czech Republic; [Dvorakova, Katerina] Res Inst Endocrinol, Dept Clin Endocrinol, CR-11694 Prague 1, Czech Republic; [Vlcek, Petr] Charles Univ Prague, Fac Med 2, Dept Nucl Med & Endocrinol, Prague, Czech Republic; [Vlcek, Petr; Skaba, Richard] Teaching Hosp Motol, Prague, Czech Republic; [Skaba, Richard] Charles Univ Prague, Dept Pediat Surg, Fac Med 2, Prague, Czech Republic; [Zelinka, Tomas] First Fac Med, Clin Dept Endocrinol & Metab, Dept Med 3, Prague, Czech Republic; [Zelinka, Tomas] Gen Teaching Hosp, Prague, Czech Republic","Vaclavikova, E (reprint author), Res Inst Endocrinol, Dept Mol Endocrinol, Narodni 8, CR-11694 Prague 1, Czech Republic.","evaclavikova@endo.cz",null,null,"GACR 301/06/P425; IGA MH CR NR/9165-3","The study was supported by GACR 301/06/P425 and IGA MH CR NR/9165-3.",null,39,8,8,"HUMANA PRESS INC","TOTOWA","999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA","0969-711X",null,null,"ENDOCRINE","Endocrine","DEC",2009,36,3,null,null,null,null,419,424,null,"10.1007/s12020-009-9242-7",null,6,"Endocrinology & Metabolism","Endocrinology & Metabolism","515VT","WOS:000271501700011"]
[null,null,null,null,"J","Paclt, I; Koudelova, J; Pacltova, D; Kopeckova, M",null,null,null,"Paclt, Ivo; Koudelova, Jitka; Pacltova, Dagmar; Kopeckova, Marta",null,null,"Dopamine beta hydroxylase (DBH) plasma activity in childhood mental disorders","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"dopamine beta hydroxylase; ADHD; child depression; child schizophrenia; noradrenergic system","PLATELET MONOAMINE-OXIDASE; ATTENTION DEFICIT DISORDER; METABOLIZING ENZYMES DBH; PSYCHIATRIC-PATIENTS; CONDUCT DISORDER; SCHIZOPHRENIC-PATIENTS; ENDOGENOUS-DEPRESSION; CEREBROSPINAL-FLUID; GENE POLYMORPHISMS; AFFECTIVE-ILLNESS","BACKGROUND: Developmental study of dopaminergic and noradrenergic systems in child psychiatric disorders are rare. DBH activity is one of noradrenergic biochemical marker that is correlate in Psychiatry to clinical and genetic data. OBJECTIVES: The main aim of the present study was to measure DBH activity at the onset of acute schizophrenia and depressive disorder in children and adolescents without pharmacological treatment and to compare these values with DBH activity in healthy controls. The authors also investigated untreated ADHD children. METHODS: We examined 42 control healthy children, 15 children non-treated with acute schizophrenia, 15 non-treated children with acute depressive disorders and 30 non-treated ADHD children, all in age 7-14. Plasma DBH level was provided by Nagatsu (1972; 1974). Depressed children were reexamined after clinical remission. RESULTS: DBH activity is statistically significantly decreased in non-treated depressive disorder and ADHD in children and adolescents. DBH activity is normalised during antidepressant therapy in child depression. Child schizophrenia patients present with normal DBH activity. CONCLUSION: These results are similar to the results that have been observed in adult patients with schizophrenia and depression and in previous studies of DBH activity in children with ADHD. These results also indicate hypoactivity of the noradrenergic system in children with ADHD and depression.","[Paclt, Ivo; Koudelova, Jitka] Charles Univ Prague, Dept Psychiat, Fac Med 1, Prague 12800 2, Czech Republic; [Pacltova, Dagmar] Dept Gen Practitioner Children & Adolescent, Prague, Czech Republic; [Kopeckova, Marta] Charles Univ Prague, Sch Med 2, Inst Biol & Med Genet, Univ Hosp Motol, Prague 12800 2, Czech Republic","Paclt, I (reprint author), Charles Univ Prague, Dept Psychiat, Fac Med 1, Ke Karlovu 11, Prague 12800 2, Czech Republic.","ivopaclt@seznam.cz",null,null," [NR/95 34/3 MZ]","Supported by grant NR/95 34/3 MZ, CR, 2007-2009.",null,54,7,8,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2009,30,5,null,null,null,null,604,609,null,null,null,6,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","565CJ","WOS:000275266300009"]
[null,null,null,null,"J","Vasakova, M; Sterclova, M; Kolesar, L; Slavcev, A; Pohunek, P; Sulc, J; Striz, I",null,null,null,"Vasakova, Martina; Sterclova, Martina; Kolesar, Libor; Slavcev, Antonij; Pohunek, Petr; Sulc, Jan; Striz, Ilja",null,null,"Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases","RESPIRATORY MEDICINE",null,null,"English","Article",null,null,null,null,null,"Lung fibrosis; Bronchoalveolar lavage fluid; Cytokines; Chemokines; Genetic polymorphism","IDIOPATHIC PULMONARY-FIBROSIS; EXPERIMENTAL HYPERSENSITIVITY PNEUMONITIS; BRONCHOALVEOLAR LAVAGE FLUID; ALVEOLAR MACROPHAGES; CC-CHEMOKINE; ANGIOGENIC ACTIVITY; SARCOIDOSIS; EXPRESSION; PATHOGENESIS; CCL18","Background: The aim of our study is to investigate correlations of T(H)1/T(H)2 cytokine gene polymorphisms and bronchoalveolar Lavage fluid (BALF) cytokine values in interstitial. Lung diseases (ILD). Methods: In 16 sarcoidosis, 7 idiopathic pulmonary fibrosis (IPF) and 8 hypersensitivity pneumonitis (HP) patients we evaluated IL-1 alpha, -1R, -1RA, -2, -4, -4R alpha, -6, -10, -12, IFN-gamma, TGF-beta 1 and TNF-alpha gene polymorphisms in peripheral blood, and MCP-1,MIP-1 alpha, MIP-1 beta, RANTES, ENA-78, FGF, G-CSIF, GM-CSF, IFN-gamma, IL-1 alpha, IL-1RA, IL-1 beta, -2, -4, -5, -6, -8, -10, -17, TNF-alpha, Tpo and VEGF values in BALF. Results: We found higher TNF-alpha values in IL-1R pst 1970 TT homozygotes regardless of diagnosis (p = 0.0126). In the sarcoidosis group IL-4R alpha(+1902)AA and IL-10(-1082)G allele correlated with higher BALF ENA-78 levels (p = 0.0258, p = 0.0230). In the HP group the IL-6 (-174)CG and IL-6(nt565)AG correlated with higher ENA-78 BALF levels (p = 0.0253). In the IPF group the IL-1 beta +3962 CC homozygotes had lower IL-1 PA BALF values (p = 0.046). BALF chemokine values did not differ between ILD subgroups, except for IL-8, which was higher in stage III sarcoidosis patients compared to stage I. Conclusion: Our results show a probable influence of gene polymorphisms, namely IL-4R alpha and IL-10 on ENA-78 BALF levels in sarcoidosis, IL-6 on ENA-78 BALF levels in HP and IL-1-beta on IL-1RA BALF values in the IPF group. The TNF-alpha BALF values correlated with IL-1R pst 1970 gene polymorphisms. (C) 2008 Elsevier Ltd. All rights reserved.","[Vasakova, Martina; Sterclova, Martina] Charles Univ Prague, Univ Thomayer Hosp, Sch Med 1, Dept Resp Dis, Prague 14059 4, Czech Republic; [Kolesar, Libor; Slavcev, Antonij; Striz, Ilja] Inst Clin & Expt Med, Dept Immunol, Prague 14021 4, Czech Republic; [Pohunek, Petr; Sulc, Jan] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Pediat, Prague 15006 5, Czech Republic","Vasakova, M (reprint author), Charles Univ Prague, Univ Thomayer Hosp, Sch Med 1, Dept Resp Dis, Videnska 800, Prague 14059 4, Czech Republic.","martina.vasakova@ftn.cz",null,null,"MHCR [9131-3/2007]","The authors thank Mgr. Jetena Skibova for statistical evaluation of the results. The study is supported by grant MHCR 9131-3/2007.",null,32,6,8,"W B SAUNDERS CO LTD","LONDON","32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND","0954-6111",null,null,"RESP MED","Respir. Med.","MAY",2009,103,5,null,null,null,null,773,779,null,"10.1016/j.rmed.2008.11.006",null,7,"Cardiac & Cardiovascular Systems; Respiratory System","Cardiovascular System & Cardiology; Respiratory System","437CC","WOS:000265462600016"]
[null,null,null,null,"J","Bindu, S; Sanosh, KP; Smetana, K; Balakrishnan, A; Kim, TN",null,null,null,"Bindu, S.; Sanosh, K. P.; Smetana, K.; Balakrishnan, A.; Kim, T. N.",null,null,"An in vivo Evaluation of Ultra-fine Grained Titanium Implants","JOURNAL OF MATERIALS SCIENCE & TECHNOLOGY",null,null,"English","Article",null,null,null,null,null,"Surfaces; Grain size; Titanium; In vivo; Biocompatibility","SEVERE PLASTIC-DEFORMATION; CELL RESPONSE; BIOMEDICAL APPLICATIONS; CORROSION-RESISTANCE; SURFACE-ROUGHNESS; FIBROBLASTS; BIOCOMPATIBILITY; ALLOYS; VITRO; BONE","The present work focuses mainly on an in vivo evaluation of ultra fine grained titanium (UFG-Ti) obtained by severe plastic deformation (SPD). The SPD on, commercially produced Grade 2 titanium (Cp-Ti) resulted in the refinement of the grain size by several orders of magnitude. Polished surfaces having similar roughness from both UFG-Ti and Cp-Ti were prepared. In vitro test revealed the presence of fibronectin, which was involved in the attachment of the cells to the substrate. Phase contrast micrographs showed the highest signal of fibronectin in UFG-Ti, indicating that it is more cytocompatible than Cp-Ti. In vivo tests, by subcutaneous implantation of the metals in the rats showed the better biocompatibility of UFG-Ti over Cp-Ti. The improved biocompatibility of UFG-Ti was attributed to the presence of surface discontinuities (in the form of nano-defects), surface energy, higher wettability, surface stress and stable TiO(2) films, which increased the protein adsorption on the surface.","[Sanosh, K. P.; Balakrishnan, A.; Kim, T. N.] Paichai Univ, Dept Informat & Elect Mat Engn, Taejon 302735, South Korea; [Bindu, S.] Paichai Univ, Dept Life Sci & Genet Engn, Taejon 302735, South Korea; [Smetana, K.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Smetana, K.] Charles Univ Prague, Inst Anat, Fac Med 2, Prague, Czech Republic; [Smetana, K.] Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Kim, TN (reprint author), Paichai Univ, Dept Informat & Elect Mat Engn, Taejon 302735, South Korea.","the_krecian@yahoo.com","kunjalukkal, sanosh/A-3855-2010",null,"Paichai Bio-Medicinal Resources Research Center (RRC)","Paichai Bio-Medicinal Resources Research Center (RRC) was acknowledged for their support.",null,38,4,4,"JOURNAL MATER SCI TECHNOL","SHENYANG","72 WENHUA RD, SHENYANG 110015, PEOPLES R CHINA","1005-0302",null,null,"J MATER SCI TECHNOL","J. Mater. Sci. Technol.","JUL",2009,25,4,null,null,null,null,556,560,null,null,null,5,"Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering","Materials Science; Metallurgy & Metallurgical Engineering","480ZE","WOS:000268775200027"]
[null,null,null,null,"J","Brabec, P; Sufliarsky, J; Linke, Z; Plank, L; Mrhalova, M; Pavlik, T; Klimes, D; Gregor, J",null,null,null,"Brabec, P.; Sufliarsky, J.; Linke, Z.; Plank, L.; Mrhalova, M.; Pavlik, T.; Klimes, D.; Gregor, J.",null,"GIST Registry Investigators","A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"Gastrointestinal stromal tumor; registry; epidemiology; incidence; survival; risk category","GIST; DIAGNOSIS; KIT","Due to problems with identification and an incomplete understanding on the gastrointestinal stromal tumors (GIST) before 2001, there has been a lack of comprehensive long-term population-based studies on GIST epidemiology at present date. We used data from the online registry of Czech and Slovak GIST patients (http://gist.registry.cz/), which has been compiled and maintained since 2006 and involves patients diagnosed from the year 2000. 278 patients were included in this study. Most of the tumors fell into the high-risk category (58.7%), followed by the intermediate (21.4%), low (16.6%) and very low (3.3%) categories. Locations other than the small intestine and stomach had significantly higher contribution of high-risk tumors. The median time of overall Survival was 93.2 months, 5-year relative survival was 78.3% overall, 71.9% for patients with high-risk tumors, 91.1% for intermediate patients, and 91.9% for patients from the low- and very low-risk category. The annual crude incidence between the years 2001-2005 was 0.52 cases per 100,000 inhabitants. The annual European ASR and World ASR were 0.44 and 0.31 per 100,000 inhabitants, respectively. Presented data generally correspond to the whole-population studies recently published, including actual data on epidemiology, clinical characteristics, and survival of patients. The registry helps in improving GIST diagnostics, knowledge about the properties and behaviour of tumors, communication among physicians, and, last but not least, therapeutical options and results.","[Brabec, P.; Pavlik, T.; Klimes, D.; Gregor, J.] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic; [Sufliarsky, J.] Natl Oncol Inst, Clin Internal Med, Bratislava, Slovakia; [Linke, Z.; Mrhalova, M.] Fac Hosp Motol, Radiotherapeut Oncol Dpt, Prague, Czech Republic; [Plank, L.] Martin Fac Hosp, Dpt Pathol Anat, Martin, Slovakia","Gregor, J (reprint author), Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic.","gregor@iba.muni.cz",null,null,"Novartis","This work was supported by the Novartis education grant. Authors thank all centers involved in the GIST project for their cooperation and data colection.",null,12,4,4,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2009,56,5,null,null,null,null,459,464,null,"10.4149/neo_2009_05_459",null,6,"Oncology","Oncology","488EY","WOS:000269333200014"]
[null,null,null,null,"J","Gebousky, P; Karny, M; Krizova, H; Wald, M",null,null,null,"Gebousky, Petr; Karny, Miroslav; Krizova, Hana; Wald, Martin",null,null,"Staging of upper limb lymphedema from routine lymphoscintigraphic examinations","COMPUTERS IN BIOLOGY AND MEDICINE",null,null,"English","Article",null,null,null,null,null,"Quantitative lymphoscintigraphy; Secondary lymphedema of upper limbs; Staging; Bayesian evaluation; Probabilistic mixtures","CANCER-RELATED LYMPHEDEMA; BREAST-CANCER; RADIONUCLIDE LYMPHOSCINTIGRAPHY; DIAGNOSIS","Secondary lymphedema of upper limbs, a frequent complication after a breast cancer therapy, can be successfully treated only when diagnosed at an early, ideally latent, stage. Lymphoscintigraphy is a promising candidate to this purpose. A slow lymphatic dynamics of upper limbs allows. however, a routine collection at most three images reflecting it. This makes an exploitation of lymphoscintigraphy to early-stage diagnosis a complex task. Recently, a Bayesian methodology extracting diagnostic information from the available sparse data has been developed. It properly detects lymphedema occurrence but not a desirable disease staging. The present paper proposes Bayesian diagnostic processing of lymphoscintigraphic and routine clinical data. Its staging ability was tested on diagnostic data of 88 women at the age of 39-84 years (60.2 +/- 10.4) with a suspicion of unilateral secondary lymphedema of upper limbs caused by a breast cancer treatment. Less than 20 of them had simply detectable disease stages. Information about accumulation dynamics of the lymphatic system contained in lymphoscintigraphic images was quantified via estimation of a simplified accumulation model [P. Gebousky, M. Karny, A. Quinn, Lymphoscintigraphy of upper limbs: a Bayesian framework. in: J.M. Bernardo, M.J. Bayarri, J.O. Berger (Eds.), Bayesian Statistics, vol. 7, University Press, Oxford, 2003, pp. 543-552]. The sole use of this approach, referred as \"Bayesian quantitative lymphoscintigraphy\", was found insufficient for a finer staging of the disease to typical categories (healthy, latent, reversible, spontaneously irreversible, elephantiasis). For this reason, the results of Bayesian quantitative lymphoscintigraphy were attached to routinely available qualitative lymphoscintigraphic inspection and clinical data. These combined data were modelled by normal probabilistic mixtures. Their Bayesian estimates were used for a computerized disease staging. The resulting model predicts expert's conclusions on the presence of a lymphedema in 95% cases. A finer staging is successful in 85% cases of suspicious limbs. Model cross-validation and a closer look on patients' data indicate that the combined data are still insufficiently informative. it calls for the further improvements of the inspection methods. Even under the current inspection conditions, the proposed processing provides clinicians a reliable quantitative \"second\" opinion on the disease staging. (c) 2008 Elsevier Ltd. All rights reserved.","[Gebousky, Petr; Karny, Miroslav] Acad Sci Czech Republic, Inst Informat Theory & Automat, Dept Adapt Syst, CR-18208 Prague 8, Czech Republic; [Krizova, Hana] Charles Univ Prague, Inst Nucl Med, Fac Med 1, Prague 12000 2, Czech Republic; [Wald, Martin] Univ Hosp Motol, Surg Clin, Prague 15006 5, Czech Republic","Karny, M (reprint author), Acad Sci Czech Republic, Inst Informat Theory & Automat, Dept Adapt Syst, POB 18, CR-18208 Prague 8, Czech Republic.","school@utia.cas.cz",null,null,"MSMT CR [2C06001, 1M0572]","This research was supported by MSMT CR by Grants 2C06001 and 1M0572.",null,26,4,4,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0010-4825",null,null,"COMPUT BIOL MED","Comput. Biol. Med.","JAN",2009,39,1,null,null,null,null,1,7,null,"10.1016/j.compbiomed.2008.10.003",null,7,"Biology; Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Mathematical & Computational Biology","Life Sciences & Biomedicine - Other Topics; Computer Science; Engineering; Mathematical & Computational Biology","407YD","WOS:000263399300001"]
[null,null,null,null,"J","Vesely, F; Novotny, K; Sosna, A",null,null,null,"Vesely, F.; Novotny, K.; Sosna, A.",null,null,"Heterotopic Excessive Wear Granuloma Mistaken for an Aneurysm of the External Iliac Artery","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"revision total hip arthroplasty; vascular injury; false aneurysm; polyethylene granuloma","TOTAL HIP-ARTHROPLASTY; FALSE ANEURYSM; FEMORAL-ARTERY","Reimplantation of a total hip arthroplasty (THA) with excessive heterotopic polyethylene granuloma is reported. An 84-year-old woman, who had undergone THA reimplantation on the right side 4.5 years previously, was indicated for revision surgery due to aseptic failure of the acetabular component. Pre-operative examination revealed a pulsating mass below the right inguinal ligament that raised the suspicion of a pseudoaneurysm of the external iliac artery. Because of this suspected late complication of the first revision arthroplasty, surgical exploration was indicated by the vascular surgeon prior the second reimplantation. A CT-scan showed a large mass attached to a preserved lumen of the external iliac artery, and this was diagnosed by the vascular surgeon as a pseudoaneurysm. However, no pseudoaneurysm was found by a vascular surgery procedure, and the large mass ventrally extending the external iliac artery appeared to be a large polyethylene granuloma well enveloped in a fibrous pseudocapsula. The granuloma was removed and the wound sutured. Twelve days later, revision total hip arthroplasty and acetabular reconstruction were successfully carried out","[Vesely, F.; Sosna, A.] LF UK, I Ortoped Klin 1, Prague 15006 5, Czech Republic; [Novotny, K.] FN Motol, Kardiochirurg Klin, Prague, Czech Republic","Vesely, F (reprint author), LF UK, I Ortoped Klin 1, Uvalu 84, Prague 15006 5, Czech Republic.","filipvesely@centrum.cz",null,null,null,null,null,15,3,3,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2009,76,6,null,null,null,null,509,512,null,null,null,4,"Orthopedics","Orthopedics","539FC","WOS:000273238000010"]
[null,null,null,null,"J","Acharya, S; Banerjee, D; Fronek, J; Fossati, N; Chemla, ES",null,null,null,"Acharya, Sanjukta; Banerjee, Debasish; Fronek, Jiri; Fossati, Nicoletta; Chemla, Eric S.",null,null,"High-Output Cardiac Failure Following Insertion of Right Femoral Artery to Left Femoral Vein PTFE Graft for Haemodialysis: A Case Report","SEMINARS IN DIALYSIS",null,null,"English","Article",null,null,null,null,null,null,"FISTULA; ACCESS; FLOW","Arteriovenous grafts used for hemodialysis can produce high-output cardiac failure as a result of shunting of blood through the dialysis access. The following case demonstrates that the problem can occur shortly after graft formation and improved with graft ligation. It caused haemodynamic compromise because of previously undiagnosed, underlying valvular heart disease. It also caused a diagnostic difficulty in the immediate postoperative period as it was mistaken for postsurgical hemorrhage.","[Acharya, Sanjukta; Banerjee, Debasish; Fronek, Jiri; Chemla, Eric S.] St Georges Hosp NHS Trust, Renal & Transplantat Unit, London SW17 0QT, England; [Fossati, Nicoletta] St Georges Hosp NHS Trust, Dept Anaesthesia, London SW17 0QT, England; [Fronek, Jiri] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Banerjee, D (reprint author), St Georges Hosp NHS Trust, Renal & Transplantat Unit, London SW17 0QT, England.","Debasish.Banerjee@stgeorges.nhs.uk",null,null,null,null,null,4,3,3,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0894-0959",null,null,"SEMIN DIALYSIS","Semin. Dial.","JUL-AUG",2009,22,4,null,null,null,null,462,464,null,"10.1111/j.1525-139X.2009.00612.x",null,3,"Urology & Nephrology","Urology & Nephrology","487HW","WOS:000269263600030"]
[null,null,null,null,"J","Sebesta, P; Stulik, J; Vyskocil, T; Kryl, J",null,null,null,"Sebesta, P.; Stulik, J.; Vyskocil, T.; Kryl, J.",null,null,"Cauda Equina Syndrome after Elective Lumbar Spine Surgery","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"spinal surgery; arachnoiditis; complication; cauda equina syndrome","SURGICAL-TREATMENT; ARACHNOIDITIS; LAMINECTOMY; ADHESION; MRI","In this case study, three patients are presented who had incomplete cauda equina syndrome following elective lumbar spine surgery for degenerative disease. In all patients, the neurological symptoms developed due to post-operative arachnoiditis. Its aetiology, pathogenesis and diagnostics are discussed, as well as the methods of prevention and therapy which are still limited and often not beyond experimentation.","[Sebesta, P.; Stulik, J.; Vyskocil, T.; Kryl, J.] FN Motol, Spondylochirurg Oddeleni, Prague 15006 5, Czech Republic; [Sebesta, P.; Stulik, J.; Vyskocil, T.; Kryl, J.] LF UK, Chirurg Klin 1 3, Prague, Czech Republic; [Stulik, J.] LF UK, Ortoped Klin Deti & Dospelych 2, Prague, Czech Republic","Sebesta, P (reprint author), FN Motol, Spondylochirurg Oddeleni, Uvalu 84, Prague 15006 5, Czech Republic.","sebestapetr@seznam.cz",null,null,null,null,null,19,2,2,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2009,76,6,null,null,null,null,505,508,null,null,null,4,"Orthopedics","Orthopedics","539FC","WOS:000273238000009"]
[null,null,null,null,"J","Hackel, M; Masopust, V; Bojar, M; Ghaly, Y; Horinek, D",null,null,null,"Haeckel, Martin; Masopust, Vaclav; Bojar, Martin; Ghaly, Youssef; Horinek, Daniel",null,null,"The Epidural Steroids in the prevention of epidural fibrosis: MRI and clinical findings","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"epidural steroids; epidural fibrosis; prevention; discectomy; pain","BACK SURGERY SYNDROME; LUMBAR DISC SURGERY; NUCLEUS PULPOSUS; INTERVERTEBRAL DISC; METHYLPREDNISOLONE; CORTICOSTEROIDS; HERNIATION; NERVE; PAIN; ARACHNOIDITIS","BACKGROUND: Epidural fibrosis (EF) represents a frequent and poorly manageable complication of lumbar disk surgery. OBJECTIVES: To investigate the influence of perioperative Epidural Steroid (ES) application on the development of EF. METHODS: One hundred and seventy eight patients underwent L4/5 or L5/S1 discectomy. The study group receiving ES comprised of eighty five patients, and a further control group comprising eighty two patients received a placebo. At a 12 month follow-up, all subjects underwent contrast magnet resonance imaging of the lumbosacral spine. One hundred and sixty seven patients filled in a predetermined questionnaire containing the Visual Analogue Scale (VAS; pain scale) during the first postoperative days and 12 months after. Intergroup differences were analysed and a correlation between the extent of EF and VAS was examined. RESULTS: The groups did not differ regarding the extent of EF. There was a statistically significant correlation between the degree of fibrosis and VAS (p<0.05). However, there was no significant difference in subjective pain assessment between both groups 12 months postoperatively. The application of ES did not influence their return to work. Patients receiving ES experienced less pain on the first and third days after surgery. The average hospital stay after surgery was shorter in the steroid treated group (4.5 days) compared to 5.2 days in the control group (p<0.05). CONCLUSIONS: The application of ES did not prove to be useful in the prevention of Failed Back Surgery Syndrome and epidural scar formation. Postoperative pain was decreased in the steroid treated group during the first postoperative week, but not 12 months postoperatively.","[Haeckel, Martin; Masopust, Vaclav; Horinek, Daniel] Charles Univ Prague, Cent Mil Hosp, Fac Med 1, Dept Neurosurg, Prague 16000 6, Czech Republic; [Bojar, Martin] Univ Hosp Motol, Sch Med 2, Dept Neurol, Prague, Czech Republic; [Horinek, Daniel] Univ Marburg, Fac Med, Dept Neurosurg, D-35033 Marburg, Germany; [Ghaly, Youssef] Charles Univ Prague, Fac Med 2, Lab Neuroirnaging Res, Inst Pathol Physiol, Prague 15800 5, Czech Republic","Horinek, D (reprint author), Charles Univ Prague, Cent Mil Hosp, Fac Med 1, Dept Neurosurg, Vojenske Nemocnice 1200, Prague 16000 6, Czech Republic.","daniel.horinek@uvn.cz",null,null,"IGA - MZ [NR-8848]","The paper is supported by a grant from IGA - MZ (NR-8848).",null,24,2,2,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.","MAR",2009,30,1,null,null,null,null,51,55,null,null,null,5,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","436PR","WOS:000265426800013"]
[null,null,null,null,"J","Jirickova, A; Sulc, J; Pohunek, P; Kittnar, O; Dohnalova, A; Kofranek, J",null,null,null,"Jirickova, A.; Sulc, J.; Pohunek, P.; Kittnar, O.; Dohnalova, A.; Kofranek, J.",null,null,"Prevalence of Tidal Expiratory Flow Limitation in Preschool Children with and without Respiratory Symptoms: Application of the Negative Expiratory Pressure (NEP) Method","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Preschool children; Respiratory disorders; Expiratory flow limitation; Negative expiratory pressure technique","OBSTRUCTIVE PULMONARY-DISEASE; DYNAMIC HYPERINFLATION; CYSTIC-FIBROSIS; CHRONIC DYSPNEA; SLEEP-APNEA; ORTHOPNEA; VOLUME; COPD; BRONCHODILATOR; GENIOGLOSSUS","Negative expiratory pressure (NEP) applied at the mouth during tidal expiration provides a non-invasive method for detecting expiratory flow limitation. Forty-two children were studied, i.e. 25 children with different respiratory symptoms (R) and 17 without any respiratory symptoms (NR). Children were examined without any sedation. A preset NEP of -5 cm H(2)O was applied; its duration did not exceed duration of tidal expiration. A significance of FL was judged by determining of a flow-limited range (in % of tidal volume). FL was found in 48 % children of R group. No patient of the NR group elicited FL (P<0.001 R vs. NR). The frequency of upper airway collapses was higher in R group (12 children) than in NR group (5 children). In conclusion, a high frequency of tidal FL in the R group was found, while it was not present in NR group. A relatively high frequency of expiratory upper airway collapses was found in both groups, but it did not differ significantly. NEP method represents a reasonable approach for tidal flow limitation testing in non-sedated preschool children.","[Jirickova, A.] Charles Univ Prague, Fac Med 1, Inst Physiol, Dept Physiol, Prague 12800 2, Czech Republic; [Sulc, J.; Pohunek, P.] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 12800 2, Czech Republic; [Sulc, J.; Pohunek, P.] Charles Univ Prague, Univ Hosp Motol, Prague 12800 2, Czech Republic; [Kofranek, J.] Charles Univ Prague, Fac Med 1, Dept Pathophysiol, Prague 12800 2, Czech Republic","Jirickova, A (reprint author), Charles Univ Prague, Fac Med 1, Inst Physiol, Dept Physiol, Albertov 5, Prague 12800 2, Czech Republic.","adriana.jirickova@lf1.cuni.cz",null,null,"Czech Ministry of Health, the Research Initiative [NR 9131-3]; Czech Ministry of Health [AV CR 1ET201210527, MZO 00064203 / 6404]","The authors wish to thank Marie Spirova and Sona Hornickova for their technical assistance. The study was supported by the Grant NR 9131-3 of the Int. Grant Agency of the Czech Ministry of Health, the Research Initiative MSM - 111100008, by the Grant AV CR 1ET201210527 and by the Research Project No. MZO 00064203 / 6404 of the Czech Ministry of Health.",null,40,2,2,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,3,null,null,null,null,373,382,null,null,null,10,"Physiology","Physiology","472JC","WOS:000268125600008"]
[null,null,null,null,"J","Sobotkova, V; Blatny, M; Jelinek, M; Hrdlicka, M; Urbanek, T",null,null,null,"Sobotkova, Veronika; Blatny, Marek; Jelinek, Martin; Hrdlicka, Michal; Urbanek, Tomas",null,null,"Typology of antisocial behavior in early adolescence and its relation to further forms of risk behavior","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"antisocial behavior; typology; substances; early adolescence","NO SAFE HAVEN; VIOLENCE EXPOSURE; URBAN YOUTH; PERSONALITY; CHILDREN","The study deals with antisocial behavior of adolescents in urban areas, its typology and its relation to substances. The sample was formed by pupils of the seventh and ninth classes of primary schools or their equivalents on the other types of schools in regional capitals of the Czech Republic. The sample was gained due to the international SAHA project and consisted of 2973 persons. The twelve years old cohort consisted of 1447 persons (54% of girls) and the fourteen years old cohort consisted of 1526 persons (53% of girls). By the means of non-hierarchic cluster analysis (k-means) of items of antisocial behavior scale, four types of persons were identified. The typology was validated by help of relation to substances (cigarettes, alcohol, marihuana, and hard drugs). The higher was the measure of antisocial behavior showed by the persons, the more the persons reported the use of substances.","[Sobotkova, Veronika; Blatny, Marek; Jelinek, Martin; Urbanek, Tomas] Psychol Ustav AV CR, Brno 60200, Czech Republic; [Hrdlicka, Michal] FN Motol, Detska Psychiat Klin UK, Prague, Czech Republic","Sobotkova, V (reprint author), Psychol Ustav AV CR, Veveri 97, Brno 60200, Czech Republic.","vero-nika@psu.cas.cz",null,null,null,null,null,44,2,2,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X","1804-6436",null,"CESK PSYCHOL","Cesk. Psychol.",null,2009,53,5,null,null,null,null,428,440,null,null,null,13,"Psychology, Multidisciplinary","Psychology","523FG","WOS:000272056900002"]
[null,null,null,null,"J","Sedlackova, J; Vondracek, P; Hermanova, M; Zamecnik, J; Hruba, Z; Haberlova, J; Kraus, J; Marikova, T; Hedvicakova, P; Vohanka, S; Fajkusova, L",null,null,null,"Sedlackova, Jana; Vondracek, Petr; Hermanova, Marketa; Zamecnik, Josef; Hruba, Zuzana; Haberlova, Jana; Kraus, Josef; Marikova, Tat'ana; Hedvicakova, Petra; Vohanka, Stanislav; Fajkusova, Lenka",null,null,"Point mutations in Czech DMD/BMD patients and their phenotypic outcome","NEUROMUSCULAR DISORDERS",null,null,"English","Article",null,null,null,null,null,"Duchenne muscular dystrophy; DMD; BMD; Point mutation; Nonsense mediated mRNA decay","MESSENGER-RNA DECAY; DUCHENNE MUSCULAR-DYSTROPHY; LGMD2A PATIENTS; GENE; EXPRESSION; TRANSCRIPTS; SEQUENCES; DELETIONS; DISEASE; MUSCLE","Duchenne and Becker muscular dystrophies (DMD/BMD) are associated with mutations in the DMD gene. We determined the mutation status of 47 patients with dystrophinopathy without deletion or duplication in the DMD gene by screening performed by reverse transcription-PCR, protein truncation test, and DNA sequencing. We describe three patients with a mutation creating a premature termination codon (p.E55X, p.E1110X, and p.S3497PfsX2) but with a mild phenotype, which present three different ways of rescuing the DMD phenotype. In one patient we detected the insertion of a repetitive sequence AluYa5 in intron 56, which led to skipping of exon 57. Further, using quantitative analysis of DMD mRNA carrying various mutated alleles, we examine levels of mRNA degradation due to nonsense mediated mRNA decay. The quantity of dystrophin mRNA is different depending on the presence of a mutation leading to a premature termination codon, and position of the analysed mRNA region with respect to its 5' end or 3' end. Average relative amounts of DMD mRNAs carrying a premature termination codon is 48% and 17%, when using primers amplifying the 5' and 3' cDNA regions, respectively. (C) 2009 Elsevier B.V. All rights reserved.","[Sedlackova, Jana; Hruba, Zuzana; Fajkusova, Lenka] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, CZ-62500 Brno, Czech Republic; [Sedlackova, Jana; Fajkusova, Lenka] Masaryk Univ, Fac Sci, Dept Funct Genom & Prote, Inst Expt Biol, CS-61137 Brno, Czech Republic; [Vondracek, Petr] Univ Hosp Brno, Dept Child Neurol, Brno, Czech Republic; [Hermanova, Marketa] Univ Hosp Brno, Inst Pathol, Brno, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Zamecnik, Josef; Haberlova, Jana; Kraus, Josef; Marikova, Tat'ana; Hedvicakova, Petra] Univ Hosp Motol, Prague, Czech Republic; [Haberlova, Jana; Kraus, Josef] Charles Univ Prague, Dept Paediat Neurol, Fac Med 2, Prague, Czech Republic; [Marikova, Tat'ana; Hedvicakova, Petra] Charles Univ Prague, Inst Biol & Med Genet, Fac Med 2, Prague, Czech Republic; [Vohanka, Stanislav] Univ Hosp Brno, Neurol Clin, Brno, Czech Republic","Fajkusova, L (reprint author), Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Cernopolni 9, CZ-62500 Brno, Czech Republic.","lfajkusova@fnbrno.cz","Fajkusova, Lenka/E-1636-2012",null,"MSMT [LC06023];  [MSM0021622415];  [VZ FNM 00064203]","This work was supported by the project MSMT LC06023, and institutional support MSM0021622415 and VZ FNM 00064203.",null,24,1,2,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0960-8966",null,null,"NEUROMUSCULAR DISORD","Neuromusc. Disord.","NOV",2009,19,11,null,null,null,null,749,753,null,"10.1016/j.nmd.2009.08.011",null,5,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","522SZ","WOS:000272020400002"]
[null,null,null,null,"J","Zvarova, J; Hanzlicek, P; Nagy, M; Preckova, P; Zvara, K; Seidl, L; Bures, V; Subrt, D; Dostalova, T; Seydlova, M",null,null,null,"Zvarova, Jana; Hanzlicek, Petr; Nagy, Miroslav; Preckova, Petra; Zvara, Karel; Seidl, Libor; Bures, Vit; Subrt, Daniel; Dostalova, Tatjana; Seydlova, Michaela",null,null,"Biomedical Informatics Research for Individualized Life-long Shared Healthcare","BIOCYBERNETICS AND BIOMEDICAL ENGINEERING",null,null,"English","Article",null,null,null,null,null,"electronic health record; semantic interoperability; dentistry; cardiology","RECORD; STORAGE","Aim: We developed a multimedia electronic health record MUDR and introduced it to the field of cardiology and dental medicine. We developed a graphical component called DentCross supported by automatic speech recognition connected to an electronic health record (EHR) in dentistry. Platform for semantic interoperability was designed utilizing international communication standards. Methods: Our approach consisted of three main steps. 1) Development of the multimedia distributed electronic health record MUDR, 2) Development of the interactive graphical DentCross component with automatic speech recognition connected to electronic health record in dentistry. 3) Development of minimal data model for cardiology (MDMC) as the base for studying semantic interoperability issues. Results: Dental health data for more than 100 patients were collected using EHR with the DentCross component, the DentCross component was used in forensic dentistry and for e-learning activities. We found that approximately 85% of the MDMC concepts are included in at least one classification system. More than 50% of MDMC are included in the SNOMED Clinical Terms. Conclusions: Structured representation of information in EHR and use of international standards, classifications and nomenclatures is a necessary prerequisite to semantic interoperability issues as well as to an automatic speech recognition.","[Zvarova, Jana; Hanzlicek, Petr; Nagy, Miroslav; Preckova, Petra] Inst Comp Sci AS CR, Dept Med Informat, EuroMISE Ctr, Prague 18205 8, Czech Republic; [Zvara, Karel; Seidl, Libor] EuroMISE Sro, Prague, Czech Republic; [Bures, Vit; Subrt, Daniel] Med Software Sro, Plzen, Czech Republic; [Dostalova, Tatjana; Seydlova, Michaela] Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague, Czech Republic; [Dostalova, Tatjana; Seydlova, Michaela] Univ Hosp Motol, Prague, Czech Republic","Zvarova, J (reprint author), Inst Comp Sci AS CR, Dept Med Informat, EuroMISE Ctr, Vodarenskou Vezi 2, Prague 18205 8, Czech Republic.","jana.zvarova@euromise.cz","Seidl, Libor/H-3868-2012; Zvarova, Jana/B-5196-2014",null,"Academy of Sciences of the Czech Republic [1ET200300413]","This work was supported by the project 1ET200300413 of the Academy of Sciences of the Czech Republic.",null,22,1,1,"PWN-POLISH SCIENTIFIC PUBL","WARSAW","UL KS TROJDENA 4, WARSAW, 02-109, POLAND","0208-5216",null,null,"BIOCYBERN BIOMED ENG","Biocybern. Biomed. Eng.",null,2009,29,2,null,null,null,null,31,41,null,null,null,11,"Engineering, Biomedical","Engineering","457AY","WOS:000266898400005"]
[null,null,null,null,"J","Vareka, I; Varekova, R; Lehnert, M; Kolar, P; Stejskal, D",null,null,null,"Vareka, Ivan; Varekova, Renata; Lehnert, Michal; Kolar, Pavel; Stejskal, David",null,null,"THE EFFECT OF FOOT TYPE AND LATERALITY ON ANKLE SPRAIN IN ELITE FEMALE VOLLEYBALL ATHLETES","KINESIOLOGY",null,null,"English","Article",null,null,null,null,null,"ankle injury; Root model; biomechanics","RISK-FACTORS; INJURY; REARFOOT; FOREFOOT; ASSOCIATION; ALIGNMENT; SYSTEM; VARUS; PAIN","Volleyball is a team game with a high incidence of ankle sprain. The purpose of our research was to investigate the ankle sprain history and incidence in elite female volleyball athletes according to the Root functional foot type and laterality. The additional aims were to investigate the foot type prevalence and the effect of age on ankle sprain incidence. Sixty-two elite female volleyball athletes (17-25 years, mean=20.7, SD=2.03) were investigated by an experienced rehabilitation physician for functional foot type according to Root, while the personal history of ankle sprain and laterality were estimated based on asking questions. The obtained data of ankle sprain cases in the subjects did not have the normal distribution (Kolmogorov-Smirnov, d=.26, p<.01). Also, the Spearman correlation and the Wilcoxon and Kruskall-Wallis tests were used to find out the significance of each case. Almost 68% of the subjects had a history of ankle sprain (1-13 cases per person, 2 cases on average). Ankle sprain has been confirmed as a very common injury in volleyball athletes. Spearman's correlation did not show the significance of age (Spearman's correlation, r1=-.1873; p<.05) in spite of the exclusion of three subjects with extremely high ankle sprain incidence (ASI) (r2=-.1656; p<.05). Laterality was not significant, either. (Wilcoxon test, p=.07). The findings supported previously described differences in the prevalence of various functional foot types - compensated rearfoot varus and flexible forefoot vaigus were the most common ones (56.6% and 27.4%, respectively), compensated forefoot varus, rigid forefoot vaigus and neutral foot were relatively rare (8.1%, 4.8% and 3.3%, respectively). Subjects with the two most common foot types had an obviously higher average incidence of ankle sprain (2.4 and 2.0, respectively) than the other ones (.8, .7 and .5, respectively), but without significance (Kruskall-Wallis, p=.44). The non-significance of foot type effect on ankle sprain frequency was questionable due to the very low prevalence or lack of other functional foot types with known empirical evidence of increased ankle sprain risk.","[Vareka, Ivan] Palacky Univ, Dept Physiotherapy, Fac PE, Olomouc 77111, Czech Republic; [Vareka, Ivan] Spa Luhacovice Inc, Luhacovice, Czech Republic; [Varekova, Renata] Palacky Univ, Dept Funct Anthropol & Physiol, Fac PE, Olomouc 77111, Czech Republic; [Lehnert, Michal] Palacky Univ, Dept Anthropomotor & Sport Training, Fac PE, Olomouc 77111, Czech Republic; [Kolar, Pavel] Charles Univ Prague, Fac Med, Dept Rehabil & Exercise, Prague, Czech Republic; [Stejskal, David] Cent Moravian Hosp Cty, Dept Lab Med, Prostejov, Czech Republic; [Stejskal, David] Cent Moravian Hosp Cty, Metab Outpatient Ctr, Prostejov, Czech Republic; [Stejskal, David] Palacky Univ, Dept Med Chem & Biochem, Fac Med & Dent, Olomouc 77111, Czech Republic","Vareka, I (reprint author), Palacky Univ, Dept Physiotherapy, Fac PE, Tr Miru 115, Olomouc 77111, Czech Republic.","ivanvareka@seznam.cz",null,null,null,null,null,29,0,0,"UNIV ZAGREB, FAC KINESIOLOGY","ZAGREB","HORVACANSKI ZAVOJ 15, ZAGREB, 10000, CROATIA","1331-1441",null,null,"KINESIOLOGY","Kinesiology","DEC",2009,41,2,null,null,null,null,164,171,null,null,null,8,"Rehabilitation; Sport Sciences","Rehabilitation; Sport Sciences","549PG","WOS:000274065500006"]
[null,null,null,null,"J","Dzupova, O; Polivkova, S; Smiskova, D; Gabrielova, A; Benes, J",null,null,null,"Dzupova, O.; Polivkova, S.; Smiskova, D.; Gabrielova, A.; Benes, J.",null,null,"Etiology and Epidemiology of Bacterial Meningitis in Adults","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"bacterial meningitis; etiological agent; fatal outcome; sequelae","PROGNOSTIC-FACTORS; PNEUMOCOCCAL MENINGITIS; RISK-FACTORS; COMPLICATIONS; SPECTRUM","Objectives: The aim of the presented part of study was to describe epidemiological characteristics of adult bacterial meningitis and detect the prognostic significance of selected pathogens for the risk of fatal outcome and sequelae. Material and methods: Prospective observational longitudinal study of adult patients treated for bacterial meningitis at a specialized unit. Anamnestic, clinical and laboratory data, complications and outcomes were recorded. Etiological agent was identified in the cerebrospinal fluid and blood by means of culture, polymerase chain reaction and latexagglutination. Results: From 1997-2006, 296 adult patients (128 women, 168 men) with acute bacterial meningitis, age range 16-85 years and median age 51 years, were hospitalized. The most frequent pathogens were Streptococcus pneumoniae in 27.7% and Neisseria meningitidis in 25.4% of patients. Listeria monocytogenes was the pathogen in 7.1%, staphylococci in 6.1% and gramnegative rods in 5.4% of patients. Etiology was not identified in 24% of patients. Pneumococci and gramnegative rods carried the highest case fatality ratio. Fifty-nine patients died (20%) and 54 patients (18%) survived with permanent sequelae. Gramnegative rods proved to be a predictor of risk of death and meningococci were conversely predictor of low risk of death. Multivariant analysis did not confirm any pathogen as predictive for risk of sequelae; meningococci and unidentified etiology were associated with less sequelae. Conclusion: Bacterial meningitis remains to carry significant morbidity and case fatality ratio. S. pneumoniae and N. meningitidis were the most frequent pathogens in the current study although many other bacterial species were identified. It is advisable to increase the etiology identification rate by means of rigorous sending of cerebrospinal fluid and blood for culture and enhanced availability of molecular diagnostic techniques for detection of all potential agents of meningitis.","FN Na Bulovce, Prague, Czech Republic; [Dzupova, O.; Polivkova, S.; Benes, J.] Charles Univ Prague, Lekarska Fak 3, Infekcni Klin 2, CR-11636 Prague 1, Czech Republic; [Smiskova, D.] Charles Univ Prague, Lekarska Fak 3, Infekcni Klin 1, CR-11636 Prague, Czech Republic","Dzupova, O (reprint author), Infekcni Klin 3 LF UK, Budinova 2, Prague 18081 8, Czech Republic.","olga.dzupova@If3.cuni.cz",null,null,null,null,null,22,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,4,null,null,null,null,331,335,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","486HZ","WOS:000269188200006"]
[null,null,null,null,"J","Latta, J; Ehler, E; Zamecnik, J",null,null,null,"Latta, J.; Ehler, E.; Zamecnik, J.",null,null,"Acquired Neuromyotonia with Minor Central Symptoms and Antibodies against Voltage-Gated Potassium Channels - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"neuromyotonia; Morvan's disease; voltage-gated potassium channels; arrhythmia; myokymia; fasciculation","CENTRAL-NERVOUS-SYSTEM; MORVANS-SYNDROME; DISCHARGES; EMG","A 52-year-old still healthy man developed, over several weeks, a myalgic syndrome with fatigue and muscle weakness, tingling and fasciculation, predominantly in the lower limbs. Such disorders caused inability to walk independently. Upon admission, the clinical findings included muscle weakness and muscle stiffness with tenderness, autonomic symptoms with sweating, intermittent tachycardia, constipation, and also personality and behavioral changes with insomnia and late-night confusion. The electromyography showed a persisting activity with discharges, which were provoked by voluntary activity, and in particular by the stimulation of motor fibres. The patient was treated with carbamazepine and methylprednisolone. Hypertonia, myalgia and central symptoms subsided. At that stage, the results came back with highly elevated antibodies against voltage-gated potassium channels in serum. However, the patient suddenly died of malignant arrhythmia.","[Latta, J.; Ehler, E.] Pardub Krajska Nemocnice AS, Neurol Klin, Pardubice 53203, Czech Republic; [Zamecnik, J.] UK 2 LF & FN Motol, Ustav Patol & Mol Med, Prague, Czech Republic","Latta, J (reprint author), Pardub Krajska Nemocnice AS, Neurol Klin, Kyjevska 44, Pardubice 53203, Czech Republic.","janci82@gmail.com",null,null,null,null,null,16,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,4,null,null,null,null,373,377,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","486HZ","WOS:000269188200013"]
[null,null,null,null,"J","Plevova, P; Walczyskova, S; Jeziskova, I; Jurckova, N; Krepelova, A; Puchmajerova, A; Pavlikova, K; Foretova, L; Zapletalova, J; Silhanova, E",null,null,null,"Plevova, P.; Walczyskova, S.; Jeziskova, I.; Jurckova, N.; Krepelova, A.; Puchmajerova, A.; Pavlikova, K.; Foretova, L.; Zapletalova, J.; Silhanova, E.",null,null,"Germline variants of the promyelocytic leukemia tumor suppressor gene in patients with familial cancer","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"breast cancer; cancer risk; colon cancer; colon polyposis; germline mutation; PML gene","LYNCH-SYNDROME; NUCLEAR-BODY; PML; MUTATIONS; PROTEINS; ROLES; CELLS","The promyelocytic leukemia (PML) gene is an important tumor suppressor gene. We tested the hypothesis that germline disruption of the PML gene may be associated with a cancer predisposition syndrome. Mutation analysis of the PML gene was performed in 111 patients with familial adult cancer or young age-onset adult cancer. These were mostly breast and colon cancer, or colon polyposis patients in whom mutation analyses of the BRCA1, BRCA2, MLH1, MSH2, APC or TP53 genes did not detect a pathogenic germline mutation. Heteroduplex analysis and direct sequencing were used for mutation screening. Mutation-specific methods were designed for frequency determination of novel variants in the general population. No deleterious nonsense or frameshift germline mutations were detected. Several missense single-nucleotide substitutions were found, including two novel missense variants, c.83C>T (p.Thr28Ile) in exon 1 in a 42-year-old breast cancer patient and c.1558C>T (p.Pro520Ser) in exon 6 in a 32-year-old colon cancer patient, that were not detected in 100 and 214 non-cancer persons, respectively. Frequency of the c.2260G>C (p.Ala754Pro) variant in isoform IV of the PML gene was higher in patients with colon polyposis and cancer than in the control group (P = 0.029). In conclusion, germline disruption of the PML gene is probably not associated with a highly penetrant susceptibility to adult-onset breast and colon cancer. Pathogenicity of c.83C>T and c.1558C>T variants in the PML gene is uncertain. Carriers of the c.2260G>C variant in PMLIV isoform may be at an increased risk of colon polyposis and cancer.","[Plevova, P.; Walczyskova, S.; Jeziskova, I.; Jurckova, N.; Silhanova, E.] Univ Ostrava, Fac Hosp Ostrava, Dept Med Genet, CZ-70852 Ostrava, Czech Republic; [Krepelova, A.; Puchmajerova, A.; Pavlikova, K.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Krepelova, A.; Puchmajerova, A.; Pavlikova, K.] Charles Univ Prague, Dept Biol & Med Genet, Fac Hosp Prague Motol, Prague, Czech Republic; [Foretova, L.] Masaryk Mem Canc Inst, Dept Canc Epidemiol & Genet, Brno, Czech Republic; [Zapletalova, J.] Palacky Univ, Dept Biophys, Fac Med, CR-77147 Olomouc, Czech Republic","Plevova, P (reprint author), Univ Ostrava, Fac Hosp Ostrava, Dept Med Genet, CZ-70852 Ostrava, Czech Republic.","pavlina.plevova@volny.cz",null,null,"Ministry of Health Care of the Czech Republic [NR/9092-3]","This work was supported by the Internal Grant Agency of the Ministry of Health Care of the Czech Republic (grant number NR/9092-3).",null,18,0,0,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2009,56,6,null,null,null,null,500,507,null,"10.4149/neo_2009_06_500",null,8,"Oncology","Oncology","501GM","WOS:000270369200007"]
[null,null,null,null,"J","Jahnova, H; Chrastina, P; Havlova, M; Zamecnik, J",null,null,null,"Jahnova, H.; Chrastina, P.; Havlova, M.; Zamecnik, J.",null,null,"Adult Form of Glutaric Aciduria Type II - Underdiagnosed Cause of Proximal Myopathy - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"glutaric aciduria type II; multiple acyl coenzyme A dehydrogenase deficiency; proximal myopathy; riboflavin","COA DEHYDROGENATION DEFICIENCY; MUTATIONS","Glutaric aciduria type II or multiple acyl-CoA dehydrogenase deficiency (MIM 231680) is an autosomal recessively inherited disorder with heterogeneous clinical manifestation and genetic background, biochemically characterized by the accumulation of specific metabolites sourcing from the deficient capacity of flavin oxidative enzymes transferring electrons into the system of electron-transfer flavoprotein (ETF) and electron-transfer flavoprotein:ubiquinone oxidoreductase (ETF:QO). Clinical phenotypes include not only the lethal neonatal forms, but also the late-onset disorder, which usually manifests with proximal myopathic syndrome and sometimes with attacks of hypoketotic hypoglycemia. The incidence of the myopathic form of glutaric aciduria type II has not been determined; nevertheless, owing to easier access to novel diagnostic methods, including tandem mass spectrometry, and the ever increasing awareness of clinicians, the number of diagnosed patients has been growing constantly. The case report of our patient, for the first time diagnosed on the DNA level in the Czech Republic, illustrates not only the clinical course of the disease, but also the possibilities of diagnostics and therapy. It might serve as an inspiration for neurological practice.","[Jahnova, H.; Chrastina, P.] VFN, Ustav Dedicnych Metab Poruch, Prague 12808 2, Czech Republic; [Jahnova, H.; Chrastina, P.; Havlova, M.] 1 LF UK, Prague, Czech Republic; [Jahnova, H.] FNKV, Klin Deti & Dorostu, Prague, Czech Republic; [Havlova, M.] VFN, Neurol Klin, Prague 12808 2, Czech Republic; [Zamecnik, J.] 2 LF UK, Prague, Czech Republic","Jahnova, H (reprint author), VFN, Ustav Dedicnych Metab Poruch, Ke Karlovu 2, Prague 12808 2, Czech Republic.","helena.jahnova@vfn.cz",null,null,null,null,null,9,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2009,72,3,null,null,null,null,260,264,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","459JD","WOS:000267097100010"]
[null,null,null,null,"J","Folbergrova, J; Druga, R; Tsenov, G; Haugvicova, R; Otahal, J",null,null,null,"Folbergrova, Jaroslava; Druga, Rastislav; Tsenov, Grygoriy; Haugvicova, Renata; Otahal, Jakub",null,null,"Posttreatment with group II metabotropic glutamate receptor agonist 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate is only weakly effective on seizures in immature rats","BRAIN RESEARCH",null,null,"English","Article",null,null,null,null,null,"DL-homocysteic acid-induced seizures; EEG recording; Energy metabolites; Neuronal degeneration; Posttreatment with 2R,4R-APDC; Partial protection","INDUCED STATUS EPILEPTICUS; HOMOCYSTEIC ACID; NEURONAL DEGENERATION; ANTICONVULSANT ACTION; GLIA ACTIVATION; CEREBRAL-CORTEX; FLUORO-JADE; DCG-IV; HIPPOCAMPUS; EPILEPSY","The present study has examined the anticonvulsant and neuroprotective effect of 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC), a selective agonist for group II metabotropic glutamate receptors (mGluRs) when given 10-15 min after the onset of seizures induced in 12-day-old rats by bilateral icv infusion Of DL-homocysteic acid (DL-HCA, 600 nmol/side). For biochemical analyses, rat pups were sacrificed during generalized clonic-tonic seizures, similar to 45-50 min after infusion Of DL-HCA. Comparable time intervals were used for sacrificing the animals which received 2R,4R-APDC (0.05 nmol/side) or saline. The severity of seizures was influenced only slightly when the agonist was given after the onset of seizures, as evaluated both from the behavioral symptoms and from EEG recordings. A tendency to lower number and a shorter duration of seizures was outlined in animals posttreated with 2R,4R-APDC, but the differences did not reach the level of statistical significance. Cortical energy metabolite changes which normally accompany seizures in immature rats barge decrease of glucose and glycogen and a marked rise of lactate) were ameliorated only partially. The neuroprotective effect of 2R,4R-APDC was evaluated after 24 h and 6 days of survival following DL-HCA-induced seizures. Massive neuronal degeneration in many brain regions, mainly in the hippocampus and thalamus, following infusion Of DL-HCA alone was only partially attenuated after 2R,4R-APDC posttreatment. The present findings clearly indicate that both anticonvulsant and neuroprotective effect of 2R,4R-APDC against DL-HCA-induced seizures is substantially diminished when the agonist is given after the onset of seizures as compared with its efficacy after the pretreatment (Exp. Neurol.192, 420-436, 2005). (C) 2009 Elsevier B.V. All rights reserved.","[Folbergrova, Jaroslava; Druga, Rastislav; Tsenov, Grygoriy; Haugvicova, Renata; Otahal, Jakub] Acad Sci Czech Republic, Inst Physiol, VVI, CR-14220 Prague 4, Czech Republic; [Haugvicova, Renata] Acad Sci Czech Republic, Inst Microbiol, VVI, CR-14220 Prague, Czech Republic","Folbergrova, J (reprint author), Acad Sci Czech Republic, Inst Physiol, VVI, Videnska 1083, CR-14220 Prague 4, Czech Republic.","folbergr@biomed.cas.cz","Otahal, Jakub/B-5833-2012; Tsenov, Grygoriy/C-3897-2012; Folbergrova, Jaroslava/C-5088-2013",null,"Grant Agency of the Czech Republic [309/05/2015, 309/08/0292]; Research Project AVOZ [50110509]","This study was supported by Grants No 309/05/2015 and 309/08/0292 from the Grant Agency of the Czech Republic and by Research Project AVOZ 50110509. The authors thank Dr.J. Vorlicek for statistical evaluation of the data and Mrs E. Ricicova for her excellent technical assistance.","Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Attwell PJE, 1998, BRAIN RES, V787, P286, DOI 10.1016/S0006-8993(97)01500-X; Battaglia G, 1998, EUR J PHARMACOL, V356, P271, DOI 10.1016/S0014-2999(98)00551-2; Becker AJ, 1999, MOL BRAIN RES, V67, P172, DOI 10.1016/S0169-328X(99)00060-1; Berent-Spillson A., 2003, EXP NEUROL, V184, pS97; Bruno V, 1998, J NEUROSCI, V18, P9594; Bruno V, 2001, J CEREBR BLOOD F MET, V21, P1013; Buisson A, 1996, EUR J NEUROSCI, V8, P138, DOI 10.1111/j.1460-9568.1996.tb01174.x; Cartmell J, 2000, J NEUROCHEM, V75, P889, DOI 10.1046/j.1471-4159.2000.0750889.x; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; De Simoni MG, 2000, EUR J NEUROSCI, V12, P2623, DOI 10.1046/j.1460-9568.2000.00140.x; FOLBERGR.J, 1972, J NEUROCHEM, V19, P2497; Folbergrova J, 2006, EXP NEUROL, V201, P105, DOI 10.1016/j.expneuiol.2006.03.031; Folbergrova J, 2007, EXP NEUROL, V204, P597, DOI 10.1016/j.expneurol.2006.12.010; Folbergrova J, 2008, NEUROPHARMACOLOGY, V54, P665, DOI 10.1016/j.neuropharm.2007.11.015; Folbergrova J, 2000, EXP NEUROL, V161, P336, DOI 10.1006/exnr.1999.7264; Folbergrova J, 2005, EXP NEUROL, V192, P420, DOI 10.1016/j.expneurol.2004.12.019; Folbergrova J, 2007, EPILEPSIA, V48, P87; Folbergrova J, 1997, EXP NEUROL, V145, P442, DOI 10.1006/exnr.1997.6464; Folbergrova J, 2001, BRAIN RES, V908, P120, DOI 10.1016/S0006-8993(01)02620-8; Fujikawa DG, 1996, BRAIN RES, V725, P11, DOI 10.1016/S0006-8993(96)00203-X; INGVAR M, 1988, ACTA NEUROPATHOL, V75, P362; Kingston AE, 1999, EUR J PHARMACOL, V377, P155, DOI 10.1016/S0014-2999(99)00397-0; Langmeier M, 2003, EPILEPSIA, V44, P299, DOI 10.1046/j.1528-1157.2003.31702.x; Lowry O.H.P., 1972, FLEXIBLE SYSTEM ENZY; Miyamoto M, 1997, NEUROSCIENCE, V77, P131, DOI 10.1016/S0306-4522(96)00442-3; Moldrich RX, 2001, NEUROSCI LETT, V299, P125, DOI 10.1016/S0304-3940(00)01732-8; Moldrich RX, 2003, EUR J PHARMACOL, V476, P3, DOI 10.1016/S0014-2999(03)02149-6; Moldrich RX, 2001, NEUROPHARMACOLOGY, V41, P8, DOI 10.1016/S0028-3908(01)00044-2; Myhrer T, 2006, EUR J PHARMACOL, V548, P83, DOI 10.1016/j.ejphar.2006.07.001; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Orlando LR, 1995, NEUROSCI LETT, V202, P109, DOI 10.1016/0304-3940(95)12219-2; Pellicciari R, 1999, CURR OPIN CHEM BIOL, V3, P433, DOI 10.1016/S1367-5931(99)80064-7; Ravizza T, 2005, EPILEPSIA, V46, P113, DOI 10.1111/j.1528-1167.2005.01006.x; Riozzi B, 2008, NEUROPHARMACOLOGY, V55, P621; Rizzi M, 2003, NEUROBIOL DIS, V14, P494, DOI 10.1016/j.nbd.2003.08.001; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schoepp DD, 2001, J PHARMACOL EXP THER, V299, P12; SHERWOOD NM, 1970, STEREOTAXIC ATLAS DE; Tang E, 1997, EUR J PHARMACOL, V327, P109, DOI 10.1016/S0014-2999(97)89649-5; Tang FR, 2004, EPILEPSY RES, V59, P167, DOI 10.1016/j.eplepsyres.2004.04.002; Vezzani A, 2008, BRAIN BEHAV IMMUN, V22, P797, DOI 10.1016/j.bbi.2008.03.009",43,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0006-8993",null,null,"BRAIN RES","Brain Res.","JUN 1",2009,1273,null,null,null,null,null,144,154,null,"10.1016/j.brainres.2009.03.045",null,11,"Neurosciences","Neurosciences & Neurology","464PC","WOS:000267516600016"]
[null,null,null,null,"J","Dorfman, R; Li, WL; Sun, L; Lin, F; Wang, YQ; Sandford, A; Pare, PD; McKay, K; Kayserova, H; Piskackova, T; Macek, M; Czerska, K; Sands, D; Tiddens, H; Margarit, S; Repetto, G; Sontag, MK; Accurso, FJ; Blackman, S; Cutting, GR; Tsui, LC; Corey, M; Durie, P; Zielenski, J; Strug, LJ",null,null,null,"Dorfman, Ruslan; Li, Weili; Sun, Lei; Lin, Fan; Wang, Yongqian; Sandford, Andrew; Pare, Peter D.; McKay, Karen; Kayserova, Hana; Piskackova, Tereza; Macek, Milan; Czerska, Kamila; Sands, Dorota; Tiddens, Harm; Margarit, Sonia; Repetto, Gabriela; Sontag, Marci K.; Accurso, Frank J.; Blackman, Scott; Cutting, Garry R.; Tsui, Lap-Chee; Corey, Mary; Durie, Peter; Zielenski, Julian; Strug, Lisa J.",null,null,"Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results","HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,null,"SINGLE-LOCUS APPROXIMATIONS; PANCREATIC-DUCT CELLS; LOD-SCORE ANALYSIS; LINKAGE ANALYSIS; HAPLOTYPE RECONSTRUCTION; OLIGOGENIC TRAITS; DISEASE SEVERITY; GENOTYPE DATA; I ERROR; ASSOCIATION","Cystic fibrosis (CF) is a monogenic disease due to mutations in the CFTR gene. Yet, variability in CF disease presentation is presumed to be affected by modifier genes, such as those recently demonstrated for the pulmonary aspect. Here, we conduct a modifier gene study for meconium ileus (MI), an intestinal obstruction that occurs in 16-20% of CF newborns, providing linkage and association results from large family and case-control samples. Linkage analysis of modifier traits is different than linkage analysis of primary traits on which a sample was ascertained. Here, we articulate a source of confounding unique to modifier gene studies and provide an example of how one might overcome the confounding in the context of linkage studies. Our linkage analysis provided evidence of a MI locus on chromosome 12p13.3, which was segregating in up to 80% of MI families with at least one affected offspring (HLOD = 2.9). Fine mapping of the 12p13.3 region in a large case-control sample of pancreatic insufficient Canadian CF patients with and without MI pointed to the involvement of ADIPOR2 in MI (p = 0.002). This marker was substantially out of Hardy-Weinberg equilibrium in the cases only, and provided evidence of a cohort effect. The association with rs9300298 in the ADIPOR2 gene at the 12p13.3 locus was replicated in an independent sample of CF families. A protective locus, using the phenotype of no-MI, mapped to 4q13.3 (HLOD = 3.19), with substantial heterogeneity. A candidate gene in the region, SLC4A4, provided preliminary evidence of association (p = 0.002), warranting further follow-up studies. Our linkage approach was used to direct our fine-mapping studies, which uncovered two potential modifier genes worthy of follow-up.","[Li, Weili; Corey, Mary; Strug, Lisa J.] Hosp Sick Children, Child Hlth Evaluat Sci Program, Toronto, ON M5G 1X8, Canada; [Dorfman, Ruslan; Sun, Lei; Lin, Fan; Wang, Yongqian; Tsui, Lap-Chee; Zielenski, Julian] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada; [Sun, Lei; Corey, Mary; Strug, Lisa J.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Sandford, Andrew; Pare, Peter D.] Univ British Columbia, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V5Z 1M9, Canada; [McKay, Karen] Childrens Hosp Westmead, Dept Resp Med, Westmead, NSW, Australia; [Kayserova, Hana] Slovak Acad Sci, Inst Mol Physiol & Genet, Bratislava 83334, Slovakia; [Piskackova, Tereza; Macek, Milan] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Czerska, Kamila; Sands, Dorota] Inst Mother & Child Hlth, Warsaw, Poland; [Tiddens, Harm] Sophia Childrens Univ Hosp, Erasmus Med Ctr Rotterdam, Rotterdam, Netherlands; [Margarit, Sonia; Repetto, Gabriela] Univ Desarrollo Santiago, Clin Alemana, Ctr Human Genet, Santiago, Chile; [Sontag, Marci K.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA; [Accurso, Frank J.] Univ Colorado Denver, Childrens Hosp, Mike McMorris Cyst Fibrosis Care & Res Ctr, Dept Pediat, Aurora, CO 80045 USA; [Blackman, Scott; Cutting, Garry R.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA; [Tsui, Lap-Chee] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China; [Durie, Peter] Hosp Sick Children, Program Physiol & Expt Med, Toronto, ON M5G 1X8, Canada","Strug, LJ (reprint author), Hosp Sick Children, Child Hlth Evaluat Sci Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.","ruslan.dorfman@gmail.com; lisa.strug@utoronto.ca","Tsui, Lap-chee/A-1081-2010; Repetto, Gabriela/C-7833-2012",null,"Genome Canada through the Ontario Genomics Institute [2004-OGI-3-05]; Canadian Cystic Fibrosis Foundation; Ontario Research Fund; NIH [HG-0004314]; Natural Sciences and Engineering Research Council; Canadian Institutes of Health Research; Ontario Women's Health Council;  [VZFNM00064203]","This project was supported by Genome Canada through the Ontario Genomics Institute per research agreement 2004-OGI-3-05, by the Canadian Cystic Fibrosis Foundation, by the Ontario Research Fund-Research Excellence Program. L.J. Strug is supported by the NIH (HG-0004314) and the Natural Sciences and Engineering Research Council. R. Dorfman was supported by the joint Fellowship of Canadian Institutes of Health Research and Ontario Women's Health Council. Support by VZFNM00064203 to Milan Macek. The authors express gratitude to all CF patients and their families for participating in this study. The authors thank Nicole Anderson, Jennifer Breaton, Mary Cristofi, Roxanne Rousseau, and Michael Van Spall for their exceptional effort in recruiting and ascertaining Canadian CF families for the study, as well Drs. Miroslava Balascakova, Vera Vavrova and Dana Zemkova for provision of patients with MI. The authors are indebted to the following individuals from member institutions of the Canadian Consortium for CF Genetic Studies for ascertaining patient data and blood samples from CF patients and their families: S. Aaron, P. Barrett, B. Beaurivage, Y. Berthiaume, P. Bigonesse, M. Boland, L. Boucher, J. Boucher, S. Bourgh, F. Brosseau, N.E. Brown, C. Brunoro, N. Bureau, A. Cantin, L. Charette, G. Cote, A. Dale, G. Davidson, K. Devesceri, R. Dicaire, V. Fauvel, A. Freitag, D. N. Garey, M. Gaul, W. Gervais, J. Gjevre, F. Gosse, A. Gravelle, B. Habbick, R. Hennessey, S. B. Holmes, J. Hopkins, D. Hughes, M. Jackson, J. Jacob, A. Jeanneret, P. Kean, W. Kepron, T. Kovesi, V. J. Kumar, L. Lands, M. LaPerriere, J. Leong, R. Levesque, D. Lougheed, M. Lowe, B. Lyttle, K. Malhotra, J. E. Marcotte, S. Marsolais, C. Martineau, E. Matouk, D. McCulloch, R. T. Michael, M. Montgomery, R. Morris, E. M. Nakielna, F. Paquet, H. Pasterkamp, N. Patterson, L. Pedder, L. Peterson, N. Petit, C. Piche, M. Plante, H. R. Rabin, K. Ramlall, F. Raymong, L. Rivard, G. Rivard, M. Roussin, M. Ruel, J. Salgado, L. Semple, E. Sheppard, F. Simard, A. Smith, M. Solomon, R. Stackhouse, J. Tabak, L. Taylor, A. Tsang, E. Tullis, C. Turtle, K. Vandamheen, M. van Spall, R. van Wylick, I. Waters, T. Wells, S. Wiltse, and P. Zuberbuhler.",null,58,17,17,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6717",null,null,"HUM GENET","Hum. Genet.","DEC",2009,126,6,null,null,null,null,763,778,null,"10.1007/s00439-009-0724-8",null,16,"Genetics & Heredity","Genetics & Heredity","521MG","WOS:000271924900004"]
[null,null,null,null,"J","Markova, J; Trnkova, Z; Michkova, P; Maaloufova, J; Stary, J; Cetkovsky, P; Schwarz, J",null,null,null,"Markova, Jana; Trnkova, Zuzana; Michkova, Petra; Maaloufova, Jacqueline; Stary, Jan; Cetkovsky, Petr; Schwarz, Jiri",null,null,"Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome","LEUKEMIA & LYMPHOMA",null,null,"English","Article",null,null,null,null,null,"Core-binding factor-acute myeloid leukemia; AML1/ETO; CBF beta/MYH11; minimal residual disease; C-KIT mutation; FLT3/ITD; FLT3 Asp835 mutation","INTERNAL TANDEM DUPLICATION; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; TIME QUANTITATIVE PCR; JAK2-V617F ACTIVATING MUTATION; AML1/MTG8 FUSION TRANSCRIPTS; MRC AML TRIALS; RT-PCR; PROGNOSTIC IMPACT; MYELODYSPLASTIC SYNDROME","Mutational analysis of C-KIT, fms-like tyrosine kinase 3 (FLT3), and JAK2 genes was performed in 60 patients with core binding factor acute myeloid leukemia (CBF-AML). Patients reaching molecular remission had lower incidence of relapse and better overall survival (OS) than those not achieving molecular remission (p = 0.008 and 0.044, respectively). The overall incidence of C-KIT mutations was 33.3%, FLT3/internal tandem duplication (ITD) 6.6%, FLT3(D835) 10.0% and JAK2(V617F) mutations 3.3%. C-KIT mutations did not predict for clinical/molecular relapse (p = 0.33). OS of patients with C-KIT mutations was identical to patients without them when all patients with CBF-AML were analyzed together (p = 0.58). When AML1/ETO-positive patients were evaluated separately, OS in C-KIT-mutated patients was slightly inferior to unmutated ones (p = 0.14). Patients with CBF-AML with a mutated C-KIT gene were also more prone to extramedullary disease (p = 0.08). Of six patients harboring various FLT3(D835) mutations, four (66.7%) relapsed, whereas among 43 cases without these mutations, 16 relapses (37%) were observed (p = 0.08). Our results on minimal residual disease, C-KIT, and FLT3/ITDs are in line with previous studies. Surprisingly, a possible role for FLT3(D835) mutations was noted in addition. These results need validation in even larger patient cohorts than ours. For routine clinical practice, it may be meaningful to screen for C-KIT mutations in AML1/ETO-positive patients, as well as for FLT3(D835) mutations in CBF-AML.","[Markova, Jana; Trnkova, Zuzana; Michkova, Petra; Maaloufova, Jacqueline; Cetkovsky, Petr; Schwarz, Jiri] Inst Hematol & Blood Transfus, CR-12820 Prague 2, Czech Republic; [Stary, Jan] Fac Hosp Motol, Dept Pediat Hematol & Oncol, Prague 5, Czech Republic","Schwarz, J (reprint author), Inst Hematol & Blood Transfus, U Nemocnice 1, CR-12820 Prague 2, Czech Republic.","jiri.schwarz@uhkt.cz",null,null,"Czech Ministry of Health [00237360001]","All the authors disclose no potential conflicts of interest. Supported by the Research project of the Czech Ministry of Health 00237360001.",null,60,15,17,"TAYLOR & FRANCIS LTD","ABINGDON","4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND","1042-8194",null,null,"LEUKEMIA LYMPHOMA","Leuk. Lymphoma",null,2009,50,9,null,null,null,null,1448,1460,null,"10.1080/10428190903085951",null,13,"Oncology; Hematology","Oncology; Hematology","503QC","WOS:000270552100011"]
[null,null,null,null,"J","Baran, R; Tosti, A; Hartmane, I; Altmeyer, P; Hercogova, J; Koudelkova, V; Ruzicka, T; Combemale, P; Mikazans, I",null,null,null,"Baran, R.; Tosti, A.; Hartmane, I.; Altmeyer, P.; Hercogova, J.; Koudelkova, V.; Ruzicka, T.; Combemale, P.; Mikazans, I.",null,null,"An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis","JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY",null,null,"English","Article",null,null,null,null,null,"ciclopirox; hydroxypropyl chitosan; onychomycosis; water-soluble nail lacquer","ITRACONAZOLE; TERBINAFINE","Background A new 8% ciclopirox-medicated nail lacquer (P-3051), based on a new technology, revealed superior properties in terms of affinity to keratin, nail permeation, and ease of use. Objective This study aims to assess the efficacy and safety of P-3051 vs. the market 8% ciclopirox nail lacquer. Methods This is a multicentre, randomized, three-arm, placebo-controlled, parallel groups, evaluator-blinded study. Overall, 467 patients with onychomycosis of at least one big toenail were randomized to receive P-3051, the reference drug or placebo in a 2 : 2 : 1 ratio for a 48-week treatment by daily application, followed by a 12-week follow-up. Results The study satisfied its objective by demonstrating that P-3051 was both superior to placebo and non-inferior to reference in the complete cure rate after a 48-week active treatment period. Switching the non-inferiority to superiority hypothesis, the superiority of P-3051 vs. reference was nearly significant at week 48 (confirmed at week 52), and it was significant at week 60 (cure rate for P-3051 is 119% higher than reference; P < 0.05). Altogether, the results on primary endpoint exceed expectations; superiority test was performed also on secondary endpoints to confirm the superiority trend of the study. At the end of follow-up, percentages of patients who achieved the endpoint 'responder' in the P-3051 group were 66% higher than reference (P < 0.05), and those who achieved the endpoint 'decrease of diseased nail' were 40% higher (P < 0.05). Conclusion Ciclopirox 8% hydrolacquer is more active than reference ciclopirox nail lacquer in the treatment of onychomycosis.","[Baran, R.] Nail Dis Ctr, Cannes, France; [Tosti, A.] Univ Bologna, Dept Dermatol, I-40138 Bologna, Italy; [Hartmane, I.; Mikazans, I.] Clin Ctr Skin & STD, Riga, Latvia; [Altmeyer, P.] Ruhr Univ Bochum, Klin Dermatol & Allergol, Bochum, Germany; [Hercogova, J.] Charles Univ Prague, Fac Med 2, Bulovka Univ Hosp, Dermatovenereol Dept, Prague, Czech Republic; [Koudelkova, V.] Fac Hosp, Dermatovenereol Clin, Hradec Kralove, Czech Republic; [Ruzicka, T.] Univ Munich, Munich, Germany; [Combemale, P.] Hop Desgenettes, Serv Dermatol, Lyon, France","Baran, R (reprint author), Nail Dis Ctr, Cannes, France.","baran.r@wanadoo.fr",null,null,null,null,null,17,16,16,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0926-9959",null,null,"J EUR ACAD DERMATOL","J. Eur. Acad. Dermatol. Venereol.","JUL",2009,23,7,null,null,null,null,773,781,null,"10.1111/j.1468-3083.2009.03164.x",null,9,"Dermatology","Dermatology","453UG","WOS:000266637800004"]
[null,null,null,null,"J","Salek, C; Minarikova, P; Benesova, L; Nosek, V; Strnad, R; Zavoral, M; Minarik, M",null,null,null,"Salek, Cyril; Minarikova, Petra; Benesova, Lucie; Nosek, Vladimir; Strnad, Robin; Zavoral, Miroslav; Minarik, Marek",null,null,"Mutation Status of K-ras, p53 and Allelic Losses at 9p and 18q Are Not Prognostic Markers in Patients with Pancreatic Cancer","ANTICANCER RESEARCH",null,null,"English","Article",null,null,null,null,null,"Pancreatic cancer; K-ras; p53; p16; DPC4; prognostic markers","DUCTAL ADENOCARCINOMA; CLINICOPATHOLOGICAL PARAMETERS; EPIGENETIC ALTERATIONS; CLINICAL-RELEVANCE; TUMOR-MARKER; EXPRESSION; CARCINOMA; DIAGNOSIS; SURVIVAL; CHEMOTHERAPY","Background: K-ras mutations and allelic losses of tumor suppressors p16 and DPC4 are perceived as potential markers for screening of pancreatic malignancy. In this study, molecular data is compared with survival statistics of the patients and whether they correlate with patients' prognosis is questioned. Patients and Methods: Fifty three consecutive patients with advanced pancreatic cancer (stage III and IV) who underwent EUS-guided fine needle aspiration (FNA) were enrolled into the study (28 males, 25 females, 63+/-10.5 years). Samples were evaluated on-site for presence of malignant cells. DNA was extracted from Giemsa stained smears using laser microdissection, and mutation status of K-ras and p53 was tested by cycling-gradient capillary electrophoresis (CGCE). In addition, allelic losses of tumor suppressor genes p16 (INK4, CDKN2A) and DPC4 (MADH4, SMAD4) were detected by monitoring the loss of heterozygosity (LOH) at 9p and 18q loci. Molecular data were compared with survival statistics using Kaplan-Meier method. Results: The median survival in K-ras positive group was 7.0 +/- 2.4 months (95% CI 2.3-11.7) and in K-ras negative group was 10.0 +/- 0.6 months (95% CI 8.7-11.3). The median survival in p53 positive group was 10.0+/-2.2 months (95% CI 5.6-14.4) and in p53 negative group was 6.0+/-2.5 months (95% CI 1.1-10.9). The median survival in LOH 9p positive group was 9.0+/-5.1 months (95% CI 0-18.9), in LOH 9p negatives was 10.0+/-5.0 months (95% CI 0.2-19.8). The median survival in LOH 18q positive group was 10.0+/-4.2 months (95% CI 1.8-18.2) and in LOH 18q negative group was 3.0+/-1.3 months (95% CI 0.5-5.5). After the adjustment for age using Cox proportional hazards model, none of the evaluated molecular markers was shown to be an independent prognostic marker for survival of patients with pancreatic cancer. Conclusion: None of the studied molecular markers was identified as an independent factor determining survival prognosis.","[Salek, Cyril; Benesova, Lucie; Minarik, Marek] Genomac Int Ltd, Lab Mol Genet & Oncol, Prague 15541 5, Czech Republic; [Salek, Cyril; Minarikova, Petra; Nosek, Vladimir; Zavoral, Miroslav] Cent Mil Hosp, Clin Internal Med, Dept Gastroenterol, Prague, Czech Republic; [Salek, Cyril; Minarikova, Petra; Nosek, Vladimir; Zavoral, Miroslav] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Strnad, Robin] Cent Mil Hosp, Dept Surg, Prague, Czech Republic; [Strnad, Robin] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Minarik, M (reprint author), Genomac Int Ltd, Lab Mol Genet & Oncol, Bavorska 856, Prague 15541 5, Czech Republic.","mminarik@email.com",null,null,"Czech Ministry of Industry and Trade research [FI-IM3/215]","The authors thank Jelena Skibova and Dr. Katerina Benesova for their substantial help with statistical analysis. This project was supported by the Czech Ministry of Industry and Trade research grant no. FI-IM3/215.",null,43,14,16,"INT INST ANTICANCER RESEARCH","ATHENS","EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE","0250-7005",null,null,"ANTICANCER RES","Anticancer Res.","MAY",2009,29,5,null,null,null,null,1803,1810,null,null,null,8,"Oncology","Oncology","462WR","WOS:000267389300078"]
[null,null,null,null,"J","Bril, V; Katzberg, H; Donofrio, P; Banach, M; Dalakas, MC; Deng, CQ; Hanna, K; Hartung, HP; Hughes, RAC; Latov, N; Merkies, ISJ; van Doorn, PA",null,null,null,"Bril, Vera; Katzberg, Hans; Donofrio, Peter; Banach, Marta; Dalakas, Marinos C.; Deng, Chunqin; Hanna, Kim; Hartung, Hans-Peter; Hughes, Richard A. C.; Latov, Norman; Merkies, Ingemar S. J.; van Doorn, Pieter A.",null,"ICE Study Grp","ELECTROPHYSIOLOGY IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY WITH IGIV","MUSCLE & NERVE",null,null,"English","Article",null,null,null,null,null,"CIDP; nerve conduction studies; intravenous immune globulin; treatment","INTRAVENOUS IMMUNOGLOBULIN TREATMENT; RANDOMIZED CONTROLLED TRIAL; ELECTRODIAGNOSTIC ABNORMALITIES; NERVE-CONDUCTION; PLASMA-EXCHANGE; DOUBLE-BLIND; POLYRADICULONEUROPATHY; CRITERIA; CIDP; IVIG","Patients with chronic inflammatory demyelinating polyneuropathy (CIDP) received immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C, Gamunex; n = 59) or placebo (n = 58) every 3 weeks for up to 24 weeks (first period) in a randomized, double-blind, parallel-group, response-conditional, crossover study. Motor and sensory nerves were assessed at baseline and endpoint/week 24. A nonsignificant trend toward improvement in the proximal amplitude of the most severely affected motor nerve was observed with IGIV-C (0.69 +/- 1.86 mV) versus placebo (0.47 +/- 2.29 mV), and a greater improvement of 1.08 +/- 2.15 mV with IGIV-C versus 0.46 +/- 2.03 mV with placebo (P = 0.089) was observed with exclusion of data from Erb's point stimulation. Greater improvements from baseline favoring IGIV-C were observed for 127/142 electrophysiologic parameters. The averaged motor amplitudes from all motor nerves significantly improved with IGIV-C versus placebo [treatment difference, 0.62 mV; 95% confidence interval (CI), 0.05, 1.20; P = 0.035], and conduction block decreased significantly (treatment difference, -5.54%; 95% CI, -10.43, -0.64; P = 0.027), particularly in the lower limbs. Overall, the data suggest that IGIV-C improves electrophysiologic parameters in CIDP.","[Bril, Vera] Univ Hlth Network, Dept Neurol, Toronto, ON, Canada; [Katzberg, Hans] Stanford Univ, Dept Neurol, Palo Alto, CA 94304 USA; [Donofrio, Peter] Vanderbilt Univ, Dept Neurol, Nashville, TN USA; [Banach, Marta] Jagiellonian Univ, Coll Med, Dept Neurol, Krakow, Poland; [Dalakas, Marinos C.] Univ London Imperial Coll Sci Technol & Med, Dept Clin Neurosci, London, England; [Deng, Chunqin; Hanna, Kim] Talecris Biotherapeut Inc, Res Triangle Pk, NC USA; [Hartung, Hans-Peter] Univ Dusseldorf, Dept Neurol, D-4000 Dusseldorf, Germany; [Hughes, Richard A. C.] Kings Coll London, Dept Clin Neurosci, London WC2R 2LS, England; [Latov, Norman] Cornell Univ, Peripheral Neuropathy Ctr, New York, NY 10021 USA; [Merkies, Ingemar S. J.; van Doorn, Pieter A.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands","Bril, V (reprint author), Univ Hlth Network, Dept Neurol, Toronto, ON, Canada.","vera.bril@utoronto.ca",null,null,null,null,"CORNBLATH DR, 1991, NEUROLOGY, V41, P617; ALBERS JW, 1985, MUSCLE NERVE, V8, P528, DOI 10.1002/mus.880080609; Ashworth NL, 2000, MUSCLE NERVE, V23, P206, DOI 10.1002/(SICI)1097-4598(200002)23:2<206::AID-MUS10>3.0.CO;2-K; Bril V, 1998, MUSCLE NERVE, V21, P1368, DOI 10.1002/(SICI)1097-4598(199811)21:11<1368::AID-MUS2>3.0.CO;2-7; BRIL V, 2000, CLIN TRIALS NEUROLOG, P479; BROMBERG MB, 1991, MUSCLE NERVE, V14, P968, DOI 10.1002/mus.880141007; Chan Yee-Cheun, 2006, Expert Rev Neurother, V6, P1545, DOI 10.1586/14737175.6.10.1545; DYCK PJ, 1994, ANN NEUROL, V36, P838, DOI 10.1002/ana.410360607; Greene DA, 1999, NEUROLOGY, V53, P580; Hahn AF, 1996, BRAIN, V119, P1067, DOI 10.1093/brain/119.4.1067; Hughes R, 2001, ANN NEUROL, V50, P195, DOI 10.1002/ana.1088; Hughes RAC, 2008, LANCET NEUROL, V7, P136, DOI 10.1016/S1474-4422(07)70329-0; Iijima M, 2005, NEUROLOGY, V64, P1471; Koller H, 2005, NEW ENGL J MED, V352, P1343, DOI 10.1056/NEJMra041347; LOGIGIAN EL, 1994, MUSCLE NERVE, V17, P1010, DOI 10.1002/mus.880170908; Magda P, 2003, ARCH NEUROL-CHICAGO, V60, P1755, DOI 10.1001/archneur.60.12.1755; Mehndiratta MM, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002062; Mendell JR, 2001, NEUROLOGY, V56, P445; Nagamatsu M, 1999, J NEUROL NEUROSUR PS, V66, P727, DOI 10.1136/jnnp.66.6.727; Saperstein DS, 2001, MUSCLE NERVE, V24, P311, DOI 10.1002/1097-4598(200103)24:3<311::AID-MUS1001>3.0.CO;2-A; Sommer C, 2005, NEUROLOGY, V65, P1924, DOI 10.1212/01.wnl.0000188879.19900.b7; VANDOORN PA, 1990, NEUROLOGY, V40, P209; WERTMAN E, 1988, EUR NEUROL, V28, P199, DOI 10.1159/000116266",23,15,15,"JOHN WILEY & SONS INC","HOBOKEN","111 RIVER ST, HOBOKEN, NJ 07030 USA","0148-639X",null,null,"MUSCLE NERVE","Muscle Nerve","APR",2009,39,4,null,null,null,null,448,455,null,"10.1002/mus.21236",null,8,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","427NA","WOS:000264784800005"]
[null,null,null,null,"J","Harmsen, MB; Azzarello-Burri, S; Gonzalez, MMG; Gillessen-Kaesbach, G; Meinecke, P; Muller, D; Rauch, A; Rossier, E; Seemanova, E; Spaich, C; Steiner, B; Wieczorek, D; Zenker, M; Kutsche, K",null,null,null,"Harmsen, May-Britt; Azzarello-Burri, Silvia; Garcia Gonzalez, M. Mar; Gillessen-Kaesbach, Gabriele; Meinecke, Peter; Mueller, Dietmar; Rauch, Anita; Rossier, Eva; Seemanova, Eva; Spaich, Christiane; Steiner, Bernhard; Wieczorek, Dagmar; Zenker, Martin; Kutsche, Kerstin",null,null,"Goltz-Gorlin (focal dermal hypoplasia) and the microphthalmia with linear skin defects (MLS) syndrome: no evidence of genetic overlap","EUROPEAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"FDH; male-lethal; MIDAS; mosaicism; X-chromosomal dominant; X-inactivation","MALE-LETHAL DISORDERS; X-INACTIVATION; MOLECULAR CHARACTERIZATION; ANGIOMA SERPIGINOSUM; PORCN GENE; CHROMOSOME; MUTATIONS; DELETION; DISEASE; AICARDI","Focal dermal hypoplasia (FDH) is an X-linked developmental disorder with male lethality characterized by patchy dermal hypoplasia, skeletal and dental malformations, and microphthalmia or anophthalmia. Recently, heterozygous loss-of-function mutations in the PORCN gene have been described to cause FDH. FDH shows some clinical overlap with the microphthalmia with linear skin defects (MLS) syndrome, another X-linked male lethal condition, associated with mutations of HCCS in the majority of cases. We performed DNA sequencing of PORCN in 13 female patients with the clinical diagnosis of FDH as well as four female patients with MLS syndrome and no mutation in HCCS. We identified PORCN mutations in all female patients with FDH. Eleven patients seem to have constitutional PORCN alterations in the heterozygous state and two individuals are mosaic for the heterozygous sequence change in PORCN. No PORCN mutation was identified in the MLS-affected patients, providing further evidence that FDH and MLS do not overlap genetically. X chromosome inactivation (XCI) analysis revealed a random or slightly skewed XCI pattern in leukocytes of individuals with intragenic PORCN mutation suggesting that defective PORCN does not lead to selective growth disadvantage, at least in leukocytes. We conclude that the PORCN mutation detection rate is high in individuals with a clear-cut FDH phenotype and somatic mosaicism can be present in a significant proportion of patients with mild or classic FDH. European Journal of Human Genetics (2009) 17, 1207-1215; doi: 10.1038/ejhg.2009.40; published online 11 March 2009","[Harmsen, May-Britt; Kutsche, Kerstin] Univ Klinikum Hamburg Eppendorf, Inst Humangenet, D-20246 Hamburg, Germany; [Azzarello-Burri, Silvia; Steiner, Bernhard] Univ Zurich, Inst Med Genet, CH-8603 Schwerzenbach, Switzerland; [Garcia Gonzalez, M. Mar] Hosp Figueres, Serv Pediat, Figueres, Spain; [Gillessen-Kaesbach, Gabriele] Med Univ Lubeck, Inst Humangenet, D-23538 Lubeck, Germany; [Mueller, Dietmar] Klinikum Chemnitz, Inst Med Genet, Chemnitz, Germany; [Meinecke, Peter] Altonaer Kinderkrankenhaus, Hamburg, Germany; [Rauch, Anita; Zenker, Martin] Univ Klinikum Erlangen, Inst Humangenet, Erlangen, Germany; [Rossier, Eva] Univ Klinikum Tubingen, Tubingen, Germany; [Seemanova, Eva] Charles Univ Prague, Dept Clin Genet, Inst Biol & Med Genet, Prague, Czech Republic; [Spaich, Christiane] Klinikum Stuttgart, Inst Klin Genet, Stuttgart, Germany; [Wieczorek, Dagmar] Univ Klinikum Essen, Inst Humangenet, Essen, Germany","Kutsche, K (reprint author), Univ Klinikum Hamburg Eppendorf, Inst Humangenet, Campus Forsch,Martinistr 52, D-20246 Hamburg, Germany.","kkutsche@uke.de","Rauch, Anita/C-5568-2014","Rauch, Anita/0000-0003-2930-3163",null,null,null,25,12,13,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813","1476-5438",null,"EUR J HUM GENET","Eur. J. Hum. Genet.","OCT",2009,17,10,null,null,null,null,1207,1215,null,"10.1038/ejhg.2009.40",null,9,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","497YP","WOS:000270101600002"]
[null,null,null,null,"J","Porchay-Balderelli, I; Pean, F; Emery, N; Maimaitiming, S; Bellili, N; Travert, F; Mohammedi, K; Roussel, R; Marre, M; Fumeron, F",null,null,null,"Porchay-Balderelli, Isabelle; Pean, Franck; Emery, Nathalie; Maimaitiming, Suliya; Bellili, Naima; Travert, Florence; Mohammedi, Kamel; Roussel, Ronan; Marre, Michel; Fumeron, Feredric",null,"DIABHYCAR Study Group","Relationships between common polymorphisms of adenosine triphosphate-binding cassette transporter Al and high-density lipoprotein cholesterol and coronary heart disease in a population with type 2 diabetes mellitus","METABOLISM-CLINICAL AND EXPERIMENTAL",null,null,"English","Article",null,null,null,null,null,null,"STOCHASTIC-EM ALGORITHM; ABCA1 GENE; HDL CHOLESTEROL; ARTERY-DISEASE; ASSOCIATION ANALYSIS; A1; RISK; ATHEROSCLEROSIS; VARIANTS; HYPERLIPIDEMIA","Patients with type 2 diabetes mellitus (T2D) have a high coronary risk partly because of low levels of high-density lipoprotein-cholesterol (HDL-C). The adenosine triphosphate-binding cassette transporter Al (ABCAl) plays a key role in HDL metabolism. We studied the association of common single nucleotide polymorphisms (SNPs) in the ABCAl gene with HDL-C levels and coronary risk in a cohort of subjects with T2D. We Studied 5 SNPs: +69C>T. +378G>C, R219K, 1883M, and R1587K. The C allele of +378G>C was significantly associated with lower HDL-C concentrations (P =.04); and the M allele of 1883M, with higher HDL-C concentrations (P =.03). No significant association was found between these SNPs and the incidence of new coronary events. Nevertheless, cross-sectional data on entry showed that the frequency of K219 was lower in patients with previous coronary heart disease (angina pectoris and/or myocardial infarction) (odds ratio, OR [95% confidence interval, CI] = 0.80 [0.65-0.98] P =.03, after adjustment for multiple risk factors other than HDL-C). The frequency of K 1587 was higher in patients with angina pectoris (OR [95% CI] = 1.27 [1.01-1.58], P =.04, after multiple adjustment). The TT genotype of the C69T SNP was less frequent in Subjects with prior myocardial infarction (OR [95% CI] = 0.28 [0.13-0.61], P =.001, after multiple adjustment). These associations persisted after further adjustment for HDL-C levels. In Conclusion, common genetic variations of ABCAl had a moderate influence on HDL-C levels and/or coronary heart disease in patients with T2D. These 2 effects were independent. (C) 2009 Elsevier Inc. All rights reserved.","[Porchay-Balderelli, Isabelle; Pean, Franck; Emery, Nathalie; Maimaitiming, Suliya; Bellili, Naima; Roussel, Ronan; Marre, Michel; Fumeron, Feredric] INSERM, U695, Xavier Bichat Sch Med, F-75018 Paris, France; [Porchay-Balderelli, Isabelle; Pean, Franck; Emery, Nathalie; Maimaitiming, Suliya; Bellili, Naima; Roussel, Ronan; Marre, Michel; Fumeron, Feredric] Univ Paris 07, Xavier Bichat Med Sch, F-75018 Paris, France; [Travert, Florence; Mohammedi, Kamel; Roussel, Ronan; Marre, Michel] Hop Xavier Bichat, Assistance Publ Hop Paris, Dept Endocrinol Diabetol & Nutr, F-75018 Paris, France","Fumeron, F (reprint author), INSERM, U695, Xavier Bichat Sch Med, BP 416,16 Rue Henri Huchard, F-75870 Paris 18, France.","frederic.fumeron@inserm.fr",null,null,null,null,"Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Brooks-Wilson A, 1999, NAT GENET, V22, P336; Brunham LR, 2008, J CLIN INVEST, V118, P403, DOI 10.1172/JCI33296; Cenarro A, 2003, J MED GENET, V40, P163, DOI 10.1136/jmg.40.3.163; Clee SM, 2001, CIRCULATION, V103, P1198; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Cuchel M, 2006, CIRCULATION, V113, P2548, DOI 10.1161/CIRCULATIONHA.104.475715; DUNN FL, 1990, DIABETES METAB REV, V6, P47; Evans D, 2003, J MOL MED-JMM, V81, P264, DOI 10.1007/s00109-003-0426-y; Francone OL, 2005, ARTERIOSCL THROM VAS, V25, P1198, DOI 10.1161/01.ATV.0000166522.69552.99; Frikke-Schmidt R, 2004, J CLIN INVEST, V114, P1343, DOI 10.1172/JC1200420361; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; Harada T, 2003, ATHEROSCLEROSIS, V169, P105, DOI 10.1016/S0021-9150(03)00135-7; Hetet G, 2001, EUR J CLIN INVEST, V31, P382, DOI 10.1046/j.1365-2362.2001.00829.x; Hodoglugil U, 2005, ATHEROSCLEROSIS, V183, P199, DOI 10.1016/j.atherosclerosis.2005.03.004; Huuskonen J, 2003, BIOCHEM BIOPH RES CO, V306, P463, DOI 10.1016/S0006-291X(03)00992-6; Kakko S, 2003, ATHEROSCLEROSIS, V166, P285, DOI 10.1016/S0021-9150(02)00232-0; Kyriakou T, 2007, HUM MOL GENET, V16, P1412, DOI 10.1093/hmg/ddm091; Marre M, 2004, BRIT MED J, V328, P495, DOI 10.1136/bmj.37970.629537.0D; Porchay I, 2006, OBESITY, V14, P1874, DOI 10.1038/oby.2006.217; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; Salinas Carlos A Aguilar, 2007, Curr Diabetes Rev, V3, P264; Schmitz G, 2002, ANN MED, V34, P334, DOI 10.1080/078538902320772098; Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77; Tregouet DA, 2004, EUR J HUM GENET, V12, P971, DOI 10.1038/sj.ejhg.5201238; Tregouet DA, 2004, ANN HUM GENET, V68, P165, DOI 10.1046/j.1529-8817.2003.00085.x; Tregouet DA, 2004, ARTERIOSCL THROM VAS, V24, P775, DOI 10.1161/01.ATV.0000121573.29550.1a; Villarreal-Molina MT, 2008, DIABETES, V57, P509, DOI 10.2337/db07-0484; Wang J, 2000, ARTERIOSCL THROM VAS, V20, P1983; Yamakawa-Kobayashi K, 2004, METABOLISM, V53, P182, DOI 10.1016/j.metabol.2003.08.009; Zwarts KY, 2002, CLIN GENET, V61, P115, DOI 10.1034/j.1399-0004.2002.610206.x",31,10,11,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0026-0495",null,null,"METABOLISM","Metab.-Clin. Exp.","JAN",2009,58,1,null,null,null,null,74,79,null,"10.1016/j.metabol.2008.08.009",null,6,"Endocrinology & Metabolism","Endocrinology & Metabolism","387TT","WOS:000261975200011"]
[null,null,null,null,"J","Phillip, M; Lebenthal, Y; Lebl, J; Zuckerman-Levin, N; Korpal-Szczyrska, M; Marques, JS; Steensberg, A; Jons, K; Kappelgaard, AM; Ibanez, L",null,null,null,"Phillip, Moshe; Lebenthal, Yael; Lebl, Jan; Zuckerman-Levin, Nehama; Korpal-Szczyrska, Maria; Marques, Jorge Sales; Steensberg, Adam; Jons, Kirsten; Kappelgaard, Anne-Marie; Ibanez, Lourdes",null,"European Norditropin SGA Study Grp","European Multicentre Study in Children Born Small for Gestational Age with Persistent Short Stature: Comparison of Continuous and Discontinuous Growth Hormone Treatment Regimens","HORMONE RESEARCH",null,null,"English","Article",null,null,null,null,null,"Small for gestational age; Growth hormone; Short stature","CATCH-UP GROWTH; DOSE-RESPONSE TRIAL; GH TREATMENT; TURNER-SYNDROME; DOUBLE-BLIND; INSULIN SENSITIVITY; ADULT HEIGHT; FINAL HEIGHT; LONG-TERM; RETARDATION","The most effective growth hormone (GH)treatment regimen for increasing height in short children born small for gestational age (SGA) has not been well defined. Methods: Short SGA children (n=151, age 3-8 years, height less than -2.5 standard deviation scores) were randomised to receive low-dose GH for 2 years (0.033/0.033 mg/kg/day, n=51), high-dose GH for 1 year and then no treatment for 1 year (0.100/0 mg/kg/day, n=51) or were untreated for 1 year then received mid-dose GH for 1 year (0/0.067 mg/kg/day, n=47). Height, bone age and adverse events were determined at check-ups every 3 months. Results: The mean +/- SD additional height gain with GH after 1 year, relative to untreated controls, was higher with discontinuous high-dose than with continuous low-dose GH (6.5 +/- 0.2 vs. 3.3 +/- 0.2 cm). After 2 years, the additional height gain was similar between high- and low-dose GH groups (between-group treatment difference=0.2, 95% CI=-0.8 to 1.2 cm, p=0.702). Patients treated exclusively in the last year had a similar height gain to those in the other treatment groups (p=0.604). Conclusions: In short SGA children, continuous low-dose and discontinuous high- dose GH regimens were associated with similar height gain. Treatment with mid-dose GH for 1 year also led to a similar improvement in growth. Copyright (C) 2008 S. Karger AG, Basel","[Phillip, Moshe] Tel Aviv Univ, Schneider Childrens Med Ctr Israel, Natl Ctr Childhood Diabet, Inst Endocrinol & Diabet, IL-69978 Tel Aviv, Israel; [Phillip, Moshe; Lebenthal, Yael] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Zuckerman-Levin, Nehama] Meyer Childrens Hosp, Rambam Med Ctr, Haifa, Israel; [Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Korpal-Szczyrska, Maria] Med Univ Gdansk, Dept Pediat Endocrinol, Gdansk, Poland; [Marques, Jorge Sales] Ctr Hosp Vila Nova Gaia, Dept Pediat, Gaia, Portugal; [Steensberg, Adam; Jons, Kirsten; Kappelgaard, Anne-Marie] Novo Nordisk AS, Global Dev, Copenhagen, Denmark; [Ibanez, Lourdes] Univ Barcelona, Hosp St Joan de Deu, Endocrine Unit, Barcelona, Spain","Phillip, M (reprint author), Tel Aviv Univ, Schneider Childrens Med Ctr Israel, Natl Ctr Childhood Diabet, Inst Endocrinol & Diabet, 14 Kaplan St,Petah Tikva 492-2, IL-69978 Tel Aviv, Israel.","mosheph@post.tau.ac.il",null,null,"Novo Nordisk A/S","This study was sponsored by Novo Nordisk A/S. The authors are grateful to the following investigators and study sites who participated in the study. Leo Dunkel, Marita Lipsanen-Nyman, Ilkka Sipila, Timo Otonkoski and Risto Lapatto, Helsinki, Raimo Voutilainen, Sirpa Tenhola, Ulla Sankilampi, Kuopio, and Paivi Tapanainen and Riitta Veijola, Oulu, Finland; Jirina Zapletalova, Olomouc, Dana Novotna, Brno, Jaroslav Skvor, Usti nad Labem, and Jan Lebl, Stanislava Kolouskova and Bozena Kalvachova, Prague, Czech Republic; Ester Liberman, Eli Hershkovitz and Neta Loewenthal, Be'er Sheva, Moshe Phillip and Yael Lebenthal, Petach-Tikva, Zvi Zadik and Amnon Zang, Rehovot, and Ze'ev Hochberg, Nehama Zukerman-Levin and Dov Tiosano, Haifa, Israel; Tomasz Romer and Alicja Korpysz, Warsaw, Jerzy Starzyk, Agata Zygmunt Gorska, Malgorzata Kumorowicz-Kopiec, Dominika Janus, Dorota Roztoczynska, Anna Kalicka-Kasperczyk, Aleksandra Gorska, Katarzyna Dolezal-Oltarzewska, Dorota Bilecka and Edyta Piatkowska, Krakow, and Maria Korpal-Szczyrska, Bohdana Dorant, Halina Kaminska and Dorota Birkholz, Gdansk, Poland; Eberhard Keller, Johannes Weigel, Alexandra Keller and Sabine Liebermann, Leipzig, Klaus-Peter Ullrich, Gotha, and Stefan Wirth and Philip Wintermeyer, Wuppertal, Germany; Manuel Jorge Fontoura Pinheiro de Magalhaes and Cintia Goncalves Castro-Correia, Porto, Mario Aires Marcelo da Fonseca, Matosinhos, Luis Francisco Simoes de Moura and Maria Alice Santos Cordeiro Mirante, Coimbra, and Jorge Manuel Sales Marques, Jacinto Americo Silva Torres, Rosa Armenia Martins Campos and Marta Vila Real Magalhaes Coelho, Vila Nova de Gaia, Portugal; Jesus Argente Oliver, Jesus Pozo, Ricardo Gracia Bouthelier, Antonio Oliver Iguacel, Amparo Rodriguez Sanchez and Dolores Rodriguez Arnao, Madrid, Concepcion Carles Genotes and Vicente Albiach, Valencia, Antonio Carrascosa Lezcano and Diego Yeste, Francisco Rodriguez-Hierro and Lourdes Ibanez, Barcelona, Juan Manuel Fernandez Garcia and Carlos ;Ruiz, Granada, Juan Pedro Lopez-Siguero, Maria Jose Martinez Aedo and Almudena del Pino, Malaga, and Manuel Pombo Arias and Jesus Barreiro Conde, Santiago de Compostela, Spain; Olle Soder and Eva Horemizova, Stockholm, Jan Aman, Orebro, and Mirek Vejvoda and Christian Penno, Helsingborg, Sweden.",null,37,9,10,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0301-0163",null,null,"HORM RES","Horm. Res.",null,2009,71,1,null,null,null,null,52,59,null,"10.1159/000173742",null,8,"Endocrinology & Metabolism","Endocrinology & Metabolism","394DB","WOS:000262424700008"]
[null,null,null,null,"J","Planka, L; Necas, A; Srnec, R; Rauser, P; Stary, D; Jancar, J; Amler, E; Filova, E; Hlucilova, J; Kren, L; Gal, P",null,null,null,"Planka, L.; Necas, A.; Srnec, R.; Rauser, P.; Stary, D.; Jancar, J.; Amler, E.; Filova, E.; Hlucilova, J.; Kren, L.; Gal, P.",null,null,"Use of Allogenic Stem Cells for the Prevention of Bone Bridge Formation in Miniature Pigs","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Growth plate; Injury; Physis; Limb deformity; Mesenchymal stem cells","DISTAL FEMORAL EPIPHYSIS; PARTIAL GROWTH ARREST; CHONDROGENIC DIFFERENTIATION; EXPERIMENTAL TRAUMA; PHYSEAL DEFECTS; SCAFFOLD; CARTILAGE; RABBITS; PLATE; TRANSPLANTATION","This study appears from an experiment previously carried out in New Zealand white rabbits. Allogenic mesenchymal stem cells (MSCs) were transplanted into an iatrogenically-created defect in the lateral section of the distal physis of the left femur in 10 miniature pigs. The right femur with the same defect served as a control. To transfer MSCs, a freshly prepared porous scaffold was used, based on collagen and chitosan, constituting a compact tube into which MSCs were implanted. The pigs were euthanized four months after the transplantation. On average, the left femur with transplanted MSCs grew more in length (0.56 +/- 0.14 cm) compared with right femurs with physeal defect without transplanted MSCs (0.14 +/- 0.3 cm). The average angular ( valgus) deformity of the left femur had an angle point of 0.78, following measurement and X-ray examination, whereas in the right femur without transplantation it was 3.7. The initial results indicate that preventive transplantation of MSCs into a physeal defect may prevent valgus deformity formation and probably also reduce disorders of the longitudinal bone growth. This part of our experiment is significant in the effort to advance MSCs application in human medicine by using pig as a model, which is the next step after experimenting on rabbits.","[Planka, L.; Stary, D.; Gal, P.] Fac Hosp Brno, Clin Pediat Surg Orthoped & Traumatol, Brno, Czech Republic; [Necas, A.; Srnec, R.; Rauser, P.] Univ Vet & Pharmaceut Sci Brno, Fac Vet Med, Small Anim Clin, Dept Surg & Orthopaed, Brno, Czech Republic; [Jancar, J.] Brno Univ Technol, Fac Chem, Inst Mat Chem, Brno, Czech Republic; [Amler, E.; Filova, E.] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Hlucilova, J.] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Prague, Czech Republic; [Kren, L.] Fac Hosp Brno, Inst Pathol & Anat, Brno, Czech Republic","Planka, L (reprint author), KDCHOT, Cernopolni 9, Brno 61300, Czech Republic.","lplanka@seznam.cz","Jancar, Josef/E-3360-2012",null,"Ministry of Health of the Czech Republic [NR9296-2/2007]; Ministry of Education, Youth and Sport of the Czech Republic [NPV II 2B06130]","This work was supported by the Ministry of Health of the Czech Republic (Research Projects of IGA MZ CR NR9296-2/2007) and Ministry of Education, Youth and Sport of the Czech Republic (NPV II 2B06130).","Ahn JI, 2004, J ORTHOP RES, V22, P1215, DOI 10.1016/j.orthres.2004.03.012; CAMPBELL CJ, 1959, J BONE JOINT SURG AM, V41, P1221; Chen F, 2003, J PEDIATR ORTHOPED, V23, P425, DOI 10.1097/00004694-200307000-00002; Chen GP, 2004, BIOCHEM BIOPH RES CO, V322, P50, DOI 10.1016/j.bbrc.2004.07.071; Filova E, 2007, PHYSIOL RES, V56, pS5; FORD LT, 1956, J BONE JOINT SURG AM, V38, P84; FOSTER BK, 1990, J ORTHOPAED RES, V8, P555, DOI 10.1002/jor.1100080412; Gal P, 2007, ACTA VET BRNO, V76, P265, DOI 10.2754/avb200776020265; Gal P, 2002, ACTA VET BRNO, V71, P327, DOI 10.2754/avb200271030327; HENNEY LHS, 1989, J AM ANIM HOSP ASSOC, V25, P573; Hui JHP, 2005, TISSUE ENG, V11, P904, DOI 10.1089/ten.2005.11.904; Indrawattana N, 2004, BIOCHEM BIOPH RES CO, V320, P914, DOI 10.1016/j.bbre.2004.06.029; Janarv P M, 1998, J Pediatr Orthop, V18, P149, DOI 10.1097/00004694-199803000-00004; Jancar J, 2007, PHYSIOL RES, V56, pS17; JANOVEC M, 1993, ACTA CHIR ORTHOP TR, V60, P325; KAWABE N, 1987, J PEDIATR ORTHOPED, V7, P381; KEY JA, 1958, J BONE JOINT SURG AM, V40, P887; Kolacna L, 2007, PHYSIOL RES, V56, pS51; Krupa P, 2007, PHYSIOL RES, V56, pS107; LANGENSKIOLD A, 1975, J BONE JOINT SURG BR, V57, P325; Lee JW, 2004, YONSEI MED J, V45, P41; Li WJ, 2005, BIOMATERIALS, V26, P599, DOI 10.1016/j.biomaterials.2004.03.005; Lisignoli G, 2005, BIOMATERIALS, V26, P5677, DOI 10.1016/j.biomaterials.2005.02.031; MANN DC, 1990, J PEDIATR ORTHOPED, V10, P713; Maretta SM, 1983, J AM VET MED ASSOC, V182, P708; Miura Y, 2002, J BONE JOINT SURG AM, V84A, P793; MIZUTA T, 1987, J PEDIATR ORTHOPED, V7, P518; PIERMATTEI DL, 1990, HDB SMALL ANIMAL ORT, P681; Planka L, 2007, ACTA VET BRNO, V76, P253, DOI 10.2754/avb200776020253; Quintavalla J, 2002, BIOMATERIALS, V23, P109, DOI 10.1016/S0142-9612(01)00086-2; SHOJA A, 2002, SLOVENSKY LEKAR, V9, P368; SYKORA I, 1983, LAB ANIMAL BREEDING; VARGA E, 2007, PHYSL RES S1, V56, pS61",33,9,10,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,6,null,null,null,null,885,893,null,null,null,9,"Physiology","Physiology","539YP","WOS:000273296600013"]
[null,null,null,null,"J","Lins, S; Kim, R; Kruger, L; Chrzanowska, KH; Seemanova, E; Digweed, M",null,null,null,"Lins, Stephan; Kim, Ryong; Krueger, Lars; Chrzanowska, Krystyna H.; Seemanova, Eva; Digweed, Martin",null,null,"Clinical variability and expression of the NBN c.657del5 allele in Nijmegen Breakage Syndrome","GENE",null,null,"English","Article",null,null,null,null,null,"DNA repair; Nonsense-mediated mRNA decay; Hypomorphic mutation; Proteasome inhibition","MESSENGER-RNA DECAY; NBS1 CONTRIBUTES; GENE-MUTATIONS; DISEASE; PROTEIN; CANCER; OVEREXPRESSION; IDENTIFICATION; TRANSFORMATION; MALIGNANCIES","Patients affected by the autosomal recessive Nijmegen Breakage Syndrome (NBS [MIM 251260]) have possibly the highest risk for developing a malignancy of all the chromosomal instability syndromes. This reflects the profound disturbance to genomic integrity and cellular homeostasis that is caused by the mutation of the essential mammalian gene, NBN. Whilst null-mutation of Nbn is lethal in the mouse, NBS patients survive due to the fact that the common human founder mutation, found in over 90% of patients, is in fact hypomorphic and leads, by alternative translation, to varying amounts of a partially functional carboxy-terminal protein fragment, p70-nibrin. The expression level of p70-nibrin correlates with cancer incidence amongst patients. Using real-time PCR we have now found that the variation in p70-nibrin expression cannot be attributed to differences in mRNA quantity and that nonsense-mediated mRNA decay is not responsible for the observed variation. We discuss an alternative explanation for p70-nibrin expression variation. (C) 2009 Elsevier B.V. All rights reserved.","[Lins, Stephan; Kim, Ryong; Krueger, Lars; Digweed, Martin] Charite, Inst Human Genet, Campus Virchow Klinikum, D-13353 Berlin, Germany; [Kim, Ryong] Red Cross Gen Hosp, Inst Clin Chem, Pyongyang, North Korea; [Chrzanowska, Krystyna H.] Childrens Mem Hlth Inst, Dept Med Genet, PL-04730 Warsaw, Poland; [Seemanova, Eva] Charles Univ Prague, Sch Med 2, Inst Biol & Med Genet, Dept Clin Genet, Prague 15006 5, Motol, Czech Republic","Digweed, M (reprint author), Charite, Inst Human Genet, Campus Virchow Klinikum, Augustenburger Pl 1, D-13353 Berlin, Germany.","martin.digweed@charite.de",null,null,"Deutsche Forschungsgemeinschaft [SFB577]","Mrs Susanne Rothe, Ms Janina Radszewski, Mrs Veronique Dutrannoy-Tonsing and Mr. Bastian Salewsky are gratefully acknowl- edged for their excellent technical assistance. We are grateful to Dr. Kenshi Komatsu for providing the NBS GM7166VA7 fibroblasts. This work was supported by the Deutsche Forschungsgemeinschaft (SFB577).",null,26,9,9,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0378-1119",null,null,"GENE","Gene","NOV 1",2009,447,1,null,null,null,null,12,17,null,"10.1016/j.gene.2009.07.013",null,6,"Genetics & Heredity","Genetics & Heredity","503IL","WOS:000270527200002"]
[null,null,null,null,"J","Seidel, MG; Minkov, M; Witt, V; Matthes-Martin, S; Potschger, U; Worel, N; Leitner, G; Stary, J; Gadner, H; Peters, C",null,null,null,"Seidel, Markus G.; Minkov, Milen; Witt, Volker; Matthes-Martin, Susanne; Poetschger, Ulrike; Worel, Nina; Leitner, Gerda; Stary, Jan; Gadner, Helmut; Peters, Christina",null,null,"Granulocyte Transfusions in Children and Young Adults Does the Dose Matter?","JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"febrile neutropenia; invasive aspergillosis; granulocyte transfusions; infectious complications; stem cell transplantation; high-dose chemotherapy","STEM-CELL TRANSPLANTATION; G-CSF; STIMULATING FACTOR; INDIUM-111-LABELED GRANULOCYTES; NEUTROPENIC PATIENTS; PEDIATRIC-PATIENTS; SEVERE INFECTIONS; DONORS; RECIPIENTS; EFFICACY","Background: Granulocyte transfusions (GTs) may increase the absolute neutrophil count (ANC) before hematopoietic regeneration in neutropenic patients after chemotherapy or hematopoietic stem cell transplantation and Support anti-infective immunity. Procedure: We assessed efficacy and tolerability of 778 GTs in 70 treatment episodes of 49 children and 10 Young adults [median age 6.28 y (range: 0.13 to 17.7 y) and 21 y (18.0 to 28.0), respectively] suffering from bacterial (n = 55) and/or fungal (n = 31) infections during neutropenia owing to conventional chemotherapy (n = 14), hematopoietic stein cell transplantation conditioning (it 44), or the underlying disease (n = 1). We analyzed the impact of body weight. organ dysfunction, neutrophil close on ANC increment. infection elimination, and survival. Results: The median day-5 ANC increment was 1460/mu L, correlating to the administered close. However, 28-day survival did not correlate to the neutrophil dose nor to the ANC increment., potentially owing to the high number of neutrophils transfused to all patients (median > 6 x 10(9)/kg within 5d). The 28-day survival probability of the total patient cohort was 0.72 +/- 0.06 and the 100-day survival was 0.52 +/- 0.07. Adverse reactions were rare including fever (<= World Health Organization grade 111. 14%), chills (3%), and mild pulmonary complications (1%). Conclusions: These data corroborate the empirical evidence that GT with sufficient cell doses and rapid availability are a feasible, well-tolerated supplemental means to fight severe infections in neutropenic patients.","[Seidel, Markus G.; Minkov, Milen; Witt, Volker; Matthes-Martin, Susanne; Poetschger, Ulrike; Gadner, Helmut; Peters, Christina] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Worel, Nina; Leitner, Gerda] Med Univ Vienna, Clin Blood Grp Serol & Transfus Med, Vienna, Austria; [Stary, Jan] Univ Hosp Praha Motol, Dept Pediat Hematol Oncol, Prague, Czech Republic","Peters, C (reprint author), St Anna Childrens Hosp, Kinderspitalgasse 6, A-1090 Vienna, Austria.","christina.peters@Stanna.at",null,null,null,null,null,22,9,9,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1077-4114",null,null,"J PEDIAT HEMATOL ONC","J. Pediatr. Hematol. Oncol.","MAR",2009,31,3,null,null,null,null,166,172,null,null,null,7,"Oncology; Hematology; Pediatrics","Oncology; Hematology; Pediatrics","415HL","WOS:000263924800004"]
[null,null,null,null,"J","Hromadnikova, I; Benesova, M; Zejskova, L; Stehnova, J; Doucha, J; Sedlacek, P; Dlouha, K; Krofta, L",null,null,null,"Hromadnikova, Ilona; Benesova, Martina; Zejskova, Lenka; Stehnova, Jana; Doucha, Jindrich; Sedlacek, Petr; Dlouha, Klara; Krofta, Ladislav",null,null,"The Effect of DYS-14 Copy Number Variations on Extracellular Fetal DNA Quantification in Maternal Circulation","DNA AND CELL BIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"CONGENITAL ADRENAL-HYPERPLASIA; QUANTITATIVE PCR MEASUREMENT; TESTIS-SPECIFIC PROTEIN; REAL-TIME PCR; SEX DETERMINATION; GENDER DETERMINATION; PRENATAL-DIAGNOSIS; GROWTH RESTRICTION; PLASMA; SERUM","The aims of our research involved to investigate DYS-14 copy number variations in healthy males, to quantify extracellular DNA in maternal circulation in normal versus complicated pregnancies, and to study variations in the DYS-14 copy number in extracellular male fetal DNA. Fifty-five healthy males, 43 uncomplicated male singleton pregnancies (23 sampled at the 16th week and 20 sampled at the 36th week), and 15 pregnancies with placental insufficiency (PI)-related complications (mean 34.1 weeks) were analyzed using real-time PCR with DYS-14 sequence, sex determining region Y (SRY), and beta-globin (GLO) genes used as markers. Increased levels of extracellular DNA were detected in PI-related complications relative to gestational age-matched controls (SRY, p<0.001; DYS-14, p=0.007; GLO, p<0.001). When the mean +2SD (standard deviation) of controls was used as a cutoff, SRY, DYS-14, and GLO achieved 91.7%, 68.8%, and 94.4% accuracy, respectively, for differentiation between normal and complicated pregnancies. Considerable variations in the DYS-14 copy number in healthy males (mean 52.6) and extracellular DNA were found. A lower DYS-14 copy number was observed in PI-related complications (mean 83.5) compared to uncomplicated pregnancies (16th week: mean 114.2, p=0.02; 36th week: mean 142.8, p=0.04). The DYS-14 copy number was higher in extracellular DNA throughout gestation relative to healthy males. We concluded that, regarding interindividual copy number variations, the DYS-14 sequence is not an optimal marker for extracellular fetal DNA quantification for differentiation between normal and complicated pregnancies.","[Hromadnikova, Ilona; Benesova, Martina; Zejskova, Lenka; Stehnova, Jana] Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Prague 10000 10, Czech Republic; [Doucha, Jindrich] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Clin Obstet & Gynecol, Prague 10000 10, Czech Republic; [Sedlacek, Petr] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 10000 10, Czech Republic; [Dlouha, Klara; Krofta, Ladislav] Inst Care Mother & Child, Prague, Czech Republic","Hromadnikova, I (reprint author), Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Ruska 87, Prague 10000 10, Czech Republic.","ilona.hromadnikova@lf3.cuni.cz",null,null,"MSM [0021620806]; SAFE [LSHB-CT-2004-503243]","We thank the staff of the Clinic of Obstetrics and Gynaecology and the Department of Paediatric Haematology and Oncology, University Hospital Motol, and the Institute for the Care of the Mother and Child for their participation in the collection of data used for this analysis. This work was supported by grant projects MSM 0021620806 and SAFE LSHB-CT-2004-503243.",null,31,8,9,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1044-5498",null,null,"DNA CELL BIOL","DNA Cell Biol.","JUL",2009,28,7,null,null,null,null,351,358,null,"10.1089/dna.2009.0855",null,8,"Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity","461RA","WOS:000267285500007"]
[null,null,null,null,"J","Merkerova, M; Vasikova, A; Bruchova, H; Libalova, H; Topinka, J; Balascak, I; Sram, RJ; Brdicka, R",null,null,null,"Merkerova, Michaela; Vasikova, Alzbeta; Bruchova, Hana; Libalova, Helena; Topinka, Jan; Balascak, Ivan; Sram, Radim J.; Brdicka, Radim",null,null,"Differential gene expression in umbilical cord blood and maternal peripheral blood","EUROPEAN JOURNAL OF HAEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"gene expression; umbilical cord blood; peripheral blood; hematopoiesis; immune system","VERSUS-HOST-DISEASE; IMMUNE-RESPONSES; UNRELATED DONORS; DENDRITIC CELLS; BONE-MARROW; TRANSPLANTATION; ADULTS; LYMPHOCYTES; ENGRAFTMENT; RECOVERY","Objectives: Umbilical cord blood (UCB) has become a useful alternative source of hematopoietic stem cells for clinical and research applications. UCB represents neonatal blood and differs from adult blood in many aspects, displaying different cell composition and various features of cellular immaturity. To understand molecular basis of phenotypic differences between neonatal and adult blood, we studied variations in transcriptome of UCB and maternal peripheral blood (PB). Methods: Using Illumina microarrays, we determined gene expression profiles of UCB and PB samples obtained from 30 mothers giving birth to living baby. Results: Out of 20 589 tested genes, 424 genes were down-regulated and 417 genes were up-regulated in UCB compared with PB. Reduced expression of many immunity-related pathways (e.g. TLR pathway, Jak-STAT pathway, cytokine-cytokine receptor interaction) in neonatal blood cells may contribute to the poor response to antigens, increasing susceptibility to infections at the time of disappearance of protective maternal antibodies. On the other hand, overexpression of erythropoiesis-related genes (glycophorins, fetal hemoglobins, enzymes catalysing heme synthesis and erythrocyte differentiation) in UCB probably enforces red cell production in newborns. Conclusions: Our study demonstrates that neonatal and maternal bloods show specific gene expression profiles, likely reflecting differences in phenotypes of immunologically immature and fully evolved hematopoietic cells.","[Merkerova, Michaela; Vasikova, Alzbeta; Bruchova, Hana; Brdicka, Radim] Inst Hematol & Blood Transfus, CR-12820 Prague 2, Czech Republic; [Libalova, Helena; Topinka, Jan; Sram, Radim J.] Acad Sci Czech Republic, Inst Expt Med, Prague 4, Czech Republic; [Balascak, Ivan] Fac Hosp Motol, Prague 5, Czech Republic","Brdicka, R (reprint author), Inst Hematol & Blood Transfus, U Nemocnice 1, CR-12820 Prague 2, Czech Republic.","Radim.Brdicka@uhkt.cz",null,null,"Czech Ministry of Education Youth and Sports [2B06088]","The authors wish to thank Mgr. Viktor Stranecky (Institute of Inherited Metabolic Disorders, 1st Faculty of Medicine of Charles University, Prague) for the array data analyses. The study was supported by the Czech Ministry of Education Youth and Sports (Grant No. 2B06088).",null,23,8,8,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0902-4441",null,null,"EUR J HAEMATOL","Eur. J. Haematol.","SEP",2009,83,3,null,null,null,null,183,190,null,"10.1111/j.1600-0609.2009.01281.x",null,8,"Hematology","Hematology","479TP","WOS:000268684100003"]
[null,null,null,null,"J","Pardini, B; Naccarati, A; Polakova, V; Smerhovsky, Z; Hlavata, I; Soucek, P; Novotny, J; Vodickova, L; Tomanova, V; Landi, S; Vodicka, P",null,null,null,"Pardini, Barbara; Naccarati, Alessio; Polakova, Veronika; Smerhovsky, Zdenek; Hlavata, Ivona; Soucek, Pavel; Novotny, Jan; Vodickova, Ludmila; Tomanova, Vera; Landi, Stefano; Vodicka, Pavel",null,null,"NBN 657del5 heterozygous mutations and colorectal cancer risk in the Czech Republic","MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS",null,null,"English","Article",null,null,null,null,null,"NBN 657del5; Colorectal cancer; NBS","NIJMEGEN-BREAKAGE-SYNDROME; REPAIR GENETIC POLYMORPHISMS; NBS1 GENE; ATAXIA-TELANGIECTASIA; BREAST-CANCER; CHROMOSOMAL INSTABILITY; LYMPHOMA; CARRIERS; PROTEIN; NIBRIN","The most frequent Nijmegen breakage syndrome (NBS)-causing mutation is a 5-base pair deletion in gene coding for nibrin (NBN 657del5), which results in a non-fully functional protein product and is particularly frequent in Central and Eastern Europe. Recent studies have investigated whether NBN 657del5 carriage may predispose to an increased risk of different types of cancer. The Czech Republic has one of the highest incidences of colorectal cancer in the world as well as high incidence of NBS. To assess whether NBN 657del5 associates with an increased risk of sporadic colorectal cancer, we have screened 771 colorectal cancer patients, 614 controls with negative colonoscopy and 818 healthy blood donors from the Czech Republic. There were no significant differences between the frequencies of heterozygous carriers among the three groups. The present results do not provide any evidence that the exceeding risk of CRC in this population is attributable to the high frequency of heterozygous carriage of the NBN 657del5. (c) 2009 Elsevier B.V. All rights reserved.","[Vodicka, Pavel] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague 14200 4, Czech Republic; [Polakova, Veronika; Hlavata, Ivona; Vodicka, Pavel] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Hlavata, Ivona; Soucek, Pavel; Vodickova, Ludmila] Natl Inst Publ Hlth, Prague, Czech Republic; [Novotny, Jan] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Tomanova, Vera] Jihlava Hosp, Dept Gastroenterol, Jihlava, Czech Republic; [Landi, Stefano] Univ Pisa, Dept Biol, I-56100 Pisa, Italy","Vodicka, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Videnska 1083, Prague 14200 4, Czech Republic.","pvodicka@biomed.cas.cz",null,null,"Czech Science Foundation [GACR 310/07/1430, GACR 305/09/P194]","This study was supported by the grants: Czech Science Foundation, no.: GACR 310/07/1430 and GACR 305/09/P194, Internal Grant Agency of the Czech Ministry of Health, no.: IGA 8563-5/2005, and MSM0021620808.",null,29,8,8,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0027-5107",null,null,"MUTAT RES-FUND MOL M","Mutat. Res.-Fundam. Mol. Mech. Mutagen.","JUN 18",2009,666,41671,null,null,null,null,64,67,null,"10.1016/j.mrfmmm.2009.04.004",null,4,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","463VX","WOS:000267462100010"]
[null,null,null,null,"J","Gal, P; Toporcer, T; Grendel, T; Vidova, Z; Smetana, K; Dvorankova, B; Gal, T; Mozes, S; Lenhardt, L; Longauer, F; Sabol, M; Sabo, J; Backor, M",null,null,null,"Gal, Peter; Toporcer, Tomas; Grendel, Tomas; Vidova, Zuzana; Smetana, Karel, Jr.; Dvorankova, Barbora; Gal, Tomas; Mozes, Stefan; Lenhardt, L'udovit; Longauer, Frantisek; Sabol, Marian; Sabo, Jan; Backor, Martin",null,null,"Effect of Atropa belladonna L. on skin wound healing: Biomechanical and histological study in rats and in vitro study in keratinocytes, 3T3 fibroblasts, and human umbilical vein endothelial cells","WOUND REPAIR AND REGENERATION",null,null,"English","Article",null,null,null,null,null,null,"MUSCARINIC RECEPTORS; CHOLINERGIC SYSTEM; EXPRESSION; DIFFERENTIATION; GROWTH; PROLIFERATION; ANGIOGENESIS; STIMULATION; MECHANISMS; EXTRACT","The effect of Atropa belladonna L. (AB) aqueous extract on skin wound healing was studied in male Sprague-Dawley rats subjected to two parallel full-thickness skin incisions on the back. Specimens for histological evaluation were collected on days 2 and 5 whereas for biomechanical testing, they were collected on day 5. In the in vitro study, a different concentration of AB extract was used to test the differentiation of keratinocytes using a panel of selected antibodies, proliferation, and cell survival of 3T3 fibroblasts and human umbilical vein endothelial cells using the MTT-assay. Results of the in vivo experiments showed in AB-treated wounds a shortened process of inflammation and accelerated collagen formation, as well as significantly increased wound stiffness as compared with control tissues. The in vitro examination showed that control keratinocytes were cytokeratin 19 free, while samples exposed to the highest AB extract concentration expressed CK19. Moreover, all concentrations were stimulatory to human umbilical vein endothelial cell proliferation. In addition, only the AB extract at the lowest tested concentration increased fibroblast growth, but higher concentrations decreased cell survival. In conclusion, our results indicate that the AB water extract positively affects early phases of skin wound healing in rats. However, the in vitro results on the inverse relation between the concentration of the AB extract and its effects on cell proliferation may be important for future research.","[Gal, Peter] E Slovak Inst Cardiovasc Dis, Kosice 04011, Slovakia; [Gal, Peter; Toporcer, Tomas; Grendel, Tomas; Sabo, Jan] Safarik Univ, Dept Med Biophys, Kosice, Slovakia; [Gal, Peter; Backor, Martin] Safarik Univ, Inst Biol & Ecol, Kosice, Slovakia; [Gal, Peter; Vidova, Zuzana] Safarik Univ, Dept Pharmacol, Kosice, Slovakia; [Smetana, Karel, Jr.; Dvorankova, Barbora; Gal, Tomas] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Smetana, Karel, Jr.; Dvorankova, Barbora] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Mozes, Stefan] Slovak Acad Sci, Inst Anim Physiol, Kosice, Slovakia; [Gal, Peter; Lenhardt, L'udovit] Univ Vet Med, Dept Pathol Anat, Kosice, Slovakia; [Longauer, Frantisek] Safarik Univ, Dept Forens Med, Kosice, Slovakia; [Sabol, Marian] Safarik Univ, Dept Med & Clin Microbiol, Kosice, Slovakia","Gal, P (reprint author), E Slovak Inst Cardiovasc Dis, Irieda SNP 1, Kosice 04011, Slovakia.","galovci@yahoo.com",null,null,"Slovak Research and Development Agency [APVV-0325-07]; Ministry of Education, Youth and Sport of the Czech Republic [MSM0021620806]","We thank Danielle Miller for her editorial help in preparing this manuscript. We also thank M. Harakal'ova, A. Sucha, I. Tomkova, and E. Vancova for their useful technical assistance. This study was supported in part by the Slovak Research and Development Agency (No. APVV-0325-07) and by the Ministry of Education, Youth and Sport of the Czech Republic (No. MSM0021620806). We thank U.S. Steel Kosice and Tatra banka (both from Slovak Republic) for buying us the Olympus BX51 fluorescence microscope.",null,32,8,8,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1067-1927",null,null,"WOUND REPAIR REGEN","Wound Repair Regen.","MAY-JUN",2009,17,3,null,null,null,null,378,386,null,"10.1111/j.1524-475X.2009.00475.x",null,9,"Cell Biology; Dermatology; Medicine, Research & Experimental; Surgery","Cell Biology; Dermatology; Research & Experimental Medicine; Surgery","448DZ","WOS:000266244600013"]
[null,null,null,null,"J","Ercan, O; Alikasifoglu, M; Erginoz, E; Janda, J; Kabicek, P; Rubino, A; Constantopoulos, A; Ilter, O; Vural, M",null,null,null,"Ercan, Oya; Alikasifoglu, Mujgan; Erginoz, Ethem; Janda, Jan; Kabicek, Pavel; Rubino, Armido; Constantopoulos, Andreas; Ilter, Ozdemir; Vural, Mehmet",null,null,"Demography of adolescent health care delivery and training in Europe","EUROPEAN JOURNAL OF PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"Adolescent health; Europe; Training","GENERAL-PRACTITIONERS; UNMET EDUCATION; YOUNG TEENAGERS; NATIONAL-SURVEY; MEDICINE; NEEDS; ATTITUDES; SERVICES; PROFESSIONALS; CONSULTATION","We aimed to determine the status of and factors associated with adolescent health care delivery and training in Europe on behalf of the European Paediatric Association-UNEPSA. A questionnaire was mailed to the presidents of 48 national paediatric societies in Europe. For statistical analyses, non-parametric tests were used as appropriate. Six of the countries had a paediatric (PSPCA), 14 had a combined and nine had a general practitioner/family doctor system for the primary care of adolescents (GP/FDSA). Paediatricians served children 17 years of age or older in 15 and 17, up to 16 years of age in three and six, and up to 14 years of age in six and six countries in outpatient and inpatient settings, respectively. Fifteen and 18 of the countries had some kind of special inpatient wards and outpatient clinics for adolescents, respectively. Twenty-eight of the countries had some kind of national/governmental screening or/and preventive health programmes for adolescents. In countries with a PSPCA, the gross national income (GNI) per capita was significantly lower than in those with a GP/FDSA, and the mean upper age limit of adolescents was significantly higher than in those with the other systems. In the eastern part of Europe, the mortality rate of 10-14 year olds was significantly higher than that in the western part (p=0.008). Training in adolescent medicine was offered in pre-graduate education in 14 countries in the paediatric curriculum and in the context of paediatric residency and GP/family physician residency programmes in 18 and nine countries, respectively. Adolescent medicine was reported as a recognised subspecialty in 15 countries and as a certified subspecialty of paediatrics in one country. In countries with a PSPCA, paediatric residents were more likely to be educated in adolescent medicine than paediatric residents in countries with a GP/FDSA. The results of the present study show that there is a need for the reconstruction and standardisation of adolescent health care delivery and training in European countries. The European Paediatric Association-UNEPSA could play a key role in the implementation of the proposals suggested in this paper.","[Ercan, Oya; Alikasifoglu, Mujgan] Istanbul Univ, Cerrahpasa Med Fac, Div Adolescent Med, Dept Paediat, Istanbul, Turkey; [Ercan, Oya] Istanbul Univ, Cerrahpasa Med Fac, Div Endocrinol, Dept Paediat, Istanbul, Turkey; [Erginoz, Ethem] Istanbul Univ, Cerrahpasa Med Fac, Dept Publ Hlth, Istanbul, Turkey; [Janda, Jan] Univ Hosp Motol, Dept Pediat 1, Prague, Czech Republic; [Kabicek, Pavel] Charles Univ Prague, Dept Paediat & Adolescent Med, Fac Med 1, Prague, Czech Republic; [Rubino, Armido] Univ Naples Federico 2, Fac Med & Chirurg, Naples, Italy; [Constantopoulos, Andreas] Univ Athens, Dept Paediat, Athens, Greece; [Vural, Mehmet] Nisantasi Ihlamur Yolu, TR-80200 Istanbul, Turkey","Vural, M (reprint author), Nisantasi Ihlamur Yolu, 2 Cehreli Apt 67-9, TR-80200 Istanbul, Turkey.","vuralm@istanbul.edu.tr",null,null,null,null,null,34,8,8,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,null,"EUR J PEDIATR","Eur. J. Pediatr.","APR",2009,168,4,null,null,null,null,417,426,null,"10.1007/s00431-008-0759-1",null,10,"Pediatrics","Pediatrics","407KR","WOS:000263362500004"]
[null,null,null,null,"J","Webb, NJA; Prokurat, S; Vondrak, K; Watson, AR; Hughes, DA; Marks, SD; Moghal, NE; Fitzpatrick, MM; Milford, DV; Saleem, MA; Jones, CA; Friman, S; Van Damme-Lombaerts, R; Janssen, F; Hamer, C; Rhodes, S",null,null,null,"Webb, Nicholas J. A.; Prokurat, Sylwester; Vondrak, Karel; Watson, Alan R.; Hughes, David A.; Marks, Stephen D.; Moghal, Nadeem E.; Fitzpatrick, Maggie M.; Milford, David V.; Saleem, Moin A.; Jones, Caroline A.; Friman, Styrbjorn; Van Damme-Lombaerts, Rita; Janssen, Francoise; Hamer, Clare; Rhodes, Sarah",null,null,"Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Renal transplantation; Basiliximab; Interleukin-2 receptor (IL2R) antibodies; Graft survival; Acute rejection; Long-term survival","PEDIATRIC RENAL-TRANSPLANTATION; CYCLOSPORINE MICROEMULSION; RECIPIENTS; TOLERABILITY; EFFICACY; CHILDREN","A total of 192 children and adolescents undergoing renal transplantation were randomly chosen to receive tacrolimus, azathioprine and corticosteroids (TAS, n=93) or tacrolimus, azathioprine, corticosteroids and two doses of basiliximab (TAS + B, n=99). Six-month outcome data have previously been reported; this manuscript reports the 2-year data. Complete 2-year data were available on 164 (85.4%) of the original 192 patients. There was a single death in the TAS arm. Kaplan-Meier estimates of survival free of graft loss at 2 years were 94.9% in the TAS + B arm and 89.6% in the TAS arm [hazard ratio (HR) 0.52; 95% confidence interval (CI) 0.17 to 1.54, P=0.23]. Estimates of survival free from rejection at 2 years were 75.2% in the TAS + B arm and 68.7% in the TAS arm (HR 0.81; 95% CI 0.46 to 1.40, P=0.44). The mean estimated glomerular filtration rate (GFR) at 2 years, was 65.8 ml/min per 1.73 m(2) body surface area in the TAS arm and 66.7 ml/min per 1.73 m(2) in the TAS + B arm (P=0.78). Blood pressure and cholesterol levels were similar in the two arms, and there was no evidence of a difference in the incidence of infection or malignancy. These data provide further evidence of a lack of benefit associated with the addition of basiliximab to a TAS regimen for European paediatric renal transplant recipients at low immunological risk.","[Webb, Nicholas J. A.] Royal Manchester Childrens Hosp, Dept Paediat Nephrol, Manchester M27 4HA, Lancs, England; [Prokurat, Sylwester] Childrens Mem Hlth Inst, Dept Paediat Nephrol, Warsaw, Poland; [Vondrak, Karel] Univ Hosp Motol, Pediat Clin, Prague, Czech Republic; [Watson, Alan R.] Children & Young Peoples Kidney Unit, Nottingham, England; [Hughes, David A.] Royal Hosp Sick Children, Dept Paediat Nephrol, Glasgow G3 8SJ, Lanark, Scotland; [Marks, Stephen D.] Great Ormond St Hosp Sick Children, Dept Paediat Nephrol, London, England; [Moghal, Nadeem E.] Royal Victoria Infirm, Dept Paediat Nephrol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Fitzpatrick, Maggie M.] St James Univ Hosp, Dept Paediat Nephrol, Leeds, W Yorkshire, England; [Milford, David V.] Birmingham Childrens Hosp, Dept Paediat Nephrol, Birmingham, W Midlands, England; [Saleem, Moin A.] Bristol Childrens Hosp, Dept Paediat Nephrol, Bristol, Avon, England; [Jones, Caroline A.] Royal Liverpool Childrens Hosp, Dept Paediat Nephrol, Liverpool L7 7DG, Merseyside, England; [Friman, Styrbjorn] SU Sahlgrenska Univ Hosp, Gothenburg, Sweden; [Van Damme-Lombaerts, Rita] U2 Gasthuisberg, Louvain, Belgium; [Janssen, Francoise] Hop Univ Enfants Reine Fabiola, Brussels, Belgium; [Hamer, Clare] Manchester Royal Infirm, Dept Transplantat, Manchester M13 9WL, Lancs, England; [Rhodes, Sarah] Pennine Acute Hosp NHS Trust, Dept Res & Dev, Manchester, Lancs, England","Webb, NJA (reprint author), Royal Manchester Childrens Hosp, Dept Paediat Nephrol, Manchester M27 4HA, Lancs, England.","nicholas.webb@cmmc.nhs.uk","Marks, Stephen/C-6818-2008",null,"Astellas (formerly Fujisawa)","This study was supported by an unrestricted educational grant from Astellas (formerly Fujisawa). The authors would like to thank all members of their transplant teams who contributed to data collection.",null,13,8,8,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","JAN",2009,24,1,null,null,null,null,177,182,null,"10.1007/s00467-008-0931-x",null,6,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","403DY","WOS:000263064300025"]
[null,null,null,null,"J","Grycova, L; Sklenovsk, P; Lansky, Z; Janovska, M; Otyepka, M; Amler, E; Teisinger, J; Kubala, M",null,null,null,"Grycova, Lenka; Sklenovsk, Petr; Lansky, Zdenek; Janovska, Marika; Otyepka, Michal; Amler, Evzen; Teisinger, Jan; Kubala, Martin",null,null,"ATP and magnesium drive conformational changes of the Na+/K+-ATPase cytoplasmic headpiece","BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES",null,null,"English","Article",null,null,null,null,null,"Na+/K+-ATPase; P-type ATPase; ATP; Magnesium; Tryptophan fluorescence; Conformational change","SARCOPLASMIC-RETICULUM CA2+-ATPASE; P-TYPE ATPASES; CALCIUM-PUMP; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; NUCLEOTIDE-BINDING; ENERGY TRANSDUCTION; ISOLATED DOMAIN; ALPHA-SUBUNIT; ION-TRANSPORT","Conformational changes of the Na+/K+-ATPase isolated large cytoplasmic segment connecting transmembrane helices M4 and M5 (C45) induced by the interaction with enzyme ligands (i.e. Mg2+ and/or ATP) were investigated by means of the intrinsic tryptophan fluorescence measurement and molecular dynamic simulations. Our data revealed that this model system consisting of only two domains retained the ability to adopt open or closed conformation, i.e. behavior, which is expected from the crystal structures of relative Ca2+-ATPase from sarco(endo)plasmic reticulum for the corresponding part of the entire enzyme. Our data revealed that the C45 is found in the closed conformation in the absence of any ligand, in the presence of Mg2+ only, or in the simultaneous presence of Mg2+ and ATP. Binding of the ATP alone (i.e. in the absence of Mg2+) induced open conformation of the C45. The fact that the transmembrane part of the enzyme was absent in our experiments suggested that the observed conformational changes are consequences only of the interaction with ATP or Mg2+ and may not be related to the transported cations binding/ release, as generally believed. Our data are consistent with the model, where ATP binding to the low-affinity site induces conformational change of the cytoplasmic part of the enzyme, traditionally attributed to E2 -> E1 transition, and subsequent Mg2+ binding to the enzyme-ATP complex induces in turn conformational change traditionally attributed to E1 -> E2 transition. (C) 2009 Elsevier B.V. All rights reserved.","[Janovska, Marika; Kubala, Martin] Palacky Univ, Biophys Lab, Fac Sci, Olomouc 77146, Czech Republic; [Grycova, Lenka; Lansky, Zdenek; Teisinger, Jan] Acad Sci Czech Republic, Inst Physiol, CR-14220 Prague 4, Czech Republic; [Sklenovsk, Petr; Otyepka, Michal] Palacky Univ, Dept Phys Chem, Fac Sci, Olomouc 77146, Czech Republic; [Amler, Evzen] Charles Univ Prague, Inst Biophys, Fac Med 2, Prague, Czech Republic","Kubala, M (reprint author), Palacky Univ, Biophys Lab, Fac Sci, Tr Svobody 26, Olomouc 77146, Czech Republic.","mkubala@prfnw.upol.cz","Otyepka, Michal/A-5922-2008; Grycova, Lenka/B-7118-2012; Teisinger, Jan /B-7122-2012; Havlikova, Marika/A-1789-2012",null,"Czech Science Foundation [GACR 203/07/0564, GACR 522-08-H003, GACR 303/07/0915]; Czech Ministry of Schools, Youth and Sports [LC512, MSM 6198959215, MSM 6198959216]","This work was supported by the grants of the Czech Science Foundation GACR 203/07/0564, GACR 522-08-H003 and GACR 303/07/0915, and the research projects of Czech Ministry of Schools, Youth and Sports LC512, MSM 6198959215 and MSM 6198959216.",null,48,7,8,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0005-2736",null,null,"BBA-BIOMEMBRANES","Biochim. Biophys. Acta-Biomembr.","MAY",2009,1788,5,null,null,null,null,1081,1091,null,"10.1016/j.bbamem.2009.02.004",null,11,"Biochemistry & Molecular Biology; Biophysics","Biochemistry & Molecular Biology; Biophysics","447KS","WOS:000266190600019"]
[null,null,null,null,"J","Sramek, J; Stulik, J; Sebesta, P; Vyskocil, T; Kryl, J; Nesnidal, P; Barna, M",null,null,null,"Sramek, J.; Stulik, J.; Sebesta, P.; Vyskocil, T.; Kryl, J.; Nesnidal, P.; Barna, M.",null,null,"Hyperextension Trauma in Patients with Cervical Spondylosis","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"cervical spine; hyperextension injury; spondylosis; myelopathy","CENTRAL CORD SYNDROME; 65 YEARS OLD; SPINE INJURIES; LAMINOPLASTY; MYELOPATHY","PURPOSE OF THE STUDY To evaluate retrospectively a group of patients with hyperextension injury to the cervical spine who were treated at the Department of Spinal Surgery of the University Hospital in Motol, Prague, between 2003 and 2006. MATERIAL The group comprised 22 patients, 17 men (77 %) and five women (23 %) in the age range of 35 to 81 years, with an average of 59.5 years. All patients had, in association with the injury, neurological deficit of varying degree. METHODS All patients underwent X-ray and magnetic resonance imaging examination and received methylprednisolone according to the National Acute Spinal Cord Injury Study (NASCIS) 2 trial. Eleven patients had urgent surgery within 24 hours of injury; eight patients were operated on within an interval of 3 days to 2 months because of the seriousness of their state and multiple morbidity; and three patients were treated conservatively. Neurological deficit in terms of upper- and lower-limb mobility was evaluated by the American Spinal Injury Association (ASIA) motor score. The values obtained for the urgently operated patients and for those operated on after a time interval were compared by Wilcoxon's two-sample test. The other aspects evaluated included trauma aetiology, level of spinal cord injury, manner of treatment, and intra-operative and post-operative complications. RESULTS The most frequent cause of injury was a low-height fall (13 patients; 59 %); car accidents ranked second (9 patients; 41 %). In five patients (22.7 %) ebriety was found. Eighteen patients had no skeletal injury (81.8 %). Four patients (18.2 %). Four patients (18.2 %) suffered fractures of articular or spinous processes, but the anterior column skeleton was intact in all. The segment most frequently affected by myopathy was C3-C4, then C4-C5 and C5-C6. Decompression was carried out to the extent of myopathy; and in the adjacent segments only if significant stenosis was present. In both subgroups of surgically treated patients (urgent and delayed management), comparisons of the ASIA scores at the time of injury and at one-year follow-up showed no significat improvement in post-operative mobility, as evaluated by Wilcoxon's two-sample test at a level of significance alpha = 5 %. No intra-operative or post-operative complications, except for early death, were recorded. In all patients the wound healed by first intention and no loosening of instrumentation was foud on follow-ups at the out-patient departments. DISCUSSION Although the greatest narrowing of the spinal canal due to spondylosis occurs at the C5-C6 segment, the C4-C5 segment sustained most injuries. Although some relevant papers report no significant difference in improved neurological deficit between patients treated surgically and those undergoing conservative therapy, we prefer surgical management, in most of the cases from the anterior approach, which allows us to remove dorsal osteophytes and perform careful decompression to prevent damage to nerve structures and to preserve those which are still intact. There was no significant difference in the outcome between urgent and delayed trauma management, which is unusual amongst other injuries associated with neurological lesions and this indicates that the timing of surgery must be strictly individual and should be carried out at a time when operative benefit outweighs operative burden. The surgical treatment used should, in the first place, lead to early recuperation and rehabilitation. CONCLUSIONS Hyperextension injuries of the cervical spine are usually associated with serious neurological deficit. A correct algorithm of examination will result in good treatment outcomes. However, these injuries require a therapy that is long-lasting and difficult, with a need for cooperation of anaesthesiologists, spinal surgeons, physical therapists and, last but not least, psychologists.","[Sramek, J.; Stulik, J.; Sebesta, P.; Vyskocil, T.; Kryl, J.; Nesnidal, P.; Barna, M.] FN Motol, Spondylochirurg Oddeleni, Prague, Czech Republic; [Stulik, J.; Sebesta, P.; Vyskocil, T.; Kryl, J.] LF UK, Chirurg Klin 1 3, Prague, Czech Republic; [Stulik, J.] LF UK, Ortoped Klin Deti & Dospelych 2, Prague, Czech Republic","Sramek, J (reprint author), FN Motol Sekretariat, Spondylochirurg Oddeleni, Uvalu 84, Prague 15000 5, Czech Republic.",null,null,null,null,null,null,29,7,8,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2009,76,2,null,null,null,null,128,132,null,null,null,5,"Orthopedics","Orthopedics","439ZY","WOS:000265668600009"]
[null,null,null,null,"J","Crha, M; Necas, A; Srnec, R; Janovec, J; Stehlik, L; Rauser, P; Urbanova, L; Planka, L; Jancar, J; Amler, E",null,null,null,"Crha, Michal; Necas, Alois; Srnec, Robert; Janovec, Jan; Stehlik, Ladislav; Rauser, Petr; Urbanova, Lucie; Planka, Ladislav; Jancar, Josef; Amler, Evzen",null,null,"Mesenchymal Stem Cells in Bone Tissue Regeneration and Application to Bone Healing","ACTA VETERINARIA BRNO",null,null,"English","Article",null,null,null,null,null,"Tissue engineering; biomaterials; scaffold; segmental bone lesion; fracture healing; growth factors; review","MARROW STROMAL CELLS; DONOR SITE MORBIDITY; MORPHOGENETIC PROTEIN; IN-VITRO; OSTEOGENIC DIFFERENTIATION; SEGMENTAL DEFECT; FEMORAL DEFECTS; REPAIR; CARTILAGE; CULTURE","This synoptic study gives a concise overview of current knowledge of bone healing, the role of mesenchymal stem cells in bone tissue regeneration and contemporary possibilities of supporting regeneration of damaged bone. Attention of research concerning the healing of fractures with extensive loss of bone tissue following trauma, the treatment of belatedly healing or non-healing fractures or the healing of segmental bone defects following tumour resection, is focused on development of three-dimensional scaffolds planted with mesenchymal stem cells that might be used for reconstruction of such large bone lesions. Presented are possibilities of transplantation of mesenchymal stem cells combined with biomaterials into bone defects, including the results of our own experimental studies dealing with the use of stem cells in the treatment of damaged tissues of the musculoskeletal system in animal models.","[Crha, Michal; Necas, Alois; Srnec, Robert; Janovec, Jan; Stehlik, Ladislav; Rauser, Petr; Urbanova, Lucie] Univ Vet & Pharmaceut Sci Brno, Dept Surg & Orthopaed, Small Anim Clin, Fac Vet Med, Brno 61242, Czech Republic; [Planka, Ladislav] Fac Hosp Brno, Dept Pediat Surg Orthopaed & Traumatol, Brno, Czech Republic; [Jancar, Josef] Brno Univ Technol, Inst Mat Chem, Brno, Czech Republic; [Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Prague, Czech Republic","Crha, M (reprint author), Univ Vet & Pharmaceut Sci Brno, Dept Surg & Orthopaed, Small Anim Clin, Fac Vet Med, Palackeho 1-3, Brno 61242, Czech Republic.","crham@vfu.cz","Jancar, Josef/E-3360-2012; Crha, Michal/E-4279-2012",null,"Ministry of Education, Youth and Sports of the Czech Republic [NPV II 2B06130]; Grant Agency of the Academy of Sciences [IAA500390702]; IGA VFU Brno [251/2009/FVL, 259/2009/FVL]","The study was supported by the Ministry of Education, Youth and Sports of the Czech Republic - project NPV II 2B06130, by the Grant Agency of the Academy of Sciences No. IAA500390702, by the IGA VFU Brno project No. 251/2009/FVL, and project IGA VFU Brno No. 259/2009/FVL.","Ahn JI, 2004, J ORTHOP RES, V22, P1215, DOI 10.1016/j.orthres.2004.03.012; Anitua E, 2004, THROMB HAEMOSTASIS, V91, P4, DOI 10.1160/TH03-07-0440; Anitua E, 2005, J ORTHOP RES, V23, P281, DOI 10.1016/j.orthres.2004.08.015; Arinzeh Treena Livingston, 2005, Foot Ankle Clin, V10, P651, DOI 10.1016/j.fcl.2005.06.004; Arinzeh TL, 2003, J BONE JOINT SURG AM, V85A, P1927; Arthur A, 2009, J CELL PHYSIOL, V218, P237, DOI 10.1002/jcp.21592; AWARD H, 2003, J ORTHOP RES, V21, P420; Barry F, 2001, EXP CELL RES, V268, P189, DOI 10.1006/excr.2001.5278; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Beirne JC, 1996, INT J ORAL MAX SURG, V25, P268, DOI 10.1016/S0901-5027(06)80053-6; Boyan BD, 1999, J BIOMED MATER RES, V46, P51, DOI 10.1002/(SICI)1097-4636(199907)46:1<51::AID-JBM6>3.3.CO;2-9; Boyne PJ, 2001, J BONE JOINT A 2 S1, V83, P146; Bruder SP, 1998, CLIN ORTHOP RELAT R, V355, P247; Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F; Bruder SP, 1999, CLIN ORTHOP S, P68; Bruder SP, 1998, J ORTHOPAED RES, V16, P155, DOI 10.1002/jor.1100160202; BUCHOLZ RW, 1987, ORTHOP CLIN N AM, V18, P323; Burkus JK, 2002, J SPINAL DISORD TECH, V15, P337; Cancedda R, 2003, STEM CELLS, V21, P610, DOI 10.1634/stemcells.21-5-610; CAPLAN AI, 1991, J ORTHOPAED RES, V9, P641, DOI 10.1002/jor.1100090504; Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198; Carter D. R., 1988, CLIN ORTHOP RELAT R, V355, P41, DOI DOI 10.1097/00003086-199810001-00006); CARTER K, 2003, BR J COMMUNITY NURS, V8, P15; Chen F, 2003, J PEDIATR ORTHOPED, V23, P425, DOI 10.1097/00004694-200307000-00002; COOK SD, 1994, CLIN ORTHOP RELAT R, P302; Devine MJ, 2002, J ORTHOPAED RES, V20, P1232, DOI 10.1016/S0736-0266(02)00051-7; DEVINE SM, 2001, CANC J S2, V7, P76; Dressler MR, 2005, J ORTHOP RES, V23, P287, DOI 10.1016/j.orthres.2004.06.017; DROSSE I, 2008, INJURY S2, V39, P9; Edgar CM, 2007, BONE, V40, P1389, DOI 10.1016/j.bone.2007.01.001; EINHORN TA, 1998, CLIN ORTHOP S, V355, P7; El-Ghannam A, 2005, EXPERT REV MED DEVIC, V2, P87, DOI 10.1586/17434440.2.1-87; Fleming JE, 2000, ORTHOP CLIN N AM, V31, P357, DOI 10.1016/S0030-5898(05)70156-5; Fossum TW, 2007, SMALL ANIMAL SURG, P930; Fried E, 2001, ARCH RATION MECH AN, V158, P1, DOI 10.1007/s002050100135; Gao T, 1996, INT ORTHOP, V20, P321, DOI 10.1007/s002640050086; Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032; Hoemann CD, 2005, J BONE JOINT SURG AM, V87A, P2671, DOI 10.2106/JBJS.D.02536; HORISAKA Y, 1991, CLIN ORTHOP RELAT R, P303; HOTZ G, 1994, INT J ORAL MAX SURG, V23, P413, DOI 10.1016/S0901-5027(05)80033-5; Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142-9612(00)00121-6; Ishaug SL, 1997, J BIOMED MATER RES, V36, P17; Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I; JANCAR J, 2007, PHYSIOL RES S1, V56, P17; Johnson EE, 1998, CLIN ORTHOP RELAT R, P105; Joshi A, 2004, BRIT DENT J, V196, P167, DOI 10.1038/sj.bdj.4810945; Kadiyala S, 1997, TISSUE ENG, V3, P173, DOI 10.1089/ten.1997.3.173; Kim J, 2007, BIOMATERIALS, V28, P1830, DOI 10.1016/j.biomaterials.2006.11.050; Kirker-Head C, 2007, BONE, V41, P247, DOI 10.1016/j.bone.2007.04.186; KIRKERHEAD C, 2006, BONE, V39, P678; Kraus KH, 2006, VET SURG, V35, P232, DOI 10.1111/j.1532-950X.2006.00142.x; Kraus KH, 1999, J INVEST SURG, V12, P115; Kuznetsov SA, 2001, J CELL BIOL, V153, P1133, DOI 10.1083/jcb.153.5.1133; Lee EH, 2006, J BONE JOINT SURG BR, V88B, P841, DOI 10.1302/0301-620X.88B7.17305; Lee JY, 2007, BIOMATERIALS, V28, P4257, DOI 10.1016/j.biomaterials.2007.05.040; Li RH, 2001, TRENDS BIOTECHNOL, V19, P255, DOI 10.1016/S0167-7799(01)01665-1; Marcacci M, 1999, CALCIFIED TISSUE INT, V64, P83, DOI 10.1007/s002239900583; Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539; Marx RE, 2004, J ORAL MAXIL SURG, V62, P489, DOI 10.1016/j.joms.2003.12.003; Meinel L, 2006, BONE, V39, P922, DOI 10.1016/j.bone.2006.04.019; Necas A, 2008, ACTA VET BRNO, V77, P277, DOI 10.2754/avb200877020277; NEUTTELMAN CR, 2006, J BIOMED MATER RES, V76, P183; Noël Danièle, 2002, Curr Opin Investig Drugs, V3, P1000; Oe K, 2007, J BONE JOINT SURG BR, V89B, P133, DOI 10.1302/0301-620X.89B1.18286; Oest ME, 2007, J ORTHOP RES, V25, P941, DOI 10.1002/jor.20372; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PLANKA L, 2007, ACTA VET BRNO, V76, P257; Planka L, 2007, ACTA VET BRNO, V76, P253, DOI 10.2754/avb200776020253; PLUHAR GE, 2004, P ACVS VET S OC 6 9, P326; Porada Christopher D, 2006, Curr Stem Cell Res Ther, V1, P365; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Reddi AH, 2000, TISSUE ENG, V6, P351, DOI 10.1089/107632700418074; Reddi AH, 2001, J BONE JOINT SURG AM, V83-A, P1; Rosenbaum Andrew J, 2008, Organogenesis, V4, P23; Salgado Antonio J, 2006, Curr Stem Cell Res Ther, V1, P345; Shirley D, 2005, J ORTHOP RES, V23, P1013, DOI 10.1016/j.orthres.2005.01.013; Silber JS, 2003, SPINE, V28, P134, DOI 10.1097/00007632-200301150-00008; Slater BJ, 2008, EXPERT OPIN BIOL TH, V8, P885, DOI [10.1517/14712598.8.7.885 , 10.1517/14712590802120981]; SMITH RKW, 2006, P 15 ANN SCI M JUN 2, P207; Srouji S, 2005, MECH AGEING DEV, V126, P281, DOI 10.1016/j.mad.2004.08.031; Stocum DL, 2001, WOUND REPAIR REGEN, V9, P429, DOI 10.1046/j.1524-475x.2001.00429.x; Vallejo LF, 2002, J BIOTECHNOL, V94, P185, DOI 10.1016/S0168-1656(01)00425-4; Viateau V, 2007, J ORTHOP RES, V25, P741, DOI 10.1002/jor.20352; Waese EYL, 2008, SKELETAL RADIOL, V37, P601, DOI 10.1007/s00256-007-0438-8; WOLFF D, 1994, J ORTHOPAED RES, V12, P439, DOI 10.1002/jor.1100120317; Yamamoto M, 1998, J BIOMAT SCI-POLYM E, V9, P439, DOI 10.1163/156856298X00550; Yoo J.U., 1998, CLIN ORTHOP RELAT R, pS73; Zaidi N, 2007, ANN NY ACAD SCI, V1117, P62, DOI 10.1196/annals.1402.074",88,7,7,"VETERINARNI A FARMACEUTICKA UNIVERZITA BRNO","BRNO","PALACKEHO 1-3, BRNO CS-612 42, CZECH REPUBLIC","0001-7213",null,null,"ACTA VET BRNO","Acta Vet. BRNO","DEC",2009,78,4,null,null,null,null,635,"U99",null,"10.2754/avb200978040635",null,11,"Veterinary Sciences","Veterinary Sciences","544EB","WOS:000273634200011"]
[null,null,null,null,"J","Sansovic, I; Knezevic, J; Musani, V; Seeman, P; Barisic, I; Pavelic, J",null,null,null,"Sansovic, Ivona; Knezevic, Jelena; Musani, Vesna; Seeman, Pavel; Barisic, Ingeborg; Pavelic, Jasminka",null,null,"GJB2 Mutations in Patients with Nonsyndromic Hearing Loss from Croatia","GENETIC TESTING AND MOLECULAR BIOMARKERS",null,null,"English","Article",null,null,null,null,null,null,"CONNEXIN 26 GENE; HIGH PREVALENCE; HIGH-FREQUENCY; RECESSIVE DEAFNESS; CHILDHOOD DEAFNESS; ASHKENAZI JEWS; DFNB1; DEL(GJB6-D13S1830); POPULATION; INDIVIDUALS","The aim of the study was to determine (1) the frequency and type of mutations in the coding region of the GJB2 gene (sequencing), (2) the frequency of splice site mutation IVS1 + 1G > A in the GJB2 gene (multiplex ligation-dependent probe amplification analysis), (3) possible copy number changes in the GJB2, GJB3, GJB6, and WFS1 genes (multiplex ligation-dependent probe amplification analysis), and (4) the frequency of del(GJB6-D13S1830) in the GJB6 gene in 58 unrelated patients with nonsyndromic hearing loss from Croatia. About 44.8% of our patients presented with mutation in the GJB2 gene. We identified seven sequence variations. Six of them had previously been reported as disease related (35delG, W24X, V37I, L90P, 313del14, and IVS1 + 1G > A), and we report here for the first time one novel variant, -24A > C. We detected the greatest frequency of 35delG allele compared to the other alleles (35.3%). Allelic frequencies of other common mutations accounted for 2.6-0.9% of analyzed chromosomes. Neither GJB6 deletion nor copy number changes in the GJB2, GJB3, GJB6, and WFS1 genes were found. The 35delG/35delG genotype was associated with severe to profound hearing loss in 94% of 35delG homozygotes. High mutation rate (44%) indicates that testing of the GJB2 gene will clarify the genetic cause in almost half of the cases of recessive nonsyndromic hearing loss in Croatia.","[Knezevic, Jelena; Musani, Vesna; Pavelic, Jasminka] Rudjer Boskovic Inst, Div Mol Med, HR-10000 Zagreb, Croatia; [Sansovic, Ivona; Barisic, Ingeborg] Univ Zagreb, Sch Med, Childrens Hosp, Dept Pediat, Zagreb 41001, Croatia; [Seeman, Pavel] Charles Univ Prague, Dept Child Neurol, Prague, Czech Republic","Pavelic, J (reprint author), Rudjer Boskovic Inst, Div Mol Med, Bijenicka C 54,POB 180, HR-10000 Zagreb, Croatia.","jpavelic@irb.hr",null,null,"Ministry of Science, Education, and Sports, Republic of Croatia [098-0982464-2394]","We thank the families, patients, and control individuals for their cooperation. This work was supported by Grant 098-0982464-2394 from the Ministry of Science, Education, and Sports, Republic of Croatia.",null,44,5,6,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1945-0265",null,null,"GENET TEST MOL BIOMA","Genet. Test. Mol. Biomark.","OCT",2009,13,5,null,null,null,null,693,699,null,"10.1089/gtmb.2009.0073",null,7,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","504FO","WOS:000270601500023"]
[null,null,null,null,"J","Gehre, F; Spisek, R; Kharat, AS; Matthews, P; Kukreja, A; Anthony, RM; Dhodapkar, MV; Vollmer, W; Tomasz, A",null,null,null,"Gehre, Florian; Spisek, Radek; Kharat, Arun S.; Matthews, Phillip; Kukreja, Anjli; Anthony, Robert M.; Dhodapkar, Madhav V.; Vollmer, Waldemar; Tomasz, Alexander",null,null,"Role of Teichoic Acid Choline Moieties in the Virulence of Streptococcus pneumoniae","INFECTION AND IMMUNITY",null,null,"English","Article",null,null,null,null,null,null,"LIPOTEICHOIC ACID; CELL-WALL; IN-VIVO; POLYSACCHARIDE; PNEUMOCOCCUS","In recent reports it was shown that genetically modified choline-free strains of Streptococcus pneumoniae (D39Cho(-) licA64 and D39ChiplicB31) expressing the type II capsular polysaccharide were virtually avirulent in the murine sepsis model, in sharp contrast to the isogenic and highly virulent strains D39Cho(-) and D39Chip, which have retained the choline residues at their surface. We now demonstrate that this choline-associated virulence is independent of Toll-like receptor 2 recognition. Also, despite the lack of virulence, choline-free strains of S. pneumoniae were able to activate splenic dendritic cells, induce secretion of proinflammatory cytokines, and produce specific protective immunity against subsequent challenge. However, after this transient engagement of the immune system the choline-free bacteria were rapidly cleared from the blood, while the isogenic virulent strain D39Cho(-) continued to grow, accompanied by prolonged expression of cytokines, eventually killing the experimental animals. The critical contribution of choline residues to the virulence potential of pneumococci appears to be the role that these amino alcohol residues play in a pneumococcal immune evasion strategy, the mechanism of which is unknown at the present time.","[Gehre, Florian; Kharat, Arun S.; Tomasz, Alexander] Rockefeller Univ, Microbiol Lab, New York, NY 10065 USA; [Spisek, Radek] Univ Hosp Moto, Dept Immunol, Prague, Czech Republic; [Spisek, Radek] Second Med Fac, Prague, Czech Republic; [Spisek, Radek; Matthews, Phillip; Kukreja, Anjli; Dhodapkar, Madhav V.] Rockefeller Univ, Lab Tumor Immunol & Immunotherapy, New York, NY 10065 USA; [Anthony, Robert M.] Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10065 USA; [Kharat, Arun S.] Marathwada Univ, Dept Biotechnol, Aurungabad, India; [Dhodapkar, Madhav V.] Yale Univ, Sect Hematol, New Haven, CT USA; [Vollmer, Waldemar] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England","Tomasz, A (reprint author), Rockefeller Univ, Microbiol Lab, 1230 York Ave, New York, NY 10065 USA.","tomasz@rockefeller.edu","Tomasz, Alexander/B-9939-2011; Spisek, Radek/E-6724-2011",null,"American Austrian Foundation; Irene Diamond Foundation","Partial support for these studies was provided by grants from the American Austrian Foundation and the Irene Diamond Foundation to the laboratory of Alexander Tomasz.","BRILES EB, 1973, J BIOL CHEM, V248, P6394; BRUNDISH DE, 1968, BIOCHEM J, V110, P573; Colino J, 2002, J EXP MED, V195, P1; Damjanovic M, 2007, J BACTERIOL, V189, P7105, DOI 10.1128/JB.00681-07; Dhodapkar KM, 2005, P NATL ACAD SCI USA, V102, P2910, DOI 10.1073/pnas.0500014102; Draing C, 2006, J BIOL CHEM, V281, P33849, DOI 10.1074/jbc.M602676200; FISCHER W, 1993, EUR J BIOCHEM, V215, P851, DOI 10.1111/j.1432-1033.1993.tb18102.x; GEHRE F, 2007, J INTERN MED, V264, P143; HORNE DS, 1993, J BACTERIOL, V175, P1717; Kharat AS, 2008, J BACTERIOL, V190, P5907, DOI 10.1128/JB.00628-08; Kharat AS, 2006, MOL MICROBIOL, V60, P93, DOI 10.1111/j.1365-2958.2006.05082.x; Majcherczyk PA, 2004, PNEUMOCCOCUS, P183; Nesin M, 1998, J INFECT DIS, V177, P707; Rane L, 1940, J BACTERIOL, V40, P695; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Severin A, 1997, MICROB DRUG RESIST, V3, P391, DOI 10.1089/mdr.1997.3.391; Tomasz A, 1964, 64 GEN M AM SOC MICR; TOMASZ A, 1967, SCIENCE, V157, P694, DOI 10.1126/science.157.3789.694; Weber JR, 2003, CURR OPIN IMMUNOL, V15, P408, DOI 10.1016/S0952-7915(03)00078-5",20,6,6,"AMER SOC MICROBIOLOGY","WASHINGTON","1752 N ST NW, WASHINGTON, DC 20036-2904 USA","0019-9567",null,null,"INFECT IMMUN","Infect. Immun.","JUL",2009,77,7,null,null,null,null,2824,2831,null,"10.1128/IAI.00986-08",null,8,"Immunology; Infectious Diseases","Immunology; Infectious Diseases","460XV","WOS:000267227000024"]
[null,null,null,null,"J","Sulakova, T; Janda, J; Cerna, J; Janstova, V; Sulakova, A; Slany, J; Feber, J",null,null,null,"Sulakova, Terezie; Janda, Jan; Cerna, Jana; Janstova, Vlasta; Sulakova, Astrid; Slany, Jaroslav; Feber, Janusz",null,null,"Arterial HTN in children with T1DM-frequent and not easy to diagnose","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"children; T1DM; HTN; ABP monitoring; OBP","AMBULATORY BLOOD-PRESSURE; GLOMERULAR-FILTRATION RATE; TYPE-1 DIABETIC-PATIENTS; PLASMA CREATININE; FOLLOW-UP; ADOLESCENTS; HYPERTENSION; MICROALBUMINURIA; BIOPSIES; VALUES","Introduction To evaluate the diagnostic efficacy of the office blood pressure (OBP) and ambulatory blood pressure monitoring (ABPM) in the assessment of hypertension (HTN) in children with diabetes mellitus type 1 (T1DM). Methods We analyzed OBP and ABPM measurements in 84 diabetic children (43 boys) obtained at a median age of 14.9 yr and 6.3 +/- 3.5 yr after diagnosis of T1DM. OBP and ABPM results were converted into standard deviation scores (SDS). In addition, we analyzed blood pressure loads and nighttime dipping. The comparison between OBP and ABPM was performed using kappa coefficient and receiver operator curve (ROC). Results HTN was diagnosed in 43/84 (51%) patients using OBP (> 95th percentile), and in 24/84 (29%) patients using ABPM ( >= 95th percentile during 24 h, day or night). Both methods were in agreement in 33 ABPM normotensive and 16 ABPM hypertensive patients (most had nighttime HTN); 32% patients had white-coat HTN and 9.5% patients had masked HTN. The kappa coefficient was 0.175 (95% CI from -0.034 to 0.384) suggesting poor agreement between OBP and ABPM. Diastolic OBP was a better predictor of ABPM HTN (ROC area under the curve (AUC) = 0.71 +/- 0.06) than systolic OBP (AUC = 0.58 +/- 0.07). The percentage of non-dippers ranged from 7 to 23% in ABPM normotensive patients, and 21-42% in ABPM hypertensive patients who also had significantly higher BP loads (p < 0.0001). Conclusion Children with T1DM often suffer from nocturnal, white coat- and masked HTN, which can not be assessed and predicted by the OBP.","[Sulakova, Terezie; Cerna, Jana; Janstova, Vlasta; Sulakova, Astrid; Slany, Jaroslav] Tech Univ Ostrava, Dept Pediat, Univ Hosp Ostrava, Ostrava 70852, Czech Republic; [Sulakova, Terezie; Cerna, Jana; Janstova, Vlasta; Sulakova, Astrid; Slany, Jaroslav] Tech Univ Ostrava, Fac Hlth Studies, Ostrava 70852, Czech Republic; [Janda, Jan] Charles Univ Prague, Dept Pediat, Sch Med 2, Prague 15400, Czech Republic; [Feber, Janusz] Univ Ottawa, Dept Pediat, Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada","Sulakova, T (reprint author), Tech Univ Ostrava, Dept Pediat, Univ Hosp Ostrava, Tr 17 I Istopadu 1790, Ostrava 70852, Czech Republic.","terezie.sulakova@fnspo.cz",null,null,null,null,null,34,5,5,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","NOV",2009,10,7,null,null,null,null,441,448,null,"10.1111/j.1399-5448.2009.00514.x",null,8,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","512LP","WOS:000271251100005"]
[null,null,null,null,"J","Lonnerholm, G; Valsecchi, MG; De Lorenzo, P; Schrappe, M; Hovi, L; Campbell, M; Mann, G; Janka-Schaub, G; Li, CK; Stary, J; Hann, I; Pieters, R",null,null,null,"Lonnerholm, Gudmar; Valsecchi, Maria Grazia; De Lorenzo, Paola; Schrappe, Martin; Hovi, Liisa; Campbell, Myriam; Mann, Georg; Janka-Schaub, Gritta; Li, Chi-Kong; Stary, Jan; Hann, Ian; Pieters, Rob",null,"Interfant-99 Study Grp","Pharmacokinetics of High-Dose Methotrexate in Infants Treated for Acute Lymphoblastic Leukemia","PEDIATRIC BLOOD & CANCER",null,null,"English","Article",null,null,null,null,null,"ALL; infants; methotrexate; phamacokinetics","CHILDREN; DRUG; CHEMOTHERAPY; RESISTANCE","Background. Interfant-99 was an international collaborative treatment protocol for infants with acute lymphoblastic leukemia (ALL). Procedure. We collected data on 103 infants at the time of their first treatment with high-close methotrexate (HD MTX), 5 g/m(2). Children <6 months of age received two-third of the calculated close based on body surface area (BSA), children 6-12 months three-fourth of the calculated dose, and children >12 months full dose. Results. The median steady-state MTX concentration at the end of the 24-hr infusion was 57.8 mu M (range 9.5-313). The median systemic clearance was 6.22 L/hr/m(2) BSA, and tended to increase with age (P = 0.099). Boys had higher clearance than girls, 6.77 and 5.28 L/hr/m(2) (P = 0.030), and tended to have lower median MTX concentration at 24 hr. Eight infants had MTX levels below 20 mu M, a level judged to be sufficient in B-lineage ALL in children >1 year of age. All infants tolerated the close well enough to receive a second dose of HD MTX without dose reduction. We found no significant effect on disease-free survival for MTX steady-state concentration, MTX clearance, or time to MTX below 0.2 mu M. Conclusions. Our data provide no Support for a change in the dosing rules for MTX used in Interfant-99. However, in view of the poor treatment results for infants, one might consider increase in the dose for patients who reach plasma levels below median after the first MTX dose. Pediatr Blood Cancer 2009;52:596-601. (C) 2009 Wiley-Liss, Inc.","[Lonnerholm, Gudmar] Univ Hosp, Dept Womens & Childrens Hlth, SE-75185 Uppsala, Sweden; [Valsecchi, Maria Grazia; De Lorenzo, Paola] Univ Milano Bicocca, Dept Clin Med & Prevent, Bicocca, Italy; [Schrappe, Martin] Univ Med Ctr Schleswig Holstein, Kiel, Germany; [Hovi, Liisa] Univ Helsinki, Helsinki, Finland; [Campbell, Myriam] Univ Chile, Chilean Natl Pediat Oncol Grp, PINDA, Dept Hematol & Oncol,Hosp Roberto Rio, Santiago, Chile; [Mann, Georg] St Anna Childrens Hosp, Vienna, Austria; [Janka-Schaub, Gritta] Univ Hosp Hamburg Eppendorf, Hamburg, Germany; [Li, Chi-Kong] Prince Wales Hosp, HKPHOSG, Shatin, Hong Kong, Peoples R China; [Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Hann, Ian] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Pieters, Rob] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands","Lonnerholm, G (reprint author), Univ Hosp, Dept Womens & Childrens Hlth, SE-75185 Uppsala, Sweden.","gudmar.lonnerholm@kbh.uu.se","Schrappe, Martin/A-8109-2010; Li, Chi Kong/J-8456-2013",null,null,null,null,16,5,5,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1545-5009",null,null,"PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","MAY",2009,52,5,null,null,null,null,596,601,null,"10.1002/pbc.21925",null,6,"Oncology; Hematology; Pediatrics","Oncology; Hematology; Pediatrics","418SK","WOS:000264168800010"]
[null,null,null,null,"J","Hulinska, D; Votypka, J; Vanousova, D; Hercogova, J; Hulinsky, V; Drevova, H; Kurzova, Z; Uherkova, L",null,null,null,"Hulinska, D.; Votypka, J.; Vanousova, D.; Hercogova, J.; Hulinsky, V.; Drevova, H.; Kurzova, Z.; Uherkova, L.",null,null,"Identification of Anaplasma phagocytophilum and Borrelia burgdorferi sensu lato in patients with erythema migrans","FOLIA MICROBIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"HUMAN GRANULOCYTIC EHRLICHIOSIS; IXODES-RICINUS TICKS; REAL-TIME PCR; POLYMERASE-CHAIN-REACTION; LYME-BORRELIOSIS; PERINATAL TRANSMISSION; HUMAN-DISEASE; AGENT; CULTURE; EUROPE","Anaplasma phagocytophilum has been first isolated from the blood of two Czech patients simultaneously with a cultivation of Borrelia burgdorferi sensu lato from their erythema migrans lesions. Cultivation of different Borrelia spp. from 12 erythema migrans biopsies, from 2 blood, one liquor and one placenta sample in BSK-H medium was successful. Adapted conventional methods targeting 16S rRNA and OspA genes for real-time polymerase chain reaction (PCR) and partial sequencing of these genes together with microscopical examinations of the blood smears provided a direct detection of the B. afzelii, B. burgdorferi, B. garinii, B. valaisiana and B. bissettii in the skin, B. garinii in the blood, placenta and liquor in 24 (36.3 %) patients, and A. phagocytophilum in 10 (15 %) patients with erythema migrans. Positive indirect IgM immunofluorescence against Anaplasma sp. was obtained in 7 cases, specific IgG antibodies were detected in 12 patients. Three women suffering from erythema migrans in the first trimester had positive PCR for Anaplasma and/or for Borrelia in the blood and two of them, later, in the placenta. Interpretation of laboratory data can bring important contribution to establishing the role of Anaplasma sp. in erythema migrans and forming the principle of precaution with laboratory diagnosis during pregnancy which always should be reflected in the resistance of Anaplasma sp. toward penicillins.","[Hulinska, D.; Votypka, J.; Drevova, H.; Kurzova, Z.; Uherkova, L.] Natl Inst Publ Hlth, WHO Ctr Reference & Res Borreliosis, Natl Reference Lab, Prague 10042, Czech Republic; [Vanousova, D.; Hercogova, J.] Charles Univ Prague, Fac Hosp Bulovka 2, CR-18000 Prague, Czech Republic; [Hulinsky, V.] Reg Hosp Nymburk, Dept Internal Med & Haematol, Nymburk 28801, Czech Republic","Hulinska, D (reprint author), Natl Inst Publ Hlth, WHO Ctr Reference & Res Borreliosis, Natl Reference Lab, Prague 10042, Czech Republic.","dhulin@szu.cz",null,null,"Ministry of Health of the Czech Republic [8263]; 6th Framework Programme EU","This work was supported by Research Grant no. 8263 of the Internal Grant Agency (IGA) of the Ministry of Health of the Czech Republic, and by the 6th Framework Programme EU (cooperative project BOVAC). The authors thank N. Holinkova and K. Kybicova for their support in providing various Bbsl strains from humans (used in validation of our assays) and technical assistance with the Ap culture. The authors also thank TIB-Molbiol for their advice and preparation of primers and TaqMan probes.",null,41,4,4,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632",null,null,"FOLIA MICROBIOL","Folia Microbiol.","MAY",2009,54,3,null,null,null,null,246,256,null,"10.1007/s12223-009-0039-0",null,11,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","478FQ","WOS:000268573600012"]
[null,null,null,null,"J","Lu, TT; Lao, O; Nothnagel, M; Junge, O; Freitag-Wolf, S; Caliebe, A; Balascakova, M; Bertranpetit, J; Bindoff, LA; Comas, D; Holmlund, G; Kouvatsi, A; Macek, M; Mollet, I; Nielsen, F; Parson, W; Palo, J; Ploski, R; Sajantila, A; Tagliabracci, A; Gether, U; Werge, T; Rivadeneira, F; Hofman, A; Uitterlinden, AG; Gieger, C; Wichmann, HE; Ruether, A; Schreiber, S; Becker, C; Nurnberg, P; Nelson, MR; Kayser, M; Krawczak, M",null,null,null,"Lu, Timothy Tehua; Lao, Oscar; Nothnagel, Michael; Junge, Olaf; Freitag-Wolf, Sandra; Caliebe, Amke; Balascakova, Miroslava; Bertranpetit, Jaume; Bindoff, Laurence Albert; Comas, David; Holmlund, Gunilla; Kouvatsi, Anastasia; Macek, Milan; Mollet, Isabelle; Nielsen, Finn; Parson, Walther; Palo, Jukka; Ploski, Rafal; Sajantila, Antti; Tagliabracci, Adriano; Gether, Ulrik; Werge, Thomas; Rivadeneira, Fernando; Hofman, Albert; Uitterlinden, Andre Gerardus; Gieger, Christian; Wichmann, Heinz-Erich; Ruether, Andreas; Schreiber, Stefan; Becker, Christian; Nuernberg, Peter; Nelson, Matthew Roberts; Kayser, Manfred; Krawczak, Michael",null,null,"An evaluation of the genetic-matched pair study design using genome-wide SNP data from the European population","EUROPEAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"population structure; matching; association; ancestry; microarray","DISEASE ASSOCIATION; GENOTYPE DATA","Genetic matching potentially provides a means to alleviate the effects of incomplete Mendelian randomization in population-based gene-disease association studies. We therefore evaluated the genetic-matched pair study design on the basis of genome-wide SNP data (309 790 markers; Affymetrix GeneChip Human Mapping 500K Array) from 2457 individuals, sampled at 23 different recruitment sites across Europe. Using pair-wise identity-by-state (IBS) as a matching criterion, we tried to derive a subset of markers that would allow identification of the best overall matching (BOM) partner for a given individual, based on the IBS status for the subset alone. However, our results suggest that, by following this approach, the prediction accuracy is only notably improved by the first 20 markers selected, and increases proportionally to the marker number thereafter. Furthermore, in a considerable proportion of cases (76.0%), the BOM of a given individual, based on the complete marker set, came from a different recruitment site than the individual itself. A second marker set, specifically selected for ancestry sensitivity using singular value decomposition, performed even more poorly and was no more capable of predicting the BOM than randomly chosen subsets. This leads us to conclude that, at least in Europe, the utility of the genetic-matched pair study design depends critically on the availability of comprehensive genotype information for both cases and controls. European Journal of Human Genetics (2009) 17, 967-975; doi:10.1038/ejhg.2008.266; published online 21 January 2009","[Lu, Timothy Tehua; Nothnagel, Michael; Junge, Olaf; Freitag-Wolf, Sandra; Caliebe, Amke; Krawczak, Michael] Univ Kiel, Inst Med Informat & Stat, D-24105 Kiel, Germany; [Lao, Oscar; Kayser, Manfred] Erasmus Univ, Med Ctr Rotterdam, Dept Forens Mol Biol, Rotterdam, Netherlands; [Balascakova, Miroslava; Macek, Milan] Charles Univ Prague, Univ Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Balascakova, Miroslava; Macek, Milan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Bertranpetit, Jaume; Comas, David] Univ Pompeu Fabra, CEXS UPF PRBB, CSIC, Inst Evolutionary Biol, Barcelona, Spain; [Bindoff, Laurence Albert] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway; [Bindoff, Laurence Albert] Univ Bergen, Dept Clin Med, Bergen, Norway; [Holmlund, Gunilla] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, Linkoping, Sweden; [Kouvatsi, Anastasia] Aristotle Univ Thessaloniki, Dept Genet Dev & Mol Biol, GR-54006 Thessaloniki, Greece; [Mollet, Isabelle] EFS RA Site Lyon, Lab Empreintes Genet, Lyon, France; [Nielsen, Finn] Univ Copenhagen, Dept Clin Biochem, Copenhagen, Denmark; [Nielsen, Finn] Univ Copenhagen, Ctr Pharmacogenom, Copenhagen, Denmark; [Parson, Walther] Med Univ Innsbruck, Inst Legal Med, Innsbruck, Austria; [Palo, Jukka; Sajantila, Antti] Univ Helsinki, Dept Forens Med, SF-00300 Helsinki, Finland; [Ploski, Rafal] Warsaw Med Univ, Dept Med Genet, Warsaw, Poland; [Tagliabracci, Adriano] Univ Ancona, Ist Med Legale, Ancona, Italy; [Gether, Ulrik] Univ Copenhagen, Dept Neurosci & Pharmacol, Mol Neuropharmacol Grp, Copenhagen, Denmark; [Gether, Ulrik] Univ Copenhagen, Dept Neurosci & Pharmacol, Ctr Pharmacogenom, Copenhagen, Denmark; [Werge, Thomas] Copenhagen Univ Hosp, Mental Hlth Ctr Sct Hans, Res Inst Biol Psychiat, Copenhagen, Denmark; [Werge, Thomas] Univ Copenhagen, Ctr Pharmacogenom, Copenhagen, Denmark; [Rivadeneira, Fernando; Uitterlinden, Andre Gerardus] Erasmus Univ, Med Ctr Rotterdam, Dept Internal Med, Genet Lab, Rotterdam, Netherlands; [Hofman, Albert; Uitterlinden, Andre Gerardus] Erasmus Univ, Med Ctr Rotterdam, Dept Epidemiol & Biostat, Rotterdam, Netherlands; [Gieger, Christian; Wichmann, Heinz-Erich] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany; [Wichmann, Heinz-Erich] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany; [Ruether, Andreas; Schreiber, Stefan] Univ Kiel, Inst Med Mol Biol, Kiel, Germany; [Becker, Christian; Nuernberg, Peter] Univ Cologne, Cologne Ctr Genom, Cologne, Germany; [Becker, Christian; Nuernberg, Peter] Univ Cologne, Inst Genet, Cologne, Germany; [Nelson, Matthew Roberts] GlaxoSmithKline Inc, Genet, Res Triangle Pk, NC USA","Krawczak, M (reprint author), Univ Kiel, Inst Med Informat & Stat, Haus 31,Arnold Heller Str 3, D-24105 Kiel, Germany.","krawczak@medinfo.uni-kiel.de","Schreiber, Stefan/B-6748-2008; Krawczak, Michael/A-8964-2010; Nothnagel, Michael/A-7759-2011; Bertranpetit, Jaume/F-8550-2012; Nothnagel, Michael/H-6887-2012; Comas, David/D-5382-2014","Comas, David/0000-0002-5075-0956","Netherlands Forensic Institute; Affymetrix; German National Genome Research Network; German Federal Ministry of Education and Research; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg; Munich Center of Health Sciences; Netherlands Organization for Scientific Research [NWO 175.010.2005.011]; European Commission [201865, QLG2-CT-2001-00916]; Czech Ministry of Health [00064203, NS/9488-3]; Helse-Vest, Regional Health Authority Norway; Swedish National Board of Forensic Medicine [99:22, 02:20]; Academy of Finland [80578, 109265, 111713]","All sample donors are gratefully acknowledged for their participation. We thank the following colleagues for their help and support: J Kooner and J Chambers of the LOLIPOP study and D Waterworth, V Mooser, G Waeber and P Vollenweider of the CoLaus study for providing access to their collections through the GlaxoSmithKline-sponsored Population Reference Sample (POPRES) project; K King for preparing the POPRES data; M Simoons, E Sijbrands, A van Belkum, J Laven, J Lindemans, E Knipers and B Stricker for their financial contribution to the Rotterdam study; P Arp, M Jhamai, W van IJken and R van Schaik for generating the Rotterdam study dataset; T Meitinger, P Lichtner, G Eckstein and all genotyping staff at the Helmholtz Zentrum Munchen for generating the KORA study dataset; H von Eller-Eberstein for providing access to the PopGen data; R Borup, C Schjerling, H Ullum, E Haastrup and numerous colleagues at the Copenhagen University Hospital Blood Bank for making the Danish data available; and S Brauer for DNA sample management. We also wish to thank Affymetrix for making the GeneChip Human Mapping 500K Array genotypes of the CEPH-CEU trios publicly available, and the Centre d'Etude du Polymorphisme Humain (CEPH) for the original sample collection. This work was supported by the Netherlands Forensic Institute (M Ka), Affymetrix (M Ka and M Kr), the German National Genome Research Network and the German Federal Ministry of Education and Research (H-EW, SS, M Kr and PN); the Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Neuherberg and the Munich Center of Health Sciences as part of LMUinnovativ (H-EW), the Netherlands Organization for Scientific Research (AGU: NWO 175.010.2005.011), the European Commission (AGU: GEFOS; 201865, AS: LD Europe; QLG2-CT-2001-00916); the Czech Ministry of Health (MM: VZFNM 00064203 and IGA NS/9488-3), Helse-Vest, Regional Health Authority Norway (LAB), the Swedish National Board of Forensic Medicine (GH: RMVFoU 99:22, 02:20) and the Academy of Finland (AS: 80578, OMLL, JP: 109265 and 111713). None of the funding organization had any influence on the design, conduct or conclusions of the study.",null,29,3,3,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,null,"EUR J HUM GENET","Eur. J. Hum. Genet.","JUL",2009,17,7,null,null,null,null,967,975,null,"10.1038/ejhg.2008.266",null,9,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","459VZ","WOS:000267141600017"]
[null,null,null,null,"J","Curila, K; Benesova, L; Penicka, M; Minarik, M; Zemanek, D; Veselka, J; Widimsky, P; Gregor, P",null,null,null,"Curila, Karol; Benesova, Lucie; Penicka, Martin; Minarik, Marek; Zemanek, David; Veselka, Josef; Widimsky, Petr; Gregor, Pavel",null,null,"Low Prevalence and Variable Clinical Presentation of Troponin I and Troponin T Gene Mutations in Hypertrophic Cardiomyopathy","GENETIC TESTING AND MOLECULAR BIOMARKERS",null,null,"English","Article",null,null,null,null,null,null,"EXPRESSION; DETERMINANTS; POPULATION; SPECTRUM","Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder caused by mutations in cardiac sarcomeric proteins. Troponin I (TNNI3) and troponin T (TNNT2) are important parts of the sarcomere in heart muscle, and mutations in their genes are responsible for development of HCM. The prevalence of mutations in these two genes is low; hence, the data on clinical outcome are scarce. Yet, some of these mutations were shown to be malignant with a high incidence of sudden death. Here, we describe the disease course in three families affected with TNNI3 and one family with TNNT2 gene mutations. In TNNI3-HCM, the phenotypic manifestation ranged from clinically silent to sudden cardiac death with the worst prognosis observed in carriers of Ala157Val mutation in exon 7. In contrast, TNNT2-HCM was associated with favorable prognosis. Thus, the findings of the present study add evidence on the phenotypic presentation of this genetic disease.","[Curila, Karol; Penicka, Martin; Widimsky, Petr; Gregor, Pavel] Charles Univ Prague, Fac Med 3, Cardioctr, Dept Cardiol, Prague 10034, Czech Republic; [Curila, Karol; Penicka, Martin; Widimsky, Petr; Gregor, Pavel] Univ Hosp Kralovske Vinohrady, Prague 10034, Czech Republic; [Benesova, Lucie; Minarik, Marek] Genomac Int, Lab Mol Genet & Oncol, Prague, Czech Republic; [Zemanek, David; Veselka, Josef] Fac Hosp Motol, Ctr Cardiovasc, Prague, Czech Republic","Curila, K (reprint author), Charles Univ Prague, Fac Med 3, Cardioctr, Dept Cardiol, Srobarova 50, Prague 10034, Czech Republic.","curila@fnkv.cz",null,null,"IGA MZ CR [NR 9164]","The authors would like to thank Patrik Sekerka and Lucie Fantova for their assistance with preparation and valuation of DNA sequencing data and Hana Linkova for echocardiographic examination. Also, we are indebted to Martina Havlikova and Blanka Kopecka for excellent technical assistance throughout the study.",null,17,2,2,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1945-0265",null,null,"GENET TEST MOL BIOMA","Genet. Test. Mol. Biomark.","OCT",2009,13,5,null,null,null,null,647,650,null,"10.1089/gtmb.2009.0041",null,4,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","504FO","WOS:000270601500016"]
[null,null,null,null,"J","Vanourkova, Z; Kramer, HJ; Erbanova, M; Backer, A; Cervenka, L; Huskova, Z; Chabova, VC; Tesar, V; Dvorak, P; Maly, J; Vaneckova, I",null,null,null,"Vanourkova, Zdenka; Kramer, Herbert J.; Erbanova, Michaela; Baecker, Angela; Cervenka, Ludek; Huskova, Zuzana; Chabova, Vera Certikova; Tesar, Vladimir; Dvorak, Pavel; Maly, Jan; Vaneckova, Ivana",null,null,"Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension","VASCULAR PHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,"Hypertension; Inducible; Endothelin receptors; Cyp1A1-Ren-2 rats","DEPENDENT MALIGNANT HYPERTENSION; END-ORGAN DAMAGE; SALT-SENSITIVE HYPERTENSION; ETA-RECEPTOR; REN-2 RATS; SYSTEM; RENIN; KIDNEY; INFLAMMATION; BOSENTAN","We found previously that selective blockade of endothelin ETA receptors is superior to nonselective ETA/ETB in attenuating hypertension and survival rate in Ren-2 transgenic rats (TGR). In the present pilot study, we were interested in whether similar effects will be found in TGR with inducible malignant hypertension (iTGR; official strain name Cyp1A1-Ren-2rats), which were derived from the original Ren-2 transgenic rat strain. Studies were performed in three-month old male iTGR. Treatment with either bosentan, a non-selective ET(A)/ET(B), or with atrasentan. a selective ET(A) receptor blocker, was started on day 2 of the experiment. Feeding with indole-3-carbinole (13C; 0.3% in rat chow), a natural xenobiotic which activates the Cyp1a1 promoter of the mouse Ren-2 gene, began on day 3 and lasted for 4 days until day 6. Systolic BP, body weight, plasma ANG II and tissue ANG II and ET-1 concentrations were determined daily. Severe hypertension developed as early as 1 day after beginning of 13C feeding which was accompanied by a significant reduction in body weight and by increases in plasma and tissue ANG II and left ventricle EN concentrations. Atrasentan or bosentan had no effects on the rise in BP or plasma and tissue ANG II concentrations but prevented the rise in heart ventricle ET-1 concentration. Our data show that blockade of the ET system does not prevent or attenuate the rapid development of severe hypertension in iTGR; a long-term protective effect of ET blockade on cardiac (and renal) damage, however. cannot be excluded and awaits further investigations. (C) 2009 Elsevier Inc. All rights reserved.","[Vanourkova, Zdenka; Erbanova, Michaela; Cervenka, Ludek; Huskova, Zuzana; Chabova, Vera Certikova; Maly, Jan; Vaneckova, Ivana] Inst Clin & Expt Med, Ctr Med Expt, CZ-14021 Prague 4, Czech Republic; [Vanourkova, Zdenka; Erbanova, Michaela; Cervenka, Ludek; Huskova, Zuzana; Chabova, Vera Certikova; Vaneckova, Ivana] Inst Clin & Expt Med, Cardiovasc Res Ctr, CZ-14021 Prague, Czech Republic; [Kramer, Herbert J.; Baecker, Angela] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic; [Chabova, Vera Certikova; Tesar, Vladimir] Charles Univ Prague, Fac Med 1, Dept Nephrol, Prague, Czech Republic; [Dvorak, Pavel] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic","Vaneckova, I (reprint author), Inst Clin & Expt Med, Ctr Med Expt, Videnska 1958-9, CZ-14021 Prague 4, Czech Republic.","ivvn@medicon.cz","Vaneckova, Ivana/B-5543-2012",null,null,null,null,34,2,2,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1537-1891",null,null,"VASC PHARMACOL","Vasc. Pharmacol.","MAY-JUN",2009,50,41795,null,null,null,null,194,199,null,"10.1016/j.vph.2009.01.002",null,6,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","421AG","WOS:000264329700008"]
[null,null,null,null,"J","Ondrouskova, E; Slovackova, J; Pelkova, V; Prochazkova, J; Soucek, K; Benes, P; Smarda, J",null,null,null,"Ondrouskova, Eva; Slovackova, Jana; Pelkova, Vendula; Prochazkova, Jirina; Soucek, Karel; Benes, Petr; Smarda, Jan",null,null,"Heavy metals induce phosphorylation of the Bcl-2 protein by Jun N-terminal kinase","BIOLOGICAL CHEMISTRY",null,null,"English","Article",null,null,null,null,null,"Bcl-2; heavy metals; Jun N-terminal kinase; phosphorylation; posttranslational modification","ENDOPLASMIC-RETICULUM; INDUCED APOPTOSIS; SIGNALING PATHWAY; FAMILY PROTEINS; BREAST-CANCER; CELL-DEATH; INHIBITION; ARREST; ZINC; MICROTUBULES","The Bcl-2 protein is one of the key components of biochemical pathways controlling programmed cell death. The function of this protein can be regulated by post-translational modifications. Phosphorylation of Bcl-2 has been considered to be significantly associated with cell cycle arrest in the G2/M phase of the cell cycle, and with cell death caused by defects of microtubule dynamics. This study shows that phosphorylation of Bcl-2 can be induced by heavy metals due to activation of the Jun N-terminal kinase pathway that is not linked to the G2/M cell cycle arrest. Furthermore, we demonstrate that hyperphosphorylated Bcl-2 protein is a more potent inhibitor of zinc-induced cell death than its hypophosphorylated mutant form. These data suggest that regulation of Bcl-2 protein function by phosphorylation is an important part of cell responses to stress.","[Ondrouskova, Eva; Slovackova, Jana; Pelkova, Vendula; Prochazkova, Jirina; Benes, Petr; Smarda, Jan] Masaryk Univ, Inst Expt Biol, Fac Sci, CZ-61137 Brno, Czech Republic; [Slovackova, Jana] Univ Hosp, Dept Pathol, CZ-62500 Brno, Czech Republic; [Pelkova, Vendula] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, CZ-15006 Prague, Czech Republic; [Prochazkova, Jirina; Soucek, Karel] Acad Sci Czech Republic, Inst Biophys, CZ-61265 Brno, Czech Republic","Smarda, J (reprint author), Masaryk Univ, Inst Expt Biol, Fac Sci, Kotlarska 2, CZ-61137 Brno, Czech Republic.","smarda@sci.muni.cz",null,null,"Ministry of Education, Youth and Sports of the Czech Republic [MSM0021622415]; Grant Agency of the Czech Republic [301/06/0036]; Grant Agency of Academy of Sciences of the Czech Republic [IAA501630801]; Czech Science Foundation [204/07/0834]; Research Plans [AVOZ50040507]; Academy of Sciences of the Czech Republic [AVOZ50040702]","We are grateful to M. Cleary, D. Huang, and S. Lin for providing the expression vectors and to Sevcikova for stable transfection of BM2 cells and for the correction of English in the manuscript. We also thank A. Kozubik and J. Hofmanova for the kind provision of FACSCalibur and J. Maresova for technical assistance. This work was funded by grant MSM0021622415 of the Ministry of Education, Youth and Sports of the Czech Republic, grant 301/06/0036 of the Grant Agency of the Czech Republic, grant IAA501630801 of the Grant Agency of Academy of Sciences of the Czech Republic, grant 204/07/0834 of the Czech Science Foundation and by the Research Plans AVOZ50040507, and AVOZ50040702 of Academy of Sciences of the Czech Republic.",null,53,1,1,"WALTER DE GRUYTER & CO","BERLIN","GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY","1431-6730",null,null,"BIOL CHEM","Biol. Chem.","JAN",2009,390,1,null,null,null,null,49,58,null,"10.1515/BC.2009.007",null,10,"Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","405TT","WOS:000263247800008"]
[null,null,null,null,"J","Stolz, AJ; Lischke, R; Schutzner, J; Petrik, F; Harustiak, T; Pafko, P",null,null,null,"Stolz, A. J.; Lischke, R.; Schutzner, J.; Petrik, F.; Harustiak, T.; Pafko, P.",null,null,"Predisposing factors of atelectasis following pulmonary lobectomy","ACTA CHIRURGICA BELGICA",null,null,"English","Article",null,null,null,null,null,"Atelectasis; chronic obstructive pulmonary disease; lobectomy","COLLEGE-OF-PHYSICIANS; NONCARDIOTHORACIC SURGERY; LUNG RESECTION; COMPLICATIONS; RISK; BRONCHOSCOPY; THORACOTOMY; STRATEGIES; CESSATION; SMOKING","Background : The aims of our study were to investigate postoperative atelectasis complicating pulmonary lobectomy, identify risk factors and evaluate its relationship to other postoperative complications. Material and methods : From January 2004 to April 2007, 412 patients underwent pulmonary lobectomy. We performed a retrospective analysis of our prospective database. Post-lobectomy atelectasis (PLA) was defined as an ipsilateral opacification of the remaining lobe with an ipsilateral shift of the mediastinum on the chest radiography, requiring bronchoscopy. Results : The incidence of PLA was 6.6%, comprising 29% of all postoperative pulmonary complications seen. There was no statistically significant difference in patient age, gender, ASA score, cardiovascular co-morbidity or operation time for the PLA group versus the group without this complication.. Current smokers were at a higher risk for PLA, but this incidence did not reach statistical significance. Chronic obstructive pulmonary disease (COPD) was the only pre-operative variable increasing the risk of PLA (p < 0.05). Patients undergoing a right upper lobectomy, either on its own or in combination with a right middle lobe resection, had a significantly higher incidence of PLA when compared with all other types of resection (p < 0.05). Conclusions : Patients with COPD and those undergoing right upper lobe resection have an increased risk of PLA. In this group of patients we should use pre-operative (cessation of cigarette smoking, treatment of airflow obstruction in patients with COPD), intra-operative (duration of operation) and postoperative (intensive physiotherapy and effective postoperative pain control) measures to decrease the risk of PLA. Although often solitary, PLA is associated with a longer hospital stay.","[Stolz, A. J.; Lischke, R.; Schutzner, J.; Harustiak, T.; Pafko, P.] Charles Univ Prague, Univ Hosp Motol, Dept Surg, Prague, Czech Republic; [Petrik, F.] Charles Univ Prague, Univ Hosp Motol, Dept Pneumol, Prague, Czech Republic","Stolz, AJ (reprint author), Univ Hosp Motol, Dept Surg, V Uvalu 84, Prague 5, Czech Republic.","stolz@seznam.cz",null,null,null,null,null,17,1,1,"ACTA MEDICAL BELGICA","BRUSSELS","AVENUE CIRCULAIRE 138 A, B-1180 BRUSSELS, BELGIUM","0001-5458",null,null,"ACTA CHIR BELG","Acta Chir. Belg.","JAN-FEB",2009,109,1,null,null,null,null,81,85,null,null,null,5,"Surgery","Surgery","419ER","WOS:000264202400016"]
[null,null,null,null,"J","Vojtovic, P; Reich, O; Selko, M; Tlaskal, T; Hostasa, J; Matejka, T; Gebauer, R; Gabriel, O; Chaloupecky, V",null,null,null,"Vojtovic, Pavel; Reich, Oleg; Selko, Marek; Tlaskal, Tomas; Hostasa, Jiri; Matejka, Tomas; Gebauer, Roman; Gabriel, Otakar; Chaloupecky, Vaclav",null,null,"Haemodynamic changes due to delayed sternal closure in newborns after surgery for congenital cardiac malformations","CARDIOLOGY IN THE YOUNG",null,null,"English","Article",null,null,null,null,null,"Infants; cardiac output; cardiac function; thermodilution; postoperative care","PULSE CONTOUR ANALYSIS; FEMORAL-ARTERY THERMODILUTION; EXTRAVASCULAR LUNG WATER; TRANSPULMONARY THERMODILUTION; ANIMAL-MODEL; DIRECT FICK; OUTPUT; PULMONARY; INFANTS; CHILDREN","Background: Delayed sternal closure is used to prevent low cardiac output syndrome in selected newborns shortly after cardiac surgery for congenital cardiac defects. Sternal closure itself often causes haemodynamic and ventilatory instability that cannot be entirely assessed by standard monitoring means. Therefore, we used transpulmonary thermodilution technique for an exact evaluation of the haemodynamic changes. Patients and methods: Between April, 2006, and December, 2008, 23 neonates aged from 1 to 30 days, with a median of 7 days, and weighing from 1.9 to 4.2 kilograms, with a median of 3.25 kilograms, were studied after biventricular corrections. Residual intracardiac shunts were excluded by echocardiography. Haemodynamic and ventilatory parameters, along with those obtained by the transpulmonary thermodilution technique, were recorded before and immediately after the sternal closure, and then at 0.5, 1, 2, 6, 12, 24, and 48 hours. Results: Chest closure caused significant decrease in systolic arterial pressure from 80.04 +/- 11.48 to 69.48 +/- 9.63 mmHg (p < 0.001), cardiac index from [median (25th/75th centile)] 2.640 (2.355/2.950) to 2.070 (1.860/2.420) l/min/m(2) (p < 0.001), stroke volume index from 18.50 (16.00/20.00) to 14.00 (11.00/17.00) ml/m(2) (p < 0.001), and dynamic lung compliance from 2.45 (2.31/3.00) to 2.30 (2.14/2.77) ml/cmH(2)O (p= 0.007). Stroke volume variation increased from 14.00 (9.25/16.75) to 18.00 (15.00/21.00) % (p < 0.001). The oxygenation index transitorily increased from 2.50 (2.14/3.15) to 3.36 (2.63/4.29) (p < 0.001). Serum lactate decreased from 1.40 (1.12/2.27) to 1.0 (0.8/1.3) mmol/l, p < 0.001 in coincidence with a haemodynamic stabilisation at a later time after chest closure. Cardiopulmonary instability caused by the sternal closure necessitated therapeutic intervention in 18 of 23 patients (78.3%). Conclusion: Delayed sternal closure causes a significant transitory decrease in stroke volume, cardiac output and arterial blood pressure. Also lung compliance and blood oxygenation are temporarily significantly compromised.","[Vojtovic, Pavel; Reich, Oleg; Selko, Marek; Tlaskal, Tomas; Hostasa, Jiri; Matejka, Tomas; Gebauer, Roman; Chaloupecky, Vaclav] Univ Hosp Motol, Kardioctr, Prague 15008 5, Czech Republic; [Vojtovic, Pavel; Reich, Oleg; Selko, Marek; Tlaskal, Tomas; Hostasa, Jiri; Matejka, Tomas; Gebauer, Roman; Chaloupecky, Vaclav] Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15008 5, Czech Republic","Vojtovic, P (reprint author), Univ Hosp Motol, Kardioctr, V Uvalu 84, Prague 15008 5, Czech Republic.","pvojtovic@seznam.cz",null,null,"Internal Grant Agency of the Ministry of Health, Czech Republic [NR 9046-3]","Supported by the grant NR 9046-3, Internal Grant Agency of the Ministry of Health, Czech Republic.",null,21,1,1,"CAMBRIDGE UNIV PRESS","CAMBRIDGE","EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND","1047-9511",null,null,"CARDIOL YOUNG","Cardiol. Young",null,2009,19,6,null,null,null,null,573,579,null,"10.1017/S1047951109991065",null,7,"Cardiac & Cardiovascular Systems; Pediatrics","Cardiovascular System & Cardiology; Pediatrics","663BS","WOS:000282858600005"]
[null,null,null,null,"J","Zelinka, T; Holaj, R; Petrak, O; Strauch, B; Kasalicky, M; Hanus, T; Melenovsky, V; Vancura, V; Burgelova, M; Widimsky, J",null,null,null,"Zelinka, Tomas; Holaj, Robert; Petrak, Ondrej; Strauch, Branislav; Kasalicky, Mojmir; Hanus, Tomas; Melenovsky, Vojtech; Vancura, Viastimil; Buergelova, Marcela; Widimsky, Jiri, Jr.",null,null,"Life-threatening arrhythmia caused by primary aldosteronism","MEDICAL SCIENCE MONITOR",null,null,"English","Article",null,null,null,null,null,"primary aldosteronism; hypokalemia; torsade de pointes","PRIMARY HYPERALDOSTERONISM; VENTRICULAR-FIBRILLATION; QT INTERVAL; DIAGNOSIS","Background: Arrhythmias are one of the typical complications of primary aldosteronism (PA), is commonly characterized by hypertension and hypokalemia. Case Report: In this report, we present 3 cases of subjects in whom primary aldosteronism manifested with life-threatening arrhythmias. In 2 subjects, after excluding organic heart disease, an implantable cardioverter defibrillator was inserted and, only after the second episode of polymorphic ventricular tachycardia accompanied with low plasma potassium levels, the diagnosis of primary aldosteronism was made. Conclusions: It is important to include diagnosis of primary aldosteronism in the diagnostic work-up of hypertensive subjects without any structural cardiovascular impairment who present with malignant arrhythmia and hypokalemia. Appropriate treatment of primary aldosteronism may avoid insertion of an implantable cardioverter defibrillator.","[Zelinka, Tomas; Holaj, Robert; Petrak, Ondrej; Strauch, Branislav; Widimsky, Jiri, Jr.] Fac Med 1, Dept Med 3, CZ-12808 Prague 2, Czech Republic; [Kasalicky, Mojmir] Fac Med 1, Dept Surg 1, CZ-12808 Prague, Czech Republic; [Zelinka, Tomas; Holaj, Robert; Petrak, Ondrej; Strauch, Branislav; Kasalicky, Mojmir; Hanus, Tomas; Widimsky, Jiri, Jr.] Gen Teaching Hosp, CZ-12808 Prague 2, Czech Republic; [Hanus, Tomas] Fac Med 1, Dept Urol, CZ-12808 Prague 2, Czech Republic; [Melenovsky, Vojtech; Vancura, Viastimil] Inst Clin & Expt Med, Dept Cardiol, Prague, Czech Republic; [Buergelova, Marcela] Inst Clin & Expt Med, Transplant Ctr, Dept Nephrol, Prague, Czech Republic","Zelinka, T (reprint author), Fac Med 1, Dept Med 3, U Nemocnice 1, CZ-12808 Prague 2, Czech Republic.","tzeli@lf1.cuni.cz",null,null,"Ministry of Health of the Czech Republic [NR/8155-5]","This study was supported by the grant NR/8155-5 from the Ministry of Health of the Czech Republic","Abdo A, 1999, CAN J CARDIOL, V15, P347; Al-Aloul Basel, 2006, Pacing Clin Electrophysiol, V29, P1303; Aydin A, 2005, TEX HEART I J, V32, P85; Catena C, 2008, ARCH INTERN MED, V168, P80, DOI 10.1001/archinternmed.2007.33; CURRY P, 1976, LANCET, V2, P231; Funder JW, 2008, J CLIN ENDOCR METAB, V93, P3266, DOI 10.1210/jc.2008-0104; MARIAN AJ, 2008, HURSTS HEART, P1811; Matsumura K, 2005, CLIN EXP PHARMACOL P, V32, P66, DOI 10.1111/j.1440-1681.2005.04161.x; MAULE S, 2006, J HYPERTENS, V242, P459; Milliez P, 2005, J AM COLL CARDIOL, V45, P1243, DOI 10.1016/j.jacc.2005.01.015; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Rossi GP, 2006, J AM COLL CARDIOL, V48, P2293, DOI 10.1016/j.jacc.2006.07.059; Rossi GP, 2008, J HYPERTENS, V26, P613, DOI 10.1097/HJH.0b013e3282f4b3e6; Sade E, 2002, ANGIOLOGY, V53, P471, DOI 10.1177/000331970205300415; Tiu SC, 2005, J CLIN ENDOCR METAB, V90, P72, DOI 10.1210/jc.2004-1149; Yang TY, 2007, INT J CLIN PRACT, V61, P392, DOI 10.1111/j.1742-1241.2006.00982.x",17,1,1,"INT SCIENTIFIC LITERATURE, INC","ALBERTSON","1125 WILLIS AVE, ALBERTSON, NY 11507 USA","1234-1010",null,null,"MED SCI MONITOR","Med. Sci. Monitor","DEC",2009,15,12,null,null,null,null,"CS174","CS177",null,null,null,4,"Medicine, Research & Experimental","Research & Experimental Medicine","537NS","WOS:000273120300026"]
[null,null,null,null,"J","Talab, R; Masopust, J; Andrys, C; Stourae, P; Hort, J; Valis, M",null,null,null,"Talab, Radomir; Masopust, Jiri; Andrys, Ctirad; Stourae, Pavel; Hort, Jakub; Valis, Martin",null,null,"Tau protein, phosphorylated tau protein, and beta-amyloid 42 levels in patients with neurodegenerative diseases complicated by cognitive deficits A non-randomized, concurrent, case-control investigation","NEURAL REGENERATION RESEARCH",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; Creutzfeldt-Jakob disease; multiple sclerosis; beta-amyloid 42; total tau protein; phosphorylated tau protein","CREUTZFELDT-JAKOB-DISEASE; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; MULTIPLE-SCLEROSIS; DIFFERENTIAL-DIAGNOSIS; AXONAL DAMAGE; CSF; DEMENTIA; MARKER; BIOMARKERS","BACKGROUND: The differential diagnosis of many neurodegenerative disorders depends primarily on clinical symptoms together with imaging methods. Recently, increased importance has been placed on the use of biomarkers for diagnosing various neurodegenerative disorders. OBJECTIVE: To assess the feasibility of tau-protein, phosphorylated tau-protein, beta-amyloid 42 (A(342), and 14-3-3 protein as biomarkers for diagnosing several neurodegenerative diseases complicated by cognitive deficits. DESIGN, TIME AND SETTING: A non-randomized, concurrent, case-control investigation was performed in three medical centers in the Czech Republic (Department of Neurology at the University Hospital in Hradec Kralove, Department of Neurology at the 2(nd) Medical Faculty, and the University Hospital Motol) between October 2000 and November 2006. PARTICIPANTS: Eighteen patients with probable Alzheimer's disease, 4 patients with Creutzfeldt-Jakob disease, 10 patients with frontotemporal dementia, 9 patients with clinically isolated syndrome suggestive of multiple sclerosis, and 7 patients with multiple sclerosis, as well as 38 race-, nationality-, and age-matched cognitively intact controls, were included in the study. Diagnoses were established based on the following criteria: the criteria for Alzheimer's disease proposed by the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association, WHO criteria for Creutzfeldt-Jakob disease, Neary criteria for frontotemporal dementia, and McDonald's criteria for multiple sclerosis. All included patients were confirmed to suffer from various degrees of dementia. METHODS: Enzyme-linked immunosorbent assay was used to measure concentrations of tau-protein, phosphorylated tau-protein, and A(342 in cerebrospinal fluid (CSF) samples collected by standard lumbar puncture from each patient. Moreover, 14-3-3 protein was assessed by Western blot in CSF of Creutzfeldt-Jakob disease patients. Cognitive status was assessed using the Mini Mental Scale Examination (MMSE) in all subjects. MAIN OUTCOME MEASURES: Establishment of biomarkers with greatest specificity and sensitivity for the investigated disorders according to Receiver Operating Characteristic curves, which were based on values from patients and controls; correlation between concentrations of given biomarkers and demographic parameters, diagnosis, duration of disease, and level of cognitive deficit. RESULTS: Increased concentrations of total tau protein and phosphorylated tau protein, and decreased levels of A(342, in CSF of Alzheimer's disease patients reached the required sensitivity/specificity ratio of 80% or greater. A marked elevation in CSF concentrations of total tau protein showed even greater sensitivity than 14-3-3 protein in Creutzfeldt-Jakob disease. There was no association between selected biomarkers and frontotemporal dementia or multiple sclerosis. Phosphorylated tau-protein was the only biomarker that noticeably correlated with MMSE scores for Alzheimer's disease. CONCLUSION: Levels of total tau protein, phosphorylated tau protein, and A beta 42 in the CSF could differentiate patients with Alzheimer's disease and Creutzfeldt-Jakob disease from healthy controls and patients with other neurodegenerative disorders. The diversity of absolute values demonstrates the necessity to establish a specific standard for each laboratory.","[Talab, Radomir; Valis, Martin] Charles Univ Prague, Dept Neurol, Fac Med, Hradec Kralove 50005, Czech Republic; [Talab, Radomir; Masopust, Jiri; Andrys, Ctirad; Valis, Martin] Univ Hosp Hradec Kralove, Hradec Kralove 50005, Czech Republic; [Masopust, Jiri] Charles Univ Prague, Dept Psychiat, Fac Med, Hradec Kralove 50005, Czech Republic; [Andrys, Ctirad] Charles Univ Prague, Inst Clin Immunol & Allergol, Hradec Kralove 50005, Czech Republic; [Stourae, Pavel] Masaryk Univ, Dept Neurol, Fac Med, Brno 62500, Czech Republic; [Stourae, Pavel] Univ Hosp Brno, Brno 62500, Czech Republic; [Hort, Jakub] Charles Univ Prague, Dept Neurol, Sch Med 2, Prague 15006, Czech Republic","Masopust, J (reprint author), Charles Univ Prague, Dept Neurol, Fac Med, Hradec Kralove 50005, Czech Republic.","masopustj@lfhk.cuni.cz",null,null,null,null,null,42,0,0,"SHENYANG EDITORIAL DEPT NEURAL REGENERATION RES","SHENYANG","PO BOX 1234, SHENYANG, LIAONING 110004, PEOPLES R CHINA","1673-5374",null,null,"NEURAL REGEN RES","Neural Regen. Res.","NOV",2009,4,11,null,null,null,null,951,957,null,"10.3969/j.issn.1673-5374.2009.11.027",null,7,"Cell Biology; Neurosciences","Cell Biology; Neurosciences & Neurology","531KR","WOS:000272665500027"]
[null,null,null,null,"J","Gebauer, RA; Tomek, V; Kubus, P; Razek, V; Matejka, T; Salameh, A; Kostelka, M; Janousek, J",null,null,null,"Gebauer, Roman A.; Tomek, Viktor; Kubus, Petr; Razek, Vit; Matejka, Tomas; Salameh, Aida; Kostelka, Martin; Janousek, Jan",null,null,"Differential effects of the site of permanent epicardial pacing on left ventricular synchrony and function in the young: implications for lead placement","EUROPACE",null,null,"English","Article",null,null,null,null,null,"Permanent pacing; Heart block; Ventricular dysfunction; Left ventricular pacing; Right ventricular pacing; Children","CARDIAC RESYNCHRONIZATION THERAPY; DUAL-CHAMBER; ATRIOVENTRICULAR-BLOCK; CHILDREN; HEART; DYSSYNCHRONY; PACEMAKER; FAILURE; ATRIAL; TRIAL","To analyse left ventricular (LV) synchrony and function with respect to the epicardial pacing site in the young. Left ventricular function and synchrony (M-mode, speckle tracking) were evaluated during mid-term follow-up in 32 children with complete non-surgical (n = 15) or surgical (n = 17) atrioventricular block (structural heart disease in 21/32) paced from LV apex (n = 19), right ventricular (RV) apex (n = 7), and RV free wall (n = 6), respectively. Data are in the following order: LV apical, RV apical, and RV free wall pacing. Septal to posterior wall motion delay (SPWMD) = median 0, 69, and 136 ms (P < 0.001), septal to lateral mechanical delay = 54 +/- 29, 73 +/- 24, and 129 +/- 70 ms (P = 0.001), apical to basal mechanical delay = 96 +/- 37, 106 +/- 50, and 79 +/- 18 ms (P NS), and LV ejection fraction (LVEF) = 57 +/- 9, 49 +/- 12, and 33 +/- 10% (P < 0.001), respectively. Left ventricular ejection fraction correlated negatively with SPWMD (R(2) = 0.454, P < 0.001) and septal to lateral mechanical delay (R(2) = 0.320, P < 0.001) but not with apical to basal mechanical delay. Right ventricular free wall pacing (P = 0.014) and SPWMD (P = 0.044) were negative multivariable predictors of LVEF. Compared with other sites, LV apical pacing preserves septal to lateral LV synchrony and systolic function and may be the preferred epicardial pacing site in the young.","[Gebauer, Roman A.; Razek, Vit; Salameh, Aida; Janousek, Jan] Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, D-04289 Leipzig, Germany; [Tomek, Viktor; Kubus, Petr; Matejka, Tomas] Univ Hosp Motol, Kardiocentrum, Prague, Czech Republic; [Tomek, Viktor; Kubus, Petr; Matejka, Tomas] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Kostelka, Martin] Univ Leipzig, Ctr Heart, Dept Cardiac Surg, Leipzig, Germany","Gebauer, RA (reprint author), Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, Strumpellstr 39, D-04289 Leipzig, Germany.","roman.gebauer@med.uni-leipzig.de",null,null,"Ministry of Health, Czech Republic [NR/9472-3]","This work was supported by the grant of the Ministry of Health, Czech Republic (NR/9472-3 to V.T. and P.K.).",null,22,13,15,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1099-5129",null,null,"EUROPACE","Europace","DEC",2009,11,12,null,null,null,null,1654,1659,null,"10.1093/europace/eup342",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","524YE","WOS:000272179500015"]
[null,null,null,null,"J","Vavrik, P; Landor, I; Tomaides, J; Popelka, S",null,null,null,"Vavrik, P.; Landor, I.; Tomaides, J.; Popelka, S.",null,null,"Medin Modular Implant for Total Knee Arthroplasty - Mid-Term Results","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"total knee replacement; mid-term results; Kaplan-Meier survival curve; anterior knee pain","REPLACEMENT; MOTION","PURPOSE OF THE STUDY To evaluate the mid-term results of total knee arthroplasty (TKA) using a Medin Modular joint prosthesis in a standard design preserving the posterior cruciate ligament. MATERIAL The study comprised 206 consecutive total knee arthroplasties, 10 bilateral, 60 in men and 136 in women. Twelve patients died of causes unrelated to the surgery and 14 knee replacements were lost to follow-up. A total of 180 were evaluated at an average follow-up of 6.5 years (range, 5 to 8.7 years). The patients ranged in age from 43 to 84 years (average, 69.5 years). The basic indication for surgery was osteoarthritis in 179 and rheumatoid arthritis in 37 cases. METHODS Pain, range of motion, stability and function were scored on a 100-point scale of the Hospital for Special Surgery (HSS) Scoring System. Subjective satisfaction was essessed by the patient's willingness to undergo the surgery again. At yearly intervals, radiographs in two projections were examined for radiolucent lines around the implant. The Kaplan-Meier survival curve was evaluated for the whole group and compared with that for non-infected cases only. The mechanical properties of the implant were most reliably shown by the survival curve for the subgroup of knee replacements free of infection. RESULTS At the final follow-up out of 180 knees, 169 were fully functioning and 11 required revision arthroplasty for the following reasons: polyethylene wear, one knee; instability, two; infection, six; patellar fracture, one; and problems associated with the femoro-patellar joint, one knee. The Kaplan-Meier curve for the whole group showed survival of 92 % of the implants at the end of the 9-years follow-up time. In the infection-free subgroup, in which aseptic loosenings were only included, there was a 95 % survival. The average range of flexion was over 106 degrees, and only 11 knees had flexion below 90 degree lack of. Extension from 5 to 10 degrees was found in four knees. Thirteen knees showed instability that did not interfere with function. In 191 knees, after surgery alignment was optimal, between 0 and 5-degree valgus; in 11 knees varus up to 5 degrees and valgus up to 10 degrees were found. No pain was recorded in 123 knees, occasional pain with no effect on function in 36 cases, and moderate pain after weight-bearing in 10 knees. By the HSS score, 136 knees had excellent and very good (over 90 points) outcomes and 21 had unsatisfactory or poor outcomes (below 85 points); the remaining 23 had satisfactory outcomes (between 89 and 85 points). The subjective evaluation was positive for 156 knees. Of 169 TKA evaluated radiographs, 141 were without signs of radiolucency, 17 showed a slight marginal radiolucent line and 11 had a more pronounced radiolucent line up to 1 mm in width, but without progression. DISCUSSION A total of 93 % of total replacements were evaluated and 7 % were lost to follow-up. Therefore, the number of remaining patients is big enough to make the group valid for assessment. The rate of complications, including 2.9 % of infected knees, is in agreement with the reported values. The occurence of polyethylene wear was negligible. A comparison of the cumulative survival curve for the whole group with that for the infection-free subgroup showed that the effect of infection on the TKA outcome was statistically significant (p=0.0431), and that late infection remains the most serious complication. Aseptic loosening plays a less important role in implant survival evaluated at mid-term intervals. CONCLUSIONS The rate of complications for Medin Modular implants evaluated at an average follow-up of 6.5 years is not different from the values reported for similar prostheses. The most serious complication is late infection. Persistent pain is usually located to the femoro-patellar articulation, but it seldom markedly affects joint function. The cumulative survival curve for the whole group was 92 % at a 9 years. The HSS evaluation of the whole group showed that 75 % of the knees achieved mor than 90 points.","[Vavrik, P.; Landor, I.; Tomaides, J.; Popelka, S.] LF UK & FN Motol, I Ortoped Klin 1, Prague 15000 5, Czech Republic","Vavrik, P (reprint author), LF UK & FN Motol, I Ortoped Klin 1, V Uvalu 83, Prague 15000 5, Czech Republic.","vavrik@atlas.cz",null,null,null,null,null,28,12,12,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2009,76,1,null,null,null,null,30,34,null,null,null,5,"Orthopedics","Orthopedics","416TJ","WOS:000264028100005"]
[null,null,null,null,"J","Landor, I; Vavrik, P; Jahoda, D; Pokorny, D; Ballay, R; Sosna, A",null,null,null,"Landor, I.; Vavrik, P.; Jahoda, D.; Pokorny, D.; Ballay, R.; Sosna, A.",null,null,"Long-Term Experience with the Combined ARBOND Hydroxyapatite Coating in Implant Osteointegration","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"osteoactive surface; hydroxyapatite; cementless; THA; osteointegration","TOTAL HIP-ARTHROPLASTY; COATED FEMORAL STEMS; FOLLOW-UP; SURVIVAL; HISTOPATHOLOGY; REPLACEMENT; OSTEOLYSIS; PROSTHESES; 10-YEAR; BONE","PURPOSE OF THE STUDY The hydroxyapatite coating of an implant surface provides osteoactive conditions that can support osteointegration of cementless joint arthroplasties. However, the possibilities of hydroxyapatite degradation, resorption and delamination that may become responsible for failure of total hip arthroplasty (THA) have been reported. The aim of the study was to assess the properties of Arbond hydroxyapatite coating by comparing the long-term survival of implants identical in construction but different in surface coating. MATERIAL One group (HA) comprised 86 patients (100 THAs) with an average age of 45.14 years (range, 22.3 to 77.4 years) at the time of surgery who received a femoral stem (Walter) with a coating of Arbond sprayed over the proximal half. The other group (control) included 92 patients (100 THAs) with an average age of 49.7 years (range, 33 to 68.7) who had an identical femoral component without coating. In both groups the conical-shaped acetabular cup (Walter) and femoral head made of sintered ceramics were used. The patients in whom one or both components were replaced or extracted were not included in the final clinical evaluation (Harris Hip Score). For the statistical analysis of survival, a stable component still in place at the date of the revision procedure was regarded as surviving; a lose component at the same date was considered a failure. Finally, 71 hips of the HA group followed up for an average of 15.51 (range, 5.6 to 18.56) years and 39 control hips at an average follow-up of 14.19 (range, 6.24 to 18.48) years were clinically evaluated. The data of patients who died in the course of study (HA group, 11; control group, 14) were included in the clinical evaluation with the date of their last follow-up. METHODS For both groups, the Kaplan-Meier survival curves were constructed for overall survival and for the survival of acetabular and femoral components separately. Differences in survival curves were evaluated with the use of Gehan's Wilcoxon test. Component survival was also calculated using 15-year life-table survivorship analysis. Differences in variables under study were assessed with the use of the two-tailed Student's t-test. A p value of less than 0.05 was considered significant. RESULTS A total of 29% hips were revised in the HA group, 27% for aseptic loosening of the acetabular cup, in 2% both components were removed because of deep infection. In the control group revision procedures were performed in 61% of the hips. Except for one case of deep infection (1%), the reason was cup loosening in 30%, stem loosening in 12% and both components loosening in 18% of the hips. The HA group showed a significantly longer survival of both total hip prostheses and individual components. The final HHS was significantly better than the initial score in both groups. There was no difference in the degree of improvement between the two groups. The radiographic data showed full osteointegration of stems in the HA group. The control group, on the other hand, had 87% of the stems with translucent lines in zone I and zone VII according to Gruen's classification. DISCUSSION The significantly longer survival of hips in the HA group gives support to the use of hydroxyapatite coating in total hip arthroplasty. The poorer results in grit-blasted implants, as compared with the literature data, can be explained by alow degree of roughness of the Walter implant surfaces. CONCLUSIONS The combined Arbond hydroxyapatite coating improves conditions for implant osteointegration in the bone.","[Landor, I.; Vavrik, P.; Jahoda, D.; Pokorny, D.; Ballay, R.; Sosna, A.] FN Motol, I Ortoped Klin 1 LF UK, Prague, Czech Republic","Landor, I (reprint author), Vinobrani 15, Prague 10600 10, Czech Republic.","landor@atlas.cz",null,null,null,null,null,27,8,9,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","JUN",2009,76,3,null,null,null,null,172,178,null,null,null,7,"Orthopedics","Orthopedics","468UP","WOS:000267849400002"]
[null,null,null,null,"J","Kotlin, R; Reicheltova, Z; Maly, M; Suttnar, J; Sobotkova, A; Salaj, P; Hirmerova, J; Riedel, T; Dyr, JE",null,null,null,"Kotlin, Roman; Reicheltova, Zuzana; Maly, Martin; Suttnar, Jiri; Sobotkova, Alzbeta; Salaj, Peter; Hirmerova, Jana; Riedel, Tomas; Dyr, Jan E.",null,null,"Two cases of congenital dysfibrinogenemia associated with thrombosis - Fibrinogen Praha III and Fibrinogen Plzen","THROMBOSIS AND HAEMOSTASIS",null,null,"English","Article",null,null,null,null,null,"Dysfibrinogenemia; fibrinogen; missense mutation; pulmonary embolism; thrombosis","ENDOPLASMIC-RETICULUM STORAGE; GAMMA-CHAIN; POLYMERIZATION SITE; COILED-COIL; ABNORMAL FIBRINOGEN; CRYSTAL-STRUCTURE; BINDING-SITE; ARG-PRO; A-ALPHA; MUTATION","Congenital dysfibrinogenemia is a rare disease characterised by inherited abnormality in the fibrinogen molecule, resulting in functional defects. Two patients, a 26-year-old woman and a 61-year-old man, both with history of thrombotic events, had abnormal coagulation test results. DNA sequencing showed the heterozygous gamma Y363N mutation (Fibrinogen Praha 111) and the heterozygous A alpha N106D mutation (Fibrinogen Plzen), respectively. Fibrin polymerisation, after addition of either thrombin or reptilase, showed remarkably delayed polymerisation in both cases. Fibrinolysis experiments showed slower tPA initiated lysis of clots. SDS-PAGE did not show any difference between normal and Praha III and Plzen fibrinogens. Both mutations had a significant effect on platelet aggregation. In the presence of either ADP or TRAP, both mutations caused the decrease of platelet aggregation. SEM revealed abnormal clot morphology, with a large number of free ends and narrower fibres of both fibrin Praha III and PIzen. Praha III mutation was situated in the polymerisation pocket \"a\". The replacement of the bulky aromatic side chain of tyrosine by the polar uncharged small side chain of asparagine may lead to a conformational change, possibly altering the conformation of the polymerisation pocket. The Plzen mutation is situated in the coiled-coil connector and this replacement of polar uncharged asparagine residue by polar acidic aspartate changes the alpha-helical conformation of the coiled-coil connector; and may destabilise hydrogen bonds in its neighborhood. Although both mutations are situated in different regions of the molecule, both mutations have a very similar effect on fibrinogen functions and both are connected with thromboses.","[Kotlin, Roman; Reicheltova, Zuzana; Suttnar, Jiri; Sobotkova, Alzbeta; Salaj, Peter; Riedel, Tomas; Dyr, Jan E.] Inst Hematol & Blood Transfus, Prague 12820 2, Czech Republic; [Maly, Martin] Motol Univ Hosp, Dept Cardiol, Prague, Czech Republic; [Hirmerova, Jana] Univ Hosp Plzen, Dept Internal Med 2, Plzen, Czech Republic; [Riedel, Tomas] Acad Sci Czech Republic, Inst Macromol Chem, Prague, Czech Republic","Kotlin, R (reprint author), Inst Hematol & Blood Transfus, Nemocnice 1, Prague 12820 2, Czech Republic.","kotlinr@uhkt.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health of the Czech Republic [NS 9636-3/2008, 2373601]; Czech Republic [KAN200670701]","This work was supported by a grant of the Internal Grant Agency of The Ministry of Health of the Czech Republic, number NS 9636-3/2008; by a grant of The Academy of Sciences of the Czech Republic, number KAN200670701; and by a grant of The Ministry of Health of the Czech Republic, number 2373601",null,44,8,8,"SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN","STUTTGART","HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY","0340-6245",null,null,"THROMB HAEMOSTASIS","Thromb. Haemost.","SEP",2009,102,3,null,null,null,null,479,486,null,"10.1160/TH08-11-0771",null,8,"Hematology; Peripheral Vascular Disease","Hematology; Cardiovascular System & Cardiology","495KN","WOS:000269890200009"]
[null,null,null,null,"J","Hromadka, R; Bartak, V; Popelka, S; Jahoda, D; Pokorny, D; Sosna, A",null,null,null,"Hromadka, R.; Bartak, V.; Popelka, S.; Jahoda, D.; Pokorny, D.; Sosna, A.",null,null,"Regional Anaesthesia of the Foot Achieved from Two Cutaneous Points of Injection: An Anatomical Study","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"ankle block; foot block; regional anaesthesia","FOREFOOT SURGERY; HALLUX-VALGUS; ANKLE-BLOCK","PURPOSE OF THE STUDY Regional anaesthesia for the lower extremity distal to the ankle joint, knows as anaesthetic ankle block or foot block, involves a series of injections of local anaesthetic to block the peripheral nerves that supply innervation to the foot. Since the tibial nerve block is not always effective, the aim of this study was to design a modified technique of anaesthetic application. MATERIAL The study was carried out on 30 human cadavers provided by the Institute of Anatomy, 1(st) Faculty of Medicine, Charles University in Prague, and included data on a total of 60 lower extremities. METHODS Information about position of the tibial nerve (or its branches, i.e., the medial plantar and lateral plantar nerves) and the sural nerve was obtained using a set of special measurement devices designed for this purpose. The following distances were measured; the length of a basic line, i.e., distance between the posterior margin of the medial maleollus and the medial edge of the Achilles tendon (at the level of the upper part of the heel bone); the distance between the medial edge of the Achilles tendon and the tibial nerve; and the distance between the tibial nerve (its deep location) in the neurovascular plexus and the basic line. The location of the sural nerve behind the lateral maleollus was found by measuring the nerve distance from the posterior margin of the lateral maleollus and measuring the distance between this margin and the lateral edge of th Achilles tendon. RESULTS The distance between the posterior margin of the medial maleollus (medial edge of the sulcus for the posterior tibial muscle tenton) and the medial edge of the Achilles tendon (at the level of the upper part of the heel bone) was 46.3 mm +/- 5.2 mm. The depth of tibial nerve location, i.e. distance from the basic line to the neurovascular plexus, was 11.6 mm +/- 1.3 mm. The distance between the posterior margin of the lateral maleollus and the lateral edge of the Achilles tendon (at the level of the upper part of the heel bone) was 37.1 mm +/- 4.3 mm. The sural nerve was located at a distance of approximately 18.3 mm +/- 1.9 mm from the posterior edge of the lateral maleollus. DISCUSSION The study was concluded by proposing a modified technique of local anaesthetic ankle block using two points of anaesthetic injection. The first point is located immediately in front of the medial edge of the Achilles tendon and above the upper edge of the calcaneus. The anaesthetic applied will block the tibial and sural nerves, with the sural nerve being blocked by the anaesthetic delivered with a needle advanced through the soft tissues ventral to the Achilles tendon. The second area of application is located at 2 cm above the ventral fold of the ankle joint on the lateral edge of the anterior tibial muscle tendon and provides subcutaneous infiltration anaesthesia for the superficial and deep peroneal nerves and the saphenous nerve. CONCLUSIONS The results of this anatomical study provided a basis for a modified technique of regional anaesthesia of the foot. Its major clinical attributes involve reduced necessity to manipulate with the patient, and sensory and motor blockage of all nerves supplying innervation to the foot from only two points of injection.","[Hromadka, R.; Bartak, V.; Popelka, S.; Jahoda, D.; Pokorny, D.; Sosna, A.] 1 LF UK, Ortoped Klin, Prague 15006 5, Czech Republic; [Hromadka, R.; Bartak, V.; Popelka, S.; Jahoda, D.; Pokorny, D.; Sosna, A.] FN Motol, Prague 15006 5, Czech Republic; [Hromadka, R.] 1 LF UK, Anat Ustav, Prague 15006 5, Czech Republic","Hromadka, R (reprint author), 1 LF UK, Ortoped Klin, Uvalu 84, Prague 15006 5, Czech Republic.","rastislav.hromadka@lf1.cuni.cz",null,null,null,null,null,15,8,8,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2009,76,2,null,null,null,null,104,109,null,null,null,6,"Orthopedics","Orthopedics","439ZY","WOS:000265668600005"]
[null,null,null,null,"J","Pacova, H; Astl, J; Martinek, J",null,null,null,"Pacova, H.; Astl, J.; Martinek, J.",null,null,"The pathogenesis of chronic inflammation and malignant transformation in the human upper airways: the role of beta-defensins, eNOS, cell proliferation and apoptosis","HISTOLOGY AND HISTOPATHOLOGY",null,null,"English","Article",null,null,null,null,null,"Tonsillitis chronica; Tonsillar carcinoma; Nasal polyposis; Defensins; Apoptosis; Proliferation","NITRIC-OXIDE SYNTHASE; EXPRESSION PATTERNS; PALATINE TONSIL; ORAL-TISSUES; CARCINOMA; BETA-DEFENSIN-2; PEPTIDES; MUCOSA; NO","The surrounding environment contains plenty of pathogens, which represent a danger of infection. The simplest way for the pathological microorganism to enter the organism is the upper airways. Inflammation of the upper airways is among the most common and frequent diseases. This category includes nasal polyposis and chronic tonsillitis. In many cases it is associated with disorders in relation to the immune response. An inflammatory infiltration of mononuclears, eosinophils, plasma and mast cells can be found in the histological structure of the polypous as well as tonsillar mucosa. One aim of this study was to determine the expression of beta-defensins and various proteins, with a possible potential role in relation to the rise and development of those changes. Another aim was to determine the relationship between the inflammatory and malignant processes in the tonsils. The samples of nasal polyps were obtained during clinically indicated endonasal surgery from patients diagnosed with nasal polyposis (n=50). The samples of tonsils were collected during surgery from patients suffering from chronic tonsillitis (n=11) or tonsillar carcinoma (n=17). Immunohistochemical procedures for the detection of human beta-defensin 1, 2, 3 (HBD-1,2, 3), Ki-67, endothelial nitric oxide synthase (eNOS) and cleaved caspase 3 were performed on cryostate and paraffin sections. It was proven that HBD are secreted in fairly large amounts in cases of chronic inflammation. Their secretion during the malignant transformation is limited. This is a very probable fact that plays a role in malignant transformation in tonsillar tissue. The crucial role in the development of chronic inflammation, and maybe that of malignant transformation, is played by eNOS and its product NO molecule. eNOS and the NO molecule are involved in cell cycle regulation, in the apoptotic processes and cell proliferation, as well as in the angiogenesis and vasculogenesis. Our result confirmed that eNOS is presented in the tissues of the upper airways in both chronic inflammation and carcinomatous processes. Ki-67 and cleaved caspase 3 were used as markers of cell proliferation and apoptosis.","[Pacova, H.; Martinek, J.] Charles Univ Prague, Fac Med 1, Inst Histol & Embryol, Prague 12801 2, Czech Republic; [Pacova, H.; Astl, J.] Fac Med 1, Dpt Otorhinolaryngol & Head & Neck Surg, Prague, Czech Republic; [Pacova, H.; Astl, J.] Teaching Hosp Motol, Prague, Czech Republic","Pacova, H (reprint author), Charles Univ Prague, Fac Med 1, Inst Histol & Embryol, Albertov 4, Prague 12801 2, Czech Republic.","Hpac@seznam.cz",null,null,"IGA Ministry of Health, CR [9077 NR]","The authors would like to express their thanks to Mrs. Blazkeova, Mrs. Kratinova, Mrs. Kolarova and Miss Kosova from the Instute of Histology and Embryology for their substantial help in processing the material and realization of immunohistochemical procedures during this experimental study. This project was supported by Grant project No. 9077 NR, IGA Ministry of Health, CR.",null,24,6,8,"F HERNANDEZ","MURCIA","PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN","0213-3911",null,null,"HISTOL HISTOPATHOL","Histol. Histopath.","JUL",2009,24,7,null,null,null,null,815,820,null,null,null,6,"Cell Biology; Pathology","Cell Biology; Pathology","450NG","WOS:000266407500002"]
[null,null,null,null,"J","Peichl, P; Kautzner, J; Gebauer, R",null,null,null,"Peichl, Petr; Kautzner, Josef; Gebauer, Roman",null,null,"Ablation of atrial tachycardias after correction of complex congenital heart diseases: utility of intracardiac echocardiography","EUROPACE",null,null,"English","Article",null,null,null,null,null,null,"INTRAATRIAL REENTRANT TACHYCARDIA; CATHETER ABLATION; GREAT-ARTERIES; MUSTARD OPERATION; MAPPING SYSTEM; TRANSPOSITION; FLUTTER; ARRHYTHMIA; FONTAN","Our goal was to analyse the utility of intracardiac echocardiography (ICE) for navigation and ablation of atrial tachycardias (ATs) after surgical correction of congenital heart disease (CHD). Catheter ablation of ATs was performed in seven patients (one woman, mean age 21 +/- 6 years) after correction of complex CHD: d-transposition of the great arteries (Mustard procedure in two patients, Senning procedure in two patients) and univentricular circulation (total cavopulmonary connection in two patients, atriopulmonary connection in one patient). The ablation was guided by a combination of electroanatomical mapping (CARTO, Biosense-Webster) and ICE (Acuson, Siemens). Intracardiac echocardiography was used during mapping to identify relevant anatomical structures and monitor tissue contact and for guidance of atrial baffle puncture. Biatrial mapping was necessary in six of seven patients and atrial baffle puncture in three. The clinical AT was abolished in all patients. No complications were noted. During follow-up of 23 +/- 13 months, two patients (28%) had arrhythmia recurrence. One patient developed atrial fibrillation, and recurrent AT in the other patient was controlled by re-ablation. Despite complicated cardiac anatomy, catheter ablation of AT after complex CHD can be performed safely and with a high success rate. Intracardiac echocardiography facilitates mapping, identification of relevant cardiac structures, and could be used for safe guidance of transbaffle puncture.","[Peichl, Petr; Kautzner, Josef] Inst Clin & Expt Med, Dept Cardiol, Prague 14021 4, Czech Republic; [Gebauer, Roman] Pediat Heart Ctr Motol, Prague, Czech Republic","Peichl, P (reprint author), Inst Clin & Expt Med, Dept Cardiol, Videnska 1958-9, Prague 14021 4, Czech Republic.","pepi@medicon.cz",null,null,"Ministry of Health of the Czech Republic [MZO 00023001]","This study was supported by research grant no.: MZO 00023001 of the Ministry of Health of the Czech Republic (Research in Cardiovascular Diseases, Diabetes Mellitus and Transplantations of LifePreserving Organs).",null,15,7,7,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1099-5129",null,null,"EUROPACE","Europace","JAN",2009,11,1,null,null,null,null,48,53,null,"10.1093/europace/eun316",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","386PD","WOS:000261894200011"]
[null,null,null,null,"J","Sedlackova, L; Nguyen, TTH; Zlacka, D; Sosna, A; Hromadnikova, I",null,null,null,"Sedlackova, Lucie; Nguyen, Thi Thu Hien; Zlacka, Denisa; Sosna, Antonin; Hromadnikova, Ilona",null,null,"Cell surface and relative mRNA expression of heat shock protein 70 in human synovial cells","AUTOIMMUNITY",null,null,"English","Article",null,null,null,null,null,"mRNA expression; Hsp70; synovial cells; real-time PCR; cell surface expression; flow cytometry","HEAT-SHOCK PROTEINS; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; ANTIINFLAMMATORY DRUGS; MOLECULAR CHAPERONES; ENHANCED EXPRESSION; MEMBRANE EXPRESSION; TISSUE; ACTIVATION; MORPHOLOGY","Heat shock proteins (Hsps) have been repeatedly implicated to participate in the pathogenesis of rheumatoid arthritis (RA). Methods: Herein, Hsp70 cell surface and mRNA expression were studied in human fibroblast-like synovial cells, dermal fibroblasts and peripheral blood leukocytes derived from 24 RA patients, who underwent synovectomy by using flow-cytometric analysis and real-time quantitative reverse-transcriptase polymerase chain reaction. For comparison, peripheral blood leukocytes of 17 healthy controls were tested. Results: Significantly higher Hsp70 membrane positivity was found on fibroblast-like synovial cells in RA patients (average 18.3%, median 16.5%) than on autologous and healthy control peripheral blood lymphocytes (RA patients: average 4.7%, median 2.9%, p=0.002; healthy controls: average 6.0%, median 4.5%, p=0.002) and/or autologous dermal fibroblasts (average 5.1%, median 4.3%, p0.001). Strong Hsp70 cell surface expression was also found on peripheral blood monocytes of RA patients (average 53.0%, median 58.1%) and healthy controls (average 49.4%, median 47.5%, p=0.52). Peripheral blood granulocytes of healthy controls (average 41.8%, median 41.4%) showed significantly increased Hsp70 expression comparing with RA patients (average 10.7%, median 6.4%, p=0.005). Significantly higher Hsp70 gene expression was observed in synovial cells of RA patients (average 2.04, median 1.7) when compared with autologous peripheral blood leukocytes (average 0.75, median 0.68; p0.001). However, the difference in Hsp70 gene expression between RA-derived synovial cells and healthy control peripheral blood leukocytes (average 1.69, median 1.64) was not observed (p=0.83). We also found significantly lower relative gene expression in peripheral blood leukocytes of RA patients in comparison with healthy controls (p0.001). Interestingly, we found that Hsp70 gene expression in RA non-affected skin dermis gained from the operation wound was 3.7-fold higher in average (average 7.6, median 8.3) when compared to autologous RA-affected synovial tissue (p0.001); 10.1-fold higher in average when compared to autologous peripheral blood leukocytes (p0.001) and 4.5-fold higher in average comparing to control peripheral blood leukocytes (p0.001). Conclusion: Hsp70 gene expression in RA-affected synovial tissue is followed by Hsp70 cell surface expression on fibroblast-like synovial cells growing from RA synovial tissue. Hsp70 may be translocated to the cell surface from the cytosol and/or Hsp70 released from inflamed synovial tissue may be captured onto the membrane of synovial cells from the extracellular space via Hsp receptors. As a physiological response to potentially harmful enviromental stress factors, skin dermis produces higher levels of Hsp70 comparing to the cells of internal organs and tissues.","[Sedlackova, Lucie; Nguyen, Thi Thu Hien; Zlacka, Denisa; Hromadnikova, Ilona] Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Prague 10000 10, Czech Republic; [Sosna, Antonin] Charles Univ Prague, Univ Hosp Motol, Clin Orthoped 1, Fac Med 1, Prague 10000 10, Czech Republic","Sedlackova, L (reprint author), Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Ruska 87, Prague 10000 10, Czech Republic.","lucie.sedlackova@lf3.cuni.cz",null,null,"University Hospital Motol in Prague; University Hospital Motol in Prague); TRANSNET [MRTN-CT-2004-512253]; STEMDIAGNOSTICS [LSHB-CT-2007-037703]","We would like to thank colleagues Assoc. Prof. Stanislav Popelka, M. D., David Veigl, M. D. and Assoc. Prof. Jan Pech, M. D. from 1st Clinic of Orthopedics, University Hospital Motol in Prague, for providing the patient samples and Pavla Vavrincova, M. D. (Rheumatology Outpatient Department, University Hospital Motol in Prague) for collaboration. This project was supported by TRANSNET (No. MRTN-CT-2004-512253) and STEMDIAGNOSTICS (No. LSHB-CT-2007-037703).",null,24,7,7,"TAYLOR & FRANCIS LTD","ABINGDON","4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND","0891-6934",null,null,"AUTOIMMUNITY","Autoimmunity",null,2009,42,1,null,null,null,null,17,24,null,"10.1080/08916930802227466",null,8,"Immunology","Immunology","391QE","WOS:000262247000002"]
[null,null,null,null,"J","Landor, I; Vavrik, P; Jahoda, D; Pokorny, D; Popelka, S; Sosna, A",null,null,null,"Landor, I.; Vavrik, P.; Jahoda, D.; Pokorny, D.; Popelka, S.; Sosna, A.",null,null,"Oblong Implants for Revision Total Hip Arthroplasty","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"oblong cup; hydroxyapatite; cementless; THR","IMPACTED BONE ALLOGRAFTS; LARGE ACETABULAR DEFECTS; FOLLOW-UP; COMPONENT; ARTHRITIS; DEFICIENCY; EXPERIENCE; PLACEMENT; POSITION; CUP","PURPOSE OF THE STUDY A prerequisite for the successful implantation of an acetabular component in a defective bone tissue is, in addition to providing sufficient primary fixation of the implant, reconstruction of the acetabular bone bed. To achieve this, one of the options involves the use of an oblong implant. Data published on this topic are sparse and therefore the aim of this study was to gain a deeper insight into this issue. In addition, we wanted to compare the results achieved with the oblong component with those obtained using its original model. MATERIAL One group comprised 111 patients with 133 sides who underwent acetabular revision for aseptic loosening or extraction of an infected acetabular component with subsequent implantation of an oblong cup (Langs-Ovale Revisionspfanne [L.O.R.], Allopro, Switzerland). The average age of this group at the time of surgery was 62.2 (range, 31-83) years, and average follow-up was 9.7 (range, 0.6-13.9) years. The other group consisted of 134 patients with 152 sides who for the same indications as the L.O.R. group received a Walter Oval cup (Medin Orthopaedics, Czech Republic). The average age at the time of surgery was 64.6 (22-86) years, and average follow-up was 7.3 (range, 1.1-9.8) years. The proportion and nature of defects and underlying clinical diagnoses in the two groups were statistically comparable The patients requiring replacement or removal of the acetabular component were not included in clinical evaluation, but their data were used for survival analysis. The clinical evaluation included: in the L.O.R. group, 115 hip joints at an average follow-up of 10.8 (range, 4.5-13.9) years and, in the Walter Oval group, 144 hip joints at an average follow-up of 7.5 (range, 2.3-9.8) years. The data of patients who died during ;the study (L.O.R., 7 Walter Oval, 11) were included in the clinical evaluation as of the date of the final follow-up. METHODS The results for each group were evaluated using the Kaplan-Meier survival analysis, with a simple survival curve and a \"worst case\" survival curve. The statistical difference between the curves was calculated by the Gehan-Wilcoxon test. Survival tables were constructed for 12 or 8 years. A comparison of the initial and the final Harris hip score (HHS) was made using the t-test. Radiographs were inspected for the signs of implant migration, the presence of translucent lines surrounding the implant and screws and screw breaks. The results were evaluated by the Chi-square and Fisher's exact tests, with the level of significance set at 0.05. RESULTS In the I.O.R. group, 18 implants (13.5%) were reimplanted or removed in the Walter Oval group it was eight cups (5.3%). Aseptic loosening was the cause of reimplantation in 8.3% and 3.9% of the hips in the L.O.R. and Walter Oval groups, respectively. Deep infection required revision surgery in 5.3% of the L.O.R hips, and in 1.3% of the Walter Oval hips. The Walter Oval group showed a longer implant survival, but this was not confirmed by the \"worst case\" analysis. The final HHS markedly improved in comparison with the initial one in both groups. No radiographic difference between the groups was found. DISCUSSION The comparison of our results with those of other methods used in the indications described here provides evidence in favour of oblong implants. The major advantage, as well as the condition of success, is the anchoring of an oblong cup in the patient's own load-bearing bone. CONCLUSIONS Acetabular defects in the range of Paprosky types IIB to IIIA are indicated for the use of oblong implants in a basic position. The Arbond hydroxyapatite coating providing an osteoactive surface for the oblong cup described significantly improves the survival of this implant in comparison with the original model.","1 LF UK, I Ortoped Klin, Prague, Czech Republic; FN Motol, Prague, Czech Republic","Landor, I (reprint author), Vinobrani 15, Prague 10000 10, Czech Republic.","landor@atlas.cz",null,null,null,null,null,29,6,6,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2009,76,6,null,null,null,null,462,472,null,null,null,11,"Orthopedics","Orthopedics","539FC","WOS:000273238000003"]
[null,null,null,null,"J","Kubes, J; Landor, I; Podskubka, A; Majernicek, M; Vcelak, J",null,null,null,"Kubes, J.; Landor, I.; Podskubka, A.; Majernicek, M.; Vcelak, J.",null,null,"Total Hip Replacement from a MIS-AL Approach (Comparison with a Standard Anterolateral Approach)","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"total hip arthroplasty; minimally invasive surgery; standard anterolateral approach","MINI-INCISION; ANTERIOR APPROACH; ARTHROPLASTY; 2-INCISION; SURGERY","PURPOSE OF THE STUDY Minimally invasive surgery (MIS) techniques have recently become a powerful and effective marketing instruments that are often perceived by the patient as the criterion of the surgeon's and institution's standard. In addition to studies reporting the benefits of minimally invasive procedures, some authors have recently found no such benefits or even pointed out some disadvantages. In this paper we present our own view of this issue. Our definition of minimally invasive surgery: a minimally invasive procedure is such that an optimally placed incision using anatomical intervals without damage to muscle insertions allows us to gain a good view of the operating field and to safely perform the planned surgery. Because of this optimal approach it is possible to make skin incisions shorter. MATERIAL Between April 21, 2005, and December 28, 2006, the first 40 MIS hip procedures were performed at the Department of Orthopaedic Surgery of the ILF Bulovka. Forty patients who, in the same period, were operated on from an anterolateral standard approach and who met the same indication criteria, including age, comprised a control group. In both groups all routinely used types of implants were included. METHODS For objective assessment of potential differences between surgical outcomes of the two techniques, the following parameters were recorded: operating time, peri-operative blood loss, pre- and post-operative Hb levels, Hb level on the first postoperative morning, amount of blood drained away with a Redon drain, number of anodyne applications (indirect evaluation of post-operative pain) and length of hospital stay. The parameters were compared for the cemented and the uncemented implants separately. The results were evaluated using the paired t-test, with the significance level set at a value of p<0.05. RESULTS A comparison of the MIS-AL results with those of the standard total hip replacement procedure did not show any significant differences, not even during further follow-up; by the end of 2008 no implant failure or necessity of revision arthroplasty was reported. DISCUSSION So far the only indisputable fact is that all the benefits of minimally invasive techniques described until now are merely related to time, as they facilitate a faster rate of soft tissue repair; therefore, these techniques only shorten recovery and thus speed up return of the operated hip to full function. CONCLUSIONS Based on comparison of the standard anterolateral and minimally invasive techniques it can be concluded that the MIS-AL approach is effective even without the use of special instrumentation. However, the results of this study failed to give unambiguous support to its advantage over the classical technique.","[Kubes, J.; Podskubka, A.; Majernicek, M.; Vcelak, J.] FN Bulovka, Ortoped Klin, IPVZ & LF UK 1, Prague, Czech Republic; [Landor, I.] FN Motol, Ortoped Klin 1, LF UK, Prague, Czech Republic","Kubes, J (reprint author), LF UK & IPVZ, Ortoped Klin 1, Budinova 2, Prague 18081 8, Czech Republic.",null,null,null,null,null,null,20,6,6,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","AUG",2009,76,4,null,null,null,null,288,294,null,null,null,7,"Orthopedics","Orthopedics","492VV","WOS:000269691300004"]
[null,null,null,null,"J","Tomek, V; Skovranek, J; Gebauer, RA",null,null,null,"Tomek, Viktor; Skovranek, Jan; Gebauer, Roman A.",null,null,"Prenatal Diagnosis and Management of Fetal Long QT Syndrome","PEDIATRIC CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"Long QT syndrome; Tachyarrhythmias; Echocardiography; Pregnancy",null,"This report describes a fetus presenting with second-degree atrioventricular block, sinus bradycardia, and transient ventricular tachycardia with ventriculoatrial dissociation. Long QT syndrome (LQTS) was suspected due to the association of heart rhythm disturbances and very short transmitral early deceleration time. This impaired relaxation of the left ventricle was explained by the extreme prolongation of the refractory period caused by the prolonged relaxation time. The infant was treated successfully with beta-blockers and implantation of a pacemaker. The prognosis is poor when LQTS presents utero or during the first week of life. To date, only a few case reports of a fetus with LQTS have been published.","[Tomek, Viktor; Skovranek, Jan; Gebauer, Roman A.] Univ Hosp Motol, Kardioctr, Prague 15008 5, Czech Republic; [Tomek, Viktor; Skovranek, Jan; Gebauer, Roman A.] Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15008 5, Czech Republic","Tomek, V (reprint author), Univ Hosp Motol, Kardioctr, V Uvalu 84, Prague 15008 5, Czech Republic.","viktor.tomek@seznam.cz",null,null,"Internal Grant Agency, Ministry of Health, Czech Republic [NR9451-3/2007]","This publication was supported by grant NR9451-3/2007 from the Internal Grant Agency, Ministry of Health, Czech Republic.",null,7,6,6,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0172-0643",null,null,"PEDIATR CARDIOL","Pediatr. Cardiol.","FEB",2009,30,2,null,null,null,null,194,196,null,"10.1007/s00246-008-9294-0",null,3,"Cardiac & Cardiovascular Systems; Pediatrics","Cardiovascular System & Cardiology; Pediatrics","403QQ","WOS:000263097500019"]
[null,null,null,null,"J","Pokorny, D; Slouf, M; Dybal, J; Zolotarevova, E; Vesely, F; Jahoda, D; Vavrik, P; Landor, I; Entlicher, G; Sosna, A",null,null,null,"Pokorny, D.; Slouf, M.; Dybal, J.; Zolotarevova, E.; Vesely, F.; Jahoda, D.; Vavrik, P.; Landor, I.; Entlicher, G.; Sosna, A.",null,null,"New Metod for Quantification of UHMWPE Wear Particles around Joint Replacements","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"ultra high-molecular weight polyethylene; total hip arthroplasty; wear; tribology; infrared spectroscopy","PERIPROSTHETIC OSTEOLYSIS; QUANTITATIVE-ANALYSIS; HIP-ARTHROPLASTY; IN-VIVO; DEBRIS; TISSUES; SIZE; STEM","PURPOSE OF THE STUDY The orthopaedic community has unanimously adopted the view that ultra high molecular weight polyethylene (UHMWPE) wear particles are a very frequent cause of aseptic implant loosening. Some studies have tried to provide objective evidence for this. We have found descriptions of particle distribution or morphology, but no report that would objectively correlate the number of particles in zones surrounding an implant with the extent of damage to these zones. The aim of this study was to develop a method allowing us to evaluate a number of samples with polyethylene abrasive wear large enough to find association between the extent of damage around a THA and the number of biologically active UHMWPE wear particles, 0.1 to 10 mu m in size. MATERIAL AND METHODS In 28 patients undergoing revision total hip arthroplasty (THA) at the 1(st) Orthopaedic Clinic, 1(st) Faculty of Medicine, Charles University, we took samples of typical osteoaggressive granuloma from defined zones around the implant; the zones corresponded to those described by Gruen and DeLee. The extent of tissue damage in each zone was evaluated on the basis of pre-operative radiographs and by the extent of osteolysis and damage to soft tissues actually observed during revision THA. The volume of wear particles in each zone was assessed by the IRc method developed by us; this is based on a quantitative evaluation of infrared spectra. To verify the methodology, a comparison between tissue damage and the number of particles in each zone was made in three randomly selected patients. RESULTS We introduced a method of detailed orthopaedic evaluation which enabled us to categorize zones around a revised THA according to the extent of damaged tissue. As a result, a series of zones ranked by the extent of damaged tissue, or an \"orthopaedist's statement\" (OS), was obtained. At the same time we adopted a method, based on infrared spectroscopy and termed IRc, by which the number of particles in the samples of damaged tissues and osteoaggressive granulomas collected from the area around a revised THA was determined. The results of evaluation were presented as numerical data that, in a defined way, were converted into a series of zones ranked according to the number of wear particles, i.e., the \"result of measurement\" (RM). In this study we verified the methods described above and made a comparison of OSs and RMs for three randomly selected patients. The very good agreement found confirmed the reliability of both methods which will soon be used to evaluate a group of patients large enough to provide statistically significant results. DISCUSSION The IRc method determines a total volume of UHMWPE wear particles, 0.1 to 10 mu m in size, which are generally considered to be most biologically active. This study suggests that the distribution of particles around a THA is uneven and that relation between tissue damage and the number of wear particles in individual zones surrounding a THA does exist. The major conclusion from the orthopaedic point of view is a confirmation of the assumption that UHMWPE wear particles are one of the chief causes of THA failure. Although this fact is generally accepted, studies correlating the number of particles with tissue damage and osteolysis in individual zones are very scarce. CONCLUSIONS The quick and simple IRc method offers a possibility to quantify polyethylene wear particles in soft tissues. The number of 0.1 to 10 mu m wear polyethylene particles correlated with pre-operative radiographic findings and orthopaedic evaluation of revision THAs in three randomly selected patients. The confirmed correlation between the extent of tissue damage in individual zones surrounding a THA and the volume of wear particles detected in these zones supports the vie that UHMWPE wear particles are one of the main causes of THA failure.","[Pokorny, D.; Vesely, F.; Jahoda, D.; Vavrik, P.; Landor, I.; Sosna, A.] 1 LF UK, Ortoped Klin, FN Motol, Prague 5, Czech Republic; [Slouf, M.; Dybal, J.] Utsav Makromol Chem AV CR, Prague, Czech Republic; [Zolotarevova, E.; Entlicher, G.] Prirodovedecka Fak UK, Katedra Biochem, Prague, Czech Republic","Pokorny, D (reprint author), 1 LF UK, Ortoped Klin, FN Motol, Uvalu 84, Prague 5, Czech Republic.","david.pokorny@LFI.cuni.cz","Slouf, Miroslav/F-6311-2012; Dybal, Jiri/A-8290-2008","Slouf, Miroslav/0000-0003-1528-802X; Dybal, Jiri/0000-0002-9148-3655",null,null,null,20,5,6,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","OCT",2009,76,5,null,null,null,null,374,381,null,null,null,8,"Orthopedics","Orthopedics","518WI","WOS:000271725900002"]
[null,null,null,null,"J","Boucek, J; Kastner, J; Skrivan, J; Grosso, E; Gibelli, B; Giugliano, G; Betka, J",null,null,null,"Boucek, J.; Kastner, J.; Skrivan, J.; Grosso, E.; Gibelli, B.; Giugliano, G.; Betka, J.",null,null,"Occult thyroid carcinoma","ACTA OTORHINOLARYNGOLOGICA ITALICA",null,null,"English","Article",null,null,null,null,null,"Thyroid; Occult carcinoma; Papillary microcarcinoma; Molecular markers; Therapeutic strategy","THYROGLOSSAL DUCT CARCINOMA; PROGNOSTIC SCORING SYSTEM; METASTATIC STRUMA OVARII; LYMPH-NODE METASTASES; D1 PROTEIN EXPRESSION; BRAF V600E MUTATION; DISTINCT TUMOR FOCI; PAPILLARY MICROCARCINOMA; CYCLIN D1; BRAF(V600E) MUTATION","Some medical definitions remain the same for many years, others change due to the progress in the diagnostic tools, which are able to distinguish markers and symptoms until then undetectable. Occult thyroid carcinoma is a general term indicating clinically different situations, whereas the incidentally detected papillary thyroid microcarcinoma is the most important from the clinical point of view. It is fundamental, for therapeutic management, to determine biological parameters which would define a small group of papillary thyroid microcarcinomas with aggressive biological behaviour. The most promising genetic and molecular markers for papillary thyroid carcinoma risk stratification are discussed in this review. Preoperative evaluation of these markers, obtained through analysis of ultrasonography-guided fine needle biopsy specimens of papillary thyroid microcarcinoma, could be very valuable in guiding treatment of this type of cancer.","[Boucek, J.; Kastner, J.; Skrivan, J.; Betka, J.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Univ Hosp Motol, Prague 15006, Czech Republic; [Grosso, E.; Gibelli, B.; Giugliano, G.] European Inst Oncol, Div Head & Neck Surg, Milan, Italy","Boucek, J (reprint author), Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Univ Hosp Motol, Uvalu 84, Prague 15006, Czech Republic.","jboucek99@seznam.cz",null,null,"Ministry of Education, Youth and Sports of The Czech Republic [2B06106]","This work was supported by the Ministry of Education, Youth and Sports of The Czech Republic (project NPV II no. 2B06106).",null,108,3,6,"PACINI EDITORE","PISA","VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY","0392-100X",null,null,"ACTA OTORHINOLARYNGO","Acta Otorhinolaryngol. Ital.","OCT",2009,29,6,null,null,null,null,296,304,null,null,null,9,"Otorhinolaryngology","Otorhinolaryngology","594RR","WOS:000277555600003"]
[null,null,null,null,"J","Jirman, R; Vavrik, P; Horak, Z",null,null,null,"Jirman, R.; Vavrik, P.; Horak, Z.",null,null,"Custom-Designed 3D Tibial Augmentation for Knee Replacement","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"custom-made implant; tibial augmentation; knee prosthesis","ANTERIOR CERVICAL FUSION; ARTHROPLASTY; EXPERIENCE; PEEK","Reconstruction with the use of custom-made implants aims at optimal replacement of lost or damaged bone structures and restoration of their funkction. In this study the development and construction of a custom-made implant and the operative technique used for the treatment of an extensive tibial defect are described. The patient was a 65-year-old man treated for over 20 years for psoriatic arthritis and severe instability of the right knee, particularly in the frontal plane, with a worsening varus deformity. The radiogram showed an extensive destruction of the medial tibial condyle that also deeply involved the lateral condyle. The extent of defect made it impossible to use any commercial tibial augmentation. The geometry of the custom-designed implant for the medial tibial condyle was constructed on the basis of a 3D defect model and the shape of the medial tibial condyle of the collateral knee seen on CT scans. After its correct shape was verified on a plastic model, its coordinates were set in the software of a machine tool, and a titanium augmentation otherwise compatible with a standard knee replacement was produced. The use of such a custom implant to complete standard total knee arthroplasty has so far been demanding in terms of organisation and manufacture. Its production in the future could be facilitated by substituting titanium for plastic material such as poly-ether-ether-ketone (PEEK).","[Jirman, R.] LF UK & VFN, Stomatol Klin 1, Prague, Czech Republic; [Vavrik, P.] LF UK & FN Motol, I Ortoped Klin 1, Prague, Czech Republic; [Jirman, R.; Horak, Z.] Czech Tech Univ, Fak Strojni, Biomech Lab, Prague, Czech Republic","Jirman, R (reprint author), Poricska 2087, Prague 19016 9, Czech Republic.",null,null,null,null,null,null,12,4,4,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2009,76,1,null,null,null,null,60,64,null,null,null,5,"Orthopedics","Orthopedics","416TJ","WOS:000264028100010"]
[null,null,null,null,"J","Gebauer, R; Cerny, S",null,null,null,"Gebauer, Roman; Cerny, Stepan",null,null,"A modification of the Ross procedure to prevent pulmonary autograft dilatation","EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY",null,null,"English","Article",null,null,null,null,null,"Aortic root; Aortic valve replacement; Ross operation","OPERATION","We present our initial experience in 10 patients operated on using a modified Ross operation. In our modification of the Ross operation the pulmonary autograft root was inserted in the Gelweave Valsalva graft to prevent dilatation of the neoaortic root. This type of graft was selected to match the discrepancy between diameters of the annulus and the sinotubular junction of the autograft and to preserve the characteristic configuration of the native root. In our group of 10 patients operated consecutively by this technique there was no change in the geometry of the neoaortic root in the follow-up 3-19 months (mean 14.6 months). (C) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.","[Gebauer, Roman; Cerny, Stepan] Na Homolce Hosp, Dept Cardiac Surg, Prague 15030 5, Czech Republic","Gebauer, R (reprint author), Na Homolce Hosp, Dept Cardiac Surg, Roentgenova 5, Prague 15030 5, Czech Republic.","rgebauer@seznam.cz",null,null,null,null,"David TE, 2000, J THORAC CARDIOV SUR, V119, P210, DOI 10.1016/S0022-5223(00)70175-9; De Paulis R, 2001, ANN THORAC SURG, V72, P487, DOI 10.1016/S0003-4975(01)02747-3; Koul B, 2007, EUR J CARDIO-THORAC, V31, P127, DOI 10.1016/j.ejcts.2006.10.005; Luciani GB, 2003, CIRCULATION, V108, P61, DOI 10.1161/01.cir.0000089183.92233.75; Roux PM, 2003, ANN THORAC SURG, V76, P1754, DOI 10.1016/S0003-4975(03)00525-3; Slater Matthew, 2005, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, P181; Stelzer P, 1998, J THORAC CARDIOV SUR, V115, P1091, DOI 10.1016/S0022-5223(98)70409-X",7,3,3,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1010-7940",null,null,"EUR J CARDIO-THORAC","Eur. J. Cardio-Thorac. Surg.","JUL",2009,36,1,null,null,null,null,195,197,null,"10.1016/j.ejcts.2009.03.009",null,3,"Cardiac & Cardiovascular Systems; Respiratory System; Surgery","Cardiovascular System & Cardiology; Respiratory System; Surgery","476UU","WOS:000268472400035"]
[null,null,null,null,"J","Bartak, V; Pech, J; Veigl, D; Hromadka, R; Pokorny, D; Sosna, A",null,null,null,"Bartak, V.; Pech, J.; Veigl, D.; Hromadka, R.; Pokorny, D.; Sosna, A.",null,null,"Os Pisiforme Transposition in the Treatment of Kienbock's Disease - Long Term Results","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"Kienbock's disease; pisiforme bone; transposition; wrist; osteoarthritis","PROXIMAL ROW CARPECTOMY; FOLLOW-UP; ARTHROPLASTY; ARTHRODESIS; OSTEOTOMY; RESECTION","PURPOSE OF THE STUDY One of the methods used for treatment of Kienbock's disease is based on transposition of the pisiform bone into free space created by removal of the lunate bone. It is performed in patients with stage IIIB to IV, as assessed by Lichtmann's score. However, this operative procedure has so far lacked an unequivocal assessment of its therapeutic value. The aim of our work was to assess the therapeutic effect of the Kuhlmann method in the treatment of advanced stages of Kienbock's disease. MATERIAL From January 1996, eighteen patients (118 wrists) diagnosed with Kienbock's disease were operated on, using the Kuhlmann method, and the group of these patients was included in this follow-up study. The average follow-up time was 7.6 +/- 2.3 years. METHODS The results were evaluated on the basis of subjective (VAS) and functional criteria (ROM, grip force, DASH questionnaire and combined Cooney score questionnaires) and radiological assessment (arthritis evaluation, C.H.I., Natrass index, RSA). RESULTS All patients experienced pain relief. The average pain assessment by VAS (10-point scale) before and after the procedure was 8.76 +/- 0.9 and 2.94 +/- 1.59, respectively. The range of motion was reduced on the operated extremity (70% compared to non-operated) as well as the grip test (57%). The average DASH score at the time of study was 20.9 +/- 12.2 and the average Cooney score was 67.6 +/- 17.4. Before the operation, eleven wrists showed signs of osteoarthritis. At the follow-up evaluation, arthritis was present in fifteen patients. We found a significant difference in average radiological parameters characterizing a carpal collapse deformity (C.H.I., Natrass index, RSA) - all parameters showed deteriorating tendencies. DISCUSSION In nine patients, necrotic changes of the lunate occurred. In the patients whose pisiforme was not affected, a moderate retardation of carpal collapse occurred. However, the discrepancy between relevant indicators (C.H.I, Natrass index, RSA) was not statistically significant when comparing both groups. Therefore, we cannot conclude as to whether or not a vital transposed pisiforme bone impedes the development of carpal collapse. The only proved difference between these two groups was in pain evaluation, measured by VAS, after the procedure CONCLUSION Although there was a good subjective assessment of the operation results, we are of the opinion that this method should not be used as a routine surgical procedure for advanced Kienbock disease. In view of a large number of failed cases we believe that this method should be considered very carefully.","[Bartak, V.] 1 LF UK, Ortoped Klin 1, Prague 15000 5, Czech Republic; FN Motol, 1 LF UK, Ortoped Klin 1, CS-15000 Prague 5, Czech Republic","Bartak, V (reprint author), 1 LF UK, Ortoped Klin 1, Uvalu 84, Prague 15000 5, Czech Republic.","vbartak@email.cz",null,null,null,null,null,24,2,2,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","AUG",2009,76,4,null,null,null,null,314,318,null,null,null,5,"Orthopedics","Orthopedics","492VV","WOS:000269691300008"]
[null,null,null,null,"J","Alan, S; Jan, S; Tomas, H; Robert, L; Jan, S; Pavel, P",null,null,null,"Alan, Stolz; Jan, Simonek; Tomas, Harustiak; Robert, Lischke; Jan, Schutzner; Pavel, Pafko",null,null,"Does Chemotherapy Increase Morbidity and Mortality After Pneumonectomy?","JOURNAL OF SURGICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"chemotherapy; mortality; pneumonectomy","CELL LUNG-CANCER; BRONCHOPLEURAL FISTULA; INDUCTION CHEMOTHERAPY; COMPLICATIONS; RISK; RESECTION; SURGERY; THERAPY; IMPACT; STUMP","Background: The impact of chemotherapy on postoperative complications after pneumonectomy remains unclear, and the procedure is often considered as potentially dangerous. Methods: This retrospective review of prospectively collected data included 269 patients operated from January 1, 1998 through December 31, 2007. Group 1 included patients those who received preoperative chemotherapy (PCT) and pneumonectomy (54 patients, 20%), and group 2 included patients who underwent pneumonectomy alone (215 patients, 80%). Results: Overall 30- and 90-day mortality rates were 5.9% and 8.9%, respectively. Postoperative mortality at 30 days was 5.6% in group 1 and 6% in group 2 (P = 0.16), and 11.1% for group 1 and 8.3% in group 2 at 90 days (P = 0.8). Incidence of postoperative respiratory failure was 3.7% in group 1 and 3.2% in group 2 (P = 0.62) incidence of empyema was 5.5% in group 1 and 2.8% in group 2 (P = 0.1). Incidence of bronchopleural fistula (BPF) was 3.7% in group 1 and 2.8% in group 2 (P = 0.55); risk of BPF was higher following right pneumonectomy (6.1%) versus left pneumonectomy (0%, P = 0.003). Conclusions: PCT does not significantly increase postoperative morbidity and early mortality after pneumonectomy in our experience.","[Alan, Stolz; Jan, Simonek; Tomas, Harustiak; Robert, Lischke; Jan, Schutzner; Pavel, Pafko] Charles Univ Prague, Dept Thorac Surg, Univ Hosp Motol, Prague, Czech Republic","Alan, S (reprint author), Charles Univ Prague, Dept Thorac Surg, Univ Hosp Motol, V Uvalu 84, Prague, Czech Republic.","stolz@seznam.cz",null,null,null,null,null,19,1,1,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","0022-4790",null,null,"J SURG ONCOL","J. Surg. Oncol.","JAN 1",2009,99,1,null,null,null,null,38,41,null,"10.1002/jso.21181",null,4,"Oncology; Surgery","Oncology; Surgery","391KN","WOS:000262232300010"]
[null,null,null,null,"J","Knutson, T; Johansson, A; Damber, JE; Fall, M; Peeker, VR",null,null,null,"Knutson, Tomas; Johansson, Annika; Damber, Jan-Erik; Fall, Magnus; Peeker, Vesely Ralph",null,null,"Intraurethral prostate injections with mepivacaine epinephrine: Effects on patient comfort, treatment time and energy consumption during high-energy transurethral microwave thermotherapy","SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Intraprostatic injections; mepivacaine epinephrine; PLFT; prostate; TUMT","LOCAL-ANESTHESIA; HYPERPLASIA","Objective. To investigate the effects of intraprostatic mepivacaine epinephrine injections administered by the Schelin catheter during high-energy transurethral microwave thermotherapy (TUMT) using the CoreTherm (R) Prostalund Feedback Treatment (R) (PLFT) system. Material and methods. The study included 85 men with lower urinary tract symptoms due to benign prostatic enlargement. One group had intraprostatic injections with mepivacaine epinephrine by the new Schelin catheter, while patients in the other group were treated without intraprostatic injections. All men were treated by TUMT using the PLFT system. Before treatment, transrectal ultrasound (TRUS) volume was measured. During the procedure, treatment time, energy consumption, cell-kill parameter and maximal prostate temperature were recorded. Patients who needed perioperative intravenous analgesics and the rate of perioperative and postoperative complications were registered. Results. The patients who had intraprostatic and periprostatic injections with mepivacaine epinephrine had shorter effective treatment time and reduced energy consumption. There was also a difference between the two groups in that 70% of patients without intraprostatic injections and only 11% of injected patients needed intravenous analgesics. No differences were found in TRUS volume, estimated cell-kill, maximal prostate temperature or complication rates. Conclusions. Intraprostatic injections with mepivacaine epinephrine distributed by the Schelin catheter reduce the number of patients needing intravenous analgesics during PLFT, as well as the treatment time and energy consumption during treatment. Besides improved patient comfort, intraprostatic and periprostatic injections condense the treatment time without side-effects, making PLFT less cumbersome for most patients.","[Knutson, Tomas; Johansson, Annika; Damber, Jan-Erik; Fall, Magnus; Peeker, Vesely Ralph] Sahlgrens Univ Hosp, Dept Urol, SE-41345 Gothenburg, Sweden","Peeker, VR (reprint author), Sahlgrens Univ Hosp, Dept Urol, SE-41345 Gothenburg, Sweden.","ralph.peeker@vgregion.se",null,null,"Swedish Research Council [K 2004-73X-15058-01A]; Sahlgrenska University Hospital [ALF Gbg-2887]","The authors would like to express their gratitude to Mrs Elisabeth Stahlgren for excellent secretarial assistance. This study was supported by the Swedish Research Council project number K 2004-73X-15058-01A and Sahlgrenska University Hospital project number ALF Gbg-2887.","Bakke A, 1994, Scand J Urol Nephrol Suppl, V157, P55; Bolmsjo M, 2000, J ENDOUROL, V14, P627, DOI 10.1089/end.2000.14.627; Bolmsjo M, 1996, BRIT J UROL, V78, P564, DOI 10.1046/j.1464-410X.1996.17213.x; CORMIO L, 1994, EUR UROL, V25, P36; Dicuio M, 2004, UROL INT, V73, P130, DOI 10.1159/000079693; HUGOSSON J, 1993, SCAND J UROL NEPHROL, V27, P381; Irani I, 1996, Br J Urol, V78, P904; Kehinde EO, 2005, MED PRIN PRACT, V14, P272, DOI 10.1159/000085749; LEACH GE, 1994, UROLOGY, V43, P149, DOI 10.1016/0090-4295(94)90034-5; Nash PA, 1996, J UROLOGY, V155, P607, DOI 10.1016/S0022-5347(01)66464-4; Rodrigues Alexandre Oliveira, 2002, Rev Hosp Clin Fac Med Sao Paulo, V57, P287, DOI 10.1590/S0041-87812002000600008; SCHAFER W, 1995, WORLD J UROL, V13, P47; Schelin S, 2002, J ENDOUROL, V16, P117, DOI 10.1089/089277902753619645; Schelin S, 2001, EUR UROL, V39, P400, DOI 10.1159/000052476; Tabet BG, 1996, J UROLOGY, V156, P1659, DOI 10.1016/S0022-5347(01)65477-6",15,1,1,"TAYLOR & FRANCIS AS","OSLO","KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY","0036-5599",null,null,"SCAND J UROL NEPHROL","Scand. J. Urol. Nephrol.",null,2009,43,4,null,null,null,null,300,306,null,"10.1080/00365590903092889",null,7,"Urology & Nephrology","Urology & Nephrology","491TP","WOS:000269602800008"]
[null,null,null,null,"J","Rozkova, D; Tiserova, H; Fucikova, J; Last'ovicka, J; Podrazil, M; Uclova, H; Budinsky, V; Prausova, J; Linke, Z; Minarik, I; Sediva, A; Spisek, R; Bartunkova, J",null,null,null,"Rozkova, Daniela; Tiserova, Hana; Fucikova, Jitka; Last'ovicka, Jan; Podrazil, Michal; Uclova, Hana; Budinsky, Vit; Prausova, Jana; Linke, Zdenek; Minarik, Ivo; Sediva, Anna; Spisek, Radek; Bartunkova, Jirina",null,null,"FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer","CLINICAL IMMUNOLOGY",null,null,"English","Review",null,null,null,null,null,"Dendritic cells; Cancer immunotherapy; Prostate cancer; Chemo-immunotherapy; PSA","REGULATORY T-CELLS; DYING TUMOR-CELLS; DENDRITIC CELLS; IMMUNE-RESPONSES; OVARIAN-CANCER; CHEMOTHERAPY; EXPOSURE; IMMUNOTHERAPY; CALRETICULIN; VACCINE","Immunotherapy has emerged as another treatment modality in cancer. The goat of immunotherapy in advanced cancer patients does not have to be the complete eradication of tumor cells but rather the restoration of a dynamic balance between tumor cells and the immune response. Appropriate combination of tumor mass reduction (by surgery and/or chemotherapy) and neutralization of tumor-induced immunosuppression might set the right conditions for the induction of anti-tumor immune response by active immunotherapy. We review experimental basis and key concepts of combined chemo-immunotherapy and document its principles in the case report of patient with hormone refractory metastatic prostate cancer with sinister prognosis. More than four hundred prostate cancer patients have been treated with DC-based immunotherapy and tumor-specific immune responses have been reported in two-thirds of them. In half of these patients, DC immunotherapy resulted in transient clinical responses. Tregs, among other factors, potently inhibit tumor-specific T cells. Prostate cancer patients have elevated numbers of circulating and tumor infiltrating Tregs and there is evidence that Tregs increase tumor growth in vivo. Because of the high frequency of circulating Tregs in our patients, we first administered metronomic cyclophosphamide. After obtaining IRB approval, we started regular vaccinations with dendritic cells (DCs) loaded with killed prostate cancer cells. In accordance with the principles of combined immunotherapy, we continued palliative chemotherapy with docetaxel to reduce the tumor cell burden. DC-based vaccination induced prostate cancer cell-specific immune response. Combined chemo-immunotherapy consisting of alternate courses of chemotherapy and vaccination with mature DCs pulsed with LNCap prostate cancer cell line led to the marked improvement in the clinical and laboratory presentation and to the decrease of PSA levels by more than 90%. (C) 2009 Elsevier Inc. All rights reserved.","[Rozkova, Daniela; Tiserova, Hana; Fucikova, Jitka; Last'ovicka, Jan; Podrazil, Michal; Uclova, Hana; Budinsky, Vit; Minarik, Ivo; Sediva, Anna; Spisek, Radek; Bartunkova, Jirina] Charles Univ Prague, Inst Immunol, Fac Med 2, Univ Hosp Motol, Prague 5, Czech Republic; [Prausova, Jana; Linke, Zdenek] Charles Univ Prague, Fac Med 2, Dept Radiotherapy & Oncol, Univ Hosp Motol, Prague 5, Czech Republic; [Minarik, Ivo] Charles Univ Prague, Fac Med 2, Dept Urol, Univ Hosp Motol, Prague 5, Czech Republic","Bartunkova, J (reprint author), Charles Univ Prague, Inst Immunol, Fac Med 2, V Uvalu 84, Prague 5, Czech Republic.","jirina.bartunkova@lfmotol.cuni.cz","Spisek, Radek/E-6724-2011",null,"Czech Ministry of Education [MSM 0021620812]; GACR [310/08/0838]","This study was supported by project MSM 0021620812 from the Czech Ministry of Education and grant GACR 310/08/0838. We would like to thank Prof. Vaclav Pelouch for his continuous support.",null,38,12,15,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1521-6616",null,null,"CLIN IMMUNOL","Clin. Immunol.","APR",2009,131,1,null,null,null,null,1,10,null,"10.1016/j.clim.2009.01.001",null,10,"Immunology","Immunology","428GC","WOS:000264835000001"]
[null,null,null,null,"J","Kuncova, K; Janda, A; Kasal, P; Zamecnik, J",null,null,null,"Kuncova, Klara; Janda, Ales; Kasal, Pavel; Zamecnik, Josef",null,null,"Immunohistochemical Prognostic Markers in Intracranial Ependymomas: Systematic Review and Meta-Analysis","PATHOLOGY & ONCOLOGY RESEARCH",null,null,"English","Review",null,null,null,null,null,"Ependymoma; Immunohistochemistry; Ki-67; Meta-analysis; MIB-1; prognosis","KI-67 IMMUNOLABELING INDEX; CENTRAL-NERVOUS-SYSTEM; EPITHELIAL DIFFERENTIATION; CELL-PROLIFERATION; LABELING INDEX; EXPRESSION; SURVIVAL; CHILDHOOD; TUMORS; CHILDREN","Distinction between grade II ependymomas and anaplastic ependymomas based on histopathological examination solely is problematic and, therefore, the management of intracranial ependymomas remains controversial. The aim of this study was to conduct a systematic review (SR) and meta-analysis (MA) of data published on immunohistochemical prognostic markers (IPM) in intracranial ependymomas (IE), and to establish an evidence-based perspective on their clinical value. Following the extensive search based on a strictly defined group of key words, 30 studies reporting results on IPM in IE were identified. Due to a pronounced inter-study heterogeneity, only 14 publications fulfilled the criteria for inclusion into SR. From the total of 67 immunohistochemical markers, 18 were found to correlate with prognosis. However, owing to inadequate data publishing, MA could be performed only with data on proliferation marker MIB-1 (Ki-67) from 5 publications, including 337 patients: The pooled hazard ratio for overall survival was 3.16 (95% confidence interval = 1.96-5.09; p < 0.001) implicating that patients suffering from tumors with higher immunohistochemical expression of MIB-1 had a significantly worse outcome. Marked inter-study heterogeneity and incomplete data publishing in primary studies significantly limited extent of the SR, and the possibility of performing MA. Although the prognostic impact of MIB-1 immunoexpression in IE could be confirmed, there remains lack of further reliable IPM that could be used in routine diagnosis. We encourage to search for new, useful markers, as well as to standardize lab-techniques and data interpretation algorithms across laboratories in order to increase data compatibility.","[Kuncova, Klara; Janda, Ales; Kasal, Pavel; Zamecnik, Josef] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Kuncova, Klara; Zamecnik, Josef] Charles Univ Prague, Univ Hosp Motol, Dept Pathol & Mol Med, Prague, Czech Republic; [Janda, Ales; Kasal, Pavel] Charles Univ Prague, Univ Hosp Motol, Dept Med Informat, Prague, Czech Republic; [Janda, Ales] Charles Univ Prague, Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic","Zamecnik, J (reprint author), Charles Univ Prague, Sch Med 2, Prague, Czech Republic.","josef.zamecnik@lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic [VZ FNM 00064203]; Ministry of Education [VZ MSM CR 0021620812]","The publication was supported in part by the grant VZ FNM 00064203 of the Ministry of Health of the Czech Republic and grant VZ MSM CR 0021620812 of the Ministry of Education. The authors state no financial conflicts of interest. We wish to thank Marie Hladikova for critical remarks on the manuscript.",null,50,6,6,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","1219-4956",null,null,"PATHOL ONCOL RES","Pathol. Oncol. Res.","DEC",2009,15,4,null,null,null,null,605,614,null,"10.1007/s12253-009-9160-2",null,10,"Oncology; Pathology","Oncology; Pathology","539UE","WOS:000273283100009"]
[null,null,null,null,"J","Hampl, V; Jakoubek, V",null,null,null,"Hampl, V.; Jakoubek, V.",null,null,"Regulation of Fetoplacental Vascular Bed by Hypoxia","PHYSIOLOGICAL RESEARCH",null,null,"English","Review",null,null,null,null,null,"Placenta; Hypoxia; Intrauterine growth restriction; Vasoconstriction; Ion channels","PULMONARY ARTERIAL-HYPERTENSION; PLACENTAL BLOOD-FLOW; POTASSIUM CHANNELS; HIGH-ALTITUDE; NITRIC-OXIDE; VASOCONSTRICTION; RESISTANCE; OXYGEN; PREGNANCY; RAT","Important fetal and perinatal pathologies, especially intrauterine growth restriction (IUGR), are thought to stem from placental hypoxia-induced vasoconstriction of the fetoplacental vessels, leading to placental hypoperfusion and thus fetal undernutrition. However, the effects of hypoxia on the fetoplacental vessels have been surprisingly little studied. We review here available experimental data on acute hypoxic fetoplacental vasoconstriction (HFPV) and on chronic hypoxic elevation of fetoplacental vascular resistance. The mechanism of HFPV includes hypoxic inhibition of potassium channels in the plasma membrane of fetoplacental vascular smooth muscle and consequent membrane depolarization that activates voltage gated calcium channels. This in turn causes calcium influx and contractile apparatus activation. The mechanism of chronic hypoxic elevation of fetoplacental vascular resistance is virtually unknown except of signs of the involvement of morphological remodeling.","[Hampl, V.; Jakoubek, V.] Charles Univ Prague, Dept Physiol, Sch Med 2, Prague 15000 5, Motol, Czech Republic; [Hampl, V.; Jakoubek, V.] Charles Univ Prague, Cardiovasc Res Ctr, Prague 15000 5, Motol, Czech Republic","Hampl, V (reprint author), Charles Univ Prague, Dept Physiol, Sch Med 2, Plzenska 130-221, Prague 15000 5, Motol, Czech Republic.",null,"Hampl, Vaclav/A-2732-2009","Hampl, Vaclav/0000-0001-5776-4624","Charles University [82/2004/C, 55/2001/c/2.LF]; Czech Ministry of Education [1M6798582302]","The experimental work of our group reviewed here was funded by the Grant Agency of the Charles University (# 82/2004/C and 55/2001/c/2.LF) and Czech Ministry of Education (# 1M6798582302). We acknowledge an inspiration by the dissertation of V. Jakoubek, although there are no direct quotations.",null,49,5,5,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,null,null,2,null,null,"S87","S93",null,null,null,7,"Physiology","Physiology","542ZC","WOS:000273537200009"]
[null,null,null,null,"J","Kopkan, L; Cervenka, L",null,null,null,"Kopkan, L.; Cervenka, L.",null,null,"Renal Interactions of Renin-Angiotensin System, Nitric Oxide and Superoxide Anion: Implications in the Pathophysiology of Salt-Sensitivity and Hypertension","PHYSIOLOGICAL RESEARCH",null,null,"English","Review",null,null,null,null,null,"Renin-angiotensin system; Superoxide anion; Nitric oxide; Renal function; Salt-sensitivity; Hypertension","THICK ASCENDING LIMB; REN-2 TRANSGENIC RATS; II-DEPENDENT HYPERTENSION; RECEPTOR-DEFICIENT MICE; DIETARY-SODIUM INTAKE; REGIONAL BLOOD-FLOW; OXIDATIVE STRESS; TUBULOGLOMERULAR FEEDBACK; ANG-II; L-ARGININE","Renin-angiotensin system (RAS) plays a key role in the regulation of renal function, volume of extracellular fluid and blood pressure. The activation of RAS also induces oxidative stress, particularly superoxide anion (O(2)(-)) formation. Although the involvement of O(2)(-) production in the pathology of many diseases is known for long, recent studies also strongly suggest its physiological regulatory function of many organs including the kidney. However, a marked accumulation of O(2)(-) in the kidney alters normal regulation of renal function and thus may contribute to the development of salt-sensitivity and hypertension. In the kidney, O(2)(-) acts as vasoconstrictor and enhances tubular sodium reabsoption. Nitric oxide (NO), another important radical that exhibits opposite effects than O(2)(-), is also involved in the regulation of kidney function. O(2)(-) rapidly interacts with NO and thus, when O(2)(-) production increases, it diminishes the bioavailability of NO leading to the impairment of organ function. As the activation of RAS, particularly the enhanced production of angiotensin II, can induce both O(2)(-) and NO generation, it has been suggested that physiological interactions of RAS, NO and O(2)(-) provide a coordinated regulation of kidney function. The imbalance of these interactions is critically linked to the pathophysiology of salt-sensitivity and hypertension.","[Kopkan, L.; Cervenka, L.] Inst Clin & Expt Med, Dept Expt Med, Prague 14000 4, Czech Republic; [Kopkan, L.; Cervenka, L.] Cardiovasc Res Ctr, Prague 14000 4, Czech Republic","Kopkan, L (reprint author), Inst Clin & Expt Med, Dept Expt Med, Videnska 1958-9, Prague 14000 4, Czech Republic.","likp@ikem.cz",null,null,"Institute for Clinical and Experimental Medicine [MZO 00023001]; Center for Cardiovascular Research [1M6798582302];  [NS/9699-4];  [KJB502030801]","We acknowledge the support provided by the grants NS/9699-4 and KJB502030801 and by financial support from the Institute for Clinical and Experimental Medicine (#MZO 00023001) and Center for Cardiovascular Research (#1M6798582302). The authors gratefully thank Dr. Josef Zicha, Institute of Physiology of the ASCR, for his valuable comments and suggestions during preparation of this manuscript.","Abe M, 2006, AM J PHYSIOL-RENAL, V291, pF350, DOI 10.1152/ajprenal.00407.2005; Abreu GR, 1999, HYPERTENSION, V34, P729; Alvarez G, 2000, HYPERTENSION, V35, P752; BACHMANN S, 1995, AM J PHYSIOL-RENAL, V268, pF885; Barri YM, 1998, KIDNEY INT, V53, P1299, DOI 10.1046/j.1523-1755.1998.00857.x; BAYLIS C, 1992, J CLIN INVEST, V90, P278, DOI 10.1172/JCI115849; Beswick RA, 2001, HYPERTENSION, V38, P1107, DOI 10.1161/hy1101.093423; Beswick RA, 2001, HYPERTENSION, V37, P781; BRAAM B, 1995, KIDNEY INT, V48, P1406, DOI 10.1038/ki.1995.429; Brannstrom K, 1999, J AM SOC NEPHROL, V10, pS213; Cervenka L, 2008, J HYPERTENS, V26, P1379, DOI 10.1097/HJH.0b013e3282fe6eaa; Chabrashvili T, 2003, AM J PHYSIOL-REG I, V285, pR117, DOI 10.1152/ajpregu.00476.2002; Chin SY, 1999, AM J PHYSIOL-RENAL, V277, pF797; Chin SY, 1998, AM J PHYSIOL-RENAL, V274, pF876; Cifuentes ME, 2000, AM J PHYSIOL-HEART C, V279, pH2234; Dickhout JG, 2002, CIRC RES, V91, P487, DOI 10.1161/01.RES.0000035243.66189.92; Erdely A, 2007, AM J PHYSIOL-RENAL, V292, pF192, DOI 10.1152/ajprenal.00146.2006; Faraci FM, 1998, AM J PHYSIOL-HEART C, V274, pH564; Fortepiani LA, 1999, J AM SOC NEPHROL, V10, P21; Franco V, 2006, J AM COLL NUTR, V25, p247S; Ghosh M, 2004, BRIT J PHARMACOL, V141, P562, DOI 10.1038/sj.bjp.0705557; Gill PS, 2006, ANTIOXID REDOX SIGN, V8, P1597, DOI 10.1089/ars.2006.8.1597; Graciano ML, 2004, J AM SOC NEPHROL, V15, P1805, DOI 10.1097/01.ASN.00000131528.00773.A9; Gross V, 1999, J AM SOC NEPHROL, V10, P1430; Guron GS, 2006, J HYPERTENS, V24, P387, DOI 10.1097/01.hjh.0000200511.02700.99; GUYTON AC, 1972, AM J MED, V52, P584, DOI 10.1016/0002-9343(72)90050-2; Haddy FJ, 2006, LIFE SCI, V79, P1585, DOI 10.1016/j.lfs.2006.05.017; HALL JE, 1980, AM J PHYSIOL, V239, pF271; Hannken T, 1998, KIDNEY INT, V54, P1923, DOI 10.1046/j.1523-1755.1998.00212.x; Haque MZ, 2004, HYPERTENSION, V43, P335, DOI 10.1161/01.HYP.0000111137.15873.4a; Helle F, 2009, AM J PHYSIOL-RENAL, V296, pF78, DOI 10.1152/ajprenal.90518.2008; Herrera M, 2006, HYPERTENSION, V47, P95, DOI 10.1161/01.HYP.0000196274.78603.85; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; HUANG WC, 1988, KIDNEY INT, V34, P631, DOI 10.1038/ki.1988.227; Huskova Z, 2006, J HYPERTENS, V24, P517, DOI 10.1097/01.hjh.0000209988.51606.c7; Huskova Z, 2007, KIDNEY BLOOD PRESS R, V30, P45, DOI 10.1159/000099028; Ichihara A, 1999, AM J PHYSIOL-RENAL, V277, pF113; Ikenaga H, 1996, AM J PHYSIOL-RENAL, V271, pF365; Ikenaga H, 1996, KIDNEY INT, V49, P34, DOI 10.1038/ki.1996.5; JACKSON CA, 1986, J HYPERTENS, V4, P215; Juncos R, 2006, AM J PHYSIOL-REG I, V290, pR79, DOI 10.1152/ajpregu.00447.2005; Kawada N, 2002, J AM SOC NEPHROL, V13, P2860, DOI 10.1097/01.ASN.0000035087.11758.ED; Kitiyakara C, 2003, J AM SOC NEPHROL, V14, P2775, DOI 10.1097/01.ASN.0000092145.90389.65; K.-Laflamme Annik, 1998, Canadian Journal of Physiology and Pharmacology, V76, P665; Kobori H, 2003, HYPERTENSION, V41, P592, DOI 10.1161/01.HYP.0000056768.03657.B4; Kopkan L, 2005, J HYPERTENS, V23, P1531, DOI 10.1097/01.hjh.0000174972.46663.5e; Kopkan L, 2006, HYPERTENSION, V47, P568, DOI 10.1161/01.HYP.0000200027.34925.93; Kopkan L, 2005, HYPERTENSION, V46, P1026, DOI 10.1161/01.HYP.0000174989.39003.58; Kopkan L, 2009, VASC PHARMACOL, V51, P175, DOI 10.1016/j.vph.2009.06.001; Kopkan L, 2007, J HYPERTENS, V25, P2257; Kopkan L, 2006, AM J PHYSIOL-RENAL, V290, pF80, DOI 10.1152/ajprenal.00090.2005; LAHERA V, 1992, J HYPERTENS, V10, pS173; Leonard AM, 2006, AM J HYPERTENS, V19, P1264, DOI 10.1016/j.amjhyper.2006.05.025; Lerman LO, 2001, HYPERTENSION, V37, P541; Liang BH, 2008, J CARDIOVASC PHARM, V51, P457, DOI 10.1097/FJC.0b013e318169e948; Lombardi D, 1999, HYPERTENSION, V33, P1013; Lopez B, 2003, HYPERTENSION, V42, P1150, DOI 10.1161/01.HYP.0000101968.09376.79; Majid DSA, 2005, AM J PHYSIOL-RENAL, V288, pF412, DOI 10.1152/ajprenal.00294.2004; Majid DSA, 2001, AM J HYPERTENS, V14, p74S, DOI 10.1016/S0895-7061(01)02073-8; Majid DSA, 2002, HYPERTENSION, V39, P293, DOI 10.1161/hy0202.104137; Makino A, 2002, HYPERTENSION, V39, P667, DOI 10.1161/hy0202.103469; Mancia G, 2007, J HYPERTENS, V25, P1751, DOI 10.1097/HJH.0b013e3282f0580f; Martinez Y, 2002, J CARDIOVASC PHARM, V40, P381, DOI 10.1097/01.FJC.0000019004.47976.0C; Mattson DL, 1996, HYPERTENSION, V27, P688; Mattson DL, 2005, AM J PHYSIOL-REG I, V289, pR991, DOI 10.1152/ajpregu.00207.2005; Mattson DL, 2006, AM J HYPERTENS, V19, P327, DOI 10.1016/j.amjhyper.2005.09.012; Mattson DL, 1998, HYPERTENSION, V31, P15; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; Moreno C, 2002, AM J PHYSIOL-REG I, V282, pR31; Mori T, 2007, HYPERTENSION, V49, P1336, DOI 10.1161/HYPERTENSIONAHA.106.085811; Mori T, 2003, HYPERTENSION, V42, P588, DOI 10.1161/01.HYP.0000091821.39824.09; Navar LG, 2004, KIDNEY INT, V65, P1522, DOI 10.1111/j.1523-1755.2004.00539.x; Nishiyama A, 2001, HYPERTENS RES, V24, P421, DOI 10.1291/hypres.24.421; Obst M, 2004, KIDNEY INT, V65, P2268, DOI 10.1111/j.1523-1755.2004.00646.x; Ollerstam A, 1997, J CLIN INVEST, V99, P2212, DOI 10.1172/JCI119394; Ortiz PA, 2003, AM J PHYSIOL-REG I, V284, pR628, DOI 10.1152/ajpregu.00401.2002; Ortiz PA, 2003, HYPERTENSION, V42, P674, DOI 10.1161/01.HYP.0000085561.00001.81; Ortiz PA, 2002, HYPERTENSION, V39, P591, DOI 10.1161/hy0202.103287; Ortiz PA, 2002, AM J PHYSIOL-RENAL, V283, pF957, DOI 10.1152/ajprenal.00102.2002; Ozawa Y, 2004, CLIN EXP HYPERTENS, V26, P219, DOI 10.1081/CEH-120030231; Patzak A, 2007, CURR OPIN NEPHROL HY, V16, P46, DOI 10.1097/MNH.0b013e328011a89b; Patzak A, 2008, AM J PHYSIOL-REG I, V294, pR429, DOI 10.1152/ajpregu.00482.2007; Pech V, 2006, AM J HYPERTENS, V19, P534, DOI 10.1016/j.amjhyper.2005.11.008; Pechanova O, 2004, J HYPERTENS, V22, P167, DOI 10.1097/01.hjh.0000098155.70956.f3; Poch E, 2001, HYPERTENSION, V38, P1204, DOI 10.1161/hy1101.099479; Quiroz Y, 2001, AM J PHYSIOL-RENAL, V281, pF38; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rajapakse NW, 2008, HYPERTENSION, V52, P1084, DOI 10.1161/HYPERTENSIONAHA.108.114298; Rauchova H, 2005, HYPERTENS RES, V28, P475, DOI 10.1291/hypres.28.475; Reckelhoff JF, 2003, AM J PHYSIOL-REG I, V284, pR893, DOI 10.1152/ajpregu.00491.2002; Rhaleb NE, 2001, HYPERTENSION, V37, P121; Rodriguez-Iturbe B, 2001, KIDNEY INT, V59, P2222, DOI 10.1046/j.1523-1755.2001.0590062222.x; Romero JC, 1999, HYPERTENSION, V34, P943; SAGNELLA GA, 1989, AM J PHYSIOL, V256, pR1171; Sanchez-Mendoza A, 1998, J HYPERTENS, V16, P697, DOI 10.1097/00004872-199816050-00018; Sasser JM, 2002, AM J PHYSIOL-REG I, V283, pR243, DOI 10.1152/ajpregu.00086.2002; Schnermann JB, 1997, AM J PHYSIOL-RENAL, V273, pF315; Schoonmaker GC, 2000, AM J PHYSIOL-RENAL, V278, pF302; Shelat SG, 1999, NEUROENDOCRINOLOGY, V69, P339, DOI 10.1159/000054436; Shokoji T, 2004, HYPERTENSION, V44, P236, DOI 10.1161/01.HYP.0000136393.26777.63; Silva GB, 2008, HYPERTENSION, V52, P1091, DOI 10.1161/HYPERTENSIONAHA.108.120212; Sullivan JC, 2002, HYPERTENSION, V39, P597, DOI 10.1161/hy0202.103286; Tan DYY, 2000, AM J PHYSIOL-REG I, V279, pR2297; Tian N, 2008, AM J PHYSIOL-REG I, V295, pR1858, DOI 10.1152/ajpregu.90650.2008; Tian N, 2006, J HYPERTENS, V24, P2263, DOI 10.1097/01.hjh.0000249705.42230.73; Tojo A, 2000, KIDNEY INT, V58, P2075, DOI 10.1046/j.1523-1755.2000.00380.x; TOLINS JP, 1994, KIDNEY INT, V46, P230, DOI 10.1038/ki.1994.264; Tomohiro A, 1997, AM J PHYSIOL-REG I, V272, pR1013; Usui M, 1999, HYPERTENSION, V34, P546; Vaneckova I, 2005, KIDNEY BLOOD PRESS R, V28, P117, DOI 10.1159/000084649; Varela M, 2004, AM J PHYSIOL-RENAL, V287, pF224, DOI 10.1152/ajprenal.00427.2003; VONTHUN AM, 1994, AM J PHYSIOL, V266, pF120; Wang CT, 1997, J AM SOC NEPHROL, V8, P535; Wang H, 2002, HYPERTENSION, V39, P662, DOI 10.1161/hy0202.103470; Wang HD, 2001, CIRC RES, V88, P947, DOI 10.1161/hh0901.089987; Wang T, 1996, AM J PHYSIOL-RENAL, V271, pF143; Weinberger MH, 2001, HYPERTENSION, V37, P429; Welch WJ, 2005, AM J PHYSIOL-HEART C, V288, pH22, DOI 10.1152/ajpheart.00626.2004; Welch WJ, 2000, AM J PHYSIOL-RENAL, V278, pF769; Welch WJ, 2003, HYPERTENSION, V41, P692, DOI 10.1161/01.HYP.0000052945.84627.8F; Wilcox CS, 2005, AM J PHYSIOL-REG I, V289, pR913, DOI 10.1152/ajpregu.00250.2005; Wilcox CS, 2000, ACTA PHYSIOL SCAND, V168, P119; Wink DA, 2001, ANTIOXID REDOX SIGN, V3, P203, DOI 10.1089/152308601300185179; Wu F, 1999, AM J PHYSIOL-RENAL, V276, pF874; Xu H, 2002, AM J PHYSIOL-HEART C, V283, pH885, DOI 10.1152/ajpheart.00134.2002; Yamada SS, 1996, HYPERTENSION, V27, P1165; Zatz R, 1998, HYPERTENSION, V32, P958; Zhang WS, 2007, AM J PHYSIOL-RENAL, V292, pF711, DOI 10.1152/ajprenal.00208.2006; Zhou MS, 2009, AM J PHYSIOL-HEART C, V296, pH833, DOI 10.1152/ajpheart.01096.2008; Zicha J, 2001, J HYPERTENS, V19, P247, DOI 10.1097/00004872-200102000-00011; Zicha J, 2006, HYPERTENS RES, V29, P1021, DOI 10.1291/hypres.29.1021; Zou AP, 1998, HYPERTENSION, V31, P271",132,5,5,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,null,null,2,null,null,"S55","S67",null,null,null,13,"Physiology","Physiology","542ZC","WOS:000273537200006"]
[null,null,null,null,"J","Krizkova, S; Fabrik, I; Adam, V; Kukacka, J; Prusa, R; Trnkova, L; Strnadel, J; Horak, V; Kizek, R",null,null,null,"Krizkova, Sona; Fabrik, Ivo; Adam, Vojtech; Kukacka, Jiri; Prusa, Richard; Trnkova, Libuse; Strnadel, Jan; Horak, Vratislav; Kizek, Rene",null,null,"Effects of Reduced Glutathione, Surface Active Agents, and Ionic Strength on the Detection of Metallothioneins by Using of Brdicka Reaction","ELECTROANALYSIS",null,null,"English","Article; Proceedings Paper","12th International Conference on Electroanalysis","JUN 16-19, 2008","Prague, CZECH REPUBLIC","European Soc Electroanal Chem, Int Soc Electrochem, Czech Chem Soc, Charles Univ, Fac Sci",null,"Differential pulse voltammetry; Adsorptive transfer stripping technique; Proteins; Metallothionein; Brdicka reaction","CURRENT STRIPPING CHRONOPOTENTIOMETRY; HEAVY-METAL IONS; ELECTROCHEMICAL-BEHAVIOR; MERCURY-ELECTRODE; EXPRESSION; BIOSENSOR; MELANOMA; LEVEL; CELLS","We investigated the effects of two surface active agents (sodium dodecyl sulfate, SDS, and polyoxyethylene sorbitol, Tween-20), ionic strength and reduced glutathione (GSH) on MT signals measured by adsorptive transfer stripping differential pulse voltammetry Brdicka reaction. If we compared the GSH and MT signals at the accumulation time of 120 s, the MT signal was more than two hundred times higher than the GSH one. The influence of Tween-20 was investigated in a broad concentration range (from 10(-8) to 10(-11) %, v/v). We found that the catalytic Cat2 signal decreased for more than 60% with increasing Tween-20 content. In the case of using SDS (10(-3) - 10(-6) M), the increase of Cat2 peak in the presence of the highest SDS concentration was determined. The height of Cat2 peak enhanced with increasing ionic strength mimicking by NaCl concentration. Based on the enhancement of the Cat2 peak we determined the ionic strength of fibroblasts sample and recalculated the concentration of MT determined there.","[Krizkova, Sona; Fabrik, Ivo; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Dept Anim Nutr & Forage Prod, Fac Agron, CZ-61300 Brno, Czech Republic; [Kukacka, Jiri; Prusa, Richard] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, CZ-15006 Prague, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Dept Chem, Fac Sci, CZ-61137 Brno, Czech Republic; [Strnadel, Jan; Horak, Vratislav] Acad Sci Czech Republic, Lab Tumour Biol, Dept Anim Embryol Cell & Tissue Differentitat, Inst Anim Physiol & Genet, CZ-27721 Libechov, Czech Republic","Kizek, R (reprint author), Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Krizkova, Sona/E-9617-2012; Kukacka, Jiri/C-4770-2013",null,null,null,null,34,20,20,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","1040-0397",null,null,"ELECTROANAL","Electroanalysis","FEB",2009,21,41762,null,null,null,null,640,644,null,"10.1002/elan.200804406",null,5,"Chemistry, Analytical; Electrochemistry","Chemistry; Electrochemistry","417GC","WOS:000264063500057"]
[null,null,null,null,"J","Cejkova, J; Ardan, T; Cejka, C; Malec, J; Jirsova, K; Filipec, M; Ickova, ER; Dotielova, D; Brunova, B",null,null,null,"Cejkova, J.; Ardan, T.; Cejka, C.; Malec, J.; Jirsova, K.; Filipec, M.; Ickova, E. Ruz; Dotielova, D.; Brunova, B.",null,null,"Ocular surface injuries in autoimmune dry eye. The severity of microscopical disturbances goes parallel with the severity of symptoms of dryness","HISTOLOGY AND HISTOPATHOLOGY",null,null,"English","Review",null,null,null,null,null,"Autoimmune dry eye; Oxidative injuries; Pro-inflammatory cytokines; Reactive oxygen and nitrogen species; Antioxidant enzymes","NITRIC-OXIDE SYNTHASE; SJOGRENS-SYNDROME; XANTHINE OXIDOREDUCTASE; TEAR FLUID; CONJUNCTIVAL EPITHELIUM; INFLAMMATORY CYTOKINES; OXIDATIVE REACTIONS; CELLS; INTERLEUKIN-1-BETA; EXPRESSION","Autoimmune dry eye (Sjogren's syndrome, SS) is a chronic systemic disease characterized by salivary and lacrimal gland inflammation and tissue damage leading to keratoconjunctivitis sicca and xerostomia. In this review attention has been devoted to the cause of the development of oxidative injuries of the ocular surface of patients suffering from SS. It was shown that lacrimal glands and diseased conjunctival epithelium reveal increased expression of pro-inflammatory cytokines which are released into the tear fluid. A high amount of pro-inflammatory cytokines highly induce the elevated expression and activity of enzymatic systems that generate reactive oxygen and nitrogen species. An abundant amount of these toxic products leads to a decrease in antioxidants and to the formation of cytotoxic related oxidants, such as peroxynitrite. All these factors, together with reactive oxygen species from polymorphonuclear leukocytes, contribute to the development of oxidative injuries at the ocular surface. From the clinical point of view it is important that the level of severity of the above described microscopical disturbances found in conjunctival epithelial cells goes parallel with the level of severity of dry eye symptoms.","[Cejkova, J.; Ardan, T.; Cejka, C.] Acad Sci Czech Republic, Inst Expt Med, Dept Eye Histochem & Pharmacol, CR-14220 Prague 4, Czech Republic; [Cejka, C.; Dotielova, D.; Brunova, B.] Charles Univ Prague, Motol Hosp, Dept Ophthalmol Children & Adults, Sch Med 2, Prague, Czech Republic; [Jirsova, K.; Filipec, M.; Ickova, E. Ruz] Gen Teaching Hosp, Eye Clin, Prague, Czech Republic; [Jirsova, K.; Filipec, M.; Ickova, E. Ruz] Gen Teaching Hosp, Lab Biol & Pathol Eye, Inst Inherited Metab Disorders, Prague, Czech Republic","Cejkova, J (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Eye Histochem & Pharmacol, Videnska 1083, CR-14220 Prague 4, Czech Republic.","cejkova@biomed.cas.cz","Jirsova, Katerina/B-8301-2012",null,"Ministry of Health of the Czech Republic [NR/8828-3]","This work was supported by a grant from the Ministry of Health of the Czech Republic No. NR/8828-3.",null,30,4,4,"F HERNANDEZ","MURCIA","PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN","0213-3911",null,null,"HISTOL HISTOPATHOL","Histol. Histopath.","OCT",2009,24,10,null,null,null,null,1357,1365,null,null,null,9,"Cell Biology; Pathology","Cell Biology; Pathology","484WO","WOS:000269079900012"]
[null,null,null,null,"J","Tomek, V; Marek, J; Jicinska, H; Skovranek, J",null,null,null,"Tomek, V.; Marek, J.; Jicinska, H.; Skovranek, J.",null,null,"Fetal Cardiology in the Czech Republic: Current Management of Prenatally Diagnosed Congenital Heart Diseases and Arrhythmias","PHYSIOLOGICAL RESEARCH",null,null,"English","Review",null,null,null,null,null,"Prenatal; Echocardiography; Congenital heart defect; Arrhythmias; Heart failure","COMPLETE ATRIOVENTRICULAR-BLOCK; ECHOCARDIOGRAPHY; EXPERIENCE; BORN; MALFORMATIONS; TACHYCARDIA; PREVENTION; ANTIBODIES; MORBIDITY; MORTALITY","Reliable diagnosis of congenital heart defects and arrhythmias in utero has been possible since the introduction of fetal echocardiography. The nation-wide prenatal ultrasound screening program in the Czech Republic enabled detection of cardiac abnormities in 1/3 of patients born with any congenital heart disease and up to 83 % of those with critical forms. Prenatal frequency of individual heart anomalies significantly differed from the postnatal frequency. Fetal isolated complete atrioventricular block and supraventricular tachycardia may lead to heart failure and are important causes of fetal mortality. The regression of heart failure was achieved by a conversion to the sinus rhythm in the supraventricular tachycardia and by increase of ventricular rate in the complete atrioventricular block.","[Tomek, V.; Marek, J.; Skovranek, J.] Univ Hosp Motol, Kardioctr, Prague 15008 5, Czech Republic; [Tomek, V.; Marek, J.; Skovranek, J.] Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15008 5, Czech Republic; [Jicinska, H.] Univ Hosp Brno, Dept Pediat Cardiol, Brno, Czech Republic","Tomek, V (reprint author), Univ Hosp Motol, Kardioctr, Uvalu 84, Prague 15008 5, Czech Republic.","viktor.tomek@fnmotol.cz",null,null,"Internal Grant Agency; Ministry of Health, Czech Republic; Ministry of Education of the Czech Republic;  [NR9451-3/2007];  [1MO510]","The publication was supported by the grant NR9451-3/2007, Internal Grant Agency, Ministry of Health, Czech Republic and 1MO510, Ministry of Education of the Czech Republic.",null,35,2,3,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,null,null,2,null,null,"S159","S166",null,null,null,8,"Physiology","Physiology","542ZC","WOS:000273537200015"]
[null,null,null,null,"J","Vernerova, Z; Kujal, P; Kramer, HJ; Backer, A; Cervenka, L; Vaneckova, I",null,null,null,"Vernerova, Z.; Kujal, P.; Kramer, H. J.; Baecker, A.; Cervenka, L.; Vaneckova, I.",null,null,"End-Organ Damage in Hypertensive Transgenic Ren-2 Rats: Influence of Early and Late Endothelin Receptor Blockade","PHYSIOLOGICAL RESEARCH",null,null,"English","Review",null,null,null,null,null,"Endothelin receptors; Hypertension; Morphology; Podocytes; Ren-2 rats","BLOOD-PRESSURE; GLOMERULAR PODOCYTE; SALT; KIDNEY; CELLS; GLOMERULOSCLEROSIS; FIBROGENESIS; INJURY","The rat strain transgenic for the murine Ren-2 renin gene (TGR) is defined as a monogenic model of angiotensin II-dependent hypertension with endogenous activation of the renin-angiotensin system. Homozygous males TGR develop malignant hypertension with a strong salt-sensitive component. These animals show severe hypertension, proteinuria and high mortality. Morphological changes of renal parenchyma correspond to chronic ischemic glomerular changes. Heterozygous TGR develop only mild hypertension and thus provide a more suitable model of hypertension regarding to clinical studies. Within the renal parenchyma, secondary focal segmental glomerulosclerosis (FSGS) predominates. High-salt diet in heterozygous animals induces transition from benign to malignant phase of hypertension. In this case, ischemic glomerular changes are superimposed on preexisting secondary FSGS. In the regression model of hypertension (late-onset treatment) the effect of salt intake is attenuated. In homozygous TGR, early selective ET(A) receptor blockade decreased blood pressure and ameliorated end-organ damage. Late selective ET(A) receptor blockade reduced podocyte injury despite final severe hypertension. Survival rate was markedly improved in both regimens with ET(A) selective blockade, while there was only partial improvement with early non-selective blockade. Both bosentan and atrasentan decreased ET-1 levels in both regimens. In heterozygous TGR, early and late ET(A) treatment substantially while ET(A)/AT(B) treatment partially improved survival rate. Significant effect on BP was found with early and late ET(A) blockade, while ET(A)/ET(B) blockade had no effect. Bosentan and atrasentan similarly decreased ET-1 levels on both regimens. In conclusion, selective ET(A) receptor blockade is superior to nonselective ET(A)/ET(B) receptor blockade in attenuating hypertension and end-organ damage. Its effect is more pronounced when applied early in the life.","[Vernerova, Z.; Kujal, P.; Cervenka, L.; Vaneckova, I.] Ctr Med Expt, Inst Clin & Expt Med, CZ-14021 Prague 4, Czech Republic; [Vernerova, Z.; Kujal, P.] Charles Univ Prague, Dept Pathol, Fac Med 3, Prague, Czech Republic; [Kramer, H. J.; Baecker, A.] Univ Bonn, Nephrol Sect, Med Policlin, D-5300 Bonn, Germany; [Cervenka, L.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic; [Cervenka, L.; Vaneckova, I.] Cardiovasc Res Ctr, Prague, Czech Republic","Vaneckova, I (reprint author), Ctr Med Expt, Inst Clin & Expt Med, Videnska 1958-9, CZ-14021 Prague 4, Czech Republic.","ivvn@medicon.cz","Vaneckova, Ivana/B-5543-2012",null,"Czech Science Foundation [305/07/J004]","This study was supported by grant no. 305/07/J004 awarded to I.V. by the Czech Science Foundation.",null,35,5,5,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,null,null,2,null,null,"S69","S78",null,null,null,10,"Physiology","Physiology","542ZC","WOS:000273537200007"]
[null,null,null,null,"J","Novak, F; Kolar, F; Hamplova, B; Mrnka, L; Pelouch, V; Ostadal, B; Novakova, O",null,null,null,"Novak, F.; Kolar, F.; Hamplova, B.; Mrnka, L.; Pelouch, V.; Ostadal, B.; Novakova, O.",null,null,"Myocardial Phospholipid Remodeling under Different Types of Load Imposed during Early Postnatal Development","PHYSIOLOGICAL RESEARCH",null,null,"English","Review",null,null,null,null,null,"Phospholipids; Cardiolipin; Myocardium; Postnatal development; Pressure overload; Chronic hypoxia; Thyroid status","FATTY-ACID-COMPOSITION; PROTEIN-KINASE-C; DEVELOPING RAT-HEART; CHRONIC HYPOXIA; VENTRICULAR MYOCARDIUM; ACYL COMPOSITION; NEONATAL-RAT; BETA-ADRENOCEPTORS; PRESSURE-OVERLOAD; SKELETAL-MUSCLE","Normal increase in hemodynamic load during early postnatal life is associated with heart growth and maturation of membrane structures that is accompanied by remodeling of membrane protein and lipid components. This review describes remodeling of phospholipids (PL) in rat myocardium during normal postnatal development and during accelerated cardiac growth induced by additional workload (aorta constriction, chronic hypoxia and hyperthyroidism) imposed on the heart early after birth. Normal physiological load after birth stimulates the development of membrane structures and synthesis of PL. While hyperthyroidism accelerates these processes, pressure overload has an inhibitory effect. These changes primarily influence the maturation of mitochondrial membranes as cardiolipin is one of the most affected PL species. The most sensitive part of PL structure in their remodeling process are PL acyl chains, particularly polyunsaturated fatty acids that are the key components determining the basic physicochemical properties of the membrane bilayer and thus the function of membrane-bound proteins and membrane-derived signaling lipid molecules. It is evident that PL remodeling may significantly influence both normal and pathological postnatal development of myocardium.","[Novak, F.; Hamplova, B.; Mrnka, L.; Novakova, O.] Charles Univ Prague, Fac Sci, Dept Cell Biol, Prague 12800 2, Czech Republic; [Novak, F.] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12800 2, Czech Republic; [Pelouch, V.] Charles Univ Prague, Fac Med 2, Prague 12800 2, Czech Republic; [Kolar, F.; Ostadal, B.] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Novak, F.; Kolar, F.; Pelouch, V.; Ostadal, B.] Cardiovasc Res Ctr, Prague, Czech Republic","Novakova, O (reprint author), Charles Univ Prague, Fac Sci, Dept Cell Biol, Vinicna 7, Prague 12800 2, Czech Republic.","olnov@natur.cuni.cz","Kolar, Frantisek/A-7852-2012; Ostadal, Bohuslav/F-7387-2014",null,"Ministry of Education, Youth and Sports of the Czech Republic [0021620858, 1M0510, AV0Z 20110509]","Supported by the Ministry of Education, Youth and Sports of the Czech Republic grants No. 0021620858, 1M0510 and grant AV0Z 20110509.",null,137,3,3,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2009,58,null,null,2,null,null,"S13","S32",null,null,null,20,"Physiology","Physiology","542ZC","WOS:000273537200003"]
[null,null,null,null,"J","de Vries, ACH; Bredius, RGM; Lankester, AC; Bierings, M; Trebo, M; Sedlacek, P; Niemeyer, CM; Zecca, M; Locatelli, F; van den Heuvel-Eibrink, MM",null,null,null,"de Vries, Andrica C. H.; Bredius, Robbert G. M.; Lankester, Arjan C.; Bierings, Marc; Trebo, Monika; Sedlacek, Petr; Niemeyer, Charlotte M.; Zecca, Marco; Locatelli, Franco; van den Heuvel-Eibrink, Marry M.",null,null,"HLA-identical umbilical cord blood transplantation from a sibling donor in juvenile myelomonocytic leukemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Letter",null,null,null,null,null,null,"STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; WORKING-GROUP; CHILDREN; JMML",null,"[van den Heuvel-Eibrink, Marry M.] Sophia Childrens Univ Hosp, Dept Pediat Oncol Hematol, Erasmus Med Ctr, NL-3015 GJ Rotterdam, Netherlands; [Bredius, Robbert G. M.; Lankester, Arjan C.] Leiden Univ, Med Ctr, Dept Pediat, Leiden, Netherlands; [Bierings, Marc] UMCU Wilhelmina Childrens Hosp, Dept Pediat Hematol Oncol, Utrecht, Netherlands; [Trebo, Monika] St Anna Childrens Hosp, Dept Pediat, A-1090 Vienna, Austria; [Sedlacek, Petr] Charles Univ Prague, Univ Hosp Motol, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Niemeyer, Charlotte M.] Univ Freiburg, Dept Pediat, D-7800 Freiburg, Germany; [Zecca, Marco; Locatelli, Franco] Univ Pavia, Fondaz IRCCS Policlin San Matteo, I-27100 Pavia, Italy","van den Heuvel-Eibrink, MM (reprint author), Sophia Childrens Univ Hosp, Dept Pediat Oncol Hematol, Erasmus Med Ctr, Room Sp 2568,Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl",null,null,null,null,null,11,5,5,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","FEB",2009,94,2,null,null,null,null,302,304,null,"10.3324/haematol.2008.000216",null,3,null,null,"404PE","WOS:000263164700027"]
[null,null,null,null,"B","Lesny, P; Krasnicanova, H; Holecek, T; Slaby, K; Vejvalka, J",null,"Karopka, T; CruzCorreia, RJ",null,"Lesny, Petr; Krasnicanova, Hana; Holecek, Tomas; Slaby, Krystof; Vejvalka, Jan",null,null,"Repositories of Reusable Auxological (Growth) Algorithms for eHealth","OPEN SOURCE IN EUROPEAN HEALTH CARE: THE TIME IS RIPE",null,null,"English","Proceedings Paper","1st International Workshop on Open Source in European Health Care","JAN , 2009","Porto, PORTUGAL",null,null,null,null,"The auxological (growth) data are suitable for being processed algorithmically by specialized software. Increasing complexity of the pediatric auxology requires the development of algorithm repositories, which allow the users to select and utilize appropriate algorithms. There are many attempts to build such repositories, however their usage is limited. In order to create the modem repository of algorithms (not limited to the pediatric auxology), we have postulated the following key principles: strong philosophical background, explicit description of the semantic paradigm and its binding to the current scientific paradigm, quality management, platform independency and interoperability and trust management. Based on these principles, we have developed and validated the indicator ontology model with strong documentation quality management, implemented as web services under the open source license model. The reference implementation of the algorithm repository operates on the intranet of the Faculty hospital in Prague Motol.","[Lesny, Petr; Krasnicanova, Hana; Slaby, Krystof; Vejvalka, Jan] Fac Hosp Prague Motol, Prague 15006 5, Czech Republic","Lesny, P (reprint author), Fac Hosp Prague Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.lesny@lfmotol.cuni.cz; hana.krasnicanova@lfmotol.cuni.cz; holecek@ojrech.cz; krystof.slaby@lfmotol.cuni.cz; jan.vejvalka@lfmotol.cuni.cz",null,null,null,null,null,10,0,0,"INSTICC-INST SYST TECHNOLOGIES INFORMATION CONTROL & COMMUNICATION","SETUBAL","AVENIDA D MANUEL L, 27A 2 ESQUERDO, SETUBAL, 2910-595, PORTUGAL",null,null,"978-989-8111-79-1",null,null,null,2009,null,null,null,null,null,null,54,58,null,null,null,5,"Medical Informatics","Medical Informatics","BJN56","WOS:000266867100008"]
[null,null,null,null,"B","Vejvalka, J; Lesny, P; Holecek, T; Slaby, K; Jarolimkova, A; Bouzkova, H",null,"Karopka, T; CruzCorreia, RJ",null,"Vejvalka, Jan; Lesny, Petr; Holecek, Tomas; Slaby, Krystof; Jarolimkova, Adela; Bouzkova, Helena",null,null,"MediGrid - Facilitating Semantic-Based processing of Biomedical Data and Knowledge","OPEN SOURCE IN EUROPEAN HEALTH CARE: THE TIME IS RIPE",null,null,"English","Proceedings Paper","1st International Workshop on Open Source in European Health Care","JAN, 2009","Porto, PORTUGAL",null,null,null,null,"New ICT approaches promise better support to the traditional ways that medicine handles information. Exploring ways to provide this support, we formulated the principles of he MediGrid: (1) Data processed by biomedical algorithms are (following the philosophical tradition of phenomenology) indicators that can be transformed into other indicators. (2) Data and algorithms can be shared across conceptual domains if documented semantic links exist to support such interconnection. The need of explicit and detailed documentation of semantics leads to the requirement of good documentation of computer procedures that implement the biomedical knowledge contained in scientifically accepted algorithms. A proof-of-concept implementation of a system based on these principles has been published on Sourceforge.","[Vejvalka, Jan; Lesny, Petr; Slaby, Krystof] Fac Hosp Prague Motol, Prague 15006 5, Czech Republic","Vejvalka, J (reprint author), Fac Hosp Prague Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.vejvalka@lfmotol.cuni.cz; petr.lesny@lfmotol.cuni.cz; holecek@ojrech.cz; krystof.slaby@lfmotol.cuni.cz; ajarolimkova@seznam.cz; bouzkova@nlk.cz",null,null,null,null,null,8,1,1,"INSTICC-INST SYST TECHNOLOGIES INFORMATION CONTROL & COMMUNICATION","SETUBAL","AVENIDA D MANUEL L, 27A 2 ESQUERDO, SETUBAL, 2910-595, PORTUGAL",null,null,"978-989-8111-79-1",null,null,null,2009,null,null,null,null,null,null,18,21,null,null,null,4,"Medical Informatics","Medical Informatics","BJN56","WOS:000266867100003"]
[null,null,null,null,"S","Dostalova, T; Jelinkova, H; Sulc, J; Koranda, P; Nemec, M; Ivanov, I; Miyagi, M; Iwai, K",null,"Rechmann, P; Fried, D",null,"Dostalova, Tat'jana; Jelinkova, Helena; Sulc, Jan; Koranda, Petr; Nemec, Michal; Ivanov, Ilja; Miyagi, Mitsunobu; Iwai, Katsumasa",null,null,"Laser brackets debonding - Tm:YAP, Nd:YAG, and GaAs diode lasers evaluation","LASERS IN DENTISTRY XV","Proceedings of SPIE",null,"English","Proceedings Paper","Conference on Lasers in Dentistry XV","JAN 24, 2009","San Jose, CA","SPIE",null,"dentistry; orthodontics; ceramic bracket debonding; GaAs diode laser; Tm:YAP laser; Nd:YAG laser","COSMETIC DENTISTRY; ORTHODONTICS; PRINCIPLES","The study demonstrates the possibility of using laser radiation for ceramic bracket removing. Three laser radiations were examined for this effect, and the removing possibility and velocity together with enamel and pulp damage were investigated. The lasers used were: a diode-pumped Tm:YAP microchip laser, diode pumped Nd:YAG laser, and GaAs diode generating 1.9 mu m, 1.44 mu m, and 0.808 mu m, respectively. The measurement of transmission and absorption of the basic element - bracket, adhesive resin, and enamel - was also made with the goal to explain the source of heat and bracket debonding. The explanation of the debonding effect is also presented. From the results it is possible to conclude that the continuously running diode pumped microchip Tm: YAP laser having output power 1W can be a good candidate for the ceramic bracket debonding procedure.","[Dostalova, Tat'jana; Ivanov, Ilja] Charles Univ Prague, Sch Med 2, Dept Paediat Stomatol, Prague 15006 5, Czech Republic","Dostalova, T (reprint author), Charles Univ Prague, Sch Med 2, Dept Paediat Stomatol, V Uvalu 84, Prague 15006 5, Czech Republic.","tatjana.dostalova@fnmotol.cz",null,null,null,null,null,11,0,0,"SPIE-INT SOC OPTICAL ENGINEERING","BELLINGHAM","1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA","0277-786X",null,"978-0-8194-7408-7","PROC SPIE",null,null,2009,7162,null,null,null,null,null,null,null,"71620C","10.1117/12.808137",null,6,"Dentistry, Oral Surgery & Medicine; Optics; Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging","Dentistry, Oral Surgery & Medicine; Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging","BSL15","WOS:000284820700008"]
[null,null,null,null,"J","Horak, D; Babic, M; Jendelova, P; Herynek, V; Trchova, M; Likavcanova, K; Kapcalova, M; Hajek, M; Sykova, E",null,null,null,"Horak, Daniel; Babic, Michal; Jendelova, Pavla; Herynek, Vit; Trchova, Miroslava; Likavcanova, Katarina; Kapcalova, Miroslava; Hajek, Milan; Sykova, Eva",null,null,"Effect of different magnetic nanoparticle coatings on the efficiency of stem cell labeling","JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS",null,null,"English","Article; Proceedings Paper","7th International Conference on Scientific and Clinical Applications of Magnetic Carriers","MAY 20-24, 2008","Vancouver, CANADA",null,null,"Magnetic nanoparticles; Maghemite; MRI; Stem cells; Biocompatibility; Contrast agent","IRON-OXIDE NANOPARTICLES; IN-VIVO TRACKING; SPINAL-CORD-INJURY; SUPERPARAMAGNETIC NANOPARTICLES; TRANSFECTION AGENTS; ARTERIAL-DISEASE; PROGENITOR CELLS; CONTRAST AGENTS; TRANSPLANTATION; POLYMERIZATION","Maghemite nanoparticles with various coatings were prepared by the coprecipitation method and characterized by transmission electron microscopy, dynamic light scattering and IR in terms of morphology, size, polydispersity and surface coating. The labeling efficiency and the viability of both rat and human mesenchymal stem cells labeled with Endorem (R), poly(L-lysine) (PLL)-modified Endorem (R), uncoated gamma-Fe(2)O(3), D-mannose-, PLL- or poly(N,N-dimethylacrylamide) (PDMAAm)-coated gamma-Fe(2)O(3) nanoparticles were compared. Coated gamma-Fe(2)O(3) nanoparticles labeled cells better than did Endorem (R). High relaxation rates and in vitro magnetic resonance imaging of cells labeled with coated nanoparticles showed clearly visible contrast compared with unlabeled cells or cells labeled with Endorem (R). (c) 2009 Elsevier B.V. All rights reserved.","[Horak, Daniel; Babic, Michal; Trchova, Miroslava] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Horak, Daniel; Babic, Michal; Jendelova, Pavla; Hajek, Milan; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Jendelova, Pavla; Likavcanova, Katarina; Kapcalova, Miroslava; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Herynek, Vit; Hajek, Milan] Inst Clin & Expt Med, Prague 14021 4, Czech Republic","Horak, D (reprint author), Acad Sci Czech Republic, Inst Macromol Chem, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic.","horak@imc.cas.cz","Babic, Michal/B-7075-2013",null,null,null,null,36,16,16,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0304-8853",null,null,"J MAGN MAGN MATER","J. Magn. Magn. Mater.","MAY",2009,321,10,null,null,null,null,1539,1547,null,"10.1016/j.jmmm.2009.02.082",null,9,"Materials Science, Multidisciplinary; Physics, Condensed Matter","Materials Science; Physics","434ME","WOS:000265278000048"]
[null,null,null,null,"J","Fabrik, I; Kukacka, J; Baloun, J; Sotornik, I; Adam, V; Prusa, R; Vajtr, D; Babula, P; Kizek, R",null,null,null,"Fabrik, Ivo; Kukacka, Jiri; Baloun, Jiri; Sotornik, Ivo; Adam, Vojtech; Prusa, Richard; Vajtr, David; Babula, Petr; Kizek, Rene",null,null,"Electrochemical Investigation of Strontium-Metallothionein Interactions-Analysis of Serum and Urine of Patients with Osteoporosis","ELECTROANALYSIS",null,null,"English","Article; Proceedings Paper","12th International Conference on Electroanalysis","JUN 16-19, 2008","Prague, CZECH REPUBLIC","European Soc Electroanal Chem, Int Soc Electrochem, Czech Chem Soc, Charles Univ, Fac Sci",null,"Strontium; Metallothionein; Differential pulse voltammetry; Brdicka reaction; Heavy metal-protein interaction; Osteoporosis; Human blood serum and urine","TRANSGENIC TOBACCO PLANTS; LIQUID-CHROMATOGRAPHY; BRDICKA REACTION; GENE-EXPRESSION; BONE-RESORPTION; QUANTIFICATION; BIOSENSOR; RATS; VOLTAMMETRY; GLUTATHIONE","The main aim of this paper is to study interaction between strontium and metallothionein (MT), and to determine changes in strontium and thiols (MT, reduced glutathione, cysteine, and homocysteine) level in plasma, serum, and urine samples of patients treated with strontium ranelate (SrR). To investigate the interactions between MT and strontium(II) ions, adsorptive transfer stripping technique coupled with differential pulse voltammetry (DPV) the Brdicka reaction was employed. Besides standard Brdicka signals (Co, RS(2)Co, Cat1, Cat2, Cat3), we observed new signal related to Sr-MT interaction. Further we investigated the effect of various time of interaction, concentration of strontium(II) ions and temperature of supporting electrolyte on Brdicka signals. Optimal time of interaction was 240 s. Under temperature of supporting electrolyte 20 degrees C, we measured linear dependence of Cat3 signal height on strontium(II) ions concentration. After that we have investigated the possibility of strontium-MT interactions, we were interested in strontium, MT and low molecular mass thiols levels in serum and urine of patients treated with strontium(II) ions to cure osteoporosis. Strontium concentration determined by atomic absorption spectrometry was 55 +/- 5 mu g/L before and 10,500 +/- 1,400 mu g/L at the 30(th) day of SrR administration. Levels of metallothionein in serum ranged from 0.1 to 6.4 mu M. Correlation between serum strontium concentration and MT level was determined and correlation coefficient was R = 0.93.","[Fabrik, Ivo; Baloun, Jiri; Adam, Vojtech; Kizek, Rene] Mendal Univ Agr & Forestry, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Kukacka, Jiri; Prusa, Richard; Vajtr, David] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Sotornik, Ivo] Inst Clin & Expt Med, Dept Nephrol, CZ-14021 Prague, Czech Republic; [Adam, Vojtech] Mendal Univ Agr & Forestry, Dept Anim Nutr & Forage Prod, Fac Agron, CZ-61300 Brno, Czech Republic; [Babula, Petr] Univ Vet & Pharmaceut Sci, Dept Nat Drugs, Fac Pharm, CZ-61242 Brno, Czech Republic","Kizek, R (reprint author), Mendal Univ Agr & Forestry, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Kukacka, Jiri/C-4770-2013",null,null,null,null,44,17,17,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","1040-0397",null,null,"ELECTROANAL","Electroanalysis","FEB",2009,21,41762,null,null,null,null,650,656,null,"10.1002/elan.200804431",null,7,"Chemistry, Analytical; Electrochemistry","Chemistry; Electrochemistry","417GC","WOS:000264063500059"]
[null,null,null,null,"J","Huska, D; Adam, V; Babula, P; Hrabeta, J; Stiborova, M; Eckschlager, T; Trnkova, L; Kizek, R",null,null,null,"Huska, Dalibor; Adam, Vojtech; Babula, Petr; Hrabeta, Jan; Stiborova, Marie; Eckschlager, Tomas; Trnkova, Libuse; Kizek, Rene",null,null,"Square-Wave Voltammetry as a Tool for Investigation of Doxorubicin Interactions with DNA Isolated from Neuroblastoma Cells","ELECTROANALYSIS",null,null,"English","Article; Proceedings Paper","12th International Conference on Electroanalysis","JUN 16-19, 2008","Prague, CZECH REPUBLIC","European Soc Electroanal Chem, Int Soc Electrochem, Czech Chem Soc, Charles Univ, Fac Sci",null,"Intercalating drug; Doxorubicin; Nucleic acids; Voltammetry; Adsorptive transfer stripping technique","GLASSY-CARBON ELECTRODE; FLOW-INJECTION ANALYSIS; ELECTROCHEMICAL BIOSENSOR; GOLD NANOPARTICLES; ETHIDIUM-BROMIDE; ANTICANCER DRUG; PASTE ELECTRODE; NUCLEIC-ACIDS; TUMOR-CELLS; BEHAVIOR","We investigated ethidium bromide intercalation into DNA molecule as a model system to test square-wave voltammetry (SWV) as a suitable method for this purpose We found that 0.13 mu g EtBr intercalates into 1 mu g dsDNA in average. Further, SWV was utilized for investigation of doxorubicin-DNA interactions. Intercalated doxorubicin reduced observed dsDNA cytosine and adenine (CA) signal, but also provided new signal called DOXO at -0.35 V. This phenomenon was observed at both single and double stranded DNA standards. We also employed adsorptive transfer stripping technique coupled with SWV for study of doxorubicin-DNA interactions. Doxorubicin intercalation into dsDNA molecule adsorbed onto working electrode was fast, because we observed considerable changes in CA and DOXO signals after 360 s. Finally, we detected doxorubicin-DNA adducts formed in doxorubicin treated neuroblastoma cells.","[Huska, Dalibor; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic; [Babula, Petr] Univ Vet & Pharmaceut Sci, Fac Pharm, Dept Nat Drugs, CZ-61242 Brno, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CZ-61137 Brno, Czech Republic","Kizek, R (reprint author), Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012",null,null,null,null,55,16,16,"WILEY-V C H VERLAG GMBH","WEINHEIM","BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY","1040-0397",null,null,"ELECTROANAL","Electroanalysis","FEB",2009,21,41762,null,null,null,null,487,494,null,"10.1002/elan.200804429",null,8,"Chemistry, Analytical; Electrochemistry","Chemistry; Electrochemistry","417GC","WOS:000264063500035"]
[null,null,null,null,"J","Huska, D; Adam, V; Zitka, O; Kukacka, J; Prusa, R; Kizek, R",null,null,null,"Huska, Dalibor; Adam, Vojtech; Zitka, Ondrej; Kukacka, Jiri; Prusa, Richard; Kizek, Rene",null,null,"Chronopotentiometric Stripping Analysis of Gelatinase B, Collagen and Their Interaction","ELECTROANALYSIS",null,null,"English","Article; Proceedings Paper","12th International Conference on Electroanalysis","JUN 16-19, 2008","Prague, CZECH REPUBLIC","European Soc Electroanal Chem, Int Soc Electrochem, Czech Chem Soc, Charles Univ, Fac Sci",null,"Matrix metalloproteinases; Chronopotentiometric stripping analysis; Collagen; Protein-protein interaction; Cancer","SENSITIVE ELECTROCHEMICAL DETECTION; MATRIX METALLOPROTEINASES; METALLOTHIONEIN DETERMINATION; CONTAINING PEPTIDES; HEAVY-METALS; FISH-TISSUES; PROTEIN P53; VOLTAMMETRY; LACTOFERRIN; ELECTRODES","Matrix metalloproteinases (MMP) belong to a group of zinc-dependent proteins that play a central role in the breakdown of extracellular matrices. Collagen, elastin, gelatin and casein are the main components of extracellular matrix cleaved by MMP This paper aims to analyze the interaction between gelatinase B (MMP-9) and collagen using chronopotentiometric stripping analysis with adsorptive transfer stripping technique (AdTS CPSA). Under optimized experimental conditions (time accumulation of 90 s, supporting electrolyte 0.2 M acetate buffer pH 5, stripping current.1 mu A), the detection limit (3 signal/noise) for MMP-9 was estimated as being 100 pM. The interaction between MMP-9 and collagen was studied according to the following scheme: i) HMDE surface was renewed. ii) Renewed surface of HMDE collagen (1 mu g/mL) was accumulated for 90 s under open circuit. iii) The electrode was rinsed in ACS grade water and immersed in 5 mu L drop of MMP-9. iv) The interaction between MMP-9 with collagen took place at open circuit. v) The electrode was then rinsed in ACS grade water. vi) The rinsed electrode was transferred into an electrochemical cell and measured in acetate buffer (pH 5). The CPSA signal of collagen after its interaction with MMP-9 increased more than 30% compared to that of only collagen. This increase in signal is likely due to the cleavage of collagen by MMP-9, hence its easy access to the electrode's surface.","[Huska, Dalibor; Adam, Vojtech; Zitka, Ondrej; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic; [Zitka, Ondrej] Masaryk Univ, Fac Sci, Dept Biochem, CZ-61137 Brno, Czech Republic; [Kukacka, Jiri; Prusa, Richard] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, CZ-15006 Prague 5, Czech Republic","Kizek, R (reprint author), Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Zitka, Ondrej/E-1107-2012; Kukacka, Jiri/C-4770-2013",null,null,null,null,40,16,16,"WILEY-V C H VERLAG GMBH","WEINHEIM","PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY","1040-0397",null,null,"ELECTROANAL","Electroanalysis","FEB",2009,21,41762,null,null,null,null,536,541,null,"10.1002/elan.200804440",null,6,"Chemistry, Analytical; Electrochemistry","Chemistry; Electrochemistry","417GC","WOS:000264063500042"]
[null,null,null,null,"J","Sedlacek, P; Vavra, V; Masova, I; Codl, D; Laznickova, T; Malaskova, L; Nyc, O; Stary, J",null,null,null,"Sedlacek, Petr; Vavra, Vladimir; Masova, Ivana; Codl, Daniel; Laznickova, Tana; Malaskova, Ludmila; Nyc, Otakar; Stary, Jan",null,null,"Successful therapy with ABLC, surgery and posaconazole for Rhizopus microsporus var. rhizopodiformis liver eumycetoma in a child with acute leukaemia","MYCOSES",null,null,"English","Letter",null,null,null,null,null,null,null,"Invasive fungal infection negatively influences the morbidity and mortality in heavily immuno-incompetent patients. Diagnosis of non-Aspergillus mould infections remains challenging despite application of a wide spectrum of non-culture-based microbiological techniques. Invasive diagnostic procedures are often essential. In this article, we present the case of a 15-month-old boy diagnosed with Rhizopus microsporus var. rhizopodiformis liver mycetoma during induction chemotherapy for acute promyelocytic leukaemia. Following surgery, he was effectively treated with a combination of ABLC and posaconazole during ongoing intensive chemotherapy. Posaconazole was also used as long-term secondary prophylaxis.","[Sedlacek, Petr; Vavra, Vladimir; Stary, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Teaching Hosp Motol, Sch Med 2, Prague 15006 5, Czech Republic; [Masova, Ivana] Inst Hlth, Lab Mycol, Prague, Czech Republic; [Codl, Daniel; Laznickova, Tana; Nyc, Otakar] Charles Univ Prague, Dept Clin Microbiol, Teaching Hosp Motol, Sch Med 2, Prague 15006 5, Czech Republic; [Malaskova, Ludmila] Masaryk Univ, Dept Clin Biochem, Fac Med, Brno, Czech Republic","Sedlacek, P (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Teaching Hosp Motol, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.sedlacek@lfmotol.cuni.cz",null,null,null,null,null,0,7,7,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0933-7407",null,null,"MYCOSES","Mycoses","MAY",2009,52,3,null,null,null,null,276,279,null,"10.1111/j.1439-0507.2008.01595.x",null,4,"Dermatology; Mycology","Dermatology; Mycology","428AM","WOS:000264820200013"]
[null,null,null,null,"J","Boelens, JJ; Bierings, M; Tilanus, M; Lie, J; Sedlacek, P",null,null,null,"Boelens, J. J.; Bierings, M.; Tilanus, M.; Lie, J.; Sedlacek, P.",null,null,"Outcomes of transplantation of unrelated cord blood in children with malignant and non-malignant diseases: an Utrecht-Prague collaborative study","BONE MARROW TRANSPLANTATION",null,null,"English","Letter",null,null,null,null,null,null,"GRAFT",null,"[Boelens, J. J.; Bierings, M.] Univ Med Ctr Utrecht, Dept Immunol Hematol, Utrecht, Netherlands; [Boelens, J. J.; Bierings, M.] Univ Med Ctr Utrecht, BMT, Utrecht, Netherlands; [Tilanus, M.] Univ Hosp Maastricht, Tissue Typing Lab, Maastricht, Netherlands; [Lie, J.] Europdonor, Leiden, Netherlands; [Sedlacek, P.] Univ Hosp Motol, Dept Paediat Hematol & Oncol, Prague, Czech Republic","Boelens, JJ (reprint author), Univ Med Ctr Utrecht, Dept Immunol Hematol, Utrecht, Netherlands.","j.j.boelens@umcutrecht.nl",null,null,null,null,null,5,1,1,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0268-3369",null,null,"BONE MARROW TRANSPL","Bone Marrow Transplant.","APR",2009,43,8,null,null,null,null,655,657,null,"10.1038/bmt.2008.367",null,3,"Biophysics; Oncology; Hematology; Immunology; Transplantation","Biophysics; Oncology; Hematology; Immunology; Transplantation","443BJ","WOS:000265884900008"]
[null,null,null,null,"J","Veselka, J",null,null,null,"Veselka, Josef",null,null,"Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Is it Safe?","CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS",null,null,"English","Letter",null,null,null,null,null,null,null,null,"Univ Hosp Motol, Ctr Cardiovasc, Prague, Czech Republic","Veselka, J (reprint author), Univ Hosp Motol, Ctr Cardiovasc, Prague, Czech Republic.",null,null,null,null,null,null,8,2,2,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1522-1946",null,null,"CATHETER CARDIO INTE","Catheter. Cardiovasc. Interv.","SEP 1",2009,74,3,null,null,null,null,520,521,null,"10.1002/ccd.22046",null,2,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","488ZO","WOS:000269389200029"]
[null,null,null,null,"J","Mannarini, L; Kratochvil, V; Calabrese, L; Silva, LG; Morbini, P; Betka, J; Benazzo, M",null,null,null,"Mannarini, L.; Kratochvil, V.; Calabrese, L.; Silva, L. Gomes; Morbini, P.; Betka, J.; Benazzo, M.",null,null,"Human Papilloma Virus (HPV) in head and neck region: review of literature","ACTA OTORHINOLARYNGOLOGICA ITALICA",null,null,"English","Review",null,null,null,null,null,"Human papillomavirus; Head and neck; Squamous cell carcinoma; Oropharynx; Oral cavity","SQUAMOUS-CELL CARCINOMA; ORAL HUMAN-PAPILLOMAVIRUS; RANDOMIZED CONTROLLED-TRIAL; POSITIVE CANCER-CELLS; RISK-FACTORS; CERVICAL-CANCER; DNA-SEQUENCE; OROPHARYNGEAL CANCERS; GENOME ORGANIZATION; HUMAN KERATINOCYTES","The evidence that human papillomavirus infection is related to head and neck squamous cell carcinoma is supported by molecular and epidemiological data. The definition of a distinct subset of head and neck squamous cell carcinoma, independent of the traditional risk factors and with different clinical presentation and outcome, has led to increasing interest in human papillomavirus infection. This review summarizes current knowledge regarding human papillomavirus biology, oncogenic mechanisms, risk factors for transmission, clinical significance and prophylactic strategies.","[Mannarini, L.; Silva, L. Gomes; Morbini, P.; Benazzo, M.] Univ Pavia, Policlin S Matteo Fdn, Dept Otolaryngol HN Surg, IRCCS, I-27100 Pavia, Italy; [Kratochvil, V.; Betka, J.] Charles Univ Prague, Fac Med 1, Dept Otolaryngol Head & Neck Surg, Prague, Czech Republic; [Calabrese, L.] European Inst Oncol, Div Head & Neck Surg, Milan, Italy","Mannarini, L (reprint author), Policlin San Matteo, Fdn IRCCS, SOC Otorinolaringoiatria, Piazzale Golgi 2, I-27100 Pavia, Italy.",null,null,null,null,null,null,108,19,20,"PACINI EDITORE","PISA","VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY","0392-100X",null,null,"ACTA OTORHINOLARYNGO","Acta Otorhinolaryngol. Ital.","JUN",2009,29,3,null,null,null,null,119,126,null,null,null,8,"Otorhinolaryngology","Otorhinolaryngology","501ZU","WOS:000270424200001"]
[null,null,null,null,"J","Gappa, M; Paton, J; Baraldi, E; Bush, A; Carlsen, KH; de Jongste, JC; Eber, E; Fauroux, B; McKenzie, S; Noel, JL; Palange, P; Pohunek, P; Priftis, K; Severin, T; Wildhaber, JH; Zivkovic, Z; Zach, M",null,null,null,"Gappa, M.; Paton, J.; Baraldi, E.; Bush, A.; Carlsen, K-H.; de Jongste, J. C.; Eber, E.; Fauroux, B.; McKenzie, S.; Noel, J-L.; Palange, P.; Pohunek, P.; Priftis, K.; Severin, T.; Wildhaber, J. H.; Zivkovic, Z.; Zach, M.",null,null,"Paediatric HERMES: update of the European Training Syllabus for Paediatric Respiratory Medicine","EUROPEAN RESPIRATORY JOURNAL",null,null,"English","Editorial Material",null,null,null,null,null,null,null,null,"[Gappa, M.] Marien Hosp Wesel, Childrens Hosp, D-46483 Wesel, Germany","Gappa, M (reprint author), Marien Hosp Wesel, Childrens Hosp, Pastor Janssen Str 8-38, D-46483 Wesel, Germany.","monika.gappa@marien-hospital-wesel.de","Eber, Ernst/B-6381-2012; Paton, James/B-9541-2008",null,null,null,"GAPPA M, 2009, BREATHE IN PRESS; Godfrey S, 2004, PEDIATR RES, V55, P521, DOI 10.1203/01.PDR.0000112037.28065.F8; Loddenkemper R, 2006, BREATHE, V3, P59; Zach MS, 2002, EUR RESPIR J, V20, P1587, DOI 10.1183/09031936.02.00401102",4,10,10,"EUROPEAN RESPIRATORY SOC JOURNALS LTD","SHEFFIELD","442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND","0903-1936",null,null,"EUR RESPIR J","Eur. Resp. J.","MAR",2009,33,3,null,null,null,null,464,465,null,"10.1183/09031936.00001209",null,2,"Respiratory System","Respiratory System","415OC","WOS:000263942400004"]
[null,null,null,null,"J","Weidenbach, M; Razek, V; Wild, F; Khambadkone, S; Berlage, T; Janousek, J; Marek, J",null,null,null,"Weidenbach, M.; Razek, V.; Wild, F.; Khambadkone, S.; Berlage, T.; Janousek, J.; Marek, J.",null,null,"Simulation of congenital heart defects: a novel way of training in echocardiography","HEART",null,null,"English","Article",null,null,null,null,null,null,"VIRTUAL-REALITY; 2-DIMENSIONAL ECHOCARDIOGRAPHY; INTERVENTIONAL-RADIOLOGY; CONSTRUCT-VALIDITY; AMERICAN-SOCIETY; TASK-FORCE; ULTRASOUND; TECHNOLOGY; GUIDELINES; EXPERIENCE","Background: Echocardiography is one of the most important diagnostic imaging modalities in paediatric cardiology. Owing to the large number of lesions, achieving expertise often requires years of training. Echocardiography is still taught using the apprenticeship model, which is time-and personnel consuming. Objectives: To extend the echocardiography simulator EchoCom to enable simulation of congenital heart lesions and validate it for training in paediatric echocardiography. Methods: The simulator consists of a life-size manikin, a dummy transducer with attached three-dimensional (3D) tracking system and a computer application. Transthoracic real-time (RT) 3D echocardiographic datasets were collected and embedded into the simulator. Two-dimensional images were calculated and resliced from these datasets according to the position of the tracking sensor. Ten RT 3D datasets of congenital heart lesions were selected for validation. Datasets were blinded and without additional information presented to 43 participants who were stratified according to their expertise (12 experts, 16 intermediates, 15 beginners). Participants were asked to list the relevant findings and make a diagnosis. Construct validation was tested comparing diagnostic performance for each group. Face and content validation were tested using a standardised questionnaire. Results: Participants judged the simulator as realistic and useful. The main drawback was the adult size of the manikin. The diagnostic performance of each group differed significantly proving construct validity. Conclusions: According to this validation the prototype simulator could make a significant contribution to training in the use of echocardiography in congenital heart disease.","[Weidenbach, M.; Razek, V.; Wild, F.; Janousek, J.] Univ Leipzig, Ctr Heart, Dept Paediat Cardiol, D-04289 Leipzig, Germany; [Khambadkone, S.; Marek, J.] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Berlage, T.] Fraunhofer Inst Appl Informat Technol, Schloss Birlinghoven, Sankt Augustin, Germany","Weidenbach, M (reprint author), Univ Leipzig, Ctr Heart, Dept Paediat Cardiol, Strumpellstr 39, D-04289 Leipzig, Germany.","weidenbach@medizin.unileipzig.de","Berlage, Thomas/B-2951-2012",null,null,null,"Baier P, 2001, Z GEBURTSH NEONATOL, V205, P213, DOI 10.1055/s-2001-19052; Dargie H, 2002, HEART, V88, P1, DOI 10.1136/heart.88.1.1; Carter FJ, 2005, SURG ENDOSC, V19, P1523, DOI 10.1007/s00464-005-0384-2; Dawson S, 2006, RADIOLOGY, V241, P17, DOI 10.1148/radiol.2411062581; Gorska-Kot A, 2006, J APPL GENETICS, V47, P191, DOI 10.1007/BF03194621; Gould DA, 2006, CLIN RADIOL, V61, P556, DOI 10.1016/j.crad.2006.01.013; Hoffman JIE, 2002, J AM COLL CARDIOL, V39, P1890, DOI 10.1016/S0735-1097(02)01886-7; Knudson MM, 2000, J TRAUMA, V48, P659, DOI 10.1097/00005373-200004000-00013; Lai WW, 2006, J AM SOC ECHOCARDIOG, V19, P1413, DOI 10.1016/j.echo.2006.09.001; Martin R., 1993, Proceedings. Computers in Cardiology 1993 (Cat. No.93CH3384-5), DOI 10.1109/CIC.1993.378513; Maul H, 2004, ULTRASOUND OBST GYN, V24, P581, DOI 10.1002/uog.1119; Pfammatter JP, 1999, ANN THORAC SURG, V68, P532, DOI 10.1016/S0003-4975(99)00511-1; PIEPER S, 1997, P INT REAL VIRT WORL, P211; Quinones MA, 2003, J AM SOC ECHOCARDIOG, V16, P379, DOI 10.1016/S0894-7317(03)00113-5; Reznek MA, 2002, ACAD EMERG MED, V9, P1319; Schijven M, 2003, SURG ENDOSC, V17, P803, DOI 10.1007/s00464-002-9151-9; Seliem MA, 2006, J AM SOC ECHOCARDIOG, V19, P121, DOI 10.1016/j.echo.2005.09.009; Stefanidis D, 2007, SURG ENDOSC, V21, P1158, DOI 10.1007/s00464-006-9112-9; Tworetzky W, 1999, J AM COLL CARDIOL, V33, P228, DOI 10.1016/S0735-1097(98)00518-X; van Dongen KW, 2007, SURG ENDOSC, V21, P1413, DOI 10.1007/s00464-006-9188-2; Weidenbach M, 2000, COMPUT BIOMED RES, V33, P11, DOI 10.1006/cbmr.1999.1527; Weidenbach M, 2005, J AM SOC ECHOCARDIOG, V18, P362, DOI 10.1016/j.echo.2004.10.025; Weidenbach M, 2007, ANAESTHESIA, V62, P347, DOI 10.1111/j.1365-2044.2007.04978.x",23,9,9,"B M J PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","1355-6037",null,null,"HEART","Heart","APR",2009,95,8,null,null,null,null,636,641,null,"10.1136/hrt.2008.156919",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","426KS","WOS:000264707800007"]
[null,null,null,null,"J","Gonzalez, MBGY; Schweigel, J; Kostelka, M; Janousek, J",null,null,null,"Gonzalez, Maria B. Y. Gonzalez; Schweigel, Joana; Kostelka, Martin; Janousek, Jan",null,null,"Cardiac Resynchronization in a Child with Dilated Cardiomyopathy and Borderline QRS Duration: Speckle Tracking Guided Lead Placement","PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"cardiac resynchronization therapy; idiopathic dilated cardiomyopathy; narrow QRS; children; heart failure","HEART-FAILURE; NARROW QRS; THERAPY; DYSSYNCHRONY","Cardiac resynchronization therapy (CRT) is proved to prevent heart transplantation in some patients with dilated cardiomyopathy and mechanical dyssynchrony. We report of the benefit of CRT accomplished by atrial synchronized single-site left ventricular pacing in an 8-year-old boy with idiopathic dilated cardiomyopathy, normal atrioventricular conduction, borderline QRS complex duration (120 ms), and marked mechanical left ventricular dyssynchrony proved by echocardiographic speckle tracking. (PACE 2009; 32:683-687)","[Gonzalez, Maria B. Y. Gonzalez; Schweigel, Joana; Janousek, Jan] Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, D-04289 Leipzig, Germany; [Kostelka, Martin] Univ Leipzig, Ctr Heart, Dept Cardiac Surg, D-04289 Leipzig, Germany","Janousek, J (reprint author), Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, Strumpellstr 39, D-04289 Leipzig, Germany.","jan.janousek@medizin.uni-leipzig.de",null,null,null,null,"Achilli A, 2003, J AM COLL CARDIOL, V42, P2117, DOI 10.1016/j.jace.2003.08.024; *AM HEART ASS TASK, 2005, J AM COLL CARDIOL, V46, P1116; Auricchio A, 2003, J AM COLL CARDIOL, V42, P2109, DOI 10.1016/j.jacc.2003.04.003; Becker M, 2007, EUR HEART J, V28, P1211, DOI 10.1093/eurheartj/ehm034; Beshai JF, 2007, NEW ENGL J MED, V357, P2461, DOI 10.1056/NEJMoa0706695; Dubin AM, 2005, J AM COLL CARDIOL, V46, P2277, DOI 10.1016/j.jacc.2005.05.096; Gorcsan J, 2007, J AM COLL CARDIOL, V50, P1476, DOI 10.1016/j.jacc.2007.06.043; JANOUSEK J, 2007, CARDIOL YOUNG S, V17, P16; Kass DA, 2008, J AM COLL CARDIOL, V51, P12, DOI 10.1016/j.jacc.2007.09.027; Rao RK, 2007, CIRCULATION, V115, P2136, DOI 10.1161/CIRCULATIONAHA.106.634444; Swedberg K, 2005, EUR HEART J, V26, P1115, DOI 10.1093/eurheartj/ehi204; Tops LF, 2007, J AM COLL CARDIOL, V50, P1180, DOI 10.1016/j.jacc.2007.06.011; Yu CM, 2005, AM HEART J, V149, P600, DOI 10.1016/j.ahj.2004.12.013; Yu CM, 2003, HEART, V89, P54, DOI 10.1136/heart.89.1.54",14,8,8,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0147-8389",null,null,"PACE","PACE-Pacing Clin. Electrophysiol.","MAY",2009,32,5,null,null,null,null,683,687,null,"10.1111/j.1540-8159.2009.02348.x",null,5,"Cardiac & Cardiovascular Systems; Engineering, Biomedical","Cardiovascular System & Cardiology; Engineering","452OM","WOS:000266550700024"]
[null,null,null,null,"J","Janousek, J",null,null,null,"Janousek, Jan",null,null,"Cardiac resynchronisation in congenital heart disease","HEART",null,null,"English","Article",null,null,null,null,null,null,"RESYNCHRONIZATION-THERAPY; DILATED CARDIOMYOPATHY; DYSSYNCHRONY; ACTIVATION; FAILURE; TRIAL",null,"Univ Leipzig, Ctr Heart, Dept Paediat Cardiol, D-04289 Leipzig, Germany","Janousek, J (reprint author), Univ Leipzig, Ctr Heart, Dept Paediat Cardiol, Strumpellstr 39, D-04289 Leipzig, Germany.","janousek@medizin.uni-leipzig.de",null,null,null,null,"American College of Cardiology/American Heart Association, 2005, J AM COLL CARDIOL, V46, P1116; Chung ES, 2008, CIRCULATION, V117, P2608, DOI 10.1161/CIRCULATIONAHA.107.743120; Diller GP, 2006, EUROPACE, V8, P267, DOI 10.1093/europace/euj048; Dubin AM, 2005, J AM COLL CARDIOL, V46, P2277, DOI 10.1016/j.jacc.2005.05.096; Dubin AM, 2005, J AM COLL CARDIOL, V46, P2290, DOI 10.1016/j.jacc.2005.09.004; Gorcsan J, 2007, J AM COLL CARDIOL, V50, P1476, DOI 10.1016/j.jacc.2007.06.043; Janousek J, 2008, PACE, V31, pS21, DOI 10.1111/j.1540-8159.2008.00949.x; Janousek J, 2004, J CARDIOVASC ELECTR, V15, P470, DOI 10.1046/j.1540-8167.2004.03481.x; JANOUSEK J, 2007, CARDIOL YOUNG S, V17, P16; Kass DA, 2008, J AM COLL CARDIOL, V51, P12, DOI 10.1016/j.jacc.2007.09.027; Khairy P, 2006, INT J CARDIOL, V109, P160, DOI 10.1016/j.ijcard.2005.06.065; Landolina M, 2007, AM J CARDIOL, V100, P1007, DOI 10.1016/j.amjcard.2007.04.043; Nelson GS, 2000, CIRCULATION, V102, P3053; Prinzen FW, 1999, J AM COLL CARDIOL, V33, P1735, DOI 10.1016/S0735-1097(99)00068-6; Rao RK, 2007, CIRCULATION, V115, P2136, DOI 10.1161/CIRCULATIONAHA.106.634444; Swedberg K, 2005, EUR HEART J, V26, P1115, DOI 10.1093/eurheartj/ehi204; TOMASKE M, 2008, INT J CARDIOL   0710; Vanagt WY, 2005, ANN THORAC SURG, V79, P932, DOI 10.1016/j.athoracsur.2004.08.053; van Oosterhout MFM, 1998, CIRCULATION, V98, P588; Wyman BT, 1999, AM J PHYSIOL-HEART C, V276, pH881",20,5,5,"B M J PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","1355-6037",null,null,"HEART","Heart","JUN",2009,95,11,null,null,null,null,940,947,null,"10.1136/hrt.2008.151266",null,8,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","446FH","WOS:000266105600019"]
[null,null,null,null,"J","Topinkova, E; Maresova, V",null,null,null,"Topinkova, Eva; Maresova, Vilma",null,null,"Tetanus and Pertussis vaccines: their usefulness in the aging population","AGING CLINICAL AND EXPERIMENTAL RESEARCH",null,null,"English","Review",null,null,null,null,null,"Aging; pertussis vaccination; tetanus vaccination","UNITED-STATES; BOOSTER VACCINATION; DIPHTHERIA; ADULTS; IMMUNITY; IMMUNIZATION; ADOLESCENTS; NETHERLANDS; TOXOIDS; PREVENTION","Immunization is a safe, effective and simple way of preventing life-threatening tetanus infection in children and adults, and is therefore recommended for all age groups in all European countries. In older persons, despite waning immunity with increasing age, the majority of vaccinees attain protective tetanus immunity under a proper vaccination schedule. Based on the scientific evidence, decennial boosters are recommended for elderly persons who have received primary tetanus vaccination in the past. Until recently, pertussis vaccination was understood as an early childhood intervention. Due to decreasing immunity, re-vaccination of youngsters and adults is recommended and is also considered for seniors 60 years and over. Routine immunization of seniors against pertussis every ten years yields a high level of protection of older individuals, and at the same time contributes to epidemiological control of pertussis in the population. (Aging Clin Exp Res 2009; 21: 229-235) (C) 2009. Editrice Kurtis","[Topinkova, Eva] Charles Univ Prague, Fac Med 1, Dept Geriatr, Prague 12000 2, Czech Republic; [Topinkova, Eva] Charles Univ Prague, Fac Med 1, Gen Teaching Hosp, Prague 12000 2, Czech Republic; [Maresova, Vilma] Charles Univ Prague, Fac Med 2, Dept Infect Dis, Prague 12000 2, Czech Republic","Topinkova, E (reprint author), Charles Univ Prague, Fac Med 1, Dept Geriatr, Londynska 15, Prague 12000 2, Czech Republic.","Topinkova.eva@vfn.cz",null,null,"IGA Ministry of Health, Czech Republic [10029-4]","The work of Prof. Topinkova was supported by a grant of IGA Ministry of Health, Czech Republic No. 10029-4.",null,46,2,3,"EDITRICE KURTIS S R L","MILAN","VIA LUIGI ZOJA 30, 20153 MILAN, ITALY","1594-0667",null,null,"AGING CLIN EXP RES","Aging Clin. Exp. Res.","JUN",2009,21,3,null,null,null,null,229,235,null,null,null,7,"Geriatrics & Gerontology","Geriatrics & Gerontology","466HP","WOS:000267652500006"]
[null,null,null,null,"J","Babjuk, M",null,null,null,"Babjuk, Marko",null,null,"The Search for the Etiology of Bladder Cancer: Are Achievements Sufficient?","EUROPEAN UROLOGY",null,null,"English","Editorial Material",null,null,null,null,null,null,"TOBACCO SMOKING; METAANALYSIS; RISK",null,"[Babjuk, Marko] Charles Univ Prague, Dept Urol, Fac Med 1 & 2, Prague, Czech Republic","Babjuk, M (reprint author), FN Motol, Dept Urol, Uvalu 84, Prague 15006 5, Czech Republic.","babjuk@volny.cz",null,null,null,null,null,10,1,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","NOV",2009,56,5,null,null,null,null,771,772,null,"10.1016/j.eururo.2009.07.014",null,2,"Urology & Nephrology","Urology & Nephrology","512ZZ","WOS:000271292500005"]
[null,null,null,null,"J","James, WPT; Caterson, ID; Coutinho, W; Finer, N; Van Gaal, LF; Maggioni, AP; Torp-Pedersen, C; Sharma, AM; Shepherd, GM; Rode, RA; Renz, CL",null,null,null,"James, W. Philip T.; Caterson, Ian D.; Coutinho, Walmir; Finer, Nick; Van Gaal, Luc F.; Maggioni, Aldo P.; Torp-Pedersen, Christian; Sharma, Arya M.; Shepherd, Gillian M.; Rode, Richard A.; Renz, Cheryl L.",null,"SCOUT Investigators","Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"CORONARY-HEART-DISEASE; PROSPECTIVELY DESIGNED OVERVIEWS; BODY-MASS INDEX; RANDOMIZED-TRIALS; BLOOD-PRESSURE; HIGH-RISK; WEIGHT-REDUCTION; EVENTS; CHOLESTEROL; PREVENTION","BACKGROUND The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P = 0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P = 0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P = 0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause.","[James, W. Philip T.] London Sch Hyg & Trop Med, London, England; [Finer, Nick] UCL, Vasc Physiol Unit, London WC1E 6BT, England; [Caterson, Ian D.] Univ Sydney, Inst Obes Nutr & Exercise, Sydney, NSW 2006, Australia; [Coutinho, Walmir] Pontificia Univ Catolica Rio de Janeiro, Rio De Janeiro, Brazil; [Van Gaal, Luc F.] Univ Antwerp Hosp, Antwerp, Belgium; [Maggioni, Aldo P.] Assoc Nazl Medici Cardiol Osped, Res Ctr, Florence, Italy; [Torp-Pedersen, Christian] Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark; [Sharma, Arya M.] Univ Alberta, Royal Alexandra Hosp, Edmonton, AB, Canada; [Shepherd, Gillian M.; Rode, Richard A.; Renz, Cheryl L.] Abbott Labs, Abbott Pk, IL 60064 USA","James, WPT (reprint author), IASO, 28 Portland Pl, London W1B 1LY, England.","jeanhjames@aol.com","Proietto, Joseph/B-3780-2012; Finer, Nick/B-9981-2009; Torp-Pedersen, Christian/E-5931-2013","Finer, Nick/0000-0003-2468-6804; ","Abbott Laboratories; Pfizer (Australia); Servier Laboratories; Eisai Pharmaceuticals; iNova Pharmaceuticals; Eli Lilly; Sanofi-Aventis; Weight Watchers; Allergan; Ache Laboratorios Farmaceuticos; Roche; Novo Nordisk; Ajinomoto; GlaxoSmithKline; Vivus; Covidien; Neuro-Search","Dr. Caterson reports receiving lecture fees and travel reimbursement from Abbott Laboratories, Pfizer (Australia), Servier Laboratories, Eisai Pharmaceuticals, iNova Pharmaceuticals and Eli Lilly, receiving royalties from Wiley-Blackwell as coeditor of an obesity textbook, and serving on an advisory board for GlaxoSmithKline, and reports that the Boden Institute of Obesity, Nutrition, and Exercise has received grants to conduct clinical trials from Sanofi-Aventis, Pfizer (Australia), Weight Watchers, and Allergan; Dr. Coutinho reports receiving lecture fees from Abbott Laboratories, Ache Laboratorios Farmaceuticos, Roche, and Novo Nordisk, serving on advisory boards for Abbott Laboratories, Ache Laboratorios Farmaceuticos, and Roche, providing expert testimony for Abbott Laboratories, and receiving travel reimbursement from Abbott Laboratories; Dr. Finer reports receiving consulting fees from Ajinomoto, lecture fees from Abbott Laboratories, and travel reimbursement from Abbott Laboratories and Novo Nordisk, serving on advisory boards for Novo Nordisk, Merck, Johnson & Johnson, Sanofi-Aventis, GlaxoSmithKline, and Shionogi, and providing expert testimony for Sanofi-Aventis and reports that Cambridge University received a grant from GlaxoSmithKline; Dr. James reports serving on advisory boards for and receiving travel reimbursement from GlaxoSmithKline; Dr. Renz, Dr. Rode, and Ms. Shepherd report being full-time employees of Abbott Laboratories and having equity interest in the company; Dr. Sharma reports receiving consulting fees from Vivus and Allergan, grants from Abbott Laboratories and Covidien, and fees for developing educational materials for and travel reimbursement from Boehringer Ingelheim, Abbott Laboratories, Novo Nordisk, Allergan, Johnson & Johnson, and Sanofi-Aventis, serving on advisory boards for Abbott Laboratories, Merck, Arena, Novo Nordisk, Sanofi-Aventis, GlaxoSmithKline, Boehringer Ingelheim, and Neuro-Search, and providing expert testimony for GlaxoSmithKline; Dr. Torp-Peder-sen reports receiving consulting fees from Neuro-Search and lecture fees from Abbott Laboratories; and Dr. Van Gaal reports receiving lecture fees from Eli Lilly and Novo Nordisk and travel reimbursement from Abbott Laboratories, AstraZeneca-Bristol-Myers Squibb, Glaxo-SmithKline, Merck, Novo Nordisk and Sanofi-Aventis and serving on advisory boards for Novo Nordisk, GlaxoSmithKline, AstraZeneca-Bristol-Myers Squibb, Eli Lilly, and Merck. No other potential conflict of interest relevant to this article was reported.","Adams TD, 2007, NEW ENGL J MED, V357, P753, DOI 10.1056/NEJMoa066603; Barr ELM DJM, 2006, AUSTR DIABETES OBESI; Turnbull F, 2008, EUR HEART J, V29, P2669, DOI 10.1093/eurheartj/ehn427; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320; Florentin M, 2008, OBES REV, V9, P378, DOI 10.1111/j.1467-789X.2007.00425.x; Fox K, 2008, LANCET, V372, P817, DOI 10.1016/S0140-6736(08)61171-X; Gordon-Larsen P, 2009, AM J CLIN NUTR, V89, P19, DOI 10.3945/ajcn.2008.26147; Gregg EW, 2005, JAMA-J AM MED ASSOC, V294, P182; Halford JCG, 2010, J PSYCHOPHARMACOL, V24, P99, DOI 10.1177/0269881108095195; Collins R, 2002, LANCET, V360, P7; Heitmann BL, 1999, INT J OBESITY, V23, P1074, DOI 10.1038/sj.ijo.0801035; Heusser K, 2006, CLIN PHARMACOL THER, V79, P500, DOI 10.1016/j.clpt.2006.02.002; *INT ASS STUD OB, INT OB TASKF PREV DA; James WPT, 2005, EUR HEART J SUPPL, V7, pL44, DOI 10.1093/eurheartj/sui086; Johansson K, 2009, OBES REV, V10, P564, DOI 10.1111/j.1467-789X.2009.00581.x; LAWES C, 2005, CORONARY HEART DIS E, P152; Lean M, 2006, BRIT MED J, V333, P794, DOI 10.1136/bmj.333.7572.794; LEAN MEJ, 1986, LANCET, V1, P723; Lyznicki JM, 2001, AM FAM PHYSICIAN, V63, P2185; Mallinckrodt CH, 2008, DRUG INF J, V42, P303; McPherson K, 2007, FORESIGHT TACKLING O; Ness AR, 2002, J EPIDEMIOL COMMUN H, V56, P218, DOI 10.1136/jech.56.3.218; Palatini P, 2009, PROG CARDIOVASC DIS, V52, P1, DOI 10.1016/j.pcad.2009.06.001; Palatini P, 2006, J HYPERTENS, V24, P603, DOI 10.1097/01.hjh.0000217838.49842.1e; Patel MR, 2006, AM HEART J, V151, P633, DOI 10.1016/j.ahj.2005.03.006; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; PEDERSEN TR, 1994, LANCET, V344, P1383; Sever PS, 2005, AM J CARDIOL, V96, p39F, DOI 10.1016/j.amjcard.2005.06.025; Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Torp-Pedersen C, 2007, EUR HEART J, V28, P2915, DOI 10.1093/eurheartj/ehm217; TUCK ML, 1981, NEW ENGL J MED, V304, P930, DOI 10.1056/NEJM198104163041602; Turnbull F, 2008, BRIT MED J, V336, P1121, DOI 10.1136/bmj.39548.738368.BE; Turnbull F, 2005, ARCH INTERN MED, V165, P1410; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Wing RR, 2001, ANNU REV NUTR, V21, P323, DOI 10.1146/annurev.nutr.21.1.323; 1996, CAN J CARDIOL, V12, P127",37,199,206,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","SEP 2",2010,363,10,null,null,null,null,905,917,null,"10.1056/NEJMoa1003114",null,13,"Medicine, General & Internal","General & Internal Medicine","645GW","WOS:000281441500004"]
[null,null,null,null,"J","Kappos, L; Radue, EW; O'Connor, P; Polman, C; Hohlfeld, R; Calabresi, P; Selmaj, K; Agoropoulou, C; Leyk, M; Zhang-Auberson, L; Burtin, P",null,null,null,"Kappos, Ludwig; Radue, Ernst-Wilhelm; O'Connor, Paul; Polman, Chris; Hohlfeld, Reinhard; Calabresi, Peter; Selmaj, Krzysztof; Agoropoulou, Catherine; Leyk, Malgorzata; Zhang-Auberson, Lixin; Burtin, Pascale",null,"FREEDOMS Study Grp","A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"SPHINGOSINE 1-PHOSPHATE RECEPTORS; CENTRAL-NERVOUS-SYSTEM; PHASE-II EXTENSION; FTY720; AGONISTS; IMMUNE","BACKGROUND Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end points measured on magnetic resonance imaging (MRI), as compared with either placebo or intramuscular interferon beta-1a, in phase 2 and 3 studies of multiple sclerosis. METHODS In our 24-month, double-blind, randomized study, we enrolled patients who had relapsing-remitting multiple sclerosis, were 18 to 55 years of age, had a score of 0 to 5.5 on the Expanded Disability Status Scale ( which ranges from 0 to 10, with higher scores indicating greater disability), and had had one or more relapses in the previous year or two or more in the previous 2 years. Patients received oral fingolimod at a dose of 0.5 mg or 1.25 mg daily or placebo. End points included the annualized relapse rate ( the primary end point) and the time to disability progression ( a secondary end point). RESULTS A total of 1033 of the 1272 patients (81.2%) completed the study. The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0.001 for either dose vs. placebo). Fingolimod at doses of 0.5 mg and 1.25 mg significantly reduced the risk of disability progression over the 24-month period (hazard ratio, 0.70 and 0.68, respectively; P = 0.02 vs. placebo, for both comparisons). The cumulative probability of disability progression (confirmed after 3 months) was 17.7% with 0.5 mg of fingolimod, 16.6% with 1.25 mg of fingolimod, and 24.1% with placebo. Both fingolimod doses were superior to placebo with regard to MRI-related measures (number of new or enlarged lesions on T(2)-weighted images, gadolinium-enhancing lesions, and brain-volume loss; P<0.001 for all comparisons at 24 months). Causes of study discontinuation and adverse events related to fingolimod included bradycardia and atrioventricular conduction block at the time of fingolimod initiation, macular edema, elevated liver-enzyme levels, and mild hypertension. CONCLUSIONS As compared with placebo, both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI. These benefits will need to be weighed against possible long-term risks.","[Kappos, Ludwig] Univ Basel, Univ Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Kappos, Ludwig] Univ Basel, Univ Hosp, Dept Biomed, CH-4031 Basel, Switzerland; [Radue, Ernst-Wilhelm] Univ Basel, Univ Hosp, Med Image Anal Ctr, CH-4031 Basel, Switzerland; [Agoropoulou, Catherine; Leyk, Malgorzata; Zhang-Auberson, Lixin; Burtin, Pascale] Novartis Pharmaceut, Basel, Switzerland; [Polman, Chris] Free Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [O'Connor, Paul] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Hohlfeld, Reinhard] Inst Klin Neuroimmunol, Munich, Germany; [Calabresi, Peter] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; [Selmaj, Krzysztof] Med Univ Lodz, Lodz, Poland","Kappos, L (reprint author), Univ Basel, Univ Hosp, Dept Neurol, CH-4031 Basel, Switzerland.","lkappos@uhbs.ch","Weissert, Robert/B-2585-2009","Weissert, Robert/0000-0002-1295-1271","Novartis Pharma; Accorda; Actelion; Allergan; Allozyne; Bayer Schering; Biogen Idec; Biogen-Dompe; Boehringer Ingelheim; Genmab; GlaxoSmithKline; Medicinova; Merck Serono; Novartis; Roche; Sanofi Aventis; Santhera; Teva Pharmaceuticals; UCB Pharma; Wyeth; Helvea; Mediservice; CSL Behring; European Community; Genzyme; Novartis Foundation; Rubato Foundation; Antisense Therapeutics; Teva; Genetech; Vertex; Ono Pharma","Supported by Novartis Pharma.Financial and other disclosures provided by the authors are available with the full text of this article at NEJM.org. Dr. Kappos reports receiving consulting or advisory fees from Accorda, Actelion, Allergan, Allozyne, Bayer Schering, Biogen Idec, Biogen-Dompe, Boehringer Ingelheim, Genmab, GlaxoSmithKline, Medicinova, Merck Serono, Novartis, Roche, Sanofi Aventis, Santhera, Teva Pharmaceuticals, UCB Pharma, and Wyeth; lecture fees from Biogen Idec, Helvea, GlaxoSmithKline, Mediservice, and Merck Serono; and grant support from Bayer Schering, Biogen Idec, CSL Behring, the European Community Research Fund, Genmab, Genzyme, GlaxoSmithKline, Medicinova, Merck Serono, Novartis, Novartis Foundation, the Rubato Foundation, Roche, Santhera, Sanofi Aventis, and UCB Pharma; Dr. Radue, receiving consulting or advisory fees from Actelion, Biogen Idec, Novartis, and Merck Serono and lecture fees from Actelion and Merck Serono; Dr. O'Connor, receiving consulting or advisory fees and grant support from Novartis; Dr. Polman, receiving consulting or lecture fees from Actelion, Antisense Therapeutics, Biogen Idec, Bayer Schering, GlaxoSmithKline, Merck Serono, Novartis, Roche, Teva, and UCB Pharma and grant support from Bayer Schering, Biogen Idec, GlaxoSmithKline, Merck Serono, Novartis, Teva, and UCB Pharma; Dr. Hohlfeld, receiving consulting, advisory, or lecture fees from Bayer, Biogen Idec, Novartis, Sanofi Aventis, and Teva and grant support from Novartis; Dr. Calabresi, receiving consulting fees from Biogen Idec, Genetech, Merck Serono, Novartis, Teva, and Vertex; lecture fees from Novartis; and grant support from Bayer Schering, Biogen Idec, Genetech, Merck Serono, Teva, and Vertex; Dr. Selmaj, receiving advisory fees from Biogen Idec, Genzyme, Ono Pharma, and Novartis and lecture fees from Biogen Idec, Merck Serono, and Genzyme; and Drs Agoropoulou, Leyk, Zhang-Auderson and Burtin report being employees of Novartis Pharma. No other potential conflict of interest relevant to this article was reported. Financial and other disclosures provided by the authors are available with the full text of this article at NEJM.org.","[Anonymous], ICH HARM TRIP GUID G; [Anonymous], 2006, DECL HELS ETH PRINC; Barkhof F, 2009, NAT REV NEUROL, V5, P256, DOI 10.1038/nrneurol.2009.41; Barske C, 2008, NEUROLOGY, V70, pA28; Bartholomaus I, 2009, NATURE, V462, P94, DOI 10.1038/nature08478; Brinkmann V, 2009, BRIT J PHARMACOL, V158, P1173, DOI 10.1111/j.1476-5381.2009.00451.x; Brinkmann V, 2007, PHARMACOL THERAPEUT, V115, P84, DOI 10.1016/j.pharmthera.2007.04.006; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C220176200; Coelho RP, 2007, J PHARMACOL EXP THER, V323, P626, DOI 10.1124/jpet.107.123927; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Foster CA, 2007, J PHARMACOL EXP THER, V323, P469, DOI 10.1124/jpet.107.127183; Jackson SJ, 2009, NEUROLOGY, V72, pA377; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kappos L, 2009, J NEUROL, V256, pS9; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; KURTZKE JF, 1983, NEUROLOGY, V33, P1444; Lublin FD, 1996, NEUROLOGY, V46, P907; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Marsolais D, 2009, NAT REV DRUG DISCOV, V8, P297, DOI 10.1038/nrd2356; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Miron VE, 2008, ANN NEUROL, V63, P61, DOI 10.1002/ana.21227; *NAT MULT SCLER SO, ADM SCOR MAN MULT SC; *NEUR, 2006, NEUR TRAIN DOC DVD S; O'Connor P, 2009, NEUROLOGY, V72, P73, DOI 10.1212/01.wnl.0000338569.32367.3d; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.206703; Rudick RA, 2009, MULT SCLER, V15, P984, DOI 10.1177/1352458509106212; Schmouder R, 2006, J CLIN PHARMACOL, V46, P895, DOI 10.1177/0091270006289853",28,516,527,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","FEB 4",2010,362,5,null,null,null,null,387,401,null,"10.1056/NEJMoa0909494",null,15,"Medicine, General & Internal","General & Internal Medicine","551FV","WOS:000274193300005"]
[null,null,null,null,"J","Cirstea, IC; Kutsche, K; Dvorsky, R; Gremer, L; Carta, C; Horn, D; Roberts, AE; Lepri, F; Merbitz-Zahradnik, T; Konig, R; Kratz, CP; Pantaleoni, F; Dentici, ML; Joshi, VA; Kucherlapati, RS; Mazzanti, L; Mundlos, S; Patton, MA; Silengo, MC; Rossi, C; Zampino, G; Digilio, C; Stuppia, L; Seemanova, E; Pennacchio, LA; Gelb, BD; Dallapiccola, B; Wittinghofer, A; Ahmadian, MR; Tartaglia, M; Zenker, M",null,null,null,"Cirstea, Ion C.; Kutsche, Kerstin; Dvorsky, Radovan; Gremer, Lothar; Carta, Claudio; Horn, Denise; Roberts, Amy E.; Lepri, Francesca; Merbitz-Zahradnik, Torsten; Koenig, Rainer; Kratz, Christian P.; Pantaleoni, Francesca; Dentici, Maria L.; Joshi, Victoria A.; Kucherlapati, Raju S.; Mazzanti, Laura; Mundlos, Stefan; Patton, Michael A.; Silengo, Margherita Cirillo; Rossi, Cesare; Zampino, Giuseppe; Digilio, Cristina; Stuppia, Liborio; Seemanova, Eva; Pennacchio, Len A.; Gelb, Bruce D.; Dallapiccola, Bruno; Wittinghofer, Alfred; Ahmadian, Mohammad R.; Tartaglia, Marco; Zenker, Martin",null,null,"A restricted spectrum of NRAS mutations causes Noonan syndrome","NATURE GENETICS",null,null,"English","Article",null,null,null,null,null,null,"RAS PROTEINS; DISORDERS; CANCER; SWITCH; KRAS","Noonan syndrome, a developmental disorder characterized by congenital heart defects, reduced growth, facial dysmorphism and variable cognitive deficits, is caused by constitutional dysregulation of the RAS-MAPK signaling pathway. Here we report that germline NRAS mutations conferring enhanced stimulus-dependent MAPK activation account for some cases of this disorder. These findings provide evidence for an obligate dependency on proper NRAS function in human development and growth.","[Wittinghofer, Alfred; Zenker, Martin] Max Planck Inst Mol Physiol, Dept Biol Struct, D-44139 Dortmund, Germany; [Cirstea, Ion C.; Dvorsky, Radovan; Gremer, Lothar; Merbitz-Zahradnik, Torsten; Ahmadian, Mohammad R.] Univ Dusseldorf, Med Ctr, Inst Biochem & Mol Biol 2, Dusseldorf, Germany; [Kutsche, Kerstin] Univ Klinikum Hamburg Eppendorf, Inst Humangenet, Hamburg, Germany; [Carta, Claudio; Pantaleoni, Francesca; Tartaglia, Marco] Ist Super Sanita, Dipartimento Ematol Oncol & Med Mol, I-00161 Rome, Italy; [Horn, Denise; Mundlos, Stefan] Charite, Inst Med Genet, D-13353 Berlin, Germany; [Roberts, Amy E.; Joshi, Victoria A.; Kucherlapati, Raju S.] Harvard Univ, Sch Med, Boston, MA USA; [Roberts, Amy E.] Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; [Lepri, Francesca; Dentici, Maria L.; Dallapiccola, Bruno] Ist Ricovero & Cura Carattere Sci Casa Sollievo S, San Giovanni Rotondo, Italy; [Lepri, Francesca; Dentici, Maria L.; Dallapiccola, Bruno] Casa Sollievo Sofferenza Ist Mendel, Rome, Italy; [Koenig, Rainer] Goethe Univ Frankfurt, Inst Human Genet, Frankfurt, Germany; [Kratz, Christian P.] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, Rockville, MD USA; [Kratz, Christian P.] Univ Freiburg, Dept Paediat & Adolescent Med, Freiburg, Germany; [Joshi, Victoria A.] Partners HealthCare Ctr Personalized Genet Med, Boston, MA USA; [Joshi, Victoria A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Mazzanti, Laura] Univ Bologna, Dipartimento Pediat, Bologna, Italy; [Patton, Michael A.] Univ London St Georges Hosp, Dept Clin Genet, London, England; [Silengo, Margherita Cirillo] Univ Turin, Dipartimento Pediat, Turin, Italy; [Rossi, Cesare] St Orsola Marcello Malpighi Hosp, Unita Operat Genet Med, Bologna, Italy; [Zampino, Giuseppe] Univ Cattolica Sacro Cuore, Ist Clin Pediat, Rome, Italy; [Digilio, Cristina] Bambino Gesu Pediat Hosp, Sez Genet Med, Rome, Italy; [Stuppia, Liborio] Univ G DAnnunzio, Dipartimento Sci Biomed, Chieti, Italy; [Seemanova, Eva] Charles Univ Prague, Univ Hosp Prague, Inst Biol & Med Genet, Prague, Czech Republic; [Pennacchio, Len A.] Univ Calif Berkeley, Lawrence Berkeley Lab, Genom Div, Berkeley, CA 94720 USA; [Pennacchio, Len A.] US DOE, Joint Genome Inst, Walnut Creek, CA USA; [Gelb, Bruce D.] Mt Sinai Sch Med, Ctr Mol Cardiol, New York, NY USA; [Gelb, Bruce D.] Mt Sinai Sch Med, Dept Pediat, New York, NY USA; [Gelb, Bruce D.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA; [Zenker, Martin] Univ Erlangen Nurnberg, Inst Human Genet, Univ Hosp Erlangen, D-8520 Erlangen, Germany; [Zenker, Martin] Otto Von Guericke Univ, Univ Hosp Magdeburg, Inst Human Genet, Magdeburg, Germany","Zenker, M (reprint author), Max Planck Inst Mol Physiol, Dept Biol Struct, Rheinlanddamm 201, D-44139 Dortmund, Germany.","reza.ahmadian@uni-duesseldorf.de; mtartaglia@iss.it; martin.zenker@med.ovgu.de","Carta, Claudio/A-7305-2013; Gremer, Lothar/H-9128-2013","Gremer, Lothar/0000-0001-7065-5027","European Research Area Network; German Research Foundation (DFG) [AH 92/5-1, KR 3473/1-1, ZE 524/4-1]; German Ministry of Science and Education [01GS08100]; Telethon-Italy [GGP07115]; Associazione Italiana Sindromi di Costello e Cardiofaciocutanea; Collaborazione Italia-USA/malattie rare","We are grateful to the subjects and their families for participating in this study. We thank A. Diem and B. Quinger (Institute of Human Genetics, Erlangen, Germany), T. Squatriti and S. Venanzi (Istituto Superiore di Sanita, Rome, Italy) and I. Jantke and S. Lorenz (Institut fur Humangenetik, Hamburg, Germany) for skillful technical assistance. The X-ray diffraction datasets were collected at the Swiss Light Source, beamline X10SA, Paul Scherrer Institut, Villigen, Switzerland. This work was supported by grants from the European Research Area Network for research programs on rare diseases (E-Rare) 2009 to M. T., M. Z. and M. R. A. (European Network on Noonan Syndrome and Related Disorders), German Research Foundation (DFG) to M. R. A. (AH 92/5-1) and C. P. K. and M. Z. (KR 3473/1-1 and ZE 524/4-1), Nationales Genomforschungsnetz Plus program of the German Ministry of Science and Education to M. R. A. (BMBF, grant 01GS08100), and Telethon-Italy (GGP07115), 'Associazione Italiana Sindromi di Costello e Cardiofaciocutanea' and 'Collaborazione Italia-USA/malattie rare' to M. T.",null,14,75,76,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","1061-4036",null,null,"NAT GENET","Nature Genet.","JAN",2010,42,1,null,null,null,null,27,29,null,"10.1038/ng.497",null,3,"Genetics & Heredity","Genetics & Heredity","536PA","WOS:000273055100012"]
[null,null,null,null,"J","Niemeyer, CM; Kang, MW; Shin, DH; Furlan, I; Erlacher, M; Bunin, NJ; Bunda, S; Finklestein, JZ; Sakamoto, KM; Gorr, TA; Mehta, P; Schmid, I; Kropshofer, G; Corbacioglu, S; Lang, PJ; Klein, C; Schlegel, PG; Heinzmann, A; Schneider, M; Stary, J; van den Heuvel-Eibrink, MM; Hasle, H; Locatelli, F; Sakai, D; Archambeault, S; Chen, L; Russell, RC; Sybingco, SS; Ohh, M; Braun, BS; Flotho, C; Loh, ML",null,null,null,"Niemeyer, Charlotte M.; Kang, Michelle W.; Shin, Danielle H.; Furlan, Ingrid; Erlacher, Miriam; Bunin, Nancy J.; Bunda, Severa; Finklestein, Jerry Z.; Sakamoto, Kathleen M.; Gorr, Thomas A.; Mehta, Parinda; Schmid, Irene; Kropshofer, Gabriele; Corbacioglu, Selim; Lang, Peter J.; Klein, Christoph; Schlegel, Paul-Gerhard; Heinzmann, Andrea; Schneider, Michaela; Stary, Jan; van den Heuvel-Eibrink, Marry M.; Hasle, Henrik; Locatelli, Franco; Sakai, Debbie; Archambeault, Sophie; Chen, Leslie; Russell, Ryan C.; Sybingco, Stephanie S.; Ohh, Michael; Braun, Benjamin S.; Flotho, Christian; Loh, Mignon L.",null,null,"Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia","NATURE GENETICS",null,null,"English","Article",null,null,null,null,null,null,"GENOTYPE-PHENOTYPE CORRELATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; GAIN-OF-FUNCTION; C-CBL; MYELOPROLIFERATIVE DISORDER; HEMATOPOIETIC-CELLS; PTPN11 MUTATIONS; NOONAN-SYNDROME","CBL encodes a member of the Cbl family of proteins, which functions as an E3 ubiquitin ligase. We describe a dominant developmental disorder resulting from germline missense CBL mutations, which is characterized by impaired growth, developmental delay, cryptorchidism and a predisposition to juvenile myelomonocytic leukemia (JMML). Some individuals experienced spontaneous regression of their JMML but developed vasculitis later in life. Importantly, JMML specimens from affected children show loss of the normal CBL allele through acquired isodisomy. Consistent with these genetic data, the common p.371Y>H altered Cbl protein induces cytokine-independent growth and constitutive phosphorylation of ERK, AKT and S6 only in hematopoietic cells in which normal Cbl expression is reduced by RNA interference. We conclude that germline CBL mutations have developmental, tumorigenic and functional consequences that resemble disorders that are caused by hyperactive Ras/Raf/MEK/ERK signaling and include neurofibromatosis type 1, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome and Legius syndrome.","[Kang, Michelle W.; Shin, Danielle H.; Sakai, Debbie; Archambeault, Sophie; Chen, Leslie; Braun, Benjamin S.; Loh, Mignon L.] Univ Calif San Francisco, Dept Pediat, Ctr Comprehens Canc, San Francisco, CA 94143 USA; [Niemeyer, Charlotte M.; Furlan, Ingrid; Erlacher, Miriam; Gorr, Thomas A.; Heinzmann, Andrea; Schneider, Michaela; Flotho, Christian] Univ Freiburg, Dept Pediat & Adolescent Med, Freiburg, Germany; [Bunin, Nancy J.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Bunda, Severa; Russell, Ryan C.; Sybingco, Stephanie S.; Ohh, Michael] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Finklestein, Jerry Z.] Miller Childrens Hosp Harbor UCLA, Jonathan Jaques Canc Ctr, Long Beach, CA USA; [Sakamoto, Kathleen M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Pediat, Los Angeles, CA 90095 USA; [Mehta, Parinda] Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Cincinnati, OH USA; [Schmid, Irene] LMU Munich Univ, von Hauner Childrens Hosp, Munich, Germany; [Kropshofer, Gabriele] Med Univ, Dept Pediat & Adolescent Med, Innsbruck, Austria; [Corbacioglu, Selim] Univ Ulm, Dept Pediat, D-7900 Ulm, Germany; [Lang, Peter J.] Univ Tubingen, Dept Pediat, Tubingen, Germany; [Klein, Christoph] Hannover Med Sch, Dept Pediat, D-3000 Hannover, Germany; [Schlegel, Paul-Gerhard] Univ Wurzburg, Dept Pediat, Wurzburg, Germany; [Stary, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [van den Heuvel-Eibrink, Marry M.] Erasmus MC, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Hasle, Henrik] Aarhus Univ, Hosp Skejby, Dept Pediat, Aarhus, Denmark; [Locatelli, Franco] Univ Pavia, Dept Pediat Hematol & Oncol, IRCCS Osped Bambino Gesu, Rome, Italy","Loh, ML (reprint author), Univ Calif San Francisco, Dept Pediat, Ctr Comprehens Canc, San Francisco, CA 94143 USA.","charlotte.niemeyer@uniklinik-freiburg.de; lohm@peds.ucsf.edu",null,null,"US National Institutes of Health [CA113557]; V Foundation for Cancer Research; NIH/NCI [K08 CA103868, R01 CA104282]; Leukemia Lymphoma Society [6059-09, 2157-08]; Frank A. Campini Foundation; Concern Foundation; Deutsche Forschungsgemeinschaft [KR3473/1-1]; Deutsche Krebshilfe [108220]; Deutsche Jose Carreras Leukamie-Stiftung [R08/19]; Canadian Cancer Society [16056]; National Institute of General Medical Sciences [T32GM007618]","We gratefully acknowledge the generous participation of the families included in this report. Supported in part by the US National Institutes of Health (CA113557 to M. L. L.); the V Foundation for Cancer Research (M. L. L. and B. S. B.); NIH/NCI (K08 CA103868 to B. S. B., R01 CA104282 to M. L. L. and B. S. B.); The Leukemia Lymphoma Society (6059-09, 2157-08 to M. L. L.); the Frank A. Campini Foundation (M. L. L. and B. S. B.); The Concern Foundation (B. S. B.); Deutsche Forschungsgemeinschaft (KR3473/1-1 to C. F.); Deutsche Krebshilfe (108220 to C.M.N. and C. F.); Deutsche Jose Carreras Leukamie-Stiftung (R08/19 to C. F.); the Canadian Cancer Society (16056 to M.O.); and the National Institute of General Medical Sciences (T32GM007618 to D. H. S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.",null,50,58,59,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","1061-4036",null,null,"NAT GENET","Nature Genet.","SEP",2010,42,9,null,null,null,null,794,"U93",null,"10.1038/ng.641",null,8,"Genetics & Heredity","Genetics & Heredity","644OM","WOS:000281388400018"]
[null,null,null,null,"J","McCormick, J; Mehta, G; Olesen, HV; Viviani, L; Macek, M; Mehta, A",null,null,null,"McCormick, Jonathan; Mehta, Gita; Olesen, Hanne V.; Viviani, Laura; Macek, Milan, Jr.; Mehta, Anil",null,"European Registry Working Grp","Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis","LANCET",null,null,"English","Article",null,null,null,null,null,null,"MORTALITY; AGE; OUTCOMES; UK","Background Country-specific patients' registries are rarely used to make international comparisons because of protocol discrepancies in data collation. We present data from a European cystic fibrosis registry that is dedicated to collection of demographic data, and assess whether the resources available in countries with and without European Union (EU) membership affects care and survival of patients. Methods Data for demographic indicators age, age at diagnosis, sex, and genotype for patients with cystic fibrosis from 35 European countries were combined, and used to establish the differences in demographic indicators between EU and non-EU countries. EU membership status in 2003 was used to divide countries. We modelled demographic indicators of EU countries on non-EU countries to estimate the size of the cystic fibrosis population if non-EU countries had had the same resources available for patients as did EU countries. Findings Data were gathered for 29 025 patients, who had a median age of 16.3 years (IQR 8.9-24.8), with a difference of 4.9 years (95% CI 4.4-5.1; p<0.0001) between EU (median 17.0 years, IQR 9.5-25.6) and non-EU countries (12.1 years, 6.0-19.2). The proportion of patients older than 40 years was higher in EU countries (1205 [5%]) than in non-EU countries (76 [2%]), with an odds ratio of 2.4 (95% CI 1.9-3.0, p<0.0001). We estimated that the cystic fibrosis population in non-EU countries would increase by 84% if patients had a demographic profile comparable to that of patients in EU countries. Interpretation Future studies need to establish the reasons for the lower proportion of patients with cystic fibrosis in non-EU countries than in EU countries, such as underdiagnosis and premature childhood mortality.","[McCormick, Jonathan] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Acad Clin Practice, Div Clin Populat Sci & Educ, Dundee DD1 9SY, Scotland; [Mehta, Gita; Mehta, Anil] Univ Dundee, Ninewells Hosp & Med Sch, Div Med Sci, Coll Med Dent & Nursing, Dundee DD1 9SY, Scotland; [Olesen, Hanne V.] Aarhus Univ Hosp, Cyst Fibrosis Ctr Aarhus, DK-8000 Aarhus, Denmark; [Viviani, Laura] Univ Milan, Dipartimento Med Lavoro, Clin Lavoro Luigi Devoto, Sez Stat Med & Biometria GA Maccacaro, Milan, Italy; [Macek, Milan, Jr.] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic; [Macek, Milan, Jr.] Univ Hosp Motol, Prague, Czech Republic","McCormick, J (reprint author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Acad Clin Practice, Div Clin Populat Sci & Educ, MACHS Bldg, Dundee DD1 9SY, Scotland.","jonathan.mccormick@nhs.net","Kahre, Tiina/D-6198-2012; Viviani, Laura/A-4787-2010",null,"European Community [LSHM-CT-2005-018932]; Czech Ministry of Health [MZOFNM2005, 9448/3]","EuroCareCF was supported by the European Community's Sixth Framework Programme for Research, priority one Life Sciences, Genomics and Biotechnology for Health (contract number LSHM-CT-2005-018932) which supported GM and Margaret Fraser; we thank Margaret Fraser for expert data validation. MM was supported by grants from the Czech Ministry of Health (local grant number MZOFNM2005, and Internal Grant Agency [IGA] number 9448/3). We thank David Sheppard, Scientific Coordinator of EuroCareCF; and all the cystic fibrosis patient groups, the legal and ethics experts of EuroCareCF, and the US Cystic Fibrosis Foundation for their support.",null,23,26,26,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0140-6736",null,null,"LANCET","Lancet","MAR 20",2010,375,9719,null,null,null,null,1007,1013,null,null,null,7,"Medicine, General & Internal","General & Internal Medicine","575YU","WOS:000276110700033"]
[null,null,null,null,"J","Bohm, M; Baumhakel, M; Teo, K; Sleight, P; Probstfield, J; Gao, P; Mann, JF; Diaz, R; Dagenais, GR; Jennings, GLR; Liu, LS; Jansky, P; Yusuf, S",null,null,null,"Boehm, Michael; Baumhaekel, Magnus; Teo, Koon; Sleight, Peter; Probstfield, Jeffrey; Gao, Peggy; Mann, Johannes F.; Diaz, Rafael; Dagenais, Gilles R.; Jennings, Garry L. R.; Liu, Lisheng; Jansky, Petr; Yusuf, Salim",null,"ONTARGET TRANSCEND Erectile Dysfun","Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials","CIRCULATION",null,null,"English","Article",null,null,null,null,null,"trials; erectile dysfunction; cardiovascular diseases; drugs","ENDOTHELIAL PROGENITOR CELLS; CONVERTING-ENZYME-INHIBITORS; CORONARY-HEART-DISEASE; SEXUAL FUNCTION; ANGIOTENSIN-II; VASCULAR-DISEASE; MEN; HYPERTENSION","Background-Although erectile dysfunction (ED) is associated with cardiovascular risk factors and atherosclerosis, it is not known whether the presence of ED is predictive of future events in individuals with cardiovascular disease. We evaluated whether ED is predictive of mortality and cardiovascular outcomes, and because inhibition of the renin-angiotensin system in high-risk patients reduces cardiovascular events, we also tested the effects on ED of randomized treatments with telmisartan, ramipril, and the combination of the 2 drugs (ONTARGET), as well as with telmisartan or placebo in patients who were intolerant of angiotensin-converting enzyme inhibitors (TRANSCEND). Methods and Results-In a prespecified substudy, 1549 patients underwent double-blind randomization, with 400 participants assigned to receive ramipril, 395 telmisartan, and 381 the combination thereof (ONTARGET), as well as 171 participants assigned to receive telmisartan and 202 placebo (TRANSCEND). ED was evaluated at baseline, at 2-year follow-up, and at the penultimate visit before closeout. ED was predictive of all-cause death (hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.21 to 2.81, P=0.005) and the composite primary outcome (HR 1.42, 95% CI 1.04 to 1.94, P=0.029), which consisted of cardiovascular death (HR 1.93, 95% CI 1.13 to 3.29, P=0.016), myocardial infarction (HR 2.02, 95% CI 1.13 to 3.58, P=0.017), hospitalization for heart failure (HR 1.2, 95% CI 0.64 to 2.26, P=0.563), and stroke (HR 1.1, 95% CI 0.64 to 1.9, P=0.742). The study medications did not influence the course or development of ED. Conclusions-ED is a potent predictor of all-cause death and the composite of cardiovascular death, myocardial infarction, stroke, and heart failure in men with cardiovascular disease. Trial treatment did not significantly improve or worsen ED. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT 00153101. (Circulation. 2010; 121: 1439-1446.)","[Boehm, Michael; Baumhaekel, Magnus] Univ Saarland, Dept Cardiol, D-6600 Saarbrucken, Germany; [Teo, Koon; Gao, Peggy; Yusuf, Salim] McMaster Univ Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; [Sleight, Peter] Univ Oxford, Oxford, England; [Probstfield, Jeffrey] Univ Washington, Sch Med, Seattle, WA USA; [Mann, Johannes F.] Schwabing Gen Hosp, Dept Nephrol Hypertens & Rheumatol, Munich, Germany; [Diaz, Rafael] Inst Cardiovasc Rosario, Dept Cardiol, Rosario, Santa Fe, Argentina; [Dagenais, Gilles R.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Jennings, Garry L. R.] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia; [Liu, Lisheng] Chinese Hypertens League Inst, Beijing, Peoples R China; [Jansky, Petr] Motol Univ Hosp, Dept Internal Med, Prague, Czech Republic","Bohm, M (reprint author), Univ Klinkum Saarlandes, Klin Innere Med Kardiol Angiol & Internist Intens, Kirrberger Str 1, D-66424 Homburg, Germany.","boehm@uks.eu","Jennings, Garry/B-3914-2009; Bohm, Michael/C-3638-2011",null,"Boehringer-Ingelheim, Germany","The ONTARGET/TRANSCEND Erectile Dysfunction Substudy was supported by Boehringer-Ingelheim, Germany.",null,28,59,63,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322",null,null,"CIRCULATION","Circulation","MAR 30",2010,121,12,null,null,null,null,1439,"U114",null,"10.1161/CIRCULATIONAHA.109.864199",null,10,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","Cardiovascular System & Cardiology","575RD","WOS:000276084400009"]
[null,null,null,null,"J","Baumgartner, H; Bonhoeffer, P; De Groot, NMS; de Haan, F; Deanfield, JE; Galie, N; Gatzoulis, MA; Gohlke-Baerwolf, C; Kaemmerer, H; Kilner, P; Meijboom, F; Mulder, BJM; Oechslin, E; Oliver, JM; Serraf, A; Szatmari, A; Thaulow, E; Vouhe, PR; Walma, E",null,null,null,"Baumgartner, Helmut; Bonhoeffer, Philipp; De Groot, Natasja M. S.; de Haan, Fokko; Deanfield, John Erik; Galie, Nazzareno; Gatzoulis, Michael A.; Gohlke-Baerwolf, Christa; Kaemmerer, Harald; Kilner, Philip; Meijboom, Folkert; Mulder, Barbara J. M.; Oechslin, Erwin; Oliver, Jose M.; Serraf, Alain; Szatmari, Andras; Thaulow, Erik; Vouhe, Pascal R.; Walma, Edmond",null,"ESC","ESC Guidelines for the management of grown-up congenital heart disease (new version 2010)","EUROPEAN HEART JOURNAL",null,null,"English","Article",null,null,null,null,null,"Congenital heart disease; Guidelines; Treatment","VENTRICULAR SEPTAL-DEFECT; AORTOPULMONARY COLLATERAL ARTERIES; CARDIOVASCULAR MAGNETIC-RESONANCE; SUPRAVALVULAR AORTIC-STENOSIS; PULMONARY VALVE-REPLACEMENT; SUDDEN CARDIAC DEATH; TERM FOLLOW-UP; PATENT DUCTUS-ARTERIOSUS; SYSTEMIC RIGHT VENTRICLE; 2ND NATURAL-HISTORY",null,"[Baumgartner, Helmut] Univ Hosp Muenster, Dept Cardiol & Angiol, Adult Congenital & Valvular Heart Dis Ctr, EMAH Zentrum, D-48149 Munster, Germany","Baumgartner, H (reprint author), Univ Hosp Muenster, Dept Cardiol & Angiol, Adult Congenital & Valvular Heart Dis Ctr, EMAH Zentrum, Albert Schweitzer Str 33, D-48149 Munster, Germany.","helmut.baumgartner@ukmuenster.de","McDonagh, Theresa/G-5091-2011",null,null,null,"Abrams DJ, 2007, CIRCULATION, V115, P1738, DOI 10.1161/CIRCULATIONAHA.106.633982; Agnoletti G, 2008, J THORAC CARDIOV SUR, V135, P568, DOI 10.1016/j.jtcvs.2007.10.020; Alghamdi AA, 2006, ANN THORAC SURG, V81, P1529, DOI 10.1016/j.athoracsur.2005.09.035; Amin Z, 2004, CATHETER CARDIO INTE, V63, P496, DOI 10.1002/ccd.20211; Ammash N, 1996, J AM COLL CARDIOL, V28, P768, DOI 10.1016/0735-1097(96)00196-9; Attie F, 2001, J AM COLL CARDIOL, V38, P2035, DOI 10.1016/S0735-1097(01)01635-7; AVILA WS, 1995, EUR HEART J, V16, P460; Babu-Narayan SV, 2006, CIRCULATION, V113, P405, DOI 10.1161/CIRCULATIONAHA.105.548727; Bassett AS, 2005, AM J MED GENET A, V138A, P307, DOI 10.1002/ajmg.a.30984; Baumgartner H, 2009, EUR J ECHOCARDIOGR, V10, P1, DOI 10.1093/ejechocard/jen303; Beauchesne LM, 2002, J AM COLL CARDIOL, V40, P285, DOI 10.1016/S0735-1097(02)01952-6; Beauchesne LM, 2001, J AM COLL CARDIOL, V38, P1728, DOI 10.1016/S0735-1097(01)01617-5; Belli E, 2007, EUR J CARDIO-THORAC, V31, P236, DOI 10.1016/j.ejcts.2006.11.035; Bonhoeffer P, 2000, LANCET, V356, P1403, DOI 10.1016/S0140-6736(00)02844-0; Bonow RO, 2005, J AM COLL CARDIOL, V45, P1334, DOI 10.1016/j.jacc.2005.02.010; Broberg CS, 2006, J AM COLL CARDIOL, V48, P356, DOI 10.1016/j.jacc.2006.03.040; Broberg CS, 2007, HEART, V93, P1599, DOI 10.1136/hrt.2006.105239; Broberg CS, 2007, J AM COLL CARDIOL, V50, P634, DOI 10.1016/j.jacc.2007.04.056; Brown ML, 2008, J AM COLL CARDIOL, V52, P460, DOI 10.1016/j.jacc.2008.03.064; BULL K, 1995, J AM COLL CARDIOL, V25, P491, DOI 10.1016/0735-1097(94)00364-V; Burch TM, 2008, ANESTH ANALG, V107, P1848, DOI 10.1213/ane.0b013e3181875a4d; Burn J, 1998, LANCET, V351, P311, DOI 10.1016/S0140-6736(97)06486-6; Butera G, 2006, AM HEART J, V151, P228, DOI 10.1016/j.ahj.2005.02.051; Caldarone CA, 2000, J THORAC CARDIOV SUR, V120, P1022, DOI 10.1067/mtc.2000.110684; CAMPBELL M, 1970, BRIT HEART J, V32, P633; Cantor WJ, 1999, AM J CARDIOL, V84, P677, DOI 10.1016/S0002-9149(99)00415-4; Chauvaud S, 2003, EUR J CARDIO-THORAC, V23, P525, DOI 10.1016/S1010-7940(02)00836-9; Cheung YF, 2005, INT J CARDIOL, V102, P509, DOI 10.1016/j.ijcard.2004.05.051; Cho JM, 2002, J THORAC CARDIOV SUR, V124, P70, DOI 10.1067/mtc.2002.120711; COHEN M, 1989, CIRCULATION, V80, P840; Connelly MS, 1996, J AM COLL CARDIOL, V27, P1238, DOI 10.1016/0735-1097(95)00567-6; Connolly HM, 2003, MAYO CLIN PROC, V78, P1491; CULLEN S, 1994, J AM COLL CARDIOL, V23, P1151; Daliento L, 1998, EUR HEART J, V19, P1845, DOI 10.1053/euhj.1998.1046; d'Udekem Y, 2007, CIRCULATION, V116, pI157, DOI 10.1161/CIRCULATIONAHA.106.676445; Davies RR, 2006, ANN THORAC SURG, V81, P169, DOI 10.1016/j.athoracsur.2005.06.026; Deanfield J, 2003, EUR HEART J, V24, P1035, DOI 10.1016/S0195-668X(03)00131-3; Dearani Joseph A, 2005, Semin Thorac Cardiovasc Surg, V17, P148, DOI 10.1053/j.semtcvs.2005.02.008; Dearani JA, 2003, ANN THORAC SURG, V75, P399, DOI 10.1016/S0003-4975(02)04547-2; DELEVAL MR, 1988, J THORAC CARDIOV SUR, V96, P682; DePaepe A, 1996, AM J MED GENET, V62, P417, DOI 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R; Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Diller GP, 2006, EUR HEART J, V27, P1737, DOI 10.1093/eurheartj/ehl116; Diller GP, 2005, CIRCULATION, V112, P828, DOI 10.1161/CIRCULATIONAHA.104.529800; Dimopoulos K, 2010, CIRCULATION, V121, P20, DOI 10.1161/CIRCULATIONAHA.109.883876; Dodge-Khatami A, 2002, ANN THORAC SURG, V73, P1759, DOI 10.1016/S0003-4975(02)03553-1; Dos L, 2005, HEART, V91, P652, DOI 10.1136/hrt.2003.029769; Drenthen W, 2005, EUR HEART J, V26, P2588, DOI 10.1093/eurheartj/ehi472; Drenthen W, 2005, EUR HEART J, V26, P2581, DOI 10.1093/eurheartj/ehi439; Du ZD, 2002, J AM COLL CARDIOL, V39, P1836, DOI 10.1016/S0735-1097(02)01862-4; Duffels MGJ, 2007, INT J CARDIOL, V120, P198, DOI 10.1016/j.ijcard.2006.09.017; Durongpisitkul K, 1998, CIRCULATION, V98, P1099; El-Najdawi EK, 2000, J THORAC CARDIOV SUR, V119, P880, DOI 10.1016/S0022-5223(00)70082-1; Engelfriet P, 2007, INT J CARDIOL, V114, P300, DOI 10.1016/j.ijcard.2006.01.025; Engelfriet P, 2005, EUR HEART J, V26, P2325, DOI 10.1093/eurheartj/ehi396; Fernandes SM, 2003, AM J CARDIOL, V91, P632, DOI 10.1016/S0002-9149(02)03328-3; Fischer G, 2003, HEART, V89, P199, DOI 10.1136/heart.89.2.199; FISHER RG, 1986, J AM COLL CARDIOL, V8, P280; FONTAN F, 1990, CIRCULATION, V81, P1520; Frigiola A, 2008, CIRCULATION, V118, pS182, DOI 10.1161/CIRCULATIONAHA.107.756825; Furer SK, 2005, MT SINAI J MED, V72, P263; Gabriel HM, 2002, J AM COLL CARDIOL, V39, P1066, DOI 10.1016/S0735-1097(02)01706-0; Galie N, 2006, CIRCULATION, V114, P48, DOI 10.1161/CIRCULATIONAHA.106.630715; Galie N, 2009, EUR RESPIR J, V34, P1219, DOI 10.1183/09031936.00139009; GARSON A, 1985, J AM COLL CARDIOL, V5, pB130; Gatzoulis MA, 2000, LANCET, V356, P975, DOI 10.1016/S0140-6736(00)02714-8; Gatzoulis MA, 1999, ANN THORAC SURG, V67, P504, DOI 10.1016/S0003-4975(98)01137-0; GATZOULIS MA, 1995, CIRCULATION, V92, P231; Gatzoulis MA, 1999, NEW ENGL J MED, V340, P839, DOI 10.1056/NEJM199903183401103; Gatzoulis MA, 2000, HEART, V83, P51, DOI 10.1136/heart.83.1.51; Gelatt M, 1997, J AM COLL CARDIOL, V29, P194; Ghai A, 2002, J AM COLL CARDIOL, V40, P1675, DOI 10.1016/S0735-1097(02)02344-6; Giardini A, 2008, ANN THORAC SURG, V85, P818, DOI 10.1016/j.athoracsur.2007.11.009; Giardini A, 2006, AM J CARDIOL, V98, P1277, DOI 10.1016/j.amjcard.2006.05.062; Gilljam T, 2000, J AM COLL CARDIOL, V36, P908, DOI 10.1016/S0735-1097(00)00812-3; Gott VL, 1999, NEW ENGL J MED, V340, P1307, DOI 10.1056/NEJM199904293401702; Graham TP, 2005, J AM COLL CARDIOL, V45, P1326, DOI 10.1016/j.jacc.2005.02.009; Groenink M, 1999, HEART, V82, P499; Guedes A, 2004, J AM COLL CARDIOL, V44, P433, DOI 10.1016/j.jacc.2004.04.037; Hager A, 2007, J THORAC CARDIOV SUR, V134, P738, DOI 10.1016/j.jtcvs.2007.04.027; Harinck E, 1996, CIRCULATION, V93, P272; Harrison DA, 1996, AM J CARDIOL, V77, P1094, DOI 10.1016/S0002-9149(96)00139-7; Hashmi A, 1998, J AM COLL CARDIOL, V31, P1120, DOI 10.1016/S0735-1097(98)00062-X; HAYES CJ, 1993, CIRCULATION, V87, P28; Hechter SJ, 2001, CARDIOL YOUNG, V11, P407, DOI 10.1017/S104795110100052X; Hickey EJ, 2008, ANN THORAC SURG, V86, P1919, DOI 10.1016/j.athoracsur.2008.08.031; Huddleston CB, 2007, PEDIATR CARDIOL, V28, P472, DOI 10.1007/s00246-007-9008-z; HUMENBERGER M, 2010, EUR HEART J IN PRESS; Jacobs J P, 2000, Ann Thorac Surg, V69, pS25; Jarrar M, 1999, AM HEART J, V138, P950, DOI 10.1016/S0002-8703(99)70022-0; JOHN S, 1981, J THORAC CARDIOV SUR, V82, P314; Kallenbach K, 2007, ANN THORAC SURG, V83, pS764, DOI 10.1016/j.athoracsur.2006.10.097; Khairy P, 2004, CIRCULATION, V109, P1994, DOI 10.1161/01.CIR.0000126495.11040.BD; Khairy P, 2007, CIRCULATION, V115, P800, DOI 10.1161/CIRCULATIONAHA.105.592378; Khairy P, 2008, CIRC-ARRHYTHMIA ELEC, V1, P250, DOI 10.1161/CIRCEP.108.776120; Khairy P, 2008, CIRCULATION, V117, P85, DOI 10.1161/CIRCULATIONAHA.107.738559; Khairy P, 2004, CARDIOL YOUNG, V14, P284, DOI 10.1017/S1047951104003063; Khairy P, 2008, CIRCULATION, V117, P363, DOI 10.1161/CIRCULATIONAHA.107.726372; Khambadkone S, 2004, CATHETER CARDIO INTE, V62, P401, DOI 10.1002/ccd.20122; KIDD L, 1993, CIRCULATION, V87, P38; Kilner PJ, 2010, EUR HEART J, V31, P794, DOI 10.1093/eurheartj/ehp586; Kim SJ, 2008, J THORAC CARDIOV SUR, V136, P108, DOI 10.1016/j.jtcvs.2007.12.032; Krumsdorf U, 2004, J AM COLL CARDIOL, V43, P302, DOI 10.1016/j.jacc.2003.10.030; Lange R, 2006, CIRCULATION, V114, P1905, DOI 10.1161/CIRCULATIONAHA.105.606046; Leonard H, 2000, HEART, V84, P499, DOI 10.1136/heart.84.5.499; Loeys BL, 2010, J MED GENET, V47, P476, DOI 10.1136/jmg.2009.072785; Losay J, 2006, J AM COLL CARDIOL, V47, P2057, DOI 10.1016/j.jacc.2005.12.061; Lurz P, 2008, CIRCULATION, V117, P1964, DOI 10.1161/CIRCULATIONAHA.107.735779; Malhotra SP, 2008, ANN THORAC SURG, V86, P147, DOI 10.1016/j.athoracsur.2008.03.040; MARELLI AJ, 1994, CIRCULATION, V89, P243; Mavroudis C, 2007, ANN THORAC SURG, V84, P1457, DOI 10.1016/j.athoracsur.2007.06.079; McElhinney DB, 2003, DIAGNOSIS MANAGEMENT, P305; MEIJBOOM F, 1994, J AM COLL CARDIOL, V24, P1358; Meijboom LJ, 2005, EUR HEART J, V26, P914, DOI 10.1093/eurheartj/ehi103; Meijboom LJ, 2005, AM J CARDIOL, V96, P1441, DOI 10.1016/j.amjcard.2005.06.094; Mertens L, 1998, J THORAC CARDIOV SUR, V115, P1063, DOI 10.1016/S0022-5223(98)70406-4; Mitropoulos FA, 2007, ANN THORAC SURG, V83, P672, DOI 10.1016/j.athoracsur.2006.07.015; Miyake T, 2008, PEDIATR INT, V50, P632, DOI 10.1111/j.1442-200X.2008.02642.x; Mohammadi S, 2005, EUR J CARDIO-THORAC, V28, P217, DOI 10.1016/j.ejcts.2005.04.014; Mukhopadhyay S, 2006, CIRCULATION, V114, P1807, DOI 10.1161/CIRCULATIONAHA.105.603001; MURPHY JG, 1993, NEW ENGL J MED, V329, P593, DOI 10.1056/NEJM199308263290901; MURPHY JG, 1990, NEW ENGL J MED, V323, P1645, DOI 10.1056/NEJM199012133232401; Murthy KS, 1999, ANN THORAC SURG, V67, P760, DOI 10.1016/S0003-4975(99)00077-6; Neumayer U, 1998, EUR HEART J, V19, P1573, DOI 10.1053/euhj.1998.1083; Niwa K, 1999, J AM COLL CARDIOL, V34, P223, DOI 10.1016/S0735-1097(99)00153-9; Niwa K, 2001, CIRCULATION, V103, P393; Nollen GJ, 2004, EUR HEART J, V25, P1146, DOI 10.1016/j.ehj.2004.04.033; Nollert G, 1997, J AM COLL CARDIOL, V30, P1374, DOI 10.1016/S0735-1097(97)00318-5; NORA JJ, 1987, AM J CARDIOL, V59, P459, DOI 10.1016/0002-9149(87)90956-8; Oechslin E, 2004, INT J CARDIOL, V97, P109, DOI 10.1016/j.ijcard.2004.08.015; Oechslin E, 2005, CIRCULATION, V112, P1106, DOI 10.1161/CIRCULATIONHA.105.534073; Oechslin EN, 2000, AM J CARDIOL, V86, P1111, DOI 10.1016/S0002-9149(00)01169-3; Oliver JM, 2003, J THORAC CARDIOV SUR, V126, P711, DOI 10.1016/S0022-5223(03)00044-8; Oliver JM, 2001, J AM COLL CARDIOL, V38, P835, DOI 10.1016/S0735-1097(01)01464-4; Oosterhof T, 2007, CIRCULATION, V116, P545, DOI 10.1161/CIRCULATIONAHA.106.659664; Pelliccia A, 2005, EUR HEART J, V26, P1422, DOI 10.1093/eurheartj/ehi325; Peng LF, 2006, CIRCULATION, V113, P2598, DOI 10.1161/CIRCULATIONAHA.105.607127; PERLOFF JK, 1993, CIRCULATION, V87, P1954; Perloff Joseph K., 1993, Cardiology Clinics, V11, P689; Perloff JK, 2003, AM J CARDIOL, V92, P182, DOI 10.1016/S0002-9149(03)00535-6; PERLOFF JK, 1988, ANN INTERN MED, V109, P406; Piran S, 2002, CIRCULATION, V105, P1189, DOI 10.1161/hc1002.105182; POIRIER NC, 2003, DIAGNOSIS MANAGEMENT, P399; PRESBITERO P, 1994, CIRCULATION, V89, P2673; Reddy VM, 2000, CIRCULATION, V101, P1826; Reddy VM, 1995, ANN THORAC SURG, V60, pS592; Redington AN, 1996, CIRCULATION, V94, P2479; Ro PS, 2004, J AM COLL CARDIOL, V44, P184, DOI 10.1016/j.jacc.2004.02.058; Roos-Hesselink JW, 2003, EUR HEART J, V24, P190, DOI 10.1016/S0195-668X(03)00383-4; Roos-Hesselink JW, 2004, EUR HEART J, V25, P1264, DOI 10.1016/j.ehj.2004.03.009; Rosenhek R, 2000, NEW ENGL J MED, V343, P611, DOI 10.1056/NEJM200008313430903; Rosenzweig EB, 1999, CIRCULATION, V99, P1858; Rossebo AB, 2008, NEW ENGL J MED, V359, P1343, DOI 10.1056/NEJMoa0804602; Sakazaki H, 2007, INT J CARDIOL, V120, P72, DOI 10.1016/j.ijcard.2006.08.081; Schwartz ML, 2004, CIRCULATION, V110, pII128, DOI 10.1161/01.CIR.0000138392.68841.d3; Schwerzmann M, 2009, EUR HEART J, V30, P1873, DOI 10.1093/eurheartj/ehp179; Shah Lisa, 2005, J Invasive Cardiol, V17, P614; Shin'oka T, 2007, J THORAC CARDIOV SUR, V133, P1318, DOI 10.1016/j.jtcvs.2006.11.063; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; Silversides CK, 2003, J AM COLL CARDIOL, V42, P1982, DOI 10.1016/j.jacc.2003.07.022; Simonneau G, 2009, J AM COLL CARDIOL, V54, pS43, DOI 10.1016/j.jacc.2009.04.012; Simonneau G, 2002, AM J RESP CRIT CARE, V165, P800, DOI 10.1164/rccm.2106079; SINGH TP, 1951, AM HEART J, V151; Siu SC, 2001, CIRCULATION, V104, P515, DOI 10.1161/hc3001.093437; Somerville J, 1997, ANNU REV MED, V48, P283; Soufflet V, 2010, AM J CARDIOL, V105, P404, DOI 10.1016/j.amjcard.2009.09.047; Sugiyama H, 2005, HEART, V91, P1058, DOI 10.1136/hrt.2004.034819; Svensson LG, 2008, ANN THORAC SURG, V85, pS1, DOI 10.1016/j.athoracsur.2007.10.099; Takkenberg JJM, 2009, CIRCULATION, V119, P222, DOI 10.1161/CIRCULATIONAHA.107.726349; Tan JL, 2005, CIRCULATION, V112, P961, DOI 10.1161/CIRCULATIONAHA.105.537928; Therrien J, 2008, INT J CARDIOL, V129, P187, DOI 10.1016/j.ijcard.2008.04.056; Tuder RM, 2009, J AM COLL CARDIOL, V54, pS3, DOI 10.1016/j.jacc.2009.04.009; Tzemos N, 2008, JAMA-J AM MED ASSOC, V300, P1317, DOI 10.1001/jama.300.11.1317; Urban Z, 2001, HUM GENET, V109, P512, DOI 10.1007/s00439-001-0608-z; Vahanian A, 2007, EUR HEART J, V28, P230, DOI 10.1093/eurheartj/ehl428; VanHare GF, 1996, AM J CARDIOL, V77, P985, DOI 10.1016/S0002-9149(96)00034-3; VANSON JAM, 1995, J THORAC CARDIOV SUR, V109, P642, DOI 10.1016/S0022-5223(95)70345-4; Veldtman GR, 2003, HEART, V89, P1067, DOI 10.1136/heart.89.9.1067; Vongpatanasin W, 1998, ANN INTERN MED, V128, P745; Voskuil M, 1999, AM J CARDIOL, V83, P558, DOI 10.1016/S0002-9149(98)00913-8; Warnes CA, 2006, CIRCULATION, V114, P2699, DOI 10.1161/CIRCULATIONAHA.105.592352; Warnes Carole A, 2008, Circulation, V118, pe714, DOI 10.1161/CIRCULATIONAHA.108.190690; Warnes CA, 2001, J AM COLL CARDIOL, V37, P1170, DOI 10.1016/S0735-1097(01)01272-4; Zipes DP, 2006, EUR HEART J, V27, P2099, DOI 10.1093/eurheartj/ehl199",184,225,231,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0195-668X",null,null,"EUR HEART J","Eur. Heart J.","DEC",2010,31,23,null,null,null,null,2915,2957,null,"10.1093/eurheartj/ehq249",null,43,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","689SY","WOS:000284950600021"]
[null,null,null,null,"J","Vida, VL; Padalino, MA; Boccuzzo, G; Tarja, E; Berggren, H; Carrel, T; Cicek, S; Crupi, G; Di Carlo, D; Di Donato, R; Fragata, J; Hazekamp, M; Hraska, V; Maruszewski, B; Metras, D; Pozzi, M; Pretre, R; Rubay, J; Sairanen, H; Sarris, G; Schreiber, C; Meyns, B; Tlaskal, T; Urban, A; Thiene, G; Stellin, G",null,null,null,"Vida, Vladimiro L.; Padalino, Massimo A.; Boccuzzo, Giovanna; Tarja, Erjon; Berggren, Hakan; Carrel, Thierry; Cicek, Sertac; Crupi, Giancarlo; Di Carlo, Duccio; Di Donato, Roberto; Fragata, Jose; Hazekamp, Mark; Hraska, Viktor; Maruszewski, Bohdan; Metras, Dominique; Pozzi, Marco; Pretre, Rene; Rubay, Jean; Sairanen, Heikki; Sarris, George; Schreiber, Christian; Meyns, Bart; Tlaskal, Tomas; Urban, Andreas; Thiene, Gaetano; Stellin, Giovanni",null,null,"Scimitar Syndrome A European Congenital Heart Surgeons Association (ECHSA) Multicentric Study","CIRCULATION",null,null,"English","Article",null,null,null,null,null,"congenital heart disease; multicenter study; scimitar syndrome","PULMONARY-HYPERTENSION; SURGICAL-TREATMENT; VENOUS DRAINAGE; INFANCY; PNEUMONECTOMY; CHILDREN; SEQUESTRATION; CHILDHOOD; VEIN; FORM","Background-Scimitar syndrome is a rare congenital heart disease. To evaluate the surgical results, we embarked on the European Congenital Heart Surgeons Association (ECHSA) multicentric study. Methods and Results-From January 1997 to December 2007, we collected data on 68 patients who underwent surgery for scimitar syndrome. Primary outcomes included hospital mortality and the efficacy of repair at follow-up. Median age at surgery was 1.4 years (interquartile range, 0.46 to 7.92 years). Forty-four patients (64%) presented with symptoms. Surgical repair included intraatrial baffle in 38 patients (56%; group 1) and reimplantation of the scimitar vein onto the left atrium in 21 patients (31%; group 2). Eight patients underwent right pneumectomy, and 1 had a right lower lobe lobectomy (group 3). Four patients died in hospital (5.9%; 1 patient in group 1, 2.6%; 3 patients in group 3, 33%). Median follow-up time was 4.5 years. There were 2 late deaths (3.1%) resulting from severe pulmonary arterial hypertension. Freedom from scimitar drainage stenosis at 13 years was 83.8% in group 1 and 85.8% in group 2. Four patients in group 1 were reoperated, and 3 patients (2 in group 1 [6%] and 1 in group 2 [4.8%]) required balloon dilation/stenting for scimitar drainage stenosis. Conclusions-The surgical treatment of this rare syndrome is safe and effective. The majority of patients were asymptomatic at the follow-up control. There were a relatively high incidence of residual scimitar drainage stenosis that is similar between the 2 reported corrective surgical techniques used. (Circulation. 2010;122:1159-1166.)","[Stellin, Giovanni] Univ Padua, Pediat & Congenital Cardiac Surg Unit, Dept Pediat & Congenital Cardiac Surg, I-35100 Padua, Italy; [Boccuzzo, Giovanna] Univ Padua, Dept Stat Sci, I-35100 Padua, Italy; [Thiene, Gaetano] Univ Padua, Dept Diagnost Sci & Special Therapies, I-35100 Padua, Italy; [Berggren, Hakan] Queen Silvia Childrens Hosp, Childrens Heart Ctr, Gothenburg, Sweden; [Carrel, Thierry] Univ Hosp Bern, Swiss Cardiovasc Ctr, Cardiovasc Surg Clin, CH-3010 Bern, Switzerland; [Cicek, Sertac] Anadolu Med Ctr, Istanbul, Turkey; [Crupi, Giancarlo] Osped Riuniti Bergamo, Dept Cardiac Surg, I-24100 Bergamo, Italy; [Di Carlo, Duccio; Di Donato, Roberto] Osped Pediat Bambino Gesu, Pediat Cardiac Surg Unit, Rome, Italy; [Fragata, Jose] Hosp Santa Marta, Sevicco Cirurgia Cardiotora, Unidade Cardiaca Pediat, Lisbon, Portugal; [Hazekamp, Mark] Leiden Univ, Med Ctr, Dept Cardiothorac Surg D6 S, Leiden, Netherlands; [Hraska, Viktor; Urban, Andreas] Asklepios Clin Sankt, German Pediat Heart Ctr, Augustin, Germany; [Maruszewski, Bohdan] Childrens Mem Hlth Inst, Dept Cardiothorac Surg, Warsaw, Poland; [Metras, Dominique] Hop Enfants La Timone, Dept Cardiothorac Surg, Marseille, France; [Pozzi, Marco] Osped Riuniti Bergamo, Dept Pediat & Congenital Cardiac Surg & Cardiol, Ancona, Italy; [Pretre, Rene] Univ Childrens Hosp, Zurich, Switzerland; [Rubay, Jean] Catholic Univ Louvain, Serv Chirurg Cardiovasc & Thorac, B-1200 Brussels, Belgium; [Sairanen, Heikki] Univ Helsinki, Hosp Children & Adolescents, Helsinki, Finland; [Sarris, George] Mitera Pediat & Hygea Hosp, Athens, Greece; [Schreiber, Christian] German Heart Ctr, Munich Clin Cardiovasc Surg, D-8000 Munich, Germany; [Meyns, Bart] Dept Cardiac Surg, Louvain, Belgium; [Tlaskal, Tomas] Univ Hosp, Dept Pediat Cardiac Surg, Prague, Czech Republic","Stellin, G (reprint author), Univ Padua, Pediat & Congenital Cardiac Surg Unit, Dept Pediat & Congenital Cardiac Surg, Via Giustiniani 2, I-35100 Padua, Italy.","giovanni.stellin@unipd.it","Vida, Vladimiro/F-3984-2012",null,null,null,"Alsoufi B, 2007, ANN THORAC SURG, V84, P2020, DOI 10.1016/j.athoracsur.2007.05.046; Barst RJ, 2004, J AM COLL CARDIOL, V43, p40S, DOI 10.1016/j.jacc.2004.02.032; BLAYSAT G, 1987, ARCH FR PEDIATR, V44, P245; Calhoun RF, 2003, ANN THORAC SURG, V76, P301, DOI 10.1016/S0003-4975(03)00107-3; CANTER CE, 1986, AM J CARDIOL, V58, P652, DOI 10.1016/0002-9149(86)90296-1; Casha A R, 2003, Interact Cardiovasc Thorac Surg, V2, P128, DOI 10.1016/S1569-9293(02)00120-2; CLEMENTS BS, 1987, THORAX, V42, P401, DOI 10.1136/thx.42.6.401; DUPUIS C, 1992, AM J CARDIOL, V70, P502, DOI 10.1016/0002-9149(92)91198-D; DUPUIS C, 1994, ARCH MAL COEUR VAISS, V87, P607; DUPUIS C, 1993, ARCH MAL COEUR VAISS, V86, P541; DUPUIS C, 1993, AM J CARDIOL, V71, P1326, DOI 10.1016/0002-9149(93)90549-R; Espinola-Zavaleta N, 2006, REV ESP CARDIOL, V59, P284, DOI 10.1016/S1885-5857(06)70034-2; FOLGER GM, 1976, ANGIOLOGY, V27, P373, DOI 10.1177/000331977602700605; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.2307/2332323; GAO YA, 1993, J AM COLL CARDIOL, V22, P873; GIKONYO DK, 1986, PEDIATR CARDIOL, V6, P193, DOI 10.1007/BF02310997; HAWORTH SG, 1983, BRIT HEART J, V50, P182; Hoffman JIE., 2009, SCIMITAR SYNDROME, P161; Huddleston CB, 1999, ANN THORAC SURG, V67, P154, DOI 10.1016/S0003-4975(98)01227-2; Ishibashi N, 2001, Kyobu Geka, V54, P875; Kamiyama M, 2004, PEDIATR SURG INT, V20, P65, DOI 10.1007/s00383-003-1085-3; KIELY B, 1967, AM J CARDIOL, V20, P102, DOI 10.1016/0002-9149(67)90115-4; KRUSKAL WILLIAM H., 1952, JOUR AMER STATIST ASSOC, V47, P583, DOI 10.2307/2280779; LAROS CD, 1987, J THORAC CARDIOV SUR, V93, P570; Mas C, 2000, CATHETER CARDIO INTE, V51, P192, DOI 10.1002/1522-726X(200010)51:2<192::AID-CCD12>3.0.CO;2-V; Mason DP, 2006, J THORAC CARDIOV SUR, V132, P704, DOI 10.1016/j.jtcvs.2006.05.010; Muta H, 1999, JPN CIRC J, V63, P729, DOI 10.1253/jcj.63.729; Najm HK, 1996, J THORAC CARDIOV SUR, V112, P1161, DOI 10.1016/S0022-5223(96)70129-0; Nedelcu Cosmina, 2008, Cardiovasc Intervent Radiol, V31 Suppl 2, pS96; Pikwer A, 2006, SCAND J SURG, V95, P190; Rajaii-Khorasani Ahmad, 2008, ANZ J Surg, V78, P419, DOI 10.1111/j.1445-2197.2008.04498.x; SCHRAMEL FMNH, 1995, EUR RESPIR J, V8, P196, DOI 10.1183/09031936.95.08020196; Shibuya K, 1996, J Am Soc Echocardiogr, V9, P174, DOI 10.1016/S0894-7317(96)90025-5; SNELLEN HA, 1968, CIRCULATION, V38, P45; STILES QR, 1969, J THORAC CARDIOV SUR, V58, P394; Tjang Yanto Sandy, 2008, J Card Surg, V23, P71, DOI 10.1111/j.1540-8191.2007.00497.x; TUMMERS RFHM, 1987, EUR HEART J, V8, P194; Uthaman B, 2008, CATHETER CARDIO INTE, V71, P671, DOI 10.1002/ccd.21430; Vida VL, 2009, ANN THORAC SURG, V88, P440, DOI 10.1016/j.athoracsur.2009.04.099; YILMAZ M, 2006, HEART SURG FORUM, V9, P843; Zagol Brian, 2006, J Invasive Cardiol, V18, pE82",41,19,19,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322","1524-4539",null,"CIRCULATION","Circulation","SEP 21",2010,122,12,null,null,null,null,1159,1166,null,"10.1161/CIRCULATIONAHA.109.926204",null,8,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","Cardiovascular System & Cardiology","652WR","WOS:000282042100005"]
[null,null,null,null,"J","Gennery, AR; Slatter, MA; Grandin, L; Taupin, P; Cant, AJ; Veys, P; Amrolia, PJ; Gaspar, HB; Davies, EG; Friedrich, W; Hoenig, M; Notarangelo, LD; Mazzolari, E; Porta, F; Bredius, RGM; Lankester, AC; Wulffraat, NM; Seger, R; Gungor, T; Fasth, A; Sedlacek, P; Neven, B; Blanche, S; Fischer, A; Cavazzana-Calvo, M; Landais, P",null,null,null,"Gennery, Andrew R.; Slatter, Mary A.; Grandin, Laure; Taupin, Pierre; Cant, Andrew J.; Veys, Paul; Amrolia, Persis J.; Gaspar, H. Bobby; Davies, E. Graham; Friedrich, Wilhelm; Hoenig, Manfred; Notarangelo, Luigi D.; Mazzolari, Evelina; Porta, Fulvio; Bredius, Robbert G. M.; Lankester, Arjen C.; Wulffraat, Nico M.; Seger, Reinhard; Guengoer, Tayfun; Fasth, Anders; Sedlacek, Petr; Neven, Benedicte; Blanche, Stephane; Fischer, Alain; Cavazzana-Calvo, Marina; Landais, Paul",null,"European Group For Blood; European Society For","Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better?","JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Primary immunodeficiency; severe combined immunodeficiency; Wiskott-Aldrich syndrome; CD40 ligand deficiency; chronic granulomatous disease; hematopoietic stem cell transplantation","BONE-MARROW-TRANSPLANTATION; CHRONIC GRANULOMATOUS-DISEASE; WISKOTT-ALDRICH-SYNDROME; COMBINED IMMUNE-DEFICIENCY; HYPER-IGM SYNDROME; THYMIC OUTPUT; EXPERIENCE; RECONSTITUTION; BLOOD; DIAGNOSIS","Background: Hematopoietic stem cell transplantation remains the only treatment for most patients with severe combined immunodeficiencies (SCIDs) or other primary immunodeficiencies (non-SCID PIDs). Objective: To analyze the long-term outcome of patients with SCID and non-SCID PID from European centers treated between 1968 and 2005. Methods: The product-limit method estimated cumulative survival; the log-rank test compared survival between groups. A Cox proportional-hazard model evaluated the impact of independent predictors on patient survival. Results: In patients with SCID, survival with genoidentical donors (n = 25) from 2000 to 2005 was 90%. Survival using a mismatched relative (n = 96) has improved (66%), similar to that using an unrelated donor (n = 46; 69%; P = .005). Transplantation after year 1995, a younger age, B(+) phenotype, genoidentical and phenoidentical donors, absence of respiratory impairment, or viral infection before transplantation were associated with better prognosis on multivariate analysis. For nonSCID PID, in contrast with patients with SCID, we confirm that, in the 2000 to 2005 period, using an unrelated donor (n = 124) gave a 3-year survival rate similar to a genoidentical donor (n = 73), 79% for both. Survival was 76% in phenoidentical transplants (n = 23) and worse in mismatched related donor transplants (n = 47; 46%; P = .016). Conclusion: This is the largest cohort study of such patients with the longest follow-up. Specific issues arise for different patient groups. Patients with B-SCID have worse survival than other patients with SCID, despite improvements in each group. For non-SCID PID, survival is worse than SCID, although more conditions are now treated. Individual disease categories now need to be analyzed so that disease-specific prognosis may be better understood and the best treatments planned. (J Allergy Clin Immunol 2010;126:602-10.)","[Gennery, Andrew R.] Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Gennery, Andrew R.; Slatter, Mary A.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Gennery, Andrew R.; Slatter, Mary A.; Cant, Andrew J.] Newcastle Upon Tyne Hosp, Fdn Trust, Dept Pediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Cavazzana-Calvo, Marina] Paris Descartes Univ, Hop Necker Enfants Malad, Hopitaux Paris, Dept Biotherapy, Paris, France; [Veys, Paul; Amrolia, Persis J.; Gaspar, H. Bobby; Davies, E. Graham] Great Ormond St Childrens Hosp, Dept Bone Marrow Transplantat, London, England; [Friedrich, Wilhelm; Hoenig, Manfred] Univ Ulm, D-89069 Ulm, Germany; [Notarangelo, Luigi D.; Mazzolari, Evelina; Porta, Fulvio] Univ Brescia Spedali Civili, Brescia, Italy; [Bredius, Robbert G. M.; Lankester, Arjen C.] Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RA Leiden, Netherlands; [Wulffraat, Nico M.] Univ Med Ctr, Immunol Sect, Dept Pediat, Utrecht, Netherlands; [Seger, Reinhard; Guengoer, Tayfun] Univ Childrens Hosp, Div Immunol Hematol Oncol, Zurich, Switzerland; [Fasth, Anders] Univ Gothenburg, Pediat Immunol & Infect Dis Unit, Dept Pediat, Gothenburg, Sweden; [Sedlacek, Petr] Univ Hosp Motol V Uvalu, Prague, Czech Republic","Gennery, AR (reprint author), Newcastle Gen Hosp, Ward 23,Westgate Rd, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.","a.r.gennery@ncl.ac.uk",null,null,null,null,null,40,69,70,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0091-6749",null,null,"J ALLERGY CLIN IMMUN","J. Allergy Clin. Immunol.","SEP",2010,126,3,null,null,null,null,602,"U342",null,"10.1016/j.jaci.2010.06.015",null,20,"Allergy; Immunology","Allergy; Immunology","646CF","WOS:000281512500029"]
[null,null,null,null,"J","von Neuhoff, C; Reinhardt, D; Sander, A; Zimmermann, M; Bradtke, J; Betts, DR; Zemanova, Z; Stary, J; Bourquin, JP; Haas, OA; Dworzak, MN; Creutzig, U",null,null,null,"von Neuhoff, Christine; Reinhardt, Dirk; Sander, Annette; Zimmermann, Martin; Bradtke, Jutta; Betts, David R.; Zemanova, Zuzana; Stary, Jan; Bourquin, Jean-Pierre; Haas, Oskar A.; Dworzak, Michael N.; Creutzig, Ursula",null,null,"Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ACUTE MYELOGENOUS LEUKEMIA; CHILDRENS-CANCER-GROUP; TUMOR-SUPPRESSOR GENE; POOR-PROGNOSIS; CYTOGENETIC ABNORMALITIES; ONCOLOGY-GROUP; DE-NOVO; FLT3 MUTATIONS; GROUP-B; TRANSLOCATION","Purpose Because cytogenetic data are essential for risk stratification of childhood acute myeloid leukemia (AML), the impact of chromosomal aberrations is crucial. Patients and Methods Data of a large group of patients younger than 18 years treated according to study AML-Berlin-Frankfurt- Munster (BFM) 98 (n = 454), including their cytogenetics, were analyzed. Results The favorable outcome in the subgroups of patients with t(8;21), inv(16), and t( 15; 17), with an overall survival of 91% (SE,4%), 92% (SE,6%), and 87% (SE,5%), respectively, was confirmed. Within this group, the 5-year probability of event-free survival (pEFS) of all 17 children with t( 8; 21) and additional aberrations apart from del(9q) or -X/-Y was 100%. As expected, the cytogenetic finding of a complex karyotype (n = 35; pEFS, 33%; SE, 8%) or a monosomy 7 (n = 12; pEFS, 17%; SE, 11%) was associated with a poor outcome. Compared with remaining patients with cytogenetic data ( pEFS, 48%; SE, 2%), prognosis in patients with an MLL rearrangement (n = 91) was inferior ( pEFS, 34%; SE, 5%; P = .0005). Particularly, children with t( 9; 11) and additional aberrations (n = 13; pEFS, 31%; SE, 14%) and MLL rearrangements other than t( 9; 11) and t( 11; 19) (n = 41; pEFS, 24%; SE, 7%) had an unfavorable outcome. Nine patients with aberrations in 12p showed an adverse prognosis ( pEFS, 11%; SE, 10%). The outcome of patients with aberrations of chromosome 5 (n = 13) was better than expected ( pEFS, 50%; SE, 13%). Conclusion Because the prognostic value of rare recurrent chromosomal aberrations still has to be elucidated, these data will contribute to future risk stratification for the treatment of pediatric AML. J Clin Oncol 28:2682-2689. (C) 2010 by American Society of Clinical Oncology","[von Neuhoff, Christine] Hannover Med Sch, D-30625 Hannover, Germany; Univ Giessen, Oncogenet Lab, Giessen, Germany; Univ Munster, Childrens Hosp, Munster, Germany; Our Ladys Childrens Hosp, Natl Ctr Med Genet, Dublin, Ireland; Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Gen Univ Hosp, Prague, Czech Republic; Charles Univ Prague, Fac Med 1, Prague, Czech Republic; Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; Univ Zurich, Zurich, Switzerland; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria","von Neuhoff, C (reprint author), Hannover Med Sch, Carl Neuberg Str 1, D-30625 Hannover, Germany.","neuhoff.christine.von@mh-hannover.de","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Deutsche Krebshilfe e.V. [70-320/70-2315-Ri 4]; Center of Oncocytogenetics, Charles University in Prague [MSM0021620813]","Supported by Deutsche Krebshilfe e.V. Grant No. 70-320/70-2315-Ri 4, research grant (Center of Oncocytogenetics, Charles University in Prague) MSM0021620813.",null,62,38,38,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,null,"J CLIN ONCOL","J. Clin. Oncol.","JUN 1",2010,28,16,null,null,null,null,2682,2689,null,"10.1200/JCO.2009.25.6321",null,8,"Oncology","Oncology","601ZV","WOS:000278108800006"]
[null,null,null,null,"J","Witjes, JA; Redorta, JP; Jacqmin, D; Sofras, F; Malmstrom, PU; Riedl, C; Jocham, D; Conti, G; Montorsi, F; Arentsen, HC; Zaak, D; Mostafid, AH; Babjuk, M",null,null,null,"Witjes, J. Alfred; Palou Redorta, Juan; Jacqmin, Didier; Sofras, Frank; Malmstrom, Per-Uno; Riedl, Claus; Jocham, Dieter; Conti, Giario; Montorsi, Francesco; Arentsen, Harm C.; Zaak, Dirk; Mostafid, A. Hugh; Babjuk, Marko",null,null,"Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations","EUROPEAN UROLOGY",null,null,"English","Review",null,null,null,null,null,"Carcinoma in situ; CIS detection; Hexaminolevulinate; Non-muscle-invasive bladder cancer; PDD; Photodynamic diagnosis; Recurrence","WHITE-LIGHT CYSTOSCOPY; CARCINOMA IN-SITU; TRANSURETHRAL RESECTION; PHOTODYNAMIC DIAGNOSIS; PHASE-III; HEXYL AMINOLEVULINATE; RECURRENCE RATE; 7 EORTC; MULTICENTER; RISK","Context: Compared with standard white-light cystoscopy, photodynamic diagnosis with blue light and the photosensitiser hexaminolevulinate has been shown to improve the visualisation of bladder tumours, reduce residual tumour rates by at least 20%, and improve recurrence-free survival. There is currently no overall European consensus outlining specifically where hexaminolevulinate is or is not indicated. Objective: Our aim was to define specific indications for hexaminolevulinate guided fluorescence cystoscopy in the diagnosis and management of non-muscle invasive bladder cancer (NMIBC). Evidence acquisition: A European expert panel was convened to review the evidence for hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and management of NMIBC (identified through a PubMed MESH search) and available guidelines from across Europe. On the basis of this information and drawing on the extensive clinical experience of the panel, specific indications for the technique were then identified through discussion. Evidence synthesis: The panel recommends that hexaminolevulinate-guided fluorescence cystoscopy be used to aid diagnosis at initial transurethral resection following suspicion of bladder cancer and in patients with positive urine cytology but negative white-light cystoscopy for the assessment of tumour recurrences in patients not previously assessed with hexaminolevulinate, in the initial follow-up of patients with carcinoma in situ (CIS) or multifocal tumours, and as a teaching tool. The panel does not currently recommend the use of hexaminolevulinate-guided fluorescence cystoscopy in patients for whom cystectomy is indicated or for use in the outpatient setting with flexible cystoscopy. Conclusions: Evidence is available to support the use of hexaminolevulinate-guided fluorescence cystoscopy in a range of indications, as endorsed by an expert panel. (c) 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.","[Witjes, J. Alfred] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands; [Palou Redorta, Juan] Univ Autonoma Barcelona, Fundacio Puigvert, E-08193 Barcelona, Spain; [Jacqmin, Didier] Univ Strasbourg, Serv Chirurg Urol, Strasbourg, France; [Sofras, Frank] Univ Crete, Dept Urol, Iraklion, Greece; [Malmstrom, Per-Uno] Univ Uppsala Hosp, Dept Surg Sci, Uppsala, Sweden; [Riedl, Claus] Landesklinikum Thermenreg Baden, Dept Urol, Baden, Austria; [Jocham, Dieter] Med Univ Lubeck, Dept Urol, D-23538 Lubeck, Germany; [Conti, Giario] St Anna Hosp, Dept Urol & Androl, Como, Italy; [Montorsi, Francesco] Univ Vita Salute San Raffaele, Milan, Italy; [Arentsen, Harm C.] Radboud Univ Nijmegen, Dept Urol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Zaak, Dirk] Univ Munich, Munich, Germany; [Mostafid, A. Hugh] N Hampshire Hosp, Basingstoke, Hants, England; [Babjuk, Marko] Charles Univ Prague, Fac Med 2, Dept Urol, Fac Hosp Motol, Prague, Czech Republic","Witjes, JA (reprint author), Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands.","F.Witjes@uro.umcn.nl","Witjes, Fred/N-9665-2013",null,"GE Healthcare","I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: This article was sponsored by an educational grant from GE Healthcare. The company had no role in the preparation or approval of the manuscript but checked the factual and medical content. Editorial control resides with the authors and editor.",null,49,45,46,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","APR",2010,57,4,null,null,null,null,607,614,null,"10.1016/j.eururo.2010.01.025",null,8,"Urology & Nephrology","Urology & Nephrology","571GH","WOS:000275739300015"]
[null,null,null,null,"J","Babjuk, M",null,null,null,"Babjuk, Marko",null,null,"Second Resection for Non-Muscle-Invasive Bladder Carcinoma: Current Role and Future Perspectives","EUROPEAN UROLOGY",null,null,"English","Article",null,null,null,null,null,null,"TRANSURETHRAL RESECTION; RECURRENCE; DIAGNOSIS; CANCER; TUMORS; TUR",null,"[Babjuk, Marko] Charles Univ Prague, FN Motol, Fac Med 2, Dept Urol, Prague 15006 5, Czech Republic; [Babjuk, Marko] Charles Univ Prague, Fac Med 1, Dept Urol, Prague 15006 5, Czech Republic","Babjuk, M (reprint author), Charles Univ Prague, FN Motol, Fac Med 2, Dept Urol, V Uvalu 84, Prague 15006 5, Czech Republic.","marek.babjuk@lfmotol.cuni.cz",null,null,"GE Healthcare","Marko Babjuk has received honoraria from GE Healthcare for lectures at meetings on bladder cancer.",null,9,8,10,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","AUG",2010,58,2,null,null,null,null,191,192,null,"10.1016/j.eururo.2010.04.019",null,2,"Urology & Nephrology","Urology & Nephrology","623MR","WOS:000279745100002"]
[null,null,null,null,"J","Tuttelmann, F; Krenkova, P; Romer, S; Nestorovic, AR; Ljujic, M; Stambergova, A; Macek, M; Macek, M; Nieschlag, E; Gromoll, J; Simoni, M",null,null,null,"Tuettelmann, F.; Krenkova, P.; Roemer, S.; Nestorovic, A. R.; Ljujic, M.; Stambergova, A.; Macek, M., Jr.; Macek, M., Sr.; Nieschlag, E.; Gromoll, J.; Simoni, M.",null,null,"A common haplotype of protamine 1 and 2 genes is associated with higher sperm counts","INTERNATIONAL JOURNAL OF ANDROLOGY",null,null,"English","Article",null,null,null,null,null,"male infertility; PRM1; PRM2; protamine; semen parameters; SNP","SINGLE-NUCLEOTIDE POLYMORPHISMS; HUMAN MALE POPULATIONS; MALE-INFERTILITY; MESSENGER-RNA; FERTILE; SPERMATOGENESIS; IDENTIFICATION; EXPRESSION; QUALITY; PROTEIN","P>Sperm chromatin compaction in the sperm head is achieved when histones are replaced by protamines during spermatogenesis. Haploinsufficiency of the protamine 1 (PRM1) or PRM2 gene causes infertility in mice. However, the published data remain inconclusive about a role of PRM1/2 variants in male infertility and their association with semen parameters. By full sequence analysis, we assessed the frequency of sequence variations in PRM1 and PRM2 in three groups of Caucasian patients with idiopathic teratozoospermia and normal (n = 88) or reduced sperm concentration (n = 83) and in men with a high percentage of normal sperm morphology and normal concentrations (n = 77). Two rare (c.54G > A and c.102G > T) and one common SNP (c.230A > C) were identified in PRM1. In PRM2, some rare heterozygous mutations and the two common intronic SNPs 298G > C and 373C > A were detected. None of the PRM1/2 variants was associated with teratozoospermia or individually with other semen parameters. However, significant linkage disequilibrium was detected between the common SNPs of PRM1 and PRM2 which formed haplotypes. Analysis of the pooled group (n = 248) revealed that homozygous carriers of the common haplotype ACC had a twofold higher sperm concentration and count than men lacking this haplotype, with sperm counts of heterozygotes for ACC being midway between the homozygotes. This markedly decreased sperm output might either be caused by spermatozoa lacking the ACC haplotype not being viable, or subject to negative selection. In addition, a significant deviation from Hardy-Weinberg-Equilibrium of these SNPs might indicate natural selection in favour of the ACC allele which leads to higher sperm output and therefore better fertility. In conclusion, for the first time we describe an association of a common haplotype formed by PRM1 and PRM2 with sperm output in a large group of men.","[Tuettelmann, F.; Nieschlag, E.; Gromoll, J.] Univ Munster, Inst Human Genet, D-48149 Munster, Germany; [Tuettelmann, F.; Roemer, S.; Simoni, M.] Univ Munster, Ctr Reprod Med & Androl, D-48149 Munster, Germany; [Krenkova, P.; Stambergova, A.; Macek, M., Jr.; Macek, M., Sr.] Fac Med 2, Ctr Reprod Genet, Inst Biol & Med Genet, Prague, Czech Republic; [Krenkova, P.; Stambergova, A.; Macek, M., Jr.; Macek, M., Sr.] Univ Hosp Motol, Prague, Czech Republic; [Nestorovic, A. R.] Inst Mol Genet & Genet Engn, Belgrade 11001, Serbia; [Simoni, M.] Univ Modena & Reggio Emilia, Dept Med Endocrinol Metab & Geriatr, Modena, Italy","Tuttelmann, F (reprint author), Univ Munster, Inst Human Genet, Vesaliusweg 12-14, D-48149 Munster, Germany.","frank.tuettelmann@ukmuenster.de","Simoni, Manuela/A-9600-2013",null,"Czech Ministry of Health [IGA NR9448-3/2007]","The authors would like to thank the patients and physicians who took care of them at the Centre of Reproductive Medicine and Andrology and Susan Nieschlag, MA, for language editing of the manuscript. This study was supported by the Czech Ministry of Health IGA NR9448-3/2007",null,24,7,8,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0105-6263","1365-2605",null,"INT J ANDROL","Int. J. Androl.","FEB",2010,33,1,null,null,null,null,"E240","E248",null,"10.1111/j.1365-2605.2009.01003.x",null,9,"Andrology","Endocrinology & Metabolism","541YH","WOS:000273457000030"]
[null,null,null,null,"J","Adam, V; Fabrik, I; Eckschlager, T; Stiborova, M; Trnkova, L; Kizek, R",null,null,null,"Adam, Vojtech; Fabrik, Ivo; Eckschlager, Tomas; Stiborova, Marie; Trnkova, Libuse; Kizek, Rene",null,null,"Vertebrate metallothioneins as target molecules for analytical techniques","TRAC-TRENDS IN ANALYTICAL CHEMISTRY",null,null,"English","Review",null,null,null,null,null,"Capillary electrophoresis; Electrochemistry; ELISA; Gel electrophoresis; High-performance liquid chromatography; Immunochemistry; Metallothionein; Saturation assay; Spectrometry; Voltammetry","LINKED-IMMUNOSORBENT-ASSAY; PLASMA-MASS SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; CAPILLARY-ZONE-ELECTROPHORESIS; BIOINORGANIC SPECIATION ANALYSIS; TRANSFER STRIPPING TECHNIQUE; RABBIT LIVER APOTHIONEINS; MERCURY SATURATION ASSAY; TUMOR-CELL LINES; HPLC-ICP-MS","Metallothioneins (MTs) are a family of ubiquitous, biologically interesting proteins that have been isolated and studied in a wide variety of organisms, including prokaryotes, plants, invertebrates and vertebrates. Due to the property of MTs being metal-inducible and their high affinity to metal ions, homeostasis of heavy-metal levels is probably their most important biological function. MTs are also involved in other important biochemical pathways, including scavenging of reactive oxygen species, activation of transcription factors and participation in carcinogenesis. Detection and quantification of MTs are not simple due to the unique primary structure and their relatively low molecular mass. Analytical methods are based on: a) detection of bound metal ion; b) detection of free -SH groups; c) protein mobility in electrical field; and, d) interaction with different types of sorbent. This review highlights techniques used for detection and determination of MTs with discussion of the advantages and the disadvantages of particular approaches. (C) 2010 Elsevier Ltd. All rights reserved.","[Adam, Vojtech; Fabrik, Ivo; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CZ-61137 Brno, Czech Republic","Kizek, R (reprint author), Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012",null,"GA AV [IAA401990701]; INCHEMBIOL [MSM0021622412]","Financial support from GA AV IAA401990701 and INCHEMBIOL MSM0021622412 is highly acknowledged. The authors wish to express their great thanks to Dr. Harry Martin and Dr. Jitka Petrlova for language correction.",null,106,64,64,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0165-9936",null,null,"TRAC-TREND ANAL CHEM","Trac-Trends Anal. Chem.","MAY",2010,29,5,null,null,null,null,409,418,null,"10.1016/j.trac.2010.02.004",null,10,"Chemistry, Analytical","Chemistry","596PW","WOS:000277698300014"]
[null,null,null,null,"J","Garin, I; Edghill, EL; Akerman, I; Rubio-Cabezas, O; Rica, I; Locke, JM; Maestro, MA; Alshaikh, A; Bundak, R; del Castillo, G; Deeb, A; Deiss, D; Fernandez, JM; Godbole, K; Hussain, K; O'Connell, M; Klupa, T; Kolouskova, S; Mohsin, F; Perlman, K; Sumnik, Z; Rial, JM; Ugarte, E; Vasanthi, T; Johnstone, K; Flanagan, SE; Martinez, R; Castano, C; Patch, AM; Fernandez-Rebollo, E; Raile, K; Morgan, N; Harries, LW; Castano, L; Ellard, S; Ferrer, J; de Nanclares, G; Hattersley, AT",null,null,null,"Garin, Intza; Edghill, Emma L.; Akerman, Ildem; Rubio-Cabezas, Oscar; Rica, Itxaso; Locke, Jonathan M.; Angel Maestro, Miguel; Alshaikh, Adnan; Bundak, Ruveyde; del Castillo, Gabriel; Deeb, Asma; Deiss, Dorothee; Fernandez, Juan M.; Godbole, Koumudi; Hussain, Khalid; O'Connell, Michele; Klupa, Thomasz; Kolouskova, Stanislava; Mohsin, Fauzia; Perlman, Kusiel; Sumnik, Zdenek; Rial, Jose M.; Ugarte, Estibaliz; Vasanthi, Thiruvengadam; Johnstone, Karen; Flanagan, Sarah E.; Martinez, Rosa; Castano, Carlos; Patch, Ann-Marie; Fernandez-Rebollo, Eduardo; Raile, Klemens; Morgan, Noel; Harries, Lorna W.; Castano, Luis; Ellard, Sian; Ferrer, Jorge; Perez de Nanclares, Guiomar; Hattersley, Andrew T.",null,"Neonatal Diabet Int Grp","Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis","PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA",null,null,"English","Article",null,null,null,null,null,"gene regulation; genetic testing; gene expression regulation; RNA instability; promoter regions","PANCREATIC BETA-CELL; ACTIVATING MUTATIONS; PROMOTER ACTIVITY; TRANSCRIPTION FACTOR; MUTANT MICE; MELLITUS; REGION; TRANSLATION; EXPRESSION; CHILDHOOD","Heterozygous coding mutations in the INS gene that encodes preproinsulin were recently shown to be an important cause of permanent neonatal diabetes. These dominantly acting mutations prevent normal folding of proinsulin, which leads to beta-cell death through endoplasmic reticulum stress and apoptosis. We now report 10 different recessive INS mutations in 15 probands with neonatal diabetes. Functional studies showed that recessive mutations resulted in diabetes because of decreased insulin biosynthesis through distinct mechanisms, including gene deletion, lack of the translation initiation signal, and altered mRNA stability because of the disruption of a polyadenylation signal. A subset of recessive mutations caused abnormal INS transcription, including the deletion of the C1 and E1 cis regulatory elements, or three different single base-pair substitutions in a CC dinucleotide sequence located between E1 and A1 elements. In keeping with an earlier and more severe beta-cell defect, patients with recessive INS mutations had a lower birth weight (-3.2 SD score vs.-2.0 SD score) and were diagnosed earlier (median 1 week vs. 10 weeks) compared to those with dominant INS mutations. Mutations in the insulin gene can therefore result in neonatal diabetes as a result of two contrasting pathogenic mechanisms. Moreover, the recessively inherited mutations provide a genetic demonstration of the essential role of multiple sequence elements that regulate the biosynthesis of insulin in man.","[Garin, Intza; Rica, Itxaso; Martinez, Rosa; Fernandez-Rebollo, Eduardo; Castano, Luis] Hosp Cruces, Endocrinol & Diabet Res Grp, Baracaldo 48903, Spain; [Garin, Intza; Akerman, Ildem; Angel Maestro, Miguel; Martinez, Rosa; Castano, Carlos; Fernandez-Rebollo, Eduardo; Castano, Luis; Ferrer, Jorge] Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Metab, Madrid 48903, Spain; [Garin, Intza; Martinez, Rosa; Fernandez-Rebollo, Eduardo; Castano, Luis] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras, Madrid 48903, Spain; [Edghill, Emma L.; Rubio-Cabezas, Oscar; Locke, Jonathan M.; Johnstone, Karen; Flanagan, Sarah E.; Patch, Ann-Marie; Morgan, Noel; Harries, Lorna W.; Ellard, Sian; Hattersley, Andrew T.] Univ Exeter, Inst Biomed & Clin Sci, Peninsula Med Sch, Exeter, Devon, England; [Akerman, Ildem; Angel Maestro, Miguel; Castano, Carlos; Ferrer, Jorge] Hosp Clin Barcelona, Barcelona, Spain; [Akerman, Ildem; Angel Maestro, Miguel; Castano, Carlos; Ferrer, Jorge] Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain; [Rubio-Cabezas, Oscar] Univ Nino Jesus, Hosp Infantil, Dept Endocrinol, Madrid, Spain; [Alshaikh, Adnan] Natl Guard Hlth Affairs, King Abdulaziz Med City, Jeddah, Saudi Arabia; [Bundak, Ruveyde] Istanbul Univ Hosp, Dept Pediat Endocrinol, Istanbul, Turkey; [Deeb, Asma] Imperial Coll London Diabet Ctr, Abu Dhabi, U Arab Emirates; [Deiss, Dorothee; Raile, Klemens] Virchow Childrens Hosp, Dept Pediat Diabetol & Endocrinol, Berlin, Germany; [Fernandez, Juan M.] Hosp Univ San Cecilio, Dept Pediat Endocrinol, Granada 18012, Spain; [Godbole, Koumudi] Deenanath Mangehskar Hosp & Res Ctr, Pune, Maharashtra, India; [Hussain, Khalid] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [O'Connell, Michele] Royal Childrens Hosp, Melbourne, Australia; [Klupa, Thomasz] Jagiellonian Univ, Coll Med, Dept Metab Dis, Krakow, Poland; [Kolouskova, Stanislava; Sumnik, Zdenek] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Mohsin, Fauzia] Bangladesh Inst Res & Rehabil Diabet Endocrine &, Pediat Diabet Team, Dhaka, Bangladesh; [Perlman, Kusiel] Hosp Sick Children, Div Endocrinol, Toronto, ON M5G 1X8, Canada; [Rial, Jose M.] Hosp Nuestra Senora Candelaria, Dept Pediat Endocrinol, Tenerife 38010, Spain; [Ugarte, Estibaliz] Hosp Basurto, Dept Endocrinol, Bilbao 48013, Spain; [Vasanthi, Thiruvengadam] Kanchi Kamakoti Childs Trust Hosp, Chennai, Tamil Nadu, India","de Nanclares, G (reprint author), Hosp Cruces, Endocrinol & Diabet Res Grp, Baracaldo 48903, Spain.","gnanclares@osakidetza.net; andrew.hattersley@pms.ac.uk","Patch, Ann-Marie/F-8060-2011; Diabetes, Enocrinologia/E-3998-2012; Rica, Itxaso /E-7645-2012; Diabetes, Genetica/E-6084-2012; cruces, bio/F-2549-2012; Castano, Luis/F-4150-2012; Harries, Lorna/D-2241-2014",null,"European Union [LSHM-CT-2006-518153, REG/F.2(2009)D/518731]; Wellcome Trust [067463/Z/2/Z, 081278/Z/06/Z]; Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas; Instituto de Salud Carlos III of the Spanish Ministry of Health [PI06/0690, CM06/00013, CP03/0064]; Basque Department of Education [BFI06.266]; Czech Ministry of Education [021620819, 64203]; Polish Diabetes Association; Research Councils United Kingdom; Peninsula Medical School","We thank Chris Boustred, Piers Fulton, Amna Khamis, Andrew Parrish, Gustavo Perez-Nanclares, Xavi Garcia, and Eleftheria Eiakogiannaki for technical assistance; Ann Kelly, Anthony Dixon, Srikanth Bellary, and Abigail Britten for supplying the Pakistani control DNAs; Dr Roland Stein (Vanderbilt University) for providing a human insulin promoter plasmid; and Dr Jun-ichi Miyazaki for the MIN6 cells. This work was funded by the European Union ( Integrated Project EURODIA LSHM-CT-2006-518153 in the Framework Programme 6 and CEED3 RTD REG/F.2(2009)D/518731 in the Framework Programme) To A. T. H. and J.F, Wellcome Trust Grants 067463/Z/2/Z ( to A. T. H.) and 081278/Z/06/Z ( to L. W. H.); the Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades Metabolicas and PI06/0690 from the Instituto de Salud Carlos III of the Spanish Ministry of Health ( to G.P.d.N.); Grant BFI06.266 from the Basque Department of Education ( to I. G.); an \"Ayuda para contratos post-Formacion Sanitaria Especializada\" from the \"Instituto de Salud Carlos III\" (FIS CM06/00013) ( to O.R.-C.); FIS researcher Grant CP03/0064 from the Instituto de Salud Carlos III of the Spanish Ministry of Health ( to G.P.d.N.); and Grants 021620819 from the Czech Ministry of Education and 64203 from the Czech Ministry of Health ( to Z.S.). Work in Poland is supported by the Polish Diabetes Association. A. T. H. is a Wellcome Trust Research Leave Fellow, L. W. H. is a Research Councils United Kingdom Academic Fellow, and J.M.L. is funded by a Peninsula Medical School PhD studentship.",null,44,44,48,"NATL ACAD SCIENCES","WASHINGTON","2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA","0027-8424",null,null,"P NATL ACAD SCI USA","Proc. Natl. Acad. Sci. U. S. A.","FEB 16",2010,107,7,null,null,null,null,3105,3110,null,"10.1073/pnas.0910533107",null,6,"Multidisciplinary Sciences","Science & Technology - Other Topics","556OC","WOS:000274599500072"]
[null,null,null,null,"J","Grenda, R; Watson, A; Trompeter, R; Tonshoff, B; Jaray, J; Fitzpatrick, M; Murer, L; Vondrak, K; Maxwell, H; van Damme-Lombaerts, R; Loirat, C; Mor, E; Cochat, P; Milford, DV; Brown, M; Webb, NJA",null,null,null,"Grenda, R.; Watson, A.; Trompeter, R.; Toenshoff, B.; Jaray, J.; Fitzpatrick, M.; Murer, L.; Vondrak, K.; Maxwell, H.; van Damme-Lombaerts, R.; Loirat, C.; Mor, E.; Cochat, P.; Milford, D. V.; Brown, M.; Webb, N. J. A.",null,null,"A Randomized Trial to Assess the Impact of Early Steroid Withdrawal on Growth in Pediatric Renal Transplantation: The TWIST Study","AMERICAN JOURNAL OF TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"Early steroid withdrawal; linear growth; pediatric kidney transplant","TACROLIMUS-BASED IMMUNOSUPPRESSION; MYCOPHENOLATE-MOFETIL; RECEIVING CYCLOSPORINE; BASILIXIMAB INDUCTION; DACLIZUMAB INDUCTION; FOLLOW-UP; CHILDREN; RECIPIENTS; THERAPY; MULTICENTER","Minimizing steroid exposure in pediatric renal transplant recipients can improve linear growth and reduce metabolic disorders. This randomized multicenter study investigated the impact of early steroid withdrawal on mean change in height standard deviation score (SDS) and the safety and efficacy of two immunosuppressive regimens during the first 6 months after transplantation. Children received tacrolimus, MMF, two doses of daclizumab and steroids until day 4 (TAC/MMF/DAC, n = 98) or tacrolimus, MMF and standard-dose steroids (TAC/MMF/STR, n = 98). Mean change in height SDS was 0.16 +/- 0.32 with TAC/MMF/DAC and 0.03 +/- 0.32 with TAC/MMF/STR. The mean treatment group difference was 0.13 (p < 0.005 [95% CI 0.04-0.22]), 0.21 in prepubertal (p = 0.009 [95% CI 0.05-0.36]) and 0.05 in pubertal children (p = ns). Frequency of biopsy-proven acute rejection was 10.2%, TAC/MMF/DAC, and 7.1%, TAC/MMF/STR. Patient and graft survival and renal function were similar. Significantly greater reductions in total cholesterol and triglycerides but significantly higher incidences of infection and anemia were found with TAC/MMF/DAC (p < 0.05 all comparisons). Early steroid withdrawal significantly aided growth at 6 months more so in prepubertal than pubertal children. This was accompanied by significantly better lipid and glucose metabolism profiles without increases in graft rejection or loss.","[Grenda, R.] Childrens Mem Hlth Inst, Warsaw, Poland; [Watson, A.] Univ Nottingham Hosp, Nottingham NG7 2UH, England; [Trompeter, R.] Great Ormond St Hosp Sick Children, London, England; [Toenshoff, B.] Univ Childrens Hosp, Heidelberg, Germany; [Jaray, J.] Semmelweis Univ, H-1085 Budapest, Hungary; [Fitzpatrick, M.] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England; [Murer, L.] Azienda Osped Padova, Dipartimento Pediat, Padua, Italy; [Vondrak, K.] Univ Hosp Motol, Prague, Czech Republic; [Maxwell, H.] Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland; [van Damme-Lombaerts, R.] Univ Ziekenhuis KU Leuven, Louvain, Belgium; [Loirat, C.] Hop Robert Debre, F-75019 Paris, France; [Mor, E.] Rabin Med Ctr, Petah Tiqwa, Israel; [Cochat, P.] Hop Femme Mere Enfant, Lyon, France; [Milford, D. V.] Birmingham Childrens Hosp, Birmingham, W Midlands, England; [Webb, N. J. A.] Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England","Grenda, R (reprint author), Childrens Mem Hlth Inst, Warsaw, Poland.","r.grenda@czd.pl",null,null,"Astellas Pharma Europe Ltd","The following investigators also participated in the TWIST study: Claude Guyot, Mihai Lucan, Bernd Hoppe, Nadeem Moghal, Moin Saleem, Caroline Jones, Luca Dello Strologo, Styrbjorn Friman, Mignon McCulloch, Nathalie Godefroid, Lars Pape, Po-Huang Lee, Alberto Edefonti, Francesco Perfumo, Dierdra Hahn. We acknowledge writing and editorial assistance provided by C. Krcmar who received payment from Astellas Pharma Europe Ltd for this work. The study sponsor, Astellas Pharma Europe Ltd, supplied funding and monitored the progress and conduct of the study.",null,36,43,44,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1600-6135",null,null,"AM J TRANSPLANT","Am. J. Transplant.","APR",2010,10,4,null,null,null,null,828,836,null,"10.1111/j.1600-6143.2010.03047.x",null,9,"Surgery; Transplantation","Surgery; Transplantation","571QA","WOS:000275768300019"]
[null,null,null,null,"J","Hedlin, G; Bush, A; Carlsen, KL; Wennergren, G; de Benedictis, FM; Melen, E; Paton, J; Wilson, N; Carlsen, KH",null,null,null,"Hedlin, G.; Bush, A.; Carlsen, K. Lodrup; Wennergren, G.; de Benedictis, F. M.; Melen, E.; Paton, J.; Wilson, N.; Carlsen, K-H.",null,"Problematic Severe Asthma","Problematic severe asthma in children, not one problem but many: a GA(2)LEN initiative","EUROPEAN RESPIRATORY JOURNAL",null,null,"English","Article",null,null,null,null,null,"Child; genes; problematic severe asthma; prognosis","RECEPTOR-BINDING-AFFINITY; CHILDHOOD ASTHMA; GLUCOCORTICOID-RECEPTOR; RESPIRATORY SYMPTOMS; CIGARETTE-SMOKING; BIRTH-COHORT; BODY-MASS; STRESS; EXACERBATIONS; ASSOCIATION","Although most children with asthma are easy to treat with low doses of safe medications, many remain symptomatic despite every therapeutic effort. The nomenclature regarding this group is confusing, and studies are difficult to compare due to the proliferation of terms describing poorly defined clinical entities. In this review of severe asthma in children, the term problematic severe asthma is used to describe children with any combination of chronic symptoms, acute severe exacerbations and persistent airflow limitation despite the prescription of multiple therapies. The approach to problematic severe asthma may vary with the age of the child, but, in general, three steps need to be taken in order to separate difficult-to-treat from severe therapy-resistant asthma. First, confirmation that the problem is really due to asthma requires a complete diagnostic re-evaluation. Secondly, the paediatrician needs to systematically exclude comorbidity, as well as personal or family psychosocial disorders. The third step is to re-evaluate medication adherence, inhaler technique and the child's environment. There is a clear need for a common international approach, since there is currently no uniform agreement regarding how best to approach children with problematic severe asthma. An essential first step is proper attention to basic care.","[Hedlin, G.] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Hedlin, G.] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Melen, E.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Wennergren, G.] Univ Gothenburg, Queen Silvia Childrens Hosp, Dept Paediat, Gothenburg, Sweden; [Bush, A.; Wilson, N.] Royal Brompton Hosp, Dept Resp Paediat, London SW3 6LY, England; [Paton, J.] Univ Glasgow, Div Dev Med, Royal Hosp Sick Children, Glasgow, Lanark, Scotland; [Carlsen, K. Lodrup; Carlsen, K-H.] Univ Oslo, Fac Med, Oslo, Norway; [Carlsen, K. Lodrup] Oslo Univ Hosp, Dept Paediat, Ulleval, Norway; [Carlsen, K-H.] Oslo Univ Hosp, Rikshosp, Oslo, Norway; [de Benedictis, F. M.] Salesi Childrens Hosp, Dept Paediat, Ancona, Italy","Hedlin, G (reprint author), Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Q2 05, S-17176 Stockholm, Sweden.","gunilla.hedlin@ki.se","Eber, Ernst/B-6381-2012",null,"European Union [FOOD-CT-2004-506378]","This review was initiated and supported by Work Package 2.8.1 of the Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN) (European Union contract number FOOD-CT-2004-506378).","Ayres JG, 1998, THORAX, V53, P315; Barton CA, 2005, J ASTHMA, V42, P249, DOI 10.1081/JAS-200057881; Bechard D E, 1998, Gastroenterology, V114, P849, DOI 10.1016/S0016-5085(98)70602-X; Belanger K, 2008, IMMUNOL ALLERGY CLIN, V28, P507, DOI 10.1016/j.iac.2008.03.011; Bergstrom SE, 2008, RESP MED, V102, P1335, DOI 10.1016/j.rmed.2008.03.020; Bergstrom SE, 2010, RESP MED, V104, P180, DOI 10.1016/j.rmed.2009.09.021; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; Bloomberg GR, 2005, IMMUNOL ALLERGY CLIN, V25, P83, DOI 10.1016/j.iac.2004.09.001; Bourdin A, 2009, THORAX, V64, P999, DOI 10.1136/thx.2008.112862; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Bush A, 2008, LANCET, V372, P1019, DOI 10.1016/S0140-6736(08)61422-1; Carroll CL, 2007, PEDIATRICS, V120, P734, DOI 10.1542/peds.2007-0409; Casale TB, 2008, J ALLERGY CLIN IMMUN, V121, P288, DOI 10.1016/j.jaci.2007.11.040; Chagani T, 1999, AM J RESP CRIT CARE, V160, P278; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chinn S, 2007, AM J RESP CRIT CARE, V176, P20, DOI 10.1164/rccm.200612-1840OC; de Benedictis D, 2007, PEDIATR PULM, V42, P683, DOI 10.1002/ppul.20650; de Benedictis FM, 1999, CHEST, V115, P550, DOI 10.1378/chest.115.2.550; Fleming L, 2009, ARCH DIS CHILD, V94, P780; Fleming L, 2007, CURR OPIN ALLERGY CL, V7, P190, DOI 10.1097/ACI.0b013e3280895d0c; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Hellings PW, 2009, IMMUNOL ALLERGY CLIN, V29, P733, DOI 10.1016/j.iac.2009.08.001; Howden-Chapman P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1411; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; KAM JC, 1993, J IMMUNOL, V151, P3460; Lang A, 2008, ALLERGY, V63, P1054, DOI 10.1111/j.1398-9995.2008.01672.x; Langley SJ, 2005, THORAX, V60, P17, DOI 10.1136/thx.2004.027839; Limb SL, 2005, J ALLERGY CLIN IMMUN, V115, P61, DOI 10.1016/j.jaci.2004.09.032; Livingston E, 2007, EUR RESPIR J, V29, P64, DOI 10.1183/09031936.06.00120505; Ma SF, 2008, GENET EPIDEMIOL, V32, P757, DOI 10.1002/gepi.20343; Malmstrom K, 2006, J ALLERGY CLIN IMMUN, V118, P591, DOI 10.1016/j.jaci.2006.04.032; Martin C. A., 1995, BNF Nutrition Bulletin, V20, P8; Matsui EC, 2008, IMMUNOL ALLERGY CLIN, V28, P665, DOI 10.1016/j.iac.2008.03.004; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Nimmagadda SR, 1997, AM J RESP CRIT CARE, V155, P87; Orrell-Valente JK, 2008, PEDIATRICS, V122, pE1186, DOI 10.1542/peds.2008-0292; Papadopoulos NG, 2007, ALLERGY, V62, P457, DOI 10.1111/j.1398-9995.2007.01341.x; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Quanjer PH, 2008, AM J RESP CRIT CARE, V178, P1262, DOI 10.1164/rccm.200805-700OC; Robinson DS, 2003, EUR RESPIR J, V22, P478, DOI 10.1183/09031936.03.00017003; Sandberg S, 2002, ACTA PAEDIATR, V91, P152, DOI 10.1080/080352502317285135; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Stordal K, 2005, ARCH DIS CHILD, V90, P956, DOI 10.1136/adc.2004.068890; STRUNK R C, 1985, Journal of the American Medical Association, V254, P1193, DOI 10.1001/jama.254.9.1193; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Toelle BG, 2004, EUR RESPIR J, V23, P66, DOI 10.1183/09031936.03.00046903; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Wolfe R, 2000, AM J RESP CRIT CARE, V162, P2177; Wright RJ, 2007, THORAX, V62, P106, DOI 10.1136/thx.2006.067926; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166",55,38,38,"EUROPEAN RESPIRATORY SOC JOURNALS LTD","SHEFFIELD","442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND","0903-1936","1399-3003",null,"EUR RESPIR J","Eur. Resp. J.","JUL",2010,36,1,null,null,null,null,196,201,null,"10.1183/09031936.00104809",null,6,"Respiratory System","Respiratory System","618YY","WOS:000279394100030"]
[null,null,null,null,"J","Meinhardt, A; Burkhardt, B; Zimmermann, M; Borkhardt, A; Kontny, U; Klingebiel, T; Berthold, F; Janka-Schaub, G; Klein, C; Kabickova, E; Klapper, W; Attarbaschi, A; Schrappe, M; Reiter, A",null,null,null,"Meinhardt, Andrea; Burkhardt, Birgit; Zimmermann, Martin; Borkhardt, Arndt; Kontny, Udo; Klingebiel, Thomas; Berthold, Frank; Janka-Schaub, Gritta; Klein, Christoph; Kabickova, Edita; Klapper, Wolfram; Attarbaschi, Andishe; Schrappe, Martin; Reiter, Alfred",null,null,"Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ACUTE-LYMPHOBLASTIC-LEUKEMIA; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; CHILDRENS ONCOLOGY GROUP; CENTRAL-NERVOUS-SYSTEM; ELDERLY-PATIENTS; INDUCED APOPTOSIS; CLINICAL-TRIALS; R-CHOP; ADOLESCENTS","Purpose The activity of rituximab in pediatric B-cell non-Hodgkin's lymphoma (B-NHL) has not yet been determined. We conducted a phase II window study to examine activity and tolerability of rituximab in newly diagnosed pediatric B-NHL. Patients and Methods Patients younger than age 19 years with CD20(+) B-NHL with at least one measurable site were eligible. Treatment consisted of rituximab at 375 mg/m(2) administered intravenously on day 1; concomitant therapy consisted of rasburicase, intrathecally (IT) triple drug (methotrexate, cytarabine, and prednisolone) on days 1 and 3 for CNS-positive patients and steroids only for anaphylaxis. Response criterion was the product of the two largest perpendicular diameters of one to three lesions and/or the percentage of blasts in bone marrow (BM) or peripheral blood (PB) within 24 hours before rituximab and on day 5. Responders had >= 25% decrease of at least one lesion or BM or PB blasts and no disease progress at other sites. Response rate (RR) was set at 45% for unfavorable activity or at 65% for favorable activity. Results From April 2004 to August 2008, 136 patients were enrolled. National Cancer Institute Common Toxicity Criteria 3/4 toxicities attributable to rituximab were general condition, 15%; fatigue, 13%; anaphylaxis, 7%; infection, 3%; glutamic-oxaloacetic transaminase/glutamic-pyruvic transaminase, 8%; no capillary leakage; and no toxic death. Forty-nine patients were not evaluable for response because of withdrawal from the study (n = 16), IT therapy in CNS-negative patients (n = 8), corticosteroid treatment (n = 3), technical inadequacy of response evaluation (n = 21), or no evaluable lesion (n = 1). Of 87 evaluable patients, 36 were responders (RR, 41.4%; 95% CI, 31% to 52%); among them, 27 of 67 with Burkitt lymphoma and seven of 15 with diffuse large B-cell lymphoma. A response was more frequently observed in BM (12 of 18) compared with solid tumor lesions (36 of 108; P = .007). Conclusion Rituximab is active as a single-agent in pediatric B-NHL even though the RR was lower than requested in the phase II plan.","Univ Giessen, Non Hodgkins Lymphoma Berlin Frankfurt Munster St, Giessen, Germany; Hosp Schleswig Holstein, Kiel, Germany; Hannover Med Sch, Ctr Child & Adolescent Med, D-3000 Hannover, Germany; Univ Dusseldorf, Ctr Child & Adolescent Med, Dusseldorf, Germany; Univ Freiburg, Ctr Child & Adolescent Med, D-7800 Freiburg, Germany; Goethe Univ Frankfurt, Frankfurt, Germany; Univ Cologne, Cologne, Germany; Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; St Anna Childrens Hosp, A-1090 Vienna, Austria","Reiter, A (reprint author), Univ Giessen, Dept Pediat Hematol & Oncol, Ctr Child & Adolescent Med, Feulgenstr 12, D-35392 Giessen, Germany.","alfred.reiter@paediat.med.uni-giessen.de","Klapper, Wolfram/D-2516-2010",null,"Deutsche Kinderkrebsstiftung (Bonn, Germany) [A 2006/6 DKS 2006.08]; Deutsche Kinderkrebsstiftung (Czech Republic) [IGA NS/9997-4, MZO FNM 2005]","Supported by the Deutsche Kinderkrebsstiftung, Grants No. A 2006/6 DKS 2006.08 (Bonn, Germany) and IGA NS/9997-4 and MZO FNM 2005 (Czech Republic).",null,33,32,34,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,null,"J CLIN ONCOL","J. Clin. Oncol.","JUL 1",2010,28,19,null,null,null,null,3115,3121,null,"10.1200/JCO.2009.26.6791",null,7,"Oncology","Oncology","617AX","WOS:000279254300005"]
[null,null,null,null,"J","Ladenstein, R; Valteau-Couanet, D; Brock, P; Yaniv, I; Castel, V; Laureys, G; Malis, J; Papadakis, V; Lacerda, A; Ruud, E; Kogner, P; Garami, M; Balwierz, W; Schroeder, H; Beck-Popovic, M; Schreier, G; Machin, D; Potschger, U; Pearson, A",null,null,null,"Ladenstein, Ruth; Valteau-Couanet, Dominique; Brock, Penelope; Yaniv, Isaac; Castel, Victoria; Laureys, Genevieve; Malis, Josef; Papadakis, Vassilios; Lacerda, Ana; Ruud, Ellen; Kogner, Per; Garami, Miklos; Balwierz, Walentyna; Schroeder, Henrik; Beck-Popovic, Maja; Schreier, Guenter; Machin, David; Potschger, Ulrike; Pearson, Andrew",null,null,"Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; RECEIVING MYELOSUPPRESSIVE CHEMOTHERAPY; NON-HODGKINS-LYMPHOMA; FEBRILE NEUTROPENIA; STAGE-4 NEUROBLASTOMA; ONCOLOGY-GROUP; METASTATIC NEUROBLASTOMA; DAILY FILGRASTIM; CHILDREN OLDER; GROWTH-FACTORS","Purpose To reduce the incidence of febrile neutropenia during rapid COJEC (cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide given in a rapid delivery schedule) induction. In the High- Risk Neuroblastoma- 1 (HR-NBL1) trial, the International Society of Paediatric Oncology European Neuroblastoma Group (SIOPEN) randomly assigned patients to primary prophylactic (PP) versus symptom-triggered granulocyte colony-stimulating factor (GCSF; filgrastim). Patients and Methods From May 2002 to November 2005, 239 patients in 16 countries were randomly assigned to receive or not receive PPGCSF. There were 144 boys with a median age of 3.1 years (range, 1 to 17 years) of whom 217 had International Neuroblastoma Staging System (INSS) stage 4 and 22 had stage 2 or 3 MYCN-amplified disease. The prophylactic arm received a single daily dose of 5 mu g/kg GCSF, starting after each of the eight COJEC chemotherapy cycles and stopping 24 hours before the next cycle. Chemotherapy was administered every 10 days regardless of hematologic recovery, provided that infection was controlled. Results The PPGCSF arm had significantly fewer febrile neutropenic episodes (P = .002), days with fever (P = .004), hospital days (P = .017), and antibiotic days (P = .001). Reported Common Toxicity Criteria (CTC) graded toxicity was also significantly reduced: infections per cycle (P = .002), fever (P = .001), severe leucopenia (P = .001), neutropenia (P = .001), mucositis (P = .002), nausea/vomiting (P = .045), and constipation (P = .008). Severe weight loss was reduced significantly by 50% (P = .013). Protocol compliance with the rapid induction schedule was also significantly better in the PPGCSF arm shown by shorter time to completion (P = .005). PPGCSF did not adversely affect response rates or success of peripheral-blood stem-cell harvest. Conclusion Following these results, PPG-GSF was advised for all patients on rapid COJEC induction.","[Ladenstein, Ruth] St Anna Childrens Hosp, A-1090 Vienna, Austria; St Anna Childrens Hosp, Childrens Canc Res Inst, Austrian Inst Technol, A-1090 Vienna, Austria; Inst Gustave Roussy, Villejuif, France; Great Ormond St Hosp Sick Children, London, England; Univ Leicester, Childrens Canc & Leukaemia Grp, Leicester, Leics, England; Royal Marsden Hosp, Sutton, Surrey, England; Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel; Hosp Univ Infantil La Fe, Valencia, Spain; Ghent Univ Hosp, B-9000 Ghent, Belgium; Univ Hosp Motol, Prague, Czech Republic; Athens Gen Paediat Hosp, Athens, Greece; Portuguese Inst Oncol, Lisbon, Portugal; Univ Oslo, Rikshosp, N-0027 Oslo, Norway; Karolinska Hosp, Astrid Lindgren Childrens Hosp, S-10401 Stockholm, Sweden; Semmelweiss Univ, Budapest, Hungary; Jagiellonian Univ, Coll Med, Krakow, Poland; Aarhus Univ Hosp, DK-8000 Aarhus, Denmark; Univ Lausanne Hosp, Lausanne, Switzerland","Ladenstein, R (reprint author), St Anna Childrens Hosp, Kinderspitalgasse 6, A-1090 Vienna, Austria.","ruth.ladenstein@ccri.at","Schreier, Guenter/C-2900-2009",null,"EC [QLRI-CT2002-01768]; Cancer Research UK (United Kingdom) [C8346/A8177]; Amgen International and Amgen UK","Supported by EC Grants No. QLRI-CT2002-01768 and C8346/A8177 from Cancer Research UK (United Kingdom), and from Amgen International and Amgen UK.",null,54,22,22,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,null,"J CLIN ONCOL","J. Clin. Oncol.","JUL 20",2010,28,21,null,null,null,null,3516,3524,null,"10.1200/JCO.2009.27.3524",null,9,"Oncology","Oncology","626YE","WOS:000280003700018"]
[null,null,null,null,"J","Sermet-Gaudelus, I; Girodon, E; Sands, D; Stremmler, N; Vavrova, V; Deneuville, E; Reix, P; Bui, S; Huet, F; Lebourgeois, M; Munck, A; Iron, A; Skalicka, V; Bienvenu, T; Roussel, D; Lenoir, G; Bellon, G; Sarles, J; Macek, M; Roussey, M; Fajac, I; Edelman, A",null,null,null,"Sermet-Gaudelus, Isabelle; Girodon, Emanuelle; Sands, Dorota; Stremmler, Nathalie; Vavrova, Vera; Deneuville, Eric; Reix, Philippe; Bui, Stephanie; Huet, Frederic; Lebourgeois, Muriel; Munck, Anne; Iron, Albert; Skalicka, Veronika; Bienvenu, Thierry; Roussel, Delphine; Lenoir, Gerard; Bellon, Gabriel; Sarles, Jacques; Macek, Milan; Roussey, Michel; Fajac, Isabelle; Edelman, Aleksander",null,null,"Clinical Phenotype and Genotype of Children with Borderline Sweat Test and Abnormal Nasal Epithelial Chloride Transport","AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE",null,null,"English","Article",null,null,null,null,null,"cystic fibrosis transmembrane conductance regulator (CFTR); cystic fibrosis; nasal potential difference; CFTR-related disorders","TRANSMEMBRANE REGULATOR GENE; NONCLASSIC CYSTIC-FIBROSIS; CFTR-RELATED DISEASES; POTENTIAL DIFFERENCE; MUTATIONS; REARRANGEMENTS; MECHANISMS; CONSENSUS; ADULTS","Rationale: The diagnosis of cystic fibrosis (CF) is based on a characteristic clinical picture in association with a sweat chloride (Cl(-)) concentration greater than 60 mmol/L or the identification of two CF-causing mutations. A challenging problem is the significant number of children for whom no definitive diagnosis is possible because they present with symptoms suggestive of CF, a sweat chloride level in the intermediate range between 30 and 60 mmol/L, and only one or no identified CF-causing mutation. Objectives: To investigate the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in the airways of children with intermediate sweat tests and inconclusive genetic findings in correlation with clinical phenotype and genotype. Methods: We developed a composite nasal potential difference (NPD) diagnostic score to discriminate patients with CF from non-CF patients. We tested NPD in 50 children (age, 6 mo to 18 yr) with equivocal diagnoses and correlated the NPD diagnostic score with clinical phenotypes and genotypes. Measurements and Main Results: Fifteen of the 50 children had NPD scores in the CF range. Eight of the 15 carried two CFTR mutations compared with only 5 of the 35 children with normal NPD scores (P = 0.01). They were significantly younger at evaluation and had recurrent lower respiratory tract infections, chronic productive coughs, and chronic Staphylococcus aureus colonization significantly more often than the 35 children with normal NPD results. Conclusions: Evaluation of CFTR function in the nasal epithelium of children with inconclusive CF diagnoses can be a useful diagnostic tool and help clinicians to individualize therapeutic strategy.","[Sermet-Gaudelus, Isabelle; Lebourgeois, Muriel; Lenoir, Gerard] Hop Necker Enfants Malad, AP HP, CRCM, F-75730 Paris, France; [Sermet-Gaudelus, Isabelle; Roussel, Delphine; Edelman, Aleksander] Univ Paris 05, Inst Natl Sante & Rech Med, U845, Paris, France; [Girodon, Emanuelle] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Serv Biochim Genet, Paris, France; [Sands, Dorota] Inst Mother & Child Hlth, Cyst Fibrosis Ctr, Warsaw, Poland; [Stremmler, Nathalie; Sarles, Jacques] Hop Enfants La Timone, Ctr Reference & Competence Mucoviscidose, Marseille, France; [Vavrova, Vera; Skalicka, Veronika; Macek, Milan] Charles Univ Prague, Cyst Fibrosis Ctr, Dept Pediat & Biol, Prague, Czech Republic; [Vavrova, Vera; Skalicka, Veronika; Macek, Milan] Charles Univ Prague, Cyst Fibrosis Ctr, Dept Med Genet, Prague, Czech Republic; [Vavrova, Vera; Skalicka, Veronika; Macek, Milan] Fac Med, Prague, Czech Republic; [Vavrova, Vera; Skalicka, Veronika; Macek, Milan] Univ Hosp Motol, Prague, Czech Republic; [Deneuville, Eric; Roussey, Michel] Hop Sud, Ctr Reference & Competence Mucoviscidose, Rennes, France; [Reix, Philippe; Bellon, Gabriel] Hop Debrousse, Ctr Reference & Competence Mucoviscidose, Lyon, France; [Bui, Stephanie] Grp Pellegrin Hop Enfants, Ctr Reference & Competence Mucoviscidose, Bordeaux, France; [Huet, Frederic] Hop Enfants Bocage, Ctr Reference & Competence Mucoviscidose, Dijon, France; [Munck, Anne] Hop Robert Debre, Ctr Reference & Competence Mucoviscidose, F-75019 Paris, France; [Bienvenu, Thierry] Hop Cochin, Serv Biochim Genet, F-75674 Paris, France; [Fajac, Isabelle] Hop Cochin, Ctr Reference & Competence Mucoviscidose, F-75674 Paris, France","Sermet-Gaudelus, I (reprint author), Hop Necker Enfants Malad, AP HP, CRCM, 156 Rue Vaugirard, F-75730 Paris, France.","isabelle.sermet@nck.aphp.fr",null,null,"Vaincre la Mucoviscidose; ABCF2 Association; Assistance Publique-Hopitaux de Paris [MZ0FNM2005]","Supported by Vaincre la Mucoviscidose, the ABCF2 Association, and Assistance Publique-Hopitaux de Paris, MZ0FNM2005.",null,33,15,15,"AMER THORACIC SOC","NEW YORK","61 BROADWAY, FL 4, NEW YORK, NY 10006 USA","1073-449X",null,null,"AM J RESP CRIT CARE","Am. J. Respir. Crit. Care Med.","OCT 1",2010,182,7,null,null,null,null,929,936,null,"10.1164/rccm.201003-0382OC",null,8,"Critical Care Medicine; Respiratory System","General & Internal Medicine; Respiratory System","660UZ","WOS:000282673200013"]
[null,null,null,null,"J","Rob, L; Halaska, M; Robova, H",null,null,null,"Rob, Lukas; Halaska, Michael; Robova, Helena",null,null,"Nerve-sparing and individually tailored surgery for cervical cancer","LANCET ONCOLOGY",null,null,"English","Review",null,null,null,null,null,null,"LAPAROSCOPIC RADICAL HYSTERECTOMY; POSTSURGICAL BLADDER FUNCTION; PELVIC AUTONOMIC NERVES; SURGICAL-TREATMENT; SEXUAL FUNCTION; LYMPH-NODES; NEOADJUVANT CHEMOTHERAPY; PARAMETRIAL INVOLVEMENT; CARDINAL LIGAMENT; PLEXUS TRAUMA","Cancer of the cervix is the second most common cancer in women worldwide, with about 500000 new cases and 273 000 deaths reported annually. Ideal surgical management of cervical cancer should reduce early and late morbidity without compromising oncological disease control. Type of surgical radicality in early cervical cancer should be a consequence of exact preoperative and intraoperative assessments of risk factors. During the past 15 years, substantial progress has been made in understanding the neuroanatomy of the autonomic pelvic plexus. This progress has resulted in individually tailored surgery for cervical cancer. The concept of preservation of autonomic nerves during radical hysterectomy has become standard in many oncogynaecological centres. Nerve-sparing radical hysterectomy and individually tailored surgery, in comparison with standard radical hysterectomy, have led to a much improved quality of life. Since 2008, there has been a new classification of radical hysterectomy, which includes nerve-sparing techniques. 5-year survival in early stage cervical cancer is 88-97% and more than 50% of women are younger than 50 years of age. Thus, we must take into consideration the quality of life of these patients. In this Review, we focus on the neuroanatomy of the pelvis and the possible damage of autonomic nerves, and suggest options for the sparing of these nerves during surgery for cervical cancer.","[Rob, Lukas; Halaska, Michael; Robova, Helena] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague 15000 5, Czech Republic","Rob, L (reprint author), Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Uvalu 84, Prague 15000 5, Czech Republic.","lukas.rob@lfmotol.cuni.cz",null,null,"Czech Ministry of Health [MZ CR NS 9905-4]","The authors are supported by grant MZ CR NS 9905-4 from the Czech Ministry of Health.",null,72,18,22,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1470-2045",null,null,"LANCET ONCOL","Lancet Oncol.","MAR",2010,11,3,null,null,null,null,292,301,null,null,null,10,"Oncology","Oncology","568MA","WOS:000275525300029"]
[null,null,null,null,"J","Kubinova, S; Horak, D; Kozubenko, N; Vanecek, V; Proks, V; Price, J; Cocks, G; Sykova, E",null,null,null,"Kubinova, Sarka; Horak, Daniel; Kozubenko, Nataliya; Vanecek, Vaclav; Proks, Vladimir; Price, Jack; Cocks, Graham; Sykova, Eva",null,null,"The use of superporous Ac-CGGASIKVAVS-OH-modified PHEMA scaffolds to promote cell adhesion and the differentiation of human fetal neural precursors","BIOMATERIALS",null,null,"English","Article",null,null,null,null,null,"Cell adhesion; Laminin; Mesenchymal stem cell; Neural cell; PolyHEMA","HYDROGELS; PEPTIDE; DEGRADATION; ATTACHMENT; OUTGROWTH; IKVAV","Modifications of poly(2-hydroxyethyl methacrylate) (PHEMA) with laminin-derived Ac-CGGASIKVAVS-OH peptide sequences have been developed to construct scaffolds that promote cell adhesion and neural differentiation. Radical copolymerization of 2-hydroxyethyl methacrylate with 2-aminoethyl methacrylate (AEMA) and ethylene dimethacrylate in the presence of ammonium oxalate crystals resulted in the formation of superporous P(HEMA-AEMA) hydrogels. They were reacted with gamma-thiobutyrolactone to yield 2-(4-sulfanylbutanamido)ethyl methacrylate (P(HEMA-AEMA)-SH) unit. The Ac-CGGASIKVAVS-OH peptide was immobilized to the sulfhydryl groups of P(HEMA-AEMA)-SH by 2,2'-dithiodipyridine linking reagent via 2-[4-(2-pyridyldisulfanyl)butanamido]ethyl methacrylate (P(HEMA-AEMA)-TPy). The adhesion and morphology of rat mesenchymal stem cells were investigated on the Ac-CGGASIKVAVS-OH-modified P(HEMA-AEMA) as well as on PHEMA, P(HEMA-AEMA)-SH and P(HEMA-AEMA)-TPy hydrogels. Superporous Ac-CGGASIKVAVS-OH-modified PHEMA scaffolds significantly increased the number of attached cells and their growth area on the hydrogel surface in the absence and in the presence of serum in the culture medium. Additionally, the Ac-CGGASIKVAVS-OH peptide supported the attachment, proliferation, differentiation and process spreading of human fetal neural stem cells during the first two weeks of expansion and contributed to the formation of a high percentage of more mature neural cells after four weeks of expansion. The Ac-CGGASIKVAVS-OH modification of superporous P(HEMA-AEMA) hydrogels improves cell adhesive properties and promotes neural stem cell differentiation. (C) 2010 Elsevier Ltd. All rights reserved.","[Horak, Daniel; Proks, Vladimir] Acad Sci Czech Republic, Inst Macromol Chem, VVI, CR-16206 Prague 6, Czech Republic; [Kubinova, Sarka; Kozubenko, Nataliya; Vanecek, Vaclav; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, VVI, Prague 14220 4, Czech Republic; [Horak, Daniel; Kozubenko, Nataliya; Vanecek, Vaclav; Proks, Vladimir; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15018 5, Czech Republic; [Price, Jack; Cocks, Graham] Kings Coll London, Ctr Cellular Basis Behav, Inst Psychiat, London SE5 9NU, England; [Vanecek, Vaclav; Sykova, Eva] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague 15006 5, Czech Republic","Horak, D (reprint author), Acad Sci Czech Republic, Inst Macromol Chem, VVI, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic.","horak@imc.cas.cz","Price, Jack/G-9510-2011",null,"EC [LSHM-CT-2007-037862, AVOZ 503 90 703, 1M0538, LC 554, GAAV IAA 500 390 902, KAN200200651, P108/10/1560, GA CR 309/08/H079]","We thank James Dutt for critical reading of the manuscript. This work was supported through grants: the EC FP6 project Artemis (LSHM-CT-2007-037862), AVOZ 503 90 703, 1M0538, LC 554, GAAV IAA 500 390 902, KAN200200651, P108/10/1560, GA CR 309/08/H079.",null,30,19,19,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0142-9612",null,null,"BIOMATERIALS","Biomaterials","AUG",2010,31,23,null,null,null,null,5966,5975,null,"10.1016/j.biomaterials.2010.04.040",null,10,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","623DZ","WOS:000279719600007"]
[null,null,null,null,"J","Zhang, F; Seeman, P; Liu, PF; Weterman, MAJ; Gonzaga-Jauregui, C; Towne, CF; Batish, SD; De Vriendt, E; De Jonghe, P; Rautenstrauss, B; Krause, KH; Khajavi, M; Posadka, J; Vandenberghe, A; Palau, F; Van Maldergem, L; Baas, F; Timmerman, V; Lupski, JR",null,null,null,"Zhang, Feng; Seeman, Pavel; Liu, Pengfei; Weterman, Marian A. J.; Gonzaga-Jauregui, Claudia; Towne, Charles F.; Batish, Sat Dev; De Vriendt, Els; De Jonghe, Peter; Rautenstrauss, Bernd; Krause, Klaus-Henning; Khajavi, Mehrdad; Posadka, Jan; Vandenberghe, Antoon; Palau, Francesc; Van Maldergem, Lionel; Baas, Frank; Timmerman, Vincent; Lupski, James R.",null,null,"Mechanisms for Nonrecurrent Genomic Rearrangements Associated with CMT1A or HNPP: Rare CNVs as a Cause for Missing Heritability","AMERICAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,null,"TOOTH DISEASE TYPE-1A; SEGMENTAL DUPLICATIONS; COMPLEX REARRANGEMENTS; HEREDITARY NEUROPATHY; REPLICATION SLIPPAGE; PRESSURE PALSIES; ALU ELEMENTS; GENE; DNA; RECOMBINATION","Genomic rearrangements involving the peripheral myelin protein gene (PMP22) in human chromosome 17p12 are associated with neuropathy: duplications cause Charcot-Marie-Tooth disease type IA (CMT1A), whereas deletions lead to hereditary neuropathy with liability to pressure palsies (HNPP). Our previous studies showed that >99% of these rearrangements are recurrent and mediated by nonallelic homologous recombination (NAHR). Rare copy number variations (CNVs) generated by nonrecurrent rearrangements also exist in 17p12, but their underlying mechanisms are not well understood. We investigated 21 subjects with rare CNVs associated with CMT1A or HNPP by oligonucleotide-based comparative genomic hybridization microarrays and breakpoint sequence analyses, and we identified 17 unique CNVs, including two genomic deletions, ten genomic duplications, two complex rearrangements, and three small exonic deletions. Each of these CNVs includes either the entire PMP22 gene, or exon(s) only, or ultraconserved potential regulatory sequences upstream of PMP22, further supporting the contention that PMP22 is the critical gene mediating the neuropathy phenotypes associated with 17p12 rearrangements. Breakpoint sequence analysis reveals that, different from the predominant NAHR mechanism in recurrent rearrangement, various molecular mechanisms, including nonhomologous end joining, Alu-Alu-mediated recombination, and replication-based mechanisms (e.g., FoSTeS and/or MMBIR), can generate nonrecurrent 17p12 rearrangements associated with neuropathy. We document a multitude of ways in which gene function can be altered by CNVs. Given the characteristics, including small size, structural complexity, and location outside of coding regions, of selected rare CNVs, their identification remains a challenge for genome analysis. Rare CNVs may potentially represent an important portion of \"missing heritability\" for human diseases.","[Zhang, Feng; Liu, Pengfei; Gonzaga-Jauregui, Claudia; Khajavi, Mehrdad; Lupski, James R.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Zhang, Feng] Fudan Univ, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; [Zhang, Feng] Fudan Univ, MOE Key Lab Contemporary Anthropol, Sch Life Sci, Shanghai 200433, Peoples R China; [Zhang, Feng] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China; [Seeman, Pavel; Posadka, Jan] Charles Univ Prague, Dept Child Neurol, DNA Lab, Sch Med 2, Prague 15006 5, Czech Republic; [Seeman, Pavel; Posadka, Jan] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Weterman, Marian A. J.; Baas, Frank] Univ Amsterdam, Acad Med Ctr, Neurogenet Lab, NL-1105 AZ Amsterdam, Netherlands; [Towne, Charles F.; Batish, Sat Dev] Athena Diagnosit Inc, Worcester, MA 01605 USA; [De Vriendt, Els; De Jonghe, Peter; Timmerman, Vincent] Univ Antwerp VIB, Dept Mol Genet, B-2610 Antwerp, Belgium; [De Vriendt, Els; De Jonghe, Peter; Timmerman, Vincent] Univ Antwerp, B-2610 Antwerp, Belgium; [Rautenstrauss, Bernd] Ctr Med Genet, D-80335 Munich, Germany; [Rautenstrauss, Bernd; Krause, Klaus-Henning] Univ Munich, Friedrich Baur Inst, D-80336 Munich, Germany; [Vandenberghe, Antoon] Biomnis Inc, F-69357 Lyon, France; [Palau, Francesc] CSIC, Inst Biomed, Valencia 46010, Spain; [Palau, Francesc] CIBERER, Valencia 46010, Spain; [Van Maldergem, Lionel] Univ Liege, Ctr Genet Humaine, B-4000 Liege, Belgium; [Lupski, James R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Lupski, James R.] Texas Childrens Hosp, Houston, TX 77030 USA","Lupski, JR (reprint author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.","jlupski@bcm.tmc.edu","Zhang, Feng/C-7735-2009; Palau, Francesc/A-9391-2014","Palau, Francesc/0000-0002-8635-5421","National Institute of Neurological Disorders and Stroke (NINDS, NIH) [R01NS058529]; Texas Children's Hospital General Clinical Research Center (GCRC) [M01RR00188]; Intellectual and Developmental Disabilities Research Centers (IDDRC) [P30HD024064]; Shanghai Pujiang Program; Ministry of Education of China [NCET-09-0322]; Ministry of Health of Czech Republic [IGA NS 10554-3]; University of Antwerp; FWO-Flanders; Belgian Federal Science Policy Office (BEL-SPO) [P6/43]; BMBF [01ES0815]","We thank all participating subjects and families for their kind cooperation in the study. We also thank Drs. E. Ehler, V. Farhanova, R. Mazanec, and J. Zvolska for sending patients to the CMT1A DNA diagnostics. This work was supported by the National Institute of Neurological Disorders and Stroke (NINDS, NIH) grant R01NS058529 to J.R.L.; Texas Children's Hospital General Clinical Research Center (GCRC) grant M01RR00188; and Intellectual and Developmental Disabilities Research Centers (IDDRC) grant P30HD024064. F.Z. is supported by Shanghai Pujiang Program and the Ministry of Education of China grant NCET-09-0322. P.S. is supported by Ministry of Health of Czech Republic grant IGA NS 10554-3. P.D.J. and V.T. are supported by a Methusalem grant of the University of Antwerp, the Fund for Scientific Research (FWO-Flanders), and the Interuniversity Attraction Poles program (P6/43) of the Belgian Federal Science Policy Office (BEL-SPO). B.R. is supported by the BMBF grant 01ES0815. J.R.L. is a consultant for Athena Diagnostics, 23andMe, and Ion Torrent Systems Inc., and holds multiple US and European patents for DNA diagnostics. Furthermore, the Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from molecular diagnostic testing (Medical Genetics Laboratories).",null,54,47,48,"CELL PRESS","CAMBRIDGE","600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA","0002-9297",null,null,"AM J HUM GENET","Am. J. Hum. Genet.","JUN 11",2010,86,6,null,null,null,null,892,903,null,"10.1016/j.ajhg.2010.05.001",null,12,"Genetics & Heredity","Genetics & Heredity","613AT","WOS:000278948900007"]
[null,null,null,null,"J","Gohring, G; Michalova, K; Beverloo, HB; Betts, D; Harbott, J; Haas, OA; Kerndrup, G; Sainati, L; Bergstraesser, E; Hasle, H; Stary, J; Trebo, M; van den Heuvel-Eibrink, MM; Zecca, M; van Wering, ER; Fischer, A; Noellke, P; Strahm, B; Locatelli, F; Niemeyer, CM; Schlegelberger, B",null,null,null,"Goehring, Gudrun; Michalova, Kyra; Beverloo, H. Berna; Betts, David; Harbott, Jochen; Haas, Oskar A.; Kerndrup, Gitte; Sainati, Laura; Bergstraesser, Eva; Hasle, Henrik; Stary, Jan; Trebo, Monika; van den Heuvel-Eibrink, Marry M.; Zecca, Marco; van Wering, Elisabeth R.; Fischer, Alexandra; Noellke, Peter; Strahm, Brigitte; Locatelli, Franco; Niemeyer, Charlotte M.; Schlegelberger, Brigitte",null,null,"Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"ACUTE MYELOID-LEUKEMIA; CYTOGENETIC ABNORMALITIES; THERAPY; MDS","To identify cytogenetic risk factors predicting outcome in children with advanced myelodysplastic syndrome, overall survival of 192 children prospectively enrolled in European Working Group of Myelodysplastic Syndrome in Childhood studies was evaluated with regard to karyotypic complexity. Structurally complex constitutes a new definition of complex karyotype characterized by more than or equal to 3 chromosomal aberrations, including at least one structural aberration. Five-year overall survival in patients with more than or equal to 3 clonal aberrations, which were not structurally complex, did not differ from that observed in patients with normal karyotype. Cox regression analysis revealed the presence of a monosomal and structurally complex karyotype to be strongly associated with poor prognosis (hazard ratio = 4.6, P < .01). Notably, a structurally complex karyotype without a monosomy was associated with a very short 2-year overall survival probability of only 14% (hazard ratio = 14.5; P < .01). The presence of a structurally complex karyotype was the strongest independent prognostic marker predicting poor outcome in children with advanced myelodysplastic syndrome. (Blood. 2010;116(19):3766-3769)","[Fischer, Alexandra; Noellke, Peter; Strahm, Brigitte; Niemeyer, Charlotte M.] Univ Hosp, Dept Adolescent & Pediat Med, D-79106 Freiburg, Germany; [Goehring, Gudrun; Schlegelberger, Brigitte] Hannover Med Sch, Inst Cell & Mol Pathol, D-3000 Hannover, Germany; [Michalova, Kyra] Charles Univ Prague, Ctr Oncocytogenet, Gen Fac Hosp, Prague, Czech Republic; [Beverloo, H. Berna] Erasmus Univ, Dept Clin Genet, Med Ctr, NL-3000 DR Rotterdam, Netherlands; [Beverloo, H. Berna; van den Heuvel-Eibrink, Marry M.; van Wering, Elisabeth R.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Betts, David; Bergstraesser, Eva] Univ Childrens Hosp, Dept Oncol, Zurich, Switzerland; [Harbott, Jochen] Univ Giessen, Dept Pediat Hematol Oncol, Giessen, Germany; [Haas, Oskar A.; Trebo, Monika] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Kerndrup, Gitte] Univ Hosp, Inst Pathol, Odense, Denmark; [Sainati, Laura] Univ Padua, Clin Oncoematol Pediat, Padua, Italy; [Hasle, Henrik] Aarhus Univ, Hosp Skejby, Dept Pediat, Aarhus, Denmark; [Stary, Jan] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [van den Heuvel-Eibrink, Marry M.] Erasmus Univ, Sophia Childrens Hosp, Dept Pediat Oncol, Rotterdam, Netherlands; [Zecca, Marco] Univ Pavia, Dept Pediat, Ist Ricovero & Cura Carattere Sci, Policlin San Matteo, I-27100 Pavia, Italy; [Locatelli, Franco] Bambino Gesu Pediat Hosp, Dept Pediat Hematol & Oncol, Rome, Italy","Niemeyer, CM (reprint author), Univ Hosp, Dept Adolescent & Pediat Med, Mathildenstr 1, D-79106 Freiburg, Germany.","charlotte.niemeyer@uniklinik-freiburg.de","Seys, Ellen/F-7416-2011",null,"COST Action (EuGESMA) [BM0801]; Czech Ministry of Education [MSM0021620813]","This work was supported by COST Action BM0801 (EuGESMA) and by the Czech Ministry of Education (MSM0021620813).",null,17,18,21,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","NOV 11",2010,116,19,null,null,null,null,3766,3769,null,"10.1182/blood-2010-04-280313",null,4,"Hematology","Hematology","678VM","WOS:000284110400016"]
[null,null,null,null,"J","Ehlers, S; Herbst, C; Zimmermann, M; Scharn, N; Germeshausen, M; von Neuhoff, N; Zwaan, CM; Reinhardt, K; Hollink, IH; Klusmann, JH; Lehrnbecher, T; Roettgers, S; Stary, J; Dworzak, M; Welte, K; Creutzig, U; Reinhardt, D",null,null,null,"Ehlers, Stephanie; Herbst, Christin; Zimmermann, Martin; Scharn, Nicole; Germeshausen, Manuela; von Neuhoff, Nils; Zwaan, Christian Michel; Reinhardt, Katarina; Hollink, Iris H.; Klusmann, Jan-Henning; Lehrnbecher, Thomas; Roettgers, Silja; Stary, Jan; Dworzak, Michael; Welte, Karl; Creutzig, Ursula; Reinhardt, Dirk",null,null,"Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated With a Higher Incidence of Relapse","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"SEVERE CONGENITAL NEUTROPENIA; ACUTE MYELOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; HYPERPROLIFERATIVE RESPONSES; CELLS; EXPRESSION; MUTATIONS; INDUCTION; CHILDREN; GROWTH","Purpose This prospective, multicenter Acute Myeloid Leukemia Berlin-Frankfurt-Muenster (AML-BFM) 98 study randomly tested the ability of granulocyte colony-stimulating factor (G-CSF) to reduce infectious complications and to improve outcomes in children and adolescents with acute myeloid leukemia (AML). However, a trend toward an increased incidence of relapses in the standard-risk (SR) group after G-CSF treatment was observed. Patients and Methods Of 154 SR patients in the AML-BFM 98 cohort, 50 patients were tested for G-CSF receptor (G-CSFR) RNA isoform I and IV expression, G-CSFR cell surface expression, and acquired mutations in the G-CSFR gene. Results In patients randomly assigned to receive G-CSF after induction, 16 patients overexpressing the G-CSFR isoform IV showed an increased 5-year cumulative incidence of relapse (50% +/- 13%) compared with 14 patients with low-level isoform IV expression (14% +/- 10%; log-rank P = .04). The level of G-CSFR isoform IV had no significant effect in patients not receiving G-CSF (P = .19). Multivariate analyses of the G-CSF-treated subgroup, including the parameters G-CSFR isoform IV overexpression, sex, and favorable cytogenetics as covariables, revealed the prognostic relevance of G-CSFR isoform IV overexpression for 5-year event-free survival (P = .031) and the 5-year cumulative incidence of relapse (P = .049). Conclusion Our results demonstrate that children and adolescents with AMLs that overexpress the differentiation-defective G-CSFR isoform IV respond to G-CSF administration after induction, but with a significantly higher incidence of relapse.","[Ehlers, Stephanie] Hannover Med Sch, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany; Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany; Goethe Univ Frankfurt, Frankfurt, Germany; Univ Giessen, Dept Pediat Hematol & Oncol, Giessen, Germany; Univ Childrens Hosp, Dept Pediat Hematol & Oncol, Munster, Germany; Erasmus MC Sophia Childrens Hosp, Dept Pediat Hematol & Oncol, Rotterdam, Netherlands; Charles Univ Prague, Sch Med 2, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; St Anna Childrens Hosp, Vienna, Austria","Ehlers, S (reprint author), Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.","ehlers.stephanie@mh-hannover.de","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Jose Carreras International Leukemia Foundation","Supported by grants from the Jose Carreras International Leukemia Foundation.",null,38,10,12,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,null,"J CLIN ONCOL","J. Clin. Oncol.","MAY 20",2010,28,15,null,null,null,null,2591,2597,null,"10.1200/JCO.2009.25.9010",null,7,"Oncology","Oncology","598JO","WOS:000277832400016"]
[null,null,null,null,"J","Salameh, A; Wustmann, A; Karl, S; Blanke, K; Apel, D; Rojas-Gomez, D; Franke, H; Mohr, FW; Janousek, J; Dhein, S",null,null,null,"Salameh, Aida; Wustmann, Anne; Karl, Sebastian; Blanke, Katja; Apel, Daniel; Rojas-Gomez, Diana; Franke, Heike; Mohr, Friedrich W.; Janousek, Jan; Dhein, Stefan",null,null,"Cyclic Mechanical Stretch Induces Cardiomyocyte Orientation and Polarization of the Gap Junction Protein Connexin43","CIRCULATION RESEARCH",null,null,"English","Article",null,null,null,null,null,"cyclic mechanical stretch; cardiomyocytes; connexin43; N-cadherin; ERK; angiotensin","NEONATAL-RAT CARDIOMYOCYTES; INDUCED CARDIAC-HYPERTROPHY; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; HEART-FAILURE; UP-REGULATION; MYOCYTES; CELLS; LOCALIZATION; INHIBITION","Rationale: Cyclic mechanical stretch (CMS) is an important physiological and pathological factor in the heart. Objective: We examined whether CMS can affect localization of gap junctions with regard to the cell axis. Methods and Results: Neonatal rat cardiomyocytes were cultured (7 days) on flexible 6-well plates. Thereafter, cells were kept static or stimulated with CMS (1 Hz; 0, 10, 20% elongation) for 0, 24, or 48 hours (with or without 10 mu mol/L PD98059, 5 mu mol/L BIM I (bisindolylmaleimide I), 2 mu mol/L H8 [N-(2-methlyamino-ethyl)-5-isoquinoline-sulfonamid], or 0.1 mu mol/L angiotensin II. Additionally, cells were exposed to 24 hours of CMS followed by 24 hours of static recovery. CMS (24 hour, 10%) induced elongation of the cardiomyocytes and orientation 79 +/- 8 degrees toward the stretch direction. Moreover, the distribution of connexin (Cx)43 together with N- cadherin changed, so that both proteins were accentuated at the cell poles, whereas in nonstretched cells, they were distributed around the cell without preferential localization. Additional angiotensin II reduced polar Cx43 accentuation. The CMS-induced changes in Cx43 were reversible within 24 hours after end of stretch, and could be completely prevented by the MEK1/2 inhibitor PD98059 but not by BIM I or H8. Moreover, stretch resulted in Cx43 protein and Cx43-mRNA upregulation and in a significant upregulation of the phosphorylated forms of ERK1/2, glycogen synthase kinase 3 beta and AKT. Furthermore, CMS resulted in a significant increase of the transcription factors activator protein 1 and CREB (cAMP response element-binding protein) in the nucleus. Conclusions: CMS results in self-organization of cardiomyocytes leading to elongated cells orientated transverse to the stretch axis, enhanced Cx43 expression and Cx43 accentuation at the cell poles. The Cx43-changes seem to depend on the ERK1/2 signaling cascade. (Circ Res. 2010;106:1592-1602.)","[Salameh, Aida] Univ Leipzig, Ctr Heart, Clin Pediat Cardiol, D-04289 Leipzig, Germany; [Wustmann, Anne; Apel, Daniel; Rojas-Gomez, Diana; Mohr, Friedrich W.; Dhein, Stefan] Univ Leipzig, Clin Cardiac Surg, D-04289 Leipzig, Germany; [Franke, Heike] Univ Leipzig, Rudolf Boehm Inst Pharmacol & Toxicol, D-04289 Leipzig, Germany","Salameh, A (reprint author), Univ Leipzig, Ctr Heart, Clin Pediat Cardiol, Struempellstr 39, D-04289 Leipzig, Germany.","aida.salameh@med.uni-leipzig.de",null,null,"Deutsche Forschungsgemeinschaft (DFG); ProCordis foundation (Leipzig)","This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG) and from the ProCordis foundation (Leipzig) (to S.D.).","Baba HA, 2003, CARDIOVASC RES, V59, P390, DOI 10.1016/S0008-6363(03)00393-6; Bailey J, 2002, J CLIN ENDOCR METAB, V87, P1717, DOI 10.1210/jc.87.4.1717; Beardslee MA, 1998, CIRC RES, V83, P629; DARROW BJ, 1995, CIRC RES, V76, P381; DAVIS LM, 1995, J CARDIOVASC ELECTR, V6, P813, DOI 10.1111/j.1540-8167.1995.tb00357.x; de Jonge HW, 2007, CELL BIOCHEM BIOPHYS, V47, P21; Dupont E, 2001, J MOL CELL CARDIOL, V33, P359, DOI 10.1006/jmcc.2000.1308; Echetebu CO, 1999, MOL HUM REPROD, V5, P757, DOI 10.1093/molehr/5.8.757; Fallon R.F., 1981, J CELL BIOL, V127, P343; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Jozwiak J, 2008, N-S ARCH PHARMACOL, V378, P459, DOI 10.1007/s00210-008-0317-4; KIM CH, 2002, CIRC RES, V90, P25; Kostin S, 2004, CARDIOVASC RES, V62, P426, DOI 10.1016/j.cardiores.2003.12.010; KWAK BR, 1995, MOL BIOL CELL, V6, P1707; Laird DW, 1996, J BIOENERG BIOMEMBR, V28, P311, DOI 10.1007/BF02110107; LAMPE PD, 1994, J CELL BIOL, V127, P1895, DOI 10.1083/jcb.127.6.1895; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Markou T, 2004, J MOL CELL CARDIOL, V37, P1001, DOI 10.1016/j.yjmcc.2004.08.002; Matsuda T, 2005, BIOCHEM BIOPH RES CO, V326, P228, DOI 10.1016/j.bbrc.2004.11.019; Matsuda T, 2006, J MOL CELL CARDIOL, V40, P495, DOI 10.1016/j.yjmcc.2005.12.010; Polontchouk L, 2001, J AM COLL CARDIOL, V38, P883, DOI 10.1016/S0735-1097(01)01443-7; Polontchouk Lioudmila, 2002, FASEB Journal, V16, P87; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Saffitz JE, 1999, CARDIOVASC RES, V42, P309, DOI 10.1016/S0008-6363(99)00023-1; Salameh A, 2006, FASEB J, V20, P365, DOI 10.1096/fj.05-4871fje; Salameh A, 2008, J PHARMACOL EXP THER, V326, P315, DOI 10.1124/jpet.108.136663; Salameh A, 2009, BRIT J PHARMACOL, V158, P198, DOI 10.1111/j.1476-5381.2009.00344.x; Sepp R, 1996, HEART, V76, P412, DOI 10.1136/hrt.76.5.412; Shanker AJ, 2005, CIRC RES, V96, P558, DOI 10.1161/01.RES.0000158964.42008.a2; Shyu KG, 2001, J MOL CELL CARDIOL, V33, P691, DOI 10.1006/jmcc.2000.1333; TenBroek EM, 2001, J CELL BIOL, V155, P1307, DOI 10.1083/jcb.200102017; THORBURN J, 1995, MOL BIOL CELL, V6, P1479; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; Wang TL, 2000, BIOCHEM BIOPH RES CO, V267, P551, DOI 10.1006/bbrc.1999.1988",35,34,35,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7330",null,null,"CIRC RES","Circ.Res.","MAY 28",2010,106,10,null,null,null,null,1592,1602,null,"10.1161/CIRCRESAHA.109.214429",null,11,"Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease","Cardiovascular System & Cardiology; Hematology","601ZL","WOS:000278107400006"]
[null,null,null,null,"J","Janda, A; Sedlacek, P; Honig, M; Friedrich, W; Champagne, M; Matsumoto, T; Fischer, A; Neven, B; Contet, A; Bensoussan, D; Bordigoni, P; Loeb, D; Savage, W; Jabado, N; Bonilla, FA; Slatter, MA; Davies, EG; Gennery, AR",null,null,null,"Janda, Ales; Sedlacek, Petr; Hoenig, Manfred; Friedrich, Wilhelm; Champagne, Martin; Matsumoto, Tadashi; Fischer, Alain; Neven, Benedicte; Contet, Audrey; Bensoussan, Danielle; Bordigoni, Pierre; Loeb, David; Savage, William; Jabado, Nada; Bonilla, Francisco A.; Slatter, Mary A.; Davies, E. Graham; Gennery, Andrew R.",null,null,"Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"BONE-MARROW-TRANSPLANTATION; SEVERE COMBINED IMMUNODEFICIENCY; COMBINED IMMUNE-DEFICIENCY; THYMUS TRANSPLANTATION; CHARGE SYNDROME; CONSTITUTION; INFANTS","Seventeen patients transplanted with hematopoietic cells to correct severe T lymphocyte immunodeficiency resulting from complete DiGeorge anomaly were identified worldwide, and retrospective data were obtained using a questionnaire-based survey. Patients were treated at a median age of 5 months (range, 2-53 months) between 1995 and 2006. Bone marrow was used in 11 procedures in 9 cases: 6 from matched unrelated donors, 4 from human leukocyte antigen (HLA)-identical siblings, and one haploidentical parent with T-cell depletion. Unmobilized peripheral blood was used in 8 cases: 5 from HLA-identical siblings, one from a matched unrelated donor, one from an HLA-identical parent, and one unrelated matched cord blood. Conditioning was used in 5 patients and graftversus-host disease prophylaxis in 11 patients. Significant graft-versus-host disease occurred in 9 patients, becoming chronic in 3. Median length of follow-up was 13 months, with transplantation from HLA-matched sibling showing the best results. Median survival among deceased patients (10 patients) was 7 months after transplantation (range, 2-18 months). The overall survival rate was 41%, with a median follow-up of 5.8 years (range, 4-11.5 years). Among survivors, median CD3 and CD4 counts were 806 (range, 644-1224) and 348 (range, 225-782) cells/mm(3), respectively, CD4(+)/CD45RA(+) cells remained very low, whereas mitogen responses were normalized. (Blood. 2010;116(13):2229-2236)","[Janda, Ales; Sedlacek, Petr] Charles Univ Prague, Dept Pediat Hematol & Oncol, Univ Hosp Motol, Prague, Czech Republic; [Janda, Ales; Sedlacek, Petr] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Hoenig, Manfred; Friedrich, Wilhelm] Univ Ulm, Dept Pediat, D-7900 Ulm, Germany; [Champagne, Martin] CHU Ste Justine, Dept Pediat Hematol & Oncol, Montreal, PQ, Canada; [Matsumoto, Tadashi] Nagasaki Univ, Sch Med, Dept Pediat, Nagasaki 852, Japan; [Fischer, Alain; Neven, Benedicte] Necker Enfants Malades Hosp, AP HP, Pediat Immunohematol Unit, Paris, France; [Contet, Audrey; Bensoussan, Danielle; Bordigoni, Pierre] Vandouevre, Dept Pediat, Nancy, France; [Loeb, David; Savage, William] Johns Hopkins Univ Hosp, Baltimore, MD 21205 USA; [Jabado, Nada] McGill Univ, Dept Pediat, Montreal Childrens Hosp Res Inst, Ctr Hlth, Montreal, PQ H3A 2T5, Canada; [Bonilla, Francisco A.] Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Slatter, Mary A.; Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Davies, E. Graham] Great Ormond St Hosp Sick Children, Dept Immunol, London, England","Janda, A (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Univ Hosp Motol, Prague, Czech Republic.","ales.janda@lfmotol.cuni.cz",null,null,"Czech Ministry of Education [VZ MSM CR 21620812]; Czech Ministry of Health [MZOFNM2005]","This work was supported in part by the Czech Ministry of Education (grant VZ MSM CR 21620812) and the Czech Ministry of Health (grant MZOFNM2005).",null,26,9,9,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","SEP 30",2010,116,13,null,null,null,null,2229,2236,null,"10.1182/blood-2010-03-275966",null,8,"Hematology","Hematology","656VR","WOS:000282369700009"]
[null,null,null,null,"J","Vlkova, M; Fronkova, E; Kanderova, V; Janda, A; Ruzickova, S; Litzman, J; Sediva, A; Kalina, T",null,null,null,"Vlkova, Marcela; Fronkova, Eva; Kanderova, Veronika; Janda, Ales; Ruzickova, Sarka; Litzman, Jiri; Sediva, Anna; Kalina, Tomas",null,null,"Characterization of Lymphocyte Subsets in Patients with Common Variable Immunodeficiency Reveals Subsets of Naive Human B Cells Marked by CD24 Expression","JOURNAL OF IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,null,"PERIPHERAL-BLOOD; ANTIGEN RECEPTOR; CVID PATIENTS; UP-REGULATION; COMPARTMENT; EXPANSION; DISEASE; DIFFERENTIATION; ABNORMALITIES; DEFICIENCY","Increased proportions of naive B cell subset and B cells defined as CD27(neg)CD21(neg)CD38(neg) are frequently found in patients with common variable immunodeficiency (CVID) syndrome. Current methods of polychromatic flow cytometry and PCR-based detection of kappa deletion excision circles allow for fine definitions and replication history mapping of infrequent B cell subsets. We have analyzed B cells from 48 patients with CVID and 49 healthy controls to examine phenotype, frequency, and proliferation history of naive B cell subsets. Consistent with previous studies, we have described two groups of patients with normal (CVID-21norm) or increased (CVID-21lo) proportions of CD27(neg)CD21(neg)CD38(neg) B cells. Upon further analyses, we found two discrete subpopulations of this subset based on the expression of CD24. The B cell subsets showed a markedly increased proliferation in CVID-21lo patients as compared with healthy controls, suggesting developmental arrest rather than increased bone marrow output. Furthermore, when we analyzed CD21(pos) naive B cells, we found two different subpopulations based on IgM and CD24 expression. They correspond to follicular (FO) I and FO II cells previously described in mice. FO I subset is significantly underrepresented in CVID-21lo patients. A comparison of the replication history of naive B cell subsets in CVID patients and healthy controls implies refined naive B cell developmental scheme, in which human transitional B cells develop into FO II and FO I. We propose that the CD27(neg)CD21(neg)CD38(neg) B cells increased in some of the CVID patients originate from the two FO subsets after loss of CD21 expression. The Journal of Immunology, 2010, 185: 6431-6438.","[Vlkova, Marcela; Litzman, Jiri] Masaryk Univ, St Annes Univ Hosp, Dept Clin Immunol & Allergol, Brno 65691, Czech Republic; [Vlkova, Marcela; Litzman, Jiri] Masaryk Univ, Fac Med, Brno 65691, Czech Republic; [Fronkova, Eva; Kanderova, Veronika; Janda, Ales; Kalina, Tomas] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague, Czech Republic; [Sediva, Anna] Charles Univ Prague, Dept Immunol, Sch Med 2, Prague, Czech Republic; [Sediva, Anna] Univ Hosp Motol, Prague, Czech Republic; [Fronkova, Eva; Kanderova, Veronika; Kalina, Tomas] Childhood Leukemia Invest Prague, Prague, Czech Republic; [Ruzickova, Sarka] Acad Sci Czech Republic, Inst Biotechnol, Lab Diagnost Autoimmune Dis, VVI, Prague, Czech Republic","Vlkova, M (reprint author), Masaryk Univ, St Annes Univ Hosp, Dept Clin Immunol & Allergol, Pekarska 53, Brno 65691, Czech Republic.","marcela.vlkova@fnusa.cz","Litzman, Jiri/E-2746-2012",null,"Czech Ministry of Health [NT-11414, 10398-3, MZ0FNM2005]; Grant Agency of the Czech Republic [310/09/P058]; Ministry of Education, Sports, and Youth of the Czech Republic [AVOZ50520701]","This work was supported by Grants NT-11414, 10398-3, and MZ0FNM2005 from the Czech Ministry of Health, Grant Agency of the Czech Republic 310/09/P058, and Research Plan AVOZ50520701 from the Ministry of Education, Sports, and Youth of the Czech Republic.",null,34,4,4,"AMER ASSOC IMMUNOLOGISTS","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","0022-1767",null,null,"J IMMUNOL","J. Immunol.","DEC 1",2010,185,11,null,null,null,null,6431,6438,null,"10.4049/jimmunol.0903876",null,8,"Immunology","Immunology","681KJ","WOS:000284311500007"]
[null,null,null,null,"J","Bruggemann, M; Schrauder, A; Raff, T; Pfeifer, H; Dworzak, M; Ottmann, OG; Asnafi, V; Baruchel, A; Bassan, R; Benoit, Y; Biondi, A; Cave, H; Dombret, H; Fielding, AK; Foa, R; Gokbuget, N; Goldstone, AH; Goulden, N; Henze, G; Hoelzer, D; Janka-Schaub, GE; Macintyre, EA; Pieters, R; Rambaldi, A; Ribera, JM; Schmiegelow, K; Spinelli, O; Stary, J; von Stackelberg, A; Kneba, M; Schrappe, M; van Dongen, JJM",null,null,null,"Brueggemann, M.; Schrauder, A.; Raff, T.; Pfeifer, H.; Dworzak, M.; Ottmann, O. G.; Asnafi, V.; Baruchel, A.; Bassan, R.; Benoit, Y.; Biondi, A.; Cave, H.; Dombret, H.; Fielding, A. K.; Foa, R.; Goekbuget, N.; Goldstone, A. H.; Goulden, N.; Henze, G.; Hoelzer, D.; Janka-Schaub, G. E.; Macintyre, E. A.; Pieters, R.; Rambaldi, A.; Ribera, J-M; Schmiegelow, K.; Spinelli, O.; Stary, J.; von Stackelberg, A.; Kneba, M.; Schrappe, M.; van Dongen, J. J. M.",null,"European Working Grp Adult Acute L; Int Berlin-Frankfurt-Munster Study","Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008","LEUKEMIA",null,null,"English","Review",null,null,null,null,null,"acute lymphoblastic leukemia; ALL; minimal residual disease; MRD; flow cytometry; PCR","ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL-RESIDUAL-DISEASE; POLYMERASE-CHAIN-REACTION; TIME QUANTITATIVE PCR; PRECURSOR-B-ALL; ACUTE PROMYELOCYTIC LEUKEMIA; BONE-MARROW-TRANSPLANTATION; IG/TCR GENE REARRANGEMENTS; STEM-CELL TRANSPLANTATION; FLOW-CYTOMETRY","Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR-and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols. Leukemia (2010) 24, 521-535; doi:10.1038/leu.2009.268; published online 24 December 2009","[Brueggemann, M.; Raff, T.; Kneba, M.] Univ Hosp Schleswig Holstein, Dept Hematol, D-24116 Kiel, Germany; [Schrauder, A.; Schrappe, M.] Univ Hosp Schleswig Holstein, Dept Pediat, D-24116 Kiel, Germany; [Pfeifer, H.; Ottmann, O. G.; Goekbuget, N.] Goethe Univ Frankfurt, Med Klin 2, Dept Hematol & Oncol, Frankfurt, Germany; [Dworzak, M.] St Anna Childrens Hosp, Dept Hematooncol, A-1090 Vienna, Austria; [Asnafi, V.; Macintyre, E. A.] AP HP GH Necker Enfants Malad & Paris Descartes U, Dept Hematol, Paris, France; [Baruchel, A.] St Louis Univ Hosp, Dept Pediat Hematol, Paris, France; [Bassan, R.; Rambaldi, A.; Spinelli, O.] Osped Riuniti Bergamo, Unita Strutturale Complessa Ematol, I-24100 Bergamo, Italy; [Benoit, Y.] Ghent Univ Hosp, Dept Pediat Hematol Oncol, B-9000 Ghent, Belgium; [Biondi, A.] Univ Milano Bicocca, Pediat Clin, Osped Nuovo San Gerardo, Monza, Italy; [Biondi, A.] Childhood Leukemia Res Ctr M Tettamanti, Monza, Italy; [Cave, H.] CHU Robert Debre, Dept Genet, Paris, France; [Dombret, H.] CHU St Louis, Dept Hematol, Paris, France; [Fielding, A. K.] UCL, Dept Hematol, London, England; [Foa, R.] Univ Roma La Sapienza, Div Hematol, Dept Cellular Biotechnol & Hematol, Rome, Italy; [Goldstone, A. H.; von Stackelberg, A.] Univ Coll London Hosp, Dept Hematol, London, England; [Goulden, N.] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Henze, G.] Charite, Univ Berlin, Dept Pediat Oncol Hematol, D-13353 Berlin, Germany; [Janka-Schaub, G. E.] Univ Hamburg Hosp, Clin Pediat Hematol & Oncol, Dept Pediat Hematol & Oncol, D-2000 Hamburg, Germany; [Pieters, R.] Sophia Childrens Univ Hosp, Erasmus MC, Univ Med Ctr, Dept Paediat Oncol & Haematol, Rotterdam, Netherlands; [Ribera, J-M] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Dept Haematol, Badalona, Spain; [Schmiegelow, K.] Univ Copenhagen, Inst Gynaecol Obstet & Paediat, Copenhagen, Denmark; [Schmiegelow, K.] Rigshosp, Univ Hosp, Paediat Clin, DK-2100 Copenhagen, Denmark; [Stary, J.] Charles Univ Prague, Dept Paediat Haematol & Oncol, CLIP, Fac Med 2, Prague, Czech Republic; [Stary, J.] Univ Hosp Motol, Prague, Czech Republic; [van Dongen, J. J. M.] Erasmus MC, Univ Med Ctr, Dept Immunol, Rotterdam, Netherlands","Bruggemann, M (reprint author), Univ Hosp Schleswig Holstein, Dept Hematol, Campus Kiel,Chemnitzstr 33, D-24116 Kiel, Germany.","m.brueggemann@med2.uni-kiel.de","Schrappe, Martin/A-8109-2010; Fielding, Adele/J-6949-2013; Bruggemann, Monika/M-8150-2013","Fielding, Adele/0000-0002-4746-7789; Bruggemann, Monika/0000-0001-5514-5010","European LeukemiaNet","This study was supported in part by the European LeukemiaNet.",null,91,76,80,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","MAR",2010,24,3,null,null,null,null,521,535,null,"10.1038/leu.2009.268",null,15,"Oncology; Hematology","Oncology; Hematology","566UV","WOS:000275399600004"]
[null,null,null,null,"J","Gefen, N; Binder, V; Zaliova, M; Linka, Y; Morrow, M; Novosel, A; Edry, L; Hertzberg, L; Shomron, N; Williams, O; Trka, J; Borkhardt, A; Izraeli, S",null,null,null,"Gefen, N.; Binder, V.; Zaliova, M.; Linka, Y.; Morrow, M.; Novosel, A.; Edry, L.; Hertzberg, L.; Shomron, N.; Williams, O.; Trka, J.; Borkhardt, A.; Izraeli, S.",null,null,"Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia (ALL); ETV6/RUNX1; TEL/AML1; microRNA","ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL LYMPHOMAS; GENE-EXPRESSION; DOWN-SYNDROME; BA/F3 CELLS; STEM-CELLS; PROLIFERATION; RNA; MUTATIONS; MICRORNAS","MicroRNAs (miRNAs) regulate the expression of multiple proteins in a dose-dependent manner. We hypothesized that increased expression of miRNAs encoded on chromosome 21 (chr 21) contribute to the leukemogenic function of trisomy 21. The levels of chr 21 miRNAs were quantified by qRT-PCR in four types of childhood acute lymphoblastic leukemia (ALL) characterized by either numerical (trisomy or tetrasomy) or structural abnormalities of chr 21. Suprisingly, high expression of the hsa-mir-125b-2 cluster, consisting of three miRNAs, was identified in leukemias with the structural ETV6/RUNX1 abnormality and not in ALLs with trisomy 21. Manipulation of ETV6/RUNX1 expression and chromatin immunoprecipitation studies showed that the high expression of the miRNA cluster is an event independent of the ETV6/RUNX1 fusion protein. Overexpression of hsa-mir-125b-2 conferred a survival advantage to Ba/F3 cells after IL-3 withdrawal or a broad spectrum of apoptotic stimuli through inhibition of caspase 3 activation. Conversely, knockdown of the endogenous miR-125b in the ETV6/RUNX1 leukemia cell line REH increased apoptosis after Doxorubicin and Staurosporine treatments. P53 protein levels were not altered by miR-125b. Together, these results suggest that the expression of hsa-mir-125b-2 in ETV6/RUNX1 ALL provides survival advantage to growth inhibitory signals in a p53-independent manner. Leukemia (2010) 24, 89-96; doi:10.1038/leu.2009.208; published online 5 November 2009","[Gefen, N.; Binder, V.; Hertzberg, L.; Izraeli, S.] Chaim Sheba Med Ctr, Sect Funct Genom & Leukemia Res, Dept Pediat Hematooncol, IL-52621 Tel Hashomer, Ramat Gan, Israel; [Gefen, N.; Hertzberg, L.; Izraeli, S.] Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; [Binder, V.; Linka, Y.; Novosel, A.; Borkhardt, A.] Univ Dusseldorf, Dept Pediat Hematol Oncol & Immunol, Dusseldorf, Germany; [Zaliova, M.; Trka, J.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague, Czech Republic; [Zaliova, M.; Trka, J.] Univ Hosp Motol, Prague, Czech Republic; [Edry, L.; Shomron, N.] Tel Aviv Univ, Sackler Fac Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel; [Morrow, M.; Williams, O.] UCL, Inst Child Hlth, London, England; [Hertzberg, L.] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel","Izraeli, S (reprint author), Chaim Sheba Med Ctr, Sect Funct Genom & Leukemia Res, Dept Pediat Hematooncol, IL-52621 Tel Hashomer, Ramat Gan, Israel.","sizraeli@sheba.health.gov.il","Xie, Huangming/B-2260-2012; Williams, Owen/B-5003-2013","Williams, Owen/0000-0002-1760-6880","National Institute of Health [R01 CA120772-01A2]; German Israeli Foundation; The Wolfson Foundation; Israel Science Foundation Morasha; Children with Leukaemia UK; Leukemia Research Fund UK; Curtis Katz [MSM0021620813, MZO00064203]; Jewish National Fund, UK; Claudine Galli Foundation; Converging Technologies program; Elterninitiative Kinderkrebsklinik Duesseldorf","We thank J Crispino, G Lavi and Y Sidi for providing reagents; M Oren for fruitful discussions and provision of reagents; the Department of Pediatric Hematology and Oncology, Dr von Haunersches Kinderspital, Munich, Germany, for providing clinical samples; members of SI and AB laboratories for helpful discussions and, in particular, P Landgraf for his excellent criticism and advice. SI, NG, VB and AB designed experiments. NG, VB, YL, MM, OW, MZ, JT, LE, NS, AN designed and performed experiments. LH analyzed data. NG, VB, AB, SI wrote the paper. This work was supported by National Institute of Health R01 CA120772-01A2 (SI), German Israeli Foundation (SI & AB), The Wolfson Foundation (SI, NS), Israel Science Foundation Morasha (SI), Children with Leukaemia UK (SI), Leukemia Research Fund UK (OW and MM), Curtis Katz (SI), MSM0021620813 and MZO00064203 (JT and MZ), Jewish National Fund, UK (SI), Claudine Galli Foundation (NG), Converging Technologies program (LH), Elterninitiative Kinderkrebsklinik Duesseldorf (AB). The study has been performed as partial fulfillment of the requirements for PhD degree of Nir Gefen and Libi Hertzberg, Sackler School of Medicine, Tel Aviv University.",null,42,41,45,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","JAN",2010,24,1,null,null,null,null,89,96,null,"10.1038/leu.2009.208",null,8,"Oncology; Hematology","Oncology; Hematology","543KW","WOS:000273577100012"]
[null,null,null,null,"J","Rotthier, A; Auer-Grumbach, M; Janssens, K; Baets, J; Penno, A; Almeida-Souza, L; Van Hoof, K; Jacobs, A; De Vriendt, E; Schlotter-Weigel, B; Loscher, W; Vondracek, P; Seeman, P; De Jonghe, P; Van Dijck, P; Jordanova, A; Hornemann, T; Timmerman, V",null,null,null,"Rotthier, Annelies; Auer-Grumbach, Michaela; Janssens, Katrien; Baets, Jonathan; Penno, Anke; Almeida-Souza, Leonardo; Van Hoof, Kim; Jacobs, An; De Vriendt, Els; Schlotter-Weigel, Beate; Loscher, Wolfgang; Vondracek, Petr; Seeman, Pavel; De Jonghe, Peter; Van Dijck, Patrick; Jordanova, Albena; Hornemann, Thorsten; Timmerman, Vincent",null,null,"Mutations in the SPTLC2 Subunit of Serine Palmitoyltransferase Cause Hereditary Sensory and Autonomic Neuropathy Type I","AMERICAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,null,"SPHINGOLIPID METABOLISM; BIOSYNTHESIS; ACCUMULATION; HOMEOSTASIS; INHIBITION; PHENOTYPE; FUMONISIN; DISEASES; PROTEIN; GENES","Hereditary sensory and autonomic neuropathy type I (HSAN-I) is an axonal peripheral neuropathy associated with progressive distal sensory loss and severe ulcerations Mutations in the first subunit of the enzyme serine palmitoyltransferase (SPT) have been associated with HSAN-I The SPT enzyme catalyzes the first and rate-limiting step in the de novo sphingolipid synthesis pathway However, different studies suggest the implication of other genes in the pathology of HSAN-I Therefore, we screened the two other known subunits of SPT, SPTLC2 and SPTLC3, in a cohort of 78 HSAN patients No mutations were found in SPTLC3, but we identified three heterozygous missense mutations in the SPTLC2 subunit of with four families presenting with a typical HSAN-I phenotype We demonstrate that these mutations result in a partial to complete loss of SPT activity in vitro and in vivo Moreover, they cause the accumulation of the atypical and neurotoxic sphingoid metabolite I-deoxy-sphinganine Our findings extend the genetic heterogeneity in HSAN-I and enlarge the group of HSAN neuropathies associated with SPT defects. We further show that HSAN-I is consistently associated with an Increased formation of the neurotoxic 1-deoxysphinganine, suggesting a common pathomechanism for HSAN-I.","[Rotthier, Annelies; Janssens, Katrien; Almeida-Souza, Leonardo; Van Hoof, Kim; Jacobs, An; Timmerman, Vincent] Univ Antwerp, Peripheral Neuropathy Grp, VIB Dept Mol Genet, B-2610 Antwerp, Belgium; [Baets, Jonathan; De Vriendt, Els; De Jonghe, Peter; Jordanova, Albena] Univ Antwerp, Neurogenet Grp, VIB Dept Mol Genet, B-2610 Antwerp, Belgium; [Rotthier, Annelies; Janssens, Katrien; Baets, Jonathan; Almeida-Souza, Leonardo; Van Hoof, Kim; Jacobs, An; De Vriendt, Els; De Jonghe, Peter; Jordanova, Albena; Timmerman, Vincent] Univ Antwerp, Neurogenet Lab, Inst Born Bunge, B-2610 Antwerp, Belgium; [Auer-Grumbach, Michaela] Med Univ Graz, Dept Internal Med, Div Endocrinol & Metab, A-8036 Graz, Austria; [Baets, Jonathan; De Jonghe, Peter] Univ Antwerp Hosp, Dept Neurol, B-2650 Antwerp, Belgium; [Penno, Anke; Hornemann, Thorsten] Univ Zurich Hosp, Inst Clin Chem, CH-8091 Zurich, Switzerland; [Penno, Anke] Competence Ctr Syst Physiol & Metab Dis, CH-8093 Zurich, Switzerland; [Schlotter-Weigel, Beate] Univ Munich, Friedrich Baur Inst, Dept Neurol, D-80336 Munich, Germany; [Loscher, Wolfgang] Innsbruck Med Univ, Dept Neurol, A-6020 Innsbruck, Austria; [Vondracek, Petr] Univ Hosp & Masaryk Univ, Dept Paediat Neurol, CZ-61300 Brno, Czech Republic; [Seeman, Pavel] Charles Univ Prague, Sch Med Prague 2, Dept Child Neurol, CZ-15006 Prague, Czech Republic; [Van Dijck, Patrick] Katholieke Univ Leuven, VIB Dept Mol Microbiol, Mol Cell Biol Lab, B-3001 Louvain, Belgium; [Hornemann, Thorsten] Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; [Hornemann, Thorsten] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, CH-8057 Zurich, Switzerland","Timmerman, V (reprint author), Univ Antwerp, Peripheral Neuropathy Grp, VIB Dept Mol Genet, B-2610 Antwerp, Belgium.",null,"Almeida-Souza, Leonardo/C-3437-2011",null,"University of Antwerp; FWO-Flanders; Medical Foundation Queen Elisabeth; Association Beige centre les Maladies Neuromusculaires; Belgian Federal Science Policy Office (BELSPO); Austrian Science Fond (FWF) [P19455-05]; Institute for Science and Technology (IWT); EMBO; BELSPO; IGA MH CR grant [10552-3]; German Society for Clinical Chemistry and Laboratory Medicine; Gebert Ruf Foundation; European Commission [LSHM-CT-2006-037631]","We are grateful to the patients and their families for their cooperation in our research project We thank the Genetic Service Facility (VIB) for DNA sequencing and Ilse Palmans and Deborah Seys for technical assistance with the yeast assays. This project was funded in part by a Methusalem grant of the University of Antwerp, the Fund for Scientific Research (FWO-Flanders), the Medical Foundation Queen Elisabeth (GSKE), the Association Beige centre les Maladies Neuromusculaires (ABMM), the Interuniversity Attraction Poles P6/43 program of the Belgian Federal Science Policy Office (BELSPO), and the Austrian Science Fond (FWF, P19455-05) A R and J B are supported by Ph D. fellowships of the Institute for Science and Technology (IWT) and FWO-Flanders, respectively A R received an EMBO Short Term Fellowship K J holds a postdoctoral fellowship from BELSPO PS is supported by an IGA MH CR grant (no 10552-3) Support for HT. was provided by the German Society for Clinical Chemistry and Laboratory Medicine (DGKL), the Gebert Ruf Foundation, and the European Commission (LSHM-CT-2006-037631)",null,35,30,32,"CELL PRESS","CAMBRIDGE","600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA","0002-9297",null,null,"AM J HUM GENET","Am. J. Hum. Genet.","OCT 8",2010,87,4,null,null,null,null,513,522,null,"10.1016/j.ajhg.2010.09.010",null,10,"Genetics & Heredity","Genetics & Heredity","665LU","WOS:000283037600007"]
[null,null,null,null,"J","Witso, E; Cinek, O; Aldrin, M; Grinde, B; Rasmussen, T; Wetlesen, T; Ronningen, KS",null,null,null,"Witso, Elisabet; Cinek, Ondrej; Aldrin, Magne; Grinde, Bjorn; Rasmussen, Trond; Wetlesen, Turid; Ronningen, Kjersti S.",null,null,"Predictors of sub-clinical enterovirus infections in infants: a prospective cohort study","INTERNATIONAL JOURNAL OF EPIDEMIOLOGY",null,null,"English","Article",null,null,null,null,null,"Enterovirus; breastfeeding; infant; multivariable logistic regression; prospective cohort study; predictors","DOSE-RESPONSE RELATIONSHIP; UNITED STATES CITIES; CONTINUING SURVEILLANCE; INTRAFAMILIAL SPREAD; DIABETES-MELLITUS; HEALTHY CHILDREN; ENTERIC VIRUSES; GROUNDWATER; ILLNESS; RISK","Background Enterovirus infections are common, although most often subclinical. The present purpose was to assess the impact of breastfeeding and other factors on enterovirus infections in infancy. Methods A prospective observational study was carried out on a population-based cohort of 639 Norwegian infants aged 3-12 months. The outcome was enterovirus RNA measured in monthly stool samples. Data on underlying determinants, such as dietary feeding and household factors, were reported in parental questionnaires. Multivariable logistic regression was performed to allow for common confounders. Statistical analyses were performed by GLLAMM using Stata 9.2, which corrects for subject-specific random effects. Results The prevalence of enterovirus in stools was 11.1% (475/4279). Risk of enterovirus infection decreased with increasing number of daily breastfeeds; the effect was most pronounced at the age of 3 months [odds ratio (OR), 0.85; 95% confidence interval (CI) 0.8-0.9, P < 0.001], gradually declining thereafter, reaching no effect at 11 months. Increased risk was associated with having one or more sibling(s) (OR 1.89; 95% CI 1.2-3.0), particularly if they attended daycare (OR 2.46; 95% CI 1.4-4.2), and with increasing exposure to other children (OR 1.04; 95% CI 1.0-1.1). There was a tendency towards higher prevalence of infection when a household's drinking water came from a well, and a protective effect of owning a dog or cat. Conclusions Several factors may modify the risk for enterovirus infections in the first year of life. This study supports the protective effect of breastfeeding. The protection decreased with age and increased with dose of ingested milk.","[Witso, Elisabet; Wetlesen, Turid; Ronningen, Kjersti S.] Norwegian Inst Publ Hlth, Dept Genes & Environm, Div Epidemiol, Oslo, Norway; [Cinek, Ondrej] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Prague, Czech Republic; [Aldrin, Magne] Norwegian Comp Ctr, Stat Anal Pattern Recognit & Image Anal SAMBA, Oslo, Norway; [Grinde, Bjorn] Norwegian Inst Publ Hlth, Dept Virol, Div Infect Dis Control, Oslo, Norway; [Rasmussen, Trond] Norwegian Inst Publ Hlth, Dept Informat Syst, Div Adm & Support, Oslo, Norway","Witso, E (reprint author), Hagedorn Res Inst, Niels Steensensvej 1,NLE2-10, DK-2820 Gentofte, Denmark.","elwi@novonordisk.com",null,null,null,null,null,46,8,8,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0300-5771",null,null,"INT J EPIDEMIOL","Int. J. Epidemiol.","APR",2010,39,2,null,null,null,null,459,468,null,"10.1093/ije/dyp333",null,10,"Public, Environmental & Occupational Health","Public, Environmental & Occupational Health","578OT","WOS:000276303800025"]
[null,null,null,null,"J","Bekku, Y; Vargova, L; Goto, Y; Vorisek, I; Dmytrenko, L; Narasaki, M; Ohtsuka, A; Fassler, R; Ninomiya, Y; Sykova, E; Oohashi, T",null,null,null,"Bekku, Yoko; Vargova, Lydia; Goto, Yoshinobu; Vorisek, Ivan; Dmytrenko, Lesia; Narasaki, Masahiro; Ohtsuka, Aiji; Faessler, Reinhard; Ninomiya, Yoshifumi; Sykova, Eva; Oohashi, Toshitaka",null,null,"Bral1: Its Role in Diffusion Barrier Formation and Conduction Velocity in the CNS","JOURNAL OF NEUROSCIENCE",null,null,"English","Article",null,null,null,null,null,null,"TYROSINE-PHOSPHATASE BETA; CENTRAL-NERVOUS-SYSTEM; EXTRACELLULAR-SPACE; LINK PROTEIN; TENASCIN-R; PERINEURONAL NETS; RAT CEREBELLUM; ANISOTROPIC DIFFUSION; VOLUME TRANSMISSION; BRAIN-DEVELOPMENT","At the nodes of Ranvier, excitable axon membranes are exposed directly to the extracellular fluid. Cations are accumulated and depleted in the local extracellular nodal region during action potential propagation, but the impact of the extranodal micromilieu on signal propagation still remains unclear. Brain-specific hyaluronan-binding link protein, Bral1, colocalizes and forms complexes with negatively charged extracellular matrix (ECM) proteins, such as versican V2 and brevican, at the nodes of Ranvier in the myelinated white matter. The link protein family, including Bral1, appears to be the linchpin of these hyaluronan-bound ECM complexes. Here we report that the hyaluronan-associated ECM no longer shows a nodal pattern and that CNS nerve conduction is markedly decreased in Bral1-deficient mice even though there were no differences between wild-type and mutant mice in the clustering or transition of ion channels at the nodes or in the tissue morphology around the nodes of Ranvier. However, changes in the extracellular space diffusion parameters, measured by the real-time iontophoretic method and diffusion-weighted magnetic resonance imaging (MRI), suggest a reduction in the diffusion hindrances in the white matter of mutant mice. These findings provide a better understanding of the mechanisms underlying the accumulation of cations due to diffusion barriers around the nodes during saltatory conduction, which further implies the importance of the Bral1-based extramilieu for neuronal conductivity.","[Bekku, Yoko; Ninomiya, Yoshifumi; Oohashi, Toshitaka] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, Okayama 7008558, Japan; [Narasaki, Masahiro; Ohtsuka, Aiji] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Human Morphol, Okayama 7008558, Japan; [Vargova, Lydia; Vorisek, Ivan; Dmytrenko, Lesia; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague 14220, Czech Republic; [Vargova, Lydia; Vorisek, Ivan; Dmytrenko, Lesia; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 14220, Czech Republic; [Vargova, Lydia; Vorisek, Ivan; Dmytrenko, Lesia; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Prague 14220, Czech Republic; [Goto, Yoshinobu] Int Univ Hlth & Welf, Fac Rehabil, Dept Occupat Therapy, Fukuoka 8318501, Japan; [Faessler, Reinhard] Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany","Oohashi, T (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, Okayama 7008558, Japan.","oohashi@cc.okayama-u.ac.jp","OOHASHI, Toshitaka/B-1599-2011",null,"Japanese Society for the Promotion of Science (JSPS) [18791206, 20791195, 15591857, 17046012]; JSPS; Academy of Sciences of the Czech Republic; Ryobi Teien Memory Foundation; Ministry of Education, Youth and Sports [1M0538, 50390512]; Grant Agency of the Czech Republic [309/09/1597]; Ministry of Health of the Czech Republic Internal [NS 9915-4]","This work was supported by a Grant-in-Aid for Scientific Research from the Japanese Society for the Promotion of Science (JSPS) (Grants 18791206 and 20791195 to Y. B., and Grants 15591857 and 17046012 to T. O.), the Researcher Exchange Program between the JSPS and the Academy of Sciences of the Czech Republic (ASCR) (to Y. B.), the Ryobi Teien Memory Foundation (to Y. B.), The Ministry of Education, Youth and Sports Grant 1M0538 (to E. S.), ASCR Grant 50390512 (to E. S.), Grant Agency of the Czech Republic Grant 309/09/1597 (to L. V. and E. S.), and Ministry of Health of the Czech Republic Internal Grant Agency Grant NS 9915-4 (to L. V.). We thank Mai Saito for technical assistance; Drs. Wei-Dong Su, Satoshi Hirakawa, and Xiao-Hong Zhou for their help with gene targeting; Dr. Hiroko Baba for kind suggestions; Dr. Yasunori Murakami for helpful comments on this manuscript; Dr. Elior Peles for the gift of anti-Caspr antibody; and James Dutt for editing this manuscript.",null,47,28,28,"SOC NEUROSCIENCE","WASHINGTON","11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA","0270-6474",null,null,"J NEUROSCI","J. Neurosci.","FEB 24",2010,30,8,null,null,null,null,3113,3123,null,"10.1523/JNEUROSCI.5598-09.2010",null,11,"Neurosciences","Neurosciences & Neurology","560VB","WOS:000274930500032"]
[null,null,null,null,"J","Kuehni, CE; Frischer, T; Strippoli, MPF; Maurer, E; Bush, A; Nielsen, KG; Escribano, A; Lucas, JSA; Yiallouros, P; Omran, H; Eber, E; O'Callaghan, C; Snijders, D; Barbato, A",null,null,null,"Kuehni, C. E.; Frischer, T.; Strippoli, M-P. F.; Maurer, E.; Bush, A.; Nielsen, K. G.; Escribano, A.; Lucas, J. S. A.; Yiallouros, P.; Omran, H.; Eber, E.; O'Callaghan, C.; Snijders, D.; Barbato, A.",null,"ERS Task Force Primary Ciliary Dys","Factors influencing age at diagnosis of primary ciliary dyskinesia in European children","EUROPEAN RESPIRATORY JOURNAL",null,null,"English","Article",null,null,null,null,null,"Bronchiectasis; ciliary motility disorders; diagnosis; epidemiology; Kartagener syndrome; primary ciliary dyskinesia","RETINITIS-PIGMENTOSA; LUNG-FUNCTION; DEFECTS; COHORT; POPULATION; MUTATIONS; SEVERITY; DISEASE","Primary ciliary dyskinesia (PCD) is a hereditary disorder of mucociliary clearance causing chronic upper and lower airways disease. We determined the number of patients with diagnosed PCD across Europe, described age at diagnosis and determined risk factors for late diagnosis. Centres treating children with PCD in Europe answered questionnaires and provided anonymous patient lists. In total, 223 centres from 26 countries reported 1,009 patients aged <20 yrs. Reported cases per million children (for 5-14 yr olds) were highest in Cyprus (111), Switzerland (47) and Denmark (46). Overall, 57% were males and 48% had situs inversus. Median age at diagnosis was 5.3 yrs, lower in children with situs inversus (3.5 versus 5.8 yrs; p<0.001) and in children treated in large centres (4.1 versus 4.8 yrs; p=0.002). Adjusted age at diagnosis was 5.0 yrs in Western Europe, 4.8 yrs in the British Isles, 5.5 yrs in Northern Europe, 6.8 yrs in Eastern Europe and 6.5 yrs in Southern Europe (p<0.001). This strongly correlated with general government expenditures on health (p<0.001). This European survey suggests that PCD in children is under-diagnosed and diagnosed late, particularly in countries with low health expenditures. Prospective studies should assess the impact this delay might have on patient prognosis and on health economic costs across Europe.","[Frischer, T.] Univ Klin Kinder & Jugendheilkunde, A-1090 Vienna, Austria; [Kuehni, C. E.; Strippoli, M-P. F.; Maurer, E.] Univ Bern, ISPM, Bern, Switzerland; [Eber, E.] Med Univ Graz, Dept Paediat & Adolescence Med, Graz, Austria; [Bush, A.] Royal Brompton Hosp, London, England; [Lucas, J. S. A.] Univ Southampton, Div Infect Inflammat & Immun, Sch Med, Southampton SO9 5NH, Hants, England; [O'Callaghan, C.] Univ Leicester, Dept Infect Immun & Inflammat, Div Child Hlth, Leicester, Leics, England; [Nielsen, K. G.] Rigshosp, Danish Paediat Pulm Serv, DK-2100 Copenhagen, Denmark; [Escribano, A.] Univ Valencia, Univ Clin Hosp, Valencia, Spain; [Yiallouros, P.] Cyprus Univ Technol, Cyprus Int Inst Environm & Publ Hlth, Limassol, Cyprus; [Omran, H.] Univ Hosp, Klin & Poliklin Allgemeinpaediat, Munster, Germany; [Snijders, D.; Barbato, A.] Univ Padua, Dept Paediat, Padua, Italy","Frischer, T (reprint author), Univ Klin Kinder & Jugendheilkunde, Wahringergurtel 18-20, A-1090 Vienna, Austria.","thomas.frischer@meduniwien.ac.at","Eber, Ernst/B-6381-2012; Lucas, Jane/C-3620-2013; Strippoli, Marie-Pierre/K-8164-2013","Strippoli, Marie-Pierre/0000-0003-3053-484X","European Respiratory Society; Swiss National Science Foundation (PROSPER) [3233-069348, 3200-069349]; Deutsche Forschungsgemeinschaft DFG [Om 6/4]","The European Respiratory Society has financially supported meetings of the PCD Task Force. C.E. Kuehni and M-P.F. Strippoli were funded by the Swiss National Science Foundation (PROSPER grants 3233-069348 and 3200-069349). H. Omran was funded by the Deutsche Forschungsgemeinschaft DFG Om 6/4.","Afzelius BA, 2006, INT J DEV BIOL, V50, P571, DOI 10.1387/ijdb.052132ba; Barbato A, 2009, EUR RESPIR J, V34, P1264, DOI 10.1183/09031936.00176608; Budny B, 2006, HUM GENET, V120, P171, DOI 10.1007/s00439-006-0210-5; Bush A, 2007, ARCH DIS CHILD, V92, P1136, DOI 10.1136/adc.2006.096958; Chilvers MA, 2003, J ALLERGY CLIN IMMUN, V112, P518, DOI 10.1067/mai.2003.1701; Coren ME, 2002, ACTA PAEDIATR, V91, P667, DOI 10.1080/080352502760069089; Ellerman A, 1997, EUR RESPIR J, V10, P2376, DOI 10.1183/09031936.97.10102376; Fliegauf M, 2007, NAT REV MOL CELL BIO, V8, P880, DOI 10.1038/nrm2278; Hornef N, 2006, AM J RESP CRIT CARE, V174, P120, DOI 10.1164/rccm.200601-084OC; Jain K, 2007, CLIN RADIOL, V62, P986, DOI 10.1016/j.crad.2007.04.015; KATSUHAR.K, 1972, CHEST, V61, P56, DOI 10.1378/chest.61.1.56; Kennedy MP, 2007, CIRCULATION, V115, P2814, DOI 10.1161/CIRCULATIONAHA.106.649038; KUHN CE, 1995, PEDIATR PULM, V19, P156, DOI 10.1002/ppul.1950190303; Latzin P, 2007, PEDIATR PULM, V42, P41, DOI 10.1002/ppul.20542; Marthin JK, 2010, AM J RESP CRIT CARE, V181, P1262, DOI 10.1164/rccm.200811-1731OC; Meeks M, 2000, PEDIATR PULM, V29, P307, DOI 10.1002/(SICI)1099-0496(200004)29:4<307::AID-PPUL11>3.0.CO;2-2; Moore A, 2006, J MED GENET, V43, P326, DOI 10.1136/jmg.2005.034868; Noone PG, 2004, AM J RESP CRIT CARE, V169, P459, DOI 10.1164/rccm.200303-365OC; O'Callaghan C, 2010, ARCH DIS CHILD, V95, P51, DOI 10.1136/adc.2009.158493; O'Callaghan C, 2007, THORAX, V62, P656, DOI 10.1136/thx.2007.083147; Schwabe GC, 2008, HUM MUTAT, V29, P289, DOI 10.1002/humu.20656; Sims EJ, 2007, LANCET, V369, P1187, DOI 10.1016/S0140-6736(07)60565-0; Stannard WA, 2010, AM J RESP CRIT CARE, V181, P307, DOI 10.1164/rccm.200903-0459OC; TORGERSEN J, 1947, ACTA RADIOL, V28, P17, DOI 10.3109/00016924709135208; United Nations, 2005, DEF MAJ AR REG; VANDORP DB, 1992, HUM GENET, V88, P331; World Health Organization (WHO), WHO STAT INF SYST WH; ZARIWALA MA, 2007, ANNU REV PHYSIOL, V69, P423",28,21,23,"EUROPEAN RESPIRATORY SOC JOURNALS LTD","SHEFFIELD","442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND","0903-1936",null,null,"EUR RESPIR J","Eur. Resp. J.","DEC",2010,36,6,null,null,null,null,1248,1258,null,"10.1183/09031936.00001010",null,11,"Respiratory System","Respiratory System","687FY","WOS:000284765600007"]
[null,null,null,null,"J","Balgobind, BV; Lugthart, S; Hollink, IH; Arentsen-Peters, STJCM; van Wering, ER; de Graaf, SSN; Reinhardt, D; Creutzig, U; Kaspers, GJL; de Bont, ESJM; Stary, J; Trka, J; Zimmermann, M; Beverloo, HB; Pieters, R; Delwel, R; Zwaan, CM; van den Heuvel-Eibrink, MM",null,null,null,"Balgobind, B. V.; Lugthart, S.; Hollink, I. H.; Arentsen-Peters, S. T. J. C. M.; van Wering, E. R.; de Graaf, S. S. N.; Reinhardt, D.; Creutzig, U.; Kaspers, G. J. L.; de Bont, E. S. J. M.; Stary, J.; Trka, J.; Zimmermann, M.; Beverloo, H. B.; Pieters, R.; Delwel, R.; Zwaan, C. M.; van den Heuvel-Eibrink, M. M.",null,null,"EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"EVI1 expression; pediatric AML; MDS1/EVI1 expression","ZINC-FINGER PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW-CELLS; GENE-EXPRESSION; ONCOLOGY-GROUP; TREATMENT STRATEGY; TRANSFORMING GENE; PR DOMAIN; AML; ACTIVATION","Overexpression of the ecotropic virus integration-1 (EVI1) gene (EVI1+), localized at chromosome 3q26, is associated with adverse outcome in adult acute myeloid leukemia (AML). In pediatric AML, 3q26 abnormalities are rare, and the role of EVI1 is unknown. We studied 228 pediatric AML samples for EVI1+ using gene expression profiling and RQ-PCR. EVI1+ was found in 20/213 (9%) of children with de novo AML, and in 4/8 with secondary AML. It was predominantly found in MLL-rearranged AML (13/47), monosomy 7 (2/3), or FAB M6/7 (6/10), and mutually exclusive with core-binding factor AML, t(15;17), and NPM1 mutations. Fluorescent in situ hybridization (FISH) was performed to detect cryptic 3q26 abnormalities. However, none of the EVI1+ patients harbored structural 3q26 alterations. Although significant differences in 4 years pEFS for EVI1+ and EVI1 pediatric AML were observed (28%+/- 11 vs 44%+/- 4, P=0.04), multivariate analysis did not identify EVI1+ as an independent prognostic factor. We conclude that EVI1+ can be found in similar to 10% of pediatric AML. Although EVI1+ was not an independent prognostic factor, it was predominantly found in subtypes of pediatric AML that are related with an intermediate to unfavorable prognosis. Further research should explain the role of EVI1+ in disease biology in these cases. Remarkably, no 3q26 abnormalities were identified in EVI1+ pediatric AML. Leukemia (2010) 24, 942-949; doi:10.1038/leu.2010.47; published online 1 April 2010","[Balgobind, B. V.; Hollink, I. H.; Arentsen-Peters, S. T. J. C. M.; Pieters, R.; Zwaan, C. M.; van den Heuvel-Eibrink, M. M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands; [van Wering, E. R.; de Graaf, S. S. N.] DCOG, The Hague, Netherlands; [Lugthart, S.; Delwel, R.] Erasmus MC, Dept Hematol, Rotterdam, Netherlands; [de Graaf, S. S. N.] Radboud Univ Nijmegen Med Ctr, Dept Pediat Oncol Hematol, Nijmegen, Netherlands; [Reinhardt, D.; Zimmermann, M.] Hannover Med Sch, Dept Pediat Hematol Oncol, AML BFM Study Grp, D-3000 Hannover, Germany; [Creutzig, U.] Univ Hosp, Dept Pediat Hematol Oncol, AML BFM Study Grp, Munster, Germany; [Kaspers, G. J. L.] Vrije Univ Amsterdam Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands; [de Bont, E. S. J. M.] Univ Groningen, Beatrix Childrens Hosp, Univ Med Ctr Groningen, Dept Pediat Oncol Hematol, Groningen, Netherlands; [Stary, J.; Trka, J.] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Beverloo, H. B.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands","van den Heuvel-Eibrink, MM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","NWO 'Netherlands Organization for Scientific Research'; KOCR 'Kinder-Oncologisch Centrum Rotterdam'; EHA","This work was funded by the NWO 'Netherlands Organization for Scientific Research' (BVB), KOCR 'Kinder-Oncologisch Centrum Rotterdam' (BVB and IHH) and EHA (SL).",null,50,19,21,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","MAY",2010,24,5,null,null,null,null,942,949,null,"10.1038/leu.2010.47",null,8,"Oncology; Hematology","Oncology; Hematology","595DS","WOS:000277591500005"]
[null,null,null,null,"J","Chernin, G; Vega-Warner, V; Schoeb, DS; Heeringa, SF; Ovunc, B; Saisawat, P; Cleper, R; Ozaltin, F; Hildebrandt, F",null,null,null,"Chernin, Gil; Vega-Warner, Virginia; Schoeb, Dominik S.; Heeringa, Saskia F.; Ovunc, Bugsu; Saisawat, Pawaree; Cleper, Roxana; Ozaltin, Fatih; Hildebrandt, Friedhelm",null,"GPN Study Grp","Genotype/Phenotype Correlation in Nephrotic Syndrome Caused by WT1 Mutations","CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,null,"DIFFUSE MESANGIAL SCLEROSIS; TUMOR SUPPRESSOR GENE; SPLICE-SITE MUTATION; DENYS-DRASH SYNDROME; WILMS-TUMOR; FRASIER-SYNDROME; GLOMERULAR-DISEASES; GERMLINE MUTATIONS; MISSENSE MUTATIONS; STEROID-RESISTANT","Background and objectives: The risk of developing Wilms tumor (WT) can be present or absent in patients with nephrotic syndrome (NS) caused by WT1 mutations. Here, the genotype/phenotype correlation regarding the outcome and risk for WT in 52 patients from 51 families with NS due to WT1 mutations is described. Design, setting, participants, & measurements: This study followed 19 patients with mutations in intron 9 splice donor site (KTS mutations), 27 patients with missense mutations, 4 patients with nonsense mutations, 1 patient with a splice site mutation in intron 8, and 1 patient with a deletion. Results: Twenty-four different WT1 mutations were detected. Sixteen of the 19 patients with KTS mutations were females. These patients had isolated NS if karyotype was 46,XX and Frasier syndrome if karyotype was 46,XY. Patients with KTS mutations presented at a significantly older age and with a slower progression toward chronic kidney disease (CKD) stage 5, compared with missense mutations. Patients with nonsense mutations presented initially with WT. Six patients with missense mutations developed WT after the diagnosis of NS (interval-range from NS onset to WT of 0.1 to 1.4 years). Conclusions: (1) KTS mutations cause isolated NS with absence of WT in 46,XX females. (2) KTS mutations cause Frasier syndrome with gonadoblastoma risk in 46,XY phenotypic females. (3) KTS mutations cause NS with a slower progression when compared with missense mutations. (4) Missense mutations can occur with and without WT. (5) WT1 analysis is important in young patients with NS for early detection and tumor prophylaxis. Clin J Am Soc Nephrol 5: 1655-1662, 2010. doi: 10.2215/CJN.09351209","[Chernin, Gil; Vega-Warner, Virginia; Schoeb, Dominik S.; Heeringa, Saskia F.; Ovunc, Bugsu; Saisawat, Pawaree; Hildebrandt, Friedhelm] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Chernin, Gil; Vega-Warner, Virginia; Schoeb, Dominik S.; Heeringa, Saskia F.; Ovunc, Bugsu; Saisawat, Pawaree; Hildebrandt, Friedhelm] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; [Cleper, Roxana] Schneider Childrens Med Ctr, Pediat Nephrol Unit, Petah Tiqwa, Israel; [Ozaltin, Fatih] Hacettepe Univ, Dept Pediat, Ankara, Turkey; [Hildebrandt, Friedhelm] Howard Hughes Med Inst, Chevy Chase, MD USA","Hildebrandt, F (reprint author), Univ Michigan Hlth Syst, 8220C MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.","fhilde@umich.edu","Bockenhauer, Detlef/C-5951-2008",null,"National Institutes of Health (NIH) [P50-DK039255, R01-DK076683]; KMD Foundation; Thrasher Research Fund","F. H. is an investigator of the Howard Hughes Medical Institute, the Frederick G. L. Huetwell professor, and a Doris Duke Distinguished Clinical Scientist, and is supported by grants from the National Institutes of Health (NIH; P50-DK039255, R01-DK076683), the KMD Foundation, and the Thrasher Research Fund.","Bruinooge SS, 2003, J CLIN ONCOL, V21, P2397, DOI 10.1200/JCO.2003.03.189; [Anonymous], 1981, KIDNEY INT, V20, P765; BRODEHL J, 1988, LANCET, V1, P380; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Barbosa AS, 1999, HUM MUTAT, V13, P146, DOI 10.1002/(SICI)1098-1004(1999)13:2<146::AID-HUMU7>3.0.CO;2-I; Bockenhauer D, 2009, PEDIATR NEPHROL, V24, P1399, DOI 10.1007/s00467-009-1135-8; Denamur E, 1999, J AM SOC NEPHROL, V10, P2219; DRASH A, 1970, J PEDIATR, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; EDDY AA, 1985, J PEDIATR, V106, P584, DOI 10.1016/S0022-3476(85)80076-7; Gbadegesin R, 2008, NEPHROL DIAL TRANSPL, V23, P1291, DOI 10.1093/ndt/gfm759; Guzzo I, 2009, PEDIATR NEPHROL, V24, P1391, DOI 10.1007/s00467-009-1144-7; HABIB R, 1985, CLIN NEPHROL, V24, P269; Heathcott RW, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9031; Hinkes BG, 2007, PEDIATRICS, V119, pE907, DOI 10.1542/peds.2006-2164; Hu M, 2004, NEPHROL DIAL TRANSPL, V19, P223, DOI 10.1093/ndt/gfg473; Jeanpierre C, 1998, AM J HUM GENET, V62, P824, DOI 10.1086/301806; Klamt B, 1998, HUM MOL GENET, V7, P709, DOI 10.1093/hmg/7.4.709; Kohsaka T, 1999, HUM MUTAT, V14, P466, DOI 10.1002/(SICI)1098-1004(199912)14:6<466::AID-HUMU4>3.3.CO;2-Y; Krediet RT, 2006, NEPHROL DIAL TRANSPL, V21, pii42; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Love JD, 2006, J PEDIATR SURG, V41, DOI 10.1016/j.jpedsurg.2006.07.012; Melo KFS, 2002, J CLIN ENDOCR METAB, V87, P2500, DOI 10.1210/jc.87.6.2500; Mrowka C, 2000, J AM SOC NEPHROL, V11, pS106; Mucha B, 2006, PEDIATR RES, V59, P325, DOI 10.1203/01pdr.0000196717.94518.f0; Niaudet P, 2006, PEDIATR NEPHROL, V21, P1653, DOI 10.1007/s00467-006-0208-1; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; Rao Aarati, 2008, Curr Opin Pediatr, V20, P1, DOI 10.1097/MOP.0b013e3282f4249a; Royer-Pokora B, 2004, AM J MED GENET A, V127A, P249, DOI 10.1002/ajmg.a.30015; Ruf RG, 2004, KIDNEY INT, V66, P564, DOI 10.1111/j.1523-1755.2004.00775.x; Ruf RG, 2004, J AM SOC NEPHROL, V15, P722, DOI 10.1097/01.ASN.0000113552.59155.72; Schumacher V, 1998, KIDNEY INT, V53, P1594, DOI 10.1046/j.1523-1755.1998.00948.x; Schumacher V, 1997, P NATL ACAD SCI USA, V94, P3972, DOI 10.1073/pnas.94.8.3972; Tajima T, 2003, HORM RES, V60, P302, DOI 10.1159/000074249",34,17,20,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1555-9041",null,null,"CLIN J AM SOC NEPHRO","Clin. J. Am. Soc. Nephrol.","SEP",2010,5,9,null,null,null,null,1655,1662,null,"10.2215/CJN.09351209",null,8,"Urology & Nephrology","Urology & Nephrology","648II","WOS:000281685600019"]
[null,null,null,null,"J","Kolar, P; Sulc, J; Kyncl, M; Sanda, J; Neuwirth, J; Bokarius, AV; Kriz, J; Kobesova, A",null,null,null,"Kolar, P.; Sulc, J.; Kyncl, M.; Sanda, J.; Neuwirth, J.; Bokarius, A. V.; Kriz, J.; Kobesova, A.",null,null,"Stabilizing function of the diaphragm: dynamic MRI and synchronized spirometric assessment","JOURNAL OF APPLIED PHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"diaphragm; stabilizing function; dynamic magnetic resonance imaging; lung function; thorax","OBSTRUCTIVE PULMONARY-DISEASE; INTRAABDOMINAL PRESSURE; RESPIRATORY ACTIVATION; POSTURAL ACTIVITY; HEALTHY-SUBJECTS; TRUNK MUSCLES; MOVEMENT; MOTION; CONTRACTION; FLUOROSCOPY","The aim was to describe diaphragmatic behavior during postural limb activities and examine the ventilatory and stabilizing functions of the diaphragm. Thirty healthy subjects were examined in the supine position using a dynamic MRI system assessed simultaneously with specialized spirometric readings. The diaphragmatic excursions (DEs) were measured at three diaphragmatic points in the sagittal plane; the diaphragm positions (DPs) as related to a reference horizontal baseline were determined. Measurements were taken during tidal breathing (TB) and isometric flexion of upper or lower extremities against external resistance together with TB. Mean DE in both upper and lower postural limb activities was greater compared with the TB condition (P < 0.05), with the effect greater for lower limb activities. Inspiratory DPs in the upper and lower extremity activities were lower compared with TB alone (P < 0.01). Expiratory DP was lower only for lower extremity activities (P < 0.01). DP was most affected at the apex of the crescent and crural (posterior) portion of the diaphragm. DEs correlated strongly with tidal volume (VT) in all conditions. Changes in DEs relative to the initial value were minimal for upper and lower extremities but were related to lower values of VT (P < 0.03). Significant involvement of the diaphragm in the limb postural activities was found. Resulting DEs and DPs differed from the TB conditions, especially in lower extremity activities. The differences between the percent changes of DEs vs. VT found for lower extremity activities were confirmed by both ventilatory and postural diaphragm recruitment in response to postural demands.","[Kolar, P.; Sulc, J.; Kriz, J.; Kobesova, A.] Charles Univ Prague, Dept Rehabil & Sports Med, Fac Med 2, Prague 15900 5, Czech Republic; [Kolar, P.; Sulc, J.; Kyncl, M.; Sanda, J.; Kriz, J.; Kobesova, A.] Univ Hosp Motol, Prague 15900 5, Czech Republic; [Kyncl, M.; Sanda, J.] Charles Univ Prague, Dept Med Imaging, Fac Med 2, Prague 15900 5, Czech Republic; [Neuwirth, J.] Charles Univ Prague, Radiol Clin, Fac Med, Prague 15900 5, Czech Republic; [Neuwirth, J.] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; [Bokarius, A. V.] Comprehens Care Consultants, Los Angeles, CA USA","Kobesova, A (reprint author), Charles Univ Prague, Dept Rehabil & Sports Med, Fac Med 2, V Uvalu 84, Prague 15900 5, Czech Republic.","alenamudr@me.com",null,null,"Foundation \"Movement Without Help,\" Prague, Czech Republic","This study was supported by the Foundation \"Movement Without Help,\" Prague, Czech Republic.",null,37,6,6,"AMER PHYSIOLOGICAL SOC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","8750-7587",null,null,"J APPL PHYSIOL","J. Appl. Physiol.","OCT",2010,109,4,null,null,null,null,1064,1071,null,"10.1152/japplphysiol.01216.2009",null,8,"Physiology; Sport Sciences","Physiology; Sport Sciences","695BF","WOS:000285344900017"]
[null,null,null,null,"J","Stary, J; Jabali, Y; Trka, J; Hrusak, O; Gajdos, P; Hrstkova, H; Sterba, J; Blazek, B; Hak, J; Prochazkova, D; Cerna, Z; Smisek, P; Sedlacek, P; Vavra, V; Mihal, V; Hrodek, O",null,null,null,"Stary, J.; Jabali, Y.; Trka, J.; Hrusak, O.; Gajdos, P.; Hrstkova, H.; Sterba, J.; Blazek, B.; Hak, J.; Prochazkova, D.; Cerna, Z.; Smisek, P.; Sedlacek, P.; Vavra, V.; Mihal, V.; Hrodek, O.",null,"Czech Pediat Hematology Working","Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,null,"TRIAL; CHILDREN",null,"[Stary, J.; Trka, J.; Hrusak, O.; Gajdos, P.; Smisek, P.; Sedlacek, P.; Vavra, V.; Hrodek, O.] Univ Hosp Motol, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Stary, J.; Trka, J.; Hrusak, O.; Gajdos, P.; Smisek, P.; Sedlacek, P.; Vavra, V.; Hrodek, O.] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Jabali, Y.] Reg Hosp, Dept Pediat, Ceske Budejovice, Czech Republic; [Hrstkova, H.] Univ Hosp Brno, Dept Pediat, Brno, Czech Republic; [Hrstkova, H.; Sterba, J.] Masaryk Univ, Childrens Hosp, Brno, Czech Republic; [Sterba, J.] Univ Hosp Brno, Dept Pediat Oncol, Brno, Czech Republic; [Blazek, B.] Teaching Hosp, Dept Pediat & Adolescent Med, Ostrava, Czech Republic; [Hak, J.] Teaching Hosp, Dept Pediat, Hradec Kralove, Czech Republic; [Prochazkova, D.] Masaryks Hosp, Dept Pediat, Usti Nad Labem, Czech Republic; [Cerna, Z.] Charles Univ Prague, Teaching Hosp, Dept Pediat, Plzen, Czech Republic; [Mihal, V.] Palacky Univ, Univ Hosp, Dept Pediat, Olomouc, Czech Republic","Stary, J (reprint author), Univ Hosp Motol, Dept Pediat Hematol Oncol, Prague, Czech Republic.","jan.stary@lfmotol.cuni.cz",null,null,null,null,null,4,11,11,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","FEB",2010,24,2,null,null,null,null,425,428,null,"10.1038/leu.2009.255",null,4,"Oncology; Hematology","Oncology; Hematology","553WO","WOS:000274397700016"]
[null,null,null,null,"J","Keil, R; Snajdauf, J; Rygl, M; Pycha, K; Kotalova, R; Drabek, J; Stovicek, J; Procke, M",null,null,null,"Keil, R.; Snajdauf, J.; Rygl, M.; Pycha, K.; Kotalova, R.; Drabek, J.; Stovicek, J.; Procke, M.",null,null,"Diagnostic efficacy of ERCP in cholestatic infants and neonates - a retrospective study on a large series","ENDOSCOPY",null,null,"English","Article",null,null,null,null,null,null,"ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; MAGNETIC-RESONANCE CHOLANGIOPANCREATOGRAPHY; EXTRAHEPATIC BILIARY ATRESIA; MR CHOLANGIOGRAPHY; TRIANGULAR CORD; LIVER-BIOPSY; CHILDREN; DISEASES; SURGERY; AGE","Background and study aims: Cholestatic jaundice in infants is a serious condition, requiring timely and accurate diagnostic evaluation. Our aim was to determine the safety and diagnostic efficacy of endoscopic retrograde cholangiopancreatography (ERCP) in the diagnosis of cholestatic liver disease in neonates and infants. Patients and methods: ERCP procedures in cholestatic infants performed in our endoscopy unit between December 1998 and March 2008 were reviewed retrospectively (n = 104 children, 48 boys, 56 girls; mean age 7 weeks, range 3-25 weeks; mean weight 4.05 kg, range 1.5-4.8 kg). Endoscopic findings were compared with final diagnoses. Statistical analysis was performed and sensitivity, specificity, positive (PPV) and negative (NPV) predictive values of ERCP were calculated both separately for each diagnosis and on aggregate. Results: Cannulation of the papilla was successful in 95 of 104 patients (success rate 91.3%). Biliary atresia of any type was found in 51 children (53.7%), with a sensitivity of 86%, a specificity of 94%, a PPV of 96%, and a NPV of 100%. Choledochal cysts were found in seven children (7.4%), with a sensitivity of 100%, a specificity of 90%, PPV of 86%, and NPV of 100%. Biliary stones were found in seven patients (7.4%). Other structural pathology was found in six patients, and no abnormality was seen in 24 patients. No severe complications occurred during or after ERCP. Conclusions: ERCP in cholestatic infants, when performed in an expert center, is a safe and reliable procedure that can detect biliary tract abnormalities (e. g. biliary atresia, bile duct stones or choledochal cysts) with high sensitivity and specificity. Laparotomies can be prevented in infants by demonstrating normal patency of the biliary tract by ERCP or by magnetic resonance cholangiography if improvements in this technique are made.","[Keil, R.; Drabek, J.; Stovicek, J.; Procke, M.] Charles Univ Prague, Motol Univ Hosp, Dept Internal Med Gastroenterol & Endoscopy, Sch Med 2, Prague, Czech Republic; [Snajdauf, J.; Rygl, M.; Pycha, K.] Charles Univ Prague, Motol Univ Hosp, Dept Pediat Surg, Sch Med 2, Prague, Czech Republic; [Kotalova, R.] Charles Univ Prague, Motol Univ Hosp, Dept Pediat, Sch Med 2, Prague, Czech Republic","Procke, M (reprint author), FN Motol, Interni Klin UK 2 LF, V Uvalu 84, Prague 15006 5, Czech Republic.","michal.procke@fnmotol.cz",null,null,null,null,null,33,7,7,"GEORG THIEME VERLAG KG","STUTTGART","RUDIGERSTR 14, D-70469 STUTTGART, GERMANY","0013-726X",null,null,"ENDOSCOPY","Endoscopy","FEB",2010,42,2,null,null,null,null,121,126,null,"10.1055/s-0029-1215372",null,6,"Gastroenterology & Hepatology; Surgery","Gastroenterology & Hepatology; Surgery","552XZ","WOS:000274329800006"]
[null,null,null,null,"J","Tapia, G; Cinek, O; Rasmussen, T; Grinde, B; Ronningen, KS",null,null,null,"Tapia, German; Cinek, Ondrej; Rasmussen, Trond; Grinde, Bjorn; Ronningen, Kjersti S.",null,null,"No Ljungan Virus RNA in Stool Samples From the Norwegian Environmental Triggers of Type 1 Diabetes (MIDIA) Cohort Study","DIABETES CARE",null,null,"English","Article",null,null,null,null,null,null,"LONGITUDINAL OBSERVATION; ENTEROVIRUS; INFANTS; VOLES","OBJECTIVE - Ljungan virus (LjV) has been proposed as a potential environmental factor for type 1 diabetes. The objective was to test for any association of LjV with type 1 diabetes. RESEARCH DESIGN AND METHODS - A nested case-control design was used to test for any association between the development of pre-diabetic autoimmunity and presence of LjV in stool samples (n = 3,803) in the Norwegian Environmental Triggers of Type 1 Diabetes (MIDIA) study. The children followed were 27 infants who developed pre-diabetic autoimmunity during or shortly after the sampling period, 54 matched control subjects, and 94 other children. RESULTS - No LjV RNA was detected. CONCLUSIONS - The results indicate that LjV is rare in young children. LjV does not seem to be involved in the development of human type 1 diabetes.","[Tapia, German; Rasmussen, Trond; Grinde, Bjorn; Ronningen, Kjersti S.] Norwegian Inst Publ Hlth, Oslo, Norway; [Tapia, German; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Tapia, G (reprint author), Norwegian Inst Publ Hlth, Oslo, Norway.","german.tapia@fhi.no",null,null,"Norwegian Organization for Health and Rehabilitation [2005/2/0128]; European Economic Area and Norway Grants [A/CZ0046/1/0014]; Ministry of Education of the Czech Republic [MSM0021620814]; Research Council of Norway [135893/330, 155300/320, 156477/730, 166515/V50]; Norwegian Diabetes Association; Children With Diabetes Foundation; New-Generis [Food-CT-2005-016320]","This study and the MIDIA project were funded by the Norwegian Organization for Health and Rehabilitation (Grant 2005/2/0128), European Economic Area and Norway Grants (Grant A/CZ0046/1/0014 through the Research Support Fund, Prague, the Czech Republic), the Ministry of Education of the Czech Republic (Grant MSM0021620814), the Research Council of Norway (Grants 135893/330, 155300/320, 156477/730, and 166515/V50), the Norwegian Diabetes Association, the Children With Diabetes Foundation (Denver, CO), and New-Generis (Grant Food-CT-2005-016320). No potential conflicts of interest relevant to this article were reported.",null,13,7,7,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0149-5992",null,null,"DIABETES CARE","Diabetes Care","MAY",2010,33,5,null,null,null,null,1069,1071,null,"10.2337/dc09-1951",null,3,"Endocrinology & Metabolism","Endocrinology & Metabolism","595RV","WOS:000277631200024"]
[null,null,null,null,"J","Cardwell, CR; Stene, LC; Joner, G; Bulsara, MK; Cinek, O; Rosenbauer, J; Ludvigsson, J; Jane, M; Svensson, J; Goldacre, MJ; Waldhoer, T; Jarosz-Chobot, P; Gimeno, SGA; Chuang, LM; Parslow, RC; Wadsworth, EJK; Chetwynd, A; Pozzilli, P; Brigis, G; Urbonaite, B; Sipetic, S; Schober, E; Devoti, G; Ionescu-Tirgoviste, C; de Beaufort, CE; Stoyanov, D; Buschard, K; Patterson, CC",null,null,null,"Cardwell, Chris R.; Stene, Lars C.; Joner, Geir; Bulsara, Max K.; Cinek, Ondrej; Rosenbauer, Joachim; Ludvigsson, Johnny; Jane, Mireia; Svensson, Jannet; Goldacre, Michael J.; Waldhoer, Thomas; Jarosz-Chobot, Przemyslawa; Gimeno, Suely G. A.; Chuang, Lee-Ming; Parslow, Roger C.; Wadsworth, Emma J. K.; Chetwynd, Amanda; Pozzilli, Paolo; Brigis, Girts; Urbonaite, Brone; Sipetic, Sandra; Schober, Edith; Devoti, Gabriele; Ionescu-Tirgoviste, Constantin; de Beaufort, Carine E.; Stoyanov, Denka; Buschard, Karsten; Patterson, Chris C.",null,null,"Maternal Age at Birth and Childhood Type 1 Diabetes: A Pooled Analysis of 30 Observational Studies","DIABETES",null,null,"English","Article",null,null,null,null,null,null,"PERINATAL RISK-FACTORS; PARENTAL AGE; ENVIRONMENTAL-FACTORS; MELLITUS; DELIVERY; IDDM; DETERMINANTS; CHILDREN; ORDER; WEIGHT","OBJECTIVE-The aim if the study was to investigate whether children born to older mothers have an increased risk of type 1 diabetes by performing a pooled analysis of previous studies using individual patient data to adjust for recognized confounders. RESEARCH DESIGN AND METHODS-Relevant studies published before June 2009 were identified from MEDLINE, Web of Science, and EMBASE. Authors of studies were contacted and asked to provide individual patient data or conduct prespecified analyses. Risk estimates of type 1 diabetes by maternal age were calculated for each study, before and after adjustment for potential confounders. Meta-analysis techniques were used to derive combined odds ratios and to investigate heterogeneity among studies. RESULTS-Data were available for 5 cohort and 25 case-control studies, including 14,724 cases of type 1 diabetes. Overall, there was, on average, a 5% (95% CI 2-9) increase in childhood type 1 diabetes odds per 5-year increase in maternal age (P = 0.006), but there was heterogeneity among studies (heterogeneity I(2) = 70%). In studies with a low risk of bias, there was a more marked increase in diabetes odds of 10% per 5-year increase in maternal age. Adjustments for potential confounders little altered these estimates. CONCLUSIONS-There was evidence of a weak but significant linear increase in the risk of childhood type 1 diabetes across the range of maternal ages, but the magnitude of association varied between studies. A very small percentage of the increase in the incidence of childhood type 1 diabetes in recent years could be explained by increases in maternal age. Diabetes 59:486-494, 2010","[Cardwell, Chris R.; Patterson, Chris C.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland; [Stene, Lars C.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Stene, Lars C.] Oslo Univ Hosp, Oslo Res Ctr, Oslo, Norway; [Joner, Geir] Univ Oslo, Inst Hlth Management & Hlth Econ, Oslo, Norway; [Bulsara, Max K.] Univ Notre Dame, Inst Hlth & Rehabil Res, Fremantle, Australia; [Cinek, Ondrej] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Rosenbauer, Joachim] Univ Dusseldorf, Leibniz Inst, German Diabet Ctr, Inst Biometr & Epidemiol, Dusseldorf, Germany; [Ludvigsson, Johnny] Linkoping Univ, Dept Paediat, Linkoping, Sweden; [Ludvigsson, Johnny] Linkoping Univ, Diabet Res Ctr, Linkoping, Sweden; [Jane, Mireia] Dept Hlth, Publ Hlth Div, Barcelona, Spain; [Svensson, Jannet] Glostrup Univ Hosp, Dept Pediat, Glostrup, Denmark; [Goldacre, Michael J.] Univ Oxford, Dept Publ Hlth, Oxford, England; [Waldhoer, Thomas] Med Univ Vienna, Dept Epidemiol, Vienna, Austria; [Jarosz-Chobot, Przemyslawa] Med Univ Silesia, Dept Pediat Endocrinol & Diabet, Katowice, Poland; [Gimeno, Suely G. A.] Univ Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil; [Chuang, Lee-Ming] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Parslow, Roger C.] Univ Leeds, Paediat Epidemiol Grp, Leeds, W Yorkshire, England; [Wadsworth, Emma J. K.] Cardiff Univ, Ctr Occupat & Hlth Psychol, Cardiff, S Glam, Wales; [Chetwynd, Amanda] Univ Lancaster, Dept Math & Stat, Lancaster, England; [Pozzilli, Paolo] Univ Campus Biomed, Rome, Italy; [Brigis, Girts] Riga Stradins Univ, Dept Epidemiol & Publ Hlth, Riga, Latvia; [Urbonaite, Brone] Kaunas Univ Med, Inst Endocrinol, Kaunas, Lithuania; [Sipetic, Sandra] Univ Belgrade, Sch Med, Inst Epidemiol, Belgrade, Serbia; [Schober, Edith] Med Univ Vienna, Dept Paediat, Vienna, Austria; [Devoti, Gabriele] Univ Lecce, Dept Social Sci & Commun, I-73100 Lecce, Italy; [Ionescu-Tirgoviste, Constantin] N Paulescu Inst Diabet, Nutr & Metab Dis Clin, Bucharest, Romania; [de Beaufort, Carine E.] Pediat Clin, Luxembourg, Luxembourg; [Stoyanov, Denka] Childrens Diabet Ctr, Sofia, Bulgaria; [Buschard, Karsten] Rigshosp, Bartholin Inst, DK-2100 Copenhagen, Denmark","Cardwell, CR (reprint author), Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.","c.cardwell@qub.ac.uk","GIMENO, SUELY/K-3888-2012; Chetwynd, Amanda/B-4727-2013","Chetwynd, Amanda/0000-0002-7659-3231","Czech Republic Ministry of Education [MSM 0021620814]; Department of Health of Catalonia; Department of Health of Taiwan [DOH 90-TD1028]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [94/0943-0]; Centro Internazionale Studi Diabete (Italy, Rome); The Swedish Child Diabetes Foundation; National Health Service (NHS) National Coordinating Centre for Research Capacity Development U.K.; Research Council of Norway; German Research Foundation [HE 24/1-1]; Ministry for Science and Technological Development of Serbia [145084]; European Commission Health Information Strand [2007115]; Diabetes U.K; Northern Ireland Department of Health and Social Services","We acknowledge support from the following: the Czech Republic Ministry of Education (Grant MSM 0021620814), Department of Health of Catalonia (C. Castell MD, PhD, Barcelona, Spain), Department of Health of Taiwan (DOH 90-TD1028), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Grant 94/0943-0), the Centro Internazionale Studi Diabete (Italy, Rome), The Swedish Child Diabetes Foundation, the National Health Service (NHS) National Coordinating Centre for Research Capacity Development U.K., the Research Council of Norway, the German Research Foundation (Grant HE 24/1-1), the Ministry for Science and Technological Development of Serbia (no. 145084, 2006-2010), EUBIROD funded by the European Commission Health Information Strand (DG-SANCO 2005, contract no. 2007115), Diabetes U.K., and the Northern Ireland Department of Health and Social Services.",null,50,16,16,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0012-1797",null,null,"DIABETES","Diabetes","FEB",2010,59,2,null,null,null,null,486,494,null,"10.2337/db09-1166",null,9,"Endocrinology & Metabolism","Endocrinology & Metabolism","554LG","WOS:000274435900020"]
[null,null,null,null,"J","Querfeld, U; Anarat, A; Bayazit, AK; Bakkaloglu, AS; Bilginer, Y; Caliskan, S; Civilibal, M; Doyon, A; Duzova, A; Kracht, D; Litwin, M; Melk, A; Mir, S; Sozeri, B; Shroff, R; Zeller, R; Wuhl, E; Schaefer, F",null,null,null,"Querfeld, Uwe; Anarat, All; Bayazit, Aysun K.; Bakkaloglu, Aysin S.; Bilginer, Yelda; Caliskan, Salim; Civilibal, Mahrnut; Doyon, Anke; Duzova, Ali; Kracht, Daniela; Litwin, Mieczyslaw; Melk, Anette; Mir, Sevgi; Sozeri, Betul; Shroff, Rukshana; Zeller, Rene; Wuehl, Elke; Schaefer, Franz",null,"4C Study Grp","The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) Study: Objectives, Design, and Methodology","CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,null,"CHRONIC-RENAL-FAILURE; INTIMA-MEDIA THICKNESS; CORONARY-ARTERY CALCIFICATIONS; LEFT-VENTRICULAR GEOMETRY; YOUNG-ADULTS; PEDIATRIC-PATIENTS; BLOOD-PRESSURE; STIFFNESS; TRANSPLANTATION; PROGRESSION","Background and objectives: Children and adolescents with chronic kidney disease (CKD) are at high risk for cardiovascular morbidity and mortality. A systemic arteriopathy and cardiomyopathy has been characterized in pediatric dialysis patients by the presence of morphologic and functional abnormalities. Design, setting, participants, & measurements: The Cardiovascular Comorbidity in Children with CKD (4C) Study is a multicenter, prospective, observational study aiming to recruit more than 600 children, aged 6 to 17 years, with initial GFR of 10 to 45 ml/min per 1.73 m(2). The prevalence, degree, and progression of cardiovascular comorbidity as well as its association with CKD progression will be explored through longitudinal follow-up. The morphology and function of the heart and large arteries will be monitored by sensitive noninvasive methods and compared with aged-matched healthy controls. Multiple clinical, anthropometric, biochemical, and pharmacologic risk factors will be monitored prospectively and related to the cardiovascular status. A whole-genome association study will be performed to identify common genetic variants associated with progression of cardiovascular alterations and/or renal failure. Monitoring will be continued as patients reach end-stage renal disease and undergo different renal replacement therapies. Results: While cardiovascular morbidity in adults is related to older age and additional risk factor load (e.g., diabetes), the role of CKD-specific factors in the initiation and progression of cardiac and vascular disease are likely to be characterized with greater sensitivity in the pediatric age group. Conclusions: The 4C study is expected to provide innovative insight into cardiovascular and renal disease progression in CKD. Clin J Am Soc Nephrol 5: 1642-1648, 2010. doi: 10.2215/CJN.08791209","[Querfeld, Uwe; Zeller, Rene] Charite, Dept Pediat Nephrol, Berlin, Germany; [Anarat, All; Bayazit, Aysun K.] Cukurova Univ, Sch Med, Dept Pediat Nephrol, Adana, Turkey; [Bakkaloglu, Aysin S.; Bilginer, Yelda; Duzova, Ali] Hacettepe Univ, Fac Med, Dept Pediat Nephrol, TR-06100 Ankara, Turkey; [Caliskan, Salim; Civilibal, Mahrnut] Istanbul Univ, Cerrahpasa Med Fac, Dept Pediat Nephrol, Istanbul, Turkey; [Schaefer, Franz] Univ Childrens Hosp Heidelberg, Ctr Pediat & Adolescent Med, Div Pediat Nephrol, D-69120 Heidelberg, Germany; [Kracht, Daniela; Melk, Anette] Hannover Med Sch, Dept Pediat Nephrol, Hannover, Germany; [Litwin, Mieczyslaw] Childrens Mem Hlth Inst, Dept Nephrol, Warsaw, Poland; [Mir, Sevgi; Sozeri, Betul] Ege Univ, Fac Med, Dept Pediat Nephrol, Izmir, Turkey; [Shroff, Rukshana] Great Ormond St Hosp Sick Children, Dept Pediat Nephrol, London WC1N 3JH, England; [Shroff, Rukshana] Inst Child Hlth, London, England","Querfeld, U (reprint author), Charite Univ Med Berlin CVK, Dept Pediat Nephrol, Augustenburger Pl 1, D-13353 Berlin, Germany.","uwe.querfeld@charite.de; franz.schaefer@med.uni-heidelberg.de","Schaefer, Franz/G-4365-2010; Litwin, Mieczyslaw/C-3868-2012; PERUZZI, LICIA/I-1873-2012; Shroff, Rukshana/C-7347-2008",null,"KfH Foundation for Preventive Medicine; Integrated Treatment and Research Center for Organ Transplantation at Hannover, Germany; German Federal Ministry for Education and Research; Coordinating Centers Warsaw, Ankara (Hacettepe University); Istanbul, Izmir (Ege University); Adana (Cukurova University)","The study has been made possible by grants of the KfH Foundation for Preventive Medicine (http://www.kfh-stiftung-praeventivmedizin.de/), the Integrated Treatment and Research Center for Organ Transplantation at Hannover, Germany (funded by German Federal Ministry for Education and Research), and local funds at the Coordinating Centers Warsaw, Ankara (Hacettepe University), Istanbul, Izmir (Ege University), and Adana (Cukurova University).","Briese S, 2008, PEDIATR NEPHROL, V23, P2241, DOI 10.1007/s00467-008-0894-y; Briese S, 2006, NEPHROL DIAL TRANSPL, V21, P1906, DOI 10.1093/ndt/gf1098; Chavers BM, 2004, ADV CHRONIC KIDNEY D, V11, P319, DOI 10.1053/j.arrt.2004.04.002; Chinali M, 2007, J AM SOC NEPHROL, V18, P593, DOI 10.1681/ASN.2006070691; Civilibal M, 2006, PEDIATR NEPHROL, V21, P1426, DOI 10.1007/s00467-006-0159-6; Civilibal M, 2009, PEDIATR NEPHROL, V24, P555, DOI 10.1007/s00467-008-1038-0; Covic A, 2006, NEPHROL DIAL TRANSPL, V21, P729, DOI 10.1093/ndt/gfi196; Eifinger F, 2000, NEPHROL DIAL TRANSPL, V15, P1892, DOI 10.1093/ndt/15.11.1892; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; FOLEY RN, 1995, J AM SOC NEPHROL, V5, P2024; Furth SL, 2006, CLIN J AM SOC NEPHRO, V1, P1006, DOI 10.2215/CJN.01941205; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Groothoff JW, 2002, J AM SOC NEPHROL, V13, P2953, DOI 10.1097/01.ASN.0000037677.16961.DF; Guerin AP, 2008, CURR OPIN NEPHROL HY, V17, P635, DOI 10.1097/MNH.0b013e32830dcd5c; Jourdan C, 2005, J HYPERTENS, V23, P1707, DOI 10.1097/01.hjh.0000178834.26353.d5; Kavey REW, 2006, CIRCULATION, V114, P2710, DOI 10.1161/CIRCULATIONAHA.106.179568; Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254; Litwin M, 2005, J AM SOC NEPHROL, V16, P1494, DOI 10.1681/ASN.2004110932; Litwin M, 2008, NEPHROL DIAL TRANSPL, V23, P2552, DOI 10.1093/ndt/gfn083; Lorenz MW, 2007, CIRCULATION, V115, P459, DOI 10.1161/CIRCULATIONAHA.106.628875; Matteucci MC, 2006, J AM SOC NEPHROL, V17, P218, DOI 10.1681/ASN.2005030276; Mitsnefes MM, 2005, J AM SOC NEPHROL, V16, P2796, DOI 10.1681/ASN.2005030291; Mitsnefes MM, 2003, CIRCULATION, V107, P864, DOI 10.1161/01.CIR.0000049744.23613.69; Mitsnefes MM, 2004, AM J KIDNEY DIS, V43, P721, DOI 10.1053/j.ajkd.2003.12.033; Mitsnefes MM, 2004, KIDNEY INT, V65, P1461, DOI 10.1111/j.1523-1755.2004.00525.x; Mitsnefes MM, 2006, J PEDIATR, V149, P671, DOI 10.1016/j.jpeds.2006.08.017; Mitsnefes MM, 2001, PEDIATR TRANSPLANT, V5, P279, DOI 10.1034/j.1399-3046.2001.005004279.x; Oh J, 2002, CIRCULATION, V106, P100, DOI 10.1161/01.CIR.0000020222.63035.C0; Schwartz GJ, 2009, J AM SOC NEPHROL, V20, P629, DOI 10.1681/ASN.2008030287; Shroff RC, 2007, J AM SOC NEPHROL, V18, P2996, DOI 10.1681/ASN.2006121397; Stein JH, 2008, J AM SOC ECHOCARDIOG, V21, P93, DOI 10.1016/j.echo.2007.11.011; Wuhl E, 2009, NEW ENGL J MED, V361, P1639; Wuhl E, 2002, J HYPERTENS, V20, P1995, DOI 10.1097/00004872-200210000-00019",33,16,16,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1555-9041",null,null,"CLIN J AM SOC NEPHRO","Clin. J. Am. Soc. Nephrol.","SEP",2010,5,9,null,null,null,null,1642,1648,null,"10.2215/CJN.08791209",null,7,"Urology & Nephrology","Urology & Nephrology","648II","WOS:000281685600017"]
[null,null,null,null,"J","Balgobind, BV; Zwaan, CM; Reinhardt, D; Arentsen-Peters, TJCM; Hollink, IHIM; de Haas, V; Kaspers, GJL; de Bont, ESJM; Baruchel, A; Stary, J; Meyer, C; Marschalek, R; Creutzig, U; den Boer, ML; Pieters, R; van den Heuvel-Eibrink, MM",null,null,null,"Balgobind, B. V.; Zwaan, C. M.; Reinhardt, D.; Arentsen-Peters, T. J. C. M.; Hollink, I. H. I. M.; de Haas, V.; Kaspers, G. J. L.; de Bont, E. S. J. M.; Baruchel, A.; Stary, J.; Meyer, C.; Marschalek, R.; Creutzig, U.; den Boer, M. L.; Pieters, R.; van den Heuvel-Eibrink, M. M.",null,null,"High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"MLL; BRE; pediatric AML",null,"Translocations involving the mixed lineage leukemia (MLL) gene, localized at 11q23, frequently occur in pediatric acute myeloid leukemia (AML). We recently reported differences in prognosis between the different translocation partners, suggesting differences in biological background. To unravel the latter, we used microarrays to generate gene expression profiles of 245 pediatric AML cases, including 53 MLL-rearranged cases. Thereby, we identified a specific gene expression signature for t(9;11)(p22;q23), and identified BRE (brain and reproductive organ expressed) to be discriminative for t(9;11)(p22;q23) (P<0.001) when compared with other MLL subtypes. Patients with high BRE expression showed a significantly better 3-year relapse-free survival (pRFS) (80 +/- 13 vs 30 +/- 10%, P=0.02) within MLL-rearranged AML cases. Moreover, multivariate analysis identified high BRE expression as an independent favorable prognostic factor within pediatric AML for RFS (HR=0.2, P=0.04). No significant differences were identified for 3-year event-free survival or for 3-year overall survival. Forced expression of BRE did not result in altered cell proliferation, apoptosis or drug sensitivity, which could explain the favorable outcome. In conclusion, overexpression of the BRE gene is predominantly found in MLL-rearranged AML with t(9;11)(p22;q23). Although further investigation for the role of BRE in leukemogenesis and outcome is warranted, high BRE expression is an independent prognostic factor for pRFS in pediatric AML. Leukemia (2010) 24, 2048-2055;doi:10.1038/leu.2010.211; published online 23 September 2010","[van den Heuvel-Eibrink, M. M.] Sophia Childrens Univ Hosp, Dept Pediat Oncol Hematol, Erasmus MC, NL-3000 CB Rotterdam, Netherlands; [Reinhardt, D.] Hannover Med Sch, AML BFM Study Grp, D-3000 Hannover, Germany; [de Haas, V.] DCOG, The Hague, Netherlands; [Kaspers, G. J. L.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [de Bont, E. S. J. M.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9713 AV Groningen, Netherlands; [Baruchel, A.] Hop St Louis, Paris, France; [Stary, J.] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Meyer, C.; Marschalek, R.] DCAL, Inst Pharmaceut Biol, ZAFES, Frankfurt, Germany; [Creutzig, U.] Univ Hosp Muenster, Munster, Germany","van den Heuvel-Eibrink, MM (reprint author), Sophia Childrens Univ Hosp, Dept Pediat Oncol Hematol, Erasmus MC, Room Sp 2456,Dr Molewaterpl 60,POB 2060, NL-3000 CB Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl","Marschalek, Rolf/D-3404-2011; Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","NWO 'Netherlands Organization for Scientfic Research'; KOCR 'Kinder-Oncologisch Centrum Rotterdam'","We thank Dr Yiu-Loon Chui, Department of Chemical Pathology and Sir YK Pao Center for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China, for providing the BRE antibody. Furthermore, we thank Dr E Hulleman for her input in the transfection experiments. This work was funded by the NWO 'Netherlands Organization for Scientfic Research' (BVB) and KOCR 'Kinder-Oncologisch Centrum Rotterdam' (BVB, IHIM).",null,43,10,10,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","DEC",2010,24,12,null,null,null,null,2048,2055,null,"10.1038/leu.2010.211",null,8,"Oncology; Hematology","Oncology; Hematology","695OF","WOS:000285380900009"]
[null,null,null,null,"J","Burger, T; Lucova, M; Moritz, RE; Oelschlager, HHA; Druga, R; Burda, H; Wiltschko, W; Wiltschko, R; Nemec, P",null,null,null,"Burger, Tomas; Lucova, Marcela; Moritz, Regina E.; Oelschlaeger, Helmut H. A.; Druga, Rastislav; Burda, Hynek; Wiltschko, Wolfgang; Wiltschko, Roswitha; Nemec, Pavel",null,null,"Changing and shielded magnetic fields suppress c-Fos expression in the navigation circuit: input from the magnetosensory system contributes to the internal representation of space in a subterranean rodent","JOURNAL OF THE ROYAL SOCIETY INTERFACE",null,null,"English","Article",null,null,null,null,null,"magnetic compass; hippocampus; entorhinal cortex; place cells; grid cells; head direction cells","HIPPOCAMPAL PLACE CELLS; BLIND MOLE-RAT; IMMEDIATE-EARLY GENES; HEAD-DIRECTION CELLS; FREELY-MOVING RAT; COMPASS ORIENTATION; VISUAL-SYSTEM; SPATIAL REPRESENTATION; TRANSCRIPTION FACTORS; SPALAX-EHRENBERGI","The neural substrate subserving magnetoreception and magnetic orientation in mammals is largely unknown. Previous experiments have demonstrated that the processing of magnetic sensory information takes place in the superior colliculus. Here, the effects of magnetic field conditions on neuronal activity in the rodent navigation circuit were assessed by quantifying c-Fos expression. Ansell's mole-rats (Fukomys anselli), a mammalian model to study the mechanisms of magnetic compass orientation, were subjected to natural, periodically changing, and shielded magnetic fields while exploring an unfamiliar circular arena. In the undisturbed local geomagnetic field, the exploration of the novel environment and/or nesting behaviour induced c-Fos expression throughout the head direction system and the entorhinal-hippocampal spatial representation system. This induction was significantly suppressed by exposure to periodically changing and/or shielded magnetic fields; discrete decreases in c-Fos were seen in the dorsal tegmental nucleus, the anterodorsal and the laterodorsal thalamic nuclei, the postsubiculum, the retrosplenial and entorhinal cortices, and the hippocampus. Moreover, in inactive animals, magnetic field intensity manipulation suppressed c-Fos expression in the CA1 and CA3 fields of the hippocampus and the dorsal subiculum, but induced expression in the polymorph layer of the dentate gyrus. These findings suggest that key constituents of the rodent navigation circuit contain populations of neurons responsive to magnetic stimuli. Thus, magnetic information may be integrated with multimodal sensory and motor information into a common spatial representation of allocentric space within this circuit.","[Burger, Tomas; Lucova, Marcela; Nemec, Pavel] Charles Univ Prague, Fac Sci, Dept Zool, CZ-12844 Prague 2, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Inst Anat, Fac Med 1, CZ-12844 Prague 2, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Inst Anat, Fac Med 2, CZ-12844 Prague 2, Czech Republic; [Moritz, Regina E.; Burda, Hynek] Univ Duisburg Essen, Dept Gen Zool, Essen, Germany; [Wiltschko, Wolfgang; Wiltschko, Roswitha] Goethe Univ Frankfurt, Dept Zool, Frankfurt, Germany; [Oelschlaeger, Helmut H. A.; Nemec, Pavel] Goethe Univ Frankfurt, Inst Anat Dr Senckenberg Anat 3, Frankfurt, Germany","Nemec, P (reprint author), Charles Univ Prague, Fac Sci, Dept Zool, Vinicna 7, CZ-12844 Prague 2, Czech Republic.","pgnemec@natur.cuni.cz","Nemec, Pavel/K-1163-2012","Nemec, Pavel/0000-0003-0277-0239","Czech Science Foundation [206/06/1469, 206/09/1364]; Ministry of Education, Youth and Sport of the Czech Republic [0021620828]","We cordially thank Clemens Poth for his assistance during the experimental stage of this study, Herve Cadiou, Martin Prevorovsky, Petr Telensky and four anonymous reviewers for commenting on the manuscript. Our work was supported by the Czech Science Foundation (206/06/1469 & 206/09/1364; to P.N.) and the Ministry of Education, Youth and Sport of the Czech Republic (0021620828; to P.N.).",null,108,9,9,"ROYAL SOC","LONDON","6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND","1742-5689",null,null,"J R SOC INTERFACE","J. R. Soc. Interface","SEP 6",2010,7,50,null,null,null,null,1275,1292,null,"10.1098/rsif.2009.0551",null,18,"Multidisciplinary Sciences","Science & Technology - Other Topics","631FT","WOS:000280332700003"]
[null,null,null,null,"J","Kabzinska, D; Strugalska-Cynowska, H; Kostera-Pruszczyk, A; Ryniewicz, B; Posmyk, R; Midro, A; Seeman, P; Barankova, L; Zimon, M; Baets, J; Timmerman, V; Guergueltcheva, V; Tournev, I; Sarafov, S; De Jonghe, P; Jordanova, A; Hausmanowa-Petrusewicz, I; Kochanski, A",null,null,null,"Kabzinska, Dagmara; Strugalska-Cynowska, Halina; Kostera-Pruszczyk, Anna; Ryniewicz, Barbara; Posmyk, Renata; Midro, Alina; Seeman, Pavel; Barankova, Lucia; Zimon, Magdalena; Baets, Jonathan; Timmerman, Vincent; Guergueltcheva, Velina; Tournev, Ivailo; Sarafov, Stayko; De Jonghe, Peter; Jordanova, Albena; Hausmanowa-Petrusewicz, Irena; Kochanski, Andrzej",null,null,"L239F founder mutation in GDAP1 is associated with a mild Charcot-Marie-Tooth type 4C4 (CMT4C4) phenotype","NEUROGENETICS",null,null,"English","Article",null,null,null,null,null,"Phenotype-genotype correlations in CMT4A disease; Founder effect; The L239F mutation in the GDAP1 gene","DIFFERENTIATION-ASSOCIATED PROTEIN-1; AUTOSOMAL RECESSIVE CMT; GLUTATHIONE TRANSFERASE; VOCAL CORD; DISEASE; GENE; FAMILY; NEUROPATHY; IDENTIFICATION; VARIABILITY","Over 40 mutations in the GDAP1 gene have been shown to segregate with Charcot-Marie-Tooth disease (CMT). Among these, only two mutations, i.e., S194X and Q163X have been reported in a sufficient number of CMT families to allow for the construction of reliable phenotype-genotype correlations. Both the S194X and Q163X mutations have been shown to segregate with an early-onset and severe neuropathy resulting in loss of ambulance at the beginning of the second decade of life. In this study, we identified the L239F mutation in the GDAP1 gene in one Bulgarian and five Polish families. We hypothesized that the L239F mutation may result from a founder effect in the European population since this mutation has previously been reported in Belgian, Czech, and Polish patients. In fact, we detected a common disease-associated haplotype within the 8q13-q21 region in the Polish, German, Italian, Czech, and Bulgarian CMT families. Like the previously detected \"regional\" S194X and Q163X mutations, respectively present in Maghreb countries and in patients of Spanish descent, the L239F mutation seems to be the most common GDAP1 pathogenic variant in the Central and Eastern European population. Given the likely presence of a common ancestor harboring the L239F mutation, we decided to compare the phenotypes of the CMT (L239F) patients collected in this study with those of previously reported cases. In contrast to CMT4A caused by the S194X and Q163X mutations, the CMT phenotype resulting from the L239F substitution represents a milder clinical entity with a long-preserved period of ambulance at least until the end of the second decade of life.","[Kabzinska, Dagmara; Strugalska-Cynowska, Halina; Hausmanowa-Petrusewicz, Irena; Kochanski, Andrzej] Polish Acad Sci, Mossakowski Med Res Ctr, Neuromuscular Unit, PL-02106 Warsaw, Poland; [Kostera-Pruszczyk, Anna; Ryniewicz, Barbara] Med Univ Warsaw, Dept Neurol, Warsaw, Poland; [Posmyk, Renata; Midro, Alina] Med Univ Bialystok, Dept Clin Genet, Bialystok, Poland; [Seeman, Pavel; Barankova, Lucia] Charles Univ Prague, Sch Med 2, Dept Child Neurol, Prague, Czech Republic; [Zimon, Magdalena; Baets, Jonathan; De Jonghe, Peter; Jordanova, Albena] Univ Antwerp VIB, Dept Mol Genet, Neurogenet Grp, B-2020 Antwerp, Belgium; [Zimon, Magdalena; Baets, Jonathan; De Jonghe, Peter; Jordanova, Albena] Univ Antwerp, Inst Born Bunge, Neurogenet Lab, B-2020 Antwerp, Belgium; [Baets, Jonathan; De Jonghe, Peter] Univ Hosp Antwerpen UZA, Div Neurol, Antwerp, Belgium; [Timmerman, Vincent] Univ Antwerp VIB, Dept Mol Genet, Peripheral Neuropathy Grp, B-2610 Antwerp, Belgium; [Guergueltcheva, Velina; Tournev, Ivailo; Sarafov, Stayko] Med Univ Sofia, Dept Neurol, Sofia, Bulgaria","Kochanski, A (reprint author), Polish Acad Sci, Mossakowski Med Res Ctr, Neuromuscular Unit, Pawinskiego 5, PL-02106 Warsaw, Poland.","andko@cmdik.pan.pl",null,null,"Polish Ministry of Science and Higher Education [402276336]; Bulgarian Ministry of Education and Science [VUL-317]; Fund for Scientific Research (FWO-Flanders); Medical Foundation Queen Elisabeth (GSKE); Association Belge contre les Maladies Neuromusculaires (ABMM); Flemish Government; Belgian Federal Science Policy Office (BELSPO) [P6/43]","The authors thank Ms. Jadwiga Kedzierska for her skillfull technical assistance. This study was supported by the Grant No. 402276336 from the Polish Ministry of Science and Higher Education to A. K. and by the Grant No. VUL-317 from the Bulgarian Ministry of Education and Science to V. G., I. T., and A.J. The work of the Belgian team was supported by the Fund for Scientific Research (FWO-Flanders), the Medical Foundation Queen Elisabeth (GSKE), the Association Belge contre les Maladies Neuromusculaires (ABMM), the Methusalem excellence grant of the Flemish Government, and the Interuniversity Attraction Poles P6/43 program of the Belgian Federal Science Policy Office (BELSPO). MZ and JB are supported by PhD fellowships of the FWO-Flanders.",null,20,2,2,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1364-6745",null,null,"NEUROGENETICS","Neurogenetics","JUL",2010,11,3,null,null,null,null,357,366,null,"10.1007/s10048-010-0237-6",null,10,"Genetics & Heredity; Clinical Neurology","Genetics & Heredity; Neurosciences & Neurology","612YO","WOS:000278942200009"]
[null,null,null,null,"J","Zolotarevova, E; Entlicher, G; Pavlova, E; Slouf, M; Pokorny, D; Vesely, F; Gallo, J; Sosna, A",null,null,null,"Zolotarevova, E.; Entlicher, G.; Pavlova, E.; Slouf, M.; Pokorny, D.; Vesely, F.; Gallo, J.; Sosna, A.",null,null,"Distribution of polyethylene wear particles and bone fragments in periprosthetic tissue around total hip joint replacements","ACTA BIOMATERIALIA",null,null,"English","Article",null,null,null,null,null,"Joint replacement; Polyethylene; Wear particles distribution; Periprosthetic tissue; Defense mechanism","UHMWPE WEAR; IN-VIVO; RADIOGRAPHIC APPEARANCE; DEBRIS; ARTHROPLASTY; OSTEOLYSIS; SIZE; QUANTIFICATION; COLLAGENASES; MACROPHAGES","Ultra-high molecular molecular weight polyethylene (UHMWPE) wear particles play a significant role in failures of total joint replacements (TJRs). In this work, we investigated the distribution of these wear particles in periprosthetic tissues obtained from nine revisions of hip TJR. In the first step, all periprosthetic tissues were combined and mechanically separated into granuloma tissue (containing hard granules visible to the naked eye) and surrounding tissue (without visible granules). In the second step, the tissues were hydrolyzed by protease from Streptomyces griseus and granules were separated by filtration; this divided the sample into four groups: (i) lyzate and (ii) non-degraded large granules from the granuloma tissue plus (iii) lyzate and (iv) non-degraded small granules from the surrounding tissue. In the third step, the large as well as small granules were hydrolyzed by collagenase from Clostridium histolyticum. In the last step, the UHMWPE wear particles from all four groups were purified by HNO(3) digestion and weighed. The purity of the isolated particles was verified by scanning electron microscopy, infrared spectroscopy and energy-dispersive X-ray analysis. Of the total amount of polyethylene particles in the whole granuloma tissue, 72% of particles in the size range 0.1-10 mu m and 68% of those larger than 10 pm were found in granules. Therefore, the formation of granules significantly lowers the effective amount of wear particles available for interaction with reactive cells and seems to be a natural defense mechanism. (C) 2010 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","[Zolotarevova, E.; Entlicher, G.] Charles Univ Prague, Fac Sci, Prague 12840 2, Czech Republic; [Pavlova, E.; Slouf, M.] Inst Macromol Chem AS CR, Vvi, Prague 16206 6, Czech Republic; [Pokorny, D.; Vesely, F.; Sosna, A.] Charles Univ Prague, Orthoped Clin, Fac Med 1, Fac Hosp Motol, Prague 15606 5, Czech Republic; [Gallo, J.] Palacky Univ, Fac Med, Orthoped Clin, Olomouc 77520, Czech Republic","Zolotarevova, E (reprint author), Charles Univ Prague, Fac Sci, Hlavova 8, Prague 12840 2, Czech Republic.","ezolotarevova@gmail.com","Slouf, Miroslav/F-6311-2012","Slouf, Miroslav/0000-0003-1528-802X","Ministry of Education, Youth and Sports of the Czech Republic [MSMT 2B06096]","This work was supported by grant of the Ministry of Education, Youth and Sports of the Czech Republic (MSMT 2B06096).",null,28,3,3,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","1742-7061",null,null,"ACTA BIOMATER","Acta Biomater.","SEP",2010,6,9,null,null,null,null,3595,3600,null,"10.1016/j.actbio.2010.04.010",null,6,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","643SG","WOS:000281318400026"]
[null,null,null,null,"J","Drevinek, P; Mahenthiralingam, E",null,null,null,"Drevinek, P.; Mahenthiralingam, E.",null,null,"Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence","CLINICAL MICROBIOLOGY AND INFECTION",null,null,"English","Review",null,null,null,null,null,"Burkholderia cepacia; epidemiology; genomics; multilocus; review; sequence typing; virulence factors","SURVIVAL IN-VIVO; CONTROLS BIOFILM FORMATION; QUORUM-SENSING SYSTEM; CEPACIA-COMPLEX; PSEUDOMONAS-CEPACIA; GENOMOVAR-III; SP-NOV; ORNIBACTIN BIOSYNTHESIS; GLOBAL EPIDEMIOLOGY; OXIDATIVE STRESS","P>Burkholderia cepacia complex (Bcc) bacteria have gained notoriety as pathogens in cystic fibrosis (CF) because they are difficult to identify and treat, and also have the ability to spread between CF individuals. Of the 17 formally named species within the complex, Burkholderia multivorans and Burkholderia cenocepacia dominate in CF. Multilocus sequence typing has proven to be a very useful tool for tracing the global epidemiology of Bcc bacteria and has shown that B. cenocepacia strains with high transmissibility, such as the ET-12 strain (ST-28) and the Czech strain (ST-32), have spread epidemically within CF populations in Canada and Europe. The majority of research on the molecular pathogenesis of Bcc bacteria has focused on the B. cenocepacia ET-12 epidemic lineage, with gene mutation, genome sequence analysis and, most recently, global gene expression studies shedding considerable light on the virulence and antimicrobial resistance of this pathogen. These studies demonstrate that the ability of B. cenocepacia to acquire foreign DNA (genomic islands, insertion sequences and other mobile elements), regulate gene expression via quorum sensing, compete for iron during infection, and mediate antimicrobial resistance and inflammation via its membrane and surface polysaccharides are key features that underpin the virulence of different strains. With the wealth of molecular knowledge acquired in the last decade on B. cenocepacia strains, we are now in a much better position to develop strategies for the treatment of pathogenic colonization with Bcc and to answer key questions on pathogenesis concerning, for example, the factors that trigger the rapid clinical decline in CF patients.","[Drevinek, P.] Charles Univ Prague, Dept Paediat, Sch Med 2, Prague 15006, Czech Republic; [Mahenthiralingam, E.] Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales","Drevinek, P (reprint author), Charles Univ Prague, Dept Paediat, Sch Med 2, Uvalu 84, Prague 15006, Czech Republic.","pavel.drevinek@Lfmotol.cuni.cz","Mahenthiralingam, Eshwar/D-3333-2009","Mahenthiralingam, Eshwar/0000-0001-9014-3790","Czech Ministry of Education [MSM0021620812]; Czech Ministry of Health [NS 10543-3]; Cystic Fibrosis Foundation [MAHENT06V0]","P. Drevinek acknowledges support from the Czech Ministry of Education (grant MSM0021620812) and the Czech Ministry of Health (grant NS 10543-3). E. Mahenthiralingam acknowledges the support for the B. cenocepacia microarray program provided by the Cystic Fibrosis Foundation (grant MAHENT06V0).",null,83,59,61,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1198-743X",null,null,"CLIN MICROBIOL INFEC","Clin. Microbiol. Infect.","JUL",2010,16,7,null,null,null,null,821,830,null,"10.1111/j.1469-0691.2010.03237.x",null,10,"Infectious Diseases; Microbiology","Infectious Diseases; Microbiology","609HC","WOS:000278645700004"]
[null,null,null,null,"J","Rozkova, D; Novotna, L; Pytlik, R; Hochova, I; Kozak, T; Bartunkova, J; Spisek, R",null,null,null,"Rozkova, Daniela; Novotna, Linda; Pytlik, Robert; Hochova, Ivana; Kozak, Tomas; Bartunkova, Jirina; Spisek, Radek",null,null,"Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation","INTERNATIONAL JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"B-Cell chronic lymphocytic leukemia; toll-like receptors; tumor immunology; B-cells; cancer immunotherapy","CHRONIC LYMPHOCYTIC-LEUKEMIA; CD38 EXPRESSION; PROGNOSTIC INDICATORS; MARKER EXPRESSION; UP-REGULATION; CPG MOTIFS; ACTIVATION; INTERLEUKIN-6; APOPTOSIS; MEMORY","Toll-like receptor (TLR) stimulation plays a crucial role in the homeostasis of human B cells. We investigated the expression of TLRs 1-9 on the cells of B-cell chronic lymphocytic leukemia (B-CLL) and analyzed the functional consequences of TLR stimulation on leukemic cells. We showed that B-CLL cells express similar set of TLRs as memory B cells of healthy donors, i.e. TLR-1, TLR-2, TLR-6, TLR-7 and TLR-9. However, in contrast to memory B cells, B-CLL cells lack TLR-4 expression. Expression of TLRs correlates with their capacity to respond to specific TLR agonists. At the level of phenotype, ODN2006 (TLR-9 agonist) is the most potent stimulus. B-CLL cells also respond to the stimulation with loxoribine, Pam3CSK4 and MALP-2 (TLR-7, TLR1/TLR2 and TLR2/TLR6 agonists, respectively). TLR-7 and TLR-9 stimulation induces production of IL-6 and TNF alpha. In 47% of tested patients, treatment with ODN2006, MALP-2 and Pam3CSK4 reduced leukemic cells survival. Stimulation of B-CLL cells with TLR-9 agonists, loxoribine, MALP-2 and Pam3CSK4 induces significant proliferation. We report that TLR stimulation induces expression of CD38, a negative prognostic marker, on B-CLL cells. Expression of CD38 is induced by direct stimulation of B-CLL cells through TLR-7 and TLR-9 or CD38 can be induced on B-CLL cells indirectly by a soluble factor induced in non-B-CLL cells after stimulation with TLR-2, TLR-3 or TLR-5 agonists; the nature of this factor remains unknown. Our results argue for cautious evaluation of immunointervention strategies based on the administration of TLR agonists in the treatment of B-CLL as their effects on B-CLL cells may be tumor promoting as well as tumor suppressing.","[Rozkova, Daniela; Novotna, Linda; Bartunkova, Jirina; Spisek, Radek] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Inst Immunol, Prague 15006 5, Motol, Czech Republic; [Pytlik, Robert] Charles Univ Prague, Gen Univ Hosp, Fac Med 1, Dept Med 1, Prague 15006 5, Motol, Czech Republic; [Hochova, Ivana] Charles Univ Prague, Univ Hosp Motel, Fac Med 2, Dept Hematol, Prague 15006 5, Motol, Czech Republic; [Kozak, Tomas] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Dept Clin Hematol, Prague 15006 5, Motol, Czech Republic","Rozkova, D (reprint author), Charles Univ Prague, Dept Immunol, Sch Med 2, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","daniela.rozkova@lfmotol.cuni.cz","Spisek, Radek/E-6724-2011; Kozak, Tomas/K-3561-2012",null,"Grant Agency of Czech Republic [310/08/P353]; Ministry of Education [MSM 0021620812]","Grant sponsor: Grant Agency of Czech Republic; Grant number: 310/08/P353; Grant sponsor: Ministry of Education; Grant number: MSM 0021620812",null,45,18,20,"JOHN WILEY & SONS INC","HOBOKEN","111 RIVER ST, HOBOKEN, NJ 07030 USA","0020-7136",null,null,"INT J CANCER","Int. J. Cancer","MAR 1",2010,126,5,null,null,null,null,1132,1143,null,"10.1002/ijc.24832",null,12,"Oncology","Oncology","547PU","WOS:000273902300010"]
[null,null,null,null,"J","Hort, J; O'Brien, JT; Gainotti, G; Pirttila, T; Popescu, BO; Rektorova, I; Sorbi, S; Scheltens, P",null,null,null,"Hort, J.; O'Brien, J. T.; Gainotti, G.; Pirttila, T.; Popescu, B. O.; Rektorova, I.; Sorbi, S.; Scheltens, P.",null,"EFNS Scientist Panel Dementia","EFNS guidelines for the diagnosis and management of Alzheimer's disease","EUROPEAN JOURNAL OF NEUROLOGY",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; dementia; diagnosis; guideline; management; review; treatment","MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID BIOMARKERS; RANDOMIZED CONTROLLED-TRIAL; CREUTZFELDT-JAKOB-DISEASE; PLACEBO-CONTROLLED TRIAL; MENTAL-STATE-EXAMINATION; CUED-RECALL TEST; DOUBLE-BLIND; DIFFERENTIAL-DIAGNOSIS; GINKGO-BILOBA","Background and objectives: In 2008 a task force was set up to develop a revision of the European Federation of the Neurological Societies (EFNS) guideline for the diagnosis and management of Alzheimer's disease (AD) and other disorders associated with dementia, published in early 2007. The aim of this revised international guideline was to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with AD. Mild cognitive impairment and non-Alzheimer dementias are not included in this guideline. Methods: The task force working group reviewed evidence from original research articles, meta-analysis, and systematic reviews, published before May 2009. The evidence was classified and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. Results: The recommendations for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of AD, behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers were all revised as compared with the previous EFNS guideline. Conclusion: A number of new recommendations and good practice points are made, namely in CSF, neuropsychology, neuroimaging and reviewing non-evidence based therapies. The assessment, interpretation, and treatment of symptoms, disability, needs, and caregiver stress during the course of AD require the contribution of many different professionals. These professionals should adhere to these guideline to improve the diagnosis and management of AD.","[Hort, J.] Charles Univ Prague, Memory Disorders Clin, Dept Neurol, Fac Med 2, Prague 15018 5, Czech Republic; [O'Brien, J. T.] Newcastle Univ, Inst Hlth & Aging, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Hort, J.] Motol Hosp, Prague 15018 5, Czech Republic; [Gainotti, G.] Catholic Univ, Policlin Gemelli, Neuropsychol Serv, Rome, Italy; [Pirttila, T.] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland; [Popescu, B. O.] Carol Davila Univ Med & Pharm, Univ Hosp, Dept Neurol, Bucharest, Romania; [Rektorova, I.] Masaryk Univ, Dept Neurol 1, Brno, Czech Republic; [Rektorova, I.] St Annes Hosp, Brno, Czech Republic; [Sorbi, S.] Univ Florence, Dept Neurol & Psychiat Sci, I-50121 Florence, Italy; [Scheltens, P.] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Scheltens, P.] Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, Amsterdam, Netherlands","Hort, J (reprint author), Charles Univ Prague, Memory Disorders Clin, Dept Neurol, Fac Med 2, Uvalu 84, Prague 15018 5, Czech Republic.","jakub.hort@seznam.cz",null,null,null,null,null,100,80,83,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1351-5101",null,null,"EUR J NEUROL","Eur. J. Neurol.","OCT",2010,17,10,null,null,null,null,1236,1248,null,"10.1111/j.1468-1331.2010.03040.x",null,13,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","649UK","WOS:000281799200006"]
[null,null,null,null,"J","Zitka, O; Kukacka, J; Krizkova, S; Huska, D; Adam, V; Masarik, M; Prusa, R; Kizek, R",null,null,null,"Zitka, O.; Kukacka, J.; Krizkova, S.; Huska, D.; Adam, V.; Masarik, M.; Prusa, R.; Kizek, R.",null,null,"Matrix Metalloproteinases","CURRENT MEDICINAL CHEMISTRY",null,null,"English","Review",null,null,null,null,null,"Matrix metalloproteinases; collagen; tissue inhibitors of matrix metalloproteinases; cysteine switch; zinc; metallothionein; tumour disease","HYPOMATURATION AMELOGENESIS IMPERFECTA; EPITHELIAL-CELL APOPTOSIS; GROWTH-PROMOTING ACTIVITY; PREVENTS CARDIAC RUPTURE; ACTIVATED PROTEIN-KINASE; HEMOPEXIN-LIKE DOMAIN; C-TERMINAL DOMAIN; TISSUE INHIBITOR; EXTRACELLULAR-MATRIX; GENE-EXPRESSION","Matrix metalloproteinases (MMPs), also known as matrixins, belong to a group of zinc-dependent proteins, which are thought to play a central role in the breakdown of extracellular matrix. Collagen, elastin, gelatin and casein are major components cleaved by MMPs. The breakdown of these components is essential for many physiological processes such as embryonic development, morphogenesis, reproduction, and tissue resorption and remodelling. MMPs also participate in pathological processes such as arthritis, cancer, cardiovascular and neurological diseases. This review summarizes current knowledge regarding these proteins, their participation in physiological and pathophysiological roles, their involvement in activation and inhibition, and their interactions with other metal-binding proteins including metallothioneins.","[Zitka, O.; Krizkova, S.; Huska, D.; Adam, V.; Kizek, R.] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Kukacka, J.; Prusa, R.] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, CZ-15006 Prague 5, Czech Republic; [Masarik, M.] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-66243 Brno, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Zitka, Ondrej/E-1107-2012; Krizkova, Sona/E-9617-2012; Kukacka, Jiri/C-4770-2013",null,"GA AV [IAA401990701]; GACR [301/09/P436]; IGAMZ [10200-3]","Financial support from GA AV IAA401990701, GACR 301/09/P436 and IGAMZ 10200-3 is highly acknowledged. The authors wish to express their thanks to Dr. Grace J. Chavis for language correction.",null,221,42,45,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","0929-8673",null,null,"CURR MED CHEM","Curr. Med. Chem.","NOV",2010,17,31,null,null,null,null,3751,3768,null,null,null,18,"Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy","Biochemistry & Molecular Biology; Pharmacology & Pharmacy","686RV","WOS:000284714300011"]
[null,null,null,null,"J","Matejas, V; Hinkes, B; Alkandari, F; Al-Gazali, L; Annexstad, E; Aytac, MB; Barrow, M; Blahova, K; Bockenhauer, D; Cheong, HI; Maruniak-Chudek, I; Cochat, P; Dotsch, J; Gajjar, P; Hennekam, RC; Janssen, F; Kagan, M; Kariminejad, A; Kemper, MJ; Koenig, J; Kogan, J; Kroes, HY; Kuwertz-Broking, E; Lewanda, AF; Medeira, A; Muscheites, J; Niaudet, P; Pierson, M; Saggar, A; Seaver, L; Suri, M; Tsygin, A; Wuhl, E; Zurowska, A; Uebe, S; Hildebrandt, F; Antignac, C; Zenker, M",null,null,null,"Matejas, Verena; Hinkes, Bernward; Alkandari, Faisal; Al-Gazali, Lihadh; Annexstad, Ellen; Aytac, Mehmet B.; Barrow, Margaret; Blahova, Kveta; Bockenhauer, Detlef; Cheong, Hae Il; Maruniak-Chudek, Iwona; Cochat, Pierre; Doetsch, Joerg; Gajjar, Priya; Hennekam, Raoul C.; Janssen, Francoise; Kagan, Mikhail; Kariminejad, Ariana; Kemper, Markus J.; Koenig, Jens; Kogan, Jillene; Kroes, Hester Y.; Kuwertz-Broeking, Eberhard; Lewanda, Amy F.; Medeira, Ana; Muscheites, Jutta; Niaudet, Patrick; Pierson, Michel; Saggar, Anand; Seaver, Laurie; Suri, Mohnish; Tsygin, Alexey; Wuehl, Elke; Zurowska, Aleksandra; Uebe, Steffen; Hildebrandt, Friedhelm; Antignac, Corinne; Zenker, Martin",null,null,"Mutations in the Human Laminin beta 2 (LAMB2) Gene and the Associated Phenotypic Spectrum","HUMAN MUTATION",null,null,"English","Article",null,null,null,null,null,"LAMB2; Pierson syndrome; nephrotic syndrome; autosomal recessive; podocyte; laminin; ocular malformation","CONGENITAL NEPHROSIS SYNDROME; DISTINCT EYE ABNORMALITIES; PIERSON-SYNDROME; MESANGIAL SCLEROSIS; MESSENGER-RNA; MICROCORIA; MICE; READTHROUGH","Mutations of LAMB2 typically cause autosomal recessive Pierson syndrome, a disorder characterized by congenital nephrotic syndrome, ocular and neurologic abnormalities, but may occasionally be associated with milder or oligosymptomatic disease variants. LAMB2 encodes the basement membrane protein laminin beta 2, which is incorporated in specific heterotrimeric laminin isoforms and has an expression pattern corresponding to the pattern of organ manifestations in Pierson syndrome. Herein we review all previously reported and several novel LAMB2 mutations in relation to the associated phenotype in patients from 39 unrelated families. The majority of disease-causing LAMB2 mutations are truncating, consistent with the hypothesis that loss of laminin beta 2 function is the molecular basis of Pierson syndrome. Although truncating mutations are distributed across the entire gene, missense mutations are clearly clustered in the N-terminal LN domain, which is important for inter-molecular interactions. There is an association of missense mutations and small in frame deletions with a higher mean age at onset of renal disease and with absence of neurologic abnormalities, thus suggesting that at least some of these may represent hypomorphic alleles. Nevertheless, genotype alone does not appear to explain the full range of clinical variability, and therefore hitherto unidentified modifiers are likely to exist. Hum Mutat 31:992-1002, 2010. (c) 2010 Wiley-Liss, Inc.","[Matejas, Verena; Uebe, Steffen; Zenker, Martin] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Human Genet, D-8520 Erlangen, Germany; [Hinkes, Bernward; Doetsch, Joerg] Univ Childrens Hosp, Erlangen, Germany; [Hinkes, Bernward; Hildebrandt, Friedhelm] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; [Hinkes, Bernward; Hildebrandt, Friedhelm] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Hinkes, Bernward; Hildebrandt, Friedhelm] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; [Al-Gazali, Lihadh] UAE Univ, Fac Med & Hlth Sci, Dept Pediat, Al Ain, U Arab Emirates; [Annexstad, Ellen] NICU Oslo Univ Hosp, Oslo, Norway; [Aytac, Mehmet B.] Istanbul Univ, Cerrahpapa Med Fac, Dept Pediat Nephrol, Istanbul, Turkey; [Barrow, Margaret] Leicester Royal Infirm, Leicester, Leics, England; [Blahova, Kveta] Charles Univ Prague, Fac Med 2, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Cheong, Hae Il] Seoul Natl Univ, Childrens Hosp, Dept Pediat, Seoul, South Korea; [Maruniak-Chudek, Iwona] Med Univ Silesia, Dept Neonatal Intens Care, Katowice, Poland; [Cochat, Pierre] Univ Lyon 1, Hop Edouard Herriot, Dept Pediat, F-69365 Lyon, France; [Gajjar, Priya] Univ Cape Town, Dept Paediat Med, ZA-7700 Rondebosch, South Africa; [Hennekam, Raoul C.] UCL, Inst Child Hlth, Great Ormond St Hosp Children, Dept Clin Genet, London, England; [Hennekam, Raoul C.] UVA, Acad Med Ctr, Dept Pediat, Amsterdam, Netherlands; [Janssen, Francoise] Univ Libre Bruxelles, Hop Univ Enfants, Dept Pediat Nephrol, Brussels, Belgium; [Kagan, Mikhail] Orenburg Reg Childrens Hosp, Dept Gastroenterol & Nephrol, Orenburg, Russia; [Kariminejad, Ariana] Kariminejad Najmabadi Pathol & Genet Ctr, Tehran, Iran; [Kemper, Markus J.] Univ Hosp Hamburg Eppendorf, Hamburg, Germany; [Koenig, Jens; Kuwertz-Broeking, Eberhard] Univ Childrens Hosp, Munster, Germany; [Kogan, Jillene] Cincinnati Childrens Hosp, Dept Human Genet, Cincinnato, OH USA; [Kroes, Hester Y.] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands; [Lewanda, Amy F.] Inova Fairfax Hosp Children, Falls Church, VA USA; [Medeira, Ana] Hosp Santa Maria, Lisbon, Portugal; [Muscheites, Jutta] Univ Rostock, Univ Childrens Hosp, D-2500 Rostock 1, Germany; [Niaudet, Patrick] Hop Necker Enfants Malad, Serv Nephrol Pediat, F-75730 Paris, France; [Pierson, Michel] Univ Childrens Hosp Nancy, Nancy, France; [Saggar, Anand] St Georges Univ London, London, England; [Seaver, Laurie] Kapiolani Med Specialists, Honolulu, HI USA; [Seaver, Laurie] Univ Hawaii, John A Burns Sch Med, Dept Pediat, Honolulu, HI 96822 USA; [Suri, Mohnish] Nottingham Univ Hosp NHS Trust, Clin Genet Serv, Nottingham, England; [Tsygin, Alexey] Sci Ctr Childrens Hlth, Moscow, Russia; [Wuehl, Elke] Univ Heidelberg, Ctr Pediat & Adolescent Med, D-6900 Heidelberg, Germany; [Zurowska, Aleksandra] Med Univ Gdansk, Dept Pediat & Adolescent Nephrol & Hypertens, Gdansk, Poland; [Antignac, Corinne] Univ Paris 05, INSERM, U574, Paris, France; [Antignac, Corinne] Hop Necker Enfants Malad, AP HP, Dept Genet, Paris, France; [Zenker, Martin] Otto Von Guericke Univ, Univ Hosp Magdeburg, Inst Human Genet, D-39120 Magdeburg, Germany","Zenker, M (reprint author), Otto Von Guericke Univ, Univ Hosp Magdeburg, Inst Human Genet, Leipziger Str 44, D-39120 Magdeburg, Germany.","martin.zenker@med.ovgu.de","Bockenhauer, Detlef/C-5951-2008; Cheong, Hae Il/J-5652-2012",null,"German Research Foundation (DFG) [SFB 423, TP A19]","We are indebted to the families of our patients for participation in our study. We are grateful to the members of the GPN (Gesellschaft fur Padiatrische Nephrologie) and Dr. Mike Urban for providing us with DNA samples from patients with syndromic forms of NS, and to Jeffrey H. Miner for helpful discussion. Grant sponsor: the German Research Foundation (DFG); grant number: SFB 423, TP A19 (to M.Z.).",null,33,33,33,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1059-7794",null,null,"HUM MUTAT","Hum. Mutat.","SEP",2010,31,9,null,null,null,null,992,1002,null,"10.1002/humu.21304",null,11,"Genetics & Heredity","Genetics & Heredity","647PN","WOS:000281631000002"]
[null,null,null,null,"J","Adam, V; Petrlova, J; Wang, J; Eckschlager, T; Trnkova, L; Kizek, R",null,null,null,"Adam, Vojtech; Petrlova, Jitka; Wang, Joseph; Eckschlager, Tomas; Trnkova, Libuse; Kizek, Rene",null,null,"Zeptomole Electrochemical Detection of Metallothioneins","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"PLASMA-MASS SPECTROMETRY; CANCER; CHRONOPOTENTIOMETRY; SPECIATION; PROTEOMICS; PROTEINS; LEVEL","Background: Thiol-rich peptides and proteins possess a large number of biological activities and may serve as markers for numerous health problems including cancer. Metallothionein (MT), a small molecular mass protein rich in cysteine, may be considered as one of the promising tumour markers. The aim of this paper was to employ chronopotentiometric stripping analysis (CPSA) for highly sensitive detection of MT. Methodology/Principal Findings: In this study, we used adsorptive transfer stripping technique coupled with CPSA for detection of cysteine, glutathione oxidized and reduced, phytochelatin, bovine serum albumin, and metallothionein. Under the optimal conditions, we were able to estimate detection limits down to tens of fg per ml. Further, this method was applied to detect metallothioneins in blood serum obtained from patients with breast cancer and in neuroblastoma cells resistant and sensitive to cisplatin in order to show the possible role of metallothioneins in carcinogenesis. It was found that MT level in blood serum was almost twice higher as compared to the level determined in healthy individuals. Conclusions/Significance: This paper brings unique results on the application of ultra-sensitive electroanalytical method for metallothionein detection. The detection limit and other analytical parameters are the best among the parameters of other techniques. In spite of the fact that the paper is mainly focused on metallothionein, it is worth mentioning that successful detection of other biologically important molecules is possible by this method. Coupling of this method with simple isolation methods such as antibody-modified paramagnetic particles may be implemented to lab-on-chip instrument.","[Adam, Vojtech; Petrlova, Jitka; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Brno, Czech Republic; [Wang, Joseph] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CS-61137 Brno, Czech Republic","Adam, V (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Wang, Joseph/C-6175-2011",null,"GAAV [IAA40199071]","Financial support from GAAV IAA40199071 is highly acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,24,25,25,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA","1932-6203",null,null,"PLOS ONE","PLoS One","JUL 6",2010,5,7,null,null,null,null,null,null,"e11441","10.1371/journal.pone.0011441",null,8,"Multidisciplinary Sciences","Science & Technology - Other Topics","620TI","WOS:000279522500009"]
[null,null,null,null,"J","Zwaan, CM; Reinhardt, D; Zimmerman, M; Hasle, H; Stary, J; Stark, B; Dworzak, M; Creutzig, U; Kaspers, GJL",null,null,null,"Zwaan, Christian M.; Reinhardt, Dirk; Zimmerman, Martin; Hasle, Henrik; Stary, Jan; Stark, Batia; Dworzak, Michael; Creutzig, Ursula; Kaspers, Gertjan J. L.",null,"Int BFM Study Grp Paediat AML","Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study","BRITISH JOURNAL OF HAEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"acute myeloid leukaemia; relapse; children; gemtuzumab ozogamicin; phase II study","STEM-CELL TRANSPLANTATION; PEDIATRIC-PATIENTS; VENOOCCLUSIVE DISEASE; INITIAL TREATMENT; DOSE CYTARABINE; EFFICACY; SAFETY; CHEMOTHERAPY; THERAPY; INDUCTION","The prognosis of children with relapsed/refractory acute myeloid leukaemia (AML) is poor, and new therapies are needed. Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody linked to the antitumor antibiotic calicheamicin. We conducted an investigator-initiated phase II study with GO to assess its efficacy and safety, administering two dosages of 7 5 mg/m(2) with a 14 d-interval. Thirty children who were refractory to re-induction at first relapse or suffered from second relapse of AML received a total of 64 infusions of GO. The response rate [complete remission (CR) and CR with insufficient platelet recovery] was 37%. Nine patients were subsequently transplanted (median time to transplant, 4 weeks, range 3-21 weeks), and three of these patients are currently in continuous CR with a median follow-up of >3 years, and can considered to be cured. This resulted in a statistically significant survival advantage for children who responded to GO versus those who did not [27% (standard error 13%) vs. 0%, respectively, P = 0.001]. All other children died, mainly from progressive disease. The treatment was generally well tolerated by most patients. The frequency of transient transaminatis was low. All but one patient received defibrotide prophylaxis during the transplant procedure, and no cases of veno-occlusive disease were noted. This study showed a favourable safety/efficacy profile of single-agent GO in children with refractory first or second relapse of AML.","[Zwaan, Christian M.] Erasmus MC, Sophia Childrens Hosp, Dept Paediat Oncol Haematol, NL-3015 GJ Rotterdam, Netherlands; [Zwaan, Christian M.; Kaspers, Gertjan J. L.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Reinhardt, Dirk; Zimmerman, Martin; Creutzig, Ursula] Hannover Med Sch, AML BFM Study Grp, D-30623 Hannover, Germany; [Hasle, Henrik] Aarhus Univ Hosp Skejby, Dept Paediat, Aarhus, Denmark; [Stary, Jan] Univ Hosp Motol, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Stark, Batia] Schneider Childrens Med Ctr Israel, Ctr Paediat Haematol Oncol, Petah Tiqwa, Israel; [Dworzak, Michael] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam Med Ctr, Dept Paediat Haematol Oncol, Amsterdam, Netherlands","Zwaan, CM (reprint author), Erasmus MC, Sophia Childrens Hosp, Dept Paediat Oncol Haematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.","c.m.zwaan@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Wyeth","CMZ and GJK received an unrestricted grant from Wyeth to support running this study.",null,36,24,25,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0007-1048",null,null,"BRIT J HAEMATOL","Br. J. Haematol.","MAR",2010,148,5,null,null,null,null,768,776,null,"10.1111/j.1365-2141.2009.08011.x",null,9,"Hematology","Hematology","554AF","WOS:000274407200009"]
[null,null,null,null,"J","Harrison, CJ; Haas, O; Harbott, J; Biondi, A; Stanulla, M; Trka, J; Izraeli, S",null,null,null,"Harrison, Christine J.; Haas, Oskar; Harbott, Jochen; Biondi, Andrea; Stanulla, Martin; Trka, Jan; Izraeli, Shai",null,null,"Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Munster study group","BRITISH JOURNAL OF HAEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukaemia; risk stratification; reverse transcriptase polymerase chain reaction; cytogenetics; fluorescence in situ hybridization","DEPENDENT PROBE AMPLIFICATION; MINIMAL RESIDUAL DISEASE; INTRACHROMOSOMAL AMPLIFICATION; CHROMOSOME-21 IAMP21; GENOMIC ALTERATIONS; MLL TRANSLOCATIONS; EXPRESSION DATA; BCP-ALL; CHILDREN; FUSION","Treatment of childhood acute lymphoblastic leukaemia (ALL) has improved considerably in recent years. A contributing factor has been the improved stratification for treatment according to a number of factors, including genetic determinants of outcome. Here we review the current diagnostic criteria of genetic abnormalities in precursor B-ALL (BCP-ALL), including the relevant technical approaches and the application of the most appropriate methods for the detection of each abnormality. The abnormalities with the most significant impact for treatment and management of BCP-ALL are t(9;22)(q34;q11)/BCR-ABL1, t(4;11)(q21;q23)/MLL-AFF1 and near-haploidy/low hypodiploidy for high risk stratification and, to a lesser extent, t(12;21)(p13;q22)/ETV6-RUNX1 and high hyperdiploidy for good risk management. Apart from the numerical abnormalities, these can be routinely tested for by reverse transcription polymerase chain reaction, providing a basic yet informative screen. However, cytogenetics, particularly fluorescence in situ hybridization may provide reliable alternative detection methods dependent upon the preferred technical approach within each protocol.","[Harrison, Christine J.] Newcastle Univ, Leukaemia Res Cytogenet Grp, No Inst Canc Res, Sir James Spence Inst,Royal Victoria Infirmary, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Haas, Oskar] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Harbott, Jochen] Univ Giessen, Dept Paediat Haematol & Oncol, Oncogenet Lab, Giessen, Germany; [Biondi, Andrea] Univ Milano Bicocca, Dept Paediat, Hosp S Gerardo, Monza, Italy; [Stanulla, Martin] Univ Med Ctr Schleswig Holstein, Dept Paediat, Lubeck, Germany; [Trka, Jan] Charles Univ Prague, Dept Paediat Haematol Oncol, Fac Med 2, Prague, Czech Republic; [Trka, Jan] Univ Hosp Motol, Prague, Czech Republic; [Izraeli, Shai] Tel Aviv Univ, Edmond & Lily Safra Childrens Hosp, Chaim Sheba Med Ctr, Leukaemia Res Ctr, IL-69978 Tel Aviv, Israel","Harrison, CJ (reprint author), Newcastle Univ, Leukaemia Res Cytogenet Grp, No Inst Canc Res, Sir James Spence Inst,Royal Victoria Infirmary, Level 5, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.","christine.harrison@newcastle.ac.uk",null,null,null,null,null,52,23,24,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0007-1048",null,null,"BRIT J HAEMATOL","Br. J. Haematol.","OCT",2010,151,2,null,null,null,null,132,142,null,"10.1111/j.1365-2141.2010.08314.x",null,11,"Hematology","Hematology","656XN","WOS:000282374500002"]
[null,null,null,null,"J","Cardwell, CR; Stene, LC; Joner, G; Davis, EA; Cinek, O; Rosenbauer, J; Ludvigsson, J; Castell, C; Svensson, J; Goldacre, MJ; Waldhoer, T; Polanska, J; Gimeno, SGA; Chuang, LM; Parslow, RC; Wadsworth, EJK; Chetwynd, A; Pozzilli, P; Brigis, G; Urbonaite, B; Sipetic, S; Schober, E; Ionescu-Tirgoviste, C; de Beaufort, CE; Stoyanov, D; Buschard, K; Patterson, CC",null,null,null,"Cardwell, C. R.; Stene, L. C.; Joner, G.; Davis, E. A.; Cinek, O.; Rosenbauer, J.; Ludvigsson, J.; Castell, C.; Svensson, J.; Goldacre, M. J.; Waldhoer, T.; Polanska, J.; Gimeno, S. G. A.; Chuang, L. -M.; Parslow, R. C.; Wadsworth, E. J. K.; Chetwynd, A.; Pozzilli, P.; Brigis, G.; Urbonaite, B.; Sipetic, S.; Schober, E.; Ionescu-Tirgoviste, C.; de Beaufort, C. E.; Stoyanov, D.; Buschard, K.; Patterson, C. C.",null,null,"Birthweight and the risk of childhood-onset type 1 diabetes: a meta-analysis of observational studies using individual patient data","DIABETOLOGIA",null,null,"English","Article",null,null,null,null,null,"Birthweight; Epidemiology; Meta-analysis; Risk factors; Type 1 diabetes mellitus","SUBSEQUENT RISK; EARLY-LIFE; IN-UTERO; POPULATION; MELLITUS; CHILDREN; DETERMINANTS; IDDM; GROWTH; UK","We investigated whether children who are heavier at birth have an increased risk of type 1 diabetes. Relevant studies published before February 2009 were identified from literature searches using MEDLINE, Web of Science and EMBASE. Authors of all studies containing relevant data were contacted and asked to provide individual patient data or conduct pre-specified analyses. Risk estimates of type 1 diabetes by category of birthweight were calculated for each study, before and after adjustment for potential confounders. Meta-analysis techniques were then used to derive combined ORs and investigate heterogeneity between studies. Data were available for 29 predominantly European studies (five cohort, 24 case-control studies), including 12,807 cases of type 1 diabetes. Overall, studies consistently demonstrated that children with birthweight from 3.5 to 4 kg had an increased risk of diabetes of 6% (OR 1.06 [95% CI 1.01-1.11]; p = 0.02) and children with birthweight over 4 kg had an increased risk of 10% (OR 1.10 [95% CI 1.04-1.19]; p = 0.003), compared with children weighing 3.0 to 3.5 kg at birth. This corresponded to a linear increase in diabetes risk of 3% per 500 g increase in birthweight (OR 1.03 [95% CI 1.00-1.06]; p = 0.03). Adjustments for potential confounders such as gestational age, maternal age, birth order, Caesarean section, breastfeeding and maternal diabetes had little effect on these findings. Children who are heavier at birth have a significant and consistent, but relatively small increase in risk of type 1 diabetes.","[Cardwell, C. R.; Patterson, C. C.] Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Belfast BT12 6BJ, Antrim, North Ireland; [Stene, L. C.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Stene, L. C.; Joner, G.] Oslo Univ Hosp, Oslo Diabet Res Ctr, Oslo, Norway; [Joner, G.] Univ Oslo, Fac Med, Oslo, Norway; [Davis, E. A.] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Cinek, O.] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Rosenbauer, J.] Univ Dusseldorf, Inst Biometr & Epidemiol, German Diabet Ctr, Leibniz Inst, Dusseldorf, Germany; [Ludvigsson, J.] Linkoping Univ, Dept Paediat, Linkoping, Sweden; [Ludvigsson, J.] Linkoping Univ, Diabet Res Ctr, Linkoping, Sweden; [Castell, C.] Advisory Comm Diabet Catalonia, Dept Hlth, Barcelona, Spain; [Svensson, J.] Glostrup Univ Hosp, Dept Pediat, Glostrup, Denmark; [Goldacre, M. J.] Univ Oxford, Dept Publ Hlth, Oxford, England; [Waldhoer, T.] Med Univ Vienna, Dept Epidemiol, Vienna, Austria; [Polanska, J.] Silesian Tech Univ, Fac Automat Control Elect & Comp Sci, Gliwice, Poland; [Gimeno, S. G. A.] Univ Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil; [Chuang, L. -M.] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Parslow, R. C.] Univ Leeds, Paediat Epidemiol Grp, Leeds, W Yorkshire, England; [Wadsworth, E. J. K.] Cardiff Univ, Ctr Occupat & Hlth Psychol, Cardiff, S Glam, Wales; [Chetwynd, A.] Univ Lancaster, Dept Math & Stat, Lancaster, England; [Pozzilli, P.] Univ Campus Biomed, Rome, Italy; [Brigis, G.] Riga Stradins Univ, Dept Publ Hlth & Epidemiol, Riga, Latvia; [Urbonaite, B.] Kaunas Univ Med, Inst Endocrinol, Kaunas, Lithuania; [Sipetic, S.] Univ Belgrade, Sch Med, Inst Epidemiol, Belgrade, Serbia; [Schober, E.] Med Univ Vienna, Dept Paediat, Vienna, Austria; [Ionescu-Tirgoviste, C.] N Paulescu Inst Diabet, Nutr & Metab Dis Clin, Bucharest, Romania; [de Beaufort, C. E.] Pediat Clin, Luxembourg, Luxembourg; [Stoyanov, D.] Childrens Diabet Ctr, Sofia, Bulgaria; [Buschard, K.] Rigshosp, Bartholin Inst, DK-2100 Copenhagen, Denmark","Cardwell, CR (reprint author), Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.","c.cardwell@qub.ac.uk","Polanska, Joanna/A-5271-2008; GIMENO, SUELY/K-3888-2012; Chetwynd, Amanda/B-4727-2013; Polanska, Joanna/H-4513-2013","Chetwynd, Amanda/0000-0002-7659-3231; Polanska, Joanna/0000-0001-8004-9864","Czech Republic Ministry of Education [0021620814]; Department of Health in Taiwan [DOH 92- TD1052]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [94/0943-0]; Centro Internazionale Studi Diabete (Italy, Rome); Swedish Child Diabetes Foundation; NHS National Coordinating Centre for Research Capacity Development UK; Research Council of Norway; German Research Foundation [HE 234/1-1]; Ministry for Science and Technological Development of Serbia [145084]; European Commission Health Information Strand [2007115]; Diabetes UK; Northern Ireland Department of Health and Social Services","The authors acknowledge support for the conduct of the original studies from the following the Czech Republic Ministry of Education (grant MSM 0021620814), the Department of Health in Taiwan (grant DOH 92- TD1052), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (grant 94/0943-0), the Centro Internazionale Studi Diabete (Italy, Rome), The Swedish Child Diabetes Foundation, the NHS National Coordinating Centre for Research Capacity Development UK, the Research Council of Norway, the German Research Foundation (grant HE 234/1-1), the Ministry for Science and Technological Development of Serbia (number 145084, 2006-2010), EUBIROD (funded by the European Commission Health Information Strand, DG-SANCO 2005, contract number 2007115), Diabetes UK and the Northern Ireland Department of Health and Social Services. Thanks also to G. Soltesz (University of Pecs, Pecs, Hungary) and G. Dahlquist (Umea University, Umea, Sweden), the co-ordinators of the EURODIAB Substudy 2. We also thank M. Jane (Department of Health, Barcelona, Spain).",null,59,22,22,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0012-186X",null,null,"DIABETOLOGIA","Diabetologia","APR",2010,53,4,null,null,null,null,641,651,null,"10.1007/s00125-009-1648-5",null,11,"Endocrinology & Metabolism","Endocrinology & Metabolism","562WU","WOS:000275087100008"]
[null,null,null,null,"J","Steinemann, D; Arning, L; Praulich, I; Stuhrmann, M; Hasle, H; Stary, J; Schlegelberger, B; Niemeyer, CM; Flotho, C",null,null,null,"Steinemann, Doris; Arning, Larissa; Praulich, Inka; Stuhrmann, Manfred; Hasle, Henrik; Stary, Jan; Schlegelberger, Brigitte; Niemeyer, Charlotte M.; Flotho, Christian",null,null,"Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Article",null,null,null,null,null,"mitotic recombination; NF1-inactivating mechnisms; juvenile myelomonocytic leukemia","NF1 GENE; RAS; MICRODELETION; INACTIVATION; GERMLINE; SPECTRUM","Children with neurofibromatosis type 1 (NF-1), being constitutionally deficient for one allele of the NF1 gene, are at greatly increased risk of juvenile myelomonocytic leukemia (JMML). NF1 is a negative regulator of RAS pathway activity, which has a central role in JMML. To further clarify the role of biallelic NF1 gene inactivation in the pathogenesis of JMML, we investigated the somatic NF1 lesion in 10 samples from children with JMML/NF-1. We report that two-thirds of somatic events involved loss of heterozygosity (LOH) at the AT,1 locus, predominantly caused by segmental uniparental disomy of large parts of chromosome arm 17q. One-third of leukemias showed compound-heterozygous NF1-inactivating mutations. A minority of cases exhibited somatic interstitial deletions. The Findings reinforce the emerging role of somatic mitotic recombination as a leukemogenic mechanism. In addition, they support the concept that biallelic NF-1 inactivation in hematopoietic progenitor cells is required for transformation to JMML in children with NF-1.","[Flotho, Christian] Univ Freiburg, Zentrum Kinder & Jugendmed, D-79106 Freiburg, Germany; [Steinemann, Doris; Praulich, Inka; Stuhrmann, Manfred; Schlegelberger, Brigitte] Hannover Med Sch, D-3000 Hannover, Germany; [Arning, Larissa] Ruhr Univ Bochum, Bochum, Germany; [Hasle, Henrik] Aarhus Univ, Hosp Skejby, Aarhus, Denmark; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic","Flotho, C (reprint author), Univ Freiburg, Zentrum Kinder & Jugendmed, Mathildenstr 1, D-79106 Freiburg, Germany.","christian.flotho@uniklinik-freiburg.de",null,null,"Deutsche Forschungsgemeinschaft [KR3473/1-1]","this work was supported by grant KR3473/1-1 from Deutsche Forschungsgemeinschaft (to C.F)",null,17,18,19,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","FEB",2010,95,2,null,null,null,null,320,323,null,"10.3324/haematol.2009.010355",null,4,null,null,"559EC","WOS:000274803700021"]
[null,null,null,null,"J","Strnad, H; Lacina, L; Kolar, M; Cada, Z; Vlcek, C; Dvorankova, B; Betka, J; Plzak, J; Chovanec, M; Sachova, J; Valach, J; Urbanova, M; Smetana, K",null,null,null,"Strnad, Hynek; Lacina, Lukas; Kolar, Michal; Cada, Zdenek; Vlcek, Cestmir; Dvorankova, Barbora; Betka, Jan; Plzak, Jan; Chovanec, Martin; Sachova, Jana; Valach, Jaroslav; Urbanova, Marketa; Smetana, Karel, Jr.",null,null,"Head and neck squamous cancer stromal fibroblasts produce growth factors influencing phenotype of normal human keratinocytes","HISTOCHEMISTRY AND CELL BIOLOGY",null,null,"English","Article",null,null,null,null,null,"Cancer microenvironment; BMP-4; IGF-2; Epithelial-mesenchymal interaction; Cancer-associated fibroblasts","EPITHELIAL-MESENCHYMAL TRANSITION; EMBRYONIC STEM-CELLS; IN-VITRO; IGF-II; PROSTATE-CANCER; GENE-EXPRESSION; OVARIAN-CANCER; CARCINOMA; TUMORS; MICROENVIRONMENT","Epithelial-mesenchymal interaction between stromal fibroblasts and cancer cells influences the functional properties of tumor epithelium, including the tumor progression and spread. We compared fibroblasts prepared from stroma of squamous cell carcinoma and normal dermal fibroblasts concerning their biological activity toward normal keratinocytes assessed by immunocytochemistry and profiling of gene activation for growth factors/cytokines by microarray chip technology. IGF-2 and BMP-4 were determined as candidate factors responsible for tumor-associated fibroblast activity that influences normal epithelia. This effect was confirmed by addition of recombinant IGF-2 and BMP4, respectively, to the culture medium. This hypothesis was also verified by inhibition experiments where blocking antibodies were employed in the medium conditioned by cancer-associated fibroblast. Presence of these growth factors was also detected in tumor samples.","[Dvorankova, Barbora; Smetana, Karel, Jr.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 12800 2, Czech Republic; [Strnad, Hynek; Kolar, Michal; Vlcek, Cestmir; Sachova, Jana; Urbanova, Marketa] Acad Sci Czech Republic, Inst Mol Genet, CR-14220 Prague 4, Czech Republic; [Lacina, Lukas] Charles Univ Prague, Inst Anat, Dept Dermatovenereol, Prague 12800 2, Czech Republic; [Betka, Jan; Urbanova, Marketa] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Prague 15006 5, Czech Republic; [Cada, Zdenek; Plzak, Jan; Chovanec, Martin] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Inst Anat, Prague 15006 5, Czech Republic","Smetana, K (reprint author), Charles Univ Prague, Inst Anat, Fac Med 1, Nemocnice 3, Prague 12800 2, Czech Republic.","karel.smetana@lf1.cuni.cz","Kolar, Michal/A-3307-2012; Strnad, Hynek/B-7361-2008","Kolar, Michal/0000-0002-4593-1525; Strnad, Hynek/0000-0002-0141-8340","Ministry of Education, Youth and Sport of the Czech Republic [MSM0021620806, NPVII 2B06106, AV0Z50520514]; Grant Agency of the Czech Republic [304/08/P175]","This study was supported by Ministry of Education, Youth and Sport of the Czech Republic, projects No. MSM0021620806, NPVII 2B06106, AV0Z50520514 and project of Grant Agency of the Czech Republic No. 304/08/P175. Authors are grateful to Iva Burdova and Vit Hajduch for excellent technical assistance.",null,52,18,18,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0948-6143",null,null,"HISTOCHEM CELL BIOL","Histochem. Cell Biol.","FEB",2010,133,2,null,null,null,null,201,211,null,"10.1007/s00418-009-0661-6",null,11,"Cell Biology; Microscopy","Cell Biology; Microscopy","545PC","WOS:000273745800006"]
[null,null,null,null,"J","Comi, G; Abramsky, O; Arbizu, T; Boyko, A; Gold, R; Havrdova, E; Komoly, S; Selmaj, K; Sharrack, B; Filippi, M",null,null,null,"Comi, G.; Abramsky, O.; Arbizu, T.; Boyko, A.; Gold, R.; Havrdova, E.; Komoly, S.; Selmaj, K.; Sharrack, B.; Filippi, M.",null,"LAQ 5063 Study Grp","Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study","MULTIPLE SCLEROSIS",null,null,"English","Article",null,null,null,null,null,"multiple sclerosis; relapsing-remitting; immunomodulator; MRI; Gadolinium-enhanced T1 lesions","CONTROLLED-TRIAL; MRI; STANDARD","Background: Laquinimod, an oral novel immunomodulator, was shown to reduce MRI-measured disease activity in relapsing-remitting MS (RRMS) patients. Objectives: To determine whether the safety and efficacy profile of laquinimod, as shown in a placebo-controlled 36-week trial (LAQ/5062), is sustained and reproducible. Methods: Two hundred and fifty seven patients entered the extension phase in which MRI was performed at the beginning and at the end of the active extension phase. Clinical assessments were performed at weeks 4, 12 and every 12 weeks thereafter. Results: Two hundred and thirty nine (93%) patients completed the extension phase and 222 (86.3%) had a final scan available. Gadolinium-enhanced (GdE) T1 lesions were significantly reduced for patients switching from placebo to 0.3/0.6 mg doses (52%, p = 0.0006). In patients initially randomized to 0.6 mg in LAQ/5062 the reduction of MRI activity observed in the placebo-controlled phase was maintained in the extension. The proportion of GdE-free patients for those who switched from placebo increased from a baseline of 31% to 47% at the end of the extension phase (p = 0.01). The most prominent safety signal was elevations of liver enzymes, reversible in all cases. Conclusions: The good efficacy and the excellent safety and tolerability profiles of laquinimod 0.6 mg/day are confirmed in this extension study.","[Comi, G.] Univ Vita Salute, Dept Neurol, I-20132 Milan, Italy; [Comi, G.] Ist Sci San Raffaele, I-20132 Milan, Italy; [Abramsky, O.] Hadassah Univ Hosp, IL-91120 Jerusalem, Israel; [Arbizu, T.] Univ Hosp Bellvitge, Barcelona, Spain; [Boyko, A.] Russian State Med Univ, Moscow 117437, Russia; [Gold, R.] Ruhr Univ Bochum, St Josef Hosp, D-4630 Bochum, Germany; [Havrdova, E.] Charles Univ Prague, Prague, Czech Republic; [Havrdova, E.] Gen Fac Hosp, Prague, Czech Republic; [Komoly, S.] Univ Pecs, Pecs, Hungary; [Selmaj, K.] Med Univ Lodz, Lodz, Poland; [Sharrack, B.] Univ Sheffield, Acad Dept Neurol, Sheffield, S Yorkshire, England; [Filippi, M.] Inst Sci, Inst Expt Neurol, Div Neurosci, Neuroimaging Res Unit, Milan, Italy; [Filippi, M.] Univ San Raffaele, Milan, Italy","Comi, G (reprint author), Univ Vita Salute, Dept Neurol, Olgettina 60, I-20132 Milan, Italy.","comi.giancarlo@hsr.it","Chapman, Joab/E-4598-2010; Zavalishin, I.A./C-3274-2012",null,"Teva Pharmaceutical Industries, Ltd.; Czech Ministry of Education [0021620849]","This study was funded by Teva Pharmaceutical Industries, Ltd. Unless otherwise stated, the trial investigators and members of the various study committees were not employed by Teva Pharmaceutical Industries and were not holders of equity interest or patent rights. All members of the Clinical Steering Committee, MRI Steering Committee, and academicians on the other committees were reimbursed for their specific services on a contractual basis by Teva Pharmaceutical Industries. EH acknowledges financial support from the Czech Ministry of Education (research program MSM 0021620849).",null,11,25,25,"SAGE PUBLICATIONS LTD","LONDON","1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND","1352-4585",null,null,"MULT SCLER","Mult. Scler.","NOV",2010,16,11,null,null,null,null,1360,1366,null,"10.1177/1352458510378127",null,7,"Clinical Neurology","Neurosciences & Neurology","673IX","WOS:000283654000009"]
[null,null,null,null,"J","Kozubenko, N; Turnovcova, K; Kapcalova, M; Butenko, O; Anderova, M; Rusnakova, V; Kubista, M; Hampl, A; Jendelova, P; Sykova, E",null,null,null,"Kozubenko, Nataliya; Turnovcova, Karolina; Kapcalova, Miroslava; Butenko, Olena; Anderova, Miroslava; Rusnakova, Vendula; Kubista, Mikael; Hampl, Ales; Jendelova, Pavla; Sykova, Eva",null,null,"Analysis of In Vitro and In Vivo Characteristics of Human Embryonic Stem Cell-Derived Neural Precursors","CELL TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"Human embryonic stem cells (hESCs); Neural differentiation; Fluorescent-activated cell sorting; RT-PCR; Transplantation","FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; GAMMA-AMINOBUTYRIC-ACID; PROGENITOR CELLS; DOPAMINERGIC-NEURONS; SUBVENTRICULAR ZONE; RECEPTOR SUBUNITS; MARKER PROMININ-1; HUMAN BLASTOCYSTS; PATCH-CLAMP","During the last decade, much progress has been made in developing protocols for the differentiation of human embryonic stem cells (hESCs) into a neural phenotype. The appropriate agent for cell therapy is neural precursors (NPs). Here, we demonstrate the derivation of highly enriched and expandable populations of proliferating NPs from the CCTL14 line of hESCs. These NPs could differentiate in vitro into functionally active neurons, as confirmed by immunohistochemical staining and electrophysiological analysis. Neural cells differentiated in vitro from hESCs exhibit broad cellular heterogeneity with respect to developmental stage and lineage specification. To analyze the population of the derived NPs, we used fluorescence-activated cell sorting (FACS) and characterized the expression of several pluripotent and neural markers, such as Nanog, SSEA-4, SSEA-1, TRA-1-60, CD24, CD133, CD56 (NCAM), beta-III-tubulin, NF70, nestin, CD271 (NGFR), CD29, CD73, and CD105 during long-term propagation. The analyzed cells were used for transplantation into the injured rodent brain; the tumorigenicity of the transplanted cells was apparently eliminated following long-term culture. These results complete the characterization of the CCTL14 line of hESCs and provide a framework for developing cell selection strategies for neural cell-based therapies.","[Kozubenko, Nataliya; Turnovcova, Karolina; Kapcalova, Miroslava; Butenko, Olena; Anderova, Miroslava; Hampl, Ales; Jendelova, Pavla; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Kozubenko, Nataliya; Turnovcova, Karolina; Kapcalova, Miroslava; Anderova, Miroslava; Hampl, Ales; Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Kozubenko, Nataliya; Turnovcova, Karolina; Kapcalova, Miroslava; Anderova, Miroslava; Hampl, Ales; Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Rusnakova, Vendula; Kubista, Mikael] Acad Sci Czech Republic, Inst Biotechnol, Prague 14220 4, Czech Republic; [Kubista, Mikael] TATAA Bioctr, Lundberg Lab, Gothenburg, Sweden; [Hampl, Ales] Masaryk Univ, Fac Med, Brno, Czech Republic","Sykova, E (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","sykova@biomed.cas.cz","Rusnakova, Vendula/H-5030-2011",null,"Academy of Sciences of the Czech Republic [AV0Z50390703, AVO250520701]; Ministry of Education, Youth and Sports of the Czech Republic [1M0538, LC554]; Academy of Science [IAA500520809]; Grant Agency of the Czech Republic [305/09/0717, 309/08/H079]; EC [FP6, LSHB-CT-2006-037328, LSHM-CT-2005-019063]","We thank Radek Sindelka for contributing to the RT-PCR expression analysis and James Dutt for critical reading of the manuscript. Support was provided by grants AV0Z50390703 and AVO250520701 from the Academy of Sciences of the Czech Republic, grants 1M0538 and LC554 from the Ministry of Education, Youth and Sports of the Czech Republic, grant IAA500520809 from the grant agency of the Academy of Science, 305/09/0717 and 309/08/H079 from the Grant Agency of the Czech Republic, the EC FP6 projects STEMS (LSHB-CT-2006-037328), and ENINET (LSHM-CT-2005-019063).",null,58,10,10,"COGNIZANT COMMUNICATION CORP","ELMSFORD","3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA","0963-6897",null,null,"CELL TRANSPLANT","Cell Transplant.",null,2010,19,4,null,null,null,null,471,486,null,null,null,16,"Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation","Cell Biology; Research & Experimental Medicine; Transplantation","612YU","WOS:000278942800009"]
[null,null,null,null,"J","Mejstrikova, E; Volejnikova, J; Fronkova, E; Zdrahalova, K; Kalina, T; Sterba, J; Jabali, Y; Mihal, V; Blazek, B; Cerna, Z; Prochazkova, D; Hak, J; Zemanova, Z; Jarosova, M; Oltova, A; Sedlacek, P; Schwarz, J; Zuna, J; Trka, J; Stary, J; Hrusak, O",null,null,null,"Mejstrikova, Ester; Volejnikova, Jana; Fronkova, Eva; Zdrahalova, Katerina; Kalina, Tomas; Sterba, Jaroslav; Jabali, Yahia; Mihal, Vladimir; Blazek, Bohumir; Cerna, Zdena; Prochazkova, Daniela; Hak, Jiri; Zemanova, Zuzana; Jarosova, Marie; Oltova, Alexandra; Sedlacek, Petr; Schwarz, Jiri; Zuna, Jan; Trka, Jan; Stary, Jan; Hrusak, Ondrej",null,null,"Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Article",null,null,null,null,null,"pediatric acute lymphoblastic leukemia; pediatric acute myeloid leukemia; mixed phenotype leukemia; biphenotypic leukemia; aberrant antigens; cytometry; acute hybrid leukemia","ACUTE LYMPHOBLASTIC LEUKEMIAS; BIPHENOTYPIC ACUTE-LEUKEMIA; MINIMAL-RESIDUAL-DISEASE; RECEPTOR GENE REARRANGEMENTS; ACTIVATING FLT3 MUTATIONS; ACUTE MYELOID-LEUKEMIA; MYELOPEROXIDASE ACTIVITY; FUSION GENE; CHILDHOOD; DIFFERENTIATION","Background Mixed phenotype acute leukemia (MPAL) represents a diagnostic and therapeutic dilemma. The European Group for the Immunological Classification of Leukemias (EGIL) scoring system unambiguously defines MPAL expressing aberrant lineage markers. Discussions surrounding it have focused on scoring details, and information is limited regarding its biological, clinical and prognostic significance. The recent World Health Organization classification is simpler and could replace the EGIL scoring system after transformation into unambiguous guidelines. Design and Methods Simple immunophenotypic criteria were used to classify all cases of childhood acute leukemia in order to provide therapy directed against acute lymphoblastic leukemia or acute myeloid leukemia. Prognosis, genotype and immunoglobulin/T-cell receptor gene rearrangement status were analyzed. Results The incidences of MPAL were 28/582 and 4/107 for children treated with acute lymphoblastic leukemia and acute myeloid leukemia regimens, respectively. In immunophenotypic principal component analysis, MPAL treated as T-cell acute lymphoblastic leukemia clustered between cases of non-mixed T-cell acute lymphoblastic leukemia and acute myeloid leukemia, while other MPAL cases were included in the respective non-mixed B-cell progenitor acute lymphoblastic leukemia or acute myeloid leukemia clusters. Analogously, immunoglobulin/T-cell receptor gene rearrangements followed the expected pattern in patients treated as having acute myeloid leukemia (non-rearranged, 4/4) or as having B-cell progenitor acute lymphoblastic leukemia (rearranged, 20/20), but were missing in 3/5 analyzed cases of MPAL treated as having T-cell acute lymphobastic leukemia. In patients who received acute lymphoblastic leukemia treatment, the 5-year event-free survival of the MPAL cases was worse than that of the non-mixed cases (53+/-10% and 76+/-2% at 5 years, respectively, P=0.0075), with a more pronounced difference among B lineage cases. The small numbers of MPAL cases treated as T-cell acute lymphoblastic leukemia or as acute myeloid leukemia hampered separate statistics. We compared prognosis of all subsets with the prognosis of previously published cohorts. Conclusions Simple immunophenotypic criteria are useful for therapy decisions in MPAL. In B lineage leukemia, MPAL confers poorer prognosis. However, our data do not justify a preferential use of current acute myeloid leukemia-based therapy in MPAL.","[Mejstrikova, Ester; Hrusak, Ondrej] Charles Univ Prague, Fac Med 2, CLIP, Dept Pediat Hematol Oncol, Prague 15006 5, Czech Republic; [Mejstrikova, Ester; Volejnikova, Jana; Fronkova, Eva; Zdrahalova, Katerina; Kalina, Tomas; Sedlacek, Petr; Zuna, Jan; Trka, Jan; Stary, Jan; Hrusak, Ondrej] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Mejstrikova, Ester; Volejnikova, Jana; Fronkova, Eva; Zdrahalova, Katerina; Kalina, Tomas; Sedlacek, Petr; Zuna, Jan; Trka, Jan; Stary, Jan; Hrusak, Ondrej] Univ Hosp Motol, Prague, Czech Republic; [Sterba, Jaroslav; Oltova, Alexandra] Univ Hosp, Dept Pediat Oncol, Brno, Czech Republic; [Sterba, Jaroslav] Univ Hosp, Dept Med Genet, Brno, Czech Republic; [Jabali, Yahia] Reg Hosp, Dept Pediat, Ceske Budejovice, Czech Republic; [Mihal, Vladimir] Palacky Univ, Fac Med, Dept Pediat, CR-77147 Olomouc, Czech Republic; [Mihal, Vladimir; Jarosova, Marie] Univ Hosp, Olomouc, Czech Republic; [Blazek, Bohumir] Teaching Hosp Ostrava, Dept Pediat, Ostrava, Czech Republic; [Cerna, Zdena] Univ Hosp Plzen, Dept Pediat, Plzen, Czech Republic; [Prochazkova, Daniela] Masaryk Hosp Usti nad Labem, Dept Pediat, Usti Nad Labem, Czech Republic; [Hak, Jiri] Fac Med Hradec Kralove, Dept Pediat, Hradec Kralove, Czech Republic; [Zemanova, Zuzana] Gen Univ Hosp, Inst Clin Biochem & Lab Diagnost, Ctr Oncocytogenet, Prague, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Fac Med 1, Prague 15006 5, Czech Republic; [Jarosova, Marie] Palacky Univ, Fac Med, Dept Hematooncol, CR-77147 Olomouc, Czech Republic; [Schwarz, Jiri] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic","Hrusak, O (reprint author), Charles Univ Prague, Fac Med 2, CLIP, Dept Pediat Hematol Oncol, V Uvalu 84, Prague 15006 5, Czech Republic.","ester.mejstrikova@lfmotol.cuni.cz; ondrej.hrusak@lfmotol.cuni.cz",null,null,"Charles University [7393/2007, 7539/2007]; Czech Ministry of Health [NPV 2806064]; FNM-MZO [2005]; Czech Ministry of Education [MSM0021620813];  [NS10004];  [MZdNR9531-3];  [GACR310/09/P058];  [P301/10/1877]","this work was supported by Charles University grants 7393/2007, 7539/2007, Czech Ministry of Health NPV 2806064, FNM-MZO 2005, NS10004 and MZdNR9531-3, GACR310/09/P058 and P301/10/1877 and by the Czech Ministry of Education with grant n. MSM0021620813.",null,37,9,9,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","JUN",2010,95,6,null,null,null,null,928,935,null,"10.3324/haematol.2009.014506",null,8,null,null,"614IW","WOS:000279051100013"]
[null,null,null,null,"J","Kubinova, S; Sykova, E",null,null,null,"Kubinova, Sarka; Sykova, Eva",null,null,"Nanotechnology for treatment of stroke and spinal cord injury","NANOMEDICINE",null,null,"English","Review",null,null,null,null,null,"cell therapy; contrast agents; magnetic resonance; nanofibers; scaffold; spinal cord lesion","MESENCHYMAL STEM-CELLS; SUPERPARAMAGNETIC IRON-OXIDE; MAGNETIC-RESONANCE TRACKING; PEPTIDE NANOFIBER SCAFFOLD; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; BONE-MARROW; RAT-BRAIN; ELECTROSPUN NANOFIBERS","The use of nanotechnology in cell therapy and tissue engineering offers promising future perspectives for brain and spinal cord injury treatment. Stem cells have been shown to selectively target injured brain and spinal cord tissue and improve functional recovery. To allow cell detection, superparamagnetic iron-oxide nanoparticles can be used to label transplanted cells. MRI is then a suitable method for the in vivo tracking of grafted cells in the host organism. CNS, and particularly spinal cord, injury is accompanied by tissue damage and the formation of physical and biochemical barriers that prevent axons from regenerating. One aspect of nanomedicine is the development of biologically compatible nanofiber scaffolds that mimic the structure of the extracellular matrix and can serve as a permissive bridge for axonal regeneration or as a drug-delivery system. The incorporation of biologically active epitopes and/or the utilization of these scaffolds as stem cell carriers may further enhance their therapeutic efficacy.","[Kubinova, Sarka; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic; [Sykova, Eva] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague, Czech Republic","Sykova, E (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220, Czech Republic.","sykova@biomed.cas.cz",null,null,"EC [LSHM-CT-2005-019063]; GACR [203/09/1242, KAN201110651, KAN200520804];  [A VOZ503 90 703];  [1M0538];  [LC 554];  [IGA MZ 1A8697-5];  [GAAV IAA 500 390 902]","This work was supported through grants: A VOZ503 90 703, 1M0538, LC 554, IGA MZ 1A8697-5, GAAV IAA 500 390 902, the EC FP6 project ENINET (LSHM-CT-2005-019063), GACR 203/09/1242 KAN201110651 and KAN200520804. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",null,88,18,20,"FUTURE MEDICINE LTD","LONDON","UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND","1743-5889",null,null,"NANOMEDICINE-UK","Nanomedicine","JAN",2010,5,1,null,null,null,null,99,108,null,"10.2217/NNM.09.93",null,10,"Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology","Biotechnology & Applied Microbiology; Science & Technology - Other Topics","544QV","WOS:000273674900015"]
[null,null,null,null,"J","Stulik, J; Kozak, J; Sebesta, P; Vyskocil, T; Kryl, J; Klezl, Z",null,null,null,"Stulik, Jan; Kozak, Jiri; Sebesta, Petr; Vyskocil, Tomas; Kryl, Jan; Klezl, Zdenek",null,null,"Total Spondylectomy of C2 Report of Three Cases and Review of the Literature","JOURNAL OF SPINAL DISORDERS & TECHNIQUES",null,null,"English","Article",null,null,null,null,null,"total spondylectomy; axis; C2; cervical spine; tumor","MULTILEVEL CERVICAL CHORDOMA; PRIMARY OSTEOGENIC-SARCOMA; OPERATIVE TECHNIQUE; SURGICAL TECHNIQUE; POLYAXIAL SCREW; SPINE; RECONSTRUCTION; RESECTION; FIXATION; EXCISION","Study Design: A report on 3 patients undergoing total spondylectomy of the C2 vertebra for tumor and the technique for C1-3 reconstruction. Objective: To illustrate the feasibility of complete resection of the C2 vertebra with preservation of the vertebral arteries and cervical nerve roots. Background: Total spondylectomy provides improved progression free survival in many patients with locally aggressive spinal tumors. However, the perceived technical demands of effectively preserving both vertebral arteries, maintaining cervical nerve roots, and biomechanical reconstruction of the cranial-cervical junction often dissuades surgeons from carrying out total spondylectomy of the C2 vertebra. Methods: A review of 3 patients undergoing total C2 spondylectomy for tumor (thyroid adenocarcinoma, chordoma, and solitary plasmocytoma) was done. The surgical procedure that was undertaken and the technique used are described. Results: Postoperatively, all 3 patients had uneventful postoperative recovery with gradual improvement in their neurologic functions. Conclusion: Preservation of bilateral vertebral arteries and all cervical nerve roots is feasible when carrying out intralesional total spondylectomy in patients with C2 vertebral body tumors and should be considered in patients thought to benefit from total C2 vertebra excision. In an attempt to augment construct stability and provide anterior column load sharing, we have used mesh cage and iliac crest graft between C1 and C3 held in place with a short cervical plate without complications.","[Klezl, Zdenek] Derbyshire Royal Infirm, Spinal Unit, Dept Trauma & Orthopaed, Derby DE1 2QY, England","Klezl, Z (reprint author), Royal Derby Hosp, Uttoxeter Rd, Derby DE22 3NE, England.","zklezl@aospine.org",null,null,null,null,"Abe E, 2000, SPINAL CORD, V38, P146, DOI 10.1038/sj.sc.3100968; Bailey CS, 2006, J NEUROSURG-SPINE, V4, P409, DOI 10.3171/spi.2006.4.5.409; Boriani S, 2006, SPINE, V31, P493, DOI 10.1097/01.brs.0000200038.30869.27; Cohen ZR, 2002, J NEUROSURG, V97, P386, DOI 10.3171/spi.2002.97.3.0386; Colak A, 2004, NEUROSURG REV, V27, P189, DOI 10.1007/s10143-003-0319-0; DEMONTE F, 2001, NEUROSURG FOCUS, V10, P1; Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014; Hart R A, 1996, Iowa Orthop J, V16, P157; Laus M, 1996, SPINE, V21, P1687, DOI 10.1097/00007632-199607150-00015; Rhines LD, 2005, J NEUROSURG-SPINE, V2, P199, DOI 10.3171/spi.2005.2.2.0199; Sar C, 2001, SPINE, V26, P1936, DOI 10.1097/00007632-200109010-00025; Stulik J, 2007, EUR SPINE J, V16, P479, DOI 10.1007/s00586-006-0241-6; Stulik J, 2007, ACTA CHIR ORTHOP TR, V74, P79; Suchomel P, 2007, J NEUROSURG-SPINE, V6, P611; Tomita K, 1997, SPINE, V22, P324, DOI 10.1097/00007632-199702010-00018",15,4,4,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1536-0652",null,null,"J SPINAL DISORD TECH","J. Spinal Disord. Tech.","DEC",2010,23,8,null,null,null,null,"E53","E58",null,"10.1097/BSD.0b013e3181d0c1e5",null,6,"Clinical Neurology; Orthopedics","Neurosciences & Neurology; Orthopedics","689QG","WOS:000284942700003"]
[null,null,null,null,"J","Chabova, VC; Walkowska, A; Kompanowska-Jezierska, E; Sadowski, J; Kujal, P; Vernerova, Z; Vanourkova, Z; Kopkan, L; Kramer, HJ; Falck, JR; Imig, JD; Hammock, BD; Vaneckova, I; Cervenka, L",null,null,null,"Chabova, Vera Certikova; Walkowska, Agnieszka; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz; Kujal, Petr; Vernerova, Zdenka; Vanourkova, Zdena; Kopkan, Libor; Kramer, Herbert J.; Falck, John R.; Imig, John D.; Hammock, Bruce D.; Vaneckova, Ivana; Cervenka, Ludek",null,null,"Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats","CLINICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"cytochrome P450 (CYP450); end-organ damage; hypertension; renin-angiotensin system (RAS); soluble epoxide hydrolase","SOLUBLE EPOXIDE HYDROLASE; SMOOTH-MUSCLE-CELLS; SALT-SENSITIVE HYPERTENSION; ACTIVATED PROTEIN-KINASE; II-INDUCED HYPERTENSION; ANGIOTENSIN-II; ARACHIDONIC-ACID; NITRIC-OXIDE; EPOXYGENASE METABOLITES; RECEPTOR BLOCKADE","Recent studies have shown that the renal CYP450 (cytochrome P450) metabolites of AA (arachidonic acid), the vasoconstrictor 20-HETE (20-hydroxyeicosatetraenoic acid) and the vasodilator EETs (epoxyeicosatrienoic acids), play an important role in the pathophysiology of AngII (angiotensin II)-dependent forms of hypertension and the associated target organ damage The present studies were performed in Ren-2 renin transgenic rats (TGR) to evaluate the effects of chronic selective inhibition of 20-HETE formation or elevation of the level of EETs, alone or in combination, on the course of hypertension and hypertension-associated end-organ damage Both young (30 days of age) prehypertensive TGR and adult (190 days of age) TGR with established hypertension were examined Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. The rats were treated with N-methylsulfonyl-12,12-dibromododec-11-enamide to inhibit 20-HETE formation and/or with N-cyclohexyl-N-dodecyl urea to inhibit soluble epoxide hydrolase and prevent degradation of EETs Inhibition in TGR of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury. This was also associated with attenuation of the responsiveness of the systemic and renal vascular beds to AngII without modifying their responses to noradrenaline (norepinephrine) Our findings suggest that altered production and/or action of 20-HETE and EETs plays a permissive role in the development of hypertension and hypertension-associated end-organ damage in this model of AngII-dependent hypertension. This information provides a basis for a search for new therapeutic approaches for the treatment of hypertension.","[Chabova, Vera Certikova; Kujal, Petr; Vernerova, Zdenka; Vanourkova, Zdena; Kopkan, Libor; Vaneckova, Ivana; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14021 Prague 4, Czech Republic; [Chabova, Vera Certikova] Charles Univ Prague, Dept Nephrol, Fac Med 1, Prague, Czech Republic; [Walkowska, Agnieszka; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz] Polish Acad Sci, Mossakowski Med Res Ctr, Lab Renal & Body Fluid Physiol, Warsaw, Poland; [Kujal, Petr; Vernerova, Zdenka] Charles Univ Prague, Dept Pathol, Fac Med 3, Prague, Czech Republic; [Vanourkova, Zdena; Kopkan, Libor; Vaneckova, Ivana] Cardiovasc Res Ctr, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Med Policlin, Nephrol Sect, Dept Med, D-5300 Bonn, Germany; [Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Ctr Canc, Davis, CA 95616 USA; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Cervenka, L (reprint author), Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14021 Prague 4, Czech Republic.",null,"Vaneckova, Ivana/B-5543-2012",null,"Czech Science Foundation (GACR) [305/08/J006, 305/07/0167, 305/07/J004]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Ministry of Health of the Czech Republic [NS/10500-3, NS/10499-3, NS/9699-4]; Academy of Science of Czech Republic [GAAV-IAA 511-700-701]; German Research Foundation (DEG), Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]; National Institutes of Health (NIH) [IIL59699, DK38226, GM31278]; Robert A Welch Foundation; National Institute of Enviromental Health Sciences (NIEHS) [R01 ES002710, P42 ES004699]","L.C was supported by the Czech Science Foundation (GACR) [grant number 305/08/J006]. A W was partly supported by the Center for Cardiovascular Research [grant number 1M6798582302] and the Institute for Clinical and Experimental Medicine [grant number MZO 00023001]. V C.C. was supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic [grant number NS/10500-3]. Z.V was supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic [grant number NS/10499-3] L.K. was supported by the Grant Agency of Academy of Science of Czech Republic [grant number GAAV-IAA 511-700-701] and the Internal Grant Agency of the Ministry of Health of the Czech Republic [grant number NS/9699-4] I V. was supported by the GACR [grants numbers 305/07/0167, 305/07/J004] H.J.K was supported by the German Research Foundation (DEG), Bonn [grant numbers Kra 436/14-2, 436 TSE 113/57/0-1]. J D.I. was supported the National Institutes of Health (NIH) [grant numbers IIL59699, DK38226] and Advancing a Healthier Wisconsin J.R.F was supported by the Robert A Welch Foundation and the NIH [grant number GM31278] B.D.H was supported by the National Institute of Enviromental Health Sciences (NIEHS) [grant number R01 ES002710] and the NIEHS Superfund Program [grant number P42 ES004699].",null,60,17,17,"PORTLAND PRESS LTD","LONDON","THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND","0143-5221",null,null,"CLIN SCI","Clin. Sci.","MAY",2010,118,41921,null,null,null,null,617,632,null,"10.1042/CS20090459",null,16,"Medicine, Research & Experimental","Research & Experimental Medicine","599HA","WOS:000277900600007"]
[null,null,null,null,"J","Krsek, P; Jahodova, A; Maton, B; Jayakar, P; Dean, P; Korman, B; Rey, G; Dunoyer, C; Vinters, HV; Resnick, T; Duchowny, M",null,null,null,"Krsek, Pavel; Jahodova, Alena; Maton, Bruno; Jayakar, Prasanna; Dean, Patricia; Korman, Brandon; Rey, Gustavo; Dunoyer, Catalina; Vinters, Harry V.; Resnick, Trevor; Duchowny, Michael",null,null,"Low-grade focal cortical dysplasia is associated with prenatal and perinatal brain injury","EPILEPSIA",null,null,"English","Article",null,null,null,null,null,"Cortical dysplasia; Epilepsy surgery; MRI; EEG; Neuropsychological assessment","NEURONAL MIGRATION DISORDERS; DEVELOPMENTAL NEUROPATHOLOGY; PEDIATRIC EPILEPSY; CEREBRAL-PALSY; MATTER LESIONS; WHITE-MATTER; MALFORMATIONS; CHILDREN; DAMAGE; CLASSIFICATION","P>Purpose: Prenatal and perinatal adverse events are reported to have a pathogenetic role in focal cortical dysplasia (FCD). However, no data are available regarding the prevalence and significance of this association. A cohort of children with significant prenatal and perinatal brain injury and histologically proven mild malformations of cortical development (mMCD) or FCD was analyzed. Methods: We retrospectively evaluated a surgical series of 200 patients with histologically confirmed mMCD/FCD. Combined historical and radiologic inclusion criteria were used to identify patients with prenatal and perinatal risk factors. Electroclinical, imaging, neuropsychological, surgical, histopathologic, and seizure outcome data were reviewed. Results: Prenatal and perinatal insults including severe prematurity, asphyxia, bleeding, hydrocephalus, and stroke occurred in 12.5% of children with mMCD/FCD (n = 25). Their epilepsy was characterized by early seizure onset, high seizure frequency, and absence of seizure control. Patients with significant prenatal and perinatal risk factors had more abnormal neurologic findings, lower intelligence quotient (IQ) scores, and slower background EEG activity than mMCD/FCD subjects without prenatal or perinatal brain injury. MRI evidence of cortical malformations was identified in 74% of patients. Most patients underwent large multilobar resections or hemispherectomies; 54% were seizure-free 2 years after surgery. Histologically \"milder\" forms of cortical malformations (mMCD and FCD type I) were observed most commonly in our series. Conclusions: Surgically remediable low-grade cortical malformations may occur in children with significant prenatally and perinatally acquired encephalopathies and play an important role in the pathogenesis of their epilepsy. Presurgical detection of dysplastic cortex has important practical consequences for surgical planning.","[Duchowny, Michael] Univ Miami, Miller Sch Med, Miami Childrens Hosp, Dept Neurol,Brain Inst, Miami, FL 33136 USA; [Krsek, Pavel; Jahodova, Alena] Charles Univ Prague, Motol Univ Hosp, Sch Med 2, Dept Pediat Neurol, Prague, Czech Republic; [Maton, Bruno; Jayakar, Prasanna; Dean, Patricia; Dunoyer, Catalina; Resnick, Trevor; Duchowny, Michael] Miami Childrens Hosp, Inst Brain, Comprehens Epilepsy Program, Miami, FL USA; [Korman, Brandon; Rey, Gustavo] Miami Childrens Hosp, Inst Brain, Neuropsychol Sect, Miami, FL USA; [Resnick, Trevor; Duchowny, Michael] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA","Duchowny, M (reprint author), Univ Miami, Miller Sch Med, Miami Childrens Hosp, Dept Neurol,Brain Inst, 3200 SW 60th Court, Miami, FL 33136 USA.","michael.duchowny@mch.com","shengkun, yu/B-8440-2012",null,"Kontakt Program [ME09042]; Daljit S. & Elaine Sarkaria Chair in Diagnostic Medicine;  [MZOFNM2005]","Supported by grants MZOFNM2005 and Kontakt Program ME09042. HV Vinters supported by the Daljit S. & Elaine Sarkaria Chair in Diagnostic Medicine. Statistical analysis was conducted by Zbynek Hrncir, MSc.",null,46,7,12,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0013-9580",null,null,"EPILEPSIA","Epilepsia","DEC",2010,51,12,null,null,null,null,2440,2448,null,"10.1111/j.1528-1167.2010.02730.x",null,9,"Clinical Neurology","Neurosciences & Neurology","688KU","WOS:000284849000011"]
[null,null,null,null,"J","Naccarati, A; Pardini, B; Polakova, V; Smerhovsky, Z; Vodickova, L; Soucek, P; Vrana, D; Holcatova, I; Ryska, M; Vodicka, P",null,null,null,"Naccarati, A.; Pardini, B.; Polakova, V.; Smerhovsky, Z.; Vodickova, L.; Soucek, P.; Vrana, D.; Holcatova, I.; Ryska, M.; Vodicka, P.",null,null,"Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic","CARCINOGENESIS",null,null,"English","Article",null,null,null,null,null,null,"P53 CODON-72 POLYMORPHISM; COLORECTAL-CANCER; BLADDER-CANCER; LUNG-CANCER; POPULATION; CARCINOMA; ADENOCARCINOMA; RECONSTRUCTION; SUSCEPTIBILITY; PROGRESSION","Pancreatic carcinoma is the fourth leading cause of cancer-related deaths in the Czech Republic, with only a minimum of patients surviving 5 years. The aetiology and molecular pathogenesis are still weakly understood. TP53 has a fundamental role in cell cycle and apoptosis and is frequently mutated in solid tumours, including pancreatic cancer. Based on the assumption that genetic variation may affect susceptibility to cancer development, the role of TP53 polymorphisms in modulating the risk of pancreatic cancer may be of major importance. We investigated four selected polymorphisms in TP53 (rs17878362:A(1)> A(2), rs1042522:G > C, rs12947788:C > T and rs17884306:G > A) in association with pancreatic cancer risk in a case-control study, including 240 cases and controls (for a total of 1827 individuals) from the Czech Republic. Carriers of the variant C allele of rs1042522 polymorphism were at an increased risk of pancreatic cancer [odds ratio (OR) 1.73; 95% confidence interval (CI) 1.26-2.39; P = 0.001]. Haplotype analysis showed that in comparison with the most common haplotype (A(1)GCG), the A(2)CCG haplotype was associated with an increased risk (OR 1.39; 95% CI 1.02-1.88; P = 0.034) and the A(1)CCG with a reduced risk (OR 0.30; 95% CI 0.12-0.76; P = 0.011) for this cancer. These results reflect previous findings of a recent association study, where haplotypes constructed on the same TP53 variants were associated with colorectal cancer risk [Polakova et al. (2009) Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum. Mutat., 30, 661-668.]. Genetic variation in TP53 may contribute, alone or in concert with other risk factors, to modify the inherited susceptibility to pancreatic cancer, as well as to other gastrointestinal cancers.","[Naccarati, A.; Pardini, B.; Polakova, V.; Vodickova, L.; Vodicka, P.] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague 14200, Czech Republic; [Smerhovsky, Z.; Vodickova, L.; Soucek, P.; Vrana, D.] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042, Czech Republic; [Ryska, M.] Charles Univ Prague, Fac Med 2, Dept Surg, Prague 15006, Czech Republic; [Vrana, D.] Charles Univ Prague, Dept Oncol, Gen Teaching Hosp, Prague 12808 2, Czech Republic; [Vrana, D.] Charles Univ Prague, Fac Med 1, Prague 12808 2, Czech Republic; [Holcatova, I.] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague 12800, Czech Republic; [Ryska, M.] Cent Mil Hosp, Prague 15006, Czech Republic","Vodicka, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Videnska 1083, Prague 14200, Czech Republic.","pvodicka@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [GACR 305/09/P194]; Internal Grant Agency of the Czech Ministry of Health [IGA 8563-5/2005, IGA 9422-3/2007]","Grant Agency of the Czech Republic (GACR 305/09/P194); Internal Grant Agency of the Czech Ministry of Health (IGA 8563-5/2005, IGA 9422-3/2007).",null,42,5,5,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0143-3334",null,null,"CARCINOGENESIS","Carcinogenesis","APR",2010,31,4,null,null,null,null,666,670,null,"10.1093/carcin/bgq032",null,5,"Oncology","Oncology","578HV","WOS:000276285200018"]
[null,null,null,null,"J","Kastner, J; Taudy, M; Lisy, J; Grabec, P; Betka, J",null,null,null,"Kastner, Jan; Taudy, Milos; Lisy, Jiri; Grabec, Paul; Betka, Jan",null,null,"Orbital and intracranial complications after acute rhinosinusitis","RHINOLOGY",null,null,"English","Article",null,null,null,null,null,"acute rhinosinusitis; intracranial complication; orbitocellulitis; endoscopic drainage; odontogenous","CELLULITIS; SINUSITIS; MANAGEMENT; CHILDREN","Background/objectives: Nowadays, intracranial abscess is a rare complication of acute rhinosinusitis. The consequent orbital and intracranial complications of acute rhinosinusitis are rare but must be mutually excluded in complicated rhinosinusitis even when proper surgical and medical treatment tend to efficiently heal the orbital complication. Methods: We report a case of a patient who primarily revealed symptoms of orbitocellulitis as a complication of odontogenous rhinosinusitis. Proper diagnostic and therapeutical measures were undertaken to manage the disease immediately after stationary admission. We strongly rely on a literature review and recommendations on diagnosis and treatment of this possibly lethal complication in the discussion. Results: Two weeks after an inconspicuous healing period, hemiparesis due to formation of an intracranial abscess developed. An emergency situation revealed the unusual character of the clinical situation. In a literature review concerning intracranial complication after acute rhinosinusitis, we demonstrate the complexity of this complication. We indicate the predisposing factors, diagnostic measures and treatment strategy. Conclusion: The possible role of underlying mechanisms of intracranial abscess formation is discussed. The correct indication of imaging methods and accurate evaluation of diminutive symptoms are essential. We recommend performing a complementary CT of the brain or MRI, even when a previous CT scan of the orbit/paranasal sinuses reveals no cerebral pathology, to avoid or minimize the number of Attire patients with consecutive orbital and intracranial complications of acute rhinosinusitis.","[Kastner, Jan; Taudy, Milos; Betka, Jan] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Prague 15006, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Imaging Methods, Prague 15006, Czech Republic; [Grabec, Paul] Charles Univ Prague, Gen Hosp, Fac Med 1, Dept Otorhinolaryngol, Prague 15006, Czech Republic","Kastner, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, V Uvalu 84, Prague 15006, Czech Republic.","jkastner@email.cz",null,null,"GAUK [203435 36/06]; IGA (Czech Republic) [IGA 9908-3]","Supported by grant GAUK 203435 36/06 and IGA 9908-3 (Czech Republic).",null,21,2,2,"INT RHINOLOGIC SOC","UTRECHT","UNIV MEDICAL CENTER UTRECHT, RM G05 127, DEPT OTORHINOL, HEIDELBERGLAAN 100, 3584 CX UTRECHT, NETHERLANDS","0300-0729",null,null,"RHINOLOGY","Rhinology","DEC",2010,48,4,null,null,null,null,457,461,null,"10.4193/Rhin09.030",null,5,"Otorhinolaryngology","Otorhinolaryngology","780XO","WOS:000291894700016"]
[null,null,null,null,"J","Hubacek, JA; Stanek, V; Gebauerova, M; Pilipcincova, A; Dlouha, D; Poledne, R; Aschermann, M; Skalicka, H; Matouskova, J; Kruger, A; Penicka, M; Hrabakova, H; Veselka, J; Hajek, P; Lanska, V; Adamkova, V; Pit'ha, J",null,null,null,"Hubacek, Jaroslav A.; Stanek, Vladimir; Gebauerova, Marie; Pilipcincova, Alexandra; Dlouha, Dana; Poledne, Rudolf; Aschermann, Michal; Skalicka, Hana; Matouskova, Jana; Kruger, Andreas; Penicka, Martin; Hrabakova, Hana; Veselka, Josef; Hajek, Petr; Lanska, Vera; Adamkova, Vera; Pit'ha, Jan",null,null,"A FTO variant and risk of acute coronary syndrome","CLINICA CHIMICA ACTA",null,null,"English","Article",null,null,null,null,null,"Acute coronary syndrome; FTO; Polymorphism; Body mass index","BODY-MASS INDEX; GENE VARIANT; ENERGY-EXPENDITURE; PHYSICAL-ACTIVITY; COMMON VARIANT; FOOD-INTAKE; FAT MASS; OBESITY; ASSOCIATION; POPULATION","Background: The Fro gene plays an important role in the determination of body weight and BMI and it has been suspected of being associated with all-case mortality. Methods: We have analyzed the FTO rs17817449 variant in consecutive 1092 male patients with acute coronary syndrome (ACS) and in 1191 randomly selected Caucasian individuals (population controls). Results: The FTO variant was significantly associated with BMI both in controls (P<0.02) and ACS patients (P<0.01). In both groups, BMI was highest in GC homozygotes and lowest in IT homozygotes. There was a significant difference between the ACS patients and controls in the frequency of the FTO genotype GC (21.4% vs. 15.9%, P<0.005). FTO GG homozygotes had a significantly increased risk of ACS, compared with TT homozygotes which was independent of age and BMI (odds ratio 1.49, 95% confidence interval 1.16-1.93). The odds ratio of ACS patients for the GC genotype remained significant even after the exclusion of diabetics (100 controls and 339 ACS patients), with OR 1.32 (95% Cl 1.01-1.72). Conclusions: This study provides an evidence of an association between the FTO variant and risk of ACS in Caucasian males. (C) 2010 Elsevier B.V. All rights reserved.","[Hubacek, Jaroslav A.; Stanek, Vladimir; Gebauerova, Marie; Pilipcincova, Alexandra; Dlouha, Dana; Poledne, Rudolf; Lanska, Vera; Adamkova, Vera; Pit'ha, Jan] Inst Clin & Expt Med, Prague, Czech Republic; [Hubacek, Jaroslav A.; Dlouha, Dana; Poledne, Rudolf; Pit'ha, Jan] Cardiovasc Res Ctr, Prague, Czech Republic; [Hubacek, Jaroslav A.; Aschermann, Michal; Skalicka, Hana; Adamkova, Vera] Univ S Bohemia, Fac Publ Hlth & Social Studies, Ceske Budejovice, Czech Republic; [Matouskova, Jana] Gen Teaching Hosp, Dept Internal Med 2, Prague, Czech Republic; [Kruger, Andreas] Homolka Hosp, Dept Cardiol, Prague, Czech Republic; [Penicka, Martin; Hrabakova, Hana; Veselka, Josef] Univ Hosp Kralovske Vinohrady, Dept Cardiol, Cardioctr, Prague, Czech Republic; [Hajek, Petr] Teaching Hosp Motol, Dept Cardiol, Prague, Czech Republic","Hubacek, JA (reprint author), IKEM DEM LMG, Videnska 1958-9, Prague 14021 4, Czech Republic.","jahb@ikem.cz",null,null,"IGA, MH, Czech Republic [NR-9093-4/2006]","This project was supported by grant no. NR-9093-4/2006 (IGA, MH, Czech Republic).",null,34,17,17,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0009-8981",null,null,"CLIN CHIM ACTA","Clin. Chim. Acta","AUG 5",2010,411,"15-16",null,null,null,null,1069,1072,null,"10.1016/j.cca.2010.03.037",null,4,"Medical Laboratory Technology","Medical Laboratory Technology","617RP","WOS:000279299100011"]
[null,null,null,null,"J","Creutzig, U; Zimmermann, M; Dworzak, M; Urban, C; Henze, G; Kremens, B; Lakomek, M; Bourquin, JP; Stary, J; Reinhardt, D",null,null,null,"Creutzig, Ursula; Zimmermann, Martin; Dworzak, Michael; Urban, Christian; Henze, Guenter; Kremens, Bernhard; Lakomek, Max; Bourquin, Jean-Pierre; Stary, Jan; Reinhardt, Dirk",null,"AML-BFM Study Grp","Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses","BRITISH JOURNAL OF HAEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"acute promyelocytic leukaemia; children; therapy; anthracyclines; cardiotoxicity","ACUTE MYELOID-LEUKEMIA; TRANS-RETINOIC ACID; ARSENIC TRIOXIDE; TRANSRETINOIC ACID; INDUCTION THERAPY; RANDOMIZED-TRIAL; AIDA PROTOCOL; PETHEMA GROUP; EARLY DEATHS; CHILDREN","P>Acute promyelocytic leukaemia (APL) treatment often includes high cumulative doses of anthracyclines, which can cause long-term cardiotoxicity. Here, we report the favourable outcome in 81 paediatric APL patients treated according to the consecutive acute myeloid leukaemia-Berlin/Frankfurt/Muenster (AML-BFM) trials -93/-98/-2004 with an anthracycline-cytarabine regimen in combination with all-trans-retinoid acid (ATRA). Outcomes achieved by treatment with a reduced cumulative anthracycline dose (350 mg/m2) were comparable to those reported for studies with higher doses. Five-year overall survival of the total cohort was 89 +/- 4% and event-free survival (pEFS) was 73 +/- 6%. Overall survival was similar when comparing AML-BFM trial periods (trial 93: 88 +/- 8%, 98: 85 +/- 7% and 2004: 94 +/- 8%, P((logrank)) = 0 center dot 63). Seventy-five (93%) patients achieved complete remission. Most fatal events occurred during the first 6 weeks of treatment. Long-term cardiotoxicity was observed in one patient. Two patients suffered from secondary haematological malignancies. Salvage treatment was effective in 7/9 patients (78%) with relapsed APL, who now are long-term survivors after second line combination treatment with arsenic trioxide (4/7 patients) and stem cell transplantation (5/7 patients). Our results demonstrate that - combined with ATRA - a lower cumulative anthracycline dose can be used safely to maintain high cure rates and promote the reduction of long-term sequelae, such as cardiotoxicity in APL patients.","[Creutzig, Ursula] Univ Childrens Hosp, Dept Paediat Haematol Oncol, Munster, Germany; [Zimmermann, Martin; Reinhardt, Dirk] Hannover Med Sch, Dept Paediat Haematol Oncol, D-3000 Hannover, Germany; [Dworzak, Michael] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Urban, Christian] Med Univ Graz, Dept Paediat & Adolescent Med, Div Paediat Haematol & Oncol, Graz, Austria; [Henze, Guenter] Charite, Univ Berlin, Dept Paediat Oncol Haematol, D-13353 Berlin, Germany; [Kremens, Bernhard] Univ Essen Gesamthsch, Dept Paediat Haematol Oncol & Endocrinol, Essen, Germany; [Lakomek, Max] Univ Childrens Hosp, Dept Paediat Haematol Oncol, Gottingen, Germany; [Bourquin, Jean-Pierre] Univ Childrens Hosp, Dept Paediat Oncol, Zurich, Switzerland; [Stary, Jan] Charles Univ Prague, Dept Paediat Haematol Oncol, Prague, Czech Republic; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic","Creutzig, U (reprint author), Klin & Poliklin Kinderheilkunde, Albert Schweitzer Str 33, D-48129 Munster, Germany.","ursula@creutzig.de","urban, christian/F-9151-2010; Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Deutsche Krebshilfe e.V; Czech Ministry of Education [MSM0021620813]","Supported by the Deutsche Krebshilfe e.V. and partly by grant from the Czech Ministry of Education (MSM0021620813). The current principal investigators of the Cooperative AML-BFM Trials are listed in Appendix 1.",null,46,14,15,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0007-1048",null,null,"BRIT J HAEMATOL","Br. J. Haematol.","MAY",2010,149,3,null,null,null,null,399,409,null,"10.1111/j.1365-2141.2010.08107.x",null,11,"Hematology","Hematology","582MO","WOS:000276601900009"]
[null,null,null,null,"J","Kopkan, L; Hess, A; Huskova, Z; Cervenka, L; Navar, LG; Majid, DSA",null,null,null,"Kopkan, Libor; Hess, Arthur; Huskova, Zuzana; Cervenka, Ludek; Navar, L. Gabriel; Majid, Dewan S. A.",null,null,"High-salt intake enhances superoxide activity in eNOS knockout mice leading to the development of salt sensitivity","AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"superoxide anion; nitric oxide; kidney function; hypertension","NITRIC-OXIDE SYNTHASE; THICK ASCENDING LIMB; ARTERIAL-PRESSURE RESPONSE; ACTIVATED PROTEIN-KINASE; BLOOD-PRESSURE; OXIDATIVE STRESS; HYPERTENSIVE-RATS; NACL ABSORPTION; NADPH OXIDASE; RENAL INJURY","Kopkan L, Hess A, Huskova Z, Cervenka L, Navar LG, Majid DS. High-salt intake enhances superoxide activity in eNOS knockout mice leading to the development of salt sensitivity. Am J Physiol Renal Physiol 299: F656-F663, 2010. First published July 7, 2010; doi:10.1152/ajprenal.00047.2010.-A deficiency in nitric oxide (NO) generation leads to salt-sensitive hypertension, but the role of increased superoxide (O(2)(-)) in such salt sensitivity has not been delineated. We examined the hypothesis that an enhancement in O(2)(-) activity induced by high-salt (HS) intake under deficient NO production contributes to the development of salt-sensitive hypertension. Endothelial NO synthase knockout (eNOS KO; total n = 64) and wild-type (WT; total n = 58) mice were given diets containing either normal (NS; 0.4%) or high-salt (HS; 4%) for 2 wk. During this period, mice were chronically treated with a O(2)(-) scavenger, tempol (400 mg/l), or an inhibitor of NADPH oxidase, apocynin (1 g/l), in drinking water or left untreated (n = 6-8 per group). Blood pressure was measured by radiotelemetry and 24-h urine samples were collected in metabolic cages. Basal mean arterial pressure (MAP) in eNOS KO was higher (125 +/- 4 vs. 106 +/- 3 mmHg) compared with WT. Feeding HS diet did not alter MAP in WT but increased it in eNOS KO to 166 +/- 9 mmHg. Both tempol and apocynin treatment significantly attenuated the MAP response to HS in eNOS KO (134 +/- 3 and 139 +/- 4 mmHg, respectively). Basal urinary 8-isoprostane excretion rates (U(Iso)V), a marker for endogenous O(2)(-) activity, were similar (2.8 +/- 0.2 and 2.4 +/- 0.3 ng/day) in both eNOS KO and WT mice. However, HS increased UIsoV more in eNOS KO than in WT (4.6 +/- 0.3 vs. 3.8 +/- 0.2 ng/day); these were significantly attenuated by both tempol and apocynin treatment. These data indicate that an enhancement in O(2)(-) activity contributes substantially to the development of salt-sensitive hypertension under NO-deficient conditions.","[Kopkan, Libor; Hess, Arthur; Navar, L. Gabriel; Majid, Dewan S. A.] Tulane Univ, Hlth Sci Ctr, Dept Physiol, New Orleans, LA 70112 USA; [Kopkan, Libor; Hess, Arthur; Navar, L. Gabriel; Majid, Dewan S. A.] Tulane Univ, Hlth Sci Ctr, Renal Ctr Excellence, New Orleans, LA 70112 USA; [Kopkan, Libor; Huskova, Zuzana; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, Prague, Czech Republic; [Kopkan, Libor; Huskova, Zuzana; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Majid, DSA (reprint author), Tulane Univ, Hlth Sci Ctr, Dept Physiol, 1430 Tulane Ave, New Orleans, LA 70112 USA.","majid@tulane.edu",null,null,"National Heart, Lung, and Blood Institute [HL-66432, HL-18426]; Louisiana Board of Regents and Tulane Enhancement; Grant Agency of the Academy of Sciences of the Czech Republic [KJB-502030801]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/9699-4]; Czech Science Foundation [305/08/P053]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Center for Cardiovascular Research [1M6798582302]; European Union [CZ.2.16/3.1.00/22126]; American Heart Association","This study was supported by the National Heart, Lung, and Blood Institute Grants HL-66432 and HL-18426 and Louisiana Board of Regents and Tulane Enhancement fund. L. Kopkan is also supported by Grant KJB-502030801 from Grant Agency of the Academy of Sciences of the Czech Republic and Grant NS/9699-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. Z. Huskova is supported by Grant No. 305/08/P053 awarded by Czech Science Foundation. L. Cervenka is currently supported by institutional finance support from the Institute for Clinical and Experimental Medicine (no. MZO 00023001) and Center for Cardiovascular Research (no. 1M6798582302). Some financial support from European Union (Operational Program Prague Competitiveness project-CEVKOON; no. CZ.2.16/3.1.00/22126) was also used in this study. A. Hess was a medical student supported by American Heart Association summer student research fellowship program.",null,51,14,14,"AMER PHYSIOLOGICAL SOC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","1931-857X",null,null,"AM J PHYSIOL-RENAL","Am. J. Physiol.-Renal Physiol.","SEP",2010,299,3,null,null,null,null,"F656","F663",null,"10.1152/ajprenal.00047.2010",null,8,"Physiology; Urology & Nephrology","Physiology; Urology & Nephrology","646KC","WOS:000281537700019"]
[null,null,null,null,"J","Quemener, S; Chen, JM; Chuzhanova, N; Benech, C; Casals, T; Macek, M; Bienvenu, T; McDevitt, T; Farrell, PM; Loumi, O; Messaoud, T; Cuppens, H; Cutting, GR; Stenson, PD; Giteau, K; Audrezet, MP; Cooper, DN; Ferec, C",null,null,null,"Quemener, Sylvia; Chen, Jian-Min; Chuzhanova, Nadia; Benech, Caroline; Casals, Teresa; Macek, Milan, Jr.; Bienvenu, Thierry; McDevitt, Trudi; Farrell, Philip M.; Loumi, Ourida; Messaoud, Taieb; Cuppens, Harry; Cutting, Garry R.; Stenson, Peter D.; Giteau, Karine; Audrezet, Marie-Pierre; Cooper, David N.; Ferec, Claude",null,null,"Complete Ascertainment of Intragenic Copy Number Mutations (CNMs) in the CFTR Gene and its Implications for CNM Formation at Other Autosomal Loci","HUMAN MUTATION",null,null,"English","Article",null,null,null,null,null,"CFTR; copy number mutation; CNM; copy number variation; CNV; deletion; duplication; CGH","CYSTIC-FIBROSIS GENE; SERIAL REPLICATION SLIPPAGE; BREAK-INDUCED REPLICATION; B DNA CONFORMATIONS; GENOMIC REARRANGEMENTS; CHRONIC-PANCREATITIS; TRYPSINOGEN LOCUS; DELETIONS; IDENTIFICATION; DUPLICATIONS","Over the last 20 years since the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, more than 1,600 different putatively pathological CFTR mutations have been identified. Until now, however, copy number mutations (CNMs) involving the CFTR gene have not been methodically analyzed, resulting almost certainly in the under-ascertainment of CFTR gene duplications compared with deletions. Here, high-resolution array comparative genomic hybridization (averaging one interrogating probe every 95 bp) was used to analyze the entire length of the CFTR gene (189 kb) in 233 cystic fibrosis chromosomes lacking conventional mutations. We succeeded in identifying five duplication CNMs that would otherwise have been refractory to analysis. Based upon findings from this and other studies, we propose that deletion and duplication CNMs in the human autosomal genome are likely to be generated in the proportion of approximately 2-3:1. We further postulate that intragenic gene duplication CNMs in other disease loci may have been routinely underascertained. Finally, our analysis of +/-20 bp flanking each of the 40 CFTR breakpoints characterized at the DNA sequence level provide support for the emerging concept that non-B DNA conformations in combination with specific sequence motifs predispose to both recurring and nonrecurring genomic rearrangements. Hum Mutat 31:421-428, 2010. (C) 2010 Wiley-Liss, Inc.","[Quemener, Sylvia; Chen, Jian-Min; Benech, Caroline; Ferec, Claude] EFS Bretagne, F-29218 Brest, France; [Quemener, Sylvia; Chen, Jian-Min; Benech, Caroline; Ferec, Claude] INSERM, U613, Brest, France; [Quemener, Sylvia; Chen, Jian-Min; Ferec, Claude] Univ Bretagne Occidentale, Fac Med & Sci Sante, Brest, France; [Quemener, Sylvia; Giteau, Karine; Audrezet, Marie-Pierre; Ferec, Claude] Hop Morvan, CHU Brest, Lab Genet Mol & Histocompatibil, Brest, France; [Chuzhanova, Nadia] Univ Cent Lancashire, Sch Comp Engn & Phys Sci, Preston PR1 2HE, Lancs, England; [Casals, Teresa] Hosp Duran & Reynals, IDIBELL, Med & Mol Genet Ctr, Barcelona, Spain; [Macek, Milan, Jr.] Charles Univ Prague, Inst Biol, Prague, Czech Republic; [Bienvenu, Thierry] Hop Cochin, Lab Biochim & Genet Mol, F-75674 Paris, France; [McDevitt, Trudi] Univ Coll Dublin, Our Ladys Hosp Sick Children, Natl Ctr Med Genet, Dublin 2, Ireland; [Farrell, Philip M.] Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI USA; [Loumi, Ourida] Univ Sci & Technol, Bab Ezzouar Inst Biol, Fac Biol Sci, Algiers, Algeria; [Messaoud, Taieb] Clin Hop Enfants, Biochim Lab, Tunis, Tunisia; [Cuppens, Harry] Catholic Univ Louvain, Ctr Human Genet, B-3000 Louvain, Belgium; [Cutting, Garry R.] Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD USA; [Stenson, Peter D.; Cooper, David N.] Cardiff Univ, Sch Med, Inst Med Genet, Cardiff, S Glam, Wales","Chen, JM (reprint author), EFS Bretagne, 46 Rue Felix Dantec, F-29218 Brest, France.","jian-min-chen@univ-brest.fr; claude.ferec@univ-brest.fr","Cooper, David/H-4384-2011; Casals, Teresa/K-4587-2012","Cooper, David/0000-0002-8943-8484; Casals, Teresa/0000-0001-6078-2823","INSERM (Institut National de la Sante et de la Recherche Medicale); VLIM (Vaincre La Mucoviscidose); Association de Transfusion Sanguine et de Biogenetique Gaetan Saleun, France;  [VZFNM00064203];  [Health-FS-2009-2231434]","This work was supported by the INSERM (Institut National de la Sante et de la Recherche Medicale), the VLIM (Vaincre La Mucoviscidose), and the Association de Transfusion Sanguine et de Biogenetique Gaetan Saleun, France; and VZFNM00064203 and Health-FS-2009-2231434 Techgene (to MM).",null,50,14,14,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1059-7794",null,null,"HUM MUTAT","Hum. Mutat.","APR",2010,31,4,null,null,null,null,421,428,null,"10.1002/humu.21196",null,8,"Genetics & Heredity","Genetics & Heredity","585FS","WOS:000276810600006"]
[null,null,null,null,"J","Maton, B; Krsek, P; Jayakar, P; Resnick, T; Koehn, M; Morrison, G; Ragheb, J; Castellano-Sanchez, A; Duchowny, M",null,null,null,"Maton, Bruno; Krsek, Pavel; Jayakar, Prasanna; Resnick, Trevor; Koehn, Monica; Morrison, Glenn; Ragheb, John; Castellano-Sanchez, Amilcar; Duchowny, Michael",null,null,"Medically intractable epilepsy in Sturge-Weber syndrome is associated with cortical malformation: Implications for surgical therapy","EPILEPSIA",null,null,"English","Article",null,null,null,null,null,"Sturge-Weber syndrome; Epilepsy; Young children; Polymicrogyria; Cortical dysplasia","PEDIATRIC EPILEPSY; FDG-PET; CHILDREN; DISEASE; ABNORMALITIES; DYSPLASIA; MIGRATION; PERFUSION; SURGERY; MRI","Purpose: Anecdotal reports have described cortical malformations in epileptic patients with Sturge-Weber syndrome (SWS). No data are available regarding the prevalence and significance of this association. Methods: We reviewed retrospectively the clinical profile, preoperative magnetic resonance imaging (MRI) studies, and pathology reports of all patients with SWS and medically intractable epilepsy evaluated in our epilepsy surgery program between 1979 and 2006. Results: Twelve patients (male/female = 7/5) were identified. Mean age at seizure onset was 11.1 +/- 16.7 months. Seizures occurred daily in seven patients and weekly in five patients. A facial port-wine stain was noted in 10 cases. Eleven patients evidenced developmental delay and eight were hemiparetic. Eight patients underwent excisional surgery for epilepsy (mean age 10.3 +/- 6.5 year), including hemispherectomy (n = 4) and focal cortical resection (n = 4). Tissue was available for neuropathology in six operated cases and revealed polymicrogyria. (n = 3) and cortical dysplasia (n = 4). Polymicrogyria. was associated with cortical dysplasia in one child. Brain MRIs were reviewed in 10 of 12 patients and were consistent with cortical malformations in all cases. Conclusions: We conclude that cortical malformations are frequent in patients with medically intractable epilepsy and Sturge-Weber-syndrome and may be the primary cause of epilepsy.","[Duchowny, Michael] Miami Childrens Hosp, Dept Neurol, Inst Brain, Miami, FL 33155 USA; [Krsek, Pavel] Charles Univ Prague, Sch Med 2, Motol Univ Hosp, Dept Pediat Neurol, Prague, Czech Republic; [Resnick, Trevor; Duchowny, Michael] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Koehn, Monica] Marshfield Clin Fdn Med Res & Educ, Dept Neurol, Marshfield, WI USA; [Morrison, Glenn; Ragheb, John] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Castellano-Sanchez, Amilcar] Miami Childrens Hosp, Dept Pathol, Miami, FL USA","Duchowny, M (reprint author), Miami Childrens Hosp, Dept Neurol, Inst Brain, 3200 SW 60th Court,Suite 302, Miami, FL 33155 USA.","michael.duchowny@mch.com",null,null," [VZ MZO 00064204]","This work was partially support by grant VZ MZO 00064204.We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.",null,51,11,12,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0013-9580",null,null,"EPILEPSIA","Epilepsia","FEB",2010,51,2,null,null,null,null,257,267,null,"10.1111/j.1528-1167.2009.02304.x",null,11,"Clinical Neurology","Neurosciences & Neurology","550RB","WOS:000274144900010"]
[null,null,null,null,"J","Rakusan, D; Kujal, P; Kramer, HJ; Huskova, Z; Vanourkova, Z; Vernerova, Z; Mrazova, I; Thumova, M; Cervenka, L; Vaneckova, I",null,null,null,"Rakusan, Dan; Kujal, Petr; Kramer, Herbert J.; Huskova, Zuzana; Vanourkova, Zdenka; Vernerova, Zdenka; Mrazova, Iveta; Thumova, Monika; Cervenka, Ludek; Vaneckova, Ivana",null,null,"Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats","AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"losartan; hypertension; direct renin inhibition; glomerular size; morphometry; washout period; blood pressure","FILTRATION BARRIER INJURY; DIRECT RENIN INHIBITION; BLOOD-PRESSURE; RECEPTOR BLOCKADE; (PRO)RENIN RECEPTOR; HYPERTENSIVE-RATS; PODOCYTE INJURY; AT(1)R BLOCKADE; ANGIOTENSIN-II; ORGAN DAMAGE","Rakusan D, Kujal P, Kramer HJ, Huskova Z,Vanourkova Z,Vernerova Z, Mrazova I, Thumova M, Cervenka L, Vaneckova I. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol 299: F758-F766, 2010. First published July 28, 2010; doi:10.1152/ajprenal.00259.2010.-The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments. BP was monitored by telemetry from the age of 32 days on (young rats) and at 100 days (adult rats). Aliskiren (10 mg.kg(-1).day(-1) in osmotic minipumps) or losartan (5 mg.kg(-1).day(-1) in drinking water) treatment was applied for 28 days in young rats and for 70 days in adult rats. In young untreated TGR, severe hypertension rapidly evolved. Adult untreated TGR exhibited stable established hypertension. Both aliskiren and losartan fully prevented the development of hypertension and cardiac hypertrophy in young TGR and normalized BP and cardiac hypertrophy in adult TGR. After cessation of aliskiren treatment in both young and adult TGR BP and cardiac hypertrophy were persistently reduced, while after losartan withdrawal BP and cardiac hypertrophy rapidly increased. In adult aliskiren-treated rats proteinuria was significantly reduced compared with losartan (the effect persisting after withdrawal of treatment), and this decrease strongly correlated with normalization of glomerular size in these animals. In conclusion, aliskiren and losartan had similar antihypertensive effects during chronic treatment, but the antihypertensive and organoprotective effects of aliskiren were persistent even after the 12-day washout period. The durable effect on proteinuria can possibly be attributed to the normalization of glomerular morphology.","[Rakusan, Dan] Charles Univ Prague, Dept Med, Fac Med 1, Nephrol Sect, Prague, Czech Republic; [Rakusan, Dan; Kujal, Petr; Huskova, Zuzana; Vanourkova, Zdenka; Vernerova, Zdenka; Mrazova, Iveta; Thumova, Monika; Cervenka, Ludek; Vaneckova, Ivana] Charles Univ Prague, Inst Clin & Expt Med, Ctr Med Expt, Prague, Czech Republic; [Kujal, Petr; Vernerova, Zdenka] Charles Univ Prague, Fac Med 3, Dept Pathol, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic; [Huskova, Zuzana; Vanourkova, Zdenka; Mrazova, Iveta; Thumova, Monika; Cervenka, Ludek; Vaneckova, Ivana] Charles Univ Prague, Cardiovasc Res Ctr, Prague, Czech Republic","Vaneckova, I (reprint author), Acad Sci Czech Republic, Inst Physiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.","ivanava@biomed.cas.cz","Vaneckova, Ivana/B-5543-2012",null,"Ministry of Health [NS/9703-4]; Institute for Clinical and Experimental Medicine [MZ 00023001]; Czech Science Foundation [305/07/J004, 308/08/J006]; Center for Cardiovascular Research [1M6798582302]; German Research Foundation [Deutsche Forschungsgemeinschaft (DFG) [433/14-2, 436 TSE 113/50, 113/56, 113/57/0-1]; German Academic Exchange Service [Deutscher Akademischer Austauschdienst (DAAD)]; DFG [433/14-2]","This study was in part supported by the Internal Grant Agency of the Ministry of Health (No. NS/9703-4). I. Vaneckova is also supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZ 00023001) and the Czech Science Foundation (Grant No. 305/07/J004). D. Rakusan is a Ph.D. student supported by the Center for Cardiovascular Research (1M6798582302). H. J. Kramer is supported by the German Research Foundation [Deutsche Forschungsgemeinschaft (DFG); Grant Nos. 433/14-2 and 436 TSE 113/50, 113/56, and 113/57/0-1] and the German Academic Exchange Service [Deutscher Akademischer Austauschdienst (DAAD)]. Portions of this work were performed during Z. Vanourkova's stay as a visiting scientist at the University of Bonn, which was supported by a grant from the DFG, Bonn (Grant No. 433/14-2). The Czech Science Foundation also supported L. Cervenka (Grant No. 308/08/J006).",null,38,10,10,"AMER PHYSIOLOGICAL SOC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","1931-857X",null,null,"AM J PHYSIOL-RENAL","Am. J. Physiol.-Renal Physiol.","OCT",2010,299,4,null,null,null,null,"F758","F766",null,"10.1152/ajprenal.00259.2010",null,9,"Physiology; Urology & Nephrology","Physiology; Urology & Nephrology","658IP","WOS:000282484000009"]
[null,null,null,null,"J","Balgobind, BV; Hollink, IHIM; Reinhardt, D; van Wering, ER; de Graaf, SSN; Baruchel, A; Stary, J; Beverloo, HB; de Greef, GE; Pieters, R; Zwaan, CM; van den Heuvel-Eibrink, MM",null,null,null,"Balgobind, Brian V.; Hollink, Iris H. I. M.; Reinhardt, Dirk; van Wering, Elisabeth R.; de Graaf, Siebold S. N.; Baruchel, Andre; Stary, Jan; Beverloo, H. Berna; de Greef, Georgine E.; Pieters, Rob; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.",null,null,"Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique","EUROPEAN JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"MLL-PTD; MLPA; Paediatric AML","DEPENDENT PROBE AMPLIFICATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; NORMAL CYTOGENETICS; PROGNOSTIC IMPACT; ADULT PATIENTS; TRISOMY 11; FLT3 GENE; AML; ACTIVATION; MUTATIONS","Mixed-lineage leukaemia (MLL)-partial tandem duplications (PTDs) are found in 3-5% of adult acute myeloid leukaemia (AML), and are associated with poor prognosis. In adult AML, MLL-PTD is only detected in patients with trisomy 11 or internal tandem duplications of FLT3 (FLT3-ITD). To date, studies in paediatric AML are scarce, and reported large differences in the frequency of MLL-PTD, frequently utilising mRNA RT-PCR only to detect MLL-PTDs. We studied the frequency of MLL-PTD in a large cohort of paediatric AML (n = 276) and the results from two different methods, i.e. mRNA RT-PCR, and multiplex ligation-dependent probe amplification (MLPA), a method designed to detect copy number differences of specific DNA sequences. In some patients with an MLL-rearrangement, MLL-PTD transcripts were detected, but were not confirmed by DNA-MLPA, indicating that DNA-MLPA can more accurately detect MLL-PTD compared to mRNA RT-PCR. In paediatric AML, MLL-PTD was detected in 7/276 patients (2.5%). One case had a trisomy 11, while the others had normal cytogenetics. Furthermore 4 of the 7 patients revealed a FLT3-ITD, which was significantly higher compared with the other AML cases (p = 0.016). In conclusion, using DNA-MLPA as a novel screenings technique in combination with mRNA RT-PCR a low frequency of MLL-PTD in paediatric AML was found. Larger prospective studies are needed to further define the prognostic relevance of MLL-PTD in paediatric AML. (C) 2010 Elsevier Ltd. All rights reserved.","[van den Heuvel-Eibrink, Marry M.] Sophia Childrens Univ Hosp, Dept Paediat Oncol Haematol, Erasmus MC, NL-3000 CB Rotterdam, Netherlands; [Reinhardt, Dirk] AML BFM Study Grp, Hannover, Germany; [van Wering, Elisabeth R.; de Graaf, Siebold S. N.] DCOG, The Hague, Netherlands; [Baruchel, Andre] St Louis Hosp, Paris, France; [Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic; [de Graaf, Siebold S. N.] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands","van den Heuvel-Eibrink, MM (reprint author), Sophia Childrens Univ Hosp, Dept Paediat Oncol Haematol, Erasmus MC, Room Sp 2456,Dr Molewaterpl 60,POB 2060, NL-3000 CB Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","NWO 'Netherlands Organisation for Scientific Research'; Kinder-Oncologisch Centrum Rotterdam (KOCR)","This project was funded by the NWO 'Netherlands Organisation for Scientific Research' (B.V.B.) and by the Kinder-Oncologisch Centrum Rotterdam (KOCR) (B.V.B. and I.H.I.M.H.).",null,43,9,9,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0959-8049",null,null,"EUR J CANCER","Eur. J. Cancer","JUL",2010,46,10,null,null,null,null,1892,1899,null,"10.1016/j.ejca.2010.02.019",null,8,"Oncology","Oncology","627JO","WOS:000280035500031"]
[null,null,null,null,"J","Vodicka, P; Polivkova, Z; Sytarova, S; Demova, H; Kucerova, M; Vodickova, L; Polakova, V; Naccarati, A; Smerhovsky, Z; Ambrus, M; Cerna, M; Hemminki, K",null,null,null,"Vodicka, Pavel; Polivkova, Zdenka; Sytarova, Sylvie; Demova, Hana; Kucerova, Marie; Vodickova, Ludmila; Polakova, Veronika; Naccarati, Alessio; Smerhovsky, Zdenek; Ambrus, Miloslav; Cerna, Marie; Hemminki, Kari",null,null,"Chromosomal damage in peripheral blood lymphocytes of newly diagnosed cancer patients and healthy controls","CARCINOGENESIS",null,null,"English","Article",null,null,null,null,null,null,"INTERMEDIATE END-POINTS; CYTOGENETIC BIOMARKERS; GENETIC POLYMORPHISMS; DNA-REPAIR; ABERRATIONS; RISK; FREQUENCY; MICRONUCLEI; INSTABILITY; ANEUPLOIDY","Background: The majority of human cancers arise from cells unable to maintain genomic stability. Recent prospective studies indicated that enhanced chromosomal aberrations (CAs) frequencies are predictive of gastrointestinal and lung cancers. However, studies on incident cancer patients are lacking; thus, we investigated chromosomal damage in newly diagnosed cancer patients and healthy individuals. Methods: We analyzed chromosomal damage in peripheral blood lymphocytes in a group of 300 incident cancer patients (with different malignancies) in comparison with 300 healthy controls. Results and Conclusions: The frequencies of aberrant cells (ACs) and CAs were significantly higher in patients (2.38 +/- 1.56 and 2.53 +/- 1.69, respectively) as compared with controls (1.81 +/- 1.31 and 1.94 +/- 1.47, respectively, P < 0.01). The percentual difference in chromatid-type aberrations (CTAs) between patients and controls was moderately significant (1.37 +/- 1.20 and 1.11 +/- 0.99, respectively, P < 0.05), whereas the difference in chromosome-type aberrations (CSAs) was stronger (1.16 +/- 1.24 versus 0.83 +/- 1.12, P < 0.01). Using binomial logistic regression, the estimated odds ratios and 95% confidence interval for ACs were 1.33 (1.18-1.49), P < 0.01; for CAs, 1.27 (1.14-1.41), P < 0.01; for CTA 1.24 (1.07-1.44), P < 0.01 and for CSA, 1.27 (1.10-1.47), P < 0.01. By stratifying patients for distinct neoplasia, markers of chromosomal damage were significantly enhanced in patients with breast, prostate and head/neck cancers, whereas no effect was recorded in patients affected by gastrointestinal cancers. The present study shows for the first time evidence of increased chromosomal damage in lymphocytes of incident cancer patients compared with healthy controls. The effects were observed in different cancer types but as the number of patients was relatively small, further studies are warranted.","[Vodicka, Pavel; Vodickova, Ludmila; Polakova, Veronika; Naccarati, Alessio] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague 14200 4, Czech Republic; [Vodicka, Pavel; Polivkova, Zdenka; Sytarova, Sylvie; Demova, Hana; Kucerova, Marie; Polakova, Veronika; Cerna, Marie] Charles Univ Prague, Fac Med 3, Dept Genet Biol & Genet, Prague, Czech Republic; [Vodickova, Ludmila; Smerhovsky, Zdenek] Natl Inst Publ Hlth, Toxicogen Unit, Prague 10042, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Dept Epidemiol, Prague 15000, Czech Republic; [Ambrus, Miloslav] Fac Hosp Kralovske Vinohrady, Dept Radiol & Oncol, Prague 10042, Czech Republic; [Hemminki, Kari] German Canc Res Ctr, Div Mol Genet Epidemiol, D-69120 Heidelberg, Germany; [Hemminki, Kari] Lund Univ, Ctr Primary Hlth Care Res, S-20502 Malmo, Sweden","Vodicka, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Videnska 1083, Prague 14200 4, Czech Republic.","pvodicka@biomed.cas.cz",null,null,"Ministry of Health of the Czech Republic [NR 8563-5/2005, NR 9423-3/2007]","Ministry of Health of the Czech Republic, projects IGA (NR 8563-5/2005, NR 9423-3/2007).",null,36,8,8,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0143-3334",null,null,"CARCINOGENESIS","Carcinogenesis","JUL",2010,31,7,null,null,null,null,1238,1241,null,"10.1093/carcin/bgq056",null,4,"Oncology","Oncology","620BD","WOS:000279473100009"]
[null,null,null,null,"J","Dickinson, AM; Pearce, KF; Norden, J; O'Brien, SG; Holler, E; Bickeboller, H; Balavarca, Y; Rocha, V; Kolb, HJ; Hromadnikova, I; Sedlacek, P; Niederwieser, D; Brand, R; Ruutu, T; Apperleyy, J; Szydlo, R; Goulmy, E; Siegert, W; de Witte, T; Gratwohl, A",null,null,null,"Dickinson, Anne M.; Pearce, Kim F.; Norden, Jean; O'Brien, Stephen G.; Holler, Ernst; Bickeboeller, Heike; Balavarca, Yesilda; Rocha, Vanderson; Kolb, Hans-Jochem; Hromadnikova, Ilona; Sedlacek, Petr; Niederwieser, Dietger; Brand, Ronald; Ruutu, Tapatti; Apperleyy, Jane; Szydlo, Richard; Goulmy, Els; Siegert, Wolfgang; de Witte, Theo; Gratwohl, Alois",null,null,"Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Article",null,null,null,null,null,"genetic risk factors; statistical modeling; hematopoietic stem cell transplantation","VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; INTERLEUKIN-10 PROMOTER POLYMORPHISM; CHRONIC MYELOGENOUS LEUKEMIA; GENE POLYMORPHISM; ALLOGENEIC TRANSPLANTATION; IL-10 POLYMORPHISMS; FOLLOW-UP; RECEPTOR; SURVIVAL","Background Non-HLA gene polymorphisms have been shown to influence outcome after allogeneic hematopoietic stem cell transplantation. Results were derived from heterogeneous, small populations and their value remains a matter of debate. Design and Methods In this study, we assessed the effect of single nucleotide polymorphisms in genes for interleukin 1 receptor antagonist (IL1RAI), interleukin 4 (IL4), interleukin 6 (IL6), interleukin 10 (IL10), interferon (IFNG), tumor necrosis factor (TNF) and the cell surface receptors tumor necrosis factor receptor II (TNFRSFIB), vitamin D receptor (VDR) and estrogen receptor alpha (ESR1) in a homogeneous cohort of 228 HLA identical sibling transplants for chronic myeloid leukemia. Three good predictors of overall survival, identified via statistical methods including Cox regression analysis, were investigated for their effects on transplant-related mortality and relapse. Predictive power was assessed after integration into the established European Group for Blood and Marrow Transplantation (EBMT) risk score. Results Absence of patient TNFRSFIB 196R, absence of donor IL10 ATA/ACC and presence of donor IL1RN allele 2 genotypes were associated with increased transplantation-related mortality and decreased survival. Application of prediction error and concordance index statistics gave evidence that integration improved the EBMT risk score. Conclusions Non-HLA genotypes were associated with survival after allogeneic hematopoietic stem cell transplantation. When three genetic polymorphisms were added into the EBMT risk model they improved the goodness of fit. Non-HLA genotyping could, therefore, be used to improve donor selection algorithms and risk assessment prior to allogeneic hematopoietic stem cell transplantation.","[Dickinson, Anne M.] Newcastle Univ, Sch Med, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Pearce, Kim F.] Newcastle Univ, Sch Math & Stat, ISRU, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Holler, Ernst] Univ Klinikum Hamatol Onkol, Regensburg, Germany; [Bickeboeller, Heike; Balavarca, Yesilda] Univ Gottingen, Dept Genet & Epidemiol, D-3400 Gottingen, Germany; [Rocha, Vanderson] Hop St Louis, Paris, France; [Kolb, Hans-Jochem] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany; [Hromadnikova, Ilona] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Sedlacek, Petr] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Niederwieser, Dietger] Univ Klin Leipzig, Klin & Poliklin, Leipzig, Germany; [Brand, Ronald] Leiden Univ Hosp, Dept Med Stat, Leiden, Netherlands; [Ruutu, Tapatti] Univ Cent Hosp, Dept Med, Div Hematol, Helsinki, Finland; [Apperleyy, Jane; Szydlo, Richard] Hammersmith Hosp, Dept Haematol, London, England; [Goulmy, Els] Univ Med Ctr, Leiden, Netherlands; [Siegert, Wolfgang] Virchow Klinikum Charite, Berlin, Germany; [de Witte, Theo] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands; [Gratwohl, Alois] Univ Basel, Univ Hosp, Basel, Switzerland","Dickinson, AM (reprint author), Newcastle Univ, Sch Med, Inst Cellular Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.","a.m.dickinson@ncl.ac.uk","Szydlo, Richard/C-6678-2012",null,"European Leukemia Net [LSH-2002-2.2.0-3]; Swiss National Research Foundation [3200B0-118176]; Swiss Cancer League; Regional Cancer League; Horton Foundation.; Amgen Europe GmbH; F Hoffmann-La Roche; Gilead Sciences; Miltenyi Biotec GmbH; Schering-Plough International Inc.; Celegene International SARL; Chugai Sanofi Aventis SNC; Fresenius Biotech GmbH; Gambro BCT; Genzyme; Pfizer; Berlex AG (Schering AG Germany); Therakos; Bristol Myers Squibb; Novartis; Cephalon; Laboratoires Pierre Fabre; GE Healthcare; European Commission [QLRI-CT-200000010]; TRANSEUROPE [QLK3-CT-2002-01936]; STEMDIAGNOSTICS [LSHB-CT-0377030]","the work was supported in part by the European Leukemia Net LSH-2002-2.2.0-3, by a grant from the Swiss National Research Foundation, 3200B0-118176 the Swiss Cancer League, the Regional Cancer League and the Horton Foundation. The EBMT is supported by grants from the corporate members: Amgen Europe GmbH, F Hoffmann-La Roche, Gilead Sciences, Miltenyi Biotec GmbH, Schering-Plough International Inc., Celegene International SARL, Chugai Sanofi Aventis SNC, Fresenius Biotech GmbH, Gambro BCT, Genzyme, Pfizer, Berlex AG (Schering AG Germany), Therakos, Bristol Myers Squibb, Novartis, Cephalon, Laboratoires Pierre Fabre and GE Healthcare. The work was also supported by European Commission Framework V and VI grants EUROBANK (contract number QLRI-CT-200000010) TRANSEUROPE (contract number QLK3-CT-2002-01936) and STEMDIAGNOSTICS (contract number LSHB-CT-0377030.",null,47,7,8,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","JUN",2010,95,6,null,null,null,null,922,927,null,"10.3324/haematol.2009.016220",null,6,null,null,"614IW","WOS:000279051100012"]
[null,null,null,null,"J","Yetgin, S; Olcay, L; Dibar, E; Conter, V; Masera, G; Valsecchi, MG; Dacou-Voutetakis, C; Henze, I; Loening, L; Schrappe, M; von Stackelberg, A; Zimmermann, M; Attarbaschi, A; Gadner, H; Mann, G; Brandalise, SR; Carroll, WL; Devidas, M; Gaynon, P; Hunger, S; Nachman, J; Janka, G; Stary, J; Gelber, RD; Bierings, M; Kamps, WA; Pieters, R; Otten, J; Suciu, S; Viana, MB; Baruchel, A; Ortega, JJ; Magyarosy, E; Perez, C; Steinberg, D; Tsurusawa, M; Zintl, F; Matsuzaki, A; Eden, TOB; Lilleyman, JS; Richards, S; Steinherz, PG; Kochupillai, V; de Toledo, JS; Appelbaum, FR; Campbell, M; Cheng, C; Pei, D; Pui, CH; Nakazawa, S; Elphinstone, T; Evans, V; Gettins, L; Hicks, C; MacKinnon, L; Morris, P; Richards, S; Wade, R; Wise, C",null,null,null,"Yetgin, S.; Olcay, L.; Dibar, E.; Conter, V.; Masera, G.; Valsecchi, M. G.; Dacou-Voutetakis, C.; Henze, I.; Loening, L.; Schrappe, M.; von Stackelberg, A.; Zimmermann, M.; Attarbaschi, A.; Gadner, H.; Mann, G.; Brandalise, S. R.; Carroll, W. L.; Devidas, M.; Gaynon, P.; Hunger, S.; Nachman, J.; Janka, G.; Stary, J.; Gelber, R. D.; Bierings, M.; Kamps, W. A.; Pieters, R.; Otten, J.; Suciu, S.; Viana, M. B.; Baruchel, A.; Ortega, J. J.; Magyarosy, E.; Perez, C.; Steinberg, D.; Tsurusawa, M.; Zintl, F.; Matsuzaki, A.; Eden, T. O. B.; Lilleyman, J. S.; Richards, S.; Steinherz, P. G.; Kochupillai, V.; de Toledo, J. S.; Appelbaum, F. R.; Campbell, M.; Cheng, C.; Pei, D.; Pui, C. H.; Nakazawa, S.; Elphinstone, T.; Evans, V.; Gettins, L.; Hicks, C.; MacKinnon, L.; Morris, P.; Richards, S.; Wade, R.; Wise, C.",null,"CALLCG","Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5659 children","BRITISH JOURNAL OF HAEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"acute leukaemia; childhood leukaemia; all; meta-analysis; leukaemia trials","RANDOMIZED-TRIAL; CANCER GROUP; RISK; CHEMOTHERAPY; DEXAMETHASONE; SURVIVAL; THERAPY; ADOLESCENTS; PREDNISONE; INTENSITY","P>Vincristine plus steroid pulses have long been a part of maintenance treatment in many protocols for childhood acute lymphoblastic leukaemia (ALL). A collaborative individual patient data meta-analysis of all randomised trials of the addition of vincristine plus prednisone/prednisolone (VP) pulses in childhood ALL was updated and extended to include trials comparing vincristine plus dexamethasone (VD) pulses to maintenance without pulses. VP pulses improved event-free survival (EFS) (70 center dot 1% vs. 62 center dot 0% at 5 years; odds ratio (OR) = 0 center dot 71; 95% confidence interval (CI) = 0 center dot 61-0 center dot 84; P = 0 center dot 00004); VD pulses did not have a significant effect (80 center dot 9% vs. 79 center dot 9% 5 year EFS; OR = 0 center dot 94; 95% CI = 0 center dot 80-1 center dot 11; P = 0 center dot 5). Heterogeneity between groups (VP or VD) was significant (P = 0 center dot 02). Neither treatment clearly affected overall survival. The difference between the VP and VD results is probably due to the greater early intensity of the backbone of the VD trial protocols and improved outcome seen in the VD trials, which were more recent. Pulses may still be useful in cases where less intensive early therapy is used and the balance between these treatments in terms of both effectiveness and toxicity needs to be considered.","Univ Oxford, CALLCG Secretariat, Oxford OX3 7LF, England","Yetgin, S (reprint author), Univ Oxford, CALLCG Secretariat, Richard Doll Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England.",null,"Schrappe, Martin/A-8109-2010",null,"Kay Kendall Leukaemia Fund [KKL293]; Cancer Research UK and Medical Research Council","The secretariat for this work was at CTSU, Oxford University. The work was funded by a grant from the Kay Kendall Leukaemia Fund (KKL293) with additional support from Cancer Research UK and Medical Research Council. Funders were not involved in the design, analysis or reporting. Writing committee: Professor T. O. B Eden, Paediatric and Adolescent Oncology Unit, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK. Professor R. Pieters, Department of Pediatric Oncology/Hematology Erasmus MC - Sophia Childrens Hospital University Medical Center, Rotterdam Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands. Dr S. Richards, Clinical Trial Service Unit, Richard Doll Building, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK.","Arico M, 2008, J CLIN ONCOL, V26, P283, DOI 10.1200/JCO.2007.12.3927; AUR RJA, 1973, BLOOD, V42, P349; BLEYER WA, 1983, J CLIN ONCOL, V1, P317; BLEYER WA, 1991, J CLIN ONCOL, V9, P1012; Bostrom BC, 2003, BLOOD, V101, P3809, DOI 10.1182/blood-2002-08-2454; *CANC LEUK GROUP B, 1972, CLIN TRIALS PDQ; Chessells JM, 1997, BRIT J HAEMATOL, V98, P945, DOI 10.1046/j.1365-2141.1997.3113127.x; Yetgin S, 2009, BRIT J HAEMATOL, V145, P376, DOI 10.1111/j.1365-2141.2009.07624.x; Richards S, 1996, LANCET, V347, P1783; Coebergh JWW, 2006, EUR J CANCER, V42, P2019, DOI 10.1016/j.ejca.2006.06.005; Conter V, 2007, LANCET, V369, P123, DOI 10.1016/S0140-6736(07)60073-7; DEMOERLOOSE B, 2008, BLOOD, V112, P11; FERNBACH DJ, 1975, CANCER, V36, P1552, DOI 10.1002/1097-0142(197511)36:5<1552::AID-CNCR2820360503>3.0.CO;2-3; HENZE G, 1982, KLIN PADIATR, V194, P195, DOI 10.1055/s-2008-1033805; HOLLAND JF, 1972, CANCER, V30, P1480, DOI 10.1002/1097-0142(197212)30:6<1480::AID-CNCR2820300611>3.0.CO;2-3; Lange BJ, 2002, BLOOD, V99, P825, DOI 10.1182/blood.V99.3.825; Mitchell CD, 2005, BRIT J HAEMATOL, V129, P734, DOI 10.1111/j.1365-2141.2005.05509.x; Ortega JJ, 1998, INT J PEDIAT HEM ONC, V5, P163; Pulte D, 2008, J NATL CANCER I, V100, P1301, DOI 10.1093/jnci/djn276; Relling MV, 1999, BLOOD, V93, P2817; Te Poele Esther M, 2007, Eur J Cancer, V43, P2532, DOI 10.1016/j.ejca.2007.07.002; VANDERDOESVANDE.A, 1998, INT J PEDIAT HEM ONC, V5, P125; Veerman AJ, 2009, LANCET ONCOL, V10, P957, DOI 10.1016/S1470-2045(09)70228-1",23,7,7,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0007-1048",null,null,"BRIT J HAEMATOL","Br. J. Haematol.","JUN",2010,149,5,null,null,null,null,722,733,null,"10.1111/j.1365-2141.2010.08148.x",null,12,"Hematology","Hematology","597VT","WOS:000277791000009"]
[null,null,null,null,"J","Hanova, M; Stetina, R; Vodickova, L; Vaclavikova, R; Hlavac, P; Smerhovsky, Z; Naccarati, A; Polakova, V; Soucek, P; Kuricova, M; Manini, P; Kumar, R; Hemminki, K; Vodicka, P",null,null,null,"Hanova, Monika; Stetina, Rudolf; Vodickova, Ludmila; Vaclavikova, Radka; Hlavac, Pavel; Smerhovsky, Zdenek; Naccarati, Alessio; Polakova, Veronika; Soucek, Pavel; Kuricova, Miroslava; Manini, Paola; Kumar, Rajiv; Hemminki, Kari; Vodicka, Pavel",null,null,"Modulation of DNA repair capacity and mRNA expression levels of XRCC1, hOGG1 and XPC genes in styrene-exposed workers","TOXICOLOGY AND APPLIED PHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,"Styrene exposure; Genotoxicity; DNA repair; DNA repair rates; Gene expression","SINGLE-STRAND BREAKS; CYTOGENETIC BIOMARKERS; URINARY METABOLITES; LAMINATION WORKERS; DAMAGE; POLYMORPHISMS; LYMPHOCYTES; ADDUCTS; CELLS; SUSCEPTIBILITY","Decreased levels of single-strand breaks in DNA (SSBs), reflecting DNA damage, have previously been observed with increased styrene exposure in contrast to a dose-dependent increase in the base-excision repair capacity. To clarify further the above aspects, we have investigated the associations between SSBs, micronuclei, DNA repair capacity and mRNA expression in XRCC1, hOGG1 and XPC genes on 71 styrene-exposed and 51 control individuals. Styrene concentrations at workplace and in blood characterized occupational exposure. The workers were divided into low (below 50 mg/m(3)) and high (above 50 mg/m(3)) styrene exposure groups. DNA damage and DNA repair capacity were analyzed in peripheral blood lymphocytes by Cornet assay. The mRNA expression levels were determined by qPCR. A significant negative correlation was observed between SSBs and styrene concentration at workplace (R = -0.38, p = 0.001); SSBs were also significantly higher in men (p = 0.001). The capacity to repair irradiation-induced DNA damage was the highest in the low exposure group (1.34 +/- 1.00 SSB/10(9) Da), followed by high exposure group (0.72 +/- 0.81 SSB/10(9) Da) and controls (0.65 +/- 0.82 SSB/10(9) Da). The mRNA expression levels of XRCC1, hOGG1 and XPC negatively correlated with styrene concentrations in blood and at workplace (p < 0.001) and positively with SSBs (p < 0.001). Micronuclei were not affected by styrene exposure, but were higher in older persons and in women (p < 0.001). In this study, we did not confirm previous findings on an increased DNA repair response to styrene-induced genotoxicity. However, negative correlations of SSBs and mRNA expression levels of XRCC1, hOGG1 and XPC with styrene exposure warrant further highly-targeted study. (C) 2010 Elsevier Inc. All rights reserved.","[Vodicka, Pavel] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague 14220, Czech Republic; [Hanova, Monika] Charles Univ Prague, Fac Sci, Dept Genet & Microbiol, Prague, Czech Republic; [Stetina, Rudolf] Purkynje Mil Med Acad, Hradec Kralove, Czech Republic; [Vodickova, Ludmila; Vaclavikova, Radka; Smerhovsky, Zdenek; Soucek, Pavel] Natl Inst Publ Hlth, Prague, Czech Republic; [Hlavac, Pavel] Reg Hyg Stn, Dept Occup Med, Hradec Kralove, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Kuricova, Miroslava] Slovak Med Univ, Res Base, Bratislava, Slovakia; [Manini, Paola] Univ Parma, Dept Clin Med Nephrol & Hlth Sci, I-43100 Parma, Italy; [Kumar, Rajiv; Hemminki, Kari] German Canc Res Ctr Deutsch Krebs Forsch Zentrum, Heidelberg, Germany","Vodicka, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Videnska 1083, Prague 14220, Czech Republic.","pvodicka@biomed.cas.cz",null,null,"Grant Agency of the Czech Academy of Sciences [IAA500390806]; Internal Grant Agency of Czech Ministry of Health [NR 9423-3]","This study was supported by Grant Agency of the Czech Academy of Sciences IAA500390806 and by Internal Grant Agency of Czech Ministry of Health NR 9423-3. We thank to Jana Slyskova, Ivona Hlavata and Dr. Barbara Pardini Naccarati for their technical help and support.",null,35,6,6,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0041-008X",null,null,"TOXICOL APPL PHARM","Toxicol. Appl. Pharmacol.","NOV 1",2010,248,3,null,null,null,null,194,200,null,"10.1016/j.taap.2010.07.027",null,7,"Pharmacology & Pharmacy; Toxicology","Pharmacology & Pharmacy; Toxicology","667OO","WOS:000283203600004"]
[null,null,null,null,"J","Lahtinen, L; Ndode-Ekane, XE; Barinka, F; Akamine, Y; Esmaeili, MH; Rantala, J; Pitkanen, A",null,null,null,"Lahtinen, Laura; Ndode-Ekane, Xavier Ekolle; Barinka, Filip; Akamine, Yumiko; Esmaeili, Mohammed Hossein; Rantala, Jukka; Pitkanen, Asla",null,null,"Urokinase-type plasminogen activator regulates neurodegeneration and neurogenesis but not vascular changes in the mouse hippocampus after status epilepticus","NEUROBIOLOGY OF DISEASE",null,null,"English","Article",null,null,null,null,null,"Angiogenesis; Epilepsy; Epileptogenesis; Granule cell dispersion; Hippocampus; Neurodegeneration; Neurogenesis; Plasminogen; Proteinase","TEMPORAL-LOBE EPILEPSY; ENDOTHELIAL GROWTH-FACTOR; GRANULE CELL DISPERSION; FOCAL CEREBRAL-ISCHEMIA; RAT HIPPOCAMPUS; DENTATE GYRUS; MICE LACKING; FACTOR VEGF; BRAIN; EXPRESSION","Expression of urokinase-type plasminogen activator (uPA) is increased after brain injury, suggesting that, like in cancer tissue, uPA plays roles in brain remodeling. Here we injured brain with intrahippocampal kainic acid (KA) injection in adult Wt and uPA-/- mice. At 20 days post-injury, uPA-/- mice had more severe loss of contralateral pyramidal (p<0.05) and hilar neurons (p<0.05) than Wt mice. The number of doublecortin (DCX)-positive newly born neurons was also reduced in uPA-/- mice as compared to Wt (p<0.01). No difference was observed in granule cell dispersion or distribution of DCX-positive neurons in the dentate gyrus. uPA deficiency did not affect the total length of hippocampal blood vessels or vessel density. No differences were observed in the severity of status epilepticus or consequent epilepsy between the genotypes. These data indicate that uPA deficiency can unfavorably modulate both delayed neurodegeneration and neurogenesis but has little effect on post-injury neuronal migration and vascular density. Our results favor the idea that elevated uPA during the post-injury phase is neuroprotective. (C) 2009 Elsevier Inc. All rights reserved.","[Lahtinen, Laura; Ndode-Ekane, Xavier Ekolle; Akamine, Yumiko; Rantala, Jukka; Pitkanen, Asla] Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland; [Barinka, Filip] Charles Univ Prague, Fac Med 2, Dept Anat, Prague 12800, Czech Republic; [Esmaeili, Mohammed Hossein] Qazvine Med Sci Univ, Dept Physiol, Qazvine, Iran","Pitkanen, A (reprint author), Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, POB 1627, FIN-70211 Kuopio, Finland.","asla.pitkanen@uku.fi",null,null,"Grant Agency of Charles University in Prague [35407]; Mobility Fund of Charles University in Prague; NENS-Network of European Neuroscience Schools; North-Savo Regional Fund of the Finnish Cultural Foundation; EC [FP6, MEST-CF-2005-019217]; The Sigrid Juselius Foundation; Academy of Finland","Supported by Grant Agency of Charles University in Prague (Grant No. 35407), Mobility Fund of Charles University in Prague, and by NENS-Network of European Neuroscience Schools (F.B.), North-Savo Regional Fund of the Finnish Cultural Foundation (L.L.), EC FP6, MEST-CF-2005-019217 (X.E.), The Sigrid Juselius Foundation (A.P.), and the Academy of Finland (A.P.). We thank Nick Hayward, MSc, for reviewing and editing the language of the manuscript.",null,60,6,6,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0969-9961",null,null,"NEUROBIOL DIS","Neurobiol. Dis.","MAR",2010,37,3,null,null,"SI",null,692,703,null,"10.1016/j.nbd.2009.12.008",null,12,"Neurosciences","Neurosciences & Neurology","560PH","WOS:000274914100022"]
[null,null,null,null,"J","Gjesing, AP; Larsen, LH; Torekov, SS; Hainerova, IA; Kapur, R; Johansen, A; Albrechtsen, A; Boj, S; Holst, B; Harper, A; Urhammer, SA; Borch-Johnsen, K; Pisinger, C; Echwald, SM; Eiberg, H; Astrup, A; Lebl, J; Ferrer, J; Schwartz, TW; Hansen, T; Pedersen, O",null,null,null,"Gjesing, Anette P.; Larsen, Lesli H.; Torekov, Signe S.; Hainerova, Irena Aldhoon; Kapur, Rahul; Johansen, Anders; Albrechtsen, Anders; Boj, Sylvia; Holst, Birgitte; Harper, Angela; Urhammer, Soren A.; Borch-Johnsen, Knut; Pisinger, Charlotta; Echwald, Soren M.; Eiberg, Hans; Astrup, Arne; Lebl, Jan; Ferrer, Jorge; Schwartz, Thue W.; Hansen, Torben; Pedersen, Oluf",null,null,"Family and Population-Based Studies of Variation within the Ghrelin Receptor Locus in Relation to Measures of Obesity","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"HORMONE SECRETAGOGUE RECEPTOR; FOOD-INTAKE; GENE; ASSOCIATION; LINKAGE","Background: The growth hormone secretagogue receptor (GHSR) is mediating hunger sensation when stimulated by its natural ligand ghrelin. In the present study, we tested the hypothesis that common and rare variation in the GHSR locus are related to increased prevalence of obesity and overweight among Whites. Methodology/Principal Findings: In a population-based study sample of 15,854 unrelated, middle-aged Danes, seven variants were genotyped to capture common variation in an 11 kbp region including GHSR. These were investigated for their individual and haplotypic association with obesity. None of these analyses revealed consistent association with measures of obesity. A -151C/T promoter mutation in the GHSR was found in two unrelated obese patients. One family presented with complete co-segregation, but the other with incomplete co-segregation. The mutation resulted in an increased transcriptional activity (p < 0.02) and introduction of a specific binding for Sp-1-like nuclear extracts relative to the wild type. The -151C/T mutation was genotyped in the 15,854 Danes with a minor allele frequency of 0.01%. No association with obesity in carriers (mean BMI: 27 +/- 4 kg/m(2)) versus non-carriers (mean BMI: 28 +/- 5 kg/m(2)) (p > 0.05) could be shown. Conclusions/Significance: In a population-based study sample of 15,854 Danes no association between GHSR genotypes and measures of obesity and overweight was found. Also, analyses of GHSR haplotypes lack consistent associations with obesity related traits. A rare functional GHSR promoter mutation variant was identified, yet there was no consistent relationship with obesity in neither family- nor population-based studies.","[Gjesing, Anette P.; Torekov, Signe S.; Kapur, Rahul; Hansen, Torben; Pedersen, Oluf] Hagedorn Res Inst, Gentofte, Denmark; [Larsen, Lesli H.; Johansen, Anders; Albrechtsen, Anders; Borch-Johnsen, Knut; Echwald, Soren M.; Hansen, Torben; Pedersen, Oluf] Steno Diabet Ctr, DK-2820 Gentofte, Denmark; [Larsen, Lesli H.; Astrup, Arne] Univ Copenhagen, Inst Human Nutr, Copenhagen, Denmark; [Hainerova, Irena Aldhoon] Charles Univ Prague, Dept Paediat, Prague, Czech Republic; [Hainerova, Irena Aldhoon] Charles Univ Prague, Ctr Res Diabet Metab & Nutr, Fac Med 3, Prague, Czech Republic; [Boj, Sylvia; Ferrer, Jorge] Inst Invest Biomed August Pi & Sunyer, Hosp Clin Barcelona, Endocrinol Unit, Barcelona, Spain; [Holst, Birgitte; Schwartz, Thue W.] Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; [Harper, Angela] Royal Vet & Agr Univ, Inst Human Nutr, Copenhagen, Denmark; [Urhammer, Soren A.] Hvidovre Univ Hosp, Dept Endocrinol, DK-2650 Hvidovre, Denmark; [Pisinger, Charlotta] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark; [Echwald, Soren M.] Exiqon, Vedbaek, Denmark; [Eiberg, Hans] Univ Copenhagen, Dept Cellular & Mol Med, Copenhagen, Denmark; [Pisinger, Charlotta; Pedersen, Oluf] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark; [Borch-Johnsen, Knut; Pedersen, Oluf] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark; [Hansen, Torben] Univ So Denmark, Fac Hlth Sci, Odense, Denmark; [Lebl, Jan] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague, Czech Republic","Gjesing, AP (reprint author), Hagedorn Res Inst, Gentofte, Denmark.","apri@hagedorn.dk","Palmer, David/E-6824-2010; Larsen, Lesli/D-2252-2011; Albrechtsen, Anders/K-4281-2013","Albrechtsen, Anders/0000-0001-7306-031X","University of Copenhagen; Danish Diabetes Association; European Union [LSHM-CT-2005-018734]; Danish Medical Research Council; Danish Agency for Science Technology and Innovation [271-06-0539]; Czech Research Project of MSM [0021620814]; Novo Nordisk","The study is part of the DanORC project (http://www.danorc.dk) and was additionally supported by the University of Copenhagen, the Danish Diabetes Association, the European Union (HEPADIP, grant no. LSHM-CT-2005-018734), the Danish Medical Research Council, the Danish Agency for Science Technology and Innovation (grant no. 271-06-0539), the Czech Research Project of MSM No. 0021620814 and a European Society of Paediatric Endocrinology (ESPE) research fellowship sponsored by Novo Nordisk. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,19,5,5,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA","1932-6203",null,null,"PLOS ONE","PLoS One","APR 9",2010,5,4,null,null,null,null,null,null,"e10084","10.1371/journal.pone.0010084",null,8,"Multidisciplinary Sciences","Science & Technology - Other Topics","580WU","WOS:000276482100010"]
[null,null,null,null,"J","Bakhtiary, F; Takacs, J; Cho, MY; Razek, V; Dahnert, I; Doenst, T; Walther, T; Borger, MA; Mohr, FW; Kostelka, M",null,null,null,"Bakhtiary, Farhad; Takacs, Judith; Cho, Mi-Young; Razek, Vit; Daehnert, Ingo; Doenst, Torsten; Walther, Thomas; Borger, Michael Andrew; Mohr, Friedrich Wilhelm; Kostelka, Martin",null,null,"Long-Term Results After Repair of Complete Atrioventricular Septal Defect With Two-patch Technique","ANNALS OF THORACIC SURGERY",null,null,"English","Article",null,null,null,null,null,null,"RISK-FACTORS; 20-YEAR EXPERIENCE; SURGICAL REPAIR; VALVE FUNCTION; REGURGITATION; REOPERATION; INFANCY","Background. Surgical management of patients with complete atrioventricular septal defect (AVSD) has advanced over the last decades. Definitive early surgical repair for AVSD has become the treatment of choice at many centers. This trend has contributed to the recent decline in postoperative mortality and good long-term results. Methods. We reviewed long-term results of 100 consecutive patients with complete AVSD undergoing definitive early repair with a two-patch technique and complete cleft closure operated on between June 1999 and June 2009. Valve performance, mortality, morbidity, and indications for reoperation were retrospectively studied. Results. Median age at operation was 3.8 months (range, 15 days to 4.7 years); median weight was 5.0 kg (range, 3.0 to 19 kg). Follow-up was 99% complete (mean 58 months; range, 1 to 120 months). Early definitive repair was performed in all patients who initially presented to our institution over the study period. There was no perioperative, in-hospital mortality, or late mortality. At the latest follow up, left atrioventricular valve (LAVV) regurgitation was absent or trace in 80 patients (80%), mild to moderate in 15 patients (15%), and moderate to severe in 4 patients (4%). Right AV valve regurgitation was none or trace in 86 patients (86%), mild to moderate in 11 patients (11%), and moderate to severe in 2 patients (2%). Actuarial freedom from reoperation for LAVV dysfunction at 1, 3, 5, and 10 years was 98%, 95%, 94%, and 94%, respectively. Actuarial freedom from reoperation for left ventricular outflow tract obstruction at 1, 3, 5, and 10 years was 100%, 99%, and remained constant by 99% at 5 and 10 years. Conclusions. Definitive early repair for complete AVSD can be performed with excellent results. The two-patch technique with complete cleft closure is a safe and reproducible surgical method that can achieve very low mortality and stable long-term outcomes, even in neonates. (Ann Thorac Surg 2010; 89: 1239-43) (C) 2010 by The Society of Thoracic Surgeons","[Bakhtiary, Farhad] Univ Leipzig, Dept Cardiovasc Surg, Ctr Heart, D-04289 Leipzig, Germany; Univ Leipzig, Dept Paediat Cardiol, Ctr Heart, D-04289 Leipzig, Germany","Bakhtiary, F (reprint author), Univ Leipzig, Dept Cardiovasc Surg, Ctr Heart, Strumpelstr 39, D-04289 Leipzig, Germany.","farhad@bakhtiary.de",null,null,null,null,"AlexiMeskishvili V, 1997, EUR J CARDIO-THORAC, V12, P460, DOI 10.1016/S1010-7940(97)00190-5; Al-Hay AA, 2003, ANN THORAC SURG, V75, P412, DOI 10.1016/S0003-4975(02)04026-2; BANDO K, 1995, J THORAC CARDIOV SUR, V110, P1543, DOI 10.1016/S0022-5223(95)70078-1; Bogers AJJC, 2000, EUR J CARDIO-THORAC, V18, P473, DOI 10.1016/S1010-7940(00)00536-4; Crawford FA, 2001, ANN THORAC SURG, V72, P1621, DOI 10.1016/S0003-4975(01)03170-8; Dodge-Khatami A, 2008, EUR J CARDIO-THORAC, V34, P745, DOI 10.1016/j.ejcts.2008.06.047; Gunther T, 1998, ANN THORAC SURG, V65, P754, DOI 10.1016/S0003-4975(98)00028-9; HANLEY FL, 1993, J THORAC CARDIOV SUR, V106, P387; HELMCKE F, 1987, CIRCULATION, V75, P175; Najm HK, 1997, CIRCULATION, V96, P311; Nicholson IA, 1999, J THORAC CARDIOV SUR, V118, P642, DOI 10.1016/S0022-5223(99)70009-7; Nunn GR, 2007, SEMIN THORAC CARDIOV, V1, P28, DOI 10.1053/j.pcsu.2007.01.009; Poirier NC, 2000, EUR J CARDIO-THORAC, V18, P54, DOI 10.1016/S1010-7940(00)00402-4; RASTELLI GC, 1966, MAYO CLIN P, V41, P196; Reddy VM, 1998, J THORAC CARDIOV SUR, V115, P1032, DOI 10.1016/S0022-5223(98)70402-7; Suzuki T, 2008, ANN THORAC SURG, V86, P596, DOI 10.1016/j.athoracsur.2008.02.032; Tweddell JS, 1996, ANN THORAC SURG, V62, P419, DOI 10.1016/0003-4975(96)00250-0; WEINTRAUB RG, 1990, J THORAC CARDIOV SUR, V99, P320; Wetter J, 2000, EUR J CARDIO-THORAC, V17, P146, DOI 10.1016/S1010-7940(99)00360-7",19,6,8,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0003-4975",null,null,"ANN THORAC SURG","Ann. Thorac. Surg.","APR",2010,89,4,null,null,null,null,1239,1243,null,"10.1016/j.athoracsur.2009.11.017",null,5,"Cardiac & Cardiovascular Systems; Respiratory System; Surgery","Cardiovascular System & Cardiology; Respiratory System; Surgery","573CK","WOS:000275885800034"]
[null,null,null,null,"J","Hejcl, A; Sedy, J; Kapcalova, M; Toro, DA; Amemori, T; Lesny, P; Likavcanova-Masinova, K; Krumbholcova, E; Pradny, M; Michalek, J; Burian, M; Hajek, M; Jendelova, P; Sykova, E",null,null,null,"Hejcl, Ales; Sedy, Jiri; Kapcalova, Miroslava; Toro, David Arboleda; Amemori, Takashi; Lesny, Petr; Likavcanova-Masinova, Katarina; Krumbholcova, Eva; Pradny, Martin; Michalek, Jiri; Burian, Martin; Hajek, Milan; Jendelova, Pavla; Sykova, Eva",null,null,"HPMA-RGD Hydrogels Seeded with Mesenchymal Stem Cells Improve Functional Outcome in Chronic Spinal Cord Injury","STEM CELLS AND DEVELOPMENT",null,null,"English","Article",null,null,null,null,null,null,"MARROW STROMAL CELLS; ENSHEATHING GLIA TRANSPLANTS; MAGNETIC-RESONANCE TRACKING; BRAIN EXTRACELLULAR-SPACE; COLONY-STIMULATING FACTOR; CHRONIC PARAPLEGIC RATS; ADULT-RAT; 2-HYDROXYETHYL METHACRYLATE; REACTIVE ASTROCYTES; SCHWANN-CELL","Chronic spinal cord injury (SCI) is characterized by tissue loss and a stable functional deficit. While several experimental therapies have proven to be partly successful for the treatment of acute SCI, treatment of chronic SCI is still challenging. We studied whether we can bridge a chronic spinal cord lesion by implantation of our newly developed hydrogel based on 2-hydroxypropyl methacrylamide, either alone or seeded with mesenchymal stem cells (MSCs), and whether this treatment leads to functional improvement. A balloon-induced compression lesion was performed in adult 2-month-old male Wistar rats. Five weeks after injury, HPMA-RGD hydrogels [N-(2-hydroxypropyl)-methacrylamide with attached amino acid sequences-Arg-Gly-Asp] were implanted into the lesion, either with or without seeded MSCs. Animals with chronic SCI served as controls. The animals were behaviorally tested using the Basso-Beattie-Bresnahan (BBB) (motor) and plantar (sensory) tests once a week for 6 months. Behavioral analysis showed a statistically significant improvement in rats with combined treatment, hydrogel and MSCs, compared with the control group (P < 0.05). Although a tendency toward improvement was found in rats treated with hydrogel only, this was not significant. Subsequently, the animals were sacrificed 6 months after SCI, and the spinal cord lesions evaluated histologically. The combined therapy (hydrogel with MSCs) prevented tissue atrophy (P < 0.05), and the hydrogels were infiltrated with axons myelinated with Schwann cells. Blood vessels and astrocytes also grew inside the implant. MSCs were present in the hydrogels even 5 months after implantation. We conclude that 5 weeks after injury, HPMA-RGD hydrogels seeded with MSCs can successfully bridge a spinal cord cavity and provide a scaffold for tissue regeneration. This treatment leads to functional improvement even in chronic SCI.","[Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, VVI, Prague 14220 4, Czech Republic; [Hejcl, Ales; Sedy, Jiri; Kapcalova, Miroslava; Toro, David Arboleda; Amemori, Takashi; Lesny, Petr; Likavcanova-Masinova, Katarina; Krumbholcova, Eva; Pradny, Martin; Michalek, Jiri; Burian, Martin; Hajek, Milan; Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Dept Neurosci, Prague, Czech Republic; [Hejcl, Ales; Sedy, Jiri; Kapcalova, Miroslava; Toro, David Arboleda; Amemori, Takashi; Lesny, Petr; Likavcanova-Masinova, Katarina; Krumbholcova, Eva; Pradny, Martin; Michalek, Jiri; Burian, Martin; Hajek, Milan; Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Hejcl, Ales] Masaryk Hosp, Dept Neurosurg, Usti Nad Labem, Czech Republic; [Krumbholcova, Eva; Pradny, Martin; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, Prague 14220 4, Czech Republic; [Burian, Martin; Hajek, Milan] Inst Clin & Expt Med, MRI Unit, Prague, Czech Republic","Sykova, E (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, VVI, Videnska 1083, Prague 14220 4, Czech Republic.","sykova@biomed.cas.cz",null,null,"EC [LSHB-CT-2005-518233]; GACR [309/08/H079]; IGA [MZ 1A8697-5];  [AV0Z50390703];  [1M0538];  [LC554];  [IAA500390902]","We thank Hana Hronova, Lenka Kohoutova, Alena Vesela, and Pavlina Mackova for excellent technical assistance. We thank James Dutt for critical reading of the manuscript. We acknowledge the support provided by the grants AV0Z50390703, 1M0538, LC554, IAA500390902, GACR 309/08/H079, IGA MZ 1A8697-5, and the EC FP6 project RESCUE (LSHB-CT-2005-518233).",null,79,31,35,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1547-3287",null,null,"STEM CELLS DEV","Stem Cells Dev.","OCT",2010,19,10,null,null,null,null,1535,1546,null,"10.1089/scd.2009.0378",null,12,"Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation","Cell Biology; Hematology; Research & Experimental Medicine; Transplantation","657DX","WOS:000282394400007"]
[null,null,null,null,"J","Hort, J; Bartos, A; Pirttila, T; Scheltens, P",null,null,null,"Hort, J.; Bartos, A.; Pirttila, T.; Scheltens, P.",null,null,"Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe","EUROPEAN JOURNAL OF NEUROLOGY",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; beta-amyloid; biomarker; cerebrospinal fluid; phosphorylated tau; total tau","MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; PHOSPHORYLATED TAU; CSF BIOMARKERS; PREDICTION; A-BETA-42; CRITERIA; ADULTS","Background and purpose: Cerebrospinal fluid (CSF) biomarkers have been reported to be useful in dementia diagnosis. Not much is known about their use in clinical practice in Europe. Methods: We analyzed data from a survey on the use of CSF biomarkers in the diagnosis of dementia across Europe using a questionnaire which was filled out by representatives of the 25 member countries of the European Federation of Neurological Societies (EFNS). Results: Cerebrospinal fluid beta-amyloid, total tau, and phosphorylated tau proteins are frequently evaluated in the majority of the countries (in 18 out of 23 countries). No major technical or ethical issues were found that would hamper the procedure's ability to become routine in early and differential diagnostics of Alzheimer's disease. Cut-off values for beta-amyloid (median 500, range 300-849 pg/ml), total tau (367; 195-450 pg/ml) and phosphorylated tau (60; 40-85 pg/ml) varied considerably amongst countries and even within every country. Conclusions: Cerebrospinal fluid analysis of beta-amyloid, tau, and phosphorylated tau is frequently used in Europe. However, the use of various cut off values seriously hampers comparability and yields a potential threat to an interpretation and balanced use in clinical practice. We recommend that each laboratory establishes normative data and that multi-centered studies should be organized to explore the reasons for any differences.","[Hort, J.] Charles Univ Prague, Memory Disorders Clin, Dept Neurol, Fac Med 2,Univ Hosp Motol, Prague, Czech Republic; [Bartos, A.] Charles Univ Prague, Fac Med 3, Dept Neurol, Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Bartos, A.] Prague Psychiat Ctr, Alzheimer Dis Ctr, Prague, Czech Republic; [Pirttila, T.] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland; [Scheltens, P.] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Alzheimer Ctr, Amsterdam, Netherlands","Hort, J (reprint author), Charles Univ Prague, Memory Disorders Clin, Dept Neurol, Fac Med 2,Univ Hosp Motol, Prague, Czech Republic.","jakub.hort@seznam.cz",null,null," [KAN200520701];  [GACR 309/09/1053]","Many thanks to all participants in this survey: Reinhold Schmidt (Austria), Jean-Pierre Brion (Belgium), Gunhild Waldemar (Denmark), Bruno Dubois (France), Alexander Tsiskaridze (Georgia), Hayrettin Tumani, Katharina Buerger (Germany), Elisabeth Kapaki (Greece), Peter Klivenyi (Hungary), Judith Aharon-Peretz (Israel), Giovanni Frisoni, Antonio Federico, Lucilla Parnetti, Daniella Galimberti, Alessandra Bizarro, (Italy), Gintaras Kaubrys (Lithuania), Frank-Erik de Leeuw (the Netherland), Olaf Aaserud, Tormod Fladby (Norway), Konrad Rejdak (Poland), Alexandre Mendonca (Portugal), Bogdan Popescu (Romania), Elka Stefanova (Serbia) Pablo Martinez-Lage (Spain), Zuzana Gdovinova (Slovakia), Miro Denislic (Slovenia), Carsten Wikkelso (Sweden), Hakan Gurvit (Turkey), Martin Rossor, Geoffrey Keir, Axel Petzold (UK). Data analysis and writing of the paper was partly supported by the project KAN200520701 and GACR 309/09/1053.",null,17,30,30,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1351-5101",null,null,"EUR J NEUROL","Eur. J. Neurol.","JAN",2010,17,1,null,null,null,null,90,96,null,"10.1111/j.1468-1331.2009.02753.x",null,7,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","534JY","WOS:000272893600016"]
[null,null,null,null,"J","Pleskacova, J; Hersmus, R; Oosterhuis, JW; Setyawati, BA; Faradz, SM; Cools, M; Wolffenbuttel, KP; Lebl, J; Drop, SL; Looijenga, LH",null,null,null,"Pleskacova, J.; Hersmus, R.; Oosterhuis, J. W.; Setyawati, B. A.; Faradz, S. M.; Cools, M.; Wolffenbuttel, K. P.; Lebl, J.; Drop, S. L.; Looijenga, L. H.",null,null,"Tumor Risk in Disorders of Sex Development","SEXUAL DEVELOPMENT",null,null,"English","Article",null,null,null,null,null,"Disorders of sex development; Germ cell tumors; Pathogenesis; Risk","GERM-CELL TUMORS; CARCINOMA-IN-SITU; TESTICULAR DYSGENESIS SYNDROME; C-KIT; DEVELOPMENT DSD; ENVIRONMENTAL ASPECTS; EXPRESSION; GENE; DIFFERENTIATION; GONADS","Certain patients with disorders of sex development (DSD), who bear Y chromosome material in their karyotype, are at increased risk for the development of type II germ cell tumors (GCT), which arise from early fetal germ cells. DSD gonads frequently harbor immature germ cells which express early fetal germ cell markers. Some of them (e.g. OCT3/4 and NANOG) seem to be of pathogenetic relevance in GCT development providing cells with the ability of pluripotency, proliferation and apoptosis suppression. Also TSPY (testis-specific protein Y-encoded), the main candidate for the so-called gonadoblastoma locus on Y chromosome, is over-expressed in germ cells of DSD patients and possibly contributes to their survival and proliferation. Nowadays, the use of immunohistochemical methods is highly relevant in identifying DSD gonads at risk. The risk for GCT development varies. While the prevalence of GCT is 15% in patients with partial androgen insensitivity, it may reach more than 30% in patients with gonadal dysgenesis. Patients with complete androgen insensitivity and ovotesticular DSD develop malignancies in 0.8% and 2.6% of cases, respectively. However, these data may be biased for various reasons. To better estimate the risk in individual groups of DSD, further investigations on large patient series are needed. Copyright (c) 2010 S. Karger AG, Basel","[Hersmus, R.; Oosterhuis, J. W.; Looijenga, L. H.] Erasmus MC Univ Med Ctr Rotterdam, Dept Pathol, Josephine Nefkens Inst, Dr Daniel Den Hoed Canc Ctr, NL-3000 CA Rotterdam, Netherlands; [Pleskacova, J.; Lebl, J.] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague, Czech Republic; [Setyawati, B. A.; Faradz, S. M.] Diponegro Univ, Dept Human Genet, Ctr Biomed Res, Fac Med, Semarang, Indonesia; [Cools, M.] Ghent Univ Hosp, Dept Pediat, Div Pediat Endocrinol, B-9000 Ghent, Belgium; [Wolffenbuttel, K. P.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Urol, Rotterdam, Netherlands; [Drop, S. L.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Endocrinol, Rotterdam, Netherlands","Looijenga, LH (reprint author), Erasmus MC Univ Med Ctr Rotterdam, Dept Pathol, Josephine Nefkens Inst, Dr Daniel Den Hoed Canc Ctr, Bldg Be,Room 430B,POB 2040, NL-3000 CA Rotterdam, Netherlands.","l.looijenga@erasmusmc.nl","Cools, Martine/J-4580-2012",null,"Novo Nordisk A/S; Translational Research Grant Erasmus MC; Flanders Research Foundation-FWO","This work was supported in part by ESPE Research Fellowship, sponsored by Novo Nordisk A/S (J.P.) as well as the Translational Research Grant Erasmus MC 2006 (R. H.) and The Flanders Research Foundation-FWO (M.C.).",null,61,22,25,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1661-5425",null,null,"SEX DEV","Sex. Dev.",null,2010,4,41763,null,null,null,null,259,269,null,"10.1159/000314536",null,11,"Developmental Biology","Developmental Biology","648AZ","WOS:000281664100009"]
[null,null,null,null,"J","Amemori, T; Jendelova, P; Ruzickova, K; Arboleda, D; Sykova, E",null,null,null,"Amemori, Takashi; Jendelova, Pavla; Ruzickova, Katerina; Arboleda, David; Sykova, Eva",null,null,"Co-transplantation of olfactory ensheathing glia and mesenchymal stromal cells does not have synergistic effects after spinal cord injury in the rat","CYTOTHERAPY",null,null,"English","Article",null,null,null,null,null,null,"STEM-CELLS; SCHWANN-CELLS; IN-VIVO; CAVITY FORMATION; LAMINA-PROPRIA; WHITE-MATTER; MIGRATION; RECOVERY; RHO; REGENERATION","Background aims. Olfactory ensheathing glia (OEG) and mesenchymal stromal cells (MSC) are suitable candidates for transplantation therapy of spinal cord injury (SCI). Both facilitate functional improvement after SCI by producing trophic factors and cytokines. In this study, the co-transplantation of both types of cells was studied to clarify their additive and/ or synergistic effects on SCI. Methods. A balloon-induced compression lesion was used to produce SCI in rats. OEG, MSC or both OEG and MSC (3 x 10<SU5</SU cells of each cell type) were implanted by intraspinal injection 1 week after SCI. The effect of transplantation was assessed using behavioral, electrophysiologic and histologic methods. Results. Hindlimb function was examined with Basso, Beattie and Bresnahan (BBB) and Plantar tests. Improvement was found in all three groups of transplanted rats with different time-courses, but there was no significant difference among the groups at the end of the experiment. Motor-evoked potentials after SCI decreased in amplitude from 7 mV to 10 mu V. Linear regression analysis showed a modest recovery in amplitude following transplantation, but no change in the control rats. Histologic findings showed that the white and gray matter were significantly spared by transplantation after SCI. Conclusions. Functional improvement was achieved with transplantation of OEG and/or MSC, but the co-transplantation of OEG and MSC did not show synergistic effects. The poor migration of OEG and MSC might prevent their concerted action. Pre-treatment with a Rho antagonist and a combination of intraspinal and intravenous injection of the cells might be beneficial for SCI therapy.","[Amemori, Takashi] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Prague 14220 4, Czech Republic; [Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Amemori, T (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Videnska 1083, Prague 14220 4, Czech Republic.","tamemori@hotmail.com",null,null,"EU [LSHM-CT-2005-019063];  [AVOZ50390703];  [IAA500390902];  [GACR309/06/1246];  [LC554];  [1M0538];  [1A8697-5]","We thank James Dutt for critical reading of the manuscript. This work was supported by the following grants: AVOZ50390703, IAA500390902, GACR309/06/1246, LC554, 1M0538 and 1A8697-5. The EU FP6 project ENINET (LSHM-CT-2005-019063.",null,67,18,20,"TAYLOR & FRANCIS AS","OSLO","KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY","1465-3249",null,null,"CYTOTHERAPY","Cytotherapy","APR",2010,12,2,null,null,null,null,212,225,null,"10.3109/14653240903440103",null,14,"Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental","Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine","563EL","WOS:000275110600010"]
[null,null,null,null,"J","Amant, F; Brepoels, L; Halaska, MJ; Gziri, MM; Van Calsteren, K",null,null,null,"Amant, Frederic; Brepoels, Lieselot; Halaska, Michael J.; Gziri, Mina Mhallem; Van Calsteren, Kristel",null,null,"Gynaecologic cancer complicating pregnancy: An overview","BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY",null,null,"English","Article",null,null,null,null,null,"cancer; pregnancy; radiotherapy; surgery; chemotherapy; neonatal","OF-THE-LITERATURE; ENDODERMAL SINUS TUMOR; CERVICAL INTRAEPITHELIAL NEOPLASIA; METASTATIC BREAST-CANCER; TERM-FOLLOW-UP; VAGINAL RADICAL TRACHELECTOMY; EPITHELIAL OVARIAN-CARCINOMA; CHEMOTHERAPY IN-UTERO; CELL LUNG-CANCER; NEOADJUVANT CHEMOTHERAPY","Cancer complicating pregnancy endangers two lives. Any approach should look at both maternal and foetal safety. Maternal prognosis will not improve by terminating the pregnancy. Imaging for staging purposes is possible, and sonar and magnetic resonance imaging are the preferred examinations. Abdominopelvic computed tomography exposes the foetus to the highest doses radiation and should be avoided. Provided a thorough maternal monitoring to ensure a stable uteroplacental blood flow and foetal oxygenation, surgical techniques that are used in non-pregnant patients are also safe for pregnant patients. Radiotherapy of the upper part of the body is possible during pregnancy, but during the third trimester the close distance may put the foetus at risk. Chemotherapy during the second or third trimester can be administered without increasing the incidence of congenital malformations. A systematic analysis, especially on the long-term outcome of the offspring after cancer treatment during pregnancy is still lacking. Here, we present a summary of issues related to the diagnosis and treatment of gynaecological malignancies during pregnancy. Firstly, we describe general diagnostic and cancer-treatment-related problems. In the second part, organ pathology including breast, cervical, ovarian, endometrial and vulvar cancer is discussed. (C) 2009 Elsevier Ltd. All rights reserved.","[Amant, Frederic; Brepoels, Lieselot; Van Calsteren, Kristel] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Louvain, Belgium; [Halaska, Michael J.] Charles Univ Prague, Fac Med 2, CR-11636 Prague 1, Czech Republic; [Gziri, Mina Mhallem] Catholic Univ Louvain, Louvain, Belgium","Amant, F (reprint author), Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Louvain, Belgium.","Frederic.amant@uz.kuleuven.ac.be",null,null,"F.W.O. [G. 0358.06, SCIE2006-17]; K.U.Leuven","Frederic Amant is clinical researcher for F.W.O.: Kristel Van Calsteren is aspirant for F.W.O.; This work is supported by F.W.O. Project G. 0358.06, 'Stichting tegen kanker Project SCIE2006-17', Research Fund K.U.Leuven.",null,162,17,20,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","1521-6934",null,null,"BEST PRACT RES CL OB","Best Pract. Res. Clin. Obstet. Gynaecol.","FEB",2010,24,1,null,null,null,null,61,79,null,"10.1016/j.bpobgyn.2009.08.001",null,19,"Obstetrics & Gynecology","Obstetrics & Gynecology","638VR","WOS:000280926100007"]
[null,null,null,null,"J","Boesgaard, TW; Pruhova, S; Andersson, EA; Cinek, O; Obermannova, B; Lauenborg, J; Damm, P; Bergholdt, R; Pociot, F; Pisinger, C; Barbetti, F; Lebl, J; Pedersen, O; Hansen, T",null,null,null,"Boesgaard, Trine W.; Pruhova, Stepanka; Andersson, Ehm A.; Cinek, Ondrej; Obermannova, Barbora; Lauenborg, Jeannet; Damm, Peter; Bergholdt, Regine; Pociot, Flemming; Pisinger, Charlotta; Barbetti, Fabrizio; Lebl, Jan; Pedersen, Oluf; Hansen, Torben",null,null,"Further evidence that mutations in INS can be a rare cause of Maturity-Onset Diabetes of the Young (MODY)","BMC MEDICAL GENETICS",null,null,"English","Article",null,null,null,null,null,null,"INSULIN GENE-MUTATIONS; CHILDREN","Background: Insulin gene (INS) mutations have recently been described as a common cause of permanent neonatal diabetes (PNDM) and a rare cause of diabetes diagnosed in childhood or adulthood. Methods: INS was sequenced in 116 maturity-onset diabetes of the young (MODYX) patients (n = 48 Danish and n = 68 Czech), 83 patients with gestational diabetes mellitus (GDM), 34 type 1 diabetic patients screened negative for glutamic acid decarboxylase (GAD), and 96 glucose tolerant individuals. The control group was randomly selected from the population-based sampled Inter99 study. Results: One novel heterozygous mutation c. 17G>A, R6H, was identified in the pre-proinsulin gene (INS) in a Danish MODYX family. The proband was diagnosed at 20 years of age with mild diabetes and treated with diet and oral hypoglycaemic agent. Two other family members who carried the INS R6H were diagnosed with diabetes when 51 years old and with GDM when 27 years old, respectively. A fourth mutation carrier had normal glucose tolerance when 20 years old. Two carriers of INS R6H were also examined twice with an oral glucose tolerance test (OGTT) with 5 years interval. They both had a similar to 30% reduction in beta-cell function measured as insulinogenic index. In a Czech MODYX family a previously described R46Q mutation was found. The proband was diagnosed at 13 years of age and had been treated with insulin since onset of diabetes. Her mother and grandmother were diagnosed at 14 and 35 years of age, respectively, and were treated with oral hypoglycaemic agents and/or insulin. Conclusion: Mutations in INS can be a rare cause of MODY and we conclude that screening for mutations in INS should be recommended in MODYX patients.","[Boesgaard, Trine W.; Andersson, Ehm A.; Bergholdt, Regine; Pociot, Flemming; Pedersen, Oluf; Hansen, Torben] Steno Diabet Ctr, DK-2820 Gentofte, Denmark; [Boesgaard, Trine W.; Andersson, Ehm A.; Bergholdt, Regine; Pociot, Flemming; Pedersen, Oluf; Hansen, Torben] Hagedorn Res Inst, Gentofte, Denmark; [Pruhova, Stepanka; Cinek, Ondrej; Obermannova, Barbora; Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Lauenborg, Jeannet; Damm, Peter] Rigshosp, Copenhagen Univ Hosp, Dept Obstet, Ctr Pregnant Women Diabet, Copenhagen, Denmark; [Pisinger, Charlotta] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark; [Barbetti, Fabrizio] Bambino Gesu Childrens Hosp IRCCS, Dept Paediat Med, Endocrinol & Diabet Unit, Rome, Italy; [Pedersen, Oluf] Univ Copenhagen, Fac Hlth Sci, Inst Biomed Sci, Copenhagen, Denmark; [Pedersen, Oluf] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark; [Hansen, Torben] Univ So Denmark, Fac Hlth Sci, Odense, Denmark","Boesgaard, TW (reprint author), Steno Diabet Ctr, DK-2820 Gentofte, Denmark.","tweb@hagedorn.dk",null,null,"Norwegian Financial Mechanism, Norway [CZ0100]","The study was supported by the Danish Medical Research Council and the Danish Diabetes Association. The authors wish to thank A. Forman, I.-L. Wantzin and M. Stendal for technical assistance, G. Lademann for secretarial support, A. L. Nielsen for database management, M. M. H. Kristensen for grant management, and the members of the Inter99 team. The authors from the Czech Republic were supported by a grant \"Monogenic diabetes in childhood: from genetic to therapy\" from Norway though the Norwegian Financial Mechanism (No CZ0100).",null,9,16,19,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2350",null,null,"BMC MED GENET","BMC Med. Genet.","MAR 12",2010,11,null,null,null,null,null,null,null,42,"10.1186/1471-2350-11-42",null,4,"Genetics & Heredity","Genetics & Heredity","579SQ","WOS:000276394100001"]
[null,null,null,null,"J","Boucek, J; Mrkvan, T; Chovanec, M; Kuchar, M; Betka, J; Boucek, V; Hladikova, M; Betka, J; Eckschlager, T; Rihova, B",null,null,null,"Boucek, Jan; Mrkvan, Tomas; Chovanec, Martin; Kuchar, Martin; Betka, Jaroslav; Boucek, Vladimir; Hladikova, Marie; Betka, Jan; Eckschlager, Tomas; Rihova, Blanka",null,null,"Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck","JOURNAL OF CELLULAR AND MOLECULAR MEDICINE",null,null,"English","Article",null,null,null,null,null,"regulatory T cells; head and neck squamous cell carcinoma; tumour markers; early recurrence; lymphocyte subpopulations","PERIPHERAL-BLOOD; IMMUNE-RESPONSES; LYMPHOCYTE SUBSETS; OVARIAN-CARCINOMA; ABSOLUTE COUNTS; CANCER-PATIENTS; TUMOR; EXPRESSION; DISEASE; CIRCULATION","Regulatory T cells (Treg) are important regulators of anti-cancer immune responses, and an increase in Treg frequency was observed in the blood of cancer patients. Blood samples from 112 patients with head and neck squamous cell carcinoma antigen (HNSCC) were obtained at the time of tumour diagnosis, and lymphocyte subpopulations (CD3+; CD3-CD16+CD56+; CD4+; CD8+; CD19+; CD4+CD45RA+) with emphasis on Treg counts (CD3+CD4+CD25+), complete blood count and tumour markers (squamous cell carcinoma [SCC]; CEA; alpha-1-antitrypsin [AAT]; Cyfra 21-1; C-reactive protein [CRP]) were analysed. The data were grouped according to TNM classification, and their significance for the course of the disease at an interval of 1 year after the end of the therapy was determined. The percentage of CD8+ cells increased and the CD/D8 ratio decreased with tumour grade. The ratio of B lymphocytes decreased in patients with locoregional metastases (11.25% versus 9.22%). Treg (15.2%) and CD4+ cells (45.3%) increased, while NK cells (11.8%) decreased in HNSCC patients compared to controls (9.0%, 38.1% and 15.8%, respectively). The data obtained at time of diagnosis were used to assess the significance of tumour markers (SCC, Cyfra 21-1 and AAT) for evaluation of prognosis. The erythrocyte counts (4.64 x 1012/l versus 4.45 x 1012/l) and haemoglobin levels (14.58 g/dl versus 14.05 g/dl) decreased, while Treg counts (8.91% versus 15.70%) increased in patients with early recurrence. Our results show that examination of these parameters could be helpful for prognostication in HNSCC patients and aid improvement of treatment strategy.","[Boucek, Jan; Chovanec, Martin; Kuchar, Martin; Betka, Jaroslav; Betka, Jan] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Boucek, Jan; Mrkvan, Tomas; Betka, Jaroslav; Rihova, Blanka] ASCR, Inst Microbiol, Vvi, Prague, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Prague 15006 5, Czech Republic; [Hladikova, Marie] Charles Univ Prague, Dept Med Informat, Fac Med 2, Prague 15006 5, Czech Republic; [Boucek, Vladimir] Hosp Rudolf & Stephania Benesov, Dept Haematol & Blood transfus, Machova, Benesov, Czech Republic; [Chovanec, Martin] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 15006 5, Czech Republic; [Chovanec, Martin] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic","Boucek, J (reprint author), Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Univ Hosp Motol, Uvalu 84, Prague 15006 5, Czech Republic.","jboucek99@seznam.cz",null,null,"Czech Ministry of Health [grant NR 8883-3]; Ministry of Education, Youth and Sports of The Czech Republic [MSM 0021620813, 1M0505]; Institutional Research Concept [AV0Z50200510]","The research was supported by the Internal Grant Agency of the Czech Ministry of Health (grant NR 8883-3), by the Ministry of Education, Youth and Sports of The Czech Republic (Grant MSM 0021620813 and No. 1M0505) and by Institutional Research Concept AV0Z50200510.",null,39,17,18,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1582-1838",null,null,"J CELL MOL MED","J. Cell. Mol. Med.","JAN-FEB",2010,14,41671,null,null,null,null,426,433,null,"10.1111/j.1582-4934.2008.00650.x",null,8,"Cell Biology; Medicine, Research & Experimental","Cell Biology; Research & Experimental Medicine","569YV","WOS:000275639700037"]
[null,null,null,null,"J","Viero, C; Shibuya, I; Kitamura, N; Verkhratsky, A; Fujihara, H; Katoh, A; Ueta, Y; Zingg, HH; Chvatal, A; Sykova, E; Dayanithi, G",null,null,null,"Viero, Cedric; Shibuya, Izumi; Kitamura, Naoki; Verkhratsky, Alexei; Fujihara, Hiroaki; Katoh, Akiko; Ueta, Yoichi; Zingg, Hans H.; Chvatal, Alexandr; Sykova, Eva; Dayanithi, Govindan",null,null,"Oxytocin: Crossing the Bridge between Basic Science and Pharmacotherapy","CNS NEUROSCIENCE & THERAPEUTICS",null,null,"English","Review",null,null,null,null,null,"ACTH; Analgesics; Behavior; c-fos-mRFP1 fusion gene; CNS; Development; Drug design; eGFP; eCFP; Glial cells; Heart; HPA; Hypothalamus; Neurohypophysis; Neuropeptides; PNS; Receptors; Stress; Transgenic rat model; Vasopressin","GREEN FLUORESCENT PROTEIN; RAT SUPRAOPTIC NUCLEUS; STIMULATED ADRENOCORTICOTROPIN RELEASE; HYPOTHALAMIC-NEUROHYPOPHYSEAL SYSTEM; INTRACELLULAR TRANSDUCTION SIGNALS; CAVEOLIN-1 ENRICHED DOMAINS; RANDOMIZED CONTROLLED-TRIAL; VASOPRESSIN V-1A RECEPTORS; SPINAL-CORD SYNAPTOSOMES; ANTERIOR-PITUITARY-CELLS","P>Is oxytocin the hormone of happiness? Probably not. However, this small nine amino acid peptide is involved in a wide variety of physiological and pathological functions such as sexual activity, penile erection, ejaculation, pregnancy, uterus contraction, milk ejection, maternal behavior, osteoporosis, diabetes, cancer, social bonding, and stress, which makes oxytocin and its receptor potential candidates as targets for drug therapy. In this review, we address the issues of drug design and specificity and focus our discussion on recent findings on oxytocin and its heterotrimeric G protein-coupled receptor OTR. In this regard, we will highlight the following topics: (i) the role of oxytocin in behavior and affectivity, (ii) the relationship between oxytocin and stress with emphasis on the hypothalamo-pituitary-adrenal axis, (iii) the involvement of oxytocin in pain regulation and nociception, (iv) the specific action mechanisms of oxytocin on intracellular Ca2+ in the hypothalamo neurohypophysial system (HNS) cell bodies, (v) newly generated transgenic rats tagged by a visible fluorescent protein to study the physiology of vasopressin and oxytocin, and (vi) the action of the neurohypophysial hormone outside the central nervous system, including the myometrium, heart and peripheral nervous system. As a short nine amino acid peptide, closely related to its partner peptide vasopressin, oxytocin appears to be ideal for the design of agonists and antagonists of its receptor. In addition, not only the hormone itself and its binding to OTR, but also its synthesis, storage and release can be endogenously and exogenously regulated to counteract pathophysiological states. Understanding the fundamental physiopharmacology of the effects of oxytocin is an important and necessary approach for developing a potential pharmacotherapy.","[Dayanithi, Govindan] Acad Sci Czech Republic, Inst Expt Med, Lab Physiol Calcium Signaling,VVI, Dept Cellular Neurophysiol,CNRS,EU Ctr Excellence, Prague 14220 4, Czech Republic; [Viero, Cedric] Cardiff Univ, Sch Med, Dept Cardiol, Wales Heart Res Inst, Cardiff, S Glam, Wales; [Shibuya, Izumi; Kitamura, Naoki] Tottori Univ, Dept Vet Physiol, Tottori 680, Japan; [Verkhratsky, Alexei] Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; [Fujihara, Hiroaki; Katoh, Akiko; Ueta, Yoichi] Univ Occupat & Environm Hlth, Sch Med, Dept Physiol, Kitakyushu, Fukuoka 807, Japan; [Zingg, Hans H.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada; [Chvatal, Alexandr; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, EU Ctr Excellence, Prague 14220 4, Czech Republic","Dayanithi, G (reprint author), Acad Sci Czech Republic, Inst Expt Med, Lab Physiol Calcium Signaling,VVI, Dept Cellular Neurophysiol,CNRS,EU Ctr Excellence, Videnska 1083, Prague 14220 4, Czech Republic.","gdaya@univ-montp2.fr","Verkhratsky, Alexei/J-4527-2013","Verkhratsky, Alexei/0000-0003-2592-9898","Centre National de la Recherche Scientifique- France; Japanese Society for Promotion of Science [FY2008, S-08216]; Grant Agency of the Czech Republic [GACR 309/08/1381, GACR 305/08/1384, GACR 309/09/1597]; Academy of Sciences of the Czech Republic [AVOZ 50390512]; Ministry of Education, Youth and Sports of the Czech Republic [LC554, 1M0538]","G. Dayanithi is supported by the \"Centre National de la Recherche Scientifique\"- France, the Japanese Society for Promotion of Science Fellowship Program (#FY2008; S-08216), and research facilities from the Institute of Experimental Medicine of the Academy of Sciences of the Czech Republic. This work was supported by the Grant Agency of the Czech Republic grants GACR 309/08/1381, GACR 305/08/1384, and GACR 309/09/1597; the Academy of Sciences of the Czech Republic grant AVOZ 50390512 and the Ministry of Education, Youth and Sports of the Czech Republic grants LC554 and 1M0538. We are very grateful to James Dutt, IEM ASCR, Prague, for critical reading and language editing of the manuscript.",null,161,41,42,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1755-5930",null,null,"CNS NEUROSCI THER","CNS Neurosci. Ther.",null,2010,16,5,null,null,null,null,"e138","e156",null,"10.1111/j.1755-5949.2010.00185.x",null,19,"Neurosciences; Pharmacology & Pharmacy","Neurosciences & Neurology; Pharmacology & Pharmacy","647TY","WOS:000281643500001"]
[null,null,null,null,"J","Cauberg, ECC; Kloen, S; Visser, M; de la Rosette, JJMCH; Babjuk, M; Soukup, V; Pesl, M; Duskova, J; de Reijke, TM",null,null,null,"Cauberg, Evelyne C. C.; Kloen, Sarah; Visser, Mike; de la Rosette, Jean J. M. C. H.; Babjuk, Marko; Soukup, Viktor; Pesl, Michael; Duskova, Jaroslava; de Reijke, Theo M.",null,null,"Narrow Band Imaging Cystoscopy Improves the Detection of Non-muscle-invasive Bladder Cancer","UROLOGY",null,null,"English","Article",null,null,null,null,null,null,"TRANSITIONAL-CELL CARCINOMA; PHOTODYNAMIC DIAGNOSIS; 7 EORTC; RECURRENCE; GRADE","OBJECTIVES To determine whether narrow band imaging (NBI) improves detection of non-muscle-invasive bladder cancer over white-light imaging (WLI) cystoscopy. METHODS We conducted a prospective, within-patient comparison on 103 consecutive procedures on 95 patients scheduled for (re-) transurethral resection of a bladder tumor (84) or bladder biopsies (19) in the Academic Medical Center, Amsterdam (September 2007 - July 2009) and in the General Faculty Hospital, Prague (January 2009 - July 2009). WLI and NBI cystoscopy were subsequently performed by different surgeons who independently indicated all tumors and suspect areas on a bladder diagram. The lesions identified were resected/biopsied and sent for histopathological examination. Number of patients with additional tumors detected by WLI and NBI were calculated; mean number of urothelial carcinomas (UCs) per patient, detection rates, and false-positive rates of both techniques were compared. RESULTS A total of 78 patients had a confirmed UC; there were 226 tumors in total. In 28 (35.9%) of these patients, a total of 39 additional tumors (17.3%) (26pTa, 6pT1, 1pT2, 6pTis) were detected by NBI, whereas 4 additional tumors (1.8%) (1pTa, 1pT1, 2pTis) within 3 patients (2.9%) were detected by WLI. The mean (SD, range) number of UCs per patient identified by NBI was 2.1 (2.6, 0-15), vs 1.7 (2.3, 0-15) by WLI (P <.001). The detection rate of NBI was 94.7% vs 79.2% for WLI (P <.001). The false-positive rate of NBI and WLI was 31.6% and 24.5%, respectively (P <.001). CONCLUSIONS NBI cystoscopy improves the detection of primary and recurrent nonmuscle invasive bladder cancer over WLI. However, further validation of the technique with comparative studies is required. UROLOGY 76: 658-663, 2010. (c) 2010 Elsevier Inc.","Med Ctr, Dept Urol, Amsterdam, Netherlands; Med Ctr, Dept Pathol, Amsterdam, Netherlands; Charles Univ Prague, Gen Fac Hosp, Fac Med 1, Dept Urol, Prague, Czech Republic; Charles Univ Prague, Gen Fac Hosp, Fac Med 1, Dept Pathol, Prague, Czech Republic","Cauberg, ECC (reprint author), Univ Amsterdam, Acad Med Ctr, POB 22660, NL-1100 DD Amsterdam, Netherlands.","e.c.cauberg@amc.uva.nl",null,null,null,null,null,13,33,34,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0090-4295",null,null,"UROLOGY","Urology","SEP",2010,76,3,null,null,null,null,658,663,null,"10.1016/j.urology.2009.11.075",null,6,"Urology & Nephrology","Urology & Nephrology","649AD","WOS:000281736300048"]
[null,null,null,null,"J","Mattocks, CJ; Morris, MA; Matthijs, G; Swinnen, E; Corveleyn, A; Dequeker, E; Muller, CR; Pratt, V; Wallace, A",null,null,null,"Mattocks, Christopher J.; Morris, Michael A.; Matthijs, Gert; Swinnen, Elfriede; Corveleyn, Anniek; Dequeker, Els; Mueller, Clemens R.; Pratt, Victoria; Wallace, Andrew",null,"EuroGentest Validation Grp","A standardized framework for the validation and verification of clinical molecular genetic tests","EUROPEAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"validation; verification; molecular genetics; statistics; diagnostic","DIAGNOSTIC-ACCURACY; CONTAMINATION; DNA; PRECISION; PCR","The validation and verification of laboratory methods and procedures before their use in clinical testing is essential for providing a safe and useful service to clinicians and patients. This paper outlines the principles of validation and verification in the context of clinical human molecular genetic testing. We describe implementation processes, types of tests and their key validation components, and suggest some relevant statistical approaches that can be used by individual laboratories to ensure that tests are conducted to defined standards. European Journal of Human Genetics (2010) 18, 1276-1288; doi: 10.1038/ejhg.2010.101; published online 28 July 2010","[Mattocks, Christopher J.] Salisbury Dist Hosp, Natl Genet Reference Lab Wessex, Salisbury SP2 8BJ, Wilts, England; [Morris, Michael A.] CMU, Serv Genet Med, Mol Diagnost Lab, Geneva, Switzerland; [Matthijs, Gert; Swinnen, Elfriede; Corveleyn, Anniek; Dequeker, Els] Ctr Human Genet EuroGentest, Louvain, Belgium; [Mueller, Clemens R.] Univ Wurzburg, Dept Human Genet, Biozentrum, D-8700 Wurzburg, Germany; [Pratt, Victoria] Quest Diagnost Nichols Inst, Chantilly, VA USA; [Wallace, Andrew] St Marys Hosp, Natl Genet Reference Lab Manchester, Manchester M13 0JH, Lancs, England","Mattocks, CJ (reprint author), Salisbury Dist Hosp, Natl Genet Reference Lab Wessex, Odstock Rd, Salisbury SP2 8BJ, Wilts, England.","chris.mattocks@salisbury.nhs.uk","Bakker, Egbert/D-3525-2009",null,"Eurogentest; UK Department of Health","We thank Patrick M Bossuyt (Department of Clinical Epidemiology, Biostatistics & Bioinformatics, Amsterdam, The Netherlands), Ian Mann (Swiss Accreditation Service) and Paul Strike (Salisbury Foundation Trust, UK) for their help and advice, and Milan Macek Jr (Charles University, Prague) for hosting the meetings. This study was funded by Eurogentest and by the UK Department of Health.","Bossuyt PM, 2003, CLIN CHEM, V49, P1, DOI 10.1373/49.1.1; Camajova J, 2009, EUR J HUM GENET, V17, P537, DOI 10.1038/ejhg.2008.209; CAREY RN, 2005, EP15A2 NCCLS; *COFRAC, 2004, 04 LAB GTA COFRAC; Eurachem, FITN PURP AN METH LA; *EUROGENTEST, FP6512148 EU EUROGEN; European co-operation for Accreditation - EA, 2003, 416 EA; *EV STAND LAB STAN, QSOP23 COMM IN HOUS; GARRETT PE, 2008, EP12A2 NCCLS; Haddow J, 2003, HUMAN GENOME EPIDEMI, P217; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; Harper R, 1999, BRIT MED J, V318, P1322; HARTLEY JL, 1993, PCR METH APPL, V3, pS10; Hauck W.W., 2008, PHARMACOPEIAL FORUM, V34, P838; *INT ORG STAND, 353412006 ISO; *INT ORG STAND, 151952003 ISO; *INT VOC METR, 992007 ISOIEC INT VO; International Organization for Standardization, 2007, 15189 ISO; International Organization for Standardization, 170252005 ISOIEC; Jennings L, 2009, ARCH PATHOL LAB MED, V133, P743, DOI 10.1043/1543-2165-133.5.743; Jones SR, 2003, EMERG MED J, V20, P453, DOI 10.1136/emj.20.5.453; Krouwer JS, 2002, EP9A2 NCCLS; KROUWER JS, 2006, EP10A3 NCCLS; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; Maddalena A, 2005, GENET MED, V7, P571, DOI 10.1097/01.GIM.0000182738.95726.ca; Menditto A, 2007, ACCREDIT QUAL ASSUR, V12, P45, DOI 10.1007/s00769-006-0191-z; *MHRA, MHRA B, V20; Prence EM, 1999, GENET TEST, V3, P201, DOI 10.1089/gte.1999.3.201; Pruvost M, 2005, BIOTECHNIQUES, V38, P569, DOI 10.2144/05384ST03; Rumke C L, 1968, Triangle, V8, P284; Sivaganesan M, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-120; Tholen DW, 2003, EP6A NCCLS; Tholen D.W., 2004, EVALUATION PRECISION; Tholen DW, 2004, EP17A NCCLS; WALLACE A, 2006, MLPA ANAL SPREADSHEE; WILSON JA, 2008, MM17 CLSI; Zhang Z, 2000, J COMPUT BIOL, V7, P203, DOI 10.1089/10665270050081478",37,27,28,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,null,"EUR J HUM GENET","Eur. J. Hum. Genet.","DEC",2010,18,12,null,null,null,null,1276,1288,null,"10.1038/ejhg.2010.101",null,13,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","682CF","WOS:000284376800004"]
[null,null,null,null,"J","Van Calsteren, K; Verbesselt, R; Ottevanger, N; Halaska, M; Heyns, L; Van Bree, R; de Bruijn, E; Chai, D; Delforge, M; Noens, L; Renard, V; Witteveen, E; Rob, L; de Hoon, J; Amant, F",null,null,null,"Van Calsteren, Kristel; Verbesselt, Rene; Ottevanger, Nelleke; Halaska, Michael; Heyns, Liesbeth; Van Bree, Rieta; de Bruijn, Ernst; Chai, Daniel; Delforge, Michel; Noens, Lucien; Renard, Vincent; Witteveen, Els; Rob, Lukas; de Hoon, Jan; Amant, Frederic",null,null,"Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study","ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA",null,null,"English","Article",null,null,null,null,null,"Chemotherapy; pharmacokinetics; pregnancy; baboon","RENAL-FUNCTION; PACLITAXEL; TISSUES; FORMULA","Objective. To determine the impact of physiologic changes of pregnancy on pharmacokinetics of chemotherapeutic agents. Design. A preclinical and a clinical case-control trial. Setting. Institute of Primate Research Nairobi and collaborating hospitals in Belgium, the Netherlands and Czech Republic. Population. Pregnant and nonpregnant women and baboons receiving chemotherapy. Methods. Chemotherapy pharmacokinetics was compared between the pregnant and nonpregnant state. Standard-dosed chemotherapy regimens were administered in pregnant and nonpregnant baboons/women, followed by serial blood samplings. Drug plasma levels were determined using high performance liquid chromatography and atomic absorption spectrometry. Main outcome measures. Area under the curve (AUC), maximal plasma concentration, terminal elimination half-life, clearance and distribution volume of each drug in pregnant and nonpregnant state. Results. Intraindividual comparative pharmacokinetic data were obtained for doxorubicin and paclitaxel/platinum in three and two baboons, respectively. In the clinical trial, two patients were exposed to doxorubicin and one patient was exposed to paclitaxel/platinum during and after pregnancy. Furthermore, a pooled analysis was performed based on 16 cycles of pregnant and 11 cycles of nonpregnant women. Numbers of pregnant/nonpregnant patients were 5/2, 7/5, 4/4 and 2/2 for paclitaxel, doxorubicin, epirubicin and platinum, respectively. For all drugs tested in the preclinical and clinical study, a decreased AUC and maximal plasma concentration and an increased distribution volume and clearance were observed in pregnancy. Conclusions. Although numbers were too small for statistical significance, pregnancy-associated physiologic alterations appear to lead to a decrease in plasma exposure of chemotherapeutic drugs. The importance of long-term follow-up of women treated with chemotherapy during pregnancy is underscored.","[Amant, Frederic] Katholieke Univ Leuven, Leuven Canc Inst LKI, Dept Obstet & Gynecol, Div Gynecol Oncol,Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; [Verbesselt, Rene; de Hoon, Jan] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Ctr Clin Pharmacol, B-3000 Louvain, Belgium; [Ottevanger, Nelleke] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Halaska, Michael; Rob, Lukas] Charles Univ Prague, Dept Obstet & Gynecol, Div Gynecol Oncol, Fac Med 2, Prague, Czech Republic; [de Bruijn, Ernst] Katholieke Univ Leuven, Lab Med Oncol, Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; [Chai, Daniel] Natl Museums Kenya, Inst Primate Res, Dept Reprod Biol, Nairobi, Kenya; [Delforge, Michel] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Hematol, B-3000 Louvain, Belgium; [Noens, Lucien] Ghent Univ Hosp, Dept Hematol, B-9000 Ghent, Belgium; [Renard, Vincent] AZ Sint Lucas, Deparment Radiotherapy Oncol & Hematol, Ghent, Belgium; [Witteveen, Els] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands","Amant, F (reprint author), Katholieke Univ Leuven, Leuven Canc Inst LKI, Dept Obstet & Gynecol, Div Gynecol Oncol,Univ Hosp Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium.","Frederic.amant@uz.kuleuven.ac.be",null,null,"Research Foundation-Flanders (F.W.O.) [G. 0358.06]; Research Fund-K.U.Leuven [OT/07/053]; Clinical Research Fund University Hospital Gasthuisberg and Nationaal kankerplan [FOD NKP 29 038]","We are very grateful to Gunther Guetens and Sonia Demarsin for their assistance in the analyses. This research is supported by Research Foundation-Flanders (F.W.O.) [Project G. 0358.06], 'Stichting tegen kanker [Project SCIE2006-17], Research Fund-K.U.Leuven [OT/07/053], Clinical Research Fund University Hospital Gasthuisberg and Nationaal kankerplan [FOD NKP 29 038]. FA is clinical researcher for Research Foundation-Flanders (F.W.O.); KVC is aspirant for Research Foundation-Flanders (F.W.O.).",null,15,24,25,"TAYLOR & FRANCIS AS","OSLO","KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY","0001-6349",null,null,"ACTA OBSTET GYN SCAN","Acta Obstet. Gynecol. Scand.","OCT",2010,89,10,null,null,null,null,1338,1345,null,"10.3109/00016349.2010.512070",null,8,"Obstetrics & Gynecology","Obstetrics & Gynecology","664MD","WOS:000282963700016"]
[null,null,null,null,"J","Skirton, H; Lewis, C; Kent, A; Coviello, DA",null,null,null,"Skirton, Heather; Lewis, Celine; Kent, Alastair; Coviello, Domenico A.",null,"Eurogentest Unit 6; ESHG Educ Comm","Genetic education and the challenge of genomic medicine: development of core competences to support preparation of health professionals in Europe","EUROPEAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"genomics; professional education; competence","CARE; SERVICES","The use of genetics and genomics within a wide range of health-care settings requires health professionals to develop expertise to practise appropriately. There is a need for a common minimum standard of competence in genetics for health professionals in Europe but because of differences in professional education and regulation between European countries, setting curricula may not be practical. Core competences are used as a basis for health professional education in many fields and settings. An Expert Group working under the auspices of the EuroGentest project and European Society of Human Genetics Education Committee agreed that a pragmatic solution to the need to establish common standards for education and practice in genetic health care was to agree to a set of core competences that could apply across Europe. These were agreed through an exhaustive process of consultation with relevant health professionals and patient groups. Sets of competences for practitioners working in primary, secondary and tertiary care have been agreed and were approved by the European Society of Human Genetics. The competences provide an appropriate framework for genetics education of health professionals across national boundaries, and the suggested learning outcomes are available to guide development of curricula that are appropriate to the national context, educational system and health-care setting of the professional involved. Collaboration between individuals from many European countries and professions has resulted in an adaptable framework for both pre-registration and continuing professional education. This competence framework has the potential to improve the quality of genetic health care for patients globally. European Journal of Human Genetics (2010) 18, 972-977; doi:10.1038/ejhg.2010.64; published online 5 May 2010","[Skirton, Heather; Lewis, Celine] Univ Plymouth, Fac Hlth, Taunton TA1 5YD, Somerset, England; [Coviello, Domenico A.] Osped Maggiore Policlin, Fdn IRCCS, Milan, Italy","Skirton, H (reprint author), Univ Plymouth, Fac Hlth, Wellington Rd, Taunton TA1 5YD, Somerset, England.","heather.skirton@plymouth.ac.uk",null,null,"EU [FP6-512148]","We thank all members of the Unit 6 Experts Group who contributed at workshops in Porto, Portugal, in 2006 and Milan, Italy, in 2007. We are also grateful for all comments received from members of the European Society for Human Genetics and the EuroGentest project teams. This document was written by Heather Skirton and Celine Lewis with the support of Alastair Kent and Domenico Coviello. This study was funded by the EuroGentest Network of Excellence Project 2005 - EU Contract no. FP6-512148.","Burke S, 2006, GENET MED, V8, P109, DOI 10.1097/01.gim.0000200159.19920.b5; Burke S, 2006, J ADV NURS, V54, P228, DOI 10.1111/j.1365-2648.2006.03805.x; Caldwell Michael D, 2007, Clin Med Res, V5, P8, DOI 10.3121/cmr.2007.724; Cassiman JJ, 2005, EUR J HUM GENET, V13, P1103, DOI 10.1038/sj.ejhg.5201484; Christianson Carol A, 2005, J Allied Health, V34, P138; Constantin CM, 2005, J MIDWIFERY WOM HEAL, V50, P197, DOI 10.1016/j.jmwh.2005.01.001; Dudlicek Laura L, 2004, J Dent Educ, V68, P809; Epstein RM, 2002, JAMA-J AM MED ASSOC, V287, P226, DOI 10.1001/jama.287.2.226; Guttmacher AE, 2007, NAT REV GENET, V8, P151, DOI 10.1038/nrg2007; Kirk M, 2008, NURS HEALTH SCI, V10, P85, DOI 10.1111/j.1442-2018.2008.00374.x; Kirk M., 2003, FIT PRACTICE GENETIC; Kraft P, 2007, HUM HERED, V63, P111, DOI 10.1159/000099183; Lewis JA, 2006, MCN-AM J MATERN-CHIL, V31, P146, DOI 10.1097/00005721-200605000-00004; Lin IB, 2009, RURAL REMOTE HEALTH, V9; Ludlam CA, 2005, HAEMOPHILIA, V11, P145, DOI 10.1111/j.1365-2516.2005.01070.x; McCann S, 2004, J CANCER EDUC, V19, P225, DOI 10.1207/s15430154jce1904_9; Plasschaert Alphons, 2002, Eur J Dent Educ, V6 Suppl 3, P33, DOI 10.1034/j.1600-0579.6.s3.5.x; Schmidtke J, 2005, GENET TEST, V9, P80, DOI 10.1089/gte.2005.9.80; Skirton Heather, 2003, Community Genet, V6, P182, DOI 10.1159/000078167; Walton MM, 2006, MED J AUSTRALIA, V184, pS60; Wold JL, 2006, PUBLIC HEALTH NURS, V23, P139, DOI 10.1111/j.1525-1446.2006.230205.x",21,22,23,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,null,"EUR J HUM GENET","Eur. J. Hum. Genet.","SEP 10",2010,18,9,null,null,null,null,972,977,null,"10.1038/ejhg.2010.64",null,6,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","641ID","WOS:000281117400003"]
[null,null,null,null,"J","Hlavata, I; Vrana, D; Smerhovsky, Z; Pardini, B; Naccarati, A; Vodicka, P; Novotny, J; Mohelnikova-Duchonova, B; Soucek, P",null,null,null,"Hlavata, Ivona; Vrana, David; Smerhovsky, Zdenek; Pardini, Barbara; Naccarati, Alessio; Vodicka, Pavel; Novotny, Jan; Mohelnikova-Duchonova, Beatrice; Soucek, Pavel",null,null,"Association between exposure-relevant polymorphisms in CYP1B1,EPHX1,NQ01,GSTM1,GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population","ONCOLOGY REPORTS",null,null,"English","Article",null,null,null,null,null,"colorectal cancer; cytochrome P450; glutathione S-transferase; polymorphism; risk","S-TRANSFERASE M1; BODY-MASS INDEX; COLON-CANCER; GENETIC POLYMORPHISMS; EPOXIDE HYDROLASE; CIGARETTE-SMOKING; METAANALYSIS; GSTM1; SUSCEPTIBILITY; EXPRESSION","Associations of functional single nucleotide polymorphisms in cytochrome P450 1B1, epoxide hydrolase 1, NAD(P)H:quinone oxidoreductase 1, glutathione S-transferase Pi-1 and deletions of glutathione S-transferases Mu-1 and theta-1 with colorectal cancer risk were investigated in a hospital-based case-control study on 495 matched pairs of Czech Caucasians. Polymorphisms were assessed by polymerase chain reaction restriction fragment length polymorphism-based methods, allele-specific multiplex and allelic discrimination by real-time polymerase chain reaction. Carriers of variant Ser allele in codon 453 of cytochrome P450 1B1 (rs1800440) were at a significantly lower risk of colorectal cancer compared to carriers of the wild-type allele (adjusted odds ratio, aOR=0.68. CI=0.51-0.89, p=0.006). The combination of polymorphisms in codons 453 and 432 (rs1056836) of cytochrome P450 I B I further increased the protective effect (aOR=0.53, CI=0.34-0.83, p=0.005). The glutathione S-transferase Mu-1 deletion was associated with a moderately elevated colorectal cancer risk (aOR=1.30, CI=1.01-1.68, p=0.044). Combination of glutathione S-transferase Mu-1 and theta-1 deletion was associated with a significantly higher colorectal cancer risk compared to the presence of both full-length genes (aOR=1.58, CI=1.01-2.47, p=0.044). Genetic polymorphisms in glutathione S-transferase Pi-1, NAD(P)H:quinone oxidoreductase 1, epoxide hydrolase 1 and deduced epoxid hydrolase 1 activity did not modify the risk of colorectal cancer. These results provide further evidence that interaction between metabolic gene variants contributes to colorectal carcinogenesis.","[Hlavata, Ivona; Vrana, David; Smerhovsky, Zdenek; Mohelnikova-Duchonova, Beatrice; Soucek, Pavel] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042, Czech Republic; [Hlavata, Ivona] Charles Univ Prague, Fac Med 3, Prague 10000, Czech Republic; [Novotny, Jan] Charles Univ Prague, Fac Med 1, Prague 12108, Czech Republic; [Vrana, David; Mohelnikova-Duchonova, Beatrice] Gen Teaching Hosp, Fac Med 1, Prague 12108, Czech Republic; [Novotny, Jan] Gen Teaching Hosp, Dept Oncol, Prague 12108, Czech Republic; [Vrana, David] Hosp Atlas, Dept Med, Zlin 76001, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Inst Epidemiol, Prague 15006, Czech Republic; [Pardini, Barbara; Naccarati, Alessio; Vodicka, Pavel] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague 14220, Czech Republic","Soucek, P (reprint author), Natl Inst Publ Hlth, Toxicogenom Unit, Srobarova 48, Prague 10042, Czech Republic.","psoucek@szu.cz",null,null,"Internal Grant Agency of the Czech Ministry of Health [IGA 10230-3]; Czech Science Foundation [GACR 310/07/1430]; Grant Agency of Charles University [GAUK 15109/2009]","The authors are grateful to Simona Susova, Ing, from the National Institute of Public Health, Prague Czech Republic, for taking part in genotyping analyses. The study was supported by grants of the Internal Grant Agency of the Czech Ministry of Health, no. IGA 10230-3, the Czech Science Foundation no. GACR 310/07/1430 and the Grant Agency of Charles University no. GAUK 15109/2009.",null,47,20,21,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1021-335X",null,null,"ONCOL REP","Oncol. Rep.","NOV",2010,24,5,null,null,null,null,1347,1353,null,"10.3892/or_0000992",null,7,"Oncology","Oncology","666JX","WOS:000283112200031"]
[null,null,null,null,"J","Mehta, G; Macek, M; Mehta, A",null,null,null,"Mehta, Gita; Macek, Milan, Jr.; Mehta, Anil",null,"European Registry Working Grp","Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Article",null,null,null,null,null,"Database; Rare disease; Geography; Chronic disease; Genetics; p.Phe508del; CFTR","UK; POPULATION; AGE; SEGREGATION; MUTATIONS; MORTALITY; SURVIVAL; OUTCOMES; CF","Background: A 35 country European cystic fibrosis (CF) demographic registry was developed to compare outcomes (EuroCareCF EC-FP6). Methods: We applied methods that had successfully created country-specific registries inviting wide participation to obtain consent and collate demographic and CFTR genotype data. Results: Among 29,095 patients, a widely different country-specific prevalence of childhood CF exists that cannot be explained by differential population frequency of mutant-CFTR or case under-ascertainment with a significant paucity of the homozygous p.Phe508del genotype that presents in childhood in >90% of cases. Conclusions: Excess premature childhood CF mortality may still occur. The better resourced Western Europe now has a similar to 5% mortality for childhood CF, which is not apparent in many of the European countries reported here. In addition, a female survival disadvantage exists. The reasons require further investigation. We showcase the value of simple data collection in one rare disease, which might interest those managing rare diseases across the globe. (C) 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Mehta, Gita; Mehta, Anil] Univ Dundee, Div Med Sci, Dundee DD1 9SY, Scotland; [Macek, Milan, Jr.] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, CZ-15006 Prague, Czech Republic; [Macek, Milan, Jr.] Univ Hosp, CZ-15006 Prague, Czech Republic","Mehta, A (reprint author), Univ Dundee, Div Med Sci, Dundee DD1 9SY, Scotland.","a.mehta@dundee.ac.uk",null,null,"European Commission; European Community [LSHM-CT-2005-018932]; MZOFNM","Funding from the European Commission for the EuroCareCF project is gratefully acknowledged, as also is help from the project Scientific Coordinator, D.N. Sheppard (Bristol, UK), as this has allowed this wide-ranging project, encompassing so many countries in Europe, to be set up for the first time. EuroCareCF was supported by the European Community's Sixth Framework Programme for Research, priority 1 \"Life Sciences, Genomics and Biotechnology for Health\", contract number LSHM-CT-2005-018932. We also acknowledge the support of MZOFNM2005 to MM.",null,29,18,19,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","DEC",2010,9,null,null,2,null,null,"S5","S64",null,"10.1016/j.jcf.2010.08.002",null,60,"Respiratory System","Respiratory System","717QG","WOS:000287061900003"]
[null,null,null,null,"J","Jakabcin, J; Spacek, R; Bystron, M; Kvasnak, M; Jager, J; Veselka, J; Kala, P; Cervinka, P",null,null,null,"Jakabcin, Jozef; Spacek, Radim; Bystron, Marian; Kvasnak, Martin; Jager, Jiri; Veselka, Josef; Kala, Petr; Cervinka, Pavel",null,null,"Long-Term Health Outcome and Mortality Evaluation After Invasive Coronary Treatment Using Drug Eluting Stents with or without the IVUS Guidance. Randomized Control Trial. HOME DES IVUS","CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS",null,null,"English","Article",null,null,null,null,null,null,"BARE-METAL STENTS; INTRAVASCULAR ULTRASOUND ANALYSIS; ARTERY-DISEASE; DOUBLE-BLIND; FOLLOW-UP; IMPLANTATION; THROMBOSIS; RISK; 6-MONTH; LESIONS","Objective: To assess the role of the intravascular ultrasound (IVUS) during implantation of Drug-eluting stents (DES) on long-term outcome in patients with complex coronary artery disease and high clinical risk profile with special attention to the development of late stent thrombosis (LST). Methods: Two hunderd and ten patients were randomly assigned to receive DES either with (N = 105) or without (N = 105) the IVUS guidance. Dual antiplatelet treatment was administered for 6 months in all patients. At 18-month follow-up, the rates of Major adverse cardiac events (MACEs) (death, myocardial infarction, and reintervention) were assessed in both groups with special attention to possible LST. Stent thrombosis was classified according to Academic Research Consortium (ARC). Results: At the 18-month follow-up, there was no significant difference between both groups regarding MACE (11% vs. 12%; P = NS). Stent thrombosis has occurred in four patients (3.8%) in the group with and in 6 patients (5.7%; P = NS) in the group without the IVUS guidance. Conclusions: In our randomized trial we failed to demonstrate the superiority of the IVUS guidance during DES implantation over standard high-pressure postdilatation. However we confirmed worrisome results concerning DES thrombosis after discontinuation of dual antiplatelet-treatment with documented stent thrombosis related events in almost 5% of patients with 50% of mortality in this high-risk clinical scenario. (C) 2009 Wiley-Liss, Inc.","[Jakabcin, Jozef; Spacek, Radim; Bystron, Marian; Kvasnak, Martin; Jager, Jiri; Cervinka, Pavel] Masaryk Hosp, Dept Cardiol, Usti Nad Labem, Czech Republic; [Veselka, Josef] Fac Hosp Motol, Dept Cardiol, Prague, Czech Republic; [Kala, Petr] Fac Hosp, Cardiovasc Dept, Brno, Czech Republic","Cervinka, P (reprint author), Socialni Pece 3316-12A, Usti Nad Labem 40113, Czech Republic.","Pavel.Cervinka@mnul.cz",null,null,null,null,null,25,22,26,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1522-1946",null,null,"CATHETER CARDIO INTE","Catheter. Cardiovasc. Interv.","MAR 1",2010,75,4,null,null,null,null,578,583,null,"10.1002/ccd.22244",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","582HW","WOS:000276588600021"]
[null,null,null,null,"J","Hirche, TO; Bradley, J; d'Alquen, D; De Boeck, K; Dembski, B; Elborn, JS; Gleiber, W; Lais, C; Malfroot, A; Wagner, TF",null,null,null,"Hirche, T. O.; Bradley, J.; d'Alquen, D.; De Boeck, K.; Dembski, B.; Elborn, J. S.; Gleiber, W.; Lais, C.; Malfroot, A.; Wagner, T. F.",null,"European Ctr Reference Network Cys","Travelling with cystic fibrosis Recommendations for patients and care team members","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Review",null,null,null,null,null,"Cystic fibrosis; Travelling; Holidays; Vacation","OBSTRUCTIVE PULMONARY-DISEASE; HYPOXIA INHALATION TEST; AIR-TRAVEL; PSEUDOMONAS-AERUGINOSA; HIGH-ALTITUDE; BURKHOLDERIA-PSEUDOMALLEI; TRANSPLANT RECIPIENTS; EUROPEAN CONSENSUS; SUMMER CAMPS; HYPOXEMIA","There are no European Guidelines on issues specifically related to travel for people with cystic fibrosis (CF) The contributors to these recommendations included 30 members of the ECORN-CF project The document is endorsed by the European Cystic Fibrosis Society and sponsored by the Executive Agency of Health and Consumers of the European Union and the Christiane Herzog Foundation The main goal of this paper is to provide patient oriented advice that complements medical aspects by offering practical suggestions for all aspects involved in planning and taking a trip The report consists of three main sections preparation for travel, important considerations during travel and at the destination, and issues specific to immunocompromised travellers People with CF should be encouraged to consult with their CF, centre prior to travel to another country The CF centre can advise on the necessary preparation for travel the need for vaccinations, essential medications that should be brought on the trip and also provide information relating to CF care in the region and plan of action in case of an emergency (C) 2010 European Cystic Fibrosis Society Published by Elsevier B V All rights reserved","[Hirche, T. O.] German Clin Diagnost DKD, Dept Pulm Med, Wiesbaden, Germany; [Bradley, J.] Univ Ulster, Hlth & Rehabil Sci Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland; [d'Alquen, D.] Univ Hosp, Dept Pediat, Wurzburg, Germany; [De Boeck, K.] Univ Hosp, Dept Pediat, Louvain, Belgium; [Dembski, B.] CF Europe Bonn & CF Assoc, Bonn, Germany; [Elborn, J. S.] Queens Univ Belfast, Ctr Infect & Immun, Belfast BT7 1NN, Antrim, North Ireland; [Gleiber, W.; Lais, C.; Wagner, T. F.] Goethe Univ Hosp, Dept Pneumol, Frankfurt, Germany; [Malfroot, A.] UZB, Cyst Fibrosis Clin, Brussels, Belgium","Wagner, TF (reprint author), Frankfurt Univ Hosp, Dept Pneumol, Theodor Stern Kai 7,Bldg 15B, D-60590 Frankfurt, Germany.",null,null,null,"European Community","This document is the result of the \"European Centres of Reference Network for Cystic Fibrosis\" (ECORN-CF) project, which was co-funded by the European Community from May 1, 2007 until April 30, 2010 The aim of the project has been to allow patients and care team members easy access to expert knowledge and advice on cystic fibrosis via an internet-based platform All collaborating partner countries provide expert advice to their patients and care team members in their mother language on a local website After translation of questions and answers into English and a quality check, they are published in a Central Archive with open access for everybody who is interested ir the topic (www ecorn-cf eu) Thus, there is a transfer of knowledge and expertise throughout Europe that guarantees the same level of expert advice in all partner countries Furthermore the program aimed to extract data on deficits in existing guidelines or lack of evidence-based guidelines and to find a European consensus for care of CF patients where it is necessary Special thanks go to Annette Pfalz and Sophie Buchberger for the outstandingly smooth coordination of the whole project and the organization of the consensus meetings Furthermore, the authors are thankful to the Executive Agency of Health and Consumers of the European Union, the European Cystic Fibrosis Society and the Christiane Herzog Foundation for the continuous support of the ECORN-CF project which was the basis for the preparation of this document","Aerospace Medical Association Medical Guidelines Task Force, 2003, AVIAT SPACE ENVIR S, V74, pA1; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/air-ccm/136.1.225; Avery RK, 2008, AM J TRANSPLANT, V8, P9, DOI 10.1111/j.1600-6143.2007.02051.x; Barben Juerg, 2005, J Cyst Fibros, V4, P227, DOI 10.1016/j.jcf.2005.06.003; BAROR O, 1992, LANCET, V339, P696, DOI 10.1016/0140-6736(92)90597-V; Blau H, 2002, CHEST, V121, P1117, DOI 10.1378/chest.121.4.1117; Brimicombe RW, 2008, J CYST FIBROS, V7, P30, DOI 10.1016/j.jcf2007.04.002; Coker RK, 2002, THORAX, V57, P289; Buchdahl RM, 2001, THORAX, V56, P877, DOI 10.1136/thorax.56.11.877; Castellani C, 2008, J CYST FIBROS, V7, P179, DOI 10.1016/j.jcf.2008.03.009; Christensen CC, 2000, EUR RESPIR J, V15, P635, DOI 10.1183/09031936.00.15463500; Cogo A, 2004, HIGH ALT MED BIOL, V5, P435, DOI 10.1089/ham.2004.5.435; *CYST FIBR WORLDW, 2008, C M ANT INF REQ PEOP; *CYST FIBR WORLDW, 2008, HYG GUID PEOPL CYST; DANKS DM, 1962, BRIT MED J, V1, P287; DESCHUTTER I, 2007, J CYST FIBROS S, V6, pS96, DOI 10.1016/S1569-1993(07)60361-0; DHAR JM, 1991, Q J MED, V78, P235; DILLARD TA, 1991, ARCH INTERN MED, V151, P1793, DOI 10.1001/archinte.151.9.1793; DILLARD TA, 1995, CHEST, V107, P352, DOI 10.1378/chest.107.2.352; DILLARD TA, 1993, CHEST, V103, P422, DOI 10.1378/chest.103.2.422; DILLARD TA, 1989, ANN INTERN MED, V111, P362; Doring Gerd, 2004, J Cyst Fibros, V3, P67, DOI 10.1016/j.jcf.2004.03.008; Doring G, 2000, EUR RESPIR J, V16, P749, DOI 10.1034/j.1399-3003.2000.16d30.x; Doring Gerd, 2007, J Cyst Fibros, V6, P85, DOI 10.1016/j.jcf.2007.02.001; Fischer R, 2005, EUR RESPIR J, V25, P718, DOI 10.1183/09031936.05.10087304; Fluge G, 2001, CLIN MICROBIOL INFEC, V7, P238, DOI 10.1046/j.1469-0691.2001.00247.x; GONG H, 1989, ANN INTERN MED, V111, P349; GONG H, 1992, CHEST, V101, P1104, DOI 10.1378/chest.101.4.1104; GONG H, 1991, J ALLERGY CLIN IMMUN, V87, P879, DOI 10.1016/0091-6749(91)90137-D; GONG H, 1993, CHEST, V104, P788, DOI 10.1378/chest.104.3.788; GRUBER W, 2004, ARBEITSKREIS SPORT M; Gumbo T, 1999, TRANSPLANTATION, V67, P482, DOI 10.1097/00007890-199902150-00024; Haworth CS, 1999, THORAX, V54, P961; Haworth CS, 1998, J ROY SOC MED, V91, P14; Hebestreit H, 2000, DTSCH Z SPORTMED, V51, P85; Holland DJ, 2002, CLIN INFECT DIS, V35, pE138, DOI 10.1086/344447; Kelly PT, 2008, CHEST, V133, P920, DOI 10.1378/chest.07-1483; Kerem Eitan, 2005, J Cyst Fibros, V4, P7, DOI 10.1016/j.jcf.2004.12.002; KESSLER WR, 1951, PEDIATRICS, V8, P648; Kriemler S, 1999, MED SCI SPORT EXER, V31, P774, DOI 10.1097/00005768-199906000-00003; Lim E, 2001, LUPUS, V10, P87, DOI 10.1191/096120301675973164; MALFROOT A, 2005, J CYST FIBROS S, V4; Malfroot Anne, 2005, J Cyst Fibros, V4, P77, DOI 10.1016/j.jcf.2004.10.003; Mayell SJ, 2009, J CYST FIBROS, V8, P71, DOI 10.1016/j.jcf.2008.09.005; Moorcroft AJ, 1998, DISABIL REHABIL, V20, P247; Moore JE, 2008, VET REC, V163, P399; Moore J E, 2002, Commun Dis Public Health, V5, P23; Murphy D, 2006, RESPIRATION, V73, P113, DOI 10.1159/000087948; MUSSION H, 2004, STAFF PATIENTS MANCH; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V152, P1956; OADES PJ, 1994, BRIT MED J, V308, P15; O'Carroll MR, 2003, THORAX, V58, P1087, DOI 10.1136/thorax.58.12.1087; Orenstein D. M., 2003, CYSTIC FIBROSIS GUID; ORENSTEIN DM, 1984, J APPL PHYSIOL, V57, P408; ORENSTEIN DM, 1983, PEDIATR RES, V17, P267, DOI 10.1203/00006450-198304000-00007; ORENSTEIN DM, 1995, SPORTS EXERCISE CHIL, P167; Peckham D, 2002, J Cyst Fibros, V1, P281, DOI 10.1016/S1569-1993(02)00100-5; PEGUES DA, 1994, J PEDIATR, V124, P694, DOI 10.1016/S0022-3476(05)81357-5; Rose D M, 2000, Eur J Med Res, V5, P9; Ruf K, 2009, J CYST FIBROS, V8, P83, DOI 10.1016/j.jcf.2008.09.008; Seccombe LM, 2004, THORAX, V59, P966, DOI 10.1136/thx.2004.022210; Sinaasappel M, 2002, J Cyst Fibros, V1, P51, DOI 10.1016/S1569-1993(02)00032-2; SPEECHLYDICK ME, 1992, RESP MED, V86, P55, DOI 10.1016/S0954-6111(06)80150-2; Thews O, 2004, EUR J APPL PHYSIOL, V92, P493, DOI 10.1007/s00421-004-1106-5; Van Damme P, 2001, J MED VIROL, V65, P6, DOI 10.1002/jmv.1094.abs; van der Meer H, 1996, Ned Tijdschr Geneeskd, V140, P1402; Verma A, 2000, J ROY SOC MED, V93, P20; Visca P, 2001, CLIN INFECT DIS, V32, pE15, DOI 10.1086/317528; WAISMAN Y, 1991, Pediatric Emergency Care, V7, P157, DOI 10.1097/00006565-199106000-00008; Webb AK, 1999, BRIT J SPORT MED, V33, P77; *WHO, 2008, COUNTRY LIST YELL FE; WILLIAMS AJ, 1976, BRIT MED J, V2, P297; World Health Organization, 2009, WHO VACC PREV DIS MO",73,3,3,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","DEC",2010,9,6,null,null,null,null,385,399,null,"10.1016/j.jcf.2010.08.013",null,15,"Respiratory System","Respiratory System","699ZI","WOS:000285701500002"]
[null,null,null,null,"J","Frederic, A; Sarah, D; Kristel, V; Sibylle, L; Michael, H; Lieselot, B; Jos, B; Fatima, C; Oreste, G; Lieven, L; Olivier, M; Patrick, N; Nelleke, O; Steven, P; Fedro, P; Roman, R; Hans-Jorg, S; Henk, S; Marie-Rose, C; David, C; Andreas, D",null,null,null,"Frederic, Amant; Sarah, Deckers; Kristel, Van Calsteren; Sibylle, Loibl; Michael, Halaska; Lieselot, Brepoels; Jos, Beijnen; Fatima, Cardoso; Oreste, Gentilini; Lieven, Lagae; Olivier, Mir; Patrick, Neven; Nelleke, Ottevanger; Steven, Pans; Fedro, Peccatori; Roman, Rouzier; Hans-Joerg, Senn; Henk, Struikmans; Marie-Rose, Christiaens; David, Cameron; Andreas, Du Bois",null,null,"Breast cancer in pregnancy: Recommendations of an international consensus meeting","EUROPEAN JOURNAL OF CANCER",null,null,"English","Review",null,null,null,null,null,"Cancer; Pregnancy; Breast; Guideline; Consensus; Chemotherapy; Radiotherapy; Surgery; Biological","CHEMOTHERAPY IN-UTERO; ANTENATAL CORTICOSTEROIDS; NONOBSTETRIC SURGERY; HUMAN PLACENTA; TRASTUZUMAB; RADIOTHERAPY; CARCINOMA; OUTCOMES; TAMOXIFEN; RADIATION","Purpose: To provide guidance for clinicians about the diagnosis, staging and treatment of breast cancer occurring during an otherwise uncomplicated pregnancy. Methods: An international expert Panel convened to address a series of questions identified by a literature review and personal experience. Issues relating to the diagnosis and management of breast cancer after delivery were outside the scope. Results: There is a paucity of large and/or randomized studies. Based on cohort studies, case series and case reports, the recommendations represent the best available evidence, albeit of a lower grade than is optimal. Recommendations: In most circumstances, serious consideration should be given to the option of treating breast cancer whilst continuing with the pregnancy. Each woman should ideally be referred to a centre with sufficient expertise, given a clear explanation of treatment options. Most diagnostic and staging examinations can be performed adequately and safely during pregnancy. Treatment should however be adapted to the clinical presentation and the trimester of the pregnancy: surgery can be performed during all trimesters of pregnancy; radiotherapy can be considered during the first and second trimester but should be postponed during the third trimester; and standard chemotherapies can be used during the second and third trimester. Since neonatal morbidity mainly appears to be related to prematurity, delivery should not be induced before 37 weeks, if at all possible. Conclusions: The treatment of breast cancer in pregnancy should be executed by experienced specialists in a multidisciplinary setting and should adhere as closely as possible to standard protocols. (C) 2010 Elsevier Ltd. All rights reserved.","[Frederic, Amant] Katholieke Univ Leuven, Div Gynecol Oncol, Dept Obstet & Gynecol, Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; [Frederic, Amant; Patrick, Neven; Marie-Rose, Christiaens] Katholieke Univ Leuven, Multidisciplinary Breast Ctr, Leuven Canc Inst LKI, UZ Gasthuisberg, B-3000 Louvain, Belgium; [Sibylle, Loibl] Ambulantes Krebszentrum Frankfurt, German Breast Grp, Dept Med, Frankfurt, Germany; [Sibylle, Loibl] Ambulantes Krebszentrum Frankfurt, Dept Res, Frankfurt, Germany; [Michael, Halaska] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Lieselot, Brepoels] Univ Hosp Gasthuisberg, Nucl Med, Leuven, Belgium; [Jos, Beijnen] Slotervaart Hosp, Netherlands Canc Inst, Amsterdam, Netherlands; [Fatima, Cardoso] Bordet Inst, Brussels, Belgium; [Oreste, Gentilini] European Inst Oncol, Breast Surg Unit, Milan, Italy; [Olivier, Mir] Paris Descartes Univ, French CALG Grp Cancers Associes La Grosesse, Paris, France; [Nelleke, Ottevanger] Radboudziekenhuis, Nijmegen, Netherlands; [Fedro, Peccatori] European Inst Oncol, Dept Med, Div Hematol Oncol, Milan, Italy; [Roman, Rouzier] Hop Tenon, French CALG Grp Canc Associes La Grosesse, F-75970 Paris, France; [Hans-Joerg, Senn] Tumor & Breast Ctr ZeTuP, St Gallen, Schweiz, Switzerland; [Henk, Struikmans] Medisch Ctr Haaglanden, The Hague, Netherlands; [David, Cameron] Western Gen Hosp, Ctr Canc, Edinburgh, Midlothian, Scotland; [David, Cameron] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland; [Andreas, Du Bois] Dr Horst Schmidt Klin, Cooperat Breast Ctr, Dept Gynecol & Gynecol Oncol, Wiesbaden, Germany","Frederic, A (reprint author), Katholieke Univ Leuven, Div Gynecol Oncol, Dept Obstet & Gynecol, Univ Hosp Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium.","Frederic.amant@uz.kuleuven.ac.be",null,null,null,null,null,90,0,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0959-8049",null,null,"EUR J CANCER","Eur. J. Cancer","DEC",2010,46,18,null,null,null,null,3158,3168,null,"10.1016/j.ejca.2010.09.010",null,11,"Oncology","Oncology","701IY","WOS:000285812800013"]
[null,null,null,null,"J","Hrebackova, J; Hrabeta, J; Eckschlager, T",null,null,null,"Hrebackova, J.; Hrabeta, J.; Eckschlager, T.",null,null,"Valproic Acid in the Complex Therapy of Malignant Tumors","CURRENT DRUG TARGETS",null,null,"English","Review",null,null,null,null,null,"Valproic acid; histone deacetylase inhibitors; antiangiogenic effect; anticancer effect; clinical studies","HISTONE DEACETYLASE INHIBITORS; ACUTE MYELOID-LEUKEMIA; TRANS-RETINOIC ACID; NITRIC-OXIDE SYNTHASE; HUMAN NEUROBLASTOMA-CELLS; HEMATOPOIETIC STEM-CELLS; PROSTATE-CANCER CELLS; GROWTH IN-VITRO; NF-KAPPA-B; GENE-EXPRESSION","Valproic acid (VPA) has been used for epilepsy treatment since the 1970s. Recently, it was demonstrated that it inhibits histone deacetylases (HDAC), modulates cell cycle, induces tumor cell death and inhibits angiogenesis in various tumor models. The exact anticancer mechanisms of VPA remains unclear, but HDAC inhibition, extracellular-regulated kinase activation, protein kinase C inhibition, Wnt-signaling activation, proteasomal degradation of HDAC, possible downregulation of telomerase activity and DNA demethylation participate in its anticancer effect. Hyperacetylation of histones, as a result of HDAC inhibition, seems to be the most important mechanism of VPA's antitumor action. Preclinical data suggest that the anticancer effect of chemotherapy is augmented when VPA is used in combination with cytostatics. Besides the effects of pretreatment with HDAC inhibitors, which increases the efficiency of 5-aza-2'-deoxycytidine, VP-16, ellipticine, doxorubicin and cisplatin, pre-exposure to VPA increases the cytotoxicity of topoisomerase II inhibitors. There are two suggested cell death mechanisms caused by potentiation of anticancer drugs by HDAC inhibitors that are neither exclusive nor synergistic. The first involves apoptosis and can be both p53 dependent or independent; the second involves mechanisms other than apoptosis. In resistant chronic myeloid leukemia (CML), VPA restores sensitivity to imatinib. We have demonstrated the synergistic effects of VPA and cisplatin in neuroblastoma cells. VPA can be taken orally, crosses the blood brain barrier and can be used for extended periods. Clinical trials in patients with malignancies are being conducted. The use of VPA prior to or together with anticancer drugs may thus prove a beneficial treatment.","[Eckschlager, T.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Eckschlager, T (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","eckschlagertomas@yahoo.com",null,null,"Ministry of Health of the Czech Republic [NR9522-3/2007]; Ministry of Education of the Czech Republic [MSM0021620813]","Research on VPA at the Department of Pediatric Hematology and Oncology, 2<SUP>nd</SUP> Faculty of Medicine, Charles University, Prague is supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic (grant NR9522-3/2007) and the Ministry of Education of the Czech Republic (grants MSM0021620813).",null,165,22,25,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","1389-4501",null,null,"CURR DRUG TARGETS","Curr. Drug Targets","MAR",2010,11,3,null,null,null,null,361,379,null,null,null,19,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","554FB","WOS:000274419800010"]
[null,null,null,null,"J","Barinka, F; Druga, R; Marusic, P; Krsek, P; Zamecnik, J",null,null,null,"Barinka, Filip; Druga, Rastislav; Marusic, Petr; Krsek, Pavel; Zamecnik, Josef",null,null,"Calretinin immunoreactivity in focal cortical dysplasias and in non-malformed epileptic cortex","EPILEPSY RESEARCH",null,null,"English","Article",null,null,null,null,null,"Epilepsy; Cortical dysplasia; Calretinin; Inhibitory interneurons","CALCIUM-BINDING PROTEINS; LOCAL-CIRCUIT NEURONS; HUMAN TEMPORAL CORTEX; CAJAL-RETZIUS CELLS; PREFRONTAL CORTEX; ALZHEIMERS-DISEASE; CALBINDIN D-28K; SYNAPTIC CONNECTIONS; HUMAN NEOCORTEX; PARVALBUMIN","Focal cortical dysplasias (FCDs) represent a prominent cause of pharmacologically intractable epilepsy. In FCD, the decrease of parvalbumin immunoreactive (PV+) inhibitory interneurons has been repeatedly documented. Here, we wanted to show whether another interneuronal population, the calretinin immunoreactive (CR+) neurons, exhibits any change in human FCD. We also investigated samples of morphologically normal temporal neocortex resected together with sclerotic hippocampus (nHSTN), where decrease of PV+ interneurons was previously documented as well Brain tissue from 24 patients surgically treated for pharmacoresistant epilepsy was examined. Calretinin immunoreactivity was qualitatively evaluated and the density of CR+ neuronal profiles was quantified. As a control, post-mortem acquired neocortical samples of nine patients without any brain affecting disease were used. CR+ neurons were located predominantly in superficial cortical layers both in controls and pathological samples. Similarly, the morphology of CR+ neurons was unaffected in pathological samples. The overall density of CR+ neurons was significantly decreased in FCD type I (to approximately 70% of control values) and even more in FCD type II (to approximately 50% of controls). In nHSTN, no change compared to controls was found in CR+ neuronal density. Our results may contribute to the better understanding of the role of individual interneuronal populations in epileptogenesis. (C) 2009 Elsevier B.V. All rights reserved.","[Barinka, Filip; Druga, Rastislav] Charles Univ Prague, Dept Anat, Fac Med 2, Prague 12800, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Dept Anat, Fac Med 1, Prague 12800, Czech Republic; [Marusic, Petr] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague 12800, Czech Republic; [Marusic, Petr] Charles Univ Prague, Dept Neurosurg, Fac Med 1, Prague 12800, Czech Republic; [Krsek, Pavel] Charles Univ Prague, Dept Paediat Neurol, Fac Med 2, Prague 12800, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 12800, Czech Republic","Barinka, F (reprint author), Charles Univ Prague, Dept Anat, Fac Med 2, U Nemocnice 3, Prague 12800, Czech Republic.","filipbarinka@yahoo.co.uk",null,null,"Agency of Charles University [35407]; Ministry of Health of the Czech Republic: IGA MZCR [NS/9915-4, NR/8843-4, VZ FNM 00064203]","This work was supported by Grant Agency of Charles University, Grant No. 35407 and by Grants of the Ministry of Health of the Czech Republic: IGA MZCR NS/9915-4, NR/8843-4 and VZ FNM 00064203.",null,48,10,10,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0920-1211",null,null,"EPILEPSY RES","Epilepsy Res.","JAN",2010,88,1,null,null,null,null,76,86,null,"10.1016/j.eplepsyres.2009.09.021",null,11,"Clinical Neurology","Neurosciences & Neurology","549NQ","WOS:000274058700007"]
[null,null,null,null,"J","Prajerova, I; Honsa, P; Chvatal, A; Anderova, M",null,null,null,"Prajerova, Iva; Honsa, Pavel; Chvatal, Alexandr; Anderova, Miroslava",null,null,"Neural Stem/Progenitor Cells Derived from the Embryonic Dorsal Telencephalon of D6/GFP Mice Differentiate Primarily into Neurons After Transplantation into a Cortical Lesion","CELLULAR AND MOLECULAR NEUROBIOLOGY",null,null,"English","Article",null,null,null,null,null,"Ischemia; Ion channels; Patch-clamp; Injury and repair","CENTRAL-NERVOUS-SYSTEM; RADIAL GLIAL-CELLS; RAT SPINAL-CORD; NEOCORTICAL PYRAMIDAL NEURONS; GATED K+ CHANNELS; STEM-CELLS; PROGENITOR CELLS; PRECURSOR CELLS; IN-VITRO; NEUROSPHERE CULTURES","D6 is a promoter/enhancer of the mDach1 gene that is involved in the development of the neocortex and hippocampus. It is expressed by proliferating neural stem/progenitor cells (NSPCs) of the cortex at early stages of neurogenesis. The differentiation potential of NSPCs isolated from embryonic day 12 mouse embryos, in which the expression of green fluorescent protein (GFP) is driven by the D6 promoter/enhancer, has been studied in vitro and after transplantation into the intact adult rat brain as well as into the site of a photochemical lesion. The electrophysiological properties of D6/GFP-derived cells were studied using the whole-cell patch-clamp technique, and immunohistochemical analyses were carried out. D6/GFP-derived neurospheres expressed markers of radial glia and gave rise predominantly to immature neurons and GFAP-positive cells during in vitro differentiation. One week after transplantation into the intact brain or into the site of a photochemical lesion, transplanted cells expressed only neuronal markers. D6/GFP-derived neurons were characterised by the expression of tetrodotoxin-sensitive Na(+)-currents and K (A)- and K (DR) currents sensitive to 4-aminopyridine. They were able to fire repetitive action potentials and responded to the application of GABA. Our results indicate that after transplantation into the site of a photochemical lesion, D6/GFP-derived NSPCs survive and differentiate into neurons, and their membrane properties are comparable to those transplanted into the non-injured cortex. Therefore, region-specific D6/GFP-derived NSPCs represent a promising tool for studying neurogenesis and cell replacement in a damaged cellular environment.","[Prajerova, Iva; Honsa, Pavel; Chvatal, Alexandr; Anderova, Miroslava] ASCR VVI, Inst Expt Med, Neurobiol Lab, Dept Cellular Neurophysiol, Prague 14220 4, Czech Republic; [Prajerova, Iva; Honsa, Pavel; Chvatal, Alexandr] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague 15006 5, Czech Republic; [Chvatal, Alexandr; Anderova, Miroslava] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague 15006 5, Czech Republic","Anderova, M (reprint author), ASCR VVI, Inst Expt Med, Neurobiol Lab, Dept Cellular Neurophysiol, Videnska 1083, Prague 14220 4, Czech Republic.","anderova@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [305/09/0717, 309/08/H079]; Academy of Sciences of the Czech Republic [AVOZ50390512]; Ministry of Education, Youth and Sports of the Czech Republic [LC554, 1M0538]; Charles University [GAUK62/2006/C/2]","The authors would like to thank to Dr. Z. Kozmik and Dr. O. Machon for their generous gift of D6/GFP mice. This study was supported by the following grants: 305/09/0717 and 309/08/H079 from the Grant Agency of the Czech Republic, AVOZ50390512 from the Academy of Sciences of the Czech Republic, LC554 and 1M0538 from the Ministry of Education, Youth and Sports of the Czech Republic and GAUK62/2006/C/2. LF from the Grant Agency of Charles University.",null,91,9,10,"SPRINGER/PLENUM PUBLISHERS","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0272-4340",null,null,"CELL MOL NEUROBIOL","Cell. Mol. Neurobiol.","MAR",2010,30,2,null,null,null,null,199,218,null,"10.1007/s10571-009-9443-x",null,20,"Cell Biology; Neurosciences","Cell Biology; Neurosciences & Neurology","570UW","WOS:000275704800005"]
[null,null,null,null,"J","Prajerova, I; Honsa, P; Chvatal, A; Anderova, M",null,null,null,"Prajerova, I.; Honsa, P.; Chvatal, A.; Anderova, M.",null,null,"DISTINCT EFFECTS OF SONIC HEDGEHOG AND Wnt-7a ON DIFFERENTIATION OF NEONATAL NEURAL STEM/PROGENITOR CELLS IN VITRO","NEUROSCIENCE",null,null,"English","Article",null,null,null,null,null,"morphogen; potassium currents; sodium currents; membrane properties; patch-clamp; neurogenesis","POSTNATAL SUBVENTRICULAR ZONE; WNT/BETA-CATENIN PATHWAY; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; PROGENITOR CELLS; ADULT BRAIN; HIPPOCAMPAL NEUROGENESIS; PRECURSOR CELLS; NEURONAL DIFFERENTIATION; FUNCTIONAL-NEURONS","Sonic hedgehog (Shh) and Wnt-7a are morphogens involved in embryonic as well as ongoing adult neurogenesis. Their effects on the differentiation and membrane properties of neonatal neural stem/progenitor cells (NS/PCs) were studied in vitro using NS/PCs transduced with either Shh or Wnt-7a. Eight days after the onset of in vitro differentiation the cells were analyzed for the expression of neuronal and glial markers using immunocytochemical and Western blot analysis, and their membrane properties were characterized using the patch-clamp technique. Our results showed that both Shh and Wnt-7a increased the numbers of cells expressing neuronal markers; however, quantitative immunocytochemical analysis showed that only Wnt-7a enhanced the outgrowth and the development of processes in these cells. In addition, Wnt-7a markedly suppressed gliogenesis. The electrophysiological analysis revealed that Wnt-7a increased, while Shh decreased the incidence of cells displaying a neuron-like current pattern, represented by outwardly rectifying K(+) currents and tetrodotoxin-sensitive Na(+) currents. Additionally, Wnt-7a increased cell proliferation only at the early stages of differentiation, while Shh promoted proliferation within the entire course of differentiation. Thus we can conclude that Shh and Wnt-7a interfere differently with the process of neuronal differentiation and that they promote distinct stages of neuronal differentiation in neonatal NS/PCs. (C) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.","[Prajerova, I.; Honsa, P.; Chvatal, A.; Anderova, M.] Acad Sci Czech Republic, Inst Expt Med, Neurobiol Lab, Dept Cellular Neurophysiol, Prague 14220 4, Czech Republic; [Prajerova, I.; Honsa, P.; Chvatal, A.] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague 15006 5, Czech Republic; [Chvatal, A.; Anderova, M.] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic","Anderova, M (reprint author), Acad Sci Czech Republic, Inst Expt Med, Neurobiol Lab, Dept Cellular Neurophysiol, Videnska 1083, Prague 14220 4, Czech Republic.","anderova@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [305/09/0717, 309/08/H079]; Academy of Sciences of the Czech Republic [AVOZ50390512]; Ministry of Education, Youth and Sports of the Czech Republic [LC554, 1M0538]; Grant Agency of Charles University [GAUK62/2006/C/2.LF]","Acknowledgments The authors would like to thank to Prof. S. Krauss (Center for Molecular Biology and Neuroscience and Institute of Medical Microbiology, Rikshospitalet, Oslo, Norway) for the generous gift of transduced NSIPCs. Further, we would like to thank to Dr. D. Kunke (Center for Molecular Biology and Neuroscience and Institute of Medical Microbiology, Rikshospitalet, Oslo, Norway) and to Dr. O. Machon (Institute of Molecular Genetics, ASCR, v. vi., Prague, Czech Republic) for their initial assistance with the cell cultures. We also thank James Dutt for helpful comments and suggestions. This study was supported by the following grants: 305/09/0717 and 309/08/H079 from the Grant Agency of the Czech Republic, AVOZ50390512 from the Academy of Sciences of the Czech Republic, LC554 and 1M0538 from the Ministry of Education, Youth and Sports of the Czech Republic and GAUK62/2006/C/2.LF from the Grant Agency of Charles University.",null,77,8,8,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0306-4522",null,null,"NEUROSCIENCE","Neuroscience","DEC 15",2010,171,3,null,null,null,null,693,711,null,"10.1016/j.neuroscience.2010.09.023",null,19,"Neurosciences","Neurosciences & Neurology","686XT","WOS:000284733700006"]
[null,null,null,null,"J","Brizova, H; Kalinova, M; Krskova, L; Mrhalova, M; Kodet, R",null,null,null,"Brizova, Helena; Kalinova, Marketa; Krskova, Lenka; Mrhalova, Marcela; Kodet, Roman",null,null,"A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase II alpha, and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma","VIRCHOWS ARCHIV",null,null,"English","Article",null,null,null,null,null,"Real-time PCR; Proliferation markers; Ki-67; Topoisomerase II alpha; TPX2; Mantle cell lymphoma; Mol Pathol; Quantitative Path; Lymphoma","CYCLIN D1 OVEREXPRESSION; EUROPEAN-MCL-NETWORK; PROGNOSTIC-FACTORS; MESSENGER-RNA; EXPRESSION; SURVIVAL; FEATURES; PROTEIN; GENE; IDENTIFICATION","A clinical course of patients with mantle cell lymphoma (MCL) is aggressive, and the disease is rarely curable. Proliferation rate is the most important prognostic factor. We developed a novel, reliable, rapid, and routinely applicable approach allowing a precise quantitative assessment of three proliferation markers, Ki-67, topoisomerase II alpha, and TPX2. A total of 95 lymphoma specimens were measured in the study by real-time reverse transcription PCR (RQ-RT-PCR). We tested the reproducibility and accuracy of the assay and correlated the results with the immunohistochemical staining of the corresponding proteins. The results obtained indicated individual variability of the mRNA expression levels, reflecting heterogeneity of the proliferation rate in individual patients. In general, we observed the highest mRNA expression in the group of Burkitt lymphomas and the lowest in patients with reactive lymphadenopathies. We found increased proliferation rate in MCLs with high cyclin D1 mRNA, indicating a quantitative control of the cell cycle. We observed a correlation between mRNA expression level and the immunohistochemical staining of corresponding proteins, which significantly argues for the prognostic significance of the mRNA expression measuring. We confirmed the accuracy of the current assay for a precise quantitative examination of the proliferation activity. Real-time RT-PCR provides a novel approach applicable for clinical trials, and it represents a potent approach allowing to stratify MCL patients for entry into clinical trials according to the expression of the proliferation signature genes in their tumors. This approach may contribute to improved and individualized therapeutic options respecting the individual progression risk of patients with MCL.","[Brizova, Helena; Kalinova, Marketa; Krskova, Lenka; Mrhalova, Marcela; Kodet, Roman] Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Brizova, Helena; Kalinova, Marketa; Krskova, Lenka; Mrhalova, Marcela; Kodet, Roman] Fac Hosp Motol, Prague 15006 5, Czech Republic","Brizova, H (reprint author), Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, V Uvalu 84, Prague 15006 5, Czech Republic.","helena.brizova@fnmotol.cz",null,null,"Internal grant of faculty hospital in Motol [9756, GAUK 46/2006/C/2.LF]; Ministry of Health [00064203/6704]","This work was supported by the Internal grant of faculty hospital in Motol no. 9756, Grant GAUK 46/2006/C/2.LF, and the Research project of the Ministry of Health no. 00064203/6704. We thank Dr. W. Klapper and the late Prof. Dr. R. Parwaresh (Department of Hematopathology and Lymph Node Registry, University Hospitals of Schleswig-Holstein, Kiel, Germany) who kindly provided us a sample of the antibody Ki-S2 against TPX2.",null,36,7,7,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0945-6317",null,null,"VIRCHOWS ARCH","Virchows Arch.","JUN",2010,456,6,null,null,null,null,671,679,null,"10.1007/s00428-010-0922-8",null,9,"Pathology","Pathology","605RD","WOS:000278363800010"]
[null,null,null,null,"J","Maxova, H; Vasil'kova, M; Novotna, J; Vajnerova, O; Banasova, A; Vizek, M; Herget, J",null,null,null,"Maxova, Hana; Vasil'kova, Marianna; Novotna, Jana; Vajnerova, Olga; Banasova, Alena; Vizek, Martin; Herget, Jan",null,null,"Prevention of Mast Cell Degranulation by Disodium Cromoglycate Delayed the Regression of Hypoxic Pulmonary Hypertension in Rats","RESPIRATION",null,null,"English","Article",null,null,null,null,null,"Chronic hypoxia; Disodium cromoglycate; Hypoxic pulmonary hypertension; Mast cells; Rat; Recovery","BLOOD-PRESSURE; RECOVERY; COLLAGEN; INHIBITION; EXPRESSION; ARTERIES","Background: Pulmonary vascular remodeling induced by chronic hypoxia regresses after return to normoxia. This regression is associated with an increased amount of collagenase in pulmonary mast cells and increased collagenolytic and elastolytic activity in the lung tissue. Objective: The role of lung mast cells during recovery from chronic hypoxia was tested by the inhibition of their degranulation by disodium cromoglycate (DSCG). Methods: Male Wistar rats (n = 46) were exposed to isobaric hypoxia (3 weeks, F(i)O(2)0.1). Thirteen of them were tested immediately at the end of exposure, 17 were treated with DSCG during the first 4 days of recovery and tested on the 5th or 14th day of recovery, 16 untreated animals were measured at the same time intervals. These groups were compared with 12 animals kept in normoxia. The rats were anesthetized (Thiopental) and their pulmonary arterial blood pressure (PAP), cardiac output and heart weight were tested, as well as the collagen composition of the walls of the peripheral pulmonary arteries. Results: DSCG applied during the first 4 days of recovery from chronic hypoxia blocked the decrease in PAP during the early phase of recovery and had no influence on PAP at a later phase. DSCG administration prevents collagen splitting in peripheral pulmonary vessels at the early phase of recovery. PAP and right ventricle hypertrophy were normalized after 14 days of return to normoxia. Conclusions: Mast cell degranulation plays a role in the regression of pulmonary hypertension during the early phase of recovery from chronic hypoxia. Copyright (C) 2010 S. Karger AG, Basel","[Maxova, Hana; Vasil'kova, Marianna; Banasova, Alena; Vizek, Martin] Charles Univ Prague, Sch Med 2, Dept Pathol Physiol, CZ-15000 Prague 5, Czech Republic; [Vajnerova, Olga; Herget, Jan] Charles Univ Prague, Sch Med 2, Dept Physiol, CZ-15000 Prague, Czech Republic; [Novotna, Jana] Charles Univ Prague, Sch Med 2, Dept Med Chem & Biochem, CZ-15000 Prague 5, Czech Republic; [Maxova, Hana; Novotna, Jana; Vajnerova, Olga; Vizek, Martin; Herget, Jan] Cardiovasc Res Ctr, Prague, Czech Republic","Maxova, H (reprint author), Charles Univ Prague, Sch Med 2, Dept Pathol Physiol, Plzenska 130-221, CZ-15000 Prague 5, Czech Republic.","hana.maxova@lfmotol.cuni.cz","Herget, Jan/I-6313-2012",null,"Grant Agency of Charles University [7228/2007]; Grant Agency of the Czech Republic [305/08/0108]; Cardiovascular Research Centre [MSMT 1M0510]","The study was supported by the Grant Agency of Charles University 7228/2007, the Grant Agency of the Czech Republic 305/08/0108, and by the Cardiovascular Research Centre MSMT 1M0510.",null,19,7,7,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0025-7931",null,null,"RESPIRATION","Respiration",null,2010,80,4,null,null,null,null,335,339,null,"10.1159/000312403",null,5,"Respiratory System","Respiratory System","642OB","WOS:000281224000010"]
[null,null,null,null,"J","Haberlova, J; Seeman, P",null,null,null,"Haberlova, Jana; Seeman, Pavel",null,null,"Utility of Charcot-Marie-Tooth Neuropathy Score in Children With Type 1A Disease","PEDIATRIC NEUROLOGY",null,null,"English","Article",null,null,null,null,null,null,"DUPLICATION","The aim of this study was to evaluate the utility of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) for evaluation of disease severity in young children with Charcot-Marie-Tooth type 1A. Current validated scoring scales for Charcot-Marie-Tooth are the CMTNS and the Neuropathy Impairment Score (NIS). Both work well for adult patients, and usually also for children over 10 years of age. There is no validation of scales for young children. Children with genetically proven Charcot-Marie-Tooth type 1A disease (n = 20, aged 3 to 10 years) were examined clinically, followed by electrophysiologic examination, and were scored under the CMTNS scale. The clinical symptoms were mild; the two most frequent symptoms were difficulty in heel walking and lower limb areflexia. The score was maximally abnormal in four of the nine categories. Categories for sensation, sensory symptoms, and motor symptoms of the arms were normal in all cases. The score was below 8 for all tested children. To conclude, the CMTNS in children aged 10 years and younger has limited sensitivity; out of nine categories, only four are useful. Thus, evaluation of disease severity and progression in young children with Charcot-Marie-Tooth disease remains limited, and there is need for other, effective scoring systems. (C) 2010 by Elsevier Inc. All rights reserved.","[Haberlova, Jana] Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague 15006, Czech Republic; [Haberlova, Jana] Charles Univ Prague, Univ Hosp Motol, Prague 15006, Czech Republic","Haberlova, J (reprint author), Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, V Uvalu 84, Prague 15006, Czech Republic.","jana.haberlova@gmail.com",null,null," [IGA MZ NR 9517-3]","This work was supported under IGA MZ NR 9517-3.",null,14,5,6,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0887-8994",null,null,"PEDIATR NEUROL","Pediatr. Neurol.","DEC",2010,43,6,null,null,null,null,407,410,null,"10.1016/j.pediatrneurol.2010.06.004",null,4,"Clinical Neurology; Pediatrics","Neurosciences & Neurology; Pediatrics","691JY","WOS:000285077300005"]
[null,null,null,null,"J","Kanderova, V; Hrusak, O; Kalina, T",null,null,null,"Kanderova, Veronika; Hrusak, Ondrej; Kalina, Tomas",null,null,"Aberrantly expressed CEACAM6 is involved in the signaling leading to apoptosis of acute lymphoblastic leukemia cells","EXPERIMENTAL HEMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"CARCINOEMBRYONIC ANTIGEN CEA; PANCREATIC ADENOCARCINOMA CELLS; ADHESION MOLECULES; KOR-SA3544 ANTIGEN; LIPID RAFTS; CD66C; FIBRONECTIN; INTEGRINS; SURVIVAL; AVIDITY","Objective. The aberrant expression of myeloid antigens on acute lymphoblastic leukemia (ALL) cells is a well-documented phenomenon. So far, there have been no reports of a functional consequence of this aberrant expression. The granulocytic marker carcinoembryonic antigen related cell adhesion molecule 6 (CEACAM6, CD66c) is a GPI-anchored molecule that is reported to be the most frequently aberrantly expressed myeloid marker in ALL with a strong correlation with genotype. Materials and Methods. We mimicked CEACAM6 signaling in ALL cells by cross-linking with anti-CEACAM6 antibody. Next, we measured a response to CEACAM6 signaling by integrin subunits expression, integrin ligand binding, phosphorylation of extracellular signal-regulated kinase 1/2 (Erk1/2), Akt, and p38 mitogen-activated protein kinase (MAPK) and apoptosis by flow cytometry. Results. Following CEACAM6 cross-linking in ALL cells, we detected Erk1/2, Akt, and p38 MAPK phosphorylation and integrin upregulation, as well as enhanced binding of integrin ligands (vascular cell adhesion molecule-1 [VCAM-1] and intercellular cell adhesion molecule-1 [ICAM-1]). However, CEACAM6 signaling resulted in an increase in apoptosis, unlike other GPI-anchored molecules, such as CD24. Conclusion. The present study is the first to demonstrate the functional consequences of CEACAM6 cross-linking in B-cell precursor ALL cells. (C) 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.","[Kalina, Tomas] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Kalina, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006 5, Czech Republic.","tomas.kalina@lfmotol.cuni.cz",null,null,"Charles University (Prague, Czech Republic) [GAUK 7539/2007]; Czech Ministry of Health (Prague, Czech Republic) [NS/10473-3]; Ministry of Sports, Youth and Education (Prague, Czech Republic) [VZ MSMT 0021620813]","This work was supported by grants from Charles University (Prague, Czech Republic) no. GAUK 7539/2007, Czech Ministry of Health (Prague, Czech Republic) no. NS/10473-3 and by a research project of the Ministry of Sports, Youth and Education (Prague, Czech Republic) no. VZ MSMT 0021620813.",null,31,5,5,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0301-472X",null,null,"EXP HEMATOL","Exp. Hematol.","AUG",2010,38,8,null,null,null,null,653,660,null,"10.1016/j.exphem.2010.03.018",null,8,"Hematology; Medicine, Research & Experimental","Hematology; Research & Experimental Medicine","631EW","WOS:000280330400005"]
[null,null,null,null,"J","Trc, T; Handl, M; Havlas, V",null,null,null,"Trc, Tomas; Handl, Milan; Havlas, Vojtech",null,null,"The anterior talo-fibular ligament reconstruction in surgical treatment of chronic lateral ankle instability","INTERNATIONAL ORTHOPAEDICS",null,null,"English","Article",null,null,null,null,null,null,"STRESS RADIOGRAPHY; TENDON GRAFT; ARTHROGRAPHY; TEARS; JOINT","Chronic lateral ankle instability causes significant problems in physical activity and accelerates development of osteoarthritic changes. The results of treatment for chronic ankle instability are often meets controversial. A surgical reconstruction of ATFL as described in this paper was performed during the period 1997-2005 on 47 patients (26 male, 21 female), with a mean age of 29.3 years. The average follow-up period was 46.2 months. All patients had clinical examination, X-ray and MRI. The mean values of the Good score improved from an average 3.32 prior to surgery to 1.19 one year after the operation. Paired t-tests showed improvements of great significance (p < 10(-28)). The Good score prior to surgery ranged from 2-4, whereas the scores one year after surgery were either 1 or 2, with a score of 1 being recorded in 38 cases (81%). In the postoperative follow-up, MRI showed a newly-formed ligament structure in all cases. The authors describe their own technique for a reconstruction of lateral ankle instability using remnants of the former ATFL. The scar tissue seems to be sufficient to form a new duplicated structure providing good stability. MRI proved to be a sensitive and specific method for identifying the extent of talo-fibular ligament injury.","[Trc, Tomas; Handl, Milan; Havlas, Vojtech] Charles Univ Prague, Fac Med 2, Dept Orthopaed Surg, Prague 15006 5, Czech Republic","Havlas, V (reprint author), Charles Univ Prague, Fac Med 2, Dept Orthopaed Surg, V Uvalu 84, Prague 15006 5, Czech Republic.","tomas.trc@fnmotol.cz; vojtech.havlas@seznam.cz",null,null,null,null,null,25,3,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0341-2695",null,null,"INT ORTHOP","Int. Orthop.","OCT",2010,34,7,null,null,null,null,991,996,null,"10.1007/s00264-010-0995-7",null,6,"Orthopedics","Orthopedics","652CU","WOS:000281979500010"]
[null,null,null,null,"J","Kayserova, J; Capkova, S; Skalicka, A; Vernerova, E; Polouckova, A; Malinova, V; Bartunkova, J; Sediva, A",null,null,null,"Kayserova, J.; Capkova, S.; Skalicka, A.; Vernerova, E.; Polouckova, A.; Malinova, V.; Bartunkova, J.; Sediva, A.",null,null,"Serum Immunoglobulin Free Light Chains in Severe Forms of Atopic Dermatitis","SCANDINAVIAN JOURNAL OF IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,null,"INFLAMMATORY DISEASES; IG; IMMEDIATE; RESPONSES; ALLERGY; MARKER; TARGET; URINE; CELLS","An increase in immunoglobulin free light chains (FLC) was recently described in several pathological conditions, including asthma. FLC pathology is classically associated with monoclonal gammopathies. Its association with allergic disorders is surprising and unexplained. We therefore tested a cohort of children with severe atopic dermatitis (SCORAD 50-80) to determine the serum levels of free kappa and lambda chains, and correlated the results with clinical status and relevant laboratory markers. Seventy-three patients with severe forms of AD, all children from 3 months to 3 years of age and ninety healthy age-matched controls were included in the study. Light chains in sera were tested using the Freelite assay (Binding Site, Birmingham, UK). There were highly significant differences in both kappa (mean: 7.05 and 3.22 mg/l) and lambda (mean: 10.99 and 9.8 mg/l) serum levels between patients and controls, respectively (P < 0.0001). The kappa/lambda ratio in patients with allergy (mean: 0.64) was significantly higher than in controls (0.33) (P < 0.0001). We further observed significantly increased levels of FLC and their ratio in the group of patients with severe forms of AD in comparison to the group of patients with a resting stage of the disease or healthy controls (P < 0.05 and P < 0.0001, respectively). On the other hand, we could not confirm any association of FLC levels with age or total IgE levels. In conclusion, an increase in FLC reflects disease activity in children with severe atopic dermatitis. FLC might thus represent an additional diagnostic marker independent of total IgE levels.","[Kayserova, J.; Skalicka, A.; Vernerova, E.; Polouckova, A.; Bartunkova, J.; Sediva, A.] Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic; [Capkova, S.] Univ Hosp Motol, Dept Dermatol, Pediat Outpatient Dept, Prague, Czech Republic; [Malinova, V.] Gen Univ Hosp, Fac Med 1, Dept Pediat & Adolescent Med, Prague, Czech Republic","Sediva, A (reprint author), Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Uvalu 84, Prague 15006, Czech Republic.","anna.sediva@fnmotol.cz",null,null,"Ministry of Health, Czech Republic [VZ MZ CR 00064203]; Ministry of Education, Youth and Sports, Czech Republic [VZ MSM 0021620812, GAUK 7840/2007]","The study was supported by the Ministry of Health, Czech Republic VZ MZ CR 00064203, the Ministry of Education, Youth and Sports, Czech Republic VZ MSM 0021620812 and GAUK 7840/2007.",null,21,3,3,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-9475",null,null,"SCAND J IMMUNOL","Scand. J. Immunol.","APR",2010,71,4,null,null,null,null,312,316,null,"10.1111/j.1365-3083.2010.02376.x",null,5,"Immunology","Immunology","573MQ","WOS:000275918400012"]
[null,null,null,null,"J","Prochazka, P; Hrabeta, J; Vicha, A; Eckschlager, T",null,null,null,"Prochazka, Pavel; Hrabeta, Jan; Vicha, Ales; Eckschlager, Tomas",null,null,"Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine","CANCER GENETICS AND CYTOGENETICS",null,null,"English","Article",null,null,null,null,null,null,"TUMOR-CELLS; DOUBLE MINUTES; HL-60 CELLS; C-MYC; AMPLIFICATION; GENES; ELIMINATION; RESISTANCE; TUMORIGENICITY; HYBRIDIZATION","Amplified MYCN, common in neuroblastomas, can be detected as double minutes (dmin) or homogenously staining chromosomal regions (hsr). Expulsion of amplified MYCN has only been described in dmin. We used hydroxyurea (HU), which accelerates the expulsion of amplified genes and cytostatics (used in neuroblastoma therapy), to describe MYCN amplification changes after chemotherapy. We used IMR-32, SK-N-AS, UKF-NB-2, UKF-NB-3, UKF-NB-4, and derived sublines resistant to doxorubicin, cisplatin, and vincristine. The loss of amplified MYCN copies was investigated using comparative genomic hybridization and by fluorescent in situ hybridization. We found expulsion of amplified MYCN from hsr in UKF-NB-4 and IMR-32 cell lines, and determined the exact number of amplified MYCN copies. After the first cultivation with HU, some amplified MYCN was lost. UKF-NB-4 lost 20 copies on average, and IMR-32 lost 15 copies (P < 0.001). After the second cultivation, cells without MYCN amplification were found. In comparison to sensitive cell lines, drug-resistant cell lines lost 17 copies on average. Our data show that expulsion of amplified MYCN genes is also possible from hsr and may be induced, not only by HU, but by other cytostatics as well. (C) 2010 Elsevier Inc. All rights reserved.","[Prochazka, Pavel; Hrabeta, Jan; Vicha, Ales; Eckschlager, Tomas] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague 15006, Czech Republic","Prochazka, P (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic.","proch.pavel@gmail.com","Prochazka, Pavel/G-4759-2012; Vicha, Ales/I-6726-2012","Vicha, Ales/0000-0003-3075-5554","Grant Agency of Charles University [7926/2007]; Ministry of Education, Youth and Sports of the Czech Republic [MSM0021620813]","We thank J. Cinatl Jr. (Institute for Medical Virology, Johann Wolfgang Goethe University Hospital, Frankfurt am Mein, Germany), who kindly provided cell lines. This research was supported by the Grant Agency of Charles University (grant 7926/2007) and by the Ministry of Education, Youth and Sports of the Czech Republic (grant MSM0021620813).",null,26,3,3,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,null,"CANCER GENET CYTOGEN","Cancer Genet. Cytogenet.","JAN 1",2010,196,1,null,null,null,null,96,104,null,"10.1016/j.cancergencyto.2009.08.005",null,9,"Oncology; Genetics & Heredity","Oncology; Genetics & Heredity","592QX","WOS:000277395600015"]
[null,null,null,null,"J","Charvat, J; Chlumsky, J; Zakovicova, E; Kvapil, M",null,null,null,"Charvat, J.; Chlumsky, J.; Zakovicova, E.; Kvapil, M.",null,null,"Common Carotid Artery Intima-media Thickness is not Increased but Distensibility is Reduced in Normotensive Patients with Type 2 Diabetes compared with Control Subjects","JOURNAL OF INTERNATIONAL MEDICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"TYPE 2 DIABETES MELLITUS; COMMON CAROTID ARTERY; INTIMA-MEDIA THICKNESS; ATHEROMA; DISTENSIBILITY","CARDIOVASCULAR MORTALITY; METABOLIC SYNDROME; BLOOD-PRESSURE; ATHEROSCLEROSIS; STIFFNESS; RISK; MANIFESTATIONS; CHOLESTEROL; DYSFUNCTION; MELLITUS","This study evaluated carotid artery parameters in normotensive patients with type 2 diabetes compared with nondiabetic control subjects. Using a high-resolution B-mode ultrasound scanner, common carotid artery intima-media thickness (IMT) and carotid tree atheroma thickness were measured in 82 patients with type 2 diabetes and 41 controls. The distensibility of the common carotid artery was calculated using the Reneman equation. Distensibility was significantly decreased and atheroma thickness was significantly increased in the diabetes group. There was no significant difference in IMT between the two groups. Stepwise linear regression analysis revealed an association between common carotid artery distensibility and post-ischaemic dilatation of the brachial artery (a measure of endothelial function), body mass index and diabetes duration in patients with type 2 diabetes. In conclusion, common carotid artery IMT in normotensive patients with type 2 diabetes is comparable to that of control subjects, whereas atheroma thickness is higher and arterial stiffness more pronounced in those with type 2 diabetes, indicating the existence of atherosclerotic changes in normotensive type 2 diabetes patients.","[Charvat, J.; Chlumsky, J.; Zakovicova, E.; Kvapil, M.] Charles Univ Prague, Fac Med 2, Dept Med, Prague 15006 5, Czech Republic","Charvat, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Med, V Uvalu 84, Prague 15006 5, Czech Republic.","jiri.charvat@lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic [NR/9520-3]","This work was supported by a grant from the Ministry of Health of the Czech Republic (NR/9520-3).",null,26,2,2,"FIELD HOUSE PUBLISHING LLP","WORTHING","6 SOMPTING AVENUE, WORTHING, BN14 8HN, ENGLAND","0300-0605",null,null,"J INT MED RES","J. Int. Med. Res.","MAY-JUN",2010,38,3,null,null,null,null,860,869,null,null,null,10,"Medicine, Research & Experimental; Pharmacology & Pharmacy","Research & Experimental Medicine; Pharmacology & Pharmacy","635SY","WOS:000280677800013"]
[null,null,null,null,"J","Seeman, T; Dusek, J; Vondrak, K; Janda, J",null,null,null,"Seeman, Tomas; Dusek, Jiri; Vondrak, Karel; Janda, Jan",null,null,"Ramipril in the treatment of proteinuria in children after renal transplantation","PEDIATRIC TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"ramipril; proteinuria; hypertension; renal transplantation; graft function","ANTIPROTEINURIC EFFICACY; BLOOD-PRESSURE; HYPERTENSION; RECIPIENTS; SURVIVAL; ADOLESCENTS; INHIBITION; MANAGEMENT; DISEASES; FAILURE","The efficacy and safety of ACEI in adult patients with hypertension and proteinuria after renal transplantation is proven however data on the effectiveness of ACEI in transplanted children are rare. The aim of the present study was to investigate the effect of ramipril on proteinuria and BP in children after R-Tx. Twelve transplanted children (median age 15.3 yr, median time after R-Tx 4.5 yr) with proteinuria with or without hypertension were prospectively treated with ramipril for six months. Proteinuria was assessed as protein/creatinine ratio. Office BP was evaluated and hypertension defined as BP >= 95th centile. Graft function was assessed (Schwartz formula). The starting dose of ramipril was 1.5 mg/m2/24-h. Proteinuria declined in 92% of children from a median 39 to 22 mg/mmol creatinine (p < 0.01). The median decline of proteinuria was 9 mg/mmol creatinine, it reached 23% of the initial values. The prevalence of hypertension did not change significantly (50% initially vs. 33% after six months). Graft function and serum potassium level did not change significantly, two children developed mild hyperkalemia. Ramipril can reduce proteinuria in most transplanted children; its antiproteinuric effect is exhibited even without BP lowering effect.","[Seeman, Tomas] Charles Univ Prague, Dept Pediat, Prague 15006, Czech Republic; Charles Univ Prague, Transplantat Ctr, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic","Seeman, T (reprint author), Charles Univ Prague, Dept Pediat, V Ulavu 84, Prague 15006, Czech Republic.","tomas.seeman@lfmotol.cuni.cz",null,null,"IGA of the Ministry of Health or the Czech Republic [NR/9524-3, 0021620819]","This study was supported by grants IGA of the Ministry of Health or the Czech Republic reg. Nr. NR/9524-3 and VZ MSMT reg. Nr. 0021620819.",null,25,0,2,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1397-3142",null,null,"PEDIATR TRANSPLANT","Pediatr. Transplant.","MAR",2010,14,2,null,null,null,null,283,287,null,"10.1111/j.1399-3046.2009.01216.x",null,5,"Pediatrics; Transplantation","Pediatrics; Transplantation","553TL","WOS:000274389600022"]
[null,null,null,null,"J","Durilova, M; Stechova, K; Petruzelkova, L; Stavikova, V; Ulmannova, T; Nevoral, J",null,null,null,"Durilova, Marianna; Stechova, Katerina; Petruzelkova, Lenka; Stavikova, Vendula; Ulmannova, Tereza; Nevoral, Jiri",null,null,"Is there any relationship between cytokine spectrum of breast milk and occurence of eosinophilic colitis?","ACTA PAEDIATRICA",null,null,"English","Article",null,null,null,null,null,"Atopy; Breast milk; Cytokine; ELISA; Eosinophilic colitis","FED INFANTS; ALLERGIC COLITIS; T-CELLS; IL-18; GAMMA; INTERLEUKIN-10; PROCTOCOLITIS; MICROFLORA; PROBIOTICS; DISEASES","Aim: The aim of our study was to analyse cytokine composition of human milk and its relationship to the development of eosinophilic colitis (EC). Methods: Cytokines were measured by ELISA method in breast milk of 20 mothers of infants who developed EC and 20 controls. Results: We found significantly higher concentrations of interferon-gamma (IFN-gamma) (Th1 cytokine) in breast milk received by EC infants compared to controls (p = 0.0004). In contrary, IL-18 (Th1-inducing cytokine) was significantly higher in breast milk received by healthy infants comparing to EC infants (p = 0.001). Regulatory cytokine transforming growth factor beta1 (TGF-beta1) showed higher concentrations in breast milk received by healthy infants, although the difference from EC group was not significant (p = 0.072). Conclusion: The results of our study showed that infants with EC were receiving breast milk with a possibly risky cytokine pattern indicating cytokine imbalance, impaired immunoregulation and the early Th1 shift.","[Durilova, Marianna; Stechova, Katerina; Petruzelkova, Lenka; Stavikova, Vendula; Ulmannova, Tereza; Nevoral, Jiri] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague 15006 5, Czech Republic","Stechova, K (reprint author), Charles Univ Prague, Dept Paediat, Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic.","info@labao.cz",null,null,"Internal Grant Agency of Ministry of Health, Czech Rep. [NR 8310-5]","This project was supported by Internal Grant Agency of Ministry of Health, Czech Rep. No NR 8310-5. We express our thanks to Katerina Flajsmanova-Tesarova for the laboratory processing of breast milk samples.",null,25,0,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0803-5253",null,null,"ACTA PAEDIATR","Acta Paediatr.","NOV",2010,99,11,null,null,null,null,1666,1670,null,"10.1111/j.1651-2227.2010.01907.x",null,5,"Pediatrics","Pediatrics","660KP","WOS:000282641600013"]
[null,null,null,null,"J","Svehlik, M; Slaby, K; Trc, T; Radvansky, J",null,null,null,"Svehlik, Martin; Slaby, Krystof; Trc, Tomas; Radvansky, Jiri",null,null,"Detecting Postoperative Change in Children With Cerebral Palsy: Net Nondimensional Versus Body Mass Oxygen Normalization","JOURNAL OF APPLIED BIOMECHANICS",null,null,"English","Article",null,null,null,null,null,"exercise performance; orthopaedic surgery; gait analysis; kinematics","ENERGY-EXPENDITURE; O-2 COST; WALKING; GAIT; SURGERY","The aim of the study is to investigate whether the net nondimensional oxygen utilization scheme is able to detect postoperative improvement in the energy cost of walking in children with cerebral palsy and to compare it with a body mass normalization scheme. We evaluated 10 children with spastic cerebral palsy before and 9 months after equinus deformity surgery. Participants walked at a given speed of 2 km/hr and 3 km/hr on a treadmill. Oxygen utilization was measured, and mass relative VO(2) and net nondimensional VO(2) were calculated. Coefficient of variation was used for the description of variability among subjects. Postoperatively, gait kinematics normalized and the mass relative VO(2) and net nondimensional VO2 showed significant improvement. Net nondimensional VO(2) is able to detect postoperative improvement with smaller variability among subjects than body mass related normalization in children with cerebral palsy.","[Svehlik, Martin; Trc, Tomas] Charles Univ Prague, Orthopaed Dept Children & Adults, Sch Med 2, Prague, Czech Republic; [Slaby, Krystof; Radvansky, Jiri] Charles Univ Prague, Dept Rehabil & Sports Med, Sch Med 2, Prague, Czech Republic","Svehlik, M (reprint author), Charles Univ Prague, Orthopaed Dept Children & Adults, Sch Med 2, Prague, Czech Republic.",null,null,null,null,null,null,19,0,0,"HUMAN KINETICS PUBL INC","CHAMPAIGN","1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA","1065-8483",null,null,"J APPL BIOMECH","J. Appl. Biomech.","NOV",2010,26,4,null,null,null,null,512,515,null,null,null,4,"Engineering, Biomedical; Sport Sciences","Engineering; Sport Sciences","699VJ","WOS:000285690700016"]
[null,null,null,null,"J","Zakovicova, E; Charvat, J; Kukacka, J; Chlumsky, J; Svab, P; Kvapil, M",null,null,null,"Zakovicova, E.; Charvat, J.; Kukacka, J.; Chlumsky, J.; Svab, P.; Kvapil, M.",null,null,"Circulating Serum Matrix Metalloproteinase-3 and Metalloproteinase-9 Are Not Associated with Echocardiographic Parameters of Diastolic Function in Asymptomatic Type 2 Diabetic Patients","JOURNAL OF INTERNATIONAL MEDICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"TYPE 2 DIABETES MELLITUS; ALBUMINURIA; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; ECHOCARDIOGRAPHY","HEART-FAILURE; TISSUE DOPPLER; DYSFUNCTION; MATRIX-METALLOPROTEINASE-9; INHIBITOR; TURNOVER; GENE; MMP9","Serum concentrations of matrix metalloproteinase (MMP) 3 and MMP9 were evaluated in 82 asymptomatic type 2 diabetes mellitus patients without cardiovascular complications and in 41 non-diabetic control subjects. In the asymptomatic diabetic patients, the correlations of these concentrations with diabetes duration, selected biochemical parameters such as glycated haemoglobin (HbA(1c)), and echocardiographic parameters of diastolic function were also assessed. Pulsed and tissue Doppler echocardiography was performed in the two groups. Mean +/- SD age was 61 +/- 6 years for the asymptomatic diabetic patients and 61 +/- 5 years for controls. Mean +/- SD concentrations of MMP3 and MMP9 were significantly higher in the asymptomatic diabetic patients (67.5 +/- 10.4 and 77.8 +/- 28.8 mu g/l, respectively) than in controls (47.2 +/- 6.1 and 51.1 +/- 13.7 mu g/l, respectively). In the asymptomatic diabetic patients, MMP3 correlated only with albuminuria (r = 0.341) and MMP9 only with HbA(1c) (r = 0.262); neither MMP was correlated with echocardiographic parameters of diastolic function. Thus, in asymptomatic type 2 diabetic patients without cardiovascular complications, serum MMP3 and MMP9 were elevated, MMP9 was associated with HbA(1c) and MMP3 was associated with albuminuria, however, MMP3 and MMP9 were not associated with echocardiographic parameters of diastolic function.",null,"Charvat, J (reprint author), Charles Univ Prague, Dept Med, Fac Hosp 2, V Uvalu 84, Prague 15006 5, Czech Republic.","jiri.charvat@lfmotol.cuni.cz","Kukacka, Jiri/C-4770-2013",null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NR/9520-3]","This work was supported by grant NR/9520-3 from the Internal Grant Agency of the Ministry of Health of the Czech Republic.",null,23,0,0,"FIELD HOUSE PUBLISHING LLP","WORTHING","6 SOMPTING AVENUE, WORTHING, BN14 8HN, ENGLAND","0300-0605",null,null,"J INT MED RES","J. Int. Med. Res.","NOV-DEC",2010,38,6,null,null,null,null,2093,2099,null,null,null,7,"Medicine, Research & Experimental; Pharmacology & Pharmacy","Research & Experimental Medicine; Pharmacology & Pharmacy","730SK","WOS:000288054400025"]
[null,null,null,null,"J","Filous, A; Hlozanek, M; Hladikova, M",null,null,null,"Filous, Ales; Hlozanek, Martin; Hladikova, Marie",null,null,"The Occurrence and Features of the Atypical Birefringence Pattern in Scanning Laser Polarimetry Using GDxVCC in Healthy Children and Its Impact on the Retinal Nerve Fiber Layer Thickness Values","JOURNAL OF GLAUCOMA",null,null,"English","Article",null,null,null,null,null,"glaucoma; children; scanning laser polarimetry; GDxVCC; atypical birefringence pattern","VARIABLE CORNEAL COMPENSATION; OPTICAL COHERENCE TOMOGRAPHY; GLAUCOMATOUS EYES; POLARIZATION COMPENSATION; DIAGNOSTIC-ACCURACY; OCULAR HYPERTENSION; SENSITIVITY; RETARDATION; DEFECTS; VCC","Purpose: To investigate the occurrence and features of the atypical birefringence pattern (ABP) images in scanning laser polarimetry with variable corneal compensation (GDxVCC) in healthy children and to assess their impact on the values of the retinal nerve fiber layer (RNFL) thickness. Methods: GDxVCC scans in 120 healthy white school-aged children with mean age +/- standard deviation (SD) 12.85 +/- 3.0 years were evaluated using typical scan score (TSS) calculation and by subjective grading of the scans. Statistical analysis including the impact of ABP on the RNFL thickness in GDxVCC Temporal-Superior-Nasal-Inferior-Temporal (TSNIT) parameters was done. Results: The ABP was found in 18 out of 120 patients (15%) at cutoff value of TSS < 80. Subjective evaluation of the scans raised the frequency of ABP to 20% of patients. The mean +/- SD values of TSNIT Average, Superior Average, and Inferior Average in 26 eyes with ABP versus 214 eyes with normal birefringence pattern were 66.99 +/- 7.29 mm versus 58.00 +/- 6.22 mm (P = 7.2E to -11), 78.43 +/- 9.27 mm versus 72.33 +/- 8.72 mm (P = 0.001) and 80.87 +/- 12.01 mm versus 70.00 +/- 10.20 mm (P = 0.000001), respectively. The same comparison in TSNIT SD showed minimal difference and was 25.42 +/- 5.84 mm versus 26.41 +/- 4.81 mm (P = 0.41). Conclusions: The occurrence of ABP in children is not rare and may significantly distort the measured values of the RNFL thickness in TSNIT parameters using GDxVCC.","[Filous, Ales; Hlozanek, Martin] Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, Prague 15006, Czech Republic; [Hladikova, Marie] Charles Univ Prague, Dept Med Informat, Fac Med 2, Prague 15006, Czech Republic","Filous, A (reprint author), Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, Uvalu 84, Prague 15006, Czech Republic.","ales.filous@lfmotol.cuni.cz",null,null,null,null,null,31,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1057-0829",null,null,"J GLAUCOMA","J. Glaucoma","SEP",2010,19,7,null,null,null,null,450,455,null,"10.1097/IJG.0b013e3181ca7318",null,6,"Ophthalmology","Ophthalmology","651EX","WOS:000281909100005"]
[null,null,null,null,"J","Kabelka, Z; Groh, D; Katra, R; Jurovcik, M",null,null,null,"Kabelka, Zdenek; Groh, Daniel; Katra, Rami; Jurovcik, Michal",null,null,"Bacterial infection complications in children with cochlear implants in the Czech Republic","INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"Cochlear implants; Infection; Complications; Pseudomonas aeruginosa; Staphylococcus aureus; Reimplantation","PSEUDOMONAS-AERUGINOSA; BIOFILM FORMATION; SURGERY; EPIDEMIOLOGY; MANAGEMENT",null,"[Kabelka, Zdenek] Charles Univ Prague, Dept Otolaryngol, Sch Med 2, Prague 15006, Czech Republic; Fac Hosp Motol, Prague 15006, Czech Republic","Kabelka, Z (reprint author), Charles Univ Prague, Dept Otolaryngol, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic.","Zdenek.Kabelka@fnmotol.cz",null,null,"VZ FN Motol, Czech Republic [00000064203/ 650]","This work was supported by the VZ FN Motol 00000064203/ 650, Czech Republic.",null,24,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0165-5876",null,null,"INT J PEDIATR OTORHI","Int. J. Pediatr. Otorhinolaryngol.","MAY",2010,74,5,null,null,null,null,499,502,null,"10.1016/j.ijpor1.2010.02.007",null,4,"Otorhinolaryngology; Pediatrics","Otorhinolaryngology; Pediatrics","597GP","WOS:000277745000012"]
[null,null,null,null,"J","Kotaska, K; Urinovska, R; Klapkova, E; Prusa, R; Rob, L; Binder, T",null,null,null,"Kotaska, K.; Urinovska, R.; Klapkova, E.; Prusa, R.; Rob, L.; Binder, T.",null,null,"Re-Evaluation of Cord Blood Arterial and Venous Reference Ranges for pH, pO(2), pCO(2), According to Spontaneous or Cesarean Delivery","JOURNAL OF CLINICAL LABORATORY ANALYSIS",null,null,"English","Article",null,null,null,null,null,"umbilical cord blood; blood gas; pH","UMBILICAL-CORD; GAS ANALYSIS; VALUES","Umbilical cord blood gas analysis (pO(2) and pCO(2)) is now recommended in all high-risk baby deliveries and in some centers it is performed routinely following all deliveries. The aim of this study was to re-evaluate cord blood arterial and venous reference ranges for pH, pO(2), pCO(2) in newborns, delivered by spontaneous vaginal delivery (SVD) and by cesarean section (CS) performed in Faculty Hospital Motol. Two groups of subjects were selected for the study. Group I consisted of 303 newborns with SVD. Group II consisted of 189 newborns delivered by cesarean section. Cord blood samples were analyzed for standard blood gas and pH, using the analytical device Rapid Lab 845 and Rapid Lab 865. We obtained reference values expressed as range (lower and upper reference value expressed as 2.5 and 97.5 percentiles) for cord blood in newborns with SVD: arterial cord blood: pH = 7.01-7.39; pCO(2) = 4.12-11.45 kPa; pO(2) = 1.49-5.06 kPa; venous cord blood: pH = 7.06-7.44; pCO(2) = 3.33-9.85 kPa; pO(2) = 1.80-6.29 kPa. We also obtained reference values for cord blood in newborns delivered by CS: arterial cord blood: pH = 7.05-7.39; pCO(2) = 5.01-10.60 kPa; pO(2) = 1.17-5.94 kPa; venous cord blood: pH = 7.10-7.42; pCO(2) = 3.88-9.36 kPa; pO(2) = 1.98-7.23 kPa. Re-evaluated reference ranges play essential role in monitoring conditions of newborns with spontaneous and caesarean delivery. J. Clin. Lab. Anal. 24:300-304, 2010. (C) 2010 Wiley-Liss, Inc.","[Kotaska, K.; Urinovska, R.; Klapkova, E.; Prusa, R.] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague 15006 5, Czech Republic; [Kotaska, K.; Urinovska, R.; Klapkova, E.; Prusa, R.; Rob, L.; Binder, T.] Fac Hosp Motol, Prague, Czech Republic; [Rob, L.; Binder, T.] Charles Univ Prague, Dept Obstet & Adult & Paediat Gynaecol, Fac Med 2, Prague 15006 5, Czech Republic","Kotaska, K (reprint author), Charles Univ Prague, Fac Hosp Motol, Fac Med 2, Dept Clin Biochem & Pathobiochem, Vuvalu 84, Prague 15006 5, Czech Republic.","kotaska@email.cz",null,null,null,null,null,16,0,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0887-8013",null,null,"J CLIN LAB ANAL","J. Clin. Lab. Anal.",null,2010,24,5,null,null,null,null,300,304,null,"10.1002/jcla.20405",null,5,"Medical Laboratory Technology","Medical Laboratory Technology","658JN","WOS:000282486400004"]
[null,null,null,null,"J","Trc, T; Chladek, P; Havlas, V",null,null,null,"Trc, T.; Chladek, P.; Havlas, V.",null,null,"Drilling and plombage (core decompression) of a femora head avascular necrosis","OSTEOLOGIE",null,null,"English","Article",null,null,null,null,null,"Avascular necrosis; femoral head; forage; core decompression; press-fit grafting","HIP; OSTEONECROSIS; OSTEOTOMY","The treatment of femoral head necrosis of adults is still rather problematic. Conservative treatment has been reported relatively unsuccessful and surgical treatment does not show convincing results either. The most effective seems to be a surgical treatment in early stages of the disease, however, the diagnosis still remains relatively complicated. For the late stages (2B and above) the most effective treatment option is represented by core decompression and vascular grafting. However, drilling and plombage (especially when using press-fit technique) seems to be successful, although not excellent. The authors describe their own method of drilling and plombage of the necrotic zone of the femoral head in 41 patients with X-ray detected necrotic changes of the femoral head. The pain measured by VAS was seen to decrease after surgery in all patients significantly. The Jacobs score was also observed to have increased (from fair to good outcome). We have not observed any large femoral head collapse after surgery, moreover, in some cases an improvement of the round shape of the femoral head was seen. It is important to mention that in all cases femoral heads with existing necrotic changes (flattening or collapse) were treated. Although the clinical improvement after surgery was not significantly high, the method we describe is a safe and simple method of diminishing pain in attempt to prepare the femoral head for further treatment in a future, without significant restriction of the indication due to necrosis (osteochondroplasty, resurfacing, THR).","[Trc, T.; Chladek, P.; Havlas, V.] Charles Univ Prague, Dept Orthopaed Surg, Fac Med 2, Prague 15008 5, Czech Republic","Trc, T (reprint author), Charles Univ Prague, Dept Orthopaed Surg, Fac Med 2, V Uvalu 84, Prague 15008 5, Czech Republic.","tomas.trc@fnmotol.cz",null,null,null,null,null,22,0,0,"SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN","STUTTGART","HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY","1019-1291",null,null,"OSTEOLOGIE","Osteologie",null,2010,19,1,null,null,null,null,36,39,null,null,null,4,"Orthopedics","Orthopedics","711EG","WOS:000286569300007"]
[null,null,null,null,"J","Kolar, P; Stulik, J; Kyncl, M",null,null,null,"Kolar, P.; Stulik, J.; Kyncl, M.",null,null,"Dynamic Magnetic Resonance Imaging of a Lumbar Spine - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"vertebrogenic syndromes; postural function; dynamic magnetic resonance imaging","STABILIZATION; KINEMATICS; DYNESYS; MRI","Patients with vertebrogenic problems are usually examined by magnetic resonance imaging (MRI) in the stationary, relaxed supine position only. This position, however, does not allow sufficient evaluation of morphological findings since these may vary under different postural, spine-loading situations. This has been confirmed by MRI assessment with the patient standing or by dynamic MRI assessment with the patient bending forwards or backwards. At this time, there is no MRI device in the Czech Republic that permits assessment with the patient standing or bending, so we perform MRI assessment while inducing stabilizing muscle activity. For lumbar spine evaluation, MRI analysis at the same time as hip flexion against some small resistance or just gravity proves to be spine-loading and therefore dynamic, since the patient needs to activate not only hip flexors, but also spinal stabilizers. Such an MRI assessment allows for intradiscal movement, shape measurement, and a degree of stability, allowing regional anatomical parameter measurements and analysis of disc/nerve root relationships during dynamic postural loading. Disturbed function of soft tissue structures in response to various postural situations may result in discrepancies between subjective symptoms, neurological signs, and morphological findings arising out of the static supine position. Stability analysis by means of dynamic MRI studies may also assist in determining the optimum surgical procedure for any given patient.","2 LF UK FN & Motole, Klin Rehabil Telovychovneho Lekarstvi, Prague 15006 5, Czech Republic; [Stulik, J.] FN Motole, Oddeleni Spondylochirurg, Prague, Czech Republic; [Kyncl, M.] FN Motole, LF UK Praze, Klin Zobrazovacfch Metod 2, Prague, Czech Republic; [Kolar, P.] FN Motole, LF UK Praze, Klin Rehabil Telovychovneho Lekarstvi 2, Prague 15006 5, Czech Republic","Kolar, P (reprint author), 2 LF UK FN & Motole, Klin Rehabil Telovychovneho Lekarstvi, Uvalu 84, Prague 15006 5, Czech Republic.","pavel.kolar@fnmotol.cz",null,null,null,null,null,10,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2010,73,4,null,null,null,null,438,442,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","648IK","WOS:000281685800014"]
[null,null,null,null,"J","Chladek, P; Trc, T",null,null,null,"Chladek, P.; Trc, T.",null,null,"Avascular necrosis of the femoral head in young adults - a double-stage solution with forage and remodeling osteochondroplasty","OSTEOLOGIE",null,null,"German","Article",null,null,null,null,null,"Avascular necrosis; femoral head; bone grafting; femoroacetabular impingement","FEMOROACETABULAR IMPINGEMENT; HIP; OSTEOARTHRITIS; OSTEONECROSIS","Avascular necrosis of the femoral head remains despite significant advances in medicine, an important pre-arthritis. Attitudes on the indication for a surgical procedure and its radicalism (joint-preserving procedure vs. arthroplasty) are different and changing. During the initial collapse of the head and an uncertain prognosis quod vitam, the indication for total hip replacement can be provided also in the end of the second decade relatively generous. But for patients who are in remission of a systemic disease, this can be considered critical even on the border of the third or fourth decade. Because of its simplicity, low morbidity and a good analgesic effect the removal of necrotic areas with a following autologous bone grafting is recommended in such cases. For further functional problems or pain after this surgery a femoroacetabular impingement syndrome must be excluded, which should be treated by open dislocation of the hip. However, the indication for any osteotomy should be made cautiously. They deteriorate the anatomy at the upper end of the femur and thus the conditions for the implantation of an endoprosthesis, which ultimately often cannot be prevented.","[Chladek, P.; Trc, T.] Karls Univ Prag, Orthopad Klin, Med Fak 2, Prague, Czech Republic","Chladek, P (reprint author), Karls Univ Prag, Orthopad Klin, Med Fak 2, V Uvalu 84, Cz Prag 5, Czech Republic.","tomas.trc@lfmotol.cuni.cz",null,null,null,null,"Agarwala S, 2009, J BONE JOINT SURG BR, V91B, P1013, DOI 10.1302/0301-620X.91B8.21518; Arlet J, 1990, J Bone Joint Surg Am, V72, P151; Chladek P, 2007, ACTA CHIR ORTHOP TR, V74, P354; Christensen CP, 2003, CLIN ORTHOP RELAT R, P75, DOI 10.1097/01.blo.0000043047.84315.4b; Ganz R, 2003, CLIN ORTHOP RELAT R, P112, DOI 10.1097/01.blo.0000096804.78689.c2; Ganz R, 2001, J BONE JOINT SURG BR, V83B, P1119, DOI 10.1302/0301-620X.83B8.11964; Le Nen D, 2004, REV CHIR ORTHOP, V90, P722, DOI 10.1016/S0035-1040(04)70752-7; MERCATI E, 1972, J CHIR-PARIS, V103, P499; NISHII T, 2007, NIPPON RINSHO S9, V28, P537; Ohzono Kenji, 2007, Clin Calcium, V17, P849; Steinberg ME, 2001, CLIN ORTHOP RELAT R, P71; Sugano N, 1999, J BONE JOINT SURG BR, V81B, P590, DOI 10.1302/0301-620X.81B4.9393; SUGIOKA Y, 1984, CLIN ORTHOP RELAT R, P12",13,0,0,"SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN","STUTTGART","HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY","1019-1291",null,null,"OSTEOLOGIE","Osteologie",null,2010,19,1,null,null,null,null,40,45,null,null,null,6,"Orthopedics","Orthopedics","711EG","WOS:000286569300008"]
[null,null,null,null,"J","Kuzelova, H; Ptacek, R; Macek, M",null,null,null,"Kuzelova, Hana; Ptacek, Radek; Macek, Milan, Jr.",null,null,"The serotonin transporter gene (5-HTT) variant and psychiatric disorders","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Review",null,null,null,null,null,"serotonin transporter; 5-HTTLPR; length variant; genetics; psychiatric disorders; SLC6A4","DEFICIT HYPERACTIVITY DISORDER; OBSESSIVE-COMPULSIVE DISORDER; NONMEDICATED ADHD BOYS; REGION POLYMORPHISM; PERSONALITY-TRAITS; SUICIDAL-BEHAVIOR; FUNCTIONAL POLYMORPHISM; ANTHROPOMETRIC CHANGES; PROMOTER POLYMORPHISM; ALCOHOL DEPENDENCE","Both serotonin and the serotonin transporter, which transports the neurotransmitter serotonin from synaptic spaces into presynaptic neurons, play an important role in the pathophysiology of several psychiatric disorders. Mutations associated with the serotonin transporter gene may result in changes in serotonin transporter function. The serotonin transporter gene promoter variant, consisting of a long (L) and a short (S) variant, is one of the major factors which contribute to the etiology of many psychiatric disorders. In this regard, many studies have been published on association of this variant with various psychiatric disorders. This repeat length variant in the promoter region of this gene has been shown to affect the rate of serotonin uptake and may play a role in post-traumatic stress disorder and depression-susceptibility in people experiencing emotional trauma. Associations between a functional variant in the serotonin transporter anxiety-related personality traits were found, as well as the risk of developing depression, alcoholism or suicidal behavior. Understanding of possible associations of these variants and psychiatric disorders would bring progress in principles and treatment of many disorders.","[Kuzelova, Hana] Charles Univ Prague, Fac Med 2, FN Motol, Inst Biol & Med Genet, Prague 15006, Czech Republic; [Kuzelova, Hana; Ptacek, Radek] Charles Univ Prague, Fac Med 1, Dept Psychiat, Prague 15006, Czech Republic","Kuzelova, H (reprint author), Charles Univ Prague, Fac Med 2, FN Motol, Inst Biol & Med Genet, Uvalu 84, Prague 15006, Czech Republic.","hana.kuzelova@lfmotol.cuni.cz","Ptacek, Radek/C-6696-2009",null," [VZFNM00064203]","Supported by VZFNM00064203.",null,73,18,19,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2010,31,1,null,null,null,null,4,10,null,null,null,7,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","737PY","WOS:000288581900002"]
[null,null,null,null,"J","Laczo, J; Andel, R; Vyhnalek, M; Vlcek, K; Magerova, H; Varjassyova, A; Tolar, M; Hort, J",null,null,null,"Laczo, J.; Andel, R.; Vyhnalek, M.; Vlcek, K.; Magerova, H.; Varjassyova, A.; Tolar, M.; Hort, J.",null,null,"Human Analogue of the Morris Water Maze for Testing Subjects at Risk of Alzheimer's Disease","NEURODEGENERATIVE DISEASES",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; Mild cognitive impairment; Spatial memory; Water maze task; Apolipoprotein E","MILD COGNITIVE IMPAIRMENT","Background: Patients with Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) have difficulties with spatial orientation. Objective: To test hypothesis that spatial navigation is impaired early in MCI patients representing the presymptomatic stage of AD. Methods: We tested patients with probable AD (n = 21), MCI, further classified according to Petersen's criteria as amnestic MCI (aMCI) single domain (n = 11), aMCI multiple domain (n = 31), or nonamnestic MCI (n = 7). The aMCI group was also stratified using cued recall according to Dubois' criteria into memory impairment of the hippocampal type (n = 10) and isolated memory retrieval impairment-nonhippocampal (n = 32) and also according to ApoE4 status into E4+ (n = 12) and E4-(n = 30). These patients and controls (n = 28) were tested in the human variant of the Morris water maze. Depending on the subtest, the subjects could use the egocentric or allocentric (hippocampus-dependent) navigation. Results: The AD and aMCI multiple domain groups were impaired in all subtests. The aMCI single domain group was impaired in allocentric subtests. The hippocampal MCI group performed poorer than the nonhippocampal MCI group and similarly to the AD group. The ApoE4+ group was as bad as the AD group when compared with the E4- group. Conclusion: aMCI subjects represent a very heterogeneous population, and spatial memory or cued recall examination can add more value to aMCI classification. ApoE4+ patients are more impaired than ApoE4- patients. Copyright (C) 2010 S. Karger AG, Basel","[Hort, J.] Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Sch Med 2, CZ-15006 Prague, Czech Republic; [Vlcek, K.] Acad Sci Czech Republic, Dept Neurophysiol Memory, Prague, Czech Republic; [Andel, R.] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Tolar, M.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA","Hort, J (reprint author), Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Sch Med 2, V Uvalu 84, CZ-15006 Prague, Czech Republic.","jakub.hort@seznam.cz","Vlcek, Kamil/B-9620-2012","Vlcek, Kamil/0000-0001-7152-3093","Czech Republic [309/09/1053, 309/09/0286]","Supported by the Grant Agency of the Czech Republic grants 309/09/1053 and 309/09/0286.",null,8,13,14,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1660-2854",null,null,"NEURODEGENER DIS","Neurodegener. Dis.",null,2010,7,41699,null,null,"SI",null,148,152,null,"10.1159/000289226",null,5,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","584GM","WOS:000276739200033"]
[null,null,null,null,"J","Pruhova, S; Dusatkova, P; Sumnik, Z; Kolouskova, S; Pedersen, O; Hansen, T; Cinek, O; Lebl, J",null,null,null,"Pruhova, Stepanka; Dusatkova, Petra; Sumnik, Zdenek; Kolouskova, Stanislava; Pedersen, Oluf; Hansen, Torben; Cinek, Ondrej; Lebl, Jan",null,null,"Glucokinase diabetes in 103 families from a country-based study in the Czech Republic: geographically restricted distribution of two prevalent GCK mutations","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"dHPLC; diabetes; founder effect; GCK-MODY; glucokinase","MODY; YOUNG; GENE; IDENTIFICATION; HNF-1-ALPHA; DIAGNOSIS; CHILDREN; POLYMORPHISMS; MELLITUS","Background: Glucokinase diabetes, also called GCK-MODY or maturity-onset diabetes of the young type 2 (MODY2), is caused by heterozygous mutations in the gene encoding glucokinase (GCK). Objective: The aim of study was to investigate the current prevalence of GCK mutations in a large cohort of Czech patients with typical clinical appearance of GCK-MODY. In addition, we reanalyzed the negative results obtained previously by screening using the denaturing high-performance liquid chromatography (dHPLC). Methods: We studied 140 unrelated Czech probands with clinical picture of GCK-MODY who were referred to our center from the whole of the Czech Republic between the years 1999-2009 by direct sequencing of GCK gene. Results: A mutation in GCK was identified in 103 of 140 probands (74%). We identified 46 different GCK mutations of which 13 were novel. Several mutations were detected in multiple families: p.Glu40Lys (20 families), p.Gly318Arg (12), p.Leu315His (7) and p.Val33Ala (six families). Direct sequencing detected a GCK mutations in 9 of 20 previously dHPLC-negative samples; the sensitivity of the dHPLC screening was calculated as 84%. Conclusions: The study shows a relatively high proportion of GCK mutations among individuals with GCK-like phenotype, confirming the effectiveness of carefully applied clinical criteria prior to genetic testing. In the Czech MODY registry, GCK-MODY represents the biggest subgroup of MODY (35%). We report several prevalent GCK mutations with a likely founder effect in the Czech population. Furthermore, our results provide ground for a possible recommendation to reinspect all negative results previously obtained by screening using dHPLC.","[Pruhova, Stepanka; Dusatkova, Petra; Sumnik, Zdenek; Kolouskova, Stanislava; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Pruhova, Stepanka] Charles Univ Prague, Dept Pediat, Univ Hosp Kralovske Vinohrady, CZ-15006 Prague, Czech Republic; [Pedersen, Oluf; Hansen, Torben] Hagedorn Res Inst, Gentofte, Denmark; [Pedersen, Oluf; Hansen, Torben] Steno Diabet Ctr, DK-2820 Gentofte, Denmark; [Pedersen, Oluf] Univ Aarhus, Aarhus, Denmark; [Pedersen, Oluf] Univ Copenhagen, Inst Biomed Sci, Copenhagen, Denmark; [Hansen, Torben] Univ So Denmark, Odense, Denmark","Lebl, J (reprint author), Charles Univ Prague, Dept Pediat, Univ Hosp Motol, V Uvalu 84, CZ-15006 Prague, Czech Republic.","jan.lebl@lfmotol.cuni.cz",null,null,"Norway through the Norwegian Financial Mechanism [CZ0100]; Czech Ministry of Health [MZ000064203]","The study was supported by a grant 'Monogenic diabetes in childhood: from genetics to therapy' from Norway through the Norwegian Financial Mechanism (No CZ0100) and by an institutional grant from the Czech Ministry of Health (grant MZ000064203).",null,25,11,11,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","DEC",2010,11,8,null,null,null,null,529,535,null,"10.1111/j.1399-5448.2010.00646.x",null,7,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","688NA","WOS:000284854900004"]
[null,null,null,null,"J","Rampichova, M; Filova, E; Varga, F; Lytvynets, A; Prosecka, E; Kolacna, L; Motlik, J; Necas, A; Vajner, L; Uhlik, J; Amler, E",null,null,null,"Rampichova, Michala; Filova, Eva; Varga, Ferdinand; Lytvynets, Andriy; Prosecka, Eva; Kolacna, Lucie; Motlik, Jan; Necas, Alois; Vajner, Ludek; Uhlik, Jiri; Amler, Evzen",null,null,"Fibrin/Hyaluronic Acid Composite Hydrogels as Appropriate Scaffolds for In Vivo Artificial Cartilage Implantation","ASAIO JOURNAL",null,null,"English","Article",null,null,null,null,null,null,"ARTICULAR-CARTILAGE; CHONDROCYTES; REPAIR; REGENERATION; DEFECTS","Hydrogels prepared from a mixture of fibrin and high-molecular weight (MW) hyaluronic acid (HA) were found to be suitable scaffolds for chondrocyte seeding and pig knee cartilage regeneration. Collagen in the hydrogels is not necessary for the formation of biomechanically stable tissue. Regenerated cartilage showed very good biomechanical and histological properties only 6 months after implantation. Notably, the quality of the healing process was dependent on the initial chondrocyte concentration of the scaffolds. These experiments were performed according to good laboratory practice (GLP). ASAIO Journal 2010; 56:563-568.","[Rampichova, Michala; Varga, Ferdinand; Prosecka, Eva; Kolacna, Lucie; Amler, Evzen] Charles Univ Prague, Inst Biophys, Fac Med 2, Prague 15006 5, Czech Republic; [Rampichova, Michala; Filova, Eva; Lytvynets, Andriy; Prosecka, Eva; Kolacna, Lucie; Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague, Czech Republic; [Motlik, Jan] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Libechov, Czech Republic; [Necas, Alois] Univ Vet & Pharmaceut Sci, Fac Vet Med, Dept Surg & Orthoped, Small Anim Clin, Brno, Czech Republic; [Vajner, Ludek; Uhlik, Jiri] Charles Univ Prague, Dept Histol & Embryol, Fac Med 2, Prague 15006 5, Czech Republic; [Vajner, Ludek; Uhlik, Jiri] Acad Sci Czech Republic, Inst Physiol, Dept Breeding & Zoohyg Lab Anim, Vvi, Prague, Czech Republic","Amler, E (reprint author), Charles Univ Prague, Inst Biophys, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","evzen.amler@lfmotol.cuni.cz","Vajner, Ludek/C-5823-2014; Uhlik, Jiri/C-6282-2014",null,"Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Ministry of Education, Youth, and Sports of the Czech Republic [NPV II 2B06130]; Grant Agency of the Academy of Sciences [IAA500390702]; Czech Science Foundation [GA202/09/1151, P304/10/1307]; EU [214539]; Grant Agency of Charles University [119209]","Supported by the Academy of Sciences of the Czech Republic (institutional research plans AV0Z50390703 and AV0Z50390512), the Ministry of Education, Youth, and Sports of the Czech Republic (research programs NPV II 2B06130), the Grant Agency of the Academy of Sciences (grant no. IAA500390702), the Czech Science Foundation (grant numbers GA202/09/1151 and P304/10/1307), the EU project BIOSCENT (ID number 214539), and the Grant Agency of Charles University (grant no. 119209). The authors are grateful to Sam Norris for proof reading of this manuscript.",null,19,10,11,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1058-2916",null,null,"ASAIO J","Asaio J.","NOV-DEC",2010,56,6,null,null,null,null,563,568,null,"10.1097/MAT.0b013e3181fcbe24",null,6,"Engineering, Biomedical; Transplantation","Engineering; Transplantation","674FH","WOS:000283719600014"]
[null,null,null,null,"J","Starkova, J; Zamostna, B; Mejstrikova, E; Krejci, R; Drabkin, HA; Trka, J",null,null,null,"Starkova, Julia; Zamostna, Blanka; Mejstrikova, Ester; Krejci, Roman; Drabkin, Harry A.; Trka, Jan",null,null,"HOX Gene Expression in Phenotypic and Genotypic Subgroups and Low HOXA Gene Expression as an Adverse Prognostic Factor in Pediatric ALL","PEDIATRIC BLOOD & CANCER",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; aberrant gene expression; hematopoiesis; homeodomain genes","ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; HOMEOBOX GENE; HOX11L2 EXPRESSION; POOR-PROGNOSIS; CANCER; MLL; OVEREXPRESSION","Background. HOX genes play an important role in both normal lymphopoiesis and leukemogenesis. However, HOX expression patterns in leukemia cells compared to normal lymphoid progenitors have not been systematically studied in acute lymphoblastic leukemia (ALL) subtypes. Procedure. The RNA expression levels of HOXA, HOXB, and CDX1/2 genes were analyzed by qRT-PCR in a cohort of 61 diagnostic pediatric ALL samples and FACS-sorted subpopulations of normal lymphoid progenitors. Results. The RNA expression of HOXA7-10, HOXA13, and HOXB2-4 genes was exclusively detected in leukemic cells and immature progenitors. The RNA expression of HOXB6 and CDX2 genes was exclusively detected in leukemic cells but not in B-lineage cells at any of the studied developmental stages. HOXA3-4, HOXA7, and HOXB3-4 genes were differentially expressed between BCP-ALL and T-ALL subgroups, and among genotypically defined MLL/AF4, TEL/AML1, BCR/ABL, hyperdiploid and normal karyotype subgroups. However, this differential expression did not define specific clusters in hierarchical cluster analysis. HOXA7 gene was low expressed at the RNA level in patients with hyperdiploid leukemia, whereas wHOXB7 and CDX2 genes were low expressed in TEL/AML1-positive and BCR/ABL-positive cases, respectively. In contrast to previous findings in acute myeloid leukemia, high HOXA RNA expression was associated with an excellent prognosis in Cox's regression model (P = 0.03). In MLL/AF4-positive ALL, lower HOXA RNA expression correlated with the methylation status of their promoters. Conclusions. HOX gene RNA expression cannot discriminate leukemia subgroups or relative maturity of leukemic cells. However, HOXA RNA expression correlates with prognosis, and particular HOX genes are expressed in specific genotypically characterized subgroups. Pediatr Blood Cancer. 2010;55:1072-1082. (C) 2010 Wiley-Liss, Inc.","[Starkova, Julia] Charles Univ Prague, Dept Pediat Hematol Oncol, Fac Med 2, CLIP, Prague 15006, Czech Republic; [Zamostna, Blanka] Charles Univ Prague, Dept Genet & Microbiol, Fac Sci, Prague, Czech Republic; [Drabkin, Harry A.] Med Univ S Carolina, Dept Hematol Oncol, Charleston, CA USA","Starkova, J (reprint author), Charles Univ Prague, Dept Pediat Hematol Oncol, Fac Med 2, CLIP, V Uvalu 84, Prague 15006, Czech Republic.","julia.starkova@lfmotol.cuni.cz",null,null,"MSMTVZ [MSM0021620813]; GACR [301/08/P532]; IGA [NR9526]","Grant sponsor: MSMTVZ; Grant number: MSM0021620813; Grant sponsor: GACR; Grant number: 301/08/P532; Grant sponsor: IGA; Grant number: NR9526.",null,45,7,10,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1545-5009",null,null,"PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","DEC 1",2010,55,6,null,null,null,null,1072,1082,null,"10.1002/pbc.22749",null,11,"Oncology; Hematology; Pediatrics","Oncology; Hematology; Pediatrics","674OT","WOS:000283757600008"]
[null,null,null,null,"J","Halaska, MJ; Novackova, M; Mala, I; Pluta, M; Chmel, R; Stankusova, H; Robova, H; Rob, L",null,null,null,"Halaska, Michael J.; Novackova, Marta; Mala, Ivana; Pluta, Marek; Chmel, Roman; Stankusova, Hana; Robova, Helena; Rob, Lukas",null,null,"A Prospective Study of Postoperative Lymphedema After Surgery for Cervical Cancer","INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER",null,null,"English","Article",null,null,null,null,null,"Cervical cancer; Lymphedema; Prevalence; Multifrequency bioelectrical impedance analysis; MFBIA","BREAST-CANCER; BIOELECTRICAL-IMPEDANCE; RADICAL TRACHELECTOMY; RISK-FACTORS; RADIOTHERAPY; EDEMA; CARCINOMA; HISTORY; ARM","Objective: Lymphedema is a severe postoperative complication in oncological surgery. Multifrequency bioelectrical impedance analysis (MFBIA) is a new method for early lymphedema detection. The objective was to establish the methodology of MFBIA for lower-limb lymphedema and to detect a lymphedema in patients undergoing cervical cancer surgery. Methods: From a population of 60 patients undergoing cervical cancer surgery, 39 underwent radical hysterectomy Wertheim III (RAD group), and 21 underwent conservative surgery (laparoscopic lymphadenectomy plus simple trachelectomy/simple hysterectomy CONS group). A control group of 29 patients (CONTR group) was used to determine the SD of impedance at zero frequency (R(0)). Patients were examined before surgery and at 3 and 6 months after surgery by MFBIA and by measuring the circumference of the lower limbs. Results: No differences were found between the CONS and RAD groups on age, height, weight, and histopathologic type of tumor. However, the number of dissected lymph nodes differed significantly between the groups (17.3 in the CONS group vs 25.8 in the RAD group, P = 0.0012). The SD of R(0) in the CONTR group was 36.0 and 39.0 for the right and the left leg, respectively. No difference in prevalence of lymphedema based on circumference method was found (35.9% in the RAD and 47.6% in the CONS groups, not statistically significant). Conclusions: No difference in the prevalence of lymphedema was found between the CONS and RAD groups. A methodology for MFBIA for the detection of lower-limb lymphedema was described.","[Halaska, Michael J.; Novackova, Marta; Pluta, Marek; Chmel, Roman; Robova, Helena; Rob, Lukas] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague 15000 5, Czech Republic; [Stankusova, Hana] Fac Hosp Motol, Dept Radiotherapy & Oncol, Prague, Czech Republic; [Mala, Ivana] Univ Econ, Fac Stat, Prague, Czech Republic","Halaska, MJ (reprint author), Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, V Uvalu 84, Prague 15000 5, Czech Republic.","mhalaska@centrum.cz",null,null,"Ministry of Health of the Czech Republic [IGA MZ NR 9455-3]","The work was supported by a grant from the Ministry of Health of the Czech Republic (IGA MZ NR 9455-3).",null,27,6,7,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X",null,null,"INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","JUL",2010,20,5,null,null,null,null,900,904,null,"10.1111/IGC.0b013e3181da29d0",null,5,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","628TG","WOS:000280144000032"]
[null,null,null,null,"J","Drevinek, P; Vosahlikova, S; Dedeckova, K; Cinek, O; Mahenthiralingam, E",null,null,null,"Drevinek, Pavel; Vosahlikova, Sarka; Dedeckova, Klara; Cinek, Ondrej; Mahenthiralingam, Eshwar",null,null,"Direct Culture-Independent Strain Typing of Burkholderia cepacia Complex in Sputum Samples from Patients with Cystic Fibrosis","JOURNAL OF CLINICAL MICROBIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"SP-NOV; MULTIVORANS; IDENTIFICATION; CENOCEPACIA","We examined if multilocus sequence typing (MLST), a method for genotyping and species identification of Burkholderia cepacia complex bacteria, could be applied directly to cystic fibrosis sputum. The redesigned nested-PCR MLST format was successfully used to accurately identify strains in 23 sputum samples, of which 8 were culture negative.","[Drevinek, Pavel; Vosahlikova, Sarka; Dedeckova, Klara; Cinek, Ondrej] Charles Univ Prague, Dept Pediat, Sch Med 2, Prague 15006, Czech Republic; [Mahenthiralingam, Eshwar] Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales","Drevinek, P (reprint author), Charles Univ Prague, Dept Pediat, Sch Med 2, Uvalu 84, Prague 15006, Czech Republic.","pavel.drevinek@Lfmotol.cuni.cz","Mahenthiralingam, Eshwar/D-3333-2009","Mahenthiralingam, Eshwar/0000-0001-9014-3790","Czech Ministry of Health [NS 10543-3]; Czech Ministry of Education [MSM0021620812]","This work was supported by grants from the Czech Ministry of Health (NS 10543-3) and the Czech Ministry of Education (MSM0021620812).",null,15,4,4,"AMER SOC MICROBIOLOGY","WASHINGTON","1752 N ST NW, WASHINGTON, DC 20036-2904 USA","0095-1137",null,null,"J CLIN MICROBIOL","J. Clin. Microbiol.","MAY",2010,48,5,null,null,null,null,1888,1891,null,"10.1128/JCM.02359-09",null,4,"Microbiology","Microbiology","592DV","WOS:000277356600059"]
[null,null,null,null,"J","Tomek, V; Vlk, R; Tlaskal, T; Skovranek, J",null,null,null,"Tomek, Viktor; Vlk, Radovan; Tlaskal, Tomas; Skovranek, Jan",null,null,"Successful Pericardio-Amniotic Shunting for Fetal Intrapericardial Teratoma","PEDIATRIC CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"IN-UTERO; MANAGEMENT; THERAPY; HYDROPS",null,"[Tomek, Viktor; Tlaskal, Tomas; Skovranek, Jan] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Tomek, Viktor; Tlaskal, Tomas; Skovranek, Jan] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Vlk, Radovan] Univ Hosp Motol, Dept Obstet & Gynecol, Prague, Czech Republic","Tomek, V (reprint author), Univ Hosp Motol, Kardioctr, Prague, Czech Republic.","viktor.tomek@fnmotol.cz",null,null,"Czech Ministry of Health [MZOFNM2005]","This publication was supported by a grant of the Czech Ministry of Health (MZOFNM2005).",null,11,1,4,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0172-0643",null,null,"PEDIATR CARDIOL","Pediatr. Cardiol.","NOV",2010,31,8,null,null,null,null,1236,1238,null,"10.1007/s00246-010-9774-x",null,3,"Cardiac & Cardiovascular Systems; Pediatrics","Cardiovascular System & Cardiology; Pediatrics","679JJ","WOS:000284157400019"]
[null,null,null,null,"J","Durila, M; Kalincik, T; Jurcenko, S; Pelichovska, M; Hadacova, I; Cvachovec, K",null,null,null,"Durila, Miroslav; Kalincik, Tomas; Jurcenko, Sergej; Pelichovska, Martina; Hadacova, Ivana; Cvachovec, Karel",null,null,"Arteriovenous differences of hematological and coagulation parameters in patients with sepsis","BLOOD COAGULATION & FIBRINOLYSIS",null,null,"English","Article",null,null,null,null,null,"antithrombin; arteriovenous difference; D-dimer; hemostasis; sepsis; thromboelastography","VENOUS-BLOOD; ORGAN FAILURE; ARTERIAL; SURGERY; DISEASE","In critically ill patients, either arterial or venous blood is usually available for sampling and measurement of basic coagulation parameters. The aim of this study was to examine whether in these patients the values of coagulation parameters differ significantly with respect to the source of the blood samples. In a group of 44 patients with severe sepsis, we compared the values of coagulation, thromboelastography and selected hematological parameters between the arterial and venous blood. In most of the investigated parameters (international normalized ratio, activated partial thromboplastin time, fibrinogen concentration, erythrocyte count, leukocyte and platelet count, hemoglobin level and thromboelastography parameters), we did not find significant differences (P>0.1). However, we found a significantly lower antithrombin activity and a significantly higher D-dimer concentration in venous blood compared to arterial blood (P<0.05). This could be associated with increased consumption of antithrombin and generation of D-dimer as a consequence of microthrombi formation in the capillaries. We therefore conclude that for the purpose of assessment of coagulation status in septic patients, arterial and venous blood cannot be treated as equivalent. Blood Coagul Fibrinolysis 21: 770-774 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Durila, Miroslav; Jurcenko, Sergej; Pelichovska, Martina; Cvachovec, Karel] Charles Univ Prague, Dept Anesthesiol & Crit Care Med, Fac Med 2, Inst Postgrad Med Educ, Prague 15006 5, Czech Republic; [Kalincik, Tomas] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; [Kalincik, Tomas] Charles Univ Prague, Dept Neurol, Fac Med 1, Gen Univ Hosp, Prague 15006 5, Czech Republic; [Hadacova, Ivana] Charles Univ Prague, Dept Clin Hematol, Fac Med 2, Prague 15006 5, Czech Republic","Durila, M (reprint author), Charles Univ Prague, Dept Anesthesiol & Crit Care Med, Fac Med 2, Inst Postgrad Med Educ, V Uvalu 84, Prague 15006 5, Czech Republic.","durila4@yahoo.com","Kalincik, Tomas/A-6911-2008",null,"Department of Anesthesiology and Critical Care Medicine, Second Faculty of Medicine and Institute for Postgraduate Medical Education, Charles University in Prague, Czech Republic","The financial support was provided by Department of Anesthesiology and Critical Care Medicine, Second Faculty of Medicine and Institute for Postgraduate Medical Education, Charles University in Prague, Czech Republic.",null,13,3,3,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0957-5235",null,null,"BLOOD COAGUL FIBRIN","Blood Coagul. Fibrinolysis","DEC",2010,21,8,null,null,null,null,770,774,null,"10.1097/MBC.0b013e32834013d7",null,5,"Hematology","Hematology","674EZ","WOS:000283718400010"]
[null,null,null,null,"J","Charvat, J; Chlumsky, J; Szabo, M; Zakovicova, E; Zamrazil, V",null,null,null,"Charvat, Jiri; Chlumsky, Jaromir; Szabo, Marcela; Zakovicova, Eva; Zamrazil, Vaclav",null,null,"The association of masked hypertension in treated type 2 diabetic patients with carotid artery IMT","DIABETES RESEARCH AND CLINICAL PRACTICE",null,null,"English","Article",null,null,null,null,null,"Masked hypertension; Type 2 diabetes mellitus; Carotid intima-media thickness; Carotid distensibility","TARGET ORGAN DAMAGE; BLOOD-PRESSURE; HOME HYPERTENSION; OFFICE; MELLITUS; PEOPLE","Objectives: To evaluate the association of masked hypertension (MH) in treated type 2 diabetic patients without history of cardiovascular disease with carotid artery target organ damage. Methods: Sixty-four type 2 diabetic patients treated for hypertension with office BP below 140/90 mm Hg were examined by 24-h BP monitoring and carotid sonography. MH was diagnosed if daily mean ambulatory BP was >= 135/85 mm Hg. The association of MH with carotid artery parameters was evaluated. Results: The average age of patients was 62 +/- 5 years. Twenty-four patients had MH (37.5%). Carotid artery IMT was 0.74 +/- 0.08 mm in patients with MH and 0.69 +/- 0.06 mm without MH (p = 0.03). The distensibility of common carotid artery was 0.24 +/- 0.07 mmHg(-1) in patients with MH and 0.29 +/- 0.1 mm Hg(-1) without MH (p = 0.14). After adjustment for age, gender, smoking, duration of diabetes, BMI and clinic blood pressure (BP) values the association of MH with carotid artery IMT was sustained. Conclusion: Masked hypertension in treated type 2 diabetic patients is associated with carotid artery IMT. (C) 2010 Elsevier Ireland Ltd. All rights reserved.","[Charvat, Jiri; Chlumsky, Jaromir; Szabo, Marcela; Zakovicova, Eva; Zamrazil, Vaclav] Charles Univ Prague, Fac Hosp 2, Dept Med, Prague 15006 5, Czech Republic","Charvat, J (reprint author), Charles Univ Prague, Fac Hosp 2, Dept Med, V Uvalu 84, Prague 15006 5, Czech Republic.","jiri.charvat@lfmotol.cuni.cz",null,null,"IGA Ministry of Health of Czech republic [NR/ 9520-3]","Supported by a grant from IGA Ministry of Health of Czech republic, NR/ 9520-3.",null,22,3,3,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0168-8227",null,null,"DIABETES RES CLIN PR","Diabetes Res. Clin. Pract.","SEP",2010,89,3,null,null,null,null,239,242,null,"10.1016/j.diabres.2010.04.014",null,4,"Endocrinology & Metabolism","Endocrinology & Metabolism","643AB","WOS:000281263000007"]
[null,null,null,null,"J","Krskova, L; Mrhalova, M; Hilska, I; Sumerauer, D; Drahokoupilova, E; Mudry, P; Kodet, R",null,null,null,"Krskova, Lenka; Mrhalova, Marcela; Hilska, Irena; Sumerauer, David; Drahokoupilova, Eva; Mudry, Peter; Kodet, Roman",null,null,"Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma","VIRCHOWS ARCHIV",null,null,"English","Article",null,null,null,null,null,"Bone marrow; Minimal disseminated disease; Real-time PCR; Alveolar rhabdomyosarcoma","POLYMERASE-CHAIN-REACTION; INTERGROUP RHABDOMYOSARCOMA; ALVEOLAR RHABDOMYOSARCOMA; MOLECULAR DIAGNOSIS; PERIPHERAL-BLOOD; MINIMAL DISEASE; TUMOR-CELLS; PCR ASSAY; EXPRESSION; CHILDREN","Childhood rhabdomyosarcoma (RMS) has two major histological subtypes: alveolar (aRMS) and embryonal. The aim of the study was to monitor minimal disseminated disease (MDD) using real-time quantitative reverse-transcription PCR (RQ-RT-PCR) of the PAX3-FKHR, PAX7-FKHR fusion genes and myoD1 gene. We prepared an assay using RQ-RT-PCR for a quantitative assessment of MDD in aRMS by using hydrolysis probe for quantification of PAX3-FKHR, PAX7-FKHR and myoD1 genes and beta-2-microglobulin housekeeping gene. Primary tumor samples (44), samples of local recurrences (26) from 48 patients with aRMS were examined by nested RT-PCR and RQ-RT-PCR techniques. Additionally, bone marrow samples (115), peripheral blood progenitor cell samples (27), and peripheral blood samples (25) from 33 aRMS patients were tested. PAX3/7-FKHR and myoD1 transcripts proved to be a sensitive tool for detection of MDD in RMS. We were able to identify 15/25 patients with bone marrow (BM) involvement at the time of presentation using RQ-RT-PCR. We analyzed PAX3-FKHR or PAX7-FKHR expression during the course of the disease. The RQ-RT-PCR results correlated well with nested RT-PCR results (p < 0.0001). The presence of metastases is the most adverse prognostic factor in RMS, and bone marrow is a frequent site of the tumor dissemination in RMS, especially in aRMS. Our results detecting the fusion transcripts or myoD1 transcript in the BM or peripheral blood suggest that patients with positive findings are at high risk of the tumor progression.","[Krskova, Lenka; Mrhalova, Marcela; Hilska, Irena; Kodet, Roman] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Krskova, Lenka; Mrhalova, Marcela; Hilska, Irena; Sumerauer, David; Drahokoupilova, Eva; Kodet, Roman] Fac Hosp Motol, Prague, Czech Republic; [Sumerauer, David; Drahokoupilova, Eva] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague, Czech Republic; [Mudry, Peter] Fac Hosp Brno, Clin Pediat Oncol, Brno, Czech Republic","Krskova, L (reprint author), Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic.","lkrskova@email.cz",null,null,"Ministry of Education, Youth and Sports of the Czech Republic [0021620813]; Ministry of Health [MZOFNM2005];  [GACR 304/07/0532]","The study was supported by the Grant GACR 304/07/0532, the Research Project of the Ministry of Education, Youth and Sports of the Czech Republic No. 0021620813 and by the Research Project of the Ministry of Health MZOFNM2005. All experiments comply with the current laws of Czech Republic.",null,19,3,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0945-6317",null,null,"VIRCHOWS ARCH","Virchows Arch.","MAY",2010,456,5,null,null,null,null,463,472,null,"10.1007/s00428-010-0913-9",null,10,"Pathology","Pathology","592BM","WOS:000277349900001"]
[null,null,null,null,"J","Brozkova, D; Mazanec, R; Haberlova, J; Sakmaryova, I; Subrt, I; Seeman, P",null,null,null,"Brozkova, Dana; Mazanec, Radim; Haberlova, Jana; Sakmaryova, Iva; Subrt, Ivan; Seeman, Pavel",null,null,"Six New Gap Junction Beta 1 Gene Mutations and Their Phenotypic Expression in Czech Patients with Charcot-Marie-Tooth Disease","GENETIC TESTING AND MOLECULAR BIOMARKERS",null,null,"English","Article",null,null,null,null,null,null,"CONNEXIN 32 GENE; DE-NOVO MUTATION; HEREDITARY NEUROPATHY; SENSORY NEUROPATHY; CENTRAL CONDUCTION; PRESSURE PALSIES; DELETION; TYPE-1; LIABILITY; FAMILIES","X-linked Charcot-Marie-Tooth (CMTX) disease is a hereditary motor and sensory neuropathy caused by mutations in the gap junction beta 1 gene (GJB1 codes for connexin 32). In this study we report six novel mutations p.Met1Arg, p.Leu9Phe, p.Ser17Tyr, p.Val63Phe, p.Val170Ile, and p.Leu212Phe in GJB1 and their phenotypic expression. These mutations affect both intracellular and extracellular parts of the GJB1 protein. The screened patients had previously excluded the duplication/deletion on 17p11.2 and the male-to-male transfer in the pedigree. Except p. Val170Ile, all reported mutations segregated with the CMT phenotype in the families and caused CMTX1 neuropathy. Mutations were not found in 200 control DNA samples. Additionally, we performed in silico analysis of the novel mutations with the program PANTHER. The PANTHER scored five mutations, all but p. Val170Ile, as likely deleterious and supported the pathogenicity of the found mutations. These results provided evidence that these five mutations are causative for CMTX1.","[Brozkova, Dana; Haberlova, Jana; Sakmaryova, Iva; Seeman, Pavel] Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague 15006, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Sch Med 2, Dept Neurol, Prague 15006, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; [Subrt, Ivan] Charles Univ Prague, Fac Med Pilsen, Inst Med Genet, Plzen, Czech Republic; [Subrt, Ivan] Univ Hosp Plzen, Plzen, Czech Republic","Brozkova, D (reprint author), Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, V Uvalu 84, Prague 15006, Czech Republic.","dana.brozkova@seznam.cz","Subrt, Ivan/A-5948-2013","Subrt, Ivan/0000-0003-2540-0863","GAUK [309];  [VZ 00064203/6506]","The authors thank J. Kofer, M. D. (family J), M. Majer, M. D. (family O), Prof. E. Seemanova, M. D. (family S), and I. Stepanova, M. D. (family J), for sending us the families for examination. The project was supported by a grant VZ 00064203/6506 and GAUK No. 309.",null,23,3,3,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1945-0265",null,null,"GENET TEST MOL BIOMA","Genet. Test. Mol. Biomark.","FEB",2010,14,1,null,null,null,null,3,7,null,"10.1089/gtmb.2009.0093",null,5,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","554GE","WOS:000274422700002"]
[null,null,null,null,"J","Zemanek, D; Veselka, J; Adla, T; Setina, M; Ferda, J",null,null,null,"Zemanek, David; Veselka, Josef; Adla, Teodor; Setina, Marek; Ferda, Jiri",null,null,"Uncommon cause of obstruction in the left ventricular outflow tract by a metastasis of adenocarcinoma","ARCHIVES OF MEDICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"left ventricular obstruction; cardiac metastasis",null,"Cardiac metastases are rare diagnoses among cardiac disorders. This case demonstrates a unique presence of an obstruction in the left ventricular outflow tract caused by the metastasis of a renal carcinoma. Adequate diagnostic and therapeutic procedures were lifesaving in this potentially fatal diagnosis.","[Zemanek, David; Veselka, Josef] Charles Univ Prague, Dept Cardiol, Univ Hosp Motol, Sch Med 1, Prague 16000, Czech Republic; [Adla, Teodor] Charles Univ Prague, Dept Imaging Methods, Univ Hosp Motol, Sch Med 1, Prague 16000, Czech Republic; [Setina, Marek] Charles Univ Prague, Dept Cardiac Surg, Univ Hosp Motol, Sch Med 1, Prague 16000, Czech Republic; [Ferda, Jiri] Charles Univ Prague, Teaching Hosp, Radiodiagnost Clin, Prague 16000, Czech Republic","Zemanek, D (reprint author), Charles Univ Prague, Dept Cardiol, Univ Hosp Motol, Sch Med 1, K Cervnemu Vrchu 844-2A, Prague 16000, Czech Republic.","zejada@seznam.cz",null,null,null,null,null,3,2,2,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922",null,null,"ARCH MED SCI","Arch. Med. Sci.","DEC",2010,6,6,null,null,null,null,981,983,null,"10.5114/aoms.2010.19313",null,3,"Medicine, General & Internal","General & Internal Medicine","703MN","WOS:000285982100026"]
[null,null,null,null,"J","Vazna, A; Musova, Z; Vlckova, M; Novotna, D; Dvorakova, L; Hrdlicka, M; Havlovicova, M; Sedlacek, Z",null,null,null,"Vazna, Alzbeta; Musova, Zuzana; Vlckova, Marketa; Novotna, Drahuse; Dvorakova, Lenka; Hrdlicka, Michal; Havlovicova, Marketa; Sedlacek, Zdenek",null,null,"FMR1 Gene Expansion, Large Deletion of Xp, and Skewed X-Inactivation in a Girl With Mental Retardation and Autism","AMERICAN JOURNAL OF MEDICAL GENETICS PART A",null,null,"English","Article",null,null,null,null,null,"fragile X syndrome; Xp deletion; array CGH; skewed X-inactivation; mental retardation; autism","FULL MUTATION; FEMALES; CHROMOSOME; PHENOTYPE; MICROPHTHALMIA","We describe a girl with mild facial anomalies, mild mental retardation, and atypical autism with a remarkable behavioral phenotype of persistent anger, aggression, and dysphoria. The occurrence of late-onset tremor and premature ovarian failure in the maternal branch of the family pointed to a possible defect in the FMR1 gene. Indeed, the patient carried a full FMR1 mutation. Unexpectedly, both alleles of the gene were almost completely methylated. Cytogenetic examination of the patient revealed in addition a large de novo deletion in band Xp22 on one of her X chromosomes. The deletion was fine mapped using oligonucleotide array CGH, and its breakpoints were localized using sequencing. The size of the deletion was about 17.4 Mb, and it contained more than 90 protein-coding genes. Microsatellite analysis indicated paternal origin of the aberrant chromosome. The large rearrangement was the most probable cause of the X-inactivation skewing, thus explaining the methylation of not only the expanded (maternal) but also the normal (paternal) FMR1 alleles. This pattern of skewed X-inactivation was confirmed using the analysis of methylation at the AR locus. The relatively mild phenotype of the patient resulted most likely from unmasking of the FMR1 defect. Although the deleted region contained many important genes, the phenotypic contribution of the rearranged X chromosome was probably limited by its almost complete inactivation. However, reduced dose of several genes escaping X-inactivation might also play a role in the phenotype of the patient. (C) 2010 Wiley-Liss, Inc.","[Vazna, Alzbeta; Musova, Zuzana; Vlckova, Marketa; Novotna, Drahuse; Havlovicova, Marketa; Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague 15006 5, Czech Republic; [Vazna, Alzbeta; Musova, Zuzana; Vlckova, Marketa; Novotna, Drahuse; Hrdlicka, Michal; Havlovicova, Marketa; Sedlacek, Zdenek] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Dvorakova, Lenka] Charles Univ Prague, Fac Med 1, Inst Inherited Metab Disorders, Prague 15006 5, Czech Republic; [Dvorakova, Lenka] Gen Univ Hosp, Prague, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Prague 15006 5, Czech Republic","Sedlacek, Z (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","zdenek.sedlacek@lfmotol.cuni.cz",null,null,"Ministries of Education and Health of the Czech Republic [NR/9457-3, MZO00064203, MSM0021620806]; European Commission [043318, 223692]","This work was supported by grants NR/9457-3, MZO00064203, and MSM0021620806 from the Ministries of Education and Health of the Czech Republic, and INCORE (043318) and CHERISH (223692) from the European Commission.",null,23,2,2,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1552-4825",null,null,"AM J MED GENET A","Am. J. Med. Genet. A","MAY",2010,"152A",5,null,null,null,null,1273,1277,null,"10.1002/ajmg.a.33352",null,5,"Genetics & Heredity","Genetics & Heredity","597ES","WOS:000277739800025"]
[null,null,null,null,"J","Brozkova, D; Mazanec, R; Haberlova, J; Sakmaryova, I; Seeman, P",null,null,null,"Brozkova, D.; Mazanec, R.; Haberlova, J.; Sakmaryova, I.; Seeman, P.",null,null,"Clinical and in silico evidence for and against pathogenicity of 11 new mutations in the MPZ gene","CLINICAL GENETICS",null,null,"English","Article",null,null,null,null,null,"CMT; CMT1B; hereditary neuropathy; HMSN III; MPZ; P0","MARIE-TOOTH-DISEASE; HEREDITARY NEUROPATHY; PRESSURE PALSIES; LATE-ONSET; PHENOTYPES; LIABILITY; 1B","Mutations in the myelin protein zero (MPZ) gene are one of the frequent causes of Charcot-Marie-Tooth (CMT) hereditary neuropathies. Because the mutation rate of MPZ gene is rather high and some mutations are reported as polymorphisms, the proper clinical, electrophysiological examination and the segregation of the new mutation in larger families are crucial for the correct interpretation of the pathogenic or non-pathogenic character of each novel mutation. We examined 11 families with novel MPZ mutations. Eight of the mutations (L48Q, T65N, E97fs, G103W, P132T, T143R, V146G, c. 645+ 1G>T) seem to be pathogenic on the basis of perfect segregation with the CMT phenotype and two (G213R and D246N), on the contrary, seem to be non-pathogenic/rare polymorphisms because they are present in healthy relatives. The character of the V46M mutation is difficult to interpret definitely; it may cause a sensory neuropathy or may also be a rare polymorphism. Phenotypes associated with each of the new mutations include severe hereditary motor and sensory neuropathy type III (HMSN III), and mild phenotype CMT1B presented mostly with only decreased or absent reflexes, foot deformities and mild or even absent atrophies in the lower limbs. Our report and careful family investigations with genotype-phenotype correlations should help to improve genetic counselling and correct interpretation of DNA testing results in further isolated patients or smaller families worldwide where these novel mutations might be found.","[Brozkova, D.; Haberlova, J.; Sakmaryova, I.; Seeman, P.] Charles Univ Prague, Sch Med 2, DNA Lab, Dept Child Neurol, Prague 15006, Czech Republic; [Mazanec, R.] Charles Univ Prague, Sch Med 2, Dept Neurol, Prague 15006, Czech Republic; Univ Hosp Motol, Prague 15006, Czech Republic","Brozkova, D (reprint author), Charles Univ Prague, Sch Med 2, DNA Lab, Dept Child Neurol, V Uvalu 84, Prague 15006, Czech Republic.","dana.brozkova@seznam.cz",null,null,"IGA MH CR NS [10552-3]","The project was supported by grant IGA MH CR NS 10552-3.",null,18,1,1,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0009-9163",null,null,"CLIN GENET","Clin. Genet.","JUL",2010,78,1,null,null,null,null,81,87,null,"10.1111/j.1399-0004.2010.01423.x",null,7,"Genetics & Heredity","Genetics & Heredity","606CB","WOS:000278397300013"]
[null,null,null,null,"J","Charvat, J; Chlumsky, J; Svab, P; Zamrazil, V",null,null,null,"Charvat, J.; Chlumsky, J.; Svab, P.; Zamrazil, V.",null,null,"The Impact of Early Diastolic Myocardial Relaxation on the Other Parameters of Diastolic Function and Association of Tissue Doppler Parameters of Diastolic Function with Diabetes Compensation and Duration in Type 2 Diabetic Patients","JOURNAL OF INTERNATIONAL MEDICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"DIABETES MELLITUS; DIASTOLIC FUNCTION; TISSUE DOPPLER ECHOCARDIOGRAPHY","LEFT-VENTRICULAR RELAXATION; OVERT HEART-DISEASE; ARTERIAL-HYPERTENSION; DYSFUNCTION; MELLITUS; ECHOCARDIOGRAPHY; PREVALENCE","This study assessed the impact of tissue Doppler derived myocardial early diastolic relaxation velocity (E(m)) on the other parameters of diastolic function (preload dependent transmitral early diastolic velocity [E], tissue Doppler derived myocardial late diastolic velocity [A(m)], preload dependent transmitral late diastolic velocity [A]) and evaluated the correlation of these parameters with selected clinical variables in type 2 diabetic patients. Using tissue Doppler echocardiography, 82 type 2 diabetic patients were evaluated, divided into two equal groups of E(m) < 7.5 cm/s or 7.5 cm/s. Patients with E(m) < 7.5 cm/s had significantly lower E/A and E(m)/A(m), and higher E/E(m) values. Multi linear regression showed a negative correlation between E(m) and glycated haemoglobin (Hb(A1c)) and duration of diabetes, a negative correlation of E(m)/Am with age, duration of diabetes and Hb(A1c), and a positive correlation of E/E(m) with age, duration of diabetes and use of diuretics. The E/A ratio only correlated negatively with age. It is concluded that Ern is a reliable parameter of diastolic function, and that the tissue Doppler parameters of diastolic function are associated with diabetes compensation and diabetes duration.","[Charvat, J.; Chlumsky, J.; Svab, P.; Zamrazil, V.] Charles Univ Prague, Fac Med 2, Dept Med, Prague 15006 5, Czech Republic","Charvat, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Med, V Uvalu 84, Prague 15006 5, Czech Republic.","jiri.charvat@lfmotol.cuni.cz",null,null,"Internal Grant Agency, Ministry of Health, Czech Republic [NR/9520-3]","This study was supported by the Internal Grant Agency, Ministry of Health, Czech Republic (NR/9520-3).",null,23,1,1,"FIELD HOUSE PUBLISHING LLP","WORTHING","6 SOMPTING AVENUE, WORTHING, BN14 8HN, ENGLAND","0300-0605",null,null,"J INT MED RES","J. Int. Med. Res.","JAN-FEB",2010,38,1,null,null,null,null,127,133,null,null,null,7,"Medicine, Research & Experimental; Pharmacology & Pharmacy","Research & Experimental Medicine; Pharmacology & Pharmacy","584YG","WOS:000276789900014"]
[null,null,null,null,"J","Zemanek, D; Tomasov, P; Prichystalova, P; Linhartova, K; Veselka, J",null,null,null,"Zemanek, D.; Tomasov, P.; Prichystalova, P.; Linhartova, K.; Veselka, J.",null,null,"Evaluation of the Right Ventricular Function in Hypertrophic Obstructive Cardiomyopathy: A Strain and Tissue Doppler Study","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Hypertrophic obstructive cardiomyopathy; Right ventricle; Strain; Strain rate; Tissue Doppler imaging; Tei index","TEI-INDEX; EUROPEAN-SOCIETY; ECHOCARDIOGRAPHY; QUANTIFICATION; HYPERTENSION; CARDIOLOGY; DISEASES","We investigated the utility of strain, strain rate, and tissue Doppler imaging (TDI) for the evaluation of the right ventricle (RV) impairment in patients with a hypertrophic obstructive cardiomyopathy (HOCM) who underwent a successful alcohol septal ablation (ASA) and were without RV hypertrophy. A group of 19 patients suffering from HOCM with 22 controls was compared. The parameters of TDI were evaluated in mitral and tricuspid annulus. Strain and strain rate derived from TDI were assessed in an apical free wall of RV, as well as in basal segments of the left ventricle. Between both groups, there were significant differences only in isovolumic pre-ejection time (79.2 +/- 17.3 ms vs. 58.5 +/- 8.1 ms, p<0.01), isovolumic relaxation time (104.7 +/- 26.2 ms vs. 77.3 +/- 24.5 ms, p<0.01), myocardial performance (Tei) index measured from TDI (0.61 +/- 0.14 vs. 0.49 +/- 0.09, p<0.01), and early peak diastolic velocity of TDI (10.6 +/- 1.67 cm/s vs. 12.6 +/- 2.21 cm/s; p<0.05). Our results suggest the impairment of both systolic and diastolic RV function in patients suffering from HOCM. TDI-related parameters appear to be more sensitive than strain and strain rate for evaluation.","[Zemanek, D.; Tomasov, P.; Linhartova, K.; Veselka, J.] Charles Univ Prague, Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc,Med Sch 1 & 2, Prague 15000, Czech Republic; [Prichystalova, P.] Brno Univ Technol, Fac Mech Engn, Inst Math, Brno, Czech Republic","Zemanek, D (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc,Med Sch 1 & 2, V Uvalu 84, Prague 15000, Czech Republic.","zejada@seznam.cz",null,null,"Internal Grant Agency, Ministry of Health, Czech Republic [NR/9164-3]; Ministry of Health, Czech Republic [000064203]","This study was supported by grant NR/9164-3 from the Internal Grant Agency, Ministry of Health, Czech Republic and by grant Nr. 000064203 from Ministry of Health, Czech Republic.",null,16,1,1,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,5,null,null,null,null,697,702,null,null,null,6,"Physiology","Physiology","683QC","WOS:000284489300008"]
[null,null,null,null,"J","Feberova, J; Dostalova, T; Hladikova, M; Kasal, P; Polasek, J; Seydlova, M; Janda, A; Schwarz, D",null,null,null,"Feberova, Jitka; Dostalova, Tatjana; Hladikova, Marie; Kasal, Pavel; Polasek, Jan; Seydlova, Michaela; Janda, Ales; Schwarz, Daniel",null,null,"Evaluation of 5-year Experience with E-learning Techniques at Charles University in Prague. Impact on Quality of Teaching and Students' Achievements","NEW EDUCATIONAL REVIEW",null,null,"English","Article",null,null,null,null,null,"e-learning; Moodle; Learning Management System; medical informatics; quality of teaching; distance learning; blended learning; long term trends","MEDICAL-EDUCATION","Since 2004 implementation of e-learning has been systematically and continuously encouraged and supported at Charles University (CU). Open source system Moodle was chosen as an optimal Learning Management System for creation and management of e-learning courses. Evaluation of the five-year experience with e-learning shows that the continuous support of a suitable environment for the management of e-learning courses leads to the development of spontaneous implementation of this approach into the teaching process. A positive impact of e-learning on teaching outcomes was demonstrated by a course focused on medical informatics.","[Feberova, Jitka; Polasek, Jan] Charles Univ Prague, Ctr Comp, Prague, Czech Republic; [Feberova, Jitka; Hladikova, Marie; Kasal, Pavel] Sch Med 2, Dept Med Informat, Prague, Czech Republic; [Dostalova, Tatjana; Seydlova, Michaela] Sch Med 2, Dept Paediat Stomatol, Prague, Czech Republic; [Janda, Ales] Sch Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Schwarz, Daniel] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic","Feberova, J (reprint author), Charles Univ Prague, Ctr Comp, Prague, Czech Republic.",null,"Schwarz, Daniel/B-6847-2012","Schwarz, Daniel/0000-0002-7261-0022",null,null,null,22,0,0,"WYDAWNICTWO ADAM MARSZALEK","TORUN","UL LUBICKA 44, TORUN, 87-100, POLAND","1732-6729",null,null,"NEW EDUC REV","New Educ. Rev.",null,2010,21,2,null,null,null,null,110,120,null,null,null,11,"Education & Educational Research","Education & Educational Research","632MV","WOS:000280429700009"]
[null,null,null,null,"J","Mejstrikova, E; Fronkova, E; Kalina, T; Omelka, M; Batinic, D; Dubravcic, K; Pospisilova, K; Vaskova, M; Luria, D; Cheng, SH; Ng, M; Leung, Y; Kappelmayer, J; Kiss, F; Izraeli, S; Stark, B; Schrappe, M; Trka, J; Stary, J; Hrusak, O",null,null,null,"Mejstrikova, Ester; Fronkova, Eva; Kalina, Tomas; Omelka, Marek; Batinic, Drago; Dubravcic, Klara; Pospisilova, Klara; Vaskova, Martina; Luria, Drorit; Cheng, Suk Hang; Ng, Margaret; Leung, Yonna; Kappelmayer, Janos; Kiss, Flora; Izraeli, Shai; Stark, Batia; Schrappe, Martin; Trka, Jan; Stary, Jan; Hrusak, Ondrej",null,null,"Detection of Residual B Precursor Lymphoblastic Leukemia by Uniform Gating Flow Cytometry","PEDIATRIC BLOOD & CANCER",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; flow cytometry; minimal residual disease; non-malignant background","BIOMED-1 CONCERTED ACTION; TIME QUANTITATIVE PCR; RECEPTOR GENE REARRANGEMENTS; ACUTE MYELOID-LEUKEMIA; BONE-MARROW; TREATMENT RESPONSE; DISEASE DETECTION; FOLLOW-UP; T-ALL; CHILDHOOD","Background. Residual disease (RD) is an important prognostic factor in acute lymphoblastic leukemia (ALL). Flow cytometry (FC)-based RD detection is easy to perform, but interpretation requires expert analysis due to individual differences among patients. Procedure. We focused at the design of standardized and reproducible RD monitoring in ALL. RD was investigated by a uniform gating strategy, which was designed internationally and tested in one center by Ig/TCR rearrangements. Results. For each gate, positivity cutoff value was assigned using quantification of non-leukemic background. Comparing to Ig/TCR at 0.1% level, 80 of 103 specimens were correctly diagnosed by FC. The predictive value of FC RD at day 15 was then analyzed. In B lineage ALL, day 15 FC significantly correlated with Ig/TCR results at day 33 and/or week 12 (P<0.01). No significant correlation was found in T lineage ALL. Conclusions. Thus, FC with preset uniform gating at day 15 predicts PCR-detectable MRD in B precursor ALL. Presented data may be used to define new polychromatic cytometric diagnostics of MRD including semiautomatic assessment. Pediatr Blood Cancer 2010;54:62-70. (C) 2009 Wiley-Liss, Inc.","[Hrusak, Ondrej] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Sch Med 2, Fac Med 2, Prague, Czech Republic; [Mejstrikova, Ester; Fronkova, Eva; Kalina, Tomas; Pospisilova, Klara; Vaskova, Martina; Trka, Jan; Hrusak, Ondrej] CLIP, Prague, Czech Republic; [Omelka, Marek] Charles Univ Prague, Fac Math & Phys, Jaroslav Hajek Ctr Theoret & Appl Stat, Prague, Czech Republic; [Batinic, Drago; Dubravcic, Klara] Univ Clin Hosp Ctr, Inst Clin, Lab Diag, Zagreb, Croatia; [Luria, Drorit; Stark, Batia] Rabin Med Ctr, Felsenstein Med Res Ctr, Schneider Childrens Med Ctr Israel, Dept Pediat Hematol Oncol, Petah Tiqwa, Israel; [Cheng, Suk Hang; Ng, Margaret; Leung, Yonna] Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Kappelmayer, Janos; Kiss, Flora] Debrecen Univ Med, Dept Clin Biochem & Mol Pathol, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary; [Izraeli, Shai] Scheba Med Ctr, Tel Hashomer, Israel; [Schrappe, Martin] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany","Hrusak, O (reprint author), Univ Hosp Motol, Dept Pediat Hematol & Oncol, Sch Med 2, Fac Med 2, Uvalu 84, Prague, Czech Republic.","ondrej.hrusak@lfmotol.cuni.cz","Schrappe, Martin/A-8109-2010",null,null,null,null,41,14,15,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1545-5009",null,null,"PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","JAN",2010,54,1,null,null,null,null,62,70,null,"10.1002/pbc.22261",null,9,"Oncology; Hematology; Pediatrics","Oncology; Hematology; Pediatrics","525ON","WOS:000272225800013"]
[null,null,null,null,"J","Cakrt, O; Chovanec, M; Funda, T; Kalitova, P; Betka, J; Zverina, E; Kolar, P; Jerabek, J",null,null,null,"Cakrt, Ondrej; Chovanec, Martin; Funda, Tomas; Kalitova, Petra; Betka, Jan; Zverina, Eduard; Kolar, Pavel; Jerabek, Jaroslav",null,null,"Exercise with visual feedback improves postural stability after vestibular schwannoma surgery","EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"Vestibular schwannoma; Vestibular rehabilitation; Visual feedback; Center of pressure; Posturography; Quality of life","ACOUSTIC NEUROMA SURGERY; SENSORY INTERACTION; BALANCE","We analyzed the effect of 2-week individualized visual feedback-based balance training on the postural control of patients undergoing retrosigmoid microsurgical removal of vestibular schwannoma. We performed prospective evaluation of 17 patients allocated into two groups: feedback group (9 patients, mean age 37 years) and standard physiotherapy group (8 patients, mean age 44 years). Patients in both the groups were treated once per day by intensive rehabilitation from 5th to 14th postoperative day. Rehabilitation of patients in the feedback group was performed using the visual feedback and force platform. Results were evaluated on the beginning and at the end of rehabilitation program (e.g. 5th and 14th postoperative day). Outcome measures included posturography during quiet stance under four different conditions by the modified Clinical Test for Sensory Interaction of Balance. Body sway was evaluated from center of foot pressure. Compensation of Center of pressure (CoP) parameters in stance on firm surface was similar in the control and feedback groups. However, in stance on foam surface with eyes closed the patients from the feedback group were better compensated and CoP parameters differed significantly (p < 0.05). This prospective clinical study suggests that specific exercises with visual feedback improve vestibulospinal compensation in patients after vestibular schwannoma surgery and thus can improve their quality of life.","[Cakrt, Ondrej; Kolar, Pavel] Charles Univ Prague, Dept Rehabil & Exercise Med, Fac Hosp Motol, Fac Med 2, Prague 15006 5, Czech Republic; [Cakrt, Ondrej; Funda, Tomas; Jerabek, Jaroslav] Czech Tech Univ, Joint Ctr Biomed Engn, Fac Biomed Engn, CR-16635 Prague, Czech Republic; [Chovanec, Martin; Kalitova, Petra; Betka, Jan; Zverina, Eduard] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Hosp Motol, Fac Med 1, Prague 15006 5, Czech Republic; [Chovanec, Martin] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 15006 5, Czech Republic; [Chovanec, Martin] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Zverina, Eduard] Charles Univ Prague, Fac Med 3, Dept Neurosurg, Fac Hosp Kralovske Vinohrady, Prague 15006 5, Czech Republic; [Jerabek, Jaroslav] Charles Univ Prague, Dept Neurol, Fac Hosp Motol, Fac Med 2, Prague 15006 5, Czech Republic","Cakrt, O (reprint author), Charles Univ Prague, Dept Rehabil & Exercise Med, Fac Hosp Motol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","ondrej.cakrt@lf2.cuni.cz",null,null,"Internal Grant Agency of the Ministry of Health of Czech Republic [NS/9909-3]","This study was supported by the research project of Internal Grant Agency of the Ministry of Health of Czech Republic no. NS/9909-3. The authors thank Pavla Polechova for her contribution to this study.",null,15,11,13,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0937-4477",null,null,"EUR ARCH OTO-RHINO-L","Eur. Arch. Oto-Rhino-Laryn.","SEP",2010,267,9,null,null,null,null,1355,1360,null,"10.1007/s00405-010-1227-x",null,6,"Otorhinolaryngology","Otorhinolaryngology","629TX","WOS:000280223700005"]
[null,null,null,null,"J","Zuna, J; Zaliova, M; Muzikova, K; Meyer, C; Lizcova, L; Zemanova, Z; Brezinova, J; Votava, F; Marschalek, R; Stary, J; Trka, J",null,null,null,"Zuna, Jan; Zaliova, Marketa; Muzikova, Katerina; Meyer, Claus; Lizcova, Libuse; Zemanova, Zuzana; Brezinova, Jana; Votava, Felix; Marschalek, Rolf; Stary, Jan; Trka, Jan",null,null,"Acute Leukemias with ETV6/ABL1 (TEL/ABL) Fusion: Poor Prognosis and Prenatal Origin","GENES CHROMOSOMES & CANCER",null,null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL-RESIDUAL-DISEASE; CHRONIC MYELOID-LEUKEMIA; ETV6-ABL GENE REARRANGEMENT; TYROSINE KINASE; TEL-ABL; CYTOGENETIC CHARACTERIZATION; MYELOPROLIFERATIVE DISORDER; IMATINIB-MESYLATE; BCR-ABL","The ETV6/ABL1 (TEL/ABL) fusion gene is a rare aberration in malignant disorders. Only 19 cases of ETV6/ABL1-positive hematological malignancy have been published, diagnosed with chronic myeloid leukemia, other types of chronic myeloproliferative neoplasm, acute myeloid leukemia or acute lymphoblastic leukemia (ALL). This study reports three new cases (aged 8 months, 5 years, and 33 years) of ALL with the ETV6/ABL1 fusion found by screening 392 newly diagnosed ALL patients (335 children and 57 adults). A thorough review of the literature and an analysis of all published data, including the three new cases, suggest poor prognosis of ETV6/ABL1-positive acute leukemias. The course of the disease in the two pediatric patients is characterized by minimal residual disease monitoring, using quantification of both the ETV6/ABL1 transcript and immunoreceptor gene rearrangements. Eosinophilia could not be confirmed as a hallmark of the ETV6/ABL1-positive disease. Studies of neonatal blood spots demonstrated that, in the child diagnosed at five years, the ETV6/ABL1 fusion initiating the ALL originated prenatally. (C) 2010 Wiley-Liss, Inc.","[Zuna, Jan; Zaliova, Marketa; Muzikova, Katerina; Stary, Jan; Trka, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Zuna, Jan; Zaliova, Marketa; Muzikova, Katerina; Stary, Jan; Trka, Jan] Univ Hosp Motol, Prague, Czech Republic; [Meyer, Claus; Marschalek, Rolf] Goethe Univ Frankfurt, Bioctr, Diagnost Ctr Acute Leukemia, Inst Pharmaceut Biol,ZAFES, Frankfurt, Germany; [Lizcova, Libuse; Zemanova, Zuzana] Gen Univ Hosp, Inst Clin Biochem & Lab Diagnost, Ctr Oncocytogenet, Prague, Czech Republic; [Lizcova, Libuse; Zemanova, Zuzana] Charles Univ Prague, Fac Med 1, Prague 15006 5, Czech Republic; [Brezinova, Jana] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic; [Votava, Felix] Charles Univ Prague, Fac Med 3, Dept Pediat, Prague 15006 5, Czech Republic","Zuna, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.zuna@lfmotol.cuni.cz","Marschalek, Rolf/D-3404-2011",null," [MSM0021620813];  [IGA-MZ NS10004];  [MZOFNM2005];  [MZOVFN2005]","Grant numbers: MSM0021620813, IGA-MZ NS10004, MZOFNM2005, MZOVFN2005.",null,41,10,10,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1045-2257",null,null,"GENE CHROMOSOME CANC","Gene Chromosomes Cancer","OCT",2010,49,10,null,null,null,null,873,884,null,"10.1002/gcc.20796",null,12,"Oncology; Genetics & Heredity","Oncology; Genetics & Heredity","640ZC","WOS:000281091900002"]
[null,null,null,null,"J","Hradsky, O; Dusatkova, P; Lenicek, M; Bronsky, J; Nevoral, J; Vitek, L; Lukas, M; Zeniskova, I; Cinek, O",null,null,null,"Hradsky, Ondrej; Dusatkova, Petra; Lenicek, Martin; Bronsky, Jiri; Nevoral, Jiri; Vitek, Libor; Lukas, Milan; Zeniskova, Ivana; Cinek, Ondrej",null,null,"The CTLA4 variants may interact with the IL23R-and NOD2-conferred risk in development of Crohn's disease","BMC MEDICAL GENETICS",null,null,"English","Article",null,null,null,null,null,null,"GENOME-WIDE ASSOCIATION; INFLAMMATORY-BOWEL-DISEASE; SUSCEPTIBILITY LOCI; GENETIC-VARIATION; CZECH POPULATION; POLYMORPHISMS; ATG16L1; PHENOTYPE; AUTOPHAGY; MULTIPLE","Background: The CTLA4 (cytotoxic T-lymphocyte antigen 4) gene is associated with several immunopathologic diseases and because of its important immuno-regulatory role it may be considered also a plausible candidate for a genetic association with inflammatory bowel diseases. Previously published studies found no association of CTLA4 with Crohn's disease itself, but some indicated an association with its subphenotypes. The aim of this study was to assess the association in the Czech population, using a set of markers shown to associate with other diseases. Methods: Six polymorphisms within the CTLA4 region were investigated in 333 patients with Crohn's disease and 482 unrelated healthy controls, all Caucasians of Czech origin. The genotypes of the SNPs were determined using the TaqMan SNP genotyping assays. Haplotypes were reconstructed using an expectation-maximization algorithm, and their association with the condition was assessed using log-linear modeling. Then, potential interactions were tested between the CTLA4 variants and other genetic factors known to confer the disease susceptibility. Results: No crude associations with Crohn's disease were found for the tested CTLA4 variants under the log-additive or dominant models. However, when stratified for the genetic risk conferred by the variants in the NOD2 (the p.Leu1007fsX1008, rs5743293) or the IL23R (p.R381Q, rs11209026), a significant negative association emerged for the minor alleles of CTLA4 CT60 (rs3087243), JO31 (rs11571302), JO27-1 (rs11571297) polymorphisms. This negative association with CTLA4 was apparent only in the strata defined by presence minor alleles at the NOD2 rs5743293 (here the CTLA4 CT60 A coffered an OR = 0.43, 95% CI 0.19 -0.95 for the presence of CT60 A), or IL23R rs11209026 (here the OR for presence of CT60 A was 0.23, 95% CI 0.07 -0.71). We observed this effect also for the haplotype consisting of minor alleles of the three tightly linked CTLA4 markers. Furthermore, this haplotype was associated with the younger age at diagnosis (OR 1.52, 95% CI 1.09 -2.11, p = 0.014). Conclusions: A protective effect of a CTLA4 haplotype was unmasked after stratification for the risk variants in the NOD2 and IL23R genes, and may point towards the biological relevance of the molecule in the pathogenesis of the disease.","[Hradsky, Ondrej; Dusatkova, Petra; Bronsky, Jiri; Nevoral, Jiri; Cinek, Ondrej] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Hradsky, Ondrej; Dusatkova, Petra; Bronsky, Jiri; Nevoral, Jiri; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Lenicek, Martin; Vitek, Libor; Lukas, Milan] Charles Univ Prague, Fac Med 1, Inst Clin Biochem & Lab Diagnost, Prague, Czech Republic; [Lukas, Milan] ISCARF IVF Lighthouse, IBD Clin & Res Ctr, Prague, Czech Republic; [Zeniskova, Ivana] Keske BudEjovice Hosp AS, Keske Budejovice, Czech Republic","Hradsky, O (reprint author), Univ Hosp Motol, Dept Pediat, Prague, Czech Republic.","ondrej.hradsky@lfmotol.cuni.cz","Vitek, Libor/A-2645-2008",null,"Czech Ministry of Health [MZOFNM2005]; University Hospital Motol; IGA [NR/9219-3/2007]","This study was supported by grants from the Czech Ministry of Health (MZOFNM2005), the University Hospital Motol and IGA - NR/9219-3/2007. Drs V. Valtrova, P. Szitanyi, R. Petro, M. Bortlik and V. Starzykova are gratefully acknowledged for providing us with samples and clinical data from their patients.",null,33,8,9,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2350",null,null,"BMC MED GENET","BMC Med. Genet.","JUN 10",2010,11,null,null,null,null,null,null,null,91,"10.1186/1471-2350-11-91",null,9,"Genetics & Heredity","Genetics & Heredity","625UL","WOS:000279920800002"]
[null,null,null,null,"J","Pourova, R; Janousek, P; Jurovcik, M; Dvorakova, M; Malikova, M; Raskova, D; Bendova, O; Leonardi, E; Murgia, A; Kabelka, Z; Astl, J; Seeman, P",null,null,null,"Pourova, Radka; Janousek, Petr; Jurovcik, Michal; Dvorakova, Marcela; Malikova, Marcela; Raskova, Dagmar; Bendova, Olga; Leonardi, Emanuela; Murgia, Alessandra; Kabelka, Zdenek; Astl, Jaromir; Seeman, Pavel",null,null,"Spectrum and Frequency of SLC26A4 Mutations Among Czech Patients with Early Hearing Loss with and without Enlarged Vestibular Aqueduct (EVA)","ANNALS OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"Deafness; EVA; hearing loss; MLPA; Pendred; SLC26A4","GENOTYPE-PHENOTYPE CORRELATIONS; PENDRED-SYNDROME; PDS GENE; CONGENITAL DEAFNESS; TEMPORAL BONE; GJB2; IDENTIFICATION; IMPAIRMENT; FAMILIES; PREVALENCE","P>Mutations in SLC26A4 cause Pendred syndrome (PS) - hearing loss with goitre - or DFNB4 - non-syndromic hearing loss (NSHL) with inner ear abnormalities such as Enlarged Vestibular Aqueduct (EVA) or Mondini Dysplasia (MD). We tested 303 unrelated Czech patients with early hearing loss (298 with NSHL and 5 with PS), all GJB2-negative, for SLC26A4 mutations and evaluated their clinical and radiological phenotype. Among 115 available HRCT/MRI scans we detected three MD (2.6%), three Mondini-like affections (2.6%), 16 EVA (13 bilateral - 19.2% and 15.6% respectively) and 61 EVA/MD-negative scans (73.4%). We found mutation(s) in 26 patients (8.6%) and biallelic mutations in eight patients (2.7%) out of 303 tested. In 18 of 26 (69%) patients, no second mutation could be detected even using MLPA. The spectrum of SLC26A4 mutations in Czech patients is broad without any prevalent mutation. We detected 21 different mutations (four novel). The most frequent mutations were p.Val138Phe and p.Leu445Trp (18% and 8.9% of pathogenic alleles respectively). Among 13 patients with bilateral EVA, six patients (50%) carry biallelic mutations. In EVA -negative patients no biallelic mutations were found but 4.9% had monoallelic mutations. SLC26A4 mutations are present mostly in patients with EVA/MD and/or progressive HL and those with affected siblings.","[Pourova, Radka; Seeman, Pavel] Charles Univ Prague, Dept Paediat Neurol, DNA Lab, Fac Med 2, Prague 15006 5, Czech Republic; [Janousek, Petr; Jurovcik, Michal; Kabelka, Zdenek] Charles Univ Prague, Fac Med 2, Dept Otorhinolaryngol, Prague 15006 5, Czech Republic; [Dvorakova, Marcela] Charles Univ Prague, Fac Med 2, Dept Radiol Tech, Prague 15006 5, Czech Republic; [Malikova, Marcela] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 15006 5, Czech Republic; [Raskova, Dagmar] Clin St Kliment, Prague 17000 7, Czech Republic; [Raskova, Dagmar] Gennet, Prague, Czech Republic; [Bendova, Olga; Astl, Jaromir] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague, Czech Republic; [Bendova, Olga; Astl, Jaromir] Univ Hosp Motol, Prague, Czech Republic; [Leonardi, Emanuela; Murgia, Alessandra] Univ Padua, Rare Dis Ctr, Dept Paediat, Padua, Italy","Pourova, R (reprint author), Charles Univ Prague, Dept Paediat Neurol, DNA Lab, Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic.","radka.pourova@post.cz",null,null,"Institute of Human Genetics in Erlangen;  [IGA NS 9913/4]","Supported by IGA NS 9913/4.We thank Dr. K. Huehne, O. Zwenger, V. Matejas, S. Uebe and Prof. B. Rautenstrauss from the Institute of Human Genetics in Erlangen for their kind support and cooperation.",null,38,7,8,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0003-4800",null,null,"ANN HUM GENET","Ann. Hum. Genet.","JUL",2010,74,null,4,null,null,null,299,307,null,"10.1111/j.1469-1809.2010.00581.x",null,9,"Genetics & Heredity","Genetics & Heredity","612PW","WOS:000278914200002"]
[null,null,null,null,"J","Maxova, H; Bacakova, L; Lisa, V; Novotna, J; Tomasova, H; Vizek, M; Herget, J",null,null,null,"Maxova, H.; Bacakova, L.; Lisa, V.; Novotna, J.; Tomasova, H.; Vizek, M.; Herget, J.",null,null,"Production of Proteolytic Enzymes in Mast Cells, Fibroblasts, Vascular Smooth Muscle and Endothelial Cells Cultivated Under Normoxic or Hypoxic Conditions","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Hypoxia; Metalloproteinases; Tryptase; Chymase; Immunofluorescence","MATRIX METALLOPROTEINASES; I COLLAGEN; EXPRESSION; LUNG; TRYPTASE; RAT; ACTIVATION; DEGRANULATION; ANEURYSMS; PROMOTES","Matrix metalloproteinases (MMPs) is a family of proteolytic enzymes involved in remodeling of extracellular matrix. Although proteolytic enzymes are produced by many cell types, mast cells seem to be more important than other types in remodeling of pulmonary arteries during hypoxia. Therefore, we tested in vitro production of MMPs and serine proteases in four cell types (mast cells, fibroblasts, vascular smooth muscle cells and endothelial cells) cultivated for 48 h under normoxic or hypoxic (3 % O(2)) conditions. MMP-13 was visualized by immunohistochemistry, MMP-2 and MMP-9 were detected by zymography in cell lysates. Enzymatic activities (MMPs, tryptase and chymase) were estimated in the cultivation media. Hypoxia had a minimal effect on total MMP activity in the cultivation media of all types of cells, but immunofluorescence revealed higher intensity of MMP-13 in the cells exposed to hypoxia except of fibroblasts. Tryptase activity was three times higher and chymase activity twice higher in mast cells cultivated in hypoxia than in those cultured in normoxia. Among all cell types studied here, mast cells are the most abundant source of proteolytic enzymes under normoxic and hypoxic conditions. Moreover, in these cells hypoxia increases the production of both specific serine proteases tryptase and chymase, which can act as MMPs activators.","[Maxova, H.; Vizek, M.] Charles Univ Prague, Dept Pathol Physiol, Sch Med 2, Prague 15000 5, Czech Republic; [Novotna, J.] Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Prague 15000 5, Czech Republic; [Herget, J.] Charles Univ Prague, Dept Physiol, Sch Med 2, Prague 15000 5, Czech Republic; [Bacakova, L.; Lisa, V.] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Maxova, H.; Bacakova, L.; Novotna, J.; Tomasova, H.; Vizek, M.; Herget, J.] Cardiovasc Res Ctr, Prague, Czech Republic","Maxova, H (reprint author), Charles Univ Prague, Dept Pathol Physiol, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic.","hana.maxova@lfmotol.cuni.cz","Bacakova, Lucie/C-2664-2012; Herget, Jan/I-6313-2012",null,"Grant Agency of the Czech Republic [305/08/0108]; Centre for Cardiovascular Research [1M0510]","This work was supported by the Grant Agency of the Czech Republic (No. 305/08/0108) and by the Centre for Cardiovascular Research (No. 1M0510). Mr. Robin Healey (Czech Technical University, Prague) is gratefully acknowledged for his language revision of the manuscript.",null,41,7,7,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,5,null,null,null,null,711,719,null,null,null,9,"Physiology","Physiology","683QC","WOS:000284489300010"]
[null,null,null,null,"J","Durila, M; Kalincik, T; Pacakova, Z; Cvachovec, K",null,null,null,"Durila, Miroslav; Kalincik, Tomas; Pacakova, Zuzana; Cvachovec, Karel",null,null,"Discard volume necessary for elimination of heparin flush effect on thromboelastography","BLOOD COAGULATION & FIBRINOLYSIS",null,null,"English","Article",null,null,null,null,null,"arterial blood sampling; coagulation; discard volume; heparin flush; kaolin-activated; thromboelastography","MOLECULAR-WEIGHT HEPARIN; UNFRACTIONATED HEPARIN; LIVER-TRANSPLANTATION; COAGULATION; HYPERCOAGULABILITY; THROMBELASTOGRAPHY; SURGERY; ASSAY","Heparin is commonly used to prevent obstruction of indwelling arterial catheters with blood clots. It is known to affect the outcomes of analysis of coagulation parameters with thromboelastography (TEG); therefore, it has been recommended to neutralize its effect with heparinase. However, heparinase may also neutralize the effect of low molecular weight heparin and endogenous heparinoids present in critically ill patients and thus yields unreliable results. The aim of this study was to evaluate the minimal discard blood volume needed to eliminate the effect of heparin flush on TEG parameters without the use of heparinase. Ten patients with indwelling arterial catheter were included in the study. Coagulation parameters were evaluated with kaolin-activated TEG. Blood samples were obtained after discarding 1, 2, 3, 4, 5 or 10 ml of blood to eliminate the effect of heparin. We investigated the influence of the discard volume on time until the first detectable clot (R), speed of clot development (alpha angle), maximal amplitude of the measured clot and time to maximal amplitude of the measured clot. We found an increase in coagulation (reflecting the heparin elimination) with the increasing discard volume between 1 and 4 ml. This was obvious from an increase in alpha angle and maximal amplitude of the measured clot and a decrease in R and time to maximal amplitude of the measured clot (P<0.001). However, values obtained after discarding 4, 5 and 10 ml of blood did not differ markedly. To obtain valid information about TEG parameters, it is necessary to discard volume of at least 4 ml of blood (i.e., five times the volume of catheter dead space). Blood Coagul Fibrinolysis 21:192-195 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Durila, Miroslav; Cvachovec, Karel] Charles Univ Prague, Dept Anesthesiol & Crit Care Med, Fac Med 2, Prague 15006 5, Czech Republic; [Durila, Miroslav; Cvachovec, Karel] Charles Univ Prague, Inst Postgrad Med Educ, Prague 15006 5, Czech Republic; [Kalincik, Tomas] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia; [Pacakova, Zuzana] Czech Univ Agr, Fac Econ & Management, Prague, Czech Republic","Durila, M (reprint author), Charles Univ Prague, Dept Anesthesiol & Crit Care Med, Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic.","durila4@yahoo.com","Kalincik, Tomas/A-6911-2008",null,"Department of Anesthesiology and Critical Care Medicine, Second Faculty of Medicine and Institute for Postgraduate Medical Education; Charles University in Prague, Prague; Czech Republic and BioVendor Company - Lekarska technika, s.r.o., Brno, Czech Republic","This study is supported by the Department of Anesthesiology and Critical Care Medicine, Second Faculty of Medicine and Institute for Postgraduate Medical Education, Charles University in Prague, Prague, Czech Republic and BioVendor Company - Lekarska technika, s.r.o., Brno, Czech Republic.",null,14,5,5,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0957-5235",null,null,"BLOOD COAGUL FIBRIN","Blood Coagul. Fibrinolysis","MAR",2010,21,2,null,null,null,null,192,195,null,"10.1097/MBC.0b013e3283338c0d",null,4,"Hematology","Hematology","555LZ","WOS:000274513600017"]
[null,null,null,null,"J","Hippmann, R; Dostalova, T; Zvarova, J; Nagy, M; Seydlova, M; Hanzlicek, P; Kriz, P; Smidl, L; Trmal, J",null,null,null,"Hippmann, R.; Dostalova, T.; Zvarova, J.; Nagy, M.; Seydlova, M.; Hanzlicek, P.; Kriz, P.; Smidl, L.; Trmal, J.",null,null,"Voice-supported Electronic Health Record for Temporomandibular Joint Disorders","METHODS OF INFORMATION IN MEDICINE",null,null,"English","Article",null,null,null,null,null,"Electronic health record; structured data entry; dentistry; temporomandibular joint disorder","OPENSDE","Objectives: To identify support of structured data entry for an electronic health record application in temporomandibular joint disorders. Methods: The methods of structuring information in dentistry are described and the interactive DentCross component is introduced. A system of structured voice-supported data entry in electronic health record on several real cases in the field of dentistry is performed. The connection of this component to the MUDRLite electronic health record is described. Results: The use of DentVoice, an application which consists of the electronic health record MUDRLite and the voice-controlled interactive component DentCross, to collect dental information required by temporomandibular joint disorders is shown. Conclusions: The DentVoice application with the DentCross component showed the practical ability of the temporomandibular joint disorder treatment support.","[Hippmann, R.; Dostalova, T.; Seydlova, M.; Kriz, P.] Charles Univ Prague, Sch Med 2, Dept Paediat Stomatol, Prague 15006, Czech Republic; [Hippmann, R.; Dostalova, T.; Zvarova, J.; Nagy, M.; Seydlova, M.; Hanzlicek, P.] Ctr Biomed Informat, Prague, Czech Republic; [Zvarova, J.; Nagy, M.; Hanzlicek, P.] Acad Sci Czech Republic, Inst Comp Sci, VVI, EuroMISE Ctr,Dept Med Informat, Prague, Czech Republic; [Smidl, L.; Trmal, J.] Univ W Bohemia, Dept Cybernet, Plzen 30614, Czech Republic","Hippmann, R (reprint author), Charles Univ Prague, Sch Med 2, Dept Paediat Stomatol, V Uvalu 84, Prague 15006, Czech Republic.","r.hip@seznam.cz","Smidl, Lubos/B-9284-2012; Zvarova, Jana/B-5196-2014",null,"Ministry of Education of the Czech Republic [1M06014]; Institute of Computer Science ASCR, v.v.i. [AV0Z10300504]","The work was supported by the project 1M06014 of the Ministry of Education of the Czech Republic and by the project AV0Z10300504 of the Institute of Computer Science ASCR, v.v.i.",null,24,5,5,"SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN","STUTTGART","HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY","0026-1270",null,null,"METHOD INFORM MED","Methods Inf. Med.",null,2010,49,2,null,null,null,null,168,172,null,"10.3414/ME9301",null,5,"Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics","Computer Science; Health Care Sciences & Services; Medical Informatics","586TO","WOS:000276936300010"]
[null,null,null,null,"J","Rampichova, M; Kostakova, E; Filova, E; Prosecka, E; Plencner, M; Ocheretna, L; Lytvynets, A; Lukas, D; Amler, E",null,null,null,"Rampichova, M.; Kostakova, E.; Filova, E.; Prosecka, E.; Plencner, M.; Ocheretna, L.; Lytvynets, A.; Lukas, D.; Amler, E.",null,null,"Non-Woven PGA/PVA Fibrous Mesh as an Appropriate Scaffold for Chondrocyte Proliferation","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"PGA; PVA; Non-woven textile; Chondrocyte; Tissue engineering","IN-VITRO; ARTICULAR-CARTILAGE; HYALURONIC-ACID; DEGRADATION; HYDROGELS; FIXATION; IMPLANTS; DELIVERY; MATRIX; BONE","Non-woven textile mesh from polyglycolic acid (PGA) was found as a proper material for chondrocyte adhesion but worse for their proliferation. Neither hyaluronic acid nor chitosan nor polyvinyl alcohol (PVA) increased chondrocyte adhesion. However, chondrocyte proliferation suffered from acidic byproducts of PGA degradation. However, the addition of PVA and/or chitosan into a wet-laid non-woven textile mesh from PGA improved chondrocyte proliferation seeded in vitro on the PGA-based composite scaffold namely due to a diminished acidification of their microenvironment. This PVA/PGA composite mesh used in combination with a proper hydrogel minimized the negative effect of PGA degradation without dropping positive parameters of the PGA wet-laid non-woven textile mesh. In fact, presence of PVA and/or chitosan in the PGA-based wet-laid non-woven textile mesh even advanced the PGA-based wet-laid non-woven textile mesh for chondrocyte seeding and artificial cartilage production due to a positive effect of PVA in such a scaffold on chondrocyte proliferation.","[Amler, E.] Charles Univ Prague, Fac Med 2, Dept Biophys, Inst Biophys, Prague 15006 5, Czech Republic; [Rampichova, M.; Filova, E.; Prosecka, E.; Plencner, M.; Lytvynets, A.; Amler, E.] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague, Czech Republic; [Kostakova, E.; Ocheretna, L.; Lukas, D.] Tech Univ Liberec, Fac Text Engn, Liberec, Czech Republic; [Amler, E.] Charles Univ Prague, Fac Med 2, Cardiovasc Res Ctr, Prague 15006 5, Czech Republic","Amler, E (reprint author), Charles Univ Prague, Fac Med 2, Dept Biophys, Inst Biophys, V Uvalu 84, Prague 15006 5, Czech Republic.","evzen.amler@lfmotol.cuni.cz",null,null,"Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Ministry of Education, Youth and Sports of the Czech Republic [2B06130, 1M0510]; Grant Agency of the Academy of Sciences [IAA500390702]; Czech Science Foundation [GA202/09/1151, P304/10/1307]; EU [214539]; Grant Agency of the Charles University [119209]","Supported by the Academy of Sciences of the Czech Republic (institutional research plans AV0Z50390703 and AV0Z50390512), Ministry of Education, Youth and Sports of the Czech Republic (research programs NPV II 2B06130 and 1M0510), Grant Agency of the Academy of Sciences grant No. IAA500390702, by Czech Science Foundation grants No. GA202/09/1151 and P304/10/1307, EU project BIOSCENT ID number 214539, and the Grant Agency of the Charles University grant No. 119209.",null,23,5,5,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,5,null,null,null,null,773,781,null,null,null,9,"Physiology","Physiology","683QC","WOS:000284489300017"]
[null,null,null,null,"J","Pleskacova, J; Rucklova, K; Popelova, J; Cerny, S; Syrucek, M; Snajderova, M; Lebl, J",null,null,null,"Pleskacova, Jana; Rucklova, Kristina; Popelova, Jana; Cerny, Stepan; Syrucek, Martin; Snajderova, Marta; Lebl, Jan",null,null,"Aortic dissection and rupture in a 16-year-old girl with Turner syndrome following previous progression of aortic dilation","EUROPEAN JOURNAL OF PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"Turner syndrome; Aortic dissection; Progression of aortic dilation","NORMAL-CHILDREN; ABNORMALITIES; DILATATION; DIMENSIONS; ADULTS; YOUNG","Aortic dissection occurs in Turner syndrome with substantially higher frequency in comparison to the general population, and its prevention is one of the main aims of cardiologic follow-up. Findings of cystic medial necrosis in the aortic wall and a high prevalence of aortic dilation suggest that a form of aortopathy exists in Turner syndrome. However, little is known about natural development of aortic dilation prior to dissection. We present a 16-year-old girl with Turner syndrome with a bicuspid aortic valve, aortic stenosis, and dilation of ascending aorta, who underwent annual echocardiographic examinations from early childhood. Significant progressions of proximal aortic dilation occurred twice at the age of 10 and 15 years. Thereafter, another rapid progression was observed during 8 months and within 3 weeks preceding dissection. Acute aortic dissection was diagnosed while the girl was waiting for elective surgery. She was successfully operated. Frequent estimations of aortic diameter in Turner patients with abnormal findings may help to anticipate this life-threatening event. Additionally, we learned that rapid progression of aortic dilation should lead to immediate surgery to prevent more risky urgent intervention following the dissection.","[Pleskacova, Jana; Rucklova, Kristina; Snajderova, Marta; Lebl, Jan] Univ Hosp Motol, Dept Pediat, Prague 15006 5, Czech Republic; [Pleskacova, Jana; Rucklova, Kristina; Snajderova, Marta; Lebl, Jan] Charles Univ Prague, Prague, Czech Republic; [Popelova, Jana; Cerny, Stepan] Hosp Na Homolce, Dept Cardiac Surg, Prague, Czech Republic; [Syrucek, Martin] Hosp Na Homolce, Dept Pathol, Prague, Czech Republic","Pleskacova, J (reprint author), Univ Hosp Motol, Dept Pediat, V Uvalu 84, Prague 15006 5, Czech Republic.","pleskac.jana@seznam.cz",null,null,"Czech Ministry of Health [VZMZO 64203-6306]; MSM [0021620814]","This article was written with research project support from the Czech Ministry of Health MZOFNM2005 (VZMZO 64203-6306) and of MSM (0021620814).",null,15,3,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,null,"EUR J PEDIATR","Eur. J. Pediatr.","OCT",2010,169,10,null,null,null,null,1283,1286,null,"10.1007/s00431-010-1197-4",null,4,"Pediatrics","Pediatrics","642SV","WOS:000281238700019"]
[null,null,null,null,"J","Maxova, H; Bacakova, L; Eckhardt, A; Miksik, I; Lisa, V; Novotna, J; Herget, J",null,null,null,"Maxova, Hana; Bacakova, Lucie; Eckhardt, Adam; Miksik, Ivan; Lisa, Vera; Novotna, Jana; Herget, Jan",null,null,"Growth of Vascular Smooth Muscle Cells on Collagen I Exposed to RBL-2H3 Mastocytoma Cells","CELLULAR PHYSIOLOGY AND BIOCHEMISTRY",null,null,"English","Article",null,null,null,null,null,"Pulmonary hypertension; Vascular remodeling; Mast cells; Proteases; Collagen degradation; Smooth muscle cell proliferation; High performance liquid chromatography; Mass spectrometry","MAST-CELLS; PULMONARY-HYPERTENSION; MATRIX METALLOPROTEINASES; MYOCARDIAL-INFARCTION; PROLIFERATION; HYPOXIA; ATHEROSCLEROSIS; INHIBITION; ARTERIES; CULTURE","Remodeling of the peripheral pulmonary vasculature during chronic hypoxia is characterized by accelerated collagenolysis and thickening of the vascular wall. Low molecular weight peptides, products of cleavage by interstitial collagenase and muscular layer in the peripheral pulmonary vessels, are typically present. The aim of this \"in vitro\" study was to verify that mast cells (RBL-2H3) as a potent source of a variety of biomolecules which can affect vessel wall remodeling are capable of splitting collagen and then facilitating the growth of vascular smooth muscle cells (VSMC). Collagen I was exposed to RBL-2H3 cells cultured 48 hours under normoxic or hypoxic (3% O(2)) conditions and then seeded with VSMC. The VSMC proliferated with the shortest doubling time and reached the highest cell population density on the collagen pre-modified with hypoxic RBL-2H3 cells. This increased growth activity of VSMC was probably due to the fragmentation of collagen by proteases released from RBL-2H3 cells. Absolute amount of collagen fragments was similar in samples exposed to normoxic and hypoxic RBL-2H3 cells, but the concentration of at least one collagen fragment was significantly higher under hypoxic conditions. Mast cells exposed to hypoxia are more capable to split collagen and facilitate the growth of VSMC. Copyright (C) 2010 S. Karger AG, Basel","[Maxova, Hana] Charles Univ Prague, Dept Pathol Physiol, Sch Med 2, Prague 15000 5, Czech Republic; [Novotna, Jana] Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Prague 15000 5, Czech Republic; [Herget, Jan] Charles Univ Prague, Dept Physiol, Sch Med 2, Prague 15000 5, Czech Republic; [Maxova, Hana; Bacakova, Lucie; Eckhardt, Adam; Miksik, Ivan; Novotna, Jana; Herget, Jan] Cardiovasc Res Ctr, Prague, Czech Republic; [Bacakova, Lucie; Eckhardt, Adam; Miksik, Ivan; Lisa, Vera] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic","Maxova, H (reprint author), Charles Univ Prague, Dept Pathol Physiol, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic.","hana.maxova@lfmotol.cuni.cz","Miksik, Ivan/A-9178-2008; Eckhardt, Adam/C-2263-2012; Bacakova, Lucie/C-2664-2012; Herget, Jan/I-6313-2012","Miksik, Ivan/0000-0001-5190-1827; Eckhardt, Adam/0000-0003-4757-5226; ","Grant Agency of the CR [305/08/0108]; Ministry of Education, Youth and Sports of the CR [1M0510]","This study was supported by the Grant Agency of the CR (grant No. 305/08/0108) and by the Centre for Cardiovascular Research (project No. 1M0510 of the Ministry of Education, Youth and Sports of the CR). We also thank Mrs. Ivana Zajanova for her excellent technical assistance. Mr. Robin Healey (Czech Technical University, Prague) is gratefully acknowledged for his language revision of the manuscript.",null,30,2,2,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1015-8987",null,null,"CELL PHYSIOL BIOCHEM","Cell. Physiol. Biochem.",null,2010,25,6,null,null,null,null,615,622,null,"10.1159/000315080",null,8,"Cell Biology; Physiology","Cell Biology; Physiology","599DI","WOS:000277890000006"]
[null,null,null,null,"J","Mares, P; Stehlikova, M",null,null,null,"Mares, Pavel; Stehlikova, Mariana",null,null,"Anticonvulsant doses of ganaxolone do not compromise motor performance in immature rats","NEUROSCIENCE LETTERS",null,null,"English","Article",null,null,null,null,null,"Cortical seizures; Behavior; Ganaxolone; Ontogeny; Rat","CORTICAL EPILEPTIC AFTERDISCHARGES; ELECTRICAL-STIMULATION; RECEPTOR; SEIZURES; NEUROSTEROIDS; MICE; ALLOPREGNANOLONE","Neuroactive steroids that function as positive modulators of GABA-A receptors are potential anticonvulsant drugs. We previously demonstrated that ganaxolone is effective against pentetrazol-induced motor seizures in immature rats. In the present study, we examined the effects of ganaxolone in another model, cortical epileptic afterdischarges (ADs). The possible side effects of ganaxolone were studied in rats 12,18, and 25 days of age following the implantation of epidural electrodes. Low-frequency stimulation of the sensorimotor cortical area elicited ADs characterized by a spike-and-wave rhythm and clonic seizures. Ganaxolone (5, 10, 20, or 40 mg/kg) was administered intraperitoneally after the first AD and stimulation was repeated five More times. The highest dose of ganaxolone (40 mg/kg) suppressed progressive prolongation of ADs in 25-day-old rats and postponed it in 12-day-old rats. No significant effect was observed in 18-day-old animals. Movements during stimulation and clonic seizures accompanying ADs were not affected by ganaxolone. Ganaxolone at doses of 20 and 40 mg/kg had no significant effect on motor function, such as surface righting, negative geotaxis, wire mesh ascending, and bar holding. After administration of 40 mg/kg ganaxolone to 18- and 25-day-old rats, spontaneous locomotion in the open field tended to decrease. Doses of ganaxolone with a moderate anticonvulsant effect in the present model did not seriously compromise motor performance. (C) 2009 Elsevier Ireland Ltd. All rights reserved.","[Mares, Pavel; Stehlikova, Mariana] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Prague 14220 4, Czech Republic; [Mares, Pavel; Stehlikova, Mariana] Charles Univ Prague, Fac Med 2, Clin Rehabil & Sport Med, Prague, Czech Republic","Mares, P (reprint author), Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Videnska 1083, Prague 14220 4, Czech Republic.","maresp@biomed.cas.cz","Mares, Pavel/F-8903-2014",null,"Grant Agency of the Czech Republic [203/06/1605]; Ministry of Education of the Czech Republic [LC554]; Academy of Sciences of the Czech Republic [AV0Z 50110905]","This study was supported by grant no. 203/06/1605 of the Grant Agency of the Czech Republic and by Research projects no. LC554 of the Ministry of Education of the Czech Republic and AV0Z 50110905 of the Academy of Sciences of the Czech Republic.",null,21,1,1,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0304-3940",null,null,"NEUROSCI LETT","Neurosci. Lett.","JAN 29",2010,469,3,null,null,null,null,396,399,null,"10.1016/j.neulet.2009.12.037",null,4,"Neurosciences","Neurosciences & Neurology","558DX","WOS:000274722100024"]
[null,null,null,null,"J","Schwabova, J; Zahalka, F; Komarek, V; Maly, T; Hrasky, P; Gryc, T; Zumrova, A",null,null,null,"Schwabova, J.; Zahalka, F.; Komarek, V.; Maly, T.; Hrasky, P.; Gryc, T.; Zumrova, A.",null,null,"A Scale for the Assessment and Rating of Ataxia","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"scale for the assessment and rating of ataxia; International Cooperative Ataxia Rating Scale; autosomal dominant spinocerebelar ataxia; ataxia; Friedreich's ataxia; posturography","SPINOCEREBELLAR ATAXIA; FRIEDREICHS-ATAXIA; CEREBELLAR-ATAXIA; ANTERIOR LOBE; RELIABILITY; DISEASE; STABILOMETRY; VALIDITY; ATROPHY; STANCE","The goal of this study was to test the validity of the Scale for Assessment and Rating of Ataxia (SARA), published in 2006, using patients with autosomal dominant spino-cereberal ataxia (AD SCA) and Friedreich's ataxia (FRDA). The data obtained was compared with that acquired from the International Cooperative Ataxia Rating Scale (ICARS) and correlated with selected posturographic parameters (PP). A total of 30 patients - 17 AD SCA and 13 FRDA - were examined. Time-monitored ICARS and SARA scales were employed. Posturographic examination on a tensometric platform followed, as per standard protocol. The results were statistically processed with tests for non-parametric correlation (Kendall's tau-b). ICARS and SARA exhibited high correlation in both groups and with AD SCA (p <0.001); mid-level correlation was evident with FRDA (p <0.05); ICARS with PP and standing and walking - part of ICARS - correlated closely with PP in both groups (p <0.01); SARA correlated at mid-level with PP in both groups and with AD SCA (p <0.05). FRDA patients did not correlate. The validity of the SARA scale, including its lower time demands, was demonstrated to be in agreement with the literature. Correlations between the scales and selected PP were established, as well as the possibility of using posturography when reviewing the validity of these scales with ataxia patients. Surprisingly, the results of the SARA scale did not correlate with PP in FRDA (p >0.05) patients and the correlation between ICARS and SARA in FRDA patients was lower (tau b = 0.545; p <0.05). The reason for this may lie in the lower number of FRDA patients tested, but SARA may just be less sensitive to the more distinctive symptoms in the dorsal column.","[Schwabova, J.; Komarek, V.; Zumrova, A.] UK 2 LF, Klin Detske Neurol, Prague 15000 5, Czech Republic; [Schwabova, J.; Komarek, V.; Zumrova, A.] FN Motole, Prague 15000 5, Czech Republic; [Zahalka, F.; Maly, T.; Hrasky, P.; Gryc, T.] FTVS UK, Lab Sportovni Motoriky, Prague, Czech Republic","Schwabova, J (reprint author), UK 2 LF, Klin Detske Neurol, Uvalu 84, Prague 15000 5, Czech Republic.","jaroslava.schwabova@lfmotol.cuni.cz",null,null,null,null,null,25,1,1,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2010,73,6,null,null,null,null,689,693,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","696MY","WOS:000285446700009"]
[null,null,null,null,"J","Cerny, R; Rozsypal, H; Kozner, P; Machala, L",null,null,null,"Cerny, Rudolf; Rozsypal, Hanus; Kozner, Pavel; Machala, Ladislav",null,null,"Bilateral Holmes-Adie syndrome as an early manifestation of the HIV neuropathy","NEUROLOGICAL SCIENCES",null,null,"English","Article",null,null,null,null,null,"Holmes-Adie syndrome; Tonic pupil; Areflexia; HIV; Polyneuropathy","VIRUS-INFECTION; TONIC PUPILS; DISEASE; AREFLEXIA","A 38-year-old HIV-1 infected woman affected with bilateral tonic pupils. Ophthalmologic examination confirmed Holmes Adie syndrome (HAS), and peripheral distal polyneuropathy, orthostatic hypotension and leg hyperhidrosis were detected on further workup. The HAS can be either idiopathic or associated with neuropathy of various etiology (autoimmune, paraneoplastic and infectious). In our patient, the pupillotonia was the first and early symptom of hitherto unrecognized HIV neuropathy. HAS has been previously observed in association with syphilis, Lyme borreliosis, herpes simplex and parvovirus B19 infection. Our case is the first report of HAS in a case of HIV infection.","[Machala, Ladislav] Charles Univ Prague, Dept Infect Dis 1, Fac Med 2, Prague 18081, Czech Republic; [Machala, Ladislav] Charles Univ Prague, Dept Infect Dis, Fac Med 3, Prague 18081, Czech Republic; [Kozner, Pavel] Univ Hosp Bulovka, Dept Ophthalmol, Prague, Czech Republic; [Rozsypal, Hanus] Charles Univ Prague, Dept Infect & Trop Dis, Fac Med 1, Univ Hosp Bulovka, Prague 18081, Czech Republic; [Cerny, Rudolf] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague 18081, Czech Republic","Machala, L (reprint author), Charles Univ Prague, Dept Infect Dis 1, Fac Med 2, Budinova 2, Prague 18081, Czech Republic.","ladimachala@centrum.cz","Cerny, Rudolf/C-7759-2014",null,null,null,null,24,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1590-1874",null,null,"NEUROL SCI","Neurol. Sci.","OCT",2010,31,5,null,null,null,null,661,663,null,"10.1007/s10072-010-0355-9",null,3,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","668LR","WOS:000283271900021"]
[null,null,null,null,"J","Drevinek, P; Baldwin, A; Lindenburg, L; Joshi, LT; Marchbank, A; Vosahlikova, S; Dowson, CG; Mahenthiralingam, E",null,null,null,"Drevinek, Pavel; Baldwin, Adam; Lindenburg, Laurens; Joshi, Lovleen Tina; Marchbank, Angela; Vosahlikova, Sarka; Dowson, Christopher G.; Mahenthiralingam, Eshwar",null,null,"Oxidative Stress of Burkholderia cenocepacia Induces Insertion Sequence-Mediated Genomic Rearrangements That Interfere with Macrorestriction-Based Genotyping","JOURNAL OF CLINICAL MICROBIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"CYSTIC-FIBROSIS PATIENTS; CEPACIA COMPLEX; INDUCED TRANSPOSITION; SUPEROXIDE-DISMUTASE; SP-NOV; EPIDEMIOLOGY; RESISTANCE","Burkholderia cenocepacia can cause serious infections and epidemics in patients with cystic fibrosis (CF). A CF population in the Czech Republic experienced an epidemic outbreak caused by a B. cenocepacia ST-32 strain. The clonality of the isolates was evident by multilocus sequence typing; however, fingerprinting profiles obtained by pulsed-field gel electrophoresis (PFGE) showed substantial band variability. We investigated whether the PFGE pattern diversity resulted from genomic rearrangements mediated by insertion sequences (IS); in addition, we determined whether stressful growth conditions altered the transposition activity of these IS. DNA probes for IS commonly found in B. cenocepacia were designed using the B. cenocepacia J2315 genome. Southern hybridization analysis of ST-32 isolates demonstrated diversity in both the copy number and the insertion site for a homologue of ISBcen20. Movement of the ISBcen20 homologue was detected when the ST-32 isolate CZ1238 was exposed to oxidative stress (growth in the presence of H(2)O(2)). PFGE analysis of CZ1238 derivatives exposed to oxidative stress demonstrated genomic rearrangements. Interestingly, when the closely related B. cenocepacia strain J2315 was exposed to oxidative stress, no movement of ISBcen20 was detected. Since frameshift mutations are present within the transposases of all copies of this IS in J2315, our data suggest that the transposase is inactive. In summary, we have demonstrated for the first time that IS movement can be mediated by oxidative stress and can lead to genomic rearrangements in the CF pathogen B. cenocepacia. These IS movements may alter the PFGE fingerprints of isolates that are clonal by other typing methods.","[Drevinek, Pavel; Lindenburg, Laurens; Joshi, Lovleen Tina; Marchbank, Angela; Mahenthiralingam, Eshwar] Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales; [Baldwin, Adam; Dowson, Christopher G.] Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; [Drevinek, Pavel; Vosahlikova, Sarka] Charles Univ Prague, Sch Med 2, Dept Paediat, Prague, Czech Republic","Drevinek, P (reprint author), Charles Univ Prague, Sch Med 2, Dept Paediat, Prague, Czech Republic.","pavel.drevinek@Lfmotol.cuni.cz","Mahenthiralingam, Eshwar/D-3333-2009","Mahenthiralingam, Eshwar/0000-0001-9014-3790","Wellcome Trust [075586]; Ministry of Education of the Czech Republic [MSM0021620812]","This work was funded by grants from the Wellcome Trust (075586) and the Ministry of Education of the Czech Republic (MSM0021620812).",null,22,10,10,"AMER SOC MICROBIOLOGY","WASHINGTON","1752 N ST NW, WASHINGTON, DC 20036-2904 USA","0095-1137",null,null,"J CLIN MICROBIOL","J. Clin. Microbiol.","JAN",2010,48,1,null,null,null,null,34,40,null,"10.1128/JCM.01433-09",null,7,"Microbiology","Microbiology","576NL","WOS:000276151500003"]
[null,null,null,null,"J","Druga, R; Mares, P; Kubova, H",null,null,null,"Druga, Rastislau; Mares, Pavel; Kubova, Hana",null,null,"Time course of neuronal damage in the hippocampus following lithium-pilocarpine status epilepticus in 12-day-old rats","BRAIN RESEARCH",null,null,"English","Article",null,null,null,null,null,"Immature rats; Degenerating cells; Fluoro-Jade B; Interneurons; Pyramidal cells","TEMPORAL-LOBE EPILEPSY; NUCLEUS REUNIENS THALAMI; TRAUMATIC BRAIN-INJURY; FLUORO-JADE-B; KAINIC ACID; MEDIODORSAL NUCLEUS; RECURRENT SEIZURES; IMMATURE BRAIN; FIELD CA1; DEGENERATION","Status epilepticus (SE) leads to serious damage in hippocampus of the adult brain. Much less is known about immature brain where neuronal degeneration may have different localization and time course. Lithium-pilocarpine SE was induced in 12-day-old male Wistar rats. Six different intervals after SE (from 4 h to 1 week) were studied using Fluoro-Jade B staining. Three to four animals were used for every interval. Severity of damage in individual parts of hippocampal formation was semi-quantified. A consistent neuronal damage occurred in all hippocampal fields (CA 1, CA 3, dentate gyrus) at all survival intervals. Hippocampal fields CA 1 and CA 3 exhibited degeneration of interneurons located mainly in stratum oriens and pyramidale at shorter intervals (4-12 h). Massive degeneration of pyramidal cells started at 24 h in CA 1 and at 48 h in CA 3. Dentate gyrus exhibited degenerating neurons in granular layer with a peak at short intervals (4-8 h), and molecular layer was spared. The lower blade of dentate gyrus was more affected than the upper blade. Damage of hilar neurons was neglibile. Our results demonstrate that SE elicited in immature rats causes acute neurodegeneration in the hippocampus. Time course of this degeneration is different for individual parts of hippocampal formation and for individual cell types. (C) 2010 Elsevier B.V. All rights reserved.","[Druga, Rastislau; Mares, Pavel; Kubova, Hana] Acad Sci Czech Republic, Dept Dev Epileptol, Inst Physiol, CZ-14220 Prague 4, Czech Republic; [Druga, Rastislau] Charles Univ Prague, Fac Med 2, Dept Anat, Prague, Czech Republic","Druga, R (reprint author), Acad Sci Czech Republic, Dept Dev Epileptol, Inst Physiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.","rastislav.dmga@lf1.cuni.cz","Kubova, Hana/C-4210-2012; Mares, Pavel/F-8903-2014",null,"Grant Agency of the Czech Republic [304/04/0464, 304/07/1137]; Academy of Sciences of the Czech Republic [AV0Z 50110905]","This study was supported by grants of the Grant Agency of the Czech Republic Nr. 304/04/0464 and 304/07/1137 and Research Project No. AV0Z 50110905 of the Academy of Sciences of the Czech Republic.",null,35,3,4,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0006-8993","1872-6240",null,"BRAIN RES","Brain Res.","OCT 8",2010,1355,null,null,null,null,null,174,179,null,"10.1016/j.brainres.2010.07.072",null,6,"Neurosciences","Neurosciences & Neurology","658QK","WOS:000282504300017"]
[null,null,null,null,"J","Svehlik, M; Zwick, EB; Steinwender, G; Saraph, V; Linhart, WE",null,null,null,"Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhardt; Saraph, Vinay; Linhart, Wolfgang E.",null,null,"Genu recurvatum in cerebral palsy - part A: influence of dynamic and fixed equinus deformity on the timing of knee recurvatum in children with cerebral palsy","JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B",null,null,"English","Article",null,null,null,null,null,"cerebral palsy; electromyography; equines; gait analysis; knee hyperextension; musculoskeletal modelling","MULTILEVEL SURGERY; GAIT ANALYSIS; CROUCH GAIT; HAMSTRINGS; ANKLE; LENGTHS; CONTRACTURE; MANAGEMENT; STANCE","The aim of the study was to confirm the hypothesis of the influence of the dynamic and fixed equinus deformity on the timing of knee recurvation (hyperextension). According to our hypothesis, dynamic equinus is linked to early and fixed equinus and to late knee hyperextension. A group 35 children with cerebral palsy (47 lower limbs) was divided into two subgroups according to the timing of maximum knee hyperextension. Clinical examination confirmed our hypothesis. Gait analysis and musculoskeletal modelling results were compared with 12 normally developing children. Both recurvatum groups had forefoot landing and neither achieved normal ankle dorsiflexion. Electromyographic examination revealed an abnormally high soleus activity in a single stance. Muscle length changes of medial gastrocnemius and soleus were in agreement with our hypothesis. Such a finding might simplify the decision as to which treatment to select for equinus deformity, present in patients with genu recurvatum. J Pediatr Orthop B 19:366-372 (c) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhardt; Saraph, Vinay; Linhart, Wolfgang E.] Med Univ Graz, Dept Paediat Orthopaed & Paediat Surg, A-8036 Graz, Austria; [Svehlik, Martin] Charles Univ Prague, Dept Children & Adult Orthopaed, Sch Med 2, Prague, Czech Republic","Svehlik, M (reprint author), Med Univ Graz, Dept Paediat Orthopaed & Paediat Surg, Auenbruggerpl 34, A-8036 Graz, Austria.","martin.spejlik@seznam.cz",null,null,null,null,null,28,3,3,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1060-152X",null,null,"J PEDIATR ORTHOP B","J. Pediatr. Orthop.-Part B","JUL",2010,19,4,null,null,null,null,366,372,null,"10.1097/BPB.0b013e32833a5f72",null,7,"Orthopedics; Pediatrics","Orthopedics; Pediatrics","615QR","WOS:000279151000018"]
[null,null,null,null,"J","Svehlik, M; Zwick, EB; Steinwender, G; Kraus, T; Linhart, WE",null,null,null,"Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhard; Kraus, Tanja; Linhart, Wolfgang E.",null,null,"Dynamic Versus Fixed Equinus Deformity in Children With Cerebral Palsy: How Does the Triceps Surae Muscle Work?","ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION",null,null,"English","Article",null,null,null,null,null,"Biomechanics; Cerebral palsy; Equinus deformity; Gait; Muscle; Rehabilitation","GASTROCNEMIUS RECESSION; MULTILEVEL SURGERY; PLANTAR FLEXORS; GAIT ANALYSIS; CROUCH GAIT; ANKLE; CONTRACTURE; LENGTHS; WALKING; SOLEUS","Svehlik M, Zwick EB, Steinwender G, Kraus T, Linhart WE. Dynamic versus fixed equinus deformity in children with cerebral palsy: how does the triceps surae muscle work? Arch Phys Med Rehabil 2010;91:1897-1903. Objectives: To detect outcome measures that could help differentiate between dynamic and fixed equinus (FEQ) deformities in children with cerebral palsy, and secondary, to describe the function of the gastrocnemius and soleus (SOL) muscles when either dynamic triceps surae tightness or FEQ contracture is present. Design: A group-comparison study. Setting: Gait analysis laboratory. Participants: Children (N=23; 31 limbs) with cerebral palsy; 12 limbs showed a fixed contracture (FEQ group) and 19 limbs showed dynamic tightness of the triceps muscle (dynamic equinus group). Healthy children (N=12) without a neurologic or orthopedic disorder served as the control group. Interventions: Not applicable. Main Outcome Measures: Time-distance, kinematic and kinetic gait variables, muscle-tendon length, and velocity parameters. Results: Maximal ankle dorsiflexion angles were decreased in both equinus groups compared with the control group. Ankle range of motion, maximal power generation of the plantar flexors, and its timing during the gait cycle were different among groups. The ankle slope parameter showed substantial differences among groups. Muscle-tendon length parameters for the SOL and the medial (MGAC) and lateral gastrocnemius muscles were abnormal in both equinus groups compared with the control group. Maximal muscle lengths of the MGAC and SOL were longer in the dynamic equinus than FEQ group. Peak lengthening velocity of the triceps surae muscle was significantly slower for all triceps surae muscles in the FEQ group than in the dynamic equinus group and occurred in the early swing phase. Conclusions: The presented results indicate that peak lengthening velocity of the triceps surae muscle might be one of the discriminating factors between FEQ and dynamic equinus deformity in children with cerebral palsy. This could help clinical decision making for treatment of an equinus gait pattern.","[Svehlik, Martin; Zwick, Ernst B.; Steinwender, Gerhard; Kraus, Tanja; Linhart, Wolfgang E.] Med Univ Graz, Dept Paediat Orthopaed, A-8036 Graz, Austria; [Svehlik, Martin] Charles Univ Prague, Fac Med 2, Dept Children & Adult Orthopaed & Traumatol, Prague, Czech Republic","Svehlik, M (reprint author), Med Univ Graz, Dept Paediat Orthopaed, Auenbruggerpl 34, A-8036 Graz, Austria.","martin.spejlik@seznam.cz",null,null,null,null,null,33,2,2,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0003-9993",null,null,"ARCH PHYS MED REHAB","Arch. Phys. Med. Rehabil.","DEC",2010,91,12,null,null,null,null,1897,1903,null,"10.1016/j.apmr.2010.09.005",null,7,"Rehabilitation; Sport Sciences","Rehabilitation; Sport Sciences","700KY","WOS:000285738900012"]
[null,null,null,null,"J","Tomasov, P; Linhartova, K; Antonova, P; Adlova, R; Alan, D; Veselka, J",null,null,null,"Tomasov, Pavol; Linhartova, Katerina; Antonova, Petra; Adlova, Radka; Alan, David; Veselka, Josef",null,null,"Combined percutaneous treatment of atrial septal defect and pulmonic or aortic stenosis in adult patients","ARCHIVES OF MEDICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"heart septal defects; septal occluder device; balloon valvuloplasty","BALLOON VALVULOPLASTY; VALVE STENOSIS; CLOSURE","Combined atrial septal defect and pulmonic or aortic stenosis are relatively uncommon conditions in adult patients, with few reported cases of percutaneous treatment. We present two patients with secundum type atrial septal defect and concomitant pulmonic or aortic stenosis and their treatment by transcatheter techniques.","[Tomasov, Pavol; Linhartova, Katerina; Antonova, Petra; Adlova, Radka; Alan, David; Veselka, Josef] Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc, Prague 15006, Czech Republic","Tomasov, P (reprint author), Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc, Uvalu 84, Prague 15006, Czech Republic.","p.tomasov@seznam.cz",null,null,"Czech Ministry of Health [MZOFNM2005]","Supported by the Czech Ministry of Health MZOFNM2005.",null,7,1,1,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922",null,null,"ARCH MED SCI","Arch. Med. Sci.","DEC",2010,6,6,null,null,null,null,976,980,null,"10.5114/aoms.2010.19312",null,5,"Medicine, General & Internal","General & Internal Medicine","703MN","WOS:000285982100025"]
[null,null,null,null,"J","Figova, K; Sobotkova, E; Duskova, M; Ludvikova, V; Vonka, V; Eckschlager, T",null,null,null,"Figova, K.; Sobotkova, E.; Duskova, M.; Ludvikova, V.; Vonka, V.; Eckschlager, T.",null,null,"In vitro and in vivo effects of reovirus on HPV16-transformed mice cells","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"reovirus type 3; HPV16-transformed mouse cell lines; apoptosis; cell cycle; immunization/challenge experiments","HUMAN-PAPILLOMAVIRUS TYPE-16; HERPES-SIMPLEX-VIRUS; ANTITUMOR IMMUNITY; ONCOLYTIC REOVIRUS; DENDRITIC CELLS; HPV16-ASSOCIATED TUMORS; THERAPY; CANCER; APOPTOSIS; MELANOMA","Oncolytic viruses are examined to serve as anticancer therapeutics. It is expected that in addition to direct oncolytic effect their action will also help eliciting a solid antitumor immunity. In presented series of experiments we have employed two HPV16-transformed mouse (strain C57/B6) cell lines, TC-1 and MK16/III/ABC (MK16), and reovirus type 3, strain Dearing (RV). Both cell lines are highly susceptible to RV and produce large amounts of infectious virus in vitro while normal human are not susceptible to RV. Still, some differences were encountered. TC-1 cells produced moderately lesser amounts of infectious virus, but, paradoxically, were more efficient producers of M antigen of RV and as a consequence of virus infection died more rapidly than simultaneously infected MK16 cells. Minor differences between the cell lines were observed in the percentage of cells arrested in theG2/M phase of the cell cycle and in some markers of apoptosis. When inoculating high doses (5x10(6)) of infected cells (MOI 10 PFU/cell) into syngeneic animals their oncogenic activity was strongly suppressed, nearly completely in the case of MK16 cells and somewhat less efficiently in the case of more oncogenic TC-1 cells. Immunizing experiments in which non-oncogenic doses (10(6)) of RV infected TC-1 cells were tested in parallel with the same doses of irradiated cells brought surprising results. When immunized animals were challenged with TC-1 cells, the irradiated cells proved to be a much better immunogen that the infected cells. However, when challenged with MK16 cells the opposite was true. It is believed that this difference was associated with the different biological properties of the cell lines tested.","[Figova, K.; Eckschlager, T.] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague 15006, Czech Republic; [Figova, K.; Eckschlager, T.] Univ Hosp Motol, Prague 15006, Czech Republic; [Sobotkova, E.; Duskova, M.; Ludvikova, V.; Vonka, V.] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic","Figova, K (reprint author), Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006, Czech Republic.","eckschlagertomas@yahoo.com",null,null,"GACR [301/05/2240, MSMT0021620813]","We thank J. Cinatl Jr. (Institute for Medical Virology, Johann Wolfgang Goethe University Hospital, Frankfurt am Mein, Germany) who kindly provided reovirus, normal human fibroblasts and Vero cells. This research was supported by the grants GACR No. 301/05/2240 and MSMT0021620813.",null,33,1,1,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2010,57,3,null,null,null,null,207,214,null,"10.4149/neo_2010_03_207",null,8,"Oncology","Oncology","592WQ","WOS:000277412800003"]
[null,null,null,null,"J","Kubinova, S; Sykova, E",null,null,null,"Kubinova, Sarka; Sykova, Eva",null,null,"Nanotechnologies in regenerative medicine","MINIMALLY INVASIVE THERAPY & ALLIED TECHNOLOGIES",null,null,"English","Review",null,null,null,null,null,"Nanotechnology; regenerative medicine; nanofibers; cell therapy; iron-oxide nanoparticles","PEPTIDE NANOFIBER SCAFFOLD; MAGNETIC-RESONANCE TRACKING; IRON-OXIDE NANOPARTICLES; MESENCHYMAL STEM-CELLS; SPINAL-CORD-INJURY; IN-VIVO; ELECTROSPUN NANOFIBERS; ANTIBACTERIAL PROPERTIES; MYOCARDIAL-INFARCTION; ENDOTHELIAL-CELLS","Nanotechnology offers promising perspectives in biomedical research as well as in clinical practice. To cover some of the latest nanotechnology trends in regenerative medicine, this review will focus on the use of nanomaterials for tissue engineering and cell therapy. Nanofibrous materials that mimic the native extracellular matrix and promote the adhesion of various cells are being developed as tissue-engineered scaffolds for the skin, bone, vasculature, heart, cornea, nervous system, and other tissues. A range of novel materials has been developed to enhance the bioactive or therapeutic properties of these nanofibrous scaffolds via surface modifications, including the immobilization of functional cell-adhesive ligands and bioactive molecules such as drugs, enzymes and cytokines. As a new approach, nanofibers prepared by using industrial scale needleless technology have been recently introduced, and their use as scaffolds to treat spinal cord injury or as cell carriers for the regeneration of the injured cornea is the subject of much current study. Cell therapy is a modern approach of regenerative medicine for the treatment of various diseases or injuries. To follow the migration and fate of transplanted cells, superparamagnetic iron oxide nanoparticles have been developed for cell labeling and non-invasive MRI monitoring of cells in the living organism, with successful applications in, e. g, the central nervous system, heart, liver and kidney and also in pancreatic islet and stem cell transplantation.","[Kubinova, Sarka; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Sykova, E (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220, Czech Republic.","sykova@biomed.cas.cz",null,null,"GAAV [IAA 500 390 902]; EC [LSHM-CT-2005-019063]; GACR [203/09/1242, KAN201110651, P108/10/1560, KAN200520804];  [AVOZ 503 90 703];  [1M0538];  [LC 554]","We thank James Dutt for critical reading of the manuscript. This work was supported through the grants: AVOZ 503 90 703, 1M0538, LC 554, GAAV IAA 500 390 902, the EC FP6 project ENINET (LSHM-CT-2005-019063), GACR 203/09/1242, KAN201110651, P108/10/1560, KAN200520804.",null,95,30,31,"TAYLOR & FRANCIS AS","OSLO","KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY","1364-5706",null,null,"MINIM INVASIV THER","Minim. Invasive Ther. Allied Technol.","JUN-AUG",2010,19,41732,null,null,null,null,144,156,null,"10.3109/13645706.2010.481398",null,13,"Surgery","Surgery","643JV","WOS:000281293500004"]
[null,null,null,null,"J","Betka, J; Chovanec, M; Klozar, J; Taudy, M; Plzak, J; Kodetova, D; Lisy, J",null,null,null,"Betka, Jan; Chovanec, Martin; Klozar, Jan; Taudy, Milos; Plzak, Jan; Kodetova, Dana; Lisy, Jiri",null,null,"Transoral and combined transoral-transcervical approach in the surgery of parapharyngeal tumors","EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"Parapharyngeal space; Transoral approach; External approach; Surgery; Salivary gland; Tumor; Nerve sheath tumor","SPACE TUMORS; MANAGEMENT; DIAGNOSIS; SKULL; BASE","The goal of parapharyngeal space (PPS) tumor surgery is to obtain adequate visualization to ensure complete removal with preservation of the surrounding nerves and vessels. Different surgical approaches have been described. Transoral approach is the most controversial one due to cited limited exposure, risk of tumor spillage, and possibility of neurovascular injury. We performed retrospective analysis of 26 consecutive patients who had undergone transoral or combined transoral-transcervical resection of PPS tumors from January 1997 to December 2007. Both approaches were safely employed to remove selected PPS tumors. Majority of treated tumors were pleomorphic adenomas (14 minor salivary gland and 7 deep lobe parotid gland tumors). Two cases of malignant salivary gland tumors, 4 nerve sheath tumors and 1 lymphangioma were also excised. Mean tumor size was 6.1 cm (range 2-11 cm). Visualization was felt to be adequate and dissection safe. Radical resection was achieved in 24 cases. Near-total resection was achieved in two cases where otherwise other approach would be suitable but cannot be undertaken because of patient refusal and comorbidities. Patients with malignant tumors had postoperative radiotherapy. Radically treated cases are disease free. One of the near-totally resected tumors needed revision surgery. Neither major complications nor disordered healing were observed. Transoral approach provides access to selected cases of PPS tumors based on preoperative imaging methods and fine-needle aspiration cytology. Risk of non-radical resection is acceptable. It can be combined with external approach to achieve safe resection of some benign tumors which would need transmandibular approach.","[Betka, Jan; Chovanec, Martin; Klozar, Jan; Taudy, Milos; Plzak, Jan] Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Fac Hosp Motol, Prague 15006 5, Czech Republic; [Chovanec, Martin; Plzak, Jan] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 15006 5, Czech Republic; [Chovanec, Martin; Plzak, Jan] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague 15006 5, Czech Republic; [Kodetova, Dana] Charles Univ Prague, Inst Pathol & Mol Med, Fac Med 2, Prague 15006 5, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Dept Radiodiagnost, Fac Med 2, Prague 15006 5, Czech Republic","Chovanec, M (reprint author), Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Fac Hosp Motol, Uvalu 84, Prague 15006 5, Czech Republic.","martin.chovanec@lf1.cuni.cz",null,null,null,null,null,16,9,10,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0937-4477",null,null,"EUR ARCH OTO-RHINO-L","Eur. Arch. Oto-Rhino-Laryn.","MAY",2010,267,5,null,null,null,null,765,772,null,"10.1007/s00405-009-1071-z",null,8,"Otorhinolaryngology","Otorhinolaryngology","573YL","WOS:000275954000017"]
[null,null,null,null,"J","Suchanek, O; Podrazil, M; Fischerova, B; Bocinska, H; Budinsky, V; Stejskal, D; Spisek, R; Bartunkova, J; Kolar, P",null,null,null,"Suchanek, Ondrej; Podrazil, Michal; Fischerova, Barbara; Bocinska, Helena; Budinsky, Vit; Stejskal, David; Spisek, Radek; Bartunkova, Jirina; Kolar, Pavel",null,null,"Intensive physical activity increases peripheral blood dendritic cells","CELLULAR IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Dendritic cells; Costimulatory molecules; Catecholamines; Physical exercise; Top sport","TOLL-LIKE RECEPTORS; IMMUNE-RESPONSE; EXERCISE; EXPRESSION; MATURATION; HUMANS; SYSTEM; IL-6","We analyzed the frequency and absolute numbers of circulating myeloid and plasmacytoid DCs in peripheral blood and evaluated their maturation status to test the hypothesis that significant physical stress to the body might induce measurable changes in DCs subsets, phenotype and function, which would complete existing knowledge about the response of the cellular immune system to an acute exercise in top sportsmen. We evaluated the heart rate and draw blood samples before and after the physical load in 18 profesional ice-hockey players. We observed an increase in leukocytes numbers with a predominant increase in the population of DCs and lymphocytes after exercise. Both myeloid and plasmacytoid DCs increased significantly. We found a correlation between the increase of peripheral blood DCs and serum epinephrine and norepinephrine levels. Increase in peripheral blood DCs also correlates with the extent of heart rate elevation during exercise. (C) 2010 Published by Elsevier Inc.","[Spisek, Radek] Charles Univ Prague, Inst Immunol, Fac Med 2, Dept Immunol, Prague 15006 5, Czech Republic; [Fischerova, Barbara; Bocinska, Helena; Kolar, Pavel] Charles Univ Prague, Dept Rehabil, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Stejskal, David] Prostejov Hosp, Dept Lab Med, Prostejov, Czech Republic","Spisek, R (reprint author), Charles Univ Prague, Inst Immunol, Fac Med 2, Dept Immunol, V Uvalu 84, Prague 15006 5, Czech Republic.","radek.spisek@lfmotol.cuni.cz","Spisek, Radek/E-6724-2011",null,"Czech Ministry of Education [VZ MSM 0021620812]; Ministry of Health Czech Republic [IGA NS10489-3/2009]","This study was supported by Research Project VZ MSM 0021620812 from The Czech Ministry of Education and by Grant IGA NS10489-3/2009 from the Ministry of Health Czech Republic.",null,27,4,6,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0008-8749",null,null,"CELL IMMUNOL","Cell. Immunol.",null,2010,266,1,null,null,null,null,40,45,null,"10.1016/j.cellimm.2010.08.010",null,6,"Cell Biology; Immunology","Cell Biology; Immunology","680RB","WOS:000284251000006"]
[null,null,null,null,"J","Makukh, H; Krenkova, P; Tyrkus, M; Bober, L; Hancarova, M; Hnateyko, O; Macek, M",null,null,null,"Makukh, Halyna; Krenkova, Petra; Tyrkus, Marta; Bober, Lyudmyla; Hancarova, Miroslava; Hnateyko, Oleh; Macek, Milan, Jr.",null,null,"A high frequency of the Cystic Fibrosis 2184insA mutation in Western Ukraine: Genotype-phenotype correlations, relevance for newborn screening and genetic testing","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Article",null,null,null,null,null,"Cystic fibrosis (OMIM 219700); CFTR gene; Genotype phenotype correlations; Western Ukraine; 2184insA; DNA diagnostics; Newborn screening; Sequencing","CFTR GENE","We present the first comprehensive report on the distribution and genotype-phenotype correlations of CF-causing mutations in Western Ukraine (former Galicia). The 2184insA mutation was identified in 17 unrelated CF patients, 2 of whom are homozygotes for this allele. This mutation is associated with the classical form of CF. The high frequency of 2184insA mutation (7.20% of all mutated CF chromosomes) suggests that it is likely of Galician origin, from where it has spread throughout Europe and beyond. The achieved 83.71% mutation detection rate fulfills the minimal pre-requisite for introduction of the \"two-tier\" (IRT/DNA) newborn screening program. (C) 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Krenkova, Petra; Hancarova, Miroslava; Macek, Milan, Jr.] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, CZ-15006 Prague 5, Czech Republic; [Krenkova, Petra; Hancarova, Miroslava; Macek, Milan, Jr.] Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Makukh, Halyna; Tyrkus, Marta; Bober, Lyudmyla; Hnateyko, Oleh] Ukrainian Acad Med Sci, Inst Hereditary Pathol, Lvov, Ukraine","Macek, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","milan.macek.jr@lfmotol.cuni.cz",null,null,"Eurogentest Fellowship [FP6-512148]; Czech Ministry of Health [MZOFNM2005]","Supported by the Eurogentest Fellowship (FP6-512148) to HM and by MZOFNM2005 from the Czech Ministry of Health to MM. We also acknowledge proofreading of the manuscript by Dr. A. Melnyk (Chicago, USA), graphical design by Dr. M. Turnovec (Prague, Czech Republic) and help of Dr. S. Koceva (Skopje, Macedonia) and Dr. J. Feigelson (Paris, France) with sequencing of selected WU patients.",null,18,5,5,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","SEP",2010,9,5,null,null,null,null,371,375,null,"10.1016/j.jcf.2010.06.001",null,5,"Respiratory System","Respiratory System","670HJ","WOS:000283411500012"]
[null,null,null,null,"J","Palova, S; Szabo, K; Charvat, J; Slavicek, J; Medova, E; Mlcek, M; Kittnar, O",null,null,null,"Palova, S.; Szabo, K.; Charvat, J.; Slavicek, J.; Medova, E.; Mlcek, M.; Kittnar, O.",null,null,"ECG Body Surface Mapping Changes in Type 1 Diabetic Patients with and without Autonomic Neuropathy","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Diabetes mellitus type 1; Autonomic neuropathy; ECG Body Surface Mapping","CORONARY-ARTERY DISEASE; POTENTIAL MAPS; MELLITUS; SYSTEM","ECG body surface mapping (BSM) parameters in patients with diabetes mellitus Type 1 (DM1) are significantly different comparing to healthy non-diabetic subjects. Hypothesis that these changes are more pronounced in DM1 patients with autonomic neuropathy (AN) was tested. The parameters of BSM were registered by diagnostic system Cardiag 112.2 in 54 DM1 patients including 25 with AN and 30 control subjects. AN was diagnosed according to Ewing criteria when two or more Ewing tests were abnormal. In classic 12-lead ECG the heart rate was increased, QRS and QT shortened (p<0.01) and QT(c) prolonged in DM1 patients. The VCG measurement of QRS-STT angles and spatial QRS-STT angle showed non-significant differences. The absolute values of maximum and minimum in depolarization and repolarization isopotential, isointegral, isoarea maps were significantly different in DM1 patients in comparison with controls (p<0.01). The changes were more pronounced in DM1 patients with AN than in DM patients without AN (p<0.05). The QT duration measured in 82 leads of thorax was significantly shortened in 68 leads of both groups of DM1 patients (p<0.01) when compared with controls. In 34 of them this shortening was more pronounced in DM1 patients with AN than in DM1 patients without AN (p<0.05). The results showed that the method of ECG BSM is capable to confirm the presence of autonomic neuropathy in diabetic patients.","[Slavicek, J.; Medova, E.; Mlcek, M.; Kittnar, O.] Charles Univ Prague, Fac Med 1, Inst Physiol, Prague 12800 2, Czech Republic; [Palova, S.; Szabo, K.; Charvat, J.] Charles Univ Prague, Fac Med 2, Dept Med, Prague 12800 2, Czech Republic","Kittnar, O (reprint author), Charles Univ Prague, Fac Med 1, Inst Physiol, Albertov 5, Prague 12800 2, Czech Republic.","otomar.kittnar@lf1.cuni.cz",null,null," [GAUK 53/2004];  [GAAV 1ET201210527]","This work was partially supported by Grants GAUK 53/2004, GAAV 1ET201210527. The authors wish to thank to Assoc. Prof Ljuba Bacharova for her kind remarks, to Dr. Eva Medova and to Mrs. Tereza Vavrikova for registration and evaluation of parameters of heart electric field, for preparation and correction of manuscript, and to Mrs. Alena Dohnalova for the statistical measurements.",null,20,2,2,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,2,null,null,null,null,203,209,null,null,null,7,"Physiology","Physiology","600VE","WOS:000278016200007"]
[null,null,null,null,"J","Bronsky, J; Jirsa, M; Nevoral, J; Hrebicek, M",null,null,null,"Bronsky, J.; Jirsa, M.; Nevoral, J.; Hrebicek, M.",null,null,"Role of Common Canalicular Transporter Gene Variations in Aetiology of Idiopathic Gallstones in Childhood","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,"cholelithiasis; polymorphism; ABCB11; ABCG8","SALT EXPORT PUMP; DISEASE; MDR3; CHOLELITHIASIS; CHOLESTASIS; ASSOCIATION; DEFICIENCY; CIRRHOSIS; LIVER","Variations in genes encoding canalicular transportes, for biliary lipids may affect concentrations of biliary lipids in bile and promote cholesterol crystallization and gallstone formation. In our study we investigated the contribution of heterozygosity for common variations considered either potentially pathogenic or susceptibility alleles for cholesterol cholelithiasis in adults (c.523A>G (p.Thr175Ala) and c.1954A>G (p.Arg652Gly) in ABCB4, c.1331T>C (p.Val444Ala) in ABCB11 and c.55 G>C (p.Asp19His) in ABCG8) to the aetiology of paediatric idiopathic gallstone disease. Genotyping was performed in 35 paediatric subjects with idiopathic gallstones with positive family history for gallstones and 150 population controls. The ABCB4 variant p.Thr175Ala was found only in the controls, not in the patients. The frequency of the remaining three variant alleles and the corresponding genotypes did not differ between patients and controls. We conclude that the studied common variations in genes encoding canalicular transporters known to contribute to genetic predisposition to cholesterol gallstones in adulthood do not contribute specifically to the aetiology of paediatric idiopathic gallstones.","[Jirsa, M.] Charles Univ Prague, Inst Clin & Expt Med, Fac Med 1, Prague 14021 4, Czech Republic; [Bronsky, J.; Nevoral, J.] Charles Univ Prague, Fac Med 2, Prague 14021 4, Czech Republic; [Bronsky, J.; Nevoral, J.] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Prague 14021 4, Czech Republic; [Hrebicek, M.] Charles Univ Prague, Inst Inherited Metab Dis, Fac Med 1, Prague 14021 4, Czech Republic","Jirsa, M (reprint author), Charles Univ Prague, Inst Clin & Expt Med, Fac Med 1, Lab Expt Hepatol Bldg ZI,Videnska 1958-9, Prague 14021 4, Czech Republic.","milan.jirsa@ikem.cz",null,null,"Ministry of Health of the Czech Republic [NR/9079-3]","This study was supported by grant NR/9079-3 from the Ministry of Health of the Czech Republic.",null,16,1,2,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2010,56,1,null,null,null,null,9,13,null,null,null,5,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","588LO","WOS:000277071800002"]
[null,null,null,null,"J","Cejka, C; Platenik, J; Sirc, J; Ardan, T; Michalek, J; Brunova, B; Cejkova, J",null,null,null,"Cejka, C.; Platenik, J.; Sirc, J.; Ardan, T.; Michalek, J.; Brunova, B.; Cejkova, J.",null,null,"Changes of Corneal Optical Properties after UVB Irradiation Investigated Spectrophotometrically","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Corneal hydration; Corneal light absorption; Absorption coefficients; UVB rays","RABBIT CORNEA; ALDEHYDE DEHYDROGENASE; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; PHOTOREFRACTIVE KERATECTOMY; ULTRAVIOLET-LIGHT; PROTECTIVE ROLE; EPITHELIUM; EYE; RAYS","Ozone depletion leads to an increase in UV rays of solar radiation reaching the surface of the Earth which is harmful to biological systems. Of the eye, the cornea is directly open to increased amount of UV rays of which mainly UVB rays are capable to induce reactive oxygen species damaging the cells. Previous studies showed that the irradiation of the cornea with UVB rays leads to morphological as well as metabolic disturbances of the cornea. Also, corneal hydration and corneal light absorption are increased after UVB rays. These changes were observed after five days of repeated irradiation of the cornea with UVB rays. The aim of the present paper was to examine how early the changes of corneal hydration and light absorption occur after UVB irradiation. The rabbit corneas were irradiated with UVB rays for one, two, three or four days. Corneal light absorption was examined spectrophotometrically and corneal hydration measured by pachymeter (as corneal thickness). Results show that changes of corneal hydration and light absorption appear early after UVB irradiation and increase along with the number of irradiations. In conclusion, irradiation of the rabbit cornea with UVB rays leads to harmful changes of its optical properties.","[Cejka, C.; Ardan, T.; Cejkova, J.] Acad Sci Czech Republic, Inst Expt Med, Lab Eye Histochem & Pharmacol, Prague 14220 4, Czech Republic; [Platenik, J.] Charles Univ Prague, Fac Med 1, Inst Med Biochem, Prague, Czech Republic; [Sirc, J.; Michalek, J.] Acad Sci Czech Republic, Inst Macromol Chem, Prague 14220 4, Czech Republic; [Cejka, C.; Brunova, B.] Charles Univ Prague, Fac Med 2, Eye Clin Children & Adults, Prague, Czech Republic","Cejkova, J (reprint author), Acad Sci Czech Republic, Inst Expt Med, Lab Eye Histochem & Pharmacol, Videnska 1083, Prague 14220 4, Czech Republic.","cejkova@biomed.cas.cz","Michalek, Jiri/D-7251-2013",null,"Grant Agency of Charles University of the Czech Republic [47/2006/C/2.LF]; Academy of Sciences of the Czech Republic [AV0Z50390512]","Supported by a grant from the Grant Agency of Charles University of the Czech Republic No. 47/2006/C/2.LF and by a grant from the Academy of Sciences of the Czech Republic AV0Z50390512.",null,37,7,8,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,4,null,null,null,null,591,597,null,null,null,7,"Physiology","Physiology","653AQ","WOS:000282054700013"]
[null,null,null,null,"J","Hercogova, J; Ricceri, F; Tripo, L; Lotti, T; Prignano, F",null,null,null,"Hercogova, Jana; Ricceri, Frederica; Tripo, Lara; Lotti, Torello; Prignano, Francesca",null,null,"Psoriasis and body mass index","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"body mass index; metabolic syndrome; obesity; psoriasis","METABOLIC SYNDROME; PLAQUE PSORIASIS; OBESITY; WEIGHT; INFLAMMATION; ASSOCIATION; THERAPY; DISEASE; RISK","Recently, it has emerged a strong association between increased adiposity, obesity, and psoriasis. Body Mass Index (BMI) is a simple index of weight-for-height that is commonly used to classify underweight, overweight and obesity in adults. Psoriasis has also been associated with systemic obesity-related disorders including type 2 diabetes, hypertension, ischemic heart disease, and combined hyperlipidemia, as a part of metabolic syndrome. Not only the obesity may be associated with higher psoriasis incidence and activity, and prevalence of obesity-related syndromes, but it may also influence the therapeutic approach to disease and the clinical response to systemic treatment. Consequently, the approach of the experienced dermatologist will take into account all the aspects of the patient clinical conditions including the analysis of BMI for the choice of the best suitable therapy.","[Prignano, Francesca] Univ Florence, Sch Med, Dept Dermatol Sci, I-50129 Florence, Italy; [Lotti, Torello; Prignano, Francesca] Chares Univ, Fac Med 2, Dept Dermatol, Prague, Czech Republic","Prignano, F (reprint author), Univ Florence, Sch Med, Dept Dermatol Sci, Via Lorenzo 2 Magnif 104, I-50129 Florence, Italy.","francesca.prignano@unifi.it",null,null,null,null,null,16,7,7,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296","1529-8019",null,"DERMATOL THER","Dermatol. Ther.","MAR-APR",2010,23,2,null,null,null,null,152,154,null,null,null,3,"Dermatology","Dermatology","574RT","WOS:000276011200008"]
[null,null,null,null,"J","Vytasek, R; Sedova, L; Vilim, V",null,null,null,"Vytasek, Richard; Sedova, Liliana; Vilim, Vladimir",null,null,"Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis","BMC MUSCULOSKELETAL DISORDERS",null,null,"English","Article",null,null,null,null,null,null,"STRESS MARKER LEVELS; DISEASE-ACTIVITY; INFLAMMATORY MARKERS; PLASMA PENTOSIDINE; MAILLARD REACTION; IGG ANTIBODIES; SYNOVIAL-FLUID; PROTEINS; N-EPSILON-(CARBOXYETHYL)LYSINE; GLYCOSYLATION","Background: Levels of pentosidine ( representative of advanced glycation end-products) in sera of patients with rheumatoid arthritis are increased when compared with sera of other diagnoses or healthy controls. These levels have been reported to correlate with clinical indices of rheumatoid arthritis activity and with laboratory markers of inflammation. The purpose of this study was to find out if these findings pertain to other advanced glycation end-products. Methods: We have developed two immunoassays based on new monoclonal antibodies to advanced glycation end-products. Antibody 103-E3 reacts with an unidentified antigen, formed in the reaction of proteins with ribose, while antibody 8-C1 responds to N-epsilon-(carboxyethyl)lysine. We have used these monoclonal antibodies to measure levels of advanced glycation end-products in sera of patients with rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and healthy controls. We calculated the correlations between advanced glycation end-product levels in rheumatoid arthritis sera and the Disease Activity Score 28 (DAS28), age, disease duration, CRP, anti-CCP, rheumatoid factor and treatment with corticosteroids, respectively. Results: Levels of both glycation products were significantly higher in sera of patients with rheumatoid arthritis when compared with sera of patients with systemic lupus erythematosus, osteoarthritis, or the healthy controls. Neither the level of N-epsilon-(carboxyethyl) lysine nor the level of the 103-E3 antigen in rheumatoid arthritis sera correlated with the DAS28-scored rheumatoid arthritis activity. The levels of both antigens in rheumatoid arthritis sera did not correlate with age, gender, corticosteroid treatment, or levels of CRP, anti-CCP antibodies, and rheumatoid factor in sera. Conclusions: We report highly specific increases in the levels of two advanced glycation end-products in sera of patients with rheumatoid arthritis. This increase could be explained neither by rheumatoid arthritis activity nor by inflammation. We propose a working hypothesis that presumes the existence of a link between advanced glycation end-product formation and induction of autoimmunity.","[Sedova, Liliana; Vilim, Vladimir] Inst Rheumatol, CZ-12850 Prague, Czech Republic; [Vytasek, Richard] Charles Univ Prague, Fac Med 2, Dept Med Chem & Biochem, CZ-15006 Prague, Czech Republic","Vilim, V (reprint author), Inst Rheumatol, Na Slupi 4, CZ-12850 Prague, Czech Republic.","vili@revma.cz","Vytasek, Richard/C-7571-2014",null,"IGA [NR/9122-4]","This study was supported by grant NR/9122-4 from IGA, MZ(sic)R. We are greatly indebted to Prof. C. Dostal for providing sera of patients with SLE, to Dr L. Senolt for providing sera of patients with OA, and to Dr M. Braun for sharing serum samples with known concentration of pentosidine. We thank all members of our \"healthy controls\" cohort for donation of sera, and M. Horackova a H. (sic)erna for technical assistance.",null,45,4,5,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2474",null,null,"BMC MUSCULOSKEL DIS","BMC Musculoskelet. Disord.","MAY 3",2010,11,null,null,null,null,null,null,null,83,"10.1186/1471-2474-11-83",null,11,"Orthopedics; Rheumatology","Orthopedics; Rheumatology","605ZY","WOS:000278390900001"]
[null,null,null,null,"J","Kunova, M; Matulka, K; Eiselleova, L; Trckova, P; Hampl, A; Dvorak, P",null,null,null,"Kunova, Michaela; Matulka, Kamil; Eiselleova, Livia; Trckova, Petra; Hampl, Ales; Dvorak, Petr",null,null,"Development of humanized culture medium with plant-derived serum replacement for human pluripotent stem cells","REPRODUCTIVE BIOMEDICINE ONLINE",null,null,"English","Article",null,null,null,null,null,"animal protein-free culture; high-density culture; human embryonic stem cells; humanized culture medium; plant-derived serum supplement; VegetaCell","FIBROBLAST-GROWTH-FACTOR; PROLONGED UNDIFFERENTIATED GROWTH; HUMAN FEEDER CELLS; SELF-RENEWAL; HUMAN BLASTOCYSTS; ANIMAL-CELLS; LINES; PROTEIN; SUPPORT; MAINTENANCE","For human embryonic stem cells (ESC) to be used in cell replacement therapies, they must be grown under good manufacturing conditions in a chemically defined medium that lacks animal proteins. This study examined the ability of a newly designed medium containing the plant-derived serum replacement VegetaCell and other reagents of human origin to support undifferentiated growth and pluripotency of human ESC. This medium was tested in several culture systems, using human fibroblasts as a feeder layer or Matrigel in a feeder-free culture. Even under the most stringent feeder-free conditions without conditioned medium, human ESC exhibited an undifferentiated morphology, expressed markers of undifferentiated cells, demonstrated high alkaline phosphatase activity and multilineage differentiation and retained a normal karyotype. Compared with human ESC grown in standard culture conditions, human ESC maintained in humanized VegetaCell medium show longer cell cycles and decreased cell death. The availability of an animal protein-free medium supplemented with the low-cost VegetaCell reagent expands the repertoire of media for culturing human ESC as well as induced pluripotent stem cells for drug testing and cell replacement therapy. (C) 2010, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.","[Kunova, Michaela; Matulka, Kamil; Eiselleova, Livia; Trckova, Petra; Hampl, Ales; Dvorak, Petr] Masaryk Univ, Fac Med, Dept Biol, Brno, Czech Republic; [Kunova, Michaela; Matulka, Kamil; Eiselleova, Livia; Trckova, Petra; Hampl, Ales; Dvorak, Petr] Masaryk Univ, Fac Med, Ctr Chem Genet, Brno, Czech Republic; [Hampl, Ales; Dvorak, Petr] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Embryol, Prague, Czech Republic; [Hampl, Ales; Dvorak, Petr] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Dvorak, P (reprint author), Masaryk Univ, Fac Med, Dept Biol, Brno, Czech Republic.","pdvorak@med.muni.cz","Vopenkova, Katerina/C-7133-2012; Dvorak, Petr/G-2509-2013","Dvorak, Petr/0000-0002-3229-140X","Ministry of Education, Youth and Sport of the Czech Republic [MSM0021622430, LC06077]; Academy of Sciences of the Czech Republic [AV0Z50390512, AV0Z50390703]; EC [LSHG-CT-2006-018739]","This study was supported by funding from the Ministry of Education, Youth and Sport of the Czech Republic (MSM0021622430, LC06077), the Academy of Sciences of the Czech Republic (AV0Z50390512, AV0Z50390703) and EC FP6 (contract LSHG-CT-2006-018739).",null,48,2,2,"REPRODUCTIVE HEALTHCARE LTD","CAMBRIDGE","DUCK END FARM, DRY DRAYTON, CAMBRIDGE, CB3 8DB, ENGLAND","1472-6483",null,null,"REPROD BIOMED ONLINE","Reprod. Biomed. Online","NOV",2010,21,5,null,null,null,null,676,686,null,"10.1016/j.rbmo.2010.06.027",null,11,"Obstetrics & Gynecology; Reproductive Biology","Obstetrics & Gynecology; Reproductive Biology","687SA","WOS:000284797000016"]
[null,null,null,null,"J","Zwick, EB; Svehlik, M; Steinwender, G; Saraph, V; Linhart, WE",null,null,null,"Zwick, Ernst B.; Svehlik, Martin; Steinwender, Gerhard; Saraph, Vinay; Linhart, Wolfgang E.",null,null,"Genu recurvatum in cerebral palsy - part B: hamstrings are abnormally long in children with cerebral palsy showing knee recurvatum","JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B",null,null,"English","Article",null,null,null,null,null,"cerebral palsy; electromyography; gait analysis; hamstrings; knee hyperextension; musculoskeletal modelling","GAIT ANALYSIS; CROUCH GAIT; LENGTHS","Hyperextension of the knee in stance (knee recurvatum) is a common disorder in patients with spastic cerebral palsy (CP). A group 35 children with CP (47 lower limbs) was divided into two subgroups according to the timing of maximum knee extension during the stance phase of gait. Gait analysis and musculoskeletal modelling data were compared with a control group of 12 normally developing children. We observed no difference in kinematics between the CP groups who showed an equinus position of the foot at initial contact. Both groups showed increased external extensor moments across the knee. The muscle-tendon lengths of the hamstrings were abnormally long at initial contact, and in both recurvatum groups, contracted faster compared with the control group. Surface electromyography revealed prolonged activity of the hamstrings in stance and early activation in swing. Abnormally long hamstrings at initial contact together with equinus position of the foot are the main causes of genu recurvatum in children with CP. J Pediatr Orthop B 19:373-378 (c) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Svehlik, Martin] Med Univ Graz, Dept Paediat Surg, Paediat Orthopaed Unit, A-8036 Graz, Austria; [Zwick, Ernst B.; Svehlik, Martin; Steinwender, Gerhard; Saraph, Vinay; Linhart, Wolfgang E.] Med Univ Graz, Dept Paediat Orthopaed, A-8036 Graz, Austria; [Svehlik, Martin] Charles Univ Prague, Sch Med 2, Dept Children & Adult Orthopaed, Prague, Czech Republic","Svehlik, M (reprint author), Med Univ Graz, Dept Paediat Surg, Paediat Orthopaed Unit, Auenbruggerpl 34, A-8036 Graz, Austria.","martin.spejlik@seznam.cz",null,null,null,null,null,22,2,2,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1060-152X",null,null,"J PEDIATR ORTHOP B","J. Pediatr. Orthop.-Part B","JUL",2010,19,4,null,null,null,null,373,378,null,"10.1097/BPB.0b013e32833822d5",null,6,"Orthopedics; Pediatrics","Orthopedics; Pediatrics","615QR","WOS:000279151000019"]
[null,null,null,null,"J","Cejka, C; Ardan, T; Sirc, J; Michalek, J; Brunova, B; Cejkova, J",null,null,null,"Cejka, Cestmir; Ardan, Taras; Sirc, Jakub; Michalek, Jiri; Brunova, Blanka; Cejkova, Jitka",null,null,"The influence of various toxic effects on the cornea and changes in corneal light transmission","GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY",null,null,"English","Article",null,null,null,null,null,"Spectrophotometric method; Corneal hydration; Corneal light transmission","RABBIT CORNEA; ULTRAVIOLET-B; UVB RAYS; HUMAN EYES; TRANSPARENCY; EXPRESSION; ALKALI; LENS; ENDOTHELIUM; IRRADIATION","Purpose Normal corneal hydration is necessary for the maintenance of corneal transparency. Damage of the corneal epithelium or endothelium by various external influences disturbs the mechanism by which the cornea maintains normal hydration and transparency. The cornea swells, and the corneal thickness increases, resulting in increased scatter and the development of corneal opacity. The transmission of light across the cornea is changed. The purpose of this study is to investigate spectrophotometrically the corneal light transmission under the influence of the various factors affecting the cornea. Methods We developed a spectrophotometric method to measure the light transmission across the cornea under the influence of various factors affecting the cornea, such as treatment with 0.9% NaCl, saline, or phosphate buffered saline (PBS), solutions employed as placebo eye drops (negative controls) in experimental studies, agents toxic to the cornea, such as diluted acids or alkalis. The method distinguishes between changes in corneal light transmission caused by altered corneal thickness (the level of hydration) and changes resulting from other corneal disturbances which in turn affect corneal light transmission. Results The results obtained show that the corneal light transmission is decreased following the application of toxic substances on the corneal surface. This decrease is highly dependent on the severity of the corneal injury evoked by individual noxes, and the resulting changes in corneal hydration and transparency. Conclusions The influence of various influences applied to the cornea, manifested as changes in corneal light transmission, can be measured using our spectrophotometric method with a high degree of sensitivity.","[Cejka, Cestmir; Ardan, Taras; Cejkova, Jitka] Acad Sci Czech Republic, Inst Expt Med, Lab Eye Histochem & Pharmacol, Ctr Excellence, Prague 14220 4, Czech Republic; [Sirc, Jakub; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, Dept Hydrogels Med, Prague 5, Czech Republic; [Cejka, Cestmir; Brunova, Blanka] Charles Univ Prague, Eye Clin Children & Adults, Fac Med 2, Prague 5, Motol, Czech Republic","Cejkova, J (reprint author), Acad Sci Czech Republic, Inst Expt Med, Lab Eye Histochem & Pharmacol, Ctr Excellence, Videnska 1083, Prague 14220 4, Czech Republic.","cestmir.cejka@seznam.cz; ardan@biomed.cas.cz; sirc@imc.cas.cz; jiri@imc.cas.cz; brunova.blanka@post.cz; cejkova@biomed.cas.cz","Michalek, Jiri/D-7251-2013",null,"Academy of Sciences of the Czech Republic [AVOZ50390512]","Supported by a grant from the Academy of Sciences of the Czech Republic AVOZ50390512",null,52,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0721-832X",null,null,"GRAEF ARCH CLIN EXP","Graefes Arch. Clin. Exp. Ophthalmol.","DEC",2010,248,12,null,null,null,null,1749,1756,null,"10.1007/s00417-010-1438-2",null,8,"Ophthalmology","Ophthalmology","687WW","WOS:000284810000009"]
[null,null,null,null,"J","Huskova, Z; Vanourkova, Z; Erbanova, M; Thumova, M; Opocensky, M; Mullins, JJ; Kramer, HJ; Burgelova, M; Cervenka, L",null,null,null,"Huskova, Zuzana; Vanourkova, Zdenka; Erbanova, Michaela; Thumova, Monika; Opocensky, Martin; Mullins, John J.; Kramer, Herbert J.; Buergelova, Marcela; Cervenka, Ludek",null,null,"Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats","JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"aldosterone; angiotensin II; high and low-salt diet; hypertension; inducible renin gene transgenic rats; renin-angiotensin system","BLOOD-PRESSURE RESEARCH; END-ORGAN DAMAGE; ANG-II; CONVERTING ENZYME; DEPENDENT HYPERTENSION; SENSITIVE HYPERTENSION; FUNCTIONAL-RESPONSES; ARTERIAL-PRESSURE; RECEPTOR BLOCKADE; SODIUM INTAKE","Objective We evaluated the effects of salt restriction and of increasing dietary salt loading on blood pressure and the renin-angiotensin system in transgenic rats with inducible hypertension. Methods Hypertension was induced in Cyp1a1-Ren-2 rats through dietary administration of the natural xenobiotic indole-3-carbinol (0.3%), which activates the renin gene. Rats were fed either a normal-salt diet (0.6% NaCl), three different high-salt diets (2, 4 and 8% NaCl) or a low-salt diet (< 0.04% NaCl). Blood pressure was monitored by radiotelemetry. Angiotensin II (ANG II) levels were determined by radioimmunoassay. Results Induction of the renin gene by administration of indole-3-carbinol resulted in normal-salt diet fed animals in the development of severe hypertension that was accompanied by marked increases in plasma and kidney ANG II levels. Feeding the low-salt diet substantially attenuated the development of hypertension. Treatment with the 2 and 4% high-salt diet did not worsen the course of hypertension and did not alter ANG II levels when compared with rats on the normal salt diet. Feeding the 8% high-salt diet exacerbated the course of hypertension and was associated with further strong increases in plasma and kidney ANG II levels. Conclusion Our results demonstrate that after induction of the renin gene in Cyp1a1-Ren-2 transgenic rats inappropriate increases in plasma and kidney ANG II levels in response to very high dietary salt intake are responsible for the development of severe hypertension in this model of inducible renin transgenic rats. J Hypertens 28:495-509 (c) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Huskova, Zuzana; Vanourkova, Zdenka; Erbanova, Michaela; Thumova, Monika; Opocensky, Martin; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Huskova, Zuzana; Vanourkova, Zdenka; Erbanova, Michaela; Thumova, Monika; Opocensky, Martin; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Mullins, John J.] Univ Edinburgh, Sch Med, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland; [Kramer, Herbert J.] Univ Bonn, Nephrol Sect, Med Policlin, D-5300 Bonn, Germany; [Buergelova, Marcela] Charles Univ Prague, Dept Nephrol, Inst Clin & Expt Med, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Cervenka, L (reprint author), Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz",null,null,"Czech Science Foundation [GAC. R 305/08/P053, GAC. R 305/08/J006]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Grant Agency of Academy of Science of Czech Republic [GAAV - IAA 511-700-701]; German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn [Kra 433/142, 436 TSE 113/50/0-1]","This study was supported by grant no. GAC. R 305/08/P053 awarded to Z. H. by the Czech Science Foundation. Z. V. is supported from the Center for Cardiovascular Research (1M6798582302). M. O. and M. T are supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). L. C. is supported by grant from Czech Science Foundation (GAC. R 305/08/J006). M. B. is supported by grant from the Grant Agency of Academy of Science of Czech Republic (GAAV - IAA 511-700-701). H.J.K. is supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn (Kra 433/142 and 436 TSE 113/50/0-1).",null,56,10,10,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,null,"J HYPERTENS","J. Hypertens.","MAR",2010,28,3,null,null,null,null,495,509,null,"10.1097/HJH.0b013e3283345d69",null,15,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","562QN","WOS:000275068200013"]
[null,null,null,null,"J","Walkowska, A; Skaroupkova, P; Huskova, Z; Vanourkova, Z; Chabova, VC; Tesar, V; Kramer, HJ; Falck, JR; Imig, JD; Kompanowska-Jezierska, E; Sadowski, J; Cervenka, L",null,null,null,"Walkowska, Agnieszka; Skaroupkova, Petra; Huskova, Zuzana; Vanourkova, Zdenka; Chabova, Vera Certikova; Tesar, Vladimir; Kramer, Herbert J.; Falck, John R.; Imig, John D.; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz; Cervenka, Ludek",null,null,"Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats","JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"20-hydroxyeicosatetraenoic acid; cytochrome P-450 metabolites; epoxyeicosatrienoic acids; renal function; renin-angiotensin system; two-kidney one-clip Goldblatt hypertension","SOLUBLE EPOXIDE HYDROLASE; REN-2 TRANSGENIC RATS; ANGIOTENSIN-II LEVELS; EPOXYEICOSATRIENOIC ACIDS; BLOOD-PRESSURE; NITRIC-OXIDE; 20-HYDROXYEICOSATETRAENOIC ACID; TUBULOGLOMERULAR FEEDBACK; HYPERPOLARIZING FACTORS; RENAL-FUNCTION","Objective The contribution of epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) as cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip (2K1C) Goldblatt hypertensive rats was investigated during the phases of initial and stable hypertension, that is, 7 or 27 days after clipping, respectively. Methods Male Hannover Sprague-Dawley rats had the right renal artery clipped or underwent sham operation. Urinary excretion of EETs, their inactive metabolites dihydroxyeicosatrienoic acids and of 20-HETE was measured. Intrarenal cytochrome P-450 protein expression and the activities of epoxygenase, omega-hydroxylase and soluble epoxide hydrolase were also determined. The responses of renal hemodynamics and electrolyte excretion of the nonclipped kidney to left renal artery infusions of inhibitors of EETs or 20-HETE formation (MS-PPOH and DDMS, respectively) were measured. Results In 2K1C rats, urinary excretion of EETs was significantly lower and that of 20- HETE was higher than that in sham-operated animals only on day 27 after clipping. Intrarenal inhibition of EETs significantly decreased renal hemodynamics and sodium excretion in sham-operated but not in 2K1C rats. Intrarenal inhibition of 20-HETE decreased sodium excretion in sham-operated rats but elicited increases in renal hemodynamics and sodium excretion in 2K1C rats. Conclusion Our results indicate that the nonclipped kidney of Goldblatt 2K1C rats in the phase of sustained hypertension exhibits decreased intrarenal EETs and elevated 20-HETE levels as compared with the kidney of sham-operated animals. This suggests that altered production and action of cytochrome P-450-derived metabolites during this stable phase contributes to the mechanism of Goldblatt 2K1C hypertension. J Hypertens 28:582-593 (c) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Walkowska, Agnieszka; Skaroupkova, Petra; Huskova, Zuzana; Vanourkova, Zdenka; Chabova, Vera Certikova; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Walkowska, Agnieszka; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz] Polish Acad Sci, Lab Renal & Body Fluid Physiol, M Mossakowski Med Res Ctr, Warsaw, Poland; [Skaroupkova, Petra; Huskova, Zuzana; Vanourkova, Zdenka] Charles Univ Prague, Cardiovasc Res Ctr, Prague, Czech Republic; [Chabova, Vera Certikova; Tesar, Vladimir] Charles Univ Prague, Dept Nephrol, Fac Med 1, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Nephrol Sect, Med Policlin, Dept Med, D-5300 Bonn, Germany; [Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Cervenka, L (reprint author), Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz",null,null,"Czech Science Foundation [305/08/J006, 305/08/P053]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Ministry of Health of the Czech Republic [NS/10499-3]; National Institutes of Health [HL59699, DK38226]; Advancing a Healthier Wisconsin; German Research Foundation (DFG), Bonn [Kra 433/14-2, 436 TSE 113/50/0-1]; Robert A. Welch Foundation; NIH [GM31278]","The present study was supported by grant No. 305/08/J006 awarded to L. C.. by Czech Science Foundation (GACR). Z.H. is supported by the grant awarded by Czech Science Foundation (GACR) No. 305/08/P053. A. W. was partly supported by the Center for Cardiovascular Research (1M6798582302) and by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). Z.V. was partly supported by grant No. NS/10499-3 awarded to L. C.. by the Internal Grant Agency of the Ministry of Health of the Czech Republic. J.D.I. is supported by grants from the National Institutes of Health (HL59699 and DK38226) and Advancing a Healthier Wisconsin. H.J.K. is supported by grants from the German Research Foundation (DFG), Bonn (Kra 433/14-2 and 436 TSE 113/50/0-1). J.R.F. was supported by the Robert A. Welch Foundation and NIH GM31278.",null,51,9,9,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,null,"J HYPERTENS","J. Hypertens.","MAR",2010,28,3,null,null,null,null,582,593,null,"10.1097/HJH.0b013e328334dfd4",null,12,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","562QN","WOS:000275068200023"]
[null,null,null,null,"J","Rakusan, D; Burgelova, M; Vaneckova, I; Vanourkova, Z; Huskova, Z; Skaroupkova, P; Mrazova, I; Opocensky, M; Kramer, HJ; Netuka, I; Maly, J; Alenina, N; Bader, M; Santos, RAS; Cervenka, L",null,null,null,"Rakusan, Dan; Buergelova, Marcela; Vaneckova, Ivana; Vanourkova, Zdenka; Huskova, Zuzana; Skaroupkova, Petra; Mrazova, Iveta; Opocensky, Martin; Kramer, Herbert J.; Netuka, Ivan; Maly, Jan; Alenina, Natalia; Bader, Michael; Santos, Robson A. S.; Cervenka, Ludek",null,null,"Knockout of Angiotensin 1-7 Receptor Mas Worsens the Course of Two-Kidney, One-Clip Goldblatt Hypertension: Roles of Nitric Oxide Deficiency and Enhanced Vascular Responsiveness to Angiotensin II","KIDNEY & BLOOD PRESSURE RESEARCH",null,null,"English","Article",null,null,null,null,null,"Two-kidney, one-clip Goldblatt hypertension; Mas receptor knockout mice; Nitric oxide deficiency","REN-2 TRANSGENIC RATS; RENAL FUNCTIONAL-RESPONSES; END-ORGAN DAMAGE; BLOOD-PRESSURE; DEPENDENT HYPERTENSION; OXIDATIVE STRESS; INTRARENAL INFUSION; NORMOTENSIVE RATS; KIDNEY-DISEASE; MICE","Aims: The present study was performed to evaluate the effects of target disruption of the G-protein-coupled receptor Mas for angiotensin 1-7 [Ang(1-7)] in knockout mice on the course of two-kidney, one-clip (2K1C) Goldblatt hypertension. Methods: Knockout and wild-type mice underwent clipping of one renal artery. Blood pressure (BP) was monitored by radiotelemetry. The mice were either untreated or chronically treated with the superoxide (O-2(-)) scavenger tempol (400 mg/l) or the inhibitor of NADPH oxidase apocynin (1 g/l) administered in drinking water. Results: Knockout mice responded to clipping by accelerated increases in BP and the final BP was significantly higher than that in wildtype mice. Chronic treatment with tempol or apocynin elicited similar antihypertensive effects in 2K1C/knockout as in 2K1C/wild-type mice. Acute nitric oxide synthase inhibition caused greater BP increases in 2K1C/wild-type than in 2K1C/knockout mice. Conclusion: Our present findings support the notion that the angiotensin-converting enzyme 2-Ang(1-7)-Mas axis serves as an important endogenous physiological counterbalancing mechanism that partially attenuates the hypertensinogenic actions of the activated renin-angiotensin system. The impairment in this axis may contribute to the deterioration of the course of 2K1C Goldblatt hypertension. Copyright (C) 2010 S. Karger AG, Basel","[Rakusan, Dan; Vaneckova, Ivana; Vanourkova, Zdenka; Huskova, Zuzana; Skaroupkova, Petra; Mrazova, Iveta; Opocensky, Martin; Maly, Jan; Cervenka, Ludek] Charles Univ Prague, Dept Expt Med, Inst Clin & Expt Med, CZ-14000 Prague 4, Czech Republic; [Rakusan, Dan] Charles Univ Prague, Dept Med 1, Thomayer Teaching Hosp, CZ-14000 Prague 4, Czech Republic; [Buergelova, Marcela] Charles Univ Prague, Dept Nephrol, Transplant Ctr, Inst Clin & Expt Med, CZ-14000 Prague 4, Czech Republic; [Vaneckova, Ivana; Vanourkova, Zdenka; Huskova, Zuzana; Netuka, Ivan; Cervenka, Ludek] Charles Univ Prague, Cardiovasc Res Ctr, CZ-14000 Prague 4, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, CZ-14000 Prague 4, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Dept Med, Nephrol Sect, Med Policlin, D-5300 Bonn, Germany; [Alenina, Natalia; Bader, Michael] Max Delbruck Ctr Mol Med, Berlin, Germany; [Santos, Robson A. S.] Univ Fed Minas Gerais, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil","Cervenka, L (reprint author), Charles Univ Prague, Dept Expt Med, Inst Clin & Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz","Santos, Robson/C-9336-2011; Vaneckova, Ivana/B-5543-2012; Nbiofar, Inct/J-9539-2013","Santos, Robson/0000-0001-8738-5852; ","Grant Agency of Academy of Science of Czech Republic (GAAV) [IAA 511-700-701]; EU [CZ.2.16/3.1.00/22126]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Czech Science Foundation (GACR) [305/08/J006, 305/07/0167, 305/07/J004, 305/08/P053]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/10499-3, NS/9703-4]; German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]","This study was supported by grant No. IAA 511-700-701 awarded to M.B. by the Grant Agency of Academy of Science of Czech Republic (GAAV). This study was also financially supported by the EU by the Operational Program Prague Competitiveness, project 'CEVKOON' (No. CZ.2.16/3.1.00/22126). Z.V. and I.N. are partly supported by the Center for Cardiovascular Research (1M6798582302). L.C. receives institutional financial support from the Institute for Clinical and Experimental Medicine (MZO 00023001) and by grant No. 305/08/J006 awarded by the Czech Science Foundation (GACR) and by grant NS/10499-3 from the Internal Grant Agency of the Ministry of Health of the Czech Republic. I.V. is supported by grants No. 305/07/0167 and No. 305/07/J004 awarded by GACR and by grant NS/9703-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. Z.H. is supported by grant No. 305/08/P053 awarded by GACR. H.J. Kramer is supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft), Bonn (Kra 436/14-2 and 436 TSE 113/57/0-1).",null,43,9,9,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096","1423-0143",null,"KIDNEY BLOOD PRESS R","Kidney Blood Pressure Res.",null,2010,33,6,null,null,null,null,476,488,null,"10.1159/000320689",null,13,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","Physiology; Urology & Nephrology; Cardiovascular System & Cardiology","699ZQ","WOS:000285702300054"]
[null,null,null,null,"J","Kujal, P; Chabova, VC; Vernerova, Z; Walkowska, A; Kompanowska-Jezierska, E; Sadowski, J; Vanourkova, Z; Huskova, Z; Opocensky, M; Skaroupkova, P; Schejbalova, S; Kramer, HJ; Rakusan, D; Maly, J; Netuka, I; Vaneckova, I; Kopkan, L; Cervenka, L",null,null,null,"Kujal, Petr; Chabova, Vera Certikova; Vernerova, Zdenka; Walkowska, Agnieszka; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz; Vanourkova, Zdenka; Huskova, Zuzana; Opocensky, Martin; Skaroupkova, Petra; Schejbalova, Stanislava; Kramer, Herbert J.; Rakusan, Dan; Maly, Jan; Netuka, Ivan; Vaneckova, Ivana; Kopkan, Libor; Cervenka, Ludek",null,null,"Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?","CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"alpha and beta adrenergic receptor antagonist; angiotensin-converting enzyme inhibitor; angiotensin-II receptor antagonist type 1; end-organ damage; glomerulosclerosis; hypertension; renin-angiotensin-aldosterone system; renoprotection","CONVERTING ENZYME-INHIBITORS; PROGRESSIVE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; END-ORGAN DAMAGE; INTRARENAL ANGIOTENSIN; GLOMERULAR INJURY; HYPERTENSIVE RATS; OXIDATIVE STRESS; SYSTEM BLOCKADE; MASS REDUCTION","P>1. Hypertension plays a critical role in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), but it has also been postulated that antihypertensive drugs that block the renin-angiotensin system (RAS) show class-specific renoprotective actions beyond their blood pressure (BP)-lowering effects. 2. Because this notion has recently been questioned, in the present study we compared the effects of a RAS-dependent antihypertensive therapy (a combination of trandolapril, an angiotensin-converting enzyme inhibitor (ACEI) and losartan, an angiotensin-II (AngII) receptor subtype 1A receptor antagonist) with a 'RAS-independent' antihypertensive therapy (a combination of labetalol, an alfa- and beta-adrenoreceptor antagonist with the diuretics, hydrochlorothiazide and furosemide) on the progression of CKD after 5/6 renal ablation (5/6 NX) in Ren-2 renin transgenic rats (TGR), a model of AngII-dependent hypertension. Normotensive transgene-negative Hannover Sprague-Dawley (HanSD) rats after 5/6 NX served as controls. 3. RAS-dependent and -independent antihypertensive therapies normalized BP and survival rate, and prevented the development of cardiac hypertrophy and glomerulosclerosis to the same degree in 5/6 NX HanSD rats and in 5/6 NX TGR. The present findings show that renoprotection, at least in rats after 5/6 NX, is predominantly BP-dependent. When equal lowering of BP was achieved, leading to normotension, cardio- and renoprotective effects were equivalent irrespective of the type of antihypertensive therapy. 4. These findings should be taken into consideration in attempts to develop new therapeutic approaches and strategies aimed to prevent the progression of CKD and to lower the incidence of ESRD.","[Kujal, Petr; Chabova, Vera Certikova; Vanourkova, Zdenka; Huskova, Zuzana; Opocensky, Martin; Skaroupkova, Petra; Schejbalova, Stanislava; Rakusan, Dan; Maly, Jan; Kopkan, Libor; Cervenka, Ludek] Charles Univ Prague, Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Kujal, Petr; Vernerova, Zdenka] Charles Univ Prague, Fac Med 3, Dept Pathol, CZ-14000 Prague, Czech Republic; [Walkowska, Agnieszka; Kompanowska-Jezierska, Elzbieta; Sadowski, Janusz] Charles Univ Prague, Fac Med 1, Dept Nephrol, CZ-14000 Prague 4, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, CZ-14000 Prague 4, Czech Republic; [Kujal, Petr; Chabova, Vera Certikova; Vanourkova, Zdenka; Huskova, Zuzana; Rakusan, Dan; Netuka, Ivan; Vaneckova, Ivana; Kopkan, Libor; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Chabova, Vera Certikova] Polish Acad Sci, Mossakowski Med Res Ctr, Lab Renal & Body Fluid Physiol, Warsaw, Poland; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany","Cervenka, L (reprint author), Charles Univ Prague, Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz","Vaneckova, Ivana/B-5543-2012",null,"Czech Science Foundation (GACR) [305/08/J006]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/10500-3, NS/10499-3, NS/9703-4, NS/9699-4]; German Research Foundation (DFG), Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]; Grant Agency of Academy of Science of Czech Republic (GAAV) [KJB 502030801]; EU [CZ.2.16/3.1.00/22126]; GACR [305/07/0167, 305/07/J004]","This study was supported by grant No. 305/08/J006 awarded to LC by Czech Science Foundation (GACR). PK, JM, MO and IN. are supported by the Center for Cardiovascular Research (1M6798582302) and by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). VCC is supported by grant No. NS/10500-3 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. ZV is supported by grant No. NS/10499-3 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. IV is supported by grants from GACR No. 305/07/0167 and No. 305/07/J004. HJK is supported by grants from the German Research Foundation (DFG), Bonn (Kra 436/14-2 and 436 TSE 113/57/0-1). ZH is supported by grant No. 305/08/P053 awarded by GACR. LC is also supported by grants No. NS/9703-4 and NS/9699-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. LK is supported by grant No. KJB 502030801 awarded by Grant Agency of Academy of Science of Czech Republic (GAAV). This study also received financial support from the EU by the Operational Program Prague - Competitiveness; project 'CEVKOON' (#CZ.2.16/3.1.00/22126).",null,55,7,7,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0305-1870",null,null,"CLIN EXP PHARMACOL P","Clin. Exp. Pharmacol. Physiol.","DEC",2010,37,12,null,null,null,null,1159,1169,null,"10.1111/j.1440-1681.2010.05453.x",null,11,"Pharmacology & Pharmacy; Physiology","Pharmacology & Pharmacy; Physiology","687HF","WOS:000284768900010"]
[null,null,null,null,"J","Sochman, J; Peregrin, JH; Burgelova, M; Kopkan, L; Kramer, HJ; Cervenka, L",null,null,null,"Sochman, Jan; Peregrin, Jan H.; Buergelova, Marcela; Kopkan, Libor; Kramer, Herbert J.; Cervenka, Ludek",null,null,"N-Acetylcysteine Attenuates Iodine Contrast Agent-Induced Nephropathy in 5/6-Nephrectomized Rats","KIDNEY & BLOOD PRESSURE RESEARCH",null,null,"English","Article",null,null,null,null,null,"Iodine contrast agent-induced nephropathy; Iohexol; Meglumine-ioxithalamate; N-acetylcysteine; 5/6-Nephrectomized Wistar rats","RADIOCONTRAST-INDUCED NEPHROPATHY; ACUTE-RENAL-FAILURE; RANDOMIZED CONTROLLED-TRIAL; SODIUM-BICARBONATE; CARDIAC-SURGERY; OXYGEN-TENSION; NITRIC-OXIDE; PREVENTION; MEDIA; METAANALYSIS","Aims: In the present study we tested the efficacy of N-acetylcysteine (NAC) to minimize nephrotoxic effects of iodine contrast agents in intact rats as well as in 5/6-nephrectomized (5/6-Nx) rats. Methods: Rats were allocated to a group of intact rats (n = 42) and a group of 5/6-Nx rats (n = 42). After 1 month of recovery from surgery, 5/6-Nx rats and intact (sham-operated) animals received either 6 ml/kg body weight (b.w.) meglumine ioxithalamate (Telebrix 350) or 6 ml/kg b.w. iohexol (Omnipaque 350) intravenously with or without pretreatment with 100 mg/kg b.w. NAC. Plasma and urinary concentrations of creatinine, sodium and protein in 24-hour urine collections were determined prior to and on days 1, 3 and 7 after drug administration. Results: In intact animals, contrast agents caused no significant changes in kidney function throughout the duration of the experiment. In contrast, significant increases in plasma creatinine levels and decreases in creatinine clearance were induced by both contrast agents in 5/6-Nx rats. These changes were significantly attenuated by NAC pretreatment. Conclusion: The results of the present study demonstrate that iodine contrast agent-induced nephropathy in 5/6-Nx rats is significantly attenuated by intravenous pretreatment with NAC. Copyright (C) 2010 S. Karger AG, Basel","[Kopkan, Libor; Cervenka, Ludek] Charles Univ Prague, Dept Expt Med, Inst Clin & Expt Med, CZ-14000 Prague 4, Czech Republic; [Sochman, Jan] Charles Univ Prague, Dept Cardiol, CZ-14000 Prague, Czech Republic; [Peregrin, Jan H.] Charles Univ Prague, Dept Diagnost & Intervent Radiol, CZ-14000 Prague 4, Czech Republic; [Buergelova, Marcela] Charles Univ Prague, Nephrol & Transplant Ctr, CZ-14000 Prague 4, Czech Republic; [Kopkan, Libor] Charles Univ Prague, Cardiovasc Res Ctr, CZ-14000 Prague 4, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, CZ-14000 Prague 4, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Dept Med, Nephrol Sect, Med Policlin, D-5300 Bonn, Germany","Cervenka, L (reprint author), Charles Univ Prague, Dept Expt Med, Inst Clin & Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz",null,null,"Institute for Clinical and Experimental Medicine [MZO 00023001]; EU [CZ.2.16/3.1.00/22126]; Grant Agency of Academy of Science of Czech Republic [GAAV - IAA 511-700-701]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/9699-4]; Czech Science Foundation [NS/10499-3 (IGA), 305/08/J006]; Center for Cardiovascular Research [1M6798582302]; German Research Foundation (DFG), Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]","This study was supported by institutional finance support from the Institute for Clinical and Experimental Medicine (#MZO 00023001). It was also supported by financial support from the EU by the Operational Program Prague - Competitiveness; Project 'CEVKOON' (#CZ.2.16/3.1.00/22126). L. K. is supported by a grant from the Grant Agency of Academy of Science of Czech Republic (GAAV - IAA 511-700-701) and by grant No. NS/9699-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. L. C. is currently supported by grant No. NS/10499-3 (IGA) and by grant No. 305/08/J006 awarded by the Czech Science Foundation and also by financial support from the Center for Cardiovascular Research (#1M6798582302). H.J.K. is supported by grants from the German Research Foundation (DFG), Bonn (Kra 436/14-2 and 436 TSE 113/57/0-1).",null,55,4,4,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096",null,null,"KIDNEY BLOOD PRESS R","Kidney Blood Pressure Res.",null,2010,33,2,null,null,null,null,149,156,null,"10.1159/000315435",null,8,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","Physiology; Urology & Nephrology; Cardiovascular System & Cardiology","606CK","WOS:000278398500008"]
[null,null,null,null,"J","Krizkova, S; Fabrik, I; Huska, D; Adam, V; Babula, P; Hrabeta, J; Eckschlager, T; Pochop, P; Darsova, D; Kukacka, J; Prusa, R; Trnkova, L; Kizek, R",null,null,null,"Krizkova, Sona; Fabrik, Ivo; Huska, Dalibor; Adam, Vojtech; Babula, Petr; Hrabeta, Jan; Eckschlager, Tomas; Pochop, Pavel; Darsova, Denisa; Kukacka, Jiri; Prusa, Richard; Trnkova, Libuse; Kizek, Rene",null,null,"An Adsorptive Transfer Technique Coupled with Brdicka Reaction to Reveal the Importance of Metallothionein in Chemotherapy with Platinum Based Cytostatics","INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES",null,null,"English","Article",null,null,null,null,null,"tumor disease; metallothionein; platinum based anticancer drugs; anticancer therapy; resistance; retinoblastoma","DIFFERENTIAL-PULSE VOLTAMMETRY; TUMOR-CELL LINES; CANCER-MORTALITY; EUROPEAN-UNION; CISPLATIN RESISTANCE; STRESS; DNA; BIOSENSOR; MECHANISM; ANTIBODIES","The drugs based on platinum metals represent one of the oldest, but also one of the most effective groups of chemotherapeutic agents. Thanks to many clinical studies it is known that resistance of tumor cells to drugs is a frequent cause of chemotherapy failure. With regard to platinum based drugs, multidrug resistance can also be connected with increased expression of low-molecular weight protein metallothionein (MT). This study aimed at investigating the interactions of MT with cisplatin or carboplatin, using the adsorptive transfer technique coupled with differential pulse voltammetry Brdicka reaction (AdTS DPV Brdicka reaction), and a comparison of in vitro results with results obtained in vivo. The results obtained from the in vitro study show a strong affinity between platinum based drugs and MT. Further, we analyzed extracts of neuroblastoma cell lines treated with cisplatin or carboplatin. It is clear that neuroblastoma UKF-NB-4 cisplatin-resistant and cisplatin-sensitive cell lines unlikely respond to the presence of the platinum-based cytostatics cisplatin and carboplatin. Finally, we determined the level of MT in samples from rabbits treated with carboplatin and patients with retinoblastoma treated with the same drug.","[Krizkova, Sona; Fabrik, Ivo; Huska, Dalibor; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Babula, Petr] Univ Vet & Pharmaceut Sci, Dept Nat Drugs, Fac Pharm, CZ-61242 Brno, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas; Pochop, Pavel; Darsova, Denisa; Kukacka, Jiri; Prusa, Richard] Teaching Hosp Motol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Pochop, Pavel; Darsova, Denisa] Charles Univ Prague, Dept Ophthalmol Children & Adults, CZ-15006 Prague 5, Czech Republic; [Kukacka, Jiri; Prusa, Richard] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, CZ-15006 Prague 5, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CZ-61137 Brno, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Krizkova, Sona/E-9617-2012; Kukacka, Jiri/C-4770-2013",null,"IGA MZ Czech Republic [NR/95323/2007];  [GA AV IAA401990701];  [IGA MZ 10200-3];  [INCHEMBIOL MSM0021622412];  [LPR 2011]","This work was supported by grants: GA AV IAA401990701, IGA MZ Czech Republic NR/95323/2007, IGA MZ 10200-3, INCHEMBIOL MSM0021622412 and LPR 2011.",null,64,11,11,"MDPI AG","BASEL","POSTFACH, CH-4005 BASEL, SWITZERLAND","1661-6596",null,null,"INT J MOL SCI","Int. J. Mol. Sci.","DEC",2010,11,12,null,null,null,null,4826,4842,null,"10.3390/ijms11124826",null,17,"Chemistry, Multidisciplinary","Chemistry","700BV","WOS:000285708000004"]
[null,null,null,null,"J","Brabec, J; Rulseh, A; Hoyt, B; Vizek, M; Horinek, D; Hort, J; Petrovicky, P",null,null,null,"Brabec, Jiri; Rulseh, Aaron; Hoyt, Brian; Vizek, Martin; Horinek, Daniel; Hort, Jakub; Petrovicky, Pavel",null,null,"Volumetry of the human amygdala - An anatomical study","PSYCHIATRY RESEARCH-NEUROIMAGING",null,null,"English","Article",null,null,null,null,null,"Anatomy; Cytoarchitecture; Aging; MRI","ALZHEIMERS-DISEASE; HIPPOCAMPAL-FORMATION; FACIAL EXPRESSION; LATERAL VENTRICLE; ENTORHINAL CORTEX; BIPOLAR DISORDER; MR-IMAGES; SCHIZOPHRENIA; BRAIN; COMPLEX","A striking feature of the studies that have addressed the measurement of the amygdala is the wide range of volumes encountered, with reports of volumes ranging from 1 to almost 4 cm(3). Another striking feature is the number of discrepancies in the landmarks adopted for manual tracing in magnetic resonance imaging (MRI). The goal of our study was to assess the anatomical volume of the amygdala on the basis of its cytoarchitecture while comparing the differences in age and sex. This study was performed on 21 normal male brains (mean age of 56.8 years) and 9 normal female brains (mean age of 61.2 years). The volume of the amygdala was measured by planimetry of Nissl-stained serial sections using ImageJ software. To address the complexity of the amygdala, we elected to use two types of amygdalar measurement that differ mainly in the definition of anterior pole boundaries. The average size of the classic amygdala was 1.24 cm(3) (S.D. = 0.14), while the average size of the amygdala with wider borders was 1.63 cm(3) (S.D. = 0.2). No interhemispheric or intersexual differences were observed for either type of amygdalar measurement. Neither sex revealed any statistically important relationship between volume of the amygdala and age. Our study was concerned exclusively with the anatomical volume of the amygdala rather than the MM volume. Nevertheless, our results may have important implications for MM studies because as of yet there is no gold standard for manual volumetry of the amygdala. (C) 2009 Elsevier Ireland Ltd. All rights reserved.","[Brabec, Jiri; Rulseh, Aaron; Hoyt, Brian; Petrovicky, Pavel] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 12800 2, Czech Republic; [Brabec, Jiri] Univ Oklahoma, Hlth Sci Ctr, Dept Neurol, Oklahoma City, OK USA; [Vizek, Martin; Horinek, Daniel] Charles Univ Prague, Inst Pathol Physiol, Sch Med 2, Prague 12800 2, Czech Republic; [Vizek, Martin; Horinek, Daniel] Charles Univ Prague, Lab Neuroimaging Res, Sch Med 2, Prague 12800 2, Czech Republic; [Hort, Jakub] Charles Univ Prague, Dept Neurol, Univ Hosp Motol, Sch Med 2, Prague 12800 2, Czech Republic","Brabec, J (reprint author), Charles Univ Prague, Inst Anat, Fac Med 1, U Nemocnice 3, Prague 12800 2, Czech Republic.","jiri.brabec@lf1.cuni.cz",null,null,"Ministry of Health of the Czech Republic; Internal Grant Agency (IGA) [MZ 2006, NR8931-4]","This work was supported by the Ministry of Health of the Czech Republic, Internal Grant Agency grant IGA MZ 2006, NR8931-4. We thank Kveta Patkova and Bohuslava Fulinova for the excellent technical assistance, and Associate Professor David Sedmera, M.D., PhD., Institute of Anatomy, for the helpful advice and comments. We are deeply indebted to the donors and their families who have made this study possible.",null,53,9,11,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0925-4927",null,null,"PSYCHIAT RES-NEUROIM","Psychiatry Res. Neuroimaging","APR 30",2010,182,1,null,null,null,null,67,72,null,"10.1016/j.pscychresns.2009.11.005",null,6,"Clinical Neurology; Neuroimaging; Psychiatry","Neurosciences & Neurology; Psychiatry","594KJ","WOS:000277536200010"]
[null,null,null,null,"J","Pivonkova, H; Benesova, J; Butenko, O; Chvatal, A; Anderova, M",null,null,null,"Pivonkova, Helena; Benesova, Jana; Butenko, Olena; Chvatal, Alexandr; Anderova, Miroslava",null,null,"Impact of global cerebral ischemia on K+ channel expression and membrane properties of glial cells in the rat hippocampus","NEUROCHEMISTRY INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"CNS injury; Patch-clamp; K+ channels; Proliferation; Kir4.1; Astrocytes; NG2 glia","SPINAL-CORD-INJURY; OLIGODENDROCYTE PROGENITOR CELLS; POTASSIUM CHANNELS; ELECTROPHYSIOLOGICAL PROPERTIES; PHYSIOLOGICAL-PROPERTIES; REACTIVE ASTROCYTES; NG2-POSITIVE CELLS; GENE-EXPRESSION; PROLIFERATION; BRAIN","Astrocytes and NG2 glia respond to CNS injury by the formation of a glial scar. Since the changes in K+ currents in astrocytes and NG2 glia that accompany glial scar formation might influence tissue outcome by altering K+ ion homeostasis, we aimed to characterize the changes in K+ currents in hippocampal astrocytes and NG2 glia during an extended time window of reperfusion after ischemic injury. Global cerebral ischemia was induced in adult rats by bilateral, 15-min common carotid artery occlusion combined with low-pressure oxygen ventilation. Using the patch-clamp technique, we investigated the membrane properties of hippocampal astrocytes and NG2 glia in situ 2 hours, 6 hours, 1 day, 3 days, 7 days or 5 weeks after ischemia. Astrocytes in the CA1 region of the hippocampus progressively depolarized starting 3 days after ischemia, which coincided with decreased Kir4.1 protein expression in the gliotic tissue. Other K+ channels described previously in astrocytes, such as Kir2.1, Kir5.1 and TREK1, did not show any changes in their protein content in the hippocampus after ischemia: however, their expression switched from neurons to reactive astrocytes, as visualized by immunohistochemistry. NG2 glia displayed increased input resistance, decreased membrane capacitance, increased delayed outwardly rectifying and A-type K+ currents and decreased inward K+ currents 3 days after ischemia, accompanied by their proliferation. Our results show that the membrane properties of astrocytes after ischemia undergo complex alterations, which might profoundly influence the maintenance of K+ homeostasis in the damaged tissue, while NG2 glia display membrane currents typical of proliferating cells. (C) 2010 Elsevier Ltd. All rights reserved.","[Pivonkova, Helena; Benesova, Jana; Butenko, Olena; Chvatal, Alexandr; Anderova, Miroslava] Acad Sci Czech Republic, Inst Expt Med, Lab Neurobiol, Dept Cellular Neurophysiol, Prague 14220 4, Czech Republic; [Butenko, Olena; Chvatal, Alexandr] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic","Anderova, M (reprint author), Acad Sci Czech Republic, Inst Expt Med, Lab Neurobiol, Dept Cellular Neurophysiol, 1083 Videnska, Prague 14220 4, Czech Republic.","anderova@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [305/09/0717, P303/10/1338]; Academy of Sciences of the Czech Republic [AVOZ 50390512]; Ministry of Education, Youth and Sports of the Czech Republic [LC554, 1M0538]","We thank Hana Hronova and Helena Pavlikova for technical assistance and Petr Pivonka for developing software for patch-clamp data analysis. We also thank James Dutt for helpful comments and suggestions. This work was supported by the Grant Agency of the Czech Republic - grant 305/09/0717, P303/10/1338, the Academy of Sciences of the Czech Republic grant AVOZ 50390512 and the Ministry of Education, Youth and Sports of the Czech Republic grants LC554 and 1M0538.",null,58,9,10,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0197-0186",null,null,"NEUROCHEM INT","Neurochem. Int.","DEC",2010,57,7,null,null,null,null,783,794,null,"10.1016/j.neuint.2010.08.016",null,12,"Biochemistry & Molecular Biology; Neurosciences","Biochemistry & Molecular Biology; Neurosciences & Neurology","682XY","WOS:000284437500011"]
[null,null,null,null,"J","Veselka, J; Zemanek, D; Tomasov, P; Homolova, S; Adlova, R; Tesar, D",null,null,null,"Veselka, Josef; Zemanek, David; Tomasov, Pavol; Homolova, Stanislava; Adlova, Radka; Tesar, David",null,null,"Complications of Low-Dose, Echo-Guided Alcohol Septal Ablation","CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS",null,null,"English","Article",null,null,null,null,null,"hypertrophic cardiomyopathy; hemodynamics; cardiomyopathy","HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; TRANSCORONARY ABLATION; SINGLE-CENTER; EXPERIENCE; PREDICTORS","Background: Alcohol septal ablation (ASA) is a catheter-based intervention that has been used as an alternative to surgical myectomy in highly symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). Methods: This retrospective study was designed to evaluate the incidence of major complications in the mid-term follow-up of low-dose (1-2.5 ml of ethanol), echo-guided alcohol septal ablation. Results: A total of 101 consecutive patients (56 +/- 15 years) with highly symptomatic HOCM were enrolled. At 6 months, there was a significant decrease in resting outflow gradient accompanied by reduction in basal septal diameter and improvement in symptoms (P < 0.01). Two patients (2%) experienced procedural ventricular tachycardias terminated by electrical cardioversion. A total of 87 patients (86%) underwent an uneventful postprocedural hospital stay. The postprocedural complete heart block occurred in 10 patients (10%), and subsequent permanent pacemaker was implanted in four cases (4%). Sustained ventricular arrhythmias requiring electrical cardioversion occurred in four patients (4%) within postprocedural hospital stay. Subsequently, ICD was not implanted in any of these cases. The patients were repeatedly examined by Holter ECG monitoring, and in the mid-term follow-up (6-50 months), they stayed asymptomatic and without any ventricular arrhythmias. Conclusion: This study demonstrates the same early incidence of complete heart block requiring permanent pacemaker implantation (4%) and sustained ventricular arrhythmias following low-dose, echo-guided ASA. (C) 2009 Wiley-Liss, Inc.","[Veselka, Josef] Charles Univ Prague, Ctr Cardiovasc, Dept Cardiol, Sch Med 1,Univ Hosp Motol, Prague 15000 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Ctr Cardiovasc, Dept Cardiol, Sch Med 1,Univ Hosp Motol, 5 Uvalu 84, Prague 15000 5, Czech Republic.","veselka.josef@seznam.cz",null,null,"Ministry of Health of the Czech Republic [00064203]","Grant sponsor: Ministry of Health of the Czech Republic; grant number: 00064203",null,17,3,5,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1522-1946",null,null,"CATHETER CARDIO INTE","Catheter. Cardiovasc. Interv.","MAR 1",2010,75,4,null,null,null,null,546,550,null,"10.1002/ccd.22326",null,5,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","582HW","WOS:000276588600015"]
[null,null,null,null,"J","Hainerova, IA; Lebl, J",null,null,null,"Hainerova, Irena Aldhoon; Lebl, Jan",null,null,"Mechanisms of Appetite Regulation","JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION",null,null,"English","Article",null,null,null,null,null,null,"NEUROMEDIN-U; OBESITY; MUTATIONS; GENE; DEFICIENCY",null,"[Hainerova, Irena Aldhoon; Lebl, Jan] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague 10034 10, Czech Republic; [Hainerova, Irena Aldhoon] Charles Univ Prague, Ctr Res Diabet Metab & Nutr, Fac Med 3, Prague 10034 10, Czech Republic","Hainerova, IA (reprint author), Charles Univ Prague, Dept Pediat, Fac Med 2, Srobarova 50, Prague 10034 10, Czech Republic.","ihainer@hotmail.com",null,null,"Czech Ministry of Education [MSM 0021620814]","The studies of monogenic obesity are supported by a research project from the Czech Ministry of Education No. MSM 0021620814.",null,10,2,2,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0277-2116",null,null,"J PEDIATR GASTR NUTR","J. Pediatr. Gastroenterol. Nutr.","DEC",2010,51,null,null,3,null,null,"S123","S124",null,"10.1097/MPG.0b013e3181f84208",null,2,"Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","687WX","WOS:000284810100005"]
[null,null,null,null,"J","Smetana, K; Zapotocky, M",null,null,null,"Smetana, K.; Zapotocky, M.",null,null,"The Effect of a Histone Deacetylase Inhibitor - Valproic Acid - on Nucleoli in Human Leukaemic Myeloblasts","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"IN-VITRO; SIZE; INSIGHTS; DENSITY; TUMORS; BLOOD; CELLS; DRUG","The present study was undertaken to provide more information on nucleolar changes induced by a histone deacetylase inhibitor such as valproic acid in leukaemic myeloblasts at the single-cell level. For this study, RNA in nucleoli was visualized by a simple but sensitive cytochemical procedure in unfixed cytospins of short-term bone marrow cultures from patients suffering from acute myeloid leukaemia. Valproic acid in leukaemic myeloblasts markedly reduced the nucleolar size and also produced significant transformation of \"active\" to \"resting\" and \"inactive\" nucleoli that reflected the alteration of the nucleolar transcription in sensitive myeloblasts. On this occasion it should be added that valproic acid significantly increased the incidence of altered myeloblasts that changed to apoptotic cells or apoptotic bodies and cell ghosts. In contrast to the above-mentioned decreased nucleolar size, the nucleolar RNA concentration, expressed by computer-assisted RNA image densitometry in valproic acid-treated myeloblasts, was not significantly changed. The results of the present study clearly indicated that the nucleolar size and transformation of \"active\" to \"sleeping\" or \"inactive\" nucleoli are convenient markers of the sensitivity and alteration of leukaemic myeloblasts produced by a histone deacetylase inhibitor, valproic acid, at the single-cell level.","[Smetana, K.] Inst Hematol & Blood Transfus, Prague 12820 2, Czech Republic; [Zapotocky, M.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Smetana, K (reprint author), Inst Hematol & Blood Transfus, U Nemocnice 1, Prague 12820 2, Czech Republic.","karel.smetana@uhkt.cz",null,null,"Ministry of Health of the Czech Republic [VZ 0002373601]; Ministry of Education, Youth and Sports of the Czech Republic [VZ 0021620813]","The present study was supported in part by the Research Development Project VZ 0002373601 of the Ministry of Health of the Czech Republic and Research Development Project VZ 0021620813 of the Ministry of Education, Youth and Sports of the Czech Republic.",null,28,1,1,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2010,56,5,null,null,null,null,201,205,null,null,null,5,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","680SO","WOS:000284254900002"]
[null,null,null,null,"J","Huska, D; Adam, V; Krizkova, S; Hrabeta, J; Eckschlager, T; Stiborova, M; Kizek, R",null,null,null,"Huska, Dalibor; Adam, Vojtech; Krizkova, Sona; Hrabeta, Jan; Eckschlager, Tomas; Stiborova, Marie; Kizek, Rene",null,null,"An electrochemical study of interaction of an anticancer alkaloid ellipticine with DNA","CHIMICA OGGI-CHEMISTRY TODAY",null,null,"English","Article",null,null,null,null,null,"ellipticine; DNA; square wave voltammetry; adsorptive transfer technique; neuroblastoma cell lines; intercalation","NEUROBLASTOMA-CELL LINES; DRUG ELLIPTICINE; ADDUCT FORMATION; CYTOCHROMES P450; STRIPPING VOLTAMMETRY; DOXORUBICIN; 13-HYDROXYELLIPTICINE; 9-HYDROXYELLIPTICINE; DEOXYGUANOSINE; BIOACTIVATION","Ellipticine (5,11-demethyl-6H-pyridol(4,3-b) carbazole) and its derivates belong to prototype compounds acting predominantly by DNA-damaging mechanisms and serving as cytotoxic agents. The aim of this work was to study the intercalation of the ellipticine into DNA. For this purpose we utilized adsorptive transfer stripping technique (AdTS) coupled with square wave voltammetry (SWV). Primarily, we investigated the influence of ellipticine on genomic DNA electrochemical signals. Decrease in redox signal of cytosine/adenine (at -1.4 V) was observed as a result of ellipticine intercalation into DNA. The decrease was proportional to increasing concentration of ellipticine. In additional experiments we investigated the changes in the reduction signal of cytosine/adenine (CA) in a genomic dsDNA, dsDNA treated with ellipticine in vitro and dsDNA isolated from UKF-NB-3 neuroblastoma cells treated with 1 mu M ellipticine. In the mentioned cases, the changes were determined.","[Huska, Dalibor; Adam, Vojtech; Krizkova, Sona; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, CZ-12840 Prague 2, Czech Republic","Kizek, R (reprint author), Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.",null,"Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Krizkova, Sona/E-9617-2012",null,"GAAV [KAN208130801]; GACR [102/08/1546, P301/10/0356]; Ministry of Education of the Czech Republic [MSM 0021620808, 1M0505]","Financial support from GAAV (KAN208130801), GACR (102/08/1546, P301/10/0356) and the Ministry of Education of the Czech Republic (MSM 0021620808 and 1M0505) is highly acknowledged.",null,30,13,13,"TEKNOSCIENZE PUBL","MILANO","VIALE BRIANZA 22, 20127 MILANO, ITALY","0392-839X",null,null,"CHIM OGGI","Chim. Oggi-Chem. Today","SEP-OCT",2010,28,5,null,"S",null,null,15,17,null,null,null,3,"Biotechnology & Applied Microbiology; Chemistry, Multidisciplinary","Biotechnology & Applied Microbiology; Chemistry","672KP","WOS:000283582200004"]
[null,null,null,null,"J","Mehta, P; Locatelli, F; Stary, J; Smith, FO",null,null,null,"Mehta, Parinda; Locatelli, Franco; Stary, Jan; Smith, Franklin O.",null,null,"Bone Marrow Transplantation for Inherited Bone Marrow Failure Syndromes","PEDIATRIC CLINICS OF NORTH AMERICA",null,null,"English","Article",null,null,null,null,null,"Inherited bone marrow failure syndromes; Bone marrow transplantation; Gene mutation; Diagnostic tests","SHWACHMAN-DIAMOND-SYNDROME; STEM-CELL TRANSPLANTATION; UMBILICAL-CORD BLOOD; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; FANCONI-ANEMIA PATIENTS; LOW-DOSE CYCLOPHOSPHAMIDE; RIBOSOMAL-PROTEIN S19; COLONY-STIMULATING FACTOR; OF-THE-LITERATURE; INTENSITY CONDITIONING REGIMEN","The inherited bone marrow failure (BMF) syndromes are characterized by impaired hematopoiesis and cancer predisposition. Most inherited BMF syndromes are also associated with a range of congenital anomalies. Progress in improving the outcomes for children with inherited BMF syndromes has been limited by the rarity of these disorders, as well as disease-specific genetic, molecular, cellular, and clinical characteristics that increase the risks of complications associated with hematopoietic stem cell transplantation (HSCT). As a result, the ability to develop innovative transplant approaches to circumvent these problems has been limited. Recent progress has been made, as best evidenced in studies adding fludarabine to the preparative regimen for children undergoing unrelated donor HSCT for Fanconi anemia. The rarity of these diseases coupled with the far more likely incremental improvements that will result from ongoing research will require prospective international clinical trials to improve the outcome for these children.","[Mehta, Parinda; Smith, Franklin O.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Mehta, Parinda; Smith, Franklin O.] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA; [Locatelli, Franco] Univ Pavia, Osped Pediat Bambino Gesu, Rome, Italy; [Locatelli, Franco] IRCCS Policlin San Matteo, Pediat Haematol Oncol Fdn, I-27100 Pavia, Italy; [Stary, Jan] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic","Smith, FO (reprint author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.","frank.smith@cchmc.org",null,null,null,null,null,166,9,11,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0031-3955",null,null,"PEDIATR CLIN N AM","Pediatr. Clin. N. Am.","FEB",2010,57,1,null,null,null,null,147,"+",null,"10.1016/j.pcl.2010.01.002",null,25,"Pediatrics","Pediatrics","588AW","WOS:000277039300009"]
[null,null,null,null,"J","Jelinek, M; Kocourek, T; Remsa, J; Miksovsky, J; Zemek, J; Smetana, K; Dvorankova, B; Luxbacher, T",null,null,null,"Jelinek, Miroslav; Kocourek, Tomas; Remsa, Jan; Miksovsky, Jan; Zemek, Josef; Smetana, Karel, Jr.; Dvorankova, Barbora; Luxbacher, Thomas",null,null,"Diamond/graphite content and biocompatibility of DLC films fabricated by PLD","APPLIED PHYSICS A-MATERIALS SCIENCE & PROCESSING",null,null,"English","Article",null,null,null,null,null,null,"ION IMPLANTATION-DEPOSITION; CARBON-FILMS; NANOCRYSTALLINE DIAMOND; PROTEIN ADSORPTION; BACTERIAL ADHESION; AMORPHOUS-CARBON; THIN-FILMS; IN-VITRO; COATINGS; KERATINOCYTES","Biocompatibility and physicochemical properties of diamond-like carbon (DLC) thin layers prepared by pulsed laser deposition method were studied. The films of high and low diamond/graphite content were prepared by changing the laser energy density on the graphite target from 4 to 11 J cm(-2). The bonds and surface properties as roughness, atomic force microscopy topology, contact angle parameters, and zeta potential were measured. The cell adhesion/proliferation on DLC layers was tested using normal human fibroblasts and keratinocytes.","[Jelinek, Miroslav; Kocourek, Tomas; Remsa, Jan; Miksovsky, Jan; Zemek, Josef] Inst Phys ASCR, Prague 18221 8, Czech Republic; [Jelinek, Miroslav; Kocourek, Tomas; Miksovsky, Jan] Czech Tech Univ, Fac Biomed Engn, Kladno 27201, Czech Republic; [Smetana, Karel, Jr.; Dvorankova, Barbora] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Smetana, Karel, Jr.; Dvorankova, Barbora] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Luxbacher, Thomas] Anton Paar GmbH, Graz, Austria","Jelinek, M (reprint author), Inst Phys ASCR, Slovance 2, Prague 18221 8, Czech Republic.","jelinek@fzu.cz",null,null,"Ministry of Education, Youth and Sports of the Czech Republic and to Institutional research [MSM 6840770012, 0021620806, AV010100521, AV010100522]","We thank to grants MSM 6840770012 and 0021620806 from Ministry of Education, Youth and Sports of the Czech Republic and to Institutional research plan No. AV010100521 and AV010100522.",null,29,9,9,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0947-8396",null,null,"APPL PHYS A-MATER","Appl. Phys. A-Mater. Sci. Process.","DEC",2010,101,4,null,null,"SI",null,579,583,null,"10.1007/s00339-010-5912-9",null,5,"Materials Science, Multidisciplinary; Physics, Applied","Materials Science; Physics","692ZV","WOS:000285195300001"]
[null,null,null,null,"J","Sykorova, V; Dvorakova, S; Ryska, A; Vcelak, J; Vaclavikova, E; Laco, J; Kodetova, D; Kodet, R; Cibula, A; Duskova, J; Hlobilkova, A; Astl, J; Vesely, D; Betka, J; Hoch, J; Smutny, S; Cap, J; Vlcek, P; Novak, Z; Bendlova, B",null,null,null,"Sykorova, V.; Dvorakova, S.; Ryska, A.; Vcelak, J.; Vaclavikova, E.; Laco, J.; Kodetova, D.; Kodet, R.; Cibula, A.; Duskova, J.; Hlobilkova, A.; Astl, J.; Vesely, D.; Betka, J.; Hoch, J.; Smutny, S.; Cap, J.; Vlcek, P.; Novak, Z.; Bendlova, B.",null,null,"BRAF(V600E) mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic","JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION",null,null,"English","Article",null,null,null,null,null,"BRAF mutation; genetics; genotype-phenotype correlation; papillary carcinoma; thyroid","CHERNOBYL NUCLEAR ACCIDENT; BRAF V600E MUTATION; HIGH PREVALENCE; RET/PTC REARRANGEMENTS; CLINICOPATHOLOGICAL FEATURES; SIGNALING PATHWAY; GENE MUTATION; HIGH-RISK; B-RAF; CANCER","Background: Activating point mutation of the BRAF gene, the most common genetic alteration reported in papillary thyroid carcinomas (PTC), has been associated with poor prognostic characteristics. Aim: Our objective was to determine the frequency of BRAF(v6000E) mutation in PTC tumor tissues from the period 1960-2007 and to correlate it with clinicopathological parameters. Subjects and methods: DNAs were extracted from 242 PTCs, 23 sporadic medullary carcinomas, one anaplastic carcinoma and 6 poorly differentiated carcinomas. The presence of BRAF(v600E) mutation was determined using single strand conformation polymorphism method and verified by direct sequencing. Results: BRAF(v600E) mutation was detected in 81 of 242 PTCs (33.5%), in one of 6 poorly differentiated carcinomas (16.7%) and in anaplastic carcinoma. BRAF(v000E) mutation was much less frequent in the follicular variant compared to classical variant and mixed follicular-classical variant of PTCs (p=0.001). BRAF(v000E) mutation was significantly associated with presence of nodal metastasis (p=0.029), more advanced TNM stage (p=0.014) and recurrence of disease (p=0.008). The mutation correlated with a higher age at diagnosis (p=0.049) and with a greater tumor size (p=0.041). Multivariate analysis confirmed these findings. The prevalence of BRAF(v000E) mutation before 1986 was significantly lower than after it (p=0.008). Conclusions: Our data suggest that BRAF(v000E) mutation is associated with high-risk clinicopathological characteristics of PTC and worse prognosis of patients. The frequency of the mutation significantly varied during the observed period but rather because of the different age distribution of patients in particular periods than as a consequence of Chernobyl accident. (J. Endocrinol. Invest. 33: 318-324, 2010) (C) 2010, Editrice Kurtis","[Sykorova, V.; Dvorakova, S.; Vcelak, J.; Vaclavikova, E.; Bendlova, B.] Inst Endocrinol, Dept Mol Endocrinol, Prague 11694 1, Czech Republic; [Ryska, A.; Laco, J.] Charles Univ Prague, Fac Med, Fingerland Dept Pathol, Hradec Kralove, Czech Republic; [Ryska, A.; Laco, J.; Cap, J.] Univ Hosp, Hradec Kralove, Czech Republic; [Kodetova, D.; Kodet, R.; Cibula, A.] 2nd Fac Med, Dept Pathol & Mol Med, Prague, Czech Republic; [Duskova, J.] Charles Univ Prague, Fac Med 1, Inst Pathol, Prague, Czech Republic; [Hlobilkova, A.] Palacky Univ, Fac Med, Inst Pathol & Lab Mol Pathol, CR-77147 Olomouc, Czech Republic; [Astl, J.; Vesely, D.; Betka, J.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague, Czech Republic; [Astl, J.; Vesely, D.; Betka, J.] Charles Univ Prague, Fac Hosp Motol, Prague, Czech Republic; [Hoch, J.; Smutny, S.] Charles Univ Prague, Fac Med 2, Dept Surg, Prague, Czech Republic; [Cap, J.] Charles Univ Prague, Dept Internal Med 2, Fac Med, Hradec Kralove, Czech Republic; [Vlcek, P.] Charles Univ Prague, Fac Med 2, Dept Nucl Med & Endocrinol, Prague, Czech Republic; [Novak, Z.] Inst Endocrinol, Dept Clin Endocrinol, Prague 11694 1, Czech Republic","Sykorova, V (reprint author), Inst Endocrinol, Dept Mol Endocrinol, Narodni 8, Prague 11694 1, Czech Republic.","vlassyk@seznam.cz","Cap, Jan/C-3377-2014",null,"IGA [MH CR NR/9165-3];  [MZO-00179906];  [MZO-00064203/6704]","We thank all the patients for their kind participation in the study. We thank log. Martin Hill, D.Sc., for performing multivariate analysis. This study was supported by grant IGA MH CR NR/9165-3 and by research projects MZO-00179906 and MZO-00064203/6704.",null,48,8,9,"EDITRICE KURTIS S R L","MILAN","VIA LUIGI ZOJA 30, 20153 MILAN, ITALY","0391-4097",null,null,"J ENDOCRINOL INVEST","J. Endocrinol. Invest.","MAY",2010,33,5,null,null,null,null,318,324,null,"10.3275/6722",null,7,"Endocrinology & Metabolism","Endocrinology & Metabolism","611YU","WOS:000278862200007"]
[null,null,null,null,"J","Mohelnikova-Duchonova, B; Vrana, D; Holcatova, I; Ryska, M; Smerhovsky, Z; Soucek, P",null,null,null,"Mohelnikova-Duchonova, Beatrice; Vrana, David; Holcatova, Ivana; Ryska, Miroslav; Smerhovsky, Zdenek; Soucek, Pavel",null,null,"CYP2A13, ADH1B, and ADH1C Gene Polymorphisms and Pancreatic Cancer Risk","PANCREAS",null,null,"English","Article",null,null,null,null,null,"pancreas; cancer; polymorphism; CYP2A13; ADH1","TOBACCO-SPECIFIC CARCINOGEN; SQUAMOUS-CELL CARCINOMA; ALDEHYDE DEHYDROGENASE; METABOLIC-ACTIVATION; ACINAR-CELLS; LUNG-CANCER; ALCOHOL; CONSUMPTION; ETHANOL; CYTOCHROME-P450","Objectives: Pancreatic carcinoma etiology and molecular pathogenesis are weakly understood. Based on the assumption that genetic variation in carcinogen metabolism further modifies the risk of exposure-related cancers, we studied the association of polymorphisms in the tobacco carcinogen-metabolizing gene CYP2A13 (Arg101Stop) and the alcohol-metabolizing genes ADH1B (Arg48His) and ADH1C (Ile350Val) with pancreatic cancer risk. Methods: Polymorphisms were studied by allelic discrimination. Results: In a hospital-based case-control study, CYP2A13 variant alleles coding an inactive enzyme were found in 7 of 265 cancer-free controls and in none of 235 pancreatic carcinoma patients. Neither ADH1B or ADH1C polymorphisms alone nor their combinations showed a significant effect on pancreatic cancer risk. Conclusions: The first study of the roles of CYP2A13, ADH1B, and ADH1C in pancreatic cancer etiology suggested that the controls may have a lower ability to bioactivate tobacco-derived procarcinogens than the cases.","[Mohelnikova-Duchonova, Beatrice; Vrana, David; Soucek, Pavel] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042 10, Czech Republic; [Vrana, David] Charles Univ Prague, Fac Med 1, Dept Oncol, Prague, Czech Republic; [Vrana, David] Gen Teaching Hosp, Prague, Czech Republic; [Holcatova, Ivana] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague, Czech Republic; [Ryska, Miroslav] Charles Univ Prague, Fac Med 2, Dept Surg, Prague, Czech Republic; [Ryska, Miroslav] Cent Mil Hosp, Prague, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Inst Epidemiol, Prague, Czech Republic","Soucek, P (reprint author), Natl Inst Publ Hlth, Toxicogenom Unit, Srobarova 48, Prague 10042 10, Czech Republic.","psoucek@szu.cz",null,null,"Ministry of Health, Czech Republic [8563-5, 9422-3]","This work was supported by the Internal grant agency of the Ministry of Health, Czech Republic (grants Nos. 8563-5 and 9422-3).",null,33,8,8,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0885-3177",null,null,"PANCREAS","Pancreas","MAR",2010,39,2,null,null,null,null,144,148,null,"10.1097/MPA.0b013e3181bab6c2",null,5,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","561WE","WOS:000275010000004"]
[null,null,null,null,"J","Kotlin, R; Reicheltova, Z; Suttnar, J; Salaj, P; Hrachovinova, I; Riedel, T; Maly, M; Oravec, M; Kvasnicka, J; Dyr, JE",null,null,null,"Kotlin, Roman; Reicheltova, Zuzana; Suttnar, Jiri; Salaj, Peter; Hrachovinova, Ingrid; Riedel, Tomas; Maly, Martin; Oravec, Milan; Kvasnicka, Jan; Dyr, Jan Evangelista",null,null,"Two novel fibrinogen variants in the C-terminus of the B beta-chain: fibrinogen Rokycany and fibrinogen Znojmo","JOURNAL OF THROMBOSIS AND THROMBOLYSIS",null,null,"English","Article",null,null,null,null,null,"Fibrinogen; Missense mutation; Hypofibrinogenemia; Thrombosis; Dysfibrinogenemia","GAMMA-CHAIN; CONGENITAL AFIBRINOGENEMIA; HYPOFIBRINOGENEMIA; DYSFIBRINOGENEMIA; MUTATIONS; SUBSTITUTION; SECRETION; ALPHA; BIOSYNTHESIS; FRAGMENT","Hereditary dysfibrinogenemia is a rare disorder wherein an inherited abnormality in fibrinogen structure may result in defective fibrin function and/or structure. Congenital hypofibrinogenemia is a rare autosomal bleeding disorder, either recessive or dominant, characterized by a low fibrinogen plasma level. A 28-year-old asymptomatic woman (fibrinogen Rokycany) and a 54-year-old man with thrombosis and pulmonary embolism (fibrinogen Znojmo) were investigated for a suspected fibrinogen mutation after abnormal coagulation tests results were obtained. DNA sequencing showed the heterozygous point mutation B beta Asn351Lys in fibrinogen Rokycany and the heterozygous point mutation B beta Arg237Ser in fibrinogen Znojmo, respectively. The kinetics of fibrinopeptide release was found to be normal in both cases. Fibrinolysis was impaired in the Znojmo variant. The average fibril diameters of Znojmo fibrin was slightly increased, but not differing significantly from normal; formed by less fibrils with abrupt fibril terminations. Rheological studies revealed a softer clot. Rokycany fibrin was formed by significantly narrower fibrils than normal fibrin; and the clot was denser than the control clot. Rheological studies revealed a stiffer clot. Impaired fibrinolysis and abnormal clot morphology may be the cause of thrombotic episodes in the patient with Znojmo mutation. New cases of hypofibrinogenemia and dysfibrinogenemia, found by routine coagulation testing, were genetically identified as a novel fibrinogen variants B beta Asn351Lys (fibrinogen Rokycany) and B beta Arg237Ser (fibrinogen Znojmo), respectively.","[Kotlin, Roman; Reicheltova, Zuzana; Suttnar, Jiri; Salaj, Peter; Hrachovinova, Ingrid; Riedel, Tomas; Dyr, Jan Evangelista] Inst Hematol & Blood Transfus, CR-12820 Prague 2, Czech Republic; [Riedel, Tomas] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague, Czech Republic; [Maly, Martin; Oravec, Milan] Motol Univ Hosp, Dept Cardiol, Prague 15006 5, Czech Republic; [Kvasnicka, Jan] Charles Univ Prague, Fac Med 1, Prague 12808 2, Czech Republic; [Kvasnicka, Jan] Thrombot Ctr Gen Univ Hosp, Prague 12808 2, Czech Republic","Kotlin, R (reprint author), Inst Hematol & Blood Transfus, U Nemocnice 1, CR-12820 Prague 2, Czech Republic.","kotlinr@uhkt.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","The Internal Grant Agency of The Ministry of Health of the Czech Republic [NS 9636-3/2008]; The Ministry of Health of the Czech Republic [2373601, MZO VFN2005]; The Academy of Sciences of the Czech Republic [KAN200670701]","This work was supported by a grant of The Internal Grant Agency of The Ministry of Health of the Czech Republic, number NS 9636-3/2008; by a grant of The Ministry of Health of the Czech Republic, number 2373601; by a grant of The Academy of Sciences of the Czech Republic, number KAN200670701; and by a grant of The Ministry of Health of the Czech Republic, number MZO VFN2005.",null,33,5,6,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0929-5305",null,null,"J THROMB THROMBOLYS","J. Thromb. Thrombolysis","OCT",2010,30,3,null,null,null,null,311,318,null,"10.1007/s11239-010-0505-1",null,8,"Hematology; Peripheral Vascular Disease","Hematology; Cardiovascular System & Cardiology","655BD","WOS:000282215300008"]
[null,null,null,null,"J","Vanourkova, Z; Kramer, HJ; Huskova, Z; Cervenka, L; Vaneckova, I",null,null,null,"Vanourkova, Z.; Kramer, H. J.; Huskova, Z.; Cervenka, L.; Vaneckova, I.",null,null,"Despite Similar Reduction of Blood Pressure and Renal ANG II and ET-1 Levels Aliskiren but not Losartan Normalizes Albuminuria in Hypertensive Ren-2 Rats","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Ren-2 rats; Hypertension; Renin-angiotensin system; Endothelin system; RAS blockade; Aliskiren; Losartan; Albuminuria","ENDOTHELIN RECEPTOR BLOCKADE; RENIN-ANGIOTENSIN SYSTEM; CONVERTING ENZYME; MAST-CELLS; KIDNEY; EXPRESSION; ACTIVATION; DISEASE; FLUID","The relationship between angiotensin II (ANG II) and endothelin-1 (ET-1) is known to be complex; both peptides can initiate and potentiate the gene expression of each other. This pilot study investigated the effects of the AT(1) receptor blocker losartan or the direct renin inhibitor aliskiren on mean arterial pressure (MAP) and albuminuria and the renal ANG II and ET-1 levels. 3-month-old male Ren-2 transgenic rats (TGR) were treated either with losartan (5 mg kg(-1) day(-1)) or aliskiren (10 mg kg(-1) day(-1)) for 10 weeks. At the end of the experiment, rats were decapitated and cortical and papillary parts of kidneys were separated. Plasma and tissue ANG II levels were measured by RIA and tissue ET-1 concentrations by ELISA. In all four groups of animals ET-1 levels were lowest in renal cortex and more than 100-fold higher in the papilla. Cortical and papillary ET-1 concentrations in untreated TGR significantly exceeded those of control HanSD rats and were significantly depressed by both drugs. In both strains, papillary ANG II concentrations were moderately but significantly higher than cortical ANG II, TGR exhibited higher ANG II levels both in cortex and papilla as compared to control HanSD rats. Aliskiren and losartan at the doses used depressed similarly the levels of ANG II in cortex and papilla and reduced ET-1 significantly in the renal cortex and papilla below control levels in HanSD rats. Albuminuria, which was more than twice as high in TGR as in HanSD rats, was normalized with aliskiren and reduced by 28 % with losartan, although MAP was reduced to a similar degree by both drugs. Despite similar reductions of MAP and renal ET-1 and ANG II levels aliskiren appears to be more effective than losartan, at the doses used, in reducing albuminuria in heterozygous hypertensive Ren-2 rats.","[Vanourkova, Z.; Huskova, Z.; Cervenka, L.; Vaneckova, I.] Inst Clin & Expt Med, Dept Expt Med, Prague, Czech Republic; [Vanourkova, Z.; Huskova, Z.; Cervenka, L.; Vaneckova, I.] Inst Clin & Expt Med, Cardiovasc Res Ctr, Prague, Czech Republic; [Kramer, H. J.] Univ Bonn, Nephrol Sect, Med Policlin, Dept Med, D-5300 Bonn, Germany; [Cervenka, L.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Vaneckova, I (reprint author), Inst Physiol AS CR, Dept Expt Hypertens, Videnska 1083, CZ-14220 Prague 4, Czech Republic.","ivanava@biomed.cas.cz","Vaneckova, Ivana/B-5543-2012",null,"Institute for Clinical and Experimental Medicine [MZ 00023001]; Czech Science Foundation [305/07/0167, 305/07/J004, 305/08/P053, 305/08/J006]; German Research Foundation (DFG, Deutsche Forschungsgemeinschaft) [433/14-2, 436 TSE 113/50, 436 TSE 113/56, 436 TSE 113/57/0-1]; German Academic Exchange Service (DAAD)","I. V. is supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZ 00023001) and the Czech Science Foundation (grants Nr. 305/07/0167 and 305/07/J004). H.J.K. is supported by the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft; grants No. 433/14-2 and 436 TSE 113/50, 113/56 and 113/57/0-1) and the German Academic Exchange Service (DAAD). Portions of this work were performed during the stay of Z.V. as a visiting scientist at the University of Bonn, which was supported by a grant from the Deutsche Forschungsgemeinschaft, Bonn (grants No. 433/14-2). Czech Science Foundation supported also Z.H. (grant Nr. 305/08/P053) and L. C. (grant Nr. 305/08/J006).",null,38,5,6,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,3,null,null,null,null,339,345,null,null,null,7,"Physiology","Physiology","631QW","WOS:000280363700004"]
[null,null,null,null,"J","Simunkova, K; Hampl, R; Hill, M; Kriz, L; Hrda, P; Janickova-Zdarska, D; Zamrazil, V; Vrbikova, J; Vondra, K",null,null,null,"Simunkova, Katerina; Hampl, Richard; Hill, Martin; Kriz, Lubomir; Hrda, Pavlina; Janickova-Zdarska, Denisa; Zamrazil, Vaclav; Vrbikova, Jana; Vondra, Karel",null,null,"Adrenocortical function in young adults with diabetes mellitus type 1","JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY",null,null,"English","Article",null,null,null,null,null,"Diabetes mellitus type 1; Low-dose Synacthen test; Young adults; Salivary cortisol; Adrenocortical function","PITUITARY-ADRENAL AXIS; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; STEROID 21-HYDROXYLASE AUTOANTIBODIES; CORTICOSTEROID-BINDING GLOBULIN; AUTOIMMUNE-DISEASES MARKERS; CLINICAL ADDISONS-DISEASE; HYPOTHALAMIC-PITUITARY; CORTISOL RESPONSE; FOLLOW-UP; ACTH TEST","In 75 young adults with diabetes mellitus type 1 (DM 1) we have performed a cross-sectional study to gain more information about their adrenocortical function. We have found in a surprisingly large portion of patients (25%) a subnormal response (<500 nmol/L, low responders) of the serum cortisol during low-dose Synacthen test, accompanied by significantly decreased stimulated values of aldosterone and salivary cortisol. Basal serum cortisol, aldosterone, and dehydroepiandrosterone sulphate (in women only) were significantly reduced in low responders as well, while ACTH, cortisol binding globulin, plasma renin activity, urinary free cortisol/24 h, and salivary cortisol did not differ. The results indicate that the disorder of adrenocortical function in low responders occurs in all adrenocortical zones. The patients with the highest risk in respect to revealed hypocorticalism were DM 1 with autoimmune thyroiditis, 13 out of 36 in contrast to 5 out of 39 suffered from isolated form of DM 1, with onset around 30 years, independently on sex. The biorhythm of salivary cortisol in low responders under real-life conditions did not significantly differ from normal responders, except of the decreased values in the morning. Antibodies against 21-hydroxylase and adrenal cortex were negative in the entire group of diabetics studied. In conclusion, this is the first study to demonstrate in as much as 25% of young adults with DM 1 patients without any signs of adrenal autoimmunity decreased both basal and stimulated serum cortisol and aldosterone levels, implying existence of subclinical primary hypocorticalism. (c) 2010 Elsevier Ltd. All rights reserved.","[Simunkova, Katerina; Hampl, Richard; Hill, Martin; Kriz, Lubomir; Hrda, Pavlina; Vrbikova, Jana; Vondra, Karel] Inst Endocrinol, Prague 11694, Czech Republic; [Janickova-Zdarska, Denisa; Zamrazil, Vaclav] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Internal Med, Prague 15006 5, Czech Republic","Simunkova, K (reprint author), Inst Endocrinol, Narodni Trida 8, Prague 11694, Czech Republic.","ksimunkova@endo.cz; kvondra@endo.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA MZCR) [NR/9154-3]","We thank the study participants and our excellent research nurses. We thank the members of our steroid research group. The study was supported by grant NR/9154-3 of the Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA MZCR).",null,36,5,5,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0960-0760",null,null,"J STEROID BIOCHEM","J. Steroid Biochem. Mol. Biol.","OCT",2010,122,41699,null,null,"SI",null,35,41,null,"10.1016/j.jsbmb.2010.04.017",null,7,"Biochemistry & Molecular Biology; Endocrinology & Metabolism","Biochemistry & Molecular Biology; Endocrinology & Metabolism","663FN","WOS:000282868500006"]
[null,null,null,null,"J","Ostadal, P; Alan, D; Vejvoda, J; Kukacka, J; Macek, M; Hajek, P; Mates, M; Kvapil, M; Kettner, J; Wiendl, M; Aschermann, O; Slaby, J; Holm, F; Telekes, P; Horak, D; Blasko, P; Zemanek, D; Veselka, J; Cepova, J",null,null,null,"Ostadal, Petr; Alan, David; Vejvoda, Jiri; Kukacka, Jiri; Macek, Milan; Hajek, Petr; Mates, Martin; Kvapil, Milan; Kettner, Jiri; Wiendl, Martin; Aschermann, Ondrej; Slaby, Josef; Holm, Frantisek; Telekes, Peter; Horak, David; Blasko, Peter; Zemanek, David; Veselka, Josef; Cepova, Jana",null,null,"Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)","TRIALS",null,null,"English","Article",null,null,null,null,null,null,"ACUTE MYOCARDIAL-INFARCTION; PLASMA PROTEIN-A; UNSTABLE ANGINA; STATIN THERAPY; ATORVASTATIN TREATMENT; REPERFUSION; SIMVASTATIN; ELEVATION; PATHWAY; EVENTS","Background: Statins have been proved to be effective in reduction of mortality and morbidity when started in the early secondary prevention in stabilized patients after acute coronary syndrome (ACS). The safety and efficacy of statin administration directly in the first-line therapy in unstable ACS patients is not clear. The aim of our study was, therefore, to assess the effect of statin treatment initiated immediately at hospital admission of patients with ACS. Methods: The trial was stopped prematurely after enrollment of one hundred and fifty-six patients with ACS that were randomized at admission to fluvastatin 80 mg (N = 78) or placebo (N = 78). Study medication was administered immediately after randomization and then once daily for 30 days; all patients were then encouraged to continue in open-label statin therapy and at the end of one-year follow-up 75% in the fluvastatin group and 78% in the placebo group were on statin therapy. Results: We did not demonstrate any difference between groups in the level of C-reactive protein, interleukin 6, and pregnancy-associated plasma protein A on Day 2 and Day 30 (primary endpoint). Fluvastatin-therapy, however, significantly reduced one-year occurrence of major adverse cardiovascular events (11.5% vs. 24.4%, odds ratio (OR) 0.40, 95% CI 0.17-0.95, P = 0.038). This difference was caused mainly by reduction of recurrent symptomatic ischemia (7.7% vs. 20.5%, OR 0.32, 95% CI 0.12-0.88, P = 0.037). Conclusions: This study failed to prove the effect of fluvastatin given as first-line therapy of ACS on serum markers of inflammation and plaque instability. Fluvastatin therapy was, however, safe and it may reduce cardiovascular event rate that supports immediate use of a statin in patients admitted for ACS.","[Ostadal, Petr; Mates, Martin; Aschermann, Ondrej] Na Homolce Hosp, Ctr Heart, Dept Cardiol, Prague, Czech Republic; [Alan, David; Vejvoda, Jiri; Hajek, Petr; Zemanek, David; Veselka, Josef] Univ Hosp Motol, Dept Cardiol, Prague, Czech Republic; [Kukacka, Jiri; Cepova, Jana] Univ Hosp Motol, Dept Clin Biochem & Pathobiochem, Prague, Czech Republic; [Kukacka, Jiri; Macek, Milan; Kvapil, Milan; Cepova, Jana] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Macek, Milan] Univ Hosp Motol, Inst Biol & Med Genet, Prague, Czech Republic; [Kvapil, Milan] Univ Hosp Motol, Dept Internal Med, Prague, Czech Republic; [Kettner, Jiri; Wiendl, Martin] Inst Clin & Expt Med, Dept Cardiol, Prague, Czech Republic; [Slaby, Josef] Hosp Kolin, Dept Med, Kolin, Czech Republic; [Holm, Frantisek; Telekes, Peter; Horak, David] Reg Hosp Liberec, Dept Cardiol, Liberec, Czech Republic; [Blasko, Peter] Fac Hosp Nitra, Dept Internal Med, Nitra, Slovakia","Ostadal, P (reprint author), Na Homolce Hosp, Ctr Heart, Dept Cardiol, Prague, Czech Republic.","ostadal@yahoo.com","Kukacka, Jiri/C-4770-2013",null,"Czech Ministry of Health [00000064203]; Novartis Pharma Czech republic","The FACS trial was supported by the Czech Ministry of Health and by Novartis Pharma Czech republic. Moreover, authors received research funds, consultancy honoraria, and speakers honoraria from AstraZeneca, Hoffman La Roche, Novartis, Pfizer, and Servier.The FACS trial was supported by the grant of the Czech Ministry of Health, No. 00000064203. Study medication, insurance, and clinical monitoring were kindly sponsored by Novartis Pharma Czech Republic.",null,24,5,5,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1745-6215",null,null,"TRIALS","Trials","MAY 25",2010,11,null,null,null,null,null,null,null,61,"10.1186/1745-6215-11-61",null,8,"Medicine, Research & Experimental","Research & Experimental Medicine","621BP","WOS:000279548900001"]
[null,null,null,null,"J","Kutil, B; Ostadal, P; Vejvoda, J; Kukacka, J; Cepova, J; Alan, D; Kruger, A; Vondrakova, D",null,null,null,"Kutil, Barbara; Ostadal, Petr; Vejvoda, Jiri; Kukacka, Jiri; Cepova, Jana; Alan, David; Krueger, Andreas; Vondrakova, Dagmar",null,null,"Alterations in serum selenium levels and their relation to troponin I in acute myocardial infarction","MOLECULAR AND CELLULAR BIOCHEMISTRY",null,null,"English","Article",null,null,null,null,null,"Selenium; Acute coronary syndrome; Myocardial infarction; Troponin I","ISCHEMIA-REPERFUSION INJURY; CARDIOVASCULAR-DISEASES; OXIDATIVE STRESS; TRACE-ELEMENTS; CARDIAC TISSUE; RISK; RAT","Selenium (Se) is an essential trace element with antioxidant function. The aim of the present study was to estimate the alterations of Se serum level during the acute phase of myocardial infarction and its relation to biomarkers of myocardial necrosis. Serum Se levels were measured at admission and after 24 h in 60 consecutive patients with acute coronary syndrome (both with and without ST elevation). Troponin I (TnI) was assessed at admission and then twice daily for 3 days; patients with normal levels were excluded. Fifty-five patients with acute MI (positive TnI) were included into the analysis. During the first day of hospitalization, patients received standard therapy, including acetylsalicylic acid, clopidogrel, and heparin or enoxaparin; all underwent urgent coronary angiography and percutaneous intervention, when appropriate. Mean Se levels at baseline and 24 h later were comparable (67.1 +/- 2.1 vs. 67.2 +/- 1.8 mu g/L, ns). Linear regression has shown significant correlation between baseline Se levels and peak TnI (y = 3.4x - 116, r(2) = 0.13, P = 0.008). Positive correlation was found also between the peak TnI and the difference from baseline to 24 h (y = 2.2x + 115, r(2) = 0.08, P = 0.04). Moreover, close negative correlation was observed between baseline Se levels and the difference from baseline to 24 h (y = -0.9x + 62.7, r(2) = 0.55, P < 0.001). Our results have shown marked individual changes in Se levels during the acute phase of MI as well as correlation between Se levels and peak TnI. These results suggest that alterations in serum Se may be related to the extent of myocardial infarction.","[Kutil, Barbara; Ostadal, Petr; Krueger, Andreas; Vondrakova, Dagmar] Na Homolce Hosp, Dept Cardiol, Ctr Cardiovasc, Prague 15030, Czech Republic; [Kutil, Barbara] Charite, D-13353 Berlin, Germany; [Vejvoda, Jiri; Alan, David] Univ Hosp Motol, Dept Cardiol, Ctr Cardiovasc, Prague, Czech Republic; [Kukacka, Jiri; Cepova, Jana] Univ Hosp Motol, Dept Clin Biochem & Pathobiochem, Prague, Czech Republic","Ostadal, P (reprint author), Na Homolce Hosp, Dept Cardiol, Ctr Cardiovasc, Roentgenova 2, Prague 15030, Czech Republic.","ostadal@yahoo.com","Kukacka, Jiri/C-4770-2013",null,"Czech Ministry of Health [00000064203]","This study was supported by the grant of the Czech Ministry of Health, Nr. 00000064203.",null,24,4,5,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0300-8177",null,null,"MOL CELL BIOCHEM","Mol. Cell. Biochem.","DEC",2010,345,41671,null,null,null,null,23,27,null,"10.1007/s11010-010-0555-x",null,5,"Cell Biology","Cell Biology","689DI","WOS:000284907100003"]
[null,null,null,null,"J","Ostadalova, I; Charvatova, Z; Wilhelm, J",null,null,null,"Ostadalova, I.; Charvatova, Z.; Wilhelm, J.",null,null,"Lipofuscin-Like Pigments in the Rat Heart During Early Postnatal Development: Effect of Selenium Supplementation","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Early postnatal development; Heart; Lipofuscin-like pigment; Selenium; Radical oxygen species","LIPID-PEROXIDATION; CARDIAC MYOCYTES; AMBIENT OXYGEN; ACCUMULATION; CELL; AGE; AUTOPHAGY; MECHANISMS; PERIOD; MOUSE","The aim of the study was to characterize a) the lipofuscin-like pigment (LFP) accumulation (an indicator of ROS production) in the rat heart during early postnatal period and b) possible antioxidative role of selenium. Experimental animals received Na(2)SeO(3) in drinking water during gravidity and up to day 15 post partum. Two fluorophores of LFP in the hearts of 1-, 4-, 7- and 15-day-old rats were evaluated by fluorescent analysis. The highest level of heart/body weight ratio in control rats was observed on day 4, in the Se-supplemented rats on day 7. Cardiac LFP content in controls increased from postnatal day 4, in the hearts of Se-supplemented rats the LFP content increased already from day 1. As compared with the Se-supplemented group the LFP content of control hearts was significantly higher on day 1 but significantly lower on day 4. LFP concentration in control hearts decreased from postnatal day 1 to 4; this decrease was followed by significant increase until day 7 and decrease to day 15. LFP concentration in the Se-supplemented hearts was the highest on postnatal day 7; it differed from controls on day 1 and 4. Significant changes of LFP suggest an important role of ROS during critical ontogenetic period.","[Ostadalova, I.] Acad Sci Czech Republic, Inst Physiol, Dept Dev Cardiol, CR-14220 Prague 4, Czech Republic; [Ostadalova, I.; Charvatova, Z.; Wilhelm, J.] Ctr Expt Cardiovasc Res, Prague, Czech Republic; [Wilhelm, J.] Charles Univ Prague, Fac Med 2, Dept Med Chem & Biochem, Prague, Czech Republic","Ostadalova, I (reprint author), Acad Sci Czech Republic, Inst Physiol, Dept Dev Cardiol, Videnska 1083, CR-14220 Prague 4, Czech Republic.","iostadal@biomed.cas.cz","Wilhelm, Jiri/C-6252-2012",null,"MSMT [1M0510]; AVOZ [501 10509]","This study was supported by grant of MSMT 1M0510, and grant AVOZ 501 10509.",null,30,4,4,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,6,null,null,null,null,881,886,null,null,null,6,"Physiology","Physiology","700CW","WOS:000285711400005"]
[null,null,null,null,"J","Filova, E; Burdikova, Z; Rampichova, M; Bianchini, P; Capek, M; Kostakova, E; Amler, E; Kubinova, L",null,null,null,"Filova, Eva; Burdikova, Zuzana; Rampichova, Michala; Bianchini, Paolo; Capek, Martin; Kostakova, Eva; Amler, Evzen; Kubinova, Lucie",null,null,"Analysis and three-dimensional visualization of collagen in artificial scaffolds using nonlinear microscopy techniques","JOURNAL OF BIOMEDICAL OPTICS",null,null,"English","Article",null,null,null,null,null,"second-harmonic generation imaging; multiphoton microscopy; tissue engineering; artificial scaffolds; collagen","2ND-HARMONIC GENERATION; ARTICULAR-CARTILAGE; BIOLOGICAL TISSUES; IN-VIVO; FLUORESCENCE; MATRIX; REPAIR; CELLS; TRANSPLANTATION; RECONSTRUCTION","Extracellularly distributed collagen and chondrocytes seeded in gelatine and poly-epsilon-caprolactone scaffolds are visualized by two-photon excitation microscopy (TPEM) and second-harmonic generation (SHG) imaging in both forward and backward nondescanned modes. Joint application of TPEM and SHG imaging in combination with stereological measurements of collagen enables us not only to take high-resolution 3-D images, but also to quantitatively analyze the collagen volume and a spatial arrangement of cell-collagen-scaffold systems, which was previously impossible. This novel approach represents a powerful tool for the analysis of collagen-containing scaffolds with applications in cartilage tissue engineering. (C) 2010 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3509112]","[Kubinova, Lucie] Acad Sci Czech Republic, Inst Physiol, Dept Biomath, Vvi, CR-14220 Prague, Czech Republic; [Filova, Eva; Rampichova, Michala; Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic; [Rampichova, Michala; Amler, Evzen] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague 15006 5, Czech Republic; [Bianchini, Paolo] Italian Inst Technol Nanophys, I-16163 Genoa, Italy; [Capek, Martin] Czech Tech Univ, Fac Biomed Engn, Kladno 27201, Czech Republic; [Kostakova, Eva] Tech Univ, Fac Text Engn, Liberec 46117, Czech Republic","Kubinova, L (reprint author), Acad Sci Czech Republic, Inst Physiol, Dept Biomath, Vvi, Videnska 1083, CR-14220 Prague, Czech Republic.","kubinova@biomed.cas.cz","Kubinova, Lucie/B-6803-2012; Capek, Martin/B-7845-2012; Bianchini, Paolo/A-9500-2008","Bianchini, Paolo/0000-0001-6457-751X","Academy of Sciences of the Czech Republic [AV0Z50110509, AV0Z50390512, AV0Z50390703]; Ministry of Education, Youth and Sports of the Czech Republic [LC06063, MSM6840770012, NPV II 2B06130, 1M0510]; Czech Science Foundation [GA102/08/0691, GA202/09/1151, GAP304/10/1307]; EU [214539, 7E09088]; Grant Agency of the Academy of Sciences [IAA500390702]","The presented study was supported by the Academy of Sciences of the Czech Republic (research projects No. AV0Z50110509, AV0Z50390512, and AV0Z50390703), the Ministry of Education, Youth and Sports of the Czech Republic (research programs LC06063, MSM6840770012, NPV II 2B06130, and 1M0510), the Czech Science Foundation (Nos. GA102/08/0691, GA202/09/1151, and GAP304/10/1307), the EU project BIOSCENT (ID number 214539, and 7E09088), and the Grant Agency of the Academy of Sciences No. IAA500390702.",null,26,3,3,"SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS","BELLINGHAM","1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA","1083-3668",null,null,"J BIOMED OPT","J. Biomed. Opt.","NOV-DEC",2010,15,6,null,null,null,null,null,null,66011,"10.1117/1.3509112",null,7,"Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging","Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging","719AI","WOS:000287171100044"]
[null,null,null,null,"J","Rossnerova, A; Balascak, I; Rossner, P; Sram, RJ",null,null,null,"Rossnerova, A.; Balascak, I.; Rossner, P., Jr.; Sram, R. J.",null,null,"Frequency of chromosomal aberrations in Prague mothers and their newborns","MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS",null,null,"English","Article",null,null,null,null,null,"Carcinogenic polycyclic aromatic hydrocarbons; Chromosomal aberrations; Fluorescence in situ hybridization; Mothers; Newborns","POLYCYCLIC AROMATIC-HYDROCARBONS; IN-SITU HYBRIDIZATION; CYTOGENETIC ANALYSIS; ENVIRONMENTAL EXPOSURE; PERIPHERAL LYMPHOCYTES; AIR-POLLUTION; CANCER-RISK; AMBIENT AIR; LIFE-STYLE; FISH","The capital city of Prague is one of the most polluted areas of the Czech Republic. The impact of air pollution on the level of chromosomal aberrations was systematically studied: analyses were performed using fluorescence in situ hybridization (FISH) with whole-chromosome painting for chromosomes #1 and #4. In the present study, we analyzed the levels of stable (one-way and two-way translocations) and unstable (acentric fragments) chromosomal aberrations in 42 mothers living in Prague and in their newborns. The average age of the mothers was 29 years (range, 20-40 years). Blood samples were collected from October 2007 to February 2008. The average levels of carcinogenic polycyclic aromatic hydrocarbons (c-PAHs) and benzo[a]pyrene (B[a]P) in respirable particles (PM2.5), as determined by stationary monitoring, were 21.0 +/- 112.3 ng/m(3) and 2.9 +/- 1.8 ng/m(3), respectively. We did not observe any effect of either c-PAH or B[a]P exposure on the genomic frequency of translocations (per 100 cells, F(G)/100) in either group due to their similar exposure during the winter months. The mean values of F(G)/100 representing stable aberrations were 0.09 +/- 0.13 vs 0.80 +/- 0.79 (p < 0.001) for newborns vs mothers, indicating a significant increase of F(G)/100 with age. On the other hand, the frequency of unstable aberrations did not differ between the two groups. Our results demonstrate how the patterns of different types of aberration differed between newborns and mothers: we observed 64.3% unstable aberrations and 35.7% stable aberrations in newborns vs 19.7% and 80.3% in mothers, respectively. Our results indicate that after birth the frequencies of aberrations are very low and that the aberrations are represented mainly by acentric fragments. The changes observed in mothers show a shift to stable aberrations represented mainly by two-way translocations. The mother's age affected the level of aberrations in newborns: the group of children born to older mothers (31-40 years) had significantly increased F(G)/100 levels. (C) 2010 Elsevier B.V. All rights reserved.","[Rossnerova, A.; Rossner, P., Jr.; Sram, R. J.] AS CR, Lab Genet Ecotoxicol, Inst Expt Med, VVI, Prague 14220 4, Czech Republic; [Balascak, I.] Charles Univ Prague, Fac Med 2, Prague 5, Czech Republic","Sram, RJ (reprint author), AS CR, Lab Genet Ecotoxicol, Inst Expt Med, VVI, Videnska 1083, Prague 14220 4, Czech Republic.","sram@biomed.cas.cz",null,null,"Ministry of Education of the Czech Republic [2B06088]; Academy of Sciences of the Czech Republic [AVOZ50390512]","We would like to thank the gynecological staff of the University Hospital in Prague-Motol for the collection of samples, Ms. Irena Chvatalova for technical assistance during the collection and processing of samples and Mr. James Dutt for language editing. The Ministry of Education of the Czech Republic (2B06088) and the Academy of Sciences of the Czech Republic (AVOZ50390512) are gratefully acknowledged for their financial support.",null,30,3,3,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1383-5718",null,null,"MUTAT RES-GEN TOX EN","Mutat. Res. Genet. Toxicol. Environ. Mutagen.","JUN 17",2010,699,41671,null,null,null,null,29,34,null,"10.1016/j.mrgentox.2010.04.015",null,6,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","620VL","WOS:000279528700006"]
[null,null,null,null,"J","Hess, L; Votava, M; Schreiberova, J; Malek, J; Horacek, M",null,null,null,"Hess, L.; Votava, M.; Schreiberova, J.; Malek, J.; Horacek, M.",null,null,"Experience with a naphthylmedetomidine - ketamine - hyaluronidase combination in inducing immobilization in anthropoid apes","JOURNAL OF MEDICAL PRIMATOLOGY",null,null,"English","Article",null,null,null,null,null,"chimpanzee; immobilization; medetomidine; naphthylmedetomidine; orangutan","ALPHA-2-ADRENOCEPTOR AGONIST NAPHTHYLMEDETOMIDINE; MEDETOMIDINE ANALOGS; ALPHA(2)-ADRENOCEPTORS; DEXMEDETOMIDINE; BEHAVIOR; MICE","Background The aim of the study was to compare the effect of naphthylmedetomidine to medetomidine on the behavior of orangutans and chimpanzees. Methods The immobilization was performed as part of a medical examination in five chimpanzees and three orangutans. Following pre-medication with midazolam (0.70-1.20 mg/kg p.o.), naphthylmedetomidine (50-70 mu g/kg), or medetomidine (20-30 mu g/kg) was given with ketamine (3 mg/kg) and hyaluronidase (150 M.U.) into musculus deltoideus. Results We observed the distinct anti-aggressive effect of naphthylmedetomidine. The immobilization with naphthylmedetomidine was shallower and the influence on cardiac frequency less substantial compared to medetomidine. The overall sedative effect of naphthylmedetomidine lasted for less time, and its effect was incompletely antagonized with atipamezole in comparison to medetomidine. Conclusions Naphthylmedetomidine could replace medetomidine for inducing immobilization and sedation. A combination of naphthylmedetomidine-ketamine is suitable for relocating animals to other cages or for painless medical examinations.","[Votava, M.] Charles Univ Prague, Fac Med 3, Dept Pharmacol, Prague 10034 10, Czech Republic; [Hess, L.] Inst Clin & Expt Med, Lab Expt Anaesthesiol, Prague, Czech Republic; [Schreiberova, J.] Univ Prague, Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; [Schreiberova, J.] Univ Prague, Fac Med, Dept Anaesthesiol & Intens Care Med Charles, Hradec Kralove, Czech Republic; [Malek, J.] Charles Univ Prague, Fac Med 3, Dept Anaesthesiol & Crit Care Med, Prague, Czech Republic; [Horacek, M.] Charles Univ Prague, Fac Med 2, Dept Anaesthesiol & Intens Care Med, Prague, Czech Republic","Votava, M (reprint author), Charles Univ Prague, Fac Med 3, Dept Pharmacol, Ruska 87, Prague 10034 10, Czech Republic.","martin.votava@lf3.cuni.cz",null,null,"Czech Ministry of Health [IGA NR/9168]","This work was supported by a grant (IGA NR/9168) from the Czech Ministry of Health. Next, we thank the Faculty of Pharmacy University of Helsinki for the provision of naphthylmedetomidine for experimental purposes.",null,13,3,3,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0047-2565",null,null,"J MED PRIMATOL","J. Med. Primatol.","JUN",2010,39,3,null,null,null,null,151,159,null,"10.1111/j.1600-0684.2010.00404.x",null,9,"Veterinary Sciences; Zoology","Veterinary Sciences; Zoology","592XS","WOS:000277415800003"]
[null,null,null,null,"J","Lotti, T; Hercogova, J; Prignano, F",null,null,null,"Lotti, Torello; Hercogova, Jana; Prignano, Francesca",null,null,"The concept of psoriatic disease: Can cutaneous psoriasis any longer be separated by the systemic comorbidities?","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"Psoriasis; comorbidities; psoriatic arthritis; cardiovascular disease; metabolic syndrome; inflammatory bowel disease; depression","RISK; ASSOCIATION; LYMPHOMA; WEIGHT","Psoriasis is a general inflammatory status in which the skin is usually visibly involved. Recent papers show that several comorbidities, including psoriatic arthritis, metabolic syndrome, cancer, osteoporosis, cardiovascular disease, chronic inflammatory bowel disease etc., are significantly associated with psoriasis. Detecting association between psoriasis and comorbidities, properly evaluate confounders and make a correct distinction among absolute risk, relative risk and clinical relevance is mandatory, before embracing the fact the psoriasis is, in fact, a complex and common international disease.","[Lotti, Torello] Univ Florence, Sch Med, Dept Dermatol Sci, I-50129 Florence, Italy; [Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatol, Prague, Czech Republic","Lotti, T (reprint author), Univ Florence, Sch Med, Dept Dermatol Sci, Via Lorenzo 2 Magnif 104, I-50129 Florence, Italy.","tlotti@unifi.it",null,null,null,null,null,16,3,3,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","MAR-APR",2010,23,2,null,null,null,null,119,122,null,null,null,4,"Dermatology","Dermatology","574RT","WOS:000276011200004"]
[null,null,null,null,"J","Zitka, O; Krizkova, S; Adam, V; Horna, A; Kukacka, J; Prusa, R; Zizkova, V; Kizek, R",null,null,null,"Zitka, Ondrej; Krizkova, Sona; Adam, Vojtech; Horna, Ales; Kukacka, Jiri; Prusa, Richard; Zizkova, Vera; Kizek, Rene",null,null,"Utilizing Automated Chip Electrophoresis for Study of Lactoferrin and Matrix Metalloproteinases","CHEMICKE LISTY",null,null,"Czech","Article",null,null,null,null,null,null,"CAPILLARY-ELECTROPHORESIS; PROTEINS; IDENTIFICATION; MICROCHIP; QUALITY; SYSTEM; VARIETY","Automated chip capillary electrophoresis was used in detection and isolation of lactoferrin and a human matrix metalloproteinase (MMP-9) as well as in investigation of interactions and cleavage of collagen with MMP-9. The method is a sensitive and simple technique superior to SDS-PAGE. It is useful in proteomic research.","[Zitka, Ondrej] Masaryk Univ, Ustav Biochem, Prirodovedecka Fak, CS-61137 Brno, Czech Republic; [Adam, Vojtech] Mendelova Univ Brne, Ustav Vyzivy Zvirat & Picninarstvi, Agron Fak, Brno 61300, Czech Republic; [Zitka, Ondrej; Krizkova, Sona; Adam, Vojtech; Kizek, Rene] Mendelova Univ Brne, Ustav Chem & Biochem, Agron Fak, Brno 61300, Czech Republic; [Horna, Ales] Univ Tomase Bati Zline, Univ Inst, Zlin 76272, Czech Republic; [Horna, Ales] Radanal SRO, Pardubice 53003, Czech Republic; [Kukacka, Jiri; Prusa, Richard] Charles Univ Prague, Ustav Klin Biochem & Patobiochem, Lekarska Fak 2, Prague 15006 5, Czech Republic; [Zizkova, Vera] Vyzkumny Ustav Pletarsky, Brno 60200, Czech Republic","Zitka, O (reprint author), Masaryk Univ, Ustav Biochem, Prirodovedecka Fak, Kotlarska 2, CS-61137 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Zitka, Ondrej/E-1107-2012; Krizkova, Sona/E-9617-2012; Horna, Ales/H-6388-2012; Kukacka, Jiri/C-4770-2013",null,null,null,null,24,3,3,"CHEMICKE LISTY","PRAGUE 6","NOVOTNEHO LAVKA 5, PRAGUE 6 116 68, CZECH REPUBLIC","0009-2770",null,null,"CHEM LISTY","Chem. Listy",null,2010,104,3,null,null,null,null,197,201,null,null,null,5,"Chemistry, Multidisciplinary","Chemistry","581SZ","WOS:000276546100010"]
[null,null,null,null,"J","Pitha, J; Hubacek, JA; Pithova, P",null,null,null,"Pitha, J.; Hubacek, J. A.; Pithova, P.",null,null,"The Connexin 37 (1019C > T) Gene Polymorphism Is Associated With Subclinical Atherosclerosis in Women With Type 1 and 2 Diabetes and in Women With Central Obesity","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Connexin 37 gene; Atherosclerosis; Ankle brachial index-women; Diabetes mellitus; Central obesity","CORONARY-ARTERY-DISEASE; RISK","The gene for connexin 37 (Cx37) is considered to be one of the candidate genes for cardiovascular disease. We evaluated the association between Cx37 (1019C>T) gene polymorphism (Pro319Ser) and ankle brachial blood pressure index (ABI) in women with type 1 (n=178) and type 2 (n=111) diabetes, and in women from general population (n=862). All women were genotyped for Cx37 polymorphism. In addition to traditional cardiovascular risk factors, ABI was analyzed. In women with type 1 diabetes, ABI significantly decreased from TT to CC carriers (p for trend=0.008). A similar trend was seen in women with type 2 diabetes (p=0.050) and in women with waist circumference above 75(th) percentile (94 cm; n=208) of the general population (p=0.049). The gene for Cx37 was associated with subclinical atherosclerosis in women with type 1 and 2 diabetes and in women with advanced central obesity. The presence of C allele indicated increased risk.","[Pitha, J.] Inst Clin & Expt Med, Lab Atherosclerosis Res, Prague 14021 4, Czech Republic; [Pithova, P.] Teaching Hosp Motol, Sch Med 2, Dept Med, Prague, Czech Republic","Pitha, J (reprint author), Inst Clin & Expt Med, Lab Atherosclerosis Res, Videnska 1952-8, Prague 14021 4, Czech Republic.","japi@medicon.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NR/9026-4/2006]","Supported by grant NR/9026-4/2006 (Internal Grant Agency of the Ministry of Health of the Czech Republic).",null,13,1,3,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,6,null,null,null,null,1029,1032,null,null,null,4,"Physiology","Physiology","700CW","WOS:000285711400021"]
[null,null,null,null,"J","Bartakova, LV; Fila, L; Adamek, S; Pozniak, J; Maly, M; Burkert, J; Simonek, J; Lischke, R",null,null,null,"Bartakova, L. V.; Fila, L.; Adamek, S.; Pozniak, J.; Maly, M.; Burkert, J.; Simonek, J.; Lischke, R.",null,null,"Lung Transplantation in Cystic Fibrosis Patients in the Czech Republic: Initial Single-Center Experience","TRANSPLANTATION PROCEEDINGS",null,null,"English","Article",null,null,null,null,null,null,"BURKHOLDERIA-CEPACIA COMPLEX; INTERNATIONAL-SOCIETY; SURVIVAL; INFECTION; HEART","Background. Lung transplantation is a well established treatment for advanced lung diseases. Methods. We compared the clinical results of patients with cystic fibrosis (CF) entered into the waiting list with those of patients after lung transplantation. Results. Among 36 patients with CF on the waiting list, 23 underwent lung transplantation, 8 died, 3 are still on the waiting list, and 2 were excluded from the waiting list. The median waiting list time of 0.48 years (range, 0.03-2.37) was insignificantly longer for patients who died compared with transplanted patients (0.97 vs 0.44 years). Mortality of waiting-list patients was 25.8%. The median survival of transplant patients of 7.48 years (range 0.00-10.85 years) was significantly lower among patients who were colonized (BCC) versus those who were not Burkholderia cepacia complex (0.19 vs 7.48 years; P = .041). The 1-, 3-, and 5-year patient survivals after lung transplantation were 72.9, 54.4, and 54.4, respectively. Conclusion. The results of patients with cystic fibrosis on the waiting list versus after lung transplantation in our center were similar to those reported in the literature. We confirmed a less favorable prognosis of BCC-colonized patients.","[Lischke, R.] Univ Hosp Motol, Thorac & Lung Transplantat Div, Transplantat Ctr, Prague, Czech Republic; [Bartakova, L. V.; Fila, L.] Charles Univ Prague, Sch Med 2, Dept Pulmonol, Prague, Czech Republic; [Burkert, J.] Charles Univ Prague, Sch Med 2, Dept Cardiac Surg, Prague, Czech Republic; [Adamek, S.; Pozniak, J.; Simonek, J.; Lischke, R.] Charles Univ Prague, Sch Med 1, Dept Surg 3, Thorac & Lung Transplantat Div, Prague, Czech Republic; [Maly, M.] Natl Inst Publ Hlth, Dept Biostat & Informat, Prague, Czech Republic","Lischke, R (reprint author), Univ Hosp Motol, Thorac & Lung Transplantat Div, Transplantat Ctr, V Uvalu 85, Prague, Czech Republic.",null,null,null,"VZ grant [00000064203]","Supported by VZ grant no. 00000064203.",null,17,2,2,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0041-1345",null,null,"TRANSPL P","Transplant. Proc.","NOV",2010,42,9,null,null,null,null,3711,3713,null,"10.1016/j.transproceed.2010.09.007",null,3,"Immunology; Surgery; Transplantation","Immunology; Surgery; Transplantation","689ZO","WOS:000284969800067"]
[null,null,null,null,"J","Melichercik, P; Jahoda, D; Bartak, V; Klapkova, E; Nyc, O; Pokorny, D",null,null,null,"Melichercik, P.; Jahoda, D.; Bartak, V.; Klapkova, E.; Nyc, O.; Pokorny, D.",null,null,"In Vitro Assessment of Vancomycin Released from Bone Grafts","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"osteomyelitis; vancomycin; bone grafts; local carriers of antibiotics; VRSA; MRSA","RESISTANT STAPHYLOCOCCUS-AUREUS; LATE HEMATOGENOUS INFECTION; CANCELLOUS BONE; PROSTHETIC JOINT; REVISION; HIP; ALLOGRAFTS; ANTIBIOTICS; OSTEOMYELITIS; COMPLICATIONS","PURPOSE OF THE STUDY Infections of the musculoskeletal system present a serious problem in orthopaedic and trauma medicine because, typically, they are often recurrent and associated with the development of resistance to antibiotics. The aim of this study was to ascertain whether the local concentration of vancomycin released from cancellous bone grafts exceeded the minimum inhibitory concentration (MIC) for vancomycin-resistant Staphylococcus aureus (VRSA >= 16 mg/L) during a 16-day in vitro experiment. MATERIAL AND METHODS Morselised grafts of spongy bone were selected as ideal local carriers of antibiotic. They were impregnated with vancomycin (Edicin (R)). Its concentration was assessed by Agilent 1200 high performance liquid chromatography coupled with a diode array detector (Agilent Technologies, USA). Morselised bone was impregnated with vancomycin at 0.1 g antibiotic per 10 g bone, and 20 samples each weighing 1 g were prepared. They were placed in test tubes with phosphate buffer at pH = 7.4 and maintained in a thermostat at 37 degrees C. During the 16-day period, buffer samples were taken at intervals and examined for vancomycin concentration by the above-described method. RESULTS During the whole experimental period, the level of released vancomycin was high above the MIC for VRSA. The maximum average concentration was obtained between day 2 and day 4 and it reached 507.68 mg/L. At this interval the vancomycin level was stable, because there was no significant difference (p > .0.005) between the values of the 2nd and the 4th day. Then a gradual decrease in antibiotic levels was detected, with an average concentration of 332.29 mg/L recorded at 16 days. DISCUSSION Recently, the occurrence of methicilin-resistant Staphylococcus aureus (MRSA) infections has been increasing as well as the risk of VRSA infections, and therefore our experiment was set up to assess the releasing properties of bone grafts impregnated with vancomycin The levels of released vancomycin were much higher than the MIC for VRSA for the whole period of measurement. This finding is different from the results of an in vitro study by Witso et al., in which the vancomycin level dropped below the MIC after 2 weeks. The decrease in vancomycin levels following its maximum values was greater than it had been expected although the samples were diluted only minimally. There are several explanations for this finding. However, from the clinical point of view it is important that, for a sufficiently long period, vancomycin is maintained at a level exceeding the MIC for VRSA. CONCLUSIONS In an in vitro experiment under conditions simulating a human internal environment, the elution of antibiotic from vancomycin-impregnated cancellous bone grafts was investigated. The local vancomycin concentrations much exceeded the MIC for VRSA for more than 2 weeks. The highest levels, i.e. the total vancomycin amount, were recorded at 2 to 4 days after carrier application. Based on the experimental results, vancomycin-loaded bone grafts can be recommended for local treatment of the musculoskeletal system infected with antibiotic-sensitive staphylococci, MRSA strains or possibly also for VRSA infections.","[Melichercik, P.; Jahoda, D.; Bartak, V.; Pokorny, D.] 1 LF UK FN Motol, Ortoped Klin 1, Prague 15000 5, Czech Republic; [Klapkova, E.] 2 LF UK FN Motol, Ustav Klin Biochem Patobiochem 2, Prague, Czech Republic; [Nyc, O.] 2 LF UK FN Motol, Ustav Lekarske Mikrobiol, Prague, Czech Republic","Melichercik, P (reprint author), 1 LF UK FN Motol, Ortoped Klin 1, V Uvalu 84, Prague 15000 5, Czech Republic.","pmeliche@seznam.cz",null,null,null,null,null,30,1,1,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","OCT",2010,77,5,null,null,null,null,411,415,null,null,null,5,"Orthopedics","Orthopedics","673PT","WOS:000283676100008"]
[null,null,null,null,"J","Lizcova, L; Zemanova, Z; Malinova, E; Jarosova, M; Mejstrikova, E; Smisek, P; Pospisilova, D; Stary, J; Michalova, K",null,null,null,"Lizcova, Libuse; Zemanova, Zuzana; Malinova, Eva; Jarosova, Marie; Mejstrikova, Ester; Smisek, Petr; Pospisilova, Dagmar; Stary, Jan; Michalova, Kyra",null,null,"A novel recurrent chromosomal aberration involving chromosome 7 in childhood myelodysplastic syndrome","CANCER GENETICS AND CYTOGENETICS",null,null,"English","Article",null,null,null,null,null,null,"IN-SITU HYBRIDIZATION; MYELOID DISORDERS; MONOSOMY-7; LEUKEMIA; CHILDREN; ADOLESCENTS; DELETION","Monosomy 7 and/or deletion of the long arm of chromosome 7 is a common cytogenetic aberration in children with myelodysplastic syndrome (MDS) and is associated with poor outcome. In this report, we present an unusual cytogenetic abnormality leading to loss of both the whole short and whole long arms of chromosome 7, which was found in the bone marrow cells of three pediatric patients with MDS. Using a combination of conventional and molecular cytogenetic methods, a tiny \"dot-like\" marker chromosome was found and described as der(7)del(7)(p11)del(7)(q11). Together with one previously published case, this chromosomal aberration represents a new rare recurrent karyotypic abnormality involving chromosome 7 in children with MDS. (C) 2010 Elsevier Inc. All rights reserved.","[Lizcova, Libuse; Zemanova, Zuzana; Malinova, Eva; Michalova, Kyra] Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Gen Univ Hosp, Prague 12808, Czech Republic; [Lizcova, Libuse; Zemanova, Zuzana; Malinova, Eva; Michalova, Kyra] Charles Univ Prague, Fac Med 1, Prague 12808, Czech Republic; [Jarosova, Marie] Univ Hosp, Dept Hematooncol, Olomouc 77900, Czech Republic; [Jarosova, Marie; Pospisilova, Dagmar] Palacky Univ, Olomouc 77900, Czech Republic; [Mejstrikova, Ester; Smisek, Petr; Stary, Jan] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague 15006, Czech Republic; [Mejstrikova, Ester; Smisek, Petr; Stary, Jan] Univ Hosp Motol, Prague 15006, Czech Republic; [Pospisilova, Dagmar] Univ Hosp, Dept Paediat, Olomouc 77900, Czech Republic","Lizcova, L (reprint author), Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Gen Univ Hosp, U Nemocnice 2, Prague 12808, Czech Republic.","libuse.lizcova@vfn.cz",null,null,"Czech Ministry of Education [MSM 21620813, MSM LC535]; Czech Ministry of Health [MZOVFN2005]","This work was supported by grants from Czech Ministry of Education MSM 21620813, MSM LC535, and Czech Ministry of Health MZOVFN2005.",null,12,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,null,"CANCER GENET CYTOGEN","Cancer Genet. Cytogenet.","AUG",2010,201,1,null,null,null,null,52,56,null,"10.1016/j.cancergencyto.2010.05.004",null,5,"Oncology; Genetics & Heredity","Oncology; Genetics & Heredity","632JR","WOS:000280420000010"]
[null,null,null,null,"J","Nesnidal, P; Stulik, J; Sebesta, P",null,null,null,"Nesnidal, P.; Stulik, J.; Sebesta, P.",null,null,"Pulmonary Polymethylmetacrylate Embolism: A Rare Complication of Percutaneous Vertebroplasty","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"complications; polymethylmetacrylate; pulmonary embolism; vertebroplasty","ACRYLIC CEMENT; POLYMETHYLMETHACRYLATE; EMBOLIZATION; KYPHOPLASTY; FRACTURES; LEAKAGE","Percutaneous vertebroplasty is a minimally invasive surgical technique involving transpedicular injection of polymethylmetacrylate into the vertebral body. The aim of this procedure is to enhance the mechanical strength of a pathologically changed vertebra. Currently, the method is most often used for painful osteoporotic vertebral fractures, aggressive haemangiomas, necrotic lesions and spinal tumours, particularly the metastatic ones. Although this method is less invasive, relatively straight-forward and effective, there may be complications. The authors present the case of a 70-year-old woman who, on the second day after surgery, developed a rare symptomatic pulmonary polymethylmetacrylate embolism after percutaneous vertebroplasty performed for osteoporotic fractures of the lumbar spine.","[Nesnidal, P.; Stulik, J.; Sebesta, P.] Spondylochirurg Oddeleni FN Motol, Prague 15006 5, Czech Republic; [Stulik, J.; Sebesta, P.] 3 Chirurg Klinika 1 LF UK, Prague, Czech Republic; [Stulik, J.; Sebesta, P.] FN Motol, Prague, Czech Republic; [Stulik, J.] Ortoped Klin Deti & Dospelych 2 LF UK, Prague, Czech Republic","Nesnidal, P (reprint author), Spondylochirurg Oddeleni FN Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","pnesnidal@centrum.cz",null,null,null,null,null,17,1,1,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","AUG",2010,77,4,null,null,null,null,337,340,null,null,null,4,"Orthopedics","Orthopedics","646JE","WOS:000281535100012"]
[null,null,null,null,"J","Pacova, H; Astl, J; Martinek, J",null,null,null,"Pacova, Hana; Astl, Jaromir; Martinek, Jindrich",null,null,"The incidence of beta-defensin-1, 2, 3 in human healthy and chronically inflamed nasal and tonsillar mucosa","JOURNAL OF APPLIED BIOMEDICINE",null,null,"English","Article",null,null,null,null,null,"beta-defensins; nasal mucosa; palatine tonsil; chronic inflammation","HUMAN BETA-DEFENSINS; STAPHYLOCOCCUS-AUREUS; PEPTIDES; EXPRESSION; CARRIAGE","The nasal and tonsillar mucosa are exposed to massive incursions of pathological microorganisms. One of the mechanisms known to prevent an invasion of pathogens is an endogenous synthesis of antimicrobial peptides, which include human beta-defensins-1, 2, 3 (HBD-1, 2, 3). The aim of this study was to demonstrate the occurrence of HBD-1, 2 and 3 in the human nasal mucosa and palatine tonsils in healthy tissues and during chronic inflammation (nasal polyposis with and without the colonization of Staphylococcus aureus and chronic tonsillitis) and to evaluate their incidence under varying conditions. Another target was to compare the occurrence of human beta-defensins in these two different entities; that is, in the nasal mucosa and in the palatine tonsil. It was assumed that the incidence of HBD-1, 2, 3 was lower in tonsils than in nasal mucosa; however, inflamed samples of tonsils and nasal mucosa showed no difference in the production of HBD-1, 2, 3. The presence of all three subfamilies of HBD was significantly lower in nasal polyps with S. aureus positive than in the negative control.","[Pacova, Hana; Martinek, Jindrich] Charles Univ Prague, Fac Med 1, Inst Histol & Embryol, Prague 12801 2, Czech Republic; [Astl, Jaromir] Fac Med 1, Dpt Otorhinolaryngol & Head & Neck Surg, Prague, Czech Republic; [Astl, Jaromir] Teaching Hosp Motol, Prague, Czech Republic","Pacova, H (reprint author), Charles Univ Prague, Fac Med 1, Inst Histol & Embryol, Albertov 4, Prague 12801 2, Czech Republic.","Hpac@seznam.cz",null,null,"IGA Ministry of Health, CR [9077 NR]","This project was supported by Grant project No. 9077 NR, IGA Ministry of Health, CR.",null,11,1,1,"UNIV SOUTH BOHEMIA","CESKA BUDEJOVICE","FAC HEALTH & SOCIAL STUD, JIROVCOVA, CESKA BUDEJOVICE, 370 04, CZECH REPUBLIC","1214-021X",null,null,"J APPL BIOMED","J. Appl. Biomed.","JUN",2010,8,2,null,null,null,null,81,86,null,"10.2478/v10136-009-0012-x",null,6,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","600FT","WOS:000277970800004"]
[null,null,null,null,"J","Vanek, P; Erhart, D; Belsan, T; Hrabal, P; Benes, V",null,null,null,"Vanek, P.; Erhart, D.; Belsan, T.; Hrabal, P.; Benes, V.",null,null,"Surgical Treatment of Neuroepithelial Tumours of the Central Surface of the Sacrum - Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"neurofibroma; ganglioneuroma; presacral tumour; transperitoneal approach; transsacral approach","PRESACRAL TUMORS; SCHWANNOMAS; MANAGEMENT; NEURILEMOMA; DIAGNOSIS","The authors present case reports of the course of therapy for two patients who underwent surgery for extensive neuroepithelial tumours located on the ventral surface of the sacrum. In the first case-report, resection of the tumour with an anterior transperitoneal approach is described, and in the second case report a tumour resection with a posterior trans-sacral approach was referred. The discussion that follows centres around the clinical manifestation of the disease resulting from presacral expansions. Differential diagnosis after detection of the expansion of the sacrum and radiological findings are mentioned. Surgical strategy and treatment after surgery, together with follow-up strategy, are discussed.","[Vanek, P.; Benes, V.] UVN Praha, Neurochirurg Klin LF UK Praze 1, Prague 16902 6, Czech Republic; [Erhart, D.] UVN Praha, Chirurg Klin LF UK Praze 2, Prague 16902 6, Czech Republic; [Belsan, T.] UVN Praha, Radiodiagnosticke Oddeleni, Prague 16902 6, Czech Republic; [Hrabal, P.] UVN Praha, Patologicko Anatomicke Oddeleni, Prague 16902 6, Czech Republic","Vanek, P (reprint author), UVN Praha, Neurochirurg Klin LF UK Praze 1, Vojenske Nemocnice 1200, Prague 16902 6, Czech Republic.","petr.vanek@uvn.cz",null,null,null,null,"ABERNATHEY CD, 1986, J NEUROSURG, V65, P286, DOI 10.3171/jns.1986.65.3.0286; Cerullo G, 2007, WORLD J GASTROENTERO, V13, P2129; Dominguez J, 1997, ACTA NEUROCHIR, V139, P954, DOI 10.1007/BF01411305; FELDENZER JA, 1989, NEUROSURGERY, V25, P884; KLIMO P, 2003, NEUROSURG FOCUS, V15, P12; Patocskai EJ, 2002, CAN J SURG, V45, P141; Popuri R, 2002, EUR RADIOL, V12, P2365, DOI 10.1007/s00330-001-1234-9; Rasmussen TB, 1940, ANN SURG, V111, P513, DOI 10.1097/00000658-194003000-00024; REGAN JF, 1977, AM J SURG, V134, P140, DOI 10.1016/0002-9610(77)90297-5; STEWART RJ, 1986, BRIT J SURG, V73, P153, DOI 10.1002/bjs.1800730227; Strouhal E, 2004, AM J PHYS ANTHROPOL, V125, P320, DOI 10.1002/ajpa.10404; TURNER ML, 1981, JAMA-J AM MED ASSOC, V245, P275, DOI 10.1001/jama.245.3.275; Whittaker LD, 1938, ANN SURG, V107, P96, DOI 10.1097/00000658-193801000-00011; WUISMAN P, 1989, ARCH ORTHOP TRAUM SU, V108, P255, DOI 10.1007/BF00936213",14,1,1,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2010,73,3,null,null,null,null,303,307,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","629UA","WOS:000280224000017"]
[null,null,null,null,"J","Votavova, H; Forsterova, K; Campr, V; Sritesky, J; Velenska, Z; Pytlik, R; Kubackova, K; Prochazka, B; Kodet, R; Spicka, I; Krejcova, H; Trneny, M; Klener, P",null,null,null,"Votavova, H.; Forsterova, K.; Campr, V.; Sritesky, J.; Velenska, Z.; Pytlik, R.; Kubackova, K.; Prochazka, B.; Kodet, R.; Spicka, I.; Krejcova, H.; Trneny, M.; Klener, P.",null,null,"Distinguishing of primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma using real-time quantitative polymerase chain reaction","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"Gene expression; primary mediastinal B-cell lymphoma; diffuse large B-cell lymphoma; formalin fixed; paraffin embedded tissue; real-time quantitative polymerase chain reaction","REL","Primary mediastinal B-cell lymphoma (PMBL) seems to be reliably distinguished from diffuse large B-cell lymphoma (DLBCL) with microarray technology. We measured expression of Fcer2, Pdl2 and Blk genes using real-time quantitative polymerase chain reaction (RTqPCR) on formalin fixed, paraffin embedded material (FFPE) and suggested a formula to discriminate PMBL from DLBCL. For 39/82 included patients the diagnosis of PMBL was expected clinico-pathologically. Diagnosis of 10/39 and 2/43 of clinically considered PMBLs and DLBCLs, respectively, was not genetically confirmed. Compared to confirmed PMBLs, unconfirmed ones showed clinical features similar to DLBCLs, e.g. spleen infiltration (p=0,028) and decreased invasiveness in pericardium (p=0,045). They tended to have more common infradiaphragmatic involvement, less often tumor sclerosis or fluidothorax. There were no immunohistochemical differences between genetically confirmed and unconfirmed PMBLs. New approach of distinguishing PMBL and DLBCL is presented. It is based on expression of three genes in routinely available FFPE material using RTqPCR.","[Votavova, H.; Forsterova, K.; Pytlik, R.; Spicka, I.; Krejcova, H.; Trneny, M.; Klener, P.] Charles Univ Prague, Fac Med 1, Dept Med 1, Dept Clin Haematol, Prague, Czech Republic; [Votavova, H.; Forsterova, K.; Sritesky, J.; Velenska, Z.; Pytlik, R.; Spicka, I.; Krejcova, H.; Trneny, M.; Klener, P.] Gen Teaching Hosp, Prague, Czech Republic; [Campr, V.; Kodet, R.] Charles Univ Prague, Fac Med 2, Teaching Hosp Motol, Dept Pathol & Mol Med, Prague, Czech Republic; [Sritesky, J.; Velenska, Z.] Charles Univ Prague, Fac Med 1, Dept Pathol, Prague, Czech Republic; [Kubackova, K.] Teaching Hosp Motol, Dept Radiat & Oncol, Prague, Czech Republic; [Prochazka, B.] Natl Inst Publ Hlth, Dept Biostat & Informat, Prague, Czech Republic","Votavova, H (reprint author), Charles Univ Prague, Fac Med 1, Dept Med 1, Dept Clin Haematol, Prague, Czech Republic.","tafka@seznam.cz",null,null,"Ministry of Education, Youth and Sports, Czech Republic [MSMT 0021620808]; Ministry of Health, Czech Republic [NS9791-4/2008]","This work was supported by Ministry of Education, Youth and Sports, Czech Republic [Grant MSMT 0021620808] and by Ministry of Health, Czech Republic [Grant NS9791-4/2008].",null,18,0,0,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2010,57,5,null,null,null,null,449,454,null,"10.4149/neo_2010_05_449",null,6,"Oncology","Oncology","674PX","WOS:000283760800009"]
[null,null,null,null,"J","Krizkova, S; Masarik, M; Eckschlager, T; Adam, V; Kizek, R",null,null,null,"Krizkova, Sona; Masarik, Michal; Eckschlager, Tomas; Adam, Vojtech; Kizek, Rene",null,null,"Effects of redox conditions and zinc(II) ions on metallothionein aggregation revealed by chip capillary electrophoresis","JOURNAL OF CHROMATOGRAPHY A",null,null,"English","Article; Proceedings Paper","25th International Symposium on Microscale BioSeparations (MSB 2010)","MAR 21-25, 2010","Prague, CZECH REPUBLIC",null,null,"Metallothionein; Chip capillary electrophoresis; Zinc; Redox conditions; Aggregation","PLASMA-MASS SPECTROMETRY; CE-ICP-MS; ZONE-ELECTROPHORESIS; METAL-BINDING; HYPHENATED TECHNIQUES; ISOFORMS; LIVER; PROTEINS; CADMIUM; POLYMERIZATION","Metallothioneins (MTs) belong to cysteine-rich proteins with unique higher structure. One of the most known MT's functions is metals detoxification and maintaining their homeostasis in a cell. Structure of MT with naturally occurred zinc(II) ions can be affected by concentration of metal ions as well as redox milieu inside a cell, however the exact explanation and biochemical effects of the structural changes are still missing. In this study we used capillary electrophoresis on chip coupled with fluorescence detection to determine structural changes of MT with increasing concentration of zinc(II) ions and under various redox conditions. To investigate the structural-dependent effects, reduced and/or oxidized apo-MT (MT without natural occurred metal ion) was prepared. Zinc binding into reduced and/or oxidized apo-MT was compared. MT was incubated with 0, 5, 15, 25, 50 and 100 mu M ZnCl(2) for 1 h in 37 degrees C. Formation of MT aggregates with increasing zinc concentration was observed by spectrophotometry, chip capillary electrophoresis, and SDS-PAGE. We found out that reduced MT forms aggregates more readily compared to oxidized MT. Using the chip capillary electrophoresis allowed us relative quantification of MT aggregation as a decrease in the area of the signal corresponding to the monomer form of MT (Mw 15 kDa, migration time 26.5 s) and its ratio to total signal (sum of all signals measured by the electrophoresis). The dependences had an exponential character with equation y = 2.4 x e(-001x), R(2) = 0.945 for 15 kDa peak area and y = 0.11 X e(-0.01x), R(2) = 0.938 for decrease of 15 kDa peak area ratio to the total signal. Zn-MT interaction was 30% faster during the first 15 min and 50% faster during the whole experiment for reduced MT. It can be concluded that formation of MT aggregates is dependent on redox state and Zn(II) concentration. (C) 2010 Elsevier B.V. All rights reserved.","[Krizkova, Sona; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Masarik, Michal] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-62500 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Krizkova, Sona/E-9617-2012",null,null,null,null,58,16,16,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0021-9673",null,null,"J CHROMATOGR A","J. Chromatogr. A","DEC 17",2010,1217,51,null,null,null,null,7966,7971,null,"10.1016/j.chroma.2010.07.022",null,6,"Biochemical Research Methods; Chemistry, Analytical","Biochemistry & Molecular Biology; Chemistry","696GK","WOS:000285429700006"]
[null,null,null,null,"J","Reekie, J; Mocroft, A; Ledergerber, B; Beniowski, M; Clotet, B; van Lunzen, J; Chiesi, A; Pradier, C; Machala, L; Lundgren, JD",null,null,null,"Reekie, J.; Mocroft, A.; Ledergerber, B.; Beniowski, M.; Clotet, B.; van Lunzen, J.; Chiesi, A.; Pradier, C.; Machala, L.; Lundgren, J. D.",null,"EuroSIDA Study Grp","History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change*","HIV MEDICINE",null,null,"English","Article",null,null,null,null,null,"virological failure; antiretroviral therapy; virological suppression; viral rebound","HIV-INFECTED PATIENTS; CLINICAL PROGRESSION; REBOUND RATES; CELL COUNT; ADHERENCE; SUCCESS; VIREMIA; NONADHERENCE; COPIES/ML; EUROSIDA","Objectives HIV-infected persons experience different patterns of viral suppression after initiating combination antiretroviral therapy (cART). The relationship between such differences and risk of virological failure after starting a new antiretroviral could help with patient monitoring strategies. Methods A total of 1827 patients on cART starting at least one new antiretroviral from 1 January 2000 while maintaining a suppressed viral load were included in the analysis. Poisson regression analysis identified factors predictive of virological failure after baseline in addition to traditional demographic variables. Baseline was defined as the date of starting new antiretrovirals. Results Four hundred and fifty-one patients (24.7%) experienced virological failure, with an incidence rate (IR) of 7.3 per 100 person-years of follow-up (PYFU) [95% confidence interval (CI) 6.7-8.0]. After adjustment, patients who had rebounded in the year prior to baseline had a 2.4-times higher rate of virological failure after baseline (95% CI 1.77-3.26; P <.0001), while there was no increased incidence in patients whose last viral rebound was > 3 years prior to baseline [Incidence rate ratio (IRR) 1.06; 95% CI 0.75-1.50; P=0.73] compared with patients who had never virally rebounded. Patients had an 86% (95% CI 1.36-2.55; P <.0001), 53% (95% CI 1.06-2.04; P=0.02) and 5% (95% CI 0.80-1.38; P=0.72) higher virological failure rate after baseline if they were virally suppressed < 50%, 50-70% and 70-90% of the time they were on cART prior to baseline, respectively, compared with those virally suppressed > 90% of the time. Discussion Intensive monitoring after a treatment switch is required in patients who have rebounded recently or have a low percentage of time suppressed while on cART. Consideration should be given to increasing the provision of adherence counselling.","[Reekie, J.] UCL, Sch Med, HIV Epidemiol Biostat Grp, Res Dept Infect & Populat Hlth,Div Populat Hlth, London NW3 2PF, England; [Ledergerber, B.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Beniowski, M.] Specialist Hosp, Dept AIDS Diagnost & Therapy, Chorzow, Poland; [Clotet, B.] Hosp Badalona Germans Trias & Pujol, Badalona, Spain; [van Lunzen, J.] Univ Med Ctr Hamburg Eppendorf, Infect Dis Unit, Hamburg, Germany; [Chiesi, A.] Ist Super Sanita, I-00161 Rome, Italy; [Pradier, C.] Hop Archet, Nice, France; [Machala, L.] Charles Univ Prague, Fac Med 3, Dept Infect Dis, Prague, Czech Republic; [Lundgren, J. D.] Univ Copenhagen, Panum Inst, Copenhagen HIV Programme, DK-2200 Copenhagen, Denmark; [Lundgren, J. D.] Rigshosp, Ctr Viral Dis, DK-2100 Copenhagen, Denmark; [Machala, L.] Charles Univ Prague, Fac Med 2, Dept Infect Dis 1, Prague, Czech Republic","Reekie, J (reprint author), UCL, Sch Med, HIV Epidemiol Biostat Grp, Res Dept Infect & Populat Hlth,Div Populat Hlth, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.","j.reekie@pcps.ucl.ac.uk","Phillips, Andrew/B-4427-2008; Mocroft, Amanda/G-8748-2011; SHCS, int. coll. A/G-4083-2011; Ledergerber, Bruno/B-5656-2009; Infektiologie, USZ/A-6921-2011; SHCS, all/G-4072-2011","Phillips, Andrew/0000-0003-2384-4807; ","European Commission [CT94-1637, CT97-2713, QLK2-2000-00773, LSHP-CT-2006-018632]; Bristol-Myers Squibb; GlaxoSmithKline; Roche; Gilead; Pfizer; Merck and Co.; Tibotec; Boehringer-Ingelheim; Swiss Federal Office for Education and Science","Primary support for EuroSIDA is provided by the European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773) and the 6th Framework (LSHP-CT-2006-018632) programmes. Current support also includes unrestricted grants from Bristol-Myers Squibb, GlaxoSmithKline, Roche, Gilead, Pfizer, Merck and Co., Tibotec and Boehringer-Ingelheim. The participation of centres from Switzerland was supported by a grant from the Swiss Federal Office for Education and Science.",null,36,13,13,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1464-2662",null,null,"HIV MED","HIV Med.","AUG",2010,11,7,null,null,null,null,469,478,null,"10.1111/j.1468-1293.2009.00816.x",null,10,"Infectious Diseases","Infectious Diseases","619QG","WOS:000279444100008"]
[null,null,null,null,"J","Bruchova, H; Vasikova, A; Merkerova, M; Milcova, A; Topinka, J; Balascak, I; Pastorkova, A; Sram, RJ; Brdicka, R",null,null,null,"Bruchova, H.; Vasikova, A.; Merkerova, M.; Milcova, A.; Topinka, J.; Balascak, I.; Pastorkova, A.; Sram, R. J.; Brdicka, R.",null,null,"Effect of Maternal Tobacco Smoke Exposure on the Placental Transcriptome","PLACENTA",null,null,"English","Article",null,null,null,null,null,"Placenta; Gene expression; Tobacco smoke exposure","INTRAUTERINE GROWTH RESTRICTION; DIFFERENTIAL GENE-EXPRESSION; C RECEPTOR GENES; LOW-BIRTH-WEIGHT; CIGARETTE-SMOKING; ENVIRONMENTAL-POLLUTANTS; TRANSPLACENTAL TRANSFER; FETAL-GROWTH; RISK-FACTOR; PREGNANCY","Smoking in pregnancy increases a woman's risk of preterm delivery resulting in serious neonatal health problems and chronic lifelong disabilities for the children (e.g, mental retardation, learning problems) To study the effects of tobacco smoke on the placental transcriptome, we performed gene expression profiling on placentas from women exposed to tobacco smoke in pregnancy (N = 12) and from those without significant exposure (N = 64). Gene expression profiles were determined by Illumina HumanRef-8 v2 Expression BeadChips with 18,216 gene probes. Microarray data were normalized by quantile method and filtered for a detection P-value <0.01. Differential gene expression was determined by moderated t-statistic A linear model was fitted for each gene given a series of arrays using ImFit function Multiple testing correction was performed using the Benjamini and Hochberg method. Abundant levels of transcripts were found for genes encoding placental hormones (CSH1, CSHL1), pregnancy-specific proteins (PSG3. PSG4, PAPPA), and hemoglobins (HBB, HHG, HBA) Comparative analysis of smokers vs nonsmokers revealed the differential expression of 241 genes (P < 0.05) In smoker cohort, we detected high up-regulation of xenobiotic genes (CYP1A1, CYP1B1, CYB5A, COX412), collagen genes (e.g, COL6A3, COL1A1, COL1A2), coagulation genes (175, F13A1) as well as thrombosis-related genes (CD36. ADAMTS9, GAS6). In smokers, we identified deregulated genes that show tissue non-specific induction and may be considered as general biomarkers of tobacco smoke exposure Further, we also found genes specifically deregulated in the exposed placentas. Functional annotation analysis suggested processes and pathways affected by tobacco smoke exposure that may represent molecular mechanisms of smoke-induced placental abnormalities (C) 2009 Elsevier Ltd. All rights reserved.","[Bruchova, H.] Inst Hematol & Blood Transfus, Dept Mol Genet, CR-12820 Prague, Czech Republic; [Milcova, A.; Topinka, J.; Pastorkova, A.; Sram, R. J.] AS CR, Inst Expt Med, VVI, Prague, Czech Republic; [Balascak, I.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Bruchova, H (reprint author), Inst Hematol & Blood Transfus, Dept Mol Genet, Nemocnice 1, CR-12820 Prague, Czech Republic.",null,null,null,"Czech Ministry of Education Youth and Sports [2B06088]","The authors wish to thank the gynecological staff of the University Hospital in Prague-Motol We thank Mgr. Viktor Stranecky (Institute of Inherited Metabolic Disorders, 1st Medical Faculty of Charles University, Prague) for microarray data analyses The work was supported by the Czech Ministry of Education Youth and Sports (Grant no. 2B06088).",null,45,13,13,"W B SAUNDERS CO LTD","LONDON","32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND","0143-4004",null,null,"PLACENTA","Placenta","MAR",2010,31,3,null,null,null,null,186,191,null,"10.1016/j.placenta.2009.12.016",null,6,"Developmental Biology; Obstetrics & Gynecology; Reproductive Biology","Developmental Biology; Obstetrics & Gynecology; Reproductive Biology","570TA","WOS:000275699700004"]
[null,null,null,null,"J","Bosanska, L; Michalsky, D; Lacinova, Z; Dostalova, I; Bartlova, M; Haluzikova, D; Matoulek, M; Kasalicky, M; Haluzik, M",null,null,null,"Bosanska, L.; Michalsky, D.; Lacinova, Z.; Dostalova, I.; Bartlova, M.; Haluzikova, D.; Matoulek, M.; Kasalicky, M.; Haluzik, M.",null,null,"The Influence of Obesity and Different Fat Depots on Adipose Tissue Gene Expression and Protein Levels of Cell Adhesion Molecules","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Adhesion molecules; Atherosclerosis; Obesity; Adipose tissue; Gene expression","TYPE-2 DIABETES-MELLITUS; E-SELECTIN CORRELATE; INSULIN-RESISTANCE; METABOLIC SYNDROME; MACROPHAGE INFILTRATION; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR-DISEASE; MENOPAUSAL WOMEN; RISK-FACTORS; SERUM-LEVELS","Increased circulating adhesion molecules in patients with obesity play an important role in the development of endothelial dysfunction/atherosclerosis. The aim of this study was to assess the contribution of various fat depots to the production of adhesion molecules in obesity. 12 women with 1st and 2nd degree of obesity, 13 women with 3rd degree of obesity and 14 lean age-matched women were included into study. Circulating levels of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selectin were measured by Luminex kits. mRNA expression of ICAM-1, VCAM-1, E-selectin, monocyte chemoattractant protein-1 (MCP-1), and CD68 in subcutaneous (SAT) and visceral adipose tissue (VAT) was measured by RT-PCR; ICAM-1 and VCAM-1 protein levels by Luminex kits, normalized to protein content. Obesity increased ICAM-1 and VCAM-1 mRNA expression and protein levels and CD68 mRNA expression in VAT. Expression of E-selectin and MCP-1 did not significantly differ between groups. Expression of ICAM-1 and VCAM-1 positively correlated with expression of CD68 in both adipose depots. In VAT, ICAM-1 and VCAM-1 expression and protein levels positively correlated with BMI. Obesity was associated with increased adhesion molecules mRNA expression and protein levels in VAT, but not in SAT. Increased adhesion molecules production in visceral fat may provide a novel direct link between visceral adiposity and increased risk of cardiovascular complications.","[Bosanska, L.; Lacinova, Z.; Dostalova, I.; Bartlova, M.; Haluzikova, D.; Matoulek, M.; Haluzik, M.] Charles Univ Prague, Fac Med 1, Dept Med 3, Prague 12808 2, Czech Republic; [Michalsky, D.] Charles Univ Prague, Fac Med 1, Dept Surg, Prague 12808 2, Czech Republic; [Haluzikova, D.] Charles Univ Prague, Fac Med 1, Dept Sports Med, Prague 12808 2, Czech Republic; [Kasalicky, M.] Cent Mil Hosp, Dept Surg, Prague, Czech Republic","Haluzik, M (reprint author), Charles Univ Prague, Fac Med 1, Dept Med 3, Nemocnice 1, Prague 12808 2, Czech Republic.","mhalu@lf1.cuni.cz",null,null," [IGA8302-5];  [MZ0VFN2005]","Supported by IGA8302-5 and MZ0VFN2005.",null,40,13,13,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,1,null,null,null,null,79,88,null,null,null,10,"Physiology","Physiology","575VJ","WOS:000276097000010"]
[null,null,null,null,"J","Klecka, J; Holubec, L; Pesta, M; Topolcan, O; Hora, M; Eret, V; Finek, J; Chottova-Dvorakova, M; Babjuk, M; Novak, K; Stolz, J",null,null,null,"Klecka, J.; Holubec, L.; Pesta, M.; Topolcan, O.; Hora, M.; Eret, V.; Finek, J.; Chottova-Dvorakova, M.; Babjuk, M.; Novak, K.; Stolz, J.",null,null,"Differential Display Code 3 (DD3/PCA3) in Prostate Cancer Diagnosis","ANTICANCER RESEARCH",null,null,"English","Article",null,null,null,null,null,"Prostate cancer; PCa; benign prostatic hyperplasia; BPH; DD3(PCA3); mRNA; RT-PCR","MOLECULAR URINE TEST; ANTIGEN; MEN; BIOMARKERS; DD3(PCA3)","Background: Early diagnosis of prostate cancer (PCa) in an organ-confined stage following radical treatment is the only potential curative approach in PCa. Prostatic-specific antigen (PSA) is very helpful in earl), diagnosis, but the main disadvantage is that it has a low positive predictive value in the range of the grey zone of 2.5-10 ng/mL, which results in a high number of needless biopsies. For this reason, new tests with better parameters are needed. One promising test is that for differential display code 3 (DD3(PCA3)), which is a prostate-specific non-coding mRNA that is highly overexpressed in prostate tumor cells. The aim of the present study was to evaluate the potential of DD3(PCA3) for mRNA in PCa diagnosis. Patients and Methods: A total of 186 patients were examined. In a group of patients with suspected PCa, one tissue specimen core was collected for testing DD3(PCA3) expression. According to the histological verification there were 100 patients with benign prostatic hyperplasia, 12 patients with prostatic intraepithelial neoplasia and 74 patients with PCa. The total RNA was isolated and DD3(PCA3) and PSA expressions were quantified using quantitative RT real-time PCR method. The DD3(PCA3)/PSA mRNA ratio was determined for all groups. Results: It was found that the levels of the mRNA expression of DD3(PCA3) were significantly higher (p<0.045) in patients with PCa than in patients with benign prostatic hyperplasia. No statistically significant differences in levels of mRNA expression of DD3(PCA3) between patients with organ-confined and those with advanced or metastatic disease, nor according to Gleason score, were found. Conclusion: DD3(PCA3) appears to be a promising marker for early detection of PCa and also for differential diagnosis between patients with benign prostate hyperplasia and those with PCa.","[Klecka, J.; Hora, M.; Eret, V.] Univ Teaching Hosp, Dept Urol, Plzen, Czech Republic; [Holubec, L.; Finek, J.] Univ Teaching Hosp, Dept Oncol, Plzen, Czech Republic; [Pesta, M.; Topolcan, O.] Charles Univ Prague, Fac Med, Cent Radioisotop Lab, Plzen, Czech Republic; [Chottova-Dvorakova, M.] Charles Univ Prague, Fac Med, Dept Physiol, Plzen, Czech Republic; [Babjuk, M.; Novak, K.; Stolz, J.] Charles Univ Prague, Univ Teaching Hosp, Fac Med 1, Dept Urol, Prague, Czech Republic","Holubec, L (reprint author), Fac Hosp, Dept Radiotherapy & Oncol, E Benese 13, Plzen 30599, Czech Republic.","holubec@fnplzen.cz","Chottova Dvorakova, Magdalena/B-1106-2010","Chottova Dvorakova, Magdalena/0000-0002-6078-1959","IGA [NR/8918-3]; research project vz msm [0021620819]","This work was supported by grant IGA NR/8918-3 and by the research project vz msm 0021620819.",null,34,12,13,"INT INST ANTICANCER RESEARCH","ATHENS","EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE","0250-7005",null,null,"ANTICANCER RES","Anticancer Res.","FEB",2010,30,2,null,null,null,null,665,670,null,null,null,6,"Oncology","Oncology","572IC","WOS:000275821200059"]
[null,null,null,null,"J","Huska, D; Adam, V; Hubalek, J; Trnkova, L; Eckschlager, T; Stiborova, M; Provaznik, I; Kizek, R",null,null,null,"Huska, Dalibor; Adam, Vojtech; Hubalek, Jaromir; Trnkova, Libuse; Eckschlager, Tomas; Stiborova, Marie; Provaznik, Ivo; Kizek, Rene",null,null,"Off-line coupling of automated pipetting system with square wave voltammetry as a tool for study of drug-DNA interaction","CHIMICA OGGI-CHEMISTRY TODAY",null,null,"English","Article",null,null,null,null,null,"ellipticine; DNA; square wave voltammetry; adsorptive transfer technique; automation","CHINESE-HAMSTER FIBROBLASTS; CELL-CYCLE ARREST; ELLIPTICINE DERIVATIVES; ELECTROCHEMICAL-BEHAVIOR; SERIES; 9-HYDROXYELLIPTICINE; SENSITIVITY; RESISTANCE; INHIBITORS; MECHANISM","Manual handling with DNA and drugs can be a source of errors, which can be eliminated also by automation of whole process of sample preparation. The aim of this work was to study interaction between DNA and ellipticine by using of off-line coupled automated pipetting system with adsorptive transfer stripping technique (AdTS) square wave voltammetry (SWV). Interaction between dsDNA and ellipticine was evident from the decrease of CA signal. Six ng of ellipticine per ml resulted in a statistically significant decrease in CA signal (the decrease was higher than the standard deviation of determinations, Student t-test). The decrease in CA signal corresponded to increasing ellipticine concentrations.","[Huska, Dalibor; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Hubalek, Jaromir] Brno Univ Technol, Dept Microelect, Fac Elect Engn & Commun, CZ-60200 Brno, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Dept Chem, Fac Sci, CZ-61137 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, CZ-12840 Prague 2, Czech Republic; [Provaznik, Ivo] Brno Univ Technol, Fac Elect Engn & Commun, Dept Biomed Engn, CZ-61200 Brno, Czech Republic","Kizek, R (reprint author), Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.",null,"Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Provaznik, Ivo/F-4121-2012",null,"GAAV [KAN208130801]; GACR [102/08/1546, P301/10/0356]; Ministry of Education of the Czech Republic [MSM 0021620808, MSM 0021630513, 1M0505, MSM 0021622412]","Financial support from GAAV (KAN208130801), GACR (102/08/1546, P301/10/0356) and the Ministry of Education of the Czech Republic (MSM 0021620808, MSM 0021630513, 1M0505 and MSM 0021622412) is highly acknowledged.",null,29,12,12,"TEKNOSCIENZE PUBL","MILANO","VIALE BRIANZA 22, 20127 MILANO, ITALY","1973-8250",null,null,"CHIM OGGI","Chim. Oggi-Chem. Today","SEP-OCT",2010,28,5,null,"S",null,null,18,20,null,null,null,3,"Biotechnology & Applied Microbiology; Chemistry, Multidisciplinary","Biotechnology & Applied Microbiology; Chemistry","672KP","WOS:000283582200005"]
[null,null,null,null,"J","Simko, F; Pechanova, O; Pelouch, V; Krajcirovicova, K; Celec, P; Palffy, R; Bednarova, K; Vrankova, S; Adamcova, M; Paulis, L",null,null,null,"Simko, Fedor; Pechanova, Olga; Pelouch, Vaclav; Krajcirovicova, Kristina; Celec, Peter; Palffy, Roland; Bednarova, Kristina; Vrankova, Stanislava; Adamcova, Michaela; Paulis, Ludovit",null,null,"Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril","JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"captopril; cardiac hypertrophy; continuous light and L-NAME-induced hypertension; fibrosis; melatonin","SPONTANEOUSLY HYPERTENSIVE-RATS; BLOOD-PRESSURE; VASCULAR REACTIVITY; N-ACETYLCYSTEINE; HEART-DISEASE; HYPERTROPHY; PINEALECTOMY; SIMVASTATIN; REGRESSION; EXPOSURE","Objective Blood pressure enhancement induced by continuous light exposure represents an attractive but rarely investigated model of experimental hypertension. Design and methods The aim of this study was to show whether the combination of continuous light (24 h/day) exposure and chronic N(G)-nitro-L-arginine-methyl ester (L-NAME) treatment induces remodelling of the left ventricle and whether captopril or melatonin can modify these potential alterations. Six groups of 3-month-old Wistar rats (nine per group) were treated for 6 weeks: control (untreated), L-NAME (40 mg/kg per day), exposed to continuous light, L-NAME treated and exposed to continuous light (L24), L24 rats treated with either captopril 100 mg/kg per day, or melatonin (10 mg/kg/24 h). Systolic blood pressure (SBP), relative weights of the left ventricle, endothelial nitric oxide synthase (eNOS) and angiotensin-converting enzyme (ACE) expression in tissues, malondialdehyde and advanced oxidation protein product concentrations in the plasma and hydroxyproline levels in collagenous protein fractions were measured. Results The continuous light and L-NAME treatment led to hypertension, left ventricular hypertrophy (LVH) and fibrosis. An increase in SBP was completely prevented by captopril and partly by melatonin in the L24 group. Both drugs reduced oxidative damage and attenuated enhanced expression of ACE in the myocardium. Neither of the drugs prevented the attenuation of eNOS expression in the combined hypertensive model. Only captopril reduced LVH development in L24, whereas captopril and melatonin reduced left ventricular hydroxyproline concentrations in soluble and insoluble collagen, respectively. The total hydroxyproline concentration was reduced only by melatonin. Conclusion In hypertension induced by a combination of continuous light and L-NAME treatment, melatonin and captopril protect the heart against pathological left ventricular remodelling differently. J Hypertens 28 (suppl 1): S13-S18 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Simko, Fedor; Krajcirovicova, Kristina; Celec, Peter; Palffy, Roland; Bednarova, Kristina; Paulis, Ludovit] Comenius Univ, Sch Med, Dept Pathophysiol, Bratislava 81108, Slovakia; [Simko, Fedor] Comenius Univ, Sch Med, Clin Med 3, Bratislava 81108, Slovakia; [Pechanova, Olga; Vrankova, Stanislava; Paulis, Ludovit] Slovak Acad Sci, Inst Normal & Pathol Physiol, Bratislava, Slovakia; [Pelouch, Vaclav] Charles Univ Prague, Sch Med 2, Dept Med Chem & Biochem, Hradec Kralove, Czech Republic; [Pelouch, Vaclav] Cardiovasc Res Ctr, Prague, Czech Republic; [Celec, Peter] Comenius Univ, Inst Mol Biomed, Bratislava 81108, Slovakia; [Adamcova, Michaela] Charles Univ Prague, Sch Med, Dept Physiol, Hradec Kralove, Czech Republic; [Paulis, Ludovit] Charite, Cardiovasc Res Ctr, D-13353 Berlin, Germany","Simko, F (reprint author), Comenius Univ, Sch Med, Dept Pathophysiol, Sasinkova 4, Bratislava 81108, Slovakia.","fedor.simko@fmed.uniba.sk",null,null,"VEGA [1/0187/09, 2/0178/09];  [APVV-0538-07];  [MSM0021620820]","This study was supported by research grants of VEGA no 1/0187/09 and 2/0178/09, APVV-0538-07 and MSM0021620820.",null,43,11,12,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,null,"J HYPERTENS","J. Hypertens.","SEP",2010,28,null,null,1,null,null,"S13","S18",null,"10.1097/01.hjh.0000388489.28213.08",null,6,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","660SZ","WOS:000282665800003"]
[null,null,null,null,"J","Pesta, M; Klecka, J; Kulda, V; Topolcan, O; Hora, M; Eret, V; Ludvikova, M; Babjuk, M; Novak, K; Stolz, J; Holubec, L",null,null,null,"Pesta, M.; Klecka, J.; Kulda, V.; Topolcan, O.; Hora, M.; Eret, V.; Ludvikova, M.; Babjuk, M.; Novak, K.; Stolz, J.; Holubec, L.",null,null,"Importance of miR-20a Expression in Prostate Cancer Tissue","ANTICANCER RESEARCH",null,null,"English","Article",null,null,null,null,null,"Prostate cancer; miRNA; miR-20a; let-7a; miR-15a; miR-16","MICRORNA EXPRESSION; CELL-PROLIFERATION; CHROMOSOME 13Q; HETEROZYGOSITY; LEUKEMIA; TARGETS; CLUSTER; POLYCISTRON; PROGRESSION; CARCINOMA","Background: MicroRNAs (miRNAs), which are endogenously expressed regulatory noncoding RNAs, have an altered expression in tumor tissues. MiRNAs regulate cancer-related processes such as cell growth and tissue differentiation, and therefore, might function as oncogenes or tumor-suppressor genes. The aim of our study was to assess the expression of mir-20a, let-7a, miR-15a and miR-16 in prostate cancer (PCa) and benign pro static hyperplasia (BPH) tissue and to investigate the relation between the expression of miRNAs and the clinicopathological features of PCa. Patients and Methods: The study group comprised 138 patients: 85 patients with BPH and 53 patients with PCa. The total RNA was isolated from the tissue specimen core and miRNA expressions were quantified using a real-time RT-PCR method (TaqMan MicroRNA Assays). U6snRNA was used for the normalization of the miRNA expression. Results: miR-20a expression was significantly higher in the group of patients with a Gleason score of 7-10 in comparison with the group of patients with a Gleason score of 0-6 (p=0.0082). We found no statistical differences in the miRNA expressions (mir-20a, let-7a, miR-15a and miR-16) in the PCa tissue samples in comparison with the BPH tissue samples. Conclusion: Our result shows that the more dedifferentiated PCa cells have a higher expression of miR-20a and this supports the oncogenic role of miR-20a in PCa carcinogenesis. The evaluation of miRNA expression could yield new information about PCa pathogenesis.","[Pesta, M.; Topolcan, O.; Holubec, L.] Charles Univ Prague, Univ Hosp Pilsen, Dept Internal Med 2, Prague, Czech Republic; [Klecka, J.; Hora, M.; Eret, V.] Charles Univ Prague, Univ Hosp Pilsen, Dept Urol, Prague, Czech Republic; [Kulda, V.] Charles Univ Prague, Univ Hosp Pilsen, Dept Biochem, Prague, Czech Republic; [Ludvikova, M.] Charles Univ Prague, Univ Hosp Pilsen, Dept Biol, Fac Med Pilsen, Prague, Czech Republic; [Babjuk, M.; Novak, K.; Stolz, J.] Charles Univ Prague, Univ Teaching Hosp, Fac Med 1, Dept Urol, Prague, Czech Republic; [Holubec, L.] Univ Hosp Plzen, Dept Oncol, Plzen, Czech Republic","Holubec, L (reprint author), Dept Radiotherapy & Oncol, E Benese 13, Plzen 30599, Czech Republic.","holubec@fnplzen.cz",null,null,"Ministry of Health of the Czech Republic [IGA NR/8918-3]; Czech government [MSM 0021620819]","This study was supported by grant IGA NR/8918-3 from the Ministry of Health of the Czech Republic and by Czech government research project MSM 0021620819.",null,29,10,12,"INT INST ANTICANCER RESEARCH","ATHENS","EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE","0250-7005",null,null,"ANTICANCER RES","Anticancer Res.","SEP",2010,30,9,null,null,null,null,3579,3583,null,null,null,5,"Oncology","Oncology","665BI","WOS:000283009400050"]
[null,null,null,null,"J","van Stralen, KJ; Tizard, EJ; Jager, KJ; Schaefer, F; Vondrak, K; Groothoff, JW; Podracka, L; Holmberg, C; Jankauskiene, A; Lewis, MA; van Damme-Lombaerts, R; Mota, C; Niaudet, P; Novljan, G; Peco-Antic, A; Sahpazova, E; Toots, U; Verrina, E",null,null,null,"van Stralen, Karlijn J.; Tizard, E. Jane; Jager, Kitty J.; Schaefer, Franz; Vondrak, Karel; Groothoff, Jaap W.; Podracka, Ludmila; Holmberg, Christer; Jankauskiene, Augustina; Lewis, M. A.; van Damme-Lombaerts, Rita; Mota, Conceicao; Niaudet, Patrick; Novljan, Gregor; Peco-Antic, Amira; Sahpazova, Emilija; Toots, Uelle; Verrina, Enrico",null,null,"Determinants of eGFR at start of renal replacement therapy in paediatric patients","NEPHROLOGY DIALYSIS TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"children; dialysis; GFR; Schwartz; start of RRT","GLOMERULAR-FILTRATION-RATE; PLASMA CREATININE CONCENTRATION; KIDNEY-TRANSPLANTATION; CHILDREN; DIALYSIS; FAILURE; ADOLESCENTS; INITIATION; TIME","Methods. Data were collected as part of the European Society of Paediatric Nephrology/European Renal Association-European Dialysis and Transplant Association registry from 14 European countries and referred to incident paediatric patients starting on renal replacement therapy (RRT) between 2002 and 2007 under the age of 18 years. Estimated glomerular filtration rate (eGFR) was calculated using the Schwartz formula. Data were adjusted for age, gender, treatment modality at start, primary cause of renal failure (PRD) and regions in Europe (eGFR(adj)). Results. Median eGFR in the 938 patients starting RRT was 10.4 mL/min/1.73 m(2) (5th and 95th percentile: 4.0-26.9). Twenty-six patients (2.8%), mainly infants with Finnish-type nephropathy, started with eGFR levels > 50 mL/min/1.73 m(2). Younger age, female gender, starting on dialysis and having a short time between the first visit to a paediatric nephrologist (PN) and start of RRT were associated with lower eGFR at start of RRT. Gender differences were only present during adolescent age and disappeared when using the same K value for both genders. The various PRDs showed large differences in the rate of decline in eGFR between the first visit to a PN and start of RRT; however, this did not result in differences in eGFR(adj) at start of RRT. Conclusions. The main determinants of eGFR at start of RRT were age, gender, treatment modality at start, and the time between the first visit to a PN and start of RRT. Research is needed to determine the consequences of these differences.","[van Stralen, Karlijn J.; Jager, Kitty J.] Univ Amsterdam, Acad Med Ctr, Dept Med, ESPN ERA EDTA Registry, NL-1105 AZ Amsterdam, Netherlands; [Tizard, E. Jane] Bristol Royal Hosp Children, Dept Paediat Nephrol, Bristol, Avon, England; [Schaefer, Franz] Univ Heidelberg, Childrens Hosp, D-6900 Heidelberg, Germany; [Vondrak, Karel] Univ Hosp Prague Motol, Dept Paediat, Prague, Czech Republic; [Podracka, Ludmila] Univ Hosp, Dept Pediat, Kosice, Slovakia; [Holmberg, Christer] Helsinki Univ Hosp, Dept Pediat Nephrol, Helsinki, Finland; [Jankauskiene, Augustina] Vilnius Univ, Children Hosp, Vilnius, Lithuania; [Lewis, M. A.] Royal Manchester Childrens Hosp, Dept Paediat Nephrol, Manchester M27 1HA, Lancs, England; [van Damme-Lombaerts, Rita] Univ Hosp Leuven, Dept Paediat Nephrol & Organ Transplantat, Louvain, Belgium; [Mota, Conceicao] Ctr Hosp Porto, Dept Pediat Nephrol, Oporto, Portugal; [Niaudet, Patrick] Hop Necker Enfants Malad, Paris, France; [Novljan, Gregor] Ljubljana Childrens Hosp, Univ Med Ctr, Dept Pediat Nephrol, Ljubljana, Slovenia; [Peco-Antic, Amira] Univ Childrens Hosp, Belgrade, Serbia; [Sahpazova, Emilija] Pediat Clin, Dept Nephrol, Skopje, Macedonia; [Toots, Uelle] SA Tallinna Lastehaigla, Tallinn, Estonia; [Verrina, Enrico] G Gaslini Inst Children, Nephrol Dialysis & Transplantat Unit, Genoa, Italy","van Stralen, KJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Med, ESPN ERA EDTA Registry, NL-1105 AZ Amsterdam, Netherlands.","K.J.vanStralen@amc.uva.nl","Schaefer, Franz/G-4365-2010",null,"European Society of Paediatric Nephrology (ESPN); European Renal Association (ERA-EDTA); NephroQUEST project; European Union [2006114]","The ESPN/ERA-EDTA registry is funded by the European Society of Paediatric Nephrology (ESPN), the European Renal Association (ERA-EDTA) and the NephroQUEST project. The NephroQUEST project has received funding from the European Union in the framework of the Public Health Programme (projec number 2006114). Furthermore, Amgen has provided an unrestricted educational grant to assist the ESPN in the financial support of the Registry.",null,26,11,11,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0931-0509",null,null,"NEPHROL DIAL TRANSPL","Nephrol. Dial. Transplant.","OCT",2010,25,10,null,null,null,null,3325,3332,null,"10.1093/ndt/gfq215",null,8,"Transplantation; Urology & Nephrology","Transplantation; Urology & Nephrology","654ML","WOS:000282172300031"]
[null,null,null,null,"J","Declerck, PJ; Darendeliler, F; Goth, M; Kolouskova, S; Micle, I; Noordam, C; Peterkova, V; Volevodz, NN; Zapletalova, J; Ranke, MB",null,null,null,"Declerck, Paul J.; Darendeliler, Feyza; Goth, Miklos; Kolouskova, Stanislava; Micle, Ioana; Noordam, Cees; Peterkova, Valentina; Volevodz, Natalia N.; Zapletalova, Jirina; Ranke, Michael B.",null,null,"Biosimilars: controversies as illustrated by rhGH","CURRENT MEDICAL RESEARCH AND OPINION",null,null,"English","Article",null,null,null,null,null,"Biopharmaceutical; Biosimilar; Follow-on biologic; Healthcare economics; Human growth hormone; Similar biological medicinal product","HUMAN GROWTH-HORMONE; NATIONAL COOPERATIVE GROWTH; CAPITAL FEMORAL EPIPHYSIS; SHORT STATURE; CHILDREN; SAFETY; EFFICACY; PRODUCTS; DATABASE; THERAPY","Background and scope: Similar biological medicinal products, also called 'biosimilars', are copies of biopharmaceutical products whose patent has expired. Whether biosimilars are truly comparable and interchangeable with their reference biopharmaceutical products in terms of quality, efficacy and tolerability, is still a matter of debate. This review discusses the controversies related to the criteria for regulatory approval of biosimilars. These concerns are illustrated using recombinant human growth hormone (rhGH) biosimilars as an example. Methods: Publications on the regulatory approval of biosimilars in general and rhGH biosimilars in particular were searched in MEDLINE by exploding and combining the medical subject heading terms 'human growth hormone', 'efficacy' or 'safety' and the free-text words 'biosimilar', 'biopharmaceutical', 'similar biological medicinal product', 'follow-up biologic' or 'biogeneric'. Searches were limited to full-text English-language articles. The websites from the European Medicines Agency (EMA) and from the American Food and Drug Administration were also consulted. Regulatory status: To obtain regulatory approval of a biosimilar product by EMA, demonstration of comparability with an approved reference biopharmaceutical product in terms of quality, efficacy and tolerability is needed. Thus, comparative quality studies, non-clinical and clinical efficacy and tolerability studies are required. However, in contrast to the reference product, comparative non-clinical pharmacokinetics, safety pharmacology, reproduction toxicology, mutagenicity and carcinogenicity studies are not mandatory to obtain approval of a biosimilar. In addition, comparable efficacy and tolerability only needs to be established by one study in a single population during a limited time interval (12 months) and often allows extrapolation to all other approved indications of the reference product. Consequently, for the currently approved rhGH biosimilars, long-term efficacy and tolerability in all indications has not been proven to the same degree as for the reference products. Conclusions: The validity of the current criteria for comparability and interchangeability of biosimilars and their reference products remains controversial. The authors conclude that long-term clinical investigations and systematic monitoring of the efficacy and tolerability of rhGH biosimilars in all indications are needed. In addition, the medico-economical environment should allow physicians to take a free and informed decision about the type of rhGH to be prescribed.","[Declerck, Paul J.] Katholieke Univ Leuven, Lab Pharmaceut Biol, Fac Pharmaceut Sci, B-3000 Louvain, Belgium; [Darendeliler, Feyza] Istanbul Fac Med, Istanbul, Turkey; [Goth, Miklos] State Hlth Ctr, Dept Internal Med 2, Budapest, Hungary; [Micle, Ioana] Univ Med & Farm Timisoara, Timisoara, Romania; [Micle, Ioana] Clin Emergency Hosp Children Louis Turcanu, Timisoara, Romania; [Kolouskova, Stanislava] Univ Hosp Motol, Prague, Czech Republic; [Noordam, Cees] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Peterkova, Valentina; Volevodz, Natalia N.] Russian Acad Sci, Endocrinol Sci Ctr, Moscow, Russia; [Zapletalova, Jirina] Palacky Univ, Univ Hosp, CR-77147 Olomouc, Czech Republic; [Zapletalova, Jirina] Palacky Univ, Fac Med, CR-77147 Olomouc, Czech Republic; [Ranke, Michael B.] Univ Childrens Hosp, Tubingen, Germany","Declerck, PJ (reprint author), Katholieke Univ Leuven, Lab Pharmaceut Biol, Fac Pharmaceut Sci, Campus Gasthuisberg O&N2,PB 824,Herestr 49, B-3000 Louvain, Belgium.","Paul.Declerck@pharm.kuleuven.be",null,null,"Pfizer Emerging Markets Europe; OTKA [68660]; Eli Lilly; Novo Nordisk; Pfizer","This study was funded by an unrestricted grant from Pfizer Emerging Markets Europe.M. G. has disclosed that he has received speaker fees from Merck Serono and Novartis and is supported by an OTKA grant No. 68660. C. N. has disclosed that he has received honoraria for consultancy/advisory board attendance from Ipsen Pharma and Pfizer. M. B. R. has disclosed that he has received honoraria for advisory board attendance from Pfizer, Germany. J.Z. has disclosed that she has received grants/research funding from Eli Lilly, Novo Nordisk and Pfizer; honoraria for consultancy/advisory board attendance from Eli Lilly, Novo Nordisk and Pfizer; and speaker fees from Eli Lilly and Pfizer. F. D., P.J.D., S. K., I. M., V. P. and N. V. have not declared any conflicts of interest regarding rhGH products.",null,52,10,11,"LIBRAPHARM/INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4 LQ, ENGLAND","0300-7995",null,null,"CURR MED RES OPIN","Curr. Med. Res. Opin.","MAY",2010,26,5,null,null,null,null,1219,1229,null,"10.1185/03007991003719642",null,11,"Medicine, General & Internal; Medicine, Research & Experimental","General & Internal Medicine; Research & Experimental Medicine","583MO","WOS:000276680900025"]
[null,null,null,null,"J","van Middendorp, JJ; Pouw, MH; Hayes, KC; Williams, R; Chhabra, HS; Putz, C; Veth, RPH; Geurts, ACH; Aito, S; Kriz, J; McKinley, W; van Asbeck, FWA; Curt, A; Fehlings, MG; Van de Meent, H; Hosman, AJF",null,null,null,"van Middendorp, J. J.; Pouw, M. H.; Hayes, K. C.; Williams, R.; Chhabra, H. S.; Putz, C.; Veth, R. P. H.; Geurts, A. C. H.; Aito, S.; Kriz, J.; McKinley, W.; van Asbeck, F. W. A.; Curt, A.; Fehlings, M. G.; Van de Meent, H.; Hosman, A. J. F.",null,"EM-SCI Study Grp Collaborators","Diagnostic criteria of traumatic central cord syndrome. Part 2: A Questionnaire Survey among Spine Specialists","SPINAL CORD",null,null,"English","Article",null,null,null,null,null,"central cord syndrome; spinal cord injury; diagnostic criteria; survey","MRI-PATHOLOGICAL CORRELATIONS; CLINICAL-TRIALS; ICCP PANEL; INJURY; GUIDELINES; RECOVERY; CONDUCT; MANAGEMENT; SCI","Study design: A questionnaire survey. Objectives: To evaluate the need for the introduction of quantitative diagnostic criteria for the traumatic central cord syndrome (TCCS). Setting: An online questionnaire survey with participants from all over the world. Methods: An invitation to participate in an eight-item online survey questionnaire was sent to surgeon members of AOSpine International. Results: Out of 3340 invited professionals, 157 surgeons (5%) from 41 countries completed the survey. Whereas most of the respondents (75%) described greater impairment of the upper extremities than of the lower extremities in their own TCCS definitions, symptoms such as sensory deficit (39%) and bladder dysfunctions (24%) were reported less frequently. Initially, any difference in motor strength between the upper and lower extremities was considered most frequently (23%) as a 'disproportionate' difference in power. However, after presenting literature review findings, the majority of surgeons (61%) considered a proposed difference of at least 10 points of power (based on the Medical Research Council scale) in favor of the lower extremities as an acceptable cutoff criterion for a diagnosis of TCCS. Most of the participants (40%) felt that applying a single criterion to the diagnosis of TCCS is insufficient for research purposes. Conclusion: Various definitions of TCCS were used by physicians involved in the spinal trauma care. The authors consider a difference of at least 10 motor score points between upper and lower extremity power a clear diagnostic criterion. For clinical research purposes, this diagnostic criterion can be considered as a face valid addendum to the commonly applied TCCS definition as introduced by Schneider et al. Spinal Cord (2010) 48, 657-663; doi:10.1038/sc.2010.72; published online 29 June 2010","[van Middendorp, J. J.; Pouw, M. H.; Veth, R. P. H.; Hosman, A. J. F.] Radboud Univ Nijmegen, Med Ctr, Spine Unit, Dept Orthopaed, NL-6500 HB Nijmegen, Netherlands; [Hayes, K. C.] Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada; [Williams, R.] Princess Alexandra Hosp, Dept Orthopaed Surg, Brisbane, Qld 4102, Australia; [Chhabra, H. S.] Indian Spinal Injuries Ctr, Spine Serv, New Delhi, India; [Putz, C.] Orthopaed Univ Hosp Heidelberg, Spine Surg & Spinal Cord Injury Ctr, Heidelberg, Germany; [Geurts, A. C. H.; Van de Meent, H.] Radboud Univ Nijmegen, Med Ctr, Dept Rehabil Med, NL-6500 HB Nijmegen, Netherlands; [Aito, S.] Careggi Univ Hosp, Spinal Unit, Florence, Italy; [Kriz, J.] Univ Hosp Motol, Dept Rehabil & Sports Med, Prague, Czech Republic; [McKinley, W.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [van Asbeck, F. W. A.] Univ Med Ctr, Rehabil Ctr De Hoogstraat, Utrecht, Netherlands; [van Asbeck, F. W. A.] Univ Med Ctr, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands; [Curt, A.] Balgrist Univ Hosp, Spinal Cord Injury Ctr, Zurich, Switzerland; [Fehlings, M. G.] Univ Toronto, Toronto Western Hosp, Spinal Program, Dept Surg, Toronto, ON M5T 2S8, Canada","van Middendorp, JJ (reprint author), Radboud Univ Nijmegen, Med Ctr, Spine Unit, Dept Orthopaed, 357,POB 9101, NL-6500 HB Nijmegen, Netherlands.","jvanmiddendorp@gmail.com","Geurts, Alexander/D-1930-2010; van Middendorp, Joost/C-7493-2011","van Middendorp, Joost/0000-0003-4822-521X","Acute Zorgregio Oost; Internationale Stiftung fur Forschung in Paraplegie (IFP)","We thank all participating members of the European Multicenter Study of Human Spinal Cord Injury (EM-SCI) and the 48th ISCoS annual scientific meeting participants for their cooperation in the preparation of this study. We also thank Dr John F Ditunno Jr for his thorough and insightful comments during earlier phases of this study. We are grateful to the AOSpine International employees, with special thanks to Michael Fawcett, Vera Capaul and Mary Anne Smith, for their enthusiasm and willingness to facilitate this survey study. We acknowledge the participating AOSpine members for their time, answers and valuable comments on the survey. This study was supported by 'Acute Zorgregio Oost' and the 'Internationale Stiftung fur Forschung in Paraplegie (IFP)'.",null,34,8,8,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1362-4393","1476-5624",null,"SPINAL CORD","Spinal Cord","SEP",2010,48,9,null,null,null,null,657,663,null,"10.1038/sc.2010.72",null,7,"Clinical Neurology; Rehabilitation","Neurosciences & Neurology; Rehabilitation","646XB","WOS:000281577000003"]
[null,null,null,null,"J","Poledne, R; Hubacek, JA; Stanek, V; Aschermann, M; Matouskova, J; Veselka, J; Widimsky, P; Cifkova, R; Lanska, V; Pitha, J",null,null,null,"Poledne, R.; Hubacek, J. A.; Stanek, V.; Aschermann, M.; Matouskova, J.; Veselka, J.; Widimsky, P.; Cifkova, R.; Lanska, V.; Pitha, J.",null,null,"Why We Are Not Able to Find the Coronary Heart Disease Gene - apoE As an Example","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"PREMATURE MYOCARDIAL-INFARCTION; APOLIPOPROTEIN-E POLYMORPHISM; CARDIOVASCULAR-DISEASE; E GENOTYPES; RISK; ASSOCIATION; MEN; INDIVIDUALS; POPULATION","The apoprotein E gene ranks among the most discussed candidate genes for cardiovascular disease. We studied whether the association between apoprotein E gene polymorphism and manifestation of acute coronary syndrome is modulated by the presence/absence of traditional cardiovascular risk factors. The population under study were 1066 patients (men under 65 years) admitted between 2006 2009 to five coronary care units in Prague (GENetic DEtermination of Myocardial Infarction in Prague) and the control population (1066 age-matched men selected from the Czech population sample). The frequency of disadvantage genotype E4(+) was significantly higher (P < 0.01) in acute coronary syndrome patients (22.38%) than in controls (16.76%). When the acute coronary syndrome group was step by step limited to non-smokers, non-diabetics and normotensive individuals, the odds ratio displayed a gradual increase from 1.35 (for the entire group) through 1.48 (non-smokers), 1.53 (non-smokers+non-diabetics) to 1.71 (non-smokers+non-diabetics+normotensives). The effect of the apoprotein E gene on the individual risk of acute coronary syndrome is non-homogenous within the patient groups. This association of apoprotein E gene with acute coronary syndrome is strongly modified by the presence/absence of traditional cardiovascular factors of atherosclerosis in a high-risk Czech population.","[Poledne, R.; Hubacek, J. A.; Stanek, V.; Cifkova, R.; Lanska, V.; Pitha, J.] IKEM, Inst Clin & Expt Med, Prague 14021 4, Czech Republic; [Poledne, R.; Hubacek, J. A.; Pitha, J.] IKEM, Cardiovasc Res Ctr, Prague 14021 4, Czech Republic; [Aschermann, M.] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Aschermann, M.] Gen Univ Hosp, Dept Med 2, Dept Cardiovasc Med, Prague, Czech Republic; [Veselka, J.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Veselka, J.] Motol Univ Hosp, Dept Cardiol, Prague, Czech Republic; [Matouskova, J.] Na Homolce Hosp, Dept Cardiol, Prague, Czech Republic; [Widimsky, P.] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Widimsky, P.] Kralovske Vinohrady Univ Hosp, Cardioctr, Dept Cardiol, Prague, Czech Republic","Poledne, R (reprint author), IKEM, Inst Clin & Expt Med, Videnska 1958-9, Prague 14021 4, Czech Republic.","rudolf.poledne@ikem.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [9093-4/2006]","This work was supported by project No. 9093-4/2006; Internal Grant Agency of the Ministry of Health of the Czech Republic.",null,21,6,7,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2010,56,5,null,null,null,null,218,222,null,null,null,5,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","680SO","WOS:000284254900005"]
[null,null,null,null,"J","Hromadnikova, I; Zejskova, L; Kotlabova, K; Jancuskova, T; Doucha, J; Dlouha, K; Krofta, L; Jirasek, JE; Vlk, R",null,null,null,"Hromadnikova, Ilona; Zejskova, Lenka; Kotlabova, Katerina; Jancuskova, Tereza; Doucha, Jindrich; Dlouha, Klara; Krofta, Ladislav; Jirasek, Jan E.; Vlk, Radovan",null,null,"Quantification of Extracellular DNA Using Hypermethylated RASSF1A, SRY, and GLO Sequences-Evaluation of Diagnostic Possibilities for Predicting Placental Insufficiency","DNA AND CELL BIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"FREE FETAL DNA; NONINVASIVE PRENATAL-DIAGNOSIS; QUANTITATIVE PCR MEASUREMENT; MATERNAL PLASMA; GROWTH RESTRICTION; PREGNANT-WOMEN; PREECLAMPSIA; ABNORMALITIES; ELEVATION; MARKER","This study evaluated quantification of fetal extracellular DNA in maternal plasma for differentiation between cases at risk of onset of placental-insufficiency-related complications and normal pregnancies. Using real-time polymerase chain reaction, fetal (sex-determining region Y [SRY] and hypermethylated RASSF1A sequence) and total (beta-globin [GLO] gene) extracellular DNA was examined in 70 normal pregnancies, 18 at risk of placental-insufficiency-related pregnancy complications, 24 preeclampsia with or without (w or w/o) intrauterine growth retardation (IUGR) (median 34.0 week), and 11 IUGR (median 28.5 week). IUGR was diagnosed when estimated fetal weight was below the 10th percentile for evaluated gestational age. Although increased levels of extracellular DNA were detected in pregnancies with preeclampsia w or w/o IUGR relative to controls (RASSF1A, p<0.001; SRY, p = 0.009; GLO, p<0.001), quantities of fetal extracellular DNA in IUGR were not statistically significant (RASSF1A, p = 0.21; SRY, p = 0.2). RASSF1A, SRY, and GLO achieved 93.1%, 93.6%, and 92.1% accuracy for differentiation between normal pregnancy and preeclampsia w or w/o IUGR. Lower sensitivity was observed for pregnancies with onset of IUGR (RASSF1A, 60.0%; SRY, 80.0%; GLO, 72.7%), but did not influence final accuracy (RASSF1A, 91.6%; SRY, 92.5%; GLO, 89.5%). Among 18 patients at risk, 8 pregnancies involving 3 female and 5 male fetuses developed preeclampsia (n = 4), IUGR (n = 3), and chronic placentopathy causing hypoxia (n = 1). Elevation of extracellular DNA was demonstrated in 3/5 (SRY), 1/8 (hypermethylated RASSF1A), and 4/8 (GLO) patients at the earliest 26 weeks and at the latest 2 weeks before the onset of symptoms. These data indicate that fetal and total extracellular DNA concentrations can be significantly elevated in plasma of patients who later developed placental-insufficiency-related pregnancy complications. However, this is strongly individualized, and not a rule for all cases, and probably depends on the actual occurrence of excessive placental trophoblast apoptosis.","[Hromadnikova, Ilona; Zejskova, Lenka; Kotlabova, Katerina; Jancuskova, Tereza] Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Prague 10000, Czech Republic; [Doucha, Jindrich; Vlk, Radovan] Charles Univ Prague, Clin Obstet & Gynecol, Fac Med 2, Univ Hosp Motol, Prague 10000, Czech Republic; [Dlouha, Klara; Krofta, Ladislav; Jirasek, Jan E.] Inst Care Mother & Child, Prague, Czech Republic","Hromadnikova, I (reprint author), Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Ruska 87, Prague 10000, Czech Republic.","ilona.hromadnikova@lf3.cuni.cz",null,null,"MSM [0021620806]","We thank the staff of the Clinic of Obstetrics and Gynecology and the Institute for the Care of Mother and Child for their participation in the collection of data. We would also like to thank Prof. Y.M. Dennis Lo from the Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, for his valuable suggestions concerning digestion of extracellular DNA by methylation-sensitive restriction enzyme. This work was supported by the grant project MSM 0021620806.",null,23,6,6,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1044-5498",null,null,"DNA CELL BIOL","DNA Cell Biol.","JUN",2010,29,6,null,null,null,null,295,301,null,"10.1089/dna.2009.0971",null,7,"Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity","612BM","WOS:000278871500004"]
[null,null,null,null,"J","Hempel, G; Relling, MV; de Rossi, G; Stary, J; De Lorenzo, P; Valsecchi, MG; Barisone, E; Boos, J; Pieters, R",null,null,null,"Hempel, Georg; Relling, Mary V.; de Rossi, Giulio; Stary, Jan; De Lorenzo, Paola; Valsecchi, Maria Grazia; Barisone, Elena; Boos, Joachim; Pieters, Rob",null,null,"Pharmacokinetics of Daunorubicin and Daunorubicinol in Infants With Leukemia Treated in the Interfant 99 Protocol","PEDIATRIC BLOOD & CANCER",null,null,"English","Article",null,null,null,null,null,"daunorubicin; infants; leukemia; pharmacokinetics","ACUTE LYMPHOBLASTIC-LEUKEMIA; RISK-FACTORS; MODEL; THERAPY; CARDIOTOXICITY; QUANTIFICATION; DOXORUBICIN; LY335979","Background. There is all extreme paucity of pharmacokinetic data for anticancer agents in infants. Therefore, we aimed at characterizing the pharmacokinetics for daunorubicin in infants and examined their relationship to age, body weight, and body Surface area. Procedure. Leukemia patients treated according to the Interfant 99 protocol received 30 mg/m(2) daunorubicin, with dose reduction to 3/4 for patients 6-12 months old and 2/3 for patients < 6 months, respectively. Plasma samples from 21 patients (aged 0.05-1.88 years) were collected and analyzed for daunorubicin and daunorubicinol. Samples from 12 children (age 1.6-18.8 years), who received daunorubicin in all earlier investigation, were used for pharmacokinetic model building using the software NONMEM. Results. Plasma concentration time profiles could be described using a two compartment model. Daunorubicin clearance was 43.9 L hr(-1) m(-2) +/- 65% and central Volume of distribution 16.4 L m(-2) +/- 46%, whereas apparent clearance of daunorubicinol was 19.1 L hr(-1) m(-2) +/- 32% and apparent Volume of distribution 228 L m(-2) +/- 80% (mean +/- interindividual variability). No age-dependency in any of the BSA-normalized pharmacokinetic parameters was observed. Consequently, due to the empirical close reduction in infants the overall exposure to daunorubicinol in infants was smaller than would be expected from older children. Patients aged < 6 months experienced more infections in the induction phase than the group aged 6-12 months at diagnosis. Other toxicities were similar in both groups. Conclusion. We observed no indication of ail age-dependency in the pharmacokinetics of daunorubicin. Pediatr Blood Cancer 2010;54:355-360. (C) 2009 Wiley-Liss, Inc.","[Hempel, Georg] Inst Pharmazeut & Med Chem, Klin Pharm, D-48149 Munster, Germany; [Hempel, Georg; Boos, Joachim] Univ Klinikum Munster, Klin & Poliklin Kinder & Jugendmed, Munster, Germany; [Relling, Mary V.] St Jude Childrens Hosp, Dept Pharmaceut, Memphis, TN 38105 USA; [de Rossi, Giulio] Osped Pediat Bambino Gesu, Res Inst, Rome, Italy; [Stary, Jan] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [De Lorenzo, Paola; Valsecchi, Maria Grazia] Univ Milano Bicocca, Osped San Gerardo Nuovo, Pediat Clin, Monza, Italy; [Barisone, Elena] Univ Turin, Dept Pediat Oncohematol, Turin, Italy; [Pieters, Rob] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands; [Pieters, Rob] DCOG, The Hague, Netherlands","Hempel, G (reprint author), Inst Pharmazeut & Med Chem, Klin Pharm, Hittorfstr 58-62, D-48149 Munster, Germany.","georg.hempel@uni-muenster.de",null,null,"German Bundesministerium fur Bildung und Forschung [1EC0401]","This work was supported by the German Bundesministerium fur Bildung und Forschung (Grant Number #1EC0401). We thank all the participating clinical centers for collecting the blood samples, Dr. William Evans and Ms. Emily Melton for St. Jude daunorubicin data, and Sandra Schulz and Petra Schulze-Westhoff for technical support.",null,19,6,6,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1545-5009",null,null,"PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","MAR",2010,54,3,null,null,null,null,355,360,null,"10.1002/pbc.22266",null,6,"Oncology; Hematology; Pediatrics","Oncology; Hematology; Pediatrics","554FR","WOS:000274421400006"]
[null,null,null,null,"J","Liscak, R; Malikova, H; Kalina, M; Vojtech, Z; Prochazka, T; Marusic, P; Vladyka, V",null,null,null,"Liscak, Roman; Malikova, Hana; Kalina, Miroslav; Vojtech, Zdenek; Prochazka, Tomas; Marusic, Petr; Vladyka, Vilibald",null,null,"Stereotactic radiofrequency amygdalohippocampectomy in the treatment of mesial temporal lobe epilepsy","ACTA NEUROCHIRURGICA",null,null,"English","Article",null,null,null,null,null,"Temporal lobe epilepsy; Stereotactic neurosurgery; Amygdalohippocampectomy; Surgical outcome","RESECTION; SURGERY; EXTENT; RADIOSURGERY; LOBECTOMY","Minimally invasive percutaneous single trajectory stereotactic radiofrequency amygdalohippocampectomy was used to treat mesial temporal lobe epilepsy (MTLE). The aim of the study was to evaluate complications and effectiveness of this procedure. A group of 51 patients with MTLE was treated using stereotactic thermo-lesion of amygdalohippocampal complex under local anaesthesia. The target was reached through the occipital approach with a single trajectory using MRI stereotactic localisation. Thermocoagulation of the amygdalohippocampal complex was planned according to the individual anatomy of each patient. Amygdalohippocampectomy was performed using a string electrode with a 10-mm active tip, and 16-38 lesions (median = 25) were performed in all patients along the 30- to 45-mm trajectory (median = 35) in the amygdalohippocampal complex. The procedure was well tolerated by all patients with no severe permanent morbidity; meningitis was recorded in two patients (4%), hematoma was detected in four patients, clinically insignificant in three of them, and one patient required temporary ventricular drainage (2%). Thirty-two patients were followed up over at least 2 years, and the clinical outcomes were evaluated by Engel's classification; 25 of them (78%) were Engel I, five (16%) were Engel II, and two (6%) were Engel IV. Stereotactic amygdalohippocampectomy is a minimally invasive procedure with low morbidity and good results that can be the method of choice in selected patients with MTLE.","[Liscak, Roman; Vladyka, Vilibald] Hosp Homolce, Dept Stereotact & Radiat Neurosurg, Prague 15030, Czech Republic; [Malikova, Hana] Hosp Homolce, Dept Radiol, Prague 15030, Czech Republic; [Kalina, Miroslav; Vojtech, Zdenek; Prochazka, Tomas] Hosp Homolce, Dept Neurol, Prague 15030, Czech Republic; [Marusic, Petr] Charles Univ Prague, Motol Hosp, Dept Neurol, Fac Med 2, Prague, Czech Republic","Liscak, R (reprint author), Hosp Homolce, Dept Stereotact & Radiat Neurosurg, Roentgenova 2, Prague 15030, Czech Republic.","roman.liscak@homolka.cz",null,null,null,null,null,32,5,5,"SPRINGER WIEN","WIEN","SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA","0001-6268",null,null,"ACTA NEUROCHIR","Acta Neurochir.","AUG",2010,152,8,null,null,null,null,1291,1298,null,"10.1007/s00701-010-0637-2",null,8,"Clinical Neurology; Surgery","Neurosciences & Neurology; Surgery","622YV","WOS:000279704300004"]
[null,null,null,null,"J","Cap, J; Ceeova, V; Skacha, M; Rezek, P; Vlcek, P; Blaha, M",null,null,null,"Cap, J.; Ceeova, V.; Skacha, M.; Rezek, P.; Vlcek, P.; Blaha, M.",null,null,"Plasma Filtration in the Treatment of Graves' Ophthalmopathy: A Randomized Study","JOURNAL OF CLINICAL APHERESIS",null,null,"English","Article",null,null,null,null,null,"thyroid-associated ophthalmopathy; treatment; plasma filtration; clinical activity score","PLASMAPHERESIS; EXCHANGE; IMMUNOADSORPTION; IMMUNOGLOBULINS; EXOPHTHALMOS; THERAPY; DISEASE; SERUM","The aim of this study was to perform a randomized study to evaluate the role of plasma filtration in the treatment of severe thyroid-associated ophthalmopathy (TAO). 20 patients were enrolled, and all patients were treated with methylprednisolone IV pulses. 10 randomly chosen patients were also subjected to plasma filtration (twice weekly in Weeks 1, 2, 4, 7, and 10). The procedure proved to be safe. All immunoglobulin classes as well as autoantibodies directed against thyroglobulin, thyroid peroxidase, and TSH receptor exhibited statistically significantly decreases. Some markers of cell-mediated immunity such as soluble antigen CD30 and monocyte chemotactic protein 1 decreased, but serum levels of other markers such as CD40 ligand and soluble protein Fas/Apo-1 did not change significantly. The decrease of immunoglobulins was long lasting, whereas cytokine levels returned to basal values before the next apheresis. Although the clinical activity score (CAS) dropped in all patients, it occurred more rapidly in patients treated with plasma filtration. The CAS difference between the two groups was statistically significant (p = 0.027). The amplitude of visual evoked potentials improved after 3 months in the plasma filtration group. At the end of the study, there was no difference between patients treated with aphereses and the control group. Eye muscle width and proptosis measured by CT scan did not differ between the two groups. We conclude that apheresis can decrease disease activity more rapidly than standard high-dose IV glucocorticoid therapy. Whether this superior treatment effect could potentially avoid surgical procedures remains to be determined. J. Clin. Apheresis 25:209-215, 2010. (C) 2010 Wiley-Liss. Inc.","[Cap, J.; Ceeova, V.; Blaha, M.] Charles Univ Prague, Fac Med, Dept Internal Med 2, Hradec Kralove, Czech Republic; [Cap, J.; Ceeova, V.; Blaha, M.] Charles Univ Prague, Teaching Hosp, Hradec Kralove, Czech Republic; [Skacha, M.; Rezek, P.; Vlcek, P.] Charles Univ Prague, Fac Med 2, Dept Nucl Med & Endocrinol, Prague, Czech Republic; [Skacha, M.; Rezek, P.; Vlcek, P.] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic","Cap, J (reprint author), Univ Hosp, Dept Internal Med 2, Sokolska 581, Hradec Kralove 50005, Czech Republic.","capj@lfhk.cuni.cz","Cap, Jan/C-3377-2014",null,"Czech Ministry of Health Agency IGA [NR 9181-3]","Contract grant sponsor: The Czech Ministry of Health Agency IGA; Contract grant number: NR 9181-3",null,28,5,5,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","0733-2459",null,null,"J CLIN APHERESIS","J. Clin. Apheresis",null,2010,25,4,null,null,null,null,209,215,null,"10.1002/jca.20244",null,7,"Hematology","Hematology","641ZH","WOS:000281171800005"]
[null,null,null,null,"J","Buggiani, G; Krysenka, A; Grazzini, M; Vasku, V; Hercogova, J; Lotti, T",null,null,null,"Buggiani, Gionata; Krysenka, Alena; Grazzini, Marta; Vasku, Vladimir; Hercogova, Jana; Lotti, Torello",null,null,"Paraneoplastic vasculitis and paraneoplastic vascular syndromes","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"paraneoplastic; syndromes; vasculitis","MOLECULAR-WEIGHT HEPARIN; GIANT-CELL ARTERITIS; TROUSSEAUS-SYNDROME; TISSUE FACTOR; CUTANEOUS VASCULITIS; LEUKOCYTOCLASTIC VASCULITIS; MONOCLONAL-ANTIBODY; ADHESION MOLECULES; SYSTEMIC-DISEASE; SOLID TUMORS","Paraneoplastic syndromes are localized or diffuse pathologic manifestations that may occur in subjects affected by neoplastic diseases, even occult ones. Among the many clinical manifestations of paraneoplastic syndromes, cutaneous ones are quite common. It is estimated that skin manifestations may represent the very first diagnostic sign of a neoplastic disease in about 1% of patients. Many paraneoplastic syndromes with skin manifestations are caused by vascular alterations. In case of solid tumors, migrant thrombophlebitis and blood hypercoagulability can be seen, whereas in case of hematological neoplasms, vasculitis, and erythromelalgia can occur. Paraneoplastic vasculitis and paraneoplastic vascular syndromes are challenging issues in dermatology and general medicine. The present article will review the actual knowledge in the argument, together with providing hints for its diagnosis and management.","[Buggiani, Gionata; Krysenka, Alena; Grazzini, Marta; Lotti, Torello] Univ Florence, Sch Med, Univ Unit Dermatol, I-50129 Florence, Italy; [Vasku, Vladimir] St Anns Fac Hosp, Brno Med Fac, Dept Dermatovenereol, Brno, Czech Republic; [Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatol, Prague, Czech Republic","Buggiani, G (reprint author), Univ Florence, Sch Med, Univ Unit Dermatol, Via Lorenzo Magnif 104, I-50129 Florence, Italy.","gionata.buggiani@unifi.it",null,null,null,null,null,66,4,5,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296","1529-8019",null,"DERMATOL THER","Dermatol. Ther.","NOV-DEC",2010,23,6,null,null,null,null,597,605,null,"10.1111/j.1529-8019.2010.01367.x",null,9,"Dermatology","Dermatology","676WI","WOS:000283949000005"]
[null,null,null,null,"J","Necas, A; Proks, P; Urbanova, L; Srnec, R; Stehlik, L; Crha, M; Rauser, P; Planka, L; Amler, E; Vojtova, L; Jancar, J",null,null,null,"Necas, Alois; Proks, Pavel; Urbanova, Lucie; Srnec, Robert; Stehlik, Ladislav; Crha, Michal; Rauser, Petr; Planka, Ladislav; Amler, Evzen; Vojtova, Lucy; Jancar, Josef",null,null,"Radiographic Assessment of Implant Failures of Titanium 3.5 LCP vs. 4.5 LCP Used for Flexible Bridging Osteosynthesis of Large Segmental Femoral Diaphyseal Defects in a Miniature Pig Model","ACTA VETERINARIA BRNO",null,null,"English","Article",null,null,null,null,null,"Fracture fixation; bone healing; comminuted fracture; nonunion; ostectomy; buttress plate","DYNAMIC COMPRESSION PLATE; MESENCHYMAL STEM-CELLS; LIMITED CONTACT; BONE-MARROW; INTRAMEDULLARY PIN; GAP MODEL; FIXATION; REGENERATION; STRAIN; REPAIR","The study describes types, absolute and relative numbers of implant failures in flexible bridging osteosynthesis using a six-hole 3.5 mm titanium Locking Compression Plate (n = 9) or a five-hole LCP 4.5 mm titanium (n = 40) selected for the fixation of segmental ostectomy of femoral diaphysis in the miniature pig used as an in vivo model in a study on the healing of a critically sized bone defect using transplantation of mesenchymal stem cells combined with biocompatible scaffolds within a broader research project. Occasional implant failure was evaluated based on radiographic examination of femurs of animals 2, 4, 8, 12 and 16 weeks after surgery. When bone defect was stabilized using 3.5 mm LCP, in 6 cases (66.7%) the screw was broken/lost in the proximal fragment of the femur 2 weeks after implantation (n = 4) and 4 weeks after implantation (n = 2). In 4 cases of these, the implant failure was accompanied also by loosening of the screw in position 3 in the proximal fragment of the femur. During ostectomy stabilization with 4.5 mm LCP, in 3 cases (7.5%) LCP was broken at the place of the empty central plate hole (without inserted screw) at the level of the segmental bone defect. Compared to the six-hole 3.5 mm LCP, the five-hole titanium 4.5 mm LCP is more suitable implant for flexible bridging osteosynthesis of a critically sized segmental defect of femoral diaphysis in the miniature pig. The results of this study will allow reducing implant failures in time-and cost-demanding transplantation experiments focused on bone healing.","[Necas, Alois; Urbanova, Lucie; Srnec, Robert; Crha, Michal; Rauser, Petr] Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Surg & Orthopaed, Brno 61242, Czech Republic; [Proks, Pavel; Stehlik, Ladislav] Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Diagnost Imaging, Brno 61242, Czech Republic; [Planka, Ladislav] Fac Hosp Brno, Dept Pediat Surg Orthopaed & Traumatol, Brno, Czech Republic; [Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague, Czech Republic; [Amler, Evzen] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague, Czech Republic; [Vojtova, Lucy; Jancar, Josef] Brno Univ Technol, Inst Mat Chem, Brno, Czech Republic","Necas, A (reprint author), Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Surg & Orthopaed, Palackeho 1-3, Brno 61242, Czech Republic.","necas@eurosat.cz","Vojtova, Lucy/D-7762-2012; Jancar, Josef/E-3360-2012; Crha, Michal/E-4279-2012",null,"Ministry of Education, Youth and Sports of the Czech Republic [NPV II 2B06130]","This work was supported by the Ministry of Education, Youth and Sports of the Czech Republic (Research Project NPV II 2B06130).",null,37,3,3,"VETERINARNI A FARMACEUTICKA UNIVERZITA BRNO","BRNO","PALACKEHO 1-3, BRNO CS-612 42, CZECH REPUBLIC","0001-7213",null,null,"ACTA VET BRNO","Acta Vet. BRNO","DEC",2010,79,4,null,null,null,null,599,"U101",null,"10.2754/avb201079040599",null,10,"Veterinary Sciences","Veterinary Sciences","722FV","WOS:000287418300012"]
[null,null,null,null,"J","Necas, A; Proks, P; Urbanova, L; Srnec, R; Stehlik, L; Crha, M; Rauser, P; Planka, L; Janovec, J; Dvorak, M; Amler, E; Vojtova, L; Jancar, J",null,null,null,"Necas, Alois; Proks, Pavel; Urbanova, Lucie; Srnec, Robert; Stehlik, Ladislav; Crha, Michal; Rauser, Petr; Planka, Ladislav; Janovec, Jan; Dvorak, Milan; Amler, Evzen; Vojtova, Lucy; Jancar, Josef",null,null,"Healing of Large Segmental Bone Defect after Implantation of Autogenous Cancellous Bone Graft in Comparison to Hydroxyapatite and 0.5% Collagen Scaffold Combined with Mesenchymal Stem Cells","ACTA VETERINARIA BRNO",null,null,"English","Article",null,null,null,null,null,"Fracture fixation; bone healing; comminuted fracture; callus; ostectomy; buttress plate","PHYSEAL DEFECTS; TRANSPLANTATION; REGENERATION; RADIOGRAPHY; CARTILAGE; REPAIR; RATS","At present, attention is focused on research into possibilities of healing large bone defects by the method of mini-invasive osteosynthesis, using implantation of biomaterials and mesenchymal stem cells (MSCs). This study evaluates the healing of segmental femoral defects in miniature pigs based on the radiological determination of the callus: cortex ratio at 16 weeks after ostectomy. The size of the formed callus was significantly larger (p < 0.05) in animals after transplantation of an autogenous cancellous bone graft (group A, callus : cortex ratio of 1.77 +/- 0.33) compared to animals after transplantation of cylindrical scaffold from hydroxyapatite and 0.5% collagen (group S, callus : cortex ratio of 1.08 +/- 0.13), or in animals after transplantation of this scaffold seeded with MSCs (group S + MSCs, callus: cortex ratio of 1.15 +/- 0.18). No significant difference was found in the size of callus between animals of group S and animals of group S + MSCs. Unlike a scaffold in the shape of the original bone column, a freely placed autogenous cancellous bone graft may allow the newly formed tissue to spread more to the periphery of the ostectomy defect. Implanted cylindrical scaffolds (with and without MSCs) support callus formation directly in the center of original bone column in segmental femoral ostectomy, and can be successfully used in the treatment of large bone defects.","[Necas, Alois; Urbanova, Lucie; Srnec, Robert; Crha, Michal; Rauser, Petr; Janovec, Jan; Dvorak, Milan] Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Surg & Orthopaed, Brno 61242, Czech Republic; [Proks, Pavel; Stehlik, Ladislav] Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Diagnost Imaging, Brno 61242, Czech Republic; [Planka, Ladislav] Fac Hosp Brno, Dept Pediat Surg Orthopaed & Traumatol, Brno, Czech Republic; [Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague, Czech Republic; [Amler, Evzen] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague, Czech Republic; [Vojtova, Lucy; Jancar, Josef] Brno Univ Technol, Inst Mat Chem, Brno, Czech Republic","Necas, A (reprint author), Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Surg & Orthopaed, Palackeho 1-3, Brno 61242, Czech Republic.","necas@eurosat.cz","Vojtova, Lucy/D-7762-2012; Jancar, Josef/E-3360-2012; Crha, Michal/E-4279-2012",null,"Ministry of Education, Youth and Sports of the Czech Republic [NPV II 2B06130]","This work was supported by the Ministry of Education, Youth and Sports of the Czech Republic (Research Project NPV II 2B06130). Preliminary results of the study were presented at the conference \"School, Science, Practice II\" in 2009 in Kosice and published in the proceedings.",null,35,3,3,"VETERINARNI A FARMACEUTICKA UNIVERZITA BRNO","BRNO","PALACKEHO 1-3, BRNO CS-612 42, CZECH REPUBLIC","0001-7213",null,null,"ACTA VET BRNO","Acta Vet. BRNO","DEC",2010,79,4,null,null,null,null,607,"U108",null,"10.2754/avb201079040607",null,7,"Veterinary Sciences","Veterinary Sciences","722FV","WOS:000287418300013"]
[null,null,null,null,"J","Hill, M; Zarubova, J; Marusic, P; Vrbikova, J; Velikova, M; Kancheva, R; Kancheva, L; Kubatova, J; Duskova, M; Zamrazilova, L; Kazihnitkova, H; Simunkova, K; Starka, L",null,null,null,"Hill, Martin; Zarubova, Jana; Marusic, Petr; Vrbikova, Jana; Velikova, Marta; Kancheva, Radmila; Kancheva, Lyudmila; Kubatova, Jana; Duskova, Michaela; Zamrazilova, Ludmila; Kazihnitkova, Hana; Simunkova, Katerina; Starka, Luboslav",null,null,"Effects of valproate and carbamazepine monotherapy on neuroactive steroids, their precursors and metabolites in adult men with epilepsy","JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY",null,null,"English","Article",null,null,null,null,null,"Epilepsy; Neuroactive steroids; Pregnanolone isomers; Androstanes; GC-MS; Carbamazepine; Valproate","CORTICOTROPIN-RELEASING HORMONE; ANTIEPILEPTIC DRUGS; DEHYDROEPIANDROSTERONE-SULFATE; SEXUAL FUNCTION; PSYCHONEUROENDOCRINE ASPECTS; AFTERDISCHARGE THRESHOLDS; ANTICONVULSANT METABOLITE; TEMPOROLIMBIC EPILEPSY; REPRODUCTIVE-STEROIDS; CATAMENIAL EPILEPSY","Only limited data is available concerning the role of unconjugated Delta(5) C19-steroids and almost no data exists regarding the neuroactive C21 and C19 3 alpha-hydroxy-5 alpha/beta-metabolites in men with epilepsy. To evaluate the alterations in serum neuroactive steroids and related substances in adult men with epilepsy on valproate and carbamazepine monotherapy, we have measured 26 unconjugated steroids, 18 steroid polar conjugates, gonadotropins and sex hormone binding globulin (SHBG) in 6 and 11 patients on valproate and carbamazepine monotherapy, respectively, and in 19 healthy adult men, using the GC-MS and immunoassays. Decreased testosterone, free androgen index, free testosterone, androstenediol,- 5 alpha-androstane-3 alpha,17 beta-diol (androstanediol), androsterone, epiandrosterone. DHEA. 7 beta-hydroxy-DHEA, and DHEAS levels were associated with epilepsy per se. Valproate (VPA) therapy increased 5 alpha-dlihydrotestosterone, androsterone, epiandrosterone, DHEA. DHEAS, and 7 beta-hydroxy-DHEA levels. Decrease in pregnenolone and 17-hydroxypregnenolone were associated with epilepsy with no effect of antiepileptic drugs (AEDs). Alternatively, the increase in progesterone levels was linked to epilepsy and VPA further Increased progesterone levels. Reduced steroid 20 alpha-hydroxy-metabolites and cortisol were connected with epilepsy without an effect of AEDs. Carbamazepine induced only slight decrease in isopregnanolone, 5 alpha,20 alpha-tetrahydroprogesterone, and androstanediol levels. (C) 2010 Elsevier Ltd. All rights reserved.","[Hill, Martin] Inst Endocrinol, Steroid Hormone Unit, CZ-11694 Prague 1, Czech Republic; [Hill, Martin] Fac Med 1, Dept Obstet & Gynecol, Prague, Czech Republic; [Hill, Martin] Gen Teaching Hosp, Prague, Czech Republic; [Zarubova, Jana] Thomayers Teaching Hosp, Dept Neurol, CZ-14059 Prague, Czech Republic; [Marusic, Petr] Charles Univ Prague, Fac Med 2, Motol Hosp, CZ-15006 Prague 5, Czech Republic; [Simunkova, Katerina] Charles Univ Prague, Dept Gen Teaching Hosp 3, Fac Med 1, CZ-11001 Prague 1, Czech Republic","Hill, M (reprint author), Inst Endocrinol, Steroid Hormone Unit, Narodni Trida 8, CZ-11694 Prague 1, Czech Republic.","mhill@endo.cz; jvrbikova@endo.cz; mvelikova@endo.cz; rkanceva@endo.cz; jkubatova@endo.cz; mduskova@endo.cz; lzamrazilova@endo.cz; hkazihnitkova@endo.cz; ksimunkova@endo.cz; lstarka@endo.cz","Perez , Claudio Alejandro/F-8310-2010","Perez , Claudio Alejandro/0000-0001-9688-184X","IGA [1A/8649-5]","Grant project IGA 1A/8649-5 supported this research.",null,67,3,3,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0960-0760",null,null,"J STEROID BIOCHEM","J. Steroid Biochem. Mol. Biol.","OCT",2010,122,4,null,null,null,null,239,252,null,"10.1016/j.jsbmb.2010.06.003",null,14,"Biochemistry & Molecular Biology; Endocrinology & Metabolism","Biochemistry & Molecular Biology; Endocrinology & Metabolism","673TW","WOS:000283687100016"]
[null,null,null,null,"J","Kotlin, R; Blazek, B; Suttnar, J; Maly, M; Kvasnicka, J; Dyr, JE",null,null,null,"Kotlin, Roman; Blazek, Bohumir; Suttnar, Jiri; Maly, Martin; Kvasnicka, Jan; Dyr, Jan E.",null,null,"Dysfibrinogenemia in childhood: two cases of congenital dysfibrinogens","BLOOD COAGULATION & FIBRINOLYSIS",null,null,"English","Article",null,null,null,null,null,"dysfibrinogenemia; fibrinogen; fibrinopeptide A; missense mutation","AMINO-ACID SUBSTITUTIONS; A-ALPHA; FIBRINOGEN VARIANT; POLYMERIZATION SITE; THROMBIN; CYS; FIBRINOPEPTIDE; ARG","A 2-year-old asymptomatic boy and his relatives were investigated for a suspected fibrinogen mutation after coagulation tests revealed a decreased functional fibrinogen level (family A). Eight-year-old and 1-year-old asymptomatic brothers were investigated for a suspected fibrinogen mutation after coagulation tests revealed a decreased functional fibrinogen level and prolonged thrombin time (family B). To identify whether genetic mutations were responsible for these dysfibrinogens, DNA extracted from the blood was analyzed. Fibrin polymerization and fibrinolysis were measured by a turbidimetric method at 450 nm. DNA analysis was performed by the Sanger method. Mass spectroscopy was performed on a Biflex IV mass spectrometer. DNA sequencing showed the heterozygous point mutation A alpha Arg16His in the fibrinogen of family A and the heterozygous point mutation A alpha Arg16Cys in the fibrinogen of family B. Kinetics of fibrinopeptide release, fibrinolysis, and fibrin polymerization were impaired in the carriers of the mutations in both families. Mass spectroscopy showed the presence of mutant fibrinogen chains in circulation. Scanning electron microscopy revealed thicker fibrin fibers, differing significantly from the normal control in both cases. Two cases of asymptomatic dysfibrinogenemias, found by routine coagulation testing, were genetically identified as new cases of fibrinogen variants Aa Arg16His and Aa Arg16Cys. Blood Coagul Fibrinolysis 21:640-648 (c) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.","[Kotlin, Roman; Suttnar, Jiri; Dyr, Jan E.] Inst Hematol & Blood Transfus, CR-12820 Prague 2, Czech Republic; [Blazek, Bohumir] Univ Ostrava, Univ Hosp Ostrava, Dept Pediat, Ostrava, Czech Republic; [Maly, Martin] Motol Univ Hosp, Dept Cardiol, Prague, Czech Republic; [Kvasnicka, Jan] First Fac Med, Dept Med 1, Clin Dept Hematol & Nephrol, Prague, Czech Republic; [Kvasnicka, Jan] Gen Teaching Hosp, Prague, Czech Republic","Kotlin, R (reprint author), Inst Hematol & Blood Transfus, U Nemocnice 1, CR-12820 Prague 2, Czech Republic.","kotlinr@uhkt.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Internal Grant Agency of the Ministry of Health of the Czech Republic [NS 9636-3/2008]; Academy of Sciences of the Czech Republic [KAN200670701]; Ministry of Health of the Czech Republic [2373601, MZO VFN2005]","The work was supported by a grant of The Internal Grant Agency of the Ministry of Health of the Czech Republic, number NS 9636-3/2008, by a grant of The Ministry of Health of the Czech Republic, number 2373601, by a grant of The Academy of Sciences of the Czech Republic, number KAN200670701, and by a grant of The Ministry of Health of the Czech Republic, number MZO VFN2005.",null,30,3,3,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0957-5235","1473-5733",null,"BLOOD COAGUL FIBRIN","Blood Coagul. Fibrinolysis","OCT",2010,21,7,null,null,null,null,640,648,null,"10.1097/MBC.0b013e32833e4284",null,9,"Hematology","Hematology","658IK","WOS:000282483500004"]
[null,null,null,null,"J","Kabicek, P; Sulek, S; Seidl, Z; Vaneckova, M; Kabickova, E; Vobruba, V; Wenchich, L; Zeman, J",null,null,null,"Kabicek, Pavel; Sulek, Stepan; Seidl, Zdenek; Vaneckova, Manuela; Kabickova, Edita; Vobruba, Vaclav; Wenchich, Laszlo; Zeman, Jiri",null,null,"Posterior Reversible Encephalopathy Syndrome (PRES) in 5-year-old girl with nephrotic syndrome","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"Posterior Reversible Encephalopathy Syndrome (PRES); children; nephrotic syndrome; hypertension; brain angioedema; MRI","STATUS EPILEPTICUS","OBJECTIVE: Posterior Reversible Encephalopathy Syndrome (PRES) is a rare complication of nephrotic syndrome in children. This clinical condition is caused by localized brain angioedema mostly in parieto-occipital region and results in dramatic and acute features as sudden loss of consciousness, epileptic paroxysms, strong headache or visual disturbances. Uncontrolled hypertension often participates in PRES development. CASE: We present the case of a 5-year-old girl treated for relapse of nephrotic syndrome. RESULTS: At the time of edema regression and weight reduction, a sudden loss of consciousness and worsening of hypertension occurred. Brain MRI demonstrated extended multifocal changes strongly suspicious of encephalitis. After exclusion of herpetic encephalitis, the clinical picture was classified as PRES. Successful antihypertensive treatment led to general improvement of the girl's health within 48 hours and resolution of MRI brain hyperintensities occurred within the next three months. CONCLUSIONS: The aim of our case report is to us remind of possible development of PRES at the time of edema regression in nephrotic syndrome.","[Kabicek, Pavel; Sulek, Stepan; Vobruba, Vaclav; Wenchich, Laszlo; Zeman, Jiri] Charles Univ Prague, Dept Pediat & Adolescent Med, Gen Univ Hosp, Prague 12808 2, Czech Republic; [Kabicek, Pavel; Sulek, Stepan; Seidl, Zdenek; Vaneckova, Manuela; Vobruba, Vaclav; Wenchich, Laszlo; Zeman, Jiri] Charles Univ Prague, Fac Med 1, Prague 12808 2, Czech Republic; [Seidl, Zdenek; Vaneckova, Manuela] Charles Univ Prague, Dept Radiol, Gen Univ Hosp, Prague 12808 2, Czech Republic; [Kabickova, Edita] Charles Univ Prague, Dept Pediat Hematooncol, Univ Hosp Motol, Prague 12808 2, Czech Republic; [Kabickova, Edita] Charles Univ Prague, Fac Med 2, Prague 12808 2, Czech Republic","Kabicek, P (reprint author), Charles Univ Prague, Dept Pediat & Adolescent Med, Gen Univ Hosp, Ke Karlovu 2, Prague 12808 2, Czech Republic.","p.kabicek@post.cz",null,null," [MSM 0021620849];  [MZ0VFN2005];  [MZ0FNM2005]","This work was carried out thanks to the support of the following grants: MSM 0021620849, MZ0VFN2005 and MZ0FNM2005.",null,11,3,3,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2010,31,3,null,null,null,null,297,300,null,null,null,4,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","632XG","WOS:000280462300003"]
[null,null,null,null,"J","Vrzalova, Z; Hruba, Z; Hrabincova, ES; Pouchla, S; Votava, F; Kolouskova, S; Fajkusova, L",null,null,null,"Vrzalova, Zuzana; Hruba, Zuzana; Hrabincova, Eva ST'Ahlova; Pouchla, Slavka; Votava, Felix; Kolouskova, Stanislava; Fajkusova, Lenka",null,null,"Identification of CYP21A2 mutant alleles in Czech patients with 21-hydroxylase deficiency","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE",null,null,"English","Article",null,null,null,null,null,"congenital adrenal hyperplasia; steroid 21-hydroxylase; 21-hydroxylase deficiency; pseudogene; chimeric gene","CONGENITAL ADRENAL-HYPERPLASIA; STEROID 21-HYDROXYLASE; RCCX MODULE; CHIMERIC CYP21P/CYP21; MUTATIONAL SPECTRUM; GENE CONVERSIONS; MOLECULAR-BASIS; COMPLEMENT; COMPONENT; DISEASE","Congenital adrenal hyperplasia (CAH) is comprised of a group of autosomal recessive disorders caused by an enzymatic deficiency which impairs the biosynthesis of cortisol and, in most of the severe cases, also the biosynthesis of aldosterone. Approximately 90-95% of all the CAH cases are due to mutations in the steroid 21-hydroxylase gene (CYP21A2). In this study, the molecular genetic analysis of CYP21A2 was performed in 267 Czech probands suspected of 21-hydroxylase deficiency (21OHD). 21OHD was confirmed in 241 probands (2 mutations were detected). In 26 probands, a mutation was found only in 1 CYP21A2 allele. A set of 30 different mutant alleles was determined. We describe i) mutated CYP21A2 alleles carrying novel point mutations (p.Thr168Asn, p.Ser 169X and p.Pro386Arg), ii) mutated CYP21A2 alleles carrying the novel chimeric gene designated as CH-7, which was detected in 21.4% of the mutant alleles, iii) an unusual genotype with a combination of the CYP21A2 duplication, 2 point mutations and the CYP21A2 large-scale gene conversion on the second allele, and (iv) a detailed analysis of the chimeric CYP21A1P/CYP21A2 genes. In conclusion, our genotyping approach allowed for the accurate identification of the CYP21A2 gene mutations in 21OHD patients and their families and provided some useful information on diagnosis and genetic counselling.","[Vrzalova, Zuzana; Hruba, Zuzana; Hrabincova, Eva ST'Ahlova; Pouchla, Slavka; Fajkusova, Lenka] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, CZ-62500 Brno, Czech Republic; [Votava, Felix] Charles Univ Prague, Fac Med 3, Dept Pediat, CZ-10034 Prague, Czech Republic; [Votava, Felix] Univ Hosp Kralovske Vinohrady, CZ-10034 Prague, Czech Republic; [Kolouskova, Stanislava] Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-15006 Prague, Czech Republic; [Kolouskova, Stanislava] Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Fajkusova, Lenka] Masaryk Univ, Fac Sci, Inst Expt Biol, Dept Funct Genom & Prote, CZ-62500 Brno, Czech Republic","Fajkusova, L (reprint author), Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Cernopolni 9, CZ-62500 Brno, Czech Republic.","lenkafajkusova@volny.cz","Fajkusova, Lenka/E-1636-2012",null,"Internal Grant Agency of the Czech Ministry of Health [NR9308-3, NS9981-3]; Czech Ministry of Education [LC06023, MSM0021622415, MSM0021620814]","This study was supported by the Internal Grant Agency of the Czech Ministry of Health (grant nos. NR9308-3 and NS9981-3) and by the Czech Ministry of Education (project nos. LC06023, MSM0021622415 and MSM0021620814).",null,31,2,3,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1107-3756",null,null,"INT J MOL MED","Int. J. Mol. Med.","OCT",2010,26,4,null,null,null,null,595,603,null,"10.3892/ijmm_00000504",null,9,"Medicine, Research & Experimental","Research & Experimental Medicine","651HF","WOS:000281917800021"]
[null,null,null,null,"J","Wawrzycki, B; Chodorowska, G; Pietrzak, A; Jazienicka, I; Skomra, D; Kowal, M; Dybiec, E; Hercogova, J",null,null,null,"Wawrzycki, Bartlomiej; Chodorowska, Grazyna; Pietrzak, Aldona; Jazienicka, Iwona; Skomra, Danuta; Kowal, Malgorzata; Dybiec, Ewa; Hercogova, Jana",null,null,"THERAPEUTIC HOTLINE: Primary cutaneous CD4+ small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"cyclophosphamide; myelodysplastic syndrome; primary cutaneous CD4+small; medium-sized pleomorphic T-cell lymphoma","WHO-EORTC; CLASSIFICATION","Cutaneous T cell lymphomas other than mycosis fungoides, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferations constitute less than 10% of all cutaneous T cell lymphomas. Primary cutaneous small/medium CD4+ T cell lymphoma is a member of this third group of cutaneous lymphomas, separated out as provisional entity in the World Health Organization classification - European Organization for Research and Treatment of Cancer (WHO-EORTC) classification. It still awaits development of more precise diagnostic criteria and optimal therapy. We report a case of primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma accompanied with myelodysplastic syndrome successfully treated with cyclophosphamide. It seems that cyclophosphamide as a single-agent chemotherapy in patients with disseminated lesions might be safe and quite effective therapeutic option.","[Wawrzycki, Bartlomiej; Chodorowska, Grazyna; Pietrzak, Aldona; Jazienicka, Iwona] Med Univ Lublin, Chair Dermatol Venereol & Pediat Dermatol, PL-20080 Lublin, Poland; [Wawrzycki, Bartlomiej; Chodorowska, Grazyna; Pietrzak, Aldona; Jazienicka, Iwona] Med Univ Lublin, Dept Dermatol Venereol & Pediat Dermatol, PL-20080 Lublin, Poland; [Skomra, Danuta] Med Univ Lublin, Dept Clin Pathomorphol, Prague, Czech Republic; [Kowal, Malgorzata] Med Univ Lublin, Chair Hematooncol & Bone Marrow Transplantat, Prague, Czech Republic; [Kowal, Malgorzata] Med Univ Lublin, Dept Hematooncol & Bone Marrow Transplantat, Prague, Czech Republic; [Dybiec, Ewa] Med Univ Lublin, Dept Pediat Radiol, Prague, Czech Republic; [Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatol, Prague, Czech Republic","Wawrzycki, B (reprint author), Med Univ Lublin, Chair Dermatol Venereol & Pediat Dermatol, Radziwillowska 13, PL-20080 Lublin, Poland.","bartekwawrzycki@o2.pl",null,null,null,null,null,14,2,2,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","NOV-DEC",2010,23,6,null,null,null,null,676,681,null,"10.1111/j.1529-8019.2010.01372.x",null,6,"Dermatology","Dermatology","676WI","WOS:000283949000010"]
[null,null,null,null,"J","Lemez, P; Attarbaschi, A; Bene, MC; Bertrand, Y; Castoldi, G; Forestier, E; Garand, R; Haas, OA; Kagialis-Girard, S; Ludwig, WD; Matutes, E; Mejstrikova, E; Pages, MP; Pickl, W; Porwit, A; Orfao, A; Schabath, R; Stary, J; Strobl, H; Talmant, P; van't Veer, MB; Zemanova, Z",null,null,null,"Lemez, Petr; Attarbaschi, Andishe; Bene, Marie C.; Bertrand, Yves; Castoldi, Gianluigi; Forestier, Erik; Garand, Richard; Haas, Oskar A.; Kagialis-Girard, Sandrine; Ludwig, Wolf-Dieter; Matutes, Estella; Mejstrikova, Ester; Pages, Marie-Pierre; Pickl, Winfried; Porwit, Anna; Orfao, Alberto; Schabath, Richard; Stary, Jan; Strobl, Herbert; Talmant, Pascaline; van't Veer, Mars B.; Zemanova, Zuzana",null,"European Grp Immunological Charact","Childhood near-tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases","EUROPEAN JOURNAL OF HAEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"Tetraploid acute lymphoblastic leukemia; polyploidy; childhood; classification; immunophenotyping; molecular genetics; prognosis","ACUTE MYELOID LEUKEMIAS; NORDIC COUNTRIES; EXPRESSION; CHILDREN; FUSION; CLASSIFICATION; REDUCTION; DIAGNOSIS; IMPACT; TRIALS","Objectives: Patients with near-tetraploid (karyotype: 81 - 103 chromosomes) acute lymphoblastic leukemia (NT-ALL) constitute about 1% of childhood ALL and data reported on them are limited and controversial. The aim of the study was to enlarge the knowledge on these rarely occurring ALL. Methods: The members of the European Group for Immunophenotyping of Leukemias (EGIL) searched retrospectively their databases for NT-ALL patients. Results: We collected data of 36 European children from seven European countries with NT-ALL diagnosed since 1992. All patients reached complete remission (CR) after induction chemotherapy. Their blasts were negative for peroxidase and BCR-ABL1. Ten children were diagnosed as T-cell ALL (T-ALL) EGIL categories (T-I n = 2, T-II n = 2, T-III n = 3, T-IV n = 3) and four displayed various structural chromosomal abnormalities. Eight of 10 T-ALL remained in 1st CR; one died in CR from sepsis and one is alive in 2nd CR. Median survival was 88 (7-213) months. B-cell precursor (BCP) ALL was diagnosed in 26 children. Thirteen were positive for ETV6-RUNX1 and are alive in 1st CR for 32-147 months. Ten children were ETV6-RUNX1 negative and remained in 1st CR for 16-163 months. One girl with hypodiploid and NT metaphases and ETV6-RUNX1-negative BCP-ALL and one of two boys with NT-BCP-ALL not examined for ETV6-RUNX1 died of infection after stem cell transplantation in 2nd/3rd CR. Secondary myelodysplastic syndrome developed in two patients with NT-BCP-ALL. Conclusions: Our data demonstrate immunophenotypic, cytogenetic, and molecular heterogeneity of NT-ALL and favorable prognosis of most NT-ALL across different immunophenotypic and/or genetic ALL subtypes.","[Lemez, Petr] Hosp Jihlava, Dept Hematol & Blood Transfus, Jihlava 58633, Czech Republic; [Attarbaschi, Andishe; Haas, Oskar A.] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Bene, Marie C.] CHU, GEIL Lab Immunol, Nancy, France; [Bene, Marie C.] Fac Med, Nancy, France; [Bertrand, Yves] Hop Debrousse, Dept Pediat Hematol, Lyon, France; [Castoldi, Gianluigi] Univ Ferrara, Inst Hematol, I-44100 Ferrara, Italy; [Forestier, Erik] Umea Univ, Dept Clin Sci, Pediat Unit, Umea, Sweden; [Garand, Richard; Talmant, Pascaline] Univ Hosp, Hematol Lab, Nantes, France; [Kagialis-Girard, Sandrine; Pages, Marie-Pierre] Hop Debrousse, Hematol Lab, Lyon, France; [Ludwig, Wolf-Dieter; Schabath, Richard] HELIOS Clin, Dept Hematol Oncol Tumor Biol, Berlin, Germany; [Matutes, Estella] Royal Marsden Hosp, Dept Haematol Oncol, London SW3 6JJ, England; [Mejstrikova, Ester; Stary, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague, Czech Republic; [Mejstrikova, Ester; Stary, Jan] Univ Hosp Motol, Prague, Czech Republic; [Pickl, Winfried; Strobl, Herbert] Univ Vienna, Inst Immunol, Vienna, Austria; [Porwit, Anna] Karolinska Univ Hosp & Inst, Dept Pathol, Stockholm, Sweden; [Orfao, Alberto] Univ Salamanca, Serv Citometria, E-37008 Salamanca, Spain; [van't Veer, Mars B.] Dr Daniel Den Hoed Canc Ctr, NL-3008 AE Rotterdam, Netherlands; [Zemanova, Zuzana] Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Gen Univ Hosp, Prague, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Fac Med 1, Prague, Czech Republic","Lemez, P (reprint author), Hosp Jihlava, Dept Hematol & Blood Transfus, Vrchlickeho 59, Jihlava 58633, Czech Republic.","plemez@post.cz","Pickl, Winfried/E-5682-2011; IBSAL, Secretaria/H-3719-2011",null,"European LeukemiaNet [WP10]; Czech Ministry of Education [MSM0021620813, MZOVFN2005]; Swedish Childhood Cancer Foundation","A part of data from 9 patients reported here (Case 4, 10, 13-16, 20, 23, 32) have been published previously (8). We thank Jaroslav Jelinek, MD, Ph.D., for his useful comments and support. This work was supported in part by the WP10 of the European LeukemiaNet and several authors were supported by grants from the Czech Ministry of Education MSM0021620813 (E.M., J.S., Z.Z.), MZOVFN2005 (Z.Z.) and the Swedish Childhood Cancer Foundation (E.F.).",null,39,2,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0902-4441",null,null,"EUR J HAEMATOL","Eur. J. Haematol.","OCT",2010,85,4,null,null,null,null,300,308,null,"10.1111/j.1600-0609.2010.01493.x",null,9,"Hematology","Hematology","652YU","WOS:000282049300003"]
[null,null,null,null,"J","Lysak, D; Kalina, T; Martinek, J; Pikalova, Z; Vokurkova, D; Jaresova, M; Marinov, I; Ondrejkova, A; Spacek, M; Stehlikova, O",null,null,null,"Lysak, D.; Kalina, T.; Martinek, J.; Pikalova, Z.; Vokurkova, D.; Jaresova, M.; Marinov, I.; Ondrejkova, A.; Spacek, M.; Stehlikova, O.",null,null,"Interlaboratory variability of CD34+stem cell enumeration. A pilot study to national external quality assessment within the Czech Republic","INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"CD34+cells; enumeration; variability; ISHAGE; survey; interlaboratory","CD34(+) HEMATOPOIETIC STEM; FLOW-CYTOMETRY; PROGENITOR CELLS; SINGLE; TRANSPLANTATION; MULTICENTER; RECIPIENTS; ASSAY","We present the results of a pilot study concerning the interlaboratory variability of CD34+ enumeration. Three surveys, each including a set of samples, were sent to participating Czech flow cytometry laboratories. The efficacy of this exercise was determined by the reduction in interlaboratory variation and the influence of method used on assay outcome. The variability in results of CD34+ enumeration declined with time. The mean coefficient of variation (CV) of measurement among laboratories dropped, from 58% in first survey to 32% in last survey. All tested variables (gating strategy, platform methodology, sample preparation) affected the variability of the assay. Sample preparation method was associated with a significant bias of absolute CD34+ cell counts. Initially, the outcome of the measurement was also affected by the participating laboratory (identified by a unique laboratory number; ULN). However, laboratories with poorer performance modified their protocols during the study, and the ULN ceased to influence the variability. This study was successful in reducing the interinstitutional variability of CD34+ enumeration. It was shown that the implementation of a standardized protocol does not guarantee accurate measurement. Our research design represents a useful tool, which allows verification of the proper use of a standardized method, the training of operators and feedback in response to the survey results.","[Lysak, D.] Charles Univ Hosp, Dept Hematol & Oncol, Plzen 30460, Czech Republic; [Kalina, T.] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Martinek, J.] P&R Lab, Novy Jicin, Czech Republic; [Pikalova, Z.] Univ Hosp Olomouc, Dept Hematooncol, Olomouc, Czech Republic; [Vokurkova, D.] Univ Hosp Hradec Kralove, Inst Clin Immunol & Allergol, Hradec Kralove, Czech Republic; [Jaresova, M.] IKEM, Diagnost Immunol Lab, Prague, Czech Republic; [Marinov, I.] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic; [Ondrejkova, A.] Reg Hosp T Bati, Dept Pulmonol, Zlin, Czech Republic; [Spacek, M.] Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Prague, Czech Republic; [Stehlikova, O.] Univ Hosp Brno, Dept Internal Med Hematooncol, Brno, Czech Republic","Lysak, D (reprint author), Charles Univ Hosp, Dept Hematol & Oncol, Alej Svobody 80, Plzen 30460, Czech Republic.","lysak@fnplzen.cz","Stehlikova, Olga/E-1723-2012",null,"Ministry of Health of the Czech Republic [IGA NR/9268-3]","The study was supported by the grant of the Ministry of Health of the Czech Republic (IGA NR/9268-3).",null,23,1,1,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1751-5521",null,null,"INT J LAB HEMATOL","Int. J. Lab. Hematol.","DEC",2010,32,6,1,null,null,null,"E229","E236",null,"10.1111/j.1751-553X.2010.01244.x",null,8,"Hematology","Hematology","672OL","WOS:000283595500006"]
[null,null,null,null,"J","Altomare, DF; Guanti, G; Hoch, J; Vician, M; Krivokapic, Z; Bergamaschi, R",null,null,null,"Altomare, D. F.; Guanti, G.; Hoch, J.; Vician, M.; Krivokapic, Z.; Bergamaschi, R.",null,"Colorectal Micrometastases Study G","Noncolonic cancer stem cells in bone marrow of colorectal cancer patients","COLORECTAL DISEASE",null,null,"English","Article",null,null,null,null,null,"Noncolonic cancer stem cells; bone marrow; colorectal cancer; immunobeads; anti-human epithelial antigen antibody; liver metastases","DISSEMINATED TUMOR-CELLS; CYTOKERATIN-POSITIVE CELLS; POLYMERASE-CHAIN-REACTION; PROGNOSTIC-SIGNIFICANCE; CARCINOMA PATIENTS; PERIPHERAL-BLOOD; APC GENE; MICROMETASTASES; METASTASES; DISEASE","Objective To investigate whether preoperative noncolonic cancer stem cells in bone marrow (BM) of R0 colorectal cancer (CRC) patients are cancer cells and impact on liver metastases (LM) rates. Method Prospective data on continuous CRC patients were collected from five centres. Bone marrow aspirates, taken at laparotomy, were sent to a single lab. Noncolonic cancer stem cells were defined according to UICC. A quantity of 3 x 106 BM cells per patient was processed with monoclonal antibodies against cytokeratin 20. APC or p53 gene mutation and microsatellite instability (MSI) were assessed in primary tumours (PT) by single-strand conformation polymorphism. Noncolonic cancer stem cells in BM of PT mutation or MSI-positive patients were isolated with immunobeads coated with magnetically labelled anti-human epithelial antigen antibody and DNA-screened for mutations. Results Although 199 patients were enrolled, 162 patients were available for analysis. No patients were lost to follow-up. Twenty-five (2-170) noncolonic cancer stem cells were found in BM of 40 patients. Twenty-two patients developed LM at 36-month follow-up. Adenomatous polyposis coli (APC) or p53 gene mutation or MSI were identified in the PT of 78 patients. The same gene mutations or MSI were not found in noncolonic cancer stem cells of the BM of these patients. After adjustment, there was no significant effect of confounding factors. Noncolonic cancer stem cells in BM had no impact on LM rates, cancer-specific death rates, or all death rates. Conclusions Preoperative noncolonic cancer stem cells in BM of R0 CRC patients were not cancer cells and had no impact on LM rates.","[Guanti, G.] Univ Bari, Dept Biomed, Bari, Italy; [Altomare, D. F.] Univ Bari, Dept Surg, Bari, Italy; [Hoch, J.] Charles Univ Prague, Dept Surg, Prague, Czech Republic; [Vician, M.] Comenius Univ, Dept Surg, Bratislava, Slovakia; [Krivokapic, Z.] Univ Belgrade, Ctr Clin, Dept Surg, Belgrade, Serbia; [Bergamaschi, R.] Forde Hlth Syst, Dept Surg, Bergen, Norway; [Altomare, D. F.] Forde Hlth Syst, Dept Res & Dev, Forde, Norway","Bergamaschi, R (reprint author), SUNY Stony Brook, Div Colon & Rectal Surg, HSC T18-060, Stony Brook, NY 11794 USA.","lutz.sally@gmail.com",null,null,"Research Council of Norway, Oslo, Norway; Embassy of France, Oslo, Norway; Norwegian Cancer Society, Oslo, Norway; Department of Surgical Sciences, University of Bergen, Bergen, Norway; Western Norway Regional Health Authority, Bergen, Norway","This study was supported in part by grants provided by the Research Council of Norway, Oslo, Norway, Embassy of France, Oslo, Norway, Norwegian Cancer Society, Oslo, Norway, Department of Surgical Sciences, University of Bergen, Bergen, Norway, and Western Norway Regional Health Authority, Bergen, Norway. The Colorectal Micrometastases Study Group wishes to thank Arne K. Sandvik, MD, Norwegian University of Science and Technology, Trondheim, Norway for having supplied liquid nitrogen, and Anne Randi Solheim, Forde, Norway for clerical assistance.",null,33,1,1,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1462-8910",null,null,"COLORECTAL DIS","Colorectal Dis.","MAR",2010,12,3,null,null,null,null,206,212,null,"10.1111/j.1463-1318.2009.01776.x",null,7,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","557LK","WOS:000274670400009"]
[null,null,null,null,"J","Humlova, Z; Klamova, H; Janatkova, I; Malickova, K; Kralikova, P; Sterzl, I; Roth, Z; Hamsikova, E; Vonka, V",null,null,null,"Humlova, Zuzana; Klamova, Hana; Janatkova, Ivana; Malickova, Karin; Kralikova, Petra; Sterzl, Ivan; Roth, Zdenek; Hamsikova, Eva; Vonka, Vladimir",null,null,"Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment","CLINICAL & DEVELOPMENTAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,null,"CHRONIC MYELOGENOUS LEUKEMIA; DERMATOMYOSITIS-LIKE ERUPTION; DOSE-DEPENDENT MANNER; ABL-KINASE INHIBITOR; T-CELL PROLIFERATION; C-REACTIVE PROTEIN; INTERFERON-ALPHA; IMATINIB MESYLATE; BCR-ABL; IFN-ALPHA","In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found significant differences in the levels of immunoglobulins, the C4 component of complement, the C-reactive protein, interleukin 6, the composition of lymphocyte population and the production of some cytokines by stimulated CD3+ cells. Eleven of these patients were followed longitudinally. After treatment with hydroxyurea, interferon alpha, imatinib mesylate and dasatinib, or various combinations thereof, hematological remission was achieved in all patients and complete cytogenetic remission in nine of them. There was a nearly general tendency towards normalization of the abnormalities observed in the patients at their enrollment.","[Humlova, Zuzana; Sterzl, Ivan] Charles Univ Prague, Fac Med 1, Dept Immunol & Microbiol, Prague 12111 2, Czech Republic; [Humlova, Zuzana; Sterzl, Ivan] Gen Teaching Hosp Prague, Prague 12111 2, Czech Republic; [Humlova, Zuzana; Janatkova, Ivana; Malickova, Karin] Charles Univ Prague, Fac Med 1, Dept Clin Biochem & Lab Med, Prague 12111 2, Czech Republic; [Klamova, Hana] Inst Hematol & Blood Transfus, Clin Dept, CR-12820 Prague 2, Czech Republic; [Kralikova, Petra] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague 15006 5, Czech Republic; [Roth, Zdenek] Natl Inst Hlth, Dept Biostat, Prague 10000 10, Czech Republic; [Hamsikova, Eva; Vonka, Vladimir] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague 2, Czech Republic","Humlova, Z (reprint author), Charles Univ Prague, Fac Med 1, Dept Immunol & Microbiol, Karlovo Namesti 32, Prague 12111 2, Czech Republic.","zuzana.humlova@seznam.cz",null,null,"Internal Granting Agency of the Ministry of Health, Czech Republic (IGA MZCR) [NC/6957-3, NR/9075-3]; Institute of Hematology and Blood Transfusion [000 273 3601]","Supported by grants from the Internal Granting Agency of the Ministry of Health, Czech Republic (IGA MZCR NC/6957-3, and NR/9075-3) and by Research Project No. 000 273 3601, Institute of Hematology and Blood Transfusion. The authors express their indebtedness to H. Tlaskalova for critical reading of the manuscript.",null,46,1,1,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","1740-2522",null,null,"CLIN DEV IMMUNOL","Clin. Dev. Immunol.",null,2010,null,null,null,null,null,null,null,null,137320,"10.1155/2010/137320",null,17,"Immunology","Immunology","706QA","WOS:000286231700001"]
[null,null,null,null,"J","Spacek, M; Hubacek, P; Markova, J; Zajac, M; Vernerova, Z; Kozak, T",null,null,null,"Spacek, M.; Hubacek, P.; Markova, J.; Zajac, M.; Vernerova, Z.; Kozak, T.",null,null,"Can We Use EBV-DNA Monitoring to Predict Disease Relapse in EBV-Positive Hodgkin Lymphoma Patients?","ACTA HAEMATOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"EPSTEIN-BARR-VIRUS; QUANTITATIVE-ANALYSIS; PLASMA; MARKER; LOAD; CELL; PCR",null,"[Spacek, M.; Markova, J.; Kozak, T.] Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, CZ-10034 Prague, Czech Republic; [Vernerova, Z.] Univ Hosp Kralovske Vinohrady, Dept Pathol, CZ-10034 Prague, Czech Republic; Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Hubacek, P.] Motol Univ Hosp, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Hubacek, P.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Zajac, M.] Motol Univ Hosp, Dept Med Microbiol, Prague, Czech Republic","Spacek, M (reprint author), Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Srobarova 50, CZ-10034 Prague, Czech Republic.","m.spacek@fnkv.cz","Kozak, Tomas/K-3561-2012",null,"Ministry of Health of the Czech Republic [NR9166]","The authors wish to acknowledge the laboratory technician Jana Sumova for laboratory work, Katerina Klaskova for gathering of the data, and Jan Stuchly for statistical analysis. This work was supported by a grant from the Ministry of Health of the Czech Republic (NR9166).",null,14,1,1,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0001-5792",null,null,"ACTA HAEMATOL-BASEL","Acta Haematol.",null,2010,124,1,null,null,null,null,23,26,null,"10.1159/000313790",null,4,"Hematology","Hematology","632XA","WOS:000280461600006"]
[null,null,null,null,"J","Lurbe, E; Cifkova, R; Cruickshank, JK; Dillon, MJ; Ferreira, I; Invitti, C; Kuznetsova, T; Laurent, S; Mancia, G; Morales-Olivas, F; Rascher, W; Redon, J; Schaefer, F; Seeman, T; Stergiou, G; Wuhl, E; Zanchetti, A",null,null,null,"Lurbe, E.; Cifkova, R.; Cruickshank, J. K.; Dillon, M. J.; Ferreira, I.; Invitti, C.; Kuznetsova, T.; Laurent, S.; Mancia, G.; Morales-Olivas, F.; Rascher, W.; Redon, J.; Schaefer, F.; Seeman, T.; Stergiou, G.; Wuehl, E.; Zanchetti, A.",null,null,"Management of high blood pressure in children and adolescents: Recommendations of the European Society of Hypertension","ANALES DE PEDIATRIA",null,null,"Spanish","Article",null,null,null,null,null,null,null,null,"[Lurbe, E.] Univ Valencia, Dept Pediat, Consorcio Hosp Gen, Valencia, Spain; [Lurbe, E.; Redon, J.] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CB06 03, Madrid, Spain; [Cifkova, R.] Inst Clin & Expt Med, Dept Cardiol Prevent, Prague, Czech Republic; [Cruickshank, J. K.] Univ Manchester, Grp Invest Cardiovasc, Manchester Royal Infirm, Div Ciencia Cardiovasc & Endocrina, Manchester, Lancs, England; [Dillon, M. J.] UCL Inst Salud Infantil, Unidad Nefrourol, London, England; [Ferreira, I.] Univ Maastricht, Dept Med Interna & Epidemiol Clin & Evaluac Tecno, Inst Invest Cardiovasc Maastricht CARIM, Inst Invest Cuidado & Salud Publ CAPHRI,Ctr Med, Maastricht, Netherlands; [Invitti, C.] IRCCS, Unidad Enfermedades Metabol & Diabet, Inst Auxol Italiano, Milan, Italy; [Kuznetsova, T.] Univ Leuven, Lab Hipertens, Leuven, Belgium; [Laurent, S.] Hosp Europeo Georges Pompidou, Dept Farmacol, Paris, France; [Mancia, G.] Univ Milano Bicocca, Osped San Gerardo, Milan, Italy; [Morales-Olivas, F.] Univ Valencia, Dept Farmacol, Valencia, Spain; [Rascher, W.] Univ Klinikum, Kinder & Jugendklin, Erlangen, Germany; [Redon, J.] Univ Valencia, Dept Med Interna, Hosp Clin, Valencia, Spain; [Schaefer, F.; Wuehl, E.] Univ Heidelberg, Div Nefrol Pediat, Ctr Med Pediat & Adolescencia, Heidelberg, Germany; [Seeman, T.] Charles Univ Prague, Dept Pediat, Hosp Univ Motol, Prague, Czech Republic","Lurbe, E (reprint author), Univ Valencia, Dept Pediat, Consorcio Hosp Gen, Valencia, Spain.",null,"Schaefer, Franz/G-4365-2010",null,null,null,null,0,0,0,"EDICIONES DOYMA S A","BARCELONA","TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN","1695-4033",null,null,"AN PEDIATR","An. Pediatr.","JUL",2010,73,1,null,null,null,null,51,51,null,"10.1016/j.anpedi.2010.04.001",null,1,"Pediatrics","Pediatrics","630YZ","WOS:000280314200011"]
[null,null,null,null,"J","Lukas, D; Pan, N; Sarkar, A; Weng, M; Chaloupek, J; Kostakova, E; Ocheretna, L; Mikes, P; Pociute, M; Amler, E",null,null,null,"Lukas, D.; Pan, N.; Sarkar, A.; Weng, M.; Chaloupek, J.; Kostakova, E.; Ocheretna, L.; Mikes, P.; Pociute, M.; Amler, E.",null,null,"Auto-model based computer simulation of Plateau-Rayleigh instability of mixtures of immiscible liquids","PHYSICA A-STATISTICAL MECHANICS AND ITS APPLICATIONS",null,null,"English","Article",null,null,null,null,null,"Rayleigh instability; Liquid mixture; Auto-model; Markov Random Field","SYSTEMS","The classic theory to derive the characteristic Rayleigh wavelength, i.e., the distance between neighbouring droplets into which an originally cylindrical liquid body disintegrates, as a consequence of Rayleigh instability, is analysed in terms of the phenomenon of self-organization due to the mechanism of 'fastest forming instability'. The paper aims at simulating this self-organization with Monte Carlo dynamics while accounting spatial interactions in lattices of Markov Random Fields that enable also modelling of Plateau-Rayleigh instability of instable mixtures of dispersed immiscible liquids. The Hammersley and Clifford theorem, concerning the general form of energy function, belonging to Markov Random Fields, is introduced for detailed classification of a simple model used for computer simulation. The relevant Auto-model, with Kawasaki dynamics, is chosen to investigate the liquid jet and the instability of the liquid's cylindrical film. The computer-simulated outputs show encouraging agreement with the classic analytical predictions on main features of the Rayleigh instability. The model is also used as a foundation stone for developing a simple analytical approach for the estimation of Rayleigh wavelength of jets and cylindrical films, composed of instable mixtures of immiscible liquids. Qualitatively, the theory agrees with both computer simulation and experiment. (C) 2010 Elsevier B.V. All rights reserved.","[Lukas, D.; Sarkar, A.; Chaloupek, J.; Kostakova, E.; Ocheretna, L.; Mikes, P.] Tech Univ Liberec, Fac Text Engn, Dept Nonwovens, Nanosci Ctr, Liberec 46117 1, Czech Republic; [Lukas, D.; Mikes, P.] Clemson Univ, Sch Mat Sci & Engn, Clemson, SC 29634 USA; [Pan, N.] Univ Calif Davis, Div Text & Clothing, Dept Biol & Agr Engn, Davis, CA 95616 USA; [Weng, M.] Zhejiang Sci Tech Univ, Minist Educ, Key Lab Adv Text Mat & Mfg Technol, Hangzhou 310018, Peoples R China; [Pociute, M.] Kaunas Univ Technol, Fac Design & Technol, LT-51424 Kaunas, Lithuania; [Amler, E.] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Prague, Czech Republic; [Amler, E.] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague, Czech Republic","Lukas, D (reprint author), Tech Univ Liberec, Fac Text Engn, Dept Nonwovens, Nanosci Ctr, Studentska 2, Liberec 46117 1, Czech Republic.","david.lukas@tul.cz","Pan, Ning/B-1315-2008","Pan, Ning/0000-0002-8772-2596","Agency of AS [IAA500390702]; Ministry of Education of the Czech Republic [CEP1-1M0554]; NTC [M02-CD03]; GACR [102/08/H081]; \"Research Center - TEXTILE, TUL\" [LN00B090]","The authors are very thankful to Konstantin Kornev from Clemson University, SC, and to Ales Linka from the Technical University of Liberec (TUL), for consultations and inspiration on the theory of Markov Random Fields respectively. The authors are also obliged to Miroslav Brezina from TUL for the introduction to the theory of H-surfaces of revolution. This work was supported by the Grant Agency of AS CR grant no. IAA500390702. D.L. and J.C. are also thankful to The Ministry of Education of the Czech Republic for their support in the frame of \"The Research Centre for Advanced Conservation Technologies\" (the project CEP1-1M0554). N.P. and D.L. acknowledge the support from NTC Grant M02-CD03 which supported their joint work at UC Davis. A.S. has been supported by GACR Grant no. 102/08/H081 \"Advanced Application of Physical Fields\". The next co-author (M.P.) is thankful for the support granted by a \"Research Center - TEXTILE, TUL\", Grant No. LN00B090. L.O. and P.M. thank Cummins Filtration for their support and interest in this work.",null,27,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0378-4371",null,null,"PHYSICA A","Physica A","JUN 1",2010,389,11,null,null,null,null,2164,2176,null,"10.1016/j.physa.2010.01.046",null,13,"Physics, Multidisciplinary","Physics","586ET","WOS:000276886300002"]
[null,null,null,null,"J","Jesina, P; Vinsova, K; Brantova, O; Tesarova, M; Hajkova, Z; Hansikova, H; Wenchich, L; Honzik, T; Magner, M; Zamecnik, J; Ryska, P; Zeman, J",null,null,null,"Jesina, P.; Vinsova, K.; Brantova, O.; Tesarova, M.; Hajkova, Z.; Hansikova, H.; Wenchich, L.; Honzik, T.; Magner, M.; Zamecnik, J.; Ryska, P.; Zeman, J.",null,null,"Myoclonic Epilepsy and Deafness in Siblings with the 7512T > C Mutation in the Mitochondrial Encoded tRNA(Ser(UCN)) Gene - Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"mitochondrial disease; myoclonic epilepsy; deafness; calcification in basal ganglia; cytochrom c oxidase deficiency; transfer RNA",null,"Mitochondrial diseases are a very heterogeneous group of disorders affecting the nervous system, heart and skeletal muscle. The mutations are situated in nuclear DNA with Mendelian heredity and in mitochondrial DNA with maternal-type heredity. We describe a natural clinical course, the results of biochemical and molecular genetic measurements from two siblings with mitochondrial disorders due to mutation 7512T>C in the gene for mitochondrial tRNA for serine. The mutation is associated with myoclonic epilepsy, deafness, ataxia, calcification in the basal ganglia and decreased cytochrome c oxidase activity. The data should prove helpful in the exact diagnosis of patients with this phenotype.","[Jesina, P.; Vinsova, K.; Brantova, O.; Tesarova, M.; Hajkova, Z.; Hansikova, H.; Wenchich, L.; Honzik, T.; Magner, M.; Zeman, J.] UK 1 LF, Klin Detskeho & Dorostoveho Lekarstvi, Prague 12808 2, Czech Republic; [Jesina, P.; Vinsova, K.; Brantova, O.; Tesarova, M.; Hajkova, Z.; Hansikova, H.; Wenchich, L.; Honzik, T.; Magner, M.; Zeman, J.] VFN Praze, Prague 12808 2, Czech Republic; [Zamecnik, J.] UK 2 LF, Ustav Patol & Mol Med, Prague, Czech Republic; [Zamecnik, J.] FN Motole, Prague, Czech Republic; [Ryska, P.] FN Hradec Kralove, Hradec Kralove, Czech Republic","Jesina, P (reprint author), UK 1 LF, Klin Detskeho & Dorostoveho Lekarstvi, Ke Karlovu 2, Prague 12808 2, Czech Republic.","paveljesina@seznam.cz","Jesina, Pavel/A-9913-2012",null,null,null,null,10,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2010,73,1,null,null,null,null,68,72,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","569KA","WOS:000275593800010"]
[null,null,null,null,"J","Magner, M; Vesela, K; Honzik, T; Jesina, P; Vobruba, V; Petrak, B; Zeman, J; Klement, P",null,null,null,"Magner, M.; Vesela, K.; Honzik, T.; Jesina, P.; Vobruba, V.; Petrak, B.; Zeman, J.; Klement, P.",null,null,"Sco2 Protein Deficiency-Based Mitochondrial Encephalomyopathy with the SMA-like Picture of Neurogenic Muscle Atrophy - Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"mitochondrial encephalopathy; neurogenic muscle atrophy; spinal muscular atrophy; SMA; cytochrome c oxidase; SCO2 gene","GENE; MUTATIONS; DISEASE; OXIDASE","Various mitochondrial diseases with clinical, electromyographical and histological signs imitating spinal muscular atrophy (\"SMA-like diseases\") with no detected mutation in SMN1 gene have been described in recent years. Respiratory chain disorder was considered due to broad impairment of the central and peripheral nervous systems (encephalopathy, neuropathy) and other tissue and organ involvement (cardiomyopathy, myopathy, hepatopathy). The number of previously-reported mitochondrial syndromes with \"SMA-like\" sign development is limited, Revealing the phenotype in a detailed clinical context may lead to targeted molecular-genetic analysis and specific diagnostics without calling upon other investigations. A typical representative of this syndrome group is mitochondrial encephalopathy with cardiomyopathy and lactic acidosis arising out of a mutation in gene coding protein Sco2 protein, which is involved in the assembly of mitochondrial cytochrome c oxidase. Two case histories are presented, of patients in whom SMA-like phenotype development led to SCO2 gene investigation and correct diagnosis.","[Petrak, B.; Klement, P.] UK 2 LF, Klin Detske Neurol, Prague 12808 2, Czech Republic; [Petrak, B.] FN Motole, Prague 12808 2, Czech Republic","Klement, P (reprint author), UK 2 LF, Klin Detske Neurol, Ke Karlovu 2, Prague 12808 2, Czech Republic.","petrklement@seznam.cz","Jesina, Pavel/A-9913-2012",null,null,null,null,9,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2010,73,1,null,null,null,null,73,75,null,null,null,3,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","569KA","WOS:000275593800011"]
[null,null,null,null,"J","Pokorna, M; Necas, E; Kratochvil, J; Skripsky, R; Andrlik, M; Franek, O",null,null,null,"Pokorna, Milana; Necas, Emanuel; Kratochvil, Jaroslav; Skripsky, Roman; Andrlik, Michal; Franek, Ondrej",null,null,"A SUDDEN INCREASE IN PARTIAL PRESSURE END-TIDAL CARBON DIOXIDE (P(ET)CO(2)) AT THE MOMENT OF RETURN OF SPONTANEOUS CIRCULATION","JOURNAL OF EMERGENCY MEDICINE",null,null,"English","Article",null,null,null,null,null,"cardiac arrest; advanced life support; capnography; end-tidal carbon dioxide; return of spontaneous circulation; asynchronous compression-ventilation; cardiopulmonary resuscitation","HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; NONINVASIVE MONITOR; CO2; OUTPUT","Background: Previous studies established that a level of partial pressure end-tidal carbon dioxide (P(ET)CO(2)) of 10 mm Hg divided patients undergoing advanced life support (ALS) into those likely to be resuscitated (values > 10 mm Hg) and those likely to die during ALS (values < 10 mm Hg). Objective: The study tested the significance of a sudden increase in the P(ET)CO(2) in signaling the return of spontaneous circulation (ROSC) during ALS. Material and Methods: P(ET)CO(2) values were continuously recorded during ALS in out-of-hospital patients with cardiac arrest. Constant ventilation was maintained by an automatic device. There were 108 patients, representing two extreme outcomes of ALS, who were subdivided into two groups. The first group included 59 patients with a single ROSC followed by a stable spontaneous circulation. The second group included 49 patients with no signs of ROSC. Results: ROSC was associated with a sudden increase in P(ET)CO(2) that remained significantly higher than before ROSC. P(ET)CO(2) did not rise during the entire ALS in the second group of patients without ROSC and was lower than in the first group of patients. Conclusions: In constantly ventilated patients, P(ET)CO(2) is significantly higher (about 10 mm Hg) after ROSC than before ROSC. A sudden increase in P(ET)CO(2) exceeding 10 mm Hg may indicate ROSC. Consequently, the rule of 10 mm Hg may be extended to include a sudden increase in continuously recorded P(ET)CO(2) by more than 10 mm Hg as an indicator of the possibility of ROSC. (C) 2010 Elsevier Inc.","[Pokorna, Milana; Kratochvil, Jaroslav; Skripsky, Roman; Franek, Ondrej] Emergency Med Serv Prague, Prague 10100, Czech Republic; [Pokorna, Milana] Univ Hosp Motol, Dept Emergency Med, Prague, Czech Republic; [Necas, Emanuel; Andrlik, Michal] Charles Univ Prague, Fac Med 1, Dept Pathophysiol, Prague, Czech Republic; [Kratochvil, Jaroslav] Univ Hosp Na Bulovce, Dept Internal Med 2, Prague, Czech Republic; [Skripsky, Roman] Thomayer Univ Hosp, Dept Anaesthesiol & Resuscitat, Prague, Czech Republic","Pokorna, M (reprint author), Emergency Med Serv Prague, Korunni 98, Prague 10100, Czech Republic.",null,null,null,"Ministry of Health of the Czech Republic [IGA NR/7970-3]; Ministry of Education, Youth and Sports of the Czech Republic [MSM 0021620806]","This work is a part of the study \"Sudden cardiac arrest in out-of-hospital care. Analysis of causes and comparison of different methods recommended for circulatory restoration.\" The study was financially supported from the grant IGA NR/7970-3 provided by the Ministry of Health of the Czech Republic and by the project MSM 0021620806 of the Ministry of Education, Youth and Sports of the Czech Republic. The authors would like to acknowledge all contributors, Drs.: T. Garnol, M. Sykorova, A. Skoupy, R. Zub, K. Kucera, D. Kobr, J. Knor, J. Vosatka, T. Charvat, M. Uher, J. Valasek, who collaborated in collection of P<INF>ET</INF>CO<INF>2</INF> data; Dr. Z. Schwarz who provided general support for the study and all cooperative physicians of Prague's hospitals and departments of pathology.",null,26,16,17,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0736-4679",null,null,"J EMERG MED","J. Emerg. Med.","JUN",2010,38,5,null,null,null,null,614,621,null,"10.1016/j.jemermed.2009.04.064",null,8,"Emergency Medicine","Emergency Medicine","610NH","WOS:000278739200012"]
[null,null,null,null,"J","Martin, RCG; Howard, J; Tomalty, D; Robbins, K; Padr, R; Bosnjakovic, PM; Tatum, C",null,null,null,"Martin, R. C. G.; Howard, J.; Tomalty, D.; Robbins, K.; Padr, R.; Bosnjakovic, P. M.; Tatum, Cliff",null,null,"Toxicity of Irinotecan-Eluting Beads in the Treatment of Hepatic Malignancies: Results of a Multi-Institutional Registry","CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY",null,null,"English","Article",null,null,null,null,null,"Irinotecan; Image guided liver directed therapy; Precision chemoembolization; Toxicity","DNA TOPOISOMERASE-I; COLORECTAL-CANCER; TRANSARTERIAL CHEMOEMBOLIZATION; LIVER METASTASES; CAMPTOTHECIN ANALOGS; ANTITUMOR-ACTIVITY; CPT-11; VITRO; TACE","Purpose To evaluate the predictors of toxicity of drug-eluting beads loaded with irinotecan (DEBIRI) in the treatment of hepatic malignancies. Materials and Methods A total of 330 patients were enrolled in a prospective, open-label, multicenter, multinational, single-arm study administering two types of drug-eluting beads (DEBIRI and drug-eluting beads loaded with doxorubicin). Complications were graded by Cancer Therapy Evaluation Program's Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. All events requiring additional physician treatment or requiring extended hospital stay or readmission within 30 days were included. Results A total of 109 patients received 187 DEBIRI treatments (range 1 to 5 per patient). The most common histology was metastatic colorectal cancer in 76% of patients, cholangiocarcinoma in 7% of patients, and other metastatic disease in 17% of patients. There were 35 patients (19%) with irinotecan treatments who sustained 158 treatment-related adverse events, with the median CTCAE event grade being CTCAE grade 2 (range 1 to 5). The most common adverse events were postembolic symptoms (42%). Multivariate analysis identified pretreatment and treatment-related risk factors as follows: lack of pretreatment with hepatic arterial lidocaine (p = 0.005), >= 3 treatments (p = 0.05), achievement of complete stasis (p = 0.04), treatment with >100 mg DEBIRI in 1 treatment (p = 0.03), and bilirubin >2.0 mu g/dl with >50% liver involvement (p = 0.05). These factors were predictive of adverse events and significantly greater hospital length of stay. Conclusions DEBIRI is safe when appropriate technique and treatment are used. Adverse events can be predicted based on pretreatment-and treatment-related factors, and their occurrence can become part of the informed consent process. Continued standardization of this treatment will lead to fewer adverse events and improved patient quality of life.","[Martin, R. C. G.] Univ Louisville, Dept Surg, Div Surg Oncol, Louisville, KY 40292 USA; [Howard, J.] N Mississippi Med Ctr, Tupelo, MS USA; [Tomalty, D.] Huntsville Dist Mem Hosp, Huntsville, AL USA; [Robbins, K.] Baptist Hlth, Little Rock, AR USA; [Padr, R.] FN Motole, Motole, Czech Republic; [Bosnjakovic, P. M.] Ctr Nis Serbia, Nish, Serbia; [Tatum, Cliff] Norton Hosp, Dept Radiol, Louisville, KY USA","Martin, RCG (reprint author), Univ Louisville, Dept Surg, Div Surg Oncol, Louisville, KY 40292 USA.","rcmart03@gwise.louisville.edu",null,null,"Biocompatibles","Supported by an Unrestricted Educational Grant from Biocompatibles. RCGM: Consultant Biocompatibles.","Aliberti C, 2006, ANTICANCER RES, V26, P3793; BURKE TG, 1995, J PHARM SCI, V84, P518, DOI 10.1002/jps.2600840426; Fiorentini G, 2007, IN VIVO, V21, P1085; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; HSIANG YH, 1989, CANCER RES, V49, P4385; JAXEL C, 1989, CANCER RES, V49, P1465; KAISER J, 2009, J ONCOL PHARM PRACT, V6, P53; KAWATO Y, 1991, CANCER RES, V51, P4187; KUNIMOTO T, 1987, CANCER RES, V47, P5944; Lewis AL, 2006, J VASC INTERV RADIOL, V17, P335, DOI 10.1097/01.RVI.0000195323.46152.B3; Martin R. C., 2009, J ONCOL, P539; Martin RCG, 2009, WORLD J SURG ONCOL, V7, DOI 10.1186/1477-7819-7-80; Mathijssen RHJ, 2001, CLIN CANCER RES, V7, P2182; MI ZH, 1994, BIOCHEMISTRY-US, V33, P10325, DOI 10.1021/bi00200a013; Morise Z, 2006, J GASTROINTEST SURG, V10, P249, DOI 10.1016/j.gassur.2005.08.004; POTMESIL M, 1994, CANCER RES, V54, P1431; Hecht JR, 1998, ONCOLOGY-NY, V12, P72; Scoggins CR, 1999, ANN SURG ONCOL, V6, P651, DOI 10.1007/s10434-999-0651-x; SLICHENMYER WJ, 1993, J NATL CANCER I, V85, P271, DOI 10.1093/jnci/85.4.271; Tang Y, 2006, J CONTROL RELEASE, V116, pE55, DOI 10.1016/j.jconrel.2006.09.047; Taylor RR, 2007, EUR J PHARM SCI, V30, P7, DOI 10.1016/j.ejps.2006.09.002; Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337",22,15,15,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0174-1551",null,null,"CARDIOVASC INTER RAD","Cardiovasc. Interv. Radiol.","OCT",2010,33,5,null,null,null,null,960,966,null,"10.1007/s00270-010-9937-4",null,7,"Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging","Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging","661EM","WOS:000282706700012"]
[null,null,null,null,"J","Bril, V; Banach, M; Dalakas, MC; Deng, CQ; Donofrio, P; Hanna, K; Hartung, HP; Hughes, RAC; Katzberg, H; Latov, N; Merkies, ISJ; Van Doorn, PA",null,null,null,"Bril, Vera; Banach, Marta; Dalakas, Marinos C.; Deng, Chunqin; Donofrio, Peter; Hanna, Kim; Hartung, Hans-Peter; Hughes, Richard A. C.; Katzberg, Hans; Latov, Norman; Merkies, Ingemar S. J.; Van Doorn, Pieter A.",null,"ICE Study Grp","ELECTROPHYSIOLOGIC CORRELATIONS WITH CLINICAL OUTCOMES IN CIDP","MUSCLE & NERVE",null,null,"English","Article",null,null,null,null,null,"polyradiculoneuropathy; chronic inflammatory demyelinating; clinical trial; peripheral nervous system diseases; polyneuropathies","INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; IMMUNE-MEDIATED POLYNEUROPATHIES; CONTROLLED TRIAL; PLASMA-EXCHANGE; DIAGNOSIS","Data are lacking on correlations between changes in nerve conduction (NC) studies and treatment response in chronic inflammatory demyelinating polyneuropathy (CIDP). This report examined data from a randomized, double-blind trial of immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C [Gamunex]; n = 59) versus placebo (n 58) every 3 weeks for up to 24 weeks in CIDP. Motor NC results and clinical measures were assessed at baseline and endpoint/week 24. Improvement from baseline in adjusted inflammatory neuropathy cause and treatment score correlated with improvement in proximally evoked compound muscle action potential (CMAP) amplitudes (r = -0.53; P < 0.001) of all nerves tested and with improvement in CMAP amplitude of the most severely affected motor nerve (r = -0.36; P < 0.001). Correlations were observed between improvement in averaged CMAP amplitudes and dominant-hand grip strength (r = 0.44; P < 0.001) and Medical Research Council sum score (r = 0.38; P < 0.001). Overall, the change in electrophysiologic measures of NC in CIDP correlated with clinical response to treatment. Muscle Nerve 42: 492-497, 2010","[Bril, Vera] Toronto Gen Hosp, Univ Hlth Network, Div Neurol, Toronto, ON M5G 2C4, Canada; [Banach, Marta] Inst Psychiat & Neurol, Dept Clin Neurophysiol, Warsaw, Poland; [Dalakas, Marinos C.] Univ London Imperial Coll Sci Technol & Med, Dept Clin Neurosci, London, England; [Deng, Chunqin; Hanna, Kim] Talecris Biotherapeut Inc, Res Triangle Pk, NC USA; [Donofrio, Peter] Vanderbilt Univ, Dept Neurol, Nashville, TN USA; [Hartung, Hans-Peter] Univ Dusseldorf, Dept Neurol, D-4000 Dusseldorf, Germany; [Hughes, Richard A. C.] Natl Hosp Neurol & Neurosurg, Cochrane Neuromuscular Dis Grp, MRC Ctr Neuromuscular Dis, London, England; [Katzberg, Hans] Stanford Univ, Dept Neurol, Palo Alto, CA 94304 USA; [Latov, Norman] Cornell Univ, Peripheral Neuropathy Ctr, New York, NY 10021 USA; [Merkies, Ingemar S. J.; Van Doorn, Pieter A.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands","Bril, V (reprint author), Toronto Gen Hosp, Univ Hlth Network, Div Neurol, 5EC 309,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.","vera.bril@utoronto.ca","Chapman, Joab/E-4598-2010",null,"Talecris Biotherapeutics Center for Science and Education","ICE study investigators: B. Adamova, S. Apostolski, F. Barroso, I. Basta, J. Bednarik, L. Benedetti, A. Buchman, J. Caress, J. Chapman, K. Chapman, S. Cho, G. Comi, U. Del Carro, V. Drory, A. Dubrovsky, E. Ehler, R. Fazio, E. Fulgenzi, G. Gibson, S. Gonzalez-Cornejo, J. Gonzalez-Jaime, M. Grandis, A. Kostera-Pruszczyk, H. Kwiecinski, C. Marchesoni, E. Meluzinova, C. Munch, S. Nations, M. Nogues, S. Oh, A. Pardal, H. Patwa, S. Pavlovic, J. Pikova-Libertinova, M. Pizzorno, R. Reisin, A. Rivero, S. Romero-Vargas, J. Ruiz-Sandoval, K. Selmaj, A. Szczudlik, F. P. Thomas, J. Trivedi, B. Tsao, A. Villa, S. Vohanka, G. Wolfe. The ICE trial was sponsored and funded by Talecris Biotherapeutics Center for Science and Education. Technical editorial assistance was provided under the direction of the authors by MedThink Communications with support from Talecris Biotherapeutics.","Ashworth NL, 2000, MUSCLE NERVE, V23, P206, DOI 10.1002/(SICI)1097-4598(200002)23:2<206::AID-MUS10>3.0.CO;2-K; Boukhris S, 2004, NEUROPHYSIOL CLIN, V34, P71, DOI 10.1016/j.neucli.2004.01.004; Bril V, 2009, MUSCLE NERVE, V39, P448, DOI 10.1002/mus.21236; BRIL V, 2008, 133 ANN M AM NEUR AS; Chan YC, 2006, J NEUROL NEUROSUR PS, V77, P114, DOI 10.1136/jnnp.2004.056515; Chan Yee-Cheun, 2006, Expert Rev Neurother, V6, P1545, DOI 10.1586/14737175.6.10.1545; DYCK PJ, 1994, ANN NEUROL, V36, P838, DOI 10.1002/ana.410360607; Hughes R, 2001, ANN NEUROL, V50, P195, DOI 10.1002/ana.1088; Hughes RAC, 2008, LANCET NEUROL, V7, P136, DOI 10.1016/S1474-4422(07)70329-0; Koller H, 2005, NEW ENGL J MED, V352, P1343, DOI 10.1056/NEJMra041347; Kuwabara S, 2002, J NEUROL NEUROSUR PS, V72, P37, DOI 10.1136/jnnp.72.1.37; Merkies ISJ, 2000, MUSCLE NERVE, V23, P1393, DOI 10.1002/1097-4598(200009)23:9<1393::AID-MUS10>3.0.CO;2-O; Merkies ISJ, 2002, J NEUROL NEUROSUR PS, V72, P596, DOI 10.1136/jnnp.72.5.596; 1991, NEUROLOGY, V41, P617",14,13,13,"JOHN WILEY & SONS INC","HOBOKEN","111 RIVER ST, HOBOKEN, NJ 07030 USA","0148-639X",null,null,"MUSCLE NERVE","Muscle Nerve","OCT",2010,42,4,null,null,null,null,492,497,null,"10.1002/mus.21733",null,6,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","658KC","WOS:000282487900006"]
[null,null,null,null,"J","van Herpen, CML; Mauer, ME; Mesia, R; Degardin, M; Jelic, S; Coens, C; Betka, J; Bernier, J; Remenar, E; Stewart, JS; Preiss, JH; van den Weyngaert, D; Bottomley, A; Vermorken, JB",null,null,null,"van Herpen, C. M. L.; Mauer, M. E.; Mesia, R.; Degardin, M.; Jelic, S.; Coens, C.; Betka, J.; Bernier, J.; Remenar, E.; Stewart, J. S.; Preiss, J. H.; van den Weyngaert, D.; Bottomley, A.; Vermorken, J. B.",null,"EORTC Head Neck Grp","Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)","BRITISH JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"HRQOL; symptoms; head and neck cancer","SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; CLINICAL-TRIALS; RADIOTHERAPY; CHEMORADIATION; DYSPHAGIA; CETUXIMAB; QLQ-C30; SPEECH","BACKGROUND: The EORTC 24971/TAX 323, a phase III study of 358 patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck, showed an improved progression-free and overall survival (OS) with less toxicity when docetaxel (T) was added to cisplatin and 5-fluorouracil (PF) for induction and given before radiotherapy (RT). The impact of the addition of docetaxel on patients' health-related quality of life (HRQOL) and symptoms was investigated. METHODS: HRQOL was assessed at baseline, at end of cycle 2, and 4, 6, and 9 months after completion of RT using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and the EORTC QLQ Head and Neck Cancer-Specific Module (EORTC QLQ-H&N35). The primary HRQOL scale was global HRQOL per protocol. RESULTS: Compliance to HRQOL assessments was 97% at baseline, but dropped to 54% by 6 months. Data were analysed up to 6 months. There was a trend towards improved global HRQOL during the treatment period. At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm, but the low compliance does not allow to draw definitive conclusions. Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2, but to a limited extent. CONCLUSION: Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner. British Journal of Cancer (2010) 103, 1173-1181. doi:10.1038/sj.bjc.6605860 www.bjcancer.com Published online 14 September 2010 (C) 2010 Cancer Research UK","[van Herpen, C. M. L.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands; [Mauer, M. E.; Coens, C.; Bottomley, A.] EORTC Headquarters, European Org Res & Treatment Canc, Brussels, Belgium; [Mesia, R.] Inst Catala Oncol, Barcelona, Spain; [Degardin, M.] Ctr Oscar Lambret, F-59020 Lille, France; [Jelic, S.] Inst Oncol & Radiol, Belgrade, Serbia; [Betka, J.] Univ Hosp Motol, Prague, Czech Republic; [Bernier, J.] Clin Genolier, Genolier, Switzerland; [Remenar, E.] Natl Inst Oncol, Budapest, Hungary; [Stewart, J. S.] Charing Cross Hosp, London, England; [Preiss, J. H.] Caritasklin St Theresia, Saarbrucken, Germany; [van den Weyngaert, D.] Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium; [Vermorken, J. B.] Univ Ziekenhuis Antwerpen, Edegem, Belgium","van Herpen, CML (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, 452,POB 9101, NL-6500 HB Nijmegen, Netherlands.","C.vanherpen@onco.umcn.nl",null,null,"Sanofi-Aventis; National Cancer Institute (Bethesda, MD, USA) [5U10-CA11488-29, 5U10 CA11488-39]; EORTC Charitable Trust","Sanofi-Aventis financially sponsored this trial. In addition, the QOL analysis was in part supported by Grant numbers 5U10-CA11488-29 through to 5U10 CA11488-39 from the National Cancer Institute (Bethesda, MD, USA), as well as by the EORTC Charitable Trust. We thank all EORTC investigators who participated in this study and the EORTC Headquarters staff who worked for this study. We thank all the patients for participating in this clinical trial to help us understand the best way to treat this cancer. The clinical trials.gov registry number was NCT00003888.",null,30,10,11,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0007-0920",null,null,"BRIT J CANCER","Br. J. Cancer","OCT 12",2010,103,8,null,null,null,null,1173,1181,null,"10.1038/sj.bjc.6605860",null,9,"Oncology","Oncology","671WL","WOS:000283542900006"]
[null,null,null,null,"J","Bartak, V; Popelka, S; Hromadka, R; Pech, J; Jahoda, D; Sosna, A",null,null,null,"Bartak, V.; Popelka, S.; Hromadka, R.; Pech, J.; Jahoda, D.; Sosna, A.",null,null,"TOEFIT-PLUS System for Replacement of the First Metatarsophalangeal Joint","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"hallux rigidus; ToeFit; first metatarsophalangeal joint; replacement","HALLUX-RIGIDUS; GREAT TOE; ARTHROPLASTY; IMPLANT","PURPOSE OF THE STUDY Hallux rigidus is a frequent disease of the first metatarsophalangeal (MTP) joint. It is a painful condition markedly reducing joint motion. For grade-3 and grade-4 disease, as classified by Coughlin, first MTP joint replacement is another option of surgical treatment, in addition to resection arthroplasty or arthrodesis. MATERIAL AND METHODS In a group of 27 patients with symptomatic hallux rigidus, 28 MTP joint replacements using a TOEFIT-PLUS implant were carried out in the 2005-2009 period. There were 24 women and three men, with an average age of 56.3 years. The average follow-up was 24 months (range, 4 to 48). Indication for surgery included hallux rigidus in 20, conditions following Keller's arthroplasty in five, necrosis of the first metatarsus head in two cases and a condition after the Austin procedure in one patient. Pain, assessed by the Kitaoka score, and the range of joint motion;were evaluated before the surgery and at the final follow-up visit this also included the radiographic assessment of implant position and its integration. RESULTS Of the 28 implants used, nine were hemiprosthetic and 19 total joint replacements. The average time between surgery and full weight-bearing was 6.6 weeks (range, 5 to 8) in both groups. The post-operative Kitaoka score was 87.1 (68-100) as compared with the preoperative value of 36.3 (24-52), and this difference was statistically significant. The range of motion at the first MTP improved from 14.7 degrees pre-operatively to 38.5 post-operatively. There was no statistically significant difference in joint function, as assessed by the Kitaoka score and range of motion, between the two groups (hemiprosthetic vs. total joint replacements). The complications included prolonged skin healing with minor dehiscence in four cases. Revision surgery was required in three cases because of restricted joint motion associated with pain. In three cases of the total joint replacement group, there was radiographic evidence of asymptomatic osteolysis around both the phalangeal and the metatarsal component. In the hemiarthroplasty group, no osteolysis was recorded. DISCUSSION Up to now several types of implants have been developed to alleviate pain and restore and maintain the first MTP motion in patients with hallux rigidus. The TOEFIT-PLUS implant belongs to the most recent ones. Our results are in agreement with those of other currently used replacements in terms of clinical and functional evaluation. The complications recorded in our study are also similar to those reported in the literature, which include aseptic loosening, dislocation and mechanical failure of the implant. There is no consistent approach to their treatment. Arthrodesis with tricortical graft seems to be an option, but it carries a considerable risk of failure. Since in our patients aseptic loosening was recorded only in the total joint replacement group, hemiarthroplasty has recently been preferred, because it has clinical and functional outcomes as good as total joint replacement. CONCLUSIONS Our results with the use of TOEFIT-PLUS replacement show that this implant is effective in the treatment of hallux rigidus advanced stages and has good clinical outcomes, i.e., maintenance of motion at the MTP joint of the big toe, pain alleviation and early weight bearing. Since hemiarthroplasty is associated with fewer complications whose potential treatment is easier, this approach seems to have a better prospect than total joint replacement.","[Bartak, V.] 1 LF UK, Ortoped Klin 1, Prague 15000 5, Czech Republic; [Bartak, V.] FN Motol, Prague 15000 5, Czech Republic","Bartak, V (reprint author), 1 LF UK, Ortoped Klin 1, V Uvalu 84, Prague 15000 5, Czech Republic.","vbartak@email.cz",null,null,null,null,null,25,8,8,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","JUN",2010,77,3,null,null,null,null,222,227,null,null,null,6,"Orthopedics","Orthopedics","621EQ","WOS:000279557700008"]
[null,null,null,null,"J","Zejskova, L; Jancuskova, T; Kotlabova, K; Doucha, J; Hromadnikova, I",null,null,null,"Zejskova, L.; Jancuskova, T.; Kotlabova, K.; Doucha, J.; Hromadnikova, I.",null,null,"Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma - Next step toward reliable non-invasive prenatal diagnostics","EXPERIMENTAL AND MOLECULAR PATHOLOGY",null,null,"English","Article",null,null,null,null,null,"DNA quantification; Hypermethylated RASSF1A sequence; SRY; GLO; Real-time PCR","REAL-TIME PCR; QUANTITATIVE-ANALYSIS; GENDER DETERMINATION; SEX DETERMINATION; DNA-METHYLATION; SERUM; RHD; PREECLAMPSIA; WOMEN; PLACENTA","We determined the feasibility of universal fetal marker detection in maternal circulation. Using real-time PCR, we compared the levels of fetal (SRY and hypermethylated RASSF1A) and total (GLO gene and total RASSF1A) extracellular DNA and fractions of extracellular fetal DNA (SRY/GLO vs. hypermethylated RASSF1A/total RASSF1A) in maternal circulation. Sensitivity and specificity reached 100% as the fetal-specific hypermethylated RASSF1A sequence was detected in all 151 examined plasma samples derived from 70 normal pregnancies with a singleton male (n = 51) or female (n = 19) fetus sampled throughout gestation and absent in nonpregnant individuals (n =29). A strong positive correlation was observed between fetal-derived hypermethylated RASSF1A and SRY (p = 0.66. P<0.001), total RASSF1A and GLO (rho=0.65,P<0.001), SRY/GLO vs. hypermethylated RASSF1A/total RASSF1A ratio (rho=0.62, P<0.001) in maternal plasma. The results indicate that a universal fetal marker could be useful not only for the confirmation of the presence of fetal cell-free DNA in maternal plasma but could enable quantification of cell-free fetal DNA in pregnancy associated disorders, independently of the sex of the fetus. (C) 2010 Elsevier Inc. All rights reserved.","[Zejskova, L.; Jancuskova, T.; Kotlabova, K.; Hromadnikova, I.] Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Prague 10000 10, Czech Republic; [Doucha, J.] Charles Univ Prague, Clin Obstet & Gynecol, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic","Zejskova, L (reprint author), Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Ruska 87, Prague 10000 10, Czech Republic.","lenka.zej@centrum.cz",null,null,"Ministry of Education, Youth and Sports, Czech Republic [MSM 0021620806]","We thank Prof. J.E. Jirasek from the Institute for the Care of Mother and Child, for his participation in the collection and processing of placenta tissue samples. This work was supported by grant project MSM 0021620806 from The Ministry of Education, Youth and Sports, Czech Republic.",null,26,7,8,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0014-4800",null,null,"EXP MOL PATHOL","Exp. Mol. Pathol.","DEC",2010,89,3,null,null,null,null,241,247,null,"10.1016/j.yexmp.2010.09.002",null,7,"Pathology","Pathology","686FX","WOS:000284683300007"]
[null,null,null,null,"J","Pokorny, D; Slouf, M; Vesely, F; Fulin, P; Jahoda, D; Sosna, A",null,null,null,"Pokorny, D.; Slouf, M.; Vesely, F.; Fulin, P.; Jahoda, D.; Sosna, A.",null,null,"Distribution of UHMWPE Wear Particles in Periprosthetic Tissues of Total Hip Replacements","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"total hip replacement; polyethylene wear; aseptic loosening","JOINT REPLACEMENTS; QUANTIFICATION; ARTHROPLASTY; DEBRIS; STEM","INTRODUCTION Information on the distribution of UHMWPE wear particles around joint replacements is essential for the understanding of aseptic loosening of implants. MATERIAL AND METHODS Samples of soft tissue from around total hip arthroplasty (THA), which had a typical appearance of polyethylene granuloma, were collected from the places corresponding to the radiological zones of Gruen and DeLee. The samples were taken from 45 patients (group N1). Since the samples varied in macroscopic appearance and/or the technique of processing, a sub-group of 15 more uniform samples (group N2) were collected by the first author in order to ensure the maximum reliability. The samples were examined for the extent of tissue damage and the amount of particles in each zone. The comprehensive orthopaedic evaluation of tissue damage was carried out as follows: the first author studied the joint replacement revision protocol and pre-operative radiograph in each patient. He evaluated the degree of damage in each zone and wrote down the results in the form of an ordered series according to increasing damage (relational statement). This ordered series was called orthopaedist's statement (OS). The amount of particles in each zone around THA was assessed by the IRc method developed in the laboratory of the second author. IRc method yielded numbers that were proportional to the volume of biologically active particles with size 0.1-10) mu m in given zones. The set of numbers from IRc method for each individual case of THA was ordered in a series (relational statement). This ordered series was called a measurement statement (MS) and could be directly compared with orthopaedist's statement (OS). The OS's and MS's for each patient were statistically evaluated, independently for each group (N1=45, N2=15), and two hypotheses were tested: a) distribution of particles in various zones around THA is uniform, b) there is an agreement between OS and MS. RESULTS The number of UHMWPE wear particles in different periprosthetic zones within each patient was significantly different in both groups (N1 and N2) at the significance level of P=0.001. The OS's and MS's were identical at the significance level P=0.05. Moreover, maximum amount of particles was found in zones ill and 7 in 40 patients out of 45. DISCUSSION Polyethylene wear debris is considered one of the major causes of THR failures. However, neither national nor international literature has provided a study that would show a statistically significant relationship between the numbers of wear particles in individual zones and the extent of tissue damage in these zones. This is most probably due to the fact that four independent methods had to be developed in order to compare OS's and MS's: 1) accurate technique of tissue sampling during THA revisions, 2) accurate method of isolating wear particles from the tissues collected, 3) efficient, reliable and reproducible quantification of UHMWPE particles and 4) correct method of statistical analysis for comparison of the orthopaedist's statements and the measurement statements for all patients involved. CONCLUSION The distribution of wear particles in the periprosthetic tissues of THA is not uniform, i.e. the amount of wear particles of each patient varies from zone to zone. The extent of tissue damage in each zone, as assessed by the orthopaedic surgeon (OS), was in a good agreement with the volume of 0.1-10 mu m particles obtained by IRc measurement (MS) of the zone. We have provided conclusive evidence that the highest number of particles is accumulated in zone Ill and zone 7. As the number of particles the zones varies and the greatest damage is repeatedly found in areas with the highest particle numbers, it can be concluded with certainly that wear particles are one of the main causes of aseptic joint implant failure.","[Pokorny, D.; Vesely, F.; Fulin, P.; Jahoda, D.; Sosna, A.] FN Motol, I Ortoped Klin 1 LF UK, Prague 5, Czech Republic; [Slouf, M.] Akad CR, Ustav Makromol Chem, Prague, Czech Republic; 1 LF UK, Ostav Biofyziky & Informatiky, Prague, Czech Republic; Prirodovedecke Fak UK, Katedra Biochem, Prague, Czech Republic","Pokorny, D (reprint author), FN Motol, I Ortoped Klin 1 LF UK, V Uvalu 84, Prague 5, Czech Republic.","david.pokorny@LF1.cuni.cz","Slouf, Miroslav/F-6311-2012","Slouf, Miroslav/0000-0003-1528-802X",null,null,null,15,7,8,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2010,77,2,null,null,null,null,87,92,null,null,null,6,"Orthopedics","Orthopedics","590GM","WOS:000277213200001"]
[null,null,null,null,"J","Popelka, S; Hromadka, R; Vavrik, P; Stursa, P; Pokorny, D; Jahoda, D; Sosna, A",null,null,null,"Popelka, Stanislav; Hromadka, Rastislav; Vavrik, Pavel; Stursa, Pavel; Pokorny, David; Jahoda, David; Sosna, Antonin",null,null,"Isolated talonavicular arthrodesis in patients with rheumatoid arthritis of the foot and tibialis posterior tendon dysfunction","BMC MUSCULOSKELETAL DISORDERS",null,null,"English","Article",null,null,null,null,null,null,"FLAT FOOT; HINDFOOT; JOINT; ANKLE; MANAGEMENT; CADAVERS; RUPTURE","Background: The foot is often affected in patients with rheumatoid arthritis. Subtalar joints are involved more frequently than ankle joints. Deformities of subtalar joints often lead to painful flatfoot and valgus deformity of the heel. Major contributors to the early development of foot deformities include talonavicular joint destruction and tibialis posterior tendon dysfunction, mainly due to its rupture. Methods: Between 2002 and 2005 we performed isolated talonavicular arthrodesis in 26 patients; twenty women and six men. Tibialis posterior tendon dysfunction was diagnosed preoperatively by physical examination and by MRI. Talonavicular fusion was achieved via screws in eight patients, memory staples in twelve patients and a combination of screws and memory staples in six cases. The average duration of immobilization after the surgery was four weeks, followed by rehabilitation. Full weight bearing was allowed two to three months after surgery. Results: The mean age of the group at the time of the surgery was 43.6 years. MRI examination revealed a torn tendon in nine cases with no significant destruction of the talonavicular joint seen on X-rays. Mean of postoperative followup was 4.5 years (3 to 7 years). The mean of AOFAS Hindfoot score improved from 48.2 preoperatively to 88.6 points at the last postoperative followup. Eighteen patients had excellent results (none, mild occasional pain), six patients had moderate pain of the foot and two patients had severe pain in evaluation with the score. Complications included superficial wound infections in two patients and a nonunion developed in one case. Conclusions: Early isolated talonavicular arthrodesis provides excellent pain relief and prevents further progression of the foot deformities in patients with rheumatoid arthritis and tibialis posterior tendon dysfunction.","[Popelka, Stanislav; Hromadka, Rastislav; Vavrik, Pavel; Pokorny, David; Jahoda, David; Sosna, Antonin] Charles Univ Prague, Fac Med 1, Orthopaed Clin 1, Prague 15006 5, Czech Republic; [Hromadka, Rastislav] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 15006 5, Czech Republic; [Stursa, Pavel] Na Homolce Hosp, Dept Radiodiagnost, Prague, Czech Republic","Popelka, S (reprint author), Charles Univ Prague, Fac Med 1, Orthopaed Clin 1, Uvalu 84, Prague 15006 5, Czech Republic.","mudr.popelka@volny.cz",null,null,null,null,null,26,7,8,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2474",null,null,"BMC MUSCULOSKEL DIS","BMC Musculoskelet. Disord.","FEB 27",2010,11,null,null,null,null,null,null,null,38,"10.1186/1471-2474-11-38",null,6,"Orthopedics; Rheumatology","Orthopedics; Rheumatology","570IF","WOS:000275666000001"]
[null,null,null,null,"J","Zemanova, M; Petruzelka, L; Pazdro, A; Kralova, D; Smejkal, M; Pazdrova, G; Honova, H",null,null,null,"Zemanova, M.; Petruzelka, L.; Pazdro, A.; Kralova, D.; Smejkal, M.; Pazdrova, G.; Honova, H.",null,null,"Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up","DISEASES OF THE ESOPHAGUS",null,null,"English","Article",null,null,null,null,null,"combined modality therapy; esophageal cancer; paclitaxel","SQUAMOUS-CELL CARCINOMA; PHASE-II TRIAL; 5-FU/RADIATION THERAPY RT; RESEARCH-NETWORK; NEOADJUVANT CHEMORADIOTHERAPY; CONTINUOUS-INFUSION; LUNG-CANCER; CHEMOTHERAPY; SURGERY; FLUOROURACIL","P>Combined modality treatment for esophageal carcinoma seems to improve survival over surgery alone. Different combinations of cytotoxic drugs have been studied to improve antitumor efficacy and limit the toxicity of chemoradiotherapy (CRT) with inconsistent results. We present a prospective study of neoadjuvant CRT with or without paclitaxel in chemotherapy schedule. One hundred seven patients (93 males, 14 females), median age 59 years (range 44-76), with operable esophageal cancer were enrolled. They received the following neoadjuvant therapy: Carboplatin, area under curve (AUC) = 6, intravenously on days 1 and 22, 5-fluorouracil (5-FU), 200 mg/m2/day, continuous infusion on days 1 to 42, radiation therapy 45 grays/25fractions/5 weeks beginning on day 1. Forty-four patients (41%) were furthermore non-randomly assigned to paclitaxel 200 mg/m2/3 h intravenously on days 1 and 22. Nutritional support from the beginning of the treatment was offered to all patients. Surgery was done within 4-8 weeks after completion of CRT, if feasible. All patients were evaluated for grade 3 plus 4 toxicities: leukopenia (28%), neutropenia (30%), anemia (6%), thrombocytopenia (31%), febrile neutropenia (6%), esophagitis (24%), nausea and vomiting (7%), pneumotoxicity (8%). Seventy-eight patients (73%) had surgery and 63 of them were completely resected. Twenty-two patients (20%) achieved pathological complete remission, and additional 20 (19%) had node-negative and esophageal wall-positive residual disease. There were 10 surgery-related deaths, mostly due to pulmonary insufficiency. Twenty-nine patients were not resected, 15 for early progression, 14 for medical reasons or patient refusal. After a median follow-up of 52 months (range 27-80), median survival of 18.0 months and 1-, 2-, 3- and 5-year survival of 56.7, 37.5, 27.0 and 21% was observed in the whole group of 107 patients. Addition of paclitaxel to carboplatin and continual infusion of FU significantly increased hematologic and non-hematologic toxicity, but treatment results as overall survival or time to progression did not differ significantly in groups with and without paclitaxel. Patients achieving pathological complete remission or nodes negativity after neoadjuvant therapy had favorable survival prognosis, whereas long-term prognosis of node positive patients was poor. Distant metastases prevailed as a cause of the treatment failure. Factors significant for survival prognosis in multivariate analysis were postoperative node negativity, performance status, and grade of dysphagia. Addition of paclitaxel to carboplatin and continual FU significantly increased hematologic and non-hematologic toxicity without influencing efficacy of the treatment. This study confirmed improved prognosis of patients after achieving negativity of nodes. Distant metastases prevailed as cause of the treatment failure. Prospectively, it is important to look for a therapeutic combination with better systemic effect.","[Zemanova, M.; Petruzelka, L.; Pazdrova, G.; Honova, H.] Charles Univ Prague, Dept Oncol, Fac Med 1, Prague 12808, Czech Republic; [Pazdro, A.; Smejkal, M.] Charles Univ Prague, Dept Surg 3, Fac Med 1, Prague 12808, Czech Republic; [Kralova, D.] Masaryk Mem Univ, Inst Biostat & Anal, Brno, Czech Republic","Zemanova, M (reprint author), Charles Univ Prague, Dept Oncol, Fac Med 1, Nemocnice 2, Prague 12808, Czech Republic.","milada.zemanova@vfn.cz",null,null," [MSM 0021620820]","The study was partially supported by the research project No. MSM 0021620820, Czech Republic. None of the authors had any conflict of interest.",null,30,5,8,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1120-8694",null,null,"DIS ESOPHAGUS","Dis. Esophagus",null,2010,23,2,null,null,null,null,160,167,null,"10.1111/j.1442-2050.2009.00984.x",null,8,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","556VT","WOS:000274622100012"]
[null,null,null,null,"J","Salameh, A; Blanke, K; Dhein, S; Janousek, J",null,null,null,"Salameh, Aida; Blanke, Katja; Dhein, Stefan; Janousek, Jan",null,null,"Cardiac Gap Junction Channels Are Upregulated by Metoprolol: An Unexpected Effect of Beta-Blockers","PHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,"Cx43; Cardiomyocytes; R-metoprolol; S-metoprolol; RS-metoprolol; ERK; cAMP","PROTEIN CONNEXIN-43; SIGNAL-TRANSDUCTION; RAT CARDIOMYOCYTES; GENE-EXPRESSION; HEART; PROPRANOLOL; STIMULATION; ISOPROTERENOL; ADRENOCEPTORS; HYPERTROPHY","Background/Aims: Since beta-adrenoceptors have been shown to affect cardiac gap junction channels, we wanted to elucidate the possible effect of metoprolol on the gap junction protein connexin-43, using racemic RS-metoprolol or the isomer R-metoprolol (no beta-adrenoceptor blockade) or S-metoprolol (beta(1)-adrenoceptor blocker). Methods: Cultured neonatal rat cardiomyocytes were exposed to either RS-metoprolol or R-metoprolol or S-metoprolol (0.1 mu mol/l each) without or with additional isoprenaline (0.1 mu mol/l) treatment for 24 h. Results: The beta-blocker treatment did not alter the frequency of spontaneously beating cardiomyocytes, whereas sole isoprenaline administration significantly enhanced the beating frequency by about 40%. This rise could be blocked by concomitant treatment with S- or RS-metoprolol but not with R-metoprolol. Connexin-43 protein was significantly enhanced by isoprenaline and by R-, S- or RS-metoprolol treatment alone as well as with the combined administration of isoprenaline and R-, S- or RS-metoprolol. Phospho-ERK1 and connexin-43 mRNA were significantly increased by isoprenaline application alone, whereas R-, S- or RS-metoprolol alone or in combination with isoprenaline exhibited no effect. Conclusion: Both isomers of metoprolol upregulate connexin-43 in cultured cardiomyocytes by a beta-adrenoceptor-independent mechanism. Since the enhanced presence of connexin-43 in cell membranes under metoprolol was not accompanied by enhanced connexin-43 mRNA, we assume that the metoprolol effect involves reduced connexin-43 degradation. Copyright (C) 2010 S. Karger AG, Basel","[Salameh, Aida] Univ Leipzig, Clin Pediat Cardiol, Ctr Heart, DE-04289 Leipzig, Germany","Salameh, A (reprint author), Univ Leipzig, Clin Pediat Cardiol, Ctr Heart, Struempellstr 39, DE-04289 Leipzig, Germany.","aida.salameh@med.uni-leipzig.de",null,null,null,null,"Beardslee MA, 1998, CIRC RES, V83, P629; BLACK JW, 1965, BRIT J PHARM CHEMOTH, V25, P577; Brito-Martins M, 2008, BRIT J PHARMACOL, V153, P751, DOI 10.1038/sj.bjp.0707619; BRODDE OE, 1986, J CARDIOVASC PHARM, V8, P16; Dang XT, 2003, MOL CELL BIOCHEM, V242, P35, DOI 10.1023/A:1021152709313; Doble BW, 2004, J CELL SCI, V117, P507, DOI 10.1242/jcs.00889; Dupont E, 2001, J MOL CELL CARDIOL, V33, P359, DOI 10.1006/jmcc.2000.1308; HAYES JS, 1984, J PHARMACOL EXP THER, V231, P633; Kabat A, 2004, J PHARMACOL EXP THER, V308, P564, DOI 10.1124/jpet.103.057554; Kostin S, 2004, CARDIOVASC RES, V62, P426, DOI 10.1016/j.cardiores.2003.12.010; Leineweber K, 2003, J CARDIOVASC PHARM, V41, P333, DOI 10.1097/00005344-200303000-00001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marano G, 2002, J HYPERTENS, V20, P763, DOI 10.1097/00004872-200204000-00036; Patrizio M, 2008, EUR J PHARMACOL, V587, P85, DOI 10.1016/j.ejphar.2008.04.017; Polontchouk Lioudmila, 2002, FASEB Journal, V16, P87; REFSNES M, 1987, EUR J BIOCHEM, V163, P457, DOI 10.1111/j.1432-1033.1987.tb10891.x; REITHMANN C, 1987, KLIN WOCHENSCHR, V65, P308, DOI 10.1007/BF01745384; Salameh A, 2006, FASEB J, V20, P365, DOI 10.1096/fj.05-4871fje; Salameh A, 2008, J PHARMACOL EXP THER, V326, P315, DOI 10.1124/jpet.108.136663; Salameh A, 2009, BRIT J PHARMACOL, V158, P198, DOI 10.1111/j.1476-5381.2009.00344.x; Salameh A, 2004, EUR J PHARMACOL, V503, P9, DOI 10.1016/j.ejphar.2004.09.024; Soriano JB, 1997, PROG CARDIOVASC DIS, V39, P445, DOI 10.1016/S0033-0620(97)80039-4; WAHLUND G, 1990, BRIT J PHARMACOL, V99, P592; Wallukat G, 2002, HERZ, V27, P683, DOI 10.1007/s00059-002-2434-z; Xia Y, 2009, ACTA PHARMACOL SIN, V30, P928, DOI 10.1038/aps.2009.92; Zheng Ming, 2004, Heart Lung Circ, V13, P179, DOI 10.1016/j.hlc.2004.02.018",26,5,7,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0031-7012",null,null,"PHARMACOLOGY","Pharmacology",null,2010,85,4,null,null,null,null,203,210,null,"10.1159/000276982",null,8,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","588YL","WOS:000277110500002"]
[null,null,null,null,"J","Popelka, S; Vavrik, P; Landor, I; Hach, J; Pech, J; Sosna, A",null,null,null,"Popelka, S.; Vavrik, P.; Landor, I.; Hach, J.; Pech, J.; Sosna, A.",null,null,"Our Experience with AES Total Ankle Replacement","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"total ankle replacement; rheumatoid arthritis; arthritis of the ankle; polyethylene wear; complications","FOLLOW-UP; CONSECUTIVE ANKLES; GAIT ANALYSIS; ARTHROPLASTY; STAR; ARTHRODESIS; NAIL","PURPOSE OF THE STUDY The method of choice for the treatment of severe ankle arthritis is either arthrodesis or joint arthroplasty. Each has its advantages and disadvantages. Arthrodesis is the definitive therapy for severe ankle destruction and instability Joint arthroplasty has an advantage in maintaining ankle mobility. However, its range of indications and its reliability and durability are more limited. The aim of this study is to present our experience with the AES prosthesis and draw attention to some drawbacks of this surgical treatment. MATERIAL From September 2003 till June 2008, 51 AES ankle replacements were carried out in 51 patients (33 women and 18 men). Their average age at the time of surgery was 53.8 years. The youngest patient was 23 and the oldest was 88 years old. The indication for surgery was rheumatoid arthritis in 10, primary arthritis in six and post-traumatic ankle arthritis in 35 patients. METHODS The patients were evaluated in 2008. The follow-up ranged from 4 months to 5 years. The patients were examined for ankle joint mobility and pain. Radiographs were assessed for potential signs of component loosening. RESULTS The results presented here are short-term ones. The pre-operative AOFAS score of 33.7 increased to 82.3 points post-operatively. The range of motion was on average 20 degrees of plantar flexion and 5 to 10 degrees of dorsiflexion. Thirty-five patients (68.7 %) were free from pain, 11 (21.5 %) experienced slight pain while walking, and five (9.8 %) patients reported more intensive pain in the joint treated. Intra-operative complications included a fracture of the medial malleolus in two (3.9 %) patients subsequently treated with screw osteosynthesis. Post-operatively, seven (13.7 %) patients experienced slow healing of the operative wound. One patient had dislocation of the polyethylene liner at 3 months after surgery. Revision surgery was carried out in seven (13.7 %) patients. Two patients suffering from increasing pain around medial malleolus underwent revision and removal of ossifications. One patient developed necrosis of the talus at 1 year after surgery. She underwent extraction of the prosthesis and ankle arthrodesis with a retrograde locking nail inserted through the heel. A large bony effect arising due to extraction of the necrotic talus was repaired using bone graft. Three (5.8 %) patients developed post-operative instability of the ankle that required revision surgery, The radiographs of another three (5.8 %) patients showed bone cysts and signs of tibial component loosening. Of these, one patient underwent surgical revision with replacement of the polyethylene liner. Cavities were freed from granuloma induced by polyethylene wear debris, and filled with bone graft from the iliac crest. DISCUSSION Total ankle replacement is a complicated surgical procedure that may results in various technical difficulties and complications. These are inversely proportional to the surgeon's experience, as also shown by literature data. CONCLUSIONS The longevity of a total ankle replacement depends, much more than in other joint replacements, on an accurate implantation technique and correct indication.","[Popelka, S.; Vavrik, P.; Landor, I.; Hach, J.; Pech, J.; Sosna, A.] FN Motol, I Ortoped Klin 1, LF UK, Prague 5, Czech Republic","Popelka, S (reprint author), FN Motol, I Ortoped Klin 1, LF UK, Uvalu 84, Prague 5, Czech Republic.","mudr.popelka@volny.cz",null,null,null,null,null,37,6,6,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2010,77,1,null,null,null,null,24,31,null,null,null,8,"Orthopedics","Orthopedics","567XS","WOS:000275482700004"]
[null,null,null,null,"J","Sterbakova, G; Vyskocil, V; Linhartova, K",null,null,null,"Sterbakova, Gabriela; Vyskocil, Vaclav; Linhartova, Katerina",null,null,"Bisphosphonates in Calcific Aortic Stenosis: Association with Slower Progression in Mild Disease - A Pilot Retrospective Study","CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"Aortic stenosis; Valve calcification; Bisphosphonates; Osteoporosis","ARTERY CALCIFICATION; VITAMIN-D; ECHOCARDIOGRAPHY; RECOMMENDATIONS; ROSUVASTATIN; IBANDRONATE; TRIAL","Objectives: An association between aortic valve calcification and osteoporosis has been observed. The aim of this study was to assess the association between bisphosphonate treatment for osteoporosis and the progression of calcific aortic stenosis (AS). Methods: A retrospective study of patients with AS (mean gradient >= 10 mm Hg), preserved renal function and two echocardiographies >8 months apart was performed. The patients were divided into those treated with bisphosphonates for osteoporosis and those not treated and then subdivided into mild (mean gradient <30 mm Hg) and moderate-to-severe AS groups. We compared the annualized gradient change between the groups and identified predictors of AS progression. Results: We analyzed the outcomes of 103 patients (51% females, age 68 +/- 10 years, follow-up 29 +/- 13 months), of whom 57 had mild and 46 moderate-to-severe AS. Bisphosphonates were taken by 28 patients, of whom 22 had mild and 6 moderate-to-severe AS. In the patients with mild AS, the annualized mean gradient change was lower in the bisphosphonate-treated than in the untreated patients (0.1 +/- 3.3 vs. 2.8 +/- 3.3 mm Hg/year; p = 0.002) and was negatively associated with bisphosphonate treatment (beta coefficient -2.36%, 95% confidence interval -4.47 to -0.26; p = 0.028) independent of age, gender and baseline gradient. Conclusion: Bisphosphonate treatment was independently associated with slower progression of mild AS in patients with preserved renal function. Copyright (C) 2010 S. Karger AG, Basel","[Linhartova, Katerina] Charles Univ Prague, Sch Med 2, Hosp Motol, Cardiovasc Ctr,Dept Cardiol, CZ-15006 Prague, Czech Republic; [Sterbakova, Gabriela] Charles Univ Prague, Sch Med Hosp, Dept Med 1, Plzen, Czech Republic; [Vyskocil, Vaclav] Charles Univ Prague, Sch Med Hosp, Dept Orthoped Surg, Plzen, Czech Republic","Linhartova, K (reprint author), Charles Univ Prague, Sch Med 2, Hosp Motol, Cardiovasc Ctr,Dept Cardiol, V Uvalu 84, CZ-15006 Prague, Czech Republic.","linhartkaterina@seznam.cz",null,null,"Czech Ministry of Health [MZOFNM2005]","This study was supported by the cardiovascular research project of the Czech Ministry of Health, MZOFNM2005.",null,22,5,5,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0008-6312",null,null,"CARDIOLOGY","Cardiology",null,2010,117,3,null,null,null,null,184,189,null,"10.1159/000321418",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","714JI","WOS:000286805500006"]
[null,null,null,null,"J","Salameh, A; Karl, S; Djilali, H; Dhein, S; Janousek, J; Daehnert, I",null,null,null,"Salameh, Aida; Karl, Sebastian; Djilali, Hjalmar; Dhein, Stefan; Janousek, Jan; Daehnert, Ingo",null,null,"Opposing and synergistic effects of cyclic mechanical stretch and alpha- or beta-adrenergic stimulation on the cardiac gap junction protein Cx43","PHARMACOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Cyclic mechanical stretch; Cardiomyocytes; Connexin43; ERK; AKT; Alpha-adrenoceptor; Beta-adrenoceptor","RAT CARDIOMYOCYTES; SIGNALING PATHWAY; HEART-FAILURE; VENTRICULAR CARDIOMYOCYTES; SYNTHASE KINASE-3-BETA; CONNEXIN EXPRESSION; GENE-EXPRESSION; UP-REGULATION; IN-VITRO; MYOCYTES","In the heart the most prominent cardiac gap junction protein is connexin43 (Cx43) Increased Cx43 expression has been identified in cardiac hypertrophy and may contribute to arrhythmias Besides acute effects on gap junction channel function chronic regulation of Cx43 expression can affect intercellular communication Since both cyclic mechanical stretch (CMS) and catecholamines play an Important role in cardiac physiology and pathophysiology we wanted to elucidate whether a prolonged beta- or alpha-adrenoceptor stimulation may modulate the effects of CMS on Cx43 expression Neonatal rat cardiomyocytes were cultured on flexible 6-well plates Thereafter cells were kept static without any treatment or stimulated with 01 mu mol/L isoprenaline or phenylephrine for 24 h without or with additional CMS (1 Hz 10% elongation) Isoprenaline and phenylephrine given alone significantly increased Cx43-protein and -mRNA level Also CMS resulted in a significant Cx43-protein and -mRNA up-regulation The combined treatment of the cells with either isoprenaline or phenylephrine and stretch also resulted in an up-regulation of Cx43-protein and -mRNA which did not exceed those of stretch isoprenaline or phenylephrine alone However while CMS reduced the Cx43-protem/mRNA ratio adrenergic stimulation increased Cx43-protem/mRNA ratio While isoprenaline and phenylephrine increased Cx43-phosphorylation additional CMS significantly reduced P-Cx43/Cx43 ratio For further investigation of the underlying signal transduction pathway we examined the phosphorylated forms of ERK1/2 GSK3 beta and AKT and could demonstrate that these protein kinases are also significantly up-regulated following stretch or adrenoceptor stimulation Again the combined treatment of cardiomyocytes with CMS and isoprenaline or phenylephrine had no additive effects Thus the combination of alpha- or beta-adrenoceptor stimulation and CMS up-regulates Cx43 expression and leads to phosphorylation of ERK1/2 and AICT (=activation) and of GSK3 beta(=inactivation) There were no significant additive effects compared to CMS or adrenergic stimulation alone indicating a possible ceiling effect However CMS and adrenergic stimulation differentially affected Cx43-protein/mRNA ratio and Cx43-phosphorylation (C) 2010 Elsevier Ltd All rights reserved","[Salameh, Aida; Karl, Sebastian; Djilali, Hjalmar; Daehnert, Ingo] Univ Leipzig, Clin Paediat Cardiol, D-04289 Leipzig, Germany; [Dhein, Stefan] Univ Leipzig, Clin Cardiac Surg, D-04289 Leipzig, Germany; [Janousek, Jan] Univ Prague, Cardioctr, Prague, Czech Republic","Salameh, A (reprint author), Univ Leipzig, Ctr Heart, Clin Pediat Cardiol, Struempellstr 39, D-04289 Leipzig, Germany.",null,null,null,"Medical faculty of the University of Leipzig","S K was supported by a grant given by the medical faculty of the University of Leipzig","Baba HA, 2003, CARDIOVASC RES, V59, P390, DOI 10.1016/S0008-6363(03)00393-6; Bailey J, 2002, J CLIN ENDOCR METAB, V87, P1717, DOI 10.1210/jc.87.4.1717; Barac YD, 2005, CARDIOVASC RES, V68, P75, DOI 10.1016/j.cardiores.2005.05.015; Beardslee MA, 1998, CIRC RES, V83, P629; DAVIS LM, 1995, J CARDIOVASC ELECTR, V6, P813, DOI 10.1111/j.1540-8167.1995.tb00357.x; Du WJ, 2009, CELLS TISSUES ORGANS, V190, P11, DOI 10.1159/000167699; Dupont E, 2001, J MOL CELL CARDIOL, V33, P359, DOI 10.1006/jmcc.2000.1308; Echetebu CO, 1999, MOL HUM REPROD, V5, P757, DOI 10.1093/molehr/5.8.757; El Jamali A, 2004, FASEB J, V18, P1096, DOI 10.1096/fj.03-1054fje; Gershtein ES, 2007, ANTICANCER RES, V27, P1777; Girao H, 2003, MOL VIS, V9, P24; Hannan RE, 2003, CLIN EXP PHARMACOL P, V30, pA53; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; Huang YS, 2004, J MOL CELL CARDIOL, V37, P755, DOI 10.1016/j.yjmcc.2004.06.011; Kim CH, 2002, CIRC RES, V90, pE25, DOI 10.1161/hh0202.104923; Kostin S, 2004, CARDIOVASC RES, V62, P426, DOI 10.1016/j.cardiores.2003.12.010; KWAK BR, 1995, MOL BIOL CELL, V6, P1707; Kwak BR, 1999, CARDIOVASC RES, V44, P370, DOI 10.1016/S0008-6363(99)00196-0; Laird DW, 2005, BBA-BIOMEMBRANES, V1711, P172, DOI 10.1016/j.bbamem.2004.09.009; LAIRD DW, 1991, BIOCHEM J, V273, P67; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LAMPE PD, 1994, J CELL BIOL, V127, P1895, DOI 10.1083/jcb.127.6.1895; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malhotra R, 2010, J BIOL CHEM, V285, P13748, DOI 10.1074/jbc.M110.109272; Markou T, 2004, J MOL CELL CARDIOL, V37, P1001, DOI 10.1016/j.yjmcc.2004.08.002; Matsuda T, 2006, J MOL CELL CARDIOL, V40, P495, DOI 10.1016/j.yjmcc.2005.12.010; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; OH SY, 1991, BIOCHIM BIOPHYS ACTA, V1094, P243, DOI 10.1016/0167-4889(91)90016-Q; Palfi A, 2006, J MOL CELL CARDIOL, V41, P149, DOI 10.1016/j.yjmcc.2006.03.427; Polontchouk Lioudmila, 2002, FASEB Journal, V16, P87; Ponicke K, 2001, N-S ARCH PHARMACOL, V364, P444, DOI 10.1007/s002100100469; Saffitz JE, 1999, CARDIOVASC RES, V42, P309, DOI 10.1016/S0008-6363(99)00023-1; Salameh A, 2006, FASEB J, V20, P365, DOI 10.1096/fj.05-4871fje; Salameh A, 2008, J PHARMACOL EXP THER, V326, P315, DOI 10.1124/jpet.108.136663; Salameh A, 2009, BRIT J PHARMACOL, V158, P198, DOI 10.1111/j.1476-5381.2009.00344.x; Salameh A, 2010, CIRC RES, V106, P1592, DOI 10.1161/CIRCRESAHA.109.214429; Schafer M, 2001, J AM COLL CARDIOL, V37, P300, DOI 10.1016/S0735-1097(00)01065-2; Schluter KD, 1998, CARDIOVASC RES, V40, P174, DOI 10.1016/S0008-6363(98)00171-0; Sepp R, 1996, HEART, V76, P412, DOI 10.1136/hrt.76.5.412; Shyu KG, 2001, J MOL CELL CARDIOL, V33, P691, DOI 10.1006/jmcc.2000.1333; TenBroek EM, 2001, J CELL BIOL, V155, P1307, DOI 10.1083/jcb.200102017; THORBURN J, 1995, MOL BIOL CELL, V6, P1479; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; Wang TL, 2000, BIOCHEM BIOPH RES CO, V267, P551, DOI 10.1006/bbrc.1999.1988; Yamada K, 2005, CIRC RES, V97, P346, DOI 10.1161/01.RES.0000178788.76568.8a",47,5,5,"ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD","LONDON","24-28 OVAL RD, LONDON NW1 7DX, ENGLAND","1043-6618",null,null,"PHARMACOL RES","Pharmacol. Res.","DEC",2010,62,6,null,null,null,null,506,513,null,"10.1016/j.phrs.2010.08.002",null,8,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","689XZ","WOS:000284965700006"]
[null,null,null,null,"J","Hromadka, R; Kubena, AA; Pokorny, D; Popelka, S; Jahoda, D; Sosna, A",null,null,null,"Hromadka, Rastislav; Kubena, Alen Antonin; Pokorny, David; Popelka, Stanislav; Jahoda, David; Sosna, Antonin",null,null,"Lesser tuberosity is more reliable than bicipital groove when determining orientation of humeral head in primary shoulder arthroplasty","SURGICAL AND RADIOLOGIC ANATOMY",null,null,"English","Article",null,null,null,null,null,"Shoulder arthroplasty; Humeral head retroversion; Bicipital groove; Greater tuberosity; Lesser tuberosity; Crest of greater tuberosity","PECTORALIS MAJOR TENDON; PROXIMAL HUMERUS; COMPUTED-TOMOGRAPHY; RETROVERSION; HEMIARTHROPLASTY; PROSTHESIS; FRACTURES; LANDMARK; REPLACEMENT; REASONS","The objective of the study was to provide statistical evaluation of position of bone landmarks of proximal humerus in relation to transepicondylar line and find out which one is the most suitable for setup of the head retroversion in case of humeral head destruction. We measured 185 dry humeral preparations (92 left, 93 right). Structures of interest on the proximal humerus were marked with pointers of custom made steel frame. Angular relationships between the humeral head axis and medial margin of the greater tuberosity, lateral margin of the lesser tuberosity, bicipital groove, and crest of the greater tuberosity were evaluated with respect to intramedullary axis of the proximal humeral shaft. The angle between the humeral head axis and medial margin of greater tuberosity was 11.5 +/- A 9.0A degrees, the angle between the lateral margin of the lesser tuberosity and the axis was 47.5 +/- A 7.4A degrees, the angle between the bicipital groove and the axis was 31.6 +/- A 8.8A degrees at the level of the humeral head. The angle between the crest of the greater tuberosity and the axis was 26.6 +/- A 9.6A degrees in plane of the surgical neck. We statistically proved that the lateral margin of lesser tuberosity is more reliable than the bicipital groove; medial margin of the greater and transepicondylar line for reconstruction of humeral head retroversion. We suggest that the lesser tuberosity should be used to determine the retroversion, especially in cases when the margin of humeral head was destructed.","[Hromadka, Rastislav; Pokorny, David; Popelka, Stanislav; Jahoda, David; Sosna, Antonin] Charles Univ Prague, Fac Med 1, Orthopaed Clin 1, Prague 15006, Czech Republic; [Hromadka, Rastislav] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 15006, Czech Republic; [Kubena, Alen Antonin] Charles Univ Prague, Fac Sci, Dept Evolut Biol, Prague 15006, Czech Republic","Hromadka, R (reprint author), Charles Univ Prague, Fac Med 1, Orthopaed Clin 1, V Uvalu 84, Prague 15006, Czech Republic.","rastho@gmail.com; voodoolinek@gmail.com; david.pokorny@lf1.cuni.cz; mudr.popelka@volny.cz; david.jahoda@post.cz; sosna.orto@email.cz",null,null,null,null,null,19,4,4,"SPRINGER FRANCE","PARIS","22 RUE DE PALESTRO, PARIS, 75002, FRANCE","1279-8517",null,null,"SURG RADIOL ANAT","Surg. Radiol. Anat.","JAN",2010,32,1,null,null,null,null,31,37,null,"10.1007/s00276-009-0543-6",null,7,"Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery","Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery","544UX","WOS:000273685900006"]
[null,null,null,null,"J","Calda, P; Brestak, M; Tomek, V; Ostadal, B; Sonek, J",null,null,null,"Calda, Pavel; Brestak, Miroslav; Tomek, Viktor; Ostadal, Bohuslav; Sonek, Jiri",null,null,"Left ventricle shortening fraction: a comparison between euploid and trisomy 21 fetuses in the first trimester","PRENATAL DIAGNOSIS",null,null,"English","Article",null,null,null,null,null,"trisomy 21; first trimester; marker; shortening fraction of the left ventricle","CARDIAC DEVELOPMENT; DOWN-SYNDROME; FETAL; PREGNANCY","Objectives Measurement of the shortening fraction of the left ventricle (SFLV) is an objective way to assess systolic performance. The aim of the study was to compare first trimester SFLV values in euploid fetuses to those in fetuses with trisomy 21. Methods We measured SFLV in 56 fetuses from 11 weeks to 13 weeks 6 days. The left ventricular diastolic diameter (LVDD) and left ventricular systolic diameter (LVSD) were measured offline, and SFLV was calculated. The data were analyzed using Mann Whitney U test. Results We found a significant difference in the SFLV measurements between the group of 49 euploid fetuses and the 7 fetuses with trisomy 21 [38.00(95% CI: 33.72-42.27) vs 49.93 (95% CI: 43.72-56.13)] (p < 0.05). There was also a significant difference in the nuchal translucency measurements between the two groups: 1.78 mm (95% CI: 1.08-2.48 mm) in the euploid population versus 5.06 mm (95% CI: 3.61-6.71 mm) in the fetuses with trisomy 21 (p < 0.05). There were no significant differences between the group of euploid fetuses and the group of trisomy 21 fetuses in the following parameters: CRL (chorionic villus sampling), LVDD and LVSD. Conclusions SFLV is a well-defined, simple measurement of systolic function of the fetal myocardium. SFLV values in fetuses with trisomy 21 appear to be significantly higher than in euploid fetuses. Copyright (C) 2010 John Wiley & Sons, Ltd.","[Calda, Pavel; Brestak, Miroslav] Charles Univ Prague, Dept Gynecol & Obstet, Fac Med 1, Fetal Med Ctr, Prague 12852 2, Czech Republic; [Calda, Pavel; Brestak, Miroslav] Charles Univ Prague, Gen Teaching Hosp, Fetal Med Ctr, Prague 12852 2, Czech Republic; [Tomek, Viktor] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Tomek, Viktor] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Ostadal, Bohuslav] Acad Sci Czech Republic, Inst Physiol, Cardiovasc Res Ctr, Prague, Czech Republic; [Sonek, Jiri] Wright State Univ, Dayton, OH 45435 USA; [Sonek, Jiri] Fetal Med Fdn USA, Dayton, OH USA","Calda, P (reprint author), Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 1, Fetal Med Ctr, Apolinarska 18, Prague 12852 2, Czech Republic.","calda@gynstart.cz","Ostadal, Bohuslav/F-7387-2014",null,null,null,null,14,3,3,"JOHN WILEY & SONS LTD","CHICHESTER","THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND","0197-3851",null,null,"PRENATAL DIAG","Prenat. Diagn.","APR",2010,30,4,null,null,null,null,368,371,null,"10.1002/pd.2500",null,4,"Genetics & Heredity; Obstetrics & Gynecology","Genetics & Heredity; Obstetrics & Gynecology","595RH","WOS:000277629600013"]
[null,null,null,null,"J","Adamek, S; Shakirzyanova, AV; Malomouzh, AI; Naumenko, NV; Vyskocil, F",null,null,null,"Adamek, S.; Shakirzyanova, A. V.; Malomouzh, A. I.; Naumenko, N. V.; Vyskocil, F.",null,null,"Interaction of Glutamate-and Adenosine-Induced Decrease of Acetylcholine Quantal Release at Frog Neuromuscular Junction","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Endplate potentials; Guanylyl cyclase; Carbacholine; ATP; NO","POST-DENERVATION DEPOLARIZATION; MOTOR-NERVE TERMINALS; NITRIC-OXIDE; RAT DIAPHRAGM; END-PLATE; NEUROTRANSMITTER RELEASE; NMDA RECEPTORS; NO-SYNTHASE; MOUSE; MODULATION","In a frog neuromuscular preparation of m. sartorius, glutamate had a reversible dose-dependent inhibitory effect on both spontaneous miniature endplate potentials (MEPP) and nerve stimulation-evoked endplate potentials (EPP). The effect of glutamate on MEPP and EPP is caused by the activation of metabotropic glutamate receptors, as it was eliminated by MCPG, an inhibitor of group I metabotropic glutamate receptors. The depression of evoked EPP, but not MEPP frequency was removed by inhibiting the NO production in the muscle by L-NAME and by ODQ that inhibits the soluble NO-sensitive guanylyl cyclase. The glutamate-induced depression of the frequency of spontaneous MEPP is apparently not caused by the stimulation of the NO cascade. The particular glutamate-stimulated NO cascade affecting the evoked EPP can be down-regulated also by adenosine receptors, as the glutamate and adenosine actions are not additive and application of adenosine partially prevents the further decrease of quantal content by glutamate. On the other hand, there is no obvious interaction between the glutamate-mediated inhibition of EPP and inhibitory pathways triggered by carbacholine and ATP. The effect of glutamate on the evoked EPP release might be due to NO-mediated modulation (phosphorylation) of the voltage-dependent Ca(2+) channels at the presynaptic release zone that are necessary for evoked quantal release and open during EPP production.","[Vyskocil, F.] Acad Sci Czech Republic, Inst Physiol, Prague 4, Czech Republic; [Vyskocil, F.] Charles Univ Prague, Dept Anim Physiol, Fac Sci, Prague, Czech Republic; [Adamek, S.] Charles Univ Prague, Fac Med 1, Surg Dept 3, Prague, Czech Republic; [Shakirzyanova, A. V.; Malomouzh, A. I.] Russian Acad Sci, Inst Biochem & Biophys, Kazan, Russia; [Naumenko, N. V.] Kazan State Med Univ, Dept Normal Physiol, Kazan, Russia","Vyskocil, F (reprint author), Acad Sci Czech Republic, Inst Physiol, Videnska 1083, Prague 4, Czech Republic.","Vyskocil@biomed.cas.cz",null,null,"Russian Foundation for Basic Research (RFBR) [07-04-01656, 10-04-01255]; Scientific Schools of Russia [SS-64631.2010.07];  [MK-8017.2010.4];  [IAA500110905];  [GACR 202/09/0806];  [AV0Z 0110509]","Supported by Russian Foundation for Basic Research (RFBR) 07-04-01656 and 10-04-01255, Russian President MK-8017.2010.4, Scientific Schools of Russia SS-64631.2010.07 for AS, AM and NN. FV was supported by IAA500110905, GACR 202/09/0806 and AV0Z 0110509.",null,48,3,3,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,5,null,null,null,null,803,810,null,null,null,8,"Physiology","Physiology","683QC","WOS:000284489300019"]
[null,null,null,null,"J","Hromadka, R; Bartak, V; Popelka, S; Pokorny, D; Jahoda, D; Sosna, A",null,null,null,"Hromadka, Rastislav; Bartak, Vladislav; Popelka, Stanislav; Pokorny, David; Jahoda, David; Sosna, Antonin",null,null,"Ankle Block Implemented Through Two Skin Punctures","FOOT & ANKLE INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"Ankle Block; Foot Block; Anesthesia of the Foot","PERIPHERAL-NERVE BLOCK; FOREFOOT SURGERY; REGIONAL ANESTHESIA; FOOT","Background: Recently, peripheral nerve blocks have increasingly been used in orthopedic surgery. The foot block is an alternative for anesthesia in cases of forefoot and midfoot operations. We propose a modification of the block technique due to potential difficulties concerning the tibial nerve. Materials and Methods: The spatial position of the tibial nerve in the neurovascular bundle, proximal to entering the tarsal tunnel and sural nerve behind lateral malleolus was measured on 60 dissected preparations. Modification of the block technique was proposed. A tibial nerve block was administered by inserting a needle, at an area above the upper edge of the heel bone, tangential to the Achilles tendon. The needle was then withdrawn and redirected to the frontal plane and inserted through the tissue, anterior to the Achilles tendon and laterally behind the lateral malleolus to block the sural nerve. A block of the saphenous nerve superficial and deep peroneal nerves was implemented by needle insertion subcutaneously two centimeters proximal to the crest of the ankle joint. The technique was then evaluated in the clinical part of the study in 84 operative procedures. Results: The tibial nerve is located 21.1 mm +/- 2.1 mm from the medial aspect of the Achilles tendon and 11.6 mm +/- 1.3 mm deep in the neurovascular bundle. The distance from the posterior margin of the lateral malleolus to the sural nerve is 18.3 mm +/- 1.9 mm. We achieved a 93% success rate in implementation of the complete foot block in 84 operations. Conclusion: The technique, proposed in the anatomical portion of the study and evaluated in the clinical part, had a similar success rate when compared to techniques published in the literature. Though comparable to currently used techniques, this technique provides easier positioning of a patient and a complete block of the foot can be done with two skin injection sites.","[Hromadka, Rastislav; Bartak, Vladislav; Popelka, Stanislav; Pokorny, David; Jahoda, David; Sosna, Antonin] Charles Univ Prague, Fac Med 1, Orthopaed Clin 1, Prague, Czech Republic; [Hromadka, Rastislav] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic","Hromadka, R (reprint author), Motol Univ Hosp, Orthopaed Clin 1, V Uvalu 84, Prague 15006 5, Czech Republic.","rastho@gmail.com",null,null,null,null,null,17,2,3,"AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC","SEATTLE","2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA","1071-1007",null,null,"FOOT ANKLE INT","Foot Ankle Int.","JUL",2010,31,7,null,null,null,null,619,623,null,"10.3113/FAI.2010.0619",null,5,"Orthopedics","Orthopedics","620HR","WOS:000279490300010"]
[null,null,null,null,"J","Machovcova, A",null,null,null,"Machovcova, Alena",null,null,"Caustic Ulcers Caused by Cement Aqua: Report of a Case","INDUSTRIAL HEALTH",null,null,"English","Article",null,null,null,null,null,"Caustic ulcers; Cement aqua; Occupational injury","SKIN BURNS; WET CEMENT","Chromium is widely used in various industries including construction sector. Skin contact with cement has been associated with allergic or irritant contact dermatitis. Contact dermatitis is one of the most frequently reported health problems among construction workers. Irritant contact dermatitis from cement ranges from cement burns to cumulative irritant contact dermatitis. Cement burns are rarely reported and are considered a severe form of acute irritant contact dermatitis. They are associated with amateur user working in a short ready-mix time-frame with poor protective measures. They usually result in significant morbidity and initially are associated with minimal discomfort. We report a typical case.","Fac Hosp Motol, Dept Dermatol, Prague 15006 5, Czech Republic","Machovcova, A (reprint author), Fac Hosp Motol, Dept Dermatol, Prague 15006 5, Czech Republic.","alena.machovcova@fnmotol.cz",null,null,"VZ FNM MZO [00064203/6904]","This study is supported by grant VZ FNM MZO 00064203/6904.",null,11,2,2,"NATL INST OCCUPATIONAL SAFETY & HEALTH, JAPAN","KAWASAKI KANAGAWA","21-1 NAGAO 6-CHOME TAMA-KU, KAWASAKI KANAGAWA, 214, JAPAN","0019-8366",null,null,"IND HEALTH","Ind. Health","MAR",2010,48,2,null,null,null,null,215,216,null,null,null,2,"Environmental Sciences; Public, Environmental & Occupational Health; Toxicology","Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology","577WZ","WOS:000276256000012"]
[null,null,null,null,"J","Weber, C; Kocher, S; Neeser, K; Bartaskova, D",null,null,null,"Weber, Christian; Kocher, Serge; Neeser, Kurt; Bartaskova, Dagmar",null,null,"Impact of self-measurement of blood glucose on complications of type 2 diabetes: economic analysis from a Czech perspective","CURRENT MEDICAL RESEARCH AND OPINION",null,null,"English","Article",null,null,null,null,null,"Diabetes complications; Diabetes mellitus; Healthcare costs; Matched-pair analysis; Self-measurement of blood glucose","GLYCEMIC CONTROL; METAANALYSIS; MORTALITY; THERAPY; RISK","Objective: A growing body of evidence indicates that self-measurement of blood glucose (SMBG) also has beneficial effects in people with type 2 diabetes, irrespective of the type of therapy. The objective of this analysis was to determine the economic impact of SMBG by comparing the cost share of self-monitoring and the direct costs of diabetes-related complications in users and non-users. Research design and methods: A matched-pair analysis based on the cohorts of a large retrospective study of patients with type 2 diabetes (ROSSO) was conducted. The average annual direct costs of diabetes monitoring, treatment-related services, complications and follow-up costs of the disease for SMBG users versus non-users were calculated from the perspective of the Czech statutory health insurance system. Univariate sensitivity analysis was performed to determine the main cost drivers. Limitations of this study are: (1) differences in medical facilities/practice between Germany and the Czech Republic, (2) causal relationship between SMBG and health outcomes is missing, (3) ROSSO underestimated the number of test strips used, (4) Czech cost data are scarce. Results: In patients treated with oral antidiabetic drugs (OAD) only, total annual costs in Czech koruna (CZK) were CZK 16 476 for SMBG users and CZK 19 440 for non-users. In patients treated with OAD + insulin, total annual costs were CZK 32 590 and CZK 48 600, respectively. The main cost drivers were stroke and myocardial infarction in patients treated with OAD only, and stroke, dialysis and myocardial infarction in patients treated with OAD + insulin. Conclusion: Cost analysis indicated that SMBG provides a rapid return on initial investment. By increasing the number of patients using SMBG, the statutory health insurance system in the Czech Republic may save several million CZK annually.","[Weber, Christian; Kocher, Serge; Neeser, Kurt] Inst Med Informat & Biostat, CH-4058 Basel, Switzerland; [Bartaskova, Dagmar] Motol Univ Hosp, Prague, Czech Republic","Neeser, K (reprint author), Inst Med Informat & Biostat, Clarastr 12, CH-4058 Basel, Switzerland.","neeser@imib.ch",null,null,"Roche Diagnostics GmbH, Mannheim, Germany","This manuscript was sponsored by an unrestricted grant from Roche Diagnostics GmbH, Mannheim, Germany. The sponsor had no form of contribution or input to the contents of the article or its drafting.",null,31,2,2,"LIBRAPHARM/INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4 LQ, ENGLAND","0300-7995",null,null,"CURR MED RES OPIN","Curr. Med. Res. Opin.","FEB",2010,26,2,null,null,null,null,289,296,null,"10.1185/03007990903479224",null,8,"Medicine, General & Internal; Medicine, Research & Experimental","General & Internal Medicine; Research & Experimental Medicine","554PL","WOS:000274446800005"]
[null,null,null,null,"J","Adamek, S; Matouskova, O; Pafko, P; Slanar, O; Perlik, F",null,null,null,"Adamek, S.; Matouskova, O.; Pafko, P.; Slanar, O.; Perlik, F.",null,null,"The role of diclofenac and piritramide in the management of acute postoperative pain in hernioplasty","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"analgesia; diclofenac; piritramide; hernioplasty; postoperative pain; human",null,"Objectives: The aim of the study was to compare the effects of diclofenac and piritramide in acute postoperative pain after hernioplasty. Background: In the treatment of moderate acute postoperative pain, non-steroidal anti-inflammatory drugs and opioids play the major role. The data on safety and effect of analgesia based on opioid and non-opioid drugs are still a controversial topic. Methods: We compared the first-line treatment effects of diclofenac and piritramide in 105 patients after hernioplasty in a retrospective manner. The subsequent therapy combined piritramide with diclofenac. We evaluated the intensity of pain and its relief using a visual analogue scale (VAS). We also evaluated the necessity of application of other analgesics. Results: One hour after the application of the first analgesic dose, we observed complete pain relief in 39.5 % of patients treated with piritramide and in 19.4 % of patients treated with diclofenac (chi(2)=5.17; p = 0.02). After the use of piritramide, the pain relief (3.84 +/- 1.27 mm) was significantly higher than after diclofenac (3.34 +/- 0.77 mm). Another injection was needed in 76 % and 54 % of patients subjected to first-line treatment based on diclofenac and piritramide, respectively. Conclusion: We observed that the first-line analgesic treatment based on piritramide was more effective when compared to that based on diclofenac (Tab. 3, Ref. 3). Full Text in free PDF www.bmj.sk.","[Adamek, S.; Pafko, P.] First Fac Med, Dept Surg 3, Prague, Czech Republic; [Adamek, S.; Pafko, P.] Univ Hosp Motol, Prague, Czech Republic; [Matouskova, O.; Slanar, O.; Perlik, F.] First Fac Med, Inst Pharmacol, Prague, Czech Republic; [Matouskova, O.; Slanar, O.; Perlik, F.] Gen Univ Hosp, Prague, Czech Republic","Pafko, P (reprint author), 1 LF UK, Dept Surg 3, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","pavel.pafko@lfmotol.cuni.cz",null,null," [VZ MSM 0021620849];  [VZ MSM 0021620820]","Supported in part by grants No. VZ MSM 0021620849 and VZ MSM 0021620820.",null,2,1,1,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248","1336-0345",null,"BRATISL MED J","Bratisl. Med. J.",null,2010,111,11,null,null,null,null,616,618,null,null,null,3,"Medicine, General & Internal","General & Internal Medicine","708IH","WOS:000286355000008"]
[null,null,null,null,"J","Hromadka, R; Kubena, AA; Pokorny, D; Popelka, S; Jahoda, D; Sosna, A",null,null,null,"Hromadka, Rastislav; Kubena, Ales Antonin; Pokorny, David; Popelka, Stanislav; Jahoda, David; Sosna, Antonin",null,null,"Attachments of muscles as landmarks for implantation of shoulder hemiarthoplasty in fractures","JOURNAL OF SHOULDER AND ELBOW SURGERY",null,null,"English","Article",null,null,null,null,null,"Shoulder arthroplasty; humeral head retroversion; transepicondylar line; greater tubercle; lesser tubercle; crest of greater tubercle","PROXIMAL HUMERUS; BICIPITAL GROOVE; COMPUTED-TOMOGRAPHY; 4-PART FRACTURES; HEMIARTHROPLASTY; ARTHROPLASTY; RETROVERSION; REPLACEMENT; MALPOSITION; ORIENTATION","Background: The attachments of muscles and the position of the humeral head are important for a good functional outcome of shoulder hemiarthroplasties after displaced fractures of the proximal humerus. Deviations in the attachments and changes in their spatial position with respect to the humeral head during surgical reconstruction change the biomechanics and reduce the range of motion of the should joint post-operatively. Methods and Results: We used 198 humerus preparations and using 3-dimensional analysis measured the angular relationships between the humeral head axis and medial margin of the greater tuberosity (11.9 degrees +/- 9.1 degrees), lateral margin of the lesser tuberosity (48.0 degrees +/- 7.8 degrees), and the crest of the greater tuberosity (27.1 degrees +/- 9.6 degrees). Conclusion: This study provides average values of the positions of the greater and lesser tuberosities with respect to the humeral head axis. We show that the greater and lesser tuberosities are more reliable than the transepicondylar line for reconstruction of humeral head retroversion.","[Hromadka, Rastislav; Pokorny, David; Popelka, Stanislav; Jahoda, David; Sosna, Antonin] Charles Univ Prague, Fac Med 1, Orthopaed Clin 1, Prague, Czech Republic; [Hromadka, Rastislav] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic; [Kubena, Ales Antonin] Charles Univ Prague, Fac Sci, Dept Evolut Biol, Prague, Czech Republic","Hromadka, R (reprint author), 1 LF UK & FN Motol, Ortoped Klin 1, Uvalu 84, Prague 15006 5, Czech Republic.","rastislav.hromadka@lf1.cuni.cz",null,null,null,null,null,22,1,1,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","1058-2746",null,null,"J SHOULDER ELB SURG","J. Shoulder Elbow Surg.","JAN",2010,19,1,null,null,null,null,130,136,null,"10.1016/j.jse.2009.03.023",null,7,"Orthopedics; Sport Sciences; Surgery","Orthopedics; Sport Sciences; Surgery","592HA","WOS:000277367800023"]
[null,null,null,null,"J","Knotek, P",null,null,null,"Knotek, Petr",null,null,"Psychological processes in chronic pain, their structure and dynamics","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"chronic pain; psychological and behavioral processes","CHRONIC MUSCULOSKELETAL PAIN; ATTENTION; MODEL; MECHANISMS; BEHAVIORS; ILLNESS; SPOUSE; FEAR","This article shows a complex viewpoint on present models of psychological processes in chronic pain that stems from researches based on neurophysiologic and psychological experiments or a multivariate analysis of clinical data. Modern conceptions of psychological changes are based on Melzack - Wall's Gate Controle Theory, Lazarus and Folkman's cognitive theory of stress, and the concept of learned pain behavior of Wilbert E. Fordyce. Two groups of models follow these above mentioned conceptions: A model of consecutive stages of psychological changes in people with chronic pain (Wade, Dougherty, Archer, Price, 1996; Knotek, Knotkova 2008), and models that focus on feedback processes during the development of psychological changes in people with chronic pain (survey in Asmundson, Vlaeyen, Crombez, 2004). A new model that includes essential aspects of both above mentioned models has been recently tested (Knotek, 2009). The article proposes an extended theoretical model that includes two triggering processes, pain and cognitive processing of pain. The main stages of psychological processes consist of fear and observation of pain, pain assessment and coping with pain, changes of affects and motivation, and adaptive or maladaptive behavior. The changes of affects and motivation have an influence on self-perception which via feedback influences cognitive processing of pain. The basic vision for the future research of chronic pain is the Neuromatrix Theory of Pain of Roland Melzack (2005) that sees pain as multidimensional experience caused by neurosignature (patterns of impulses of neural network that represent body - self neuromatrix in the brain).","[Knotek, Petr] FN Motol, Ctr Laceni & Vyzkum Stavu, Prague 15006 5, Czech Republic; [Knotek, Petr] FN Motol, Oddeleni Klin Psychol, Prague 15006 5, Czech Republic","Knotek, P (reprint author), FN Motol, Ctr Laceni & Vyzkum Stavu, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.knotek@fnmotol.cz",null,null,null,null,null,68,1,1,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2010,54,6,null,null,null,null,546,563,null,null,null,18,"Psychology, Multidisciplinary","Psychology","709NT","WOS:000286448100002"]
[null,null,null,null,"J","Riede, FT; Dahnert, I; Razek, V; Kostelka, M",null,null,null,"Riede, F. T.; Daehnert, I.; Razek, V.; Kostelka, M.",null,null,"Rupture of the papillary muscle of the tricuspid valve - echocardiographic diagnosis of a rare anomaly leading to critical tricuspid valve regurgitation in the newborn","EUROPEAN JOURNAL OF PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"Cyanosis; Newborn; Rupture of the papillary muscle; Tricuspid valve; Echocardiography",null,"We present the case of a male full-term neonate who presented at 4 h of age with severe cyanosis unresponsive to mechanical ventilation and oxygen supplementation. The diagnosis of rupture of the papillary muscle of the tricuspid valve was made by echocardiography. Preoperative stabilization was achieved by adding nitric oxide and extracorporeal membrane oxygenation therapy could be avoided. Corrective surgery was successfully performed on the 7th day of life. Follow-up examination at 2 months of age revealed an excellent postoperative result. Perinatal rupture of the papillary muscle and/or chordae tendineae of the tricuspid valve is exceedingly rare and usually lethal when untreated or diagnosed late. Therefore, timely diagnosis is mandatory for adequate preoperative management and subsequent surgical treatment.","[Riede, F. T.; Daehnert, I.; Razek, V.; Kostelka, M.] Univ Leipzig, Ctr Heart, D-04289 Leipzig, Germany","Riede, FT (reprint author), Univ Leipzig, Ctr Heart, Strumpellstr 39, D-04289 Leipzig, Germany.","frank-thomas.riede@med.uni-leipzig.de",null,null,null,null,"AGNASTOPOULOS PV, 2007, ANN THORAC SURG, V83, P1458; ALKALAY AL, 1988, AM J DIS CHILD, V142, P753; Benvenuti L A, 1992, Am J Cardiovasc Pathol, V4, P79; DONELLY WH, 1980, J PEDIAT, V96, P295; Fleming GA, 2008, PEDIATR CARDIOL, V29, P442, DOI 10.1007/s00246-007-9109-8; Hamaoka A, 2009, EUR J PEDIATR, V168, P741, DOI 10.1007/s00431-008-0818-7; Lim KA, 2004, CARDIOL YOUNG, V14, P450, DOI 10.1017/S1047951104004172; Pinto C A, 1992, Arq Bras Cardiol, V58, P475; Sachdeva R, 2007, ANN THORAC SURG, V83, P680, DOI 10.1016/j.athoracsur.2006.06.054",9,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,null,"EUR J PEDIATR","Eur. J. Pediatr.","FEB",2010,169,2,null,null,null,null,165,166,null,"10.1007/s00431-009-0996-y",null,2,"Pediatrics","Pediatrics","536GI","WOS:000273032500004"]
[null,null,null,null,"J","Janousek, J; Gebauer, RA; Weidenbach, M",null,null,null,"Janousek, J.; Gebauer, R. A.; Weidenbach, M.",null,null,"Pediatric dysrhythmia","MONATSSCHRIFT KINDERHEILKUNDE",null,null,"German","Article",null,null,null,null,null,"Cardiac dysrhythmia; Tachycardia, supraventricular; Arrhythmia, genetic; Heart failure; Death, sudden","LONG-QT SYNDROME; RADIOFREQUENCY CATHETER ABLATION; SUPRAVENTRICULAR TACHYCARDIA; CHILDREN; RECURRENCE","Diagnosis and therapy of cardiac dysrhythmia has become an important subspecialization in pediatric cardiology. The limited possibilities of antiarrhythmic drug therapy and antibradycardia pacing have been expanded by completely new and fascinating developments over the last 30 years. Curative treatment for the majority of tachyarrhythmias has been achieved by catheter ablation. Secondary as well as primary prevention of sudden arrhythmic death has become possible thanks to implantable defibrillators. Multiple hereditary life-threatening arrhythmia syndromes have been discovered and give a fascinating insight into the molecular genetic background of arrhythmogenesis. Cardiac resynchronization therapy has evolved into one of the few causal treatment strategies for heart failure and points toward intriguing remodeling processes at the cellular level. The following article provides practical as well as background knowledge of some of these developments.","[Janousek, J.] Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15006, Czech Republic; [Janousek, J.] Univ Hosp Motol, Kardioctr, Prague 15006, Czech Republic; [Gebauer, R. A.; Weidenbach, M.] Univ Leipzig, Herzzentrum, Klin Kinderkardiol, Leipzig, Germany","Janousek, J (reprint author), Univ Hosp Motol, Cardiovasc Res Ctr, V Uvalu 84, Prague 15006, Czech Republic.","jan.janousek@lfmotol.cuni.cz",null,null,null,null,null,15,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0026-9298",null,null,"MONATSSCHR KINDERH","Mon.schr. Kinderheilkd.","OCT",2010,158,10,null,null,null,null,938,945,null,"10.1007/s00112-010-2176-6",null,8,"Pediatrics","Pediatrics","662RT","WOS:000282829900008"]
[null,null,null,null,"J","Polanska, M; Hulejova, H; Petrtyl, M; Bastl, Z; Spirovova, I; Krulis, Z; Horak, Z; Veigl, D; Senolt, L",null,null,null,"Polanska, M.; Hulejova, H.; Petrtyl, M.; Bastl, Z.; Spirovova, I.; Krulis, Z.; Horak, Z.; Veigl, D.; Senolt, L.",null,null,"Surface Modification of Cyclic Olefin Copolymers for Osteochondral Defect Repair Can Increase Pro-Destructive Potential of Human Chondrocytes In Vitro","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Osteochondral defects; Cycloolefin copolymer; Chondrocytes; Biocompatibility","MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; CYTOTOXICITY; PATHOGENESIS; ARTHRITIS; COLLAGEN","Materials on the basis of cycloolefin copolymers (COC) are suitable for subchondral defect repairs. The objective of this study was to evaluate the influence of surface modification of COC and COC/LLDPE blends on the viability and gene expression of chondrocytes. Human chondrocytes were incubated on the surface of the studied materials. Half of the materials were plasmatically modified with a subsequent type II collagen application. The gene expression of matrix metalloproteinases (MMP-1,-3,-13), pro-inflammatory cytokines (IL-1, TNF-alpha) and apoptotic molecules (BAX, Bcl-2) was evaluated using quantitative Taq-Man PCR after 48 h incubation. Chondrocyte viability was evaluated by the MTT test after 2, 4 and 8 days of incubation. The synthesis of MMPs was measured by ELISA assay in cell culture medium after 48 h of incubation. Chondrocytes incubated on plasmatically modified in contrast to unmodified materials demonstrated significantly increased gene expression of IL-1 (p<0.05), MMP-1 and MMP-3 (p<0.05 for both comparisons) as well as MMP-13 (p<0.001). Increased gene expression was confirmed by significantly increased production of active forms of particular MMPs into the cell culture medium. Unlike surface unmodified polymers, the modified materials showed time-dependent reduction of chondrocyte viability. The gene expression of TNF-a and apoptotic molecules by chondrocytes was not significantly changed by different materials. Cycloolefin copolymers and their blends may represent suitable materials for tissue engineering, however, their surface modification followed by collagen type II application may, at least under in vitro conditions, reduce the viability of chondrocytes and induce their pro-destructive behavior. The potential benefit or disadvantage of surface modifications of materials for osteochondral defect repairs needs to be further elucidated.","[Polanska, M.; Hulejova, H.; Senolt, L.] Charles Univ Prague, Fac Med 1, Inst Rheumatol, Prague 12850 2, Czech Republic; [Petrtyl, M.] Czech Tech Univ, Fac Civil Engn, CR-16635 Prague, Czech Republic; [Bastl, Z.; Spirovova, I.] Acad Sci Czech Republic, Inst Phys Chem, Prague, Czech Republic; [Krulis, Z.; Horak, Z.] Acad Sci Czech Republic, Inst Macromol Chem, Prague, Czech Republic; [Veigl, D.] Fac Med 1, Orthoped Clin 1, Prague, Czech Republic; [Veigl, D.] Fac Hosp Motol, Prague, Czech Republic","Polanska, M (reprint author), Charles Univ Prague, Fac Med 1, Inst Rheumatol, Slupi 4, Prague 12850 2, Czech Republic.","polanska@revma.cz",null,null,"Grant Agency of the Czech Republic [106/06/0761]","The presented work was carried out with the support of a implants. grant provided by Grant Agency of the Czech Republic, reg. no. 106/06/0761.",null,21,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,2,null,null,null,null,247,253,null,null,null,7,"Physiology","Physiology","600VE","WOS:000278016200012"]
[null,null,null,null,"J","Sramek, J; Jirsak, V; Barna, M; Nesnidal, P",null,null,null,"Sramek, J.; Jirsak, V.; Barna, M.; Nesnidal, P.",null,null,"Development of the PLIF and TLIF Techniques","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"posterior lumbar interbody fusion; transforaminal lumbar interbody fusion","LUMBAR INTERBODY FUSION; FOLLOW-UP","PLIF (posterior lumbar interbody fusion) and TLIF (transforaminal lumbar interbody fusion) are surgical techniques employed in cases of degenerative lumbar spinal disorders. They involve a surgical approach to the area of the lumbar intervertebral disc, its resection, and subsequent application of biocompatible material that will achieve fusion of two or more vertebrae. Briggs and Milligan published the PLIF method in 1944, involving application of cancellous bone grafts into the intervertebral space. Others, but mainly Cloward, further improved this technique. Bagby and Kuslich introduced a cylindrical stainless steel cage in the 1980's, while Brantigan used a rectangular cage made of a polyether-etherketone polymer (PEEK), reinforced with carbon fiber. Implants of variable shape and materials characterize spinal fusion technique improvements in the 1990's. Current trends work towards the development of a stand-alone cage without the need for posterior stabilization. Though the PLIF and TLIF techniques have been extensively used and verified, lumbar fusion may become unstable or even fail when biomechanical laws are neglected.","[Sramek, J.] Fak Biomed Inzenyrstvi CVUT, Kladno, Czech Republic; [Jirsak, V.] Fak Stavebni CVUT, Prague, Czech Republic; [Barna, M.; Nesnidal, P.] FN Motole, Spondylochirurg Oddeleni, Prague, Czech Republic","Sramek, J (reprint author), Untere Bergstr 42, Bogen 94327, Czech Republic.","jiri.sramek@spinesurgery.cz",null,null,null,null,"Abbushi A, 2009, EUR SPINE J, V18, P1621, DOI 10.1007/s00586-009-1036-3; BELAND S, 1990, HIGH PERFORMANCE THE, P33; BLUME HG, 1985, CLIN ORTHOP RELAT R, P75; Blumenthal Scott L, 2003, Spine J, V3, P301, DOI 10.1016/S1529-9430(03)00004-4; Bobyn JD, 1999, J BONE JOINT SURG BR, V81B, P907, DOI 10.1302/0301-620X.81B5.9283; Brantigan John W, 2004, Spine J, V4, P681, DOI 10.1016/j.spinee.2004.05.253; Briggs H, 1944, J BONE JOINT SURG, V26, P125; Brislin B, 2002, ORTHOP CLIN N AM, V33, P367, DOI 10.1016/S0030-5898(01)00013-X; Burkus J K, 2001, Neurosurg Focus, V10, pE11; CLOWARD RB, 1958, J NEUROSURG, V15, P602, DOI 10.3171/jns.1958.15.6.0602; CLOWARD RB, 1953, J NEUROSURG, V10, P154, DOI 10.3171/jns.1953.10.2.0154; Errico TJ, 2005, CLIN ORTHOP RELAT R, P106, DOI 10.1097/01.blo.0000165718.22159.d9; Faundez AA, 2008, J SPINAL DISORD TECH, V21, P175, DOI 10.1097/BSD.0b013e318074bb7d; Folman Yoram, 2006, J Surg Orthop Adv, V15, P203; Grant JP, 2001, SPINE, V26, P889, DOI 10.1097/00007632-200104150-00012; GROEGER R, VICTREX HIGH PERFORM; Harms JG, 1998, ORTHOP TRAUMATOL, V6, P88; Hrabalek L, 2009, CESK SLOV NEUROL N, V72, P38; JASLOW IA, 1946, SURG GYNECOL OBSTET, V82, P215; Kim JW, 2007, J KOREAN NEUROSURG S, V42, P251, DOI 10.3340/jkns.2007.42.4.251; KURTZ SM, 2006, SPINE TECHNOLOGY HDB, P194; Kuslich SD, 1998, SPINE, V23, P1267, DOI 10.1097/00007632-199806010-00019; Leckie S, 2009, CURR ORTHOP PRACT, V20, P222; LIN GY, 1993, ACTA NEUROL SIN, V2, P134; LIN PM, 1983, CLIN ORTHOPAEDICS, V180, P154; LIN PM, 1985, CLIN ORTHOPAEDICS, V193, P90; Matejka J, 2009, ACTA CHIR ORTHOP TR, V76, P388; Meisel HJ, 2008, EUR SPINE J, V17, P1735, DOI 10.1007/s00586-008-0799-2; Moskowitz A, 2002, ORTHOP CLIN N AM, V33, P359, DOI 10.1016/S0030-5898(01)00008-6; PERRIN G, 2005, P 3 WORLD SPIN M 200; Schleicher P, 2008, J NEUROSURG-SPINE, V9, P363, DOI 10.3171/SPI.2008.9.10.363; STEFFEE AD, 1993, SPINE, V18, P1160, DOI 10.1097/00007632-199307000-00007; TAYLOR BA, 2005, SURG TECHNIQUES SPIN, P1239; Vanek P, 2007, CESK SLOV NEUROL N, V70, P552; Vohanka S, 2009, CESK SLOV NEUROL N, V72, P405; WENDSCHE P, 2005, P INT 23 COURS PERC; Wood KB, 2000, OPERAT TECH ORTHOP, V10, P320, DOI 10.1016/S1048-6666(00)80032-4",37,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2010,73,5,null,null,null,null,492,496,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","673EB","WOS:000283640800002"]
[null,null,null,null,"J","Barinka, F; Druga, R",null,null,null,"Barinka, F.; Druga, R.",null,null,"Calretinin Expression in the Mammalian Neocortex: A Review","PHYSIOLOGICAL RESEARCH",null,null,"English","Review",null,null,null,null,null,"Calcium-binding proteins; Interneurons; Inhibition; Neuroprotection; Neurovascular coupling","CALCIUM-BINDING PROTEINS; LOCAL-CIRCUIT NEURONS; MONKEY PREFRONTAL CORTEX; HUMAN TEMPORAL CORTEX; TERM POTENTIATION INDUCTION; MICE LACKING CALRETININ; NITRIC-OXIDE SYNTHASE; PRIMARY VISUAL-CORTEX; RAT FRONTAL-CORTEX; IMMUNOREACTIVE NEURONS","In the mammalian neocortex, the calcium-binding protein calretinin is expressed in a subset of cortical interneurons. In the recent years, research on interneurons is one of the most rapidly growing fields in neuroscience. This review summarizes the actual knowledge of the functions of calretinin in neuronal homeostasis and particularly of the distribution, connectivity and physiological properties of calretinin expressing interneurons in the neocortex of rodents and primates, including humans. The possible neuroprotective role of calretinin and the presumed \"resistance\" of calretinin-expressing interneurons to various pathological processes are also discussed.","[Barinka, F.; Druga, R.] Charles Univ Prague, Dept Anat, Fac Med 2, Prague 12800, Czech Republic; [Druga, R.] Charles Univ Prague, Dept Anat, Fac Med 1, Prague 12800, Czech Republic; [Druga, R.] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, Prague, Czech Republic","Druga, R (reprint author), Charles Univ Prague, Dept Anat, Fac Med 2, U Nemocnice 3, Prague 12800, Czech Republic.","rastislav.druga@lf1.cuni.cz",null,null,"Grant Agency of Charles University [35407]; Grant Agency of the Czech Republic [304/07/1137, 309/07/1136]","This work was supported by Grant Agency of Charles University, Grant No. 35407 and by Grant Agency of the Czech Republic, Grant No. 304/07/1137 and 309/07/1136.",null,108,14,14,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2010,59,5,null,null,null,null,665,677,null,null,null,13,"Physiology","Physiology","683QC","WOS:000284489300005"]
[null,null,null,null,"J","Nyc, O; Matejkova, J",null,null,null,"Nyc, O.; Matejkova, J.",null,null,"Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review","FOLIA MICROBIOLOGICA",null,null,"English","Review",null,null,null,null,null,null,"GRAM-NEGATIVE BACILLI; CYSTIC-FIBROSIS; ANTIMICROBIAL SUSCEPTIBILITY; XANTHOMONAS-MALTOPHILIA; ACINETOBACTER-BAUMANNII; CLINICAL STRAINS; RISK-FACTORS; INFECTIONS; RESISTANCE; EMERGENCE","Stenotrophomonas maltophilia (Sm) plays an important role as an opportunistic pathogen in immunocompromised individuals. The growing detection rates of this bacterium in hospitalized patients are associated with the invasiveness of therapeutic and diagnostic procedures and the selection pressure of antibiotic therapy. A broad range of infections that can be caused by Sm is frequently bound to biofilm. The high level of intrinsic resistance to many unrelated antibiotics and increasing acquired resistance to the drug of choice, trimethoprim-sulfamethoxazole pose a threat for the near future when our treatment options may become depleted. Prevention of colonization and infection consists in consequent implementation of the rules governing nosocomial infection control, rational use of antibiotics including the optimization of selection and testing of antimicrobial agents suitable for the treatment of stenotrophomonad infections.","[Nyc, O.; Matejkova, J.] Charles Univ Prague, Dept Clin Microbiol, Fac Med 2, Prague 15006, Czech Republic","Nyc, O (reprint author), Charles Univ Prague, Dept Clin Microbiol, Fac Med 2, Prague 15006, Czech Republic.",null,null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [9138-3/2007]","This work was partially supported by grant of the Internal Grant Agency of the Ministry of Health of the Czech Republic (no. 9138-3/2007).",null,55,11,13,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632",null,null,"FOLIA MICROBIOL","Folia Microbiol.","MAY",2010,55,3,null,null,null,null,286,294,null,"10.1007/s12223-010-0043-4",null,9,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","607AA","WOS:000278469400015"]
[null,null,null,null,"J","Robova, H; Halaska, M; Pluta, M; Skapa, P; Strnad, P; Lisy, J; Rob, L",null,null,null,"Robova, Helena; Halaska, Michael; Pluta, Marek; Skapa, Petr; Strnad, Pavel; Lisy, Jiri; Rob, Lukas",null,null,"The Role of Neoadjuvant Chemotherapy and Surgery in Cervical Cancer","INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER",null,null,"English","Review",null,null,null,null,null,"Neoadjuvant chemotherapy; Cervical cancer","GYNECOLOGIC-ONCOLOGY-GROUP; RADICAL TRACHELECTOMY; CENTROPELVIC RECURRENCE; PREOPERATIVE SELECTION; SQUAMOUS CARCINOMA; HYSTERECTOMY; TRIAL; SIZE","The role of neoadjuvant chemotherapy (NAC) in \"bulky\" and locally advanced cervical cancer has been of interest for the last 25 years, and in many countries, NAC has become the standard of care. In the present paper, we review our 10 years' experience with high-dose-density NAC in cervical cancer management in 141 women (CervNAC I protocol). High-dose-density neoadjuvant chemotherapy and radical surgery has resulted in high clinical response rates and seems to be feasible in the management of stage IB bulky cervical cancer. Neoadjuvant chemotherapy reduces tumor volume and positivity of lymph nodes and thus minimizes the need for postoperative radiotherapy or chemoradiotherapy. Tumor size reduction and node negativity allows less radical surgical procedures such as modified radical hysterectomy or nerve-sparing radical hysterectomy. Early and especially late toxicity of our high-dose density chemotherapy is acceptable. Neoadjuvant chemotherapy followed by surgery represents a valid alternative to primary chemoradiotherapy in young and sexually active patients. Five-year survival in patients who underwent surgery in our study was 80.6%. Currently, 3 papers with 3 approaches have been published on NAC before fertility-sparing surgery. One of the limitations of fertility-preserving surgery is deep stromal invasion and tumors larger than 2 cm. The idea underlying NAC is to reduce the size of the cervical tumor to preserve fertility. In the present paper, we also review our experience with high-dose-density NAC in fertility-sparing surgery in 15 women (LAP3-NAC protocol).","[Robova, Helena; Halaska, Michael; Pluta, Marek; Strnad, Pavel; Rob, Lukas] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, Prague 15000 5, Czech Republic; [Skapa, Petr] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15000 5, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Fac Med 2, Dept Radiol, Prague 15000 5, Czech Republic","Rob, L (reprint author), Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, V Uvalu 84, Prague 15000 5, Czech Republic.","lukas.rob@lfmotol.cuni.cz",null,null," [MZ0FNM2005]","This work was supported by grant MZ0FNM2005.",null,18,9,10,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X",null,null,"INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","OCT",2010,20,null,null,2,null,null,"S42","S46",null,"10.1111/IGC.0b013e3181f60d73",null,5,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","673DZ","WOS:000283640600011"]
[null,null,null,null,"J","Rob, L; Pluta, M; Skapa, P; Robova, H",null,null,null,"Rob, Lukas; Pluta, Marek; Skapa, Petr; Robova, Helena",null,null,"Advances in fertility-sparing surgery for cervical cancer","EXPERT REVIEW OF ANTICANCER THERAPY",null,null,"English","Review",null,null,null,null,null,"cervical cancer; fertility-sparing surgery; radical trachelectomy; sentinel lymph node; simple trachelectomy","ABDOMINAL RADICAL TRACHELECTOMY; SENTINEL LYMPH-NODES; OF-THE-LITERATURE; VAGINAL TRACHELECTOMY; NEOADJUVANT CHEMOTHERAPY; PELVIC LYMPHADENECTOMY; PARAMETRIAL INVOLVEMENT; PRESERVING SURGERY; PATHOLOGICAL EVALUATION; CONSERVATIVE SURGERY","This article reviews the literature on fertility-sparing surgery in early cervical cancer. The article evaluates selection criteria, preoperative management and the most frequent surgical procedures used for preservation of fertility in cervical cancer. The article also analyzes oncological, fertility and pregnancy results. Oncological outcomes are not statistically different among single groups (vaginal radical trachelectomy, abdominal radical trachelectomy, simple trachelectomy or cone with or without neoadjuvant chemotherapy). Oncological results after fertility-sparing procedures in women with tumors smaller than 2 cm are comparable with women with the same risk factors after radical hysterectomy. Pregnancy following fertility-sparing surgery is associated with a variety of adverse pregnancy outcomes, especially second-trimester loss and preterm delivery. Less radical procedures (simple trachelectomy or cone with or without neoadjuvant chemotherapy) show statistically significant better pregnancy results. The pregnancy rate after abdominal radical trachelectomy was dramatically lower than in women treated with other types of fertility-sparing surgery. In the future, it will be necessary to optimize the technique and management of fertility-sparing surgery in order to attain good oncological results. Pregnancy outcomes should be given high priority. Fertility-sparing surgery is valuable for women who want to preserve their reproductive capability.","[Rob, Lukas; Pluta, Marek; Robova, Helena] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, Div Gynecol Oncol, Prague, Czech Republic; [Skapa, Petr] Charles Univ Prague, Fac Med 2, Dept Pathol Anat & Mol Med, Prague, Czech Republic","Rob, L (reprint author), Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, Div Gynecol Oncol, Prague, Czech Republic.","lukas.rob@lfmotol.cuni.cz",null,null," [NS 9914-4]","This work was supported by grant NS 9914-4. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.",null,83,2,4,"EXPERT REVIEWS","LONDON","UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND","1473-7140",null,null,"EXPERT REV ANTICANC","Expert Rev. Anticancer Ther","JUL",2010,10,7,null,null,null,null,1101,1114,null,"10.1586/ERA.10.61",null,14,"Oncology","Oncology","633XJ","WOS:000280540200021"]
[null,null,null,null,"J","Kriz, J; Kafunkova, P; Schreier, B; Kolar, P",null,null,null,"Kriz, J.; Kafunkova, P.; Schreier, B.; Kolar, P.",null,null,"Body Weight Support Locomotion Training in Spinal Cord Injured Patients","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"spinal cord injury; plasticity; locomotion; rehabilitation; robotic device; treadmill","GAIT REHABILITATION; PARAPLEGIC PATIENTS; PLASTICITY; WALKING; FEASIBILITY; INDIVIDUALS; PATTERN; HUMANS","Body weight support locomotion training is a classical rehabilitation method in patients who have suffered injury to the spinal cord. It is based on the discovery that repetitive cyclic passive movements can stimulate locomotor centres in the spinal cord. Numerous studies have documented motor recovery in vertebrate animals and in incomplete spinal-cord-injured humans. Manual-assisted, body-weight support treadmill training requires a large number of physiotherapists working in an ergonomically inconvenient position. New approaches to robotic locomotion training are therefore being developed. The aim is to design a device that provides minimal necessary locomotion assistance depending on the severity of the motor impairment.","[Kriz, J.; Kafunkova, P.; Schreier, B.; Kolar, P.] UK 2 LF & FN Motole, Klin Rehabilitace & Telovychovneho Lekarstvi, Spinalni Jednotka, Prague 15006 5, Czech Republic","Kriz, J (reprint author), UK 2 LF & FN Motole, Klin Rehabilitace & Telovychovneho Lekarstvi, Spinalni Jednotka, Praha Ovalu 84, Prague 15006 5, Czech Republic.","jiri.kriz@fnmotol.cz",null,null,null,null,null,37,1,1,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2010,73,2,null,null,null,null,124,130,null,null,null,7,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","593AC","WOS:000277422500002"]
[null,null,null,null,"J","Kotaskova, J; Marusic, P",null,null,null,"Kotaskova, J.; Marusic, P.",null,null,"Functional Significance of a Temporal Lobe","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"temporal pole; epilepsy; emotion recognition; social cognition; theory of mind","FACIAL EMOTION RECOGNITION; FAMOUS FACES; EPILEPSY; MEMORY; HIPPOCAMPUS; CORTEX; BRAIN; POLE; PROSOPAGNOSIA; PERFORMANCE","The temporal pole is the least explored part of the temporal lobe, and not only anatomically. Its functional significance is also poorly understood. Due to the large number of connections with the amygdala and orbitofrontal cortex involved, the temporal pole is assumed to be part of the limbic system. It is involved in recognition of facial and emotional features, social-emotional empathy (theory of mind), naming of objects and persons and other memory functions, matters that are not routinely tested in neuropsychological assessment. An important expansion of knowledge of temporal pole functions has been enabled by the use of functional neuro-imaging methods, especially positron emission tomography and functional magnetic resonance. An impairment of functions associated with the temporal pole has been observed in Alzheimer's disease, schizophrenia and psychosis. The aim of this review is to summarize basic knowledge of temporal pole function in temporal lobe epilepsy patients.","[Kotaskova, J.; Marusic, P.] LF UK FN Motole, Neurol Klin 2, Prague 15006 5, Czech Republic","Kotaskova, J (reprint author), LF UK FN Motole, Neurol Klin 2, Uvalu 84, Prague 15006 5, Czech Republic.","jana.amlerova@seznam.cz",null,null,null,null,"Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; AHERN GL, 1979, NEUROPSYCHOLOGIA, V17, P693, DOI 10.1016/0028-3932(79)90045-9; Ammerlaan EJG, 2008, ACTA NEUROBIOL EXP, V68, P214; Benedetti F, 2009, SCHIZOPHR RES, V114, P154, DOI 10.1016/j.schres.2009.06.021; BENTON AL, 1972, J NEUROL SCI, V15, P167, DOI 10.1016/0022-510X(72)90004-4; BLAIZOT X, 2010, CEREB CORTE IN PRESS; Bohbot VD, 1998, NEUROPSYCHOLOGIA, V36, P1217, DOI 10.1016/S0028-3932(97)00161-9; Borod JC, 1997, NEUROPSYCHOL REV, V7, P41, DOI 10.1007/BF02876972; Bowles B, 2007, P NATL ACAD SCI USA, V104, P16382, DOI 10.1073/pnas.0705273104; Brazdil M, 2009, NEUROIMAGE, V47, P376, DOI 10.1016/j.neuroimage.2009.03.081; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cabeza Roberto, 2000, Current Opinion in Neurology, V13, P415, DOI 10.1097/00019052-200008000-00008; Chabardes S, 2002, EPILEPTIC DISORD, V4, pS9; Glikmann-Johnston Y, 2008, BRAIN, V131, P3006, DOI 10.1093/brain/awn213; Glosser G, 2003, NEUROLOGY, V61, P81; Gonsalves BD, 2005, NEURON, V47, P751, DOI 10.1016/j.neuron.2005.07.013; HOREL JA, 1987, BEHAV BRAIN RES, V23, P29, DOI 10.1016/0166-4328(87)90240-3; Kier EL, 2004, AM J NEURORADIOL, V25, P677; Killgore WDS, 2007, SOC COGN AFFECT NEUR, V2, P240, DOI 10.1093/scan/nsm020; Kirsch HE, 2008, NEUROLOGY, V71, P1854, DOI 10.1212/01.wnl.0000333214.33299.fc; Lavenex P, 2004, J COMP NEUROL, V472, P371, DOI 10.1002/cne.20079; Leijten FSS, 2005, EPILEPSIA, V46, P431, DOI 10.1111/j.0013-9580.2005.33604.x; Maguire EA, 1999, BRAIN, V122, P1839, DOI 10.1093/brain/122.10.1839; McClelland S, 2006, EPILEPSIA, V47, P1337, DOI 10.1111/j.1528-1167.2006.00557.x; Meletti S, 2003, NEUROLOGY, V60, P426; Meletti S, 2009, EPILEPSIA, V50, P1547, DOI 10.1111/j.1528-1167.2008.01978.x; MIER D, 2010, PSYCHOL MED IN PRESS; Mitchell JP, 2009, PHILOS T R SOC B, V364, P1309, DOI 10.1098/rstb.2008.0318; MORECRAFT RJ, 1992, J COMP NEUROL, V323, P341, DOI 10.1002/cne.903230304; Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052; Rapcsak SZ, 2000, NEUROLOGY, V54, P575; Schacher M, 2006, NEUROLOGY, V66, P81, DOI 10.1212/01.wnl.0000191303.91188.00; Schacher M, 2006, EPILEPSIA, V47, P2141, DOI 10.1111/j.1528-1167.2006.00857.x; Seidenberg M, 2002, NEUROPSYCHOLOGIA, V40, P446, DOI 10.1016/S0028-3932(01)00096-3; Todorov A, 2008, SOC COGN AFFECT NEUR, V3, P195, DOI 10.1093/scan/nsn013; Vollm BA, 2006, NEUROIMAGE, V29, P90, DOI 10.1016/j.neuroimage.2005.07.022; Vuilleumier P, 2003, BRAIN, V126, P889, DOI 10.1093/brain/awg086",38,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2010,73,4,null,null,null,null,387,391,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","648IK","WOS:000281685800004"]
[null,null,null,null,"J","Plzak, J; Lacina, L; Chovanec, M; Dvorankova, B; Szabo, P; Cada, Z; Smetana, K",null,null,null,"Plzak, Jan; Lacina, Lukas; Chovanec, Martin; Dvorankova, Barbora; Szabo, Pavol; Cada, Zdenek; Smetana, Karel, Jr.",null,null,"Epithelial-Stromal Interaction in Squamous Cell Epithelium-derived Tumors: An Important New Player in the Control of Tumor Biological Properties","ANTICANCER RESEARCH",null,null,"English","Review",null,null,null,null,null,"Cancer-associated fibroblasts; cancer microenvironment; tumor stroma; squamous cell carcinoma; basal cell carcinoma; review","EPIDERMAL STEM-CELLS; BREAST-CANCER; IN-VITRO; MESENCHYMAL TRANSITIONS; NORMAL KERATINOCYTES; HAIR FOLLICLE; ORAL-CAVITY; CARCINOMA; MICROENVIRONMENT; EXPRESSION","Mesenchymal-epithelial interaction is important in the morphogenesis of squamous epithelia and their appendages, and in the control of the hair cycle postnatally. This review summarizes data regarding the interaction between stromal fibroblasts and tumor cells, with an emphasis on tumors originating from squamous epithelium. Tumor stromal fibroblasts as important element of the cancer stem cell niche are able to participate in the control of the biological properties of tumors. We propose these stromal cells and their products as novel targets for anticancer therapy.","[Plzak, Jan; Lacina, Lukas; Chovanec, Martin; Dvorankova, Barbora; Szabo, Pavol; Cada, Zdenek; Smetana, Karel, Jr.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Plzak, Jan; Chovanec, Martin; Cada, Zdenek] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague 12800 2, Czech Republic; [Lacina, Lukas] Charles Univ Prague, Fac Med 1, Dept Dermatovenereol, Prague 12800 2, Czech Republic; [Plzak, Jan; Lacina, Lukas; Chovanec, Martin; Dvorankova, Barbora; Smetana, Karel, Jr.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 12800 2, Czech Republic","Smetana, K (reprint author), Charles Univ Prague, Fac Med 1, Inst Anat, Nemocnice 3, Prague 12800 2, Czech Republic.","jan.pizak@lfl.cuni.cz; karel.smetana@lfl.cuni.cz",null,null,"Ministry of Education, Youth and Sport of the Czech Republic [MSM0021620806, 1M0538, NPVII 2B06106, 304/08/P175]; European Comission [MRTN-CT-2005-019561]","Some of the results presented in this review were obtained in research projects supported by the Ministry of Education, Youth and Sport of the Czech Republic (project no. MSM0021620806, 1M0538 and NPVII 2B06106), Grant Agency of the Czech Republic (project no. 304/08/P175) and European Comission (contract no. MRTN-CT-2005-019561).",null,63,5,5,"INT INST ANTICANCER RESEARCH","ATHENS","EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE","0250-7005",null,null,"ANTICANCER RES","Anticancer Res.","FEB",2010,30,2,null,null,null,null,455,462,null,null,null,8,"Oncology","Oncology","572IC","WOS:000275821200026"]
[null,null,null,null,"J","Cerny, R; Kapla, J; Machala, L",null,null,null,"Cerny, R.; Kapla, J.; Machala, L.",null,null,"Focal Affections of CNS in Patients with HIV Infection","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"HIV; focal CNS affections; brain toxoplasmosis; primary lymphoma","CENTRAL-NERVOUS-SYSTEM; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE-DEFICIENCY-SYNDROME; RESONANCE-IMAGING FINDINGS; SCLEROSIS-LIKE ILLNESS; NEUROLOGICAL COMPLICATIONS; VIRUS-INFECTION; SYNDROME AIDS","Focal affections of the CNS are an important cause of morbidity and mortality in HIV-infected patients. HIV infection is rarely considered in patients with focal CNS symptomatology in the Czech Republic, a setting with low prevalence of HIV positivity. Nevertheless, delay in establishing a correct diagnosis has a negative influence on the patient's prognosis and puts health-care workers at risk of infection. The most important causes of focal CNS affections in HIV-positive patients are: brain toxoplasmosis, primary CNS lymphoma, and progressive multifocal leuko-encephalopathy. The aetiology of other focal CNS affections in HIV-positive persons is similar to the situation in the normal population, but the incidence of these CNS affections in HIV-positive patients tends to be higher. A possible connection with HIV infection should be always taken in account, in order to establish a correct diagnosis as soon as possible, when the therapy can be most effective.","[Cerny, R.] 2 LF UK FN & Motole, Neurol Klin Dospelych, Prague 15006 5, Czech Republic; [Kapla, J.] Klin Infektnich Nemoci LF UK FN, Hradec Kralove, Czech Republic; [Machala, L.] LF UK FN Na, I Infekcni Klin 2, LF UK Klin, Prague, Czech Republic","Cerny, R (reprint author), 2 LF UK FN & Motole, Neurol Klin Dospelych, Uvalu 84, Prague 15006 5, Czech Republic.","rudolf.cerny@lfmotol.cuni.cz","Cerny, Rudolf/C-7759-2014",null,null,null,null,48,2,2,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2010,73,4,null,null,null,null,374,378,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","648IK","WOS:000281685800002"]
[null,null,null,null,"J","Melter, O; Radojevic, B",null,null,null,"Melter, O.; Radojevic, B.",null,null,"Small colony variants of Staphylococcus aureus - review","FOLIA MICROBIOLOGICA",null,null,"English","Review",null,null,null,null,null,null,"CYSTIC-FIBROSIS PATIENTS; PSEUDOMONAS-AERUGINOSA; METHICILLIN-RESISTANT; INTRACELLULAR PERSISTENCE; ANTIBIOTIC-RESISTANCE; RECURRENT INFECTIONS; EXFOLIATIVE TOXINS; ENDOTHELIAL-CELLS; LUNG INFECTION; HEMB MUTANT","Bacterial variants of Staphylococcus aureus called small colony variants (SCVs) originate by mutations in metabolic genes, resulting in emergence of auxotrophic bacterial subpopulations. These variants are not particularly virulent but are able to persist viable inside host cells. SCVs show their characteristic auxotrophic growth deficiency and depressed alpha-cytotoxin activity. Environmental pressure such as antibiotics, select for isogenic SCV cells that are frequently found coexisting with their parent wild-type strains in a mixed bacterial culture. SCV strains often grow on blood agar as non-pigmented or pinpoint pigmented colonies and their key biochemical tests are often non-reactive. Their altered metabolism or auxotrophism can result in long generation time and thus SCV phenotype, more often than not SCV can be overgrown by their wild-type counterparts and other competitive respiratory flora. This could affect laboratory detection. Thus, molecular methods, such as 16S rRNA partial sequencing or amplification of species-specific DNA targets (e.g. coagulase, nuclease) directly from clinical material or isolated bacterial colonies, become the method of choice. Patients at risk of infection by S. aureus SCVs include cystic fibrosis patients (CF), patients with skin and foreign-body related infections and osteomyelitis, as they suffer from chronic staphylococcal infections and are subject to long-term antibiotic therapy. Molecular evidence of SCV development has not been found except for some random mutations of the thymidylate synthase gene (thyA) described in SCV S. aureus strains of CF patients. These variants are able to bypass the antibiotic effect of folic acid antagonists such as sulfonamides and trimethoprim. Resistance to gentamicin and aminoglycosides in the hemin or menadione auxotrophic SCVs was hypothesized as being due to decreased influx of the drugs into cells as a result of decreased ATP production and decreased electrochemical gradient on cell membranes.","[Melter, O.; Radojevic, B.] Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Prague 15006 5, Motol, Czech Republic","Melter, O (reprint author), Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Uvalu 84, Prague 15006 5, Motol, Czech Republic.","oto.melter@lfmotol.cuni.cz",null,null," [MZ 0 FNM 2005]","We thank A. Malmgren for reviewing the manuscript. This work was supported by the research project MZ 0 FNM 2005.",null,72,14,15,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632",null,null,"FOLIA MICROBIOL","Folia Microbiol.","NOV",2010,55,6,null,null,null,null,548,558,null,"10.1007/s12223-010-0089-3",null,11,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","709UG","WOS:000286466300002"]
[null,null,null,null,"J","Bojar, M; Zajac, M; Meluzinova, E; Houzvickova, E; Libertinova, J; Liskova, P; Mat'oska, V; Nyc, O; Minarikova, M",null,null,null,"Bojar, M.; Zajac, M.; Meluzinova, E.; Houzvickova, E.; Libertinova, J.; Liskova, P.; Mat'oska, V.; Nyc, O.; Minarikova, M.",null,null,"Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis","MULTIPLE SCLEROSIS",null,null,"English","Letter",null,null,null,null,null,null,"NEUTRALIZING ANTIBODIES; INTERFERON-BETA",null,"[Bojar, M.; Meluzinova, E.; Houzvickova, E.; Libertinova, J.; Liskova, P.; Minarikova, M.] Charles Univ Prague, Dept Neurol, Prague Med Sch 2, Univ Hosp Motol, Prague, Czech Republic; [Zajac, M.; Nyc, O.] Charles Univ Prague, Inst Clin Microbiol, Prague Med Sch 2, Univ Hosp Motol, Prague, Czech Republic; [Mat'oska, V.] Hosp Na Homolce, Lab Mol Diagnost, Prague, Czech Republic","Bojar, M (reprint author), Charles Univ Prague, Dept Neurol, Prague Med Sch 2, Univ Hosp Motol, Prague, Czech Republic.","martin.bojar@lfmotol.cuni.cz",null,null,null,null,null,6,0,0,"SAGE PUBLICATIONS LTD","LONDON","1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND","1352-4585",null,null,"MULT SCLER","Mult. Scler.","DEC",2010,16,12,null,null,null,null,1529,1530,null,"10.1177/1352458510382248",null,2,"Clinical Neurology","Neurosciences & Neurology","687EW","WOS:000284762800018"]
[null,null,null,null,"J","Fronek, J; Hearfield, H; Fassiadis, N; Magrill, D; Morsy, M; Kessaris, N",null,null,null,"Fronek, Jiri; Hearfield, Hollie; Fassiadis, Nick; Magrill, Dan; Morsy, Mohamed; Kessaris, Nicos",null,null,"Inferior Epigastric Vein as an Interposition Graft for Renal Transplant Artery Reconstruction","TRANSPLANTATION",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Fronek, Jiri; Hearfield, Hollie; Fassiadis, Nick; Magrill, Dan; Morsy, Mohamed; Kessaris, Nicos] St George Hosp, Living Donor Kidney Transplant Programme, Renal Transplant Unit, London SW17 0QT, England; [Fronek, Jiri] Charles Univ Prague, Prague, Czech Republic","Fronek, J (reprint author), St George Hosp, Living Donor Kidney Transplant Programme, Renal Transplant Unit, Blackshaw Rd, London SW17 0QT, England.","jiri.fronek@stgeorges.nhs.uk",null,null,null,null,null,1,1,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0041-1337",null,null,"TRANSPLANTATION","Transplantation","NOV 27",2010,90,10,null,null,null,null,1132,1133,null,"10.1097/TP.0b013e3181f7c06c",null,3,"Immunology; Surgery; Transplantation","Immunology; Surgery; Transplantation","681JX","WOS:000284309500017"]
[null,null,null,null,"J","Urbanova, M; Plzak, J; Strnad, H; Betka, J",null,null,null,"Urbanova, Marketa; Plzak, Jan; Strnad, Hynek; Betka, Jan",null,null,"Circulating nucleic acids as a new diagnostic tool","CELLULAR & MOLECULAR BIOLOGY LETTERS",null,null,"English","Review",null,null,null,null,null,"Circulating nucleic acids; RNA; DNA; Diagnostics; Cancer","POLYMERASE-CHAIN-REACTION; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER PATIENTS; BARR-VIRUS DNA; REAL-TIME PCR; MATERNAL PLASMA; MESSENGER-RNA; FETAL DNA; NASOPHARYNGEAL CARCINOMA; COLORECTAL-CANCER","The discovery of circulating nucleic acids in the 1940s opened up new possibilities for the non-invasive detection, monitoring and screening of various human disorders. Several tumour markers that enable early cancer detection or tumour behaviour prediction have been detected in the plasma of cancer patients. Maternal plasma analysis can be used to detect certain fetal abnormalities, with the quantification of cell-free nucleic acids used to screen for several pregnancy-associated disorders. Some other applications are in transplant monitoring and graft rejection assessment, and in certain medical emergencies such as trauma and burn severity stratification. Many studies have yielded promising results in this field, but the techniques have yet to be applied in routine clinical practice. Large-scale studies using similar technologies and a broad spectrum of patients are still needed to verify the results of the various studies.","[Urbanova, Marketa; Plzak, Jan; Betka, Jan] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Fac Hosp Motol,Inst Postgrad Med, Prague 15006 5, Czech Republic; [Urbanova, Marketa; Strnad, Hynek] Acad Sci Czech Republic, Inst Mol Genet, Dept Genom & Bioinformat, CR-14220 Prague 4, Czech Republic; [Plzak, Jan] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Plzak, Jan] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic","Plzak, J (reprint author), Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Fac Hosp Motol,Inst Postgrad Med, Uvalu 84, Prague 15006 5, Czech Republic.","jan.plzak@lf1.cuni.cz","Zhou, Feng/E-9510-2011; Strnad, Hynek/B-7361-2008","Strnad, Hynek/0000-0002-0141-8340","GAUK [60608]; MSMT NPV II [2B06106]","This study was supported by grant GAUK No. 60608 and project MSMT NPV II. No. 2B06106.",null,94,4,4,"VERSITA","WARSAW","SOLIPSKA 14A-1, 02-482 WARSAW, POLAND","1425-8153",null,null,"CELL MOL BIOL LETT","Cell. Mol. Biol. Lett.","JUN",2010,15,2,null,null,null,null,242,259,null,"10.2478/s11658-010-0004-6",null,18,"Biochemistry & Molecular Biology; Cell Biology","Biochemistry & Molecular Biology; Cell Biology","574CS","WOS:000275966600005"]
[null,null,null,null,"J","Krizkova, S; Masarik, M; Majzlik, P; Kukacka, J; Kruseova, J; Adam, V; Prusa, R; Eckschlager, T; Stiborova, M; Kizek, R",null,null,null,"Krizkova, Sona; Masarik, Michal; Majzlik, Petr; Kukacka, Jiri; Kruseova, Jarmila; Adam, Vojtech; Prusa, Richard; Eckschlager, Tomas; Stiborova, Marie; Kizek, Rene",null,null,"Serum metallothionein in newly diagnosed patients with childhood solid tumours","ACTA BIOCHIMICA POLONICA",null,null,"English","Article; Proceedings Paper","16th European Bioenergetics Conference","JUL 17-22, 2010","Warsaw, POLAND","Nencki Inst Expt Biol, Polish Biochem Soc, Sect Bioenerget","Univ Warsaw, Old Lib","metallothionein; cancer; serum; Brdicka reaction; marker","BRDICKA REACTION; BREAST-CANCER; GENE-EXPRESSION; BLOOD-SERUM; ORAL-CAVITY; CELL LINES; ANTIBODIES; MARKER; LEVEL; ZINC","Tumour markers are substances produced by malignant cells or by the organism as a response to cancer development. Determination of their levels can, therefore, be used to monitor the risk, presence and prognosis of a cancer disease or to monitor the therapeutic response or early detection of residual disease. Time-consuming imaging methods, examination of cerebrospinal fluid or tumour tissue and assays for hormones and tumour markers have been used for cancer diagnosis. However, no specific marker for diagnosis of childhood solid tumours has been discovered yet. In this study, metallothionein (MT) was evaluated as a prospective marker for such diseases. Serum metallothionein levels of patients with childhood solid tumours were determined using differential pulse voltammetry - Brdicka reaction. A more than 5-fold increase in the amount of metallothionein was found in sera of patients suffering from cancer disease, compared with those in sera of healthy donors. The average metallothionein level in the sera of healthy volunteers was 0.5 +/- 0.2 mu mol.dm(-3) and was significantly different (P<0.05, determined using the Schefe test) from the average MT level found in serum samples of patients suffering from childhood solid tumours (3.4 +/- 0.8 mu mol.dm(-3)). Results found in this work indicate that the MT level in blood serum can be considered as a promising marker for diagnostics, prognosis and estimation of therapy efficiency of childhood tumours.","[Krizkova, Sona; Majzlik, Petr; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Brno, Czech Republic; [Masarik, Michal] Masaryk Univ, Dept Pathol Physiol, Fac Med, Brno, Czech Republic; [Kukacka, Jiri] Czech Tech Univ, Fac Biomed Engn, Dept Biomed Technol, CR-16635 Prague, Czech Republic; [Kukacka, Jiri; Prusa, Richard] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague, Czech Republic; [Kukacka, Jiri; Kruseova, Jarmila; Prusa, Richard; Eckschlager, Tomas] Charles Univ Prague, Fac Hosp Motol, Prague, Czech Republic; [Kruseova, Jarmila; Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, Prague, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Krizkova, Sona/E-9617-2012; Kukacka, Jiri/C-4770-2013",null,null,null,null,58,17,18,"ACTA BIOCHIMICA POLONICA","WARSAW","PASTEURA 3, 02-093 WARSAW, POLAND","0001-527X",null,null,"ACTA BIOCHIM POL","Acta Biochim. Pol.",null,2010,57,4,null,null,null,null,561,566,null,null,null,6,"Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","700GP","WOS:000285726300023"]
[null,null,null,null,"J","Opatrna, S; Matousovic, K; Klaboch, J; Schuck, O",null,null,null,"Opatrna, Sylvie; Matousovic, Karel; Klaboch, Jan; Schueck, Otto",null,null,"Importance of Serum [Na+] and [Cl-] Difference in Acid-Base Status Classification","ANESTHESIA AND ANALGESIA",null,null,"English","Letter",null,null,null,null,null,null,"STEWART; DISORDERS; DIAGNOSIS",null,"[Opatrna, Sylvie; Klaboch, Jan] Charles Univ Prague, Dept Med, Sch Med, Plzen, Czech Republic; [Opatrna, Sylvie; Klaboch, Jan] Teaching Hosp, Plzen, Czech Republic; [Matousovic, Karel; Schueck, Otto] Motol Univ Hosp, Prague, Czech Republic; [Matousovic, Karel; Schueck, Otto] Charles Univ Prague, Dept Med, Sch Med 2, Prague, Czech Republic","Opatrna, S (reprint author), Charles Univ Prague, Dept Med, Sch Med, Plzen, Czech Republic.","opatrna@fnplzen.cz",null,null,null,null,null,5,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0003-2999",null,null,"ANESTH ANALG","Anesth. Analg.","JUL",2010,111,1,null,null,null,null,243,243,null,"10.1213/ANE.0b013e3181dd8a33",null,1,"Anesthesiology","Anesthesiology","617LF","WOS:000279281500047"]
[null,null,null,null,"J","Jelinek, M; Smetana, K; Kocourek, T; Dvorankova, B; Zemek, J; Remsa, J; Luxbacher, T",null,null,null,"Jelinek, M.; Smetana, K.; Kocourek, T.; Dvorankova, B.; Zemek, J.; Remsa, J.; Luxbacher, T.",null,null,"Biocompatibility and sp(3)/sp(2) ratio of laser created DLC films","MATERIALS SCIENCE AND ENGINEERING B-ADVANCED FUNCTIONAL SOLID-STATE MATERIALS",null,null,"English","Article; Proceedings Paper","1st European and International Conference on Bioinspired and Biointegrated Materials as New Frontiers Nanomaterials held at the 2009 EMRS Spring Meeting","JUN 08-12, 2009","Strasbourg, FRANCE","European Mat Res Sci",null,"Biocompatibility; Thin films; DLC; Laser ablation; In vitro; Zeta potential","ION IMPLANTATION-DEPOSITION; AMORPHOUS-CARBON FILMS; THIN-FILMS; DIAMOND; PHOTOELECTRON; SPECTROSCOPY","Thin diamond-like carbon (DLC) films of various diamond/graphitic content were created using pulsed laser deposition method. \"Diamond\" sp(3) concentration in region from 32% to 62% was determined using X-ray photoelectron and Auger spectroscopy (XPS/XAES). Zeta potential test was conducted to measure electric surface properties. In vitro test of DLC layers was arranged using normal human fibroblasts. The study was stressed on cytotoxicity, adhesion and cell proliferation. Correlations between sp(3), sp(2) bonds and surface and biological properties of DLC layers are discussed. (c) 2010 Elsevier B.V. All rights reserved.","[Jelinek, M.; Kocourek, T.; Zemek, J.; Remsa, J.] Inst Phys ASCR, Prague 18221 8, Czech Republic; [Jelinek, M.; Kocourek, T.] Czech Tech Univ, Fac Biomed Engn, Kladno 27201, Czech Republic; [Smetana, K.; Dvorankova, B.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Smetana, K.; Dvorankova, B.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Luxbacher, T.] Anton Paar GmbH, A-8054 Graz, Austria","Jelinek, M (reprint author), Inst Phys ASCR, Na Slovance 2, Prague 18221 8, Czech Republic.","jelinek@fzu.cz",null,null,null,null,null,26,19,20,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0921-5107",null,null,"MATER SCI ENG B-ADV","Mater. Sci. Eng. B-Adv. Funct. Solid-State Mater.","MAY 25",2010,169,41699,null,null,"SI",null,89,93,null,"10.1016/j.mseb.2010.01.010",null,5,"Materials Science, Multidisciplinary; Physics, Condensed Matter","Materials Science; Physics","608MP","WOS:000278588700017"]
[null,null,null,null,"J","Castellani, C; Macek, M; Cassiman, JJ; Duff, A; Massie, J; ten Kate, LP; Barton, D; Cutting, G; Dallapiccola, B; Dequeker, E; Girodon, E; Grody, W; Highsmith, EW; Kaariainen, H; Kruip, S; Morris, M; Pignatti, PF; Pypops, U; Schwarz, M; Soller, M; Stuhrman, M; Cuppens, H",null,null,null,"Castellani, Carlo; Macek, Milan, Jr.; Cassiman, Jean-Jacques; Duff, Alistair; Massie, John; ten Kate, Leo P.; Barton, David; Cutting, Garry; Dallapiccola, Bruno; Dequeker, Elisabeth; Girodon, Emmanuelle; Grody, Wayne; Highsmith, Edward W.; Kaariainen, Helenal; Kruip, Stephan; Morris, Michael; Pignatti, Pier Franco; Pypops, Ulrike; Schwarz, Martin; Soller, Maria; Stuhrman, Manfred; Cuppens, Harry",null,null,"Benchmarks for Cystic Fibrosis carrier screening: A European consensus document","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Review",null,null,null,null,null,"Cystic Fibrosis; CFTR; Genetic analysis; Carrier screening; Carrier testing","LUNG-DISEASE; PRENATAL-DIAGNOSIS; GENETIC MODIFIERS; PREGNANT-WOMEN; MUTATIONS; IDENTIFICATION; POPULATIONS; ASSOCIATION; EXPERIENCE; ATTITUDES","This paper presents an overview of the conclusions from an international conference convened to address current issues related to the provision of Cystic Fibrosis carrier screening within Europe. Consensus was not aimed at stating whether such a programme should be implemented. Instead the focus was to provide a framework for countries and agencies who are considering or planning its establishment. The general principles and target population of Cystic Fibrosis carrier screening, advantages and disadvantages, health economics, monitoring and future evaluative and research directions were covered. A range of screening strategies have been assessed and compared: pre-conceptional and prenatal screening; individual and couple screening; sequential and simultaneous sampling or testing. Furthermore, technical issues were examined with respect to the choice of the panel of mutations, its detection rate, sensitivity, management of intermediate 'at-risk' couples, screening approach to different populations and ethnic minorities, and assurance of laboratory quality control. The consensus statement also aims to establish the benchmarks for communicating with health care providers, the general public and potential and actual participants before and after the genetic test. (C) 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Castellani, Carlo] Verona Cyst Fibrosis Ctr, Verona, Italy; [Macek, Milan, Jr.] Charles Univ Prague 2, Sch Med, Dept Biol & Med Genet, Prague, Czech Republic; [Macek, Milan, Jr.] Univ Hosp Motol, Prague, Czech Republic; [Dequeker, Elisabeth] Katholieke Univ Leuven, Ctr Human Genet, Biomed Qual Assurance Res Unit, Louvain, Belgium; [Duff, Alistair] St James Univ Hosp, Leeds Reg Cyst Fibrosis Unit, Leeds, W Yorkshire, England; [Massie, John] Royal Childrens Hosp, Dept Resp Med, Melbourne, Vic, Australia; [ten Kate, Leo P.] Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands; [ten Kate, Leo P.] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Barton, David] Our Ladys Hosp Sick Children, Natl Ctr Med Genet, Dublin, Ireland; [Cutting, Garry] Johns Hopkins Univ, Baltimore, MD USA; [Dallapiccola, Bruno] Osped Pediat Bambino Gesu, IRCCS, Rome, Italy; [Girodon, Emmanuelle] Hop Henri Mondor, Serv Biochim & Genet, F-94010 Creteil, France; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Path & Lab Med, Div Med Genet, Los Angeles, CA USA; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Med Genet, Los Angeles, CA 90024 USA; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Human Genet, Div Med Genet, Los Angeles, CA USA; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Path & Lab Med, Div Mol Pathol, Los Angeles, CA USA; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Pediat, Div Mol Pathol, Los Angeles, CA 90024 USA; [Grody, Wayne] Univ Calif Los Angeles, Sch Med, Dept Human Genet, Div Mol Pathol, Los Angeles, CA USA; [Highsmith, Edward W.] Mayo Clin, Mol Genet Lab, Rochester, MN USA; [Kaariainen, Helenal] Natl Inst Hlth & Welf, Helsinki, Finland; [Kruip, Stephan] Mukoviszidose eV German CF Selfhelp Assoc, Bonn, Germany; [Morris, Michael] Hop Univ Geneve, Serv Med Genet, Lab Diagnost Mol, Geneva, Switzerland; [Pignatti, Pier Franco] Univ Verona, Sect Biol & Genet, I-37100 Verona, Italy; [Schwarz, Martin] St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; [Soller, Maria] Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; [Stuhrman, Manfred] Hannover Med Sch, Inst Humangenet, Hannover, Germany","Castellani, C (reprint author), Azienda Osped Univ Integrata Verona, Cyst Fibrosis Ctr, Piazzale Stefani 1, I-37126 Verona, Italy.","carlo.castellani@ospedaleuniverona.it",null,null,"Mukoviszidose ev; Cystic Fibrosis Foundation; EuroCareCF [LSHM-CT-2005-018932]; EuroGenTest NoE [LSHB-CT-2004-512148]; Bayer HealthCare; Solvay Pharmaceuticals; Luminex; Abbott Molecular; Innogenetics","The organisers of the Consensus Conference would like to thank Wolf Rogowski for external health economic advice as well as the organisations which supported the meeting: Mukoviszidose ev, Cystic Fibrosis Foundation, EuroCareCF (LSHM-CT-2005-018932) and the EuroGenTest NoE (LSHB-CT-2004-512148). Supported by MZOFNM2005 to MM.This consensus conference was sponsored by some commercial companies: Bayer HealthCare, Solvay Pharmaceuticals, Luminex, Abbott Molecular, Innogenetics. These companies had no role in the design and conduct of the consensus conference, and in the preparation, review, or approval of the manuscript.",null,81,12,12,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","MAY",2010,9,3,null,null,null,null,165,178,null,"10.1016/j.jcf.2010.02.005",null,14,"Respiratory System","Respiratory System","614BG","WOS:000279029400003"]
[null,null,null,null,"J","Horak, Z; Pokorny, D; Fulin, P; Slouf, M; Jahoda, D; Sosna, A",null,null,null,"Horak, Z.; Pokorny, D.; Fulin, P.; Slouf, M.; Jahoda, D.; Sosna, A.",null,null,"Polyetheretherketone (PEEK). Part I: Prospects for Use in Orthopaedics and Traumatology","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Review",null,null,null,null,null,"PAEK; PEEK; polyetheretherketone; joint replacement; total hip arthroplasty","INTERBODY LUMBAR FUSION; TOTAL HIP-ARTHROPLASTY; CARBON-FIBER IMPLANT; PEEK; BIOCOMPATIBILITY; CRYSTALLIZATION; IRRADIATION; COMPOSITES; EXPERIENCE; MORPHOLOGY","On the basis of current studies, polyaryletherketone (PAEK) polymers appear to be materials with great prospects for medical application. The most important member of this family of semi-crystalline thermoplastics is polyetheretherketone (PEEK) with its composites. The excellent properties of this material find their use in the treatment of various disorders of the skeletal system. At present they are used with advantage to construct spinal implants, and replacements for other orthopaedic applications and for dental and trauma medicine are at advanced stages of clinical testing.","[Pokorny, D.; Jahoda, D.; Sosna, A.] I Ortoped Klin 1 LF UK, FN Motol, Prague 5, Czech Republic; [Horak, Z.] Ustav Makromol Chem AV CR, Skupina Vyvoje Recyklace Polymernich Mat, Prague, Czech Republic; [Fulin, P.] PGS, 1 Lekarska Fak UK, Prague, Czech Republic; [Slouf, M.] Ustav Makromol Chem AV CR, Skupina Morfol Polymeru, Prague, Czech Republic","Pokorny, D (reprint author), I Ortoped Klin 1 LF UK, FN Motol, V Uvalu 84, Prague 5, Czech Republic.","david.pokorny@LF1.cuni.cz","Slouf, Miroslav/F-6311-2012","Slouf, Miroslav/0000-0003-1528-802X",null,null,null,37,5,5,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2010,77,6,null,null,null,null,463,469,null,null,null,7,"Orthopedics","Orthopedics","704US","WOS:000286081700004"]
[null,null,null,null,"J","Pokorny, D; Fulin, P; Slouf, M; Jahoda, D; Landor, I; Sosna, A",null,null,null,"Pokorny, D.; Fulin, P.; Slouf, M.; Jahoda, D.; Landor, I.; Sosna, A.",null,null,"Polyetheretherketone (PEEK). Part II: Application in Clinical Practice","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Review",null,null,null,null,null,"polyetheretherketone; PEEK; joint replacement; wear; shoulder arthroplasty; total hip arthroplasty; total knee arthroplasty","FIBER-REINFORCED PEEK; TOTAL HIP-ARTHROPLASTY; IN-VITRO; BIOLOGICAL RESPONSE; FEMORAL STEM; ORTHOPEDIC IMPLANTS; TENSILE PROPERTIES; KNEE REPLACEMENT; BEARING SURFACES; CAMBRIDGE CUP","Polyetheretherketone (PEEK) is one of the up-to-date organic polymer thermoplastics with applications in orthopaedics and trauma medicine. This study presents a detailed analysis of its tests and applications in clinical medicine, A wide range of PEEK modifications and composites are commercially available, e.g., PEEK-Classix, PEEK-Optima, Endolign and Motis. They differ in their physical properties, which makes them suitable for different applications. Other forms, so-called PEEK bioactive composites, contain beta-tricalcium phosphate and hydroxyapatite. Research in this field is also concerned with the surface finish of this polymer thermoplastic and involves macroporous titanium and hydroxyapatite layers, or treatment with laser for an exactly defined surface structure. The clinical applications of PEEK and its composites include, in addition to components for spinal surgery, osteosynthesis plates, screws, intramedullary nails or external fixators, which are implants still at the stage of prototypes. In this review, attention is paid to the use of PEEK thermoplastics for joint replacement. Mid-term studies involving hundreds of patients have shown that, for instance, the VerSys Epoch Fullcoat Hip System (Zimmer) has a markedly lower stress-shielding effect. Carbon fibre-reinforced (CFR-PEEK) composites are used to make articulating components for total hip replacement. Their convenient properties allow for production of much thinner liners and an enlargement of the femoral head diameter, thus reducing the wear of joint implants. CFR-PEEK composites are particularly effective for hip resurfacing in which the Mitch PCR (Stryker) acetabular component has been used with good results. The MOTIS polymer acetabular cup (Invibio Ltd.) is another example. Further PEEK applications include the construction of finger-joint prostheses (Mathys AG), suture anchors (Stryker) and various kinds of augmentations (Medin). Based on the information obtained, the authors suggest further use for CFR-PEEK composites, such as the construction of articulating liners for total shoulder joint replacement, particularly in reverse shoulder arthroplasty.","[Pokorny, D.; Jahoda, D.; Landor, I.; Sosna, A.] I Ortoped Klin 1LF UK, FN Motol, Prague 15000 5, Czech Republic; [Fulin, P.] I Lekafska Fak UK, PGS, Prague, Czech Republic; [Slouf, M.] Ustav Makromol Chem AV CR, Skupina Morfol Polymeru, Prague, Czech Republic","Pokorny, D (reprint author), I Ortoped Klin 1LF UK, FN Motol, V Uvalu 84, Prague 15000 5, Czech Republic.","david.pokorny@LF1.cuni.cz","Slouf, Miroslav/F-6311-2012","Slouf, Miroslav/0000-0003-1528-802X",null,null,null,61,4,4,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2010,77,6,null,null,null,null,470,478,null,null,null,9,"Orthopedics","Orthopedics","704US","WOS:000286081700005"]
[null,null,null,null,"J","Pochop, P; Darsova, D; Kukacka, J; Tesfaye, H; Vajner, L; Uhlik, J; Kodetova, D; Malis, J; Dotrelova, D",null,null,null,"Pochop, Pavel; Darsova, Denisa; Kukacka, Jiri; Tesfaye, Hundie; Vajner, Ludek; Uhlik, Jiri; Kodetova, Daniela; Malis, Josef; Dotrelova, Dagmar",null,null,"Intravitreal carboplatin concentration and area under concentration versus time curve after intravitreal and periocular delivery","EUROPEAN JOURNAL OF OPHTHALMOLOGY",null,null,"English","Article; Proceedings Paper","17th Congress of the SOE","JUN 13-16, 2009","Amsterdam, NETHERLANDS","SOE",null,"AUC; Carboplatin concentration; Local treatment; Intravitreal seeding; Periocular injection; Rabbit; Retinoblastoma; Transcorneal","TRANSGENIC MURINE RETINOBLASTOMA; SUBCONJUNCTIVAL CARBOPLATIN; INTRAOCULAR RETINOBLASTOMA; CHEMOTHERAPY; PHARMACOKINETICS; CRYOTHERAPY; THERAPY; EYE","PURPOSE. To determine platinum (Pt) concentrations and area under the concentration versus time curve (AUC) of the vitreous humor after periocular or transcorneal intravitreal administration of carboplatin in rabbits. METHODS. Eighteen albino rabbits were included in an in vivo experiment. Each animal received a single dose of either 30 mg of carboplatin by periocular injection (POI30 group: n=6) or 15 mg by periocular injection (POI15 group: n=6), or 0.05 mg by transcorneal intravitreal injection (TII group: n=6), respectively, into the right eye. Vitreous humor from the right eyes and plasma samples were collected post dose at 1, 2, 6, 24, 48, 168, and 336 hours or 448 hours, respectively. Flameless atomic absorption spectroscopy was employed to analyze total platinum concentrations in blood and vitreous humor AUC was calculated using the trapezoidal rule. RESULTS. Pt concentration was mostly <1 mg/L (0-3.15 mg/L) in the vitreous humor samples and >= 2 mg/L (2.33-7.3 mg/L) in the blood samples 1 hour after administration in POI groups. Markedly higher Pt concentrations were found 1 hour after intravitreal (Ill) administration (10.285-66.759 mg/L) and decreased below 1 mg/L no less than 168 hours after administration. The mean AUC for Pt in vitreous humor was significantly lower (p=0.0001) after both POI30 and POI15 administration compared to TII route (8.955 +/- 2.464 mg/L/min). CONCLUSIONS. These findings proved that intravitreal carboplatin delivery enables the achievement of relatively stable concentrations and AUC of platinum in the rabbit vitreous humor This moreover suggests that transcorneal intravitreal delivery of carboplatin aiming to treat retinoblastoma vitreous seeding is a promising mode of chemotherapy. (Eur J Ophthalmol 2010; 20: 745-51)","[Pochop, Pavel; Darsova, Denisa; Dotrelova, Dagmar] Charles Univ Prague, Fac Med 2, Dept Ophthalmol Children & Adults, Prague 15006 5, Czech Republic; [Kukacka, Jiri; Tesfaye, Hundie] Charles Univ Prague, Fac Med 2, Div Clin Pharm, Dept Clin Biochem & Pathobiochem, Prague 15006 5, Czech Republic; [Vajner, Ludek; Uhlik, Jiri] Charles Univ Prague, Fac Med 2, Dept Histol & Embryol, Prague 15006 5, Czech Republic; [Kodetova, Daniela] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Malis, Josef] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague 15006 5, Czech Republic","Pochop, P (reprint author), Charles Univ Prague, Fac Med 2, Dept Ophthalmol Children & Adults, Uvalu 84, Prague 15006 5, Czech Republic.","pavel.pochop@gmail.com","Kukacka, Jiri/C-4770-2013; Vajner, Ludek/C-5823-2014; Uhlik, Jiri/C-6282-2014",null,null,null,null,13,2,2,"WICHTIG EDITORE","MILAN","72/74 VIA FRIULI, 20135 MILAN, ITALY","1120-6721",null,null,"EUR J OPHTHALMOL","Eur. J. Ophthalmol.","JUL-AUG",2010,20,4,null,null,null,null,745,751,null,null,null,7,"Ophthalmology","Ophthalmology","629JF","WOS:000280191600016"]
[null,null,null,null,"J","Babjuk, M",null,null,null,"Babjuk, Marko",null,null,"Current Value of Neoadjuvant Chemotherapy Prior to Cystectomy","EUROPEAN UROLOGY SUPPLEMENTS",null,null,"English","Article; Proceedings Paper","7th Meeting of the EAU Section of Oncological Urology (ESOU)","JAN 15-17, 2010","Vienna, AUSTRIA","European Assoc Urol",null,"Bladder cancer; Cisplatin-based combination; Distant metastases; Invasive; M-VAC; Neoadjuvant chemotherapy; Radical cystectomy","TRANSITIONAL-CELL-CARCINOMA; INVASIVE BLADDER-CANCER; GEMCITABINE PLUS CISPLATIN; RADICAL CYSTECTOMY; RANDOMIZED-TRIAL; THERAPY; SERIES; METHOTREXATE; METAANALYSIS; VINBLASTINE","Context: Radical cystectomy with a pelvic lymph node dissection is considered the most effective treatment option today for patients with muscle-invasive bladder cancer. Unfortunately, in spite of some progress, disease-specific survival rates after cystectomy have not dramatically changed in the last few decades. The significant risk of distant failure indicates that additional systemic treatment is mandatory. Objective: The primary objective of the review was to summarize the data about the benefit of neoadjuvant systemic chemotherapy before cystectomy for muscle-invasive bladder cancer. Evidence acquisition: The papers evaluating cystectomy cohorts were analyzed including a thorough analysis of treatment failures. The papers presenting prospective randomized trials and meta-analyses on neoadjuvant chemotherapy in bladder cancer were critically reviewed. Evidence synthesis: The rationale for chemotherapy before cystectomy is to treat micrometastases beyond the margins of local therapy already present at the time of diagnosis of invasive bladder cancer. Results of prospective randomized trials indicate survival benefit after neoadjuvant platinum-based combination chemotherapy. To improve the interpretation of data from prospective randomized trials, several meta-analyses were conducted. The most recent meta-analysis, published in 2005, evaluated the individual data from 3005 patients enrolled in 11 prospective controlled trials that compared neoadjuvant chemotherapy plus local treatment with local treatment alone. The data comprised 98% of all patients from known eligible randomized controlled trials. The analysis found significant survival benefit associated with platinum-based combination chemotherapy. It was equivalent to a 5% absolute improvement in overall survival (p = 0.003) and a 9% improvement in disease-free survival (p < 0.0001) at 5 yr. Conclusions: Radical cystectomy with pelvic lymph node dissection remains the standard treatment for muscle-invasive bladder cancer. The quality of surgery is essential for optimal treatment results. The data from prospective randomized trials and meta-analyses provide support for preoperative application of platinum-based combination chemotherapy in all patients. (C) 2010 European Association of Urology. Published by Elsevier B. V. All rights reserved.","[Babjuk, Marko] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 1, Prague, Czech Republic; [Babjuk, Marko] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, Prague, Czech Republic","Babjuk, M (reprint author), FN Motol, Dept Urol, V Uvalu 84, Prague 15006 5, Czech Republic.","marek.babjuk@lfmotol.cuni.cz",null,null,null,null,null,25,1,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-9056",null,null,"EUR UROL SUPPL","Eur. Urol. Suppl.","APR",2010,9,3,null,null,null,null,424,427,null,"10.1016/j.eursup.2010.02.001",null,4,"Urology & Nephrology","Urology & Nephrology","581MJ","WOS:000276527200009"]
[null,null,null,null,"J","Hlinakova, P; Dostalova, T; Danek, J; Nedoma, J; Hlavacek, I",null,null,null,"Hlinakova, P.; Dostalova, T.; Danek, J.; Nedoma, J.; Hlavacek, I.",null,null,"Temporomandibular joint and its two-dimensional and three-dimensional modelling","MATHEMATICS AND COMPUTERS IN SIMULATION",null,null,"English","Article; Proceedings Paper","1st IMACS International Conference on Computational Biomechanics and Biology (ICCBB 2007)","SEP 10-14, 2007","Pilsen, CZECH REPUBLIC","IMACS","Univ W Bohemia","Dentistry; Temporomandibular joint; Mathematical modelling; Contact problem; Finite element method","JAW","Detailed knowledge about the function and morphology of temporomandibular joint are necessary for clinical applications and for analyses of the function of temporomandibular joint prosthesis. Movements of temporomandibular Joint are biomechanically sophisticated and are up-to-date not clear Therefore, the aim of the paper is to give the suitable mathematical approach for analyses of temporomandibular joint In the paper the analysis of the temporomandibular joint, loaded by traction and compression forces. is presented and shortly discussed The obtained results, based on two- and three-dimensional mathematical models, represent an introductory work for further studies of biomechanical aspects of temporomandibular joint and of its artificial replacements The models are based on the theory of contact problems in linear elasticity. For the numerical solutions of the investigated problems the FEM approaches are used and the used algorithm is based on an active-set method for quadratic programming (C) 2009 IMACS. Published by Elsevier B V All rights reserved","[Danek, J.] Univ W Bohemia, Dept Math, Plzen, Czech Republic; [Hlinakova, P.; Dostalova, T.] Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague, Czech Republic; [Danek, J.; Nedoma, J.; Hlavacek, I.] Acad Sci Czech Republic, Inst Comp Sci, Prague, Czech Republic; [Hlavacek, I.] Acad Sci Czech Republic, Inst Math, CR-11567 Prague, Czech Republic","Danek, J (reprint author), Univ W Bohemia, Dept Math, Plzen, Czech Republic.",null,"Nedoma, Jiri/E-8735-2014",null,null,null,null,9,1,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0378-4754",null,null,"MATH COMPUT SIMULAT","Math. Comput. Simul.","FEB",2010,80,6,null,null,"SI",null,1256,1268,null,"10.1016/j.matcom.2009.08.007",null,13,"Computer Science, Interdisciplinary Applications; Computer Science, Software Engineering; Mathematics, Applied","Computer Science; Mathematics","579OE","WOS:000276380400022"]
[null,null,null,null,"J","Tlaskal, T; Chaloupecky, V; Hucin, B; Gebauer, R; Krupickova, S; Reich, O; Skovranek, J; Tax, P",null,null,null,"Tlaskal, Tomas; Chaloupecky, Vaclav; Hucin, Bohumil; Gebauer, Roman; Krupickova, Sylvia; Reich, Oleg; Skovranek, Jan; Tax, Petr",null,null,"Long-term results after correction of persistent truncus arteriosus in 83 patients","EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY",null,null,"English","Article; Proceedings Paper","23rd Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery","OCT 18-21, 2009","Vienna, AUSTRIA",null,null,"Congenital heart disease; Persistent truncus arteriosus; Surgery; Long-term results; Re-interventions","OUTFLOW TRACT RECONSTRUCTION; INTERRUPTED AORTIC-ARCH; NEONATAL REPAIR; EXPERIENCE; VALVE; MANAGEMENT; OUTCOMES; REOPERATION; SURVIVAL; CONDUIT","Objective: This study aims to analyse long-term results after correction of truncus arteriosus in all patients operated in one institution over 28 years. Methods: Between 1981 and 2009, 83 patients, median age 54 days, underwent repair of truncus arteriosus. Interrupted aortic arch was present in 14 (17%), severe truncal valve insufficiency in 10 (12%) and non-confluent pulmonary arteries in five (6%) patients. Repair with reconstruction of the right ventricular to pulmonary artery continuity was performed using a valved conduit in 80, and other methods in three patients. At the same time, correction of interrupted aortic arch was done in 14 and truncal valve repair in eight patients. Survivors were repeatedly examined echocardiographically for assessment of residual heart lesions. Results: The early mortality was 19 (23%). Out of 35 patients operated between 1981 and 1996, 17(46%) died, and out of 48 patients operated between 1997 and 2009, two (4%) died. Operation before 1997 ( p = 0.001) and aortic cross-clamping time >90 min ( p = 0.009) were found to be risk factors of death. Eight (10%) patients died late, a median of 68 days after surgery. Fifty-seven (69%) patients were followed for 10.9 +/- 6.7 years. Three (4%) patients were lost. Twenty-five (30%) patients are alive with their original conduit 7.5 +/- 5.2 years after correction. Twenty-eight patients required 41 re-operations for conduit dysfunction with first replacement at mean 5.8 +/- 4.1 (range 0.1-14.1 years) years after correction. Nine (11%) patients required 12 truncal valve replacements. Eleven (13%) patients required balloon dilatation or stent for conduit obstruction, pulmonary branch stenosis, aortic arch obstruction or stenosis of vena cava. Recent clinical examination was undertaken in 53 (64%) patients and 49 (59% or 77% of early survivors) are in good/very good condition. Conclusions: Truncus arteriosus remains a challenging heart disease. With growing experience, the early mortality decreased to 4%, but numerous re-interventions for conduit obstruction, pulmonary branch stenosis and truncal valve insufficiency are required. Surgery before 1997 and prolonged cross-clamping were risk factors of death. Pulmonary homografts had the best re-intervention-free survival. Statistically, however, the difference between conduits was not significant. Dysplastic valve and truncal valve insufficiency represent risk factors presenting the need for truncal valve replacement. (C) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.","[Tlaskal, Tomas] Univ Hosp Motol, Kardiocentrum, Prague 15006 5, Czech Republic; Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15006 5, Czech Republic","Tlaskal, T (reprint author), Univ Hosp Motol, Kardiocentrum, V Uvalu 84, Prague 15006 5, Czech Republic.","tomas.tlaskal@lfmotol.cuni.cz",null,null,null,null,null,25,7,9,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1010-7940",null,null,"EUR J CARDIO-THORAC","Eur. J. Cardio-Thorac. Surg.","JUN",2010,37,6,null,null,null,null,1278,1284,null,"10.1016/j.ejcts.2009.12.022",null,7,"Cardiac & Cardiovascular Systems; Respiratory System; Surgery","Cardiovascular System & Cardiology; Respiratory System; Surgery","614UY","WOS:000279086500008"]
[null,null,null,null,"J","Tlaskal, T; Vojtovic, P; Reich, O; Hucin, B; Gebauer, R; Kucera, V",null,null,null,"Tlaskal, Tomas; Vojtovic, Pavel; Reich, Oleg; Hucin, Bohumil; Gebauer, Roman; Kucera, Vladimir",null,null,"Improved results after the primary repair of interrupted aortic arch: impact of a new management protocol with isolated cerebral perfusion","EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY",null,null,"English","Article; Proceedings Paper","23rd Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery","OCT 18-21, 2009","Vienna, AUSTRIA",null,null,"Congenital heart defects; Interrupted aortic arch; Primary repair in neonates; Isolated cerebral perfusion; Long-term results","VENTRICULAR SEPTAL-DEFECT; LOW-FLOW PERFUSION; OUTFLOW TRACT OBSTRUCTION; HEART-SURGEONS-SOCIETY; CIRCULATORY SUPPORT; TRUNCUS ARTERIOSUS; STAGE REPAIR; OUTCOMES; EXPERIENCE; INFANT","Objective: The aim of this retrospective study was to analyse results and risk factors of death after the repair of the interrupted aortic arch, and to compare results obtained with the use of deep hypothermic circulatory arrest versus isolated cerebral perfusion. Methods: The primary repair of the interrupted aortic arch and associated heart lesions was performed in 50 consecutive patients. The median age was 5 days and the mean weight was 3.1 +/- 0.6 kg. The interrupted aortic arch was of type A in 12 (24%) patients, type B in 37(74%) and type C in one (2%) patient. Ventricular septal defect was present in 48 (96%) patients, subaortic stenosis in 15 (30%), truncus arteriosus in 14 (28%), transposition of the great arteries in two (4%), aortopulmonary window in two (4%) and double-outlet right ventricle in one (2%). The surgery consisted of reconstruction of the aortic arch by direct anastomosis and repair of associated heart lesions. In 25 (50%) patients, aortic arch reconstruction was performed using hypothermic circulatory arrest (group I) and in 25 by isolated cerebral perfusion (group II). The duration of cardiopulmonary bypass, aortic cross-clamping and circulatory arrest or isolated cerebral perfusion was 191 +/- 46 min, 90 +/- 24 min and 40 +/- 14 min, respectively, in group I; and 194 +/- 39 min, 74 +/- 20 min and 31 +/- 6 min, respectively, in group II. Results: There were 10(20%) deaths in this series, eight (32%) in group land two (8%) in group II. Out of 12 patients operated before 1995, seven (58%) patients died; and out of 38 patients operated between 1995 and 2009, three (8%) patients died (p = 0.008). By Cox multifactorial analysis, the earlier date of operation represented the only risk factor of death (p = 0.037). Twelve (71%) survivors in group I and five (22%) survivors in group II required re-intervention, most often for subaortic stenosis, aortic arch obstruction or conduit obstruction. All patients remain in the New York Heart Association (NYHA) class I or II at median 12.6 years in group I, and 1.7 years in group II, respectively, after surgery. Conclusions: Interrupted aortic arch can be repaired in neonates with a mortality of 5-10%. The results depend on experience. Isolated cerebral perfusion was joined with decreased mortality but it did not influence the occurrence of neurological complications. (C) 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.","[Tlaskal, Tomas] Univ Hosp Motol, Kardioctr, Prague 15006 5, Czech Republic; Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15006 5, Czech Republic","Tlaskal, T (reprint author), Univ Hosp Motol, Kardioctr, V Uvalu 84, Prague 15006 5, Czech Republic.","tomas.tlaskal@lfmotol.cuni.cz",null,null,null,null,null,25,5,7,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1010-7940",null,null,"EUR J CARDIO-THORAC","Eur. J. Cardio-Thorac. Surg.","JUL",2010,38,1,null,null,null,null,52,58,null,"10.1016/j.ejcts.2010.01.052",null,7,"Cardiac & Cardiovascular Systems; Respiratory System; Surgery","Cardiovascular System & Cardiology; Respiratory System; Surgery","623ML","WOS:000279744400011"]
[null,null,null,null,"J","Dusatkova, P; Vesela, K; Pruhova, S; Lebl, J; Cinek, O",null,null,null,"Dusatkova, P.; Vesela, K.; Pruhova, S.; Lebl, J.; Cinek, O.",null,null,"Lack of PAX4 mutations in 53 Czech MODYX families","DIABETIC MEDICINE",null,null,"English","Letter",null,null,null,null,null,null,"CLINICAL CHARACTERISTICS; YOUNG",null,"[Dusatkova, P.; Vesela, K.; Pruhova, S.; Lebl, J.; Cinek, O.] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Fac Med 2, Prague, Czech Republic","Dusatkova, P (reprint author), Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Fac Med 2, Prague, Czech Republic.",null,null,null,null,null,null,8,1,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0742-3071",null,null,"DIABETIC MED","Diabetic Med.","DEC",2010,27,12,null,null,null,null,1459,1460,null,"10.1111/j.1464-5491.2010.03126.x",null,2,"Endocrinology & Metabolism","Endocrinology & Metabolism","678JR","WOS:000284070400018"]
[null,null,null,null,"J","Rob, L; Pluta, M; Robova, H",null,null,null,"Rob, Lukas; Pluta, Marek; Robova, Helena",null,null,"Less radical surgery than radical hysterectomy in early stage cervical cancer - A pilot study","GYNECOLOGIC ONCOLOGY",null,null,"English","Letter",null,null,null,null,null,null,"INVOLVEMENT",null,"[Rob, Lukas; Pluta, Marek; Robova, Helena] Fac Hosp Motol, Dept Obstet & Gynecol, Fac Med 2, Prague 15000 5, Czech Republic","Rob, L (reprint author), Fac Hosp Motol, Dept Obstet & Gynecol, Fac Med 2, V Uvalu 84, Prague 15000 5, Czech Republic.","lukas.rob@lfmotol.cuni.cz",null,null,null,null,null,7,0,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0090-8258","1095-6859",null,"GYNECOL ONCOL","Gynecol. Oncol.","APR",2010,117,1,null,null,null,null,148,148,null,"10.1016/j.ygyno.2009.12.007",null,1,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","582JV","WOS:000276594200028"]
[null,null,null,null,"J","Formankova, R; Sedlacek, P; Keslova, P; Sramkova, L; Zizkova, H; Stary, J",null,null,null,"Formankova, Renata; Sedlacek, Petr; Keslova, Petra; Sramkova, Lucie; Zizkova, Hana; Stary, Jan",null,null,"Adoptive immunotherapy, chemotherapy, and second allogeneic transplant in the treatment of post-transplant relapse of acute leukemia in children: a single center experience","LEUKEMIA & LYMPHOMA",null,null,"English","Letter",null,null,null,null,null,null,"STEM-CELL TRANSPLANTATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHIMERISM",null,"[Formankova, Renata; Sedlacek, Petr; Keslova, Petra; Sramkova, Lucie; Stary, Jan] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague 15006 5, Czech Republic; [Zizkova, Hana] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic","Formankova, R (reprint author), Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006 5, Czech Republic.","renata.formankova@lfmotol.cuni.cz",null,null,null,null,null,11,2,2,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","1042-8194",null,null,"LEUKEMIA LYMPHOMA","Leuk. Lymphoma","OCT",2010,51,10,null,null,null,null,1936,1940,null,"10.3109/10428194.2010.504873",null,5,"Oncology; Hematology","Oncology; Hematology","663NS","WOS:000282895200028"]
[null,null,null,null,"J","Prusa, R; Doupovcova, J; Warunek, D; Stankovic, AK",null,null,null,"Prusa, Richard; Doupovcova, Jana; Warunek, David; Stankovic, Ana K.",null,null,"Improving laboratory efficiencies through significant time reduction in the preanalytical phase","CLINICAL CHEMISTRY AND LABORATORY MEDICINE",null,null,"English","Letter",null,null,null,null,null,"analysis of variance (ANOVA); blood collection tube; centrifugation time; clinical acceptance limits; clotting time; collection time; confidence interval; emergency department; preanalytical turnaround time; total turnaround time","EMERGENCY-DEPARTMENT; TURNAROUND TIME; QUALITY",null,"[Prusa, Richard; Doupovcova, Jana] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague 15006, Czech Republic; [Prusa, Richard; Doupovcova, Jana] Fac Hosp Motol, Prague 15006, Czech Republic; [Warunek, David; Stankovic, Ana K.] BD Diagnost Preanalyt Syst, Franklin Lakes, NJ USA","Prusa, R (reprint author), Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, V Uvalu 84,Praha 5, Prague 15006, Czech Republic.","richard.prusa@fnmotol.cz",null,null,null,null,null,7,2,2,"WALTER DE GRUYTER & CO","BERLIN","GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY","1434-6621",null,null,"CLIN CHEM LAB MED","Clin. Chem. Lab. Med.","FEB",2010,48,2,null,null,null,null,293,296,null,"10.1515/CCLM.2010.036",null,4,"Medical Laboratory Technology","Medical Laboratory Technology","552JM","WOS:000274286000023"]
[null,null,null,null,"J","Seeman, T; Seemanova, E; Nuernberg, G; Nuernberg, P; Janssen, S; Otto, EA",null,null,null,"Seeman, Tomas; Seemanova, Eva; Nuernberg, Gudrun; Nuernberg, Peter; Janssen, Sabine; Otto, Edgar A.",null,null,"Polycystic kidney and hepatic disease with mental retardation is nephronophthisis 11 caused by MKS3/TMEM67 mutations","PEDIATRIC NEPHROLOGY",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Seeman, Tomas] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Sch Med 2, Prague 15006, Czech Republic; [Seemanova, Eva] Charles Univ Prague, Dept Clin Genet, Inst Biol & Med Genet, Univ Hosp Motol,Med Sch 2, Prague 15006, Czech Republic; [Nuernberg, Gudrun; Nuernberg, Peter] Univ Cologne, Cologne Ctr Genom, Cologne, Germany; [Janssen, Sabine; Otto, Edgar A.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA","Seeman, T (reprint author), Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic.","tomas.seeman@lfmotol.cuni.cz",null,null,null,null,null,4,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","NOV",2010,25,11,null,null,null,null,2375,2376,null,"10.1007/s00467-010-1591-1",null,2,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","648WN","WOS:000281725200025"]
[null,null,null,null,"J","Matousovic, K; Novak, J; Julian, BA; Mestecky, J",null,null,null,"Matousovic, Karel; Novak, Jan; Julian, Bruce A.; Mestecky, Jiri",null,null,"Tissue distribution and biological activities of immune complexes are determined by their size and composition","NEPHROLOGY DIALYSIS TRANSPLANTATION",null,null,"English","Letter",null,null,null,null,null,null,"IGA NEPHROPATHY; ANTIBODIES",null,"[Matousovic, Karel] Prague Charles Univ, Prague, Czech Republic; [Novak, Jan; Julian, Bruce A.; Mestecky, Jiri] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; [Julian, Bruce A.; Mestecky, Jiri] Univ Alabama, Dept Med, Birmingham, AL 35294 USA; [Julian, Bruce A.] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; [Mestecky, Jiri] Charles Univ Prague, Dept Med, Prague, Czech Republic","Matousovic, K (reprint author), Prague Charles Univ, Prague, Czech Republic.","kmatousovic@hotmail.com",null,null,null,null,null,5,1,1,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0931-0509",null,null,"NEPHROL DIAL TRANSPL","Nephrol. Dial. Transplant.","MAR",2010,25,3,null,null,null,null,1007,1007,null,"10.1093/ndt/gfp585",null,1,"Transplantation; Urology & Nephrology","Transplantation; Urology & Nephrology","561OQ","WOS:000274987800058"]
[null,null,null,null,"J","Musil, Z; Puchmajerova, A; Krepelova, A; Vicha, A; Panczak, A; Vesela, J; Widimsky, J; Turkova, H; Lisy, J; Kohoutova, M",null,null,null,"Musil, Zdenek; Puchmajerova, Alena; Krepelova, Anna; Vicha, Ales; Panczak, Ales; Vesela, Jitka; Widimsky, Jiri; Turkova, Hana; Lisy, Jiri; Kohoutova, Milada",null,null,"Paraganglioma in a 13-year-old girl: a novel SDHB gene mutation in the family?","CANCER GENETICS AND CYTOGENETICS",null,null,"English","Letter",null,null,null,null,null,null,"PHEOCHROMOCYTOMA; TUMORS",null,"[Musil, Zdenek; Krepelova, Anna; Panczak, Ales; Vesela, Jitka; Kohoutova, Milada] Charles Univ Prague, Fac Med 1, Inst Biol & Med Genet, Prague 12800 2, Czech Republic; [Musil, Zdenek; Panczak, Ales; Vesela, Jitka; Widimsky, Jiri; Turkova, Hana; Kohoutova, Milada] Gen Teaching Hosp, Prague 12800 2, Czech Republic; [Puchmajerova, Alena; Krepelova, Anna] Charles Univ Prague, Fac Med 2, Inst Biol & Med Genet, Prague 12800 2, Czech Republic; [Musil, Zdenek] Charles Univ Prague, Fac Sci, Dept Anthropol & Human Genet, Prague 12800 2, Czech Republic; [Puchmajerova, Alena; Krepelova, Anna; Vicha, Ales] Motol Univ Hosp, Prague, Czech Republic; [Vicha, Ales] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 12800 2, Czech Republic; [Widimsky, Jiri; Turkova, Hana] Charles Univ Prague, Fac Med 1, Dept Med 3, Dept Endocrinol & Metab, Prague 12800 2, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Fac Med 2, Dept Radiol Tech, Prague 12800 2, Czech Republic","Musil, Z (reprint author), Charles Univ Prague, Fac Med 1, Inst Biol & Med Genet, Albertov 4, Prague 12800 2, Czech Republic.","musil.z@seznam.cz","Vicha, Ales/I-6726-2012","Vicha, Ales/0000-0003-3075-5554",null,null,null,11,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0165-4608",null,null,"CANCER GENET CYTOGEN","Cancer Genet. Cytogenet.","MAR",2010,197,2,null,null,null,null,189,192,null,"10.1016/j.cancergencyto.2009.11.010",null,4,"Oncology; Genetics & Heredity","Oncology; Genetics & Heredity","626OB","WOS:000279974200013"]
[null,null,null,null,"J","van Stralen, KJ; Tizard, EJ; Verrina, E; Schaefer, F; Jager, KJ",null,null,null,"van Stralen, Karlijn J.; Tizard, E. Jane; Verrina, Enrico; Schaefer, Franz; Jager, Kitty J.",null,"ESPN ERA-EDTA Registry Study Grp","Demographics of paediatric renal replacement therapy in Europe: 2007 annual report of the ESPN/ERA-EDTA registry","PEDIATRIC NEPHROLOGY",null,null,"English","Letter",null,null,null,null,null,null,"CHILDREN",null,"[van Stralen, Karlijn J.] Univ Amsterdam, Acad Med Ctr, Dept Med Informat J1B, ESPN ERA EDTA Registry, NL-1100 DE Amsterdam, Netherlands; [Tizard, E. Jane] Bristol Royal Hosp Children, Dept Paediat Nephrol, Bristol, Avon, England; [Verrina, Enrico] G Gaslini Inst Children, Nephrol Dialysis & Transplantat Unit, Genoa, Italy; [Schaefer, Franz] Ctr Pediat & Adolescent Med, Div Pediat Nephrol, Heidelberg, Germany; [Jager, Kitty J.] Univ Amsterdam, Acad Med Ctr, Dept Med Informat J1B, ERA EDTA Registry, NL-1100 DE Amsterdam, Netherlands","van Stralen, KJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Med Informat J1B, ESPN ERA EDTA Registry, POB 22700, NL-1100 DE Amsterdam, Netherlands.","k.j.vanStralen@amc.uva.nl","Schaefer, Franz/G-4365-2010",null,null,null,"Jager KJ, 2007, KIDNEY INT, V72, P412, DOI 10.1038/sj.ki.5002341; Mehls O, 1996, NEPHROL DIAL TRANSPL, V11, P22; Stel VS, 2009, NDT PLUS, V2, P514; Tizard EJ, 2009, NEPHROL DIAL TRANSPL, V24, P2615, DOI 10.1093/ndt/gfp275; van der Heijden BJ, 2004, PEDIATR NEPHROL, V19, P213, DOI 10.1007/s00467-003-1376-x",5,12,12,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","JUL",2010,25,7,null,null,null,null,1379,1382,null,"10.1007/s00467-010-1472-7",null,4,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","599VA","WOS:000277940700028"]
[null,null,null,null,"J","Charvat, F; Maskova, J; Belina, F; Buric, I; Lacman, J; Fuksa, Z; Vrana, J",null,null,null,"Charvat, Frantisek; Maskova, Jana; Belina, Frantisek; Buric, Ivo; Lacman, Jiri; Fuksa, Zdenek; Vrana, Jiri",null,null,"Portal Vein Erosion: A Rare Hemorrhagic Complication of Acute Pancreatitis Treated by Percutaneous Stent-graft Placement","JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Charvat, Frantisek; Maskova, Jana; Buric, Ivo; Lacman, Jiri; Vrana, Jiri] Cent Mil Hosp, Dept Radiol, Prague 16902 6, Czech Republic; [Belina, Frantisek] Cent Mil Hosp, Dept Surg, Prague 16902 6, Czech Republic; [Fuksa, Zdenek] Cent Mil Hosp, Intens Care Unit, Prague 16902 6, Czech Republic","Charvat, F (reprint author), Cent Mil Hosp, Dept Radiol, U Vojenske Nemocnice 1200, Prague 16902 6, Czech Republic.",null,null,null,null,null,"Balthazar EJ, 2001, PANCREATOLOGY, V1, P306, DOI 10.1159/000055829; Kirby JM, 2008, CARDIOVASC INTER RAD, V31, P957, DOI 10.1007/s00270-007-9138-y; Ko HS, 2003, ABDOM IMAGING, V28, P700, DOI 10.1007/s00261-003-0014-1; Mortele KJ, 2004, EUR J RADIOL, V52, P67, DOI 10.1016/j.ejrad.2003.10.006; NORDBACK I, 1989, INT SURG, V74, P36; Rasmussen IC, 2006, UPSALA J MED SCI, V111, P329",6,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1051-0443",null,null,"J VASC INTERV RADIOL","J. Vasc. Interv. Radiol.","MAR",2010,21,3,null,null,null,null,411,412,null,"10.1016/j.jvir.2009.11.011",null,2,"Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease","Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology","592GZ","WOS:000277367700020"]
[null,null,null,null,"J","Melichercikova, V; Urban, J; Goroncy-Bermes, P",null,null,null,"Melichercikova, V.; Urban, J.; Goroncy-Bermes, P.",null,null,"Residual effect of antiseptic substances on human skin","JOURNAL OF HOSPITAL INFECTION",null,null,"English","Letter",null,null,null,null,null,null,"HAND DISINFECTION; CHLORHEXIDINE; COLONIZATION",null,"[Goroncy-Bermes, P.] Schulke & Mayr GmbH, D-22851 Norderstedt, Germany; [Melichercikova, V.; Urban, J.] Natl Inst Publ Hlth, Natl Reference Lab Disinfect & Sterilisat, Prague, Czech Republic","Goroncy-Bermes, P (reprint author), Schulke & Mayr GmbH, Robert Koch Str 2, D-22851 Norderstedt, Germany.","peter.goroncy-bermes@schuelke.com",null,null,null,null,"BARTZOKAS CA, 1987, INFECT CONT HOSP EP, V8, P163; CHRISTIANSEN B, 1991, ZBL HYG UMWELTMED, V192, P99; CREMIEUX A, 1989, APPL ENVIRON MICROB, V55, P2944; Dettenkofer M, 2002, INFECTION, V30, P282, DOI 10.1007/s15010-002-2182-2; *EUR COMM STAND, 127912005 EN EUR COM; Lipp Allyson, 2005, Br J Perioper Nurs, V15, P12; NICOLETTI G, 1990, J HOSP INFECT, V15, P323, DOI 10.1016/0195-6701(90)90089-7; Valles J, 2008, INFECT CONT HOSP EP, V29, P847, DOI 10.1086/590259",8,0,0,"W B SAUNDERS CO LTD","LONDON","32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND","0195-6701",null,null,"J HOSP INFECT","J. Hosp. Infect.","JUL",2010,75,3,null,null,null,null,238,239,null,"10.1016/j.jhin.2009.12.010",null,2,"Infectious Diseases","Infectious Diseases","625JZ","WOS:000279892700019"]
[null,null,null,null,"J","Neoptolemos, JP; Stocken, DD; Bassi, C; Ghaneh, P; Cunningham, D; Goldstein, D; Padbury, R; Moore, MJ; Gallinger, S; Mariette, C; Wente, MN; Izbicki, JR; Friess, H; Lerch, MM; Dervenis, C; Olah, A; Butturini, G; Doi, R; Lind, PA; Smith, D; Valle, JW; Palmer, DH; Buckels, JA; Thompson, J; McKay, CJ; Rawcliffe, CL; Buchler, MW",null,null,null,"Neoptolemos, John P.; Stocken, Deborah D.; Bassi, Claudio; Ghaneh, Paula; Cunningham, David; Goldstein, David; Padbury, Robert; Moore, Malcolm J.; Gallinger, Steven; Mariette, Christophe; Wente, Moritz N.; Izbicki, Jakob R.; Friess, Helmut; Lerch, Markus M.; Dervenis, Christos; Olah, Attila; Butturini, Giovanni; Doi, Ryuichiro; Lind, Pehr A.; Smith, David; Valle, Juan W.; Palmer, Daniel H.; Buckels, John A.; Thompson, Joyce; McKay, Colin J.; Rawcliffe, Charlotte L.; Buechler, Markus W.",null,"European Study Grp Pancreatic Canc","Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial","JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION",null,null,"English","Article",null,null,null,null,null,null,"CURATIVE RESECTION; CHEMORADIATION; SURVIVAL; MULTICENTER; THERAPY; CHEMORADIOTHERAPY; ADENOCARCINOMA; CARCINOMA","Context Adjuvant fluorouracil has been shown to be of benefit for patients with resected pancreatic cancer. Gemcitabine is known to be the most effective agent in advanced disease as well as an effective agent in patients with resected pancreatic cancer. Objective To determine whether fluorouracil or gemcitabine is superior in terms of overall survival as adjuvant treatment following resection of pancreatic cancer. Design, Setting, and Patients The European Study Group for Pancreatic Cancer (ESPAC)-3 trial, an open-label, phase 3, randomized controlled trial conducted in 159 pancreatic cancer centers in Europe, Australasia, Japan, and Canada. Included in ESPAC-3 version 2 were 1088 patients with pancreatic ductal adenocarcinoma who had undergone cancer resection; patients were randomized between July 2000 and January 2007 and underwent at least 2 years of follow-up. Interventions Patients received either fluorouracil plus folinic acid (folinic acid, 20 mg/m(2), intravenous bolus injection, followed by fluorouracil, 425 mg/m(2) intravenous bolus injection given 1-5 days every 28 days) (n=551) or gemcitabine (1000 mg/m2 intravenous infusion once a week for 3 of every 4 weeks) (n=537) for 6 months. Main Outcome Measures Primary outcome measure was overall survival; secondary measures were toxicity, progression-free survival, and quality of life. Results Final analysis was carried out on an intention-to-treat basis after a median of 34.2 (interquartile range, 27.1-43.4) months' follow-up after 753 deaths (69%). Median survival was 23.0 (95% confidence interval [CI], 21.1-25.0) months for patients treated with fluorouracil plus folinic acid and 23.6 (95% CI, 21.4-26.4) months for those treated with gemcitabine (chi(2)(1) = 0.7; P = .39; hazard ratio, 0.94 [95% CI, 0.81-1.08]). Seventy-seven patients (14%) receiving fluorouracil plus folinic acid had 97 treatment-related serious adverse events, compared with 40 patients (7.5%) receiving gemcitabine, who had 52 events (P<.001). There were no significant differences in either progression-free survival or global quality-of-life scores between the treatment groups. Conclusion Compared with the use of fluorouracil plus folinic acid, gemcitabine did not result in improved overall survival in patients with completely resected pancreatic cancer.","[Neoptolemos, John P.; Ghaneh, Paula; Rawcliffe, Charlotte L.] Univ Liverpool, Liverpool Canc Res UK Canc Trials Unit, Liverpool Canc Res UK Ctr, Liverpool L69 3GA, Merseyside, England; [Stocken, Deborah D.] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England; [Bassi, Claudio; Butturini, Giovanni] Univ Verona, Dept Surg, I-37100 Verona, Italy; [Cunningham, David] Royal Marsden Natl Hlth Serv Fdn Trust, London, England; [Cunningham, David] Royal Marsden Natl Hlth Serv Fdn Trust, Surrey, England; [Goldstein, David; Padbury, Robert] Australasian Gastrointestinal Trials Grp, Camperdown, NSW, Australia; [Moore, Malcolm J.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; [Gallinger, Steven] Univ Toronto, Fac Med, Dept Surg, Univ Hlth Network, Toronto, ON M5S 1A1, Canada; [Mariette, Christophe] Univ Hosp Claude Huriez, Dept Digest & Oncol Surg, Lille, France; [Wente, Moritz N.; Buechler, Markus W.] Univ Heidelberg, Dept Surg, D-6900 Heidelberg, Germany; [Izbicki, Jakob R.] Univ Hamburg, Dept Gen Visceral & Thorac Surg, Hamburg, Germany; [Friess, Helmut] Tech Univ Munich, Dept Surg, Munich, Germany; [Lerch, Markus M.] Ernst Moritz Arndt Univ Greifswald, Dept Med A, Greifswald, Germany; [Dervenis, Christos] Agia Olga Hosp, Athens, Greece; [Olah, Attila] Petz Aladar Hosp, Gyor, Hungary; [Doi, Ryuichiro] Kyoto Univ, Dept Surg, Kyoto, Japan; [Lind, Pehr A.] Karolinska Stockholm Soder Hosp, Dept Oncol, Stockholm, Sweden; [Smith, David] Clatterbridge Ctr Oncol, Bebington, Merseyside, England; [Valle, Juan W.] Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England; [Palmer, Daniel H.; Buckels, John A.] Univ Hosp Birmingham Natl Hlth Serv Fdn Trust, Queen Elizabeth Hosp, Birmingham, W Midlands, England; [Thompson, Joyce] Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; [McKay, Colin J.] Glasgow Royal Infirm, Lister Dept Surg, Glasgow G4 0SF, Lanark, Scotland","Neoptolemos, JP (reprint author), Univ Liverpool, Liverpool Canc Res UK Canc Trials Unit, Canc Res UK Ctr, 5th Floor,UCD Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.","j.p.neoptolemos@liverpool.ac.uk","Gallinger, Steven/E-4575-2013; Yip, Desmond/G-2043-2014","Yip, Desmond/0000-0002-2806-2401","Cancer Research UK; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia; Cancer Council of New South Wales; Cancer Council of Queensland; Cancer Council of Victoria; Cancer Council of South Australia; National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital","This study was supported by Cancer Research UK; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia, Cancer Councils of New South Wales, Queensland, Victoria, and South Australia. Dr Cunningham's work is funded in part by the National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital.","BAKKEVOLD KE, 1993, EUR J CANCER, V29A, P698, DOI 10.1016/S0959-8049(05)80349-1; Berger AC, 2008, J CLIN ONCOL, V26, P5918, DOI 10.1200/JCO.2008.18.6288; Burris HA, 1997, J CLIN ONCOL, V15, P2403; Butturini G, 2008, ARCH SURG-CHICAGO, V143, P75, DOI 10.1001/archsurg.2007.17; Carter R, 2009, INT J CANCER, V124, P2960, DOI 10.1002/ijc.24270; Cox DR, 1972, J R STAT SOC B, V187, P220; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]; KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899; KAPLAN EL, 1958, JAMA-J AM MED ASSOC, V457, P481; Kosuge T, 2006, JPN J CLIN ONCOL, V36, P159, DOI 10.1093/jjco/hyi234; National Cancer Institute Division of Cancer Treatment and Diagnosis, 1999, COMM TOX CRIT CTC VE; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Pedrazzoli Sergio, 1999, Digestive Surgery, V16, P337, DOI 10.1159/000018744; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Regine WF, 2008, JAMA-J AM MED ASSOC, V299, P1019, DOI 10.1001/jama.299.9.1019; ROYSTON P, 1994, APPL STAT-J ROY ST C, V43, P429, DOI 10.2307/2986270; Smeenk HG, 2007, ANN SURG, V246, P734, DOI 10.1097/SLA.0b013e318156eef3; Takada T, 2002, CANCER, V95, P1685, DOI 10.1002/cncr.10831; Twombly R, 2008, J NATL CANCER I, V100, P1670, DOI 10.1093/jnci/djn428; Ueno H, 2009, BRIT J CANCER, V101, P908, DOI 10.1038/sj.bjc.6605256; Wagner M, 2004, BRIT J SURG, V91, P586, DOI 10.1002/bjs.4484",24,180,186,"AMER MEDICAL ASSOC","CHICAGO","515 N STATE ST, CHICAGO, IL 60654-0946 USA","0098-7484",null,null,"JAMA-J AM MED ASSOC","JAMA-J. Am. Med. Assoc.","SEP 8",2010,304,10,null,null,null,null,1073,1081,null,"10.1001/jama.2010.1275",null,9,"Medicine, General & Internal","General & Internal Medicine","646RM","WOS:000281559800017"]
[null,null,null,null,"J","Anders, M; Dvorakova, J; Rathova, L; Havrankova, P; Pelcova, P; Vaneckova, M; Jech, R; Holcat, M; Seidl, Z; Raboch, J",null,null,null,"Anders, Martin; Dvorakova, Jana; Rathova, Lucie; Havrankova, Petra; Pelcova, Petra; Vaneckova, Manuela; Jech, Robert; Holcat, Martin; Seidl, Zdenek; Raboch, Jiri",null,null,"Efficacy of repetitive transcranial magnetic stimulation for the treatment of refractory chronic tinnitus: A randomized, placebo controlled study","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"rTMS; transcranial magnetic stimulation; neuronavigation; chronic refractory tinnitus","MOTOR CORTEX EXCITABILITY; DOUBLE-BLIND; RTMS; SUPPRESSION; DEPRESSION; PLASTICITY","OBJECTIVE: The pathophysiologic mechanisms of idiopathic tinnitus remain unclear. Low frequency rTMS applied over the auditory cortex has been proposed as a new and causally oriented treatment approach for pathological conditions with abnormal, increased cortical activity including tinnitus with increased activity in the auditory cortex. However available studies are characterized by a positive reports on the therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) for treatment of tinnitus, there are few details about the duration of specific treatment effects. DESIGN: The design of the study was randomized, prospective, placebo-controlled. Right-handed patients were treated with either real or sham 1 Hz frequency rTMS over a period of two weeks. Fifty-two patients with chronic, treatment resistant tinnitus and stable medication were enrolled in the study after giving written informed consent and forty-two patients completed the study and were included in data analysis. RESULTS: The ability to reduce the symptoms of tinnitus appeared in both randomized groups immediately after the 1 Hz rTMS and sham stimulation phase. There was a significant reduction in both groups of the tinnitus total score on the Tinnitus Handicap Inventory (THI) (real rTMS p=0.005; sham rTMS p=0.049) and Tinnitus Questionnaire (TQ) total score (real rTMS p=0.003; sham rTMS p=0.049). On the THI evaluation scale, in the real rTMS a mild worsening was noted during week 6 in comparison with the state attained in week 2. During the subsequent course of the study a significant reduction of the total score persisted in the case of THI (real rTMS week 14 p=0.033 and borderline week 26 p=0.058).The reduction of symptoms as evaluated using the TQ was significant compared to baseline in the real rTMS group at week 2, 6 and 14 (p=0.003; p=0.024; p=0.022). The group treated with sham stimulation reached significant reduction of symptoms only at week 2 (p=0.049). A comparison of the difference in the recorded values of the total score during follow-up in relation to baseline expressed as a percentage demonstrates the difference in the effect of rTMS and sham stimulation as evaluated by both the basic scales. Graphical analysis of mean patterns of treatment response according to stimulation type shows a similarity between treatment response patterns evaluated by reduction of the total scores using THI and TQ. CONCLUSIONS: The principal finding of this study is that real 1 Hz rTMS treatment was capable of significantly reducing the total baseline score of basic scales that measure tinnitus severity. This result is important as it proves that significant reduction of symptoms can be achieved even in a group of patients with long-term symptoms resistant to pharmacological treatment.","[Anders, Martin; Dvorakova, Jana; Pelcova, Petra; Raboch, Jiri] Charles Univ Prague, Dept Psychiat, Fac Med 1, Prague 12000 2, Czech Republic; [Anders, Martin; Dvorakova, Jana; Havrankova, Petra; Pelcova, Petra; Vaneckova, Manuela; Seidl, Zdenek; Raboch, Jiri] Gen Teaching Hosp, Prague 12000 2, Czech Republic; [Rathova, Lucie; Jech, Robert; Holcat, Martin] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Prague 12000 2, Czech Republic; [Rathova, Lucie; Jech, Robert; Holcat, Martin] Motol Teaching Hosp, Prague, Czech Republic; [Havrankova, Petra] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague 12000 2, Czech Republic; [Vaneckova, Manuela; Seidl, Zdenek] Charles Univ Prague, Dept Radiol, Fac Med 1, Prague 12000 2, Czech Republic","Anders, M (reprint author), Charles Univ Prague, Dept Psychiat, Fac Med 1, Ke Karlovu 11, Prague 12000 2, Czech Republic.","martin.anders@vfn.cz",null,null," [IGA MZCR NR/8805-4];  [MSM 0021620849]","This study was supported by research grants IGA MZCR NR/8805-4 and MSM 0021620849.",null,40,16,17,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2010,31,2,null,null,null,null,238,249,null,null,null,12,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","596RF","WOS:000277702100013"]
[null,null,null,null,"J","Pietrzak, A; Chodorowska, G; Szepietowski, J; Zalewska-Janowska, A; Krasowska, D; Hercogova, J",null,null,null,"Pietrzak, Aldona; Chodorowska, Grazyna; Szepietowski, Jacek; Zalewska-Janowska, Anna; Krasowska, Dorota; Hercogova, Jana",null,null,"Psoriasis and serum lipid abnormalities","DERMATOLOGIC THERAPY",null,null,"English","Editorial Material",null,null,null,null,null,null,"CARDIOVASCULAR RISK-FACTORS; MYOCARDIAL-INFARCTION; INSULIN SENSITIVITY; METABOLIC SYNDROME; CHOLESTEROL LEVELS; ELEVATED TRIGLYCERIDE; ACITRETIN THERAPY; FISH OIL; DISEASE; PROFILE",null,"[Pietrzak, Aldona; Chodorowska, Grazyna; Krasowska, Dorota] Med Univ Lublin, Chair & Dept Dermatol Venereol & Pediat Dermatol, Lublin, Poland; [Szepietowski, Jacek] Univ Med, Dept Dermatol Venereol & Allergol, Ludwik Hirszweld Inst Immunol & Expt Therapy, Polish Acad Sci, Wroclaw, Poland; [Zalewska-Janowska, Anna] Med Univ Lodz, Dept Psychodermatol, Lodz, Poland; [Hercogova, Jana] Charles Univ Prague, Dept Dermatol, Bulovka Univ Hosp, Prague, Czech Republic","Pietrzak, A (reprint author), Med Univ Lublin, Chair & Dept Dermatol Venereol & Pediat Dermatol, Lublin, Poland.",null,null,null,null,null,null,72,6,6,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","MAR-APR",2010,23,2,null,null,null,null,160,173,null,null,null,14,"Dermatology","Dermatology","574RT","WOS:000276011200010"]
[null,null,null,null,"J","Ehler, E; Marvan, R; Vanek, D",null,null,null,"Ehler, Edvard; Marvan, Richard; Vanek, Daniel",null,null,"Evaluation of 14 Y-chromosomal Short Tandem Repeat Haplotype with Focus on DYS449, DYS456, and DYS458: Czech Population Sample","CROATIAN MEDICAL JOURNAL",null,null,"English","Article",null,null,null,null,null,null,"PCR AMPLIFICATION KIT; REFERENCE DATABASE; GENE FLOW; STR LOCI; DNA; PERSPECTIVE; DIVERSITY; UPDATE; EUROPE","Aim To evaluate the novel triplex polymerase chain reaction (PCR) assay for the analysis of polymorphic Y-chromosomal short tandem repeat loci (Y-STR). Methods A total of 14 Y-STR loci was analyzed. Allele frequencies for 3 tetrameric Y-STR loci (DYS449, DYS456, and DYS458) and extended haplotype loci typed by Y-PLEX (TM) 12 system were investigated in a sample of 50 unrelated healthy Czech male donors. We computed the relevant intra-population statistic parameters for our data (gene diversity, average gene diversity over loci, and mean number of pairwise differences) and compared our sample set with other Central European populations using R(ST) pairwise genetic distance. Results We focused on the comparison of genetic diversity between the Y-STR extended haplotype loci and that of the 3 additional loci, and on the benefit of using DYS449, DYS456, and DYS458 in forensic and population genetics applications. Total gene diversity in our sample set was 0.998367 when using all 14 loci. Our data analysis revealed very high genetic diversity at DYS449 locus (0.876735), which surpasses even the diversity at DYS385a/b (0.819592). Population comparison showed no difference between Czech, Bavarian, Austrian, and Saxon sample set. A minor difference was found between Czech and Polish sample set. Conclusion Typing of 3 Y-chromosomal microsatellite polymorphisms may provide a useful complement to already established sets of Y-STRs.","[Ehler, Edvard; Marvan, Richard] Charles Univ Prague, Fac Sci, Dept Anthropol & Human Genet, CR-12844 Prague 2, Czech Republic; [Ehler, Edvard; Marvan, Richard] Charles Univ Prague, Fac Educ, Dept Biol & Environm Studies, CR-12844 Prague, Czech Republic; [Vanek, Daniel] Forens DNA Serv, Prague, Czech Republic","Ehler, E (reprint author), Charles Univ Prague, Fac Sci, Dept Anthropol & Human Genet, Vinicna 7, CR-12844 Prague 2, Czech Republic.","eda.ehler@seznam.cz",null,null,"Ministry of Education, Youth, and Sports of the Czech Republic [LN00B107, MSM 0021620843]","This research was supported by grant LN00B107 of the Ministry of Education, Youth, and Sports of the Czech Republic to the European Centre for Medical Informatics, Statistics, and Epidemiology (EuroMISE Centre), Institute of Computer Science, Academy of Sciences of the Czech Republic, D.V.i.E.E. was supported also by grant MSM 0021620843 of the Ministry of Education, Youth, and Sports of the Czech Republic. The authors appreciate helpful comments from Jack Freeman. We are also grateful to the 3 anonymous reviewers for their helpful comments to the early version of the manuscript.",null,24,4,5,"MEDICINSKA NAKLADA","ZAGREB","VLASKA 69, HR-10000 ZAGREB, CROATIA","0353-9504",null,null,"CROAT MED J","Croat. Med. J.","FEB",2010,51,1,null,null,null,null,54,60,null,"10.3325/cmj.2010.51.54",null,7,"Medicine, General & Internal","General & Internal Medicine","565TZ","WOS:000275319000008"]
[null,null,null,null,"J","Babjuk, M",null,null,null,"Babjuk, Marko",null,null,"What is the Optimal Treatment Strategy for T1 Bladder Tumors?","EUROPEAN UROLOGY",null,null,"English","Editorial Material",null,null,null,null,null,null,"BACILLUS-CALMETTE-GUERIN; RANDOMIZED CLINICAL-TRIALS; TRANSURETHRAL RESECTION; INTRAVESICAL MITOMYCIN; CANCER; METAANALYSIS; PROGRESSION; RECURRENCE; IMPROVE; RISK",null,"[Babjuk, Marko] Charles Univ Prague, Dept Urol, Fac Med 1 & 2, Prague, Czech Republic","Babjuk, M (reprint author), FN Motol, Dept Urol, V Uvalu 84, Prague 15006 5, Czech Republic.","babjuk@volny.cz",null,null,null,null,null,12,2,3,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","JAN",2010,57,1,null,null,null,null,32,34,null,"10.1016/j.eururo.2009.10.015",null,3,"Urology & Nephrology","Urology & Nephrology","537HX","WOS:000273105000012"]
[null,null,null,null,"J","Soukup, J; Papezova, H; Kubena, AA; Mikolajova, V",null,null,null,"Soukup, J.; Papezova, H.; Kubena, A. A.; Mikolajova, V.",null,null,"Dissociation in non-clinical and clinical sample of Czech adolescents. Reliability and validity of the Czech version of the Adolescent Dissociative Experiences Scale","EUROPEAN PSYCHIATRY",null,null,"English","Article",null,null,null,null,null,"A-DES; Dissociation; ADHD; Adolescents; Intercultural","CHILDHOOD SEXUAL-ABUSE; GENERAL-POPULATION; SOMATOFORM DISSOCIATION; PSYCHOMETRIC CHARACTERISTICS; AFFECT DYSREGULATION; TRAUMA; SYMPTOMS; QUESTIONNAIRE; STUDENTS; CHILDREN","Objective. - The purpose of this study was to examine psychometric properties of the Czech language version of the Adolescent Dissociative Experiences Scale (A-DES) [2]. Method. - 653 non-clinical participants and 162 adolescent psychiatric inpatients completed Czech versions of the A-DES and the Somatoform Dissociation Questionnaire (SDQ-20), and provided further information (data regarding demographic variables, diagnoses, further psychopathology). Results. - The Czech A-DES has very good internal consistency, test-retest reliability and a good validity, though its predictive power is limited. The ADES scores significantly correlate with the measure of somatoform dissociation, a presence of clinician-observed dissociative symptoms, reported traumatic experiences, self injurious behavior, and polysymptomatic diagnostic picture. A-DES scores were significantly higher in ADHD group, but not in a group with a diagnosis of a dissociative disorder. Conclusion. - The authors stress that all adolescent psychiatric patients who show more complex behavioral disturbances, have histories of trauma, show self-injurious behaviors or have ADHD diagnosis should be screened for dissociation. (C) 2010 Elsevier Masson SAS. All rights reserved.","[Soukup, J.] Gen Teaching Hosp, Dependency Treatment Ctr, Prague, Czech Republic; [Papezova, H.] Charles Univ Prague, Med Sch 1, Psychiat Clin, Prague, Czech Republic; [Kubena, A. A.] Charles Univ Prague, Sch Pharm, Dept Social & Clin Pharm, Hradec Kralove, Czech Republic; [Kubena, A. A.] Charles Univ Prague, Sch Nat Sci, Dept Philosophy & Hist Sci, Prague, Czech Republic; [Mikolajova, V.] Charles Univ Prague, Med Sch 2, Child Psychiat Clin, Prague, Czech Republic","Soukup, J (reprint author), Oddeleni Lecby Zavislosti VFN, Apolinarska 4, Prague 12000, Czech Republic.","honzasoukup@yahoo.com",null,null,null,null,null,35,2,2,"ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER","PARIS","23 RUE LINOIS, 75724 PARIS, FRANCE","0924-9338",null,null,"EUR PSYCHIAT","Eur. Psychiat.","NOV",2010,25,7,null,null,null,null,390,395,null,"10.1016/j.eurpsy.2010.03.011",null,6,"Psychiatry","Psychiatry","689IH","WOS:000284920800005"]
[null,null,null,null,"J","Mrazova, M; Celec, P",null,null,null,"Mrazova, Marcela; Celec, Peter",null,null,"A Systematic Review of Randomized Controlled Trials Using Music Therapy for Children","JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE",null,null,"English","Review",null,null,null,null,null,null,"INTERACTIVE MUSIC; PRETERM INFANTS; LIVE MUSIC; ADOLESCENTS; AUTISM; BRAIN; BEHAVIORS; ATTENTION; ANXIETY; STRESS","Background: Music therapy is a promising approach widening the potential applications of psychotherapy. Music influences both, psychologic and physiologic parameters, and children are especially responsive to this form of therapy. Many aspects of its action mechanisms remain to be elucidated, underscoring the need for evidence-based medicine (EBM) for clinical use of music therapy. Aims: This review seeks to highlight some of the issues of music therapy research and to initiate a discussion about the need for international multicenter cooperation to bring scientifically sound evidence of the benefits of music therapy in pediatric patients. Methods: Scientific bibliographic databases were searched for randomized controlled trials on use of music therapy for children. Identified articles were evaluated according to criteria for scientific quality. Results: Twenty-eight studies were identified. Most of the trials were biased by the number of participants, and some trials showed the need to improve design of control groups. Indeed, the novelty of this area of study has produced a large number of different studies (with variability in diagnoses, interventions, control groups, duration, and/or outcome parameters), and there is a need for a more homogeneous and systematic approach. Available studies highlight the need to address reproducibility issues. Conclusions: This analysis identifies the need for a subsequent series of clinical studies on the efficacy of music in the pediatric population, with more focus on eligibility criteria with respect to EBM and reproducibility.","[Celec, Peter] Comenius Univ, Inst Mol Biomed, Bratislava 81108, Slovakia; [Mrazova, Marcela] Charles Univ Prague, Dept Child Psychiat, Med Sch 2, Prague, Czech Republic; [Celec, Peter] Comenius Univ, Inst Pathophysiol, Bratislava 81108, Slovakia; [Celec, Peter] Comenius Univ, Dept Mol Biol, Bratislava 81108, Slovakia","Celec, P (reprint author), Comenius Univ, Inst Mol Biomed, Sasinkova 4, Bratislava 81108, Slovakia.","petercelec@gmail.com",null,null,null,null,null,54,2,2,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1075-5535",null,null,"J ALTERN COMPLEM MED","J. Altern. Complement Med.","OCT",2010,16,10,null,null,null,null,1089,1095,null,"10.1089/acm.2009.0430",null,7,"Integrative & Complementary Medicine","Integrative & Complementary Medicine","665SH","WOS:000283055300012"]
[null,null,null,null,"J","Babjuk, M",null,null,null,"Babjuk, Marko",null,null,"New Insights in Intravesical Treatment for Intermediate- and High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma","EUROPEAN UROLOGY",null,null,"English","Editorial Material",null,null,null,null,null,null,"CANCER",null,"Charles Univ Prague, Fac Med 2&1, Dept Urol, FN Motol, Prague 15006 5, Czech Republic","Babjuk, M (reprint author), Charles Univ Prague, Fac Med 2&1, Dept Urol, FN Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","marek.babjuk@lfmotol.cuni.cz",null,null,null,null,null,8,2,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","MAY",2010,57,5,null,null,null,null,774,776,null,"10.1016/j.eururo.2010.01.004",null,3,"Urology & Nephrology","Urology & Nephrology","571GK","WOS:000275739600009"]
[null,null,null,null,"J","Antonova, P; Jacobs, DI; Bojar, M; Cerny, R; Ciharova, K; Frick, MA; Fintel, B; DeHovitz, J; Bennett, CL",null,null,null,"Antonova, Petra; Jacobs, Daniel I.; Bojar, Martin; Cerny, Rudolf; Ciharova, Katerina; Frick, Melissa A.; Fintel, Bara; DeHovitz, Jack; Bennett, Charles L.",null,null,"Czech health two decades on from the Velvet Revolution","LANCET",null,null,"English","Editorial Material",null,null,null,null,null,null,null,null,"[Bennett, Charles L.] Northwestern Univ, Feinberg Sch Med, Dept Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Antonova, Petra] Univ Hosp Motol, Ctr Cardiovasc, Prague, Czech Republic; [Jacobs, Daniel I.; Frick, Melissa A.; Fintel, Bara; Bennett, Charles L.] Northwestern Univ, Feinberg Sch Med, Buehler Ctr Aging Hlth & Soc, Chicago, IL 60611 USA; [Bojar, Martin; Cerny, Rudolf] Charles Univ Prague, Dept Neurol, Prague, Czech Republic; [DeHovitz, Jack] Suny Downstate Med Ctr, Sch Publ Hlth, Brooklyn, NY 11203 USA; [Ciharova, Katerina] Innovat Leadership Advisors, Prague, Czech Republic","Bennett, CL (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.","cbenne@northwestern.edu","Cerny, Rudolf/C-7759-2014",null,null,null,null,8,2,2,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0140-6736",null,null,"LANCET","Lancet","JAN 16",2010,375,9710,null,null,null,null,179,181,null,"10.1016/S0140-6736(09)61293-9",null,3,"Medicine, General & Internal","General & Internal Medicine","546ZH","WOS:000273853800008"]
[null,null,null,null,"J","Gappa, M; Noel, JL; Severin, T; Paton, JY",null,null,null,"Gappa, M.; Noel, J-L.; Severin, T.; Paton, J. Y.",null,"Paediat HERMES Task Force","European Curriculum Recommendations for Training in Paediatric Respiratory Medicine: one step further","EUROPEAN RESPIRATORY JOURNAL",null,null,"English","Editorial Material",null,null,null,null,null,null,"HERMES; SYLLABUS",null,"[Gappa, M.] Hannover Med Sch, D-30625 Hannover, Germany; [Noel, J-L.; Severin, T.] ERS Headquarters, Lausanne, Switzerland; [Paton, J. Y.] Univ Glasgow, Div Dev Med, Glasgow, Lanark, Scotland","Gappa, M (reprint author), Hannover Med Sch, Carl Neuberg Str 1, D-30625 Hannover, Germany.","gappa@marien-hospital-wesel.de","Eber, Ernst/B-6381-2012; Paton, James/B-9541-2008",null,null,null,"GAPPA M, 2010, BREATHE IN PRESS, V7; Gappa M, 2009, EUR RESPIR J, V33, P464, DOI 10.1183/09031936.00001209; GAPPA M, 2009, BREATHE, V5, P236; Gappa M, 2010, PAEDIATR RESPIR REV, V11, P64, DOI 10.1016/j.prrv.2009.11.003; Gappa M, 2010, PEDIATR PULM, V45, P14, DOI 10.1002/ppul.21165; Loddenkemper R, 2008, EUR RESPIR J, V32, P538, DOI 10.1183/09031936.00090908; Loddenkemper R, 2006, EUR RESPIR J, V28, P470, DOI 10.1183/09031936.06.00084306; Zach MS, 2002, EUR RESPIR J, V20, P1587, DOI 10.1183/09031936.02.00401102",8,2,2,"EUROPEAN RESPIRATORY SOC JOURNALS LTD","SHEFFIELD","442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND","0903-1936",null,null,"EUR RESPIR J","Eur. Resp. J.","SEP",2010,36,3,null,null,null,null,478,479,null,"10.1183/09031936.00097410",null,2,"Respiratory System","Respiratory System","658DI","WOS:000282470000006"]
[null,null,null,null,"J","Gappa, M",null,null,null,"Gappa, M.",null,"Paediat HERMES ERS Task Force","Paediatric Respiratory Medicine - The European Perspective","PAEDIATRIC RESPIRATORY REVIEWS",null,null,"English","Editorial Material",null,null,null,null,null,null,"SYLLABUS",null,null,null,null,"Eber, Ernst/B-6381-2012",null,null,null,"Gappa M, 2009, EUR RESPIR J, V33, P464, DOI 10.1183/09031936.00001209; GAPPA M, 2009, BREATHE, V5, P236; Loddenkemper R, 2006, BREATHE, V3, P59; Zach MS, 2002, EUR RESPIR J, V20, P1587, DOI 10.1183/09031936.02.00401102",4,2,2,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","1526-0542",null,null,"PAEDIATR RESPIR REV","Paediatr. Respir. Rev.","MAR",2010,11,1,null,null,null,null,64,65,null,"10.1016/j.prrv.2009.11.003",null,2,"Pediatrics; Respiratory System","Pediatrics; Respiratory System","581UM","WOS:000276550300013"]
[null,null,null,null,"J","Zemanek, D; Svab, P; Veselka, J",null,null,null,"Zemanek, David; Svab, Premysl; Veselka, Josef",null,null,"Power Doppler Myocardial Contrast Echocardiography in Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy","CLINICAL CARDIOLOGY",null,null,"English","Editorial Material",null,null,null,null,null,null,null,null,"[Zemanek, David; Svab, Premysl; Veselka, Josef] Univ Hosp Motol, Dept Cardiol, Prague, Czech Republic","Zemanek, D (reprint author), Univ Hosp Motol, Dept Cardiol, Prague, Czech Republic.","zejada@seznam.cz",null,null,null,null,null,0,0,0,"JOHN WILEY & SONS INC","HOBOKEN","111 RIVER ST, HOBOKEN, NJ 07030 USA","0160-9289",null,null,"CLIN CARDIOL","Clin. Cardiol.","DEC",2010,33,12,null,null,null,null,"E82","E82",null,"10.1002/clc.20656",null,1,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","703KT","WOS:000285977500017"]
[null,null,null,null,"J","Mohapl, M; Vanek, P; Bradac, O; Horinek, D; Saur, K; Mohaplova, M",null,null,null,"Mohapl, M.; Vanek, P.; Bradac, O.; Horinek, D.; Saur, K.; Mohaplova, M.",null,null,"Comparison of the Benefits of the Lumbar Infusion Test and Lumbar Drainage in the Treatment of Hydrocephalus","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"normal pressure hydrocephalus; lumbar infusion test; external lumbar drainage","NORMAL-PRESSURE HYDROCEPHALUS; CEREBROSPINAL-FLUID; PREDICTIVE VALUE; SHUNT SURGERY; CSF DRAINAGE","The authors present the results of a prospective study comparing the benefits of the lumbar infusion test and external lumbar drainage in the diagnosis of normal-pressure hydrocephalus. Over a period of 24 months, 60 patients (age 29-83, average 66.5) were examined. The main symptom was gait impairment (53 patients), while disturbances of memory were noted in 44 subjects and incontinence in 36 individuals. All three were present in 28 subjects. A lumbar infusion test was performed on all patients, with a resistance to outflow >12 mmHg/ml/min or more considered as the level of cerebrospinal fluid resorption impairment. A lumbar infusion test followed immediately after the lumbar infusion test procedure and the effect of cerebrospinal fluid derivation was evaluated after 120 hours. The lumbar infusion test was positive in 23 subjects and 19 individuals in this group showed significant improvement after external lumbar drainage, while no significant improvement was observed in 4 of them. In the group with negative lumbar infusion test, an improvement was noted in 12 of the 37 subjects. The lumbar infusion test is a simple and effective method of diagnostic evaluation in patients in whom a diagnosis of normal-pressure hydrocephalus is suspected. Due to lower sensitivity, the diagnostic algorithm should also include lumbar drainage test in the event of negative or borderline results.","[Mohapl, M.; Vanek, P.; Bradac, O.; Horinek, D.; Saur, K.] UVN Praha, LF UK 1, Neurochirurg Klin, Prague 16902, Czech Republic; [Mohapl, M.; Vanek, P.; Bradac, O.; Horinek, D.; Saur, K.] UVN Praha, IPVZ, Prague 16902, Czech Republic; [Mohaplova, M.] 2 LF UK, Detska Psychiat Klin, Prague, Czech Republic; [Mohaplova, M.] FN Motole, Prague, Czech Republic","Mohapl, M (reprint author), UVN Praha, LF UK 1, Neurochirurg Klin, Vojenske Nemocnice 1 200, Prague 16902, Czech Republic.","milan.mohapl@gmail.com",null,null,null,null,null,30,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2010,73,6,null,null,null,null,685,688,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","696MY","WOS:000285446700008"]
[null,null,null,null,"J","Ramsey, BW; Davies, J; McElvaney, NG; Tullis, E; Bell, SC; Drevinek, P; Griese, M; McKone, EF; Wainwright, CE; Konstan, MW; Moss, R; Ratjen, F; Sermet-Gaudelus, I; Rowe, SM; Dong, QM; Rodriguez, S; Yen, K; Ordonez, C; Elborn, JS",null,null,null,"Ramsey, Bonnie W.; Davies, Jane; McElvaney, N. Gerard; Tullis, Elizabeth; Bell, Scott C.; Drevinek, Pavel; Griese, Matthias; McKone, Edward F.; Wainwright, Claire E.; Konstan, Michael W.; Moss, Richard; Ratjen, Felix; Sermet-Gaudelus, Isabelle; Rowe, Steven M.; Dong, Qunming; Rodriguez, Sally; Yen, Karl; Ordonez, Claudia; Elborn, J. Stuart",null,"VX08 770 102 Study Grp","A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"RANDOMIZED CONTROLLED-TRIAL; PSEUDOMONAS-AERUGINOSA; PULMONARY-FUNCTION; IDENTIFICATION; QUESTIONNAIRE; AZITHROMYCIN; MECHANISMS; GUIDELINES; HEALTH; VX-770","Background Increasing the activity of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein is a potential treatment for cystic fibrosis. Methods We conducted a randomized, double-blind, placebo-controlled trial to evaluate ivacaftor (VX-770), a CFTR potentiator, in subjects 12 years of age or older with cystic fibrosis and at least one G551D-CFTR mutation. Subjects were randomly assigned to receive 150 mg of ivacaftor every 12 hours (84 subjects, of whom 83 received at least one dose) or placebo (83, of whom 78 received at least one dose) for 48 weeks. The primary end point was the estimated mean change from baseline through week 24 in the percent of predicted forced expiratory volume in 1 second (FEV1). Results The change from baseline through week 24 in the percent of predicted FEV1 was greater by 10.6 percentage points in the ivacaftor group than in the placebo group (P < 0.001). Effects on pulmonary function were noted by 2 weeks, and a significant treatment effect was maintained through week 48. Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P < 0.001). In addition, through week 48, subjects in the ivacaftor group scored 8.6 points higher than did subjects in the placebo group on the respiratory-symptoms domain of the Cystic Fibrosis Questionnaire-revised instrument (a 100-point scale, with higher numbers indicating a lower effect of symptoms on the patient's quality of life) (P < 0.001). By 48 weeks, patients treated with ivacaftor had gained, on average, 2.7 kg more weight than had patients receiving placebo (P < 0.001). The change from baseline through week 48 in the concentration of sweat chloride, a measure of CFTR activity, with ivacaftor as compared with placebo was -48.1 mmol per liter (P < 0.001). The incidence of adverse events was similar with ivacaftor and placebo, with a lower proportion of serious adverse events with ivacaftor than with placebo (24% vs. 42%). Conclusions Ivacaftor was associated with improvements in lung function at 2 weeks that were sustained through 48 weeks. Substantial improvements were also observed in the risk of pulmonary exacerbations, patient-reported respiratory symptoms, weight, and concentration of sweat chloride. (Funded by Vertex Pharmaceuticals and others; VX08-770-102 ClinicalTrials.gov number, NCT00909532.)","[Ramsey, Bonnie W.] Univ Washington, Dept Pediat, Seattle, WA 98105 USA; [Davies, Jane] Royal Brompton & Harefield Natl Hlth Serv Fdn Tru, Res Biomed Res Unit, London, England; [McElvaney, N. Gerard] Beaumont Hosp, Royal Coll Surg Ireland, Beaumont, TX USA; [McKone, Edward F.; Wainwright, Claire E.] St Vincents Univ Hosp, Dublin 4, Ireland; [Ratjen, Felix] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Bell, Scott C.] Prince Charles Hosp, Dept Thorac Med, Brisbane, Qld 4032, Australia; [Bell, Scott C.; Wainwright, Claire E.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Drevinek, Pavel] Charles Univ Prague, Dept Pediat, Sch Med 2, Prague, Czech Republic; [Griese, Matthias] Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; [Konstan, Michael W.] Case Western Reserve Univ, Sch Med, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Moss, Richard] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Tullis, Elizabeth] Univ Toronto, St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Sermet-Gaudelus, Isabelle] Hop Necker Enfants Malad, Ctr Invest Clin, Paris, France; [Rowe, Steven M.] Univ Alabama Birmingham, Birmingham, AL USA; [Dong, Qunming; Rodriguez, Sally; Yen, Karl; Ordonez, Claudia] Vertex Pharmaceut, Cambridge, MA USA; [Elborn, J. Stuart] Queens Univ Belfast, Ctr Infect & Immun, Belfast, Antrim, North Ireland; [Ramsey, Bonnie W.] Seattle Childrens Hosp, Seattle, WA USA","Ramsey, BW (reprint author), Univ Washington, Dept Pediat, 4800 Sand Point Way NE,Box 5371, Seattle, WA 98105 USA.","bonnie.ramsey@seattlechildrens.org","McElvaney, Noel/A-6809-2010; Bell, Scott/A-7241-2011; Gough, Ethan/B-8633-2012; Serisier, David/C-6986-2012","Bell, Scott/0000-0001-8651-7139; Serisier, David/0000-0002-7484-7904","Vertex Pharmaceuticals; National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton; Harefield National Health Service Foundation Trust; Imperial College London; Cystic Fibrosis Foundation Therapeutic Development Center; Institute for Translational Health Sciences; National Center for Research Resources of the National Institutes of Health (NIH) [UL1 RR025014, UL1 RR024153, UL1 RR 025005]; Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center; Clinical Translational Research Center [UL1-RR-024134]; NIH [UL1 RR024989, P30 DK27651, UL1 RR 025758, K23 DK075788, 5UL1 RR025777, 1UL1 RR025744]; Northern Ireland Clinical Research Network (Respiratory Medicine);  [VX08-770-102]","Funded by Vertex Pharmaceuticals and others; VX08-770-102 ClinicalTrials.gov number, NCT00909532.Supported by Vertex Pharmaceuticals; grants from the National Institute for Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield National Health Service Foundation Trust and Imperial College London; grants from the Cystic Fibrosis Foundation Therapeutic Development Center; the Institute for Translational Health Sciences; the National Center for Research Resources of the National Institutes of Health (NIH) (UL1 RR025014 to the University of Washington, UL1 RR024153 to Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center, and UL1 RR 025005 to Johns Hopkins University); the Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center (to Seattle Children's Hospital); Clinical Translational Research Center (UL1-RR-024134 to the University of Pennsylvania/Children's Hospital of Philadelphia); and the NIH (UL1 RR024989 and P30 DK27651 to Case Western Reserve University, UL1 RR 025758 to Children's Hospital Boston, K23 DK075788 and 5UL1 RR025777 to the University of Alabama at Birmingham, and 1UL1 RR025744 to Stanford University); and an infrastructure grant from Northern Ireland Clinical Research Network (Respiratory Medicine).",null,26,193,197,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","NOV 3",2011,365,18,null,null,null,null,1663,1672,null,null,null,10,"Medicine, General & Internal","General & Internal Medicine","840FL","WOS:000296424200005"]
[null,null,null,null,"J","Granger, CB; Alexander, JH; McMurray, JJV; Lopes, RD; Hylek, EM; Hanna, M; Al-Khalidi, HR; Ansell, J; Atar, D; Avezum, A; Bahit, MC; Diaz, R; Easton, JD; Ezekowitz, JA; Flaker, G; Garcia, D; Geraldes, M; Gersh, BJ; Golitsyn, S; Goto, S; Hermosillo, AG; Hohnloser, SH; Horowitz, J; Mohan, P; Jansky, P; Lewis, BS; Lopez-Sendon, JL; Pais, P; Parkhomenko, A; Verheugt, FWA; Zhu, J; Wallentin, L",null,null,null,"Granger, Christopher B.; Alexander, John H.; McMurray, John J. V.; Lopes, Renato D.; Hylek, Elaine M.; Hanna, Michael; Al-Khalidi, Hussein R.; Ansell, Jack; Atar, Dan; Avezum, Alvaro; Cecilia Bahit, M.; Diaz, Rafael; Easton, J. Donald; Ezekowitz, Justin A.; Flaker, Greg; Garcia, David; Geraldes, Margarida; Gersh, Bernard J.; Golitsyn, Sergey; Goto, Shinya; Hermosillo, Antonio G.; Hohnloser, Stefan H.; Horowitz, John; Mohan, Puneet; Jansky, Petr; Lewis, Basil S.; Luis Lopez-Sendon, Jose; Pais, Prem; Parkhomenko, Alexander; Verheugt, Freek W. A.; Zhu, Jun; Wallentin, Lars",null,"ARISTOTLE Comm Investigators","Apixaban versus Warfarin in Patients with Atrial Fibrillation","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"ANTICOAGULANT-THERAPY; TRIAL; DABIGATRAN; EVENTS; STROKE; RISK","Background Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin. Methods In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause. Results The median duration of follow-up was 1.8 years. The rate of the primary outcome was 1.27% per year in the apixaban group, as compared with 1.60% per year in the warfarin group (hazard ratio with apixaban, 0.79; 95% confidence interval [CI], 0.66 to 0.95; P<0.001 for noninferiority; P=0.01 for superiority). The rate of major bleeding was 2.13% per year in the apixaban group, as compared with 3.09% per year in the warfarin group (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P<0.001), and the rates of death from any cause were 3.52% and 3.94%, respectively (hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P=0.047). The rate of hemorrhagic stroke was 0.24% per year in the apixaban group, as compared with 0.47% per year in the warfarin group (hazard ratio, 0.51; 95% CI, 0.35 to 0.75; P<0.001), and the rate of ischemic or uncertain type of stroke was 0.97% per year in the apixaban group and 1.05% per year in the warfarin group (hazard ratio, 0.92; 95% CI, 0.74 to 1.13; P=0.42). Conclusions In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. (Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.govnumber, NCT00412984.)","[Granger, Christopher B.; Alexander, John H.; Lopes, Renato D.; Al-Khalidi, Hussein R.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27715 USA; [McMurray, John J. V.] Univ Glasgow, Glasgow, Lanark, Scotland; [Hylek, Elaine M.] Boston Univ, Med Ctr, Boston, MA USA; [Hanna, Michael; Geraldes, Margarida; Mohan, Puneet] Bristol Myers Squibb Co, Princeton, NJ USA; [Ansell, Jack] Lenox Hill Hosp, New York, NY 10021 USA; [Atar, Dan] Oslo Univ Hosp, Oslo, Norway; [Avezum, Alvaro] Dante Pazzanese Inst Cardiol, Sao Paulo, Brazil; [Cecilia Bahit, M.; Diaz, Rafael] ECLA Estudios Cardiol Latinoamer, Rosario, Santa Fe, Argentina; [Easton, J. Donald] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Ezekowitz, Justin A.] Univ Alberta, Edmonton, AB, Canada; [Flaker, Greg] Univ Missouri Hlth Care, Columbia, MO USA; [Garcia, David] Univ New Mexico, Albuquerque, NM 87131 USA; [Gersh, Bernard J.] Mayo Clin, Rochester, MN USA; [Golitsyn, Sergey] Russian Cardiol Res Ctr, Moscow, Russia; [Goto, Shinya] Tokai Univ, Sch Med, Kanagawa 2591100, Japan; [Hermosillo, Antonio G.] Inst Nacl Cardiol, Tlalpan Cp, Mexico; [Hohnloser, Stefan H.] Goethe Univ Frankfurt, Frankfurt, Germany; [Horowitz, John] Univ Adelaide, Adelaide, SA, Australia; [Jansky, Petr] Motol Univ Hosp, Prague, Czech Republic; [Lewis, Basil S.] Lady Davis Carmel Med Ctr, Haifa, Israel; [Luis Lopez-Sendon, Jose] Hosp Univ La Paz, Madrid, Spain; [Pais, Prem] St Johns Med Coll, Bangalore, Karnataka, India; [Parkhomenko, Alexander] Inst Cardiol, Kiev, Ukraine; [Verheugt, Freek W. A.] Onze Lieve Vrouw Hosp, Amsterdam, Netherlands; [Zhu, Jun] Fuwai Hosp, Beijing, Peoples R China; [Wallentin, Lars] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden","Granger, CB (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, DUMC Box 3850, Durham, NC 27715 USA.","christopher.granger@duke.edu","FENICI, RICCARDO/J-4628-2012; Ezekowitz, Justin/C-4579-2013; Walters, Darren/A-7069-2011; Granger, Christopher/D-3458-2014","FENICI, RICCARDO/0000-0002-4664-2653; Granger, Christopher/0000-0002-0045-3291","Bristol-Myers Squibb; Pfizer; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim, GlaxoSmithKline; Medtronic Foundation; Merck; Sanofi-Aventis; Astellas; Hoffmann-La Roche; Novartis; Otsuka Pharmaceutical; Medicines Company; Merck/Schering-Plough; Regado Biosciences; Ortho-McNeil-Janssen; PolyMedix; Bayer; Daiichi Sankyo; Johnson Johnson; GlaxoSmithKline; Amgen; Abbott; Servier; Amorcyte; Abbott Laboratories; GE Healthcare; St. Jude Medical, Medispec; Boston Scientific; Otuska; Otuska, Eisai; Medtronics-Japan; Tanabe-Mitsubishi; Takeda; Mochida; MSD; Cardiome; St. Jude Medical; Medtronic Vascular; Regado Biotechnologies; Portola; CSL Behring; Athera Biotechnologies; Schering-Plough;  [NCT00412984]","Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.govnumber, NCT00412984.Dr. Granger reports receiving grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, the Medtronic Foundation, Merck, Sanofi-Aventis, Astellas, and the Medicines Company, consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann-La Roche, Novartis, Otsuka Pharmaceutical, Sanofi-Aventis, and the Medicines Company, and support from the Medtronic Foundation and Merck for travel, accommodations, or meeting expenses; Dr. Alexander, receiving grants from Merck/Schering-Plough and Regado Biosciences and consulting fees from Merck/Schering-Plough, AstraZeneca, Boehringer Ingelheim, Ortho-McNeil-Janssen, PolyMedix, Regado Biosciences, and Bayer; Dr. Lopes, receiving grants from Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo and consulting fees from Bristol-Myers Squibb; Dr. Hylek, receiving consulting fees from Johnson & Johnson, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Merck, Pfizer, and Ortho-McNeil-Janssen and lecture fees from Boehringer Ingelheim; Dr. Hanna, being an employee of Bristol-Myers Squibb and receiving stock as part of his compensation; Dr. Ansell, being a member of Bristol-Myers Squibb's data and safety monitoring boards, receiving consulting fees from Ortho-McNeil-Janssen, Daiichi Sankyo, Boehringer Ingelheim, and Bristol-Myers Squibb, and receiving payments from Daiichi Sankyo for developing educational presentations; Dr. Atar, receiving consulting fees or honoraria from Bristol-Myers Squibb; Dr. Avezum, receiving consulting fees from Boehringer Ingelheim and GlaxoSmithKline; Dr. Bahit, receiving consulting fees or honoraria and other research support from Bristol-Myers Squibb; Dr. Diaz, receiving consulting fees or honoraria and other research support from Bristol-Myers Squibb; Dr. Ezekowitz, receiving research support, honoraria, and payments for continuing medical education events from AstraZeneca, Amgen, Abbott, Servier, Johnson & Johnson, Pfizer, and Bristol-Myers Squibb; Dr. Flaker, receiving consulting fees from Boehringer Ingelheim and Sanofi-Aventis and grants from Boehringer Ingelheim and Sanofi-Aventis; Dr. Garcia, receiving consulting fees from Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, and Daiichi Sankyo and payments from Boehringer Ingelheim for developing educational presentations; Dr. Geraldes, being an employee of Bristol-Myers Squibb and receiving stock or stock options annually; Dr. Gersh, receiving consulting fees from Ortho-McNeil-Janssen, Amorcyte, Abbott Laboratories, GE Healthcare, St. Jude Medical, Medispec, Merck, and Boston Scientific; Dr. Goto, being a board member of Bristol-Myers Squibb and Sanofi-Aventis, receiving grants from Boehringer Ingelheim, Otuska, Eisai, Sanofi-Aventis, and Daiichi Sankyo, consulting fees from Eisai, lecture fees from Eisai, Otsuka, Daiichi Sankyo, Sanofi-Aventis, Bayer, Novartis, AstraZeneca, Asteras, Pfizer, Medtronics-Japan, Tanabe-Mitsubishi, Takeda, Mochida, and MSD, and payments from Bayer and Sanofi-Aventis for developing educational presentations; Dr. Hermosillo, receiving consulting fees or honoraria from Bristol-Myers Squibb; Dr. Hohnloser, receiving consulting fees from Sanofi-Aventis, St. Jude Medical, Boehringer Ingelheim, Cardiome, and Medtronic Vascular and lecture fees from Sanofi-Aventis, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, and St. Jude Medical; Dr. Horowitz, receiving research support from Bristol-Myers Squibb; Dr. Mohan, being an employee of Bristol-Myers Squibb and receiving performance-based stock or stock options annually; Dr.Lewis, being an dvisory board member for Bayer Healthcare; Dr. Lopez-Sendon, receiving grants from Bristol-Myers Squibb, Boehringer Ingelheim, and Bayer and consulting fees from Boehringer Ingelheim; Dr. Parkhomenko, receiving consulting; fees and grants from Borshchiagovsky Chemical-Pharmaceutical Plant; Dr. Verheugt, receiving lecture fees from Bayer and AstraZeneca and consulting fees from Bayer and Daiichi Sankyo; and Dr. Wallentin, receiving grants from Bristol-Myers Squibb, Pfizer, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Schering-Plough, and Merck, consulting fees from Regado Biotechnologies, Portola, CSL Behring, Athera Biotechnologies, Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline, and lecture fees from Bristol-Myers Squibb, Pfizer, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Schering-Plough, and Merck. No other potential conflict of interest relevant to this article was reported.",null,16,864,902,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","SEP 15",2011,365,11,null,null,null,null,981,992,null,"10.1056/NEJMoa1107039",null,12,"Medicine, General & Internal","General & Internal Medicine","819UR","WOS:000294857300006"]
[null,null,null,null,"J","Connolly, SJ; Eikelboom, J; Joyner, C; Diener, HC; Hart, R; Golitsyn, S; Flaker, G; Avezum, A; Hohnloser, SH; Diaz, R; Talajic, M; Zhu, J; Pais, P; Budaj, A; Parkhomenko, A; Jansky, P; Commerford, P; Tan, RS; Sim, KH; Lewis, BS; Van Mieghem, W; Lip, GYH; Kim, JH; Lanas-Zanetti, F; Gonzalez-Hermosillo, A; Dans, AL; Munawar, M; O'Donnell, M; Lawrence, J; Lewis, G; Afzal, R; Yusuf, S",null,null,null,"Connolly, Stuart J.; Eikelboom, John; Joyner, Campbell; Diener, Hans-Christoph; Hart, Robert; Golitsyn, Sergey; Flaker, Greg; Avezum, Alvaro; Hohnloser, Stefan H.; Diaz, Rafael; Talajic, Mario; Zhu, Jun; Pais, Prem; Budaj, Andrzej; Parkhomenko, Alexander; Jansky, Petr; Commerford, Patrick; Tan, Ru San; Sim, Kui-Hian; Lewis, Basil S.; Van Mieghem, Walter; Lip, Gregory Y. H.; Kim, Jae Hyung; Lanas-Zanetti, Fernando; Gonzalez-Hermosillo, Antonio; Dans, Antonio L.; Munawar, Muhammad; O'Donnell, Martin; Lawrence, John; Lewis, Gayle; Afzal, Rizwan; Yusuf, Salim",null,null,"Apixaban in Patients with Atrial Fibrillation","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"ANTITHROMBOTIC THERAPY; KNEE REPLACEMENT; PREVENT STROKE; WARFARIN; ASPIRIN; TRIAL; THROMBOPROPHYLAXIS; ANTICOAGULATION; METAANALYSIS; CLOPIDOGREL","BACKGROUND Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many patients are not suitable candidates for or are unwilling to receive vitamin K antagonist therapy, and these patients have a high risk of stroke. Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients. METHODS In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to determine whether apixaban was superior. The mean follow up period was 1.1 years. The primary outcome was the occurrence of stroke or systemic embolism. RESULTS Before enrollment, 40% of the patients had used a vitamin K antagonist. The data and safety monitoring board recommended early termination of the study because of a clear benefit in favor of apixaban. There were 51 primary outcome events (1.6% per year) among patients assigned to apixaban and 113 (3.7% per year) among those assigned to aspirin (hazard ratio with apixaban, 0.45; 95% confidence interval [CI], 0.32 to 0.62; P<0.001). The rates of death were 3.5% per year in the apixaban group and 4.4% per year in the aspirin group (hazard ratio, 0.79; 95% CI, 0.62 to 1.02; P = 0.07). There were 44 cases of major bleeding (1.4% per year) in the apixaban group and 39 (1.2% per year) in the aspirin group (hazard ratio with apixaban, 1.13; 95% CI, 0.74 to 1.75; P = 0.57); there were 11 cases of intracranial bleeding with apixaban and 13 with aspirin. The risk of a first hospitalization for cardiovascular causes was reduced with apixaban as compared with aspirin (12.6% per year vs. 15.9% per year, P<0.001). The treatment effects were consistent among important subgroups. CONCLUSIONS In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing the risk of major bleeding or intracranial hemorrhage.","[Connolly, Stuart J.; Eikelboom, John; Lewis, Gayle; Afzal, Rizwan; Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; [Connolly, Stuart J.; Eikelboom, John; Lewis, Gayle; Afzal, Rizwan; Yusuf, Salim] Hamilton Hlth Sci, Hamilton, ON, Canada; [Joyner, Campbell] Univ Toronto, Toronto, ON, Canada; [Diener, Hans-Christoph] Univ Duisburg Essen, Essen, Germany; [Hart, Robert] Univ Texas San Antonio, San Antonio, TX USA; [Golitsyn, Sergey] Russian Cardiol Res & Prod Ctr, Moscow, Russia; [Flaker, Greg] Univ Missouri, Columbia, MO 65211 USA; [Avezum, Alvaro] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil; [Hohnloser, Stefan H.] Goethe Univ Frankfurt, Frankfurt, Germany; [Diaz, Rafael] Estudios Clin Latinoamer, Rosario, Argentina; [Talajic, Mario] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada; [Zhu, Jun] Chinese Acad Med Sci, FuWai Hosp, Beijing 100037, Peoples R China; [Zhu, Jun] Peking Union Med Coll, Beijing 100021, Peoples R China; [Pais, Prem] St Johns Med Coll, Bangalore, Karnataka, India; [Pais, Prem] Res Inst, Bangalore, Karnataka, India; [Budaj, Andrzej] Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland; [Parkhomenko, Alexander] Inst Cardiol, Kiev, Ukraine; [Jansky, Petr] Univ Hosp Motol, Prague, Czech Republic; [Commerford, Patrick] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa; [Sim, Kui-Hian] Clin Res Ctr, Sarawak, Malaysia; [Tan, Ru San] Natl Heart Ctr, Singapore, Singapore; [Lewis, Basil S.] Lady Davis Carmel Med Ctr, Haifa, Israel; [Van Mieghem, Walter] Ziekenhuis Oost Limburg Campus, St Jan, Genk, Belgium; [Lip, Gregory Y. H.] City Hosp, Birmingham, W Midlands, England; [Kim, Jae Hyung] Catholic Univ Korea, St Pauls Hosp, Seoul, South Korea; [Lanas-Zanetti, Fernando] Univ La Frontera, Temuco, Chile; [Gonzalez-Hermosillo, Antonio] Inst Nacl Cardiol Ignacio Chavez, Mexico City, DF, Mexico; [Dans, Antonio L.] Univ Philippines, Coll Med, Manila, Philippines; [Munawar, Muhammad] Harapan Kita Hosp, Jakarta, Indonesia; [O'Donnell, Martin] HRB Clin Res Facil, Galway, Ireland; [Lawrence, John] Bristol Myers Squibb Co, Princeton, NJ USA","Connolly, SJ (reprint author), McMaster Univ, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.","stuart.connolly@phri.ca",null,null,"Boehringer Ingelheim; Sanofi-Aventis; Portola; Merck; Eli Lilly; AstraZeneca; Novartis; Bristol-Myers Squibb; Abbott; Bayer Vital; CoAxia; D-Pharm; Fresenius; GlaxoSmithKline; Janssen-Cilag; Knoll; Merck Sharpe and Dohme; Medtronic; MindFrame; Neurobiological Technologies; Novo-Nordisk; Paion; Parke-Davis; Pfizer; Sankyo; Schering-Plough; Servier; Solvay; Thrombogenics; Wyeth; Yamaguchi; Takeda; Bayer; Borschagovskiy; Astellas; Orion; Daiichi; Biotronic; St. Jude Medical","Dr. Connolly reports receiving payment for serving on the boards of Boehringer Ingelheim, Sanofi-Aventis, Portola, and Merck, consulting fees from Boehringer Ingelheim, Sanofi-Aventis, Portola, and Merck, grant support on behalf of his institution, McMaster University, from Boehringer Ingelheim, Sanofi-Aventis, Portola, and Bristol-Myers Squibb, and lecture fees from Boehringer Ingelheim, Sanofi-Aventis, and Portola; Dr. Eikelboom, receiving consulting fees from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, AstraZeneca, and Novartis and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, and AstraZeneca; Dr. Joyner, receiving honoraria from Hamilton Health Sciences as the cochair of the RELY adjudication committee; Dr. Diener, receiving payment for serving on the boards of Abbott, AstraZeneca, Boehringer Ingelheim, CoAxia, D-Pharm, GlaxoSmithKline, Janssen-Cilag, Medtronic, MindFrame, Neurobiological Technologies, Novartis, Sanofi-Aventis, Servier, and Solvay, consulting fees from Abbott, AstraZeneca, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, CoAxia, D-Pharm, Fresenius, GlaxoSmithKline, Janssen-Cilag, Knoll, Merck Sharpe and Dohme, Medtronic, MindFrame, Neurobiological Technologies, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Sankyo, Schering-Plough, Servier, Solvay, Thrombogenics, Wyeth, and Yamaguchi, grant support on behalf of his institution, University Duisburg-Essen, from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Janssen-Cilag, and Sanofi-Aventis, lecture fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Bayer Vital, Boehringer Ingelheim, CoAxia, D-Pharm, GlaxoSmithKline, Merck Sharpe and Dohme, MindFrame, Neurobiological Technologies, Novartis, Sanofi-Aventis, Servier, Solvay, and Thrombogenics, payment from Boehringer Ingelheim and Sanofi-Aventis for manuscript preparation, and payment from Boehringer Ingelheim for developing educational presentations; Dr. Flaker, receiving payment for serving as a consultant on Bristol-Myers Squibb's advisory board; Dr. Avezum, receiving payment from Boehringer Ingelheim for giving lectures in the Satellite Symposium; Dr. Hohnloser, receiving consulting fees from Boehringer Ingelheim, St. Jude Medical, Sanofi-Aventis, and Cardiome, and lecture fees from Boehringer Ingelheim, St. Jude Medical, Sanofi-Aventis, and Cardiome; Dr. Talajic, receiving consulting fees from Boehringer Ingelheim and Bristol-Myers Squibb, grant support on behalf of his institution, the Montreal Heart Institute, from Boehringer Ingelheim, and lecture fees from Boehringer Ingelheim and Bristol-Myers Squibb; Dr. Budaj, receiving consulting fees from Sanofi-Aventis, Eli Lilly, Novartis, and AstraZeneca, grant support both for himself and on behalf of his institution, Grochowski Hospital, from Sanofi-Aventis, Boehringer Ingelheim, GlaxoSmithKline, Bristol-Myers Squibb, and AstraZeneca, lecture fees from Sanofi-Aventis, Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca, and reimbursement for travel, accommodations, or meeting expenses from Sanofi-Aventis, Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca; Dr. Parkhomenko, receiving consulting fees from AstraZeneca, Merck Sharpe and Dohme, Bayer, Takeda, GlaxoSmithKline, Borschagovskiy, Servier, Sanofi-Aventis, Astellas, and Boehringer Ingelheim, lecture fees from Servier, Orion, GlaxoSmithKline, and Pfizer, and payment from Servier and Pfizer for developing educational presentations; Dr.Commerford, having testified as an expert witness on the importance of anticoagulation in atrial fibrllation, receiving consulting fees from UpToDate and reimbursement for committee meeting expenses on behalf of his institution, the Cardiac Clinic, from Boehringer Ingelheim, Sanofi-Aventis, and Bristol-Myers Squibb; Dr. Tan, receiving payment for serving on a regional advisory board for Bayer; Dr. Lewis, receiving consulting fees from Bristol-Myers Squibb; Dr. Lip, receiving consulting fees from Astellas, Boehringer Ingelheim, Bayer, Daiichi, Merck, Portola, Biotronic, Sanofi-Aventis, and AstraZeneca, grant support on behalf of his institution, City Hospital, from Bayer, lecture fees from Boehringer Ingelheim, Bayer, Merck, and Sanofi-Aventis, and payment from Boehringer Ingelheim for developing educational presentations; Dr. Lawrence, being an employee of Bristol-Myers Squibb; and Dr. Yusuf, receiving consulting fees from Boehringer Ingelheim, Sanofi-Aventis, Novartis, AstraZeneca, Bristol-Myers Squibb, and Glaxo-SmithKline, and grant support from Boehringer Ingelheim, Sanofi-Aventis, Novartis, AstraZeneca, GlaxoSmithKline, and Bristol-Myers Squibb. No other potential conflict of interest relevant to this article was reported.Supported by Bristol-Myers Squibb and Pfizer.",null,25,497,526,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","MAR 3",2011,364,9,null,null,null,null,806,817,null,"10.1056/NEJMoa1007432",null,12,"Medicine, General & Internal","General & Internal Medicine","729DJ","WOS:000287928400006"]
[null,null,null,null,"J","Alexander, JH; Lopes, RD; James, S; Kilaru, R; He, YH; Mohan, P; Bhatt, DL; Goodman, S; Verheugt, FW; Flather, M; Huber, K; Liaw, D; Husted, SE; Lopez-Sendon, J; De Caterina, R; Jansky, P; Darius, H; Vinereanu, D; Cornel, JH; Cools, F; Atar, D; Leiva-Pons, JL; Keltai, M; Ogawa, H; Pais, P; Parkhomenko, A; Ruzyllo, W; Diaz, R; White, H; Ruda, M; Geraldes, M; Lawrence, J; Harrington, RA; Wallentin, L",null,null,null,"Alexander, John H.; Lopes, Renato D.; James, Stefan; Kilaru, Rakhi; He, Yaohua; Mohan, Puneet; Bhatt, Deepak L.; Goodman, Shaun; Verheugt, Freek W.; Flather, Marcus; Huber, Kurt; Liaw, Danny; Husted, Steen E.; Lopez-Sendon, Jose; De Caterina, Raffaele; Jansky, Petr; Darius, Harald; Vinereanu, Dragos; Cornel, Jan H.; Cools, Frank; Atar, Dan; Luis Leiva-Pons, Jose; Keltai, Matyas; Ogawa, Hisao; Pais, Prem; Parkhomenko, Alexander; Ruzyllo, Witold; Diaz, Rafael; White, Harvey; Ruda, Mikhail; Geraldes, Margarida; Lawrence, Jack; Harrington, Robert A.; Wallentin, Lars",null,"APPRAISE-2 Investigators","Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"ST-SEGMENT ELEVATION; FACTOR XA INHIBITOR; HIGH-RISK PATIENTS; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; KNEE REPLACEMENT; DOUBLE-BLIND; ASPIRIN; CLOPIDOGREL; WARFARIN","Background Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. Methods We conducted a randomized, double-blind, placebo-controlled clinical trial comparing apixaban, at a dose of 5 mg twice daily, with placebo, in addition to standard antiplatelet therapy, in patients with a recent acute coronary syndrome and at least two additional risk factors for recurrent ischemic events. Results The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events. With a median follow-up of 241 days, the primary outcome of cardiovascular death, myocardial infarction, or ischemic stroke occurred in 279 of the 3705 patients (7.5%) assigned to apixaban (13.2 events per 100 patient-years) and in 293 of the 3687 patients (7.9%) assigned to placebo (14.0 events per 100 patient-years) (hazard ratio with apixaban, 0.95; 95% confidence interval [CI], 0.80 to 1.11; P = 0.51). The primary safety outcome of major bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) definition occurred in 46 of the 3673 patients (1.3%) who received at least one dose of apixaban (2.4 events per 100 patient-years) and in 18 of the 3642 patients (0.5%) who received at least one dose of placebo (0.9 events per 100 patient-years) (hazard ratio with apixaban, 2.59; 95% CI, 1.50 to 4.46; P = 0.001). A greater number of intracranial and fatal bleeding events occurred with apixaban than with placebo. Conclusions The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events. (Funded by BristolMyers Squibb and Pfizer; APPRAISE-2 ClinicalTrials. gov number, NCT00831441.)","[Alexander, John H.; Lopes, Renato D.; Kilaru, Rakhi; Harrington, Robert A.] Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC 27715 USA; [James, Stefan; Wallentin, Lars] Uppsala Clin Res Ctr, Uppsala, Sweden; [He, Yaohua; Mohan, Puneet; Liaw, Danny; Geraldes, Margarida; Lawrence, Jack] Bristol Myers Squibb Co, Princeton, NJ USA; [Bhatt, Deepak L.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Bhatt, Deepak L.] Vet Affairs Boston Healthcare Syst, Boston, MA USA; [Goodman, Shaun] Canadian Heart Res Ctr, Toronto, ON, Canada; [Verheugt, Freek W.] Onze Lieve Vrouw Hosp, Amsterdam, Netherlands; [Flather, Marcus] Royal Brompton Hosp, Clin Trials & Evaluat Unit, London, England; [Huber, Kurt] Wilhelminenspital Stadt Wien, Vienna, Austria; [Husted, Steen E.] Aarhus Univ Hosp, Dept Cardiol & Med A, Aarhus Amtssygehus, DK-8000 Aarhus, Denmark; [Lopez-Sendon, Jose] Hosp Univ La Paz, Madrid, Spain; [De Caterina, Raffaele] Univ G DAnnunzio, Inst Cardiol, Chieti, Italy; [De Caterina, Raffaele] Univ G DAnnunzio, Univ Cardiol Div, Chieti, Italy; [Jansky, Petr] Motol Univ Hosp, Prague, Czech Republic; [Darius, Harald] Neukoelln Med Ctr, Berlin, Germany; [Vinereanu, Dragos] Univ Hosp Bucharest, Bucharest, Romania; [Cornel, Jan H.] Med Ctr Alkmaar, Alkmaar, Netherlands; [Cools, Frank] Acad Ziekenhuis Klina, Brasschaat, Belgium; [Atar, Dan] Oslo Univ Hosp, Oslo, Norway; [Luis Leiva-Pons, Jose] Hosp Cent Dr Ignacio Morones Prieto, San Luis Potosi, Mexico; [Keltai, Matyas] Hungarian Inst Cardiol, Budapest, Hungary; [Ogawa, Hisao] Kumamoto Univ, Kumamoto, Japan; [Pais, Prem] St Johns Med Coll, Bangalore, Karnataka, India; [Parkhomenko, Alexander] Inst Cardiol, Kiev, Ukraine; [Ruzyllo, Witold] Inst Cardiol, Warsaw, Poland; [Diaz, Rafael] ECLA Estudios Cardiol Latinoamer, Rosario, Santa Fe, Argentina; [White, Harvey] Auckland City Hosp, Green Lane Cardiovasc Res Unit, Auckland, New Zealand; [Ruda, Mikhail] Cardiol Res Ctr, Moscow, Russia; [Flather, Marcus] Harefield NHS Fdn Trust, London, England","Alexander, JH (reprint author), Duke Univ, Duke Clin Res Inst, Med Ctr, DUMC Box 3850, Durham, NC 27715 USA.","john.h.alexander@duke.edu","Avanzas, Pablo/B-6811-2008","Avanzas, Pablo/0000-0002-4958-6108","Bristol-Myers Squibb; Pfizer","Supported by Bristol-Myers Squibb and Pfizer.",null,40,212,217,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","AUG 25",2011,365,8,null,null,null,null,699,708,null,"10.1056/NEJMoa1105819",null,10,"Medicine, General & Internal","General & Internal Medicine","811JM","WOS:000294205300005"]
[null,null,null,null,"J","Sherry, N; Hagopian, W; Ludvigsson, J; Jain, SM; Wahlen, J; Ferry, RJ; Bode, B; Aronoff, S; Holland, C; Carlin, D; King, KL; Wilder, RL; Pillemer, S; Bonvini, E; Johnson, S; Stein, KE; Koenig, S; Herold, KC; Daifotis, AG",null,null,null,"Sherry, Nicole; Hagopian, William; Ludvigsson, Johnny; Jain, Sunil M.; Wahlen, Jack; Ferry, Robert J., Jr.; Bode, Bruce; Aronoff, Stephen; Holland, Christopher; Carlin, David; King, Karen L.; Wilder, Ronald L.; Pillemer, Stanley; Bonvini, Ezio; Johnson, Syd; Stein, Kathryn E.; Koenig, Scott; Herold, Kevan C.; Daifotis, Anastasia G.",null,"Protege Trial Investigators","Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial","LANCET",null,null,"English","Article",null,null,null,null,null,null,"MONOCLONAL-ANTIBODY; INSULIN-SECRETION; IMMUNE THERAPY; MELLITUS","Background Findings of small studies have suggested that short treatments with anti-CD3 monoclonal antibodies that are mutated to reduce Fc receptor binding preserve beta-cell function and decrease insulin needs in patients with recent-onset type 1 diabetes. In this phase 3 trial, we assessed the safety and efficacy of one such antibody, teplizumab. Methods In this 2-year trial, patients aged 8-35 years who had been diagnosed with type 1 diabetes for 12 weeks or fewer were enrolled and treated at 83 clinical centres in North America, Europe, Israel, and India. Participants were allocated (2:1:1:1 ratio) by an interactive telephone system, according to computer-generated block randomisation, to receive one of three regimens of teplizumab infusions (14-day full dose, 14-day low dose, or 6-day full dose) or placebo at baseline and at 26 weeks. The Protege study is still underway, and patients and study staff remain masked through to study closure. The primary composite outcome was the percentage of patients with insulin use of less than 0.5 U/kg per day and glycated haemoglobin A(1c) (HbA(1c)) of less than 6-5% at 1 year. Analyses included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT00385697. Findings 763 patients were screened, of whom 516 were randomised to receive 14-day full-dose teplizumab (n=209), 14-day low-dose teplizumab (n=102), 6-day full-dose teplizumab (n=106), or placebo (n=99). Two patients in the 14-day full-dose group and one patient in the placebo group did not start treatment, so 513 patients were eligible for efficacy analyses. The primary outcome did not differ between groups at 1 year: 19.8% (41/207) in the 14-day full-dose group; 13.7% (14/102) in the 14-day low-dose group; 20.8% (22/106) in the 6-day full-dose group; and 20.4% (20/98) in the placebo group. 5% (19/415) of patients in the teplizumab groups were not taking insulin at 1 year, compared with no patients in the placebo group at 1 year (p=0.03). Across the four study groups, similar proportions of patients had adverse events (414/417 [99%] in the teplizumab groups vs 98/99 [99%] in the placebo group) and serious adverse events (42/417 [10%] vs 9/99 [9%]). The most common clinical adverse event in the teplizumab groups was rash (220/417 [53%] vs 20/99 [20%] in the placebo group). Interpretation Findings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in beta-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.","[Sherry, Nicole] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Hagopian, William] NW Diabet Res Inst, Seattle, WA USA; [Ludvigsson, Johnny] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Div Pediat, Linkoping, Sweden; [Jain, Sunil M.] TOTALL Diabet Hormone Res Inst, Indore, Madhya Pradesh, India; [Wahlen, Jack] Endocrine Res Specialists, Ogden, UT USA; [Ferry, Robert J., Jr.] Le Bonheur Childrens Hosp, Div Pediat Endocrinol & Metab, Memphis, TN USA; [Ferry, Robert J., Jr.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Bode, Bruce] Atlanta Diabet Associates, Atlanta, GA USA; [Aronoff, Stephen] Res Inst Dallas, Dallas, TX USA; [Holland, Christopher; Carlin, David; King, Karen L.; Bonvini, Ezio; Johnson, Syd; Stein, Kathryn E.; Koenig, Scott; Daifotis, Anastasia G.] MacroGenics, Rockville, MD USA; [Wilder, Ronald L.] PAREXEL Int, Durham, NC USA; [Pillemer, Stanley] Amer Biopharma Corp, Gaithersburg, MD USA; [Herold, Kevan C.] Yale Univ, New Haven, CT USA","Sherry, N (reprint author), Massachusetts Gen Hosp Children, 175 Cambridge St,Room 537, Boston, MA 02114 USA.","nsherry@partners.org",null,null,"MacroGenics; Juvenile Diabetes Research Foundation; Eli Lilly; US National Institutes of Health [R21 HD059292, T35 DK007405]; Le Bonheur Foundation (Memphis TN, USA); Juvenile Diabetes Foundation [2008-502]","Funding MacroGenics, the Juvenile Diabetes Research Foundation, and Eli Lilly.CH, DC, KLK, EB, SJ, KES, SK, and AGD are employees of MacroGenics and potentially own shares or options in the company. NS, JL, SA, BB, JW, and RJF received research and travel support for this study from MacroGenics. JL has received advisory board support from Johnson & Johnson. RJF has received research support within the past 3 years from Tolerx (to study otelixizumab for recent-onset type 1 diabetes); unrelated research support from the US National Institutes of Health (grants R21 HD059292 and T35 DK007405), Gabrielle's Angel Foundation, Eli Lilly, Diamyd, Pfizer, and Novo Nordisk; and unrestricted research support from Le Bonheur Foundation (Memphis TN, USA). WH chairs the data safety and monitoring board for the BHT-3021-01 insulin plasmid trial (Bayhill Pharmaceuticals). KCH has received research support from MacroGenics, and support from the Juvenile Diabetes Foundation (grant 2008-502) for laboratory studies on patients' samples from Prot g. RLW is a former employee of MacroGenics and holds restricted stock in the company, and is now an employee of Parexel International, the lead contract research organisation that coordinated the Prot g trial globally. SA has received speaking honoraria from Eli Lilly. SP was formerly employed by MacroGenics and received stock options while employed there. SMJ declares that he has no conflicts of interest.","American Diabetes Association, 2006, DIABETES CARE S1, V29, pS43; BOLT S, 1993, EUR J IMMUNOL, V23, P403, DOI 10.1002/eji.1830230216; Chatenoud L, 2010, NAT REV ENDOCRINOL, V6, P149, DOI 10.1038/nrendo.2009.275; Skyler JS, 2002, NEW ENGL J MED, V346, P1685; EvaluatePharma, IDFS 20 WORLD DIAB C; Gandhi GY, 2008, CLIN ENDOCRINOL, V69, P244, DOI 10.1111/j.1365-2265.2008.03179.x; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; HOLM S, 1979, SCAND J STAT, V6, P65; Keymeulen B, 2009, BLOOD, V115, P1145; Keymeulen B, 2010, DIABETOLOGIA, V53, P614, DOI 10.1007/s00125-009-1644-9; Keymeulen B, 2005, NEW ENGL J MED, V352, P2598, DOI 10.1056/NEJMoa043980; Ludvigsson J, 2008, NEW ENGL J MED, V359, P1909, DOI 10.1056/NEJMoa0804328; Luo XR, 2010, IMMUNITY, V32, P488, DOI 10.1016/j.immuni.2010.04.002; PR Newswire, TOL GLAXOSMITHKLINE; Sherry NA, 2006, DIABETES, V55, P3238, DOI 10.2337/db05-1034; Silverstein J, 2005, DIABETES CARE, V28, P186, DOI 10.2337/diacare.28.1.186; Steele C, 2004, DIABETES, V53, P426, DOI 10.2337/diabetes.53.2.426; SHAMOON H, 1993, NEW ENGL J MED, V329, P977; Van Belle TL, 2011, PHYSIOL REV, V91, P79, DOI 10.1152/physrev.00003.2010; Xu DL, 2000, CELL IMMUNOL, V200, P16, DOI 10.1006/cimm.2000.1617",20,104,106,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0140-6736",null,null,"LANCET","Lancet","AUG 6",2011,378,9790,null,null,null,null,487,497,null,"10.1016/S0140-6736(11)60931-8",null,11,"Medicine, General & Internal","General & Internal Medicine","809SO","WOS:000294077200028"]
[null,null,null,null,"J","Henry, DH; Costa, L; Goldwasser, F; Hirsh, V; Hungria, V; Prausova, J; Scagliotti, GV; Sleeboom, H; Spencer, A; Vadhan-Raj, S; von Moos, R; Willenbacher, W; Woll, PJ; Wang, JM; Jiang, Q; Jun, S; Dansey, R; Yeh, H",null,null,null,"Henry, David H.; Costa, Luis; Goldwasser, Francois; Hirsh, Vera; Hungria, Vania; Prausova, Jana; Scagliotti, Giorgio Vittorio; Sleeboom, Harm; Spencer, Andrew; Vadhan-Raj, Saroj; von Moos, Roger; Willenbacher, Wolfgang; Woll, Penella J.; Wang, Jianming; Jiang, Qi; Jun, Susie; Dansey, Roger; Yeh, Howard",null,null,"Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"KAPPA-B LIGAND; PLACEBO-CONTROLLED TRIAL; LONG-TERM EFFICACY; SKELETAL COMPLICATIONS; RECEPTOR ACTIVATOR; SOLID TUMORS; LUNG-CANCER; PHASE-III; PAMIDRONATE; BISPHOSPHONATES","Purpose This study compared denosumab, a fully human monoclonal anti-receptor activator of nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients with advanced cancer and bone metastases (excluding breast and prostate) or myeloma. Patients and Methods Eligible patients were randomly assigned in a double-blind, double-dummy design to receive monthly subcutaneous denosumab 120 mg (n = 886) or intravenous ZA 4 mg (dose adjusted for renal impairment; n = 890). Daily supplemental calcium and vitamin D were strongly recommended. The primary end point was time to first on-study SRE (pathologic fracture, radiation or surgery to bone, or spinal cord compression). Results Denosumab was noninferior to ZA in delaying time to first on-study SRE (hazard ratio, 0.84; 95% CI, 0.71 to 0.98; P = .0007). Although directionally favorable, denosumab was not statistically superior to ZA in delaying time to first on-study SRE (P = .03 unadjusted; P = .06 adjusted for multiplicity) or time to first-and-subsequent (multiple) SRE (rate ratio, 0.90; 95% CI, 0.77 to 1.04; P = .14). Overall survival and disease progression were similar between groups. Hypocalcemia occurred more frequently with denosumab. Osteonecrosis of the jaw occurred at similarly low rates in both groups. Acute-phase reactions after the first dose occurred more frequently with ZA, as did renal adverse events and elevations in serum creatinine based on National Cancer Institute Common Toxicity Criteria for Adverse Events grading. Conclusion Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma. Denosumab represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment. J Clin Oncol 29: 1125-1132. (C) 2011 by American Society of Clinical Oncology","[Henry, David H.] Penn Hosp, Joan Karnell Canc Ctr, Philadelphia, PA 19106 USA; Hosp Santa Maria, Lisbon, Portugal; Inst Mol Med, Lisbon, Portugal; Teaching Hosp Cochin, Paris, France; McGill Univ, Ctr Hlth, Montreal, PQ, Canada; Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil; Univ Hosp Motol, Prague, Czech Republic; Univ Torino, Orbassano, Italy; HagaZiekenhuis Leyenburg, The Hague, Netherlands; Alfred Hosp, Melbourne, Vic, Australia; Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; Kantonsspital Graubunden, Chur, Switzerland; Med Univ Innsbruck, Innsbruck, Austria; Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England; Amgen Inc, Thousand Oaks, CA USA","Henry, DH (reprint author), Penn Hosp, Joan Karnell Canc Ctr, 230 W Washington Sq, Philadelphia, PA 19106 USA.","davidhenry@pennoncology.com","Hungria, Vania/G-3141-2012",null,"Amgen, Thousand Oaks, CA; Amgen; Centocor Ortho Biotech; Watson Pharmaceuticals; Novartis","Supported by Amgen, Thousand Oaks, CA.Research Funding: David H. Henry, Amgen, Centocor Ortho Biotech, Watson Pharmaceuticals; Luis Costa, Amgen, Novartis; Harm Sleeboom, Amgen, Novartis; Saroj Vadhan-Raj, Amgen; Wolfgang Willenbacher, Amgen; Penella J. Woll, Amgen",null,39,205,209,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,null,"J CLIN ONCOL","J. Clin. Oncol.","MAR 20",2011,29,9,null,null,null,null,1125,1132,null,"10.1200/JCO.2010.31.3304",null,8,"Oncology","Oncology","736YZ","WOS:000288532500024"]
[null,null,null,null,"J","Babjuk, M; Oosterlinck, W; Sylvester, R; Kaasinen, E; Bohle, A; Palou-Redorta, J; Roupret, M",null,null,null,"Babjuk, Marko; Oosterlinck, Willem; Sylvester, Richard; Kaasinen, Eero; Boehle, Andreas; Palou-Redorta, Juan; Roupret, Morgan",null,null,"EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update","EUROPEAN UROLOGY",null,null,"English","Article",null,null,null,null,null,"Bacillus Calmette-Guerin (BCG); Bladder cancer; Cystectomy; Cystoscopy; Diagnosis; EAU Guidelines; Follow-up; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR); Urothelial carcinoma","BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL CARCINOMA; RANDOMIZED CLINICAL-TRIALS; IMMEDIATE POSTOPERATIVE INSTILLATION; INTRAVESICAL MITOMYCIN-C; FOLLOW-UP CYSTOSCOPY; LONG-TERM EFFICACY; PHASE-III TRIAL; IN-SITU; TRANSURETHRAL RESECTION","Context and objective: To present the 2011 European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC). Evidence acquisition: Literature published between 2004 and 2010 on the diagnosis and treatment of NMIBC was systematically reviewed. Previous guidelines were updated, and the level of evidence (LE) and grade of recommendation (GR) were assigned. Evidence synthesis: Tumours staged as Ta, T1, or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection (TUR) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TUR is essential for the patient's prognosis. Where the initial resection is incomplete or where a high-grade or T1 tumour is detected, a second TUR should be performed within 2-6 wk. In papillary tumours, the risks of both recurrence and progression may be estimated for individual patients using the scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups-separately for recurrence and progression-is pivotal to recommending adjuvant treatment. For patients with a low risk of tumour recurrence and progression, one immediate instillation of chemotherapy is recommended. Patients with an intermediate or high risk of recurrence and an intermediate risk of progression should receive one immediate instillation of chemotherapy followed by a minimum of 1 yr of bacillus Calmette-Guerin (BCG) intravesical immunotherapy or further instillations of chemotherapy. Papillary tumours with a high risk of progression and CIS should receive intravesical BCG for 1 yr. Cystectomy may be offered to the highest risk patients, and it is at least recommended in BCG failure patients. The long version of the guidelines is available from the EAU Web site (www.uroweb.org). Conclusions: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. (C) 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.","[Babjuk, Marko] Charles Univ Prague, Dept Urol, Fac Med 2, Hosp Motol, Prague 15006 5, Czech Republic; [Oosterlinck, Willem] Ghent Univ Hosp, Dept Urol, B-9000 Ghent, Belgium; [Sylvester, Richard] European Org Res & Treatment Canc Headquarters, Dept Biostat, Brussels, Belgium; [Kaasinen, Eero] Hyvinkaa Hosp, Dept Urol, Hyvinkaa, Finland; [Boehle, Andreas] HELIOS Agnes Karll Hosp, Dept Urol, Bad Schwartau, Germany; [Palou-Redorta, Juan] Univ Autonoma Barcelona, Dept Urol, Fundacio Puigvert, E-08193 Barcelona, Spain; [Roupret, Morgan] Univ Paris 06, Fac Med, Dept Urol, Pitie Salpetriere Hosp,AP HP,GHU Est, Paris, France","Babjuk, M (reprint author), Charles Univ Prague, Dept Urol, Fac Med 2, Hosp Motol, Uvalu 84, Prague 15006 5, Czech Republic.","marek.babjuk@lfmotol.cuni.cz",null,null,"GSK; Astra Zeneca; Pfizer Foundation","I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Marko Babjuk receives speaker honoraria from GE Healthcare and GSK. Willem Oosterlinck is a company consultant and receives fellowship and travel grants from GSK, receives speaker honoraria from Pfizer, participates in trials for Amgen, Astra Zeneca, and Astellas, and receives fellowships and travel and research grants from Astra Zeneca. Morgan Roupret has nothing to disclose. Juan Palou-Redorta is a consultant and receives speaker honoraria from Sanofi-Pasteur and General Electric. He also participates in trials for General Electric. Andreas Bohle receives speaker honoraria from Sanofi-Aventis, Medac, Bard, and Fresenius. Eero Kaasinen receives research grants from the Pfizer Foundation and for a research group at Pfizer. Richard Sylvester is a consultant for Bioniche, Allergan, and Astra Zeneca, and he received speaker honoraria from the Kyowa 2008 EAU Satellite Symposium.",null,72,272,281,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","JUN",2011,59,6,null,null,null,null,997,1008,null,"10.1016/j.eururo.2011.03.017",null,12,"Urology & Nephrology","Urology & Nephrology","756MM","WOS:000290015300023"]
[null,null,null,null,"J","Roupret, M; Zigeuner, R; Palou, J; Boehle, A; Kaasinen, E; Sylvester, R; Babjuk, M; Oosterlinck, W",null,null,null,"Roupret, Morgan; Zigeuner, Richard; Palou, Juan; Boehle, Andreas; Kaasinen, Eero; Sylvester, Richard; Babjuk, Marko; Oosterlinck, Willem",null,null,"European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update","EUROPEAN UROLOGY",null,null,"English","Article",null,null,null,null,null,"Guidelines; Urothelial carcinoma; Prognosis; Urinary markers; Renal pelvis; Ureter; Laparoscopy; Ureteroscopy; Nephroureterectomy","LAPAROSCOPIC RADICAL NEPHROURETERECTOMY; SINGLE-CENTER EXPERIENCE; IN-SITU HYBRIDIZATION; LONG-TERM EXPERIENCE; RENAL PELVIS; PROGNOSTIC-FACTORS; CALMETTE-GUERIN; MULTIINSTITUTIONAL ANALYSIS; MICROSATELLITE INSTABILITY; URETEROSCOPIC MANAGEMENT","Context: The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper urinary tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to incorporate present recommendations into daily clinical practice. Objective: This paper provides a brief overview of the EAU guidelines on UUT-UCC as an aid to clinicians in their daily practice. Evidence acquisition: The recommendations provided in the current guidelines are based on a thorough review of available UUT-UCC guidelines and papers identified using a systematic search of Medline. Data on urothelial malignancies and UUT-UCCs in the literature were searched using Medline with the following keywords: urinary tract cancer, urothelial carcinomas, upper urinary tract, carcinoma, transitional cell, renal pelvis, ureter, bladder cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. A panel of experts weighted the references. Evidence synthesis: There is a lack of data in the current literature to provide strong recommendations due to the rarity of the disease. A number of recent multicentre studies are now available, whereas earlier publications were based only on limited populations. However, most of these studies have been retrospective analyses. The TNM classification 2009 is recommended. Recommendations are given for diagnosis as well as for radical and conservative treatment; prognostic factors are also discussed. Recommendations are provided for patient follow-up after different therapeutic options. Conclusions: These guidelines contain information for the diagnosis and treatment of individual patients according to a current standardised approach. When determining the optimal treatment regimen, physicians must take into account each individual patient's specific clinical characteristics with regard to renal function including medical comorbidities; tumour location, grade and stage; and molecular marker status. (C) 2011 European Association of Urology. Published by Elsevier B. V. All rights reserved.","[Roupret, Morgan] Univ Paris 06, Fac Med Pierre & Marie Curie, Assistance Publ Hop Paris, Dept Urol,Pitie Salpetriere Hosp,GHU Est, Paris, France; [Zigeuner, Richard] Med Univ Graz, Dept Urol, Graz, Austria; [Palou, Juan] Fundacio Puigvert, Dept Urol, Barcelona, Spain; [Boehle, Andreas] HELIOS Agnes Karll Hosp, Dept Urol, D-23611 Bad Schwartau, Germany; [Kaasinen, Eero] Hyvinkaa Hosp, Dept Urol, Hysinkaa, Finland; [Sylvester, Richard] European Org Res & Treatment Canc Headquarters, Dept Biostat, B-1200 Brussels, Belgium; [Babjuk, Marko] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, Prague, Czech Republic; [Oosterlinck, Willem] Ghent Univ Hosp, Dept Urol, B-9000 Ghent, Belgium","Roupret, M (reprint author), Hop Pitie, Dept Urol, 47-83 Bvd Hop, F-75013 Paris, France.","morgan.roupret@psl.aphp.fr",null,null,"Pfizer Foundation; Pfizer; Astra Zeneca; Sanofi-Aventis","I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Juan Palou is a consultant and honorarium speaker for Sanofi-Pasteur and a consultant, honorarium speaker, and trial participant for General Electric. Andreas Boehle is an honorarium speaker for Sanofi-Aventis, Medac, Bard, and Fresenius. Eero Kaasinen has received research grants from the Pfizer Foundation and for a research group from Pfizer. Richard Sylvester is a consultant for Bioniche, Allergan, and Astra Zeneca, and he was an honorarium speaker for the Kyowa 2008 EAU Satellite Symposium. Marko Babjuk is an honorarium speaker for GE Healthcare and Novartis. Willem Oosterlinck is an honorarium speaker for Organan, Sanofi-Aventis, Novartis, and Pfizer; he participates in trials conducted by Amgen, Astra Zeneca, Novartis, and Astellas; he has received fellowships and travel grants from Astra Zeneca and Sanofi-Aventis and research grants from Astra Zeneca.",null,117,153,155,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","APR",2011,59,4,null,null,null,null,584,594,null,"10.1016/j.eururo.2010.12.042",null,11,"Urology & Nephrology","Urology & Nephrology","730DT","WOS:000288013700027"]
[null,null,null,null,"J","Eliasson, H; Sonesson, SE; Sharland, G; Granath, F; Simpson, JM; Carvalho, JS; Jicinska, H; Tomek, V; Dangel, J; Zielinsky, P; Respondek-Liberska, M; Freund, MW; Mellander, M; Bartrons, J; Gardiner, HM",null,null,null,"Eliasson, Hakan; Sonesson, Sven-Erik; Sharland, Gurleen; Granath, Fredrik; Simpson, John M.; Carvalho, Julene S.; Jicinska, Hana; Tomek, Viktor; Dangel, Joanna; Zielinsky, Paulo; Respondek-Liberska, Maria; Freund, Matthias W.; Mellander, Mats; Bartrons, Joaquim; Gardiner, Helena M.",null,"Fetal Working Grp European Assoc","Isolated Atrioventricular Block in the Fetus A Retrospective, Multinational, Multicenter Study of 175 Patients","CIRCULATION",null,null,"English","Article",null,null,null,null,null,"atrioventricular block; fetal heart; lupus erythematosus, systemic; therapeutics","STRUCTURAL HEART-DISEASE; FETAL TREATMENT IMPROVES; STEROID-THERAPY; INFANTS BORN; ABNORMALITIES; DEXAMETHASONE; ANTIBODIES; CHILDHOOD; DIAGNOSIS; MOTHERS","Background-Isolated complete atrioventricular block in the fetus is a rare but potentially lethal condition in which the effect of steroid treatment on outcome is unclear. The objective of this work was to study risk factors associated with death and the influence of steroid treatment on outcome. Methods and Results-We studied 175 fetuses diagnosed with second-or third-degree atrioventricular block (2000-2007) retrospectively in a multinational, multicenter setting. In 80% of 162 pregnancies with documented antibody status, atrioventricular block was associated with maternal anti-Ro/SSA antibodies. Sixty-seven cases (38%) were treated with fluorinated corticosteroids for a median of 10 weeks (1-21 weeks). Ninety-one percent were alive at birth, and survival in the neonatal period was 93%, similar in steroid-treated and untreated fetuses, regardless of degree of block and/or presence of anti-Ro/SSA. Variables associated with death were gestational age <20 weeks, ventricular rate <= 50 bpm, fetal hydrops, and impaired left ventricular function at diagnosis. The presence of >= 1 of these variables was associated with a 10-fold increase in mortality before birth and a 6-fold increase in the neonatal period independently of treatment. Except for a lower gestational age at diagnosis in treated than untreated (23.4 +/- 2.9 versus 24.9 +/- 4.9 weeks; P = 0.02), risk factors were distributed equally between treatment groups. Two-thirds of survivors had a pacemaker by 1 year of age; 8 children developed cardiomyopathy. Conclusions-Risk factors associated with a poor outcome were gestation <20 weeks, ventricular rate <= 50 bpm, hydrops, and impaired left ventricular function. No significant effect of treatment with fluorinated corticosteroids was seen. (Circulation. 2011; 124: 1919-1926.)","[Eliasson, Hakan] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Pediat Cardiol Q1 03, S-17176 Stockholm, Sweden; [Granath, Fredrik] Karolinska Univ Hosp, Clin Epidemiol Unit, S-17176 Stockholm, Sweden; [Granath, Fredrik] Karolinska Inst, Stockholm, Sweden","Eliasson, H (reprint author), Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Pediat Cardiol Q1 03, S-17176 Stockholm, Sweden.","hakan.eliasson@karolinska.se","Simpson, John/J-6001-2013",null,"Fetal Working Group; Stockholm County Council; Karolinska Institutet; Swedish Heart Lung Foundation; Karolinska Institutet Research Foundations; Freemason's in Stockholm Foundation for Children's Welfare and Samariten Foundation","This study was devised by the Fetal Working Group of the European Association of Pediatric Cardiology, and financial support for site visits by Dr Eliasson was provided by the Fetal Working Group. Financial support for Drs Eliasson and Sonesson was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Heart Lung Foundation, and Karolinska Institutet Research Foundations. Dr Eliasson was also supported by Freemason's in Stockholm Foundation for Children's Welfare and Samariten Foundation.","Askanase AD, 2002, LUPUS, V11, P145, DOI 10.1191/0961203302lu173oa; Berg C, 2005, ULTRASOUND OBST GYN, V26, P4, DOI 10.1002/uog.1918; Breur JMPJ, 2004, ULTRASOUND OBST GYN, V24, P467, DOI 10.1002/uog.1713; COPEL JA, 1995, AM J OBSTET GYNECOL, V173, P1384, DOI 10.1016/0002-9378(95)90621-5; Costedoat-Chalumeau N, 2003, ANN RHEUM DIS, V62, P1010, DOI 10.1136/ard.62.10.1010; Cuneo BF, 2007, AM J CARDIOL, V100, P661, DOI 10.1016/j.amjcard.2007.03.081; Gerosa M, 2007, RHEUMATOLOGY, V46, P1285, DOI 10.1093/rheumatology/kem073; GROVES AMM, 1995, CIRCULATION, V92, P3394; Ismail K M, 2001, J Matern Fetal Med, V10, P175, DOI 10.1080/714904328; Jaeggi ET, 2002, J AM COLL CARDIOL, V39, P130, DOI 10.1016/S0735-1097(01)01697-7; Jaeggi ET, 2004, CIRCULATION, V110, P1542, DOI 10.1161/01.CIR.0000142046.58632.3A; Lopes LM, 2008, CIRCULATION, V118, P1268, DOI 10.1161/CIRCULATIONAHA.107.735118; Michaëlsson M, 1972, Cardiovasc Clin, V4, P85; Modi N, 2001, PEDIATR RES, V50, P581, DOI 10.1203/00006450-200111000-00008; Raboisson MJ, 2005, J AM SOC ECHOCARDIOG, V18, P375, DOI 10.1016/j.echo.2004.10.023; Rosenthal E, 2005, CIRCULATION, V111, pE287, DOI 10.1161/01.CIR.0000164275.69617.B2; Saleeb S, 1999, ARTHRITIS RHEUM, V42, P2335, DOI 10.1002/1529-0131(199911)42:11<2335::AID-ANR12>3.0.CO;2-3; Theander E, 2001, J RHEUMATOL, V28, P373; Villain E, 2006, J AM COLL CARDIOL, V48, P1682, DOI 10.1016/j.jacc.2006.07.034; Whitelaw A, 2000, ARCH DIS CHILD, V83, pF154, DOI 10.1136/fn.83.2.F154",20,20,22,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322","1524-4539",null,"CIRCULATION","Circulation","NOV 1",2011,124,18,null,null,null,null,1919,1926,null,"10.1161/CIRCULATIONAHA.111.041970",null,8,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","Cardiovascular System & Cardiology","842JB","WOS:000296593800014"]
[null,null,null,null,"J","Rob, L; Skapa, P; Robova, H",null,null,null,"Rob, Lukas; Skapa, Petr; Robova, Helena",null,null,"Fertility-sparing surgery in patients with cervical cancer","LANCET ONCOLOGY",null,null,"English","Review",null,null,null,null,null,null,"VAGINAL RADICAL TRACHELECTOMY; OF-THE-LITERATURE; NEOADJUVANT CHEMOTHERAPY; PELVIC LYMPHADENECTOMY; PRESERVING SURGERY; ABDOMINAL TRACHELECTOMY; PARAMETRIAL INVOLVEMENT; CONSERVATIVE SURGERY; INITIAL-EXPERIENCE; DARGENTS OPERATION","There are several types of fertility saving procedures that can be done in patients with cervical cancer, which differ in terms of surgical approach and extent of paracervical resection. This review assesses oncological and pregnancy results after different procedures. The oncological results of vaginal radical trachelectomies (VRT) and abdominal radical trachelectomies (ART) are similar for tumours less than 2 cm in size, and are now considered safe surgical procedures. Oncological outcomes of VRT and ART in tumours larger than 2 cm are also identical, but the results cannot be considered satisfactory. Preliminary findings of less radical procedures (ie, deep cone and simple trachelectomy) in patients with tumours less than 2 cm, and negative sentinel and other pelvic lymph nodes, are comparable with the results of VRT and ART Downstaging tumours larger than 2 cm by neoadjuvant chemotherapy is still an experimental procedure and will need multicentre cooperation to verify its oncological safety. Pregnancy results vary statistically with the different methods.","[Rob, Lukas; Skapa, Petr; Robova, Helena] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague 15000 5, Czech Republic","Rob, L (reprint author), Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Uvalu 84, Prague 15000 5, Czech Republic.","lukas.rob@Ifmotol.cuni.cz",null,null," [MZ0FNM2005]","This work was supported by grant MZ0FNM2005.",null,75,51,56,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1470-2045",null,null,"LANCET ONCOL","Lancet Oncol.","FEB",2011,12,2,null,null,null,null,192,200,null,"10.1016/S1470-2045(10)70084-X",null,9,"Oncology","Oncology","720NB","WOS:000287286300026"]
[null,null,null,null,"J","Pannasch, U; Vargova, L; Reingruber, J; Ezan, P; Holcman, D; Giaume, C; Sykova, E; Rouach, N",null,null,null,"Pannasch, Ulrike; Vargova, Lydia; Reingruber, Juergen; Ezan, Pascal; Holcman, David; Giaume, Christian; Sykova, Eva; Rouach, Nathalie",null,null,"Astroglial networks scale synaptic activity and plasticity","PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA",null,null,"English","Article",null,null,null,null,null,"hippocampus; neuroglial interactions","LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL CELLS; GLUTAMATE UPTAKE; EXTRACELLULAR POTASSIUM; SILENT SYNAPSES; GLIAL-CELLS; TIME-COURSE; TRANSMISSION; EXCITABILITY; ASTROCYTES","Astrocytes dynamically interact with neurons to regulate synaptic transmission. Although the gap junction proteins connexin 30 (Cx30) and connexin 43 (Cx43) mediate the extensive network organization of astrocytes, their role in synaptic physiology is unknown. Here we show, by inactivating Cx30 and Cx43 genes, that astroglial networks tone down hippocampal synaptic transmission in CA1 pyramidal neurons. Gap junctional networking facilitates extracellular glutamate and potassium removal during synaptic activity through modulation of astroglial clearance rate and extracellular space volume. This regulation limits neuronal excitability, release probability, and insertion of postsynaptic AMPA receptors, silencing synapses. By controlling synaptic strength, connexins play an important role in synaptic plasticity. Altogether, these results establish connexins as critical proteins for extracellular homeostasis, important for the formation of functional synapses.","[Pannasch, Ulrike; Ezan, Pascal; Giaume, Christian; Rouach, Nathalie] CNRS, UMR 7241, Ctr Interdisciplinary Res Biol, F-75005 Paris, France; [Vargova, Lydia; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague 15006, Czech Republic; [Vargova, Lydia; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006, Czech Republic; [Vargova, Lydia; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Prague 14220, Czech Republic; [Reingruber, Juergen; Holcman, David] Ecole Normale Super, CNRS, UMR 8197, Inst Biol, F-75005 Paris, France; [Reingruber, Juergen; Holcman, David] Ecole Normale Super, INSERM, U1024, Dept Computat Biol & Math, F-75005 Paris, France; [Pannasch, Ulrike; Ezan, Pascal; Giaume, Christian; Rouach, Nathalie] Coll France, INSERM, U1050, F-75005 Paris, France","Rouach, N (reprint author), CNRS, UMR 7241, Ctr Interdisciplinary Res Biol, F-75005 Paris, France.","nathalie.rouach@college-de-france.fr","Holcman, David/L-9243-2013",null,"Human Frontier Science Program Organization; Agence Nationale de la Recherche; Institut National de la Sante et de la Recherche Medicale; French Research Ministry; Deutsche Forschungsgemeinschaft; Franco Czech Barrande Program (Hubert Curien Program); Grant Agency of the Czech Republic [309/09/1597]; Academy of Sciences of the Czech Republic [AVOZ50390512]; Ministry of Education, Youth and Sports of the Czech Republic [1M0538]","We thank O. Chever, A. Tzingounis, D. Schmitz, and A. Koulakoff for helpful discussions and/or technical assistance, as well as K. Willecke for providing the Cx30<SUP>-/-</SUP>Cx43fl/fl:hGFAP-Cre mice. This work was supported by grants from the Human Frontier Science Program Organization (Career Development Award), Agence Nationale de la Recherche (Programme Jeunes Chercheurs), and Institut National de la Sante et de la Recherche Medicale (to N.R.); postdoctoral fellowships from the French Research Ministry and Deutsche Forschungsgemeinschaft (to U.P.); and a grant from the Franco Czech Barrande Program (Hubert Curien Program) (to N.R. and L.V.), Grant 309/09/1597 from the Grant Agency of the Czech Republic (to L.V. and E.S.), Grant AVOZ50390512 from the Academy of Sciences of the Czech Republic (to E.S.) and Grant 1M0538 from the Ministry of Education, Youth and Sports of the Czech Republic (to E.S.).",null,34,54,64,"NATL ACAD SCIENCES","WASHINGTON","2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA","0027-8424",null,null,"P NATL ACAD SCI USA","Proc. Natl. Acad. Sci. U. S. A.","MAY 17",2011,108,20,null,null,null,null,8467,8472,null,"10.1073/pnas.1016650108",null,6,"Multidisciplinary Sciences","Science & Technology - Other Topics","765OZ","WOS:000290719600076"]
[null,null,null,null,"J","Jungraithmayr, TC; Hofer, K; Cochatt, P; Chemin, G; Cortina, G; Fargue, S; Grimm, P; Knueppel, T; Kowarsch, A; Neuhaus, T; Pagel, P; Pfeiffer, KP; Schafer, F; Schonermarck, U; Seeman, T; Toenshoff, B; Weber, S; Winn, MP; Zschocke, J; Zimmerhackl, LB",null,null,null,"Jungraithmayr, Therese C.; Hofer, Katrin; Cochatt, Pierre; Chemin, Gil; Cortina, Gerard; Fargue, Sonja; Grimm, Paul; Knueppel, Tanja; Kowarsch, Andreas; Neuhaus, Thomas; Pagel, Philipp; Pfeiffer, Karl P.; Schaefer, Franz; Schoenermarck, Ulf; Seeman, Tomas; Toenshoff, Burkhard; Weber, Stefanie; Winn, Michelle P.; Zschocke, Johannes; Zimmerhackl, Lothar B.",null,null,"Screening for NPHS2 Mutations May Help Predict FSGS Recurrence after Transplantation","JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,null,"FOCAL SEGMENTAL GLOMERULOSCLEROSIS; RESISTANT NEPHROTIC SYNDROME; RENAL-TRANSPLANTATION; GLOMERULAR-DISEASE; PODOCIN MUTATIONS; SPECTRUM; CHILDREN; R229Q","Steroid-resistant focal segmental glomerulosclerosis (FSGS) often recurs after renal transplantation. In this international survey, we sought to identify genotype-phenotype correlations of recurrent FSGS. We surveyed 83 patients with childhood-onset primary FSGS who received at least one renal allograft and analyzed 53 of these patients for NPHS2 mutations. The mean age at diagnosis was 6.7 years, and the mean age at first renal transplantation was 13 years. FSGS recurred in 30 patients (36%) after a median of 13 days (range, 1.5 to 152 days). Twenty-three patients received a second kidney transplant, and FSGS recurred in 11 (48%) after a median of 16 days (range, 2.7 to 66 days). None of the 11 patients with homozygous or compound heterozygous NPHS2 mutations developed recurrent FSGS compared with 45% of patients without mutations. These data suggest that genetic testing for pathogenic mutations may be important for prognosis and treatment of FSGS both before and after transplantation.","[Jungraithmayr, Therese C.; Hofer, Katrin; Cortina, Gerard; Zimmerhackl, Lothar B.] Med Univ, Innsbruck, Austria; [Cochatt, Pierre; Fargue, Sonja] Hop Herriot, Lyon, France; [Chemin, Gil] Univ Michigan Hlth Syst, Ann Arbor, MI USA; [Knueppel, Tanja; Schaefer, Franz; Toenshoff, Burkhard; Weber, Stefanie] Univ Childrens Hosp, Heidelberg, Germany; [Grimm, Paul] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Kowarsch, Andreas; Pagel, Philipp] Tech Univ Munich, Munich, Germany; [Neuhaus, Thomas] Univ Zurich, Zurich, Switzerland; [Pfeiffer, Karl P.; Zschocke, Johannes] Univ Innsbruck, A-6020 Innsbruck, Austria; [Seeman, Tomas] Med Univ Grosshadern, Munich, Germany; [Seeman, Tomas] Prague Agr Univ, Prague, Czech Republic; [Winn, Michelle P.] Duke Univ, Med Ctr, Durham, NC USA","Jungraithmayr, TC (reprint author), Univ Kinderklin Innsbruck, Anichstr 35, A-6020 Innsbruck, Austria.","therese.jungraithrnayr@uki.at",null,null,"Gesellschaft padiatrische Nephrologie (GPN); European Society of Pediatric Nephrology (ESPN), Duke University Medical Center, Durham, NC; Medical University Innsbruck, Austria","This study was supported by the Gesellschaft padiatrische Nephrologie (GPN), the European Society of Pediatric Nephrology (ESPN), Duke University Medical Center, Durham, NC, and the Medical University Innsbruck, Austria. Parts of this study have been presented before and appeared in abstract form (WTC 2006, IPTA 2007, IPNA 2007, ASN 2007). This abstract was selected as one of the eight best abstracts at the Annual Meeting of the ASN in San Francisco 2007 (JASN, SU-FC121). One part of the genetic analyses was done in the laboratory of Professor F. Hildebrandt, University of Michigan, and was published before; another part was performed at the laboratory of Professor F. Schaefer, University Children Hospital, Heidelberg, Germany; and the third part by the group of Professor Winn, Duke University Medical Center, Durham, NC. We thank Dr. Oberaigner, Institute for Epidemiology and Statistics, TILAK, Innsbruck, Austria, for statistical assistance. We thank the following centers and colleagues for their important contribution to this study: Hacettepe, Universitesi, Ankara, Turkey, Prof. Soylemezoglu, Dr. Bilginer; University Childrens Hospital Erlangen, Germany, Prof. Dotsch, Dr. Plank; Landeskrankenhaus Feldkirch, Austria, Dr. Neyer; University Childrens Hospital Freiburg, Germany, Dr. Pohl; Medical University Innsbruck, Austria, Prof. Mayer, Dr. Rudnicki; Medical University Innsbruck, Austria, Pediatrics I, Dr. Clara, cand.med. Celik; Childrens Hospital Munchen-Schwabing, Germany, Prof. Montoya; Rikshospitalet University Hospital, Oslo, Norway, Dr. Bjerre, Dr. Kyte; Dialysezentrum Villingen-Schwenningen, Germany, Dr. Schulz.","Baum MA, 2001, KIDNEY INT, V59, P328, DOI 10.1046/j.1523-1755.2001.00494.x; Bertelli R, 2003, AM J KIDNEY DIS, V41, P1314, DOI 10.1016/S0272-6386(03)00364-0; Boute N, 2000, NAT GENET, V24, P349; Caridi G, 2003, J AM SOC NEPHROL, V14, P1278, DOI 10.1097/01.ASN.0000060578.79050.E0; Caridi G, 2005, PEDIATR RES, V57, p54R, DOI 10.1203/01.PDR.0000160446.01907.B1; COCHAT P, 1993, PEDIATR NEPHROL, V7, P50; Fine RN, 2007, PEDIATR NEPHROL, V22, P496, DOI 10.1007/s00467-006-0361-6; Hariharan S, 1999, TRANSPLANTATION, V68, P635, DOI 10.1097/00007890-199909150-00007; Jungraithmayr TC, 2005, PEDIATR TRANSPLANT, V9, P226, DOI 10.1111/j.1399-3046.2005.00297.x; Karle SM, 2002, J AM SOC NEPHROL, V13, P388; Newstead CG, 2003, NEPHROL DIAL TRANSPL, V18, P68, DOI 10.1093/ndt/gfg1068; Pardon A, 2006, NEPHROL DIAL TRANSPL, V21, P1053, DOI 10.1093/ndt/gfk005; Pereira AC, 2004, KIDNEY INT, V65, P1026, DOI 10.1111/j.1523-1755.2004.00479.x; PINTO J, 1981, TRANSPLANTATION, V32, P83, DOI 10.1097/00007890-198108000-00001; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; Ruf RG, 2004, J AM SOC NEPHROL, V15, P722, DOI 10.1097/01.ASN.0000113552.59155.72; STEPHANIAN E, 1992, TRANSPLANTATION, V53, P755, DOI 10.1097/00007890-199204000-00009; Swaminathan S, 2006, CLIN J AM SOC NEPHRO, V1, P483, DOI 10.2215/CJN.00710805; TEJANI A, 1992, J AM SOC NEPHROL, V2, pS258; Tsukaguchi H, 2002, J CLIN INVEST, V110, P1659, DOI 10.1172/JCI200216242; Weber S, 2004, KIDNEY INT, V66, P571, DOI 10.1111/j.1523-1755.2004.00776.x; Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215",22,18,21,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1046-6673",null,null,"J AM SOC NEPHROL","J. Am. Soc. Nephrol.","MAR",2011,22,3,null,null,null,null,579,585,null,"10.1681/ASN.2010010029",null,7,"Urology & Nephrology","Urology & Nephrology","740GE","WOS:000288778800025"]
[null,null,null,null,"J","Nyc, O; Pituch, H; Matejkova, J; Obuch-Woszczatynski, P; Kuijper, EJ",null,null,null,"Nyc, Otakar; Pituch, Hanna; Matejkova, Jana; Obuch-Woszczatynski, Piotr; Kuijper, Ed J.",null,null,"Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland","LANCET",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Nyc, Otakar; Matejkova, Jana] Charles Univ Prague, Fac Med 2, Dept Med Microbiol, Prague 5, Czech Republic; [Pituch, Hanna; Obuch-Woszczatynski, Piotr] Med Univ Warsaw, Dept Med Microbiol, Warsaw, Poland; [Kuijper, Ed J.] Leiden Univ, Med Ctr, Dept Med Microbiol, Leiden, Netherlands","Nyc, O (reprint author), Charles Univ Prague, Fac Med 2, Dept Med Microbiol, Prague 5, Czech Republic.","otakar.nyc@seznam.cz",null,null,null,null,null,3,6,6,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0140-6736",null,null,"LANCET","Lancet","APR 23",2011,377,9775,null,null,null,null,1407,1407,null,null,null,1,"Medicine, General & Internal","General & Internal Medicine","755UF","WOS:000289963000025"]
[null,null,null,null,"J","Marenholz, I; Rivera, VAG; Esparza-Gordillo, J; Bauerfeind, A; Lee-Kirsch, MA; Ciechanowicz, A; Kurek, M; Piskackova, T; Macek, M; Lee, YA",null,null,null,"Marenholz, Ingo; Rivera, Vladimir A. Gimenez; Esparza-Gordillo, Jorge; Bauerfeind, Anja; Lee-Kirsch, Min-Ae; Ciechanowicz, Andrzej; Kurek, Michael; Piskackova, Tereza; Macek, Milan; Lee, Young-Ae",null,null,"Association Screening in the Epidermal Differentiation Complex (EDC) Identifies an SPRR3 Repeat Number Variant as a Risk Factor for Eczema","JOURNAL OF INVESTIGATIVE DERMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"PROLINE-RICH PROTEINS; CORNIFIED CELL ENVELOPES; ATOPIC-DERMATITIS; STRUCTURAL PROTEINS; GENE-EXPRESSION; FILAGGRIN; SKIN; FAMILY; CORNIFICATION; POLYMORPHISM","The genetically determined impairment of the skin barrier is a primary cause of eczema. As numerous genes essential for an intact epidermis reside within the epidermal differentiation complex (EDC), we screened the National Center for Biotechnology Information (NCBI) database for putatively functional polymorphisms in the EDC genes and tested them for association with eczema. We identified 20 polymorphisms with predicted major impact on protein function. Of these, 4 were validated in 94 eczema patients: a nonsense mutation in FLG2 (rs12568784), a stop codon mutation in LCE1D (rs41268500), a 24-bp deletion in SPRR3 (rs28989168), and a frameshift mutation in S100A3 (rs11390146). The minor allele frequencies were 15.1, 6.1, 47.2, and 0.4%, respectively. Association testing of the validated polymorphisms in 555 eczema patients and 375 controls identified a significant effect of rs28989168 (SPRR3) on eczema. The association was replicated in another 1,314 cases and 1,322 controls, yielding an overall odds ratio of 1.30 (95% confidence interval 1.12-1.51; P = 0.00067) for a dominant mode of inheritance. Small proline-rich proteins (SPRRs) are crossbridging proteins in the cornified cell envelope (CE), which provides the main barrier function of stratified squamous epithelia. The SPRR3 variant associated with eczema carried an extra 24-bp repeat in the central domain, which may alter the physical properties of the CE.","[Marenholz, Ingo; Rivera, Vladimir A. Gimenez; Esparza-Gordillo, Jorge; Lee, Young-Ae] Campus Virchow Klinikum, Charite, Pediat Pneumol & Immunol & Expt & Clin Res Ctr, D-13353 Berlin, Germany; [Marenholz, Ingo; Rivera, Vladimir A. Gimenez; Esparza-Gordillo, Jorge; Bauerfeind, Anja; Lee, Young-Ae] Max Delbruck Ctr Mol Med, Berlin, Germany; [Lee-Kirsch, Min-Ae] Tech Univ Dresden, Klin Kinder & Jugendmed, Dresden, Germany; [Ciechanowicz, Andrzej] Pomeranian Med Univ, Dept Lab Diagnost & Mol Med, Szczecin, Poland; [Kurek, Michael] Pomeranian Med Univ, Dept Clin Allergol, Szczecin, Poland; [Piskackova, Tereza; Macek, Milan] Charles Univ Prague, Dept Biol & Med Genet, Med Sch & Fac 2, Hosp Motol, Prague, Czech Republic","Lee, YA (reprint author), Campus Virchow Klinikum, Charite, Pediat Pneumol & Immunol & Expt & Clin Res Ctr, Augustenburger Pl 1, D-13353 Berlin, Germany.","yo.lee@charite.de",null,null,"German Ministry of Education and Research (BMBF) through the Clinical Research Group for Allergy at Charite Berlin; National Genome Research Network (NGFN); EMBO [522-2006]; Marie Curie EIF fellowship [039868];  [MZ0FNM2005]","We thank all the subjects with eczema and their families and physicians for their participation. We thank Iv Gwinner-Buhring, F Kussebi, C Ockeloen, T Schilling, and I Schulz for subject evaluation. We are grateful to C Flachmeier, S Kolberg, M Schwarz, and I Szangolies for technical assistance. We thank L Ghys and M De Longueville (UCB Pharma) and the following EPAAC and ETAC investigators for providing case samples: O Rybnicek (Brno, Czech Republic), J Chladkova, T Chyba (Hradec Kralove, Czech Republic), F Kopriva (Olomouc, Czech Republic), OS. kopkova, V Balcarek (Ostrava, Czech Republic), H Honomichlova, P Honomichlova-Houdkova, P Honomichl (Plzen Lochotin, Czech Republic), M Spicakova, S Kynclova, V Petru, A Carbolova, K Kopecka, P Pohunek, T Svobodova, V Spicak, K Kopecka, M Maltulka (Praha, Czech Republic), M Kaczmarski, B Cudowska, J Wasilewska, E Matuszfewska (Bialystok, Poland), T Malaczynska, B Klajna-Kraluk (Gdansk, Poland), J Sokalska, E Masnica-Wasylkowska, I Biegun-Awramineko, M Chlon (Gliwice Poland), T Latos, E Pomaranska, G Gaszczyk, B Makuch, J Stanisz, J Bokiej (Karpacz, Poland), G Lis, E Cichocka-Jarosz, I Glodzik, T Szczerbinski (Krakow, Poland), D Chlebna-Sokol, A Stanczyk, J Wlazlowski, I Ligenza, B Kamer, K Pyziak, R Pasowska, J Zwaigzne-Raczynska (Lodz, Poland), A Emeryk, H Milanowska, G Zywicka, M Bartkowiak-Emeryk, E Chojna (Lublin, Poland), A Swiatly, A Szczawinska-Poplonyk, M Kulesza-Kazecka, J Alkiewicz, A Breborowicz (Poznan, Poland), R Kurzawa, A Wojcik, U JedrysKlucjasz, E Urbanek-Jozwik (Rabka Zdroj, Poland), L Dymek, A Dymek, A Bozek (Strzelce Opolskie, Poland), D Chmielewska-Szewczyk, J Lange, J Peradzynska, M Kulus, E Najberg, E Nowicka, A Chrupek (Warszawa, Poland), A Boznanski, E Willak-Janc, A Latkowska, E Sikorska, and MT Jarlinska (Wroclaw, Poland). The study was funded by the German Ministry of Education and Research (BMBF) through the Clinical Research Group for Allergy at Charite Berlin and the National Genome Research Network (NGFN). This work was supported by an EMBO long-term fellowship (522-2006) and by a Marie Curie EIF fellowship (039868) to JEG. This work was done in Berlin, Germany. This work was supported by MZ0FNM2005 to MM.",null,30,15,15,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","0022-202X",null,null,"J INVEST DERMATOL","J. Invest. Dermatol.","AUG",2011,131,8,null,null,null,null,1644,1649,null,"10.1038/jid.2011.90",null,6,"Dermatology","Dermatology","792HA","WOS:000292731100012"]
[null,null,null,null,"J","Schmid, JP; Canioni, D; Moshous, D; Touzot, F; Mahlaoui, N; Hauck, F; Kanegane, H; Lopez-Granados, E; Mejstrikova, E; Pellier, I; Galicier, L; Galambrun, C; Barlogis, V; Bordigoni, P; Fourmaintraux, A; Hamidou, M; Dabadie, A; Le Deist, F; Haerynck, F; Ouachee-Chardin, M; Rohrlich, P; Stephan, JL; Lenoir, C; Rigaud, S; Lambert, N; Milili, M; Schiff, C; Chapel, H; Picard, C; de Saint Basile, G; Blanche, S; Fischer, A; Latour, S",null,null,null,"Schmid, Jana Pachlopnik; Canioni, Danielle; Moshous, Despina; Touzot, Fabien; Mahlaoui, Nizar; Hauck, Fabian; Kanegane, Hirokazu; Lopez-Granados, Eduardo; Mejstrikova, Ester; Pellier, Isabelle; Galicier, Lionel; Galambrun, Claire; Barlogis, Vincent; Bordigoni, Pierre; Fourmaintraux, Alain; Hamidou, Mohamed; Dabadie, Alain; Le Deist, Francoise; Haerynck, Filomeen; Ouachee-Chardin, Marie; Rohrlich, Pierre; Stephan, Jean-Louis; Lenoir, Christelle; Rigaud, Stephanie; Lambert, Nathalie; Milili, Michele; Schiff, Claudin; Chapel, Helen; Picard, Capucine; de Saint Basile, Genevieve; Blanche, Stephane; Fischer, Alain; Latour, Sylvain",null,null,"Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"NATURAL-KILLER-CELLS; BARR-VIRUS INFECTION; SAP FAMILY ADAPTERS; HUMORAL IMMUNITY; T-CELLS; DISEASE; SLAM; GENE; XIAP; LYMPHOHISTIOCYTOSIS","X-linked lymphoproliferative syndromes (XLP) are primary immunodeficiencies characterized by a particular vulnerability toward Epstein-Barr virus infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH). XLP type 1 (XLP-1) is caused by mutations in the gene SH2D1A (also named SAP), whereas mutations in the gene XIAP underlie XLP type 2 (XLP-2). Here, a comparison of the clinical phenotypes associated with XLP-1 and XLP-2 was performed in cohorts of 33 and 30 patients, respectively. HLH (XLP-1, 55%; XLP-2, 76%) and hypogammaglobulinemia (XLP-1, 67%; XLP-2, 33%) occurred in both groups. Epstein-Barr virus infection in XLP-1 and XLP-2 was the common trigger of HLH (XLP-1, 92%; XLP-2, 83%). Survival rates and mean ages at the first HLH episode did not differ for both groups, but HLH was more severe with lethal outcome in XLP-1 (XLP-1, 61%; XLP-2, 23%). Although only XLP-1 patients developed lymphomas (30%), XLP-2 patients (17%) had chronic hemorrhagic colitis as documented by histopathology. Recurrent splenomegaly often associated with cytopenia and fever was preferentially observed in XLP-2 (XLP-1, 7%; XLP-2, 87%) and probably represents minimal forms of HLH as documented by histopathology. This first phenotypic comparison of XLP subtypes should help to improve the diagnosis and the care of patients with XLP conditions. (Blood. 2011; 117(5): 1522-1529)","[Schmid, Jana Pachlopnik; Moshous, Despina; Hauck, Fabian; Lenoir, Christelle; Rigaud, Stephanie; Lambert, Nathalie; de Saint Basile, Genevieve; Fischer, Alain; Latour, Sylvain] Hop Necker Enfants Malad, INSERM, U768, Lab Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France; [Schmid, Jana Pachlopnik; Moshous, Despina; Hauck, Fabian; Rigaud, Stephanie; Picard, Capucine; de Saint Basile, Genevieve; Fischer, Alain; Latour, Sylvain] Univ Paris 05, Inst Federatif Rech Necker Enfants Malades IFR94, Paris, France; [Schmid, Jana Pachlopnik; Moshous, Despina; Touzot, Fabien; Mahlaoui, Nizar; de Saint Basile, Genevieve; Blanche, Stephane; Fischer, Alain] Hop Necker Enfants Malad, AP HP, Unite Immunol & Hematol Pediat, F-75015 Paris, France; [Canioni, Danielle] Hop Necker Enfants Malad, AP HP, Serv Anat & Cytol Pathol, F-75015 Paris, France; [Kanegane, Hirokazu] Toyama Univ, Grad Sch Med, Dept Pediat, Toyama 930, Japan; [Lopez-Granados, Eduardo; Chapel, Helen] Univ Oxford, Nuffield Dept Med, Dept Clin Immunol, Oxford, England; [Mejstrikova, Ester] Charles Univ Prague, Dept Pediat Hematol & Oncol, Teaching Hosp Motol, Prague, Czech Republic; [Mejstrikova, Ester] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Pellier, Isabelle] CHU Angers, Unite Hematol Immunol Oncol Pediat, Angers, France; [Pellier, Isabelle] Ctr Rech Cancerol Nantes Angers, INSERM, U892, Nantes, France; [Galicier, Lionel] Hop St Louis, Serv Immunohematol, AP HP, F-75475 Paris, France; [Galambrun, Claire; Barlogis, Vincent] Hop Enfants La Timone, Serv Hematol Pediat, Marseille, France; [Bordigoni, Pierre] CHU Nancy, Dept Hematooncol Pediat & Transplantat Medullaire, Vandoeuvre Les Nancy, France; [Fourmaintraux, Alain] Grp Hosp Sud Reunion, Serv Neonatol, St Pierre, Reunion; [Hamidou, Mohamed] CHU Nantes, F-44035 Nantes 01, France; [Dabadie, Alain] CHU Rennes, Serv Hepatogastroenterol, Rennes, France; [Le Deist, Francoise] Univ Montreal, Dept Microbiol & Immunol, CHU St Justine, Montreal, PQ H3C 3J7, Canada; [Le Deist, Francoise] Univ Montreal, Dept Pediat, CHU St Justine, Montreal, PQ H3C 3J7, Canada; [Haerynck, Filomeen] Ghent Univ Hosp, Dept Child Immunol, B-9000 Ghent, Belgium; [Ouachee-Chardin, Marie] CHU Hop Robert Debre, AP HP, Serv Hematol, Paris, France; [Rohrlich, Pierre] INSERM, UMR645, Besancon, France; [Rohrlich, Pierre] Univ Franche Comte, F-25030 Besancon, France; [Rohrlich, Pierre] CHU Besancon, Serv Pediat, F-25030 Besancon, France; [Stephan, Jean-Louis] CHU St Etienne, Hop Nord, Unite Hematol & Oncol Pediat, St Etienne, France; [Lambert, Nathalie; Picard, Capucine] Hop Necker Enfants Malad, Ctr Etud Deficits Immunitaires, F-75015 Paris, France; [Milili, Michele; Schiff, Claudin] Ctr E3 Ctr Immunol Marseille Luminy, Marseille, France; [Picard, Capucine] Hop Necker Enfants Malad, INSERM, U980, GHMI, F-75015 Paris, France","Latour, S (reprint author), Hop Necker Enfants Malad, INSERM, U768, Lab Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France.","sylvain.latour@inserm.fr",null,null,"Inserm; Agence Nationale de la Recherche [ANR-05-MIM-010, ANR-08-MIEN-012-01]; XLP Research Trust (United Kingdom); Czech Ministery of Health [NS 10 480-3]; Fondazione Ettore e Valeria Rossi; Walter und Gertrud Siegenthaler Stiftung","This work was supported by grants from Inserm, the Agence Nationale de la Recherche (ANR-05-MIM-010 and ANR-08-MIEN-012-01; S.L.), the XLP Research Trust (United Kingdom; S.L.), the Czech Ministery of Health (NS 10 480-3; E.M.), the Fondazione Ettore e Valeria Rossi (J.P.S.), and the Walter und Gertrud Siegenthaler Stiftung (J.P.S.). S.L. is a senior scientist of Center National de la Recherche Scientifique (CNRS, France).",null,36,43,45,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","FEB 3",2011,117,5,null,null,null,null,1522,1529,null,"10.1182/blood-2010-07-298372",null,8,"Hematology","Hematology","715WV","WOS:000286925500018"]
[null,null,null,null,"J","Booth, C; Gilmour, KC; Veys, P; Gennery, AR; Slatter, MA; Chapel, H; Heath, PT; Steward, CG; Smith, O; O'Meara, A; Kerrigan, H; Mahlaoui, N; Cavazzana-Calvo, M; Fischer, A; Moshous, D; Blanche, S; Pachlopnick-Schmid, J; Latour, S; de Saint-Basile, G; Albert, M; Notheis, G; Rieber, N; Strahm, B; Ritterbusch, H; Lankester, A; Hartwig, NG; Meyts, I; Plebani, A; Soresina, A; Finocchi, A; Pignata, C; Cirillo, E; Bonanomi, S; Peters, C; Kalwak, K; Pasic, S; Sedlacek, P; Jazbec, J; Kanegane, H; Nichols, KE; Hanson, IC; Kapoor, N; Haddad, E; Cowan, M; Choo, S; Smart, J; Arkwright, PD; Gaspar, HB",null,null,null,"Booth, Claire; Gilmour, Kimberly C.; Veys, Paul; Gennery, Andrew R.; Slatter, Mary A.; Chapel, Helen; Heath, Paul T.; Steward, Colin G.; Smith, Owen; O'Meara, Anna; Kerrigan, Hilary; Mahlaoui, Nizar; Cavazzana-Calvo, Marina; Fischer, Alain; Moshous, Despina; Blanche, Stephane; Pachlopnick-Schmid, Jana; Latour, Sylvain; de Saint-Basile, Genevieve; Albert, Michael; Notheis, Gundula; Rieber, Nikolaus; Strahm, Brigitte; Ritterbusch, Henrike; Lankester, Arjan; Hartwig, Nico G.; Meyts, Isabelle; Plebani, Alessandro; Soresina, Annarosa; Finocchi, Andrea; Pignata, Claudio; Cirillo, Emilia; Bonanomi, Sonia; Peters, Christina; Kalwak, Krzysztof; Pasic, Srdjan; Sedlacek, Petr; Jazbec, Janez; Kanegane, Hirokazu; Nichols, Kim E.; Hanson, I. Celine; Kapoor, Neena; Haddad, Elie; Cowan, Morton; Choo, Sharon; Smart, Joanne; Arkwright, Peter D.; Gaspar, Hubert B.",null,null,"X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"STEM-CELL TRANSPLANTATION; BARR-VIRUS INFECTION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; CUTTING EDGE; T-CELLS; LYMPHOCYTIC VASCULITIS; ENCODING GENE; SAP; ACTIVATION; MONONUCLEOSIS","X-linked lymphoproliferative disease (XLP1) is a rare immunodeficiency characterized by severe immune dysregulation and caused by mutations in the SH2D1A/SAP gene. Clinical manifestations are varied and include hemophagocytic lymphohistiocytosis (HLH), lymphoma and dysgammaglobulinemia, often triggered by Epstein-Barr virus infection. Historical data published before improved treatment regimens shows very poor outcome. We describe a large cohort of 91 genetically defined XLP1 patients collected from centers worldwide and report characteristics and outcome data for 43 patients receiving hematopoietic stem cell transplant (HSCT) and 48 untransplanted patients. The advent of better treatment strategies for HLH and malignancy has greatly reduced mortality for these patients, but HLH still remains the most severe feature of XLP1. Survival after allogeneic HSCT is 81.4% with good immune reconstitution in the large majority of patients and little evidence of posttransplant lymphoproliferative disease. However, survival falls to 50% in patients with HLH as a feature of disease. Untransplanted patients have an overall survival of 62.5% with the majority on immunoglobulin replacement therapy, but the outcome for those untransplanted after HLH is extremely poor (18.8%). HSCT should be undertaken in all patients with HLH, because outcome without transplant is extremely poor. The outcome of HSCT for other manifestations of XLP1 is very good, and if HSCT is not undertaken immediately, patients must be monitored closely for evidence of disease progression. (Blood. 2011;117(1):53-62)","[Booth, Claire; Gilmour, Kimberly C.; Veys, Paul; Gaspar, Hubert B.] Inst Child Hlth, Ctr Immunodeficiency, Mol Immunol Unit, London WC1N 1EH, England; [Gennery, Andrew R.; Slatter, Mary A.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Chapel, Helen] Univ Oxford, Dept Clin Immunol, Nuffield Dept Med, Oxford, England; [Chapel, Helen] Oxford Radcliffe Hosp, Oxford, England; [Heath, Paul T.] St George Hosp, London, England; [Steward, Colin G.] Royal Hosp Children, Bone Marrow Transplant Unit, Bristol, Avon, England; [Smith, Owen; O'Meara, Anna; Kerrigan, Hilary] Our Ladys Childrens Hosp, Dept Haematol & Oncol, Dublin, Ireland; [Mahlaoui, Nizar; Cavazzana-Calvo, Marina; Fischer, Alain; Moshous, Despina; Blanche, Stephane; Pachlopnick-Schmid, Jana] Assistance Publ Hop Paris, Hop Necker Enfants Malad, Unite Immuno Hematol & Rhumatol Pediat, Paris, France; [Latour, Sylvain; de Saint-Basile, Genevieve] Hop Necker Enfants Malad, INSERM, U678, Paris, France; [Albert, Michael; Notheis, Gundula; Rieber, Nikolaus] Univ Munich, Dr Von Haunerschen Kinderspital, Dept Pediat Hematol Oncol & Infect Immun, D-80337 Munich, Germany; [Strahm, Brigitte] Univ Freiburg, Ctr Pediat & Adolescent Med, Freiburg, Germany; [Ritterbusch, Henrike] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, Freiburg, Germany; [Lankester, Arjan] Leiden Univ, Med Ctr, Dept Pediat, Div Immunol Haematol Oncol Bone Marrow Transplant, Leiden, Netherlands; [Hartwig, Nico G.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Paediat Infect Dis & Immunol, Rotterdam, Netherlands; [Meyts, Isabelle] Univ Hosp Leuven, Dept Paediat, Louvain, Belgium; [Plebani, Alessandro; Soresina, Annarosa] Univ Brescia, Dept Pediat, Brescia, Italy; [Finocchi, Andrea] Univ Roma Tor Vergata, Childrens Hosp Bambino Gesu, Dept Pediat, Unit Immunoinfectivol, Rome, Italy; [Pignata, Claudio; Cirillo, Emilia] Univ Naples Federico 2, Dept Pediat, Naples, Italy; [Bonanomi, Sonia] Uni Milano Bicocca, Osped San Gerardo, Pediat Clin, Ctr Trapianto Midollo Osseo, Monza, Italy; [Peters, Christina] St Anna Childrens Hosp, Bone Marrow Transplantat Unit, A-1090 Vienna, Austria; [Kalwak, Krzysztof] Med Acad Wroclaw, Dept Paediat Haematol & Oncol, Wroclaw, Poland; [Pasic, Srdjan] Mother & Child Hlth Inst Dr Vukan Cupic, Dept Paediat Immunol, Belgrade, Serbia; [Pasic, Srdjan] Mother & Child Hlth Inst Dr Vukan Cupic, Dept Pathol, Belgrade, Serbia; [Pasic, Srdjan] Mother & Child Hlth Inst Dr Vukan Cupic, Dept Transfus Med, Belgrade, Serbia; [Sedlacek, Petr] Charles Univ Prague, Univ Hosp Motol, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Jazbec, Janez] Univ Ljubljana, Med Ctr, Div Hematol & Oncol, Dept Pediat, Ljubljana 61000, Slovenia; [Kanegane, Hirokazu] Toyama Univ, Grad Sch Med, Dept Paediat, Toyama 930, Japan; [Nichols, Kim E.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Hanson, I. Celine] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Kapoor, Neena] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Res Immunol Bone Marrow Transplantat, Los Angeles, CA 90033 USA; [Haddad, Elie] Univ Montreal, Ctr Hosp Univ St Justine, Dept Pediat & Microbiol & Immunol, Montreal, PQ, Canada; [Cowan, Morton] Univ Calif San Francisco, Childrens Hosp, Pediat Blood & Marrow Transplant Div, San Francisco, CA 94143 USA; [Choo, Sharon; Smart, Joanne] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Arkwright, Peter D.] Univ Manchester, Royal Manchester Childrens Hosp, Manchester, Lancs, England","Gaspar, HB (reprint author), Inst Child Hlth, Ctr Immunodeficiency, Mol Immunol Unit, 30 Guilford St, London WC1N 1EH, England.","h.gaspar@ich.ucl.ac.uk","Plebani, Alessandro/C-8593-2011; Arkwright, Peter/C-5149-2012; Pignata, Claudio/O-2466-2013","Pignata, Claudio/0000-0003-1568-9843","Wellcome Trust [082159/2/07/2]","This work was supported by the Wellcome Trust (082159/2/07/2; C.B. is a Clinical Research Fellow).",null,41,40,44,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","JAN 6",2011,117,1,null,null,null,null,53,62,null,"10.1182/blood-2010-06-284935",null,10,"Hematology","Hematology","703FO","WOS:000285963900014"]
[null,null,null,null,"J","Cardwell, CR; Stene, LC; Joner, G; Bulsara, MK; Cinek, O; Rosenbauer, J; Ludvigsson, J; Svensson, J; Goldacre, MJ; Waldhoer, T; Jarosz-Chobot, P; Gimeno, SGA; Chuang, LM; Roberts, CL; Parslow, RC; Wadsworth, EJK; Chetwynd, A; Brigis, G; Urbonaite, B; Sipetic, S; Schober, E; Devoti, G; Ionescu-Tirgoviste, C; de Beaufort, CE; Stoyanov, D; Buschard, K; Radon, K; Glatthaar, C; Patterson, CC",null,null,null,"Cardwell, Chris R.; Stene, Lars C.; Joner, Geir; Bulsara, Max K.; Cinek, Ondrej; Rosenbauer, Joachim; Ludvigsson, Johnny; Svensson, Jannet; Goldacre, Michael J.; Waldhoer, Thomas; Jarosz-Chobot, Przemyslawa; Gimeno, Suely G. A.; Chuang, Lee-Ming; Roberts, Christine L.; Parslow, Roger C.; Wadsworth, Emma J. K.; Chetwynd, Amanda; Brigis, Girts; Urbonaite, Brone; Sipetic, Sandra; Schober, Edith; Devoti, Gabriele; Ionescu-Tirgoviste, Constantin; de Beaufort, Carine E.; Stoyanov, Denka; Buschard, Karsten; Radon, Katja; Glatthaar, Christopher; Patterson, Chris C.",null,null,"Birth order and childhood type 1 diabetes risk: a pooled analysis of 31 observational studies","INTERNATIONAL JOURNAL OF EPIDEMIOLOGY",null,null,"English","Article",null,null,null,null,null,"Diabetes mellitus; type 1; epidemiology; birth order; meta-analysis","MATERNAL AGE; EARLY-LIFE; MELLITUS; CHILDREN; DETERMINANTS; ONSET; IDDM; INFECTIONS; DELIVERY; UK","Background The incidence rates of childhood onset type 1 diabetes are almost universally increasing across the globe but the aetiology of the disease remains largely unknown. We investigated whether birth order is associated with the risk of childhood diabetes by performing a pooled analysis of previous studies. Methods Relevant studies published before January 2010 were identified from MEDLINE, Web of Science and EMBASE. Authors of studies provided individual patient data or conducted pre-specified analyses. Meta-analysis techniques were used to derive combined odds ratios (ORs), before and after adjustment for confounders, and investigate heterogeneity. Results Data were available for 6 cohort and 25 case-control studies, including 11 955 cases of type 1 diabetes. Overall, there was no evidence of an association prior to adjustment for confounders. After adjustment for maternal age at birth and other confounders, a reduction in the risk of diabetes in second- or later born children became apparent [fully adjusted OR = 0.90 95% confidence interval (CI) 0.83-0.98; P = 0.02] but this association varied markedly between studies (I(2) = 67%). An a priori subgroup analysis showed that the association was stronger and more consistent in children < 5 years of age (n = 25 studies, maternal age adjusted OR = 0.84 95% CI 0.75, 0.93; I(2) = 23%). Conclusion Although the association varied between studies, there was some evidence of a lower risk of childhood onset type 1 diabetes with increasing birth order, particularly in children aged < 5 years. This finding could reflect increased exposure to infections in early life in later born children.","[Cardwell, Chris R.] Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Belfast BT12 6BJ, Antrim, North Ireland; [Stene, Lars C.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Stene, Lars C.] Oslo Univ Hosp, Oslo Diabet Res Ctr, Oslo, Norway; [Joner, Geir] Univ Oslo, Inst Hlth Management & Hlth Econ, Oslo, Norway; [Bulsara, Max K.] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Bulsara, Max K.] Univ Notre Dame, Inst Hlth & Rehabil Res, Fremantle, Australia; [Cinek, Ondrej] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Rosenbauer, Joachim] Univ Dusseldorf, Leibniz Inst, Inst Biometr & Epidemiol, German Diabet Ctr, Dusseldorf, Germany; [Ludvigsson, Johnny] Linkoping Univ, Dept Paediat, Linkoping, Sweden; [Ludvigsson, Johnny] Linkoping Univ, Diabet Res Ctr, Linkoping, Sweden; [Svensson, Jannet] Glostrup Univ Hosp, Dept Pediat, Glostrup, Denmark; [Goldacre, Michael J.] Univ Oxford, Dept Publ Hlth, Oxford, England; [Waldhoer, Thomas] Med Univ Vienna, Dept Epidemiol, Vienna, Austria; [Jarosz-Chobot, Przemyslawa] Med Univ Silesia, Dept Pediat Endocrinol & Diabet, Katowice, Poland; [Gimeno, Suely G. A.] Univ Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil; [Chuang, Lee-Ming] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Roberts, Christine L.] Univ Sydney, Kolling Inst Med Res, Sydney, NSW 2006, Australia; [Parslow, Roger C.] Univ Leeds, Paediat Epidemiol Grp, Leeds, W Yorkshire, England; [Wadsworth, Emma J. K.] Cardiff Univ, Ctr Occupat & Hlth Psychol, Cardiff, S Glam, Wales; [Chetwynd, Amanda] Univ Lancaster, Dept Math & Stat, Lancaster, England; [Brigis, Girts] Riga Stradins Univ, Dept Publ Hlth & Epidemiol, Riga, Latvia; [Urbonaite, Brone] Kaunas Univ Med, Inst Endocrinol, Kaunas, Lithuania; [Sipetic, Sandra] Univ Belgrade, Sch Med, Inst Epidemiol, Belgrade, Serbia; [Schober, Edith] Med Univ Vienna, Dept Paediat, Vienna, Austria; [Devoti, Gabriele] Univ Lecce, Dept Social Sci & Commun, I-73100 Lecce, Italy; [Ionescu-Tirgoviste, Constantin] N Paulescu Inst Diabet, Nutr & Metab Dis Clin, Bucharest, Romania; [de Beaufort, Carine E.] Pediat Clin, Luxembourg, Luxembourg; [Stoyanov, Denka] Childrens Diabet Ctr, Sofia, Bulgaria; [Buschard, Karsten] Rigshosp, Bartholin Inst, DK-2100 Copenhagen, Denmark; [Radon, Katja] Hosp LMU Munich, Inst Occupat & Environm Med, Munich, Germany; [Radon, Katja] Hosp LMU Munich, Outpatient Clin Occupat & Environm Med, Munich, Germany; [Glatthaar, Christopher] Sir Charles Gairdner Hosp, Perth, WA, Australia","Cardwell, CR (reprint author), Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.","c.cardwell@qub.ac.uk","GIMENO, SUELY/K-3888-2012; Chetwynd, Amanda/B-4727-2013","Chetwynd, Amanda/0000-0002-7659-3231","Czech Republic Ministry of Education [MSM 0021620814]; Department of Health of Taiwan [DOH 90-TD1028]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [94/0943-0]; Swedish Child Diabetes Foundation; NHS National Coordinating Centre for Research Capacity Development UK; Australian National Health and Medical Research Council (NHMRC) [457302]; Research Council of Norway; German Research Foundation [HE 234/1-1]; Ministry for Science and Technological Development of Serbia [145084]; European Commission Health Information Strand [2007115]; Diabetes UK; Northern Ireland Department of Health and Social Services","This pooled analysis was not directly funded but the authors acknowledge support for the conduct of the original studies from the following: the Czech Republic Ministry of Education (grant MSM 0021620814), Department of Health of Taiwan (DOH 90-TD1028), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (grant 94/0943-0), The Swedish Child Diabetes Foundation, the NHS National Coordinating Centre for Research Capacity Development UK, Australian National Health and Medical Research Council (NHMRC) (project grant #457302), the Research Council of Norway, the German Research Foundation (grant HE 234/1-1), the Ministry for Science and Technological Development of Serbia (No. 145084, 2006-2010), EUBIROD funded by the European Commission Health Information Strand (DG-SANCO 2005, Contract No 2007115), Diabetes UK and the Northern Ireland Department of Health and Social Services.",null,48,14,15,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0300-5771",null,null,"INT J EPIDEMIOL","Int. J. Epidemiol.","APR",2011,40,2,null,null,null,null,363,374,null,"10.1093/ije/dyq207",null,12,"Public, Environmental & Occupational Health","Public, Environmental & Occupational Health","745LB","WOS:000289165800015"]
[null,null,null,null,"J","Rees, L; Azocar, M; Borzych, D; Watson, AR; Buscher, A; Edefonti, A; Bilge, I; Askenazi, D; Leozappa, G; Gonzales, C; van Hoeck, K; Secker, D; Zurowska, A; Ronnholm, K; Bouts, AHM; Stewart, H; Ariceta, G; Ranchin, B; Warady, BA; Schaefer, F",null,null,null,"Rees, Lesley; Azocar, Marta; Borzych, Dagmara; Watson, Alan R.; Buescher, Anja; Edefonti, Alberto; Bilge, Ilmay; Askenazi, David; Leozappa, Giovanna; Gonzales, Claudia; van Hoeck, Koen; Secker, Donna; Zurowska, Aleksandra; Ronnholm, Kai; Bouts, Antonia H. M.; Stewart, Heather; Ariceta, Gema; Ranchin, Bruno; Warady, Bradley A.; Schaefer, Franz",null,"Int Pediat Peritoneal Dialysis Net","Growth in Very Young Children Undergoing Chronic Peritoneal Dialysis","JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,null,"CHRONIC-RENAL-FAILURE; HORMONE TREATMENT; INFANTS","Very young children with chronic kidney disease often have difficulty maintaining adequate nutrition, which contributes to the high prevalence of short stature in this population. Characteristics of the dialysis prescription and supplemental feeding via a nasogastric (NG) tube or gastrostomy may improve growth, but this is not well understood. Here, we analyzed data from 153 children in 18 countries who commenced chronic peritoneal dialysis at <24 months of age. From diagnosis to last observation, 57 patients were fed on demand, 54 by NG tube, and 10 by gastrostomy; 26 switched from NG to gastrostomy; and 6 returned from NG to demand feeding. North American and European centers accounted for nearly all feeding by gastrostomy. Standardized body mass index (BMI) uniformly decreased during periods of demand feeding and increased during NG and gastrostomy feeding. Changes in BMI demonstrated significant regional variation: 26% of North American children were obese and 50% of Turkish children were malnourished at last observation (P < 0.005). Body length decreased sharply during the first 6 to 12 months of life and then tended to stabilize. Time fed by gastrostomy significantly associated with higher lengths over time (P < 0.001), but adjustment for baseline length attenuated this effect. In addition, the use of biocompatible peritoneal dialysate and administration of growth hormone independently associated with improved length, even after adjusting for regional factors. In summary, growth and nutritional status vary regionally in very young children treated with chronic peritoneal dialysis. The use of gastrostomy feeding, biocompatible dialysis fluid, and growth hormone therapy associate with improved linear growth.","[Rees, Lesley] Great Ormond St Hosp Sick Children, Renal Off, London WC1N 3JH, England; [Azocar, Marta] Hosp Ninos Luis Calvo Mackenna, Santiago, Chile; [Borzych, Dagmara; Schaefer, Franz] Ctr Pediat & Adolescent Med, Heidelberg, Germany; [Borzych, Dagmara; Zurowska, Aleksandra] Med Univ Gdansk, Gdansk, Poland; [Watson, Alan R.] Children & Young Peoples Kidney Unit, Notthingham, England; [Buescher, Anja] Univ Kinderklin Essen, Essen, Germany; [Edefonti, Alberto] Fdn Osped Maggiore Policlin, Milan, Italy; [Bilge, Ilmay] Istanbul Univ, Fac Med, Istanbul, Turkey; [Askenazi, David] Childrens Hosp Alabama, Birmingham, AL USA; [Leozappa, Giovanna] Unita Dialisi, Rome, Italy; [Gonzales, Claudia] Hosp Sotero del Rio, Santiago, Chile; [van Hoeck, Koen] Univ Antwerp Hosp, Edegem, Belgium; [Secker, Donna] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Ronnholm, Kai] HUCH Hosp Children & Adolescents, Helsinki, Finland; [Bouts, Antonia H. M.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Stewart, Heather] Univ N Carolina, Chapel Hill, NC USA; [Ariceta, Gema] Hosp Cruces, Baracaldo, Spain; [Ranchin, Bruno] Hop Femme Mere Enfant, Lyon, France; [Warady, Bradley A.] Childrens Mercy Hosp, Kansas City, MO 64108 USA","Rees, L (reprint author), Great Ormond St Hosp Sick Children, Renal Off, London WC1N 3JH, England.","Reesl@gosh.nhs.uk","Hereditarias, Renales /E-4244-2012; Rees, Lesley/C-5027-2008; Cruces, Bio Cruces/F-5487-2012; Schaefer, Franz/G-4365-2010; Ariceta, Gema/J-4100-2012",null,"International Society for Peritoneal Dialysis; Baxter Health Care; Fresenius Medical Care, Ipsen; Pfizer; IBM; Sandoz; IPPN","The authors gratefully acknowledge the support of the International Society for Peritoneal Dialysis, Baxter Health Care, Fresenius Medical Care, Ipsen, Pfizer, IBM, and Sandoz. We also appreciate the continued dedicated support of IPPN by the medical and nursing staff in all collaborating centers.","Coleman JE, 1998, NEPHROL DIAL TRANSPL, V13, P2041, DOI 10.1093/ndt/13.8.2041; FINE RN, 1995, PEDIATR NEPHROL, V9, P452; Fischbach M, 2009, PEDIATR NEPHROL, V24, P1633, DOI 10.1007/s00467-008-0979-7; GUILLOT M, 1980, ARCH FR PEDIATR, V37, P497; Kari JA, 2000, KIDNEY INT, V57, P1681, DOI 10.1046/j.1523-1755.2000.00013.x; Karlberg J, 1996, PEDIATR NEPHROL, V10, P283; KDOQI Work Group, 2009, AM J KIDNEY DIS, V53, pS11; Ledermann SE, 2002, PEDIATR NEPHROL, V17, P246; Ledermann SE, 2000, J PEDIATR, V136, P24, DOI 10.1016/S0022-3476(00)90044-1; Maxwell H, 1996, ARCH DIS CHILD, V74, P40; Mekahli D, 2010, CLIN J AM SOC NEPHRO, V5, P10, DOI 10.2215/CJN.05600809; Mencarelli F, 2009, PEDIATR NEPHROL, V24, P1039, DOI 10.1007/s00467-008-1084-7; Parekh RS, 2001, J AM SOC NEPHROL, V12, P2418; Ramage IJ, 1999, PERITON DIALYSIS INT, V19, P231; Rees L, 2007, PEDIATR NEPHROL, V22, P1689, DOI 10.1007/s00467-006-0279-z; Rees L, 2010, PEDIATR NEPHROL, V25, P699, DOI 10.1007/s00467-009-1309-4; REES L, 1989, ARCH DIS CHILD, V64, P573; STRIFE CF, 1986, AM J DIS CHILD, V140, P438; WHO Multicentre Growth Reference Study Group, 2006, WHO CHILD GROWTH STA",19,9,10,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1046-6673",null,null,"J AM SOC NEPHROL","J. Am. Soc. Nephrol.","DEC",2011,22,12,null,null,null,null,2303,2312,null,"10.1681/ASN.2010020192",null,10,"Urology & Nephrology","Urology & Nephrology","863WJ","WOS:000298198700023"]
[null,null,null,null,"J","Hollink, IHIM; van den Heuvel-Eibrink, MM; Arentsen-Peters, STCJM; Pratcorona, M; Abbas, S; Kuipers, JE; van Galen, JF; Beverloo, HB; Sonneveld, E; Kaspers, GJJL; Trka, J; Baruchel, A; Zimmermann, M; Creutzig, U; Reinhardt, D; Pieters, R; Valk, PJM; Zwaan, CM",null,null,null,"Hollink, Iris H. I. M.; van den Heuvel-Eibrink, Marry M.; Arentsen-Peters, Susan T. C. J. M.; Pratcorona, Marta; Abbas, Saman; Kuipers, Jenny E.; van Galen, Janneke F.; Beverloo, H. Berna; Sonneveld, Edwin; Kaspers, Gert-Jan J. L.; Trka, Jan; Baruchel, Andre; Zimmermann, Martin; Creutzig, Ursula; Reinhardt, Dirk; Pieters, Rob; Valk, Peter J. M.; Zwaan, C. Michel",null,null,"NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-SITU HYBRIDIZATION; HEMATOPOIETIC MALIGNANCIES; NPM1 MUTATIONS; LEUKEMOGENESIS; NUP98-HOXA9; REARRANGEMENTS; PREVALENCE; ACTIVATION; SIGNATURES","Translocations involving nucleoporin 98kD (NUP98) on chromosome 11p15 occur at relatively low frequency in acute myeloid leukemia (AML) but can be missed with routine karyotyping. In this study, high-resolution genome-wide copy number analyses revealed cryptic NUP98/NSD1 translocations in 3 of 92 cytogenetically normal (CN)-AML cases. To determine their exact frequency, we screened > 1000 well-characterized pediatric and adult AML cases using a NUP98/NSD1-specific RT-PCR. Twenty-three cases harbored the NUP98/NSD1 fusion, representing 16.1% of pediatric and 2.3% of adult CN-AML patients. NUP98/NSD1-positive AML cases had significantly higher white blood cell counts (median, 147 x 10(9)/L), more frequent FAB-M4/M5 morphology (in 63%), and more CN-AML (in 78%), FLT3/internal tandem duplication (in 91%) and WT1 mutations (in 45%) than NUP98/NSD1-negative cases. NUP98/NSD1 was mutually exclusive with all recurrent type-II aberrations. Importantly, NUP98/NSD1 was an independent predictor for poor prognosis; 4-year event-free survival was < 10% for both pediatric and adult NUP98/NSD1-positive AML patients. NUP98/NSD1-positive AML showed a characteristic HOX-gene expression pattern, distinct from, for example, MLL-rearranged AML, and the fusion protein was aberrantly localized in nuclear aggregates, providing insight into the leukemogenic pathways of these AMLs. Taken together, NUP98/NSD1 identifies a previously unrecognized group of young AML patients, with distinct characteristics and dismal prognosis, for whom new treatment strategies are urgently needed. (Blood. 2011; 118(13):3645-3656)","[Zwaan, C. Michel] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands; [Pratcorona, Marta; Abbas, Saman; van Galen, Janneke F.; Beverloo, H. Berna; Valk, Peter J. M.] Erasmus Univ, Med Ctr, Rotterdam, Netherlands; [Sonneveld, Edwin; Kaspers, Gert-Jan J. L.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Kaspers, Gert-Jan J. L.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Trka, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Baruchel, Andre] Hosp St Louis, Paris, France; [Zimmermann, Martin; Reinhardt, Dirk] Hannover Med Sch, Acute Myeloid Leukemia Berlin Frankfurt Munster A, D-3000 Hannover, Germany; [Creutzig, Ursula] Univ Hosp, AML BFM Study Grp, Munster, Germany","Zwaan, CM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.","c.m.zwaan@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Pediatric Oncology Foundation Rotterdam (KOCR) foundation, Rotterdam, The Netherlands; Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Health, Spain [CM08/00027]","I.H.I.M.H. has been supported by a grant from the Pediatric Oncology Foundation Rotterdam (KOCR) foundation, Rotterdam, The Netherlands. M. P. has been supported by a grant (CM08/00027) from Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Health, Spain.",null,46,26,28,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","SEP 29",2011,118,13,null,null,null,null,3645,3656,null,"10.1182/blood-2011-04-346643",null,12,"Hematology","Hematology","826MW","WOS:000295359300030"]
[null,null,null,null,"J","van Delft, FW; Horsley, S; Colman, S; Anderson, K; Bateman, C; Kempski, H; Zuna, J; Eckert, C; Saha, V; Kearney, L; Ford, A; Greaves, M",null,null,null,"van Delft, Frederik W.; Horsley, Sharon; Colman, Sue; Anderson, Kristina; Bateman, Caroline; Kempski, Helena; Zuna, Jan; Eckert, Cornelia; Saha, Vaskar; Kearney, Lyndal; Ford, Anthony; Greaves, Mel",null,null,"Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"TEL-AML1 FUSION GENE; CHROMOSOME TRANSLOCATIONS; CHILDHOOD LEUKEMIA; TEL DELETION; CANCER; CHILDREN; IDENTIFICATION; LEUKEMOGENESIS; ABNORMALITIES; SELECTION","B-cell precursor childhood acute lymphoblastic leukemia with ETV6-RUNX1 (TELAML1) fusion has an overall good prognosis, but relapses occur, usually after cessation of treatment and occasionally many years later. We have investigated the clonal origins of relapse by comparing the profiles of genomewide copy number alterations at presentation in 21 patients with those in matched relapse (12-119 months). We identified, in total, 159 copy number alterations at presentation and 231 at relapse (excluding Ig/TCR). Deletions of CDKN2A/B or CCNC (6q16.2-3) or both increased from 38% at presentation to 76% in relapse, suggesting that cell-cycle deregulation contributed to emergence of relapse. A novel observation was recurrent gain of chromosome 16 (2 patients at presentation, 4 at relapse) and deletion of plasmocytoma variant translocation 1 in 3 patients. The data indicate that, irrespective of time to relapse, the relapse clone was derived from either a major or minor clone at presentation. Backtracking analysis by FISH identified a minor subclone at diagnosis whose genotype matched that observed in relapse similar to 10 years later. These data indicate subclonal diversity at diagnosis, providing a variable basis for intraclonal origins of relapse and extended periods (years) of dormancy, possibly by quiescence, for stem cells in ETV6-RUNX1(+) acute lymphoblastic leukemia. (Blood. 2011; 117(23): 6247-6254)","[van Delft, Frederik W.; Horsley, Sharon; Colman, Sue; Anderson, Kristina; Bateman, Caroline; Kearney, Lyndal; Ford, Anthony; Greaves, Mel] Inst Canc Res, Sect Haematooncol, Sutton SM2 5NG, Surrey, England; [Kempski, Helena] Great Ormond St Hosp Sick Children, Paediat Malignancy Cytogenet Unit, London, England; [Zuna, Jan] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CLIP, Prague, Czech Republic; [Eckert, Cornelia] Charite, Dept Pediat Oncol Hematol, D-13353 Berlin, Germany; [Saha, Vaskar] Univ Manchester, Manchester Acad Hlth Sci Ctr, CRUK Childrens Canc Grp, Manchester, Lancs, England; [Saha, Vaskar] Cent Manchester Hosp Univ Trust, Manchester, Lancs, England","Greaves, M (reprint author), Inst Canc Res, Sect Haematooncol, Brookes Lawley Bldg,15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.","mel.greaves@icr.ac.uk",null,null,"Leukemia Research Fund (LRF); Kay Kendall Intermediate Fellowship (F.W.v.D.);  [MSM0021620813];  [NS/1000-4]","This work was supported by a Leukemia Research Fund (LRF) grant (M.G.), Kay Kendall Intermediate Fellowship (F.W.v.D.) and (grants MSM0021620813 and NS/1000-4; J.Z.).",null,48,25,25,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","JUN 9",2011,117,23,null,null,null,null,6247,6254,null,"10.1182/blood-2010-10-314674",null,8,"Hematology","Hematology","775DI","WOS:000291438000026"]
[null,null,null,null,"J","Krizkova, S; Zitka, O; Masarik, M; Adam, V; Stiborova, M; Eckschlager, T; Chavis, GJ; Kizek, R",null,null,null,"Krizkova, Sona; Zitka, Ondrej; Masarik, Michal; Adam, Vojtech; Stiborova, Marie; Eckschlager, Tomas; Chavis, Grace J.; Kizek, Rene",null,null,"Assays for determination of matrix metalloproteinases and their activity","TRAC-TRENDS IN ANALYTICAL CHEMISTRY",null,null,"English","Review",null,null,null,null,null,"Activity-based profiling; Cancer; Disease marker; Enzymatic method; Fluorimetric method; Immunochemical method; In-vivo imaging; Matrix metalloproteinase (MMP); Multiple-enzyme/multiple-reagent assay system (MEMRAS); Phage display","IN-SITU ZYMOGRAPHY; CHRONOPOTENTIOMETRIC STRIPPING ANALYSIS; GELATIN ZYMOGRAPHY; REVERSE ZYMOGRAPHY; PHAGE DISPLAY; MATRIX-METALLOPROTEINASE-9 ACTIVITY; PROTEOLYTIC-ENZYMES; TISSUE INHIBITORS; PROTEASE ASSAY; VIVO","Matrix metalloproteinases (MMPs) are involved in many physiological and pathological processes. Due to their ability to cleave and to remodel components of surrounding tissues, MMPs may affect cell migration, differentiation, growth, inflammatory processes, neovascularization, wound healing, apoptosis, the uterine cycle and many other actions within the body, including those needed for tumorigenesis and other diseases. MMPs can therefore be used as potential markers for detecting various cancers, neurodegenerative, and immune and cardiovascular diseases. Numerous MMP assays were developed for clinical and research purposes, but far more attention has been devoted to understanding their biological functions. Due to differences in methodology, results obtained in various laboratory settings are difficult to compare because of the lack of standards and analytical methods of validation. Limits of detection of particular methods used for identifying MMPs are also disputable. Enzymatic, immunochemical and fluorimetric methods are particularly suitable for clinical use. In-vivo imaging methods offer many potential advantages in cancer research and diagnostics. Other methods are subject to investigation [e.g., phage display, multiple-enzyme/multiple-reagent assay system (MEMRAS) and activity-based profiling]. (C) 2011 Elsevier Ltd. All rights reserved.","[Krizkova, Sona; Zitka, Ondrej; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Masarik, Michal] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-62500 Brno, Czech Republic; [Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 6, Czech Republic; [Chavis, Grace J.] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA","Kizek, R (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Zitka, Ondrej/E-1107-2012; Krizkova, Sona/E-9617-2012",null,"CEITEC [CZ.1.05/1.1.00/02.0068]; GA AV [IAA401990701]; IGAMZ [10200-3]; NANOSEMED GA AV [KAN208130801]; GACR [P301/10/0356]","Financial support from CEITEC CZ.1.05/1.1.00/02.0068, GA AV IAA401990701, IGAMZ 10200-3, NANOSEMED GA AV KAN208130801 and GACR P301/10/0356 is highly acknowledged.",null,130,3,3,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0165-9936",null,null,"TRAC-TREND ANAL CHEM","Trac-Trends Anal. Chem.","DEC",2011,30,11,null,null,null,null,1819,1832,null,"10.1016/j.trac.2011.06.016",null,14,"Chemistry, Analytical","Chemistry","869TQ","WOS:000298621500017"]
[null,null,null,null,"J","Fucikova, J; Kralikova, P; Fialova, A; Brtnicky, T; Rob, L; Bartunkova, J; Spisek, R",null,null,null,"Fucikova, Jitka; Kralikova, Petra; Fialova, Anna; Brtnicky, Tomas; Rob, Lukas; Bartunkova, Jirina; Spisek, Radek",null,null,"Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response","CANCER RESEARCH",null,null,"English","Article",null,null,null,null,null,null,"GROUP BOX-1 PROTEIN; TOLL-LIKE RECEPTORS; DENDRITIC CELLS; CALRETICULIN EXPOSURE; CROSS-PRESENTATION; NECROTIC CELLS; T-CELLS; CANCER; DEATH; IMMUNOGENICITY","Immunogenic cell death is characterized by the early surface exposure of chaperones including calreticulin and HSPs, which affect dendritic cell (DC) maturation and the uptake and presentation of tumor antigens. It has also been shown that it is characterized by the late release of high mobility group box 1 (HMGB1), which acts through Toll-like receptor 4 (TLR4) and augments the presentation of antigens from dying tumor cells to DCs. Most of the data on immunogenic tumor cell death were obtained using mouse models. In this study, we investigated the capacity of clinically used chemotherapeutics to induce immunogenic cell death in human tumor cell lines and primary tumor cells. We found that only anthracyclines induced a rapid translocation of calreticulin, HSP70, and HSP90 to the cell surface and the release of HMGB1 12 hours after the treatment. The interaction of immature DCs with immunogenic tumor cells led to an increased tumor cell uptake and induces moderate phenotypic maturation of DCs. Killed tumor cell-loaded DCs efficiently stimulated tumor-specific IFN-gamma-producing T cells. DCs pulsed with killed immunogenic tumor cells also induced significantly lower numbers of regulatory T cells than those pulsed with nonimmunogenic tumor cells. These data indicate that human prostate cancer, ovarian cancer, and acute lymphoblastic leukemia cells share the key features of immunogenic cell death with mice tumor cells. These data also identify anthracyclines as anticancer drugs capable of inducing immunogenic cell death in sensitive human tumor cells. Cancer Res; 71(14); 4821-33. (C) 2011 AACR.","[Spisek, Radek] Charles Univ Prague, Inst Immunol, Fac Med 2, Dept Immunol, Prague 5, Czech Republic; [Brtnicky, Tomas; Rob, Lukas] Fac Med 2, Dept Gynecol & Obstet, Prague, Czech Republic; [Brtnicky, Tomas; Rob, Lukas] Univ Hosp Motol, Prague, Czech Republic","Spisek, R (reprint author), Charles Univ Prague, Inst Immunol, Fac Med 2, Dept Immunol, V Uvalu 84, Prague 5, Czech Republic.","radek.spisek@lfmotol.cuni.cz","Spisek, Radek/E-6724-2011",null,"Charles University [GAUK 8976/2008];  [GACR 310/08/0838]","This study was supported by grant GACR 310/08/0838. J. Fucikova was supported by grant GAUK 8976/2008 provided by Charles University.",null,30,33,38,"AMER ASSOC CANCER RESEARCH","PHILADELPHIA","615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA","0008-5472",null,null,"CANCER RES","Cancer Res.","JUL 15",2011,71,14,null,null,null,null,4821,4833,null,"10.1158/0008-5472.CAN-11-0950",null,13,"Oncology","Oncology","792QN","WOS:000292763700010"]
[null,null,null,null,"J","Olk-Batz, C; Poetsch, AR; Nollke, P; Claus, R; Zucknick, M; Sandrock, I; Witte, T; Strahm, B; Hasle, H; Zecca, M; Stary, J; Bergstraesser, E; De Moerloose, B; Trebo, M; van den Heuvel-Eibrink, MM; Wojcik, D; Locatelli, F; Plass, C; Niemeyer, CM; Flotho, C",null,null,null,"Olk-Batz, Christiane; Poetsch, Anna R.; Noellke, Peter; Claus, Rainer; Zucknick, Manuela; Sandrock, Inga; Witte, Tania; Strahm, Brigitte; Hasle, Henrik; Zecca, Marco; Stary, Jan; Bergstraesser, Eva; De Moerloose, Barbara; Trebo, Monika; van den Heuvel-Eibrink, Marry M.; Wojcik, Dorota; Locatelli, Franco; Plass, Christoph; Niemeyer, Charlotte M.; Flotho, Christian",null,"European Working Grp Myelodysplast","Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; MYELODYSPLASTIC SYNDROME; RETROSPECTIVE ANALYSIS; RAS MUTATIONS; TRANSPLANTATION; CHILDREN; SURVIVAL; CANCER; CELLS","Aberrant DNA methylation contributes to the malignant phenotype in virtually all types of cancer, including myeloid leukemia. We hypothesized that CpG island hypermethylation also occurs in juvenile myelomonocytic leukemia (JMML) and investigated whether it is associated with clinical, hematologic, or prognostic features. Based on quantitative measurements of DNA methylation in 127 JMML cases using mass spectrometry (MassARRAY), we identified 4 gene CpG islands with frequent hypermethylation: BMP4 (36% of patients), CALCA (54%), CDKN2B (22%), and RARB (13%). Hypermethylation was significantly associated with poor prognosis: when the methylation data were transformed into prognostic scores using a LASSO Cox regression model, the 5-year overall survival was 0.41 for patients in the top tertile of scores versus 0.72 in the lowest score tertile (P = .002). Among patients given allogeneic hematopoietic stem cell transplantation, the 5-year cumulative incidence of relapse was 0.52 in the highest versus 0.10 in the lowest score tertile (P = .007). In multivariate models, DNA methylation retained prognostic value independently of other clinical risk factors. Longitudinal analyses indicated that some cases acquired a more extensively methylated phenotype at relapse. In conclusion, our data suggest that a high-methylation phenotype characterizes an aggressive biologic variant of JMML and is an important molecular predictor of outcome. (Blood. 2011;117(18):4871-4880)","[Olk-Batz, Christiane; Noellke, Peter; Sandrock, Inga; Strahm, Brigitte; Niemeyer, Charlotte M.; Flotho, Christian] Univ Med Ctr, Dept Pediat & Adolescent Med, Freiburg, Germany; [Olk-Batz, Christiane] Univ Freiburg, Dept Biol, D-79106 Freiburg, Germany; [Poetsch, Anna R.; Claus, Rainer; Witte, Tania; Plass, Christoph] German Canc Res Ctr, Div Epigenom & Canc Risk Factors, D-6900 Heidelberg, Germany; [Zucknick, Manuela] German Canc Res Ctr, Div Biostat, D-6900 Heidelberg, Germany; [Hasle, Henrik] Aarhus Univ Hosp Skejby, Dept Pediat, Aarhus, Denmark; [Zecca, Marco] Policlin San Matteo, Fdn Ist Ricovero & Cura Carattere Sci, I-27100 Pavia, Italy; [Stary, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Stary, Jan] Czech Pediat Hematol Working Grp, Prague, Czech Republic; [Bergstraesser, Eva] Univ Childrens Hosp, Dept Pediat Hematol Oncol, Zurich, Switzerland; [De Moerloose, Barbara] Ghent Univ Hosp, Dept Pediat Hematol Oncol, B-9000 Ghent, Belgium; [Trebo, Monika] St Anna Childrens Hosp, Dept Pediat, A-1090 Vienna, Austria; [van den Heuvel-Eibrink, Marry M.] Erasmus MC, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [van den Heuvel-Eibrink, Marry M.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Wojcik, Dorota] Wroclaw Med Univ, Dept Pediat Hematol Oncol, Wroclaw, Poland; [Locatelli, Franco] Univ Pavia, IRCCS Osped Bambino Gesu, Dept Pediat Hematol Oncol, Rome, Italy","Flotho, C (reprint author), Univ Freiburg, Zentrum Kinder & Jugendmed, Mathildenstr 1, D-79106 Freiburg, Germany.","christian.flotho@uniklinik-freiburg.de",null,null,"Deutsche Forschungsgemeinschaft [KR3473/1-1]; Epigenetic Dysregulation in Myeloid Neoplasia [SPP1463]; Deutsche Krebshilfe [108220]; Deutsche Jose Carreras Leukamiestiftung [R08/19]; Sofia Luce Rebuffat Foundation; European Union [BM0801]; Forderverein fur krebskranke Kinder Freiburg","This work was supported by Deutsche Forschungsgemeinschaft (grant no. KR3473/1-1 to C.F.); by Priority Program SPP1463 \"Epigenetic Dysregulation in Myeloid Neoplasia\" (to C.P., C.M.N., and C.F.); by Deutsche Krebshilfe (grant no. 108220 to C.M.N. and C.F.); by Deutsche Jose Carreras Leukamiestiftung (grant no. R08/19 to C.F.); by the Sofia Luce Rebuffat Foundation (to F.L.); by the European Union COST Action BM0801 (EuGESMA); and by the Forderverein fur krebskranke Kinder Freiburg.",null,40,14,14,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","MAY 5",2011,117,18,null,null,null,null,4871,4880,null,"10.1182/blood-2010-8-298968",null,10,"Hematology","Hematology","759VD","WOS:000290275700031"]
[null,null,null,null,"J","Creutzig, U; Zimmermann, M; Bourquin, JP; Dworzak, MN; von Neuhoff, C; Sander, A; Schrauder, A; Teigler-Schlegel, A; Stary, J; Corbacioglu, S; Reinhardt, D",null,null,null,"Creutzig, Ursula; Zimmermann, Martin; Bourquin, Jean-Pierre; Dworzak, Michael N.; von Neuhoff, Christine; Sander, Annette; Schrauder, Andre; Teigler-Schlegel, Andrea; Stary, Jan; Corbacioglu, Selim; Reinhardt, Dirk",null,null,"Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"ACUTE MYELOID-LEUKEMIA; GROUP-B; PROGNOSTIC-SIGNIFICANCE; CHILDREN; CANCER; MUTATIONS; THERAPY; TRIAL; KIT; INTENSIFICATION","Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) sub-types requires intensification remained to be determined. In the 2 successive studies (AML-BFM-1998 and AML-BFM-2004), 220 CBF-AML patients were treated using the same chemotherapy backbone, whereby reinduction with high-dose cytarabine and mitoxantrone (HAM) was scheduled for these cohorts only in study AML-BFM-1998 but not in AML-BFM-2004 against the background to minimize over-treatment. Five-year overall survival (OS) and event-free survival (EFS) were significantly higher and the cumulative incidence of relapse (CIR) lower in t(8;21) patients treated with HAM (n = 78) compared with without HAM (n = 53): OS 92% +/- 3% versus 80% +/- 6%, p(logrank)0.047, EFS 84% +/- 4% versus 59% +/- 7%, p(logrank)0.001, and CIR 14% +/- 4% versus 34% +/- 7%, p((gray)) 0.006. These differences were not seen for inv(16) (n = 43 and 46, respectively): OS 93% +/- 4% versus 94% +/- 4%, EFS 75% +/- 7% versus 71% +/- 9% and CIR 15% +/- 6% versus 23% +/- 8% (not significant). The subtype t(8; 21), but not inv(16), was an independent predictor of worse outcome without HAM reinduction. Based on our data, a 5-year OS of > 90% can be expected for CBF-AML, when stratifying t(8;21), but not inv(16), patients to high-risk chemotherapy, including HAM reinduction. (Blood. 2011;118(20):5409-5415)","[Creutzig, Ursula] Univ Hosp Muenster, Munster, Germany; [Creutzig, Ursula; Zimmermann, Martin; Sander, Annette; Reinhardt, Dirk] Hannover Med Sch, D-3000 Hannover, Germany; [Bourquin, Jean-Pierre] Univ Zurich, Zurich, Switzerland; [Dworzak, Michael N.] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Dworzak, Michael N.] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Schrauder, Andre] Univ Childrens Hosp, Dept Pediat Hematol Oncol, Kiel, Germany; [Teigler-Schlegel, Andrea] Univ Giessen, Dept Hematol Oncol, Oncogenet Lab, Giessen, Germany; [Stary, Jan] Charles Univ Prague, Prague, Czech Republic; [Stary, Jan] Czech Pediat Hematol Working Grp, Prague, Czech Republic; [Corbacioglu, Selim] Univ Regensburg, Dept Pediat Hematol Oncol & Stem Cell Transplanta, Regensburg, Germany","Creutzig, U (reprint author), Klin & Poliklin Kinderheilkunde, Albert Schweitzer Campus 1, D-48149 Munster, Germany.","ursula@creutzig.de","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Deutsche Krebshilfe e.V.; Czech Ministry of Education [MSM0021620813]","This work was supported by the Deutsche Krebshilfe e.V. and partly by the Czech Ministry of Education (grant MSM0021620813).",null,32,13,14,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","NOV 17",2011,118,20,null,null,null,null,5409,5415,null,"10.1182/blood-2011-07-364661",null,7,"Hematology","Hematology","851JT","WOS:000297265400010"]
[null,null,null,null,"J","Coenen, EA; Raimondi, SC; Harbott, J; Zimmermann, M; Alonzo, TA; Auvrignon, A; Beverloo, HB; Chang, M; Creutzig, U; Dworzak, MN; Forestier, E; Gibson, B; Hasle, H; Harrison, CJ; Heerema, NA; Kaspers, GJL; Leszl, A; Litvinko, N; Lo Nigro, L; Morimoto, A; Perot, C; Reinhardt, D; Rubnitz, JE; Smith, FO; Stary, J; Stasevich, I; Strehl, S; Taga, T; Tomizawa, D; Webb, D; Zemanova, Z; Pieters, R; Zwaan, CM; van den Heuvel-Eibrink, MM",null,null,null,"Coenen, Eva A.; Raimondi, Susana C.; Harbott, Jochen; Zimmermann, Martin; Alonzo, Todd A.; Auvrignon, Anne; Beverloo, H. Berna; Chang, Myron; Creutzig, Ursula; Dworzak, Michael N.; Forestier, Erik; Gibson, Brenda; Hasle, Henrik; Harrison, Christine J.; Heerema, Nyla A.; Kaspers, Gertjan J. L.; Leszl, Anna; Litvinko, Nathalia; Lo Nigro, Luca; Morimoto, Akira; Perot, Christine; Reinhardt, Dirk; Rubnitz, Jeffrey E.; Smith, Franklin O.; Stary, Jan; Stasevich, Irina; Strehl, Sabine; Taga, Takashi; Tomizawa, Daisuke; Webb, David; Zemanova, Zuzana; Pieters, Rob; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.",null,null,"Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"ACUTE MYELOID-LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; ONCOLOGY-GROUP; MYELODYSPLASTIC SYNDROME; COMPLEX KARYOTYPE; UP-REGULATION; CHILDRENS-CANCER; POOR-PROGNOSIS; GENE-MUTATIONS; TRIALS","We previously demonstrated that outcome of pediatric 11q23/MLL-rearranged AML depends on the translocation partner (TP). In this multicenter international study on 733 children with 11q23/MLL-rearranged AML, we further analyzed which additional cytogenetic aberrations (ACA) had prognostic significance. ACAs occurred in 344 (47%) of 733 and were associated with unfavorable outcome (5-year overall survival [OS] 47% vs 62%, P < .001). Trisomy 8, the most frequent specificACA(n = 130/344, 38%), independently predicted favorable outcome within the ACAs group (OS 61% vs 39%, P = .003; Cox model for OS hazard ratio (HR) 0.54, P = .03), on the basis of reduced relapse rate (26% vs 49%, P < .001). Trisomy 19 (n = 37/344, 11%) independently predicted poor prognosis in ACAs cases, which was partly caused by refractory disease (remission rate 74% vs 89%, P = .04; OS 24% vs 50%, P < .001; HR 1.77, P = .01). Structural ACAs had independent adverse prognostic value for event-free survival (HR 1.36, P = .01). Complex karyotype, defined as >= 3 abnormalities, was present in 26% (n = 192/733) and showed worse outcome than those without complex karyotype (OS 45% vs 59%, P = .003) in univariate analysis only. In conclusion, like TP, specific ACAs have independent prognostic significance in pediatric 11q23/MLL-rearranged AML, and the mechanism underlying these prognostic differences should be studied. (Blood. 2011;117(26):7102-7111)","[Coenen, Eva A.; Pieters, Rob; van den Heuvel-Eibrink, Marry M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3000 CB Rotterdam, Netherlands; [Raimondi, Susana C.; Alonzo, Todd A.; Heerema, Nyla A.; Smith, Franklin O.] Childrens Oncol Grp, Arcadia, CA USA; [Raimondi, Susana C.; Rubnitz, Jeffrey E.] St Jude Childrens Hosp, Memphis, TN 38105 USA; [Harbott, Jochen] Univ Giessen, Dept Pediat Hematol & Oncol, Acute Myeloid Leukemia Berlin Frankfurt Munster S, Giessen, Germany; [Zimmermann, Martin; Reinhardt, Dirk] Hannover Med Sch, Acute Myeloid Leukemia Berlin Frankfurt Munster S, D-3000 Hannover, Germany; [Auvrignon, Anne] Hop Trousseau, French Leucemie Aique Myeloide Enfant, F-75571 Paris, France; [Beverloo, H. Berna] Dutch Working Grp Hemato Oncol Genome Diagnost, Dutch Childhood Oncol Grp, The Hague, Netherlands; [Chang, Myron] Childrens Oncol Grp, Ctr Data, Gainesville, FL USA; [Beverloo, H. Berna] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands; [Creutzig, Ursula] Univ Hosp, Acute Myeloid Leukemia Berlin Frankfurt Munster S, Munster, Germany; [Dworzak, Michael N.; Strehl, Sabine] Childrens Canc Res Inst, Vienna, Austria; [Forestier, Erik] Umea Univ, Nord Soc Pediat Hematol & Oncol, Dept Clin Sci, Umea, Sweden; [Gibson, Brenda] Royal Hosp Sick Children, Dept Pediat Oncol Hematol, Glasgow G3 8SJ, Lanark, Scotland; [Hasle, Henrik] Univ Aarhus, Hosp Skejby, Nord Soc Pediat Hematol & Oncol, Dept Pediat, Aarhus, Denmark; [Harrison, Christine J.] Newcastle Univ, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Heerema, Nyla A.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam, Med Ctr, Acute Myeloid Leukemia Comm, Int Berlin Frankfurt Munster Study Grp, Amsterdam, Netherlands; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands; [Leszl, Anna] Univ Padua, Clin Pediat, Italian Assoc Pediat Hematol Oncol, Padua, Italy; [Litvinko, Nathalia; Stasevich, Irina] Res Ctr Pediat Oncol & Hematol, Minsk, Byelarus; [Lo Nigro, Luca] Univ Catania, Pediat Clin, Italian Assoc Pediat Hematol Oncol, Catania, Italy; [Morimoto, Akira] Japanese Pediat Leukemia Lymphoma Study Grp, Nagoya, Aichi, Japan; [Morimoto, Akira] Jichi Med Univ, Sch Med, Dept Pediat, Shimotsuke, Tochigi, Japan; [Smith, Franklin O.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Smith, Franklin O.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA; [Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic; [Taga, Takashi] Shiga Univ Med Sci, Dept Pediat, Shiga, Japan; [Tomizawa, Daisuke] Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Tokyo, Japan; [Webb, David] Great Ormond St Hosp Sick Children, London, England; [Zemanova, Zuzana] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Zemanova, Zuzana] Gen Univ Hosp, Ctr Oncocytogenet, Prague, Czech Republic","van den Heuvel-Eibrink, MM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rm Sp2568,Dr Molewaterplein 60,POB 2060, NL-3000 CB Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Rotterdam Oncology Research Foundation KOCR; Parents' Foundation Giessen; Swedish Childhood Cancer Foundation; Ministry of Health, Labor and Welfare, Japan","This work was funded by the Rotterdam Oncology Research Foundation KOCR (E.A.C.), the Parents' Foundation Giessen (J.H.), the Swedish Childhood Cancer Foundation (E.S.F.), and by a grant for Clinical Cancer Research from the Ministry of Health, Labor and Welfare, Japan (A.M., T.T., D.T.).",null,46,12,12,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","JUN 30",2011,117,26,null,null,null,null,7102,7111,null,"10.1182/blood-2010-12-328302",null,10,"Hematology","Hematology","785QO","WOS:000292244000019"]
[null,null,null,null,"J","Kuipers, JE; Coenen, EA; Balgobind, BV; Stary, J; Baruchel, A; de Haas, V; de Bont, ESJM; Reinhardt, D; Kaspers, GJL; Cloos, J; Danen-van Oorschot, AA; den Boer, ML; Marschalek, R; Meyer, C; Pieters, R; Zwaan, CM; van den Heuvel-Eibrink, MM",null,null,null,"Kuipers, Jenny E.; Coenen, Eva A.; Balgobind, Brian V.; Stary, Jan; Baruchel, Andre; de Haas, Valerie; de Bont, Eveline S. J. M.; Reinhardt, Dirk; Kaspers, Gertjan J. L.; Cloos, Jacqueline; Danen-van Oorschot, Astrid A.; den Boer, Monique L.; Marschalek, Rolf; Meyer, Claus; Pieters, Rob; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.",null,null,"High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23)","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; DRUG SENSITIVITY; ONCOLOGY-GROUP; IN-VIVO; CELL; CHILDREN; RESISTANCE; CHILDHOOD; TSLC1; AML","Pediatric mixed-lineage leukemia (MLL)-rearranged acute monoblastic leukemia with t(9;11)(p22;q23) has a favorable outcome compared with other MLL-rearranged AML. The biologic background for this difference remains unknown. Therefore, we compared gene expression profiles (GEPs; Affymetrix HGU133 + 2.0) of 26 t(9; 11)(p22;q23) patients with 42 other MLL-rearranged AML. patients to identify differentially expressed genes. IGSF4, a cell-cell adhesion molecule, was found to be highly expressed in t(9; 11)(p22; q23) patients, which was confirmed by real-time quantitative polymerase chain reaction and Western blot. IGSF4 expression within t(9;11)(p22;q23) patients was 4.9 times greater in French-American-British morphology classification (FAB)-M5 versus other FAB-types (P = .001). Methylation status investigation showed that high IGSF4-expressing t(9;11)(p22;q23) patients with FAB-M5 have no promoter hypermethylation, whereas all other cases do. Cell-line incubation with demethylating agent decitabine resulted in promoter demethylation and increased expression of IGSF4. Down-regulation of IGSF4 by siRNA did not affect proliferation or drug sensitivity. In a cohort of 79 MLL-rearranged AML cases, we show significant better overall survival for cases with high IGSF4 expression (5-year overall survival 0.70 vs 0.37, P = .03) In conclusion, we identified IGSF4 overexpression to be discriminative for t(9;11)(p22;q23) patients with FAB-M5, regulated partially by promoter methylation and resulting in survival benefit. (Blood.2011;117(3):928-935)","[van den Heuvel-Eibrink, Marry M.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, NL-3000 CB Rotterdam, Netherlands; [Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Baruchel, Andre] St Louis Hosp, Paris, France; [de Haas, Valerie] DCOG, The Hague, Netherlands; [de Bont, Eveline S. J. M.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9713 AV Groningen, Netherlands; [Reinhardt, Dirk] AML BFM Study Grp, Hannover, Germany; [Kaspers, Gertjan J. L.; Cloos, Jacqueline] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [Marschalek, Rolf; Meyer, Claus] Goethe Univ Frankfurt, ZAFES, DCAL, Inst Pharmaceut Biol, Frankfurt, Germany","van den Heuvel-Eibrink, MM (reprint author), Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, Room Sp2568,Dr Molewaterpl 60, NL-3000 CB Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl","Marschalek, Rolf/D-3404-2011; Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Pediatric Oncology Foundation Rotterdam (KOCR); NWO (Netherlands Organization for Scientific Research); Foundation KiKa, Amstelveen, The Netherlands; Deutsche Krebshilfe [107819]","Pediatric Oncology Foundation Rotterdam (KOCR) has funded part of the work of E.A.C. and B.V.B. The work of B.V.B. was also funded by the NWO (Netherlands Organization for Scientific Research). The work of J.E.K. and A.A.D.-v.O. was supported by a grant from the Foundation KiKa, Amstelveen, The Netherlands. R.M. has been partially funded by grant 107819 from Deutsche Krebshilfe.",null,32,7,7,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","JAN 20",2011,117,3,null,null,null,null,928,935,null,"10.1182/blood-2010-05-286138",null,8,"Hematology","Hematology","709GM","WOS:000286426300025"]
[null,null,null,null,"J","Rejman, D; Rabatinova, A; Pombinho, AR; Kovackova, S; Pohl, R; Zbornikova, E; Kolar, M; Bogdanova, K; Nyc, O; Sanderova, H; Latal, T; Bartunek, P; Krasny, L",null,null,null,"Rejman, Dominik; Rabatinova, Alzbeta; Pombinho, Antonio R.; Kovackova, Sona; Pohl, Radek; Zbornikova, Eva; Kolar, Milan; Bogdanova, Katerina; Nyc, Otakar; Sanderova, Hana; Latal, Tomas; Bartunek, Petr; Krasny, Libor",null,null,"Lipophosphonoxins: New Modular Molecular Structures with Significant Antibacterial Properties","JOURNAL OF MEDICINAL CHEMISTRY",null,null,"English","Article",null,null,null,null,null,null,"1ST MEMBRANE STEP; PEPTIDOGLYCAN BIOSYNTHESIS; ANTIFUNGAL ANTIBIOTICS; NUCLEOSIDE ANTIBIOTICS; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; GENE-EXPRESSION; STREPTOMYCES SP; POLYOXIN-D; RESISTANCE","Novel compounds termed lipophosphonoxins were prepared using a simple and efficient synthetic approach. The general structure of lipophosphonoxins consists of four modules: (i) a nucleoside module, (ii) an iminosugar module, (iii) a hydrophobic module (lipophilic alkyl chain), and (iv) a phosphonate linker module that holds together modules i-iii. Lipophosphonoxins displayed significant antibacterial properties against a panel of Gram-positive species, including multiresistant strains. The minimum inhibitory concentration (MIC) values of the best inhibitors were in the 1-12 mu g/mL range, while their cytotoxic concentrations against human cell lines were significantly above this range. The modular nature of this artificial scaffold offers a large number of possibilities for further modifications/exploitation of these compounds.","[Rejman, Dominik; Kovackova, Sona; Pohl, Radek; Zbornikova, Eva] Acad Sci Czech Republic, Inst Organ Chem & Biochem, VVI, CR-16610 Prague 6, Czech Republic; [Rabatinova, Alzbeta; Sanderova, Hana] Acad Sci Czech Republic, Inst Microbiol, VVI, CR-14220 Prague 4, Czech Republic; [Pombinho, Antonio R.; Bartunek, Petr] Acad Sci Czech Republic, Ctr Chem Genet, VVI, CR-14220 Prague 4, Czech Republic; [Pombinho, Antonio R.; Bartunek, Petr] Acad Sci Czech Republic, CZ OPENSCREEN, Inst Mol Genet, VVI, CR-14220 Prague 4, Czech Republic; [Latal, Tomas] TRIOS Ltd, Prague 14900, Czech Republic; [Kolar, Milan; Bogdanova, Katerina] Palacky Univ, Dept Microbiol, Fac Med & Dent, Olomouc 77900, Czech Republic; [Nyc, Otakar] Teaching Hosp Motol, Dept Med Microbiol, Prague 15006 6, Czech Republic; [Nyc, Otakar] Charles Univ Prague, Fac Med 2, Prague 15006 6, Czech Republic","Rejman, D (reprint author), Acad Sci Czech Republic, Inst Organ Chem & Biochem, VVI, Flemingovo Nam 2, CR-16610 Prague 6, Czech Republic.","rejman@uochb.cas.cz; krasny@biomed.cas.cz","Rejman, Dominik/D-6901-2011",null,"Ministry of Education, Youth and Sports of the Czech Republic and Trios [2B06065]; Ministry of Education, Youth and Sports of the Czech Republic [LC06077]; Czech Science Foundation [204/09/0583, P302/11/0855]; Institutional Research Concepts [AV0Z50200510, Z40550506]","Support by grant nos. 2B06065 (Ministry of Education, Youth and Sports of the Czech Republic and Trios), LC06077 (Ministry of Education, Youth and Sports of the Czech Republic), 204/09/0583 and P302/11/0855 (Czech Science Foundation), and Institutional Research Concepts AV0Z50200510 and Z40550506 is gratefully acknowledged. The authors are indebted to the staff of the Department of Organic Analysis for the measurements of HR-MS.",null,31,4,4,"AMER CHEMICAL SOC","WASHINGTON","1155 16TH ST, NW, WASHINGTON, DC 20036 USA","0022-2623",null,null,"J MED CHEM","J. Med. Chem.","NOV 24",2011,54,22,null,null,null,null,7884,7898,null,"10.1021/jm2009343",null,15,"Chemistry, Medicinal","Pharmacology & Pharmacy","847VW","WOS:000297001600011"]
[null,null,null,null,"J","Maeda-Chubachi, T; Chi-Burris, K; Simons, BD; Freedman, SF; Khaw, PT; Wirostko, B; Yan, E",null,null,null,"Maeda-Chubachi, Tomoko; Chi-Burris, Katherine; Simons, Brad D.; Freedman, Sharon F.; Khaw, Peng T.; Wirostko, Barbara; Yan, Eric",null,"A6111137 Study Grp","Comparison of Latanoprost and Timolol in Pediatric Glaucoma: A Phase 3, 12-Week, Randomized, Double-Masked Multicenter Study","OPHTHALMOLOGY",null,null,"English","Article",null,null,null,null,null,null,"STURGE-WEBER-SYNDROME; OPEN-ANGLE GLAUCOMA; OPEN-LABEL; MANAGEMENT; CHILDHOOD; THERAPY; SAFETY; 5-YEAR","Objective: To compare the efficacy and safety of latanoprost versus timolol in pediatric patients with glaucoma. Design: Prospective, randomized, double-masked, 12-week, multicenter study. Participants: Individuals aged <= 18 years with glaucoma. Methods: Stratified by age, diagnosis, and intraocular pressure (IOP) level, subjects were randomized (1:1) to latanoprost vehicle at 8 AM and latanoprost 0.005% at 8 PM or timolol 0.5% (0.25% for those aged <3 years) twice daily (8 AM, 8 PM). At baseline and weeks 1, 4, and 12, IOP and ocular safety were assessed and adverse events were recorded. Therapy was switched to open-label latanoprost PM and timolol AM and PM for uncontrolled IOP. Main Outcome Measures: Mean IOP reduction from baseline to week 12. Latanoprost was considered noninferior to timolol if the lower limit of the 95% confidence interval (CI) of the difference was >-3 mmHg. A proportion of responders (subjects with >= 15% IOP reduction at weeks 4 and 12) were evaluated. Analyses were performed in diagnosis subgroups: primary congenital glaucoma (PCG) and non-PCG. Results: In total, 137 subjects were treated (safety population; 12-18 years, n=48; 3-<12 years, n=55; 0-<3 years, n=34). Mean age was 8.8 +/- 5.5 years, and mean baseline IOP was 27.7 +/- 6.17 mmHg; 125 subjects completed the study, and 107 subjects were in the per protocol population. Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).Responder rates were 60% for latanoprost and 52% for timolol (P=0.33). Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively. Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group. Both therapies were well tolerated. Conclusions: Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG. Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011;118:2014-2021 (C) 2011 by the American Academy of Ophthalmology.","[Maeda-Chubachi, Tomoko; Chi-Burris, Katherine] Pfizer Inc, New London, CT 06320 USA; [Freedman, Sharon F.] Duke Eye Ctr, Durham, NC USA; [Khaw, Peng T.] Moorfields Eye Hosp, NIHR Biomed Res Ctr Ophthalmol, London, England; [Khaw, Peng T.] UCL Inst Ophthalmol, London, England; [Wirostko, Barbara] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA; [Yan, Eric] Pfizer Inc, New York, NY USA","Maeda-Chubachi, T (reprint author), Pfizer Inc, 50 Pequot Ave,B3240, New London, CT 06320 USA.","tomoko.maeda@pfizer.com",null,null,"Pfizer Inc, New York, New York; NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital; UCL Institute of Ophthalmology; Pfizer Inc.","This study was sponsored by Pfizer Inc, New York, New York. The sponsor participated in the design of the study; in the management, analysis, and interpretation of the data; and in the preparation, review, and approval of the manuscript. Peng T. Khaw, MD, was funded by the NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology.The authors thank Charles Bosworth, PhD, for contributions to the conduct of the study, including its conception and design. Editorial support, including contributing to the first draft of the article, revising after author comments, and styling the article for journal submission, was provided by Jane G. Murphy, PhD, of Zola Associates and was funded by Pfizer Inc.","Alm A, 1998, PROG RETIN EYE RES, V17, P291, DOI 10.1016/S1350-9462(97)00003-7; Alm A, 2004, ARCH OPHTHALMOL-CHIC, V122, P957, DOI 10.1001/archopht.122.7.957; Altuna JC, 1999, J GLAUCOMA, V8, P199; Biglan AW, 2006, J AAPOS, V10, P7, DOI 10.1016/j.jaapos.2005.10.001; Black AC, 2009, J AAPOS, V13, P558, DOI 10.1016/j.jaapos.2009.10.003; Distelhorst JS, 2003, AM FAM PHYSICIAN, V67, P1937; Enyedi LB, 2002, SURV OPHTHALMOL, V47, pS129, DOI 10.1016/S0039-6257(02)00303-X; Enyedi LB, 1999, J AAPOS, V3, P33, DOI 10.1016/S1091-8531(99)70092-3; European Agency for the Evaluation of Medicinal Products, 2000, POINTS CONS SWITCH S; Goldberg I, 2008, EUR J OPHTHALMOL, V18, P408; ICH E9, 1998, FED REG, V63, P49583; Levy Jaime, 2004, Harefuah, V143, P876; Levy J, 2004, HAREFUAH, V143, P910; Mandal AK, 2006, PEDIAT GLAUCOMAS, P5, DOI 10.1016/B978-0-7506-7336-5.50008-6; Marquis RE, 2005, DRUG AGING, V22, P1, DOI 10.2165/00002512-200522010-00001; Moore Will, 2007, Paediatr Drugs, V9, P71, DOI 10.2165/00148581-200709020-00001; Ong T, 2003, BRIT J OPHTHALMOL, V87, P1091, DOI 10.1136/bjo.87.9.1091; Papadopoulos M, 2007, INVEST OPHTH VIS SCI, V48, P4100, DOI 10.1167/iovs.06-1350; Papadopoulos M, 2007, EYE, V21, P1319, DOI 10.1038/sj.eye.6702850; Papadopoulos M, 2005, PEDIAT OPHTHALMOLOGY, P458; Realini T, 2002, OPHTHALMOLOGY, V109, P1955, DOI 10.1016/S0161-6420(02)01437-9; Taylor RH, 1999, J AAPOS, V3, P308, DOI 10.1016/S1091-8531(99)70028-5; Terraciano Anthony J, 2002, Curr Opin Ophthalmol, V13, P97, DOI 10.1097/00055735-200204000-00008; Toris CB, 2008, SURV OPHTHALMOL, V53, pS107, DOI 10.1016/j.survophthal.2008.08.010; van der Valk R, 2005, OPHTHALMOLOGY, V112, P1177, DOI 10.1016/j.ophtha.2005.01.042; Whitson JT, 2008, J AAPOS, V12, P239, DOI 10.1016/j.jaapos.2007.11.004; Yang CB, 1998, AM J OPHTHALMOL, V126, P600, DOI 10.1016/S0002-9394(98)00129-9",27,3,3,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0161-6420",null,null,"OPHTHALMOLOGY","Ophthalmology","OCT",2011,118,10,null,null,null,null,2014,2021,null,"10.1016/j.ophtha.2011.03.010",null,8,"Ophthalmology","Ophthalmology","835WG","WOS:000296066900020"]
[null,null,null,null,"J","Torekov, SS; Ma, L; Grarup, N; Hartmann, B; Hainerova, IA; Kielgast, U; Kissow, H; Rosenkilde, M; Lebl, J; Witte, DR; Jorgensen, T; Sandbaek, A; Lauritzen, T; Madsen, OD; Wang, J; Linneberg, A; Madsbad, S; Holst, JJ; Hansen, T; Pedersen, O",null,null,null,"Torekov, S. S.; Ma, L.; Grarup, N.; Hartmann, B.; Hainerova, I. A.; Kielgast, U.; Kissow, H.; Rosenkilde, M.; Lebl, J.; Witte, D. R.; Jorgensen, T.; Sandbaek, A.; Lauritzen, T.; Madsen, O. D.; Wang, J.; Linneberg, A.; Madsbad, S.; Holst, J. J.; Hansen, T.; Pedersen, O.",null,"GIANT Consortium","Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1","DIABETOLOGIA",null,null,"English","Article",null,null,null,null,null,"Genetics of type 2 diabetes; Insulin secretion in vivo; Insulin sensitivity and resistance; Islets; Metabolic physiology in vivo; Monogenic forms of diabetes","HAPLOTYPE MAP; ASSOCIATION; RISK; GENOME; IMPACT; INDEX","The glucagon gene (GCG) encodes several hormones important for energy metabolism: glucagon, oxyntomodulin and glucagon-like peptide (GLP)-1 and -2. Variants in GCG may associate with type 2 diabetes, obesity and/or related metabolic traits. GCG was re-sequenced as a candidate gene in 865 European individuals. Twenty-nine variants were identified. Four variants that were considered to have a likelihood for altered functionality: rs4664447, rs7581952, Ile158Val and Trp169Ter, were genotyped in 17,584 Danes. When examined in 5,760 treatment-naive individuals, homozygous carriers of the low frequency (minor allele frequency 2.3%) G allele of rs4664447, predicted to disrupt an essential splice enhancer binding site, had lower levels of fasting plasma glucose (mean +/- SD, 4.8 +/- 1.2 vs 5.5 +/- 0.8 mmol/l, p = 0.004); fasting serum insulin (22 +/- 14 vs 42 +/- 27 pmol/l, p = 0.04); glucose-stimulated serum insulin (159 +/- 83 vs 290 +/- 183 pmol/l, p = 0.01) and adult height (165 +/- 10 vs 172 +/- 9 cm, p = 0.0009) compared with A allele carriers. During oral glucose tolerance and hyperglycaemic arginine stimulation tests, the plasma AUC for GLP-1 (730 +/- 69 vs 1,334 +/- 288 pmol/l x min, p = 0.0002) and basal and stimulated levels of serum insulin and plasma glucagon were similar to 50% decreased (p < 0.001) among three homozygous carriers compared with nine matched wild-type carriers. rs7581952, Ile158Val and Trp169Ter (where 'Ter' indicates 'termination') variants of GCG did not significantly associate or co-segregate with the metabolic traits examined. Re-sequencing of GCG revealed a low frequency intronic variant, rs4664447, and follow-up physiological studies suggest that this variant in homozygous form may cause decreased fasting and stimulated levels of insulin, glucagon and GLP-1. Overall, our findings suggest that variation in GCG has no major impact on carbohydrate metabolism in the study populations examined.","[Torekov, S. S.; Grarup, N.; Hartmann, B.; Kissow, H.; Holst, J. J.; Hansen, T.; Pedersen, O.] Univ Copenhagen, Fac Hlth Sci, Novo Nordisk Fdn Ctr Basic Metabol Res, Copenhagen, Denmark; [Torekov, S. S.; Hartmann, B.; Kissow, H.; Holst, J. J.; Pedersen, O.] Univ Copenhagen, Dept Biomed Sci, Fac Hlth Sci, DK-2200 Copenhagen, Denmark; [Ma, L.; Wang, J.] Beijing Genom Inst Shenzhen, Shenzhen, Peoples R China; [Hainerova, I. A.; Lebl, J.] Charles Univ Prague, Dept Paediat, Prague, Czech Republic; [Kielgast, U.; Madsbad, S.] Hvidovre Univ Hosp, Dept Endocrinol, DK-2650 Hvidovre, Denmark; [Rosenkilde, M.] Univ Copenhagen, Fac Hlth Sci, Dept Neurosci & Pharmacol, Copenhagen, Denmark; [Witte, D. R.] Steno Diabet Ctr, DK-2820 Gentofte, Denmark; [Jorgensen, T.; Linneberg, A.] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark; [Sandbaek, A.; Lauritzen, T.] Univ Aarhus, Dept Gen Practice, Aarhus, Denmark; [Madsen, O. D.; Hansen, T.; Pedersen, O.] Hagedorn Res Inst, Gentofte, Denmark; [Hansen, T.] Univ So Denmark, Fac Hlth Sci, Odense, Denmark; [Pedersen, O.] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark","Torekov, SS (reprint author), Univ Copenhagen, Fac Hlth Sci, Novo Nordisk Fdn Ctr Basic Metabol Res, Copenhagen, Denmark.","Torekov@sund.ku.dk","Madsen, Ole/A-7415-2011",null,"Danish Research Council; Lundbeck Foundation Centre of Applied Medical Genomics for Personalized Disease Prediction, Prevention and Care; University of Copenhagen; MSM VZ [0021620814]; University Investment Capital (UNIK): Food, Fitness & Pharma for Health and Disease from the Danish Ministry of Science, Technology and Innovation","We are most grateful to M. McCarthy and A. Morris representing the DIAGRAM+ consortium, and J. Florez, I. Barroso and E. Wheeler representing MAGIC, who kindly provided us with information about GCG genotype information from meta-analyses data. This study has been orally presented at the 46th Annual Meeting of the EASD, Stockholm, 20-24 September 2010. We are grateful to the participating patients. From the Hagedorn Research Institute, we thank A. Forman, T. Lorentzen and M. Stendal for technical assistance, A. Nielsen for data management, G. Lademann for secretarial support and T. Boesgaard and T. Sparso for scientific discussions. From the Department of Biomedical Sciences, University of Copenhagen, we thank S. Pilgaard and L. Albaek for technical assistance. The research was supported by grants from the Danish Research Council, the Lundbeck Foundation Centre of Applied Medical Genomics for Personalized Disease Prediction, Prevention and Care, the University of Copenhagen, the Czech research project of MSM VZ No. 0021620814 and the University Investment Capital (UNIK): Food, Fitness & Pharma for Health and Disease from the Danish Ministry of Science, Technology and Innovation.",null,23,2,2,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0012-186X",null,null,"DIABETOLOGIA","Diabetologia","NOV",2011,54,11,null,null,null,null,2820,2831,null,"10.1007/s00125-011-2265-7",null,12,"Endocrinology & Metabolism","Endocrinology & Metabolism","830TJ","WOS:000295679800011"]
[null,null,null,null,"J","Rob, L; Robova, H",null,null,null,"Rob, Lukas; Robova, Helena",null,null,"Cervical cancer: balancing obstetrical and oncological outcomes reply","LANCET ONCOLOGY",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Rob, Lukas; Robova, Helena] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague, Czech Republic","Rob, L (reprint author), Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague, Czech Republic.","lukas.rob@lfmotol.cuni.cz",null,null,null,null,null,1,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1470-2045",null,null,"LANCET ONCOL","Lancet Oncol.","MAY",2011,12,5,null,null,null,null,422,423,null,null,null,2,"Oncology","Oncology","771FQ","WOS:000291143000014"]
[null,null,null,null,"J","Balgobind, BV; Van den Heuvel-Eibrink, MM; De Menezes, RX; Reinhardt, D; Hollink, IHIM; Arentsen-Peters, STJCM; van Wering, ER; Kaspers, GJL; Cloos, J; de Bont, ESJM; Cayuela, JM; Baruchel, A; Meyer, C; Marschalek, R; Trka, J; Stary, J; Beverloo, HB; Pieters, R; Zwaan, CM; den Boer, ML",null,null,null,"Balgobind, Brian V.; Van den Heuvel-Eibrink, Marry M.; De Menezes, Renee X.; Reinhardt, Dirk; Hollink, Iris H. I. M.; Arentsen-Peters, Susan T. J. C. M.; van Wering, Elisabeth R.; Kaspers, Gertjan J. L.; Cloos, Jacqueline; de Bont, Evelien S. J. M.; Cayuela, Jean-Michel; Baruchel, Andre; Meyer, Claus; Marschalek, Rolf; Trka, Jan; Stary, Jan; Beverloo, H. Berna; Pieters, Rob; Zwaan, C. Michel; den Boer, Monique L.",null,null,"Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Article",null,null,null,null,null,"pediatric acute myeloid leukemia; gene expression profile; cytogenetic subtype; classification; microarray","ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERNAL TANDEM DUPLICATION; ACUTE MYELOGENOUS LEUKEMIA; MINIMAL-RESIDUAL-DISEASE; NORMAL KARYOTYPE; PROGNOSTIC-SIGNIFICANCE; CEBPA MUTATIONS; GROUP-B; AML 10; FLT3","Background Pediatric acute myeloid leukemia is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. The genetic subtype is currently detected by different diagnostic procedures which differ in success rate and/or specificity. Design and Methods We examined the potential of gene expression profiles to classify pediatric acute myeloid leukemia. Gene expression microarray data of 237 children with acute myeloid leukemia were collected and a double-loop cross validation approach was used to generate a subtype-predictive gene expression profile in the discovery cohort (n=157) which was then tested for its true predictive value in the independent validation cohort (n=80). The classifier consisted of 75 probe sets, representing the top 15 discriminating probe sets for MLL-rearranged, t(8;21)(q22;q22), inv(16)(p13q22), t(15;17)(q21;q22) and t(7;12)(q36;p13)-positive acute myeloid leukemia. Results These cytogenetic subtypes represent approximately 40% of cases of pediatric acute myeloid leukemia and were predicted with 92% and 99% accuracy in the discovery and independent validation cohort, respectively. However, for NPM1, CEBPA, MLL(-PTD), FLT3(-ITD), KIT, PTPN11 and N/K-RAS gene expression signatures had limited predictive value. This may be caused by a limited frequency of these mutations and by underlying cytogenetics. This latter is exemplified by the fact that different gene expression signatures were discovered for FLT3-ITD in patients with normal cytogenetics and in those with t(15;17)(q21;q22)-positive acute myeloid leukemia, which pointed to HOXB-upregulation being specific for FLT3-ITD(+) cytogenetically normal acute myeloid leukemia. Conclusions In conclusion, gene expression profiling correctly predicted the most prevalent cytogenetic subtypes of pediatric acute myeloid leukemia with high accuracy. In clinical practice, this gene expression signature may replace multiple diagnostic tests for approximately 40% of pediatric acute myeloid leukemia cases whereas only for the remaining cases (predicted as 'acute myeloid leukemia-other') are additional tests indicated. Moreover, the discriminative genes reveal new insights into the biology of acute myeloid leukemia subtypes that warrants follow-up as potential targets for new therapies.","[den Boer, Monique L.] Erasmus MC, Sophia Childrens Hosp, Dept Pediat Oncol & Hematol, NL-3000 CB Rotterdam, Netherlands; [De Menezes, Renee X.] LUMC, Ctr Human & Clin Genet, Leiden, Netherlands; [Reinhardt, Dirk] AML BFM Study Grp, Hannover, Germany; [van Wering, Elisabeth R.] DCOG, The Hague, Netherlands; [Kaspers, Gertjan J. L.; Cloos, Jacqueline] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [de Bont, Evelien S. J. M.] Univ Groningen, Beatrix Childrens Hosp, Univ Med Ctr Groningen, Groningen, Netherlands; [Cayuela, Jean-Michel; Baruchel, Andre] St Louis Hosp, Paris, France; [Meyer, Claus; Marschalek, Rolf] DCAL, ZAFES, Inst Pharmaceut Biol, Frankfurt, Germany; [Trka, Jan; Stary, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic","den Boer, ML (reprint author), Erasmus MC, Sophia Childrens Hosp, Dept Pediat Oncol & Hematol, Room Sp2456,POB 2060, NL-3000 CB Rotterdam, Netherlands.","m.l.denboer@eras-musmc.nl","Marschalek, Rolf/D-3404-2011; Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","'Netherlands Organisation for Scientific Research' (NWO); Dutch Cancer Society [EMCR 2005-3662, EMCR 2003-2871]; Center of Medical Systems Biology (CMSB); Quality of Life Foundation, the Netherlands; Czech Ministry of Education [COST-OC09051]","BVB was funded by the 'Netherlands Organisation for Scientific Research' (NWO). RXM was partially funded by the Dutch Cancer Society (grant EMCR 2005-3662) and the Center of Medical Systems Biology (CMSB) established by the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research (NGI/NWO). HBB was partly funded by the Dutch Cancer Society (grant EMCR 2003-2871). This research was sponsored by a grant from the Quality of Life Foundation, the Netherlands (R.P, MLDB). JT was funded by the Czech Ministry of Education (grant COST-OC09051).",null,56,20,20,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","FEB",2011,96,2,null,null,null,null,221,230,null,"10.3324/haematol.2010.029660",null,10,null,null,"726ZI","WOS:000287766500009"]
[null,null,null,null,"J","Balgobind, BV; Hollink, IHIM; Arentsen-Peters, STCJM; Zimmermann, M; Harbott, J; Beverloo, HB; von Bergh, ARM; Cloos, J; Kaspers, GJL; de Haas, V; Zemanova, Z; Stary, J; Cayuela, JM; Baruchel, A; Creutzig, U; Reinhardt, D; Pieters, R; Zwaan, CM; van den Heuvel-Eibrink, MM",null,null,null,"Balgobind, Brian V.; Hollink, Iris H. I. M.; Arentsen-Peters, Susan T. C. J. M.; Zimmermann, Martin; Harbott, Jochen; Beverloo, H. Berna; von Bergh, Anne R. M.; Cloos, Jacqueline; Kaspers, Gertjan J. L.; de Haas, Valerie; Zemanova, Zuzana; Stary, Jan; Cayuela, Jean-Michel; Baruchel, Andre; Creutzig, Ursula; Reinhardt, Dirk; Pieters, Rob; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.",null,null,"Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Article",null,null,null,null,null,"pediatric AML; type I/II aberrations; mutation; prognostic factor","INTERNAL TANDEM DUPLICATION; CHILDRENS ONCOLOGY GROUP; TYROSINE KINASE INHIBITOR; COLONY-STIMULATING FACTOR; PROGNOSTIC-SIGNIFICANCE; TREATMENT STRATEGY; KIT MUTATIONS; MOUSE MODEL; FLT3; AML","Background Several studies of pediatric acute myeloid leukemia have described the various type-I or type-II aberrations and their relationship with clinical outcome. However, there has been no recent comprehensive overview of these genetic aberrations in one large pediatric acute myeloid leukemia cohort. Design and Methods We studied the different genetic aberrations, their associations and their impact on prognosis in a large pediatric acute myeloid leukemia series (n=506). Karyotypes were studied, and hotspot regions of NPM1, CEPBA, MLL, WT1, FLT3, N-RAS, K-RAS, PTPN11 and KIT were screened for mutations of available samples. The mutational status of all type-I and type-II aberrations was available in 330 and 263 cases, respectively. Survival analysis was performed in a subset (n=385) treated on consecutive acute myeloid leukemia Berlin-Frankfurt-Munster Study Group and Dutch Childhood Oncology Group treatment protocols. Results Genetic aberrations were associated with specific clinical characteristics, e. g. significantly higher diagnostic white blood cell counts in MLL-rearranged, WT1-mutated and FLT3-ITD-positive acute myeloid leukemia. Furthermore, there was a significant difference in the distribution of these aberrations between children below and above the age of two years. Non-random associations, e. g. KIT mutations with core-binding factor acute myeloid leukemia, and FLT3-ITD with t(15;17)(q22;q21), NPM1- and WT1-mutated acute myeloid leukemia, respectively, were observed. Multivariate analysis revealed a 'favorable karyotype', i.e. t(15;17)(q22;q21), t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22). NPM1 and CEBPA double mutations were independent factors for favorable event-free survival. WT1 mutations combined with FLT3-ITD showed the worst outcome for 5-year overall survival (22 +/- 14%) and 5-year event-free survival (20 +/- 13%), although it was not an independent factor in multivariate analysis. Conclusions Integrative analysis of type-I and type-II aberrations provides an insight into the frequencies, non-random associations and prognostic impact of the various aberrations, reflecting the heterogeneity of pediatric acute myeloid leukemia. These aberrations are likely to guide the stratification of pediatric acute myeloid leukemia and may direct the development of targeted therapies.","[Balgobind, Brian V.; Hollink, Iris H. I. M.; Arentsen-Peters, Susan T. C. J. M.; Pieters, Rob; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3000 CB Rotterdam, Netherlands; [Zimmermann, Martin; Reinhardt, Dirk] Hannover Med Sch, Dept Pediat Oncol Hematol, D-3000 Hannover, Germany; [Harbott, Jochen] Univ Giessen, Dept Pediat Hematol Oncol, Giessen, Germany; [Beverloo, H. Berna; von Bergh, Anne R. M.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands; [Cloos, Jacqueline; Kaspers, Gertjan J. L.] Vrije Univ Amsterdam Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands; [Kaspers, Gertjan J. L.; de Haas, Valerie] DCOG, The Hague, Netherlands; [Zemanova, Zuzana; Stary, Jan] Gen Univ Hosp, Ctr Oncocytogenet, Prague, Czech Republic; [Zemanova, Zuzana; Stary, Jan] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Cayuela, Jean-Michel; Baruchel, Andre] Hop St Louis, Dept Hematol, Paris, France; [Creutzig, Ursula] Univ Hosp Muenster, Dept Pediat Hematol Oncol, Munster, Germany","van den Heuvel-Eibrink, MM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Room Sp 2456,Dr Molewaterpl 60,POB 2060, NL-3000 CB Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","'Netherlands Organisation for Scientific Research' (NWO); KOCR foundation; Dutch Cancer Society [EMCR 2003-2871]","BB was funded by the 'Netherlands Organisation for Scientific Research' (NWO) and the KOCR foundation. IH was funded by the KOCR foundation. HBB was partly funded by the Dutch Cancer Society (grant EMCR 2003-2871).",null,61,17,18,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","OCT",2011,96,10,null,null,null,null,1478,1487,null,"10.3324/haematol.2010.038976",null,10,null,null,"837XR","WOS:000296245000014"]
[null,null,null,null,"J","Ambros, IM; Brunner, B; Aigner, G; Bedwell, C; Beiske, K; Benard, J; Bown, N; Combaret, V; Couturier, J; Defferrari, R; Gross, N; Jeison, M; Lunec, J; Marques, B; Martinsson, T; Mazzocco, K; Noguera, R; Schleiermacher, G; Speleman, F; Stallings, R; Tonini, GP; Tweddle, DA; Valent, A; Vicha, A; Van Roy, N; Villamon, E; Ziegler, A; Preuner, S; Drobics, M; Ladenstein, R; Amann, G; Schuit, RJL; Potschger, U; Ambros, PF",null,null,null,"Ambros, Inge M.; Brunner, Bettina; Aigner, Gerhard; Bedwell, Clare; Beiske, Klaus; Benard, Jean; Bown, Nick; Combaret, Valerie; Couturier, Jerome; Defferrari, Raffaella; Gross, Nicole; Jeison, Marta; Lunec, John; Marques, Barbara; Martinsson, Tommy; Mazzocco, Katia; Noguera, Rosa; Schleiermacher, Gudrun; Speleman, Frank; Stallings, Ray; Tonini, Gian Paolo; Tweddle, Deborah A.; Valent, Alexander; Vicha, Ales; Van Roy, Nadine; Villamon, Eva; Ziegler, Andrea; Preuner, Sandra; Drobics, Mario; Ladenstein, Ruth; Amann, Gabriele; Schuit, Robert J. L.; Poetschger, Ulrike; Ambros, Peter F.",null,null,"A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma","CLINICAL CANCER RESEARCH",null,null,"English","Article",null,null,null,null,null,null,"DEPENDENT PROBE AMPLIFICATION; PEDIATRIC-ONCOLOGY-GROUP; MYCN AMPLIFICATION; GENETIC-MARKERS; CHROMOSOME 1P; TUMORS; STRATIFICATION; CLASSIFICATION; IDENTIFICATION; HETEROGENEITY","Purpose: Precise and comprehensive analysis of neuroblastoma genetics is essential for accurate risk evaluation and only pangenomic/multilocus approaches fulfill the present-day requirements. We present the establishment and validation of the PCR-based multiplex ligation-dependent probe amplification (MLPA) technique for neuroblastoma. Experimental Design: A neuroblastoma-specific MLPA kit was designed by the SIOP Europe Neuroblastoma Biology Committee in cooperation with MRC-Holland. The contained target sequences cover 19 chromosomal arms and reference loci. Validation was performed by single locus and pangenomic techniques (n = 174). Dilution experiments for determination of minimal tumor cell percentage were performed and testing of reproducibility was checked by interlaboratory testing (n = 15). Further 156 neuroblastomas were used for establishing the amplification cutoff level. Results: The MLPA technique was tested in 310 neuroblastomas and 8 neuroblastoma cell lines (including validation and amplification cutoff level testing). Intertechnique validation showed a high concordance rate (99.5%). Interlaboratory MLPA testing (kappa = 0.95, P < 0.01) revealed 7 discrepant of 1,490 results (0.5%). Validation by pangenomic techniques showed a single discordance of 190 consensus results (0.5%). The test results led to formulation of interpretation standards and to a kit revision. The minimal tumor cell percentage was fixed at 60%. Conclusions: The recently designed neuroblastoma-specific MLPA kit covers all chromosomal regions demanded by the International Neuroblastoma Risk Group for therapy stratification and includes all hitherto described genetic loci of prognostic interest for future studies and can be modified or extended at any time. Moreover, the technique is cost effective, reliable, and robust with a high interlaboratory and intertechnique concordance. Clin Cancer Res; 17(4); 792-804. (C) 2011 AACR.","[Ambros, Inge M.; Brunner, Bettina; Ziegler, Andrea; Preuner, Sandra; Poetschger, Ulrike; Ambros, Peter F.] CCRI, St Anna Kinderkrebsforsch, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Aigner, Gerhard; Drobics, Mario] Technol GmbH, AIT Austrian Inst, Informat Management & eHlth, Safety & Secur Dept, Vienna, Austria; [Ladenstein, Ruth] St Anna Childrens Hosp, Vienna, Austria; [Amann, Gabriele] Univ Vienna, Inst Klin Pathol, Vienna, Austria; [Lunec, John; Tweddle, Deborah A.] Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Beiske, Klaus] Oslo Univ Hosp, Rikshosp, Dept Pathol, Oslo, Norway; [Benard, Jean; Valent, Alexander] Inst Gustave Roussy, Serv Pathol Mol, Dept Biol & Pathol Med, Villejuif, France; [Combaret, Valerie] Ctr Leon Berard, Lab Rech Translat, F-69373 Lyon, France; [Couturier, Jerome] Inst Curie Hosp, Serv Genet Oncol, Unite Cytogenet, Paris, France; [Schleiermacher, Gudrun] Inst Curie, Dept Pediat Oncol, Paris, France; [Defferrari, Raffaella; Mazzocco, Katia; Tonini, Gian Paolo] Natl Inst Canc Res, Genoa, Italy; [Gross, Nicole] Univ Hosp, Dept Pediat, Lausanne, Switzerland; [Jeison, Marta] Schneider Childrens Med Ctr Israel, Pediat Hematol Oncol Dept, Ca Cytogenet Lab, Petah Tiqwa, Israel; [Marques, Barbara] Inst Nacl Saude Dr Ricardo Jorge, Dept Genet, Lisbon, Portugal; [Martinsson, Tommy] Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Biomed, Dept Clin Genet, Gothenburg, Sweden; [Noguera, Rosa; Villamon, Eva] Univ Valencia, Med Sch Valencia, Dept Pathol, Valencia, Spain; [Speleman, Frank; Van Roy, Nadine] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium; [Stallings, Ray] Royal Coll Surgeons Ireland, Dublin 2, Ireland; [Stallings, Ray] Our Ladys Childrens Hosp, Childrens Res Ctr, Crumlin, Ireland; [Vicha, Ales] 2nd Med Fac, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Vicha, Ales] Fac Hosp Motol, Prague, Czech Republic; [Schuit, Robert J. L.] MRC Holland, Amsterdam, Netherlands","Ambros, IM (reprint author), CCRI, St Anna Kinderkrebsforsch, Childrens Canc Res Inst, Zimmermannpl 10, A-1090 Vienna, Austria.","ambros@ccri.at","Vicha, Ales/I-6726-2012; Stallings, Raymond/A-7213-2008; Martinsson, Tommy/J-4140-2013","Vicha, Ales/0000-0003-3075-5554; Martinsson, Tommy/0000-0002-9403-3123","Jubilaumsfondsprojekt [13422]; St. Anna Kinderkrebsforschung; Italian Neuroblastoma Foundation, Neuroblastoma Society; Cancer Research UK; UK Department of Health; Instituto de Salud Carlos III [RD06/0020/70102]; Fundacion de la Association Espanola Contra el Cancer (FAECC) [20090840]; Societe Francaise des Cancers de l'Entfant (SFCE); Federation Enfants Sante; National Resource Centre for Childhood Solid Tumours (KSSB), Norway","This work was funded in part by the Jubilaumsfondsprojekt (13422); the St. Anna Kinderkrebsforschung; the Italian Neuroblastoma Foundation, Neuroblastoma Society; Cancer Research UK and the UK Department of Health; Instituto de Salud Carlos III (RD06/0020/70102) and the Fundacion de la Association Espanola Contra el Cancer (FAECC; 20090840); the Societe Francaise des Cancers de l'Entfant (SFCE); the Federation Enfants & Sante; and the National Resource Centre for Childhood Solid Tumours (KSSB), Norway.",null,33,17,18,"AMER ASSOC CANCER RESEARCH","PHILADELPHIA","615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA","1078-0432",null,null,"CLIN CANCER RES","Clin. Cancer Res.","FEB 15",2011,17,4,null,null,null,null,792,804,null,"10.1158/1078-0432.CCR-10-0830",null,13,"Oncology","Oncology","728ZM","WOS:000287913200018"]
[null,null,null,null,"J","Konopac, M; Dusatkova, P; Cinek, O",null,null,null,"Konopac, Martin; Dusatkova, Petra; Cinek, Ondrej",null,null,"SNPman: a program for genotype calling using run data from TaqMan allelic discrimination","BIOINFORMATICS",null,null,"English","Article",null,null,null,null,null,null,null,"The SNPman program calls the genotypes of single nucleotide polymorphisms (SNP) from TaqMan allelic discrimination assays. It utilizes the fluorescence data collected over the whole PCR run, rather than relying on the end point fluorescence measurements that is the basis of the genotype calling process in most software solutions sold with the real-time instruments. This inspection of run data facilitates genotype calls in difficult sample sets, especially in those containing various concentrations of DNA or inhibitors, as indicated by results of a reanalysis of 3738 genotyping samples. The program works with data from three different widely used PCR instruments.","[Konopac, Martin; Dusatkova, Petra; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Dept Paediat, CZ-15006 Prague, Czech Republic; [Dusatkova, Petra; Cinek, Ondrej] Univ Hosp Motol, Dept Paediat, CZ-15006 Prague, Czech Republic; [Konopac, Martin] Czech Tech Univ, Fac Biomed Engn, Kladno, Czech Republic","Cinek, O (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat, CZ-15006 Prague, Czech Republic.","Ondrej.Cinek@Lfmotol.cuni.cz",null,null,"Czech Ministry of Education [MSM0021620814]","Czech Ministry of Education (grant MSM0021620814).",null,5,0,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1367-4803",null,null,"BIOINFORMATICS","Bioinformatics","AUG 15",2011,27,16,null,null,null,null,2306,2308,null,"10.1093/bioinformatics/btr383",null,3,"Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability","Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Computer Science; Mathematical & Computational Biology; Mathematics","803ZC","WOS:000293620800022"]
[null,null,null,null,"J","Zaliova, M; Madzo, J; Cario, G; Trka, J",null,null,null,"Zaliova, M.; Madzo, J.; Cario, G.; Trka, J.",null,null,"Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; TEL/AML1; fusion gene; RNAi; childhood leukemia","ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMERASE-CHAIN-REACTION; FUSION GENE; PRELEUKEMIC ACTIVITY; TEL-AML1; DIFFERENTIATION; PROMOTER; T(12/21); PROTEIN; TRANSLOCATIONS","Translocation (12;21), the most frequent chromosomal aberration in childhood acute lymphoblastic leukemia, creates TEL/AML1 fusion gene. Resulting hybrid protein was shown to have a role in pre-leukemia establishment. To address its role for leukemic cell survival, we applied RNA interference to silence TEL/AML1 in leukemic cells. We designed and tested 11 different oligonucleotides targeting the TEL/AML1 fusion site. Using most efficient siRNAs, we achieved an average of 74-86% TEL/AML1 protein knockdown in REH and UOC-B6 leukemic cells, respectively. TEL/AML1 silencing neither decreased cell viability, nor induced apoptosis. On the contrary, it resulted in the modest but significant increase in the S phase fraction and in higher proliferation rate. Opposite effects on cell cycle distribution and proliferation were induced by AML1 silencing, thus, supporting our hypothesis that TEL/AML1 may block AML1-mediated promotion of G1/S progression through the cell cycle. In line with the lack of major effect on phenotype, we found no significant changes in clonogenic potential and global gene expression pattern upon TEL/AML1 depletion. Our data suggest that though TEL/AML1 is important for the (pre)leukemic clone development, it may be dispensable for leukemic cell survival and would not be a suitable target for gene-specific therapy. Leukemia (2011) 25, 313-320; doi:10.1038/leu.2010.277; published online 26 November 2010","[Zaliova, M.; Madzo, J.; Trka, J.] Charles Univ Prague, Dept Paediat Haematol & Oncol, CLIP, Sch Med 2,Fac Med 2, Prague 15006 5, Czech Republic; [Zaliova, M.; Madzo, J.; Trka, J.] Univ Hosp Motol, Prague, Czech Republic; [Cario, G.] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany","Zaliova, M (reprint author), Charles Univ Prague, Dept Paediat Haematol & Oncol, CLIP, Sch Med 2,Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","marketa.zaliova@lfmotol.cuni.cz",null,null," [MSM0021620813];  [MZ0FNM2005]","This work was supported by grants MSM0021620813 and MZ0FNM2005.",null,37,2,3,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","FEB",2011,25,2,null,null,null,null,313,320,null,"10.1038/leu.2010.277",null,8,"Oncology; Hematology","Oncology; Hematology","719GC","WOS:000287188600016"]
[null,null,null,null,"J","Volejnikova, J; Mejstrikova, E; Valova, T; Reznickova, L; Hodonska, L; Mihal, V; Sterba, J; Jabali, Y; Prochazkova, D; Blazek, B; Hak, J; Cerna, Z; Hrusak, O; Stary, J; Trka, J; Fronkova, E",null,null,null,"Volejnikova, Jana; Mejstrikova, Ester; Valova, Tatana; Reznickova, Leona; Hodonska, Ladislava; Mihal, Vladimir; Sterba, Jaroslav; Jabali, Yahia; Prochazkova, Daniela; Blazek, Bohumir; Hak, Jiri; Cerna, Zdenka; Hrusak, Ondrej; Stary, Jan; Trka, Jan; Fronkova, Eva",null,null,"Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; peripheral blood; minimal residual disease; day 15; childhood","TIME QUANTITATIVE PCR; RECEPTOR GENE REARRANGEMENTS; CLINICAL-SIGNIFICANCE; BONE-MARROW; AIEOP-BFM; CONCERTED ACTION; CHILDREN; IMMUNOGLOBULIN; LINEAGE; THERAPY","Background Most minimal residual disease-directed treatment interventions in current treatment protocols for acute lymphoblastic leukemia are based on bone marrow testing, which is a consequence of previous studies showing the superiority of bone marrow over peripheral blood as an investigational material. Those studies typically did not explore the prognostic impact of peripheral blood involvement and lacked samples from very early time points of induction. Design and Methods In this study, we employed real-time quantitative polymerase chain reaction analysis to examine minimal residual disease in 398 pairs of blood and bone marrow follow-up samples taken from 95 children with B-cell precursor acute lymphoblastic leukemia treated with the ALL IC-BFM 2002 protocol. Results We confirmed the previously published poor correlation between minimal residual disease in blood and marrow at early treatment time points, with levels in bone marrow being higher than in blood in most samples (median 7.9-fold, range 0.04-8,293-fold). A greater involvement of peripheral blood at diagnosis was associated with a higher white blood cell count at diagnosis (P=0.003) and with enlargement of the spleen (P=0.0004) and liver (P=0.05). At day 15, a level of minimal residual disease in blood lower than 10(-4) was associated with an excellent 5-year relapse-free survival in 78 investigated patients (100% versus 69 +/- 7%; P=0.0003). Subgroups defined by the level of minimal residual disease in blood at day 15 (high-risk: >= 10(-2), intermediate-risk: <10(-2) and >= 10(-4), standard-risk: <10(-4)) partially correlated with bone marrow-based stratification described previously, but the risk groups did not match completely. No other time point analyses were predictive of outcome in peripheral blood, except for a weak association at day 8. Conclusions Minimal residual disease in peripheral blood at day 15 identified a large group of patients with an excellent prognosis and added prognostic information to the risk stratification based on minimal residual disease at day 33 and week 12.","[Volejnikova, Jana; Mejstrikova, Ester; Valova, Tatana; Reznickova, Leona; Hodonska, Ladislava; Hrusak, Ondrej; Stary, Jan; Trka, Jan; Fronkova, Eva] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006, Czech Republic; [Volejnikova, Jana; Mejstrikova, Ester; Valova, Tatana; Reznickova, Leona; Hodonska, Ladislava; Hrusak, Ondrej; Stary, Jan; Trka, Jan; Fronkova, Eva] Univ Hosp Motol, Prague, Czech Republic; [Volejnikova, Jana; Mejstrikova, Ester; Valova, Tatana; Reznickova, Leona; Hodonska, Ladislava; Hrusak, Ondrej; Stary, Jan; Trka, Jan; Fronkova, Eva] CLIP, Prague, Czech Republic; [Mihal, Vladimir] Palacky Univ, Dept Pediat, Olomouc, Czech Republic; [Mihal, Vladimir] Univ Hosp Olomouc, Olomouc, Czech Republic; [Sterba, Jaroslav] Masaryk Univ, Dept Pediat Oncol, CS-60177 Brno, Czech Republic; [Sterba, Jaroslav] Univ Hosp Brno, Brno, Czech Republic; [Jabali, Yahia] Reg Hosp Ceske Budejovice, Dept Pediat, Ceske Budejovice, Czech Republic; [Prochazkova, Daniela] Masaryk Hosp Usti Nad Labem, Dept Pediat, Usti Nad Labem, Czech Republic; [Blazek, Bohumir] Univ Hosp Ostrava, Dept Pediat, Ostrava, Czech Republic; [Hak, Jiri] Univ Hosp Hradec Kralove, Dept Pediat, Hradec Kralove, Czech Republic; [Cerna, Zdenka] Univ Hosp Plzen, Dept Pediat, Plzen, Czech Republic","Fronkova, E (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006, Czech Republic.","eva.fronkova@lfmotol.cuni.cz",null,null,"Czech Ministry of Education, Youth and Sports [MSM 0021620813]; Czech Ministry of Health [IGA NS10472-3]; Czech Science Foundation [310/09/P058]; GAUK [437911]","this work was supported by grants from the Czech Ministry of Education, Youth and Sports (MSM 0021620813), Czech Ministry of Health (IGA NS10472-3), Czech Science Foundation (310/09/P058) and GAUK 437911.",null,37,4,6,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","DEC",2011,96,12,null,null,null,null,1815,1821,null,"10.3324/haematol.2011.042937",null,7,null,null,"868SB","WOS:000298544400015"]
[null,null,null,null,"J","Bronsky, J; Nedvidkova, J; Krasnicanova, H; Vesela, M; Schmidtova, J; Koutek, J; Kellermayer, R; Chada, M; Kabelka, Z; Hrdlicka, M; Nevoral, J; Prusa, R",null,null,null,"Bronsky, Jiri; Nedvidkova, Jara; Krasnicanova, Hana; Vesela, Marie; Schmidtova, Jana; Koutek, Jiri; Kellermayer, Richard; Chada, Martin; Kabelka, Zdenek; Hrdlicka, Michal; Nevoral, Jiri; Prusa, Richard",null,null,"Changes of Orexin A Plasma Levels in Girls with Anorexia Nervosa During Eight Weeks of Realimentation","INTERNATIONAL JOURNAL OF EATING DISORDERS",null,null,"English","Article",null,null,null,null,null,"orexin A; hypocretin 1; leptin; anorexia nervosa; nutritional status","FOOD-INTAKE; A LEVELS; LEPTIN; DEFICIENCY; CHILDREN; HYPOCRETIN-1; HYPOTHALAMUS; NARCOLEPSY; RECEPTORS; SECRETION","Objective: Orexin A (OXA) is a hypothalamic neuropeptide involved in regulation of food intake and nutritional status. There are multiple disturbances of neuropeptide signaling described in girls with anorexia nervosa (AN), but OXA levels have not been addressed in this population to date. Therefore, we analyzed OXA levels of AN girls in this study. Method: OXA (radioimmunoassay/RIA/method), leptin, insulinlike growth factor-1 (IGF-1), and insulinlike growth factor-1 binding protein-3 (IGFBP-3) levels were measured before and after 8 weeks of realimentation in 36 girls with AN and in 14 healthy controls (control group: CG). Results: Average weight increased significantly in AN during the study (p < .0001), while plasma levels of OXA decreased (before realimentation: 56.2 +/- 2.4 pg/ml; after realimentation: 47.5 +/- 1.4 pg/ml; p = .0025). OXA levels before realimentation differed from levels in the CG (47.15 +/- 2.6 pg/ml, p = .034), but not afterward. We did not find any correlation between OXA and age, height, weight, BMI; or IGF-1, IGFBP-3, and leptin levels. Discussion: OXA levels in untreated AN patients differ significantly from healthy subjects and decrease during realimentation. These findings indicate that OXA may be involved in the nutritional regulation of malnourished children and adolescents. (C) 2010 by Wiley Periodicals, Inc.","[Bronsky, Jiri] Charles Univ Prague, Dept Pediat, Gastroenterol Unit, Med Fac 2, Prague 15006 5, Czech Republic; [Bronsky, Jiri; Krasnicanova, Hana; Vesela, Marie; Schmidtova, Jana; Koutek, Jiri; Chada, Martin; Kabelka, Zdenek; Hrdlicka, Michal; Nevoral, Jiri; Prusa, Richard] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Bronsky, Jiri; Chada, Martin; Prusa, Richard] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Med Fac 2, Prague 15006 5, Czech Republic; [Nedvidkova, Jara] Inst Endocrinol, Dept Mol Endocrinol, Prague 11694 1, Czech Republic; [Schmidtova, Jana; Koutek, Jiri; Hrdlicka, Michal] Charles Univ Prague, Dept Pediat Psychiat, Med Fac 2, Prague 15006 5, Czech Republic; [Kellermayer, Richard] Baylor Coll Med, Sect Pediat Gastroenterol, Houston, TX 77030 USA; [Chada, Martin] Univ Erlangen Nurnberg, Dept Pediat, Erlangen, Germany; [Kabelka, Zdenek] Charles Univ Prague, Dept ENT, Med Fac 2, Prague 15006 5, Czech Republic","Bronsky, J (reprint author), Charles Univ Prague, Dept Pediat, Gastroenterol Unit, Med Fac 2, V Uvalu 84, Prague 15006 5, Czech Republic.","bronsky@email.cz",null,null,"Danone Institute [VZ 64203/6903]","The first author received research grant from Danone institute on the topic of regulatory peptides of nutritional status.Supported by VZ 64203/6903 from Danone Institute.",null,33,5,5,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0276-3478",null,null,"INT J EAT DISORDER","Int. J. Eating Disord.","SEP",2011,44,6,null,null,null,null,547,552,null,"10.1002/eat.20857",null,6,"Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology","Psychology; Nutrition & Dietetics; Psychiatry","808DR","WOS:000293957300009"]
[null,null,null,null,"J","Starkova, J; Gadgil, S; Qiu, YH; Zhang, NX; Hermanova, I; Kornblau, SM; Drabkin, HA",null,null,null,"Starkova, Julia; Gadgil, Sharvari; Qiu, Yi Hua; Zhang, Nianxiang; Hermanova, Ivana; Kornblau, Steven M.; Drabkin, Harry A.",null,null,"Up-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signaling","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Article",null,null,null,null,null,"acute myeloid leukemia; FLT3; DLX1; DLX2; TGF beta","ACUTE PROMYELOCYTIC LEUKEMIA; GROWTH-FACTOR-BETA; HOX EXPRESSION; BREAST-CANCER; HEMATOPOIETIC PROGENITORS; MYELOID LEUKEMIAS; HOMEOBOX GENE; STEM-CELL; TARGET; PROTEIN","Background Activating mutations in fms-like tyrosine kinase-3 (FLT3) are frequent in acute myeloid leukemia and represent both a poor prognostic feature and a therapeutic target. We have identified a previously unrecognized downstream effect of FLT3 activation, namely up-regulation of the homeodomain genes, DLX1 and DLX2. Design and Methods MV4; 11 cells with FLT3-internal tandem duplication mutation, RS4;11 cells with wild-type FLT3 and blasts from patients with acute myeloid leukemia were used to pursue the relation between FLT3, DLX1/2 and transforming growth factor-beta (TGF beta). Real-time quantitative reverse transcriptase polymerase chain reaction, western blot and reverse-phase protein array were performed to detect changes in gene and protein expression. RNA interference and MTS assays were used to study the interaction of PKC412, FLT3 inhibitor and TGF beta 1. Results A direct relationship between FLT3 activity and DLX1/2 expression was revealed by both inhibition and up-regulation of FLT3 signaling in MV4; 11 and RS4; 11 cell lines, respectively, in isolated blast cells from patients with acute myeloid leukemia, and in reverse-phase protein array assays of samples from patients with acute myeloid leukemia. Mechanistically, the link between FLT3 and DLX1 expression appears to involve MAPK signaling through the ERK and JNK pathways. To determine whether elevated DLX1 had a functional consequence, we explored the reported inhibition by DLX1 on TGF beta/Smad signaling. Indeed, TGF beta responses were blunted by FLT3 activation in a DLX1-dependent manner and FLT3 inhibition resulted in a time-dependent increase in nuclear phospho-Smad2. Conclusions These findings suggest that alterations in DLX1/2 contribute to the biological consequences of FLT3 activation.","[Starkova, Julia; Hermanova, Ivana; Drabkin, Harry A.] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol Oncol, Prague 15006, Czech Republic; [Starkova, Julia; Drabkin, Harry A.] Med Univ S Carolina, Div Hematol Oncol, Charleston, SC 29425 USA; [Gadgil, Sharvari] Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Aurora, CO USA; [Qiu, Yi Hua; Zhang, Nianxiang; Kornblau, Steven M.] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA","Starkova, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat Haematol Oncol, V Uvalu 84, Prague 15006, Czech Republic.","julia.starkova@lfmotol.cuni.cz",null,null,"National Institutes of Health [CA97710];  [GACR 301/08/P532];  [MSM0021620813];  [IGA NR9526]","HD was supported by the National Institutes of Health, CA97710. JS was supported by GACR 301/08/P532, MSM0021620813 and IGA NR9526.",null,45,3,4,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","JUN",2011,96,6,null,null,null,null,820,828,null,"10.3324/haematol.2010.031179",null,9,null,null,"783MT","WOS:000292088100010"]
[null,null,null,null,"J","Strahm, B; Nollke, P; Zecca, M; Korthof, ET; Bierings, M; Furlan, I; Sedlacek, P; Chybicka, A; Schmugge, M; Bordon, V; Peters, C; O'Marcaigh, A; de Heredia, CD; Bergstraesser, E; Moerloose, BD; van den Heuvel-Eibrink, MM; Stary, J; Trebo, M; Wojcik, D; Niemeyer, CM; Locatelli, F",null,null,null,"Strahm, B.; Noellke, P.; Zecca, M.; Korthof, E. T.; Bierings, M.; Furlan, I.; Sedlacek, P.; Chybicka, A.; Schmugge, M.; Bordon, V.; Peters, C.; O'Marcaigh, A.; de Heredia, C. D.; Bergstraesser, E.; Moerloose, B. D.; van den Heuvel-Eibrink, M. M.; Stary, J.; Trebo, M.; Wojcik, D.; Niemeyer, C. M.; Locatelli, F.",null,"EWOG-MDS Study Grp","Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"myelodysplastic syndrome; stem cell transplantation; children","ACUTE MYELOID-LEUKEMIA; JUVENILE MYELOMONOCYTIC LEUKEMIA; BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; CHILDHOOD; GRAFT; CLASSIFICATION; EXPERIENCE; SURVIVAL; THERAPY","We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n = 53), RAEB in transformation (RAEB-T, n = 29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n = 15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n = 57) or alternative family donor (n = 1). Stem cell source was bone marrow (n = 69) or peripheral blood (n = 28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS. Leukemia (2011) 25, 455-462; doi:10.1038/leu.2010.297; published online 7 January 2011","[Strahm, B.; Noellke, P.; Furlan, I.; Niemeyer, C. M.] Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, D-79106 Freiburg, Germany; [Zecca, M.] IRCCS Policlin, Dept Pediat, San Matteo, Italy; [Korthof, E. T.] Leiden Univ, Med Ctr, Div Stem Cell Transplantat, Dept Pediat, Leiden, Netherlands; [Bierings, M.] Univ Hosp Children, Dept Hematol, Utrecht, Netherlands; [Sedlacek, P.; Stary, J.] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Chybicka, A.; Wojcik, D.] Med Univ, Dept Pediat Bone Marrow Transplantat Oncol & Hema, Wroclaw, Poland; [Schmugge, M.; Bergstraesser, E.] Univ Childrens Hosp, Dept Hematol & Oncol, Zurich, Switzerland; [Bordon, V.; Moerloose, B. D.] Ghent Univ Hosp, Dept Pediat Hematol & Oncol, B-9000 Ghent, Belgium; [Peters, C.; Trebo, M.] St Anna Childrens Hosp, Dept Pediat, A-1090 Vienna, Austria; [O'Marcaigh, A.] Our Ladys Hosp Sick Children, Dept Hematol & Oncol, Dublin, Ireland; [de Heredia, C. D.] Hosp Valle De Hebron, Dept Pediat Oncol & Hematol, Barcelona, Spain; [van den Heuvel-Eibrink, M. M.] Erasmus MC, Rotterdam, Netherlands; [van den Heuvel-Eibrink, M. M.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Locatelli, F.] Univ Pavia, IRCCS Osped Bambino Gesu, Dept Pediat Hematol & Oncol, Rome, Italy","Strahm, B (reprint author), Univ Freiburg, Dept Pediat & Adolescent Med, Div Pediat Hematol & Oncol, Mathildenstr 1, D-79106 Freiburg, Germany.","brigitte.strahm@uniklinik-freiburg.de","Seys, Ellen/F-7416-2011",null,null,null,null,29,17,17,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924","1476-5551",null,"LEUKEMIA","Leukemia","MAR",2011,25,3,null,null,null,null,455,462,null,"10.1038/leu.2010.297",null,8,"Oncology; Hematology","Oncology; Hematology","732CB","WOS:000288159500008"]
[null,null,null,null,"J","Carlsen, KCL; Hedlin, G; Bush, A; Wennergren, G; de Benedictis, FM; De Jongste, JC; Baraldi, E; Pedroletti, C; Barbato, A; Malmstrom, K; Pohunek, P; Pedersen, S; Piacentini, GL; Middelveld, RJM; Carlsen, KH",null,null,null,"Carlsen, K. C. Lodrup; Hedlin, G.; Bush, A.; Wennergren, G.; de Benedictis, F. M.; De Jongste, J. C.; Baraldi, E.; Pedroletti, C.; Barbato, A.; Malmstrom, K.; Pohunek, P.; Pedersen, S.; Piacentini, G. L.; Middelveld, R. J. M.; Carlsen, K. H.",null,"PSACI Grp","Assessment of problematic severe asthma in children","EUROPEAN RESPIRATORY JOURNAL",null,null,"English","Article",null,null,null,null,null,"Asthma; child; diagnostics; severe","QUALITY-OF-LIFE; EXHALED NITRIC-OXIDE; EXERCISE-INDUCED BRONCHOCONSTRICTION; RANDOMIZED CONTROLLED-TRIAL; TO-TREAT ASTHMA; LUNG-FUNCTION; DIFFICULT ASTHMA; AIRWAY HYPERRESPONSIVENESS; SPUTUM INDUCTION; CHILDHOOD ASTHMA","Assessment of problematic severe asthma in children should be performed in a stepwise manner to ensure an optimal approach. A four-step assessment scheme is proposed. First, a full diagnostic work-up is performed to exclude other diseases which mimic asthma. Secondly, a multi-disciplinary assessment is performed to identify issues that may need attention, including comorbidities. Thirdly, the pattern of inflammation is assessed, and finally steroid responsiveness is documented. Based upon these four steps an optimal individualised treatment plan is developed. In this article the many gaps in our current knowledge in all these steps are highlighted, and recommendations for current clinical practice and future research are made. The lack of good data and the heterogeneity of problematic severe asthma still limit our ability to optimise the management on an individual basis in this small, but challenging group of patients.","[Carlsen, K. C. Lodrup] Univ Oslo, Dept Paediat, Women & Childrens Div, Oslo Univ Hosp, NO-0407 Oslo, Norway; [Carlsen, K. C. Lodrup; Carlsen, K. H.] Univ Oslo, Fac Med, NO-0407 Oslo, Norway; [Hedlin, G.; Pedroletti, C.] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Bush, A.] Royal Brompton Hosp, Dept Resp Paediat, London SW3 6LY, England; [Wennergren, G.] Univ Gothenburg, Dept Paediat, Queen Silvia Childrens Hosp, Gothenburg, Sweden; [de Benedictis, F. M.] Salesi Childrens Hosp, Dept Paediat, Ancona, Italy; [De Jongste, J. C.] Erasmus Univ, Med Center, Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands; [Baraldi, E.; Barbato, A.] Univ Padua, Sch Med, Dept Paediat, Padua, Italy; [Malmstrom, K.] Univ Helsinki, Cent Hosp, Dept Allergy, Helsinki, Finland; [Pohunek, P.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Pohunek, P.] Univ Hosp Motol, Prague, Czech Republic; [Pedersen, S.] Univ So Denmark, Dept Paediat, Kolding Hosp, Kolding, Denmark; [Piacentini, G. L.] Univ Verona, Dept Paediat, I-37100 Verona, Italy; [Middelveld, R. J. M.] Karolinska Inst, Inst Environm Med, Ctr Allergy Res, S-10401 Stockholm, Sweden","Carlsen, KCL (reprint author), Univ Oslo, Dept Paediat, Women & Childrens Div, Oslo Univ Hosp, NO-0407 Oslo, Norway.","k.c.l.carlsen@medisin.uio.no",null,null,"Global Allergy and Asthma European Network (GA2LEN; EU) [FOOD-CT-2004-506378]","This article was initiated and financially supported by the Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN; EU contract number FOOD-CT-2004-506378).",null,80,15,15,"EUROPEAN RESPIRATORY SOC JOURNALS LTD","SHEFFIELD","442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND","0903-1936",null,null,"EUR RESPIR J","Eur. Resp. J.","FEB",2011,37,2,null,null,null,null,432,440,null,"10.1183/09031936.00091410",null,9,"Respiratory System","Respiratory System","713IF","WOS:000286730400030"]
[null,null,null,null,"J","Tapia, G; Cinek, O; Rasmussen, T; Witso, E; Grinde, B; Stene, LC; Ronningen, KS",null,null,null,"Tapia, German; Cinek, Ondrej; Rasmussen, Trond; Witso, Elisabet; Grinde, Bjorn; Stene, Lars Christian; Ronningen, Kjersti Skjold",null,null,"Human Enterovirus RNA in Monthly Fecal Samples and Islet Autoimmunity in Norwegian Children With High Genetic Risk for Type 1 Diabetes The MIDIA study","DIABETES CARE",null,null,"English","Article",null,null,null,null,null,null,"BETA-CELL AUTOIMMUNITY; INFECTIONS; PREVALENCE; INFANTS; COHORT","OBJECTIVE- To test whether the frequency of human enterovirus RNA in fecal samples collected monthly from early infancy was associated with development of multiple islet autoantibodies in children with the highest risk HLA genotype. RESEARCH DESIGN AND METHODS- Individuals carrying the HLA DRB1*0401-DQA1*03-DQB1*0302/DRB1*03-DQA1*05-DQB1*02 genotype were identified at birth and followed with monthly stool samples from age 3 to 35 months. Blood samples taken at age 3, 6, 9, and 12 months and then annually were tested for autoantibodies to insulin, GAD 65 and IA-2. Among 911 children, 27 developed positivity for two or more islet autoantiboclies in two or more consecutive samples (case subjects). Two control subjects per case subject were matched by follow-up time, date of birth, and county of residence. Stool samples were analyzed for enterovirus with a semiquantitative real-time RT-PCR. RESULTS- The frequency of human enterovirus RNA in stool samples from case subjects before seroconversion (43 of 339, 12.7%) did not differ from the frequency in control subjects (94 of 692, 13.6%) (P = 0.97). Results remained essentially unchanged after adjustment for potential confounders, restriction to various time windows before seroconversion, or infections in the 1st year of life or after inclusion of samples collected after seroconversion. There was no difference in the average quantity of enterovirus RNA or in the frequency of repeatedly positive samples. The estimated relative risk for islet autoimmunity per enterovirus RNA positive sample during follow-up (nested case-control analysis) was 1.12 (95% CI 0.66-1.91). CONCLUSIONS- There was no support for the hypothesis that fecal shedding of enteroviral RNA is a major predictor of advanced islet autoimmunity.","[Tapia, German; Rasmussen, Trond; Witso, Elisabet; Grinde, Bjorn; Stene, Lars Christian; Ronningen, Kjersti Skjold] Norwegian Inst Publ Hlth, Oslo, Norway; [Tapia, German; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Tapia, G (reprint author), Norwegian Inst Publ Hlth, Oslo, Norway.","german.tapia@fhi.no",null,null,"Norwegian Organization for Health and Rehabilitation [2005/2/0128]; Prague, the Czech Republic [A/CZ0046/1/0014]; Ministry of Education of the Czech Republic [MSM0021620814]; Research Council of Norway [135893/330, 155300/320, 156477/730, 166515N50]; Norwegian Diabetes Association; NewGeneris [Food-CT-2005-016320]","This study and the MIDIA project were funded by the Norwegian Organization for Health and Rehabilitation (2005/2/0128), the EEA/Norway funds (grant A/CZ0046/1/0014 through the Research Support Fund, Prague, the Czech Republic), the Ministry of Education of the Czech Republic (grant MSM0021620814), the Research Council of Norway (grants 135893/330, 155300/320, 156477/730, and 166515N50), the Norwegian Diabetes Association, Children with Diabetes Foundation (Denver, CO), and NewGeneris (grant Food-CT-2005-016320).",null,14,15,15,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0149-5992",null,null,"DIABETES CARE","Diabetes Care","JAN",2011,34,1,null,null,null,null,151,155,null,"10.2337/dc10-1413",null,5,"Endocrinology & Metabolism","Endocrinology & Metabolism","710FT","WOS:000286497000031"]
[null,null,null,null,"J","Kramer, AM; van Stralen, KJ; Jager, KJ; Schaefer, F; Verrina, E; Seeman, T; Lewis, MA; Boehm, M; Simonetti, GD; Novljan, G; Groothoff, JW",null,null,null,"Kramer, A. Marijn; van Stralen, Karlijn J.; Jager, Kitty J.; Schaefer, Franz; Verrina, Enrico; Seeman, Tomas; Lewis, Malcolm A.; Boehm, Michael; Simonetti, Giacomo D.; Novljan, Gregor; Groothoff, Jaap W.",null,null,"Demographics of blood pressure and hypertension in children on renal replacement therapy in Europe","KIDNEY INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"blood pressure; children; dialysis; end-stage renal disease; hypertension; transplantation","HEMODIALYSIS-PATIENTS; UNITED-STATES; PREVALENCE; FAILURE; DIALYSIS; REGISTRY","Hypertension is a well-known complication in children on renal replacement therapy and an important risk factor for cardiovascular disease in later life. In order to define the prevalence of and risk factors for hypertension among children, we enrolled 3337 pediatric patients from 15 countries in the ESPN/ERA-EDTA Registry of whom 464 were on hemodialysis, 851 on peritoneal dialysis, and 2023 had received a renal allograft. Hypertension was defined as either systolic or diastolic blood pressures in the 95th percentile or greater for age, height, and gender or use of antihypertensive medication. Analyses were adjusted for age, gender, duration, and modality of renal replacement therapy. In 10 countries in which information on the use of antihypertensive medication was available, hypertension was present in over two-thirds of hemodialysis, peritoneal dialysis, or transplant patients. Blood pressure values above the 95th percentile were significantly more prevalent in very young patients (under 3 years) compared to 13- to 17-year olds (odds ratio 2.47), during the first year compared to over 5 years of renal replacement therapy (odds ratio 1.80), and in patients on hemodialysis compared to transplant recipients or those on peritoneal dialysis (odds ratios of 2.48 and 1.59, respectively). Over time, mean blood pressures decreased in both hemodialysis and transplant patients, but not in peritoneal dialysis patients. Hence, our findings highlight the extent of the problem of hypertension in children with end-stage renal disease in Europe. Kidney International (2011) 80, 1092-1098; doi:10.1038/ki.2011.232; published online 3 August 2011","[Kramer, A. Marijn; van Stralen, Karlijn J.; Jager, Kitty J.] Univ Amsterdam, Acad Med Ctr, Dept Med Informat, ESPN ERA EDTA Registry, NL-1100 DE Amsterdam, Netherlands; [Schaefer, Franz] Univ Hosp, Dept Pediat Nephrol, Heidelberg, Germany; [Verrina, Enrico] Gaslini Childrens Hosp, Dept Pediat Nephrol, Genoa, Italy; [Seeman, Tomas] Univ Childrens Hosp Motol Prague, Dept Pediat Nephrol, Prague, Czech Republic; [Lewis, Malcolm A.] Royal Manchester Childrens Hosp, Dept Pediat Nephrol, Manchester M27 1HA, Lancs, England; [Boehm, Michael] Univ Kinderklin Wien, Dept Pediat Nephrol, Vienna, Austria; [Simonetti, Giacomo D.] Univ Pediat Hosp, Dept Pediat Nephrol, Bern, Switzerland; [Novljan, Gregor] Univ Med Ctr, Dept Pediat Nephrol, Ljubljana, Slovenia; [Groothoff, Jaap W.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat Nephrol, NL-1105 AZ Amsterdam, Netherlands","van Stralen, KJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Med Informat, ESPN ERA EDTA Registry, POB 22700, NL-1100 DE Amsterdam, Netherlands.","K.J.vanStralen@amc.uva.nl","Schaefer, Franz/G-4365-2010",null,"European Society of Pediatric Nephrology (ESPN); European Renal Association and European Dialysis and Transplant Association (ERA-EDTA); NephroQUEST project; European Union [2006114]; Amgen","The ESPN/ERA-EDTA Registry is funded by the European Society of Pediatric Nephrology (ESPN), the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA), and the NephroQUEST project. The NephroQUEST project has received funding from the European Union in the framework of the Public Health Program (project number 2006114). Furthermore, Amgen has provided an unrestricted educational grant to assist the ESPN in the financial support of the Registry. We thank the patients, their parents, and the staff of all the dialysis and transplant units who have contributed data via their national registries and contact persons. We also thank P Cochat, R Coppo, and D Haffner for being members of the ESPN/ERA-EDTA Registry Committee, D Shitza, R Kramar, R Oberbauer, S Baiko, A Sukalo, K van Hoeck, F Collart, JM des Grottes, R Lombaerts, D Pokrajac, D Roussinov, Z Puretic, D Batinic, K Vondrak, J Heaf, U Toots, P Finne, C Gronhagen-Riska, C Holmberg, C Couchoud, P Niaudet, L le Mignot, E Sahpazova, G Gersdorf, C Scholz, G Ioannidis, G Reusz, S Turi, L Szabo, T Szabo, F Paglialonga, S Picca, E Vidal, A Jankauskiene, S Pavicevic, T Leivestad, D Brackman, A Zurowska, I Zagozdzon, C Mota, M Almeida, C Afonso, G Mircescu, L Garneata, E Podgoreanu, M Gafencu, EA Molchanova, NA Tomilina, BT Bikbov, A Peco-Antic, M Kostic, B Spasojevic-Dimitrijeva, D Paripovic, L Podracka, G Kolvek, J Buturovic-Ponikvar, N Battelino, A Alonso Melgar, and the Spanish Pediatric Registry, S Schon, J KG Prutz, A Seeberger, L Backman, M Herthelius, CE Kuenhi, E Maurer, A Hoitsma, A Hemke, WF Tromp, N Schoenmaker, R Topaloglu, D Ivanov, D Ansell, and C Inward for contributing data to the ESPN/ERA-EDTA Registry.",null,19,12,12,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","0085-2538",null,null,"KIDNEY INT","Kidney Int.","NOV",2011,80,10,null,null,null,null,1092,1098,null,"10.1038/ki.2011.232",null,7,"Urology & Nephrology","Urology & Nephrology","842OW","WOS:000296609800013"]
[null,null,null,null,"J","Bizzetto, R; Bonfim, C; Rocha, V; Socie, G; Locatelli, F; Chan, KW; Ramirez, O; Stein, J; Nabhan, S; Miranda, E; Passweg, J; de Souza, CACA; Gluckman, E; Ebmt, ESW",null,null,null,"Bizzetto, Renata; Bonfim, Carmen; Rocha, Vanderson; Socie, Gerard; Locatelli, Franco; Chan, KaWah; Ramirez, Oscar; Stein, Joel; Nabhan, Samir; Miranda, Eliana; Passweg, Jakob; Antonio de Souza, Carmino C. A.; Gluckman, Eliane; EBMT, Eurocord SAA-WP",null,null,"Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Article",null,null,null,null,null,"cord blood transplantation; hereditary bone marrow failure syndromes; engraftment; HLA compatibility","STEM-CELL TRANSPLANTATION; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; SHWACHMAN-DIAMOND SYNDROME; DYSKERATOSIS-CONGENITA; PROGENITOR CELLS; BLACKFAN ANEMIA; CHRONIC GVHD; PHASE-I/II; NEUTROPENIA; DISEASE","Background Allogeneic stem cell transplantation is the only curative option for patients with hereditary bone marrow failure syndromes. Umbilical cord blood is an alternative source of stem cells for allogeneic transplantation. Design and Methods This multicenter, retrospective study is based on data reported to the Eurocord Registry about patients with hereditary bone marrow failure syndrome who underwent umbilical cord blood transplantation. Results Sixty-four patients with hereditary bone marrow failure syndromes were transplanted from related (n=20) or unrelated donors (n=44). Diagnoses were Diamond-Blackfan anemia (21 patients), congenital amegakaryocytic thrombocytopenia (16 patients), dyskeratosis congenita (8 patients), Shwachman-Diamond syndrome (2 patients), severe congenital neutropenia (16 patients) and unclassified (1 patient). In the group of patients who received grafts from related donors, all patients but one received an HLA-matched sibling transplant. The median number of total nucleated cells infused was 5x10(7)/kg. The cumulative incidence of neutrophil recovery at 60 days was 95%. Two patients had grade II-IV acute graft-versus-host disease, while the 2-year cumulative incidence of chronic graft-versus-host disease was 11%. The 3-year overall survival rate was 95%. In the group of patients who received grafts from unrelated donors, 86% had HLA-mismatched grafts and three received two umbilical cord blood units. The median number of total nucleated cells infused was 6.1x10(7)/kg. The cumulative incidence of neutrophil recovery at day 60 in this group was 55%. The 100-day cumulative incidence of grade II-IV acute graft-versus-host disease was 24%, while the 2-year cumulative incidence of chronic graft-versus-host disease was 53%. The 3-year overall survival rate was 61%; better overall survival was associated with age less than 5 years (P=0.01) and 6.1x10(7)/kg or more total nucleated cells infused (P=0.05). Conclusions In patients with hereditary bone marrow failure syndromes, related umbilical cord blood transplantation is associated with excellent outcomes while increasing cell dose and better HLA matching might provide better results in unrelated umbilical cord blood transplantation.","[Bizzetto, Renata; Rocha, Vanderson; Gluckman, Eliane] Eurocord, Hosp St Louis, APHP, IUH, Paris, France; [Bizzetto, Renata; Miranda, Eliana; Antonio de Souza, Carmino C. A.] Univ Estadual Campinas, Campinas, SP, Brazil; [Bonfim, Carmen; Nabhan, Samir] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil; [Rocha, Vanderson; Socie, Gerard] St Louis Hosp, APHP, Bone Marrow Transplant Unit, IUH, Paris, France; [Locatelli, Franco] Univ Pavia, Osped Bambino Gesu, IRCCS, Rome, Italy; [Chan, KaWah] Texas Transplant Inst, San Antonio, TX USA; [Chan, KaWah] Methodist Childrens Hosp, San Antonio, TX USA; [Ramirez, Oscar] Fdn Clin Vale Lili, Cali, Colombia; [Stein, Joel] Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel; [Passweg, Jakob] Univ Hosp Geneva, Geneva, Switzerland","Gluckman, E (reprint author), Eurocord Hosp St Louis, 1 Ave Claude Vellefaux, Paris 10, France.","eliane.gluckman@sls.aphp.fr","Sangue, Inct/I-1919-2013",null,null,null,"Al-Ahmari A, 2004, BONE MARROW TRANSPL, V33, P829, DOI 10.1038/sj.bmt.1704445; Bacigalupo A, 2009, BIOL BLOOD MARROW TR, V15, P1628, DOI 10.1016/j.bbmt.2009.07.004; Ballmaier M, 2009, BRIT J HAEMATOL, V146, P3, DOI 10.1111/j.1365-2141.2009.07706.x; Boxer LA, 2007, PEDIATR BLOOD CANCER, V49, P609, DOI 10.1002/pbc.21282; Burroughs L, 2009, HEMATOL ONCOL CLIN N, V23, P233, DOI 10.1016/j.hoc.2009.01.007; Cesaro S, 2005, BRIT J HAEMATOL, V131, P231, DOI 10.1111/j.1365-2141.2005.05758.x; Delaney C, 2010, NAT MED, V16, P232, DOI 10.1038/nm.2080; de Lima M, 2008, BONE MARROW TRANSPL, V41, P771, DOI 10.1038/sj.bmt.1705979; Donadieu J, 2005, BONE MARROW TRANSPL, V36, P787, DOI 10.1038/sj.bmt.1705141; Ferry C, 2005, BONE MARROW TRANSPL, V35, P45, DOI 10.1038/sj.bmt.1704718; Frassoni F, 2008, LANCET ONCOL, V9, P831, DOI 10.1016/S1470-2045(08)70180-3; Gazda HT, 2006, BRIT J HAEMATOL, V135, P149, DOI 10.1111/j.1365-2141.2006.06268.x; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; Gluckman E, 2008, BONE MARROW TRANSPL, V41, P127, DOI 10.1038/sj.bmt.1705960; Gluckman E, 2007, BIOL BLOOD MARROW TR, V13, P1073, DOI 10.1016/j.bbmt.2007.05.015; Gungor T, 2003, BONE MARROW TRANSPL, V31, P407, DOI 10.1038/sj.bmt.1703844; King S, 2005, BRIT J HAEMATOL, V131, P636, DOI 10.1111/j.1365-2141.2005.05819.x; Locatelli F, 2003, BLOOD, V101, P2137, DOI 10.1182/blood-2002-07-2090; MacMillan ML, 2010, SEMIN HEMATOL, V47, P37, DOI 10.1053/j.seminhematol.2009.10.004; Mugishima H, 2007, Pediatr Transplant, V11, P601, DOI 10.1111/j.1399-3046.2006.00616.x; Myers KC, 2009, BIOL BLOOD MARROW TR, V15, P279, DOI 10.1016/j.bbmt.2008.11.037; Nobili B, 2002, BRIT J HAEMATOL, V119, P573, DOI 10.1046/j.1365-2141.2002.03835_2.x; Rocha V, 1998, BRIT J HAEMATOL, V103, P243, DOI 10.1046/j.1365-2141.1998.00949.x; ROCHA V, 2006, BIOL BLOOD MARROW S, V12, pS134; Rocha V, 2000, NEW ENGL J MED, V342, P1846, DOI 10.1056/NEJM200006223422501; Rocha Vanderson, 2010, Biol Blood Marrow Transplant, V16, pS126, DOI 10.1016/j.bbmt.2009.11.001; Rocha V, 2009, BRIT J HAEMATOL, V147, P262, DOI 10.1111/j.1365-2141.2009.07883.x; Roy V, 2005, BIOL BLOOD MARROW TR, V11, P600, DOI 10.1016/j.bbmt.2005.05.005; Schrezenmeier H, 2007, BLOOD, V110, P1397, DOI 10.1182/blood-2007-03-081596; Sieff CA, 2000, BRIT J HAEMATOL, V111, P30, DOI 10.1046/j.1365-2141.2000.02263.x; Teo JT, 2008, PEDIATRICS, V122, pE139, DOI 10.1542/peds.2007-3415; Vigorito AC, 2009, BLOOD, V114, P702, DOI 10.1182/blood-2009-03-208983; Walne AJ, 2009, BRIT J HAEMATOL, V145, P164, DOI 10.1111/j.1365-2141.2009.07598.x; Zeidler C, 2000, BLOOD, V95, P1195",34,9,10,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","JAN",2011,96,1,null,null,null,null,134,141,null,"10.3324/haematol.2010.027839",null,8,null,null,"715RT","WOS:000286902400021"]
[null,null,null,null,"J","Oschlies, I; Burkhardt, B; Chassagne-Clement, C; d'Amore, ES; Hansson, U; Hebeda, K; Mc Carthy, K; Kodet, R; Maldyk, J; Mullauer, L; Porwit, A; Schmatz, AI; Tinguely, M; Abramov, D; Wotherspoon, A; Zimmermann, M; Reiter, A; Klapper, W",null,null,null,"Oschlies, Ilske; Burkhardt, Birgit; Chassagne-Clement, Catherine; d'Amore, Emanuel S.; Hansson, Ulrika; Hebeda, Konnie; Mc Carthy, Keith; Kodet, Roman; Maldyk, Jadwiga; Muellauer, Leonhard; Porwit, Anna; Schmatz, Ana-Iris; Tinguely, Marianne; Abramov, Dimitry; Wotherspoon, Andrew; Zimmermann, Martin; Reiter, Alfred; Klapper, Wolfram",null,null,"Diagnosis and Immunophenotype of 188 Pediatric Lymphoblastic Lymphomas Treated Within a Randomized Prospective Trial: Experiences and Preliminary Recommendations From the European Childhood Lymphoma Pathology Panel","AMERICAN JOURNAL OF SURGICAL PATHOLOGY",null,null,"English","Article",null,null,null,null,null,"MPAL; TdT; CD34; lymphoblastic; ALL; precursor; B-LBL; T-LBL","MERKEL CELL-CARCINOMA; TRANSCRIPTION FACTORS; ACUTE LEUKEMIAS; EXPRESSION; PAX5; SURVIVAL; PITFALL; LINEAGE; TDT","The majority of lymphoblastic (precursor cell) neoplasms presents as leukemias. Consequently, the guidelines for lineage determination and subtyping of precursor cell neoplasms were primarily established for flow cytometry methods. Large-scale studies of nonleukemic lymphoblastic lymphomas are lacking so far. We analyzed a large series of pediatric patients with lymphoblastic lymphoma treated within a prospective randomized trial (the Euro-LB 02 study). Among 193 lymphomas, in which a detailed immunohistochemical analysis was carried out, there were several unusual and diagnostically challenging morphologic and immunophenotypical variants. These included 11 lymphomas with mixed phenotypes expressing markers of at least 2 hematopoietic lineages, 7 terminal deoxynucleotide transferase-negative lymphoblastic lymphomas, and 3 undifferentiated hematopoietic neoplasms that could not be assigned to any lineage with certainty. Our data indicate that World Health Organzation guidelines for lineage determination and subtyping of precursor cell leukemia need to be adapted before they can be applied to immunohistochemical diagnosis of lymphoma. Using the experience from this cohort we suggest a resource-saving diagnostic staining panel for the immunohistochemical analysis of precursor cell neoplasms in formalin-fixed paraffin-embedded tissue.","[Oschlies, Ilske; Abramov, Dimitry; Klapper, Wolfram] Univ Kiel, Dept Pathol, Hematopathol Sect, D-2300 Kiel, Germany; [Oschlies, Ilske; Abramov, Dimitry; Klapper, Wolfram] Univ Kiel, Lymph Node Registry, D-2300 Kiel, Germany; [Burkhardt, Birgit; Zimmermann, Martin; Reiter, Alfred] Univ Giessen, NHL BFM Study Ctr, Dept Pediat Hematol & Oncol, Giessen, Germany; [Schmatz, Ana-Iris] Leibniz Univ Hannover, Dept Pediat Hematol, D-30167 Hannover, Germany; [Schmatz, Ana-Iris] Leibniz Univ Hannover, Dept Oncol, D-30167 Hannover, Germany; [Chassagne-Clement, Catherine] Ctr Leon Berard, Dept Biopathol, F-69373 Lyon, France; [d'Amore, Emanuel S.] Osped San Bortolo, Dept Pathol, Vicenza, Italy; [Hansson, Ulrika] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Porwit, Anna] Karolinska Univ Hosp & Inst, Dept Pathol, Stockholm, Sweden; [Hebeda, Konnie] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands; [Mc Carthy, Keith] Chettenham Gen Hosp, Dept Pathol, Cheltenham, Glos, England; [Wotherspoon, Andrew] Royal Marsden Hosp, Dept Histopathol, London SW3 6JJ, England; [Kodet, Roman] Charles Univ Prague, Dept Pathol & Mol Med, Sch Med 2, Prague, Czech Republic; [Maldyk, Jadwiga] Childrens Hosp, Dept Pathol, Warsaw, Poland; [Tinguely, Marianne] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland; [Muellauer, Leonhard] Med Univ Vienna, Dept Pathol, Vienna, Austria; [Kodet, Roman] Charles Univ Prague, Fac Hosp, Prague, Czech Republic","Klapper, W (reprint author), Univ Hosp Schleswig Holstein, Hematopathol Sect, Arnold Heller Str 3,Haus 14, D-24105 Kiel, Germany.","wklapper@path.uni-kiel.de",null,null,"Deutsche Krebshilfe Bonn [102595, 107813]; national study groups of participating centers; TransAid foundation; Kinderkrebsinitiative Buchholz, Holm-Seppensen, Germany; Kinder-Krebs-Initiative Buchholz, Holm-Seppensen; national study groups for pediatric Non-Hodgkin Lymphoma of the participating pathologists; Deutsche Krebshilfe [107813]","Supported by the Deutsche Krebshilfe Bonn (projekt Nr. 102595 and 107813) and national study groups of participating centers. D. A. was supported by the TransAid foundation. W. K. and I.O. were supported by the Kinderkrebsinitiative Buchholz, Holm-Seppensen, Germany.Supported by the Kinder-Krebs-Initiative Buchholz, Holm-Seppensen and the national study groups for pediatric Non-Hodgkin Lymphoma of the participating pathologists. The NHL-BFM study center as the international coordination center of the trial was supported by the Deutsche Krebshilfe (grant No. 107813).",null,29,5,5,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0147-5185",null,null,"AM J SURG PATHOL","Am. J. Surg. Pathol.","JUN",2011,35,6,null,null,null,null,836,844,null,"10.1097/PAS.0b013e318213e90e",null,9,"Pathology; Surgery","Pathology; Surgery","763NW","WOS:000290567400007"]
[null,null,null,null,"J","Henry, DH; Costa, L; Goldwasser, F; Hirsh, V; Hungria, V; Prausova, J; Scagliotti, GV; Sleeboom, H; Spencer, A; Vadhan-Raj, S; von Moos, R; Willenbacher, W; Wang, JM; Jiang, Q; Jun, S; Dansey, R; Yeh, H",null,null,null,"Henry, David H.; Costa, Luis; Goldwasser, Francois; Hirsh, Vera; Hungria, Vania; Prausova, Jana; Scagliotti, Giorgio Vittorio; Sleeboom, Harm; Spencer, Andrew; Vadhan-Raj, Saroj; von Moos, Roger; Willenbacher, Wolfgang; Wang, Jianming; Jiang, Qi; Jun, Susie; Dansey, Roger; Yeh, Howard",null,null,"Ras Inhibition and the Survival Benefit Favoring Zoledronic Acid Compared With Denosumab in Patients With Multiple Myeloma Reply","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Henry, David H.] Joan Karnell Canc Ctr, Philadelphia, PA USA; [Costa, Luis] Hosp Santa Maria, Lisbon, Portugal; [Goldwasser, Francois] Teaching Hosp Cochin, Paris, France; [Hirsh, Vera] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Hungria, Vania] Irmandade Santa Casa de Misericordia Sao Paulo, Sao Paulo, Brazil; [Prausova, Jana] Univ Hosp Motol, Prague, Czech Republic; [Scagliotti, Giorgio Vittorio] Univ Torino, Orbassano, Italy; [Sleeboom, Harm] HagaZiekenhuis Leyenburg, The Hague, Netherlands; [Spencer, Andrew] Alfred Hosp, Melbourne, Vic, Australia; [Vadhan-Raj, Saroj] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [von Moos, Roger] Kantonsspital Graubunden, Chur, Switzerland; [Willenbacher, Wolfgang] Med Univ Innsbruck, Innsbruck, Austria; [Wang, Jianming; Jiang, Qi; Jun, Susie; Dansey, Roger; Yeh, Howard] Amgen Inc, Thousand Oaks, CA USA","Henry, DH (reprint author), Joan Karnell Canc Ctr, Philadelphia, PA USA.",null,"Hungria, Vania/G-3141-2012",null,null,null,null,10,0,0,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,null,"J CLIN ONCOL","J. Clin. Oncol.","JUL 1",2011,29,19,null,null,null,null,2736,2737,null,"10.1200/JCO.2011.35.9182",null,3,"Oncology","Oncology","785EP","WOS:000292210500035"]
[null,null,null,null,"J","Zuna, J; Madzo, J; Krejci, O; Zemanova, Z; Kalinova, M; Muzikova, K; Zapotocky, M; Starkova, J; Hrusak, O; Horak, J; Trka, J",null,null,null,"Zuna, Jan; Madzo, Jozef; Krejci, Ondrej; Zemanova, Zuzana; Kalinova, Marketa; Muzikova, Katerina; Zapotocky, Michal; Starkova, Julia; Hrusak, Ondrej; Horak, Jiri; Trka, Jan",null,null,"ETV6/RUNX1 (TEL/AML1) is a frequent prenatal first hit in childhood leukemia","BLOOD",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Zuna, Jan; Madzo, Jozef; Krejci, Ondrej; Kalinova, Marketa; Muzikova, Katerina; Zapotocky, Michal; Starkova, Julia; Hrusak, Ondrej; Trka, Jan] Charles Univ Prague, Childhood Leukaemia Invest Prague, Prague 15006 5, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Fac Med 1, Prague 15006 5, Czech Republic; [Horak, Jiri] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague 15006 5, Czech Republic; [Zuna, Jan; Madzo, Jozef; Krejci, Ondrej; Kalinova, Marketa; Muzikova, Katerina; Zapotocky, Michal; Starkova, Julia; Hrusak, Ondrej; Trka, Jan] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague 15006 5, Czech Republic","Zuna, J (reprint author), Charles Univ Prague, Childhood Leukaemia Invest Prague, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.zuna@lfmotol.cuni.cz",null,null,null,null,null,0,8,9,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","JAN 6",2011,117,1,null,null,null,null,368,369,null,"10.1182/blood-2010-09-309070",null,2,"Hematology","Hematology","703FO","WOS:000285963900052"]
[null,null,null,null,"J","Botev, R; Mallie, JP; Wetzels, JFM; Couchoud, C; Schuck, O",null,null,null,"Botev, Rossini; Mallie, Jean-Pierre; Wetzels, Jack F. M.; Couchoud, Cecile; Schueck, Otto",null,null,"The Clinician and Estimation of Glomerular Filtration Rate by Creatinine-based Formulas: Current Limitations and Quo Vadis","CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,null,"CHRONIC KIDNEY-DISEASE; BODY-SURFACE AREA; CHRONIC RENAL-INSUFFICIENCY; COCKCROFT-GAULT EQUATIONS; S-CYSTATIN-C; SERUM CREATININE; TRANSPLANT RECIPIENTS; SUBCUTANEOUS INJECTION; PREDICTIVE PERFORMANCE; NONDIABETIC PATIENTS","The GFR has a paramount diagnostic and staging role in the Kidney Disease Outcome Quality Initiative Clinical Practice Guidelines for Chronic Kidney Disease (K/DOQI-CKD). The most widely used serum creatinine-based formulas in adults for estimated GFR (eGFR) are the Cockcroft-Gault (CG) and Modification of Diet in Renal Disease Study (MDRD). Recently, a new Chronic Kidney Disease Epidemiology Collaboration equation has been developed. Review of the literature revealed that CG and MDRD formulas correctly assigned overall only 64% and 62%, respectively, of the subjects to their actual K/DOQI-CKD classification's GFR groups as determined by measured GFR (mGFR). This suggests that approximately 10 million (38%) subjects may have been misclassified on the basis of estimated CKD prevalence of 26.3 million adults in the United States. The purpose of this review is to help the clinician understand the limitations of using eGFR in daily practice. We also elaborate upon issues such as the differences among markers of mGFR, the validity of adjusting GFR for body surface area in certain populations, the limited data on boundaries for normal mGFR according to age, gender, and race, the need for calibration of a wide spectrum of serum creatinine measurements, the lack of actual eGFR value above 60 ml/min per 1.73 m(2) and reference for normal mGFR in the clinical laboratories' reports, and the performance evaluation of the eGFR formulas. Several pitfalls have to be overcome before we can reliably determine health and disease in daily nephrology practice to preserve the first rule of practicing medicine: primum non nocere. Clin J Am Soc Nephrol 6: 937-950, 2011. doi: 10.2215/CJN.09241010","[Botev, Rossini] Hawaii Permanent Med Grp, Dept Nephrol, Honolulu, HI 96819 USA; [Mallie, Jean-Pierre] Nancy Univ, Nancy, France; [Wetzels, Jack F. M.] Radboud Univ Nijmegen, Med Ctr, Dept Nephrol, NL-6525 ED Nijmegen, Netherlands; [Couchoud, Cecile] Agence Biomed, French ESRD Registry REIN, La Plaine St Denis, France; [Schueck, Otto] Univ Hosp Motol, Internal Clin, Prague, Czech Republic","Botev, R (reprint author), Hawaii Permanent Med Grp, Dept Nephrol, 3288 Moanalua Rd, Honolulu, HI 96819 USA.","Rossini.C.Botev@kp.org","Wetzels, Jack/A-1720-2014",null,null,null,null,107,25,25,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1555-9041",null,null,"CLIN J AM SOC NEPHRO","Clin. J. Am. Soc. Nephrol.","APR",2011,6,4,null,null,null,null,937,950,null,"10.2215/CJN.09241010",null,14,"Urology & Nephrology","Urology & Nephrology","746DU","WOS:000289223600034"]
[null,null,null,null,"J","Chekina, N; Horak, D; Jendelova, P; Trchova, M; Benes, MJ; Hruby, M; Herynek, V; Turnovcova, K; Sykova, E",null,null,null,"Chekina, Nataliya; Horak, Daniel; Jendelova, Pavla; Trchova, Miroslava; Benes, Milan J.; Hruby, Martin; Herynek, Vit; Turnovcova, Karolina; Sykova, Eva",null,null,"Fluorescent magnetic nanoparticles for biomedical applications","JOURNAL OF MATERIALS CHEMISTRY",null,null,"English","Article",null,null,null,null,null,null,"IRON-OXIDE NANOPARTICLES; SUPERPARAMAGNETIC NANOPARTICLES; O-CARBOXYMETHYLCHITOSAN; DRUG-DELIVERY; IN-VIVO; CHITOSAN; CELLS; BIODEGRADATION; SEPARATION; PARTICLES","The simultaneous combination of optical and magnetic resonance imaging (MRI) would greatly benefit in vivo disease diagnosis as well as in situ monitoring of living cells. In order to design dual detection of cells involving simultaneous imaging by fluorescent microscopy and MRI, nanoparticles with two reporters, a fluorescent dye and a superparamagnetic core, included in one particle were synthesized and characterized. The gamma-Fe(2)O(3) nanoparticles obtained by coprecipitation and oxidation were coated with silica (SiO(2)) or carboxymethyl chitosan (CMCS) and labeled with fluorescein isothiocyanate (FITC). The fluorescent label was covalently bound to the nanoparticles and was not quenched by the iron oxide core. The nanoparticles successfully labeled rat mesenchymal stem cells (rMSCs) in vitro. Relaxation time measurements found large amounts of iron inside the cells with FITC-labeled gamma-Fe(2)O(3)-SiO(2)-AP nanoparticles. Both MR and fluorescent imaging of a rat brain with implanted rMSCs labeled with FITC-labeled CMCS-modified silica-coated gamma-Fe(2)O(3) nanoparticles were performed.","[Chekina, Nataliya; Horak, Daniel; Trchova, Miroslava; Benes, Milan J.; Hruby, Martin] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Horak, Daniel; Jendelova, Pavla; Herynek, Vit; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Jendelova, Pavla; Turnovcova, Karolina; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Herynek, Vit] Inst Clin & Expt Med, Prague 14021 4, Czech Republic","Horak, D (reprint author), Acad Sci Czech Republic, Inst Macromol Chem, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic.","horak@imc.cas.cz",null,null,"Grant Agency of the Czech Republic [203/09/1242, 309/08/H079]; Academy of Sciences of the Czech Republic [KAN200200651]; Center for Cell Therapy and Tissue Repair [1M0538]; EU [228980]","The financial support of the Grant Agency of the Czech Republic (grant No. 203/09/1242 and 309/08/H079), the Academy of Sciences of the Czech Republic (KAN200200651), the Center for Cell Therapy and Tissue Repair (grant 1M0538) and the EU grant No. 228980 (CAMINEMS) is gratefully acknowledged.",null,57,23,23,"ROYAL SOC CHEMISTRY","CAMBRIDGE","THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND","0959-9428",null,null,"J MATER CHEM","J. Mater. Chem.",null,2011,21,21,null,null,null,null,7630,7639,null,"10.1039/c1jm10621j",null,10,"Chemistry, Physical; Materials Science, Multidisciplinary","Chemistry; Materials Science","764YG","WOS:000290670000017"]
[null,null,null,null,"J","Martin, RCG; Joshi, J; Robbins, K; Tomalty, D; Bosnjakovik, P; Derner, M; Padr, R; Rocek, M; Scupchenko, A; Tatum, C",null,null,null,"Martin, Robert C. G.; Joshi, Jonathan; Robbins, Ken; Tomalty, Dana; Bosnjakovik, Petar; Derner, Milous; Padr, Radek; Rocek, Miloslav; Scupchenko, Alexander; Tatum, Cliff",null,null,"Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in Unresectable Colorectal Liver Metastases Refractory to Systemic Chemotherapy: Results of Multi-Institutional Study","ANNALS OF SURGICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"PHASE-II TRIAL; ARTERIAL INFUSION; RANDOMIZED-TRIAL; FOLINIC-ACID; CANCER; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; MULTICENTER; RADIOEMBOLIZATION","Introduction. Response rates and overall outcome for patients who have failed first-line and in some cases second-line chemotherapy are as low as 12% and 7 months, respectively. The aim of this study is to evaluate the efficacy of hepatic arterial sulfonate hydrogel microsphere (drug-eluting beads), irinotecan preloaded therapy (DEBIRI) in metastatic colorectal cancer refractory to systemic chemotherapy. Methods. This was a multicenter multinational single-arm study of metastatic colorectal cancer patients who received DEBIRI after failing systemic chemotherapy from 10/2006 to 8/2008. Primary endpoints were safety, tolerance, tumor response rates, and overall survival. Results. Fifty-five patients who had received prior systemic chemotherapy and who underwent a total of 99 DEBIRI treatments were reviewed. The median number of DEBIRI treatments was 2 (range 1-5), median treatment dose was 100 mg (range 100-200 mg), with total hepatic treatment of 200 mg (range 200-650 mg), with 86% of treatments performed as lobar infusion and 30% of patients treated with concurrent simultaneous chemotherapy. Adverse events occurred in 28% of patients with median grade of 2 (range 1-3) with no deaths at 30 days post procedure. Response rates were 66% at 6 months and 75% at 12 months. Overall survival in these patients was 19 months, with progression-free survival of 11 months. Conclusions. Hepatic arterial drug-eluting bead, irinotecan (DEBIRI) was safe and effective in treatment of metastatic colorectal cancer (MCC) refractory to multiple lines of systemic chemotherapy. DEBIRI is an acceptable therapy for treatment of metastatic colorectal cancer to the liver.","[Martin, Robert C. G.; Joshi, Jonathan] Univ Louisville, Sch Med, Div Surg Oncol, Louisville, KY 40292 USA; [Robbins, Ken] Baptist Hlth, Little Rock, AR USA; [Tomalty, Dana] Huntsville Dist Mem Hosp, Huntsville, AL USA; [Bosnjakovik, Petar] Univ Clin Ctr, Inst Radiol, Nish, Serbia; [Derner, Milous] Inst Clin & Intervent Radiol, Usti Nad Labem, Czech Republic; [Rocek, Miloslav] Inst Clin & Intervent Radiol IKEM, Dept Diagnost & Intervent Radiol, Prague 4, Czech Republic; [Padr, Radek] Charles Univ Prague, Univ Hosp Motol, Dept Radiol, Prague, Czech Republic; [Padr, Radek] Charles Univ Prague, Univ Hosp Motol, Dept Pediat Hematol, Prague, Czech Republic; [Padr, Radek] Charles Univ Prague, Univ Hosp Motol, Dept Oncol, Prague, Czech Republic; [Padr, Radek] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Scupchenko, Alexander] Reg Oncol Dispenser, Samara, Russia; [Tatum, Cliff] Norton Radiol, Louisville, KY USA","Martin, RCG (reprint author), Univ Louisville, Sch Med, Div Surg Oncol, Louisville, KY 40292 USA.","Robert.Martin@louisville.edu",null,null,"Biocompatibles","The research registry reported on herein received support from an unrestricted educational grant from Biocompatibles. R.C.G.M. has served as a consultant for Biocompatibles.",null,26,33,33,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1068-9265","1534-4681",null,"ANN SURG ONCOL","Ann. Surg. Oncol.","JAN",2011,18,1,null,null,null,null,192,198,null,"10.1245/s10434-010-1288-5",null,7,"Oncology; Surgery","Oncology; Surgery","710BU","WOS:000286486700032"]
[null,null,null,null,"J","Stanke, F; Becker, T; Kumar, V; Hedtfeld, S; Becker, C; Cuppens, H; Tamm, S; Yarden, J; Laabs, U; Siebert, B; Fernandez, L; Macek, M; Radojkovic, D; Ballmann, M; Greipel, J; Cassiman, JJ; Wienker, TF; Tummler, B",null,null,null,"Stanke, Frauke; Becker, Tim; Kumar, Vinod; Hedtfeld, Silke; Becker, Christian; Cuppens, Harry; Tamm, Stephanie; Yarden, Jennifer; Laabs, Ulrike; Siebert, Benny; Fernandez, Luis; Macek, Milan, Jr.; Radojkovic, Dragica; Ballmann, Manfred; Greipel, Joachim; Cassiman, Jean-Jacques; Wienker, Thomas F.; Tuemmler, Burkhard",null,null,"Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia","JOURNAL OF MEDICAL GENETICS",null,null,"English","Article",null,null,null,null,null,null,"DELTA-F508 HOMOZYGOUS TWINS; HAPLOTYPE ANALYSIS; DISEASE SEVERITY; LUNG-DISEASE; DECREASES EXPRESSION; ASSOCIATION ANALYSIS; FLUID TRANSPORT; SIB PAIRS; MUTATIONS; SODIUM","Background The cystic fibrosis (CF) basic defect, caused by dysfunction of the apical chloride channel CFTR in the gastrointestinal and respiratory tract epithelia, has not been employed so far to support the role of CF modifier genes. Methods Patients were selected from 101 families with a total of 171 F508del-CFTR homozygous CF patients to identify CF modifying genes. A candidate gene based association study of 52 genes on 16 different chromosomes with a total of 182 genetic markers was performed. Differences in haplotype and/or diplotype distribution between case and reference CF subpopulations were analysed. Results Variants at immunologically relevant genes were associated with the manifestation of the CF basic defect (0.01< Praw< 0.0001 at IL1B, TLR9, TNF alpha, CD95, STAT3 and TNFR). The intragenic background of F508del-CFTR chromosomes determined disease severity and manifestation of the basic defect (Praw=0.0009). Allele distributions comparing transmitted and non-transmitted alleles were distorted at several loci unlinked to CFTR. Conclusions The inherited capabilities of the innate and adaptive immune system determine the manifestation of the CF basic defect. Variants on F508del-CFTR chromosomes contribute to the observed patient-to-patient variability among F508del-CFTR homozygotes. A survivor effect, manifesting as a transmission disequilibrium at many loci, is consistent with the improvement of clinical care over the last decades, resulting in a depletion of risk alleles at modifier genes. Awareness of non-genetic factors such as improvement of patient care over time is crucial for the interpretation of CF modifier studies.","[Stanke, Frauke; Kumar, Vinod; Hedtfeld, Silke; Becker, Christian; Tamm, Stephanie; Laabs, Ulrike; Siebert, Benny; Fernandez, Luis; Ballmann, Manfred; Tuemmler, Burkhard] Hannover Med Sch, Dept Pediat, D-30625 Hannover, Germany; [Becker, Tim; Wienker, Thomas F.] Univ Bonn, Inst Med Biometry Informat & Epidemiol, D-5300 Bonn, Germany; [Cuppens, Harry; Yarden, Jennifer; Radojkovic, Dragica; Cassiman, Jean-Jacques] Katholieke Univ Leuven, Dept Human Genet, Louvain, Belgium; [Macek, Milan, Jr.] Charles Univ Prague, Sch Med, Dept Biol & Med Genet, Prague, Czech Republic; [Macek, Milan, Jr.] Univ Hosp Motel, Prague, Czech Republic; [Radojkovic, Dragica] Inst Mol Genet & Genet Engn, Belgrade 11001, Serbia; [Greipel, Joachim] Hannover Med Sch, Dept Biophys Chem, D-30625 Hannover, Germany","Stanke, F (reprint author), Hannover Med Sch, Dept Pediat OE6710, Carl Neuberg Str 1, D-30625 Hannover, Germany.","mekus.frauke@mh-hannover.de",null,null,"Deutsche Forschungsgemeinschaft [SFB 621, C7]; European Union [QL G1-CF-2001-01005]; Deutsche Fordergesellschaft fur die Mukoviszidoseforschung eV; Mukoviszidose eV;  [VZFNM00064203];  [NE9488/3]","VK was a member of the International Research Training Group Pseudomonas: Pathogenicity and Biotechnology (IRTG653 of the Deutsche Forschungsgemeinschaft). The support of the Fritz-Thyssen-Stiftung (to FS and TB) for analysis of the SCNN1B/SCNN1G-locus is gratefully acknowledged. MM Jr was supported by VZFNM00064203 and NE9488/3. This study was supported by a grant to BT from the Deutsche Forschungsgemeinschaft (SFB 621, project C7). This work was executed as part of the European Cystic Fibrosis Twin and Sibling Study and financially supported by the European Union (QL G1-CF-2001-01005), the Deutsche Fordergesellschaft fur die Mukoviszidoseforschung eV and the Mukoviszidose eV. The funding organisations had no influence on the study design, data analysis and interpretation or intention to publish.",null,41,20,20,"B M J PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","0022-2593",null,null,"J MED GENET","J. Med. Genet.","JAN",2011,48,1,null,null,null,null,24,31,null,"10.1136/jmg.2010.080937",null,8,"Genetics & Heredity","Genetics & Heredity","695PB","WOS:000285383600004"]
[null,null,null,null,"J","Levova, K; Moserova, M; Kotrbova, V; Sulc, M; Henderson, CJ; Wolf, CR; Phillips, DH; Frei, E; Schmeiser, HH; Mares, J; Arlt, VM; Stiborova, M",null,null,null,"Levova, Katerina; Moserova, Michaela; Kotrbova, Vera; Sulc, Miroslav; Henderson, Colin J.; Wolf, C. Roland; Phillips, David H.; Frei, Eva; Schmeiser, Heinz H.; Mares, Jaroslav; Arlt, Volker M.; Stiborova, Marie",null,null,"Role of Cytochromes P450 1A1/2 in Detoxication and Activation of Carcinogenic Aristolochic Acid I: Studies with the Hepatic NADPH:Cytochrome P450 Reductase Null (HRN) Mouse Model","TOXICOLOGICAL SCIENCES",null,null,"English","Article",null,null,null,null,null,"aristolochic acid; cytochrome P450; metabolism; DNA adducts; P-32-postlabeling","BALKAN ENDEMIC NEPHROPATHY; CHINESE HERBS NEPHROPATHY; DNA ADDUCT FORMATION; ANTICANCER DRUG ELLIPTICINE; PROSTAGLANDIN-H SYNTHASE; METABOLIC-ACTIVATION; UROTHELIAL CANCER; GENE-EXPRESSION; ENVIRONMENTAL-POLLUTANT; SUDAN-I","Aristolochic acid (AA) causes aristolochic acid nephropathy, Balkan endemic nephropathy, and their urothelial malignancies. To identify enzymes involved in the metabolism of aristolochic acid I (AAI), the major toxic component of AA we used HRN (hepatic cytochrome P450 [Cyp] reductase null) mice, in which NADPH:Cyp oxidoreductase (Por) is deleted in hepatocytes. AAI was demethylated by hepatic Cyps in vitro to 8-hydroxy-aristolochic acid I (AAIa), indicating that less AAI is distributed to extrahepatic organs in wild-type (WT) mice. Indeed, AAI-DNA-adduct levels were significantly higher in organs of HRN mice, having low hepatic AAI demethylation capacity, than in WT mice. Absence of AAI demethylation in HRN mouse liver was confirmed in vitro; hepatic microsomes from WT, but not from HRN mice, oxidized AAI to AAIa. To define the role of hepatic Cyps in AAI demethylation, modulation of AAIa formation by CYP inducers was investigated. We conclude that AAI demethylation is attributable mainly to Cyp1a1/2. The higher AAI-DNA adduct levels in HRN than WT mice were the result of the lack of hepatic AAI demethylation concomitant with a higher activity of cytosolic NAD(P)H:quinone oxidoreductase (Nqo1), which activates AAI. Mouse hepatic Cyp1a1/2 also activated AAI to DNA adducts under hypoxic conditions in vitro, but in renal microsomes, Por and Cyp3a are more important than Cyp1a for AAI-DNA adduct formation. We propose that AAI activation and detoxication in mice are dictated mainly by AAI binding affinity to Cyp1a1/2 or Nqo1, by their turnover, and by the balance between oxidation and reduction of AAI by Cyp1a.","[Levova, Katerina; Moserova, Michaela; Kotrbova, Vera; Sulc, Miroslav; Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12840 2, Czech Republic; [Henderson, Colin J.; Wolf, C. Roland] Biomed Res Inst, Canc Res UK Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; [Phillips, David H.; Arlt, Volker M.] Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England; [Frei, Eva] German Canc Res Ctr, Natl Ctr Tumour Dis, Div Prevent Oncol, D-69120 Heidelberg, Germany; [Schmeiser, Heinz H.] German Canc Res Ctr, Res Grp Genet Alterat Carcinogenesis, D-69120 Heidelberg, Germany; [Mares, Jaroslav] Charles Univ Prague, Sch Med 2, Inst Biol & Med Genet, Prague 15006 5, Czech Republic; [Mares, Jaroslav] Univ Hosp Motol, Prague 15006 5, Czech Republic","Stiborova, M (reprint author), Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, Prague 12840 2, Czech Republic.","stiborov@natur.cuni.cz",null,null,"Grant Agency of Czech Republic [303/09/0472, 305/09/H008]; Ministry of Education of Czech Republic [MSM0021620808, 1M0505]; Cancer Research UK","The authors would like to thank to Grant Agency of Czech Republic (grants 303/09/0472, and 305/09/H008) and to the Ministry of Education of Czech Republic (grants MSM0021620808 and 1M0505). Work at the Biomedical Research Centre and Institute of Cancer Research is supported by Cancer Research UK.",null,77,19,19,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1096-6080",null,null,"TOXICOL SCI","Toxicol. Sci.","MAY",2011,121,1,null,null,null,null,43,56,null,"10.1093/toxsci/kfr050",null,14,"Toxicology","Toxicology","753VG","WOS:000289807200005"]
[null,null,null,null,"J","Anderova, M; Vorisek, I; Pivonkova, H; Benesova, J; Vargova, L; Cicanic, M; Chvatal, A; Sykova, E",null,null,null,"Anderova, Miroslava; Vorisek, Ivan; Pivonkova, Helena; Benesova, Jana; Vargova, Lydia; Cicanic, Michal; Chvatal, Alexandr; Sykova, Eva",null,null,"Cell death/proliferation and alterations in glial morphology contribute to changes in diffusivity in the rat hippocampus after hypoxia-ischemia","JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM",null,null,"English","Article",null,null,null,null,null,"astrocytes; extracellular volume; microglia; neurons; NG2-glia; tortuosity; water diffusion","EXTRACELLULAR-SPACE; IN-SITU; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE; SPINAL-CORD; BRAIN; INJURY; ASTROCYTES; CORTEX; PROLIFERATION","To understand the structural alterations that underlie early and late changes in hippocampal diffusivity after hypoxia/ischemia (H/I), the changes in apparent diffusion coefficient of water (ADC(W)) were studied in 8-week-old rats after H/I using diffusion-weighted magnetic resonance imaging (DW-MRI). In the hippocampal CA1 region, ADC(W) analyses were performed during 6 months of reperfusion and compared with alterations in cell number/cell-type composition, glial morphology, and extracellular space (ECS) diffusion parameters obtained by the real-time iontophoretic method. In the early phases of reperfusion (1 to 3 days) neuronal cell death, glial proliferation, and developing gliosis were accompanied by an ADC(W) decrease and tortuosity increase. Interestingly, ECS volume fraction was decreased only first day after H/I. In the late phases of reperfusion (starting 1 month after H/I), when the CA1 region consisted mainly of microglia, astrocytes, and NG2-glia with markedly altered morphology, ADC(W), ECS volume fraction and tortuosity were increased. Three-dimensional confocal morphometry revealed enlarged astrocytes and shrunken NG2-glia, and in both the contribution of cell soma/processes to total cell volume was markedly increased/decreased. In summary, the ADC(W) increase in the CA1 region underlain by altered cellular composition and glial morphology suggests that considerable changes in extracellular signal transmission might occur in the late phases of reperfusion after H/I. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 894-907; doi:10.1038/jcbfm.2010.168; published online 29 September 2010","[Anderova, Miroslava] Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Neurobiol Lab,Vvi, Prague 14220 4, Czech Republic; [Anderova, Miroslava; Vorisek, Ivan; Pivonkova, Helena; Benesova, Jana; Vargova, Lydia; Cicanic, Michal; Chvatal, Alexandr; Sykova, Eva] Acad Sci Czech Republic, Dept Neurosci, Prague 14220 4, Czech Republic; [Anderova, Miroslava; Vorisek, Ivan; Pivonkova, Helena; Vargova, Lydia; Cicanic, Michal; Chvatal, Alexandr; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Anderova, Miroslava; Vorisek, Ivan; Pivonkova, Helena; Vargova, Lydia; Cicanic, Michal; Chvatal, Alexandr; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Vorisek, Ivan; Sykova, Eva] Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, Prague, Czech Republic","Anderova, M (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Neurobiol Lab,Vvi, Videnska 1083, Prague 14220 4, Czech Republic.","anderova@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [305/09/0717, 309/09/1597, P303/10/1338]; Ministry of Education, Youth and Sports of the Czech Republic [AVOZ 50390512, LC554]; Ministry of Health of the Czech Republic [MZ0IKEM2005]","This study was supported by Grants 305/09/0717, 309/09/1597, and P303/10/1338 from the Grant Agency of the Czech Republic, AVOZ 50390512, LC554 from the Ministry of Education, Youth and Sports of the Czech Republic and grant MZ0IKEM2005 from the Ministry of Health of the Czech Republic.",null,38,12,13,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","0271-678X",null,null,"J CEREBR BLOOD F MET","J. Cereb. Blood Flow Metab.","MAR",2011,31,3,null,null,null,null,894,907,null,"10.1038/jcbfm.2010.168",null,14,"Endocrinology & Metabolism; Hematology; Neurosciences","Endocrinology & Metabolism; Hematology; Neurosciences & Neurology","727ZS","WOS:000287842700011"]
[null,null,null,null,"J","Vasovcak, P; Pavlikova, K; Sedlacek, Z; Skapa, P; Kouda, M; Hoch, J; Krepelova, A",null,null,null,"Vasovcak, Peter; Pavlikova, Kristyna; Sedlacek, Zdenek; Skapa, Petr; Kouda, Martin; Hoch, Jiri; Krepelova, Anna",null,null,"Molecular Genetic Analysis of 103 Sporadic Colorectal Tumours in Czech Patients","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"MISMATCH REPAIR DEFICIENCY; APC MUTATIONS; MICROSATELLITE INSTABILITY; SOMATIC MUTATION; BRAF MUTATION; BETA-CATENIN; HUMAN BREAST; CANCER RISK; POLYPOSIS; MYH","The Czech Republic has one of the highest incidences of colorectal cancer (CRC) in Europe. To evaluate whether sporadic CRCs in Czech patients have specific mutational profiles we analysed somatic genetic changes in known CRC genes (APC, KRAS, TP53, CTNNB1, MUTYH and BRAF, loss of heterozygosity (LOH) at the APC locus, microsatellite instability (MSI), and methylation of the MLH1 promoter) in 103 tumours from 102 individuals. The most frequently mutated gene was APC (68.9% of tumours), followed by KRAS (31.1%), TP53 (27.2%), BRAF (8.7%) and CTNNB1 (1.9%). Heterozygous germline MUTYH mutations in 2 patients were unlikely to contribute to the development of their CRCs. LOH at the APC locus was found in 34.3% of tumours, MSI in 24.3% and MLH1 methylation in 12.7%. Seven tumours (6.9%) were without any changes in the genes tested. The analysis yielded several findings possibly specific for the Czech cohort. Somatic APC mutations did not cluster in the mutation cluster region (MCR). Tumours with MSI but no MLH1 methylation showed earlier onset and more severe mutational profiles compared to MSI tumours with MLH1 methylation. TP53 mutations were predominantly located outside the hot spots, and transitions were underrepresented. Our analysis supports the observation that germline MUTYH mutations are rare in Czech individuals with sporadic CRCs. Our findings suggest the influence of specific ethnic genetic factors and/or lifestyle and dietary habits typical for the Czech population on the development of these cancers.","[Vasovcak, Peter; Pavlikova, Kristyna; Sedlacek, Zdenek; Krepelova, Anna] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic; [Vasovcak, Peter; Pavlikova, Kristyna; Sedlacek, Zdenek; Skapa, Petr; Kouda, Martin; Hoch, Jiri; Krepelova, Anna] Univ Hosp Motol, Prague, Czech Republic; [Skapa, Petr] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Kouda, Martin; Hoch, Jiri] Charles Univ Prague, Dept Surg, Fac Med 2, Prague, Czech Republic","Vasovcak, P (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic.","pevas78@hotmail.com",null,null,"Ministry of Health of the Czech Republic [MZOFNM2005]","Funding was provided by grant MZOFNM2005, Ministry of Health of the Czech Republic (http://www.mzcr.cz/En/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,51,8,10,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA","1932-6203",null,null,"PLOS ONE","PLoS One","AUG 25",2011,6,8,null,null,null,null,null,null,"e24114","10.1371/journal.pone.0024114",null,9,"Multidisciplinary Sciences","Science & Technology - Other Topics","812MQ","WOS:000294298000047"]
[null,null,null,null,"J","Herynek, V; Berkova, Z; Dovolilova, E; Jirak, D; Kriz, J; Girman, P; Saudek, F; Hajek, M",null,null,null,"Herynek, Vit; Berkova, Zuzana; Dovolilova, Eva; Jirak, Daniel; Kriz, Jan; Girman, Peter; Saudek, Frantisek; Hajek, Milan",null,null,"Improved detection of pancreatic islets in vivo using double contrast","CONTRAST MEDIA & MOLECULAR IMAGING",null,null,"English","Article",null,null,null,null,null,"pancreatic islets; transplantation; cellular labeling; contrast enhanced MRI; double contrast","TRANSPLANTATION; LIVER; AGENT; MRI","The transplantation of pancreatic islets containing beta-cells, which produce insulin, is an alternative approach to the treatment of type 1 diabetes mellitus. The non-invasive visualization of transplanted islets can be performed using MRI; however, this requires labeling of the islets with a suitable contrast agent prior to transplantation. The detection of islets labeled by iron oxide-based contrast agents and transplanted into the liver tissue can be significantly improved using the intravenous administration of a suitable gadolinium contrast agent prior to MRI. The applied contrast agent not only improves the contrast-to-noise ratio, but also eliminates artifacts that may lead to an overestimation of the number of hypointense spots and their area; thus it improves the accuracy of automated and semi-automated procedures used for transplanted islet segmentation and quantification. Copyright (C) 2011 John Wiley & Sons, Ltd.","[Herynek, Vit; Jirak, Daniel; Hajek, Milan] Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, MR Unit, Prague 14021, Czech Republic; [Herynek, Vit; Berkova, Zuzana; Dovolilova, Eva; Jirak, Daniel; Girman, Peter; Saudek, Frantisek; Hajek, Milan] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Berkova, Zuzana; Dovolilova, Eva; Kriz, Jan; Girman, Peter; Saudek, Frantisek] Inst Clin & Expt Med, Ctr Diabet, Pancreat Islet Lab, Prague 14021, Czech Republic","Herynek, V (reprint author), Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, MR Unit, Videnska 1958-9, Prague 14021, Czech Republic.","vit.herynek@medicon.cz",null,null,"Czech Science Foundation [GACR 203/09/1242]; Ministry of Health of the Czech Republic [MZ0IKEM2005]; Ministry of Education, Youth and Sports of the Czech Republic [1M0538]; ENCITE-European Commission [201842]","The study was supported by grants GACR 203/09/1242, the Czech Science Foundation; MZ0IKEM2005, the Ministry of Health of the Czech Republic; 1M0538, the Ministry of Education, Youth and Sports of the Czech Republic; ENCITE-European Commission Research - 7th Framework Programme No. 201842.",null,12,6,6,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1555-4309",null,null,"CONTRAST MEDIA MOL I","Contrast Media Mol. Imaging","JUL-AUG",2011,6,4,null,null,null,null,308,313,null,"10.1002/cmmi.432",null,6,"Radiology, Nuclear Medicine & Medical Imaging","Radiology, Nuclear Medicine & Medical Imaging","825QB","WOS:000295295100016"]
[null,null,null,null,"J","Skoumalova, A; Ivica, J; Santorova, P; Topinkova, E; Wilhelm, J",null,null,null,"Skoumalova, A.; Ivica, J.; Santorova, P.; Topinkova, E.; Wilhelm, J.",null,null,"The lipid peroxidation products as possible markers of Alzheimer's disease in blood","EXPERIMENTAL GERONTOLOGY",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; Diagnostic biomarkers; Oxidative stress; Lipofuscin-like pigments","MILD COGNITIVE IMPAIRMENT; FREE-RADICAL DAMAGE; OXIDATIVE STRESS; MALONDIALDEHYDE; ERYTHROCYTES; BIOMARKERS; BRAIN","Oxidative stress, which is present in Alzheimer's disease (AD), results in the formation of various end-products of free radical reactions with proteins and lipids. At present there are no reliable diagnostic biomarkers of AD in the blood. Therefore, specific products of lipid peroxidation in the blood of AD patients were investigated. Lipophilic extracts of erythrocytes in the group of patients with AD (n = 44) and age-matched controls (n = 16) were studied. The end-products of lipid peroxidation, so called lipofuscin-like pigments (LFP), were analysed by fluorescence spectroscopy. It was found that the level of these products is significantly increased in erythrocytes of AD patients compared to controls. LFP were further separated by means of HPLC into individual fractions to study their composition in AD and controls. The specific fraction of LFP in AD patients, which was isolated, might represent a disease-specific product in the blood. (c) 2010 Elsevier Inc. All rights reserved.","[Skoumalova, A.; Ivica, J.; Santorova, P.; Wilhelm, J.] Charles Univ Prague, Dept Med Chem & Biochem, Fac Med 2, Prague 15006, Czech Republic; [Topinkova, E.] Charles Univ Prague, Dept Geriatr, Fac Med 1, Prague 15006, Czech Republic; [Topinkova, E.] Gen Fac Hosp, Prague, Czech Republic","Skoumalova, A (reprint author), Charles Univ Prague, Dept Med Chem & Biochem, Fac Med 2, Plzenska 221-130, Prague 15006, Czech Republic.","alice.skoumalova@lfmotol.cuni.cz","Wilhelm, Jiri/C-6252-2012",null,"Czech Science Foundation [220 032]","This research was supported by The Czech Science Foundation, grant number 220 032.",null,22,9,9,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0531-5565",null,null,"EXP GERONTOL","Exp. Gerontol.","JAN",2011,46,1,null,null,null,null,38,42,null,"10.1016/j.exger.2010.09.015",null,5,"Geriatrics & Gerontology","Geriatrics & Gerontology","710UP","WOS:000286542800006"]
[null,null,null,null,"J","Kos, P; Varga, F; Handl, M; Kautzner, J; Chudacek, V; Drzik, M; Povysil, C; Trc, T; Amler, E; Hanus, M",null,null,null,"Kos, Petr; Varga, Ferdinand; Handl, Milan; Kautzner, Jakub; Chudacek, Vaclav; Drzik, Milan; Povysil, Ctibor; Trc, Tomas; Amler, Evzen; Hanus, Martin",null,null,"Correlation of dynamic impact testing, histopathology and visual macroscopic assessment in human osteoarthritic cartilage","INTERNATIONAL ORTHOPAEDICS",null,null,"English","Article",null,null,null,null,null,null,"ARTICULAR-CARTILAGE; MECHANICAL-PROPERTIES; KNEE OSTEOARTHRITIS; INDENTATION PROBE; OVINE MODEL; REPAIR; THICKNESS; BONE; DEGENERATION; STIFFNESS","Improved staging of cartilage degeneration is required, particularly during the early stages. We correlated mechanical properties with histological and macroscopic findings. One hundred and twenty cartilage samples were obtained during total knee arthroplasty. Two adjacent plugs were harvested-one for histological classification and one for macroscopic and biomechanical purposes. Dynamic impact testing was performed; normal stress, dissipated energy (a dagger E), tangent modulus and stiffness were evaluated. Samples were classified according to six categories of the ICRS histological scale. Mechanical characteristics revealing significant differences between the groups (p < 0.01) were specific damping and related absolute a dagger E. A significant correlation was found between the macroscopic score and specific damping, as well as absolute and relative a dagger E (p < 0.01). A strong relation was revealed between relative a dagger E and cartilage thickness (p < 0.001; R (2) = 0.69). Only a dagger E correlated with the condition of the cartilage-the value increased with decreasing quality-and is the most suitable characteristic. This change appears substantial in initial stages of cartilage deterioration.","[Kos, Petr; Handl, Milan; Kautzner, Jakub; Trc, Tomas; Hanus, Martin] Charles Univ Prague, Univ Hosp Motol, Orthopaed Clin 2, Prague 15006 5, Czech Republic; [Varga, Ferdinand; Amler, Evzen] Charles Univ Prague, Dept Biophys, Fac Med 2, Prague 15006 5, Czech Republic; [Chudacek, Vaclav] Czech Tech Univ, Dept Cybernet, CR-16635 Prague, Czech Republic; [Drzik, Milan] Ctr Int Laser, Bratislava, Slovakia; [Povysil, Ctibor] Charles Univ Prague, Inst Pathol Anat, Fac Med 1, Prague 15006 5, Czech Republic","Kos, P (reprint author), Charles Univ Prague, Univ Hosp Motol, Orthopaed Clin 2, V Uvalu 84, Prague 15006 5, Czech Republic.","kos.petr@email.cz",null,null,"Ministry of Industry of the Czech Republic [FI IM4/205, FT TA5/020]","This work was supported by Grants FI IM4/205 and FT TA5/020 from the Ministry of Industry of the Czech Republic.",null,27,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0341-2695",null,null,"INT ORTHOP","Int. Orthop.","NOV",2011,35,11,null,null,null,null,1733,1739,null,"10.1007/s00264-010-1195-1",null,7,"Orthopedics","Orthopedics","834RW","WOS:000295982400021"]
[null,null,null,null,"J","Hrdlicka, M; Vodicka, J; Havlovicova, M; Urbanek, T; Blatny, M; Dudova, I",null,null,null,"Hrdlicka, Michal; Vodicka, Jan; Havlovicova, Marketa; Urbanek, Tomas; Blatny, Marek; Dudova, Iva",null,null,"Brief Report: Significant Differences in Perceived Odor Pleasantness Found in Children with ASD","JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS",null,null,"English","Article",null,null,null,null,null,"Autism; Asperger's syndrome; Sensory abnormalities; Olfactory; Pleasantness; Sniffin' Sticks","OLFACTORY SENSITIVITY; AUTISM; IDENTIFICATION; DISORDER; METAANALYSIS; INDIVIDUALS; STIMULI","The aim of our study was to explore possible differences in estimation of odor pleasantness in children with autism spectrum disorders (ASD) compared to controls. Thirty-five patients with Asperger's syndrome and high functioning autism (mean age 10.8 +/- A 3.6 years; 31 boys) were compared with 35 healthy control subjects (mean age 10.4 +/- A 2.4 years; 28 boys). Odor pleasantness was assessed on a 5-point scale using the Sniffin' Sticks test (Identification part of the test). Patients with ASD, compared to healthy controls, perceived the smell of cinnamon and pineapple as significantly less pleasant (p < 0.05); at the trend level, the same was true of cloves (p < 0.1). The possibility of olfactory dysfunctions as an autism biomarker is discussed.","[Hrdlicka, Michal; Dudova, Iva] Charles Univ Prague, Fac Med 2, Dept Child Psychiat, Prague 15006, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague 15006, Czech Republic; [Vodicka, Jan] Univ Pardubice, Fac Hlth Studies, Dept Otorhinolaryngol & Head & Neck Surg, Pardubice, Czech Republic; [Havlovicova, Marketa] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 15006, Czech Republic; [Urbanek, Tomas; Blatny, Marek] Acad Sci Czech Republic, Inst Psychol, Brno, Czech Republic","Hrdlicka, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Child Psychiat, V Uvalu 84, Prague 15006, Czech Republic.","michal.hrdlicka@lfmotol.cuni.cz",null,null,null,null,null,21,8,8,"SPRINGER/PLENUM PUBLISHERS","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0162-3257",null,null,"J AUTISM DEV DISORD","J. Autism Dev. Disord.","APR",2011,41,4,null,null,null,null,524,527,null,"10.1007/s10803-010-1084-x",null,4,"Psychology, Developmental","Psychology","733JQ","WOS:000288259400015"]
[null,null,null,null,"J","Hradsky, O; Dusatkova, P; Lenicek, M; Bronsky, J; Duricova, D; Nevoral, J; Vitek, L; Lukas, M; Cinek, O",null,null,null,"Hradsky, Ondrej; Dusatkova, Petra; Lenicek, Martin; Bronsky, Jiri; Duricova, Dana; Nevoral, Jiri; Vitek, Libor; Lukas, Milan; Cinek, Ondrej",null,null,"Two Independent Genetic Factors Responsible for the Associations of the IBD5 Locus with Crohn's Disease in the Czech Population","INFLAMMATORY BOWEL DISEASES",null,null,"English","Article",null,null,null,null,null,"Crohn's disease; IBD5; SLC22A4; SLC22A5; haplotype","GENOME-WIDE ASSOCIATION; INFLAMMATORY-BOWEL-DISEASE; CATION TRANSPORTER GENES; SUSCEPTIBILITY LOCI; ULCERATIVE-COLITIS; FUNCTIONAL VARIANTS; OCTN1/2 VARIANTS; CARD15; POLYMORPHISMS; PHENOTYPE","Background: The role of the IBD5 locus in development of Crohn's disease (CD) has not been clarified. In the Czech population we examined its genetic association using variants of the SLC22A4 (rs1050152) SLC22A5 (rs2631367), two single nucleotide polymorphisms (SNPs) shown to be associated with CD in genome-wide studies (rs6596075 and rs2188962), and four SNPs previously shown to tag the haplotype blocks 4, 7, 9, 10 of the IBD5 locus (IGR2063b_1, IGR2230a_1, IGR100Xa_1, IGR3236a_1). Methods: The genotype, phenotype, and allelic frequencies were compared between 469 unrelated patients with CD (177 pediatric-onset, 292 adult-onset) and 470 unrelated healthy controls, all Caucasians of Czech ancestry. Results: The most significant difference between patients and controls was found for the SNP rs6596075 (odds ratio [OR] = 0.70 for the G allele; 95% CI 0.52-0.94) in the dominant model and SNP IGR2063b_1 (OR = 1.38 for the G allele; 95% CI 1.14-1.67) in the log-additive model. We found a strong linkage disequilibrium across the IBD5 locus except rs6596075. The haplotype consisting of minor alleles of all tested SNPs except rs6596075 was carried by 31% patients and 23% control subjects (OR = 1.35, 95% CI 1.06-1.72). The association of variants in SLC22A4 and SLC22A5 was dependent on this risk haplotype, while the strong association of the rs6596075 was seemingly independent. In the analysis of subphenotypes we found only an association of the penetrating disease with rs6596075 (OR = 2.13; 95% CI 1.31-3.47). Conclusions: Our study confirms the importance of IBD5 in determining CD susceptibility, and demonstrates that two independent genetic factors may be responsible for the association observed within this locus.","[Hradsky, Ondrej; Dusatkova, Petra; Bronsky, Jiri; Nevoral, Jiri; Cinek, Ondrej] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Hradsky, Ondrej; Dusatkova, Petra; Bronsky, Jiri; Nevoral, Jiri; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; [Lenicek, Martin; Vitek, Libor] Charles Univ Prague, Inst Clin Biochem & Lab Diagnost, Fac Med 1, Prague 15006 5, Czech Republic; [Duricova, Dana; Lukas, Milan] ISCARE IVF Lighthouse, IBD Clin & Res Ctr, Prague, Czech Republic","Hradsky, O (reprint author), Charles Univ Prague, Dept Pediat, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","ondrej.hradsky@lfmotol.cuni.cz","Vitek, Libor/A-2645-2008",null,"Czech Ministry of Health [MZOFNM2005]; GAUK [7660/2007]","Supported by grants from the Czech Ministry of Health (MZOFNM2005) and GAUK 7660/2007.",null,43,3,3,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1078-0998",null,null,"INFLAMM BOWEL DIS","Inflamm. Bowel Dis.","JUL",2011,17,7,null,null,null,null,1523,1529,null,"10.1002/ibd.21532",null,7,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","787ZM","WOS:000292415200007"]
[null,null,null,null,"J","Malikova, H; Liscak, R; Vojtech, Z; Prochazka, T; Vymazal, J; Vladyka, V; Druga, R",null,null,null,"Malikova, Hana; Liscak, Roman; Vojtech, Zdenek; Prochazka, Tomas; Vymazal, Josef; Vladyka, Vilibald; Druga, Rastislav",null,null,"Stereotactic radiofrequency amygdalohippocampectomy: Does reduction of entorhinal and perirhinal cortices influence good clinical seizure outcome?","EPILEPSIA",null,null,"English","Article",null,null,null,null,null,"Temporal lobe epilepsy; Surgery; MRI; Volumetry","TEMPORAL-LOBE EPILEPSY; SELECTIVE AMYGDALOHIPPOCAMPECTOMY; INTRINSIC CONNECTIONS; RESECTION; SURGERY; EXTENT; LOBECTOMY; MEMORY; AMYGDALA; COMPLEX","Purpose: Stereotactic radiofrequency amygdalohippocampectomy (SAHE) has been modified recently in our center for the therapy of mesial temporal epilepsy (MTLE). It has promising clinical results comparable with microsurgical amygdalohippocampectomy despite smaller volume reduction of the hippocampus. We hypothesized that the extent of perirhinal and entorhinal cortex (PRC, EC) reduction could explain the clinical outcome. Therefore, we performed, retrospectively, volumetric analysis of PRC and EC and compared it with the seizure control. Methods: Twenty-six consecutive patients with MTLE treated by SAHE were included. PRC and EC volumes were measured from magnetic resonance imaging (MRI) records obtained before and 1 year after SAHE. The clinical outcome was assessed each year after SAHE using Engel's classification. Key Findings: Twenty-six patients were analyzed. The volume of PRC decreased by 46 +/- 17% (p < 10(-12)); EC volume decreased by 56 +/- 20% (p < 10(-10)). Two years after the procedure, 73% of patients were classified as Engel's I, 19% as Engel's II; in 2 (8%) the treatment failed (were reoperated). Eighteen patients finished 3 years follow-up; 72% of them were classified as Engel's I, 17% as Engel's II, and in 2 (11%) above-mentioned patients the treatment failed. Thirteen patients finished 4 years of follow-up, 11 of them as Engel's I. There was no significant correlation of the clinical outcome to PRC and EC volume reductions. Significance: The clinical effect of SAHE is not clearly explained by the volume reductions of PRC and EC (nor of the hippocampus and the amygdala). It promotes opinion that the extent of resection/destruction is not important for seizure outcomes.","[Malikova, Hana; Vymazal, Josef] Hosp Na Homolce, Dept Radiol, Prague 15000 5, Czech Republic; [Malikova, Hana; Druga, Rastislav] Charles Univ Prague, Fac Med 2, Inst Anat, Prague, Czech Republic; [Liscak, Roman; Vladyka, Vilibald] Hosp Na Homolce, Dept Stereotact & Radiat Neurosurg, Prague 15000 5, Czech Republic; [Vojtech, Zdenek; Prochazka, Tomas] Hosp Na Homolce, Dept Neurol, Prague 15000 5, Czech Republic; [Vymazal, Josef] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic","Malikova, H (reprint author), Hosp Na Homolce, Dept Radiol, Roentgenova 2, Prague 15000 5, Czech Republic.","hana.malikova@homolka.cz","shengkun, yu/B-8440-2012",null,"Czech Ministry of Education [MSMT 0021620849]; Grant Agency of the Czech Republic [309/07/1337]","JV was supported by the Czech Ministry of Education (research program MSMT 0021620849). RD was supported by the Grant Agency of the Czech Republic grant No. 309/07/1337.",null,38,2,3,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0013-9580",null,null,"EPILEPSIA","Epilepsia","MAY",2011,52,5,null,null,null,null,932,940,null,"10.1111/j.1528-1167.2011.03048.x",null,9,"Clinical Neurology","Neurosciences & Neurology","762QK","WOS:000290494300013"]
[null,null,null,null,"J","Patil, S; Jirak, D; Saudek, F; Hajek, M; Scheffler, K",null,null,null,"Patil, S.; Jirak, D.; Saudek, F.; Hajek, M.; Scheffler, K.",null,null,"Positive contrast visualization of SPIO-labeled pancreatic islets using echo-dephased steady-state free precession","EUROPEAN RADIOLOGY",null,null,"English","Article",null,null,null,null,null,"Pancreatic islets; Positive contrast; Iron-oxide; Echo-dephasing; Susceptibility","IRON-OXIDE NANOPARTICLES; MAGNETIC-RESONANCE; CELLS; TRANSPLANTATION; PARTICLES; GRASP; MRI","Objective MRI has recently been introduced as a promising method of monitoring the transplanted pancreatic islets labelled with superparamagnetic iron oxide (SPIO). However, the traditional T(2)*-weighted approach frequently yields ambiguous results because of the negative contrast of the SPIO particles on the background of other body components. This obstacle could be overcome with the use of a novel method known as echo-dephased steady state free precession (SSFP), generating positive contrast in the presence of paramagnetic material. Methods In phantoms, we achieved exact localisation and clear positive contrast visualisation of human SPIO labelled islets. Using the proposed method we demonstrated the ability to detect even a single pancreatic islet against a homogeneous background. Results In vivo experiments in rats confirmed reliable and accurate localisation of transplanted SPIO labelled islets. Conclusion The echo-dephased SSFP technique could successfully visualise SPIO-labelled human and rat pancreatic islets yielding a positive contrast.","[Jirak, D.; Hajek, M.] Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, Prague 14021, Czech Republic; [Patil, S.] Siemens Corp, Ctr Appl Med Imaging, Corp Res, Baltimore, MD USA; [Saudek, F.] Inst Clin & Expt Med, Ctr Diabet, Prague 14021, Czech Republic; [Patil, S.; Scheffler, K.] Univ Basel Hosp, Dept Radiol, Div Radiol Phys, CH-4031 Basel, Switzerland; [Jirak, D.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Jirak, D (reprint author), Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, Videnska 1958-9, Prague 14021, Czech Republic.","daniel.jirak@ikem.cz",null,null,"EU [201842]; Swiss National Science Foundation [325230-118377]","We thank J. Kriz, E. Dovolilova and Z. Berkova from the Laboratory of Pancreatic Islets, Diabetes Center at the Institute for Clinical and Experimental Medicine, Prague, for providing pancreatic islets. This work was supported by a grant from the ENCITE - Seventh EU Framework Program 201842, and a grant from the Swiss National Science Foundation No. 325230-118377. S. Patil and D. Jirak contributed equally to this article.",null,20,8,8,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0938-7994",null,null,"EUR RADIOL","Eur. Radiol.","JAN",2011,21,1,null,null,null,null,214,220,null,"10.1007/s00330-010-1909-1",null,7,"Radiology, Nuclear Medicine & Medical Imaging","Radiology, Nuclear Medicine & Medical Imaging","689AO","WOS:000284899700029"]
[null,null,null,null,"J","Honetschlagerova, Z; Sporkova, A; Kopkan, L; Huskova, Z; Hwang, SH; Hammock, BD; Imig, JD; Kramer, HJ; Kujal, P; Vernerova, Z; Chabova, VC; Tesar, V; Cervenka, L",null,null,null,"Honetschlaegerova, Zuzana; Sporkova, Alexandra; Kopkan, Libor; Huskova, Zuzana; Hwang, Sung H.; Hammock, Bruce D.; Imig, John D.; Kramer, Herbert J.; Kujal, Petr; Vernerova, Zdenka; Chabova, Vera C.; Tesar, Vladimir; Cervenka, Ludek",null,null,"Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats","JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"AT(1) receptor antagonist; cytochrome P-450 metabolites; epoxyeicosatrienoic acids; malignant hypertension; renal autoregulation; renin-angiotensin system; sodium excretion; soluble epoxide hydrolase","RENIN-ANGIOTENSIN SYSTEM; ARACHIDONIC-ACID; BLOOD-PRESSURE; RENAL HEMODYNAMICS; NITRIC-OXIDE; II LEVELS; KIDNEY; AUTOREGULATION; METABOLITES; MECHANISMS","Objective In the present study, we compared the effects of treatment with the novel soluble epoxide hydrolase (sEH) inhibitor (c-AUCB) with those of the AT(1) receptor antagonist losartan on blood pressure (BP), autoregulation of renal blood flow (RBF) and on glomerular filtration rate (GFR) and the pressure-natriuresis relationship in response to stepwise reduction in renal arterial pressure (RAP) in Cyp1a1-Ren-2 transgenic rats. Methods Hypertension was induced in Cyp1a1-Ren-2 rats through dietary administration for 11 days of the natural xenobiotic indole-3-carbinol (I3C) which activates the renin gene. Treatment with c-AUCB and losartan was started 48 h before initiating administration of the diet containing I3C. Rats were prepared for renal functional studies to evaluate in-vivo renal autoregulatory efficiency when RAP was gradually decreased by an aortic clamp. Results I3C administration resulted in the development of severe hypertension which was associated with markedly lower basal RBF and GFR and substantially impaired autoregulatory efficiency as well as a suppression of the pressure-natriuresis relationship when compared with noninduced rats. Treatment with c-AUCB significantly decreased BP, improved autoregulatory efficiency of RBF and GFR and the slope of pressure-natriuresis relationship. Treatment with losartan completely prevented the impaired autoregulation and pressure-natriuresis relationship as well as the development of hypertension in I3C-induced rats. Conclusion Our present findings indicate that chronic treatment with the sEH inhibitor c-AUCB substantially attenuates the development of malignant hypertension in I3C-induced rats likely via improvement of the renal autoregulatory efficiency and the pressure-natriuresis relationship. J Hypertens 29: 1590-1601 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.","[Honetschlaegerova, Zuzana; Sporkova, Alexandra; Kopkan, Libor; Huskova, Zuzana; Kujal, Petr; Vernerova, Zdenka; Chabova, Vera C.; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Honetschlaegerova, Zuzana; Sporkova, Alexandra; Kopkan, Libor; Huskova, Zuzana] Cardiovasc Res Ctr, Prague, Czech Republic; [Hwang, Sung H.; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; [Hwang, Sung H.; Hammock, Bruce D.] Univ Calif Davis, UCD Canc Ctr, Davis, CA 95616 USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI USA; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Serv Nephrol, D-5300 Bonn, Germany; [Kujal, Petr; Vernerova, Zdenka] Charles Univ Prague, Fac Med 3, Dept Pathol, Prague, Czech Republic; [Chabova, Vera C.; Tesar, Vladimir] Charles Univ Prague, Fac Med 1, Dept Nephrol, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Cervenka, L (reprint author), Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz",null,null,"European Commission [IRG 247847, CZ.2.16/3.1.00/22126]; Czech Science Foundation (GACR) [303/10/P170]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Internal Grant Agency of the Ministry of Health [NS/10499-3, NS/10500-3]; German Research Foundation (DFG), Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]; Deutsche Akademische Austauschdienst (DAAD), Bonn-Prague University; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/9699-4, NS/9703-4]","This study was supported by Marie Curie Fellowship from the European Commission - Program - PEOPLE (IRG 247847) and postdoctoral fellowship from the Czech Science Foundation (GACR; 303/10/P170), received by A. S. Z.H. and A. S. are partly supported from the Center for Cardiovascular Research (1M6798582302). L. C. is supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001) and by grant no. NS/10499-3 and by grant no. NS/10500-3 awarded by the Internal Grant Agency of the Ministry of Health. H.J.K. was supported by grants from the German Research Foundation (DFG), Bonn (Kra 436/14-2 and 436 TSE 113/57/0-1) and the Deutsche Akademische Austauschdienst (DAAD), Bonn-Prague University partnership. L. K. is supported by grant no. NS/9699-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. L. C.. was also supported by grant nos. NS/9703-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. This study also received financial support from the European Commission by the Operational Program Prague - Competitiveness; project 'CEVKOON' (#CZ.2.16/3.1.00/22126).",null,39,9,9,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,null,"J HYPERTENS","J. Hypertens.","AUG",2011,29,8,null,null,null,null,1590,1601,null,"10.1097/HJH.0b013e328349062f",null,12,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","791TL","WOS:000292688400018"]
[null,null,null,null,"J","Sponarova, D; Horak, D; Trchova, M; Jendelova, P; Herynek, V; Mitina, N; Zaichenko, A; Stoika, R; Lesny, P; Sykova, E",null,null,null,"Sponarova, Daniela; Horak, Daniel; Trchova, Miroslava; Jendelova, Pavla; Herynek, Vit; Mitina, Nataliya; Zaichenko, Alexander; Stoika, Rostyslav; Lesny, Petr; Sykova, Eva",null,null,"The Use of Oligoperoxide-Coated Magnetic Nanoparticles to Label Stem Cells","JOURNAL OF BIOMEDICAL NANOTECHNOLOGY",null,null,"English","Article",null,null,null,null,null,"Magnetic; Nanoparticles; Stem Cells; Iron Oxide; Oligoperoxide","IRON-OXIDE NANOPARTICLES; BIOMEDICAL APPLICATIONS; SURFACE; NANOCRYSTALS; PARTICLES; MICROSTRUCTURE; INITIATORS; COMPLEXES; SYSTEMS; TUMORS","Iron oxide nanoparticles obtained by the coprecipitation of Fe(II) and Fe(III) salts and oxidation were coated with a novel poly(vinyl acetate-co-5-tert-(butylperoxy)-5-methylhex-1-en-3-yne-co-butyl acrylate-co-maleic anhydride) (PVBM) oligomer to ensure colloidal stability. The magnetic nanoparticles were thoroughly characterized by a range of physico-chemical methods, which proved the presence of the coating on the particles. Experiments with rat mesenchymal stem cells (rMSCs) confirmed that PVBM-coated gamma-Fe(2)O(3) nanoparticles were not cytotoxic and that the average efficiency of stem cell labeling was good and comparable to that obtained with commercial agents. The cells labeled with PVBM-coated gamma-Fe(2)O(3) nanoparticles displayed excellent contrast on magnetic resonance (MR) images. Such particles are thus promising for in vivo MR imaging of transplanted cells. Moreover, PVBM offers the possibility of additional modification by grafting compounds that reduce non-specific protein adsorption.","[Sponarova, Daniela; Horak, Daniel; Trchova, Miroslava] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Horak, Daniel; Jendelova, Pavla; Lesny, Petr; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Jendelova, Pavla; Lesny, Petr; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Herynek, Vit] Inst Clin & Expt Med, Prague 14021 4, Czech Republic; [Mitina, Nataliya; Zaichenko, Alexander] Lviv Polytech Natl Univ, UA-79013 Lvov, Ukraine; [Stoika, Rostyslav] Natl Acad Sci Ukraine, Inst Cell Biol, UA-79005 Lvov, Ukraine","Horak, D (reprint author), Acad Sci Czech Republic, Inst Macromol Chem, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic.",null,null,null,"Grant Agency of the Czech Republic [203/09/1242, P503/10/0664]; Center for Cell Therapy and Tissue Repair [1M0538]; Academy of Sciences of the Czech Republic [KAN201110651, KAN401220801]","The authors gratefully acknowledge support from the Grant Agency of the Czech Republic (grant 203/09/1242 and P503/10/0664), the Center for Cell Therapy and Tissue Repair (grant 1M0538) and the Academy of Sciences of the Czech Republic (grants KAN201110651 and KAN401220801).",null,30,39,39,"AMER SCIENTIFIC PUBLISHERS","STEVENSON RANCH","25650 NORTH LEWIS WAY, STEVENSON RANCH, CA 91381-1439 USA","1550-7033",null,null,"J BIOMED NANOTECHNOL","J. Biomed. Nanotechnol.","JUN",2011,7,3,null,null,null,null,384,394,null,"10.1166/jbn.2011.1289",null,11,"Nanoscience & Nanotechnology; Medicine, Research & Experimental","Science & Technology - Other Topics; Research & Experimental Medicine","793YD","WOS:000292858900008"]
[null,null,null,null,"J","Gumulec, J; Masarik, M; Krizkova, S; Adam, V; Hubalek, J; Hrabeta, J; Eckschlager, T; Stiborova, M; Kizek, R",null,null,null,"Gumulec, J.; Masarik, M.; Krizkova, S.; Adam, V.; Hubalek, J.; Hrabeta, J.; Eckschlager, T.; Stiborova, M.; Kizek, R.",null,null,"Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma","CURRENT MEDICINAL CHEMISTRY",null,null,"English","Review",null,null,null,null,null,"Zinc; Cancer; Prostate Carcinoma; Breast Carcinoma; Homeostasis; Low Molecular Mass Thiols; Metallothionein; Glutathione; Zinc Intake; Apoptosis; ZnT and ZIP transporters","NF-KAPPA-B; CANCER-CELLS; INTRACELLULAR ZINC; OXIDATIVE STRESS; TRANSPORTER EXPRESSION; TRACE-ELEMENTS; DNA-BINDING; EPITHELIAL-CELLS; BRDICKA REACTION; SUPPLEMENT USE","Zinc(II) ions contribute to a number of biological processes e. g. DNA synthesis, gene expression, enzymatic catalysis, neurotransmission, and apoptosis. Zinc(II) dysregulation, deficiency and over-supply are connected with various diseases, particularly cancer. 98 % of human body zinc(II) is localized in the intracellular compartment, where zinc(II) is bound with low affinity to metallothionein (MT). Zinc transporters ZIP and ZnT maintain transmembrane transport from/to cells or organelles. Imbalance of their regulation is described in cancers, particularly prostate (down-regulated zinc transporters ZIP1, 2, 3 and ZnT-2) and breast, notably its high-risk variant (up-regulated ZIP6, 7, 10). As a result, intracellular and even blood plasma zinc(II) levels are altered. MT protects cells against oxidative stress, because it cooperates with reduced glutathione (GSH). Recent studies indicate elevated serum level of MT in a number of malignancies, among others in breast, and prostate. MT together with zinc(II) affect apoptosis and proliferation, thus together with its antioxidative effects it may affect cancer. To date, only little is known about the influence of zinc(II) and MT on cancer, while these compounds may play an important role in pathogenesis. This review concludes current data regarding the impact of zinc(II) on the pathogenesis of breast and prostate cancers with potential outlines of new, targeted therapy and prevention. Moreover, blood plasma zinc(II) and MT levels and dietary zinc(II) intake are discussed in relation to breast and prostate cancer risk.","[Krizkova, S.; Adam, V.; Kizek, R.] Mendel Univ, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Gumulec, J.; Masarik, M.] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-62500 Brno, Czech Republic; [Masarik, M.; Krizkova, S.; Adam, V.; Hubalek, J.; Kizek, R.] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Hubalek, J.] Brno Univ Technol, Dept Microelect, Fac Elect Engn & Commun, CZ-61600 Brno, Czech Republic; [Hrabeta, J.; Eckschlager, T.] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Hrabeta, J.; Eckschlager, T.] Charles Univ Prague, Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Stiborova, M.] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic","Kizek, R (reprint author), Mendel Univ, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Krizkova, Sona/E-9617-2012; Gumulec, Jaromir/D-7638-2012","Gumulec, Jaromir/0000-0002-9658-3444","GACR [301/09/P436]; IGA MZ NS [10200-3]; GA AV [IAA40199070]; NANOSEMED GA AV [KAN208130801]; CEITEC [CZ.1.05/1.1.00/02.0068]","We highly acknowledge the support from grants GACR 301/09/P436, IGA MZ NS 10200-3, GA AV IAA40199070, NANOSEMED GA AV KAN208130801 and CEITEC CZ.1.05/1.1.00/02.0068.",null,151,20,20,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","0929-8673",null,null,"CURR MED CHEM","Curr. Med. Chem.","NOV",2011,18,33,null,null,null,null,5041,5051,null,null,null,11,"Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy","Biochemistry & Molecular Biology; Pharmacology & Pharmacy","875LI","WOS:000299031000003"]
[null,null,null,null,"J","Cools, M; Pleskacova, J; Stoop, H; Hoebeke, P; Van Laecke, E; Drop, SLS; Lebl, J; Oosterhuis, JW; Looijenga, LHJ; Wolffenbuttel, KP",null,null,null,"Cools, M.; Pleskacova, J.; Stoop, H.; Hoebeke, P.; Van Laecke, E.; Drop, S. L. S.; Lebl, J.; Oosterhuis, J. W.; Looijenga, L. H. J.; Wolffenbuttel, K. P.",null,"Mosaicism Collaborative Grp","Gonadal Pathology and Tumor Risk in Relation to Clinical Characteristics in Patients with 45,X/46,XY Mosaicism","JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM",null,null,"English","Article",null,null,null,null,null,null,"GERM-CELL TUMORS; SEX DEVELOPMENT DSD; CARCINOMA IN-SITU; DYSGENETIC GONADS; MATURATION DELAY; CANDIDATE GENE; GONADOBLASTOMA; DIFFERENTIATION; EXPRESSION; DISORDERS","Context: Gonadectomy is avoided whenever possible in boys with 45,X/46,XY. However, no clinical markers are currently available to guide clinicians in predicting gonadal tumor risk or hormone production. Objective: The objective of the study was to test the hypothesis that gonadal histology and risk for development of a malignant germ cell tumor are reflected by the clinical presentation of a 45, X/46, XY individual. Design: The design of the study was the correlation of clinical data [external masculinization score (EMS), pubertal outcome] with pathology data (gonadal phenotype, tumor risk). Setting: This was a multicenter study involving two multidisciplinary disorder of sex development teams. Patients: Patients included genetically proven 45, X/46, XY (and variants) cases, of whom at least one gonadal biopsy or gonadectomy specimen was available, together with clinical details. Interventions: Patients (n = 48) were divided into three groups, based on the EMS. Gonadal histology and tumor risk were assessed on paraffin-embedded samples (n = 87) by morphology and immunohistochemistry on the basis of established criteria. Main Outcome Measures: Gonadal differentiation and tumor risk in the three clinical groups were measured. Clinical outcome in patients with at least one preserved gonad was also measured. Results: Tumor risk in the three groups was significantly related to the gonadal differentiation pattern (P < 0.001). In boys, hormone production was sufficient and was not predicted by the EMS. Conclusions: The EMS reflects gonadal differentiation and tumor risk in patients with 45, X/46, XY. In boys, testosterone production is often sufficient, but strict follow-up is warranted because of malignancy risk, which appears inversely related to EMS. In girls, tumor risk is limited but gonads are not functional, making gonadectomy the most reasonable option. (J Clin Endocrinol Metab 96: E1171-E1180, 2011)","[Cools, M.] Ghent Univ Hosp, Dept Pediat, Div Pediat Endocrinol, B-9000 Ghent, Belgium; [Hoebeke, P.; Van Laecke, E.] Ghent Univ Hosp, Dept Urol, B-9000 Ghent, Belgium; Univ Ghent, B-9000 Ghent, Belgium; [Drop, S. L. S.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat, NL-3000 DR Rotterdam, Netherlands; [Wolffenbuttel, K. P.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Urol, Div Pediat Endocrinol, NL-3000 DR Rotterdam, Netherlands; [Pleskacova, J.; Stoop, H.; Oosterhuis, J. W.; Looijenga, L. H. J.] Sophia Childrens Univ Hosp, Dr Daniel Den Hoed Canc Ctr, Josephine Nefkens Inst, Erasmus Med Ctr,Dept Pathol, NL-3000 DR Rotterdam, Netherlands; [Pleskacova, J.; Lebl, J.] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat, Prague 10034, Czech Republic","Cools, M (reprint author), Ghent Univ Hosp, Dept Pediat, Div Pediat Endocrinol, Pintelaan 185, B-9000 Ghent, Belgium.","martine.cools@ugent.be","Cools, Martine/J-4580-2012",null,"Flanders Research Foundation; Novo Nordisk A/S","We thank explicitly all referring clinicians (J. P. Bourguignon, M. Maes, G. Massa, G. Holmdahl, R. Gannaway, R. Goerse, O. Hiort, C. Clementson, J. Horejsi, M. Snajderova, J. Zapletalova, and D. Novotna) as well as the Pathology Departments of the University Hospital Ghent and the University Hospital Prague-Motol for their support in collecting tissue and clinical data. Members of the Mosaicism Collaborative Group include the following: J. P. Bourguignon, Department of Pediatrics, Sart Tilman University Hospital, Liege, Belgium; Kockum C. Clementson, Department of Pediatric Surgery, University Hospital Lund, Sweden; R. Gannaway, Department of Human and Molecular Genetics, Virginia Commonwealth University Medical Center, Richmond, VA; D. Gisselsson, Department of Clinical Genetics, University Hospital Lund, Sweden; R. Goerse, Department of Gynecology, University Hospital Regensburg, Germany; O. Hiort, Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Lubeck, Germany; G. Holmdahl, Department of Pediatric Surgery, Queen Silvia Children's Hospital, Gothenburg, Sweden; M. Maes, Department of Pediatrics, University Hospital Saint-Luc, Brussels, Belgium; and G. Massa, Department of Pediatrics, Virga Jesse Hospital, Hasselt, Belgium.This work was supported by research grants from the Flanders Research Foundation (to M. C.) and the European Society of Pediatric Endocrinology, sponsored by Novo Nordisk A/S (to J.P.).",null,48,10,11,"ENDOCRINE SOC","CHEVY CHASE","8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA","0021-972X",null,null,"J CLIN ENDOCR METAB","J. Clin. Endocrinol. Metab.","JUL",2011,96,7,null,null,null,null,"E1171","E1180",null,"10.1210/jc.2011-0232",null,10,"Endocrinology & Metabolism","Endocrinology & Metabolism","788OO","WOS:000292454500019"]
[null,null,null,null,"J","Wadstrom, J; Biglarnia, A; Gjertsen, H; Sugitani, A; Fronek, J",null,null,null,"Wadstrom, Jonas; Biglarnia, Alireza; Gjertsen, Henrik; Sugitani, Atsushi; Fronek, Jiri",null,null,"Introducing Hand-Assisted Retroperitoneoscopic Live Donor Nephrectomy: Learning Curves and Development Based on 413 Consecutive Cases in Four Centers","TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"Hand assistance; Hand-assisted retroperitoneoscopic nephrectomy; Live donor nephrectomy; Living donors; Morbidity; Safety; Learning curve; Multicenter; Review","LAPAROSCOPIC PARTIAL NEPHRECTOMY; RANDOMIZED CONTROLLED-TRIAL; RADICAL NEPHRECTOMY; SINGLE-CENTER; TRANSPERITONEAL; COMPLICATIONS; EXPERIENCE; SURGERY; KIDNEY; RHABDOMYOLYSIS","Background. Hand-assisted and retroperitoneoscopic techniques reduce the risk of bleeding and intraabdominal complications in living donor nephrectomy (LDN). This study reports on our four-center experience, development, and learning curves from the first 413 LDNs using a hand-assisted retroperitoneoscopic (HARS) technique. Methods. The first 413 consecutive donors operated on using HARS were included in the study. Donor demographics, perioperative and postoperative data, complications, and recipient outcomes have been compiled. The data were analyzed as a whole and separately for each center, looking at center differences and learning curves over time. Results. Significant differences were found in donor demographics between centers for the variables: age, body mass index, number of arteries, and side of operation. Mean operating time was 170.2 min, with significant differences between centers. Operating time was also significantly influenced by learning curves, sex/body mass index, and side of operation. Warm ischemia time differed significantly between centers and was influenced by center-wise learning and number of arteries. Overall conversion rate was 2.4% and differed significantly between centers. There was no mortality and no intraabdominal complications. Apart from the conversions and one pulmonary embolism, there were no major intraoperative or postoperative complications. Overall 3-month graft survival was 99%, with 96% immediate onset of function and 1% ureteral complications. Conclusions. The HARS technique reduces the risk of intraabdominal complications. It can be implemented with excellent donor and recipient outcomes despite different population demographics and center/surgeon-related tradition and experience. On the basis of our experience, we recommend the technique to increase the safety margin of LDN.","[Wadstrom, Jonas; Biglarnia, Alireza] Univ Uppsala Hosp, Dept Surg, SE-75185 Uppsala, Sweden; [Gjertsen, Henrik] Karolinska Univ Hosp, Dept Transplantat Surg, Stockholm, Sweden; [Sugitani, Atsushi] Fujita Hlth Univ, Dept Organ Transplantat & Regenerat Med, Aichi, Japan; [Fronek, Jiri] Univ London St Georges Hosp, Renal Transplant Unit, London, England; [Fronek, Jiri] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Wadstrom, J (reprint author), Univ Uppsala Hosp, Dept Surg, SE-75185 Uppsala, Sweden.","jonas.wadstrom@akademiska.se",null,null,"medical faculty of Uppsala University","This work was supported by the medical faculty of Uppsala University.",null,80,9,9,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0041-1337",null,null,"TRANSPLANTATION","Transplantation","FEB 27",2011,91,4,null,null,null,null,462,469,null,"10.1097/TP.0b013e3182052baf",null,8,"Immunology; Surgery; Transplantation","Immunology; Surgery; Transplantation","718MR","WOS:000287127600017"]
[null,null,null,null,"J","Novotny, M; Vasilenko, T; Varinska, L; Smetana, K; Szabo, P; Sarissky, M; Dvorankova, B; Mojzis, J; Bobrov, N; Toporcerova, S; Sabol, F; Matthews, BJO; Gal, P",null,null,null,"Novotny, Martin; Vasilenko, Tomas; Varinska, Lenka; Smetana, Karel, Jr.; Szabo, Pavol; Sarissky, Marek; Dvorankova, Barbora; Mojzis, Jan; Bobrov, Nikita; Toporcerova, Silvia; Sabol, Franitsek; Matthews, Bryan J. O.; Gal, Peter",null,null,"ER-alpha agonist induces conversion of fibroblasts into myofibroblasts, while ER-beta agonist increases ECM production and wound tensile strength of healing skin wounds in ovariectomised rats","EXPERIMENTAL DERMATOLOGY",null,null,"English","Article",null,null,null,null,null,"cell differentiation; hormone replacement therapy; myofibroblast; oestrogen receptor; regeneration; tissue repair","ESTROGEN-RECEPTOR-BETA; MATRIX-METALLOPROTEINASE ACTIVITY; HORMONE REPLACEMENT THERAPY; ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; ENDOTHELIAL-CELLS; IN-VIVO; EXPRESSION; REPAIR; 17-BETA-ESTRADIOL","Oestrogen deprivation is one of the major factors responsible for many age-related processes, including poor wound healing in women. Previously, it has been shown that oestrogens have a modulatory effect in different wound-healing models. Therefore, in this study, the effect of selective oestrogen receptor (ER) agonists (PPT - ER-alpha agonist, DPN - ER-beta agonist) on excisional and incisional wound-healing models was compared in ovariectomised rats in vivo as well as on human dermal fibroblasts (HDF) and human umbilical endothelial cells (HUVEC) in vitro. In the in vivo study, 4 months after either ovariectomy or sham ovariectomy, Sprague-Dawley rats were randomly divided into four groups and subjected to two incisional and excisional wounds: (i) control sham operated, vehicle-treated; (ii) ovariectomised, vehicle-treated; (iii) ovariectomised, PPT treated; (iv) ovariectomised, DPN treated. In the in vitro study, HDFs and HUVECs were used. After treatment with ER agonists, cells were processed for immunocytochemistry and gelatin zymography. Our study shows that stimulation of ER-alpha leads to the differentiation of fibroblasts into myofibroblasts both in vivo and in vitro. On the other hand, the formation of extracellular matrix was more prominent, and wound tensile strength (TS) was increased when ER-beta was stimulated. In contrast, stimulation of ER-alpha led to a more prominent increase in the expression of MMP-2 and decrease in wound T'S. New information is presented in this investigation concerning oestrogen replacement therapy (ERT) in different wound-healing models. This study demonstrates that the ERT should be both wound and receptor-type specific.","[Novotny, Martin; Vasilenko, Tomas; Gal, Peter] E Slovak Inst Cardiovasc Dis, Dept Biomed Res, Kosice 04011, Slovakia; [Novotny, Martin] Pavol Jozef Safarik Univ, Dept Pathol Physiol, Kosice, Slovakia; [Vasilenko, Tomas; Gal, Peter] Univ Vet Med & Pharm, Dept Pathol Anat, Kosice, Slovakia; [Vasilenko, Tomas] Slovak Hlth Univ, Clin Surg 3, Kosice, Slovakia; [Vasilenko, Tomas] Kosice Saca Hosp, Kosice, Slovakia; [Varinska, Lenka; Sarissky, Marek; Mojzis, Jan; Gal, Peter] Pavol Jozef Safarik Univ, Dept Pharmacol, Kosice, Slovakia; [Smetana, Karel, Jr.; Szabo, Pavol; Dvorankova, Barbora; Gal, Peter] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Smetana, Karel, Jr.; Szabo, Pavol; Dvorankova, Barbora] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague, Czech Republic; [Bobrov, Nikita] Pavol Jozef Safarik Univ, Dept Forens Med, Kosice, Slovakia; [Toporcerova, Silvia] Pavol Jozef Safarik Univ, Dept Obstet & Gynecol 2, Kosice, Slovakia; [Sabol, Franitsek] E Slovak Inst Cardiovasc Dis, Clin Heart Surg, Kosice 04011, Slovakia; [Matthews, Bryan J. O.] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England","Gal, P (reprint author), E Slovak Inst Cardiovasc Dis, Dept Biomed Res, Ondavska Ul C 8, Kosice 04011, Slovakia.","galovci@yahoo.com",null,null,"Ministry of Education, Youth and Sport of the Czech Republic [MSM0021620806]; EC Marie Curie Research Training Network [2005-019561]; Ministry of Education, Science, Research and Sport of the Slovak Republic (VEGA) [1/1095/11]; Charles Univeristy","We thank Iva Burdova, Vit Hajduch and Magdalena Majnusova for technical assistance. This study was supported in part by the Ministry of Education, Youth and Sport of the Czech Republic (No. MSM0021620806), by the EC Marie Curie Research Training Network (No. 2005-019561) by the Ministry of Education, Science, Research and Sport of the Slovak Republic (VEGA - No. 1/1095/11) and by Specific University Research Programme of Charles Univeristy.",null,48,8,8,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0906-6705",null,null,"EXP DERMATOL","Exp. Dermatol.","SEP",2011,20,9,null,null,null,null,703,708,null,"10.1111/j.1600-0625.2011.01284.x",null,6,"Dermatology","Dermatology","816JH","WOS:000294594000002"]
[null,null,null,null,"J","Tachezy, R; Smahelova, J; Salakova, M; Arbyn, M; Rob, L; Skapa, P; Jirasek, T; Hamsikova, E",null,null,null,"Tachezy, Ruth; Smahelova, Jana; Salakova, Martina; Arbyn, Marc; Rob, Lukas; Skapa, Petr; Jirasek, Tomas; Hamsikova, Eva",null,null,"Human Papillomavirus Genotype Distribution in Czech Women and Men with Diseases Etiologically Linked to HPV","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"INVASIVE CERVICAL-CANCER; SQUAMOUS-CELL CARCINOMA; AGED 16-26 YEARS; INTRAEPITHELIAL LESIONS; PARTICLE VACCINE; PCR DETECTION; END-POINTS; INFECTION; PREVALENCE; WORLDWIDE","Background: The HPV prevalence and genotype distribution are important for the estimation of the impact of HPV-based cervical cancer screening and HPV vaccination on the incidence of diseases etiologically linked to HPVs. The HPV genotype distribution varies across different geographical regions. Therefore, we investigated the type-specific HPV prevalence in Czech women and men with anogenital diseases. Methods: We analyzed 157 squamous cell carcinoma samples, 695 precancerous lesion samples and 64 cervical, vulvar and anal condylomata acuminate samples. HPV detection and typing were performed by PCR with GP5+/6+ primers, reverse line blot assay and sequencing. Results: Thirty different HPV genotypes were detected in our study, HPV 16 being the most prevalent type both in precancerous lesions (45%) and squamous cell carcinomas (59%). In benign lesions, HPV 6 (72%) was the most common type. Altogether, 61% of carcinoma samples and 43% of precancerous lesion samples contained HPV 16 and/or 18. The presence of HPV types related to the vaccinal ones (HPV 31, 45, 33, 52, 58) were detected in 16% of carcinoma samples and 18% of precancerous lesion samples. HPV 16 and/or 18 were present in 76% of cervical cancer samples, 33% of CIN1, 43% CIN2 and 71% of CIN3 samples. HPV types 6 and/or 11 were detected in 84% samples of condylomata acuminate samples. Conclusions: The prevalence of vaccinal and related HPV types in patients with HPV-associated diseases in the Czech Republic is very high. We may assume that the implementation of routine vaccination against HPV would greatly reduce the burden of HPV-associated diseases in the Czech Republic.","[Tachezy, Ruth; Smahelova, Jana; Salakova, Martina; Hamsikova, Eva] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic; [Arbyn, Marc] Sci Inst Publ Hlth, Canc Epidemiol Unit, Brussels, Belgium; [Rob, Lukas] Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 2, Prague, Czech Republic; [Skapa, Petr] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Jirasek, Tomas] Charles Univ Prague, Dept Pathol, Fac Med 3, Prague, Czech Republic","Tachezy, R (reprint author), Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic.","rutach@uhkt.cz",null,null,"Ministry of Health of the Czech Republic [NS 10/656-3/2009]; European Commission (DG of SANCO, Luxembourg, Grand-Duchy of Luxembourg); DG Research of the European Commission [242061]; Sanofi-Pasteur MSD (manufacturer of a quadrivalent HPV vaccine)","This work was supported by grant NS 10/656-3/2009 from the Ministry of Health of the Czech Republic). M. Arbyn was supported by the European Commission (DG of SANCO, Luxembourg, Grand-Duchy of Luxembourg), through the ECCG project (European Cooperation on development and implementation of Cancer screening and prevention Guidelines, IARC, Lyon, France) and the 7th Framework Programme of DG Research of the European Commission through the PREHDICT project (grant No. 242061, coordinated by the Vrije Universiteit Amsterdam, the Netherlands). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.The authors have read the journal's policy and RT, LR, and EH have the following conflicts: membership in the Czech GSK advisory board for the prevention of cervical carcinoma. MA had membership in the Belgian advisory board up to 2008 for Cervarix (bivalent HPV vaccine, produced by GSK) and received travel funding from Sanofi-Pasteur MSD (manufacturer of a quadrivalent HPV vaccine). MS, JS, TJ, and PS have declared that no competing interests exist.",null,46,7,7,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA","1932-6203",null,null,"PLOS ONE","PLoS One","JUL 13",2011,6,7,null,null,null,null,null,null,"e21913","10.1371/journal.pone.0021913",null,8,"Multidisciplinary Sciences","Science & Technology - Other Topics","792WQ","WOS:000292781500021"]
[null,null,null,null,"J","Stepanek, I; Indrova, M; Bieblova, J; Fucikova, J; Spisek, R; Bubenik, J; Reinis, M",null,null,null,"Stepanek, I.; Indrova, M.; Bieblova, J.; Fucikova, J.; Spisek, R.; Bubenik, J.; Reinis, M.",null,null,"EFFECTS OF 5-AZACYTIDINE AND TRICHOSTATIN A ON DENDRITIC CELL MATURATION","JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS",null,null,"English","Article",null,null,null,null,null,"dendritic cell maturation; 5-azacytidine; trichostatin A; epigenetics; cellular vaccines","IMMUNE-RESPONSES; LARGE QUANTITIES; IN-VITRO; ACTIVATION; EXPRESSION; TUMORS; DNA; IMMUNOGENICITY; INDUCTION; VACCINES","Maturation of dendritic cells (DC) towards functional antigen-presenting cells is a complex process, the regulation of which may also involve epigenetic mechanisms. Thus, it is of interest to investigate how gene expression changes during DC maturation can be influenced with epigenetic agents, such as DNA methyltransferase or histone deacetylase inhibitors. Here, we document the effects of DNA methyltransferase inhibitor 5-azacytidine (5AC) and histone deacetylase inhibitor trichostatin A (TSA) on the murine bone marrow-derived, as well as on the human monocyte-derived DC maturation. The major impact of 5AC and TSA on the DC maturation process consisted in the inhibition of unmethylated CpG oligodeoxynucleotide (CpG ODN) 1826 or LPS-induced activation of pro- and anti-inflammatory cytokine gene expression activation. In the in vitro studies, TSA but not 5AC significantly reduced the capacity of the peptide-pulsed DC to induce total spleen as well as CD8(+) or CD4(+) cell proliferation. IFN gamma production by the specific CD4(+) spleen cells co-cultured with TSA- but not with 5AC-treated DC was lower, as compared to the cytokine production after co-cultivation with untreated mature DC. Collectively, these results demonstrate the potential of epigenetic agents, which are under intensive investigation as promising anti-tumour agents, to hamper the immune response induction through their inhibitory effects on DC.","[Stepanek, I.; Indrova, M.; Bieblova, J.; Bubenik, J.; Reinis, M.] Acad Sci Czech Republic, Inst Mol Genet, Vvi, CR-14220 Prague 4, Czech Republic; [Fucikova, J.; Spisek, R.] Charles Univ Prague, Dept Immunol, Fac Med 2, Prague, Czech Republic; [Fucikova, J.; Spisek, R.] Univ Hosp Motol, Prague, Czech Republic","Reinis, M (reprint author), Acad Sci Czech Republic, Inst Mol Genet, Vvi, Videnska 1083, CR-14220 Prague 4, Czech Republic.","milan.reinis@img.cas.cz",null,null,"Academy of Sciences of the Czech Republic [IAA500520605, AV0Z50520514]; Grant Agency of the Czech Republic [301/10/2174, 301/09/1024]; Grant Agency of the Ministry of Health of the Czech Republic [IGA NS 10489-3/2009]; European Union [FP6 LSHB-CT-2006-018933]; Faculty of Science, Charles University, Prague","This work was supported by grant Nos. IAA500520605 from the Academy of Sciences of the Czech Republic, 301/10/2174 and 301/09/1024 from the Grant Agency of the Czech Republic, AV0Z50520514 from the Academy of Sciences of the Czech Republic, IGA NS 10489-3/2009 from the Grant Agency of the Ministry of Health of the Czech Republic, and in part by the Sixth Research Framework Programme of the European Union, Clinigene NoE (FP6 LSHB-CT-2006-018933). The authors are grateful to Pavel Otahal from the Institute of Molecular Genetics for providing OT-II mice, Marie Maleckova and Renata Tureckova for excellent technical assistance and Sarka Takacova and Jana Simova for editorial help. This study was presented in part at the 2nd European Congress of Immunology (Berlin 2009) and at the 9th CIMT Annual Meeting (Mainz 2011). Ivan Stepanek was supported in part by the Faculty of Science, Charles University, Prague.",null,28,1,1,"BIOLIFE SAS","SILVA MARINA (TE)","VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY","0393-974X",null,null,"J BIOL REG HOMEOS AG","J. Biol. Regul. Homeost. Agents","OCT-DEC",2011,25,4,null,null,null,null,517,529,null,null,null,13,"Endocrinology & Metabolism; Immunology; Medicine, Research & Experimental; Physiology","Endocrinology & Metabolism; Immunology; Research & Experimental Medicine; Physiology","876XQ","WOS:000299141500004"]
[null,null,null,null,"J","Soukupova, J; Pohlreich, P; Seemanova, E",null,null,null,"Soukupova, Jana; Pohlreich, Petr; Seemanova, Eva",null,null,"Characterisation of ATM Mutations in Slavic Ataxia Telangiectasia Patients","NEUROMOLECULAR MEDICINE",null,null,"English","Article",null,null,null,null,null,"ATM; Ataxia telangiectasia; Mutation; Sequencing; MLPA","BREAST-CANCER DEVELOPMENT; GENE-MUTATIONS; FAMILIAL BREAST; ALLELES; RISK; NOMENCLATURE; POPULATION; MORTALITY; FREQUENCY; VARIANTS","Ataxia telangiectasia (AT) is a genomic instability syndrome characterised, among others, by progressive cerebellar degeneration, oculocutaneous telangiectases, immunodeficiency, elevated serum alpha-phetoprotein level, chromosomal breakage, hypersensitivity to ionising radiation and increased cancer risk. This autosomal recessive disorder is caused by mutations in the ataxia telangiectasia mutated (ATM) gene coding for serine/threonine protein kinase with a crucial role in response to DNA double-strand breaks. We characterised genotype and phenotype of 12 Slavic AT patients from 11 families. Mutation analysis included sequencing of the entire coding sequence, adjacent intron regions, 3'UTR and 5'UTR of the ATM gene and multiplex ligation-dependent probe amplification (MLPA) for the detection of large deletions/duplications at the ATM locus. The high incidence of new and individual mutations demonstrates a marked mutational heterogeneity of AT in the Czech Republic. Our data indicate that sequence analysis of the entire coding region of ATM is sufficient for a high detection rate of mutations in ATM and that MLPA analysis for the detection of deletions/duplications seems to be redundant in the Slavic population.","[Soukupova, Jana; Pohlreich, Petr] Charles Univ Prague, Fac Med 1, Dept Biochem & Expt Oncol, Prague 12853, Czech Republic; [Seemanova, Eva] Charles Univ Prague, Inst Biol & Med Genet, Dept Clin Genet, Sch Med 2, Prague 12853, Czech Republic","Soukupova, J (reprint author), Charles Univ Prague, Fac Med 1, Dept Biochem & Expt Oncol, Nemocnice 5, Prague 12853, Czech Republic.","jproko@lf1.cuni.cz",null,null," [NS10304-3/2009];  [MSM0021620808]","We thank especially Marie Epsteinova for her excellent technical assistance. Supported by: NS10304-3/2009 and MSM0021620808.",null,35,1,1,"HUMANA PRESS INC","TOTOWA","999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA","1535-1084",null,null,"NEUROMOL MED","Neuromol. Med.","SEP",2011,13,3,null,null,null,null,204,211,null,"10.1007/s12017-011-8152-z",null,8,"Neurosciences","Neurosciences & Neurology","809PH","WOS:000294068700006"]
[null,null,null,null,"J","Arenberger, P; Arenbergerova, M; Drozenova, H; Hladikova, M; Holcova, S",null,null,null,"Arenberger, P.; Arenbergerova, M.; Drozenova, H.; Hladikova, M.; Holcova, S.",null,null,"Effect of topical heparin and levomenol on atopic dermatitis: a randomized four-arm, placebo-controlled, double-blind clinical study","JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY",null,null,"English","Article",null,null,null,null,null,"(-)-alpha-bisabolol; atopic dermatitis; combination justification; heparin; levomenol","SUBCUTANEOUS HEPARIN; CONTACT-DERMATITIS; DIFFERENCE; OSTEOARTHRITIS; BISABOLOL","Background The aim of the controlled double-blind trial was to demonstrate the superiority of a topical combination product over its single constituents. Patients and Methods A total of 278 patients with atopic dermatitis were randomized into four groups: 79 patients were treated with a topical combination of levomenol and heparin (A), 80 patients with levomenol alone (B), 78 patients with heparin alone (C) and 41 patients with the cream base with no active substances (D). The medication was applied twice daily for 8 weeks. Efficacy criteria included the severity of pruritus (visual analogue scale, VAS) and the SCORing Atopic Dermatitis (SCORAD) index as well as the overall assessment of efficacy and tolerance by both physician and patient. Results The improvement of pruritus and SCORAD values in Group A was significantly higher compared with Groups B-D (ancova, P < 7 x 10-8). The improvement of pruritus in Group A approximately corresponded to the cumulative effect of the two single active substances, with mean improvements of itching of -41.3, -13.3, -21.3 and +0.6 mm VAS in Groups A-D, respectively (95% CI 7.1-13.5, 2.9-9.2 and 10.4-18.3 mm for the comparisons A vs. B, A vs. C and A vs. D). Conclusion The combination of levomenol and heparin proved to be significantly more efficacious in the treatment of pruritus and inflamed skin than the preparations of the single components.","[Arenberger, P.; Arenbergerova, M.; Drozenova, H.] Charles Univ Prague, Fac Med 3, Dept Dermatovenereol, Prague, Czech Republic; [Hladikova, M.] Charles Univ Prague, Fac Med 2, Dept Med Informat, Prague, Czech Republic; [Holcova, S.] Outpatient Dept Dermatovenereol, Brno, Czech Republic","Arenberger, P (reprint author), Charles Univ Prague, Fac Med 3, Dept Dermatovenereol, Prague, Czech Republic.","pa@avemedica.cz",null,null,"Harras Pharma","This clinical study was supported by funds from Harras Pharma, the marketing authorization holder of the study medication. The sponsor was, however, not involved in the planning, execution, evaluation and publication of the clinical trial. These tasks were carried out under the responsibility of the principal investigator.",null,20,0,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0926-9959",null,null,"J EUR ACAD DERMATOL","J. Eur. Acad. Dermatol. Venereol.","JUN",2011,25,6,null,null,null,null,688,694,null,"10.1111/j.1468-3083.2010.03950.x",null,7,"Dermatology","Dermatology","763DA","WOS:000290533200009"]
[null,null,null,null,"J","Rotnaglova, E; Tachezy, R; Salakova, M; Prochazka, B; Kosl'abova, E; Vesela, E; Ludvikova, V; Hamsikova, E; Klozar, J",null,null,null,"Rotnaglova, Eliska; Tachezy, Ruth; Salakova, Martina; Prochazka, Bohumir; Kosl'abova, Eva; Vesela, Eva; Ludvikova, Viera; Hamsikova, Eva; Klozar, Jan",null,null,"HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers","INTERNATIONAL JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"HPV; tonsillar cancer; prognosis; antibodies","HUMAN-PAPILLOMAVIRUS INFECTION; SQUAMOUS-CELL CARCINOMA; NECK-CANCER; RISK-FACTORS; PHYSICAL STATUS; OROPHARYNGEAL CANCERS; FAVORABLE PROGNOSIS; POSITIVE HEAD; ORAL-CAVITY; SURVIVAL","The association of high-risk human papillomaviruses (HR HPVs) with tonsillar cancer (TC) has been documented. Because patients with HPV-associated tumors show better survival rates, modification of their treatment regimen is being considered. It is therefore crucial to find markers for the identification of patients whose tumors are linked to viral infection. A cohort of 109 patients with primary TC was screened for HPV DNA presence in the tumor tissues and HPV-specific antibodies in sera. Data regarding risk factors and clinical parameters were collected. Forty-five specimens were analyzed for the expression of viral E6 and E2-region mRNA, and the p16 and p53 protein expression status was assessed by immunohistochemistry. The overall prevalence of HPV DNA in TC tissues was 65.1%. Ninety-three percent of HR HPV DNA-positive samples expressed E6*I mRNA. E2-region mRNA expression was detected in 36% of positive samples, which implies that the virus is integrated in 64% of HPV DNA/RNA-positive tumors. p16 overexpression and the presence of antibodies specific to HPV16 E6/E7 oncoproteins correlated well with HPV DNA and RNA presence. The disease-specific survival rate of patients with HPV DNA-positive tumors was significantly higher than that of HPV DNA-negative patients. In addition to providing further evidence of the involvement of HPV infection in the etiopathogenesis of a proportion of TC cases, our study demonstrates that p16 immunostaining and anti-E6/E7 antibodies as surrogate markers of HPV involvement represent specific, sensitive and clinically accessible assays for the identification of TC patients who have a considerably better prognosis.","[Klozar, Jan] Charles Univ Prague, Motol Univ Hosp, Inst Postgrad Med Educ, Dept Otolaryngol & Head & Neck Surg,Fac Med 1, Prague 15006 5, Czech Republic; [Rotnaglova, Eliska; Tachezy, Ruth; Salakova, Martina; Kosl'abova, Eva; Ludvikova, Viera; Hamsikova, Eva] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic; [Prochazka, Bohumir] Natl Inst Publ Hlth, Dept Sci Informat & Biostat, Prague, Czech Republic; [Vesela, Eva] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 15006 5, Czech Republic","Klozar, J (reprint author), Charles Univ Prague, Motol Univ Hosp, Inst Postgrad Med Educ, Dept Otolaryngol & Head & Neck Surg,Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.klozar@lfmotol.cuni.cz",null,null,"Grant Agency of the Ministry of Health of the Czech Republic [NR 9466-3]; Grant Agency of the 1st Faculty of Medicine, Charles University in Prague [GAUK 8808]; Charles University in Prague [260 510]","Grant sponsor: Grant Agency of the Ministry of Health of the Czech Republic; Grant number: NR 9466-3; Grant sponsor: Grant Agency of the 1st Faculty of Medicine, Charles University in Prague; Grant number: GAUK 8808; Grant sponsor: Charles University in Prague (University Research Support Grant); Grant number: 260 510",null,50,14,15,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0020-7136",null,null,"INT J CANCER","Int. J. Cancer","JUL 1",2011,129,1,null,null,null,null,101,110,null,"10.1002/ijc.25889",null,10,"Oncology","Oncology","756BS","WOS:000289987300010"]
[null,null,null,null,"J","Lenicek, M; Duricova, D; Komarek, V; Gabrysova, B; Lukas, M; Smerhovsky, Z; Vitek, L",null,null,null,"Lenicek, Martin; Duricova, Dana; Komarek, Viktor; Gabrysova, Bronislava; Lukas, Milan; Smerhovsky, Zdenek; Vitek, Libor",null,null,"Bile Acid Malabsorption in Inflammatory Bowel Disease: Assessment by Serum Markers","INFLAMMATORY BOWEL DISEASES",null,null,"English","Article",null,null,null,null,null,"bile acid malabsorption; Crohn's disease; 7 alpha-hydroxycholest-4-en-3-one; ileal disease; inflammatory bowel disease","CHRONIC DIARRHEA; DIURNAL-VARIATION; CROHNS-DISEASE; HUMAN ILEAL; 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; HYPEROXALURIA; TRANSPORTER; ABSORPTION; EXPRESSION; THERAPY","Background: Bile acid malabsorption (BAM) is a common feature of Crohn's disease (CD). We aimed to determine whether BAM develops only in patients with a resected distal ileum or if it also occurs in patients who have not undergone surgery for CD. Methods: The study included 347 patients with CD or ulcerative colitis (UC) and 119 healthy subjects (controls). BAM was assessed by measurement of serum levels of 7 alpha-hydroxycholest-4-en-3-one (C4) and fibroblast growth factor 19 (FGF19). We surveyed members of the European Crohn's and Colitis Organization and International Organization for the Study of Inflammatory Bowel Disease to collect current information about BAM diagnosis. Results: The severity of BAM was associated with resection of the distal ileum. Compared with controls, patients who received moderate or extensive ileal resection had significantly increased levels of serum C4 (12 versus 62 versus 243 mu g/L, respectively; P < 0.001). However, BAM was also present in a substantial number of the patients with CD who were not treated by surgery who had ileitis or colitis (14% and 11%, respectively). There was an indirect, proportional relationship between levels of C4 and FGF19 (P < 0.001). Conclusions: The most severe BAM occurs in CD patients after resection of the distal ileum, but BAM can occur in surgically untreated CD patients, regardless of disease localization. Laboratory tests for BAM should become a part of the algorithm for diagnosis of CD to identify patients who might respond to therapies such as bile acid sequestrants. FGF19 appears to be a reliable marker of BAM.","[Vitek, Libor] Charles Univ Prague, Fac Med 1, Dept Internal Med 4, Prague 12808 2, Czech Republic; [Lenicek, Martin; Gabrysova, Bronislava; Lukas, Milan; Vitek, Libor] Charles Univ Prague, Fac Med 1, Dept Clin Biochem & Lab Diagnost, Prague 12808 2, Czech Republic; [Duricova, Dana; Komarek, Viktor; Lukas, Milan] ISCARE IVF, IBD Res Ctr, Prague, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Inst Epidemiol 2, Prague 12808 2, Czech Republic; [Smerhovsky, Zdenek] Natl Inst Publ Hlth, Prague, Czech Republic","Vitek, L (reprint author), Charles Univ Prague, Fac Med 1, Dept Internal Med 4, U Nemocnice 2, Prague 12808 2, Czech Republic.","vitek@cesnet.cz","Vitek, Libor/A-2645-2008",null,"Czech Ministry of Education [2B06155]; Czech Ministry of Health [NR-9219-3/2007]","Supported by government grants from both the Czech Ministry of Education (No. 2B06155) and the Czech Ministry of Health (No. NR-9219-3/2007). The granting agencies had no influence on the collection, analysis, interpretation of data, writing of the report, nor on the decision to submit the article for publication.",null,33,12,13,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1078-0998",null,null,"INFLAMM BOWEL DIS","Inflamm. Bowel Dis.","JUN",2011,17,6,null,null,null,null,1322,1327,null,"10.1002/ibd.21502",null,6,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","761ZQ","WOS:000290442400030"]
[null,null,null,null,"J","van der Leest, RJT; de Vries, E; Bulliard, JL; Paoli, J; Peris, K; Stratigos, AJ; Trakatelli, M; Maselis, TJEML; Situm, M; Pallouras, AC; Hercogova, J; Zafirovik, Z; Reusch, M; Olah, J; Bylaite, M; Dittmar, HC; Scerri, L; Correia, O; Medenica, L; Bartenjev, I; Guillen, C; Cozzio, A; Bogomolets, OV; del Marmol, V",null,null,null,"van der Leest, R. J. T.; de Vries, E.; Bulliard, J-L.; Paoli, J.; Peris, K.; Stratigos, A. J.; Trakatelli, M.; Maselis, T. J. E. M. L.; Situm, M.; Pallouras, A. C.; Hercogova, J.; Zafirovik, Z.; Reusch, M.; Olah, J.; Bylaite, M.; Dittmar, H. C.; Scerri, L.; Correia, O.; Medenica, L.; Bartenjev, I.; Guillen, C.; Cozzio, A.; Bogomolets, O. V.; del Marmol, V.",null,"Euromelanoma Grp","The Euromelanoma skin cancer prevention campaign in Europe: characteristics and results of 2009 and 2010","JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY",null,null,"English","Article",null,null,null,null,null,null,"CUTANEOUS MELANOMA; RISK-FACTORS; OLDER MEN; MALIGNANT-MELANOMA; SCREENING CAMPAIGN; AMERICAN-ACADEMY; WESTERN-EUROPE; MORTALITY; TRENDS; METAANALYSIS","Background Euromelanoma is a skin cancer education and prevention campaign that started in 1999 in Belgium as Melanoma day. Since 2000, it is active in a large and growing number of European countries under the name Euromelanoma. Objective To evaluate results of Euromelanoma in 2009 and 2010 in 20 countries, describing characteristics of screenees, rates of clinically suspicious lesions for skin cancer and detection rates of melanomas. Methods Euromelanoma questionnaires were used by 20 countries providing their data in a standardized database (Belgium, Croatia, Cyprus, Czech Republic, FYRO Macedonia, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Malta, Moldavia, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland and Ukraine). Results In total, 59 858 subjects were screened in 20 countries. Most screenees were female (64%), median ages were 43 (female) and 46 (male) and 33% had phototype I or II. The suspicion rates ranged from 1.1% to 19.4% for melanoma (average 2.8%), from 0.0% to 10.7% for basal cell carcinoma (average 3.1%) and from 0.0% to 1.8% for squamous cell carcinoma (average 0.4%). The overall positive predictive value of countries where (estimation of) positive predictive value could be determined was 13.0%, melanoma detection rates varied from 0.1% to 1.9%. Dermoscopy was used in 78% of examinations with clinically suspected melanoma; full body skin examination was performed in 72% of the screenees. Conclusion Although the population screened during Euromelanoma was relatively young, high rates of clinically suspected melanoma were found. The efficacy of Euromelanoma could be improved by targeting high- risk populations and by better use of dermoscopy and full body skin examination.","[van der Leest, R. J. T.; de Vries, E.] Erasmus MC, Dept Dermatol, Rotterdam, Netherlands; [de Vries, E.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Bulliard, J-L.] CHUV, IUMSP, Canc Epidemiol Unit, Dept Publ Hlth, Lausanne, Switzerland; [Bulliard, J-L.] Univ Lausanne, Lausanne, Switzerland; [Paoli, J.] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Sahlgrenska Univ Hosp,Dept Dermatol, Gothenburg, Sweden; [Peris, K.] Univ Aquila, Dept Dermatol, I-67100 Laquila, Italy; [Stratigos, A. J.] Univ Athens, A Sygros Hosp, Dept Dermatol, Athens, Greece; [Trakatelli, M.] Aristotle Univ Thessaloniki, Papageorgiou Hosp, Dept Dermatol, Thessaloniki, Greece; [del Marmol, V.] Univ Libre Bruxelles, Dept Dermatol, Hop Erasme, Brussels, Belgium","van der Leest, RJT (reprint author), Erasmus MC, Dept Dermatol, Rotterdam, Netherlands.","r.vanderleest@erasmusmc.nl",null,null,"multiple Dermatological Societies; Cancer Leagues","The Euromelanoma campaigns in all participating European countries were sponsored by multiple Dermatological Societies, Cancer Leagues and (Pharmaceutical) companies, specific for each country. Names of sponsors are available through the corresponding author. The database collection and database analysis were not sponsored.","Baade P, 2005, AUST NZ J PUBL HEAL, V29, P383, DOI 10.1111/j.1467-842X.2005.tb00211.x; Bulliard JL, 2008, J EUR ACAD DERMATOL, V22, P365, DOI 10.1111/j.1468-3083.2007.02316.x; Chellini E, 2007, MELANOMA RES, V17, P129, DOI 10.1097/CMR.0b013e3280a60865; Conejo-Mir Julian, 2005, Actas Dermosifiliogr, V96, P217, DOI 10.1016/S0001-7310(05)73073-8; del Marmol V, 2009, EUR J CANCER, V45, P1532, DOI 10.1016/j.ejca.2008.12.023; de Vries E, 2004, EUR J CANCER, V40, P2355, DOI 10.1016/j.ejca.2004.06.003; de Vries E, 2004, EUR J CANCER, V40, P1045, DOI 10.1016/j.ejca.2003.12.021; de Vries E, 2003, INT J CANCER, V107, P119, DOI 10.1002/ijc.11360; Gandini S, 2005, EUR J CANCER, V41, P45, DOI 10.1016/j.ejca.2004.10.016; Gandini S, 2005, EUR J CANCER, V41, P2040, DOI 10.1016/j.ejca.2005.03.034; Gandini S, 2005, EUR J CANCER, V41, P28, DOI 10.1016/j.ejca.2004.10.015; Garbe C, 2009, CLIN DERMATOL, V27, P3, DOI 10.1016/j.clindermatol.2008.09.001; Geller AC, 2003, J AM ACAD DERMATOL, V48, P34, DOI 10.1067/mjd.2003.9; Geller AC, 2009, ARCH DERMATOL, V145, P409, DOI 10.1001/archdermatol.2009.8; Hollestein LM, 2011, Ann Oncol, DOI [10.1093/annonc/mdr128, DOI 10.1093/ANNONC/MDR128]; Karim-Kos HE, 2008, EUR J CANCER, V44, P1345, DOI 10.1016/j.ejca.2007.12.015; Koh HK, 1996, J AM ACAD DERMATOL, V34, P971, DOI 10.1016/S0190-9622(96)90274-1; La Vecchia C, 1999, INT J CANCER, V81, P62, DOI 10.1002/(SICI)1097-0215(19990331)81:1<62::AID-IJC12>3.0.CO;2-2; Paoli J, 2009, J EUR ACAD DERMATOL, V23, P1304, DOI 10.1111/j.1468-3083.2009.03316.x; Pollitt RA, 2011, CANCER-AM CANCER SOC, V117, P152, DOI 10.1002/cncr.25355; Stratigos A, 2007, J EUR ACAD DERMATOL, V21, P56, DOI 10.1111/j.1468-3083.2006.01865.x; Swetter SM, 2009, ARCH DERMATOL, V145, P488, DOI 10.1001/archdermatol.2009.42; Swetter SM, 2009, ARCH DERMATOL, V145, P397, DOI 10.1001/archdermatol.2008.603; Truyers C, 2010, EUR J DERMATOL, V20, P517, DOI 10.1684/ejd.2010.0969; Calonge N, 2009, ANN INTERN MED, V150, P188; Vandaele MM, 2000, J EUR ACAD DERMATOL, V14, P470, DOI 10.1046/j.1468-3083.2000.00127.x; van der Aa MA, 2011, EUR J CANCER, V47, P1056, DOI 10.1016/j.ejca.2010.11.020; Youl PH, 2010, INT J CANCER, V128, P2158",28,13,13,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0926-9959",null,null,"J EUR ACAD DERMATOL","J. Eur. Acad. Dermatol. Venereol.","DEC",2011,25,12,null,null,null,null,1455,1465,null,"10.1111/j.1468-3083.2011.04228.x",null,11,"Dermatology","Dermatology","860MQ","WOS:000297952800015"]
[null,null,null,null,"J","Benes, J; Kazdova, L; Drahota, Z; Houstek, J; Medrikova, D; Kopecky, J; Kovarova, N; Yrbacky, M; Sedmera, D; Strnad, H; Kolar, M; Petrak, J; Benada, O; Skaroupkova, P; Cervenka, L; Melenovsky, V",null,null,null,"Benes, Jan; Kazdova, Ludmila; Drahota, Zdenek; Houstek, Josef; Medrikova, Dasa; Kopecky, Jan; Kovarova, Nikola; Yrbacky, Marek; Sedmera, David; Strnad, Hynek; Kolar, Michal; Petrak, Jiri; Benada, Oldrich; Skaroupkova, Petra; Cervenka, Ludek; Melenovsky, Vojtech",null,null,"Effect of metformin therapy on cardiac function and survival in a volume-overload model of heart failure in rats","CLINICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"AMP-activated protein kinase (AMPK); energy metabolism; heart failure; metformin; survival; volume overload","ACTIVATED PROTEIN-KINASE; HEREDITARY HYPERTRIGLYCERIDEMIC RATS; CYTOCHROME-C-OXIDASE; FATTY-ACID OXIDATION; FAILING HEART; SKELETAL-MUSCLE; INSULIN SENSITIVITY; DIABETES-MELLITUS; GENE-EXPRESSION; MECHANISMS","Advanced HF (heart failure) is associated with altered substrate metabolism. Whether modification of substrate use improves the course of HF remains unknown. The antihyperglycaemic drug MET (metformin) affects substrate metabolism, and its use might be associated with improved outcome in diabetic HE The aim of the present study was to examine whether MET would improve cardiac function and survival also in non-diabetic HE Volume-overload HF was induced in male Wistar rats by creating ACF (aortocaval fistula). Animals were randomized to placebo/MET (300 nng.kg(-1) of body weight.day(-1), 0.5% in food) groups and underwent assessment of metabolism, cardiovascular and mitochondrial functions (n=6-12/group) in advanced HF stage (week 21). A separate cohort served for survival analysis (n=10-90/group). The ACF group had marked cardiac hypertrophy, increased LVEDP (left ventricular end-diastolic pressure) and lung weight confirming decompensated HF, increased circulating NEFAs (non-esterified 'free' fatty acids), intra-abdominal fat depletion, lower glycogen synthesis in the skeletal muscle (diaphragm), lower myocardial triacylglycerol (triglyceride) content and attenuated myocardial C-14-glucose and C-14-palmitate oxidation, but preserved mitochondrial respiratory function, glucose tolerance and insulin sensitivity. MET therapy normalized serum NEFAs, decreased myocardial glucose oxidation, increased myocardial palmitate oxidation, but it had no effect on myocardial gene expression, AMPK (AMP-activated protein kinase) signalling, ATP level, mitochondrial respiration, cardiac morphology, function and long-term survival, despite reaching therapeutic serum levels (2.2 +/- 0.7 mu g/ml). In conclusion, MET-induced enhancement of myocardial fatty acid oxidation had a neutral effect on cardiac function and survival. Recently reported cardioprotective effects of MET may not be universal to all forms of HF and may require AMPK activation or ATP depletion. No increase in mortality on MET supports its safe use in diabetic HF.","[Benes, Jan; Melenovsky, Vojtech] Inst Clin & Expt Med IKEM, Dept Cardiol, Prague, Czech Republic; [Benes, Jan; Kazdova, Ludmila; Skaroupkova, Petra; Cervenka, Ludek; Melenovsky, Vojtech] Inst Clin & Expt Med IKEM, Ctr Med Expt, Prague, Czech Republic; [Benes, Jan; Cervenka, Ludek; Melenovsky, Vojtech] Cardiovasc Res Ctr, Prague, Czech Republic; [Drahota, Zdenek; Houstek, Josef; Medrikova, Dasa; Kopecky, Jan; Kovarova, Nikola; Yrbacky, Marek; Sedmera, David] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Sedmera, David] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic; [Strnad, Hynek; Kolar, Michal] Acad Sci Czech Republic, Inst Mol Genet, Prague, Czech Republic; [Petrak, Jiri] Charles Univ Prague, Fac Med 1, Inst Pathol Physiol, Prague, Czech Republic; [Petrak, Jiri] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic; [Benada, Oldrich] Acad Sci Czech Republic, Inst Microbiol Vvi, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Benes, J (reprint author), Inst Clin & Expt Med IKEM, Dept Cardiol, Prague, Czech Republic.","jan.benes@ikem.cz","Vrbacky, Marek/A-1044-2010; Kolar, Michal/A-3307-2012; Kopecky, Jan/B-8244-2012; Houstek, Josef/C-5019-2012; Sedmera, David/C-2146-2012; Strnad, Hynek/B-7361-2008; Kovarova, Nikola/D-1129-2014; Drahota, Zdenek/F-8296-2014","Vrbacky, Marek/0000-0001-7218-8370; Kolar, Michal/0000-0002-4593-1525; Strnad, Hynek/0000-0002-0141-8340; ","EU [CZ.2.16/3.1.00/22126]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Center for Cardiovascular Research [MSMT-1MO510]; Ministry of Heath [MZO-00023001, IGA MZCR 10300-3, NS10497-3/2009, IGA MZCR NS 9757-4]; Ministry of Education [MSMT-1MO510, VZ 0021620806, 1M6837805002, LC06044, SVV-2010-254260507]; Grant agency of the Czech Republic [305/09/1390]; Academy of Sciences of the Czech Republic [AV0Z50520514, AV0Z50110509, AV0Z50200510]","This work was supported by the EU Operational Program Prague Competitiveness project 'CEVKOON' [grant number CZ.2.16/3.1.00/22126 (to L.C.)], institutional support of the Institute for Clinical and Experimental Medicine [grant number MZO 00023001 (to V.M., J.B. and L.C.)], Center for Cardiovascular Research [grant number MSMT-1MO510 (to V.M. J.B. and L.C.)], the Ministry of Heath [grant numbers MZO-00023001 (to V.M. and L.C.), IGA MZCR 10300-3 (to J.P.), NS10497-3/2009 (to V.M.), IGA MZCR NS 9757-4 (to L.K.)]; the Ministry of Education [grant numbers MSMT-1MO510 (to V.M., J.B. and L.C.), VZ 0021620806 (to D.S. and J.P.), 1M6837805002 (to H.S., M.K., J.H., D.M. and J.K.), LC06044, SVV-2010-254260507 (to J.P.), the Grant agency of the Czech Republic [grant number 305/09/1390 (to V.M.)], and the Academy of Sciences of the Czech Republic [grant numbers AV0Z50520514 (to H.S. and M.K.), AV0Z50110509 (to D.S., J.H., D.M. and J.K.), AV0Z50200510 (to O.B.).",null,60,12,12,"PORTLAND PRESS LTD","LONDON","THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND","0143-5221",null,null,"CLIN SCI","Clin. Sci.","JUL",2011,121,41671,null,null,null,null,29,41,null,"10.1042/CS20100527",null,13,"Medicine, Research & Experimental","Research & Experimental Medicine","797UI","WOS:000293155200004"]
[null,null,null,null,"J","Hollink, IHIM; van den Heuvel-Eibrink, MM; Arentsen-Peters, STCJM; Zimmermann, M; Peeters, JK; Valk, PJM; Balgobind, BV; Sonneveld, E; Kaspers, GJL; de Bont, ESJM; Trka, J; Baruchel, A; Creutzig, U; Pieters, R; Reinhardt, D; Zwaan, CM",null,null,null,"Hollink, Iris H. I. M.; van den Heuvel-Eibrink, Marry M.; Arentsen-Peters, Susan T. C. J. M.; Zimmermann, Martin; Peeters, Justine K.; Valk, Peter J. M.; Balgobind, Brian V.; Sonneveld, Edwin; Kaspers, Gertjan J. L.; de Bont, Eveline S. J. M.; Trka, Jan; Baruchel, Andre; Creutzig, Ursula; Pieters, Rob; Reinhardt, Dirk; Zwaan, C. Michel",null,null,"Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Article",null,null,null,null,null,"Pediatric acute myeloid leukemia; CEBPA mutation; promoter hypermethylation; molecular marker; prognostic significance","BINDING-PROTEIN-ALPHA; ACUTE LYMPHOBLASTIC-LEUKEMIA; GENE-EXPRESSION PROFILES; CELLULAR-DRUG RESISTANCE; FACTOR-C/EBP-ALPHA; TRANSCRIPTION FACTOR; PROGNOSTIC-SIGNIFICANCE; INITIATING CELLS; AML; DIFFERENTIATION","Background Dysfunctioning of CCAAT/enhancer binding protein alpha (C/EBP alpha) in acute myeloid leukemia can be caused, amongst others, by mutations in the encoding gene (CEBPA) and by promoter hypermethylation. CEBPA-mutated acute myeloid leukemia is associated with a favorable outcome, but this may be restricted to the case of double mutations in CEBPA in adult acute myeloid leukemia. In pediatric acute myeloid leukemia, data on the impact of these mutations are limited to one series, and data on promoter hypermethylation are lacking. Our objective was to investigate the characteristics, gene expression profiles and prognostic impact of the different CEBPA aberrations in pediatric acute myeloid leukemia. Design and Methods We screened a large pediatric cohort (n=252) for CEBPA single and double mutations by direct sequencing, and for promoter hypermethylation by methylation-specific polymerase chain reaction. Furthermore, we determined the gene-expression profiles (Affymetrix HGU133 plus 2.0 arrays) of this cohort (n=237). Results Thirty-four mutations were identified in 20 out of the 252 cases (7.9%), including 14 double-mutant and 6 single-mutant cases. CEBPA double mutations conferred a significantly better 5-year overall survival compared with single mutations (79% versus 25%, respectively; P=0.04), and compared with CEBPA wild-type acute myeloid leukemia excluding core-binding factor cases (47%; P=0.07). Multivariate analysis confirmed that the double mutations were an independent favorable prognostic factor for survival (hazard ratio 0.23, P=0.04). The combination of screening for promoter hypermethylation and gene expression profiling identified five patients with silenced CEBPA, of whom four cases relapsed. All cases characteristically expressed T-lymphoid markers. Moreover, unsupervised clustering of gene expression profiles showed a clustering of CEBPA double-mutant and silenced cases, pointing towards a common hallmark of abrogated C/EBP alpha-functioning in these acute myeloid leukemias. Conclusions We showed the independent favorable outcome of patients with CEBPA double-mutant acute myeloid leukemia in a large pediatric series. This molecular marker may, therefore, improve risk-group stratification in pediatric acute myeloid leukemia. For the first time, CEBPA-silenced cases are suggested to confer a poor outcome in pediatric acute myeloid leukemia, indicating that further investigation of this aberration is needed. Furthermore, clustering of gene expression profiles provided insight into the biological similarities and diversities of the different aberrations in CEBPA in pediatric acute myeloid leukemia.","[Zimmermann, Martin; Reinhardt, Dirk] Hannover Med Sch, AML BFM Study Grp, Hannover, Germany; [Peeters, Justine K.; Valk, Peter J. M.] Erasmus MC, Rotterdam, Netherlands; [Zwaan, C. Michel] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands; [Sonneveld, Edwin; Kaspers, Gertjan J. L.] DCOG, The Hague, Netherlands; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [de Bont, Eveline S. J. M.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Groningen, Netherlands; [Trka, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Baruchel, Andre] Hop St Louis, Paris, France; [Creutzig, Ursula] Univ Hosp, AML BFM Study Grp, Munster, Germany","Zwaan, CM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.","c.m.zwaan@eras-musmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","KOCR foundation; Netherlands Organisation for Scientific Research (NWO); Deutsche Krebshilfe; Czech Ministry of Education [MSM0021620813]","this work was funded by the KOCR foundation (IHIMH and BVB) and the Netherlands Organisation for Scientific Research (NWO) (BVB). This work was further supported in part by the Deutsche Krebshilfe (DR), and the Czech Ministry of Education (MSM0021620813) (JT).",null,43,9,11,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078","1592-8721",null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","MAR",2011,96,3,null,null,null,null,384,392,null,"10.3324/haematol.2010.031336",null,9,"Hematology","Hematology","740BQ","WOS:000288767000008"]
[null,null,null,null,"J","Bakkaloglu, SA; Borzych, D; Ha, IS; Serdaroglu, E; Buscher, R; Salas, P; Patel, H; Drozdz, D; Vondrak, K; Watanabe, A; Villagra, J; Yavascan, O; Valenzuela, M; Gipson, D; Ng, KH; Warady, BA; Schaefer, F",null,null,null,"Bakkaloglu, Sevcan A.; Borzych, Dagmara; Ha, Il Soo; Serdaroglu, Erkin; Buescher, Rainer; Salas, Paulina; Patel, Hiren; Drozdz, Dorota; Vondrak, Karel; Watanabe, Andreia; Villagra, Jorge; Yavascan, Onder; Valenzuela, Maria; Gipson, Deborah; Ng, K. H.; Warady, Bradley A.; Schaefer, Franz",null,"Int Pediat Peritoneal Dialysis","Cardiac Geometry in Children Receiving Chronic Peritoneal Dialysis: Findings from the International Pediatric Peritoneal Dialysis Network (IPPN) Registry","CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,null,"LEFT-VENTRICULAR HYPERTROPHY; CHRONIC KIDNEY-DISEASE; GROUP TUPEPD REPORT; LONG-TERM DIALYSIS; BODY-MASS INDEX; BLOOD-PRESSURE; PARATHYROID-HORMONE; SECONDARY HYPERPARATHYROIDISM; CARDIOVASCULAR-DISEASE; YOUNG-ADULTS","Background and objectives Left ventricular hypertrophy (LVH) is an independent risk factor and an intermediate end point of dialysis-associated cardiovascular comorbidity. We utilized a global pediatric registry to assess the prevalence, incidence, and predictors of LVH as well as its evolution in the longitudinal follow-up in dialyzed children. Design, setting, participants, & measurements Cross-sectional echocardiographic, clinical, and biochemical data were evaluated in 507 children on peritoneal dialysis (PD), and longitudinal data were evaluated in 128 patients. The 95(th) percentile of LV mass index relative to height age was used to define LVH. Results The overall LVH prevalence was 48.1%. In the prospective analysis, the incidence of LVH developing de novo in patients with normal baseline LV mass was 29%, and the incidence of regression from LVH to normal LV mass 40% per year on PD. Transformation to and regression from concentric LV geometry occurred in 36% and 28% of the patients, respectively. Hypertension, high body mass index, use of continuous ambulatory peritoneal dialysis, renal disease other than hypo/dysplasia, and hyperparathyroidism were identified as independent predictors of LVH. The use of renin-angiotensin system (RAS) antagonists and high total fluid output (sum of urine and ultrafiltration) were protective from concentric geometry. The risk of LVH at 1 year was increased by higher systolic BP standard deviation score and reduced in children with renal hypo/dysplasia. Conclusions Using height-adjusted left ventricular mass index reference data, LVH is highly prevalent but less common than previously diagnosed in children on PD. Renal hypo/dysplasia is protective from LVH, likely because of lower BP and polyuria. Hypertension, fluid overload, and hyperparathyroidism are modifiable determinants of LVH. Clin J Am Soc Nephrol 6: 1926-1933, 2011. doi: 10.2215/CJN.05990710","[Bakkaloglu, Sevcan A.] Gazi Univ, Dept Pediat Nephrol, TR-06500 Ankara, Turkey; [Borzych, Dagmara] Med Univ Gdansk, Gdansk, Poland; [Borzych, Dagmara] Ctr Pediat & Adolescent Med, Heidelberg, Germany; [Ha, Il Soo] Seoul Natl Univ, Childrens Hosp, Seoul, South Korea; [Serdaroglu, Erkin] Dr Behcet Uz Children Res & Educ Hosp, Izmir, Turkey; [Buescher, Rainer] Univ Childrens Hosp, Essen, Germany; [Salas, Paulina] Hosp Dr Exequiel Gonzales Cortes, Santiago, Chile; [Patel, Hiren] Nationwide Childrens Hosp, Columbus, OH USA; [Drozdz, Dorota] Jagiellonian Univ, Coll Med, Krakow, Poland; [Vondrak, Karel] Univ Hosp Motol, Prague, Czech Republic; [Watanabe, Andreia] Hosp Clin FMUSP, Inst Crianca, Sao Paulo, Brazil; [Villagra, Jorge] Hosp Base Osorno, Osorno, Chile; [Yavascan, Onder] Izmir Tepecik Teaching & Res Hosp, Izmir, Turkey; [Valenzuela, Maria] Hosp Guillermo Grant Benavente, Concepcion, Chile; [Gipson, Deborah] Univ N Carolina, Chapel Hill, NC USA; [Ng, K. H.] Shaw NKF NUH Childrens Kidney Ctr, Singapore, Singapore; [Warady, Bradley A.] Childrens Mercy Hosp, Kansas City, MO 64108 USA","Bakkaloglu, SA (reprint author), Gazi Univ, Dept Pediat Nephrol, TR-06500 Ankara, Turkey.","sevcan@gazi.edu.tr","Schaefer, Franz/G-4365-2010; Ng, Kar Hui/C-9157-2012; Patel, Hiren/E-3835-2011","Ng, Kar Hui/0000-0002-6919-8575; ","International Society for Peritoneal Dialysis; Baxter Health Care; Fresenius Medical Care; Ipsen; Pfizer; IBM","We gratefully acknowledge the support by the International Society for Peritoneal Dialysis, Baxter Health Care, Fresenius Medical Care, Ipsen, Pfizer, and IBM. We also appreciate the continued dedicated support of IPPN by the medical staff in all collaborating centers. Both S.A.B. and D.B. contributed equally to the study.",null,38,10,10,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1555-9041",null,null,"CLIN J AM SOC NEPHRO","Clin. J. Am. Soc. Nephrol.","AUG",2011,6,8,null,null,null,null,1926,1933,null,"10.2215/CJN.05990710",null,8,"Urology & Nephrology","Urology & Nephrology","805IZ","WOS:000293721400020"]
[null,null,null,null,"J","Slyskova, J; Naccarati, A; Polakova, V; Pardini, B; Vodickova, L; Stetina, R; Schmuczerova, J; Smerhovsky, Z; Lipska, L; Vodicka, P",null,null,null,"Slyskova, Jana; Naccarati, Alessio; Polakova, Veronika; Pardini, Barbara; Vodickova, Ludmila; Stetina, Rudolf; Schmuczerova, Jana; Smerhovsky, Zdenek; Lipska, Ludmila; Vodicka, Pavel",null,null,"DNA Damage and Nucleotide Excision Repair Capacity in Healthy Individuals","ENVIRONMENTAL AND MOLECULAR MUTAGENESIS",null,null,"English","Article",null,null,null,null,null,"BPDE-induced DNA repair capacity; comet assay; interindividual variability; biological and lifestyle characteristics; genetic polymorphism","ALKALINE COMET ASSAY; CANCER-RISK; MOLECULAR EPIDEMIOLOGY; LUNG-CANCER; OXIDATIVE DAMAGE; BREAST-CANCER; STRAND BREAKS; POLYMORPHISMS; ASSOCIATION; GENES","Interindividual differences in DNA repair capacity (DRC) represent an important source of variability in genome integrity and thus influence health risk. In the last decade, DRC measurement has attracted attention as a potential biomarker in cancer prediction. Aim of the present exploratory study was to characterize the variability in DNA damage and DRC on 100 healthy individuals and to identify biological, lifestyle, or genetic factors modulating these parameters. The ultimate goal was to obtain reference data from cancer-free population, which may constitute background for further investigations on cancer patients. The endogenous DNA damage was measured as a level of DNA single-strand breaks and DRC, specific for nucleotide excision repair (NER), was evaluated using modified comet assay, following the challenge of peripheral blood mononuclear cells with benzo[a]pyrene diolepoxide. Additionally, genetic polymorphisms in NER genes (XPA, XPC, XPD, and XPG) were assessed. We have observed a substantial interindividual variability for both examined parameters. DNA damage was significantly affected by gender and alcohol consumption (P = 0.003 and P = 0.012, respectively), whereas DRC was associated with family history of cancer (P = 0.012). The stratification according to common variants in NER genes showed that DNA damage was significantly modulated by the presence of the variant T allele of XPC Ala499Val polymorphism (P = 0.01), while DRC was modulated by the presence of the A allele of XPA G23A polymorphism (P = 0.048). Our results indicate the range of endogenous DNA single-strand breaks and capacity of NER in healthy volunteers as well as the role of potentially relevant confounders. Environ. Mol. Mutagen. 52:511-517, 2011. (C) 2011Wiley-Liss, Inc.","[Slyskova, Jana; Naccarati, Alessio; Polakova, Veronika; Pardini, Barbara; Vodickova, Ludmila; Schmuczerova, Jana; Vodicka, Pavel] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Prague 14220, Czech Republic; [Slyskova, Jana] Charles Univ Prague, Dept Genet & Microbiol, Fac Sci, Prague, Czech Republic; [Vodickova, Ludmila; Smerhovsky, Zdenek] Natl Inst Publ Hlth, Dept Toxicogen, Prague, Czech Republic; [Stetina, Rudolf] Univ Def, Fac Mil Hlth Sci, Dept Toxicol, Hradec Kralove, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Inst Epidemiol, Fac Med 2, Prague, Czech Republic; [Lipska, Ludmila] Fac Thomayer Hosp, Prague, Czech Republic","Vodicka, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Videnska 1083, Prague 14220, Czech Republic.","pvodicka@biomed.cas.cz","Lipska, Ludmila/H-1759-2011",null,"Grant Agency of the Czech Republic [CZ:GACR:GAP304/10/1286]; EEA/Norway; Czech Republic [A/CZ0046/2/0012]; Grant Agency of Charles University [CZ:GAUK 124710]","Grant sponsor: Grant Agency of the Czech Republic; Grant Number CZ:GACR:GAP304/10/1286; Grant sponsor: EEA/Norway Grants and the Czech Republic; Grant Number A/CZ0046/2/0012; Grant sponsor: Grant Agency of Charles University; Grant Number CZ:GAUK 124710.",null,45,10,10,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0893-6692",null,null,"ENVIRON MOL MUTAGEN","Environ. Mol. Mutagen.","AUG",2011,52,7,null,null,null,null,511,517,null,"10.1002/em.20650",null,7,"Environmental Sciences; Genetics & Heredity; Toxicology","Environmental Sciences & Ecology; Genetics & Heredity; Toxicology","811DL","WOS:000294182300001"]
[null,null,null,null,"J","Mameniskiene, R; Bast, T; Bentes, C; Canevini, MP; Dimova, P; Granata, T; Hogenhaven, H; Jakubi, BJ; Marusic, P; Melikyan, G; Michelucci, R; Mukhin, KY; Oehl, B; Ragona, F; Rossetti, AO; Rubboli, G; Schubert, S; Stephani, U; Strobel, J; Vignoli, A; Zarubova, J; Wolf, P",null,null,null,"Mameniskiene, Ruta; Bast, Thomas; Bentes, Carla; Canevini, Maria P.; Dimova, Petia; Granata, Tiziana; Hogenhaven, Hans; Jakubi, Bosanka Jocic; Marusic, Petr; Melikyan, Gayane; Michelucci, Roberto; Mukhin, Konstantin Y.; Oehl, Bernhard; Ragona, Francesca; Rossetti, Andrea O.; Rubboli, Guido; Schubert, Susanne; Stephani, Ulrich; Strobel, Julia; Vignoli, Aglaia; Zarubova, Jana; Wolf, Peter",null,null,"Clinical course and variability of non-Rasmussen, nonstroke motor and sensory epilepsia partialis continua: A European survey and analysis of 65 cases","EPILEPSIA",null,null,"English","Article",null,null,null,null,null,"Epilepsia partialis continua etiologies; Nonprogressive epilepsia partialis continua; Sensory epilepsia partialis continua; Focal status epilepticus; Aura continua; Developments of epilepsia partialis continua","STATUS EPILEPTICUS; EEG; FEATURES","Purpose: To gain new insights into the clinical presentation, causes, treatment and prognosis of epilepsia partialis continua (EPC), and to develop hypotheses to be tested in a prospective investigation. Methods: In this retrospective multicenter study, all cases were included that fulfilled these criteria: constantly repeated fragments of epileptic seizures, with preserved consciousness, lasting 1 h and representing locally restricted motor or sensory epileptic activity. Single episodes were included when they lasted for a minimum of 1 day. EPC with Rasmussen syndrome and acute stroke were excluded. Key Findings: Three time courses with two subtypes each were distinguished, that is, EPC as a solitary event (de novo or in preexistent epilepsy); chronic repetitive nonprogressive EPC (with frequent or rare episodes); and chronic persistent nonprogressive EPC (primarily or evolving out of an episodic course). These were unrelated to etiologies (morphologic lesions 34%, inflammatory 29%, systemic disorders 9%, idiopathic 5%, unknown 23%). Precipitation and inhibition of seizures is a frequent feature of EPC. Levetiracetam and topiramate have improved the possibilities for pharmacotherapy. Topiramate seems to be particularly effective with dysontogenetic etiologies. Significance: The existence of several clearly distinct courses of nonprogressive EPC is a new finding. These distinctions will be further investigated in a prospective study with precise protocols for electroencephalography (EEG), imaging, and other studies. This should better establish the relation of motor and somatosensory EPC; further clarify the relations, pathogenesis, and significance of the different types and their etiologies; and possibly identify more semiologic variants. It should also provide more precise knowledge about therapy and modification of ictogenesis by external stimuli.","[Mameniskiene, Ruta] Vilnius Univ Hosp, Santariskiu Klin, Dept Neurol, LT-08661 Vilnius, Lithuania; [Bast, Thomas] Epilepsy Ctr Kork, Kehl, Germany; [Bentes, Carla] Hosp Santa Maria, Dept Neurol, Lisbon, Portugal; [Canevini, Maria P.; Vignoli, Aglaia] Univ Milan, Epilepsy Ctr, San Paolo Hosp, Milan, Italy; [Dimova, Petia] St Naum Univ Hosp Neurol & Psychiat, Clin Child Neurol, Sofia, Bulgaria; [Granata, Tiziana; Ragona, Francesca] Fdn Ist Nazl Neurol C Besta, Milan, Italy; [Hogenhaven, Hans; Wolf, Peter] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark; [Jakubi, Bosanka Jocic] Dept Pediat Neurol, Pediat Clin, Nish, Serbia; [Marusic, Petr] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Prague, Czech Republic; [Melikyan, Gayane] Yerevan State Univ, Dept Neurol & Epileptol, Yerevan 375049, Armenia; [Michelucci, Roberto] Bellaria Hosp, Neurol Unit, Dept Neurosci, Bologna, Italy; [Mukhin, Konstantin Y.] Med Ctr Child Neurol & Epilepsy, Moscow, Russia; [Oehl, Bernhard] Univ Hosp Freiburg, Epilepsy Ctr, Freiburg, Germany; [Rossetti, Andrea O.] CHUV, Dept Neurol, Lausanne, Switzerland; [Schubert, Susanne] Univ Childrens Hosp, Dept Pediat Neurol, Heidelberg, Germany; [Stephani, Ulrich; Strobel, Julia] Univ Kiel, Neuropediat Dept, Kiel, Germany; [Zarubova, Jana] Thomayers Teaching Hosp, Postgrad Med Sch, Dept Neurol, Prague, Czech Republic; [Wolf, Peter] Epilepsy Ctr Bethel, Bielefeld, Germany; [Wolf, Peter] Danish Epilepsy Ctr, Dianalund, Denmark","Mameniskiene, R (reprint author), Vilnius Univ Hosp, Santariskiu Klin, Dept Neurol, Santariskiu 2, LT-08661 Vilnius, Lithuania.","ruta.mameniskiene@santa.lt","Stephani, Ulrich/D-1004-2010",null,null,null,null,40,9,10,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0013-9580",null,null,"EPILEPSIA","Epilepsia","JUN",2011,52,6,null,null,null,null,1168,1176,null,"10.1111/j.1528-1167.2010.02974.x",null,9,"Clinical Neurology","Neurosciences & Neurology","788QY","WOS:000292460700020"]
[null,null,null,null,"J","Frolich, L; Ashwood, T; Nilsson, J; Eckerwall, G",null,null,null,"Froelich, Lutz; Ashwood, Tim; Nilsson, Jonas; Eckerwall, Goran",null,"Sirocco Investigator","Effects of AZD3480 on Cognition in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase IIb Dose-Finding Study","JOURNAL OF ALZHEIMERS DISEASE",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; AZD3480; cognitive impairment; NNR agonist; randomized controlled trial","COMPUTERIZED ASSESSMENT SYSTEM; NICOTINIC RECEPTOR AGONIST; HEALTHY MALE-VOLUNTEERS; DOUBLE-BLIND; HUMAN BRAIN; ISPRONICLINE; DONEPEZIL; DEMENTIA; TC-1734; SUBTYPES","AZD3480 is a selective agonist of the central alpha 4 beta 2 and alpha 2 beta 2 neuronal nicotinic cholinergic receptors (NNRs). Its effects on cognition were investigated in 567 patients with mild-to-moderate Alzheimer's disease (AD) (Mini Mental State Examination [MMSE] 12-26). Mean baseline MMSE was 21 (SD +/- 3.7), with 61% of patients having mild disease (MMSE 21-26). Mean age was 74 (range 58-85) years. Patients were randomized to one of 5 treatment groups: AZD3480 5 mg, 20 mg or 35/100 mg, donepezil 10 mg (active comparator) or placebo, and treated once daily for 12 weeks. The primary outcome measure was change from baseline at Week 12 on the AD Assessment Scale-Cognitive Subscale (ADAS-Cog). Neither AZD3480 nor donepezil showed a statistically significant improvement versus placebo on ADAS-Cog. Improvements in a number of secondary outcome measures (MMSE, AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and Disability Assessment for Dementia [DAD]) were observed for AZD3480 and for donepezil. A post-hoc analysis on ADAS-Cog, excluding patients with very mild AD (MMSE 25-26) indicated improvement versus placebo for AZD3480 20 mg (-1.4, 95% CI: -3.0; 0.2) and donepezil (-1.0, 95% CI: -2.3; 0.3). AZD3480 was well tolerated. The study did not meet proof of concept criteria, since neither AZD3480 nor donepezil were statistically significantly superior to placebo on ADAS-Cog and was considered to be inconclusive. Further studies are required to determine the therapeutic potential of stimulating alpha 4 beta 2 receptors with NNRs in AD patients.","[Froelich, Lutz] Univ Heidelberg, Cent Inst Mental Hlth, Med Fac Mannheim, Div Geriatr Psychiat, D-68159 Mannheim, Germany; [Ashwood, Tim; Eckerwall, Goran] AstraZeneca R&D, Clin Neurosci, Sodertalje, Sweden; [Nilsson, Jonas] AstraZeneca R&D, Stat & Informat, Sodertalje, Sweden","Frolich, L (reprint author), Univ Heidelberg, Cent Inst Mental Hlth, Med Fac Mannheim, Div Geriatr Psychiat, Sq J 5, D-68159 Mannheim, Germany.","lutz.froelich@zi-mannheim.de",null,null,"AstraZeneca Ltd.; NIA Alzheimer's Disease Cooperative Study [AG 10483]","The study was sponsored by AstraZeneca Ltd.The ADCS-CGIC was used with permission from the NIA Alzheimer's Disease Cooperative Study (NIA Grant AG 10483).","Albert SM, 1996, J AM GERIATR SOC, V44, P1342; Birks J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD005593; Birks J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001190.pub2.; Bohme GA, 2004, DRUG DEVELOP RES, V62, P26, DOI 10.1002/ddr.10352; Breese CR, 2000, NEUROPSYCHOPHARMACOL, V23, P351, DOI 10.1016/S0893-133X(00)00121-4; Buccafusco JJ, 2005, TRENDS PHARMACOL SCI, V26, P352, DOI 10.1016/j.tips.2005.05.007; COHENMANSFIELD J, 1989, J GERONTOL, V44, pM77; Cummings JL, 2004, NEW ENGL J MED, V351, P56; DUNBAR G, 2010, J PSYCHOPHARMACOL, DOI DOI 10.1177/0269881110367727; Dunbar G, 2007, PSYCHOPHARMACOLOGY, V191, P919, DOI 10.1007/s00213-006-0675-x; Dunbar G, 2006, J CLIN PHARMACOL, V46, P715, DOI 10.1177/0091270006288730; Dunbar GC, 2006, J MOL NEUROSCI, V30, P169, DOI 10.1385/JMN/30:1-2:169; DUNBAR GC, 2006, 9 INT GEN SPRINGF S; Dunbar GC, 2007, J PSYCHOPHARMACOL, V21, P171, DOI 10.1177/0269881107066855; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gatto GJ, 2004, CNS DRUG REV, V10, P147; Gauthier S, 1997, Int Psychogeriatr, V9 Suppl 1, P163, DOI 10.1017/S1041610297004857; Gelinas I, 1999, AM J OCCUP THER, V53, P471; Gold M, 2009, ALZHEIMERS DEMENT, V5, P86; Gotti C, 2006, TRENDS PHARMACOL SCI, V27, P482, DOI 10.1016/j.tips.2006.07.004; GURLEY D, 2008, 2008 NEUR M PLANN WA, P172; Harrison J, 2007, ARCH NEUROL-CHICAGO, V64, P1323, DOI 10.1001/archneur.64.9.1323; Levin ED, 2006, PSYCHOPHARMACOLOGY, V184, P523, DOI 10.1007/s00213-005-0164-7; Maher-Edwards G, 2008, ALZHEIMERS DEMENT S2, V4, pT772, DOI 10.1016/j.jalz.2008.05.2411; MAZZULLA EC, 2009, SOC NEUROSCIENCE ANN, P771; McShane R, 2006, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003154.PUB5; Mohr E, 1996, Int Psychogeriatr, V8, P397, DOI 10.1017/S1041610296002761; MOORE WC, 2008, 2008 NEUR M PLANN WA, P167; Newhouse P, 1996, DRUG DEVELOP RES, V38, P278, DOI 10.1002/(SICI)1098-2299(199607/08)38:3/4<278::AID-DDR17>3.0.CO;2-V; NICHOLL CG, 1995, INT J GERIATR PSYCH, V10, P199, DOI 10.1002/gps.930100306; Paterson D, 2000, PROG NEUROBIOL, V61, P75, DOI 10.1016/S0301-0082(99)00045-3; Perry E, 2000, EUR J PHARMACOL, V393, P215, DOI 10.1016/S0014-2999(00)00064-9; Rogers SL, 1998, NEUROLOGY, V50, P136; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; SIMPSON PM, 1991, INT J GERIATR PSYCH, V6, P95, DOI 10.1002/gps.930060208; ZARIT S, 1985, HIDDEN VICTIMS ALZHE, P73; Zarit S. H., 2002, FAMILY PROFESSIONAL, P20; ZARIT SH, 1980, GERONTOLOGIST, V20, P649; ZARIT SH, 1986, GERONTOLOGIST, V26, P260",41,9,10,"IOS PRESS","AMSTERDAM","NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS","1387-2877",null,null,"J ALZHEIMERS DIS","J. Alzheimers Dis.",null,2011,24,2,null,null,null,null,363,374,null,"10.3233/JAD-2010-101554",null,12,"Neurosciences","Neurosciences & Neurology","747WS","WOS:000289352400015"]
[null,null,null,null,"J","Honetschlagerova, Z; Huskova, Z; Vanourkova, Z; Sporkova, A; Kramer, HJ; Hwang, SH; Tsai, HJ; Hammock, BD; Imig, JD; Cervenka, L; Kopkan, L",null,null,null,"Honetschlaegerova, Zuzana; Huskova, Zuzana; Vanourkova, Zdenka; Sporkova, Alexandra; Kramer, Herbert J.; Hwang, Sung Hee; Tsai, Hsing-Ju; Hammock, Bruce D.; Imig, John D.; Cervenka, Ludek; Kopkan, Libor",null,null,"Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension","JOURNAL OF PHYSIOLOGY-LONDON",null,null,"English","Article",null,null,null,null,null,null,"INTRARENAL ANGIOTENSIN-II; END-ORGAN DAMAGE; DEPENDENT MALIGNANT HYPERTENSION; AT(1) RECEPTOR BLOCKADE; ARACHIDONIC-ACID; NITRIC-OXIDE; EPOXYEICOSATRIENOIC ACIDS; BLOOD-PRESSURE; IN-VITRO; INFLAMMATION","Non-technical summary Arachidonic acid metabolites called epoxyeicosatrienoic acids (EETs) influence vascular tone and renal tubular sodium and water transport and thus have been implicated in the control of blood pressure. Inhibition of the enzyme soluble epoxide hydrolase (sEH), which reduces EET degradation to the corresponding diols, leads to substantial attenuation of malignant hypertension in a transgenic rat strain harbouring the mouse renin gene particularly via an improvement of renal function. The observed antihypertensive and renoprotective effects of this novel pharmacological approach provide a potentially new direction in antihypertensive therapy. Abstract In the present study, we examined the effects of soluble epoxide hydrolase (sEH) inhibition on the development of angiotensin II-dependent hypertension and on renal function in transgenic rats with inducible expression of the mouse renin gene (strain name Cyp1a1-Ren-2). Hypertension was induced in these rats by indole-3-carbinol (I3C; 0.3% in the diet) for 12 days. The sEH inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (c-AUCB) was given in two doses (13 or 26 mg l-1) in drinking water. Blood pressure (BP), body weight (BW) and renal excretory parameters were monitored in conscious animals during the experiment. Renal haemodynamics was assessed at the end of treatment in anaesthetized rats. I3C administration resulted in severe hypertension with a rise in systolic BP from 118 +/- 2 to 202 +/- 3 mmHg, a loss of BW from 266 +/- 5 to 228 +/- 4 g and a rise in proteinuria from 14 +/- 2 to 34 +/- 3 mg day-1. Both doses of c-AUCB significantly attenuated the development of hypertension (systolic BP of 181 +/- 4 and 176 +/- 4 mmHg, respectively), the loss in BW (256 +/- 4 and 259 +/- 3 g, respectively) and the degree of proteinuria (27 +/- 2 and 25 +/- 3 mg day-1, respectively) to a similar extent. Moreover, c-AUCB prevented the reduction in renal plasma flow (5.4 +/- 0.4 vs. 4.6 +/- 0.3 ml min-1 g-1) and significantly increased sodium excretion (0.84 +/- 0.16 vs. 0.38 +/- 0.08 mu mol min-1 g-1) during I3C administration. These data suggest that the oral administration of c-AUCB displays antihypertensive effects in Ren-2 transgenic rats with inducible malignant hypertension via an improvement of renal function.","[Honetschlaegerova, Zuzana; Huskova, Zuzana; Vanourkova, Zdenka; Sporkova, Alexandra; Cervenka, Ludek; Kopkan, Libor] Inst Clin & Expt Med, Dept Expt Med, CZ-14021 Prague 4, Czech Republic; [Honetschlaegerova, Zuzana; Huskova, Zuzana; Vanourkova, Zdenka; Sporkova, Alexandra; Kopkan, Libor] Cardiovasc Res Ctr, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany; [Hwang, Sung Hee; Tsai, Hsing-Ju; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic; [Hwang, Sung Hee; Tsai, Hsing-Ju; Hammock, Bruce D.] Univ Calif Davis, UCD Canc Ctr, Davis, CA 95616 USA","Kopkan, L (reprint author), Inst Clin & Expt Med, Dept Expt Med, Videnska 1958-9, CZ-14021 Prague 4, Czech Republic.","libor.kopkan@ikem.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA) [NS/9699-4]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Center for Cardiovascular Research [1M6798582302]; Grant Agency of the Academy of Science of the Czech Republic [KJB 502030801]; Czech Science Foundation (GACR) [305/08/P053, P303/10/P170, 305/08/J006]; Deutsche Forschungsgemeinschaft (DFG) [436 TSE 113/57/0-1]; Deutscher Akademischer Austauschdienst (DAAD); NIH [HL59699, DK38226]; Howard Hughes Foundation; NIEHS [R01 ES02710, P42 ES004699]; IGA [NS/10499-3]; EU [CZ.2.16/3.1.00/22126]","This study was supported by grant NS/9699-4 awarded to L.K. by the Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA) and also by institutional finance support from the Institute for Clinical and Experimental Medicine (no. MZO 00023001) and financial support from the Center for Cardiovascular Research (no. 1M6798582302). L.K. and Z.Ho. are also partly supported by grant KJB 502030801 from the Grant Agency of the Academy of Science of the Czech Republic. Z.Hu. is supported by grant No. 305/08/P053 and A.S. is supported by grant P303/10/P170 awarded by the Czech Science Foundation (GACR). H.J.K. is supported by the Deutsche Forschungsgemeinschaft (DFG) No. 436 TSE 113/57/0-1 and Deutscher Akademischer Austauschdienst (DAAD). J.D.I. is an Established Investigator of the American Heart Association and these studies were supported by NIH grants HL59699 and DK38226. H.-J.T. was supported in part by the Howard Hughes Foundation and a fellowship from the NIEHS Supported Basic Research Program. Partial support was provided by NIEHS Grant R01 ES02710 and NIEHS Superfund Basic Research Program P42 ES004699 awarded to B.D.H.. L.C. is currently supported by grant No. 305/08/J006 (GACR) and grant NS/10499-3 (IGA). This study was also supported by the EU by the Operational Program Prague - Competitiveness; project 'CEVKOON' (no. CZ.2.16/3.1.00/22126).",null,47,9,9,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0022-3751",null,null,"J PHYSIOL-LONDON","J. Physiol.-London","JAN",2011,589,1,null,null,null,null,207,219,null,"10.1113/jphysiol.2010.199505",null,13,"Neurosciences; Physiology","Neurosciences & Neurology; Physiology","700RB","WOS:000285760900020"]
[null,null,null,null,"J","Witso, E; Tapia, G; Cinek, O; Pociot, FM; Stene, LC; Ronningen, KS",null,null,null,"Witso, Elisabet; Tapia, German; Cinek, Ondrej; Pociot, Flemming Michael; Stene, Lars C.; Ronningen, Kjersti S.",null,null,"Polymorphisms in the Innate Immune IFIH1 Gene, Frequency of Enterovirus in Monthly Fecal Samples during Infancy, and Islet Autoimmunity","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"BETA-CELL AUTOIMMUNITY; BLOOD MONONUCLEAR-CELLS; FUNCTION MUTATIONS; RISK-FACTOR; RIG-I; TYPE-1; INFECTIONS; RNA; ASSOCIATION; CHILDREN","Interferon induced with helicase C domain 1 (IFIH1) senses and initiates antiviral activity against enteroviruses. Genetic variants of IFIH1, one common and four rare SNPs have been associated with lower risk for type 1 diabetes. Our aim was to test whether these type 1 diabetes-associated IFIH1 polymorphisms are associated with the occurrence of enterovirus infection in the gut of healthy children, or influence the lack of association between gut enterovirus infection and islet autoimmunity. After testing of 46,939 Norwegian newborns, 421 children carrying the high risk genotype for type 1 diabetes (HLA-DR4-DQ8/DR3-DQ2) as well as 375 children without this genotype were included for monthly fecal collections from 3 to 35 months of age, and genotyped for the IFIH1 polymorphisms. A total of 7,793 fecal samples were tested for presence of enterovirus RNA using real time reverse transcriptase PCR. We found no association with frequency of enterovirus in the gut for the common IFIH1 polymorphism rs1990760, or either of the rare variants of rs35744605, rs35667974, rs35337543, while the enterovirus prevalence marginally differed in samples from the 8 carriers of a rare allele of rs35732034 (26.1%, 18/69 samples) as compared to wild-type homozygotes (12.4%, 955/7724 samples); odds ratio 2.5, p = 0.06. The association was stronger when infections were restricted to those with high viral loads (odds ratio 3.3, 95% CI 1.3-8.4, p = 0.01). The lack of association between enterovirus frequency and islet autoimmunity reported in our previous study was not materially influenced by the IFIH1 SNPs. We conclude that the type 1 diabetes-associated IFIH1 polymorphisms have no, or only minor influence on the occurrence, quantity or duration of enterovirus infection in the gut. Its effect on the risk of diabetes is likely to lie elsewhere in the pathogenic process than in the modification of gut infection.","[Witso, Elisabet; Tapia, German; Stene, Lars C.] Norwegian Inst Publ Hlth, Oslo, Norway; [Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Pociot, Flemming Michael] Glostrup Res Inst, Glostrup, Denmark; [Ronningen, Kjersti S.] Univ Oslo, Rikshosp, Oslo Univ Hosp, N-0027 Oslo, Norway","Witso, E (reprint author), Norwegian Inst Publ Hlth, Oslo, Norway.","elisabet.witso@gmail.com",null,null,"Norwegian Organization for Health and Rehabilitation [2008/0182]; Ministry of Education of the Czech Republic [MSM0021620814]; Ministry of Health of the Czech Republic [IGA MZ 11465-5]; Research Council of Norway [135893/330, 155300/320, 156477/730, 166515/V50]; Norwegian Diabetes Association; Sigurd K. Thoresen's Legacy","This study and the MIDIA project were funded by the Norwegian Organization for Health and Rehabilitation (2008/0182), the Ministry of Education of the Czech Republic (grant MSM0021620814) and the Ministry of Health of the Czech Republic (IGA MZ 11465-5), the Research Council of Norway (grants 135893/330, 155300/320, 156477/730, and 166515/V50), the Norwegian Diabetes Association and Sigurd K. Thoresen's Legacy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,39,6,7,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA","1932-6203",null,null,"PLOS ONE","PLoS One","NOV 14",2011,6,11,null,null,null,null,null,null,"e27781","10.1371/journal.pone.0027781",null,6,"Multidisciplinary Sciences","Science & Technology - Other Topics","855HK","WOS:000297554300053"]
[null,null,null,null,"J","Pfister, R; Cairns, R; Erdmann, E; Schneider, CA",null,null,null,"Pfister, R.; Cairns, R.; Erdmann, E.; Schneider, C. A.",null,"PROactive Invest","Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study","DIABETIC MEDICINE",null,null,"English","Article",null,null,null,null,null,"atrial fibrillation; bundle branch block; diabetes; heart rate; QT-interval","ELEVATED HEART-RATE; PIOGLITAZONE CLINICAL-TRIAL; OF-CARDIOLOGY FOUNDATION; CORONARY-ARTERY-DISEASE; BUNDLE-BRANCH BLOCK; QT INTERVAL; ATRIAL-FIBRILLATION; ASSOCIATION ELECTROCARDIOGRAPHY; AHA/ACCF/HRS RECOMMENDATIONS; ARRHYTHMIAS COMMITTEE","Aims Although a resting electrocardiograph is broadly applied in clinical practice for evaluating patients with Type 2 diabetes and cardiovascular disease, the independent prognostic relevance of electrocardiographic signs has not thoroughly been examined. Methods Baseline 12-lead electrocardiographs available in 5231 of the 5238 participants of the PROactive trial were analysed for heart rate, heart rate corrected QT-interval, presence of atrial fibrillation/flutter, left axis deviation, right and left bundle branch block. The association of electrocardiographic signs with total mortality, the principal secondary composite endpoint (death, myocardial infarction and stroke) and serious adverse heart failure events was examined by Cox-regression analysis. Results Two hundred and twenty-three (4.3%) patients showed atrial fibrillation/flutter, 213 (4.1%) patients had right bundle branch block, 111 (2.1%) patients had left bundle branch block and 706 (13.5%) patients had left axis deviation. Mean cQT-interval was 418 ms (+/- 25 ms) and mean heart rate was 72/min (+/- 14/min). In multivariate adjusted analyses, heart rate and cQT-interval were significantly associated with mortality, the composite secondary endpoint and heart failure, whereas right and left bundle branch blocks were significantly associated with heart failure only. Left axis deviation was associated with heart failure and atrial fibrillation/flutter was associated with mortality and heart failure in univariate but not multivariate analyses. Conclusion Easily assessable electrocardiographic signs such as heart rate, cQT-interval and bundle branch blocks were predictive for adverse outcome independently of multiple risk factor adjustment and should be considered in clinical care.","[Pfister, R.; Erdmann, E.; Schneider, C. A.] Univ Cologne, Herzzentrum, Dept Internal Med 3, D-50937 Cologne, Germany; [Cairns, R.] Isaac Newton Ctr, Nottingham, England","Pfister, R (reprint author), Univ Cologne, Herzzentrum, Dept Internal Med 3, Kerpenerstr 62, D-50937 Cologne, Germany.","roman.pfister@uk-koeln.de",null,null,"Takeda Europe R&D Centre Ltd., London, UK; Eli Lilly and Company, Indianapolis, IN, USA","This study was funded by Takeda Europe R&D Centre Ltd., London, UK and Eli Lilly and Company, Indianapolis, IN, USA. We would like to thank the PROactive investigators (see also Supporting Information, Appendix S1) and Z. Tolman for his help in editing the manuscript.","Boccalandro F, 2003, AM J CARDIOL, V92, P544, DOI 10.1016/S0002-9149(03)00722-7; Boner G, 2005, DIABETOLOGIA, V48, P1980, DOI 10.1007/s00125-005-1893-1; Butler J, 2008, CIRC-HEART FAIL, V1, P125, DOI 10.1161/CIRCHEARTFAILURE.108.768457; Cardoso CRL, 2003, J DIABETES COMPLICAT, V17, P169, DOI 10.1016/S1056-8727(02)00206-4; Charbonnel B, 2004, DIABETES CARE, V27, P1647, DOI 10.2337/diacare.27.7.1647; Chugh SS, 2009, CIRCULATION, V119, P663, DOI 10.1161/CIRCULATIONAHA.108.797035; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Du X, 2009, EUR HEART J, V30, P1128, DOI 10.1093/eurheartj/ehp055; Erdmann E, 2007, DIABETES CARE, V30, P2773, DOI 10.2337/dc0-0717; EWING DJ, 1991, DIABETOLOGIA, V34, P182, DOI 10.1007/BF00418273; Festa A, 2000, AM J CARDIOL, V86, P1117, DOI 10.1016/S0002-9149(00)01170-X; Giannoglou GD, 2008, INT J CARDIOL, V126, P302, DOI 10.1016/j.ijcard.2007.08.077; Guzman E, 2004, ANN NONINVAS ELECTRO, V9, P362, DOI 10.1111/j.1542-474X.2004.94577.x; Jeong Joon Hoon, 2004, Korean Journal of Internal Medicine, V19, P171; Kannell WB, 1999, ARCH INTERN MED, V159, P1197, DOI 10.1001/archinte.159.11.1197; KANNEL WB, 1985, AM HEART J, V109, P876, DOI 10.1016/0002-8703(85)90653-2; Linnemann B, 2003, EXP CLIN ENDOCR DIAB, V111, P215; Nichols GA, 2009, DIABETES CARE, V32, P1851, DOI 10.2337/dc09-0939; Okin PM, 2004, DIABETES, V53, P434, DOI 10.2337/diabetes.53.2.434; Palatini P, 2006, J HYPERTENS, V24, P603, DOI 10.1097/01.hjh.0000217838.49842.1e; Rautaharju PM, 2009, CIRCULATION, V119, pE241, DOI 10.1161/CIRCULATIONAHA.108.191096; SAGIE A, 1992, AM J CARDIOL, V70, P797, DOI 10.1016/0002-9149(92)90562-D; Schnabel RB, 2009, LANCET, V373, P739, DOI 10.1016/S0140-6736(09)60443-8; Stern S, 2009, CIRCULATION, V120, P1633, DOI 10.1161/CIRCULATIONAHA.109.897496; Stettler C, 2007, DIABETOLOGIA, V50, P186, DOI 10.1007/s00125-006-0483-1; Sumner G, 2009, J CARDIOVASC ELECTR, V20, P781, DOI 10.1111/j.1540-8167.2009.01440.x; Surawicz B, 2009, J AM COLL CARDIOL, V53, P976, DOI 10.1016/j.jacc.2008.12.013; Tikkanen JT, 2009, NEW ENGL J MED, V361, P2529, DOI 10.1056/NEJMoa0907589; Vinik AI, 2003, DIABETES CARE, V26, P1553, DOI 10.2337/diacare.26.5.1553",29,6,6,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0742-3071",null,null,"DIABETIC MED","Diabetic Med.","OCT",2011,28,10,null,null,null,null,1206,1212,null,"10.1111/j.1464-5491.2011.03281.x",null,7,"Endocrinology & Metabolism","Endocrinology & Metabolism","821VX","WOS:000295003600013"]
[null,null,null,null,"J","Urayama, KY; Holcatova, I; Janout, V; Foretova, L; Fabianova, E; Adamcakova, Z; Ryska, M; Martinek, A; Shonova, O; Brennan, P; Scelo, G",null,null,null,"Urayama, Kevin Y.; Holcatova, Ivana; Janout, Vladimir; Foretova, Lenka; Fabianova, Eleonora; Adamcakova, Zora; Ryska, Miroslav; Martinek, Arnost; Shonova, Olga; Brennan, Paul; Scelo, Ghislaine",null,null,"Body mass index and body size in early adulthood and risk of pancreatic cancer in a central European multicenter case-control study","INTERNATIONAL JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"body mass index; body size; pancreatic cancer; risk factor; weight gain","PHYSICAL-ACTIVITY; BREAST-CANCER; ANTHROPOMETRIC FACTORS; OBESITY; COHORT; POPULATION; WOMEN; METAANALYSIS; ADIPOSITY; HISTORY","The relationship between two measures of excess body weight, body mass index (BMI) and body size score, and risk of pancreatic cancer was examined among 574 pancreatic cancer cases and 596 frequency-matched controls from the Czech Republic and Slovakia enrolled between 2004 and 2009. Analyses using multivariable logistic regression showed an increased risk of pancreatic cancer associated with elevated quartiles of BMI at ages 20 [fourth quartile: odds ratio (OR) = 1.79, 95% confidence interval (CI): 1.23, 2.61] and 40 (fourth quartile: OR = 1.57, 95% CI: 1.09, 2.27) compared to the lowest quartile. Consistent results were observed for body size score at ages 20 (high versus low: OR = 1.66, 95% CI: 1.08, 2.57) and 40 (medium versus low: OR = 1.36, 95% CI: 1.00, 1.86), but no association was found for BMI and body size score at 2 years before the interview. Stronger risk estimates for BMI were observed in males than females, particularly at age 20, but the analysis of body size yielded similar estimates by sex. When considering excess body weight at both ages 20 and 40 jointly, the highest risk estimates were observed among subjects with elevated levels at both time periods in the analysis of BMI (OR = 1.86, 95% CI: 1.32, 2.62) and body size (OR = 1.53, 95% CI: 1.09, 2.13). These findings, based on two different measures, provide strong support for an increased risk of pancreatic cancer associated with excess body weight, possibly strongest during early adulthood.","[Scelo, Ghislaine] Int Agcy Res Canc, Genet Epidemiol Grp, F-69008 Lyon, France; [Holcatova, Ivana] Charles Univ Prague, Inst Hyg & Epidemiol, Fac Med 1, Prague, Czech Republic; [Janout, Vladimir] Palacky Univ, Fac Med, Dept Prevent Med, CR-77147 Olomouc, Czech Republic; [Foretova, Lenka] Masaryk Mem Canc Inst, Dept Canc Epidemiol & Genet, Brno, Czech Republic; [Fabianova, Eleonora; Adamcakova, Zora] Reg Author Publ Hlth Banska Bystrica, Banska Bystrica, Slovakia; [Ryska, Miroslav] Charles Univ Prague, Sch Med 2, Dept Surg, Prague, Czech Republic; [Ryska, Miroslav] CMH, Prague, Czech Republic; [Martinek, Arnost] Univ Ostrava, Fac Med, Dept Internal Med, Ostrava, Czech Republic; [Shonova, Olga] Reg Hosp, Dept Gastroenterol, Ceske Budejovice, Czech Republic","Scelo, G (reprint author), Int Agcy Res Canc, Genet Epidemiol Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.","scelog@iarc.fr",null,null,"US National Cancer Institute at the National Institutes of Health [R03 CA123546-02]; Ministry of Health of the Czech Republic [NR 9029-4/2006, MZ0 MOU 2005, NR9422-3, NR9998-3]; Ministry of Health of Slovakia [MZSR2007/17-RUVZBB-02]","Grant sponsor: US National Cancer Institute at the National Institutes of Health; Grant number: R03 CA123546-02; Grant sponsor: Ministry of Health of the Czech Republic; Grant numbers: NR 9029-4/2006, MZ0 MOU 2005, NR9422-3, NR9998-3; Grant sponsor: Ministry of Health of Slovakia; Grant number: MZSR2007/17-RUVZBB-02",null,50,3,3,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0020-7136",null,null,"INT J CANCER","Int. J. Cancer","DEC 15",2011,129,12,null,null,null,null,2875,2884,null,"10.1002/ijc.25959",null,10,"Oncology","Oncology","853WM","WOS:000297456400012"]
[null,null,null,null,"J","Steiner, B; Rosendahl, J; Witt, H; Teich, N; Keim, V; Schulz, HU; Pfutzer, R; Luhr, M; Gress, TM; Nickel, R; Landt, O; Koudova, M; Macek, M; Farre, A; Casals, T; Desax, MC; Gallati, S; Gomez-Lira, M; Audrezet, MP; Ferec, C; des Georges, M; Claustres, M; Truninger, K",null,null,null,"Steiner, Bernhard; Rosendahl, Jonas; Witt, Heiko; Teich, Niels; Keim, Volker; Schulz, Hans-Ulrich; Pfuetzer, Roland; Luhr, Matthias; Gress, Thomas M.; Nickel, Renate; Landt, Olfert; Koudova, Monika; Macek, Milan, Jr.; Farre, Antoni; Casals, Teresa; Desax, Marie-Claire; Gallati, Sabina; Gomez-Lira, Macarena; Audrezet, Marie Pierre; Ferec, Claude; des Georges, Marie; Claustres, Mireille; Truninger, Kaspar",null,null,"Common CFTR Haplotypes and Susceptibility to Chronic Pancreatitis and Congenital Bilateral Absence of the Vas Deferens","HUMAN MUTATION",null,null,"English","Article",null,null,null,null,null,"CFTR; CBAVD; idiopathic chronic pancreatitis","IDIOPATHIC CHRONIC-PANCREATITIS; CONDUCTANCE REGULATOR GENE; CYSTIC-FIBROSIS GENE; DISSEMINATED BRONCHIECTASIS; MUTATIONS; POPULATION; POLYMORPHISMS; VARIANT; RECONSTRUCTION; ASSOCIATION","CFTR mutations enhance susceptibility for idiopathic chronic pancreatitis (ICP) and congenital bilateral absence of the vas deferens (CBAVD); however, it is unknown why CFTR heterozygotes are at increased disease risk. We recently showed that common CFTR variants are associated with aberrantly spliced transcripts. Here, we genotyped for common CFTR variants and tested for associations in two ICP (ICP-A: 126 patients, 319 controls; ICP-B: 666 patients, 1,181 controls) and a CBAVD population (305 patients, 319 controls). Haplotype H10 (TG11-T7-470V) conferred protection (ICP-A: OR 0.19, P<0.0001; ICP-B: OR 0.78, P=0.06; CBAVD OR 0.08, P<0.001), whereas haplotype H3 (TG10-T7-470M) increased disease risk (ICP-A: OR 8.34, P=0.003; ICP-B: OR 1.88, P=0.007; CBAVD: OR 5.67, P=0.01). The risk of heterozygous CFTR mutations carriers for ICP (OR 2.44, P<0.001) and CBAVD (OR 14.73, P<0.001) was fully abrogated by the H10/H10 genotype. Similarly, ICP risk of heterozygous p.Asn34Ser SPINK1 mutation carriers (OR 10.34, P<0.001) was compensated by H10/H10. Thus, common CFTR haplotypes modulate ICP and CBAVD susceptibility alone and in heterozygous CFTR and p.Asn34Ser mutation carriers. Determination of these haplotypes helps to stratify carriers into high-and low-risk subjects, providing helpful information for genetic counseling. Hum Mutat 32:912-920, 2011. (C) 2011 Wiley-Liss, Inc.","[Truninger, Kaspar] SRO Hosp Langenthal, Clin Internal Med, Div Gastroenterol, Langenthal, Switzerland; [Steiner, Bernhard] Univ Zurich, Cantonal Hosp Lucerne, Schwerzenbach & Childrens Hosp, Inst Med Genet, Luzern, Switzerland; [Rosendahl, Jonas; Keim, Volker] Univ Leipzig, Dept Gastroenterol & Hepatol, Leipzig, Germany; [Witt, Heiko] Campus Virchow Klinikum, Charite, Dept Gastroenterol & Hepatol, Berlin, Germany; [Teich, Niels] Internist Gemeinschaftspraxis Verdauungs & Stoffw, Leipzig, Germany; [Schulz, Hans-Ulrich] Otto Von Guericke Univ, Dept Surg, Magdeburg, Germany; [Pfuetzer, Roland] Evangel Krankenhaus Kalk GmbH, Div Internal Med, Cologne, Germany; [Luhr, Matthias] Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden; [Gress, Thomas M.] Univ Marburg, Dept Gastroenterol Endocrinol & Metab, Marburg, Germany; [Nickel, Renate] Charite, Dept Pediat, Berlin, Germany; [Landt, Olfert] TIB MOLBIOL GmbH, Berlin, Germany; [Koudova, Monika; Macek, Milan, Jr.] Univ Hosp Motol, Cyst Fibrosis Ctr, Dept Biol & Med Genet, Prague, Czech Republic; [Koudova, Monika; Macek, Milan, Jr.] Second Fac Med, Prague, Czech Republic; [Farre, Antoni] Hosp Santa Creu & S Pau, Dept Gastroenterol, Barcelona, Spain; [Casals, Teresa] IDIBELL, Med & Mol Genet Ctr, Barcelona, Spain; [Desax, Marie-Claire] Cantonal Hosp Olten, Dept Internal Med, Olten, Switzerland; [Gallati, Sabina] Univ Bern, Inselspital, Dept Pediat, Div Human Genet, CH-3010 Bern, Switzerland; [Gomez-Lira, Macarena] Univ Verona, Sect Biol & Genet, Dept Life & Reprod Sci, I-37100 Verona, Italy; [Audrezet, Marie Pierre; Ferec, Claude] Univ Bretagne Occidentale, INSERM, Brest, France; [des Georges, Marie; Claustres, Mireille] CHU Montpellier, Hop Arnaud de Villeneuve, Genet Mol Lab, Montpellier, France; [des Georges, Marie; Claustres, Mireille] INSERM, U827, Montpellier, France; [des Georges, Marie; Claustres, Mireille] Univ Montpellier 1, UFR Med, Montpellier, France","Truninger, K (reprint author), SRO Hosp Langenthal, Clin Internal Med, Div Gastroenterol, Langenthal, Switzerland.","k.truninger@sro.ch","Casals, Teresa/K-4587-2012; LABO, U827/A-8632-2008","Casals, Teresa/0000-0001-6078-2823; ","Amelie Waring-Stiftung [MZ0FNM2005, FIS PI080041]; Swiss National Foundation [3200-066767.01, 310000-112652, ISCiii G03/156, PI050804]; Hanne Lieberman-Stiftung, Zurich, Switzerland","Contract grant sponsor: Amelie Waring-Stiftung; Contract grant numbers: MZ0FNM2005 (to M.M.Jr.); FIS PI080041 (to T. C.); Contract grant sponsor: The Swiss National Foundation; Contract grant numbers: 3200-066767.01; 310000-112652 (to S. G.); ISCiii G03/156; FIS/FEDER PI050804 (to T. C.); Contract grant sponsor: Hanne Lieberman-Stiftung, Zurich, Switzerland (to K. T.).",null,35,3,3,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1059-7794",null,null,"HUM MUTAT","Hum. Mutat.","AUG",2011,32,8,null,null,null,null,912,920,null,"10.1002/humu.21511",null,9,"Genetics & Heredity","Genetics & Heredity","808EW","WOS:000293961000008"]
[null,null,null,null,"J","Hanova, M; Vodickova, L; Vaclavikova, R; Smerhovsky, Z; Stetina, R; Hlavac, P; Naccarati, A; Slyskova, J; Polakova, V; Soucek, P; Kumar, R; Hemminki, K; Vodicka, P",null,null,null,"Hanova, Monika; Vodickova, Ludmila; Vaclavikova, Radka; Smerhovsky, Zdenek; Stetina, Rudolf; Hlavac, Pavel; Naccarati, Alessi; Slyskova, Jana; Polakova, Veronika; Soucek, Pavel; Kumar, Rajiv; Hemminki, Kari; Vodicka, Pavel",null,null,"DNA damage, DNA repair rates and mRNA expression levels of cell cycle genes (Tp53, p21(CDKNIA), BCL2 and BAX) with respect to occupational exposure to styrene","CARCINOGENESIS",null,null,"English","Article",null,null,null,null,null,null,"SINGLE-STRAND BREAKS; POLYMORPHISMS; P53; WORKERS; ASSOCIATION; BIOMARKERS; P21; SUSCEPTIBILITY; P21(WAF1/CIP1); LYMPHOCYTES","We studied the relationship between DNA damage, DNA repair rates and messenger RNA (mRNA) expression levels of cell cycle genes TP53, p21(CDKNIA), BCL2 and BAX in a group of 71 styrene-exposed workers and 51 control individuals. The exposure was assessed by measuring the concentration of styrene at workplace and in blood. Parameters of DNA damage [measured as single-strand breaks (SSBs) and endonuclease III-sensitive sites], gamma-irradiation-specific DNA repair rates and mRNA levels of studied genes were analyzed in peripheral blood lymphocytes. The workers were divided into low (<50 mg/m(3)) and high (>50 mg/m(3)) styrene exposure groups. We found negative correlations between mRNA expression of TP53, BCL2, BAX and styrene exposure (P < 0.001 for all parameters). In contrast, p21(CDKNIA) mRNA expression significantly increased with increasing styrene exposure (P = 0.001). SSBs and endonuclease Insensitive sites increased with increasing mRNA levels of TP53 (P < 0.001 for both) and BCL2 (P = 0.038, P = 0.002, respectively), whereas the same parameters decreased with increasing mRNA levels of p21(CDKNIA) (P < 0.001, P = 0.007, respectively). gamma-Irradiation-specific DNA repair rates increased with p21(CDKNIA) mRNA levels up to the low exposure level (P = 0.044). Our study suggests a possible relationship between styrene exposure, DNA damage and transcript levels of key cell cycle genes.","[Hanova, Monika; Vodickova, Ludmila; Naccarati, Alessi; Slyskova, Jana; Polakova, Veronika; Vodicka, Pavel] Acad Sci Czech Republic, Dept Mol Biol Canc, Inst Expt Med, Prague 4, Czech Republic; [Hanova, Monika; Slyskova, Jana] Charles Univ Prague, Dept Genet & Microbiol, Fac Sci, CR-12844 Prague 2, Czech Republic; [Vodickova, Ludmila; Vaclavikova, Radka; Smerhovsky, Zdenek; Soucek, Pavel] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042 10, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; [Stetina, Rudolf] Purkinje Mil Med Acad, Dept Toxicol, Hradec Kralove 50001, Czech Republic; [Hlavac, Pavel] Dept Occupat Med, Reg Hyg Stn, Hradec Kralove 50101, Czech Republic; [Kumar, Rajiv; Hemminki, Kari] DKFZ, German Canc Res Ctr, D-69120 Heidelberg, Germany","Vodicka, P (reprint author), Acad Sci Czech Republic, Dept Mol Biol Canc, Inst Expt Med, Videnska 1083, Prague 4, Czech Republic.","pvodicka@biomed.cas.cz",null,null,"Grant Agency of the Academy of Sciences of the CR [IAA500390806]; Grant Agency of the Czech Republic-The Czech Science Foundation (Grantova agentura Ceske republiky) [310/07/1430, A/CZ0046/2/0012]","The Grant Agency of the Academy of Sciences of the CR (IAA500390806), Grant Agency of the Czech Republic-The Czech Science Foundation (Grantova agentura Ceske republiky) (310/07/1430, A/CZ0046/2/0012).",null,36,1,1,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0143-3334",null,null,"CARCINOGENESIS","Carcinogenesis","JAN",2011,32,1,null,null,null,null,74,79,null,"10.1093/carcin/bgq213",null,6,"Oncology","Oncology","707RF","WOS:000286303000012"]
[null,null,null,null,"J","Pietrzak, A; Chodorowska, G; Jazienicka, I; Osemlak, P; Wawrzycki, B; Terlecki, P; Mieczkowska, J; Mosiewicz, J; Zubilewicz, T; Szubstarski, F; Krupski, W; Hercogova, J; Szepietowski, JC; Lotti, T",null,null,null,"Pietrzak, Aldona; Chodorowska, Grazyna; Jazienicka, Iwona; Osemlak, Pawel; Wawrzycki, Bartlomiej; Terlecki, Piotr; Mieczkowska, Jolanta; Mosiewicz, Jerzy; Zubilewicz, Tomasz; Szubstarski, Franciszek; Krupski, Witold; Hercogova, Jana; Szepietowski, Jacek C.; Lotti, Torello",null,null,"Psoriatic erythroderma coexisting with erythema multiforme-like lesions induced by retinoids or retinoids combined with an antibiotic: case report","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"erythema multiforme-like lesions; erytroderma; psoriasis; treatment","PLAQUE PSORIASIS; THERAPY","Psoriasis is currently considered a multifactorial disease, which can coexist with many somatic and psychological disorders. We present the case of a 50-year-old woman referred to our department due to erythroderma with concomitant peculiar violaceous, polycyclic lesions most likely induced by medications. Past medical history revealed numerous systemic disorders, including metabolic syndrome, hypertension, cardiac insufficiency, obesity, and depression. Additional examinations and consultations demonstrated dyslipidemia, xanthelasma, incomplete block of the right branch of His bundle, thyreocardiac syndrome, benign adrenal tumor, and delusions. Recently, psoriasis has been intensively studied. We present the case in which erythroderma was most likely triggered by acitretin combined with ceftriaxone. Treatment of many diseases and psychiatric disturbances coexisting with psoriasis is extremely difficult and requires cooperation of various specialists.","[Pietrzak, Aldona; Chodorowska, Grazyna; Jazienicka, Iwona; Wawrzycki, Bartlomiej] Med Univ Lublin, Dept Dermatol Venereol & Pediat Dermatol, PL-20080 Lublin, Poland; [Osemlak, Pawel] Med Univ Lublin, Dept Pediat Surg & Traumatol, PL-20080 Lublin, Poland; [Terlecki, Piotr; Zubilewicz, Tomasz] Med Univ Lublin, Dept Vasc Surg & Angiol, PL-20080 Lublin, Poland; [Mieczkowska, Jolanta; Mosiewicz, Jerzy] Med Univ Lublin, Dept Internal Dis, PL-20080 Lublin, Poland; [Krupski, Witold] Med Univ Lublin, Dept Radiol 2, PL-20080 Lublin, Poland; [Szubstarski, Franciszek] 1st Mil Hosp, Dept Pathomorphol, Lublin, Poland; [Szepietowski, Jacek C.] Wroclaw Med Univ, Dept Dermatol Venereol & Allergol, Wroclaw, Poland; [Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatol, Prague, Czech Republic; [Lotti, Torello] Univ Rome G Marconi, Dept Dermatol & Venereol 2, Rome, Italy","Pietrzak, A (reprint author), Med Univ Lublin, Dept Dermatol Venereol & Pediat Dermatol, Radziwillowska 13, PL-20080 Lublin, Poland.","aldonkapietrzak@tlen.pl",null,null,null,null,null,16,0,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","NOV-DEC",2011,24,6,null,null,null,null,587,590,null,"10.1111/j.1529-8019.2012.01410.x",null,4,"Dermatology","Dermatology","928SQ","WOS:000303004600010"]
[null,null,null,null,"J","Novy, P; Urban, J; Leuner, O; Vadlejch, J; Kokoska, L",null,null,null,"Novy, Pavel; Urban, Jan; Leuner, Olga; Vadlejch, Jaroslav; Kokoska, Ladislav",null,null,"In vitro synergistic effects of baicalin with oxytetracycline and tetracycline against Staphylococcus aureus","JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY",null,null,"English","Article",null,null,null,null,null,"antimicrobial agents; flavonoid; staphylococci; synergy","BETA-LACTAMS; RESISTANT","Objectives: In this study we examined the in vitro synergistic effect of baicalin, the flavone constituent of Scutellaria spp., in combinations with oxytetracycline and tetracycline on the growth of Staphylococcus aureus. Methods: The MICs were determined by the broth microdilution method and the effect of combinations was evaluated according to the sum of fractional inhibitory concentration indices (FICIs). Results: Synergistic activity (FICI <= 0.5) was observed for combinations of baicalin with oxytetracycline or tetracycline against 4 of 10 strains tested, whereas the baicalin/oxytetracycline combination possessed the strongest synergistic effect (FICI=0.418). Conclusions: Baicalin acts synergistically with oxytetracycline and tetracycline, enhancing its antimicrobial activity against S. aureus, including methicillin- and tetracycline-resistant strains.","[Novy, Pavel; Leuner, Olga; Kokoska, Ladislav] Czech Univ Life Sci Prague, Inst Trop & Subtrop, Dept Crop Sci & Agroforestry, Prague 16521 6, Suchdol, Czech Republic; [Urban, Jan] Natl Inst Publ Hlth, Natl Reference Lab Disinfect & Sterilizat, Prague 10042 10, Czech Republic; [Vadlejch, Jaroslav; Kokoska, Ladislav] Czech Univ Life Sci Prague, Fac Agrobiol Food & Nat Resources, Dept Zool & Fisheries, Prague 16521 6, Suchdol, Czech Republic","Kokoska, L (reprint author), Czech Univ Life Sci Prague, Inst Trop & Subtrop, Dept Crop Sci & Agroforestry, Kamycka 129, Prague 16521 6, Suchdol, Czech Republic.","kokoska@its.czu.cz","Leuner, Olga/F-9239-2012; Novy, Pavel/C-1704-2013",null,"CSF [525/08/H060]; MSM [6046070901]","This research was supported by projects CSF 525/08/H060 and MSM 6046070901.","Chang Ping-Chin, 2007, Journal of Microbiology Immunology and Infection, V40, P56; Clinical and Laboratory Standards Institute, 2009, M07A8 CLSI; European Committee for Antimicrobial Susceptibility Testing, 2000, CLIN MICROBIOL INFEC, V6, P503; Fujita M, 2005, MICROBIOL IMMUNOL, V49, P391; Gibbons S, 2008, PLANTA MED, V74, P594, DOI 10.1055/s-2008-1074518; Liu IX, 2000, J PHARM PHARMACOL, V52, P361, DOI 10.1211/0022357001773922; Li-Weber M, 2009, CANCER TREAT REV, V35, P57, DOI 10.1016/j.ctrv.2008.09.005; Odds FC, 2003, J ANTIMICROB CHEMOTH, V52, P1, DOI 10.1093/jac/dkg301; Ruhe JJ, 2005, CLIN INFECT DIS, V40, P1429, DOI 10.1086/429628; Zhao WH, 2001, ANTIMICROB AGENTS CH, V45, P1737, DOI 10.1128/AAC.45.6.1737-1742.2001",10,7,9,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0305-7453",null,null,"J ANTIMICROB CHEMOTH","J. Antimicrob. Chemother.","JUN",2011,66,6,null,null,null,null,1298,1300,null,"10.1093/jac/dkr108",null,3,"Infectious Diseases; Microbiology; Pharmacology & Pharmacy","Infectious Diseases; Microbiology; Pharmacology & Pharmacy","763VM","WOS:000290587800018"]
[null,null,null,null,"J","Pokorna, M; Necas, E; Skripsky, R; Kratochvil, J; Andrlik, M; Franek, O",null,null,null,"Pokorna, Milana; Necas, Emanuel; Skripsky, Roman; Kratochvil, Jaroslav; Andrlik, Michal; Franek, Ondrej",null,null,"How accurately can the aetiology of cardiac arrest be established in an out-of-hospital setting? Analysis by \"Concordance in Diagnosis Crosscheck Tables\"","RESUSCITATION",null,null,"English","Article",null,null,null,null,null,"Aetiology of cardiac arrest; Out-of-hospital care; Cardiopulmonary resuscitation; Thrombolytic therapy; Myocardial infarction; Pulmonary embolism","AUSTRALIAN-RESUSCITATION-COUNCIL; AMERICAN-HEART-ASSOCIATION; BASIC LIFE-SUPPORT; CARDIOPULMONARY-RESUSCITATION; STROKE-FOUNDATION; UTSTEIN STYLE; SUDDEN-DEATH; TASK-FORCE; SURVIVAL; DISEASE","Introduction: Several previous studies have focused on establishing the cause of cardiac arrest (CA) during cardiopulmonary resuscitation (CPR) provided in an out-of-hospital setting. Objectives: To analyze the ability of professional advanced life support providers to correctly establish the aetiology of cardiac arrest during out-of-hospital CPR. Study design: A retrospective cohort study analysing 211 cases of out-of-hospital cardiac arrest. Method: The aetiology assumed by out-of-hospital physicians was compared with the diagnosis that was later established by clinicians or pathologists. Results: Cases were sorted into five diagnostic groups and the overall diagnostic concordance was 74.4% (157 of 211 cases). The cardiac aetiology was presumed in 132 out of 211 patients and confirmed in 135 out of 211 patients. However, an analysis of individual cases of the cardiac causes of cardiac arrest revealed diagnostic matches in only 112 cases. Acute myocardial infarction (AMI) or pulmonary embolism (PE), both of which represent cases that can be potentially influenced by thrombolytic therapy, were presumed in 74 (53 + 21) and confirmed in 97 (77 + 20) cases, however with individual diagnostic matches in only 55 cases. Conclusion: This study demonstrates the importance of analysing concordance in presumed and definitive diagnosis of individual cases, since an overall comparison in a cohort of cases may be highly misleading. It introduces the method of the crosscheck table for visualization and comparison of presumed and final diagnoses. The two alternative approaches of inclusion rule for applying the thrombolytic therapy in out-of-hospital care were discussed with regard to the recent TROICA study. (C) 2010 Elsevier Ireland Ltd. All rights reserved.","[Pokorna, Milana; Skripsky, Roman; Kratochvil, Jaroslav; Franek, Ondrej] Emergency Med Serv Prague, Prague 10100 10, Czech Republic; [Pokorna, Milana; Kratochvil, Jaroslav] Univ Hosp Motol, Emergency Dept, Prague 15006, Czech Republic; [Pokorna, Milana; Skripsky, Roman] Charles Univ Prague, Fac Med 1, Dept Anesthesiol & Intens Care, Prague 14000, Czech Republic; [Necas, Emanuel; Andrlik, Michal] Charles Univ Prague, Fac Med 1, Inst Pathol Physiol, Prague 12800, Czech Republic","Pokorna, M (reprint author), Emergency Med Serv Prague, Korunni 98, Prague 10100 10, Czech Republic.","MilanaP@seznam.cz",null,null,"Ministry of Health of the Czech Republic [IGA NR/7970-3];  [MSM 0021620806]","The work was supported by the grants IGA NR/7970-3 provided by the Ministry of Health of the Czech Republic and MSM 0021620806. We would like to thank Petra Sukupova for her help in collecting data from the hospitals and all cooperative physicians of Prague's hospitals and departments of pathology.",null,40,2,2,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0300-9572",null,null,"RESUSCITATION","Resuscitation","APR",2011,82,4,null,null,null,null,391,397,null,"10.1016/j.resuscitation.2010.11.026",null,7,"Critical Care Medicine; Emergency Medicine","General & Internal Medicine; Emergency Medicine","750NS","WOS:000289555800006"]
[null,null,null,null,"J","Arboleda, D; Forostyak, S; Jendelova, P; Marekova, D; Amemori, T; Pivonkova, H; Masinova, K; Sykova, E",null,null,null,"Arboleda, David; Forostyak, Serhiy; Jendelova, Pavla; Marekova, Dana; Amemori, Takashi; Pivonkova, Helena; Masinova, Katarina; Sykova, Eva",null,null,"Transplantation of Predifferentiated Adipose-Derived Stromal Cells for the Treatment of Spinal Cord Injury","CELLULAR AND MOLECULAR NEUROBIOLOGY",null,null,"English","Article",null,null,null,null,null,"Adipose tissue; Differentiation; Mesenchymal stromal cells; Spinal cord lesion; Transplantation","MESENCHYMAL STEM-CELLS; BONE-MARROW; TISSUE-REPAIR; IN-VITRO; GROWTH; DIFFERENTIATION; RATS; EXPRESSION; NEUROSPHERES; RECOVERY","Adipose-derived stromal cells (ASCs) are an alternative source of stem cells for cell-based therapies of neurological disorders such as spinal cord injury (SCI). In the present study, we predifferentiated ASCs (pASCs) and compared their behavior with na < ve ASCs in vitro and after transplantation into rats with a balloon-induced compression lesion. ASCs were predifferentiated into spheres before transplantation, then pASCs or ASCs were injected intraspinally 1 week after SCI. The cells' fate and the rats' functional outcome were assessed using behavioral, histological, and electrophysiological methods. Immunohistological analysis of pASCs in vitro revealed the expression of NCAM, NG2, S100, and p75. Quantitative RT-PCR at different intervals after neural induction showed the up-regulated expression of the glial markers NG2 and p75 and the neural precursor markers NCAM and Nestin. Patch clamp analysis of pASCs revealed three different types of membrane currents; however, none were fast activating Na(+) currents indicating a mature neuronal phenotype. Significant improvement in both the pASC and ASC transplanted groups was observed in the BBB motor test. In vivo, pASCs survived better than ASCs did and interacted closely with the host tissue, wrapping host axons and oligodendrocytes. Some transplanted cells were NG2- or CD31-positive, but no neuronal markers were detected. The predifferentiation of ASCs plays a beneficial role in SCI repair by promoting the protection of denuded axons; however, functional improvements were comparable in both the groups, indicating that repair was induced mainly through paracrine mechanisms.","[Arboleda, David; Forostyak, Serhiy; Jendelova, Pavla; Marekova, Dana; Amemori, Takashi; Pivonkova, Helena; Masinova, Katarina; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Vvi, Prague 14220 4, Czech Republic; [Arboleda, David; Forostyak, Serhiy; Jendelova, Pavla; Marekova, Dana; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic","Jendelova, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Vvi, Videnska 1083, Prague 14220 4, Czech Republic.","pavla.jendelova@lfmotol.cuni.cz; sykova@biomed.cas.cz",null,null," [AV0Z50390703];  [AVOZ50390512];  [1M0538];  [GA CR 309/08/H079];  [GA CR 305/09/0717];  [GA CR 304/10/0320];  [IAA50390902]","This study was supported by the grants AV0Z50390703, AVOZ50390512, 1M0538, GA CR 309/08/H079, GA CR 305/09/0717, GA CR 304/10/0320, and IAA50390902. The authors thank James Dutt for the critical reading of the manuscript.",null,44,18,19,"SPRINGER/PLENUM PUBLISHERS","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0272-4340",null,null,"CELL MOL NEUROBIOL","Cell. Mol. Neurobiol.","OCT",2011,31,7,null,null,null,null,1113,1122,null,"10.1007/s10571-011-9712-3",null,10,"Cell Biology; Neurosciences","Cell Biology; Neurosciences & Neurology","824AA","WOS:000295169500017"]
[null,null,null,null,"J","Marek, J; Tomek, V; Skovranek, J; Povysilova, V; Samanek, M",null,null,null,"Marek, Jan; Tomek, Viktor; Skovranek, Jan; Povysilova, Viera; Samanek, Milan",null,null,"Prenatal ultrasound screening of congenital heart disease in an unselected national population: a 21-year experience","HEART",null,null,"English","Article",null,null,null,null,null,null,"OUTLET RIGHT VENTRICLE; FETAL DIAGNOSIS; CARDIAC-MALFORMATIONS; AORTIC-VALVE; SURVIVAL; FETUSES; PREVALENCE; CHILDREN; BORN; ECHOCARDIOGRAPHY","Objective To determine the prevalence and spectrum of congenital heart disease (CHD) and the impact of a national prenatal ultrasound screening programme on outcome in a well-characterised population. Design and setting A comprehensive registry was created of all paediatric and fetal patients with CHD over a 21-year period (1986-2006) in the Czech Republic. The centralised healthcare system enabled confirmation of prenatal and postnatal findings clinically and by post mortem. Patients and results In the entire cohort of 9475 fetuses referred for detailed cardiac evaluation, 1604 (16.9%) had CHD, of which 501 (31.2%) had additional extracardiac anomalies. In the pregnancies which continued, 59 (8.6%) of 685 fetuses died in utero, and 626 (91.4%) babies were born alive. Prenatal detection rate was highest in double outlet right ventricle (77.3%) and hypoplastic left heart (50.6%). Detection rate increased significantly (p<0.001) for 12/17 lesions comparing 1986-1999 and 2000-2006. In recent years, detection of hypoplastic left heart reached 95.8% while transposition of the great arteries was diagnosed antenatally in only 25.6%. Conclusion The nationwide prenatal ultrasound screening programme enabled detection of major cardiac abnormalities in 1/3 of patients born with any CHD and 80% of those with critical forms. Nevertheless, owing to the severity of lesions and associated extracardiac anomalies, the overall mortality of antenatally diagnosed CHD remains high. These findings are important for the understanding natural history of CHD for the establishing of screening programmes in Europe.","[Marek, Jan; Tomek, Viktor; Skovranek, Jan; Samanek, Milan] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Marek, Jan; Tomek, Viktor; Skovranek, Jan; Samanek, Milan] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Povysilova, Viera] Univ Hosp Motol, Inst Pathol & Mol Biol, Sch Med 2, Prague, Czech Republic","Marek, J (reprint author), Great Ormond St Hosp Sick Children, London WC1N 3JH, England.","marekj@gosh.nhs.uk",null,null,"Ministry of Health of the Czech Republic [MZO-0064203/6203]","This work was supported by a grant from the Ministry of Health of the Czech Republic: MZO-0064203/6203.",null,39,20,24,"B M J PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","1355-6037",null,null,"HEART","Heart","JAN",2011,97,2,null,null,null,null,124,130,null,"10.1136/hrt.2010.206623",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","695OE","WOS:000285380800008"]
[null,null,null,null,"J","Fric, P; Gabrovska, D; Nevoral, J",null,null,null,"Fric, Premysl; Gabrovska, Dana; Nevoral, Jiri",null,null,"Celiac disease, gluten-free diet, and oats","NUTRITION REVIEWS",null,null,"English","Review",null,null,null,null,null,"avenin; celiac disease; gluten-free diet; oats","T-CELL RESPONSES; DERMATITIS-HERPETIFORMIS; CEREAL PROTEINS; VILLOUS ATROPHY; TOXIC GLIADIN; UNITED-STATES; CHILDREN; ADULT; FOODS; AVENINS","Oats in a gluten-free diet increase the diet's nutritional value, but their use remains controversial. Contamination with prolamins of other cereals is frequent, and some clinical and experimental studies support the view that a subgroup of celiac patients may be intolerant to pure oats. Thus, this issue is more complex than previously suggested. In order to produce oats that are safe for all celiac patients, the following topics should be addressed: selection of oat cultivars with low avenin content, research on such recombinant varieties of oats, development of assay methods to detect avenins in oat products, guidelines for the agricultural processing of oats and the manufacture of oat products, as well as guidelines for following up with celiac patients who consume oats.","[Fric, Premysl] Charles Univ Prague, Dept Med, Fac Med 1, CZ-16902 Prague 6, Czech Republic; [Fric, Premysl] Charles Univ Prague, Cent Mil Hosp, CZ-16902 Prague 6, Czech Republic; [Gabrovska, Dana] Food Res Inst, Dept Nutrit Subst, Prague, Czech Republic; [Nevoral, Jiri] Charles Univ Prague, Dept Pediat, Fac Med 2, CZ-16902 Prague, Czech Republic; [Nevoral, Jiri] Charles Univ Prague, Hosp Motol, CZ-16902 Prague, Czech Republic","Fric, P (reprint author), Charles Univ Prague, Dept Med, Fac Med 1, CZ-16902 Prague 6, Czech Republic.","premysl.fric@uvn.cz",null,null,null,null,null,75,5,6,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0029-6643",null,null,"NUTR REV","Nutr. Rev.","FEB",2011,69,2,null,null,null,null,107,115,null,"10.1111/j.1753-4887.2010.00368.x",null,9,"Nutrition & Dietetics","Nutrition & Dietetics","715LI","WOS:000286885600005"]
[null,null,null,null,"J","Bombieri, C; Claustres, M; De Boeck, K; Derichs, N; Dodge, J; Girodon, E; Sermet, I; Schwarz, M; Tzetis, M; Wilschanski, M; Bareil, C; Bilton, D; Castellani, C; Cuppens, H; Cutting, GR; Drevinek, P; Farrell, P; Elborn, JS; Jarvi, K; Kerem, B; Kerem, E; Knowles, M; Macek, M; Munck, A; Radojkovic, D; Seia, M; Sheppard, DN; Southern, KW; Stuhrmann, M; Tullis, E; Zielenski, J; Pignatti, PF; Ferec, C",null,null,null,"Bombieri, C.; Claustres, M.; De Boeck, K.; Derichs, N.; Dodge, J.; Girodon, E.; Sermet, I.; Schwarz, M.; Tzetis, M.; Wilschanski, M.; Bareil, C.; Bilton, D.; Castellani, C.; Cuppens, H.; Cutting, G. R.; Drevinek, P.; Farrell, P.; Elborn, J. S.; Jarvi, K.; Kerem, B.; Kerem, E.; Knowles, M.; Macek, M., Jr.; Munck, A.; Radojkovic, D.; Seia, M.; Sheppard, D. N.; Southern, K. W.; Stuhrmann, M.; Tullis, E.; Zielenski, J.; Pignatti, P. F.; Ferec, C.",null,null,"Recommendations for the classification of diseases as CFTR-related disorders","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Article",null,null,null,null,null,"CFTR-related disorders; CBAVD (Congenital Bilateral Absence of Vas Deferens); Pancreatitis; Bronchiectasis; Functional tests; NPD (Nasal Potential Difference); ICM (Intestinal Current Measurement)","FIBROSIS-TRANSMEMBRANE-CONDUCTANCE; CONGENITAL BILATERAL ABSENCE; REGULATOR GENE-MUTATIONS; IDIOPATHIC CHRONIC-PANCREATITIS; RESIDUAL CHLORIDE SECRETION; NASAL POTENTIAL DIFFERENCE; CATIONIC TRYPSINOGEN GENE; ALCOHOLIC CHRONIC-PANCREATITIS; DELTA-F508 HOMOZYGOUS TWINS; ION-CHANNEL FUNCTION","Several diseases have been clinically or genetically related to cystic fibrosis (CF), but a consensus definition is lacking. Here, we present a proposal for consensus guidelines on cystic fibrosis transmembrane conductance regulator (CFTR)-related disorders (CFTR-RDs), reached after expert discussion and two dedicated workshops. A CFTR-RD may be defined as \"a clinical entity associated with CFTR dysfunction that does not fulfil diagnostic criteria for CF\". The utility of sweat testing, mutation analysis, nasal potential difference, and/or intestinal current measurement for the differential diagnosis of CF and CFTR-RD is discussed. Algorithms which use genetic and functional diagnostic tests to distinguish CF and CFTR-RDs are presented. According to present knowledge, congenital bilateral absence of vas deferens (CBAVD), acute recurrent or chronic pancreatitis and disseminated bronchiectasis, all with CFTR dysfunction, are CFTR-RDs. (C) 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Bombieri, C.; Pignatti, P. F.] Univ Verona, Dept Life & Reprod Sci, Sect Biol & Genet, I-37134 Verona, Italy; [Claustres, M.; Bareil, C.] CHU Montpellier, Lab Genet Mol, Montpellier, France; [Claustres, M.; Bareil, C.] IURC, INSERM, U827, Montpellier, France; [De Boeck, K.] Univ Hosp, Dept Pediat Pediat Pulmonol, Louvain, Belgium; [Derichs, N.] Hannover Med Sch, CF Ctr, D-30623 Hannover, Germany; [Dodge, J.] Univ Wales Swansea, Dept Child Hlth, Singleton Hosp, Swansea SA2 8QA, W Glam, Wales; [Girodon, E.] Grp Hosp Henri Mondor, APHP, Serv Biochim Genet, Creteil, France; [Girodon, E.] Hop Henri Mondor, INSERM, Equipe 11, U955, F-94010 Creteil, France; [Sermet, I.] Univ Paris 05, Hop Necker, F-75015 Paris, France; [Schwarz, M.] St Marys Hosp, Reg Mol Genet Serv, Manchester M13 0JH, Lancs, England; [Tzetis, M.] Univ Athens, Dept Med Genet, St Sophias Childrens Hosp, Athens, Greece; [Wilschanski, M.] Hadassah Univ Hosp, Pediat Gastroenterol Unit, IL-91120 Jerusalem, Israel; [Wilschanski, M.] Hadassah Univ Hosp, Cyst Fibrosis Ctr, IL-91120 Jerusalem, Israel; [Bilton, D.] Royal Brompton Hosp, London SW3 6LY, England; [Castellani, C.] Univ Integrata Verona, Verona Cyst Fibrosis Ctr, Azienda Osped, Verona, Italy; [Cuppens, H.] Katholieke Univ Leuven, Dept Human Genet, B-3000 Louvain, Belgium; [Cutting, G. R.] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Sch Med, Baltimore, MD 21287 USA; [Drevinek, P.] Charles Univ Prague, Dept Pediat, Fac Med 2, CZ-15006 Prague, Czech Republic; [Drevinek, P.] Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Farrell, P.] Univ Wisconsin, Dept Pediat & Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI USA; [Elborn, J. S.] Queens Univ, Sch Med Dent & Biomed Sci, Belfast BT7 1NN, Antrim, North Ireland; [Jarvi, K.] Univ Toronto, Mt Sinai Hosp, Div Urol, Toronto, ON M5G 1X5, Canada; [Kerem, B.] Hebrew Univ Jerusalem, Dept Genet, Inst Life Sci, IL-91904 Jerusalem, Israel; [Kerem, E.] Hadassah Hebrew Univ, Dept Pediat & Pediat Pulmonol, Med Ctr, Jerusalem, Israel; [Knowles, M.] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Centerr, Chapel Hill, NC 27599 USA; [Macek, M., Jr.] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, CZ-15006 Prague, Czech Republic; [Munck, A.] Univ Hosp Robert Debre, AP HP, Dept Pediat Gastroenterol & Nutr, CF Ctr, F-75019 Paris, France; [Radojkovic, D.] Univ Belgrade, Inst Mol Genet & Genet Engn, Belgrade, Serbia; [Seia, M.] Osped Maggiore Policlin, Lab Genet Med, Fdn IRCCS Ca Granda, Milan, Italy; [Sheppard, D. N.] Univ Bristol, Sch Physiol & Pharmacol, Bristol BS8 1TD, Avon, England; [Southern, K. W.] Univ Liverpool, Inst Child Hlth, Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England; [Stuhrmann, M.] Hannover Med Sch, Inst Human Genet, D-3000 Hannover, Germany; [Tullis, E.] Univ Toronto, Adult Cyst Fibrosis Ctr, St Michaels Hosp, Toronto, ON M5S 1A1, Canada; [Tullis, E.] Univ Toronto, Div Respirol, Dept Med, Toronto, ON M5S 1A1, Canada; [Zielenski, J.] Hosp Sick Children, Genet & Genom Biol Program, Toronto, ON M5G 1X8, Canada; [Ferec, C.] CHU Brest, Genet Mol Genet Epidemiol INSERM U613, Lab Mol Genet, F-29200 Brest, France","Ferec, C (reprint author), CHU Brest, Genet Mol Genet Epidemiol INSERM U613, Lab Mol Genet, 46 Rue Felix Le Dantec, F-29200 Brest, France.","claude.ferec@univ-brest.fr","LABO, U827/A-8632-2008",null,"European Union [LSHM-CT-2005-018932]; Czech Ministry of Health [MZ0FNM2005]","We would like to particularly thank, Dr Dominique Hubert (Paris), Dr Dominique Grenet (Suresnes), Dr Laurence Bassinet (Creteil), Dr Vincent Izard (Clamart), Dr Jean-Claude Soufir (Paris) and Dr Jean-Marc Rigot (Lille) for their excellent assistance with the diagnostic algorithms and Drs Peter Durie and Tanja Gonska (Toronto) for stimulating discussions. This work was supported by the European Union Sixth Framework Programme (contract no. LSHM-CT-2005-018932, EuroCareCF) and the Czech Ministry of Health (MZ0FNM2005 to Milan Macek Jr).",null,170,35,35,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","JUN",2011,10,null,null,2,null,null,"S86","S102",null,null,null,17,"Respiratory System","Respiratory System","783FX","WOS:000292068000014"]
[null,null,null,null,"J","Shestivska, V; Nemec, A; Drevinek, P; Sovova, K; Dryahina, K; Spanel, P",null,null,null,"Shestivska, Violetta; Nemec, Alexandr; Drevinek, Pavel; Sovova, Kristyna; Dryahina, Kseniya; Spanel, Patrik",null,null,"Quantification of methyl thiocyanate in the headspace of Pseudomonas aeruginosa cultures and in the breath of cystic fibrosis patients by selected ion flow tube mass spectrometry","RAPID COMMUNICATIONS IN MASS SPECTROMETRY",null,null,"English","Article",null,null,null,null,null,null,"SOLID-PHASE MICROEXTRACTION; HYDROGEN-CYANIDE; SIFT-MS; BRONCHOALVEOLAR LAVAGE; AIR; CHILDREN; O-2(+); H3O+; NO+","Infection by Pseudomonas aeruginosa (PA) is a major cause of morbidity and mortality in patients with cystic fibrosis (CF). Breath analysis could potentially be a useful diagnostic of such infection, and analyses of volatile organic compounds (VOCs) emitted from PA cultures are an important part of the search for volatile breath markers of PA lung infection. Our pilot experiments using solid-phase microextraction, SPME and gas chromatography/mass spectrometric (GC/MS) analyses of volatile compounds produced by PA strains indicated a clear presence of methyl thiocyanate. This provided a motivation to develop a method for real-time online quantification of this compound by selected ion flow tube mass spectrometry, SIFT-MS. The kinetics of reactions of H(3)O(+), NO(+) and O(2)(+center dot) with methyl thiocyanate at 300K were characterized and the characteristic product ions determined (proton transfer for H3O+, rate constant 4.6 x 10(-9) cm(3) s(-1); association for NO(+), 1.7 x 10(-9) cm(3) s(-1) and nondissociative charge transfer for O(2)(+center dot), 4.3 x 10(-9) cm(3) s(-1)). The kinetics library was extended by a new entry for methyl thiocyanate accounting for overlaps with isotopologues of hydrated hydronium ions. Solubility of methyl thiocyanate in water (Henry's law constant) was determined using standard reference solutions and the linearity and limits of detection of both SIFT-MS and SPME-GC/MS methods were characterized. Thirty-six strains of PA with distinct genotype were cultivated under identical conditions and 28 of them (all also producing HCN) were found to release methyl thiocyanate in headspace concentrations greater than 6 parts per billion by volume (ppbv). SIFT-MS was also used to analyze the breath of 28 children with CF and the concentrations of methyl thiocyanate were found to be in the range 2-21 ppbv (median 7 ppbv). Copyright (C) 2011 John Wiley & Sons, Ltd.","[Shestivska, Violetta; Sovova, Kristyna; Dryahina, Kseniya; Spanel, Patrik] Acad Sci Czech Republic, J Heyrovsky Inst Phys Chem, CR-18223 Prague 8, Czech Republic; [Nemec, Alexandr] Ctr Epidemiol & Microbiol, Natl Inst Publ Hlth, Prague 10042, Czech Republic; [Drevinek, Pavel] Charles Univ Prague, Sch Med 2, Dept Paediat, Prague 15006 5, Czech Republic; [Sovova, Kristyna] Charles Univ Prague, Fac Sci, Dept Phys Macromol Chem, Prague 12840 2, Czech Republic","Spanel, P (reprint author), Acad Sci Czech Republic, J Heyrovsky Inst Phys Chem, Dolejskova 3, CR-18223 Prague 8, Czech Republic.","spanel@jh-inst.cas.cz","Nemec, Alexandr/C-4447-2008; Spanel, Patrik/B-6574-2008","Nemec, Alexandr/0000-0003-0608-9598; Spanel, Patrik/0000-0002-9868-8282","GACR [203/09/0256, 203/09/P172]","We gratefully acknowledge funding for this study by GACR (Project Nos. 203/09/0256 and 203/09/P172). We are grateful to all the patients participating in the breath analysis study and their parents, to the staff of the CF clinic, especially to the paediatric nurse Katerina Austova for assisting with the patient admissions, and to Martina Maixnerova for her help in cultivating the PA strains. We would also like to thank David Smith for reading and correcting the manuscript.",null,30,28,28,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0951-4198",null,null,"RAPID COMMUN MASS SP","Rapid Commun. Mass Spectrom.","SEP 15",2011,25,17,null,null,null,null,2459,2467,null,"10.1002/rcm.5146",null,9,"Biochemical Research Methods; Chemistry, Analytical; Spectroscopy","Biochemistry & Molecular Biology; Chemistry; Spectroscopy","812DE","WOS:000294267200013"]
[null,null,null,null,"J","MacManus, DG; Miller, DH; Kappos, L; Gold, R; Havrdova, E; Limmroth, V; Polman, CH; Schmierer, K; Yousry, TA; Eraksoy, M; Meluzinova, E; Dufek, M; Yang, M; O'Neill, GN; Dawson, K",null,null,null,"MacManus, D. G.; Miller, D. H.; Kappos, L.; Gold, R.; Havrdova, E.; Limmroth, V.; Polman, C. H.; Schmierer, K.; Yousry, T. A.; Eraksoy, M.; Meluzinova, E.; Dufek, M.; Yang, M.; O'Neill, G. N.; Dawson, K.",null,null,"BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis","JOURNAL OF NEUROLOGY",null,null,"English","Article",null,null,null,null,null,"Clinical trial; Multiple sclerosis; MRI; Dimethyl fumarate; BG-12; Hypointense lesions","RESONANCE-IMAGING FINDINGS; T1-WEIGHTED SPIN-ECHO; FUMARIC-ACID ESTERS; HYPOINTENSE LESIONS; NRF2; ACTIVATION; EXPRESSION; GENES; CELLS; INDUCTION","BG-12, an immunomodulatory agent, reduces frequency of new gadolinium-enhancing (Gd+) lesions in relapsing multiple sclerosis (MS). This study reports the effect of 240 mg BG-12 orally three times daily (tid) for 24 weeks on the evolution of new Gd+ lesions to T1-hypointense lesions. Brain magnetic resonance imaging (MRI) scans from patients in placebo and 240 mg BG-12 tid arms of a phase 2b study were examined retrospectively. Included patients had at least one new Gd+ lesion from weeks 4 to 12. Week 24 scans were analyzed for number and proportion of new Gd+ lesions that evolved to T1-hypointense lesions. Eighteen patients receiving BG-12 and 38 patients receiving placebo were included in the analysis. The analysis tracked 147 new Gd+ lesions in patients from the BG-12 group and 221 Gd+ lesions in patients from the placebo group. The percentage of Gd+ lesions that evolved to T1-hypointense lesions was 34% lower with BG-12 treatment versus placebo (29%, BG-12; 44%, placebo; odds ratio 0.51; 95% confidence interval 0.43, 0.61; p < 0.0001). In addition to reducing frequency of new Gd+ lesions, BG-12 significantly reduced probability of their evolution to T1-hypointense lesions in patients with MS compared with placebo.","[MacManus, D. G.; Miller, D. H.; Schmierer, K.; Yousry, T. A.] UCL, Inst Neurol, NMR Res Unit, London WC1N 3BG, England; [Schmierer, K.] Barts & London Queen Marys Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Neurosci & Trauma, Neuroimmunol Grp, London E1 1BB, England; [Kappos, L.] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Gold, R.] St Josef Hosp, Univ Clin Bochum, D-44791 Bochum, Germany; [Havrdova, E.] Charles Univ Prague, Fac Med 1, Prague 12108 2, Czech Republic; [Limmroth, V.] Univ Cologne, Cologne City Hosp, D-51109 Cologne, Germany; [Polman, C. H.] Vrije Univ Amsterdam Med Ctr, NL-1007 MB Amsterdam, Netherlands; [Eraksoy, M.] Istanbul Univ, Istanbul Fac Med, Dept Neurol, Istanbul, Turkey; [Meluzinova, E.] Charles Univ Prague, Motol Univ Hosp, Sch Med 2, Dept Neurol, Prague, Czech Republic; [Dufek, M.] Masaryk Univ, CS-60177 Brno, Czech Republic; [Yang, M.; O'Neill, G. N.; Dawson, K.] Biogen Idec Inc, Cambridge, MA 02142 USA","Miller, DH (reprint author), UCL, Inst Neurol, NMR Res Unit, London WC1N 3BG, England.","d.miller@ion.ucl.ac.uk","Yousry, Tarek/B-3417-2009",null,"Biogen Idec, Inc.; Swiss MS Society; Czech Ministry of Education [MSM 0021620849]; Biogen Idec; UK Department of Health's National Institute for Health Research Biomedical Research Center (UCLH/UCL Comprehensive Biomedical Research Trust); MS Society of Great Britain and Northern Ireland; GlaxoSmithKline; Novartis; Acorda Therapeutics; Actelion Pharmaceuticals; Allozyne; BaroFold; Bayer Health Care; BayerSchering Pharma; Bayhill; Boehringer-Ingelheim; Eisai; Elan; Genmab; Merck-Serono; Medici-Nova; Sanofi-Aventis; Santhera Pharmaceuticals; Shire; Roche; Teva; UCB; Wyeth; Swiss National Research Foundation; European Union; Gianni Rubatto; Roche Research Foundations; BayerSchering; Genzyme; Actelion; Antisense Therapeutics; Bayer; MSD; Pfizer; Schering AG; NIHR UCLH Comprehensive Biomedical Research Centre; MRC; Wellcome Trust","The authors acknowledge the contributions of Hema Gowda and Matthew Hasson, Scientific Connexions, Newtown, PA, USA, for technical and editorial assistance in preparing this manuscript for submission. Their work was funded by Biogen Idec, Inc. The authors also acknowledge the role of Virginia Santana with respect to MRI data management. Ludwig Kappos is supported by the Swiss MS Society. Eva Havrdova is supported by the Czech Ministry of Education (Research Program MSM 0021620849). This study was supported by Biogen Idec. Funding was received from the UK Department of Health's National Institute for Health Research Biomedical Research Center's funding scheme (UCLH/UCL Comprehensive Biomedical Research Trust). The NMR Research Unit at the UCL Institute of Neurology is supported by the MS Society of Great Britain and Northern Ireland. Statistical analyses were conducted by M. Yang, MS, Biogen Idec, Cambridge, MA. Please see online resource 1 for a list of BG-12 Phase 2b Study Investigators.D. G. MacManus declares no conflicts of interest. D. H. Miller has received honoraria through payments to his employer, UCL Institute of Neurology, for advisory committees and/or consultancy in multiple sclerosis studies from BayerSchering, Biogen Idec, GlaxoSmithKline, and Novartis. He has received research grant support through his employer for performing central MRI analysis for multiple sclerosis trials from Biogen Idec, GlaxoSmithKline, and Novartis. L. Kappos has served as a principal investigator and member or chair of planning and steering committees or advisory boards in corporate-sponsored clinical trials in multiple sclerosis and other neurological diseases. Sponsoring companies for these trials include Acorda Therapeutics, Actelion Pharmaceuticals, Allozyne, BaroFold, Bayer Health Care, BayerSchering Pharma, Bayhill, Biogen Idec, Boehringer-Ingelheim, Eisai, Elan, Genmab, GlaxoSmithKline, Merck-Serono, Medici-Nova, Novartis, Sanofi-Aventis, Santhera Pharmaceuticals, Shire, Roche, Teva, UCB, Wyeth, and others. He has lectured at medical conferences or in public on various aspects of the diagnosis and management of multiple sclerosis; in many cases these lectures have been sponsored by nonrestricted educational grants from one or another of the above-listed companies. Honoraria and other payments for all these activities have been exclusively used for funding research of his department. Research and the clinical operations (nursing and patient care services) of the MS Center in Basel have been supported by nonrestricted grants from one or more of these companies and by grants from the Swiss MS Society, the Swiss National Research Foundation, the European Union, and the Gianni Rubatto, Novartis, and Roche Research Foundations. R. Gold has served as a speaker or consultant for and received scientific grant support from BayerSchering, Biogen Idec, Merck-Serono, Novartis, and Teva. E. Havrdova has received honoraria for lecturing and consulting from Bayer Health Care, Biogen Idec, Genzyme, Merck-Serono, Novartis, Sanofi-Aventis, and Teva. She has received funding for clinical trials and served on advisory boards for Actelion, Bayer Health Care, Biogen Idec, Genzyme, GlaxoSmithKline, Merck-Serono, Novartis, Sanofi-Aventis, and Teva. V. Limmroth has received research support and honoraria for consultancy from Antisense Therapeutics, Bayer, Biogen Idec, GlaxoSmithKline, Merck-Serono, MSD, Pfizer, Sanofi-Aventis, and Teva. C. H. Polman has received consulting fees from Actelion, Antisense Therapeutics, BayerSchering, Biogen Idec, GlaxoSmithKline, Merck-Serono, Novartis, Roche, Teva, and UCB; lecture fees from Biogen Idec, Novartis, Schering AG, and Teva; and grant support from BayerSchering, Biogen Idec, GlaxoSmithKline, Merck-Serono, Novartis, Teva, and UCB. K. Schmierer received research support from Biogen Idec to perform the MRI analysis of the phase 2b trial of BG-12. He has received honoraria for speaking from Merck-Serono, Novartis, and Sanofi-Aventis. T. A. Yousry has served on a scientific advisory board for UCB; received honoraria and funding for travel for serving on scientific boards for Biogen Idec; and received research support from Biogen Idec, GlaxoSmithKline, Novartis, the NIHR UCLH Comprehensive Biomedical Research Centre, the MS Society of Great Britain and Northern Ireland, the MRC, and the Wellcome Trust. He serves on the editorial board for European Radiology. M. Eraksoy serves on the medical advisory board for Biogen Idec. E. Meluzinova declares no conflicts of interest. M.Dufek has served as a subinvestigato for a clinical trial for Biogen Idec (109MS301). M. Yang, K. Dawson, and G.N. O'Neill are employees of and have equity interest in Biogen Idec.",null,26,22,23,"SPRINGER HEIDELBERG","HEIDELBERG","TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY","0340-5354",null,null,"J NEUROL","J. Neurol.","MAR",2011,258,3,null,null,null,null,449,456,null,"10.1007/s00415-010-5777-z",null,8,"Clinical Neurology","Neurosciences & Neurology","729BZ","WOS:000287924200014"]
[null,null,null,null,"J","Ruffini, E; Van Raemdonck, D; Detterbeck, F; Rocco, G; Thomas, P; Venuta, F",null,null,null,"Ruffini, Enrico; Van Raemdonck, Dirk; Detterbeck, Frank; Rocco, Gaetano; Thomas, Pascal; Venuta, Federico",null,"European Soc Thoracic Surg Thymic","Management of Thymic Tumors A Survey of Current Practice among Members of the European Society of Thoracic Surgeons","JOURNAL OF THORACIC ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"Thymoma; Thymic carcinoma; Surgery; Survey","SURGICAL-TREATMENT; INVASIVE THYMOMA; MULTIMODALITY TREATMENT; EPITHELIAL NEOPLASMS; NONINVASIVE THYMOMA; PLEURAL RECURRENCE; COMPLETE RESECTION; PROGNOSTIC-FACTORS; INTERGROUP TRIAL; CLASSIFICATION","Introduction: Management of thymoma has largely been based on single-institution retrospective, observational studies. The European Society of Thoracic Surgeons (ESTS) Thymic Working Group has investigated the current practice among ESTS members. Methods: A questionnaire divided into seven sections with 24 questions was designed, and it was delivered to ESTS members. Results: Forty-four centers replied to the questionnaire. The results indicate that there is a general agreement concerning (1) the value of computed tomography scan for preoperative assessment; (2) the uselessness of a routine histologic confirmation before surgery; (3) the role of the World Health Organization classification; (4) the importance of complete and extended resection; (5) the role of surgery for recurrent disease; and (6) the need of a multidisciplinary team, including thoracic surgeons, pathologists, medical, and radiation oncologists. On the other hand, there is still a considerable debate about (1) the role of positron emission tomography scan for preoperative assessment; (2) a consistent and reliable staging system; (3) the usefulness of postoperative treatments for stages II and III diseases; (4) the management of type C thymoma; and (5) the role of extrapleural pneumonectomy for stage IVA thymoma. Conclusions: The survey provides a large, multiinstitutional overview of the clinical practice in the management of thymic tumors by ESTS members. Responses show some areas of agreement along with several areas of controversy. It is conceivable that a consequent step forward will be the creation of a collaborative effort within the ESTS and with other organizations for the creation of standard recommendations and guidelines for the management of thymic malignancies.","[Ruffini, Enrico] Univ Turin, Dept Thorac Surg, Turin, Italy; [Van Raemdonck, Dirk] Univ Hosp Leuven, Dept Thorac Surg, Louvain, Belgium; [Detterbeck, Frank] Yale Univ, Dept Thorac Surg, New Haven, CT USA; [Rocco, Gaetano] Pascale Fdn, Natl Canc Inst, Dept Thorac Surg, Naples, Italy; [Thomas, Pascal] Univ Mediterranean, N Univ Hosp, Dept Thorac Surg, Marseille, France; [Thomas, Pascal] Univ Hosp Syst Marseille, Marseille, France; [Venuta, Federico] Univ Roma La Sapienza, Policlin Umberto I, Dept Thorac Surg, Rome, Italy","Ruffini, E (reprint author), Univ Turin, Dept Thorac Surg, Turin, Italy.","enrico.ruffini@unito.it","Thomas, Pascal/G-7457-2011; Spaggiari, Lorenzo/G-7915-2012; Thomas, Pascal/E-5036-2010",null,null,null,"Cardillo G, 2010, EUR J CARDIO-THORAC, V37, P819, DOI 10.1016/j.ejcts.2009.11.001; Chalabreysse L, 2002, AM J SURG PATHOL, V26, P1605, DOI 10.1097/00000478-200212000-00008; CURRAN WJ, 1988, J CLIN ONCOL, V6, P1722; Davenport E, 2008, ANN THORAC SURG, V86, P673, DOI 10.1016/j.athoracsur.2008.03.055; De Giacomo T, 2007, J THORAC CARDIOV SUR, V134, P1364, DOI 10.1016/j.jtcvs.2007.05.066; Detterbeck FC, 2004, ANN THORAC SURG, V77, P1860, DOI 10.1016/j.athoracsur.2003.10.001; Engels EA, 2003, INT J CANCER, V105, P546, DOI 10.1002/ijc.11099; GAMONDES JP, 1991, EUR J CARDIO-THORAC, V5, P124, DOI 10.1016/1010-7940(91)90210-B; Haniuda M, 1996, ANN SURG, V224, P219, DOI 10.1097/00000658-199608000-00016; Ishikawa Y, 2009, ANN THORAC SURG, V88, P952, DOI 10.1016/j.athoracsur.2009.05.019; KIRSCHNER PA, 1990, ANN THORAC SURG, V49, P550; KOGA K, 1994, PATHOL INT, V44, P359; Kondo K, 2003, ANN THORAC SURG, V76, P878, DOI 10.1016/S0003-4975(03)00555-1; Kubota K, 1996, BRIT J CANCER, V73, P882, DOI 10.1038/bjc.1996.157; Liu HC, 2002, ANN THORAC SURG, V73, P1076, DOI 10.1016/S0003-4975(01)03607-4; LOEHRER PJ, 1994, J CLIN ONCOL, V12, P1164; Loehrer PJ, 1997, J CLIN ONCOL, V15, P3093; Lucchi M, 2005, ANN THORAC SURG, V79, P1840, DOI 10.1016/j.athoracsur.2004.12.047; Lucchi M, 2008, EUR J CARDIO-THORAC, V33, P707, DOI 10.1016/j.ejcts.2008.01.015; Lucchi M, 2009, J THORAC CARDIOV SUR, V137, P1185, DOI 10.1016/j.jtcvs.2008.09.033; MAGGI G, 1991, ANN THORAC SURG, V51, P152; Margaritora S, 2010, ANN THORAC SURG, V89, P245, DOI 10.1016/j.athoracsur.2009.08.074; MARX A, 2004, WHO CLASSIFICATION T, V7, P152; MASAOKA A, 1981, CANCER, V48, P2485, DOI 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R; Moran CA, 2008, HEMATOL ONCOL CLIN N, V22, pXI, DOI 10.1016/j.hoc.2008.03.013; Muller-Hermelink HK, 2004, PATHOLOGY GENETICS T, P196; Nakagawa K, 2003, J THORAC CARDIOV SUR, V126, P1134, DOI 10.1016/S0022-5223(03)00798-0; NAKAHARA K, 1988, J THORAC CARDIOV SUR, V95, P1041; Okumura M, 1999, J THORAC CARDIOV SUR, V117, P605; Okumura M, 2002, CANCER, V94, P624, DOI 10.1002/cncr.10226; Puri Varun, 2009, Thorac Surg Clin, V19, P7, DOI 10.1016/j.thorsurg.2008.09.006; Rea F, 2004, EUR J CARDIO-THORAC, V26, P412, DOI 10.1016/j.ejcts.2004.04.041; REA F, 1993, J THORAC CARDIOV SUR, V106, P543; Regnard JF, 1996, J THORAC CARDIOV SUR, V112, P376, DOI 10.1016/S0022-5223(96)70265-9; Regnard JF, 1997, ANN THORAC SURG, V64, P1593, DOI 10.1016/S0003-4975(97)01175-2; Rosai J, 1999, HISTOLOGICAL TYPING, P9; Ruffini E, 1997, J THORAC CARDIOV SUR, V113, P55, DOI 10.1016/S0022-5223(97)70399-4; Ruffini Enrico, 2009, Thorac Surg Clin, V19, P121, DOI 10.1016/j.thorsurg.2008.09.005; Wright CD, 2003, ANN THORAC SURG, V76, P1641; Singhal S, 2003, ANN THORAC SURG, V76, P1635, DOI 10.1016/S0003-4975(03)00819-1; Tomiyama N, 2001, J COMPUT ASSIST TOMO, V25, P388, DOI 10.1097/00004728-200105000-00010; Egan TM, 1997, ANN THORAC SURG, V64, P1591; Venuta F, 2003, ANN THORAC SURG, V76, P1872; Venuta F, 2003, ANN THORAC SURG, V76, P1866, DOI 10.1016/S0003-4975(03)01020-8; Venuta F, 2010, EUR J CARDIO-THORAC, V37, P13, DOI 10.1016/j.ejcts.2009.05.038; Venuta F, 1997, ANN THORAC SURG, V64, P1585, DOI 10.1016/S0003-4975(97)00629-2; Venuta Federico, 2009, Thorac Surg Clin, V19, P71, DOI 10.1016/j.thorsurg.2008.09.008; Wilkins KB, 1999, ANN SURG, V230, P562, DOI 10.1097/00000658-199910000-00012; Wright CD, 2008, CRIT REV ONCOL HEMAT, V65, P109, DOI 10.1016/j.critrevonc.2007.04.005; Wright CD, 2006, ANN THORAC SURG, V82, P1234, DOI 10.1016/j.athoracsur.2006.05.028; Wright CD, 2005, J THORAC CARDIOV SUR, V130, P1413, DOI 10.1016/j.jtcvs.2005.07.026; Yagi K, 1996, ANN THORAC SURG, V61, P521, DOI 10.1016/0003-4975(95)00983-3; YAMAKAWA Y, 1991, CANCER, V68, P1984, DOI 10.1002/1097-0142(19911101)68:9<1984::AID-CNCR2820680923>3.0.CO;2-P",53,20,21,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1556-0864",null,null,"J THORAC ONCOL","J. Thorac. Oncol.","MAR",2011,6,3,null,null,null,null,614,623,null,"10.1097/JTO.0b013e318207cd74",null,10,"Oncology; Respiratory System","Oncology; Respiratory System","719VR","WOS:000287240100029"]
[null,null,null,null,"J","van Geldorp, IE; Delhaas, T; Gebauer, RA; Frias, P; Tomaske, M; Friedberg, MK; Tisma-Dupanovic, S; Elders, J; Fruh, A; Gabbarini, F; Kubus, P; Illikova, V; Tsao, S; Blank, AC; Hiippala, A; Sluysmans, T; Karpawich, P; Clur, SA; Ganame, X; Collins, KK; Dann, G; Thambo, JB; Trigo, C; Nagel, B; Papagiannis, J; Rackowitz, A; Marek, J; Nurnberg, JH; Vanagt, WY; Prinzen, FW; Janousek, J",null,null,null,"van Geldorp, Irene E.; Delhaas, Tammo; Gebauer, Roman A.; Frias, Patrick; Tomaske, Maren; Friedberg, Mark K.; Tisma-Dupanovic, Svjetlana; Elders, Jan; Fruh, Andreas; Gabbarini, Fulvio; Kubus, Petr; Illikova, Viera; Tsao, Sabrina; Blank, Andreas Christian; Hiippala, Anita; Sluysmans, Thierry; Karpawich, Peter; Clur, Sally-Ann; Ganame, Xavier; Collins, Kathryn K.; Dann, Gisela; Thambo, Jean-Benoit; Trigo, Conceicao; Nagel, Bert; Papagiannis, John; Rackowitz, Annette; Marek, Jan; Nuernberg, Jan-Hendrik; Vanagt, Ward Y.; Prinzen, Frits W.; Janousek, Jan",null,"Assoc European Paediat Cardiology","Impact of the permanent ventricular pacing site on left ventricular function in children: a retrospective multicentre survey","HEART",null,null,"English","Article",null,null,null,null,null,null,"CONGESTIVE-HEART-FAILURE; CARDIAC RESYNCHRONIZATION; ATRIAL-FIBRILLATION; PEDIATRIC-PATIENTS; PUMP FUNCTION; FOLLOW-UP; BLOCK; CARDIOMYOPATHY; THERAPY; YOUNG","Background Chronic right ventricular (RV) pacing is associated with deleterious effects on cardiac function. Objective In an observational multicentre study in children with isolated atrioventricular (AV) block receiving chronic ventricular pacing, the importance of the ventricular pacing site on left ventricular (LV) function was investigated. Methods Demographics, maternal autoantibody status and echocardiographic measurements on LV end-diastolic and end-systolic dimensions and volumes at age < 18 years were retrospectively collected from patients undergoing chronic ventricular pacing (> 1 year) for isolated AV block. LV fractional shortening (LVFS) and, if possible LV ejection fraction (LVEF) were calculated. Linear regression analyses were adjusted for patient characteristics. Results From 27 centres, 297 children were included, in whom pacing was applied at the RV epicardium (RVepi, n = 147), RV endocardium (RVendo, n = 113) or LV epicardium (LVepi, n = 37). LVFS was significantly affected by pacing site (p = 0.001), and not by maternal autoantibody status (p = 0.266). LVFS in LVepi (39 +/- 5%) was significantly higher than in RVendo (33 +/- 7%, p< 0.001) and RVepi (35 +/- 8%, p = 0.001; no significant difference between RV-paced groups, p = 0.275). Subnormal LVFS (LVFS<28%) was seen in 16/113 (14%) RVendo-paced and 21/147 (14%) RVepi-paced children, while LVFS was normal (LVFS >= 28%) in all LVepi-paced children (p = 0.049). These results are supported by the findings for LVEF (n = 122): LVEF was < 50% in 17/69 (25%) RVendo- and in 10/35 (29%) RVepi-paced patients, while LVEF was < 50% in 17/18 (94%) LVepi-paced patients. Conclusion In children with isolated AV block, permanent ventricular pacing site is an important determinant of LV function, with LVFS being significantly higher with LV pacing than with RV pacing.","[van Geldorp, Irene E.] Maastricht Univ, Dept Cardiol, Med Ctr, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands; [van Geldorp, Irene E.; Delhaas, Tammo; Vanagt, Ward Y.] Maastricht Univ, Dept Pediat, Med Ctr, NL-6200 MD Maastricht, Netherlands; [Delhaas, Tammo] Maastricht Univ, Dept Biomed Engn, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands; [Gebauer, Roman A.] Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, Leipzig, Germany; [Frias, Patrick] Emory Univ, Sch Med, Sibley Heart Ctr, Atlanta, GA USA; [Tomaske, Maren] Univ Childrens Hosp, Zurich, Switzerland; [Friedberg, Mark K.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Tisma-Dupanovic, Svjetlana] Childrens Mercy Hosp, Dept Cardiol, Kansas City, MO 64108 USA; [Elders, Jan] Radboud Univ Nijmegen Med Ctr, Dept Pediat Cardiol, Nijmegen, Netherlands; [Fruh, Andreas] Oslo Univ Hosp, Dept Pediat Cardiol, Oslo, Norway; [Gabbarini, Fulvio] Osped Infantile Regina Margherita, Dept Pediat Cardiol, Turin, Italy; [Kubus, Petr; Janousek, Jan] Univ Hosp Motol, Cardioctr, Prague, Czech Republic; [Kubus, Petr; Janousek, Jan] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Illikova, Viera] Childrens Cardiac Ctr, Dept Pediat Cardiol, Bratislava, Slovakia; [Tsao, Sabrina] Childrens Mem Hosp, Dept Electrophysiol, Chicago, IL 60614 USA; [Blank, Andreas Christian] Wilhelmina Childrens Hosp, Univ Med Ctr, Dept Pediat Cardiol, Utrecht, Netherlands; [Hiippala, Anita] Helsinki Univ Hosp, Hosp Children & Adolescents, Dept Pediat Cardiol, Helsinki, Finland; [Sluysmans, Thierry] Clin Univ St Luc, Dept Pediat & Congenital Cardiol, B-1200 Brussels, Belgium; [Karpawich, Peter] Wayne State Univ, Childrens Hosp Michigan, Sch Med, Dept Cardiac Electrophysiol, Detroit, MI USA; [Clur, Sally-Ann] Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, Dept Pediat Cardiol, NL-1105 AZ Amsterdam, Netherlands; [Ganame, Xavier; Vanagt, Ward Y.] Univ Hosp Gasthuisberg, Dept Pediat Cardiol, B-3000 Louvain, Belgium; [Collins, Kathryn K.] Univ Colorado, Dept Pediat Cardiol, Childrens Hosp, Denver, CO 80202 USA; [Dann, Gisela] Univ Hosp Gottingen, Dept Pediat Cardiol, Gottingen, Germany; [Thambo, Jean-Benoit] Bordeaux Univ, Hop Cardiol Haut Leveque, Dept Congenital Heart Dis, Bordeaux, France; [Trigo, Conceicao] Santa Marta Hosp, Dept Pediat Cardiol, Lisbon, Portugal; [Nagel, Bert] Univ Childrens Hosp, Dept Pediat Cardiol, Graz, Austria; [Papagiannis, John] Mitera Childrens Hosp, Dept Pediat Cardiol, Maroussi, Greece; [Rackowitz, Annette] Erasmus Univ, Sophia Kinderziekenhuis, Med Ctr, Dept Pediat Cardiol, Rotterdam, Netherlands; [Marek, Jan] Great Ormond St Hosp Sick Children, Dept Cardiothorac, London, England; [Nuernberg, Jan-Hendrik] Klinikum Links Weser, Dept Congenital Heart Dis & Pediat Cardiol, Bremen, Germany; [Vanagt, Ward Y.; Prinzen, Frits W.] Maastricht Univ, Dept Physiol, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands","van Geldorp, IE (reprint author), Maastricht Univ, Dept Cardiol, Med Ctr, Cardiovasc Res Inst Maastricht, POB 616, NL-6200 MD Maastricht, Netherlands.","i.vangeldorp@maastrichtuniversity.nl",null,null,"University Hospital Motol [MZOFNM2005]","JJ was supported by the research project of University Hospital Motol MZOFNM2005.",null,34,17,18,"B M J PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","1355-6037",null,null,"HEART","Heart","DEC",2011,97,24,null,null,null,null,2051,2055,null,"10.1136/heartjnl-2011-300197",null,5,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","857AW","WOS:000297687200052"]
[null,null,null,null,"J","Pietrzak, A; Jastrzebska, I; Chodorowska, G; Maciejewski, R; Mosiewicz, J; Krupski, W; Prystupa, A; Szubstarski, F; Szepietowski, JC; Hercogova, J",null,null,null,"Pietrzak, A.; Jastrzebska, I.; Chodorowska, G.; Maciejewski, R.; Mosiewicz, J.; Krupski, W.; Prystupa, A.; Szubstarski, F.; Szepietowski, J. C.; Hercogova, J.",null,null,"Psoriasis and unreported excessive alcohol intake - a simple screening approach","JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY",null,null,"English","Review",null,null,null,null,null,null,"LIVER-DISEASE; RISK-FACTOR; BIOMARKERS; DRINKING; ETHANOL; CONSUMPTION; MARKERS; SMOKING; WOMEN; RATIO","Psoriasis is a chronic immune-mediated skin disease of complex aetiology. Alcohol overuse has long been suspected to contribute to psoriasis pathology, and the knowledge of individual's drinking pattern may be of substantial importance for managing the disease. Unfortunately, a number of patients fail to admit to their true alcohol consumption and there is no single sign, symptom or laboratory parameter adequate for alcohol abuse diagnosis. However, there are some laboratory findings that, when present, should raise physician's suspicion that alcohol may be a problem. The aim of this article was to present simple, widely available and relatively reliable laboratory markers that might effectively assist physicians in establishing patient's drinking status. A possible screening approach is illustrated by two distinct reports of psoriatic patients who initially concealed having the problem with alcohol. Received: 23 November 2010; Accepted: 1 April 2011","[Jastrzebska, I.] Med Univ Lublin, Dept Internal Med & Internal Med Nursing, Lublin, Poland; [Pietrzak, A.; Chodorowska, G.] Med Univ Lublin, Dept Dermatol Venereol & Paediat Dermatol, Lublin, Poland; [Maciejewski, R.] Med Univ Lublin, Dept Human Anat, Lublin, Poland; [Mosiewicz, J.; Prystupa, A.] Med Univ Lublin, Dept Internal Med, Lublin, Poland; [Krupski, W.] Med Univ Lublin, Dept Radiol, Lublin, Poland; [Szubstarski, F.] Mil Hosp, Dept Pathomorphol, Lublin, Poland; [Szepietowski, J. C.] Wroclaw Med Univ, Dept Dermatol Venereol & Allergol, Wroclaw, Poland; [Hercogova, J.] Charles Univ Prague, Bulovka Univ Hosp, Dept Dermatol, Fac Med 2, Prague, Czech Republic","Jastrzebska, I (reprint author), Med Univ Lublin, Dept Internal Med & Internal Med Nursing, Lublin, Poland.","ivjastrzebska@wp.pl",null,null,null,null,null,32,0,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0926-9959",null,null,"J EUR ACAD DERMATOL","J. Eur. Acad. Dermatol. Venereol.","NOV",2011,25,11,null,null,null,null,1261,1268,null,"10.1111/j.1468-3083.2011.04101.x",null,8,"Dermatology","Dermatology","840TJ","WOS:000296463900003"]
[null,null,null,null,"J","Forostyak, S; Jendelova, P; Kapcalova, M; Arboleda, D; Sykova, E",null,null,null,"Forostyak, Serhiy; Jendelova, Pavla; Kapcalova, Miroslava; Arboleda, David; Sykova, Eva",null,null,"Mesenchymal stromal cells prolong the lifespan in a rat model of amyotrophic lateral sclerosis","CYTOTHERAPY",null,null,"English","Article",null,null,null,null,null,"amyotrophic lateral sclerosis; human superoxide dismutase 1; mesenchymal stromal cells; motor neurons; neurodegenerative diseases; stem cells","TRANSGENIC MOUSE MODEL; STEM-CELLS; SPINAL-CORD; SURVIVAL; THERAPY; ALS; TRANSPLANTATION; MICE; DEGENERATION; RECOVERY","Background aims. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the loss of brain and spinal cord motor neurons (MN). The intraspinal and systemic grafting of mesenchymal stromal cells (MSC) was used to treat symptomatic transgenic rats overexpressing human superoxide dismutase 1 (SOD1) in order to alleviate the disease course and prolong the animals 'lifespan. Methods. At the age of 16 weeks (disease onset) the rats received two grafts of MSC expressing green fluorescent protein (GFP(+) MSC) on the same day, intraspinally (10(5) cells) and intravenously (2 x 10(6) cells). Sham-treated animals were injected with phosphate-buffered saline (PBS). Motor activity, grip strength and body weight were tested, followed by immunohistochemical analysis. Results. The combined grafting of MSC into symptomatic rats had a significant effect on motor activity and grip strength starting 4 weeks after transplantation. The lifespan of animals in the treated group was 190 +/- 3.33 days compared with 179 +/- 3.6 days in the control group of animals. Treated rats had a larger number of MN at the thoracic and lumbar levels; these MN were of larger size, and the intensity of terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick-end labeling (TUNEL) staining in the somas of apoptotic MN at the thoracic level was much lower than in sham-treated animals. Transplanted GFP(+) MSC survived in the spinal cord until the end stage of the disease and migrated both rostrally and caudally from the injection site. Conclusions. Intraspinal and intravenous transplantation of MSC has a beneficial and possibly synergistic effect on the lifespan of ALS animals.","[Forostyak, Serhiy; Jendelova, Pavla; Kapcalova, Miroslava; Arboleda, David; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Forostyak, Serhiy; Jendelova, Pavla; Kapcalova, Miroslava; Arboleda, David; Sykova, Eva] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic; [Forostyak, Serhiy; Jendelova, Pavla; Kapcalova, Miroslava; Arboleda, David; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague, Czech Republic","Sykova, E (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","sykova@biomed.cas.cz",null,null," [AV0Z50390703];  [LC554];  [1M0538];  [GA CR 309/08/H079];  [GA CR 301/11/0189]","This study was supported by the grants AV0Z50390703, LC554, 1M0538, GA CR 309/08/H079 and GA CR 301/11/0189. We thank James Dutt for critical reading of the manuscript.",null,42,10,10,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","1465-3249",null,null,"CYTOTHERAPY","Cytotherapy","OCT",2011,13,9,null,null,null,null,1036,1046,null,"10.3109/14653249.2011.592521",null,11,"Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental","Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine","820KJ","WOS:000294904300003"]
[null,null,null,null,"J","Krol, L; Stuchly, J; Hubacek, P; Keslova, P; Sedlacek, P; Stary, J; Hrusak, O; Kalina, T",null,null,null,"Krol, L.; Stuchly, J.; Hubacek, P.; Keslova, P.; Sedlacek, P.; Stary, J.; Hrusak, O.; Kalina, T.",null,null,"Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT","BONE MARROW TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"human T-cells; hematopoietic SCT; children; CMV; immunologic monitoring; IFN-gamma; IL-2","ALLOGENEIC MARROW TRANSPLANTATION; HUMAN CYTOMEGALOVIRUS-INFECTION; IMMUNE RECONSTITUTION; FUNCTIONAL SIGNATURES; VIRAL-INFECTION; CD8+T CELLS; RECIPIENTS; CD4(+); CD8(+); DISEASE","Depletion of cellular immunity as a consequence of conditioning before allogeneic hematopoietic SCT (HSCT) frequently results in CMV reactivation, which may in turn lead to life-threatening infections and require timely antiviral treatment. We have investigated the functional signatures of CMV-specific CD4+ and CD8+ T-cells in 191 samples from 118 individuals. We compared healthy donors with both patients with high and undetectable viral loads, and those who controlled and did not control their CMV reactivations. Polychromatic flow-cytometric measurements of CD154 (CD40L), intracellular cytokines (IFN gamma, IL2) and a degranulation marker (CD107a) allowed us to assess the functional status of various T-cells simultaneously. We found that dual IFN gamma/IL2-producing CD8+ T-cells were present in patients controlling their CMV reactivations but absent from non-controllers. CD8+ T-cells that produce only IFN gamma were the most abundant subtype, but they most likely represent non-protective memory cells. Distinct functional signatures were examined by hierarchical clustering, and this revealed that, unlike polyfunctional CD8+ T-cells, CD8+ T-cells that produce IFN gamma alone were not functioning in concert with other subsets. In conclusion, our study revealed functional signatures that may be useful for immune monitoring, and it could change the interpretation of previous studies that assessed only IFN gamma. Bone Marrow Transplantation (2011) 46, 1089-1098; doi: 10.1038/bmt.2010.261; published online 8 November 2010","[Krol, L.; Stuchly, J.; Hubacek, P.; Keslova, P.; Sedlacek, P.; Stary, J.; Hrusak, O.; Kalina, T.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague 15006 5, Czech Republic; [Krol, L.; Stuchly, J.; Hubacek, P.; Keslova, P.; Sedlacek, P.; Stary, J.; Hrusak, O.; Kalina, T.] Univ Hosp Motol, Prague, Czech Republic; [Krol, L.; Stuchly, J.; Hrusak, O.; Kalina, T.] CLIP Childhood Leukemia Invest Prague, Prague, Czech Republic; [Stuchly, J.] Charles Univ Prague, Fac Math & Phys, Dept Numer Math, Prague 15006 5, Czech Republic","Kalina, T (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","tomas.kalina@lfmotol.cuni.cz",null,null,"Charles University [47807]; Ministry of Health of Czech Republic [NS/9996-4, MSMT21620813, MZOFNM2005]","We thank D Thurner, D Kotus and L Gondorcinova for the technical assistance; V Kanderova for helpful discussions; the nurses of the Charles University 2nd Faculty of Medicine and University Hospital Motol HSCT unit, namely V Cepelakova, B Nagyova and A Pertlova, for handling patients samples; the physicians of the HSCT unit (R Formankova, M Matulova and A Stetsko) for outstanding patient care; M Zajac for serology testing; and K Kopecky and M Kopecka for collecting samples from healthy individuals. We thank all of our patients and healthy blood donors. The project was supported by Charles University Grant No. 47807, Ministry of Health of Czech Republic Grant No. NS/9996-4, MSMT21620813 and MZOFNM2005.",null,46,7,7,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0268-3369",null,null,"BONE MARROW TRANSPL","Bone Marrow Transplant.","AUG",2011,46,8,null,null,null,null,1089,1098,null,"10.1038/bmt.2010.261",null,10,"Biophysics; Oncology; Hematology; Immunology; Transplantation","Biophysics; Oncology; Hematology; Immunology; Transplantation","806CB","WOS:000293779000009"]
[null,null,null,null,"J","Havlas, V; Kos, P; Jendelova, P; Lesny, P; Trc, T; Sykova, E",null,null,null,"Havlas, V.; Kos, P.; Jendelova, P.; Lesny, P.; Trc, T.; Sykova, E.",null,null,"Comparison of Chondrogenic Differentiation of Adipose Tissue-Derived Mesenchymal Stem Cells with Cultured Chondrocytes and Bone Marrow Mesenchymal Stem Cells","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"bone marrow; adipose tissue; transforming growth factor beta; cartilage; pellet culture system","DEEP CARTILAGE DEFECTS; GENE-EXPRESSION; GROWTH-FACTORS; STROMAL CELLS; KNEE; TRANSPLANTATION; SPHEROIDS","PURPOSE OF THE STUDY Many congenital and acquired disorders as well as sequelae of injury are associated with articular cartilage degeneration, which adversely affects the patient's quality of life. The currently used cell therapy with cultured chondrocytes has its disadvantages due to a process of de-differentiation of chondrocytes during cultivation. We believe that the mesenchymal stem cell therapy offers a new treatment options. MATERIAL AND METHODS The adult mesenchymal stem cells (MSCs) for chondrocyte differentiation are usually obtained from bone marrow mesenchymal stem cells (BMSCs). In this study these cells were compared with mesenchymal stem cells derived from adipose tissue (AMSCs). The aim of the study was to verify the ability of human BMSCs and AMSCs to differentiate into chondrocytes in vitro in the presence or absence of transforming growth factor beta (TGF-beta 1). Human BMSCs and AMSCs were collected from healthy donors during orthopaedic surgeries, in vitro cultured in three passages to obtain the required quantity of cells. A pellet culture system was used for chondrocyte differentiation. RESULTS At 21 days of cultivation, cell aggregates grown in the chondrogenic medium were larger than those cultured in the control medium. Both the BMSCs and AMSCs pellet cultures showed spontaneous chondrogenesis. Histological staining with haematoxylin and eosin and Masson's trichrome stains, as well as immunohistochemical staining to detect type II collagen revealed no apparent differences between the pellet cultures with TGF-beta 1 presence and those without it. The real-time RT-PCR detected expression of the type II collagen gene in all tested cultures. In the BMSCs pellet culture only, TGF-beta 1 presence resulted in a decrease in type I collagen mRNA levels and in an increase in type II collagen mRNA values. DISCUSSION Our results showed an in vitro chondrogenic potential of mature human mesenchymal stem cells derived from both bone marrow and adipose tissue. In agreement with the relevant literature data, we suggest that both cell types have an equal prospect for use in cartilage tissue engineering.","[Havlas, V.; Kos, P.; Trc, T.] Ortopedicka Klin UK 2 LF, Prague, Czech Republic; [Havlas, V.; Kos, P.; Jendelova, P.; Lesny, P.; Trc, T.; Sykova, E.] FN Motol, Prague, Czech Republic; [Jendelova, P.; Lesny, P.; Sykova, E.] Ctr Bunecne Terapie & Tkanovych Nahrad 2 LF UK, Prague, Czech Republic; [Jendelova, P.; Sykova, E.] Ustav Expt Med AV CR, Prague, Czech Republic","Havlas, V (reprint author), Ortopedicka Klin 2 LF UK Detska & Dospela Ortoped, V Uvalu 84, Prague 15006 5, Czech Republic.","vojtech.havlas@lfmotol.cuni.cz",null,null,null,null,null,30,6,7,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2011,78,2,null,null,null,null,138,144,null,null,null,7,"Orthopedics","Orthopedics","764OL","WOS:000290641200008"]
[null,null,null,null,"J","Horvath, R; Rozkova, D; Last'ovicka, J; Polouckova, A; Sedlacek, P; Sediva, A; Spisek, R",null,null,null,"Horvath, R.; Rozkova, D.; Last'ovicka, J.; Polouckova, A.; Sedlacek, P.; Sediva, A.; Spisek, R.",null,null,"Expansion of T helper type 17 lymphocytes in patients with chronic granulomatous disease","CLINICAL AND EXPERIMENTAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Th17 lymphocytes; hyper-IgE; chronic granulomatous disease; candida infections","HYPER-IGE SYNDROME; T(H)17 CELLS; DENDRITIC CELLS; INTERLEUKIN-17; RESPONSES; PATHWAY; CARD9; IL-23; IL-17; DIFFERENTIATION","Hyper-immunoglobulin (Ig) E syndrome (HIES) is a primary immunodeficiency associated with mutations in STAT3 resulting in impaired development of T helper type 17 (Th17) lymphocytes. HIES patients with a reduced frequency of Th17 cells present with infections caused by Staphylococcus aureus and/or Candida strains. The same spectrum of pathogens is present in patients with chronic granulomatous disease (CGD). We analysed the characteristics of the Th17 compartment in HIES and CGD. HIES patients showed very low numbers of Th17 cells. By contrast, the frequency of Th17 cells and production of Th17-derived cytokines was significantly higher among CGD patients when compared to both control samples and HIES. Naive CD4(+) cells in CGD patients had a normal capacity to differentiate into IL-17-producing cells and the numbers of Th17 cells in the CGD patients normalized following successful bone marrow transplantation. Our findings complement recent data on the importance of Th17 cells for elimination of infections with C. albicans and S. aureus.","[Spisek, R.] Charles Univ Prague, Inst Immunol, Sch Med 2, Dept Immunol, Prague 5, Czech Republic; [Sedlacek, P.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague 5, Czech Republic; [Sedlacek, P.] Univ Hosp Motol, Prague, Czech Republic","Spisek, R (reprint author), Charles Univ Prague, Inst Immunol, Sch Med 2, Dept Immunol, V Uvalu 84, Prague 5, Czech Republic.","radek.spisek@lfmotol.cuni.cz",null,null,"Ministry of Health Czech Republic [IGA NS10489-3/2009]; Czech Ministry of Education [MSM 0021620812]","This study was supported by grant IGA NS10489-3/2009 from the Ministry of Health Czech Republic and project MSM 0021620812 from The Czech Ministry of Education.",null,32,5,7,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0009-9104",null,null,"CLIN EXP IMMUNOL","Clin. Exp. Immunol.","OCT",2011,166,1,null,null,null,null,26,33,null,"10.1111/j.1365-2249.2011.04449.x",null,8,"Immunology","Immunology","820NW","WOS:000294913700003"]
[null,null,null,null,"J","Zieg, J; Blahova, K; Seeman, T; Bronsky, J; Dvorakova, H; Pechova, M; Janda, J; Matousovic, K",null,null,null,"Zieg, Jakub; Blahova, Kveta; Seeman, Tomas; Bronsky, Jiri; Dvorakova, Hana; Pechova, Marta; Janda, Jan; Matousovic, Karel",null,null,"Urinary transforming growth factor-beta 1 in children with obstructive uropathy","NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"alpha 1-microglobulin; microalbuminuria; obstructive uropathy; proteinuria; transforming growth factor-beta 1","URETEROPELVIC JUNCTION OBSTRUCTION; EPIDERMAL-GROWTH-FACTOR; TRACT OBSTRUCTION; CONGENITAL HYDRONEPHROSIS; TRANSFORMING-GROWTH-FACTOR-BETA(1); NEPHROPATHY; KIDNEY; SYSTEM","Aim: Obstructive uropathies (OU) in childhood constitute one of the major causes of chronic renal insufficiency. Transforming growth factor-beta 1 (TGF-beta 1) is considered to be the major fibrogenic growth factor. The aim of the present study was to investigate urinary TGF-beta 1 levels in children with obstructive and non-obstructive uropathies (NOU). Methods: This study involved 19 children with OU, 11 children with non-obstructive hydronephrosis and 21 healthy children. Urinary TGF-beta 1, proteinuria, microalbuminuria and urinary alpha 1-microglobulin were measured, and renal function was assesed. The results were statistically analyzed. Results: Mean urinary TGF-beta 1 concentrations in patients with OU were significantly higher than those with NOU (4.14 +/- 0.67 creatinine vs 1.80 +/- 1 0.24 pg/mmol creatinine, P < 0.05) and healthy controls (1.66 +/- 0.28 pg/mmol creatinine, P < 0.05). Positive correlations of urinary TGF-beta 1 concentrations with proteinuria (r = 0.87, P < 0.0001) and urinary alpha 1-microglobulin (r = 0.82, P = 0.0002) were found in patients with OU. Conclusion: Children with OU have higher urinary TGF-beta 1 than children with NOU. Urinary TGF-beta 1 may be a useful non-invasive tool for the differential diagnosis between OU and NOU in children. A positive correlation of TGF-beta 1 with markers of renal tissue damage in patients with OU was found.","[Zieg, Jakub; Blahova, Kveta; Seeman, Tomas; Bronsky, Jiri; Dvorakova, Hana; Janda, Jan] Charles Univ Prague, Univ Hosp Motol, Dept Paediat, Sch Med 2, Prague 15006, Czech Republic; [Pechova, Marta] Charles Univ Prague, Univ Hosp Motol, Dept Med Chem & Biochem, Sch Med 2, Prague 15006, Czech Republic; [Matousovic, Karel] Charles Univ Prague, Univ Hosp Motol, Dept Internal Med, Sch Med 2, Prague 15006, Czech Republic","Zieg, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Paediat, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic.","jakubzieg@hotmail.com",null,null,"MZOFNM [VZ 0006420301]; Czech Ministry of Health; MSMT of the Czech Republic [VZ 0021620819]","This work was supported by grant VZ 0006420301 MZOFNM 2005, the Czech Ministry of Health and by grant VZ 0021620819 MSMT of the Czech Republic.",null,19,5,5,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1320-5358",null,null,"NEPHROLOGY","Nephrology","AUG",2011,16,6,null,null,null,null,595,598,null,"10.1111/j.1440-1797.2011.01459.x",null,4,"Urology & Nephrology","Urology & Nephrology","798VS","WOS:000293240900009"]
[null,null,null,null,"J","Vargova, L; Homola, A; Cicanic, M; Kuncova, K; Krsek, P; Marusic, P; Sykova, E; Zamecnik, J",null,null,null,"Vargova, L.; Homola, A.; Cicanic, M.; Kuncova, K.; Krsek, P.; Marusic, P.; Sykova, E.; Zamecnik, J.",null,null,"The diffusion parameters of the extracellular space are altered in focal cortical dysplasias","NEUROSCIENCE LETTERS",null,null,"English","Article",null,null,null,null,null,"Epilepsy; Focal cortical dysplasia; Diffusion; Extracellular space volume; Tortuosity","TEMPORAL NEOCORTEX; VOLUME FRACTION; BRAIN; TRANSMISSION; MECHANISMS; TORTUOSITY; ISCHEMIA; EPILEPSY; CHANNELS; TISSUE","Most hypotheses concerning the mechanisms underlying seizure activity in focal cortical dysplasia (FCD) are based on alterations in synaptic transmission and glial dysfunction. However, neurons may also communicate by extrasynaptic transmission, which was recently found to affect epileptiform activity under experimental conditions and which is mediated by the diffusion of neuroactive substances in the extracellular space (ECS). The ECS diffusion parameters were therefore determined using the real-time iontophoretic method in human neocortical tissue samples obtained from surgically treated epileptic patients. The obtained values of the extracellular space volume fraction and tortuosity were then correlated with the histologicaly assessed type of cortical malformation (FCD type I or II). While the extracellular volume remained unchanged (FCD l) or larger (FCD II) than in normal/control tissue, tortuosity was significantly increased in both types of dysplasia, indicating the presence of additional diffusion barriers and compromised diffusion, which might be another factor contributing to the epileptogenicity of FCD. (C) 2011 Elsevier Ireland Ltd. All rights reserved.","[Vargova, L.; Homola, A.; Cicanic, M.; Sykova, E.] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague 15006 5, Czech Republic; [Vargova, L.; Homola, A.; Cicanic, M.; Sykova, E.] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague 15006 5, Czech Republic; [Vargova, L.; Homola, A.; Cicanic, M.; Sykova, E.] AS CR, Inst Expt Med, Dept Neurosci, Prague, Czech Republic; [Kuncova, K.; Zamecnik, J.] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 15006 5, Czech Republic; [Kuncova, K.; Krsek, P.; Marusic, P.; Zamecnik, J.] Univ Hosp Motol, Prague, Czech Republic; [Krsek, P.] Charles Univ Prague, Dept Paediat Neurol, Fac Med 2, Prague 15006 5, Czech Republic; [Marusic, P.] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague 15006 5, Czech Republic","Vargova, L (reprint author), Charles Univ Prague, Dept Neurosci, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","lyide.vargova@lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic [NS9915-4]","This study was supported by a grant from the Ministry of Health of the Czech Republic IGA MZCR No. NS9915-4.",null,28,5,5,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0304-3940",null,null,"NEUROSCI LETT","Neurosci. Lett.","JUL 15",2011,499,1,null,null,null,null,19,23,null,"10.1016/j.neulet.2011.05.023",null,5,"Neurosciences","Neurosciences & Neurology","793EW","WOS:000292804200005"]
[null,null,null,null,"J","Jakubova, R; Mickova, A; Buzgo, M; Rampichova, M; Prosecka, E; Tvrdik, D; Amler, E",null,null,null,"Jakubova, R.; Mickova, A.; Buzgo, M.; Rampichova, M.; Prosecka, E.; Tvrdik, D.; Amler, E.",null,null,"Immobilization of thrombocytes on PCL nanofibres enhances chondrocyte proliferation in vitro","CELL PROLIFERATION",null,null,"English","Article",null,null,null,null,null,null,"PLATELET-RICH PLASMA; STEM-CELLS; CHONDROGENIC DIFFERENTIATION; TISSUE-REPAIR; FIBROCYTES; EXPANSION; MATRIX","Objectives: The aim of this study was to develop functionalized nanofibres as a simple delivery system for growth factors (GFs) and make nanofibre cell-seeded scaffold implants a one-step intervention. Materials and methods: We have functionalized polycaprolactone (PCL) nanofibres with thrombocytes adherent on them. Immobilized, these thrombocytes attached to nanofibre scaffolds were used as a nanoscale delivery system for native (autologous) proliferation and differentiation factors, in vitro. Pig chondrocytes were seeded on the thrombocyte-coated scaffolds and levels of proliferation and differentiation of these cells were compared with those seeded on non-coated scaffolds. Results: Immobilized thrombocytes on PCL nanofibres effectively enhanced chondrocyte proliferation due to time-dependent degradation of thrombocytes and release of their GFs. Conclusions: These simply functionalized scaffolds present new possibilities for nanofibre applications, as smart cell scaffolds equipped with a GF delivery tool.","[Jakubova, R.; Mickova, A.; Buzgo, M.; Prosecka, E.; Amler, E.] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague 15006 5, Motol, Czech Republic; [Jakubova, R.] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague, Czech Republic; [Tvrdik, D.] Charles Univ Prague, Fac Med 1, Inst Pathol, Prague 15006 5, Motol, Czech Republic; [Tvrdik, D.] Charles Univ Prague, Gen Teaching Hosp, Prague 15006 5, Motol, Czech Republic; [Buzgo, M.] Charles Univ Prague, Fac Sci, Dept Cell Biol, Prague 15006 5, Motol, Czech Republic","Jakubova, R (reprint author), Charles Univ Prague, Fac Med 2, Inst Biophys, Uvalu 84, Prague 15006 5, Motol, Czech Republic.","jakubova@biomed.cas.cz",null,null,"Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Ministry of Education, Youth and Sports of the Czech Republic [NPV II 2B06130, 1M0510, P304/10/1307]; Grant Agency of the Academy of Sciences [IAA500390702]; Czech Science Foundation [GA202/09/1151]; EU [7E09088]; Grant Agency of the Charles University [119009, 96610, 119209, 97110, 80009]","This study was supported by the Academy of Sciences of the Czech Republic (Institutional research plans AV0Z50390703 and AV0Z50390512), Ministry of Education, Youth and Sports of the Czech Republic (research programs NPV II 2B06130, 1M0510, P304/10/1307), and Grant Agency of the Academy of Sciences grant no. IAA500390702 and by Czech Science Foundation grant no. GA202/09/1151, EU project BIOSCENT ID number 7E09088, the Grant Agency of the Charles University grants No.119009, 96610, 119209, 97110, 80009.",null,32,5,5,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0960-7722",null,null,"CELL PROLIFERAT","Cell Prolif.","APR",2011,44,2,null,null,null,null,183,191,null,"10.1111/j.1365-2184.2011.00737.x",null,9,"Cell Biology","Cell Biology","735XW","WOS:000288455000009"]
[null,null,null,null,"J","Veselka, J; Tomasov, P; Zemanek, D",null,null,null,"Veselka, Josef; Tomasov, Pavol; Zemanek, David",null,null,"Long-Term Effects of Varying Alcohol Dosing in Percutaneous Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Randomized Study With a Follow-up up to 11 Years","CANADIAN JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"COMPLICATIONS; ETHANOL","Background: Highly symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) are candidates for alcohol septal ablation (ASA). We wanted to determine long-term (> 60 months) clinical and echocardiographic outcomes of patients treated with low (1-2 mL) or high (> 2 mL) doses of alcohol. Methods: Seventy-six patients were randomized into 2 arms in a 1: 1 ratio, and subsequently were treated by ASA with a low (1-2 mL) or high (> 2 mL) dose of alcohol. Clinical and echocardiographic examinations were performed at baseline, 1 year after the procedure, and at the end of follow-up (at least 60 months after ASA). Results: Both groups of patients matched in all baseline clinical and echocardiographic data. In a total of 76 patients, 86 septal branches were ablated in 80 ASA procedures (2 repeat procedures in each group). There were no differences in postprocedural complications. Seven patients (4 vs 3 patients; not significant) died during follow-up (60-138 months; median 85 months). Pressure gradients decreased significantly in both groups (from 74 +/- 36 to 24 +/- 32 mm Hg in the low-dose group and from 74 +/- 39 mm Hg to 18 +/- 20 mm Hg in the high-dose group). There were no significant differences between the groups, and all main hemodynamic and echocardiographic changes occurred in the first postprocedural year. At final examination, there were no patients with New York Heart Association class > 2 dyspnea in either group. Conclusions: This study demonstrates that ASA for obstructive hypertrophic cardiomyopathy is safe and effective in long-term follow-up. No differences in long-term efficacy and safety were found between low and high doses of alcohol.","[Veselka, Josef; Tomasov, Pavol; Zemanek, David] Charles Univ Prague, Sch Med 2, Ctr Cardiovasc, Univ Hosp Motol,Dept Cardiol, Prague 15000 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Sch Med 2, Ctr Cardiovasc, Univ Hosp Motol,Dept Cardiol, V Uvalu 84, Prague 15000 5, Czech Republic.","veselka.josef@seznam.cz",null,null,"Ministry of Health of the Czech Republic [VZFNM2005, NT/11401-5/2011]","This work was supported by a grant from the Ministry of Health of the Czech Republic VZFNM2005 and NT/11401-5/2011.",null,18,4,5,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0828-282X",null,null,"CAN J CARDIOL","Can. J. Cardiol.","NOV-DEC",2011,27,6,null,null,null,null,763,767,null,"10.1016/j.cjca.2011.09.001",null,5,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","861AJ","WOS:000297990600020"]
[null,null,null,null,"J","Fucikova, J; Rozkova, D; Ulcova, H; Budinsky, V; Sochorova, K; Pokorna, K; Bartunkova, J; Spisek, R",null,null,null,"Fucikova, Jitka; Rozkova, Daniela; Ulcova, Hana; Budinsky, Vit; Sochorova, Klara; Pokorna, Katerina; Bartunkova, Jirina; Spisek, Radek",null,null,"Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials","JOURNAL OF TRANSLATIONAL MEDICINE",null,null,"English","Article",null,null,null,null,null,"cancer immunotherapy; dendritic cells; Poly I:C; culture media; clinical use","POLYINOSINIC POLYCYTIDYLIC ACID; REGULATORY T-CELLS; CLINICAL-APPLICATION; MELANOMA PATIENTS; SCALE GENERATION; MATURE; ANTIGEN; MATURATION; MONOCYTES; VACCINATION","Background: For clinical applications, dendritic cells (DCs) need to be generated using GMP-approved reagents. In this study, we tested the characteristics of DCs generated in two clinical grade culture media and activated by three maturation stimuli, Poly I: C, LPS and the mixture of proinflammatory cytokines in order to identify the optimal combination of culture media and activation stimulus for the clinical use. Method: We tested DCs generation using two GMP-certified culture media, CellGro and RPMI+5% human AB serum and evaluated DCs morphology, viability and capapability to mature. We tested three maturation stimuli, PolyI:C, LPS and the mixture of proinflammatory cytokines consisting of IL-1, IL-6, TNF and prostaglandin E2. We evaluated the capacity of activated DCs to induce antigen-specific T cells and regulatory T lymphocytes. Results: Cell culture in CellGro resulted in a higher yield of immature DCs resulting from increased number of adherent monocytes. DCs that were generated in CellGro and activated using Poly I:C were the most efficient in expanding antigen-specific T cells compared to the DCs that were generated in other media and activated using LPS or the cocktail of proinflammatory cytokines. A comparison of all tested combinations revealed that DCs that were generated in CellGro and activated using Poly I:C induced low numbers of regulatory T cells. Conclusion: In this study, we identified monocyte-derived DCs that were generated in CellGro and activated using Poly I:C as the most potent clinical-grade DCs for the induction of antigen-specific T cells.","[Fucikova, Jitka; Rozkova, Daniela; Ulcova, Hana; Budinsky, Vit; Sochorova, Klara; Bartunkova, Jirina; Spisek, Radek] Charles Univ Prague, Dept Immunol, Fac Med 2, Prague, Czech Republic; [Fucikova, Jitka; Rozkova, Daniela; Ulcova, Hana; Budinsky, Vit; Sochorova, Klara; Bartunkova, Jirina; Spisek, Radek] Univ Hosp Motol, Prague, Czech Republic; [Rozkova, Daniela; Sochorova, Klara; Pokorna, Katerina] Sotio, Prague, Czech Republic","Spisek, R (reprint author), Charles Univ Prague, Dept Immunol, Fac Med 2, Prague, Czech Republic.","radek.spisek@lfmotol.cuni.cz",null,null,"Ministry of Health [IGA NT 12402-5, IGA NT 11559-5];  [GACR 310/08/H077]","This study was supported by grants IGA NT 12402-5 and IGA NT 11559-5 from the Ministry of Health. JF was supported by grant GACR 310/08/H077.",null,53,3,3,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1479-5876",null,null,"J TRANSL MED","J. Transl. Med.","DEC 30",2011,9,null,null,null,null,null,null,null,223,"10.1186/1479-5876-9-223",null,10,"Medicine, Research & Experimental","Research & Experimental Medicine","876LE","WOS:000299108200001"]
[null,null,null,null,"J","Kolouskova, S; Zemkova, D; Bartosova, J; Skalicka, V",null,null,null,"Kolouskova, Stanislava; Zemkova, Daniela; Bartosova, Jana; Skalicka, Veronika",null,null,"Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 3-year prospective study","JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM",null,null,"English","Article",null,null,null,null,null,"cystic fibrosis; cystic fibrosis related diabetes; insulinopenia; insulin treatment; pulmonary function tests","ABNORMAL GLUCOSE-TOLERANCE; DIABETES-MELLITUS; SENSITIVITY; CHILDREN; ADOLESCENTS; INTOLERANCE; RESISTANCE; CLEARANCE; MORTALITY; GLARGINE","Cystic fibrosis related diabetes (CFRD) is an insulinopenic condition. We aimed to detect insulinopenia early and to evaluate the impact of low dose insulin on nutritional status and forced expiratory volume in first second (FEV(1)). Out of 142 cystic fibrosis patients (CFpts) older than 10 years, 28 with abnormal oral glucose tolerance test in spite of normal fasting glycemia were found to have decreased first phase insulin release and started low dose insulin therapy (median age 15.4 years). Sex and age matched CFpts with normal glucose tolerance (NGT) were observed for comparison. Whereas nutritional status improved following 3 years of insulin administration, FEV(1) stabilized in insulin-treated insulinopenic subjects (73.8 +/- 4.3% vs. 73.5 +/- 4.4 %), but decreased in the parallel group with NGT who remained without insulin treatment (71.1 +/- 3.8 % vs. 61.0 +/- 4.0 %; p=0.001). We conclude that low dose insulin improves nutritional status and stabilizes pulmonary functions. Regular estimation of stimulated insulin secretion in CFpts may allow optimizing treatment.","[Bartosova, Jana] Charles Univ Prague, Dept Pediat, Fac Med 2, CZ-15006 Prague 5, Czech Republic; Univ Hosp Prague Motol, CZ-15006 Prague 5, Czech Republic","Bartosova, J (reprint author), Charles Univ Prague, Dept Pediat, Fac Med 2, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","Jan.Lebl@Lfmotol.cuni.cz",null,null,"Czech Ministry of Health [MZ000064203]","The research project was supported by an institutional grant from the Czech Ministry of Health (grant MZ000064203). The authors have no relevant conflict of interest to disclose. They would like to acknowledge the patients and their families for an excellent collaboration and Michaela Vyhnankova for the technical assistance.",null,36,3,3,"WALTER DE GRUYTER & CO","BERLIN","GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY","0334-018X",null,null,"J PEDIATR ENDOCR MET","J. Pediatr. Endocrinol. Metab.","AUG",2011,24,41858,null,null,null,null,449,454,null,"10.1515/JPEM.2011.050",null,6,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","854BE","WOS:000297468700009"]
[null,null,null,null,"J","Veselka, J; Maly, M; Zemanek, D; Hajek, P; Martinkovicova, L; Tomsov, P",null,null,null,"Veselka, Josef; Maly, Martin; Zemanek, David; Hajek, Petr; Martinkovicova, Lucie; Tomsov, Pavol",null,null,"Effect of MGuard Net Protective Stent on the Release of Troponin I in Patients With Acute Coronary Syndromes A Randomized Controlled Trial","INTERNATIONAL HEART JOURNAL",null,null,"English","Article",null,null,null,null,null,"Stent; Acute coronary syndrome; Coronary stenosis","DISTAL EMBOLIZATION; MICROEMBOLIZATION; INTERVENTION; EXPERIENCE","This study was designed to determine whether the treatment of patients with unstable angina pectoris or non-Q-wave myocardial infarction with a stent containing a protection net to prevent coronary microembolization affects the severity of biomarker release. The MGuard stent (InspireMD, Tel Aviv, Israel) was designed as a plaque/thrombus-trapping device, using a conventional bare metal stent covered with an ultrathin, flexible mesh net. We hypothesized that this stent would partly eliminate distal embolization and decrease subsequent troponin I (TnI) release. Forty-six acute coronary syndrome patients referred for percutaneous coronary intervention (PCI) were included and randomized in this study. Serum concentrations of TnI were measured prior to, as well as 24 and 48 hours after, the PCI procedure. Technical success was 95% and 100% in the MGuard group and non-MGuard group, respectively. A transient no-reflow phenomenon was observed in one interventional procedure in each group of patients (5% versus 4%; NS). Two patients (one in each group) died during the hospital stay. There was no statistically significant difference in median post-procedural TnI levels in either group. The results suggest that coronary stenting with a stent system containing a protection net to prevent coronary microembolization (eg the MGuard stent) in patients with acute coronary syndromes does not decrease procedural myocardial injury, as measured by TnI release. It seems likely that stenting with the MGuard stent is feasible, however, its safety should be verified in larger studies. (Int Heart J 2011; 52: 203-206)","[Veselka, Josef; Maly, Martin; Zemanek, David; Hajek, Petr; Martinkovicova, Lucie; Tomsov, Pavol] Charles Univ Prague, Univ Hosp Motol, Dept Cardiol, Cardio Vasc Ctr, Prague 15000 5, Czech Republic; [Veselka, Josef; Maly, Martin; Zemanek, David; Hajek, Petr; Martinkovicova, Lucie; Tomsov, Pavol] Charles Univ Prague, Sch Med 2, Prague 15000 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, CardioVasc Ctr, Dept Cardiol, Univ Hosp Motol, V Uvalu 84, Prague 15000 5, Czech Republic.",null,"Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health of the Czech Republic [00064203]","The work was supported by a grant from the Ministry of Health of the Czech Republic, No. 00064203.",null,12,2,3,"INT HEART JOURNAL ASSOC","TOKYO","UNIV TOKYO, GRADUATE SCHOOL MEDICINE, DEPT CARDIOVASCULAR MEDICINE, HONGO 7-3-1, BUNKYO-KU, TOKYO, 113-8655, JAPAN","1349-2365",null,null,"INT HEART J","Int. Heart J.","JUL",2011,52,4,null,null,null,null,203,206,null,null,null,4,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","836SC","WOS:000296130400002"]
[null,null,null,null,"J","Peckova, M; Charvat, J; Schuck, O; Hill, M; Svab, P; Horackova, M",null,null,null,"Peckova, M.; Charvat, J.; Schuck, O.; Hill, M.; Svab, P.; Horackova, M.",null,null,"The Association between Left Ventricular Diastolic Function and a Mild-to-moderate Decrease in Glomerular Filtration Rate in Patients with Type 2 Diabetes Mellitus","JOURNAL OF INTERNATIONAL MEDICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"TYPE 2 DIABETES MELLITUS; LEFT VENTRICULAR DIASTOLIC FUNCTION; RENAL FUNCTION; ECHOCARDIOGRAPHY; ESTIMATED GLOMERULAR FILTRATION RATE","CHRONIC KIDNEY-DISEASE; CHRONIC-RENAL-FAILURE; ECHOCARDIOGRAPHIC-ASSESSMENT; DOPPLER-ECHOCARDIOGRAPHY; FILLING PRESSURES; TISSUE DOPPLER; DYSFUNCTION; CARDIOMYOPATHY; HYPERTROPHY; IMPACT","This prospective study evaluated the relationship between echocardiography parameters of left ventricular (LV) diastolic function and mild-to-moderate renal function impairment in 82 patients with type 2 diabetes mellitus. The mean age of the patients was 61.1 years. A significant correlation was found between estimated glomerular filtration rate (eGFR) and the ratio of peak velocity of early transmitral flow (E) to peak velocity of early diastolic mitral annular motion (E'). Cluster analysis revealed two subgroups of patients with different E' values but comparable eGFRs. The correlation between eGFR and E/E' was significant in 38 patients with E' <= 7.1 cm/s, but not significant in 44 patients with E' > 7.1 cm/s. The results suggest that the deterioration of LV relaxation (E') represents the underlying condition for the association between mild-to-moderate renal function impairment and the non-invasive parameter of LV end-diastolic pressure (E/E'), in patients with type 2 diabetes without any previous cardiovascular event and with wellcontrolled blood pressure.","[Peckova, M.; Charvat, J.; Schuck, O.; Svab, P.; Horackova, M.] Charles Univ Prague, Univ Hosp Motol, Dept Med, Sch Med 2, Prague 15006 5, Czech Republic; [Hill, M.] Inst Endocrinol, Prague, Czech Republic","Peckova, M (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Med, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","marenkapecka@gmail.com",null,null,"Ministry of Health, Prague, Czech Republic [IGA MH CR NR/9520-3]","This study was supported by a research grant (IGA MH CR NR/9520-3) from the Ministry of Health, Prague, Czech Republic.",null,28,2,2,"FIELD HOUSE PUBLISHING LLP","WORTHING","6 SOMPTING AVENUE, WORTHING, BN14 8HN, ENGLAND","0300-0605",null,null,"J INT MED RES","J. Int. Med. Res.","NOV-DEC",2011,39,6,null,null,null,null,2178,2186,null,null,null,9,"Medicine, Research & Experimental; Pharmacology & Pharmacy","Research & Experimental Medicine; Pharmacology & Pharmacy","887HC","WOS:000299916500014"]
[null,null,null,null,"J","Veselka, J; Zimolova, P; Spacek, M; Hajek, P; Maly, M; Tomasov, P; Martinkovicova, L; Zemanek, D",null,null,null,"Veselka, Josef; Zimolova, Petra; Spacek, Miloslav; Hajek, Petr; Maly, Martin; Tomasov, Pavol; Martinkovicova, Lucie; Zemanek, David",null,null,"Comparison of Carotid Artery Stenting in Patients With Single Versus Bilateral Carotid Artery Disease and Factors Affecting Midterm Outcome","ANNALS OF VASCULAR SURGERY",null,null,"English","Article",null,null,null,null,null,null,"RANDOMIZED CONTROLLED-TRIAL; HIGH-RISK PATIENTS; ENDARTERECTOMY; STENOSIS; ANGIOPLASTY; STROKE; PROTECTION; REGISTRY; PREDICTORS; SELECTION","Background: Carotid artery stenting (CAS) is the method of choice for carotid artery revascularization of patients at high risk for carotid endarterectomy. In this study, we compared the midterm results of CAS in patients with unilateral versus bilateral carotid artery disease. Methods and Results: This is a retrospective analysis of 1-year outcome of 273 consecutive patients in whom 342 CAS procedures were performed. The incidence of periprocedural transient ischemic attacks (TIAs) differed significantly (8% vs. 1%; p = 0.01) among patients with and without bilateral internal carotid disease, and a tendency to a lower occurrence of early adverse events (death, stroke, periprocedural TIA, periprocedural myocardial infarction) was subsequently shown (11% vs. 5%; p = 0.12). At 1-year follow-up, there was a high incidence of adverse events (death, stroke, periprocedural TIA, periprocedural myocardial infarction, restenosis) in patients with bilateral carotid artery disease (40% vs. 14%; p < 0.01), which was mainly driven by a higher incidence of death, periprocedural TIA, and restenosis (p <= 0.02 for all). According to multivariate analysis, the independent predictors of midterm adverse events were left ventricular dysfunction, male gender, bilateral carotid artery disease, renal insufficiency, cerebral symptoms within the last 6 months before the intervention, and low-density lipoprotein cholesterol level. Conclusions: At midterm follow-up, patients with bilateral carotid artery disease treated by CAS have significantly more adverse events than those with unilateral disease.","[Veselka, Josef; Zimolova, Petra; Spacek, Miloslav; Hajek, Petr; Maly, Martin; Tomasov, Pavol; Martinkovicova, Lucie; Zemanek, David] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Cardiol,Cardiovasc Ctr, Prague 15500 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Cardiol,Cardiovasc Ctr, V Uvalu 84, Prague 15500 5, Czech Republic.","veselka.josef@seznam.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health of the Czech Republic [00064203]","The authors thank Eva Hansvenclova for the assistance in data collection and registry analysis. They also express their gratitude to Dr. Marek Maly for the analysis of the statistics and his help in the evaluation of the data. The study was supported by a grant from the Ministry of Health of the Czech Republic Nr 00064203.",null,35,2,2,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0890-5096",null,null,"ANN VASC SURG","Ann. Vasc. Surg.","AUG",2011,25,6,null,null,null,null,796,804,null,"10.1016/j.avsg.2011.02.011",null,9,"Surgery; Peripheral Vascular Disease","Surgery; Cardiovascular System & Cardiology","799FG","WOS:000293269500011"]
[null,null,null,null,"J","Hrdlicka, M",null,null,null,"Hrdlicka, Michal",null,null,"Autobiographies of persons with autism: unknown views on inner experience of autistic handicap","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"autism; Asperger syndrome; autobiographies",null,"The article analyses three autobiographies of autistic individuals translated into the Czech language Nobody nowhere (Donna Williams), Life behind glass (Wendy Lawson), and Life with Asperger syndrome: a story of psychotherapy (Christine Preissmann). It shows, how the authors describe their specific symptoms and interests, family and partner relationships and career. The analysis focuses on strategies that were selected by the authors for coping with the autistic handicap. It comes to a conclusion that autistic persons consider different symptoms to be the worst than those conventionally described in textbooks and monographs on autism. In these three autobiographies, sensory overload in stressful situations was estimated from the subjective point of view to be the most unpleasant symptom.","Lekarska Fak UK Praha 1, Detska Psychiat Klin, LF UK & FN Motol 2, Prague 15006 5, Motol, Czech Republic","Hrdlicka, M (reprint author), Lekarska Fak UK Praha 1, Detska Psychiat Klin, LF UK & FN Motol 2, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","Michal.Hrdlicka@lfmotol.cuni.cz",null,null,null,null,null,22,2,2,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X","1804-6436",null,"CESK PSYCHOL","Cesk. Psychol.",null,2011,55,1,null,null,null,null,82,89,null,null,null,8,"Psychology, Multidisciplinary","Psychology","743NE","WOS:000289024200008"]
[null,null,null,null,"J","Krskova, L; Augustinakova, A; Drahokoupilova, E; Sumerauer, D; Mudry, P; Kodet, R",null,null,null,"Krskova, L.; Augustinakova, A.; Drahokoupilova, E.; Sumerauer, D.; Mudry, P.; Kodet, R.",null,null,"Rhabdomyosarcoma: Molecular analysis of Igf2, MyoD1 and Myogenin expression","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"Rhabdomyosarcoma; Real-time RT-PCR; Igf2; MyoD1; Myogenin; Loss of heterozygosity","GROWTH-FACTOR-II; EMBRYONAL RHABDOMYOSARCOMA; COLORECTAL-CANCER; WILMS-TUMOR; GENE; OVEREXPRESSION; DIFFERENTIATION; METHYLATION; MYOBLASTS; MUSCLE","Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. There are two major histopathological types of RMS - embryonal (eRMS) and alveolar (aRMS). A molecular study of Igf2, MyoD1 and Myogenin was performed to determine the expression profiles and to assess the possible utility of these genes as potential treatment targets. Patients with RMS showed up to 100-fold increase of Igf2 transcription in comparison with normal skeletal muscle. Our data suggest that overexpression of Igf2 occurs in RMS of both histological subtypes. No correlation between the results of Igf2 mRNA expression and LOH at the 11p15 region (p=0.12) was observed, but there was a trend of a higher expression of Igf2 mRNA in RMS samples with LOH. We observed a high level of MyoD1 mRNA in both aRMS and eRMS, and we detected a similar level of MyoD1 mRNA in RMS and normal skeletal muscles. There was a correlation between the results of MyoD1 mRNA expression and LOH at the 11p15 region. We did not observe any statistical difference in the level of Myogenin mRNA in the subgroups of RMS. Analogous to MyoD1, we observed a similar level of Myogenin mRNA in RMS and normal skeletal muscles.","[Krskova, L.; Augustinakova, A.; Kodet, R.] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Krskova, L.; Augustinakova, A.; Drahokoupilova, E.; Sumerauer, D.; Kodet, R.] Fac Hosp Motol, Prague, Czech Republic; [Drahokoupilova, E.; Sumerauer, D.] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Mudry, P.] Fac Hosp Brno, Clin Pediat Oncol, Brno, Czech Republic","Krskova, L (reprint author), Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague, Czech Republic.","lkrskova@email.cz",null,null,"Ministry of Health [MZOFNM2005];  [GACR 304/07/0532];  [MSM 0021620813]","The study was supported by the Grant GACR 304/07/0532, MSM 0021620813 and the Research Project of the Ministry of Health MZOFNM2005.",null,39,2,2,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2011,58,5,null,null,null,null,415,423,null,"10.4149/neo_2011_05_415",null,9,"Oncology","Oncology","825VH","WOS:000295309700008"]
[null,null,null,null,"J","Havlas, V; Kautzner, J; Trc, T; Kaplan, A",null,null,null,"Havlas, V.; Kautzner, J.; Trc, T.; Kaplan, A.",null,null,"Arthroscopic Technique Using Crossed K-wires for Avulsion Fractures of Intercondylar Eminence in Children","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"intercondylar eminence; knee arthroscopy; minimally invasive surgery; ACL; paediatric trauma","TIBIAL EMINENCE; SUTURE FIXATION; CANNULATED SCREW; MANAGEMENT; REDUCTION","PURPOSE OF THE STUDY Avulsion fractures of the intercondylar eminence (ICE) of the tibia have become increasingly frequent in older school age. Due to recent advances in arthroscopic techniques, it is now possible to treat them by minimally invasive methods. This retrospective study presents evaluation of clinical outcomes of an arthroscopic technique using crossed K-wires. MATERIAL Thirty-five patients with ICE avulsion fracture, 17 girls and 18 boys at an average age of 13 years (7-18), were included in this study. All were indicated for surgical treatment on the basis of radiographic evidence of McKeever type II and III fractures. METHODS The technique of arthroscopic reduction and fixation with crossed K-wires was used. The clinical evaluation of knee stability (anterior drawer test and Lachmann s-test) was made by one clinician. The modified Tegner-Lysholm score was assessed. RESULTS Of the 35 patients, 26 (74%) had minimal knee instability (anterior drawer up to 5 mm), two patients were primarily converted to open reduction with good results, and three (8.5%) experienced temporary knee instability (anterior drawer of 5-10 mm) that resolved spontaneously within 24 months of surgery. Four patients (11.5%) had symptoms of persistent residual instability (anterior drawer more than 10 mm) and were indicated for anterior cruciate ligament reconstruction at a later stage. The average Tegner-Lysholm scores were 86.3/100 and 98.6/100 at 6 and 24 months, respectively. DISCUSSION At the present time at our department, McKeever type II and III avulsion fractures of the intercondylar eminence are indicated for minimally invasive surgical treatment. By exact reduction it is possible to decrease the risk of post-operative knee instability. The current trend is the use of arthroscopy-assisted minimally invasive techniques such as the method of K-wire fixation described here. CONCLUSIONS Arthroscopic surgery for ICE avulsion fractures shows good results, is associated with low post-operative risks, is minimally invasive and easy to reproduce. It can be recommended as the method of choice for treating ICE avulsion injury in children.","[Havlas, V.; Kautzner, J.; Trc, T.] LF UK Praze, Ortoped Klin 2, Prague, Czech Republic; [Kaplan, A.] Univ Karlovy Praze, Katedra Atlet, Fak Telesne Vychovy & Sportu, Prague, Czech Republic","Havlas, V (reprint author), LF UK & FN Motole, Ortoped Klin 2, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","vojtech.havlas@lfmotol.cuni.cz",null,null,null,null,null,21,1,1,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","AUG",2011,78,4,null,null,null,null,343,347,null,null,null,5,"Orthopedics","Orthopedics","824HB","WOS:000295191900010"]
[null,null,null,null,"J","Dusatkova, P; Pruhova, S; Sumnik, Z; Kolouskova, S; Obermannova, B; Cinek, O; Lebl, J",null,null,null,"Dusatkova, Petra; Pruhova, Stepanka; Sumnik, Zdenek; Kolouskova, Stanislava; Obermannova, Barbora; Cinek, Ondrej; Lebl, Jan",null,null,"HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes","JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM",null,null,"English","Article",null,null,null,null,null,"diabetes; HNF1A-MODY; hypoglycemia; macrosomia","HYPERINSULINEMIC HYPOGLYCEMIA; HNF4A; GENE","Background: HNF1A-MODY (MODY3) is a common subtype of autosomal dominant diabetes. Unlike HNF4-MODY where fetal macrosomia and early postnatal hyperinsulinemic hypoglycemia have been reported, history of transient insulin overproduction has not yet been recognized in individuals with HNF1A-MODY. Case report: Here, we report on a 40-year-old male patient with HNF1A mutation p.Arg272His (c.815G>A) having a history of fetal macrosomia (4750 g, 59 cm), and, at least, one attack of symptomatic hypoglycemia in childhood. Diabetes was subsequently diagnosed at 19 years of age. The proband's daughter who developed diabetes at 16 years carries the same mutation, but her birth weight and length were in the upper normal range, and she never experienced hypoglycemic symptoms. Conclusion: The observation of fetal macrosomia and hypoglycemia in childhood is indicative of a biphasic impact of the HNF1A mutation on beta-cell function over the lifespan, leading from inappropriate insulin oversecretion to final clinical diabetes.","[Dusatkova, Petra; Pruhova, Stepanka; Sumnik, Zdenek; Kolouskova, Stanislava; Obermannova, Barbora; Cinek, Ondrej; Lebl, Jan] Univ Hosp Motol, Dept Pediat, CZ-15006 Prague, Czech Republic; [Dusatkova, Petra; Pruhova, Stepanka; Sumnik, Zdenek; Kolouskova, Stanislava; Obermannova, Barbora; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Pruhova, Stepanka] Univ Hosp Kralovske Vinohrady, Dept Pediat, Prague, Czech Republic; [Pruhova, Stepanka] Charles Univ Prague, Fac Med 3, Prague, Czech Republic","Lebl, J (reprint author), Univ Hosp Motol, Dept Pediat, V Uvalu 84, CZ-15006 Prague, Czech Republic.","jan.lebl@lfmotol.cuni.cz",null,null,"Norway through the Norwegian Financial Mechanism [CZ0100]; IGA MZCR [NT11402]; Czech Ministry of Health [MZ000064203]","The studies of subjects with monogenic diabetes are supported by a grant from Norway through the Norwegian Financial Mechanism (No. CZ0100), by a grant from IGA MZCR (grant NT11402) and by an institutional grant from the Czech Ministry of Health (grant MZ000064203). The authors have no relevant conflict of interest to disclose. They would like to acknowledge the patient and his family. Klara Vesela is thanked for her technical assistance.",null,6,1,1,"WALTER DE GRUYTER & CO","BERLIN","GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY","0334-018X",null,null,"J PEDIATR ENDOCR MET","J. Pediatr. Endocrinol. Metab.","APR",2011,24,41732,null,null,null,null,187,189,null,"10.1515/JPEM.2011.083",null,3,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","854AJ","WOS:000297466600015"]
[null,null,null,null,"J","Babjuk, M",null,null,null,"Babjuk, Marko",null,null,"Should a Second Transurethral Resection Be Performed in All Patients with T1 or High-Grade Non-Muscle-Invasive Bladder Cancer?","EUROPEAN UROLOGY SUPPLEMENTS",null,null,"English","Article",null,null,null,null,null,"Bladder cancer; TURB; Second resection; Understaging; Tumour persistence","TRANSITIONAL-CELL-CARCINOMA; UROTHELIAL CARCINOMA; 7 EORTC; RECURRENCE; RISK; PROGRESSION; EXPERIENCE; QUALITY; TUMORS; CYSTECTOMY","Context: Transurethral resection (TUR) is a critical step in the management of non-muscle-invasive bladder cancer (NMIBC). Because of the high risk of tumour persistence and understaging, the routine second TUR performed after 2-6 wk is recommended by European Association of Urology guidelines in all patients with T1 or high-grade NMIBC. Objective: To summarise arguments that support the recommendation of routine second TUR in all patients with T1 or high-grade NMIBC. Evidence acquisition: Data and arguments were retrieved from a critically selected list of articles and abstracts dealing with the surgical treatment of NMIBC. Evidence synthesis: In patients with T1 tumours, the risk of tumour persistence and tumour understaging detected by the second TUR was 33-78% and 2-28%, respectively. The pathologic finding achieved by second TUR can modify the treatment strategy in a significant number of patients. Correct staging in NMIBC enables the selection of the optimal treatment modality and improves results. Conclusions: The second TUR confirmed the presence of residual cancer and tumour understaging in a significant number of T1 and high-grade tumours. This is a strong argument that supports the recommendation of second TUR in patients with T1 or high-grade NMIBC. (C) 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.","[Babjuk, Marko] Charles Univ Praha, Hosp Motol, Fac Med 2, Dept Urol, Prague, Czech Republic","Babjuk, M (reprint author), FN Motol, Dept Urol, V Uvalu 84, Prague 15006 5, Czech Republic.","marek.babjuk@lfmotol.cuni.cz",null,null,null,null,null,28,0,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-9056",null,null,"EUR UROL SUPPL","Eur. Urol. Suppl.","MAY",2011,10,3,null,null,null,null,"E8","E11",null,"10.1016/j.eursup.2011.03.005",null,4,"Urology & Nephrology","Urology & Nephrology","765RQ","WOS:000290726700003"]
[null,null,null,null,"J","Darsova, D; Dotrelova, D",null,null,null,"Darsova, D.; Dotrelova, D.",null,null,"Bilateral Syphylitic Chorioretinitis in a 33-year-old Pervitin User","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"atypical form of posterior uveitis; neurochorioretinitis; neurosyphilis; syphilis","SYPHILIS","Neurochorioretinitis is an inflammatory process affecting the optic nerve, choroid and retina. Neurochoroiditis is the least frequent type of optic neuritis. It is most often associated with viral infections and cat-scratch fever, less common with syphilis and Lyme disease The authors describe the clinical course of neurochoroiditis in a 33-year-old, otherwise healthy woman who was referred to our clinic with acute decreased central visual acuity (6/60) in the right eye. She had complained of headache, low-grade fever, hoarseness and generalized Skin rash four months previously. However, her symptoms had resolved spontaneously. She reported pervitin (methyl amphetamine) abuse within the previous year. Ophthalmic examination disclosed bilateral neurochorioretinitis, perivasculitis and a dusty vitreous haze. Fluorescein angiography revealed vasculitis. Positive direct and indirect treponemal tests confirmed a diagnosis of syphylis. Early recognition of the clinical manifestation of syphilis and prompt commencement of treatment with crystalline penicillin improved functional and anatomical changes in both eyes within four weeks. This data should may helpful in the exact diagnosis of neurosyphilis. The case report illustrates syphilis diagnosed by an ophthalmologist in terms of the atypical form of posterior uveitis.","[Darsova, D.] FN Motole, Prague 15006 5, Czech Republic; [Darsova, D.] Ocni Klin & Dospelych 2 LF UK, Prague 15006 5, Czech Republic","Darsova, D (reprint author), Ocni Klin & Dospelych 2 LF UK, V Uvalu 84, Prague 15006 5, Czech Republic.","denisa.darsova@centrum.cz",null,null,null,null,null,9,1,1,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2011,74,2,null,null,null,null,197,200,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","751GG","WOS:000289604900009"]
[null,null,null,null,"J","Mixa, V; Skaba, R; Kraus, J; Cvachovec, K",null,null,null,"Mixa, Vladimr; Skaba, Richard; Kraus, Josef; Cvachovec, Karel",null,null,"Influence of anesthesia on the results of intraoperative diagnostic electromyostimulation in patients with anorectal malformation","JOURNAL OF PEDIATRIC SURGERY",null,null,"English","Article",null,null,null,null,null,"Anorectal malformation; Stimulation electromyography; Caudal epidural anesthesia; Posterior sagittal anorectoplasty; Compound muscle action potential CMAP","CHILDREN; INFANTS; CISATRACURIUM; PHARMACODYNAMICS; PHARMACOLOGY","Background and Purpose: Stimulation electromyography (sEMG) is useful in identifying the sphincter muscle (M) in patients with anorectal malformations (ARMs). This study evaluates the effect of anesthetic agents and M relaxants on sEMG findings. Materials and Methods: Seventeen infants (10 boys and 7 girls) with a mean age of 6.3 months and mean body weight of 6.7 kg were included in a prospective randomized study. Anesthesia was induced by sevoflurane and opioids, and an epidural catheter was inserted caudally. Stimulation electromyography of levator ani M using 14 mA current was used, and latency and amplitude of the evoked compound M action potential (CMAP) were recorded. Patients were randomized into 2 groups. Group A received a local anesthetic epidurally, and sEMG was performed. Administration of the M relaxant and measurement of M response followed. In group B drug administration, sEMG and response measurement were performed after administration of M relaxant. Results: Baseline CMAP was recorded in all patients. Average latency was 4.1 milliseconds, and average amplitude was 0.43 mV. In group A, the average latency was 4.0 milliseconds, and average amplitude was 0.65 mV. After administration of the M relaxant, the CMAP disappeared. In group B, no CMAP was observed immediately after administration of the M relaxant. Conclusion: Administration of the inhalational anesthetic, opioids, and local anesthetic did not influence the M response of M fibers in the levator ani M on sEMG and enables its localization during ARM reconstruction. Nondepolarizing M relaxation completely abolished the response. If M relaxant is necessary, cisatracurium is used. The most suitable method of anesthesia for ARM surgery appears to be inhalational anesthesia supplemented by opioids and epidural analgesia. (C) 2011 Elsevier Inc. All rights reserved.","[Mixa, Vladimr; Cvachovec, Karel] Charles Univ Prague, Fac Med 2, Dept Anesthesiol, Prague 15006, Czech Republic; [Skaba, Richard] Charles Univ Prague, Fac Med 2, Dept Pediat Surg, Prague 15006, Czech Republic; [Kraus, Josef] Charles Univ Prague, Fac Med 2, Dept Child Neurol, Prague 15006, Czech Republic; [Mixa, Vladimr; Skaba, Richard; Kraus, Josef; Cvachovec, Karel] Motal Hosp, Prague 15006, Czech Republic","Mixa, V (reprint author), Charles Univ Prague, Fac Med 2, Dept Anesthesiol, Prague 15006, Czech Republic.","vmxa@volny.cz",null,null,null,null,null,18,0,0,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0022-3468",null,null,"J PEDIATR SURG","J. Pediatr. Surg.","NOV",2011,46,11,null,null,null,null,2135,2139,null,"10.1016/j.jpedsurg.2011.07.021",null,5,"Pediatrics; Surgery","Pediatrics; Surgery","846AH","WOS:000296869100022"]
[null,null,null,null,"J","Hajek, P; Adla, T; Taborska, K; Veselka, J",null,null,null,"Hajek, Petr; Adla, Theodor; Taborska, Katerina; Veselka, Josef",null,null,"Computed tomography angiography-guided recanalization of saphenous vein graft chronic total occlusion","ARCHIVES OF MEDICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"computed tomography angiography; coronary artery bypass graft occlusion; percutaneous coronary intervention","PERCUTANEOUS CORONARY INTERVENTION; BYPASS-SURGERY; CT; EXPERIENCE; ARTERIES","Computed tomography (CT) angiography can augment conventional coronary angiography relative to length of vessel occlusion and quality of distal run-off. In this case report we describe the significance of CT angiography in the revascularization decision-making process of a patient following occlusion of both coronary artery bypass grafts.","[Hajek, Petr] Univ Hosp Motol, CardioVasc Ctr, Dept Cardiol, Prague 15006 5, Czech Republic; [Hajek, Petr; Veselka, Josef] Charles Univ Prague, Dept Cardiol, CardioVasc Ctr, Sch Med 1, Prague, Czech Republic; [Adla, Theodor] Charles Univ Prague, Dept Imaging Methods, Sch Med 2, Prague, Czech Republic; [Taborska, Katerina] Charles Univ Prague, Dept Nucl Med, Sch Med 2, Prague, Czech Republic","Hajek, P (reprint author), Univ Hosp Motol, CardioVasc Ctr, Dept Cardiol, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.hajek@fnmotol.cz",null,null,"Czech Ministry of Health [VZFNM000064203]","Supported by the Czech Ministry of Health VZFNM000064203.",null,9,0,0,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922",null,null,"ARCH MED SCI","Arch. Med. Sci.","AUG",2011,7,4,null,null,null,null,732,735,null,"10.5114/aoms.2011.24147",null,4,"Medicine, General & Internal","General & Internal Medicine","821QA","WOS:000294988300030"]
[null,null,null,null,"J","Schejbalova, A; Trc, T; Havlas, V",null,null,null,"Schejbalova, A.; Trc, T.; Havlas, V.",null,null,"Patella Alta in Cerebral Palsy Patients","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"patella alta; distal patellar realignment; patellar ligament plication","RECTUS FEMORIS TRANSFER; PERSISTENT CROUCH GAIT; EXTENSION OSTEOTOMY; TENDON ADVANCEMENT; TRANSFER SURGERY; KNEE FLEXION; CHILDREN; OUTCOMES","PURPOSE OF THE STUDY The absence of active knee extension in cerebral palsy patients is often due to elevation of the patellar ligament causing the patella to run outside the intercondylar groove. Distal patellar realignment can be achieved by either patellar ligament shortening or transposition of the patellar ligament distally. MATERIAL In the 1992-2008 period we indicated 95 knees for the distal realignment procedure involving a bone block in children 12 to 18 years old, and 46 knees in children aged between 8 and 16 years for shortening of patellar ligament using the method of rafage in the early period, and modified plication from 2003. METHODS Clinical and radiographic findings were evaluated pre-operatively and at 6 weeks, 6 months and 1 year after surgery. In the cases treated by patellar ligament shortening, the Insall-Salvati index was assessed post-operatively. Physical examination included local findings and the patient's ability to change locomotion. RESULTS Improved locomotion and maintenance of knee extension during standing and walking were recorded in 89 of the 95 knees with distal patellar realignment (93.68%) and in 40 of the 46 kness with patellar ligament shortening (86.96%). DISCUSSION Distal realignment of the patellar ligament or its shortening should be indicated as a follow-up treatment after muscular balance has been gained at persistent knee joint flexion during standing and walking, and the inability of active extension. The distal realignment procedure with a bone block should be indicated only after growth cessation because otherwise genu recurvatum may develop. Concurrently with this procedure, it is necessary to carry out distal realignment of the proximal ligament of the rectus femoris muscle. CONCLUSIONS Shortening of the patellar ligament using modified plication or its distal realignment involving a bone block are two options for the treatment of patella alta that is indicated in the absence of active knee extension in cerebral palsy patients.",null,"Schejbalova, A (reprint author), LF & FN Motol Detska & Dospela Ortopedie & Trauma, Ortoped Klin UK 2, V Uvalu 84, Prague 15006 5, Czech Republic.","schejbalovaa@seznam.cz",null,null,null,null,null,30,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","AUG",2011,78,4,null,null,null,null,348,354,null,null,null,7,"Orthopedics","Orthopedics","824HB","WOS:000295191900011"]
[null,null,null,null,"J","Filous, A; Osmera, J; Hlozanek, M; Mahelkova, G",null,null,null,"Filous, Ales; Osmera, Jakub; Hlozanek, Martin; Mahelkova, Gabriela",null,null,"Central corneal thickness in microphthalmic eyes with or without history of congenital cataract surgery","EUROPEAN JOURNAL OF OPHTHALMOLOGY",null,null,"English","Article",null,null,null,null,null,"Central corneal thickness; Microphthalmos; Microcornea; Congenital cataract surgery; Aphakia; Pseudophakia","INTRAOCULAR-PRESSURE; CHILDREN; GLAUCOMA; CHILDHOOD; APHAKIA; IMPACT; AGE","PURPOSE. To determine the central corneal thickness (CCT) in microphthalmic aphakic or pseudophakic eyes as well as in microphthalmic eyes without any history of eye surgery. METHODS. Thirty-two patients with a mean age of 6.41 +/- 5.24 years after congenital cataract surgery with absolute microcornea, i.e., horizontal corneal diameter (HCD) < 10 mm, or relative microcornea, i.e., HCD 10-11 mm but in the affected eke at least 0.5 mm smaller compared to the fellow eye, formed group A. Thirteen patients of mean age 0.94 +/- 1.22 years with absolute or relative microcornea plus another developmental anomaly of an eye without any history of eye surgery formed group B. The patients with corneal edema or scars were excluded. The control group consisted of 124 healthy school-aged children. Horizontal corneal diameter was measured with caliper and CCT with an ultrasound pachymeter In infants, these measurements were performed under general anesthesia. RESULTS. In 48 eyes in group A and in 16 eyes in group B, the mean CCT was 635.13 +/- 65.35 mu m and 642.31 +/- 93.07 mu m, respectively, which was significantly greater (p < 0.0001 and p=0.0018) in comparison with the mean CCT (553.58 +/- 33.12 mu m) in the control group. Regression curve demonstrated the significant increase of CCT values along with the decrease of HCD in microphthalmic eyes. CONCLUSIONS. Small corneas in microphthalmic eyes either with or without congenital cataract surgery have significantly higher CCT. The results demonstrate significant negative correlation between horizontal corneal diameter and CCT.","[Filous, Ales; Osmera, Jakub; Hlozanek, Martin; Mahelkova, Gabriela] Charles Univ Prague, Fac Med 2, Dept Ophthalmol Children & Adults, Prague 5, Czech Republic","Filous, A (reprint author), Charles Univ Prague, Fac Med 2, Dept Ophthalmol Children & Adults, Prague 5, Czech Republic.","ales.filous@lfmotol.cuni.cz; gabriela.czakoova@lfmotol.cuni.cz",null,null,null,null,null,27,0,0,"WICHTIG EDITORE","MILAN","72/74 VIA FRIULI, 20135 MILAN, ITALY","1120-6721",null,null,"EUR J OPHTHALMOL","Eur. J. Ophthalmol.","JUL-AUG",2011,21,4,null,null,null,null,374,378,null,"10.5301/EJO.2010.6090",null,5,"Ophthalmology","Ophthalmology","807BH","WOS:000293866400004"]
[null,null,null,null,"J","Cinek, O",null,null,null,"Cinek, Ondrej",null,null,"Epidemiology of Childhood Type 1 Diabetes Mellitus: Lessons from Central and Eastern European Data","HORMONE RESEARCH IN PAEDIATRICS",null,null,"English","Article",null,null,null,null,null,"Epidemiology; Etiology; Incidence; Type 1 diabetes mellitus","RISK; EURODIAB; TRENDS; POPULATION; WORLDWIDE","Background: Over the past 15 years, the incidence of type 1 diabetes mellitus (T1DM) in Central and Eastern Europe has grown rapidly from an initially low rate. This growth cannot be attributed to genetic factors: it appears that changing environmental exposures are responsible, though no single environmental factor can be pinpointed. Since the end of the 1980s, the populations in this part of Europe have experienced rapid changes that are being investigated as possible etiologic environmental factors. These changes may not differ in nature from similar changes observed in Western Europe, yet they undoubtedly differ in the speed of the change. This is exemplified by recent changes in reproductive behavior that resulted in the extremely swift increase in average maternal age and varying patterns of crude natality observed in some populations. However, studies performed in Central and Eastern Europe have not revealed any unique patterns of associations with putative risk factors. Conclusion: No data indicate that Eastern or Central European countries form any special entity with respect to T1DM epidemiology. The T1DM incidence trends should continue to be actively observed, as such observations are a potential source of information on disease etiology. Copyright (C) 2011 S. Karger AG, Basel","[Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-16300 Prague, Czech Republic","Cinek, O (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Makovskeho 1331, CZ-16300 Prague, Czech Republic.","ondrej.cinek@lfmotol.cuni.cz",null,null,"Czech Ministry of Education [MSM 0021620814]; Pfizer","The author receives support from the Czech Ministry of Education (grant MSM 0021620814).O.C. declares no conflict of interest. He received an honorarium from Pfizer in association with his presentation and resulting manuscript for the proceedings for the 41st International Symposium sponsored by Pfizer.",null,22,0,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1663-2818",null,null,"HORM RES PAEDIAT","Horm. Res. Paediatr.",null,2011,76,null,null,1,null,null,52,56,null,"10.1159/000329168",null,5,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","796UI","WOS:000293077900012"]
[null,null,null,null,"J","Darsova, D; Pochop, P; Vajner, L; Kodetova, D; Uhlik, J; Kukacka, J; Dotrelova, D",null,null,null,"Darsova, Denisa; Pochop, Pavel; Vajner, Ludek; Kodetova, Daniela; Uhlik, Jiri; Kukacka, Jiri; Dotrelova, Dagmar",null,null,"Evaluation of toxicity after periocular and intravitreal administration of carboplatin in rabbit eyes","ACTA VETERINARIA BRNO",null,null,"English","Article",null,null,null,null,null,"Carboplatin chemotherapy; New Zealand White Rabbits; intravitreal treatment; periocular toxicity; retinoblastoma","SUBCONJUNCTIVAL CARBOPLATIN; INTRAOCULAR RETINOBLASTOMA; FIBRIN SEALANT; CHEMOTHERAPY; INJECTION; TUMOR; PHARMACOKINETICS; COMPLICATIONS; RADIOTHERAPY; OXALIPLATIN","The aim of this study was to characterize the extent of toxicity of focal carboplatin administration and to identify the dose limiting toxicity in rabbit eyes depending on administered concentrations. New Zealand white male rabbits (n = 18) were treated with 1 of 3 regimens: a single periocular injection of 15 mg of carboplatin (group I), a single periocular injection of 30 mg of carboplatin (group II) and a single transcorneal intravitreal injection of 0.05 mg of carboplatin (group III). Ophthalmologic examinations and vitreous samplings were performed under dissociative anaesthesia at regular intervals during next 2 (groups I and III) or 3 (group II) weeks. Carboplatin concentrations in vitreous samples were assessed by atomic absorption spectroscopy. At the end of experiments, all rabbit eyes were obtained for histopathologic examination. Clinical and histological evidence of toxicity was graded into four grades according to anatomical structures of the rabbit eye. The dose limiting toxicity was reached in group II after periocular injection of 30 mg of carboplatin and in group III after intravitreal injection of 0.05 mg of carboplatin. No systemic toxicity was observed in any group. Focal carboplatin administration may decrease systemic exposure to this cytotoxic drug in the retinoblastoma treatment. This moreover suggests that focal carboplatin administration is a promising approach and challenge for advanced retinoblastoma chemotherapy.","[Darsova, Denisa; Pochop, Pavel; Dotrelova, Dagmar] Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, Prague 15006 5, Czech Republic; [Darsova, Denisa; Pochop, Pavel; Kukacka, Jiri; Dotrelova, Dagmar] Motol Hosp, Prague 15006 5, Czech Republic; [Vajner, Ludek; Uhlik, Jiri] Charles Univ Prague, Dept Histol & Embryol, Fac Med 2, Prague 15006 5, Czech Republic; [Kodetova, Daniela] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 15006 5, Czech Republic; [Kukacka, Jiri] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague 15006 5, Czech Republic","Darsova, D (reprint author), Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","denisa.darsova@centrum.cz","Kukacka, Jiri/C-4770-2013; Vajner, Ludek/C-5823-2014; Uhlik, Jiri/C-6282-2014",null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [9532]; Grant Agency of Charles University [63008]","This study was supported by the Grant No. 9532 of the Internal Grant Agency of the Ministry of Health of the Czech Republic and by the Grant No. 63008 of the Grant Agency of Charles University.",null,24,0,0,"VETERINARNI A FARMACEUTICKA UNIVERZITA BRNO","BRNO","PALACKEHO 1-3, BRNO CS-612 42, CZECH REPUBLIC","0001-7213",null,null,"ACTA VET BRNO","Acta Vet. BRNO",null,2011,80,4,null,null,null,null,385,390,null,"10.2754/avb201180040385",null,6,"Veterinary Sciences","Veterinary Sciences","912PF","WOS:000301811400011"]
[null,null,null,null,"J","Kocourkova, J; Koutek, J",null,null,null,"Kocourkova, Jana; Koutek, Jiri",null,null,"Is mentalization an inspiration for eating disorder psychotherapy?","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"eating disorders; mentalization; psychotherapy","BORDERLINE PERSONALITY-DISORDER; ANOREXIA-NERVOSA; REFLECTIVE FUNCTION; WORDS","Is mentalization an inspiration for eating disorder psychotherapy? I Kocourkova, J. Koutek The ability of understanding the mind-body relationship is reduced in patients with eating disorders, the patients suffer from the lack of the reflective function. Mentalization represents the ability to attribute mental states including beliefs, intents, desires, emotions to oneself and others. The ability of understanding is an important determinant of self-organization and self-representation. Psychotherapy aspires to improve both the mentalization function and reflective capacity. The mentalization theory gives impetus not only to its application in the psychotherapeutic techniques but also brings new inspiration for the psychotherapeutic starting points in psychology and psychiatry.","[Kocourkova, Jana; Koutek, Jiri] Detska Psychiat Klin FN Motol UK, Prague, Czech Republic","Kocourkova, J (reprint author), Detska Psychiat Klin FN Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","Jana.Kocourkova@lfmotol.cuni.cz",null,null,null,null,null,10,0,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X","1804-6436",null,"CESK PSYCHOL","Cesk. Psychol.",null,2011,55,2,null,null,null,null,180,183,null,null,null,4,"Psychology, Multidisciplinary","Psychology","760VZ","WOS:000290353600007"]
[null,null,null,null,"J","Kubrycht, J; Maxova, H; Nyc, O; Vajner, L; Novotna, J; Hezinova, A; Trnkova, A; Vrablova, K; Vytasek, R; Valouskova, V",null,null,null,"Kubrycht, J.; Maxova, H.; Nyc, O.; Vajner, L.; Novotna, J.; Hezinova, A.; Trnkova, A.; Vrablova, K.; Vytasek, R.; Valouskova, V.",null,null,"Isolation of Rat Lung Mast Cells for Purposes of One-Week Cultivation Using Novel Percoll Variant Percoll PLUS","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Hypoxia; Lung mast cells; Percoll; C-kit; Progenitor; Secretion","C-TYPE LECTIN; RBL-2H3 CELLS; MATRIX METALLOPROTEINASES; HISTAMINE-RELEASE; HYPOXIA; EXPRESSION; INTERLEUKIN-18; ACTIVATION; SEPARATION; VANCOMYCIN","Prolonged cultivation of separated rat lung mast cells (LMC) in vitro is necessary to better investigate a possible role of LMC in different stages of tissue remodeling induced by hypoxia. Rat lung mast cells (LMC) were separated using a protocol including an improved proteolytic extraction and two subsequent density gradient separations on Ficoll-Paque PLUS and a new generation of Percoll, i.e. Percoll PLUS. Instead of usual isotonic stock Percoll solution, an alternative \"asymptotically isotonic\" stock solution was more successful in our density separation of LMC on Percoll PLUS. Separated cells were cultivated for six days in media including stem cell factor, interleukins IL-3 and IL-6, and one of two alternative mixtures of antibiotics. These cultivations were performed without any contamination and with only rare changes in cell size and morphology. Model co-cultivation of two allogenic fractions of LMC often caused considerable rapid changes in cell morphology and size. In contrast to these observations no or rare morphological changes were found after cultivation under hypoxic conditions. In conclusions, we modified separation on Percoll PLUS to be widely used, altered LMC separation with respect to purposes of long-lasting cultivation and observed some model morphological changes of LMC.","[Kubrycht, J.; Maxova, H.; Vajner, L.; Novotna, J.; Hezinova, A.; Trnkova, A.; Vrablova, K.; Vytasek, R.; Valouskova, V.] Cardiovasc Res Ctr, Prague, Czech Republic; [Valouskova, V.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague 15000 5, Czech Republic; [Maxova, H.; Hezinova, A.] Charles Univ Prague, Dept Pathol Physiol, Fac Med 2, Prague 15000 5, Czech Republic; [Vajner, L.; Vrablova, K.] Charles Univ Prague, Dept Histol & Embryol, Fac Med 2, Prague 15000 5, Czech Republic; [Novotna, J.; Vytasek, R.] Charles Univ Prague, Dept Med Chem & Biochem, Fac Med 2, Prague 15000 5, Czech Republic; [Nyc, O.] Charles Univ Prague, Dept Microbiol, Fac Med 2, Prague 15000 5, Czech Republic","Kubrycht, J (reprint author), Charles Univ Prague, Dept Physiol, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic.","jkub@post.cz","Vajner, Ludek/C-5823-2014; Vytasek, Richard/C-7571-2014",null,"Grant Agency of the Czech Republic [305/08/0108]; Cardiovascular Research Centre [MSMT 1M0510]","The study was supported by the Grant Agency of the Czech Republic 305/08/0108 and by the Cardiovascular Research Centre MSMT 1M0510.",null,45,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2011,60,1,null,null,null,null,83,93,null,null,null,11,"Physiology","Physiology","737IZ","WOS:000288563800009"]
[null,null,null,null,"J","Maxova, H; Hezinova, A; Vizek, M",null,null,null,"Maxova, H.; Hezinova, A.; Vizek, M.",null,null,"Disodium Cromoglycate Attenuates Hypoxia Induced Enlargement of End-Expiratory Lung Volume in Rats","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Chronic hypoxia; End-expiratory lung volume; Tissue remodeling; Mast cells; Disodium cromoglycate","MAST-CELL DEGRANULATION; PULMONARY-HYPERTENSION; MATRIX METALLOPROTEINASES; REGRESSION; HYPERCAPNIA; PREVENTION; EXPRESSION; EXPOSURE","Mechanism responsible for the enlargement of end-expiratory lung volume (EELV) induced by chronic hypoxia remains unclear. The fact that the increase in EELV persists after return to normoxia suggests involvement of morphological changes. Because hypoxia has been also shown to activate lung mast cells, we speculated that they could play in the mechanism increasing EELV similar role as in vessel remodeling in hypoxic pulmonary hypertension (HPH). We, therefore, tested an effect of mast cells degranulation blocker disodium cromoglycate (DSCG) on hypoxia induced EELV enlargement. Ventilatory parameters, EELV and right to left heart weight ratio (RV/LV+S) were measured in male Wistar rats. The experimental group (H+DSCG) was exposed to 3 weeks of normobaric hypoxia and treated with DSCG during the first four days of hypoxia, control group was exposed to hypoxia only (H), two others were kept in normoxia as non-treated (N) and treated (N+DSCG) groups. DSCG treatment significantly attenuated the EELV enlargement (H+DSCG=6.1 +/- 0.8; H=9.2 +/- 0.9; ml +/- SE) together with the increase in minute ventilation (H+DSCG=190 +/- 8; H=273 +/- 10; ml/min +/- SE) and RV/LV+S (H+DSCG=0.39 +/- 0.03; H=0.50 +/- 0.06).","[Maxova, H.; Hezinova, A.; Vizek, M.] Charles Univ Prague, Dept Pathophysiol, Fac Med 2, Prague 15000 5, Czech Republic; [Maxova, H.; Hezinova, A.; Vizek, M.] Cardiovasc Res Ctr, Prague, Czech Republic","Maxova, H (reprint author), Charles Univ Prague, Dept Pathophysiol, Fac Med 2, Plzenska 221, Prague 15000 5, Czech Republic.","hana.maxova@lfmotol.cuni.cz",null,null,"Grant Agency of the Czech Republic [305/08/0108]; Cardiovascular Research Centre [MSMT 1M0510]","This work was supported by grants from the Grant Agency of the Czech Republic (305/08/0108), and from the Cardiovascular Research Centre (MSMT 1M0510).",null,22,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2011,60,5,null,null,null,null,831,834,null,null,null,4,"Physiology","Physiology","863JW","WOS:000298159900012"]
[null,null,null,null,"J","Darsova, D; Pochop, P; Stepankova, J; Dotrelova, D",null,null,null,"Darsova, D.; Pochop, P.; Stepankova, J.; Dotrelova, D.",null,null,"Unilateral Intravitreal Hemorrhage after Methamphetamine (Pervitin) Overdose in a 16-year-old Boy: a Variant of the Terson's Syndrome - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"stroke; intracranial haemorrhage; methamphetamine; pars plana vitrectomy; pervitin; retinal sub-inner limiting membrane haemorrhage; Terson's syndrome; intravitreal haemorrhage","ND-YAG; CHILDREN","The authors record a rare case of hypertensis crisis complicated by stroke, intracranial haemorrhage and unilateral intraocular haemorrhage after methamphetamine (pervitin) overdose in a 16-year-old boy had led to a hypertensive crisis giving rise to Terson's syndrome: intracranial haemorrhage, elevation of intracranial pressure and subsequent unilateral intraocular haemorrhage. In the course of 19 days of intensive care with artificial pulmonary ventilation, the intracranial pressure oscillated between 20 and 40 mmHg, central left hemiparesis occurred and right-side intravitreal haemorrhage was diagnosed by an ophthalmologist. After three months of insufficient spontaneous resorption of intravitreal haemorrhage, we performed pars plana vitrectomy (PPV). Visual acuity in the right eye improved after surgery from 6/24 to 6/9. With modern intensive care and optimal timing of PPV, Terson's syndrome should be recognized as a reversible cause of blindness in patients surviving intracranial haemorrhage.","[Darsova, D.; Pochop, P.; Stepankova, J.; Dotrelova, D.] FN Motole, LF UK, Ocni Klin Deti & Dospelych 2, Prague 15006 5, Czech Republic","Darsova, D (reprint author), FN Motole, LF UK, Ocni Klin Deti & Dospelych 2, V Uvalu 84, Prague 15006 5, Czech Republic.","denisa.darsova@centrum.cz",null,null,null,null,"De Maeyer K, 2007, BRIT J OPHTHALMOL, V91, P869, DOI 10.1136/bjo.2006.109132; Elner VM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1141, DOI 10.1001/archopht.126.8.1141; Hlozanek M, 2006, EUR J OPHTHALMOL, V16, P478; Monshizadeh R, 2002, J AAPOS, V6, P56, DOI 10.1067/mpa.2002.120645; North Metro Task Force, METH; Schloff S, 2002, OPHTHALMOLOGY, V109, P1472, DOI 10.1016/S0161-6420(02)01086-2",6,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2011,74,3,null,null,null,null,344,347,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","792OS","WOS:000292757000015"]
[null,null,null,null,"J","Dudova, I; Vodicka, J; Havlovicova, M; Sedlacek, Z; Urbanek, T; Hrdlicka, M",null,null,null,"Dudova, Iva; Vodicka, Jan; Havlovicova, Marketa; Sedlacek, Zdenek; Urbanek, Tomas; Hrdlicka, Michal",null,null,"Odor detection threshold, but not odor identification, is impaired in children with autism","EUROPEAN CHILD & ADOLESCENT PSYCHIATRY",null,null,"English","Article",null,null,null,null,null,"Autism spectrum disorders; Sensory abnormalities; Olfactory; Sniffin' Sticks; Odor threshold; Odor identification","OLFACTORY FUNCTION; YOUNG-CHILDREN; DEVELOPMENTAL DISORDERS; SENSORY ABNORMALITIES; SPECTRUM DISORDERS; ALLERGIC RHINITIS; CHILDHOOD AUTISM; SMELL; DISCRIMINATION; PERFORMANCE","The aim of our study was to examine odor detection thresholds and odor identification in autistic subjects. Thirty-five patients with Asperger's syndrome and high functioning autism (mean age 10.8 +/- A 3.6 years; 31 boys) were compared with 35 healthy control subjects (mean age 10.4 +/- A 2.4 years; 28 boys). There were no significant differences between groups with regard to mean age (p = 0.598) and gender proportion (p = 0.324). Olfactory testing used the Sniffin' Sticks test (threshold and identification parts only). Participants with Asperger's syndrome and high functioning autism, in comparison with healthy controls, were significantly impaired relative to odor detection thresholds (6.3 +/- A 3.1 vs. 7.9 +/- A 2.0; p = 0.025). Autistic participants were significantly better in correctly identifying the odor of an orange (94 vs. 63%; p < 0.05) and significantly worse at correctly identifying the odor of cloves (40 vs. 74%; p < 0.05). With regard to identification of fourteen other substances, there were no significant differences. There was no significant difference between autistic and control subjects on the total score of olfactory identification (p = 0.799). Odor identification ability (as expressed by this total score) correlated significantly with age in the control group (p = 0.049), but not in the autism group (p = 0.103). We found impaired odor detection and almost normal odor identification in children with autism. Implications for further research are discussed.","[Dudova, Iva; Hrdlicka, Michal] Charles Univ Prague, Fac Med 2, Dept Child Psychiat, Prague 15006, Czech Republic; [Vodicka, Jan] Univ Pardubice, Dept Otorhinolaryngol & Head & Neck Surg, Fac Hlth Studies, Pardubice 53203, Czech Republic; [Havlovicova, Marketa; Sedlacek, Zdenek] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 15006, Czech Republic; [Urbanek, Tomas] Acad Sci Czech Republic, Inst Psychol, Brno 60200, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 1, Prague 12108, Czech Republic","Dudova, I (reprint author), Charles Univ Prague, Fac Med 2, Dept Child Psychiat, V Uvalu 84, Prague 15006, Czech Republic.","iva.dudova@lfmotol.cuni.cz",null,null,"Ministry of Education, Youth and Sports, Czech Republic [MSM 0021620849]; Ministry of Health, Czech Republic [MZ0FNM2005, 1A-8667/4]; Institute of Psychology, Academy of Science, Czech Republic [AV0Z70250504]","Supported by the Ministry of Education, Youth and Sports, Czech Republic (research grant MSM 0021620849), the Ministry of Health, Czech Republic (research grants MZ0FNM2005 and 1A-8667/4), and by the Institute of Psychology, Academy of Science, Czech Republic (research plan AV0Z70250504). We thank the Autism Research Center (University of Cambridge, UK) for use of the CAST screening tool that was used in our research.",null,39,14,14,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1018-8827",null,null,"EUR CHILD ADOLES PSY","Eur. Child Adolesc. Psych.","JUL",2011,20,7,null,null,null,null,333,340,null,"10.1007/s00787-011-0177-1",null,8,"Psychology, Developmental; Pediatrics; Psychiatry","Psychology; Pediatrics; Psychiatry","792LJ","WOS:000292745900002"]
[null,null,null,null,"J","Bronsky, J; Mitrova, K; Karpisek, M; Mazoch, J; Durilova, M; Fisarkova, B; Stechova, K; Prusa, R; Nevoral, J",null,null,null,"Bronsky, Jiri; Mitrova, Katarina; Karpisek, Michal; Mazoch, Jiri; Durilova, Marianna; Fisarkova, Barbora; Stechova, Katerina; Prusa, Richard; Nevoral, Jiri",null,null,"Adiponectin, AFABP, and Leptin in Human Breast Milk During 12 Months of Lactation","JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION",null,null,"English","Article",null,null,null,null,null,"adipocyte fatty acid-binding protein; adiponectin; breast milk; leptin; nutritional programming","ACID-BINDING PROTEIN; RECEPTOR ISOFORM; FOOD-INTAKE; SERUM; ADIPOSITY; OBESITY; MOTHERS; LIFE; INFANTS","Objectives: Adiponectin, adipocyte fatty acid-binding protein (AFABP), and leptin have been shown to be present in human breast milk (BM). We determined intraindividual changes of BM levels of these proteins during 12 months of lactation. Subjects and Methods: Proteins were measured using a high-sensitivity enzyme-linked immunosorbent assay method in 72 healthy mothers after delivery (day 0, D0) and after 1, 3, 6, and 12 months of lactation. Results: Adiponectin levels in BM on D0 were 22.8 +/- 0.8 (mean +/- standard error of the mean), in 1 month (M1) 22.0 +/- 0.6, in 3 months (M3) 20.5 +/- 0.6, in 6 months (M6) 21.4 +/- 0.8, and in 12 months (M12) 25.7 +/- 1.4 ng/mL. AFABP levels were 12.3 +/- 2.0, 6.2 +/- 1.3, 1.3 +/- 0.2, 2.5 +/- 1.0, and 4.6 +/- 1.9 ng/mL, respectively. Leptin levels were 0.3 +/- 0.04, 0.2 +/- 0.03, 0.1 +/- 0.01, 0.1 +/- 0.02, and 0.2 +/- 0.04 ng/mL, respectively. We found significantly higher levels of adiponectin in M12 in comparison to M3 and M6 (P = 0.0026), higher levels of AFABP in D0 and M1 when compared with M3, M6, and M12 (P < 0.0001), and higher levels of leptin on D0 than in M1, M3, M6, and M12 (P < 0.0001). AFABP levels correlated negatively with infants' body weight in M1, but there was no correlation throughout the lactation period between body weight and other proteins. We found positive correlation between adiponectin, AFABP, and leptin throughout the lactation. Conclusions: All of the hormones were detectable in BM up to 12 months of lactation, with decreasing trend until M3 and subsequent increase till M12. We speculate that higher levels in M6 and M12 may be caused by longer intervals between breast-feeding due to the introduction of complementary food.","[Bronsky, Jiri; Mitrova, Katarina; Durilova, Marianna; Stechova, Katerina; Nevoral, Jiri] Charles Univ Prague, Dept Paediat, Med Fac 2, Prague 15006 5, Czech Republic; [Prusa, Richard] Univ Hosp Motol, Med Fac 2, Dept Clin Biochem & Pathobiochem, Prague 15006 5, Czech Republic; [Karpisek, Michal; Mazoch, Jiri] Univ Vet & Pharmaceut Sci, Fac Pharm, Dept Human Pharmacol & Toxicol, Brno, Czech Republic; [Fisarkova, Barbora] Charles Univ Prague, Dept Neonatol, Med Fac 2, Prague 15006 5, Czech Republic","Bronsky, J (reprint author), Charles Univ Prague, Dept Paediat, Med Fac 2, V Uvalu 84, Prague 15006 5, Czech Republic.","bronsky@email.cz",null,null,"VZ MZO [64203/6903]","The present study was supported by research grant VZ MZO 64203/6903 (VZ FNM 2005).",null,19,10,10,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0277-2116",null,null,"J PEDIATR GASTR NUTR","J. Pediatr. Gastroenterol. Nutr.","APR",2011,52,4,null,null,null,null,474,477,null,"10.1097/MPG.0b013e3182062fcc",null,4,"Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","737AZ","WOS:000288541100021"]
[null,null,null,null,"J","Soucek, O; Lebl, J; Snajderova, M; Kolouskova, S; Rocek, M; Hlavka, Z; Cinek, O; Rittweger, J; Sumnik, Z",null,null,null,"Soucek, Ondrej; Lebl, Jan; Snajderova, Marta; Kolouskova, Stanislava; Rocek, Miloslav; Hlavka, Zdenek; Cinek, Ondrej; Rittweger, Joern; Sumnik, Zdenek",null,null,"Bone geometry and volumetric bone mineral density in girls with Turner syndrome of different pubertal stages","CLINICAL ENDOCRINOLOGY",null,null,"English","Article",null,null,null,null,null,null,"QUANTITATIVE COMPUTED-TOMOGRAPHY; GROWTH-HORMONE TREATMENT; PROXIMAL RADIUS; FRACTURES; THERAPY; ABSORPTIOMETRY; OSTEOPOROSIS; CHILDREN; SPINE; SIZE","P>Objective An increased rate of fractures has been reported in patients with Turner syndrome (TS). We aimed to assess bone geometry and volumetric bone mineral density (vBMD) at the radius in girls with TS and to evaluate the relationships between bone parameters and fracture history. Methods and design Sixty-seven girls with TS aged 6-19 years treated currently or in the past with growth hormone (GH) and/or oestrogens were examined using peripheral quantitative computed tomography. Results were compared to reference data. Results Cortical area and cortical thickness were low in all age groups (all P < 0 center dot 001). Height-adjusted total bone area at the diaphysis was increased in prepubertal and postpubertal girls (mean Z-score 1 center dot 0, P < 0 center dot 05 for both) and normal in the pubertal group (mean Z-score 0 center dot 1). Cortical vBMD was decreased (mean age-specific Z-scores -2 center dot 0, -1 center dot 6 and -1 center dot 0 for prepubertal, pubertal and postpubertal groups, respectively, P < 0 center dot 01 for all groups). Height- , age- and cortical thickness-adjusted cortical vBMD was positively correlated to the duration of GH therapy (P = 0 center dot 012) and to oestrogen administration (P = 0 center dot 047). Girls with a history of fractures had lower total vBMD at the metaphysis compared to nonfractured TS girls (mean Z-scores -1 center dot 7 vs -0 center dot 9, P = 0 center dot 04). Conclusions There is a cortical bone deficit in girls with TS characterized by low cortical area, thin cortex and probably decreased cortical vBMD. Early commencement of GH therapy, as well as oestrogen replacement, is associated with higher cortical vBMD. Further studies should investigate the potential causality of this relation.","[Soucek, Ondrej; Lebl, Jan; Snajderova, Marta; Kolouskova, Stanislava; Cinek, Ondrej; Sumnik, Zdenek] Univ Hosp Motol, Dept Pediat, Fac Med 2, Prague 15006, Czech Republic; [Rocek, Miloslav] Univ Hosp Motol, Dept Radiol Tech, Fac Med 2, Prague 15006, Czech Republic; [Hlavka, Zdenek] Charles Univ Prague, Fac Math & Phys, Dept Probabil & Math Stat, Prague, Czech Republic; [Rittweger, Joern] German Aerosp Ctr DLR, Inst Aerosp Med, Cologne, Germany; [Rittweger, Joern] Manchester Metropolitan Univ, Inst Biomed Res Human Movement & Hlth, Manchester M15 6BH, Lancs, England","Soucek, O (reprint author), Univ Hosp Motol, Dept Pediat, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","ondrej.soucek@lfmotol.cuni.cz","Rittweger, Jorn/A-4308-2009",null,"Charles University [GAUK 47609]; Czech Ministry of Health [VZ MZ 64203]; Czech Ministry of Education [MSMT 21620819]","This work was supported by Charles University (GAUK 47609), Czech Ministry of Health (VZ MZ 64203) and Czech Ministry of Education (MSMT 21620819).",null,36,8,8,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-0664",null,null,"CLIN ENDOCRINOL","Clin. Endocrinol.","APR",2011,74,4,null,null,null,null,445,452,null,"10.1111/j.1365-2265.2010.03955.x",null,8,"Endocrinology & Metabolism","Endocrinology & Metabolism","730YK","WOS:000288073300006"]
[null,null,null,null,"J","Kocian, P; Sedivcova, M; Drgac, J; Cerna, K; Hoch, J; Kodet, R; Bartunkova, J; Spisek, R; Fialova, A",null,null,null,"Kocian, Petr; Sedivcova, Monika; Drgac, Jan; Cerna, Katerina; Hoch, Jiri; Kodet, Roman; Bartunkova, Jirina; Spisek, Radek; Fialova, Anna",null,null,"Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: Their relationship to KRAS mutational status and disease recurrence","HUMAN IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Colorectal cancer; KRAS; Tumor-infiltrating lymphocytes","RAS GENE-MUTATIONS; K-RAS; PROGNOSTIC VALUE; T-CELLS; P53 OVEREXPRESSION; INVASIVE MARGIN; IMMUNE CELLS; HUMAN-COLON; SURVIVAL; CARCINOMA","The prognosis of newly diagnosed colorectal cancer patients relies mostly on tumor-node metastasis classification. However, analyses of tumor-infiltrating lymphocytes and several molecular markers have also shown promising prognostic value. Mutations in the proto-oncogene KRAS, which occur early in colorectal carcinogenesis, have been demonstrated to be common in human colorectal cancer (CRC); however, their prognostic significance remains controversial. We examined the correlations between KRAS mutational status and tumor-infiltrating immune cells with respect to CRC recurrence. Mutations in KRAS were identified in 45.5% of the primary carcinomas in our cohort of patients: 65% in codon 12 and 35% in codon 13. Although codon 13 KRAS mutations were associated with disease relapse, they were present in both disease-free and relapsed patients. However, disease-free and relapsed patients differed markedly in their patterns of tumor-infiltrating immune cells. There was a trend toward decreased density of tumor-infiltrating lymphocytes (TILs) within the group of relapsed cases. In addition, relapsed patients with codon 13 mutations had markedly lower levels of tumor-infiltrating mature DC-LAMP(+) dendritic cells (DCs) and higher frequency of CD1a(+) cells compared with disease-free patients. Our data suggest that CRC patients with low levels of TILs, a high CD1a(+)/DC-LAMP(+) tumor-infiltrating DC ratio, and a KRAS mutation in codon 13 are at a high risk of disease recurrence. (C) 2011 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.","[Kocian, Petr; Bartunkova, Jirina; Spisek, Radek; Fialova, Anna] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague 15006 5, Czech Republic; [Kocian, Petr; Drgac, Jan; Hoch, Jiri; Kodet, Roman; Bartunkova, Jirina; Spisek, Radek; Fialova, Anna] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Kocian, Petr; Hoch, Jiri] Charles Univ Prague, Fac Med 2, Dept Surg, Prague 15006 5, Czech Republic; [Sedivcova, Monika; Cerna, Katerina] Charles Univ Prague, Sch Med, Dept Pathol, Plzen 30460, Czech Republic; [Sedivcova, Monika; Cerna, Katerina] Charles Univ Prague, Univ Hosp, Plzen 30460, Czech Republic; [Drgac, Jan; Kodet, Roman] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic","Fialova, A (reprint author), Charles Univ Prague, Fac Med 2, Dept Immunol, V Uvalu 84, Prague 15006 5, Czech Republic.","anna.fialova@lfmotol.cuni.cz",null,null,"Czech Ministry of Education [MSM 0021620812]; Charles University [GAUK 9939/2009]","We thank Vit Budinsky for technical help with fluorescence microscopy. This project was supported by Research Grant MSM 0021620812 from the Czech Ministry of Education and GAUK 9939/2009 from Charles University.",null,36,4,4,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0198-8859",null,null,"HUM IMMUNOL","Hum. Immunol.","NOV",2011,72,11,null,null,null,null,1022,1028,null,"10.1016/j.humimm.2011.07.312",null,7,"Immunology","Immunology","841WO","WOS:000296546100006"]
[null,null,null,null,"J","Veselka, J; Cadova, P; Tomasov, P; Theodor, A; Zemanek, D",null,null,null,"Veselka, Josef; Cadova, Pavla; Tomasov, Pavol; Theodor, Adla; Zemanek, David",null,null,"Dual-Source CT Angiography for Detection and Quantification of In-Stent Restenosis in the Left Main Coronary Artery: Comparison with Intracoronary Ultrasound and Coronary Angiography","JOURNAL OF INVASIVE CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"computed tomography coronary angiography; coronary angiography; intravascular ultrasound","FRACTIONAL FLOW RESERVE; COMPUTED-TOMOGRAPHY; INTRAVASCULAR ULTRASOUND; FOLLOW-UP; REGISTRY; DISEASE; REVASCULARIZATION; STENOSIS; OUTCOMES; PATENCY","Objectives. The aim of this study was to evaluate the diagnostic accuracy of dual-source computed tomography coronary angiography (CTCA) compared to coronary angiography (CAG) and intravascular ultrasound (IVUS) for detection and quantification of in-stent restenosis after left main (LM) coronary artery stenting. Materials and Methods. Fifty-one patients with percutaneous coronary intervention of the LM were prospectively evaluated. Thirty-four of them underwent 56 complete follow-up examinations (CTCA, CAG, and IVUS as gold standard examination) that focused on detection and quantification of restenosis. Results. Sensitivity, specificity, and positive and negative predictive values were 100%, 94%, 50%, and 100% for CAG, respectively, and 100%, 74%, 18%, and 100% for CTCA, respectively. There was a correlation between the minimal luminal areas (MLA) measured by CTCA and IVUS (r = 0.63; P<.01). A Bland-Alt-man analysis showed that the MLA measured by CTCA was underestimated (mean difference, 2.14 +/- 2.24 mm(2)). Conclusion. Dual-source CTCA has a high negative predictive value and might be considered a less invasive alternative to CAG for exclusion of LM in-stent restenosis. However, there was only a moderate correlation between the MLA measurements by IVUS and CTCA in the stented LMs. Moreover, the present results suggest a systematic underestimation of MLAs measured by CTCA. Therefore, finding of any restenosis according to CTCA should be re-evaluated by CAG or, better, by subsequent IVUS.","[Veselka, Josef; Cadova, Pavla; Tomasov, Pavol; Theodor, Adla; Zemanek, David] Charles Univ Prague, Ctr Cardiovasc, Sch Med 2, Dept Cardiol,Univ Hosp Motol, Prague 15000 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Ctr Cardiovasc, Sch Med 2, Dept Cardiol,Univ Hosp Motol, V Uvalu 84, Prague 15000 5, Czech Republic.","veselka.josef@seznam.cz",null,null,"Ministry of Health of the CZ [00064203]","This study was supported by a grant from the Ministry of Health of the CZ No. 00064203.",null,19,4,4,"H M P COMMUNICATIONS","MALVERN","83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA","1042-3931",null,null,"J INVASIVE CARDIOL","J. Invasive Cardiol.","NOV",2011,23,11,null,null,null,null,460,464,null,null,null,5,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","873MO","WOS:000298887600011"]
[null,null,null,null,"J","Veselka, J; Zemanek, D; Hajek, P; Maly, M; Adlova, R; Martinkovicova, L; Tomasov, P; Tesar, D",null,null,null,"Veselka, Josef; Zemanek, David; Hajek, Petr; Maly, Martin; Adlova, Radka; Martinkovicova, Lucie; Tomasov, Pavol; Tesar, David",null,null,"Effect of Two-Day Atorvastatin Pretreatment on Long-Term Outcome of Patients With Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention","AMERICAN JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"PERIPROCEDURAL MYOCARDIAL-INFARCTION; PREPROCEDURAL STATIN THERAPY; RANDOMIZED-TRIAL; MICROEMBOLIZATION; METAANALYSIS; IMPACT","Several randomized studies and meta-analyses have suggested that pretreatment with statins may decrease periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI). The purpose of this randomized study was to investigate the effect of a 2-day atorvastatin therapy before PCI on long-term clinical outcome. Two hundred statin-naive patients with stable angina pectoris referred for PCI were enrolled and randomized (ratio 1:1) to 2-day pretreatment with atorvastatin 80 mg/day and subsequent PCI (atorvastatin group), or immediate PCI (control group). The registry group comprised 182 consecutive patients on long-term statin therapy referred for immediate PCI during the same period as randomized patients. We compared the first occurrence of MI or death during long-term follow-up. There were no significant differences in most clinical characteristics and early results among the 3 groups. Median follow-up was 45 months (1 to 59). Incidences of death/MI were 11.4%, 12.9%, and 13.8% in the atorvastatin, control, and registry groups, respectively. In the same groups, age-adjusted estimated 4-year freedom from death/MI was 0.78 versus 0.75 versus 0.80, respectively (p = 0.882, log-rank test). In multivariate analysis, only age of patients (odds ratio 1.04, 95% confidence interval 1.02 to 1.07, p < 0.001) was identified as a significant predictor of death or MI during follow-up. In conclusion, these results suggest that 2-day therapy with high-dose atorvastatin before PCI did not influence occurrence of periprocedural MI or long-term clinical outcomes. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1295-1299)","[Veselka, Josef; Zemanek, David; Hajek, Petr; Maly, Martin; Adlova, Radka; Martinkovicova, Lucie; Tomasov, Pavol; Tesar, David] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Cardiol,Cardiovasc Ctr, Prague, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Cardiol,Cardiovasc Ctr, Prague, Czech Republic.","veselka.josef@seznam.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health of the Czech Republic [00064203]","This work was supported by Grant 00064203 from the Ministry of Health of the Czech Republic.",null,18,4,4,"EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC","BRIDGEWATER","685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA","0002-9149",null,null,"AM J CARDIOL","Am. J. Cardiol.","MAY 1",2011,107,9,null,null,null,null,1295,1299,null,"10.1016/j.amjcard.2010.12.040",null,5,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","764CI","WOS:000290605600008"]
[null,null,null,null,"J","Veselka, J; Hajek, P; Maly, M; Zemanek, D; Adlova, R; Tomasov, P; Martinkovicova, L; Tesar, D; Cervinka, P",null,null,null,"Veselka, Josef; Hajek, Petr; Maly, Martin; Zemanek, David; Adlova, Radka; Tomasov, Pavol; Martinkovicova, Lucie; Tesar, David; Cervinka, Pavel",null,null,"Predictors of coronary intervention-related myocardial infarction in stable angina patients pre-treated with statins","ARCHIVES OF MEDICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"C-reactive protein; stent; myocardial infarction","C-REACTIVE PROTEIN; LONG-TERM MORTALITY; ATORVASTATIN; ELEVATION; RISK; INFLAMMATION; EVENTS; IMPACT; EXTENT; DAMAGE","Introduction: Pen-procedural myocardial infarction (PMI) is a frequent and prognostically important complication of percutaneous coronary intervention (PCI). This study was designed to determine the predictors of PMI in patients pre-treated with statins. Material and methods: A total of 418 stable angina pectoris patients taking statins and aspirin were included. All the patients underwent PCI. Serum concentrations of creatine kinase (CK-MB mass) and troponin I (TnI) were measured prior to and then within 16 to 24 hours after PCI. The incidence of PMI was assessed using the established criteria (>= 3 times upper limit of normal). Results: Four hundred and eighteen stable patients (63 +/- 10 years, 68% males) were treated by PCI. The technical success rate of PCI was 99%. The incidence of PMI based on CK-MB mass or TnI release was 12% (PMI group). There were no significant differences in baseline clinical and procedural characteristics between PMI and non-PMI groups except for the balloon inflation time (40 +/- 44 s vs. 26 +/- 27 s; p = 0.02) and the proportion of treated type C lesions (42% vs. 28%; p = 0.03). In multivariate analysis, the independent predictors of PMI were balloon inflation time (OR = 1.01; 95% CI 1.001-1.020; p = 0.02) and pre-procedural level of C-reactive protein (OR = 1.38; 95% CI 1.059-1.808; p = 0.02). Conclusions: These results suggest that C-reactive protein and balloon ischaemic time are independent predictors of PMI in stable angina patients pre-treated with statins.","[Veselka, Josef; Hajek, Petr; Maly, Martin; Zemanek, David; Adlova, Radka; Tomasov, Pavol; Martinkovicova, Lucie; Tesar, David] Charles Univ Prague, Dept Cardiol, Sch Med 2, Univ Hosp Motol, Prague 15000 5, Czech Republic; [Cervinka, Pavel] Masaryk Hosp, Dept Cardiol, Usti Nad Labem, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Dept Cardiol, Sch Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15000 5, Czech Republic.","veselka.josef@seznam.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health of the Czech Republic [00064203]","The work was supported by the grant of the Ministry of Health of the Czech Republic Nr. 00064203.",null,21,4,4,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922",null,null,"ARCH MED SCI","Arch. Med. Sci.","FEB",2011,7,1,null,null,null,null,67,72,null,"10.5114/aoms.2011.20606",null,6,"Medicine, General & Internal","General & Internal Medicine","765ZL","WOS:000290747800011"]
[null,null,null,null,"J","Hajek, P; Macek, M; Lashkevich, A; Kluckova, N; Hladikova, M; Hansvenclova, E; Maly, M; Veselka, J; Krebsova, A",null,null,null,"Hajek, Petr; Macek, Milan, Sr.; Lashkevich, Andrej; Kluckova, Nana; Hladikova, Marie; Hansvenclova, Eva; Maly, Martin; Veselka, Josef; Krebsova, Alice",null,null,"Influence of concomitant heparin administration on pregnancy-associated plasma protein-A levels in acute coronary syndrome with ST segment elevation","ARCHIVES OF MEDICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"pregnancy-associated plasma protein-A; myocardial infarction; heparin; percutaneous coronary intervention","MAJOR BASIC-PROTEIN; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; CELL-SURFACE; PAPP-A; PROFORM; MARKER","Introduction: The time course of pregnancy-associated plasma protein-A (PAPP-A) levels was studied at admission, immediately after percutaneous coronary intervention (PCI) and 1, 2, 4, 6, 12, 24 and 48 h after PCI in acute coronary syndrome with ST segment elevation (ACS-STE) to determine the impact of PCI, concomitant clinical complications and heparin administration. Material and methods: Pregnancy-associated plasma protein-A serum levels, examined by the Kryptor (TM) system, were studied in 30 heparinized PCI ACS-STE patients, in 10 elective PCIs and 12 coronary angiographies with heparin, and in 5 patients with normal coronary angiogram without heparin. Results: Heparin caused a high PAPP-A increase in ACS-STE patients, in all patients with heparin without ACS and angiographic signs of significant atherosclerosis. This increase was directly associated with heparin dosage and activated clotting time (ACT) (r = 0.71, p = 0.0001) and inversely with the interval between heparin applications and time of serum sampling. It was followed by a rapid decrease within 1 to 2 h and return to normal levels in 10 to 12 h. In ACS-STE patients the decrease was significantly slower than in heparinized elective PCI and angiography patients. The PAPP-A increase was not significantly dependent on the length of PCI. Persistent increase after 24 h was associated in 4/7 patients with concomitant clinical complications. Conclusions: The diagnostic validity of PAPP-A can be verified only within the 1st h after clinical onset of ACS before heparin administration, the prognostic value in heparinized patients not earlier than 12 h after the last heparin application, if ACT is normal and serious clinical concomitant complications are eliminated.","[Hajek, Petr; Hansvenclova, Eva; Maly, Martin; Veselka, Josef] Univ Hosp Motol, Dept Cardiol, Prague 15006 5, Czech Republic; [Hajek, Petr; Hansvenclova, Eva; Maly, Martin; Veselka, Josef] Charles Univ Prague, Dept Cardiol, Ctr Cardiovasc, Prague, Czech Republic; [Macek, Milan, Sr.; Lashkevich, Andrej; Kluckova, Nana; Hladikova, Marie] Charles Univ Prague, Dept Biol & Med Genet, Prague, Czech Republic; [Krebsova, Alice] Humboldt Univ, Klinikum Rudolf Virchow, Dept Internal Med Cardiol, D-10099 Berlin, Germany","Hajek, P (reprint author), Univ Hosp Motol, Dept Cardiol, Uvalu 84, Prague 15006 5, Czech Republic.","petr.hajek@fnmotol.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828"," [MZOFNM2005]","Supported by MZOFNM2005. Critical review of Prof. M. Macek Jr, MD, DSc is appreciated. Petr Hajek and Milan Macek Sr. contributed equally to this work.",null,23,3,3,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922",null,null,"ARCH MED SCI","Arch. Med. Sci.","DEC",2011,7,6,null,null,null,null,977,983,null,"10.5114/AOMS.2011.26609",null,7,"Medicine, General & Internal","General & Internal Medicine","872TA","WOS:000298831300011"]
[null,null,null,null,"J","Kuklova, P; Zemkova, D; Kyncl, M; Pycha, K; Stranak, Z; Melichar, J; Snajdauf, J; Rygl, M",null,null,null,"Kuklova, P.; Zemkova, D.; Kyncl, M.; Pycha, K.; Stranak, Z.; Melichar, J.; Snajdauf, J.; Rygl, M.",null,null,"Large diaphragmatic defect: are skeletal deformities preventable?","PEDIATRIC SURGERY INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"Congenital diaphragmatic hernia; Synthetic nonabsorbable patch; Gore-Tex; Somatic growth; Skeletal deformity; Thoracic index","TERM-FOLLOW-UP; HERNIA REPAIR; MORBIDITY; SURVIVORS; MANAGEMENT; OUTCOMES; CHILDREN; INFANTS; SIZE; RISK","The aim of study was to compare growth, nutritional status and incidence of chest wall deformities and scoliosis in survivors of large congenital diaphragmatic hernia (CDH) defect (Gore-Tex patch reconstruction) with survivors with smaller defects and primary reconstruction. An anthropometric study of 53 children who underwent CDH repair in neonatal period was carried out. Weight, height, and skin-fold thickness were measured, scoliosis and chest wall deformity were evaluated. Body mass index (BMI) and thoracic index (TI) were calculated using standard rules. The measured data were compared with national population standard with the use of standard deviation score (SDS). According to the type of diaphragmatic reconstruction, the patients were divided into two groups [Gore-Tex patch (10) versus primary repair (43)]. Student t test and Fisher exact tests were used for statistical analysis. Pectus excavatum was found in 25 (47%) patients, poor posture in 33% and significant scoliosis in 5%. Compared with the population norm, CDH children had a significantly lower body height SDS (mean -0.39, p < 0.05), weight SDS (mean -0.75, p < 0.001), BMI (mean SDS -0.68, p < 0.001) and lower TI (mean SDS -0.62, p < 0.01). Gore-Tex versus primary repair group significantly differed in incidence of pectus excavatum and BMI (PE: p = 0.027, BMI SDS: p = 0.016). A majority of anthropometric parameters (weight, height, thoracic index, and thorax circumference) and incidence of scoliosis and poor posture in children after Gore-Tex patch reconstruction did not significantly differ from children after primary repair. The differences in some anthropometric parameters (weight, BMI, and TI) and in the skeletal deformity suggest that the CDH not only disturbs normal lung growth, but also seems to have implications on some other aspects of somatic development. Whether these changes could be related to the type of diaphragmatic reconstruction or rather to the size of the defect remains uncertain.","[Kuklova, P.; Pycha, K.; Snajdauf, J.; Rygl, M.] Charles Univ Prague, Dept Pediat Surg, Fac Med 2, Prague 15000 5, Czech Republic; [Kuklova, P.; Zemkova, D.; Kyncl, M.; Pycha, K.; Snajdauf, J.; Rygl, M.] Charles Univ Prague, Univ Hosp Motol, Prague 15000 5, Czech Republic; [Zemkova, D.] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague 15000 5, Czech Republic; [Kyncl, M.] Charles Univ Prague, Dept Imaging Methods, Fac Med 2, Prague 15000 5, Czech Republic; [Stranak, Z.; Melichar, J.] Inst Care Mother & Child, Prague 14700 4, Czech Republic","Rygl, M (reprint author), Charles Univ Prague, Dept Pediat Surg, Fac Med 2, V Uvalu 84, Prague 15000 5, Czech Republic.","mrygl@yahoo.com",null,null,"IGA Ministry of Health Czech Republic [NS10572-3/2009]","Supported by a grant NS10572-3/2009 IGA Ministry of Health Czech Republic.",null,34,2,2,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0179-0358",null,null,"PEDIATR SURG INT","Pediatr. Surg. Int.","DEC",2011,27,12,null,null,null,null,1343,1349,null,"10.1007/s00383-011-2973-6",null,7,"Pediatrics; Surgery","Pediatrics; Surgery","852HU","WOS:000297349200016"]
[null,null,null,null,"J","Vicha, A; Holzerova, M; Krepelova, A; Musil, Z; Prochazka, P; Sumerauer, D; Kodet, R; Eckschlager, T; Jarosova, M",null,null,null,"Vicha, Ales; Holzerova, Milena; Krepelova, Anna; Musil, Zdenek; Prochazka, Pavel; Sumerauer, David; Kodet, Roman; Eckschlager, Tomas; Jarosova, Marie",null,null,"Molecular Cytogenetic Characterization in Four Pediatric Pheochromocytomas and Paragangliomas","PATHOLOGY & ONCOLOGY RESEARCH",null,null,"English","Article",null,null,null,null,null,"Pheochromocytoma; Paraganglioma; Comparative genomic hybridization; Pediatric; Microarray","COMPARATIVE GENOMIC HYBRIDIZATION; MALIGNANT PHEOCHROMOCYTOMA; SPORADIC PHEOCHROMOCYTOMAS; FAMILIAL PHEOCHROMOCYTOMA; CHROMOSOMES 1P; LINDAU DISEASE; FREQUENT LOSS; HETEROZYGOSITY; MUTATIONS; CHILDREN","Pheochromocytomas (PCCs) are rare tumors among children and adolescents and therefore are not genetically well characterized. The most frequently observed chromosomal changes in PCC are losses of 1p, 3q and/or 3p, 6q, 17p, 11q, 22q, and gains of 9q and 17q. Aberrations involving chromosome 11 are more common in malignant tumors. Unfortunately information about gene aberrations in childhood PCC's is limited. We used comparative genomic hybridization (CGH) and array comparative genomic hybridization (aCGH) to screen for copy number changes in four children suffering from pheochromocytoma or paraganglioma. Patients were diagnosed at the age 13 or 14 years. Bilateral pheochromocytoma was associated with von Hippel-Lindau syndrome (VHL). Multiple paraganglioma was associated with a germline mutation in SDHB. We found very good concordance between the results of CGH and aCGH techniques. Losses were observed more frequently than gains. All cases had a loss of chromosome 11 or 11p. Other aberrations were loss of chromosome 3 and 11 in sporadic pheochromocytoma, and loss of 3p and 11p in pheochromocytoma, which carried the VHL mutation. The deletion of chromosome 1p and other changes were observed in paragangliomas. We conclude that both array CGH and CGH analysis identified similar chromosomal regions involved in tumorigenesis of pheochromocytoma and paragangliomas, but we found 3 discrepancies between the methods. We didn't find any, of the proposed, molecular markers of malignancy in our benign cases and therefore we speculate that molecular cytogenetic examination may be helpful in separating benign and malignant forms in the future.","[Vicha, Ales; Prochazka, Pavel; Sumerauer, David; Eckschlager, Tomas] Charles Univ Prague, Med Sch 2, Dept Pediat Hematol & Oncol, Prague 5, Motol, Czech Republic; [Vicha, Ales; Prochazka, Pavel; Sumerauer, David; Eckschlager, Tomas] Univ Hosp Motol, Fak Nemocnice Motole, Prague 5, Motol, Czech Republic; [Holzerova, Milena; Jarosova, Marie] Palacky Univ, Sch Med, Dept Hematooncol, CR-77147 Olomouc, Czech Republic; [Holzerova, Milena; Jarosova, Marie] Univ Hosp, Olomouc, Czech Republic; [Krepelova, Anna] Charles Univ Prague, Med Sch 2, Inst Biol & Med Genet, Prague 5, Motol, Czech Republic; [Kodet, Roman] Charles Univ Prague, Med Sch 2, Dept Pathol & Mol Med, Prague 5, Motol, Czech Republic; [Musil, Zdenek] Charles Univ Prague, Fac Med 1, Inst Biol & Med Genet, Prague 5, Motol, Czech Republic; [Musil, Zdenek] Gen Teaching Hosp, Prague, Czech Republic; [Musil, Zdenek] Charles Univ Prague, Fac Sci, Dept Antropol & Human Genet, Prague 5, Motol, Czech Republic","Vicha, A (reprint author), Charles Univ Prague, Med Sch 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 5, Motol, Czech Republic.","ales.vicha@lfmotol.cuni.cz","Prochazka, Pavel/G-4759-2012; Vicha, Ales/I-6726-2012","Vicha, Ales/0000-0003-3075-5554","Czech Ministry of Education, Youth and Sports [MSM0021620813, MSM0021620808]; Czech Ministry of Health [MZ0FNM2005]","This work was supported by the Czech Ministry of Education, Youth and Sports (MSM0021620813 and MSM0021620808), and a Research Project of the Czech Ministry of Health (MZ0FNM2005)",null,33,2,2,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","1219-4956",null,null,"PATHOL ONCOL RES","Pathol. Oncol. Res.","DEC",2011,17,4,null,null,null,null,801,808,null,"10.1007/s12253-011-9385-8",null,8,"Oncology; Pathology","Oncology; Pathology","829NA","WOS:000295588000003"]
[null,null,null,null,"J","Zemanek, D; Tomasov, P; Homolova, S; Linhartova, K; Veselka, J",null,null,null,"Zemanek, David; Tomasov, Pavol; Homolova, Stanislava; Linhartova, Katerina; Veselka, Josef",null,null,"Sublingual isosorbide dinitrate for the detection of obstruction in hypertrophic cardiomyopathy","EUROPEAN JOURNAL OF ECHOCARDIOGRAPHY",null,null,"English","Article",null,null,null,null,null,"Hypertrophic cardiomyopathy; obstruction; left ventricular outflow tract; provoking test","OUTFLOW TRACT OBSTRUCTION; AMYL NITRITE; EXERCISE; PROVOCATION; GRADIENTS","Aims Hypertrophic cardiomyopathy (HCM) is predominantly associated with left ventricular outflow tract (LVOT) obstruction. The assessment of the obstruction with a provoking test should be a routine part of HCM evaluation. The aim of the study was to determine the utility of a sublingual spray application of isosorbide dinitrate (ISDN) for detection of an obstruction. Methods and results We have prospectively analysed 77 consecutive HCM patients, measuring the LVOT gradient at rest, using the sublingual spray application of ISDN (2.5 mg; after 2, 5, and 10 min), and with exercise echocardiography. An obstruction was defined as a gradient >= 30 mmHg. An obstruction was present in 15 patients (19%) at rest, in 42 patients (55%) after ISDN, and in 55 patients (71%) after exercise. The ISDN test had a sensitivity of 76% and the specificity of 100% relative to exercise echocardiography, while at-rest measurements had a sensitivity of 27% and a specificity of 100%. The chronological difference in the prevalence of obstructions during the ISDN test was statistically significant (P < 0.05); at ISDN plus 2 min, obstructions were seen in only 29 patients (38%, gradient 28.8 +/- 25.0 mmHg), however, at ISDN plus 5 and 10 min, obstructions were found in 42 patients (55%, gradient 44.5 +/- 39.6 mmHg). Conclusion The ISDN test is a reliable screening method for the detection of an HCM obstruction, however, the measurement should be delayed 5-10 min after the application of ISDN. Patients with negative ISDN tests should undergo exercise echocardiography.","[Zemanek, David; Linhartova, Katerina; Veselka, Josef] Charles Univ Prague, Dept Cardiol, Univ Hosp Motol, Med Sch 1&2, Prague 15021, Czech Republic; [Tomasov, Pavol; Homolova, Stanislava] Charles Univ Prague, Med Sch 2, Prague 15021, Czech Republic","Zemanek, D (reprint author), Charles Univ Prague, Dept Cardiol, Univ Hosp Motol, Med Sch 1&2, V Uvalu 84, Prague 15021, Czech Republic.","zejada@seznam.cz",null,null,"Ministry of Health, Czech Republic; Internal Grant Agency, Ministry of Health, Czech Republic [NT 11401-5]","This study was supported by grant MZOFNM 2005 from Ministry of Health, Czech Republic and by grant NT 11401-5 from the Internal Grant Agency, Ministry of Health, Czech Republic.",null,16,2,2,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1525-2167",null,null,"EUR J ECHOCARDIOGR","Eur. J. Echocardiogr.","SEP",2011,12,9,null,null,null,null,684,687,null,"10.1093/ejechocard/jer115",null,4,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","834LN","WOS:000295961300011"]
[null,null,null,null,"J","Cakrt, O; Slaby, K; Viktorinova, L; Kolar, P; Jerabek, J",null,null,null,"Cakrt, Ondrej; Slaby, Krystof; Viktorinova, Lucie; Kolar, Pavel; Jerabek, Jaroslav",null,null,"Subjective visual vertical in patients with idiopatic scoliosis","JOURNAL OF VESTIBULAR RESEARCH-EQUILIBRIUM & ORIENTATION",null,null,"English","Article",null,null,null,null,null,"Scoliosis; adolescent; vestibular function; otolith system; bucket method","BRAIN-STEM; OTOLITH; LESIONS; HUMANS; LATEROPULSION; DISSOCIATION; PERCEPTION; SYSTEM","Idiopathic scoliosis (IS) is characterized by a three-dimensional deviation of the vertebral column and its etiopathogenesis is unknown. Various factors are associated with idiopathic scoliosis, among these a prominent role has been attributed to integration of vestibular information with graviception for perception of space. Subjective visual vertical (SVV) is a sensitive sign of verticality perception. The aim of this study was to determine if SVV in adolescents with IS is different from healthy controls. Examination of SVV was performed using the bucket method. Binocular measurements of SVV were made in 23 adolescents with IS (age 14.5 +/- 2.5, mean +/- SD) and 23 healthy subjects (age 14.0 +/- 2.9). The groups differed significantly on SVV deviation (p < 0.01): healthy controls (-0.04 degrees +/- 0.64 degrees), IS group (0.86 degrees +/- 1.39 degrees). There was also significant difference in SVV uncertainty (p < 0.001): healthy controls (1.50 degrees +/- 0.94 degrees), IS group (2.46 +/- 0.82 degrees). We conclude that the perception of visual vertical is altered in IS which may play role in development of IS.","[Cakrt, Ondrej; Slaby, Krystof; Viktorinova, Lucie; Kolar, Pavel] Charles Univ Prague, Dept Rehabil & Sports Med, Fac Med 2, Fac Hosp Motol, Prague 15006 5, Czech Republic; [Cakrt, Ondrej; Jerabek, Jaroslav] Czech Tech Univ, Fac Biomed Engn, CR-16635 Prague, Czech Republic; [Jerabek, Jaroslav] Charles Univ Prague, Dept Neurol, Fac Med 2, Fac Hosp Motol, Prague 15006 5, Czech Republic","Cakrt, O (reprint author), Charles Univ Prague, Dept Rehabil & Sports Med, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","ondrej.cakrt@lf2.cuni.cz",null,null,null,null,null,23,2,2,"IOS PRESS","AMSTERDAM","NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS","0957-4271",null,null,"J VESTIBUL RES-EQUIL","J. Vestib. Res.-Equilib. Orientat.",null,2011,21,3,null,null,null,null,161,165,null,"10.3233/VES-2011-0414",null,5,"Neurosciences; Otorhinolaryngology","Neurosciences & Neurology; Otorhinolaryngology","808BA","WOS:000293946900006"]
[null,null,null,null,"J","Wilhelm, J; Ost'adalova, I; Vytasek, R; Vajner, L",null,null,null,"Wilhelm, Jiri; Ost'adalova, Ivana; Vytasek, Richard; Vajner, Ludek",null,null,"Generation of hydrogen peroxide in the developing rat heart: the role of elastin metabolism","MOLECULAR AND CELLULAR BIOCHEMISTRY",null,null,"English","Article",null,null,null,null,null,"Rat heart; Development; Hydrogen peroxide; Elastin; Fluorescence","LYSYL OXIDASE; PROTECTS; CELLS","Reports describing production of reactive oxygen species in neonatal heart are missing. As lysyl oxidase is potentially important source of H(2)O(2), we studied its role during ontogenic development of rat heart. H(2)O(2) was detected in thin sections of developing rat heart by fluorescence microscopy with the use of fluorescence probe 2'-7'-dichlorofluorescin. The experimental design comprised foetuses 21 days after conception, and then the animals sampled on the 1st, 4th, 7th, 10th, 15th, 30th and 60th day after birth. We also used 7-month-old animals as an example of ageing effects. Since the day 4 on, H(2)O(2) was produced only extracellularly up to the day 15, between days 30 and 60 intracellular production was detected as well, and in 7-month-old animals only extracellular production was observed. The specific inhibitors of lysyl oxidase almost completely quenched the H(2)O(2)-dependent fluorescence. Starting from day 7, blue autofluorescence specific to oxidized proteins developed in the vessel wall. Intracellular blue autofluorescence specific to autoxidation products developed after day 30. Chloroform extraction diminished the intracellular blue fluorescence, leaving the extracellular fluorescence intact. This confirmed the protein nature of the fluorophores. Lysyl oxidase is significant source of H(2)O(2) in the heart vessel wall during development and H(2)O(2) oxidatively modifies elastin producing protein blue autofluorescence.","[Wilhelm, Jiri; Vytasek, Richard] Charles Univ Prague, Cardiovasc Res Ctr, Sch Med 2, Dept Med Chem & Biochem, Prague 15000 5, Czech Republic; [Ost'adalova, Ivana] Acad Sci Czech Republic, Inst Physiol, Cardiovasc Res Ctr, CR-14220 Prague 4, Czech Republic; [Vajner, Ludek] Charles Univ Prague, Dept Histol & Embryol, Sch Med 2, Prague 15000 5, Czech Republic","Wilhelm, J (reprint author), Charles Univ Prague, Cardiovasc Res Ctr, Sch Med 2, Dept Med Chem & Biochem, Plzenska 221, Prague 15000 5, Czech Republic.","jiri.wilhelm@lfmotol.cuni.cz","Wilhelm, Jiri/C-6252-2012; Vajner, Ludek/C-5823-2014; Vytasek, Richard/C-7571-2014",null,"Grant Agency of Czech Republic [P303/11/0298]","The study was supported by Grant Agency of Czech Republic, grant no. P303/11/0298.",null,19,1,1,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0300-8177",null,null,"MOL CELL BIOCHEM","Mol. Cell. Biochem.","DEC",2011,358,41671,null,null,null,null,215,220,null,"10.1007/s11010-011-0937-8",null,6,"Cell Biology","Cell Biology","838JZ","WOS:000296286700024"]
[null,null,null,null,"J","Vaskova, M; Kovac, M; Volna, P; Angelisova, P; Mejstrikova, E; Zuna, J; Brdicka, T; Hrusak, O",null,null,null,"Vaskova, Martina; Kovac, Martin; Volna, Petra; Angelisova, Pavla; Mejstrikova, Ester; Zuna, Jan; Brdicka, Tomas; Hrusak, Ondrej",null,null,"High expression of cytoskeletal protein drebrin in TEL/AML1(pos) B-cell precursor acute lymphoblastic leukemia identified by a novel monoclonal antibody","LEUKEMIA RESEARCH",null,null,"English","Article",null,null,null,null,null,"Drebrin; Acute lymphoblastic leukemia; Gene expression profiling; TEL/AML1; Flow cytometry; Monoclonal antibody; Immunophenotyping","EMBRYO","The expression of drebrin, a cytoskeletal protein newly estimated by expression profiling to correlate with the genotype and prognosis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), was examined by independent methods. After demonstrating its higher expression in TEL/AML1(pos) BCP-ALL by quantitative reverse transcriptase polymerase chain reaction, we developed an anti-drebrin monoclonal antibody (mAb). In a cohort of 86 children with BCP-ALL, we found increased expression of drebrin in TEL/AML1(pos) ALL. In conclusion, relationship of drebrin expression and prognosis or genotype can now be assessed using flow cytometry. (C) 2011 Elsevier Ltd. All rights reserved.","[Vaskova, Martina; Kovac, Martin; Volna, Petra; Mejstrikova, Ester; Zuna, Jan; Hrusak, Ondrej] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague 15006, Czech Republic; [Vaskova, Martina; Kovac, Martin; Volna, Petra; Mejstrikova, Ester; Zuna, Jan; Hrusak, Ondrej] CLIP, Prague, Czech Republic; [Angelisova, Pavla; Brdicka, Tomas] Acad Sci Czech Republic, Inst Mol Genet, Lab Mol Immunol, Prague, Czech Republic","Hrusak, O (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","ondrej.hrusak@lfmotol.cuni.cz",null,null,"Ministry of Education, Youth and Sports of the Czech Republic [2B06064]","Grant support. National Program of Research II (project 2B06064) from Ministry of Education, Youth and Sports of the Czech Republic.",null,8,1,1,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0145-2126",null,null,"LEUKEMIA RES","Leuk. Res.","AUG",2011,35,8,null,null,null,null,1111,1113,null,"10.1016/j.leukres.2011.03.028",null,3,"Oncology; Hematology","Oncology; Hematology","792ID","WOS:000292735300024"]
[null,null,null,null,"J","Zaliova, M; Meyer, C; Cario, G; Vaskova, M; Marschalek, R; Stary, J; Zuna, J; Trka, J",null,null,null,"Zaliova, Marketa; Meyer, Claus; Cario, Gunnar; Vaskova, Martina; Marschalek, Rolf; Stary, Jan; Zuna, Jan; Trka, Jan",null,null,"TEL/AML1-Positive Patients Lacking TEL Exon 5 Resemble Canonical TEL/AML1 Cases","PEDIATRIC BLOOD & CANCER",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; childhood leukemia; TEL/AML1","ACUTE LYMPHOBLASTIC-LEUKEMIA; FUSION PROTEIN; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIPTIONAL REPRESSION; TEL-AML1 TRANSLOCATION; PRELEUKEMIC ACTIVITY; EXPRESSION PATTERNS; TUMOR-SUPPRESSOR; BONE-MARROW; STEM-CELLS","Background. The TEL/AML1 fusion gene which represents the most frequent genetic abnormality in childhood ALL, usually results from genomic breakpoints in TEL intron 5 and AML1 intron 1 or 2. At the protein level, the helix loop helix domain and exon 5-coded central region of TEL are typically fused to almost entire AML1 including DNA-binding domain. Procedure. We identified two ALL patients with genomic breakpoints within TEL intron 4 resulting in variant TEL/AML1 fusion lacking the TEL exon 5-coded central region. This region was supposed to play an important role in TEL/AML1 function, particularly in TEL/AML1-mediated transcriptional repression of AML1 targets. We aimed at investigating the impact of the loss of this region on disease behavior and TEL/AML1 function. We compared clinical and biological characteristics, treatment response, and outcome of the variant versus classical TEL/AML1 cases, analyzed genome wide gene expression profiles and performed reporter gene assay. Results. No distinct differences between variant and classical TEL/AML1 cases were observed including gene expression profiling and detailed immunophenotyping. By using reporter gene assay, we showed that the loss of the central region does not influence the TEL/AML1-mediated transcriptional repression. Conclusions. The deletion of the central region did not affect the TEL/AML1-specific phenotype; we did not find any relevant differences in clinical and biological features when variant versus classical TEL/AML1-positive cases were compared. Thus, our data does not support hypothesis that the central region of TEL is indispensable for TEL/AML1 driven leukemogenesis. Pediatr Blood Cancer. 2011;56:217-225. (C) 2010 Wiley-Liss, Inc.","[Zaliova, Marketa] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, CLIP,Fac Med 2, Prague 15006 5, Czech Republic; [Zaliova, Marketa; Vaskova, Martina; Stary, Jan; Zuna, Jan; Trka, Jan] Univ Hosp Motol, Prague, Czech Republic; [Meyer, Claus; Marschalek, Rolf] Goethe Univ Frankfurt, Inst Pharmaceut Biol, ZAFES,Bioctr, Diagnost Ctr Acute Leukemia, Frankfurt, Germany; [Cario, Gunnar] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany","Zaliova, M (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, CLIP,Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","marketa.zaliova@lfmotol.cuni.cz","Marschalek, Rolf/D-3404-2011",null," [MSM0021620813];  [MZOFNM2005]","This work was supported by grants MSM0021620813 and MZOFNM2005. Authors would like to acknowledge all participating centers within the Czech Pediatric Hematology Working Group (CPH) for clinical management and sample collection.",null,47,1,1,"WILEY-LISS","HOBOKEN","DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA","1545-5009",null,null,"PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","FEB",2011,56,2,null,null,null,null,217,225,null,"10.1002/pbc.22686",null,9,"Oncology; Hematology; Pediatrics","Oncology; Hematology; Pediatrics","703YI","WOS:000286017500009"]
[null,null,null,null,"J","Klapkova, E; Kukacka, J; Kotaska, K; Suchanska, I; Urinovska, R; Prusa, R",null,null,null,"Klapkova, Eva; Kukacka, Jiri; Kotaska, Karel; Suchanska, Iveta; Urinovska, Romana; Prusa, Richard",null,null,"The Influence of 7-OH Methotrexate Metabolite on Clinical Relevance of Methotrexate Determination","CLINICAL LABORATORY",null,null,"English","Article",null,null,null,null,null,"Methotrexate; 7-hydroxymethotrexate; high performance liquid chromatography; 2,4-diamino-N(10)-methylpteroic acid; fluorescence polarization immunoassays","ACUTE LYMPHOBLASTIC-LEUKEMIA; PERFORMANCE LIQUID-CHROMATOGRAPHY; ACUTE LYMPHOCYTIC-LEUKEMIA; HIGH-DOSE METHOTREXATE; PLASMA; CHILDREN; SERUM; 7-HYDROXYMETHOTREXATE; RADIOIMMUNOASSAY; PHARMACOKINETICS","Background: A modified high performance liquid chromatographic (HPLC) method has been developed for the simultaneous determination of methotrexate (MTX) and its main metabolite 7-hydroxymethotrexate (7-OHMTX) and compared to the immunochemical fluorescence polarization immunoassay (FPIA2) determination of methotrexate. Methods: Methotrexate was determined by HPLC with UV detection at 303 nm after precipitation of proteins with trichloroacetic acid. Fluorescence polarization immunoassays (FPIA2) of methotrexate were performed on the TDx FLx Immunoassay Analyzer. Results: Our data indicate good correlation between methotrexate levels >1 mu mol/L determined by HPLC and FPIA2. (r = 0.94, Spearman correlation coefficient). However, concentrations of methotrexate <1 mu mol/L measured by fluorescence polarization immunoassay were overestimated. Conclusions: The concentration of MTX <1 mu mol/L are overestimated due to the cross reactivity with metabolites 7-OHMTX and 2,4-diamino-N(10)-methylpteroic acid (DAMPA). The cross reaction may affect the therapy and lead to relapse in children with acute lymphoblastic leukemia. (Clin. Lab. 2011;57:599-606)","[Klapkova, Eva; Kukacka, Jiri; Kotaska, Karel; Suchanska, Iveta; Urinovska, Romana; Prusa, Richard] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med & Fac Hosp Motol 2, Prague, Czech Republic; [Kukacka, Jiri] Czech Tech Univ, Dept Biomed Technol, Fac Biomed Engn, Chem Sci Biochem & Lab Diagnost Div, Prague, Czech Republic","Klapkova, E (reprint author), Fac Med & Fac Hosp Motol, V Uvalu 84, Prague 15006, Czech Republic.","eva.klapkova@email.cz","Kukacka, Jiri/C-4770-2013",null,null,null,null,18,1,1,"CLIN LAB PUBL","HEIDELBERG","IM BREITSPIEL 15, HEIDELBERG, D-69126, GERMANY","1433-6510",null,null,"CLIN LAB","Clin. Lab.",null,2011,57,41858,null,null,null,null,599,606,null,null,null,8,"Medical Laboratory Technology","Medical Laboratory Technology","825DL","WOS:000295251000017"]
[null,null,null,null,"J","Kozak, J; Kobesova, A; Vrba, I; Steindler, J; Kolar, P",null,null,null,"Kozak, Jiri; Kobesova, Alena; Vrba, Ivan; Steindler, Jiri; Kolar, Pavel",null,null,"Peripheral, nerve stimulation in intractable neuropathic pain","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"chronic neuropathic pain; complex regional pain syndrome; neurostimulation therapy; peripheral nerve stimulation; multidisciplinary approach","REFLEX SYMPATHETIC DYSTROPHY; MANAGEMENT; SYSTEM; NEUROSTIMULATION; SYMPTOMS; RELIEF","Peripheral nerve stimulation (PNS) is a neurostimulation analgesic technique. PNS is utilized to treat peripheral neuropathic pain. It is highly sophisticated and a specialized technique used where other forms of treatment have failed. This paper describes the PNS procedure, its therapeutic principles, indications, and the comprehensive care for patients after the PNS implant. First, we summarize our experience using this type of invasive treatment. In the second part, a case of intractable neuropathic pain following repeated surgery to the ulnar nerve is reported. Prior to PNS, the patient underwent multiple types of antineuralgic treatment with no significant result. Only after the PNS application, was a significant analgesic effect achieved.","[Kozak, Jiri; Kobesova, Alena; Kolar, Pavel] Charles Univ Prague, Fac Med 2, Dept Rehabil & Sports Med, Prague 15006 5, Czech Republic; [Kozak, Jiri] Charles Univ Prague, Fac Med 2, Pain Management Ctr, Prague 15006 5, Czech Republic; [Kozak, Jiri; Kobesova, Alena; Steindler, Jiri; Kolar, Pavel] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Vrba, Ivan] Hosp Na Homolce, Dept Anesthesiol & Resuscitat, Prague, Czech Republic; [Steindler, Jiri] Charles Univ Prague, Fac Med 2, Dept Neurosurg, Prague 15006 5, Czech Republic","Kobesova, A (reprint author), Charles Univ Prague, Fac Med 2, Dept Rehabil & Sports Med, V Uvalu 84, Prague 15006 5, Czech Republic.","alenamudr@me.com",null,null,"foundation Movement without Help, Prague, Czech Republic;  [VZ 0021620816/ 2006-2011]","This study was supported by the foundation Movement without Help, Prague, Czech Republic and by VZ 0021620816/ 2006-2011 grant.",null,47,1,1,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2011,32,3,null,null,null,null,226,233,null,null,null,8,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","809XJ","WOS:000294089700002"]
[null,null,null,null,"J","Paulasova, P; Diblik, J; Trkova, M; Macek, M; Sedlacek, Z",null,null,null,"Paulasova, Petra; Diblik, Jan; Trkova, Marie; Macek, Milan, Sr.; Sedlacek, Zdenek",null,null,"Increased sperm aneuploidy in two male carriers of germline TP53 mutations","CANCER GENETICS",null,null,"English","Article",null,null,null,null,null,"Li-Fraumeni syndrome; TP53 gene; fluorescence in situ hybridization","FAMILIAL SYNDROME; TURNER-SYNDROME; BREAST-CANCER; P53 MUTATIONS; SPERMATOGENESIS; FREQUENCY; ABNORMALITIES; CHECKPOINT; NEOPLASMS; CARCINOMA","Li-Fraumeni syndrome is a rare autosomal dominant cancer predisposition syndrome characterized by a broad spectrum of tumors. The disorder is caused by germline mutations in the TP53 gene. We studied chromosomes in the sperm of two male carriers of TP53 mutations. We observed increased sperm aneuploidy, mainly concerning the gonosomes when compared to four normal male controls. This observation may correlate with the involvement of the p53 protein in spermatogenesis, with its role in aneuploidy in cancer, and with the occurrence of two cases of Turner syndrome in families with germline TP53 mutations reported in the literature.","[Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Sedlacek, Z (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic.","zdenek.sedlacek@lfmotol.cuni.cz",null,null,"Ministry of Health [MZOFNM2005, IGA NR 9448-3/2007]; Ministry of Education of the Czech Republic [MSM0021620813]","The authors would like to thank Dr. Roman Krejci for assistance with the statistical analysis. This work was supported by grants MZOFNM2005 and IGA NR 9448-3/2007 from the Ministry of Health, and MSM0021620813 from the Ministry of Education of the Czech Republic.",null,27,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","2210-7762",null,null,"CANCER GENET-NY","Cancer Genet.","MAY",2011,204,5,null,null,null,null,278,281,null,"10.1016/j.cancergen.2011.03.003",null,4,"Oncology; Genetics & Heredity","Oncology; Genetics & Heredity","782PD","WOS:000292020700007"]
[null,null,null,null,"J","Goetz, M; Prihodova, I; Hrdlicka, M",null,null,null,"Goetz, Michal; Prihodova, Iva; Hrdlicka, Michal",null,null,"Long lasting complex nocturnal hallucinations during Osmotic Release Oral System (OROS) methylphenidate treatment in a 7-year old girl","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"ADHD; methyplhenidate; Osmotic Release Oral System (OROS); sleep; confussional arousals; hallucinations; children; side effects","ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; VISUAL HALLUCINATIONS; ADHD; CHILDREN; SLEEP; BOYS","We report a case of a girl with Attention deficit hyperactivity disorder (ADHD) and Oppositional defiant disorder (ODD) who experienced a 3-hour episode of nocturnal complex bizarre visual hallucinations when treated with 18 mg Osmotic Release Oral System (OROS) methylphenidate (MPH). Nocturnal polysomnography performed two weeks later revealed REM sleep reduction (17%) and fragmentation. Two episodes of confusional arousals were recorded. This finding is typical of parasomnia associated with NREM sleep - disorder of arousal. We hypothesize that this preexisting sleep impairment represents a factor of vulnerability to MPH sleep side effects. In our search of literature, we found no report of nocturnal hallucination alone during treatment with stimulants.","[Goetz, Michal; Hrdlicka, Michal] Charles Univ Prague, Dept Child & Adolescent Psychiat, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Prihodova, Iva] Charles Univ Prague, Fac Med 1, Dept Neurol, Gen Teaching Hosp Prague, Prague 15006 5, Czech Republic","Goetz, M (reprint author), Charles Univ Prague, Dept Child & Adolescent Psychiat, Fac Med 2, Univ Hosp Motol, Uvalu 84, Prague 15006 5, Czech Republic.","michal.goetz@lfmotol.cuni.cz",null,null,"Charles University [GAUK 383/2010]","Supported by Charles University Grant GAUK 383/2010",null,19,0,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2011,32,5,null,null,null,null,619,622,null,null,null,4,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","896CV","WOS:000300543900006"]
[null,null,null,null,"J","Odehnal, M; Malec, J; Malcova, I; Dotrelova, D",null,null,null,"Odehnal, M.; Malec, J.; Malcova, I.; Dotrelova, D.",null,null,"Eyelid Implants in Lagophtalmus Therapy","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"facial nerve palsy; lagophtalmus; eyelid; surgical implant; gold implant","GOLD WEIGHT IMPLANTATION; FACIAL PALSY; LAGOPHTHALMOS; PARALYSIS; REHABILITATION","The authors report their experience with eyelid surgical implants, applied in lagophtalmus therapy of facial nerve palsy. A total of 29 patients (three of them children) were operated upon during the period between 2004 and 2010 at the Eye Clinic for Children and Adults (Prague, Motol Hospital). Progressive corneal keratopathy was the main indication for operation. The average follow-up period was 4.5 years. The eyelid surgical implants were made of pure gold. Eyelid function before and after surgery was evaluated in terms of the House-Brackmann scale. Eyelid function improved in all patients and corneal keratopathy improved in 75% of them. Lagophtalmus was reduced from an average diameter of 6.5 mm (4.5-9.5 mm) before operation to an average diameter of 1.5 mm (0-2.5 mm) after operation. Twenty-seven of the patients operated upon considered that eyelid surgery had improved their quality of life.","[Odehnal, M.; Malec, J.; Malcova, I.; Dotrelova, D.] 2 LF UK & FN Motole, Ocni Klin Deti & Dospelych, Prague 15006 5, Czech Republic","Odehnal, M (reprint author), 2 LF UK & FN Motole, Ocni Klin Deti & Dospelych, V Uvalu 84, Prague 15006 5, Czech Republic.","milan.odehnal@fnmotol.cz",null,null,null,null,null,17,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2011,74,4,null,null,null,null,459,462,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","809EZ","WOS:000294035900008"]
[null,null,null,null,"J","Laczo, J; Andel, R; Vlcek, K; Matoska, V; Vyhnalek, M; Tolar, M; Bojar, M; Hort, J",null,null,null,"Laczo, Jan; Andel, Ross; Vlcek, Kamil; Matoska, Vaclav; Vyhnalek, Martin; Tolar, Martin; Bojar, Martin; Hort, Jakub",null,null,"Spatial Navigation and APOE in Amnestic Mild Cognitive Impairment","NEURODEGENERATIVE DISEASES",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; Mild cognitive impairment; Apolipoprotein E; Spatial navigation; Morris water maze; Memory","APOLIPOPROTEIN-E GENOTYPE; ALZHEIMERS-DISEASE; ELDERLY INDIVIDUALS; EPSILON-4 ALLELE; BRAIN-FUNCTION; E GENE; MEMORY; RISK; APOE-EPSILON-4; ATTENTION","Background: The effect of APOE epsilon 4 allele (epsilon 4) on spatial navigation in amnestic mild cognitive impairment (aMCI) is unknown. Objective: Our purpose was to examine the characteristics of spatial navigation impairment in epsilon 4-positive (epsilon 4+) and epsilon 4-negative (epsilon 4-) aMCI subgroups. Methods: Blood samples were collected to determine the APOE genotype. A total of 34 aMCI patients were stratified into aMCI-epsilon 4- (n = 23) and aMCI-epsilon 4+ (n = 11) groups. Control (n = 28) and mild Alzheimer's disease (AD; n = 16) groups were also used. We used a human analogue of the Morris water maze (enclosed arena 2.9 m in diameter) to examine body-centered (egocentric) and world-centered (allocentric) spatial navigation. Results: The aMCI-epsilon 4+ group performed poorer on spatial navigation than the aMCI-epsilon 4-group in both egocentric and allocentric tasks even though these 2 groups did not differ in global cognitive functioning or neuropsychological tests. The aMCI-epsilon 4+ and mild AD groups performed similarly on all Morris Water Maze tasks and were outperformed by the aMCI-epsilon 4- group, which also resembled the control group in performance on the egocentric tasks. The aMCI groups showed poor spatial navigation learning regardless of their epsilon 4 positivity. Conclusion: We found more profound deficits in spatial navigation in aMCI-epsilon 4+ relative to aMCI-epsilon 4- patients. The aMCI-epsilon 4+ group resembled the mild AD group in spatial navigation performance. Although the epsilon 4 genotype was indicative of spatial navigation performance, it was not indicative of the aMCI patients' ability to learn the tasks. Spatial navigation testing represents a promising area with respect to identifying individuals at higher risk for AD among the heterogeneous MCI population. Copyright (C) 2010 S. Karger AG, Basel","[Laczo, Jan; Vyhnalek, Martin; Bojar, Martin; Hort, Jakub] Charles Univ Prague, Sch Med 2, Dept Neurol, Memory Disorders Unit, CZ-15006 Prague 5, Czech Republic; [Vlcek, Kamil] Acad Sci Czech Republic, Inst Physiol, Memory Disorders Unit, Prague, Czech Republic; [Matoska, Vaclav] Homolka Hosp, Dept Clin Biochem Hematol & Immunol, Prague, Czech Republic; [Laczo, Jan; Vyhnalek, Martin; Hort, Jakub] Int Clin Res Ctr, Brno, Czech Republic; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Tolar, Martin] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA","Hort, J (reprint author), Charles Univ Prague, Sch Med 2, Dept Neurol, Memory Disorders Unit, Uvalu 84, CZ-15006 Prague 5, Czech Republic.","Jakub.Hort@seznam.cz","Vlcek, Kamil/B-9620-2012","Vlcek, Kamil/0000-0001-7152-3093","Grant Agency of the Czech Republic [309/09/1053, 309/09/0286]; Ministry of Education, Youth and Sports of the Czech Republic [1M0517, LC554, AV0Z50110509]","The study was supported by the Grant Agency of the Czech Republic Grants 309/09/1053 and 309/09/0286, Ministry of Education, Youth and Sports of the Czech Republic Grants 1M0517 and LC554, and research project AV0Z50110509.",null,43,13,13,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1660-2854",null,null,"NEURODEGENER DIS","Neurodegener. Dis.",null,2011,8,4,null,null,null,null,169,177,null,"10.1159/000321581",null,9,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","763LT","WOS:000290559000002"]
[null,null,null,null,"J","Dvorankova, B; Szabo, P; Lacina, L; Gal, P; Uhrova, J; Zima, T; Kaltner, H; Andre, S; Gabius, HJ; Sykova, E; Smetana, K",null,null,null,"Dvorankova, Barbora; Szabo, Pavol; Lacina, Lukas; Gal, Peter; Uhrova, Jana; Zima, Tomas; Kaltner, Herbert; Andre, Sabine; Gabius, Hans-Joachim; Sykova, Eva; Smetana, Karel, Jr.",null,null,"Human Galectins Induce Conversion of Dermal Fibroblasts into Myofibroblasts and Production of Extracellular Matrix: Potential Application in Tissue Engineering and Wound Repair","CELLS TISSUES ORGANS",null,null,"English","Article",null,null,null,null,null,"Extracellular matrix; Fibronectin; Keratinocyte; Lectin; Tissue engineering","MESENCHYMAL STEM-CELLS; STROMAL FIBROBLASTS; ENDOGENOUS LECTINS; EPIDERMAL-CELLS; EXPRESSION; TUMOR; GROWTH; DIFFERENTIATION; KERATINOCYTES; BINDING","Members of the galectin family of endogenous lectins are potent adhesion/growth-regulatory effectors. Their multi-functionality opens possibilities for their use in bioapplications. We studied whether human galectins induce the conversion of human dermal fibroblasts into myofibroblasts (MFBs) and the production of a bioactive extracellular matrix scaffold is suitable for cell culture. Testing a panel of galectins of all three subgroups, including natural and engineered variants, we detected activity for the proto-type galectin-1 and galectin-7, the chimera-type galectin-3 and the tandem-repeat-type galectin-4. The activity of galectin-1 required the integrity of the carbohydrate recognition domain. It was independent of the presence of TGF-beta 1, but it yielded an additive effect. The resulting MFBs, relevant, for example, for tumor progression, generated a matrix scaffold rich in fibronectin and galectin-1 that supported keratinocyte culture without feeder cells. Of note, keratinocytes cultured on this substratum presented a stem-like cell phenotype with small size and keratin-19 expression. In vivo in rats, galectin-1 had a positive effect on skin wound closure 21 days after surgery. In conclusion, we describe the differential potential of certain human galectins to induce the conversion of dermal fibroblasts into MFBs and the generation of a bioactive cell culture substratum. Copyright (C) 2011 S. Karger AG, Basel","[Dvorankova, Barbora; Szabo, Pavol; Lacina, Lukas; Gal, Peter; Smetana, Karel, Jr.] Charles Univ Prague, Fac Med 1, Inst Anat, CZ-12800 Prague 2, Czech Republic; [Lacina, Lukas] Charles Univ Prague, Fac Med 1, Dept Dermatovenerol, CZ-12800 Prague 2, Czech Republic; [Uhrova, Jana; Zima, Tomas] Charles Univ Prague, Fac Med 1, Inst Clin Biochem, CZ-12800 Prague 2, Czech Republic; [Uhrova, Jana; Zima, Tomas] Charles Univ Prague, Fac Med 1, Diagnost Lab, CZ-12800 Prague 2, Czech Republic; [Dvorankova, Barbora; Szabo, Pavol; Lacina, Lukas; Sykova, Eva; Smetana, Karel, Jr.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, CZ-12800 Prague 2, Czech Republic; [Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Gal, Peter] Univ Vet Med & Pharm, Dept Biomed Res, E Slovak Inst Cardiovasc Dis, Kosice, Slovakia; [Gal, Peter] Univ Vet Med & Pharm, Dept Biomed Res, Dept Pathol Anat, Kosice, Slovakia; [Kaltner, Herbert; Andre, Sabine; Gabius, Hans-Joachim] Univ Munich, Inst Physiol Chem, Fac Vet Med, D-8000 Munich, Germany","Smetana, K (reprint author), Charles Univ Prague, Fac Med 1, Inst Anat, U Nemocnice 3, CZ-12800 Prague 2, Czech Republic.","karel.smetana@lf1.cuni.cz",null,null,"Ministry of Education, Youth and Sports of the Czech Republic [MSM 0021620806, 1M0538]; Charles University in Prague; EC research program GlycoHIT [ID 260600]; Verein zur Forderung des biologisch-technologischen Fortschritts in der Medizin e.V. (Heidelberg, Germany)","This study was supported by the Ministry of Education, Youth and Sports of the Czech Republic projects No. MSM 0021620806 and 1M0538, the Charles University in Prague, the EC research program GlycoHIT (contract ID 260600) and the Verein zur Forderung des biologisch-technologischen Fortschritts in der Medizin e.V. (Heidelberg, Germany). The authors are grateful to Dr. James Dutt for the language revision and to Iva Burdova, Dr. Tomas Vasilenko and Magdalena Majnusova for excellent technical assistance.",null,42,12,12,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1422-6405",null,null,"CELLS TISSUES ORGANS","Cells Tissues Organs",null,2011,194,6,null,null,null,null,469,480,null,"10.1159/000324864",null,12,"Anatomy & Morphology; Cell Biology; Developmental Biology","Anatomy & Morphology; Cell Biology; Developmental Biology","850RX","WOS:000297216700003"]
[null,null,null,null,"J","Lassuthova, P; Mazanec, R; Vondracek, P; Siskova, D; Haberlova, J; Sabova, J; Seeman, P",null,null,null,"Lassuthova, P.; Mazanec, R.; Vondracek, P.; Siskova, D.; Haberlova, J.; Sabova, J.; Seeman, P.",null,null,"High frequency of SH3TC2 mutations in Czech HMSN I patients","CLINICAL GENETICS",null,null,"English","Article",null,null,null,null,null,"Charcot; Marie; Tooth 4C; mutation; peripheral neuropathy; SH3TC2 gene","DISEASE TYPE 4C; PROTEIN; NEUROPATHY; DATABASE; PANTHER; ASD","Charcot-Marie-Tooth (CMT) neuropathy type 4C (CMT4C) is an autosomal recessive (AR), demyelinating neuropathy with early spine deformities caused by mutations in the SH3TC2 gene. To determine the spectrum of SH3TC2 mutations in the Czech population, the entire coding region of SH3TC2 was sequenced in 60 unrelated Czech patients. The prevalent mutation was shown to be the p. Arg954Stop. Therefore, 412 additional patients referred for CMT testing were tested for the presence of p. Arg954Stop only. Of 60 patients in whom the SH3TC2 gene was sequenced, at least one mutation was detected in 13 (21.7%) patients and biallelic pathogenic mutations were detected in 7 (11.6%) patients. Of the 412 patients tested for p. Arg954Stop, the mutation was found in 8 patients (1.94%), 6 were homozygous and 2 were heterozygous. The second causative mutation was detected by sequencing in one of the patients but not in the other. Nine novel sequence variants were detected. Their pathogenicity was further tested in silico and in control samples. Mutations in the SH3TC2 gene are a frequent cause of demyelinating hereditary neuropathy among Czech patients. In total, at least one mutation was found in 21 unrelated patients. CMT4C seems to be the most frequent type of AR CMT and one of the most frequent of all CMT types. Mutation p. Arg954Stop is highly prevalent in the Czech population. Patients with demyelinating neuropathy along with non-dominant mode of inheritance and negative for CMT1A/hereditary neuropathy with liability to pressure palsy should be tested for the presence of the p. Arg954Stop mutation or other mutations in the SH3TC2 gene.","[Lassuthova, P.; Haberlova, J.; Sabova, J.; Seeman, P.] Univ Hosp Motol, Sch Med 2, Dept Child Neurol, DNA Lab, Prague 15000, Czech Republic; [Mazanec, R.] Univ Hosp Motol, Sch Med 2, Dept Neurol, Prague 15000, Czech Republic; [Vondracek, P.] Univ Hosp Brno, Clin Pediat Neurol, Brno, Czech Republic; [Siskova, D.] Thomayer Univ Hosp, Dept Child Neurol, Prague, Czech Republic","Lassuthova, P (reprint author), Univ Hosp Motol, Sch Med 2, Dept Child Neurol, DNA Lab, V Uvalu 84, Prague 15000, Czech Republic.","petra.lassuthova@gmail.com",null,null,"Czech Ministry of Health [IGA NT 11521/4]","This study was supported by the Czech Ministry of Health (grant IGA NT 11521/4). We thank the patients and their families for their participation in the study.",null,22,8,9,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0009-9163","1399-0004",null,"CLIN GENET","Clin. Genet.","OCT",2011,80,4,null,null,null,null,334,345,null,"10.1111/j.1399-0004.2011.01640.x",null,12,"Genetics & Heredity","Genetics & Heredity","820QN","WOS:000294920600005"]
[null,null,null,null,"J","Zieg, J; Krepelova, A; Baradaran-Heravi, A; Levtchenko, E; Guillen-Navarro, E; Balascakova, M; Sukova, M; Seeman, T; Dusek, J; Simankova, N; Rosik, T; Skalova, S; Lebl, J; Boerkoel, CF",null,null,null,"Zieg, Jakub; Krepelova, Anna; Baradaran-Heravi, Alireza; Levtchenko, Elena; Guillen-Navarro, Encarna; Balascakova, Miroslava; Sukova, Martina; Seeman, Tomas; Dusek, Jiri; Simankova, Nadezda; Rosik, Tomas; Skalova, Sylva; Lebl, Jan; Boerkoel, Cornelius F.",null,null,"Rituximab resistant evans syndrome and autoimmunity in Schimke immuno-osseous dysplasia","PEDIATRIC RHEUMATOLOGY",null,null,"English","Article",null,null,null,null,null,"Schimke immuno; osseous dysplasia; Unilateral renal agenesis; Nephrotic syndrome; Evans syndrome; Rituximab","COMMON VARIABLE IMMUNODEFICIENCY; WISKOTT-ALDRICH-SYNDROME; OF-THE-LITERATURE; IMMUNOOSSEOUS DYSPLASIA; NEPHROTIC SYNDROME; SPONDYLOEPIPHYSEAL DYSPLASIA; THROMBOCYTOPENIC PURPURA; DISORDERS; DEFICIENCY; ASSOCIATION","Autoimmunity is often observed among individuals with primary immune deficiencies; however, the frequency and role of autoimmunity in Schimke immuno-osseous dysplasia (SIOD) has not been fully assessed. SIOD, which is caused by mutations of SMARCAL1, is a rare autosomal recessive disease with its prominent features being skeletal dysplasia, T cell deficiency, and renal failure. We present a child with severe SIOD who developed rituximab resistant Evans syndrome (ES). Consistent with observations in several other immunodeficiency disorders, a review of SIOD patients showed that approximately a fifth of SIOD patients have some features of autoimmune disease. To our best knowledge this case represents the first patient with SIOD and rituximab resistant ES and the first study of autoimmune disease in SIOD.","[Zieg, Jakub; Seeman, Tomas; Dusek, Jiri; Simankova, Nadezda; Rosik, Tomas; Lebl, Jan] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Krepelova, Anna; Balascakova, Miroslava] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Baradaran-Heravi, Alireza; Boerkoel, Cornelius F.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada; [Levtchenko, Elena] Univ Hosp Leuven, Dept Pediat Nephrol, Louvain, Belgium; [Guillen-Navarro, Encarna] Hosp Univ Virgen La Arrixaca, Serv Pediat, Unidad Genet Med, Murcia, Spain; [Sukova, Martina] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Skalova, Sylva] Charles Univ Prague, Fac Med, Dept Pediat, Prague, Czech Republic; [Skalova, Sylva] Charles Univ Prague, Univ Hosp Hradec Kralove, Prague, Czech Republic","Zieg, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat, Prague, Czech Republic.","jakubzieg@hotmail.com",null,null,"Czech Ministry of Health [VZ 0006420301]; March of Dimes; Gillson Longenbaugh Foundation; Dana Foundation; Microscopy, and Administrative Cores of the Mental Retardation and Developmental Disabilities Research Center at Baylor College of Medicine; Burroughs Wellcome Foundation; National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health; Institute of Human Development, Child and Youth Health from the SickKids Foundation; Canadian Institutes of Health Research; Association Autour D'Emeric et D'Anthony; The Little Giants Foundation","This work was supported in part by grant VZ 0006420301 MZOFNM 2005, the Czech Ministry of Health. It was also supported by the March of Dimes (C.F.B.); the Gillson Longenbaugh Foundation (C.F.B.); the Dana Foundation (C.F.B.), the New Development Award, Microscopy, and Administrative Cores of the Mental Retardation and Developmental Disabilities Research Center at Baylor College of Medicine (C.F.B.); the Burroughs Wellcome Foundation (C.F.B.); the National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health (C.F.B.); the New Investigator Grant: Institute of Human Development, Child and Youth Health from the SickKids Foundation - Canadian Institutes of Health Research (C.F.B.); the Association Autour D'Emeric et D'Anthony (C.F.B.); and The Little Giants Foundation (C.F.B.). C.F.B. is a scholar of the Michael Smith Foundation for Health Research and a Clinical Investigator of the Child & Family Research Institute.",null,39,3,3,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1546-0096",null,null,"PEDIATR RHEUMATOL","Pediatr. Rheumatol.","SEP 13",2011,9,null,null,null,null,null,null,null,27,"10.1186/1546-0096-9-27",null,6,"Pediatrics; Rheumatology","Pediatrics; Rheumatology","829PR","WOS:000295596800001"]
[null,null,null,null,"J","Vasovcak, P; Senkerikova, M; Hatlova, J; Krepelova, A",null,null,null,"Vasovcak, Peter; Senkerikova, Maria; Hatlova, Jana; Krepelova, Anna",null,null,"Multiple primary malignancies and subtle mucocutaneous lesions associated with a novel PTEN gene mutation in a patient with Cowden syndrome: Case report","BMC MEDICAL GENETICS",null,null,"English","Article",null,null,null,null,null,null,"SYNDROME PLEASE STAND; GASTROINTESTINAL POLYPOSIS; GERMLINE MUTATIONS; PTEN/MMAC1 GENE; DISEASE; HAMARTOMA; PATHWAY; WILL","Background: Cowden syndrome (CS) is a cancer predisposition syndrome associated with increased risk of breast, thyroid, and endometrial cancers, and is characterized by development of benign mucocutaneous lesions. Case presentation: Here we report on a 58-year-old woman with multiple primary malignancies and subtle mucocutaneous lesions such as small polyps and wart-like papulas. Over a period of 23 years, she developed various malignant neoplasms including thyroid, ovarian, stomach, and colon carcinomas, and a benign meningioma. Direct sequencing analysis of the PTEN gene revealed a novel germline mutation (c.438delT, p.Leu146X). Conclusion: This case demonstrates that Cowden syndrome is a multi-system disease that can result in the development of multiple malignant and benign tumors.","[Vasovcak, Peter; Krepelova, Anna] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Vasovcak, Peter; Krepelova, Anna] Univ Hosp Motol, Prague, Czech Republic; [Senkerikova, Maria] Univ Hosp, Dept Med Genet, Hradec Kralove, Czech Republic; [Hatlova, Jana] Fac Med, Fingerlands Dept Pathol, Hradec Kralove, Czech Republic","Vasovcak, P (reprint author), Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic.","pevas78@hotmail.com",null,null," [VZ MZO 00064203]","Supported by: VZ MZO 00064203",null,28,3,3,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2350",null,null,"BMC MED GENET","BMC Med. Genet.","MAR 15",2011,12,null,null,null,null,null,null,null,38,"10.1186/1471-2350-12-38",null,4,"Genetics & Heredity","Genetics & Heredity","741HR","WOS:000288855300001"]
[null,null,null,null,"J","Gonsorcikova, L; Vaxillaire, M; Pruhova, S; Dechaume, A; Dusatkova, P; Cinek, O; Pedersen, O; Froguel, P; Hansen, T; Lebl, J",null,null,null,"Gonsorcikova, Lucie; Vaxillaire, Martine; Pruhova, Stepanka; Dechaume, Aurelie; Dusatkova, Petra; Cinek, Ondrej; Pedersen, Oluf; Froguel, Philippe; Hansen, Torben; Lebl, Jan",null,null,"Familial mild hyperglycemia associated with a novel ABCC8-V84I mutation within three generations","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"ABCC8; diabetes; hyperglycemia; MODY; SUR1","NEONATAL DIABETES-MELLITUS; SULFONYLUREA RECEPTOR; INSULIN-SECRETION; CHANNEL SUBUNITS; GENE; DOMINANT","We present a unique case of a 19-year-old man with a positive family history of persistent mild hyperglycemia and a novel V84I mutation in ABCC8. The proband was initially detected to have fasting hyperglycemia (ranging 6.1-6.4 mmol/L) at the age of 12 years. Increased fasting blood glucose was also subsequently detected in five additional family members (in his twin brother, sister, mother, maternal aunt, and grandfather). The grandfather has been known to have mild diabetes since 30 years and has never been treated. After having excluded a causative mutation in five maturity-onset diabetes of the young genes (MODY1-4 and 6), we identified a novel ABCC8 V84I mutation, which segregated with autosomal dominant transmission of mild hyperglycemia within three generations. This mutation that is located in a conserved area of transmembrane domain TMD0 seems to be a rare cause of clinical phenotype resembling glucokinase-deficient diabetes.","[Gonsorcikova, Lucie; Pruhova, Stepanka; Dusatkova, Petra; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-15006 Prague 5, Czech Republic; [Vaxillaire, Martine; Dechaume, Aurelie; Froguel, Philippe] Univ Lille 2, Inst Pasteur, Lille Inst Biol, CNRS,UMR8090, Lille, France; [Pruhova, Stepanka] Charles Univ Prague, Fac Med 3, Dept Pediat, CZ-15006 Prague 5, Czech Republic; [Pedersen, Oluf; Hansen, Torben] Steno Diabet Ctr, Gentofte, Denmark; [Pedersen, Oluf; Hansen, Torben] Hagedorn Res Inst, Gentofte, Denmark; [Pedersen, Oluf] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark; [Pedersen, Oluf] Univ Aarhus, Fac Hlth Sci, Aarhus, Denmark; [Froguel, Philippe] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England; [Hansen, Torben] Univ So Denmark, Fac Hlth Sci, Odense, Denmark","Lebl, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","jan.lebl@lfmotol.cuni.cz",null,null,"Norway through the Norwegian Financial Mechanism [CZ0100]; Czech Ministry of Education [MSM 0021620814]; Czech Ministry of Health [MZ 000064203]","The study was supported by a grant from Norway through the Norwegian Financial Mechanism (No CZ0100), by an institutional grant from the Czech Ministry of Education (grant MSM 0021620814) and by an institutional grant from the Czech Ministry of Health (grant MZ 000064203). The authors would like to acknowledge the patient and his family. Klara Vesela is thanked for her technical assistance.",null,16,2,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","MAY",2011,12,3,2,null,null,null,266,269,null,"10.1111/j.1399-5448.2010.00719.x",null,4,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","754XZ","WOS:000289892500009"]
[null,null,null,null,"J","Stulik, J; Nesnidal, P; Sebesta, P; Vyskocil, T; Kryl, J",null,null,null,"Stulik, J.; Nesnidal, P.; Sebesta, P.; Vyskocil, T.; Kryl, J.",null,null,"Kyphotic Deformities of the Cervical Spine","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"cervical spine; kyphosis; osteotomy; deformity correction","SPONDYLOTIC MYELOPATHY; POSTLAMINECTOMY KYPHOSIS; ANKYLOSING-SPONDYLITIS; DEGENERATIVE DISEASE; PLATE STABILIZATION; SCREW FIXATION; RIGID PLATES; FOLLOW-UP; ANTERIOR; FUSION","PURPOSE OF THE STUDY The development of a cervical kyphotic deformity can be associated with a degenerative disease, trauma, tumour, developmental anomaly and also a surgical procedure. Post-operative kyphosis can develop after both the anterior and posterior surgical approaches. The deformity can also result from systemic diseases, such as ankylosing spondylitis or rheumatoid arthritis. The aim of the study was to make the clinical and radiographic evaluation of a group of patients with kyphotic deformity treated at our department. MATERIAL Between May 2005 and April 2010, a total of 102 patients underwent correction of cervical kyphosis at our department. (Center for Spinal Surgery). Of them, 90 patients with complete medical records and post-operative periods longer than 6 months were included in this study. There were 36 men and 54 women ranging in age from 13 to 90 years and with an average of 56.7 years. In six patients cervical kyphosis was caused by an inveterate injury, in 71 by degenerative disease, in six it developed in association with rheumatoid arthritis, and in seven patients it was due to previous surgery. Patients with acute trauma, tumour, infectious disease or congenital anomaly were not included. METHODS All patients were examined before surgery by radiography in antero-posterior and lateral projection, including flexion-extension bending films, and by CT scanning of ultrathin cross-sections with sagittal, frontal and recently also 3D reconstructions. Magnetic resonance imaging in three planes was also performed. On the basis of the results and clinical examination, the operative strategy was planned. Surgery was carried out from the anterior or the posterior approach, or the combined approach was used. Three-stage surgery was performed in one patient. The surgical outcome was assessed using the Nurick score and Neck Disability Index (NDI), the Visual Analogue Scale (VAS) was used to evaluate pain intensity or paraesthesia. Statistical analysis was done using the Chi-square test and paired t-test. RESULTS The average NDI value was 25.5 before surgery and 14.3 and 14.9 at one and two years after surgery, respectively. Compared with the pre-operative state, improvement or no changes were recorded in 89.7 % of the patients; transient deterioration occurred in 10.3 %. Improvements found were as follows: by one degree in 46.2 % of the patients, by two degrees in 18 %, by three degrees in 5.1 % and by five degrees in 2.6 % of the patients. The condition remained unchanged in 18 % of the patients. The average outcome was an improvement by one degree. The average pre-operative Nurick score was 0.7; an average post-operative value of 0.6 was recorded at both one and two years of follow-up. The average VAS value for neck and radicular pain was 5.7 pre-operatively, and 2.5 and 2.7 at one and two post-operative years, respectively. Out of 90 patients, complete bone union was achieved at 6 months after surgery in 88 patients (97.8 %). The average pre-operative value for the cervical curvature index (Ishihara) was -13.7; the average pre-operative cervical kyphosis was -14.4 degrees, ranging from -2.2 to -44.0 degrees. After surgery, the average Ishihara index was +15.3 and the average lordosis was + 13.5 degrees, with a range of -16.0 to + 37.4 degrees. DISCUSSION A single/isolated anterior approach can be used for fixed deformities without ankylosing spondylitis. It allows for decompression of the anterior pathology and for correction of cervical kyphosis with use of instrumentation and structural graft. A combined ventral-dorsal approach is appropriate in fixed deformities or deformities involving the cervico-thoracic junction. The main principle of correction is to lengthen the cervical spinal column in the front and to shorten it at the back by anterior decompression with or without instrumentation and by subsequent posterior stabilisation. An isolated/single dorsal correction can be used in the case of successful correction by traction or specific head positioning on the table without anterior nerve compression. In severe fixed deformities such as Bekhterev's disease, the chin can be so close to the chest as to interfere with eating and breathing. The deformity most often develops at the cervico-thoracic junction and requires treatment by osteotomy. CONCLUSIONS The results of the study showed a marked improvement in the patients' quality of life after kyphosis correction, improved neurological status and an improved posture seen on radiograms of the cervical spine. The study also revealed a higher number of potential complications associated, in particular, with corrective osteotomy. The best results were achieved with the combined surgical approach; however, the choice of a surgical method was independent of the patient's clinical status.","[Stulik, J.; Nesnidal, P.; Sebesta, P.; Vyskocil, T.; Kryl, J.] Spondylochirurg Oddeleni FN Motol, Chirurg Klin 3, Prague 15006 5, Czech Republic; [Stulik, J.; Sebesta, P.; Vyskocil, T.; Kryl, J.] 1 LF UK FN Motol, Chirurg Klin 3, Prague, Czech Republic; [Stulik, J.] 2 LF UK FN Motol, Ortoped Klin Deti Dospelych, Prague, Czech Republic","Stulik, J (reprint author), Spondylochirurg Oddeleni FN Motol, Chirurg Klin 3, V Uvalu 84, Prague 15006 5, Czech Republic.",null,null,null,null,null,null,35,1,1,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","JUN",2011,78,3,null,null,null,null,215,224,null,null,null,10,"Orthopedics","Orthopedics","789RD","WOS:000292533100005"]
[null,null,null,null,"J","Trc, T; Bohmova, J",null,null,null,"Trc, Tomas; Bohmova, Jana",null,null,"Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA)","INTERNATIONAL ORTHOPAEDICS",null,null,"English","Article",null,null,null,null,null,null,"ANTIRHEUMATIC DRUG TRIALS; CLINICAL-TRIALS; ARTHRITIS","This was a 13-week, multicentre, randomised, parallel, double-blind study. One hundred men and women volunteers aged >= 40 years with knee osteoarthritis (KOA) were randomised to once daily enzymatic hydrolysed collagen (EHC) 10 g or glucosamine sulphate (GS) 1.5 g for 90 consecutive days. Follow-up took place after two weeks and after one, two and three months. Primary [visual analogue scale (VAS), Western Ontario and McMaster Universities (WOMAC Index)] and secondary outcomes variables, assessed at weeks two, four, eight and 12, were KOA pain intensity measured by quadruple visual analogue scales in the target knee, the WOMAC total score index, patient's and investigator's global assessments of disease activity, joint assessment, use of rescue medication (ibuprofen 400 mg tablets) and assessment of Quality of Life index (SF-36 Questionnaire). Safety and tolerability were also evaluated. Clear improvement was observed in both joint pain and symptoms in patients with KOA treated with EHC (Colatech (R)) and significant differences were observed. Mean reductions from baseline for EHC 10 g daily and GS 1.5 g, respectively, were KOA pain intensity reduction in the target knee for Colatech (R) (p<0.05): WOMAC index decrease <= 15 points at the last visit (day 90) for Colatech (R) in 16 patients (34.04%) (p<0.05) and for glucosamine in six patients (13.04%); total score index for painful joints: Colatech (R) 1.6 (p<0.05) and glucosamine 1.8; total score index for swollen joints: Colatech (R) 0.5 (p<0.05) and glucosamine 0.7; patient's global assessment of efficacy as the sum of improvement good + ideal: 80.8% for Colatech (R) and 46.6% for glucosamine (p<0.05). EHC (Colatech (R)) showed superior improvement over GS in the SF-36 Questionnaire in the Physical Health Index (42.0 for Colatech and 40.0 for glucosamine). The incidence of adverse events was similar in both groups. Both EHC and GS were well tolerated.","[Trc, Tomas] Charles Univ Prague, Orthopaed Clin, Sch Med 2, Prague, Czech Republic; [Bohmova, Jana] Fac Hosp Brno, Dept Rheumatol, Brno, Czech Republic","Trc, T (reprint author), Charles Univ Prague, Orthopaed Clin, Sch Med 2, Prague, Czech Republic.","tomas.trc@lfmotol.cuni.cz",null,null,null,null,null,20,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0341-2695",null,null,"INT ORTHOP","Int. Orthop.","MAR",2011,35,3,null,null,null,null,341,348,null,"10.1007/s00264-010-1010-z",null,8,"Orthopedics","Orthopedics","742RA","WOS:000288961000005"]
[null,null,null,null,"J","Kocourkova, J; Soltysova, M; Mohaplova, M; Hrdlicka, M",null,null,null,"Kocourkova, Jana; Soltysova, Marcela; Mohaplova, Marketa; Hrdlicka, Michal",null,null,"Anorexia nervosa in a blind girl","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"eating disorders; anorexia nervosa; blindness; adolescence; body image","WOMAN TOTALLY BLIND","Eating disorders represent significant psychopathological spectrum, particularly in adolescent girls. One of the risk factors associated with eating disorders is a strong emphasis of western visual-oriented culture on physical appearance and slimness. However, sensory handicap leading to disability to see one's own body and bodies of others does not mean that eating disorder cannot develop in blind people. The authors believe that body image is a mental construct that is not dependent on sensory perception only. They present the case of an adolescent patient, blind from early childhood, who shows symptoms of mental anorexia, depression, suicidal behavior and self-harming.","[Kocourkova, Jana; Hrdlicka, Michal] Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Prague 15006, Czech Republic; [Kocourkova, Jana; Soltysova, Marcela; Mohaplova, Marketa; Hrdlicka, Michal] Univ Hosp Motol, Prague, Czech Republic","Kocourkova, J (reprint author), Charles Univ Prague, Dept Child Psychiat, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","Jana.Kocourkova@lfmotol.cuni.cz",null,null,null,null,null,12,1,1,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2011,32,6,null,null,null,null,748,750,null,null,null,3,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","896CW","WOS:000300544000003"]
[null,null,null,null,"J","Prosecka, E; Rampichova, M; Vojtova, L; Tvrdik, D; Melcakova, S; Juhasova, J; Plencner, M; Jakubova, R; Jancar, J; Necas, A; Kochova, P; Klepacek, J; Tonar, Z; Amler, E",null,null,null,"Prosecka, E.; Rampichova, M.; Vojtova, L.; Tvrdik, D.; Melcakova, S.; Juhasova, J.; Plencner, M.; Jakubova, R.; Jancar, J.; Necas, A.; Kochova, P.; Klepacek, J.; Tonar, Z.; Amler, E.",null,null,"Optimized conditions for mesenchymal stem cells to differentiate into osteoblasts on a collagen/hydroxyapatite matrix","JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A",null,null,"English","Article",null,null,null,null,null,"collagen/HA scaffold; MSCs; osteoblasts; pore size; mechanical testing","BONE TISSUE REGENERATION; COLLAGEN SCAFFOLDS; ENGINEERED BONE; HYDROXYAPATITE; BIOMATERIALS; CARTILAGE; OSTEOGENESIS; CARBONATE; SURFACE","Collagen/hydroxyapatite (HA) composite scaffolds are known to be suitable scaffolds for seeding with mesenchymal stem cells (MSCs) differentiated into osteoblasts and for the in vitro production of artificial bones. However, the optimal collagen/HA ratio remains unclear. Our study confirmed that a higher collagen content increased scaffold stiffness but that a greater stiffness was not sufficient for bone tissue formation, a complex process evidently also dependent on scaffold porosity. We found that the scaffold pore diameter was dependent on the concentration of collagen and HA and that it could play a key role in cell seeding. In conclusion, the optimal scaffold for new bone formation and cell proliferation was found to be a composite scaffold formed from 50 wt % HA in 0.5 wt % collagen I solution. (C) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 99A: 307-315, 2011.","[Prosecka, E.; Rampichova, M.; Plencner, M.; Jakubova, R.; Amler, E.] Acad Sci Czech Republic, Inst Expt Med, Dept Tissue Engn, Prague 14240, Czech Republic; [Prosecka, E.; Rampichova, M.; Plencner, M.; Jakubova, R.; Amler, E.] Charles Univ Prague, Inst Biophys, Prague 15006 5, Motol, Czech Republic; [Vojtova, L.; Jancar, J.] Tech Univ, Dept Mat Sci, Fac Chem, Brno 61200, Czech Republic; [Tvrdik, D.; Melcakova, S.] Charles Univ Prague, Inst Pathol, Dept Mol Pathol, Prague 12800, Czech Republic; [Juhasova, J.] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Dept Cell Regenerat & Plast, Libechov 27721, Czech Republic; [Necas, A.] Univ Vet & Pharmaceut Sci, Fac Vet Med, Small Anim Clin, Dept Surg & Orthopaed, Brno 61242, Czech Republic; [Kochova, P.; Klepacek, J.; Tonar, Z.] Univ W Bohemia, Fac Sci Appl, Dept Mech, Plzen 30614, Czech Republic","Prosecka, E (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Tissue Engn, Videnska 1083, Prague 14240, Czech Republic.","prosecka@biomed.cas.cz","Vojtova, Lucy/D-7762-2012; Jancar, Josef/E-3360-2012",null,"Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Ministry of Education, Youth and Sports of the Czech Republic [NPV II 2B06130, 1M0510, P304/10/1307, 4977751303]; Grant Agency of the Academy of Sciences [IAA500390702]; Czech Science Foundation [GA202/09/1151]; EU [7E09088]; Grant Agency of the Charles University [119009, 96610, 119209, 97110, 80009]; Grant Agency of Czech Republic [106/09/P226]; Ministry of Education of the Czech Republic [ME 10145]","Contract grant sponsor: Academy of Sciences of the Czech Republic; contract grant numbers: AV0Z50390703, AV0Z50390512.Contract grant sponsor: Ministry of Education, Youth and Sports of the Czech Republic; contract grant numbers: NPV II 2B06130, 1M0510, P304/10/1307, 4977751303.Contract grant sponsor: Grant Agency of the Academy of Sciences; contract grant number: IAA500390702.Contract grant sponsor: Czech Science Foundation; contract grant number: GA202/09/1151.Contract grant sponsor: EU Project BIOSCENT; contract grant number: 7E09088.Contract grant sponsor: The Grant Agency of the Charles University; contract grant numbers: 119009, 96610, 119209, 97110, 80009.Contract grant sponsor: Grant Agency of Czech Republic; contract grant number: 106/09/P226.Contract grant sponsor: The Ministry of Education of the Czech Republic (project ERA-NET CARSILA); contract grant number: ME 10145",null,31,4,4,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1549-3296",null,null,"J BIOMED MATER RES A","J. Biomed. Mater. Res. Part A","NOV",2011,"99A",2,null,null,null,null,307,315,null,"10.1002/jbm.a.33189",null,9,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","823RQ","WOS:000295142400018"]
[null,null,null,null,"J","Lebl, J; Lebenthal, Y; Kolouskova, S; Steensberg, A; Jons, K; Kappelgaard, AM; Ibanez, L; Phillip, M",null,null,null,"Lebl, Jan; Lebenthal, Yael; Kolouskova, Stanislava; Steensberg, Adam; Jons, Kirsten; Kappelgaard, Anne-Marie; Ibanez, Lourdes; Phillip, Moshe",null,null,"Metabolic Impact of Growth Hormone Treatment in Short Children Born Small for Gestational Age","HORMONE RESEARCH IN PAEDIATRICS",null,null,"English","Article",null,null,null,null,null,"Growth hormone; Small for gestational age; Short stature; Metabolic impact","CATCH-UP GROWTH; DOSE-RESPONSE TRIAL; SERUM LEPTIN LEVELS; LOW-BIRTH-WEIGHT; BODY-MASS INDEX; SHORT STATURE; GH DEFICIENCY; IGF-I; PREPUBERTAL CHILDREN; LONGITUDINAL CHANGES","Background: Growth hormone (GH) treatment in short children born small for gestational age (SGA) may result in metabolic changes with potential long-term effects. Methods: 149 short SGA children (mean birth weight 2.0 +/- 0.6 kg, age 5.5 +/- 1.5 years, height standard deviation score (SDS) -3.1 +/- 0.6) were randomised to: low-dose GH therapy (0.033 mg/kg/day) for 2 years; high-dose GH therapy (0.100 mg/kg/day) for 1 year, or mid-dose GH therapy (0.067 mg/kg/day) for 1 year. Leptin, ghrelin, insulin-like growth factor-I (IGF-I), IGF binding protein-1 (IGFBP-1), lipids, fasting blood glucose and fasting insulin were assessed at baseline, 12 and 24 months. Results: After 1 year of active treatment, GH significantly reduced serum ghrelin and increased IGF-I SDS and insulin levels. Regression analysis showed an inverse correlation between ghrelin and IGF-I SDS (p < 0.001). Leptin and IGFBP-1 also declined (both p < 0.05). Changes in insulin levels reversed upon discontinuation. Improvements in lipid profile were nonsignificant and fasting blood glucose levels remained within the normal range. Conclusion: In short SGA children, ghrelin and leptin reductions associated with GH treatment may occur through a negative feedback loop of the GH-IGF-I axis. Consequently, via ghrelin and leptin suppression, GH treatment may modify food intake and body composition and potentially improve long-term metabolic outcomes. Copyright (C) 2011 S. Karger AG, Basel","[Lebl, Jan; Kolouskova, Stanislava] Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-15006 Prague, Czech Republic; [Lebenthal, Yael; Phillip, Moshe] Tel Aviv Univ, Inst Endocrinol & Diabet, Schneider Childrens Med Ctr Israel, IL-69978 Tel Aviv, Israel; [Lebenthal, Yael; Phillip, Moshe] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Steensberg, Adam; Jons, Kirsten; Kappelgaard, Anne-Marie] Novo Nordisk AS, Global Dev, Copenhagen, Denmark; [Ibanez, Lourdes] Univ Barcelona, Endocrine Unit, Hosp St Joan de Deu, Barcelona, Spain; [Ibanez, Lourdes] Inst Salud Carlos III, CIBERDEM CIBER Diabet & Enfermedades Metab Asocia, Madrid, Spain","Lebl, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat, Uvalu 84, CZ-15006 Prague, Czech Republic.","jan.lebl@lfmotol.cuni.cz","Ibanez, Lourdes/F-8316-2014",null,"Novo Nordisk A/S","The authors would like to thank Mr. Peter Budka and Dr. Catherine Jones (Watermeadow Medical) for their editorial assistance, which was supported by Novo Nordisk A/S. This study was funded by Novo Nordisk A/S.",null,48,3,4,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1663-2818",null,null,"HORM RES PAEDIAT","Horm. Res. Paediatr.",null,2011,76,4,null,null,null,null,254,261,null,"10.1159/000329729",null,8,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","839TR","WOS:000296392700006"]
[null,null,null,null,"J","Dostalova, T; Jelinkova, H; Sulc, J; Nemec, M; Jelinek, M; Fibrich, M; Michalik, P; Miyagi, M; Seydlova, M",null,null,null,"Dostalova, Tatjana; Jelinkova, Helena; Sulc, Jan; Nemec, Michal; Jelinek, Michal; Fibrich, Martin; Michalik, Pavel; Miyagi, Mitsunobu; Seydlova, Michaela",null,null,"Ceramic Bracket Debonding by Tm:YAP Laser Irradiation","PHOTOMEDICINE AND LASER SURGERY",null,null,"English","Article",null,null,null,null,null,null,"COSMETIC DENTISTRY; ORTHODONTICS; PRINCIPLES; ENAMEL","Objective: The aim of this study was to prepare a simple and reliable method for ceramic bracket debonding, ensuring minimal changes in the enamel structure and an acceptable temperature rise in the pulp. Background data: Ceramic bracket debonding is based on the principle of degrading the strength of adhesive resin between the tooth and ceramic bracket. The search for a safe and efficient method of adhesive resin removal following debonding has resulted in the introduction of a wide range of instruments and procedures, among which proper use of laser irradiation can be promising. Methods: The debonding of two types of ceramic brackets utilized a diode-pumped Thulium: Ytterbium-Aluminium-Perovskite (Tm:YAP) microchip laser generating irradiation at a wavelength of 1998nm (spot size 3 mm; focused by lens), with two power settings (1-2 W). Loss of enamel and residual resin on teeth, as well as rise in temperature inside the tooth were subsequently investigated in detail. Results: A 1W power of irradiation during a 60-sec period resulted in a temperature rise from 3 to 4 degrees C in the approximate root location. This power is also suitable for debracketing from the point of view of damage to enamel lying below the bracket. Only a slight damage to the enamel was registered by SEM compared to conventional bracket removal. Conclusions: Use of a Tm: YAP laser (wavelength 1998 nm, power 1W, irradiance 14W/cm(2), interacting time 60 sec) which is at the same time compact and small enough to be used in the dental practice, together with moderate cooling, could be an efficient tool for debracketing.","[Dostalova, Tatjana; Michalik, Pavel; Seydlova, Michaela] Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague 15006 5, Czech Republic; [Jelinkova, Helena; Sulc, Jan; Nemec, Michal; Jelinek, Michal; Fibrich, Martin] Czech Tech Univ, Fac Nucl Sci & Phys Engn, CR-11519 Prague, Czech Republic; [Miyagi, Mitsunobu] Tohoku Univ, Grad Sch Engn, Dept Elect Commun, Sendai, Miyagi 980, Japan","Dostalova, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, V Uvalu 84, Prague 15006 5, Czech Republic.","tatjana.dostalova@fnmotol.cz",null,null,"Czech Ministry of Education [MSM6840770022]; IGA MZCR [9991-4]","This research has been supported by a grant of the Czech Ministry of Education, No. MSM6840770022 \"Laser systems, irradiation, and modern optical applications\"; and by an IGA MZCR 9991-4 grant.",null,22,3,3,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1549-5418",null,null,"PHOTOMED LASER SURG","Photomed. Laser Surg.","JUL",2011,29,7,null,null,null,null,477,484,null,"10.1089/pho.2010.2870",null,8,"Surgery","Surgery","788MB","WOS:000292447900006"]
[null,null,null,null,"J","Obermannova, B; Pfaeffle, R; Zygmunt-Gorska, A; Starzyk, J; Verkauskiene, R; Smetanina, N; Bezlepkina, O; Peterkova, V; Frisch, H; Cinek, O; Child, CJ; Blum, WF; Lebl, J",null,null,null,"Obermannova, Barbora; Pfaeffle, Roland; Zygmunt-Gorska, Agata; Starzyk, Jerzy; Verkauskiene, Rasa; Smetanina, Natalija; Bezlepkina, Olga; Peterkova, Valentina; Frisch, Herwig; Cinek, Ondrej; Child, Christopher J.; Blum, Werner F.; Lebl, Jan",null,null,"Mutations and Pituitary Morphology in a Series of 82 Patients with PROP1 Gene Defects","HORMONE RESEARCH IN PAEDIATRICS",null,null,"English","Article",null,null,null,null,null,"PROP1; Hypopituitarism; Pituitary size, mass; Magnetic resonance imaging","HORMONE DEFICIENCY; GLAND; ENLARGEMENT; MR; COHORT; CHILDREN; SIBLINGS; DELETION; HEIGHT; GROWTH","Background/Aims: Defects of the PROP1 gene are the most prevalent genetic cause of combined pituitary hormone deficiency. Previous observations in affected patients have shown pituitary size ranging from hypoplasia to overt pituitary mass and evolution of size over the lifespan. Methods: We evaluated pituitary size and morphology in PROP1-mutation carriers who originated from Central and Eastern Europe. We analyzed 112 pituitary magnetic resonance imaging (MRI) scans from 82 patients (42 males) aged 2.5-72.7 (median 16.6) years from 60 kindreds. Results: Among the 120 independent PROP1 alleles, the most prevalent mutations were delGA301/302 (99 alleles) and delA150 (13 alleles). Median pituitary height at first MRI was 4.7 mm (range 1.0-20.7) and median volume was 127.6 mm(3) (range 7.5-3,087.0). Pituitary size did not differ between sexes and did not correlate with hormonal phenotype, but significantly decreased with increasing age. However, evaluation of individual values suggested a biphasic mode with increasing volume during childhood, peak in adolescence, and subsequent regression in adulthood. Conclusion: Although pituitary size was increased in a number of PROP1-deficient patients, none of them suffered permanent damage from pituitary mass; therefore, any proposed surgery should be postponed as long as possible and ultimately may not be necessary due to the self-limiting nature of the pituitary enlargement. Copyright (C) 2011 S. Karger AG, Basel","[Obermannova, Barbora; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-15006 Prague 5, Czech Republic; [Pfaeffle, Roland] Univ Leipzig, Dept Pediat, Leipzig, Germany; [Zygmunt-Gorska, Agata; Starzyk, Jerzy] Jagiellonian Univ, Polish Amer Pediat Inst, Dept Pediat & Adolescent Endocrinol, Krakow, Poland; [Verkauskiene, Rasa; Smetanina, Natalija] Lithuanian Univ Hlth Sci, Med Acad, Dept Pediat Endocrinol, Kaunas, Lithuania; [Bezlepkina, Olga; Peterkova, Valentina] Endocrinol Res Ctr, Moscow, Russia; [Frisch, Herwig] Univ Vienna, Dept Pediat, Vienna, Austria; [Child, Christopher J.] Eli Lilly & Co, Lilly Res Labs, Windlesham, Surrey, England; [Blum, Werner F.] Eli Lilly & Co, Lilly Res Labs, Bad Homburg, Germany","Lebl, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","Jan.Lebl@Lfmotol.cuni.cz",null,null,"MSM [0021620814]","The authors are grateful to Jurgen Klammt for the laboratory workup, to Jana Cerna, Vaclav Hana, Bozena Kalvachova, Eberhard Keller, Dana Novotna, Vladimir Weiss and Jirina Zapletalova for the patients' clinical care, to Jan Vosahlo for the technical support, to Alan G. Zimmermann, Lilly Research Laboratories, Indianapolis, Ind., USA, for statistical advice, to Elena P. Shavrikova, PSI Ltd, Russia, for statistical analysis, to Peter Bates, CMWS, UK, for manuscript editing and finally to John Parks for valuable comments on interpretation of the results. The laboratory workup of non-GeNeSIS patients from the Czech Republic and Lithuania was supported by research project MSM No. 0021620814.",null,28,2,2,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1663-2818",null,null,"HORM RES PAEDIAT","Horm. Res. Paediatr.",null,2011,76,5,null,null,null,null,348,354,null,"10.1159/000332693",null,7,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","855PN","WOS:000297576800009"]
[null,null,null,null,"J","Votava, M; Hess, L; Schreiberova, J; Malek, J; Stein, K",null,null,null,"Votava, Martin; Hess, Ladislav; Schreiberova, Jitka; Malek, Jiri; Stein, Karel",null,null,"Short term pharmacological immobilization in macaque monkeys","VETERINARY ANAESTHESIA AND ANALGESIA",null,null,"English","Article",null,null,null,null,null,"alpha(2)-adrenergic agonist; anaesthesia; fentanyl; medetomidine; midazolam; primate","MACACA-MULATTA; KETAMINE; NAPHTHYLMEDETOMIDINE; MEDETOMIDINE; COMBINATION; PROTOCOLS","Objective To develop a safe and effective immobilization protocol in rhesus monkeys, which is not based on dissociative anaesthetic agent. Study design Prospective, randomised, experimental trial. Animals Twenty rhesus monkeys, weighing 2.6-8.0 kg, 1-3 years of age, of both sexes. Methods The monkeys received 50 mu g kg(-1) medetomidine, 0.25 mg kg(-1) midazolam and 5 mu g kg(-1) fentanyl with 150 IU hyaluronidase intramuscularly (IM). The animals were closely observed for behavioural changes and reaction to sound stimulus. Pulse rate and oxygen saturation of haemoglobin (SpO(2)) were monitored every 5 minutes, for 20 minutes. After this period, 250 mu g kg(-1) atipamezole or a placebo was administered IM and behavioural changes were closely observed. Results Full immobilization was observed after mean 269 +/- SD 116 seconds. Ten minutes after injection mean arterial oxygen saturation of haemoglobin was 94 +/- 4%, but did not fall significantly further. The median pulse rate was 116 beats minute(-1) 5 minutes after the administration of the drug. This level further decreased to a median level of 108 beats minute(-1) 20 minutes after the drug's administration. The median time to recover from immobilization was significantly shorter after atipamezole administration when compared to placebo (2.7 versus 55 minutes). All animals awoke smoothly and no side effects such as vomiting or agitation were observed. Conclusions Short term and reversible pharmacological immobilization was achieved using combination of midazolam, medetomidine, and fentanyl. Clinical relevance The present study demonstrates that 20-minute pharmacological immobilization with a combination of midazolam, medetomidine, and fentanyl is feasible in rhesus monkeys with minimal effect on heart rate.","[Votava, Martin] Charles Univ Prague, Dept Pharmacol, Fac Med 2, Prague 15006 5, Czech Republic; [Hess, Ladislav] Inst Clin & Expt Med, Lab Expt Anaesthesiol, Prague, Czech Republic; [Schreiberova, Jitka] Charles Univ Prague, Dept Anaesthesiol & Intens Care Med, Fac Med, Hradec Kralove, Czech Republic; [Schreiberova, Jitka] Charles Univ Prague, Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; [Malek, Jiri] Charles Univ Prague, Dept Anaesthesiol & Crit Care Med, Fac Med 3, Prague 15006 5, Czech Republic; [Stein, Karel] Mil Hlth Insurance Co, Prague, Czech Republic","Votava, M (reprint author), Charles Univ Prague, Dept Pharmacol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","martin.votava@lfmotol.cuni.cz",null,null,"Czech Ministry of Health [NT 11284-4/2010]","This work was supported by the grant IGA NT 11284-4/2010 from the Czech Ministry of Health.",null,10,1,1,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1467-2987",null,null,"VET ANAESTH ANALG","Vet. Anaesth. Analg.","SEP",2011,38,5,null,null,null,null,490,493,null,"10.1111/j.1467-2995.2011.00637.x",null,4,"Veterinary Sciences","Veterinary Sciences","806HU","WOS:000293797700010"]
[null,null,null,null,"J","Brozkova, D; Mazanec, R; Rychly, Z; Haberlova, J; Bohm, J; Stanek, J; Plevova, P; Lisonova, J; Sabova, J; Sakmaryova, I; Seeman, P",null,null,null,"Brozkova, Dana; Mazanec, Radim; Rychly, Zdenek; Haberlova, Jana; Boehm, Jiri; Stanek, Jan; Plevova, Pavlina; Lisonova, Jana; Sabova, Jana; Sakmaryova, Iva; Seeman, Pavel",null,null,"FOUR NOVEL POINT MUTATIONS IN THE PMP22 GENE WITH PHENOTYPES OF HNPP AND DEJERINE-SOTTAS NEUROPATHY","MUSCLE & NERVE",null,null,"English","Article",null,null,null,null,null,"Charcot-Marie-Tooth neuropathy; CMT1A; Dejerine-Sottas neuropathy; hereditary neuropathy with liability to pressure palsies; PMP22 gene","MARIE-TOOTH DISEASE; HEREDITARY NEUROPATHY; PRESSURE PALSIES; SITE MUTATION; LIABILITY; SEQUENCE; IDENTIFICATION; DUPLICATION; TYPE-1A","We report four novel point mutations in the PMP22 gene with two different phenotypes: mutation p.Ser79Thr arose de novo in a patient with the Dejerine-Sottas neuropathy (DSN) phenotype; and mutations c.78+5 G>A, c.320-1 G>C, and p.Trp140Stop segregated with HNPP in 5 families. Our findings show that point mutations in PMP22 may be more likely in HNPP patients than in CMT1 patients after exclusion of CMT1A/HNPP. Muscle Nerve 44: 819-822, 2011","[Brozkova, Dana; Haberlova, Jana; Lisonova, Jana; Sabova, Jana; Sakmaryova, Iva; Seeman, Pavel] Charles Univ Prague, DNA Lab, Dept Child Neurol, Med Sch 2, Prague 15006, Czech Republic; [Brozkova, Dana; Mazanec, Radim; Haberlova, Jana; Lisonova, Jana; Sabova, Jana; Sakmaryova, Iva; Seeman, Pavel] Univ Hosp Motol, Prague 15006, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Dept Neurol, Med Sch 2, Prague 15006, Czech Republic; [Rychly, Zdenek] Cent Mil Hosp, Dept Neurol, Prague, Czech Republic; [Boehm, Jiri] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague 15006, Czech Republic; [Boehm, Jiri] Gen Teaching Hosp, Prague, Czech Republic; [Stanek, Jan] Fac Hosp, EMG Lab, Dept Child Neurol, Ostrava, Czech Republic; [Plevova, Pavlina] Fac Hosp, Dept Med Genet, Ostrava, Czech Republic","Brozkova, D (reprint author), Charles Univ Prague, DNA Lab, Dept Child Neurol, Med Sch 2, V Uvalu 84, Prague 15006, Czech Republic.","dana.brozkova@seznam.cz",null,null,"IGA MH CR NS [10552-3]","This study was supported by IGA MH CR NS 10552-3.",null,17,0,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0148-639X",null,null,"MUSCLE NERVE","Muscle Nerve","NOV",2011,44,5,null,null,null,null,819,822,null,"10.1002/mus.22189",null,4,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","839TU","WOS:000296393100021"]
[null,null,null,null,"J","Wilhelm, J; Ivica, J; Kagan, D; Svoboda, P",null,null,null,"Wilhelm, Jiri; Ivica, Josko; Kagan, Dmytro; Svoboda, Petr",null,null,"Early postnatal development of rat brain is accompanied by generation of lipofuscin-like pigments","MOLECULAR AND CELLULAR BIOCHEMISTRY",null,null,"English","Article",null,null,null,null,null,"Brain; Early development; Lipofuscin-like pigments; Fluorescence; Rat","LOW-DENSITY-LIPOPROTEIN; BODY GAMMA-IRRADIATION; LIPID-PEROXIDATION; OXIDATIVE STRESS; FREE-RADICALS; MITOCHONDRIA; CELLS; ERYTHROCYTES; ACCUMULATION; MECHANISMS","The increased generation of free radicals results in the formation of fluorescent end-products of lipid peroxidation, lipofuscin-like pigments (LFPs). The authors observed that LFPs are generated in rat brain after a normal birth during 5 postnatal days. The experimental design of the study comprised 10 groups of animals. The authors measured prenatal values 1 day and 7 days before birth, and then the animals were sampled on postnatal day 1, 2, 5, 10, 15, 25, 35, and 90. Maximum LFP concentration is achieved on the postnatal day 2. Starting from postnatal day 10, LFP concentration returns to prenatal values. A new rise in LFP concentration is observed at 3 months of age. This is associated with the beginning of the aging process. LFPs were characterized by fluorescence spectroscopy using tridimensional excitation spectra, synchronous spectra and their derivatives, and HPLC with fluorescence detection. It was possible to discern several tens of fluorescent compounds of unknown structure that are generated and metabolized during early development. The authors suggest that LFPs are formed after respiratory burst of microglia phagocytosing apoptotic cells.","[Wilhelm, Jiri; Ivica, Josko] Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Prague 15000 5, Czech Republic; [Kagan, Dmytro; Svoboda, Petr] CR Acad Sci, Inst Physiol, Prague 14220 4, Czech Republic","Wilhelm, J (reprint author), Charles Univ Prague, Dept Med Chem & Biochem, Sch Med 2, Plzenska 221, Prague 15000 5, Czech Republic.","jiri.wilhelm@lfmotol.cuni.cz","Svoboda, Petr/C-2619-2012; Wilhelm, Jiri/C-6252-2012",null,"Grant Agency of AS CR [IAA500110606]; Centre of Neurosciences (Ministry of Education of the Czech Republic) [LC 554]; Academy of Sciences of the Czech Republic [AV0Z50110509]","This study was supported by Grant Agency of AS CR (IAA500110606), The Centre of Neurosciences (project of Ministry of Education of the Czech Republic LC 554), and by the Academy of Sciences of the Czech Republic (AV0Z50110509).",null,27,0,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0300-8177",null,null,"MOL CELL BIOCHEM","Mol. Cell. Biochem.","JAN",2011,347,41671,null,null,null,null,157,162,null,"10.1007/s11010-010-0623-2",null,6,"Cell Biology","Cell Biology","696DG","WOS:000285421500017"]
[null,null,null,null,"J","Kodet, O; Dvorankova, B; Lacina, L; Andre, S; Kaltner, H; Gabius, HJ; Smetana, K",null,null,null,"Kodet, O.; Dvorankova, B.; Lacina, L.; Andre, S.; Kaltner, H.; Gabius, H. -J.; Smetana, K., Jr.",null,null,"Comparative Analysis of the Nuclear Presence of Adhesion/Growth-Regulatory Galectins and Reactivity in the Nuclei of Interphasic and Mitotic Cells","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,"lectin; mitose; cell nucleus; Ki67","ENDOGENOUS LECTINS; HUMAN-BREAST; RT-PCR/IMMUNOHISTOCHEMISTRY; PROGNOSTIC RELEVANCE; STRUCTURAL-CHANGES; TUMOR PROGRESSION; SQUAMOUS-CELL; UP-REGULATION; EXPRESSION; BINDING","Nuclear galectins participate in splicing of pre-mRNA. In this study we detected galectins-1, -2, -3 and -7 and their glycoligands in three types of cells: fibroblasts, cancer epithelial cells and melanoma cells. The results demonstrated that the nuclear expression of distinct types of galectins and their ligands in interphasic nuclei is dependent on the cell type. The extensive binding of labelled galectins-1 and -2 to mitotic cells (around chromosomes, in mitotic spindle and in bridge connecting both daughter cells) suggests their role during the cell division.","[Kodet, O.; Dvorankova, B.; Lacina, L.; Smetana, K., Jr.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Kodet, O.; Lacina, L.] Charles Univ Prague, Fac Med 1, Dept Dermatovenereol & Venerol, Prague 12800 2, Czech Republic; [Kodet, O.; Lacina, L.] Gen Univ Hosp Prague, Prague 12800 2, Czech Republic; [Dvorankova, B.; Lacina, L.; Smetana, K., Jr.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 12800 2, Czech Republic; [Andre, S.; Kaltner, H.; Gabius, H. -J.] Univ Munich, Fac Vet Med, Inst Physiol Chem, Munich, Germany","Smetana, K (reprint author), Charles Univ Prague, Fac Med 1, Inst Anat, U Nemocnice 3, Prague 12800 2, Czech Republic.","karel.smetana@lfl.cuni.cz",null,null,"Ministry of Education, Youth and Sport of the Czech Republic [MSM 0021620806, 1M0538]; Charles University","This study was supported by the Ministry of Education, Youth and Sport of the Czech Republic, projects Nos. MSM 0021620806 and 1M0538, and by the Charles University project for support of specific university research.",null,63,2,2,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2011,57,3,null,null,null,null,125,132,null,null,null,8,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","790FV","WOS:000292574800006"]
[null,null,null,null,"J","Zedkova, I; Dudova, I; Urbanek, T; Hrdlicka, M",null,null,null,"Zedkova, Iveta; Dudova, Iva; Urbanek, Tomas; Hrdlicka, Michal",null,null,"Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"schizophrenia; antipsychotics; onset of action; adolescence","DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; RISPERIDONE; OLANZAPINE; TRIAL; TOLERABILITY; ZIPRASIDONE; QUETIAPINE; CLOZAPINE; EFFICACY","OBJECTIVES: The aim of our study was to assess the time to 'first improvement' associated with specific atypical (AAP) and typical (TAP) antipsychotic drugs in patients with early-onset schizophrenia and other related psychotic disorders. METHODS: This study involved a systematic chart review of all patients receiving routine clinical care in our department, with selected AAPs and TAPs, for schizophrenic psychoses, between 1997 and 2007. During this period, our review identified 296 teenage patients (141 males, 155 females; mean age 16.0 +/- 1.5 years). The time to first improvement could be estimated in 258 patients; of these, 195 patients (76%) had been treated with AAPs and 63 patients (24%) with TAPs. We found that most patients were taking risperidone (N=96), followed by olanzapine (64 patients). Other patient numbers were as follows: ziprasidone (16 patients), quetiapine (12 patients), clozapine (7 patients), haloperidol (15 patients), perphenazine (28 patients), and sulpiride (20 patients). RESULTS: The mean time to first improvement was 6.9 (+/- 4.2) days in the AAP group and 5.8 (+/- 3.5) days in the TAP group; the difference was significant at the trend level (p=0.063). With respect to individual drugs, the mean time to first improvement was 7.1 (+/- 4.1) days for risperidone, 6.7 (+/- 4.2) days for olanzapine, 6.5 (+/- 5.2) days for ziprasidone, 6.1 (+/- 4.4) days for quetiapine, 7.4 (+/- 3.0) days for clozapine, 5.2 (+/- 2.4) days for haloperidol, 5.9 (+/- 3.8) days for perphenazine, and 6.0 (+/- 3.9) days for sulpiride. Differences among drugs were not significant (p=0.680). CONCLUSIONS: Analysis revealed a significant group level trend indicating that typical antipsychotic drugs have faster onsets of action than atypical antipsychotic drugs.","[Zedkova, Iveta; Dudova, Iva; Hrdlicka, Michal] Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Prague 15006, Czech Republic; [Urbanek, Tomas] Acad Sci, Inst Psychol, Brno, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 1, Prague 15006, Czech Republic","Hrdlicka, M (reprint author), Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Uvalu 84, Prague 15006, Czech Republic.","michal.hrdlicka@lfmotol.cuni.cz",null,null,"Ministry of Education, Youth and Sports, the Czech Republic [MSM 0021620849]","Supported by Ministry of Education, Youth and Sports, the Czech Republic (research grant MSM 0021620849).",null,21,2,2,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2011,32,5,null,null,null,null,667,670,null,null,null,4,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","896CV","WOS:000300543900015"]
[null,null,null,null,"J","Haberlova, J; Mazanec, R; Ridzon, P; Barankova, L; Nurnberg, G; Nurnberg, P; Sticht, H; Huehne, K; Seeman, P; Rautenstrauss, B",null,null,null,"Haberlova, J.; Mazanec, R.; Ridzon, P.; Barankova, L.; Nuernberg, G.; Nuernberg, P.; Sticht, H.; Huehne, K.; Seeman, P.; Rautenstrauss, B.",null,null,"Phenotypic Variability in a Large Czech Family with a Dynamin 2-Associated Charcot-Marie-Tooth Neuropathy","JOURNAL OF NEUROGENETICS",null,null,"English","Article",null,null,null,null,null,"CMT; Dynamin 2; DNM2; peripheral neuropathy","LINKAGE ANALYSIS; CENTRONUCLEAR MYOPATHY; MUTATIONS; PROGRAM; DISEASE; GENE","Mutations in the Dynamin 2 gene (DNM2) cause autosomal dominant centronuclear myopathy or autosomal dominant (AD) Charcot-Marie-Tooth (CMT) disease. Here the authors report one large Czech family with 15 members affected with an AD CMT phenotype of extraordinary variability. Genetic linkage analysis using SNP arrays revealed a locus of about 9.6 Mb on chromosome 19p13.1-13.2. In this critical interval, 373 genes were located. The only gene herein known to be associated with an intermediate type of CMT was Dynamin 2 (DNM2). Subsequent sequence analysis of the DNM2 gene in the index patient revealed a novel missense mutation p.Met580Thr. This missense mutation segregated with the neuropathy, indicating the causal character of this mutation. The phenotype of CMT in this family shows mild to moderate impairment with relatively preserved upper limbs and a very broad range of the onset of clinical symptoms from an early onset around the age of 12 to the late onset during the fifth decade. Electrophysiology showed an intermediate type of peripheral neuropathy. The motor median nerve conduction velocity varied from 36 m/s to normal values with signs of asymmetrical affection of peripheral nerves. No additional symptoms such as cranial nerve involvement, cataract, and signs of neutropenia or myopathy syndrome were observed in any member of the family yet. The progression was slow with no loss of ambulation. The authors suggest that the characterization of clinical variability in a single family may help to direct the genetic analysis directly to the rarely observed DNM2 mutations.</.","[Rautenstrauss, B.] Med Genet Zentrum, D-90491 Munich, Germany; [Rautenstrauss, B.] Univ Munich, Friedrich Baur Inst, Munich, Germany; [Haberlova, J.; Mazanec, R.; Ridzon, P.; Barankova, L.; Seeman, P.] Univ Hosp Motol, Dept Child Neurol, Dept Neurol, Prague, Czech Republic; [Nuernberg, G.; Nuernberg, P.] ATLAS Biolabs GmbH, CCG, Berlin, Germany; [Sticht, H.] Univ Erlangen Nurnberg, Fak Med, Inst Biochem, D-8520 Erlangen, Germany; [Sticht, H.] Emil Fischer Zentrum, Erlangen, Germany; [Huehne, K.] Univ Hosp Erlangen Nuremberg, Inst Human Genet, Erlangen, Germany","Rautenstrauss, B (reprint author), Med Genet Zentrum, Bayerstr 3-5, D-90491 Munich, Germany.","rautenstrauss@mgz-muenchen.de",null,null,"DFG; IGA MZ CR [NS 10554-3]","The authors thank all family members for participating in this study. This work was funded by a DFG grant to B.R. and a IGA MZ CR No NS 10554-3 grant to J.H., R.M., and P.S.",null,20,1,1,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0167-7063",null,null,"J NEUROGENET","J. Neurogenet.","DEC",2011,25,4,null,null,null,null,182,188,null,"10.3109/01677063.2011.627484",null,7,"Genetics & Heredity; Neurosciences","Genetics & Heredity; Neurosciences & Neurology","849GR","WOS:000297114100008"]
[null,null,null,null,"J","Urdzikova, L; Likavcanova-Masinova, K; Vanecek, V; Ruzicka, J; Sedy, J; Sykova, E; Jendelova, P",null,null,null,"Urdzikova, Lucia; Likavcanova-Masinova, Katarina; Vanecek, Vaclav; Ruzicka, Jiri; Sedy, Jiri; Sykova, Eva; Jendelova, Pavla",null,null,"Flt3 ligand synergizes with granulocyte-colony-stimulating factor in bone marrow mobilization to improve functional outcome after spinal cord injury in the rat","CYTOTHERAPY",null,null,"English","Article",null,null,null,null,null,"axonal sprouting; bone marrow mobilization; Flt3 ligand; granulocyte-colony-stimulating factor; neuroprotection; spinal cord injury","STROMAL CELL-CULTURES; ACUTE ISCHEMIC-STROKE; STEM-CELLS; DENDRITIC CELLS; IN-VIVO; CEREBRAL-ISCHEMIA; SCIATIC-NERVE; BRAIN-INJURY; G-CSF; TRANSPLANTATION","Background aims. The effect of granulocyte-colony-stimulating factor (G-CSF) and/or the cytokine fms-like thyrosin kinase 3 (Flt3) ligand on functional outcome and tissue regeneration was studied in a rat model of spinal cord injury (SCI). Methods. Rats with a balloon-induced compression lesion were injected with G-CSF and/or Flt3 ligand to mobilize bone marrow cells. Behavioral tests (Basso-Beattie-Bresnahan and plantar test), blood counts, morphometric evaluation of the white and gray matter, and histology were performed 5 weeks after SCI. Results. The mobilization of bone marrow cells by G-CSF, Flt3 ligand and their combination improved the motor and sensory performance of rats with SCI, reduced glial scarring, increased axonal sprouting and spared white and gray matter in the lesion. The best results were obtained with a combination of G-CSF and Flt3. G-CSF alone or in combination with Flt3 ligand significantly increased the number of white blood cells, but not red blood cells or hemoglobin content, during and after the time-course of bone marrow stimulation. The combination of factors led to infiltration of the lesion by CD11b(+) cells. Conclusions. The observed improvement in behavioral and morphologic parameters and tissue regeneration in animals with SCI treated with a combination of both factors could be associated with a prolonged time-course of mobilization of bone marrow cells. The intravenous administration of G-CSF and/or Flt3 ligand represents a safe and effective treatment modality for SCI.","[Urdzikova, Lucia; Likavcanova-Masinova, Katarina; Vanecek, Vaclav; Ruzicka, Jiri; Sedy, Jiri; Sykova, Eva; Jendelova, Pavla] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic; [Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague, Czech Republic","Jendelova, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","jendel@biomed.cas.cz","Yin, Ming/E-4879-2012",null," [GAAV IAA500390902];  [LC554];  [1M0538];  [AVOZ 503905703]","We thank James Dutt for critical reading of the manuscript. We thank Amgen Inc. for providing us with Flt3 ligand and LABVET laboratory (Prague, Czech Republic) for the evaluation of blood samples. We acknowledge the support provided by grants GAAV IAA500390902, LC554, 1M0538 and AVOZ 503905703.",null,71,1,1,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","1465-3249",null,null,"CYTOTHERAPY","Cytotherapy","OCT",2011,13,9,null,null,null,null,1090,1104,null,"10.3109/14653249.2011.575355",null,15,"Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental","Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine","820KJ","WOS:000294904300008"]
[null,null,null,null,"J","Jiruska, P; Marusic, P; Jefferys, JGR; Krsek, P; Cmejla, R; Sebronova, V; Komarek, V",null,null,null,"Jiruska, Premysl; Marusic, Petr; Jefferys, John G. R.; Krsek, Pavel; Cmejla, Roman; Sebronova, Vera; Komarek, Vladimir",null,null,"Sturge-Weber syndrome: a favourable surgical outcome in a case with contralateral seizure onset and myoclonic-astatic seizures","EPILEPTIC DISORDERS",null,null,"English","Article",null,null,null,null,null,"Sturge-Weber syndrome; myoclonic-astatic seizures; contralateral seizure onset; epilepsy surgery","SECONDARY BILATERAL SYNCHRONY","Sturge-Weber syndrome is a neurocutaneous disorder classically characterized by the presence of facial port-wine stain and ipsilateral leptomeningeal angiomatosis. It is often associated with refractory epilepsy which requires surgical treatment. We present a case of a patient who initially presented with partial seizures of temporo-occipital origin, ipsilateral to the pial angiomatosis. During the course of the disease, the patient developed medically refractory epilepsy with partial seizures originating predominantly from the contralateral temporo-occipital area as well as myoclonic and myoclonicastatic seizures. Resection of the occipital and temporal lobe affected by the pial angioma resulted in favourable outcome. Bilateral dysfunction observed in Sturge-Weber syndrome may result in an increased capability of focal discharges to generate synchronous epileptiform activity leading to an increased incidence of generalised seizures, most probably via a mechanism of secondary bilateral synchrony. [Published with video sequences]","[Marusic, Petr] Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Jiruska, Premysl; Jefferys, John G. R.] Univ Birmingham, Neuronal Networks Grp, Sch Clin & Expt Med, Birmingham, W Midlands, England; [Jiruska, Premysl; Krsek, Pavel; Sebronova, Vera; Komarek, Vladimir] Charles Univ Prague, Dept Pediat Neurol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Cmejla, Roman] Czech Tech Univ, Dept Circuit Theory, Fac Elect Engn, CR-16635 Prague, Czech Republic","Marusic, P (reprint author), Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.marusic@fnmotol.cz","Jiruska, Premysl/C-4001-2012; Jefferys, John/E-6132-2012","Jefferys, John/0000-0003-0106-4412","Epilepsy Research UK [A0937]; Motol Hospital [VZ MZOFNM2005-6504]","This work was supported by grants from Epilepsy Research UK (A0937) and Motol Hospital (VZ MZOFNM2005-6504).",null,13,1,1,"JOHN LIBBEY EUROTEXT LTD","MONTROUGE","127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE","1294-9361",null,null,"EPILEPTIC DISORD","Epileptic Disord.","MAR",2011,13,1,null,null,1,null,76,81,null,"10.1684/epd.2011.0407",null,6,"Clinical Neurology","Neurosciences & Neurology","742LW","WOS:000288946300011"]
[null,null,null,null,"J","Szabo, P; Kolar, M; Dvorankova, B; Lacina, L; Stork, J; Vlcek, C; Strnad, H; Tvrdek, M; Smetana, K",null,null,null,"Szabo, Pavol; Kolar, Michal; Dvorankova, Barbora; Lacina, Lukas; Stork, Jiri; Vlcek, Cestmir; Strnad, Hynek; Tvrdek, Miroslav; Smetana, Karel, Jr.",null,null,"Mouse 3T3 fibroblasts under the influence of fibroblasts isolated from stroma of human basal cell carcinoma acquire properties of multipotent stem cells","BIOLOGY OF THE CELL",null,null,"English","Article",null,null,null,null,null,"basal cell carcinoma (BCC); keratinocyte; stem cell plasticity; stem cell; tumour stroma","BONE MORPHOGENETIC PROTEIN-6; BREAST-CANCER CELLS; NERVE GROWTH-FACTOR; NORMAL KERATINOCYTES; PROSTATE-CANCER; GENE-EXPRESSION; FACTOR-II; IN-VITRO; BINDING; SKIN","Background information. Multipotent nnesenchymal stem cells can participate in the formation of a microenvironment stimulating the aggressive behaviour of cancer cells. Moreover, cells exhibiting pluripotent ESC (embryonic stem cell) markers (Nanog and Oct4) have been observed in many tumours. Here, we investigate the role of cancer-associated fibroblasts in the formation of stem cell supporting properties of tumour stroma. We test the influence of fibroblasts isolated from basal cell carcinoma on mouse 3T3 fibroblasts, focusing on the expression of stem cell markers and plasticity in vitro by means of microarrays, qRT-PCR (quantitative real-time PCR) and immunohistochemistry. Results. We demonstrate the biological activity of the cancer stromal fibroblasts by influencing the 3T3 fibroblasts to express markers such as Oct4, Nanog and Sox2 and to show differentiation potential similar to mesenchymal stem cells. The role of growth factors such as IGF2 (insulin-like growth factor 2), FGF7 (fibroblast growth factor 7), LEP (leptin), NGF (nerve growth factor) and TGF beta (transforming growth factor beta), produced by the stromal fibroblasts, is established to participate in their bioactivity. Uninduced 3T3 do not express the stem cell markers and show minimal differentiation potential. Conclusions. Our observations indicate the pro-stem cell activity of cancer-associated fibroblasts and underline the role of epithelial-mesenchymal interaction in tumour biology.","[Dvorankova, Barbora; Smetana, Karel, Jr.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, CZ-15000 Prague 5, Czech Republic; [Szabo, Pavol; Dvorankova, Barbora; Lacina, Lukas; Smetana, Karel, Jr.] Charles Univ Prague, Inst Anat, Fac Med 1, CZ-12800 Prague 2, Czech Republic; [Szabo, Pavol; Kolar, Michal; Vlcek, Cestmir; Strnad, Hynek] Acad Sci Czech Republic, Inst Mol Genet, CZ-13220 Prague 4, Czech Republic; [Lacina, Lukas; Stork, Jiri] Charles Univ Prague, Fac Med 1, Dept Dermatovenereol, CZ-12808 Prague 2, Czech Republic; [Tvrdek, Miroslav] Charles Univ Prague, Fac Med 3, Dept Plast Surg, CZ-10034 Prague 10, Czech Republic","Smetana, K (reprint author), Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, V Uvalu 84, CZ-15000 Prague 5, Czech Republic.","karel.smetana@lf1.cuni.cz","Kolar, Michal/A-3307-2012; Strnad, Hynek/B-7361-2008","Kolar, Michal/0000-0002-4593-1525; Strnad, Hynek/0000-0002-0141-8340","Ministry of Education Youth and Sport of the Czech Republic [MSM0021620806, 1M0021620803, 1M6837805002, NPVII 2B06106, 1M0538]; Academy of Sciences of the Czech Republic [AV0Z50520514]; Charles University in Prague","This study was supported by Ministry of Education Youth and Sport of the Czech Republic [Project numbers MSM0021620806, 1M0021620803, 1M6837805002, NPVII 2B06106 and 1M0538], by the Academy of Sciences of the Czech Republic [Project number AV0Z50520514], and by the Charles University in Prague.",null,64,5,5,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0248-4900",null,null,"BIOL CELL","Biol. Cell","MAY",2011,103,5,null,null,null,null,233,248,null,"10.1042/BC20100113",null,16,"Cell Biology","Cell Biology","788FN","WOS:000292430900003"]
[null,null,null,null,"J","Tomek, A; Matoska, V; Eisert, C; Serebruany, VL",null,null,null,"Tomek, Ales; Matoska, Vaclav; Eisert, Christian; Serebruany, Victor L.",null,null,"Optimization of Anticoagulation with Warfarin for Stroke Prevention: Pharmacogenetic Considerations","AMERICAN JOURNAL OF THERAPEUTICS",null,null,"English","Article",null,null,null,null,null,"Warfarin; stroke prevention; pharmacogenetics","K EPOXIDE REDUCTASE; NONVALVULAR ATRIAL-FIBRILLATION; GAMMA-GLUTAMYL CARBOXYLASE; TRANSIENT ISCHEMIC ATTACK; ORAL ANTICOAGULATION; CYTOCHROME P4502C9; COST-EFFECTIVENESS; AFRICAN-AMERICANS; DOSE REQUIREMENTS; RANDOMIZED-TRIAL","Warfarin is a cornerstone of oral anticoagulation for stroke prevention. Anticoagulation with warfarin in patients with atrial fibrillation is over twice as effective in secondary prevention of stroke as any other tested alternatives, including all other antithrombotic drugs or surgical interventions. General belief is that warfarin is capable of preventing 20 ischemic strokes for every hemorrhagic one it causes. However, warfarin is one of the most feared agents as a result of its woeful safety profile and difficulties in maintaining the proper daily dose. Recent research in pharmacogenetics predominantly focused on elucidating the influence of individual genetic predispositions to administered warfarin. Although the incorporation of genotype information improves the accuracy of adequate dose prediction, an improvement in anticoagulation control or a reduction in hemorrhagic complications has not been yet convincingly demonstrated. It is clear that identifying an individual patient's risk for hemorrhage on warfarin will require more broad clinical and genetic studies. Future research focused on patients with stroke should concentrate on defining the possible differences, especially focusing on predicting bleeding events in general and intracranial hemorrhages in particular. The purpose of this review is to summarize the existing evidence about pharmacogenetics of warfarin in general, especially focusing on stroke prevention.","[Serebruany, Victor L.] HeartDrugTM Res Labs, Osler Med Ctr, Towson, MD 21204 USA; [Tomek, Ales] Charles Univ Prague, Dept Neurol, Sch Med 2, Prague, Czech Republic; [Tomek, Ales; Matoska, Vaclav] Hosp Na Homolce, Lab Mol Diagnost, Prague, Czech Republic; [Eisert, Christian; Serebruany, Victor L.] Johns Hopkins Univ Baltimore, HeartDrugTM Res Labs, Baltimore, MD USA","Serebruany, VL (reprint author), HeartDrugTM Res Labs, Osler Med Ctr, 7600 Osler Dr,Suite 307, Towson, MD 21204 USA.","Heartdrug@aol.com",null,null,null,null,null,57,3,3,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1075-2765",null,null,"AM J THER","Am. J. Ther.","MAY",2011,18,3,null,null,null,null,"E55","E66",null,"10.1097/MJT.0b013e3181cea0cd",null,12,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","763LD","WOS:000290557200003"]
[null,null,null,null,"J","Stiborova, M; Mares, J; Frei, E; Arlt, VM; Martinek, V; Schmeiser, HH",null,null,null,"Stiborova, Marie; Mares, Jaroslav; Frei, Eva; Arlt, Volker M.; Martinek, Vaclav; Schmeiser, Heinz H.",null,null,"The Human Carcinogen Aristolochic Acid I Is Activated to Form DNA Adducts by Human NAD(P)H:quinone Oxidoreductase Without the Contribution of Acetyltransferases or Sulfotransferases","ENVIRONMENTAL AND MOLECULAR MUTAGENESIS",null,null,"English","Article",null,null,null,null,null,"aristolochic acid; NAD(P)H:quinone oxidoreductase; sulfotransferase; acetyltransferase; DNA adducts; molecular modeling","BALKAN ENDEMIC NEPHROPATHY; CHINESE HERBS NEPHROPATHY; P-32 POSTLABELING ANALYSIS; CYTOCHROMES P450 1A1; HUMAN CANCER HAZARD; NAD(P)H-QUINONE OXIDOREDUCTASE; UROTHELIAL CANCER; DT-DIAPHORASE; REDUCTIVE ACTIVATION; METABOLIC-ACTIVATION","Ingestion of aristolochic acid (AA) is associated with development of urothelial tumors linked with AA nephropathy and is implicated in the development of Balkan endemic nephropathy-associated urothelial tumors. We investigated the efficiency of human NAD(P)H:quinone oxidoreductase (NQO1) to activate aristolochic acid I (AAI) and used in silico docking, using soft-soft (flexible) docking procedure, to study the interactions of AAI with the active site of human NQO1. AAI binds to the active site of NQO1 indicating that the binding orientation allows for direct hydride transfer (i.e., two electron reductions) to the nitro group of AAI. NQO1 activated AAI, generating DNA adduct patterns reproducing those found in urothelial tissues from humans exposed to AA. Because reduced aromatic nitro-compounds are often further activated by sulfotransferases (SULTs) or N,O-acetlytransferases (NATs), their roles in AAI activation were investigated. Our results indicate that phase II reactions do not play a major role in AAI bioactivation; neither native enzymes present in human hepatic or renal cytosols nor human SULT1A1, -1A2, -1A3, -1E, or -2A nor NAT1 or NAT2 further enhanced DNA adduct formation by AAI. Instead under the in vitro conditions used, DNA adducts arise by enzymatic reduction of AAI through the formation of a cyclic hydroxamic acid (N-hydroxyaristolactam I) favored by the carboxy group in peri position to the nitro group without additional conjugation. These results emphasize the major importance of NQO1 in the metabolic activation of AAI and provide the first evidence that initial nitroreduction is the rate limiting step in AAI activation. Environ. Mol. Mutagen. 52: 448459, 2011. (C) 2011 Wiley-Liss, Inc.","[Stiborova, Marie; Martinek, Vaclav] Charles Univ Prague, Dept Biochem, Fac Sci, Prague 12840 2, Czech Republic; [Mares, Jaroslav] Charles Univ Prague, Inst Biol & Med Genet, Sch Med 2, Prague 15006 5, Czech Republic; [Mares, Jaroslav] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Frei, Eva] German Canc Res Ctr, Div Prevent Oncol, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany; [Arlt, Volker M.] Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England; [Schmeiser, Heinz H.] German Canc Res Ctr, Res Grp Genet Alterat Carcinogenesis, D-69120 Heidelberg, Germany","Stiborova, M (reprint author), Charles Univ Prague, Dept Biochem, Fac Sci, Albertov 2030, Prague 12840 2, Czech Republic.","stiborov@natur.cuni.cz; jarosalv.mares@lfmotol.cuni.cz","Martinek, Vaclav/E-6710-2011","Martinek, Vaclav/0000-0003-3321-4526","Grant Agency of the Czech Republic [303/09/0472, 203/09/0812]; Ministry of Education of the Czech Republic [MSM 0021620808, 1M0505]; Cancer Research UK; Association for International Cancer Research (AICR)","Grant sponsor: Grant Agency of the Czech Republic, 303/09/0472, 203/09/0812); Grant sponsor: Ministry of Education of the Czech Republic, MSM 0021620808, 1M0505; Grant sponsor: Cancer Research UK and Association for International Cancer Research (AICR).",null,74,16,16,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0893-6692",null,null,"ENVIRON MOL MUTAGEN","Environ. Mol. Mutagen.","JUL",2011,52,6,null,null,null,null,448,459,null,"10.1002/em.20642",null,12,"Environmental Sciences; Genetics & Heredity; Toxicology","Environmental Sciences & Ecology; Genetics & Heredity; Toxicology","798ZI","WOS:000293250700003"]
[null,null,null,null,"J","Hill, M; Vrbikova, J; Zarubova, J; Kancheva, R; Velikoa, M; Kancheva, L; Kubatova, J; Duskova, M; Marusic, P; Parizek, A; Starka, L",null,null,null,"Hill, Martin; Vrbikova, Jana; Zarubova, Jana; Kancheva, Radmila; Velikoa, Marta; Kancheva, Lyudmila; Kubatova, Jana; Duskova, Michaela; Marusic, Petr; Parizek, Antonin; Starka, Luboslav",null,null,"The steroid metabolome in lamotrigine-treated women with epilepsy","STEROIDS",null,null,"English","Article",null,null,null,null,null,"Lamotrigine; Epilepsy; Neuroactive steroids; Pregnanolone isomers; Androstanes gas chromatography-mass spectrometry","REPRODUCTIVE ENDOCRINE CONSIDERATIONS; ICTAL CIRCULATING LEVELS; CATAMENIAL EPILEPSY; SEIZURE FREQUENCY; ANTICONVULSANT METABOLITE; ANTIEPILEPTIC THERAPY; HORMONAL-THERAPY; SERUM-LEVELS; ALLOPREGNANOLONE; PROGESTERONE","Background: Epilepsy in women may be associated with reproductive disorders and alterations in serum steroid levels. Some steroids can be induced by epilepsy and/or treatment with antiepileptic drugs; however, there are still limited data available concerning this effect on the levels of other neuroactive steroid metabolites such as 3a-hydroxy-5a/b-reduced androstanes. Aim: To evaluate steroid alterations in women with epilepsy (WINE) on lamotrigine monotherapy. Subjects and methods: Eleven WWE and 11 age-matched healthy women underwent blood sampling in both phases of their menstrual cycles (MCs). The steroid metabolome, which included 30 unconjugated steroids, 17 steroid polar conjugates, gonadotropins, and sex hormone-binding globulin (SHBG), was measured using gas chromatography-mass spectrometry (GC-MS) and radioimmunoassay (RIA). Results: WWE had lower cortisol levels (status p < 0.001), but elevated levels of unconjugated 17-hydroxypregnenolone (status p < 0.001). Progesterone was higher in the follicular menstrual phase (FP) in WWE than in the controls (status x menstrual phase p < 0.05, Bonferroni multiple comparisons p < 0.05), whereas 17-hydroxyprogesterone was higher in WWE in both menstrual phases (status p < 0.001). The steroid conjugates were mostly elevated in WWE. The levels of 54p-reduced androstanes in WWE that were significantly higher than the controls were etiocholanolone (status p <0.001), 5 alpha-androstane-3 alpha,17 beta-diol (status p < 0.001), and the 5 alpha/beta-reduced androstane polar conjugates (status p < 0.001). Conclusions: WWE showed a trend toward higher circulating 3 alpha-hydroxy-5 alpha/beta-reduced androstanes, increased activity of 17 alpha-hydroxylase/17,20 lyase in the Delta(5)-steroid metabolic pathway, and increased levels of the steroid polar conjugates. (C) 2011 Elsevier Inc. All rights reserved.","[Hill, Martin; Vrbikova, Jana; Kancheva, Radmila; Velikoa, Marta; Kancheva, Lyudmila; Kubatova, Jana; Duskova, Michaela; Starka, Luboslav] Inst Endocrinol, CZ-11694 Prague 1, Czech Republic; [Hill, Martin; Parizek, Antonin] Fac Med 1, Dept Obstet & Gynecol, Prague 12851 2, Czech Republic; [Hill, Martin; Parizek, Antonin] Gen Teaching Hosp, Prague 12851 2, Czech Republic; [Zarubova, Jana] Thomayer Univ Hosp, Neurol Clin, Dept Neurol, CZ-14059 Prague 4, Krc, Czech Republic; [Marusic, Petr] Charles Univ Prague, Fac Med 2, Motol Hosp, CZ-15006 Prague 5, Czech Republic","Hill, M (reprint author), Inst Endocrinol, Narodni Trida 8, CZ-11694 Prague 1, Czech Republic.","mhill@endo.cz; jvrbikova@endo.cz; jana.zarubova@ftn.cz; rkanceva@endo.cz; mveliko-va@endo.cz; lkantcheva@endo.cz; jkubatova@endo.cz; mduskova@endo.cz; petr.marusic@1fmotol.cz; parizek@porodnice.cz; lstarka@endo.cz","Perez , Claudio Alejandro/F-8310-2010","Perez , Claudio Alejandro/0000-0001-9688-184X","IGA [NS/9790-4]","The grant project IGA NS/9790-4 supported this research.",null,45,2,2,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0039-128X",null,null,"STEROIDS","Steroids","NOV",2011,76,12,null,null,null,null,1351,1357,null,"10.1016/j.steroids.2011.07.002",null,7,"Biochemistry & Molecular Biology; Endocrinology & Metabolism","Biochemistry & Molecular Biology; Endocrinology & Metabolism","831QF","WOS:000295745500017"]
[null,null,null,null,"J","Vlcek, M; Landor, I; Visna, P; Vavrik, P; Sindelarova, J; Sosna, A",null,null,null,"Vlcek, M.; Landor, I.; Visna, P.; Vavrik, P.; Sindelarova, J.; Sosna, A.",null,null,"Multidirectional Screw Fixation in the Treatment of Distal Radius Fractures Using Angle-Stable Plates","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"intra-articular fractures of the distal radius; volar approach; angle-stable locking plate; multidirectional angle-stabile screw","DORSALLY DISPLACED FRACTURES; LOCKING PLATING SYSTEM; VOLAR PLATE; SURGICAL-TREATMENT; INTERNAL-FIXATION; OPEN REDUCTION; PART; PALMAR; COMPLICATIONS; MANAGEMENT","PURPOSE OF THE STUDY Intra-articular fractures of the distal radius are treated predominantly by open reduction and internal fixation with various types of angle-stable plates. In this study we compare functional and radiographic outcomes in patients with intra-articular distal radius fractures treated with either angle-stable plates with rigid-direction screw insertion or multidirectional angle-stable plates. MATERIAL AND METHODS The LCP group included 37 patients with an average age of 50 years (range 20-81 years) who were treated using angle-stable plates with rigid-direction screw insertion (LOP, Synthes). The APTUS group comprising 41 patients with an average age of 48.9 years (range 22-77 years) was treated by angle-stable implants in which screws can pivot freely in all directions (Aptus, Medartis). There was no significant difference between the groups in relation to fracture severity, age or other relevant characteristics. In all cases we used the volar approach. The final evaluation of treatment outcome was made at 12 months after surgery. We measured the range of wrist motion and hand grip strength, and compared the values with those obtained in the contralateral wrist. The results evaluated on the scoring systems of Gartland and Werley and of Castaing, and the DASH score were compared between the groups. The findings on radiographs were compared with the anatomical standard in the distal radius region. RESULTS In the LOP group, the average values, as compared with the contralateral side, were as follows: volar flexion, 84.2 %; dorsal flexion, 82.4 %; radial deviation, 83.2 %; ulnar deviation, 89.1 %; pronation, 98.6 %; supination, 97.4 %. In the APTUS group, the values in comparison with the other wrist were: volar flexion, 84.1 %; dorsal flexion, 91.8 %; radial deviation, 95.1 %; ulnar deviation, 92.8 %; pronation, 99.0 %; supination, 98.1 %. The values statistically comparable with the contralateral side were those in pronation, supination and hand grip strength in both groups. In addition, in the APTUS group, the values corresponding to the healthy wrist function were achieved in both radial and ulnar deviation. There were no differences in the values based on the scoring systems between the LOP and APTUS groups. As for the radiographic parameters, only the reconstruction of radial length was optimal. The other parameters differed from the anatomical standard. However, all patients met the criteria of successful healing of a distal radius fracture. Secondary fragment displacement during healing was recorded in two patients of the LOP group and in one of the APTUS group. Transient irritation of the median nerve was observed in five LOP group patients and in only one APTUS group patient. One patient in each group had an extensor tendon rupture. Reflex sympathetic dystrophy syndrome was diagnosed in two LOP group patients and in three APTUS group patients. DISCUSSION The surgical treatment of complex fractures of the distal radius using the angle-stable implants has generally achieved very good functional and radiographic outcomes with a low rate of complications. In the APTUS group, in contrast to the LOP group, the extent of radial and ulnar deviation corresponded to that found in the healthy wrist. The reason was a low-profile design of the plate and the screws, and the system with multidirectional angle-stable screws. The fewer cases of median nerve irritation in the APTUS group can be explained by the use of a different operative approach reducing the risk of direct mechanical nerve injury. In contrast to other authors, flexor tendon ruptures were not recorded in our groups. CONCLUSIONS The treatment of distal radius fractures by the angle-stable locking plate system from the volar approach achieved comparable functional and radiographic outcomes with both rigid-direction screw insertion and multidirectional screw insertion.","[Vlcek, M.; Landor, I.; Vavrik, P.; Sosna, A.] FN Motole, LF UK 1, Ortoped Klin 1, Prague 15006 5, Czech Republic; [Visna, P.] Zent Klin Bad Berka, Klin Orthopadie & Unfallchirug, Bad Berka, Germany; [Sindelarova, J.] Fak Strojni CVUT, Lab Biomech Cloveka, Prague, Czech Republic","Landor, I (reprint author), FN Motol, LF UK 1, Ortoped Klin 1, V Uvalu 84, Prague 15006 5, Czech Republic.","landor@atlas.cz",null,null,null,null,null,37,1,2,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2011,78,1,null,null,null,null,27,33,null,null,null,7,"Orthopedics","Orthopedics","731XJ","WOS:000288143500004"]
[null,null,null,null,"J","Majek, P; Reicheltova, Z; Suttnar, J; Maly, M; Oravec, M; Pecankova, K; Dyr, JE",null,null,null,"Majek, Pavel; Reicheltova, Zuzana; Suttnar, Jiri; Maly, Martin; Oravec, Milan; Pecankova, Klara; Dyr, Jan E.",null,null,"Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1","JOURNAL OF TRANSLATIONAL MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"CORONARY-ARTERY DISEASE; D-BINDING PROTEIN; MYOCARDIAL-INFARCTION; ASPIRIN RESISTANCE; HEART-DISEASE; CHAIN","Background: The aim of this proteomic study was to look for changes taking place in plasma proteomes of patients with acute myocardial infarction (AMI), unstable angina pectoris (UAP), and stable angina pectoris (SAP). Methods: Depleted plasma proteins were separated by 2D SDS-PAGE (pI 4-7), and proteomes were compared using Progenesis SameSpots statistical software. Proteins were identified by nanoLC-MS/MS. Proteins were quantified using commercial kits. Apolipoprotein A1 was studied using 1D and 2D SDS-PAGE, together with western blotting. Results: Reciprocal comparison revealed 46 unique, significantly different spots; proteins in 34 spots were successfully identified and corresponded to 38 different proteins. Discrete comparisons of patient groups showed 45, 41, and 8 significantly different spots when AMI, UAP, and SAP were compared with the control group. On the basis of our proteomic data, plasma levels of two of them, alpha-1 microglobulin and vitamin D-binding protein, were determined. The data, however, failed to prove the proteins to be suitable markers or risk factors in the studied groups. The plasma level and isoform representation of apolipoprotein A1 were also estimated. Using 1D and 2D SDS-PAGE, together with western blotting, we observed extra high-molecular weight apolipoprotein A1 fractions presented only in the patient groups, indicating that the novel high-molecular weight isoforms of apolipoprotein A1 may be potential new markers or possible risk factors of cardiovascular disease. Conclusion: The reported data show plasma proteome changes in patients with AMI, UAP, and SAP. We propose some apolipoprotein A1 fractions as a possible new disease-associated marker of cardiovascular disorders.","[Majek, Pavel; Reicheltova, Zuzana; Suttnar, Jiri; Pecankova, Klara; Dyr, Jan E.] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic; [Maly, Martin; Oravec, Milan] Charles Univ Prague, Dept Cardiol, Fac Med 2, Prague, Czech Republic","Majek, P (reprint author), Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic.","pavel.majek@uhkt.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health, Czech Republic [NS10633-3/2009, MZOFNM2005, MZ 02373601]; Academy of Sciences, Czech Republic [KAN200670701]","This study was supported by Grants NS10633-3/2009, MZOFNM2005 and MZ 02373601, from the Ministry of Health, Czech Republic; and by Grant KAN200670701 from the Academy of Sciences, Czech Republic.",null,24,13,14,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1479-5876",null,null,"J TRANSL MED","J. Transl. Med.","JUN 1",2011,9,null,null,null,null,null,null,null,84,"10.1186/1479-5876-9-84",null,7,"Medicine, Research & Experimental","Research & Experimental Medicine","780AF","WOS:000291822600001"]
[null,null,null,null,"J","Maruta, C; Guerreiro, M; de Mendonca, A; Hort, J; Scheltens, P",null,null,null,"Maruta, C.; Guerreiro, M.; de Mendonca, A.; Hort, J.; Scheltens, P.",null,null,"The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia","EUROPEAN JOURNAL OF NEUROLOGY",null,null,"English","Article",null,null,null,null,null,"dementia diagnosis; neuropsychological tests","PRIMARY DEGENERATIVE DEMENTIA; FRONTAL-LOBE DEMENTIA; ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; COGNITIVE IMPAIRMENT; DEPRESSION SCALE; SENILE-DEMENTIA; RATING-SCALE; TEST-BATTERY; DISORDERS","Background and purpose: The centres dedicated to dementia throughout Europe use different neuropsychological tests in clinical practice. The European Federation of Neurological Societies task force on neuropsychological tests produced this survey on neuropsychological tests currently being used in different European countries to gather knowledge on the practice of dementia centres and to promote the harmonization of such instruments and future multicentre collaborations. Methods: National representatives of 34 countries received a questionnaire and 25 (73.5%) sent it back. Results: A few instruments, Mini-Mental State Examination (MMSE), Trail Making Test (TMT), Verbal Fluency and Clock Drawing Test, were available in all countries. Wechsler Adult Intelligence Scales and MMSE were reported to be valid, respectively, in 20 (80%) and 19 (76%) countries, whereas Verbal Fluency and Stroop Test are valid in 18 (72%) of them. Of the 25 countries, 17 have validation norms for Clock Drawing Test and TMT (68%), and Neuropsychiatric Inventory, Alzheimer's Disease Assessment Scale - Cognitive Subscale, Rey Complex Figure Test, Digit Symbol and Beck Depression Inventory were standardized in 16 countries (64%). The remaining tests were validated, at most, in about half of them. Not all countries certificate neuropsychology. Conclusions: Despite the substantial differences in the tools used by the EFNS countries for most domains surveyed by the questionnaire, there is at least one neuropsychological instrument used by about 80% of the countries. There is clearly the need for a broader consensus in the use of neuropsychological tests for dementia diagnosis.","[Maruta, C.; Guerreiro, M.; de Mendonca, A.] Univ Lisbon, Inst Mol Med, Fac Med, P-1699 Lisbon, Portugal; [Hort, J.] Charles Univ Prague, Memory Clin, Dept Neurol, Fac Med 2, Prague, Czech Republic; [Hort, J.] Motol Hosp Prague, Prague, Czech Republic; [Scheltens, P.] Vrije Univ Amsterdam, Dept Neurol, Med Ctr, Amsterdam, Netherlands","de Mendonca, A (reprint author), Inst Mol Med, Neurosci Lab, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal.","mendonca@fm.ul.pt",null,null,"Fundacao para a Ciencia e Tecnologia; Fundacao Calouste Gulbenkian","Carolina Maruta, Manuela Guerreiro and Alexandre de Mendonca receive funding from Fundacao para a Ciencia e Tecnologia and Fundacao Calouste Gulbenkian.",null,103,11,13,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1351-5101",null,null,"EUR J NEUROL","Eur. J. Neurol.","FEB",2011,18,2,null,null,null,null,279,"E23",null,"10.1111/j.1468-1331.2010.03134.x",null,10,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","706NP","WOS:000286225400016"]
[null,null,null,null,"J","Stepanek, O; Kalina, T; Draber, P; Skopcova, T; Svojgr, K; Angelisova, P; Horejsi, V; Weiss, A; Brdicka, T",null,null,null,"Stepanek, Ondrej; Kalina, Tomas; Draber, Peter; Skopcova, Tereza; Svojgr, Karel; Angelisova, Pavla; Horejsi, Vaclav; Weiss, Arthur; Brdicka, Tomas",null,null,"Regulation of Src Family Kinases Involved in T Cell Receptor Signaling by Protein-tyrosine Phosphatase CD148","JOURNAL OF BIOLOGICAL CHEMISTRY",null,null,"English","Article",null,null,null,null,null,null,"SEVERE COMBINED IMMUNODEFICIENCY; ANTIGEN RECEPTOR; MOLECULAR-CLONING; IMMUNE CELLS; IN-VITRO; CD45; ACTIVATION; EXPRESSION; DEP-1; PHOSPHORYLATION","CD148 is a receptor-like protein-tyrosine phosphatase known to inhibit transduction of mitogenic signals in non-hematopoietic cells. Similarly, in the hematopoietic lineage, CD148 inhibited signal transduction downstream of T cell receptor. However, it also augmented immunoreceptor signaling in B cells and macrophages via dephosphorylating C-terminal tyrosine of Src family kinases (SFK). Accordingly, endogenous CD148 compensated for the loss of the main SFK activator CD45 in murine B cells and macrophages but not in T cells. Hypothetical explanations for the difference between T cells and other leukocyte lineages include the inability of CD148 to dephosphorylate a specific set of SFKs involved in T cell activation or the lack of CD148 expression during critical stages of T cell development. Here we describe striking differences in CD148 expression between human and murine thymocyte subsets, the only unifying feature being the absence of CD148 during the positive selection when the major developmental block occurs under CD45 deficiency. Moreover, we demonstrate that similar to CD45, CD148 has both activating and inhibitory effects on the SFKs involved in TCR signaling. However, in the absence of CD45, activating effects prevail, resulting in functional complementation of CD45 deficiency in human T cell lines. Importantly, this is independent of the tyrosines in the CD148 C-terminal tail, contradicting the recently proposed phosphotyrosine displacement model as a mechanism of SFK activation by CD148. Collectively, our data suggest that differential effects of CD148 in T cells and other leukocyte subsets cannot be explained by the CD148 inability to activate T cell SFKs but rather by its dual inhibitory/activatory function and specific expression pattern.","[Stepanek, Ondrej; Draber, Peter; Skopcova, Tereza; Angelisova, Pavla; Horejsi, Vaclav; Brdicka, Tomas] Acad Sci Czech Republic, Inst Mol Genet, CR-14220 Prague, Czech Republic; [Kalina, Tomas; Svojgr, Karel] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006, Czech Republic; [Kalina, Tomas; Svojgr, Karel] Charles Univ Prague, Fac Med 2, Childhood Leukemia Invest Prague, Prague 15006, Czech Republic; [Weiss, Arthur] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; [Weiss, Arthur] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA","Brdicka, T (reprint author), Inst Mol Genet ASCR, Videnska 1083, Prague 14220, Czech Republic.","tomas.brdicka@img.cas.cz","Stepanek, Ondrej/F-8882-2013","Stepanek, Ondrej/0000-0002-2735-3311","National Institutes of Health [AI066120]; National Program of Research II Project [2B06064]; Ministry of Education, Youth, and Sports of the Czech Republic [1M0506]; Faculty of Science, Charles University, Prague","This work was supported, in whole or in part, by National Institutes of Health Grant AI066120. This work was also supported by National Program of Research II Project 2B06064 and Center of Molecular and Cellular Immunology Project 1M0506 from Ministry of Education, Youth, and Sports of the Czech Republic.Ph.D. students supported in part by the Faculty of Science, Charles University, Prague.",null,51,12,12,"AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA","0021-9258",null,null,"J BIOL CHEM","J. Biol. Chem.","JUN 24",2011,286,25,null,null,null,null,22101,22112,null,"10.1074/jbc.M110.196733",null,12,"Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","778QP","WOS:000291719900016"]
[null,null,null,null,"J","Poljakova, J; Hrebackova, J; Dvorakova, M; Moserova, M; Eskschlager, T; Hrabeta, J; Gottlicherova, M; Kopejtkova, B; Frei, E; Kizek, R; Stiborova, M",null,null,null,"Poljakova, Jitka; Hrebackova, Jana; Dvorakova, Marketa; Moserova, Michaela; Eskschlager, Tomas; Hrabeta, Jan; Goettlicherova, Marketa; Kopejtkova, Barbora; Frei, Eva; Kizek, Rene; Stiborova, Marie",null,null,"Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"Ellipticine; valproic acid; Trichostatin A; neuroblastoma; cytotoxicity; DNA adduct","PEROXIDASE-MEDIATED OXIDATION; HUMAN CYTOCHROME-P450 ENZYMES; DRUG ELLIPTICINE; ADDUCT FORMATION; IN-VIVO; TOPOISOMERASE-II; SUDAN-I; SODIUM VALPROATE; GENE-EXPRESSION; CANCER-CELLS","OBJECTIVES: Valproic acid (VPA) and trichostatin A (TSA) exert antitumor activity as histone deacetylase inhibitors, whereas ellipticine action is based mainly on DNA intercalation, inhibition of topoisomerase II and formation of cytochrome P450 (CYP)- and peroxidase-mediated covalent DNA adducts. This is the first report on the molecular mechanism of combined treatment of human neuroblastoma UKF-NB-3 and UKF-NB-4 cells with these compounds. METHODS: HPLC with UV detection was employed for the separation and characterization of ellipticine metabolites formed by microsomes and peroxidases. Covalent DNA modifications by ellipticine in neuroblastoma cells and in incubations with microsomes and peroxidases were detected by P-32-postlabeling. Expression of CYP enzymes, peroxidases and cytochrome b(5) was examined by Western blot. RESULTS: The cytotoxicity of ellipticine to neuroblastomas was increased by pretreating these cells with VPA or TSA. A higher sensitivity of cells to ellipticine correlated with an increase in formation of covalent ellipticine-derived DNA adducts in these cells. To evaluate the mechanisms of this finding, we invest gated the modulation by VPA and TSA of CYP- and peroxidase-mediated ellipticine-derived DNA adduct formation in vitro. The effects of ellipticine in the presence of VPA and TSA on expression of CYPs and peroxidases relevant for ellipticine activation and levels of cytochrome b(5) and P-glycoprotein in neuroblastoma cells were also investigated. Based on these studies, we attribute most of the enhancing effects of VPA and TSA on ellipticine cytotoxicity to enhanced ellipticine-DNA adduct formation caused by an increase in levels of cytochrome b5, CYP3A 4 and CYP1A1 in neuroblastoma cells. A lower sensitivity of UKF-NB-4 cells to combined effects of ellipticine with VPA and TSA than of UKF-NB-3 cells is also attributable to high levels of P-glycoprotein expressed in this cell line. CONCLUSION: The results found here warrant further studies and may help in the design of new protocols geared to the treatment of high risk neuroblastomas.","[Poljakova, Jitka; Dvorakova, Marketa; Moserova, Michaela; Goettlicherova, Marketa; Kopejtkova, Barbora; Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12840 2, Czech Republic; [Hrebackova, Jana; Eskschlager, Tomas; Hrabeta, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague 12840 2, Czech Republic; [Hrebackova, Jana; Eskschlager, Tomas; Hrabeta, Jan] Univ Hosp Motol, Prague, Czech Republic; [Frei, Eva] German Canc Res Ctr, Natl Ctr Tumour Dis, Div Prevent Oncol, D-6900 Heidelberg, Germany; [Kizek, Rene] Mendel Univ, Fac Agron, Dept Chem & Biochem, Brno, Czech Republic","Stiborova, M (reprint author), Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, Prague 12840 2, Czech Republic.","stiborov@natur.cuni.cz","Kizek, Rene/D-7748-2012",null,"Grant Agency of the Czech Republic [P301/10/0356]; Ministry of Education of the Czech Republic [MSM0021620813, MSM0021620808, 1M0505]","This work was supported in part by Grant Agency of the Czech Republic, grant P301/10/0356, Ministry of Education of the Czech Republic, grants MSM0021620813, MSM0021620808 and 1M0505 - Center of Targeted Therapeutics. We thank prof. J.Cinatl, Jr. (J. W. Goethe University, Frankfurt, Germany) for providing cell lines.",null,76,11,11,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2011,32,null,null,1,null,null,101,116,null,null,null,16,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","896CX","WOS:000300544100014"]
[null,null,null,null,"J","Sporkova, A; Kopkan, L; Varcabova, S; Huskova, Z; Hwang, SH; Hammock, BD; Imig, JD; Kramer, HJ; Cervenka, L",null,null,null,"Sporkova, Alexandra; Kopkan, Libor; Varcabova, Sarka; Huskova, Zuzana; Hwang, Sung Hee; Hammock, Bruce D.; Imig, John D.; Kramer, Herbert J.; Cervenka, Ludek",null,null,"Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats","AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"renovascular hypertension; cytochrome P-450 metabolites; epoxyeicosatrienoic acids; hydroxyeicosatrienoic acids; renal functions; blood pressure autoregulation; glomerular filtration rate; renal blood flow; cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid; HET-0016","SOLUBLE EPOXIDE HYDROLASE; SALT-SENSITIVE HYPERTENSION; AT(1) RECEPTOR BLOCKADE; REN-2 TRANSGENIC RATS; ANGIOTENSIN-II LEVELS; DAHL SS/JR RATS; ARACHIDONIC-ACID; NITRIC-OXIDE; EPOXYEICOSATRIENOIC ACIDS; 20-HYDROXYEICOSATETRAENOIC ACID","Alterations in renal function contribute to Goldblatt two-kidney, one-clip (2K1C) hypertension. A previous study indicated that bioavailability of cytochrome P-450 metabolites epoxyeicosatrienoic acids (EETs) is decreased while that of 20-hydroxyeicosatetraenoic acids (20-HETE) is increased in this model. We utilized the inhibitor of soluble epoxide hydrolase cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (c-AUCB) and HET-0016, the inhibitor of 20-HETE production, to study the role of EETs and 20-HETE in the regulation of renal function. Chronic c-AUCB treatment significantly decreased systolic blood pressure (SBP) (133 +/- 1 vs. 163 +/- 3 mmHg) and increased sodium excretion (1.23 +/- 0.10 vs. 0.59 +/- 0.03 mmol/day) in 2K1C rats. HET-0016 did not affect SBP and sodium excretion. In acute experiments, renal blood flow (RBF) was decreased in 2K1C rats (5.0 +/- 0.2 vs. 6.9 +/- 0.2 ml.min(-1).g(-1)). c-AUCB normalized RBF in 2K1C rats (6.5 +/- 0.6 ml.min(-1).g(-1)). HET-0016 also increased RBF in 2K1C rats (5.8 +/- 0.2 ml.min(-1).g(-1)). Although RBF and glomerular filtration rate (GFR) remained stable in normotensive rats during renal arterial pressure (RAP) reductions, both were significantly reduced at 100 mmHg RAP in 2K1C rats. c-AUCB did not improve autoregulation but increased RBF at all RAPs and shifted the pressure-natriuresis curve to the left. HET-0016-treated 2K1C rats exhibited impaired autoregulation of RBF and GFR. Our data indicate that c-AUCB displays antihypertensive properties in 2K1C hypertension that are mediated by an improvement of RBF and pressure natriuresis. While HET-0016 enhanced RBF, its anti-natriuretic effect likely prevented it from producing a blood pressure-lowering effect in the 2K1C model.","[Sporkova, Alexandra; Kopkan, Libor; Varcabova, Sarka; Huskova, Zuzana; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, CZ-14000 Prague 4, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic; [Sporkova, Alexandra; Kopkan, Libor; Varcabova, Sarka; Huskova, Zuzana] Charles Univ Prague, Fac Med 2, Cardiovasc Res Ctr, Prague, Czech Republic; [Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Univ Calif Davis Canc Ctr, Davis, CA 95616 USA; [Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany","Sporkova, A (reprint author), Inst Clin & Expt Med, Dept Expt Med, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","alhc@ikem.cz",null,null,"EU [CZ.2.16/3.1.00/22126]; European Commission [IRG 247847]; Czech Science Foundation (GACR) [303/10/P170]; GACR [305/08/J006]; Internal Grant Agency of the Ministry of Health of the Czech [NS/10499-3]; Institute for Clinical and Experimental Medicine [MZO 00023001]; Internal Grant Agency of the Ministry of Health of the Czech Republic; Grant Agency of the Academy of Science of Czech Republic [KJB 502030801]; National Institutes of Health [HL-59699, DK-38226]; Advancing a Healthier Wisconsin; German Research Foundation (DFG), Bonn [Kra 433/14-2, 436 TSE 113/50/0-1]; Howard Hughes Foundation; National Institute of Environmental Health Sciences (NIEHS) [R37 ES-02710, P42 ES-004699]","L. Cervenka was supported by EU (the Operational Program Prague) Competitiveness; project \"CEVKOON\" (#CZ.2.16/3.1.00/22126). This study was supported by a Marie Curie Fellowship from the European Commission Program PEOPLE (IRG 247847) and a postdoctoral fellowship from the Czech Science Foundation (GACR; 303/10/P170) received by A. Sporkova. This study was also supported by Grant No. 305/08/J006 awarded to L. Cervenka by GACR and by grant NS/10499-3 awarded to L. Cervenka by the Internal Grant Agency of the Ministry of Health of the Czech and by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). L. Kopkan is supported by Grant No. NS/9699-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic and partially supported by a grant from the Grant Agency of the Academy of Science of Czech Republic (KJB 502030801). J. D. Imig is supported by National Institutes of Health Grants HL-59699 and DK-38226 and Advancing a Healthier Wisconsin. H. J. Kramer is supported by grants from the German Research Foundation (DFG), Bonn (Kra 433/14-2 and 436 TSE 113/50/0-1). S. H. Hwang was supported, in part, by the Howard Hughes Foundation and a fellowship from the National Institute of Environmental Health Sciences (NIEHS) Supported Basic Research Program. Partial support was provided by NIEHS Grant R37 ES-02710 and NIEHS Superfund Basic Research Program Grant P42 ES-004699 awarded to B. D. Hammock.",null,60,10,10,"AMER PHYSIOLOGICAL SOC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","0363-6119",null,null,"AM J PHYSIOL-REG I","Am. J. Physiol.-Regul. Integr. Comp. Physiol.","JUN",2011,300,6,null,null,null,null,"R1468","R1475",null,"10.1152/ajpregu.00215.2010",null,8,"Physiology","Physiology","776KA","WOS:000291532000025"]
[null,null,null,null,"J","Pressler, T; Bohmova, C; Conway, S; Dumcius, S; Hjelte, L; Hoiby, N; Kollberg, H; Tummler, B; Vavrova, V",null,null,null,"Pressler, T.; Bohmova, C.; Conway, S.; Dumcius, S.; Hjelte, L.; Hoiby, N.; Kollberg, H.; Tuemmler, B.; Vavrova, V.",null,null,"Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Article",null,null,null,null,null,"Cystic fibrosis; Pseudomonas aeruginosa; Chronic infection; Definitions","CYSTIC-FIBROSIS PATIENTS; PULMONARY-FUNCTION; SERUM ANTIBODIES; LUNG-DISEASE; COLONIZATION; CHILDREN; PREVALENCE; SURVIVAL; THERAPY","Chronic pulmonary infection with P aeruginosa develops in most patients with cystic fibrosis (CF); by adulthood 80% of patients are infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF. Chronic infection is preceded by an intermittent stage of infection. The initial stage is characteristically followed by the gradual emergence of mucoid variants of the colonizing strains and a rise in anti-Pseudomonas antibodies. In addition to optimizing existing therapeutic strategies, effective new agents need to be identified. Studies in patients with CF are particularly challenging: the progressive nature of the disease and the wide variation in severity influence considerably the outcome of drug testing. A validated, universally accepted, and clinically useful classification of patients infected with P aeruginosa, particularly those chronically infected, is needed that can be used as both a criterion for patient selection for clinical trials and as a study endpoint. (C) 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Pressler, T.] Copenhagen Univ Hosp, Cyst Fibrosis Ctr, DK-2100 Copenhagen, Denmark; [Bohmova, C.; Vavrova, V.] Univ Hosp Motol, Prague 5, Czech Republic; [Conway, S.] St James Hosp, Leeds LS9 7TF, W Yorkshire, England; [Dumcius, S.] Vilnius State Univ, LT-08661 Vilnius, Lithuania; [Hjelte, L.] Karolinska Inst, CF Ctr, S-14186 Huddinge, Sweden; [Kollberg, H.] Uppsala CF Ctr, S-75185 Uppsala, Sweden; [Tuemmler, B.] Hannover Med Sch, D-30625 Hannover, Germany","Pressler, T (reprint author), Copenhagen Univ Hosp, Cyst Fibrosis Ctr, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.","tanja.pressler@rh.regionh.dk",null,null,"European Union [LSHM-CT-2005-018932]","This work was supported by the European Union Sixth Framework Programme (contract no. LSHM-CT-2005-018932, EuroCareCF).",null,24,7,7,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","JUN",2011,10,null,null,2,null,null,"S75","S78",null,null,null,4,"Respiratory System","Respiratory System","783FX","WOS:000292068000011"]
[null,null,null,null,"J","Klukowska, A; Komrska, V; Jansen, M; Laguna, P",null,null,null,"Klukowska, A.; Komrska, V.; Jansen, M.; Laguna, P.",null,null,"Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate (R): interim report from an ongoing prospective clinical study","HAEMOPHILIA",null,null,"English","Article",null,null,null,null,null,"factor VIII; haemophilia A; inhibitors; Octanate (R); previously untreated patients; surgery","SEVERE HEMOPHILIA-A; RISK-FACTORS; TOLERANCE INDUCTION; IMMUNE TOLERANCE; CANAL COHORT; FACTOR-IX; RECOMBINANT; CONCENTRATE; PRODUCTS; CHILDREN","For patients with haemophilia A (HA), lifelong replacement therapy with factor VIII (FVIII) concentrates is the treatment of choice. Octanate (R) is a plasma-derived, human, von Willebrand factor-stabilized FVIII product with demonstrated haemostatic efficacy in patients with HA. The aim of this ongoing study is to assess the immunogenicity of Octanate (R) in previously untreated patients (PUPs), monitoring for development of FVIII inhibitors. Interim data on 39 PUPs treated for bleeding, prophylactically and for surgical coverage are reported. Two of 39 subjects (5.1%) developed clinically relevant inhibitor titres over the course of the study. Another two displayed inhibitors that disappeared spontaneously without Octanate (R) dose change. All inhibitors developed under on-demand treatment and before exposure day (ED) 50. Remarkably, no inhibitor was observed in PUPs receiving prophylaxis with Octanate (R). Of 39 subjects, 30 had exceeded 50 EDs at the time of this analysis. All inhibitor subjects were found to have large FVIII gene defects, either intron 22-inversions or large deletions. Octanate (R) was well-tolerated and the adverse event profile was consistent with the population studied. The haemostatic efficacy of Octanate (R) in prophylaxis and treatment of bleeding were generally rated as 'excellent', and no complication was reported for surgery. Notable FVIII activity was present in blood at 15 min postadministration, and levels remained high at 1 h. Mean incremental in vivo recovery (IVR) was 2.0 (+/- 0.6) % IU-1kg-1. These interim results indicate Octanate (R) to be an efficacious, well-tolerated human FVIII product for management of HA in PUPs, associated with a minimal risk of inhibitors.","[Klukowska, A.; Laguna, P.] Med Univ Warsaw, Dept Pediat Hematol & Oncol, PL-00576 Warsaw, Poland; [Komrska, V.] Motol Univ Hosp, Prague, Czech Republic; [Jansen, M.] Octapharma, Vienna, Austria","Klukowska, A (reprint author), Med Univ Warsaw, Dept Pediat Hematol & Oncol, Marszalkowska 24, PL-00576 Warsaw, Poland.","aklukowska@poczta.onet.pl",null,null,"Octapharma Ltd.","MJ is an employee of Octapharma Ag, Vienna, Austria and AK has received speaker fees from Octapharma Ltd.",null,36,7,7,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1351-8216",null,null,"HAEMOPHILIA","Haemophilia","MAY",2011,17,3,null,null,null,null,399,406,null,"10.1111/j.1365-2516.2010.02428.x",null,8,"Hematology","Hematology","754YQ","WOS:000289894200003"]
[null,null,null,null,"J","Remlova, E; Dostalova, T; Michalusova, I; Vranova, J; Navratil, L; Rosina, J",null,null,null,"Remlova, Eva; Dostalova, Tatjana; Michalusova, Iva; Vranova, Jana; Navratil, Leos; Rosina, Jozef",null,null,"Hemangioma Curative Effect of PDL, Alexandrite, Er:YAG and CO2 Lasers","PHOTOMEDICINE AND LASER SURGERY",null,null,"English","Article",null,null,null,null,null,null,"PORT-WINE STAINS; PULSED DYE-LASER; VASCULAR MALFORMATIONS; NM LASER; SURGERY","Objective: Hemangioma is a mesenchymal benign tumor formed by blood vessels. Anomalies affect up to 10% of children and they are more common in females than in males. The aim of this study was to evaluate hemangioma treatment using four different types of lasers, namely, alexandrite, Er:YAG, CO2, and pulsed dye laser (PDL). Background data: The argon laser was the first to be used for dermatological patients, namely, with port wine stains (PWS) in the late 1960s and early 1970s. A variety of different lasers and light sources were useful in the treatment of vascular lesions, e. g., KTP, Nd:YAG, CO2, PDL, and Er:YAG. Methods: A group of 869 consecutive patients with hemangioma was retrospectively reviewed. The patients including in our study were divided into four groups according to the type of laser used: Alexandrite laser (n = 85, 58 women and 20 men), CO2 laser (n = 78, 58 women and 20 men), Er:YAG laser (n = 105, 87 women and 18 men), and PDL laser (n = 601, 453 women and 148 men). All patients were treated in one session without anesthesia application. The ablative systems vaporized the tissues until the hemangioma was removed. The non-ablative systems used one shot, which destroyed the hemangioma blood vessels. Results: For the treatment efficacy analysis, the following factors were evaluated: therapeutic effect (yes vs. no), loss of pigment (yes vs. no), and appearance of scar (yes vs. no). From results it was evident that the therapeutic effect of all the lasers except alexandrite was very high; almost 100%. In the CO2 and the Er:YAG laser groups a high percentage of side effects was also observed. Exposure to these lasers caused loss of pigment and scar formation in many cases. The best therapeutic effect, with only minor side effects, has been achieved with the PDL laser. Conclusion: It was confirmed that PDL (595 nm, 1.5 ms, 7 mm, 9 - 11 J/cm(2)) had optimal effect without scars. Er:YAG or CO2 laser radiation with specific characteristics was also useful for small superficial lesions.","[Remlova, Eva] Ave Laser Ctr, Olomouc 77900 9, Czech Republic; [Dostalova, Tatjana; Michalusova, Iva] Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague, Czech Republic; [Vranova, Jana; Rosina, Jozef] Charles Univ Prague, Fac Med 3, Dept Med Biophys & Med Informat, Prague, Czech Republic; [Vranova, Jana; Navratil, Leos; Rosina, Jozef] Czech Tech Univ, Fac Biomed Engn, Kladno, Czech Republic","Remlova, E (reprint author), Ave Laser Ctr, Ibsenova 17, Olomouc 77900 9, Czech Republic.","evareml@centrum.cz",null,null,"Czech Ministry of Education [IGA MZCR 9991-4]","This research has been supported by a Grant of the Czech Ministry of Education, IGA MZCR 9991-4 Grant.",null,25,4,6,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1549-5418",null,null,"PHOTOMED LASER SURG","Photomed. Laser Surg.","DEC",2011,29,12,null,null,null,null,815,825,null,"10.1089/pho.2011.3058",null,11,"Surgery","Surgery","863HC","WOS:000298152400009"]
[null,null,null,null,"J","Spacek, M; Hubacek, P; Markova, J; Zajac, M; Vernerova, Z; Kamaradova, K; Stuchly, J; Kozak, T",null,null,null,"Spacek, Martin; Hubacek, Petr; Markova, Jana; Zajac, Miroslav; Vernerova, Zdenka; Kamaradova, Katerina; Stuchly, Jan; Kozak, Tomas",null,null,"Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients","APMIS",null,null,"English","Article",null,null,null,null,null,"Hodgkin lymphoma; Epstein-Barr virus; PCR; LMP1; EBER","LYMPHOPROLIFERATIVE DISEASE; QUANTITATIVE-ANALYSIS; GENOMES; MARKER; LOAD; CELL; PCR","Epstein-Barr virus (EBV) is associated with approximately one-third of Hodgkin lymphoma (HL) cases. EBV-DNA is often present in the plasma and whole blood of EBV-associated HL patients. However, the significance of EBV-DNA monitoring is debated. In a cohort of 165 adult HL patients, EBV-DNA viral load was prospectively monitored both in the plasma and whole blood. Diagnostic tissue samples of all patients were histologically reviewed; in 72% nodular sclerosis was detected, 24% presented with mixed cellularity (MC), and 5% had other type of HL. Tissues from 150 patients were also analyzed for the presence of latent EBV infection using in situ hybridization for EBV-encoded RNA (EBER) and immunohistochemistry for latent membrane protein (LMP1). Using these methods, 29 (19%) patients were classified as EBV positive. Using real-time quantitative PCR, 22 (76%) of EBV-positive HL patients had detectable EBV-DNA in the plasma and 19 (66%) patients in whole blood prior to therapy. In the group of EBV-negative HL cases, three (2%) patients had detectable plasma EBV-DNA and 30 (25%) patients whole blood EBV-DNA before treatment. EBV-positive HL was significantly associated with EBV-DNA positivity both in the plasma and whole blood in pretreatment samples, increasing age and MC subtype. Serial analysis of plasma EBV-DNA showed that response to therapy was associated with decline in viral load. Moreover, significantly increased plasma EBV-DNA level recurred before disease relapse in one patient. Our results further suggest that the assessment of plasma EBV-DNA viral load might be of value for estimation of prognosis and follow-up of patients with EBV-positive HL.","[Spacek, Martin; Markova, Jana; Kozak, Tomas] Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Prague 10034 10, Czech Republic; [Spacek, Martin; Markova, Jana; Vernerova, Zdenka; Kozak, Tomas] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Hubacek, Petr; Stuchly, Jan] Charles Univ Prague, Dept Paediat Hematol & Oncol, Motol Univ Hosp, Prague, Czech Republic; [Hubacek, Petr; Kamaradova, Katerina; Stuchly, Jan] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Zajac, Miroslav] Motol Univ Hosp, Dept Med Microbiol, Prague, Czech Republic; [Vernerova, Zdenka] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Pathol, Prague, Czech Republic; [Kamaradova, Katerina] Charles Univ Prague, Dept Pathol & Mol Med, Motol Univ Hosp, Prague, Czech Republic; [Stuchly, Jan] CLIP Childhood Leukemia Invest Prague, Prague, Czech Republic; [Stuchly, Jan] Charles Univ Prague, Fac Math & Phys, Dept Numer Math, Prague, Czech Republic","Spacek, M (reprint author), Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Srobarova 50, Prague 10034 10, Czech Republic.","m.spacek@fnkv.cz","Kozak, Tomas/K-3561-2012",null,"Ministry of Health of the Czech Republic [NR9166]","The authors acknowledge the laboratory technician Jana Sumova for laboratory work and Katerina Klaskova for gathering of the data. The authors have no conflicts of interest with respect to the topic of the study. This work was supported by a grant (NR9166) from the Ministry of Health of the Czech Republic.",null,23,4,6,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0903-4641",null,null,"APMIS","APMIS","JAN",2011,119,1,null,null,null,null,10,16,null,"10.1111/j.1600-0463.2010.02685.x",null,7,"Immunology; Microbiology; Pathology","Immunology; Microbiology; Pathology","692LF","WOS:000285153600002"]
[null,null,null,null,"J","Slaastad, H; Wu, WW; Goullart, L; Kanderova, V; Tjonnfjord, G; Stuchly, J; Kalina, T; Holm, A; Lund-Johansen, F",null,null,null,"Slaastad, Heidi; Wu, Weiwei; Goullart, Luiz; Kanderova, Veronika; Tjonnfjord, Geir; Stuchly, Jan; Kalina, Tomas; Holm, Anders; Lund-Johansen, Fridtjof",null,null,"Multiplexed immuno-precipitation with 1725 commercially available antibodies to cellular proteins","PROTEOMICS",null,null,"English","Article",null,null,null,null,null,"Antibody microarrays; Chromatographic enrichment; Fluorescent labeling; Multiplexed proteomics technology; Protein arrays","MICROARRAYS; EXPRESSION; PROTEOMICS","Antibody array analysis of complex samples requires capture reagents with exceptional specificity. The frequency of antibodies with label-based detection may be as low as 5%. Here, however, we show that as many as 25% of commercially available antibodies are useful when biotinylated cellular proteins are fractionated by size exclusion chromatography (SEC) first. A microsphere multiplex with 1725 antibodies to cellular proteins was added to 24 SEC fractions, labelled with streptavidin and analyzed by flow cytometry (microsphere-based affinity proteomics, MAP) The SEC-MAP approach resolved different targets captured by each antibody as reactivity peaks across the separation range of the SEC column (10-670kDa). Complex reactivity profiles demonstrated that most antibodies bound more than one target. However, specific binding was readily detected as reactivity peaks common for different antibodies to the same protein. We optimized sample preparation and found that amine-reactive biotin rarely inhibited antibody binding when the biotin to lysine ratio was kept below 1: 1 during labelling. Moreover, several epitopes that were inaccessible to antibodies in native proteins were unmasked after heat denaturation with 0.1% of SDS. The SEC-MAP format should allow researchers to build multiplexed assays with antibodies purchased for use in e. g. Western blotting.","[Slaastad, Heidi; Wu, Weiwei; Goullart, Luiz; Holm, Anders; Lund-Johansen, Fridtjof] Oslo Univ Hosp, Rikshosp, Dept Immunol, N-0027 Oslo, Norway; [Slaastad, Heidi; Tjonnfjord, Geir] Oslo Univ Hosp, Rikshosp, Dept Haematol, N-0027 Oslo, Norway; [Kanderova, Veronika; Stuchly, Jan; Kalina, Tomas] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague, Czech Republic; [Kanderova, Veronika; Stuchly, Jan; Kalina, Tomas] Univ Hosp Motol, Prague, Czech Republic","Lund-Johansen, F (reprint author), Oslo Univ Hosp, Rikshosp, Dept Immunol, N-0027 Oslo, Norway.","fridtjof.lund-johansen@medisin.uio.no",null,null,"Norwegian Research Council (FUGE); University of Oslo; Norwegian Cancer Society; Norwegian Financial Mechanism [A/CZ0046/2/0008]; EEA Financial Mechanism","This work was supported by grants from the Norwegian Research Council (FUGE to F.L.J.), University of Oslo (to W.W.), the Norwegian Cancer Society (to F.L.J.) and EEA Financial Mechanism and Norwegian Financial Mechanism, grant A/CZ0046/2/0008, to T.K. and F.L.J.",null,15,4,4,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1615-9853",null,null,"PROTEOMICS","Proteomics","DEC",2011,11,23,null,null,null,null,4578,4582,null,"10.1002/pmic.201000744",null,5,"Biochemical Research Methods; Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","855RS","WOS:000297582600013"]
[null,null,null,null,"J","Mohelnikova-Duchonova, B; Marsakova, L; Vrana, D; Holcatova, I; Ryska, M; Smerhovsky, Z; Slamova, A; Schejbalova, M; Soucek, P",null,null,null,"Mohelnikova-Duchonova, Beatrice; Marsakova, Lenka; Vrana, David; Holcatova, Ivana; Ryska, Miroslav; Smerhovsky, Zdenek; Slamova, Alena; Schejbalova, Miriam; Soucek, Pavel",null,null,"Superoxide Dismutase and Nicotinamide Adenine Dinucleotide Phosphate Quinone Oxidoreductase Polymorphisms and Pancreatic Cancer Risk","PANCREAS",null,null,"English","Article",null,null,null,null,null,"pancreas; cancer; susceptibility; superoxide dismutase; quinone oxidoreductase","GENE POLYMORPHISMS; OXIDATIVE STRESS; OVARIAN-CANCER; FREE-RADICALS; BLADDER; MNSOD; LUNG; ADENOCARCINOMA; EXPRESSION; PROSTATE","Objectives: Pancreatic carcinoma etiology and molecular pathogenesis is weakly understood. According to the assumption that genetic variation in carcinogen metabolism further modifies the risk of exposure-related cancers, an association of functional polymorphisms in oxidative stress-modifying genes superoxide dismutase 2 (SOD2 [Ala16Val, rs4880]), SOD3 (Arg231Gly, rs1799895), nicotinamide adenine dinucleotide phosphate: quinone oxidoreductase (NQO1 [Pro187Ser, rs1800566], and NQO2 (Phe47Leu, rs1143684) with pancreatic cancer risk was studied. Methods: Polymorphisms were studied by allelic discrimination. Results: In a hospital-based case-control study on 500 individuals (235 cases and 265 controls) of Czech white origin, SOD2, SOD3, NQO1, and NQO2 polymorphisms showed no significant association with pancreatic cancer risk. Major lifestyle factors such as smoking and alcohol, coffee, or tea consumption did not modify the effect of the studied polymorphisms. Conclusions: The first European study of the SOD2, SOD3, NQO1, and NQO2 roles in pancreatic cancer etiology did not find significant associations. Despite this observation, other populations with different lifestyle(s) may be at risk and should be further studied.","[Mohelnikova-Duchonova, Beatrice; Marsakova, Lenka; Vrana, David; Soucek, Pavel] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042 10, Czech Republic; [Holcatova, Ivana; Slamova, Alena; Schejbalova, Miriam] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague, Czech Republic; [Marsakova, Lenka] Charles Univ Prague, Fac Sci, Prague, Czech Republic; [Vrana, David] Charles Univ Prague, Dept Oncol, Prague, Czech Republic; [Holcatova, Ivana; Slamova, Alena; Schejbalova, Miriam] Gen Teaching Hosp, Prague, Czech Republic; [Ryska, Miroslav] Charles Univ Prague, Dept Surg, Fac Med 2, Prague, Czech Republic; [Ryska, Miroslav] Cent Mil Hosp, Prague, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Inst Epidemiol, Fac Med 2, Prague, Czech Republic","Soucek, P (reprint author), Natl Inst Publ Hlth, Toxicogenom Unit, Srobarova 48, Prague 10042 10, Czech Republic.","psoucek@szu.cz","Marsakova, Lenka/F-8637-2014",null,"Internal Grant Agency of the Ministry of Health, Prague, Czech Republic [9422-3]","This study was supported by grant No. 9422-3 from the Internal Grant Agency of the Ministry of Health, Prague, Czech Republic.",null,37,4,4,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0885-3177",null,null,"PANCREAS","Pancreas","JAN",2011,40,1,null,null,null,null,72,78,null,"10.1097/MPA.0b013e3181f74ad7",null,7,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","695MX","WOS:000285375900015"]
[null,null,null,null,"J","Valis, M; Masopust, J; Bazant, J; Rihova, Z; Kalnicka, D; Urban, A; Zumrova, A; Hort, J",null,null,null,"Valis, Martin; Masopust, Jiri; Bazant, Jan; Rihova, Zuzana; Kalnicka, Dita; Urban, Ales; Zumrova, Alena; Hort, Jakub",null,null,"Cognitive changes in spinocerebellar ataxia type 2","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"spinocerebellar ataxia type 2; cognitive impairment; neuropsychological assessment; motor functions","CEREBELLUM; FAMILIES; DEFICITS","OBJECTIVES: Cognitive disorders and dementia occur in 19 to 42% of patients with spinocerebellar ataxia type 2 (SCA2). Neuropsychological tests can reveal executive dysfunction, impaired visual and verbal memory, tongue and speech impairment, attention disorders and impaired verbal fluency. METHODS: We performed psychiatric and neuropsychological examinations in 12 patients diagnosed with genetically confirmed SCA2 and 12 healthy volunteers matching the patients in age, gender, and length of education. The level of motor impairment was determined using the brief ataxia rating scale (BARS). The neuropsychological examination focused on testing executive functions, short-term visual and verbal memory, attention, psychomotor tempo, visual motor coordination, learning ability and comprehension ability. The tests were divided into two subgroups according to the difficulty of motor tasks. The cognitive abilities composite score (CACS) was determined by calculating the arithmetic mean of T scores of the respective tests. RESULTS: Patients with SCA2 had significantly lower CACSs (p=0.00005) compared to the healthy volunteers. Patients exhibited impaired performance in both difficult and simple motor tests. The severity of cognitive impairment was related to the age at the onset of the disease (p=0.002) but not to the duration or to the overall BARS score. CONCLUSIONS: Compared to healthy volunteers, patients with SCA2 exhibited significantly worse cognitive performance in all areas tested, including the tests of simple motor tasks. Moreover, the cognitive performance of patients worsened as the difficulty of the motor tasks increased.","[Valis, Martin; Rihova, Zuzana] Charles Univ Prague, Fac Med, Dept Neurol, Hradec Kralove 50005, Czech Republic; [Valis, Martin; Masopust, Jiri; Bazant, Jan; Rihova, Zuzana; Kalnicka, Dita; Urban, Ales] Univ Hosp, Hradec Kralove 50005, Czech Republic; [Masopust, Jiri; Bazant, Jan; Kalnicka, Dita; Urban, Ales] Charles Univ Prague, Fac Med, Dept Psychiat, Hradec Kralove 50005, Czech Republic; [Zumrova, Alena] Charles Univ Prague, Fac Med 2, Dept Paediat Neurol, Prague, Czech Republic; [Zumrova, Alena; Hort, Jakub] Motol Univ Hosp, Prague, Czech Republic; [Hort, Jakub] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague, Czech Republic; [Hort, Jakub] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic","Valis, M (reprint author), Charles Univ Prague, Fac Med, Dept Neurol, Nezvalova 256, Hradec Kralove 50005, Czech Republic.","valismar@seznam.cz",null,null,"Ministry of Education of the Czech Republic [MSM 0021620816]","This study was supported by the Research Project of the Ministry of Education of the Czech Republic, MSM 0021620816.",null,17,4,4,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2011,32,3,null,null,null,null,354,359,null,null,null,6,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","809XJ","WOS:000294089700024"]
[null,null,null,null,"J","Horak, D; Matulka, K; Hlidkova, H; Lapcikova, M; Benes, MJ; Jaros, J; Hampl, A; Dvorak, P",null,null,null,"Horak, Daniel; Matulka, Kamil; Hlidkova, Helena; Lapcikova, Monika; Benes, Milan J.; Jaros, Josef; Hampl, Ales; Dvorak, Petr",null,null,"Pentapeptide-modified poly(N,N-diethylacrylamide) hydrogel scaffolds for tissue engineering","JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS",null,null,"English","Article",null,null,null,null,null,"poly(N,N-diethylacrylamide); porosity; YIGSR peptide; embryonic stem cells; hydrogel","COVALENTLY IMMOBILIZED PROTEINS; CRITICAL SOLUTION TEMPERATURE; EMBRYONIC STEM-CELLS; AQUEOUS-SOLUTIONS; POROUS HYDROGELS; PHASE-TRANSITION; DRUG-DELIVERY; SELF-RENEWAL; METHACRYLATE); SUPPORT","Poly(N,N-diethylacrylamide) (PDEAAm) hydrogel scaffolds were prepared by radical copolymerization of N, N-diethylacrylamide (DEAAm), N,N'-methylenebisacrylamide and methacrylic acid in the presence of (NH(4))(2)SO(4) or NaCl. The hydrogels were characterized by low-vacuum scanning electron microscopy in the water-swollen state, water and cyclohexane regain, and by mercury porosimetry. The pentapeptide, YIGSR-NH(2), was immobilized on the hydrogel. Human embryonic stem cells (hESCs) were cultured with the hydrogels to test their biocompatibility. The results suggest that the PDEAAm hydrogel scaffolds are nontoxic and sup-port hESC attachment and proliferation, and that interconnected pores of the scaffolds are important for hESC cultivation. Immobilization of YIGSR-NH(2) pentapeptide on the PDEAAm surface improved both adhesion and growth of hESCs compared with the unmodified hydrogel. The YIGSR-NH(2)-modified PDEAAm hydrogels may be a useful tool for tissue-engineering purposes. (c) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 98B: 54-67, 2011.","[Horak, Daniel; Hlidkova, Helena; Lapcikova, Monika; Benes, Milan J.] Acad Sci Czech Republic, Inst Macromol Chem, Vvi, CR-16206 Prague 6, Czech Republic; [Horak, Daniel; Jaros, Josef; Hampl, Ales; Dvorak, Petr] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15000 5, Czech Republic; [Matulka, Kamil; Jaros, Josef; Hampl, Ales; Dvorak, Petr] Masaryk Univ, Dept Biol, Fac Med, Brno 62500, Czech Republic; [Hampl, Ales; Dvorak, Petr] Acad Sci Czech Republic, Inst Expt Med, Vvi, Prague 14220 4, Czech Republic","Horak, D (reprint author), Acad Sci Czech Republic, Inst Macromol Chem, Vvi, CR-16206 Prague 6, Czech Republic.","horak@imc.cas.cz","Vopenkova, Katerina/C-7133-2012; Dvorak, Petr/G-2509-2013","Dvorak, Petr/0000-0002-3229-140X","EU [LSHM-CT-2007-037862]; Grant Agency of the Czech Republic [P304/11/0731]; Ministry of Education, Youth and Sports of the Czech Republic [MSM0021622430, 1M0538, LC06077]","Contract grant sponsor: EU grant Artemis; contract grant number: LSHM-CT-2007-037862.Contract grant sponsor: Grant Agency of the Czech Republic; contract grant number: P304/11/0731.Contract grant sponsor: Ministry of Education, Youth and Sports of the Czech Republic; contract grant numbers: MSM0021622430, 1M0538, LC06077",null,49,2,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1552-4973",null,null,"J BIOMED MATER RES B","J. Biomed. Mater. Res. Part B","JUL",2011,"98B",1,null,null,null,null,54,67,null,"10.1002/jbm.b.31832",null,14,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","777EP","WOS:000291598900007"]
[null,null,null,null,"J","Vrbikova, J; Zamrazilova, H; Sedlackova, B; Sanajderova, M",null,null,null,"Vrbikova, Jana; Zamrazilova, Hana; Sedlackova, Barbora; Sanajderova, Marta",null,null,"Metabolic syndrome in adolescents with polycystic ovary syndrome","GYNECOLOGICAL ENDOCRINOLOGY",null,null,"English","Article",null,null,null,null,null,"Polycystic ovary syndrome; metabolic syndrome; insulin resistance; obesity","INSULIN-RESISTANCE; OBESE ADOLESCENTS; PREVALENCE; WOMEN; PCOS; RISK","The aim of the presented study is to evaluate metabolic features in adolescents with polycystic ovary syndrome (PCOS) in comparison with age-and BMI-matched subjects. Forty-three adolescents with PCOS according to ESHRE criteria were prospectively evaluated and compared with 48 control subjects. Blood sampling was done in the early follicular phase of menstrual cycle, between 1st and 5th day, for plasma glucose, total and high-density lipoprotein (HDL)-cholesterol, triglycerides, insulin and C peptide. The diagnosis of metabolic syndrome was done according to IDF adolescent criteria. Adolescents with PCOS have increased low-density lipoprotein (LDL)-cholesterol (p < 0.002), decreased HDL-cholesterol (p < 0.0007) and increased C peptide levels (p < 0.02) in comparison with healthy adolescents. Total cholesterol, triglycerides, fasting blood glucose, fasting insulin, HOMA-IR, waist-to-hip ratio, systolic and diastolic blood pressure did not differ between the groups. There was no difference when we compared the prevalence of adolescents with at least one feature of metabolic syndrome between PCOS (17 from 43) and healthy controls (27 from 48). In conclusion, adolescents with PCOS have less favourable blood lipid profiles with higher LDL-cholesterol and lower levels of HDL-cholesterol and are more insulin resistant than their healthy counterparts having higher fasting C peptide levels.","[Vrbikova, Jana; Zamrazilova, Hana; Sedlackova, Barbora] Inst Endocrinol, Dept Clin Endocrinol, Prague 11694 1, Czech Republic; [Sanajderova, Marta] Charles Univ Prague, Fac Med 2, Pediat Clin, Prague 15000 5, Czech Republic","Vrbikova, J (reprint author), Inst Endocrinol, Dept Clin Endocrinol, Narodni 8, Prague 11694 1, Czech Republic.","jvrbikova@endo.cz",null,null,"Czech Ministry of Health, IGA agency [NS 9839-4/2008]","This work was supported by the grant of Czech Ministry of Health, IGA agency No NS 9839-4/2008.",null,17,1,1,"INFORMA HEALTHCARE","NEW YORK","52 VANDERBILT AVE, NEW YORK, NY 10017 USA","0951-3590",null,null,"GYNECOL ENDOCRINOL","Gynecol. Endocrinol.","OCT",2011,27,10,null,null,null,null,820,822,null,"10.3109/09513590.2010.508851",null,3,"Endocrinology & Metabolism; Obstetrics & Gynecology","Endocrinology & Metabolism; Obstetrics & Gynecology","829WW","WOS:000295617600016"]
[null,null,null,null,"J","Ehler, E; Vanek, D; Stenzl, V; Vancata, V",null,null,null,"Ehler, Edvard; Vanek, Daniel; Stenzl, Vlastimil; Vancata, Vaclav",null,null,"Y-chromosomal diversity of the Valachs from the Czech Republic: model for isolated population in Central Europe","CROATIAN MEDICAL JOURNAL",null,null,"English","Article",null,null,null,null,null,null,"STR HAPLOTYPES; CROATIAN POPULATION; REFERENCE DATABASE; GENE FLOW; LOCI; PERSPECTIVE; NETWORKS; LINEAGES; HERITAGE; SAMPLE","Aim To evaluate Y-chromosomal diversity of the Moravian Valachs of the Czech Republic and compare them with a Czech population sample and other samples from Central and South-Eastern Europe, and to evaluate the effects of genetic isolation and sampling. Methods The first sample set of the Valachs consisted of 94 unrelated male donors from the Valach region in northeastern Czech Republic border-area. The second sample set of the Valachs consisted of 79 men who originated from 7 paternal lineages defined by surname. No close relatives were sampled. The third sample set consisted of 273 unrelated men from the whole of the Czech Republic and was used for comparison, as well as published data for other 27 populations. The total number of samples was 3244. Y-short tandem repeat (STR) markers were typed by standard methods using PowerPlex (R) Y System (Promega) and Yfiler (R) Amplification Kit (Applied Biosystems) kits. Y-chromosomal haplogroups were estimated from the haplotype information. Haplotype diversity and other intra-and inter-population statistics were computed. Results The Moravian Valachs showed a lower genetic variability of Y-STR markers than other Central European populations, resembling more to the isolated Balkan populations (Aromuns, Csango, Bulgarian, and Macedonian Roma) than the surrounding populations (Czechs, Slovaks, Poles, Saxons). We illustrated the effect of sampling on Valach paternal lineages, which includes reduction of discrimination capacity and variability inside Y-chromosomal haplogroups. Valach modal haplotype belongs to R1a haplogroup and it was not detected in the Czech population. Conclusion The Moravian Valachs display strong substructure and isolation in their Y chromosomal markers. They represent a unique Central European population model for population genetics.","[Ehler, Edvard; Vancata, Vaclav] Charles Univ Prague, Fac Educ, Dept Biol & Environm Studies, Prague 11639 1, Czech Republic; [Ehler, Edvard] Charles Univ Prague, Fac Sci, Dept Anthropol & Human Genet, Prague 11639 1, Czech Republic; [Vanek, Daniel] Forens DNA Serv, Prague, Czech Republic; [Vanek, Daniel] Charles Univ Prague, Fac Med 2, Prague 11639 1, Czech Republic; [Stenzl, Vlastimil] Inst Criminalist, Dept Forens Genet, Prague, Czech Republic; [Vancata, Vaclav] Masaryk Univ, Fac Sci, Inst Anthropol, CS-61137 Brno, Czech Republic","Ehler, E (reprint author), Charles Univ Prague, Fac Educ, Dept Biol & Environm Studies, MD Rettigove 4, Prague 11639 1, Czech Republic.","eda.ehler@seznam.cz",null,null,"Ministry of Education, Youth, and Sports of the Czech Republic [MSM 0021620843]; Charles University in Prague, Czech Republic [UK 218/2005/B-BIO/PedF]; Ministry of the Interior of the Czech Republic [VD20072010B14]","EE was supported by grants MSM 0021620843 (Ministry of Education, Youth, and Sports of the Czech Republic). EE and VV were supported by grant UK 218/2005/B-BIO/PedF (Charles University in Prague, Czech Republic). VS was supported by the grant VD20072010B14 (Ministry of the Interior of the Czech Republic).",null,42,1,1,"MEDICINSKA NAKLADA","ZAGREB","VLASKA 69, HR-10000 ZAGREB, CROATIA","0353-9504",null,null,"CROAT MED J","Croat. Med. J.","JUN",2011,52,3,null,null,null,null,358,367,null,"10.3325/cmj.2011.52.358",null,10,"Medicine, General & Internal","General & Internal Medicine","794CS","WOS:000292873600013"]
[null,null,null,null,"J","Vaneckova, I; Huskova, Z; Vanourkova, Z; Cervenka, L",null,null,null,"Vaneckova, Ivana; Huskova, Zuzana; Vanourkova, Zdenka; Cervenka, Ludek",null,null,"Castration Has Antihypertensive and Organoprotective Effects in Male but Not in Female Heterozygous Ren-2 Rats","KIDNEY & BLOOD PRESSURE RESEARCH",null,null,"English","Article",null,null,null,null,null,"Ren-2 rats; Hypertension; Sexual dimorphism; Age; Sex hormones; Renin-angiotensin system","SPONTANEOUSLY HYPERTENSIVE-RATS; RENIN-ANGIOTENSIN SYSTEM; END-ORGAN DAMAGE; TRANSGENIC RATS; BLOOD-PRESSURE; RECEPTOR BLOCKADE; AT(2) RECEPTORS; RENAL-DISEASE; SEX-HORMONES; NITRIC-OXIDE","Gender differences in the regulation of blood pressure (BP) and the contributions of the renin-angiotensin system remain controversial. We assessed the effect of castration on BP and organ damage, as well as angiotensin II (ANG II), estradiol and testosterone levels in heterozygous Ren-2 transgenic (TGR) rats and transgene-negative Hannover Sprague-Dawley control rats. Male TGR had severe hypertension throughout the experiment, while the BP of female TGR declined after 5 months to normotensive levels. Ovariectomy had no effect on BP, cardiac hypertrophy or proteinuria in female Ren-2 TGR. On the contrary, BP and cardiac hypertrophy were significantly reduced in castrated male TGR as compared to sham-operated TGR. Moreover, proteinuria in these animals was normalized to the levels of control rats. ANG II levels did not differ between male and female TGR, and no effect of castration on plasma and tissue ANG II levels was found either in male or female TGR at the end of the experiment. In conclusion, the contribution of the renin-angiotensin system to the gender difference in BP homeostasis seems to be negligible in aging heterozygous Ren-2 transgenic rats. Copyright (C) 2010 S. Karger AG, Basel","[Vaneckova, Ivana; Huskova, Zuzana; Vanourkova, Zdenka; Cervenka, Ludek] Inst Clin & Expt Med, Ctr Expt Med, Prague, Czech Republic; [Vaneckova, Ivana; Huskova, Zuzana; Vanourkova, Zdenka; Cervenka, Ludek] Inst Clin & Expt Med, Cardiovasc Res Ctr, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Vaneckova, I (reprint author), Acad Sci Czech Republic, Inst Physiol, Vvi, Videnska 1083, CZ-14220 Prague 4, Czech Republic.","ivanava@biomed.cas.cz","Vaneckova, Ivana/B-5543-2012",null,"Czech Science Foundation (GACR) [305/08/J006, 305/07/J004]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/10500-3, NS/10499-3]; Center for Cardiovascular Research [1M6798582302]; Institute for Clinical and Experimental Medicine [MZO 00023001]; EU [CZ.2.16/3.1.00/22126]","We thank Mrs. Dagmar Markova and Radka Kuzelkova for their excellent technical assistance and Josef Zicha for his valuable comments during the preparation of the manuscript. This study was supported by grant No. 305/08/J006 awarded to L.C. and grant No. 305/07/J004 awarded to I.V. by the Czech Science Foundation (GACR) and by grants No. NS/10500-3 and No. NS/10499-3 by the Internal Grant Agency of the Ministry of Health of the Czech Republic. I.V. was also supported by the Center for Cardiovascular Research (1M6798582302) and by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). This study was also supported by the financial support from the EU by the Operational Program Prague - Competitiveness; project 'CEVKOON' (No. CZ.2.16/3.1.00/22126).",null,36,1,1,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096",null,null,"KIDNEY BLOOD PRESS R","Kidney Blood Pressure Res.",null,2011,34,1,null,null,null,null,46,52,null,"10.1159/000322618",null,7,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","Physiology; Urology & Nephrology; Cardiovascular System & Cardiology","710VQ","WOS:000286545500006"]
[null,null,null,null,"J","Stehlik, D; Pytlik, R; Rychtrmocova, H; Vesela, R; Kopecny, Z; Trc, T",null,null,null,"Stehlik, D.; Pytlik, R.; Rychtrmocova, H.; Vesela, R.; Kopecny, Z.; Trc, T.",null,null,"Xenogeneic Protein Free Cultivation of Mesenchymal Multipotent Stromal Cells","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"cell therapy; tissue engineering; multipotent mesenchymal stromal cells; good manufacturing practice; growth factors; human serum","STEM-CELLS; IN-VITRO; PROGENITOR CELLS; MARROW; SERUM; DIFFERENTIATION; EXPANSION; PROLIFERATION; GROWTH","PURPOSE OF THE STUDY The aim of this study was to compare the standard laboratory method of cultivation of mesenchymal multipotent stromal cells (MSC) and a novel technique of rapid MSC expansion focused on simple clinical use. MATERIAL AND METHODS Bone marrow mononuclear cells of donors were cultured for 14 days by the standard and the new cultivation method. The standard method (STD) was based on an alpha MEM medium supplemented with foetal calf serum (FCS). The new animal protein-free method (CLI) was based on the clinical grade medium CellgroTM, pooled human serum and human recombinant growth factors (EGF, PDGF-BB, M-CSF, FGF-2) supplemented with dexamethasone, insulin and ascorbic acid. The cell product was analyzed by flow cytometry. Furthermore, the cell products of STD and CLI methods were differentiated in vitro, and histochemical and immunohistochemical analyses, electron microscopy and elemental analysis were performed. Some cells were seeded on biodegradable scaffolds, in vivo implanted into immunodeficient mice for 6 weeks and evaluated by histological methods. RESULTS Yields of the CLI method after 14 days of cultivation were 40-fold higher than those obtained by the STD technique (p<0.05). Cell products of both STD and CLI methods fulfilled the criteria of MSC in terms of antigen expression assessed by flow cytometry, as well as osteogenic, chondrogenic and adipogenic in vitro differentiation assays. Moreover, these cells seeded on three-dimensional scaffolds cultured in osteogenic medium produced mineral deposits and a fibrillar extracellular matrix seen with the electron microscope. Deposits examined by element analysis contained calcium and phosphorus at a ratio of 5 to 3, which corresponded to hydroxyapatite. The cell product seeded on biodegradable scaffolds and implanted into immunodeficient mice was able to form a bone-like calcified tissue with blood supply of mouse origin. DISCUSSION The currently used methods of cultivation have certain disadvantages compared to the CLI technique, such as a longer cultivation period, need of primary expansion and reseeding and use of FCS with all its potential risks. High yields of cells obtained by the CLI method in a very short time make the use of cultured cells potentially suitable for an acute trauma management. Other therapeutic non-orthotopic applications of CLI-cultured cells have to be further investigated. CONCLUSIONS The CLI method is unique, rapid, simple and lacking the addition of animal proteins. CLI-cultured cells fulfil the criteria of MSC. The CLI method potentially allows for closed system cultivation in good manufacturing practice (GMP) conditions. It seems to be easily transferable to good clinical practice compared to other protocols and should extend the possibilities of cell therapy and tissue engineering of cartilage and bone. The new method is protected by Czech patent 301 148 and by europian patent EP 1999250 according to Czech and international laws.","[Stehlik, D.; Kopecny, Z.; Trc, T.] 2 LF UK, Klin Ortoped Deti & Dospelych, Prague 15600 5, Czech Republic; [Stehlik, D.; Pytlik, R.; Rychtrmocova, H.; Vesela, R.] 1 LF UK, Interni Klin 1, Prague, Czech Republic; [Stehlik, D.] 1 LF UK, Anatom Ustav, Prague, Czech Republic; [Stehlik, D.; Kopecny, Z.; Trc, T.] FN Motol, Prague 15600 5, Czech Republic","Stehlik, D (reprint author), 2 LF UK, Klin Ortoped Deti & Dospelych, V Uvalu 84, Prague 15600 5, Czech Republic.","stehlikd@seznam.cz",null,null,null,null,null,26,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2011,78,6,null,null,null,null,537,543,null,null,null,7,"Orthopedics","Orthopedics","871XQ","WOS:000298771400008"]
[null,null,null,null,"J","Hlubocky, J; Mokracek, A; Novacek, V; Vojacek, J; Burkert, J; Kochova, P; Klepacek, J; Pepper, J; Spatenka, J",null,null,null,"Hlubocky, J.; Mokracek, A.; Novacek, V.; Vojacek, J.; Burkert, J.; Kochova, P.; Klepacek, J.; Pepper, J.; Spatenka, J.",null,null,"Mechanical Properties of Mitral Allografts Are Not Reasonably Influenced by Cryopreservation in Sheep Model","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Mitral allograft; Cryopreservation; Maxwell model; Viscoelastic properties; Mitral valve","TISSUE; VALVE","A mitral allograft is used exceptionally in the mitral, as well as in the tricuspid position, mostly as an experimental surgical procedure. The authors decided to evaluate the possibility of inserting a cryopreserved mitral allograft into the tricuspid position in a sheep experimental model. Within the framework of this experimental project the mechanical properties of the cryopreserved mitral allograft were tested. A novel methodology studying the functional unit composed of mitral annulus, leaflet, chordae tendinaea, and papillary muscle is presented. A five-parameter Maxwell model was applied to characterize the viscoelastic behavior of sheep mitral valves. A control group of 39 fresh mitral specimens and a test group of 13 cryopreserved mitral allografts from tissue bank were tested. The testing protocol consisted of six loading cycles with 1 mm elongation every 5 min. There was no significant difference in the mean values of the determined parameters (p>0.05) which confirms the main hypothesis that cryopreservation does not influence significantly material parameters characterizing the tissue mechanics. Slight discrepancy is observed in variances of viscous parameters suggesting that the values of the test group may be spread over larger interval due to the treatment.","[Hlubocky, J.] Gen Univ Hosp, Dept Cardiovasc Surg, Prague, Czech Republic; [Mokracek, A.] Hosp Ceske Budejovice, Dept Cardiac Surg, Ceske Budejovice, Czech Republic; [Novacek, V.; Burkert, J.; Spatenka, J.] Univ Hosp Motol, Dept Cardiac Surg, Prague, Czech Republic; [Novacek, V.; Burkert, J.; Spatenka, J.] Univ Hosp Motol, Transplant Ctr, Prague, Czech Republic; [Vojacek, J.] Univ Hosp, Dept Cardiac Surg, Hradec Kralove, Czech Republic; [Kochova, P.] Univ W Bohemia, Dept Mech, Plzen 30614, Czech Republic; [Klepacek, J.] Univ W Bohemia, New Technol Ctr, Plzen 30614, Czech Republic; [Pepper, J.] Royal Brompton Hosp, Acad Dept Cardiac Surg, London SW3 6LY, England","Hlubocky, J (reprint author), Gen Univ Hosp, Dept Cardiovasc Surg, Prague, Czech Republic.",null,null,null,null,null,null,19,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2011,60,3,null,null,null,null,475,482,null,null,null,8,"Physiology","Physiology","797PA","WOS:000293138600008"]
[null,null,null,null,"J","Rada, V; Nevoral, J; Flajsmanova, K; Rockova, S; Krcmarova, I; Grmanova, M; Vlkova, E; Novakova, I; Killer, J; Kopecny, J",null,null,null,"Rada, Vojtech; Nevoral, Jiri; Flajsmanova, Katerina; Rockova, Sarka; Krcmarova, Ivana; Grmanova, Martina; Vlkova, Eva; Novakova, Ivana; Killer, Jiri; Kopecny, Jan",null,null,"Occurrence of bifidobacteria in human milk","MILCHWISSENSCHAFT-MILK SCIENCE INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"Human milk (Bifidobacteria)","LACTIC-ACID BACTERIA; BREAST-MILK; INFANT GUT; LYSOZYME; STRAINS","Two groups of human milk samples were tested: The first group (18) originated from mothers with babies without bifidobacteria in their faecal flora (BIF-), the second (43) from mothers with babies with bifidobacteria in their faecal flora (BIF+). The occurrence of bifidobacteria in faeces was tested using cultivation method and FISH. For the detection of bifidobacteria in milk, the samples were subcultivated in TPY broth with mupirocin and subsequently the fructose-6-phosphate phosphoketolase activity (F6PPK) was determined. Infants of mothers from BIF+ group had high numbers of bifidobacteria (usually higher than 9 log CFU/g) in their faeces. On the contrary, infants of mothers from BIF- group did not contain detectable amounts of bifidobacteria in their faecal samples. These babies possessed significant amounts of clostridia in their faecal flora. While 35% of milks from BIF+ group expressed F6PPK activity and therefore contained live bifidobacteria, no bifidobacteria were detected in milks from BIF- group. Number of cultivable bifidobacteria in F6PPK-positive milk varied from 1.60 to 4.10 log CFU/ml. It could be concluded that human milk is probably not the primary source of bifidobacteria for infants. It seems that bifidobacteria occur in mothers' milks as a consequence of contamination from infant.","[Rada, Vojtech; Rockova, Sarka; Krcmarova, Ivana; Grmanova, Martina; Vlkova, Eva] Czech Univ Life Sci, Fac Agrobiol Food & Nat Resources, Dept Microbiol Nutr & Dietet, Prague, Czech Republic; [Nevoral, Jiri; Flajsmanova, Katerina] Univ Hosp, Dept Paediat, Prague, Czech Republic; [Novakova, Ivana] Slovak Univ Agr, Dept Microbiol, Prague 14220 4, Krc, Czech Republic; [Killer, Jiri; Kopecny, Jan] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Prague 14220 4, Krc, Czech Republic","Rada, V (reprint author), Czech Univ Life Sci, Fac Agrobiol Food & Nat Resources, Dept Microbiol Nutr & Dietet, Prague, Czech Republic.","rada@af.czu.cz",null,null,"Ministry of Health of the Czech Republic [IGA MZ NR/8310-5]","This study was supported by grant IGA MZ NR/8310-5 of the Ministry of Health of the Czech Republic.","Gagnon M, 2004, INT J FOOD MICROBIOL, V92, P69, DOI 10.1016/j.ijfoodmicro.2003.07.010; Gueimonde M, 2007, NEONATOLOGY, V92, P64, DOI 10.1159/000100088; Guglielmotti DM, 2007, INT DAIRY J, V17, P916, DOI 10.1016/j.idairyj.2006.11.004; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1111/J.1469-8137.2009.02874.X; Kozakova D, 2005, EUR FOOD RES TECHNOL, V221, P774, DOI 10.1007/s00217-005-0026-x; MAIDAK BL, 1994, NUCLEIC ACIDS RES, V22, P3485, DOI 10.1093/nar/22.17.3485; Martin R, 2009, APPL ENVIRON MICROB, V75, P965, DOI 10.1128/AEM.02063-08; Martin R, 2003, J PEDIATR, V143, P754, DOI 10.1016/j.jpeds.2003.09.028; Orban JI, 2000, J MICROBIOL METH, V40, P221, DOI 10.1016/S0167-7012(00)00133-0; OSSERMAN EF, 1966, J EXP MED, V124, P921, DOI 10.1084/jem.124.5.921; Sinkiewicz G, 2005, PEDIATR RES, V58, P415, DOI 10.1203/00006450-200508000-00381; Thompson JD, 1997, NUCLEIC ACIDS RES, V24, P4876, DOI DOI 10.1093/NAR/25.24.4876; Vlkova E, 2005, J MICROBIOL METH, V60, P365, DOI 10.1016/j.mimet.2004.10.012; WEISBURG WG, 1991, J BACTERIOL, V173, P697",14,0,0,"A V A AGRARVERLAG","KEMPTEN","PROSCHESTR 2, 87437 KEMPTEN, GERMANY","0026-3788",null,null,"MILCHWISSENSCHAFT","Milchwiss.-Milk Sci. Int.",null,2011,66,2,null,null,null,null,123,126,null,null,null,4,"Food Science & Technology","Food Science & Technology","745SN","WOS:000289186300002"]
[null,null,null,null,"J","Melenovsky, V; Benes, J; Skaroupkova, P; Sedmera, D; Strnad, H; Kolar, M; Vlcek, C; Petrak, J; Benes, J; Papousek, F; Oliyarnyk, O; Kazdova, L; Cervenka, L",null,null,null,"Melenovsky, Vojtech; Benes, Jan; Skaroupkova, Petra; Sedmera, David; Strnad, Hynek; Kolar, Michal; Vlcek, Cestmir; Petrak, Jiri; Benes, Jiri, Jr.; Papousek, Frantisek; Oliyarnyk, Olena; Kazdova, Ludmila; Cervenka, Ludek",null,null,"Metabolic characterization of volume overload heart failure due to aorto-caval fistula in rats","MOLECULAR AND CELLULAR BIOCHEMISTRY",null,null,"English","Article",null,null,null,null,null,"Heart failure; Lipid metabolism; Insulin; Triglycerides; Body composition; Free fatty acids","INDUCED CARDIAC-HYPERTROPHY; INDEPENDENT RISK-FACTOR; FATTY-ACID-METABOLISM; FAILING HUMAN HEART; INSULIN-RESISTANCE; ADIPOSE-TISSUE; SUBSTRATE; OXIDATION; DISEASE; GLUCOSE","Metabolic interactions between adipose tissue and the heart may play an active role in progression of heart failure (HF). The aim of the study was to examine changes in myocardial and adipose tissue metabolism and gene expression in a rat HF model induced by chronic volume overload. HF was induced by volume overload from aorto-caval fistula (ACF) in 3-month-old male Wistar rats and animals were studied in the phase of decompensated HF (22nd week). HF rats showed marked eccentric cardiac hypertrophy, pulmonary congestion, increased LV end-diastolic pressure, and intraabdominal fat depletion. HF rats had preserved glucose tolerance, but increased circulating free fatty acids (FFA) and attenuated insulin response during oral glucose challenge. Isolated organ studies showed preserved responsiveness of adipose tissue lipolysis and lipogenesis to epinephrine and insulin in ACF. The heart of HF animals had markedly reduced triglyceride content (almost to half of controls), attenuated anti-oxidative reserve (GSH/GSSG), upregulated HF markers (ANP, periostin, thrombospondin-4), specific signaling pathways (Wnt, TGF-beta), and downregulated enzymes of mitochondrial fatty acid oxidation, citric acid cycle, and respiratory chain. Adipose tissue transcription profiling showed upregulated receptor for gastric inhibitory polypeptide. In conclusion, ACF-induced HF model displays several deregulations of systemic metabolism. Despite elevation of systemic FFAs, myocardial triglycerides are low and insulin levels are attenuated, arguing against a role of lipotoxicity or insulin resistance in this model. Attenuated postprandial insulin response and relative lack of its antilipolytic effects may facilitate intraabdominal fat depletion observed in ACF-HF animals.","[Melenovsky, Vojtech; Benes, Jan] Inst Clin & Expt Med IKEM, Dept Cardiol, Prague 14021 4, Czech Republic; [Melenovsky, Vojtech; Benes, Jan; Skaroupkova, Petra; Cervenka, Ludek] Inst Clin & Expt Med IKEM, Cardiovasc Res Ctr, Prague 14021 4, Czech Republic; [Oliyarnyk, Olena; Kazdova, Ludmila] Inst Clin & Expt Med IKEM, Dept Expt Med, Prague 14021 4, Czech Republic; [Sedmera, David; Papousek, Frantisek] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Strnad, Hynek; Kolar, Michal; Vlcek, Cestmir] Acad Sci Czech Republic, Inst Mol Genet, Prague, Czech Republic; [Petrak, Jiri] Charles Univ Prague, Fac Med 1, Inst Pathol Physiol, Prague, Czech Republic; [Sedmera, David; Benes, Jiri, Jr.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Div Physiol, Prague, Czech Republic","Melenovsky, V (reprint author), Inst Clin & Expt Med IKEM, Dept Cardiol, Videnska 1958-9, Prague 14021 4, Czech Republic.","vojtech.melenovsky@ikem.cz","Kolar, Michal/A-3307-2012; Sedmera, David/C-2146-2012; Strnad, Hynek/B-7361-2008","Kolar, Michal/0000-0002-4593-1525; Strnad, Hynek/0000-0002-0141-8340","Ministry of Heath [MZO-00023001, IGA MZCR NS-10300-3, NS10497-3/2009]; Ministry of Education [MSMT-1MO510, VZ 0021620806, 0021620806, 1M6837805002]; Grant agency [305/09/1390]; Academy of sciences, Czech Republic [AV0Z50520514, AV0Z50110509]","This study was supported by Ministry of Heath [MZO-00023001 to V.M. and L.C., IGA MZCR NS-10300-3 to J.P., NS10497-3/2009 to V.M.]; Ministry of Education [MSMT-1MO510 to V.M., J.B. and L.C., VZ 0021620806 to D.S., 0021620806 to J.P., 1M6837805002 to H.S. and M.K.]; the Grant agency [305/09/1390 to V.M.]; and the Academy of sciences [AV0Z50520514 to H.S. and M.K, AV0Z50110509 to D.S.] of the Czech Republic.",null,60,13,15,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0300-8177",null,null,"MOL CELL BIOCHEM","Mol. Cell. Biochem.","AUG",2011,354,41671,null,null,null,null,83,96,null,"10.1007/s11010-011-0808-3",null,14,"Cell Biology","Cell Biology","785GO","WOS:000292215600010"]
[null,null,null,null,"J","Bilton, D; Canny, G; Conway, S; Dumcius, S; Hjelte, L; Proesmans, M; Tummler, B; Vavrova, V; De Boeck, K",null,null,null,"Bilton, D.; Canny, G.; Conway, S.; Dumcius, S.; Hjelte, L.; Proesmans, M.; Tuemmler, B.; Vavrova, V.; De Boeck, K.",null,null,"Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Article",null,null,null,null,null,"Pulmonary exacerbation; Cystic fibrosis; Outcome parameters; Definition; Consensus","CYSTIC-FIBROSIS","Pulmonary exacerbations represent a key outcome variable in clinical trials of cystic fibrosis (CF). As there is variation in the trigger for use of intravenous antibiotics compared to the use of oral antibiotics or new nebulised therapy for treatment of exacerbations, the consensus view is that use of intravenous antibiotics cannot be regarded as the key defining character for an exacerbation on its own. The consensus view is that the clinical need for additional treatment as indicated by a recent change in clinical parameters provides the best definition of an exacerbation. Which parameters to include as well as the problems associated with the use of scoring systems and symptom clusters are being discussed. (C) 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Bilton, D.] Royal Brompton Hosp, London SW3 6NP, England; [Canny, G.] Our Ladys Hosp Sick Children, Dublin 12, Ireland; [Conway, S.] St James Hosp, Leeds LS9 7TF, W Yorkshire, England; [Dumcius, S.] Vilnius State Univ, LT-08661 Vilnius, Lithuania; [Hjelte, L.] Stockholm CF Ctr, S-14186 Stockholm, Sweden; [Proesmans, M.; De Boeck, K.] Univ Hosp Leuven, B-3000 Louvain, Belgium; [Tuemmler, B.] Hannover Med Sch, D-30625 Hannover, Germany; [Vavrova, V.] Univ Hosp Motol, Prague 15006 5, Czech Republic","Bilton, D (reprint author), Royal Brompton Hosp, Sydney St, London SW3 6NP, England.","D.Bilton@rbht.nhs.uk","Gough, Ethan/B-8633-2012",null,"European Union [LSHM-CT-2005-018932]","This work was supported by the European Union Sixth Framework Programme (contract no. LSHM-CT-2005-018932, EuroCareCF).",null,9,14,14,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","JUN",2011,10,null,null,2,null,null,"S79","S81",null,null,null,3,"Respiratory System","Respiratory System","783FX","WOS:000292068000012"]
[null,null,null,null,"J","Bruha, R; Marecek, Z; Pospisilova, L; Nevsimalova, S; Vitek, L; Martasek, P; Nevoral, J; Petrtyl, J; Urbanek, P; Jiraskova, A; Ferenci, P",null,null,null,"Bruha, Radan; Marecek, Zdenek; Pospisilova, Lenka; Nevsimalova, Sona; Vitek, Libor; Martasek, Pavel; Nevoral, Jiri; Petrtyl, Jaromir; Urbanek, Petr; Jiraskova, Alena; Ferenci, Peter",null,null,"Long-term follow-up of Wilson Disease: natural history, treatment, mutations analysis and phenotypic correlation","LIVER INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"D-penicillamine; long-term outcome; mutational analysis; Wilson disease; zinc salts","CLINICAL PRESENTATION; H1069Q MUTATION; DIAGNOSIS; COPPER; GENE; ZINC; ATP7B","Background and aims: Wilson disease (WD) is an inherited disorder of copper metabolism. When treated, the outcome can be excellent, although the long-term survival has yet to be well documented. The aim of this study was to describe the long-term outcome of a cohort of patients with WD and to assess those factors affecting the phenotypic manifestation of WD. Methods: The presence of mutations to the ATP7B gene, the clinical manifestations, treatments and the long-term outcomes were analysed retrospectively in 117 patients with WD (59 men and 58 women, aged at evaluation 38.5 +/- 11, range 16-63 years). Results: Fifty-five patients with a neurological presentation, 51 patients with a hepatic presentation and 11 asymptomatic patients were followed up for an average of 15.1 +/- 10 years (median 12 years, range 1-41 years). The H1069Q ATP7B gene mutation was the most frequent genetic variant (54.3%); the frequency of this mutation did not differ between patients with either the hepatic or the neurological presentation (P = 0.099). D-penicillamine or zinc salts (81 and 17% respectively) were used for treatment, and three patients underwent liver transplantation. The majority of symptomatic patients became asymptomatic, or improved, during the follow-up (82% patients with hepatic presentation, 69% with neurological presentation). The long-term survival of patients with WD did not differ from that of the general Czech population (P = 0.95). Conclusions: Long-term follow-up shows a satisfactory response in the great majority of adequately treated patients with WD and survival coincides with that of the general population.","[Bruha, Radan; Vitek, Libor; Petrtyl, Jaromir; Jiraskova, Alena] Charles Univ Prague, Dept Internal Med 4, Fac Med 1, Gen Teaching Hosp, Prague 12808 2, Czech Republic; [Marecek, Zdenek; Urbanek, Petr] Charles Univ Prague, Dept Internal Med, Fac Med 1, Prague 12808 2, Czech Republic; [Marecek, Zdenek; Urbanek, Petr] Charles Univ Prague, Cent Mil Hosp, Prague 12808 2, Czech Republic; [Pospisilova, Lenka; Martasek, Pavel] Charles Univ Prague, Lab Mitochondrial Disorders, Dept Pediat, Fac Med 1, Prague 12808 2, Czech Republic; [Nevsimalova, Sona] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague 12808 2, Czech Republic; [Nevoral, Jiri] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague 12808 2, Czech Republic; [Ferenci, Peter] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria","Bruha, R (reprint author), Charles Univ Prague, Dept Internal Med 4, Fac Med 1, Gen Teaching Hosp, U Nemocnice 2, Prague 12808 2, Czech Republic.","bruha@cesnet.cz","Vitek, Libor/A-2645-2008",null,"Czech Ministry of Health [9406/3]","This study was supported by Grant IGA MZ CR No. 9406/3, provided by the Czech Ministry of Health.",null,31,10,11,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1478-3223",null,null,"LIVER INT","Liver Int.","JAN",2011,31,1,null,null,null,null,83,91,null,"10.1111/j.1478-3231.2010.02354.x",null,9,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","690NH","WOS:000285011000011"]
[null,null,null,null,"J","Koblizek, V; Tomsova, M; Cermakova, E; Papousek, P; Pracharova, S; Mandalia, RAA; Ceral, J; Novosad, J; Fila, L; Sedlak, V; Ruta, J; Bartos, V; Salajka, F; Hrnciarik, M",null,null,null,"Koblizek, Vladimir; Tomsova, Marketa; Cermakova, Eva; Papousek, Petr; Pracharova, Sarka; Mandalia, Rajiv A. A.; Ceral, Jiri; Novosad, Jakub; Fila, Libor; Sedlak, Vratislav; Ruta, Jiri; Bartos, Vladimir; Salajka, Frantisek; Hrnciarik, Michal",null,null,"Impairment of nasal mucociliary clearance in former smokers with stable chronic obstructive pulmonary disease relates to the presence of a chronic bronchitis phenotype","RHINOLOGY",null,null,"English","Article",null,null,null,null,null,"nasal epithelium; mucociliary clearance; ciliary frequency; COPD; former smokers","CILIARY BEAT FREQUENCY; CHRONIC MUCUS HYPERSECRETION; FUNCTIONAL-ANALYSIS; LOWER AIRWAY; COPD; DYSKINESIA; SYMPTOMS; EPITHELIUM; SMOKING; PATTERN","Background: Associations between nasal and bronchial impairment have been repeatedly described in chronic obstructive pulmonary disease (COPD), whereas nasal mucociliary clearance (MCC) in COPD patients is not yet fully understood. We studied nasal MCC parameters in COPD patients and compared them with healthy adults (HA) and with cystic fibrosis (CF) patients with compromised MCC. Methodology: An observational study of 98 COPD ex-smokers and subjects from control groups evaluated for nasal MCC time (NMCCt) and by digital video microscopy of nasal mucosa recording ciliary beat frequency (CBF) and ciliary beat pattern. Results: The NMCCt was decreased in HA compared to those with COPD and decreased in those with COPD compared to those with CF. CBF in COPD was lower compared to HA. The index of ciliary dyskinesia in COPD patients differed from HA. We detected higher NMCCt and lower nasal CBF in patients with chronic bronchitis phenotype (CB) compared to non-CB patients. Conclusions: We confirmed the presence of impaired nasal MCC in COPD ex-smokers. These impairments were apparent predominantly in the CB phenotype.","[Koblizek, Vladimir; Papousek, Petr; Pracharova, Sarka; Mandalia, Rajiv A. A.; Fila, Libor; Sedlak, Vratislav; Ruta, Jiri; Bartos, Vladimir; Salajka, Frantisek; Hrnciarik, Michal] Charles Univ Prague, Fac Med, Dept Pulm, Hradec Kralove, Czech Republic; [Koblizek, Vladimir; Tomsova, Marketa; Papousek, Petr; Pracharova, Sarka; Mandalia, Rajiv A. A.; Ceral, Jiri; Sedlak, Vratislav; Ruta, Jiri; Bartos, Vladimir; Salajka, Frantisek; Hrnciarik, Michal] Charles Univ Prague, Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; [Tomsova, Marketa] Charles Univ Prague, Fac Med, Fingerland Dept Pathol, Hradec Kralove, Czech Republic; [Cermakova, Eva] Charles Univ Prague, Fac Med Hradec Kralove, Comp Technol Ctr, Hradec Kralove, Czech Republic; [Ceral, Jiri] Charles Univ Prague, Fac Med, Dept Internal Med 1, Hradec Kralove, Czech Republic; [Novosad, Jakub] Charles Univ Prague, Fac Med, Dept Clin Immunol & Allergol, Hradec Kralove, Czech Republic; [Fila, Libor] Charles Univ Prague, Univ Hosp Motol, Hradec Kralove, Czech Republic","Koblizek, V (reprint author), Charles Univ Prague, Univ Hosp, Dept Pneumol, Sokolska St 581, Hradec Kralove, Czech Republic.","koblizek@fnhk.cz",null,null,"Grant Agency of the Ministry of Health of Czech Republic [NR8407-4/2005]; Ministry of Education, Youth and Sports, Czech Republic [MSM 0021620820]; GSK; Boehringer Ingelheim; Bayer; Nycomed; Novartis","The authors acknowledge Catherine McGrath PhD for proofreading the manuscript, our nurses Katerina Zohova and Radka Vojackova for assistance and Vera Fabianova for administrative assistance; the Grant Agency of the Ministry of Health of Czech Republic [Grant NR8407-4/2005] and the Ministry of Education, Youth and Sports, Czech Republic [Grant MSM 0021620820] for financial support.VK received lecture fees from GSK ($2000), from Boehringer Ingelheim ($2000), from Bayer ($2000), from Nycomed ($2000), from Novartis ($1000) and declares no conflicts of interest related to this article. MT, EC, SP, PP, RM, JC, FS, LF, JR, VB, FS, MH declare no conflicts of interest to this article. JN received compensation for industry-sponsored study by Quintiles (up to $1000) and lectures fees by GSK (up to $1000). He also declares that there is no conflict of interest relevant to this article. VS received lecture fees from GSK ($1000), Boehringer Ingelheim ($1000) and declares no conflicts of interest relevant to this article.",null,50,9,10,"INT RHINOLOGIC SOC","UTRECHT","UNIV MEDICAL CENTER UTRECHT, RM G05 127, DEPT OTORHINOL, HEIDELBERGLAAN 100, 3584 CX UTRECHT, NETHERLANDS","0300-0729",null,null,"RHINOLOGY","Rhinology","OCT",2011,49,4,null,null,null,null,397,406,null,"10.4193/Rhino11.051",null,10,"Otorhinolaryngology","Otorhinolaryngology","853VP","WOS:000297454100004"]
[null,null,null,null,"J","Vrzalova, Z; Hruba, Z; Hrabincova, ES; Vrabelova, S; Votava, F; Kolouskova, S; Fajkusova, L",null,null,null,"Vrzalova, Zuzana; Hruba, Zuzana; Hrabincova, Eva Stahlova; Vrabelova, Slavka; Votava, Felix; Kolouskova, Stanislava; Fajkusova, Lenka",null,null,"Chimeric CYP21A1P/CYP21A2 genes identified in Czech patients with congenital adrenal hyperplasia","EUROPEAN JOURNAL OF MEDICAL GENETICS",null,null,"English","Article",null,null,null,null,null,"Congenital adrenal hyperplasia; Steroid 21-hydroxylase gene; 21-Hydroxylase deficiency; Chimeric gene","STEROID 21-HYDROXYLASE DEFICIENCY; COMPLEMENT COMPONENT C4A; HUMAN INHERITED DISEASE; CYP21P/CYP21 GENE; RECOMBINATION HOTSPOT; MOLECULAR-BASIS; CYP21; DELETION; CHI; DNA","Congenital adrenal hyperplasia (CAH) comprises a group of autosomal recessive disorders caused by an enzymatic deficiency which impairs the biosynthesis of cortisol and, in the majority of severe cases, also the biosynthesis of aldosterone. Approximately 95% of all CAH cases are caused by mutations in the steroid 21-hydroxylase gene (CYP21A2). The CYP21A2 gene and its inactive pseudogene (CYP21A1P) are located within the HLA class III region of the major histocompatibility complex (MHC) locus on chromosome 6p21.3. In this study, we describe chimeric CYP21A1P/CYP21A2 genes detected in our patients with 21-hydroxylase deficiency (21OHD). Chimeric CYP21A1P/CYP21A2 genes were present in 171 out of 508 mutated CYP21A2 alleles (33.8%). We detected four types of chimeric CYP21A1P/CYP21A2 genes: three of them have been described previously as CH-1, CH-3, CH-4, and one type is novel. The novel chimeric gene, termed CH-7, was detected in 21.4% of the mutant alleles. Possible causes of CYP21A1P/CYP21A2 formation are associated with 1) high recombination rate in the MHC locus, 2) high recombination rate between highly homologous genes and pseudogenes in the CYP21 gene area, and 3) the existence of chi-like sequences and repetitive minisatellite consensus sequences in CYP21A2 and CYP21A1P which play a role in promoting genetic recombination. (C) 2010 Elsevier Masson SAS. All rights reserved.","[Vrzalova, Zuzana; Hruba, Zuzana; Hrabincova, Eva Stahlova; Vrabelova, Slavka; Fajkusova, Lenka] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, CZ-62500 Brno, Czech Republic; [Votava, Felix] Charles Univ Prague, Dept Pediat, Fac Med 3, CZ-10034 Prague, Czech Republic; [Votava, Felix] Univ Hosp Kralovske Vinohrady, CZ-10034 Prague, Czech Republic; [Kolouskova, Stanislava] Charles Univ Prague, Dept Pediat, Fac Med 2, CZ-15006 Prague, Czech Republic; [Kolouskova, Stanislava] Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Fajkusova, Lenka] Masaryk Univ, Fac Sci, Dept Funct Genom & Prote, Inst Expt Biol, CZ-62500 Brno, Czech Republic","Fajkusova, L (reprint author), Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Cernopolni 9, CZ-62500 Brno, Czech Republic.","lenkafajkusova@volny.cz","Fajkusova, Lenka/E-1636-2012",null,"Internal Grant Agency of the Czech Ministry of Health [NR9308-3, NS9981-3]; Czech Ministry of Education [LC06023, MSM0021622415]","This work was supported by the Internal Grant Agency of the Czech Ministry of Health (NR9308-3 and NS9981-3) and by the Czech Ministry of Education (projects LC06023, MSM0021622415).",null,40,9,10,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1769-7212",null,null,"EUR J MED GENET","Eur. J. Med. Genet.","MAR-APR",2011,54,2,null,null,null,null,112,117,null,"10.1016/j.ejmg.2010.10.005",null,6,"Genetics & Heredity","Genetics & Heredity","805QL","WOS:000293744000003"]
[null,null,null,null,"J","Creutzig, U; Zimmermann, M; Bourquin, JP; Dworzak, MN; Fleischhack, G; von Neuhoff, C; Sander, A; Schrauder, A; von Stackelberg, A; Ritter, J; Stary, J; Reinhardt, D",null,null,null,"Creutzig, Ursula; Zimmermann, Martin; Bourquin, Jean-Pierre; Dworzak, Michael N.; Fleischhack, Gudrun; von Neuhoff, Christine; Sander, Annette; Schrauder, Andre; von Stackelberg, Arend; Ritter, Joerg; Stary, Jan; Reinhardt, Dirk",null,null,"CNS Irradiation in Pediatric Acute Myleoid Leukemia: Equal Results by 12 or 18 Gy in Studies AML-BFM98 and 2004","PEDIATRIC BLOOD & CANCER",null,null,"English","Article",null,null,null,null,null,"AML; clinical trials; leukemia; molecular diagnosis and therapy; outcomes research; radiation therapy","ACUTE MYELOID-LEUKEMIA; LYMPHOCYTIC LEUKEMIA; AML TRIALS; CHILDREN; CHILDHOOD; THERAPY; DIAGNOSIS; CHEMOTHERAPY; CYTARABINE; EXPERIENCE","Background. The impact of preventive central nervous system irradiation (CNS-RT) in childhood acute myeloid leukemia (AML) is still discussed. As results of study AML-BFM87 revealed an increased risk for relapse when CNS-RT was not performed, studies AML-BFM98 and -2004 randomized CNS-RT of 18 or 12 Gy in order to evaluate the efficacy of the lower dose and to reduce late effects. Procedures. To achieve a power of 80% for non-inferiority (range 11%) 240 patients per group were required. Out of 722 eligible patients, 486 patients < 18 years were randomized to receive 12 Gy (n = 249) or 18 Gy (n = 237). Since this was a non-inferiority study, the analysis was performed for treated (12 Gy: n = 252 and 18 Gy: n = 219). Results. Five-year survival, event-free survival and cumulative incidence of relapse were similar in patients who received 12 or 18 Gy, respectively (82 +/- 3% vs. 79 +/- 3%, 68 +/- 3% vs. 63 +/- 3%, and 30 +/- 3% vs. 34 +/- 3%). The lower limit of the one-sided confidence interval for the 5% difference in 5-years pEFS was 2%. There were six relapses with CNS involvement (one in the 12 Gy, and five in the 18 Gy group). Conclusion. Results demonstrate no disadvantage for patients irradiated with a reduced CNS dose of 12 Gy. Pediatr Blood Cancer 2011; 57: 986-992. (C) 2011 Wiley-Liss, Inc.","[Creutzig, Ursula; Ritter, Joerg] Univ Hosp Muenster, Munster, Germany; [Zimmermann, Martin; von Neuhoff, Christine; Sander, Annette; Reinhardt, Dirk] Hannover Med Sch, D-3000 Hannover, Germany; [Bourquin, Jean-Pierre] Univ Zurich, Zurich, Switzerland; [Dworzak, Michael N.] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Fleischhack, Gudrun] Univ Childrens Med Hosp, Dept Pediat Hematol Oncol, Bonn, Germany; [Schrauder, Andre] Univ Kiel, Dept Pediat Hematol & Oncol, D-24098 Kiel, Germany; [von Stackelberg, Arend] Charite, Dept Pediat Oncol Hematol, D-13353 Berlin, Germany; [Stary, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic","Creutzig, U (reprint author), Klin & Poliklin Kinderheilkunde, Albert Schweitzer Str 33, D-48129 Munster, Germany.","ursula@creutzig.de","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Deutsche Krebshilfe e.V.; Czech Ministry of Education [MSM0021620813]","Grant sponsor: Deutsche Krebshilfe e.V.; Grant sponsor: Czech Ministry of Education; Grant number: MSM0021620813.",null,23,8,8,"WILEY PERIODICALS, INC","MALDEN","COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA","1545-5009",null,null,"PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","DEC",2011,57,6,null,null,null,null,986,992,null,"10.1002/pbc.22955",null,7,"Oncology; Hematology; Pediatrics","Oncology; Hematology; Pediatrics","825FX","WOS:000295257700016"]
[null,null,null,null,"J","Zitka, O; Krizkova, S; Huska, D; Adam, V; Hubalek, J; Eckschlager, T; Kizek, R",null,null,null,"Zitka, Ondrej; Krizkova, Sona; Huska, Dalibor; Adam, Vojtech; Hubalek, Jaromir; Eckschlager, Tomas; Kizek, Rene",null,null,"Chip gel electrophoresis as a tool for study of matrix metalloproteinase 9 interaction with metallothionein","ELECTROPHORESIS",null,null,"English","Article",null,null,null,null,null,"Chip gel electrophoresis; Interaction; Matrix metalloproteinases; Metallothionein; Voltammetry","MATRIX METALLOPROTEINASES MMPS; COLLAGENOLYTIC ACTIVITY; GELATINASE-B; IN-VIVO; CANCER; INHIBITORS; ASSAYS; CELLS","Matrix metalloproteinases (MMPs) play numerous roles in physiological and pathological processes including cancer. Interactions of MMPs with other zinc-binding proteins are of great interest mainly from the point of view of the participation of these proteins in carcinogenesis. The aim of this study was to utilize chip gel electrophoresis for investigation of matrix metalloproteinase 9 (gelatinase B, MMP-9) interactions with collagen. The interaction was observed and the effect of temperature was tested. We further focused on the study of activation of MMP-9 by the presence of zinc-binding proteins called metallothioneins (MT). We confirmed the basic presumption of the activation of MMP-9 by the presence of MT similar to the temperature effect. Moreover, we chose the method of differential pulse voltammetry Brdicka reaction to verify our results. It can be concluded that the activity of MMP-9 was higher in the presence of MT in comparison with the experimental collagen(type I)-MMP-9 mixture in vitro.","[Zitka, Ondrej; Krizkova, Sona; Huska, Dalibor; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Hubalek, Jaromir] Brno Univ Technol, Dept Microelect, Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Prague, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Zitka, Ondrej/E-1107-2012; Krizkova, Sona/E-9617-2012",null," [KAN208130801];  [LPR 2011];  [GAAV IAA401990701]","The financial support from the grants KAN208130801, LPR 2011 and GAAV IAA401990701 is highly acknowledged.",null,22,8,8,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0173-0835",null,null,"ELECTROPHORESIS","Electrophoresis","APR",2011,32,8,null,null,null,null,857,860,null,"10.1002/elps.201000526",null,4,"Biochemical Research Methods; Chemistry, Analytical","Biochemistry & Molecular Biology; Chemistry","747WW","WOS:000289352900009"]
[null,null,null,null,"J","Novak, J; Kafkova, LR; Suzuki, H; Tomana, M; Matousovic, K; Brown, R; Hall, S; Sanders, JT; Eison, TM; Moldoveanu, Z; Novak, L; Novak, Z; Mayne, R; Julian, BA; Mestecky, J; Wyatt, RJ",null,null,null,"Novak, Jan; Kafkova, Leona Raskova; Suzuki, Hitoshi; Tomana, Milan; Matousovic, Karel; Brown, Rhubell; Hall, Stacy; Sanders, John T.; Eison, T. Matthew; Moldoveanu, Zina; Novak, Lea; Novak, Zdenek; Mayne, Richard; Julian, Bruce A.; Mestecky, Jiri; Wyatt, Robert J.",null,null,"IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells","NEPHROLOGY DIALYSIS TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"autoimmunity; circulating immune complexes; glycosylation; immunoglobulin; O-linked glycans","IMMUNOGLOBULIN-A NEPHROPATHY; ABERRANTLY GLYCOSYLATED IGA1; GLOMERULAR-FILTRATION-RATE; HENOCH-SCHONLEIN PURPURA; GALACTOSE-DEFICIENT IGA1; HINGE REGION; O-GLYCOSYLATION; NEPHRITIS; DEPOSITION; PROLIFERATION","Background. Circulating immune complexes (CIC) containing galactose (Gal)-deficient IgA1 from adults with IgA nephropathy (IgAN) induce proliferation of cultured mesangial cells, but activities of CIC from pediatric patients with the disease have not been studied. Methods. CIC of different sizes were isolated from sera of pediatric and adult IgAN patients and their effects on cultured human mesangial cells (MC) were assessed by measuring cellular proliferation, expression of IL-6 and IL-8 and laminin and phosphotyrosine signaling. Results. Large CIC from pediatric IgAN patients (>800 kDa) containing Gal-deficient IgA1 stimulated cellular proliferation, whereas in some patients, smaller CIC were inhibitory. Addition of stimulatory and inhibitory CIC to MC differentially altered phosphorylation patterns of three major tyrosine-phosphorylated proteins of molecular mass 37, 60 and 115 kDa. The stimulatory CIC transiently increased tyrosine-phosphorylation of the 37-kDa protein and decreased phosphorylation of the other two proteins, whereas the inhibitory CIC increased phosphorylation of all three proteins. Furthermore, we investigated the influence of IgA1-containing CIC from sera of children with IgAN with clinically active disease (i.e., abnormal urinalysis and/or serum creatinine concentration) or inactive disease (i.e., normal urinalysis and serum creatinine concentration) on the expression of IL-6 and IL-8 genes by mesangial cells. Real-time reverse transcription-polymerase chain reaction results showed that the CIC from a patient with active disease stimulated MC to express the two cytokine genes at higher levels than did the CIC from a patient with inactive disease. Moreover, stimulatory CIC increased production of the extracellular matrix protein laminin. Conclusion. These data indicate that sera of pediatric IgAN patients contain biologically active CIC with Gal-deficient IgA1.","[Novak, Jan; Kafkova, Leona Raskova; Suzuki, Hitoshi; Matousovic, Karel; Brown, Rhubell; Hall, Stacy; Moldoveanu, Zina; Julian, Bruce A.; Mestecky, Jiri] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; [Suzuki, Hitoshi] Juntendo Univ, Fac Med, Tokyo, Japan; [Tomana, Milan; Julian, Bruce A.; Mestecky, Jiri] Univ Alabama, Dept Med, Birmingham, AL 35294 USA; [Sanders, John T.; Eison, T. Matthew; Wyatt, Robert J.] Univ Tennessee, Hlth Sci Ctr, Le Bonheur Childrens Hosp, Childrens Fdn Res Ctr,Dept Pediat, Memphis, TN USA; [Novak, Lea] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; [Novak, Zdenek] Childrens Hosp Alabama, Birmingham, AL USA; [Mayne, Richard] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; [Mestecky, Jiri] Charles Univ Prague, Fac Med 1, Inst Microbiol & Immunol, Prague, Czech Republic","Novak, J (reprint author), Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA.","jannovak@uab.edu",null,null,"National Institutes of Health [DK078244, DK082753, DK080301, DK061525, DK083663, DK071802]; General Clinical Research Centers of the University of Alabama at Birmingham [M01 RR00032]; University of Tennessee Health Sciences Center [M01 RR00211]; Ministry of Health of the Czech Republic [MSM 6198959216, MSM 0021620819, MSM 0021620812]","This work was supported by grants DK078244, DK082753, DK080301, DK061525, DK083663 and DK071802 from the National Institutes of Health, by General Clinical Research Centers of the University of Alabama at Birmingham (M01 RR00032) and the University of Tennessee Health Sciences Center (M01 RR00211), Research Projects of the Ministry of Health of the Czech Republic No. MSM 6198959216, MSM 0021620819 and MSM 0021620812 and a generous gift from Anna and Donald Waite. The authors express their appreciation to Catherine V. Barker and Sue Y. Woodford (University of Alabama at Birmingham) and Dr Kimberly Fisher and Sandra Grimes (University of Tennessee) for help with collecting clinical samples, Rose Kulhavy (University of Alabama at Birmingham) for providing IgA1 myeloma proteins and Candace Kirksey and Claretha Nichols for the processing of serum samples.",null,40,7,7,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0931-0509",null,null,"NEPHROL DIAL TRANSPL","Nephrol. Dial. Transplant.","NOV",2011,26,11,null,null,null,null,3451,3457,null,"10.1093/ndt/gfr448",null,8,"Transplantation; Urology & Nephrology","Transplantation; Urology & Nephrology","839FH","WOS:000296350400007"]
[null,null,null,null,"J","Rossnerova, A; Spatova, M; Pastorkova, A; Tabashidze, N; Veleminsky, M; Balascak, I; Solansky, I; Sram, RJ",null,null,null,"Rossnerova, Andrea; Spatova, Milada; Pastorkova, Anna; Tabashidze, Nana; Veleminsky, Milos, Jr.; Balascak, Ivan; Solansky, Ivo; Sram, Radim J.",null,null,"Micronuclei levels in mothers and their newborns from regions with different types of air pollution","MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS",null,null,"English","Article",null,null,null,null,null,"Automated image analysis; Benzo[a]pyrene; Micronuclei; Mothers; Newborns","POLYCYCLIC AROMATIC-HYDROCARBONS; ENVIRONMENTAL-POLLUTANTS; CHROMOSOMAL-ABERRATIONS; LYMPHOCYTE MICRONUCLEI; CORD BLOOD; IMAGE-ANALYSIS; TOBACCO-SMOKE; DNA-DAMAGE; VITAMIN-E; EXPOSURE","The aim of this study was to analyze genetic damage in human lymphocytes measured using automated image analysis of micronuclei (MN) in a group of 178 mothers and their newborns from two locations in the Czech Republic. The concentrations of benzo[a]pyrene (B[a]B), particulate matter of aerodynamic diameter <2.5 mu m (PM2.5) and benzene were measured by stationary monitoring in the winter season of 2008/2009 in the capital city of Prague and in Ceske Budejovice, a regional city in a rural area. The 3-month mean concentration of B[a]P before delivery was lower in Prague in comparison with Ceske Budejovice: 1.9 +/- 0.5 ng/m(3) vs. 3.2 +/- 0.2 ng/m(3) (p < 0.001). The opposite trend was found for PM2.5 and benzene: 27.0 +/- 2.5 mu g/m(3) and 2.5 +/- 0.5 mu g/m(3) vs. 24.5 +/- 0.7 mu g/m(3) and 2.1 +/- 0.8 mu g/m(3) (p < 0.001) for Prague vs. Ceske Budejovice, respectively. The average age of the mothers was 31 years (range, 18-49 years). The frequencies of MN per 1000 binucleated cells were 8.35 +/- 3.06 vs. 6.47 +/- 2.35 (p < 0.001) for mothers from Prague and Ceske Budejovice, respectively, and 2.17 +/- 1.32 vs. 3.82 +/- 2.43 (p < 0.001) for newborns from Prague and Ceske Budejovice, respectively. Other factors, including vitamin intake, exposure to tobacco smoke, body mass index (BMI) before pregnancy, the education level of the mothers and the impact of the mothers' and fathers' ages were analyzed in our study. The results suggest that the different sensitivity of the study groups to various mixtures of carcinogenic pollutants could be affected by significant differences in lifestyle factors. Possible higher genetic damage was analyzed in newborns of smoking mothers, and the birth weight of this group was 7.4% lower (p < 0.05) in comparison with the newborns of nonsmoking mothers. No impact of the age of the mothers or fathers on MN frequency in the newborns was observed. (C) 2011 Elsevier B.V. All rights reserved.","[Rossnerova, Andrea; Spatova, Milada; Pastorkova, Anna; Tabashidze, Nana; Solansky, Ivo; Sram, Radim J.] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Veleminsky, Milos, Jr.] Hosp Ceske Budejovice, Ceske Budejovice 37087, Czech Republic; [Balascak, Ivan] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic","Sram, RJ (reprint author), Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic.","sram@biomed.cas.cz",null,null,"Ministry of Education of the Czech Republic [2B06088]","We would like to thank the pediatric and gynecological staff of the University Hospital in Prague-Motol and of the Hospital Ceske Budejovice, a.s. for the collection of samples, Ms. Milada Kostirova for the analysis of vitamins and Mr. James Dutt for language editing. The Ministry of Education of the Czech Republic (grant # 2B06088) is gratefully acknowledged for financial support.",null,43,7,7,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0027-5107",null,null,"MUTAT RES-FUND MOL M","Mutat. Res.-Fundam. Mol. Mech. Mutagen.","OCT 1",2011,715,41671,null,null,null,null,72,78,null,"10.1016/j.mrfmmm.2011.07.011",null,7,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","830NR","WOS:000295664200010"]
[null,null,null,null,"J","Stiborova, M; Mares, J; Levova, K; Pavlickova, J; Barta, F; Hodek, P; Frei, E; Schmeiser, HH",null,null,null,"Stiborova, Marie; Mares, Jaroslav; Levova, Katerina; Pavlickova, Jana; Barta, Frantisek; Hodek, Petr; Frei, Eva; Schmeiser, Heinz H.",null,null,"Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"aristolochic acid; cytochrome P450; metabolism; DNA adducts; P-32-postlabeling","BALKAN ENDEMIC NEPHROPATHY; CHINESE HERBS NEPHROPATHY; PROSTAGLANDIN-H SYNTHASE; DNA-ADDUCTS; REDUCTIVE ACTIVATION; UROTHELIAL CANCER; PROTECTS MICE; RENAL INJURY; RISK-FACTOR; SUDAN-I","OBJECTIVE: The herbal drug aristolochic acid (AA) derived from Aristolochia species has been shown to be the cause of aristolochic acid nephropathy (AAN) Balkan endemic nephropathy (BEN) and their urothelial malignancies. One of the common features of AAN and BEN is that not all individuals exposed to AA suffer from nephropathy and tumor development. One cause for these different responses may be individual differences in the activities of the emzymes catalyzing the biotransformation of AA. Thus, the identification of enzymes principally involved in the metabolism of AAI, the major toxic component of AA, and detailed knowledge of their catalytic specificities is of major importance. Therefore, the present study has been designed to evaluate the cytochrome P450 (CYP)-mediated oxidative detoxification and reductive activation of AAI in a rat model. METHODS: DNA adduct formation was investigated by the nuclease PI version of the P-32-postlabeling method. The GYP-mediated formation of a detoxication metabolite of AAI, 8-hydroxyaristolochic acid I (AAIa), in vitro in rat hepatic microsomes was determined by HPLC. RESULTS: Rat hepatic CYPs both detoxicate AAI by its oxidation to AAIa and reductively activate this carcinogen to a cyclic N-acylnitrenium ion feu ming AAI-DNA adducts in vitro. To define the role of hepatic CYPs in AAI demethylation and activation, the modulation of AAIa and AAI-DNA adduct formation by GYP inducers and selective CYP inhibitors was investigated. Based on these studies, we attribute the major role of CYP1A1 and 1A2 in AAI detoxicatim by its demethylation to AAIa, and, under hypoxic conditions also to AAI activation to species forming DNA adducts. Using microsomes of Baculovirus transfected insect cells (Supersomes (TM)) containing recombinantly expressed rat CYPs, NADPH:CYP reductase and/or cytochrome b(5), a major role of CYP1A1 and 1A2 in both reactions in vitro was confirmed. CONCLUSION: Based on the results found in this and former studies we propose that AAI activation and detoxication in rats are dictated mainly by AAI binding affinity to CYP1A1/2 or NADPH(P)H:quinone oxidoreductase, by their turnover and by the balance between oxidation and reduction of AAI by CYP1A.","[Stiborova, Marie; Levova, Katerina; Pavlickova, Jana; Barta, Frantisek; Hodek, Petr] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12840 2, Czech Republic; [Mares, Jaroslav] Charles Univ Prague, Sch Med 2, Inst Biol & Med Genet, Prague 12840 2, Czech Republic; [Mares, Jaroslav] Univ Hosp Motol, Prague, Czech Republic; [Frei, Eva] German Canc Res Ctr, Natl Ctr Tumour Dis, Div Prevent Oncol, D-6900 Heidelberg, Germany; [Schmeiser, Heinz H.] German Canc Res Ctr, Res Grp Genet Alterat Carcinogenesis, D-6900 Heidelberg, Germany","Stiborova, M (reprint author), Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, Prague 12840 2, Czech Republic.","stiborov@natur.cuni.cz","Hodek, Petr/G-1561-2010",null,"Grant Agency of Czech Republic [301/09/0472]; Ministry of Education of Czech Republic [MSM0021620808, 1M0505]","The authors would like to thank to Grant Agency of Czech Republic (grant 301/09/0472) and to the Ministry of Education of Czech Republic (grants MSM0021620808 and 1M0505).",null,51,6,6,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2011,32,null,null,1,null,null,121,130,null,null,null,10,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","896CX","WOS:000300544100016"]
[null,null,null,null,"J","Kubinova, S; Horak, D; Hejcl, A; Plichta, Z; Kotek, J; Sykova, E",null,null,null,"Kubinova, Sarka; Horak, Daniel; Hejcl, Ales; Plichta, Zdenek; Kotek, Jiri; Sykova, Eva",null,null,"Highly superporous cholesterol-modified poly(2-hydroxyethyl methacrylate) scaffolds for spinal cord injury repair","JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A",null,null,"English","Article",null,null,null,null,null,"2-hydroxyethyl methacrylate; scaffold; hydrogel; cholesterol; spinal cord repair; stem cells","NEGATIVE SURFACE-CHARGES; POLYELECTROLYTE COMPLEXES; AXONAL REGENERATION; CELL-ADHESION; STROMAL CELLS; STEM-CELLS; HYDROGELS; DELIVERY; BIOCOMPATIBILITY; STRATEGIES","Modifications of poly(2-hydroxyethyl methacrylate) (PHEMA) with cholesterol and the introduction of large pores have been developed to create highly superporous hydrogels that promote cell-surface interactions and that can serve as a permissive scaffold for spinal cord injury (SCI) treatment. Highly superporous cholesterol-modified PHEMA scaffolds have been prepared by the bulk radical copolymerization of 2-hydroxyethyl methacrylate (HEMA), cholesterol methacrylate (CHLMA), and ethylene dimethacrylate (EDMA) cross-linking agent in the presence of ammonium oxalate crystals to establish interconnected pores in the scaffold. Moreover, 2-[(methoxycarbonyl)methoxy]ethyl methacrylate (MCMEMA) was incorporated in the polymerization recipe and hydrolyzed, thus introducing carboxyl groups in the hydrogel to control its swelling and softness. The hydrogels supported the in vitro adhesion and proliferation of rat mesenchymal stem cells. In an in vivo study of acute rat SCI, hydrogels were implanted to bridge a hemisection cavity. Histological evaluation was done 4 weeks after implantation and revealed the good incorporation of the implanted hydrogels into the surrounding tissue, the progressive infiltration of connective tissue and the ingrowth of neurofilaments, Schwann cells, and blood vessels into the hydrogel pores. The results show that highly superporous cholesterol-modified PHEMA hydrogels have bioadhesive properties and are able to bridge a spinal cord lesion. (C) 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 99A: 618-629, 2011.","[Kubinova, Sarka; Hejcl, Ales; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Horak, Daniel; Plichta, Zdenek; Kotek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Horak, Daniel; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Hejcl, Ales] Masaryk Hosp, Dept Neurosurg, Usti Nad Labem 40011, Czech Republic; [Sykova, Eva] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague 15006 5, Czech Republic","Kubinova, S (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","sarka.k@biomed.cas.cz",null,null,"Czech Science Foundation [P304/11/0731, P304/11/P633, 108/10/1560, P304/11/0653]; Academy of Sciences of the Czech Republic [KAN200520804, IAA500390902]; Ministry of Education, Youth and Sports of the Czech republic [1M0538]","Contract grant sponsor: Czech Science Foundation; contract grant numbers: P304/11/0731, P304/11/P633, 108/10/1560, P304/11/0653Contract grant sponsor: Academy of Sciences of the Czech Republic; contract grant numbers: KAN200520804, IAA500390902Contract grant sponsor: Ministry of Education, Youth and Sports of the Czech republic; contract grant number: 1M0538",null,47,5,5,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1549-3296",null,null,"J BIOMED MATER RES A","J. Biomed. Mater. Res. Part A","DEC",2011,"99A",4,null,null,null,null,618,629,null,"10.1002/jbm.a.33221",null,12,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","848AR","WOS:000297019200012"]
[null,null,null,null,"J","Cerezo, LA; Kuncova, K; Mann, H; Tomcik, M; Zamecnik, J; Lukanidin, E; Neidhart, M; Gay, S; Grigorian, M; Vencovsky, J; Senolt, L",null,null,null,"Cerezo, Lucie Andres; Kuncova, Klara; Mann, Herman; Tomcik, Michal; Zamecnik, Josef; Lukanidin, Eugene; Neidhart, Michel; Gay, Steffen; Grigorian, Mariam; Vencovsky, Jiri; Senolt, Ladislav",null,null,"The metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathies","RHEUMATOLOGY",null,null,"English","Article",null,null,null,null,null,"S100A4; Polymyositis; Dermatomyositis; Peripheral blood mononuclear cells; Myocytes; Inflammation","HUMAN ARTICULAR CHONDROCYTES; RHEUMATOID-ARTHRITIS; MUSCLE-TISSUE; CLASS-I; POLYMYOSITIS; DERMATOMYOSITIS; EXPRESSION; CELLS; IMMUNOLOCALIZATION; RECEPTORS","Objectives. The S100A4 protein is known as a metastasis promoting factor; however, its involvement in non-malignant diseases such as RA and psoriasis has been recently described. The aim of this study was to investigate the expression and possible role of S100A4 in idiopathic inflammatory myopathies. Methods. S100A4 protein expression was detected by immunohistochemistry in muscle tissue from control individuals (n = 11) and patients with PM and DM (n = 8/6). IF staining was used to co-localize S100A4 with selected cells. Cytokine expression and protein synthesis in S100A4-treated cells were analysed by RT-PCR and ELISA. Results. S100A4 protein was significantly up-regulated in muscle tissue of patients with inflammatory myopathies compared with control individuals and was associated particularly with the presence of mononuclear infiltrates. Only few regenerating muscle fibres in PM/DM expressed S100A4. Then we analysed the effect of S100A4 on human myocytes and peripheral blood mononuclear cells (PBMCs). Although S100A4 did not affect myocytes, stimulation of PBMCs with S100A4 significantly induced the expression and synthesis of TNF-alpha, IL-1 beta and IL-6, but not of IFN-alpha. We showed that S100A4 is not directly involved in perforin/granzyme B-induced apoptosis and that it does not modulate the expression of Bax and Bcl2 mRNA in myocytes and PBMCs. Conclusion. Increased expression of S100A4 in inflamed muscle tissue highlights its potential role in the pathogenesis of inflammatory myopathies. S100A4 may act as a cytokine-like factor indirectly promoting muscle fibre damage by stimulating mononuclear cells to increase the synthesis of pro-inflammatory cytokines.","[Cerezo, Lucie Andres; Mann, Herman; Tomcik, Michal; Vencovsky, Jiri; Senolt, Ladislav] Charles Univ Prague, Fac Med 1, Dept Expt & Clin Rheumatol, Prague 12850 2, Czech Republic; [Kuncova, Klara; Zamecnik, Josef] Charles Univ Prague, Dept Pathol & Mol Med, Sch Med 2, Prague 12850 2, Czech Republic; [Kuncova, Klara; Zamecnik, Josef] Charles Univ Prague, Univ Hosp Motol, Prague 12850 2, Czech Republic; [Lukanidin, Eugene; Grigorian, Mariam] Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; [Neidhart, Michel; Gay, Steffen] Univ Zurich Hosp, Ctr Expt Rheumatol, Zurich, Switzerland; [Neidhart, Michel; Gay, Steffen] Zurich Ctr Integrat Human Physiol, Zurich, Switzerland","Senolt, L (reprint author), Charles Univ Prague, Fac Med 1, Dept Rheumatol, Inst Rheumatol, Na Slupi 4, Prague 12850 2, Czech Republic.","seno@revma.cz",null,null,"Ministry of Health of the Czech Republic [00023728]","The study was supported by Ministry of Health of the Czech Republic Research Project No. 00023728.",null,27,4,4,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1462-0324",null,null,"RHEUMATOLOGY","RHEUMATOLOGY","OCT",2011,50,10,null,null,null,null,1766,1772,null,"10.1093/rheumatology/ker218",null,7,"Rheumatology","Rheumatology","824AZ","WOS:000295172600007"]
[null,null,null,null,"J","Rockova, S; Nevoral, J; Rada, V; Marsik, P; Sklenar, J; Hinkova, A; Vlkova, E; Marounek, M",null,null,null,"Rockova, Sarka; Nevoral, Jiri; Rada, Vojtech; Marsik, Petr; Sklenar, Jan; Hinkova, Andrea; Vlkova, Eva; Marounek, Milan",null,null,"Factors affecting the growth of bifidobacteria in human milk","INTERNATIONAL DAIRY JOURNAL",null,null,"English","Article",null,null,null,null,null,null,"OLIGOSACCHARIDES; INFANTS; PREBIOTICS; PROTEINS","Five strains of bifidobacteria of human origin and 2 strains of bifidobacteria of animal origin were tested for growth in 10 samples of human milk. Growth of Bifidobacterium bifidum in human milk was accompanied by a decrease in pH and production of acids. The number of viable cells of Bifidobacterium animalis was decreased from 6 log cfu mL(-1) to 3 log cfu mL(-1) after incubation in human milk. There were significant differences (P < 0.05) between bacterial counts of B. bifidum and B. animalis in milk samples tested. Resistance to lysozyme and the ability to utilise human milk oligosaccharides (HMOs) were identified as the most important factors affecting the growth of bifidobacteria in human milk. Four out of 5 strains of human origin were resistant to lysozyme and utilised HMOs. In contrast, B. animalis was susceptible to lysozyme and did not utilise HMOs. (C) 2011 Elsevier Ltd. All rights reserved.","[Rockova, Sarka; Rada, Vojtech; Vlkova, Eva] Czech Univ Life Sci, Dept Microbiol Nutr & Dietet, Fac Agrobiol Food & Nat Resources, Prague 16521 6, Czech Republic; [Nevoral, Jiri] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague 15006 5, Czech Republic; [Marsik, Petr] Acad Sci CR, Joint Lab Inst Expt Bot, Vvi, Plant Biotechnol Lab, Prague 16502 6, Czech Republic; [Marsik, Petr] Res Inst Crop Prod, Vvi, Prague 16502 6, Czech Republic; [Sklenar, Jan] Acad Sci CR, Inst Microbiol, Dept Immunol, Prague 14220, Czech Republic; [Hinkova, Andrea] Prague Inst Chem Technol, Dept Carbohydrate Chem & Technol, CR-16628 Prague 6, Czech Republic; [Marounek, Milan] Acad Sci CR, Inst Anim Physiol & Genet, Vvi, Prague 14220, Czech Republic","Rada, V (reprint author), Czech Univ Life Sci, Dept Microbiol Nutr & Dietet, Fac Agrobiol Food & Nat Resources, Kamycka 129, Prague 16521 6, Czech Republic.","rada@af.czu.cz",null,null,"Ministry of Education, Youth and Sports of Czech Republic [6046070901]; Czech Science Foundation [523/07/0572, 525/08/H060]","This study was supported by grant MSM No. 6046070901 of Ministry of Education, Youth and Sports of Czech Republic and by grants 523/07/0572, and 525/08/H060 of the Czech Science Foundation. We thank Dr. Ingrid Kocourkova from the Institute for the Care of Mother and Child (Prague, Czech Republic) for supplying us with human milk samples.",null,25,4,4,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0958-6946",null,null,"INT DAIRY J","Int. Dairy J.","JUL",2011,21,7,null,null,null,null,504,508,null,"10.1016/j.idairyj.2011.02.005",null,5,"Food Science & Technology","Food Science & Technology","758YR","WOS:000290205100008"]
[null,null,null,null,"J","Ivady, G; Madar, L; Nagy, B; Gonczic, F; Ajzner, E; Dzsudzsak, E; Dvorakova, L; Gombos, E; Kappelmayer, J; Macek, M; Balogh, I",null,null,null,"Ivady, Gergely; Madar, Laszlo; Nagy, Bela; Gonczic, Ferenc; Ajzner, Eva; Dzsudzsak, Erika; Dvorakova, Lenka; Gombos, Eva; Kappelmayer, Janos; Macek, Milan, Jr.; Balogh, Istvan",null,null,"Distribution of CFTR mutations in Eastern Hungarians: Relevance to genetic testing and to the introduction of newborn screening for cystic fibrosis","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Article",null,null,null,null,null,"Cystic fibrosis; Hungary; Eastern Hungarians; 2184insA; CFTRdele2,3(21 kb); DNA diagnostics; Newborn screening","IDENTIFICATION; POPULATIONS; DIAGNOSIS; CONSENSUS; SEQUENCE; EUROPE","Background: The aim of this study was characterization of an updated distribution of CFTR mutations in a representative cohort of 40 CF patients with the classical form of the disease drawn from Eastern Hungary. Due to the homogeneity of the Hungarian population our data are generally applicable to other regions of the country, including the sizeable diaspora. Methods: We utilized the recommended \"cascade\" CFTR mutation screening approach, initially using a commercial assay, followed by examination of the common \"Slavic\" deletion CFTRdele2,3(21 kb). Subsequently, the entire CFTR coding region of the CFTR gene was sequenced in patients with yet unidentified mutations. Results: The Elucigene CF29 (TM) v2 assay detected 81.25% of all CF causing mutations. An addition of the CFTRdele2,3(21 kb) increased the mutation detection rate to 86.25%. DNA sequencing enabled us to identify mutations on 79/80 CF alleles. Mutations [CFTRdele2,3(21 kb), p.Gln685ThrfsX4 (2184insA) were found at an unusually high frequency, each comprising 5.00% of all CF alleles. Conclusion: We have identified common CF causing mutations in the Hungarian population with the most common mutations (p.Phe508del, p.Asn1303Lys, CFTRdele2,3(21 kb), 2184insA, p.Gly542X, and p.Leu101X), comprising over 93.75% of all CF alleles. Obtained data are applicable to the improvement of DNA diagnostics in Hungary and beyond, and are the necessary prerequisite for the introduction of a nationwide \"two tier\" CF newborn screening program. (C) 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Balogh, Istvan] Univ Debrecen, Med & Hlth Sci Ctr, Dept Clin Biochem & Mol Pathol, H-4032 Debrecen, Hungary; [Nagy, Bela] Univ Debrecen, Dept Pediat, H-4032 Debrecen, Hungary; [Gonczic, Ferenc] Kenezy Gyula Cty Hosp, Debrecen, Hungary; [Ajzner, Eva] Josa Andras Cty Hosp, Nyiregyhaza, Hungary; [Dvorakova, Lenka; Macek, Milan, Jr.] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Dvorakova, Lenka; Macek, Milan, Jr.] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic","Balogh, I (reprint author), Univ Debrecen, Med & Hlth Sci Ctr, Dept Clin Biochem & Mol Pathol, Nagyerdei Krt 98, H-4032 Debrecen, Hungary.","balogh@med.unideb.hu","Balogh, Istvan/A-4752-2013",null,"Czech Ministry of Health [MZOFNM2005, IGA NS9986-3]; TAMOP [4.2.1./B-091/1/KONV-2010-0007]","This work was supported by a MZOFNM2005, IGA NS9986-3 from the Czech Ministry of Health to MM Jr., by the TAMOP 4.2.1./B-091/1/KONV-2010-0007 project to IB.",null,22,4,4,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","MAY",2011,10,3,null,null,null,null,217,220,null,"10.1016/j.jcf.2010.12.009",null,4,"Respiratory System","Respiratory System","781TO","WOS:000291959600012"]
[null,null,null,null,"J","Tapia, G; Cinek, O; Rasmussen, T; Grinde, B; Stene, LC; Ronningen, KS",null,null,null,"Tapia, German; Cinek, Ondrej; Rasmussen, Trond; Grinde, Bjorn; Stene, Lars C.; Ronningen, Kjersti S.",null,null,"Longitudinal study of parechovirus infection in infancy and risk of repeated positivity for multiple islet autoantibodies: the MIDIA study","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"diabetes mellitus; type 1; epidemiology; human parechovirus; nested case; control study; polymerase chain reaction","STOOL SAMPLES; NORWEGIAN INFANTS; IDENTIFICATION; CHILDREN; ENTEROVIRUS; ASSOCIATION","The objective of this study was to investigate a possible association between human parechovirus infections in early infancy, diagnosed in fecal samples, and the development of islet autoimmunity. In the 'Environmental Triggers of Type 1 Diabetes: The MIDIA study', newborns with the highest genetic risk for type 1 diabetes were identified and followed with regular fecal sampling and questionnaires. A nested case-control study, including 27 children who developed islet autoimmunity (repeatedly positive for two or three autoantibodies) and 53 children matched for age and community of residence was used. Monthly stool samples from these children were analyzed for human parechovirus using a semi-quantitative real-time polymerase chain reaction. There was no significant difference in the prevalence of human parechovirus in stool samples when cases and controls were compared: 13.0 and 11.1%, respectively. There was also not any difference as to the number of infection episodes. In analyses restricted to samples collected 3, 6 or 12 months prior to seroconversion for islet autoantibodies, there was a suggestive association in the shortest time window of 3 months (20.8 vs. 8.8%, odds ratio = 3.2, 95% CI 1.2 - 8.5, uncorrected p = 0.022). No symptoms were associated with human parechovirus infection. A subset of the positive samples (n = 31) were sequenced, suggesting that human parechovirus 1 was the dominant genotype. The present study does not support strong associations between human parechovirus infections and the signs of islet autoimmunity. The weak association of parechovirus present in the last 3 months before development of autoimmunity warrants further investigation.","[Tapia, German; Ronningen, Kjersti S.] Norwegian Inst Publ Hlth, Dept Genes & Environm, N-0403 Oslo, Norway; [Tapia, German; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, CR-11636 Prague 1, Czech Republic; [Rasmussen, Trond] Norwegian Inst Publ Hlth, Dept Informat Syst, N-0403 Oslo, Norway; [Grinde, Bjorn] Norwegian Inst Publ Hlth, Dept Virol, N-0403 Oslo, Norway; [Stene, Lars C.] Norwegian Inst Publ Hlth, Dept Chron Dis, N-0403 Oslo, Norway","Tapia, G (reprint author), Norwegian Inst Publ Hlth, Dept Genes & Environm, Postboks 4404 Nydalen, N-0403 Oslo, Norway.","german.tapia@fhi.com",null,null,"The Norwegian Organization for Health and Rehabilitation [2005/2/0128]; EEA/Norway, Prague, The Czech Republic [A/CZ0046/1/0014]; The Ministry of Education of the Czech Republic [MSM0021620814]; The Czech ministry of Health [NT 11465-5]; The Research Council of Norway [135893/330, 155300/320, 156477/730, 166515/V50]; The Norwegian Diabetes Association; Children with Diabetes Foundation (Denver, CO, USA); NewGeneris [Food-CT-2005-016320]","This study and the MIDIA project were funded by The Norwegian Organization for Health and Rehabilitation (grant 2005/2/0128), the EEA/Norway (grant A/CZ0046/1/0014 through the Research Support Fund, Prague, The Czech Republic), The Ministry of Education of the Czech Republic (grant MSM0021620814), The Czech ministry of Health (grant NT 11465-5), The Research Council of Norway (grants 135893/330, 155300/320, 156477/730, 166515/V50), The Norwegian Diabetes Association, and Children with Diabetes Foundation (Denver, CO, USA), NewGeneris (grants Food-CT-2005-016320). We thank the public health care nurses for their effort in the recruitment to the MIDIA study and to the follow-up of high-risk children, the staff at the Biobank, Norwegian Institute of Public Health for DNA extraction and genotyping. In particular, we would like to express our gratitude to all the parents for their efforts in handling their child's type 1 diabetes risk, for providing delivered blood and fecal samples from their children and completing the questionnaires.",null,16,4,4,"WILEY-BLACKWELL PUBLISHING, INC","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","FEB",2011,12,1,null,null,null,null,58,62,null,"10.1111/j.1399-5448.2010.00658.x",null,5,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","711UT","WOS:000286617600010"]
[null,null,null,null,"J","Petrak, J; Pospisilova, J; Sedinova, M; Jedelsky, P; Lorkova, L; Vit, O; Kolar, M; Strnad, H; Benes, J; Sedmera, D; Cervenka, L; Melenovsky, V",null,null,null,"Petrak, Jiri; Pospisilova, Jana; Sedinova, Miroslava; Jedelsky, Petr; Lorkova, Lucie; Vit, Ondrej; Kolar, Michal; Strnad, Hynek; Benes, Jan; Sedmera, David; Cervenka, Ludek; Melenovsky, Vojtech",null,null,"Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aortocaval fistula model provides support for new potential therapeutic targets - monoamine oxidase A and transglutaminase 2","PROTEOME SCIENCE",null,null,"English","Article",null,null,null,null,null,"Heart failure; hypertrophy; annexins; monoamine oxidase; transglutaminase","OXIDATIVE STRESS; TISSUE TRANSGLUTAMINASE; SYSTOLIC DYSFUNCTION; FAILING HEART; METABOLISM; EXPRESSION; DISEASE; MITOCHONDRIAL; HYPERTROPHY; ADIPONECTIN","Background: Chronic hemodynamic overloading leads to heart failure (HF) due to incompletely understood mechanisms. To gain deeper insight into the molecular pathophysiology of volume overload-induced HF and to identify potential markers and targets for novel therapies, we performed proteomic and mRNA expression analysis comparing myocardium from Wistar rats with HF induced by a chronic aorto-caval fistula (ACF) and sham-operated rats harvested at the advanced, decompensated stage of HF. Methods: We analyzed control and failing myocardium employing iTRAQ labeling, two-dimensional peptide separation combining peptide IEF and nano-HPLC with MALDI-MS/MS. For the transcriptomic analysis we employed Illumina RatRef-12v1 Expression BeadChip. Results: In the proteomic analysis we identified 2030 myocardial proteins, of which 66 proteins were differentially expressed. The mRNA expression analysis identified 851 differentially expressed mRNAs. Conclusions: The differentially expressed proteins confirm a switch in the substrate preference from fatty acids to other sources in the failing heart. Failing hearts showed downregulation of the major calcium transporters SERCA2 and ryanodine receptor 2 and altered expression of creatine kinases. Decreased expression of two NADPH producing proteins suggests a decreased redox reserve. Overexpression of annexins supports their possible potential as HF biomarkers. Most importantly, among the most up-regulated proteins in ACF hearts were monoamine oxidase A and transglutaminase 2 that are both potential attractive targets of low molecular weight inhibitors in future HF therapy.","[Petrak, Jiri; Pospisilova, Jana; Lorkova, Lucie; Vit, Ondrej] Charles Univ Prague, Inst Pathol Physiol, Fac Med 1, Prague, Czech Republic; [Sedinova, Miroslava; Jedelsky, Petr] Charles Univ Prague, Fac Sci, Prague, Czech Republic; [Kolar, Michal; Strnad, Hynek] Acad Sci Czech Republic, Inst Mol Genet, Prague, Czech Republic; [Benes, Jan; Cervenka, Ludek; Melenovsky, Vojtech] Inst Clin & Expt Med IKEM, Dept Expt Med, Prague, Czech Republic; [Benes, Jan; Cervenka, Ludek; Melenovsky, Vojtech] Inst Clin & Expt Med IKEM, Dept Cardiol, Prague, Czech Republic; [Sedmera, David] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Sedmera, David] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Petrak, J (reprint author), Charles Univ Prague, Inst Pathol Physiol, Fac Med 1, Prague, Czech Republic.","jpetr@lf1.cuni.cz","Kolar, Michal/A-3307-2012; Sedmera, David/C-2146-2012; Strnad, Hynek/B-7361-2008; Jedelsky, Petr/C-5879-2009","Kolar, Michal/0000-0002-4593-1525; Strnad, Hynek/0000-0002-0141-8340; Jedelsky, Petr/0000-0003-3813-2343","Grant agency of the Czech Republic [305/09/1390]; EU [CZ.2.16/3.1.00/22126]; Ministry of Health CR [MZO-00023001, 00023736, IGA MZCR NS10300-3, NS10497-3/2009, NT 12248-5]; Ministry of Education [MSMT-1MO510, VZ 0021620806, 0021620858, LC06044, SVV-2011-262507]; Academy of Sciences of the Czech Republic [AV0Z50110509]","This work was supported by the Grant agency of the Czech Republic 305/09/1390, by the EU Operational Program Prague - Competitiveness; project \"CEVKOON\" (CZ.2.16/3.1.00/22126), and by grants from the Ministry of Health CR (MZO-00023001, 00023736, IGA MZCR NS10300-3, NS10497-3/2009, NT 12248-5; from the Ministry of Education (MSMT-1MO510, VZ 0021620806, 0021620858, LC06044 and SVV-2011-262507) and also by the Academy of Sciences of the Czech Republic (AV0Z50110509). We thank to Mrs. Petra Skaroupkova for invaluable help with rat surgical techniques. Special thanks also to Mrtva Ryba.",null,53,3,3,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1477-5956",null,null,"PROTEOME SCI","Proteome Sci.","NOV 11",2011,9,null,null,null,null,null,null,null,69,"10.1186/1477-5956-9-69",null,12,"Biochemical Research Methods","Biochemistry & Molecular Biology","853DS","WOS:000297407000001"]
[null,null,null,null,"J","Cejka, C; Ardan, T; Sirc, J; Michalek, J; Benes, J; Brunova, B; Rosina, J",null,null,null,"Cejka, Cestmir; Ardan, Taras; Sirc, Jakub; Michalek, Jiri; Benes, Jiri; Brunova, Blanka; Rosina, Jozef",null,null,"Hydration and Transparency of the Rabbit Cornea Irradiated with UVB-Doses of 0.25 J/cm(2) and 0.5 J/cm(2) Compared with Equivalent UVB Radiation Exposure Reaching the Human Cornea from Sunlight","CURRENT EYE RESEARCH",null,null,"English","Article",null,null,null,null,null,"UVB irradiation; Photokeratitis; Corneal hydration; transparency","ULTRAVIOLET-RADIATION; OPTICAL-PROPERTIES; EPITHELIAL-CELLS; OXIDATIVE DAMAGE; RAYS; LENS; SINGLE; EYE; EXPRESSION; APOPTOSIS","Purpose: Exposure of the cornea to UV radiation from sunlight evokes intraocular inflammation, photokeratitis. Photokeratitis is caused by UVB radiation. It is accompanied by changes of corneal hydration and light absorption. The aim of this study was to examine the effect of two UVB doses on corneal optics in rabbits and to compare these UVB doses with the equivalent exposure of UVB radiation reaching the human cornea from sunlight. Materials and Methods: Rabbit corneas were irradiated with a daily UVB dose of 0.25 J/cm(2) or 0.5 J/cm(2) for 4 days. One day after finishing the irradiations the rabbits were sacrificed and corneal light absorption measured using our spectrophotometrical method. Corneal hydration was examined using an ultrasonic Pachymeter every experimental day before the irradiation procedure and the last day before sacrificing the animals. Results: Changes in corneal optics appeared after the repeated exposure of the cornea to a UVB dose of 0.25 J/cm(2) and massively increased after the repeated exposure of the cornea to a UVB dose of 0.5 J/cm(2). The first significant changes in corneal hydration appeared after a single exposure of the cornea to a UVB dose of 0.25 J/cm(2). Conclusions: Changes in corneal hydration appeared after the exposure of the rabbit cornea to a single UVB dose equivalent to 2.6 hours of solar UVB radiation reaching the human cornea, as measured by UVB sensors embedded in the eyes of mannequin heads facing the sun on a beach at noon in July. Repeated exposure of the rabbit cornea to the same UVB dose evoked profound changes in corneal optics. Although comparison of experimental and outdoor conditions are only approximate, the results in rabbits point to the danger for the human eye from UVB radiation when short stays in sunlight are repeated for several consecutive days without UV protection.","[Cejka, Cestmir; Ardan, Taras] Acad Sci Czech Republic, Inst Expt Med, Ctr Excellence, Lab Eye Histochem & Pharmacol, Prague 14220 4, Czech Republic; [Sirc, Jakub; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, Prague 14220 4, Czech Republic; [Benes, Jiri] Charles Univ Prague, Fac Med 1, Inst Biophys & Informat, Prague, Czech Republic; [Brunova, Blanka] Charles Univ Prague, Fac Med 2, Eye Clin Children & Adults, Prague, Czech Republic; [Rosina, Jozef] Charles Univ Prague, Fac Med 3, Dept Med Biophys & Informat, Prague, Czech Republic","Cejka, C (reprint author), Acad Sci Czech Republic, Inst Expt Med, Ctr Excellence, Lab Eye Histochem & Pharmacol, Videnska 1083, Prague 14220 4, Czech Republic.","cestmir.cejka@seznam.cz","Michalek, Jiri/D-7251-2013",null," [CZ: AVOZ50390512]","This study was supported by grant CZ: AVOZ50390512.",null,38,3,3,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0271-3683",null,null,"CURR EYE RES","Curr. Eye Res.","JUL",2011,36,7,null,null,null,null,607,613,null,"10.3109/02713683.2011.574332",null,7,"Ophthalmology","Ophthalmology","775FM","WOS:000291444100003"]
[null,null,null,null,"J","Maheu, E; Zaim, M; Appelboom, T; Jeka, S; Tre, T; Maasalu, K; Berenbaum, F",null,null,null,"Maheu, E.; Zaim, M.; Appelboom, T.; Jeka, S.; Tre, T.; Maasalu, K.; Berenbaum, F.",null,null,"Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non-inferiority, prospective, randomised, controlled trial","CLINICAL AND EXPERIMENTAL RHEUMATOLOGY",null,null,"English","Article",null,null,null,null,null,"hyaluronans; non-inferiority comparative trial; intra-articular treatment; molecular weight; knee OA","DOUBLE-BLIND; CLINICAL-TRIALS; RECOMMENDATIONS; METAANALYSIS; ACID; MANAGEMENT; INJECTIONS; HIP; VISCOSUPPLEMENTATION; ARTHRITIS","Objectives To compare the efficacy and safety of a \"medium\" molecular weight (MW) hyaluronan product (F60027, Structovial (R)) with a \"high\" MW (Hylan G-F20, Synvisc (R)). Methods Prospective, randomised, multicentre, double-blind, active controlled, parallel-group study with a non-inferiority design. Patients with symptomatic KOA, global pain >= 40 mm (VAS, 0-100), Lequesne index (LFI, 0-24) score >7 and radiological Kellgren-Lawrence grade 213 were centrally randomised to receive F60027 or Hylan G-F20, administered via three weekly injections, with regular follow-up evaluations up to week 24 (W24). The primary outcome was LFI score change over 24 weeks. Secondary outcomes comprised pain VAS, quality of life, patient's and physician's global assessments, rescue medication consumption and OMERACT-OARSI responders rate. Results 276 patients were analysed in the fill analysis dataset (FAS), 236 in the Per Protocol dataset (PP). In the main efficacy analysis (PP), the difference of the LFI score change over 24 weeks between F60027 (-4.67 (0.27)) and Hylan G-F20 (-4.54 (0.28)) was 0.132 [95%CI: -0.598, 0.861] which met the predefined non-inferiority margin. Analyses of secondary efficacy criteria showed clinically relevant improvements of all outcomes at W24 for each treatment on both PP/FAS populations. Changes of LFI score between baseline and W24 were -5.73 in the F60027 and -5.57 in the Hylan G-F20 group (PP dataset). Few local reactions were reported: 3.6% of patients in each group. Conclusion F60027 and Hylan G-F20 were equally effective in reducing functional impairment and relieving pain in KOA patients, and well-tolerated.","[Maheu, E.; Berenbaum, F.] St Antoine Hosp, Dept Rheumatol, Paris, France; [Zaim, M.] Inst Rech Pierre Fabre, Clin Dept, Ramonville St Agne, France; [Appelboom, T.] Erasmus Hosp, Dept Rheumatol, Brussels, Belgium; [Jeka, S.] Nzoz Nasz Lekarz, Dept Rheumatol, Torun, Poland; [Tre, T.] Charles Univ Prague, Dept Orthopaed, Fac Med 2, Prague, Czech Republic; [Maasalu, K.] Tartu Univ Hosp, OCRC, Dept Traumatol & Orthopaed, Tartu, Estonia","Maheu, E (reprint author), 4 Bd Beaumarchais, F-75011 Paris, France.","emaheu@wanadoo.fr",null,null,"Institut de Recherche Pierre Fabre; Pierre Fabre laboratories","E. Maheu received honoraria for designing and conducting this trial as co-investigator; M. Zaim is an employee of Institut de Recherche Pierre Fabre, who supported this work; F. Berenbaum serves as a consultant to and receives research support from Pierre Fabre laboratories; the other co-authors have declared no competing interests.",null,30,3,3,"CLINICAL & EXPER RHEUMATOLOGY","PISA","VIA SANTA MARIA 31, 56126 PISA, ITALY","0392-856X",null,null,"CLIN EXP RHEUMATOL","Clin. Exp. Rheumatol.","MAY-JUN",2011,29,3,null,null,null,null,527,535,null,null,null,9,"Rheumatology","Rheumatology","797CK","WOS:000293101500010"]
[null,null,null,null,"J","Kremlacek, J; Valis, M; Masopust, J; Urban, A; Zumrova, A; Talab, R; Kuba, M; Kubova, Z; Langrova, J",null,null,null,"Kremlacek, Jan; Valis, Martin; Masopust, Jiri; Urban, Ales; Zumrova, Alena; Talab, Radomir; Kuba, Miroslav; Kubova, Zuzana; Langrova, Jana",null,null,"An Electrophysiological Study of Visual Processing in Spinocerebellar Ataxia Type 2 (SCA2)","CEREBELLUM",null,null,"English","Article",null,null,null,null,null,"Spinocerebellar ataxia type 2; Visual evoked potentials; Event-related potentials; Motion processing","MOTION-ONSET VEPS; EVOKED-POTENTIALS; PATTERN; PROGRESSION; DISEASE","Reports of visual functional impairment in spinocerebellar ataxia type 2 (SCA2) have been studied previously using pattern reversal visually evoked potentials (VEPs) with contradictory results. To provide additional evidence to this area, visual functions were studied using VEPs and event-related potentials (ERPs) in a group of ten patients with genetically verified SCA2. The electrophysiological examination included pattern reversal and motion-onset VEPs as well as visually driven oddball ERPs with an evaluation of a target and a pre-attentive response. In six patients, we found abnormal visual/cognitive processing that differed from normal values in latency, but not in the amplitude of the dominant VEP/ERP peaks. Among the VEPs/ERPs used, the motion-onset VEPs exhibited the highest sensitivity and showed a strong Spearman correlation to SCA2 duration (from r = 0.82 to r = 0.90, p < 0.001) and clinical state assessed by Brief Ataxia Rating Scale (from r = 0.71 (p = 0.022) to r = 0.80 (p < 0.001)). None of the VEP/ERP latencies showed a correlation to the triplet repeats of the SCA2 gene. In three patients, we did not find any visual/cognitive pathology, and one subject showed only a single subtle prolongation of the VEP peak. The observed visual/cognitive deficit was related to the subjects' clinical state and the illness duration, but no relationship to the genetic marker of SCA2 was found. From the VEP/ERP types used, the motion-onset VEPs seems to be the most promising candidate for clinical state monitoring rather than a tool for early diagnostic use.","[Kremlacek, Jan; Kuba, Miroslav; Kubova, Zuzana; Langrova, Jana] Charles Univ Prague, Fac Med, Dept Pathophysiol, Hradec Kralove 50038, Czech Republic; [Kremlacek, Jan; Valis, Martin; Talab, Radomir] Charles Univ Prague, Univ Hosp Hradec Kralove, Dept Neurol, Fac Med, Hradec Kralove 50038, Czech Republic; [Masopust, Jiri; Urban, Ales] Charles Univ Prague, Univ Hosp Hradec Kralove, Dept Psychiat, Fac Med, Hradec Kralove 50038, Czech Republic; [Zumrova, Alena] Charles Univ Prague, Fac Med 2, Neurogenet Ctr, Hradec Kralove 50038, Czech Republic; [Zumrova, Alena] Fac Hosp Motol, Prague, Czech Republic","Kremlacek, J (reprint author), Charles Univ Prague, Fac Med, Dept Pathophysiol, Simkova 870, Hradec Kralove 50038, Czech Republic.","jan.kremlacek@lfhk.cuni.cz","Kremlacek, Jan/A-4313-2008","Kremlacek, Jan/0000-0001-8641-4287","Grant Agency of the Czech Republic [309/09/0869]","This study is supported by Grant Agency of the Czech Republic 309/09/0869.",null,28,3,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1473-4222",null,null,"CEREBELLUM","Cerebellum","MAR",2011,10,1,null,null,null,null,32,42,null,"10.1007/s12311-010-0220-7",null,11,"Neurosciences","Neurosciences & Neurology","721DB","WOS:000287330600005"]
[null,null,null,null,"J","Gultekin, M; Dursun, P; Vranes, B; Laky, R; Bossart, M; Grabowski, JP; Piek, JMJ; Manchanda, R; Grimm, C; Dallaku, K; Babloyan, S; Moisei, A; Van Gorp, T; Cadron, I; Markov, P; Micevska, A; Halaska, M; Steffensen, KD; Gristsenko, L; Nissi, R; Lambaudie, E; Tsitsishvili, Z; Haidopoulos, D; Tsolakidis, D; Novak, Z; Peiretti, M; Dunenova, G; Macuks, R; Hetland, TE; Michelsen, TM; Martins, FC; Achimas-Cadariu, P; Ulrikh, EA; Uharcek, P; Malic, S; Ognjenovic, D; Zapardiel, I; Johann, S; Sukhin, VS; Manchanda, R",null,null,null,"Gultekin, Murat; Dursun, Polat; Vranes, Boris; Laky, Rene; Bossart, Michaela; Grabowski, Jacek P.; Piek, Jurgen M. J.; Manchanda, Ranjit; Grimm, Christoph; Dallaku, Kastriot; Babloyan, Syuzanna; Moisei, Anna; Van Gorp, Toon; Cadron, Isabelle; Markov, Peter; Micevska, Ana; Halaska, Michael; Steffensen, Karina Dahl; Gristsenko, Liidia; Nissi, Ritva; Lambaudie, Eric; Tsitsishvili, Zaza; Haidopoulos, Dimitrios; Tsolakidis, Dimitrios; Novak, Zoltan; Peiretti, Michele; Dunenova, Gauhar; Macuks, Ronalds; Hetland, Thea E.; Michelsen, Trond M.; Martins, Filipe C.; Achimas-Cadariu, Patriciu; Ulrikh, Elena A.; Uharcek, Peter; Malic, Sladjana; Ognjenovic, Dejan; Zapardiel, Ignacio; Johann, Silke; Sukhin, Vladyslav S.; Manchanda, Ranjit",null,null,"Gynecologic Oncology Training Systems in Europe A Report From the European Network of Young Gynaecological Oncologists","INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER",null,null,"English","Article",null,null,null,null,null,"ESGO; ENYGO; Training; Gynecologic oncology; Training systems; European Network of Young Gynaecological Oncologists","OVARIAN-CANCER PATIENTS; SURVIVAL","Objective: The objectives of the study were to highlight some of the differences in training systems and opportunities for training in gynecologic oncology across Europe and to draw attention to steps that can be taken to improve training prospects and experiences of European trainees in gynecologic oncology. Methods: The European Network of Young Gynaecological Oncologists national representatives from 34 countries were asked to review and summarize the training system in their countries of origin and fulfill a mini-questionnaire evaluating different aspects of training. We report analysis of outcomes of the mini-questionnaire and subsequent discussion at the European Network of Young Gynaecological Oncologists national representatives Asian Pacific Organization for Cancer Prevention meeting in Istanbul (April 2010). Results: Training fellowships in gynecologic oncology are offered by 18 countries (53%). The median duration of training is 2.5 years (interquartile range, 2.0-3.0 years). Chemotherapy administration is part of training in 70.5% (24/34) countries. Most of the countries (26/34) do not have a dedicated national gynecologic-oncology journal. All trainees reported some or good access to training in advanced laparoscopic surgical techniques, whereas 41% indicated no access, and 59% some access to training opportunities in robotic surgery. European countries were grouped into 3 different categories on the basis of available training opportunities in gynecologic oncology: well-structured, moderately structured, and loosely structured training systems. Conclusions: There is a need for further harmonization and standardization of training programs and structures in gynecologic oncology across Europe. This is of particular relevance for loosely structured countries that lag behind the moderately structured and well-structured ones.","[Gultekin, Murat] Baskent Univ Hosp, Turkish Minist Hlth, Ankara, Turkey; [Dursun, Polat] Baskent Univ Hosp, Dept Obstet & Gynaecol, Ankara, Turkey; [Vranes, Boris] Clin Ctr Serbia, Gynecol & Obstet Univ Clin, Belgrade, Serbia; [Laky, Rene] Gynaekol & Geburtshilfe Verbund Krages Burgenland, Oberwart Oberpullendorf, Austria; [Bossart, Michaela] Univ Freiburg, Dept Obstet & Gynaecol, Ctr Hosp, Freiburg, Germany; [Grabowski, Jacek P.] Kliniken Essen Mitte, Dept Gynecol & Gynecol Oncol, Essen, Germany; [Grabowski, Jacek P.] Karol Marcinkowski Univ Med Sci, Dept Oncol, Div Gynecol, Poznan, Poland; [Piek, Jurgen M. J.] Vrije Univ Amsterdam, Ctr Gynaecol Oncol Amsterdam, Med Ctr, Amsterdam, Netherlands; [Manchanda, Ranjit] UCL, EGA Inst Womens Hlth, London, England; [Grimm, Christoph] Med Univ Vienna, Dept Gynaecol & Gynaecol Oncol, Ctr Comprehens Canc, Vienna, Austria; [Dallaku, Kastriot] Obstetr Gynaecol Univ Hosp Koco Gliozheni, Tirana, Albania; [Babloyan, Syuzanna] Yerevan State Med Univ, Dept Obstet & Gynecol 1, Erebouni MC, Yerevan, Armenia; [Moisei, Anna] Belarusian Med Acad Postgrad Educ, Dept Oncol, Minsk, Byelarus; [Van Gorp, Toon] MUMC, Div Gynaecol Oncol, Maastricht, Netherlands; [Cadron, Isabelle] Katholieke Univ Leuven, Div Gynaecol Oncol, Dept Obstet & Gynaecol, Louvain, Belgium; [Markov, Peter] Maichin Dom Univ Hosp, Dept Gynecol Surg, Sofia, Bulgaria; [Micevska, Ana] Univ Hosp Gynecol & Obstet, Skopje, Macedonia; [Halaska, Michael] Charles Univ Prague, Prague, Czech Republic; [Steffensen, Karina Dahl] Vejle Hosp, Dept Clin Oncol & Radiotherapy, Vejle, Denmark; [Gristsenko, Liidia] N Estonian Reg Hosp, Dept Womans Dis, Surg Clin, Ctr Oncol, Tallinn, Estonia; [Nissi, Ritva] Oulu Univ, Dept Obstet & Gynecol, Oulu, Finland; [Lambaudie, Eric] Paoli Calmettes Inst, Dept Oncol Surg, Marseille, France; [Tsitsishvili, Zaza] Tbilisi Canc Ctr, Tbilisi, Rep of Georgia; [Haidopoulos, Dimitrios] Alexandra Hosp, Dept Obstet & Gynecol 1, Gynecol Oncol Unit, Athens, Greece; [Tsolakidis, Dimitrios] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece; [Novak, Zoltan] Univ Szeged, Dept Obstet & Gynaecol, Szeged, Hungary; [Peiretti, Michele] European Inst Oncol, Div Gynecol Oncol, Unit Prevent Gynecol, Milan, Italy; [Dunenova, Gauhar] Almaty Oncol Clin, Dept Gynaecol Oncol, Alma Ata, Kazakhstan; [Macuks, Ronalds] Riga Stradins Univ, Dept Gynecol & Obstet, Riga, Latvia; [Hetland, Thea E.] Norwegian Radium Hosp, Dept Gynaecol Oncol, Oslo, Norway; [Michelsen, Trond M.] Oslo Univ Hosp, Women & Childrens Div, Oslo, Norway; [Martins, Filipe C.] Coimbra Univ Hosp, Dept Obstet & Gynaecol, Coimbra, Portugal; [Achimas-Cadariu, Patriciu] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania; [Ulrikh, Elena A.] St Petersburg NN Petrov Res Inst, St Petersburg, Russia; [Uharcek, Peter] Fac Hosp Nitra, Dept Obstet & Gynaecol, Nitra, Slovakia; [Malic, Sladjana] Univ Med Ctr, Dept Obstet & Gynaecol, Ljubljana, Slovenia; [Ognjenovic, Dejan] Ptuj Teaching Hosp, Dept Gynecol & Gynecol Oncol, Ptuj, Slovenia; [Zapardiel, Ignacio] Santa Cristina Univ Hosp, Dept Gynaecol, Madrid, Spain; [Johann, Silke] Cantonal Hosp Schaffhausen, Dept Obstet & Gynaecol, Schaffhausen, Switzerland; [Sukhin, Vladyslav S.] Grigoriev Inst Med Radiol NAMS Ukraine, Dept Gynaecol Oncol, Kharkov, Ukraine; [Van Gorp, Toon] GROW Sch Oncol & Dev Biol, Maastricht, Netherlands","Gultekin, M (reprint author), IIkiz Sokak 4-1, TR-06000 Sihhiye, Turkey.","mrtgultekin@yahoo.com","Van Gorp, Toon/H-3235-2011; Achimas-Cadariu, Patriciu/C-7040-2012","Van Gorp, Toon/0000-0002-1573-8716; ","ESGO","The ENYGO thanks the ENYGO national representatives who participated in that survey and the ESGO and its executive and educational board for the support of its activities.",null,10,2,2,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X",null,null,"INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","NOV",2011,21,8,null,null,null,null,1500,1506,null,"10.1097/IGC.0b013e3182202d17",null,7,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","841ZH","WOS:000296553200027"]
[null,null,null,null,"J","Freiberger, T; Grombirkova, H; Ravcukova, B; Jarkovsky, J; Kuklinek, P; Krystufkova, O; Hanzlikova, J; Dankova, E; Kopecky, O; Zachova, R; Lahodna, M; Vasakova, M; Grodecka, L; Litzman, J",null,null,null,"Freiberger, T.; Grombirkova, H.; Ravcukova, B.; Jarkovsky, J.; Kuklinek, P.; Krystufkova, O.; Hanzlikova, J.; Dankova, E.; Kopecky, O.; Zachova, R.; Lahodna, M.; Vasakova, M.; Grodecka, L.; Litzman, J.",null,null,"No Evidence for Linkage between the Hereditary Angiooedema Clinical Phenotype and the BDKR1, BDKR2, ACE or MBL2 gene","SCANDINAVIAN JOURNAL OF IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,null,"C1 INHIBITOR DEFICIENCY; RECEPTOR GENE; EXON-1 POLYMORPHISM; ALTERED FREQUENCY; LECTIN PATHWAY; B-2 RECEPTOR; ANGIO-EDEMA; MUTATIONS","Hereditary angiooedema (HAE) is a life-threatening disease with poor clinical phenotype correlation with its causal mutation in the C1 inhibitor (SERPING1) gene. It is characterized by substantial symptom variability even in affected members of the same family. Therefore, it is likely that genetic factors outside the SERPING1 gene have an influence on disease manifestation. In this study, functional polymorphisms in genes with a possible disease-modifying effect, B1 and B2 bradykinin receptors (BDKR1, BDKR2), angiotensin-converting enzyme (ACE) and mannose-binding lectin (MBL2), were analysed in 36 unrelated HAE patients. The same analysis was carried out in 69 HAE patients regardless of their familial relationship. No significant influence of the studied polymorphisms in the BDKR1, BDKR2, ACE and MBL2 genes on overall disease severity, localization and severity of particular attacks, frequency of oedema episodes or age of disease onset was detected in either group of patients. Other genetic and/or environmental factors should be considered to be responsible for HAE clinical variability in Caucasians.","[Freiberger, T.; Grombirkova, H.; Ravcukova, B.; Grodecka, L.] Ctr Cardiovasc Surg & Transplantat, Mol Genet Lab, Brno 60300, Czech Republic; [Freiberger, T.; Kuklinek, P.; Litzman, J.] Masaryk Univ, St Annes Univ Hosp, Fac Med, Inst Clin Immunol & Allergol, Brno, Czech Republic; [Jarkovsky, J.] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic; [Krystufkova, O.] Inst Rheumatol, Prague, Czech Republic; [Hanzlikova, J.] Univ Hosp, Inst Immunol & Allergol, Plzen, Czech Republic; [Dankova, E.] Immunia, Prague, Czech Republic; [Kopecky, O.] Charles Univ Prague, Fac Med, Dept Internal Med 2, Univ Teaching Hosp, Hradec Kralove, Czech Republic; [Zachova, R.] Motol Univ Hosp, Inst Immunol, Prague, Czech Republic; [Lahodna, M.] Hosp Ceske Budejovice, Dept Internal Med, Ceske Budejovice, Czech Republic; [Vasakova, M.] Thomayers Fac Hosp, Clin Pneumol, Prague, Czech Republic","Freiberger, T (reprint author), Ctr Cardiovasc Surg & Transplantat, Mol Genet Lab, Vystavni 17-19, Brno 60300, Czech Republic.","tomas.freiberger@cktch.cz","Freiberger, Tomas/D-8421-2011; Grodecka, Lucie/E-1043-2012; Litzman, Jiri/E-2746-2012","Freiberger, Tomas/0000-0001-6532-7053; ","Internal grant agency of the Ministry of Health, Czech Republic [NR7921-3, NR9192-3]","We thank Lenka Suchankova for the technical help. The study was supported by the grants Nos. NR7921-3 and NR9192-3 of the Internal grant agency of the Ministry of Health, Czech Republic.",null,26,2,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-9475",null,null,"SCAND J IMMUNOL","Scand. J. Immunol.","JUL",2011,74,1,null,null,null,null,100,106,null,"10.1111/j.1365-3083.2011.02547.x",null,7,"Immunology","Immunology","785UB","WOS:000292254900013"]
[null,null,null,null,"J","Rusina, R; Kovacs, GG; Fiala, J; Hort, J; Ridzon, P; Holmerova, I; Strobel, T; Matej, R",null,null,null,"Rusina, Robert; Kovacs, Gabor G.; Fiala, Jindrich; Hort, Jakub; Ridzon, Petr; Holmerova, Iva; Stroebel, Thomas; Matej, Radoslav",null,null,"FTLD-TDP with motor neuron disease, visuospatial impairment and a progressive supranuclear palsy-like syndrome: broadening the clinical phenotype of TDP-43 proteinopathies. A report of three cases","BMC NEUROLOGY",null,null,"English","Article",null,null,null,null,null,null,"FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; CORTICOBASAL SYNDROME; PROGRANULIN GENE; DEMENTIA; MUTATIONS; PARKINSONISM; PATHOLOGY; CRITERIA; CHROMOSOME-17","Background: Frontotemporal lobar degeneration with ubiquitin and TDP-43 positive neuronal inclusions represents a novel entity (FTLD-TDP) that may be associated with motor neuron disease (FTLD-MND); involvement of extrapyramidal and other systems has also been reported. Case presentation: We present three cases with similar clinical symptoms, including Parkinsonism, supranuclear gaze palsy, visuospatial impairment and a behavioral variant of frontotemporal dementia, associated with either clinically possible or definite MND. Neuropathological examination revealed hallmarks of FTLD-TDP with major involvement of subcortical and, in particular, mesencephalic structures. These cases differed in onset and progression of clinical manifestations as well as distribution of histopathological changes in the brain and spinal cord. Two cases were sporadic, whereas the third case had a pathological variation in the progranulin gene 102 delC. Conclusions: Association of a \"progressive supranuclear palsy-like\" syndrome with marked visuospatial impairment, motor neuron disease and early behavioral disturbances may represent a clinically distinct phenotype of FTLD-TDP. Our observations further support the concept that TDP-43 proteinopathies represent a spectrum of disorders, where preferential localization of pathogenetic inclusions and neuronal cell loss defines clinical phenotypes ranging from frontotemporal dementia with or without motor neuron disease, to corticobasal syndrome and to a progressive supranuclear palsy-like syndrome.","[Rusina, Robert; Fiala, Jindrich; Ridzon, Petr] Thomayer Teaching Hosp, Dept Neurol, Prague, Czech Republic; [Rusina, Robert; Fiala, Jindrich; Ridzon, Petr] Inst Postgrad Educ Med, Prague, Czech Republic; [Hort, Jakub] Motol Teaching Hosp, Prague, Czech Republic; [Hort, Jakub] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague, Czech Republic; [Kovacs, Gabor G.; Stroebel, Thomas] Med Univ Vienna, Inst Neurol, Vienna, Austria; [Hort, Jakub] Int Clin Res Ctr, Brno, Czech Republic; [Holmerova, Iva] Charles Univ Prague, Ctr Gerontol, Prague, Czech Republic; [Holmerova, Iva] Charles Univ Prague, Fac Humanity Studies, Prague, Czech Republic; [Matej, Radoslav] Thomayer Teaching Hosp, Dept Pathol & Mol Med, Prague, Czech Republic; [Matej, Radoslav] Charles Univ Prague, Ctr Clin Neurosci, Fac Med 1, Prague, Czech Republic; [Matej, Radoslav] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague, Czech Republic","Rusina, R (reprint author), Thomayer Teaching Hosp, Dept Neurol, Prague, Czech Republic.","robert.rusina@ftn.cz","Kovacs, Gabor/A-7468-2013",null,"Austrian-Czech bilateral OAD project [2008-12/CZ 04/2008]; Czech Ministry of Education [MSM 0021620849]; Grant Agency of Czech Republic [309/09/1053, 309/09/P204]","This study was partly supported by Austrian-Czech bilateral OAD project (2008-12/CZ 04/2008), by the Czech Ministry of Education (research program MSM 0021620849) and grants 309/09/1053 and 309/09/P204 of the Grant Agency of Czech Republic. The authors wish to thank Pavel Fendrych, MD, PhD (IKEM hospital, Prague, Czech Republic), Josef Vymazal, MD, DSc (Homolka Hospital Prague, Czech Republic) and Zdenek Seidl, MD, PhD (General Faculty Hospital, Prague, Czech Republic), for providing MRI services, and Tom Secrest for revisions on the English version of this article.",null,36,2,2,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2377",null,null,"BMC NEUROL","BMC Neurol.","MAY 10",2011,11,null,null,null,null,null,null,null,50,"10.1186/1471-2377-11-50",null,11,"Clinical Neurology","Neurosciences & Neurology","776MC","WOS:000291538200001"]
[null,null,null,null,"J","Havranek, O; Spacek, M; Hubacek, P; Mocikova, H; Markova, J; Trneny, M; Kleibl, Z",null,null,null,"Havranek, O.; Spacek, M.; Hubacek, P.; Mocikova, H.; Markova, J.; Trneny, M.; Kleibl, Z.",null,null,"Alterations of CHEK2 forkhead-associated domain increase the risk of Hodgkin lymphoma","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"Hodgkin lymphoma; checkpoint kinase 2 gene (CHEK2, CHK2); germ-line mutation; genetic predisposition; risk assessment","CHK2 PROTEIN-KINASE; BREAST-CANCER; FHA DOMAIN; GENE; PHOSPHORYLATION; OLIGOMERIZATION; CLASSIFICATION; SUSCEPTIBILITY; ACTIVATION; MUTATIONS","Checkpoint kinase 2 gene (CHEK2) codes for an important mediator of DNA damage response pathway. Mutations in the CHEK2 gene increase the risk of several cancer types, however, their role in Hodgkin lymphoma (HL) has not been studied so far. The most frequent CHEK2 alterations (including c.470T>C; p.I157T) cluster into the forkhead-associated (FHA) domain-coding region of the CHEK2 gene. We performed mutation analysis of the CHEK2 gene segment coding for FHA domain using denaturing high-performance liquid chromatography in 298 HL patients and analyzed the impact of characterized CHEK2 gene variants on the risk of HL development and progression-free survival (PFS). The overall frequency of CHEK2 alterations was significantly higher in HL patients (17/298; 5.7%) compared to the previously analyzed non-cancer controls (19/683; 2.8%;p = 0.04). Presence of any alteration within the analyzed region of the CHEK2 gene was associated with increased risk of HL development (OR = 2.11; 95% CI = 1.08 - 4.13;p = 0.04). The most frequent I157T mutation was found in 4.0% of HL patients and 2.5% of controls (p = 0.22), however, the frequency of 5 other alterations (excluding I157T) was significantly higher in HL cases and associated with increased risk of HL development (OR = 5.81; 95% CI = 1.12 - 30.12;p = 0.03). PFS in HL patients did not differ between CHEK2 mutation carriers and non-carriers. The predominant I157T mutation together with other alterations in its proximity represent moderate genetic predisposition factor increasing the risk of HL development.","[Havranek, O.; Trneny, M.] Charles Univ Prague, Fac Med 1, Dept Med 1, Dept Hematol, Prague 12853 2, Czech Republic; [Spacek, M.; Mocikova, H.; Markova, J.] Charles Univ Prague, Fac Med 3, Prague 12853 2, Czech Republic; [Hubacek, P.] Charles Univ Prague, Fac Med 2, Prague 12853 2, Czech Republic; [Kleibl, Z.] Charles Univ Prague, Fac Med 1, Inst Biochem & Expt Oncol, Prague 12853 2, Czech Republic; [Havranek, O.; Trneny, M.] Gen Univ Hosp Prague, Prague, Czech Republic; [Spacek, M.; Mocikova, H.; Markova, J.] Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Prague, Czech Republic; [Hubacek, P.] Motol Univ Hosp, Dept Med Microbiol, Prague, Czech Republic; [Hubacek, P.] Motol Univ Hosp, Dept Pediat Hematol & Oncol, Prague, Czech Republic","Havranek, O (reprint author), Charles Univ Prague, Fac Med 1, Dept Med 1, Dept Hematol, Nemocnice 5, Prague 12853 2, Czech Republic.","zdekleje@lfl.cuni.cz","Kleibl, Zdenek/A-2009-2008",null,"Grant Agency of Charles University in Prague [GAUK 33508]; Ministry of Education, Youth and Sports of Czech Republic [MSM0021620808, MSM0021620813]","This work was supported by research grant of Grant Agency of Charles University in Prague No. GAUK 33508 and Research Project of the Ministry of Education, Youth and Sports of Czech Republic No. MSM0021620808 and No. MSM0021620813. We thank to Dr. Drahomira Springer providing the control blood samples, and hematologists and their patients for their collaboration. The special thank belongs to Ing. Jaroslava Hajkova for great help with isolation of DNA samples, to Mrs Helena Achylisova for sample handling and to Ing. Stanislav Kormunda for help with statistical analyses.",null,23,2,2,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2011,58,5,null,null,null,null,392,395,null,"10.4149/neo_2011_05_392",null,4,"Oncology","Oncology","825VH","WOS:000295309700005"]
[null,null,null,null,"J","Wawrzycki, B; Chodorowska, G; Pietrzak, A; Krasowska, D; Wasik, S; Dybiec, E; Lotti, T; Hercegova, J",null,null,null,"Wawrzycki, B.; Chodorowska, G.; Pietrzak, A.; Krasowska, D.; Wasik, Sz; Dybiec, E.; Lotti, T.; Hercegova, J.",null,null,"Recurrent skin eruption in patient with chronic lymphocytic leukemia and lymphocytic infiltrates of the dermis resembling Sweet's syndrome","GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA",null,null,"English","Article",null,null,null,null,null,"Sweet syndrome; Skin diseases; Leukemia, lymphocytic, chronic, B-cell","FEBRILE NEUTROPHILIC DERMATOSIS; MYELODYSPLASIA","Sweet's syndrome (acute febrile dermatosis) is characterized by fever, peripheral neutrophil leukocytosis, acute onset of tender erythematous skin lesions (papules, nodules or plaques), and histological findings of a dense infiltrate consisting predominantly of mature neutrophils. Malignancy-associated Sweet's syndrome constitutes approximately 21% of patients, the majority of whom suffer from hematologic disorder. We report the case of patient with chronic lymphocytic leukemia with recurrent eruptions of tender, pseudovesiculated nodules and plaques with good response to corticosteroid therapy, resembling Sweet's syndrome. However, histological examination revealed lymphocytic infiltrate in the dermis, which made impossible to establish diagnosis of acute febrile dermatosis according to diagnostic criteria. Association of the skin eruptions with leukemia was implied by improvement of skin lesions after chemotherapy. We present review of the literature reporting cases with atypical histopathological presentations which preceded classical histological appearances, that were mainly associated with hematological malignancies and discuss them in the context of our patient.","[Wawrzycki, B.; Chodorowska, G.; Pietrzak, A.; Krasowska, D.] Med Univ Lublin, Dept Dermatol Venereol & Pediat Dermatol, PL-20080 Lublin, Poland; [Wasik, Sz] Med Univ Lublin, Dept Hematooncol & Bone Marrow Transplantat, PL-20080 Lublin, Poland; [Dybiec, E.] Med Univ Lublin, Dept Pediat Radiol, PL-20080 Lublin, Poland; [Lotti, T.] Univ Florence, Dept Dermatol Sci, Florence, Italy; [Hercegova, J.] Charles Univ Prague, Dept Dermatol, Fac Med 2, Prague, Czech Republic","Wawrzycki, B (reprint author), Med Univ Lublin, Dept Dermatol Venereol & Pediat Dermatol, Radziwillowska 13, PL-20080 Lublin, Poland.","bariekwawrzycki@o2.pl",null,null,null,null,null,25,1,1,"EDIZIONI MINERVA MEDICA","TURIN","CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY","0026-4741",null,null,"GIORN ITAL DERMAT V","G. Ital. Dermatol. Venereol.","DEC",2011,146,6,null,null,null,null,487,492,null,null,null,6,"Dermatology","Dermatology","854GZ","WOS:000297484300007"]
[null,null,null,null,"J","Ritchie, CW; Ames, D; Burke, JR; Bustin, J; Connelly, P; Laczo, J; Portet, F",null,null,null,"Ritchie, Craig W.; Ames, David; Burke, James R.; Bustin, Julian; Connelly, Peter; Laczo, Jan; Portet, Florence",null,null,"An international perspective on advanced neuroimaging: cometh the hour or ivory tower?","INTERNATIONAL PSYCHOGERIATRICS",null,null,"English","Article",null,null,null,null,null,"dementia; neuroimaging; diagnosis; magnetic resonance imaging; PET scan; amyloid; Alzheimer's disease","MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; PREVALENCE; MULTICENTER; MATTER; SPECT; RISK","Over the past five to ten years, neuroimaging capability for neurodegenerative diseases has made remarkable progress. However, debate remains as to the true clinical utility of these advanced and costly investigations. Not only is the place of these tests in diagnostic algorithms unclear, but the access to them varies both within and between countries. We sought to gather informed opinion from recognized leaders in the field who can combine both an academic and a clinical perspective on the use of neuroimaging in their own countries. Opinion is presented from Scotland, Argentina, the Czech Republic, France, the USA and Australia. The emerging consensus was one of ongoing caution. While in most countries there was a sense that the use of more advanced imaging techniques was growing, their hour has not yet cometh. However, these techniques, rather than falling from the Ivory Tower, should descend slowly step by step onto fertile and receptive clinics from where better clinical guidelines will emerge.","[Ritchie, Craig W.] Univ London Imperial Coll Sci Technol & Med, Ctr Mental Hlth, Claybrook Ctr, London, England; [Ames, David] Natl Ageing Res Unit, Melbourne, Vic, Australia; [Burke, James R.] Duke Univ, Med Ctr, Memory Disorders Clin, Durham, NC USA; [Bustin, Julian] INECO, Buenos Aires, Aires, Argentina; [Bustin, Julian] Favaloro Fdn, Inst Neurosci, Buenos Aires, Aires, Argentina; [Connelly, Peter] Murray Royal Hosp, Perth, Scotland; [Laczo, Jan] Charles Univ Prague, Sch Med 2, Dept Neurol, Prague, Czech Republic; [Portet, Florence] CHU Gui de Chauliac, Neurol Dept B, Montpellier, France","Ritchie, CW (reprint author), Univ London Imperial Coll Sci Technol & Med, Ctr Mental Hlth, Claybrook Ctr, 37 Claybrook Rd, London, England.","c.ritchie@imperial.ac.uk",null,null,"GE Healthcare","FP has sat on an advisory board for GE Healthcare, and CWR has received honoraria for chairing a neuroimaging meeting sponsored by GE Healthcare.",null,22,1,1,"CAMBRIDGE UNIV PRESS","NEW YORK","32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA","1041-6102",null,null,"INT PSYCHOGERIATR","Int. Psychogeriatr.","SEP",2011,23,null,null,2,null,null,"S58","S64",null,"10.1017/S1041610211000901",null,7,"Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology","Psychology; Geriatrics & Gerontology; Psychiatry","821MD","WOS:000294978200008"]
[null,null,null,null,"J","Havranek, O; Spacek, M; Hubacek, P; Mocikova, H; Benesova, K; Soucek, P; Trneny, M; Kleibl, Z",null,null,null,"Havranek, Ondrej; Spacek, Martin; Hubacek, Petr; Mocikova, Heidi; Benesova, Katerina; Soucek, Pavel; Trneny, Marek; Kleibl, Zdenek",null,null,"No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma","LEUKEMIA RESEARCH",null,null,"English","Article",null,null,null,null,null,"TP53 gene (p53); Arg72Pro polymorphism (R72P); Non-Hodgkin lymphoma; Hodgkin lymphoma; Genetic predisposition; Prognosis","B-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; GERMLINE VARIATION; DNA-REPAIR; GENES; P53; MUTATIONS; SURVIVAL; ARG72PRO; CANCER","The role of the TP53 gene's R72P polymorphism in non-Hodgkin lymphoma (NHL) has been analyzed in several studies but it has not been studied in Hodgkin lymphoma (HL). We have evaluated the role of R72P in 340 NHL and 298 HL patients. There was no difference in the R72P frequency between analyzed lymphoma cases and 749 controls. We found no association of R72P with the risk of NHL and HL development [OR(ArgPro/ProPro) = 0.9 (95% CI 0.7-1.2) and 1.2 (95% CI 0.9-1.5), respectively] or with survival. Our results support the evidence that R72P is not a prognostic factor in Caucasian NHL patients, and they indicate its irrelevance for HL development or prognosis. (C) 2011 Elsevier Ltd. All rights reserved.","[Kleibl, Zdenek] Charles Univ Prague, Fac Med 1, Inst Biochem & Expt Oncol, Prague 12853 2, Czech Republic; [Havranek, Ondrej; Benesova, Katerina; Trneny, Marek] Charles Univ Prague, Fac Med 1, Dept Hematol, Dept Med 1, Prague 12853 2, Czech Republic; [Havranek, Ondrej; Benesova, Katerina; Trneny, Marek] Gen Univ Hosp, Prague, Czech Republic; [Spacek, Martin; Mocikova, Heidi] Charles Univ Prague, Fac Med 3, Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Prague 12853 2, Czech Republic; [Hubacek, Petr] Charles Univ Prague, Fac Med 2, Motol Univ Hosp, Dept Pediat Hematol & Oncol,Dept Med Microbiol, Prague 12853 2, Czech Republic; [Soucek, Pavel] Natl Inst Publ Hlth, Toxicogen Unit, Prague, Czech Republic","Kleibl, Z (reprint author), Charles Univ Prague, Fac Med 1, Inst Biochem & Expt Oncol, U Nemocnice 5, Prague 12853 2, Czech Republic.","zdekleje@lf1.cuni.cz","Kleibl, Zdenek/A-2009-2008",null,"Grant Agency of Charles University in Prague [GAUK 33508]; Ministry of Education, Youth and Sports of Czech Republic [MSM0021620808, MSM0021620813]","This work was supported by research grant of Grant Agency of Charles University in Prague, No. GAUK 33508 and Research Projects of the Ministry of Education, Youth and Sports of Czech Republic, Nos. MSM0021620808 and MSM0021620813.",null,13,1,1,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0145-2126",null,null,"LEUKEMIA RES","Leuk. Res.","AUG",2011,35,8,null,null,null,null,1117,1119,null,"10.1016/j.leukres.2011.04.001",null,3,"Oncology; Hematology","Oncology; Hematology","792ID","WOS:000292735300026"]
[null,null,null,null,"J","Balik, V; Lehto, H; Hoza, D; Phornsuwannapha, S; Toninelli, S; Romani, R; Sulla, I; Hernesniemi, J",null,null,null,"Balik, V.; Lehto, H.; Hoza, D.; Phornsuwannapha, S.; Toninelli, S.; Romani, R.; Sulla, I.; Hernesniemi, J.",null,null,"Post-Traumatic Frontal and Parieto-Occipital Extradural Haematomas: a Retrospective Analysis of 41 Patients and Review of the Literature","CENTRAL EUROPEAN NEUROSURGERY",null,null,"English","Article",null,null,null,null,null,"epidural; frontal; parietal; occipital; extradural haematoma; epidural haematoma","CHRONIC EPIDURAL HEMATOMA; HEAD-INJURY; IPSILATERAL EXOPHTHALMOS; CONSERVATIVE MANAGEMENT; SUBPERIOSTEAL HEMATOMA; COMATOSE PATIENTS; CHILDREN; SURGERY; TOMOGRAPHY; EXPERIENCE","Background: The purpose of this study was to analyse the differences between patients with frontal (FEDH) or parieto-occipital (POEDH) epidural haematomas and evaluate possible statistically significant prognostic factors. Material and methods: In this retrospective study of a group of 41 patients with a FEDH (17) or POEDH (24 individuals), the authors analysed the influence of gender, age, type of injury, clinical presentation, Glasgow coma scale (GCS) score on admission, radiological findings, and time interval from trauma to surgery on outcomes. A good recovery and moderate disability were considered a \"good\" or \"favourable outcome\", whereas severe disability, a vegetative state or death was a \"poor outcome\". Results: In the POEDH subgroup, a higher GCS score on admission and a younger age were statistically significant prognostic factors for a better outcome (p = 0.006, rs = 0.702). In the subgroup of patients with FEDHs, the results were not significant. However, patients with FEDHs more frequently had \"good outcomes\" than members of the POEDH subgroup (88.2 vs. 70.9%). Children (<= 18 years old) constituted a smaller portion of the POEDH subgroup (12.5%) than those in the FEDH subgroup (41.2%). The evaluation of time intervals between the accident and surgery (<= 24 h vs. >24 h) showed no significant influence on outcomes in any of the studied subgroups. However, patients undergoing surgery within 24 h of their injury had a less favourable GCS score on admission than those operated on more than 24 h after their injury. Subacute and chronic clinical courses predominated in patients with a FEDH (10/17 FEDH vs. 11/22 POEDH). Different accompanying intradural lesions occurred in 12 patients of the POEDH subgroup, but only in 2 of the FEDH subgroup (50 vs. 11.8%). However, the presence of such lesions did not significantly deteriorate surgical outcomes in either of the subgroups.","[Sulla, I.] Pavol Jozef Safarik Univ Kosice, Fac Med, AD Ctr, Dept Neurosurg, Kosice 04011, Slovakia; [Balik, V.] Univ Hosp Olomouc, Dept Neurosurg, Olomouc, Czech Republic; [Lehto, H.; Toninelli, S.; Romani, R.; Hernesniemi, J.] Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland; [Hoza, D.] Charles Univ Prague, Prague, Czech Republic; [Hoza, D.] Univ Hosp Motol, Dept Neurosurg, Prague, Czech Republic; [Phornsuwannapha, S.] Police Gen Hosp, Dept Surg, Div Neurosurg, Bangkok, Thailand","Sulla, I (reprint author), Pavol Jozef Safarik Univ Kosice, Fac Med, AD Ctr, Dept Neurosurg, Trieda SNP 1, Kosice 04011, Slovakia.","sullaigorz@gmail.com",null,null,null,null,null,94,0,0,"GEORG THIEME VERLAG KG","STUTTGART","RUDIGERSTR 14, D-70469 STUTTGART, GERMANY","1868-4904",null,null,"CENT EUR NEUROSURG","Cent. Eur. Neurosurg.","NOV",2011,72,4,null,null,null,null,169,175,null,"10.1055/s-0031-1286261",null,7,"Clinical Neurology; Surgery","Neurosciences & Neurology; Surgery","846HN","WOS:000296887900001"]
[null,null,null,null,"J","Kozner, P; Filous, A; Jilich, D; Brozek, B; Maly, M; Machala, L",null,null,null,"Kozner, Pavel; Filous, Ales; Jilich, David; Brozek, Bretislav; Maly, Marek; Machala, Ladislav",null,null,"Scanning Laser Polarimetry in Human Immunodeficiency Virus-Infected Patients","NEURO-OPHTHALMOLOGY",null,null,"English","Article",null,null,null,null,null,"HIV; retinal nerve fibre layer thickness; scanning laser polarimetry","NERVE-FIBER-LAYER; VARIABLE CORNEAL COMPENSATION; POSITIVE PATIENTS; HAART ERA; THICKNESS; RETINOPATHY; GLAUCOMA","The aim of the study was to evaluate the effect of human immunodeficiency virus infection on the retinal nerve fibre layer. The thickness was assessed in 48 human immunodeficiency virus-positive patients using scanning laser polarimetry. Results were compared to normal values and tested against factors suspected to affect the retinal nerve fibre layer. The mean value of the thickness was 57.65 +/- 6.18 mu m in our cohort. No significant correlation between the retinal nerve fibre layer thickness and the immune profile or antiretroviral therapy was detected. However, a significant negative correlation between the retinal nerve fibre layer thickness with increasing length of human immunodeficiency virus infection was found.","[Kozner, Pavel; Brozek, Bretislav] Univ Hosp Bulovka, Dept Ophthalmol, Prague, Czech Republic; [Filous, Ales] Charles Univ Prague, Fac Med 2, Dept Ophthalmol Children & Adults, Prague, Czech Republic; [Jilich, David] Charles Univ Prague, Fac Med 1, Dept Infect & Trop Dis, Prague, Czech Republic; [Maly, Marek] State Inst Hlth, Dept Stat, Prague, Czech Republic; [Machala, Ladislav] Charles Univ Prague, Fac Med 3, Dept Infect Dis, Prague, Czech Republic","Machala, L (reprint author), Bulovka Hosp, Budinova 2, Prague 18081 8, Czech Republic.","ladimachala@centrum.cz",null,null,null,null,null,17,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0165-8107",null,null,"NEURO-OPHTHALMOLOGY","Neuro-Ophthalmol.","AUG",2011,35,4,null,null,null,null,187,190,null,"10.3109/01658107.2011.595042",null,4,"Clinical Neurology; Ophthalmology","Neurosciences & Neurology; Ophthalmology","798FU","WOS:000293188800003"]
[null,null,null,null,"J","Dzirbikova, Z; Kiss, A; Okuliarova, M; Kopkan, L; Cervenka, L; Zeman, M",null,null,null,"Dzirbikova, Zuzana; Kiss, Alexander; Okuliarova, Monika; Kopkan, Libor; Cervenka, Ludek; Zeman, Michal",null,null,"Expressions of per1 Clock Gene and Genes of Signaling Peptides Vasopressin, Vasoactive Intestinal Peptide, and Oxytocin in the Suprachiasmatic and Paraventricular Nuclei of Hypertensive TGR[mREN2]27 Rats","CELLULAR AND MOLECULAR NEUROBIOLOGY",null,null,"English","Article",null,null,null,null,null,"Hypertension; Circadian rhythm; Suprachiasmatic nucleus; Paraventricular nucleus; Vasopressin; Oxytocin","MESSENGER-RNA EXPRESSION; BLOOD-PRESSURE CONTROL; CIRCADIAN-RHYTHMS; TGR(MREN-2)27 RATS; TRANSGENIC RATS; ANGIOTENSIN-II; HYPOTHALAMUS; HEART; BRAIN; RECEPTORS","Hypertensive rats with multiple extra copies of the renin gene (TGR) exert an inverted circadian blood pressure (BP) profile. We investigated whether circadian oscillations in the hypothalamic suprachiasmatic nucleus (SCN), a main circadian oscillator, and the paraventricular nucleus (PVN), involved in BP control, are influenced in TGR rats. The expression of the clock gene per1, a marker of circadian timing, was measured in the SCN and PVN. Moreover, the expression of genes encoding vasopressin (AVP), vasoactive intestinal peptide (VIP) in the SCN, and AVP and oxytocin (OXT) in the PVN were studied by in situ hybridization. Expression of the per1 gene showed a distinct circadian rhythm in both the SCN and PVN with no differences observed between the TGR and control Sprague-Dawley (SD) rats. The expression of avp in the SCN was rhythmic in both strains and moderately higher in TGR than in SD rats while no significant changes were found in the PVN. The expression of vip in the SCN and oxt in the PVN did not differ between both strains. Our results may indicate that changes occurring downstream to the SCN are responsible for the development of the inverted BP rhythm in TGR hypertensive rats.","[Dzirbikova, Zuzana; Okuliarova, Monika; Zeman, Michal] Comenius Univ, Fac Nat Sci, Dept Anim Physiol & Ethol, Bratislava 84215, Slovakia; [Kiss, Alexander] Slovak Acad Sci, Inst Expt Endocrinol, SK-83306 Bratislava, Slovakia; [Kopkan, Libor; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, Prague, Czech Republic; [Kopkan, Libor; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Zeman, M (reprint author), Comenius Univ, Fac Nat Sci, Dept Anim Physiol & Ethol, Mlynska Dolina B2, Bratislava 84215, Slovakia.","mzeman@fns.uniba.sk",null,null,"Institute for Clinical and Experimental Medicine [MZO 00023001];  [APVV 20-022-704];  [APVV-0214-07];  [CENDO]","This study was supported by the grants APVV No. 20-022-704, APVV-0214-07, CENDO. L.C. and L.K. are supported by the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001). We thank professor D. Jezova (Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia) for providing the avp probe.",null,34,0,0,"SPRINGER/PLENUM PUBLISHERS","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0272-4340",null,null,"CELL MOL NEUROBIOL","Cell. Mol. Neurobiol.","MAR",2011,31,2,null,null,null,null,225,232,null,"10.1007/s10571-010-9612-y",null,8,"Cell Biology; Neurosciences","Cell Biology; Neurosciences & Neurology","726VC","WOS:000287753500005"]
[null,null,null,null,"J","Vavrik, P; Landor, I; Popelka, S; Kasal, P; Fialka, R; Hach, J; Holub, J",null,null,null,"Vavrik, P.; Landor, I.; Popelka, S.; Kasal, P.; Fialka, R.; Hach, J.; Holub, J.",null,null,"The National Register of Joint Replacements of the Czech Republic","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"English","Article",null,null,null,null,null,"Czech National Hip Arthroplasty Register-hip joint replacement revisions hip arthroplasty survival curve; hip joint replacement revision rate",null,"The National Register of Joint Replacements of the Czech Republic was established as part of the National Health Information System in 2002. The register's administrator is the Institute of Health Information and Statistics of the Czech Republic, the Czech Society for Orthopaedics and Traumatology acts as its guarantee for scientific standard. The register is financed from state resources. It was launched into full operation in 2003 and it currently focuses on hip joint replacements. Register of knee and shoulder joint replacements is being prepared. The register provides aggregate epidemiological data and other statistics, including the Revision Rate - RR and survival curves (Kaplan Meier) for the main monitored groups of patients and implants used. More complex analytical evaluation methods are being set up. In years 2003-2009 there were 72 hospitals participating in the register's activities, 63 037 primary implantations and 8 931 revision surgeries were registered. In terms of gender share there is a prevalence of females amounting to 59,9% in primary implantations and to 64,7% in revision surgeries. The age structure covers the entire range of adult population, however, more than 50% of the replacements are being implanted between 60-74 years of age. Most frequent indications for primary implantation are idiopathic osteoarthritis 68,6%, post-traumatic conditions 13,53% and post-dysplasia arthritis 9,39%. The most frequent indications for revision surgery are aseptic loosening of acetabular component 40,9%, aseptic loosening of femoral component - 21,65% and recurrent luxation - 6,37%. 29 650 (47,04%) of primary implantations were cemented, 22 028 (34,94%) non-cemented, 10 924 (17,33%) hybrid with cemented femur and 435 (0,69%) were hybrid with cemented acetabulum. Most widely used is the classic anterolateral approach -77,76% in primary implantations and 52,35% in revision surge-ries. Bone grafts were used in 24,37% of primary implantations and 43,03% of revisions. Most widely used implants in primary implantations were cemented cup Muller (Aesculap) 10 196 pcs, cemented steel stem Poldi AK (Beznoska) 9 932 pcs, from the non-cemented models the cup Plasmacup SC (Aesculap) 6 738 pcs and stem SL Zweyrni.iller Alloclassic (Zimmer) 2 708 pcs. Most widely used implants in revision surgeries in general are noncemented oval cup Medin (HA) 740 pcs and non-cemented stem Wagner (Zimmer) 407 pcs. The Revision Rates of primary implantations indicated for infection in the samples from individual years were at the close of their monitoring in June 2010 as follows: 2003 - RR 0, 37%, 2004 - RR 0,36%, 2005 - RR 0,35%, 2006 - RR 0,28%, 2007 - RR 0,18%, 2008 - RR 0,10%, 2009 - RR 0,10%. The cumulated survival probability (Kaplan-Meier) in year 8 of the monitoring represent 97,27% for cemented implants, 96,53% for non-cemented, 96,73% for hybrid with cemented femur and 95,08% for hybrid with cemented cup.","[Vavrik, P.; Landor, I.; Popelka, S.; Hach, J.] Charles Univ Prague, Orthopaed Clin 1, Fac Med 1, Prague 15000 5, Czech Republic; [Kasal, P.] Charles Univ Prague, Dept Med Informat, Fac Med 2, Prague 15000 5, Czech Republic; [Fialka, R.] Coordinat Ctr Dept Hlth Informat Syst, Prague 14021 4, Czech Republic; [Holub, J.] Inst Hlth Informat & Stat Czech Republ, Prague 12801 2, Czech Republic","Vavrik, P (reprint author), Charles Univ Prague, Orthopaed Clin 1, Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic.","pvavrik@atlas.cz",null,null,null,null,null,13,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.",null,2011,78,null,null,"S",null,null,5,"+",null,null,null,67,"Orthopedics","Orthopedics","817TP","WOS:000294699800002"]
[null,null,null,null,"J","de Boer, R; Clemens, M; Renczes, G; Kotasek, D; Prausova, J; Marschner, N; Hedenus, M; Doshi, S; Hendricks, L; Osterborg, AC",null,null,null,"de Boer, Richard; Clemens, Michael; Renczes, Gabor; Kotasek, Dusan; Prausova, Jana; Marschner, Norbert; Hedenus, Michael; Doshi, Sameer; Hendricks, Lisa; Osterborg, Anders C.",null,null,"Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies","MEDICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"Erythropoiesis; Anaemia; Haemoglobin; Phase 1 clinical trial; Phase 2 clinical trial; Randomised controlled trial","RECOMBINANT-HUMAN-ERYTHROPOIETIN; DARBEPOETIN-ALPHA; DOUBLE-BLIND; EPOETIN-ALPHA; TRIAL; CANCER","AMG 114 is a novel, hyperglycosylated erythropoiesis-stimulating agent. In preclinical studies, AMG 114 demonstrated increased potency and longer half-life than darbepoetin alfa and epoetin alfa. This phase I/II, randomised, double-blind, placebo-controlled, dose-escalation study evaluated safety, pharmacokinetics, and efficacy of AMG 114 in patients with non-myeloid malignancies and chemotherapy-induced anaemia. Patients were randomised (1:5) to receive subcutaneous placebo or AMG 114 Q3W for 6 weeks in 3 dose cohorts of 15 mu g (cohort A1), 50 mu g (cohort A2), or 200 mu g (cohort A3). Safety endpoints included incidence of adverse events and dose-limiting toxicities (DLTs). The PK profile of AMG 114 was evaluated. Efficacy was assessed by change in haemoglobin from baseline to end of treatment. Forty-eight patients enrolled: 8 received placebo, 40 received AMG 114. No DLTs were observed; adverse events were consistent with underlying malignancies. The PK profile was dose-proportional over the dose range tested; terminal half-life of AMG 114 was approximately 130 h. Mean change (range) in haemoglobin from baseline in AMG 114-treated patients was -0.16 (-1.8 to 1.3), 0.21 (-1.5 to 3.4), and 0.76 (-1.0 to 2.9) g/dl in cohorts A1, A2, and A3, respectively. AMG 114 appeared to be well tolerated, but the study was halted, in part because of modest efficacy.","[de Boer, Richard] Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia; [Clemens, Michael] Klinikum Mutterhaus Borromaerinnen gGmbH, Innere Med Hamatol Onkol Kardiol 1, D-54290 Trier, Germany; [Renczes, Gabor] Goodwill Res Ltd, H-1034 Budapest, Hungary; [Kotasek, Dusan] Adelaide Canc Ctr, Kurralta Pk, SA 5037, Australia; [Prausova, Jana] Univ Hosp V Motole, Dept Radiotherapy & Oncol, Prague 15006, Czech Republic; [Hedenus, Michael] Sundsvall Hosp, Dept Internal Med, S-85186 Sundsvall, Sweden; [Doshi, Sameer; Hendricks, Lisa] Amgen Inc, Thousand Oaks, CA 91320 USA; [Osterborg, Anders C.] Karolinska Univ Hosp, Dept Hematol Oncol, S-17176 Stockholm, Sweden; [Marschner, Norbert] Onkol Schwerpunktpraxis, D-79106 Freiburg, Germany","de Boer, R (reprint author), Royal Melbourne Hosp, Dept Med Oncol, Grattan St, Parkville, Vic 3050, Australia.","richard.deboer@wh.org.au",null,null,"Amgen; Roche; Cougar Pharmaceuticals; Sanofi-Aventis; Wyeth; Pfizer; Amgen Inc","The authors thank the patients and their families for participation in the study and the clinical study staff at all participating institutions. We also wish to thank Julia R. Gage, PhD, for writing assistance on behalf of Amgen Inc. The Source of support is Amgen Inc.Richard de Boer, Gabor Renczes, Jana Prausova, Norbert Marschner, and Michael Hedenus have no conflicts to disclose. Michael Clemens received financial support from Amgen for documentation of the study data. Dusan Kotasek has received honoraria from Roche Australia and research funding from Amgen, Roche, Cougar Pharmaceuticals, Sanofi-Aventis, Wyeth, and Pfizer. Sameer Doshi and Lisa Hendricks are employees and shareholders of Amgen Inc. Anders C. Osterborg has received honoraria for lectures at symposia sponsored by Amgen.","[Anonymous], 2010, AR DARB ALF PRESCR I; Beveridge RA, 2003, PHARMACOTHERAPY, V23, p101S, DOI 10.1592/phco.23.16.101S.31971; Bohlius J, 2009, LANCET, V373, P1532, DOI 10.1016/S0140-6736(09)60502-X; Canon JL, 2006, J NATL CANCER I, V98, P273, DOI 10.1093/jnci/djj053; EGRIE JC, 1986, IMMUNOBIOLOGY, V172, P213; Egrie JC, 2001, BRIT J CANCER, V84, P3, DOI 10.1054/bjoc.2001.1746; Egrie JC, 2003, EXP HEMATOL, V31, P290, DOI 10.1016/S0301-472X(03)00006-7; ELLIOTT S, 2006, P AM ASS CANC RES, V47; Elliott S, 2004, EXP HEMATOL, V32, P1146, DOI 10.1016/j.exphem.2004.08.004; *EUR MED AG, 2008, QUEST ANSW EP RISK T; Glaspy J, 2005, EUR J CANCER, V41, P1140, DOI 10.1016/j.ejca.2005.01.021; Herrington JD, 2005, AM J HEALTH-SYST PH, V62, P54; Houts AC, 2006, SUPPORT CARE CANCER, V14, P1195, DOI 10.1007/s00520-006-0075-0; Ludwig H, 2009, J CLIN ONCOL, V27, P2838, DOI 10.1200/JCO.2008.19.1130; Morrison VA, 2007, J MANAGE CARE PHARM, V13, P337; *ORTH BIOT PROD LP, 2010, PROCR EP ALF PRESCR; Schwartzberg L, 2003, CLIN THER, V25, P2781, DOI 10.1016/S0149-2918(03)80333-8; Vansteenkiste J, 2002, J NATL CANCER I, V94, P1211",18,0,0,"HUMANA PRESS INC","TOTOWA","999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA","1357-0560",null,null,"MED ONCOL","Med. Oncol.","DEC",2011,28,4,null,null,null,null,1210,1217,null,"10.1007/s12032-010-9725-7",null,8,"Oncology","Oncology","851GM","WOS:000297256400044"]
[null,null,null,null,"J","Burgetova, A; Seidl, Z; Lisy, J; Dusek, P; Masek, M; Vaneckova, M",null,null,null,"Burgetova, A.; Seidl, Z.; Lisy, J.; Dusek, P.; Masek, M.; Vaneckova, M.",null,null,"Diffusion-weighted Image and the Prediction of Brain Venous Thrombosis Development on Magnetic Resonance - Two Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"cerebral venous thrombosis; magnetic resonance imaging; diffusion weighted imaging; posterior reversible encephalopathy syndrome","VASOGENIC EDEMA; MR","We present two cases with diagnoses of cerebral venous thrombosis with extensive pathological changes supporting ischemia on conventional MR imaging (MRI). MR angiography disclosed thrombosis of the vein of Galen and cerebral sinuses. The findings were different on diffusion-weighted imaging (DWI) and on ADC maps. The first case exhibited high signal intensity on DWI and intermediate-to-low signal intensity on ADC (apparent diffusion coefficient) maps in the affected area. This indicated cytotoxic oedema and ischemic lesions. The second case showed intermediate-to-low signal intensity on DWI and high signal intensity on ADC maps. This indicated vasogenic oedema. The severe clinical status of both patients necessitated admittance to the intensive care unit and anticoagulation therapy. In the first case, six months after symptoms onset, signs of organic psychosyndrome, cephalea and vertigo remained. MRI indicated that a residue of the haemorrhage ischemic lesion in the left thalamus persisted, with high signal on T2WI and low signal with mild hypersignal margin on T1WI. In the second case, MR findings and normalization of clinical status after anticoagulation therapy indicated complete remission. We suggest that DWI and ADC contribute to diagnosis and enable a certain degree of prediction of clinical course.","[Burgetova, A.; Seidl, Z.; Masek, M.; Vaneckova, M.] VFN Praze, LF UK, Radiodiagnost Klin 1, Prague 12808 2, Czech Republic; [Seidl, Z.] Vyssi Zdravotnicka Skola, Prague 5, Czech Republic; [Lisy, J.] FN Motole, LF UK, Klin Zobrazovacich Metod 2, Prague, Czech Republic; [Dusek, P.] VFN Praze, LF UK, Neurol Klin 1, Prague 12808 2, Czech Republic","Burgetova, A (reprint author), VFN Praze, LF UK, Radiodiagnost Klin 1, Katerinska 30, Prague 12808 2, Czech Republic.","andrea.burgetova@vfn.cz",null,null,null,null,"Keller E, 1999, STROKE, V30, P1144; Kinoshita T, 2003, CLIN IMAG, V27, P307, DOI 10.1016/S0899-7071(02)00592-2; Lovblad KO, 2000, NEURORADIOLOGY, V42, P728; Lovblad KO, 2001, CEREBROVASC DIS, V11, P169, DOI 10.1159/000047634; Rother J, 1996, J CEREBR BLOOD F MET, V16, P1353; Schaefer PW, 1997, STROKE, V28, P1082; Stam J, 2005, NEW ENGL J MED, V352, P1791, DOI 10.1056/NEJMra042354; ugate JE, 2010, MAYO CLIN P, V58, P427; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; YUH WTC, 1994, AM J NEURORADIOL, V15, P309",10,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2011,74,3,null,null,null,null,339,343,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","792OS","WOS:000292757000014"]
[null,null,null,null,"J","Jakubikova, M; Prihodova, I; Barna, M; Stulik, J; Vanek, P; Benes, V; Nevsimalova, S",null,null,null,"Jakubikova, M.; Prihodova, I.; Barna, M.; Stulik, J.; Vanek, P.; Benes, V.; Nevsimalova, S.",null,null,"Spinal Complications in Genetic Syndromes - Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"achondroplasia; Down's syndrome; spinal stenosis; atlantoaxial instability; spinal fusion; decompression laminectomy","ATLANTOAXIAL INSTABILITY; DOWN-SYNDROME; ACHONDROPLASIA; STENOSIS","Distinct genetic syndromes (achondroplasia, Down's syndrome) are associated with congenital or degenerative vertebral abnormalities and with involvement of the ligamentous apparatus. In patients with achondroplasia, vertebral deformities may result in spinal stenosis, nerve root compression and development of myelopathy. The most common spinal complication in Down's syndrome is atlanto-axial instability. This condition is associated with a shift of C1/C2 vertebrae and subsequent compression of dorsal roots, spinal cord and the development of cervical myelopathy. Two case reports of patients with these genetic disorders are presented. Surgical intervention was considered necessary in both of them.","[Jakubikova, M.; Prihodova, I.; Nevsimalova, S.] 1 LF UK & VFN, Neurol Klin, Prague 12821 2, Czech Republic; [Jakubikova, M.; Prihodova, I.; Nevsimalova, S.] 1 LF UK & VFN, Ctr Klin Neuroved, Prague 12821 2, Czech Republic; [Barna, M.; Stulik, J.] 1 LF UK & FN Motole, Chirurg Klin 3, Spondylochirurg Oddeleni, Prague, Czech Republic; [Vanek, P.; Benes, V.] 1 LF UK & UNV Praha, Neurochirurg Klin, Prague, Czech Republic","Jakubikova, M (reprint author), 1 LF UK & VFN, Neurol Klin, Katerinska 30, Prague 12821 2, Czech Republic.","michala.jakubikova@vfn.cz",null,null,null,null,"Ain MC, 2004, SPINE, V29, P2075, DOI 10.1097/01.brs.0000138411.14588.47; ALVAREZ N, 1986, APPL RES MENT RETARD, V7, P67, DOI 10.1016/0270-3092(86)90019-6; Bagley CA, 2006, J NEUROSURG, V104, P166, DOI 10.3171/ped.2006.104.3.166; Baitner AC, 2000, J PEDIATR ORTHOPED, V20, P594; Donath J, 1925, WIEN ARCH INN MED, V10, P1; Gordon N, 2000, BRAIN DEV-JPN, V22, P3, DOI 10.1016/S0387-7604(99)00075-3; Hall J G, 1988, Basic Life Sci, V48, P3; Jeong ST, 2006, J BONE JOINT SURG BR, V88B, P1192, DOI 10.1302/0301-620X.88B9.17758; PARROT JM, B SOC ANTROPOLOGIE P; PUESCHEL SM, 1987, PEDIATRICS, V80, P555; Sciubba DM, 2007, J NEUROSURG, V106, P372, DOI 10.3171/ped.2007.106.5.372; SPITZER R, 1961, CAN MED ASSOC J, V84, P567",12,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2011,74,4,null,null,null,null,482,485,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","809EZ","WOS:000294035900014"]
[null,null,null,null,"J","Pozzilli, C; Schweikert, B; Ecari, U; Oentrich, W",null,null,null,"Pozzilli, Carlo; Schweikert, Bernd; Ecari, Ugo; Oentrich, Wolfgang",null,"BetaPlus Study Grp","Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis - Results of the BetaPlus observational cohort study","JOURNAL OF THE NEUROLOGICAL SCIENCES",null,null,"English","Article",null,null,null,null,null,"Multiple Sclerosis; Adherence; Interferon beta-1b; Coping styles; Autoinjector devices; Nurses","DEPRESSION SCALE; THERAPY; MS; RELIABILITY; INTERFERONS; SPECIALIST; MEDICATION; VALIDITY; ANXIETY; PEOPLE","Background: Low adherence to treatment in Multiple Sclerosis (MS) has been shown to lead to poor health outcomes. Various strategies to improve adherence have been suggested including educative programs, injection devices and dedicated nurse assistance. Objective: To assess the impact of elements of the patient support program on adherence; to explore disease factors affecting adherence; and to determine whether these factors influence the choices of supportive elements. Methods: A prospective, observational cohort study was conducted. MS patients were eligible if they had switched to Interferon beta-1b (IFNB-1b) between 1 and 3 months prior to inclusion. Data were collected at months 6, 12, 18 and 24 after inclusion. Adherence was defined as completion of both study protocol and medication at 24 months. Patients underwent evaluations of disability, quality of life, depression, and coping styles. Results: A total of 1077 patients from 15 countries were included, of which 61.8% were adherent to IFNB-1b after 24-months. Depression, quality of life and autoinjector devices were baseline predictors of adherence at 24-months. Coping styles did not show to have substantial impact on adherence. Lower quality of life increased the probability of choosing supportive elements. Conclusion: The study showed that the usage of autoinjector devices chosen during the study was the strongest predictor of drug adherence of all the supportive elements tested in this study. (C) 2011 Elsevier B.V. All rights reserved.","[Pozzilli, Carlo] Univ Roma La Sapienza, Univ Rome, Dept Neurol Sci, S Andrea Hosp,Multiple Sclerosis Ctr, I-00185 Rome, Italy; [Schweikert, Bernd] I3 Innovus, Hlth Econ & Outcomes, D-81829 Munich, Germany; [Ecari, Ugo] Domedica Slr, Dept Med, I-40129 Bologna, Italy; [Oentrich, Wolfgang] Bayer Schering Pharma AG, D-13353 Berlin, Germany","Pozzilli, C (reprint author), Univ Roma La Sapienza, Univ Rome, Dept Neurol Sci, S Andrea Hosp,Multiple Sclerosis Ctr, Viale Univ 30, I-00185 Rome, Italy.","carlo.pozzilli@uniroma1.it",null,null,"Bayer Schering Pharma AG, Germany","This research was funded by Bayer Schering Pharma AG, Germany.","Brochet B, 2006, REV NEUROL-FRANCE, V162, P735, DOI 10.1016/S0035-3787(06)75071-8; Bussfeld P, 2010, FORTSCHR NEUROL PSYC, V78, P139, DOI 10.1055/s-0029-1245148; Cella DF, 1996, NEUROLOGY, V47, P129; Chesney MA, 2006, BRIT J HEALTH PSYCH, V11, P421, DOI 10.1348/135910705X53155; Devonshire V, 2010, EUR J NEUROL    0614; Folkman S, 1988, MANUAL WAYS COPING Q; Forbes A, 2006, INT J NURS STUD, V43, P985, DOI 10.1016/j.ijnurstu.2005.11.019; Ghubash R, 2000, INT J SOC PSYCHIATR, V46, P241, DOI 10.1177/002076400004600402; Girouard Nathalie, 2008, Can J Neurosci Nurs, V30, P18; Holland N, 2001, Rehabil Nurs, V26, P221; IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; KURTZKE JF, 1983, NEUROLOGY, V33, P1444; LODE K, 2009, ACTA NEUROL SCA 1228; Lode K, 2007, MULT SCLER, V13, P792, DOI 10.1177/1352458506073482; Lugaresi A, 2009, EXPERT OPIN DRUG DEL, V6, P995, DOI 10.1517/17425240903134769; Madonna M G, 1999, J Neurosci Nurs, V31, P332; McCabe MP, 2004, J PSYCHOSOM RES, V56, P355, DOI 10.1016/S0022-3999(03)00132-6; Mohr DC, 2001, ANN BEHAV MED, V23, P125, DOI 10.1207/S15324796ABM2302_7; Moreau T, 2009, EUR NEUROL, V62, P79, DOI 10.1159/000222777; MURRELL SA, 1983, AM J EPIDEMIOL, V117, P173; O'Rourke KET, 2005, MULT SCLER, V11, P46, DOI 10.1191/1352458505ms1131oa; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Paolicelli Damiano, 2009, Biologics, V3, P369; PATY DW, 1993, NEUROLOGY, V43, P662; Portaccio E, 2008, EUR NEUROL, V59, P131, DOI 10.1159/000111875; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rio Jordi, 2005, Multiple Sclerosis, V11, P306, DOI 10.1191/1352458505ms1173oa; SHINAR D, 1986, STROKE, V17, P241; Steinberg SC, 2010, CLIN DRUG INVEST, V30, P89, DOI 10.2165/11533330-000000000-00000; Treadaway K, 2009, J NEUROL, V256, P568, DOI 10.1007/s00415-009-0096-y; Tremlett HL, 2003, NEUROLOGY, V61, P551; Turner AP, 2007, MULT SCLER, V13, P1146, DOI 10.1177/1352458507078911; While A, 2009, J CLIN NURS, V18, P2635, DOI 10.1111/j.1365-2702.2008.02459.x",33,9,9,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0022-510X",null,null,"J NEUROL SCI","J. Neurol. Sci.","AUG 15",2011,307,41671,null,null,null,null,120,126,null,"10.1016/j.jns.2011.04.026",null,7,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","796KF","WOS:000293049500022"]
[null,null,null,null,"J","Foltan, R; Hoffmannova, J; Pavlikova, G; Hanzelka, T; Klima, K; Horka, E; Adamek, S; Sedy, J",null,null,null,"Foltan, Rene; Hoffmannova, Jirina; Pavlikova, Gabriela; Hanzelka, Tomas; Klima, Karel; Horka, Edita; Adamek, Svatopluk; Sedy, Jiri",null,null,"The influence of orthognathic surgery on ventilation during sleep","INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY",null,null,"English","Article",null,null,null,null,null,"orthognathic surgery; obstructive sleep apnea; ventilation; sleep","MANDIBULAR SETBACK SURGERY; APNEA SYNDROME; AIRWAY SIZE; MAXILLOMANDIBULAR ADVANCEMENT; EXPANSION","Orthognathic surgery has varying effects on respiratory parameters. The authors undertook a prospective study of patients requiring mandibular advancement, mandibular setback and maxillary Le Fort I advancement, and surgically assisted rapid maxillary expansion (SARME). Breathing parameters were monitored in a sleep laboratory the night before the operation and in a mean of 9.5 months after the operation. In patients treated with mandibular advancement, the respiratory disturbance index (RDI), oxygen desaturation index (ODI), and number of obstructive apnoeas (OAs) improved significantly. In patients treated with mandibular setback and maxillary Le Fort I advancement, the RDI, ODI, index of flow limitations (IFL), number of obstructive hypopnoeas (OHs), OA, and oxygen saturation deteriorated. In contrast, patients treated with SARME improved only mildly. These results indicate that bimaxillary surgery for Class III malocclusion increased upper airway resistance, probably because of a more dorsal positioning of the base of the tongue, representing an iatrogenic obstructive sleep apnoea (OSA). A young person would probably be able to balance such a decline in respiratory function using different adaptative mechanisms. Mandibular advancement significantly improved respiratory parameters during sleep. The possible effect of orthognathic surgery on the upper airways should be incorporated into the treatment plan.","[Horka, Edita; Sedy, Jiri] Charles Univ Prague, Inst Dent Res, Fac Med 1, Prague 12800 2, Czech Republic; [Horka, Edita; Sedy, Jiri] Gen Univ Hosp, Prague 12800 2, Czech Republic; [Foltan, Rene; Hoffmannova, Jirina; Pavlikova, Gabriela; Hanzelka, Tomas; Klima, Karel] Charles Univ Prague, Dept Oral & Maxillofacial Surg, Fac Med 1, Prague 12800 2, Czech Republic; [Adamek, Svatopluk] Fac Med 1, Dept Surg 3, Prague, Czech Republic; [Adamek, Svatopluk] Teaching Hosp Motol, Prague, Czech Republic; [Sedy, Jiri] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic","Sedy, J (reprint author), Charles Univ Prague, Inst Dent Res, Fac Med 1, Karlovo Namesti 32, Prague 12800 2, Czech Republic.","jirisedy@hotmail.com",null,null,null,null,null,22,8,8,"CHURCHILL LIVINGSTONE","EDINBURGH","JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND","0901-5027",null,null,"INT J ORAL MAX SURG","Int. J. Oral Maxillofac. Surg.","FEB",2011,40,2,null,null,null,null,146,149,null,"10.1016/j.ijom.2010.10.006",null,4,"Dentistry, Oral Surgery & Medicine; Surgery","Dentistry, Oral Surgery & Medicine; Surgery","736DQ","WOS:000288471100004"]
[null,null,null,null,"J","Sedlackova, L; Sosna, A; Vavrincova, P; Frydl, J; Guerriero, V; Raynes, DA; Hromadnikova, I",null,null,null,"Sedlackova, L.; Sosna, A.; Vavrincova, P.; Frydl, J.; Guerriero, V.; Raynes, D. A.; Hromadnikova, I.",null,null,"Heat shock protein gene expression profile may differentiate between rheumatoid arthritis, osteoarthritis, and healthy controls","SCANDINAVIAN JOURNAL OF RHEUMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"HSP70 COCHAPERONE HSPBP1; IN-VITRO; ANTIBODIES; HSP-70","Objective: Heat shock proteins (Hsps) have been repeatedly implicated in the pathogenesis of rheumatoid arthritis (RA). The aim of this work was to study Hsp mRNA and protein levels to determine whether they can be used to differentiate between RA, osteoarthritis (OA), and healthy controls. Methods: Hsp27, Hsp60, Hsp70, Hsp90 alpha, and HspBP1 mRNA expression was analysed using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) in 24 RA, 11 OA, and 21 healthy controls. Hsp70 and HspBP1 protein levels were measured in serum using an enzyme-linked immunosorbent assay (ELISA). Results: Hsp gene expression profiles differ significantly between inflammatory (RA) and non-inflammatory (OA) joint diseases, showing significantly increased Hsp27 and Hsp90 alpha mRNA levels in RA synovial tissues. Up-regulated Hsp60 and Hsp90 alpha together with down-regulated Hsp70 and elevated HspBP1//Hsp70 mRNA ratios can be used to differentiate between RA patients and healthy individuals through analysis of peripheral blood samples. Despite increased HspBP1 levels in RA sera, Hsp70 levels and the HspBP1//Hsp70 protein ratio remained identical in the RA patients and healthy individuals, which may contribute to the inhibition of Hsp70 anti-apoptotic activity. Conclusion: Hsp gene expression analysis can be implemented as a new diagnostic approach to facilitate differentiation between RA, OA, and healthy controls.","[Sedlackova, L.; Hromadnikova, I.] Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Prague 10000 10, Czech Republic; [Sosna, A.] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Clin Orthopaed 1, Prague 10000 10, Czech Republic; [Vavrincova, P.] Univ Hosp Motol, Outpatient Dept Rheumatol, Prague, Czech Republic; [Frydl, J.] Charles Univ Prague, Dept Children & Adult Orthopaed & Traumatol, Fac Med 2, Prague 10000 10, Czech Republic; [Guerriero, V.; Raynes, D. A.] Univ Arizona, Dept Anim Sci, Tucson, AZ 85721 USA; [Guerriero, V.] Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA","Sedlackova, L (reprint author), Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Ruska 87, Prague 10000 10, Czech Republic.","lucie.sedlackova@lf3.cuni.cz",null,null,"TRANSNET [MRTN-CT-2004-512253]; STEMDIAGNOSTICS [LSHB-CT-2007-037703]","We thank Associate Professor Stanislav Popelka, Dr David Veigl, and Associate Professor Jan Pech, from The First Clinic of Orthopaedics, University Hospital Motol, Prague, for providing tissue samples and their kind collaboration. We would also thank Roman Volchenkov (currently at The Gade Institute, University of Bergen, Norway), who was employed from April 2008 to June 2009 as an early stage researcher on the TRANSNET project, for his participation in the designing and testing of TaqMan systems for the detection of Hsps. Thanks also to Zuzana Imryskova, who participated in testing of patients with osteoarthritis. This project was supported by TRANSNET (No. MRTN-CT-2004-512253) and STEMDIAGNOSTICS (No. LSHB-CT-2007-037703).",null,15,6,7,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0300-9742",null,null,"SCAND J RHEUMATOL","Scand. J. Rheumatol.",null,2011,40,5,null,null,null,null,354,357,null,"10.3109/03009742.2011.552522",null,4,"Rheumatology","Rheumatology","828BV","WOS:000295476300005"]
[null,null,null,null,"J","Nedorostova, L; Kloucek, P; Urbanova, K; Kokoska, L; Smid, J; Urban, J; Valterova, I; Stolcova, M",null,null,null,"Nedorostova, Lenka; Kloucek, Pavel; Urbanova, Klara; Kokoska, Ladislav; Smid, Jakub; Urban, Jan; Valterova, Irena; Stolcova, Miluse",null,null,"Antibacterial effect of essential oil vapours against different strains of Staphylococcus aureus, including MRSA","FLAVOUR AND FRAGRANCE JOURNAL",null,null,"English","Article",null,null,null,null,null,"essential oils; plant volatiles; vapour phase; micro-atmosphere; disc volatilization method, SPME","RESISTANT; BACTERIA; PHASE; INHIBITION; CARVACROL; MODEL","The aim of this study was to identify antimicrobial properties of selected essential oils in the vapour phase against different strains of Staphylococcus aureus, including MRSA and resistant clinical isolates. The resistance pattern of used S. aureus strains was checked by disc diffusion method against three antibiotics. Essential oils tested were obtained by hydro-distillation and characterized by GC-MS and SPME-GC. Their antimicrobial properties in the vapour phase were determined by the micro-atmosphere method. Among the essential oils tested, the most active was Armoracia rusticana with MICs ranging from 8.3 to 17 mu l/l, followed by Origanum syriacum (8.3-130 mu l/l), Allium sativum (8.3-530 mu l/l), Satureja hortensis (17-130 mu l/l), Satureja montana (33-260 mu l/l), Thymus vulgaris (33-260 mu l/l), and Thymus serpyllum (33-530 mu l/l). To the best of our knowledge, this is the first report of their antimicrobial properties in vapour phase against a collection of strains and clinical isolates of S. aureus, including MRSA. Based on the results, the essential oils tested can be considered as effective anti-staphylococcal natural products with specific application possibilities due to the activity in the vapour phase. Copyright (C) 2011 John Wiley & Sons, Ltd.","[Nedorostova, Lenka; Kloucek, Pavel; Smid, Jakub; Stolcova, Miluse] Czech Univ Life Sci Prague, Dept Crop Prod, Fac Agrobiol Food & Nat Resources, Prague 16521 6, Suchdol, Czech Republic; [Urbanova, Klara; Valterova, Irena] Acad Sci Czech Republic, Inst Organ Chem & Biochem, CR-16610 Prague 6, Czech Republic; [Kokoska, Ladislav] Czech Univ Life Sci Prague, Dept Crop Sci & Agroforestry, Inst Trop & Subtrop, Prague 16521 6, Suchdol, Czech Republic; [Kokoska, Ladislav] Czech Univ Life Sci Prague, Dept Zool & Fisheries, Fac Agrobiol Food & Nat Resources, Prague 16521 6, Suchdol, Czech Republic; [Urban, Jan] Natl Inst Publ Hlth, Ctr Epidemiol & Microbiol, Prague 10042 10, Czech Republic","Kloucek, P (reprint author), Czech Univ Life Sci Prague, Dept Crop Prod, Fac Agrobiol Food & Nat Resources, Kamycka 129, Prague 16521 6, Suchdol, Czech Republic.","kloucek@af.czu.cz; irena@uochb.cas.cz","Valterova, Irena/H-1823-2012",null,"Czech Science Foundation [525/09/P503]; Ministry of Education, Youth and Sports [MSMT 6046070901]","This study was supported by Czech Science Foundation project 525/09/P503 and by the Ministry of Education, Youth and Sports project MSMT 6046070901.","Adams R.P., 2007, IDENTIFICATION ESSEN; Bakkali F, 2008, FOOD CHEM TOXICOL, V46, P446, DOI 10.1016/j.fct.2007.09.106; Blot SI, 2002, ARCH INTERN MED, V162, P2229, DOI 10.1001/archinte.162.19.2229; Burt S, 2004, INT J FOOD MICROBIOL, V94, P223, DOI 10.1016/j.ijfoodmicro.2004.03.022; Chao S, 2008, FLAVOUR FRAG J, V23, P444, DOI 10.1002/ffj.1904; Doran AL, 2009, LETT APPL MICROBIOL, V48, P387, DOI 10.1111/j.1472-765X.2009.02552.x; Edwards-Jones V, 2004, BURNS, V30, P772, DOI 10.1016/j.burns.2004.06.006; Hiramatsu K, 2001, TRENDS MICROBIOL, V9, P486, DOI 10.1016/S0966-842X(01)02175-8; Hood JR, 2010, J ANTIMICROB CHEMOTH, V65, P285, DOI 10.1093/jac/dkp400; Inouye S, 2001, J ANTIMICROB CHEMOTH, V47, P565, DOI 10.1093/jac/47.5.565; Iten F, 2009, PLANTA MED, V75, P1231, DOI 10.1055/s-0029-1185541; Kalemba D, 2003, CURR MED CHEM, V10, P813, DOI 10.2174/0929867033457719; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Krist S, 2008, FLAVOUR FRAG J, V23, P353, DOI 10.1602/ffj.1993; Lebosse R, 1997, J AGR FOOD CHEM, V45, P2836, DOI 10.1021/jf960957e; Lin CM, 2000, J FOOD PROTECT, V63, P727; LOPEZ P, J AGR FOOD CHEM, V53, P6939; Nedorostova L, 2009, FOOD CONTROL, V20, P157, DOI 10.1016/j.foodcont.2008.03.007; Roller S, 2009, J ALTERN COMPLEM MED, V15, P275, DOI 10.1089/acm.2008.0268; Sherry E, 2004, PHYTOMEDICINE, V11, P95, DOI 10.1078/0944-7113-00378; Ultee A, 2002, APPL ENVIRON MICROB, V68, P1561, DOI 10.1128/AEM.68.4.1561-1568.2002; Ward SM, 1998, FOOD RES INT, V31, P19, DOI 10.1016/S0963-9969(98)00054-4",22,6,6,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0882-5734",null,null,"FLAVOUR FRAG J","Flavour Frag. J.","NOV",2011,26,6,null,null,null,null,403,407,null,"10.1002/ffj.2068",null,5,"Chemistry, Applied; Food Science & Technology","Chemistry; Food Science & Technology","847MN","WOS:000296977100006"]
[null,null,null,null,"J","Pavlikova, G; Foltan, R; Burian, M; Horka, E; Adamek, S; Hejcl, A; Hanzelka, T; Sedy, J",null,null,null,"Pavlikova, G.; Foltan, R.; Burian, M.; Horka, E.; Adamek, S.; Hejcl, A.; Hanzelka, T.; Sedy, J.",null,null,"Piezosurgery prevents brain tissue damage: an experimental study on a new rat model","INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY",null,null,"English","Article",null,null,null,null,null,"piezosurgery; brain; lesion; surgery; rat","CORD INJURED RATS; SPINAL-CORD; SURGERY; EXPERIENCE; ELEVATION; OSTEOTOMY","Piezosurgery is a promising meticulous system for bone cutting, based on ultrasound microvibrations. It is thought that the impact of piezosurgery on the integrity of soft tissue is generally low, but it has not been examined critically. The authors undertook an experimental study to evaluate the brain tissue response to skull bone removal using piezosurgery compared with a conventional drilling method. In Wistar male rats, a circular bone window was drilled to the parietal bone using piezosurgery on one side and a conventional bone drill on the other side. The behavioural performance of animals was evaluated using the motor BBB test and sensory plantar test. The brains of animals were evaluated by magnetic resonance imaging (MRI) and histology. The results of MRI showed significantly increased depth and width of the brain lesion in the region of conventional drilling compared with the region where piezosurgery was used. Cresylviolet and NF 160 staining confirmed these findings. There was no significant difference in any of the behavioural tests between the two groups. In conclusion, piezosurgery is a safe method for the performance of osteotomy in close relation to soft tissue, including an extremely injury-sensitive tissue such as brain.","[Sedy, J.] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Pavlikova, G.; Foltan, R.; Hanzelka, T.] Charles Univ Prague, Fac Med 1, Dept Oral & Maxillofacial Surg, Prague, Czech Republic; [Pavlikova, G.; Foltan, R.; Horka, E.; Hanzelka, T.; Sedy, J.] Gen Univ Hosp, Prague, Czech Republic; [Burian, M.] Inst Clin & Expt Med, Dept Radiol, MR Unit, Prague, Czech Republic; [Horka, E.; Sedy, J.] Charles Univ Prague, Fac Med 1, Inst Dent Res, Prague, Czech Republic; [Adamek, S.] Charles Univ Prague, Fac Med 1, Dept Surg 3, Prague, Czech Republic; [Adamek, S.] Univ Hosp Motol, Prague, Czech Republic","Sedy, J (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","jirisedy@hotmail.com",null,null,"Grant agency of the Academy of Sciences of the Czech Republic [GA AV AV0Z50390703]; Czech Ministry of Education [CZ:MSMT CR:1M0538, CZ:MSMT CR:LC554]; Grant Agency of the Czech Republic GACR [304/10/0320]","For funding, the authors would like to thank the Grant agency of the Academy of Sciences of the Czech Republic GA AV AV0Z50390703, and Czech Ministry of Education CZ:MSMT CR:1M0538 and CZ:MSMT CR:LC554 and Grant Agency of the Czech Republic GACR 304/10/0320.",null,16,5,5,"CHURCHILL LIVINGSTONE","EDINBURGH","JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND","0901-5027",null,null,"INT J ORAL MAX SURG","Int. J. Oral Maxillofac. Surg.","AUG",2011,40,8,null,null,null,null,840,844,null,"10.1016/j.ijom.2011.05.008",null,5,"Dentistry, Oral Surgery & Medicine; Surgery","Dentistry, Oral Surgery & Medicine; Surgery","820XG","WOS:000294938800011"]
[null,null,null,null,"J","Bocsi, J; Hanzka, MC; Osmancik, P; Hambsch, J; Dahnert, I; Sack, U; Bellinghausen, W; Schneider, P; Janousek, J; Kostelka, M; Tarnok, A",null,null,null,"Bocsi, Jozsef; Haenzka, Marie-Christin; Osmancik, Pavel; Hambsch, Joerg; Daehnert, Ingo; Sack, Ulrich; Bellinghausen, Wilfried; Schneider, Peter; Janousek, Jan; Kostelka, Martin; Tarnok, Attila",null,null,"Modulation of the Cellular and Humoral Immune Response to Pediatric Open Heart Surgery by Methylprednisolone","CYTOMETRY PART B-CLINICAL CYTOMETRY",null,null,"English","Article",null,null,null,null,null,"pediatric cardiac surgery; congenital heart defects; cardiopulmonary bypass; immune response; methylprednisolone","SYSTEMIC INFLAMMATORY RESPONSE; ADHESION MOLECULE EXPRESSION; HIGH-DOSE METHYLPREDNISOLONE; PROTEIN-LOSING ENTEROPATHY; SEPTAL-DEFECT REPAIR; CARDIOPULMONARY BYPASS; CARDIAC-SURGERY; COMPLEMENT ACTIVATION; FLOW-CYTOMETRY; CARDIOVASCULAR-SURGERY","Background: With the intention to reduce overshooting immune response, glucocorticoids are frequently administered perioperatively in children undergoing open heart surgery. In a retrospective study we investigated extensively the modulation of the humoral and cellular immune response by methylprednisolone (MP). Methods: This study was carried out on blood samples from two groups of children who had undergone surgical correction of atrial or ventricular septal defects, either without (MP(-), n = 10), or with MP administration (MP(+), n = 23, dose median 11 (IQR 10-16) mg kg(-1) body weight) before cardiopulmonary bypass (CPB, duration median 42 (IQR 36-65) min). EDTA blood was obtained 24 h preoperatively, after anesthesia, at CPB begin and end, 4, 24, and 48 h after surgery, at discharge and at out-patient follow-up (median 8.2 (IQR 3.3-12.2) months after surgery). Complex blood analysis including clinical chemistry and flow cytometry were performed to monitor humoral immune response, differential blood count, lymphocyte subsets, and the degree of activation of various leukocyte subpopulations. Results: The patients' postoperative courses and follow-up were uneventful. Release of IL-6 and 118 was reduced and that of the anti-inflammatory cytokine IL-10 upregulated by MP. Significant increase of circulating neutrophils and monocytes as inflammatory reaction to surgery and CPB contact was detected in both groups. However, invasion of monocytes to the periphery was delayed with MP. CD4+ and CD8+ T-lymphocyte counts were lower with MP treatment. B-lymphocyte count increased significantly after surgery in MP(+) but remained constant in MP(-) group. Conclusions: MP treatment partially decreased the pro-inflammatory effect of CPB surgery and induced anti-inflammatory effect on the cellular and humoral level. (C) 2011 International Clinical Cytometry Society","[Bocsi, Jozsef; Haenzka, Marie-Christin; Hambsch, Joerg; Daehnert, Ingo; Schneider, Peter; Janousek, Jan; Tarnok, Attila] Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, D-04289 Leipzig, Germany; [Osmancik, Pavel] Charles Univ Prague, Med Sch 3, Dept Cardiol, Cardioctr, Prague, Czech Republic; [Osmancik, Pavel] Univ Hosp Kralovske Vinohraly, Prague, Czech Republic; [Sack, Ulrich] Univ Leipzig, IKIT, Inst Clin Immunol, D-04289 Leipzig, Germany; [Bellinghausen, Wilfried] Univ Leipzig, Ctr Heart, Dept Anesthesiol, D-04289 Leipzig, Germany; [Kostelka, Martin] Univ Leipzig, Ctr Heart, Dept Cardiac Surg, D-04289 Leipzig, Germany","Tarnok, A (reprint author), Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, Strumpelistr 39, D-04289 Leipzig, Germany.","tarnok@medizin.uni-leipzig.de",null,null,"Deutsche Stiftung fur Herzforschung, Frankfurt, Germany [MSM-0021620817]; Ministry of Education, Youth and Physical Education of the Czech Republic [MSM 0021620817]","Grant sponsor: Deutsche Stiftung fur Herzforschung, Frankfurt, Germany; Grant number: MSM-0021620817; Grant sponsor: Charles University research grant provided by the Ministry of Education, Youth and Physical Education of the Czech Republic; Grant number: MSM 0021620817.",null,59,5,5,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1552-4949",null,null,"CYTOM PART B-CLIN CY","Cytom. Part B-Clin. Cytom.","JUL",2011,"80B",4,null,null,null,null,212,220,null,"10.1002/cyto.b.20587",null,9,"Medical Laboratory Technology; Pathology","Medical Laboratory Technology; Pathology","787HI","WOS:000292366800002"]
[null,null,null,null,"J","Kutilek, P; Farkasova, B",null,null,null,"Kutilek, Patrik; Farkasova, Barbora",null,null,"Prediction of lower extremities' movement by angle-angle diagrams and neural networks","ACTA OF BIOENGINEERING AND BIOMECHANICS",null,null,"English","Article",null,null,null,null,null,"simulation; walking; artificial intelligence; gait angles; cyclograms; artificial neural networks","MUSCLE ACTIVATION; OLDER-ADULTS; GAIT; WALKING; PATTERNS; MODEL","In contemporary science, the analysis of human walking is extensively used. The prediction of leg motion, as well as rehabilitation, can be usable for orthosis and prosthesis programing. Our work is focused on predicting of human walking by angle-angle diagrams, also called cyclograms. The applications of cyclograms in conjunction with artificial intelligence offers wide area of applications in medicine. But until now, this approach has not been studied or applied in practice.","[Kutilek, Patrik] Czech Tech Univ, Fac Biomed Engn, Kladno, Czech Republic; [Farkasova, Barbora] Motol Univ Hosp Prague, Dept Biomed Engn, Prague, Czech Republic","Kutilek, P (reprint author), Czech Tech Univ, Fac Biomed Engn, Sq Sitna 3105, Kladno, Czech Republic.","kutilek@fbmi.cvut.cz",null,null,"Faculty of Biomedical Engineering, Czech Technical University in Prague [MSM 6840770012]; Ministry of Education, Youth and Sports of the Czech Republic","This is the work of the Faculty of Biomedical Engineering, Czech Technical University in Prague, within the frames of the research program No. MSM 6840770012 Transdisciplinary Biomedical Engineering Research II of the Czech Technical University sponsored by the Ministry of Education, Youth and Sports of the Czech Republic.",null,37,5,5,"WROCLAW UNIV TECHNOLOGY","WROCLAW","WROCLAW UNIV TECHNOLOGY, MECHANICAL DEPT, WYBRZEZE WYSPIANSKIEGO 27, WROCLAW, 50-370, POLAND","1509-409X",null,null,"ACTA BIOENG BIOMECH","Acta Bioeng. Biomech.",null,2011,13,2,null,null,null,null,57,65,null,null,null,9,"Biophysics; Engineering, Biomedical","Biophysics; Engineering","857RP","WOS:000297736700006"]
[null,null,null,null,"J","van der Linden, P; Gazdzik, TS; Jahoda, D; Heylen, RJ; Skowronski, JC; Pellar, D; Kofranek, I; Gorecki, AZ; Fagrell, B; Keipert, PE; Hardiman, YJ; Levy, H",null,null,null,"van der Linden, Philippe; Gazdzik, Tadeusz S.; Jahoda, David; Heylen, Rene J.; Skowronski, Jan C.; Pellar, David; Kofranek, Ivo; Gorecki, Andrzej Z.; Fagrell, Bengt; Keipert, Peter E.; Hardiman, Yun J.; Levy, Howard",null,"6090 Study Investigators","A Double-Blind, Randomized, Multicenter Study of MP4OX for Treatment of Perioperative Hypotension in Patients Undergoing Primary Hip Arthroplasty Under Spinal Anesthesia","ANESTHESIA AND ANALGESIA",null,null,"English","Article",null,null,null,null,null,null,"ACUTE-RENAL-FAILURE; ACID-BASE STATUS; HEMOGLOBIN MP4; UNCONTROLLED HEMORRHAGE; ORTHOPEDIC-SURGERY; ANESTHETIZED SWINE; BLOOD SUBSTITUTES; ELDERLY-PATIENTS; OXYGEN; HEMOSPAN","BACKGROUND: MP4OX (oxygenated polyethylene glycol-modified hemoglobin) is a novel oxygen therapeutic agent specifically developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia. In this study, we investigated the ability of MP4OX to treat hypotensive episodes. In addition, the tolerability profile of MP4OX in a large surgical population was established. METHODS: Patients from 21 study sites in 5 countries, scheduled to undergo primary hip arthroplasty under spinal anesthesia, were randomized in a double-blind manner to receive MP4OX or hydroxyethyl starch (HES) solution (Voluven (R); HES 130/0.4). Patients received the first 250-mL dose of investigational product when systolic blood pressure decreased to the predefined dosing trigger. A second 250-mL dose was given only if the systolic blood pressure decreased to the same trigger level after administration of the first dose. The primary efficacy outcome was total duration of all hypotensive episodes during surgery and the first 6 hours after skin closure. RESULTS: Of the 474 patients randomized, 405 reached the dosing trigger and received at least 1 dose. The mean total duration of all hypotensive episodes was significantly shorter (P < 0.0001) in the MP4OX group (52.4 +/- 71.50 minutes; range, 3-442 minutes) compared with the HES group (137.6 +/- 120.21 minutes; range, 5-435 minutes). The overall incidence of adverse events (AEs) in the intent-to-treat population was similar between the MP4OX and HES groups (75.2% vs 73.4%; P = 0.733). Transient increases in laboratory values were reported in more patients in the MP4OX group versus HES controls for aspartate aminotransferase (13.4% vs 7.4%; P = 0.052), alanine aminotransferase (6.9% vs 4.9%; P = 0.409), lipase (9.7% vs 3.6%; P = 0.015), and troponin (8.1% vs 2.0%; P = 0.006). There was no significant difference in the incidence of serious AEs reported (6.4% in MP4OX group vs 3.0% in HES controls; P = 0.106). Certain AEs did occur more frequently in the MP4OX group, including nausea (23.8% vs 14.3%; P = 0.016), bradycardia (14.9% vs 5.9%; P = 0.003), hypertension (8.4% vs 2.5%; P = 0.009), and oliguria (5.9% vs 1.5%; P = 0.019). The composite morbidity and ischemia end points did not reveal any differences between the 2 treatment groups. CONCLUSIONS: Administration of MP4OX achieved the end point of treating perioperative hypotension in patients undergoing primary hip arthroplasty under spinal anesthesia. The study was not powered to demonstrate clinical benefit based on the composite morbidity or ischemia outcomes. Although efficacy end points with sufficient power were met, MP4OX is not being proposed for use in routine surgery where the risk-benefit profile would not be favorable based on the safety profile demonstrated in this study. (Anesth Analg 2011; 112: 759-73)","[Keipert, Peter E.; Hardiman, Yun J.; Levy, Howard] Sangart Inc, San Diego, CA 92121 USA; [van der Linden, Philippe] CHU Brugmann, Dept Anesthesiol, Brussels, Belgium; [Gazdzik, Tadeusz S.] Wojewodzki Szpital Specjalistyczny 5, Katedra & Oddzial Klin Ortoped, Sosnowiec, Poland; [Jahoda, David] Ortoped Klin, Fakultni Nemocnice V Motole 1, Prague, Czech Republic; [Heylen, Rene J.] ZOL Genk, Dept Anesthesiol, Genk, Belgium; [Skowronski, Jan C.] Samodzielny Publ Szpital Klin AM, Klin Ortoped & Traumatol AMB, Bialystok, Poland; [Pellar, David] Fakultni Nemocnice Hradec Kralove, Ortoped Klin, Hradec Kralove, Czech Republic; [Kofranek, Ivo] Fakultni Nemocnice Bulovce, Ortoped Klin, Prague, Czech Republic; [Gorecki, Andrzej Z.] Szpital Klin Dzieciatka Jezus, Katedra & Klin Ortoped & Traumatol, Warsaw, Poland; [Fagrell, Bengt] Karolinska Inst, Stockholm, Sweden; [Fagrell, Bengt] Karolinska Univ Hosp, Stockholm, Sweden","Levy, H (reprint author), Sangart Inc, 6175 Lusk Blvd, San Diego, CA 92121 USA.","hlevy@sangart.com","Gommers, Diederik/E-9385-2010",null,"Sangart, Inc., San Diego, CA","Sponsored and supported by Sangart, Inc., San Diego, CA.","Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Boldt J, 2009, INTENS CARE MED, V35, P1331, DOI 10.1007/s00134-009-1520-6; CRITCHLEY LAH, 1994, BRIT J ANAESTH, V73, P464, DOI 10.1093/bja/73.4.464; Drobin D, 2004, J APPL PHYSIOL, V96, P1843, DOI 10.1152/japplphysiol.00530.2003; Ertmer C, 2010, ANESTHESIOLOGY, V112, P936, DOI 10.1097/ALN.0b013e3181d3d493; Frank B, 1999, AM J GASTROENTEROL, V94, P463; Hoste EAJ, 2006, CRIT CARE, V10, DOI 10.1186/cc4915; Huter L, 2009, CRIT CARE, V13, DOI 10.1186/cc7726; Hyderally H, 2002, MT SINAI J MED, V69, P55; JOINT EUR SOC, 2000, J AM COLL CARDIOL, V36, P959; Juelsgaard P, 1998, EUR J ANAESTH, V15, P656; Kauvar DS, 2005, CRIT CARE, V9, P1, DOI 10.1186/cc3779; Keipert PE, 2008, JAMA-J AM MED ASSOC, V300, P1295, DOI 10.1001/jama.300.11.1295-b; Levey AS, 2003, ANN INTERN MED, V139, P137; Lui FE, 2008, BIOCHEMISTRY-US, V47, P10773, DOI 10.1021/bi801116k; Mangano DT, 2006, NEW ENGL J MED, V354, P353, DOI 10.1056/NEJMoa051379; Natanson C, 2008, JAMA-J AM MED ASSOC, V299, P2304, DOI 10.1001/jama.299.19.jrv80007; Nieminen MS, 2005, EUR HEART J, V26, P384; Olofsson C, 2006, ANESTHESIOLOGY, V105, P1153, DOI 10.1097/00000542-200612000-00015; Olofsson C, 2008, TRANSFUSION MED, V18, P28, DOI 10.1111/j.1365-3148.2007.00811.x; Olson JS, 2004, FREE RADICAL BIO MED, V36, P685, DOI 10.1016/j.freeradbiomed.2003.11.030; Riesmeier A, 2009, ANESTH ANALG, V108, P650, DOI 10.1213/ane.0b013e3181923722; Silverman TA, 2009, ANESTHESIOLOGY, V111, P946, DOI 10.1097/ALN.0b013e3181ba3c2c; Sural S, 2000, RENAL FAILURE, V22, P87; Tsai AG, 2006, BLOOD, V108, P3603, DOI 10.1182/blood-2006-02-005272; Tsai AG, 2003, AM J PHYSIOL-HEART C, V285, pH1411, DOI 10.1152/ajpheart.00307.2003; Vandegriff KD, 2008, BIOCONJUGATE CHEM, V19, P2163, DOI 10.1021/bc8002666; Vandegriff KD, 2009, ARTIF ORGANS, V33, P133, DOI 10.1111/j.1525-1594.2008.00697.x; Viele MK, 1997, ANESTHESIOLOGY, V86, P848, DOI 10.1097/00000542-199704000-00015; White HD, 2000, NEW ENGL J MED, V343, P317, DOI 10.1056/NEJM200008033430502; Winslow RM, 2008, BBA-PROTEINS PROTEOM, V1784, P1382, DOI 10.1016/j.bbapap.2008.04.032; Young MA, 2005, CRIT CARE MED, V33, P1794, DOI 10.1097/01.CCM.0000172648.55309.13; Young MA, 2007, J TRAUMA, V63, P1234, DOI 10.1097/TA.0b013e31815bd7b0; Young MA, 2009, J CARDIOTHOR VASC AN, V23, P339, DOI 10.1053/j.jvca.2008.08.006",34,5,5,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0003-2999",null,null,"ANESTH ANALG","Anesth. Analg.","APR",2011,112,4,null,null,null,null,759,773,null,"10.1213/ANE.0b013e31820c7b5f",null,15,"Anesthesiology","Anesthesiology","739ET","WOS:000288697000005"]
[null,null,null,null,"J","Adamek, S; Vyskocil, F",null,null,null,"Adamek, Svatopluk; Vyskocil, Frantisek",null,null,"Potassium-selective microelectrode revealed difference in threshold potassium concentration for cortical spreading depression in female and male rat brain","BRAIN RESEARCH",null,null,"English","Article",null,null,null,null,null,"Spreading depression threshold; Rat cortex; Potassium in brain; Potassium-selective microelectrode; Gender difference","AXON INITIAL SEGMENT; CEREBRAL-ISCHEMIA; ANOXIC DEPOLARIZATION; NEURONAL POLARITY; SODIUM-CHANNELS; MIGRAINE; MECHANISMS; VOLTAGE; PHOSPHORYLATION; MAINTENANCE","It has been found with potassium-selective microelectrodes that the threshold extracellular concentration of potassium [K+](e) for eliciting fast spreading depression from the site of administration 1.5 mm away is 80% lower in the rat female cortex (8.0 +/- 0.6 mM) than in the male cortex (14.4 +/- 0.4 mM). The rate of the first slow phase of [K+](e) rise before reaching the threshold and speed of SD propagation were similar for both sexes as well as the rise of the second active fast phase of the [K+](e) increase. Lower [K+](e) threshold in females can facilitate the rapid K+ release from the nerve tissue cells that may cause a cerebrovascular vasodilatation and the attack of migraine pain. (C) 2010 Elsevier B.V. All rights reserved.","[Vyskocil, Frantisek] Acad Sci Czech Republic, Inst Physiol, Prague 4, Czech Republic; [Adamek, Svatopluk] Charles Univ Prague, Surg Dept 3, Fac Med 1, Prague, Czech Republic; [Vyskocil, Frantisek] Charles Univ Prague, Dept Anim Physiol, Fac Sci, Prague, Czech Republic","Vyskocil, F (reprint author), Acad Sci Czech Republic, Inst Physiol, Videnska 1083, Prague 4, Czech Republic.","vyskocil@biomed.cas.cz",null,null," [IAA500110905];  [AV0Z 0110509]","This study was supported by grants IAA500110905 and AV0Z 0110509.",null,34,4,4,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0006-8993",null,null,"BRAIN RES","Brain Res.","JAN 25",2011,1370,null,null,null,null,null,215,219,null,"10.1016/j.brainres.2010.11.018",null,5,"Neurosciences","Neurosciences & Neurology","717RU","WOS:000287065900020"]
[null,null,null,null,"J","Broulik, PD; Broulikova, A; Adamek, S; Libansky, P; Tvrdon, J; Broulikova, K; Kubinyi, J",null,null,null,"Broulik, P. D.; Broulikova, A.; Adamek, S.; Libansky, P.; Tvrdon, J.; Broulikova, K.; Kubinyi, J.",null,null,"Improvement of Hypertension after Parathyroidectomy of Patients Suffering from Primary Hyperparathyroidism","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY",null,null,"English","Article",null,null,null,null,null,null,"PLASMA-RENIN ACTIVITY; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; HORMONE; PREVALENCE; HUMANS","Background. Primary hyperparathyroidism (PHPT) is one of the most common endocrine conditions and is accompanied by hypertension and increased cardiovascular mortality. The purpose of this study was to evaluate the effect of parathyroidectomy on systolic and diastolic blood pressure (BP) in hypertensive patients with PHPT and whether hypertension occurs more frequently in PHPT than in control group. Methods. A total of 1020 patients with proved PHPT who underwent surgery were compared with with 1020 age, sex, BMI, and smoking status matched controls. We evaluated changes in serum calcium, parathyroid hormone (PTH), uric acid, and BP before and 6 months after surgery. Results. Parathyroidectomy corrected PHPT and resulted in a substantial fall in both mean systolic (150 +/- 3.8 to 138 +/- 3.6mmHg) and mean diastolic pressures (97 +/- 3 to 88 +/- 2.8mmHg) of the hypertensive subjects; P < .01. In these patients, PTH, calcium, and uric acid normalized. 726 patients from 1020 with PHPT (69.8%) were found to be hypertensive whilst only 489 (47.8%) from 1020 of our control group. Conclusion. Parathyroidectomy in hypertensive patients reduces systolic and diastolic BP. PHPT is accompanied by a variety of metabolic complications, which are a risk factor for hypertension, and parathyroidectomy can improve these metabolic complications.","[Broulik, P. D.; Broulikova, A.; Broulikova, K.] Charles Univ Prague, Dept Med 3, Fac Med 1, Prague, Czech Republic; [Adamek, S.; Libansky, P.; Tvrdon, J.] Charles Univ Prague, Dept Surg 3, Fac Med 1, Prague, Czech Republic; [Kubinyi, J.] Charles Univ Prague, Dept Nucl Med, Fac Med 1, Prague, Czech Republic","Broulik, PD (reprint author), Charles Univ Prague, Dept Med 3, Fac Med 1, Prague, Czech Republic.","pbrou@lf1.cuni.cz",null,null,"Ministry of Education Youth and Sports of Czech republic [MSM 0021620807]","This work was supported by the research projects MSM 0021620807 granted by the Ministry of Education Youth and Sports of Czech republic.",null,28,4,4,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","1687-8337","1687-8345",null,"INT J ENDOCRINOL","Int. J. Endocrinol.",null,2011,null,null,null,null,null,null,null,null,309068,"10.1155/2011/309068",null,6,"Endocrinology & Metabolism","Endocrinology & Metabolism","744MC","WOS:000289097600001"]
[null,null,null,null,"J","Plzak, J; Kalitova, P; Urbanova, M; Betka, J",null,null,null,"Plzak, J.; Kalitova, P.; Urbanova, M.; Betka, J.",null,null,"Subcutaneous calcification in the pectoralis major flap: a late complication of radiotherapy","BRITISH JOURNAL OF RADIOLOGY",null,null,"English","Article",null,null,null,null,null,null,null,"Heterotopic calcification following radiotherapy is a very rare event. Here, we report a case of a patient who underwent surgical intervention including pectoralis major flap reconstruction for locally advanced pharyngolaryngeal squamous cell carcinoma with skin invasion. He was followed up post-operatively with adjuvant radiotherapy. 13 years after the treatment, suspect resistance in the myocutaneous flap region appeared and was diagnosed as a calcification. To date, the occurrence of subcutaneous calcification in the myocutaneous flap in the neck has not been described as a late complication of neck irradiation.","[Plzak, J.; Kalitova, P.; Urbanova, M.; Betka, J.] Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Fac Hosp Motol, Prague 15800 5, Czech Republic; [Plzak, J.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 15800 5, Czech Republic; [Kalitova, P.] Charles Univ Prague, Inst Physiol, Fac Med 1, Prague 15800 5, Czech Republic; [Urbanova, M.] Acad Sci Czech Republic, Inst Mol Genet, Dept Genom & Bioinformat, Prague, Czech Republic","Plzak, J (reprint author), Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Fac Hosp Motol, V Uvalu 84, Prague 15800 5, Czech Republic.","jan.plzak@lf1.cuni.cz",null,null,"NPV II [2B06106, 260510]","This study was supported by the grants NPV II 2B06106 and 260510.",null,5,2,2,"BRITISH INST RADIOLOGY","LONDON","36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND","0007-1285",null,null,"BRIT J RADIOL","Br. J. Radiol.","NOV",2011,84,1007,null,null,null,null,"E221","E223",null,"10.1259/bjr/29175509",null,3,"Radiology, Nuclear Medicine & Medical Imaging","Radiology, Nuclear Medicine & Medical Imaging","842AT","WOS:000296558700006"]
[null,null,null,null,"J","Tomka, M; Machovcova, A; Pelclova, D; Petanova, J; Arenbergerova, M; Prochazkova, J",null,null,null,"Tomka, Milan; Machovcova, Alena; Pelclova, Daniela; Petanova, Jitka; Arenbergerova, Monika; Prochazkova, Jarmila",null,null,"Orofacial granulomatosis associated with hypersensitivity to dental amalgam","ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY",null,null,"English","Article",null,null,null,null,null,null,"LYMPHOCYTE-TRANSFORMATION TEST; ORO-FACIAL GRANULOMATOSIS; DELAYED-HYPERSENSITIVITY; DIAGNOSTIC-VALUE; ALLERGY; MERCURY; NICKEL; GOLD; SENSITIVITY; SARCOIDOSIS","Orofacial granulomatosis is a clinicopathologic entity characterized by chronic swelling of the lip and possible soft tissues in the orofacial region owing to granulomatous inflammation of unknown cause. We present 3 cases of orofacial granulomatosis associated with allergic contact dermatitis to dental materials. Previous treatment with corticosteroids did not have any therapeutic effect. Patch testing revealed a positive reaction to several allergens, including dental amalgam and mercury in 2 cases. A lymphocyte transformation test modified for metals was used to evaluate lymphocyte reactivity. After the removal of the suspected allergens, all patients experienced recovery within 1 month, with the exception of the lip swelling, which gradually subsided over several months. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112: 335-341)","[Tomka, Milan; Prochazkova, Jarmila] Charles Univ Prague, Fac Med 1, Inst Dent Res, Prague 12111 2, Czech Republic; [Tomka, Milan; Pelclova, Daniela; Petanova, Jitka; Prochazkova, Jarmila] Gen Univ Hosp, Prague, Czech Republic; [Pelclova, Daniela] Charles Univ Prague, Fac Med 1, Dept Occupat Med, Prague 12111 2, Czech Republic; [Petanova, Jitka] Charles Univ Prague, Fac Med 1, Inst Microbiol & Immunol, Prague 12111 2, Czech Republic; [Arenbergerova, Monika] Charles Univ Prague, Fac Med 3, Dept Dermatovenereol, Prague 12111 2, Czech Republic; [Arenbergerova, Monika] Teaching Hosp Kralovske Vinohrady, Kralovske, Russia","Tomka, M (reprint author), Charles Univ Prague, Fac Med 1, Inst Dent Res, Karlovo Namesti 32, Prague 12111 2, Czech Republic.","tomka@vus.cz","Pelclova, Daniela/D-8922-2014",null,"Czech Ministry of Health [NS 10577-3];  [MZO FNM 2005/6904];  [MSM 0021620807]","Supported by an IGA grant from the Czech Ministry of Health (no. NS 10577-3) and by grants MZO FNM 2005/6904 and MSM 0021620807.",null,30,2,2,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","1079-2104",null,null,"ORAL SURG ORAL MED O","Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.","SEP",2011,112,3,null,null,null,null,335,341,null,"10.1016/j.tripleo.2011.03.030",null,7,"Dentistry, Oral Surgery & Medicine","Dentistry, Oral Surgery & Medicine","804AT","WOS:000293626600025"]
[null,null,null,null,"J","Bartak, V; Hromadka, R; Fulin, P; Jahoda, D; Sosna, A; Popelka, S",null,null,null,"Bartak, V.; Hromadka, R.; Fulin, P.; Jahoda, D.; Sosna, A.; Popelka, S.",null,null,"Anatomical Study of Flexor Hallucis Brevis Insertion. Implications for Clinical Practice","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"flexor hallucis brevis; metatarsophalangeal joint; proximal phalanx; hallux rigidus; hallux valgus","SCARF OSTEOTOMY; RIGIDUS; KELLER; COMPLICATIONS; ARTHROPLASTY; REPLACEMENT; VALGUS","PURPOSE OF THE STUDY The flexor hallucis brevis (FHB) is one of the short muscles of the foot. It divides in front into two portions, which are inserted into the medial and lateral sides of the base of the first phalanx of the great toe. The detailed knowledge of its insertion into the proximal phalangeal base is decisive in any surgery involving the first metatarsophalangeal (MTP) joint, such as implant arthroplasty, resection arthroplasty or amputation. Complications resulting from injury to this insertion are commonly known. The aim of this study was to describe in detail the morphology of FHB insertion sites and to determine a safe extent of resection to be done at the base of the proximal phalanx. MATERIAL AND METHODS In 36 cadaver specimens we measured FHB insertion length from the plantar side of the proximal phalangeal base and from the plane perpendicular to the long axis of the phalanx and passing through the base of the concave articular surface of the phalanx. RESULTS Measured from the plantar base of the proximal phalanx, the mean length of the medial insertion site was 11.5 +/- 0.9 mm (range, 9.5 to 13.0 mm) and that of the lateral insertion site was 9.5 +/- 1.1 mm (range, 8.0 to 11.5 mm). After resection, the mean values for medial and lateral FBH insertion sites were 8.5 +/- 1.7 mm (range, 6.5 to 11.0 mm) and 7.1 +/- 1.4 mm (range, 5.5 to 9.5 mm), respectively. The mean total proximal phalangeal length was 33.1 +/- 2.2 mm (range, 28.5 to 37.0 mm), reduced after resection to 30.5 +/- 2.1 mm (range, 26.0 to 34.5 mm). DISCUSSION Our results show that the medial insertion site, where the medial FHB tendon and distal part of the abductor hallucis muscle are joining, is longer than the lateral site. Therefore the length of the lateral site is decisive for preserving FHB function. Since the plane perpendicular to the long axis of the phalanx and passing through the base of the concave articular surface of the phalanx is almost identical with the beginnings of FHB insertions, it seems optimal for clinical practice to perform the initial resection along this plane. CONCLUSIONS To preserve at least one third of the FHB insertion, the final resection should not exceed 4 mm or 13% of the proximal phalangeal length, as measured from the reference plane defined above.","[Bartak, V.; Hromadka, R.; Fulin, P.; Jahoda, D.; Sosna, A.; Popelka, S.] FN Motol, LF UK 1, Ortopedicka Klin 1, Prague 5, Czech Republic; [Hromadka, R.] LF UK 1, Anatom Ustav, Prague, Czech Republic","Bartak, V (reprint author), FN Motol, LF UK 1, Ortopedicka Klin 1, V Uvalu 84, Prague 5, Czech Republic.","vbartak@email.cz",null,null,null,null,null,18,2,2,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2011,78,2,null,null,null,null,145,148,null,null,null,4,"Orthopedics","Orthopedics","764OL","WOS:000290641200009"]
[null,null,null,null,"J","Stolz, A; Pafko, P; Harustiak, T; Smejkal, M; Simonek, J; Schutzner, J; Lischke, R",null,null,null,"Stolz, A.; Pafko, P.; Harustiak, T.; Smejkal, M.; Simonek, J.; Schutzner, J.; Lischke, R.",null,null,"Risk factor analysis for early mortality and morbidity following pneumonectomy for non-small cell lung cancer","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"pneumonectomy; mortality; lung cancer","BRONCHOPLEURAL FISTULA; INDUCTION CHEMOTHERAPY; COMPLICATIONS; RESECTION; THERAPY; CARCINOMA; INCREASE","Objectives: The purpose of this report is to analyze factors affecting morbidity and mortality following pneumonectomy for non-small cell lung cancer (NSCLC). Methods: We reviewed our institutional experience with all consecutive patients undergoing pneumonectomy for NSCLC from 1998 to 2010. Patients were analyzed with regard to hospital mortality and morbidity and long-term outcome. Results: There were 310 patients following pneumonectomy. Overall 30-day mortality rate was 5.5%. Chronic obstructive pulmonary disease, induction therapy, smoking habits and obesity had no statistical influence on short-term outcome. Coronary artery disease and respiratory failure were identified as risk factors for increased 30-day mortality (p<0.01). Right pneumonectomy and presence of respiratory failure with mechanical ventilation increases the incidence of bronchopleural fistula (p<0.01). Conclusions: Patients with right pneumonectomies are at increased risk. Coronary artery disease and respiratory failure adversely affect morbidity and mortality after this procedure (Tab. 3, Ref. 19). Full Text in free PDF www.bmj.sk.","[Stolz, A.; Pafko, P.; Harustiak, T.; Smejkal, M.; Simonek, J.; Schutzner, J.; Lischke, R.] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, CZ-15000 Prague 5, Czech Republic","Stolz, A (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, V Uvalu 84, CZ-15000 Prague 5, Czech Republic.","stolz@seznam.cz",null,null,null,null,null,19,2,2,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248",null,null,"BRATISL MED J","Bratisl. Med. J.",null,2011,112,4,null,null,null,null,165,169,null,null,null,5,"Medicine, General & Internal","General & Internal Medicine","749WW","WOS:000289503300002"]
[null,null,null,null,"J","Fulin, P; Bartak, V; Pokorny, D; Jahoda, D; Tomaides, J; Sosna, A",null,null,null,"Fulin, P.; Bartak, V; Pokorny, D.; Jahoda, D.; Tomaides, J.; Sosna, A.",null,null,"Long-Term Results of the SVL Total Knee Arthroplasty","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"total knee arthroplasty; total joint replacement; Kaplan-Meier; SVL","CLINICAL-PRACTICE; SYSTEM; MINIMUM","PURPOSE OF THE STUDY The aim of the study was to evaluate the long-term results of the total knee replacement Beznoska SVL implanted at the 1st Department of Orthopaedic Surgery, 1st Faculty of Medicine, Charles University and Motol University Hospital Prague, in the 1997/2009 period. MATERIAL AND METHODS The SVL implant is a non-constrained knee replacement, anatomically similar to the bone it replaces, which preserves the posterior cruciate ligament. A total of 1101 knee joint replacements were evaluated in 973 patients, of whom 128 underwent bilateral arthroplasty. Kaplan-Meier curves were used to estimate the cumulative survival of implants. Clinical outcomes were assessed using the Knee Society clinical rating system (KS score) and radiographic data evaluation was also included. RESULTS Using KS scores, the results were excellent in 997, good in 75, satisfactory in 19 and poor in 10 knees. The average range of motion was 0.16 to 106.31 degrees. The complications included flexion contracture, as the most frequent problem (13 knees), 10 knees were infected, aseptic loosening due to polyethylene granuloma was found in eight knees and anterior knee pain was experienced in six cases. At follow-up of 12.5 years implant survivorship was 98 %, as evaluated by the Kaplan-Meier analysis. DISCUSSION A comparison of SVL implant survivorship with other knee replacement designs is discussed. It should be emphasized that the clinical outcome depends not only on implant quality, but also on the operative technique used and the surgeon's experience and skills. It is the SVL system that allows for the balancing of knee joint stability and thus enables even less experienced surgeons to make use of a more sophisticated implantation technique. CONCLUSIONS Total knee replacement using the SVL Beznoska implant is a safe, reliable and economic treatment with excellent clinical outcomes.","[Fulin, P.; Bartak, V; Pokorny, D.; Jahoda, D.; Tomaides, J.; Sosna, A.] FN Molol, Ortoped Klin 1, LF UK Praha 1, Prague 15006 5, Czech Republic","Pokorny, D (reprint author), FN Molol, Ortoped Klin 1, LF UK Praha 1, V Uvalu 84, Prague 15006 5, Czech Republic.","david.pokorny@lf1.cuni.cz",null,null,null,null,"Dalury DF, 2008, J ARTHROPLASTY, V23, P175, DOI 10.1016/j.arth.2007.03.039; Dixon MC, 2005, J BONE JOINT SURG AM, V87A, P598, DOI 10.2106/JBJS.C.00591; DUNGL P., 2005, Ortopedie; EWALD FC, 1989, CLIN ORTHOP RELAT R, P9; Fulin P, 2011, ACTA CHIR ORTHOP TR, V78, P131; Horak Z, 2010, ACTA CHIR ORTHOP TR, V77, P463; INSALL JN, 1989, CLIN ORTHOP RELAT R, P13; Koudela K, 2010, ACTA CHIR ORTHOP TR, V77, P304; Krbec M, 2004, Acta Chir Orthop Traumatol Cech, V71, P179; Kubes R, 2003, Acta Chir Orthop Traumatol Cech, V70, P39; Parsch D, 2009, INT ORTHOP, V33, P431, DOI 10.1007/s00264-008-0543-x; Pokorny D, 2005, Acta Chir Orthop Traumatol Cech, V72, P277; Pokorny D, 2010, ACTA CHIR ORTHOP TR, V77, P470; Santini AJA, 2008, INT ORTHOP, V32, P459, DOI 10.1007/s00264-007-0351-8; Schai PA, 1998, J BONE JOINT SURG BR, V80B, P850, DOI 10.1302/0301-620X.80B5.8368; Starek M, 2004, Acta Chir Orthop Traumatol Cech, V71, P352; Vavrik P, 2000, Acta Chir Orthop Traumatol Cech, V67, P121; Vavrik P, 2009, ACTA CHIR ORTHOP TR, V76, P30",18,2,2,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2011,78,6,null,null,null,null,524,527,null,null,null,4,"Orthopedics","Orthopedics","871XQ","WOS:000298771400006"]
[null,null,null,null,"J","Brestak, M; Sonek, J; Tomek, V; McKenna, D; Calda, P",null,null,null,"Brestak, Miroslav; Sonek, Jiri; Tomek, Viktor; McKenna, David; Calda, Pavel",null,null,"Shortening fraction of the right ventricle: a comparison between euploid and trisomy 21 fetuses at week 11 to week 13 and 6 days of gestation","PRENATAL DIAGNOSIS",null,null,"English","Article",null,null,null,null,null,"trisomy 21; first trimester; marker; shortening fraction of the right ventricle","PULMONARY VASCULAR-DISEASE; ATRIOVENTRICULAR SEPTAL-DEFECT; DOWN-SYNDROME; CARDIAC DEVELOPMENT; AIRWAY-OBSTRUCTION; FETAL; CHILDREN; HYPERTENSION; PREGNANCY; INFANTS","Objectives This study was designed to compare the first trimester shortening fraction of the right ventricle (SFRV) values between euploid fetuses and fetuses with trisomy 21. Methods SFRV was measured in 58 first trimester fetuses between September 2008 and February 2010. The stored M-mode images were used to obtain the right ventricular diastolic diameter (RVDD) and right ventricular systolic diameter (RVSD) measurements offline. Results The SFRV values were found to be significantly greater in the 9 fetuses with trisomy 21 as compared to the group of 49 euploid fetuses (mean: 48.6 mm; range: 36-56.25 mm vs mean: 34.11 mm; range: 22.73-43.48 mm) (p < 0.0001). The RVDD measurements were also found to be significantly greater in the fetuses with trisomy 21 than in the euploid fetuses (mean: 3.08 mm; range: 2.2-4.7 mm vs mean: 2.54 mm; range: 1.9-3.6 mm) (p = 0.03). There was no difference in the RVSD measurements between the two groups [mean: 1.56 mm; range: 1.2-2.3 mm (trisomy 21 fetuses) vs mean: 1.67 mm; range: 1.3-2.4 mm (euploid fetuses)] (p = 0.17). Conclusions The SFRV values in fetuses with trisomy 21 appear to be significantly greater than in the euploid fetuses. The RVDD also appears to be greater in fetuses with trisomy 21 than in the euploid fetuses. Copyright (C) 2011 John Wiley & Sons, Ltd.","[Brestak, Miroslav; Calda, Pavel] Charles Univ Prague, Fetal Med Ctr, Sch Med 1, Dept Obstet & Gynecol, Prague 12852 2, Czech Republic; [Brestak, Miroslav; Calda, Pavel] Gen Univ Hosp, Prague, Czech Republic; [Sonek, Jiri; McKenna, David] Fetal Med Fdn USA, Dayton, OH USA; [Sonek, Jiri; McKenna, David] Wright State Univ, Dayton, OH 45435 USA; [Tomek, Viktor] Univ Hosp Motol, Kardioctr & Cardiovasc Res Ctr, Prague, Czech Republic","Calda, P (reprint author), Charles Univ Prague, Fetal Med Ctr, Sch Med 1, Dept Obstet & Gynecol, Apolinarska 18, Prague 12852 2, Czech Republic.","calda@gynstart.cz",null,null,null,null,null,33,1,1,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0197-3851",null,null,"PRENATAL DIAG","Prenat. Diagn.","AUG",2011,31,8,null,null,null,null,760,764,null,"10.1002/pd.2760",null,5,"Genetics & Heredity; Obstetrics & Gynecology","Genetics & Heredity; Obstetrics & Gynecology","805QA","WOS:000293742900004"]
[null,null,null,null,"J","Vranova, J; Vinakurau, S; Richter, J; Starec, M; Fiserova, A; Rosina, J",null,null,null,"Vranova, Jana; Vinakurau, Stepan; Richter, Jan; Starec, Miroslav; Fiserova, Anna; Rosina, Jozef",null,null,"The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques","RADIATION ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"3-dimensional conformal radiotherapy (3DCRT); gastrointestinal and genitourinary toxicity; prostate cancer; NK cells; PTV parameters; pelvic bone marrow","STEREOTACTIC BODY RADIOTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; DOSE-VOLUME ANALYSIS; QUALITY-OF-LIFE; RADIATION-THERAPY; IRRADIATION; INCONTINENCE; COMBINATION; PREDICTORS; ANTIGEN","Background: Our research compared whole pelvic (WP) and prostate-only (PO) 3-dimensional conformal radiotherapy (3DCRT) techniques in terms of the incidence and evolution of acute and late toxicity of the rectum and urinary bladder, and identified the PTV-parameters influencing these damages and changes in antitumor immune response. Methods: We analyzed 197 prostate cancer patients undergoing 3DCRT for gastrointestinal (GI) and genitourinary (GU) toxicities, and conducted a pilot immunological study including flow cytometry and an NK cell cytotoxicity assay. Acute and late toxicities were recorded according to the RTOG and the LENT-SOMA scales, respectively. Univariate and multivariate analyses were conducted for factors associated with toxicity. Results: In the WP group, an increase of acute rectal toxicity was observed. A higher incidence of late GI/GU toxicity appeared in the PO group. Only 18 patients (WP-7.76% and PO-11.11%) suffered severe late GI toxicity, and 26 patients (WP-11.21% and PO-16.05%) severe late GU toxicity. In the majority of acute toxicity suffering patients, the diminution of late GI/GU toxicity to grade 1 or to no toxicity after radiotherapy was observed. The 3DCRT technique itself, patient age, T stage of TNM classification, surgical intervention, and some dose-volume parameters emerged as important factors in the probability of developing acute and late GI/GU toxicity. The proportion and differentiation of NK cells positively correlated during 3DCRT and negatively so after its completion with dose-volumes of the rectum and urinary bladder. T and NKT cells were down-regulated throughout the whole period. We found a negative correlation between leukocyte numbers and bone marrow irradiated by 44-54 Gy and a positive one for NK cell proportion and doses of 5-25 Gy. The acute GU, late GU, and GI toxicities up-regulated the T cell (CTL) numbers and NK cytotoxicity. Conclusion: Our study demonstrates the association of acute and late damage of the urinary bladder and rectum, with clinical and treatment related factors. The 3DCRT itself does not induce the late GI or GU toxicity and rather reduces the risk of transition from acute to late toxicity. We have described for the first time the correlation between organs at risk, dose-volume parameters, and the immunological profile.","[Richter, Jan; Fiserova, Anna] Acad Sci Czech Republic, Inst Microbiol, Dept Immunol & Gnotobiol, Vvi, Prague, Czech Republic; [Vranova, Jana; Starec, Miroslav; Rosina, Jozef] Charles Univ Prague, Fac Med 3, Dept Med Biophys & Med Informat, Prague, Czech Republic; [Vinakurau, Stepan] Charles Univ Prague, Dept Radiotherapy & Oncol, Motol Univ Hosp, Prague, Czech Republic; [Vranova, Jana; Rosina, Jozef] Czech Tech Univ, Fac Biomed Engn, Kladno, Czech Republic","Fiserova, A (reprint author), Acad Sci Czech Republic, Inst Microbiol, Dept Immunol & Gnotobiol, Vvi, Prague, Czech Republic.","fiserova@biomed.cas.cz",null,null,"Grant agency of the Charles University; GAUK [109908/2008]; Grant agency of the Academy of Sciences of the Czech Republic [IAA500200620]","We thank Drs. Bela Malinova, Anna Kindlova, Jana Prausova, and Michaela Matouskova for excellent cooperation and valuable comments. The work was supported by the Grant agency of the Charles University, GAUK 109908/2008 and the Grant agency of the Academy of Sciences of the Czech Republic, IAA500200620.",null,40,1,1,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1748-717X",null,null,"RADIAT ONCOL","Radiat. Oncol.","JUL 27",2011,6,null,null,null,null,null,null,null,87,"10.1186/1748-717X-6-87",null,13,"Oncology; Radiology, Nuclear Medicine & Medical Imaging","Oncology; Radiology, Nuclear Medicine & Medical Imaging","813ER","WOS:000294350100001"]
[null,null,null,null,"J","Veigl, D; Vavrik, P; Pokorny, D; Slouf, M; Pavlova, E; Landor, I",null,null,null,"Veigl, D.; Vavrik, P.; Pokorny, D.; Slouf, M.; Pavlova, E.; Landor, I.",null,null,"Comparison of in Vivo Characteristics of Polyethylene Wear Particles Produced by a Metal and a Ceramic Femoral Component in Total Knee Replacement","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"total knee replacement; zirconia ceramic femoral component; comparative study; polyethylene wear; in vivo measurement","MOLECULAR-WEIGHT POLYETHYLENE; UHMWPE WEAR; TOTAL HIP; PERIPROSTHETIC OSTEOLYSIS; JOINT REPLACEMENT; SYNOVIAL-FLUID; ARTHROPLASTY; QUANTIFICATION; PROSTHESIS; TISSUES","PURPOSE OF THE STUDY The aim of the study was to evaluate in vivo and compare, in terms of the quality and number of ultra high-molecular polyethylene (UHMWPE) wear particles, total knee replacements of identical construction differing only in the material used for femoral component production, i.e., CoCrMo alloy or ZrO2 ceramics. MATERIAL AND METHODS Samples of pen-prosthetic granuloma tissue were collected in two patients with total knee replacement suffering from implant migration, who were matched in relevant characteristics. The primary knee replacement in Patient 1 with a CoCrMo femoral component was done 7.2 years and in Patient 2 with a ZrO2 implant 6.8 years before this assessment. The polyethylene wear-induced granuloma was analysed by the MORF method enabling us to assess the shape and size of wear debris and the IRc method for assessment of particle concentration. RESULTS In the granuloma tissue samples of Patient 1, on the average, particles were 0.30 mm in size and their relative volume was 0.19. In the Patient 2 tissue samples, the average size of particles was 0.33 mm and their relative volume was 0.26. There was no significant difference in either particle morphology or their concentration in the granuloma tissue between the two patients. DISCUSSION One of the options of how to reduce the production of polyethylene wear particles is to improve the tribological properties of contacting surfaces in total knee replacement by substituting a cobalt-chrome femoral component with a zirconia ceramic femoral component. The previous in vitro testing carried out with a mechanical simulator under conditions approaching a real weight-bearing in the human body did show a nearly three-fold decrease in the number of UHMWPE wear particles in zirconia components. The evaluation of granuloma tissue induced by the activity of a real prosthetic joint for nearly seven years, however, did not reveal any great difference in either quality or quantity of polyethylene debris between the two replacements. The difference of surface roughness between CoCrMo (Ra = 0.05) and ZrO2 (Ra = 0.02) components did not play any role in in vivo conditions. CONCLUSIONS In accordance with a previous clinical study, this evaluation of the quality and quantity of UHMWPE wear particles produced by a ceramic femoral component in vivo failed to demonstrate any advantage of zirconia ceramic components over the cobalt-chrome femoral components so far used.","[Veigl, D.; Vavrik, P.; Pokorny, D.; Landor, I.] I Ortoped Klin 1 LF UK, Prague 15000 5, Czech Republic; [Veigl, D.; Vavrik, P.; Pokorny, D.; Landor, I.] FN Motol, Prague, Czech Republic; [Slouf, M.; Pavlova, E.] Ustav Makromol Chem AV CR, Prague, Czech Republic","Vavrik, P (reprint author), I Ortoped Klin 1 LF UK, V Uvalu 83, Prague 15000 5, Czech Republic.","pvavrik@atlas.cz","Slouf, Miroslav/F-6311-2012","Slouf, Miroslav/0000-0003-1528-802X",null,null,null,49,1,1,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2011,78,1,null,null,null,null,49,55,null,null,null,7,"Orthopedics","Orthopedics","731XJ","WOS:000288143500008"]
[null,null,null,null,"J","Stolz, A; Pafko, P; Lischke, R; Harustiak, T; Simonek, J; Schutzner, J; Adamek, S",null,null,null,"Stolz, A.; Pafko, P.; Lischke, R.; Harustiak, T.; Simonek, J.; Schutzner, J.; Adamek, S.",null,null,"Time trend in the surgical therapy of lung cancer","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"lung cancer; mortality; time trends","CARCINOMA; RESECTION; SURVIVAL; LONG","Background: The purpose of our study was to clarify results of surgery for non-small cell lung cancer (NSCLC) and its time trends. Methods: We retrospectively reviewed our prospective database of patients who underwent surgery for NSCLC between 1998 and 2009 in our institution. Patients were divided into two equal 6-year periods according to the year of surgery (1998-2003 and 2004-2009). Results: One thousand, four hundred and twelve patients underwent operation for NSCLC. We performed 985 lobectomies with 30-days mortality of 1.8 % and 300 pneumonectomies with 30-days mortality of 5.7 %. Median of survival of all 1412 patients was 4.3 year and 5-year survival was 45 %. The percentage of female patients, lobectomies and adenocarcinomas increased over time, as well as the age of our patients. Outcome improved over time, with significant decrease in a 30-days mortality after pneumonectomy (8.2 % vs 2.3 %, p=0.029). The overall 3-year survival improved in patients with stage III (30 % vs 40 %, p=0.012). Conclusion: Outcomes of lung resection for NSCLC improved over time despite a worsening of some elements of preoperative status. The shift in histological distribution was associated with an increasing proportion of patients with stage I, a lower operative mortality and better 3- and 5-year survival. These trends are due to improvement of preoperative evaluation, preoperative and postoperative care (Tab. 1, Fig. 2, Ref. 9). Full Text in free PDF www.bmj.sk.","[Stolz, A.; Pafko, P.; Lischke, R.; Harustiak, T.; Simonek, J.; Schutzner, J.; Adamek, S.] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, CZ-15000 Prague 5, Czech Republic","Adamek, S (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, V Uvalu 84, CZ-15000 Prague 5, Czech Republic.","sadamek@post.cz",null,null,null,null,null,9,1,1,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248",null,null,"BRATISL MED J","Bratisl. Med. J.",null,2011,112,4,null,null,null,null,174,176,null,null,null,3,"Medicine, General & Internal","General & Internal Medicine","749WW","WOS:000289503300004"]
[null,null,null,null,"J","Tomek, V; Janousek, J; Reich, O; Gilik, J; Gebauer, RA; Skovranek, J",null,null,null,"Tomek, V.; Janousek, J.; Reich, O.; Gilik, J.; Gebauer, R. A.; Skovranek, J.",null,null,"Atrioventricular Conduction Time in Fetuses Assessed by Doppler Echocardiography","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Atrioventricular block; Prenatal ultrasonography; Fetus; Doppler echocardiography","CONGENITAL HEART-BLOCK; NEONATAL LUPUS; PR INTERVAL; FETAL; ANTIBODIES; THERAPY; REGISTRY; MOTHERS; WOMEN; RISK","We performed measurement of mechanical atrioventricular conduction time intervals in human fetuses assessed by Doppler echocardiography and provided reference values. We found that atrioventricular conduction time interval was prolonged with gestational age and decreased with increasing fetal heart rate. No correlation between gestational age and heart rate was found. Using normal limits established by this study, mechanical atrioventricular interval > 135 ms in the 20(th) week and/or > 145 ms in the 26(th) week of gestation could be suspected of having the first-degree AV block. We compared reference values with fetuses of mothers with anti-SSA Ro/SSB La autoantibodies, being in risk of isolated congenital heart block development. One of 21 fetuses of mothers with positive autoantibodies was affected by prolonged atrioventricular interval according to the established limits, with sinus rhythm after the birth.","[Tomek, V.; Janousek, J.; Reich, O.; Gilik, J.; Gebauer, R. A.; Skovranek, J.] Univ Hosp Motol, Kardioctr & Cardiovasc Res Ctr, Prague 15008 5, Czech Republic","Tomek, V (reprint author), Univ Hosp Motol, Kardioctr & Cardiovasc Res Ctr, V Uvalu 84, Prague 15008 5, Czech Republic.","viktor.tomek@fnmotol.cz",null,null,"Czech Ministry of Health [MZOFNM2005]","The publication was supported by a grant of the Czech Ministry of Health (MZOFNM2005).",null,22,1,1,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2011,60,4,null,null,null,null,611,616,null,null,null,6,"Physiology","Physiology","822OD","WOS:000295057100003"]
[null,null,null,null,"J","Guttler, K; Landor, I; Vavrik, P; Popelka, S; Sosna, A; Krasensky, J",null,null,null,"Guettler, K.; Landor, I.; Vavrik, P.; Popelka, S.; Sosna, A.; Krasensky, J.",null,null,"Total Elbow Replacement in Patients with Rheumatoid Arthritis","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"total elbow arthroplasty; unconstrained; semi-constrained; Souter-Strathclyde; Coonrad-Morrey","TERM-FOLLOW-UP; ARTHROPLASTY; PROSTHESIS; EXPERIENCE; IMPLANT; WEAR","PURPOSE OF THE STUDY Total elbow arthroplasty is associated with a higher occurrence of complications than is usual for large-joint replacements. Two kinds of prostheses, unconstrained and semi-constrained, are currently used and each has its supporters or opponents. In this study the results of the two techniques used in our patients are evaluated and compared. MATERIAL Two groups of elbows in patients with rheumatoid arthritis were evaluated. One comprised 58 elbows treated by Souter-Strathclyde total elbow arthroplasty (S-S group). The mean age of the patients at the time of surgery was 53 years (range, 22 to 71) and the mean follow-up was 9.5 years (range, 0.7 to 16.7). The other group included 63 elbows treated by Coonrad-Morrey elbow arthroplasty (C-M group). The mean age of the patients at the time of surgery was 54 years (range, 26 to 75) and the mean follow-up was 4.21 years (range, 0.28 to 7.87). METHODS The Kaplan-Meier analysis was used to estimate implant survival in each group. Clinical assessment included range of motion and pain experience. The Mayo Elbow Performance Score (MEPS) was used as a clinical rating scale for the whole group. Radiographs were taken in two basic projections. The elbows with an implant removed or re-implanted were excluded from the evaluation. The patients were studied prospectively. The results were statistically analysed, with the level of significance set at 0.05. RESULTS All patients experienced pain relief after surgery. In the S-S group, 35 elbows were free from pain (77.7 %), in the C-M group this was 53 elbows (88.3 %). The range of motion improved after arthroplasty in both groups. Flexion more than 110 degrees was achieved in twice as many elbows in the C-M group than in the S-S group. Flexion contracture in the S-S group did not improve significantly. MEPS values after surgery improved in both groups, with significantly better results in the C-M group. In the S-S group, four elbow arthroplasties (6.9 %) showed instability, which was treated by replacement with a semi-constrained implant in one case and managed by articulated external fixation of the elbow for 6 weeks in three cases. Radiolucent lines were detected in five replacements (11.1 %) along the whole ulnar component width, in 12 (26.6 %) in the olecranon region and in 14 (31.1 %) in the distal humeral component. In the C-M group no radiolucency was recorded around the component. In the S-S group, revision surgery was carried out in 13 arthroplasties (22.4 %); of these, 10 (17.2 %) were due to aseptic loosening, one (1.7 %) due to instability and one (1.7 %) because of deep infection. In the C-M group, three elbows required revision (4.8 %), one for periprosthetic fracture (1.6 %) and two for deep infection (3.2 %). The results of survival analysis did not differ between the two groups. DISCUSSION The weak point of Souter-Strathclyde total elbow arthroplasty is the ulnar component whose impairment and subsequent wear are involved in all cases of aseptic loosening. An insufficient length of the humeral component is another risk factor. Even natural movements of the elbow joint produce concentration of stresses on a small surface; this gradually weakens component fixation in bone and results in aseptic loosening. A higher risk of failure in Coonrad-Morrey elbow arthroplasty is associated with polyethylene lining of the hinge mechanism. CONCLUSIONS The Coonrad-Morrey total elbow replacement is at present considered the method of choice. It is easier to perform and provides better functional outcomes than the Souter-Strathclyde elbow implant.","[Guettler, K.; Landor, I.; Vavrik, P.; Popelka, S.; Sosna, A.; Krasensky, J.] FN Motole, Ortoped Klin LF UK I 1, Prague 15006 5, Czech Republic","Landor, I (reprint author), FN Motole, Ortoped Klin LF UK I 1, V Uvalu 84, Prague 15006 5, Czech Republic.","landor@atlas.cz",null,null,null,null,"Aldridge JM, 2006, J BONE JOINT SURG BR, V88B, P509, DOI 10.1302/0301-620X.88B4; BOEREMA L, 1942, ACTA CHIR SCAND, V86, P511; Dainton JN, 2002, J SHOULDER ELB SURG, V11, P486, DOI 10.1067/mse.2002.124528; EWALD FC, 1980, J BONE JOINT SURG AM, V62, P1259; GARRETT JC, 1977, CLIN ORTHOP RELAT R, P170; Gill DRJ, 1998, J BONE JOINT SURG AM, V80A, P1327; Goldberg SH, 2008, J BONE JOINT SURG AM, V90A, P609, DOI [10.2106/JBJS.F.01286, 10.2106/JBJS.F.O1286]; Gschwend N, 1999, J BONE JOINT SURG BR, V81B, P1005, DOI 10.1302/0301-620X.81B6.9495; Ikavalko M, 2002, J BONE JOINT SURG BR, V84B, P77, DOI 10.1302/0301-620X.84B1.11848; Kleinman WB, 1999, J HAND SURG-AM, V24A, P886; KUDO H, 1990, J BONE JOINT SURG AM, V72A, P355; Landor I, 2006, J BONE JOINT SURG BR, V88B, P1460, DOI 10.1302/0301-620X.88B11.17807; Landor I, 1994, Acta Chir Orthop Traumatol Cech, V61, P68; Landor I, 2009, ACTA CHIR ORTHOP TR, V76, P172; Lee BP, 2005, J BONE JOINT SURG AM, V87A, P1080, DOI 10.2106/JBJS.D.02163; Little CP, 2005, J BONE JOINT SURG AM, V87A, P2439, DOI 10.2106/JBJS.D.02927; Morrey BF, 1993, ELBOW ITS DISORDERS, P74; MORREY BF, 1992, J BONE JOINT SURG AM, V74A, P479; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P1050; POLL RG, 1994, SOUTER STRATHCLYDE T, P200; DEE R, 1972, Journal of Bone and Joint Surgery British Volume, V54, P88; Rahme H, 2002, ACTA ORTHOP SCAND, V73, P251, DOI 10.1080/000164702320155202; Rozing P, 2000, J BONE JOINT SURG BR, V82B, P1129, DOI 10.1302/0301-620X.82B8.10148; Rozkydal Z, 2009, ACTA CHIR ORTHOP TR, V76, P281; SCHLEIN AP, 1976, CLIN ORTHOP RELAT R, P222; SOUTER WA, 1985, ELBOW JOINT; SOUTER WA, 1981, ENG MED, V10, P59; Throckmorton T, 2010, J BONE JOINT SURG AM, V92A, P1432, DOI 10.2106/JBJS.I.00145; Trail IA, 1999, J BONE JOINT SURG BR, V81B, P80, DOI 10.1302/0301-620X.81B1.8440; VALSTAR LR, 2002, ACTA ORTHOP SCAND, V73, P264; van der Lugt JCT, 2004, J BONE JOINT SURG AM, V86A, P465; Van Gorder GW, 1940, J BONE JOINT SURG, V22, P278; Vavrik P, 2009, ACTA CHIR ORTHOP TR, V76, P30",33,1,1,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","OCT",2011,78,5,null,null,null,null,423,430,null,null,null,8,"Orthopedics","Orthopedics","853MK","WOS:000297430200006"]
[null,null,null,null,"J","Judl, T; Jahoda, D; Landor, I; Pokorny, D; Melichercik, P; Sosna, A",null,null,null,"Judl, T.; Jahoda, D.; Landor, I.; Pokorny, D.; Melichercik, P.; Sosna, A.",null,null,"Cement-within-Cement Femoral Stem Reimplantation Technique","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"revision THA; bone cement; cement-within-cement; stem loosening; wear","TOTAL HIP-ARTHROPLASTY; REVISION; JOINT","PURPOSE OF THE STUDY The reimplantation of a cemented femoral component at revision is always a challenge for the orthopaedic surgeon, particularly when the cement mantle is intact. The aim of this study was to provide evidence that the recementing of a femoral stem into the original cement mantle can be included in routine surgical procedures. MATERIAL AND METHODS A group of 104 patients with femoral stem revision, followed-up for an average of 50.2 months, were retrospectively reviewed. The outcome evaluation was focused, in the first place, on survivorship of the femoral component, acetabular migration, and dislocation and infection after revision arthroplasty. Hip function evaluation was based on the Harris hip scores before surgery and at the latest follow-up. On radiographs Gruen zones were assessed pre-operatively and at the latest follow-up. The results were statistically evaluated using the Kaplan-Meier survival analysis (Statistica 8.0). RESULTS Of the 104 patients, only three (2.9 %) had stem re-revision due to its loosening. Further 16 patients underwent revision for other post-operative complications. The success rate of reimplantation in our group including all post-operative complications was 81.7 %. The average Harris scores were 56 before surgery and 87 at the latest follow-up. Radiolucent lines in Gruen zones were on average 0.45 mm in width before revision and 0.15 mm at the latest follow-up. Fourteen patients had second revision within 20 months of the first and only five were revised after a long period. DISCUSSION The cement-within-cement exchange of a femoral component is a relatively frequent orthopaedic procedure. Despite this frequency, however, there have not been enough literature reports based on large patient groups to give support to its routine use. The aim of this study was to demonstrate on a large patient group that recementing a femoral stem into the original intact cement mantle can be considered an established operative technique. Our results suggest that the list of indications for this technique, as described by Lieberman and Nelson, can be extended by the following: broken stem with an intact distal cement mantle, replacement of a monoblock femoral component due to severe head damage, loosening of the femoral component without impairment of the distal cement mantle, conversion of a cervico-capital to a total hip replacement and the need of removing all bone cement. No risk is associated with reimplantation of the original component if there is no need for a different implant to correct angle or length stability. A new implant is always used when any part of the femoral component has been damaged mechanically. If only the proximal stem requires recementing, the use of the original component is preferred because of absolute cement/stem cohesion. The number of our patients in which the technique failed was generally in agreement with the results of other authors. CONCLUSIONS Utilisation of the original cement mantle of a femoral component is one of the options at revision arthroplasty. It requires rational considerations based on the type of surgery, state of the cement mantle, and type of material used for the femoral stem. The method is indicated preferably in the hips with an intact cement mantle treated for loosening of the acetabular component, recurrent dislocation or unequal leg-length in monoblock femoral components. In such situations the removal of well-fixed cement would also involve a considerable loss of bone tissue. The follow-up outcomes showed that the involvement of the cement-within-cement technique in routinely used surgical procedures is fully justified.","[Judl, T.; Jahoda, D.; Landor, I.; Pokorny, D.; Melichercik, P.; Sosna, A.] 1 Ortoped Klin 1 LF UK FN & Motol, Prague, Czech Republic","Jahoda, D (reprint author), 1 Ortoped Klin 1 LF UK, V Uvalu 84, Prague 15006 5, Czech Republic.","david.jahoda@post.cz",null,null,null,null,null,26,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","OCT",2011,78,5,null,null,null,null,416,422,null,null,null,7,"Orthopedics","Orthopedics","853MK","WOS:000297430200005"]
[null,null,null,null,"J","Adamek, S; Libansky, P; Lischke, R; Foltan, R; Kubinyi, J; Broulik, P",null,null,null,"Adamek, S.; Libansky, P.; Lischke, R.; Foltan, R.; Kubinyi, J.; Broulik, P.",null,null,"Surgical Therapy of Primary Hyperparathyrodism in the Context of Orthopaedic Diagnosis and Treatment: Our Experiences in 441 Patients","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"primary hyperparathyroidism; surgical treatment; hyperparathyroid osteodystrophy; hungry bone syndrome","HUNGRY BONE SYNDROME; PARATHYROID CARCINOMA","PURPOSE OF THE STUDY Primary hyperparathyroidism is an endocrine disorder affecting calcium and phosphate metabolism. It is surgically treated by removing hyperfunctional parathyroid tissue. The aim of the study was to show, based on surgical results, that the introduction of serum calcium screening in orthopaedic therapy is effective. The detection of hypercalcemia and diagnosis of primary hyperparathyroidism allow for a good timing of endocrine surgery in relation to an orthopaedic procedure. MATERIAL AND METHODS This retrospective study included 441 patients in the age range of 18 to 83 years who underwent parathyroidectomy between 2004 and 2007. Skeletal disorders were diagnosed by clinical, radiographic and densitometric examination; calcium levels were measured after surgery. Bone repair after parathyroidectomy was followed up by the endocrinologist for 1 year. RESULTS Before surgery, 48 % of the patients had skeletal disorders. Adenoma was found in 87%, double adenoma in 2%, hyperplasia in 10 % and parathyroid carcinoma in 0.5 % of the patients. Complications involved transient paresthesia of the recurrent laryngeal nerve (1 %), transient hypocalcemia (0.5 %), transient post-operative arrhythmias (0.5%),temporary psychological problems (0.7 %) and post-operative bleeding (0.5%). None of the patients died. Serum calcium levels were as follows: 2.90 +/- 0.01 mmol/L pre-operatively; 2.44 +/- 0.01 mmol/L on the evening of surgery; 2.30 +/- 0.01 mmol/L on the 1st day; 2.19 +/- 0.01 mmol/L on the 2nd day; and 2.18 +/- 0.01 mmol/L on the 3rd post-operative day. On the 3rd post-operative day most of the patients were discharged from the hospital. Normal calcium levels were achieved in 98 % of the surgically treated patients. DISCUSSION AND CONCLUSIONS The study provides evidence for the efficiency of calcium screening in primary hyperparathyroidism and shows the feasibility of involving endocrine surgery in the course of orthopaedic treatment.","[Adamek, S.; Libansky, P.; Lischke, R.] LF UK & FN Motol, Chirurg Klin 1 3, Prague 15006 5, Motol, Czech Republic; [Foltan, R.] LF UK & VFN, Stomatol Klin 1, Prague, Czech Republic; [Kubinyi, J.] LF UK & VFN, Ustav Nukl Med 1, Prague, Czech Republic; [Broulik, P.] LF UK & VFN, Interni Klin 1 3, Prague, Czech Republic","Adamek, S (reprint author), LF UK & FN Motol, Chirurg Klin 1 3, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","sadamek@post.cz",null,null,null,null,null,25,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","AUG",2011,78,4,null,null,null,null,355,360,null,null,null,6,"Orthopedics","Orthopedics","824HB","WOS:000295191900012"]
[null,null,null,null,"J","Kaniakova, M; Lindovsky, J; Krusek, J; Adamek, S; Vyskocil, F",null,null,null,"Kaniakova, Martina; Lindovsky, Jiri; Krusek, Jan; Adamek, Svatopluk; Vyskocil, Frantisek",null,null,"Dual effect of lobeline on alpha 4 beta 2 rat neuronal nicotinic receptors","EUROPEAN JOURNAL OF PHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,"Nicotinic acetylcholine receptor; alpha 4 beta 2; Lobeline","ACETYLCHOLINE-RECEPTORS; XENOPUS OOCYTES; BINDING-SITES; AGONIST; PHARMACOLOGY; INHIBITION; POTENTIATION; MECHANISM; DESENSITIZATION; ACTIVATION","The effect of lobeline on rat alpha 4 beta 2 nicotinic receptors expressed in COS cells was studied using the patch-clamp technique. Currents were recorded in whole-cell mode 2-4 days after cell transfection by plasmids coding the alpha 4 beta 2 combination of receptor subunits. In cells sensitive to acetylcholine, the application of lobeline evoked minor responses (up to 2% of maximal acetylcholine response). When acetylcholine was applied to the background of an already running application of lobeline, acetylcholine responses were inhibited in a concentration- and time dependent manner. However, when lobeline was applied simultaneously with acetylcholine without any prepulse or during an already running application of acetylcholine, the acetylcholine responses were potentiated up to 300-600% of that of the control. The site of lobeline action overlaps with the cholinergic site, as was proven by the partially protective effect of (+)-tubocurarine. Thus, lobeline can apparently desensitize receptors when applied alone (inhibition) whereas its binding to a second agonist site with the first one already occupied by acetylcholine leads to channel opening (potentiation). (C) 2011 Elsevier B.V. All rights reserved.","[Kaniakova, Martina; Lindovsky, Jiri; Krusek, Jan; Vyskocil, Frantisek] Acad Sci Czech Republ VVI, Inst Physiol, Prague 14220, Czech Republic; [Adamek, Svatopluk] Charles Univ Prague, Fac Med 1, Dept Surg 3, Prague, Czech Republic; [Vyskocil, Frantisek] Charles Univ Prague, Dept Anim Physiol & Dev Biol, Prague 12000, Czech Republic","Krusek, J (reprint author), Acad Sci Czech Republ VVI, Inst Physiol, Videnska 1083, Prague 14220 4, Czech Republic.","krusek@biomed.cas.cz","Krusek, Jan/B-6341-2012; Kaniakova, Martina/C-2593-2012",null," [202/09/0806];  [IAA500110905];  [AV0Z 50110509];  [LC554]","This work was supported by grant nos. 202/09/0806, IAA500110905, AV0Z 50110509 and LC554.",null,33,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0014-2999",null,null,"EUR J PHARMACOL","Eur. J. Pharmacol.","MAY 11",2011,658,41700,null,null,null,null,108,113,null,"10.1016/j.ejphar.2011.02.012",null,6,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","756KQ","WOS:000290010500008"]
[null,null,null,null,"J","Machovcova, A",null,null,null,"Machovcova, Alena",null,null,"COLOPHONY, A HIDDEN ALLERGEN ON ECG ELECTRODES IN A BOY AFTER CARDIOVASCULAR SURGERY","PEDIATRIC DERMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"CONTACT-DERMATITIS","We report on the first case identifying colophony as a hidden allergen in declared acrylate-based conductive and adhesive foam electrodes. This surgery was followed by continuous electrocardiogram monitoring. The patch tests showed strong positive reactions to colophony. The presence of colophony on the electrocardiogram electrodes was not declared, but it was used in the soldering process during manufacture, which deposited a small amount that was sufficient to induce sensitization.","Fac Hosp Motol, Dept Dermatol, Prague 15006 5, Czech Republic","Machovcova, A (reprint author), Fac Hosp Motol, Dept Dermatol, Prague 15006 5, Czech Republic.","alena.machovcova@fnmotol.cz",null,null," [VZ FNM MZO 00064203/6904]","This study is supported by grant VZ FNM MZO 00064203/6904. We thank Professor Steve Diskin, Ph.D., for his language assistance.",null,6,0,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0736-8046",null,null,"PEDIATR DERMATOL","Pediatr. Dermatol.","MAY-JUN",2011,28,3,null,null,null,null,345,347,null,null,null,4,"Dermatology; Pediatrics","Dermatology; Pediatrics","769QX","WOS:000291034400030"]
[null,null,null,null,"J","Knotek, P",null,null,null,"Knotek, Petr",null,null,"State-Trait Depression Inventory - Czech version","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"state; trait; depression; Czech version of STDI",null,"Czech version of STDI involves 20 items, 10 items measure Depression State (S-Dep), and 10 items measure Depression Trait (T-Dep). Both scales involve 5 items measuring absence of depression, Euthymia, and 5 items measuring presence of depression, Dysthymia. Each item was translated several times, and backward translated to English. The author of the original STDI selected 61 backward translated items that semantically correspond to the tested constructs. These items were administered to 268 secondary school and university students (172 female, 96 male). The factor analysis has shown two factors of state and trait for both Dysthymia and Euthymia. The Czech version of STDI corresponds to 3 criteria: 1) Items are not visibly similar. 2) Each item of the Czech STDI corresponds to exactly one item of the original STDI. 3) Factors including items that fulfill criteria 1) and 2) and reach the highest Cronbach's Alpha levels have been chosen for Czech version STDI. The Alpha of S-Dep is 0.84, for T-Dep is 0.86. A concurrent validity is approximately the same as in the original STDI. The Czech version of STDI is available for research purposes only.","[Knotek, Petr] FN Motol, Ctr Pro Leceni & Vyzkum Bolestivych Stavu, Prague 15006 5, Czech Republic; [Knotek, Petr] FN Motol, Oddeleni Klin Psychol, Prague 15006 5, Czech Republic","Knotek, P (reprint author), FN Motol, Ctr Pro Leceni & Vyzkum Bolestivych Stavu, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.knotek@fnmotol.cz",null,null,null,null,null,32,0,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2011,55,3,null,null,null,null,234,244,null,null,null,11,"Psychology, Multidisciplinary","Psychology","789AI","WOS:000292485300004"]
[null,null,null,null,"J","Bar, M; Mikulik, R; Skoloudik, D; Czerny, D; Lipina, R; Sames, M; Choc, M; Novak, Z; Stary, M; Benes, V; Smrcka, M; Filip, M; Vondrackova, D; Chlouba, V; Suchomel, P; Haninec, P; Brzezny, R; Juran, V",null,null,null,"Bar, Michal; Mikulik, Robert; Skoloudik, David; Czerny, Daniel; Lipina, Radim; Sames, Martin; Choc, Milan; Novak, Zdenek; Stary, Marian; Benes, Vladimir; Smrcka, Martin; Filip, Michal; Vondrackova, Denisa; Chlouba, Vladimir; Suchomel, Petr; Haninec, Pavel; Brzezny, Richard; Juran, Vilem",null,null,"Decompressive surgery for malignant supratentorial infarction remains underutilized after guideline publication","JOURNAL OF NEUROLOGY",null,null,"English","Article",null,null,null,null,null,"Malignant ischemic stroke; Decompressive surgery; Guideline; Utilization; Eligible criteria; Prevalence","MIDDLE CEREBRAL-ARTERY; TERRITORY INFARCTION; HEMICRANIECTOMY","Decompressive surgery < 48 h from stroke onset reduces the prevalence of mortality and morbidity from malignant supratentorial infarction. We investigated if utilization of decompressive surgery changed in the Czech Republic (CZ) after the release of new guidelines regarding treatment of malignant brain infarction. The volume of decompressive surgery in 2009 in all centers in the CZ was assessed using the same methodology as in 2006. All neurosurgery departments in the CZ were asked to complete a questionnaire and asked to identify all cases of decompressive surgery for malignant brain infarction through a combination of discharge codes for \"brain infarction\" and \"decompressive surgery\" from electronic hospital charts. Data for 56 patients were obtained from 15 of the 16 neurosurgery departments in the CZ. The average age was 53 +/- A 13; number of males 20; median time to surgery was 48 h (range 24-62); median NIHSS score was 25 (IQR, 20-30); median infarct volume was 300 cm(3) [interquartile (IQR, 250-350)]; mean shift on CT was 10.6 +/- A 3.6 mm and size of hemicraniectomy was 125 cm(2) (IQR, 110-154). A favorable outcome was achieved in 45% of the patients. The number of procedures increased from 39 in 2,006 to 2,056 in 2009. Based on data from one stroke center, 10% suffered from malignant supratentorial infarction and 2.3% met the criteria for decompressive surgery. In 2009, as compared to 2006, the volume of decompressive surgery carried out moderately increased. However, procedures remained underutilized because only similar to 10% of those who needed decompressive surgery underwent surgery.","[Bar, Michal; Skoloudik, David; Czerny, Daniel; Lipina, Radim] Fac Hosp Ostrava, Dept Neurosurg, Dept Neurol, Ostrava 70852, Czech Republic; [Bar, Michal; Skoloudik, David; Czerny, Daniel; Lipina, Radim] Fac Hosp Ostrava, Dept Radiol, Ostrava 70852, Czech Republic; [Mikulik, Robert; Novak, Zdenek] St Anne Hosp, Int Clin Res Ctr, Dept Neurol, Brno, Czech Republic; [Mikulik, Robert; Novak, Zdenek] St Anne Hosp, Dept Neurosurg, Brno, Czech Republic; [Sames, Martin] Masaryk Hosp, Dept Neurosurg, Usti Nad Labem, Czech Republic; [Choc, Milan] Fac Hosp, Dept Neurosurg, Plzen, Czech Republic; [Stary, Marian] City Hosp, Dept Neurosurg, Ostrava, Czech Republic; [Benes, Vladimir] Mil Hosp Prague, Dept Neurosurg, Prague, Czech Republic; [Smrcka, Martin; Juran, Vilem] Fac Hosp, Dept Neurosurg, Brno, Czech Republic; [Filip, Michal] Bata Hosp, Dept Neurosurg, Zlin, Czech Republic; [Vondrackova, Denisa] Na Homolce Hosp, Dept Neurol, Prague, Czech Republic; [Chlouba, Vladimir] Reg Hosp, Dept Neurosurg, Ceske Budejovice, Czech Republic; [Suchomel, Petr] Reg Hosp, Dept Neurosurg, Liberec, Czech Republic; [Haninec, Pavel] Fac Hosp Kralovske Vinohrady, Dept Neurosurg, Prague, Czech Republic; [Brzezny, Richard] Fac Hosp, Dept Neurosurg, Prague, Czech Republic","Bar, M (reprint author), Fac Hosp Ostrava, Dept Neurosurg, Dept Neurol, Tr 17 Listopadu 1790, Ostrava 70852, Czech Republic.","michal.bar@fno.cz",null,null,null,null,"ADEYOE O, 2010, J STROKE CEREBROVASC, DOI DOI 10.1016/J.JSTROKECEREBROVASCULARDIS2010.01.006; Bar M, 2010, J NEUROSURG, V113, P897, DOI 10.3171/2009.10.JNS09888; Curry WT, 2005, NEUROSURGERY, V56, P681, DOI 10.1227/01.NEU.0000156604.41886.62; *ESO EX COMM, 2009, GUID MAN ISCH STROK, P60; Gupta R, 2004, STROKE, V35, P539, DOI 10.1161/01.STR.0000109772.64650.18; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; KALITA Z, 2004, CZECH SLOVAK NEUROL, V67, P4; KASNER EC, 2001, STROKE, V32, P2117; SILVER FL, 1984, STROKE, V15, P492; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4",11,0,0,"SPRINGER HEIDELBERG","HEIDELBERG","TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY","0340-5354",null,null,"J NEUROL","J. Neurol.","SEP",2011,258,9,null,null,null,null,1689,1694,null,"10.1007/s00415-011-6003-3",null,6,"Clinical Neurology","Neurosciences & Neurology","814RG","WOS:000294474200015"]
[null,null,null,null,"J","Kolar, P; Smrzova, J; Kobesova, A",null,null,null,"Kolar, P.; Smrzova, J.; Kobesova, A.",null,null,"Developmental Coordination Disorder - Developmental Dyspraxia","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"developmental co-ordination disturbance; developmental dyspraxia; minimum brain dysfunction; central co-ordination disturbance; motor dexterity; sensory integration","INTEGRATING SENSORY INFORMATION; OCCUPATIONAL-THERAPY; MOTOR PROFICIENCY; CHILDREN; ATTENTION; SUBTYPES; INTERVENTIONS; IMPAIRMENTS; ADOLESCENTS; PERFORMANCE","Developmental dyspraxia is a motor learning difficulty that affects co-ordination of complex motor stereotypes and impairs dexterity. According to various references, dyspraxia occurs in 6-10% of the population, boys being affected four times more frequently than girls. Dyspraxia is classified as a specific type of motor learning impairment similar to dyslexia and dysgraphia. It may occur as a separate diagnosis or comorbidity with other types of motor learning difficulties may be identified. Dyspraxia is further subcategorized into ideational (gnostic, sensory, perceptional), motor (executive, expressive) and ideomotor types. Ideational dyspraxia results from abnormal processing of one or more (multi-sensory dyspraxia) types of sensory information: proprioceptive, tactile, vestibular, optic or acoustic. Executive dyspraxia manifests with impaired selective movements, postural adaptation failure, insufficient muscular relaxation, impaired equilibrium, inadequate strength adaptation, impairment of motor fluency, speed and rhythm and compromised movement estimation. To diagnose dyspraxia is quite difficult and various standardized tests serve that purpose, e.g. the movement assessment battery for children (MABC) and the Bruininks-Oseretsky test of motor proficiency (BOTMP) were designed to identify children with developmental dyspraxia. Various studies have demonstrated that children usually do not improve spontaneously without treatment. Research indicates that childhood problems resulting from developmental dyspraxia are highly resistant to short-term treatment. The sooner the child receives treatment, the better the prognosis. Treatment at pre-school age is the most effective. Therapeutic strategies should be integrated into the activities of daily life.","[Kolar, P.] LF UK, Klin Rehabil & Telovychovneho Lekarstvi 2, Prague 15006 5, Czech Republic; FN Motole, Prague 15006 5, Czech Republic","Kolar, P (reprint author), LF UK, Klin Rehabil & Telovychovneho Lekarstvi 2, Uvalu 84, Prague 15006 5, Czech Republic.","pavel.kolar@fnmotol.cz",null,null,null,null,"Adib N, 2005, RHEUMATOLOGY, V44, P744, DOI 10.1093/rheumatology/keh557; Alloway TP, 2009, J LEARN DISABIL-US, V42, P372, DOI 10.1177/0022219409335214; American Psychiatric Association, 2000, DSM 4 TR DIAGN STAT; Angelaki DE, 2008, ANNU REV NEUROSCI, V31, P125, DOI 10.1146/annurev.neuro.31.060407.125555; AYRES A J, 1963, Am J Occup Ther, V17, P221; Ayres AJ, 1972, SENSORY INTEGRATION; Ayres J, 2005, SENSORY INTEGRATION; Borel L, 2008, NEUROPHYSIOL CLIN, V38, P375, DOI 10.1016/j.neucli.2008.09.002; Brown T, 2009, PHYS OCCUP THER PEDI, V29, P86, DOI 10.1080/01942630802574908; Cahova P, 2010, NEUROL PRO PRAXI, V11, P373; Cousins M, 2003, HUM MOVEMENT SCI, V22, P433, DOI 10.1016/j.humov.2003.09.003; Crawford SG, 2008, HUM MOVEMENT SCI, V27, P154, DOI 10.1016/j.humov.2007.09.002; Davies PL, 2010, AM J OCCUP THER, V64, P391, DOI 10.5014/ajot.2010.09070; Dewey D, 1995, BRAIN COGNITION, V29, P254, DOI 10.1006/brcg.1995.1281; Dewey D, 2002, HUM MOVEMENT SCI, V21, P905, DOI 10.1016/S0167-9457(02)00163-X; Drtilkova I., 2007, HYPERKINETICKA PORUC; Gibbs J, 2007, ARCH DIS CHILD, V92, P534, DOI 10.1136/adc.2005.088054; Gillberg Christopher, 2003, Neural Plasticity, V10, P59, DOI 10.1155/NP.2003.59; Henderson SE, 2007, MOVEMENT ASSESSMENT; Hillier S, 2007, INTERNET J ALLIED HL, V5; Holsti L, 2002, J DEV BEHAV PEDIATR, V23, P9; HORAK FB, 1988, DEV MED CHILD NEUROL, V30, P64; Hung WWY, 2010, J REHABIL MED, V42, P122, DOI 10.2340/16501977-0496; Isableu B, 2010, NEUROSCIENCE, V169, P1199, DOI 10.1016/j.neuroscience.2010.05.072; Kaplan BJ, 1998, HUM MOVEMENT SCI, V17, P471, DOI 10.1016/S0167-9457(98)00010-4; Kaplan BJ, 2001, J LEARN DISABIL-US, V34, P555, DOI 10.1177/002221940103400608; Kipiani T, 2007, GEORGIAN MED NEWS, V142, P42; Kirby A, 2007, J ROY SOC MED, V100, P182, DOI 10.1258/jrsm.100.4.182; Kirby A, 2004, BRIT J GEN PRACT, V54, P6; Kirbyova A, 2000, NESIKOVNE DITE DYSPR; Koenig KP, 2010, AM J OCCUP THER, V64, P430, DOI 10.5014/ajot.2010.09073; Kolar P, 2009, REHABILITACE KLIN PR, P35; Lackner JR, 2005, ANNU REV PSYCHOL, V56, P115, DOI 10.1146/annurev.psych.55.090902.142023; LASZLO JI, 1983, Q J EXP PSYCHOL-A, V35, P411; Le Normand MT, 2000, J CLIN EXP NEUROPSYC, V22, P408, DOI 10.1076/1380-3395(200006)22:3;1-V;FT408; Lingam R, 2010, PEDIATRICS, V125, pe1109; LOSSE A, 1991, DEV MED CHILD NEUROL, V33, P55; Macnab JJ, 2001, HUM MOVEMENT SCI, V20, P49, DOI 10.1016/S0167-9457(01)00028-8; Magalhaes LC, 2006, DEV MED CHILD NEUROL, V48, P937, DOI 10.1017/S0012162206002040; May-Benson TA, 2010, AM J OCCUP THER, V64, P403, DOI 10.5014/ajot.2010.09071; MIKA J, 1982, ORIENTACNI TEST DYNA; Miller LJ, 2007, AM J OCCUP THER, V61, P135; Missiuna C, 2006, CAN MED ASSOC J, V175, P471, DOI 10.1503/cmaj.051202; MISSIUNA C, 1995, AM J OCCUP THER, V49, P619; Miyahara M, 2000, RES DEV DISABIL, V21, P367, DOI 10.1016/S0891-4222(00)00049-4; O'Hare Anne, 2002, Dyslexia, V8, P234, DOI 10.1002/dys.230; O'Brien JC, 2008, J MOTOR BEHAV, V40, P43, DOI 10.3200/JMBR.40.1.43-61; O'Hare A, 1999, DEV MED CHILD NEUROL, V41, P597, DOI 10.1017/S0012162299001255; Pearsall-Jones JG, 2010, HUM MOVEMENT SCI, V29, P787, DOI 10.1016/j.humov.2010.04.006; Peters JM, 2001, CHILD CARE HLTH DEV, V27, P399, DOI 10.1046/j.1365-2214.2001.00217.x; Piek JP, 1999, DEV MED CHILD NEUROL, V41, P159, DOI 10.1017/S0012162299000341; Pitcher TM, 2003, DEV MED CHILD NEUROL, V45, P525; Pless M, 2000, Pediatr Phys Ther, V12, P183; Polatajko HJ, 2010, AM J OCCUP THER, V64, P415, DOI 10.5014/ajot.2010.09072; POLATAJKO HJ, 1995, DEV MED CHILD NEUROL, V37, P310; Polatajko Helene J, 2005, Semin Pediatr Neurol, V12, P250, DOI 10.1016/j.spen.2005.12.007; Portwood M, 2000, UNDERSTANDING DEV DY; Richardson AJ, 2000, PROSTAG LEUKOTR ESS, V63, P1, DOI 10.1054/plef.2000.0184; Ruzicka E, 2004, KLIN NEUROLOGIE, P469; Ruzicka E, 2004, KLIN NEUROLOGIE, P143; Sagnol C, 2007, DEV PSYCHOBIOL, V49, P421, DOI 10.1002/dev.20211; Sanger TD, 2006, PEDIATRICS, V118, P2159, DOI 10.1542/peds.2005-3016; Steinman KJ, 2010, J CHILD NEUROL, V25, P71, DOI 10.1177/0883073809342591; Tsai CL, 2009, BRAIN COGNITION, V71, P246, DOI 10.1016/j.bandc.2009.08.006; Visser J, 2003, HUM MOVEMENT SCI, V22, P479, DOI 10.1016/j.humov.2003.09.005; Williams J, 2010, DEV MED CHILD NEUROL, V52, P232, DOI 10.1111/j.1469-8749.2009.03544.x; WILLOUGHBY C, 1995, AM J OCCUP THER, V49, P787; WILSON BN, 1995, AM J OCCUP THER, V49, P8; Wilson BN, 2009, PHYS OCCUP THER PEDI, V29, P182, DOI 10.1080/01942630902784761; Zelinkova O, 2008, DYSLEXIE PREDSKOLNIM; Zwicker JG, 2011, INT J DEV NEUROSCI, V29, P145, DOI 10.1016/j.ijdevneu.2010.12.002; Zwicker JG, 2009, J CHILD NEUROL, V24, P1273, DOI 10.1177/0883073809333537",72,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2011,74,5,null,null,null,null,533,538,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","822CE","WOS:000295020500004"]
[null,null,null,null,"J","Novotny, K; Padr, R; Landor, I; Sosna, A",null,null,null,"Novotny, K.; Padr, R.; Landor, I.; Sosna, A.",null,null,"Vascular Injuries in Joint Replacement Surgery","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Review",null,null,null,null,null,null,"TOTAL HIP-ARTHROPLASTY; MANAGEMENT; ARTERY","latrogenic injuries to blood vessels in joint replacement surgery are rare events that occur as few per thousand. However, their sequelae are serious. The patient may either bleed to death, because vascular injury is not obvious and therefore difficult to diagnose, or lose the limb due to ischaemia. The highest risk of vascular injury is associated with repeat surgery and loosening of the acetabular component. We distinguish sharp and blunt force injuries. The former are caused by implants, sharp instruments, bone fragments or bone cement debris. The latter arise from stretching over a part of implanted material. Bleeding can be inapparent or apparent. Inapparent bleeding is difficult to diagnose and is recognized from the dynamics of blood losses. Haemodynamic instability or, in a worse case, even hypovolaemic shock may be the only signs of bleeding. Occlusion of an artery is manifested by limb ischaemia. The seriousness and progression of ischaemia depends on the rate of arterial occlusion, potential pathways for collateral circulation and the degree of atherosclerotic vascular disease. The patient with conduction anaesthesia does not feel pain and therefore the diagnosis must primarily be based on arterial pulsation in the limb and its skin colour. A pseudoaneurysm can develop due to a partially weakened vascular wall and its rupture is a life-threatening complication. Its presence is recognized as a pulsating mass in the groin. An arteriovenous fistula which arises from traumatic communication between the two vessels may lead to cardiac failure. The diagnosis is based on examination by sonography and digital subtraction angiography. The results of CT angiography and MR angiography are difficult to evaluate because of the presence of metal implants. In apparent bleeding it is sometimes difficult to locate the source. It is recommended to perform digital compression and gain access to the vessels from the extraperitoneal approach. When an expanding haematoma or ischaemia is present, the artery can be treated by surgical exploration or percutaneous transluminal angioplasty. A possibility of vascular injury should be taken into account particularly in revision arthroplasty. To check blood flow in the limb before surgery is advisable. If the procedure entails a significant risk of post-operative complications, a vascular surgeon should be available. In the case of acute intra-operative bleeding, the source should be localised as soon as possible, the site compressed and an expert assistance called in. When the source is not obvious, it should not be attempted to apply vascular clamps or clips at random; this may do even more damage to the vessel.","[Novotny, K.] LF UK Motol, Kardiovaskularni Klin 2, Prague, Czech Republic; [Padr, R.] LF UK Motol, Klin Zobrazovacich Metod 2, Prague, Czech Republic; [Landor, I.; Sosna, A.] FN Motol, LF UK, Ortopedicka Klin 1 1, Prague, Czech Republic","Novotny, K (reprint author), LF UK, Kardiochirurg Klin 2, V Uvalu 84, Prague 15006 5, Czech Republic.","kanoy@atlas.cz",null,null,null,null,null,18,1,1,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","JUN",2011,78,3,null,null,null,null,200,207,null,null,null,8,"Orthopedics","Orthopedics","789RD","WOS:000292533100003"]
[null,null,null,null,"J","Chernyshov, PV; Jirakova, A; Hercogova, J",null,null,null,"Chernyshov, P. V.; Jirakova, A.; Hercogova, J.",null,null,"Comparative study of the quality of life of children with atopic dermatitis from Ukraine and the Czech Republic","JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY",null,null,"English","Letter",null,null,null,null,null,null,"SEVERITY; GENDER",null,"[Chernyshov, P. V.] Natl Med Univ, Dept Dermatol & Venereol, Kiev, Ukraine; [Jirakova, A.; Hercogova, J.] Charles Univ Prague, Dermatovenerol Dept, Fac Med 2, Prague, Czech Republic","Chernyshov, PV (reprint author), Natl Med Univ, Dept Dermatol & Venereol, Kiev, Ukraine.","chernyshovpavel@ukr.net",null,null,null,null,null,7,4,4,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0926-9959",null,null,"J EUR ACAD DERMATOL","J. Eur. Acad. Dermatol. Venereol.","DEC",2011,25,12,null,null,null,null,1483,1484,null,"10.1111/j.1468-3083.2010.03945.x",null,2,"Dermatology","Dermatology","860MQ","WOS:000297952800021"]
[null,null,null,null,"J","Ptacek, R; Kuzelova, H; Stefano, GB",null,null,null,"Ptacek, Radek; Kuzelova, Hana; Stefano, George B.",null,null,"Dopamine D4 receptor gene DRD4 and its association with psychiatric disorders","MEDICAL SCIENCE MONITOR",null,null,"English","Review",null,null,null,null,null,"DRD4; dopamine receptor gene; psychiatric disorders; ADHD","OBSESSIVE-COMPULSIVE DISORDER; DEFICIT HYPERACTIVITY DISORDER; NONMEDICATED ADHD BOYS; NOVELTY SEEKING; ANTIDEPRESSANT TREATMENT; ANTHROPOMETRIC CHANGES; NICOTINE DEPENDENCE; COMT POLYMORPHISMS; 7-REPEAT ALLELE; SCHIZOPHRENIA","Dopamine receptors control neural signals that modulates behavior. Dopamine plays an important role in normal attention; that is the reason for studying the genes of the dopaminergic system, mainly in connection with disorders of attention. DRD4 influences the postsynaptic action of dopamine and is implicated in many neurological processes, exhibits polymorphism and is one of the most studied genes in connection with psychiatric disorders. Associations were found with ADHD (attention deficit hyperactivity disorder), substance dependences, several specific personality traits, and reaction to stress. These findings have implications for pharmacogenetics. This article reviews the principle published associations of DRD4 variants with psychiatric disorders.","[Ptacek, Radek; Kuzelova, Hana] Charles Univ Prague, Fac Med 1, Psychiat Clin, Prague 12801 2, Czech Republic; [Kuzelova, Hana] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 12801 2, Czech Republic; [Stefano, George B.] SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA","Ptacek, R (reprint author), Charles Univ Prague, Fac Med 1, Psychiat Clin, Ke Karlovu 12, Prague 12801 2, Czech Republic.","ptacek@neuro.cz","Ptacek, Radek/C-6696-2009",null,null,null,null,108,6,6,"INT SCIENTIFIC LITERATURE, INC","SMITHTOWN","361 FOREST LANE, SMITHTOWN, NY 11787 USA","1234-1010",null,null,"MED SCI MONITOR","Med. Sci. Monitor","SEP",2011,17,9,null,null,null,null,"RA215","RA220",null,null,null,6,"Medicine, Research & Experimental","Research & Experimental Medicine","840XT","WOS:000296476100024"]
[null,null,null,null,"J","Hampl, R; Snajderova, M; Mardesic, T",null,null,null,"Hampl, R.; Snajderova, M.; Mardesic, T.",null,null,"Antimullerian Hormone (AMH) Not Only a Marker for Prediction of Ovarian Reserve","PHYSIOLOGICAL RESEARCH",null,null,"English","Review",null,null,null,null,null,"Antimullerian hormone; Physiological function; Pathophysiology; Male development; Reproduction","ANTI-MULLERIAN HORMONE; ASSISTED REPRODUCTION; INSULIN-RESISTANCE; INHIBIN B; WOMEN; ANDROGEN; RELEVANCE; CANCER; NUMBER","The main characteristics of the Antimullerian hormone from the points of view of biochemistry, molecular genetics, physiological functions and importance for diagnostics in reproductive endocrinology and related biomedical fields are reviewed. The role of the hormone in male and female development, its participation in oocyte maturation including selection of a dominant follicle are summarized, as well as its changes under various pathological situations in both sexes. The physiological changes of serum AMH leves in the life span in both sexes and their alterations under various pathological conditions are provided, too.","[Hampl, R.] Inst Endocrinol, Prague 11694 1, Czech Republic; [Snajderova, M.] Charles Univ Prague, Dept Pediat, Sch Med 2, Prague, Czech Republic; [Snajderova, M.] Univ Hosp Motol, Prague, Czech Republic; [Mardesic, T.] Sanat Pronatal, Prague, Czech Republic","Hampl, R (reprint author), Inst Endocrinol, Narodni 8, Prague 11694 1, Czech Republic.","rhampl@endo.cz",null,null,null,null,null,24,5,5,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2011,60,2,null,null,null,null,217,223,null,null,null,7,"Physiology","Physiology","771KF","WOS:000291154900005"]
[null,null,null,null,"J","Ptacek, R; Kuzelova, H; Stefano, GB",null,null,null,"Ptacek, Radek; Kuzelova, Hana; Stefano, George B.",null,null,"Genetics in Psychiatry - Up-to-date Review 2011","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Review",null,null,null,null,null,"psychiatric genetics; genes; polymorphism; genetic variants","DEFICIT HYPERACTIVITY DISORDER; OBSESSIVE-COMPULSIVE DISORDER; GAS CHROMATOGRAPHY/MASS SPECTROMETRY; SINGLE NUCLEOTIDE POLYMORPHISM; POSTTRAUMATIC-STRESS-DISORDER; DOPAMINE TRANSPORTER GENE; OXIDE-COUPLED REGULATION; WHITE BLOOD-CELLS; ENDOGENOUS MORPHINE; RECEPTOR GENE","Psychiatric genetics is a popular and much-discussed topic. Many candidate genes have been investigated in relation to psychiatric disorders and many connections have been found. The utilization of these investigations is currently at a theoretical level. Nevertheless, these findings of candidate genes will be important for further research and subsequent clinical use, for example in pharmacogenetics). Due to the rapidly growing number of empirical studies that provide profound analysis of different genes and their variants in different psychiatrical symptomatology, the field is highly divided, and providing a succinct overview is challenging. This article attempts to provide an up-to-date review of the most important and most discussed genes (mainly transporter and receptor genes) contributing to the etiology of psychiatric disorders.","[Ptacek, Radek; Kuzelova, Hana] Charles Univ Prague, Fac Med 1, Clin Psychiary, Prague 12801 2, Czech Republic; [Kuzelova, Hana] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 12801 2, Czech Republic; [Stefano, George B.] SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA","Ptacek, R (reprint author), Charles Univ Prague, Fac Med 1, Clin Psychiary, Ke Karlovu 11, Prague 12801 2, Czech Republic.","ptacek@neuro.cz","Ptacek, Radek/C-6696-2009",null,null,null,null,197,2,2,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2011,32,4,null,null,null,null,389,399,null,null,null,11,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","827PI","WOS:000295440000004"]
[null,null,null,null,"J","Horinek, D; Urbanova, B; Netuka, D; Ostry, S; Vyhnalek, M; Mohapl, M; Bojar, M; Charvat, F; Benes, V",null,null,null,"Horinek, D.; Urbanova, B.; Netuka, D.; Ostry, S.; Vyhnalek, M.; Mohapl, M.; Bojar, M.; Charvat, F.; Benes, V.",null,null,"Cognitive Impairement in Internal Carotid Artery Stenosis and the Influence of Therapeutical Interventions","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"carotid artery disease; cognitive disorders; carotid artery stenting; carotid endarterectomy; intracranial embolism; hypoxia-ischemia of the brain","NEUROPSYCHOLOGICAL TEST-PERFORMANCE; TRANSIENT ISCHEMIC ATTACKS; IC BYPASS-SURGERY; CEREBROVASCULAR RESERVE; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; STENT PLACEMENT; ENDARTERECTOMY; IMPAIRMENT; ANGIOPLASTY","The paper reviews the literature on cognitive impairment in patients with internal carotid artery (ICA) stenosis, its possible causes and the influence of therapeutic interventions (carotid endarterectomy and carotid artery stenting, CEA and CAS) on cognitive function. The studies published are heterogenous in terms of patient samples, methods and results. There is a moderate evidence that ICA stenosis is an independent risk factor in cognitive impairment. Possible mechanisms influencing cognitive function are embolization and hypoperfusion. One recent hypothis is that cognitive dysfunction is related to impairment of cerebral haemodynamics rather than to structural changes arising out of embolization. The results of multicentre studies assessing the influence of therapeutic interventions on cognitive function have been inconclusive. The current state of knowledge is not sufficient to have any impact on indications for therapy.","[Horinek, D.; Netuka, D.; Ostry, S.; Mohapl, M.; Benes, V.] UVN, LF UK, Neurochirurg Klin 1, Prague 16000 6, Czech Republic; [Urbanova, B.; Vyhnalek, M.; Bojar, M.] FN Motole, Neurol Klin Dospelych 2, LF UK, Prague, Czech Republic; [Charvat, F.] UVN, Radiodiagnost Oddeleni, Prague 16000 6, Czech Republic; [Horinek, D.] FN Sv Anny, Mezinarodni Ctr Klin Vyzkumu, Brno, Czech Republic","Horinek, D (reprint author), UVN, LF UK, Neurochirurg Klin 1, Vojenske Nemocnice 1200, Prague 16000 6, Czech Republic.","daniel.horinek@uvn.cz",null,null,null,null,null,42,1,1,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2011,74,3,null,null,null,null,254,259,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","792OS","WOS:000292757000002"]
[null,null,null,null,"J","Adamovicova, M; Jech, R; Urgosik, D; Spackova, N; Krepelova, A",null,null,null,"Adamovicova, Miriam; Jech, Robert; Urgosik, Dusan; Spackova, Natasa; Krepelova, Anna",null,null,"Pallidal Stimulation in Siblings with Pantothenate Kinase-Associated Neurodegeneration: Four-Year Follow-Up","MOVEMENT DISORDERS",null,null,"English","Letter",null,null,null,null,null,null,"DEEP BRAIN-STIMULATION; HALLERVORDEN-SPATZ-SYNDROME; IRON ACCUMULATION; DYSTONIA; MR",null,"[Adamovicova, Miriam] Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague, Czech Republic; [Adamovicova, Miriam; Jech, Robert; Spackova, Natasa] Gen Univ Hosp, Prague, Czech Republic; [Jech, Robert; Spackova, Natasa] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague, Czech Republic; [Urgosik, Dusan] Na Homolce Hosp, Dept Stereotact & Radiat Neurosurg, Prague, Czech Republic; [Krepelova, Anna] Charles Univ Prague, Fac Med 2, Inst Biol & Med Genet, Prague, Czech Republic","Adamovicova, M (reprint author), Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague, Czech Republic.","adamovicova.m@seznam.cz",null,null,null,null,null,18,6,6,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0885-3185",null,null,"MOVEMENT DISORD","Mov. Disord.","JAN",2011,26,1,null,null,null,null,184,187,null,"10.1002/mds.23349",null,4,"Clinical Neurology","Neurosciences & Neurology","732IO","WOS:000288178400037"]
[null,null,null,null,"J","Ruzicka, E; Zarubova, K; Nutt, JG; Bloem, BR",null,null,null,"Ruzicka, Evzen; Zarubova, Katerina; Nutt, John G.; Bloem, Bastiaan R.",null,null,"Silly Walks in Parkinson's Disease: Unusual Presentation of Dopaminergic-Induced Dyskinesias","MOVEMENT DISORDERS",null,null,"English","Letter",null,null,null,null,null,null,"LEVODOPA-INDUCED DYSKINESIAS",null,"[Ruzicka, Evzen; Zarubova, Katerina] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague, Czech Republic; [Ruzicka, Evzen] Charles Univ Prague, Ctr Clin Neurosci, Fac Med 1, Prague, Czech Republic; [Ruzicka, Evzen] Charles Univ Prague, Gen Univ Hosp, Prague, Czech Republic; [Zarubova, Katerina] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Bloem, Bastiaan R.] Radboud Univ Nijmegen, Dept Neurol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Bloem, Bastiaan R.] Radboud Univ Nijmegen, Parkinson Ctr Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands","Ruzicka, E (reprint author), Charles Univ Prague, Dept Neurol, Fac Med 2, Prague, Czech Republic.","eruzi@lf1.cuni.cz","Bloem, Bastiaan/E-3812-2010",null,null,null,null,7,0,0,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0885-3185",null,null,"MOVEMENT DISORD","Mov. Disord.","AUG 1",2011,26,9,null,null,null,null,1782,1784,null,"10.1002/mds.23667",null,3,"Clinical Neurology","Neurosciences & Neurology","812AX","WOS:000294261200046"]
[null,null,null,null,"J","Krizkova, S; Zitka, O; Masarik, M; Adam, V; Stiborova, M; Eckschlager, T; Hubalek, J; Kizek, R",null,null,null,"Krizkova, S.; Zitka, O.; Masarik, M.; Adam, V; Stiborova, M.; Eckschlager, T.; Hubalek, J.; Kizek, R.",null,null,"Clinical importance of matrix metalloproteinases","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Review",null,null,null,null,null,"matrix metalloproteinases; clinical diagnostics; zymography; cancer","HUMAN PROSTATE-CANCER; HEMOPEXIN-LIKE DOMAIN; IN-SITU ZYMOGRAPHY; GELATINASE-B MMP-9; EXTRACELLULAR-MATRIX; IV COLLAGENASE; PHAGE DISPLAY; INTERSTITIAL COLLAGENASE; REVERSE ZYMOGRAPHY; 92-KDA GELATINASE","This review gives a brief summary on clinical applications of MMPs and their determination. Primarily, the activity of MMPs in cancer formation, development and metastasis is discussed. Further, survey on methods including fluorimetric methods, zymographies, Western-blotting, immunocapture assay, enzyme-linked immunosorbent assay, immunocytochemistry and immunohistochennistry, phage display, multiple-enzyme/multiple-reagent system, activity profiling, chronopotentiometric stripping analysis and imaging methods for detection and determination of MMPs follows (Fig. 3, Ref. 100). Full Text in free PDF www.bmj.sk.","[Krizkova, S.; Zitka, O.; Masarik, M.; Adam, V; Stiborova, M.; Eckschlager, T.; Hubalek, J.; Kizek, R.] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Zitka, Ondrej/E-1107-2012; Krizkova, Sona/E-9617-2012",null,"GA AV [IAA401990701]; GACR [301/09/P436, P301/10/0356]; IGAMZ [10200-3]; NANOSEMED GA AV [KAN208130801]","Financial support from GA AV IAA401990701, GACR 301/09/P436, IGAMZ 10200-3, NANOSEMED GA AV KAN208130801 and GACR P301/10/0356 is highly acknowledged.","Afzal S, 1996, LAB INVEST, V74, P406; Attiga FA, 2000, CANCER RES, V60, P4629; BODE W, 1995, STRUCTURE, V3, P527, DOI 10.1016/S0969-2126(01)00185-X; Bode W, 2003, BIOCHEM SOC SYMP, V70, P1; Borkakoti N, 2000, J MOL MED-JMM, V78, P261, DOI 10.1007/s001090000113; Bovee JVMG, 2010, NAT REV CANCER, V10, P481, DOI 10.1038/nrc2869; Buttner FH, 1998, BIOCHEM J, V333, P159; Capper SJ, 1999, ANN NY ACAD SCI, V878, P487, DOI 10.1111/j.1749-6632.1999.tb07704.x; Chambaut-Guerin AM, 2000, J NEUROCHEM, V74, P508, DOI 10.1046/j.1471-4159.2000.740508.x; Cheng XC, 2008, J ENZYM INHIB MED CH, V23, P154, DOI 10.1080/14756360701511292 ; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dai Y, 2007, CHINESE MED J-PEKING, V120, P2017; DAVIES B, 1993, CANCER RES, V53, P5365; Dhanaraj V, 1996, STRUCTURE, V4, P375, DOI 10.1016/S0969-2126(96)00043-3; DOLLERY CM, 1995, CIRC RES, V77, P863; Dragutinovic VV, 2006, WORLD J GASTROENTERO, V12, P105; Egawa N, 2006, J BIOL CHEM, V281, P37576, DOI 10.1074/jbc.M606993200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Escaff S, 2010, BRIT J CANCER, V102, P922, DOI 10.1038/sj.bjc.6605569; Ferrario A, 2004, CANCER RES, V64, P2328, DOI 10.1158/0008-5472.CAN-04-0071; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Freije JMP, 2003, ADV EXP MED BIOL, V532, P91; Freije JR, 2006, J PROTEOME RES, V5, P1186, DOI 10.1021/pr050483b; George J, 2003, J BIOMOL SCREEN, V8, P72, DOI 10.1177/1087057102239778; Gogly B, 1998, ANAL BIOCHEM, V255, P211, DOI 10.1006/abio.1997.2318; GomisRuth FX, 1996, J MOL BIOL, V264, P556, DOI 10.1006/jmbi.1996.0661; GROSS J, 1962, P NATL ACAD SCI USA, V48, P1014, DOI 10.1073/pnas.48.6.1014; Hanemaaijer R, 1998, MATRIX BIOL, V17, P657, DOI 10.1016/S0945-053X(98)90116-0; Hattori S, 2002, ANAL BIOCHEM, V301, P27, DOI 10.1006/abio.2001.5479; Herr AE, 2007, P NATL ACAD SCI USA, V104, P5268, DOI 10.1073/pnas.0607254104; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; Huska D, 2009, ELECTROANAL, V21, P536, DOI 10.1002/elan.200804440; Kataoka H, 1999, AM J PATHOL, V154, P457, DOI 10.1016/S0002-9440(10)65292-3; Kehoe JW, 2005, CHEM REV, V105, P4056, DOI 10.1021/cr000261r; Kelly PJ, 2008, STROKE, V39, P100, DOI 10.1161/STROKEAHA.107.488189; Kerrigan J J, 2000, J Orthod, V27, P227; Kopczynska E, 2007, WSPOTCZESNA ONKOL, V11, P355; Kurschat P, 2002, J PATHOL, V197, P179, DOI 10.1002/path.1080; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; Lohi J, 2001, J BIOL CHEM, V276, P10134, DOI 10.1074/jbc.M001599200; Lombard C, 2005, BIOCHIMIE, V87, P265, DOI 10.1016/j.biochi.2005.01.007; Lopez-Avila V, 2008, CLIN MED INSIGHTS CA; MACHADO DE, 2010, J EXP CLIN CANC RES, V29, P9; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeta N, 2007, ONCOLOGY-BASEL, V73, P118, DOI 10.1159/000121000; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; MURPHY G, 1994, J BIOL CHEM, V269, P6632; Murphy G, 1995, ACTA ORTHOP SCAND, V66, P55; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nemori R, 2005, J HISTOCHEM CYTOCHEM, V53, P1227, DOI 10.1369/jhc.5A6631.2005; Obiso RJ, 1997, INFECT IMMUN, V65, P1431; Ohkubo S, 1999, BIOCHEM BIOPH RES CO, V266, P308, DOI 10.1006/bbrc.1999.1816; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; OKADA Y, 1992, J BIOL CHEM, V267, P21712; Oliver GW, 1997, ANAL BIOCHEM, V244, P161, DOI 10.1006/abio.1996.9895; PAJOUH MS, 1991, J CANCER RES CLIN, V117, P144, DOI 10.1007/BF01613138; Perentes JY, 2009, NAT METHODS, V6, P143, DOI [10.1038/nmeth.1295, 10.1038/NMETH.1295]; POULSOM R, 1992, AM J PATHOL, V141, P389; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Purwar R, 2008, J INVEST DERMATOL, V128, P59, DOI 10.1038/sj.jid.5700940; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RASER KJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P211, DOI 10.1006/abbi.1995.1284; Rasmussen FH, 2004, BIOCHEMISTRY-US, V43, P2987, DOI 10.1021/bi036063m; RAWDANOWICZ TJ, 1994, J CLIN ENDOCR METAB, V79, P530, DOI 10.1210/jc.79.2.530; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; Sakimoto T, 2007, JPN J OPHTHALMOL, V51, P343, DOI 10.1007/s10384-007-0455-0; Scherer RL, 2008, CANCER METAST REV, V27, P679, DOI 10.1007/s10555-008-9152-9; Sheu BC, 2001, CANCER RES, V61, P237; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; Sroka IC, 2008, PROSTATE, V68, P463, DOI 10.1002/pros.20718; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Stracke JO, 2000, FEBS LETT, V478, P52, DOI 10.1016/S0014-5793(00)01819-6; THOMPSON EW, 1994, BREAST CANCER RES TR, V31, P357, DOI 10.1007/BF00666168; Tomita T, 1996, DIS COLON RECTUM, V39, P1255, DOI 10.1007/BF02055119; Travaglino E, 2008, EUR J HAEMATOL, V80, P216, DOI 10.1111/j.1600-0609.2007.01012.x; Tung CH, 2000, CANCER RES, V60, P4953; Ueno H, 1997, CANCER RES, V57, P2055; Uria JA, 2000, CANCER RES, V60, P4745; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375; Wagner S, 2006, CURR MED CHEM, V13, P2819, DOI 10.2174/092986706778522002; Wang P, 2004, J BIOL CHEM, V279, P51148, DOI 10.1074/jbc.M409074200; Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933; Wilson EM, 2001, ANN MED, V33, P623, DOI 10.3109/07853890109002108; Wu ZS, 2008, INT J CANCER, V122, P2050, DOI 10.1002/ijc.23337; Ye S, 2000, MATRIX BIOL, V19, P623, DOI 10.1016/S0945-053X(00)00102-5; Yu Q, 2000, GENE DEV, V14, P163; Zhao JX, 2007, EUR J NEUROL, V14, P510, DOI 10.1111/j.1468-1331.2006.01705.x; Zitka O, 2010, CURR MED CHEM, V17, P3751; Zucker SN, 2001, NAT MED, V7, P655, DOI 10.1038/89016",99,3,3,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248","1336-0345",null,"BRATISL MED J","Bratisl. Med. J.",null,2011,112,8,null,null,null,null,435,440,null,null,null,6,"Medicine, General & Internal","General & Internal Medicine","796KD","WOS:000293049300003"]
[null,null,null,null,"J","Kotlabova, K; Doucha, J; Hromadnikova, I",null,null,null,"Kotlabova, Katerina; Doucha, Jindrich; Hromadnikova, Ilona",null,null,"Placental-specific microRNA in maternal circulation - identification of appropriate pregnancy-associated microRNAs with diagnostic potential","JOURNAL OF REPRODUCTIVE IMMUNOLOGY",null,null,"English","Article; Proceedings Paper","7th International Workshop on Reproductive Immunology, Immunological Tolerance and Immunology of Preeclampsia","AUG, 2010","Tioman Isl, MALAYSIA",null,null,"MicroRNA; Maternal plasma; Normal pregnancy; Real-time PCR","FETAL SEX DETERMINATION; REAL-TIME PCR; QUANTITATIVE-ANALYSIS; GROWTH RESTRICTION; EXTRACELLULAR DNA; HUMAN TISSUES; PLASMA; EXPRESSION; PREECLAMPSIA; SERUM","The goal of this study was to identify placental specific microRNAs present in maternal plasma that differentiate between women with normal pregnancies and nonpregnant individuals. The selection of appropriate pregnancy-associated microRNAs with diagnostic potential was based on the following criteria: (1) detection rate of 100% in full-term placentas, (2) detection rate of >= 67% in maternal plasma throughout gestation (at least four positive wells out of six tested wells) and (3) not detectable in whole peripheral blood and plasma samples of nonpregnant individuals. Initially, we tested microRNAs (miR-34c, miR-372, miR-135b and miR-518b), which had been previously identified as pregnancy-associated microRNAs. Additionally, we selected 16 other highly specific placental microRNAs (miR-512-5p, miR-515-5p, miR-224, miR-516-5p, miR-517*, miR-136, miR-518f*, miR-519a, miR-519d, miR-519e, miR-520a*, miR-520h, miR-524-5p, miR-525, miR-526a, and miR-526b) from the miRNAMap database. Seven microRNAs (miR-516-5p, miR-517*, miR-518b, miR-520a*, miR-520h, miR-525 and miR-526a) were identified as new pregnancy associated microRNAs with diagnostic potential. Their levels in maternal plasma during the 36th week of gestation corresponded to 45.0-427.0 pg of total RNA (enriched for small RNAs) per milliliter of maternal plasma. (C) 2011 Elsevier Ireland Ltd. All rights reserved.","[Kotlabova, Katerina; Hromadnikova, Ilona] Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Prague 10000 10, Czech Republic; [Doucha, Jindrich] Charles Univ Prague, Univ Hosp Motol, Clin Obstet & Gynecol, Fac Med 2, Prague 10000 10, Czech Republic","Kotlabova, K (reprint author), Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Ruska 87, Prague 10000 10, Czech Republic.","katerina.kotlabova@lf3.cuni.cz; jindrich.d@seznam.cz; ilona.hromadnikova@lf3.cuni.cz",null,null,null,null,null,39,24,25,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0165-0378",null,null,"J REPROD IMMUNOL","J. Reprod. Immunol.","MAY",2011,89,2,null,null,"SI",null,185,191,null,"10.1016/j.jri.2011.02.006",null,7,"Immunology; Reproductive Biology","Immunology; Reproductive Biology","782MB","WOS:000292012700011"]
[null,null,null,null,"J","Pokorny, J; Stanek, V; Vrana, M",null,null,null,"Pokorny, J.; Stanek, V.; Vrana, M.",null,null,"Sudden Cardiac Death Thirty Years Ago and at Present. The Role of Autonomic Disturbances in Acute Myocardial Infarction Revisited","PHYSIOLOGICAL RESEARCH",null,null,"English","Review",null,null,null,null,null,"Sudden death; Myocardial ischemia; Ventricular fibrillation; Autonomic disturbances; Prevention","NERVOUS-SYSTEM; FIBRILLATION THRESHOLD; HEART-FAILURE; MORTALITY; ISCHEMIA; CARVEDILOL; TRIAL; CATECHOLAMINES; PROPRANOLOL; STIMULATION","The most common cause of sudden cardiac death is ventricular fibrillation (VF). In addition to the status, size and location of the ventricular focus, a major pathogenic mechanism triggering VF is autonomic dysbalance (disturbance). This term refers to a wide range of reflex changes in the ratio of sympathetic to vagal ventricular activation over time, occurring immediately after coronary artery occlusion at the onset of acute myocardial infarction (AMI). Another trigger of VF is autonomic disturbance due to emotional stress. Experimental and clinical research into autonomic disturbances associated with coronary artery occlusion and emotional stress was given considerable attention as early as some 30 years ago when researchers were already searching for ways of inhibiting autonomic disturbances using predominant sympathetic and vagal activation by beta-blockers (BB) and atropine, respectively. The aim of our paper is to compare results obtained 30 years ago with current status of experimental and clinical research into SCD prevention. Another aim is to identify questions that have remained unanswered to date; answers to these outstanding questions could help further reduce the risk of SCD.","[Pokorny, J.] Univ Hosp Motol, Emergency Dept, Prague 15000 5, Czech Republic; [Stanek, V.] Inst Clin & Expt Med, Dept Cardiol, Prague, Czech Republic; [Vrana, M.] Inst Clin & Expt Med, Expt Dept, Prague, Czech Republic","Pokorny, J (reprint author), Univ Hosp Motol, Emergency Dept, V Uvalu 84, Prague 15000 5, Czech Republic.","jxpokorny@seznam.cz",null,null,null,null,null,47,5,6,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2011,60,5,null,null,null,null,715,728,null,null,null,14,"Physiology","Physiology","863JW","WOS:000298159900001"]
[null,null,null,null,"J","Jech, R; Bares, M; Krepelova, A; Urgosik, D; Havrankova, P; Ruzicka, E",null,null,null,"Jech, Robert; Bares, Martin; Krepelova, Anna; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen",null,null,"DYT 6-A Novel THAP1 Mutation With Excellent Effect on Pallidal DBS","MOVEMENT DISORDERS",null,null,"English","Letter",null,null,null,null,null,null,"DEEP BRAIN-STIMULATION; DYSTONIA",null,"[Jech, Robert; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Jech, Robert; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic; [Jech, Robert; Urgosik, Dusan; Havrankova, Petra; Ruzicka, Evzen] Gen Univ Hosp, Prague, Czech Republic; [Bares, Martin] Masaryk Univ, Fac Med, St Annes Hosp, Dept Neurol 1, Brno, Czech Republic; [Krepelova, Anna] Charles Univ Prague, Fac Med 2, Inst Biol & Med Genet, Prague, Czech Republic; [Urgosik, Dusan] Na Homolce Hosp, Dept Stereotact & Radiat Neurosurg, Prague, Czech Republic","Jech, R (reprint author), Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic.","jech@cesnet.cz","Bares, Martin/E-3700-2012",null,null,null,null,7,7,8,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0885-3185",null,null,"MOVEMENT DISORD","Mov. Disord.","APR",2011,26,5,null,null,null,null,924,925,null,"10.1002/mds.23599",null,2,"Clinical Neurology","Neurosciences & Neurology","762AT","WOS:000290445400060"]
[null,null,null,null,"J","Ivica, J; Skoumalova, A; Topinkova, E; Wilhelm, J",null,null,null,"Ivica, Josko; Skoumalova, Alice; Topinkova, Eva; Wilhelm, Jiri",null,null,"HPLC Separation of Fluorescent Products of Lipid Peroxidation in Erythrocytes and Mitochondria","CHROMATOGRAPHIA",null,null,"English","Article; Proceedings Paper","16th International Symposium on Separation Sciences, New Advancements in Chromatography and Capillary Electromigration Techniques (16th ISSS)","SEP 06-10, 2010","Rome, ITALY","Italian Chem Soc, Cent European Grp Separat Sci (CEGSS), Div Chem Environm & Cultural Heritage, European Soc Separat Sci (EuSSS), Italian Res Council (CNR)",null,"Column liquid chromatography; Lipofuscin-like pigments; Malondialdehyde; Mitochondria; Erythrocytes","LIPOFUSCIN-LIKE PIGMENTS; ALPHA-KETOGLUTARATE DEHYDROGENASE; BODY GAMMA-IRRADIATION; FREE-RADICAL DAMAGE; AMINO-ACIDS; OXIDATIVE PHOSPHORYLATION; END-PRODUCTS; MALONDIALDEHYDE; MALONALDEHYDE; FLUOROPHORES","Polyunsaturated fatty acids found in membrane phospholipids are readily oxidized by free radicals producing highly reactive aldehydes such as malondialdehyde. These aldehydes react with biological material to form fluorescent lipid peroxidation end products known as lipofuscin-like pigments. We studied fluorescent pigments from beef heart mitochondria incubated with malondialdehyde in vitro and from erythrocytes of patients with Alzheimer's disease to evaluate their potential as markers of oxidative stress and to develop HPLC methods for their qualitative analysis. We used tridimensional fluorescence spectral arrays and synchronous fluorescence spectra in connection with HPLC separation with fluorescence detection. Stable fluorophores were found in both models and were successfully resolved into several distinctive fractions. This creates the basis for further characterization of this relatively less studied group of products of oxidative damage.","[Ivica, Josko; Skoumalova, Alice; Wilhelm, Jiri] Charles Univ Prague, Dept Med Chem & Biochem, Fac Med 2, Prague 15006, Czech Republic; [Topinkova, Eva] Charles Univ Prague, Dept Geriatr, Fac Med 1, Prague 12000, Czech Republic","Ivica, J (reprint author), Charles Univ Prague, Dept Med Chem & Biochem, Fac Med 2, Plzenska 221-130, Prague 15006, Czech Republic.","josko.ivica@gmail.com","Wilhelm, Jiri/C-6252-2012",null,null,null,null,30,2,2,"SPRINGER HEIDELBERG","HEIDELBERG","TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY","0009-5893",null,null,"CHROMATOGRAPHIA","Chromatographia","JUN",2011,73,null,null,1,"SI",null,"S67","S73",null,"10.1007/s10337-010-1887-0",null,7,"Biochemical Research Methods; Chemistry, Analytical","Biochemistry & Molecular Biology; Chemistry","766RT","WOS:000290804900008"]
[null,null,null,null,"S","Dostalova, T; Jelinkova, H; Sulc, J; Koranda, P; Nemec, M; Fibrich, M; Jelinek, M; Michalik, P; Miyagi, M",null,"Rechmann, P; Fried, D",null,"Dostalova, Tatjana; Jelinkova, Helena; Sulc, Jan; Koranda, Petr; Nemec, Michal; Fibrich, Martin; Jelinek, Michal; Michalik, Pavel; Miyagi, Mitsunobu",null,null,"Influence of Tm:YAP laser irradiation on tensile strength for bracket debonding","LASERS IN DENTISTRY XVII","Proceedings of SPIE",null,"English","Proceedings Paper","Conference on Lasers in Dentistry XVII","JAN 23, 2011","San Francisco, CA","SPIE",null,"dentistry; orthodontics; ceramic bracket debonding; tensile strength; Tm: YAP laser","CERAMIC ORTHODONTIC BRACKETS","The aim of our study was the investigation of tensile strength needed for bracket debonding. A diode-pumped Tm: YAP microchip laser generating a continuous 2um radiation with a maximum output power of 4W was used for debonding purposes. A group of 60 brackets was debonded using classical and laser irradiation methods - the dose from 1 W to 4 W for 60 s. The tensile strength without laser irradiation was in the range from 39.6 N (full ceramic bracket group) to 63.7 N (ceramic bracket with metal slot group). After irradiation, the tensile strength was lowered from 35.1 N (full ceramic bracket group) to 48.8 N (ceramic bracket with metal slot group). The results of our study generally agree with the previous studies, substantiating the fact that lasers can be used effectively to thermally soften the adhesive resin for removal of ceramic brackets. From the practical point of view the conclusion is that during laser irradiation thermal ablation occurs and the bracket is removed from the enamel together with the rest of the adhesive resin. Laser debonding is easier and certain heat diffusion occurred.","[Dostalova, Tatjana; Michalik, Pavel] Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague 15006 5, Czech Republic","Dostalova, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague 15006 5, Czech Republic.","tatjana.dostalova@fnmotol.cz",null,null,null,null,null,15,1,1,"SPIE-INT SOC OPTICAL ENGINEERING","BELLINGHAM","1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA","0277-786X",null,"978-0-8194-8421-5","PROC SPIE",null,null,2011,7884,null,null,null,null,null,null,null,788404,"10.1117/12.873745",null,6,"Dentistry, Oral Surgery & Medicine; Optics; Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging","Dentistry, Oral Surgery & Medicine; Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging","BWF76","WOS:000293824300003"]
[null,null,null,null,"J","Kriz, J; Jirak, D; Koblas, T; Vilk, G; Girman, P; Hajek, M; Saudek, F",null,null,null,"Kriz, J.; Jirak, D.; Koblas, T.; Vilk, G.; Girman, P.; Hajek, M.; Saudek, F.",null,null,"Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Tool to Monitor the Blood Supply to an Artificial Cavity Used as a Site for Islet Transplantation in Rats","TRANSPLANTATION PROCEEDINGS",null,null,"English","Article; Proceedings Paper","13th World Congress of the International-Pancreas-and-Islet-Transplant-Association (IPITA)","JUN 01-04, 2011","Prague, CZECH REPUBLIC","Int Pancreas & Islet Transplant Assoc (IPITA)",null,null,"POSITRON-EMISSION-TOMOGRAPHY; VASCULARIZATION; ENGRAFTMENT; MODEL; TIME; MRI","Background. The transplantation of islets of Langerhans isolated from one donor pancreas can rarely release a diabetic recipient from insulin injections. The major reason is the destruction of 50%-60% of the transplanted tissue, which proceeds typically within a few hours after the insertion of the islets into the portal vein. Therefore, several groups have focused on development of an artificial site for islet transplantation. The main aim of the present study was to test the efficacy of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to evaluate the blood supply feeding the artificially created cavities for islet transplantation. Methods. Two rounded devices were implanted: one device subcutaneously and the second one into the greater omentum of each animal. On the day of implantation as well as 1, 3, and 4 weeks later, we quickly injected the vascular specific MR contrast agent Vasovist (0.05 mL/100 g) intravenously. Penetration of the contrast agent was monitored by DCE-MRI. The influence of the contrast agent on the signal intensity observed within selected target areas was calculated with the use of ImageJ software. Results. The penetration of the contrast agent was detected by the increase in signal intensity within implanted devices. The signal increase caused by the contrast compound was normalized to kidney tissue. On day of implantation of the device, no signal due to the contrast agent was detected in all devices. However, over the following weeks, there was an increase in signal detection within the omental device to 34%, 21%, and 14% of that of the kidney. Within the subcutaneously implanted devices there was an increase in signal detection up to 11%, 10%, and 7% of that detected in the kidney. Conclusions. The optimal time for transplantation of pancreatic islets into our omental device was 1 week after implantation of the scaffold. Also, the blood supply feeding the subcutaneous devices was regarded to be inadequate.","[Kriz, J.; Koblas, T.; Girman, P.; Saudek, F.] Inst Clin & Expt Med, Ctr Diabet, Prague 14021, Czech Republic; [Jirak, D.; Hajek, M.] Inst Clin & Expt Med, MR Unit, Prague 14021, Czech Republic; [Jirak, D.; Girman, P.] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague, Czech Republic; [Vilk, G.] Univ Western Ontario, Dept Biochem, London, ON, Canada","Kriz, J (reprint author), Inst Clin & Expt Med, Ctr Diabet, Videnska 1958-9, Prague 14021, Czech Republic.","jkri@ikem.cz",null,null,null,null,null,14,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0041-1345",null,null,"TRANSPL P","Transplant. Proc.","NOV",2011,43,9,null,null,null,null,3226,3230,null,"10.1016/j.transproceed.2011.09.012",null,5,"Immunology; Surgery; Transplantation","Immunology; Surgery; Transplantation","854HL","WOS:000297485500020"]
[null,null,null,null,"J","Lebedev, AV; Pelouch, V; Ivanova, MV; Levitsky, DO",null,null,null,"Lebedev, Alexander V.; Pelouch, Vaclav; Ivanova, Marina V.; Levitsky, Dmitri O.",null,null,"A QUANTITATIVE EVALUATION OF REDOX-ACTIVE COMPOUNDS IN HUMAN BLOOD LIPIDS","HEMOGLOBIN",null,null,"English","Article; Proceedings Paper","19th International Conference on Chelation (ICOC)","NOV 13-16, 2009","London, ENGLAND",null,null,"Redox active compounds (RACs); Blood lipids; Vitamin E; Phenols; Quinones","TOTAL ANTIOXIDANT CAPACITY; RADICAL SCAVENGERS; HUMAN PLASMA; VITAMIN-E; ASSAY; VEGETABLES; TOCOPHEROL; DISEASE; LEVEL; CELLS","Endogenous low molecular weight redox active compounds (RACs) comprise antioxidants, pro-oxidants, transition metal cations and metal chelators. Traditional electrochemical methods of measuring RACs are limited to aqueous solutions, thus providing information of only hydrophilic RAC pools. In a large number of diseases associated with oxidative stress and/or with metal toxicity, redox states of hydrophilic as well as hydrophobic compartments are modified, and therefore development of methods for their detection is both necessary and important. The pools of lipid soluble RACs in reduced and oxidized forms in n-hexane extracts obtained from blood plasma, erythrocytes and whole blood of healthy donors were determined by spectrophotometric detection of the 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radicals, which stoichiometrically interacts with hydrogen donors in non polar solutions. Measurements of RACs in extracts before and after treatment with NaBH(4) provided information about the levels of both reduced and oxidized RACs. Vitamin E was also determined using a fluorescence method. The results have shown that vitamin E is the major RAC in blood plasma lipids but not in blood cell lipids, where other phenols and quinones appear to predominate.","[Lebedev, Alexander V.; Ivanova, Marina V.] Cardiol Res Ctr, Inst Expt Cardiol, Moscow 121552, Russia; [Pelouch, Vaclav] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Levitsky, Dmitri O.] Univ Nantes, Fac Sci & Tech, Nantes, France","Lebedev, AV (reprint author), Cardiol Res Ctr, Inst Expt Cardiol, 3rd Cherepkovskaya St 15A, Moscow 121552, Russia.","avleb@cardio.ru",null,null,null,null,null,27,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0363-0269",null,null,"HEMOGLOBIN","Hemoglobin",null,2011,35,3,null,null,null,null,247,254,null,"10.3109/03630269.2011.570191",null,8,"Biochemistry & Molecular Biology; Hematology","Biochemistry & Molecular Biology; Hematology","766PJ","WOS:000290797500008"]
[null,null,null,null,"J","Cermak, J; Jonasova, A; Vondrakova, J; Walterova, L; Hochova, I; Siskova, M; Neuwirtova, R",null,null,null,"Cermak, Jaroslav; Jonasova, Anna; Vondrakova, Jana; Walterova, Lenka; Hochova, Ivana; Siskova, Magda; Neuwirtova, Radana",null,null,"EFFICACY AND SAFETY OF ADMINISTRATION OF ORAL IRON CHELATOR DEFERIPRONE IN PATIENTS WITH EARLY MYELODYSPLASTIC SYNDROME","HEMOGLOBIN",null,null,"English","Article; Proceedings Paper","19th International Conference on Chelation (ICOC)","NOV 13-16, 2009","London, ENGLAND",null,null,"Iron overload; Myelodysplasia syndrome (MDS); Deferiprone (L1); Treatment; Ferritin; Agranulocytosis","THALASSEMIA MAJOR; BETA-THALASSEMIA; THERAPY; ERYTHROPOIETIN; ANEMIA; 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE; DESFERRIOXAMINE; DEFEROXAMINE; OVERLOAD; SURVIVAL","Forty-eight patients with early myelodysplastic syndrome (MDS) without excess of blasts, with average initial serum ferritin levels of 2739.5 mu g/L (range 825-11287 mu g/L), were treated with deferiprone (L1) in a daily dose of 40-90 mg/kg. Median duration of chelation treatment was 10.9 months (range 4-24 months). Chelation was effective (maintained or decreased iron stores) in 16 out of 22 patients (73%) with serum ferritin levels <2000 mu g/L in contrast to only 12 out of 26 patients with serum ferritin levels >2000 mu g/L. Combination of L1 with recombinant human erythropoietin (rHuEPO) (30-40 kU/week) resulted in effective chelation in five additional patients with serum ferritin levels >3000 mu g/L. Incidence of adverse effects was comparable to that in thalassemic patients. Gastrointestinal symptoms represented the most frequent adverse effect of L1 therapy (37.5% of patients) that limited an effective escalation of the daily dose of the drug and led to discontinuation of the treatment for six patients. A decreased number of granulocytes was observed in five (13%) patients and agranulocytosis occurred in two patients (4%). Granulocyte counts were restored after cessation of L1 treatment and administration of granulocyte colony stimulating factor (G-CSF) in all but one patient. Administration of L1 in a daily dose of at least 75 mg/kg may represent an alternative approach in treatment of mild and moderate iron overload in MDS patients who cannot be treated with deferasirox (DFRA) or deferoxamine (DFO).","[Cermak, Jaroslav] Inst Hematol & Blood Transfus, Dept Clin Hematol, CR-12820 Prague, Czech Republic; [Jonasova, Anna; Siskova, Magda; Neuwirtova, Radana] Fac Hosp, Dept Internal Med 1, Prague 2, Czech Republic; [Vondrakova, Jana] Palacky Univ, Dept Hematol, Fac Hosp, CR-77147 Olomouc, Czech Republic; [Walterova, Lenka] Reg Hosp, Dept Hematol, Liberec, Czech Republic; [Hochova, Ivana] Fac Hosp, Dept Hematol, Prague Motol, Czech Republic","Cermak, J (reprint author), Inst Hematol & Blood Transfus, Dept Clin Hematol, U Nemocnice 1, CR-12820 Prague, Czech Republic.","cermak@uhkt.cz",null,null,null,null,null,26,8,8,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0363-0269",null,null,"HEMOGLOBIN","Hemoglobin",null,2011,35,3,null,null,null,null,217,227,null,"10.3109/03630269.2011.578515",null,11,"Biochemistry & Molecular Biology; Hematology","Biochemistry & Molecular Biology; Hematology","766PJ","WOS:000290797500005"]
[null,null,null,null,"J","Lischke, R; Pozniak, J; Vondrys, D; Elliott, MJ; Rea, F; Cerfolio, R; Bertani, A; Schmid, R",null,null,null,"Lischke, Robert; Pozniak, Jiri; Vondrys, David; Elliott, Martin J.; Rea, F.; Cerfolio, R.; Bertani, A.; Schmid, R.",null,null,"Novel biodegradable stents in the treatment of bronchial stenosis after lung transplantation","EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY",null,null,"English","Article; Proceedings Paper","24th Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery","SEP 11-15, 2010","Geneva, SWITZERLAND","European Assoc Cardio Thorac Surg",null,"Transplantation; Lung; Stent","SINGLE RUNNING SUTURE; KNITTED AIRWAY STENT; COMPLICATIONS; MANAGEMENT; ANASTOMOSES","Objective: To evaluate the safety and effectiveness of novel biodegradable (BD) stents to treat bronchial anastomotic stenosis in patients after lung transplantation. Methods: Twenty BD stents were implanted endoscopically in six patients (median age 41.5 years (range 35-57 years)) with post-transplant bronchial anastomotic stenoses, between 2006 and 2010. All stents were custom-made from bio-absorbable polydioxanone (PDS). The median stent diameter was 12 mm (8-17 mm) and median length was 20 mm (12-30 mm). All patients were evaluated clinically, by bronchoscopy and high-definition computed tomography (CT). Results: The stenosis was initially relieved in all cases. There was no bleeding, perforation or displacement after BD stent implantation. Four patients needed multiple stenting for anastomotic re-stenosis. Median time to any re-stenting was 5 months (2-15 months). There was one sudden death, 1 year after the last BD stent implantation, from a pulmonary embolus. All five survivors are in good clinical condition up to 4 years' follow-up (median 40 months, range 7-48 months) since first stenting and intervention-free up to 44 months (median 24 months, range 7-44 months). Conclusions: This small pilot study shows that BD stents are a safe, effective and reliable alternative to classical metallic stents in patients with anastomotic stenosis after lung transplantation, and may avoid the need for permanent stenting. Crown Copyright (C) 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.","[Lischke, Robert; Pozniak, Jiri] Univ Hosp Motol, Prague, Czech Republic; [Vondrys, David; Elliott, Martin J.] Great Ormond St Hosp Sick Children, London WC1N 3JH, England","Vondrys, D (reprint author), 65 Cavalry Sq, London SW3 4RB, England.","david@vondrys.com",null,null,null,null,null,25,14,14,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1010-7940",null,null,"EUR J CARDIO-THORAC","Eur. J. Cardio-Thorac. Surg.","SEP",2011,40,3,null,null,null,null,619,624,null,"10.1016/j.ejcts.2010.12.047",null,6,"Cardiac & Cardiovascular Systems; Respiratory System; Surgery","Cardiovascular System & Cardiology; Respiratory System; Surgery","806QF","WOS:000293824000025"]
[null,null,null,null,"J","Sediva, A; Polouckova, A; Podrazil, M; Fronkova, E; Kalina, T",null,null,null,"Sediva, A.; Polouckova, A.; Podrazil, M.; Fronkova, E.; Kalina, T.",null,null,"Characterization of the B-cell compartment in a patient with Schnitzler syndrome","SCANDINAVIAN JOURNAL OF RHEUMATOLOGY",null,null,"English","Letter",null,null,null,null,null,null,"ANAKINRA",null,"[Sediva, A.; Polouckova, A.; Podrazil, M.] Charles Univ Prague, Dept Immunol, Fac Med 2, Prague 15006, Czech Republic; [Fronkova, E.; Kalina, T.] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague 15006, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Sediva, A (reprint author), Charles Univ Prague, Dept Immunol, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","anna.sediv@fmotol.cuni.cz",null,null,null,null,null,10,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0300-9742",null,null,"SCAND J RHEUMATOL","Scand. J. Rheumatol.","MAR",2011,40,2,null,null,null,null,158,160,null,"10.3109/03009742.2010.507219",null,3,"Rheumatology","Rheumatology","731RU","WOS:000288127800016"]
[null,null,null,null,"J","Durila, M; Bures, J; Pelichovska, M; Cvavhovec, K",null,null,null,"Durila, M.; Bures, J.; Pelichovska, M.; Cvavhovec, K.",null,null,"Hypocoagulation state in severe systemic inflammatory response syndrome/sepsis is consistent with endogenous heparinoid effect as detected by thromboelastography","ANAESTHESIA AND INTENSIVE CARE",null,null,"English","Letter",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Durila M, 2010, BLOOD COAGUL FIBRIN, V21, P192, DOI 10.1097/MBC.0b013e3283338c0d; Gibbs NM, 2006, ANAESTH INTENS CARE, V34, P579; Gouvea G, 2009, PEDIATR TRANSPLANT, V13, P1053, DOI 10.1111/j.1399-3046.2008.01108.x; Senzolo M, 2009, LIVER INT, V29, P754, DOI 10.1111/j.1478-3231.2009.01977.x",4,0,0,"AUSTRALIAN SOC ANAESTHETISTS","EDGECLIFF","P O BOX 600, EDGECLIFF, NSW 2027, AUSTRALIA","0310-057X",null,null,"ANAESTH INTENS CARE","Anaesth. Intensive Care","MAY",2011,39,3,null,null,null,null,508,509,null,null,null,2,"Anesthesiology; Critical Care Medicine","Anesthesiology; General & Internal Medicine","773GV","WOS:000291295900034"]
[null,null,null,null,"J","Cerny, V; Herold, I; Cvachovec, K; Sevcik, P; Adamus, M",null,null,null,"Cerny, Vladimir; Herold, Ivan; Cvachovec, Karel; Sevcik, Pavel; Adamus, Milan",null,null,"Guidelines for Managing Neuromuscular Block: Not Only Czech Beer Deserves a Taste","ANESTHESIA AND ANALGESIA",null,null,"English","Letter",null,null,null,null,null,null,"MANAGEMENT",null,"[Cerny, Vladimir] Dalhousie Univ, Dept Anesthesia, Halifax, NS, Canada; [Herold, Ivan] Hosp Mlada Boleslav, Dept Anesthesia & Intens Care, Mlada Boleslav, Czech Republic; [Cvachovec, Karel] Charles Univ Prague, Fac Hosp Motol, Dept Anesthesia & Intens Care, Prague, Czech Republic; [Sevcik, Pavel] Masaryk Univ, Fac Hosp Brno, Fac Med, Dept Anesthesia & Intens Care, Brno, Czech Republic; [Adamus, Milan] Palacky Univ, Fac Hosp Olomouc, Fac Med & Dent, Dept Anesthesia & Intens Care, CR-77147 Olomouc, Czech Republic","Cerny, V (reprint author), Dalhousie Univ, Dept Anesthesia, Halifax, NS, Canada.","milan.adamus@seznam.cz",null,null,null,null,null,8,1,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0003-2999",null,null,"ANESTH ANALG","Anesth. Analg.","FEB",2011,112,2,null,null,null,null,482,482,null,"10.1213/ANE.0b013e3181fff10b",null,1,"Anesthesiology","Anesthesiology","711GV","WOS:000286576000034"]
[null,null,null,null,"J","Lizcova, L; Zemanova, Z; Malinova, E; Michalova, K; Smisek, P; Stary, J",null,null,null,"Lizcova, Libuse; Zemanova, Zuzana; Malinova, Eva; Michalova, Kyra; Smisek, Petr; Stary, Jan",null,null,"Jumping translocations in bone marrow cells of pediatric patients with hematologic malignancies: a rare cytogenetic phenomenon","CANCER GENETICS",null,null,"English","Letter",null,null,null,null,null,null,"LEUKEMIA; DISEASE; 1Q",null,"[Lizcova, Libuse; Zemanova, Zuzana; Malinova, Eva; Michalova, Kyra] Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem, Prague, Czech Republic; [Lizcova, Libuse; Zemanova, Zuzana; Malinova, Eva; Michalova, Kyra] Charles Univ Prague, Diagnost Lab, Gen Univ Hosp, Prague, Czech Republic; [Lizcova, Libuse; Zemanova, Zuzana; Malinova, Eva; Michalova, Kyra] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Smisek, Petr; Stary, Jan] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague, Czech Republic; [Smisek, Petr; Stary, Jan] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic","Lizcova, L (reprint author), Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem, Prague, Czech Republic.","libuse.lizcova@vfn.cz",null,null,null,null,null,11,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","2210-7762",null,null,"CANCER GENET-NY","Cancer Genet.","JUN",2011,204,6,null,null,null,null,348,349,null,"10.1016/j.cancergen.2011.04.008",null,2,"Oncology; Genetics & Heredity","Oncology; Genetics & Heredity","799DF","WOS:000293263000010"]
[null,null,null,null,"J","Cmejla, R; Ludikova, B; Pospisilova, D; Sukova, M; Blatny, J",null,null,null,"Cmejla, Radek; Ludikova, Barbora; Pospisilova, Dagmar; Sukova, Martina; Blatny, Jan",null,null,"Can mutations in the ribosomal protein S26 (RPS26) gene lead to Klippel-Feil syndrome in Diamond-Blackfan anemia patients? An update from the Czech Diamond-Blackfan Anemia registry","BLOOD CELLS MOLECULES AND DISEASES",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Ludikova, Barbora; Pospisilova, Dagmar] Palacky Univ, Dept Pediat, CR-77147 Olomouc, Czech Republic; [Cmejla, Radek] Inst Hematol & Blood Transfus, Dept Cell Physiol, CR-12820 Prague, Czech Republic; [Sukova, Martina] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Blatny, Jan] Univ Hosp Brno, Dept Pediat Hematol, Brno, Czech Republic","Pospisilova, D (reprint author), Palacky Univ, Dept Pediat, CR-77147 Olomouc, Czech Republic.","pospisid@fnol.cz",null,null,null,null,null,8,2,2,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1079-9796",null,null,"BLOOD CELL MOL DIS","Blood Cells Mol. Dis.","APR 15",2011,46,4,null,null,null,null,300,301,null,"10.1016/j.bcmd.2011.02.003",null,2,"Hematology","Hematology","753DV","WOS:000289746800007"]
[null,null,null,null,"J","Ilina, M; Lowe, M; Marek, J",null,null,null,"Ilina, Maria; Lowe, Martin; Marek, Jan",null,null,"Response to \"Resolution of Dyssynchronous Left Ventricular Failure via Cardiac Resynchronization and Subsequent Radiofrequency Ablation in an Infant with Preexcitation\"","PEDIATRIC CARDIOLOGY",null,null,"English","Letter",null,null,null,null,null,null,"INTIMAL PLAQUE-FORMATION; CORONARY-ARTERY; CATHETER ABLATION; PATHWAYS",null,"[Ilina, Maria; Marek, Jan] Great Ormond St Hosp Sick Children, Dept Cardiol, London WC1N 3JH, England; [Lowe, Martin] Heart Hosp, Dept Adult Congenital Heart Dis, London, England","Ilina, M (reprint author), Great Ormond St Hosp Sick Children, Dept Cardiol, Great Ormond St, London WC1N 3JH, England.","maria.ilina@btinternet.com",null,null,null,null,"Bertram H, 2001, CIRCULATION, V103, P538; Ilina MV, 2010, PEDIATR CARDIOL, V31, P897, DOI 10.1007/s00246-010-9733-6; Kriebel T, 2009, PACE, V32, P1197, DOI 10.1111/j.1540-8159.2009.02465.x; Mandapati R, 2003, AM J CARDIOL, V92, P947, DOI 10.1016/S0002-9149(03)00975-5; Paul T, 1997, AM HEART J, V133, P436, DOI 10.1016/S0002-8703(97)70185-6; Sarquella-Brugada G, 2010, 44 AEPC ANN M INNSBR; Sarquella-Brugada G, 2010, PEDIATR CARDIOL, V31, P1257, DOI 10.1007/s00246-010-9791-9; Schneider HE, 2009, HEART RHYTHM, V6, P461, DOI 10.1016/j.hrthm.2009.01.029; Sturm M, 2004, Z KARDIOL, V93, P884, DOI 10.1007/s00392-004-0142-9",9,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0172-0643",null,null,"PEDIATR CARDIOL","Pediatr. Cardiol.","JAN",2011,32,1,null,null,null,null,119,120,null,"10.1007/s00246-010-9848-9",null,2,"Cardiac & Cardiovascular Systems; Pediatrics","Cardiovascular System & Cardiology; Pediatrics","704PR","WOS:000286065400026"]
[null,null,null,null,"J","Ferlito, A; Robbins, KT; Shah, JP; Medina, JE; Silver, CE; Al-Tamimi, S; Fagan, JJ; Paleri, V; Takes, RP; Bradford, CR; Devaney, KO; Stoeckli, SJ; Weber, RS; Bradley, PJ; Suarez, C; Leemans, CR; Coskun, HH; Pitman, KT; Shaha, AR; de Bree, R; Hartl, DM; Haigentz, M; Rodrigo, JP; Hamoir, M; Khafif, A; Langendijk, JA; Owen, RP; Sanabria, A; Strojan, P; Poorten, VV; Werner, JA; Bien, S; Woolgar, JA; Zbaren, P; Betka, J; Folz, BJ; Genden, EM; Talmi, YP; Strome, M; Botas, JHG; Olofsson, J; Kowalski, LP; Holmes, JD; Hisa, Y; Rinaldo, A",null,null,null,"Ferlito, Alfio; Robbins, K. Thomas; Shah, Jatin P.; Medina, Jesus E.; Silver, Carl E.; Al-Tamimi, Shawkat; Fagan, Johannes J.; Paleri, Vinidh; Takes, Robert P.; Bradford, Carol R.; Devaney, Kenneth O.; Stoeckli, Sandro J.; Weber, Randal S.; Bradley, Patrick J.; Suarez, Carlos; Leemans, C. Rene; Coskun, H. Hakan; Pitman, Karen T.; Shaha, Ashok R.; de Bree, Remco; Hartl, Dana M.; Haigentz, Missak, Jr.; Rodrigo, Juan P.; Hamoir, Marc; Khafif, Avi; Langendijk, Johannes A.; Owen, Randall P.; Sanabria, Alvaro; Strojan, Primoz; Poorten, Vincent Vander; Werner, Jochen A.; Bien, Stanislaw; Woolgar, Julia A.; Zbaeren, Peter; Betka, Jan; Folz, Benedikt J.; Genden, Eric M.; Talmi, Yoav P.; Strome, Marshall; Gonzalez Botas, Jesus Herranz; Olofsson, Jan; Kowalski, Luiz P.; Holmes, Jon D.; Hisa, Yasuo; Rinaldo, Alessandra",null,null,"PROPOSAL FOR A RATIONAL CLASSIFICATION OF NECK DISSECTIONS","HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK",null,null,"English","Editorial Material",null,null,null,null,null,null,"HEAD; CHEMORADIATION; TERMINOLOGY; SURGERY; ACADEMY; UPDATE",null,"[Ferlito, Alfio; Rinaldo, Alessandra] Univ Udine, ENT Clin, Dept Surg Sci, I-33100 Udine, Italy; [Robbins, K. Thomas] So Illinois Univ, Sch Med, Div Otolaryngol Head & Neck Surg, Springfield, IL USA; [Shah, Jatin P.; Shaha, Ashok R.] Mem Sloan Kettering Canc Ctr, Head & Neck Serv, New York, NY 10021 USA; [Medina, Jesus E.] Univ Oklahoma, Hlth Sci Ctr, Dept Otorhinolaryngol, Oklahoma City, OK USA; [Silver, Carl E.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Surg, Bronx, NY 10467 USA; [Silver, Carl E.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Otolaryngol Head & Neck Surg, Bronx, NY 10467 USA; [Al-Tamimi, Shawkat] Royal Med Serv, King Hussein Med Ctr, Dept Otolaryngol Head & Neck Surg, Amman, Jordan; [Fagan, Johannes J.] Univ Cape Town, Fac Hlth Sci, Div Otolaryngol, ZA-7925 Cape Town, South Africa; [Paleri, Vinidh] Newcastle Upon Tyne Fdn Hosp NHS Trust, Dept Otolaryngol Head & Neck Surg, Newcastle Upon Tyne, Tyne & Wear, England; [Takes, Robert P.] Radboud Univ Nijmegen, Med Ctr, Dept Otolaryngol Head & Neck Surg, NL-6525 ED Nijmegen, Netherlands; [Bradford, Carol R.] Univ Michigan, Dept Otolaryngol Head & Neck Surg, Ann Arbor, MI 48109 USA; [Devaney, Kenneth O.] Allegiance Hlth, Dept Pathol, Jackson, MI USA; [Stoeckli, Sandro J.] Kantonsspital, Dept Otorhinolaryngol Head & Neck Surg, St Gallen, Switzerland; [Weber, Randal S.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Bradley, Patrick J.] Univ Nottingham Hosp, Dept Otorhinolaryngol Head & Neck Surg, Nottingham NG7 2UH, England; [Suarez, Carlos; Rodrigo, Juan P.] Hosp Univ Cent Asturias, Dept Otolaryngol, Oviedo, Spain; [Suarez, Carlos; Rodrigo, Juan P.] Inst Univ Oncol Principado Asturias, Oviedo, Spain; [Leemans, C. Rene; de Bree, Remco] Vrije Univ Amsterdam Med Ctr, Dept Otolaryngol Head & Neck Surg, Amsterdam, Netherlands; [Coskun, H. Hakan] Uludag Univ Sch Med, Dept Otolaryngol Head & Neck Surg, Bursa, Turkey; [Pitman, Karen T.] Univ Mississippi, Med Ctr, Dept Otolaryngol & Communicat Sci, Jackson, MS 39216 USA; [Hartl, Dana M.] Inst Gustave Roussy, Dept Otolaryngol Head & Neck Surg, Villejuif, France; [Hartl, Dana M.] Sorbonne Nouvelle, Lab Phonet & Phonol, Paris, France; [Haigentz, Missak, Jr.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Oncol, Bronx, NY 10467 USA; [Hamoir, Marc] St Luc Univ Hosp & Canc Ctr, Dept Head & Neck Surg, Head & Neck Oncol Program, Brussels, Belgium; [Khafif, Avi] Assuta Med Ctr, ARM Ctr Adv Otolaryngol Head & Neck Surg, Head & Neck Surg & Oncol Unit, Tel Aviv, Israel; [Langendijk, Johannes A.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands; [Owen, Randall P.] Mt Sinai Sch Med, Dept Surg, Div Metab Endocrine & Minimally Invas Surg, New York, NY USA; [Sanabria, Alvaro] Univ La Sabana Fdn Abood Shaio, Dept Surg, Bogota, Colombia; [Strojan, Primoz] Inst Oncol, Dept Radiat Oncol, Ljubljana, Slovenia; [Poorten, Vincent Vander] Univ Hosp Leuven, Dept Otorhinolaryngol Head & Neck Surg, Leuven, Belgium; [Werner, Jochen A.] Univ Marburg, Dept Otolaryngol Head & Neck Surg, Marburg, Germany; [Bien, Stanislaw] Holy Cross Canc Ctr, Dept Otolaryngol Head & Neck Surg, Kielce, Poland; [Woolgar, Julia A.] Univ Liverpool Dent Hosp, Liverpool, Merseyside, England; [Zbaeren, Peter] Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Bern, Switzerland; [Betka, Jan] Charles Univ Prague, Fac Hosp Motol, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague, Czech Republic; [Folz, Benedikt J.] Karl Hansen Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Bad Lippspringe, Germany; [Genden, Eric M.] Mt Sinai Med Ctr, Dept Otolaryngol Head & Neck Surg, New York, NY 10029 USA; [Talmi, Yoav P.] Tel Aviv Univ, Sackler Sch Med, Chaim Sheba Med Ctr, Head & Neck Serv, IL-69978 Tel Aviv, Israel; [Strome, Marshall] Cleveland Clin, Head & Neck Inst, Dept Otolaryngol & Communicat Disorders, Cleveland, OH 44106 USA; [Gonzalez Botas, Jesus Herranz] Univ Hosp A Coruna, Dept Otorhinolaryngol, La Coruna, Spain; [Olofsson, Jan] Haukeland Hosp, Dept Otolaryngol Head & Neck Surg, N-5021 Bergen, Norway; [Kowalski, Luiz P.] Ctr Tratamento & Pesquisa Hosp Canc AC Camargo, Dept Otorhinolaryngol Head & Neck Surg, Sao Paulo, Brazil; [Holmes, Jon D.] Univ Alabama, Dept Oral & Maxillofacial Surg, Birmingham, AL USA; [Hisa, Yasuo] Kyoto Prefectural Univ Med, Dept Otolaryngol Head & Neck Surg, Kyoto, Japan","Ferlito, A (reprint author), Univ Udine, ENT Clin, Dept Surg Sci, I-33100 Udine, Italy.","a.ferlito@uniud.it","Oncogenomica, Inct/H-9999-2013",null,null,null,null,24,7,7,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1043-3074",null,null,"HEAD NECK-J SCI SPEC","Head Neck-J. Sci. Spec. Head Neck","MAR",2011,33,3,null,null,null,null,445,450,null,"10.1002/hed.21614",null,6,"Otorhinolaryngology; Surgery","Otorhinolaryngology; Surgery","721RP","WOS:000287372900024"]
[null,null,null,null,"J","Bos-Veneman, NGP; Olieman, R; Tobiasova, Z; Hoekstra, PJ; Katsovich, L; Bothwell, ALM; Leckman, JF; Kawikova, I",null,null,null,"Bos-Veneman, Netty G. P.; Olieman, Renske; Tobiasova, Zuzana; Hoekstra, Pieter J.; Katsovich, Lily; Bothwell, Alfred L. M.; Leckman, James F.; Kawikova, Ivana",null,null,"Altered immunoglobulin profiles in children with Tourette syndrome","BRAIN BEHAVIOR AND IMMUNITY",null,null,"English","Article",null,null,null,null,null,"Tic disorder; Tourette syndrome; Symptom exacerbation; Immunoglobulin","OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; MYCOPLASMA-PNEUMONIAE INFECTION; TIC DISORDER; T-CELLS; ADOLESCENTS; AUTISM; SCALE; RESPONSIVITY; ASSOCIATION","Background: Post-infectious autoimmunity and immune deficiency have been implicated in the pathogenesis of Tourette syndrome (TS). We asked here whether B cell immunity of patients with TS differs from healthy subjects. Methods: In two independent cross-sectional samples, we compared serum levels of IgG1, IgG2, IgG3, IgG4, IgM, IgA, and IgE in 21 patients with TS from Yale University (17 males, 4 females, 8-16 years) versus 21 healthy controls (13 males, 8 females, 7-17 years); and in 53 patients with IS from Groningen University (45 males, 8 females, 6-18 years) versus 53 healthy controls (22 males, 31 females, 6-18 years), respectively. We also investigated correlations between Ig concentrations and symptom severity. In 13 additional patients (9 males, 4 females, age range 9-14), we established Ig profiles at time points before, during, and after symptom exacerbations. Results: IgG3 levels were significantly lower in Yale patients compared to healthy children (medians 0.28 versus 0.49 mg/ml, p = .04), while levels of IgG2, IgG4, and IgM in patients were lower at trend-level significance (p Decreased IgG3 (medians 0.45 versus 0.52 mg/ml; p = .05) and IgM (medians 0.30 versus 0.38 mg/ml; p = .04) levels were replicated in the Groningen patients. Ig levels did not correlate with symptom severity. There was a trend-level elevation of IgG1 during symptom exacerbations (p = .09). Conclusion: These pilot data indicate that at least some patients with IS have decreased serum IgG3, and possibly also IgM levels, though only few subjects had fully expressed Ig immunodeficiency. Whether these changes are related to TS pathogenesis needs to be investigated. (C) 2010 Elsevier Inc. All rights reserved.","[Olieman, Renske; Tobiasova, Zuzana; Katsovich, Lily; Bothwell, Alfred L. M.; Kawikova, Ivana] Yale Univ, Dept Immunobiol, Sch Med, New Haven, CT 06511 USA; [Bos-Veneman, Netty G. P.; Hoekstra, Pieter J.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, NL-9700 AB Groningen, Netherlands; [Leckman, James F.] Yale Univ, Sch Med, Yale Child Study Ctr, New Haven, CT 06511 USA","Kawikova, I (reprint author), Yale Univ, Sch Med, POB 207900,230 S Frontage Rd,Room 1-382, New Haven, CT 06519 USA.","N.Bos-Veneman@Accare.nl; renskeolieman@hotmail.com; zuzana.tobiasova@yale.edu; p.hoekstra@accare.nl; lily.katsovich@yale.edu; alfred.bothwell@yale.edu; james.leckman@yale.edu; ivana.kawikova@yale.edu",null,null,"Tourette's Syndrome Association; National Institute of Health [MH066187, P01MH049351, R01MH061940, R01NS42240, MH014235, K05 MH076273, M01RR006022, RR00125]; Groningen University; Marco Polo Scholarship; Czech Ministry of Education [MSM 00211620812]; NIH; Klingenstein Third Generation Foundation; John Wiley and Sons; McGraw Hill; Oxford University Press","The research was supported by Tourette's Syndrome Association (IK), National Institute of Health Grant Nos. MH066187, P01MH049351 (JFL), R01MH061940 (JFL), R01NS42240, MH014235, K05 MH076273 (JFL), M01RR006022, and RR00125. Dr. Olieman was supported during her stay at Yale University by Groningen University Funds, Marco Polo Scholarship and Tourette's Syndrome Association. Dr. Tobiasova was supported by Tourette's Syndrome Association and by the Czech Ministry of Education (MSM 00211620812). Support of James F. Leckman for the past three years: NIH (salary and research funding), Tourette Syndrome Association (research funding), Klingenstein Third Generation Foundation (medical student fellowship program), John Wiley and Sons (book royalties), McGraw Hill (book royalties), Oxford University Press (book royalties). Other authors do not claim any conflict of interest.","Baron-Cohen S, 1999, PSYCHOL MED, V29, P1151, DOI 10.1017/S003329179900896X; Boscarino JA, 2004, ANN NY ACAD SCI, V1032, P141, DOI 10.1196/annals.1314.011; Brynska A, 2001, EUR CHILD ADOLES PSY, V10, P200; Bussone G, 2009, AUTOIMMUN REV, V8, P332, DOI 10.1016/j.autrev.2008.11.004; CHAPPELL P, 1994, BIOL PSYCHIAT, V36, P35, DOI 10.1016/0006-3223(94)90060-4; Corbett BA, 2008, PSYCHONEUROENDOCRINO, V33, P810, DOI 10.1016/j.psyneuen.2008.03.014; Du XL, 2006, GENOMICS, V87, P693, DOI 10.1016/j.ygeno.2006.02.003; Gabbay V, 2009, PROG NEURO-PSYCHOPH, V33, P967, DOI 10.1016/j.pnpbp.2009.05.001; Gill JM, 2009, PERSPECT PSYCHIATR C, V45, P262, DOI 10.1111/j.1744-6163.2009.00229.x; Giovannoni Gavin, 2006, Adv Neurol, V99, P159; Goldstein MF, 2008, CLIN DEV IMMUNOL, DOI 10.1155/2008/624850; Gotovac K, 2010, PROG NEURO-PSYCHOPH, V34, P597, DOI 10.1016/j.pnpbp.2010.02.018; Heuer L, 2008, AUTISM RES, V1, P275, DOI 10.1002/aur.42; Hoekstra PJ, 2004, CELL MOL LIFE SCI, V61, P886, DOI 10.1007/s00018-003-3320-4; Hoekstra PJ, 2005, J CHILD ADOL PSYCHOP, V15, P285, DOI 10.1089/cap.2005.15.285; Inoue-Sakurai C, 2000, PREV MED, V31, P467, DOI 10.1006/pmed.2000.0744; Ivarsson T, 2008, J ANXIETY DISORD, V22, P969, DOI 10.1016/j.janxdis.2007.10.003; KAWIKOVA I, 2010, BIOL PSYCHIAT, V67, P596; Kawikova I, 2007, BIOL PSYCHIAT, V61, P273, DOI 10.1016/j.biopsych.2006.06.012; KIESSLING LS, 1993, PEDIATRICS, V92, P39; Krnic EK, 2007, CLIN EXP IMMUNOL, V149, P303, DOI 10.1111/j.1365-2249.2007.03410.x; LECKMAN JF, 1989, J AM ACAD CHILD PSY, V28, P566, DOI 10.1097/00004583-198907000-00015; Leckman JF, 2005, BIOL PSYCHIAT, V57, P667, DOI 10.1016/j.biopsych.2004.12.004; Leckman JF, 2002, LANCET, V360, P1577, DOI 10.1016/S0140-6736(02)11526-1; LESLIE DL, 2008, J AM ACAD CHILD ADOL; Libbey JE, 2008, J AUTISM DEV DISORD, V38, P324, DOI 10.1007/s10803-007-0400-6; Lin HQ, 2007, J CHILD PSYCHOL PSYC, V48, P157, DOI 10.1111/j.1469-7610.2006.01687.x; Lit L, 2007, AM J MED GENET B, V144B, P958, DOI 10.1002/ajmg.b.30550; Lombroso PJ, 2008, BRAIN DEV-JPN, V30, P231, DOI 10.1016/j.braindev.2007.09.001; Martino D, 2009, MOVEMENT DISORD, V24, P1267, DOI 10.1002/mds.22504; Mell LK, 2005, PEDIATRICS, V116, P56, DOI 10.1542/peds.2004-2058; Meyts I, 2006, PEDIATR ALLERGY IMMU, V17, P544, DOI 10.1111/j.1399-3038.2006.00454.x; Moller JC, 2008, EUR J NEUROL, V15, P749, DOI 10.1111/j.1468-1331.2008.02159.x; Muller N, 2000, AM J PSYCHIAT, V157, P481; Muller N, 2004, PSYCHIAT RES, V129, P119, DOI 10.1016/j.psychres.2004.04.009; NOYES J, 1986, ANN ALLERGY, V57, P273; Oxelius V A, 1986, Monogr Allergy, V20, P106; Riedel M, 1998, LANCET, V351, P418, DOI 10.1016/S0140-6736(05)78357-4; Ritchie RF, 1998, J CLIN LAB ANAL, V12, P371, DOI 10.1002/(SICI)1098-2825(1998)12:6<371::AID-JCLA7>3.0.CO;2-T; Scahill L, 1997, J AM ACAD CHILD PSY, V36, P844, DOI 10.1097/00004583-199706000-00023; Scahill L, 1996, J CHILD ADOL PSYCHOP, V6, P191, DOI 10.1089/cap.1996.6.191; Shibuya A, 2000, NAT IMMUNOL, V1, P441, DOI 10.1038/80886; Sommershof A, 2009, BRAIN BEHAV IMMUN, V23, P1117, DOI 10.1016/j.bbi.2009.07.003; Swedo SE, 1998, AM J PSYCHIAT, V155, P264; WARREN RP, 1994, ARCH PEDIAT ADOL MED, V148, P180; Woof JM, 2006, J PATHOL, V208, P270, DOI 10.1002/path.1877; YADDANAPUDI K, 2009, MOL PSYCHIAT; Yel L, 2009, INT ARCH ALLERGY IMM, V150, P291, DOI 10.1159/000222682",48,6,6,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0889-1591",null,null,"BRAIN BEHAV IMMUN","Brain Behav. Immun.","MAR",2011,25,3,null,null,null,null,532,538,null,"10.1016/j.bbi.2010.12.003",null,7,"Immunology; Neurosciences","Immunology; Neurosciences & Neurology","725DY","WOS:000287626600018"]
[null,null,null,null,"J","Fulin, P; Pokorny, D; Slouf, M; Lapcikova, M; Pavlova, E; Zolotarevova, E",null,null,null,"Fulin, P.; Pokorny, D.; Slouf, M.; Lapcikova, M.; Pavlova, E.; Zolotarevova, E.",null,null,"MORF Method for Assessment of the Size and Shape of UHMWPE Wear Microparticles and Nanoparticles in Periprosthetic Tissues","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"UHMWPE; wear debris; total joint replacement; morphology of wear particles","TOTAL HIP-ARTHROPLASTY; FAILED TOTAL HIP; POLYETHYLENE WEAR; IN-VIVO; RADIOGRAPHIC APPEARANCE; KNEE ARTHROPLASTY; SYNOVIAL-FLUID; PARTICLES; DEBRIS; REPLACEMENT","PURPOSE OF STUDY Aseptic loosening of total joint replacement (TJR) due to wear of ultra-high molecular weight polyethylene (UHMWPE) is regarded as one of the major problems in the field of arthroplasty. This work describes a newly developed method, called MORF, which completely describes the morphology of UHMWPE wear particles. The differences in wear particle morphology may help to elucidate individual differences in TJR failures. MATERIAL AND METHODS During the years 2002-2010, a set of 47 typical damaged periprosthetic tissues, coming from 16 TJR revisions, was collected. Isolated on polycarbonate (PC) filters were quantified. Quantification of the particles consisted in determination of their concentration and description of their morphology by means of the newly developed MORF method. Firstly, the micrographs of isolated UHMWPE particles were obtained with a scanning electron microscope (Quanta 200 FEG; FEI) at two magnifications: x1200 and x6000. Secondly, both high- and low-magnification micrographs were processed by a standard image analysis software (program NIS Elements; Laboratory Imaging) in order to obtain basic morphological descriptors. Finally, the results from image analysis of high- and low- magnification micrographs were combined by means of our own program MDISTR in order to obtain correct particle sizes and shapes. RESULTS In the first stage, the method was applied to 25 samples and yielded an average particle size of 0.51 mu m. In the second stage, the method was further improved in order to calculate not only the size of particles but also the shape of descriptors. The improved method was applied to eight samples and gave an average size of particles (equivalent diameter, D) in the range of 0.27 - 0.60 mu m, circularity (C) of 0.66-0.85 and elongation (E) of 1.75-1.79, suggesting that the great majority of particles were approximately spherical. Finally, in the third stage, the MORF method was applied to two exceptional samples which contained extremely small wear particles (D = 18.5 nm and 21.2 nm). The shape of these small wear nanoparticles (C = 0.97 and 0.93; E = 1.29 and 1.35) was even more spherical than that of wear microparticles described above. This was one of the first two studies which proved the presence of UHMWPE wear nanoparticles in vivo. DISCUSSION Our newly developed MORF method described in this contribution yields both size and shape descriptors of UHMWPE wear particles, with sizes from 0.1 to 10 pm, which are regarded as most biologically active. The main objective of the method is to yield the highest accuracy. This is achieved by parallel analyses of high- and low-magnification micrographs taken of the same sample. In the end, the two analyses are combined together in order to obtain the correct and complete size and shape description of all particles in the sample. The morphology of UHMWPE wear particles influences TJR lifetime both directly (size and shape of the particles is related to their biological activity) and indirectly (for the given total volumetric wear, size and shape of the particles influence their concentration, which is associated with the biological response of the organism). CONCLUSION The authors have developed a new method which yields a complete description of the size and shape of UHMWPE wear particles in periprosthetic tissues. The method, which was called MORF, can be applied to studies of TJR failures and also used to evaluate the quality of different UHMWPE components of TJR. The method is quite universal and therefore can be used not only for analyses of wear particles, but also for other types of particles, such as microparticles in polymer blends or inorganic/metallic nanoparticles.","[Fulin, P.; Pokorny, D.] I Ortopedicka Klin 1 LF UK, Prague 15006 5, Czech Republic; [Fulin, P.; Pokorny, D.] FN Motol, Prague 15006 5, Czech Republic; [Slouf, M.; Lapcikova, M.; Pavlova, E.] Ustav Makromol Chem AV CR, Prague, Czech Republic; [Zolotarevova, E.] Prirodovedecka Fak UK, Katedra Biochem, Prague, Czech Republic","Fulin, P (reprint author), I Ortopedicka Klin 1 LF UK, V Uvalu 84, Prague 15006 5, Czech Republic.","petrfulin@volny.cz","Slouf, Miroslav/F-6311-2012","Slouf, Miroslav/0000-0003-1528-802X",null,null,null,33,4,4,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2011,78,2,null,null,null,null,131,137,null,null,null,7,"Orthopedics","Orthopedics","764OL","WOS:000290641200007"]
[null,null,null,null,"J","Oosterlinck, W; Sylvester, R; Babjuk, M; Kaasinen, E; Bohle, A; Palou-Redorta, J; Roupret, M",null,null,null,"Oosterlinck, Willem; Sylvester, Richard; Babjuk, Marco; Kaasinen, Eero; Bohle, Andreas; Palou-Redorta, Juan; Roupret, Morgan",null,"European Assoc Urol","Should All Patients Receive an Immediate Chemotherapeutic Drug Instillation After Resection of Papillary Bladder Tumors?","EUROPEAN UROLOGY",null,null,"English","Editorial Material",null,null,null,null,null,null,"RANDOMIZED CLINICAL-TRIALS; SINGLE-DOSE INSTILLATION; TRANSURETHRAL RESECTION; POSTOPERATIVE INSTILLATION; DOUBLE-BLIND; STAGE TA; CANCER; EPIRUBICIN; CARCINOMA; RECURRENCE",null,"[Oosterlinck, Willem; Sylvester, Richard; Babjuk, Marco; Kaasinen, Eero; Bohle, Andreas; Palou-Redorta, Juan; Roupret, Morgan; European Assoc Urol] Ghent Univ Hosp, Dept Urol, B-9000 Ghent, Belgium","Oosterlinck, W (reprint author), Ghent Univ Hosp, Dept Urol, Pintelaan 185, B-9000 Ghent, Belgium.","willem.oosterlinck@ugent.be",null,null,null,null,"Babjuk M, 2008, EUR UROL, V54, P303, DOI 10.1016/j.eururo.2008.04.051; Berrum-Svennung I, 2008, J UROLOGY, V179, P105; Berrum-Svennung I, 2008, J UROLOGY, V179, P101, DOI 10.1016/j.juro.2007.08.166; Bohle A, 2009, EUR UROL, V56, P495, DOI 10.1016/j.eururo.2009.06.010; Brausi MA, 2010, EUR UROL SUPPL, V9, P406, DOI 10.1016/j.eursup.2010.02.002; Cai T, 2008, J UROLOGY, V180, P110, DOI 10.1016/j.juro.2008.03.038; Dobruch J, 2009, BJU INT, V104, P170, DOI 10.1111/j.1464-410X.2009.08654.x; Gudjonsson S, 2009, EUR UROL, V55, P773, DOI 10.1016/j.eururo.2009.01.006; Hendricksen K, 2008, EUR UROL, V53, P984, DOI 10.1016/j.eururo.2007.12.033; Kaasinen E, 2002, EUR UROL, V42, P167, DOI 10.1016/S0302-2838(02)00260-9; OOSTERLINCK W, 1993, J UROLOGY, V149, P749; Rajala P, 2002, J UROLOGY, V168, P981, DOI 10.1097/01.ju.0000026417.33622.7d; Sylvester RJ, 2008, EUR UROL, V53, P709, DOI 10.1016/j.eururo.2008.01.015; Sylvester RJ, 2004, J UROLOGY, V171, P2186, DOI 10.1097/01.ju.0000125486.92260.b2",14,4,4,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","MAR",2011,59,3,null,null,null,null,374,376,null,"10.1016/j.eururo.2010.12.002",null,3,"Urology & Nephrology","Urology & Nephrology","712IA","WOS:000286658600022"]
[null,null,null,null,"J","Tobiasova, Z; Zhang, LF; Yi, T; Qin, LF; Manes, TD; Kulkarni, S; Lorber, MI; Rodriguez, FC; Choi, JM; Tellides, G; Pober, JS; Kawikova, I; Bothwell, ALM",null,null,null,"Tobiasova, Zuzana; Zhang, Lufeng; Yi, Tai; Qin, Linfeng; Manes, Thomas D.; Kulkarni, Sanjay; Lorber, Marc I.; Rodriguez, Frederick C.; Choi, Je-Min; Tellides, George; Pober, Jordan S.; Kawikova, Ivana; Bothwell, Alfred L. M.",null,null,"Peroxisome Proliferator-Activated Receptor-gamma Agonists Prevent In Vivo Remodeling of Human Artery Induced by Alloreactive T Cells","CIRCULATION",null,null,"English","Article",null,null,null,null,null,"arteriosclerosis; mice; PPAR gamma; T-lymphocytes; vascular diseases","INTIMA-MEDIA THICKNESS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TYPE-2 DIABETES-MELLITUS; SMOOTH-MUSCLE-CELLS; INTERFERON-GAMMA; TRANSPLANT ARTERIOSCLEROSIS; TRANSENDOTHELIAL MIGRATION; ENDOTHELIAL-CELLS; PPAR-GAMMA; INDEPENDENT MECHANISMS","Background-Ligands activating the transcription factor peroxisome proliferator-activated receptor-gamma (PPAR gamma) have antiinflammatory effects. Vascular rejection induced by allogeneic T cells can be responsible for acute and chronic graft loss. Studies in rodents suggest that PPAR gamma agonists may inhibit graft vascular rejection, but human T-cell responses to allogeneic vascular cells differ from those in rodents, and the effects of PPAR gamma in human transplantation are unknown. Methods and Results-We tested the effects of PPAR gamma agonists on human vascular graft rejection using a model in which human artery is interposed into the abdominal aorta of immunodeficient mice, followed by adoptive transfer of allogeneic (to the artery donor) human peripheral blood mononuclear cells. Interferon-gamma -dependent rejection ensues within 4 weeks, characterized by intimal thickening, T-cell infiltrates, and vascular cell activation, a response resembling clinical intimal arteritis. The PPAR gamma agonists 15-deoxy-prostaglandin-J(2), ciglitazone, and pioglitazone reduced intimal expansion, intimal infiltration of CD45RO(+) memory T cells, and plasma levels of inflammatory cytokines. The PPAR gamma antagonist GW9662 reversed the protective effects of PPAR gamma agonists, confirming the involvement of PPAR gamma -mediated pathways. In vitro, pioglitazone inhibited both alloantigen-induced proliferation and superantigen-induced transendothelial migration of memory T cells, indicating the potential mechanisms of PPAR gamma effects. Conclusion-Our results suggest that PPAR gamma agonists inhibit allogeneic human memory T cell responses and may be useful for the treatment of vascular graft rejection. (Circulation. 2011;124:196-205.)","[Tobiasova, Zuzana; Zhang, Lufeng; Yi, Tai; Manes, Thomas D.; Rodriguez, Frederick C.; Pober, Jordan S.; Kawikova, Ivana; Bothwell, Alfred L. M.] Yale Univ, Dept Immunobiol, Sch Med, New Haven, CT 06520 USA; [Qin, Linfeng; Kulkarni, Sanjay; Lorber, Marc I.; Tellides, George] Yale Univ, Dept Surg, Sch Med, New Haven, CT 06520 USA; [Choi, Je-Min] Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea; [Choi, Je-Min] Hanyang Biomed Res Inst, Seoul, South Korea","Kawikova, I (reprint author), Yale Univ, Dept Immunobiol, Sch Med, POB 208011,300 Cedar St, New Haven, CT 06520 USA.","ivana.kawikova@yale.edu; alfred.bothwell@yale.edu","qin, lingfeng/D-9242-2012",null,"Pfizer [RO1 HL088258, PO1-HL070295]; Takeda Pharmaceuticals North America, Inc.; Czech Ministry of Education [MSM 00211620812]; Ministry of Education, Science and Technology [2011-0012859]","This work was supported by a pilot grant from Pfizer to Dr Kawikova, RO1 HL088258 to Dr Bothwell, and PO1-HL070295 to Drs Pober, Tellides, and Bothwell, as well as by Takeda Pharmaceuticals North America, Inc., to Drs Bothwell and Kawikova. Dr Tobiasova was partially supported by MSM 00211620812 by the Czech Ministry of Education. Dr Choi was partially supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2011-0012859).","Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Adams AB, 2003, J CLIN INVEST, V111, P1887, DOI 10.1172/JCI200317477; Artwohl M, 2005, DIABETOLOGIA, V48, P586, DOI 10.1007/s00125-005-1672-z; Atkinson C, 2004, J HEART LUNG TRANSPL, V23, P427, DOI 10.1016/S1053-2498(03)00222-5; Crosby MB, 2005, MOL IMMUNOL, V42, P1303, DOI 10.1016/j.molimm.2004.12.009; Davidson M, 2008, CIRCULATION, V117, P2123, DOI 10.1161/CIRCULATIONAHA.107.746610; Davis MM, 2008, IMMUNITY, V29, P835, DOI 10.1016/j.immuni.2008.12.003; Diab A, 2002, J IMMUNOL, V168, P2508; Forst T, 2008, DIABETES VASC DIS RE, V5, P298, DOI 10.3132/dvdr.2008.043; Halloran PF, 1997, TRANSPLANT P, V29, P1041, DOI 10.1016/S0041-1345(96)00361-2; Hontecillas R, 2007, J IMMUNOL, V178, P2940; Joner M, 2007, ARTERIOSCL THROM VAS, V27, P182, DOI 10.1161/01.ATV.0000251021.28725.e8; Kostadinova R, 2005, CURR MED CHEM, V12, P2995, DOI 10.2174/092986705774462905; Kosuge H, 2006, CIRCULATION, V113, P2613, DOI 10.1161/CIRCULATIONAHA.105.594101; Kreisel D, 2002, NAT MED, V8, P233, DOI 10.1038/nm0302-233; Langenfeld MR, 2005, CIRCULATION, V111, P2525, DOI 10.1161/01.CIR.0000165072.01672.21; Lechler RI, 2003, NAT REV IMMUNOL, V3, P147, DOI 10.1038/nri1002; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; Lin YL, 2003, EUR J IMMUNOL, V33, P2736, DOI 10.1002/eji.200324087; Manes TD, 2008, J IMMUNOL, V180, P8386; Manes TD, 2007, J IMMUNOL, V178, P3237; Manes TD, 2010, J IMMUNOL, V184, P5186, DOI 10.4049/jimmunol.0902938; Manes TD, 2011, J IMMUNOL, V186, P1763, DOI 10.4049/jimmunol.1002835; Marx N, 2008, DIABETES VASC DIS RE, V5, P345, DOI 10.3132/dvdr.2008.048; Mazzone T, 2006, JAMA-J AM MED ASSOC, V296, P2572, DOI 10.1001/jama.296.21.joc60158; Mitchell RN, 2009, ANNU REV PATHOL-MECH, V4, P19, DOI 10.1146/annurev.pathol.3.121806.151449; MOMOSE Y, 1991, Chemical and Pharmaceutical Bulletin (Tokyo), V39, P1440; Mora PF, 2005, AM J MED SCI, V329, P86, DOI 10.1097/00000441-200502000-00006; Nadig SN, 2010, NAT MED, V16, P809, DOI 10.1038/nm.2154; Natarajan C, 2002, GENES IMMUN, V3, P59, DOI 10.1038/sj/gene/6363832; Onuta G, 2007, TRANSPLANTATION, V84, P517, DOI 10.1097/01.tp.0000276983.91892.99; Peiris M, 2007, J NEUROSCI METH, V163, P245, DOI 10.1016/j.jneumeth.2007.03.013; PERSHADSINGH HA, 1993, HYPERTENSION, V21, P1020; Pober JS, 2003, SPRINGER SEMIN IMMUN, V25, P167, DOI 10.1007/s00281-003-0135-1; Ranjbaran H, 2007, J IMMUNOL, V178, P592; Ray DM, 2006, J IMMUNOL, V177, P5068; Religa P, 2005, CARDIOVASC RES, V65, P535, DOI 10.1016/j.cardiores.2004.10.011; SALOMON RN, 1991, AM J PATHOL, V138, P791; SAVAGE COS, 1993, TRANSPLANTATION, V56, P128, DOI 10.1097/00007890-199307000-00024; Scher JU, 2005, CLIN IMMUNOL, V114, P100, DOI 10.1016/j.clim.2004.09.008; Shiao SL, 2007, J IMMUNOL, V179, P4397; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Valujskikh A, 2002, AM J TRANSPLANT, V2, P501, DOI 10.1034/j.1600-6143.2002.20603.x; Wang YN, 2004, FASEB J, V18, P606, DOI 10.1096/fj.03-0840fje; Weyand CM, 2008, CURR OPIN LIPIDOL, V19, P469, DOI 10.1097/MOL.0b013e32830bfdc2; Wohlfert EA, 2007, J IMMUNOL, V178, P4129; Yang J, 2007, P NATL ACAD SCI USA, V104, P19954, DOI 10.1073/pnas.0704397104; Yi T, 2006, TRANSPLANTATION, V81, P559, DOI 10.1097/01.tp.0000198737.12507.19; Yi T, 2008, TRANSPLANTATION, V86, P719, DOI 10.1097/TP.0b013e318183eefa",49,2,3,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322",null,null,"CIRCULATION","Circulation","JUL 12",2011,124,2,null,null,null,null,196,"U199",null,"10.1161/CIRCULATIONAHA.110.015396",null,17,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","Cardiovascular System & Cardiology","790PO","WOS:000292601900017"]
[null,null,null,null,"J","Spisek, R",null,null,null,"Spisek, Radek",null,null,"Immunology in the heart of the High Tatra mountains","EUROPEAN JOURNAL OF IMMUNOLOGY",null,null,"English","News Item",null,null,null,null,null,null,null,null,"Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Prague, Czech Republic","Spisek, R (reprint author), Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Prague, Czech Republic.","radek.spisek@lfmotol.cuni.cz","Spisek, Radek/E-6724-2011",null,null,null,"Allhorn M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-3; Asemissen AM, 2009, CANCER IMMUNOL IMMUN, V58, P1169, DOI 10.1007/s00262-009-0706-7; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Fridman WH, 2010, CURR TOP MICROBIOL I; GROS J, 2010, IMMUNITY, V33, P375; McKinney EF, 2010, NAT MED, V16, P591; McKinney EF, 2010, NAT MED, V16, P586, DOI 10.1038/nm.2130; Morova J, 2008, P NATL ACAD SCI USA, V105, P5355, DOI 10.1073/pnas.0711400105; Rivino L, 2010, J EXP MED, V207, P565, DOI 10.1084/jem.20091021",9,3,3,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0014-2980",null,null,"EUR J IMMUNOL","Eur. J. Immunol.","MAR",2011,41,3,null,null,null,null,561,565,null,null,null,5,"Immunology","Immunology","731HU","WOS:000288097700001"]
[null,null,null,null,"J","Babjuk, M",null,null,null,"Babjuk, Marko",null,null,"What Are the Limitations of Endoscopic Management of Urothelial Carcinoma of the Upper Urinary Tract?","EUROPEAN UROLOGY",null,null,"English","Editorial Material",null,null,null,null,null,null,"TRANSITIONAL-CELL CARCINOMA; EXPERIENCE; THERAPY",null,"Charles Univ Prague, Fac Med 2, Hosp Motol, Dept Urol, Prague 15006 5, Czech Republic","Babjuk, M (reprint author), Charles Univ Prague, Fac Med 2, Hosp Motol, Dept Urol, V Uvalu 84, Prague 15006 5, Czech Republic.","marek.babjuk@lfmotol.cuni.cz",null,null,null,null,null,10,1,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","NOV",2011,60,5,null,null,null,null,961,963,null,"10.1016/j.eururo.2011.08.021",null,3,"Urology & Nephrology","Urology & Nephrology","836WW","WOS:000296149400022"]
[null,null,null,null,"J","Dusatkova, P; Pruhova, S; Sumnik, Z; Kolouskova, S; Obermannova, B; Cinek, O; Lebl, J",null,null,null,"Dusatkova, Petra; Pruhova, Stepanka; Sumnik, Zdenek; Kolouskova, Stanislava; Obermannova, Barbora; Cinek, Ondrej; Lebl, Jan",null,null,"HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes","JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM",null,null,"English","Article",null,null,null,null,null,"diabetes; HNF1A-MODY; hypoglycemia; macrosomia","HYPERINSULINEMIC HYPOGLYCEMIA; HNF4A; GENE","Background : HNF1A-MODY (MODY3) is a common subtype of autosomal dominant diabetes. Unlike HNF4-MODY where fetal macrosomia and early postnatal hyperinsulinemic hypoglycemia have been reported, a history of transient insulin overproduction has not been recognized in individuals with HNF1A-MODY yet. Case report : Here, we report a 40-year-old male patient with HNF1A mutation p.Arg272His (c.815G > A) with a history of fetal macrosomia (4750 g, 59 cm) and, at least, one attack of symptomatic hypoglycemia in childhood. Diabetes was subsequently diagnosed at 19 years. The proband's daughter who developed diabetes at 16 years carries the same mutation, but her birth weight and length were in the upper normal range, and she never experienced hypoglycemic symptoms. Conclusion : The observation of fetal macrosomia and hypoglycemia in childhood is suggestive of a biphasic impact of the HNF1A mutation on beta-cell function over the lifespan, leading from inappropriate insulin oversecretion to final clinical diabetes.","[Lebl, Jan] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, CZ-15006 Prague, Czech Republic; Charles Univ Prague, Fac Med 2, CZ-15006 Prague, Czech Republic","Lebl, J (reprint author), Charles Univ Prague, Dept Pediat, Univ Hosp Motol, V Uvalu 84, CZ-15006 Prague, Czech Republic.","jan.lebl@lfmotol.cuni.cz",null,null,"Norway through the Norwegian Financial Mechanism [CZ0100]; Czech Ministry of Health [MZ000064203]; IGA MZCR [NT11402]","The studies of subjects with monogenic diabetes are supported by a grant from Norway through the Norwegian Financial Mechanism (No. CZ0100), by an institutional grant from the Czech Ministry of Health (grant MZ000064203) and by a grant from IGA MZCR (grant NT11402). The authors have no relevant conflict of interest to disclose. They would like to acknowledge the patient and his family. Klara Vesela is thanked for her technical assistance.",null,6,1,1,"WALTER DE GRUYTER & CO","BERLIN","GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY","0334-018X",null,null,"J PEDIATR ENDOCR MET","J. Pediatr. Endocrinol. Metab.","JUN",2011,24,41795,null,null,null,null,377,379,null,"10.1515/JPEM.2011.049",null,3,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","854AP","WOS:000297467200024"]
[null,null,null,null,"J","Tobiasova, Z; van der Lingen, KHB; Scahill, L; Leckman, JF; Zhang, Y; Chae, W; McCracken, JT; McDougle, CJ; Vitiello, B; Tierney, E; Aman, MG; Arnold, LE; Katsovich, L; Hoekstra, PJ; Volkmar, F; Bothwell, ALM; Kawikova, I",null,null,null,"Tobiasova, Zuzana; van der Lingen, Klaas H. B.; Scahill, Lawrence; Leckman, James F.; Zhang, Yan; Chae, Wookjin; McCracken, James T.; McDougle, Christopher J.; Vitiello, Benedetto; Tierney, Elaine; Aman, Michael G.; Arnold, L. Eugene; Katsovich, Liliya; Hoekstra, Pieter J.; Volkmar, Fred; Bothwell, Alfred L. M.; Kawikova, Ivana",null,null,"Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13","JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,null,"HIGH-FUNCTIONING AUTISM; SPECTRUM DISORDERS; NECROTIZING ENTEROCOLITIS; SCHIZOPHRENIC-PATIENTS; ANTIBRAIN ANTIBODIES; CEREBROSPINAL-FLUID; CYTOKINE PRODUCTION; INTESTINAL BARRIER; IMMUNE-RESPONSES; NITRIC-OXIDE","Risperidone has been shown to improve serious behavioral problems in children with autism. Here we asked whether risperidone-associated improvement was related to changes in concentrations of inflammatory molecules in the serum of these subjects. Seven molecules were identified as worthy of further assessment by performing a pilot analysis of 31 inflammatory markers in 21 medication-free subjects with autism versus 15 healthy controls: epidermal growth factor (EGF), interferon-gamma (IFN-gamma), interleukin (IL)-13, IL-17, monocyte chemoattractant protein-1 (MCP-1), IL-1 and IL-1-receptor antagonist. Serum concentrations of these markers were then established in a different set of subjects that participated in a double-blind, clinical trial and an expanded group of healthy subjects. In the first analysis, samples obtained from subjects with autism at baseline visits were compared to visits after 8-week treatment with placebo (n = 37) or risperidone (n = 40). The cytokine concentrations remained stable over the 8-week period for both risperidone and placebo groups. In the second analysis, we explored further the differences between medication-free subjects with autism (n = 77) and healthy controls (recruited independently; n = 19). Serum levels of EGF were elevated in subjects with autism (median = 103 pg/mL, n = 75) in comparison to healthy controls (75 pg/mL, n = 19; p<0.05), and levels of IL-13 were decreased in autism (median = 0.8 pg/mL, n = 77) in comparison to controls (9.8 pg/mL, n = 19; p = 0.0003). These changes did not correlate with standardized measures used for a diagnosis of autism. In summary, risperidone-induced clinical improvement in subjects with autism was not associated with changes in the serum inflammatory markers measured. Whether altered levels of EGF and IL-13 play a role in the pathogenesis or phenotype of autism requires further investigation.","[Tobiasova, Zuzana; van der Lingen, Klaas H. B.; Zhang, Yan; Chae, Wookjin; Kawikova, Ivana] Yale Univ, Dept Immunobiol, Sch Med, New Haven, CT 06520 USA; [van der Lingen, Klaas H. B.; Leckman, James F.; Volkmar, Fred] Yale Univ, Ctr Child Study, Sch Med, New Haven, CT 06520 USA; [Scahill, Lawrence] Yale Univ, Sch Nursing, New Haven, CT 06520 USA; [McCracken, James T.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst, Div Child & Adolescent Psychiat, Los Angeles, CA 90095 USA; [McDougle, Christopher J.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN USA; [Vitiello, Benedetto] NIMH, Bethesda, MD 20892 USA; [Tierney, Elaine] Johns Hopkins Univ, Sch Med, Dept Psychiat, Kennedy Krieger Inst, Baltimore, MD 21205 USA; [Aman, Michael G.] Ohio State Univ, Nisonger Ctr, Columbus, OH 43210 USA; [Arnold, L. Eugene] Ohio State Univ, Dept Psychiat, Columbus, OH 43210 USA; [van der Lingen, Klaas H. B.; Hoekstra, Pieter J.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, NL-9700 AB Groningen, Netherlands","Kawikova, I (reprint author), Yale Univ, Dept Immunobiol, Sch Med, 630 TAC,300 Cedar St, New Haven, CT 06520 USA.","ivana.kawikova@yale.edu",null,null,"NIMH [N01MH70001, N01MH80011, N01MH70010, MH01805, N01MH70009]; Czech Ministry of Education [MSM 0021620812]; Klaas van der Lingen by Groningen University; Bristol-Myers Squibb Co.;  [1474]","Autism Speaks grant number 1474 to Ivana Kawikova, NIMH grant N01MH70001 to Indiana University, NIMH grant number N01MH80011 to Ohio State University, NIMH grants N01MH70010 and MH01805 to University of California Los Angeles, NIMH grant N01MH70009 to Yale.This study was supported by a grant from Autism Speaks (to Dr. Kawikova). Dr. Tobiasova was partially supported by Czech Ministry of Education (MSM 0021620812) and Klaas van der Lingen by Groningen University Fund. The analysis was performed on archived samples collected during previous studies performed by the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Dr. McCracken at University of California Los Angeles; Dr. Aman at Ohio State University; Dr. McDougle at Indiana University; Dr. Scahill at Yale University; Dr. Tierney at Kennedy Krieger Institute. The RUPP network was funded by NIMH: N01MH70001 to IU, N01MH80011 to OSU, N01MH70010 and MH01805 to UCLA, N01MH70009 to Yale. Collection of serum samples of healthy controls was supported by The Brian and Linda Richmand Foundation at Yale University (to Dr. Leckman). Christopher J. McDougle is a consultant to Bristol-Myers Squibb Co., F. Hoffmann-LaRoche, Ltd., and Forest Research Institute; has received research grants from Bristol-Myers Squibb Co., and is a member of the speaker's bureau for Bristol-Myers Squibb Co. Pieter Hoekstra has been paid consultant for Shire, Eli Lilly, and Desitin. James McCracken has had research contracts with Seaside, Bristol-Myers Squibb, has been consultant for Shionogi, BioMarin and receives honoraria from CME Outfitters, Veritas, Tourette Syndrome Association and APSARD. Drs. Zhang, Chae, Vitiello, Arnold, Volkmar, and Bothwell and Ms. Katsovich have no conflicts of interest or financial ties to disclose.","Ashwood P, 2011, BRAIN BEHAV IMMUN, V25, P840, DOI 10.1016/j.bbi.2010.09.002; Ashwood P, 2008, J NEUROIMMUNOL, V204, P149, DOI 10.1016/j.jneuroim.2008.07.006; Ashwood P, 2011, BRAIN BEHAV IMMUN, V25, P40, DOI 10.1016/j.bbi.2010.08.003; Bauman ML, 2005, INT J DEV NEUROSCI, V23, P183, DOI 10.1016/j.ijdevneu.2004.09.006; Brown EC, 2002, RES DEV DISABIL, V23, P45, DOI 10.1016/S0891-4222(01)00091-9; Buie T, 2010, PEDIATRICS, V125, pS1, DOI 10.1542/peds.2009-1878C; Campbell DB, 2009, PEDIATRICS, V123, P1018, DOI 10.1542/peds.2008-0819; Cazzullo CL, 2002, PROG NEURO-PSYCHOPH, V26, P33, DOI 10.1016/S0278-5846(01)00221-4; Chez MG, 2007, PEDIATR NEUROL, V36, P361, DOI 10.1016/j.pediatrneurol.2007.01.012; Clark JA, 2006, AM J PHYSIOL-GASTR L, V291, pG938, DOI 10.1152/ajpgi.00090.2006; Corbett BA, 2009, AUTISM RES, V2, P39, DOI 10.1002/aur.64; Courchesne E, 2011, BRAIN RES, V1380, P138, DOI 10.1016/j.brainres.2010.09.101; Crespo-Facorro B, 2008, PSYCHIAT RES, V158, P206, DOI 10.1016/j.psychres.2006.08.005; Croonenberghs J, 2002, NEUROPSYCHOBIOLOGY, V45, P1, DOI 10.1159/000048665; de Magistris L, 2010, J PEDIATR GASTR NUTR, V51, P418, DOI 10.1097/MPG.0b013e3181dcc4a5; DEufemia P, 1996, ACTA PAEDIATR, V85, P1076, DOI 10.1111/j.1651-2227.1996.tb14220.x; Emanuele E, 2010, CLIN BIOCHEM, V43, P317, DOI 10.1016/j.clinbiochem.2009.10.005; Enstrom AM, 2009, BRAIN BEHAV IMMUN, V23, P124, DOI 10.1016/j.bbi.2008.08.001; Erbagci AB, 2001, MEDIAT INFLAMM, V10, P109, DOI 10.1080/09629350120072761; Erickson CA, 2005, J AUTISM DEV DISORD, V35, P713, DOI 10.1007/s10803-005-0019-4; Geschwind DH, 2008, CELL, V135, P391, DOI 10.1016/j.cell.2008.10.016; Goines P, 2010, CURR OPIN NEUROL, V23, P111, DOI 10.1097/WCO.0b013e3283373514; Iseri E, 2011, J AUTISM DEV DISORD, V41, P237, DOI 10.1007/s10803-010-1046-3; Jahanshahi G, 2004, DIGEST DIS SCI, V49, P1752, DOI 10.1007/s10620-004-9564-5; Jyonouchi H, 2005, NEUROPSYCHOBIOLOGY, V51, P77, DOI 10.1159/000084164; Jyonouchi H, 2002, NEUROPSYCHOBIOLOGY, V46, P76, DOI 10.1159/000065416; Jyonouchi H, 2001, J NEUROIMMUNOL, V120, P170, DOI 10.1016/S0165-5728(01)00421-0; Kasaian MT, 2008, BIOCHEM PHARMACOL, V76, P147, DOI 10.1016/j.bcp.2008.04.002; KASSELBERG AG, 1985, J HISTOCHEM CYTOCHEM, V33, P315; Levite M, 2008, CURR OPIN PHARMACOL, V8, P460, DOI 10.1016/j.coph.2008.05.001; Levitt P, 2009, J CLIN INVEST, V119, P747, DOI 10.1172/JCI37934; Li XH, 2009, J NEUROIMMUNOL, V207, P111, DOI 10.1016/j.jneuroim.2008.12.002; Libbey JE, 2005, J NEUROVIROL, V11, P1, DOI 10.1080/13550280590900553; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Miettinen PJ, 1997, ANN MED, V29, P531, DOI 10.3109/07853899709007477; Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003; Moller HJ, 2005, EXPERT OPIN PHARMACO, V6, P803, DOI 10.1517/1465566.6.5.803; Mostafa GA, 2009, J Child Neurol, V25, P328; Nair RR, 2008, SEMIN PERINATOL, V32, P107, DOI 10.1053/j.semperi.2008.01.007; Pan WH, 1999, PEPTIDES, V20, P1091, DOI 10.1016/S0196-9781(99)00094-7; Pardo Carlos A, 2005, Int Rev Psychiatry, V17, P485, DOI 10.1080/02646830500381930; Puri Neelu, 2008, J Carcinog, V7, P9; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Singer HS, 2008, J NEUROIMMUNOL, V194, P165, DOI 10.1016/j.jneuroim.2007.11.004; Singer HS, 2006, J NEUROIMMUNOL, V178, P149, DOI 10.1016/j.jneuroim.2006.05.025; SINGH VK, 1991, CLIN IMMUNOL IMMUNOP, V61, P448, DOI 10.1016/S0090-1229(05)80015-7; Singh VK, 1996, J Neuroimmunol, V66, P43; Song XQ, 2009, BIOL PSYCHIAT, V65, P481, DOI 10.1016/j.biopsych.2008.10.018; SPARROW SS, 1984, APPL RES MENT RETARD, V5, P219, DOI 10.1016/S0270-3092(84)80003-X; Sugihara G, 2007, PROG NEURO-PSYCHOPH, V31, P412, DOI 10.1016/j.pnpbp.2006.10.010; Suzuki K, 2007, BIOL PSYCHIAT, V62, P267, DOI 10.1016/j.biopsych.2006.08.001; Sweeten TL, 2004, BIOL PSYCHIAT, V55, P434, DOI 10.1016/j.biopsych.200309.001; Toschi L, 2010, FUTURE ONCOL, V6, P239, DOI [10.2217/fon.09.164, 10.2217/FON.09.164]; Toyoda T, 2007, BIOCHEM BIOPH RES CO, V360, P715, DOI 10.1016/j.bbrc.2007.06.051; VANNOORDEN S, 1977, HISTOCHEMISTRY, V52, P329; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Vinter-Jensen L, 1999, APMIS Suppl, V93, P1; Volkmar F, 2005, Annu Rev Psychol, V56, P15; Wong RWC, 2003, CELL MOL LIFE SCI, V60, P113, DOI 10.1007/s000180300007; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; Yip J, 2007, ACTA NEUROPATHOL, V113, P559, DOI 10.1007/s00401-006-0176-3; Zhang XY, 2005, NEUROPSYCHOPHARMACOL, V30, P1532, DOI 10.1038/sj.npp.1300756; Zhang XY, 2009, PSYCHOPHARMACOLOGY, V204, P177, DOI 10.1007/s00213-008-1447-6; Zimmerman AW, 2005, PEDIATR NEUROL, V33, P195, DOI 10.1016/j.pediatrneurol.2005.03.014; Zimmerman AW, 2007, BRAIN BEHAV IMMUN, V21, P351, DOI 10.1016/j.bbi.2006.08.005",68,1,1,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1044-5463",null,null,"J CHILD ADOL PSYCHOP","J. Child Adolesc. Psychopharmacol.","DEC",2011,21,6,null,null,null,null,555,564,null,"10.1089/cap.2010.0134",null,10,"Pediatrics; Pharmacology & Pharmacy; Psychiatry","Pediatrics; Pharmacology & Pharmacy; Psychiatry","866RP","WOS:000298399800006"]
[null,null,null,null,"J","Paech, C; Suchowerskyj, P; Gebauer, RA",null,null,null,"Paech, Christian; Suchowerskyj, Philipp; Gebauer, Roman Anton",null,null,"Successful Treatment of a Newborn With Genetically Confirmed Long QT Syndrome 3 and Repetitive Torsades De Pointes Tachycardia","PEDIATRIC CARDIOLOGY",null,null,"English","Editorial Material",null,null,null,null,null,null,null,null,"[Paech, Christian; Suchowerskyj, Philipp; Gebauer, Roman Anton] Univ Leipzig, Dept Pediat Cardiol, Ctr Heart, D-04289 Leipzig, Germany","Paech, C (reprint author), Univ Leipzig, Dept Pediat Cardiol, Ctr Heart, D-04289 Leipzig, Germany.","christian.paech@med.uni-leipzig.de",null,null,null,null,"Betrian Blasco P, 2007, INT J CARDIOL, V117, pe61, DOI 10.1016/j.ijcard.2006.11.126; Hoorntje T, 1999, INT J CARDIOL, V71, P289, DOI 10.1016/S0167-5273(99)00151-5; Howley LW, 2010, PACE, V33, P377, DOI 10.1111/j.1540-8159.2009.02550.x; Silver ES, 2009, J INTERV CARD ELECTR, V26, P41, DOI 10.1007/s10840-009-9428-1",4,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0172-0643",null,null,"PEDIATR CARDIOL","Pediatr. Cardiol.","OCT",2011,32,7,null,null,null,null,1060,1061,null,"10.1007/s00246-011-0037-2",null,2,"Cardiac & Cardiovascular Systems; Pediatrics","Cardiovascular System & Cardiology; Pediatrics","821FG","WOS:000294959700037"]
[null,null,null,null,"J","Trc, T; Havlas, V; Rybka, D",null,null,null,"Trc, T.; Havlas, V.; Rybka, D.",null,null,"Baker's Procedure in the Treatment of Pes Equinus in Cerebral Palsy Patients","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"pes equinus; Silfverskiold test; Baker's procedure","ACHILLES-TENDON; CHILDREN; DEFORMITY; SOLEUS; GASTROCNEMIUS; OUTCOMES; SURGERY; VULPIUS; MUSCLE","PURPOSE OF THE STUDY Surgical procedures on muscles in cerebral palsy are regarded as essential interventions. The tactics for surgery on the triceps surae muscle in the treatment of spastic pes equinus involve several surgical options at different muscle levels. MATERIAL AND METHODS In the 1992-2008 period, Baker's procedure, prolongation of the triceps muscle in the common part of the gastrocnemius and soleus aponeuroses, was indicated in 114 children, aged between 3 and 18 years, mostly with spastic hemiplegia (45.7 %) or diplegia (42.9 %). In both groups, the isolated Baker's procedures and the combined procedures were clinically assessment at 2 and 6 months after surgery. RESULTS Clinical examination at a follow up of 8 weeks showed that all patients achieved 5 to 10 degrees of dorsiflexion of the foot. A maximum of Achilles tendon stretch out was achieved in seven patients (6.14%) after 6 months. In one patient (0.9%) an excessive dorsiflexion was recorded. DISCUSSION The choice of surgical tactics for treatment of spastic pes equinus is related to a positive or a negative result of the Silfverskiold test, because this shows the degree of contracture of the gastrocnemius and soleus muscles. Prolongation at their joint aponeurosis should be indicated when the test shows partly positive results, and muscle balance at all levels of the lower extremity should be maintained. CONCLUSIONS Baker's procedure is one of the options to treat spastic pes equinus. The surgery is indicated primarily in isolated pes equinus and in children with spastic hemiplegia with low risk of Achilles tendon excessive elongation.","[Havlas, V.] LF UK, Ortopedicka Klin 2, Prague 15006 5, Czech Republic; FN Motole Detska & Dospela Ortopedie & Traumatol, Prague 15006 5, Czech Republic","Havlas, V (reprint author), LF UK, Ortopedicka Klin 2, V Uvalu 84, Prague 15006 5, Czech Republic.","vojtech.havlas@lfmotol.cuni.cz",null,null,null,null,"BAKER LD, 1964, J BONE JOINT SURG AM, V46, P1; Boireau P, 2002, REV CHIR ORTHOP, V88, P705; Borton DC, 2001, J BONE JOINT SURG BR, V83B, P364, DOI 10.1302/0301-620X.83B3.10827; Boyd RN, 2000, DEV MED CHILD NEUROL, V42, P32, DOI 10.1017/S0012162200000074; Chen L, 2009, FOOT ANKLE CLIN, V14, P627, DOI 10.1016/j.fcl.2009.08.002; Chladek P, 2009, ACTA CHIR ORTHOP TR, V76, P295; Chomiak J, 2009, ACTA CHIR ORTHOP TR, V76, P194; Dietz Frederick R, 2006, Iowa Orthop J, V26, P27; FILHO MCD, 2010, J PEDIAT ORTHOP B, V19, P226; Fuchs A, 2004, ORTHOPADE, V33, P1173, DOI 10.1007/s00132-004-0685-5; Hromadka R, 2009, ACTA CHIR ORTHOP TR, V76, P104; JAVORS JR, 1987, J PEDIATR ORTHOPED, V7, P191; Katz K, 2000, FOOT ANKLE INT, V21, P1011; Langova K, 2010, ACTA CHIR ORTHOP TR, V77, P118; Orendurff MS, 2002, GAIT POSTURE, V15, P130, DOI 10.1016/S0966-6362(01)00154-0; Papavasiliou AS, 2009, EUR J PAEDIATR NEURO, V13, P387, DOI 10.1016/j.ejpn.2008.07.009; Poul J, 2003, Acta Chir Orthop Traumatol Cech, V70, P292; Sala DA, 1997, DEV MED CHILD NEUROL, V39, P45; SCHEJBALOVA A, 2004, CES SLOV NEUROL NEUR, V67, P171; Schejbalova A, 2009, INT ORTHOP, V33, P1713, DOI 10.1007/s00264-008-0676-y; Schejbalova A, 2008, ACTA CHIR ORTHOP TR, V75, P355; SCHEJBALOVA A, 2004, CES SLOV NEUROL NEUR, V67, P363; SCHEJBALOVA A, 2004, CES SLOV NEUROL NEUR, V67, P267; Sponer P, 2008, ACTA CHIR ORTHOP TR, V75, P134; Steinwender G, 2001, J PEDIATR ORTHOPED, V21, P102; STRAYER LM, 1950, J BONE JOINT SURG AM, V32-A, P671; Svehlik M, 2010, ARCH PHYS MED REHAB, V91, P1897, DOI 10.1016/j.apmr.2010.09.005; Tachdjian M.O., 1990, PEDIAT ORTHOPEDICS; Tylkowski CM, 2009, J PEDIATR ORTHOPED, V29, P771, DOI 10.1097/BPO.0b013e3181b76a7c; Yngve DA, 1996, J PEDIATR ORTHOPED, V16, P759",30,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","JUN",2011,78,3,null,null,null,null,232,236,null,null,null,5,"Orthopedics","Orthopedics","789RD","WOS:000292533100007"]
[null,null,null,null,"J","Buller, HR; Prins, MH; Lensing, AWA; Decousus, H; Jacobson, BF; Minar, E; Chlumsky, J; Verhamme, P; Wells, P; Agnelli, G; Cohen, A; Berkowitz, SD; Bounameaux, H; Davidson, BL; Misselwitz, F; Gallus, AS; Raskob, GE; Schellong, S; Segers, A",null,null,null,"Buller, Harry R.; Prins, Martin H.; Lensing, Anthonie W. A.; Decousus, Herve; Jacobson, Barry F.; Minar, Erich; Chlumsky, Jaromir; Verhamme, Peter; Wells, Phil; Agnelli, Giancarlo; Cohen, Alexander; Berkowitz, Scott D.; Bounameaux, Henri; Davidson, Bruce L.; Misselwitz, Frank; Gallus, Alex S.; Raskob, Gary E.; Schellong, Sebastian; Segers, Annelise",null,"EINSTEIN-PE Investigators","Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; XA INHIBITOR RIVAROXABAN; VENOUS THROMBOEMBOLISM; UNFRACTIONATED HEPARIN; ATRIAL-FIBRILLATION; INITIAL TREATMENT; WARFARIN; TRIAL; PREVENTION","BACKGROUND A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism. METHODS In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS Rivaroxaban was noninferior to standard therapy (noninferiority margin, 2.0; P = 0.003) for the primary efficacy outcome, with 50 events in the rivaroxaban group (2.1%) versus 44 events in the standard-therapy group (1.8%) (hazard ratio, 1.12; 95% confidence interval [CI], 0.75 to 1.68). The principal safety outcome occurred in 10.3% of patients in the rivaroxaban group and 11.4% of those in the standard-therapy group (hazard ratio, 0.90; 95% CI, 0.76 to 1.07; P = 0.23). Major bleeding was observed in 26 patients (1.1%) in the rivaroxaban group and 52 patients (2.2%) in the standard-therapy group (hazard ratio, 0.49; 95% CI, 0.31 to 0.79; P = 0.003). Rates of other adverse events were similar in the two groups. CONCLUSIONS A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. (Funded by Bayer HealthCare and Janssen Pharmaceuticals; EINSTEIN-PE ClinicalTrials.gov number,NCT00439777.)","[Buller, Harry R.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; [Prins, Martin H.] Maastricht Univ, Med Ctr, Dept Epidemiol, Care Res Inst, Maastricht, Netherlands; [Prins, Martin H.] Maastricht Univ, Med Ctr, Dept Epidemiol, Publ Hlth Res Inst, Maastricht, Netherlands; [Lensing, Anthonie W. A.; Misselwitz, Frank] Bayer HealthCare, Wuppertal, Germany; [Decousus, Herve] Univ St Etienne, INSERM CIE3, Ctr Hosp Univ, St Etienne, France; [Jacobson, Barry F.] Univ Witwatersrand, Johannesburg Hosp, Dept Hematol & Mol Med, Johannesburg, South Africa; [Minar, Erich] Med Univ Vienna, Dept Angiol, Vienna, Austria; [Chlumsky, Jaromir] Univ Hosp Motol, Dept Internal Med, Prague, Czech Republic; [Verhamme, Peter] Univ Hosp Leuven, Dept Vasc Med & Hemostasis, Louvain, Belgium; [Wells, Phil] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Wells, Phil] Ottawa Hosp, Ottawa, ON, Canada; [Agnelli, Giancarlo] Univ Perugia, Osped Santa Maria della Misericordia, Sez Med Interna & Cardiovasc, I-06100 Perugia, Italy; [Cohen, Alexander] Kings Coll Hosp London, London, England; [Berkowitz, Scott D.] Bayer HealthCare, Montville, NJ USA; [Bounameaux, Henri] Univ Hosp Geneva, Div Angiol & Hemostasis, Geneva, Switzerland; [Davidson, Bruce L.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA; [Gallus, Alex S.] Flinders Med Ctr, Adelaide, SA, Australia; [Gallus, Alex S.] Flinders Univ S Australia, Adelaide, SA 5001, Australia; [Raskob, Gary E.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; [Schellong, Sebastian] Municipal Hosp Friedrichstadt, Dresden, Germany; [Segers, Annelise] Int Clin Trial Org, Amsterdam, Netherlands; [Segers, Annelise] Management Acad Res Org, Amsterdam, Netherlands","Buller, HR (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, F4-275,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.","h.r.buller@amc.uva.nl",null,null,"Bayer HealthCare; Janssen Pharmaceuticals","Supported by Bayer HealthCare and Janssen Pharmaceuticals.",null,22,192,196,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","APR 5",2012,366,14,null,null,null,null,1287,1297,null,"10.1056/NEJMoa1113572",null,11,"Medicine, General & Internal","General & Internal Medicine","919QJ","WOS:000302343000006"]
[null,null,null,null,"J","Parving, HH; Brenner, BM; McMurray, JJV; de Zeeuw, D; Haffner, SM; Solomon, SD; Chaturvedi, N; Persson, F; Desai, AS; Nicolaides, M; Richard, A; Xiang, ZH; Brunel, P; Pfeffer, MA; Juncos, L; Orias, M; Kuschnir, E; Rusculleda, M; Garcia, S; Farias, E; Lema, L; Hominal, M; Montana, O; Sala, J; Diaz, M; Piskorz, D; Vita, N; Litwak, L; Sinay, I; Marin, M; Massari, P; Majul, C; Aizemberg, D; Azize, GM; Bartolacci, I; Reboredo, A; Vico, M; Milesi, R; Sessa, H; Wassermann, A; Margulis, F; Zangroniz, P; Watschinger, B; Prager, R; Toplak, H; Paulweber, B; Drexel, H; Francesconi, C; Foeger, B; Mayer, G; Braun, RK; Brath, H; Gaal, LV; Niepen, PVD; Persu, A; Vercammen, C; Vriese, AD; Coucke, F; Mathieu, C; Fery, F; Treille, S; Meeus, G; Acker, KV; Scheen, A; Tits, J; Ruige, J; Krzesinski, JM; Hollanders, G; Lienart, F; Dendale, P; Quinonez, M; Arnouts, P; Vanuytsel, J; Zanella, M; Mion, D; Forti, A; Almeida, F; Cunha, R; de Paula, RB; Brandao, A; Rocha, J; Krieger, E; Feitosa, G; Saraiva, J; Martin, J; Hissa, MN; Schmid, H; Felicio, J; Sgarbi, J; Oigman, W; Bowering, K; Garceau, C; Berlingieri, JC; Weisnagel, SJ; Hardin, P; Powell, C; Turcot, R; Muirhead, N; Aronson, R; Barima, YT; Steele, AW; Pandey, S; Woo, V; Cha, J; Dattani, D; Godin, C; Gupta, M; Leiter, L; Saunders, K; Tellier, G; Ting, G; Tobe, S; Chouinard, G; Schlosser, R; Khandwala, H; Ekoe, JM; Harris, SB; Pichette, V; Lachance, P; Ooi, TC; Tildesley, H; Barrett, B; Cournoyer, S; Lu, J; Zhang, H; Liu, X; Yan, S; Qi, X; Li, Q; Li, H; Lv, X; Yang, J; Sun, N; Xia, W; Wang, N; Tong, N; Mei, C; Gu, S; Zhang, J; Chen, X; Li, L; Su, B; Wang, L; Qiu, M; Wu, X; Liu, Z; Jia, W; Xu, G; Dong, J; Zhu, D; Mei, C; Gu, S; Zhang, J; Chen, X; Li, L; Su, B; Wang, L; Qiu, M; Wu, X; Liu, Z; Jia, W; Xu, G; Dong, J; Zhu, D; Zhang, M; Yan, J; Liu, B; Chen, J; Fu, J; Yan, L; Zhan, X; Zhong, L; yang, T; Ma, J; Xu, M; Xu, X; Shi, B; Ji, Q; Zhong, H; He, R; Yuan, Z; Zhou, Z; Lin, H; Yang, W; Ke, Y; Li, Q; Hong, T; Franco, C; Casas, L; Triana, A; Botero, R; Jaramillo, C; Hernandez, E; Barrera, C; Blanco, D; Stipal, R; Widimsky, P; Dohnalova, L; Komroskova, M; Kvapil, M; Belobradkova, J; Tesar, V; Cifkova, R; Vodnansky, P; Kocourkova, B; Christiansen, JS; Lervang, H; Perrild, H; Rossing, P; Oestergaard, O; Juhl, H; Thorsteinsson, B; Snorgaard, O; Urhammer, S; Egstrup, K; Tikkanen, T; Helin, K; Rinne, J; Lahtela, J; Strand, J; Valtonen, E; Saari, M; Kananen, K; Savela, K; Marre, M; Blacher, J; Aldigier, JC; Zaoui, P; Fauvel, JP; Gouet, D; Valensi, PE; Charpentier, G; Marechaud, R; Penfornis, A; Ovize, M; Kovalchuck, AA; Haller, H; Dellanna, F; Schoen, N; Groeschel, W; Eickhoff, F; Hanefeld, M; Merke, J; Rambausek, M; Zimmermann, U; Stuetz, W; Vosskuehler, A; Hevendehl, G; Schax, U; Lehmann, G; Haack, A; Hilgenberg, J; Klausmann, G; Adelberger, V; Gessner, S; Fiesselmann, A; Oerter, E; Hohenstatt, T; Groeschel, A; Behnke, T; Sisting, RT; Schoch, D; Bieler, T; Schleyer, S; Altes, U; Klepzig, G; Rudofsky, G; Mueller, G; Burkhardt, F; Reschke, K; Senftleber, I; Wiesweg, CK; Herrmann, HJ; Brandstetter, R; Segner, A; Nickenig, G; Schmitt, H; Rippert, R; Goebel, R; Schreibmueller, F; Pencz, I; Ott, P; Siamopoulos, K; Migdalis, I; Pappas, S; Pagkalos, E; Yalouris, A; Tsapas, A; Maltezos, E; Tentolouris, N; Papadakis, I; Ioannidis, G; Goumenos Guatemala, D; Corona, V; Gonzalez, R; Haase, F; Monterroso, V; Sanchez, V; Turcios, E; Wyss, F; Arango, JL; Bako, B; Deak, L; Domotor, E; Dudas, M; Fulop, T; Kiss, I; Koranyi, L; Lengyel, Z; Nyirati, G; Oroszlan, T; Aniko, S; Voros, P; Kapocsi, J; Wittmann, I; Paragh, G; Abraham, G; Tandon, N; Thomas, N; Mohan, V; Sahay, R; Sethi, B; Rao, V; Kumar, S; Chowdhury, S; Dharmalingam, M; Seshiah, V; Bantwal, G; Viswanathan, V; Yajnik, C; Adhikari, P; Hiremath, J; Bha Ittacharyya, A; Dani, S; Modi, KK; Glorioso, N; Morosetti, M; Veglio, F; Perticone, F; Dotta, F; Quarello, F; Sesti, G; Aiello, A; D'Ospina, A; Giordano, C; Novo, S; Ferri, C; Capuano, V; Trimarco, B; Tonolo, G; Villa, G; De Pellegrin, A; Zanette, G; Federici, M; Aucello, G; Piatti, P; Vinciguerra, A; Mannarino, E; Taddei, S; Filetti, S; Grandaliano, G; Marchionni, N; Lambiase, C; Locatelli, F; Scanferla, F; Lembo, G; Leotta, S; Mos, L; Calatola, P; Fogari, R; David, S; Pedrinelli, R; Pignone, AM; Cozzolino, D; Bevilacqua, MT; Catena, C; Del Prato, S; Cerasola, G; Frontoni, S; Falcone, C; Porta, A; Bonora, E; Cocchi, R; Fucili, A; Frisinghelli, A; Volpe, M; Carugo, S; Gambardella, S; Spagnuolo, V; Maglia, G; D'Angelo, AR; Corsi, A; Limone, PP; Guarnieri, A; Ghigo, E; Ronchi, E; Ravera, M; Scioli, GA; Sekiguchi, M; Aoki, S; Ogawa, Y; Seino, H; Onishi, Y; Tojo, A; Narimiya, M; Iwaita, Y; Takeda, H; Shimizu, H; Yamada, T; Kojima, S; Zushi, S; Kaneko, S; Matsumoto, A; Kajiyama, S; Fujita, H; Shikata, K; Tone, A; Matsubayashi, S; Tanaka, S; Sekigami, T; Tatsukawa, Y; Abe, N; Kawahara, K; Kasahara, H; Maeda, Y; Suzuki, Y; Okamoto, H; Tachi, K; Yamada, K; Uzu, T; Itou, T; Fukui, T; Kim, S; Kim, Y; Cho, W; Kwak, I; Chae, D; Oh, H; Ha, S; Shin, Y; Cha, D; Kim, Y; Kim, S; Kang, S; Lim, C; Song, J; Lim, C; Song, J; Kwon, Y; Badariene, J; Labutiniene, IP; Zabuliene, L; Poteliuniene, V; Miglinas, M; Kooy, A; van den Meiracker, AH; Smak Gregoor, PJH; Luik, AJ; Potter van Loon, BJ; Feenstra, HJ; Kaasjager, HAH; Viergever, PP; Woittiez, AJJ; van Bemmel, T; Lieverse, AG; Simsek, S; Gaillard, CAJM; van der Zwaan, C; Lok, DJA; Spiering, W; Nierop, PR; Baggen, MGA; Leendert, RJM; de Jong, A; Leurs, PB; Vincent, HH; Wins, EHR; Voors, AA; Ronner, E; Heeg, JE; van Hal, JMC; Boermans, T; Feis, WL; Mostard, G; Bakker, RC; Dunselman, PHJM; Jorde, R; Skeie, S; Istad, H; Skjelvan, G; Gronert, J; Tomala, T; Gudnason, S; Tarje Torvik, D; Risberg, K; Abedini, S; Cabrera, W; Medina, B; Medina, F; Herrada, B; Saavedra, A",null,null,null,"Parving, Hans-Henrik; Brenner, Barry M.; McMurray, John J. V.; de Zeeuw, Dick; Haffner, Steven M.; Solomon, Scott D.; Chaturvedi, Nish; Persson, Frederik; Desai, Akshay S.; Nicolaides, Maria; Richard, Alexia; Xiang, Zhihua; Brunel, Patrick; Pfeffer, Marc A.; Juncos, Luis; Orias, Marcelo; Kuschnir, Emilio; Rusculleda, Marcelo; Garcia, Sergio; Farias, Eduardo; Lema, Luis; Hominal, Miguel; Montana, Oscar; Sala, Jorgelina; Diaz, Monica; Piskorz, Daniel; Vita, Nestor; Litwak, Leon; Sinay, Isaac; Marin,, Marcos; Massari,, Pablo; Majul, Claudio; Aizemberg,, D.; Azize, Guillermo Moises; Bartolacci, Ines; Reboredo, Ana; Vico, Marisa; Milesi, Ricardo; Sessa, Horacio; Wassermann,, Alfredo; Margulis,, Fernando; Zangroniz, Pedro; Watschinger,, B.; Prager, R.; Toplak, H.; Paulweber, B.; Drexel, H.; Francesconi, C.; Foeger, B.; Mayer,, G.; Braun,, R.K.; Brath, H.; Gaal, L.V.; Niepen, P.V.D.; Persu, A.; Vercammen, C.; Vriese, A.D.; Coucke, F.; Mathieu, C.; Fery, F.; Treille, S.; Meeus, G.; Acker, K.V.; Scheen, A.; Tits, J.; Ruige, J.; Krzesinski, J.M.; Hollanders, G.; Lienart, F.; Dendale, P.; Quinonez, M.; Arnouts, P.; Vanuytsel, J.; Zanella, M.; Mion, D; Forti, A.; Almeida, F.; Cunha, R.; de Paula, R.B.; Brandao, A.; Rocha, J.; Krieger, E.; Feitosa, G.; Saraiva, J.; Martin, J.; Hissa, M.N.; Schmid, H.; Felicio, J.; Sgarbi,, J.; Oigman, W.; Bowering, K.; Garceau, C.; Berlingieri, J.C.; Weisnagel, S.J.; Hardin, P.; Powell, C.; Turcot, R.; Muirhead, N.; Aronson, R.; Barima, Y.T.; Steele, A.W.; Pandey, S.; Woo, V.; Cha, J.; Dattani, D.; Godin, C.; Gupta, M.; Leiter, L.; Saunders, K.; Tellier, G.; Ting, R; Tobe, S.; Chouinard, G.; Schlosser, R.; Khandwala,, H.; Ekoe,, J.M.; Harris,, S.B.; Pichette, V.; Lachance, P.; Ooi, TC; Tildesley,, H.; Barrett, B.; Cournoyer, S.; Lu, J; Zhang, J.; Liu, X.; Yan, S.; Qi, X.; Li, Q.; Li, H.; Lv, X.; Yang, J.; Sun, N.; Xia, W.; Wang, N.; Tong, N.; Mei, C.; Gu, S.; Zhang, J.; Chen, X.; Li, L.; Su, B.; Wang, L.; Qiu, M.; Wu, X.; Liu, Z.; Jia, W.; Xu, G.; Dong, J.; Zhu, D.; Mei, C.; Gu, S.; Zhang, J.; Chen, X.; Li, L.; Su, B.; Wang, L.; Qiu, M.; Wu, X.; Liu, Z.; Jia, W.; Xu, G.; Dong, J.; Zhu, D.; Zhang, M.; Yan, J.; Liu, B.; Chen, J.; Fu, J.; Yan, L.; Zhan, X.; Zhong, L.; yang, T.; Ma, J.; Xu, M.; Xu, X.; Shi, B.; Ji, Q.; Zhong, H.; He, R.; Yuan, Z.; Zhou, Z.; Lin, H.; Yang, W.; Ke, Y.; Li, Q.; Hong, T.; Franco, C.; Casas, L.; Triana, A.; Botero, R.; Jaramillo, C.; Hernandez, E.; Barrera, C.; Blanco, D.; Stipal, R.; Widimsky, P; Dohnalova, L.; Komroskova,, M.; Kvapil, M.; Belobradkova, J.; Tesar, V.; Cifkova, R.; Vodnansky, P.; Kocourkova, B.; Christiansen, J.S.; Lervang,, H-H; Perrild, H.; Rossing, P.; Oestergaard, O.; Juhl, H.; Thorsteinsson, B.; Snorgaard, O.; Urhammer, S.; Egstrup, K.; Tikkanen, T; Helin, K.; Rinne, J.; Lahtela, J.; Strand, J.; Valtonen, E.; Saari, M.; Kananen, K.; Savela, K.; Marre, M.; Blacher, J.; Aldigier, J-C; Zaoui, P.; Fauvel, J-P; Gouet, D.; Valensi, P-E; Charpentier, G.; Marechaud, R.; Penfornis, A.; Ovize, M; Kovalchuck, A.A.; Haller, H.; Dellanna, F.; Schoen, N.; Groeschel, W.; Eickhoff, F.; Hanefeld, M.; Merke, J.; Rambausek, M.; Zimmermann, U.; Stuetz, W.; Vosskuehler, A.; Hevendehl, G.; Schax, U.; Lehmann,, G.; Haack, A.; Hilgenberg, J.; Klausmann, G.; Adelberger, V.; Gessner, S.; Fiesselmann, A.; Oerter, E.; Hohenstatt, T.; Groeschel, A.; Behnke, T.; Sisting, R.T.; Schoch,, D.; Bieler, T.; Schleyer, S.; Altes, U; Klepzig, G.; Rudofsky, G.; Mueller, G.; Burkhardt, F.; Reschke, K.; Senftleber, I.; Wiesweg, C.K.; Herrmann, HJ; Brandstetter, R.; Segner, A.; Nickenig, G.; Schmitt, H.; Rippert, R.; Goebel, R.; Schreibmueller, F.; Pencz, I.; Ott, P; Siamopoulos, K.; Migdalis,, I; Pappas, S; Pagkalos, E.; Yalouris, A.; Tsapas, A; Maltezos, E.; Tentolouris, N.; Papadakis, I; Ioannidis, G.; Goumenos Guatemala, D.; Corona, V.; Gonzalez, R.; Haase, F.; Monterroso, V.; Sanchez, V.; Turcios, E.; Wyss, F.; Arango, JL; Bako, B.; Deak, L.; Domotor, E.; Dudas, M; Fulop, T.; Kiss, I.; Koranyi, L.; Lengyel, Z.; Nyirati, G.; Oroszlan, T.; Aniko, S.; Voros, P.; Kapocsi, J.; Wittmann, I.; Paragh,, G; Abraham, G.; Tandon, N.; Thomas, N.; Mohan, V.; Sahay, R.; Sethi, B.; Rao, V.; Kumar, S; Chowdhury, S.; Dharmalingam, M.; Seshiah, V.; Bantwal, G.; Viswanathan, V.; Yajnik, C.; Adhikari, P.; Hiremath, J.; Bha Ittacharyya, A.; Dani,, S.; Modi, KK; Glorioso, N.; Morosetti, M.; Veglio, F.; Perticone, F.; Dotta, F.; Quarello, F.; Sesti, G.; Aiello, A; D'Ospina, A; Giordano, C; Novo, S; Ferri, C; Capuano, V.; Trimarco, B.; Tonolo, G.; Villa, G.; De Pellegrin, A.; Zanette, G.; Federici, M.; Aucello, G.; Piatti, P.; Vinciguerra, A.; Mannarino, E.; Taddei, S; Filetti, S; Grandaliano, G.; Marchionni, N.; Lambiase, C.; Locatelli, F.; Scanferla, F.; Lembo, G.; Leotta, S.; Mos, L.; Calatola, P.; Fogari, R.; David, S.; Pedrinelli, R.; Pignone,, A.M.; Cozzolino, D.; Bevilacqua, M.T.; Catena,, C.; Del Prato, S.; Cerasola, G.; Frontoni, S.; Falcone, C.; Porta, A.; Bonora, E.; Cocchi, R.; Fucili, A.; Frisinghelli, A.; Volpe, M.; Carugo, S.; Gambardella, S.; Spagnuolo, V.; Maglia, G.; D'Angelo, A.R.; Corsi, A.; Limone, P.P.; Guarnieri, A.; Ghigo, E.; Ronchi, E.; Ravera, M.; Scioli, G.A.; Sekiguchi, M.; Aoki, S.; Ogawa, Y.; Seino, H.; Onishi, Y.; Tojo, A; Narimiya, M.; Iwaita, Y.; Takeda, H.; Shimizu, H.; Yamada, T.; Kojima, S.; Zushi, S.; Kaneko, S.; Matsumoto, A.; Kajiyama, S.; Fujita, H.; Shikata, K.; Tone, A.; Matsubayashi, S.; Tanaka, S.; Sekigami, T.; Tatsukawa, Y.; Abe, N.; Kawahara, K.; Kasahara, H.; Maeda, Y.; Suzuki, Y.; Okamoto, H.; Tachi, K.; Yamada, K.; Uzu, T.; Itou, T.; Fukui, T.; Kim, S.; Kim, Y.; Cho, W.; Kwak, I.; Chae, D.; Oh, H.; Ha, S.; Shin, Y; Cha, D.; Kim, Y.; Kim, S.; Kang, S.; Lim, C.; Song, J.; Lim, C.; Song, J.; Kwon, Y.; Badariene, J.; Labutiniene, I.P.; Zabuliene,, L.; Poteliuniene, V.; Miglinas, M.; Kooy, A; van den Meiracker, A.H.; Smak Gregoor, P.J.H.; Luik, A.J.; Potter van Loon, B.J.; Feenstra, H.J.; Kaasjager, H.A.H.; Viergever,, P.P.; Woittiez, A.J.J.; van Bemmel, T.; Lieverse, A.G.; Simsek, S.; Gaillard, C.A.J.M.; van der Zwaan, C.; Lok, Dirk J.A.; Spiering, Wilco; Nierop,, P.R.; Baggen, M.G.A.; Leendert, R.J.M.; de Jong, A; Leurs, P.B.; Vincent, H.H.; Wins, E.H.R.; Voors, A.A.; Ronner, E.; Heeg, J.E.; van Hal, J.M.C.; Boermans, Ton; Feis, W.L.; Mostard, G.; Bakker, R.C.; Dunselman, P.H.J.M.; Jorde,, R.; Skeie,, S.; Istad,, H; Skjelvan, G.; Gronert, J.; Tomala, T.; Gudnason, S; Tarje Torvik, D.; Risberg,, K.; Abedini, S.; Cabrera, W.; Medina,, B.; Medina, F.; Herrada, B.; Saavedra, A",null,"ALTITUDE Investigators","Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"GLOMERULAR-FILTRATION-RATE; CONVERTING-ENZYME INHIBITORS; LEFT-VENTRICULAR DYSFUNCTION; HEART-FAILURE; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; CARDIOVASCULAR MORTALITY; SYSTOLIC DYSFUNCTION; BLOOD-PRESSURE; FOLLOW-UP","BACKGROUND This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P = 0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, = 6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P < 0.001 for both comparisons). CONCLUSIONS The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.)","[Parving, Hans-Henrik] Univ Copenhagen, Rigshosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark; [Parving, Hans-Henrik] Aarhus Univ, Fac Hlth Sci, Aarhus, Denmark; [Persson, Frederik] Steno Diabet Ctr, DK-2820 Gentofte, Denmark; [Brenner, Barry M.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; [Solomon, Scott D.; Desai, Akshay S.; Pfeffer, Marc A.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; [McMurray, John J. V.] Univ Glasgow, Cardiovasc Res Ctr, British Heart Fdn, Glasgow, Lanark, Scotland; [Chaturvedi, Nish] Univ London Imperial Coll Sci Technol & Med, London, England; [de Zeeuw, Dick] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, Groningen, Netherlands; [Haffner, Steven M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med & Clin Epidemiol, San Antonio, TX 78229 USA; [Nicolaides, Maria; Richard, Alexia; Xiang, Zhihua; Brunel, Patrick] Novartis Pharmaceut, Basel, Switzerland","Parving, HH (reprint author), Univ Copenhagen, Rigshosp, Dept Med Endocrinol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.","hhparving@dadlnet.dk","Solomon, Scott/I-5789-2013; Polonia, Jorge/J-8288-2013; FMUP, CINTESIS/C-6631-2014; de Zeeuw, Dick/E-9080-2014","FMUP, CINTESIS/0000-0001-7248-2086; ",null,null,"Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Dagenais GR, 2006, LANCET, V368, P581, DOI 10.1016/S0140-6736(06)69201-5; Desai AS, 2011, AM J KIDNEY DIS, V58, P717, DOI 10.1053/j.ajkd.2011.05.020; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Fleming TR, 1996, ANN INTERN MED, V125, P605; Gaede P, 2003, NEW ENGL J MED, V348, P383; Gheorghiade M, 2011, EUR J HEART FAIL, V13, P100, DOI 10.1093/eurjhf/hfq209; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Heart Outcomes Prevention Evaluation Study Investigators, 2000, LANCET, V356, P860; Holman RR, 2008, NEW ENGL J MED, V359, P1565, DOI 10.1056/NEJMoa0806359; Holtkamp FA, 2011, EUR HEART J, V32, P1493, DOI 10.1093/eurheartj/ehr017; Krum H, 2011, EUR J HEART FAIL, V13, P107, DOI 10.1093/eurjhf/hfq212; Levey AS, 2006, ANN INTERN MED, V145, P247; Levey AS, 2008, ANN INTERN MED, V149, P519; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Mann JFE, 2008, LANCET, V372, P547, DOI 10.1016/S0140-6736(08)61236-2; Masson S, 2010, J CARD FAIL, V16, P964, DOI 10.1016/j.cardfail.2010.06.417; Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; McMurray JJV, 2008, CIRC-HEART FAIL, V1, P17, DOI 10.1161/CIRCHEARTFAILURE.107.740704; Miao Y, 2011, DIABETOLOGIA, V54, P44, DOI 10.1007/s00125-010-1922-6; Oparil S, 2007, LANCET, V370, P221, DOI 10.1016/S0140-6736(07)61124-6; Parving HH, 2008, NEW ENGL J MED, V358, P2433, DOI 10.1056/NEJMoa0708379; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Parving HH, 2009, NEPHROL DIAL TRANSPL, V24, P1663, DOI 10.1093/ndt/gfn721; Pfeffer MA, 2008, CIRCULATION, V118, P2491, DOI 10.1161/CIRCULATIONAHA.108.821512; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pfeffer MA, 2010, DIALOGUES CARDIOVASC, V15, P130; Ruggenenti P, 1998, LANCET, V352, P1252, DOI 10.1016/S0140-6736(98)04433-X; Sampson UK, 2007, EUR HEART J, V28, P685, DOI 10.1093/eurheartj/ehl197; Schjoedt KJ, 2004, DIABETOLOGIA, V47, P1936, DOI 10.1007/s00125-004-1542-0; Seshasai SRK, 2011, NEW ENGL J MED, V364, P829; Solomon SD, 2011, EUR HEART J, V32, P1227, DOI 10.1093/eurheartj/ehq522; Staessen JA, 2006, LANCET, V368, P1449, DOI 10.1016/S0140-6736(06)69442-7; The Emerging Risk Factors Collaboration, 2011, NEW ENGL J MED, V364, P1281; Gerstein HC, 2000, LANCET, V355, P253; Verma S, 2011, EUR HEART J, V32, P2135, DOI 10.1093/eurheartj/ehr066; Yusuf S, 2008, NEW ENGL J MED, V358, P1547",39,132,133,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","DEC 6",2012,367,23,null,null,null,null,2204,2213,null,"10.1056/NEJMoa1208799",null,10,"Medicine, General & Internal","General & Internal Medicine","048DO","WOS:000311890600007"]
[null,null,null,null,"J","Gold, R; Kappos, L; Arnold, DL; Bar-Or, A; Giovannoni, G; Selmaj, K; Tornatore, C; Sweetser, MT; Yang, M; Sheikh, SI; Dawson, KT",null,null,null,"Gold, Ralf; Kappos, Ludwig; Arnold, Douglas L.; Bar-Or, Amit; Giovannoni, Gavin; Selmaj, Krzysztof; Tornatore, Carlo; Sweetser, Marianne T.; Yang, Minhua; Sheikh, Sarah I.; Dawson, Katherine T.",null,"DEFINE Study Investigators","Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis","NEW ENGLAND JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"CONTROLLED TRIAL; OXIDATIVE STRESS; CELLS; FINGOLIMOD; DISABILITY; PATHWAY","BACKGROUND BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective properties in preclinical experiments and to result in significant reductions in disease activity on magnetic resonance imaging (MRI) in a phase 2, placebo-controlled study involving patients with relapsing-remitting multiple sclerosis. METHODS We conducted a randomized, double-blind, placebo-controlled phase 3 study involving patients with relapsing-remitting multiple sclerosis. Patients were randomly assigned to receive oral BG-12 at a dose of 240 mg twice daily, BG-12 at a dose of 240 mg three times daily, or placebo. The primary end point was the proportion of patients who had a relapse by 2 years. Other end points included the annualized relapse rate, the time to confirmed progression of disability, and findings on MRI. RESULTS The estimated proportion of patients who had a relapse was significantly lower in the two BG-12 groups than in the placebo group (27% with BG-12 twice daily and 26% with BG-12 thrice daily vs. 46% with placebo, P<0.001 for both comparisons). The annualized relapse rate at 2 years was 0.17 in the twice-daily BG-12 group and 0.19 in the thrice-daily BG-12 group, as compared with 0.36 in the placebo group, representing relative reductions of 53% and 48% with the two BG-12 regimens, respectively (P<0.001 for the comparison of each BG-12 regimen with placebo). The estimated proportion of patients with confirmed progression of disability was 16% in the twice-daily BG-12 group, 18% in the thrice-daily BG-12 group, and 27% in the placebo group, with significant relative risk reductions of 38% with BG-12 twice daily (P = 0.005) and 34% with BG-12 thrice daily (P = 0.01). BG-12 also significantly reduced the number of gadolinium-enhancing lesions and of new or enlarging T-2-weighted hyperintense lesions (P<0.001 for the comparison of each BG-12 regimen with placebo). Adverse events associated with BG-12 included flushing and gastrointestinal events, such as diarrhea, nausea, and upper abdominal pain, as well as decreased lymphocyte counts and elevated liver aminotransferase levels. CONCLUSIONS In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the number of lesions on MRI.","[Gold, Ralf] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, D-44791 Bochum, Germany; [Kappos, Ludwig] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Kappos, Ludwig] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland; [Arnold, Douglas L.] NeuroRx Res, Montreal, PQ, Canada; [Arnold, Douglas L.; Bar-Or, Amit] McGill Univ, Montreal Neurol Hosp & Inst, Montreal, PQ, Canada; [Giovannoni, Gavin] Queen Mary Univ London, Blizard Inst Cell & Mol Sci, Barts & London Sch Med & Dent, London, England; [Selmaj, Krzysztof] Med Univ Lodz, Lodz, Poland; [Tornatore, Carlo] Georgetown Univ Hosp, Washington, DC 20007 USA; [Sweetser, Marianne T.; Yang, Minhua; Sheikh, Sarah I.; Dawson, Katherine T.] Biogen Idec Inc, Weston, MA USA","Gold, R (reprint author), Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Gudrunstr 56, D-44791 Bochum, Germany.","ralf.gold@ruhr-uni-bochum.de",null,null,"Biogen Idec","Funded by Biogen Idec; DEFINE ClinicalTrials.gov number, NCT00420212.","[Anonymous], 1996, ICH HARM TRIP GUID G; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Fox RJ, 2012, NEW ENGL J MED, V367, P1087, DOI 10.1056/NEJMoa1206328; Ghoreschi K, 2011, J EXP MED, V208, P2291, DOI 10.1084/jem.20100977; Gilgun-Sherki Y, 2004, J NEUROL, V251, P261, DOI 10.1007/s00415-004-0348-9; Jacobs LD, 1996, ANN NEUROL, V40, P480; Johnson DA, 2010, TOXICOL SCI, V114, P237, DOI 10.1093/toxsci/kfp274; JOHNSON KP, 1995, NEUROLOGY, V45, P1268; Kappos L, 2009, LANCET, V373, P1340; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; KURTZKE JF, 1983, NEUROLOGY, V33, P1444; Linker RA, 2011, BRAIN, V134, P678, DOI 10.1093/brain/awq386; Loewe R, 2002, J IMMUNOL, V168, P4781; Lublin FD, 1996, NEUROLOGY, V46, P907; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.206703; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; PRISMS Study Group, 2001, NEUROLOGY, V57, P1146; Scannevin RH, 2012, J PHARMACOL EXP THER, V341, P274, DOI 10.1124/jpet.111.190132; Francis G, 2001, NEUROLOGY, V56, P1628; Vollmer TL, 2011, MULT SCLER, V17, pS507; World Medical Association, DECL HELS ETH PRINC",21,109,109,"MASSACHUSETTS MEDICAL SOC","WALTHAM","WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA","0028-4793",null,null,"NEW ENGL J MED","N. Engl. J. Med.","SEP 20",2012,367,12,null,null,null,null,1098,1107,null,"10.1056/NEJMoa1114287",null,10,"Medicine, General & Internal","General & Internal Medicine","007AS","WOS:000308861800005"]
[null,null,null,null,"J","Pearse, RM; Moreno, RP; Bauer, P; Pelosi, P; Metnitz, P; Spies, C; Vallet, B; Vincent, JL; Hoeft, A; Rhodes, A",null,null,null,"Pearse, Rupert M.; Moreno, Rui P.; Bauer, Peter; Pelosi, Paolo; Metnitz, Philipp; Spies, Claudia; Vallet, Benoit; Vincent, Jean-Louis; Hoeft, Andreas; Rhodes, Andrew",null,"Trial Grp European Soc Intensive; Trial Grp European Soc","Mortality after surgery in Europe: a 7 day cohort study","LANCET",null,null,"English","Article",null,null,null,null,null,null,"SURGICAL QUALITY IMPROVEMENT; LONG-TERM SURVIVAL; NONCARDIAC SURGERY; CRITICAL-CARE; POSTOPERATIVE COMPLICATIONS; INPATIENT SURGERY; CANCER-SURGERY; MAJOR SURGERY; RISK; POPULATION","Background Clinical outcomes after major surgery are poorly described at the national level. Evidence of heterogeneity between hospitals and health-care systems suggests potential to improve care for patients but this potential remains unconfirmed. The European Surgical Outcomes Study was an international study designed to assess outcomes after non-cardiac surgery in Europe. Methods We did this 7 day cohort study between April 4 and April 11, 2011. We collected data describing consecutive patients aged 16 years and older undergoing inpatient non-cardiac surgery in 498 hospitals across 28 European nations. Patients were followed up for a maximum of 60 days. The primary endpoint was in-hospital mortality. Secondary outcome measures were duration of hospital stay and admission to critical care. We used chi(2) and Fisher's exact tests to compare categorical variables and the t test or the Mann-Whitney U test to compare continuous variables. Significance was set at p<0.05. We constructed multilevel logistic regression models to adjust for the differences in mortality rates between countries. Findings We included 46 539 patients, of whom 1855 (4%) died before hospital discharge. 3599 (8%) patients were admitted to critical care after surgery with a median length of stay of 1.2 days (IQR 0.9-3.6). 1358 (73%) patients who died were not admitted to critical care at any stage after surgery. Crude mortality rates varied widely between countries (from 1.2% [95% CI 0.0-3.0] for Iceland to 21.5% [16.9-26.2] for Latvia). After adjustment for confounding variables, important differences remained between countries when compared with the UK, the country with the largest dataset (OR range from 0.44 [95% CI 0.19-1.05; p=0.06] for Finland to 6.92 [2.37-20.27; p=0.0004] for Poland). Interpretation The mortality rate for patients undergoing inpatient non-cardiac surgery was higher than anticipated. Variations in mortality between countries suggest the need for national and international strategies to improve care for this group of patients.","[Pearse, Rupert M.] Queen Mary Univ London, Barts & London Sch Med & Dent, London, England; [Moreno, Rui P.] Ctr Hosp Lisboa Cent, Hosp Sao Jose, EPE, UCINC, Lisbon, Portugal; [Bauer, Peter] Med Univ Vienna, Sect Med Stat, Vienna, Austria; [Metnitz, Philipp] Med Univ Vienna, Dept Anaesthesia & Gen Intens Care, Vienna, Austria; [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, IRCCS AOU San Martino IST, Genoa, Italy; [Spies, Claudia] Charite, D-13353 Berlin, Germany; [Vallet, Benoit] Univ Hosp, Lille, France; [Vincent, Jean-Louis] Univ Libre Brussels, Erasme Hosp, Brussels, Belgium; [Hoeft, Andreas] Univ Bonn, Dept Anaesthesiol, Bonn, Germany; [Rhodes, Andrew] St Georges Healthcare NHS Trust, London, England; [Rhodes, Andrew] St Georges Univ London, London, England","Pearse, RM (reprint author), Royal London Hosp, Adult Crit Care Unit, London E1 1BB, England.","r.pearse@qmul.ac.uk","Mouton, Ronelle/A-9934-2012; Pearse, Rupert/H-5426-2011; Ercole, Ari/B-6288-2009; Kirk-Bayley, Justin/A-1608-2013; Sander, Michael/H-5434-2012; Stourac, Petr/J-3610-2012; Arteta Arteta, Donaldo/D-3894-2014","Pearse, Rupert/0000-0002-4373-5934; Kirk-Bayley, Justin/0000-0001-9493-045X; Stourac, Petr/0000-0003-1944-5926; Arteta Arteta, Donaldo/0000-0001-8909-563X","European Society of Intensive Care Medicine; European Society of Anaesthesiology","This study was funded by the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. RP is a National Institute for Health Research (UK) Clinician Scientist.","Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1; Bilimoria KY, 2008, J CLIN ONCOL, V26, P4626, DOI 10.1200/JCO.2007.15.6356; Canet J, 2010, ANESTHESIOLOGY, V113, P1338, DOI 10.1097/ALN.0b013e3181fc6e0a; Care quality commission, 2012, HEART SURG UK; Clement ND, 2012, J BONE JOINT SURG BR, V94B, P200, DOI 10.1302/0301-620X.94B2.28114; Derogar M, 2012, J CLIN ONCOL, V30, P1615, DOI 10.1200/JCO.2011.40.3568; Devereaux PJ, 2012, JAMA-J AM MED ASSOC, V307, P2295, DOI 10.1001/jama.2012.5502; Finks JF, 2011, NEW ENGL J MED, V364, P2128, DOI 10.1056/NEJMsa1010705; Ghaferi AA, 2009, NEW ENGL J MED, V361, P1368, DOI 10.1056/NEJMsa0903048; Ghaferi AA, 2009, ANN SURG, V250, P1029, DOI 10.1097/SLA.0b013e3181bef697; Glance LG, 2012, ANN SURG, V255, P696, DOI 10.1097/SLA.0b013e31824b45af; Hamilton MA, 2011, ANESTH ANALG, V112, P1392, DOI 10.1213/ANE.0b013e3181eeaae5; Head J, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1469; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jhanji S, 2008, ANAESTHESIA, V63, P695, DOI 10.1111/j.1365-2044.2008.05560.x; Khuri SF, 2005, ANN SURG, V242, P326, DOI 10.1097/01.sla.0000179621.33268.83; Mason M., 2011, KNOWING RISK REV PER; Metnitz PGH, 2005, INTENS CARE MED, V31, P1336, DOI 10.1007/s00134-005-2762-6; Noordzij PG, 2010, ANESTHESIOLOGY, V112, P1105, DOI 10.1097/ALN.0b013e3181d5f95c; Pearse RM, 2006, CRIT CARE, V10, DOI 10.1186/cc4928; Pearse RM, 2008, CRIT CARE MED, V36, P1323, DOI [10.1097/CCM.0b013e31816a091b, 10.1097/CCM.0b013e31816091b]; Pearse RM, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2865; Pearse RM, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5759; Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8; Rowell KS, 2007, J AM COLL SURGEONS, V204, P1293, DOI 10.1016/j.jamcollsurg.2007.03.024; Squadrone V, 2005, JAMA-J AM MED ASSOC, V293, P589, DOI 10.1001/jama.293.5.589; Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8; Wunsch H, 2008, CRIT CARE MED, V36, P2787, DOI 10.1097/CCM.0b013e318186aec8; Yu PC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010607",29,71,72,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0140-6736",null,null,"LANCET","Lancet","SEP 22",2012,380,9847,null,null,null,null,1059,1065,null,null,null,7,"Medicine, General & Internal","General & Internal Medicine","007VL","WOS:000308916400026"]
[null,null,null,null,"J","Van Cutsem, E; Tabernero, J; Lakomy, R; Prenen, H; Prausova, J; Macarulla, T; Ruff, P; van Hazel, GA; Moiseyenko, V; Ferry, D; McKendrick, J; Polikoff, J; Tellier, A; Castan, R; Allegra, C",null,null,null,"Van Cutsem, Eric; Tabernero, Josep; Lakomy, Radek; Prenen, Hans; Prausova, Jana; Macarulla, Teresa; Ruff, Paul; van Hazel, Guy A.; Moiseyenko, Vladimir; Ferry, David; McKendrick, Joe; Polikoff, Jonathan; Tellier, Alexia; Castan, Remi; Allegra, Carmen",null,null,"Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ENDOTHELIAL GROWTH-FACTOR; ADVANCED SOLID TUMORS; VEGF-TRAP; ANGIOGENESIS; BEVACIZUMAB; CONSORTIUM; RECURRENT","Purpose Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody. We studied the effect of adding the novel antiangiogenic agent aflibercept (also known as ziv-aflibercept in the United States) to FOLFIRI in patients with mCRC previously treated with oxaliplatin, including patients who received prior bevacizumab. Patients and Methods Patients were randomly assigned to receive aflibercept (4 mg/kg intravenously; 612 patients) or placebo (614 patients) every 2 weeks in combination with FOLFIRI. Treatment was administered until disease progression or unacceptable toxicity. The primary end point was overall survival. Results Adding aflibercept to FOLFIRI significantly improved overall survival relative to placebo plus FOLFIRI (hazard ratio [HR], 0.817; 95.34% CI, 0.713 to 0.937; P = .0032) with median survival times of 13.50 versus 12.06 months, respectively. Aflibercept also significantly improved progression-free survival (PFS; HR, 0.758; 95% CI, 0.661 to 0.869; P < .0001), with median PFS times of 6.90 versus 4.67 months, respectively. The effects on overall survival and PFS exhibited a consistent trend across prespecified subgroup analyses, including bevacizumab pretreated patients. Response rate was 19.8% (95% CI, 16.4% to 23.2%) with aflibercept plus FOLFIRI compared with 11.1% (95% CI, 8.5% to 13.8%) with placebo plus FOLFIRI (P = .0001). Adverse effects reported with aflibercept combined with FOLFIRI included the characteristic anti-vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities. Conclusion Aflibercept in combination with FOLFIRI conferred a statistically significant survival benefit over FOLFIRI combined with placebo in patients with mCRC previously treated with oxaliplatin. J Clin Oncol 30:3499-3506. (C) 2012 by American Society of Clinical Oncology","[Van Cutsem, Eric] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium; [Tabernero, Josep; Macarulla, Teresa] Vall dHebron Univ Hosp, Barcelona, Spain; [Lakomy, Radek] Masaryk Mem Canc Inst, Brno, Czech Republic; [Prausova, Jana] Fak Nemocnice Motole, Prague, Czech Republic; [Ruff, Paul] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa; [van Hazel, Guy A.] Univ Western Australia, Nedlands, WA 6009, Australia; [McKendrick, Joe] Monash Univ, Clayton, Vic 3800, Australia; [Moiseyenko, Vladimir] Oncol Res Inst Na NN Petrov, St Petersburg, Russia; [Ferry, David] Russells Hall Hosp, Dudley, W Midlands, England; [Tellier, Alexia; Castan, Remi] Sanofi Rech, Vitry Sur Seine, France; [Allegra, Carmen] Univ Florida, Gainesville, FL USA","Van Cutsem, E (reprint author), Univ Hosp Gasthuisberg, Digest Oncol Unit, Herestr 49, B-3000 Louvain, Belgium.","eric.vancutsem@uz.kuleuven.ac.be","Moiseyenko, Vladimir/E-8892-2014","Moiseyenko, Vladimir/0000-0003-4807-7915","Sanofi; Regeneron Pharmaceuticals; Amgen","Supported by Sanofi, in collaboration with Regeneron Pharmaceuticals.Eric Van Cutsem, Sanofi; Radek Lakomy, Sanofi; Paul Ruff, Sanofi, Amgen","Chu QSC, 2009, EXPERT OPIN BIOL TH, V9, P263, DOI [10.1517/14712590802666397 , 10.1517/14712590802666397]; de Groot JF, 2011, J CLIN ONCOL, V29, P2689, DOI 10.1200/JCO.2010.34.1636; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Freyer G, 2008, J CLIN ONCOL S, V26, p630s; Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Isambert N, 2008, J CLIN ONCOL S, V26, p167s; Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399; Leighl NB, 2010, J THORAC ONCOL, V5, P1054, DOI 10.1097/JTO.0b013e3181e2f7fb; Limentani S, 2008, J CLIN ONCOL S, V26, p167s; Lockhart AC, 2010, J CLIN ONCOL, V28, P207, DOI 10.1200/JCO.2009.22.9237; Patnaik A, 2008, J CLIN ONCOL S, V26, p167s; Rixe O, 2008, J CLIN ONCOL S, V26, p167s; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Tang P, 2008, J CLIN ONCOL S, V26, p184s; Tew WP, 2007, J CLIN ONCOL S, V25, p295s; Tew WP, 2010, CLIN CANCER RES, V16, P358, DOI 10.1158/1078-0432.CCR-09-2103; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Twardowski P, 2010, UROLOGY, V76, P923, DOI 10.1016/j.urology.2010.04.025; Verslype C, 2008, J CLIN ONCOL S, V26, p631s; Yao J, 2011, P NATL ACAD SCI USA, V108, P11590, DOI 10.1073/pnas.1109029108; Zetter BR, 1998, ANNU REV MED, V49, P407",27,102,102,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,null,"J CLIN ONCOL","J. Clin. Oncol.","OCT 1",2012,30,28,null,null,null,null,3499,3506,null,"10.1200/JCO.2012.42.8201",null,8,"Oncology","Oncology","016KS","WOS:000309517700015"]
[null,null,null,null,"J","Joensuu, H; Vehtari, A; Riihimaki, J; Nishida, T; Steigen, SE; Brabec, P; Plank, L; Nilsson, B; Cirilli, C; Braconi, C; Bordoni, A; Magnusson, MK; Linke, Z; Sufliarsky, J; Federico, M; Jonasson, JG; Dei Tos, AP; Rutkowski, P",null,null,null,"Joensuu, Heikki; Vehtari, Aki; Riihimaki, Jaakko; Nishida, Toshirou; Steigen, Sonja E.; Brabec, Peter; Plank, Lukas; Nilsson, Bengt; Cirilli, Claudia; Braconi, Chiara; Bordoni, Andrea; Magnusson, Magnus K.; Linke, Zdenek; Sufliarsky, Jozef; Federico, Massimo; Jonasson, Jon G.; Dei Tos, Angelo Paolo; Rutkowski, Piotr",null,null,"Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts","LANCET ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"IMATINIB MESYLATE; STRATIFICATION; MUTATIONS; GIST; KIT; PROGNOSTICATION; VALIDATION; RESECTION; CRITERIA; SYSTEM","Background The risk of recurrence of gastrointestinal stromal tumour (GIST) after surgery needs to be estimated when considering adjuvant systemic therapy. We assessed prognostic factors of patients with operable GIST, to compare widely used risk-stratification schemes and to develop a new method for risk estimation. Methods Population-based cohorts of patients diagnosed with operable GIST, who were not given adjuvant therapy, were identified from the literature. Data from ten series and 2560 patients were pooled. Risk of tumour recurrence was stratified using the National Institute of Health (NIH) consensus criteria, the modified consensus criteria, and the Armed Forces Institute of Pathology (AFIP) criteria. Prognostic factors were examined using proportional hazards and non-linear models. The results were validated in an independent centre-based cohort consisting of 920 patients with GIST. Findings Estimated 15-year recurrence-free survival (RFS) after surgery was 59.9% (95% CI 56.2-63.6); few recurrences occurred after the first 10 years of follow-up. Large tumour size, high mitosis count, non-gastric location, presence of rupture, and male sex were independent adverse prognostic factors. In receiver operating characteristics curve analysis of 10-year RFS, the NIH consensus criteria, modified consensus criteria, and AFIP criteria resulted in an area under the curve (AUC) of 0.79 (95% CI 0.76-0.81), 0.78 (0.75-0.80), and 0.82 (0.80-0.85), respectively. The modified consensus criteria identified a single high-risk group. Since tumour size and mitosis count had a nonlinear association with the risk of GIST recurrence, novel prognostic contour maps were generated using non-linear modelling of tumour size and mitosis count, and taking into account tumour site and rupture. The non-linear model accurately predicted the risk of recurrence (AUC 0.88, 0.86-0.90). Interpretation The risk-stratification schemes assessed identify patients who are likely to be cured by surgery alone. Although the modified NIH classification is the best criteria to identify a single high-risk group for consideration of adjuvant therapy, the prognostic contour maps resulting from non-linear modelling are appropriate for estimation of individualised outcomes.","[Joensuu, Heikki] Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland; [Vehtari, Aki; Riihimaki, Jaakko] Aalto Univ, Dept Biomed Engn & Computat Sci, Espoo, Finland; [Nishida, Toshirou] Osaka Police Hosp, Osaka, Japan; [Steigen, Sonja E.] Univ Hosp No Norway, Tromso, Norway; [Steigen, Sonja E.] Univ Tromso, Tromso, Norway; [Brabec, Peter] Masaryk Univ, Inst Biostat & Anal, CS-60177 Brno, Czech Republic; [Plank, Lukas] Comenius Univ, Dept Pathol, Jessenius Med Fac, Martin, Slovakia; [Plank, Lukas] Univ Hosp, Martin, Slovakia; [Nilsson, Bengt] Sahlgrens Univ Hosp, Dept Surg, Gothenburg, Sweden; [Cirilli, Claudia] Registro Tumori Prov Modena, Modena, Italy; [Braconi, Chiara] Ctr Reg Genet Oncol, Ancona, Italy; [Bordoni, Andrea] Insitute Pathol S Switzerland, Ticino Canc Registry, Locarno, Switzerland; [Magnusson, Magnus K.] Landspitali Univ Hosp, Dept Lab Hematol & Pathol, Reykjavik, Iceland; [Sufliarsky, Jozef] Natl Canc Inst, Dept Internal Med, Bratislava, Slovakia; [Linke, Zdenek] Fac Hosp Motol, Radiotherapeut Oncol Dept, Prague, Czech Republic; [Federico, Massimo] Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy; [Jonasson, Jon G.] Univ Iceland, Fac Med, Reykjavik, Iceland; [Jonasson, Jon G.] Landspitali Univ Hosp, Dept Pathol, Reykjavik, Iceland; [Dei Tos, Angelo Paolo] Gen Hosp Treviso, Treviso, Italy; [Rutkowski, Piotr] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland; [Rutkowski, Piotr] Inst Oncol, Warsaw, Poland","Joensuu, H (reprint author), Univ Helsinki, Cent Hosp, Dept Oncol, Haartmaninkatu 4,POB 180, FIN-00029 Helsinki, Finland.","heikki.joensuu@hus.fi","Vehtari, Aki/A-7584-2008","Vehtari, Aki/0000-0003-2164-9469","Academy of Finland [218068, 218248, 129230, 131449]; Cancer Society of Finland; Sigrid Juselius Foundation; Helsinki University [TYH7206]; Novartis; Novartis Oncology","APDT has received a research grant from Novartis. All other authors declared no conflicts of interest.This study was supported by Academy of Finland (grants 218068, 218248, 129230, and 131449), Cancer Society of Finland, Sigrid Juselius Foundation, and Helsinki University Research Funds (grant TYH7206). Novartis Oncology provided financial support for the GIST registry in the Czech Republic and the Slovak Republic.",null,30,47,51,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1470-2045",null,null,"LANCET ONCOL","Lancet Oncol.","MAR",2012,13,3,null,null,null,null,265,274,null,"10.1016/S1470-2045(11)70299-6",null,10,"Oncology","Oncology","900IO","WOS:000300880600034"]
[null,null,null,null,"J","Wan, JJ; Yourshaw, M; Mamsa, H; Rudnik-Schoneborn, S; Menezes, MP; Hong, JE; Leong, DW; Senderek, J; Salman, MS; Chitayat, D; Seeman, P; von Moers, A; Graul-Neumann, L; Kornberg, AJ; Castro-Gago, M; Sobrido, MJ; Sanefuji, M; Shieh, PB; Salamon, N; Kim, RC; Vinters, HV; Chen, ZG; Zerres, K; Ryan, MM; Nelson, SF; Jen, JC",null,null,null,"Wan, Jijun; Yourshaw, Michael; Mamsa, Hafsa; Rudnik-Schoeneborn, Sabine; Menezes, Manoj P.; Hong, Ji Eun; Leong, Derek W.; Senderek, Jan; Salman, Michael S.; Chitayat, David; Seeman, Pavel; von Moers, Arpad; Graul-Neumann, Luitgard; Kornberg, Andrew J.; Castro-Gago, Manuel; Sobrido, Maria-Jesus; Sanefuji, Masafumi; Shieh, Perry B.; Salamon, Noriko; Kim, Ronald C.; Vinters, Harry V.; Chen, Zugen; Zerres, Klaus; Ryan, Monique M.; Nelson, Stanley F.; Jen, Joanna C.",null,null,"Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration","NATURE GENETICS",null,null,"English","Article",null,null,null,null,null,null,"AMYOTROPHIC-LATERAL-SCLEROSIS; DNA-SEQUENCING DATA; HORN CELL DISEASE; CEREBELLAR HYPOPLASIA; HEXANUCLEOTIDE REPEAT; MUSCULAR-ATROPHY; HUMAN GENOME; TYPE-1; ONSET; INVOLVEMENT","RNA exosomes are multi-subunit complexes conserved throughout evolution(1) and are emerging as the major cellular machinery for processing, surveillance and turnover of a diverse spectrum of coding and noncoding RNA substrates essential for viability(2). By exome sequencing, we discovered recessive mutations in EXOSC3 (encoding exosome component 3) in four siblings with infantile spinal motor neuron disease, cerebellar atrophy, progressive microcephaly and profound global developmental delay, consistent with pontocerebellar hypoplasia type 1 (PCH1; MIM 607596)(3-6). We identified mutations in EXOSC3 in an additional 8 of 12 families with PCH1. Morpholino knockdown of exosc3 in zebrafish embryos caused embryonic maldevelopment, resulting in small brain size and poor motility, reminiscent of human clinical features, and these defects were largely rescued by co-injection with wild-type but not mutant exosc3 mRNA. These findings represent the first example of an RNA exosome core component gene that is responsible for a human disease and further implicate dysregulation of RNA processing in cerebellar and spinal motor neuron maldevelopment and degeneration.","[Wan, Jijun; Mamsa, Hafsa; Hong, Ji Eun; Leong, Derek W.; Shieh, Perry B.; Vinters, Harry V.; Jen, Joanna C.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Yourshaw, Michael; Chen, Zugen; Nelson, Stanley F.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA; [Rudnik-Schoeneborn, Sabine; Zerres, Klaus] Univ Hosp Rhein Westfal TH RWTH Aachen, Fac Med, Inst Human Genet, Aachen, Germany; [Menezes, Manoj P.] Childrens Hosp Westmead, Inst Neurosci & Muscle Res, Westmead, NSW, Australia; [Senderek, Jan] Univ Hosp RWTH Aachen, Fac Med, Inst Neuropathol, Aachen, Germany; [Salman, Michael S.] Childrens Hosp, Sect Pediat Neurol, Winnipeg, MB R3A 1S1, Canada; [Salman, Michael S.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Chitayat, David] Univ Toronto, Mt Sinai Hosp, Dept Obstet & Gynecol, Prenatal Diag & Med Genet Program, Toronto, ON M5G 1X5, Canada; [Chitayat, David] Univ Toronto, Hosp Sick Children, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada; [Seeman, Pavel] Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague, Czech Republic; [Seeman, Pavel] Univ Hosp Motol, Prague, Czech Republic; [von Moers, Arpad] Deutsch Rotes Kreuz DRK Kliniken Berlin Westend, Dept Pediat, Berlin, Germany; [Graul-Neumann, Luitgard] Charite, Inst Med & Human Genet, D-13353 Berlin, Germany; [Kornberg, Andrew J.; Ryan, Monique M.] Univ Melbourne, Murdoch Childrens Res Inst, Royal Childrens Hosp, Melbourne, Qld, Australia; [Castro-Gago, Manuel] Univ Santiago de Compostela, Fac Med, Dept Pediat, Serv Neuropediat,Hosp Clin Univ, Santiago De Compostela, Spain; [Sobrido, Maria-Jesus] Clin Hosp Santiago de Compostela, Serv Galego Saude SERGAS, Fdn Publ Galega Med Xen, Santiago De Compostela, Spain; [Sobrido, Maria-Jesus] Inst Hlth Carlos III, Ctr Biomed Network Res Rare Dis CIBERER, Barcelona, Spain; [Sanefuji, Masafumi] Kyushu Univ, Grad Sch Med Sci, Fukuoka 812, Japan; [Salamon, Noriko] Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA USA; [Kim, Ronald C.] Univ Calif Irvine, Dept Pathol, Irvine, CA 92717 USA; [Kim, Ronald C.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA; [Vinters, Harry V.; Nelson, Stanley F.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA; [Nelson, Stanley F.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA","Jen, JC (reprint author), Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.","jjen@ucla.edu","Menezes, Manoj/K-6372-2012",null,"NIH/National Eye Institute (NEI) [R01 EY015311, NINDS R01 NS064183]; Deutsche Forschungsgemeinschaft [Ru-746/1-1]; IZKF Aachen [N5-4]; Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS 10552-3]; Xunta de Galicia-Plan Galego de InvestigaCion, Desenvolvemento e Innovacion Tecnoloxica (INCITE) [10PXIB9101280PR]","The authors are grateful for the generosity of the families who participated in this study. The sequencing and analytical work were supported by the Bioinformatics and Genomics Core of the UCLA Muscular Dystrophy Core Center (US National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) P30AR057230) within the Center for Duchenne Muscular Dystrophy. We appreciate fibroblasts from three subjects from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) Brain and Tissue Bank for Developmental Disorders. We acknowledge the contribution of clinical data by P. Carpenter (University of California, Irvine). The work was supported by the NIH/National Eye Institute (NEI) (R01 EY015311 and NINDS R01 NS064183 to J.C.J.), Deutsche Forschungsgemeinschaft (Ru-746/1-1 to S.R.-S. and K.Z.), IZKF Aachen (N5-4 to S.R.-S. and J.S.), the Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence (M. M. R.), the Internal Grant Agency of the Ministry of Health of the Czech Republic (NS 10552-3 to P. S.) and Xunta de Galicia-Plan Galego de InvestigaCion, Desenvolvemento e Innovacion Tecnoloxica (INCITE) (10PXIB9101280PR to M.-J.S.).",null,47,24,24,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","1061-4036",null,null,"NAT GENET","Nature Genet.","JUN",2012,44,6,null,null,null,null,704,"U134",null,"10.1038/ng.2254",null,7,"Genetics & Heredity","Genetics & Heredity","949BT","WOS:000304551100020"]
[null,null,null,null,"J","Amant, F; Van Calsteren, K; Halaska, MJ; Gziri, MM; Hui, W; Lagae, L; Willemsen, MA; Kapusta, L; Van Calster, B; Wouters, H; Heyns, L; Han, SN; Tomek, V; Mertens, L; Ottevanger, PB",null,null,null,"Amant, Frederic; Van Calsteren, Kristel; Halaska, Michael J.; Gziri, Mina Mhallem; Hui, Wei; Lagae, Lieven; Willemsen, Michel A.; Kapusta, Livia; Van Calster, Ben; Wouters, Heidi; Heyns, Liesbeth; Han, Sileny N.; Tomek, Viktor; Mertens, Luc; Ottevanger, Petronella B.",null,null,"Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study","LANCET ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"BLOOD-BRAIN-BARRIER; BREAST-CANCER; TRANSPLACENTAL TRANSFER; P-GLYCOPROTEIN; BABOON MODEL; YOUNG-ADULTS; IN-UTERO; PREGNANCY; ANTHRACYCLINES; ADOLESCENCE","Background Chemotherapy for the treatment of maternal cancers during pregnancy has become more acceptable in the past decade; however, the effect of prenatal exposure to chemotherapy on cardiac and neuro developmental outcomes of the off spring is still uncertain. We aimed to record the general health, cardiac function, and neurodevelopmental outcomes of children who were prenatally exposed to chemotherapy. Methods We did an interim analysis of a multicentre observational cohort study assessing children who were prenatally exposed to maternal cancer staging and treatment, including chemotherapy. We assessed children at birth, at age 18 months, and at age 5-6, 8-9, 11-12, 14-15, or 18 years. We did clinical neurological examinations, tests of the general level of cognitive functioning (Bayley or intelligence quotient [IQ] test), electrocardiography and echocardiography, and administered a questionnaire on general health and development. From age 5 years, we also did audiometry, the Auditory Verbal Learning Test, and subtasks of the Children's Memory Scale, and the Test of Everyday Attention for Children, and we also completed the Child Behavior Checklist. This study is registered with ClinicalTrials.gov, number NCT00330447. Findings 236 cycles of chemotherapy were administered in 68 pregnancies. We assessed 70 children, born at a median gestational age of 35.7 weeks (range 28.3-41.0; IQR 3.3; 47 women at <37 weeks), with a median follow-up period of 22.3 months (range 16.8-211.6; IQR 54.9). Although neurocognitive outcomes were within normal ranges, cognitive development scores were lower for children who were born preterm than for those born at full term. When controlling for age, sex, and country, the score for IQ increased by an average 11.6 points (95% CI 6.0-17.1) for each additional month of gestation (p<0.0001). Our measurements of the children's behaviour, general health, hearing, and growth corresponded with those of the general population. Cardiac dimensions and functions were within normal ranges. We identified a severe neurodevelopmental delay in both members of one twin pregnancy. Interpretation Fetal exposure to chemotherapy was not associated with increased CNS, cardiac or auditory morbidity, or with impairments to general health and growth compared with the general population. However, subtle changes in cardiac and neurocognitive measurements emphasise the need for longer follow-up. Prematurity was common and was associated with impaired cognitive development. Therefore, iatrogenic preterm delivery should be avoided when possible.","[Amant, Frederic; Van Calsteren, Kristel; Heyns, Liesbeth; Han, Sileny N.] Katholieke Univ Leuven, Leuven Canc Inst, Univ Hosp Leuven, B-3000 Louvain, Belgium; [Van Calsteren, Kristel; Gziri, Mina Mhallem; Van Calster, Ben] Katholieke Univ Leuven, Dept Obstet & Gynaecol, Univ Hosp Leuven, B-3000 Louvain, Belgium; [Lagae, Lieven; Wouters, Heidi] Katholieke Univ Leuven, Dept Paediat, Univ Hosp Leuven, B-3000 Louvain, Belgium; [Mertens, Luc] Katholieke Univ Leuven, Div Imaging & Cardiovasc Dynam, B-3000 Louvain, Belgium; [Halaska, Michael J.] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague, Czech Republic; [Willemsen, Michel A.] Radboud Univ Nijmegen, Med Ctr, Dept Paediat Neurol, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands; [Kapusta, Livia] Radboud Univ Nijmegen, Med Ctr, Dept Paediat Cardiol, NL-6525 ED Nijmegen, Netherlands; [Ottevanger, Petronella B.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands; [Kapusta, Livia] Edit Wolfson Med Ctr, Holon, Israel; [Tomek, Viktor] Fac Hosp Motol, Paediat Cardioctr, Prague, Czech Republic; [Hui, Wei; Mertens, Luc] Hosp Sick Children, Div Cardiol, Toronto, ON M5G 1X8, Canada","Amant, F (reprint author), Katholieke Univ Leuven, Leuven Canc Inst, Univ Hosp Leuven, Herestr 49, B-3000 Louvain, Belgium.","frederic.amant@uzleuven.be",null,null,"Research Foundation-Flanders [G 0358.06, SCIE2006-17]; Research Fund-K.U. Leuven [OT/07/053]; Flemish Government, Agency for Innovation by Science and Technology [TBM070706-IOTA3]; Stichting tegen Kanker; University Hospitals Leuven; Ministery of Health [NKP 29 038]; Clinical Research Fund-UZ Gasthuisberg","Funding Research Foundation-Flanders; Research Fund-K U Leuven; Agency for Innovation by Science and Technology; Stichting tegen Kanker; Clinical Research Fund-University Hospitals Leuven; and Belgian Cancer Plan, Ministery of Health.This report was presented as a late breaking abstract during the European Multidisciplinary Cancer Congress in Stockholm, Sweden (Sept 26, 2011). FA is senior clinical researcher and BVC postdoctoral researcher for the Research Foundation-Flanders; this research is supported by Research Foundation-Flanders Project G 0358.06, \"Stichting tegen kanker Project SCIE2006-17\", Research Fund-K.U. Leuven (OT/07/053), Flemish Government, Agency for Innovation by Science and Technology Project TBM070706-IOTA3, Clinical Research Fund-UZ Gasthuisberg, and Belgian Cancer Plan, Ministry of Health NKP 29 038. We thank the parents and children for their participation in our study, and all colleagues who contributed to this study. We thank Javier Ganame and Daisy Thijs (Leuven), Bob Rijk and Imke Tomasouw-Janssen (Nijmegen) for echocardiographic assessment of the children. We thank Ilse De Croock, Griet De Mulder, and Caroline Sterken (Leuven); Anja Vinck (Nijmegen); and Jitka Zackova (Prague) for cognitive evaluation of the children. We thank Anna Jansen from Vrije Universiteit Brussel for mutational analysis in two patients. We thank Liesbet Van Eycken from the Belgian Cancer Registry and Frank De Smet from the National Alliance of Christian Sickness Funds for helping with data extraction. We thank Marieke Taal, Diane Wolput, and Marie-Astrid Van Hoorick for their administrative support. The full list of investigators is in the appendix.",null,37,34,34,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1470-2045",null,null,"LANCET ONCOL","Lancet Oncol.","MAR",2012,13,3,null,null,null,null,256,264,null,"10.1016/S1470-2045(11)70363-1",null,9,"Oncology","Oncology","900IO","WOS:000300880600033"]
[null,null,null,null,"J","Neoptolemos, JP; Moore, MJ; Cox, TF; Valle, JW; Palmer, DH; McDonald, AC; Carter, R; Tebbutt, NC; Dervenis, C; Smith, D; Glimelius, B; Charnley, RM; Lacaine, F; Scarfe, AG; Middleton, MR; Anthoney, A; Ghaneh, P; Halloran, CM; Lerch, MM; Olah, A; Rawcliffe, CL; Verbeke, CS; Campbell, F; Buchler, MW",null,null,null,"Neoptolemos, John P.; Moore, Malcolm J.; Cox, Trevor F.; Valle, Juan W.; Palmer, Daniel H.; McDonald, Alexander C.; Carter, Ross; Tebbutt, Niall C.; Dervenis, Christos; Smith, David; Glimelius, Bengt; Charnley, Richard M.; Lacaine, Francois; Scarfe, Andrew G.; Middleton, Mark R.; Anthoney, Alan; Ghaneh, Paula; Halloran, Christopher M.; Lerch, Markus M.; Olah, Attila; Rawcliffe, Charlotte L.; Verbeke, Caroline S.; Campbell, Fiona; Buechler, Markus W.",null,"European Study Grp Pancreatic Canc","Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial","JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION",null,null,"English","Article",null,null,null,null,null,null,"PANCREATIC-CANCER; AMPULLARY CARCINOMA; PROGNOSTIC-FACTORS; TRACT CANCER; PANCREATICODUODENECTOMY; CHEMORADIOTHERAPY; DIFFERENTIATION","Context Patients with periampullary adenocarcinomas undergo the same resectional surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant chemotherapy has been shown to have a survival benefit for pancreatic cancer, there have been no randomized trials for periampullary adenocarcinomas. Objective To determine whether adjuvant chemotherapy (fluorouracil or gemcitabine) provides improved overall survival following resection. Design, Setting, and Patients The European Study Group for Pancreatic Cancer (ESPAC)-3 periampullary trial, an open-label, phase 3, randomized controlled trial (July 2000-May 2008) in 100 centers in Europe, Australia, Japan, and Canada. Of the 428 patients included in the primary analysis, 297 had ampullary, 96 had bile duct, and 35 had other cancers. Interventions One hundred forty-four patients were assigned to the observation group, 143 patients to receive 20 mg/m(2) of folinic acid via intravenous bolus injection followed by 425 mg/m(2) of fluorouracil via intravenous bolus injection administered 1 to 5 days every 28 days, and 141 patients to receive 1000 mg/m(2) of intravenous infusion of gemcitabine once a week for 3 of every 4 weeks for 6 months. Main Outcome Measures The primary outcome measure was overall survival with chemotherapy vs no chemotherapy; secondary measures were chemotherapy type, toxic effects, progression-free survival, and quality of life. Results Eighty-eight patients (61%) in the observation group, 83 (58%) in the fluorouracil plus folinic acid group, and 73 (52%) in the gemcitabine group died. In the observation group, the median survival was 35.2 months (95%% CI, 27.2-43.0 months) and was 43.1 (95%, CI, 34.0-56.0) in the 2 chemotherapy groups (hazard ratio, 0.86; (95% CI, 0.66-1.11; chi(2)=1.33; P=.25). After adjusting for independent prognostic variables of age, bile duct cancer, poor tumor differentiation, and positive lymph nodes and after conducting multiple regression analysis, the hazard ratio for chemotherapy compared with observation was 0.75 (95% CI, 0.57-0.98; Wald chi(2)=4.53, P=.03). Conclusions Among patients with resected periampullary adenocarcinoma, adjuvant chemotherapy, compared with observation, was not associated with a significant survival benefit in the primary analysis; however, multivariable analysis adjusting for prognostic variables demonstrated a statistically significant survival benefit associated with adjuvant chemotherapy","[Neoptolemos, John P.; Cox, Trevor F.; Ghaneh, Paula; Halloran, Christopher M.; Rawcliffe, Charlotte L.; Campbell, Fiona] Univ Liverpool, Canc Res United Kingdom Ctr, Liverpool Canc Trials Unit, Inst Translat Med, Liverpool L69 3GA, Merseyside, England; [Moore, Malcolm J.] Princess Margaret Hosp, Dept Med, Div Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada; [Valle, Juan W.] Univ Manchester, Sch Canc & Enabling Sci, Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 9PL, Lancs, England; [Palmer, Daniel H.] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Sch Canc Sci, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England; [McDonald, Alexander C.] Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Carter, Ross] Glasgow Royal Infirm, Dept Surg, Glasgow G4 0SF, Lanark, Scotland; [Tebbutt, Niall C.] Austin Hlth, Ludwig Oncol Unit, Melbourne, Vic, Australia; [Dervenis, Christos] Agia Olga Hosp, Dept Surg, Athens, Greece; [Smith, David] Clatterbridge Ctr Oncol, Bebington, Merseyside, England; [Glimelius, Bengt] Uppsala Univ, Akad Sjukhuset, Dept Oncol, Uppsala, Sweden; [Charnley, Richard M.] Freeman Rd Hosp, Dept Surg, Newcastle Upon Tyne, Tyne & Wear, England; [Lacaine, Francois] Hop Tenon, Serv Chirurg Digest & Viscerale, F-75970 Paris, France; [Scarfe, Andrew G.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; [Middleton, Mark R.] Oxford Univ Hosp NHS Trust, Churchill Hosp, Dept Oncol, Oxford, England; [Anthoney, Alan] St James Univ Hosp, Dept Oncol, Leeds, W Yorkshire, England; [Lerch, Markus M.] Ernst Moritz Arndt Univ Greifswald, Dept Med, Greifswald, Germany; [Olah, Attila] Petz Aladar Hosp, Dept Surg, Gyor, Hungary; [Verbeke, Caroline S.] Karolinska Univ Hosp, Dept Pathol, Stockholm, Sweden; [Buechler, Markus W.] Heidelberg Univ, Dept Surg, D-6900 Heidelberg, Germany","Neoptolemos, JP (reprint author), Univ Liverpool, Canc Res United Kingdom Ctr, Liverpool Canc Trials Unit, Inst Translat Med, UCD Bldg,Daulby St,5th Floor, Liverpool L69 3GA, Merseyside, England.","j.p.neoptolemos@liverpool.ac.uk","Cox, Trevor/E-5567-2013",null,"Cancer Research United Kingdom; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia; Cancer Council of New South Wales; Cancer Council of Queensland; Cancer Council of Victoria; Cancer Council of South Australia; Australasian Gastro-Intestinal Trials Group; Liverpool NIHR Pancreas Biomedical Research Unit; Oxford NIHR Biomedical Research Centre","The study was supported by Cancer Research United Kingdom; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia, Cancer Councils of New South Wales, Queensland, Victoria and South Australia and The Australasian Gastro-Intestinal Trials Group. JPN is part funded Liverpool NIHR Pancreas Biomedical Research Unit. MM is part funded Oxford NIHR Biomedical Research Centre.","Albores-Saavedra J, 2009, J SURG ONCOL, V100, P598, DOI 10.1002/jso.21374; Albores-Saavedra J, 2010, WHO CLASSIFICATION T, P87; Berberat PO, 2009, EJSO-EUR J SURG ONC, V35, P187, DOI 10.1016/j.ejso.2008.01.030; Carter R, 2009, INT J CANCER, V124, P2960, DOI 10.1002/ijc.24270; COX DR, 1972, J R STAT SOC B, V34, P187; de Castro SMM, 2004, J GASTROINTEST SURG, V8, P775, DOI 10.1016/j.gassur.2004.08.006; Ehehalt F, 2011, ANN SURG, V254, P302, DOI 10.1097/SLA.0b013e31821994a8; Hatzaras I, 2010, ANN SURG ONCOL, V17, P991, DOI 10.1245/s10434-009-0883-9; Henson DE, 2009, ARCH PATHOL LAB MED, V133, P67, DOI 10.1043/1543-2165-133.1.67; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; O'Connell JB, 2008, ANN SURG ONCOL, V15, P1820, DOI 10.1245/s10434-008-9886-1; Pedrazzoli Sergio, 1999, Digestive Surgery, V16, P337, DOI 10.1159/000018744; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Riall TS, 2006, SURGERY, V140, P764, DOI 10.1016/j.surg.2006.04.006; Riall TS, 2005, J GASTROINTEST SURG, V9, P1191, DOI 10.1016/j.gassur.2005.08.034; Schonleben F, 2009, J GASTROINTEST SURG, V13, P1510, DOI 10.1007/s11605-009-0917-4; Sessa F, 2007, VIRCHOWS ARCH, V451, P649, DOI 10.1007/s00428-007-0444-1; Showalter TN, 2011, J GASTROINTEST SURG, V15, P1411, DOI 10.1007/s11605-011-1518-6; Smith RA, 2008, J GASTROINTEST SURG, V12, P1422, DOI 10.1007/s11605-008-0554-3; Sobin LH, 1997, TNM CLASSIFICATION M; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Westgaard A, 2009, HISTOPATHOLOGY, V54, P337, DOI 10.1111/j.1365-2559.2009.03227.x; Westgaard A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-170; Winter JM, 2010, J GASTROINTEST SURG, V14, P379, DOI 10.1007/s11605-009-1080-7",28,27,28,"AMER MEDICAL ASSOC","CHICAGO","330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA","0098-7484","1538-3598",null,"JAMA-J AM MED ASSOC","JAMA-J. Am. Med. Assoc.","JUL 11",2012,308,2,null,null,null,null,147,156,null,"10.1001/jama.2012.7352",null,10,"Medicine, General & Internal","General & Internal Medicine","971QS","WOS:000306219500028"]
[null,null,null,null,"J","Biondi, A; Schrappe, M; De Lorenzo, P; Castor, A; Lucchini, G; Gandemer, V; Pieters, R; Stary, J; Escherich, G; Campbell, M; Li, CK; Vora, A; Arico, M; Rottgers, S; Saha, V; Valsecchi, MG",null,null,null,"Biondi, Andrea; Schrappe, Martin; De Lorenzo, Paola; Castor, Anders; Lucchini, Giovanna; Gandemer, Virginie; Pieters, Rob; Stary, Jan; Escherich, Gabriele; Campbell, Myriam; Li, Chi-Kong; Vora, Ajay; Arico, Maurizio; Roettgers, Silja; Saha, Vaskar; Valsecchi, Maria Grazia",null,null,"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study","LANCET ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"STEM-CELL TRANSPLANTATION; TYROSINE KINASE; AIEOP-BFM; T-CELL; CHEMOTHERAPY; THERAPY; COMBINATION; STRATIFICATION; INHIBITION; MESYLATE","Background Trials of imatinib have provided evidence of activity in adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (ALL), but the drug's role when given with multidrug chemotherapy to children is unknown. This study assesses the safety and efficacy of oral imatinib in association with a Berlin-Frankfurt-Munster intensive chemotherapy regimen and allo geneic stem-cell transplantation for paediatric patients with Philadelphia-chromosome-positive ALL. Methods Patients aged 1-18 years recruited to national trials of front-line treatment for ALL were eligible if they had t(9;22)(q34;q11). Patients with abnormal renal or hepatic function, or an active systemic infection, were ineligible. Patients were enrolled by ten study groups between 2004 and 2009, and were classified as good risk or poor risk according to early response to induction treatment. Good-risk patients were randomly assigned by a web-based system with permuted blocks (size four) to receive post-induction imatinib with chemotherapy or chemotherapy only in a 1: 1 ratio, while all poor-risk patients received post-induction imatinib with chemotherapy. Patients were stratified by study group. The chemotherapy regimen was modelled on a Berlin-Frankfurt-Munster high-risk backbone; all received four post-induction blocks of chemotherapy after which they became eligible for stem-cell transplantation. The primary endpoints were disease-free survival at 4 years in the good-risk group and event-free survival at 4 years in the poor-risk group, analysed by intention to treat and a secondary analysis of patients as treated. The trial is registered with EudraCT (2004-001647-30) and ClinicalTrials.gov, number NCT00287105. Findings Between Jan 1, 2004, and Dec 31, 2009, we screened 229 patients and enrolled 178: 108 were good risk and 70 poor risk. 46 good-risk patients were assigned to receive imatinib and 44 to receive no imatinib. Median follow-up was 3.1 years (IQR 2.0-4.6). 4-year disease-free survival was 72.9% (95% CI 56.1-84.1) in the good-risk, imatinib group versus 61.7% (45.0-74.7) in the good-risk, no imatinib group (p=0.24). The hazard ratio (HR) for failure, adjusted for minimal residual disease, was 0.63 (0.28-1.41; p=0.26). The as-treated analysis showed 4-year disease-free survival was 75.2% (61.0-84.9) for good-risk patients receiving imatinib and 55.9% (36.1-71.7) for those who did not receive imatinib (p=0.06). 4-year event-free survival for poor-risk patients was 53.5% (40.4-65.0). Serious adverse events were much the same in the good-risk groups, with infections caused by myelosuppression the most common. 16 patients in the good-risk imatinib group versus ten in the good-risk, no imatinib group (p=0.64), and 24 in the poor-risk group, had a serious adverse event. Interpretation Our results suggests that imatinib in conjunction with intensive chemotherapy is well tolerated and might be beneficial for treatment of children with Philadelphia-chromosome-positive ALL.","[Biondi, Andrea; De Lorenzo, Paola; Lucchini, Giovanna] Univ Milano Bicocca, Dept Paediat, Monza, Italy; [De Lorenzo, Paola; Valsecchi, Maria Grazia] Univ Milano Bicocca, Dept Clin & Prevent Med, Monza, Italy; [De Lorenzo, Paola; Valsecchi, Maria Grazia] Univ Milano Bicocca, EsPhALL Trial Data Ctr, Monza, Italy; [Schrappe, Martin] Univ Med Ctr, Dept Paediat, Kiel, Germany; [Schrappe, Martin] Univ Kiel, Kiel, Germany; [Castor, Anders] Univ Lund Hosp, S-22185 Lund, Sweden; [Gandemer, Virginie] CHU Hop S, Dept Paediat Haematol Oncol, Rennes, France; [Pieters, Rob] Univ Med Ctr Rotterdam, Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands; [Stary, Jan] Univ Hosp Motol, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Escherich, Gabriele] Univ Med Ctr Hamburg Eppendorf, Clin Paediat Haematol & Oncol, Hamburg, Germany; [Campbell, Myriam] Univ Chile, Hosp Roberto del Rio, Div Paediat Haematol Oncol, Santiago, Chile; [Li, Chi-Kong] Prince Wales Hosp, Dept Paediat, Shatin, Hong Kong, Peoples R China; [Vora, Ajay] Sheffield Childrens Hosp, Sheffield, S Yorkshire, England; [Arico, Maurizio] Azienda Osped Univ Meyer, Florence, Italy; [Roettgers, Silja] Univ Giessen, Oncogenet Lab, Giessen, Germany; [Saha, Vaskar] Univ Manchester, Sch Canc & Enabling Sci, Manchester Acad Hlth Sci Ctr, Cent Manchester Univ Hosp Fdn Trust, Manchester M13 9PL, Lancs, England","Biondi, A (reprint author), Hosp S Gerardo, Fdn MBBM, Dept Paediat, I-20900 Monza, Italy.","andrea.biondi@unimib.it","Li, Chi Kong/J-8456-2013",null,"Projet Hospitalier de Recherche Clinique-Cancer (France); Fondazione Tettamanti-De Marchi (Italy); Associazione Italiana per la Ricerca sul Cancro (Italy) [AIRC-IG 8666, AIRC-IG 5017]; Novartis Germany; Cancer Research UK; Leukaemia Lymphoma Research; Central Manchester University Hospitals Foundation Trust; Central Manchester University Hospitals Foundation Trust (UK)","Projet Hospitalier de Recherche Clinique-Cancer (France), Fondazione Tettamanti-De Marchi and Associazione Italiana per la Ricerca sul Cancro (Italy), Novartis Germany, Cancer Research UK, Leukaemia Lymphoma Research, and Central Manchester University Hospitals Foundation Trust.The study was supported by Projet Hospitalier de Recherche Clinique-Cancer (France), Fondazione Tettamanti-De Marchi and Associazione Italiana per la Ricerca sul Cancro (AIRC-IG 8666 to AB and AIRC-IG 5017 to MGV; Italy), Central Manchester University Hospitals Foundation Trust (UK) Novartis Germany, which provided funds for data management, and Cancer Research UK. Analysis of minimal residual disease was funded by a grant from Leukaemia Lymphoma Research.",null,33,20,23,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1470-2045",null,null,"LANCET ONCOL","Lancet Oncol.","SEP",2012,13,9,null,null,null,null,936,945,null,"10.1016/S1470-2045(12)70377-7",null,10,"Oncology","Oncology","000XZ","WOS:000308425600021"]
[null,null,null,null,"J","Corbacioglu, S; Cesaro, S; Faraci, M; Valteau-Couanet, D; Gruhn, B; Rovelli, A; Boelens, JJ; Hewitt, A; Schrum, J; Schulz, AS; Muller, I; Stein, J; Wynn, R; Greil, J; Sykora, KW; Matthes-Martin, S; Fuhrer, M; O'Meara, A; Toporski, J; Sedlacek, P; Schlegel, PG; Ehlert, K; Fasth, A; Winiarski, J; Arvidson, J; Mauz-Korholz, C; Ozsahin, H; Schrauder, A; Bader, P; Massaro, J; D'Agostino, R; Hoyle, M; Iacobelli, M; Debatin, KM; Peters, C; Dini, G",null,null,null,"Corbacioglu, Selim; Cesaro, Simone; Faraci, Maura; Valteau-Couanet, Dominique; Gruhn, Bernd; Rovelli, Attilio; Boelens, Jaap J.; Hewitt, Annette; Schrum, Johanna; Schulz, Ansgar S.; Mueller, Ingo; Stein, Jerry; Wynn, Robert; Greil, Johann; Sykora, Karl-Walter; Matthes-Martin, Susanne; Fuehrer, Monika; O'Meara, Anne; Toporski, Jacek; Sedlacek, Petr; Schlegel, Paul G.; Ehlert, Karoline; Fasth, Anders; Winiarski, Jacek; Arvidson, Johan; Mauz-Koerholz, Christine; Ozsahin, Hulya; Schrauder, Andre; Bader, Peter; Massaro, Joseph; D'Agostino, Ralph; Hoyle, Margaret; Iacobelli, Massimo; Debatin, Klaus-Michael; Peters, Christina; Dini, Giorgio",null,null,"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","LANCET",null,null,"English","Article",null,null,null,null,null,null,"BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; RISK-FACTORS; COMPETING RISKS; CHILDREN; LIVER; RECIPIENTS; DIAGNOSIS; COHORT; BLOOD","Background Hepatic veno-occlusive disease is a leading cause of morbidity and mortality after haemopoietic stem-cell transplantation (HSCT). We aimed to assess whether defibrotide can reduce the incidence of veno-occlusive disease in this setting. Methods In our phase 3 open-label, randomised controlled trial, we enrolled patients at 28 European university hospitals or academic medical centres. Eligible patients were younger than 18 years, had undergone myeloablative conditioning before allogeneic or autologous HSCT, and had one or more risk factor for veno-occlusive disease based on modified Seattle criteria. We centrally assigned eligible participants on the basis of a computer-generated randomisation sequence (1: 1), stratified by centre and presence of osteopetrosis, to receive intravenous defibrotide prophylaxis (treatment group) or not (control group). The primary endpoint was incidence of veno-occlusive disease by 30 days after HSCT, adjudicated by a masked, independent review committee, in eligible patients who consented to randomisation (intention-to-treat population), and was assessed with a competing risk approach. Patients in either group who developed veno-occlusive disease received defibrotide for treatment. We assessed adverse events to 180 days after HSCT in all patients who received allocated prophylaxis. This trial is registered with ClinicalTrials.gov, number NCT00272948. Findings Between Jan 25, 2006, and Jan 29, 2009, we enrolled 356 eligible patients to the intention-to-treat population. 22 (12%) of 180 patients randomly allocated to the defibrotide group had veno-occlusive disease by 30 days after HSCT compared with 35 (20%) of 176 controls (risk difference -7.7%, 95% CI -15.3 to -0.1; Z test for competing risk analysis p=0.0488; log-rank test p=0.0507). 154 (87%) of 177 patients in the defibrotide group had adverse events by day 180 compared with 155 (88%) of 176 controls. Interpretation Defibrotide prophylaxis seems to reduce incidence of veno-occlusive disease and is well tolerated. Thus, such prophylaxis could present a useful clinical option for this serious complication of HSCT.","[Corbacioglu, Selim] Univ Regensburg, D-93053 Regensburg, Germany; [Cesaro, Simone] Univ Padua, Padua, Italy; [Faraci, Maura; Dini, Giorgio] G Gaslini Inst Children, Genoa, Italy; [Valteau-Couanet, Dominique] Inst Gustave Roussy, Villejuif, France; [Gruhn, Bernd] Univ Hosp Jena, Jena, Germany; [Rovelli, Attilio] Univ Milano Bicocca, Monza, Italy; [Boelens, Jaap J.] Univ Med Ctr, Utrecht, Netherlands; [Hewitt, Annette] Great Ormond St Hosp Sick Children, London, England; [Schrum, Johanna] Univ Hamburg Eppendorf, Hamburg, Germany; [Schulz, Ansgar S.; Debatin, Klaus-Michael] Univ Childrens Hosp, Ulm, Germany; [Mueller, Ingo] Univ Childrens Hosp, Tubingen, Germany; [Stein, Jerry] Schneider Childrens Med Ctr, Petah Tiqwa, Israel; [Wynn, Robert] Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England; [Greil, Johann] Univ Childrens Hosp, Heidelberg, Germany; [Sykora, Karl-Walter] Hannover Med Sch, Hannover, Germany; [Matthes-Martin, Susanne; Peters, Christina] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Fuehrer, Monika] Univ Childrens Hosp, Munich, Germany; [O'Meara, Anne] Our Ladys Childrens Hosp, Dublin, Ireland; [Toporski, Jacek] Skane Univ Hosp, Lund, Sweden; [Sedlacek, Petr] Univ Hosp Motol, Prague, Czech Republic; [Schlegel, Paul G.] Univ Childrens Hosp, Wurzburg, Germany; [Ehlert, Karoline] Univ Childrens Hosp, Munster, Germany; [Fasth, Anders] Univ Gothenburg, Dept Pediat, Gothenburg, Sweden; [Winiarski, Jacek] Karolinska Inst, Stockholm, Sweden; [Arvidson, Johan] Uppsala Univ, Childrens Hosp, Uppsala, Sweden; [Mauz-Koerholz, Christine] Univ Halle Wittenberg, Halle, Germany; [Ozsahin, Hulya] Univ Childrens Hosp, Geneva, Switzerland; [Schrauder, Andre] Univ Hosp Schleswig Holstein, Kiel, Germany; [Bader, Peter] Univ Childrens Hosp, Frankfurt, Germany; [Massaro, Joseph; D'Agostino, Ralph] Boston Univ, Boston, MA 02215 USA; [Hoyle, Margaret; Iacobelli, Massimo] Gentium SpA, Villa Guardia, Como, Italy","Corbacioglu, S (reprint author), Univ Regensburg, Childrens Hosp Regensburg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.","selim.corbacioglu@klinik.uni-regensburg.de",null,null,"Gentium; Medac; Gentium SpA; European Blood and Marrow Transplantation (EBMT) Group; European Group for Blood and Marrow Transplantation","SCo, JM, and RD'A received fees from Gentium for review activities on this report. JM received payment from Gentium for writing and reviewing the report. JM received payment from Gentium for writing assistance. SCo and CP's institution received grants to their institutions from Gentium and KW-S's institution received a grant from Medac. CP has given lectures and is on the speakers bureau for the Center for International Blood and Marrow Transplant Research, Amgen, and Fresenius. SCo, JM, and SM-M have received support for travel relating to the report from Gentium. SCo and JM have received consultancy fees or honorarium from Gentium and CP has received such fees from Medac. MH and MI are employees and have stock in Gentium. CP has received support for travel, accommodation, and meetings from Amomed and Gentium. All other authors declare that they have no conflicts of interest.This trial was supported by Gentium SpA and the European Blood and Marrow Transplantation (EBMT) Group (clinical trial insurance and study management/monitoring costs). We thank the nurses, staff, clinical research coordinators, and especially the patients and families involved in the trial for their participation; the following contributors for their support in this clinical trial: Stefan Suciu (Organization for Research and Treatment of Cancer in Brussels, Belgium), Lawrence Faulkner (Cure2Children Foundation in Florence, Italy), Mutlu Arat (Sisli Florence Nightingale Hospital in Istanbul, Turkey), and Paul Richardson (Dana-Farber Cancer Institute in Boston, MA, USA) from the Data and Safety Monitoring Board; Jacek Wachowiak (Poznan University of Medical Sceinces, Poznan, Poland), Guido Finazzi (Ospedali Riuniti in Bergamo, Italy), and Tiziano Barbui (Research Foundation of Ospedale Maggiore in Bergamo, Italy) from the Independent Review Committee; and Michael Pfitzenmaier, Rainer Muche, Friederike Rohlmann, and Susanne Stohr for their contributions to data management; Marco Sardella and Giorgia Finetto of Gentium SpA for safety and study management; and Cornelio Uderzo for his thorough review of the manuscript. Medical writing support was provided by Katherine Duxbury and Kate Silverthorne at FireKite (Berkshire, UK) and sponsored by Gentium SpA.Gentium SpA, European Group for Blood and Marrow Transplantation.",null,39,16,16,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0140-6736",null,null,"LANCET","Lancet","APR 7",2012,379,9823,null,null,null,null,1301,1309,null,"10.1016/S0140-6736(11)61938-7",null,9,"Medicine, General & Internal","General & Internal Medicine","922FB","WOS:000302531100027"]
[null,null,null,null,"J","Devonshire, V; Havrdova, E; Radue, EW; O'Connor, P; Zhang-Auberson, L; Agoropoulou, C; Haring, DA; Francis, G; Kappos, L",null,null,null,"Devonshire, Virginia; Havrdova, Eva; Radue, Ernst Wilhelm; O'Connor, Paul; Zhang-Auberson, Lixin; Agoropoulou, Catherine; Haering, Dieter Adrian; Francis, Gordon; Kappos, Ludwig",null,"FREEDOMS Study Grp","Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study","LANCET NEUROLOGY",null,null,"English","Article",null,null,null,null,null,null,"ORAL FINGOLIMOD; INTRAMUSCULAR INTERFERON; CLINICAL-TRIALS; FTY720","Background Fingolimod 0.5 mg once daily is approved for treatment of relapsing multiple sclerosis (MS). In the phase 3, 2-year FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in MS) study, fingolimod significantly reduced annualised relapse rates (ARRs) and the risk of confirmed disability progression compared with placebo. We aimed to investigate whether the beneficial treatment effect reported for the overall population is consistent in subgroups of patients with different baseline characteristics. Methods We did subgroup analyses of ARRs (primary outcome) and confirmed disability progression (a secondary outcome) over 24 months in the FREEDOMS study, a randomised, double-blind study that included 1272 patients with relapsing-remitting MS who were assigned 1:1:1 to fingolimod (0.5 mg or 1.25 mg) or placebo once daily for 24 months. Subgroups were predefined, predefined and slightly modified, or defined post hoc, by demographic factors (including sex and age), disease characteristics (including baseline disability scores, relapse rates, and lesion parameters), and response to previous therapy (including analyses in patients eligible for fingolimod treatment according to the European label). Data were analysed by intention to treat. The FREEDOMS study is registered with ClinicalTrials.gov, number NCT00289978. Findings Treatment with fingolimod 0.5 mg was associated with significantly lower ARRs versus placebo across all subgroups except for patients aged over 40 years. ARR ratios ranged from 0.76 (95% CI 0.54-1.09; p=0.13) in patients aged over 40 years to 0.29 (0.16-0.52; p<0.0001) in patients who had relapse activity despite receiving interferon beta during the year before study enrolment. Hazard ratios for confirmed disability progression over 24 months with fingolimod 0.5 mg versus placebo ranged from 0.85 (95% CI 0.53-1.36; p=0.50) in patients with a T2 lesion volume of 3300 mm(3) or less to 0.32 (0.14-0.73; p=0.0066) in patients with an EDSS over 3.5. In patients who relapsed and had lesion activity despite treatment with interferon beta in the previous year, the ARR ratio for fingolimod 0.5 mg versus placebo was 0.38 (95% CI 0.21-0.68, p=0.0011), and for treatment-naive patients with rapidly evolving severe disease it was 0.33 (0.18-0.62, p=0.0006). Hazard ratios for confirmed disability progression over 24 months were 0.68 (0.29-1.62; p=0.39) and 0.73 (0.25-2.07; p=0.55), respectively, in these groups. Interpretation Patients with relapsing-remitting MS with a wide spectrum of clinical and MRI features including subgroups specified by the European label can potentially benefit from treatment with 0.5 mg fingolimod.","[Radue, Ernst Wilhelm; Kappos, Ludwig] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Radue, Ernst Wilhelm; Kappos, Ludwig] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland; [Devonshire, Virginia] Univ British Columbia, Hosp Multiple Sclerosis Clin, Vancouver, BC V5Z 1M9, Canada; [Havrdova, Eva] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague, Czech Republic; [O'Connor, Paul] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Zhang-Auberson, Lixin; Agoropoulou, Catherine; Haering, Dieter Adrian] Novartis, Basel, Switzerland; [Francis, Gordon] Novartis, E Hanover, NJ USA","Kappos, L (reprint author), Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland.","lkappos@uhbs.ch","Weissert, Robert/B-2585-2009","Weissert, Robert/0000-0002-1295-1271","Novartis; Bayer; Biogen Idec; Genzyme; Merck Serono; Teva; Schering; Actelion; Celgene; EMD Serono; Sanofi Genzyme; Receptos; Advancell; Allozyne; Bayhill; BioMarin; CSL Behring; Eli Lilly; EU; Genmab; GeNeuro SA; Gianni Rubatto Foundation; Glenmark; MediciNova; Mitsubishi Pharma; Novartis Research Foundation; Novonordisk; Peptimmune; Roche; Roche Research Foundation; Santhera; Sanofi-Aventis; Swiss MS Society; Swiss National Research Foundation; UCB; Wyeth; Czech Ministry of Education [MSM 0021620849]; Canadian MS Society","VD has received fees for consultancy or speaking in the past 3 years from Novartis. EH has received fees for board membership, consultancy or speaking, or grants in the past 3 years from Bayer, Biogen Idec, Genzyme, Merck Serono, Novartis, and Teva. EWR has received fees for board membership, consultancy, or speaking in the past 3 years from Bayer Schering, Biogen Idec, Merck Serono, and Novartis. PO'C has received fees for board membership or consultancy, or grants in the past 3 years from Actelion, Biogen Idec, Celgene, EMD Serono, Novartis, Sanofi Genzyme, Receptos, and Teva. The University Hospital Basel, as employer of LK, has received and dedicated to research support fees for board membership, consultancy or speaking, or grants in the past 3 years from Actelion, Advancell, Allozyne, Bayer, Bayhill, Biogen Idec, BioMarin, CSL Behring, Eli Lilly, EU, Genmab, GeNeuro SA, Gianni Rubatto Foundation, Glenmark, Merck Serono, MediciNova, Mitsubishi Pharma, Novartis, Novartis Research Foundation, Novonordisk, Peptimmune, Roche, Roche Research Foundation, Santhera, Sanofi-Aventis, Swiss MS Society, Swiss National Research Foundation, Teva, UCB, and Wyeth. CA, LZ-A, DAH and CF are employees of Novartis.We thank the patients who participated in the FREEDOMS study, the study site personnel, and Louise Verrall (Oxford Pharmagenesis, funded by Novartis) and Hashem Salloukh (Novartis) for editorial assistance. EH has been supported by the Czech Ministry of Education, Research program MSM 0021620849. LK is supported by the Swiss MS Society. PO'C receives support from the Canadian MS Society in his role as Medical Advisor.",null,17,23,23,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1474-4422",null,null,"LANCET NEUROL","Lancet Neurol.","MAY",2012,11,5,null,null,null,null,420,428,null,"10.1016/S1474-4422(12)70056-X",null,9,"Clinical Neurology","Neurosciences & Neurology","930KM","WOS:000303138300013"]
[null,null,null,null,"J","Loibl, S; Han, SN; von Minckwitz, G; Bontenbal, M; Ring, A; Giermek, J; Fehm, T; Van Calsteren, K; Linn, SC; Schlehe, B; Gziri, MM; Westenend, PJ; Muller, V; Heyns, L; Rack, B; Van Calster, B; Harbeck, N; Lenhard, M; Halaska, MJ; Kaufmann, M; Nekljudova, V; Amant, F",null,null,null,"Loibl, Sibylle; Han, Sileny N.; von Minckwitz, Gunter; Bontenbal, Marijke; Ring, Alistair; Giermek, Jerzy; Fehm, Tanja; Van Calsteren, Kristel; Linn, Sabine C.; Schlehe, Bettina; Gziri, Mina Mhallem; Westenend, Pieter J.; Mueller, Volkmar; Heyns, Liesbeth; Rack, Brigitte; Van Calster, Ben; Harbeck, Nadia; Lenhard, Miriam; Halaska, Michael J.; Kaufmann, Manfred; Nekljudova, Valentina; Amant, Frederic",null,null,"Treatment of breast cancer during pregnancy: an observational study","LANCET ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"PRETERM BIRTH; CHEMOTHERAPY; OUTCOMES; ANTHRACYCLINES; PROGNOSIS; CHILDREN; FEATURES; TAXANES; MODEL; AGE","Background Little is known about the treatment of breast cancer during pregnancy. We aimed to determine whether treatment for breast cancer during pregnancy is safe for both mother and child. Methods We recruited patients from seven European countries with a primary diagnosis of breast cancer during pregnancy; data were collected retrospectively if the patient was diagnosed before April, 2003 (when the registry began), or prospectively thereafter, irrespective of the outcome of pregnancy and the type and timing of treatment. The primary endpoint was fetal health for up to 4 weeks after delivery. The registry is ongoing. The study is registered with ClinicalTrials.gov, number NCT00196833. Findings From April, 2003, to December, 2011, 447 patients were registered, 413 of whom had early breast cancer. Median age was 33 years (range 22-51). At the time of diagnosis, median gestational age was 24 weeks (range 5-40). 197 (48%) of 413 women received chemotherapy during pregnancy with a median of four cycles (range one to eight). 178 received an anthracycline, 15 received cyclophosphamide, methotrexate, and fluorouracil, and 14 received a taxane. Birthweight was affected by chemotherapy exposure after adjustment for gestational age (p=0.018), but not by number of chemotherapy cycles (p=0.71). No statistical difference between the two groups was observed for premature deliveries before the 37th week of gestation. 40 (10%) of 386 infants had side-effects, malformations, or new-born complications; these events were more common in infants born before the 37th week of gestation than they were in infants born in the 37th week or later (31 [16%] of 191 infants vs nine [5%] of 195 infants; p=0.0002). In infants for whom maternal treatment was known, adverse events were more common in those who received chemotherapy in utero compared with those who were not exposed (31 [15%] of 203 vs seven [4%] of 170 infants; p=0.00045). Two infants died; both were exposed to chemotherapy and delivered prematurely, but both deaths were thought not to be related to treatment. Median disease-free survival for women with early breast cancer was 70.6 months (95% CI 62.1-105.5) in women starting chemotherapy during pregnancy and 94.4 months (lower 95% CI 64.4; upper 95% CI not yet reached) in women starting chemotherapy after delivery (unadjusted hazard ratio 1.13 [95% CI 0.76-1.69]; p=0.539). Interpretation Although our data show that infants exposed to chemotherapy in utero had a lower birthweight at gestational age than did those who were unexposed, and had more complications, these differences were not clinically significant and, since none of the infants was exposed to chemotherapy in the first trimester, were most likely related to premature delivery. Delay of cancer treatment did not significantly affect disease-free survival for mothers with early breast cancer. Because preterm birth was strongly associated with adverse events, a full-term delivery seems to be of paramount importance.","[Loibl, Sibylle; von Minckwitz, Gunter; Nekljudova, Valentina] GBG Forsch GmbH, German Breast Grp, D-63263 Neu Isenburg, Germany; [Han, Sileny N.; Amant, Frederic] Katholieke Univ Leuven, Multidisciplinary Breast Canc Ctr, Leuven Canc Inst, Louvain, Belgium; [Gziri, Mina Mhallem; Heyns, Liesbeth] Katholieke Univ Leuven, Dept Oncol, Louvain, Belgium; [Bontenbal, Marijke] Erasmus MC Daniel den Hoed Canc Ctr, BOOG Dept Med Oncol, Rotterdam, Netherlands; [Ring, Alistair] Royal Sussex Cty Hosp, Sussex Canc Ctr, Brighton & Sussex Med Sch, Brighton BN2 5BE, E Sussex, England; [Giermek, Jerzy] Inst Warsaw Breast Canc & Reconstruct Surg Clin, Ctr Oncol, Warsaw, Poland; [Fehm, Tanja] Univ Women Hosp, Tubingen, Germany; [Van Calster, Ben] Univ Hosp Gasthuisberg, Dept Dev & Regenerat, Louvain, Belgium; [Van Calster, Ben] Univ Hosp Gasthuisberg, Leuven Canc Inst, Louvain, Belgium; [Linn, Sabine C.] Netherlands Canc Inst, BOOG Dept Med Oncol, Amsterdam, Netherlands; [Linn, Sabine C.] Antoni Van Leeuwenhoek Hosp, Amsterdam, Netherlands; [Schlehe, Bettina] Univ Women Hosp Heidelberg, Heidelberg, Germany; [Westenend, Pieter J.] BOOG Lab Pathol, Dordrecht, Netherlands; [Mueller, Volkmar] Univ Med Ctr Hamburg Eppendorf, Dept Gynaecol, Hamburg, Germany; [Rack, Brigitte] Univ Munich, Frauenklin Innenstadt, Munich, Germany; [Harbeck, Nadia] Univ Cologne, Breast Ctr, Dept Obstet & Gynaecol, Cologne, Germany; [Lenhard, Miriam] Hosp LMU Munich, Dept Obstet & Gynaecol, Grosshadern, Germany; [Halaska, Michael J.] Charles Univ Prague, Dept Obstet & Gynaecol, CR-11636 Prague 1, Czech Republic; [Kaufmann, Manfred] Goethe Univ Frankfurt, Dept Obstet & Gynaecol, Frankfurt, Germany","Loibl, S (reprint author), GBG Forsch GmbH, German Breast Grp, Martin Behaim Str 12, D-63263 Neu Isenburg, Germany.","sibylle.loibl@germanbreastgroup.de",null,null,"BANSS Foundation, Biedenkopf, Germany; Ministry of Health, Belgium; University Hospital Frankfurt; German Breast Group; Research Foundation-Flanders [G 0358.06]; Clinical Research Fund-UZ Gasthuisberg; Belgian Ministry of Health, Belgium","BANSS Foundation, Biedenkopf, Germany and the Belgian Cancer Plan, Ministry of Health, Belgium.Results from this study were presented in part at the 33rd San Antonio Breast Cancer Symposium (San Antonio, TX, USA) on Dec 8-12, 2010). We thank all contributors to these registries, especially Ingrid Mandjes, Petra Fehr, Christiane Prator, and Werner Rettwitz. We are grateful for the long running grant from the independent BANSS Foundation, Biedenkopf, Germany, and the support of the University Hospital Frankfurt and the German Breast Group. This research is supported by Research Foundation-Flanders (Project G 0358.06), Clinical Research Fund-UZ Gasthuisberg, and the Belgian Cancer Plan, Belgian Ministry of Health, Belgium.",null,32,16,16,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1470-2045",null,null,"LANCET ONCOL","Lancet Oncol.","SEP",2012,13,9,null,null,null,null,887,896,null,"10.1016/S1470-2045(12)70261-9",null,10,"Oncology","Oncology","000XZ","WOS:000308425600016"]
[null,null,null,null,"J","Bacq, Y; Sentilhes, L; Reyes, HB; Glantz, A; Kondrackiene, J; Binder, T; Nicastri, PL; Locatelli, A; Floreani, A; Hernandez, I; Di Martino, V",null,null,null,"Bacq, Yannick; Sentilhes, Loic; Reyes, Humberto B.; Glantz, Anna; Kondrackiene, Jurate; Binder, Tomas; Nicastri, Pier Luigi; Locatelli, Anna; Floreani, Annarosa; Hernandez, Ismael; Di Martino, Vincent",null,null,"Efficacy of Ursodeoxycholic Acid in Treating Intrahepatic Cholestasis of Pregnancy: A Meta-analysis","GASTROENTEROLOGY",null,null,"English","Article",null,null,null,null,null,"Liver Disease; Preterm Birth; Drug; Newborn","RANDOMIZED CONTROLLED-TRIAL; ADENOSYL-L-METHIONINE; OBSTETRIC CHOLESTASIS; S-ADENOSYLMETHIONINE; PREVALENCE; MANAGEMENT; MECHANISMS; PLACEBO","BACKGROUND & AIMS: We performed a meta-analysis to evaluate the effects of ursodeoxycholic acid (UDCA) on pruritus, liver test results, and outcomes of babies born to women with intrahepatic cholestasis of pregnancy (ICP). METHODS: We performed a systematic review of 9 published, randomized controlled trials (3 double blinded) that compared the effects of UDCA to other drugs, placebo, or no specific treatment (controls) in patients with ICP. We analyzed data from 454 patients: 207 received only UDCA, 70 received only placebo, 42 received cholestyramine, 36 received dexamethasone for 1 week and then placebo for 2 weeks, 65 received S-adenosyl-methionine, and 34 received no specific treatment. To achieve consistency among end points, a standard questionnaire was sent to all corresponding authors. For each end point, we performed pooled analysis that compared the effects of UDCA with those of all controls and UDCA with those of placebos. RESULTS: In pooled analyses that compared UDCA with all controls, UDCA was associated with total resolution of pruritus (odds ratio [OR], 0.23; 95% confidence interval [CI], 0.07-0.74; P < .01), reduced pruritis (OR, 0.27; 95% CI, 0.13-0.55; P < .0001), normalization of serum levels of alanine aminotransferase (ALT) (OR, 0.23; 95% CI, 0.10-0.50; P < .001), decreased serum level of ALT (OR, 0.24; 95% CI, 0.11-0.52; P < .0001), reduced serum levels of bile acids (OR, 0.37; 95% CI, 0.19-0.75; P < .001), fewer premature births (OR, 0.44; 95% CI, 0.24-0.79; P < .01), reduced fetal distress (OR, 0.46; 95% CI, 0.25-0.86; P < .01), less frequent respiratory distress syndrome (OR, 0.30; 95% CI, 0.12-0.74; P < .01), and fewer neonates in the intensive care unit (OR, 0.49; 95% CI, 0.25-0.98; P = .046). In pooled analyses that compared the effects of UDCA with placebo, UDCA reduced pruritus (OR, 0.21; 95% CI, 0.07-0.62; P < .01), normalized (OR, 0.18; 95% CI, 0.06-0.52; P < .001) or decreased serum levels of ALT (OR, 0.12; 95% CI, 0.05-0.31; P < .0001), and reduced serum levels of bile acids (OR, 0.30; 95% CI, 0.12-0.73; P < .01). CONCLUSIONS: Based on a meta-analysis, UDCA is effective in reducing pruritus and improving liver test results in patients with ICP; UDCA therapy might also benefit fetal outcomes.","[Bacq, Yannick] CHRU Tours, Serv Hepatogastroenterol, F-37044 Tours, France; [Sentilhes, Loic] Angers Univ Hosp, Dept Obstet & Gynecol, Angers, France; [Reyes, Humberto B.; Hernandez, Ismael] Univ Chile, Dept Expt Med, Santiago, Chile; [Glantz, Anna] Sahlgrenska Univ, Dept Obstet & Gynecol, Gothenburg, Sweden; [Kondrackiene, Jurate] Lithuanian Univ Hlth Sci, Dept Gastroenterol, Kaunas, Lithuania; [Binder, Tomas] Charles Univ Prague, Sch Med, Dept Obstet & Gynecol, Prague, Czech Republic; [Nicastri, Pier Luigi] Univ Bari, Dept Obstet & Gynecol, Bari, Italy; [Locatelli, Anna] ISBM San Gerardo, Dept Obstet & Gynecol, Monza, Italy; [Floreani, Annarosa] Univ Padua, Dept Surg & Gastroenterol Sci, Padua, Italy; [Di Martino, Vincent] Univ Franche Comte, UPRES EA 4266, F-25030 Besancon, France; [Di Martino, Vincent] CHRU Besancon, Serv Hepatol, Besancon, France","Bacq, Y (reprint author), CHRU Tours, Serv Hepatogastroenterol, F-37044 Tours, France.","bacq@med.univ-tours.fr",null,null,null,null,null,38,14,15,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0016-5085",null,null,"GASTROENTEROLOGY","Gastroenterology","DEC",2012,143,6,null,null,null,null,1492,1501,null,"10.1053/j.gastro.2012.08.004",null,10,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","042XJ","WOS:000311505100027"]
[null,null,null,null,"J","Salameh, A; Dhein, S; Blanke, K; Rastan, A; Hiyasat, B; Dietze, A; Sobiraij, A; Dahnert, I; Janousek, J",null,null,null,"Salameh, Aida; Dhein, Stefan; Blanke, Katja; Rastan, Ardawan; Hiyasat, Bahi; Dietze, Anna; Sobiraij, Axel; Daehnert, Ingo; Janousek, Jan",null,null,"Right or Left Ventricular Pacing in Young Minipigs With Chronic Atrioventricular Block Long-Term In Vivo Cardiac Performance, Morphology, Electrophysiology, and Cellular Biology","CIRCULATION",null,null,"English","Article",null,null,null,null,null,"cardiac pacing, artificial; myocardial contraction; pediatrics; ventricular remodeling","HEART-FAILURE; RESYNCHRONIZATION THERAPY; GENE-EXPRESSION; DUAL-CHAMBER; SINGLE-SITE; CHILDREN; MODEL; CARDIOMYOPATHY; DYSFUNCTION; MECHANISMS","Background-Left ventricular (LV) dyssynchrony may occur as a result of right ventricular (RV) pacing and is a known risk factor for the development of heart failure. In children with complete atrioventricular block, pacing-induced dyssynchrony lasting for decades might be especially deleterious for LV function. To determine the hemodynamic and ultrastructural remodeling after either RV free wall or LV apical pacing, we used a chronic minipig model. Methods and Results-Fourteen piglets 8 weeks of age underwent atrioventricular node ablation and were paced from either the RV free wall or the LV apex at 120 bpm for 1 year (7 age-matched minipigs served as controls with spontaneous heart rates of 104 +/- 5 bpm). Echocardiographic examinations, pressure-volume loops, patch-clamp investigations, and examinations of connexin43, calcium-handling proteins, and histomorphology were carried out. RV free wall-paced minipigs exhibited significantly more LV dyssynchrony than LV apex-paced animals, which was accompanied by worsening of LV function (maximum LV mechanical delay/LV ejection fraction: RV free wall pacing, 154 +/- 36 ms/28 +/- 3%, LV apical pacing, 52 +/- 19 ms/45 +/- 2%, control 47 +/- 14 ms/62 +/- 1%; P = 0.0001). At the cellular level, both pacemaker groups exhibited a significant reduction in L-type calcium and peak sodium current, shortening of action potential duration and amplitude, increased cell capacity, and alterations in the calcium-handling proteins that were similar for RV free wall-and LV apex-paced animals. Conclusions-The observed molecular remodeling seemed to be more dependent on heart rate than on dyssynchrony. LV apical pacing is associated with less dyssynchrony, a more physiological LV contraction pattern, and preserved LV function as opposed to RV free wall pacing. (Circulation. 2012; 125: 2578-2587.)","[Salameh, Aida; Blanke, Katja; Daehnert, Ingo] Univ Leipzig, Dept Paediat Cardiol, Ctr Heart, D-04289 Leipzig, Germany; [Dhein, Stefan; Rastan, Ardawan; Hiyasat, Bahi; Dietze, Anna] Univ Leipzig, Dept Cardiac Surg, Ctr Heart, D-04289 Leipzig, Germany; [Sobiraij, Axel] Univ Leipzig, Fac Vet, D-04289 Leipzig, Germany; [Janousek, Jan] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Janousek, Jan] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic","Salameh, A (reprint author), Univ Leipzig, Dept Paediat Cardiol, Ctr Heart, Struempellstr 39, D-04289 Leipzig, Germany.","aida.salameh@med.uni-leipzig.de",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NT 12321-3]","Dr Janousek was supported by research grant NT 12321-3 from the Internal Grant Agency of the Ministry of Health of the Czech Republic.",null,43,4,4,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322",null,null,"CIRCULATION","Circulation","MAY 29",2012,125,21,null,null,null,null,2578,"U290",null,"10.1161/CIRCULATIONAHA.111.079087",null,29,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","Cardiovascular System & Cardiology","981MQ","WOS:000306972800014"]
[null,null,null,null,"J","Mejstrikova, E; Janda, A; Hrusak, O; Buckova, H; Vlckova, M; Hancarova, M; Freiberger, T; Ravcukova, B; Vesely, K; Fajkusova, L; Kopeckova, L; Sumerauer, D; Kabickova, E; Sediva, A; Stary, J; Sedlacek, Z",null,null,null,"Mejstrikova, Ester; Janda, Ales; Hrusak, Ondrej; Buckova, Hana; Vlckova, Marketa; Hancarova, Miroslava; Freiberger, Tomas; Ravcukova, Barbora; Vesely, Karel; Fajkusova, Lenka; Kopeckova, Lenka; Sumerauer, David; Kabickova, Edita; Sediva, Anna; Stary, Jan; Sedlacek, Zdenek",null,null,"Skin Lesions in a Boy With X-linked Lymphoproliferative Disorder: Comparison of 5 SH2D1A Deletion Cases","PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"SH2D1A; ODZ1; SAP; teneurin; X-linked lymphoproliferative syndrome; aplastic anemia; lymphoma; dermatitis; psoriasis; dermatosclerosis; vesiculobullous skin disease","BARR-VIRUS INFECTION; DISEASE XLP; DEFICIENCY; GENE; LYMPHOMA; BROTHERS","SH2D1A gene defects are the cause of X-linked lymphoproliferative disorder (XLP-1), a rare condition characterized by severe immune dysregulation. We present a patient lacking the typical symptoms of XLP-1, but experiencing a severe unusual skin condition encompassing features of dermatosclerosis and vesiculobullous skin disease. A maternal cousin of the patient was diagnosed with XLP-1 and found to carry a deletion of the SH2D1A gene. SH2D1A deletion was also identified in our patient, which offered a possible explanation for his skin symptoms. Subsequent analysis showed that the deletion in both cousins was identical and involved the whole SH2D1A gene and a part of the adjacent ODZ1 gene. High phenotypic variability of XLP-1 observed in this family prompted us to analyze the genotype-phenotype correlation of 2 different-sized deletions involving SH2D1A and ODZ1 in 5 patients from 2 families, and we report the clinical and laboratory data on these individuals. Our findings illustrate the wide clinical variability of XLP-1, both inter-and intrafamilial, which may complicate the diagnosis of this condition. The comparison of phenotypes of our patients argues against a strong involvement of the ODZ1 gene in the skin disorder and other symptoms observed in our index patient. His hitherto not described severe skin condition extends the phenotypic range of XLP-1. Pediatrics 2012;129:e523-e528","[Janda, Ales] Univ Med Ctr Freiburg, CCI, D-79095 Freiburg, Germany; [Mejstrikova, Ester; Janda, Ales; Hrusak, Ondrej; Sumerauer, David; Kabickova, Edita; Stary, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Vlckova, Marketa; Hancarova, Miroslava; Sedlacek, Zdenek] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Mejstrikova, Ester; Hrusak, Ondrej] Charles Univ Prague, Fac Med 2, Dept Childhood Leukemia Invest Prague CLIP, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic; [Janda, Ales] Univ Freiburg, D-79095 Freiburg, Germany; [Buckova, Hana] Masaryk Univ, Fac Med, Univ Hosp Brno, Dermatol Div,Dept Pediat, Brno, Czech Republic; [Freiberger, Tomas; Ravcukova, Barbora] Masaryk Univ, Ctr Cardiovasc Surg & Transplantat, Mol Genet Lab, Brno, Czech Republic; [Freiberger, Tomas; Ravcukova, Barbora] Masaryk Univ, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Vesely, Karel] Masaryk Univ, St Annes Hosp, Inst Pathol Anat 1, Brno, Czech Republic; [Vesely, Karel] Masaryk Univ, Fac Med, Brno, Czech Republic; [Fajkusova, Lenka; Kopeckova, Lenka] Univ Hosp Brno, Ctr Mol Biol & Gene Therapy, Brno, Czech Republic; [Sediva, Anna] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague, Czech Republic","Janda, A (reprint author), Univ Med Ctr Freiburg, CCI, Breisacher Str 117, D-79095 Freiburg, Germany.","ales.janda@uniklinik-freiburg.de","Freiberger, Tomas/D-8421-2011; Fajkusova, Lenka/E-1636-2012","Freiberger, Tomas/0000-0001-6532-7053; ","European Society for Immunodeficiencies; Baxter;  [IGA NS/9997-4];  [NS/10480-3];  [NS/10398-3];  [MSM0021620813];  [MZOFNM2005];  [BMBF 01 EO 0803]","Dr Janda received an unrestricted fellowship grant from the European Society for Immunodeficiencies provided by Baxter; the other authors have indicated they have no financial relationships relevant to this article to disclose.This work was supported by grants IGA NS/9997-4, NS/10480-3, NS/10398-3, MSM0021620813, MZOFNM2005, and BMBF 01 EO 0803.",null,20,0,0,"AMER ACAD PEDIATRICS","ELK GROVE VILLAGE","141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA","0031-4005",null,null,"PEDIATRICS","Pediatrics","FEB",2012,129,2,null,null,null,null,"E523","E528",null,"10.1542/peds.2011-0870",null,6,"Pediatrics","Pediatrics","893YZ","WOS:000300395100035"]
[null,null,null,null,"J","Kizek, R; Adam, V; Hrabeta, J; Eckschlager, T; Smutny, S; Burda, JV; Frei, E; Stiborova, M",null,null,null,"Kizek, Rene; Adam, Vojtech; Hrabeta, Jan; Eckschlager, Tomas; Smutny, Svatopluk; Burda, Jaroslav V.; Frei, Eva; Stiborova, Marie",null,null,"Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances","PHARMACOLOGY & THERAPEUTICS",null,null,"English","Review",null,null,null,null,null,"Anthracyclines; Ellipticine; Adduct formation; Nanocarriers","METASTATIC BREAST-CANCER; CELL-CYCLE ARREST; PEROXIDASE-MEDIATED OXIDATION; ADDUCT FORMATION; PHASE-II; CYTOCHROMES P450; IN-VIVO; ELECTROCHEMICAL BIOSENSOR; DOXORUBICIN INTERACTIONS; INDUCED CARDIOMYOPATHY","Over the past forty years, anthracyclines and ellipticines have attracted attention as promising cytostatics. In this review, we focus on their mechanisms of cytoxicity, DNA-damaging effects and adverse side-effects. We also summarize ways to enhance the therapeutic effects of these drugs together with a decrease in their adverse effects. Current drug design strategies are focused on drug bioavailability and their tissue targeting, whereas drug delivery to specific intracellular compartments is rarely addressed. Therefore, therapies utilizing the antineoplastic activities of anthracyclines and ellipticines combined with novel strategies such as nanotechnologies for safer drug delivery, as well as strategies based on gene therapy, could significantly contribute to medical practice. (C) 2011 Elsevier Inc. All rights reserved.","[Kizek, Rene; Adam, Vojtech] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas] Charles Univ Prague, Sch Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas; Smutny, Svatopluk] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Smutny, Svatopluk] Charles Univ Prague, Sch Med 2, Dept Surg 1, CZ-15006 Prague 5, Czech Republic; [Burda, Jaroslav V.] Charles Univ Prague, Fac Math & Phys, Dept Chem Phys & Opt, CZ-12116 Prague 2, Czech Republic; [Frei, Eva] German Canc Res Ctr, Natl Ctr Tumor Dis, Div Prevent Oncol, D-69120 Heidelberg, Germany; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Burda, Jaroslav/C-9199-2009; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012",null," [RECAMT GA AVIAA401990701];  [GA CRP205/10/0228];  [GA CR P301/10/0356]","Financial support from grants RECAMT GA AVIAA401990701, GA CRP205/10/0228, and GA CR P301/10/0356 is gratefully acknowledged.",null,173,30,30,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0163-7258",null,null,"PHARMACOL THERAPEUT","Pharmacol. Ther.","JAN",2012,133,1,null,null,null,null,26,39,null,"10.1016/j.pharmthera.2011.07.006",null,14,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","888BU","WOS:000299979600003"]
[null,null,null,null,"J","van Dongen, JJM; Lhermitte, L; Bottcher, S; Almeida, J; van der Velden, VHJ; Flores-Montero, J; Rawstron, A; Asnafi, V; Lecrevisse, Q; Lucio, P; Mejstrikova, E; Szczepanski, T; Kalina, T; de Tute, R; Bruggemann, M; Sedek, L; Cullen, M; Langerak, AW; Mendonca, A; Macintyre, E; Martin-Ayuso, M; Hrusak, O; Vidriales, MB; Orfao, A",null,null,null,"van Dongen, J. J. M.; Lhermitte, L.; Boettcher, S.; Almeida, J.; van der Velden, V. H. J.; Flores-Montero, J.; Rawstron, A.; Asnafi, V.; Lecrevisse, Q.; Lucio, P.; Mejstrikova, E.; Szczepanski, T.; Kalina, T.; de Tute, R.; Brueggemann, M.; Sedek, L.; Cullen, M.; Langerak, A. W.; Mendonca, A.; Macintyre, E.; Martin-Ayuso, M.; Hrusak, O.; Vidriales, M. B.; Orfao, A.",null,"EuroFlow Consortium EU-FP6 LSHB-CT","EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"EuroFlow; antibody panel; lymphoma; flow cytometry; 8-color immunostaining; standardization; hematological malignancies","ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; ACUTE MYELOID-LEUKEMIA; CHRONIC LYMPHOPROLIFERATIVE DISORDERS; NON-HODGKINS-LYMPHOMA; PERIPHERAL T-CELL; INTERNATIONAL CONSENSUS RECOMMENDATIONS; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; NERVOUS-SYSTEM INVOLVEMENT","Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on expert opinions, but they have not been validated. Here we present the validated EuroFlow 8-color antibody panels for immunophenotyping of hematological malignancies. The single-tube screening panels and multi-tube classification panels fit into the EuroFlow diagnostic algorithm with entries defined by clinical and laboratory parameters. The panels were constructed in 2-7 sequential design-evaluation-redesign rounds, using novel Infinicyt software tools for multivariate data analysis. Two groups of markers are combined in each 8-color tube: (i) backbone markers to identify distinct cell populations in a sample, and (ii) markers for characterization of specific cell populations. In multi-tube panels, the backbone markers were optimally placed at the same fluorochrome position in every tube, to provide identical multidimensional localization of the target cell population(s). The characterization markers were positioned according to the diagnostic utility of the combined markers. Each proposed antibody combination was tested against reference databases of normal and malignant cells from healthy subjects and WHO-based disease entities, respectively. The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.","[van Dongen, J. J. M.; van der Velden, V. H. J.; Langerak, A. W.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, NL-3015 GE Rotterdam, Netherlands; [Lhermitte, L.; Asnafi, V.; Macintyre, E.] Univ Paris 05, Hop Necker Enfants Malades, AP HP, Dept Hematol, Paris, France; [Lhermitte, L.; Asnafi, V.; Macintyre, E.] Univ Paris 05, UMR CNRS 8147, Paris, France; [Boettcher, S.; Brueggemann, M.] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany; [Almeida, J.; Flores-Montero, J.; Lecrevisse, Q.; Orfao, A.] Univ Salamanca USAL, Dept Med, Canc Res Ctr IBMCC CSIC, Salamanca, Spain; [Almeida, J.; Flores-Montero, J.; Lecrevisse, Q.; Orfao, A.] Inst Biomed Res Salamanca IBSAL, Salamanca, Spain; [Rawstron, A.; de Tute, R.; Cullen, M.] Univ Leeds UNIVLEEDS, HMDS, Leeds, W Yorkshire, England; [Lucio, P.; Mendonca, A.] Portuguese Inst Oncol IPOLFG, Dept Hematol, Lisbon, Portugal; [Mejstrikova, E.; Kalina, T.; Hrusak, O.] Charles Univ DPH O, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Szczepanski, T.; Sedek, L.] Med Univ Silesia SUM, Dept Pediat Hematol & Oncol, Zabrze, Poland; [Martin-Ayuso, M.] Cytognos SL, Salamanca, Spain; [Vidriales, M. B.] Univ Hosp Salamanca HUS, Dept Hematol, Salamanca, Spain; [Vidriales, M. B.] IBSAL, Salamanca, Spain; [Almeida, J.; Flores-Montero, J.; Lecrevisse, Q.; Orfao, A.] Univ Salamanca USAL, Cytometry Serv, Salamanca, Spain","van Dongen, JJM (reprint author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.","j.j.m.vandongen@erasmusmc.nl","Bruggemann, Monika/M-8150-2013","Bruggemann, Monika/0000-0001-5514-5010","European Commission [STREP EU-FP6, LSHB-CT-2006-018708]; Spanish Network of Cancer Research Centers [ISCIII RTICC-RD06/0020/0035-FEDER]; Fondo de Investigacion Sanitaria, Ministerio de Ciencia e Innovacion (Madrid, Spain) [FIS 08/90881, FIS PS09/02430]; Consejeria de Educacion, Junta de Castilla y Leon (Valladolid, Spain) [GR37 EDU/894/2009, SA016-A-09]; Direccion General de Cooperacion Internacional y Relaciones Institucionales, Secretaria de Estado de Investigacion, Ministerio de Ciencia e Innovacion (Madrid, Spain) [PIB2010BZ-00565]; Ministry of Health Czech Republic [NT/12425-4, NS/10480-3]; Charles University [23010]; UNCE [204012]; International Society for Advancement of Cytometry (ISAC); Leukemia and Lymphoma Research (LLR)","We are grateful to Dr Jean-Luc Sanne of the European Commission for his support and monitoring of the EuroFlow project. We thank Marieke Comans-Bitter for graphic design of the figures and for her continuous support in the management of the EuroFlow Consortium, and Bibi van Bodegom, Caroline Linker and Monique van Rossum for their secretarial support of the consortium activities. We are grateful to Ria Bloemberg and Gellof van Steenis for their support in the financial management of the project funds. We are also thankful to Maria Gomez da Silva, Evan Jensen, Joana Caetano, Teresa Faria, Ana Santos and Isabel Santos. The research activities of the EuroFlow Consortium were supported by the European Commission (grant STREP EU-FP6, LSHB-CT-2006-018708, entitled 'Flow cytometry for fast and sensitive diagnosis and follow-up of hematological malignancies') and the following national grants: Spanish Network of Cancer Research Centers (ISCIII RTICC-RD06/0020/0035-FEDER), FIS 08/90881 and FIS PS09/02430 from the 'Fondo de Investigacion Sanitaria', Ministerio de Ciencia e Innovacion (Madrid, Spain); GR37 EDU/894/2009 and SA016-A-09 from the Consejeria de Educacion, Junta de Castilla y Leon (Valladolid, Spain); PIB2010BZ-00565 from the Direccion General de Cooperacion Internacional y Relaciones Institucionales, Secretaria de Estado de Investigacion, Ministerio de Ciencia e Innovacion (Madrid, Spain); Ministry of Health Czech Republic (NT/12425-4 and NS/10480-3); and Charles University grant No. 23010 and UNCE No. 204012; Tomas Kalina is supported as an 'ISAC Scholar' by the International Society for Advancement of Cytometry (ISAC); Andy Rawstron was supported by Leukemia and Lymphoma Research (LLR).",null,297,40,40,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","SEP",2012,26,9,null,null,null,null,1908,1975,null,"10.1038/leu.2012.120",null,68,"Oncology; Hematology","Oncology; Hematology","999VK","WOS:000308342900002"]
[null,null,null,null,"J","Rink, M; Ehdaie, B; Cha, EK; Green, DA; Karakiewicz, PI; Babjuk, M; Margulis, V; Raman, JD; Svatek, RS; Fajkovic, H; Lee, RK; Novara, G; Hansen, J; Daneshmand, S; Lotan, Y; Kassouf, W; Fritsche, HM; Pycha, A; Fisch, M; Scherr, DS; Shariat, SF",null,null,null,"Rink, Michael; Ehdaie, Behfar; Cha, Eugene K.; Green, David A.; Karakiewicz, Pierre I.; Babjuk, Marko; Margulis, Vitaly; Raman, Jay D.; Svatek, Robert S.; Fajkovic, Harun; Lee, Richard K.; Novara, Giacomo; Hansen, Jens; Daneshmand, Siamak; Lotan, Yair; Kassouf, Wassim; Fritsche, Hans-Martin; Pycha, Armin; Fisch, Margit; Scherr, Douglas S.; Shariat, Shahrokh F.",null,"BCRC; UTUCC","Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery","EUROPEAN UROLOGY",null,null,"English","Article",null,null,null,null,null,"Bladder cancer; Upper tract urothelial carcinoma; Transitional cell carcinoma; Radical cystectomy; Radical nephroureterectomy; Prognosis; Survival","TRANSITIONAL-CELL CARCINOMA; UPPER URINARY-TRACT; CANCER-SPECIFIC SURVIVAL; BLADDER-CANCER; LYMPH-NODES; NEPHROURETERECTOMY; CYSTECTOMY; DIAGNOSIS; SERIES; DELAY","Background: Dissimilarities in management and outcomes exist between upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB). Objective: The aim of this study was to analyze the stage-specific impact of upper or lower urinary tract tumor location on oncologic outcomes. Design, setting, and participants: Data were collected from 4335 patients with UCB treated with radical cystectomy (RC) and bilateral pelvic lymphadenectomy (PLND), 877 patients with ureteral UTUC, and 1615 with pelvicalyceal UTUC treated with radical nephroureterectomy (RNU). No patient received preoperative chemotherapy or radiation therapy. Interventions: Patients were treated with RC and bilateral PLND or RNU. Measurements: Outcomes were assessed according to primary tumor location. Results and limitations: Compared to UTUC patients, UCB patients had more advanced tumor stage and higher grade, and they were more likely to harbor lymphovascular invasion (LVI) and lymph node metastasis (p < 0.001). In non-muscle-invasive tumor stages, UCB patients were more likely to experience disease recurrence and mortality compared to renal pelvicalyceal tumor patients (p < 0.002) but not ureteral tumors (p > 0.05). In pT2 and pT3 tumors, there was no difference in outcomes between the three tumor locations. In pT4 tumors, patients with ureteral and pelvicalyceal tumors were more likely to experience disease recurrence and mortality compared to UCB patients (p < 0.004). These stage-specific findings were unchanged after adjustment for the effects of age, gender, tumor grade, LVI, lymph node status, and adjuvant chemotherapy. This study is limited by its retrospective and multicenter nature. Conclusions: Stage-specific differences in outcomes exist between UCB and UTUC. The differentially worse outcomes by stage between UCB and UTUC patients underline the differences between both cancer entities and the need for individualized stage-specific management for each patient. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.","[Rink, Michael; Ehdaie, Behfar; Cha, Eugene K.; Green, David A.; Fajkovic, Harun; Lee, Richard K.; Scherr, Douglas S.; Shariat, Shahrokh F.] Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, New York, NY 10021 USA; [Rink, Michael; Hansen, Jens; Fisch, Margit] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Karakiewicz, Pierre I.; Hansen, Jens] Univ Montreal, Montreal, PQ, Canada; [Babjuk, Marko] Charles Univ Prague, Fac Med 2, Hosp Motol, Prague, Czech Republic; [Margulis, Vitaly; Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Raman, Jay D.] Penn State Milton S Hershey Med Ctr, Hershey, PA USA; [Svatek, Robert S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Fajkovic, Harun] Gen Hosp St Poelten, St Polten, Austria; [Novara, Giacomo] Univ Padua, Padua, Italy; [Daneshmand, Siamak] Univ So Calif, Los Angeles, CA USA; [Kassouf, Wassim] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Fritsche, Hans-Martin] Univ Regensburg, Caritas St Josef Med Ctr, Regensburg, Germany; [Pycha, Armin] Gen Hosp Bolzano, Bolzano, Italy","Shariat, SF (reprint author), New York Presbyterian Hosp, Brady Urol Hlth Ctr, Weill Cornell Med Coll, 525 E 68th St,Box 94,Starr 900, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,"New York Community Trust","Dr. Michael Rink and Dr. David A. Green are supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust. The authors want to thank the members of the Bladder Cancer Research Consortium (BCRC) and the Upper Tract Urothelial Carcinoma Collaboration (UTUCC): Patrick J. Bastian, Karim Bensalah, Christian Bolenz, Thomas F. Chromecki, Colin P. Dinney, Mario Fernandez, Vincenzo Ficarra, Yves Fradet, Jonathan I. Izawa, Wareef Kabbani, Eiji Kikuchi, Theresa M. Koppie, Seth P. Lerner, Juan Ignacio Martinez-Salamanca, Kazumasa Matsumoto, Francesco Montorsi, Casey K. Ng, Mototsuga Oya, Jean-Jacques Patard, Mesut Remzi, Marco Roscigno, Arthur I. Sagalowsky, Mark P. Schoenberg, Christian Seitz, Eila Skinner, Philipp Strobel, Derya Tilki, Stefan Tritschler, Thomas J. Walton, Alon Weizer, J. Stuart Wolf, Christopher G. Wood, and Richard Zigeuner.",null,37,8,8,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","OCT",2012,62,4,null,null,null,null,677,684,null,"10.1016/j.eururo.2012.02.018",null,8,"Urology & Nephrology","Urology & Nephrology","002UX","WOS:000308563100026"]
[null,null,null,null,"J","Rink, M; Xylinas, E; Babjuk, M; Hansen, J; Pycha, A; Comploj, E; Lotan, Y; Sun, M; Karakiewicz, PI; Abdennabi, J; Fajkovic, H; Loidl, W; Chun, FK; Fisch, M; Scherr, DS; Shariat, SF",null,null,null,"Rink, Michael; Xylinas, Evanguelos; Babjuk, Marko; Hansen, Jens; Pycha, Armin; Comploj, Evi; Lotan, Yair; Sun, Maxine; Karakiewicz, Pierre I.; Abdennabi, Joual; Fajkovic, Harun; Loidl, Wolfgang; Chun, Felix K.; Fisch, Margit; Scherr, Douglas S.; Shariat, Shahrokh F.",null,null,"Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer","JOURNAL OF UROLOGY",null,null,"English","Article",null,null,null,null,null,"urinary bladder; urothelium; carcinoma; smoking; survival","TRANSITIONAL-CELL CARCINOMA; CIGARETTE-SMOKING; TRANSURETHRAL RESECTION; UROTHELIAL CARCINOMA; UNITED-STATES; RISK; MUSCLE; STAGE; ASSOCIATION; CONSUMPTION","Purpose: We investigated the effects of cigarette smoking status, cumulative exposure and time from cessation on disease recurrence and progression in patients with a history of recurrent nonmuscle invasive bladder cancer. Materials and Methods: A total of 390 patients with recurrent nonmuscle invasive bladder cancer were treated with transurethral resection of the bladder, of whom 159 (41%) received instillation therapy immediately postoperatively and 73 (19%) received adjuvant intravesical immunotherapy or chemotherapy. Smoking history included smoking status, number of cigarettes per day, smoking duration in years and years since smoking cessation. Cumulative smoking exposure was categorized as light short-term-19 or fewer cigarettes per day and 19.9 years or less, moderate-all combinations except light short-term and heavy long-term, and heavy long-term-20 or greater cigarettes per day and 20 years or greater. Results: A total of 91 (23%), 192 (49%) and 107 patients (28%) were never, former and current smokers, respectively. Of ever smokers 56 (19%), 156 (52%) and 87 (29%) were light short-term, moderate and heavy long-term smokers, respectively. There was no difference in the risk of disease recurrence and progression among current, former and never smokers. On univariable analyses in ever smokers the risk of disease recurrence and progression increased with augmented smoking intensity (p <= 0.015), duration (p <0.001) and cumulative exposure (p <0.001). On multivariable analyses cumulative smoking exposure was an independent risk factor for disease recurrence and progression (p <0.003). Smoking cessation greater than 10 years before treatment was independently associated with decreased disease recurrence compared to current smoking (HR 0.4, p <0.001). In addition, current smokers had worse survival than former smokers, who in turn had worse survival than never smokers (p >0.05). Conclusions: There is a dose-response relationship of smoking exposure and smoking cessation with disease recurrence and progression in ever smokers with a history of recurrent nonmuscle invasive bladder cancer. These findings support counseling on smoking cessation benefits.","[Shariat, Shahrokh F.] Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Div Med Oncol,Dept Urol, New York, NY 10065 USA; [Rink, Michael; Hansen, Jens; Chun, Felix K.; Fisch, Margit] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany; [Xylinas, Evanguelos] Paris Descartes Univ, Cochin Hosp, AP HP, Paris, France; [Babjuk, Marko] Charles Univ Prague, Fac Med 2, Hosp Motol, Prague, Czech Republic; [Pycha, Armin; Comploj, Evi] Gen Hosp Bolzano, Bolzano, Italy; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Sun, Maxine; Karakiewicz, Pierre I.] Univ Montreal, Montreal, PQ, Canada; [Abdennabi, Joual] Univ Hosp Ibn Rochd, Casablanca, Morocco; [Fajkovic, Harun] Gen Hosp St Poelten, St Polten, Austria; [Loidl, Wolfgang] St Vincents Hosp, Linz, Austria","Shariat, SF (reprint author), Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Div Med Oncol,Dept Urol, 525 E 68th St,Box 94,Starr 900, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,"New York Community Trust","Supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust (MR).",null,28,6,6,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0022-5347",null,null,"J UROLOGY","J. Urol.","DEC",2012,188,6,null,null,null,null,2120,2127,null,"10.1016/j.juro.2012.08.029",null,8,"Urology & Nephrology","Urology & Nephrology","043WM","WOS:000311581400021"]
[null,null,null,null,"J","Cardwell, CR; Stene, LC; Ludvigsson, J; Rosenbauer, J; Cinek, O; Svensson, J; Perez-Bravo, F; Memon, A; Gimeno, SG; Wadsworth, EJK; Strotmeyer, ES; Goldacre, MJ; Radon, K; Chuang, LM; Parslow, RC; Chetwynd, A; Karavanaki, K; Brigis, G; Pozzilli, P; Urbonaite, B; Schober, E; Devoti, G; Sipetic, S; Joner, G; Ionescu-Tirgoviste, C; de Beaufort, CE; Harrild, K; Benson, V; Savilahti, E; Ponsonby, AL; Salem, M; Rabiei, S; Patterson, CC",null,null,null,"Cardwell, Chris R.; Stene, Lars C.; Ludvigsson, Johnny; Rosenbauer, Joachim; Cinek, Ondrej; Svensson, Jannet; Perez-Bravo, Francisco; Memon, Anjum; Gimeno, Suely G.; Wadsworth, Emma J. K.; Strotmeyer, Elsa S.; Goldacre, Michael J.; Radon, Katja; Chuang, Lee-Ming; Parslow, Roger C.; Chetwynd, Amanda; Karavanaki, Kyriaki; Brigis, Girts; Pozzilli, Paolo; Urbonaite, Brone; Schober, Edith; Devoti, Gabriele; Sipetic, Sandra; Joner, Geir; Ionescu-Tirgoviste, Constantin; de Beaufort, Carine E.; Harrild, Kirsten; Benson, Victoria; Savilahti, Erkki; Ponsonby, Anne-Louise; Salem, Mona; Rabiei, Samira; Patterson, Chris C.",null,null,"Breast-Feeding and Childhood-Onset Type 1 Diabetes A pooled analysis of individual participant data from 43 observational studies","DIABETES CARE",null,null,"English","Article",null,null,null,null,null,null,"MELLITUS; RISK; METAANALYSIS; ANTIBODIES; INFECTION; EUROPE; TRENDS; LIFE","OBJECTIVE-To investigate if there is a reduced risk of type 1 diabetes in children breastfed or exclusively breastfed by performing a pooled analysis with adjustment for recognized confounders. RESEARCH DESIGN AND METHODS-Relevant studies were identified from literature searches using MEDLINE, Web of Science, and EMBASE. Authors of relevant studies were asked to provide individual participant data or conduct prespecified analyses. Meta-analysis techniques were used to combine odds ratios (ORs) and investigate heterogeneity between studies. RESULTS-Data were available from 43 studies including 9,874 patients with type 1 diabetes. Overall, there was a reduction in the risk of diabetes after exclusive breast-feeding for >2 weeks (20 studies; OR = 0.75, 95% CI 0.64-0.88), the association after exclusive breast-feeding for >3 months was weaker (30 studies; OR = 0.87, 95% CI 0.75-1.00), and no association was observed after (nonexclusive) breast-feeding for >2 weeks (28 studies; OR = 0.93, 95% CI 0.81-1.07) or >3 months (29 studies; OR = 0.88, 95% CI 0.78-1.00). These associations were all subject to marked heterogeneity (I-2 = 58, 76, 54, and 68%, respectively). In studies with lower risk of bias, the reduced risk after exclusive breast-feeding for >2 weeks remained (12 studies; OR = 0.86, 95% CI 0.75-0.99), and heterogeneity was reduced (I-2 = 0%). Adjustments for potential confounders altered these estimates very little. CONCLUSIONS-The pooled analysis suggests weak protective associations between exclusive breast-feeding and type 1 diabetes risk. However, these findings are difficult to interpret because of the marked variation in effect and possible biases (particularly recall bias) inherent in the included studies. Diabetes Care 35: 2215-2225, 2012","[Cardwell, Chris R.; Patterson, Chris C.] Queens Univ Belfast, Sch Med & Dent, Belfast, Antrim, North Ireland; [Stene, Lars C.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Stene, Lars C.] Oslo Univ Hosp, Oslo Diabet Res Ctr, Oslo, Norway; [Ludvigsson, Johnny] Linkoping Univ Hosp, Dept Clin Expt Med, Div Pediat, S-58185 Linkoping, Sweden; [Rosenbauer, Joachim] Univ Dusseldorf, Inst Biometr & Epidemiol, German Diabet Ctr, Leibniz Inst Duesseldorf, D-40225 Dusseldorf, Germany; [Cinek, Ondrej] Charles Univ Prague, Dept Paediat, Fac Med 2, Motol, Czech Republic; [Cinek, Ondrej] Univ Hosp Motol, Motol, Czech Republic; [Svensson, Jannet] Herlev Univ Hosp, Pediat Dept, DK-2730 Herlev, Denmark; [Perez-Bravo, Francisco] Univ Chile, Dept Nutr, Fac Med, Lab Nutr Genom, Santiago, Chile; [Memon, Anjum] Brighton & Sussex Med Sch & NHS Brighton & Hove, Div Primary Care & Publ Hlth, Brighton, E Sussex, England; [Gimeno, Suely G.] Univ Fed Sao Paulo, Prevent Med Dept, Sao Paulo, Brazil; [Wadsworth, Emma J. K.] Cardiff Univ, Cardiff Work Environm Res Ctr, Cardiff, S Glam, Wales; [Strotmeyer, Elsa S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Ctr Aging & Populat Hlth, Pittsburgh, PA USA; [Goldacre, Michael J.] Univ Oxford, Dept Publ Hlth, Oxford, England; [Radon, Katja] Hosp Ludwig Maximilian Univ Munich, Inst & Outpatient Clin Occupat & Environm Med, Munich, Germany; [Chuang, Lee-Ming] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Parslow, Roger C.] Univ Leeds, Paediat Epidemiol Grp, Leeds, W Yorkshire, England; [Chetwynd, Amanda] Univ Lancaster, Math & Stat Dept, Lancaster, England; [Karavanaki, Kyriaki] Univ Athens, Univ 2, Dept Pediat, Sch Med, Athens, Greece; [Brigis, Girts] Riga Stradins Univ, Dept Publ Hlth & Epidemiol, Riga, Latvia; [Pozzilli, Paolo] Univ Campus Biomed, Rome, Italy; [Urbonaite, Brone] Lithuanian Univ Hlth Sci, Inst Endocrinol, Kaunas, Lithuania; [Schober, Edith] Med Univ Vienna, Dept Paediat, Vienna, Austria; [Devoti, Gabriele] Univ Salento, Dept Social Sci & Commun, Lecce, Italy; [Sipetic, Sandra] Univ Belgrade, Sch Med, Belgrade, Serbia; [Joner, Geir] Univ Oslo, Fac Med, Inst Hlth & Soc, Oslo, Norway; [Joner, Geir] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Ionescu-Tirgoviste, Constantin] N Paulescu Inst Diabet, Nutr & Metab Dis Clin, Bucharest, Romania; [de Beaufort, Carine E.] Clin Pediat Luxembourg, Luxembourg, Luxembourg; [Harrild, Kirsten] Univ Aberdeen, Med Stat Team, Aberdeen, Scotland; [Benson, Victoria] Univ Oxford, Cancer Epidemiol Unit, Oxford, England; [Savilahti, Erkki] Univ Helsinki, Hosp Children & Adolescents, Helsinki, Finland; [Ponsonby, Anne-Louise] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Salem, Mona] Ain Shams Univ, Dept Paediat, Cairo, Egypt; [Rabiei, Samira] Shahid Beheshti Univ Med Sci & Hlth Serv, Fac Nutr Sci & Food Technol, Tehran, Iran","Cardwell, CR (reprint author), Queens Univ Belfast, Sch Med & Dent, Belfast, Antrim, North Ireland.","c.cardwell@qub.ac.uk","Chetwynd, Amanda/B-4727-2013; Strotmeyer, Elsa/F-3015-2014","Chetwynd, Amanda/0000-0002-7659-3231; ","National Institutes of Health [R01-DK-46498, R01-DK-42316]; Chinese Foundation of Health; Department of Health, Executive Yuan, Republic of China [DOH91-TD1167]; Ministry for Science and Technology of the Republic of Serbia [175042]; German Research Foundation [HE 234/1-1]; Research Council of Norway [148359/330]","This work was supported by National Institutes of Health grants R01-DK-46498 and R01-DK-42316, the Chinese Foundation of Health, a grant (DOH91-TD1167) from the Department of Health, Executive Yuan, Republic of China, the Ministry for Science and Technology of the Republic of Serbia through Contract 175042 (2011-2014), a grant from the German Research Foundation (HE 234/1-1), and the Research Council of Norway (148359/330).",null,21,5,5,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0149-5992",null,null,"DIABETES CARE","Diabetes Care","NOV",2012,35,11,null,null,null,null,2215,2225,null,"10.2337/dc12-0438",null,11,"Endocrinology & Metabolism","Endocrinology & Metabolism","041TM","WOS:000311424100023"]
[null,null,null,null,"J","Soukup, V; Babjuk, M; Bellmunt, J; Dalbagni, G; Giannarini, G; Hakenberg, OW; Herr, H; Lechevallier, E; Ribal, MJ",null,null,null,"Soukup, Viktor; Babjuk, Marko; Bellmunt, Joaquim; Dalbagni, Guido; Giannarini, Gianluca; Hakenberg, Oliver W.; Herr, Harry; Lechevallier, Eric; Ribal, Maria J.",null,null,"Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature","EUROPEAN UROLOGY",null,null,"English","Article",null,null,null,null,null,"Cystoscopy; Follow-up; Muscle-invasive bladder cancer; Non-muscle-invasive bladder cancer; Progression; Radical cystectomy; Recurrence","TRANSITIONAL-CELL-CARCINOMA; BACILLUS-CALMETTE-GUERIN; URINARY-TRACT TUMORS; EORTC RISK TABLES; RADICAL CYSTECTOMY; UROTHELIAL CARCINOMA; MULTIVARIATE-ANALYSIS; URETHRAL RECURRENCE; PROGNOSTIC-FACTORS; STAGE-TA","Context: Follow-up of patients treated for bladder cancer (BCa) is of great importance for both non-muscle-invasive BCa (NMIBC) and muscle-invasive BCa (MIBC) because of the high incidence of recurrence and progression. The schedule and methods of follow-up should reflect the individual clinical situation. Objective: To evaluate the existing evidence for intensity and duration of follow-up recommendations in patients after surgical treatment of BCa. Evidence acquisition: We searched the Medline, Embase, and Cochrane databases for published data on the follow-up of patients with NMIBC and MIBC after radical cystectomy (RC). Evidence synthesis: Follow-up in patients with NMIBC is necessary because of the high probability of tumour recurrence and the risk of progression. Cystoscopy plus cytology are the standard methods for follow-up. Cystoscopy should be done 3 mo after the transurethral resection in every patient, and the frequency after that depends on the individual recurrence/progression risk. Cytology should be used as an adjunctive method to cystoscopy in intermediate-and high-risk patients. None of the currently available urinary markers or imaging methods can substitute for cystoscopy-based follow-up. High-risk NMIBC patients require regular lifelong upper urinary tract monitoring. Follow-up in MIBC is based on the fact that early detection of recurrence after RC allows for timely treatment with the aim of improving outcomes. Patients with extra-vesical and lymph node-positive disease should have the most intensive follow-up because of the highest recurrence risk. Routine upper urinary tract imaging is advisable for all patients and should continue in the long term. Follow-up also allows for early detection of urinary diversion-related complications, the rate of which increases with time. Conclusions: Follow-up in BCa is necessary for diagnosing recurrence and progression, as well as for evaluating complications after radical treatment. Since randomised studies investigating the most appropriate follow-up schedule are lacking, most recommendations are based on only the retrospective experience. Nonetheless, reasonable recommendations can be made until further prospective randomised studies testing different follow-up schedules have been performed. (C) 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.","[Soukup, Viktor] Charles Univ Prague, Gen Teaching Hosp, Dept Urol, Prague 12808 2, Czech Republic; [Soukup, Viktor] Charles Univ Prague, Fac Med 1, Prague 12808 2, Czech Republic; [Babjuk, Marko] Charles Univ Prague, Hosp Motol, Dept Urol, Prague 12808 2, Czech Republic; [Babjuk, Marko] Charles Univ Prague, Fac Med 2, Prague 12808 2, Czech Republic; [Bellmunt, Joaquim] Univ Hosp del Mar, Med Oncol Serv, Barcelona, Spain; [Dalbagni, Guido; Herr, Harry] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA; [Giannarini, Gianluca] Univ Bern, Inselspital, Dept Urol, CH-3010 Bern, Switzerland; [Hakenberg, Oliver W.] Univ Rostock, Dept Urol, Rostock, Germany; [Lechevallier, Eric] Hop Conception, Marseille, France; [Ribal, Maria J.] Univ Barcelona, Hosp Clin, Dept Urol, Barcelona, Spain","Soukup, V (reprint author), Charles Univ Prague, Gen Teaching Hosp, Dept Urol, Ke Karlovu 6, Prague 12808 2, Czech Republic.","viktor.soukup@seznam.cz",null,null,null,null,null,95,5,5,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","AUG",2012,62,2,null,null,null,null,290,302,null,"10.1016/j.eururo.2012.05.008",null,13,"Urology & Nephrology","Urology & Nephrology","966MF","WOS:000305841100030"]
[null,null,null,null,"J","Kalina, T; Flores-Montero, J; van der Velden, VHJ; Martin-Ayuso, M; Bottcher, S; Ritgen, M; Almeida, J; Lhermitte, L; Asnafi, V; Mendonca, A; de Tute, R; Cullen, M; Sedek, L; Vidriales, MB; Perez, JJ; te Marvelde, JG; Mejstrikova, E; Hrusak, O; Szczepanski, T; van Dongen, JJM; Orfao, A",null,null,null,"Kalina, T.; Flores-Montero, J.; van der Velden, V. H. J.; Martin-Ayuso, M.; Boettcher, S.; Ritgen, M.; Almeida, J.; Lhermitte, L.; Asnafi, V.; Mendonca, A.; de Tute, R.; Cullen, M.; Sedek, L.; Vidriales, M. B.; Perez, J. J.; te Marvelde, J. G.; Mejstrikova, E.; Hrusak, O.; Szczepanski, T.; van Dongen, J. J. M.; Orfao, A.",null,"EuroFlow Consortium EU-FP6 LSHB-CT","EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"flow cytometry; standardization; compensation; software; fluorochromes; immunophenotyping","MINIMAL RESIDUAL DISEASE; CHRONIC LYMPHOPROLIFERATIVE DISORDERS; INTERNATIONAL CONSENSUS RECOMMENDATIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOLYMPHOID NEOPLASIA; HEMATOLOGIC NEOPLASIA; MEDICAL INDICATIONS; QUALITY-CONTROL; COMPENSATION; REAGENTS","The EU-supported EuroFlow Consortium aimed at innovation and standardization of immunophenotyping for diagnosis and classification of hematological malignancies by introducing 8-color flow cytometry with fully standardized laboratory procedures and antibody panels in order to achieve maximally comparable results among different laboratories. This required the selection of optimal combinations of compatible fluorochromes and the design and evaluation of adequate standard operating procedures (SOPs) for instrument setup, fluorescence compensation and sample preparation. Additionally, we developed software tools for the evaluation of individual antibody reagents and antibody panels. Each section describes what has been evaluated experimentally versus adopted based on existing data and experience. Multicentric evaluation demonstrated high levels of reproducibility based on strict implementation of the EuroFlow SOPs and antibody panels. Overall, the 6 years of extensive collaborative experiments and the analysis of hundreds of cell samples of patients and healthy controls in the EuroFlow centers have provided for the first time laboratory protocols and software tools for fully standardized 8-color flow cytometric immunophenotyping of normal and malignant leukocytes in bone marrow and blood; this has yielded highly comparable data sets, which can be integrated in a single database.","[van der Velden, V. H. J.; te Marvelde, J. G.; van Dongen, J. J. M.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, NL-3015 GE Rotterdam, Netherlands; [Kalina, T.; Mejstrikova, E.; Hrusak, O.] Charles Univ DPH O, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Flores-Montero, J.; Almeida, J.; Orfao, A.] Univ Salamanca USAL, Dept Med, Canc Res Ctr IBMCC CSIC, Salamanca, Spain; [Flores-Montero, J.; Almeida, J.; Orfao, A.] Univ Salamanca USAL, Cytometry Serv, Salamanca, Spain; [Flores-Montero, J.; Almeida, J.; Orfao, A.] Inst Biomed Res Salamanca IBSAL, Salamanca, Spain; [Martin-Ayuso, M.] Cytognos SL, Salamanca, Spain; [Boettcher, S.; Ritgen, M.] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany; [Lhermitte, L.; Asnafi, V.] Univ Paris 05, Hop Necker, AP HP, Dept Hematol, Paris, France; [Lhermitte, L.; Asnafi, V.] Univ Paris 05, AP HP, UMR CNRS 8147, Paris, France; [Mendonca, A.] Portuguese Inst Oncol IPOLFG, Dept Hematol, Lisbon, Portugal; [de Tute, R.; Cullen, M.] Univ Leeds UNIVLEEDS, HMDS, Leeds, W Yorkshire, England; [Sedek, L.; Szczepanski, T.] Med Univ Silesia SUM, Dept Pediat Hematol & Oncol, Zabrze, Poland; [Vidriales, M. B.; Perez, J. J.] Univ Hosp Salamanca HUS, Dept Hematol, Salamanca, Spain; [Vidriales, M. B.; Perez, J. J.] IBSAL, Salamanca, Spain","van Dongen, JJM (reprint author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.","j.j.m.vandongen@erasmusmc.nl",null,null,"European Commission [STREP EU-FP6, LSHB-CT-2006-018708]; Spanish Network of Cancer Research Centers [ISCIII RTICC-RD06/0020/0035-FEDER]; Fondo de Investigacion Sanitaria, Ministerio de Ciencia e Innovacion (Madrid, Spain) [FIS 08/90881]; Consejeria de Educacion, Junta de Castilla y Leon, Valladolid, Spain [SA016A-09]; Direccion General de Cooperacion Internacional y Relaciones Institucionales, Secretaria de Estado de Investigacion, Ministerio de Ciencia e Innovacion (Madrid, Spain) [PIB2010BZ-00565]; Czech Ministry of Education [MSM0021620813]; Czech Ministry of Health grant [NT/12425-4]; International Society for Advancement of Cytometry","We are grateful to Dr Jean-Luc Sanne of the European Commission for his support and monitoring of the EuroFlow project. We thank Marieke Comans-Bitter for graphic design of the figures and for her continuous support in the management of the EuroFlow Consortium, and Bibi van Bodegom, Caroline Linker, and Monique van Rossum for their secretarial support of the consortium activities. We are grateful to Ria Bloemberg and Gellof van Steenis for support in the financial management of the project funds. The research activities of the EuroFlow Consortium were supported by the European Commission (grant STREP EU-FP6, LSHB-CT-2006-018708, entitled 'Flow cytometry for fast and sensitive diagnosis and follow-up of hematological malignancies') and the following national grants: Spanish Network of Cancer Research Centers (ISCIII RTICC-RD06/0020/0035-FEDER), FIS 08/90881 from the 'Fondo de Investigacion Sanitaria', Ministerio de Ciencia e Innovacion (Madrid, Spain), SA016A-09 from the Consejeria de Educacion, Junta de Castilla y Leon, Valladolid, Spain, and PIB2010BZ-00565 from the Direccion General de Cooperacion Internacional y Relaciones Institucionales, Secretaria de Estado de Investigacion, Ministerio de Ciencia e Innovacion (Madrid, Spain). T Kalina, E Mejstrikova and O Hrusak were supported by the Czech Ministry of Education Grant No. MSM0021620813, Czech Ministry of Health grant NT/12425-4 and TK is supported as an ISAC Scholar by The International Society for Advancement of Cytometry.",null,63,24,24,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","SEP",2012,26,9,null,null,null,null,1986,2010,null,"10.1038/leu.2012.122",null,25,"Oncology; Hematology","Oncology; Hematology","999VK","WOS:000308342900004"]
[null,null,null,null,"J","Patterson, CC; Gyurus, E; Rosenbauer, J; Cinek, O; Neu, A; Schober, E; Parslow, RC; Joner, G; Svensson, J; Castell, C; Bingley, PJ; Schoenle, E; Jarosz-Chobot, P; Urbonaite, B; Rothe, U; Krzisnik, C; Ionescu-Tirgoviste, C; Weets, I; Kocova, M; Stipancic, G; Samardzic, M; de Beaufort, CE; Green, A; Dahlquist, GG; Soltesz, G",null,null,null,"Patterson, C. C.; Gyuerues, E.; Rosenbauer, J.; Cinek, O.; Neu, A.; Schober, E.; Parslow, R. C.; Joner, G.; Svensson, J.; Castell, C.; Bingley, P. J.; Schoenle, E.; Jarosz-Chobot, P.; Urbonaite, B.; Rothe, U.; Krzisnik, C.; Ionescu-Tirgoviste, C.; Weets, I.; Kocova, M.; Stipancic, G.; Samardzic, M.; de Beaufort, C. E.; Green, A.; Dahlquist, G. G.; Soltesz, G.",null,null,"Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase","DIABETOLOGIA",null,null,"English","Article",null,null,null,null,null,"Epidemiology; Incidence; Temporal change; Trends; Type 1 diabetes","COHORT; CHILDREN; SWEDEN","The aim of the study was to describe 20-year incidence trends for childhood type 1 diabetes in 23 EURODIAB centres and compare rates of increase in the first (1989-1998) and second (1999-2008) halves of the period. All registers operate in geographically defined regions and are based on a clinical diagnosis. Completeness of registration is assessed by capture-recapture methodology. Twenty-three centres in 19 countries registered 49,969 new cases of type 1 diabetes in individuals diagnosed before their 15th birthday during the period studied. Ascertainment exceeded 90% in most registers. During the 20-year period, all but one register showed statistically significant changes in incidence, with rates universally increasing. When estimated separately for the first and second halves of the period, the median rates of increase were similar: 3.4% per annum and 3.3% per annum, respectively. However, rates of increase differed significantly between the first half and the second half for nine of the 21 registers with adequate coverage of both periods; five registers showed significantly higher rates of increase in the first half, and four significantly higher rates in the second half. The incidence rate of childhood type 1 diabetes continues to rise across Europe by an average of approximately 3-4% per annum, but the increase is not necessarily uniform, showing periods of less rapid and more rapid increase in incidence in some registers. This pattern of change suggests that important risk exposures differ over time in different European countries. Further time trend analysis and comparison of the patterns in defined regions is warranted.","[Patterson, C. C.] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland; [Gyuerues, E.; Soltesz, G.] Univ Pecs, Dept Paediat, Pecs, Hungary; [Rosenbauer, J.] Univ Dusseldorf, Inst Biometr & Epidemiol, German Diabet Ctr, Leibniz Inst Diabet Res, D-40225 Dusseldorf, Germany; [Cinek, O.] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague, Czech Republic; [Cinek, O.] Univ Hosp Motol, Prague, Czech Republic; [Neu, A.] Univ Childrens Hosp, Tubingen, Germany; [Schober, E.] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria; [Parslow, R. C.] Univ Leeds, Leeds Inst Genet Hlth & Therapeut, Leeds, W Yorkshire, England; [Joner, G.] Ullevaal Univ Hosp, Dept Pediat, Oslo, Norway; [Svensson, J.] Univ Copenhagen, Dept Paediat, Herlev, Denmark; [Castell, C.] Govt Catalonia, Dept Hlth, Barcelona, Spain; [Bingley, P. J.] Univ Bristol, Sch Clin Sci, Bristol, Avon, England; [Schoenle, E.] Univ Childrens Hosp, Dept Endocrinol & Diabetol, Zurich, Switzerland; [Jarosz-Chobot, P.] Med Univ Silesia, Dept Pediat Endocrinol & Diabet, Katowice, Poland; [Urbonaite, B.] Lithuanian Univ Hlth Sci, Inst Endocrinol, Kaunus, Lithuania; [Rothe, U.] Tech Univ Dresden, Dept Epidemiol & Hlth Care Res, D-01062 Dresden, Germany; [Krzisnik, C.] Univ Childrens Hosp, Dept Pediat, Ljubljana, Slovenia; [Ionescu-Tirgoviste, C.] N Paulescu Inst Diabet & Metab Dis, Nutr & Metab Dis Clin, Bucharest, Romania; [Weets, I.] Univ Libre Brussels, Diabet Res Ctr, Brussels, Belgium; [Kocova, M.] Univ Childrens Hosp, Dept Endocrinol & Genet, Skopje, Macedonia; [Stipancic, G.] Univ Hosp Sestre Milosrdnice, Dept Paediat, Zagreb, Croatia; [Samardzic, M.] Univ Childrens Hosp, Dept Endocrinol & Diabet, Podgorica, Montenegro; [de Beaufort, C. E.] Paediat Clin, Dept Paediat Diabet & Endocrinol, Luxembourg, Luxembourg; [Green, A.] Univ So Denmark, Odense Patient Data Exploratory Network, Odense, Denmark; [Dahlquist, G. G.] Umea Univ, Dept Clin Sci, Umea, Sweden","Patterson, CC (reprint author), Queens Univ Belfast, Ctr Publ Hlth, Inst Clin Sci Block B,Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.","c.patterson@qub.ac.uk",null,null,"Belgian Fund for Scientific Research; Federal Ministry of Education and Research [01GI0802, 01GI0859]; South-Eastern Norway Regional Health Authority; Swedish Research Council [07531]; Diabetes UK; UK Healthcare Quality Improvement Partnership; European Community Concerted Action Program [BMH1-CT92-0043, BMH4-CT96-0577, IC20-CT96-0070]","The authors acknowledge the Austrian Diabetes Incidence Study Group, the Belgian Diabetes Registry (fellowship for I. Weets from the Belgian Fund for Scientific Research), the Danish Study Group of Diabetes in Childhood, the Baden-Wurttemberg Diabetes Incidence Registry (DIARY), the German Paediatric Surveillance Unit, Dusseldorf University and DPV Science Initiative, Ulm University, the German Competence Network Diabetes Mellitus (Federal Ministry of Education and Research, support codes 01GI0802, 01GI0859), the Saxonian Childhood Diabetes Register Group, the Hungarian Childhood Diabetes Epidemiology Group, the Norwegian Childhood Diabetes Study Group (supported by the South-Eastern Norway Regional Health Authority), the Catalan Epidemiology Type 1 Diabetes Study Group, the Swedish Childhood Diabetes Study Group (supported by the Swedish Research Council, Project number 07531), the Northern Ireland Childhood Diabetes Group, the Bart's-Oxford Study Group (supported by Diabetes UK) and the Yorkshire Register of Diabetes in Children and Young People (supported by the UK Healthcare Quality Improvement Partnership). The collaboration was supported in part by European Community Concerted Action Program grants (BMH1-CT92-0043, BMH4-CT96-0577 and IC20-CT96-0070).",null,9,32,32,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0012-186X",null,null,"DIABETOLOGIA","Diabetologia","AUG",2012,55,8,null,null,null,null,2142,2147,null,"10.1007/s00125-012-2571-8",null,6,"Endocrinology & Metabolism","Endocrinology & Metabolism","970IW","WOS:000306122600009"]
[null,null,null,null,"J","Fernandes, JF; Rocha, V; Labopin, M; Neven, B; Moshous, D; Gennery, AR; Friedrich, W; Porta, F; de Heredia, CD; Wall, D; Bertrand, Y; Veys, P; Slatter, M; Schulz, A; Chan, KW; Grimley, M; Ayas, M; Gungor, T; Ebell, W; Bonfim, C; Kalwak, K; Taupin, P; Blanche, S; Gaspar, HB; Landais, P; Fischer, A; Gluckman, E; Cavazzana-Calvo, M",null,null,null,"Fernandes, Juliana F.; Rocha, Vanderson; Labopin, Myriam; Neven, Benedicte; Moshous, Despina; Gennery, Andrew R.; Friedrich, Wilhelm; Porta, Fulvio; Diaz de Heredia, Cristina; Wall, Donna; Bertrand, Yves; Veys, Paul; Slatter, Mary; Schulz, Ansgar; Chan, Ka Wah; Grimley, Michael; Ayas, Mouhab; Gungor, Tayfun; Ebell, Wolfram; Bonfim, Carmem; Kalwak, Krzysztof; Taupin, Pierre; Blanche, Stephane; Gaspar, H. Bobby; Landais, Paul; Fischer, Alain; Gluckman, Eliane; Cavazzana-Calvo, Marina",null,"Eurocord Inborn Errors Working","Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood?","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW-TRANSPLANTATION; TERM IMMUNE RECONSTITUTION; HOST DISEASE; EXPERIENCE; CHILDREN; PHENOTYPE; ANEMIA; GRAFT","Pediatric patients with SCID constitute medical emergencies. In the absence of an HLA-identical hematopoietic stem cell (HSC) donor, mismatched related-donor transplantation (MMRDT) or unrelated-donor umbilical cord blood transplantation (UCBT) are valuable treatment options. To help transplantation centers choose the best treatment option, we retrospectively compared outcomes after 175 MMRDTs and 74 UCBTs in patients with SCID or Omenn syndrome. Median follow-up time was 83 months and 58 months for UCBT and MMRDT, respectively. Most UCB recipients received a myeloablative conditioning regimen; most MMRDT recipients did not. UCB recipients presented a higher frequency of complete donor chimerism (P = .04) and faster total lymphocyte count recovery (P = .04) without any statistically significance with the preparative regimen they received. The MMRDT and UCBT groups did not differ in terms of T-cell engraftment, CD4(+) and CD3(+) cell recoveries, while Ig replacement therapy was discontinued sooner after UCBT (adjusted P = .02). There was a trend toward a greater incidence of grades II-IV acute GVHD (P = .06) and more chronic GVHD (P = .03) after UCBT. The estimated 5-year overall survival rates were 62% +/- 4% after MMRDT and 57% +/- 6% after UCBT. For children with SCID and no HLA-identical sibling donor, both UCBT and MMRDT represent available HSC sources for transplantation with quite similar outcomes. (Blood. 2012;119(12):2949-2955)","[Cavazzana-Calvo, Marina] Univ Paris 05, Hop Necker Enfants Malad, Dept Biotherapy, F-75015 Paris, France; [Fernandes, Juliana F.; Rocha, Vanderson; Gluckman, Eliane] Hop St Louis, Paris, France; [Fernandes, Juliana F.; Rocha, Vanderson] Univ Sao Paulo, Inst Crianca, Sao Paulo, Brazil; [Labopin, Myriam] Univ Paris 06, Hop St Antoine, CEREST TC, Paris, France; [Neven, Benedicte; Moshous, Despina; Blanche, Stephane; Fischer, Alain] Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, Paris, France; [Gennery, Andrew R.; Slatter, Mary] Newcastle Univ, Newcastle upon Tyne Hosp Fdn Trust, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Friedrich, Wilhelm; Schulz, Ansgar] Univ Ulm, Ulm, Germany; [Porta, Fulvio] Univ Brescia, Spedali Civili, Spedali Civili P, Brescia, Italy; [Diaz de Heredia, Cristina] Hosp Infantil Vall Hebron, Serv Hemat & Oncol Pediat, Barcelona, Spain; [Wall, Donna] Univ Manitoba, Winnipeg, MB, Canada; [Bertrand, Yves] Hop Debrousse, Inst Hematol & Oncol Pediat, Lyon, France; [Veys, Paul; Gaspar, H. Bobby] Great Ormond St Hosp Sick Children, Dept Bone Marrow Transplantat, London WC1N 3JH, England; [Chan, Ka Wah; Grimley, Michael] Texas Transplant Inst, Div Pediat Blood & Marrow Transplantat, San Antonio, TX USA; [Chan, Ka Wah; Grimley, Michael] Methodist Childrens Hosp, San Antonio, TX USA; [Ayas, Mouhab] King Faisal Specialist Hosp & Res Ctr, Dept Pediat Hematol Oncol, Riyadh 11211, Saudi Arabia; [Gungor, Tayfun] Univ Childrens Hosp, Div Immunol Hematol Oncol, Zurich, Switzerland; [Ebell, Wolfram] Univ Charite, Dept Pediat, Berlin, Germany; [Bonfim, Carmem] Univ Fed Parana, Bone Marrow Transplantat Unit, BR-80060000 Curitiba, Parana, Brazil; [Kalwak, Krzysztof] Med Acad Wroclaw, Dept Pediat Hematol & Oncol, Wroclaw, Poland; [Taupin, Pierre; Landais, Paul] Hop Necker Enfants Malad, Assistance Publ Hop Paris, EA 4472, Serv Biostat & Informat Med, Paris, France; [Taupin, Pierre; Landais, Paul; Fischer, Alain; Cavazzana-Calvo, Marina] Univ Paris 05, Fac Med, F-75015 Paris, France","Cavazzana-Calvo, M (reprint author), Univ Paris 05, Hop Necker Enfants Malad, Dept Biotherapy, 149 Rue Sevres, F-75015 Paris, France.","m.cavazzana@nck.aphp.fr","Fernandes, Juliana/H-9838-2013","Fernandes, Juliana/0000-0002-5764-1621",null,null,"Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Bertrand Y, 1999, J PEDIATR, V134, P740, DOI 10.1016/S0022-3476(99)70291-X; Bhattacharya A, 2005, BONE MARROW TRANSPL, V36, P295, DOI 10.1038/sj.bmt.1705054; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Cavazzana-Calvo M, 2007, BLOOD, V109, P4575, DOI 10.1182/blood-2006-07-029090; de Heredia CD, 2008, BONE MARROW TRANSPL, V41, P627, DOI 10.1038/sj.bmt.1705946; FINE J, 1999, J AM STAT ASSOC, V94, P196; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; Frangoul H, 2010, BONE MARROW TRANSPL, V45, P283, DOI 10.1038/bmt.2009.137; GATTI RA, 1968, LANCET, V2, P1366; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; Gluckman E, 2006, CURR OPIN IMMUNOL, V18, P565, DOI 10.1016/j.coi.2006.07.014; Gluckman E, 2009, HAEMATOL-HEMATOL J, V94, P451, DOI 10.3324/haematol.2009.005694; Gluckman E, 2011, BRIT J HAEMATOL, V154, P441, DOI 10.1111/j.1365-2141.2011.08598.x; GLUCKSBE.H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Haddad E, 1998, BLOOD, V91, P3646; Klein AK, 2001, BIOL BLOOD MARROW TR, V7, P454, DOI 10.1016/S1083-8791(01)80013-6; Klingebiel T, 2010, BLOOD, V115, P3437, DOI 10.1182/blood-2009-03-207001; Knutsen AP, 2000, J CLIN IMMUNOL, V20, P466, DOI 10.1023/A:1026463900925; Komanduri KV, 2007, BLOOD, V110, P4543, DOI 10.1182/blood-2007-05-092130; Lagresle-Peyrou C, 2011, J ALLERGY CLIN IMMUN, V128, P230, DOI 10.1016/j.jaci.2011.02.008; Neven B, 2009, BLOOD, V113, P4114, DOI 10.1182/blood-2008-09-177923; Niehues T, 2001, BRIT J HAEMATOL, V114, P42, DOI 10.1046/j.1365-2141.2001.02900.x; REISNER Y, 1983, BLOOD, V61, P341; Slatter MA, 2008, J ALLERGY CLIN IMMUN, V121, P361, DOI 10.1016/j.jaci.2007.10.035; STORB R, 1983, ANN INTERN MED, V98, P461",27,18,18,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","MAR 22",2012,119,12,null,null,null,null,2949,2955,null,"10.1182/blood-2011-06-363572",null,7,"Hematology","Hematology","916RU","WOS:000302121700033"]
[null,null,null,null,"J","Kolar, P; Sulc, J; Kyncl, M; Sanda, J; Cakrt, O; Andel, R; Kumagai, K; Kobesova, A",null,null,null,"Kolar, Pavel; Sulc, Jan; Kyncl, Martin; Sanda, Jan; Cakrt, Ondrej; Andel, Ross; Kumagai, Kathryn; Kobesova, Alena",null,null,"Postural Function of the Diaphragm in Persons With and Without Chronic Low Back Pain","JOURNAL OF ORTHOPAEDIC & SPORTS PHYSICAL THERAPY",null,null,"English","Article",null,null,null,null,null,"dynamic magnetic resonance imaging; lung function; spinal disorders; stabilizing function; thorax","TRUNK MUSCLE-ACTIVITY; UPPER-LIMB MOVEMENT; INTRAABDOMINAL PRESSURE; STRENGTH; CONTRACTION; RECRUITMENT; ACTIVATION; PEOPLE; MOTION; SPINE","STUDY DESIGN: A case-control study. OBJECTIVES: To examine the function of the diaphragm during postural limb activities in patients with chronic low back pain and healthy controls. BACKGROUND: Abnormal stabilizing function of the diaphragm may be an etiological factor in spinal disorders. However, a study designed specifically to test the dynamics of the diaphragm in chronic spinal disorders is lacking. METHODS: Eighteen patients with chronic low back pain due to chronic overloading, as ascertained via clinical assessment and magnetic resonance imaging, and 29 healthy subjects were examined. Both groups presented with normal pulmonary function test results. A dynamic magnetic resonance imaging system and specialized spirometric readings were used with subjects in the supine position. Measurements during tidal breathing (TB) and isometric flexion of the upper and lower extremities against external resistance with TB were performed. Standard pulmonary function tests, including respiratory muscle drive (PImax and PEmax), were also assessed. RESULTS: Using multivariate analysis of covariance, smaller diaphragm excursions and higher diaphragm position were found in the patient group (P<.05) during the upper extremity TB and lower extremity TB conditions. Maximum changes were found in costal and middle points of the diaphragm. A 1-way analysis of covariance showed a steeper slope in the middle-posterior diaphragm in the patient group both in the upper extremity TB and lower extremity TB conditions (P<.05). CONCLUSION: Patients with chronic low back pain appear to have both abnormal position and a steeper slope of the diaphragm, which may contribute to the etiology of the disorder. J Orthop Sports Phys Ther 2012;42(4):352-362, Epub 21 December 2011. doi:10.2519/7ospt.2012.3830","[Kolar, Pavel; Sulc, Jan; Cakrt, Ondrej; Kobesova, Alena] Charles Univ Prague, Dept Rehabil & Sport Med, Fac Med 2, Prague 15006 5, Czech Republic; [Kolar, Pavel; Sulc, Jan; Kyncl, Martin; Sanda, Jan; Cakrt, Ondrej; Kobesova, Alena] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Kyncl, Martin; Sanda, Jan] Charles Univ Prague, Dept Radiol, Fac Med 2, Prague 15006 5, Czech Republic; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Andel, Ross] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Kumagai, Kathryn] Azusa Pacific Univ, Dept Phys Therapy, Azusa, CA USA","Kobesova, A (reprint author), Charles Univ Prague, Dept Rehabil & Sport Med, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","alenamudr@me.com",null,null,null,null,null,38,4,4,"J O S P T,","ALEXANDRIA","1111 NORTH FAIRFAX ST, STE 100, ALEXANDRIA, VA 22314-1436 USA","0190-6011",null,null,"J ORTHOP SPORT PHYS","J. Orthop. Sports Phys. Ther.","APR",2012,42,4,null,null,null,null,352,362,null,"10.2519/jospt.2012.3830",null,11,"Orthopedics; Rehabilitation; Sport Sciences","Orthopedics; Rehabilitation; Sport Sciences","918SR","WOS:000302271900009"]
[null,null,null,null,"J","Nedelska, Z; Andel, R; Laczo, J; Vlcek, K; Horinek, D; Lisy, J; Sheardova, K; Bures, J; Hort, J",null,null,null,"Nedelska, Zuzana; Andel, Ross; Laczo, Jan; Vlcek, Kamil; Horinek, Daniel; Lisy, Jiri; Sheardova, Katerina; Bures, Jan; Hort, Jakub",null,null,"Spatial navigation impairment is proportional to right hippocampal volume","PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA",null,null,"English","Article",null,null,null,null,null,null,"MILD COGNITIVE IMPAIRMENT; MORRIS WATER TASK; ALZHEIMERS-DISEASE; TOPOGRAPHICAL DISORIENTATION; PLACE NAVIGATION; SEGMENTATION; ORIENTATION; MEDIATION; NETWORK; LESIONS","Cognitive deficits in older adults attributable to Alzheimer's disease (AD) pathology are featured early on by hippocampal impairment. Among these individuals, deterioration in spatial navigation, manifested by poor hippocampus-dependent allocentric navigation, may occur well before the clinical onset of dementia. Our aim was to determine whether allocentric spatial navigation impairment would be proportional to right hippocampal volume loss irrespective of general brain atrophy. We also contrasted the respective spatial navigation scores of the real-space human Morris water maze with its corresponding 2D computer version. We included 42 cognitively impaired patients with either amnestic mild cognitive impairment (n = 23) or mild and moderate AD (n = 19), and 14 cognitively intact older controls. All participants underwent 1.5T MRI brain scanning with subsequent automatic measurement of the total brain and hippocampal (right and left) volumes. Allocentric spatial navigation was tested in the real-space version of the human Morris water maze and in its corresponding computer version. Participants used two navigational cues to locate an invisible goal independent of the start position. We found that smaller right hippocampal volume was associated with poorer navigation performance in both the real-space (beta = -0.62, P < 0.001) and virtual (beta = -0.43, P = 0.026) versions, controlling for demographic variables, total brain and left hippocampal volumes. In subsequent analyses, the results were significant in cognitively impaired (P <= 0.05) but not in cognitively healthy (P > 0.59) subjects. The respective real-space and virtual scores strongly correlated with each other. Our findings indicate that the right hippocampus plays a critical role in allocentric navigation, particularly when cognitive impairment is present.","[Vlcek, Kamil; Bures, Jan] Acad Sci Czech Republic, Inst Physiol, Dept Neurophysiol Memory, CR-14220 Prague 4, Czech Republic; [Nedelska, Zuzana; Laczo, Jan; Hort, Jakub] Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Fac Med 2, Prague 15006 5, Czech Republic; [Nedelska, Zuzana; Laczo, Jan; Lisy, Jiri; Hort, Jakub] Motol Univ Hosp, Prague 15006 5, Czech Republic; [Nedelska, Zuzana; Andel, Ross; Laczo, Jan; Vlcek, Kamil; Horinek, Daniel; Sheardova, Katerina; Hort, Jakub] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno 65691, Czech Republic; [Andel, Ross] Univ S Florida, Coll Behav & Community Sci, Sch Aging Studies, Tampa, FL 33620 USA; [Horinek, Daniel] Univ Marburg, Dept Neurosurg, D-35033 Marburg, Germany; [Lisy, Jiri] Charles Univ Prague, Dept Radiol, Fac Med 2, Prague 15006 5, Czech Republic","Bures, J (reprint author), Acad Sci Czech Republic, Inst Physiol, Dept Neurophysiol Memory, Videnska 1083, CR-14220 Prague 4, Czech Republic.","bures@biomed.cas.cz; jakub.hort@lfmotol.cuni.cz","Vlcek, Kamil/B-9620-2012","Vlcek, Kamil/0000-0001-7152-3093","Grant Agency of the Czech Republic [309/09/1053, 309/09/0286]; St. Anne's University Hospital, Brno, International Clinical Research Center [CZ.1.05/1.1.00/02.0123]; Ministry of Education, Youth and Sports of the Czech Republic [1M0517, LC554]; Research Project [AV0Z50110509]; Agency of the Ministry of Health [IGA NS 10331]","Support for this work was provided by Grant Agency of the Czech Republic Grants 309/09/1053 and 309/09/0286; European Regional Development Fund Project St. Anne's University Hospital, Brno, International Clinical Research Center CZ.1.05/1.1.00/02.0123; Ministry of Education, Youth and Sports of the Czech Republic Grants 1M0517 and LC554; Research Project AV0Z50110509; and Internal Grant Agency of the Ministry of Health Grant IGA NS 10331.",null,36,15,15,"NATL ACAD SCIENCES","WASHINGTON","2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA","0027-8424",null,null,"P NATL ACAD SCI USA","Proc. Natl. Acad. Sci. U. S. A.","FEB 14",2012,109,7,null,null,null,null,2590,2594,null,"10.1073/pnas.1121588109",null,5,"Multidisciplinary Sciences","Science & Technology - Other Topics","895IH","WOS:000300489200084"]
[null,null,null,null,"J","Kramarzova, K; Stuchly, J; Willasch, A; Gruhn, B; Schwarz, J; Cermak, J; Machova-Polakova, K; Fuchs, O; Stary, J; Trka, J; Boublikova, L",null,null,null,"Kramarzova, K.; Stuchly, J.; Willasch, A.; Gruhn, B.; Schwarz, J.; Cermak, J.; Machova-Polakova, K.; Fuchs, O.; Stary, J.; Trka, J.; Boublikova, L.",null,null,"Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"Wilms' tumor gene 1 (WT1); isoforms; acute myeloid leukemia; myelodysplastic syndrome; real-time quantitative PCR (qPCR)","MINIMAL RESIDUAL DISEASE; TUMOR SUPPRESSOR GENE; POLYMERASE-CHAIN-REACTION; DNA-BINDING SPECIFICITY; ZINC-FINGER DOMAIN; MESSENGER-RNA; PROTEIN WT1; PROGNOSTIC-SIGNIFICANCE; QUANTITATIVE PCR; SPLICE VARIANTS","Wilms' tumor gene 1 (WT1) functions including some contradictory effects may be explained by the presence and interactions of its isoforms, however, their evaluation has been so far complicated by several technical problems. We designed unique quantitative PCR systems for direct quantification of the major WT1 isoforms A[EX5 - /KTS -], B[+ / -], C[- / +] and D[+ / +] and verified their sensitivity, specificity and reproducibility in extensive testing. With this method we evaluated WT1 total and isoform expression in 23 normal bone marrow (BM) samples, 73 childhood acute myeloid leukemia (AML), 20 childhood myelodysplastic syndrome (MDS), 9 childhood severe aplastic anemia (SAA), 30 adult AML and 29 adult MDS patients. WT1 isoform patterns showed differences among these samples and clustered them into groups representing the specific diagnoses (P<0.0001). Isoform profiles were independent of total WT1 expression and possess certain common features-overexpression of isoform D and EX5[+] variants. The KTS[+]/KTS[+] ratio was less variable than the EX5[+]/EX5[-] ratio and differed between children and adults (P<0.001); the EX5[+]/EX5[-] ratio varied between diagnoses (AML vs MDS, P<0.001). These findings bring new insights into WT1 isoform function and suggest that the ratio of WT1 isoforms, particularly EX5 variants, is probably crucial for the process of malignant transformation.","[Kramarzova, K.; Stuchly, J.; Stary, J.; Trka, J.; Boublikova, L.] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Willasch, A.] Goethe Univ, Hosp Children & Adolescents 2 3, Dept Pediat Hematol Oncol & Hemostaseol, Frankfurt, Germany; [Gruhn, B.] Univ Hosp Jena, Dept Pediat, Jena, Germany; [Schwarz, J.; Cermak, J.; Machova-Polakova, K.; Fuchs, O.] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic","Trka, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15006, Czech Republic.","jan.trka@lfmotol.cuni.cz",null,null,"Charles University [GAUK 81709]; COST Program [OC 09051];  [IGA NS10488-3]","We thank Ondrej Cinek from the Department of Pediatrics, Pavel Seeman from the Department of Pediatric Neurology, Zdenek Sedlacek from the Institute of Medical Biology and Genetics, 2nd Faculty of Medicine, Charles University in Prague, Olfert Landt from TIB-MOLBIOL, Berlin, Germany and Fiona Quinn from the Cancer Molecular Diagnostics Laboratory, St James's Hospital, Dublin, for their invaluable advice and experienced opinions during method development and testing. We also appreciated the help of Katerina Muzikova, Ester Mejstrikova and Martina Sukova from the Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague, and Jana Markova from the Institute of Hematology and Blood Transfusion, Prague, with the identification and initial processing of some samples. We thank the staff of the participating Czech Pediatric Hematology Working Group centers for cooperation. This study is supported by the grant IGA NS10488-3. KK was supported by the Charles University (GAUK 81709) solely and JT by the COST Program (OC 09051).",null,55,4,5,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","SEP",2012,26,9,null,null,null,null,2086,2095,null,"10.1038/leu.2012.76",null,10,"Oncology; Hematology","Oncology; Hematology","999VK","WOS:000308342900014"]
[null,null,null,null,"J","Ouda, L; Druga, R; Syka, J",null,null,null,"Ouda, Ladislav; Druga, Rastislav; Syka, Josef",null,null,"Distribution of SMI-32-immunoreactive neurons in the central auditory system of the rat","BRAIN STRUCTURE & FUNCTION",null,null,"English","Article",null,null,null,null,null,"SMI-32; Superior olivary complex; Inferior colliculus; Medial geniculate body; Auditory cortex; Rat","LATERAL GENICULATE-NUCLEUS; SUPERIOR OLIVARY COMPLEX; ECHIDNA TACHYGLOSSUS-ACULEATUS; PYRAMIDAL PROJECTION NEURONS; DORSAL COCHLEAR NUCLEUS; MOUSE-BRAIN SLICE; INFERIOR COLLICULUS; TRAPEZOID BODY; MEDIAL NUCLEUS; NEUROFILAMENT PROTEIN","SMI-32 antibody recognizes a non-phosphorylated epitope of neurofilament proteins, which are thought to be necessary for the maintenance of large neurons with highly myelinated processes. We investigated the distribution and quantity of SMI-32-immunoreactive(-ir) neurons in individual parts of the rat auditory system. SMI-32-ir neurons were present in all auditory structures; however, in most regions they constituted only a minority of all neurons (10-30%). In the cochlear nuclei, a higher occurrence of SMI-32-ir neurons was found in the ventral cochlear nucleus. Within the superior olivary complex, SMI-32-ir cells were particularly abundant in the medial nucleus of the trapezoid body (MNTB), the only auditory region where SMI-32-ir neurons constituted an absolute majority of all neurons. In the inferior colliculus, a region with the highest total number of neurons among the rat auditory subcortical structures, the percentage of SMI-32-ir cells was, in contrast to the MNTB, very low. In the medial geniculate body, SMI-32-ir neurons were prevalent in the ventral division. At the cortical level, SMI-32-ir neurons were found mainly in layers III, V and VI. Within the auditory cortex, it was possible to distinguish the Te1, Te2 and Te3 areas on the basis of the variable numerical density and volumes of SMI-32-ir neurons, especially when the pyramidal cells of layer V were taken into account. SMI-32-ir neurons apparently form a representative subpopulation of neurons in all parts of the rat central auditory system and may belong to both the inhibitory and excitatory systems, depending on the particular brain region.","[Ouda, Ladislav; Syka, Josef] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Dept Anat, Fac Med 1 & 2, Prague, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Dept Anat, Fac Med 2, Prague, Czech Republic","Ouda, L (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220, Czech Republic.","ouda@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [309/07/1336, AV0Z50390512, LC 554]","The authors wish to thank Mrs. J. Janouskova for her technical assistance. This study was supported by the Grant Agency of the Czech Republic (309/07/1336), AV0Z50390512 and LC 554.",null,94,2,2,"SPRINGER HEIDELBERG","HEIDELBERG","TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY","1863-2653",null,null,"BRAIN STRUCT FUNCT","Brain Struct. Funct.","JAN",2012,217,1,null,null,null,null,19,36,null,"10.1007/s00429-011-0329-6",null,18,"Anatomy & Morphology; Neurosciences","Anatomy & Morphology; Neurosciences & Neurology","922UC","WOS:000302572800003"]
[null,null,null,null,"J","Creutzig, U; van den Heuvel-Eibrink, MM; Gibson, B; Dworzak, MN; Adachi, S; de Bont, E; Harbott, J; Hasle, H; Johnston, D; Kinoshita, A; Lehrnbecher, T; Leverger, G; Mejstrikova, E; Meshinchi, S; Pession, A; Raimondi, SC; Sung, LL; Stary, J; Zwaan, CM; Kaspers, GJL; Reinhardt, D",null,null,null,"Creutzig, Ursula; van den Heuvel-Eibrink, Marry M.; Gibson, Brenda; Dworzak, Michael N.; Adachi, Souichi; de Bont, Eveline; Harbott, Jochen; Hasle, Henrik; Johnston, Donna; Kinoshita, Akitoshi; Lehrnbecher, Thomas; Leverger, Guy; Mejstrikova, Ester; Meshinchi, Soheil; Pession, Andrea; Raimondi, Susana C.; Sung, Lillian; Stary, Jan; Zwaan, Christian M.; Kaspers, Gertjan J. L.; Reinhardt, Dirk",null,"AML Comm Int BFM Study Grp","Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","BLOOD",null,null,"English","Review",null,null,null,null,null,null,"ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; TRANS-RETINOIC ACID; INDEPENDENT PROGNOSTIC RELEVANCE; COOPERATIVE-STUDY-GROUP; HIGH-DOSE CYTARABINE; AML 10 TRIAL; PNEUMOCYSTIS-CARINII PNEUMONITIS","Despite major improvements in outcome over the past decades, acute myeloid leukemia (AML)remains a life-threatening malignancy in children, with current survival rates of similar to 70%. State-of-the-art recommendations in adult AML have recently been published in this journal by Dohner et al. The primary goal of an international expert panel of the International BFM Study Group AML Committee was to set standards for the management, diagnosis, response assessment, and treatment in childhood AML. This paper aims to discuss differences between childhood and adult AML, and to highlight recommendations that are specific to children. The particular relevance of new diagnostic and prognostic molecular markers in pediatric AML is presented. The general management of pediatric AML, the management of specific pediatric AML cohorts (such as infants)or subtypes of the disease occurring in children (such as Down syndrome related AML), as well as new therapeutic approaches, and the role of supportive care are discussed. (Blood. 2012;120(16):3187-3205)","[Creutzig, Ursula; Reinhardt, Dirk] Hannover Med Sch, Dept Pediat Hematol Oncol, D-30625 Hannover, Germany; [van den Heuvel-Eibrink, Marry M.; Zwaan, Christian M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Gibson, Brenda] Royal Hosp Sick Children, Dept Haematol, Glasgow G3 8SJ, Lanark, Scotland; [Dworzak, Michael N.] Med Univ Vienna, Dept Pediat, St Anna Childrens Hosp, Vienna, Austria; [Dworzak, Michael N.] Med Univ Vienna, Dept Pediat, Childrens Canc Res Inst, Vienna, Austria; [Adachi, Souichi] Kyoto Univ, Grad Sch Med, Dept Human Hlth Sci, Kyoto, Japan; [de Bont, Eveline] Univ Groningen, Dept Pediat, Univ Med Ctr Groningen, Div Pediat Oncol Hematol, NL-9700 AB Groningen, Netherlands; [Harbott, Jochen] Univ Giessen, Oncogenet Lab, Dept Pediat Hematol & Oncol, Giessen, Germany; [Hasle, Henrik] Aarhus Univ, Hosp Skejby, Dept Pediat, Aarhus, Denmark; [Johnston, Donna] Childrens Hosp Eastern Ontario, Div Hematol Oncol, Ottawa, ON K1H 8L1, Canada; [Kinoshita, Akitoshi] St Marianna Univ, Sch Med, Dept Pediat, Kawasaki, Kanagawa, Japan; [Lehrnbecher, Thomas] Goethe Univ Frankfurt, Frankfurt, Germany; [Leverger, Guy] Univ Paris 07, Trousseau Hosp, AP HP, Dept Haemato Immuno Oncol, F-75221 Paris 05, France; [Mejstrikova, Ester] Charles Univ Prague, Sch Med 2, Dept Paediat Haematol & Oncol, Childhood Leukaemia Invest Prague, Prague, Czech Republic; [Meshinchi, Soheil] Univ Washington, Sch Med, Div Pediat Hematol Oncol, Seattle, WA USA; [Meshinchi, Soheil] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; [Pession, Andrea] Univ Bologna, Pediat Oncol & Hematol Lalla Seragnoli Unit, Bologna, Italy; [Raimondi, Susana C.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Sung, Lillian] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; [Stary, Jan] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Stary, Jan] Czech Pediat Hematol Working Grp CPH, Prague, Czech Republic; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands","Creutzig, U (reprint author), Hannover Med Sch, Childrens Hosp, Dept Paediat Haematol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.","ursula@creutzig.de","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056",null,null,null,224,20,23,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","OCT 18",2012,120,16,null,null,null,null,3187,3205,null,"10.1182/blood-2012-03-362608",null,19,"Hematology","Hematology","044KX","WOS:000311619200009"]
[null,null,null,null,"J","Hirabayashi, S; Flotho, C; Moetter, J; Heuser, M; Hasle, H; Gruhn, B; Klingebiel, T; Thol, F; Schlegelberger, B; Baumann, I; Strahm, B; Stary, J; Locatelli, F; Zecca, M; Bergstraesser, E; Dworzak, M; van den Heuvel-Eibrink, MM; De Moerloose, B; Ogawa, S; Niemeyer, CM; Wlodarski, MW",null,null,null,"Hirabayashi, Shinsuke; Flotho, Christian; Moetter, Jessica; Heuser, Michael; Hasle, Henrik; Gruhn, Bernd; Klingebiel, Thomas; Thol, Felicitas; Schlegelberger, Brigitte; Baumann, Irith; Strahm, Brigitte; Stary, Jan; Locatelli, Franco; Zecca, Marco; Bergstraesser, Eva; Dworzak, Michael; van den Heuvel-Eibrink, Marry M.; De Moerloose, Barbara; Ogawa, Seishi; Niemeyer, Charlotte M.; Wlodarski, Marcin W.",null,"European Working Grp MDS Childhood","Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"JUVENILE MYELOMONOCYTIC LEUKEMIA; RISK MYELODYSPLASTIC SYNDROMES; CLASSIFICATION","Somatic mutations of the spliceosomal machinery occur frequently in adult patients with myelodysplastic syndrome (MDS). We resequenced SF3B1, U2AF35, and SRSF2 in 371 children with MDS or juvenile myelomonocytic leukemia. We found missense mutations in 2 juvenile myelomonocytic leukemia cases and in 1 child with systemic mastocytosis with MDS. In 1 juvenile myelomonocytic leukemia patient, the SRSF2 mutation that initially coexisted with an oncogenic NRAS mutation was absent at relapse, whereas the NRAS mutation persisted and a second, concomitant NRAS mutation later emerged. The patient with systemic mastocytosis and MDS carried both mutated U2AF35 and KIT in a single clone as confirmed by clonal sequencing. In the adult MDS patients sequenced for control purposes, we detected previously reported mutations in 7/30 and a novel SRSF2 deletion (c.284_307del) in 3 of 30 patients. These findings implicate that spliceosome mutations are rare in pediatric MDS and juvenile myelomonocytic leukemia and are unlikely to operate as driver mutations. (Blood. 2012; 119(11):e96-e99)","[Hirabayashi, Shinsuke; Flotho, Christian; Moetter, Jessica; Strahm, Brigitte; Niemeyer, Charlotte M.; Wlodarski, Marcin W.] Univ Freiburg, D-79106 Freiburg, Germany; [Heuser, Michael; Thol, Felicitas] Hannover Med Sch, D-3000 Hannover, Germany; [Hasle, Henrik] Aarhus Univ Hosp Skejby, Aarhus, Denmark; [Gruhn, Bernd] Univ Hosp Jena, Dept Pediat, Jena, Germany; [Klingebiel, Thomas] Goethe Univ Frankfurt, Frankfurt, Germany; [Schlegelberger, Brigitte] Hannover Med Sch, Inst Cell & Mol Pathol, D-3000 Hannover, Germany; [Baumann, Irith] Boblingen Clin, Clin Ctr SW, Dept Pathol, Boblingen, Germany; [Stary, Jan] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic; [Locatelli, Franco] Univ Pavia, Ist Ricovero & Cura Carattere Sci Osped Bambino G, I-27100 Pavia, Italy; [Zecca, Marco] Fdn Ist Ricovero & Cura Carattere Sci Policlin Sa, Pavia, Italy; [Bergstraesser, Eva] Univ Childrens Hosp, Zurich, Switzerland; [Dworzak, Michael] Med Univ Vienna, Dept Pediat, St Anna Childrens Hosp, Vienna, Austria; [van den Heuvel-Eibrink, Marry M.] Erasmus MC, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [van den Heuvel-Eibrink, Marry M.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [De Moerloose, Barbara] Ghent Univ Hosp, Dept Pediat Hematol Oncol, Ghent, Belgium; [Ogawa, Seishi] Univ Tokyo, Grad Sch Med, Canc Genom Project, Tokyo, Japan","Wlodarski, MW (reprint author), Univ Freiburg, Mathildenstr 1, D-79106 Freiburg, Germany.","marcin.wlodarski@uniklinik-freiburg.de",null,null,"Deutsche Krebshilfe [109005]; Deutsche Forschungsgemeinschaft [FL345/4-1]","This work was supported by Deutsche Krebshilfe (109005; M.W.W.) and Deutsche Forschungsgemeinschaft (FL345/4-1; C.F.).",null,19,16,17,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","MAR 15",2012,119,11,null,null,null,null,"E96","E99",null,"10.1182/blood-2011-12-395087",null,4,"Hematology","Hematology","914HZ","WOS:000301941700002"]
[null,null,null,null,"J","Ellinghaus, E; Stanulla, M; Richter, G; Ellinghaus, D; Kronnie, GT; Cario, G; Cazzaniga, G; Horstmann, M; Grumayer, RP; Cave, H; Trka, J; Cinek, O; Teigler-Schlegel, A; ElSharawy, A; Hasler, R; Nebel, A; Meissner, B; Bartram, T; Lescai, F; Franceschi, C; Giordan, M; Nurnberg, P; Heinzow, B; Zimmermann, M; Schreiber, S; Schrappe, M; Franke, A",null,null,null,"Ellinghaus, E.; Stanulla, M.; Richter, G.; Ellinghaus, D.; Kronnie, G. Te; Cario, G.; Cazzaniga, G.; Horstmann, M.; Gruemayer, R. Panzer; Cave, H.; Trka, J.; Cinek, O.; Teigler-Schlegel, A.; ElSharawy, A.; Haesler, R.; Nebel, A.; Meissner, B.; Bartram, T.; Lescai, F.; Franceschi, C.; Giordan, M.; Nuernberg, P.; Heinzow, B.; Zimmermann, M.; Schreiber, S.; Schrappe, M.; Franke, A.",null,"German Berlin-Frankfurt-Munster","Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"genome-wide association study; childhood acute lymphoblastic leukemia; TP63","P53 HOMOLOG; B-CELL; MUTATIONAL ANALYSIS; GENE-EXPRESSION; BREAST-CANCER; P63; PTPRJ; ASSOCIATION; 14Q11.2; 10Q21.2","Acute lymphoblastic leukemia (ALL) is a malignant disease of the white blood cells. The etiology of ALL is believed to be multifactorial and likely to involve an interplay of environmental and genetic variables. We performed a genome-wide association study of 355 750 single-nucleotide polymorphisms (SNPs) in 474 controls and 419 childhood ALL cases characterized by a t(12; 21)(p13;q22) - the most common chromosomal translocation observed in childhood ALL - which leads to an ETV6-RUNX1 gene fusion. The eight most strongly associated SNPs were followed-up in 951 ETV6-RUNX1-positive cases and 3061 controls from Germany/Austria and Italy, respectively. We identified a novel, genome-wide significant risk locus at 3q28 (TP63, rs17505102, P-CMH = 8.94 x 10(-9), OR = 0.65). The separate analysis of the combined German/Austrian sample only, revealed additional genome-wide significant associations at 11q11 (OR8U8, rs1945213, P = 9.14 x 10(-11), OR = 0.69) and 8p21.3 (near INTS10, rs920590, P = 6.12 x 10(-9), OR = 1.36). These associations and another association at 11p11.2 (PTPRJ, rs3942852, P = 4.95 x 10(-7), OR = 0.72) remained significant in the German/Austrian replication panel after correction for multiple testing. Our findings demonstrate that germline genetic variation can specifically contribute to the risk of ETV6-RUNX1-positive childhood ALL. The identification of TP63 and PTPRJ as susceptibility genes emphasize the role of the TP53 gene family and the importance of proteins regulating cellular processes in connection with tumorigenesis.","[Ellinghaus, E.; Richter, G.; Ellinghaus, D.; ElSharawy, A.; Haesler, R.; Nebel, A.; Schreiber, S.; Franke, A.] Univ Kiel, Inst Clin Mol Biol, D-24105 Kiel, Germany; [Stanulla, M.; Cario, G.; Meissner, B.; Bartram, T.; Schrappe, M.] Univ Hosp Schleswig Holstein, Dept Pediat, D-24105 Kiel, Germany; [Kronnie, G. Te; Giordan, M.] Univ Padua, Dept Pediat, Lab Pediat Hematol Oncol, Padua, Italy; [Cazzaniga, G.] Univ Milano Bicocca, Childrens Hosp, M Tettamanti Res Ctr, Monza, Italy; [Horstmann, M.] Univ Med Ctr, Clin Pediat Hematol & Oncol, Hamburg, Germany; [Horstmann, M.] Childrens Canc Ctr, Res Ctr, Hamburg, Germany; [Gruemayer, R. Panzer] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Cave, H.] Hop Robert Debre, Dept Genet, F-75019 Paris, France; [Trka, J.] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Cinek, O.] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Teigler-Schlegel, A.] Univ Giessen, Dept Pediat Hematol & Oncol, Oncogenet Lab, Giessen, Germany; [Lescai, F.] UCL, Div Res Strategy, London, England; [Franceschi, C.] Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy; [Nuernberg, P.] Univ Cologne, Cologne Ctr Genom, D-50931 Cologne, Germany; [Heinzow, B.] State Social Serv Agcy Schleswig Holstein, Kiel, Germany; [Heinzow, B.] Univ Notre Dame, Sydney Med Sch, Sydney, NSW, Australia; [Zimmermann, M.] Hannover Med Sch, D-3000 Hannover, Germany; [Schreiber, S.] Univ Kiel, Univ Hosp Schleswig Holstein, Dept Gen Internal Med, D-24105 Kiel, Germany; [Schreiber, S.] Univ Kiel, Univ Hosp Schleswig Holstein, Popgen Biobank, D-24105 Kiel, Germany","Franke, A (reprint author), Univ Kiel, Inst Clin Mol Biol, Schittenhelmstr 12, D-24105 Kiel, Germany.","martin.stanulla@uk-sh.de; a.franke@mucosa.de","Ellinghaus, Eva/E-6490-2012; Franke, Andre/B-2151-2010; Nebel, Almut/E-4196-2010; Ellinghaus, David/G-4467-2012; Hasler, Robert/A-4908-2009","Franke, Andre/0000-0003-1530-5811; ","German Ministry of Education and Research (BMBF) through the National Genome Research Network (NGFN); popgen biobank; Federal Radiation Protection Agency [3609S30013]; Deutsche Krebshilfe; Madeleine Schickedanz Kinderkrebs-Stiftung","The authors wish to thank all ALL patients, families and physicians for their cooperation. Also, we wish to thank T Wesse, T Henke, M Wittig, R Vogler, L Tittmann and B Fedders for expert technical help. We are grateful to C Becker, R Niemiec and C Kluck for genotyping the samples of GWAS panel A. Prof Dr T Wienker and Dr M Steffens (IMBIE, University of Bonn) are acknowledged for performing the quality control of the GWAS control data set. This study was supported by the German Ministry of Education and Research (BMBF) through the National Genome Research Network (NGFN), the popgen biobank, the Federal Radiation Protection Agency (project no. 3609S30013), the Deutsche Krebshilfe and the Madeleine Schickedanz Kinderkrebs-Stiftung. The project received infrastructure support through the DFG excellence cluster 'Inflammation at Interfaces'. This study was conducted within the frame of the International BFM Study Group.",null,41,16,16,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","MAY",2012,26,5,null,null,null,null,902,909,null,"10.1038/leu.2011.302",null,8,"Oncology; Hematology","Oncology; Hematology","940IP","WOS:000303883500006"]
[null,null,null,null,"J","Punthakee, Z; Bosch, J; Dagenais, G; Diaz, R; Holman, R; Probstfield, JL; Ramachandran, A; Riddle, MC; Ryden, LE; Zinman, B; Afzal, R; Yusuf, S; Gerstein, HC",null,null,null,"Punthakee, Z.; Bosch, J.; Dagenais, G.; Diaz, R.; Holman, R.; Probstfield, J. L.; Ramachandran, A.; Riddle, M. C.; Ryden, L. E.; Zinman, B.; Afzal, R.; Yusuf, S.; Gerstein, H. C.",null,"TIDE Trial Investigators","Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial","DIABETOLOGIA",null,null,"English","Article",null,null,null,null,null,"Cardiovascular disease; Pioglitazone; Placebo-controlled randomised trial; Rosiglitazone; Type 2 diabetes; Vitamin D","IMPAIRED GLUCOSE-TOLERANCE; INTIMA-MEDIA THICKNESS; D SUPPLEMENTATION; FASTING GLUCOSE; HEART-FAILURE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; GLYBURIDE MONOTHERAPY; MACROVASCULAR EVENTS; DIABETES-MELLITUS","Conflicting data regarding cardiovascular effects of thiazolidinediones (TZDs) and extra-skeletal effects of vitamin D supported the need for a definitive trial. The Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) trial aimed to assess the effects of TZDs (rosiglitazone and pioglitazone) on cardiovascular outcomes and the effects of vitamin D (cholecalciferol) on cancers and mortality. A large multicentre 3 x 2 factorial double-blind placebo-controlled randomised trial recruited from outpatient primary care and specialty clinics in 33 countries. From June 2009 to July 2010, 1,332 people with type 2 diabetes and other cardiovascular risk factors aged a parts per thousand yen50 years whose HbA(1c) was 6.5-9.5% (48-80 mmol/mol) when using two or fewer glucose-lowering drugs were randomised by a central computer system to placebo (n = 541), rosiglitazone 4-8 mg/day (n = 399) or pioglitazone 30-45 mg/day (n = 392); 1,221 participants were randomised to placebo (n = 614) or vitamin D 1,000 IU/day (n = 607). Participants and all study personnel were blind to treatment allocation. The primary outcome for the TZD arm was the composite of myocardial infarction, stroke or cardiovascular death, and for the vitamin D arm it was cancer or all-cause death. All randomised participants were included in the primary analysis. From the study design, 16,000 people were to be followed for approximately 5.5 years. However, the trial was stopped prematurely because of regulatory concerns after a mean of 162 days without consideration of the accrued data. In the TZD arm, the cardiovascular outcome occurred in five participants (0.9%) in the placebo groups and three participants (0.4%) in the TZD groups (two allocated to pioglitazone, one to rosiglitazone). In the vitamin D arm, the primary outcome occurred in three participants (0.5%) in the placebo group and in two participants (0.3%) receiving vitamin D. Adverse events were comparable in all groups. Uncertainty persists regarding the clinically relevant risks and benefits of TZDs and vitamin D because of the early cancellation of this comprehensive trial. ClinicalTrials.gov NCT00879970 The study was funded by GlaxoSmithKline.","[Punthakee, Z.; Bosch, J.; Afzal, R.; Yusuf, S.; Gerstein, H. C.] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; [Dagenais, G.] Quebec Univ Laval, Inst Univ Cardiol & Pneumol, Quebec City, PQ, Canada; [Diaz, R.] Inst Cardiovasc Rosario, Rosario, Santa Fe, Argentina; [Holman, R.] Oxford Ctr Diabet Oxford, Oxford, England; [Probstfield, J. L.] Univ Washington Seattle, Seattle, WA USA; [Ramachandran, A.] India Diabet Res Fdn Chennai, Madras, Tamil Nadu, India; [Riddle, M. C.] Oregon Hlth & Sci Univ Portland, Portland, OR USA; [Ryden, L. E.] Karolinska Inst Stockholm, Stockholm, Sweden; [Zinman, B.] Univ Toronto, Toronto, ON, Canada","Punthakee, Z (reprint author), McMaster Univ, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.","zubin.punthakee@mcmaster.ca","Reboldi, Gianpaolo/A-3444-2009; Gerstein, Hertzel/B-1235-2013; Zinman, Bernard/E-7266-2013","Reboldi, Gianpaolo/0000-0002-9877-0702; Gerstein, Hertzel/0000-0001-8072-2836; ","GlaxoSmithKline; Boehringer Ingelheim; sanofi-aventis; Bristol-Myers Squibb; Amylin; Bayer; Merck; Merck and Novartis; Lilly; Merck Serono; MSD; Novo Nordisk","H. C. Gerstein, S. Yusuf and Z. Punthakee's institution received funding to conduct the TIDE trial from GlaxoSmithKline, manufacturer of rosiglitazone. Z. Punthakee has received honoraria for advice and speaking from GlaxoSmithKline, Boehringer Ingelheim, Lilly, Merck Frosst, NovoNordisk and sanofi-aventis. G. Dagenais has received consulting and lecture fees from GlaxoSmithKline, Boehringer Ingelheim and sanofi-aventis and grant support from sanofi-aventis. R. Diaz has received consulting fees or honoraria and other research support from Bristol-Myers Squibb. R. Holman has received research support from Amylin, Bayer, Merck and Novartis, attended advisory boards with Amylin, Lilly, Merck, Novartis and Novo Nordisk, and given lectures supported by Bayer, Lilly, Merck and Merck Serono. A. Ramachandran has received honoraria for advice and speaking from sanofi-aventis, MSD and Lilly. M. C. Riddle has received honoraria for consulting and/or speaking from Amylin, Lilly, Novo Nordisk and sanofi-aventis, and also research grant support through his institution from Amylin, Lilly, GlaxoSmithKline and sanofi-aventis. L. E. Ryden has received honoraria for advice and lectures by AstraZeneca, Roche and Bristol-Myers Squibb. B. Zinman has received honoraria for consulting from GlaxoSmithKline and Lilly. S. Yusuf has received consulting fees from Boehringer Ingelheim, sanofi-aventis, Novartis, AstraZeneca, Bristol-Myers Squibb and GlaxoSmithKline. H. C. Gerstein has received honoraria for consulting and speaking from GlaxoSmithKline, sanofi-aventis, Lilly, Novo Nordisk, Bayer, Merck, Johnson and Johnson, Roche, Abbot and AstraZeneca. The remaining authors declare that they have no duality of interest associated with this manuscript. Funding and supply of the investigational medicines for this trial was provided by GlaxoSmithKline, the manufacturer of rosiglitazone. In collaboration with H. C. Gerstein, S. Yusuf and an international scientific committee, the sponsor GlaxoSmithKline had input to the design of the trial. The sponsor reviewed the manuscript and provided minor comments.","[Anonymous], 1991, JAMA, V265, P3255; Autier P, 2007, ARCH INTERN MED, V167, P1730, DOI 10.1001/archinte.167.16.1730; Baigent C, 2010, OXFORD TXB MED, P31; BAUCUS M, 2010, STAFF REPORT GLAXOSM; Chlebowski RT, 2008, J NATL CANCER I, V100, P1581, DOI 10.1093/jnci/djn360; Choi D, 2004, DIABETES CARE, V27, P2654, DOI 10.2337/diacare.27.11.2654; Cigolini M, 2006, DIABETES CARE, V29, P722, DOI 10.2337/diacare.29.03.06.dc05-2148; Dagenais GR, 2008, DIABETES CARE, V31, P1007, DOI 10.2337/dc07-1868; DeFronzo RA, 2011, NEW ENGL J MED, V364, P1104, DOI 10.1056/NEJMoa1010949; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; *FOOD DRUG ADM, 2011, 13 14 JUL 2010 M END; *FOOD DRUG ADM, 2010, FOOD DRUG ADM FDA DR; Foody JM, 2002, JAMA-J AM MED ASSOC, V287, P883, DOI 10.1001/jama.287.7.883; Freemantle N, 2005, BRIT MED J, V331, P836, DOI 10.1136/bmj.331.7520.836; Frye RL, 2009, NEW ENGL J MED, V360, P2503; Gerstein HC, 2010, AM HEART J, V160, P1, DOI 10.1016/j.ahj.2010.05.019; Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8; HARRIS G, 2010, NY TIMES        0219; Holick MF, 2010, ENDOCRIN METAB CLIN, V39, P381, DOI 10.1016/j.ecl.2010.02.016; Home PD, 2009, LANCET, V373, P2125, DOI 10.1016/S0140-6736(09)60953-3; Hsia J, 2007, CIRCULATION, V115, P846, DOI 10.1161/CIRCULATIONAHA.106.673491; Inzucchi SE, 2005, DIABETES CARE, V28, P1680, DOI 10.2337/diacare.28.7.1680; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; Kaul S, 2010, CIRCULATION, V121, P1868, DOI 10.1161/CIR.0b013e3181d34114; Lachin JM, 2011, CLIN J AM SOC NEPHRO, V6, P1032, DOI 10.2215/CJN.09291010; Lago RM, 2007, LANCET, V370, P1129, DOI 10.1016/S0140-6736(07)61514-1; Lappe JM, 2007, AM J CLIN NUTR, V85, P1586; Lonn EM, 2009, J AM COLL CARDIOL, V53, P2028, DOI 10.1016/j.jacc.2008.12.072; Mannucci E, 2010, INT J CARDIOL, V143, P135, DOI 10.1016/j.ijcard.2009.01.064; Masoudi FA, 2005, CIRCULATION, V111, P583, DOI 10.1161/01.CIR.0000154542.13412.B1; Mazzone T, 2006, JAMA-J AM MED ASSOC, V296, P2572, DOI 10.1001/jama.296.21.joc60158; MUNDY A, 2010, WALL STREET J   0419; Nagajothi N, 2008, AM J THER, V15, P506, DOI 10.1097/MJT.0b013e318167180c; Nissen SE, 2008, JAMA-J AM MED ASSOC, V299, P1561, DOI 10.1001/jama.299.13.1561; Phung OJ, 2010, JAMA-J AM MED ASSOC, V303, P1410, DOI 10.1001/jama.2010.405; Qayyum Rehan, 2006, J Clin Hypertens (Greenwich), V8, P19, DOI 10.1111/j.1524-6175.2005.04784.x; Riche DM, 2007, DIABETES CARE, V30, P384, DOI 10.2337/dc06-1854; Richter B, 2007, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD006063.PUB2; Richter B, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006060.pub2; Sarafidis PA, 2010, AM J KIDNEY DIS, V55, P835, DOI 10.1053/j.ajkd.2009.11.013; Scragg R, 2004, DIABETES CARE, V27, P2813, DOI 10.2337/diacare.27.12.2813; Sidhu JS, 2004, ARTERIOSCL THROM VAS, V24, P930, DOI 10.1161/01.ATV.0000124890.40436.77; Tan M, 2004, CLIN THER, V26, P680, DOI 10.1016/S0149-2918(04)90068-9; Vijay SK, 2009, ACTA DIABETOL, V46, P27, DOI 10.1007/s00592-008-0054-7; Wactawski-Wende J, 2006, NEW ENGL J MED, V354, P684, DOI 10.1056/NEJMoa055222; Wang TJ, 2008, CIRCULATION, V117, P503, DOI 10.1161/CIRCULATIONAHA.107.706127; Weykamp C, 2008, CLIN CHEM, V54, P240, DOI 10.1373/clinchem.2007.097402; Yki-Jarvinen H, 2005, LANCET, V366, P1241, DOI 10.1016/S0140-6736(05)67504-6; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421",50,12,13,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0012-186X",null,null,"DIABETOLOGIA","Diabetologia","JAN",2012,55,1,null,null,null,null,36,45,null,"10.1007/s00125-011-2357-4",null,10,"Endocrinology & Metabolism","Endocrinology & Metabolism","857SI","WOS:000297739000009"]
[null,null,null,null,"J","Lohr, JM; Haas, SL; Bechstein, WO; Bodoky, G; Cwiertka, K; Fischbach, W; Folsch, UR; Jager, D; Osinsky, D; Prausova, J; Schmidt, WE; Lutz, MP",null,null,null,"Loehr, J. M.; Haas, S. L.; Bechstein, W. -O.; Bodoky, G.; Cwiertka, K.; Fischbach, W.; Foelsch, U. R.; Jaeger, D.; Osinsky, D.; Prausova, J.; Schmidt, W. E.; Lutz, M. P.",null,"CT4001 Study Grp","Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial","ANNALS OF ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"cationic liposomes; EndoTAG (TM)-1; liposomal paclitaxel; pancreatic cancer; vascular targeting","THERAPEUTIC-EFFICACY; CHEMOTHERAPY; COMBINATION; PLACEBO; TUMORS; METAANALYSIS; LEAKINESS; CISPLATIN; ERLOTINIB; BENEFIT","Paclitaxel embedded in cationic liposomes (EndoTAG (TM)-1; ET) is an innovative agent targeting tumor endothelial cells. This randomized controlled phase II trial evaluated the safety and efficacy of ET in combination with gemcitabine (GEM) in advanced pancreatic cancer (PDAC). Chemotherapy-naive patients with locally advanced or metastatic disease were randomly assigned to receive weekly GEM 1000 mg/m(2) or GEM plus twice-weekly ET 11, 22 or 44 mg/m(2) for 7 weeks. After a safety run-in of 100 patients, a second cohort continued treatment. End points included overall survival (OS), progression-free survival (PFS), tumor response and safety. Two hundred and twelve patients were randomly allocated to the study and 200 were treated (80% metastatic, 20% locally advanced). Adverse events were manageable and reversible. Transient thrombocytopenia and infusion reactions with chills and pyrexia mostly grade 1 or 2 occurred in the ET groups. Disease control rate after the first treatment cycle was 43% with GEM and 60%, 65% and 52% in the GEM + ET cohorts. Median PFS reached 2.7 compared with 4.1, 4.6 and 4.4 months, respectively. Median OS was 6.8 compared with 8.1, 8.7 and 9.3 months, respectively. Treatment of advanced PDAC with GEM + ET was generally well tolerated. GEM + ET showed beneficial survival and efficacy. A randomized phase III trial should confirm this positive trend.","[Loehr, J. M.] Karolinska Inst, CLINTEC, Dept Surg Gastroenterol, SE-14186 Stockholm, Sweden; [Loehr, J. M.; Haas, S. L.] Univ Hosp Mannheim, Dept Med 2, Mannheim, Germany; [Bechstein, W. -O.] Univ Hosp Frankfurt, Dept Gen & Visceral Surg, Frankfurt, Germany; [Bodoky, G.] Szent Laszlo Hosp, Dept Oncol, Budapest, Hungary; [Cwiertka, K.] Univ Hosp Olomouc, Dept Oncol, Olomouc, Czech Republic; [Fischbach, W.] Klinikum Aschaffenburg, Dept Med 2, Aschaffenburg, Germany; [Foelsch, U. R.] Univ Hosp Schleswig Holstein, Dept Gen Internal Med, Kiel, Germany; [Jaeger, D.] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany; [Osinsky, D.] Inst Oncol AMS Ukraine, Kiev, Ukraine; [Prausova, J.] Univ Hosp Prague, Dept Oncol Radiotherapy, Prague, Czech Republic; [Schmidt, W. E.] Ruhr Univ Bochum, St Josef Hosp, Dept Med 1, Bochum, Germany; [Lutz, M. P.] Caritasklin St Theresia, Dept Med, Saarbrucken, Germany","Lohr, JM (reprint author), Karolinska Inst, CLINTEC, Dept Surg Gastroenterol, K53, SE-14186 Stockholm, Sweden.","matthias.lohr@ki.se",null,null,"MediGene AG, Martinsried, Germany","MediGene AG, Martinsried, Germany.","Abu Lila AS, 2010, PHARM RES-DORDR, V27, P1171, DOI 10.1007/s11095-010-0110-1; Albain KS, 2008, J CLIN ONCOL, V26, P3950, DOI 10.1200/JCO.2007.11.9362; Apte MV, 2004, PANCREAS, V29, P179, DOI 10.1097/00006676-200410000-00002; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bayraktar S, 2010, WORLD J GASTROENTERO, V16, P673, DOI 10.3748/wjg.v16.i6.673; Bramhall SR, 2002, BRIT J CANCER, V87, P161, DOI 10.1038/sj.bjc.6600446; Bria E, 2007, CANCER, V110, P525, DOI 10.1002/cncr.22809; Burris HA, 1997, J CLIN ONCOL, V15, P2403; Campbell RB, 2002, CANCER RES, V62, P6831; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Eichhorn M. E., 2004, Angiogenesis, V7, P133, DOI 10.1007/s10456-004-1428-2; Eichhorn ME, 2010, INT J CANCER, V126, P1235, DOI 10.1002/ijc.24846; Heinemann V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-82; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]; Kindler HL, 2009, EJC SUPPL, V7, P361; Kleeff J, 2007, INT J CANCER, V121, P699, DOI 10.1002/ijc.22871; Korc M, 2003, Mol Cancer, V2, P8, DOI 10.1186/1476-4598-2-8; Kosmidis P, 2002, J CLIN ONCOL, V20, P3578, DOI 10.1200/JCO.2002.12.112; Kulke MH, 2009, J CLIN ONCOL; Lam AP, 2010, AM J CLIN ONCOL-CANC, V33, P121, DOI 10.1097/COC.0b013e3181a31920; Lohr M, 2006, NAT CLIN PRACT GASTR, V3, P236, DOI 10.1038/ncpgasthep0469; Lutz MP, 2005, J CLIN ONCOL, V23, P9250, DOI 10.1200/JCO.2005.02.1980; Mahadevan D, 2007, MOL CANCER THER, V6, P1186, DOI 10.1158/1535-7163.MCT-06-0686; McDonald DM, 2002, CANCER RES, V62, P5381; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Nieto J, 2008, ONCOLOGIST, V13, P562, DOI 10.1634/theoncologist.2007-0181; O'Reilly Eileen M, 2009, Gastrointest Cancer Res, V3, pS11; Philip PA, 2007, J CLIN ONCOL, V25, P4509; Philip PA, 2009, J CLIN ONCOL, V27, P5660, DOI 10.1200/JCO.2009.21.9022; Ramanathan R, 2009, J CLIN ONCOL S, V27; Saif MW, 2010, ANTICANCER RES, V30, P2905; Saif MW, 2010, CANCER INVEST, V28, P186, DOI 10.3109/07357900903179591; Schmitt-Sody M, 2003, CLIN CANCER RES, V9, P2335; Strieth Sebastian, 2004, International Journal of Cancer, V110, P117, DOI 10.1002/ijc.20083; Strieth S, 2008, CLIN CANCER RES, V14, P4603, DOI 10.1158/1078-0432.CCR-07-4738; Sultana A, 2007, J CLIN ONCOL, V25, P2607, DOI 10.1200/JCO.2006.09.2551; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Thurston G, 1998, J CLIN INVEST, V101, P1401, DOI 10.1172/JCI965; Van Cutsem E, 2009, J CLIN ONCOL, V27, P2231, DOI 10.1200/JCO.2008.20.0238; Van Cutsem E, 2004, J CLIN ONCOL, V22, P1430, DOI 10.1200/JCO.2004.10.112",42,11,12,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0923-7534",null,null,"ANN ONCOL","Ann. Oncol.","MAY",2012,23,5,null,null,null,null,1214,1222,null,"10.1093/annonc/mdr379",null,9,"Oncology","Oncology","933CH","WOS:000303336400019"]
[null,null,null,null,"J","Inthal, A; Zeitlhofer, P; Zeginigg, M; Morak, M; Grausenburger, R; Fronkova, E; Fahrner, B; Mann, G; Haas, OA; Panzer-Grumayer, R",null,null,null,"Inthal, A.; Zeitlhofer, P.; Zeginigg, M.; Morak, M.; Grausenburger, R.; Fronkova, E.; Fahrner, B.; Mann, G.; Haas, O. A.; Panzer-Gruemayer, R.",null,null,"CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"childhood ALL; relapse leukemia; high hyperdiploid karyotype; CREBBP; SNP","MINIMAL RESIDUAL DISEASE; AIEOP-BFM; LANDSCAPE; ORIGINS","Despite their apparently good prognosis B15% of high hyperdiploid (HD) childhood acute lymphoblastic leukemia (ALL) cases relapse. To search for responsible risk factors we determined copy number aberrations as well as copy neutral loss of heterozygosity (LOH) in 13 matched diagnosis and relapse samples and added the data of the only three available cases from the literature. Deletions and copy neutral LOH in 3 and 2 of the 16 cases directed us to the histone-modifying CREB-binding protein (CREBBP) gene, whose functional impairment is implicated in drug resistance. We therefore screened all samples for mutations in this gene and discovered 9 acquired sequence mutations in 7/16 cases, leading to an overall frequency of somatic CREBBP aberrations in HD ALL relapse cases of 63% that is considerably higher than that of the reported, mainly non-HD ALL (18.3%). Moreover, mutations in HD cases occur almost exclusively in the HAT domain (8/9; 89%). Hot spot mutations are present at diagnosis in 18.8% of relapsing HD ALL cases but in none of 40 respective cases remaining in long-term remission. Thus, the particular high incidence of CREBBP mutations in relapse-prone HD ALL cases could eventually be exploited for refined risk stratification and customized treatment in this genetic subgroup.","[Panzer-Gruemayer, R.] Childrens Canc Res Inst, Leukemia Biol Grp, A-1090 Vienna, Austria; [Zeitlhofer, P.; Haas, O. A.] Medgen At GmbH, Diagnost Lab, Vienna, Austria; [Fronkova, E.] Charles Univ Prague, Mol Genet Lab, Dept Pediat Haematol Oncol, Sch Med 2, Prague, Czech Republic; [Fahrner, B.; Mann, G.; Haas, O. A.; Panzer-Gruemayer, R.] Med Univ Vienna, Dept Pediat, St Anna Kinderspital, Vienna, Austria","Panzer-Grumayer, R (reprint author), Childrens Canc Res Inst, Leukemia Biol Grp, Zimmermannpl 10, A-1090 Vienna, Austria.","renate.panzer@ccri.at",null,null,"Austrian National Bank [ONB 12519, 13881]; Austrian Science Fund [P18046-B12, FWF P 22073-B19]; St Anna Kinderkrebsforschung","We thank the patients and their parents as well as physicians involved in this study, Andishe Attarbaschi for providing clinical data and Marion Zavadil for proofreading. This study is supported in part by Grants from the Austrian National Bank (ONB 12519 and 13881) to GM, Grant P18046-B12 of the Austrian Science Fund (FWF P 22073-B19) and the St Anna Kinderkrebsforschung to RP-G.",null,26,11,11,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","AUG",2012,26,8,null,null,null,null,1797,1803,null,"10.1038/leu.2012.60",null,7,"Oncology; Hematology","Oncology; Hematology","990RW","WOS:000307650000007"]
[null,null,null,null,"J","Pagel, J; Beutel, K; Lehmberg, K; Koch, F; Maul-Pavicic, A; Rohlfs, AK; Al-Jefri, A; Beier, R; Ousager, LB; Ehlert, K; Gross-Wieltsch, U; Jorch, N; Kremens, B; Pekrun, A; Sparber-Sauer, M; Mejstrikova, E; Wawer, A; Ehl, S; zur Stadt, U; Janka, G",null,null,null,"Pagel, Julia; Beutel, Karin; Lehmberg, Kai; Koch, Florian; Maul-Pavicic, Andrea; Rohlfs, Anna-Katharina; Al-Jefri, Abdullah; Beier, Rita; Ousager, Lilian Bomme; Ehlert, Karoline; Gross-Wieltsch, Ute; Jorch, Norbert; Kremens, Bernhard; Pekrun, Arnulf; Sparber-Sauer, Monika; Mejstrikova, Ester; Wawer, Angela; Ehl, Stephan; zur Stadt, Udo; Janka, Gritta",null,null,"Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5)","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"LINKED LYMPHOPROLIFERATIVE DISEASE; SENSORINEURAL HEARING-LOSS; EPITHELIAL-CELLS; PRIMARY IMMUNODEFICIENCY; GENOTYPE-PHENOTYPE; GRANULE EXOCYTOSIS; XIAP DEFICIENCY; PERFORIN GENE; SYNTAXIN 3; CHILDREN","Familial hemophagocytic lymphohistiocytosis (FHL) is a genetically determined hyperinflammatory syndrome caused by uncontrolled immune response mediated by T-lymphocytes, natural killer (NK) cells, and macrophages. STXBP2 mutations have recently been associated with FHL5. To better characterize the genetic and clinical spectrum of FHL5, we analyzed a cohort of 185 patients with suspected FHL for mutations in STXBP2. We detected biallelic mutations in 37 patients from 28 families of various ethnic origins. Missense mutations and mutations affecting 1 of the exon 15 splice sites were the predominant changes detectable in this cohort. Patients with exon 15 splice-site mutations (n = 13) developed clinical manifestations significantly later than patients with other mutations (median age, 4.1 year vs 2 months) and showed less severe impairment of degranulation and cytotoxic function of NK cells and CTLs. Patients with FHL5 showed several atypical features, including sensorineural hearing deficit, abnormal bleeding, and, most frequently, severe diarrhea that was only present in early-onset disease. In conclusion, we report the largest cohort of patients with FHL5 so far, describe an extended disease spectrum, and demonstrate for the first time a clear genotype-phenotype correlation. (Blood. 2012; 119(25): 6016-6024)","[Beutel, Karin; Lehmberg, Kai; Janka, Gritta] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, D-20246 Hamburg, Germany; [Pagel, Julia; Koch, Florian; zur Stadt, Udo] Childrens Canc Ctr, Res Inst, Hamburg, Germany; [Beutel, Karin; Ehlert, Karoline] Univ Childrens Hosp Munster, Munster, Germany; [Maul-Pavicic, Andrea; Ehl, Stephan] Univ Freiburg, Ctr Chron Immunodeficiency, D-79106 Freiburg, Germany; [Rohlfs, Anna-Katharina] Univ Med Ctr Hamburg Eppendorf, Dept Voice Speech & Hearing Disorders, D-20246 Hamburg, Germany; [Al-Jefri, Abdullah] King Faisal Specialist Hosp & Res Ctr, Sect Pediat Stem Cell Transplantat, Dept Pediat Hematol Oncol, Riyadh 11211, Saudi Arabia; [Beier, Rita] Hannover Med Sch, Dept Pediat Hematol & Oncol, D-3000 Hannover, Germany; [Ousager, Lilian Bomme] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense, Denmark; [Gross-Wieltsch, Ute] Olga Hosp, Klinikum Stuttgart, Stuttgart, Germany; [Jorch, Norbert] Gilead Childrens Hosp, Bielefeld, Germany; [Kremens, Bernhard] Univ Essen Gesamthsch, Essen, Germany; [Pekrun, Arnulf] Prof Hess Childrens Hosp, Bremen, Germany; [Sparber-Sauer, Monika] Univ Ulm, Dept Pediat, D-7900 Ulm, Germany; [Mejstrikova, Ester] Charles Univ Prague, Dept Pediat Hematol & Oncol, Teaching Hosp Motol, Prague, Czech Republic; [Mejstrikova, Ester] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Wawer, Angela] Tech Univ Munich, Dept Pediat, Munich, Germany; [zur Stadt, Udo] Univ Med Ctr Hamburg Eppendorf, Ctr Diagnost, D-20246 Hamburg, Germany","Janka, G (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Martinistr 52, D-20246 Hamburg, Germany.","janka@uke.uni-hamburg.de",null,null,"Bundesministerium fur Bildung und Forschung (BMBF) [BMBF 01 EO 0803]; European Union (EU) [HEALTH-F2-2008-201461]; Fordergemeinschaft Kinder-Krebs-Zentrum Hamburg e.V","This work was supported by grants from the Bundesministerium fur Bildung und Forschung (BMBF; grant BMBF 01 EO 0803, S. E.), the European Union (EU FP7 grant agreement HEALTH-F2-2008-201461), and Fordergemeinschaft Kinder-Krebs-Zentrum Hamburg e.V.",null,45,9,9,"AMER SOC HEMATOLOGY","WASHINGTON","2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","JUN 21",2012,119,25,null,null,null,null,6016,6024,null,"10.1182/blood-2011-12-398958",null,9,"Hematology","Hematology","987EG","WOS:000307398700016"]
[null,null,null,null,"J","Strippoli, MPF; Frischer, T; Barbato, A; Snijders, D; Maurer, E; Lucas, JSA; Eber, E; Karadag, B; Pohunek, P; Zivkovic, Z; Escribano, A; O'Callaghan, C; Bush, A; Kuehni, CE",null,null,null,"Strippoli, Marie-Pierre F.; Frischer, Thomas; Barbato, Angelo; Snijders, Deborah; Maurer, Elisabeth; Lucas, Jane S. A.; Eber, Ernst; Karadag, Bulent; Pohunek, Petr; Zivkovic, Zorica; Escribano, Amparo; O'Callaghan, Chris; Bush, Andrew; Kuehni, Claudia E.",null,"ERS Task Force Primary Ciliary","Management of primary ciliary dyskinesia in European children: recommendations and clinical practice","EUROPEAN RESPIRATORY JOURNAL",null,null,"English","Article",null,null,null,null,null,"Bronchiectasis; ciliary motility disorders; diagnosis; Kartagener syndrome; primary ciliary dyskinesia; therapy","MUTATIONS; DIAGNOSIS; STATE; CARE","The European Respiratory Society Task Force on primary ciliary dyskinesia (PCD) in children recently published recommendations for diagnosis and management. This paper compares these recommendations with current clinical practice in Europe. Questionnaires were returned by 194 paediatric respiratory centres caring for PCD patients in 26 countries. In most countries, PCD care was not centralised, with a median (interquartile range) of 4 (2-9) patients treated per centre. Overall, 90% of centres had access to nasal or bronchial mucosa! biopsy. Samples were analysed by electron microscopy (77%) and ciliary function tests (57%). Nasal nitric oxide was used for screening in 46% of centres and saccharine tests in 36%. Treatment approaches varied widely, both within and between countries. European region, size of centre and the country's general government expenditure on health partly defined availability of advanced diagnostic tests and choice of treatments. In conclusion, we found substantial heterogeneity in management of PCD within and between countries, and poor concordance with current recommendations. This demonstrates how essential it is to standardise management and decrease inequality between countries. Our results also demonstrate the urgent need for research: to simplify PCD diagnosis, to understand the natural history and to test the effectiveness of interventions.","[Strippoli, Marie-Pierre F.; Maurer, Elisabeth; Kuehni, Claudia E.] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Frischer, Thomas] Univ Klin Kinder & Jugendheilkunde, Vienna, Austria; [Barbato, Angelo; Snijders, Deborah] Univ Padua, Dept Paediat, Padua, Italy; [Lucas, Jane S. A.] Univ Southampton, Sch Med, Div Infect Inflammat & Immun, NIHR Resp Res Unit, Southampton, Hants, England; [Eber, Ernst] Med Univ Graz, Dept Paediat & Adolescence Med, Graz, Austria; [Karadag, Bulent] Marmara Univ, Div Paediat Pulmonol, Istanbul, Turkey; [Pohunek, Petr] Univ Hosp Motol, Div Resp Dis, Dept Paediat, Prague, Czech Republic; [Zivkovic, Zorica] European Univ, Childrens Hosp Lung Dis & TB, Med Ctr Dr Dragisa Misov, Belgrade, Serbia; [Zivkovic, Zorica] European Univ, US Med Sch, Belgrade, Serbia; [Escribano, Amparo] Univ Valencia, Paediat Pulmonol Unit, Univ Clin Hosp, Valencia, Spain; [O'Callaghan, Chris] UCL, Portex Unit, Inst Child Hlth, London, England; [O'Callaghan, Chris] Great Ormond St Hosp Sick Children, London, England; [Bush, Andrew] Royal Brompton Hosp, Dept Paediat Resp Med, London SW3 6LY, England","Kuehni, CE (reprint author), Univ Bern, Inst Social & Prevent Med, Finkenhubelweg 11, CH-3012 Bern, Switzerland.","kuehni@ispm.unibe.ch","Lucas, Jane/C-3620-2013; Strippoli, Marie-Pierre/K-8164-2013","Strippoli, Marie-Pierre/0000-0003-3053-484X","Swiss National Science Foundation (PROSPER) [3233-069348, 3200-069349, SNF 3200B0-122341]; Ministry of Health (Czech Republic) [MZ0FNM2005]; Ministry of Science, Serbia [41004]","The European Respiratory Society has financially supported meetings of the Primary Ciliary Dyskinesia Task Force. This paper is not considered part of the official task force report; the full, official report has previously been published in the European Respiratory Journal (Fur Respir J 2009; 34: 1264-1276). C.E. Kuehni and M-P.F. Strippoli were funded by the Swiss National Science Foundation (PROSPER grants 3233-069348 and 3200-069349, SNF 3200B0-122341). Local data collection in the Czech Republic was supported by a research project of the Ministry of Health (Czech Republic; no. MZ0FNM2005). This work was supported by the Ministry of Science, Serbia (grant no. 41004).",null,21,7,7,"EUROPEAN RESPIRATORY SOC JOURNALS LTD","SHEFFIELD","442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND","0903-1936",null,null,"EUR RESPIR J","Eur. Resp. J.","JUN",2012,39,6,null,null,null,null,1482,1491,null,"10.1183/09031936.00073911",null,10,"Respiratory System","Respiratory System","960ED","WOS:000305369900030"]
[null,null,null,null,"J","Creutzig, U; Zimmermann, M; Bourquin, JP; Dworzak, MN; Kremens, B; Lehrnbecher, T; von Neuhoff, C; Sander, A; von Stackelberg, A; Schmid, I; Stary, J; Steinbach, D; Vormoor, J; Reinhardt, D",null,null,null,"Creutzig, U.; Zimmermann, M.; Bourquin, J-P; Dworzak, M. N.; Kremens, B.; Lehrnbecher, T.; von Neuhoff, C.; Sander, A.; von Stackelberg, A.; Schmid, I.; Stary, J.; Steinbach, D.; Vormoor, J.; Reinhardt, D.",null,null,"Favorable outcome in infants with AML after intensive first- nd second-line treatment: an AML-BFM study group report","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"acute myeloid leukemia; infants; children; treatment","ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; CELL TRANSPLANTATION; PEDIATRIC-PATIENTS; CNS-IRRADIATION; CHILDREN; THERAPY; TRIALS; CHEMOTHERAPY","Infants <1 year of age have a high prevalence of prognostically unfavorable leukemias and a presumed susceptibility to treatment-related toxicities. A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n = 59) and -2004 (n = 66). Treatment regimens of both studies were comparable, consisting of intensive induction followed by four courses (mainly high-dose cytarabine and anthracyclines). Allogeneic-hematopoietic stem-cell-transplantation (allo-HSCT) in 1st remission was optional for high-risk (HR) patients. Most infants (120/125 = 96%) were HR patients according to morphological, cytogenetic/molecular genetic and response criteria. Five-year overall survival was 66 +/- 4%, and improved from 61 +/- 6% in study-98 to 75 +/- 6% in study-2004 (P-logrank 0.14) and event-free survival rates were 44 +/- 6% and 51 +/- 6% (P-logrank 0.66), respectively. Results in HR infants were similar to those of older HR children (1-<2- or 2-<10-year olds, P-logrank 0.90 for survival). Survival rates of HSCT in 1st remission, initial partial response and after relapse were high (13/14, 2/8 and 20/30 patients, respectively). The latter contributes to excellent 5-year survival after relapse (50 +/- 8%). Despite more severe infections and pulmonary toxicities in infants, treatment-related death rate was identical to that of older children (3%). Our data indicate that intensive frontline and relapse AML treatment is feasible in infants, toxicities are manageable, and outcome is favorable. Leukemia (2012) 26, 654-661; doi:10.1038/leu.2011.267; published online 4 October 2011","[Creutzig, U.] Univ Hosp Munster, Klin & Poliklin Kinderheilkunde Pediat Hematol &, D-48149 Munster, Germany; [Creutzig, U.; Zimmermann, M.; von Neuhoff, C.; Sander, A.; Reinhardt, D.] Hannover Med Sch, D-3000 Hannover, Germany; [Bourquin, J-P] Univ Zurich, Zurich, Switzerland; [Dworzak, M. N.] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Kremens, B.] Univ Essen Gesamthsch, Essen, Germany; [Lehrnbecher, T.] Goethe Univ Frankfurt, Frankfurt, Germany; [von Stackelberg, A.] Charite, D-13353 Berlin, Germany; [Schmid, I.] Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; [Stary, J.] Charles Univ Prague, Prague, Czech Republic; [Stary, J.] Czech Pediat Hematol Working Grp CPH, Prague, Czech Republic; [Steinbach, D.] Univ Hosp Ulm, Ulm, Germany; [Vormoor, J.] Newcastle Univ, Newcastle Canc Ctr, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England","Creutzig, U (reprint author), Univ Childrens Hosp Munster, Klin & Poliklin Kinderheilkunde Pediat Hematol &, Albert Schweitzer Campus 1, D-48149 Munster, Germany.","ursula@creutzig.de","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Deutsche Krebshilfe e.V.; Czech Ministry of Education [MSM0021620813]","We thank the colleagues, data managers and technicians of the participating hospitals for their valuable cooperation, Jans-Enno Muller for competent data management and Ursula Bernsmann for her help in preparing the manuscript. The studies were supported by the Deutsche Krebshilfe e.V. and partly by grant from the Czech Ministry of Education (MSM0021620813).",null,36,5,6,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","APR",2012,26,4,null,null,null,null,654,661,null,"10.1038/leu.2011.267",null,8,"Oncology; Hematology","Oncology; Hematology","925UX","WOS:000302788300011"]
[null,null,null,null,"J","Luesink, M; Hollink, IHIM; van der Velden, VHJ; Knops, RHJN; Boezeman, JBM; de Haas, V; Trka, J; Baruchel, A; Reinhardt, D; van der Reijden, BA; van den Heuvel-Eibrink, MM; Zwaan, CM; Jansen, JH",null,null,null,"Luesink, Maaike; Hollink, Iris H. I. M.; van der Velden, Vincent H. J.; Knops, Ruth H. J. N.; Boezeman, Jan B. M.; de Haas, Valerie; Trka, Jan; Baruchel, Andre; Reinhardt, Dirk; van der Reijden, Bert A.; van den Heuvel-Eibrink, Marry M.; Zwaan, C. Michel; Jansen, Joop H.",null,null,"High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"FAMILIAL MYELODYSPLASTIC SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION FACTOR GATA-2; MINIMAL RESIDUAL DISEASE; HUMAN HEMATOPOIETIC STEM; GENE-EXPRESSION; ERYTHROID-DIFFERENTIATION; CLINICAL-SIGNIFICANCE; MONOMAC SYNDROME; WT1 EXPRESSION","In acute myeloid leukemia (AML), aberrant expression and mutations of transcription factors have been correlated with disease outcome. In the present study, we performed expression and mutation screening of GATA2, which is an essential transcription factor for regulation of myeloid lineage determination, in de novo pediatric AML patients. GATA2 mutations were detected in 5 of 230 patients, representing a frequency of 2.2% overall and 9.8% in cytogenetically normal AML. GATA2 expression analysis demonstrated that in 155 of 237 diagnostic samples (65%), GATA2 expression was higher than in normal BM. In complete remission, normalization of GATA2 expression was observed, whereas GATA2 expression levels stayed high in patients with resistant disease. High GATA2 expression at diagnosis was an independent poor prognostic factor for overall survival (hazard ratio [HR] = 1.7, P = .045), event-free survival (HR = 2.1, P = .002), and disease-free survival (HR = 2.3, P = .004). The prognostic impact of GATA2 was particularly evident in specific AML subgroups. In patients with French-American-British M5 morphology, inv(16), or high WT1 expression, significant differences in survival were observed between patients with high versus normal GATA2 expression. We conclude that high GATA2 expression is a novel poor prognostic marker in pediatric AML, which may contribute to better risk-group stratification and risk-adapted therapy in the future. (Blood. 2012; 120(10):2064-2075)","[Luesink, Maaike; Knops, Ruth H. J. N.; Boezeman, Jan B. M.; van der Reijden, Bert A.; Jansen, Joop H.] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Hematol Lab, NL-6525 GA Nijmegen, Netherlands; [Luesink, Maaike; Knops, Ruth H. J. N.; Boezeman, Jan B. M.; van der Reijden, Bert A.; Jansen, Joop H.] Nijmegen Ctr Mol Life Sci, Nijmegen, Netherlands; [Hollink, Iris H. I. M.; van den Heuvel-Eibrink, Marry M.; Zwaan, C. Michel] Sophia Childrens Univ Hosp, Erasmus Med Ctr MC, Rotterdam, Netherlands; [van der Velden, Vincent H. J.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [de Haas, Valerie] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Trka, Jan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Baruchel, Andre] Hop St Louis, Paris, France; [Reinhardt, Dirk] Hannover Med Sch, Acute Myeloid Leukemia Berlin Frankfurt Munster S, D-3000 Hannover, Germany","Jansen, JH (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Hematol Lab, Geert Grootepl 8, NL-6525 GA Nijmegen, Netherlands.","j.jansen@labgk.umcn.nl","Reinhardt, Dirk/D-3939-2011; van der Reijden, Bert/A-3543-2014","Reinhardt, Dirk/0000-0003-4313-9056; ","Dutch Children Cancerfree Foundation (KiKa) [70]","This study was supported by The Dutch Children Cancerfree Foundation (KiKa; grant 70 to V.H.J.v.d.V.).",null,52,5,5,"AMER SOC HEMATOLOGY","WASHINGTON","2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","SEP 6",2012,120,10,null,null,null,null,2064,2075,null,"10.1182/blood-2011-12-397083",null,12,"Hematology","Hematology","009RU","WOS:000309043700017"]
[null,null,null,null,"J","Dekking, EHA; van der Velden, VHJ; Varro, R; Wai, H; Bottcher, S; Kneba, M; Sonneveld, E; Koning, A; Boeckx, N; Van Poecke, N; Lucio, P; Mendonca, A; Sedek, L; Szczepanski, T; Kalina, T; Kanderova, V; Hoogeveen, P; Flores-Montero, J; Chillon, MC; Orfao, A; Almeida, J; Evans, P; Cullen, M; Noordijk, AL; Vermeulen, PM; de Man, MT; Dixon, EP; Comans-Bitter, WM; van Dongen, JJM",null,null,null,"Dekking, E. H. A.; van der Velden, V. H. J.; Varro, R.; Wai, H.; Boettcher, S.; Kneba, M.; Sonneveld, E.; Koning, A.; Boeckx, N.; Van Poecke, N.; Lucio, P.; Mendonca, A.; Sedek, L.; Szczepanski, T.; Kalina, T.; Kanderova, V.; Hoogeveen, P.; Flores-Montero, J.; Chillon, M. C.; Orfao, A.; Almeida, J.; Evans, P.; Cullen, M.; Noordijk, A. L.; Vermeulen, P. M.; de Man, M. T.; Dixon, E. P.; Comans-Bitter, W. M.; van Dongen, J. J. M.",null,"EuroFlow Consortium EU-FP6 LSHB-CT","Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"PML-RARA protein; t(15;17); APL; immunobead; flow cytometry","RESIDUAL DISEASE DETECTION; MONOCLONAL-ANTIBODY PG-M3; POLYMERASE-CHAIN-REACTION; GENE TRANSCRIPTS; CANCER PROGRAM; VARIANT; ALPHA; TRANSLOCATIONS; EUROPE; PLZF","The PML-RARA fusion protein is found in approximately 97% of patients with acute promyelocytic leukemia (APL). APL can be associated with life-threatening bleeding complications when undiagnosed and not treated expeditiously. The PML-RARA fusion protein arrests maturation of myeloid cells at the promyelocytic stage, leading to the accumulation of neoplastic promyelocytes. Complete remission can be obtained by treatment with all-trans-retinoic acid (ATRA) in combination with chemotherapy. Diagnosis of APL is based on the detection of t(15; 17) by karyotyping, fluorescence in situ hybridization or PCR. These techniques are laborious and demand specialized laboratories. We developed a fast (performed within 4-5 h) and sensitive (detection of at least 10% malignant cells in normal background) flow cytometric immunobead assay for the detection of PML-RARA fusion proteins in cell lysates using a bead-bound anti-RARA capture antibody and a phycoerythrin-conjugated anti-PML detection antibody. Testing of 163 newly diagnosed patients (including 46 APL cases) with the PML-RARA immunobead assay showed full concordance with the PML-RARA PCR results. As the applied antibodies recognize outer domains of the fusion protein, the assay appeared to work independently of the PML gene break point region. Importantly, the assay can be used in parallel with routine immunophenotyping for fast and easy diagnosis of APL.","[Dekking, E. H. A.; van der Velden, V. H. J.; Hoogeveen, P.; Noordijk, A. L.; Vermeulen, P. M.; de Man, M. T.; Comans-Bitter, W. M.; van Dongen, J. J. M.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, NL-3015 GE Rotterdam, Netherlands; [Dekking, E. H. A.; Noordijk, A. L.; Vermeulen, P. M.; de Man, M. T.] Dynomics, Rotterdam, Netherlands; [Varro, R.; Wai, H.] BD Biosci, San Jose, CA USA; [Boettcher, S.; Kneba, M.] Univ Klin Schleswig Holstein, Dept Med 2, Kiel, Germany; [Sonneveld, E.; Koning, A.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Boeckx, N.; Van Poecke, N.] Univ Hosp Leuven, Dept Lab Med, Louvain, Belgium; [Lucio, P.; Mendonca, A.] Inst Portugues Oncol Francisco Gentil, Dept Hematol, Lisbon, Portugal; [Sedek, L.; Szczepanski, T.] Med Univ Silesia, Dept Pediat Hematol & Oncol, Zabrze, Poland; [Kalina, T.; Kanderova, V.] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Flores-Montero, J.; Chillon, M. C.; Orfao, A.; Almeida, J.] Univ Salamanca, Canc Res Ctr IBMCC CSIC USAL, Dept Med, E-37008 Salamanca, Spain; [Flores-Montero, J.; Chillon, M. C.; Orfao, A.; Almeida, J.] Univ Salamanca, Cytometry Serv, E-37008 Salamanca, Spain; [Evans, P.; Cullen, M.] St James Univ Hosp, Haematol Malignancy Diagnost Serv, Leeds LS9 7TF, W Yorkshire, England; [Dixon, E. P.] BD Diagnost, Durham, NC USA","van Dongen, JJM (reprint author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.","j.j.m.vandongen@erasmusmc.nl",null,null,"European Commission [STREP EU-FP6, LSHB-CT-2006-018708]","The research and development of the flow cytometric immunobead assay and the EuroFlow Consortium were supported by the European Commission (grant STREP EU-FP6, LSHB-CT-2006-018708; Flow cytometry for fast and sensitive diagnosis and follow-up of hematological malignancies). We are grateful to Dr Jean-Luc Sanne of the European Commission for his support and monitoring of the EuroFlow project. We thank Dr P Valk (Department of Hematology, Erasmus MC, Rotterdam) for providing extra APL samples. We thank Dr Charlene Bush-Donovan, Dr Frans Nauwelaers, Dr Mark Herberger and Dr Vera Imper (BD Biosciences) for their technical support in the design and production of the prototype PML-RARA immunobead assay.",null,26,3,3,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","SEP",2012,26,9,null,null,null,null,1976,1985,null,"10.1038/leu.2012.125",null,10,"Oncology; Hematology","Oncology; Hematology","999VK","WOS:000308342900003"]
[null,null,null,null,"J","Patel, K; Akhter, J; Kobrynski, L; Gathman, B; Davis, O; Sullivan, KE",null,null,null,"Patel, Kiran; Akhter, Javeed; Kobrynski, Lisa; Gathman, Benjamin; Davis, Onika; Sullivan, Kathleen E.",null,"Int DiGeorge Syndrome","Immunoglobulin Deficiencies: The B-Lymphocyte Side of DiGeorge Syndrome","JOURNAL OF PEDIATRICS",null,null,"English","Article",null,null,null,null,null,null,"22Q11.2 DELETION SYNDROME; SYNDROME VELOCARDIOFACIAL SYNDROME; T-CELL PRODUCTION","DiGeorge syndrome is associated with a T-lymphocyte immunodeficiency. The prevalence of hypogammaglobulinemia has not been reported. We found that 3% of patients with DiGeorge syndrome were receiving immunoglobulin replacement therapy and 6% of patients over the age of 3 years had hypogammaglobulinemia. We conclude that DiGeorge syndrome is associated with significant humoral immune deficiency. (J Pediatr 2012;161:950-3).","[Patel, Kiran; Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Div Allergy Immunol, Dept Pediat, Philadelphia, PA 19104 USA; [Akhter, Javeed] Advocate Christ Med Ctr, Div Pediat Pulmonol, Oak Lawn, IL USA; [Kobrynski, Lisa] Emory Childrens Ctr, Div Allergy Immunol, Atlanta, GA USA; [Gathman, Benjamin] Univ Freiburg, D-79106 Freiburg, Germany; [Gathman, Benjamin] Univ Med Ctr Freiburg, European Soc Immunodeficiencies Registry Working, Freiburg, Germany; [Davis, Onika] US Immunodeficiency Network Registry, Towson, MD USA","Sullivan, KE (reprint author), Childrens Hosp Philadelphia, Div Allergy Immunol, Dept Pediat, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.","sullivak@mail.med.upenn.edu",null,null,null,null,"Boyle M, 2008, PHARM POLICY LAW, V10, P133; Chien Yin-Hsiu, 2002, Journal of Microbiology Immunology and Infection, V35, P187; DiGeorge AM, 1968, BIRTH DEFECTS OAS, V4, P116; DiGeorge AM, 1965, J PEDIATR, V67, P907; Finocchi A, 2006, PEDIATR ALLERGY IMMU, V17, P382, DOI 10.1111/j.1399-3038.2006.00409.x; Gennery AR, 2002, ARCH DIS CHILD, V86, P422, DOI 10.1136/adc.86.6.422; JOLLIFF CR, 1982, CLIN CHEM, V28, P126; JUNKER AK, 1995, J PEDIATR, V127, P231, DOI 10.1016/S0022-3476(95)70300-4; MacLeish S, 2006, J ALLERGY CLIN IMMUN, V117, pS174, DOI 10.1016/j.jaci.2005.12.693; McLean-Tooke A, 2008, J ALLERGY CLIN IMMUN, V122; Smith CA, 1998, CLIN DIAGN LAB IMMUN, V5, P415; Sullivan KE, 1998, CLIN IMMUNOL IMMUNOP, V86, P141, DOI 10.1006/clin.1997.4463; Sullivan KE, 2002, CLIN DIAGN LAB IMMUN, V9, P1129, DOI 10.1128/CDLI.9.5.1129-1131.2002; Sullivan KE, 1999, CLIN DIAGN LAB IMMUN, V6, P906; Zemble R, 2010, CLIN IMMUNOL, V136, P409, DOI 10.1016/j.clim.2010.04.011",15,2,2,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0022-3476",null,null,"J PEDIATR-US","J. Pediatr.","NOV",2012,161,5,null,null,null,null,950,"+",null,"10.1016/j.jpeds.2012.06.018",null,5,"Pediatrics","Pediatrics","027RJ","WOS:000310370600037"]
[null,null,null,null,"J","Kacerovska, D; Kerl, K; Michal, M; Filipova, H; Vrtel, R; Vanecek, T; Zelenakova, H; Kraus, J; Kodet, R; Kazakov, DV",null,null,null,"Kacerovska, Denisa; Kerl, Katrin; Michal, Michal; Filipova, Hana; Vrtel, Radek; Vanecek, Tomas; Zelenakova, Hana; Kraus, Jaroslav; Kodet, Roman; Kazakov, Dmitry V.",null,null,"Giant angiofibromas in tuberous sclerosis complex: A possible role for localized lymphedema in their pathogenesis","JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY",null,null,"English","Article",null,null,null,null,null,"adenoma sebaceum; elephantiasis; fibrous papule; giant angiofibroma; localized lymphedema; tuberous sclerosis complex","OF-THE-LITERATURE; PAGETOID DYSKERATOSIS; DIAGNOSTIC-CRITERIA; ADENOMA SEBACEUM; CONSENSUS CONFERENCE; TSC1; ASSOCIATION; GENE; IDENTIFICATION; ELEPHANTIASIS","Background: Giant angiofibromas in patients with tuberous sclerosis complex (TSC) are rare. Objective: We sought to report two patients who had TSC with unusually large and disfiguring facial angiofibromas and to identify underlying histopathologic changes that may possibly explain the clinical features. Methods: We performed a clinicopathologic, immunohistochemical, and molecular biologic study using 42 lesional specimens and peripheral blood from one of the two patients. The immunohistochemical investigations were mainly focused on the vascular moiety of the lesions. TSC1 and TSC2 alterations were studied using multiplex ligation-dependent probe amplification for large deletion/duplication mutations, whereas screening for small mutations was performed using polymerase chain reaction amplification of individual coding exons and exon-intron junctions of both genes followed by an analysis on denaturation gradient gel electrophoresis. Results: Histopathologic examination revealed, in addition to findings typical of angiofibroma, several unusual features including multinucleated giant cells containing multiple intracytoplasmic vacuoles, Touton-like cells, emperipolesis, pagetoid dyskeratosis, vacuolar alteration at the dermoepidermal junction, Civatte bodies, and melanophages in the subjacent dermis. Numerous dilated lymphatic vessels were detected indicating localized lymphostasis, probably caused by secondary lymphedema. The lymphatic nature of the vessels was confirmed by immunohistochemical study. Genetic testing for TSC1 and TSC2 gene mutations revealed a substitution on position c.2251C>T resulting in a nonsense mutation R751X in fragment 20.2. Limitations: Histopathologic specimens and peripheral blood were available from only one patient. Conclusion: Localized lymphedema may contribute to the formation of large disfiguring angiofibromas in patients with TSC. (J Am Acad Dermatol 2012; 67:1319-26.)","[Kacerovska, Denisa; Michal, Michal; Vanecek, Tomas; Kazakov, Dmitry V.] Charles Univ Prague, Fac Med Pilsen, Sikls Dept Pathol, Prague, Czech Republic; [Kacerovska, Denisa; Michal, Michal; Vanecek, Tomas; Kazakov, Dmitry V.] Biopt Lab, Plzen, Czech Republic; [Kerl, Katrin] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; [Filipova, Hana; Vrtel, Radek] Univ Hosp, Dept Clin Genet & Fetal Med, Olomouc, Czech Republic; [Zelenakova, Hana] Diagnost Inst Social Care, Tloskov, Spain; [Kraus, Jaroslav] Hosp Benesov, Dept Otorhinolaryngol, Benesov, Czech Republic; [Kodet, Roman] Fac Med 2, Inst Pathol & Mol Med, Prague, Czech Republic; [Kodet, Roman] Teachers Hosp, Prague, Czech Republic","Kazakov, DV (reprint author), Charles Univ Prague, Med Fac Hosp, Sikls Dept Pathol, Alej Svobody 80, Plzen 30460, Czech Republic.","kazakov@medima.cz",null,null,null,null,null,48,0,0,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0190-9622",null,null,"J AM ACAD DERMATOL","J. Am. Acad. Dermatol.","DEC",2012,67,6,null,null,null,null,1319,1326,null,"10.1016/j.jaad.2012.03.021",null,8,"Dermatology","Dermatology","051ML","WOS:000312131200058"]
[null,null,null,null,"J","Styczynski, J; Balduzzi, A; Gil, L; Labopin, M; Hamladji, RM; Marktel, S; Yesilipek, MA; Fagioli, F; Ehlert, K; Matulova, M; Dalle, JH; Wachowiak, J; Miano, M; Messina, C; Diaz, MA; Vermylen, C; Eyrich, M; Badell, I; Dreger, P; Gozdzik, J; Hutt, D; Rascon, J; Dini, G; Peters, C",null,null,null,"Styczynski, Jan; Balduzzi, Adriana; Gil, Lidia; Labopin, Myriam; Hamladji, Rose-Marie; Marktel, Sarah; Yesilipek, M. Akif; Fagioli, Franca; Ehlert, Karoline; Matulova, Martina; Dalle, Jean-Hugues; Wachowiak, Jacek; Miano, Maurizio; Messina, Chiara; Diaz, Miguel Angel; Vermylen, Christiane; Eyrich, Matthias; Badell, Isabel; Dreger, Peter; Gozdzik, Jolanta; Hutt, Daphna; Rascon, Jelena; Dini, Giorgio; Peters, Christina",null,"European Grp Blood Marrow","Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"MATCHED UNRELATED DONORS; BONE-MARROW; G-CSF; ALLOGENEIC TRANSPLANTATION; ADVERSE EVENTS; ACUTE-LEUKEMIA; CHILDREN; ADOLESCENTS; SAFETY; EXPERIENCE","We investigated prospectively factors influencing the safety of hematopoietic stem cell (HSC) collection in 453 pediatric donors. The children in the study donated either BM or peripheral blood stem cells (PBSCs) according to center policy. A large variability in approach to donor issues was observed between the participating centers. Significant differences were observed between BM and PBSC donors regarding pain, blood allotransfusion, duration of hospital stay, and iron supplementation; however, differences between the groups undergoing BM vs PBSC donation preclude direct risk comparisons between the 2 procedures. The most common adverse event was pain, reported mainly by older children after BM harvest, but also observed after central venous catheter (CVC) placement for PBSC collection. With regard to severe adverse events, one patient (0.7%) developed a pneumothorax with hydrothorax after CVC placement for PBSC collection. The risk of allotransfusion after BM harvest was associated with a donor age of < 4 years and a BM harvest volume of > 20 mL/kg. Children < 4 years were at higher risk than older children for allotransfusion after BM harvest and there was a higher risk of complications from CVC placement before apheresis. We conclude that PBSC and BM collection are safe procedures in children. (Blood. 2012;119(12):2935-2942)","[Styczynski, Jan] Nicholas Copernicus Univ, Coll Med, Dept Pediat Hematol & Oncol, PL-85094 Bydgoszcz, Poland; [Balduzzi, Adriana] Univ Milano Bicocca, Osped San Gerardo, Pediat Clin, Monza, Italy; [Gil, Lidia] Univ Med Sci, Dept Hematol, Poznan, Poland; [Labopin, Myriam] Univ Paris 06, European Grp Blood & Marrow Transplantat Off, Paris, France; [Hamladji, Rose-Marie] Ctr Pierre & Marie Curie, Algiers, Algeria; [Marktel, Sarah] Sci Inst HS Raffaele, Pediat Bone Marrow Transplantat Unit, Milan, Italy; [Yesilipek, M. Akif] Akdeniz Univ, Sch Med, TR-07058 Antalya, Turkey; [Fagioli, Franca] Osped Infantile Regina Margherita, Turin, Italy; [Ehlert, Karoline] Univ Childrens Hosp Muenster, Munster, Germany; [Matulova, Martina] Univ Hosp Motol, Prague, Czech Republic; [Dalle, Jean-Hugues] Hop Robert Debre, F-75019 Paris, France; [Miano, Maurizio; Dini, Giorgio] Childrens Res Hosp, Inst G Gaslini, Genoa, Italy; [Messina, Chiara] Univ Padua, Dept Pediat Hematol & Oncol, Padua, Italy; [Diaz, Miguel Angel] Nino Jesus Childrens Hosp, Madrid, Spain; [Vermylen, Christiane] Clin Univ St Luc, B-1200 Brussels, Belgium; [Eyrich, Matthias] Univ Wurzburg, Dept Pediat, Wurzburg, Germany; [Badell, Isabel] Hosp Santa Creu St Pau, Barcelona, Spain; [Dreger, Peter] Univ Heidelberg Hosp, Heidelberg, Germany; [Gozdzik, Jolanta] Univ Childrens Hosp, Krakow, Poland; [Hutt, Daphna] Edmond & Lily Safra Childrens Hosp, Tel Hashomer, Israel; [Rascon, Jelena] Vilnius Univ Hosp Santariskiu Klinikos, Childrens Hosp, Vilnius, Lithuania; [Peters, Christina] St Anna Childrens Hosp, A-1090 Vienna, Austria","Styczynski, J (reprint author), Nicholas Copernicus Univ, Coll Med, Dept Pediat Hematol & Oncol, Ul Curie Sklodowskiej 9, PL-85094 Bydgoszcz, Poland.","jstyczynski@cm.umk.pl",null,null,null,null,null,36,5,5,"AMER SOC HEMATOLOGY","WASHINGTON","1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","MAR 22",2012,119,12,null,null,null,null,2935,2942,null,"10.1182/blood-2011-04-349688",null,8,"Hematology","Hematology","916RU","WOS:000302121700031"]
[null,null,null,null,"J","Vesely, F; Zolotarevova, E; Spundova, M; Kaftan, F; Slouf, M; Entlicher, G",null,null,null,"Vesely, F.; Zolotarevova, E.; Spundova, M.; Kaftan, F.; Slouf, M.; Entlicher, G.",null,null,"Simple colorimetric methods for determination of sub-milligram amounts of ultra-high molecular weight polyethylene wear particles","ACTA BIOMATERIALIA",null,null,"English","Article",null,null,null,null,null,"Joint replacement; Polyethylene wear particles; Wear particles determination; Colorimetric methods","UHMWPE WEAR; HIP-ARTHROPLASTY; PERIPROSTHETIC TISSUES; JOINT REPLACEMENTS; DEBRIS; OXIDATION; QUANTIFICATION; FAILURE; NUMBER","New colorimetric methods are described for determination of sub-milligram amounts of ultra-high molecular weight polyethylene (UHMWPE) wear particles. These methods are based on the irreversible binding of the fluorescein-conjugated bovine serum albumin or the hydrophobic dye Oil Red O to wear particles. UHMWPE particles bind both substances from their solutions and thus decrease the absorbance of these solutions. The decrease is linearly dependent on the amount of added wear particles in the sub-milligram range suitable for practical use. The newly developed method offers improved accuracy and precision compared to Fourier transformed infrared spectroscopy (Slouf M. et al. Quantification of UHMWPE wear in periprosthetic tissues of hip arthoplasty: description of a new method based on IR and comparison with radiographic appearance. Wear 2008;265:674-684.) (C) 2012 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","[Zolotarevova, E.; Spundova, M.; Entlicher, G.] Charles Univ Prague, Dept Biochem, Fac Sci, Prague 12840 2, Czech Republic; [Vesely, F.] Charles Univ Prague, Fac Hosp Motol, Fac Med 1, Orthoped Clin, Prague 15606 5, Czech Republic; [Kaftan, F.] Inst Organ Chem & Biochem AS CR, Vvi, Prague 16610 6, Czech Republic; [Slouf, M.] Inst Macromol Chem AS CR, Vvi, Prague 16206 6, Czech Republic","Zolotarevova, E (reprint author), Charles Univ Prague, Dept Biochem, Fac Sci, Hlavova 8, Prague 12840 2, Czech Republic.","ezolotarevova@gmail.com","Slouf, Miroslav/F-6311-2012","Slouf, Miroslav/0000-0003-1528-802X","Ministry of Education, Youth and Sports of the Czech Republic [MSMT 2B06096]; Internal Grant Agency of Ministry of Health of the Czech Republic (IGA MZ CR) [12229-4/2011]; Grant Agency of the Czech Republic (GA CR) [P503/11/0163]","This work was supported by grants from the Ministry of Education, Youth and Sports of the Czech Republic (MSMT 2B06096), from the Internal Grant Agency of Ministry of Health of the Czech Republic (IGA MZ CR NT 12229-4/2011) and from Grant Agency of the Czech Republic (GA CR P503/11/0163).",null,20,0,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","1742-7061",null,null,"ACTA BIOMATER","Acta Biomater.","MAY",2012,8,5,null,null,null,null,1935,1938,null,"10.1016/j.actbio.2012.01.010",null,4,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","928NL","WOS:000302989700028"]
[null,null,null,null,"J","Valentino, LA; Mamonov, V; Hellmann, A; Quon, DV; Chybicka, A; Schroth, P; Patrone, L; Wong, WY",null,null,null,"Valentino, L. A.; Mamonov, V.; Hellmann, A.; Quon, D. V.; Chybicka, A.; Schroth, P.; Patrone, L.; Wong, W. -Y.",null,"Prophylaxis Study Grp","A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management","JOURNAL OF THROMBOSIS AND HAEMOSTASIS",null,null,"English","Article",null,null,null,null,null,"factor VIII; hemophilia A; previously treated patients; prophylaxis","RECOMBINANT FACTOR-VIII; PHARMACOKINETICS; CHILDREN; EFFICACY; PLASMA; SAFETY; EXPERIENCE; THERAPY; RISK",". Background: Prophylaxis with factor (F)VIII is considered the optimal treatment for managing hemophilia A patients without inhibitors. Objectives: To compare the efficacy of two prophylaxis regimens (primary outcome) and of on-demand and prophylaxis treatments (secondary outcome), and to continue the evaluation of immunogenicity and overall safety of the ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM). Patients/Methods: Previously on-demand-treated patients aged 759 years (n = 66) with FVIII levels = 2% received 6 months of on-demand treatment and then were randomized to 12 months of either standard (2040 IU kg-1 every other day) or pharmacokinetic (PK)-tailored (2080 IU kg-1 every third day) prophylaxis, both regimens intended to maintain FVIII trough levels at or above 1%. Efficacy was evaluated in terms of annualized bleeding rates (ABRs). As subjects were first treated on-demand and then on prophylaxis, statistical comparisons between these treatments were paired. Results: Twenty-two (33.3%) subjects on prophylaxis experienced no bleeding episodes, whereas none treated on-demand were free from an episode of bleeding. ABRs for the two prophylaxis regimens were comparable, whereas differences between on-demand and either prophylaxis were statistically significant (P < 0.0001): median (interquartile range [IQR]) ABRs were 43.9 (21.9), 1.0 (3.5), 2.0 (6.9) and 1.1 (4.9) during on-demand treatment, standard, PK-tailored and any prophylaxis, respectively. There were no differences in FVIII consumption or adverse event rates between prophylaxis regimens. No subject developed FVIII inhibitors. Conclusions: The present study demonstrates comparable safety and effectiveness for two prophylaxis regimens and that prophylaxis significantly reduces bleeding compared with on-demand treatment. PK-tailored prophylaxis offers an alternative to standard prophylaxis for the prevention of bleeding.","[Valentino, L. A.] Rush Univ, Med Ctr, Hemophilia & Thrombophilia Ctr, Chicago, IL 60612 USA; [Mamonov, V.] Russian Acad Med Sci, Hematol Res Ctr, Dept Reconstruct Orthoped Surg Hemophilia Patient, Moscow, Russia; [Hellmann, A.] Med Univ Gdansk, Dept Hematol & Transplantol, Gdansk, Poland; [Quon, D. V.] Orthoped Hosp, Hemophilia Treatment Ctr, Los Angeles, CA USA; [Chybicka, A.] Wroclaw Med Univ, Dept Pediat Bone Marrow Transplantat, Wroclaw, Poland; [Chybicka, A.] Wroclaw Med Univ, Dept Hematol & Oncol, Wroclaw, Poland; [Schroth, P.; Patrone, L.; Wong, W. -Y.] Baxter Healthcare Corp, Westlake Village, CA USA","Valentino, LA (reprint author), Rush Univ, Med Ctr, Hemophilia & Thrombophilia Ctr, 1653 W Congress Pkwy,Room 1591 Jelke Bldg, Chicago, IL 60612 USA.","lvalentino@rush.edu",null,null,"Baxter Healthcare Corporation","P. Schroth, L. Patrone, and W. Y. Wong are employees of Baxter Healthcare Corporation, the sponsor of the study. L. A. Valentino, V. Mamonov, and D. V. Quon have received consultancy, honoraria, and/or research funding from Baxter Healthcare Corporation. A. Hellmann and A. Chybicka have no conflict of interest disclosures.","ALEDORT LM, 1994, J INTERN MED, V236, P391; Biss TT, 2008, HAEMOPHILIA, V14, P923, DOI 10.1111/j.1365-2516.2008.01810.x; Blanchette VS, 2008, J THROMB HAEMOST, V6, P1319, DOI 10.1111/j.1538-7836.2008.03032.x; Centers for Disease Control and Prevention, 2005, REP UN DAT COLL PROG, V7; Collins PW, 2010, J THROMB HAEMOST, V8, P269, DOI 10.1111/j.1538-7836.2009.03703.x; Collins PW, 2009, J THROMB HAEMOST, V7, P413, DOI 10.1111/j.1538-7836.2008.03270.x; Fischer K, 2002, HAEMOPHILIA, V8, P745, DOI 10.1046/j.1365-2516.2002.00695.x; Gouw SC, 2007, BLOOD, V109, P4648, DOI 10.1182/blood-2006-11-056291; Gringeri A, 2011, J THROMB HAEMOST, V9, P700, DOI 10.1111/j.1538-7836.2011.04214.x; Hacker MR, 2001, HAEMOPHILIA, V7, P392, DOI 10.1046/j.1365-2516.2001.00534.x; Hoots WK, 2006, THROMB HAEMOSTASIS, V96, P433, DOI 10.1160/TH06-02-0125; Iorio A, 2011, COCHRANE DB SYST REV, V9; Lee CA, 2007, HAEMOPHILIA, V13, P20, DOI 10.1111/j.1365-2516.2007.01536.x; Lee M, 2006, HAEMOPHILIA, V12, P1, DOI 10.1111/j.1365-2516.2006.01253.x; LEE ML, 1990, J LAB CLIN MED, V115, P745; Lofqvist T, 1997, J INTERN MED, V241, P395, DOI 10.1046/j.1365-2796.1997.130135000.x; Manco-Johnson MJ, 2007, NEW ENGL J MED, V357, P535, DOI 10.1056/NEJMoa067659; MANCOJOHNSON MJ, 1994, AM J HEMATOL, V47, P113, DOI 10.1002/ajh.2830470209; Morado M, 2005, HAEMOPHILIA, V11, P79, DOI 10.1111/j.1365-2516.2005.00921.x; National Hemophilia Foundation, 2007, 179 MASAC; NILSSON IM, 1992, J INTERN MED, V232, P25; Royal S, 2002, HAEMOPHILIA, V8, P44, DOI 10.1046/j.1365-2516.2002.00581.x; Shapiro A, 2009, EXPERT OPIN BIOL TH, V9, P273, DOI 10.1517/14712590902729392 ; Tarantino MD, 2004, HAEMOPHILIA, V10, P428, DOI 10.1111/j.1365-2516.2004.00932.x; VERBRUGGEN B, 1995, THROMB HAEMOSTASIS, V73, P247; Ware JE, 2007, USERS MANUAL SF36V2",26,25,25,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1538-7933",null,null,"J THROMB HAEMOST","J. Thromb. Haemost.","MAR",2012,10,3,null,null,null,null,359,367,null,"10.1111/j.1538-7836.2011.04611.x",null,9,"Hematology; Peripheral Vascular Disease","Hematology; Cardiovascular System & Cardiology","900HC","WOS:000300876600005"]
[null,null,null,null,"J","Stratigos, AJ; Forsea, AM; van der Leest, RJT; de Vries, E; Nagore, E; Bulliard, JL; Trakatelli, M; Paoli, J; Peris, K; Hercogova, J; Bylaite, M; Maselis, T; Correia, O; del Marmol, V",null,null,null,"Stratigos, A. J.; Forsea, A. M.; van der Leest, R. J. T.; de Vries, E.; Nagore, E.; Bulliard, J. -L.; Trakatelli, M.; Paoli, J.; Peris, K.; Hercogova, J.; Bylaite, M.; Maselis, T.; Correia, O.; del Marmol, V.",null,null,"Euromelanoma: a dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future","BRITISH JOURNAL OF DERMATOLOGY",null,null,"English","Review",null,null,null,null,null,null,"PREVENTION CAMPAIGN; SCREENING CAMPAIGN; MALIGNANT-MELANOMA; MORTALITY; TRENDS","Euromelanoma is a dermatologist-led skin cancer prevention programme conducting an annual screening and public education campaign in over 20 European countries. Within its 10-year history, Euromelanoma has screened over 260 000 individuals across Europe, detecting a significant number of cutaneous melanomas and nonmelanoma skin cancers, identifying high-risk individuals for further surveillance and promoting awareness on the suspicious features of melanoma and the hazardous effects of ultraviolet exposure. In this review article, we summarize the history of the Euromelanoma campaign, present its organizational structure and discuss the results of the campaign in individual countries and on a European scale. Euromelanoma has had a significant impact on melanoma prevention and early diagnosis in participating countries and, despite many challenges, has positively influenced public health attitudes towards regular mole examination and the implementation of preventive measures against skin cancer.","[del Marmol, V.] Univ Libre Brussels, Dept Dermatol, Hop Erasme, Brussels, Belgium; [Stratigos, A. J.] Univ Athens, Dept Dermatol, A Sygros Hosp, Athens, Greece; [Forsea, A. M.] Carol Davila Univ Med & Pharm Bucharest, Dept Dermatol, Bucharest, Romania; [van der Leest, R. J. T.] Erasmus Univ, Dept Dermatol, Med Ctr, Rotterdam, Netherlands; [de Vries, E.] Erasmus Univ, Dept Publ Hlth, Med Ctr, Rotterdam, Netherlands; [Nagore, E.] Inst Valenciano Oncol, Dept Dermatol, Valencia, Spain; [Bulliard, J. -L.] Univ Lausanne Hosp, Canc Epidemiol Unit, Inst Social & Prevent Med IUMSP, Lausanne, Switzerland; [Trakatelli, M.] Aristotle Univ Thessaloniki, Dept Dermatol & Venereol 2, Papageorgiou Hosp, GR-54006 Thessaloniki, Greece; [Paoli, J.] Univ Gothenburg, Dept Dermatol, Inst Clin Sci, Sahlgrenska Acad,Sahlgrenska Univ Hosp, Gothenburg, Sweden; [Peris, K.] Univ Aquila, Dept Dermatol, I-67100 Laquila, Italy; [Hercogova, J.] Charles Univ Prague, Dept Dermatol, Fac Med 2, Univ Hosp Bulovka, Prague, Czech Republic; [Bylaite, M.] Vilnius State Univ, Dept Dermatol, Clin Infect Dis Dermatovenereol & Microbiol, Fac Med, Vilnius, Lithuania; [Correia, O.] Univ Porto, Ctr Dermatol Epidermis, Inst CUF, P-4100 Oporto, Portugal; [Correia, O.] Univ Porto, Fac Med, P-4100 Oporto, Portugal","del Marmol, V (reprint author), Univ Libre Brussels, Dept Dermatol, Hop Erasme, Brussels, Belgium.","v.marmol@skynet.be",null,null,"European Skin Cancer Foundation (ESCF)","We are grateful to all colleagues across Europe who have supported and contributed to the Euromelanoma campaign. The Euromelanoma campaigns in all participating European countries were sponsored by multiple dermatological societies, cancer leagues and (pharmaceutical) companies, specific for each country. Names of sponsors are available through the corresponding author. Funding for publication of this supplement was provided by the European Skin Cancer Foundation (ESCF).",null,14,8,8,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0007-0963",null,null,"BRIT J DERMATOL","Br. J. Dermatol.","AUG",2012,167,null,null,2,"SI",null,99,104,null,"10.1111/j.1365-2133.2012.11092.x",null,6,"Dermatology","Dermatology","987AO","WOS:000307389000014"]
[null,null,null,null,"J","Sitarz, KS; Yu-Wai-Man, P; Pyle, A; Stewart, JD; Rautenstrauss, B; Seeman, P; Reilly, MM; Horvath, R; Chinnery, PF",null,null,null,"Sitarz, Kamil S.; Yu-Wai-Man, Patrick; Pyle, Angela; Stewart, Joanna D.; Rautenstrauss, Bernd; Seeman, Pavel; Reilly, Mary M.; Horvath, Rita; Chinnery, Patrick F.",null,null,"MFN2 mutations cause compensatory mitochondrial DNA proliferation","BRAIN",null,null,"English","Letter",null,null,null,null,null,null,"OPA1 MUTATIONS; OPTIC ATROPHY; MTDNA; DISEASE; REPLICATION; MITOFUSIN-2; NEUROPATHY; MUSCLE; MODEL",null,"[Sitarz, Kamil S.; Yu-Wai-Man, Patrick; Pyle, Angela; Stewart, Joanna D.; Horvath, Rita; Chinnery, Patrick F.] Newcastle Univ, Inst Med Genet, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; [Yu-Wai-Man, Patrick] Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Stewart, Joanna D.] IfADo Leibniz Res Ctr Working Environm & Human Fa, Dortmund, Germany; [Rautenstrauss, Bernd] Univ Munich, Friedrich Baur Inst, Munich, Germany; [Seeman, Pavel] Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague, Czech Republic; [Seeman, Pavel] Univ Hosp Motol, Prague, Czech Republic; [Reilly, Mary M.] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London WC1N 3BG, England; [Horvath, Rita; Chinnery, Patrick F.] Royal Victoria Infirm, Dept Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England","Yu-Wai-Man, P (reprint author), Newcastle Univ, Inst Med Genet, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.","patrick.yu-wai-man@ncl.ac.uk","Stewart, Joanna/H-1614-2012",null,null,null,null,15,8,8,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0006-8950",null,null,"BRAIN","Brain","AUG",2012,135,null,8,null,null,null,null,null,"e219","10.1093/brain/aws049",null,3,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","984DQ","WOS:000307170300003"]
[null,null,null,null,"J","Rink, M; Xylinas, E; Babjuk, M; Pycha, A; Karakiewicz, PI; Novara, G; Dahlem, R; Shariat, SF",null,null,null,"Rink, Michael; Xylinas, Evanguelos; Babjuk, Marko; Pycha, Armin; Karakiewicz, Pierre I.; Novara, Giacomo; Dahlem, Roland; Shariat, Shahrokh F.",null,null,"Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guerin Immunotherapy in Non-muscle-invasive Bladder Cancer","EUROPEAN UROLOGY",null,null,"English","Letter",null,null,null,null,null,null,"UROTHELIAL CARCINOMA; RISK",null,"[Rink, Michael; Xylinas, Evanguelos; Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Urol, New York, NY USA; [Rink, Michael; Dahlem, Roland] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany; [Xylinas, Evanguelos] Paris Descartes Univ, Cochin Hosp, APHP, Dept Urol, Paris, France; [Babjuk, Marko] Charles Univ Prague, Fac Med 2, Hosp Motol, Dept Urol, Prague, Czech Republic; [Karakiewicz, Pierre I.] Univ Montreal, Dept Urol, Montreal, PQ, Canada; [Pycha, Armin] Gen Hosp Bolzano, Dept Urol, Bolzano, Italy; [Novara, Giacomo] Univ Padua, Dept Urol, Padua, Italy; [Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Med Oncol, New York, NY USA","Shariat, SF (reprint author), Cornell Univ, Weill Med Coll, Dept Urol, New York Presbyterian Hosp, 525 E 68th St,Box 94,Starr 900, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,null,null,null,8,2,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","DEC",2012,62,6,null,null,null,null,1204,1206,null,"10.1016/j.eururo.2012.08.057",null,4,"Urology & Nephrology","Urology & Nephrology","033GZ","WOS:000310783500051"]
[null,null,null,null,"J","Mickova, A; Buzgo, M; Benada, O; Rampichova, M; Fisar, Z; Filova, E; Tesarova, M; Lukas, D; Amler, E",null,null,null,"Mickova, Andrea; Buzgo, Matej; Benada, Oldrich; Rampichova, Michala; Fisar, Zdenek; Filova, Eva; Tesarova, Martina; Lukas, David; Amler, Evzen",null,null,"Core/Shell Nanofibers with Embedded Liposomes as a Drug Delivery System","BIOMACROMOLECULES",null,null,"English","Article",null,null,null,null,null,null,"TISSUE ENGINEERING APPLICATIONS; ELECTROSPUN NANOFIBERS; CELL INFILTRATION; SCAFFOLDS; ENCAPSULATION; FIBERS; RELEASE; MESHES; LIMITATIONS; MICROFIBER","The broader application of liposomes in regenerative medicine is hampered by their short half-life and inefficient retention at the site of application. These disadvantages could be significantly reduced by their combination with nanofibers. We produced 2 different nanofiber-liposome systems in the present study, that is, liposomes blended within nanofibers and core/shell nanofibers with embedded liposomes. Herein, we demonstrate that blend electrospinning does not conserve intact liposomes. In contrast, coaxial electrospinning enables the incorporation of liposomes into nanofibers. We report polyvinyl alcohol-core/poly-epsilon-caprolactone-shell nanofibers with embedded liposomes and show that they preserve the enzymatic activity of encapsulated horseradish peroxidase. The potential of this system was also demonstrated by the enhancement of mesenchymal stem cell proliferation., In conclusion, intact liposomes incorporated into nanofibers by coaxial electrospinning are very promising as a drug delivery system.","[Mickova, Andrea; Buzgo, Matej; Rampichova, Michala; Amler, Evzen] Charles Univ Prague, Fac Med 2, Dept Biophys, Prague 15006 5, Czech Republic; [Mickova, Andrea; Buzgo, Matej; Rampichova, Michala; Filova, Eva; Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Vvi, Prague 14220 4, Czech Republic; [Benada, Oldrich] Acad Sci Czech Republic, Inst Microbiol, Vvi, Lab Mol Struct Characterizat, CR-14220 Prague 4, Czech Republic; [Fisar, Zdenek] Charles Univ Prague, Fac Med 1, Dept Psychiat, Prague 15006 5, Czech Republic; [Filova, Eva; Amler, Evzen] Czech Tech Univ, Fac Biomed Engn, Kladno 27201, Czech Republic; [Tesarova, Martina] Acad Sci Czech Republic, Inst Parasitol, Ctr Biol, Electron Microscopy Lab, CR-37005 Ceske Budejovice, Czech Republic; [Lukas, David] Tech Univ Liberec, Dept Nonwovens, Liberec 46117, Czech Republic","Buzgo, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Biophys, Uvalu 84, Prague 15006 5, Czech Republic.","buzgo@labdemo.cz","Fisar, Zdenek/A-3295-2008",null,"Academy of Sciences of the Czech Republic (Institutional Research Plans) [AV0Z50390703, AV0Z50390512]; Ministry of Education, Youth, and Sports of the Czech Republic [NPV II 2B06130, 1M0510, MSM0021620849, 4977751303]; Grant Agency of the Academy of Sciences [IAA500390702]; Czech Science Foundation [GA202/09/1151, P304/10/1307]; Charles University [96610, 80009, 97110, 330611, 384311, 164010]; Grant Agency of the Czech Republic [106/09/P226]; Ministry of Health of the Czech Republic [NT12156]; Ministry of Education of the Czech Republic [ME 10145]","This research was supported by the Academy of Sciences of the Czech Republic (Institutional Research Plans AV0Z50390703 and AV0Z50390512), the Ministry of Education, Youth, and Sports of the Czech Republic (Research Programs NPV II 2B06130 and 1M0510, Grant No. MSM0021620849, and Project MSM Grant No. 4977751303), the Grant Agency of the Academy of Sciences (Grant No. IAA500390702), grants from the Czech Science Foundation (Grants Nos. GA202/09/1151 and P304/10/1307), the Grant Agency of Charles University (Grant Nos. 96610, 80009, 97110, 330611, 384311, and 164010), the Grant Agency of the Czech Republic (Grant No. 106/09/P226), Internal Grant Agency of the Ministry of Health of the Czech Republic (Grant No. NT12156), and the Ministry of Education of the Czech Republic (Project ERA-NET CARSILA, No, ME 10145). Cactus Communications Inc. provided language help and proofreading of the manuscript (www.editage.com).",null,54,17,17,"AMER CHEMICAL SOC","WASHINGTON","1155 16TH ST, NW, WASHINGTON, DC 20036 USA","1525-7797",null,null,"BIOMACROMOLECULES","Biomacromolecules","APR",2012,13,4,null,null,null,null,952,962,null,"10.1021/bm2018118",null,11,"Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science","Biochemistry & Molecular Biology; Chemistry; Polymer Science","929OV","WOS:000303076200002"]
[null,null,null,null,"J","Vanousova, D; Zakoucka, H; Jilich, D; Rozsypal, H; Stankova, M; Zufanova, S; Vojackova, N; Hercogova, J; Marvan, J; Machala, L",null,null,null,"Vanousova, D.; Zakoucka, H.; Jilich, D.; Rozsypal, H.; Stankova, M.; Zufanova, S.; Vojackova, N.; Hercogova, J.; Marvan, J.; Machala, L.",null,null,"First detection of Chlamydia trachomatis LGV biovar in the Czech Republic, 2010-2011","EUROSURVEILLANCE",null,null,"English","Article",null,null,null,null,null,null,"LYMPHOGRANULOMA-VENEREUM; SEX; MEN","We present four cases of proctitis in HIV-infected men having sex with men (MSM) living in the Czech Republic. The causative agent in all cases was the lymphogranuloma venereum (LGV) biovar of Chlamydia trachomatis. The spread of proctitis caused by C. trachomatis serovars L1-3 among MSM has been observed in several European countries, the United States and Canada since 2003. To our knowledge, no LGV cases in eastern Europe have been published to date. Between February 2010 and February 2011, four men who have sex with men (MSM) infected with human immunodeficiency virus (HIV), who were under regular observation for HIV infection at the Bulovka University Hospital AIDS Center in Prague, Czech Republic, developed symptoms of acute proctitis. The most prominent symptom in all four patients was intensive rectal pain lasting on average 10 days (range: 7-21 days). Other symptoms included blood in the stool or pinkish mucous discharge, constipation and tenesmus. Case 1 also had one enlarged, painful inguinal lymph node. Anoscopies were performed on Case 1 and Case 3 and revealed congested, irritated mucous membranes with a whitish coating. None of the patients had urethritis, fever, or other systemic symptoms (see Table). To our knowledge, these cases are the first LGV infections detected in the region.","[Vanousova, D.; Vojackova, N.; Hercogova, J.] Charles Univ Prague, Dept Dermatovenereol, Fac Med 2, Prague, Czech Republic; [Marvan, J.] Univ Hosp Bulovka, Dept Surg, Prague, Czech Republic; [Zakoucka, H.; Zufanova, S.] Natl Inst Publ Hlth, Natl Reference Lab Diagnost Syphilis & Chlamydia, Prague, Czech Republic; [Jilich, D.; Rozsypal, H.; Stankova, M.] Charles Univ Prague, Dept Infect & Trop Dis, Fac Med 1, Prague, Czech Republic; [Machala, L.] Charles Univ Prague, Dept Infect Dis, Fac Med 3, Prague, Czech Republic","Vanousova, D (reprint author), Charles Univ Prague, Dept Dermatovenereol, Fac Med 2, Prague, Czech Republic.","ladimachala@centrum.cz",null,null,null,null,null,16,0,0,"EUR CENTRE DIS PREVENTION & CONTROL","STOCKHOLM","TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN","1560-7917",null,null,"EUROSURVEILLANCE","Eurosurveillance","JAN 12",2012,17,2,null,null,null,null,5,7,20055,null,null,3,"Infectious Diseases","Infectious Diseases","877HZ","WOS:000299169700002"]
[null,null,null,null,"J","Halaska, M; Maxova, K; Sottner, O; Svabik, K; Mlcoch, M; Kolarik, D; Mala, I; Krofta, L; Halaska, MJ",null,null,null,"Halaska, Michael; Maxova, Katerina; Sottner, Oldrich; Svabik, Kamil; Mlcoch, Michal; Kolarik, Dusan; Mala, Ivana; Krofta, Ladislav; Halaska, Michael J.",null,null,"A multicenter, randomized, prospective, controlled study comparing sacrospinous fixation and transvaginal mesh in the treatment of posthysterectomy vaginal vault prolapse","AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY",null,null,"English","Article",null,null,null,null,null,"pelvic organ prolapse quantification prolapse; Prolift; quality-of-life questionnaires; sacrospinous fixation","PELVIC ORGAN PROLAPSE; RECONSTRUCTIVE SURGERY; URINARY-INCONTINENCE; POLYPROPYLENE MESH; GENITAL PROLAPSE; GRAFT USE; REPAIR; ANTERIOR; SLINGPLASTY; WOMEN","OBJECTIVE: The objective of the study was to compare recurrence and complication rates for sacrospinous fixation (SSF) and prolene mesh techniques for the primary treatment of posthysterectomy vaginal vault prolapse. STUDY DESIGN: Patients undergoing surgery for vault prolapse were included in a multicenter, randomized, controlled study comparing SSF or total mesh (Prolift; Gynecare/Ethicon, Somerville, NJ). The examination included pelvic organ prolapse quantification, urodynamics, ultrasound, and quality-of-life (QoL) questionnaires before and 3 and 12 months after surgery. RESULTS: Of 168 randomized patients, 83 underwent SSF and 85 mesh repair. Prolapse recurrence after 12 months occurred in 39.4% of the SSF group and in 16.9% of the mesh group (P = .003). The mesh exposure rate was 20.8%. No difference in QoL improvement as well as of de novo stress urinary incontinence and overactive bladder onset was found. CONCLUSION: Mesh exposure occurrence was balanced against a lower prolapse recurrence rate in the patients undergoing mesh surgery compared with those undergoing SSF.","[Halaska, Michael; Maxova, Katerina; Sottner, Oldrich; Svabik, Kamil; Kolarik, Dusan] Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 1, CR-18000 Prague 8, Czech Republic; [Halaska, Michael; Maxova, Katerina; Sottner, Oldrich; Kolarik, Dusan] Hosp Bulovka, Prague, Czech Republic; [Svabik, Kamil] Gen Fac Hosp, Prague, Czech Republic; [Krofta, Ladislav] Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 3, CR-18000 Prague 8, Czech Republic; [Krofta, Ladislav] Inst Care Mother & Child, Prague, Czech Republic; [Mala, Ivana] Univ Econ, Fac Informat & Stat, Prague, Czech Republic; [Halaska, Michael] Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 2, CR-18000 Prague 8, Czech Republic; [Halaska, Michael] Fac Hosp Motol, Prague, Czech Republic; [Mlcoch, Michal] Bata Hosp Zlin, Dept Obstet & Gynecol, Zlin, Czech Republic","Halaska, MJ (reprint author), Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 1, Budinova 2, CR-18000 Prague 8, Czech Republic.","michael.halaska@lf1.cuni.cz",null,null,"Ministry of Health Care of the Czech Republic [NS 10453-3/2009]","This work was supported by grant NS 10453-3/2009 from the Ministry of Health Care of the Czech Republic, which did not participate in the study design, data collection, data analysis, manuscript preparation, or publication decisions.",null,36,3,3,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0002-9378",null,null,"AM J OBSTET GYNECOL","Am. J. Obstet. Gynecol.","OCT",2012,207,4,null,null,null,null,null,null,"301.e1","10.1016/j.ajog.2012.08.016",null,7,"Obstetrics & Gynecology","Obstetrics & Gynecology","025SA","WOS:000310212000028"]
[null,null,null,null,"J","Harambat, J; van Stralen, KJ; Espinosa, L; Groothoff, JW; Hulton, SA; Cerkauskiene, R; Schaefer, F; Verrina, E; Jager, KJ; Cochat, P",null,null,null,"Harambat, Jerome; van Stralen, Karlun J.; Espinosa, Laura; Groothoff, Jaap W.; Hulton, Sally-Anne; Cerkauskiene, Rimante; Schaefer, Franz; Verrina, Enrico; Jager, Kitty J.; Cochat, Pierre",null,"ESPN ERA EDTA Registry","Characteristics and Outcomes of Children with Primary Oxalosis Requiring Renal Replacement Therapy","CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,null,"PRIMARY HYPEROXALURIA TYPE-1; LIVER-KIDNEY TRANSPLANTATION; ALLOGRAFT SURVIVAL; UNITED-STATES; REGISTRY; GROWTH; EXPERIENCE; MUTATION; INFANTS; DISEASE","Background and objectives Primary hyperoxaluria (PH) as a cause of ESRD in children is believed to have poor outcomes. Data on management and outcomes of these children remain scarce. Design, setting, participants, & measurements This study included patients aged <19 years who started renal replacement therapy (RRT) between 1979 and 2009 from 31 countries providing data to a large European registry. Results Of 9247 incident patients receiving RRT, 100 patients had PH. PH children were significantly younger than non-PH children at the start of RRT. The median age at RRT of PH children decreased from 9.8 years in 1979-1989 to 1.5 years in 2000-2009. Survival was 86%, 79%, and 76% among PH patients at 1, 3, and 5 years after the start of RRT, compared with 97%, 94%, and 92% in non-PH patients, resulting in a three-fold increased risk of death over non-PH patients. PH and non-PH patient survival improved over time. Sixty-eight PH children received a first kidney (n=13) or liver-kidney transplantation (n=55). Although the comparison was hampered by the lower number of kidney transplantations primarily derived from the earlier era of RRT, kidney graft survival in PH patients was 82%, 79%, and 76% at 1, 3, and 5 years for liver-kidney transplantation and 46%, 28%, and 14% at 1, 3, and 5 years for kidney transplantation alone, compared with 95%, 90%, and 85% in non-PH patients. Conclusions The outcomes of PH children with ESRD are still poorer than in non-PH children but have substantially improved over time. Clin J Am Soc Nephrol 7: 458-465, 2012. doi: 10.2215/CJN.07430711","[Harambat, Jerome; van Stralen, Karlun J.; Jager, Kitty J.] Univ Amsterdam, Acad Med Ctr, Dept Med Informat, ESPN ERA EDTA Registry, NL-1100 DE Amsterdam, Netherlands; [Harambat, Jerome] Univ Bordeaux, Bordeaux, France; [Espinosa, Laura] La Paz Pediat Hosp, Madrid, Spain; [Groothoff, Jaap W.] Acad Med Ctr, Emma Childrens Hosp, Amsterdam, Netherlands; [Hulton, Sally-Anne] NHS Trust, Birmingham Childrens Hosp, Birmingham, AL USA; [Cerkauskiene, Rimante] Vilnius Univ, Vilnius, Lithuania; [Schaefer, Franz] Univ Childrens Hosp, Heidelberg, Germany; [Verrina, Enrico] Gaslini Childrens Hosp, Genoa, Italy; [Cochat, Pierre] Univ Lyon, Lyon, France; [Cochat, Pierre] Hosp Civils Lyon, Lyon, France; [Cerkauskiene, Rimante] Univ Childrens Hosp, Vilnius, Lithuania","van Stralen, KJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Med Informat, ESPN ERA EDTA Registry, POB 22700, NL-1100 DE Amsterdam, Netherlands.","K.J.vanStralen@amc.uva.nl","Schaefer, Franz/G-4365-2010",null,"ERA-EDTA QUEST initiative; Amgen","The ESPN/ERA-EDTA Registry is funded by ESPN, ERA-EDTA, and the NephroQUEST project. The NephroQUEST project has received funding from the European Union in the framework of the Public Health Program (Project 2006114). J.H. was supported by an ERA-EDTA QUEST initiative research fund and received travel assistance from Astellas Pharma, Fresenius Medical Care, Pfizer, and Sandoz. Amgen has provided an unrestricted educational grant to assist the ESPN in the financial support of the registry.","Bergstralh EJ, 2010, AM J TRANSPLANT, V10, P2493, DOI 10.1111/j.1600-6143.2010.03271.x; Brinkert F, 2009, TRANSPLANTATION, V87, P1415, DOI 10.1097/TP.0b013e3181a27939; BROYER M, 1990, NEPHROL DIAL TRANSPL, V5, P332; Cibrik DM, 2002, TRANSPLANTATION, V74, P707, DOI 10.1097/00007890-200209150-00020; Cochat P, 2006, PEDIATR NEPHROL, V21, P1075, DOI 10.1007/s00467-006-0124-4; Cochat P, 1999, J PEDIATR, V135, P746, DOI 10.1016/S0022-3476(99)70095-8; DANPURE CJ, 1986, FEBS LETT, V201, P20, DOI 10.1016/0014-5793(86)80563-4; European Commission, EUR STAT DAT; Fargue S, 2009, KIDNEY INT, V76, P767, DOI 10.1038/ki.2009.237; Gagnadoux MF, 2001, PEDIATR NEPHROL, V16, P946; Harambat J, 2010, KIDNEY INT, V77, P443, DOI 10.1038/ki.2009.435; Harps E, 2011, TRANSPLANTATION, V91, P1127, DOI 10.1097/TP.0b013e318216c1bb; Hoppe B, 2009, KIDNEY INT, V75, P1264, DOI 10.1038/ki.2009.32; Illies F, 2006, KIDNEY INT, V70, P1642, DOI 10.1038/sj.ki.5001806; Jamieson NV, 2005, AM J NEPHROL, V25, P282, DOI 10.1159/000086359; LEUMANN E, 1995, NEPHROL DIAL TRANSPL, V10, P14; Lieske JC, 2005, AM J NEPHROL, V25, P290, DOI 10.1159/000086360; Mehls O, 1996, NEPHROL DIAL TRANSPL, V11, P22; Millan MT, 2003, TRANSPLANTATION, V76, P1458, DOI 10.1097/01.TP.0000084203.76110.AC; MILLINER DS, 1994, NEW ENGL J MED, V331, P1553, DOI 10.1056/NEJM199412083312304; National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, 2004, PEDIATRICS, V114, P555, DOI DOI 10.1542/PEDS.114.2.S2.555; Nissel R, 2006, TRANSPLANTATION, V82, P48, DOI 10.1097/01.tp.0000225831.35143.06; Ogden CL, 2002, PEDIATRICS, V109, P45, DOI 10.1542/peds.109.1.45; Perera MTPR, 2011, NEPHROL DIAL TRANSPL, V26, P354, DOI 10.1093/ndt/gfq353; Saborio P, 1999, KIDNEY INT, V56, P1094, DOI 10.1046/j.1523-1755.1999.00619.x; Scheinman JI, 2010, PEDIATR NEPHROL, V25, P2217, DOI 10.1007/s00467-010-1594-y; SCHEINMAN JI, 1984, KIDNEY INT, V25, P804, DOI 10.1038/ki.1984.93; Sterne JAC, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2393; Tizard EJ, 2009, NEPHROL DIAL TRANSPL, V24, P2615, DOI 10.1093/ndt/gfp275; Twisk JWR, 2003, APPL LONGITUDINAL DA, P318; U. S. Renal Data System, 2010, USRDS 2010 ANN DAT R; van der Heijden BJ, 2004, PEDIATR NEPHROL, V19, P213, DOI 10.1007/s00467-003-1376-x; van Stralen KJ, 2010, NEPHROL DIAL TRANSPL, V25, P3325, DOI 10.1093/ndt/gfq215; van Woerden CS, 2003, NEPHROL DIAL TRANSPL, V18, P273, DOI 10.1093/ndt/18.2.273; WATTS RWE, 1985, Q J MED, V57, P697; Williams EL, 2009, HUM MUTAT, V30, P910, DOI 10.1002/humu.21021",36,13,13,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1555-9041",null,null,"CLIN J AM SOC NEPHRO","Clin. J. Am. Soc. Nephrol.","MAR",2012,7,3,null,null,null,null,458,465,null,"10.2215/CJN.07430711",null,8,"Urology & Nephrology","Urology & Nephrology","904TZ","WOS:000301222100014"]
[null,null,null,null,"J","Coras, R; Boer, OJ; Armstrong, D; Becker, A; Jacques, TS; Miyata, H; Thom, M; Vinters, HV; Spreafico, R; Oz, B; Marucci, G; Pimentel, J; Muhlebner, A; Zamecnik, J; Buccoliero, AM; Rogerio, F; Streichenberger, N; Arai, N; Bugiani, M; Vogelgesang, S; Macaulay, R; Salon, C; Hans, V; Polivka, M; Giangaspero, F; Fauziah, D; Kim, JH; Liu, L; Dandan, W; Gao, J; Lindeboom, B; Blumcke, I; Aronica, E",null,null,null,"Coras, Roland; de Boer, Onno J.; Armstrong, Dawna; Becker, Albert; Jacques, Thomas S.; Miyata, Hajime; Thom, Maria; Vinters, Harry V.; Spreafico, Roberto; Oz, Buge; Marucci, Gianluca; Pimentel, Jose; Muehlebner, Angelika; Zamecnik, Josef; Buccoliero, Anna Maria; Rogerio, Fabio; Streichenberger, Nathalie; Arai, Nobutaka; Bugiani, Marianna; Vogelgesang, Silke; Macaulay, Rob; Salon, Carolin; Hans, Volkmar; Polivka, Marc; Giangaspero, Felice; Fauziah, Dyah; Kim, Jang-Hee; Liu, Lei; Dandan, Wang; Gao, Jing; Lindeboom, Benjamin; Bluemcke, Ingmar; Aronica, Eleonora",null,null,"Good interobserver and intraobserver agreement in the evaluation of the new ILAE classification of focal cortical dysplasias","EPILEPSIA",null,null,"English","Article",null,null,null,null,null,"Brain; Epilepsy; Neuropathology; Classification; Agreement; Reproducibility","MALFORMATIONS; FEATURES; EPILEPSY; SYSTEM; MRI","Purpose: An International League Against Epilepsy (ILAE) consensus classification system for focal cortical dysplasias (FCDs) has been published in 2011 specifying clinicopathologic FCD variants. The aim of the present work was to microscopically assess interobserver agreement and intraobserver reproducibility for FCD categories among an international group of neuropathologists with different levels of experience and access to epilepsy surgery tissue. Methods: Surgical FCD specimens covering a broad histopathology spectrum were retrieved from 22 patients with epilepsy. Three surgical nonepilepsy specimens served as controls. A total of 188 slides with routine or immunohistochemical stainings were digitalized with a slide scanner to allow Internet-based microscopy review. Nine experienced neuropathologists were invited to review these cases twice at a time gap of 3 months and different orders of case presentation. The 2011 ILAE FCD consensus classification served as instruction. Kappa analysis was calculated to estimate interobserver and intraobserver agreement levels. In a third evaluation round, 21 additional neuropathologists with different experience and access to epilepsy surgery reviewed the same case series. Key Findings: Interobserver agreement was good (kappa = 0.6360), with 84% consensus of diagnoses during the first evaluation (21 of 25 cases). Kappa values increased to 0.6532 after reevaluation, and consensus was obtained in 24 (96%) of 25 cases. Overall intraobserver reproducibility was also good (kappa = 0.7824, ranging from 0.4991 to 1.000). Fewest changes in the classification were made in the FCD type II group (2.2% of 225 original diagnoses), whereas the majority of changes occurred in FCD type III (13.7% of 225 original diagnoses). In the third evaluation round, interobserver agreement was reflected by the level of experience of each neuropathologist, with kappa values ranging from moderate (0.5056; high level of experience >40 cases/year) to low (0.3265; low level of experience <10 cases/year). Significance: Our study achieved a good and reliable interobserver agreement among the group of expert neuropathologists originally involved in the ILAE FCD consensus classification system. Intraobserver reproducibility in this group was even more robust. These results showed considerable improvement compared to a previous study evaluating the 2004 Palmini FCD classification. Agreement levels were lower in our second group of neuropathologists and were related to their level of access and experience with epilepsy surgery specimens. These results suggested that the more precise ILAE definition of FCD histopathology patterns improves operational procedures in the diagnosis of FCDs. On the other hand, microscopic assessment of FCD is a challenge and requires sustained experience and teaching. The virtual slide review system allowed testing of this hypothesis and reached a widespread group of participating colleagues from different centers all over the world. We propose to further use this tool as a teaching device and also to address other epilepsy-associated entities still difficult to classify such as hippocampal sclerosis, long-term epilepsy-associated tumors, or mild malformations of cortical development (mMCDs), which were not yet covered by current ILAE classification systems.","[Coras, Roland] Univ Hosp Erlangen, Dept Neuropathol, D-91054 Erlangen, Germany; [de Boer, Onno J.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Armstrong, Dawna] Baylor Coll Med, Houston, TX 77030 USA; [Armstrong, Dawna] Texas Childrens Hosp, Houston, TX 77030 USA; [Becker, Albert] Univ Hosp Bonn, Dept Neuropathol, Bonn, Germany; [Jacques, Thomas S.] Great Ormond St Hosp NHS Trust, London, England; [Jacques, Thomas S.] UCL Inst Child Hlth, London, England; [Miyata, Hajime] Res Inst Brain & Blood Vessels, Dept Neuropathol, Akita, Japan; [Thom, Maria] UCL, Inst Neurol, Dept Neuropathol, London, England; [Vinters, Harry V.] Univ Calif Los Angeles, Med Ctr, Dept Pathol & Lab Med Neuropathol, Los Angeles, CA 90024 USA; [Vinters, Harry V.] Univ Calif Los Angeles, Med Ctr, Dept Neurol, Los Angeles, CA 90024 USA; [Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Spreafico, Roberto] IRCCS Fdn Neurol Inst Carlo Besta, Dept Epilepsy Clin & Expt Neurophysiol, Milan, Italy; [Oz, Buge] Istanbul Univ, Cerrahpasa Med Fac, Dept Pathol, Istanbul, Turkey; [Marucci, Gianluca] Univ Bologna, Bellaria Hosp, Sect Pathol, Bologna, Italy; [Pimentel, Jose] EPE Hosp Santa Maria, CHLN, Dept Neurol, Neuropathol Lab, Lisbon, Portugal; [Muehlebner, Angelika] Med Univ Vienna, Inst Neurol, Vienna, Austria; [Muehlebner, Angelika] Med Univ Vienna, Dept Pediat, Vienna, Austria; [Zamecnik, Josef] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Zamecnik, Josef] Fac Hosp Motol, Prague, Czech Republic; [Buccoliero, Anna Maria] Univ Florence, Pathol Lab, Childrens Hosp Meyer, Florence, Italy; [Rogerio, Fabio] Univ Estadual Campinas, Fac Med Sci, Dept Pathol, Campinas, Brazil; [Streichenberger, Nathalie] Univ Lyon, Neuropathol Lab, Lyon, France; [Arai, Nobutaka] Tokyo Metropolitan Inst Med Sci, Brain Pathol Res Ctr, Tokyo 113, Japan; [Bugiani, Marianna] Vrije Univ Amsterdam, Med Ctr, Dept Pathol & Pediat Child Neurol, Amsterdam, Netherlands; [Vogelgesang, Silke] Ernst Moritz Arndt Univ Greifswald, Dept Neuropathol, Greifswald, Germany; [Macaulay, Rob] Dalhousie Univ, Dept Pathol, Halifax, NS, Canada; [Salon, Carolin] Univ Hosp Grenoble, Dept Pathol, Grenoble, France; [Hans, Volkmar] Evangel Krankenhaus Bielefeld, Inst Neuropathol, Bielefeld, Germany; [Polivka, Marc] Lariboisiere Hosp, Dept Pathol, Paris, France; [Giangaspero, Felice] Neuromed Inst, Dept Neurol Sci, Pozzilli, Italy; [Fauziah, Dyah] Airlangga Univ, Dept Pathol, Surabaya, Indonesia; [Kim, Jang-Hee] Ajou Univ, Sch Med, Dept Pathol, Suwon 441749, South Korea; [Liu, Lei] Capital Med Univ, Beijing Friendship Hosp, Dept Neurol, Beijing, Peoples R China; [Dandan, Wang] Tsinghua Univ, Dept Pathol, Yuquan Hosp, Beijing 100084, Peoples R China; [Gao, Jing] Beijing Union Med Coll Hosp, Dept Neurol, Beijing, Peoples R China; [Lindeboom, Benjamin; Aronica, Eleonora] Univ Amsterdam, Acad Med Ctr, Dept Neuro Pathol, NL-1012 WX Amsterdam, Netherlands","Coras, R (reprint author), Univ Hosp Erlangen, Dept Neuropathol, Schwabachanlage 6, D-91054 Erlangen, Germany.","roland.coras@uk-erlangen.de","Becker, Albert/F-6248-2012; Rogerio, Fabio/B-9391-2013",null,null,null,null,15,8,8,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0013-9580",null,null,"EPILEPSIA","Epilepsia","AUG",2012,53,8,null,null,null,null,1341,1348,null,"10.1111/j.1528-1167.2012.03508.x",null,8,"Clinical Neurology","Neurosciences & Neurology","001EI","WOS:000308442800014"]
[null,null,null,null,"J","Bodor, C; Renneville, A; Smith, M; Charazac, A; Iqbal, S; Etancelin, P; Cavenagh, J; Barnett, MJ; Kramarzova, K; Krishnan, B; Matolcsy, A; Preudhomme, C; Fitzgibbon, J; Owen, C",null,null,null,"Boedoer, Csaba; Renneville, Aline; Smith, Matthew; Charazac, Aurrlie; Iqbal, Sameena; Etancelin, Pascaline; Cavenagh, Jamie; Barnett, Michael J.; Kramarzova, Karolina; Krishnan, Biju; Matolcsy, Andras; Preudhomme, Claude; Fitzgibbon, Jude; Owen, Carolyn",null,null,"Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Article",null,null,null,null,null,"familial; myelodysplastic syndromes; GATA2; monosomy 7","ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; SPORADIC MONOCYTOPENIA; AUTOSOMAL-DOMINANT; PLATELET DISORDER; PREDISPOSITION; PROPENSITY; GENE","While most myelodysplastic syndrome/acute myeloid leukemia cases are sporadic, rare familial cases occur and provide some insight into leukemogenesis. The most clearly defined familial cases result from inherited mutations in RUNX1 or CEBPA. Recently, novel germline mutations in GATA2 have been reported. We, therefore, investigated individuals from families with one or more first-degree relatives with myelodysplastic syndrome/acute myeloid leukemia with wild-type RUNX1 and CEBPA, for GATA2 mutations. Screening for other recurrent mutations was also performed. A GATA2 p. Thr354Met mutation was observed in a pedigree in which 2 first-degree cousins developed high-risk myelodysplastic syndrome with monosomy 7. They were also observed to have acquired identical somatic ASXL1 mutations and both died despite stem cell transplantation. These findings confirm that germline GATA2 mutations predispose to familial myelodysplastic syndrome/acute myeloid leukemia, and that monosomy 7 and ASXL1 mutations may be recurrent secondary genetic abnormalities triggering overt malignancy in these families.","[Owen, Carolyn] Univ Calgary, Div Hematol & Hematol Malignancies, Calgary, AB, Canada; [Kramarzova, Karolina] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague, Czech Republic; [Barnett, Michael J.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Barnett, Michael J.] Vancouver Gen Hosp, Vancouver, BC, Canada; [Barnett, Michael J.] British Columbia Canc Agcy, Leukemia BMT Program British Columbia, Vancouver, BC V5Z 4E6, Canada; [Renneville, Aline; Etancelin, Pascaline; Preudhomme, Claude] CHRU Lille, Hematol Lab, Ctr Biol Pathol, Lille, France; [Boedoer, Csaba; Matolcsy, Andras] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, H-1085 Budapest, Hungary; [Boedoer, Csaba; Smith, Matthew; Charazac, Aurrlie; Iqbal, Sameena; Cavenagh, Jamie; Fitzgibbon, Jude] Queen Mary Univ London, Barts Canc Inst, Ctr Haematooncol, London EC1M 6BQ, England","Owen, C (reprint author), Foothills Med Ctr, 603 South Tower,1403-29th St NW, Calgary, AB T2N 2T9, Canada.","j.fitzgibbon@qmul.ac.uk; carolyn.owen@albertahealthservices.ca",null,null,"European Hematology Association [2009/01]; Lady Tata Memorial Trust (London, UK); Sangara Family Fund through the Department of Leukemia/Bone Marrow Transplantation; Division of Hematology (Vancouver, BC), from Cancer Research United Kingdom","this work was funded by the Partner Fellowship (2009/01) awarded by the European Hematology Association and by grants from the Lady Tata Memorial Trust (London, UK), the Sangara Family Fund through the Department of Leukemia/Bone Marrow Transplantation, Division of Hematology (Vancouver, BC), from Cancer Research United Kingdom.",null,21,7,7,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","JUN",2012,97,6,null,null,null,null,890,894,null,"10.3324/haematol.2011.054361",null,5,null,null,"969PA","WOS:000306066500019"]
[null,null,null,null,"J","Lassen, MR; Fisher, W; Mouret, P; Agnelli, G; George, D; Kakkar, A; Mismetti, P; Turpie, AGG",null,null,null,"Lassen, M. R.; Fisher, W.; Mouret, P.; Agnelli, G.; George, D.; Kakkar, A.; Mismetti, P.; Turpie, A. G. G.",null,"SAVE Investigators","Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE","JOURNAL OF THROMBOSIS AND HAEMOSTASIS",null,null,"English","Article",null,null,null,null,null,"anticoagulant; enoxaparin; orthopedic surgery; prophylaxis; semuloparin; venous thromboembolism","MOLECULAR-WEIGHT HEPARIN; ARTHROPLASTY; REPLACEMENT; THROMBOSIS; ENOXAPARIN; AVE5026","Background: Semuloparin is a novel ultra-low-molecular-weight heparin under development for venous thromboembolism (VTE) prevention in patients at increased risk, such as surgical and cancer patients. Objectives: Three Phase III studies compared semuloparin and enoxaparin after major orthopedic surgery: elective knee replacement (SAVE-KNEE), elective hip replacement (SAVE-HIP1) and hip fracture surgery (SAVE-HIP2). Patients/Methods: All studies were multinational, randomized and double-blind. Semuloparin and enoxaparin were administered for 710 days after surgery. Mandatory bilateral venography was to be performed between days 7 and 11. The primary efficacy endpoint was a composite of any deep vein thrombosis, non-fatal pulmonary embolism or all-cause death. Safety outcomes included major bleeding, clinically relevant non-major (CRNM) bleeding, and any clinically relevant bleeding (major bleeding plus CRNM). Results: In total, 1150, 2326 and 1003 patients were randomized in SAVE-KNEE, SAVE-HIP1 and SAVE-HIP2, respectively. In all studies, the incidences of the primary efficacy endpoint were numerically lower in the semuloparin group vs. the enoxaparin group, but the difference was statistically significant only in SAVE-HIP1. In SAVE-HIP1, clinically relevant bleeding and major bleeding were significantly lower in the semuloparin vs. the enoxaparin group. In SAVE-KNEE and SAVE-HIP2, clinically relevant bleeding tended to be higher in the semuloparin group, but rates of major bleeding were similar in the two groups. Other safety parameters were generally similar between treatment groups. Conclusions: Semuloparin was superior to enoxaparin for VTE prevention after hip replacement surgery, but failed to demonstrate superiority after knee replacement surgery and hip fracture surgery. Semuloparin and enoxaparin exhibited generally similar safety profiles.","[Lassen, M. R.] Copenhagen Univ Hosp Glostrup, Spine Ctr Copenhagen, Clin Trial Unit, DK-2600 Glostrup, Denmark; [Fisher, W.] McGill Univ, Ctr Hlth, Dept Orthopaed Surg, Montreal, PQ, Canada; [Mouret, P.] Klinikum Frankfurt Hoechst, Frankfurt, Germany; [Agnelli, G.] Univ Perugia, I-06100 Perugia, Italy; [George, D.] Duke Univ, Med Ctr, Durham, NC USA; [Kakkar, A.] Thrombosis Res Inst, London SW3 6LR, England; [Kakkar, A.] UCL, London, England; [Mismetti, P.] Univ St Etienne, Clin Pharmacol Unit, St Etienne, France; [Turpie, A. G. G.] McMaster Univ, Hamilton, ON, Canada","Lassen, MR (reprint author), Copenhagen Univ Hosp Glostrup, Spine Ctr Copenhagen, Clin Trial Unit, DK-2600 Glostrup, Denmark.","mrud0006@glo.regionh.dk",null,null,"Sanofi (Paris, France); Sanofi; Bayer; Pfizer; Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Exelixis; GlaxoSmithKline; Ipsen; Ipsen, Janssen; Novartis; Viamet; Bayer HealthCare; Eisai","The studies described in this manuscript were funded by Sanofi (Paris, France). The authors received editorial/writing support in the preparation of this manuscript, funded by Sanofi. The authors were fully responsible for the contents and editorial decisions for this manuscript. All authors have read and approved the final draft of the manuscript.M. R. Lassen has served as a consultant for Astellas Europe, Bayer HealthCare, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Pfizer, Protola Pharma and Sanofi. W. Fisher has received honoraria and expenses, and research funding from Sanofi, Bayer, Pfizer and Boehringer Ingelheim. P. Mouret has been a consultant for and has received honoraria from Bayer HealthCare, Sanofi and Bristol-Myers Squibb. G. Agnelli has had a consultant or advisory role for Bayer and Boehringer Ingelheim and has received honoraria from Bayer, Boehringer Ingelheim, GlaxoSmithKline and Sanofi. D. George has had a consultant or advisory role for Astellas, Bayer, Dendreon, Genentech/Roche, Ipsen, Janssen, Medivation, Novartis, Pfizer, Sanofi and Viamet; has been on the Speakers Bureau for Dendreon, Genentech/Roche, GlaxoSmithKline, Janssen, Novartis, Pfizer and Sanofi; and received research support from Bristol-Myers Squibb, Dendreon, Exelixis, GlaxoSmithKline, Ipsen, Janssen, Novartis, Pfizer and Viamet. A. Kakkar has received research funding from and has served on advisory boards with Bayer HealthCare, Sanofi, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb and Eisai; has been a consultant for Bayer HealthCare, Sanofi, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Eisai, ARYx Therapeutics and Canyon; and has received honoraria from Bayer HealthCare, Sanofi, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Eisai and GlaxoSmithKline. P. Mismetti has served as a member of Steering Committees for Sanofi. A. G. G. Turpie has served as a consultant for Astellas Europe, Bayer HealthCare, Portola Pharma and Sanofi.","Dubruc C, 2009, BLOOD, V114, P1073; Fisher W, 2009, PATHOPHYSIOL HAEM S1, V37, P203; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Ginsberg JS, 2009, J ARTHROPLASTY, V24, P1, DOI 10.1016/j.arth.2008.01.132; Handoll HH, 2002, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD000305; Howard AW, 1998, THROMB HAEMOSTASIS, V79, P902; Lassen MR, 2009, NEW ENGL J MED, V361, P594, DOI 10.1056/NEJMoa0810773; Lassen MR, 2009, PATHOPHYSIOL HAEM S1, V37, P131; Lassen MR, 2009, J THROMB HAEMOST, V7, P566, DOI 10.1111/j.1538-7836.2009.03301.x; Mouret P, 2009, PATHOPHYSIOL HAEM S1, V37, P131; Nicolaides AN, 2006, INT ANGIOL, V25, P101; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; Viskov C, 2009, J THROMB HAEMOST, V7, P1143, DOI 10.1111/j.1538-7836.2009.03447.x",13,6,6,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1538-7933",null,null,"J THROMB HAEMOST","J. Thromb. Haemost.","MAY",2012,10,5,null,null,null,null,822,832,null,"10.1111/j.1538-7836.2012.04701.x",null,11,"Hematology; Peripheral Vascular Disease","Hematology; Cardiovascular System & Cardiology","934KK","WOS:000303442800012"]
[null,null,null,null,"J","Neckar, J; Kopkan, L; Huskova, Z; Kolar, F; Papousek, F; Kramer, HJ; Hwang, SH; Hammock, BD; Imig, JD; Maly, J; Netuka, I; Ostadal, B; Cervenka, L",null,null,null,"Neckar, Jan; Kopkan, Libor; Huskova, Zuzana; Kolar, Frantisek; Papousek, Frantisek; Kramer, Herbert J.; Hwang, Sung Hee; Hammock, Bruce D.; Imig, John D.; Maly, Jiri; Netuka, Ivan; Ostadal, Bohuslav; Cervenka, Ludek",null,null,"Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension","CLINICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"angiotensin II; epoxyeicosatrienoic acid; hypertension; kidney; myocardial ischaemia/reperfusion injury; soluble epoxide hydrolase inhibitor","EPOXYEICOSATRIENOIC ACIDS; INFARCT SIZE; ISCHEMIC CONTRACTURE; MYOCARDIAL-ISCHEMIA; VASCULAR FUNCTION; ARACHIDONIC-ACID; GLOBAL-ISCHEMIA; ORGAN DAMAGE; REPERFUSION; HEARTS","The present study was undertaken to evaluate the effects of chronic treatment with c-AUCB {cis-444-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid}, a novel inhibitor of sEH (soluble epoxide hydrolase), which is responsible for the conversion of biologically active EETs (epoxyeicosatrienoic acids) into biologically inactive DHETEs (dihydroxyeicosatrienoic acids), on BP (blood pressure) and myocardial infarct size in male heterozygous TGR (Ren-2 renin transgenic rats) with established hypertension. Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. Myocardial ischaemia was induced by coronary artery occlusion. Systolic BP was measured in conscious animals by tail plethysmography. c-AUCB was administrated in drinking water. Renal and myocardial concentrations of EETs and DHETEs served as markers of internal production of epoxygenase metabolites. Chronic treatment with c-AUCB, which resulted in significant increases in the availability of biologically active epoxygenase metabolites in TGR (assessed as the ratio of EETs to DHETEs), was accompanied by a significant reduction in BP and a significantly reduced infarct size in TGR as compared with untreated TGR. The cardioprotective action of c-AUCB treatment was completely prevented by acute administration of a selective EETs antagonist [14, 15-epoxyeicosa-5(Z)-enoic acid], supporting the notion that the improved cardiac ischaemic tolerance conferred by sEH inhibition is mediated by EETs actions at the cellular level. These findings indicate that chronic inhibition of sEH exhibits antihypertensive and cardioprotective actions in this transgenic model of angiotensin II-dependent hypertension.","[Neckar, Jan; Kolar, Frantisek; Papousek, Frantisek; Netuka, Ivan; Ostadal, Bohuslav] Acad Sci Czech Republic, Inst Physiol, Dept Dev Cardiol, Prague, Czech Republic; [Neckar, Jan; Kopkan, Libor; Huskova, Zuzana; Kolar, Frantisek; Papousek, Frantisek; Maly, Jiri; Ostadal, Bohuslav; Cervenka, Ludek] Cardiovasc Res Ctr, Prague, Czech Republic; [Kopkan, Libor; Huskova, Zuzana; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Polyclin, Nephrol Sect, Bonn, Germany; [Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; [Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, UCD Canc Ctr, Davis, CA 95616 USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Neckar, J (reprint author), Acad Sci Czech Republic, Inst Physiol, Dept Dev Cardiol, Prague, Czech Republic.","neckar@biomed.cas.cz","Kolar, Frantisek/A-7852-2012; Ostadal, Bohuslav/F-7387-2014",null,"Institute for Clinical and Experimental Medicine [MZO 00023001]; Internal Grant Agency of the Ministry of Health [NS/9703-4, NS/10499-3]; Grant Agency of the Academy of Sciences of the Czech Republic [IAAX01110901, KAN 200520703]; Deutsche Forschungsgemeinschaft, Bonn [Kra 436/14-2,, 436, TSE 113/57/0-1]; Deutsche Akademische Austauschdienst, Bonn-Prague University; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/9699-4]; Center for Cardiovascular Research [1M6798582302]; National Institutes of Health [HL 59699, DK 38226]; 'Advancing a Healthier Wisconsin' grant; National Institute of Environmental Health Sciences (NIEHS) [R01 ES02710, P42 ES004699]; European Commission [CZ.2.16/3.1.00/22126]","This work was supported by Institute for Clinical and Experimental Medicine [MZO 00023001] and Internal Grant Agency of the Ministry of Health [grant numbers NS/9703-4, NS/10499-3] (to L.C.); the Grant Agency of the Academy of Sciences of the Czech Republic [IAAX01110901 and KAN 200520703] (to J.N., F.P. and F.K.); the Deutsche Forschungsgemeinschaft, Bonn [grant numbersKra 436/14-2,436 TSE 113/57/0-1] and the Deutsche Akademische Austauschdienst, Bonn-Prague University partnership (to H.J.K.); the Internal Grant Agency of the Ministry of Health of the Czech Republic [grant number NS/9699-4] (to L.K.); and the Center for Cardiovascular Research [1M6798582302] (to J.M., I.N. and B.O.); National Institutes of Health [grant numbers HL 59699, DK 38226] and by an 'Advancing a Healthier Wisconsin' grant (to J.D.I.); and the National Institute of Environmental Health Sciences (NIEHS) [grant number R01 ES02710] and NIEHS Superfund Basic Research Program [grant number P42 ES004699] (to B.D.H.). This study was also supported by the European Commission through the Operational Program Prague Competitiveness project CEVKOON (Centrum experimentalniho vyzkumu chorob krevniho obehu a organovych nahrad) [CZ.2.16/3.1.00/22126].",null,43,4,4,"PORTLAND PRESS LTD","LONDON","THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND","0143-5221",null,null,"CLIN SCI","Clin. Sci.","JUN",2012,122,41984,null,null,null,null,513,525,null,"10.1042/CS20110622",null,13,"Medicine, Research & Experimental","Research & Experimental Medicine","953RP","WOS:000304891200002"]
[null,null,null,null,"J","Mendizabal, I; Lao, O; Marigorta, UM; Wollstein, A; Gusmao, L; Ferak, V; Ioana, M; Jordanova, A; Kaneva, R; Kouvatsi, A; Kucinskas, V; Makukh, H; Metspalu, A; Netea, MG; de Pablo, R; Pamjav, H; Radojkovic, D; Rolleston, SJH; Sertic, J; Macek, M; Comas, D; Kayser, M",null,null,null,"Mendizabal, Isabel; Lao, Oscar; Marigorta, Urko M.; Wollstein, Andreas; Gusmao, Leonor; Ferak, Vladimir; Ioana, Mihai; Jordanova, Albena; Kaneva, Radka; Kouvatsi, Anastasia; Kucinskas, Vaidutis; Makukh, Halyna; Metspalu, Andres; Netea, Mihai G.; de Pablo, Rosario; Pamjav, Horolma; Radojkovic, Dragica; Rolleston, Sarah J. H.; Sertic, Jadranka; Macek, Milan, Jr.; Comas, David; Kayser, Manfred",null,null,"Reconstructing the Population History of European Romani from Genome-wide Data","CURRENT BIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"WORLDWIDE HUMAN-POPULATIONS; POSITIVE SELECTION; GENETIC-VARIATION; Y-CHROMOSOME; PATTERNS; HOMOZYGOSITY; DIVERGENCE; DIVERSITY; LINEAGES; GYPSIES","The Romani, the largest European minority group with approximately 11 million people [1], constitute a mosaic of languages, religions, and lifestyles while sharing a distinct social heritage. Linguistic [2] and genetic [3-8] studies have located the Romani origins in the Indian subcontinent. However, a genome-wide perspective on Romani origins and population substructure, as well as a detailed reconstruction of their demographic history, has yet to be provided. Our analyses based on genome-wide data from 13 Romani groups collected across Europe suggest that the Romani diaspora constitutes a single initial founder population that originated in north/northwestern India 1.5 thousand years ago (kya). Our results further indicate that after a rapid migration with moderate gene flow from the Near or Middle East, the European spread of the Romani people was via the Balkans starting -0.9 kya. The strong population substructure and high levels of homozygosity we found in the European Romani are in line with genetic isolation as well as differential gene flow in time and space with non-Romani Europeans. Overall, our genome-wide study sheds new light on the origins and demographic history of European Romani.","[Mendizabal, Isabel; Marigorta, Urko M.; Comas, David] Univ Pompeu Fabra, Inst Biol Evolut CSIC UPF, Dept Ciencies Salut & Vida, Barcelona 08003, Spain; [Lao, Oscar; Wollstein, Andreas; Kayser, Manfred] Erasmus MC Univ Med Ctr Rotterdam, Dept Forens Mol Biol, NL-3000 CA Rotterdam, Netherlands; [Gusmao, Leonor] Univ Porto IPATIMUP, Inst Pathol & Mol Immunol, P-4200465 Oporto, Portugal; [Gusmao, Leonor] Fed Univ Para UFPA, Med & Human Genet Lab, BR-66075970 Belem, Para, Brazil; [Gusmao, Leonor] Fed Univ Para UFPA, Mol Biol & Genet Postgrad Program, BR-66075970 Belem, Para, Brazil; [Ferak, Vladimir] Comenius Univ, Fac Nat Sci, Dept Mol Biol, Bratislava 84112, Slovakia; [Ioana, Mihai] Univ Med & Pharm Craiova, Craiova 200349, Romania; [Ioana, Mihai] Univ Med & Pharm Carol Davila Bucharest, Bucharest 020021, Romania; [Jordanova, Albena] Univ Antwerp VIB, Dept Mol Genet, B-2610 Antwerp, Belgium; [Jordanova, Albena; Kaneva, Radka] Med Univ Sofia, Mol Med Ctr, Dept Chem & Biochem, Sofia 1431, Bulgaria; [Kouvatsi, Anastasia] Aristotle Univ Thessaloniki, Sch Biol, Dept Genet Dev & Mol Biol, Thessaloniki 54124, Greece; [Kucinskas, Vaidutis] Vilnius State Univ, Fac Med, Dept Human & Med Genet, LT-08661 Vilnius, Lithuania; [Makukh, Halyna] Ukrainian Acad Med Sci, Inst Hereditary Pathol, UA-79008 Lvov, Ukraine; [Metspalu, Andres] Univ Tartu, Estonian Genome Ctr, EE-51010 Tartu, Estonia; [Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Inst Infect Inflammat & Immun, NL-6525 GA Nijmegen, Netherlands; [de Pablo, Rosario] Hosp Univ Puerta de Hierro, Serv Inmunol, Majadahonda 28222, Spain; [Pamjav, Horolma] Network Forens Sci Inst, Inst Forens Med, DNA Lab, H-1536 Budapest, Hungary; [Radojkovic, Dragica] Univ Belgrade, Inst Mol Genet & Genet Engn, Belgrade 11010, Serbia; [Rolleston, Sarah J. H.] Univ Wales Hosp, Inst Med Genet, Cardiff CF144XW, S Glam, Wales; [Sertic, Jadranka] Zagreb Univ Hosp Ctr, Clin Inst Lab Diag, Zagreb 10000, Croatia; [Sertic, Jadranka] Univ Zagreb, Sch Med, Dept Chem Biochem & Clin Biochem, Zagreb 10000, Croatia; [Macek, Milan, Jr.] Charles Univ Prague, Univ Hosp Motol, Dept Biol & Med Genet, Prague 15006, Czech Republic; [Macek, Milan, Jr.] Charles Univ Prague, Fac Med 2, Prague 15006, Czech Republic","Comas, D (reprint author), Univ Pompeu Fabra, Inst Biol Evolut CSIC UPF, Dept Ciencies Salut & Vida, Barcelona 08003, Spain.","david.comas@upf.edu; m.kayser@erasmusmc.nl","Gusmao, Leonor/B-3122-2013; Comas, David/D-5382-2014","Gusmao, Leonor/0000-0003-0432-6481; Comas, David/0000-0002-5075-0956","Basque Government [BFI107.4]; Erasmus MC University Medical Center Rotterdam; Universitat Pompeu Fabra; Netherlands Organization of Scientific Research; CAPES/Brazil; Estonian Government [SF0180142s08]; Spanish Government MCINN [CGL2010-14944/BOS]; Czech Republic Ministry of Health [CZ.2.16/3.1.00/24022, 00064203]; Republic of Serbia Ministry of Education and Science [ON173008]; Belgium University of Antwerp [IWS BOFUA 2008/23064]; Portuguese Foundation for Science and Technology (FCT) [PTDC/ANT/70413/2006]; FCT","We thank Jordi Cami and Francesc Valenti for their valuable help in collecting Romani samples from Spain, Natasa Petrovic for collecting Romani samples from Serbia, Lazarus P. Lazarou for collecting Romani samples from Wales, UK, Jasenka Hauselmaier for the recruitment of Romani samples from Croatia, and Ivaylo Tumev for the recruitment of Romani samples from Bulgaria. We are grateful to Mark Stoneking for his valuable comments on the manuscript. I.M. was supported by a PhD grant by the Basque Government (Hezkuntza, Unibertsitate eta Ikerketa Saila, Eusko Jaurlaritza, BFI107.4). O.L., A.W., and M.K. were supported by the Erasmus MC University Medical Center Rotterdam. U.M.M. was supported by a PhD grant by Universitat Pompeu Fabra. M.G.N. was supported by a Vici grant of the Netherlands Organization of Scientific Research. L.G. was supported by an Invited Professor grant from CAPES/Brazil. A.M. was supported by the Estonian Government grant SF0180142s08. This study was supported in parts by Spanish Government MCINN grant CGL2010-14944/BOS to D.C., Czech Republic Ministry of Health grants CZ.2.16/3.1.00/24022 and 00064203 to M.M., Republic of Serbia Ministry of Education and Science grant ON173008 to D.R., Belgium University of Antwerp grant IWS BOFUA 2008/23064 to A.J., and Portuguese Foundation for Science and Technology (FCT) project grant PTDC/ANT/70413/2006 to L.G. IPATIMUP is an Associate Laboratory of the Portuguese Ministry of Education and Science and is partially supported by the FCT.",null,33,3,3,"CELL PRESS","CAMBRIDGE","600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA","0960-9822",null,null,"CURR BIOL","Curr. Biol.","DEC 18",2012,22,24,null,null,null,null,2342,2349,null,"10.1016/j.cub.2012.10.039",null,8,"Biochemistry & Molecular Biology; Cell Biology","Biochemistry & Molecular Biology; Cell Biology","060EX","WOS:000312760400025"]
[null,null,null,null,"J","Kraus, T; Heidari, N; Svehlik, M; Schneider, F; Sperl, M; Linhart, W",null,null,null,"Kraus, Tanja; Heidari, Nima; Svehlik, Martin; Schneider, Frank; Sperl, Matthias; Linhart, Wolfgang",null,null,"Outcome of repaired unstable meniscal tears in children and adolescents","ACTA ORTHOPAEDICA",null,null,"English","Article",null,null,null,null,null,null,"ANTERIOR CRUCIATE LIGAMENT; ARTHROSCOPIC REPAIR; KNEE-JOINT; FOLLOW-UP; PUBERTAL CHANGES; AVASCULAR ZONE; SUTURE REPAIR; RECONSTRUCTION; YOUNGER; PATTERN","Background Unstable meniscal tears are rare injuries in skeletally immature patients. Loss of a meniscus increases the risk of subsequent development of degenerative changes in the knee. This study deals with the outcome of intraarticular meniscal repair and factors that affect healing. Parameters of interest were type and location of the tear and also the influence of simultaneous reconstruction of a ruptured ACL. Methods We investigated the outcome of 25 patients (29 menisci) aged 15 (4-17) years who underwent surgery for full thickness meniscal tears, either as isolated lesions or in combination with ACL ruptures. Intraoperative documentation followed the IKDC 2000 standard. Outcome measurements were the Tegner score (pre- and postoperatively) and the Lysholm score (postoperatively) after an average follow-up period of 2.3 years, with postoperative arthroscopy and MRT in some cases. Results 24 of the 29 meniscal lesions healed (defined as giving an asymptomatic patient) regardless of location or type. 4 patients re-ruptured their menisci (all in the pars intermedia) at an average of 15 months after surgery following a new injury. Mean Lysholm score at follow-up was 95, the Tegner score deteriorated, mean preoperative score: 7.8 (4-10); mean postoperative score: 7.2 (4-10). Patients with simultaneous ACL reconstruction had a better outcome. Interpretation All meniscal tears in the skeletally immature patient are amenable to repair. All recurrent meniscal tears in our patients were located in the pars intermedia; the poorer blood supply in this region may give a higher risk of re-rupture. Simultaneous ACL reconstruction appears to benefit the results of meniscal repair.","[Kraus, Tanja; Svehlik, Martin; Schneider, Frank; Sperl, Matthias; Linhart, Wolfgang] Med Univ Graz, Dept Pediat Orthopaed, Graz, Austria; [Svehlik, Martin] Charles Univ Prague, Dept Orthopaed & Traumatol Children & Adults, Fac Med 2, Prague, Czech Republic; [Heidari, Nima] Bristol Royal Infirm & Gen Hosp, Dept Limb Reconstruct, Bristol, Avon, England","Kraus, T (reprint author), Med Univ Graz, Dept Pediat Orthopaed, Graz, Austria.","tanja.kraus@medunigraz.at",null,null,null,null,null,46,3,3,"INFORMA HEALTHCARE","NEW YORK","52 VANDERBILT AVE, NEW YORK, NY 10017 USA","1745-3674",null,null,"ACTA ORTHOP","Acta Orthop.","JUN",2012,83,3,null,null,null,null,261,266,null,"10.3109/17453674.2012.693017",null,6,"Orthopedics","Orthopedics","952GX","WOS:000304781000010"]
[null,null,null,null,"J","Kraus, T; Lidder, S; Svehlik, M; Rippel, K; Schneider, F; Eberl, R; Linhart, W",null,null,null,"Kraus, Tanja; Lidder, Surjit; Svehlik, Martin; Rippel, Karoline; Schneider, Frank; Eberl, Robert; Linhart, Wolfgang",null,null,"Patella re-alignment in children with a modified Grammont technique Outcome in 65 knees after mean 8 years","ACTA ORTHOPAEDICA",null,null,"English","Article",null,null,null,null,null,null,"MEDIAL PATELLOFEMORAL LIGAMENT; OPERATIVE TREATMENT; FOLLOW-UP; RECURRENT DISLOCATION; PROXIMAL REALIGNMENT; RANDOMIZED PATIENTS; INSTABILITY; ADOLESCENTS; SURGERY; OSTEOARTHRITIS","Background and purpose In skeletally immature patients, surgical options due to recurrent patella dislocation are limited, because bony procedures bear the risk of growth disturbances. In this retrospective study, we report the long-term functional and radiographic outcome in skeletally immature patients using the modified Grammont surgical technique. Patients Between 1999 and 2004, 65 skeletally immature knees (49 children) were treated with a modified Grammont procedure: an open lateral release and a shift of the patella tendon insertion below the growth plate on the tuberositas tibia, allowing the tendon to medialize. At mean 8 (5.6-11) years after surgery, 58 knees in 43 patients were evaluated by clinical examination, from functional scores (Lysholm, Tegner), and from radiographs of the knees. Results Mean Lysholm score was 82 postoperatively. Tegner score decreased from 6.2 to 5. Eight knees had a single dislocation within 3 months of surgery. 3 knees had repeated late dislocations, all with a high grade of trochlea dysplasia. 6 knees showed mild signs of osteoarthritis. No growth disturbances were observed. Interpretation The modified Grammont technique in skeletally immature patients allows restoration of the distal patella tendon alignment by dynamic positioning. Long-term results showed that there were no growth disturbances and that there was good functional outcome. However, patients with a high grade of trochlea dysplasia tended to re-dislocate.","[Kraus, Tanja; Rippel, Karoline; Schneider, Frank; Eberl, Robert; Linhart, Wolfgang] Med Univ Graz, Dept Paediat Orthopaed, Graz, Austria; [Svehlik, Martin] Charles Univ Prague, Fac Med 2, Dept Orthopaed & Traumatol Children & Adults, Prague, Czech Republic","Kraus, T (reprint author), Med Univ Graz, Dept Paediat Orthopaed, Graz, Austria.","tanjakraus@medunigraz.at",null,null,null,null,null,39,2,2,"INFORMA HEALTHCARE","NEW YORK","52 VANDERBILT AVE, NEW YORK, NY 10017 USA","1745-3674",null,null,"ACTA ORTHOP","Acta Orthop.","OCT",2012,83,5,null,null,null,null,504,510,null,"10.3109/17453674.2012.736168",null,7,"Orthopedics","Orthopedics","023EM","WOS:000310015700012"]
[null,null,null,null,"J","Lehrnbecher, T; Aplenc, R; Pereira, FR; Lassaletta, A; Caselli, D; Kowalczyk, J; Chisholm, J; Sung, LL",null,null,null,"Lehrnbecher, Thomas; Aplenc, Richard; Rivas Pereira, Fernanda; Lassaletta, Alvaro; Caselli, Desiree; Kowalczyk, Jerzy; Chisholm, Julia; Sung, Lillian",null,"SIOP Supportive Care Working Grp","Variations in non-pharmacological anti-infective measures in childhood leukemia - results of an international survey","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; acute myeloid leukemia; child; infection; non-pharmacological anti-infective measures","ACUTE MYELOID-LEUKEMIA; NEUTROPENIC DIET; INDUCTION THERAPY; CHILDREN; TRIALS; INFECTIONS","Background Standardization in clinical practice may lead to improved outcomes. Unfortunately, little is known about the variability of non-pharmacological anti-infective measures in children with cancer. Design and Methods A web-based survey assessed institutional recommendations regarding restrictions of social contacts, pets and food and instructions on wearing face masks in public for children with standard-risk acute lymphoblastic leukemia and acute myeloid leukemia during intensive chemotherapy. Results A total of 336 institutions in 27 countries responded to the survey (range, 1-76 institutions per country; overall response rate 61%). Most institutions recommend that patients with acute myeloid leukemia avoid indoor public places and daycare, kindergarten and school, whereas recommendations for patients with acute lymphoblastic leukemia differ considerably by institution. In terms of restrictions related to pets, there was a wide variability between institutions for both acute lymphoblastic and acute myeloid leukemia patients. Most, but not all institutions do not allow children with either acute lymphoblastic or acute myeloid leukemia to eat raw meat, raw seafood or unpasteurized milk. Whereas most institutions do not routinely recommend that patients with acute lymphoblastic leukemia wear face masks in public, advice on this matter varies for patients with acute myeloid leukemia. Conclusions The survey demonstrates that there is a wide variation in recommendations on non-pharmacological anti-infective measures between different institutions, countries and continents. This information may be used to encourage harmonization of supportive care practices and future clinical trials.","[Lehrnbecher, Thomas] Goethe Univ Frankfurt, Paediat Haematol & Oncol Childrens Hosp 3, D-60590 Frankfurt, Germany; [Aplenc, Richard] Childrens Hosp Philadelphia, Philadelphia, PA USA; [Rivas Pereira, Fernanda] Childrens Hosp Gutierrez, Argentine Treatment Grp Acute Leukemias GATLA, Buenos Aires, DF, Argentina; [Lassaletta, Alvaro] Hosp Nino Jesus, Madrid, Spain; [Caselli, Desiree] Univ Meyer, Azienda Osped, Florence, Italy; [Kowalczyk, Jerzy] Med Univ Lublin, Lublin, Poland; [Chisholm, Julia] Royal Marsden Hosp, Sutton, Surrey, England; [Sung, Lillian] Hosp Sick Children, Toronto, ON M5G 1X8, Canada","Lehrnbecher, T (reprint author), Goethe Univ Frankfurt, Paediat Haematol & Oncol Childrens Hosp 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.","Thomas.Lehrnbecher@kgu.de",null,null,null,null,"Bochennek K, 2011, CLIN MICROBIOL INFEC, V17, P1868, DOI 10.1111/j.1469-0691.2011.03483.x; Castagnola E, 2008, BONE MARROW TRANSPL, V41, P339, DOI 10.1038/sj.bmt.1705921; DeMille D, 2006, ONCOL NURS FORUM, V33, P337, DOI 10.1188/ONF.06.337-343; Gardner A, 2008, J CLIN ONCOL, V26, P5684, DOI 10.1200/JCO.2008.16.4681; Hargrave DR, 2001, BRIT J HAEMATOL, V112, P293, DOI 10.1046/j.1365-2141.2001.02543.x; Kommission fur Krankenhaushygiene und Infektionspravention beim Robert Koch-Institut (RKI), 2010, BUNDESGESUNDHEITSBLA, V53, P357; Lehrnbecher T, 2008, EUR J CANCER, V44, P1861, DOI 10.1016/j.ejca.2008.06.022; Lehrnbecher T, 2009, BRIT J HAEMATOL, V147, P125, DOI 10.1111/j.1365-2141.2009.07844.x; Maschmeyer G, 2009, ANN ONCOL, V20, P1560, DOI 10.1093/annonc/mdp034; Moody K, 2002, J PEDIAT HEMATOL ONC, V24, P717, DOI 10.1097/00043426-200212000-00007; Moody K, 2006, J PEDIAT HEMATOL ONC, V28, P126, DOI 10.1097/01.mph.0000210412.33630.fb; Rungoe C, 2010, PEDIATR BLOOD CANCER, V55, P304, DOI 10.1002/pbc.22423; Sander A, 2010, LEUKEMIA, V24, P1422, DOI 10.1038/leu.2010.127; Schrappe M, 2000, LEUKEMIA, V14, P2205, DOI 10.1038/sj.leu.2401973; Sung L, 2004, J CLIN ONCOL, V22, P3350, DOI 10.1200/JCO.2004.09.106; Sung LL, 2007, BLOOD, V110, P3532, DOI 10.1182/blood-2007-05-091942; U.S. Food and Drug Administration (FDA), RAW MILK MAY POS HLT; Zitella Laura J, 2006, Clin J Oncol Nurs, V10, P739, DOI 10.1188/06.CJON.739-750",18,0,0,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOL-HEMATOL J","Haematol-Hematol. J.","OCT",2012,97,10,null,null,null,null,1548,1552,null,"10.3324/haematol.2012.062885",null,5,null,null,"025QZ","WOS:000310208400018"]
[null,null,null,null,"J","Radue, EW; O'Connor, P; Polman, CH; Hohlfeld, R; Calabresi, P; Selmaj, K; Mueller-Lenke, N; Agoropoulou, C; Holdbrook, F; de Vera, A; Zhang-Auberson, L; Francis, G; Burtin, P; Kappos, L",null,null,null,"Radue, Ernst-Wilhelm; O'Connor, Paul; Polman, Chris H.; Hohlfeld, Reinhard; Calabresi, Peter; Selmaj, Krystof; Mueller-Lenke, Nicole; Agoropoulou, Catherine; Holdbrook, Frederick; de Vera, Ana; Zhang-Auberson, Lixin; Francis, Gordon; Burtin, Pascale; Kappos, Ludwig",null,"FTY720 Res Evaluating Effects","Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis","ARCHIVES OF NEUROLOGY",null,null,"English","Article",null,null,null,null,null,null,"PLACEBO-CONTROLLED TRIAL; BRAIN ATROPHY; CEREBRAL ATROPHY; ORAL FINGOLIMOD; FTY720 FINGOLIMOD; RELAPSING MS; INTERFERON; DISABILITY; IMPAIRMENT; LESIONS","Objective: To assess the impact of fingolimod (FTY720) therapy on magnetic resonance imaging measures of inflammatory activity and tissue damage in patients participating in a 2-year, placebo-controlled, phase 3 study. Design: Patients with active relapsing-remitting multiple sclerosis were randomized to receive fingolimod, 0.5 mg; fingolimod, 1.25 mg; or placebo for 2 years. Standardized magnetic resonance imaging scans were obtained at months 0, 6, 12, and 24 and centrally evaluated for number and volume of T1 gadolinium-enhancing, T2 hyperintense, and T1 hypointense lesions and for percentage of brain volume change. Findings were compared across subgroups by treatment and baseline characteristics. Setting: Worldwide, multicenter clinical trial. Patients: Patients were part of the fingolimod FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) clinical trial for relapsing-remitting multiple sclerosis (N=1272). Main Outcome Measures: We measured the effect of therapy on acute inflammatory activity, burden of disease, and irreversible loss of brain volume. Results: Fingolimod therapy resulted in rapid and sustained reductions in inflammatory lesion activity as assessed by gadolinium-enhancing and new/newly enlarged T2 lesions after 6, 12, and 24 months of therapy (P<.001, all comparisons vs placebo). Changes in T2 hyperintense and T1 hypointense lesion volume also significantly favored fingolimod (P<.05, all comparisons). Fingolimod, 0.5 mg (licensed dose), significantly reduced brain volume loss during months 0 to 6, 0 to 12, 12 to 24, and 0 to 24 (P<.05, all comparisons) vs placebo, and subgroup analyses confirmed these effects over 2 years irrespective of the presence/absence of gadolinium-enhancing lesions, T2 lesion load, previous treatment status, or level of disability. Conclusion: These results, coupled with the significant reductions in relapse rates and disability progression reported previously, support the positive impact on long-term disease evolution.","[Radue, Ernst-Wilhelm; Mueller-Lenke, Nicole] Univ Basel Hosp, Med Image Anal Ctr, CH-4031 Basel, Switzerland; [Kappos, Ludwig] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Kappos, Ludwig] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland; [Agoropoulou, Catherine; de Vera, Ana; Zhang-Auberson, Lixin; Burtin, Pascale] Novartis Pharma AG, Basel, Switzerland; [O'Connor, Paul] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Polman, Chris H.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [Hohlfeld, Reinhard] Klinikum LMU Munchen, Inst Clin Neuroimmunol, Munich, Germany; [Calabresi, Peter] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; [Selmaj, Krystof] Med Acad, Dept Neurol, Lodz, Poland; [Holdbrook, Frederick; Francis, Gordon] Novartis Pharmaceut, E Hanover, NJ USA","Radue, EW (reprint author), Univ Basel Hosp, Med Image Anal Ctr, Schanzenstr 55, CH-4031 Basel, Switzerland.","eradue@uhbs.ch",null,null,"Actelion; Basilea Pharmaceutica Ltd; Biogen Idec; Merck Serono; Novartis; Novartis Pharma AG; Bayer Schering; GlaxoSmithKline; Roche; Teva; UCB; Bayer Schering Pharma; sanofi-aventis; Abbott; Bayer; EMD-Serono; Genentech; Vertex; Genzyme; ONO Pharmaceuticals; Swiss MS Society; Swiss National Research Foundation; European Union; Gianni Rubatto Foundation; Roche Research Foundation; Novartis Pharma AG, Basel, Switzerland","Dr Radue has received personal compensation from Bayer Schering, Biogen Idec, Novartis, and Merck Serono for consulting and speaking services and financial support for research activities from Actelion, Basilea Pharmaceutica Ltd, Biogen Idec, Merck Serono, and Novartis. Dr O'Connor has received personal compensation for consulting and serving on scientific advisory boards and research funding from Novartis Pharma AG. Dr Polman has received honoraria and/or consultation fees and/or research support from Actelion, Biogen Idec, Bayer Schering, GlaxoSmithKline, Merck Serono, Novartis, Roche, Teva, and UCB. Dr Hohlfeld has received personal compensation for serving on scientific advisory boards and/or speaking activities as principal or on advisory boards from Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, sanofi-aventis, and Teva and research grant support from Bayer Schering Pharma, Biogen Idec, Novartis, sanofi-aventis, and Teva. Dr Calabresi has received personal compensation for consulting and serving on scientific advisory boards from Abbott, Biogen Idec, Genzyme, Novartis, Teva, and Vaccinex and has received research funding from Abbott, Bayer, Biogen Idec, EMD-Serono, Genentech, Teva, and Vertex. Dr Selmaj has received honoraria and/or consultation fees and/or research support from Biogen Idec, Genzyme, Merck Serono, Novartis, ONO Pharmaceuticals, and Roche. Drs Agoropoulou, Burtin, de Vera, and Zhang-Auberson are employees of Novartis Pharma AG. Drs Holdbrook and Francis are employees of Novartis Pharmaceuticals Corporation. Dr Kappos has received compensation, used as research funding, for consulting, serving on scientific advisory boards, acting as a clinical trial principal investigator and member or chair of planning and steering committees, and/or speaking activities as principal or on advisory boards from Actelion, Advancell, Allozyne, BaroFold, Bayer HealthCare, Bayer Schering Pharma, Bayhill, Biogen Idec, BioMarin, CSL Behring, Elan, Genmab, GeNeuro SA, GenMark, GlaxoSmithKline, Lilly, Merck Serono, MediciNova, Novartis, Novo Nordisk, Peptimmune, sanofi-aventis, Santhera, Roche, Teva, UCB, and Wyeth. Research and clinical operations (nursing and patient care services) at the MS Center in Basel have been supported by unrestricted grants from 1 or more of these companies and by grants from the Swiss MS Society, the Swiss National Research Foundation, the European Union, the Gianni Rubatto Foundation, Novartis, and the Roche Research Foundation.The study was funded by Novartis Pharma AG, Basel, Switzerland.We thank the patients and investigators who took part in this study. They thank Hashem Salloukh of Novartis Pharma AG and Tom Potter and Sarah Griffiths of Oxford PharmaGenesis Ltd for editorial assistance, collating comments from authors and other named contributors, and editing the manuscript for submission. Such editorial help was funded by Novartis Pharma AG.","Anderson VM, 2006, J MAGN RESON IMAGING, V23, P605, DOI 10.1002/jmri.20550; Anderson VM, 2007, J NEUROL, V254, P1588, DOI 10.1007/s00415-007-0599-3; Barkhof F, 2009, NAT REV NEUROL, V5, P256, DOI 10.1038/nrneurol.2009.41; Bermel RA, 2006, LANCET NEUROL, V5, P158, DOI 10.1016/S1474-4422(06)70349-0; Brinkmann V, 2009, BRIT J PHARMACOL, V158, P1173, DOI 10.1111/j.1476-5381.2009.00451.x; Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Choi JW, 2011, P NATL ACAD SCI USA, V108, P751, DOI 10.1073/pnas.1014154108; Chun J, 2010, CLIN NEUROPHARMACOL, V33, P91, DOI 10.1097/WNF.0b013e3181cbf825; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; De Stefano N, 2010, NEUROLOGY, V74, P1868, DOI 10.1212/WNL.0b013e3181e24136; Fisher E, 2008, ANN NEUROL, V64, P255, DOI 10.1002/ana.21436; Fisher E, 2002, NEUROLOGY, V59, P1412; Gauthier SA, 2009, ARCH NEUROL-CHICAGO, V66, P234, DOI 10.1001/archneurol.2008.567; Hardmeier M, 2003, ARCH NEUROL-CHICAGO, V60, P1736, DOI 10.1001/archneur.60.12.1736; Hardmeier M, 2005, NEUROLOGY, V64, P236; Jasperse B, 2007, ARCH NEUROL-CHICAGO, V64, P190, DOI 10.1001/archneur.64.2.190; Kappos L, 1999, LANCET, V353, P964, DOI 10.1016/S0140-6736(98)03053-0; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Khatri B, 2011, LANCET NEUROL, V10, P520, DOI 10.1016/S1474-4422(11)70099-0; KURTZKE JF, 1983, NEUROLOGY, V33, P1444; Leist TP, 2001, ARCH NEUROL-CHICAGO, V58, P57, DOI 10.1001/archneur.58.1.57; Leist TP, 2010, NEUROLOGY, V74, pS54, DOI 10.1212/WNL.0b013e3181c98011; Mesaros S, 2008, J NEUROL, V255, P1378, DOI 10.1007/s00415-008-0924-5; Miller DH, 2007, NEUROLOGY, V68, P1390, DOI 10.1212/01.wnl.0000260064.77700.fd; Miron VE, 2010, AM J PATHOL, V176, P2682, DOI 10.2353/ajpath.2010.091234; Molyneux PD, 2000, BRAIN, V123, P2256, DOI 10.1093/brain/123.11.2256; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.206703; Richert ND, 2006, NEUROLOGY, V66, P551, DOI 10.1212/01.wnl.0000197982.78063.06; Rudick RA, 2000, MULT SCLER, V6, P365, DOI 10.1177/135245850000600601; Sahraian MA, 2010, ACTA NEUROL SCAND, V122, P1, DOI 10.1111/j.1600-0404.2009.01221.x; Sahraian M.A., 2008, MRI ATLAS MS LESIONS; Seewann A, 2009, ACTA NEUROL SCAND, V119, P349, DOI 10.1111/j.1600-0404.2008.01137.x; Soliven B, 2011, NEUROLOGY, V76, pS9, DOI 10.1212/WNL.0b013e31820d9507; van den Elskamp IJ, 2010, NEURORADIOLOGY, V52, P875, DOI 10.1007/s00234-009-0645-1; Zivadinov R, 2005, J NEUROL SCI, V233, P73, DOI 10.1016/j.jns.2005.03.006; Zivadinov R, 2008, NEUROLOGY, V71, P136, DOI 10.1212/01.wnl.0000316810.01120.05",37,10,10,"AMER MEDICAL ASSOC","CHICAGO","515 N STATE ST, CHICAGO, IL 60654-0946 USA","0003-9942",null,null,"ARCH NEUROL-CHICAGO","Arch. Neurol.","OCT",2012,69,10,null,null,null,null,1259,1269,null,"10.1001/archneurol.2012.1051",null,11,null,null,"016TC","WOS:000309541400004"]
[null,null,null,null,"J","Krizkova, S; Ryvolova, M; Hrabeta, J; Adam, V; Stiborova, M; Eckschlager, T; Kizek, R",null,null,null,"Krizkova, Sona; Ryvolova, Marketa; Hrabeta, Jan; Adam, Vojtech; Stiborova, Marie; Eckschlager, Tomas; Kizek, Rene",null,null,"Metallothioneins and zinc in cancer diagnosis and therapy","DRUG METABOLISM REVIEWS",null,null,"English","Review",null,null,null,null,null,"Apoptosis; cancer; resistance; metallothioneins; zinc; NF-kappa B; protein p53; prognostic factor; tumor marker","NF-KAPPA-B; INHIBITORY FACTOR METALLOTHIONEIN-3; SQUAMOUS-CELL CARCINOMA; ANTISENSE DOWN-REGULATION; TRANSCRIPTION FACTOR-IIIA; SUPPRESSOR PROTEIN P53; NERVOUS-SYSTEM TUMORS; BREAST-CANCER; GENE-EXPRESSION; OXIDATIVE STRESS","Metallothioneins (MTs) are involved in protection against oxidative stress (OS) and toxic metals and they participate in zinc metabolism and its homeostasis. Disturbing of zinc homeostasis can lead to formation of reactive oxygen species, which can result in OS causing alterations in immunity, aging, and civilization diseases, but also in cancer development. It is not surprising that altered zinc metabolism and expression of MTs are of great interest in the case of studying of oncogenesis and cancer prognosis. The role of MTs and zinc in cancer development is tightly connected, and the structure and function of MTs are strongly dependent on Zn2+ redox state and its binding to proteins. Antiapoptic effects of MTs and their interactions with proteins nuclear factor kappa B, protein kinase C, esophageal cancer-related gene, and p53 as well as the role of MTs in their proliferation, immunomodulation, enzyme activation, and interaction with nitric oxide are reviewed. Utilization of MTs in cancer diagnosis and therapy is summarized and their importance for chemoresistance is also mentioned.","[Krizkova, Sona; Ryvolova, Marketa; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Krizkova, Sona; Ryvolova, Marketa; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, Brno, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Hrabeta, Jan; Eckschlager, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, Prague, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz",null,null,"CYTORES [GA CR P301/10/0356, CEITEC CZ.1.05/1.1.00/02.0068, IGA TP 6/2012]","Financial support from CYTORES GA CR P301/10/0356, CEITEC CZ.1.05/1.1.00/02.0068, IGA TP 6/2012 and project for conceptual development of research organization 00064203 is greatly acknowledged.",null,223,11,11,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0360-2532",null,null,"DRUG METAB REV","Drug Metab. Rev.","DEC",2012,44,4,null,null,null,null,287,301,null,"10.3109/03602532.2012.725414",null,15,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","052SL","WOS:000312218600002"]
[null,null,null,null,"J","Rolo, J; Miragaia, M; Turlej-Rogacka, A; Empel, J; Bouchami, O; Faria, NA; Tavares, A; Hryniewicz, W; Fluit, AC; de Lencastre, H",null,null,null,"Rolo, Joana; Miragaia, Maria; Turlej-Rogacka, Agata; Empel, Joanna; Bouchami, Ons; Faria, Nuno A.; Tavares, Ana; Hryniewicz, Waleria; Fluit, Ad C.; de Lencastre, Herminia",null,"CONCORD Working Grp","High Genetic Diversity among Community-Associated Staphylococcus aureus in Europe: Results from a Multicenter Study","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"PANTON-VALENTINE-LEUKOCIDIN; CASSETTE CHROMOSOME MEC; METHICILLIN-RESISTANT; NASAL CARRIAGE; UNITED-STATES; PCR STRATEGY; STRAINS; INFECTIONS; SEQUENCE; CLONES","Background: Several studies have addressed the epidemiology of community-associated Staphylococcus aureus (CA-SA) in Europe; nonetheless, a comprehensive perspective remains unclear. In this study, we aimed to describe the population structure of CA-SA and to shed light on the origin of methicillin-resistant S. aureus (MRSA) in this continent. Methods and Findings: A total of 568 colonization and infection isolates, comprising both MRSA and methicillin-susceptible S. aureus (MSSA), were recovered in 16 European countries, from community and community-onset infections. The genetic background of isolates was characterized by molecular typing techniques (spa typing, pulsed-field gel electrophoresis and multilocus sequence typing) and the presence of PVL and ACME was tested by PCR. MRSA were further characterized by SCCmec typing. We found that 59% of all isolates were associated with community-associated clones. Most MRSA were related with USA300 (ST8-IVa and variants) (40%), followed by the European clone (ST80-IVc and derivatives) (28%) and the Taiwan clone (ST59-IVa and related clonal types) (15%). A total of 83% of MRSA carried Panton-Valentine leukocidin (PVL) and 14% carried the arginine catabolic mobile element (ACME). Surprisingly, we found a high genetic diversity among MRSA clonal types (ST-SCCmec), Simpson's index of diversity = 0.852 (0.788-0.916). Specifically, about half of the isolates carried novel associations between genetic background and SCCmec. Analysis by BURP showed that some CA-MSSA and CA-MRSA isolates were highly related, suggesting a probable local acquisition/loss of SCCmec. Conclusions: Our results imply that CA-MRSA origin, epidemiology and population structure in Europe is very dissimilar from that of USA.","[Rolo, Joana; Miragaia, Maria; Bouchami, Ons; Faria, Nuno A.; Tavares, Ana; de Lencastre, Herminia] Univ Nova Lisboa, Inst Tecnol Quim & Biol, Mol Genet Lab, P-2780156 Oeiras, Portugal; [Turlej-Rogacka, Agata; Empel, Joanna; Hryniewicz, Waleria] Natl Med Inst, Div Clin Microbiol & Infect Prevent, Warsaw, Poland; [Bouchami, Ons] Lab Natl Bone Marrow Transplantat Ctr, Tunis, Tunisia; [Fluit, Ad C.] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands; [de Lencastre, Herminia] Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA","Rolo, J (reprint author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Mol Genet Lab, P-2780156 Oeiras, Portugal.","lencash@mail.rockefeller.edu","Hryniewicz, Waleria/J-3168-2012; Faria, Nuno/B-9229-2009; Rolo, Joana/G-4447-2011","Faria, Nuno/0000-0003-3762-9809; Rolo, Joana/0000-0002-5291-212X","European Commission [CONCORD-HEALTH-F3-2008-222718]; Fundacao para a Ciencia e Tecnologia (FCT), Portugal [SFRH/BD/72675/2010, SFRH/BPD/66514/2009, SFRH/BD/44220/2008]; Ministry of Science and Higher Education, Poland [1216/7. PR UE/2009/7]; FCT [Pest-OE/EQB/LAO004/2011]; Internal Grant Agency, Ministry of Health [IGA9642-4, IGA NT12395-5/2011]; Hungarian National Scientific Research Fund [OTKA T 46186]","JR, OB and AT-R were supported by fellowships from project CONCORD-HEALTH-F3-2008-222718 from the European Commission. JR, NAF and AT were supported by grants SFRH/BD/72675/2010, SFRH/BPD/66514/2009 and SFRH/BD/44220/2008 from Fundacao para a Ciencia e Tecnologia (FCT), Portugal. JE and WH were supported by a grant no 1216/7. PR UE/2009/7 from the Ministry of Science and Higher Education, Poland. This work was funded by project CONCORD-HEALTH-F3-2008-222718 from the European Commission. The work performed at Instituto de Tecnologia Quimica e Biologica was supported additionally by FCT through grant #Pest-OE/EQB/LAO004/2011. The work performed at National Medicines Institute was partially supported by the Mikrobank 2 Programme from the Ministry of Science and Higher Education, Poland. The study was partially supported by a grant from the Internal Grant Agency, Ministry of Health (CZ), IGA9642-4 (for Czech Republic - Helena Zemlickova, Marta Fridrichova) and IGA NT12395-5/2011 (Oto Melter, Czech Republic). The isolation and characterization of the Hungarian strains were supported in part by the Hungarian National Scientific Research Fund, Grant No.: OTKA T 46186, to Ferenc Rozgonyi. The other participants did not receive additional funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","Aires-de-Sousa M, 2006, J CLIN MICROBIOL, V44, P619, DOI 10.1128/JCM.44.2.619-621.2006; Balis E, 2007, J CHEMOTHERAPY, V19, P703; Campanile F, 2011, EUR J CLIN IN PRESS; Carpaij N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016419; Hunt C, 1999, JAMA-J AM MED ASSOC, V282, P1123; Chung M, 2000, MICROB DRUG RESIST, V6, P189, DOI 10.1089/mdr.2000.6.189; Clinical and Laboratory Standards Institute, 2009, M100S19 CLSI; Conceicao T, 2011, EUR J CLIN MICROBIOL, V30, P293, DOI 10.1007/s10096-010-1087-8; Coombs GW, 2004, J CLIN MICROBIOL, V42, P4735, DOI 10.1128/JCM.42.10.4735-4743.2004; Costello ME, 2011, EUR J CLIN MICROBIOL, V30, P1163, DOI 10.1007/s10096-011-1203-4; Cremieux AC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007204; Daskalaki M, 2010, CLIN MICROBIOL INFEC, V16, P74, DOI 10.1111/j.1469-0691.2009.02830.x; DeLeo FR, 2010, LANCET, V375, P1557, DOI 10.1016/S0140-6736(09)61999-1; de Sousa MA, 2003, J CLIN MICROBIOL, V41, P2027, DOI 10.1128/JCM.41.5.2027-2032.2003; de Sousa MA, 2005, J CLIN MICROBIOL, V43, P5150, DOI 10.1128/JCM.43.10.5150-5157.2005; Deurenberg RH, 2009, CURR MOL MED, V9, P100; Diep BA, 2008, J INFECT DIS, V197, P1523, DOI 10.1086/587907; Diep BA, 2010, P NATL ACAD SCI USA, V107, P5587, DOI 10.1073/pnas.0912403107; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; Enright MC, 2000, J CLIN MICROBIOL, V38, P1008; Faria NA, 2008, J CLIN MICROBIOL, V46, P136, DOI 10.1128/JCM.01684-07; Francis JS, 2005, CLIN INFECT DIS, V40, P100, DOI 10.1086/427148; Garcia-Alvarez L, 2011, LANCET INFECT DIS, V11, P595, DOI 10.1016/S1473-3099(11)70126-8; Ghebremedhin B, 2009, J CLIN MICROBIOL, V47, P2975, DOI 10.1128/JCM.00648-09; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Green SM, 2010, J MED MICROBIOL, V59, P1084, DOI 10.1099/jmm.0.018986-0; Grundmann H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000215; Highlander SK, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-99; Huang YC, 2011, INT J ANTIMICROB AG, V38, P2, DOI 10.1016/j.ijantimicag.2011.01.011; Ito T, 2009, ANTIMICROB AGENTS CH, V53, P4961, DOI 10.1128/AAC.00579-09; Issartel B, 2005, J CLIN MICROBIOL, V43, P3203, DOI 10.1128/JCM.43.7.3203-3207.2005; Jappe U, 2008, J INVEST DERMATOL, V128, P2655, DOI 10.1038/jid.2008.133; Kanerva M, 2009, J CLIN MICROBIOL, V47, P2655, DOI 10.1128/JCM.00771-09; Katayama Y, 2000, ANTIMICROB AGENTS CH, V44, P1549, DOI 10.1128/AAC.44.6.1549-1555.2000; Kawaguchiya M, 2011, MICROB DRUG RESIST, V17, P241, DOI 10.1089/mdr.2010.0136; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Larsen AR, 2009, J CLIN MICROBIOL, V47, P3765, DOI 10.1128/JCM.00934-09; Larsen AR, 2009, J CLIN MICROBIOL, V47, P73, DOI 10.1128/JCM.01557-08; Li SS, 2011, ANTIMICROB AGENTS CH, V55, P3046, DOI 10.1128/AAC.01475-10; Loffler B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000715; Lozano C, 2011, INT J MED MICROBIOL, V301, P500, DOI 10.1016/j.ijmm.2011.02.004; Manzur A, 2008, CLIN MICROBIOL INFEC, V14, P377, DOI 10.1111/j.1469-0691.2007.01934.x; Mellmann A, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-98; Milheirico C, 2007, ANTIMICROB AGENTS CH, V51, P3374, DOI 10.1128/AAC.00275-07; Milheirico C, 2007, J ANTIMICROB CHEMOTH, V60, P42, DOI 10.1093/jac/dkm112; Miragaia M, 2005, MICROB DRUG RESIST, V11, P83, DOI 10.1089/mdr.2005.11.83; Nubel U, 2008, P NATL ACAD SCI USA, V105, P14130, DOI 10.1073/pnas.0804178105; Okuma K, 2002, J CLIN MICROBIOL, V40, P4289, DOI 10.1128/JCM.40.11.4289-4294.2002; Oliveira DC, 2006, J ANTIMICROB CHEMOTH, V58, P23, DOI 10.1093/jac/dkl208; Otter JA, 2010, LANCET INFECT DIS, V10, P227, DOI 10.1016/S1473-3099(10)70053-0; Otter JA, 2011, J HOSP INFECT, V79, P189, DOI 10.1016/j.jhin.2011.04.028; Robert J, 2011, ANTIMICROB AGENTS CH, V55, P1734, DOI 10.1128/AAC.01221-10; Shore AC, 2011, ANTIMICROB AGENTS CH, V55, P3765, DOI 10.1128/AAC.00187-11; SIMPSON EH, 1949, NATURE, V163, P688, DOI 10.1038/163688a0; Skramm I, 2011, APMIS, V119, P522, DOI 10.1111/j.1600-0463.2011.02758.x; Song JH, 2011, J ANTIMICROB CHEMOTH, V66, P1061, DOI 10.1093/jac/dkr024; Stam-Bolink EM, 2007, EUR J CLIN MICROBIOL, V26, P723, DOI 10.1007/s10096-007-0352-y; Tenover FC, 2006, J CLIN MICROBIOL, V44, P108, DOI 10.1128/JCM.44.1.108-118.2006; The European Commission of the European Communities European Union website, 2000, OFFICIAL J EUR COM L, V28; The European Parliament the Council of the EU European Union website, 1998, OFFICIAL J EUR COM L, V268; Tristan A, 2007, EMERG INFECT DIS, V13, P594; Tseng CW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006387; UDO EE, 1993, J HOSP INFECT, V25, P97, DOI 10.1016/0195-6701(93)90100-E; Zhang KY, 2005, J CLIN MICROBIOL, V43, P5026, DOI 10.1128/JCM.43.10.5026-5033.2005",64,25,26,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","APR 27",2012,7,4,null,null,null,null,null,null,"e34768","10.1371/journal.pone.0034768",null,10,"Multidisciplinary Sciences","Science & Technology - Other Topics","959TJ","WOS:000305336000017"]
[null,null,null,null,"J","Hollink, IHIM; Feng, Q; Danen-van Oorschot, AA; Arentsen-Peters, STCJM; Verboon, LJ; Zhang, P; de Haas, V; Reinhardt, D; Creutzig, U; Trka, J; Pieters, R; van den Heuvel-Eibrink, MM; Wang, J; Zwaan, CM",null,null,null,"Hollink, I. H. I. M.; Feng, Q.; Danen-van Oorschot, A. A.; Arentsen-Peters, S. T. C. J. M.; Verboon, L. J.; Zhang, P.; de Haas, V.; Reinhardt, D.; Creutzig, U.; Trka, J.; Pieters, R.; van den Heuvel-Eibrink, M. M.; Wang, J.; Zwaan, C. M.",null,null,"Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model","LEUKEMIA",null,null,"English","Letter",null,null,null,null,null,null,"ACUTE MYELOID-LEUKEMIA; PREVALENCE; GENOME; IDH2",null,"[Hollink, I. H. I. M.; Danen-van Oorschot, A. A.; Arentsen-Peters, S. T. C. J. M.; Verboon, L. J.; Pieters, R.; van den Heuvel-Eibrink, M. M.; Zwaan, C. M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Feng, Q.; Zhang, P.; Wang, J.] Beijing Genom Inst, Dept Canc Res, Beijing, Peoples R China; [de Haas, V.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Reinhardt, D.] Hannover Med Sch, Dept Pediat Oncol Hematol, AML BFM Study Grp, D-3000 Hannover, Germany; [Creutzig, U.] Univ Childrens Hosp, AML BFM Study Grp, Munster, Germany; [Trka, J.] Charles Univ Prague, Sch Med 2, Hannover Med Sch, Dept Pediat Oncol Hematol, Prague, Czech Republic","Hollink, IHIM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands.","c.m.zwaan@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056",null,null,null,9,6,7,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","FEB",2012,26,2,null,null,null,null,371,373,null,"10.1038/leu.2011.210",null,4,"Oncology; Hematology","Oncology; Hematology","894HZ","WOS:000300419100024"]
[null,null,null,null,"J","Dedeckova, K; Fila, L; Skalicka, V; Bartosova, J; Kucerova, T; Vavrova, V; Zemkova, D; Kalferstova, L; Melter, O; Cinek, O; Drevinek, P",null,null,null,"Dedeckova, Klara; Fila, Libor; Skalicka, Veronika; Bartosova, Jana; Kucerova, Tereza; Vavrova, Vera; Zemkova, Dana; Kalferstova, Lucie; Melter, Oto; Cinek, Ondrej; Drevinek, Pavel",null,null,"PCR detection of Burkholderia cepacia complex as one of key factors to handle a long-term outbreak","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Article",null,null,null,null,null,null,"CYSTIC-FIBROSIS; SP-NOV; EPIDEMIOLOGY; CENOCEPACIA; INFECTION; IDENTIFICATION; DIVERSITY; PROVIDES; STRAINS; DNA","Background: Once the outbreak with Burkholderia cenocepacia ST32 was identified in the Prague cystic fibrosis (CF) centre, molecular tools were implemented into diagnostic routine in order to complement infection control measures with as accurate as possible microbiological service. In addition, genotyping techniques were applied as part of an infection surveillance program to assign species and strain status in samples positive for Burkholderia cepacia complex (Bcc). We sought to evaluate a usefulness of Bcc-specific PCR in infection control and to map evolution of the outbreak. Methods: Since 2001, 6109 respiratory samples from 299 CF patients were examined not only by conventional culture, but also by PCR, detecting Bcc directly in sputum. Results: Diagnosis of Bcc infection was established by culture in 54 patients already prior to 2001. As 39 more patients were diagnosed by culture and/or PCR during 2001-2010, this represented annual prevalence of 18.5%-28.9%. Twelve of 39 patients were culture negative at the time of their first PCR positivity. Although 2/3 of them became subsequently culture positive, the time delay in diagnostics of the infection by culture ranged from 1 to 22 months. New cases of Bcc infection were detected every year, however a dramatic drop was observed for the epidemic strain ST32. Conclusion: A likely factor contributing to the end of ST32 epidemic was segregation of Bcc infected patients that included also patients with no culture, but PCR positivity. The diagnostic PCR led to timely identification of cases with 'culture-invisible' infection. (C) 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Dedeckova, Klara; Skalicka, Veronika; Bartosova, Jana; Kucerova, Tereza; Vavrova, Vera; Zemkova, Dana; Kalferstova, Lucie; Cinek, Ondrej; Drevinek, Pavel] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague 15006 5, Czech Republic; [Dedeckova, Klara; Fila, Libor; Skalicka, Veronika; Bartosova, Jana; Kucerova, Tereza; Vavrova, Vera; Zemkova, Dana; Kalferstova, Lucie; Melter, Oto; Cinek, Ondrej; Drevinek, Pavel] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Fila, Libor] Charles Univ Prague, Dept Pneumol, Fac Med 2, Prague 15006 5, Czech Republic; [Melter, Oto; Drevinek, Pavel] Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Prague 15006 5, Czech Republic","Drevinek, P (reprint author), Charles Univ Prague, Dept Paediat, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","pavel.drevinek@Lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic [NS10543-3, NT12405-5]","This work was funded by grants from Ministry of Health of the Czech Republic NS10543-3 and NT12405-5.",null,21,2,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","SEP",2012,11,5,null,null,null,null,440,445,null,"10.1016/j.jcf.2012.04.005",null,6,"Respiratory System","Respiratory System","015FM","WOS:000309431800012"]
[null,null,null,null,"J","Seeman, T",null,null,null,"Seeman, Tomas",null,null,"Ambulatory Blood Pressure Monitoring in Pediatric Renal Transplantation","CURRENT HYPERTENSION REPORTS",null,null,"English","Article",null,null,null,null,null,"Hypertension; Blood pressure; BP; Children; Pediatric; Ambulatory blood pressure monitoring; ABPM; Renal transplantation; Graft function; Graft survival; Left ventricular hypertrophy; Antihypertensive therapy.; Control of hypertension","LEFT-VENTRICULAR MASS; TARGET-ORGAN DAMAGE; LONG-TERM GRAFT; KIDNEY-TRANSPLANTATION; MASKED HYPERTENSION; ALLOGRAFT FUNCTION; CARDIOVASCULAR-DISEASE; ARTERIAL-HYPERTENSION; HEALTHY-CHILDREN; ADOLESCENTS","Hypertension is a common and serious complication after renal transplantation. It is an important risk factor for graft loss and adverse cardiovascular outcomes. Blood pressure (BP) in transplanted children should be measured not only by clinic BP (cBP) measurement, but also by ambulatory blood pressure monitoring (ABPM), because ABPM has distinct advantages over cBP, specifically the ability to reveal nocturnal, masked or white-coat hypertension. These types of hypertension are common in transplanted children (nocturnal hypertension 36-71 %, masked hypertension 24-45 %). It may also reveal uncontrolled hypertension in treated children, thereby improving control of hypertension. Regular use of ABPM and ABPM-guided therapy of hypertension may help to decrease cardiovascular and renal target organ damage in transplanted children. Therefore, ABPM should be routinely performed in all transplanted children at least once a year, regardless of the values of cBP.","[Seeman, Tomas] Charles Univ Prague, Univ Hosp Motol, Transplantat Ctr, Fac Med 2, Prague 15006, Czech Republic; [Seeman, Tomas] Charles Univ Prague, Fac Med Plzen, Biomed Ctr, Plzen, Czech Republic","Seeman, T (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Fac Med 2, Uvalu 84, Prague 15006, Czech Republic.","tomas.seeman@lfmotol.cuni.cz",null,null,"European Regional Development Fund [CZ.1.05/2.1.00/03.0076]; project (Ministry of Health, Czech Republic) for conceptual development of research organization [00064203]; Internal Grant Agency of the Ministry of Health of the Czech Republic; Pediatric Academic Societies","T. Seeman is supported by the project CZ.1.05/2.1.00/03.0076 from European Regional Development Fund and by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic).T. Seeman has received a grant from the Internal Grant Agency of the Ministry of Health of the Czech Republic, has served as a consultant to Otsuka Pharmaceuticals, and has received payment for lectures, including service on speaker bureaus from the Pediatric Academic Societies.",null,67,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1522-6417",null,null,"CURR HYPERTENS REP","Curr. Hypertens. Rep.","DEC",2012,14,6,null,null,null,null,608,618,null,"10.1007/s11906-012-0301-8",null,11,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","032TL","WOS:000310741900018"]
[null,null,null,null,"J","Vojackova, N; Fialova, J; Hercogova, J",null,null,null,"Vojackova, Nadezda; Fialova, Jorga; Hercogova, Jana",null,null,"Management of lymphedema","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"complex decongestive physical therapy; compression; manual lymph drainage","INTERMITTENT PNEUMATIC COMPRESSION; COMPLEX DECONGESTIVE PHYSIOTHERAPY; EXTREMITY LYMPHEDEMA; LYMPHATIC THERAPY; CANCER; EDEMA","The basic principle of the management of lymphedema is so called complex decongestive physical therapy. This therapy is divided into two phases: (i) edema reduction phase an initial intensive treatment phase aiming for limb volume reduction; and (ii) maintenance phase following long-term phase to sustain a manageable limb volume. The first phase consists of a number of physical therapeutic approaches which are: manual lymph drainage, pneumatic pump drainage, low-stretch bandaging, exercises, and skin care. Long-term maintenance phase consists of self-lymph drainage, low-stretch bandaging, or compressive garments, and sometimes when indicated pneumatic pump drainage, exercises, and skin care.","Charles Univ Prague, Dermatovenereol Dept, Sch Med 2, Prague, Czech Republic; Bulovka Hosp, Prague, Czech Republic","Vojackova, N (reprint author), Fac Hosp, Dermatovenereol Dept, Budinova 2, Prague 18000, Czech Republic.","nadavojackova@seznam.cz",null,null,null,null,null,22,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","JUL-AUG",2012,25,4,null,null,"SI",null,352,357,null,"10.1111/j.1529-8019.2012.01534.x",null,6,"Dermatology","Dermatology","000SD","WOS:000308407500008"]
[null,null,null,null,"J","Zamecnik, J; Homola, A; Cicanic, M; Kuncova, K; Marusic, P; Krsek, P; Sykova, E; Vargova, L",null,null,null,"Zamecnik, Josef; Homola, Ales; Cicanic, Michal; Kuncova, Klara; Marusic, Petr; Krsek, Pavel; Sykova, Eva; Vargova, Lydia",null,null,"The extracellular matrix and diffusion barriers in focal cortical dysplasias","EUROPEAN JOURNAL OF NEUROSCIENCE",null,null,"English","Article",null,null,null,null,null,"epilepsy; extracellular space; extrasynaptic transmission; tenascin; tortuosity","CENTRAL-NERVOUS-SYSTEM; RAT SPINAL-CORD; SYNAPTIC PLASTICITY; TENASCIN-R; REACTIVE ASTROGLIOSIS; VOLUME TRANSMISSION; BRAIN; SPACE; PARAMETERS; EPILEPTOGENESIS","Focal cortical dysplasias (FCDs) of the brain are recognized as a frequent cause of intractable epilepsy. To contribute to the current understanding of the mechanisms of epileptogenesis in FCD, our study provides evidence that not only cellular alterations and synaptic transmission, but also changed diffusion properties of the extracellular space (ECS), induced by modified extracellular matrix (ECM) composition and astrogliosis, might be involved in the generation or spread of seizures in FCD. The composition of the ECM in FCD and non-malformed cortex (in 163 samples from 62 patients) was analyzed immunohistochemically and correlated with the corresponding ECS diffusion parameter values determined with the real-time iontophoretic method in freshly resected cortex (i.e. the ECS volume fraction and the geometrical factor tortuosity, describing the hindrances to diffusion in the ECS). The ECS in FCD was shown to differ from that in non-malformed cortex, mainly by the increased accumulation of certain ECM molecules (tenascin R, tenascin C, and versican) or by their reduced expression (brevican), and by the presence of an increased number of astrocytic processes. The consequent increase of ECS diffusion barriers observed in both FCD type I and II (and, at the same time, the enlargement of the ECS volume in FCD type II) may alter the diffusion of neuroactive substances through the ECS, which mediates one of the important modes of intercellular communication in the brain extrasynaptic volume transmission. Thus, the changed ECM composition and altered ECS diffusion properties might represent additional factors contributing to epileptogenicity in FCD.","[Zamecnik, Josef; Kuncova, Klara] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15006, Czech Republic; [Zamecnik, Josef; Kuncova, Klara; Marusic, Petr; Krsek, Pavel] Univ Hosp Motol, Prague 15006, Czech Republic; [Homola, Ales; Cicanic, Michal; Sykova, Eva; Vargova, Lydia] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague 15006, Czech Republic; [Homola, Ales; Cicanic, Michal; Sykova, Eva; Vargova, Lydia] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006, Czech Republic; [Homola, Ales; Cicanic, Michal; Sykova, Eva; Vargova, Lydia] AS CR, Inst Expt Med, Dept Neurosci, Prague, Czech Republic; [Marusic, Petr] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague 15006, Czech Republic; [Krsek, Pavel] Charles Univ Prague, Fac Med 2, Dept Pediat Neurol, Prague 15006, Czech Republic","Zamecnik, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, V Uvalu 84, Prague 15006, Czech Republic.","josef.zamecnik@lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic (IGA MZCR) [NS9915-4]; Institutional Project CDRO [00064203]; Academy of Sciences of the Czech Republic [AVOZ50390512]; Ministry of Education, Youth and Sports of the Czech Republic [1M0538]","This study was supported by grants from the Ministry of Health of the Czech Republic (IGA MZCR No. NS9915-4 and Institutional Project CDRO 00064203 (FN Motol), grant AVOZ50390512 from the Academy of Sciences of the Czech Republic, and grant 1M0538 from the Ministry of Education, Youth and Sports of the Czech Republic.",null,56,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0953-816X",null,null,"EUR J NEUROSCI","Eur. J. Neurosci.","JUL",2012,36,1,null,null,null,null,2017,2024,null,"10.1111/j.1460-9568.2012.08107.x",null,8,"Neurosciences","Neurosciences & Neurology","967JJ","WOS:000305903000007"]
[null,null,null,null,"J","Cicanic, M; Sykova, E; Vargova, L",null,null,null,"Cicanic, Michal; Sykova, Eva; Vargova, Lydia",null,null,"Bral1: \"Superglue\" for the extracellular matrix in the brain white matter","INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY",null,null,"English","Article",null,null,null,null,null,"Bral1/Hapln2; Node of Ranvier; Extracellular matrix; Signal transmission","CENTRAL-NERVOUS-SYSTEM; HYALURONAN-BINDING DOMAIN; LINK PROTEIN; RAT CEREBELLUM; MICE DEFICIENT; ADULT-MOUSE; TENASCIN-R; RANVIER; CNS; DIFFUSION","Bral1 is a link protein that stabilizes the binding between lecticans and hyaluronic acid and thus maintains the extracellular matrix assembly in the CNS. Bral1 is specifically located in the white matter around the nodes of Ranvier. Recent studies suggest its function in promoting saltatory neural conduction. This article reviews the current knowledge about the structure, expression and function of this link protein. (C) 2012 Elsevier Ltd. All rights reserved.","[Cicanic, Michal; Sykova, Eva; Vargova, Lydia] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague 15006 5, Czech Republic; [Cicanic, Michal; Sykova, Eva; Vargova, Lydia] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic; [Cicanic, Michal; Sykova, Eva; Vargova, Lydia] AS CR, Inst Expt Med, Dept Neurosci, Prague, Czech Republic","Vargova, L (reprint author), Charles Univ Prague, Fac Med 2, Dept Neurosci, V Uvalu 84, Prague 15006 5, Czech Republic.","lydie.vargova@lfmotol.cuni.cz",null,null," [GACR 309/09/1597];  [P304/11/0184]","The work was supported by grants GACR 309/09/1597 and P304/11/0184.",null,30,1,1,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","1357-2725",null,null,"INT J BIOCHEM CELL B","Int. J. Biochem. Cell Biol.","APR",2012,44,4,null,null,null,null,596,599,null,"10.1016/j.biocel.2012.01.009",null,4,"Biochemistry & Molecular Biology; Cell Biology","Biochemistry & Molecular Biology; Cell Biology","921ZJ","WOS:000302516300006"]
[null,null,null,null,"J","Honsa, P; Pivonkova, H; Dzamba, D; Filipova, M; Anderova, M",null,null,null,"Honsa, Pavel; Pivonkova, Helena; Dzamba, David; Filipova, Marcela; Anderova, Miroslava",null,null,"Polydendrocytes Display Large Lineage Plasticity following Focal Cerebral Ischemia","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"OLIGODENDROCYTE PRECURSOR CELLS; SPINAL-CORD-INJURY; K+ CHANNEL EXPRESSION; NEURAL STEM-CELLS; GLIAL-CELLS; NG2 CELLS; PROGENITOR CELLS; NG2-EXPRESSING CELLS; SUBVENTRICULAR ZONE; RAT HIPPOCAMPUS","Polydendrocytes (also known as NG2 glial cells) constitute a fourth major glial cell type in the adult mammalian central nervous system (CNS) that is distinct from other cell types. Although much evidence suggests that these cells are multipotent in vitro, their differentiation potential in vivo under physiological or pathophysiological conditions is still controversial. To follow the fate of polydendrocytes after CNS pathology, permanent middle cerebral artery occlusion (MCAo), a commonly used model of focal cerebral ischemia, was carried out on adult NG2creBAC:ZEG double transgenic mice, in which enhanced green fluorescent protein (EGFP) is expressed in polydendrocytes and their progeny. The phenotype of the EGFP(+) cells was analyzed using immunohistochemistry and the patch-clamp technique 3, 7 and 14 days after MCAo. In sham-operated mice (control), EGFP(+) cells in the cortex expressed protein markers and displayed electrophysiological properties of polydendrocytes and oligodendrocytes. We did not detect any co-labeling of EGFP with neuronal, microglial or astroglial markers in this region, thus proving polydendrocyte unipotent differentiation potential under physiological conditions. Three days after MCAo the number of EGFP(+) cells in the gliotic tissue dramatically increased when compared to control animals, and these cells displayed properties of proliferating cells. However, in later phases after MCAo a large subpopulation of EGFP(+) cells expressed protein markers and electrophysiological properties of astrocytes that contribute to the formation of glial scar. Importantly, some EGFP(+) cells displayed membrane properties typical for neural precursor cells, and moreover these cells expressed doublecortin (DCX) - a marker of newly-derived neuronal cells. Taken together, our data indicate that polydendrocytes in the dorsal cortex display multipotent differentiation potential after focal ischemia.","[Honsa, Pavel; Pivonkova, Helena; Dzamba, David; Filipova, Marcela; Anderova, Miroslava] Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Prague, Czech Republic; [Honsa, Pavel; Pivonkova, Helena; Dzamba, David] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Honsa, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Prague, Czech Republic.","anderova@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [CZ: GA CR: GA309/09/0717, GA P303/12/0855, GA 309/08/H079]; Grant Agency of Charles University [CZ: GA UK:383711]","This work was supported by the Grant Agency of the Czech Republic - CZ: GA C.R: GA309/09/0717, GA P303/12/0855 and GA 309/08/H079, and by the Grant Agency of Charles University - CZ: GA UK:383711. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,56,5,5,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","MAY 10",2012,7,5,null,null,null,null,null,null,"e36816","10.1371/journal.pone.0036816",null,14,"Multidisciplinary Sciences","Science & Technology - Other Topics","959TN","WOS:000305336400038"]
[null,null,null,null,"J","Cinek, O; Kulich, M; Sumnik, Z",null,null,null,"Cinek, Ondrej; Kulich, Michal; Sumnik, Zdenek",null,null,"The incidence of type 1 diabetes in young Czech children stopped rising","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"prediction; stagnation; type 1 diabetes incidence","AGED LESS-THAN-15 YEARS; PROSPECTIVE REGISTRATION; INCIDENCE TRENDS; EUROPE; INCREASE","Aims: The aim was to assess trends in incidence of pediatric type 1 diabetes (T1D) using data recorded by the population-based Czech Childhood Diabetes Register over 1989-2009. Methods: New cases of childhood-onset T1D aged 0-14.9 yr were recorded using the EURODIAB protocol by two independent sources with the combined estimated completeness of 98.6%. The incidence was modeled by Poisson regression, and the effects of age and calendar time on incidence were assessed using piecewise linear functions. Results: A total of 5155 cases was ascertained over 1989-2009 from an average pediatric population of 1.76 million. Two points of change in the incidence trend were identified by the modeling: in 1995 the incidence accelerated, while in 2001 the growth in incidence significantly slowed down in all ages up to 10 yr. In the youngest age category, 0-4 yr at onset, the rapid average annual rise of 15% over 1996-2001 suddenly changed into stagnation over 2002-2009. Conclusions: Our data contribute to the notion that long- and intermediate-term predictions from the past incidence developments of incidence are difficult, as abrupt changes in the trend can occur. Caution should be exercised against too far-reaching incidence predictions, even if the population has experienced a previous history of a very fast rise in T1D incidence.","[Cinek, Ondrej; Kulich, Michal; Sumnik, Zdenek] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague 5, Motol, Czech Republic; [Kulich, Michal] Charles Univ Prague, Fac Math & Phys, Dept Probabil & Math Stat, Prague 5, Motol, Czech Republic","Cinek, O (reprint author), Charles Univ Prague, Dept Paediat, Fac Med 2, V Uvalu 84, Prague 5, Motol, Czech Republic.","Ondrej.Cinek@Lfmotol.cuni.cz","Kulich, Michal/B-1483-2013","Kulich, Michal/0000-0002-2812-8968","Czech Ministry of Education [MSM0021620814]","Dr. V. Letocha, the chairman of the Association of Parents and Friends of Diabetic Children, is thanked for providing us with anonymized member database as the secondary ascertainment source. The network of the physicians collaborating with the Czech Childhood Diabetes Register is gratefully acknowledged for providing data (in alphabetical order): Drs A. Bacikova, J. Bartosova, A. Benesova, H. Borska, L. Brazdova, J. Brozova, V. Brtnikova, M. Cvejn, O. Capek, J. Cerna, B. Cervickova, J. Cesek, J. Cizek, K. Dimova, K. Fiklik, N. Filakova, G. Fritscherova, P. Gogelova, M. Gregora, J. Helclova, E. Hlad'akova, M. Honkova, J. Horska, S. Hyckova, J. Chocholova, J. Chudackova, V. Janstova, Z. Jezova, M. Jirickova, M. Kobsa, L. Kocinova, S. Kolouskova, P. Konecna, P. Kotalikova, J. Kotlar, P. Krupkova, M. Kubelkova, A. Kudlickova, D. Kutilova, J. Kytnarova, J. Lebl, A. Lysakova, M. Machalkova, J. Maly, J. Matejkova, D. Mayerova, M. Micek, O. Michalkova, P. Mikyska, D. Neumann, B. Obermannova, M. Panek, M. Pejchlova, K. Polockova, R. Pomahacova, V. Prokop, M. Prichystalova, Y. Ptoszkova, A. Rajna, I. Roschlova, S. Rucki, J. Rytir, J. Salaskova, M. Schubert, P. Skala, D. Slavickova, R. Slovacek, J. Soucek, M. Svojsik, M. Sykora, J. Skvor, M. Snajderova, K. Stechova, A. Tomaides, L. Tyce, P. Vaner, H. Vavrova, J. Vavrinec, J. Venhacova, J. Vosahlo, M. Vracovska, L. Zlamalova. The Register is supported by grant from the Czech Ministry of Education, grant MSM0021620814.",null,13,4,4,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","NOV",2012,13,7,null,null,null,null,559,563,null,"10.1111/j.1399-5448.2012.00858.x",null,5,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","030EI","WOS:000310551600008"]
[null,null,null,null,"J","Stechova, K; Halbhuber, Z; Hubackova, M; Kayserova, J; Petruzelkova, L; Vcelakova, J; Kolouskova, S; Ulmannova, T; Faresjo, M; Neuwirth, A; Spisek, R; Sediva, A; Filipp, D; Sumnik, Z",null,null,null,"Stechova, Katerina; Halbhuber, Zbynek; Hubackova, Miluse; Kayserova, Jana; Petruzelkova, Lenka; Vcelakova, Jana; Kolouskova, Stanislava; Ulmannova, Tereza; Faresjo, Maria; Neuwirth, Ales; Spisek, Radek; Sediva, Anna; Filipp, Dominik; Sumnik, Zdenek",null,null,"Case report: type 1 diabetes in monozygotic quadruplets","EUROPEAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"type 1 diabetes; monozygotic quadruplets; enteroviral infection; gene expression array; cytokine array; genetic predisposition to diabetes","PATTERN-RECOGNITION RECEPTORS; T-CELLS; HIGH-RISK; AUTOIMMUNITY; INFECTIONS; DISEASE; GENE; BETA; PATHOGENESIS; EXPRESSION","Type 1 diabetes (T1D) is an autoimmune disease characterized by the lack of insulin due to an autoimmune destruction of pancreatic beta cells. Here, we report a unique case of a family with naturally conceived quadruplets in which T1D was diagnosed in two quadruplets simultaneously. At the same time, the third quadruplet was diagnosed with the pre-diabetic stage. Remarkably, all four quadruplets were positive for anti-islet cell antibodies, GAD65 and IA-A2. Monozygotic status of the quadruplets was confirmed by testing 14 different short tandem repeat polymorphisms. Serological examination confirmed that all quadruplets and their father suffered from a recent enteroviral infection of EV68-71 serotype. To assess the nature of the molecular pathological processes contributing to the development of diabetes, immunocompetent cells isolated from all family members were characterized by gene expression arrays, immune-cell enumerations and cytokine-production assays. The microarray data provided evidence that viral infection, and IL-27 and IL-9 cytokine signalling contributed to the onset of T1D in two of the quadruplets. The propensity of stimulated immunocompetent cells from non-diabetic members of the family to secrete high level of IFN-alpha further corroborates this conclusion. The number of T regulatory cells as well as plasmacytoid and/or myeloid dendritic cells was found diminished in all family members. Thus, this unique family is a prime example for the support of the so-called 'fertile-field' hypothesis proposing that genetic predisposition to anti-islet autoimmunity is 'fertilized' and precipitated by a viral infection leading to a fully blown T1D. European Journal of Human Genetics (2012) 20, 457-462; doi: 10.1038/ejhg.2011.212; published online 23 November 2011","[Stechova, Katerina] Univ Hosp Motol, Lab Autoimmune Dis, Dept Paediat, Prague 15006 5, Czech Republic; [Stechova, Katerina; Hubackova, Miluse; Petruzelkova, Lenka; Vcelakova, Jana; Kolouskova, Stanislava; Ulmannova, Tereza; Sumnik, Zdenek] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic; [Halbhuber, Zbynek] Cent European Biosyst, Prague, Czech Republic; [Kayserova, Jana; Spisek, Radek; Sediva, Anna] Charles Univ Prague, Dept Immunol, Fac Med 2, Prague, Czech Republic; [Faresjo, Maria] Jonkoping Univ, Dept Nat Sci & Biomed, Sch Hlth Sci, Jonkoping, Sweden; [Faresjo, Maria] Linkoping Univ, Fac Hlth Sci, Div Paediat, Dept Clin & Expt Med, Linkoping, Sweden; [Faresjo, Maria] Linkoping Univ, Fac Hlth Sci, Diabet Res Ctr, Dept Clin & Expt Med, Linkoping, Sweden; [Neuwirth, Ales; Filipp, Dominik] Inst Mol Genet AS CR, Immunobiol Lab, Prague, Czech Republic","Stechova, K (reprint author), Univ Hosp Motol, Lab Autoimmune Dis, Dept Paediat, V Uvalu 84, Prague 15006 5, Czech Republic.","katerina.stechova@lfmotol.cuni.cz",null,null,"Czech Ministry of Education [NPVII 2B06019]; Ministry of Education, Youth and Sports of the Czech Republic [VZ MSM 0021620812]; Ministry of Health [MZOFNM2005]; project GACR [P302/10/1679]; Czech Ministry of Education, Youth and Sports [NPVII 2B08066]; Academy of Sciences of the Czech Republic [AVOZ50520514]","Gene expression study was exclusively supported by project NPVII 2B06019 from the Czech Ministry of Education. Studies on Tregs and DCs were supported by the project VZ MSM 0021620812 from the Ministry of Education, Youth and Sports of the Czech Republic, and by the project MZOFNM2005 from the Ministry of Health and by the project GACR P302/10/1679. AN and DF as well as the cytokine analysis were supported by the project NPVII 2B08066 from the Czech Ministry of Education, Youth and Sports. This work was also partially supported by Grant AVOZ50520514 from the Academy of Sciences of the Czech Republic.",null,48,4,4,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,null,"EUR J HUM GENET","Eur. J. Hum. Genet.","APR",2012,20,4,null,null,null,null,457,462,null,"10.1038/ejhg.2011.212",null,6,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","911RI","WOS:000301736600015"]
[null,null,null,null,"J","Spacek, M; Martinkovicova, L; Zimolova, P; Veselka, J",null,null,null,"Spacek, Miloslav; Martinkovicova, Lucie; Zimolova, Petra; Veselka, Josef",null,null,"Mid-term outcomes of carotid artery stenting in patients with angiographic string sign","CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS",null,null,"English","Article",null,null,null,null,null,"angiographic string sign; preocclusive atherosclerosis; carotid artery stenting; patient profiles","CEREBRAL PROTECTION; ENDARTERECTOMY; STENOSIS; FEASIBILITY; DIAGNOSIS; SURGERY; TRIAL; RISK","Objectives: To report on early and mid-term outcomes of carotid artery stenting (CAS) in patients with angiographic string sign (SS). Background: Little is known about the prognosis of patients with carotid SS treated by CAS. Methods: We retrospectively evaluated early and mid-term outcomes, together with ultrasound findings, in patients with SS treated by CAS at our institution. Results: Of 308 CAS procedures, SS was diagnosed in 6.2% (19 patients, 58% symptomatic). Carotid stent implantation was successful in 18 patients (success rate 95%). There were no peri-procedural adverse events. One patient suffered from a transient ischemic attack during hospitalization and died of pneumonia. All remaining patients completed a 30-day follow-up, and no complications were reported (asymptomatic restenosis was diagnosed in 1 patient and successfully redilated). Six patients died of causes unrelated to CAS (pneumonia, decompensated heart failure, and contralateral stroke) before completing a 6-month follow-up. However, these patients presented with more pronounced, unfavorable clinical and angiographic characteristics compared to the rest of the patients. Conclusions: We suggest that CAS might be performed with acceptable procedural risk in patients presenting with SS, which is unsuitable for surgery. However, patients' clinical and angiographic characteristics must be carefully evaluated when considering interventional therapy, regardless of the favorable procedural outcomes. (C) 2011 Wiley Periodicals, Inc.","[Spacek, Miloslav; Martinkovicova, Lucie; Zimolova, Petra; Veselka, Josef] Charles Univ Prague, Dept Cardiol, CardioVasc Ctr, Motol Univ Hosp,Med Sch 2, Prague 15006 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Dept Cardiol, CardioVasc Ctr, Motol Univ Hosp,Med Sch 2, V Uvalu 84, Prague 15006 5, Czech Republic.","veselka.josef@seznam.cz",null,null,"Ministry of Health of the Czech Republic [00064203]","Grant sponsor: Ministry of Health of the Czech Republic; grant number: 00064203",null,17,4,4,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1522-1946",null,null,"CATHETER CARDIO INTE","Catheter. Cardiovasc. Interv.","JAN",2012,79,1,null,null,null,null,174,179,null,"10.1002/ccd.23144",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","868QS","WOS:000298539300037"]
[null,null,null,null,"J","Malikova, J; Votava, F; Vrzalova, Z; Lebl, J; Cinek, O",null,null,null,"Malikova, Jana; Votava, Felix; Vrzalova, Zuzana; Lebl, Jan; Cinek, Ondrej",null,null,"Genetic analysis of the CYP21A2 gene in neonatal dried blood spots from children with transiently elevated 17-hydroxyprogesterone","CLINICAL ENDOCRINOLOGY",null,null,"English","Article",null,null,null,null,null,null,"CONGENITAL ADRENAL-HYPERPLASIA; STEROID 21-HYDROXYLASE DEFICIENCY; SEQUENCE VARIANTS; DIAGNOSIS; MUTATION; ASSAY","Background Neonatal screening for congenital adrenal hyperplasia (CAH) identifies a certain proportion of newborns with transient moderate elevation of 17-hydroxyprogesterone (17-OHP). These children require regular follow-up until normalization of their 17-OHP levels. We investigated the possibility of reducing the individuals' recall rates by using genetic methods on their original neonatal dried blood spots. Patients and Methods We analysed neonatal dried blood spots from 753 subjects with transiently elevated levels of 17-OHP. The CYP21A2 gene was sequenced to detect point mutations, and the presence of CYP21A2 was further confirmed by two methods utilizing the difference between CYP21A2 and its CYP21A1P pseudogene in the sequence of exon 3 (8-bp deletion). The accuracy of the methods was verified using samples from 70 subjects with known CYP21A2 mutations and 181 healthy children. Result Among the 701 successfully sequenced samples from subjects with transiently elevated 17-OHP, 670 (95%) had no point mutations or novel variants in the CYP21A2 gene. We found no individuals carrying genotypes consistent with the diagnosis of CAH (i.e. homozygotes or compound heterozygotes for point mutations, large deletions or rearrangements). However, 21 heterozygous carriers of known point mutations that cause the classic and nonclassic forms of CAH were identified. Additionally, we detected eight heterozygous and two homozygous point variants with unknown functional significance. Conclusion Although CAH caused by 21-hydroxylase deficiency could be genetically excluded with a reasonable degree of confidence in 95% of the genotyped subjects that had transiently elevated 17-OHP, the performance of the tests was suboptimal when performed using dried blood spots and time-consuming in comparison with the current practice of repeated measurements of 17-OHP. The introduction of this method into clinical practice seems to be impractical at this stage.","[Lebl, Jan] Univ Hosp Motol, Dept Pediat, CZ-15006 Prague, Czech Republic; [Malikova, Jana; Lebl, Jan; Cinek, Ondrej] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague, Czech Republic; [Votava, Felix] Charles Univ Prague, Dept Pediat, Fac Med 3, Prague, Czech Republic; [Votava, Felix] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Vrzalova, Zuzana] Univ Hosp, Ctr Mol Biol & Gene Therapy, Brno, Czech Republic; [Vrzalova, Zuzana] Masaryk Univ, Brno, Czech Republic","Lebl, J (reprint author), Univ Hosp Motol, Dept Pediat, V Uvalu 84, CZ-15006 Prague, Czech Republic.","jan.lebl@Lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic [IGA NS 9981-3/2008]; Ministry of Education of the Czech Republic [MSM0021620814]","This study was supported by the Ministry of Health of the Czech Republic (grant IGA NS 9981-3/2008) and the Ministry of Education of the Czech Republic (grant no. MSM0021620814).",null,32,2,3,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0300-0664",null,null,"CLIN ENDOCRINOL","Clin. Endocrinol.","AUG",2012,77,2,null,null,null,null,187,194,null,"10.1111/j.1365-2265.2012.04358.x",null,8,"Endocrinology & Metabolism","Endocrinology & Metabolism","971SF","WOS:000306223400004"]
[null,null,null,null,"J","Spatenka, J; Seeman, T; Foltynova, E; Burkert, J; Dusek, J; Vondrak, K; Janda, J; Habrmanova, A; Krejcova, J; Matousovic, K",null,null,null,"Spatenka, Jaroslav; Seeman, Tomas; Foltynova, Eva; Burkert, Jan; Dusek, Jiri; Vondrak, Karel; Janda, Jan; Habrmanova, Anna; Krejcova, Jana; Matousovic, Karel",null,null,"Effect of donor/recipient body weight ratio, donor weight, recipient weight and donor age on kidney graft function in children","NEPHROLOGY DIALYSIS TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"absolute GFR; body weight; children; eGFR; kidney transplantation","RENAL-TRANSPLANTATION; GLOMERULAR NUMBER; UNITED-STATES; ADULT DONORS; VOLUME; SIZE; OUTCOMES; INFANTS; GROWTH; MASS","We hypothesized that supplementing a higher mass of renal parenchyma from adult donors, and their younger age, would improve graft function in paediatric recipients. We calculated estimated glomerular filtration rate (eGFR; Schwartz formula) and absolute glomerular filtration rate (absGFR) in 57 renal-grafted children (1995-2007) aged 3.1-17.9 years, weighing 12.9-85.0 kg, on discharge from the hospital after transplantation (TPL), 1 year after TPL and at the last follow-up (1.5-11.7 years after TPL). We correlated their eGFR with the individual ratio between the donor and the recipient body weight at the time of TPL (donor/recipient body weight ratio; D/R BWR), and we evaluated the effect of the donor and the actual recipient body weight on the eGFR and absGFR. The D/R BWR varied from 0.65 to 5.23. We found a significant positive correlation between D/R BWR and eGFR at discharge from the hospital (P < 0.001), 1-year post-TPL (P < 0.001) and at the last follow-up (P < 0.05). Using multiple linear regression analyses, we found that both eGFR and absGFR values were much more determined by the actual recipient weight than by the donor weight (27/6% and 43/4% at discharge, by 24/4% and 57/0% 1 year after TPL, and 0/0% and 20/0% at the end of the follow-up). A tendency for lower eGFR with increasing age of donors was apparent at discharge and 1 year after TPL, but it reached statistical significance only at the last follow-up (r = 0.4254, P < 0.01). In paediatric renal transplants, the value of D/R BWR directly correlated with eGFR in the early and late posttransplant periods. However, this correlation was mainly influenced by the recipient weight, while the donor weight played only a minor or negligible role.","[Spatenka, Jaroslav; Foltynova, Eva; Burkert, Jan; Habrmanova, Anna; Krejcova, Jana; Matousovic, Karel] Univ Hosp Motol, Transplantat Ctr, Prague, Czech Republic; [Seeman, Tomas; Dusek, Jiri; Vondrak, Karel; Janda, Jan] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic; [Matousovic, Karel] Charles Univ Prague, Dept Med, Fac Med 2, Prague, Czech Republic; [Matousovic, Karel] Charles Univ Prague, Dept Med 1, Prague, Czech Republic; [Matousovic, Karel] Univ Hosp Plzen, Plzen, Czech Republic","Matousovic, K (reprint author), Univ Hosp Motol, Transplantat Ctr, Prague, Czech Republic.","kmatousovic@hotmail.com",null,null,"Research Project MSM The Czech Republic [0021620819]; VZ MZ [0006420301]","This work was supported by The Research Project MSM The Czech Republic No. 0021620819 and VZ MZ No. 0006420301.",null,32,2,2,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0931-0509",null,null,"NEPHROL DIAL TRANSPL","Nephrol. Dial. Transplant.","FEB",2012,27,2,null,null,null,null,820,824,null,"10.1093/ndt/gfr319",null,5,"Transplantation; Urology & Nephrology","Transplantation; Urology & Nephrology","894IV","WOS:000300421300056"]
[null,null,null,null,"J","Hlozanek, M; Osmera, J; Lezatkova, P; Sedlackova, P; Filous, A",null,null,null,"Hlozanek, Martin; Osmera, Jakub; Lezatkova, Pavlina; Sedlackova, Petra; Filous, Ales",null,null,"The retinal nerve fibre layer thickness in glaucomatous hydrophthalmic eyes assessed by scanning laser polarimetry with variable corneal compensation in comparison with age-matched healthy children","ACTA OPHTHALMOLOGICA",null,null,"English","Article",null,null,null,null,null,"children; GDxVCC; glaucoma; hydrophthalmos; RNFL thickness; scanning laser polarimetry","OPTICAL COHERENCE TOMOGRAPHY; GDX VCC; NEUROPATHY",". Purpose: To compare the thickness of the retinal nerve fibre layer (RNFL) in hydrophthalmic glaucomatous eyes in children with age-matched healthy controls using scanning laser polarimetry with variable corneal compensation (GDxVCC). Methods: Twenty hydrophthalmic eyes of 20 patients with the mean age of 10.64 +/- 3.02 years being treated for congenital or infantile glaucoma were included in the analysis. Evaluation of RNFL thickness measured by GDxVCC in standard Temporal-Superior-Nasal-Inferior-Temporal (TSNIT) parameters was performed. The results were compared to TSNIT values of an age-matched control group of 120 healthy children published recently as referential values. The correlation between horizontal corneal diameter and RNFL thickness in hydrophthalmic eyes was also investigated. Results: The mean +/- SD values in TSNIT Average, Superior Average, Inferior Average and TSNIT SD in hydrophthalmic eyes were 52.3 +/- 11.4, 59.7 +/- 17.1, 62.0 +/- 15.6 and 20.0 +/- 7.8 mu m, respectively. All these values were significantly lower compared to referential TSNIT parameters of age-matched healthy eyes (p = 0.021, p = 0.001, p = 0.003 and p = 0.018, respectively). A substantial number of hydrophthalmic eyes laid below the level of 5% probability of normality in respective TSNIT parameters: 30% of the eyes in TSNIT average, 50% of the eyes in superior average, 30% of the eyes in inferior average and 45% of the eyes in TSNIT SD. No significant correlation between enlarged corneal diameter and RNFL thickness was found. Conclusions: The mean values of all standard TSNIT parameters assessed using GDxVCC in hydrophthalmic glaucomatous eyes in children were significantly lower in comparison with referential values of healthy age-matched children.","[Hlozanek, Martin; Osmera, Jakub; Lezatkova, Pavlina; Sedlackova, Petra; Filous, Ales] Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, FN Motol, Prague 15006 5, Czech Republic","Filous, A (reprint author), Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, FN Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","ales.filous@lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic, Prague, IGA [NR 8463/5]","Financial Support: Supported by Ministry of Health of the Czech Republic, Prague, IGA grant NR 8463/5.",null,21,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1755-375X",null,null,"ACTA OPHTHALMOL","Acta Ophthalmol.","DEC",2012,90,8,null,null,null,null,709,712,null,"10.1111/j.1755-3768.2011.02133.x",null,4,"Ophthalmology","Ophthalmology","047PI","WOS:000311852500031"]
[null,null,null,null,"J","Dusatkova, P; Pruhova, S; Borowiec, M; Vesela, K; Antosik, K; Lebl, J; Mlynarski, W; Cinek, O",null,null,null,"Dusatkova, Petra; Pruhova, Stepanka; Borowiec, Maciej; Vesela, Klara; Antosik, Karolina; Lebl, Jan; Mlynarski, Wojciech; Cinek, Ondrej",null,null,"Ancestral mutations may cause a significant proportion of GCK-MODY","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"founder effect; GCK-MODY; haplotype analysis; mutation age estimation","GLUCOKINASE GENE; POPULATION; PREVALENCE; LINKAGE; HUMANS; COMMON; YOUNG; AGE","Background Although the literature indicates that ancestral mutations in the glucokinase (GCK) gene are rare, we have detected a high frequency of four prevalent mutations that together are responsible for over one third of the GCK mutations in our Czech National Register of monogenic diabetes. Therefore, we studied their potential ancestral origin in our and neighbouring Polish populations. Methods We analysed the lineage of four mutations in the GCK gene p.Glu40Lys (21 apparently unrelated families), p.Leu315His (15 families), p.Gly318Arg (26 families), and p.Val33Ala (10 families) using genotypes of 16 single nucleotide polymorphisms that span a 14 Mb region around the gene. Haplotypes were reconstructed using Phase and Haploview programmes, and their age was estimated using dmle+. Results We found strong evidence that supports ancestral origin of three of the four mutations: the p.Glu40Lys mutation was associated with an 11-marker long conserved haplotype, the p.Leu315His mutation was associated with a 7-marker haplotype, and the p.Gly318Arg mutation was associated with an 8-marker haplotype. None of these haplotypes were detected in the general population with a frequency >0.5%. The ages of the mutations were roughly estimated to be between 82 and 110 generations old (95% credible sets 65151). The fourth prevalent mutation, p.Val33Ala, lacked statistically significant evidence for the founder effect, although there were some indications for its common origin. Conclusions The large proportion of families carrying three ancestral mutations in GCK indicates that the previously assumed rarity of the founder effect with regard to GCK-maturity onset diabetes of the young (MODY) should be reconsidered.","[Dusatkova, Petra; Pruhova, Stepanka; Vesela, Klara; Lebl, Jan; Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Dept Paediat, CZ-15006 Prague, Czech Republic; [Borowiec, Maciej; Antosik, Karolina; Mlynarski, Wojciech] Med Univ Lodz, Dept Paediat Oncol Hematol & Diabetol, PL-91738 Lodz, Poland","Cinek, O (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat, Univ Hosp Motol, V Uvalu 84, CZ-15006 Prague, Czech Republic.","ondrej.cinek@Lfmotol.cuni.cz",null,null,"Grant Agency of the Charles University in Prague [GAUK 0840/2010]; Czech Ministry of Health [MZ NT/11402]; Innovative Economy Operational Programme - Activity 1.2 (TEAM Programme); Ministry of Science and Higher Education [N407 277734, N402 478137, N407 022535]","The study was supported by the Grant Agency of the Charles University in Prague (GAUK 0840/2010) and the Czech Ministry of Health (grant MZ NT/11402).The recruitment and mutation analysis of the GCK gene in Polish samples was funded by the Innovative Economy Operational Programme - Activity 1.2 (TEAM Programme coordinated by the Foundation for Polish Science) and the Ministry of Science and Higher Education (grant numbers: N407 277734, N402 478137, and N407 022535).",null,25,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","SEP",2012,13,6,null,null,null,null,489,498,null,"10.1111/j.1399-5448.2011.00845.x",null,10,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","996XG","WOS:000308127500013"]
[null,null,null,null,"J","Kriz, P; Seydlova, M; Dostalova, T; Valenta, Z; Chleborad, K; Zvarova, J; Feberova, J; Hippmann, R",null,null,null,"Kriz, Pavel; Seydlova, Michaela; Dostalova, Tatjana; Valenta, Zdenek; Chleborad, Karel; Zvarova, Jana; Feberova, Jitka; Hippmann, Radek",null,null,"Dental implants and improvement of oral health-related quality of life","COMMUNITY DENTISTRY AND ORAL EPIDEMIOLOGY",null,null,"English","Article",null,null,null,null,null,"dental implant; oral health-related quality of life","PATIENT SATISFACTION; CLINICAL-TRIAL","Objectives: Oral health-related quality of life (OHRQoL) is a multifaceted field involving many factors. The aim of our study was to assess whether implant therapy improves OHRQoL in dental patients. Methods: Patients receiving at least one implant completed a health-related questionnaire before and after the implantation (minimum 1.5 months). Questions covered the functional and aesthetic scales (AS). Paired differences in individual scores were analysed using the Wilcoxon signed-rank test. A univariate analysis of covariance was used to relate overall and scale-specific average paired differences to age, gender, marital and educational status. Multivariate analysis of covariance was used to assess interactions between the covariates and different scales of outcome. All tests were performed at statistical significance level a = 0.05. Results: All twelve Wilcoxon tests supported an improvement in OHRQoL after implant placement. On the AS, the mean difference in OHRQoL scores was found to be associated with marital status, presence of aesthetic reasons for undergoing the surgery and number of front teeth replaced by implants. On the functional scale (FS), most significant associations were observed with the number of front teeth replaced via implantation, followed by the presence of chewing problems and marital status. The multivariate analysis helped to identify the covariates that varied significantly over the two scales of interest. Conclusions: Effects of covariates responding significantly differently on different scales should not be summarized using an overall univariate analysis, using paired score differences averaged over all items. Such effect summary would be misleading. In the present study, significant implant-related improvements in OHRQoL were observed on both the aesthetic and FS in patients with at least one implant in the front dental area.","[Kriz, Pavel; Seydlova, Michaela; Dostalova, Tatjana; Chleborad, Karel; Hippmann, Radek] Charles Univ Prague, Sch Med 2, Prague 15006, Czech Republic; [Seydlova, Michaela; Dostalova, Tatjana; Valenta, Zdenek; Zvarova, Jana; Hippmann, Radek] Ctr Biomed Informat, Prague, Czech Republic; [Valenta, Zdenek; Zvarova, Jana] AS CR, Inst Comp Sci, Dept Med Informat, Prague, Czech Republic; [Feberova, Jitka] Charles Univ Prague, Ctr Comp, Prague 15006, Czech Republic","Seydlova, M (reprint author), Charles Univ Prague, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic.","michaela.seydlova@seznam.cz","Valenta, Zdenek/E-5094-2011; Zvarova, Jana/B-5196-2014","Valenta, Zdenek/0000-0001-7119-9764; ","MSMT CR [1M06014];  [D-2009-56]","The work was supported by grant D-2009-56 and partially through the 1M06014 of MSMT CR project.",null,14,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0301-5661","1600-0528",null,"COMMUNITY DENT ORAL","Community Dentist. Oral Epidemiol.","FEB",2012,40,null,null,1,"SI",null,65,70,null,"10.1111/j.1600-0528.2011.00668.x",null,6,"Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational Health","Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational Health","898UU","WOS:000300768600010"]
[null,null,null,null,"J","Butenko, O; Dzamba, D; Benesova, J; Honsa, P; Benfenati, V; Rusnakova, V; Ferroni, S; Anderova, M",null,null,null,"Butenko, Olena; Dzamba, David; Benesova, Jana; Honsa, Pavel; Benfenati, Valentina; Rusnakova, Vendula; Ferroni, Stefano; Anderova, Miroslava",null,null,"The Increased Activity of TRPV4 Channel in the Astrocytes of the Adult Rat Hippocampus after Cerebral Hypoxia/Ischemia","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"BERGMANN GLIAL-CELLS; CORTICAL ASTROCYTES; CATION CHANNEL; IN-SITU; CALCIUM OSCILLATIONS; NA+-CA2+ EXCHANGER; GLUTAMATE RELEASE; MEMBRANE CURRENTS; NEURONAL-ACTIVITY; OXIDATIVE STRESS","The polymodal transient receptor potential vanilloid 4 (TRPV4) channel, a member of the TRP channel family, is a calcium-permeable cationic channel that is gated by various stimuli such as cell swelling, low pH and high temperature. Therefore, TRPV4-mediated calcium entry may be involved in neuronal and glia pathophysiology associated with various disorders of the central nervous system, such as ischemia. The TRPV4 channel has been recently found in adult rat cortical and hippocampal astrocytes; however, its role in astrocyte pathophysiology is still not defined. In the present study, we examined the impact of cerebral hypoxia/ischemia (H/I) on the functional expression of astrocytic TRPV4 channels in the adult rat hippocampal CA1 region employing immunohistochemical analyses, the patch-clamp technique and microfluorimetric intracellular calcium imaging on astrocytes in slices as well as on those isolated from sham-operated or ischemic hippocampi. Hypoxia/ischemia was induced by a bilateral 15-minute occlusion of the common carotids combined with hypoxic conditions. Our immunohistochemical analyses revealed that 7 days after H/I, the expression of TRPV4 is markedly enhanced in hippocampal astrocytes of the CA1 region and that the increasing TRPV4 expression coincides with the development of astrogliosis. Additionally, adult hippocampal astrocytes in slices or cultured hippocampal astrocytes respond to the TRPV4 activator 4-alpha-phorbol-12,-13-didecanoate (4 alpha PDD) by an increase in intracellular calcium and the activation of a cationic current, both of which are abolished by the removal of extracellular calcium or exposure to TRP antagonists, such as Ruthenium Red or RN1734. Following hypoxic/ischemic injury, the responses of astrocytes to 4 alpha PDD are significantly augmented. Collectively, we show that TRPV4 channels are involved in ischemia-induced calcium entry in reactive astrocytes and thus, might participate in the pathogenic mechanisms of astroglial reactivity following ischemic insult.","[Butenko, Olena; Dzamba, David; Benesova, Jana; Honsa, Pavel; Anderova, Miroslava] Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Prague, Czech Republic; [Butenko, Olena; Dzamba, David; Benesova, Jana; Honsa, Pavel] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Benfenati, Valentina] CNR, Inst Study Nanostruct Mat, Bologna, Italy; [Rusnakova, Vendula] Acad Sci Czech Republic, Inst Biotechnol, Gene Express Lab, Prague, Czech Republic; [Ferroni, Stefano] Univ Bologna, Dept Human & Gen Physiol, Bologna, Italy","Butenko, O (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Prague, Czech Republic.","anderova@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [GA CR:P303/10/1338, GA CR:309/08/H079]; Academy of Sciences of the Czech Republic [AVOZ50390512]; Ministry of Education, Youth and Sports of the Czech Republic [LC554]","This study was supported by the grants GA CR:P303/10/1338 and GA CR:309/08/H079 from the Grant Agency of the Czech Republic, AVOZ50390512 from the Academy of Sciences of the Czech Republic, and LC554 from the Ministry of Education, Youth and Sports of the Czech Republic. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,82,9,10,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","JUN 27",2012,7,6,null,null,null,null,null,null,"e39959","10.1371/journal.pone.0039959",null,23,"Multidisciplinary Sciences","Science & Technology - Other Topics","966GL","WOS:000305825800082"]
[null,null,null,null,"J","Benesova, J; Rusnakova, V; Honsa, P; Pivonkova, H; Dzamba, D; Kubista, M; Anderova, M",null,null,null,"Benesova, Jana; Rusnakova, Vendula; Honsa, Pavel; Pivonkova, Helena; Dzamba, David; Kubista, Mikael; Anderova, Miroslava",null,null,"Distinct Expression/Function of Potassium and Chloride Channels Contributes to the Diverse Volume Regulation in Cortical Astrocytes of GFAP/EGFP Mice","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"K+-CL-COTRANSPORTER; 3-DIMENSIONAL CONFOCAL MORPHOMETRY; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; GLIAL-CELLS; IN-SITU; MOLECULAR-MECHANISMS; CULTURED ASTROCYTES; RAT HIPPOCAMPUS; GLIOMA-CELLS","Recently, we have identified two astrocytic subpopulations in the cortex of GFAP-EGFP mice, in which the astrocytes are visualized by the enhanced green-fluorescent protein (EGFP) under the control of the human glial fibrillary acidic protein (GFAP) promotor. These astrocytic subpopulations, termed high response-(HR-) and low response-(LR-) astrocytes, differed in the extent of their swelling during oxygen-glucose deprivation (OGD). In the present study we focused on identifying the ion channels or transporters that might underlie the different capabilities of these two astrocytic subpopulations to regulate their volume during OGD. Using three-dimensional confocal morphometry, which enables quantification of the total astrocytic volume, the effects of selected inhibitors of K+ and Cl- channels/transporters or glutamate transporters on astrocyte volume changes were determined during 20 minute-OGD in situ. The inhibition of volume regulated anion channels (VRACs) and two-pore domain potassium channels (K-2P) highlighted their distinct contributions to volume regulation in HR-/LR-astrocytes. While the inhibition of VRACs or K-2P channels revealed their contribution to the swelling of HR-astrocytes, in LR-astrocytes they were both involved in anion/K+ effluxes. Additionally, the inhibition of Na+-K+-Cl- co-transporters in HR-astrocytes led to a reduction of cell swelling, but it had no effect on LR-astrocyte volume. Moreover, employing real-time single-cell quantitative polymerase chain reaction (PCR), we characterized the expression profiles of EGFP-positive astrocytes with a focus on those ion channels and transporters participating in astrocyte swelling and volume regulation. The PCR data revealed the existence of two astrocytic subpopulations markedly differing in their gene expression levels for inwardly rectifying K+ channels (Kir4.1), K-2P channels (TREK-1 and TWIK-1) and Cl- channels (ClC2). Thus, we propose that the diverse volume changes displayed by cortical astrocytes during OGD mainly result from their distinct expression patterns of ClC2 and K-2P channels.","[Benesova, Jana; Honsa, Pavel; Pivonkova, Helena; Dzamba, David; Anderova, Miroslava] Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Prague, Czech Republic; [Rusnakova, Vendula; Kubista, Mikael] Acad Sci Czech Republic, Inst Biotechnol, Gene Express Lab, Prague, Czech Republic; [Benesova, Jana; Honsa, Pavel; Pivonkova, Helena; Dzamba, David] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Kubista, Mikael] TATAA Bioctr, Gothenburg, Sweden","Benesova, J (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Cellular Neurophysiol, Prague, Czech Republic.","anderova@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [CZ:GA CR:GA P303/10/1338, CZ:GA CR:GA 309/08/H079]; Academy of Sciences of the Czech Republic [UEM AV CR - AV0Z50390703]","This study was supported by the grants: CZ:GA CR:GA P303/10/1338 and CZ:GA CR:GA 309/08/H079 from the Grant Agency of the Czech Republic and UEM AV CR - AV0Z50390703 from the Academy of Sciences of the Czech Republic. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,53,9,9,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","JAN 11",2012,7,1,null,null,null,null,null,null,"e29725","10.1371/journal.pone.0029725",null,13,"Multidisciplinary Sciences","Science & Technology - Other Topics","906ON","WOS:000301355700041"]
[null,null,null,null,"J","Seeman, T; Dostalek, L; Gilik, J",null,null,null,"Seeman, Tomas; Dostalek, Lukas; Gilik, Jiri",null,null,"Control of Hypertension in Treated Children and Its Association With Target Organ Damage","AMERICAN JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"antihypertensive therapy; blood pressure; children; control; hypertension; left ventricular hypertrophy","LEFT-VENTRICULAR HYPERTROPHY; BLOOD-PRESSURE CONTROL; CHRONIC KIDNEY-DISEASE; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR-DISEASE; PRACTICE GUIDELINES; RENAL-FAILURE; TASK-FORCE; ADOLESCENTS; MANAGEMENT","BACKGROUND The aim of our study was to investigate the control of hypertension (HT) in treated children using ambulatory blood pressure (BP) monitoring (ABPM). METHODS We retrospectively reviewed all ABPM studies in our center. Controlled HT was defined as systolic and diastolic BP index (patients' BP divided by the 95th percentile) at daytime and nighttime <1.0 or alternatively as BP load (percentage of BP readings above the 95th percentile) <25% in children on antihypertensive therapy. RESULTS A total of 195 ABPM studies were included. The mean age was 13.6 +/- 4.0 years. One hundred and thirty two children had renoparenchymal HT, 10 renovascular (RVH), 10 endocrine, 4 cardiovascular, 29 primary (PH) and 5 children other forms of HT. 53% of all children had controlled HT. There was no difference in the prevalence of controlled HT between primary and secondary HI (52% and 53%) using the BP index criterion. Children with renoparenchymal HT had significantly better control of HT than children with RVH (58% vs. 20% P = 0.02). The use of angiotensin-converting enzyme inhibitors (ACEI) monotherapy was significantly more effective in controlling HT than the use of calcium-channel blockers (CCB, P = 0.02).The prevalence of left ventricular hypertrophy in children with uncontrolled HT (assessed in 58 patients) was significantly higher than in children with controlled HT (46% vs. 13%, P < 0.01). CONCLUSIONS This is the first pediatric study, to our knowledge, on BP control in hypertensive children using ABPM. It indicates that control of HT is inadequate in similar to 50% of treated children. Inadequate control of HT is associated with target organ damage in this population.","[Seeman, Tomas; Dostalek, Lukas] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Med Sch 2, Prague, Czech Republic; [Gilik, Jiri] Univ Hosp Motol, Kardiocentrum, Prague, Czech Republic; [Gilik, Jiri] Univ Hosp Motol, Ctr Cardiovasc Res, Prague, Czech Republic","Seeman, T (reprint author), Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Med Sch 2, Prague, Czech Republic.","tomas.seeman@lfmotol.cuni.cz",null,null,"Ministry of Education of the Czech Republic [0021620819]; Ministry of Health [0006420301 MZOFNM2005]","We thank our colleagues performing some of the ABPM studies. This study was supported by grant Ministry of Education of the Czech Republic VZ Nr. 0021620819 and Ministry of Health VZ Nr. 0006420301 MZOFNM2005. Results were presented at the IPNA meeting 2010 in New York.",null,28,8,8,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0895-7061",null,null,"AM J HYPERTENS","Am. J. Hypertens.","MAR",2012,25,3,null,null,null,null,389,395,null,"10.1038/ajh.2011.218",null,7,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","893VN","WOS:000300385900019"]
[null,null,null,null,"J","Cinek, O; Sumnik, Z; de Beaufort, C; Rurik, I; Vazeou, A; Madacsy, L; Papo, NL; Danne, T",null,null,null,"Cinek, Ondrej; Sumnik, Zdenek; de Beaufort, Carine; Rurik, Imre; Vazeou, Andriani; Madacsy, Laszlo; Papo, Natalie L.; Danne, Thomas",null,"SWEET Grp","Heterogeneity in the systems of pediatric diabetes care across the European Union","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"delivery of health care; reimbursement; QC",null,"Background It is known that the systems of pediatric diabetes care differ across the member states of the European Union (EU). The aim of this project was to characterize some of the main differences among the national systems. Methods Data were collected using two questionnaires. The first one was distributed among leading centers of pediatric diabetes (one per country) with the aim of establishing an overview of the systems, national policies, quality control (QC) and financing of pediatric diabetes care. Responses were received from all 27 EU countries. The second questionnaire was widely disseminated among all 354 International Society for Pediatric and Adolescent Diabetes members with a domicile in an EU country; it included questions related to individual pediatric diabetes centers. A total of 108 datasets were collected and processed from healthcare professionals who were treating more than 29?000 children and adolescents with diabetes. Data on the reimbursement policies were verified by representatives of the pharmaceutical and medical device companies. Results The collected data reflect the situation in 2009. There was a notable heterogeneity among the systems for provision of pediatric diabetes care across the EU. Only 20/27 EU countries had a pediatric diabetes register. Nineteen countries had officially recognized centers for pediatric diabetes, but only nine of them had defined criteria for becoming such a center. A system for QC of pediatric diabetes at the national level was reported in 7/26 countries. Reimbursement for treatment varied significantly across the EU, potentially causing inequalities in access to modern technologies. Conclusions The collected data help develop strategies toward improving equity and access to modern pediatric diabetes care across Europe.","[Cinek, Ondrej; Sumnik, Zdenek] Univ Hosp Motol, Dept Pediat, CZ-15006 Prague 5, Czech Republic; [Cinek, Ondrej; Sumnik, Zdenek] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague, Czech Republic; [de Beaufort, Carine] Pediat Clin, DECCP, Luxembourg, Luxembourg; [Rurik, Imre] Debrecen Univ Med, Dept Family & Occupat Med, H-4012 Debrecen, Hungary; [Vazeou, Andriani] PA Kyriakou Childrens Hosp, Dept Pediat, Athens, Greece; [Vazeou, Andriani] PA Kyriakou Childrens Hosp, Ctr Diabet, Athens, Greece; [Madacsy, Laszlo] Semmelweis Univ, Dept Pediat, Budapest, Hungary; [Papo, Natalie L.] Medtron Int Trading Sarl, Diabet Europe, Tolochenaz, Switzerland; [Danne, Thomas] Diabet Zentrum Kinder & Jugendliche, Kinder & Jugendkrankenhaus AUF DER BULT, Hannover, Germany","Cinek, O (reprint author), Univ Hosp Motol, Dept Pediat, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","Ondrej.Cinek@Lfmotol.cuni.cz",null,null,null,null,null,0,3,3,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","SEP",2012,13,null,null,16,"SI",null,5,14,null,"10.1111/j.1399-5448.2012.00907.x",null,10,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","996OO","WOS:000308100400002"]
[null,null,null,null,"J","Vasovcak, P; Krepelova, A; Menigatti, M; Puchmajerova, A; Skapa, P; Augustinakova, A; Amann, G; Wernstedt, A; Jiricny, J; Marra, G; Wimmer, K",null,null,null,"Vasovcak, P.; Krepelova, A.; Menigatti, M.; Puchmajerova, A.; Skapa, P.; Augustinakova, A.; Amann, G.; Wernstedt, A.; Jiricny, J.; Marra, G.; Wimmer, K.",null,null,"Unique mutational profile associated with a loss of TDG expression in the rectal cancer of a patient with a constitutional PMS2 deficiency","DNA REPAIR",null,null,"English","Article",null,null,null,null,null,"TDG; Colorectal cancer; CMMR-D syndrome; MMR repair; Supermutator","THYMINE-DNA GLYCOSYLASE; BASE EXCISION-REPAIR; HEREDITARY COLORECTAL-CANCER; MISMATCH-REPAIR; TURCOT-SYNDROME; EARLY-ONSET; GENE; NEUROFIBROMATOSIS; TUMORS; URACIL","Cells with DNA repair defects have increased genomic instability and are more likely to acquire secondary mutations that bring about cellular transformation. We describe the frequency and spectrum of somatic mutations involving several tumor suppressor genes in the rectal carcinoma of a 13-year-old girl harboring biallelic, germline mutations in the DNA mismatch repair gene PMS2. Apart from microsatellite instability, the tumor DNA contained a number of C:G -> T:A or G:C -> A:T transitions in CpG dinucleotides, which often result through spontaneous deamination of cytosine or 5-methylcytosine. Four DNA glycosylases, UNG2, SMUG1, MBD4 and TDG, are involved in the repair of these deamination events. We identified a heterozygous missense mutation in TDG, which was associated with TDG protein loss in the tumor. The CpGs mutated in this patient's tumor are generally methylated in normal colonic mucosa. Thus, it is highly likely that loss of TDG contributed to the supermutator phenotype and that most of the point mutations were caused by deamination of 5-methylcytosine to thymine, which remained uncorrected owing to the TDG deficiency. This case provides the first in vivo evidence of the key role of TDG in protecting the human genome against the deleterious effects of 5-methylcytosine deamination. (C) 2012 Elsevier B.V. All rights reserved.","[Vasovcak, P.; Krepelova, A.; Puchmajerova, A.] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 15006 5, Czech Republic; [Vasovcak, P.; Krepelova, A.; Puchmajerova, A.; Skapa, P.; Augustinakova, A.] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Menigatti, M.; Jiricny, J.; Marra, G.] Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; [Menigatti, M.; Jiricny, J.; Marra, G.] Swiss Fed Inst Technol, CH-8057 Zurich, Switzerland; [Skapa, P.; Augustinakova, A.] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Amann, G.] Med Univ Vienna, Dept Pathol, A-1090 Vienna, Austria; [Wernstedt, A.; Wimmer, K.] Med Univ Innsbruck, Div Human Genet, A-6020 Innsbruck, Austria","Vasovcak, P (reprint author), Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, V Uvalu 84, Prague 15006 5, Czech Republic.","pevas78@hotmail.com",null,null,"Ministry of Health, Czech Republic, (University Hospital Motol, Prague,Czech Republic) [00064203]; Austrian Science Fond [\"Fonds zur Forderung der wissenschaftlichen Forschung\" (FWF)] [P21172-B12]; Swiss National Science Foundation [310030B-133123, 31003A-122186]; Cancer League Switzerland [KFS-02739-02-2011]","We thank Primo Schar for kindly providing a polyclonal anti-TDG antibody and Ritva Haider for performing the IHC analyses. The work was supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague,Czech Republic). The generous support by the Austrian Science Fond [\"Fonds zur Forderung der wissenschaftlichen Forschung\" (FWF), grant no. P21172-B12 to AW and KW], the Swiss National Science Foundation (grants no. 310030B-133123 to JJ and 31003A-122186 to GM), and the Cancer League Switzerland (grant no. KFS-02739-02-2011 to MM) is also gratefully acknowledged.",null,49,3,3,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1568-7864",null,null,"DNA REPAIR","DNA Repair","JUL 1",2012,11,7,null,null,null,null,616,623,null,"10.1016/j.dnarep.2012.04.004",null,8,"Genetics & Heredity; Toxicology","Genetics & Heredity; Toxicology","982HK","WOS:000307033500003"]
[null,null,null,null,"J","Seeman, T; Pohl, M; Palyzova, D; John, U",null,null,null,"Seeman, Tomas; Pohl, Michael; Palyzova, Daniela; John, Ulrike",null,null,"Microalbuminuria in children with primary and white-coat hypertension","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Microalbuminuria; Blood pressure; Ambulatory blood pressure monitoring; Primary hypertension; White-coat hypertension; Children","LEFT-VENTRICULAR HYPERTROPHY; AMBULATORY BLOOD-PRESSURE; TARGET-ORGAN DAMAGE; MASKED HYPERTENSION; ADOLESCENTS; DETERMINANTS; PREVALENCE; FREQUENCY; DISEASE; HARVEST","Microalbuminuria serves as an early marker of hypertension-related renal damage in adults. However, data on the prevalence of microalbuminuria in paediatric hypertensive patients in general and in children with white-coat hypertension (WCH) specifically are lacking. The aim of our study was to investigate the prevalence of microalbuminuria in children with primary hypertension (PH) and WCH, respectively. This was a retrospective case review of children with PH and WCH treated at three paediatric nephrology centres. Untreated children with either form of hypertension for whom measurements of urinary albumin excretion (UAE) had been performed were enrolled in the study. The study cohort comprised 52 children (39 boys) with hypertension (26 children with PH, 26 with WCH). Microalbuminuria (> 3.2 mg/mmol creatinine) was present in 20% of children with PH and none of the children with WCH (p < 0.01). Children with PH had a higher median UAE than those with WCH (1.27 +/- 1.92 vs. 0.66 +/- 0.46 mg/mmol creatinine, p < 0.05). Based on these results, we suggest that children with PH have an increased prevalence of microalbuminuria, while children with WCH show no signs of hypertension-related renal damage.","[Seeman, Tomas] Charles Univ Prague, Univ Hosp Motol, Dept Paediat, Sch Med 2, Prague 15006 5, Czech Republic; [Pohl, Michael; John, Ulrike] Univ Jena, Dept Paediat, Jena, Germany; [Palyzova, Daniela] Charles Univ Prague, Sch Med 3, Dept Paediat, Prague 15006 5, Czech Republic","Seeman, T (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Paediat, Sch Med 2, Uvalu 84, Prague 15006 5, Czech Republic.","tomas.seeman@lfmotol.cuni.cz",null,null,"VZ MZ CR [0006420301 MZOFNM2005]","This study was supported by grant VZ MZ CR No 0006420301 MZOFNM2005. We thank the colleagues from the Department of Biochemistry and Pathobiochemistry for measurements of urinary albumin concentration.",null,32,3,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","MAR",2012,27,3,null,null,null,null,461,467,null,"10.1007/s00467-011-2019-2",null,7,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","881RU","WOS:000299506100017"]
[null,null,null,null,"J","Cinek, O; Tapia, G; Witso, E; Kramna, L; Holkova, K; Rasmussen, T; Stene, LC; Ronningen, KS",null,null,null,"Cinek, Ondrej; Tapia, German; Witso, Elisabet; Kramna, Lenka; Holkova, Katerina; Rasmussen, Trond; Stene, Lars C.; Ronningen, Kjersti S.",null,null,"Enterovirus RNA in Peripheral Blood May Be Associated with the Variants of rs1990760, a Common Type 1 Diabetes Associated Polymorphism in IFIH1","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"BETA-CELL AUTOIMMUNITY; RIG-I; MULTIPLE-SCLEROSIS; FUNCTION MUTATIONS; MONONUCLEAR-CELLS; RISK-FACTOR; INFECTIONS; POPULATION; LOCUS; MDA5","Objective: Polymorphisms in the IFIH1 (common rs1990760 and four rare rs35667974, rs35337543, rs35744605, rs35732034) have been convincingly associated with type 1 diabetes. The encoded protein (interferon-induced helicase C domain-containing protein 1) senses double-stranded RNA during replication of Picornavirales, including Enterovirus, a genus suspected in the etiology of type 1 diabetes. We therefore investigated whether the polymorphisms are associated with differences in the frequency of enterovirus RNA in blood. Research Design and Methods: The study included 1001 blood samples, each from a child participating in the Norwegian 'Environmental Triggers of Type 1 Diabetes: the MIDIA study'. The enterovirus RNA was tested using qualitative semi-nested real-time reverse transcriptase PCR on RNA extracted from frozen cell packs after removal of plasma. Stool samples previously analyzed for enterovirus RNA were available in 417 children. Results: The genotypes of IFIH1 rs1990760 were associated with different frequencies of enterovirus RNA in blood (7.0%, 14.4% and 9.5% bloods were enterovirus positive among children carrying the Ala/Ala, Ala/Thr and Thr/Thr genotypes, respectively, p = 0.012). This association remained essentially unchanged after adjustment for age and calendar year. The presence of enterovirus in the concomitantly sampled stool further increased the likelihood of enterovirus RNA in blood (odds ratio 2.40, CI 95% 1.13-4.70), but did not affect the association with IFIH1 rs1990760. The rare polymorphisms (individually, or pooled) were not significantly associated with enterovirus RNA in blood. Conclusions: The common IFIH1 SNP may modify the frequency of enterovirus RNA in blood of healthy children. This effect can help explain the association of IFIH1 with type 1 diabetes.","[Cinek, Ondrej; Kramna, Lenka; Holkova, Katerina] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic; [Cinek, Ondrej; Kramna, Lenka; Holkova, Katerina] Univ Hosp Motol, Prague, Czech Republic; [Tapia, German; Witso, Elisabet; Rasmussen, Trond; Stene, Lars C.] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway; [Ronningen, Kjersti S.] Univ Oslo, Rikshosp, Oslo Univ Hosp, N-0027 Oslo, Norway","Cinek, O (reprint author), Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic.","Ondrej.Cinek@Lfmotol.cuni.cz",null,null,"Norwegian Organization for Health and Rehabilitation [2008/0182]; Ministry of Health of the Czech Republic [IGA MZ 11465-5]; Research Council of Norway [135893/330, 155300/320, 156477/730, 166515/V50]; Norwegian Diabetes Association; ISPAD Research Fellowship ((International Society for Pediatric and Adolescent Diabetes)","This study and the MIDIA project were funded by the Norwegian Organization for Health and Rehabilitation (2008/0182), the Ministry of Health of the Czech Republic (IGA MZ 11465-5), the Research Council of Norway (grants 135893/330, 155300/320, 156477/730 and 166515/V50) and the Norwegian Diabetes Association. O.C. was supported by the ISPAD Research Fellowship ((International Society for Pediatric and Adolescent Diabetes). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,38,2,2,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","NOV 7",2012,7,11,null,null,null,null,null,null,"e48409","10.1371/journal.pone.0048409",null,7,"Multidisciplinary Sciences","Science & Technology - Other Topics","048TK","WOS:000311935800056"]
[null,null,null,null,"J","Dostalova, T; Jelinkova, H; Sulc, J; Nemec, M; Fibrich, M; Jelinek, M; Michalik, P; Buckova, M",null,null,null,"Dostalova, T.; Jelinkova, H.; Sulc, J.; Nemec, M.; Fibrich, M.; Jelinek, M.; Michalik, P.; Buckova, M.",null,null,"Bond strengths evaluation of laser ceramic bracket debonding","LASER PHYSICS",null,null,"English","Article",null,null,null,null,null,null,"ORTHODONTIC BRACKETS","Ceramic brackets often used for an orthodontic treatment can lead to problems such as enamel tear outs because of their low fracture resistance and high bond strengths. Therefore the aim of our study was to investigate the positive laser radiation effect on bracket debonding. Moreover, the influence of the enamel shape surface under the bracket and laser radiation power on the debonding strength was investigated. The source of the radiation was the longitudinally diode-pumped Tm:YAP laser operating at 1997 nm. To eliminate the tooth surface roughness the flat enamel surface was prepared artificially and the bracket was bonded on it. The debonding was accomplished by Tm:YAP laser radiation with different the power value while recording the temperature rise in the pulp. To simulate the debonding process in vivo the actual bond strength was measured by the digital force gauge. The results were analyzed by scanning electron microscope.","[Dostalova, T.; Michalik, P.; Buckova, M.] Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague 15006 5, Czech Republic; [Jelinkova, H.; Sulc, J.; Nemec, M.; Fibrich, M.; Jelinek, M.] Czech Tech Univ, Fac Nucl Sci & Phys Engn, CR-11519 Prague, Czech Republic","Dostalova, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague 15006 5, Czech Republic.","tatjana.dostalova@fnmotol.cz",null,null,"FN MOTOL [IGA 13351-4, 00064203];  [RVO 68407700]","This research has been supported by the research grant RVO 68407700 and also by the grant IGA 13351-4, and 00064203 (FN MOTOL).",null,19,0,0,"IOP PUBLISHING LTD","BRISTOL","TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND","1054-660X",null,null,"LASER PHYS","Laser Phys.","SEP",2012,22,9,null,null,null,null,1395,1400,null,"10.1134/S1054660X12090046",null,6,"Optics; Physics, Applied","Optics; Physics","999DQ","WOS:000308289900006"]
[null,null,null,null,"J","VojacKova, N; Fialova, J; Vanousova, D; Hercogova, J",null,null,null,"VojacKova, Nadezda; Fialova, Jorga; Vanousova, Daniela; Hercogova, Jana",null,null,"Pemphigus vulgaris treated with adalimumab: case study","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"adalimumab; biological therapy; corticosteroids; pemphigus vulgaris","REFRACTORY PEMPHIGUS; INFLIXIMAB","The study describes the case of a patient with a clinical and histopathological diagnosis of pemphigus vulgaris accompanied by severe side-effects of combined immunosuppressive therapy, who achieved a remission of the disease with adalimumab. Pemphigus vulgaris is a chronic blistering disease of the skin and mucous membranes. Before corticosteroids were introduced, mortality was high. Corticosteroids are currently used as first-line therapy. To reduce the dose of corticosteroids, therapeutic combinations with corticosteroid-sparing immunosuppressive agents are used. The therapy brings a number of complications due to its side effects. To achieve a remission of the disease by treating our patient with combined immunosuppressives, we administered adalimumab and achieved a very good clinical response.","[VojacKova, Nadezda] Charles Univ Prague, Sch Med, Dept Dermatovenereol 2, CR-18000 Prague, Czech Republic; [VojacKova, Nadezda] Bulovka Hosp, CR-18000 Prague, Czech Republic","VojacKova, N (reprint author), Charles Univ Prague, Sch Med, Dept Dermatovenereol 2, Budinova 2, CR-18000 Prague, Czech Republic.","nadavojackova@seznam.cz",null,null,null,null,null,10,1,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","JAN-FEB",2012,25,1,null,null,null,null,95,97,null,"10.1111/j.1529-8019.2012.01433.x",null,3,"Dermatology","Dermatology","942YT","WOS:000304088300011"]
[null,null,null,null,"J","Veisova, D; Macakova, E; Rezabkova, L; Sulc, M; Vacha, P; Sychrova, H; Obsil, T; Obsilova, V",null,null,null,"Veisova, Dana; Macakova, Eva; Rezabkova, Lenka; Sulc, Miroslav; Vacha, Petr; Sychrova, Hana; Obsil, Tomas; Obsilova, Veronika",null,null,"Role of individual phosphorylation sites for the 14-3-3-protein-dependent activation of yeast neutral trehalase Nth1","BIOCHEMICAL JOURNAL",null,null,"English","Article",null,null,null,null,null,"14-3-3 protein; Bmh; enzymatic activity; neutral trehalase (Nth 1); phosphorylation; Saccharomyces cerevisiae","DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TYROSINE-HYDROXYLASE; 14-3-3 BINDING; BAKERS-YEAST; GENE; PURIFICATION; COMPLEX; APOPTOSIS; INSIGHTS","Trehalases are important highly conserved enzymes found in a wide variety of organisms and are responsible for the hydrolysis of trehalose that serves as a carbon and energy source as well as a universal stress protectant. Emerging evidence indicates that the enzymatic activity of the neutral trehalase Nth1 in yeast is enhanced by 14-3-3 protein binding in a phosphorylation-dependent manner through an unknown mechanism. In the present study, we investigated in detail the interaction between Saccharomyces cerevisiae Nth1 and 14-3-3 protein isoforms Bmh1 and Bmh2. We determined four residues that are phosphorylated by PKA (protein kinase A) in vitro within the disordered N-terminal segment of Nth1. Sedimentation analysis and enzyme kinetics measurements show that both yeast 14-3-3 isoforms form a stable complex with phosphorylated Nth1 and significantly enhance its enzymatic activity. The 14-3-3-dependent activation of Nth1 is significantly more potent compared with Ca2+ -dependent activation. Limited proteolysis confirmed that the 14-3-3 proteins interact with the N-terminal segment of Nth1 where all phosphorylation sites are located. Site-directed mutagenesis in conjunction with the enzyme activity measurements in vitro and the activation studies of mutant forms in vivo suggest that Ser(60) and Ser(83) are sites primarily responsible for PKA-dependent and 14-3-3-mediated activation of Nth1.","[Veisova, Dana; Macakova, Eva; Rezabkova, Lenka; Vacha, Petr; Sychrova, Hana; Obsil, Tomas; Obsilova, Veronika] Acad Sci Czech Republic, Inst Physiol, Vvi, CR-14220 Prague 4, Czech Republic; [Rezabkova, Lenka; Vacha, Petr; Obsil, Tomas] Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843 2, Czech Republic; [Sulc, Miroslav] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12843 2, Czech Republic; [Sulc, Miroslav] Acad Sci Czech Republic, Inst Microbiol, Vvi, CR-14220 Prague 4, Czech Republic","Obsilova, V (reprint author), Acad Sci Czech Republic, Inst Physiol, Vvi, Videnska 1083, CR-14220 Prague 4, Czech Republic.","obsilova@biomed.cas.cz","Sychrova, Hana /B-1350-2012; Obsilova, Veronika/B-7116-2012; Obsil, Tomas/B-7142-2012","Obsilova, Veronika/0000-0003-0851-7680; ","Czech Science Foundation [P207/11/0455]; Grant Agency of the Charles University [350111]; Grant Agency of the Academy of Sciences of the Czech Republic [IAA500110801]; Academy of Sciences of the Czech Republic [Institute of Physiology] [AV0Z50110509]; Academy of Sciences of the Czech Republic [Institute of Microbiology] [AV0Z50200510]; Ministry of Education, Youth and Sports of the Czech Republic [MSM0021620857]","This work was supported by the Czech Science Foundation [grant number P207/11/0455], Grant Agency of the Charles University [grant number 350111], Grant Agency of the Academy of Sciences of the Czech Republic [grant number IAA500110801], Academy of Sciences of the Czech Republic [research project AV0Z50110509 of the Institute of Physiology and AV0Z50200510 of the Institute of Microbiology] and Ministry of Education, Youth and Sports of the Czech Republic [research project MSM0021620857].",null,48,13,13,"PORTLAND PRESS LTD","LONDON","THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND","0264-6021",null,null,"BIOCHEM J","Biochem. J.","MAY 1",2012,443,null,3,null,null,null,663,670,null,"10.1042/BJ20111615",null,8,"Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","941DP","WOS:000303944200008"]
[null,null,null,null,"J","Hercogova, J; Schwartz, RA; Lotti, TM",null,null,null,"Hercogova, Jana; Schwartz, Robert A.; Lotti, Torello M.",null,null,"Classification of vitiligo: a challenging endeavor","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"classification; treatment; vitiligo","GENERALIZED VITILIGO; SUSCEPTIBILITY LOCI; HUMAN MELANOCYTES; LESIONAL SKIN; EPIDEMIOLOGY; EPIDERMIS; TETRAHYDROBIOPTERIN; BIOSYNTHESIS; CONFIRMATION; MECHANISMS","The classification of vitiligo is mandatory for clinical and research purposes. Although the etiology and pathobiology of vitiligo remain unknown, a working classification of vitiligo is imperative for the scientific community to communicate. The authors delineate herein their efforts for vitiligo classification utilizing clinical, genetic, pathobiological, epidemiological, and molecular characteristics of vitiligo. These different classification approaches may aid clinicians to identify the most suitable treatment for each individual vitiligo subject.","[Lotti, Torello M.] Univ Rome G Marconi, I-00193 Rome, Italy; [Hercogova, Jana] Charles Univ Prague, Sch Med 2, Dept Dermatol & Venereol, Prague, Czech Republic; [Schwartz, Robert A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [Lotti, Torello M.] Vitiligo Res Fdn, New York, NY USA","Lotti, TM (reprint author), Univ Rome G Marconi, Via Vittoria Colonna 11, I-00193 Rome, Italy.","professor@torellolotti.it",null,null,null,null,null,31,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","NOV-DEC",2012,25,null,null,1,"SI",null,"S10","S16",null,"10.1111/dth.12010",null,7,"Dermatology","Dermatology","053VW","WOS:000312304200002"]
[null,null,null,null,"J","Lotti, TM; Hercogova, J; Schwartz, RA; Tsampau, D; Korobko, I; Pietrzak, A; Mitrevska, NT; Valle, Y; Buggiani, G",null,null,null,"Lotti, Torello M.; Hercogova, Jana; Schwartz, Robert A.; Tsampau, Dionigi; Korobko, Igor; Pietrzak, Aldona; Mitrevska, Natasa Teovska; Valle, Yan; Buggiani, Gionata",null,null,"Treatments of vitiligo: what's new at the horizon","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"treatment; vitiligo","TOPICAL CAPSAICIN; PROSTAGLANDIN E-2; PROLIFERATION; LATANOPROST; MELANOCYTES; PIPERINE; EFFICACY; ANALOGS; REPIGMENTATION; PIGMENTATION","Vitiligo is a manageable disease. However, current vitiligo treatments can be considered suboptimal as they do not guarantee high efficacy and cannot be standardized for most patients. Recently, combination therapies have been introduced in order to obtain better results and reduce risks in the management of the disease. Novel efficacious products are hereunder discussed to improve the therapeutic options for vitiligo patients.","[Lotti, Torello M.; Tsampau, Dionigi; Buggiani, Gionata] Univ Rome G Marconi, Rome, Italy; [Lotti, Torello M.; Korobko, Igor; Valle, Yan] Vitiligo Res Fdn, New York, NY USA; [Schwartz, Robert A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Dermatol & Pathol, Newark, NJ 07103 USA; [Hercogova, Jana] Charles Univ Prague, Sch Med 2, Dept Dermatol & Venerol, Prague, Czech Republic; [Korobko, Igor] Russian Acad Sci, Inst Gene Biol, Moscow, Russia; [Pietrzak, Aldona] Med Univ Lublin, Dept Dermatol Venerol & Pediat Dermatol, Lublin, Poland; [Mitrevska, Natasa Teovska] Gen Hosp Remedika, Dept Dermatol, Skopje, Macedonia","Hercogova, J (reprint author), Charles Univ Prague, Bulovka Hosp, Dermatovenereol Dept, Prague 218081 8, Czech Republic.","jana.hercogova@gmail.com",null,null,null,null,null,49,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","NOV-DEC",2012,25,null,null,1,"SI",null,"S32","S40",null,"10.1111/dth.12011",null,9,"Dermatology","Dermatology","053VW","WOS:000312304200005"]
[null,null,null,null,"J","Hubackova, M; Vaclavikova, R; Ehrlichova, M; Mrhalova, M; Kodet, R; Kubackova, K; Vrana, D; Gut, I; Soucek, P",null,null,null,"Hubackova, Miluse; Vaclavikova, Radka; Ehrlichova, Marie; Mrhalova, Marcela; Kodet, Roman; Kubackova, Katerina; Vrana, David; Gut, Ivan; Soucek, Pavel",null,null,"Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas","INTERNATIONAL JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"breast; cancer; prognosis; superoxide dismutase; quinone oxidoreductase","DISEASE-FREE SURVIVAL; OXIDATIVE STRESS; CANCER PATIENTS; ANTIOXIDANT ENZYME; TUMOR-SUPPRESSOR; CLINICAL-TRIAL; DT-DIAPHORASE; UP-REGULATION; LUNG-CANCER; EXPRESSION","Associations of transcript levels of oxidative stress-modifying genes SOD2, SOD3, NQO1 and NQO2 and their functional single nucleotide polymorphisms (SNPs) rs4880, rs1799895, rs2536512, rs699473, rs1800566 and rs1143684 with prognosis of breast cancer patients were studied. SNPs were assessed by allelic discrimination in a cohort of 321 breast cancer patients from the Czech Republic. Transcript levels were determined by real-time polymerase chain reaction (PCR) with absolute quantification in tumor and adjacent non-neoplastic control tissues. Both genotypes and transcript levels were then compared with available clinical data on patients. Patients carrying low activity allele Leu in NQO2 rs1143684 had a greater incidence of stage 0 or I disease (i.e., better prognosis) than patients with the Phe/Phe genotype. This association was more evident in patients without expression of progesterone receptors (p = 0.031). Patients carrying the Thr allele in SOD3 rs2536512 SNP had a significantly greater incidence of tumors expressing estrogen receptors than patients carrying the Ala/Ala genotype (p = 0.007). SOD3 transcript level was significantly higher in grade 1 or 2 tumors than in grade 3 tumors (p = 0.006). Patients carrying T allele in SOD3 rs699473 SNP had significantly poorer progression-free survival (PFS) than patients carrying the CC genotype (p = 0.038). The same applied to the subgroup of patients treated by hormonal regimens (p = 0.021). Patients carrying the high activity Ala/Ala genotype in SOD2 (rs4880) had significantly poorer PFS than Val allele carriers in the group treated by cyclophosphamide but not hormonal regimens (p = 0.004). Our results suggest that NQO2, SOD2 and SOD3 may significantly modify prognosis of breast cancer patients and that their significance should be further characterized.","[Hubackova, Miluse; Vaclavikova, Radka; Ehrlichova, Marie; Vrana, David; Gut, Ivan; Soucek, Pavel] Natl Inst Publ Hlth, Toxicogenom Unit, Prague 10042 10, Czech Republic; [Hubackova, Miluse] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Mrhalova, Marcela; Kodet, Roman; Kubackova, Katerina] Charles Univ Prague, Hosp Motol, Prague, Czech Republic; [Mrhalova, Marcela; Kodet, Roman] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Kubackova, Katerina] Charles Univ Prague, Fac Med 2, Dept Radiotherapy & Oncol, Prague, Czech Republic; [Vrana, David] Nemocnice Atlas, Dept Med, Zlin, Czech Republic","Soucek, P (reprint author), Natl Inst Publ Hlth, Toxicogenom Unit, Srobarova 48, Prague 10042 10, Czech Republic.","psoucek@szu.cz",null,null,"Internal Grant Agency of the Czech Ministry of Health [9799-4]; Faculty Hospital Motol [MZO FNM 2005/6704]; Grant Agency of Charles University [94507]","Grant sponsor: Internal Grant Agency of the Czech Ministry of Health; Grant number: 9799-4; Grant sponsor: Faculty Hospital Motol; Grant number: MZO FNM 2005/6704; Grant sponsor: Grant Agency of Charles University; Grant number: 94507",null,40,12,12,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0020-7136",null,null,"INT J CANCER","Int. J. Cancer","JAN 15",2012,130,2,null,null,null,null,338,348,null,"10.1002/ijc.26006",null,11,"Oncology","Oncology","864QI","WOS:000298254400011"]
[null,null,null,null,"J","Provaznikova, D; Rittich, S; Malina, M; Seeman, T; Marinov, I; Riedl, M; Hrachovinova, I",null,null,null,"Provaznikova, Dana; Rittich, Simon; Malina, Michal; Seeman, Tomas; Marinov, Iuri; Riedl, Magdalena; Hrachovinova, Ingrid",null,null,"Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Thrombotic microangiopathy; Thrombocytopenia; aHUS; Membrane cofactor protein (MCP CD46); Kidney disease","MEMBRANE COFACTOR PROTEIN; FACTOR-H-AUTOANTIBODIES; SYNDROME AHUS; CD46; DISEASE; CLUSTER; IMPACT; HUS","Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Mutations in genes encoding regulators of the alternative complement pathway (CFH, MCP, C3, CFI, CFB, THBD, and CFHR1-5) are connected with this disease. Polymorphisms (SNPs) in these genes might also influence the manifestation of aHUS. We have analyzed the genes of CFH, CFI, MCP, and C3 in a cohort of 10 unrelated Czech patients with clinically diagnosed familial aHUS. Surprisingly, 4 patients had mutations only in MCP, without mutations in any of the other genes that cause aHUS. Mutations, as yet unpublished, were widely distributed over the gene (SCR2 domain, signal peptide, and cytoplasmic region). The phenotype of the patients and their close relatives (14 individuals) was also investigated. Functional examination of MCP was also provided and proved lower expression on granulocytes in all mutations. Severity of disease varied, but onset was never earlier than 5 years of age. Penetrance of disease was 50% among carriers. We found that the severity and recurrence of the disease within families varied and might also be dependent on SNPs. Mutations in the MCP gene seems to be a common etiology of aHUS in Czech patients.","[Provaznikova, Dana; Rittich, Simon; Hrachovinova, Ingrid] Inst Hematol & Blood Transfus, Coagulat Lab, CR-12820 Prague 2, Czech Republic; [Malina, Michal; Seeman, Tomas] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Malina, Michal; Seeman, Tomas] Charles Univ Prague, Prague, Czech Republic; [Marinov, Iuri] Inst Hematol & Blood Transfus, Flow Cytometry Lab, CR-12820 Prague 2, Czech Republic; [Riedl, Magdalena] Med Univ Innsbruck, Dept Pediat, Innsbruck, Austria","Provaznikova, D (reprint author), Inst Hematol & Blood Transfus, Coagulat Lab, CR-12820 Prague 2, Czech Republic.","D.provaz@centrum.cz","kavukcu, salih/B-3417-2012",null,"IGA of Ministry of Health CR [NR/9258-3, NT11457-5]","We thank the following clinicians for their help in collecting samples: Eva Jancova, Vladimir Senigl, Sona Stepankova. This work was supported by grants from the IGA of Ministry of Health CR (NR/9258-3, NT11457-5).",null,27,2,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","JAN",2012,27,1,null,null,null,null,73,81,null,"10.1007/s00467-011-1943-5",null,9,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","855EG","WOS:000297546000011"]
[null,null,null,null,"J","Buggiani, G; Tsampau, D; Krysenka, A; De Giorgi, V; Hercogova, J",null,null,null,"Buggiani, Gionata; Tsampau, Dionigi; Krysenka, Alena; De Giorgi, Vincenzo; Hercogova, Jana",null,null,"Fractional CO2 laser: a novel therapeutic device for refractory necrobiosis lipoidica","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"CO2 laser; necrobiosis lipoidica; fractional",null,"Necrobiosis lipoidica diabeticorum is a granulomatous skin disease of uncertain pathogenesis. Many therapeutic approaches have been reported in the literature, but none of them can be considered the gold standard. Fractional CO2 laser treatment shows peculiar effects in the skin, mainly due to its ability of modulating cytokine pathways of tissue-repairing mechanisms. Thus, we propose fractional CO2 laser in the management of refractory necrobiosis lipoidica in selected recalcitrant patients.","[Tsampau, Dionigi; De Giorgi, Vincenzo] Azienda Sanit Firenze, Florence, Italy; [Krysenka, Alena; De Giorgi, Vincenzo] Univ Florence, Sch Med, Florence, Italy; [Hercogova, Jana] Charles Univ Prague, Dept Dermatol, Fac Med 2, Prague, Czech Republic","Buggiani, G (reprint author), Via Leonardo da Vinci 66, I-50053 Florence, Italy.","g.buggiani@gmail.com",null,null,null,null,null,5,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","NOV-DEC",2012,25,6,null,null,null,null,612,614,null,"10.1111/j.1529-8019.2012.01531.x",null,3,"Dermatology","Dermatology","049IM","WOS:000311976000014"]
[null,null,null,null,"J","de Beaufort, C; Vazeou, A; Sumnik, Z; Cinek, O; Hanas, R; Danne, T; Aschemeier, B; Forsander, G",null,null,null,"de Beaufort, Carine; Vazeou, Andreani; Sumnik, Zdenek; Cinek, Ondrej; Hanas, Ragnar; Danne, Thomas; Aschemeier, Baerbel; Forsander, Gun",null,"SWEET Grp","Harmonize care to optimize outcome in children and adolescents with diabetes mellitus: treatment recommendations in Europe","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"children diabetes; ISPAD Clinical Practice Consensus Guidelines; SWEET","GUIDELINES; SERVICES; UK","Objective Identify and evaluate current treatment recommendations in Europe for the care of children with diabetes in view of the European Union (EU) recommendations for Reference Centers. Methods A questionnaire was sent in 2008 to representatives of all EU countries and Norway, all known to be actively involved in pediatric diabetes care. Participants were asked whether specific guidelines were recommended and applied in their countries; when possible, they were invited to forward their national guidelines. As a second step, we evaluated the guideline mostly used in relationship to the recommendations of the EU. Results Information was obtained from all EU countries (including Scotland and Norway). National guidelines, as available, were forwarded for review. A 15/29 reported to use the International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines (CPCG), whereas 10 reported using national guidelines. These national guidelines were partly based on and/or compatible with ISPAD guidelines, but in most cases were far less detailed. The size and presentation differed (web based, booklet, page or chapter in adult guidelines). In four countries, no specific guidelines were used. As ISPAD CPCG were used most frequently, its content was evaluated within the EU Centres of Reference recommendations and minor changes were made in agreement with the ISPAD editor. Discussion Differences between guidelines may influence surveillance and quality of care in pediatric diabetes within Europe. Although a majority of countries is using or at least mentioning the ISPAD CPCG, their implementation as EU standard needs further endorsement. As language difficulties may hamper its implementation on a wider scale, further translation of the ISPAD guidelines should be endorsed to render it accessible to all healthcare professionals. With respect to the content, some changes were then made in agreement with the editors, adjusting them to the European context. For European Reference Centers, some further guidance on research may be included. Once implemented on an EU wide level, benchmarking of carefully defined robust quality of care and quality of life indicators will allow us to improve these guidelines on a regular basis ensuring an evidence-based care for all children with diabetes.","[de Beaufort, Carine] CHL Luxembourg, DECCP, L-1210 Luxembourg, Luxembourg; [Vazeou, Andreani] PA Kyriakou Childrens Hosp, Dept Pediat, Athens, Greece; [Vazeou, Andreani] PA Kyriakou Childrens Hosp, Ctr Diabet, Athens, Greece; [Sumnik, Zdenek; Cinek, Ondrej] Univ Hosp Motol, Prague, Czech Republic; [Hanas, Ragnar] Uddevalla Cent Hosp, Dept Pediat, Uddevalla, Sweden; [Danne, Thomas; Aschemeier, Baerbel] Kinder & Jugendkrankenhaus AUF DER BULT, Diabet Ctr Children & Adolescents, Hannover, Germany; [Forsander, Gun] Sahlgrens Univ Hosp, Queen Silvia Childrens Hosp, Gothenburg, Sweden","de Beaufort, C (reprint author), CHL Luxembourg, DECCP, 4 Rue E Barble, L-1210 Luxembourg, Luxembourg.","Debeaufort.Carine@chl.lu",null,null,"EU [2007104]","The Sweet consortium is acknowledged. This report has been prepared within the SWEET project, financially supported by the EU project 2007104.",null,13,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1399-543X","1399-5448",null,"PEDIATR DIABETES","Pediatr. Diabetes","SEP",2012,13,null,null,16,"SI",null,15,19,null,"10.1111/j.1399-5448.2012.00908.x",null,5,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","996OO","WOS:000308100400003"]
[null,null,null,null,"J","Lotti, T; Bruscino, N; Hercogova, J; de Giorgi, V",null,null,null,"Lotti, Torello; Bruscino, Nicola; Hercogova, Jana; de Giorgi, Vincenzo",null,null,"Controversial issues on melanoma","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"melanoma; sentinel lymph node biopsy; sun exposure; UV ray (UVR)","SENTINEL NODE BIOPSY; EARLY-STAGE MELANOMA; CUTANEOUS MELANOMA; LYMPH-NODES; MITOTIC RATE; SELECTIVE LYMPHADENECTOMY; SKIN-CANCER; EXPOSURE; UV; EXPERIENCE","In this chapter, we try to debate two of the most several controversial points about melanoma: the role of the ultraviolet (UV) ray exposure and the position of the sentinel node biopsy in the dermatological daily activity. It has been demonstrated as a direct relationship between UV exposure and the risk of developing melanoma, but it is also true that a chronic continuous UV ray exposure can develop a protective action. Nodal evaluation is one of the most important prognostic indicators to be considered for the patient outcome. The aims for which sentinel node biopsy is so often adopted can be summarized in three points: a detailed nodal staging, a regional disease control, and a possible overall improved survival. At present, many authors do not think that it let the overall survival grow; therefore, they suggest its use only to stage regional lymph nodes and accurately identify patients who could benefit through an early complete regional lymphadenectomy.","[Lotti, Torello; Bruscino, Nicola; de Giorgi, Vincenzo] Univ Rome G Marconi, Div Dermatol, I-00193 Rome, Italy; [Hercogova, Jana] Charles Univ Prague, Bulovka Univ Hosp, Dept Dermatol, Fac Med 2, Prague, Czech Republic","Lotti, T (reprint author), Univ Rome G Marconi, Div Dermatol, Via Vittoria Colonna 11, I-00193 Rome, Italy.","professor@torellolotti.it",null,null,null,null,null,32,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","SEP-OCT",2012,25,5,null,null,"SI",null,458,462,null,"10.1111/j.1529-8019.2012.01524.x",null,5,"Dermatology","Dermatology","017QK","WOS:000309605300010"]
[null,null,null,null,"J","Maresova, KB; Franek, T; Vondracek, T; Stepan, JJ",null,null,null,"Maresova, Kristyna Brabnikova; Franek, Tomas; Vondracek, Tomas; Stepan, Jan J.",null,null,"A comparison of the acute effects of calcium and strontium ranelate on the serum marker of bone resorption","CLINICAL CHEMISTRY AND LABORATORY MEDICINE",null,null,"English","Article",null,null,null,null,null,"bone markers; calcium; collagen type I; strontium ranelate","SENSING RECEPTOR; I COLLAGEN; OSTEOPOROSIS; TELOPEPTIDES; OSTEOCLASTS; CROSSLAPS; WOMEN","Background: To investigate the mechanism by which strontium ranelate (SrR) inhibits the bone resorption, this study compared the effects of SrR and calcium on parathyroid hormone (PTH) and the biochemical marker of bone resorption (serum type I collagen cross-linked C-telopepticle, beta CTX). Methods: In 10 healthy young subjects, after overnight fasting, 1000 mg of elemental calcium and 2000 mg of SrR containing 600 mg Sr2+ were administered consecutively with a 1 week washout period. During the control period no drug was given. Fasting blood samples were drawn at baseline and throughout the next 5-h period. Results: After the ingestion of either calcium or SrR, there was a significant increase in serum calcium and strontium concentrations, and a decrease in serum beta CTX and intact PTH concentrations as compared to the baseline values (p<0.05). In the fasting subjects, no significant differences in the variable were found as compared to the baseline values. Conclusions: The decrease in PTH and the marker of bone resorption observed after the SrR administration is comparable to the decrease observed after the calcium administration in young adults.","[Maresova, Kristyna Brabnikova; Vondracek, Tomas; Stepan, Jan J.] Charles Univ Prague, Inst Rheumatol, Fac Med 1, Prague, Czech Republic; [Franek, Tomas] Charles Univ Prague, Univ Hosp Motol, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague, Czech Republic","Maresova, KB (reprint author), Charles Univ Prague, Inst Rheumatol, Fac Med 1, Prague, Czech Republic.","maresova.kristyna@seznam.cz","Stepan, Jan /A-7280-2013","Stepan, Jan /0000-0003-1541-8306","MZd CR [000 237280]","The study was fully supported by the grant MZd CR 000 237280.",null,15,1,1,"WALTER DE GRUYTER GMBH","BERLIN","GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY","1434-6621",null,null,"CLIN CHEM LAB MED","Clin. Chem. Lab. Med.",null,2012,50,2,null,null,null,null,333,335,null,"10.1515/CCLM.2011.781",null,3,"Medical Laboratory Technology","Medical Laboratory Technology","914ZB","WOS:000301991300018"]
[null,null,null,null,"J","Borowiec, M; Fendler, W; Dusatkova, P; Antosik, K; Pruhova, S; Cinek, O; Mysliwiec, M; Jarosz-Chobot, P; Malecki, MT; Mlynarski, W",null,null,null,"Borowiec, M.; Fendler, W.; Dusatkova, P.; Antosik, K.; Pruhova, S.; Cinek, O.; Mysliwiec, M.; Jarosz-Chobot, P.; Malecki, M. T.; Mlynarski, W.",null,null,"HbA1c-based diabetes diagnosis among patients with glucokinase mutation (GCK-MODY) is affected by a genetic variant of glucose-6-phosphatase (G6PC2)","DIABETIC MEDICINE",null,null,"English","Article",null,null,null,null,null,null,null,"Aims Genetic variation at the rs560887 locus of the glucose-6-phosphatase, catalytic 2 gene (G6PC2) is known to affect regulation of fasting glycaemia. We determined the rs560887 genotype of patients with monogenic diabetes and glucokinase gene mutations (GCK-MODY) and correlated the genotypes with HbA1c levels. Methods Patients from families with GCK-MODY were recruited from two large cohorts from Poland (n = 128) and the Czech Republic (n = 154). Genotypes at the rs560887 polymorphic site in G6PC2 were examined using real-time quantitative polymerase chain reaction. The effect of rs560887 genotype on age at diagnosis of GCK-MODY and initial HbA1c levels were evaluated separately within both cohorts. Following that, a meta-analysis of rs560887 genotypeHbA1c associations of both Polish and Czech cohorts was performed to confirm homogeneity of findings and validate cohort-specific results. Results GG homozygosity at rs560887 was associated with marginally elevated HbA1c levels (P = 0.07 in both cohorts). The effects observed in both groups were very homogeneous (Q = 0.18; P = 0.68). Meta-analysis showed that GG homozygosity at rs560887 was associated with mean HbA1c levels higher by 2.4 mmol/mol (0.24%), 95% CI 0.54.4 mmol/mol (0.050.44%) than in individuals with other genotypes. Additionally, meta-analysis of both cohorts showed that GG homozygous individuals had higher odds of reaching the 48 mmol/mol (6.5%) diagnostic threshold of diabetes; (odds ratio 1.90; 95% CI 1.073.36; P = 0.03). No such effects were observed for age at diagnosis of diabetes. Conclusions Variation at the rs560887 locus of G6PC2 is associated with worse glycated haemoglobin levels in individuals with GCK mutations; GG homozygotes are more likely to meet diagnostic criteria for diabetes based on HbA1c level.","[Borowiec, M.; Fendler, W.; Antosik, K.; Mlynarski, W.] Med Univ Lodz, Dept Paediat Oncol Haematol & Diabetol, Lodz, Poland; [Dusatkova, P.; Pruhova, S.; Cinek, O.] Charles Univ Prague, Dept Paediat, Univ Hosp Motol, Fac Med 2, Prague, Czech Republic; [Mysliwiec, M.] Med Univ Gdansk, Dept Paediat Oncol Haematol & Endocrinol, Gdansk, Poland; [Jarosz-Chobot, P.] Silesian Med Univ Katowice, Dept Paediat Endocrinol & Diabet, Katowice, Poland; [Malecki, M. T.] Jagiellonian Univ Cracow, Coll Med, Dept Metab Dis, Krakow, Poland","Mlynarski, W (reprint author), Med Univ Lodz, Dept Paediat Oncol Haematol & Diabetol, Lodz, Poland.","wojciech.mlynarski@umed.lodz.pl",null,null,"Innovative Economy Operational Programme-Activity 1.2; Ministry of Science and Higher Education [N402 478137, N407 022535, IP2010 008870]; Czech Ministry of Health [NT11402]; European Union Framework Programme 7","The project was funded by the Innovative Economy Operational Programme-Activity 1.2 (the TEAM Programme coordinated by the Foundation for Polish Science); Ministry of Science and Higher Education-grant numbers: N402 478137, N407 022535 and IP2010 008870. Recruitment of the Czech patients was supported by an institutional grant from the Czech Ministry of Health (NT11402). MTM has received financial support from the European Union Framework Programme 7 CEED3 grant.",null,10,0,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0742-3071",null,null,"DIABETIC MED","Diabetic Med.","NOV",2012,29,11,null,null,null,null,1465,1469,null,"10.1111/j.1464-5491.2012.03671.x",null,5,"Endocrinology & Metabolism","Endocrinology & Metabolism","017QE","WOS:000309604600023"]
[null,null,null,null,"J","Pietrzak, A; Bartosinska, J; Hercogova, J; Lotti, TM; Chodorowska, G",null,null,null,"Pietrzak, Aldona; Bartosinska, Joanna; Hercogova, Jana; Lotti, Torello M.; Chodorowska, Grazyna",null,null,"Metabolic syndrome in vitiligo","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"metabolic abnormalities; oxidative stress; vitiligo","ADIPOSE-TISSUE; HOMOCYSTEINE; INFLAMMATION; MELANIN","Vitiligo is an acquired, depigmenting skin disease with still unclear, multifactorial etiopathogenesis. However, there is growing evidence that vitiligo affects not only the skin but it may also be connected with metabolic abnormalities, including glucose intolerance and lipid abnormalities, all of which confirms the systemic nature of the disease. Recently, it has been shown that melanocytes, especially those found in the adipose tissue, due to their ability to decrease inflammation and oxidative damage, are capable of preventing the metabolic syndrome. The article presents updated knowledge on potential metabolic disturbances in vitiligo.","[Pietrzak, Aldona; Bartosinska, Joanna; Chodorowska, Grazyna] Med Univ, Dept Dermatol Venereol & Paediat Dermatol, PL-20080 Lublin, Poland; [Hercogova, Jana] Charles Univ Prague, Bulovka Univ Hosp, Fac Med 2, Dept Dermatol, Prague, Czech Republic; [Lotti, Torello M.] Univ Rome G Marconi, Rome, Italy","Pietrzak, A (reprint author), Med Univ, Dept Dermatol Venereol & Paediat Dermatol, 13 Radziwillowska St, PL-20080 Lublin, Poland.","aldonkapietrzak@o2.pl",null,null,null,null,null,15,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","NOV-DEC",2012,25,null,null,1,"SI",null,"S41","S43",null,"10.1111/dth.12012",null,3,"Dermatology","Dermatology","053VW","WOS:000312304200006"]
[null,null,null,null,"J","Valle, Y; Lotti, TM; Hercogova, J; Schwartz, RA; Korobko, IV",null,null,null,"Valle, Yan; Lotti, Torello M.; Hercogova, Jana; Schwartz, Robert A.; Korobko, Igor V.",null,null,"Multidisciplinary approach to R&D in vitiligo, a neglected skin disease","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"biobanking; bioinformatics; biopharma; economics; neglected; orphan; therapy; vitiligo","WIDE ASSOCIATION; DRUG DISCOVERY; GENETICS","A global interest in therapies for neglected diseases is rising, but traditional biopharma research and development (R&D) process is prohibitively expensive to justify cost of their development. Vitiligo is a multifactorial orphan disease that affects at minimum 35 million people worldwide, yet no therapeutic solutions exist. The present authors describe a budget-minded pursuit of the new therapy development for vitiligo, which includes a multidiscipline collaboration and effective bridging between academic research, biobanking, and bioinformatics. The present authors anticipate that the present authors' theoretically induced and empirically guided discovery process will enable development of more leads, with a much greater probability of success and under tighter budgets compared with those of the biopharma company. Ultimately, the multidisciplinary approach described below facilitates the collaborative development of personalized treatments for different patient subpopulations in vitiligo and other neglected diseases.","[Valle, Yan; Lotti, Torello M.; Korobko, Igor V.] VR Fdn, New York, NY 10119 USA; [Schwartz, Robert A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Dermatol & Pathol, Newark, NJ 07103 USA; [Lotti, Torello M.] Univ Rome G Marconi, Rome, Italy; [Hercogova, Jana] Charles Univ Prague, Sch Med 2, Dept Dermatol & Venereol, Prague, Czech Republic; [Korobko, Igor V.] Russian Acad Sci, Inst Gene Biol, Moscow, Russia","Valle, Y (reprint author), VR Fdn, 1 Penn Plaza,6205, New York, NY 10119 USA.","yan@vrfoundation.org",null,null,"VR Foundation (NY, USA)","This work was supported by the VR Foundation (NY, USA). The authors specially thank Philippe Delesalle, the CEO of Carbonfay LLC, for helping with bio-IT algorithm development and programming work.",null,35,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296","1529-8019",null,"DERMATOL THER","Dermatol. Ther.","NOV-DEC",2012,25,null,null,1,"SI",null,"S1","S9",null,"10.1111/dth.12009",null,9,"Dermatology","Dermatology","053VW","WOS:000312304200001"]
[null,null,null,null,"J","Tsampau, D; Buggiani, G; Hercogova, J; Lotti, T",null,null,null,"Tsampau, Dionigi; Buggiani, Gionata; Hercogova, Jana; Lotti, Torello",null,null,"Cutaneous necrotizing vasculitis: a rational therapeutic approach","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"dermatologic therapy; necrotizing vasculitis; palpable purpura","HYPOCOMPLEMENTEMIC URTICARIAL-VASCULITIS; LEUKOCYTOCLASTIC VASCULITIS; RHEUMATOID-ARTHRITIS; POLYARTERITIS-NODOSA; INFLIXIMAB; DAPSONE; AZATHIOPRINE; PATHOGENESIS; ETANERCEPT; COLCHICINE","Cutaneous necrotizing vasculitis is a heterogeneous group of disorders characterized clinically by palpable purpura, and histologically by a segmental angiocentric inflammatory condition with fibrinoid necrosis of the vessel wall, endothelial swelling, and nuclear dust of the post capillary venules. Often, the skin seems the only organ apparently damaged, but systemic involvement may occur. In up to 60% of cases of cutaneous necrotizing vasculitis, the cause remains unknown; in others, it may be due to a variety of underlying conditions such as drugs, chemicals, food allergens, infections, chronic inflammatory systemic disorders, or malignant neoplasms. A rational therapeutic approach of vasculitis begins with the identification and stoppage of any suspected underlying condition. This may be all that is required for the treatment, because it is usually followed by the clearing of cutaneous lesions, and systemic signs and symptoms. In other cases, local and/or systemic anti-inflammatory and/or immunosuppressive therapy is recommended.","[Lotti, Torello] Univ Rome G Marconi, Chairman Dept Res Sci Life, Rome, Italy; [Tsampau, Dionigi; Buggiani, Gionata] Univ Florence, Sch Med, Univ Unit Dermatol, Florence, Italy; [Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatol, Prague, Czech Republic","Lotti, T (reprint author), Univ Rome G Marconi, Chairman Dept Res Sci Life, Via Vittoria Colonna 1100193, Rome, Italy.","professor@torellolotti.it",null,null,null,null,null,44,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","JUL-AUG",2012,25,4,null,null,"SI",null,335,339,null,"10.1111/j.1529-8019.2012.01480.x",null,5,"Dermatology","Dermatology","000SD","WOS:000308407500006"]
[null,null,null,null,"J","Papadopoulos, NG; Arakawa, H; Carlsen, KH; Custovic, A; Gern, J; Lemanske, R; Le Souef, P; Makela, M; Roberts, G; Wong, G; Zar, H; Akdis, CA; Bacharier, LB; Baraldi, E; van Bever, HP; de Blic, J; Boner, A; Burks, W; Casale, TB; Castro-Rodriguez, JA; Chen, YZ; El-Gamal, YM; Everard, ML; Frischer, T; Geller, M; Gereda, J; Goh, DY; Guilbert, TW; Hedlin, G; Heymann, PW; Hong, SJ; Hossny, EM; Huang, JL; Jackson, DJ; de Jongste, JC; Kalayci, O; Ait-Khaled, N; Kling, S; Kuna, P; Lau, S; Ledford, DK; Lee, SI; Liu, AH; Lockey, RF; Lodrup-Carlsen, K; Lotvall, J; Morikawa, A; Nieto, A; Paramesh, H; Pawankar, R; Pohunek, P; Pongracic, J; Price, D; Robertson, C; Rosario, N; Rossenwasser, LJ; Sly, PD; Stein, R; Stick, S; Szefler, S; Taussig, LM; Valovirta, E; Vichyanond, P; Wallace, D; Weinberg, E; Wennergren, G; Wildhaber, J; Zeiger, RS",null,null,null,"Papadopoulos, N. G.; Arakawa, H.; Carlsen, K. -H.; Custovic, A.; Gern, J.; Lemanske, R.; Le Souef, P.; Makela, M.; Roberts, G.; Wong, G.; Zar, H.; Akdis, C. A.; Bacharier, L. B.; Baraldi, E.; van Bever, H. P.; de Blic, J.; Boner, A.; Burks, W.; Casale, T. B.; Castro-Rodriguez, J. A.; Chen, Y. Z.; El-Gamal, Y. M.; Everard, M. L.; Frischer, T.; Geller, M.; Gereda, J.; Goh, D. Y.; Guilbert, T. W.; Hedlin, G.; Heymann, P. W.; Hong, S. J.; Hossny, E. M.; Huang, J. L.; Jackson, D. J.; de Jongste, J. C.; Kalayci, O.; Ait-Khaled, N.; Kling, S.; Kuna, P.; Lau, S.; Ledford, D. K.; Lee, S. I.; Liu, A. H.; Lockey, R. F.; Lodrup-Carlsen, K.; Lotvall, J.; Morikawa, A.; Nieto, A.; Paramesh, H.; Pawankar, R.; Pohunek, P.; Pongracic, J.; Price, D.; Robertson, C.; Rosario, N.; Rossenwasser, L. J.; Sly, P. D.; Stein, R.; Stick, S.; Szefler, S.; Taussig, L. M.; Valovirta, E.; Vichyanond, P.; Wallace, D.; Weinberg, E.; Wennergren, G.; Wildhaber, J.; Zeiger, R. S.",null,null,"International consensus on (ICON) pediatric asthma","ALLERGY",null,null,"English","Review",null,null,null,null,null,"asthma; children; consensus; guidelines; wheeze","INHALED FLUTICASONE PROPIONATE; RANDOMIZED CONTROLLED-TRIAL; GRASS-POLLEN IMMUNOTHERAPY; NITRIC-OXIDE MEASUREMENTS; ACTING BETA-AGONISTS; HOUSE-DUST MITE; LONG-TERM; CHILDHOOD ASTHMA; AIRWAY HYPERRESPONSIVENESS; PRESCHOOL-CHILDREN","Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has decided to propose an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference. The principles of pediatric asthma management are generally accepted. Overall, the treatment goal is disease control. To achieve this, patients and their parents should be educated to optimally manage the disease, in collaboration with healthcare professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re-evaluate and fine-tune treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype-specific treatment choices; however, this goal has not yet been achieved.","[Papadopoulos, N. G.] Univ Athens, Dept Allergy, Pediat Clin 2, Athens 11527, Greece; [Arakawa, H.] Gunma Univ, Grad Sch Med, Dept Pediat, Gunma, Japan; [Carlsen, K. -H.] Oslo Univ Hosp, Dept Pediat, Oslo, Norway; [Custovic, A.] Univ Hosp S Manchester NHS Fdn Trust, Resp Res Grp, Manchester, Lancs, England; [Gern, J.] Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI USA; [Lemanske, R.] Univ Wisconsin, Sch Med & Publ Hlth, Div Pediat Allergy Immunol & Rheumatol, Madison, WI USA; [Le Souef, P.] Univ Western Australia, Princess Margaret Hosp, Sch Pediat & Child Hlth, Perth, WA 6009, Australia; [Makela, M.] Univ Helsinki, Cent Hosp, Pediat Unit, Helsinki, Finland; [Roberts, G.] Southampton Univ Hosp NHS Trust, Acad Unit Human Dev & Hlth, Southampton, Hants, England; [Wong, G.] Chinese Univ Hong Kong, Dept Pediat, Sha Tin, Hong Kong, Peoples R China; [Zar, H.] Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Pediat & Child Hlth, ZA-7925 Cape Town, South Africa; [Akdis, C. A.] Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Bacharier, L. B.] Washington Univ, Sch Med, Dept Pediat, Div Pediat Allergy Immunol & Pulm Med, St Louis, MO 63110 USA; [Baraldi, E.] Univ Padua, Dept Pediat, Unit Allergy & Resp Med, Padua, Italy; [Bacharier, L. B.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [van Bever, H. P.] Natl Univ Hlth Syst, Natl Univ Hosp, Childrens Med Inst, Dept Paediat, Singapore, Singapore; [de Blic, J.] Univ Paris 05, AP HP, Serv Pneumol & Allergol Pediat, Paris, France; [Boner, A.] Univ Verona, Dept Paediat, I-37100 Verona, Italy; [Burks, W.] Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA; [Casale, T. B.] Creighton Univ, Div Allergy & Immunol, Dept Med, Omaha, NE 68178 USA; [Castro-Rodriguez, J. A.] Pontificia Univ Catolica Chile, Sch Med, Santiago, Chile; [El-Gamal, Y. M.] Ain Shams Univ, Pediat Allergy & Immunol Unit, Cairo, Egypt; [Chen, Y. Z.] Capital Inst Pediat, Beijing, Peoples R China; [Everard, M. L.] Sheffield Childrens Hosp, Dept Resp Med, Sheffield, S Yorkshire, England; [Geller, M.] Geller Allergy & Immunol Clin, Rio De Janeiro, Brazil; [Frischer, T.] Univ Childrens Hosp Vienna, Vienna, Austria; [Gereda, J.] Clin Ricardo Palma, Dept Allergy & Immunol, Lima, Peru; [Goh, D. Y.] Natl Univ Singapore Hosp, Dept Paediat, Singapore 117548, Singapore; [Hedlin, G.] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Heymann, P. W.] Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Hong, S. J.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pediat,Childhood Asthma Atopy Ctr, Seoul, South Korea; [Hossny, E. M.] Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, Cairo, Egypt; [Huang, J. L.] Chang Gung Childrens Hosp, Dept Pediat, Div Allergy Asthma & Rheumatol, Tao Yuan, Taiwan; [Jackson, D. J.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [de Jongste, J. C.] Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Dept Pediat, Rotterdam, Netherlands; [Kalayci, O.] Hacettepe Univ, Sch Med, Ihsan Dogramaci Childrens Hosp, Pediat Allergy & Asthma Unit, Ankara, Turkey; [Ait-Khaled, N.] Int Union TB & Lung Dis, Algiers, Algeria; [Kling, S.] Univ Stellenbosch, Tygerberg Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa; [Kuna, P.] Med Univ Lodz, Barlicki Univ Hosp, Dept Med 2, Lodz, Poland; [Lau, S.] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Ledford, D. K.; Lockey, R. F.] Univ S Florida, Div Allergy Immunol, Tampa, FL USA; [Lee, S. I.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat,Environm Hlth Ctr, Seoul, South Korea; [Liu, A. H.] Univ Colorado Denver, Sch Med, Denver, CO USA; [Szefler, S.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Lodrup-Carlsen, K.] Ullevaal Univ Hosp, Dept Paediat, Woman & Child Div, Oslo, Norway; [Morikawa, A.] Gunma Univ, Kita Kanto Allergy Inst, Gunma, Japan; [Lotvall, J.] Univ Gothenburg, Krefting Res Ctr, Gothenburg, Sweden; [Nieto, A.] Childrens Hosp La Fe, Pediat Allergy Unit, Valencia, Spain; [Paramesh, H.] Lakeside Med Ctr & Hosp, Bangalore, Karnataka, India; [Pawankar, R.] Nippon Med Sch, Dept Pediat, Div Allergy & Immunol, Tokyo 113, Japan; [Pohunek, P.] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Prague, Czech Republic; [Pongracic, J.] Childrens Mem Hosp, Div Allergy & Immunol, Chicago, IL 60614 USA; [Price, D.] Univ Aberdeen, Primary Care Resp Soc UK, Aberdeen, Scotland; [Robertson, C.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Rosario, N.] Hosp Clin UFPR, Div Pediat Allergy, Curitiba, Parana, Brazil; [Rossenwasser, L. J.] Childrens Mercy Hosp, Kansas City, MO 64108 USA; [Sly, P. D.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Stein, R.] Pontificia Univ Catolica RGS, Hosp Sao Lucas, Pediat Pulm Serv, Porto Alegre, RS, Brazil; [Stick, S.] Princess Margaret Hosp Children, Dept Resp Med, Perth, WA, Australia; [Taussig, L. M.] Univ Denver, Off Provost, Denver, CO USA; [Valovirta, E.] Univ Turku, Allergy Clin, Terveystalo Turku, Turku, Finland; [Vichyanond, P.] Siriraj Hosp, Fac Med, Int Affairs & Ctr Excellence, Bangkok, Thailand; [Weinberg, E.] Univ Cape Town, Red Cross Childrens Hosp, Allergy Unit, ZA-7925 Cape Town, South Africa; [Wallace, D.] Nova SE Univ, Ft Lauderdale, FL 33314 USA; [Wennergren, G.] Univ Gothenburg, Dept Pediat, Gothenburg, Sweden; [Wildhaber, J.] Univ Childrens Hosp, Dept Resp Med, Zurich, Switzerland; [Zeiger, R. S.] Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA","Papadopoulos, NG (reprint author), Univ Athens, Dept Allergy, Pediat Clin 2, 41 Fidippidou St, Athens 11527, Greece.","ngp@allergy.gr","Sly, Peter/F-1486-2010; Custovic, Adnan/A-2435-2012; Casale, Thomas/K-4334-2013","Sly, Peter/0000-0001-6305-2201; ","Nestle; MSD; Deviblis (EBT); MRC Moulton Charitable Foundation; Merck Inc; Astra Zeneca; GlaxoSmithKline; AstraZeneca; Novartis Research; PREDICTA: European Commission [260895]; Swiss National Science Foundation Research; MeDALL: European Commission [261357]; Christine Kuhne-Center for Allergy Research and Education Research; Food Allergy and Anaphylaxis Network; Food Allergy Initiative; NIH; National Peanut Board; SHS; Wallace Research Foundation; Altus Pharmaceuticals; Inspire Pharmaceuticals; National Institutes of Health; NIH [U01]; AAAAI/GlaxoSmithKline; Pharmaxis; Grupo Uriach Pharma; Turkish National Science Foundation; Hacettepe University; GSK; Adamed; SymbioPharm; Airsonett; Forest Pharmaceuticals; Viro Pharma; Novartis; ALA, Pharmaceuticals; National and regional grants for research in our group; Novartis Pharma; MEDA Pharma; CBF LETI; Allergopharma; Inmunotek; UK National Health Service; Aerocrine; Boehringer Ingelheim; Merck; Mundipharma; Nycomed; Pfizer; Teva; Ross; Abbott; Merck Sharp Dohme; Genentech; MedImmune; Thermofisher","N. G. Papadopoulos has received payment for consultancy from Abbott and for lectures from MSD, and grants from Nestle, MSD, Deviblis (EBT). K.-H. Carlsen has served on an international consultatory paediatric board for GSK, and given presentations for GSK, MSD, PolarMed and Schering Plough. A. Custovic has received payment for consultancy and lectures from Novartis and for lectures from Glaxo-SmithKline, Thermo Fisher Scientific, Airsonet, MSD, and grants from MRC Moulton Charitable Foundation. J. Gern has received payment for board membership from 3V Bio-Sciences, for consultancy form GlaxoSmithKline, Biota, Centocor, Boehringer Ingelheim, MedImmune, Gilead, Theraclone, Synairgen, Pulmatrix, and grants from Merck Inc, Astra Zeneca, GlaxoSmithKline. R. Lemanske has received payment for consultancy from Merck, Sepracor, SA Boney and Associates Ltd, GlaxoSmithKline, American Institute of Research, Genentech, Inc., Double Helix Development, Inc., for lectures from Michigan Public Health Institute, Allegheny General Hospital, American Academy of Pediatrics, West Allegheny Health Systems, Inc., California Chapter 4, AAP, Colorado Allergy Society, Pennsylvania Allergy and Asthma Association, Harvard Pilgrim Health, California Society of Allergy, NYC Allergy Society, World Allergy Organization, American College of Chest Physicians, AAAAI, for Employment from University of Wisconsin School of Medicine and Public Health, for Royalties from Elsevier, and grants from National Heart Lung and Blood Institute, Pharmaxis. P. Le Souef has received a grant from AstraZeneca. G. Roberts is a member of the steering committee for the GAP trial, paid by ALK. C. A. Akdis has received payment for consultancy from Actellion, Aventis, Stallergenes, Allergopharma, Circacia, Swiss Institute of Allergy and Asthma Research, University of Zurich, Switzerland, and grants from Novartis Research on immunoregulation in asthma, PREDICTA: European Commission's Seventh Framework programme No. 260895 Research on virus induced exacerbations, Swiss National Science Foundation Research on T cell interaction with the epithelium, MeDALL: European Commission's Seventh Framework Programme No. 261357 Research on early initiation of asthma, Christine Kuhne-Center for Allergy Research and Education Research on severe allergies. L. B. Bacharier has received payment for consultancy from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, Schering, Cephalon and for lectures from Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, Merck, Schering. J. de Blic is member of the steering committee for the GAP trial, paid by ALK. He is also a member of the advisory board on asthma in children for GSK, MSD, CHIESI, and Stallergenes. W. Burks has consulted for Dannon Co. Probiotics, Exploramed Development LLC, Intelliject, McNeil Nutritionals, Merck & Co., Novartis, Nutricia, Pfizer, Portola Pharmaceuticals and Schering-Plough; has received grants from the Food Allergy and Anaphylaxis Network, the Food Allergy Initiative, the NIH, the National Peanut Board, SHS, and the Wallace Research Foundation; and owns stock or stock options in Allertein and Mast Cell, Inc. T. B. Casale has received payment from consultancy from MedImmune. J. A. Castro-Rodriguez has received payment for development of educational presentation from AZ, GSK, MSD, Novartis. T. Frischer has worked on a national advisory board for MSD. T. W.Guilbert has received honoraria from GlaxoSmithKline, AstraZeneca, PeerPoint Medical Education Institute, Merck, and Antidote; has received research support from Altus Pharmaceuticals, Inspire Pharmaceuticals, and the National Institutes of Health; and is a member of the American Lung Association, the American Thoracic Society, and the American Academy of Pediatrics. P. W. Heymann has received payment for Employment from University of Virginia and grant from NIH/U01 grant. D. J. Jackson has received payment for consultancy from Gilead and grants from NIH, AAAAI/GlaxoSmithKline, Pharmaxis. O. Kalayci has received payment for consultancy from MERCK and received lecture fee from Grupo Uriach Pharma, and grants from Turkish National Science Foundation, Hacettepe University. S. Kling has received payment for Ethics lectures from MSD (Merck) and travel expenses from Cipla Medpro with Sponsorship to Allergy Society of South Africa (ALLSA) Congress 2010; money paid to ALLSA. P. Kuna has received payment for board membership and for lectures from AstraZeneca, Boehringer, MSD, and lecture fee from GSK, Adamed. S. Lau has received payment for consultancy from Merck, for lectures from Symbiopharm, Novartis, ALK, AstraZeneca, and grants from SymbioPharm, Airsonett. D. K. Ledford has received payment for consultancy from Genentech, for expert testimony from Shook Hardy & Bacon, and grants from Forest Pharmaceuticals, Viro Pharma. A. H. Liu has served on the speakers' bureau for Merck, Aerocrine, and Phadia; has served on the speakers' bureau and advisory board for GlaxoSmithKline and AstraZeneca; and has received a research grant from Novartis. R. F. Lockey has received payment for Board membership from the World Allergy Organization, for consultancy from Merck, ALK, for employment from the University of Florida, VA Hospital, for expert testimony from two law firms, and received grants from ALA, Pharmaceuticals. He has also received payment for lectures from Merck, AstraZeneca, royalties from Informa Publishing, for travel expenses to World Allergy Organization meetings, international congresses for presenting lectures; and owns stock or stock options in Roth IRA acct. K. Lodrup Carlsen has received payment for lectures from GlaxoSmithKline in the last year (once) and grants from National and regional grants for research in our group. J. Lotvall has consulted for Glaxo-SmithKline, Novartis, and Merck; has received grants from GlaxoSmithKline; and has received payment for lectures from AstraZeneca, Glaxo-SmithKline, Novartis, and Merck. A. Nieto has received payment for board membership, consultancy and lecture fee from Novartis Pharma, MEDA Pharma, CBF LETI, MSD, Allergopharma, and also for development of educational presentations from Schering-Plough and grants from Inmunotek. P. Pohunek has received lecture honoraria from AstraZeneca, GSK, MSD, UCB Pharma and travel support for scientific meetings by AstraZeneca, GSK, MSD and Chiesi. D. Price has consultant arrangements with Boehringer Ingelheim, GlaxoSmithKline, Merck, Mundipharma, Novartis and Teva; he or his research team have received grants and support for research in respiratory disease from the following organizations in the last 5 years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Pfizer and Teva. He has spoken for Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Pfizer and Teva, he has shares in AKL Ltd., which produces phytopharmaceuticals, and he is the sole owner of Research n Real Life Ltd. N. Rosario has received payment for board membership from Sanofi Aventis, Takeda, MSD, for consultancy from MSD, Sanofi Aventis, GSK, for lectures from MSD, Sanofi Aventis, GSK, Takeda, Ache, Danone and for development of educational presentations from MSD, Sanofi Aventis, Danone. L. J. Rosenwasser has received payment for board membership from WAO and for consultancy from Genentech, Novartis, AZ, Regeneron, Sanofi. R. Stein has received payment for lectures from Abbott. S. Szefler has received payment for consultancy from Merck, Genentech, Schering, Boehringer-Ingehlheim, Novartis, GlaxoSmithKline, for lectures from Merck, manuscript preparation from Genentech, for patents from NHLBI CARE Network, and grants from GlaxoSmithKline, Ross, Abbott. G. Wennergren has received has received fees for lectures from Novartis, Merck Sharp & Dohme, AstraZeneca and GlaxoSmithKline. J. Wildhaber has served on national and international advisory boards of Nycomed and MSD and has received research grants from AstraZeneca, GSK and MSD. R. S. Zeiger has received payment for consultancy from Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, MedImmune, ScheringPlough, Sunovion, Novartis, NHLBI/Penn State and grants from Genentech, GlaxoSmithKline, Aerocrine, Merck, MedImmune, Thermofisher. H. Arakawa, M. Makela, G. Wong, H. Zar, E. Baraldi, H. P. van Bever, A. Boner, Y. Z. Chen, Y. M. El-Gamal, M. L. Everard, M. Geller, J. Gereda, D. Y. Goh, G. Hedlin, S. J. Hong, E. M. Hossny, J. L. Huang, J. C. de Jongste, N. Ait-Khaled, S. I. Lee, A. Morikawa, H. Paramesh, R. Pawankar, J. Pongracic, C. Robertson, D. Sly, S. Stick, L. M. Taussig, E. Valovirta, P. Vichyanond, D. Wallace, E. Weinberg, have no conflicts of interest to declare.",null,142,23,33,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0105-4538",null,null,"ALLERGY","Allergy","AUG",2012,67,8,null,null,null,null,976,997,null,"10.1111/j.1398-9995.2012.02865.x",null,22,"Allergy; Immunology","Allergy; Immunology","972WR","WOS:000306312500002"]
[null,null,null,null,"J","Doring, G; Flume, P; Heijerman, H; Elborn, JS; Angyalosi, G; Assael, B; Bell, S; Bilton, D; De Boeck, K; Bush, A; Campbell, PW; Cattaneo, A; Dembowsky, K; Drevinek, P; Dubois, C; Eichler, I; Elborn, JS; Flume, PA; Foweraker, JE; Gallagher, C; Gartner, S; Geller, DE; Goldman, M; Goss, CH; Gupta, R; Heijerman, HG; Henig, N; Higgins, M; Hjelte, L; Hoiby, N; Jongejan, R; Knoch, M; Konstan, MW; Muhlebach, MS; Nieuwenhuizen, PW; Parkins, MD; Pressler, T; Quittner, AL; Ratjen, F; Ramsey, BW; Smyth, A; Thieroff-Ekerdt, R; Tullis, E; van der Ent, CK; Vazquez, C; Wainwright, CE",null,null,null,"Doering, Gerd; Flume, Patrick; Heijerman, Harry; Elborn, J. Stuart; Angyalosi, G.; Assael, B.; Bell, S.; Bilton, D.; De Boeck, K.; Bush, A.; Campbell, P. W., III; Cattaneo, A.; Dembowsky, K.; Drevinek, P.; Dubois, C.; Eichler, I.; Elborn, J. S.; Flume, P. A.; Foweraker, J. E.; Gallagher, C.; Gartner, S.; Geller, D. E.; Goldman, M.; Goss, C. H.; Gupta, R.; Heijerman, H. G.; Henig, N.; Higgins, M.; Hjelte, L.; Hoiby, N.; Jongejan, R.; Knoch, M.; Konstan, M. W.; Muhlebach, M. S.; Nieuwenhuizen, P. W.; Parkins, M. D.; Pressler, T.; Quittner, A. L.; Ratjen, F.; Ramsey, B. W.; Smyth, A.; Thieroff-Ekerdt, R.; Tullis, E.; van der Ent, C. K.; Vazquez, C.; Wainwright, C. E.",null,"Consensus Study Grp","Treatment of lung infection in patients with cystic fibrosis: Current and future strategies","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Review",null,null,null,null,null,null,"PSEUDOMONAS-AERUGINOSA INFECTION; RESISTANT STAPHYLOCOCCUS-AUREUS; INHALED AZTREONAM LYSINE; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; TOBRAMYCIN INHALATION POWDER; RANDOMIZED CONTROLLED-TRIAL; YOUNG-CHILDREN; PULMONARY-FUNCTION; DOUBLE-BLIND; STENOTROPHOMONAS-MALTOPHILIA","In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the Major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed. (C) 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Doering, Gerd] Univ Tubingen, Inst Med Microbiol & Hyg, D-72074 Tubingen, Germany; [Flume, Patrick] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Heijerman, Harry] Ziekenhuis Leyenburg, Dept Pathol, NL-2545 CH The Hague, Netherlands; [Elborn, J. Stuart] Queens Univ, Ctr Infect & Immun, Belfast BT9 7AB, Antrim, North Ireland","Doring, G (reprint author), Univ Tubingen, Inst Med Microbiol & Hyg, Wilhelmstr 31, D-72074 Tubingen, Germany.","gerd.doering@med.uni-tuebingen.de",null,null,null,null,"Aaron SD, 2005, LANCET, V366, P463, DOI 10.1016/S0140-6736(05)67060-2; Abbott J, 2011, J CYST FIBROS, V10, P82, DOI DOI 10.1016/S1569-1993(11)60013-1; Amadori A, 2009, RESP MED, V103, P407, DOI 10.1016/j.rmed.2008.09.024; Amin R, 2011, PEDIATR PULM, V46, P554, DOI 10.1002/ppul.21417; Annemans L, 2011, HLTH EC NONECONOMICS; [Anonymous], GUID ECFSPR; [Anonymous], 2009, CHMP GUID CLIN DEV M; Anstead M, J CYST FIBR IN PRESS; Assael BM, J CYST FIBR IN PRESS; Bambha K, 2004, EUR J GASTROEN HEPAT, V16, P519, DOI 10.1097/01.meg.000010834341221.46; Baumann Ulrich, 2003, J Cyst Fibros, V2, P84, DOI 10.1016/S1569-1993(03)00024-9; Bellis G, 2007, J CYST FIBROS, V6, P179, DOI 10.1016/j.jcf.2006.07.001; Bjarnsholt T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010115; Blainey PC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004458; Briesacher BA, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-5; Burns JL, 2001, J INFECT DIS, V183, P444, DOI 10.1086/318075; Canton R, 2005, CLIN MICROBIOL INFEC, V11, P690, DOI 10.1111/j.1469-0691.2005.01217.x; Chuchalin Alexander, 2007, Paediatr Drugs, V9 Suppl 1, P21, DOI 10.2165/00148581-200709001-00004; Ciofu O, 2010, MICROBIOL-SGM, V156, P1108, DOI 10.1099/mic.0.033993-0; Ciofu O, 2001, J ANTIMICROB CHEMOTH, V48, P391, DOI 10.1093/jac/48.3.391; Clancy JP, 2010, PEDIATR PULM, P299; Cox MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011044; Cystic Fibrosis Foundation, 2010, CYST FIBR FDN PAT RE; Dalboge C, 2012, J CYST FIBROS; Dasenbrook EC, 2010, JAMA-J AM MED ASSOC, V303, P2386, DOI 10.1001/jama.2010.791; Dasenbrook EC, 2008, AM J RESP CRIT CARE, V178, P814, DOI 10.1164/rccm.200802-327OC; del Pozo JL, 2007, CLIN PHARMACOL THER, V82, P204, DOI 10.1038/sj.clpt.2007.6100247; de Vrankrijker AMM, 2011, CLIN MICROBIOL INFEC, V17, P1381, DOI 10.1111/j.1469-0691.2010.03429.x; de Vrankrijker AMM, 2010, PAEDIATR RESPIR REV, V11, P246, DOI 10.1016/j.prrv.2010.07.003; Doring Gerd, 2004, J Cyst Fibros, V3, P67, DOI 10.1016/j.jcf.2004.03.008; Doring G, 2010, FEMS MICROBIOL REV; Doring G, 2007, P NATL ACAD SCI USA, V104, P11020, DOI 10.1073/pnas.0702403104; Doring Gerd, 2009, Cell Microbiol, V11, P208, DOI 10.1111/j.1462-5822.2008.01271.x; Doring G, 2000, EUR RESPIR J, V16, P749, DOI 10.1034/j.1399-3003.2000.16d30.x; Dorkin H, 2011, PEDIAT PULMONOL S34, pA235; Drummond MF, 1987, METHODS EC EVALUATIO; Eakin MN, 2011, J CYST FIBROS, V10, P258, DOI 10.1016/j.jcf.2011.03.005; Emerson J, 2002, PEDIATR PULM, V34, P91, DOI 10.1002/ppul.10127; Esther CR, 2005, PEDIATR PULM, V40, P39, DOI 10.1002/ppul.20222; Fauroux B, 1997, PEDIATR INFECT DIS J, V16, P354, DOI 10.1097/00006454-199704000-00004; Feldman C, 1999, EUR RESPIR J, V13, P1022, DOI 10.1034/j.1399-3003.1999.13e15.x; Fibrosis Trust Cystic, 2009, ANT TREATM CYST FIBR; Fleet J, J CYST FIBR IN PRESS; Flume PA, 2007, AM J RESP CRIT CARE, V176, P957, DOI 10.1164/rccm.200705-664OC; Flume PA, 2009, AM J RESP CRIT CARE, V180, P802, DOI 10.1164/rccm.200812-1845PP; Fodor AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045001; Foweraker JE, 2009, ANTIMICROB AGENTS CH, V53, P4809, DOI 10.1128/AAC.00269-09; Foweraker JE, 2005, J ANTIMICROB CHEMOTH, V55, P921, DOI 10.1093/jac/dki146; Gangell C, 2011, CLIN INFECT DIS, V53, P425, DOI 10.1093/cid/cir399; Geller DE, 1999, CHEST, V116, P639, DOI 10.1378/chest.116.3.639; Geller DE, 2007, PEDIATR PULM, V42, P307, DOI 10.1002/ppal.20594; Geller DE, 2011, AM J RESP CRIT CARE, V183, P1510, DOI 10.1164/rccm.201008-1293OC; Gibson RL, 2003, AM J RESP CRIT CARE, V167, P841, DOI 10.1164/rccm.200208-855OC; Gibson RL, 2007, PEDIATR PULM, V42, P610, DOI 10.1002/ppul.20625; Goss CH, 2011, J CYST FIBROS, V10, P298, DOI 10.1016/j.jcf.2011.06.002; Goss Christopher H, 2007, Proc Am Thorac Soc, V4, P378, DOI 10.1513/pats.200703-039BR; Goss CH, 2002, AM J RESP CRIT CARE, V166, P356, DOI 10.1164/rccm.2109078; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; Hansen CR, 2008, J CYST FIBROS, V7, P523, DOI 10.1016/j.jcf.2008.06.009; Hansen SK, 2011, ISME J; Heijerman H, 2009, J CYST FIBROS, V8, P295, DOI 10.1016/j.jcf.2009.04.005; Herrmann G, 2010, J INFECT DIS, P202; Hoiby N, 2010, INT J ANTIMICROB AG, V35, P322, DOI 10.1016/j.ijantimicag.2009.12.011; Hoiby N, 2010, FUTURE MICROBIOL, V5, P1663, DOI [10.2217/fmb.10.125, 10.2217/FMB.10.125]; Høiby N, 2005, J Cyst Fibros, V4 Suppl 2, P49, DOI 10.1016/j.jcf.2005.05.018; Iles Richard, 2003, J Cyst Fibros, V2, P120, DOI 10.1016/S1569-1993(03)00064-X; Johansen HK, J CYST FIBR IN PRESS; KARPATI F, 1994, INFECTION, V22, P258, DOI 10.1007/BF01739911; Klepac-Ceraj V, 2010, ENVIRON MICROBIOL, V12, P1293, DOI 10.1111/j.1462-2920.2010.02173.x; Knudsen PK, 2009, J CYST FIBROS, V8, P135, DOI 10.1016/j.jcf.2008.11.001; Konstan MW, 2011, PEDIATR PULM, V46, P230, DOI 10.1002/ppul.21356; Konstan MW, 2011, J CYST FIBROS, V10, P54, DOI 10.1016/j.jcf.2010.10.003; Kozlowska WJ, 2008, AM J RESP CRIT CARE, V178, P42, DOI 10.1164/rccm.200710-1599OC; KUMANA CR, 1994, DRUGS, V47, P902, DOI 10.2165/00003495-199447060-00004; Lee Tim W R, 2003, J Cyst Fibros, V2, P29, DOI 10.1016/S1569-1993(02)00141-8; LeLorier J, 2000, CLIN THER, V22, P140, DOI 10.1016/S0149-2918(00)87985-0; Lillquist YP, 2011, J CYST FIBROS, V10, P175, DOI 10.1016/j.jcf.2011.01.002; LiPuma JJ, 2010, CLIN MICROBIOL REV, V23, P299, DOI 10.1128/CMR.00068-09; Mainz JG, 2012, J CYST FIBROS, V11, P158, DOI 10.1016/j.jcf.2011.10.009; Mastella G, 2000, EUR RESPIR J, V16, P464, DOI 10.1034/j.1399-3003.2000.016003464.x; Mayer-Hamblett N, 2012, PEDIATR PULM, V47, P125, DOI 10.1002/ppul.21525; McCormick J, 2010, LANCET, V375, P1007, DOI 10.1016/S0140-6736(09)62161-9; Mccoy KS, 2008, AM J RESP CRIT CARE, V178, P921, DOI 10.1164/rccm.200712-1804OC; Meers P, 2008, J ANTIMICROB CHEMOTH, V61, P859, DOI 10.1093/jac/dkn059; MEYER KC, 1991, AM REV RESPIR DIS, V144, P580; Miall LS, 2001, ARCH DIS CHILD, V84, P160, DOI 10.1136/adc.84.2.160; Modi AC, 2006, J PEDIATR PSYCHOL, V31, P846, DOI 10.1093/jpepsy/jsj096; Moskowitz SM, 2008, PEDIATR PULM, V43, P874, DOI 10.1002/ppul.20873; Moskowitz SM, 2010, PEDIAT PULMONOL, V6, P184; Mowat E, 2011, AM J RESP CRIT CARE, V183, P1674, DOI 10.1164/rccm.201009-1430OC; Muhlebach MS, 2011, J CYST FIBROS, V10, P201, DOI 10.1016/j.jcf.2011.02.004; Muhlebach MS, 2006, PEDIATR PULM, V41, P445, DOI 10.1002/ppul.20396; Mulcahy LR, 2010, J BACTERIOL, V192, P6191, DOI 10.1128/JB.01651-09; Munck A, 2001, PEDIATR PULM, V32, P288, DOI 10.1002/ppul.1121; National Institute for Clinical Excellence, 2004, GUID METH TECHN APPR; Noah TL, 2010, PEDIATR PULM, V45, P281, DOI 10.1002/ppul.21176; Norskov-Lauritsen N, 2010, J CLIN MICROBIOL, V48, P2981, DOI 10.1128/JCM.00383-10; Oermann CM, 2010, PEDIATR PULM, V45, P1121, DOI 10.1002/ppul.21301; Okusanya OO, 2000, ANTIMICROB AGENTS CH, V53, P3847; Olivier KN, 2003, AM J RESP CRIT CARE, V167, P835, DOI 10.1164/rccm.200207-679OC; Ordonez CL, 2003, AM J RESP CRIT CARE, V168, P1471, DOI 10.1164/rccm.200306-731OC; Pamp SJ, 2008, MOL MICROBIOL, V68, P223, DOI 10.1111/j.1365-2958.2008.06152.x; Parkins MD, 2011, CHEST; Perez-Martinez I, 2011, ANTIMICROB AGENTS CH, V55, P3399, DOI 10.1128/AAC.01801-10; Pressler T, 2009, J CYST FIBROS, V8, P37, DOI 10.1016/j.jcf.2008.08.002; Proesmans M, J CYST FIBR IN PRESS; Proesmans M, 2006, EUR RESPIR J, V27, P937, DOI 10.1183/09031936.06.00100805; Que C, 2006, THORAX, V61, P155, DOI 10.1136/thx.2005.043372; Quittner AL, 2012, KENDIG CHEMICKS DISO, P251; Ramsey BW, 1999, NEW ENGL J MED, V340, P23, DOI 10.1056/NEJM199901073400104; Ratjen F, 2007, PEDIAT PULMONOL, V42, P249; Ratjen F, 2010, THORAX, V65, P286, DOI 10.1136/thx.2009.121657; Ratjen F, 2001, LANCET, V358, P983, DOI 10.1016/S0140-6736(01)06124-4; Razvi S, 2007, CYSTIC FIBROSIS, P123; REGELMANN WE, 1990, AM REV RESPIR DIS, V141, P914; Renna M, 2011, J CLIN INVEST, V121, P3554, DOI 10.1172/JCI46095; Retsch-Bogart GZ, 2009, CHEST, V135, P1223, DOI 10.1378/chest.08-1421; Rogers GB, 2011, J CYST FIBROS, V10, P387, DOI 10.1016/j.jcf.2011.06.014; Rogers GB, 2003, J CLIN MICROBIOL, V41, P3548, DOI 10.1128/JCM.41.8.3548-3558.2003; Rogers GB, 2006, J CLIN MICROBIOL, V44, P2601, DOI 10.1128/JCM.02282-05; Rogers GB, 2004, J CLIN MICROBIOL, V42, P5176, DOI 10.1128/JCM.42.11.5176-5183.2004; Rogers GB, 2010, CLIN MICROBIOL INFEC, V16, P1656, DOI 10.1111/j.1469-0691.2010.03189.x; Rosenfeld M, 2001, PEDIATR PULM, V32, P356, DOI 10.1002/ppul.1144; Rosenfeld M, 2001, J PEDIATR, V139, P572, DOI 10.1067/mpd.2001.117785; Ryan G, 2011, COCHRANE DB SYST REV; Sagel SD, 2009, J PEDIATR, V154, P183, DOI 10.1016/j.jpeds.2008.08.001; Saiman L, 2010, JAMA-J AM MED ASSOC, V303, P1707, DOI 10.1001/jama.2010.563; Sanders DB, 2010, AM J RESP CRIT CARE, V182, P627, DOI 10.1164/rccm.200909-1421OC; Sawicki GS, 2008, PEDIATR PULM, V43, P1117, DOI 10.1002/ppul.20914; Sawicki GS, 2011, PEDIATR PULM, V46, P36, DOI 10.1002/ppul.21325; Schechter MS, 2012, CURR OPIN PULM MED, V18, P596, DOI 10.1097/MCP.0b013e328358d533; Schechter MS, 2009, J PEDIATR-US, V155, P634, DOI 10.1016/j.jpeds.2009.04.059; Schuster A, THORAX IN PRESS; Sibley CD, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000184; Sibley CD, 2008, P NATL ACAD SCI USA, V105, P15070, DOI 10.1073/pnas.0804326105; Simoens S, 2011, CHEMOTHER RES PRACT; Smith AL, 1999, J PEDIATR, V134, P413, DOI 10.1016/S0022-3476(99)70197-6; Smith AL, 2003, CHEST, V123, P1495, DOI 10.1378/chest.123.5.1495; Smith EE, 2006, P NATL ACAD SCI USA, V103, P8487, DOI 10.1073/pnas.0602138103; Smyth A, 2008, THORAX, V63, P180, DOI 10.1136/thx.2006.060905; Smyth A, 2001, PROPHYLACTIC ANTIBIO; Sox HC, 2009, ANN INTERN MED, V151, P203; Stenbit AE, 2011, CURR OPIN PULM MED, V17, P442, DOI 10.1097/MCP.0b013e32834b8c04; STRANDVIK B, 1992, ACTA PAEDIATR, V81, P340, DOI 10.1111/j.1651-2227.1992.tb12239.x; Stutman HR, 2002, J PEDIATR, V140, P299, DOI 10.1067/mpd.2002.121930; Taccetti G, 2012, THORAX, V67, P853, DOI 10.1136/thoraxjnl-2011-200832; Taccetti G, 2005, EUR RESPIR J, V26, P1; Talmaciu I, 2000, PEDIATR PULM, V30, P10, DOI 10.1002/1099-0496(200007)30:1<10::AID-PPUL3>3.0.CO;2-Q; Tateda K, 2001, ANTIMICROB AGENTS CH, V45, P1930, DOI 10.1128/AAC.45.6.1930-1933.2001; Taylor-Robinson D, 2012, THORAX, V67, P860, DOI 10.1136/thoraxjnl-2011-200953; Thornton J, 2005, J Cyst Fibros, V4, P239, DOI 10.1016/j.jcf.2005.08.003; Tramper-Stranders GA, 2011, CLIN MICROBIOL INFEC; Trapnell BC, 2012, AM J RESP CRIT CARE, V185, P171, DOI 10.1164/rccm.201105-0924OC; Treggiari MM, 2011, ARCH PEDIAT ADOL MED, V165, P847, DOI 10.1001/archpediatrics.2011.136; Treggiari MM, 2007, PEDIATR PULM, V42, P751, DOI 10.1002/ppul.20665; Tullis E, 2012, JOURNAL OF CYSTIC FI, V11, pS11; Tunney MM, 2011, THORAX, V66, P579, DOI 10.1136/thx.2010.137281; Tunney MM, 2008, AM J RESP CRIT CARE, V177, P995, DOI [10.1164/rccm.200708-1151OC, 10.1164/rccm.200708-1151]; Ulrich M, 2010, THORAX, V65, P978, DOI 10.1136/thx.2010.137745; U.S. Department of Health and Human Services Food and Drug Administration, 1998, GUID IND DEV ANT DRU; VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2; Vanderhelst E, 2012, J CYST FIBROS, V11, P2, DOI 10.1016/j.jcf.2011.08.006; VanDevanter DR, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-137; van Ewijk BE, 2006, THORAX, V61, P641, DOI 10.1136/thx.2006.062372; Wainwright CE, 2011, JAMA-J AM MED ASSOC, V306, P163, DOI 10.1001/jama.2011.954; Waters V, 2011, AM J RESP CRIT CARE, V183, P635, DOI 10.1164/rccm.201009-1392OC; Wiesemann HG, 1998, PEDIATR PULM, V25, P88, DOI 10.1002/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J; Worlitzsch D, 2009, CLIN MICROBIOL INFEC, V15, P4544; Yang L, 2011, P NATL ACAD SCI USA, V108, P7481, DOI 10.1073/pnas.1018249108; Yousef AA, 2010, PAEDIATR RESPIR REV, V11, P108, DOI 10.1016/j.prrv.2009.12.003; Zhao JC, 2012, P NATL ACAD SCI USA, V109, P5809, DOI 10.1073/pnas.1120577109",171,21,21,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","DEC",2012,11,6,null,null,null,null,461,479,null,"10.1016/j.jcf.2012.10.004",null,19,"Respiratory System","Respiratory System","051HC","WOS:000312115900001"]
[null,null,null,null,"J","Jiraskova, A; Novotny, J; Novotny, L; Vodicka, P; Pardini, B; Naccarati, A; Schwertner, HA; Hubacek, JA; Puncocharova, L; Smerhovsky, Z; Vitek, L",null,null,null,"Jiraskova, Alena; Novotny, Jan; Novotny, Ladislav; Vodicka, Pavel; Pardini, Barbara; Naccarati, Alessio; Schwertner, Harvey A.; Hubacek, Jaroslav A.; Puncocharova, Lucie; Smerhovsky, Zdenek; Vitek, Libor",null,null,"Association of serum bilirubin and promoter variations in HMOX1 and UGT1A1 genes with sporadic colorectal cancer","INTERNATIONAL JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"bilirubin; bilirubin UDP-glucuronosyl transferase; colorectal cancer; genetic variations; Gilbert syndrome; heme oxygenase; oxidative stress; UGT1A1","SQUAMOUS-CELL CARCINOMA; HEME OXYGENASE-1 EXPRESSION; LYMPH-NODE METASTASIS; THERAPEUTIC APPLICATIONS; CARDIOVASCULAR-DISEASE; OXIDATIVE STRESS; HO-1 PROMOTER; POLYMORPHISM; RISK; POPULATION","Heme oxygenase-1 (HMOX1) and bilirubin UDP-glucuronosyltransferase (UGT1A1) enzymes, both involved in bilirubin homeostasis, play an important role in the oxidative stress defense. The objective of our study was to assess the effect of promoter variations of HMOX1 and UGT1A1 genes and of serum bilirubin on the risk of sporadic colorectal cancer (CRC). This exploratory case-control study was based on 777 CRC patients and 986 controls from the Czech Republic. The (GT)n and (TA)n dinucleotide variations in HMOX1 and UGT1A1 gene promoters, respectively, were determined by fragment analysis. In addition, the A(-413)T variant in HMOX1 promoter was also analyzed using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Serum bilirubin levels were compared in a subset of 174 cases and 247 controls, for whom biochemical data were available. After adjustment for age, a significant association between CRC risk and UGT1A1*28 allele carrier status was detected [odds ratio (95% confidence intervals) = 0.80 (0.600.97), p = 0.022]. No association between CRC risk and individual HMOX1 gene variants was observed, although a diplotype analysis revealed an increased risk for a specific HMOX1 genotype combination. These effects were more pronounced in males. Substantially lower serum bilirubin levels were detected in CRC patients compared to the controls (p < 0.001); each 1 mu mol/L decrease in serum bilirubin was associated with a 7% increase of CRC risk (p < 0.001). In conclusion, UGT1A1*28 allele carrier status might be a protective factor against the development of CRC in the male population, whereas low serum bilirubin levels are associated with an increased risk of CRC in both genders.","[Jiraskova, Alena; Vitek, Libor] Charles Univ Prague, Dept Internal Med 4, Fac Med 1, Prague 12808 2, Czech Republic; [Jiraskova, Alena; Vitek, Libor] Charles Univ Prague, Dept Clin Biochem & Lab Diagnost, Fac Med 1, Prague 12808 2, Czech Republic; [Novotny, Jan] Charles Univ Prague, Dept Oncol, Fac Med 1, Prague 12808 2, Czech Republic; [Novotny, Ladislav] Charles Univ Prague, Inst Hyg & Epidemiol, Fac Med 1, Prague 12808 2, Czech Republic; [Novotny, Ladislav] Charles Univ Prague, Dept Internal Med 3, Fac Med 1, Prague 12808 2, Czech Republic; [Vodicka, Pavel] Charles Univ Prague, Inst Biol & Med Genet, Fac Med 1, Prague 12808 2, Czech Republic; [Vodicka, Pavel; Pardini, Barbara; Naccarati, Alessio] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Schwertner, Harvey A.] Wilford Hall USAF Med Ctr, San Antonio, TX 78236 USA; [Hubacek, Jaroslav A.] Inst Clin & Expt Med, Prague, Czech Republic; [Puncocharova, Lucie] Charles Univ Prague, Dept Surg 3, Fac Med 1, Prague 12808 2, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Inst Epidemiol 2, Prague 12808 2, Czech Republic; [Smerhovsky, Zdenek] Natl Inst Publ Hlth, Prague, Czech Republic","Vitek, L (reprint author), Charles Univ Prague, Dept Internal Med 4, Fac Med 1, U Nemocnice 2, Prague 12808 2, Czech Republic.","vitek@cesnet.cz","Vitek, Libor/A-2645-2008",null,"Czech Ministry of Education [ME849, LH11030, 2B06155]; Grant Agency of the Czech Republic [CZ:GA CR:GA307/10/1430]; Czech Ministry of Health [00023001]","Grant sponsor: Czech Ministry of Education; Grant numbers: ME849, LH11030, 2B06155; Grant sponsor: Grant Agency of the Czech Republic; Grant number: CZ:GA CR:GA307/10/1430; Grant sponsor: Czech Ministry of Health; Grant number: 00023001",null,47,8,8,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0020-7136",null,null,"INT J CANCER","Int. J. Cancer","OCT 1",2012,131,7,null,null,null,null,1549,1555,null,"10.1002/ijc.27412",null,7,"Oncology","Oncology","980TJ","WOS:000306915700022"]
[null,null,null,null,"J","Derumeaux, G; Ernande, L; Serusclat, A; Servan, E; Bruckert, E; Rousset, H; Senn, S; Van Gaal, L; Picandet, B; Gavini, F; Moulin, P",null,null,null,"Derumeaux, Genevieve; Ernande, Laura; Serusclat, Andre; Servan, Evelyne; Bruckert, Eric; Rousset, Hugues; Senn, Stephen; Van Gaal, Luc; Picandet, Brigitte; Gavini, Francois; Moulin, Philippe",null,"REGULATE Trial Investigators","Echocardiographic Evidence for Valvular Toxicity of Benfluorex: A Double-Blind Randomised Trial in Patients with Type 2 Diabetes Mellitus","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"HEART-DISEASE; VALVE ABNORMALITIES; PARKINSONS-DISEASE; 5-HT2B RECEPTORS; FENFLURAMINE; SEROTONIN; VALVULOPATHY; PHENTERMINE; REGURGITATION; PERGOLIDE","Objectives: REGULATE trial was designed to compare the efficacy and safety of benfluorex versus pioglitazone in type 2 diabetes mellitus (DM) patients. Methods: Double-blind, parallel-group, international, randomised, non-inferiority trial. More than half of the 196 participating centres were primary care centres. Patients eligible had type 2 DM uncontrolled on sulfonylurea. 846 were randomised. They received study treatment for 1 year. 423 patients were allocated to benfluorex (150 to 450 mg/day) and 423 were allocated to pioglitazone (30 to 45 mg/day). Primary efficacy criterion was HbA(1c). Safety assessment included blinded echocardiographic evaluation of cardiac and valvular status. Results: At baseline, patients were 59.1+/-10.5 years old with HbA(1c) 8.3+/-0.8%, and DM duration 7.1+/-6.0 years. During the study, mean HbA(1c) significantly decreased in both groups (benfluorex: from 8.30+/-0.80 to 7.77+/-1.31 versus pioglitazone: from 8.30+/-0.80 to 7.45+/-1.30%). The last HbA(1c) value was significantly lower with pioglitazone than with benfluorex (p<0.001) and non-inferiority of benfluorex was not confirmed (p = 0.19). Among the 615 patients with assessable paired echocardiography (310 benfluorex, 305 pioglitazone), 314 (51%) had at least one morphological valvular abnormality and 515 (84%) at least one functional valvular abnormality at baseline. Emergent morphological abnormalities occurred in 8 patients with benfluorex versus 4 with pioglitazone (OR 1.99), 95% CI (0.59 to 6.69). Emergent regurgitation (new or increased by one grade or more) occurred more frequently with benfluorex (82 patients, 27%) than with pioglitazone (33 patients, 11%) (OR 2.97), 95% CI (1.91 to 4.63) and were mainly rated grade 1; grade 2 (mild) was detected in 2 patients with benfluorex and 3 with pioglitazone. There was no moderate or severe regurgitation. Conclusion: After 1 year of exposure, our results show a 2.97 fold increase in the incidence of valvular regurgitation with benfluorex and provide evidence for the valvular toxicity of this drug.","[Derumeaux, Genevieve; Ernande, Laura; Servan, Evelyne] Hop Louis Pradel, Echocardiog Lab, Lyon, France; [Serusclat, Andre] Hop Louis Pradel, Dept Med Imaging & Endocrinol, Lyon, France; [Bruckert, Eric] Hop La Pitie Salpetriere, Dept Endocrinol & Metab, Paris, France; [Rousset, Hugues] Ctr Hosp, Pierre Benite, France; [Senn, Stephen] Univ Glasgow, Dept Stat, Glasgow, Lanark, Scotland; [Van Gaal, Luc] Univ Antwerp Hosp, Fac Med, Dept Diabetol Metab & Clin Nutr, Edegem, Belgium; [Picandet, Brigitte; Gavini, Francois] Inst Rech Int Servier, F-92415 Courbevoie, France; [Moulin, Philippe] Univ Lyon 1, Hosp Civils Lyon, Hop Louis Pradel, Dept Endocrinol, F-69365 Lyon, France","Derumeaux, G (reprint author), Hop Louis Pradel, Echocardiog Lab, Lyon, France.","philippe.moulin@chu-lyon.fr","Senn, Stephen/B-2903-2013","Senn, Stephen/0000-0002-7558-8473","Servier","The trial was fully funded by Servier. There was no additional external funding. The study was designed by the principal investigator (PM) submitted and discussed by the scientific committee and finally approved by the funder. The funder delegated data collection to contract research organization (Euraxi France; Chiltern International SARL Germany, Czechia, India, Roumania; Clindev Pty Ltd South Africa; Gecem Tunisia; Parexel International Argentina). Statistical analysis was performed by one of the co-authors (FG) under the supervision of the scientific committee. Funder had no role in the decision to publish, the manuscript was fully written by the first and the last authors, revised and approved by the co-authors.","AFSSAPS, 2009, NAT PHARM COMM M TUE; Bhattacharyya S, 2009, LANCET, V374, P577, DOI 10.1016/S0140-6736(09)60252-X; Boutet K, 2009, EUR RESPIR J, V33, P684, DOI 10.1183/09031936.00086308; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Dahl CF, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-34; Droogmans S, 2009, AM J PHYSIOL-HEART C, V296, pH1940, DOI 10.1152/ajpheart.01177.2008; Fitzgerald LW, 2000, MOL PHARMACOL, V57, P75; Frachon I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010128; Gustafsson BI, 2005, CIRCULATION, V111, P1517, DOI 10.1161/01.CIR.0000159356.42064.48; Huang XP, 2009, MOL PHARMACOL, V76, P710, DOI 10.1124/mol.109.058057; Jollis JG, 2000, CIRCULATION, V101, P2071; Levy RJ, 2006, CIRCULATION, V113, P2, DOI 10.1161/CIRCULATIONAHA.105.593459; Mekontso-Dessap A, 2006, CIRCULATION, V113, P81, DOI 10.1161/CIRCULATIONAHA.105.554667; Moulin P, 2006, DIABETES CARE, V29, P515, DOI 10.2337/diacare.29.03.06.dc05-1439; Nebigil CG, 2003, CIRCULATION, V108, P902, DOI 10.1161/01.CIR.0000081520.25714.D9; Nesto RW, 2003, CIRCULATION, V108, P2941, DOI 10.1161/01.CIR.0000103683.99399.7E; Noize P, 2006, FUND CLIN PHARMACOL, V20, P577, DOI 10.1111/j.1472-8206.2006.00441.x; Rafel RJ, 2003, REV ESP CARDIOL, V56, P215; Roth BL, 2007, NEW ENGL J MED, V356, P6, DOI 10.1056/NEJMp068265; Rothman RB, 2000, CIRCULATION, V102, P2836; Rothman RB, 2000, AM J CARDIOL, V85, P913, DOI 10.1016/S0002-9149(99)00896-6; Setola V, 2003, MOL PHARMACOL, V63, P1223, DOI 10.1124/mol.63.6.1223; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; Thevis M, 2010, ANAL BIOAN IN PRESS; Van Camp G, 2004, LANCET, V363, P1179, DOI 10.1016/S0140-6736(04)15945-X; Weill A, 2010, PHARMACOEPIDEM DR S, V19, P1256, DOI 10.1002/pds.2044; Weissman NJ, 1998, NEW ENGL J MED, V339, P725, DOI 10.1056/NEJM199809103391103; Zanettini R, 2007, NEW ENGL J MED, V356, P39, DOI 10.1056/NEJMoa054830; Zoghbi WA, 2003, J AM SOC ECHOCARDIOG, V16, P777, DOI 10.1016/S0894-7317(03)00335-3",29,8,8,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","JUN 19",2012,7,6,null,null,null,null,null,null,"e38273","10.1371/journal.pone.0038273",null,12,"Multidisciplinary Sciences","Science & Technology - Other Topics","963VI","WOS:000305652700013"]
[null,null,null,null,"J","Harris, RA; Nagy-Szakal, D; Pedersen, N; Opekun, A; Bronsky, J; Munkholm, P; Jespersgaard, C; Andersen, P; Melegh, B; Ferry, G; Jess, T; Kellermayer, R",null,null,null,"Harris, R. Alan; Nagy-Szakal, Dorottya; Pedersen, Natalia; Opekun, Antone; Bronsky, Jiri; Munkholm, Pia; Jespersgaard, Cathrine; Andersen, PaalSkytt; Melegh, Bela; Ferry, George; Jess, Tine; Kellermayer, Richard",null,null,"Genome-wide peripheral blood leukocyte DNA methylation microarrays identified a single association with inflammatory bowel diseases","INFLAMMATORY BOWEL DISEASES",null,null,"English","Article",null,null,null,null,null,"inflammatory bowel disease; DNA methylation; peripheral blood; twin; TEPP","COLITIS; TWINS; SUSCEPTIBILITY; EPIDEMIOLOGY; EPIGENETICS; CONCORDANCE; POPULATION; INHIBITION; PREVALENCE; INCREASES","Background: Crohn's disease (CD) and ulcerative colitis (UC) are common forms of inflammatory bowel disease (IBD). Monozygotic (MZ) twin discordance rates and epidemiologic data implicate that environmental changes and epigenetic factors may play a pathogenic role in IBD. DNA methylation (the methylation of cytosines within CpG dinucleotides) is an epigenetic modification, which can respond to environmental influences. We investigated whether DNA methylation might be connected with IBD in peripheral blood leukocyte (PBL) DNA by utilizing genome-wide microarrays. Methods: Two different high-throughput microarray-based methods for genome-wide DNA methylation analysis were employed. First, DNA isolated from MZ twin pairs concordant (CD: 4; UC: 3) and discordant (CD: 4; UC: 7) for IBD was interrogated by a custom-made methylation-specific amplification microarray (MSAM). Second, the recently developed Illumina Infinium HumanMethylation450 BeadChip arrays were used on 48 samples of PBL DNA from discordant MZ twin pairs (CD: 3; UC: 3) and treatment-naive pediatric cases of IBD (CD: 14; UC: 8), as well as controls (n = 14). The microarrays were validated with bisulfite pyrosequencing. Results: The MSAMs did not yield significant IBD associations. The Methylation BeadChip approach identified a single DNA methylation association of IBD at TEPP (testis, prostate and placenta-expressed protein) when DNA isolated selectively from peripheral blood mononuclear cells was analyzed (8.6% increase in methylation between CD and control, FDR = 0.0065). Conclusions: Microarray interrogation of IBD-dependent DNA methylation from PBLs appears to have limited ability to detect significant disease associations. More detailed and/or selective approaches may be useful for the elucidation of connections between the DNA methylome and IBD in the future.","[Nagy-Szakal, Dorottya; Opekun, Antone; Ferry, George; Kellermayer, Richard] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Sect Pediat Gastroenterol, Houston, TX 77030 USA; [Harris, R. Alan] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Nagy-Szakal, Dorottya; Kellermayer, Richard] USDA ARS Childrens Nutr Res Ctr, Houston, TX USA; [Pedersen, Natalia; Munkholm, Pia] Herlev Univ Hosp, Gastroenterol Unit, DK-2730 Herlev, Denmark; [Opekun, Antone] Baylor Coll Med, Dept Gasteonterol TMC Digest Dis Ctr, Houston, TX 77030 USA; [Bronsky, Jiri] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Bronsky, Jiri] Univ Hosp Motol, Prague, Czech Republic; [Jespersgaard, Cathrine] Statens Serum Inst, Dept Clin Biochem & Immunol, DK-2300 Copenhagen, Denmark; [Andersen, PaalSkytt] Statens Serum Inst, Dept Microbiol Surveillance & Res, DK-2300 Copenhagen, Denmark; [Melegh, Bela] Univ Pecs, Dept Med Genet, Pecs, Hungary; [Jess, Tine] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark","Kellermayer, R (reprint author), Texas Childrens Hosp, Baylor Coll Med, Sect Pediat Gastroenterol Hepatol & Nutr, 6621 Fannin St,CC1010-00, Houston, TX 77030 USA.","kellerma@bcm.edu",null,null,"Broad Medical Research Program, the Broad Foundation [IBD-0252]; Crohn's and Colitis Foundation of America-Children's Digestive Health and Nutrition Foundation/North American Society of Pediatric Gastroenterology Hepatology and Nutrition (CCFA) [2426]; Child Health Research Career Development Agency of the Baylor College of Medicine (NIH) [5K12 HD041648]; Public Health Service grant [DK56338]","R.K. was supported in part by the Broad Medical Research Program, the Broad Foundation (IBD-0252); the Crohn's and Colitis Foundation of America-Children's Digestive Health and Nutrition Foundation/North American Society of Pediatric Gastroenterology Hepatology and Nutrition (CCFA Ref. No. 2426); the Child Health Research Career Development Agency of the Baylor College of Medicine (NIH Grant No. 5K12 HD041648); and a Public Health Service grant DK56338, funding the Texas Medical Center Digestive Diseases Center.",null,45,7,7,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1078-0998",null,null,"INFLAMM BOWEL DIS","Inflamm. Bowel Dis.","DEC",2012,18,12,null,null,null,null,2334,2341,null,"10.1002/ibd.22956",null,8,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","039JR","WOS:000311242400017"]
[null,null,null,null,"J","Stiborova, M; Indra, R; Moserova, M; Cerna, V; Rupertova, M; Martinek, V; Eckschlager, T; Kizek, R; Frei, E",null,null,null,"Stiborova, Marie; Indra, Radek; Moserova, Michaela; Cerna, Vera; Rupertova, Martina; Martinek, Vaclav; Eckschlager, Tomas; Kizek, Rene; Frei, Eva",null,null,"Cytochrome b(5) Increases Cytochrome P450 3A4-Mediated Activation of Anticancer Drug Ellipticine to 13-Hydroxyellipticine Whose Covalent Binding to DNA Is Elevated by Sulfotransferases and N,O-Acetyltransferases","CHEMICAL RESEARCH IN TOXICOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ADDUCT FORMATION; MICROSOMAL CYTOCHROME; HUMAN NEUROBLASTOMA; AGENT ELLIPTICINE; ESCHERICHIA-COLI; SOLVATION MODEL; IONIC SOLUTES; FREE-ENERGIES; CANCER-CELLS; P450 1A1","The antineoplastic alkaloid ellipticine is a prodrug, whose pharmacological efficiency is dependent on its cytochrome P450 (P450)- and/or peroxidase-mediated activation in target tissues. The P450 3A4 enzyme oxidizes ellipticine to five 3 metabolites, mainly to 13-hydroxy- and 12-hydroxyellipticine, the metabolites responsible for the formation of ellipticine-13-ylium and ellipticine-12-ylium ions that generate covalent DNA adducts. Cytochrome b(5) alters the ratio of ellipticine p metabolites formed by P450 3A4. While the amounts of the detoxication metabolites (7-hydroxy- and 9-hydroxyellipticine) were not changed with added cytochrome b(5), 12-hydroxy- and 13-hydroxyellipticine, and ellipticine N-2-oxide increased considerably. The P450 3A4-mediated oxidation of ellipticine was significantly changed only by holo-cytochrome 65, while apo-cytochrome b(5) without heme or Mn-cytochrome b(5) had no such effect. The change in amounts of metabolites resulted in an increased formation of covalent ellipticine-DNA adducts, one of the DNA-damaging mechanisms of ellipticine antitumor action. The amounts of 13-hydroxy- and 12-hydroxyellipticine formed by P450 3A4 were similar, but more than 7-fold higher levels of the adduct. were formed by 13-hydrox-yellipticine than by 12-hydroxyellipticine. The higher susceptibility of 13-hydroxyellipticine toward heterolytic dissociation to ellipticine-13-ylium in comparison to dissociation of 12-hydroxyellipticine to ellipticine-12ylium, determined by quantum chemical calculations, explains this phenomenon. The amounts of the 13-hydroxyellipticinederived DNA adduct significantly increased upon reaction of 13-hydroxyellipticine with either 3'-phosphoadenosine-5'phosphosulfate or acetyl-CoA catalyzed by human sulfotransferases 1A1, 1A2, 1A3, and 2A1, or N,O-acetyltransferases 1 and 2. The calculated reaction free energies of heterolysis of the sulfate and acetate esters are by 10-17 kcal/mol more favorable than the energy of hydrolysis of 13-hydroxyellipticine, which could explain the experimental data.","[Stiborova, Marie; Indra, Radek; Moserova, Michaela; Cerna, Vera; Rupertova, Martina; Martinek, Vaclav] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12840 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague 12840 2, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Brno, Czech Republic; [Frei, Eva] German Canc Res Ctr, Natl Ctr Tumor Dis, Div Prevent Oncol, D-69120 Heidelberg, Germany","Stiborova, M (reprint author), Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, Prague 12840 2, Czech Republic.","stiborov@natur.cuni.cz","Kizek, Rene/D-7748-2012; Martinek, Vaclav/E-6710-2011","Martinek, Vaclav/0000-0003-3321-4526","Agency of the Czech Republic [P301/10/0356, 203/09/0812]; Charles University in Prague [UNCE 42]; Ministry of Education of the Czech Republic [LM2010005]","This work was supported by the Grant Agency of the Czech Republic (grants P301/10/0356 and 203/09/0812) and Charles University in Prague (grant UNCE #42). The access to the Meta Centrum computing facilities provided under the program LM2010005 funded by the Ministry of Education of the Czech Republic is highly appreciated.",null,63,6,6,"AMER CHEMICAL SOC","WASHINGTON","1155 16TH ST, NW, WASHINGTON, DC 20036 USA","0893-228X",null,null,"CHEM RES TOXICOL","Chem. Res. Toxicol.","MAY",2012,25,5,null,null,null,null,1075,1085,null,"10.1021/tx3000335",null,11,"Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology","Pharmacology & Pharmacy; Chemistry; Toxicology","944WR","WOS:000304235000011"]
[null,null,null,null,"J","Sumpelmann, R; Kretz, FJ; Luntzer, R; de Leeuw, TG; Mixa, V; Gabler, R; Eich, C; Hollmann, MW; Osthaus, WA",null,null,null,"Suempelmann, Robert; Kretz, Franz-Josef; Luntzer, Robert; de Leeuw, Thomas G.; Mixa, Vladimir; Gaebler, Ralf; Eich, Christoph; Hollmann, Markus W.; Osthaus, Wilhelm A.",null,null,"Hydroxyethyl starch 130/0.42/6:1 for perioperative plasma volume replacement in 1130 children: results of an European prospective multicenter observational postauthorization safety study (PASS)","PEDIATRIC ANESTHESIA",null,null,"English","Article",null,null,null,null,null,"hydroxyethyl starch; safety; adverse drug reactions; neonates; infants; children","LACTATED RINGERS SOLUTION; FLUID MANAGEMENT; ANAPHYLACTOID REACTIONS; CARDIAC-SURGERY; ACID-BASE; ANION GAP; 6-PERCENT; ALBUMIN; TRANSFUSION; HES","Introduction: Third-generation hydroxyethyl starch (HES) is now approved also for the use in children, but safety studies including large numbers of pediatric patients are still missing. Therefore, we performed an European multicentric prospective observational postauthorization safety study (PASS) to evaluate the use of HES 130/0.42/6:1 in normal saline (ns-HES) or a balanced electrolyte solution (bal-HES) in children undergoing surgery. Methods: Children aged up to 12 years with ASA risk scores of I-III receiving nsHES (Venofundin 6%; Braun) or bal-HES (Tetraspan 6%; Braun) were followed perioperatively. Demographic data, surgical procedures performed, anesthesia, hemodynamic and laboratory data, adverse events (AE), and adverse drug reactions (ADR) were documented using a standardized case report form. Results: Of 1130 children studied at 11 European pediatric centers from 2006 to 2009 (ns-HES, 629 children; bal-HES, 475 children; mean age, 3.6 +/- 3.8 [ range, day of birth-12 years]; and body weight, 15.4 +/- 13 [0.9-90 kg]), 1104 were included for analysis. The mean infused HES volume was 10.6 +/- 5.8 (0.83-50) ml.kg(-1). In the 399 (36.1%) cases with blood gas analysis before and after HES infusion, hemoglobin and strong ion difference decreased significantly in both groups, whereas bicarbonate and base excess (BE before infusion: ns-HES) 1.8 +/- 3.1, bal-HES) 1.2 +/- 3.3 mM; after infusion: ns-HES) 2.5 +/- 2.8; bal-HES) 1.1 +/- 3.2 mM, P < 0.05) decreased only with ns-HES but remained stable with bal-HES. Chloride concentrations increased in both groups and were significantly higher with ns-HES (Cl before infusion: ns-HES 105.5 +/- 3.6, bal-HES 104.9 +/- 2.9 mM; Cl after infusion: ns-HES 107.6 +/- 3.4, bal-HES 106.3 +/- 2.9 mM, P < 0.05). For the AE/ADR rates, dose-response but no age relationships could be demonstrated. No serious and no severe ADR directly related to HES (i. e. anaphylactoid reaction, clotting disorders, renal failure) were observed. Conclusion: Moderate doses of HES 130/0.42/6: 1 for perioperative plasma volume replacement seem to be safe even in neonates and small infants. The probability of serious ADR is lower than 0.3%. Changes in acid-base balance may be decreased when HES is used in an acetate-containing balanced electrolyte solution instead of normal saline. Caution should be exercised in patients with renal function disturbances and those with an increased bleeding risk.","[Suempelmann, Robert; Osthaus, Wilhelm A.] Hannover Med Sch, Klin Anasthesiol & Intens Med, D-30625 Hannover, Germany; [Kretz, Franz-Josef] Olga Hosp, Klin Anasthesie & Operat Intens Med, Stuttgart, Germany; [Luntzer, Robert] Danube Hosp Vienna, Dept Anesthesiol & Gen Intens Care, Vienna, Austria; [de Leeuw, Thomas G.] Erasmus MC, Dept Anesthesia, Sophias Children Hosp, Rotterdam, Netherlands; [Mixa, Vladimir] Fac Hosp Motol, Clin Anaesthesiol & Resuscitat, Prague, Czech Republic; [Gaebler, Ralf] Univ Klinikum Carl Gustav Carus, Klin & Poliklin Anasthesiol & Intens Therapie, Dresden, Germany; [Eich, Christoph] Kinderkrankenhaus Bult, Abt Anasthesie Kinderintens & Notfallmed, Hannover, Germany; [Hollmann, Markus W.] Univ Amsterdam, Acad Med Ctr, Dept Anesthesiol, NL-1105 AZ Amsterdam, Netherlands","Sumpelmann, R (reprint author), Hannover Med Sch, Klin Anasthesiol OE 8050, Carl Neuberg Str 1, D-30625 Hannover, Germany.","suempelmann.robert@mh-hannover.de",null,null,null,null,null,35,4,5,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1155-5645",null,null,"PEDIATR ANESTH","Pediatr. Anesth.","APR",2012,22,4,null,null,null,null,371,378,null,"10.1111/j.1460-9592.2011.03776.x",null,8,"Anesthesiology; Pediatrics","Anesthesiology; Pediatrics","901SJ","WOS:000300986800011"]
[null,null,null,null,"J","Valach, J; Fik, Z; Strnad, H; Chovanec, M; Plzak, J; Cada, Z; Szabo, P; Sachova, J; Hroudova, M; Urbanova, M; Steffl, M; Paces, J; Mazanek, J; Vlcek, C; Betka, J; Kaltner, H; Andre, S; Gabius, HJ; Kodet, R; Smetana, K; Gal, P; Kolar, M",null,null,null,"Valach, Jaroslav; Fik, Zdenek; Strnad, Hynek; Chovanec, Martin; Plzak, Jan; Cada, Zdenek; Szabo, Pavol; Sachova, Jana; Hroudova, Miluse; Urbanova, Marketa; Steffl, Martin; Paces, Jan; Mazanek, Jiri; Vlcek, Cestmir; Betka, Jan; Kaltner, Herbert; Andre, Sabine; Gabius, Hans-Joachim; Kodet, Roman; Smetana, Karel, Jr.; Gal, Peter; Kolar, Michal",null,null,"Smooth muscle actin-expressing stromal fibroblasts in head and neck squamous cell carcinoma: Increased expression of galectin-1 and induction of poor prognosis factors","INTERNATIONAL JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"carcinoma; stroma; myofibroblast; actin; lectin","REGULATORY GALECTINS; NORMAL KERATINOCYTES; UP-REGULATION; CANCER; TUMORS; GROWTH; MYOFIBROBLASTS; ACTIVATION; PROFILES; NETWORK","Tumor stroma is an active part influencing the biological properties of malignancies via molecular cross-talk. Cancer-associated fibroblasts play a significant role in this interaction. These cells frequently express smooth muscle actin and can be classified as myofibroblasts. The adhesion/growth-regulatory lectin galectin-1 is an effector for their generation. In our study, we set the presence of smooth muscle actin-positive cancer-associated fibroblasts in relation to this endogenous lectin and an in vivo competitor (galectin-3). In squamous cell carcinomas of head and neck, upregulation of galectin-1 presence was highly significantly correlated to presence of smooth muscle actin-positive cancer-associated fibroblasts in the tumor (p = 4 x 10-8). To pinpoint further correlations on the molecular level, we applied microarray analyses to the transcription profiles of the corresponding tumors. Significant correlations of several transcripts were detected with the protein level of galectin-1 in the cancer-associated fibroblasts. These activated genes (MAP3K2, TRIM23, PTPLAD1, FUSIP1, SLC25A40 and SPIN1) are related to known squamous-cell-carcinoma poor-prognosis factors, NF-kappa B upregulation and splicing downregulation. These results provide new insights into the significance of presence of myofibroblasts in squamous cell carcinoma.","[Valach, Jaroslav; Fik, Zdenek; Chovanec, Martin; Plzak, Jan; Cada, Zdenek; Szabo, Pavol; Smetana, Karel, Jr.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Valach, Jaroslav; Mazanek, Jiri] Charles Univ Prague, Fac Med 1, Dept Stomatol, Prague 12800 2, Czech Republic; [Fik, Zdenek; Chovanec, Martin; Plzak, Jan; Cada, Zdenek; Steffl, Martin; Betka, Jan] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol Head & Neck Surg, Prague 12800 2, Czech Republic; [Strnad, Hynek; Szabo, Pavol; Sachova, Jana; Hroudova, Miluse; Urbanova, Marketa; Steffl, Martin; Paces, Jan; Vlcek, Cestmir; Kolar, Michal] Acad Sci Czech Republic, Inst Mol Genet, Lab Genom & Bioinformat, CR-14220 Prague 4, Czech Republic; [Kaltner, Herbert; Andre, Sabine; Gabius, Hans-Joachim] Univ Munich, Inst Physiol Chem, Fac Vet Med, D-8000 Munich, Germany; [Kodet, Roman] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 12800 2, Czech Republic; [Gal, Peter] Charles Univ Prague, Fac Med 1, Inst Histol & Embryol, Prague 12800 2, Czech Republic; [Gal, Peter] E Slovak Inst Cardiovasc Dis, Dept Biomed Res, Kosice, Slovakia","Smetana, K (reprint author), Charles Univ Prague, Fac Med 1, Inst Anat, U Nemocnice 3, Prague 12800 2, Czech Republic.","karel.smetana@lf1.cuni.cz; kolarmi@img.cas.cz","Kolar, Michal/A-3307-2012; Strnad, Hynek/B-7361-2008; Steffl, Martin/A-9789-2013","Kolar, Michal/0000-0002-4593-1525; Strnad, Hynek/0000-0002-0141-8340; ","Ministry of Education, Youth and Sports of the Czech Republic [NPVII 2B06106]; Academy of Sciences of the Czech Republic [AV0Z50520514]; Charles University project for Specific University Research [264510]; Charles University project UNCE [204013]; Charles University [PRVOUK/1LF/1]; EC research program GlycoHIT [260600]","Grant sponsor: Ministry of Education, Youth and Sports of the Czech Republic; Grant number: NPVII 2B06106; Grant sponsor: Academy of Sciences of the Czech Republic; Grant number: AV0Z50520514; Grant sponsor: Charles University project for Specific University Research; Grant number: 264510; Grant sponsor: Charles University project UNCE; Grant number: 204013; Grant sponsor: Charles University project PRVOUK/1LF/1, EC research program GlycoHIT; Grant number: 260600",null,52,4,4,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0020-7136","1097-0215",null,"INT J CANCER","Int. J. Cancer","DEC 1",2012,131,11,null,null,null,null,2499,2508,null,"10.1002/ijc.27550",null,10,"Oncology","Oncology","011SN","WOS:000309185400004"]
[null,null,null,null,"J","Patrinos, GP; Smith, TD; Howard, H; Al-Mulla, F; Chouchane, L; Hadjisavvas, A; Hamed, SA; Li, XT; Marafie, M; Ramesar, RS; Ramos, FJ; de Rave, T; El-Ruby, MO; Shrestha, TR; Sobrido, MJ; Tadmouri, G; Witsch-Baumgartner, M; Zilfali, BA; Auerbach, AD; Carpenter, K; Cutting, GR; Dung, VC; Grody, W; Hasler, J; Jorde, L; Kaput, J; Macek, M; Matsubara, Y; Padilla, C; Robinson, H; Rojas-Martinez, A; Taylor, GR; Vihinen, M; Weber, T; Burn, J; Qi, M; Cotton, RGH; Rimoin, D",null,null,null,"Patrinos, George P.; Smith, Timothy D.; Howard, Heather; Al-Mulla, Fand; Chouchane, Lotfi; Hadjisavvas, Andreas; Hamed, Sherifa A.; Li, Xi-Tao; Marafie, Makia; Ramesar, Rajkumar S.; Ramos, Feliciano J.; de Rave, Thomy; El-Ruby, Mona O.; Shrestha, Tilak Ram; Sobrido, Maria-Jess; Tadmouri, Ghazi; Witsch-Baumgartner, Martina; Zilfali, Bin Alwi; Auerbach, Arleen D.; Carpenter, Kevin; Cutting, Garry R.; Vu Chi Dung; Grody, Wayne; Hasler, Julia; Jorde, Lynn; Kaput, Jim; Macek, Milan; Matsubara, Yoichi; Padilla, Carmancita; Robinson, Helen; Rojas-Martinez, Augusto; Taylor, Graham R.; Vihinen, Mauno; Weber, Tom; Burn, John; Qi, Ming; Cotton, Richard G. H.; Rimoin, David",null,"Int Confederation Countries","Human variome project country nodes: Documenting genetic information within a country","HUMAN MUTATION",null,null,"English","Article",null,null,null,null,null,"human variome project; country nodes; national; ethnic mutation databases; populations; genomic variation; genomics","INHERITED DISORDERS; DATABASES LSDBS; GREECE; POPULATION; MUTATIONS; GUIDELINES; CURATION; HEALTH; REGION","The Human Variome Project (http://www.humanvariomeproject.org) is an international effort aiming to systematically collect and share information on all human genetic variation. The two main pillars of this effort are gene/disease-specific databases and a network of Human Variome Project Country Nodes. The latter are nationwide efforts to document the genomic variation reported within a specific population. The development and successful operation of the Human Variome Project Country Nodes are of utmost importance to the success of Human Variome Project's aims and goals because they not only allow the genetic burden of disease to be quantified in different countries, but also provide diagnosticians and researchers access to an up-to-date resource that will assist them in their daily clinical practice and biomedical research, respectively. Here, we report the discussions and recommendations that resulted from the inaugural meeting of the International Confederation of Countries Advisory Council, held on 12th December 2011, during the 2011 Human Variome Project Beijing Meeting. We discuss the steps necessary to maximize the impact of the Country Node effort for developing regional and country-specific clinical genetics resources and summarize a few well-coordinated genetic data collection initiatives that would serve as paradigms for similar projects. Hum Mutat 33:15131519, 2012. (c) 2012 Wiley Periodicals, Inc.","[Patrinos, George P.] Univ Patras, Dept Pharm, Sch Hlth Sci, GR-26504 Patras, Greece; [Smith, Timothy D.; Howard, Heather; Robinson, Helen; Cotton, Richard G. H.] Human Variome Project Int Ltd, Melbourne, Vic, Australia; [Al-Mulla, Fand] Kuwait Univ, Fac Med, Mol Pathol Unit, Kuwait, Kuwait; [Chouchane, Lotfi] Weill Cornell Med Coll Qatar, Dept Med Genet, Doha, Qatar; [Hadjisavvas, Andreas] Cyprus Inst Neurol & Gent, Dept Electron Microscopy & Mol Pathol, Nicosia, Cyprus; [Hamed, Sherifa A.] Assiut Univ Hosp, Dept Neurol & Psychiat, Assiut, Egypt; [Li, Xi-Tao] Beijing Hua Yi Nat Med Inst, Beijing, Peoples R China; [Marafie, Makia] Matern Hosp, Kuwait Med Genet Ctr, Kuwait, Kuwait; [Ramesar, Rajkumar S.] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7700 Rondebosch, South Africa; [Ramos, Feliciano J.] AEGH, Zaragoza, Spain; [Ramos, Feliciano J.] Univ Zaragoza, Sch Med, Zaragoza, Spain; [de Rave, Thomy] Katholieke Univ Leuven, Dept Clin Genet, Louvain, Belgium; [El-Ruby, Mona O.] Natl Res Ctr, Dept Clin Genet, Cairo, Egypt; [Shrestha, Tilak Ram] Tribhuvan Univ, Cent Dept Biotechnol, Kathmandu, Nepal; [Sobrido, Maria-Jess] Inst Hlth Carlos III, Ctr Network Biomed Res Rare Dis CIBERER, Madrid, Spain; [Tadmouri, Ghazi] Ctr Arab Genome Studies, Dubai, U Arab Emirates; [Witsch-Baumgartner, Martina] Med Univ Innsbruck, Div Human Genet, Innsbruck, Austria; [Zilfali, Bin Alwi] Univ Sains Malaysia, Sch Med Sci, Kubang Kerian, Kelantan, Malaysia; [Auerbach, Arleen D.] Rockefeller Univ, Lab Human Genet & Hematol, New York, NY 10021 USA; [Carpenter, Kevin] Univ Sydney, Childrens Hosp Westmead, Dept Med Genet, Sydney, NSW 2006, Australia; [Cutting, Garry R.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Vu Chi Dung] Vietnam Natl Hosp Pediat, Dept Med Genet & Metab, Hanoi, Vietnam; [Grody, Wayne] Univ Coll Los Angeles, Dept Pathol & Lab Med, Sch Med, Los Angeles, CA USA; [Grody, Wayne] Univ Coll Los Angeles, Dept Pediat, Sch Med, Los Angeles, CA USA; [Grody, Wayne] Univ Coll Los Angeles, Dept Human Genet, Sch Med, Los Angeles, CA USA; [Hasler, Julia] Univ Zimbabwe, Dept Biochem, Harare, Zimbabwe; [Jorde, Lynn] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA; [Kaput, Jim] Nestle Inst Hlth Sci, Clin Translat Unit, Lausanne, Switzerland; [Macek, Milan] Charles Univ Prague, Dept Biol & Med Genet, Fac Med, Prague, Czech Republic; [Matsubara, Yoichi] Tohoku Univ, Sch Med, Dept Med Genet, Sendai, Miyagi 980, Japan; [Padilla, Carmancita] Univ Philippines, Coll Med, Manila, Philippines; [Robinson, Helen] Univ Melbourne, Nossal Inst Global Hlth, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia; [Rojas-Martinez, Augusto] Univ Autonoma Nuevo Leon, Latin Amer Network Human Genet Soc, Monterrey, Mexico; [Rojas-Martinez, Augusto] Univ Autonoma Nuevo Leon, Ctr Invest & Desarrollo Ciencias Salud, Monterrey, Mexico; [Rojas-Martinez, Augusto] Univ Autonoma Nuevo Leon, Sch Med, Monterrey, Mexico; [Taylor, Graham R.] Canc Res, Reg DNA Lab, Leeds, Yorks, England; [Vihinen, Mauno] Lund Univ, Dept Expt Med Sci, S-22100 Lund, Sweden; [Weber, Tom] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA; [Burn, John] Newcastle Univ, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Qi, Ming] Zhejiang Univ, Sch Med, Affiliated Hosp 1,Beijing Genome Inst,CAS, ADINOVO Ctr Genet & Genom Med,James Watson Inst G, Hangzhou 310003, Zhejiang, Peoples R China; [Qi, Ming] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, New York, NY USA; [Cotton, Richard G. H.] Univ Melbourne, Dept Pathol, Fac Med Dent & Hlth Sci, Melbourne, Vic 3010, Australia; [Rimoin, David] Cedars Sinai Med Ctr, Div Med Genet, Los Angeles, CA USA","Patrinos, GP (reprint author), Univ Patras, Dept Pharm, Sch Med, Univ Campus, GR-26504 Patras, Greece.","gpatrinos@upatras.gr","ROJAS MARTINEZ, AUGUSTO/D-1710-2011","ROJAS MARTINEZ, AUGUSTO/0000-0003-3765-6778","Golden Helix Institute of Biomedical Research budget; REGENPSI network; Conselleria de Educacion; Xunta de Galicia [2009/019]; Fondo de investigacion Sanitaria; Institute of Health Carlos III, Spain (Miguel Servet program); FEDER funds; USM Short Term research grant [304/PPSP/61311034]; MOSTIER Biotek research grant [304/PPSP/6150113/K105];  [CZ.2.16/3.1.00/24022];  [00064203]","Contract grant sponsors: Establishment of HVP Country Nodes has been supported by CZ.2.16/3.1.00/24022 and 00064203 grants to M. M.); the Golden Helix Institute of Biomedical Research budget (to G. P. P); the REGENPSI network (to M.-J.S.); Conselleria de Educacion; Xunta de Galicia (2009/019); Fondo de investigacion Sanitaria; Institute of Health Carlos III, Spain (Miguel Servet program); FEDER funds; USM Short Term research grant (304/PPSP/61311034); MOSTIER Biotek research grant (304/PPSP/6150113/K105) and the contributions from members of 1mhgvc.",null,37,4,4,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1059-7794",null,null,"HUM MUTAT","Hum. Mutat.","NOV",2012,33,11,null,null,null,null,1513,1519,null,"10.1002/humu.22147",null,7,"Genetics & Heredity","Genetics & Heredity","019RA","WOS:000309755800004"]
[null,null,null,null,"J","Hoffmann, J; Fiser, K; Weaver, J; Dimmick, I; Loeher, M; Pircher, H; Martin-Ruiz, C; Veerasamy, M; Keavney, B; von Zglinicki, T; Spyridopoulos, I",null,null,null,"Hoffmann, Jedrzej; Fiser, Karel; Weaver, Jolanta; Dimmick, Ian; Loeher, Monika; Pircher, Hanspeter; Martin-Ruiz, Carmen; Veerasamy, Murugapathy; Keavney, Bernard; von Zglinicki, Thomas; Spyridopoulos, Ioakim",null,null,"High-Throughput 13-Parameter Immunophenotyping Identifies Shifts in the Circulating T-Cell Compartment Following Reperfusion in Patients with Acute Myocardial Infarction","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"ST-SEGMENT ELEVATION; POLYCHROMATIC FLOW-CYTOMETRY; PRIMARY ANGIOPLASTY; RECEPTOR ACTIVATION; LYMPHOCYTES; INJURY; EXPRESSION; MEMORY; ASSOCIATION; POPULATIONS","Rationale: With the advent of primary PCI (PPCI), reperfusion is achieved in almost all patients presenting with acute myocardial infarction. However, despite multiple trials, reperfusion injury has not been successfully dealt with so far. In mouse models, CD4(+) T lymphocytes (T cells) have been shown to be crucial instigators of reperfusion injury. Objective: Our goal was to investigate the role of CD4(+) T cells during myocardial reperfusion following PPCI by developing a protocol for high-throughput multiplexed flow cytometric analysis and multivariate flow clustering. Methods and Results: 13-parameter immunophenotyping and hierarchical cluster analysis (HCA) identified a unique CD4(+)CD57(+) T-cell population in PPCI patients that reflected acute proliferation in the CD4(+) T-cell compartment. CD4(+)CCR7(+) T cells were specifically depleted from peripheral blood during the first 30 min of myocardial reperfusion after PPCI, suggesting a potential role for the chemokine receptor CCR7 in T-cell redistribution to either peripheral tissues or migration to the infarcted heart during ischemia/reperfusion following PPCI. Conclusions: High-throughput polychromatic flow cytometry and HCA are capable of objective, time and cost efficient assessment of the individual T-cell immune profile in different stages of coronary heart disease and have broad applications in clinical trials.","[Hoffmann, Jedrzej; Dimmick, Ian; Loeher, Monika; Veerasamy, Murugapathy; Keavney, Bernard; Spyridopoulos, Ioakim] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Martin-Ruiz, Carmen; von Zglinicki, Thomas] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Weaver, Jolanta] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Pircher, Hanspeter] Univ Freiburg, Dept Immunol, Inst Med Microbiol & Hyg, D-79106 Freiburg, Germany; [Fiser, Karel] Charles Univ Prague, Med Sch 2, Dept Paediat Haematol & Oncol, CLIP, Prague, Czech Republic","Spyridopoulos, I (reprint author), Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.","ioakim.spyridopoulos@newcastle.ac.uk",null,null,"UK NIHR Biomedical Research Centre; Newcastle Healthcare Charity; Newcastle Upon Tyne Hospitals NHS Charity","This work was supported by the UK NIHR Biomedical Research Centre award to the Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Healthcare Charity and Newcastle Upon Tyne Hospitals NHS Charity (all to IS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,33,4,4,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","OCT 16",2012,7,10,null,null,null,null,null,null,"e47155","10.1371/journal.pone.0047155",null,11,"Multidisciplinary Sciences","Science & Technology - Other Topics","024UX","WOS:000310135800029"]
[null,null,null,null,"J","Hayes, WN; Watson, AR; Callaghan, N; Wright, E; Stefanidis, CJ",null,null,null,"Hayes, Wesley N.; Watson, Alan R.; Callaghan, Nichola; Wright, Elizabeth; Stefanidis, Constantinos J.",null,"European Pediat Dialysis Working","Vascular access: choice and complications in European paediatric haemodialysis units","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Vascular access; Paediatrics; Haemodialysis; Central venous catheter; Arteriovenous fistula; Arteriovenous graft","CATHETER-RELATED BACTEREMIA; ARTERIOVENOUS-FISTULAS; CHILDREN; DIALYSIS; HEMODIAFILTRATION; POPULATION; ALTEPLASE; STENOSIS; SURVIVAL; TRIAL","European and U.S. guidelines emphasise that permanent vascular access in the form of arteriovenous fistulae (AVF) or grafts (AVG) are preferable to central venous catheters (CVC) in paediatric patients on long-term haemodialysis. We report vascular access choice and complication rates in 13 European paediatric nephrology units. A survey of units participating in the European Pediatric Dialysis Working Group requesting data on type of vascular access, routine care and complications in patients on chronic haemodialysis between March 2010 and February 2011. Information was complied on 111 patients in 13 participating centres with a median age of 14 (range 0.25-20.2) years. Central venous catheters were used in 67 of 111 (60%) patients, with 42 patients (38%) having an AVF and two patients (2%) having an AVG. Choice of vascular access was significantly related to patient age, with patients with AVF/AVG having a median age of 16 years compared to 12 years for patients with CVCs (p < 0.001). Routine CVC exit site care and catheter lock solution use differed between centres. CVC infections requiring intravenous antibiotics were reported at a rate of 1.9 and exit site infections at a rate of 1.8 episodes/1000 catheter days. Overall infective complications necessitating CVC change occurred at a rate of 0.9 episodes/1000 catheter days. No infective complications were reported in patients with AVF/AVG access. The rate of CVC infections requiring intravenous antibiotics was significantly lower in patients in whom CVC exit sites were cleaned weekly as opposed to every dialysis session (relative risk with every session cleaning vs. weekly cleaning 2.58, 95% confidence interval 1.17-5.69). Catheter malfunction (inadequate blood flow) was a more prevalent complication necessitating 22.4 thrombolytic interventions/1000 catheter days and 2.1 CVC changes/1000 catheter days. Central venous catheters remain the predominant choice of vascular access in Europe despite problems of malfunction and infection. AVF/AVG were predominantly used in adolescents without reported complications. More regular exit site cleaning may predispose to CVC infection, but this observation requires prospective evaluation.","[Hayes, Wesley N.; Watson, Alan R.; Callaghan, Nichola] Nottingham Childrens Hosp, Nottingham NG7 2UH, England; [Wright, Elizabeth] Great Ormond St Hosp Sick Children, London, England; [Stefanidis, Constantinos J.] A & P Kyriakou Childrens Hosp, Athens, Greece","Watson, AR (reprint author), Nottingham Childrens Hosp, QMC Campus,Derby Rd, Nottingham NG7 2UH, England.","judith.hayes@nuh.nhs.uk","Ariceta, Gema/J-4100-2012; Shroff, Rukshana/C-7347-2008",null,null,null,"Agarwal AK, 2007, SEMIN DIALYSIS, V20, P53, DOI 10.1111/j.1525-139X.2007.00242.x; [Anonymous], 2011, NAPRTCS ANN REPORT; Araya CE, 2007, AM J KIDNEY DIS, V50, P119, DOI 10.1053/j.ajkd.2007.04.005; Astor BC, 2001, AM J KIDNEY DIS, V38, P494, DOI 10.1053/ajkd.2001.26833; BARRETT N, 1988, NEPHROL DIAL TRANSPL, V3, P423; Bourquelot P, 2003, THER APHER DIAL, V7, P498, DOI 10.1046/j.1526-0968.2003.00098.x; Chand DH, 2009, PEDIATR NEPHROL, V24, P1121, DOI 10.1007/s00467-008-0812-3; Chand DH, 2008, AM J KIDNEY DIS, V51, P1016, DOI 10.1053/j.ajkd.2008.02.309; Fadel FI, 2008, INT UROL NEPHROL, V40, P489, DOI 10.1007/s11255-007-9259-x; Fadrowski JJ, 2009, AM J KIDNEY DIS, V53, P91, DOI 10.1053/j.ajkd.2008.08.011; Fischbach M, 2010, NEPHROL DIAL TRANSPL, V25, P867, DOI 10.1093/ndt/gfp565; Fischbach M, 2004, NEPHROL DIAL TRANSPL, V19, P2360, DOI 10.1093/ndt/gfh403; Fischbach M, 2005, PEDIATR NEPHROL, V20, P1054, DOI 10.1007/s00467-005-1876-y; Gittins NS, 2007, ARCH DIS CHILD, V92, P499, DOI 10.1136/adc.2006.100065; Goldstein SL, 2009, KIDNEY INT, V76, P1063, DOI 10.1038/ki.2009.303; Hemmelgarn BR, 2011, NEW ENGL J MED, V364, P303, DOI 10.1056/NEJMoa1011376; Hussain F, 2010, PEDIATR NEPHROL, V25, P1941; Krishnamurthy G, 2011, CARDIOVASC INTER RAD, V34, P14, DOI 10.1007/s00270-010-9865-3; Leonard MB, 2003, KIDNEY INT, V63, P744, DOI 10.1046/j.1523-1755.2003.00788.x; Lewis MA, 2010, NEPHRON CLIN PRACT, V115, pC279, DOI 10.1159/000301237; Lok CE, 2011, KIDNEY INT, V79, P587, DOI 10.1038/ki.2010.471; Male C, 2003, BLOOD, V101, P4273, DOI 10.1182/blood-2002-09-2731; Mokrzycki MH, 2010, KIDNEY INT, V78, P1218, DOI 10.1038/ki.2010.332; National Kidney Foundation, 2006, NAT KIDN FDN DIS OUT; National Patient Safety Agency, 2008, NPSA2008444RRR002; Onder AM, 2009, PEDIATR NEPHROL, V24, P1741, DOI 10.1007/s00467-009-1154-5; Peynircioglu B, 2007, J VASC INTERV RADIOL, V18, P875, DOI 10.1016/j.jvir.2007.04.016; Piraino B, 2010, NAT REV NEPHROL, V6, P259, DOI 10.1038/nrneph.2010.45; Ramage IJ, 2005, AM J KIDNEY DIS, V45, P708, DOI 10.1053/j.ajkd.2004.12.010; Sharma A, 1999, PEDIATR NEPHROL, V13, P245; Sheth RD, 2001, AM J KIDNEY DIS, V38, P553, DOI 10.1053/ajkd.2001.26852; Stefanidis CJ, 2010, EXPERT REV ANTI-INFE, V8, P1; Valentini RP, 2008, PEDIATR NEPHROL, V23, P291, DOI 10.1007/s00467-007-0658-0; Zaritsky JJ, 2008, PEDIATR NEPHROL, V23, P2061, DOI 10.1007/s00467-008-0956-1",34,3,4,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","JUN",2012,27,6,null,null,null,null,999,1004,null,"10.1007/s00467-011-2079-3",null,6,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","934OC","WOS:000303452700017"]
[null,null,null,null,"J","Rink, M; Shariat, SF; Xylinas, E; Fitzgerald, JP; Hansen, J; Green, DA; Kamat, AM; Novara, G; Daneshmand, S; Fradet, Y; Tagawa, ST; Bastian, PJ; Kassouf, W; Trinh, QD; Karakiewicz, PI; Fritsche, HM; Tilki, D; Chun, FK; Volkmer, BG; Babjuk, M; Merseburger, AS; Scherr, DS; Lotan, Y; Svatek, RS",null,null,null,"Rink, Michael; Shariat, Shahrokh F.; Xylinas, Evanguelos; Fitzgerald, John P.; Hansen, Jens; Green, David A.; Kamat, Ashish M.; Novara, Giacomo; Daneshmand, Siamak; Fradet, Yves; Tagawa, Scott T.; Bastian, Patrick J.; Kassouf, Wassim; Quoc-Dien Trinh; Karakiewicz, Pierre I.; Fritsche, Hans-Martin; Tilki, Derya; Chun, Felix K.; Volkmer, Bjoern G.; Babjuk, Marko; Merseburger, Axel S.; Scherr, Douglas S.; Lotan, Yair; Svatek, Robert S.",null,null,"Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?","WORLD JOURNAL OF UROLOGY",null,null,"English","Article",null,null,null,null,null,"Bladder cancer; Survival; Recurrence; Radical cystectomy; Lymph node; Transitional cell carcinoma","INVASIVE BLADDER-CANCER; TRANSITIONAL-CELL CARCINOMA; LYMPH-NODES; PELVIC LYMPHADENECTOMY; PROSTATE-CANCER; DISSECTION; STANDARDIZATION; PROGNOSIS; SURVIVAL; NUMBER","To determine whether the number of lymph nodes (LNs) examined is associated with outcomes in patients without nodal metastasis after radical cystectomy (RC). We retrospectively analyzed data from 4,188 patients treated at 12 centers with RC and pelvic lymphadenectomy without neo-adjuvant chemotherapy for urothelial carcinoma of the bladder (UCB). Outcomes of patients without LN metastasis (n = 3,088) were examined according to the LN yield analyzed as continuous variable, tertiles, and using the cutoffs of a parts per thousand yen9 and a parts per thousand yen20. The median nodal yield was 18 (range 1-123; IQR:20). A total of 2591 (84 %) and 1445 (47 %) patients had a LN yield a parts per thousand yen9 and a parts per thousand yen20, respectively. Median follow-up was 47 months (IQR:70). In multivariable analyses that adjusted for the standard clinicopathologic factors, higher LN yield was associated with a decreased risk of disease recurrence (continuous: HR = 0.996, p = 0.05; 3rd vs 1st tertile: HR = 0.853, p = 0.048; cutoff a parts per thousand yen20: HR = 0.851, p = 0.032). In the subgroups of patients with muscle-invasive UCB or those with a parts per thousand yen9 LN removed, LN yield was not associated with outcomes (p values > 0.05). In this large multicenter cohort of patients with node-negative UCB, higher nodal yield improved recurrence-free survival when all patients were analyzed. Patients with a high LN yield (a parts per thousand yen20 LN removed or 3rd tertile) had the largest benefit. The lack of prognostic significance of LN yield in patients with muscle-invasive UCB or those stratified by 9 LNs removed suggests that this effect is weak. Further prospective studies are needed to help identify preoperatively the optimal template for each patient.","[Rink, Michael; Shariat, Shahrokh F.; Xylinas, Evanguelos; Green, David A.; Tagawa, Scott T.; Scherr, Douglas S.] Cornell Univ, New York Presbyterian Hosp, Weill Cornell Med Coll, Brady Urol Hlth Ctr, New York, NY 10021 USA; [Rink, Michael; Hansen, Jens; Chun, Felix K.] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Fitzgerald, John P.; Svatek, Robert S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Hansen, Jens; Quoc-Dien Trinh; Karakiewicz, Pierre I.] Univ Montreal, Montreal, PQ, Canada; [Kamat, Ashish M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Novara, Giacomo] Univ Padua, Padua, Italy; [Daneshmand, Siamak] Univ So Calif, Los Angeles, CA USA; [Fradet, Yves] Univ Laval, Quebec City, PQ, Canada; [Bastian, Patrick J.; Tilki, Derya] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany; [Kassouf, Wassim] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Fritsche, Hans-Martin] Univ Regensburg, Caritas St Josef Med Ctr, Regensburg, Germany; [Volkmer, Bjoern G.] Hosp Kassel, Kassel, Germany; [Babjuk, Marko] Charles Univ Prague, Hosp Motol, Fac Med 2, Prague, Czech Republic; [Merseburger, Axel S.] Hannover Med Sch, D-3000 Hannover, Germany; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA","Shariat, SF (reprint author), Cornell Univ, New York Presbyterian Hosp, Weill Cornell Med Coll, Brady Urol Hlth Ctr, 525 E 68th St,Box 94,Starr 900, New York, NY 10021 USA.","sfshariat@gmail.com; svatek@uthscsa.edu",null,null,"Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust","Dr. Michael Rink is supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust.",null,25,3,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0724-4983",null,null,"WORLD J UROL","World J. Urol.","DEC",2012,30,6,null,null,null,null,807,814,null,"10.1007/s00345-012-0910-5",null,8,"Urology & Nephrology","Urology & Nephrology","046VW","WOS:000311793500012"]
[null,null,null,null,"J","Vaclavikova, R; Ehrlichova, M; Hlavata, I; Pecha, V; Kozevnikovova, R; Trnkova, M; Adamek, J; Edvardsen, H; Kristensen, VN; Gut, I; Soucek, P",null,null,null,"Vaclavikova, Radka; Ehrlichova, Marie; Hlavata, Ivona; Pecha, Vaclav; Kozevnikovova, Renata; Trnkova, Marketa; Adamek, Jan; Edvardsen, Hege; Kristensen, Vessela N.; Gut, Ivan; Soucek, Pavel",null,null,"Detection of frequent ABCB1 polymorphisms by high-resolution melting curve analysis and their effect on breast carcinoma prognosis","CLINICAL CHEMISTRY AND LABORATORY MEDICINE",null,null,"English","Article",null,null,null,null,null,"ABCB1; breast carcinoma; high resolution melting; multidrug resistance; polymorphisms","SINGLE NUCLEOTIDE POLYMORPHISMS; MULTIDRUG-RESISTANCE; MDR1 GENE; P-GLYCOPROTEIN; CANCER PATIENTS; ALLERGIC RHINITIS; IDENTIFICATION; ASSOCIATION; POPULATION; CHEMOTHERAPY","Background: The ABCB1 gene encodes P-glycoprotein implicated in the development of cellular drug resistance. The aim of this study was to develop high-resolution melting (HRM) analysis for determination of ABCB1 polymorphisms and evaluate their associations with clinical data of breast carcinoma patients. Methods: HRM analysis was designed to assess five single nucleotide polymorphisms (SNPs) in ABCB1 (rs2214102, rs1128503, rs2032582, rs2032583 and rs1045642) in genomic DNA from 103 breast carcinoma patients. Results were confirmed by direct DNA sequencing. Results: HRM analysis revealed distinct patterns of melting curves for the respective genotypes of all followed SNPs. Sensitivity of HRM analysis compared with direct DNA sequencing was superior (97.1% vs. 93.9%). The overall accuracy of HRM was 97.6%. The coefficients of variation in replicate experiments encompassed the range 0.002%-0.038%. On the basis of the examined SNPs, one strong haplotype block containing rs2032582 and rs1128503 SNPs was identified. Significant associations of rs2032582 SNP with tumor size, negative HER-2/neu status, and family history of breast carcinoma were found. Patients carrying the ancestral homozygous genotype (GG) in rs2214102 had significantly worse progression-free survival in comparison with carriers of the non-ancestral allele (A) in the adjuvant set (p = 0.005). Conclusions: A rapid, accurate, low-cost and time-effective method for screening ABCB1 SNPs was developed. Significant associations of ABCB1 rs2032582 and rs2214102 SNPs with prognostic factors and survival of patients were found.","[Vaclavikova, Radka] Natl Inst Publ Hlth, Toxicogen Unit, Dept Toxicol & Safety, Prague 10042 10, Czech Republic; [Pecha, Vaclav; Kozevnikovova, Renata] MEDICON, Dept Oncosurg, Prague, Czech Republic; [Trnkova, Marketa] Biolab Ltd Praha, Prague, Czech Republic; [Adamek, Jan] Motol Univ Hosp, Dept Surg, Prague, Czech Republic; [Edvardsen, Hege; Kristensen, Vessela N.] Oslo Univ Hosp, Radiumhosp, Inst Canc Res, Dept Genet, Oslo, Norway; [Kristensen, Vessela N.] Univ Oslo, Dept Clin Mol Biol EpiGen, Akerhus Univ Hosp, Oslo, Norway","Vaclavikova, R (reprint author), Natl Inst Publ Hlth, Toxicogen Unit, Dept Toxicol & Safety, Srobarova 48, Prague 10042 10, Czech Republic.","rvaclavikova@szu.cz",null,null,"Internal Grant Agency of the Czech Ministry of Health [NS9803-4, NS9799-4]","This study was supported by grants of the Internal Grant Agency of the Czech Ministry of Health (No. NS9803-4 to I. G.) and (No. NS9799-4 to P.S.).",null,42,3,3,"WALTER DE GRUYTER & CO","BERLIN","GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY","1434-6621",null,null,"CLIN CHEM LAB MED","Clin. Chem. Lab. Med.","NOV",2012,50,11,null,null,null,null,1999,2007,null,"10.1515/cclm-2012-0103",null,9,"Medical Laboratory Technology","Medical Laboratory Technology","032EJ","WOS:000310695300020"]
[null,null,null,null,"J","Votavova, H; Merkerova, MD; Krejcik, Z; Fejglova, K; Vasikova, A; Pastorkova, A; Tabashidze, N; Topinka, J; Balascak, I; Sram, RJ; Brdicka, R",null,null,null,"Votavova, Hana; Merkerova, Michaela Dostalova; Krejcik, Zdenek; Fejglova, Kamila; Vasikova, Alzbeta; Pastorkova, Anna; Tabashidze, Nana; Topinka, Jan; Balascak, Ivan; Sram, Radim J.; Brdicka, Radim",null,null,"Deregulation of Gene Expression Induced by Environmental Tobacco Smoke Exposure in Pregnancy","NICOTINE & TOBACCO RESEARCH",null,null,"English","Article",null,null,null,null,null,null,"CIGARETTE-SMOKE; HUMAN PLACENTA; DNA-ADDUCTS; HEALTH; MOTHERS; TRANSCRIPTOME; METABOLISM; CHILDREN; NICOTINE; SURVIVAL","Environmental tobacco smoke (ETS) exposure in pregnant women may have detrimental effects such as spontaneous abortion, lower birth weight, stillbirth, and reduced infant lung function. To extend our knowledge on the molecular effects of tobacco smoke exposure in pregnancy, we analyzed transcriptome alterations in passive smokers (PS) and compared them with those in active smokers (AS). Using Illumina Expression Beadchips with 24,526 transcript probes, gene expression patterns were assayed in placentas from PS (N = 25) exposed to ETS throughout pregnancy and nonexposed (NS) counterparts (N = 34) and in cord blood cells from their newborns. ETS exposure was evaluated by questionnaire disclosure and cotinine measurement in maternal and cord blood. A total of 158 genes were significantly deregulated in the placentas of PS compared with NS. These genes were associated with the extracellular matrix, apoptosis, placental function, blood clotting, response to stress, and lipid metabolism. Cord blood of the newborns of PS displayed differential expression of 114 genes encoding mainly adhesion molecules and regulators of immunologic response. A comparison of the affected pathways between PS and AS indicated that ETS exposure and active smoking in pregnancy partly employ the same molecular mechanisms. This study demonstrates that even low dose exposure to ETS during pregnancy leads to significant deregulation of transcription in placental and fetal cells. These data suggest that the effect of ETS on the fetus is primarily indirect, mediated via deregulation of placental functions.","[Votavova, Hana; Merkerova, Michaela Dostalova; Krejcik, Zdenek; Fejglova, Kamila; Vasikova, Alzbeta; Brdicka, Radim] Inst Hematol & Blood Transfus, Dept Mol Genet, CR-12820 Prague 2, Czech Republic; [Pastorkova, Anna; Tabashidze, Nana; Topinka, Jan; Sram, Radim J.] Acad Sci Czech Republic, Inst Expt Med, Lab Genet Ecotoxicol, Prague, Czech Republic; [Balascak, Ivan] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Votavova, H (reprint author), Inst Hematol & Blood Transfus, Dept Mol Genet, U Nemocnice 1, CR-12820 Prague 2, Czech Republic.","hana.bruchova@uhkt.cz","Krejcik, Zdenek/A-3505-2013",null,"Czech Ministry of Education Youth and Sports [2B06088]","This work was supported by the Czech Ministry of Education Youth and Sports (grant number 2B06088).",null,37,3,3,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1462-2203",null,null,"NICOTINE TOB RES","Nicotine Tob. Res.","SEP",2012,14,9,null,null,null,null,1073,1082,null,"10.1093/ntr/ntr325",null,10,"Substance Abuse; Public, Environmental & Occupational Health","Substance Abuse; Public, Environmental & Occupational Health","002PY","WOS:000308545800010"]
[null,null,null,null,"J","Kaniakova, M; Krausova, B; Vyklicky, V; Korinek, M; Lichnerova, K; Vyklicky, L; Horak, M",null,null,null,"Kaniakova, Martina; Krausova, Barbora; Vyklicky, Vojtech; Korinek, Miloslav; Lichnerova, Katarina; Vyklicky, Ladislav; Horak, Martin",null,null,"Key Amino Acid Residues within the Third Membrane Domains of NR1 and NR2 Subunits Contribute to the Regulation of the Surface Delivery of N-methyl-D-aspartate Receptors","JOURNAL OF BIOLOGICAL CHEMISTRY",null,null,"English","Article",null,null,null,null,null,null,"FUNCTIONAL NMDA RECEPTORS; ER RETENTION SIGNAL; ENDOPLASMIC-RETICULUM; CELL-SURFACE; TERMINAL DOMAIN; LURCHER MUTATION; TRAFFICKING; EXPRESSION; CHANNELS; KAINATE","N-methyl-D-aspartate (NMDA) receptors are glutamate ionotropic receptors that play critical roles in synaptic transmission, plasticity, and excitotoxicity. The functional NMDA receptors, heterotetramers composed mainly of two NR1 and two NR2 subunits, likely pass endoplasmic reticulum quality control before they are released from the endoplasmic reticulum and trafficked to the cell surface. However, the mechanism underlying this process is not clear. Using truncated and mutated NMDA receptor subunits expressed in heterologous cells, we found that the M3 domains of both NR1 and NR2 subunits contain key amino acid residues that contribute to the regulation of the number of surface functional NMDA receptors. These key residues are critical neither for the interaction between the NR1 and NR2 subunits nor for the formation of the functional receptors, but rather they regulate the early trafficking of the receptors. We also found that the identified key amino acid residues within both NR1 and NR2 M3 domains contribute to the regulation of the surface expression of unassembled NR1 and NR2 subunits. Thus, our data identify the unique role of the membrane domains in the regulation of the number of surface NMDA receptors.","[Kaniakova, Martina; Krausova, Barbora; Vyklicky, Vojtech; Korinek, Miloslav; Lichnerova, Katarina; Vyklicky, Ladislav; Horak, Martin] Acad Sci Czech Republic, Inst Physiol, Vvi, CR-14220 Prague 4, Czech Republic; [Vyklicky, Vojtech] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Horak, M (reprint author), Acad Sci Czech Republic, Inst Physiol, Vvi, Videnska 1083, CR-14220 Prague 4, Czech Republic.","mhorak@biomed.cas.cz","Horak, Martin/F-9819-2010; Kaniakova, Martina/C-2593-2012; Vyklicky, Ladislav/C-1851-2012; Korinek, Miloslav/C-5401-2012",null,"Grant Agency of the Czech Republic [P303/11/0075, P304/12/G069, P303/12/1464]; Marie Curie International Reintegration Grant [PIRG-GA-2010-276827]; Research Project of the AS; Research Project of the CR [AV0Z50110509, RVO:67985823]","This work was supported by the Grant Agency of the Czech Republic Grants P303/11/0075, P304/12/G069, and P303/12/1464); by Marie Curie International Reintegration Grant PIRG-GA-2010-276827; and by Research Projects of the AS CR AV0Z50110509 and RVO:67985823.",null,41,3,3,"AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA","0021-9258",null,null,"J BIOL CHEM","J. Biol. Chem.","JUL 27",2012,287,31,null,null,null,null,26423,26434,null,"10.1074/jbc.M112.339085",null,12,"Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","980TN","WOS:000306916300067"]
[null,null,null,null,"J","Baumann, I; Fuhrer, M; Behrendt, S; Campr, V; Csomor, J; Furlan, I; de Haas, V; Kerndrup, G; Leguit, RJ; De Paepe, P; Noellke, P; Niemeyer, C; Schwarz, S",null,null,null,"Baumann, Irith; Fuehrer, Monika; Behrendt, Sonja; Campr, Vit; Csomor, Judit; Furlan, Ingrid; de Haas, Valerie; Kerndrup, Gitte; Leguit, Roos J.; De Paepe, Pascale; Noellke, Peter; Niemeyer, Charlotte; Schwarz, Stephan",null,null,"Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood: reproducibility of histopathological diagnostic criteria","HISTOPATHOLOGY",null,null,"English","Article",null,null,null,null,null,"histopathology; hypocellular refractory cytopenia of childhood; interobserver study; severe aplastic anaemia","ACUTE MYELOID-LEUKEMIA; IMMUNOSUPPRESSIVE THERAPY; MYELODYSPLASTIC SYNDROMES; CYTOGENETIC ABNORMALITIES; WORKING GROUP; CHILDREN; EXPERIENCE; EVOLUTION; GLOBULIN; DISEASE","Baumann I, Fuhrer M, Behrendt S, Campr V, Csomor J, Furlan I, de Haas V, Kerndrup G, Leguit R J, De Paepe P, Noellke P, Niemeyer C & Schwarz S ?(2012) Histopathology similar to 61, 1017 Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood: reproducibility of histopathological diagnostic criteria Aims: To evaluate the reproducibility and reliability of the histomorphological criteria differentiating severe aplastic anaemia (SAA) and hypoplastic refractory cytopenia of childhood (RCC), the most frequently acquired hypocellular bone marrow conditions of childhood. Methods and results: We performed a double-blind interobserver study of 100 different cases of SAA and RCC among seven haematopathologists of the European Working Group of MDS in Childhood (EWOG-MDS) and the German SAA study. Cases with foci of typical myelodysplastic syndrome (MDS) morphology, such as patchy erythropoiesis with defective maturation, in an otherwise highly hypocellular or adipocytic bone marrow were classified as having RCC. Bone marrow samples without a patchy distribution, few scattered myeloid cells or haematopoietic aplasia were diagnosed as SAA. In only four of 100 cases did the reference pathologists not reach agreement regarding classification as SAA or RCC. The kappa index was 0.79. Conclusions: Our results show that the vast majority of SAA and RCC cases can be reliably differentiated by morphological means alone. A clear differentiation between SAA and RCC at presentation is mandatory for optimizing therapy strategies, and might be responsible for the fact that, in the German childhood SAA study, the probability of developing clonal disease after immunosuppressive therapy has dropped to 3%.","[Baumann, Irith] Boeblingen Hosp, Dept Pathol, Clin Ctr SW, Boblingen, Germany; [Fuehrer, Monika; Behrendt, Sonja] Univ Munich, Childrens Univ Hosp, Dept Haematol & Oncol, Munich, Germany; [Campr, Vit] Univ Hosp Motol, Dept Pathol, Prague, Czech Republic; [Csomor, Judit] Semmelweis Univ, Dept Pathol, H-1085 Budapest, Hungary; [Furlan, Ingrid; Noellke, Peter; Niemeyer, Charlotte] Univ Freiburg, Div Haematol & Oncol, Dept Paediat & Adolescent Med, D-79106 Freiburg, Germany; [de Haas, Valerie] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Kerndrup, Gitte] Vejle Hosp, Dept Pathol, Vejle, Denmark; [Leguit, Roos J.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [De Paepe, Pascale] Ghent Univ Hosp, Dept Pathol, Ghent, Belgium; [Schwarz, Stephan] Univ Med Ctr Erlangen, Dept Pathol, Erlangen, Germany","Baumann, I (reprint author), Boeblingen Hosp, Dept Pathol, Clin Ctr SW, Boblingen, Germany.","i.baumann@klinikverbund-suedwest.de",null,null,null,null,null,23,3,3,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0309-0167",null,null,"HISTOPATHOLOGY","Histopathology","JUL",2012,61,1,null,null,null,null,10,17,null,"10.1111/j.1365-2559.2011.04156.x",null,8,"Cell Biology; Pathology","Cell Biology; Pathology","963FG","WOS:000305604900002"]
[null,null,null,null,"J","Mitropoulos, K; Innocenti, F; van Schaik, RH; Lezhava, A; Tzimas, G; Kollia, P; Macek, M; Fortina, P; Patrinos, GP",null,null,null,"Mitropoulos, Konstantinos; Innocenti, Federico; van Schaik, Ron H.; Lezhava, Alexander; Tzimas, Giannis; Kollia, Panagoula; Macek, Milan, Jr.; Fortina, Paolo; Patrinos, George P.",null,null,"Institutional Profile Golden Helix Institute of Biomedical Research: interdisciplinary research and educational activities in pharmacogenomics and personalized medicine","PHARMACOGENOMICS",null,null,"English","Article",null,null,null,null,null,null,"INHERITED DISORDERS; GENETIC-ANALYSIS; GREECE; DATABASE; FREQUENCIES; POPULATION; EUROPE; HEALTH; VIEW","The Golden Helix Institute of Biomedical Research is an international nonprofit scientific organization with interdisciplinary research and educational activities in the field of genome medicine in Europe, Asia and Latin America. These activities are supervised by an international scientific advisory council, consisting of world leaders in the field of genomics and translational medicine. Research activities include the regional coordination of the Pharmacogenomics for Every Nation Initiative in Europe, in an effort to integrate pharmacogenomics in developing countries, the development of several national/ethnic genetic databases and related web services and the critical assessment of the impact of genetics and genomic medicine on society in various countries. Educational activities also include the organization of the Golden Helix Symposia (R), which are high-profile scientific research symposia in the field of personalized medicine and the Golden Helix Pharmacogenomics Days, an international educational activity focused on pharmacogenomics, as part of its international pharmacogenomics education and outreach efforts.","[Mitropoulos, Konstantinos] Golden Helix Inst Biomed Res, Athens, Greece; [Innocenti, Federico] Univ N Carolina, Inst Pharmacogen & Individualized Therapy, Chapel Hill, NC USA; [van Schaik, Ron H.] Erasmus Univ, Med Ctr, Dept Clin Chem, Pharmacogen Core Lab, Rotterdam, Netherlands; [Lezhava, Alexander] Riken Inst Phys & Chem Res, Yokohama, Kanagawa, Japan; [Tzimas, Giannis] Technol Educ Inst Messolonghi, Fac Management & Econ, Dept Appl Informat Management & Finance, Mesolongion, Greece; [Kollia, Panagoula] Univ Athens, Dept Biol, Sch Phys Sci, GR-15701 Athens, Greece; [Macek, Milan, Jr.] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Macek, Milan, Jr.] Inst Biol & Med Genet, Sch Med 2, Dept Mol Genet, Prague, Czech Republic; [Macek, Milan, Jr.] Natl Cyst Fibrosis Ctr, Prague, Czech Republic; [Fortina, Paolo] Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Genom Lab, Dept Canc Genom, Philadelphia, PA 19107 USA; [Fortina, Paolo] Univ Roma La Sapienza, Dipartimento Med Sperimentale, Rome, Italy","Patrinos, GP (reprint author), Univ Patras, Sch Hlth Sci, Dept Pharm, Univ Campus, GR-26504 Patras, Greece.","gpatrinos@upatras.gr",null,null,"Hellenic National Secretariat of Research and Technology [EL-96870498-01-000166]; European Commission","Most of the work has been partly funded by the Hellenic National Secretariat of Research and Technology (EL-96870498-01-000166), the European Commission and donations from international corporate entities, foundations and individuals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",null,21,3,3,"FUTURE MEDICINE LTD","LONDON","UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND","1462-2416",null,null,"PHARMACOGENOMICS","Pharmacogenomics","MAR",2012,13,4,null,null,null,null,387,392,null,"10.2217/PGS.12.7",null,6,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","903ED","WOS:000301098000013"]
[null,null,null,null,"J","Filkova, M; Hulejova, H; Kuncova, K; Plestilova, L; Cerezo, LA; Mann, H; Klein, M; Zamecnik, J; Gay, S; Vencovsky, J; Senolt, L",null,null,null,"Filkova, Maria; Hulejova, Hana; Kuncova, Klara; Plestilova, Lenka; Cerezo, Lucie Andres; Mann, Herman; Klein, Martin; Zamecnik, Josef; Gay, Steffen; Vencovsky, Jiri; Senolt, Ladislav",null,null,"Resistin in idiopathic inflammatory myopathies","ARTHRITIS RESEARCH & THERAPY",null,null,"English","Article",null,null,null,null,null,null,"MUSCLE REGENERATION; ENDOTHELIAL-CELLS; SYNOVIAL-FLUID; IN-VITRO; POLYMYOSITIS; DERMATOMYOSITIS; EXPRESSION; ADIPOKINE; MYOSITIS; DISEASE","Introduction: The purpose of this study was to evaluate and compare the serum levels and local expression of resistin in patients with idiopathic inflammatory myopathies to controls, and to determine the relationship between resistin levels, inflammation and disease activity. Methods: Serum resistin levels were determined in 42 patients with inflammatory myopathies and 27 healthy controls. The association among resistin levels, inflammation, global disease activity and muscle strength was examined. The expression of resistin in muscle tissues from patients with inflammatory myopathies and healthy controls was evaluated. Gene expression and protein release from resistin-stimulated muscle and mononuclear cells were assessed. Results: In patients with inflammatory myopathies, the serum levels of resistin were significantly higher than those observed in controls (8.53 +/- 6.84 vs. 4.54 +/- 1.08 ng/ml, P < 0.0001) and correlated with C-reactive protein (CRP) levels (r = 0.328, P = 0.044) and myositis disease activity assessment visual analogue scales (MYOACT) (r = 0.382, P = 0.026). Stronger association was observed between the levels of serum resistin and CRP levels (r = 0.717, P = 0.037) as well as MYOACT (r = 0.798, P = 0.007), and there was a trend towards correlation between serum resistin and myoglobin levels (r = 0.650, P = 0.067) in anti-Jo-1 positive patients. Furthermore, in patients with dermatomyositis, serum resistin levels significantly correlated with MYOACT (r = 0.667, P = 0.001), creatine kinase (r = 0.739, P = 0.001) and myoglobin levels (r = 0.791, P = 0.0003) and showed a trend towards correlation with CRP levels (r = 0.447, P = 0.067). Resistin expression in muscle tissue was significantly higher in patients with inflammatory myopathies compared to controls, and resistin induced the expression of interleukins (IL)-1 beta and IL-6 and monocyte chemoattractant protein (MCP)-1 in mononuclear cells but not in myocytes. Conclusions: The results of this study indicate that higher levels of serum resistin are associated with inflammation, higher global disease activity index and muscle injury in patients with myositis-specific anti-Jo-1 antibody and patients with dermatomyositis. Furthermore, up-regulation of resistin in muscle tissue and resistin-induced synthesis of pro-inflammatory cytokines in mononuclear cells suggest a potential role for resistin in the pathogenesis of inflammatory myopathies.","[Filkova, Maria; Hulejova, Hana; Plestilova, Lenka; Cerezo, Lucie Andres; Mann, Herman; Klein, Martin; Vencovsky, Jiri; Senolt, Ladislav] Charles Univ Prague, Dept Expt Rheumatol, Fac Med 1, Inst Rheumatol, Prague 12850 2, Czech Republic; [Kuncova, Klara; Zamecnik, Josef] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 15006 5, Czech Republic; [Gay, Steffen] Univ Zurich Hosp, Ctr Expt Rheumatol, CH-8091 Zurich, Switzerland","Senolt, L (reprint author), Charles Univ Prague, Dept Expt Rheumatol, Fac Med 1, Inst Rheumatol, Slupi 4, Prague 12850 2, Czech Republic.","seno@revma.cz",null,null,"MH CR [NS/10614-3, 262512, 00023728]","This work was supported by MH CR research project NS/10614-3, research project 262512 and research project 00023728.",null,33,3,3,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1478-6354",null,null,"ARTHRITIS RES THER","Arthritis Res. Ther.",null,2012,14,3,null,null,null,null,null,null,"R111","10.1186/ar3836",null,9,"Rheumatology","Rheumatology","090IL","WOS:000314972600013"]
[null,null,null,null,"J","Boelle, PY; Viviani, L; Busson, PF; Olesen, HV; Ravilly, S; Stern, M; Assael, BM; Barreto, C; Drevinek, P; Thomas, M; Krivec, U; Mei-Zahav, M; Vibert, JF; Clement, A; Mehta, A; Corvol, H",null,null,null,"Boelle, Pierre-Yves; Viviani, Laura; Busson, Pierre-Francois; Olesen, Hanne V.; Ravilly, Sophie; Stern, Martin; Assael, Baroukh M.; Barreto, Celeste; Drevinek, Pavel; Thomas, Muriel; Krivec, Uros; Mei-Zahav, Meir; Vibert, Jean-Francois; Clement, Annick; Mehta, Anil; Corvol, Harriet",null,"French CF Modifier Gene Study Inve; European CF Registry Working Grp","Reference percentiles for FEV1 and BMI in European children and adults with cystic fibrosis","ORPHANET JOURNAL OF RARE DISEASES",null,null,"English","Article",null,null,null,null,null,"Cystic fibrosis; Forced expiratory volume in one second; Body mass index; Registry","LUNG-DISEASE SEVERITY; GROWTH; POPULATION; NUTRITION; SURVIVAL; MUTATION; DATABASE; CHARTS; CF","Background: The clinical course of Cystic Fibrosis (CF) is usually measured using the percent predicted FEV1 and BMI Z-score referenced against a healthy population, since achieving normality is the ultimate goal of CF care. Referencing against age and sex matched CF peers may provide valuable information for patients and for comparison between CF centers or populations. Here, we used a large database of European CF patients to compute CF specific reference equations for FEV1 and BMI, derived CF-specific percentile charts and compared these European data to their nearest international equivalents. Methods: 34859 FEV1 and 40947 BMI observations were used to compute European CF specific percentiles. Quantile regression was applied to raw measurements as a function of sex, age and height. Results were compared with the North American equivalent for FEV1 and with the WHO 2007 normative values for BMI. Results: FEV1 and BMI percentiles illustrated the large variability between CF patients receiving the best current care. The European CF specific percentiles for FEV1 were significantly different from those in the USA from an earlier era, with higher lung function in Europe. The CF specific percentiles for BMI declined relative to the WHO standard in older children. Lung function and BMI were similar in the two largest contributing European Countries (France and Germany). Conclusion: The CF specific percentile approach applied to FEV1 and BMI allows referencing patients with respect to their peers. These data allow peer to peer and population comparisons in CF patients.","[Boelle, Pierre-Yves; Vibert, Jean-Francois; Clement, Annick; Corvol, Harriet] Hop St Antoine, Hop Trousseau, AP HP, Dept Publ Hlth,Pediat Pulm Dept, F-75571 Paris, France; [Boelle, Pierre-Yves; Busson, Pierre-Francois; Vibert, Jean-Francois; Clement, Annick; Corvol, Harriet] INSERM, U938, U707, Paris, France; [Boelle, Pierre-Yves; Vibert, Jean-Francois; Clement, Annick; Corvol, Harriet] Univ Paris 06, Paris, France; [Viviani, Laura] Univ Milan, Dipartimento Sci Clin & Comunita, Milan, Italy; [Olesen, Hanne V.] Aarhus Univ Hosp, Cyst Fibrosis Ctr Aarhus, DK-8000 Aarhus N, Denmark; [Ravilly, Sophie] Vaincre Mucoviscidose, Paris, France; [Stern, Martin] Univ Klin Kinder & Jugendmed, Tubingen, Germany; [Assael, Baroukh M.] Verona CF Ctr, Verona, Italy; [Barreto, Celeste] Portuguese Registry Cyst Fibrosis Collaborat Grp, Lisbon, Portugal; [Drevinek, Pavel] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Thomas, Muriel] Sci Inst Publ Hlth, Belgian Cyst Fibrosis Registry, Brussels, Belgium; [Krivec, Uros] Univ Childrens Hosp, Univ Med Ctr Ljubljana, Unit Pulm Dis, Ljubljana, Slovenia; [Mei-Zahav, Meir] Israeli Natl CF Registry, Jerusalem, Israel; [Mehta, Anil] Univ Dundee, Div Med Sci, Dundee, Scotland","Corvol, H (reprint author), Hop St Antoine, Hop Trousseau, AP HP, Dept Publ Hlth,Pediat Pulm Dept, F-75571 Paris, France.","harriet.corvol@trs.aphp.fr","Viviani, Laura/A-4787-2010",null,"Chiesi Farmaceutici, Italy","The ECFSPR was funded by an unrestricted grant from Chiesi Farmaceutici, Italy. Institut National de la Sante et de la Recherche Medicale. Assistance Publique-Hopitaux de Paris. Universite Pierre et Marie Curie Paris. Agence Nationale de la Recherche. DGS, Association Vaincre La Mucoviscidose. Chancellerie des Universites (Legs Poix). Association Agir Informer Contre la Mucoviscidose. GIS-Institut des Maladies Rares. Societe Francaise de la Mucoviscidose. In addition to the authors, we would like to thank European Registry Working Group Members; Austria: ELLEMUNTER. H., Medizinische Universitat. Innsbruck. Austria. Bulgaria: GALEVA. I., Pediatric Clinic. Alexansdrovsky University Hospital. Sofia. Bulgaria. France: Lydie Lemonnier. Vaincre la Mucoviscidose. Paris. France. Greece: HATZIAGOROU. E., Cystic Fibrosis Center of the Aristotelian University of Thessaloniki. Thessaloniki. Greece. Hungary: UJHELYI, R. Cystic Fibrosis Outpatient Care Centre. Heim Pal Hospital for Children. Budapest. Hungary. Ireland: FLETCHER, G. The Cystic Fibrosis Registry of Ireland. Ireland. The Netherlands: GULMANS. V. Dutch Cystic Fibrosis Foundation (NCFS). The Netherlands. Russia: KASHIRSKAYA. N., Research Centre for Medical Genetics. Russian Academy of Medical Sciences. Moscow. Russia. Sweden: LINDBLAD. A., Department of Pediatrics. Queen Silvia Childrens Hospital. Sahgrenska University Hospital. Gothenburg. Sweden. The authors would like to thank the computer specialists and the clinical research assistants involved in the data collection. namely: Sandrine Larroude, Alexandra Blondel and Pauline Touche. We would like to especially thank the patients and families who participated in this study and the contributing French CF Centers and Principal Investigators. ABELY, M., American Memorial Hospital. Reims/BASSINET, L., Centre Hospitalier Intercommunal de Creteil, Creteil/BELLEGUIC, C., Hopital Pontchaillou. Rennes/BELLON, G. Hopital Femme Mere Enfant, Bron/BESSACI, K., American Memorial Hospital, Reims/BONNEL, A.S., Hopital Andre Mignot. Le Chesnay/BREMONT, F. Hopital des Enfants de Toulouse. Toulouse/BROUARD, J. Centre Hospitalier Universitaire de Caen. Caen/BUI, S. Hopital Des Enfants Groupe Pellegrin Bordeaux/CHIRON, R., Hopital Arnaud de Villeneuve. Montpellier/CHUMBIFLORES, R. Hopital de la Tronche. Grenoble/CLEMENT, A. Hopital Armand Trousseau. Paris/CORVOL, H., Hopital Armand Trousseau, Paris/DALPHIN, J.C. CNRS-UFC, UMR 6249 Chrono-environnement. Hopital Jean Minjoz, Besancon/DALPHIN, M.L. Centre Hospitalier Universitaire de Besancon. Besancon/DAVID, V. Hopital Mere-Enfant Nantes/DE MIRANDA, S. Hopital Foch, Suresnes/DERELLE, J. Hopital d'Enfants. Vandoeuvre les Nancy/DOMBLIDES, P. Hopital Haut Leveque Pessac/DOMINIQUE, S. Centre Hospitalier Universitaire Charles Nicolle. Rouen/DUBUS, J.C., Hopital d'Enfants de la Timone. Marseille/DURIEU, I. UCBL1. Groupe Hospitalier Lyon Sud. Hospices Civils de Lyon. Pierre Benite/DURY, S. Hopital Maison Blanche. Reims/ELLAFFI, M. Centre Hospitalier Universitaire de Caen. Caen/EPAUD, R. Centre Hospitalier Intercommunal de Creteil, Creteil/FANTON, A., Hopital d'Enfants du Bocage, Dijon/FAYON, M., Hopital Des Enfants Groupe Pellegrin. Bordeaux/FLEURENCE, E. Hopital d'Enfants, Saint-Denis de la Reunion/FOUCAUD, P., Hopital Andre Mignot, Le Chesnay/GINIES, J.L. Centre Hospitalier Universitaire d'Angers. Angers/GODBERT, B. Hopital de Brabois. Vandoeuvre les Nancy/GRENET, D. Hopital Foch Suresnes/GUILLOT, M. Centre Hospitalier Robert Bisson. Lisieux/HERAUD, M. C. Centre Hospitalier Estaing. Clermont-Ferrand/HOUSSET, B.Centre Hospitalier Intercommunal de Creteil. Creteil/HUBERT, D. Hopital Cochin. Paris/HUET, F. Hopital d'Enfants du Bocage. Dijon/KESSLER, R., Hopital Civil. Strasbourg/LABBE, A. Centre Hospitalier Estaing. Clermont-Ferrand/LAURANS, M. Centre Hospitalier Universitaire de Caen. Caen/LE BOURGEOIS, M. Necker Hopital d'Enfants Malades. Paris/LE ROUX, P., Hopital Jacques Monod. Montivilliers/LLERENA, C. Hopital de la Tronche. Grenoble/LOEUILLE, G. A. Centre Hospitalier de Dunkerque. Dunkerque/MARGUET, C. Centre Hospitalier Universitaire Charles Nicolle. Rouen/MELY, L., Hopital Renee Sabran. Giens/MOISAN-PETIT, V. Centre Hospitalier Bretagne Atlantique. Vannes/MUNCK, A. Hopital Robert Debre. Paris/MURRIS-ESPIN, M., Hopital Larrey. Toulouse/NOVE JOSSERAND, R. Groupe Hospitalier Lyon Sud. Hospices Civils de Lyon. Pierre Benite/PAUTARD, J.C., Hopital Nord. Amiens/PIN, I., INSERM U823 Universite Joseph Fourier. Hopital de la Tronche. Grenoble/PRAMIL, S. Centre Hospitalier Universitaire Charles Nicolle. Rouen/PREVOTAT, A. Hopital Calmette Lille/RAMES, C. Hopital Nord. Amiens/RAULT, G. Centre de Perharidy. Roscoff/REIX, P. Hopital Femme Mere Enfant. Bron/REMUS, N. Centre Hospitalier Intercommunal de Creteil. Creteil/RENOUIL, M., Groupe Hospitalier Sud Reunion. Saint-Pierre de la Reunion/REYNAUD-GAUBERT, M., Hopital Nord. Marseille/RICHAUD THIRIEZ, B. Hopital Jean Minjoz, Besancon/ROUSSEY, M. Universite de Rennes 1. Hopital Sud Annexe Pediatrique. Rennes/SERMETGAUDELUS, I. Necker Hopital d'Enfants Malades. Paris/STREMLER, N. Hopital d'Enfants de la Timone. Marseille/UFFREDI, M.L. Centre Hospitalier Bretagne Atlantique. Vannes/URBAN, T. Centre Hospitalier Universitaire d'Angers. Angers/VIGNERON, P. Centre Hospitalier Bretagne Sud Lorient/WALLAERT, B., Hopital Calmette. Lille/WEISS, L. Hopital de Hautepierre, Strasbourg/WIZLA, N., Hopital Jeanne de Flandre, Lille.",null,29,2,2,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1750-1172",null,null,"ORPHANET J RARE DIS","Orphanet J. Rare Dis.","SEP 7",2012,7,null,null,null,null,null,null,null,64,"10.1186/1750-1172-7-64",null,8,"Medicine, Research & Experimental","Research & Experimental Medicine","053FN","WOS:000312256500001"]
[null,null,null,null,"J","Forsander, G; Pellinat, M; Volk, M; Muller, M; Pinelli, L; Magnen, A; Danne, T; Aschemeier, B; de Beaufort, C",null,null,null,"Forsander, Gun; Pellinat, Martin; Volk, Michael; Muller, Markus; Pinelli, Leonardo; Magnen, Agnes; Danne, Thomas; Aschemeier, Baerbel; de Beaufort, Carine",null,"SWEET Grp","Technical solution for data collection, data safety and data privacy legislation: experiences from the SWEET study","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"data collection; diabetes mellitus; pediatrics; registers; safety; SWEET","QUALITY IMPROVEMENT; CHILDHOOD; IMPLEMENTATION; ADOLESCENTS; CHILDREN","Background One of the most important tasks of the SWEET study is benchmarking the data collected. Information on the occurrence of the disease of diabetes, the treatment, and their outcomes in children from the different member states of European Union (EU) is crucial. How the collection of data is realized is essential, concerning both the technical issues and the results. The creation of SWEET Centers of Reference (CoR), all over Europe will be facilitated by the access to safe data collection, where legal aspects and privacy are ascertained. Objective To describe the rationale for- and the technical procedure in the data collection implementation, in the SWEET study. Subjects Selected data on all patients treated at SWEET CoR are collected. Methods The SWEET project data collection and management system, consists of modular components for data collection, online data interchange, and a database for statistical analysis. Conclusion The SWEET study and the organization of CoR aims for the goal of offering an updated, secure, and continuous evaluation of diabetes treatment regimens for all children with diabetes in Europe. To support this goal, an appropriate and secure data management system as described in this paper has been created.","[Forsander, Gun] Sahlgrens Univ Hosp, Queen Silvia Childrens Hosp, SE-41685 Gothenburg, Sweden; [Pellinat, Martin] Vis Tree Software Inc, San Diego, CA 92108 USA; [Volk, Michael; Muller, Markus] Axaris Software & Syst GmbH, DE-89081 Ulm, Germany; [Pinelli, Leonardo] Univ Verona, Unit Pediat Diabet Nutr & Obes, I-37134 Verona, Italy; [Magnen, Agnes] Sanofi Aventis Grp France, F-75013 Paris, France; [Danne, Thomas; Aschemeier, Baerbel] Kinder & Jugendkrankenhaus AUD DER BULT, Diabet Ctr Children & Adolescents, Hannover, Germany; [de Beaufort, Carine] CHL Luxembourg, DECCP, L-1210 Luxembourg, Luxembourg","Forsander, G (reprint author), Sahlgrens Univ Hosp, Queen Silvia Childrens Hosp, SE-41685 Gothenburg, Sweden.","gun.forsander@vgregion.se",null,null,"Executive Agency for Health and Consumers (EAHC); Bayer HealthCare; Dexcom; Diabetes Foundation UK; Hannoversche Kinderheilanstalt Hanover, Germany; Johnson Johnson; Lilly-Diabetes Excellence Center; Medtronic Foundation; Medtronic; Novo Nordisk; Roche; Sanofi Aventis","The project was supported by the Executive Agency for Health and Consumers (EAHC) as well as through unrestricted educational grants from the following foundations and corporate sponsors: Bayer HealthCare, Dexcom, Diabetes Foundation UK. Hannoversche Kinderheilanstalt Hanover, Germany, Johnson & Johnson, Lilly-Diabetes Excellence Center, Medtronic Foundation, Medtronic, Novo Nordisk, Roche, Sanofi Aventis.","Collmann C, 2004, TELEMED J E-HEALTH, V10, P311; DCCT Res Grp, 1994, J PEDIATR-US, V125, P177; Ducan B, 1974, Pediatrics, V54, P497; Gudbjornsdottir S, 2003, DIABETES CARE, V26, P1270, DOI 10.2337/diacare.26.4.1270; Hanberger L, 2008, DIABETES CARE, V31, P927, DOI 10.2337/dc07-1863; Jaisson S, 2011, ANN BIOL CLIN-PARIS, V69, P63, DOI 10.1684/abc.2010.0511; Margeirsdottir HD, 2010, PEDIATR DIABETES, V11, P88, DOI 10.1111/j.1399-5448.2009.00542.x; Milton B, 2006, DIABETIC MED, V23, P821, DOI 10.1111/j.1464-5491.2006.01796.x; Munthe C, 2012, HEALTH CARE ANAL, V20, P231, DOI 10.1007/s10728-011-0183-y; Patterson CC, 2009, LANCET, V373, P2027, DOI 10.1016/S0140-6736(09)60568-7; Simckes AM, 2002, CLIN PEDIATR, V41, P549, DOI 10.1177/000992280204100801",11,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1399-543X","1399-5448",null,"PEDIATR DIABETES","Pediatr. Diabetes","SEP",2012,13,null,null,16,"SI",null,39,48,null,"10.1111/j.1399-5448.2012.00911.x",null,10,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","996OO","WOS:000308100400006"]
[null,null,null,null,"J","Danne, T; Lion, S; Madaczy, L; Veeze, H; Raposo, F; Rurik, I; Aschemeier, B; Kordonouri, O",null,null,null,"Danne, Thomas; Lion, Sylvia; Madaczy, Lazlo; Veeze, Henk; Raposo, Fillipe; Rurik, Imre; Aschemeier, Baerbel; Kordonouri, Olga",null,"SWEET Grp","Criteria for Centers of Reference for pediatric diabetes - a European perspective","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"audit; electronic health record; HbA1c; quality control; reference centers","METABOLIC-CONTROL; CHILDREN; ADOLESCENTS; MELLITUS; GERMANY; CARE","SWEET is an acronym standing for Better control in pediatric and adolescent diabeteS: Working to crEate CEnTers of Reference (CORs) and is based on a partnership of established national and European diabetes organizations such as International Diabetes Federation, Federation of European Nurses in Diabetes, and Primary Care Diabetes Europe (PCDE, www.sweet-project.eu). A three-level classification of centers has been put forward. In addition to centers for local care, SWEET collaborating centers on their way to being a COR have been defined. Peer-audited CORs with a continuous electronic documentation of at least 150 pediatric patients with diabetes treated by a multidisciplinary team based on the International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice recommendations have been created in 12 European countries. In 2011, they cared for between 150 to more than 700 youth with diabetes with an average hemoglobin A1c between 7.6 and 9.2%. Although these clinics should not be regarded as representative for the whole country, the acknowledgment as COR includes a common objective of targets and guidelines as well as recognition of expertise in treatment and education at the center. In a first step, the SWEET Online platform allows 12 countries using 11 languages to connect to one unified diabetes database. Aggregate data are de-identified and exported for longitudinal health and economic data analysis. Through their network, the CORs wish to obtain political influence on a national and international level and to facilitate dissemination of new approaches and techniques. The SWEET project hopes to extend from the initial group of centers within countries, throughout Europe, and beyond with the help of the ISPAD network.","[Danne, Thomas; Aschemeier, Baerbel; Kordonouri, Olga] Kinder & Jugendkrankenhaus AUF DER BULT, D-30173 Hannover, Germany; [Lion, Sylvia] Lilly Diabet, Global Advocacy & Profess Relat, F-92158 Suresnes, France; [Madaczy, Lazlo] Semmelweis Univ, Dept Pediat 1, Budapest, Hungary; [Veeze, Henk] Stichting Diabeter, NL-3011 TG Rotterdam, Netherlands; [Raposo, Fillipe] APDP, P-1250203 Lisbon, Portugal; [Rurik, Imre] Debrecen Univ Med, Dept Family & Occupat Med, H-4032 Debrecen, Hungary; [Rurik, Imre] Primary Care Diabet Europe, Ekeren, Belgium","Danne, T (reprint author), Kinder & Jugendkrankenhaus AUF DER BULT, Janusz Korczak Allee 12, D-30173 Hannover, Germany.","danne@hka.de",null,null,null,null,"Cinek O, 2012, PEDIATR DIABETES, V13, P5, DOI 10.1111/j.1399-5448.2012.00907.x; Danne T, 2001, DIABETES CARE, V24, P1342, DOI 10.2337/diacare.24.8.1342; de Beaufort CE, 2007, DIABETES CARE, V30, P2245, DOI 10.2337/dc07-0475; DCCT Res Grp, 1994, J PEDIATR-US, V125, P177; Forsander G, 2012, PEDIATR DIABETES, V13, P39, DOI 10.1111/j.1399-5448.2012.00911.x; Gerstl EM, 2008, EUR J PEDIATR, V167, P447, DOI 10.1007/s00431-007-0586-9; Hanas R, 2009, PEDIATR DIABETES, V10, P1, DOI 10.1111/j.1399-5448.2009.00577.x; Hanberger L, 2008, DIABETES CARE, V31, P927, DOI 10.2337/dc07-1863; Milton B, 2006, DIABETIC MED, V23, P821, DOI 10.1111/j.1464-5491.2006.01796.x; Mortensen HB, 1997, DIABETES CARE, V20, P714, DOI 10.2337/diacare.20.5.714; Munthe C, 2012, HEALTH CARE ANAL, V20, P231, DOI 10.1007/s10728-011-0183-y; Patterson CC, 2009, LANCET, V373, P2027, DOI 10.1016/S0140-6736(09)60568-7; Summersett G M, 2003, Pediatr Diabetes, V4, P137, DOI 10.1034/j.1399-5448.2003.t01-1-00020.x; Swift PGF, 2010, PEDIATR DIABETES, V11, P271, DOI 10.1111/j.1399-5448.2009.00596.x; von Sengbusch S, 2006, DIABETIC MED, V23, P122, DOI 10.1111/j.1464-5491.2005.01754.x",15,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","SEP",2012,13,null,null,16,"SI",null,62,75,null,"10.1111/j.1399-5448.2012.00914.x",null,14,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","996OO","WOS:000308100400008"]
[null,null,null,null,"J","Bezdicek, O; Motak, L; Axelrod, BN; Preiss, M; Nikolai, T; Vyhnalek, M; Poreh, A; Ruzicka, E",null,null,null,"Bezdicek, Ondrej; Motak, Ladislav; Axelrod, Bradley N.; Preiss, Marek; Nikolai, Tomas; Vyhnalek, Martin; Poreh, Amir; Ruzicka, Evzen",null,null,"Czech Version of the Trail Making Test: Normative Data and Clinical Utility","ARCHIVES OF CLINICAL NEUROPSYCHOLOGY",null,null,"English","Article",null,null,null,null,null,"Trail Making Test; Czech; amnestic mild cognitive impairment; Alzheimers disease; normative data","NEUROPSYCHOLOGICAL TEST-PERFORMANCE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; TEST INDEXES; TEST-A; TEST-B; AGE; NORMS; DEMENTIA","The Trail Making Test (TMT) comprises two psychomotor tasks that measure a wide range of visual-perceptual and executive functions. The purpose of this study was to provide Czech normative data and to examine the relationship between derived TMT indices and demographic variables. The TMT was administered to 421 healthy adults. Two clinical groups (n 126) were evaluated to investigate the clinical utility of the TMT-derived scores: amnestic mild cognitive impairment (n 90) and Alzheimers disease (n 36). Statistical analyses showed that age and education, but not gender, were significantly associated with TMT completion times and derived scores. Of all the indices, only the TMT ratio score was insensitive to age. We present normative values for the Czech version of the TMT, providing a reference for measuring individual performance in native Czech speakers. Moreover, we found that accuracy on the TMT was improved with the attenuation of age.","[Bezdicek, Ondrej; Nikolai, Tomas; Ruzicka, Evzen] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague 12821 2, Czech Republic; [Bezdicek, Ondrej; Nikolai, Tomas; Ruzicka, Evzen] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague 12821 2, Czech Republic; [Bezdicek, Ondrej; Nikolai, Tomas; Ruzicka, Evzen] Charles Univ Prague, Gen Univ Hosp Prague, Prague 12821 2, Czech Republic; [Motak, Ladislav] Univ Lyon, Lyon, France; [Motak, Ladislav] LESCOT, IFSTTAR, Bron, France; [Axelrod, Bradley N.] John D Dingell Dept Vet Affairs Med Ctr, Detroit, MI USA; [Preiss, Marek] Charles Univ Prague, Fac Med 3, Prague Psychiat Ctr, Prague 12821 2, Czech Republic; [Vyhnalek, Martin] Charles Univ Prague, Fac Med 2, Dept Neurol, Memory Disorders Clin, Prague 12821 2, Czech Republic; [Vyhnalek, Martin] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Poreh, Amir] Cleveland State Univ, Cleveland, OH 44115 USA","Bezdicek, O (reprint author), Charles Univ Prague, Fac Med 1, Dept Neurol, Katerinska 30, Prague 12821 2, Czech Republic.","ondrejb@yahoo.com",null,null,"Czech Ministry of Education [MSM0021620849, GAUK 251196 118410, MSMT 1M0517]; European Regional Development Fund [FNUSA-ICRC CZ.1.05/1.1.00/02.0123]","The work was supported by grants from the Czech Ministry of Education (Research Program MSM0021620849, GAUK 251196 118410, and MSMT 1M0517) and by the European Regional Development Fund (Project FNUSA-ICRC CZ.1.05/1.1.00/02.0123).",null,55,1,1,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0887-6177",null,null,"ARCH CLIN NEUROPSYCH","Arch. Clin. Neuropsychol.","DEC",2012,27,8,null,null,null,null,906,914,null,"10.1093/arclin/acs084",null,9,"Psychology, Clinical; Psychology","Psychology","044RO","WOS:000311641000009"]
[null,null,null,null,"J","van Stralen, KJ; Krischock, L; Schaefer, F; Verrina, E; Groothoff, JW; Evans, J; Heaf, J; Ivanov, D; Kostic, M; Maringhini, S; Podracka, L; Printza, N; Pundziene, B; Reusz, GS; Vondrak, K; Jager, KJ; Tizard, EJ",null,null,null,"van Stralen, Karlijn J.; Krischock, Leah; Schaefer, Franz; Verrina, Enrico; Groothoff, Jaap W.; Evans, Jonathan; Heaf, James; Ivanov, Dimitar; Kostic, Mirjana; Maringhini, Silvio; Podracka, Ludmila; Printza, Nikoleta; Pundziene, Birute; Reusz, Gyorgy S.; Vondrak, Karel; Jager, Kitty J.; Tizard, E. Jane",null,"ESPN ERA-EDTA Registry","Prevalence and predictors of the sub-target Hb level in children on dialysis","NEPHROLOGY DIALYSIS TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"anaemia; children; dialysis; Hb","CHRONIC KIDNEY-DISEASE; ERYTHROPOIESIS-STIMULATING AGENTS; PEDIATRIC HEMODIALYSIS-PATIENTS; PERFORMANCE MEASURES PROJECT; RENAL-FAILURE; HEMOGLOBIN TARGETS; MAINTENANCE HEMODIALYSIS; ANEMIA; MORTALITY; ADOLESCENTS","Background. Anaemia is a common and potentially treatable co-morbidity of end-stage renal disease. We aimed to determine the prevalence of the sub-target haemoglobin (Hb) level among European children on dialysis and to identify factors associated with a low Hb level. Methods. From the European Society for Paediatric Nephrology (ESPN)/European Renal Association-European Dialysis Transplant Association (ERA-EDTA) registry, data were available on 2351 children between 1 month and 18 years of age, totalling 5546 measurements from 19 countries. Results. The mean Hb level was 10.8 g/dL (5th-95th percentiles, 7.4-13.9). Among those above 2 years of age, the mean Hb level was 10.9 g/dL (11.4% below 8.5 g/dL), while it was 10.3 g/dL among those below 2 years (11.2% below 8.0 g/dL). A total of 91.2% of the patients were on an erythropoiesis-stimulating agent (ESA). Hb levels increased with age and were higher in peritoneal dialysis compared with haemodialysis patients. Patients with congenital anomalies of the kidney and urinary tract showed the highest Hb levels, and those with cystic kidney diseases or metabolic disorders the lowest ones. Ferritin levels between 25 and 50 ng/mL were associated with the highest Hb levels. We found a weak inverse association between parathyroid hormone (PTH) and Hb. Whereas standardized blood pressure (BP) was not elevated in patients with above-target Hb, elevated systolic BP z-score was noted in those with sub-target Hb levels. Conclusions. Sub-target Hb levels remain common in children on dialysis, in spite of virtually all children being treated with ESA; although we cannot exclude under-dosing. Optimal ferritin levels seemed to be slightly lower in children (25-50 ng/mL) than those in adults. Other risk factors for sub-target Hb are dialysis modality and a high PTH level.","[van Stralen, Karlijn J.; Groothoff, Jaap W.; Jager, Kitty J.] Univ Amsterdam, Acad Med Ctr, Dept Med Informat, NL-1105 AZ Amsterdam, Netherlands; [Krischock, Leah] Royal Hosp Sick Children, Dept Paediat Nephrol, Glasgow G3 8SJ, Lanark, Scotland; [Schaefer, Franz] Univ Heidelberg, Ctr Pediat & Adolescent Med, Heidelberg, Germany; [Evans, Jonathan] Nottingham Univ Hosp NHS Trust, Dept Paediat Nephrol, Nottingham, England; [Verrina, Enrico] G Gaslini Hosp, Genoa, Italy; [Heaf, James] Univ Copenhagen, Herlev Hosp, Dept Nephrol, DK-2730 Herlev, Denmark; [Ivanov, Dimitar] Univ Kiev, Dept Pediat Nephrol, Kiev, Ukraine; [Kostic, Mirjana] Univ Childrens Hosp, Dept Nephrol, Belgrade, Serbia; [Maringhini, Silvio] G Di Cristina Childrens Hosp, Paediat Nephrol Unit, Palermo, Italy; [Podracka, Ludmila] Klin Deti & Dorastu LF UPJS & DFN, Kosice, Slovakia; [Printza, Nikoleta] Aristotle Univ Thessaloniki, Dept Pediat 1, GR-54006 Thessaloniki, Greece; [Pundziene, Birute] Hosp Lithuanian Univ Hlth Sci, Pediat Nephrol Dept, Kaunas, Lithuania; [Reusz, Gyorgy S.] Semmelweis Univ Budapest, Budapest, Hungary; [Vondrak, Karel] Univ Hosp Prague Motol, Prague, Czech Republic; [Tizard, E. Jane] Bristol Royal Hosp Children, Bristol, Avon, England","van Stralen, KJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Med Informat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.","K.J.vanStralen@amc.uva.nl",null,null,"European Society of Paediatric Nephrology (ESPN); European Renal Association; European Dialysis and Transplant Association (ERA-EDTA); NephroQUEST project; European Union [2006114]","We would like to thank the patients, their parents and the staff of all the dialysis and transplant units who have contributed data via their national registries and contact persons. We also would like to thank P. Cochat, R. Coppo, D. Haffner and M. Lewis for being members of the ESPN/ERA-EDTA Registry Committee, D. Shitza, R. Kramar, R. Oberbauer, S. Baiko, A. Sukalo, K. van Hoeck, F. Collart, J.M. des Grottes, R. Lombaerts, D. Pokrajac, D. Roussinov, Z. Puretic, D. Batinic, T. Seeman, K. V., J.H., U. Toots, P. Finne, C. Gronhagen-Riska, C. Holmberg, C. Couchoud, P. Niaudet, L. le Mignot, E. Sahpazova, G. Gersdorf, C. Scholz, G. Ioannidis, G. Reusz, S. Turi, L. Szabo, T. Szabo, F. Paglialonga, S. Picca, E. Vidal, A. Jankauskiene, S. Pavicevic, T. Leivestad, D. Brackman, A. Zurowska, I. Zagozdzon, C. Mota, M. Almeida, C. Afonso, G. Mircescu, L. Garneata, E. Podgoreanu, M. Gafencu, E. A. Molchanova, N.A. Tomilina, B. T. Bikbov, A. Peco-Antic, M. K., B. Spasojevic-Dimitrijeva, D. Paripovic, L. Podracka, G. Kolvek, J. Buturovic-Ponikvar, G. Novljan, N. Battelino, A. Alonso Melgar and the Spanish Pediatric Registry, S. Schon, J. K. G. Prutz, A. Seeberger, L. Backman, M. Herthelius, C. E. Kuenhi, E. Maurer, A. Hoitsma, A. Hemke, W. F. Tromp, N. Schoenmaker, R. Topaloglu, D. I., D. Ansell and C. Inward for contributing data to the ESPN/ERA-EDTA Registry. The ESPN/ERA-EDTA registry is funded by the European Society of Paediatric Nephrology (ESPN), the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) and the NephroQUEST project. The NephroQUEST project has received funding from the European Union in the framework of the Public Health Programme (project number 2006114). Furthermore, Amgen has provided an unrestricted grant to assist the ESPN in the financial support of the Registry.",null,38,1,1,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0931-0509",null,null,"NEPHROL DIAL TRANSPL","Nephrol. Dial. Transplant.","OCT 10",2012,27,10,null,null,null,null,3950,3957,null,"10.1093/ndt/gfs178",null,8,"Transplantation; Urology & Nephrology","Transplantation; Urology & Nephrology","031IA","WOS:000310631500043"]
[null,null,null,null,"J","Lange, K; Klotmann, S; Sassmann, H; Aschemeier, B; Wintergerst, E; Gerhardsson, P; Kordonouri, O; Szypowska, A; Danne, T",null,null,null,"Lange, Karin; Klotmann, Susan; Sassmann, Heike; Aschemeier, Baerbel; Wintergerst, Eva; Gerhardsson, Peter; Kordonouri, Olga; Szypowska, Agnieszka; Danne, Thomas",null,"SWEET Grp","A pediatric diabetes toolbox for creating centres of reference","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"children; education program; multidisciplinary care; parents; SWEET","ADOLESCENTS; CHILDREN; EDUCATION; INTERVENTIONS; MELLITUS; OUTCOMES; YOUTH; CARE","Introduction ISPAD guidelines recommend age appropriate diabetes education concepts for young patients and their families as well as tools for nutritional management, psychosocial assessment, and psychological advice but their implementation in Europe is presently unknown. Methods On the basis of a structured survey among the European SWEET members information on established tools and programs in national languages were analyzed using an extensive literature and desk search. These were differentiated according to five age-groups and five target groups (young people with diabetes, parents, and other close relations, carers in school and nursery, and healthcare professionals). Results Responses and original tools were received from 11 SWEET countries reflecting the European status in 2011. More or less structured information for parents, close relations, and carers in school or nursery are available in all 11 participating countries. However, only two countries followed the recommendations of having published a structured, curriculum lead, and evaluated program for different age-groups and carers. One of these was evaluated nationwide and funded by the respective National Health Care System after accreditation. In addition a huge variety of creative tools, e.g., booklets, leaflets, games, videos, and material for educating children of different age-groups and their parents are available but most of them are not linked to a structured education program. Conclusions Harmonizing and integrating these materials into quality assured structured holistic national education programs will be an important future task for the ongoing SWEET project. A comprehensive European diabetes educational toolbox is aimed to be published and continuously updated on the SWEET website.","[Lange, Karin; Sassmann, Heike] Hannover Med Sch, Dept Med Psychol, D-30625 Hannover, Germany; [Klotmann, Susan; Aschemeier, Baerbel; Kordonouri, Olga; Danne, Thomas] Kinder & Jugendkrankenhaus AUF DER BULT, Diabet Ctr Children & Adolescents, Hannover, Germany; [Wintergerst, Eva] Bayer Consumer Care AG, Diabet Care, Basel, Switzerland; [Gerhardsson, Peter] DexCom Inc, San Diego, CA USA; [Szypowska, Agnieszka] Med Univ Warsaw, Dept Paediat, Warsaw, Poland","Lange, K (reprint author), Hannover Med Sch, Dept Med Psychol, OE 5430,Carl Neuberg Str 1, D-30625 Hannover, Germany.","lange.karin@mh-hannover.de",null,null,null,null,"Arbeitsgemeinschaft fur Padiatrische Diabetologie, 2011, INF TEACH; Association Luxembourgeoise du Diabete, 2012, BEH MEIN DIAB 2 6 JA, P1; Australasian Paediatric Endocrine Group, 2004, CLIN PRACT GUID TYP; Blasig S, 2011, PEDIAT DIABETES S15, V12, P72; Couch R, 2008, EVIDENCE REPORTS TEC; DAWN Study Group, 2007, CHANG DIAB DAWN YOUT; Delamater AM, 2009, PEDIATR DIABETES, V10, P175, DOI 10.1111/j.1399-5448.2009.00580.x; DH Diabetes Policy Team, 2007, MAK EV YOUNG PERS DI; Funnell MM, 2010, DIABETES CARE, V33, pS89, DOI 10.2337/dc10-S089; Gage H, 2004, PATIENT EDUC COUNS, V53, P333, DOI 10.1016/j.pec.2003.06.003; Grey M, 2000, J PEDIATR-US, V137, P107, DOI 10.1067/mpd.2000.106568; Hampson SE, 2000, DIABETES CARE, V23, P1416, DOI 10.2337/diacare.23.9.1416; Holterhus PM, 2009, DIAGNOSTIK THERAPIE, P1; Hurter P, 2008, KOMPENDIUM PADIATRIS, P1; Hurter P, 2011, KINDER JUGENDLICHE D, P1; Hurter P, 2005, DIABETES KINDERN BEH, P1; IDF Consultative Section on Diabetes Education, 2008, INT CURR DIAB HLTH P; Kulzer B, 2011, DIABETOL STOFFWECHS, V6, pS143; Laffel LMB, 2003, J PEDIATR-US, V142, P409, DOI 10.1067/mpd.2003.138; Lange K, 2001, DIABETES STOFFWECH H, V10, p59 ; Lange K, 1998, DIABETES STOFFWEC S1, V7, P62; Lange K, 2011, DEUT MED WOCHENSCHR, V136, P1106, DOI 10.1055/s-0031-1280518; Lange K, 2009, DID LEITF CURR ZUM P, V2; Lange K, 2009, DIABETES BASICS, p[1, 1, 1, 1]; Le Conseil d'Administration de l'AJD, 2011, AID JEUN DIAB; Le Conseil d'Administration de l'AJD AJD, 2011, SEQUENCES AJD; Murphy HR, 2006, DIABETIC MED, V23, P935, DOI 10.1111/j.1464-5491.2005.01816.x; National Institute for Clinical Excellence in UK (NICE), 2004, NAT I CLIN EXC UK NI; Neuman D, 2008, END ABSTR, V17, pP51; Nordfeldt S, 2005, ACTA PAEDIATR, V94, P1395, DOI 10.1080/08035250510039874; Nordfeldt S, 2002, PRACTICAL DIABETES I, V19, P131, DOI 10.1002/pdi.363; P eruUicova J, 2007, DIABETES MELLITUS 1; Rains JC, 2005, HEADACHE, V45, P479, DOI 10.1111/j.1526-4610.2005.05099.x; Silverstein J, 2005, DIABETES CARE, V28, P186, DOI 10.2337/diacare.28.1.186; SWIFT PGF, 2000, ISPAD INT SOC PED AD; Swift PGF, 2009, PEDIATR DIABETES, V10, P51, DOI 10.1111/j.1399-5448.2009.00570.x",36,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","SEP",2012,13,null,null,16,"SI",null,49,61,null,"10.1111/j.1399-5448.2012.00913.x",null,13,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","996OO","WOS:000308100400007"]
[null,null,null,null,"J","Coenen, EA; Driessen, EMC; Zwaan, CM; Stary, J; Baruchel, A; de Haas, V; de Bont, ESJM; Reinhardt, D; Kaspers, GJL; Arentsen-Peters, STCJM; Meyer, C; Marschalek, R; Pieters, R; Stam, RW; van den Heuvel-Eibrink, MM",null,null,null,"Coenen, Eva A.; Driessen, Emma M. C.; Zwaan, C. Michel; Stary, Jan; Baruchel, Andre; de Haas, Valerie; de Bont, Eveline S. J. M.; Reinhardt, Dirk; Kaspers, Gertjan J. L.; Arentsen-Peters, Susan T. C. J. M.; Meyer, Claus; Marschalek, Rolf; Pieters, Rob; Stam, Ronald W.; van den Heuvel-Eibrink, Marry M.",null,null,"CBL mutations do not frequently occur in paediatric acute myeloid leukaemia","BRITISH JOURNAL OF HAEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"CBL; RAS-pathway; acute myeloid leukaemia; infant acute lymphoblastic leukaemia; MLL-rearrangements","ACUTE LYMPHOBLASTIC-LEUKEMIA; ACQUIRED UNIPARENTAL DISOMY; C-CBL; MYELOMONOCYTIC LEUKEMIA; ONCOGENIC KRAS; EXPRESSION; RESISTANCE; CELLS; MODEL; FLT3","RAS-pathway mutations, causing a proliferative advantage, occur in acute myeloid leukaemia (AML) and MLL-rearranged leukaemia. Recently, mutations in the Casitas B lineage lymphoma (CBL) gene were reported to be involved in RAS-pathway activation in various myeloid malignancies, but their role in paediatric AML is still unknown. We performed mutation analysis of 283 newly diagnosed and 33 relapsed paediatric AML cases. Only two mutant cases (0.7%) were identified in the newly diagnosed paediatric AML samples, of which one was MLL-rearranged. Both mutant cases showed CBL mRNA expression in the range of the non-mutated cases. Phosphorylated extracellular signal-regulated kinase (pERK) was not correlated with CBL protein expression (n = 11). In conclusion, we report a very low CBL mutation frequency in paediatric AML, which, together with the lack of difference in protein and mRNA expression, illustrates the limited role of CBL in paediatric AML.","[Coenen, Eva A.; Driessen, Emma M. C.; Zwaan, C. Michel; Arentsen-Peters, Susan T. C. J. M.; Pieters, Rob; Stam, Ronald W.; van den Heuvel-Eibrink, Marry M.] Erasmus MC Sophia Childrens Hosp, Dept Paediat Oncol Haematol, NL-3000 CB Rotterdam, Netherlands; [Stary, Jan] Charles Univ Prague, Med Sch 2, Dept Paediat Haematol Oncol, Prague, Czech Republic; [Baruchel, Andre] St Louis Hosp, Dept Haematol, Paris, France; [de Haas, Valerie; Pieters, Rob] DCOG, The Hague, Netherlands; [de Bont, Eveline S. J. M.] Univ Groningen, Beatrix Childrens Hosp, Univ Med Ctr Groningen, Dept Paediat Oncol Haematol, Groningen, Netherlands; [Reinhardt, Dirk] AML BFM Study Grp, Hannover, Germany; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam, Med Ctr, Dept Paediat Oncol Haematol, Amsterdam, Netherlands; [Meyer, Claus; Marschalek, Rolf] DCAL, ZAFES, Inst Pharmaceut Biol, Frankfurt, Germany","van den Heuvel-Eibrink, MM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Paediat Oncol Haematol, Room Sp2568,Dr Molewaterpl 60,POB 2060, NL-3000 CB Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","Rotterdam Oncology Research Foundation 'KOCR'; foundation KiKa 'Kinderen kankervrij'","The authors would like to thank the members and participating institutes of the INTERFANT-99 study for generously providing leukaemic samples. This work was supported by the Rotterdam Oncology Research Foundation 'KOCR' (EAC) and the foundation KiKa 'Kinderen kankervrij' (EAC, EMCD, STA-P, RWS). The institutions financially supporting this study had no role in study design, data collection, data analysis, data interpretation or writing of the report.",null,37,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0007-1048",null,null,"BRIT J HAEMATOL","Br. J. Haematol.","DEC",2012,159,5,null,null,null,null,577,584,null,"10.1111/bjh.12068",null,8,"Hematology","Hematology","035VY","WOS:000310980700013"]
[null,null,null,null,"J","Buggiani, G; Tsampau, D; Hercogova, J; Rossi, R; Brazzini, B; Lotti, T",null,null,null,"Buggiani, Gionata; Tsampau, Dionigi; Hercogova, Jana; Rossi, Riccardo; Brazzini, Benedetta; Lotti, Torello",null,null,"Clinical efficacy of a novel topical formulation for vitiligo: compared evaluation of different treatment modalities in 149 patients","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"phototherapy; treatments; vitiligo",null,"Current vitiligo treatments are not always satisfactory for both patients and dermatologists. Recently, combination therapies have been introduced in order to obtain better results and reduce risks in the management of the disease. Novel efficacious products are needed to improve the therapeutic possibilities of dermatologists in the respect of safety for the patients. The objective of the present study was to evaluate the effects of a novel topical in a gel formulation containing phenylalanine, cucumis melo extract, and acetyl cysteine in vitiligo. The present study used an open observational study to evaluate the efficacy and safety of the investigated product, given alone or in combination with 311-nm narrow band microphototherapy. Results were compared with those obtained treating a matched patient population with microphototherapy alone and with clobetasol propionate 0.05% ointment alone. One hundred forty-nine patients suffering from symmetrical vitiligo affecting less than 10% of the skin surface were evaluated. Patients affected by acral vitiligo only were excluded from the analysis. Treatment duration was scheduled for 12 weeks. Excellent repigmentation (>75%) was achieved by 3873% of patients, depending on the treatment regimen. Mild to moderate side effects were observed only in patients treated with clobetasol 0.05% ointment. The tested gel formulation showed a good efficacy in improving vitiligo repigmentation. No side effects were observed.","[Buggiani, Gionata; Lotti, Torello] Univ Florence, Sch Med, Florence, Italy; [Tsampau, Dionigi; Rossi, Riccardo] Azienda Sanit Firenze, Florence, Italy; [Hercogova, Jana] Charles Univ Prague, Dept Dermatol, Fac Med 2, Prague, Czech Republic; [Brazzini, Benedetta] Univ London Imperial Coll Sci Technol & Med, London, England","Buggiani, G (reprint author), Via Leonardo da Vinci 66, I-50053 Florence, Italy.","g.buggiani@gmail.com",null,null,null,null,null,10,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","SEP-OCT",2012,25,5,null,null,"SI",null,472,476,null,"10.1111/j.1529-8019.2012.01484.x",null,5,"Dermatology","Dermatology","017QK","WOS:000309605300013"]
[null,null,null,null,"J","Martin, D; Lange, K; Sima, A; Kownatka, D; Skovlund, S; Danne, T; Robert, JJ",null,null,null,"Martin, Delphine; Lange, Karin; Sima, Alexandra; Kownatka, Dagmar; Skovlund, Soren; Danne, Thomas; Robert, Jean-Jacques",null,"SWEET Grp","Recommendations for age-appropriate education of children and adolescents with diabetes and their parents in the European Union","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"education; guidelines; recommendations; SWEET; type 1 diabetes","CARE","Education is the keystone of diabetes care, and structured self-management education is the key to a successful outcome. Existing guidelines provide comprehensive guidance on the various aspects of education and offer general and organizational principles of education, detailed curricula at different ages and stages of diabetes, and recommendations on models, methods, and tools to attain educative objectives. The International Society for Pediatric and Adolescent Diabetes guidelines give the most elaborate and detailed descriptions and recommendations on the practice of education, which other national guidelines address on specific aspects of education and care. The aim of the work package on education developed by Better Control in Paediatric and Adolescent Diabetes in the European Union: Working to Create Centers of Reference (SWEET) project was not to generate new guidelines but to evaluate how the existing guidelines were implemented in some pediatric diabetes reference centers. The SWEET members have completed a questionnaire that elaborates on the many aspects of delivery of education. This survey highlights a profound diversity of practices across centers in Europe, in terms of organization as well as the practices and the content of initial and continuing education. A toolbox is being developed within SWEET to facilitate exchanges on all aspects of education and to establish a process of validation of materials, tools, written structured age-adjusted programs, and evaluation procedures for the education of children and adolescents with diabetes.","[Martin, Delphine; Robert, Jean-Jacques] Univ Paris 05, Hop Necker Enfants Malad, F-75743 Paris 15, France; [Lange, Karin] Hannover Med Sch, Dept Med Psychol, D-3000 Hannover, Germany; [Sima, Alexandra] Fdn Cristian Serban, Ctr Med Clin Evaluare & Recuperare Copii & Adoles, Buzias 1919, Romania; [Kownatka, Dagmar] Roche Diagnost Deutschland GmbH, D-68305 Mannheim, Germany; [Skovlund, Soren] Novo Nordisk AS, Global Patient Res, DK-22880 Bagsvaerd, Denmark; [Danne, Thomas] Kinder & Jugendkrankenhaus AUF DER BULT, Diabet Ctr Children & Adolescents, Diabet Zentrum Kinder & Jugendliche, Hannover, Germany","Robert, JJ (reprint author), Univ Paris 05, Hop Necker Enfants Malad, 149 Rue Sevres, F-75743 Paris 15, France.","jean-jacques.robert@nck.aphp.fr",null,null,null,null,"Aanstoot HJ, 2009, PEDIATR DIABETES, V10, P21, DOI 10.1111/j.1399-5448.2009.00611.x; Aanstoot HJ, 2007, PEDIATR DIABETES, V8, P8, DOI 10.1111/j.1399-5448.2007.00326.x; ADA Position Statement, 2004, DIABETES CARE S1, V27, pS1228; ANDERSON RM, 1995, DIABETES CARE, V18, P943, DOI 10.2337/diacare.18.7.943; Australasian Paediatric Endocrine Group, 2004, CLIN PRACT GUID TYP; Barlow JH, 2004, CHILD CARE HLTH DEV, V30, P637, DOI 10.1111/j.1365-2214.2004.00474.x; Diabetes UK Department of Health, 2005, STRUCT PAT ED DIAB R; Hampson S E, 2001, Health Technol Assess, V5, P1; Holterhus PM, 2009, DIAGNOSTIK THERAPIE, pS1; International Diabetes Federation (IDF), 2003, INT STAD DIAB ED; [ISPAD Clinical Practice Consensus Guidelines 2009 Compendium International Society for Pediatric and Adolescent Diabetes], 2007, PEDIAT DIABETES, V8, P103; Lange K, 2007, PEDIATR DIABETES, V8, P63, DOI 10.1111/j.1399-5448.2007.00277.x; Lange K, 2009, PEDIATR DIABETES, V10, P28, DOI 10.1111/j.1399-5448.2009.00613.x; Mensing C, 2005, DIABETES CARE, V28, pS72, DOI 10.2337/diacare.28.suppl_1.S72; National Institute for Clinical Excellence UK (NICE), 2003, GUID US PAT ED MOD; National Institute for Clinical Excellence UK (NICE), 2004, TYP 1 DIAB DIAGN MAN; Silverstein J, 2005, DIABETES CARE, V28, P186, DOI 10.2337/diacare.28.1.186",17,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","SEP",2012,13,null,null,16,"SI",null,20,28,null,"10.1111/j.1399-5448.2012.00909.x",null,9,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","996OO","WOS:000308100400004"]
[null,null,null,null,"J","Waldron, S; Rurik, I; Madacsy, L; Donnasson-Eudes, S; Rosu, M; Skovlund, SE; Pankowska, E; Allgrove, J",null,null,null,"Waldron, Sheridan; Rurik, Imre; Madacsy, Laszlo; Donnasson-Eudes, Sylvie; Rosu, Mihaela; Skovlund, Soren Eik; Pankowska, Ewa; Allgrove, Jeremy",null,"SWEET Grp","Good practice recommendations on paediatric training programmes for health care professionals in the EU","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"children; multidisciplinary; recommendations; standards; SWEET; training; type 1 diabetes","METABOLIC-CONTROL; ADOLESCENTS; CHILDREN; ENDOCRINOLOGY","Part of the SWEET Project: EU (European Union), Better Control in Paediatric and Adolescent Diabetes: Working to Create Centres of Reference, was specifically to examine the training of health care professionals (HCPs) across the EU. Several types of information were collected during 2009, and these included a literature search, workshops of the SWEET members, examination of the data collected by the Hvidore Study Group and the Diabetes Attitudes, Wishes, and Needs (DAWN) Youth initiative, and a questionnaire distributed to SWEET members and professional colleagues who cared for children and young people (CYP) with diabetes. It was clear from the information collected that there was no European or global consensus either on a curriculum for the training of the paediatric diabetes multidisciplinary team (MDT) or individual professions in paediatric diabetes. A minority of countries had well-established training but, for the majority, there was little standardisation or accreditation. Moreover, most countries did not have available courses for training the diabetes MDT and training was not mandatory. Of the courses that were available more were accredited for doctors and nurses but fewer for the other professions. As a consequence, the majority of HCP posts in paediatric diabetes do not demand prior experience in the specialty. Standardised accredited training and continuous professional development (CPD) opportunities are severely limited. The SWEET Project supports a standardised, accredited approach to training and CPD of the MDT and for individual professions. As a consequence, a curriculum for the training of the MDT was developed, and this is now ready for implementation.","[Waldron, Sheridan; Allgrove, Jeremy] Barts Hlth NHS Trust, Royal London Hosp, London E1 1BB, England; [Rurik, Imre] Debrecen Univ Med, Fac Publ Hlth, Dept Family & Occupat Med, H-4032 Debrecen, Hungary; [Madacsy, Laszlo] Semmelweis Univ, Dept Paediat, Budapest, Hungary; [Donnasson-Eudes, Sylvie] Johnson & Johnson Diabet Inst EMEA, Paris, France; [Rosu, Mihaela] Fdn Cristian Serban, Ctr Med Clin Evaluare & Recuperare Copii & Adoles, Buzias 1919, Romania; [Rosu, Mihaela] Univ Med & Farm Timisoara, Timisoara, Romania; [Skovlund, Soren Eik] Novo Nordisk AS, Global Patient Res, DK-22880 Bagsvaerd, Denmark; [Pankowska, Ewa] Inst Mother & Child Hlth, Dept Paediat, PL-01122 Warsaw, Poland","Waldron, S (reprint author), Barts Hlth NHS Trust, Royal London Hosp, London E1 1BB, England.","sheridan.waldron@btinternet.com",null,null,"European Union; SWEET; Diabetes Foundation, UK","We wish to thank Professor Thomas Danne for initiating and leading the SWEET Project, Dr Barbel Aschemeier for her organisational skills and support, and the European Union Public Health Programme and SWEET corporate sponsors for financially making the project viable. We wish especially to thank the Diabetes Foundation, UK, a charity that supports diabetes research, particularly in the area of juvenile diabetes, for their continued financial support to develop the SWEET Project in the UK, and to Josie Goodsell, SWEET UK Administrator, for her expert data management. We wish to thank Dr Peter Swift and Soren E Skovlund for their contributions on behalf of the Hvidore Study Group and the DAWN Youth Initiative. We also wish to thank NHS Diabetes in the UK for their continued support of this project. Lastly, we wish to thank all SWEET members for their contributions to WP 4.","American Diabetes Association, 2010, STAND MED CAR DIAB 2; [Anonymous], 2006, SPECIALIST NURSING S; [Anonymous], 2009, SUPPORTING CHILDREN; Australasian Pediatric Endocrine Group, 2005, CLIN PRACT GUID TYP; Cinek O, 2012, PEDIATR DIABETES, V13, P5, DOI 10.1111/j.1399-5448.2012.00907.x; Danne T, 2001, DIABETES CARE, V24, P1342, DOI 10.2337/diacare.24.8.1342; DAWN Study Group, 2007, CHANG DIAB DAWN YOUT; de Beaufort C, 2012, PEDIATR DIABETES, V13, P15, DOI 10.1111/j.1399-5448.2012.00908.x; de Beaufort CE, 2007, DIABETES CARE, V30, P2245, DOI 10.2337/dc07-0475; Department of Health, 2004, NAT SERV FRAM CHILDR; DH Diabetes Policy Team, 2007, MAK EV YOUNG PERS DI; Dunger DB, 2004, PEDIATRICS, V113, P133; Edge JA, 2010, PRACT DIAB INT, V27, P139; European Society for Paediatric Endocrinology, 2010, EUR TRAIN SYLL PAED; German Diabetes Association, CLIN GUID PSYCH FACT; Hammick M, 2009, MED TEACH, V31, P1, DOI 10.1080/01421590802585561; Hindmarsh PC, 2001, HORM RES, V56, P188, DOI 10.1159/000048117; IDF, 2009, INT STAND DIAB ED; International Diabetes Federation, 2009, INT STAND DIAB ED; International Diabetes Federation, 2008, INT CURR DIAB HLTH P; Leroy S, 2010, CRITICAL ISSUE MATRI; Mortensen HB, 1997, DIABETES CARE, V20, P714, DOI 10.2337/diacare.20.5.714; National Collaborating Centre for Women's and Children's Health, 2004, TYP 1 DIAB DIAGN MAN; NICE, 2004, TYP 1 DIAB DIAGN MAN; Petrak Frank, 2005, Curr Diabetes Rev, V1, P255, DOI 10.2174/157339905774574329; Peyrot M, 2009, PEDIATR DIABETES, V10, P37, DOI 10.1111/j.1399-5448.2009.00612.x; Pihoker C, 2009, PEDIATR DIABETES, V10, P58, DOI 10.1111/j.1399-5448.2009.00585.x; RCPCH, 2009, FRAM COMP LEV 3 TRAI; Royal College of Nursing, GUID NEWL APP NURS S; Royal College of Pediatrics and Child Health, 2010, CURR PAED TRAIN PAED; SWEET Project EU, 2011, BETT CONTR PED AD DI; Swift PGF, 2010, PEDIATR DIABETES, V11, P271, DOI 10.1111/j.1399-5448.2009.00596.x; Training Research and Education for Nurses in Diabetes UK, 2010, TRAINING RES ED NURS; Waldron S, 2011, PRACT DIAB INT, DOI [10. 1002/pdi. 1597:218-223a, DOI 10.1002/PDI.1597:218-223A]",34,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","SEP",2012,13,null,null,16,"SI",null,29,38,null,"10.1111/j.1399-5448.2012.00910.x",null,10,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","996OO","WOS:000308100400005"]
[null,null,null,null,"J","Nucci, AM; Becker, DJ; Virtanen, S; Cuthbertson, D; Softness, B; Huot, C; Wasikowa, R; Dosch, HM; Akerblom, HK; Knip, M",null,null,null,"Nucci, Anita M.; Becker, Dorothy J.; Virtanen, Suvim; Cuthbertson, David; Softness, Barney; Huot, Celine; Wasikowa, Renata; Dosch, Hans Michael; Akerblom, Hans K.; Knip, Mikael",null,"TRIGR Study Grp","Growth differences between North American and European children at risk for type 1 diabetes","PEDIATRIC DIABETES",null,null,"English","Article",null,null,null,null,null,"Europe; growth; North America; T1D; mellitus","EARLY WEIGHT-GAIN; BIRTH-WEIGHT; ACCELERATOR HYPOTHESIS; LINEAR GROWTH; CHILDHOOD; OVERWEIGHT; OBESITY; PREDICTORS; WORLDWIDE; TRENDS","Aim To evaluate the relationships between early growth and regional variations in type 1 diabetes (T1D) incidence in an international cohort of children with familial and genetic risk for T1D. Methods Anthropometric indices between birth to 5 yr of age were compared among regions and T1D proband in 2160 children participating in the Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk study. Results Children in Northern Europe had the highest weight z-score between birth to 12 months of age, while those in Southern Europe and USA had the lowest weight and length/height z-scores at most time points (p < 0.005 to p < 0.001). Few differences in z-score values for weight, height, and body mass index were found by maternal T1D status. Using International Obesity Task Force criteria, the obesity rates generally increased with age and at 5 yr were highest in males in Northern Europe (6.0%) and in females in Canada (12.8%). However, no statistically significance difference was found by geographic region. In Canada, the obesity rate for female children of mothers with and without T1D differed significantly at 4 and 5 yr (6.0 vs. 0.0% and 21.3 vs. 1.9%, respectively; p < 0.0125) but no differences by maternal T1D status were found in other regions. Conclusions There are regional differences in early childhood growth that are consistent with the higher incidence of T1D in Northern Europe and Canada as compared to Southern Europe. Our prospective study from birth will allow evaluation of relationships between growth and the emerging development of autoimmunity and progression to T1D by region in this at-risk population of children.","[Nucci, Anita M.] Georgia State Univ, Div Nutr, Atlanta, GA 30302 USA; [Becker, Dorothy J.] UPMC, Childrens Hosp Pittsburgh, Div Endocrinol, Pittsburgh, PA 15224 USA; [Virtanen, Suvim] Natl Inst Hlth & Welf, Nutr Unit, Helsinki 00300, Finland; [Virtanen, Suvim] Univ Tampere, Tampere Sch Publ Hlth, FIN-33101 Tampere, Finland; [Virtanen, Suvim] Tampere Univ Hosp, Res Unit, Tampere 33014, Finland; [Cuthbertson, David] Univ S Florida, Pediat Epidemiol Ctr, Tampa, FL 33612 USA; [Softness, Barney] Columbia Univ Coll Phys & Surg, Naomi Berrie Diabet Ctr, New York, NY 10032 USA; [Huot, Celine] CHU Ste Justine, Montreal, PQ H3T 1C5, Canada; [Wasikowa, Renata] Med Acad Wroclaw, Dept Endocrinol, PL-50376 Wroclaw, Poland; [Dosch, Hans Michael] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Akerblom, Hans K.; Knip, Mikael] Univ Helsinki, Childrens Hosp, Helsinki 00014, Finland; [Akerblom, Hans K.] Univ Helsinki, Biomedicum Helsinki Inst, Helsinki 00014, Finland; [Knip, Mikael] Tampere Univ Hosp, Dept Pediat, Tampere 33014, Finland; [Knip, Mikael] Univ Helsinki, Cent Hosp, Helsinki 00014, Finland; [Knip, Mikael] Folkhalsan Res Ctr, Helsinki 00014, Finland","Nucci, AM (reprint author), Georgia State Univ, Div Nutr, Urban Life Bldg,140 Decatur St,Suite 870, Atlanta, GA 30303 USA.","anucci@gsu.edu","Tillmann, Vallo/G-8118-2012",null,"National Institute of Child Health and Human Development and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health [HD040364, HD042444, HD051997]; Canadian Institutes of Health Research; Juvenile Diabetes Research Foundation International; Commission of the European Communities [QLK1-2002-00372]; EFSD/JDRF/Novo Nordisk Focused Research Grant; Academy of Finland","This work was supported by Grant Numbers HD040364, HD042444, and HD051997 from the National Institute of Child Health and Human Development and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health), Canadian Institutes of Health Research, the Juvenile Diabetes Research Foundation International, the Commission of the European Communities (specific RTD programme 'Quality of Life and management of Living Resources', contract number QLK1-2002-00372 'Diabetes Prevention'. It does not reflect its views and in no way anticipates the Commission's future policy in this area, the EFSD/JDRF/Novo Nordisk Focused Research Grant and the Academy of Finland. The study formulas were provided free of charge by Mead Johnson Nutritionals.","BLOM L, 1992, DIABETOLOGIA, V35, P528, DOI 10.1007/BF00400480; Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Dabelea D, 2007, DIABETES CARE, V30, pS169, DOI 10.2337/dc07-s211; Dahlquist GG, 2005, DIABETOLOGIA, V48, P1114, DOI 10.1007/s00125-005-1759-6; Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics, 2000, CDC GROWTH CHARTS US; Department of Health and Human Services Centers for Disease Control and Prevention National Institutes of Health, 2011, BOD MASS IND CONS PR; Bessaoud K, 2006, DIABETIC MED, V23, P857, DOI 10.1111/j.1464-5491.2006.01925.x; Green A, 1998, DIABETOLOGIA, V41, P1151; Dahlquist G, 2002, DIABETES CARE, V25, P1755; Harder T, 2009, AM J EPIDEMIOL, V169, P1428, DOI 10.1093/aje/kwp065; Harjutsalo V, 2006, DIABETES, V55, P1517, DOI 10.2337/db05-1296; Hummel S, 2009, DIABETES CARE, V32, P921, DOI 10.2337/dc08-1943; Hypponen E, 1999, DIABETES CARE, V22, P1961, DOI 10.2337/diacare.22.12.1961; Hypponen E, 2000, DIABETES CARE, V23, P1755, DOI 10.2337/diacare.23.12.1755; Kibirige M, 2003, DIABETES CARE, V26, P2865, DOI 10.2337/diacare.26.10.2865; Libman IM, 2003, DIABETES CARE, V26, P2871, DOI 10.2337/diacare.26.10.2871; Libman IM, 2003, DIABETES CARE, V26, P2876, DOI 10.2337/diacare.26.10.2876; Ljungkrantz M, 2008, PEDIATR DIABETES, V9, P50, DOI 10.1111/j.1399-5448.2007.00360.x; O'Loughlin J, 2000, AM J EPIDEMIOL, V152, P739, DOI 10.1093/aje/152.8.739; PALMER JP, 1989, DIABETES, V38, P1211, DOI 10.2337/diabetes.38.10.1211; Patterson CC, 2009, LANCET, V373, P2027, DOI 10.1016/S0140-6736(09)60568-7; Podar T, 1999, DIABETES CARE, V22, P2092; SONGER TJ, 1986, BRIT MED J, V292, P1419; TRIGR Study Group, 2007, PEDIAT DIABETES, V8, P117; Virtanen SM, 2003, AM J CLIN NUTR, V78, P1053; Wang Y, 2006, INT J PEDIATR OBES, V1, P11, DOI 10.1080/17477160600586747; Wilkin TJ, 2001, DIABETOLOGIA, V44, P914, DOI 10.1007/s001250100548; Wilkin TJ, 2002, DIABETES, V51, P3468, DOI 10.2337/diabetes.51.12.3468",28,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1399-543X","1399-5448",null,"PEDIATR DIABETES","Pediatr. Diabetes","AUG",2012,13,5,null,null,null,null,425,431,null,"10.1111/j.1399-5448.2011.00840.x",null,7,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","981HJ","WOS:000306957300007"]
[null,null,null,null,"J","Kappos, L; Gold, R; Miller, DH; MacManus, DG; Havrdova, E; Limmroth, V; Polman, CH; Schmierer, K; Yousry, TA; Eraksoy, M; Meluzinova, E; Dufek, M; Yang, MH; Dawson, K; O'Neill, GN",null,null,null,"Kappos, Ludwig; Gold, Ralf; Miller, David H.; MacManus, David G.; Havrdova, Eva; Limmroth, Volker; Polman, Chris H.; Schmierer, Klaus; Yousry, Tarek A.; Eraksoy, Mefkure; Meluzinova, Eva; Dufek, Michal; Yang, Minhua; Dawson, Kate; O'Neill, Gilmore N.",null,null,"Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study","MULTIPLE SCLEROSIS JOURNAL",null,null,"English","Article",null,null,null,null,null,"BG-12; demographics; disease modifying therapies; multiple sclerosis; relapsing/remitting; subpopulation","OXIDATIVE STRESS; DISABILITY; NEUROTOXICITY; PROGRESSION; FUMARATE; EFFICACY; BG00012; NRF2","Background: In a phase 2b study in patients with relapsing-remitting MS (RRMS), BG-12 240 mg three times daily significantly reduced the number of new gadolinium-enhanced (Gd+) lesions from weeks 12 to 24 (primary end point) by 69% compared with placebo. Objective: In this analysis, the effect of BG-12 240 mg three times daily on the number of Gd+ lesions from weeks 12 to 24 was evaluated in subgroups based on baseline disease characteristics and demographics. Methods: Two hundred and fifty-seven patients were randomized equally to receive BG-12 (120 mg once daily or three times daily or 240 mg three times daily) or placebo. Results: BG-12 240 mg three times daily significantly reduced the number of new Gd+ lesions compared with placebo in the following subgroups: Expanded Disability Status Scale (EDSS) score <= 2.5 (74%), EDSS score > 2.5 (63%), no Gd+ lesions (80%), >= 1 Gd+ lesion (55%), age < 40 years (49%), age >= 40 years (89%), female patients (81%), disease duration <= 6 years (81%) and disease duration > 6 years (54%) (all comparisons p < 0.05). Conclusion: BG-12 demonstrated efficacy in patients with RRMS by decreasing new Gd+ lesion development across a range of subgroups defined by baseline disease characteristics or demographics.","[Kappos, Ludwig] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland; [Kappos, Ludwig] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland; [Gold, Ralf] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany; [Miller, David H.; MacManus, David G.; Schmierer, Klaus; Yousry, Tarek A.] UCL Inst Neurol, London, England; [Havrdova, Eva] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Limmroth, Volker] City Hosp Cologne, Cologne, Germany; [Polman, Chris H.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [Schmierer, Klaus] Barts & London Queen Marys Sch Med & Dent, Blizard Inst Cell & Mol Sci, London, England; [Eraksoy, Mefkure] Istanbul Univ, Istanbul, Turkey; [Meluzinova, Eva] Charles Univ Prague, Dept Neurol, Sch Med 2, Prague, Czech Republic; [Meluzinova, Eva] Motol Univ Hosp, Prague, Czech Republic; [Dufek, Michal] Masaryk Univ, Brno, Czech Republic; [Yang, Minhua; Dawson, Kate; O'Neill, Gilmore N.] Biogen Idec Inc, Cambridge, MA USA","Kappos, L (reprint author), Univ Basel Hosp, Dept Neurol, Petersgraben 4, CH-4031 Basel, Switzerland.","lkappos@uhbs.ch","Yousry, Tarek/B-3417-2009",null,"Biogen Idec, Inc.; Swiss MS Society; Czech Ministry of Education [MSM 0021620849]; UCLH/UCL Comprehensive Biomedical Research Centre (CBRC); University Hospital Basel; Swiss National Research Foundation; European Union; Gianni Rubatto Foundation; Novartis Foundation; Roche Research Foundation; BayerSchering; Biogen Idec; Merck-Serono; Novartis; Teva; GlaxoSmithKline; Antisense Therapeutics; Bayer; MSD; Pfizer; Sanofi-Aventis; Actelion; Roche; UCB; Schering AG; NIHR UCLH Comprehensive Biomedical Research Centre; MS Society of Great Britain and Northern Ireland; MRC; Wellcome Trust","This study was supported by Biogen Idec, Inc., the Swiss MS Society (to LK), the Czech Ministry of Education (Research Programme MSM 0021620849) (to EH) and the UCLH/UCL Comprehensive Biomedical Research Centre (CBRC).Ludwig Kappos has received grant support through the University Hospital Basel as a principal investigator and member or chair of planning and steering committees or advisory boards from Acorda Therapeutics, Actelion Pharmaceuticals, Allozyne, Bayer Health Care, BayerSchering Pharma, Biogen Idec, Elan, Genmab, GlaxoSmithKline, Merck-Serono, Novartis, Sanofi-Aventis, Santhera Pharmaceuticals, Roche, Teva, UCB, Wyeth, and others. Research of the MS Center in Basel has been supported by grants from the Swiss MS Society, the Swiss National Research Foundation, the European Union, and the Gianni Rubatto, Novartis, and Roche Research Foundations. Ralf Gold has served as a speaker or consultant for and received scientific grant support from BayerSchering, Biogen Idec, Merck-Serono, Novartis, and Teva. David H Miller has received honoraria through payments to his employer, UCL Institute of Neurology, for advisory committees and/or consultancy in multiple sclerosis studies from BayerSchering, Biogen Idec, GlaxoSmithKline, and Novartis. He has received research grant support through his employer for performing central MRI analysis for multiple sclerosis trials from Biogen Idec, GlaxoSmithKline, and Novartis. David G MacManus declares no conflicts of interest. E Havrdova has received honoraria for lecturing and consulting from Bayer Health Care, Biogen Idec, Genzyme, Merck-Serono, Novartis, Sanofi-Aventis, and Teva. She has received funding for clinical trials and served on advisory boards for Actelion, Bayer Health Care, Biogen Idec, Genzyme, GlaxoSmithKline, Merck-Serono, Novartis, Sanofi-Aventis, and Teva. Volker Limmroth has received research support and honoraria for consultancy from Antisense Therapeutics, Bayer, Biogen Idec, GlaxoSmithKline, Merck-Serono, MSD, Pfizer, Sanofi-Aventis, and Teva. Chris H Polman has received consulting fees from Actelion, Antisense Therapeutics, BayerSchering, Biogen Idec, GlaxoSmithKline, Merck-Serono, Novartis, Roche, Teva, and UCB; lecture fees from Biogen Idec, Novartis, Schering AG, and Teva; and grant support from BayerSchering, Biogen Idec, GlaxoSmithKline, Merck-Serono, Novartis, Teva, and UCB. Klaus Schmierer received research support from Biogen Idec to perform the MRI analysis of the phase 2b trial of BG-12. He has received honoraria for speaking from Merck-Serono, Novartis, and Sanofi-Aventis. Tarek A Yousry has served on a scientific advisory board for UCB; received honoraria and funding for travel for serving on scientific boards for Biogen Idec; and received research support from Biogen Idec, GlaxoSmithKline, Novartis, the NIHR UCLH Comprehensive Biomedical Research Centre, the MS Society of Great Britain and Northern Ireland, the MRC, and the Wellcome Trust. Mefkure Eraksoy serves on the medical advisory board for Biogen Idec. Eva Meluzinova declares no conflicts of interest. Michal Dufek has served as a subinvestigator for a clinical trial for Biogen Idec (109MS301). Minhua Yang, Kate Dawson and Gilmore N O'Neill are employees of and have equity interest in Biogen Idec.",null,19,16,16,"SAGE PUBLICATIONS LTD","LONDON","1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND","1352-4585",null,null,"MULT SCLER J","Mult. Scler. J.","MAR",2012,18,3,null,null,null,null,314,321,null,"10.1177/1352458511421054",null,8,"Clinical Neurology","Neurosciences & Neurology","900YP","WOS:000300928700009"]
[null,null,null,null,"J","Han, SS; Yeager, M; Moore, LE; Wei, MH; Pfeiffer, R; Toure, O; Purdue, MP; Johansson, M; Scelo, G; Chung, CC; Gaborieau, V; Zaridze, D; Schwartz, K; Szeszenia-Dabrowska, N; Davis, F; Bencko, V; Colt, JS; Janout, V; Matveev, V; Foretova, L; Mates, D; Navratilova, M; Boffetta, P; Berg, CD; Grubb, RL; Stevens, VL; Thun, MJ; Diver, WR; Gapstur, SM; Albanes, D; Weinstein, SJ; Virtamo, J; Burdett, L; Brisuda, A; McKay, JD; Fraumeni, JF; Chatterjee, N; Rosenberg, PS; Rothman, N; Brennan, P; Chow, WH; Tucker, MA; Chanock, SJ; Toro, JR",null,null,null,"Han, Summer S.; Yeager, Meredith; Moore, Lee E.; Wei, Ming-Hui; Pfeiffer, Ruth; Toure, Ousmane; Purdue, Mark P.; Johansson, Mattias; Scelo, Ghislaine; Chung, Charles C.; Gaborieau, Valerie; Zaridze, David; Schwartz, Kendra; Szeszenia-Dabrowska, Neonilia; Davis, Faith; Bencko, Vladimir; Colt, Joanne S.; Janout, Vladimir; Matveev, Vsevolod; Foretova, Lenka; Mates, Dana; Navratilova, M.; Boffetta, Paolo; Berg, Christine D.; Grubb, Robert L., III; Stevens, Victoria L.; Thun, Michael J.; Diver, W. Ryan; Gapstur, Susan M.; Albanes, Demetrius; Weinstein, Stephanie J.; Virtamo, Jarmo; Burdett, Laurie; Brisuda, Antonin; McKay, James D.; Fraumeni, Joseph F., Jr.; Chatterjee, Nilanjan; Rosenberg, Philip S.; Rothman, Nathaniel; Brennan, Paul; Chow, Wong-Ho; Tucker, Margaret A.; Chanock, Stephen J.; Toro, Jorge R.",null,null,"The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma","HUMAN MOLECULAR GENETICS",null,null,"English","Article",null,null,null,null,null,null,"GENOME-WIDE ASSOCIATION; KIDNEY CANCER; FAMILY-HISTORY; MUTATIONS; SEQUENCES; RESOURCE; OBESITY; DESIGN; COMMON; TRIAL","In follow-up of a recent genome-wide association study (GWAS) that identified a locus in chromosome 2p21 associated with risk for renal cell carcinoma (RCC), we conducted a fine mapping analysis of a 120 kb region that includes EPAS1. We genotyped 59 tagged common single-nucleotide polymorphisms (SNPs) in 2278 RCC and 3719 controls of European background and observed a novel signal for rs9679290 [P 5.75 10(8), per-allele odds ratio (OR) 1.27, 95 confidence interval (CI): 1.171.39]. Imputation of common SNPs surrounding rs9679290 using HapMap 3 and 1000 Genomes data yielded two additional signals, rs4953346 (P 4.09 10(14)) and rs12617313 (P 7.48 10(12)), both highly correlated with rs9679290 (r(2) 0.95), but interestingly not correlated with the two SNPs reported in the GWAS: rs11894252 and rs7579899 (r(2) 0.1 with rs9679290). Genotype analysis of rs12617313 confirmed an association with RCC risk (P 1.72 10(9), per-allele OR 1.28, 95 CI: 1.181.39) In conclusion, we report that chromosome 2p21 harbors a complex genetic architecture for common RCC risk variants.","[Han, Summer S.; Yeager, Meredith; Moore, Lee E.; Wei, Ming-Hui; Pfeiffer, Ruth; Toure, Ousmane; Purdue, Mark P.; Chung, Charles C.; Colt, Joanne S.; Albanes, Demetrius; Weinstein, Stephanie J.; Burdett, Laurie; Fraumeni, Joseph F., Jr.; Chatterjee, Nilanjan; Rosenberg, Philip S.; Rothman, Nathaniel; Chow, Wong-Ho; Tucker, Margaret A.; Chanock, Stephen J.; Toro, Jorge R.] NCI, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA; [Berg, Christine D.] NCI, Canc Prevent Div, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA; [Yeager, Meredith] NCI, Core Genotyping Facil, Adv Technol Ctr, NIH,SAIC Frederick Inc, Frederick, MD 21701 USA; [Johansson, Mattias; Scelo, Ghislaine; Gaborieau, Valerie; McKay, James D.; Brennan, Paul] IARC, Lyon, France; [Zaridze, David; Matveev, Vsevolod] NN Blokhin Canc Res Ctr, Moscow, Russia; [Schwartz, Kendra] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA; [Zaridze, David] Wayne State Univ, Dept Family Med, Detroit, MI USA; [Szeszenia-Dabrowska, Neonilia] Inst Occupat Med, Dept Epidemiol, Lodz, Poland; [Davis, Faith] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA; [Bencko, Vladimir] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague, Czech Republic; [Janout, Vladimir] Palacky Univ, CR-77147 Olomouc, Czech Republic; [Foretova, Lenka; Navratilova, M.] Masaryk Mem Canc Inst, Dept Canc Epidemiol & Genet, Brno, Czech Republic; [Mates, Dana] Inst Publ Hlth, Bucharest, Romania; [Boffetta, Paolo] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA; [Grubb, Robert L., III] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA; [Stevens, Victoria L.; Thun, Michael J.; Diver, W. Ryan; Gapstur, Susan M.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA; [Virtamo, Jarmo] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland; [Brisuda, Antonin] Univ Hosp Motol, Dept Urol, Prague, Czech Republic; [Toro, Jorge R.] DC VAMC, Washington, DC USA","Toro, JR (reprint author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,Execut Plaza S,Room 7012, Rockville, MD 20892 USA.","toroj@mail.nih.gov","Szeszenia-Dabrowska, Neonila/F-7190-2010; Zaridze, David/K-5605-2013",null,"Division of Cancer Epidemiology and Genetics; National Cancer Institute; NIH; DHHS; Bethesda, MD, USA; European Commission [IC15-CT96-0313]","This research was supported in part by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA, and by European Commission INCOCOPERNICUS grant IC15-CT96-0313.",null,44,6,6,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0964-6906",null,null,"HUM MOL GENET","Hum. Mol. Genet.","MAR 1",2012,21,5,null,null,null,null,1190,1200,null,"10.1093/hmg/ddr551",null,11,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","891UL","WOS:000300242000020"]
[null,null,null,null,"J","Macfarlane, TV; Macfarlane, GJ; Thakker, NS; Benhamou, S; Bouchardy, C; Ahrens, W; Pohlabeln, H; Lagiou, P; Lagiou, A; Castellsague, X; Agudo, A; Slamova, A; Plzak, J; Merletti, F; Richiardi, L; Talamini, R; Barzan, L; Kjaerheim, K; Canova, C; Simonato, L; Conway, DI; McKinney, PA; Thomson, P; Sloan, P; Znaor, A; Healy, CM; McCartan, BE; Marron, M; Brennan, P",null,null,null,"Macfarlane, T. V.; Macfarlane, G. J.; Thakker, N. S.; Benhamou, S.; Bouchardy, C.; Ahrens, W.; Pohlabeln, H.; Lagiou, P.; Lagiou, A.; Castellsague, X.; Agudo, A.; Slamova, A.; Plzak, J.; Merletti, F.; Richiardi, L.; Talamini, R.; Barzan, L.; Kjaerheim, K.; Canova, C.; Simonato, L.; Conway, D. I.; McKinney, P. A.; Thomson, P.; Sloan, P.; Znaor, A.; Healy, C. M.; McCartan, B. E.; Marron, M.; Brennan, P.",null,null,"Role of medical history and medication use in the aetiology of upper aerodigestive tract cancers in Europe: the ARCAGE study","ANNALS OF ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"aspirin use; epidemiology; gastroesophageal reflux; medical history; medication use; upper aerodigestive tract cancer","NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ORAL-CANCER; HUMAN-PAPILLOMAVIRUS; RISK-FACTORS; ESOPHAGEAL; ASPIRIN; HEAD","Background: The study aimed to investigate the role of medical history (skin warts, Candida albicans, herpetic lesions, heartburn, regurgitation) and medication use (for heartburn; for regurgitation; aspirin) in the aetiology of upper aerodigestive tract (UADT) cancer. Methods: A multicentre (10 European countries) case-control study [Alcohol-Related CAncers and GEnetic susceptibility (ARCAGE) project]. Results: There were 1779 cases of UADT cancer and 1993 controls. History of warts or C. albicans infection was associated with a reduced risk [odds ratio (OR) 0.80, 95% confidence interval (CI) 0.68-0.94 and OR 0.73, 95% CI 0.60-0.89, respectively] but there was no association with herpetic lesions, heartburn, regurgitation or medication for related symptoms. Regurgitation was associated with an increased risk for cancer of the oesophagus (OR 1.47, 95% CI 0.98-2.21). Regular aspirin use was not associated with risk of UADT cancer overall but was associated with a reduced risk for cancer of oesophagus (OR 0.51, 95% CI 0.28-0.96), hypopharynx (OR 0.53, 95% CI 0.28-1.02) and larynx (OR 0.74, 95% CI 0.54-1.01). Conclusions: A history of some infections appears to be a marker for decreased risk of UADT cancer. The role of medical history and medication use varied by UADT subsites with aspirin use associated with a decreased risk of oesophageal cancer and suggestive of a decreased risk of hypopharyngeal and laryngeal cancers.","[Macfarlane, T. V.] Univ Aberdeen, Sch Med & Dent, Dept Dent, Aberdeen AB25 2ZR, Scotland; [Thakker, N. S.] Univ Manchester, Sch Dent, Manchester, Lancs, England; [Benhamou, S.] Fdn Jean Dausset CEPH, INSERM, U946, Paris, France; [Benhamou, S.] Inst Gustave Roussy, CNRS, FRE2939, Villejuif, France; [Bouchardy, C.] Canc Registry, Geneva, Switzerland; [Ahrens, W.; Pohlabeln, H.] Univ Bremen, Bremen Inst Prevent Res & Social Med BIPS, D-28359 Bremen, Germany; [Lagiou, P.; Lagiou, A.] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, GR-11527 Athens, Greece; [Lagiou, A.] Athens Technol Educ Inst, Athens, Greece; [Castellsague, X.] Catalan Inst Oncol ICO, Canc Epidemiol Res Program, Unit Infect & Canc, Barcelona, Spain; [Castellsague, X.] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain; [Agudo, A.] Catalan Inst Oncol ICO, Canc Epidemiol Res Program, Unit Nutr Environm & Canc UNEC, Barcelona, Spain; [Slamova, A.] Charles Univ Prague, Inst Hyg & Epidemiol, Prague, Czech Republic; [Plzak, J.] Charles Univ Prague, Hosp Motol, Dept Otorhinolaryngol & Head & Neck Surg, Prague, Czech Republic; [Merletti, F.; Richiardi, L.] Ctr Ric Med Sperimentale, Canc Epidemiol Unit, Turin, Italy; [Merletti, F.; Richiardi, L.] Univ Turin, Turin, Italy; [Talamini, R.] IRCCS, Natl Canc Inst, Unit Epidemiol & Biostat, Aviano, Italy; [Barzan, L.] Azienda Osped S Maria Angeli, Unit Otolaryngol, Pordenone, Italy; [Kjaerheim, K.] Canc Registry Norway, Oslo, Norway; [Canova, C.] Univ London Imperial Coll Sci Technol & Med, London, England; [Simonato, L.] Univ Padua, Dept Environm Med & Publ Hlth, Padua, Italy; [Conway, D. I.] Univ Glasgow, Sch Med, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [McKinney, P. A.] Univ Leeds, Ctr Epidemiol & Biostat, Edinburgh, Midlothian, Scotland; [McKinney, P. A.] NHS Natl Serv Scotland, Informat Serv Div, Edinburgh, Midlothian, Scotland; [Thomson, P.; Sloan, P.] Newcastle Univ, Sch Dent, Newcastle Upon Tyne, Tyne & Wear, England; [Znaor, A.] Croatian Natl Canc Registry, Zagreb, Croatia; [Healy, C. M.] Dublin Dent Univ Hosp, Trinity Coll Dublin, Dublin, Ireland; [McCartan, B. E.] Royal Coll Surgeons Ireland, Sch Med & Hlth Sci, Dublin 2, Ireland; [Marron, M.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Biostat Epidemiol & Informat IMBEI, Mainz, Germany; [Brennan, P.] Int Agcy Res Canc, F-69372 Lyon, France","Macfarlane, TV (reprint author), Univ Aberdeen, Sch Med & Dent, Dept Dent, Cornhill Rd, Aberdeen AB25 2ZR, Scotland.","Tatiana.Macfarlane@abdn.ac.uk",null,null,"European Community [QLK1-CT-2001-00182]; University of Athens Medical School; Padova University [CPDA057222]; Compagnia San Paolo, Associazione Italiana per la Ricerca sul Cancro","European Community (5th Framework Programme) (QLK1-CT-2001-00182); University of Athens Medical School, for the Athens centre; Padova University (Contract No CPDA057222) for the Padova centre; Compagnia San Paolo, Associazione Italiana per la Ricerca sul Cancro, for the Turin centre.",null,33,2,2,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0923-7534",null,null,"ANN ONCOL","Ann. Oncol.","APR",2012,23,4,null,null,null,null,1053,1060,null,"10.1093/annonc/mdr335",null,8,"Oncology","Oncology","919CI","WOS:000302298000035"]
[null,null,null,null,"J","Gazova, I; Vlcek, K; Laczo, J; Nedelska, Z; Hyncicova, E; Mokrisova, I; Sheardova, K; Hort, J",null,null,null,"Gazova, Ivana; Vlcek, Kamil; Laczo, Jan; Nedelska, Zuzana; Hyncicova, Eva; Mokrisova, Ivana; Sheardova, Katerina; Hort, Jakub",null,null,"Spatial navigation-a unique window into physiological and pathological aging","FRONTIERS IN AGING NEUROSCIENCE",null,null,"English","Review",null,null,null,null,null,"spatial navigation; physiological ageing; pathological ageing; mild cognitive impairment; Alzheimer's disease; allocentric navigation; egocentric navigation","MILD COGNITIVE IMPAIRMENT; ALZHEIMERS ASSOCIATION WORKGROUPS; AGE-RELATED DIFFERENCES; TEMPORAL-LOBE ATROPHY; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; ENTORHINAL CORTEX; AMNESTIC SYNDROME; PLACE NAVIGATION; DISEASE","Spatial navigation is a skill of determining and maintaining a trajectory from one place to another. Mild progressive decline of spatial navigation develops gradually during the course of physiological ageing. Nevertheless, severe spatial navigation deficit can be the first sign of incipient Alzheimer's disease (AD), occurring in the stage of mild cognitive impairment (MCI), preceding the development of a full blown dementia. Patients with amnestic MCI, especially those with the hippocampal type of amnestic syndrome, are at very high risk of AD. These patients present with the same pattern of spatial navigation impairment as do the patients with mild AD. Spatial navigation testing of elderly as well as computer tests developed for routine clinical use thus represents a possibility for further investigation of this cognitive domain, but most of all, an opportunity for making early diagnosis of AD.","[Gazova, Ivana; Laczo, Jan; Nedelska, Zuzana; Hyncicova, Eva; Mokrisova, Ivana; Hort, Jakub] Charles Univ Prague, Fac Med 2, Memory Disorders Clin, Dept Neurol, Prague 15006 5, Czech Republic; [Gazova, Ivana; Laczo, Jan; Nedelska, Zuzana; Hyncicova, Eva; Mokrisova, Ivana; Hort, Jakub] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Gazova, Ivana; Vlcek, Kamil; Laczo, Jan; Nedelska, Zuzana; Sheardova, Katerina; Hort, Jakub] Int Clin Res Ctr, Brno, Czech Republic; [Gazova, Ivana; Vlcek, Kamil; Laczo, Jan; Nedelska, Zuzana; Sheardova, Katerina; Hort, Jakub] St Annes Univ Hosp Brno, Brno, Czech Republic; [Vlcek, Kamil] Acad Sci Czech Republic, Inst Physiol, Dept Neurophysiol Memory, Vvi, Prague, Czech Republic","Gazova, I (reprint author), Charles Univ Prague, Fac Med 2, Memory Disorders Clin, Dept Neurol, V Uvalu 84, Prague 15006 5, Czech Republic.","ivana.gazova1@gmail.com","Vlcek, Kamil/B-9620-2012","Vlcek, Kamil/0000-0001-7152-3093","Grant Agency of the Czech Republic [309/09/1053, 309/09/0286]; European Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; Internal Grant Agency of the Ministry of Health of the Czech Republic Grant [NT11225-4]; Ministry of Education, Youth and Sports of the Czech Republic [1M0517, LC554, AV0Z50110509]; Grant Agency of Charles University in Prague [2120145]; Institutional Support of Laboratory Research Grant [2/2012, 699002]","This work was supported by Grant Agency of the Czech Republic Grants 309/09/1053 and 309/09/0286; European Regional Development Fund-Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123); Internal Grant Agency of the Ministry of Health of the Czech Republic Grant NT11225-4; Ministry of Education, Youth and Sports of the Czech Republic Grants 1M0517 and LC554, and research project AV0Z50110509, Grant Agency of Charles University in Prague (No. 2120145) and Institutional Support of Laboratory Research Grant No. 2/2012 (699002).",null,82,8,8,"FRONTIERS RESEARCH FOUNDATION","LAUSANNE","PO BOX 110, LAUSANNE, 1015, SWITZERLAND","1663-4365",null,null,"FRONT AGING NEUROSCI","Front. Aging Neurosci.","JUN 21",2012,4,null,null,null,null,null,null,null,16,"10.3389/fnagi.2012.00016",null,6,"Geriatrics & Gerontology; Neurosciences","Geriatrics & Gerontology; Neurosciences & Neurology","054WN","WOS:000312376200001"]
[null,null,null,null,"J","Melter, O; Arvand, M; Votypka, J; Hulinska, D",null,null,null,"Melter, Oto; Arvand, Mardjan; Votypka, Jiri; Hulinska, Dagmar",null,null,"Bartonella quintana Transmission from Mite to Family with High Socioeconomic Status","EMERGING INFECTIOUS DISEASES",null,null,"English","Letter",null,null,null,null,null,null,"CAT-SCRATCH DISEASE; DERMANYSSUS-GALLINAE; HENSELAE DNA; PCR; AGENTS",null,"[Melter, Oto] Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Prague 15006 5, Czech Republic; [Votypka, Jiri; Hulinska, Dagmar] Natl Inst Publ Hlth, Prague, Czech Republic","Melter, O (reprint author), Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic.","oto.melter@lfmotol.cuni.cz",null,null,null,null,null,10,2,2,"CENTERS  DISEASE CONTROL","ATLANTA","1600 CLIFTON RD, ATLANTA, GA 30333 USA","1080-6040",null,null,"EMERG INFECT DIS","Emerg. Infect. Dis","JAN",2012,18,1,null,null,null,null,163,165,null,"10.3201/eid1801.110186",null,3,"Immunology; Infectious Diseases","Immunology; Infectious Diseases","874QK","WOS:000298973000035"]
[null,null,null,null,"J","Stiborova, M; Eckschlager, T; Poljakova, J; Hrabeta, J; Adam, V; Kizek, R; Frei, E",null,null,null,"Stiborova, M.; Eckschlager, T.; Poljakova, J.; Hrabeta, J.; Adam, V.; Kizek, R.; Frei, E.",null,null,"The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment","CURRENT MEDICINAL CHEMISTRY",null,null,"English","Review",null,null,null,null,null,"Chromatin remodeling; histone acetylation; histone deacetylase; histone deacetylase inhibitor; anticancer drugs; DNA-damaging drugs; ionizing radiation; combined treatment modalities; mechanisms of combined treatment; apoptosis","SUBEROYLANILIDE HYDROXAMIC ACID; CELL LUNG-CANCER; ANTICANCER DRUG ELLIPTICINE; MULTIPLE-MYELOMA CELLS; NITRIC-OXIDE SYNTHASE; CONSTITUTIVE ANDROSTANE RECEPTOR; BETA-PHENYLETHYL ISOTHIOCYANATE; ENHANCES RADIATION SENSITIVITY; VORINOSTAT PLUS BORTEZOMIB; HUMAN CYTOCHROMES P450","Histone deacetylase (HDAC) inhibitors are a group of anticancer drugs which cause growth arrest and apoptosis of several tumor cells. HDAC inhibitors have been also found to increase the anticancer efficacy of several treatment modalities i.e. chemotherapy or radiotherapy. Here, we review the literature on combinations of HDAC inhibitors both with ionizing radiation and with other drugs, highlighting DNA-damaging compounds. The results of numerous studies with several types of cancer cells discussed in this review demonstrate that HDAC inhibitors enhance the effect of DNA damaging agents, such as inhibitors of topoisomerases, inhibitors of DNA synthesis, DNA-intercalators and agents covalently modifying DNA (i.e. doxorubicin, etoposid, 5-fluorouracil, cisplatin, melphalan, temozolomide and ellipticine) or of irradiation. Hence, the use of HDAC inhibitors combined with these antitumor drugs or ionizing radiation is a promising tool which may make treatment of patients suffering from many types of cancer more efficient. Several molecular mechanisms are responsible for the observed higher sensitivity of tumor cells towards therapeutic agents elicited by HDAC inhibitors. These mechanisms are discussed also in this review.","[Stiborova, M.; Poljakova, J.] Charles Univ Prague, Dept Biochem, Fac Sci, CR-11636 Prague 1, Czech Republic; [Eckschlager, T.; Hrabeta, J.] Charles Univ Prague, Fac Med 2, Dept Paediat Hematol & Oncol, CR-11636 Prague 1, Czech Republic; [Eckschlager, T.; Hrabeta, J.] Univ Hosp Motol, Prague, Czech Republic; [Adam, V.; Kizek, R.] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Brno, Czech Republic; [Adam, V.; Kizek, R.] Brno Univ Technol, Cent European Inst Technol, Brno, Czech Republic; [Frei, E.] German Canc Res Ctr, Natl Ctr Tumor Dis, Div Prevent Oncol, Heidelberg, Germany","Stiborova, M (reprint author), Charles Univ Prague, Dept Biochem, Fac Sci, CR-11636 Prague 1, Czech Republic.","stiborov@natur.cuni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012",null,"Grant Agency of the Czech Republic [P301/10/0356]; CEITEC [CZ.1.05/1.1.00/02.0068]; Charles University in Prague [42]; Operational Program Research & Development for innovation","This work was supported by the Grant Agency of the Czech Republic (grant P301/10/0356), CEITEC (CZ.1.05/1.1.00/02.0068) funded by the Operational Program Research & Development for innovation and Charles University in Prague (grant UNCE #42).",null,235,7,8,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","0929-8673","1875-533X",null,"CURR MED CHEM","Curr. Med. Chem.","SEP",2012,19,25,null,null,null,null,4218,4238,null,null,null,21,"Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy","Biochemistry & Molecular Biology; Pharmacology & Pharmacy","011JR","WOS:000309161400003"]
[null,null,null,null,"J","Lee, BW; Schwartz, RA; Hercogova, J; Valle, Y; Lotti, TM",null,null,null,"Lee, Brian W.; Schwartz, Robert A.; Hercogova, Jana; Valle, Yan; Lotti, Torello M.",null,null,"Vitiligo road map","DERMATOLOGIC THERAPY",null,null,"English","Review",null,null,null,null,null,"biomarkers; vitiligo; melanocyte; pigmentation; melanogenesis","HEPATOCYTE GROWTH-FACTOR; MELANOCYTE-STIMULATING HORMONE; NON-SEGMENTAL VITILIGO; NARROW-BAND-UVB; EXTRACELLULAR-MATRIX COMPONENTS; PSORALEN PLUS ULTRAVIOLET; FACTOR SCATTER FACTOR; C-KIT LIGAND; NITRIC-OXIDE; T-CELLS","Vitiligo is a depigmenting disorder stemming from melanocyte loss or dysfunction. It has a complex, multifaceted etiology. We constructed a vitiligo road map, consisting of basic science, clinical, and treatment components, in order to better portray our current understanding of vitiligo pathogenesis and reflect upon novel biomarkers and therapeutic targets for future research. The melanocyte map elaborates on the molecular processes and intracellular signaling pathways initiated by various external autocrine/paracrine factors in representing normal melanocyte homeostatic functions modulating its viability, proliferation, differentiation, dendricity, migration, and melanogenic processes. This vitiligo map identifies known inducers/triggers of vitiligo onset and progression that cultivate a microenvironment for melanocyte disappearance, real or functional. This map describes the molecular mechanisms of currently utilized clinical and experimental treatments of vitiligo that facilitate repigmentation.","[Lee, Brian W.; Schwartz, Robert A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [Hercogova, Jana] Charles Univ Prague, Fac Med 2, Dept Dermatovenereol, Prague, Czech Republic; [Hercogova, Jana] Bulovka Hosp, Prague, Czech Republic; [Valle, Yan] Vitiligo Res Fdn, New York, NY USA; [Lotti, Torello M.] Univ Rome Guglielmo Marconi, Dept Dermatol Sci, Rome, Italy; [Lotti, Torello M.] Univ Rome Guglielmo Marconi, Off Vice Chancellor, Rome, Italy","Schwartz, RA (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, 185 S Orange Ave, Newark, NJ 07103 USA.","roschwar@cal.berkley.edu",null,null,null,null,null,147,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296",null,null,"DERMATOL THER","Dermatol. Ther.","NOV-DEC",2012,25,null,null,1,"SI",null,"S44","S56",null,"10.1111/dth.12006",null,13,"Dermatology","Dermatology","053VW","WOS:000312304200007"]
[null,null,null,null,"J","Sochor, J; Hynek, D; Krejcova, L; Fabrik, I; Krizkova, S; Gumulec, J; Adam, V; Babula, P; Trnkova, L; Stiborova, M; Hubalek, J; Masarik, M; Binkova, H; Eckschlager, T; Kizek, R",null,null,null,"Sochor, Jiri; Hynek, David; Krejcova, Ludmila; Fabrik, Ivo; Krizkova, Sona; Gumulec, Jaromir; Adam, Vojtech; Babula, Petr; Trnkova, Libuse; Stiborova, Marie; Hubalek, Jaromir; Masarik, Michal; Binkova, Hana; Eckschlager, Tomas; Kizek, Rene",null,null,"Study of Metallothionein Role in Spinocellular Carcinoma Tissues of Head and Neck Tumours using Brdicka Reaction","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"electrochemical detection; cancer; voltammetry; catalytic signal; oral cancer; marker; metastases","SQUAMOUS-CELL CARCINOMA; DIFFERENTIAL-PULSE VOLTAMMETRY; TRANSFER STRIPPING TECHNIQUE; SALIVARY-GLANDS; X-IRRADIATION; FISH-TISSUES; BLOOD-SERUM; RAT-LIVER; EXPRESSION; CANCER","Malignant tumours of head and neck localisation represent serious health problem. All over the world, there is about 650 000 of patients who fall ill with head and neck carcinoma per year. Treatment of this malignity is based especially on the well-timed surgery intervention and radiotherapy. Therefore, alternative ways of diagnostics, which would replace commonly used biopsy in combination with computed tomography, are intensely searched. Attention is devoted especially to molecules, whose levels are changed in body due to malignant process and malignant disease progression. The main objective of this study consisted in determination of metallothionein (/MT)/ levels in tumour tissues of patients suffering from head and neck tumours using differential pulse voltammetry Brdicka reaction. Fifty-five samples of tumour tissue (45 % laryngeal, 40 % oropharyngeal, 9 % hypopharyngeal and 6 % oral cavity cancer) were included in this study. After describing of differences in differential pulse voltammograms of individual tumour localisations, content of MT were determined in the above mentioned localisations. The highest MT level was determined in the tissues of oral tumours (170 +/- 70 mu g/g) followed by hypopharynx (160 +/- 70 mu g/g) and larynx (160 +/- 70 mu g/g). The relatively lowest MT level was determined in tumours of oropharynx (130 +/- 50 mu g/g). MT level related to the size of primary tumour focus oscillates with the increasing tumour size. Notwithstanding this fact, the increasing tendency with tumour disease progression is observable. Similar tendency was determined for MT level related to the metastatic activity of tumours, where MT level increased with tumour spreading into local lymph nodes. Our results supported findings on the possible connection of MT and tumour progression.","[Sochor, Jiri; Hynek, David; Krejcova, Ludmila; Fabrik, Ivo; Krizkova, Sona; Gumulec, Jaromir; Adam, Vojtech; Babula, Petr; Trnkova, Libuse; Hubalek, Jaromir; Masarik, Michal; Kizek, Rene] Mendel Univ, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Sochor, Jiri; Hynek, David; Krizkova, Sona; Adam, Vojtech; Babula, Petr; Trnkova, Libuse; Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Gumulec, Jaromir; Masarik, Michal] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-62500 Brno, Czech Republic; [Binkova, Hana] Masaryk Univ, Fac Med, Dept Otorhinolaryngol & Head & Neck Surg, CZ-62500 Brno, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CZ-61137 Brno, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Hubalek, Jaromir] Brno Univ Technol, Fac Elect Engn & Commun, Dept Microelect, CZ-61600 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Sochor, J (reprint author), Mendel Univ, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Sochor, Jiri/E-1135-2012; Hynek, David/E-5702-2012; Krejcova, Ludmila/E-8440-2012; Krizkova, Sona/E-9617-2012; Gumulec, Jaromir/D-7638-2012","Gumulec, Jaromir/0000-0002-9658-3444","CYTORES [GA CR P301/10/0356]; CEITEC [CZ.1.05/1.1.00/02.0068]","Financial support from CYTORES GA CR P301/10/0356 and CEITEC CZ.1.05/1.1.00/02.0068 is highly acknowledged.",null,69,20,20,"ELECTROCHEMICAL SCIENCE GROUP","BELGRADE","A SPOMENICE 7/12 , 19210 BOR, BELGRADE, VJ 12, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","MAR",2012,7,3,null,null,null,null,2136,2152,null,null,null,17,"Electrochemistry","Electrochemistry","924ZR","WOS:000302730300032"]
[null,null,null,null,"J","Krejcova, L; Fabrik, I; Hynek, D; Krizkova, S; Gumulec, J; Ryvolova, M; Adam, V; Babula, P; Trnkova, L; Stiborova, M; Hubalek, J; Masarik, M; Binkova, H; Eckschlager, T; Kizek, R",null,null,null,"Krejcova, Ludmila; Fabrik, Ivo; Hynek, David; Krizkova, Sona; Gumulec, Jaromir; Ryvolova, Marketa; Adam, Vojtech; Babula, Petr; Trnkova, Libuse; Stiborova, Marie; Hubalek, Jaromir; Masarik, Michal; Binkova, Hana; Eckschlager, Tomas; Kizek, Rene",null,null,"Metallothionein Electrochemically Determined using Brdicka Reaction as a Promising Blood Marker of Head and Neck Malignant Tumours","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"electrochemical detection; head and neck cancer; voltammetry; catalytic signal; metallothionein; marker","SQUAMOUS-CELL CARCINOMA; CARBON-PASTE ELECTRODE; PART 1 EPIDEMIOLOGY; HUMAN-PAPILLOMAVIRUS; OROPHARYNGEAL CANCER; TELOMERASE ACTIVITY; ZINC(II) IONS; FISH-TISSUES; LEVEL; EXPRESSION","There are more than half of million patients who fall ill with head and neck carcinoma per year, which 6 % of annually newly diagnosed malignant diseases in the world. Group of head and neck tumours includes tumours occurring in the upper respiratory tract and upper digestive tract. They include tumours occurring in the area of oral cavity, tumours of hard and soft palate, gingivae and tongue. However, suitable markers in the case of head and neck carcinoma have not been satisfactory identified. Metallothioneins as a group of proteins with unknown but important role in development of a tumour can be assumed as a potential marker. Therefore, electrochemical monitoring of metallothionein levels in patients suffering from primary malignant tumour in head and neck area and examination of a suitability of electrochemical detection as a technique to be used in clinical practise are the most important aims of this study. Differential pulse voltammetry Brdicka reaction was optimized (time of accumulation 240 s, dilution of a sample 100 times and sample injection 10 mu l) and used for analysis off blood obtained from 145 patients with newly diagnosed malignant tumour disease in the head and neck area. As a control, fifty eight blood samples were used. The obtained data enabled us to suggest reference MT level in blood of healthy human within the interval from 0.2 to 0.8 mu M. In the tumour blood samples, the most extend group was represented by patients suffering from oropharyngeal cancer (n = 69, 47.5 %), laryngeal cancer (n = 36, 24.8 %), hypopharyngeal cancer (n = 14, 9.6 %), oral cavity cancer (n = 18, 12.4 %) and rarely occurring nasal cavity and paranasal sinus cancer (n = 4, 2.7 %) and parotid carcinoma (n = 4, 2.7%). Age median of the studied group was 60 years. Determined MT levels in blood of patients varied from 1.08 to 6.39 mu M, whereas average values differed in the accordance with tumour localization. Differences between individual localizations are discussed. In conclusion, MT levels are closely associated with the rate of tumour differentiation, stage of tumour disease and tumour cell characteristics. Our study demonstrates not only changes in blood MT levels in patients suffering from malignant tumour disease in head and neck area, but also suitability of electrochemical techniques for blood analysis.","[Krejcova, Ludmila; Fabrik, Ivo; Hynek, David; Krizkova, Sona; Gumulec, Jaromir; Ryvolova, Marketa; Adam, Vojtech; Babula, Petr; Trnkova, Libuse; Hubalek, Jaromir; Masarik, Michal; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Krejcova, Ludmila; Hynek, David; Krizkova, Sona; Ryvolova, Marketa; Adam, Vojtech; Babula, Petr; Trnkova, Libuse; Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Gumulec, Jaromir; Masarik, Michal] Masaryk Univ, Dept Pathol Physiol, Fac Med, CZ-62500 Brno, Czech Republic; [Binkova, Hana] Masaryk Univ, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med, CZ-62500 Brno, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Dept Chem, Fac Sci, CZ-61137 Brno, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, CZ-12840 Prague 2, Czech Republic; [Hubalek, Jaromir] Brno Univ Technol, Dept Microelect, Fac Elect Engn & Commun, CZ-61600 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague 5, Czech Republic","Krejcova, L (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Ryvolova, Marketa/D-8243-2012; Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Hynek, David/E-5702-2012; Krejcova, Ludmila/E-8440-2012; Krizkova, Sona/E-9617-2012; Gumulec, Jaromir/D-7638-2012","Gumulec, Jaromir/0000-0002-9658-3444","CYTORES GA CR [P301/10/0356]; RECAMT GA AV [IAA401990701]; CEITEC [CZ.1.05/1.1.00/02.0068]","Financial support from CYTORES GA CR P301/10/0356, RECAMT GA AV IAA401990701 and CEITEC CZ.1.05/1.1.00/02.0068 is highly acknowledged. The results were presented at 11th Workshop of Physical Chemists end Electrochemists held in Brno, Czech Republic.",null,86,19,19,"ELECTROCHEMICAL SCIENCE GROUP","BELGRADE","A SPOMENICE 7/12 , 19210 BOR, BELGRADE, VJ 12, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","MAR",2012,7,3,null,null,null,null,1767,1784,null,null,null,18,"Electrochemistry","Electrochemistry","924ZR","WOS:000302730300003"]
[null,null,null,null,"J","Borgmann-Staudt, A; Rendtorff, R; Reinmuth, S; Hohmann, C; Keil, T; Schuster, FR; Holter, W; Ehlert, K; Keslova, P; Lawitschka, A; Jarisch, A; Strauss, G",null,null,null,"Borgmann-Staudt, A.; Rendtorff, R.; Reinmuth, S.; Hohmann, C.; Keil, T.; Schuster, F. R.; Holter, W.; Ehlert, K.; Keslova, P.; Lawitschka, A.; Jarisch, A.; Strauss, G.",null,null,"Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence","BONE MARROW TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"allogeneic haematopoietic stem cell transplantation; cytotoxic therapy; pregnancy outcome; fertility; childhood","BONE-MARROW-TRANSPLANTATION; INDUCED OVARIAN FAILURE; BREAST-CANCER; CHEMOTHERAPY; RADIOTHERAPY; RADIATION; HORMONE; WOMEN","Infertility is a major late effect in patients receiving haematopoietic stem cell transplantation (HSCT). The aim of this study was to determine the proportion of patients having fertility impairment after allogeneic HSCT in childhood/adolescence and to identify the potential risk factors. Treatment and fertility data of paediatric patients with malignant and non-malignant diseases treated with allogeneic HSCT between 2000 and 2005 were collected from seven European centres. Data were obtained for 138 female and 206 male patients after a median follow-up of 6 years (range 3-12). The patients' median age was 13 years (range 4-28) at the time of HSCT and 19 (range 12-35) years at the time of the enquiry. Seven children were born to the overall group, all at term and healthy. Fertility impairment was suspected in 69% males and 83% females. Start of treatment at age >= 13 years was a risk factor in females (odds ratio (OR) 4.7; 95% confidence interval (CI), 1.5 to 14.9), whereas pre-pubertal therapy was a risk factor in males (OR 0.4; 95% CI, 0.2 to 0.8). The major treatment-related risk factors were BU in females (OR 47.4; 95% CI, 5.4 to 418.1) and TBI in males (OR 7.7; 95% CI, 2.3 to 25.4). In light of the significant proportion of HSCT patients reviewed with impaired fertility, fertility conservation procedures should be considered for all patients undergoing HSCT, particularly those receiving TBI or BU-based preparative regimens. Bone Marrow Transplantation (2012) 47, 271-276; doi:10.1038/bmt.2011.78; published online 11 April 2011","[Borgmann-Staudt, A.] Charite, Campus Virchow Klinikum, Klin Padiatrie MS Onkol Hamatol, Dept Paediat Oncol & Haematol, D-13353 Berlin, Germany; [Hohmann, C.; Keil, T.] Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Schuster, F. R.] Univ Dusseldorf, Clin Pediat Oncol Hematol & Clin Immunol, Fac Med, Ctr Child & Adolescent Hlth, D-40225 Dusseldorf, Germany; [Holter, W.] Erlangen Univ Hosp, Dept Paediat, Dept Immunol & Oncol, Erlangen, Germany; [Ehlert, K.] Univ Childrens Hosp Muenster, Dept Paediat Haematol & Oncol, Munster, Germany; [Keslova, P.] Motol Univ Hosp, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Lawitschka, A.] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Jarisch, A.] Univ Frankfurt Hosp, Dept Haematol, Frankfurt, Germany","Borgmann-Staudt, A (reprint author), Charite, Campus Virchow Klinikum, Klin Padiatrie MS Onkol Hamatol, Dept Paediat Oncol & Haematol, Augustenburger Pl 1,Mittelallee 6A, D-13353 Berlin, Germany.","anja.borgmann@charite.de",null,null,null,null,null,23,18,19,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0268-3369",null,null,"BONE MARROW TRANSPL","Bone Marrow Transplant.","FEB",2012,47,2,null,null,null,null,271,276,null,"10.1038/bmt.2011.78",null,6,"Biophysics; Oncology; Hematology; Immunology; Transplantation","Biophysics; Oncology; Hematology; Immunology; Transplantation","894GM","WOS:000300415100017"]
[null,null,null,null,"J","Tognetti, L; Martinelli, C; Berti, S; Hercogova, J; Lotti, T; Leoncini, F; Moretti, S",null,null,null,"Tognetti, L.; Martinelli, C.; Berti, S.; Hercogova, J.; Lotti, T.; Leoncini, F.; Moretti, S.",null,null,"Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment","JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY",null,null,"English","Review",null,null,null,null,null,null,"RESISTANT STAPHYLOCOCCUS-AUREUS; RESEARCH NETWORK STARNET; RISK-FACTORS; EMERGENCY-DEPARTMENT; NECROTIZING FASCIITIS; INTRAVENOUS IMMUNOGLOBULIN; HOSPITALIZED-PATIENTS; PRACTICE GUIDELINES; PREVALENCE; MANAGEMENT","Bacterial skin and soft tissues infections (SSTI) often determine acute disease and frequent emergency recovering, and they are one of the most common causes of infection among groups of different ages. Given the variable presentation of SSTI, a thorough assessment of their incidence and prevalence is difficult. The presence of patient-related (local or systemic) or environmental risk factors, along with the emergence of multi-drug resistant pathogens, can promote SSTI. These infections may present with a wide spectrum of clinical features and different severity, and can be classified according to various criteria. Many bacterial species can cause SSTI, but Gram-positive bacteria are the most frequently isolated, with a predominance of Staphylococcus aureus and Streptococcus pyogenes. The diagnosis of SSTI requires an extended clinical history, a thorough physical examination and a high index of suspicion. Early diagnosis is particularly important in complicated infections, which often require laboratory studies, diagnostic imaging and surgical exploration. SSTI management should conform to the epidemiology, the aetiology, the severity and the depth of the infection. Topical, oral or systemic antimicrobial therapy and drainage or debridement could be necessary, along with treatment of a significant underlying disease. This review discusses the epidemiology, the pathogenesis and the classification of bacterial SSTI, describes their associated risk factors and their clinical presentations. The authors provide a rational diagnostic and therapeutic approach to SSTI in respect of antibiotic resistance and currently available antimicrobial agents.","[Tognetti, L.; Moretti, S.] Univ Florence, Dept Crit Care Med & Surg, Div Clin Prevent & Oncol Dermatol, Florence, Italy; [Martinelli, C.; Leoncini, F.] Azienda Osped Univ Careggi, Infect Dis Unit, Florence, Italy; [Berti, S.] Univ Florence, Dept Sci Woman & Childs Hlth, Florence, Italy; [Hercogova, J.] Charles Univ Prague, Dept Dermatol, Med Sch 2, Prague, Czech Republic; [Lotti, T.] Guglielmo Marconi Univ, Chair Dermatol & Venereol, Rome, Italy","Tognetti, L (reprint author), Univ Florence, Dept Crit Care Med & Surg, Div Clin Prevent & Oncol Dermatol, Florence, Italy.","linda.tognetti@gmail.com",null,null,null,null,null,61,6,6,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0926-9959",null,null,"J EUR ACAD DERMATOL","J. Eur. Acad. Dermatol. Venereol.","AUG",2012,26,8,null,null,null,null,931,941,null,"10.1111/j.1468-3083.2011.04416.x",null,11,"Dermatology","Dermatology","975LT","WOS:000306513500001"]
[null,null,null,null,"J","Zapotocky, M; Mejstrikova, E; Smetana, K; Stary, J; Trka, J; Starkova, J",null,null,null,"Zapotocky, Michal; Mejstrikova, Ester; Smetana, Karel; Stary, Jan; Trka, Jan; Starkova, Julia",null,null,"Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically","CANCER LETTERS",null,null,"English","Article",null,null,null,null,null,"Valproic acid; AML1/ETO; Acute myeloid leukemia; Differentiation; Apoptosis","ACUTE MYELOID-LEUKEMIA; TRANS-RETINOIC ACID; HISTONE DEACETYLASE INHIBITORS; GENE-EXPRESSION; CELLULAR-DIFFERENTIATION; FUSION PARTNER; HEMATOPOIESIS; T(8/21); COMPLEX; TARGET","Valproic acid (VPA) has extensive effects on leukemic blasts through its inhibition of histone deacetylases. The main goal of this study was to identify the subgroup of patients who may benefit most from VPA treatment. We examined the significance of t(8:21) chromosomal aberration for VPA treatment response among acute myeloid leukemia (AML) patients by direct comparison of AML1/ETO-negative vs. positive leukemic cell-lines as well as bone marrow blasts from AML patients. In t(8; 21) AML, leukemogenesis is supposed to be induced via aberrant recruitment of histone deacetylases. AML cell lines of different genotypes (Kasumi-1, Kasumi-6, MV4;11, K562) and diagnostic bone marrow samples from patients were treated with VPA. VPA induced apoptosis in AML1/ETO-positive and MLL-AF4-positive cells in a dose-dependent manner. Differentiation, as indicated by changes in immunophenotype, was observed only in AML1/ETO-positive cells. VPA increased the expression of AML1 target genes - PU.1, C/EBPa, BPI and IGFBP7 only in AML1/ETO-positive cells. This AML1/ETO-specific effect was confirmed also using patient blasts isolated at the time of diagnosis. AML1/ETO-positive leukemia shows specific mechanism of VPA residing from differentiation followed by apoptosis that is accompanied by an increase in the expression of repressed AML1 target genes. Our data suggest that AML1/ETO-positive patients might derive the greatest benefit from VPA treatment. (C) 2012 Elsevier Ireland Ltd. All rights reserved.","[Zapotocky, Michal; Mejstrikova, Ester; Stary, Jan; Trka, Jan; Starkova, Julia] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, CLIP, Prague 15006, Czech Republic; [Smetana, Karel] Charles Univ Prague, Sch Med 1, Inst Hematol & Blood Transfus, Prague, Czech Republic","Trka, J (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, CLIP, V Uvalu 84, Prague 15006, Czech Republic.","jan.trka@lfmotol.cuni.cz",null,null,"Czech Ministry of Education [OC09051, MSM0021620813]; Zentiva (part of the Sanofi-Aventis group)","This work was supported by OC09051 and MSM0021620813 by Czech Ministry of Education, and Zentiva (part of the Sanofi-Aventis group).",null,40,5,5,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0304-3835",null,null,"CANCER LETT","Cancer Lett.","JUN 28",2012,319,2,null,null,null,null,144,153,null,"10.1016/j.canlet.2011.12.041",null,10,"Oncology","Oncology","934ZV","WOS:000303487500004"]
[null,null,null,null,"J","Jirakova, A; Vojackova, N; Gopfertova, D; Hercogova, J",null,null,null,"Jirakova, Anna; Vojackova, Nadezda; Goepfertova, Dana; Hercogova, Jana",null,null,"A comparative study of the impairment of quality of life in Czech children with atopic dermatitis of different age groups and their families","INTERNATIONAL JOURNAL OF DERMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ECZEMA; IMPACT; DERMATOLOGY; CONSULTATION; SEVERITY; INFANTS; GENDER; INDEX","Background Atopic dermatitis (AD) still remains one of the most common childhood inflammatory skin diseases. As a chronic disease, it can have a physical and psychological effect on social functioning of the affected child as well as their family. The objective of this study was to evaluate the quality of life of children with AD of different age groups and their families. Methods A total of 203 children with a diagnosis of AD from newborn to 18 years of age and 202 of their parents took part in our study (as one parent did not return the questionnaire). All participants, according to their age, completed the following questionnaires: Infants Dermatitis Quality of Life Index (IDQOL); Childrens Dermatology Life Quality Index (CDLQI) text and cartoon version; and Dermatitis Family Impact questionnaire (DFI). Results The mean total IDQOL score in our study was 8.18 (SD = 5.84, n = 120). The mean total CDLQI scores in the groups of children from 7 to 13 and from 14 to 18 years were 8.58 (SD = 4.98, n = 48) and 9.89 (SD = 5.26, n = 35). There was also a proven influence of the childs AD on the quality of life of his parents with the mean score: 7.98 (SD = 6.41, n = 202). Conclusions The study demonstrated and confirmed that AD significantly impairs the childrens quality of life in all age groups and also quality of life of their families. Such data give us patient-oriented information that is of great importance for understanding the situation of individuals with AD and its influence on members of their family.","[Jirakova, Anna] Charles Univ Prague, Fac Med 2, Dept Dermatovenereol, Sch Med 2, Prague 18100 8, Czech Republic; [Jirakova, Anna; Vojackova, Nadezda; Hercogova, Jana] Fac Hosp Bulovka, Prague, Czech Republic; [Vojackova, Nadezda; Goepfertova, Dana] Charles Univ Prague, Sch Med 2, Dept Epidemiol, Prague 18100 8, Czech Republic","Jirakova, A (reprint author), Charles Univ Prague, Fac Med 2, Dept Dermatovenereol, Sch Med 2, Budinova 2, Prague 18100 8, Czech Republic.","annajirakova@seznam.cz",null,null,null,null,null,24,4,4,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0011-9059",null,null,"INT J DERMATOL","Int. J. Dermatol.","JUN",2012,51,6,null,null,null,null,688,692,null,"10.1111/j.1365-4632.2011.05175.x",null,5,"Dermatology","Dermatology","945DU","WOS:000304253800009"]
[null,null,null,null,"J","Veselka, J; Zimolova, P; Martinkovicova, L; Tomasov, P; Hajek, P; Maly, M; Spacek, M; Zemanek, D; Tesar, D",null,null,null,"Veselka, Josef; Zimolova, Petra; Martinkovicova, Lucie; Tomasov, Pavol; Hajek, Petr; Maly, Martin; Spacek, Miloslav; Zemanek, David; Tesar, David",null,null,"Comparison of mid-term outcomes of carotid artery stenting for moderate versus critical stenosis","ARCHIVES OF MEDICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"carotid stenosis; stenting; follow-up","ENDARTERECTOMY; PROTECTION; SAFETY; TRIAL","Introduction: Little is known about the prognosis of moderate versus critical carotid stenosis treated by carotid artery stenting (CAS). Material and methods: This was a retrospective analysis of a single-centre registry including 271 consecutive patients (69 +/- 9 years, 87% at high risk for surgery), in whom 308 procedures were performed. The study included both symptomatic (>= 50% carotid artery stenosis) and asymptomatic (>= 70% carotid artery stenosis) patients. The primary endpoint was the rate of adverse events during follow-up (range 1-48 months), defined as all-cause death or stroke. Results: We treated 115 critical and 193 moderate stenoses and implanted 318 stents (56% with closed cell design). Embolic protection systems were used in 296 cases (96%). The technical success rate was 98.2% in the critical stenoses group and 99% in the moderate group (NS). During follow-up, the incidence of the primary endpoint was 12.9% (13 pts) in the critical stenoses group and 14.7% (25 pts) in the moderate stenoses group (estimated 3-year freedom from death/stroke was 0.844 vs. 0.812; log-rank test p = 0.983). Left ventricular ejection fraction < 40%, significant contralateral carotid artery occlusion or stenosis and renal insufficiency were identified as significant predictors of the primary endpoint (p < 0.03). Conclusions: Carotid artery stenting with embolic protection systems in patients at high risk for carotid endarterectomy is safe. Patients with initially moderate and critical stenoses have an identical mid-term prognosis with regard to death and stroke.","[Veselka, Josef; Zimolova, Petra; Martinkovicova, Lucie; Tomasov, Pavol; Hajek, Petr; Maly, Martin; Spacek, Miloslav; Zemanek, David; Tesar, David] Charles Univ Prague, Dept Cardiol, Univ Hosp Motol, Sch Med 2,Cardiovasc Ctr, Prague 15000 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Dept Cardiol, Univ Hosp Motol, Sch Med 2,Cardiovasc Ctr, Uvalu 84, Prague 15000 5, Czech Republic.","veselka.josef@seznam.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health of the Czech Republic [00064203]","The authors thank Eva Hansvenclova for her assistance in the data collection and registry analysis. The study was supported by grant No. 00064203 from the Ministry of Health of the Czech Republic.",null,22,3,3,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922",null,null,"ARCH MED SCI","Arch. Med. Sci.","FEB",2012,8,1,null,null,null,null,75,80,null,"10.5114/aoms.2012.27285",null,6,"Medicine, General & Internal","General & Internal Medicine","909HC","WOS:000301553600016"]
[null,null,null,null,"J","Hodyc, D; Johnson, E; Skoumalova, A; Tkaczyk, J; Maxova, H; Vizek, M; Herget, J",null,null,null,"Hodyc, D.; Johnson, E.; Skoumalova, A.; Tkaczyk, J.; Maxova, H.; Vizek, M.; Herget, J.",null,null,"Reactive Oxygen Species Production in the Early and Later Stage of Chronic Ventilatory Hypoxia","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Free radicals; Nitric oxide; Chronic hypoxia; Oxidative stress; Pulmonary hypertension","OXIDASE-DERIVED SUPEROXIDE; PULMONARY-HYPERTENSION; NITRIC-OXIDE; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE; RAT LUNGS; GENERATION; VASOCONSTRICTION; PEROXYNITRITE","Pulmonary hypertension resulting from chronic hypoxia is at least partly caused by the increased production of reactive oxygen species (ROS). The goal of the presented study was to investigate the dynamics and the site of production of ROS during chronic hypoxia. In our study Wistar rats were kept for 1, 4 and 21 days in an isobaric hypoxic chamber (F-iO2=0.1), while controls stayed in normoxia. We compared NO production in expired air, plasma and perfusate drained from isolated rat lungs and measured superoxide concentration in the perfusate. We also detected the presence of superoxide products (hydrogen peroxide and peroxynitrite) and the level of ROS-induced damage expressed as the concentration of lipid peroxydation end products. We found that the production and release of ROS and NO during early phase of chronic hypoxia has specific timing and differs in various compartments, suggesting the crucial role of ROS interaction for development of hypoxic pulmonary hypertension.","[Hodyc, D.; Johnson, E.; Herget, J.] Charles Univ Prague, Sch Med 2, Dept Physiol, Prague 15000, Czech Republic; [Skoumalova, A.] Charles Univ Prague, Sch Med 2, Dept Med Chem & Biochem, Prague 15000, Czech Republic; [Tkaczyk, J.; Maxova, H.; Vizek, M.] Charles Univ Prague, Sch Med 2, Dept Pathol Physiol, Prague 15000, Czech Republic","Hodyc, D (reprint author), Charles Univ Prague, Sch Med 2, Dept Physiol, Plzenska 221-130, Prague 15000, Czech Republic.","daniel.hodyc@lfmotol.cuni.cz","Herget, Jan/I-6313-2012",null,"Czech Science Foundation [GACR P303/10/P343, GACR 305/08/0108, MSMT 1M 0510]","The study was supported by the Czech Science Foundation, GACR P303/10/P343, GACR 305/08/0108 and MSMT 1M 0510.",null,30,3,3,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2012,61,2,null,null,null,null,145,151,null,null,null,7,"Physiology","Physiology","975JK","WOS:000306507400003"]
[null,null,null,null,"J","Djakow, J; Svobodova, T; Hrach, K; Uhlik, J; Cinek, O; Pohunek, P",null,null,null,"Djakow, Jana; Svobodova, Tamara; Hrach, Karel; Uhlik, Jiri; Cinek, Ondrej; Pohunek, Petr",null,null,"Effectiveness of sequencing selected exons of DNAH5 and DNAI1 in diagnosis of primary ciliary dyskinesia","PEDIATRIC PULMONOLOGY",null,null,"English","Article",null,null,null,null,null,"primary ciliary dyskinesia; molecular genetics; sequencing; hot-spot exons; founder mutations; DNAH5 gene; DNAI1 gene","NASAL NITRIC-OXIDE; DYNEIN ARM DEFECTS; FUNCTIONAL-ANALYSIS; BEAT PATTERN; MUTATIONS; CHILDREN; ULTRASTRUCTURE; SPECTRUM; ALLELES; COMPLEX","Introduction Primary ciliary dyskinesia (PCD) is a rare genetically heterogenous condition. Mutations in DNAH5 or DNAI1 genes can be found in about a third of the patients with PCD. Increased occurrence of mutations was described in several exons of these long genes. The objective of the study was to test the sensitivity of sequencing of selected 13 exons (as compared to costly sequencing of all 100 exons of the two genes), and to determine the prevalence of the DNAH5 or DNAI1 mutations in the Czech PCD database. Methods The Czech national PCD database has identified 31 pediatric patients, diagnosed based on clinical findings and tests on the ciliated epithelium. Twenty-seven patients from 24 families agreed on genetic testing. In the first step, direct sequencing of selected 13 exons (9 of DNAH5 and 4 of DNAI1) was performed, and then we compared its effectiveness in detecting at least one mutation with results of sequencing all 100 exons of the two genes. Results The sequencing of all exons identified compound heterozygosity for PCD mutations in nine patients from eight families (DNAH5 in eight and DNAI1 in one patient), and heterozygozity for a DNAH5 mutation of uncertain functional significance in one additional patient. The first step of selected exon sequencing detected a mutation in five out of these eight families, its actual sensitivity being 62.5%, with a high predictive value. The phenotypic and clinical characteristics of all the paediatric patients with PCD are shown. Conclusions Selected exon sequencing detects at least one mutated allele in over a half of our patients who have PCD due to DNAH5 or DNAI1 mutations. To lower the costs of the genetic testing, targeted step-wise genetic testing may be a reasonable approach to detect mutations in PCD patients, especially if their phenotype is taken into account. Pediatr Pulmonol. 2012. 47:864875. (c) 2012 Wiley Periodicals, Inc.","[Djakow, Jana; Svobodova, Tamara; Hrach, Karel; Cinek, Ondrej; Pohunek, Petr] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague 15006, Czech Republic; [Djakow, Jana; Svobodova, Tamara; Hrach, Karel; Cinek, Ondrej; Pohunek, Petr] Univ Hosp Motol, Prague, Czech Republic; [Hrach, Karel] Univ JE Purkyne, Inst Hlth Studies, Usti Nad Labem, Czech Republic; [Uhlik, Jiri] Charles Univ Prague, Fac Med 2, Dept Histol & Embryol, Prague 15006, Czech Republic","Djakow, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat, V Uvalu 84, Prague 15006, Czech Republic.","jana.djakow@lfmotol.cuni.cz","Uhlik, Jiri/C-6282-2014",null,"Charles University Grant Agency [48409]; Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA) [NT11469-5]","Funding source: Charles University Grant Agency, Number: 48409, Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA), Number: NT11469-5.",null,40,2,3,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","8755-6863",null,null,"PEDIATR PULM","Pediatr. Pulmonol.","SEP",2012,47,9,null,null,null,null,864,875,null,"10.1002/ppul.22520",null,12,"Pediatrics; Respiratory System","Pediatrics; Respiratory System","989GF","WOS:000307547600004"]
[null,null,null,null,"J","Novackova, M; Halaska, MJ; Robova, H; Mala, I; Pluta, M; Chmel, R; Rob, L",null,null,null,"Novackova, Marta; Halaska, Michael J.; Robova, Helena; Mala, Ivana; Pluta, Marek; Chmel, Roman; Rob, Lukas",null,null,"A Prospective Study in Detection of Lower-Limb Lymphedema and Evaluation of Quality of Life After Vulvar Cancer Surgery","INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER",null,null,"English","Article",null,null,null,null,null,"Vulvar cancer; Lymphedema; Multifrequency Bioelectrical Impedance Analysis; Quality of life; Lymphadenectomy","GYNECOLOGICAL CANCER; NODE DISSECTION; CERVICAL-CANCER; INGUINOFEMORAL LYMPHADENECTOMY; EUROPEAN-ORGANIZATION; FOLLOW-UP; MANAGEMENT; CARCINOMA; PREVALENCE; BREAST","Background: Lower-limb lymphedema is one of the most disabling adverse effects of vulvar cancer surgery. Multifrequency Bioelectrical Impedance Analysis (MFBIA) is a modern noninvasive method to detect lymphedema. The first aim of this study was to prospectively determine the prevalence of secondary lower-limb lymphedema after surgical treatment for vulvar cancer using objective methods, circumference measurements and MFBIA technique. The second aim was to compare quality of life (QoL) before and 6 months after vulvar surgery. Methods: Twenty-nine patients underwent vulvar cancer surgery in our study: 17 underwent inguinofemoral lymphadenectomy (RAD), and 12 underwent sentinel lymph node biopsy (CONS). Patients were examined before and 6 months after vulvar surgery by measuring the circumference of the lower limbs and with MFBIA. A control group of 27 healthy women was also measured. To evaluate QoL, the European Organisation for Research and Treatment of Cancer (EORTC) QoL questionnaires (QLQ-C30 and QLQ-CX24) were administered to patients before and 6 months after surgery. Results: Using circumference measurement, 9 lymphedemas (31%) were diagnosed: 3 (25%) in the CONS and 6 (37.5%) in the RAD group (P = 0.69). After vulvar surgery, patients in the RAD group reported more fatigue and worsening of physical and role functioning. When comparing both groups, the RAD group had significantly worse parameters in social functioning, fatigue, and dyspnea. Conclusions: Lower radicality in inguinofemoral lymphadenectomy shows a trend toward lower morbidity and significantly improves QoL. Multifrequency Bioelectrical Impedance Analysis was tested in these patients as a noninvasive, objective method for lymphedema detection. Detection of lymphedema based on subjective evaluations proved to have an unsatisfactory sensitivity. Less radical surgery showed objectively better results in QoL.","[Novackova, Marta; Halaska, Michael J.; Robova, Helena; Pluta, Marek; Chmel, Roman; Rob, Lukas] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague 15000 5, Czech Republic; [Mala, Ivana] Univ Econ, Fac Informat & Stat, Prague, Czech Republic; [Mala, Ivana] Univ Econ, Fac Hosp Motol, Prague, Czech Republic","Novackova, M (reprint author), Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, V Uvalu 84, Prague 15000 5, Czech Republic.","marta.novackova@seznam.cz",null,null,"Ministry of Health of the Czech Republic [IGA MZ 9914-4]","The work was supported by grant of the Ministry of Health of the Czech Republic IGA MZ 9914-4.",null,36,2,2,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X",null,null,"INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","JUL",2012,22,6,null,null,null,null,1081,1088,null,"10.1097/IGC.0b013e31825866d0",null,8,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","967LH","WOS:000305908800028"]
[null,null,null,null,"J","Cipro, S; Hrebackova, J; Hrabeta, J; Poljakova, J; Eckschlager, T",null,null,null,"Cipro, Simon; Hrebackova, Jana; Hrabeta, Jan; Poljakova, Jitka; Eckschlager, Tomas",null,null,"Valproic acid overcomes hypoxia-induced resistance to apoptosis","ONCOLOGY REPORTS",null,null,"English","Article",null,null,null,null,null,"valproic acid; hypoxia; apoptosis; neuroblastoma","ANTAGONIZES P53-MEDIATED APOPTOSIS; HISTONE DEACETYLASE INHIBITORS; INDUCIBLE FACTOR 1-ALPHA; NEUROBLASTOMA-CELLS; ANTITUMOR-ACTIVITY; GENE-EXPRESSION; TUMOR HYPOXIA; CANCER CELLS; HIF-1-ALPHA; PROTEIN","Valproic acid (VPA), a histone deacetylase inhibitor (HDACi), has been shown to be an effective tool in cancer treatment. Although its ability to induce apoptosis has been described in many cancer types, the data come from experiments performed in normoxic (21% O-2) conditions only. Therefore, we questioned whether VPA would be equally effective under hypoxic conditions (1% O-2), which is known to induce resistance to apoptosis. Four neuroblastoma cell lines were used: UKF-NB-3, SK-N-AS, plus one cisplatin-resistant subline derived from each of the two original sensitive lines. All were treated with VPA and incubated under hypoxic conditions. Measurement of apoptosis and viability using TUNEL assay and Annexin V/propidium iodide labeling revealed that VPA was even more effective under hypoxic conditions. We show here that hypoxia-induced resistance to chemotherapeutic agents such as cisplatin could be overcome using VPA. We also demonstrated that apoptosis pathways induced by VPA do not differ between normoxic and hypoxic conditions. VPA-induced apoptosis proceeds through the mitochondrial pathway, not the extrinsic pathway (under both normoxia and hypoxia), since inhibition of caspase-8 failed to decrease apoptosis or influence bid cleavage. Our data demonstrated that VPA is more efficient in triggering apoptosis under hypoxic conditions and overcomes hypoxia-induced resistance to cisplatin. The results provide additional evidence for the use of VPA in neuroblastoma (NBL) treatment.","[Cipro, Simon; Hrebackova, Jana; Hrabeta, Jan; Poljakova, Jitka; Eckschlager, Tomas] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague 15000 5, Czech Republic; [Cipro, Simon; Hrebackova, Jana; Hrabeta, Jan; Poljakova, Jitka; Eckschlager, Tomas] Univ Hosp Motol, Prague 15000 5, Czech Republic; [Poljakova, Jitka] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12840 2, Czech Republic","Eckschlager, T (reprint author), Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, V Uvalu 84, Prague 15000 5, Czech Republic.","eckschlagertomas@yahoo.com",null,null," [GAUK 72208/2008];  [GACR P301/10/0356]","This study was supported by grants GAUK 72208/2008 and GACR P301/10/0356. We thank Professor Jindrich Cinatl who kindly provided cell lines and Dr Michael Pfaffl for developing and freely distributing REST-MCS software for calculating relative expression in real-time PCR techniques.",null,44,2,2,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1021-335X",null,null,"ONCOL REP","Oncol. Rep.","APR",2012,27,4,null,null,null,null,1219,1226,null,"10.3892/or.2011.1577",null,8,"Oncology","Oncology","911XK","WOS:000301757600046"]
[null,null,null,null,"J","Spacek, M; Zimolova, P; Veselka, J",null,null,null,"Spacek, Miloslav; Zimolova, Petra; Veselka, Josef",null,null,"Carotid Artery Stenting Without Post-Dilation","JOURNAL OF INTERVENTIONAL CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"CEREBRAL PROTECTION DEVICES; HIGH-RISK PATIENTS; TRANSCRANIAL DOPPLER; ANGIOPLASTY; OUTCOMES; IMPACT","Introduction: The aim of this study is to report the feasibility, safety, and 1-year restenosis rate of carotid artery stenting (CAS) without post-dilation. Methods: Between April 2006 and November 2009, 254 consecutive patients (68.7 +/- 8.5 years old, 31% symptomatic) underwent 308 CAS procedures with the intention of avoiding post-dilation (eligibility criteria were stenosis of less than 30% after stent placement with no overt signs of calcification). Comparison and analysis of mid-term clinical outcomes and restenosis rates of CAS with or without post-dilation was performed retrospectively. Results: Overall, 27 patients (study group) were eligible for treatment without post-dilation. No significant difference in adverse events was found between the study and control group. In the study group, 2 transient ischemic attacks (7.4%) occurred immediately after the procedure and no other neurological complications were reported during the 30-day, 6-month, and 1-year follow-ups (3 patients died from causes unrelated to the procedure). Two asymptomatic restenosis cases were diagnosed in the study group within the first 12-months after the procedure compared to 16 significant restenosis cases diagnosed in the control group (7.4% vs 5.7%, NS). All of them were successfully treated with repeated intervention. Conclusion: We suggest that CAS without post-dilation is feasible and probably safe with a low rate of cerebrovascular events and restenosis in a selected group of patients. We also suggest that CAS with postdeployment stenosis of less than 20% and without overt signs of severe calcification might be performed without post-dilation. (J Interven Cardiol 2012;25:190-196)","[Spacek, Miloslav; Zimolova, Petra; Veselka, Josef] Charles Univ Prague, Dept Cardiol, Motol Univ Hosp, Sch Med 2,CardioVasc Ctr, Prague 15006 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Dept Cardiol, Motol Univ Hosp, Sch Med 2,CardioVasc Ctr, V Uvalu 84, Prague 15006 5, Czech Republic.","veselka.josef@seznam.cz",null,null,"Ministry of Health of the Czech Republic [00064203]","This study was supported by a grant from the Ministry of Health of the Czech Republic No. 00064203.",null,16,2,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0896-4327",null,null,"J INTERV CARDIOL","J. Interv. Cardiol.","APR",2012,25,2,null,null,null,null,190,196,null,"10.1111/j.1540-8183.2011.00694.x",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","922LJ","WOS:000302548300013"]
[null,null,null,null,"J","Kayserova, J; Zentsova-Jaresova, I; Budinsky, V; Rozkova, D; Kopecka, J; Vernerova, E; Pohunek, P; Skalicka, V; Spisek, R; Sediva, A",null,null,null,"Kayserova, J.; Zentsova-Jaresova, I.; Budinsky, V.; Rozkova, D.; Kopecka, J.; Vernerova, E.; Pohunek, P.; Skalicka, V.; Spisek, R.; Sediva, A.",null,null,"Selective Increase in Blood Dendritic Cell Antigen-3-Positive Dendritic Cells in Bronchoalveolar Lavage Fluid in Allergic Patients","SCANDINAVIAN JOURNAL OF IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ANTIGEN-PRESENTING CELLS; HUMAN LUNG; AIRWAY INFLAMMATION; PERIPHERAL-BLOOD; MANNOSE RECEPTOR; MITE ALLERGEN; DC-SIGN; SUBSETS; EXPRESSION; DIFFERENTIATION","Dendritic cells (DCs) are specific antigen-presenting cells that play critical roles in the initiation and polarization of immune responses. DCs residing in the lungs might be detected in the bronchoalveolar lavage fluid (BALF). We analysed DC compartment in the peripheral blood and BALF of patients with allergy and in controls. Plasmacytoid and four distinct subsets of myeloid DCs [characterized by the expression of blood dendritic cell antigen (BDCA)-1+ and -3+ and CD16 positivity or negativity] were detected in both tested compartments. We further evaluated the expression of C-type lectins [mannose receptor (MR), dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and dendritic and epithelial cells (DEC)-205] relevant to the pathogenesis of asthma. Interestingly, we found a selective increase in the frequency of myeloid DC-expressing BDCA-3 and MR particularly in BALF from allergic patients. Specific and highly statistically significant increase in BDCA-3+ and/or MR+ DCs brings a novel characteristic to BAL analysis in allergic patients.","[Sediva, A.] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Prague 15009, Czech Republic; [Kayserova, J.; Zentsova-Jaresova, I.; Budinsky, V.; Rozkova, D.; Kopecka, J.; Vernerova, E.; Spisek, R.; Sediva, A.] Charles Univ Prague, Dept Immunol, Fac Med 2, Prague, Czech Republic; [Kopecka, J.] Life Technol Czech Republ, Prague, Czech Republic; [Pohunek, P.; Skalicka, V.] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic","Sediva, A (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, V Uvalu 84, Prague 15009, Czech Republic.","anna.sediva@fnmotol.cz",null,null,"Czech Ministry of Health [MZ0FNM2005]; Czech Ministry of Education, Youth and Sports [MSM0021620812]","This work was supported by the project MZ0FNM2005 from the Czech Ministry of Health and by the project MSM0021620812of the Czech Ministry of Education, Youth and Sports.",null,35,2,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-9475",null,null,"SCAND J IMMUNOL","Scand. J. Immunol.","MAR",2012,75,3,null,null,null,null,305,313,null,"10.1111/j.1365-3083.2011.02649.x",null,9,"Immunology","Immunology","895MB","WOS:000300499200007"]
[null,null,null,null,"J","Hermanova, I; Zaliova, M; Trka, J; Starkova, J",null,null,null,"Hermanova, Ivana; Zaliova, Marketa; Trka, Jan; Starkova, Julia",null,null,"Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase","EXPERIMENTAL HEMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL-LINES; IN-VITRO; DRUG-SENSITIVITY; UP-REGULATION; MTT-ASSAY; RESISTANCE; CHILDREN; GENE; CHEMOSENSITIVITY","Childhood acute lymphoblastic leukemia (ALL) is treated with combined chemotherapy, including L-asparaginase (L-asp). Recent studies question the traditional view that the level of asparagine synthetase (ASNS), an enzyme producing the intracellular asparagine, correlates with the response to L-asp treatment. However, the importance of ASNS in response to L-asp has neither been confirmed nor refuted so far. In this study, we wanted to elucidate the effect of ASNS expression level on the sensitivity of ALL cells to L-asp treatment. We used four ALL cell lines (NALM-6, RS4;11, REH, and UOCB6) and 30 diagnostic bone marrow samples of ALL patients to study the relationship between ASNS expression and sensitivity to L-asp using MTS proliferation assay. RNA interference was used to study the effect of a range of ASNS levels on the response to L-asp treatment. Using a cell line model with a gradually knocked-down ASNS gene, we defined a cutoff level below which ASNS gene expression does not correlate with sensitivity to L-asp. Importantly, ASNS gene expression in patients' ALL blasts is below this level. We confirmed that there was no correlation between ASNS gene expression and sensitivity to L-asp in ALL blasts. In addition, we show that cells with low ASNS expression level do not respond to asparagine deprivation by upregulation of ASNS gene expression. In conclusion, the ASNS expression level does not predict sensitivity to L-asp in leukemic blasts. Moreover, cell lines with high basal expression of ASNS cannot serve as a valid model for studies on the relationship between the ASNS and L-asp cytotoxic effect. (C) 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.","[Hermanova, Ivana; Zaliova, Marketa; Trka, Jan; Starkova, Julia] Charles Univ Prague, Childhood Leukaemia Invest Prague, Fac Med 2, Dept Pediat Hematol Oncol, Prague 15006, Czech Republic","Trka, J (reprint author), Charles Univ Prague, Childhood Leukaemia Invest Prague, Fac Med 2, Dept Pediat Hematol Oncol, V Uvalu 84, Prague 15006, Czech Republic.","jan.trka@lfmotol.cuni.cz",null,null," [MSM002162081];  [GAUK 92710];  [IGA NT12429]","I.H., J.T., and J.S. were supported by MSM002162081, GAUK 92710, and IGA NT12429. We thank professor Michael S. Kilberg for providing us with asparagine synthetase antibody. The collaboration of all Czech Pediatric Hematology Centers is greatly appreciated.",null,35,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0301-472X",null,null,"EXP HEMATOL","Exp. Hematol.","AUG",2012,40,8,null,null,null,null,657,665,null,"10.1016/j.exphem.2012.04.005",null,9,"Hematology; Medicine, Research & Experimental","Hematology; Research & Experimental Medicine","986CX","WOS:000307319500006"]
[null,null,null,null,"J","Jahodova, A; Krsek, P; Komarek, V; Kudr, M; Kyncl, M; Zamecnik, J; Tichy, M",null,null,null,"Jahodova, Alena; Krsek, Pavel; Komarek, Vladimir; Kudr, Martin; Kyncl, Martin; Zamecnik, Josef; Tichy, Michal",null,null,"Frontal lobe epilepsy with atypical seizure semiology resembling shuddering attacks or wet dog shake seizures","EPILEPTIC DISORDERS",null,null,"English","Article",null,null,null,null,null,"frontal lobe epilepsy; wet dog shake attacks; focal cortical dysplasia; epilepsy surgery; seizure semiology; shuddering","BEHAVIOR; CHILDREN","We report a girl with a drug-resistant frontal lobe epilepsy caused by focal cortical dysplasia, who exhibited uncommon seizures. The seizures consisted of shoulder or whole body shuddering after a short psychic aura and face grimacing. Consciousness was fully preserved. The seizures resembled \"wet dog shake\" seizures described in rat models of epilepsy or shuddering attacks in infants. EEG findings were inconclusive, however, MRI showed a clear dysplastic lesion in the right frontal mesial and polar structures. The patient underwent an extended lesionectomy guided by neuronavigation and intraoperative electrocorticography. Focal cortical dysplasia type lb was histologically confirmed and the patient has been seizure-free for the three years following resection. [Published with video sequences]","[Krsek, Pavel] Charles Univ Prague, Motol Hosp, Sch Med 2, Dept Pediat Neurol,Motol Epilepsy Ctr, CZ-15006 Prague 5, Czech Republic; [Kyncl, Martin] Charles Univ Prague, Motol Hosp, Sch Med 2, Dept Radiol, CZ-15006 Prague 5, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Motol Hosp, Sch Med 2, Dept Pathol, CZ-15006 Prague 5, Czech Republic; [Tichy, Michal] Charles Univ Prague, Motol Hosp, Sch Med 2, Dept Neurosurg, CZ-15006 Prague 5, Czech Republic","Krsek, P (reprint author), Charles Univ Prague, Motol Hosp, Sch Med 2, Dept Pediat Neurol,Motol Epilepsy Ctr, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","pavel.krsek@post.cz",null,null,"Kontakt Program [ME09042];  [MZOFNM2005-6504]","This work was supported by grants MZOFNM2005-6504 and Kontakt Program ME09042.",null,19,1,1,"JOHN LIBBEY EUROTEXT LTD","MONTROUGE","127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE","1294-9361",null,null,"EPILEPTIC DISORD","Epileptic Disord.","MAR",2012,14,1,null,null,null,null,69,75,null,"10.1684/epd.2012.0495",null,7,"Clinical Neurology","Neurosciences & Neurology","922RF","WOS:000302564900009"]
[null,null,null,null,"J","Pantoflicek, T; Koblihova, E; Ryska, M",null,null,null,"Pantoflicek, Tomas; Koblihova, Eva; Ryska, Miroslav",null,null,"S-Adenosylmethionine does not Reduce Ischaemia-Reperfusion Injury to a Marginal Liver Graft in an In vivo Experiment","HEPATO-GASTROENTEROLOGY",null,null,"English","Article",null,null,null,null,null,"Liver transplantation; Liver steatosis; Ischaemia-reperfusion injury; S-adenosylmethionine","ADENOSYL-L-METHIONINE; RAT-LIVER; N-ACETYLCYSTEINE; MONOCLONAL-ANTIBODY; DEFICIENT DIET; TRANSPLANTATION","Background/Aims: There are a limited number of appropriate cadaver liver donors. One possible solution is the use of marginal liver grafts from cadaver donors for liver transplantation. Methodology: Rats with liver steatosis were divided into four containing seven animals steatotic liver grafts; +S-adenosylmethionine; I-b: steatotic liver grafts were transplanted; no S-adenosylmethionine; II-a: normal liver grafts, +S-adenosylmethionine; II-b: normal liver grafts. Blood samples were taken at days -1, 3 and 14. Results: ALT values at day 14: 1.75 +/- 1.10 mu kat/L (in group I-a), 1.91 +/- 1.41 mu kat/L (in group I-b), 2.13 +/- 1.85 mu kat/L (in group II-a) and 2.08 +/- 1.35 mu kat/L (in group II-b). There were no significant differences between these values. GSH values at day 14 post-transplantation were: 44.90 +/- 8.61 mu M/ mg (in group I-a), 43.82 +/- 8.58 mu M/mg (in group I-b), 41.65 +/- 4.87 mu M/mg (in group II-a) and 42.71 +/- 4.17 mu M/ mg (in control group II-b). Conclusions: Our study did not demonstrate the positive effect of S-adenosylmethionine on ischaemia-reperfusion injury during liver transplantation in rats.","[Pantoflicek, Tomas; Koblihova, Eva; Ryska, Miroslav] Charles Univ Prague, Fac Med 2, Dept Surg 2, Ctr Cell Therapy & Tissue Engn, Prague 16000 6, Czech Republic; [Pantoflicek, Tomas; Koblihova, Eva; Ryska, Miroslav] Cent Mil Hosp, Fac Med 2, Dept Surg, Prague 16000 6, Czech Republic","Pantoflicek, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Surg 2, Ctr Cell Therapy & Tissue Engn, Vojenske Nemocnice 1200, Prague 16000 6, Czech Republic.","tomas@pantoflicek.cz",null,null,"Centre for Cell Therapy and Tissue Engineering [LN00A065];  [S-8120]","The study was supported by the Research Centre LN00A065, Centre for Cell Therapy and Tissue Engineering and grant NO S-8120.",null,16,1,1,"H G E UPDATE MEDICAL PUBLISHING S A","ATHENS","PO BOX 17257, ATHENS GR-10024, GREECE","0172-6390",null,null,"HEPATO-GASTROENTEROL","Hepato-Gastroenterol.","JAN-FEB",2012,59,113,null,null,null,null,216,218,null,"10.5754/hge11239",null,3,"Gastroenterology & Hepatology; Surgery","Gastroenterology & Hepatology; Surgery","907DF","WOS:000301397300050"]
[null,null,null,null,"J","Raudenska, J",null,null,null,"Raudenska, Jaroslava",null,null,"Model of cognitive-behavioral therapy in adult patients with chronic pain states of nonmalignant etiology","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"cognitive-behavioral therapy; chronic pain; quality of life","RANDOMIZED CONTROLLED-TRIALS; DISORDERS; METAANALYSIS; MANAGEMENT; ANXIETY","Model of cognitive-behavioral therapy in adult patients with chronic pain states of nonmalignant etiology J. Raudenska Pain, from its origin through its treatment and in its subsequent maintenance, is influenced by psychosocial factors. For this reason, psychotheraphy is also used in pain treatment. The use of cognitive-behavioral therapy (CBT) is dominant. The paper describes the history of CBT and its three basic approaches: behavioral, (operant), cognitive, and cognitive-behavioral. The indications to CBT and the most frequent problems in treatment are isolated. Basic CBT techniques in chronic pain treatment, namely the cognitive restructuration and the practice of skills for pain and stress management (education, adaptive positive self-instruction, relaxation and imagination, increasing activity, exposition, structured problem solving, and relapse coping) are specified. Particular fields of chronic pain which represent the goal of multidisciplinary program of pain treatment including CBT are examined. The author structures basic assumptions of successful program: direct and indirect positive reinforcement of pain behavior, positive reinforcement of required behavior, improvement of physical condition, cognitive reframing, education, training in CBT in pain treatment, and conforming to the CBT principles. The paper sumarizes the efficiency of CBT in chronic pain treatment in adult patients, describes problems in its monitoring and suggests some innovations for increasing its use.","Oddeleni Klin Psychol FN Motol & 2 LF UK, Prague 15006, Czech Republic","Raudenska, J (reprint author), Oddeleni Klin Psychol FN Motol & 2 LF UK, Ovalu 84, Prague 15006, Czech Republic.","Jaroslava.Raudenska@fnmotol.cz",null,null,null,null,null,57,1,1,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X","1804-6436",null,"CESK PSYCHOL","Cesk. Psychol.",null,2012,56,5,null,null,null,null,473,487,null,null,null,15,"Psychology, Multidisciplinary","Psychology","042KF","WOS:000311469400007"]
[null,null,null,null,"J","Veselka, J; Tomasov, P; Zemanek, D",null,null,null,"Veselka, Josef; Tomasov, Pavol; Zemanek, David",null,null,"Mid-Term Outcomes of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy in Patients With Sigmoid Versus Neutral Ventricular Septum","JOURNAL OF INVASIVE CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"ablation; obstruction; hypertrophic cardiomyopathy; sigmoid septum","OUTFLOW TRACT OBSTRUCTION; TRANSCORONARY ABLATION; ECHOCARDIOGRAPHY; RISK; AGE","Background. The aim of this study was to determine whether the differences in the baseline septal morphology influenced outcomes of patients after alcohol septal ablation (ASA). Methods. A total of 100 consecutive, highly symptomatic patients with HOCM and a neutral or sigmoid septum (74 patients vs 26 patients) underwent ASA and were examined clinically and echocardiographically at baseline and at follow-up (median 30 months vs 24 months). Results. At baseline, a neutral septum morphology was associated with a thicker basal septum [21 (19-24) mm vs 19 (18-20) mm; P<0.01] and higher pressure gradient at rest [59 (39-80) mm vs 43 (33-50) mm; P<0.01], but a similar pressure gradient after provocation [100 (72-120) mmHg vs 97 (70-110) mmHg; P=0.31], and subsequently both resting gradient [10 (10-16) mmHg vs 12 (10-15) mmHg; P=0.67] and provoked gradient after ASA [20 (1030) mmHg vs 18 (12-25) mmHg; P=0.71]. Four patients died during follow-up (4% vs 4%; NS). Pressure gradient, septum thickness and symptoms decreased significantly in both groups. Conclusions. Patients treated with ASA who had a sigmoid septum were characterized at baseline by a thinner basal septum and lower pressure gradient at rest. However, they showed an identical pressure gradient after provocation and subsequently after ASA. ASA was safe and effective in both groups of patients. J INVASIVE CARDIOL 2012;24(12):636-640","Charles Univ Prague, Sch Med 2, Dept Cardiol, CR-11636 Prague 1, Czech Republic; Univ Hosp Motol, Prague 15000 5, Czech Republic","Veselka, J (reprint author), Univ Hosp Motol, Dept Cardiol, V Uvalu 84, Prague 15000 5, Czech Republic.","josef.veselka@fnmotol.cz",null,null,"Ministry of Health, Czech Republic [00064203]","Supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic)",null,19,0,1,"H M P COMMUNICATIONS","MALVERN","83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA","1042-3931",null,null,"J INVASIVE CARDIOL","J. Invasive Cardiol.","DEC",2012,24,12,null,null,null,null,636,640,null,null,null,5,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","109EH","WOS:000316348300011"]
[null,null,null,null,"J","Trc, T; Stastny, E",null,null,null,"Trc, T.; Stastny, E.",null,null,"Oblong Acetabular Cup, Type TC, for Revision Total Hip Arthroplasty","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"total hip replacement; revision total hip arthroplasty; oblong cup","FOLLOW-UP; RECONSTRUCTION; REPLACEMENT; COMPONENT","PURPOSE OF THE STUDY Revision total hip arthroplasty is a demanding surgical procedure. It involves a massive loss of acetabular bone stock associated with primary implant removal, and a complicated revision cup fixation in the highly damaged surrounding bone. The authors describe the use of a novel oblong acetabular cup, type TC (Trc-Cingr), for replacement of a loose acetabular component. The aim of the study is to present this novel implant with evaluation of the first clinical results and to report on the authors' experience with revision arthroplasty assessed at 24 to 62 months of follow-up. MATERIAL The TC cup was used in revision total hip arthroplasty in 40 patients treated between February 2004 and June 2007. Aseptic loosening of a cemented cup was an indication for surgery in the majority of patients. The first 10 treated patients were supervised, according to the strict rules of good clinical practice, by the State Institute for Drug Control. A total of 31 patients were evaluated. There were 20 women and 11 men with an average age of 68 years (range, 41 to 81 years) at the time of primary implantation. METHODS At the end of 2009, 31 patients were evaluated at a follow-up of 24 to 62 months (average, 44.8 months) after revision surgery. The patients' age, gender, body mass index, physical activity, diagnosis for indication, implant size and intra- and post-operative complications were recorded. The development of secondary implant stability was assessed on X-ray films taken at 3, 6, and 12 months and then at 1 year after surgery. Attention was paid to implant and screw positions and potential implant migration and signs of osteolysis around the cup and screws. An objective assessment of the results was obtained by comparing the pre- and post-operative values of the Harris hip score (HHS). RESULTS A femoral component was replaced together with a revision cup in 20 patients. The average HHS value increased from 41.86 points pre-operatively to 82.70 points post-operatively. The results were recorded as excellent in six, very good in 17, satisfactory in six and poor in two patients. The radiographic findings showed good bone-implant integration in 26 patients and radiolucent lines <= 1mm in width in DeLee zone 3 in three patients. In one overweight patient, discontinuity of two proximally inserted screws, but no detectable implant migration, was recorded. There was only one case of proximal migration of the TC cup, with osteolysis detected around all screws (Paprosky type 3B defect). DISCUSSION The acetabular cup is the most frequently re-implanted component in our country. This is due to a high proportion of total hip arthroplasties with the previous frequent use of a cemented POLDI prosthesis whose neck in a valgus position probably played its role in increased wear of the cup. Acetabular bone defects are usually extensive and the operative tactics are based on the Paprosky classification. Type 3A and 36 defects, exceptionally also type 2C defects, are most serious and acetabular cup replacement is most difficult. The oval-shaped uncemented TC cup was developed with the objective to reconstruct defects on the bottom of the acetabulum, with stable and firm primary fixation of the implant secured in bone with implant augmentation screws and additional fixation screws. Good primary fixation with bone grafting to fill defects and spaces between implant ribs should facilitate bone remodelling in the close vicinity of the cup. A minimum of 24 months after revision cup implantation is regarded as sufficient for an objective evaluation of hip function and radiographic evidence of good bone-implant integration.","[Trc, T.; Stastny, E.] Univ Karlovy, Fak Nemocnice Motole, Lekarske Fak, Klin Detske & Dospele Ortopedie Traumatol 2, Prague, Czech Republic","Trc, T (reprint author), FN Motol, Ortoped Klin Deti & Dospelych LF UK 2, V Uvalu 84, Prague 15018 5, Czech Republic.","tomas.trc@lfmotol.cuni.cz",null,null,null,null,null,18,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2012,79,6,null,null,null,null,506,511,null,null,null,6,"Orthopedics","Orthopedics","065IZ","WOS:000313143300005"]
[null,null,null,null,"J","Spacek, M; Zimolova, P; Veselka, J",null,null,null,"Spacek, Miloslav; Zimolova, Petra; Veselka, Josef",null,null,"Takayasu Arteritis: Use of Drug-Eluting Stent and Balloon to Treat Recurring Carotid Restenosis","JOURNAL OF INVASIVE CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"Takayasu arteritis; restenosis; drug-eluting stent; drug-eluting balloon","STENOSIS","Takayasu arteritis (TA) is an inflammatory disease affecting large and medium-sized arteries and causing occlusive, aneurysmal, or stenotic lesions. It is also known that with chronic course, the disease has a tendency to recur at either the same site or different. We report a patient with TA whose carotid stenosis was initially treated with bare metal stents but the patient suffered from recurring localized restenosis. Eventually, the patient was treated with (off-label) coronary drug-eluting stent and drug-eluting balloon with favorable long-term outcome. Therefore, we suggest that drug-eluting interventions might have a place in treatment of TA patients with recurring restenosis. J INVASIVE CARDIOL 2012; 24(9): E190-E192","[Spacek, Miloslav; Zimolova, Petra; Veselka, Josef] Charles Univ Prague, Sch Med 2, Dept Cardiol, CardioVasc Ctr,Motol Univ Hosp, Prague 15006 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Sch Med 2, Dept Cardiol, CardioVasc Ctr,Motol Univ Hosp, V Uvalu 84, Prague 15006 5, Czech Republic.","veselka.josef@seznam.cz",null,null,null,null,null,7,0,0,"H M P COMMUNICATIONS","MALVERN","83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA","1042-3931",null,null,"J INVASIVE CARDIOL","J. Invasive Cardiol.","SEP",2012,24,9,null,null,null,null,"E190","E192",null,null,null,3,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","030BT","WOS:000310543300004"]
[null,null,null,null,"J","Krizova, E",null,null,null,"Krizova, Eva",null,null,"VOLUNTEERING AND MUTUAL AID IN HEALTH AND SOCIAL CARE IN THE CZECH REPUBLIC AS AN EXAMPLE OF ACTIVE CITIZENSHIP","CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH",null,null,"English","Article",null,null,null,null,null,"civic sector; health and social services; formal and informal volunteering; altruism; motivation","SERVICE","This article informs about recent research findings on voluntary and mutual aid in the Czech Republic with a special attention paid to formal volunteering in health and social care. The data suggest that public involvement is comparable to middle-frequency experienced in European countries. In this respect, volunteering is higher in the Czech Republic than in other former Eastern European countries and is an evidence of a successful and rapid restoration of the civic sector. New patterns of volunteering featured by planning, coordination, and contracting have spread out being strongly supported by national and EU policy measures. Managerial patterns of volunteering are dominating in health and social care institutions. Volunteering in health and social care is firmly motivated by emotional altruism; however, reciprocal (instrumental) and normative motivations are also present, though to a lesser extent compared to other sectors of volunteer activities. In the managerial pattern of volunteering altruism is balanced with personal gains and benefits for those who volunteer. Volunteering is deeply embedded in a civic, humanitarian paradigm instead of a religious faith and duty.","Charles Univ Prague, Dept Med Eth & Humanities, Fac Med 2, Prague 10506 5, Czech Republic","Krizova, E (reprint author), Charles Univ Prague, Dept Med Eth & Humanities, Fac Med 2, Plzenska 130-221, Prague 10506 5, Czech Republic.","evakriz@centrum.cz",null,null,"Norwegian Financial Funds (EEA); Norwegian Financial Funds (NFF)","The theoretical framework was elaborated and the data have been gathered from an original questionnaire within the research project The Patterns and Values of Volunteering in the Czech and Norwegian society which was co-funded by the Norwegian Financial Funds (EEA and NFF) in 2009-2010 and led by Pavol Fric from the Charles University/Faculty of Social Sciences.",null,23,0,0,"NATL INST PUBLIC HEALTH","PRAGUE 10","DEPT SCIENTIFIC INFORMATION, SROBAROVA 48, PRAGUE 10, 100 42, CZECH REPUBLIC","1210-7778",null,null,"CENT EUR J PUBL HEAL","Cent. Eur. J. Public Health","JUN",2012,20,2,null,null,null,null,110,115,null,null,null,6,"Public, Environmental & Occupational Health","Public, Environmental & Occupational Health","970TB","WOS:000306154100004"]
[null,null,null,null,"J","Darsova, D; Pochop, P; Uhlik, J; Klapkova, E; Tesfaye, H; Kodetova, D; Lestak, J; Malis, J; Vajner, L",null,null,null,"Darsova, Denisa; Pochop, Pavel; Uhlik, Jiri; Klapkova, Eva; Tesfaye, Hundie; Kodetova, Daniela; Lestak, Jan; Malis, Josef; Vajner, Ludek",null,null,"Topotecan vitreous and plasma levels and retinal toxicity after transcorneal intravitreal delivery in healthy albino rabbits: Alternative retinoblastoma treatment","BIOMEDICAL PAPERS-OLOMOUC",null,null,"English","Article",null,null,null,null,null,"intravitreal drug delivery; intravitreal seeding; periocular injection; retinoblastoma; topotecan","INTRAOCULAR RETINOBLASTOMA; FIBRIN SEALANT; CHEMOTHERAPY; CARBOPLATIN; INJECTION; CHILDREN; AGENTS","Aim. To determine intravitreal and plasma concentrations and retinal toxicity after transcorneal intravitreal injection of 1 mu g and 2 mu g of topotecan (Hycamtin). Method. Twelve healthy albino rabbits were included in this in vivo experiment. Six anesthetized albino rabbits received a single transcorneal intravitreal injection of 1 mu g (group A) or 2 mu g (group B) of topotecan. Vitreous and blood samples were collected until 168 h. Left eyes were treated with the same volume of saline. Plasma and vitreous levels of topotecan were determined by high-performance liquid chromatography. Area under the plasma concentration time curve (AUC) was calculated using trapezoidal rule. Clinical evidence of toxicity was classified into four grades according to anatomical structures. Electroretinograms (ERGs) were recorded. Results. Time to maximum concentration was observed up to 2 h after drug injection in group A whereas up to 1 h in group B. Low levels of topotecan were detected in plasma in both groups and in the vitreous humor of the contralateral eye in group B. Topotecan levels (mean vitreous AUC in group A 2.55 mu g/mL. h and in group B 5.338 mu g/mL. h) were detectable up to 6 h in both groups. We observed following structural changes in rabbit eyes: corneal vascularization, cataract, hemophthalmus, choroidal edema and focal retinal atrophy. Abnormal ERGs were obtained. Conclusion. Our findings proved that transcorneal intravitreal administration of 1 mu g and 2 mu g of topotecan results in potentially cytotoxic intraocular concentrations. More studies are needed to establish the safety of topotecan for retinoblastoma in children.","[Darsova, Denisa; Pochop, Pavel] Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, Prague, Czech Republic; [Darsova, Denisa; Pochop, Pavel; Klapkova, Eva; Tesfaye, Hundie; Kodetova, Daniela; Malis, Josef] Motol Hosp, Prague, Czech Republic; [Uhlik, Jiri; Vajner, Ludek] Charles Univ Prague, Dept Histol & Embryol, Fac Med 2, Prague, Czech Republic; [Klapkova, Eva; Tesfaye, Hundie] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague, Czech Republic; [Kodetova, Daniela] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Malis, Josef] Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Lestak, Jan] Clin Jan Lestak, Dept Ophthalmol, Prague, Czech Republic","Darsova, D (reprint author), Charles Univ Prague, Dept Ophthalmol Children & Adults, Fac Med 2, Prague, Czech Republic.","denisa.darsova@centrum.cz","Vajner, Ludek/C-5823-2014; Uhlik, Jiri/C-6282-2014",null,"Grant Agency of Charles University [63008]; GlaxoSmithKline, England","To GlaxoSmithKline, England for topotecan donation. Supported by a grant of the Grant Agency of Charles University No. 63008.",null,21,0,0,"PALACKY UNIV, MEDICAL FAC","OLOMOUC","CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC","1213-8118",null,null,"BIOMED PAP","Biomed. Pap-Olomouc",null,2012,156,4,null,null,null,null,318,323,null,"10.5507/bp.2011.068",null,6,"Engineering, Biomedical; Medicine, Research & Experimental","Engineering; Research & Experimental Medicine","063GB","WOS:000312983100006"]
[null,null,null,null,"J","Kafka, P; Vajnerova, O; Herget, J; Hampl, V",null,null,null,"Kafka, P.; Vajnerova, O.; Herget, J.; Hampl, V.",null,null,"Rho-Kinase Inhibition Attenuates Acute Hypoxic Fetoplacental Vasoconstriction in the Rat","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Hypoxic fetoplacental vasoconstriction; Calcium sensitization; Rho-kinase pathway; Placenta; Fasudil","SMOOTH-MUSCLE; PULMONARY; PLACENTA; ARTERIES; CALCIUM","The vessels on the fetal side of the placenta differ from most other vascular beds except the lungs in that they respond to acute hypoxia by vasoconstriction. An essential role of calcium influx in the mechanism of this hypoxic fetoplacental vasoconstriction (HFPV) has been shown previously. That finding does not, however, exclude the possible involvement of other mechanisms of vascular tone regulation. In this study we tested the hypothesis that Rho-kinase-mediated calcium sensitization is involved in HFPV. We used a model of isolated rat placenta dually perfused (from both the maternal and fetal side) with Krebs salt solution saturated with normoxic and hypoxic gas mixture respectively at constant flow rate. Rho-kinase pathway was inhibited by fasudil (10 mu M). We found that fasudil reduced basal normoxic fetoplacental vascular resistance and completely prevented HFPV. This suggests that the activity of Rho-kinase signaling pathway is essential for HFPV.","[Kafka, P.; Vajnerova, O.; Herget, J.; Hampl, V.] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague 15000 5, Czech Republic; [Kafka, P.] Charles Univ Prague, Fac Med 3, Dept Anaesthesiol & Intens Care Med, Prague 15000 5, Czech Republic","Kafka, P (reprint author), Charles Univ Prague, Fac Med 2, Dept Physiol, Plzenska 130-221, Prague 15000 5, Czech Republic.","petrkaf@yahoo.com","Hampl, Vaclav/A-2732-2009","Hampl, Vaclav/0000-0001-5776-4624","Grant Agency of the Czech Republic [305/08/0108]; Second Faculty of Medicine, Charles University in Prague","The study was supported by the Grant Agency of the Czech Republic 305/08/0108 and by the Second Faculty of Medicine, Charles University in Prague.",null,13,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2012,61,null,null,2,null,null,"S43","S48",null,null,null,6,"Physiology","Physiology","026FM","WOS:000310260000006"]
[null,null,null,null,"J","Kotaska, K; Dusek, P; Prusa, R; Vesely, S; Babjuk, M",null,null,null,"Kotaska, Karel; Dusek, Pavel; Prusa, Richard; Vesely, Stepan; Babjuk, Marek",null,null,"Urine and Serum Cathepsin B Concentrations in the Transitional Cell Carcinoma of the Bladder","JOURNAL OF CLINICAL LABORATORY ANALYSIS",null,null,"English","Article",null,null,null,null,null,"transitional cell carcinoma; bladder; cathepsin B; invasive; noninvasive tumors","CANCER; EXPRESSION; INHIBITORS; NEOPLASMS; WORLD","Background: It has been shown that expression and activity of lysosomal proteolytic enzymes (i.e., cathepsin B) correlate with tumor progression in various neoplasms. We investigate possible correlation of cathepsin B concentrations with grading and invasivity of tumorous bladder tissue. Method: Cathepsin B concentrations in serum and urine were measured in 40 patients (29 men, 11 women, mean age 68 years) with transitional cell carcinoma (TCC) of the bladder without metastases and in control group of 64 healthy subjects (28 men, 36 women, mean age 55 years) using commercially available enzymatic immunoassay. Concentration of cathepsin B in urine was adjusted on creatinine. Urinary creatinine in all samples was measured by enzymatic creatinase method. Patients were divided into groups according to the grading (low grading: 18 patients, high grading: 22 patients) and invasivity of the carcinoma (nonmuscle-invasive tumors: 23 patients, invasive tumors: 17 patients). Result: Concentrations of cathepsin B in urine were significantly elevated in patients than in control group (Median = 3.87 mu g/L vs. 1.35 mu g/L, P = 0.0002). Similarly, the ratio of U-cathepsin B/creatinine was significantly higher in patients (Median: 0.44 mu g/mmol creatinine vs. 0.17 mu g/mmol creatinine, P < 0.0001). U-cathepsin B may prove to be useful biomarker (area under the curve [AUC] = 0.72 and 0.73 for the U-cathepsin B/creatinine ratio, respectively). S-cathepsin B significantly correlated with grading of carcinoma (P = 0.02) and U-cathepsin B and U-cathepsin B/creatinine are positively associated with invasive tumors (P = 0.0001 and P = 0.002). Conclusion: Cathepsin B concentrations correlate well with grading and invasivity of tumors and may have diagnostic value in investigation of bladder cell carcinoma. New index U-cathepsin B/Creatinine ratio is more appropriate biomarker to monitor TCC, than U-cathepsin B so far. J. Clin. Lab. Anal. 26:61-65, 2012. (C) 2012 Wiley Periodicals, Inc.","[Dusek, Pavel; Vesely, Stepan; Babjuk, Marek] Charles Univ Prague, Fac Med 2, Dept Urol, Prague 15006 5, Czech Republic; [Kotaska, Karel; Dusek, Pavel; Prusa, Richard; Vesely, Stepan; Babjuk, Marek] Univ Hosp Motol, Prague 15006, Czech Republic; [Kotaska, Karel; Prusa, Richard] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, Prague 15006 5, Czech Republic","Dusek, P (reprint author), Charles Univ Prague, Fac Med 2, Fac Hosp Motol, Dept Urol, Vuvalu 84, Prague 15006 5, Czech Republic.","kotaska@email.cz; pav.dusek@gmail.com",null,null,"IGA MZ CR","This work was supported by the research grant IGA MZ CR.",null,21,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0887-8013",null,null,"J CLIN LAB ANAL","J. Clin. Lab. Anal.",null,2012,26,2,null,null,null,null,61,65,null,"10.1002/jcla.21483",null,5,"Medical Laboratory Technology","Medical Laboratory Technology","931YN","WOS:000303255400003"]
[null,null,null,null,"J","Palova, S; Havlin, J; Charvat, J",null,null,null,"Palova, Sabina; Havlin, Jan; Charvat, Jiri",null,null,"The association of heart rate variability examined in supine and standing position with ambulatory blood pressure monitoring in anorexia nervosa","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"anorexia nervosa; blood pressure; ABPM; heart rate variability","POWER","OBJECTIVE: To evaluate the association of heart rate variability (HRV) examined in supine and standing position with ambulatory blood pressure monitoring (ABPM) in patients with anorexia nervosa (AN). METHODS: HRV in supine and standing position and ABPM were examined in 30 AN patients and 30 control subjects. The correlations between HRV and ABPM were evaluated. RESULTS: The average age was 25 +/- 5 in AN patients and 25 +/- 4 years in controls (NS). LF (low frequency) power in AN patients and controls was comparable in supine position. LF power significantly increased during standing in controls, but no increment was detected in AN patients. The HF (high frequency) power was significantly increased in AN patients in supine position, but after standing was comparable with controls. The ratio LF/HF was lower both in supine and standing position in AN patients but the differences did not reach statistical significance. Blood pressure values in AN patients were comparable with controls in supine position but were significantly lower in standing position. Ambulatory blood pressure values were significantly lower in AN patients during active but not sleeping period. In standing position HF and LF powers positively and LF/HF negatively correlated with ABPM blood pressure values during active period in controls while in AN patients only LF power correlated with diastolic and mean blood pressures. CONCLUSION: The lower ABPM values in AN patients during active period in comparison with control subjects may be explained by HRV changes, mainly by its impaired relations with blood pressure in standing position.","[Charvat, Jiri] Charles Univ Prague, Dept Med, Fac Med 2, Prague 15006 5, Czech Republic; Fac Hosp Motol, Prague, Czech Republic","Charvat, J (reprint author), Charles Univ Prague, Dept Med, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","jiri.charvat@lfmotol.cuni.cz",null,null,null,null,null,21,0,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2012,33,2,null,null,null,null,196,200,null,null,null,5,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","955RD","WOS:000305037700014"]
[null,null,null,null,"J","Kaluzova, M; Petrak, B; Lisy, J; Vaculik, M; Bendova, S; Komarek, V",null,null,null,"Kaluzova, M.; Petrak, B.; Lisy, J.; Vaculik, M.; Bendova, S.; Komarek, V.",null,null,"Idiopathic Aqueductal Stenosis and Developmental Speech Disorder in Children with Neurofibromatosis von Recklinghausen type 1-Two Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"neurofibromatosis von Recklinghausen type 1; hydrocephalus; aqueductal stenosis; speech development disorder","NF1 GENE","Neurofibromatosis von Recklinghausen type 1 (NF1) is an autosomal dominant neurocutaneous disorder, with incidence of 1 : 2,500-3,000 and a high rate of new mutations. This multisystem disorder is frequently associated with tumours. Hydrocephalus in NF1 patients is either secondary to brain expansion or as a result of idiopathic aqueductal stenosis. Learning disability, behavioural problems and speech development disorders are common in NF1 children. We are presenting two case reports of NF1 children with developmental speech disorder and hydrocephalus consequent to idiopathic aqueductal stenosis. One child developed stenosis during follow up. Coincidence of hydrocephalus due to idiopathic aqueductal stenosis and severe developmental speech disorder has not been described yet.","[Kaluzova, M.; Petrak, B.; Komarek, V.] 2 LF UK & FN Motole, Klin Detske Neurol, Prague 15006 5, Czech Republic; [Lisy, J.] 2 LF UK & FN Motole, Klin Zobrazovacich Metod, Prague 15006 5, Czech Republic; [Vaculik, M.] 2 LF UK & FN Motole, Oddeleni Neurochirurg, Prague 15006 5, Czech Republic; [Bendova, S.] 2 LF UK & FN Motole, Ustav Biol & Lekarske Genetiky, Prague 15006 5, Czech Republic","Kaluzova, M (reprint author), 2 LF UK & FN Motole, Klin Detske Neurol, V Uvalu 84-1, Prague 15006 5, Czech Republic.","marie_kaluzova@centrum.cz",null,null,null,null,null,12,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,5,null,null,null,null,633,636,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","010IJ","WOS:000309087800017"]
[null,null,null,null,"J","Mixa, V; Kraus, J; Skaba, R; Cvachovec, K",null,null,null,"Mixa, V.; Kraus, J.; Skaba, R.; Cvachovec, K.",null,null,"Intraoperative Monitoring of Anorectal Sphincter Complex during a Surgery in Children with Anorectal Malformations","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"perioperative electromyostimulation; anorectal malformation; anorectal sphincter complex; caudal epidural anesthesia","ELECTRICAL-STIMULATION; MANAGEMENT; DISORDERS; RESPONSES","Diagnostic perioperative electromyostimulation of the sphincter complex muscles with bipolar Pena stimulator is used for anorectal reconstruction in children with congenital anorectal malformations (ARM). The objective of this study was to develop an accurate technique for perioperative measurement of electromyographic parameters in children with ARM and, consequently, to determine the most suitable method of general anesthesia. A Key Point EMG v3.22 (Medtronic) was used. The tissue of the sphincter complex was stimulated with a bipolar electrode and a DCN 25 thin concentric needle electrode was used for recording. Intensity of the stimulation was 14 mA administered over 0.2 ms. The method was used in 17 patients repeatedly during a surgery for anorectal malformation. The examinations were performed at various stages of anesthesia: after induction and during epidural blockade or after administration of a muscle relaxant. The results were compared to scarce data in the literature and confirmed their validity. Through evaluation of the results, the described method was found to be sufficiently accurate. A combination of inhalation anesthesia, opioids and epidural block, with an exclusion of non-depolarizing muscle relaxants, was determined to be the most useful method of anesthesia.","[Mixa, V.; Cvachovec, K.] 2 LF UK, Klin Anesteziol Resuscitace & Intenzivni Med, Prague 15006 5, Czech Republic; [Mixa, V.; Cvachovec, K.] FN Moto, Prague 15006 5, Czech Republic; [Kraus, J.] 2 LF UK, Klin Detske Neurol, Prague 15006 5, Czech Republic; [Skaba, R.] 2 LF UK, Klin Detske Chirurg, Prague 15006 5, Czech Republic","Mixa, V (reprint author), 2 LF UK, Klin Anesteziol Resuscitace & Intenzivni Med, Prague 15006 5, Czech Republic.","vmxa@volny.cz",null,null,null,null,null,12,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,4,null,null,null,null,468,471,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","987RO","WOS:000307435000012"]
[null,null,null,null,"J","Kayserova, J; Sismova, K; Zentsova-Jaresova, I; Katina, S; Vernerova, E; Polouckova, A; Capkova, S; Malinova, V; Striz, I; Sediva, A",null,null,null,"Kayserova, J.; Sismova, K.; Zentsova-Jaresova, I.; Katina, S.; Vernerova, E.; Polouckova, A.; Capkova, S.; Malinova, V.; Striz, I.; Sediva, A.",null,null,"A Prospective Study in Children With a Severe Form of Atopic Dermatitis: Clinical Outcome in Relation to Cytokine Gene Polymorphisms","JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Allergic rhinitis; Allergy; Atopic dermatitis; Single nucleotide polymorphism; Cytokines","RECEPTOR-ALPHA GENE; SERUM IGE LEVELS; INTERLEUKIN-4 RECEPTOR; CONFER SUSCEPTIBILITY; ASTHMA; ASSOCIATION; VARIANTS; POPULATION; PHENOTYPES; HAPLOTYPE","Background and Objective: The course of atopic dermatitis (AD) in childhood is characterized by typical changes in phenotype, including a shift from skin involvement to respiratory allergy usually around the third year of age. We thus designed a prospective study to monitor the outcome of severe AD and to investigate the association between cytokine gene polymorphisms and clinical manifestations. Methods: Clinical and laboratory follow-up of 94 patients with severe AD and 103 healthy controls was performed using routine methodology. Allele, genotype, and haplotype frequencies of single nucleotide polymorphisms of 13 selected cytokine/receptor genes were analyzed using PCR with sequence-specific primers. Results: In our study, genotypes of 7 polymorphisms-IL-4 -1098G/T and -590C/T, IL-6 -174C/G and nt565A/G, and IL-10 -1082A/G, -819C/T, and -592A/C were significantly associated with atopic AD (P<.05). A significant association was also found for TNF-alpha AA and IL-4 GC haplotypes and AD. We confirm the progressive clinical improvement of AD together with a decrease in the severity index SCORAD (SCORing atopic dermatitis) during childhood (P<.05). We found significant differences between IL-4R alpha + 1902 A/G and positivity of tree pollen-specific IgE (P<.05) in the AD group. Moreover, a weak association was also found between IL-10 -819C/T and IL-10 -590A/C and the appearance of allergic rhinitis (P<0.1). Conclusions: We confirmed a clinical shift in allergic phenotype in the first 3 years of life, and showed an association between IL-4, IL-6, and IL-10 polymorphisms and AD. Our data indicate that IL-4 alpha and IL-10 polymorphisms may be considered predictive factors of respiratory allergy in children with AD.","[Kayserova, J.; Sismova, K.; Zentsova-Jaresova, I.; Vernerova, E.; Polouckova, A.; Sediva, A.] Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic; [Katina, S.] Comenius Univ, Fac Math Phys & Informat, Dept Appl Math & Stat, Bratislava, Slovakia; [Katina, S.] Slovak Acad Sci, Inst Normal & Pathol Physiol, Bratislava, Slovakia; [Capkova, S.] Univ Hosp Motol, Paediat Outpatient Dept, Paediat Dept Dermatol, Prague, Czech Republic; [Malinova, V.] Gen Univ Hosp, Fac Med 1, Dept Paediat & Adolescent Med, Prague, Czech Republic; [Striz, I.] Inst Clin & Expt Med, Dept Immunogenet, Prague, Czech Republic","Sediva, A (reprint author), Charles Univ Prague, Dept Immunol, Fac Med 2, Univ Hosp Motol, Vuvalu 84, Prague 15006, Czech Republic.","anna.sediva@fnmotol.cz",null,null,"Czech Republic Ministry of Health [MZ0FNM2005]; Ministry of Education, Youth and Sports [VZ MSM 0021620812];  [VEGA 1/0077/09]","This study was supported by the project MZ0FNM2005 of the Czech Republic Ministry of Health, and by project VZ MSM 0021620812 of the Ministry of Education, Youth and Sports. The statistical analysis was partially supported by the project VEGA 1/0077/09.",null,41,4,4,"ESMON PUBLICIDAD S A","BARCELONA","CALLE BALMES 209, 3 2, BARCELONA, 08006, SPAIN","1018-9068",null,null,"J INVEST ALLERG CLIN","J. Invest. Allergol. Clin. Immunol.",null,2012,22,2,null,null,null,null,92,101,null,null,null,10,"Allergy; Immunology","Allergy; Immunology","924AT","WOS:000302663600003"]
[null,null,null,null,"J","Dostalova, T; Hlinakova, P; Kasparova, M; Rehacek, A; Vavrickova, L; Navratil, L",null,null,null,"Dostalova, Tatjana; Hlinakova, Petra; Kasparova, Magdalena; Rehacek, Adam; Vavrickova, Lenka; Navratil, Leos",null,null,"Effectiveness of Physiotherapy and GaAlAs Laser in the Management of Temporomandibular Joint Disorders","PHOTOMEDICINE AND LASER SURGERY",null,null,"English","Article",null,null,null,null,null,null,"THERAPY","Objective: Low-level laser therapy (LLLT) is a treatment method commonly used in physiotherapy for musculoskeletal disorders. The aim of this study was to monitor the function of temporomandibular joint (TMJ) and surrounding tissues and compare the objective measurements of the effect of LLLT. Background data: LLLT has been considered effective in reducing pain and muscular tension; thus improving the quality of patients' lives. Materials and Methods: TMJ function was evaluated by cephalometric tracing analysis, orthopantomogram, TMJ tomogram, and computer face-bow record. Interalveolar space between central incisors before and after therapy was measured. Patients evaluated pain on the Visual Analog Scale. LLLT was performed in five treatment sessions (energy density of 15.4 J/cm(2)) by semiconductive GaAlAs laser with an output of 280 mW, emitting radiation wavelength of 830 mm. The laser supplied a spot of similar to 0.2 cm(2). Results: Baseline comparisons between the healthy patients and patients with low-level laser application show that TMJ pain during function is based on anatomical and function changes in TMJ areas. Significant differences were seen in the posterior and anterior face height. The results comparing healthy and impaired TMJ sagittal condyle paths showed that patients with TMJ pain during function had significantly flatter nonanatomical movement during function. After therapy, the unpleasant feeling was reduced from 27.5 to 4.16 on the pain Visual Analog Scale. The pain had reduced the ability to open the mouth from 34 to 42 mm. Conclusions: The laser therapy was effective in the improvement of the range of temporomandibular disorders (TMD) and promoted a significant reduction of pain symptoms.","[Dostalova, Tatjana; Hlinakova, Petra; Kasparova, Magdalena; Rehacek, Adam] Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague 15006 5, Czech Republic; [Vavrickova, Lenka] Charles Univ Prague, Dept Stomatol, Hradec Kralove, Czech Republic; [Navratil, Leos] Charles Univ Prague, Dept Med Biophys & Med Informat, Fac Med 3, Prague 15006 5, Czech Republic","Dostalova, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, V Uvalu 84, Prague 15006 5, Czech Republic.","tatjana.dostalova@fnmotol.cz",null,null,"Czech Ministry of Education by IGA MZCR [9902-4, 9991-4]; GAUK [89008]","This research has been supported by a Grant of the Czech Ministry of Education by IGA MZCR 9902-4, 9991-4 Grant, and GAUK No.: 89008.",null,24,2,2,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1549-5418",null,null,"PHOTOMED LASER SURG","Photomed. Laser Surg.","MAY",2012,30,5,null,null,null,null,275,280,null,"10.1089/pho.2011.3171",null,6,"Surgery","Surgery","936MN","WOS:000303594600007"]
[null,null,null,null,"J","Svojgr, K; Kalina, T; Kanderova, V; Skopcova, T; Brdicka, T; Zuna, J",null,null,null,"Svojgr, Karel; Kalina, Tomas; Kanderova, Veronika; Skopcova, Tereza; Brdicka, Tomas; Zuna, Jan",null,null,"The adaptor protein NTAL enhances proximal signaling and potentiates corticosteroid-induced apoptosis in T-ALL","EXPERIMENTAL HEMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL-ACTIVATION; LINKER; ERK; EXPRESSION; SELECTION; LAB","The biology of T-cell acute lymphoblastic leukemia (ALL) is characterized by functional pre - T-cell receptor (TCR) signaling. Non - T-cell activation linker (NTAL) is a nonenzymatic transmembrane adaptor molecule that is involved in the proximal signaling of lymphocytes. In our previous work, we found an association between high NTAL expression in T-cell ALL blasts and a favorable response to initial glucocorticoid treatment. In the present study, we confirm our previous observation in an experimental model. In addition, the molecular mechanism of the contribution of NTAL to malignant T-cell ALL blast signaling and to methylprednisolone-induced cell death is analyzed. In the in vitro experiments, we used the T-cell ALL Jurkat cell line (Jurkat/wt) and derived Jurkat cell line with stable NTAL expression (Jurkat/NTAL(+)). Cell signaling and cell death after methylprednisolone treatment and after TCR stimulation were analyzed using flow cytometry, Western blot, and quantitative polymerase chain reaction. Jurkat/NTAL(+) cells are significantly more sensitive to both methyl prednisolone treatment and TCR-induced stimulation. In addition, after TCR stimulation, Jurkat/NTAL(+) cells show a higher level of intracellular extracellular signal-regulated kinase 1/2 (ERK) phosphorylation and increased expression of the CD69 activation marker on the cell surface than the Jurkat/wt cells. The ERK inhibitor U0126 almost completely abrogates TCR-induced cell death and, importantly, reverses the sensitizing effect of the NTAL protein on methylprednisolone-induced cell death. In conclusion, NTAL acts as a tumor suppressor that enhances the proximal signaling of leukemic blasts. The key downstream molecule responsible for the biological effect of TCR signaling is ERK. Higher ERK phosphorylation leads to enhanced cell death after TCR stimulation and increases cell sensitivity to methylprednisolone-induced cell death. (C) 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.","[Svojgr, Karel; Kalina, Tomas; Kanderova, Veronika; Zuna, Jan] Charles Univ Prague, CLIP, Dept Pediat Hematol & Oncol, Fac Med 2, Prague 15006 5, Czech Republic; [Svojgr, Karel; Kalina, Tomas; Kanderova, Veronika; Zuna, Jan] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Skopcova, Tereza; Brdicka, Tomas] Acad Sci Czech Republic, Inst Mol Genet, Prague, Czech Republic","Svojgr, K (reprint author), Charles Univ Prague, CLIP, Dept Pediat Hematol & Oncol, Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic.","karel.svojgr@lfmotol.cuni.cz",null,null," [NS/10473-3];  [MSM 0021620813];  [MSMT NPV 2B06064]","This study was supported by grants NS/10473-3, MSM 0021620813, and MSMT NPV 2B06064.",null,16,2,2,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0301-472X",null,null,"EXP HEMATOL","Exp. Hematol.","MAY",2012,40,5,null,null,null,null,379,385,null,"10.1016/j.exphem.2012.01.011",null,7,"Hematology; Medicine, Research & Experimental","Hematology; Research & Experimental Medicine","932OT","WOS:000303301100003"]
[null,null,null,null,"J","Kotaska, K; Kolarova, J; Kotrcova, K; Cepova, J; Prusa, R",null,null,null,"Kotaska, Karel; Kolarova, Jitka; Kotrcova, Katerina; Cepova, Jana; Prusa, Richard",null,null,"Correlation Between Common Genetic Variants and Risk Factors Associated with Prediction of Cardiovascular Diseases in Dyslipidemic Patients","GENETIC TESTING AND MOLECULAR BIOMARKERS",null,null,"English","Article",null,null,null,null,null,null,"ANGIOTENSIN-CONVERTING ENZYME; ISCHEMIC-HEART-DISEASE; CORONARY-ARTERY-DISEASE; APOLIPOPROTEIN-B GENE; BETA-FIBRINOGEN GENE; MYOCARDIAL-INFARCTION; DELETION POLYMORPHISM; ATHEROSCLEROSIS RISK; HYPERCHOLESTEROLEMIA; METAANALYSIS","Aims: The aim of the study was to investigate genetic variants predicting cardiovascular events in patients with dyslipidemia and compare its relationship with common risk factors including hyperlipidemia, metabolic syndrome, history of acute myocardial infarction, thrombosis, obesity, and smoking. Materials and Methods: Five hundred two individuals divided into six groups corresponding with the risk factors and a control group of normolypidemic patients were analyzed for the presence of eight mutations and polymorphisms (endothelial nitric oxide synthase -786T -> C and G894T; lymphotoxin A C804A; angiotensin-converting enzyme [ACE] ins/del; human platelet antigen 1 a/b; beta-fibrinogen -455G -> A; apolipoprotein B [ApoB] R3500Q; APOE E2/E3/E4) using the ViennaLab CVD Strip assay. Results: ACE deletions are the most frequent genetic variants in risk groups of dyslipidemic patients (from 58% in cardiovascular events to 51% in smokers). We found a strong relationship between genetic variants and risk factors. G894T is significantly associated with smoking (value of odds ratio [OR] = 1.62, p = 0.04), and ACE deletions are negatively associated with cardiovascular events (OR = 0.62, p = 0.03). Conclusion: Significant associations between genetic variants predicting cardiovascular events and common risk factors in dyslipidemic patients were found.","[Kotaska, Karel; Kolarova, Jitka; Kotrcova, Katerina; Cepova, Jana; Prusa, Richard] Charles Univ Prague, Fac Hosp Motol, Fac Med 2, Dept Clin Biochem & Pathobiochem, Prague 15006 5, Czech Republic","Kotaska, K (reprint author), Charles Univ Prague, Fac Hosp Motol, Fac Med 2, Dept Clin Biochem & Pathobiochem, Uvalu 84, Prague 15006 5, Czech Republic.","kotaska@email.cz",null,null,null,null,null,30,2,2,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1945-0265",null,null,"GENET TEST MOL BIOMA","Genet. Test. Mol. Biomark.","MAR",2012,16,3,null,null,null,null,210,214,null,"10.1089/gtmb.2011.0129",null,5,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","912EH","WOS:000301777000011"]
[null,null,null,null,"J","Barinka, F; Salaj, M; Rybar, J; Krajcovicova, E; Kubova, H; Druga, R",null,null,null,"Barinka, Filip; Salaj, Martin; Rybar, Jan; Krajcovicova, Eva; Kubova, Hana; Druga, Rastislav",null,null,"Calretinin, parvalbumin and calbindin immunoreactive interneurons in perirhinal cortex and temporal area Te3V of the rat brain: Qualitative and quantitative analyses","BRAIN RESEARCH",null,null,"English","Article",null,null,null,null,null,"Perirhinal cortex; Calcium-binding protein; Calretinin; Parvalbum in; Calbindin; Interneuron","CORTICES IN-VITRO; POSTRHINAL CORTICES; ENTORHINAL CORTEX; PARAHIPPOCAMPAL REGION; VISUAL-CORTEX; RHINAL INTERACTIONS; STATUS EPILEPTICUS; KINDLED SEIZURES; LOBE EPILEPSY; GUINEA-PIG","The perirhinal cortex (PRC) composed of areas 35 and 36 forms an important route for activity transfer between the hippocampus-entorhinal cortex and neocortex. Its function in memory formation and consolidation as well as in the initiation and spreading of epileptic activity was already partially elucidated. We studied the general pattern of calretinin (CR), parvalbumin (PV) and calbindin (CB) immunoreactivity and its corrected relative optical density (cROD) as well as morphological features and density of CR and PV immunoreactive (CR+, PV+) interneurons in the rat PRC. Neighboring neocortical association area Te3V was analyzed as well. The PRC differed from the Te3V in higher CR and lower PV overall immunorectivity level. On CR immunostained sections, the difference between high cROD value in area 35 and low cROD value in area Te3V reached statistical significance (p<0.05). The pattern of CB immunoreactivity was similar to that of the neocortex. Vertically oriented bipolar neurons were the most common morphological type of CR+ neurons, multipolar neuronal morphology was typical among PV+ neurons and vertically oriented bipolar neurons and multipolar neurons were approximately equally frequent among CB+ neurons. The density of CR+ and PV+ neurons was stereologically measured. While the density of PV+ neurons was not significantly different in PRC when compared to Te3V, density of CR+ neurons in area 35 was significantly higher by comparison with Te3V (p<0.05). Further, the overall neuronal density was measured on Nissl stained sections and the proportion of CR+ and PV+ interneurons was expressed as a percentage of the total neurons counts. The percentage of CR+ interneurons was higher in area 35 by comparison with area Te3 (p<0.05), while the percentage of PV+ interneurons did not significantly differ among the examined areas. In conclusion, the PRC possesses specific interneuronal equipment with unusually high proportion of CR+ interneurons, what might be of importance for the presumed gating function of PRC in normal and diseased states. (C) 2011 Elsevier B.V. All rights reserved.","[Barinka, Filip; Salaj, Martin; Rybar, Jan; Druga, Rastislav] Charles Univ Prague, Dept Anat, Fac Med 2, Prague 12800, Czech Republic; [Rybar, Jan] Charles Univ Prague, Fac Med 2, Dept Paediat Neurol, Prague 15006, Czech Republic; [Krajcovicova, Eva; Kubova, Hana; Druga, Rastislav] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, CR-14220 Prague, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Fac Med 1, Dept Anat, Prague 12800, Czech Republic","Barinka, F (reprint author), Univ Regensburg, Dept Neurol, Bezirksklinikum Regensburg, Univ Str 84, D-93053 Regensburg, Germany.","filipbarinka@yahoo.co.uk","Kubova, Hana/C-4210-2012",null,"Grant Agency of Charles University [35407]","We thank to Dr. L. Kubinova (Institute of Physiology, Academy of Sciences of the Czech Republic) for her valuable comments on stereology. We also thank to Mrs. B. Cejkova for excellent technical assistance. This work was supported by Grant Agency of Charles University, grant no. 35407.",null,54,2,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0006-8993",null,null,"BRAIN RES","Brain Res.","FEB 3",2012,1436,null,null,null,null,null,68,80,null,"10.1016/j.brainres.2011.12.014",null,13,"Neurosciences","Neurosciences & Neurology","907FT","WOS:000301403900007"]
[null,null,null,null,"J","Snorek, M; Hodyc, D; Sedivy, V; Durisova, J; Skoumalova, A; Wilhelm, J; Neckar, J; Kolar, F; Herget, J",null,null,null,"Snorek, M.; Hodyc, D.; Sedivy, V.; Durisova, J.; Skoumalova, A.; Wilhelm, J.; Neckar, J.; Kolar, F.; Herget, J.",null,null,"Short-Term Fasting Reduces the Extent of Myocardial Infarction and Incidence of Reperfusion Arrhythmias in Rats","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Myocardial ischemia/reperfusion; Arrhythmias; Infarction; Fasting; Ketone bodies","CALORIE RESTRICTION; REDOX STATE; VENTRICULAR-ARRHYTHMIAS; OXIDATIVE STRESS; REDUCTIVE STRESS; H2O2 PRODUCTION; INJURY; HEART; ISCHEMIA; DAMAGE","The effect of three-day fasting on cardiac ischemic tolerance was investigated in adult male Wistar rats. Anesthetized open-chest animals (pentobarbitone 60 mg/kg, i.p.) were subjected to 20-min left anterior descending coronary artery occlusion and 3-h reperfusion for infarct size determination. Ventricular arrhythmias were monitored during ischemia and at the beginning (3 min) of reperfusion. Myocardial concentrations of beta-hydroxybutyrate and acetoacetate were measured to assess mitochondrial redox state. Short-term fasting limited the infarct size (48.5 +/- 3.3 % of the area at risk) compared to controls (74.3 +/- 2.2 %) and reduced the total number of premature ventricular complexes (12.5 +/- 5.8) compared to controls (194.9 +/- 21.9) as well as the duration of ventricular tachycardia (0.6 +/- 0.4 s vs. 18.8 +/- 2.5 s) occurring at early reperfusion. Additionally, fasting increased the concentration of beta-hydroxybutyrate and beta-hydroxybutyrate/acetoacetate ratio (87.8 +/- 27.0) compared to controls (7.9 +/- 1.7), reflecting altered mitochondrial redox state. It is concluded that three-day fasting effectively protected rat hearts against major endpoints of acute I/R injury. Further studies are needed to find out whether these beneficial effects can be linked to altered mitochondrial redox state resulting from increased ketogenesis.","[Snorek, M.; Hodyc, D.; Sedivy, V.; Herget, J.] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague 15006 5, Czech Republic; [Skoumalova, A.; Wilhelm, J.] Charles Univ Prague, Fac Med 2, Dept Med Chem & Biochem, Prague 15006 5, Czech Republic; [Snorek, M.] Ceske Budejovice Hosp, Ctr Heart, Ceske Budejovice, Czech Republic; [Neckar, J.; Kolar, F.] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Snorek, M.; Hodyc, D.; Sedivy, V.; Durisova, J.; Skoumalova, A.; Wilhelm, J.; Neckar, J.; Kolar, F.; Herget, J.] Cardiovasc Res Ctr, Prague, Czech Republic","Snorek, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Physiol, Plzenska 130-221, Prague 15006 5, Czech Republic.","michal.snorek@lfmotol.cuni.cz","Kolar, Frantisek/A-7852-2012",null,"Grant Agency of Charles University [60009/2009]; Centre for Cardiovascular Research [MSMT 1M 0510]; Czech Science Foundation [GACR 305/08/0108]","Supported by the Grant Agency of Charles University (60009/2009), Centre for Cardiovascular Research (MSMT 1M 0510) and Czech Science Foundation (GACR 305/08/0108).",null,43,2,2,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2012,61,6,null,null,null,null,567,574,null,null,null,8,"Physiology","Physiology","078ZC","WOS:000314138600002"]
[null,null,null,null,"J","Cakrt, O; Vyhnalek, M; Slaby, K; Funda, T; Vuillerme, N; Kolar, P; Jerabek, J",null,null,null,"Cakrt, Ondrej; Vyhnalek, Martin; Slaby, Krystof; Funda, Tomas; Vuillerme, Nicolas; Kolar, Pavel; Jerabek, Jaroslav",null,null,"Balance rehabilitation therapy by tongue electrotactile biofeedback in patients with degenerative cerebellar disease","NEUROREHABILITATION",null,null,"English","Article",null,null,null,null,null,"Cerebellar ataxia; neurorehabilitation; biofeedback; postural control; physiotherapy; posturography","BILATERAL VESTIBULAR LOSS; SUBSTITUTION; ATAXIA; DYSFUNCTION; SYSTEM","Few clinical studies have evaluated physiotherapeutic interventions in patients with degenerative cerebellar ataxia. Investigations on the effectiveness of biofeedback-based interventions for training postural control in these patients have not been conducted yet. The aim of the present study was to assess the effectiveness of a 2-week intensive tongue-placed electrotactile biofeedback program for patients with progressive cerebellar ataxia. Subjects were seven adult patients suffering from cerebellar degeneration. Postural control was assessed with static posturography in two sensory conditions eyes open/closed on firm surface. For quantification of postural behavior, we used area, sway path and mean velocity of the centre of foot pressure (CoP). Effects of treatment were determined by comparing Pre, Post and one month follow-up (Retention) experimental sessions. Analysis of measured CoP parameters for tests on firm surface showed a significant main effect of visual condition and no difference across test sessions under open eyes condition. Under eyes closed condition, there were significant differences between Pre versus Post and Pre versus Retention, while the difference Post versus Retention was not significant. Our results suggest that a balance rehabilitation program with postural exercise performed with a head position-based tongue-placed biofeedback system could significantly improve bipedal postural control in patients suffering from degenerative cerebellar ataxia.","[Cakrt, Ondrej; Slaby, Krystof; Kolar, Pavel] Charles Univ Prague, Dept Rehabil & Sports Med, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic; [Cakrt, Ondrej; Funda, Tomas; Jerabek, Jaroslav] Czech Tech Univ, Fac Biomed Engn, CR-16635 Prague, Kladno, Czech Republic; [Vyhnalek, Martin; Jerabek, Jaroslav] Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic; [Vyhnalek, Martin] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Vuillerme, Nicolas] CNRS UJF EPHE, FRE 3405, AGIM AGeing Imaging Modeling Lab, Fac Med, La Tronche, France","Cakrt, O (reprint author), Charles Univ Prague, Dept Rehabil & Sports Med, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","ondrej.cakrt@lf2.cuni.cz","Nicolas, Vuillerme/C-6692-2009",null,"Foundation \"Movement without help\"; European Regional Development Fund [CZ.1.05/1.1.00/02.0123];  [IGA NS 10005-4]","This work was supported by the Foundation \"Movement without help\". Martin Vyhnalek was supported by grant IGA NS 10005-4 and European Regional Development Fund - Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123). The authors would like to greatly acknowledge Zuzana Musova, Department of Biology and Medical Genetics, 2nd Faculty of Medicine, Charles University Prague, Czech Republic, for her help with genetic analysis, Helen S. Cohen, EdD, Baylor College of Medicine, TX, USA, for her language corrections and comments.",null,23,1,2,"IOS PRESS","AMSTERDAM","NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS","1053-8135",null,null,"NEUROREHABILITATION","Neurorehabilitation",null,2012,31,4,null,null,null,null,429,434,null,"10.3233/NRE-2012-00813",null,6,"Clinical Neurology; Rehabilitation","Neurosciences & Neurology; Rehabilitation","052GV","WOS:000312186600012"]
[null,null,null,null,"J","Rygl, M; Kuklova, P; Zemkova, D; Slaby, K; Pycha, K; Stranak, Z; Melichar, J; Snajdauf, J",null,null,null,"Rygl, M.; Kuklova, P.; Zemkova, D.; Slaby, K.; Pycha, K.; Stranak, Z.; Melichar, J.; Snajdauf, J.",null,null,"Defect-diaphragmatic ratio: a new parameter for assessment of defect size in neonates with congenital diaphragmatic hernia","PEDIATRIC SURGERY INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"Congenital diaphragmatic hernia; Synthetic non-absorbable patch; Gore-Tex; Defect-diaphragmatic ratio; Thoracic index","TERM-FOLLOW-UP; PROSTHETIC PATCHES; MUSCLE FLAP; REPAIR; SURVIVAL; MANAGEMENT; MORBIDITY","The aim of our study is to introduce a new objective method of perioperative evaluation of the size of diaphragmatic defect to enable comparison of results among various centres and methods used for diaphragmatic reconstruction. Prospective observational study of neonates with congenital diaphragmatic hernia (CDH) and respiratory distress within 24 h of birth operated on from January 2009 to December 2011. Weight, length, thoracic shape and the diameters of diaphragmatic defect were measured. To determine the relative size of the defect, a defect-diaphragmatic ratio (DDR = defect area:diaphragm area x 100) was calculated. The measured and calculated data were subsequently compared between Gore-Tex patch group (GT) and primary repair group (PR). Mann-Whitney U test was used for statistical analysis. Forty-seven patients with CDH were admitted during study period. The overall survival rate was 79 % (37/47). Preoperative stabilization was achieved in 85 % (40/47). Survival of operated neonates was 93 % (37/40). Diaphragmatic reconstruction with Gore-Tex patch was used in 7 neonates (17 %), and primary repair in 33 (83 %). Mortality in Gore-Tex group was 29 %; mortality in primary repair group was 3 %. Data of anthropometric measurement were complete in 34 children (5 GT and 29 PR). Significant differences were found between GT group and PR group in the size of diaphragmatic defect with the transverse and sagittal diameters of defect (48.0 +/- A 5.7 vs. 30.1 +/- A 5.9, P < 0.00061; 34.0 +/- A 12.5 vs. 16.0 +/- A 7.3, P < 0.0022) and DDR (18.29 +/- A 4.60 vs. 5.77 +/- A 3.28, P < 0.0005), respectively. The value of DDR as an objective criterion of the extent of diaphragmatic defect was confirmed by the close correlation between DDR and feasibility of primary repair in the study group. This objective assessment of defect size may improve comparing various surgical techniques and results of different centres, and thus facilitates sharing experience with management of neonates with CDH.","[Rygl, M.; Kuklova, P.; Pycha, K.; Snajdauf, J.] Charles Univ Prague, Dept Pediat Surg, Fac Med 2, Prague 15006 5, Czech Republic; [Rygl, M.; Kuklova, P.; Zemkova, D.; Slaby, K.; Pycha, K.; Snajdauf, J.] Charles Univ Prague, Teaching Hosp Motol, Prague 15006 5, Czech Republic; [Zemkova, D.] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague 15006 5, Czech Republic; [Slaby, K.] Charles Univ Prague, Dept Rehabil & Sport Med, Fac Med 2, Prague 15006 5, Czech Republic; [Stranak, Z.; Melichar, J.] Inst Care Mother & Child, Prague 14700 4, Czech Republic","Rygl, M (reprint author), Charles Univ Prague, Dept Pediat Surg, Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic.","mrygl@yahoo.com; dana.zemkova@fnmotol.cz; krystof.slaby@lfmotol.cuni.cz; Z.Stranak@seznam.cz",null,null,"Ministry of Health Czech Republic [IGA NS10572-3/2009]; GAUK [62809]","Supported by a grant NS10572-3/2009 IGA Ministry of Health Czech Republic and GAUK 62809.",null,24,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0179-0358",null,null,"PEDIATR SURG INT","Pediatr. Surg. Int.","OCT",2012,28,10,null,null,null,null,971,976,null,"10.1007/s00383-012-3113-7",null,6,"Pediatrics; Surgery","Pediatrics; Surgery","008OB","WOS:000308965300005"]
[null,null,null,null,"J","Peckova, M; Charvat, J; Schuck, O; Zamrazil, V; Bilek, R; Hill, M; Svab, P; Horackova, M",null,null,null,"Peckova, M.; Charvat, J.; Schuck, O.; Zamrazil, V.; Bilek, R.; Hill, M.; Svab, P.; Horackova, M.",null,null,"Plasma Adrenomedullin and Subclinical Cardiorenal Syndrome in Patients with Type 2 Diabetes Mellitus","JOURNAL OF INTERNATIONAL MEDICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"CARDIORENAL SYNDROME; ECHOCARDIOGRAPHY; ESTIMATED GLOMERULAR FILTRATION RATE; LEFT VENTRICULAR DIASTOLIC FUNCTION; ADRENOMEDULLIN; TYPE 2 DIABETES MELLITUS","BRAIN NATRIURETIC PEPTIDE; VENTRICULAR DIASTOLIC FUNCTION; EMERGENCY-DEPARTMENT PRIDE; GLOMERULAR-FILTRATION-RATE; CONGESTIVE-HEART-FAILURE; CHRONIC KIDNEY-DISEASE; CONSENSUS CONFERENCE; FILLING PRESSURES; TISSUE DOPPLER; RENAL-FUNCTION","OBJECTIVE: To evaluate whether plasma adrenomedullin is involved in the previously reported significant inverse correlation between left ventricular (LV) end-diastolic pressure (peak velocity of early transmitral flow/peak velocity of early diastolic mitral annular motion ratio [E/E']) and estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes mellitus, mild-to-moderate renal function impairment and LV relaxation impairment (E' <= 7.1 cm/s). METHODS: Plasma adrenomedullin concentration, E/E' and eGFR were assessed in 82 patients with type 2 diabetes. RESULTS: Plasma adrenomedullin concentration was positively correlated with eGFR in patients with or without LV relaxation impairment, and inversely correlated with E/E' in patients with LV relaxation impairment. Multivariate linear regression analysis supported a role for plasma adrenomedullin in the association between E/E' and eGFR. CONCLUSION: These results support the hypothesis that adrenomedullin modulates the interaction between the heart and kidneys in early subclinical cardiorenal syndrome in patients with type 2 diabetes mellitus.","[Peckova, M.; Charvat, J.; Schuck, O.; Svab, P.; Horackova, M.] Charles Univ Prague, Dept Med, Sch Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Zamrazil, V.; Bilek, R.; Hill, M.] Res Inst Endocrinol, CR-11694 Prague, Czech Republic","Peckova, M (reprint author), Charles Univ Prague, Dept Med, Sch Med 2, Univ Hosp Motol, V Ovalu 84, Prague 15006 5, Czech Republic.","marenkapecka@gmail.com",null,null,"Ministry of Health, Prague, Czech Republic [IGA MZ CR NR/9520-3]","This study was supported by a research grant from the Ministry of Health, Prague, Czech Republic (No. IGA MZ CR NR/9520-3).",null,36,1,1,"FIELD HOUSE PUBLISHING LLP","WORTHING","6 SOMPTING AVENUE, WORTHING, BN14 8HN, ENGLAND","0300-0605",null,null,"J INT MED RES","J. Int. Med. Res.","JUL-AUG",2012,40,4,null,null,null,null,1552,1559,null,null,null,8,"Medicine, Research & Experimental; Pharmacology & Pharmacy","Research & Experimental Medicine; Pharmacology & Pharmacy","011UY","WOS:000309192900035"]
[null,null,null,null,"J","Soucek, O; Komrska, V; Hlavka, Z; Cinek, O; Rocek, M; Zemkova, D; Lebl, J; Sumnik, Z",null,null,null,"Soucek, O.; Komrska, V.; Hlavka, Z.; Cinek, O.; Rocek, M.; Zemkova, D.; Lebl, J.; Sumnik, Z.",null,null,"Boys with haemophilia have low trabecular bone mineral density and sarcopenia, but normal bone strength at the radius","HAEMOPHILIA",null,null,"English","Article",null,null,null,null,null,"bone strength; children; haemophilia; pQCT; sarcopenia; volumetric bone density","QUANTITATIVE COMPUTED-TOMOGRAPHY; LONG-TERM PROPHYLAXIS; PROXIMAL RADIUS; CHILDREN; RISK; FRACTURE; OSTEOPOROSIS; ADOLESCENTS; GEOMETRY; INJURY","Although a decreased areal bone mineral density (BMD) has been reported in patients with haemophilia, data are lacking that would reflect the three-dimensional structure of the bone and the muscle-bone relationship. We aimed to assess volumetric BMD, bone geometry and muscle-bone phenotype in boys with haemophilia, and to describe the association between clinical characteristics of haemophilia and bone quality and structure. A cross-sectional study was conducted in 41 boys with haemophilia (mean age 12.4, range 6.619.8 years) using peripheral quantitative CT (pQCT) at the nondominant forearm. Results were transformed into Z-scores using previously published reference data. Significant differences were tested by one-sample t-test or sign test. Two-sample t-test and anova were used to compare results between subgroups of patients divided according to the severity of the disease, the fracture history and the number of joint and muscle bleedings. Boys with haemophilia had a decreased trabecular volumetric BMD (mean Z-score -0.5, P < 0.01), while their cortical volumetric BMD was increased (mean Z-score 0.4, P < 0.05). The volumetric bone mineral content and the bone geometry at the radial diaphysis were normal when adjusted for patients shorter body height. Muscle area was decreased (mean Z-score -1.0, P < 0.001), irrespective of age. No association was observed of bone quality parameters and bone geometry with the disease severity, fracture history or number of bleedings. Bone strength measured at the diaphysis of the radius is not impaired in boys with haemophilia. The finding of the decreased trabecular bone density can be most likely attributed to their sarcopenia.","[Soucek, O.; Cinek, O.; Zemkova, D.; Lebl, J.; Sumnik, Z.] Charles Univ Prague, Univ Hosp Motol, Dept Paediat, Fac Med 2, Prague 15006, Czech Republic; [Komrska, V.] Charles Univ Prague, Univ Hosp Motol, Dept Paediat Haematol & Oncol, Fac Med 2, Prague 15006, Czech Republic; [Hlavka, Z.] Charles Univ Prague, Fac Math & Phys, Dept Probabil & Math Stat, Prague 15006, Czech Republic; [Rocek, M.] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Radiol, Prague 15006, Czech Republic","Soucek, O (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Paediat, Fac Med 2, Uvalu 84, Prague 15006, Czech Republic.","ondrej.soucek@lfmotol.cuni.cz",null,null,"Charles University (GAUK) [47609]; Czech Ministry of Health [MZ0FNM2005 64203]; Czech Ministry of Education (MSMT) [21620819]","OS performed and analysed the pQCT scans, designed the research study and wrote the paper, VK coordinated the clinical part of the study, ZH performed the statistical analyses, OC contributed to the discussion and reviewed the manuscript, MR, DZ and JL coordinated the clinical part of the study and ZS designed the research study and prepared the manuscript. This work was supported by a grant from the Charles University (GAUK 47609 to OS), by a grant from the Czech Ministry of Health (MZ0FNM2005 64203 to DZ) and by a grant from the Czech Ministry of Education (MSMT 21620819 to ZS). We would like to acknowledge all the patients participating in our study.",null,32,1,1,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1351-8216",null,null,"HAEMOPHILIA","Haemophilia","MAR",2012,18,2,null,null,null,null,222,228,null,"10.1111/j.1365-2516.2011.02616.x",null,7,"Hematology","Hematology","897PL","WOS:000300665000022"]
[null,null,null,null,"J","Stuchly, J; Kanderova, V; Fiser, K; Cerna, D; Holm, A; Wu, WW; Hrusak, O; Lund-Johansen, F; Kalina, T",null,null,null,"Stuchly, Jan; Kanderova, Veronika; Fiser, Karel; Cerna, Daniela; Holm, Anders; Wu, Weiwei; Hrusak, Ondrej; Lund-Johansen, Fridtjof; Kalina, Tomas",null,null,"An automated analysis of highly complex flow cytometry-based proteomic data","CYTOMETRY PART A",null,null,"English","Article",null,null,null,null,null,"protein array; flow cytometry; data analysis; bioinformatics","ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC LYMPHOPROLIFERATIVE DISORDERS; CHROMOSOME-POSITIVE LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL; PHILADELPHIA-CHROMOSOME; CLINICAL RESISTANCE; INDUCED APOPTOSIS; CELL LINES; KINASE","The combination of color-coded microspheres as carriers and flow cytometry as a detection platform provides new opportunities for multiplexed measurement of biomolecules. Here, we developed a software tool capable of automated gating of color-coded microspheres, automatic extraction of statistics from all subsets and validation, normalization, and cross-sample analysis. The approach presented in this article enabled us to harness the power of high-content cellular proteomics. In size exclusion chromatography-resolved microsphere-based affinity proteomics (Size-MAP), antibody-coupled microspheres are used to measure biotinylated proteins that have been separated by size exclusion chromatography. The captured proteins are labeled with streptavidin phycoerythrin and detected by multicolor flow cytometry. When the results from multiple size exclusion chromatography fractions are combined, binding is detected as discrete reactivity peaks (entities). The information obtained might be approximated to a multiplexed western blot. We used a microsphere set with >1,000 subsets, presenting an approach to extract biologically relevant information. The R-project environment was used to sequentially recognize subsets in two-dimensional space and gate them. The aim was to extract the median streptavidin phycoerythrin fluorescence intensity for all 1,000+ microsphere subsets from a series of 96 measured samples. The resulting text files were subjected to algorithms that identified entities across the 24 fractions. Thus, the original 24 data points for each antibody were compressed to 14 integrated values representing the areas of individual antibody reactivity peaks. Finally, we provide experimental data on cellular protein changes induced by treatment of leukemia cells with imatinib mesylate. The approach presented here exemplifies how large-scale flow cytometry data analysis can be efficiently processed to employ flow cytometry as a high-content proteomics method. (C) 2011 International Society for Advancement of Cytometry","[Stuchly, Jan; Kanderova, Veronika; Fiser, Karel; Cerna, Daniela; Hrusak, Ondrej; Kalina, Tomas] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague 5, Czech Republic; [Stuchly, Jan; Kanderova, Veronika; Fiser, Karel; Cerna, Daniela; Hrusak, Ondrej; Kalina, Tomas] Univ Hosp Motol, Prague 5, Czech Republic; [Stuchly, Jan; Kanderova, Veronika; Fiser, Karel; Cerna, Daniela; Hrusak, Ondrej; Kalina, Tomas] CLIP Childhood Leukemia Invest Prague, Prague, Czech Republic; [Stuchly, Jan] Charles Univ Prague, Fac Math & Phys, Dept Numer Math, Prague, Czech Republic; [Holm, Anders; Wu, Weiwei; Lund-Johansen, Fridtjof] Univ Oslo, Rikshosp, Med Ctr, Dept Immunol, N-0027 Oslo, Norway","Kalina, T (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, V Uvalu 84, Prague 5, Czech Republic.","tomas.kalina@lfmotol.cuni.cz",null,null,"Norway grant [A/CZ0046/2/0008]; Czech Ministry of Health [NS/10473-3]; Czech Ministry of Education [NPV2B06064, MSMT0021620813]; ISAC","Grant sponsor: Norway grant; Grant number: A/CZ0046/2/0008; Grant sponsor: Czech Ministry of Health; Grant number: NS/10473-3; Grant sponsor: Czech Ministry of Education; Grant numbers: NPV2B06064 and MSMT0021620813.T.K. is supported as an ISAC Scholar by The International Society for Advancement of Cytometry.",null,42,1,1,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1552-4922",null,null,"CYTOM PART A","Cytom. Part A","FEB",2012,"81A",2,null,null,null,null,120,129,null,"10.1002/cyto.a.22011",null,10,"Biochemical Research Methods; Cell Biology","Biochemistry & Molecular Biology; Cell Biology","880AQ","WOS:000299376900007"]
[null,null,null,null,"J","Matousovic, K; Martinek, V; Spatenka, J; Stejskal, J; Chadimova, M",null,null,null,"Matousovic, Karel; Martinek, Vojtech; Spatenka, Jaroslav; Stejskal, Josef; Chadimova, Maria",null,null,"Malignant Wegener's Granulomatosis with Fibrosing Mediastinitis and Vena Cava Superior Syndrome","RENAL FAILURE",null,null,"English","Article",null,null,null,null,null,"immunosuppression; vena cava superior syndrome; Wegener's granulomatosis; fibrosing mediastinitis; glomerulonephritis",null,"A 47-year-old man was admitted to hospital for migratory joint pain, fatigue, and cough with bloody sputum and proteinuria with increased serum creatinine level. Diagnosis of Wegener's granulomatosis was established. During follow-up, the vena cava superior syndrome developed. The patient died of respiratory failure after 12 years of follow-up. The autopsy revealed rigid, whitish, 12 mm thick tissue, which embedded and compressed the large vessels upwards from their origin in the heart, thus causing vena cava superior syndrome. This tissue was composed of fibrous material without inflammatory cellulization. We consider this fibrous tissue as a manifestation of fibrosing mediastinitis that may or may not share pathogenesis with Wegener's granulomatosis.","[Matousovic, Karel] Charles Univ Prague, Dept Med, Univ Hosp Motol, Sch Med 2, Prague 15006, Czech Republic; [Matousovic, Karel; Martinek, Vojtech] Charles Univ Prague, Dept Med, Sch Med 2, Prague 15006, Czech Republic; [Matousovic, Karel] Charles Univ Prague, Dept Med, Sch Med, Plzen, Czech Republic; [Matousovic, Karel] Charles Univ Prague, Teaching Hosp, Plzen, Czech Republic; [Spatenka, Jaroslav] Univ Hosp Motol, Transplantat Ctr, Prague, Czech Republic; [Stejskal, Josef; Chadimova, Maria] Charles Univ Prague, Dept Pathol & Mol Med, Sch Med 2, Prague 15006, Czech Republic","Matousovic, K (reprint author), Charles Univ Prague, Dept Med, Univ Hosp Motol, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic.","kmatousovic@hotmail.com",null,null,"Main Research Project (Czech Republic) [MSM 0021620819]","This study was supported by the Main Research Project No MSM 0021620819 (Czech Republic).",null,6,1,1,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0886-022X",null,null,"RENAL FAILURE","Ren. Fail.",null,2012,34,2,null,null,null,null,244,246,null,"10.3109/0886022X.2011.647208",null,3,"Urology & Nephrology","Urology & Nephrology","885MZ","WOS:000299784400019"]
[null,null,null,null,"J","Cakrt, O; Funda, T; Cerny, R; Kolar, P; Muzik, J; Jerabek, J",null,null,null,"Cakrt, O.; Funda, T.; Cerny, R.; Kolar, P.; Muzik, J.; Jerabek, J.",null,null,"Diagnostically Specific Findings in Posturography - Two Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"posturography; frequency analysis; stance examination; postural instability; cerebellar ataxia; primary orthostatic tremor","PRIMARY ORTHOSTATIC TREMOR; PARKINSONS-DISEASE; POSTURAL SWAY","Posturography is an electrophysiological method for evaluation of balance in unsteady patients. Posturography is very accurate but has very low specificity for nosologic diagnosis when basic routinely evaluated parameters, e.g. centre of pressure displacement etc., are used. However, power spectra analysis (Fast Fourier Transformation) of centre of pressure displacement during quiet stance can identify postural abnormalities patognomic for specific lesions of nervous system. We present two neurological disorders with specific posturographic patterns. Typical 3Hz sway in patients with anterior lobe cerebellar atrophy and increase sway in higher power spectra (12-18 Hz) in patients suffering from primary orthostatic tremor.","[Cakrt, O.; Kolar, P.] Klin Rehabil & Telovychovneho Lekarstvi 2 LF UK &, Prague 15006 5, Czech Republic; [Cakrt, O.; Funda, T.; Muzik, J.] Spolecne Pracoviste Biomed Inzenyrstvi FBMI & 1 L, Fak Biomed Inzenyrstvi, Ceske Vysoke Ueni Tech Praze, Prague, Czech Republic; [Cerny, R.; Jerabek, J.] Neurol Klin Dospelych 2 LF UK & FN Motole, Prague, Czech Republic","Cakrt, O (reprint author), Klin Rehabil & Telovychovneho Lekarstvi 2 LF UK &, V Uvalu 84, Prague 15006 5, Czech Republic.","ondrej.cakrt@lfmotol.cuni.cz",null,null,null,null,null,16,1,1,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,1,null,null,null,null,88,91,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","902HF","WOS:000301028500014"]
[null,null,null,null,"J","Horacek, O; Chlumsky, J; Mazanec, R; Kolar, P; Andel, R; Kobesova, A",null,null,null,"Horacek, Ondrej; Chlumsky, Jan; Mazanec, Radim; Kolar, Pavel; Andel, Ross; Kobesova, Alena",null,null,"Pulmonary function in patients with hereditary motor and sensory neuropathy: A comparison of patients with and without spinal deformity","NEUROMUSCULAR DISORDERS",null,null,"English","Article",null,null,null,null,null,"Hereditary motor and sensory neuropathy; Charcot Marie Tooth disease; Spinal deformity; Respiratory muscle function; Static lung volume","MARIE-TOOTH-DISEASE; VOCAL CORD PARESIS; IDIOPATHIC SCOLIOSIS; DYSFUNCTION; MUTATION; WEAKNESS; VALUES; GENE","We assessed pulmonary function in hereditary motor and sensory neuropathy. Fourteen neuropathy patients without spinal deformity (group 1), 14 with spinal deformity (group 2), and 16 individuals with idiopathic spinal deformity (group 3) matched to group 2 for age, height and Cobb angle, were included. Hereditary motor and sensory neuropathy severity was measured with Charcot-Marie-Tooth Neuropathy Score. All participants exhibited mild decrease in maximal inspiratory pressure at the mouth. One-way analysis of variance yielded significant main effects for lung volumes - slow vital capacity, forced expiratory volume in 1 s, and total lung capacity (p's < .01), attributable to greater volumes in group 1 compared to groups with spinal deformity - and transfer factor for carbon monoxide (p = .013), reflecting differences between groups 1 vs. 2. Slow vital capacity and total lung capacity correlated with maximal inspiratory pressure at the mouth in group 2, whereas slow vital capacity correlated with muscle work in group 3 (p's < .05). Decreased lung volume may be due to impaired respiratory muscle strength in hereditary motor and sensory neuropathy with spinal deformity and due to spinal deformity in idiopathic patients. (C) 2012 Elsevier B.V. All rights reserved.","[Horacek, Ondrej; Kolar, Pavel; Kobesova, Alena] Charles Univ Prague, Dept Rehabil & Sports Med, Fac Med 2, Prague 15006 5, Czech Republic; [Horacek, Ondrej; Mazanec, Radim; Kolar, Pavel; Kobesova, Alena] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Chlumsky, Jan] Charles Univ Prague, Dept Pneumol, Thomayer Hosp, Fac Med 1, Prague 15006 5, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague 15006 5, Czech Republic; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Andel, Ross] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic","Kobesova, A (reprint author), Charles Univ Prague, Dept Rehabil & Sports Med, Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic.","alenamudr@me.com",null,null,"foundation Movement without Help, Prague, Czech Republic;  [OPPK CZ.2.16/3.1.00/24022]","This study was supported by the foundation Movement without Help, Prague, Czech Republic, and by Grant OPPK CZ.2.16/3.1.00/24022.",null,38,0,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0960-8966",null,null,"NEUROMUSCULAR DISORD","Neuromusc. Disord.","DEC",2012,22,12,null,null,null,null,1083,1089,null,"10.1016/j.nmd.2012.05.008",null,7,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","071PE","WOS:000313605900007"]
[null,null,null,null,"J","Brozkova, DS; Nevsimalova, S; Mazanec, R; Rautenstrauss, B; Seeman, P",null,null,null,"Brozkova, Dana Safka; Nevsimalova, Sona; Mazanec, Radim; Rautenstrauss, Bernd; Seeman, Pavel",null,null,"Charcot-Marie-Tooth neuropathy due to a novel EGR2 gene mutation with mild phenotype - Usefulness of human mapping chip linkage analysis in a Czech family","NEUROMUSCULAR DISORDERS",null,null,"English","Article",null,null,null,null,null,"EGR2; CMT; MPZ; Demyelinating neuropathy; Linkage analysis","GROWTH-RESPONSE 2; MYELIN PROTEIN ZERO; MISSENSE MUTATION; DISEASE TYPE-1; R359W","Charcot-Marie-Tooth neuropathies (CMT) are a group of clinically and genetically heterogeneous disorders of the peripheral nervous system. Selection of candidate disease genes for mutation analysis is sometimes difficult since more than 40 genes and loci are known to be associated with CMT neuropathies. Hence a Czech family Cz-CMT with demyelinating type of autosomal dominant CMT disease was investigated by genome-wide linkage analysis by means of single-nucleotide polymorphism (SNP) arrays. Among 35 regions with linkage, five carried known CMT genes. In the final result a novel early growth response 2 missense mutation c.1235 A>G, p.Glu412Gly was found. Surprisingly, the more severely affected proband carried an additional heterozygous myelin protein zero variant p.Asp246Asn detected previously, which may modify the phenotype. However, this MPZ variant is benign in heterozygous state alone, because it is also carried by the patient's healthy father. (C) 2012 Elsevier B.V. All rights reserved.","[Brozkova, Dana Safka; Seeman, Pavel] Charles Univ Prague, DNA Lab, Dept Child Neurol, Sch Med 2, Prague 15006, Czech Republic; [Brozkova, Dana Safka; Mazanec, Radim; Seeman, Pavel] Univ Hosp Motol, Prague, Czech Republic; [Nevsimalova, Sona] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague 15006, Czech Republic; [Nevsimalova, Sona] Gen Teaching Hosp, Prague, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Dept Neurol, Sch Med 2, Prague 15006, Czech Republic; [Rautenstrauss, Bernd] Ctr Med Genet, Munich, Germany; [Rautenstrauss, Bernd] LMU, Munich, Germany","Brozkova, DS (reprint author), Charles Univ Prague, DNA Lab, Dept Child Neurol, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic.","dana.brozkova@seznam.cz",null,null,"GAUK [309]","This study was supported by the GAUK 309.",null,23,0,0,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0960-8966",null,null,"NEUROMUSCULAR DISORD","Neuromusc. Disord.","AUG",2012,22,8,null,null,null,null,742,746,null,"10.1016/j.nmd.2012.04.002",null,5,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","990GV","WOS:000307619900009"]
[null,null,null,null,"J","Hajek, P; Macek, M; Peskova, M; Hladikova, M; Hansvenclova, E; Maly, M; Veselka, J; Krebsova, A",null,null,null,"Hajek, Petr; Macek, Milan, Sr.; Peskova, Martina; Hladikova, Marie; Hansvenclova, Eva; Maly, Martin; Veselka, Josef; Krebsova, Alice",null,null,"High positive predictive value of PAPP-A for acute coronary syndrome diagnosis in heparin-na < ve patients","JOURNAL OF THROMBOSIS AND THROMBOLYSIS",null,null,"English","Article",null,null,null,null,null,"Acute coronary syndrome; Pregnancy-associated plasma protein-A; Troponin; Diagnostic significance","PLASMA-PROTEIN-A; ELEVATION MYOCARDIAL-INFARCTION; PREGNANCY; MARKER; INCREASE","Pregnancy-associated plasma protein-A (PAPP-A) was studied as a marker of acute coronary syndrome (ACS). It has been shown that its levels are increased by heparin administration. Therefore, the aim of our study was to ascertain the diagnostic significance of PAPP-A in heparin-na < ve patients and compare it with (TnI). We prospectively studied 67 heparin-na < ve patients with acute chest pain. The patients were independently grouped according to the presence or absence of ACS. PAPP-A levels were significantly increased in ACS patients (8.6 vs. 7.3 mIU/l; P = 0.006) with high positive (95.7%) and lower negative predictive values (47.7%). In multivariate analysis, its levels were strongly predictive of a final diagnosis of ACS (OR 41.8; 95th CI 2.64-662.6; P = 0.008). The diagnostic significance of PAPP-A was not higher than TnI even within 6 h after the onset of chest pain [the area under the ROC curve (AUC) was 0.69 for PAPP-A and 0.91 for TnI, respectively; P = 0.08]. We observed no difference in the AUC in NSTE-ACS patients (0.73 for PAPP-A and 0.79 for TnI (P = 0.5)). PAPP-A levels were an independent predictor of ACS diagnosis in heparin-na < ve patients. Its diagnostic significance was not higher than TnI even within a short period after the onset of chest pain. In troponin-negative NSTE-ACS patients, PAPP-A helped make the correct final diagnosis.","[Hajek, Petr; Hansvenclova, Eva; Maly, Martin; Veselka, Josef] Charles Univ Prague, Dept Cardiol, Prague 15006 5, Czech Republic; [Hajek, Petr; Macek, Milan, Sr.; Peskova, Martina; Hladikova, Marie; Hansvenclova, Eva; Maly, Martin; Veselka, Josef] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Macek, Milan, Sr.; Peskova, Martina; Hladikova, Marie] Charles Univ Prague, Dept Biol & Med Genet, Prague 15006 5, Czech Republic; [Krebsova, Alice] Humboldt Univ, Dept Internal Med Cardiol, Virchow Klinikum, D-10099 Berlin, Germany","Hajek, P (reprint author), Charles Univ Prague, Dept Cardiol, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.hajek@fnmotol.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","MZOFNM from Czech Ministry of Health","Supported by the MZOFNM 2005 from the Czech Ministry of Health. The cooperation of the staff of the Emergency Department of Motol University Hospital and the Emergency Department of Kladno District Hospital is highly appreciated.",null,20,0,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0929-5305",null,null,"J THROMB THROMBOLYS","J. Thromb. Thrombolysis","JUL",2012,34,1,null,null,null,null,99,105,null,"10.1007/s11239-012-0679-9",null,7,"Hematology; Peripheral Vascular Disease","Hematology; Cardiovascular System & Cardiology","962EN","WOS:000305523300014"]
[null,null,null,null,"J","Veselka, J; Cadova, P; Adla, T; Zemanek, D",null,null,null,"Veselka, Josef; Cadova, Pavla; Adla, Theodor; Zemanek, David",null,null,"Dual-source computed tomography angiography and intravascular ultrasound assessment of restenosis in patients after coronary stenting for bifurcation left main stenosis: a pilot study","ARCHIVES OF MEDICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"stent; left main stenosis; intervention; computed tomography","ELUTING STENTS; ARTERY-DISEASE; TASK-FORCE; CARDIOLOGY; REGISTRY; LESIONS; REVASCULARIZATION; CLASSIFICATION; INTERVENTION; ASSOCIATION","Introduction: The aim of this prospective study was to evaluate the diagnostic accuracy of dual-source computed tomography coronary angiography (CTCA) compared to intravascular ultrasound (IVUS) for the detection of restenosis in patients who underwent coronary stenting for bifurcation left main (LM) stenosis. Material and methods: Twenty-four patients underwent percutaneous intervention of the LM and were subsequently examined (median 9.2 months after procedure) using IVUS and CTCA for the detection of restenosis. Results: Significant restenosis was detected according to IVUS examination in 6 patients (25%) and 8 segments (13%). Based on segment analysis, sensitivity, specificity, positive and negative predictive values of CTCA for the detection of restenosis were 89%, 68%, 32%, 97%, respectively. There was moderate to good correlation between the minimal luminal area (MLA), measured by CTCA and IVUS for LM, the left anterior descending artery (LAD) and the left circumflex artery (LCx) (r = 0.64, p < 0.01; r = 0.49, p = 0.03; r = 0.76, p < 0.01, respectively). A Bland-Altman analysis showed that the MLAs measured by CTCA were underestimated in all segments (mean difference 1.67 +/-2.2 mm(2) for LM; 2.0 +/-2.0 mm(2) for LAD; 1.79 +/-1.79 mm(2) for LCx). An ROC analysis of the MLAs derived by CTCA for detecting significant stenosis was performed. The area under the curve for all analysed segments was 0.73. Conclusions: The present study demonstrates that in patients after LM bifurcation stenting CTCA performs well in the exclusion of in-segment restenosis. However, due to the low positive predictive value of CTCA, the finding of any restenosis should be confirmed by invasive examination.","[Veselka, Josef; Cadova, Pavla; Zemanek, David] Charles Univ Prague, Univ Hosp Motol, Med Sch 2, Dept Cardiol, Prague 15000 5, Czech Republic; [Adla, Theodor] Charles Univ Prague, Univ Hosp Motol, Med Sch 2, Dept Imaging Methods, Prague, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Med Sch 2, Dept Cardiol, Vuvalu 84, Prague 15000 5, Czech Republic.","veselka.josef@seznam.cz",null,null,"Ministry of Health of the Czech Republic [00064203]","This study was supported by a grant from the Ministry of Health of the Czech Republic No. 00064203. The authors thank Eva Hansvenclova for her assistance in the data collection and study analysis.",null,22,0,0,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922",null,null,"ARCH MED SCI","Arch. Med. Sci.","JUN",2012,8,3,null,null,null,null,455,461,null,"10.5114/aoms.2012.29220",null,7,"Medicine, General & Internal","General & Internal Medicine","970RO","WOS:000306150200011"]
[null,null,null,null,"J","Kriz, P; Seydlova, M; Dostalova, T; Valenta, Z; Chleborad, K; Zvarova, J; Feberova, J; Hippmann, R",null,null,null,"Kriz, Pavel; Seydlova, Michaela; Dostalova, Tatjana; Valenta, Zdenek; Chleborad, Karel; Zvarova, Jana; Feberova, Jitka; Hippmann, Radek",null,null,"Oral health-related quality of life and dental implants - preliminary study","CENTRAL EUROPEAN JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,"Dentistry; Implant; Quality of life","PATIENT SATISFACTION; CLINICAL-TRIAL; PROSTHESES","Oral health-related quality of life (OHRQoL) is multifaceted and involves many factors. One of them is the use of dental implants. It was the aim of our study to assess whether implant therapy might improve OHRQoL. We consulted patients with at least one Astra Tech implant. Each patient completed oral health questionnaires, which were then statistically evaluated using the Wilcoxon signed-ranks test and Analysis of Covariance from a functional and aesthetic point of view. Differential response on individual scales was assessed using multivariate approach. All twelve marginal Wilcoxon tests showed an overall improvement in OHQoL (alpha = 0.05). On the aesthetic scale, OHRQoL was found to be associated with marital status, aesthetic reasons for undergoing surgery and number of front teeth replaced by implants. On the functional scale, three covariates were statistically significantly and appeared to have affected the levels of OHRQoL. The most significant explanatory effect was observed for the number of front teeth replaced via implantation, followed by the presence of chewing problems. Marital status was also found to have significantly affected the OHRQoL functional scale. Significant implant-related improvements in both scales were observed in patients with at least one implant in the front dental area.","[Kriz, Pavel; Seydlova, Michaela; Dostalova, Tatjana; Chleborad, Karel; Hippmann, Radek] Charles Univ Prague, Sch Med 2, Prague 15006, Czech Republic; [Seydlova, Michaela; Dostalova, Tatjana; Valenta, Zdenek; Zvarova, Jana; Hippmann, Radek] Ctr Biomed Informat, Prague 18207 8, Czech Republic; [Valenta, Zdenek; Zvarova, Jana] Inst Comp Sci AS CR, Dept Med Informat, Prague 18207 8, Czech Republic; [Feberova, Jitka] Charles Univ Prague, Ctr Comp, Prague 1, Czech Republic","Seydlova, M (reprint author), Charles Univ Prague, Sch Med 2, V Uvalu 84, Prague 15006, Czech Republic.","michaela.seydlova@seznam.cz","Zvarova, Jana/B-5196-2014; Valenta, Zdenek/E-5094-2011","Valenta, Zdenek/0000-0001-7119-9764","MSMT CR [1M06014];  [D-2009-56]","The work was supported by grant D-2009-56 and partially through the 1M06014 of MSMT CR project.",null,19,0,0,"VERSITA","WARSAW","SOLIPSKA 14A-1, 02-482 WARSAW, POLAND","1895-1058","1644-3640",null,"CENT EUR J MED","Cent. Eur. J. Med.","APR",2012,7,2,null,null,null,null,209,215,null,"10.2478/s11536-011-0125-y",null,7,"Medicine, General & Internal","General & Internal Medicine","889EB","WOS:000300055200013"]
[null,null,null,null,"J","Hancarova, M; Drabova, J; Zmitkova, Z; Vlckova, M; Hedvicakova, P; Novotna, D; Vlckova, Z; Vejvalkova, S; Marikova, T; Sedlacek, Z",null,null,null,"Hancarova, Miroslava; Drabova, Jana; Zmitkova, Zuzana; Vlckova, Marketa; Hedvicakova, Petra; Novotna, Drahuse; Vlckova, Zdenka; Vejvalkova, Sarka; Marikova, Tatana; Sedlacek, Zdenek",null,null,"Array comparative genome hybridization in patients with developmental delay: two example cases","NEW BIOTECHNOLOGY",null,null,"English","Article",null,null,null,null,null,null,"MENTAL-RETARDATION; AUTISM; 1Q21.1","Developmental delay is often a predictor of mental retardation (MR) or autism, two relatively frequent developmental disorders severely affecting intellectual and social functioning. The causes of these conditions remain unknown in most patients. They have a strong genetic component, but the specific genetic defects can only be identified in a fraction of patients. Recent developments in genomics supported the establishment of the causal link between copy number variants in the genomes of some patients and their affection. One of the techniques suitable for this analysis is array comparative genome hybridization, which can be used both for detailed mapping of chromosome rearrangements identified by classical cytogenetics and for the identification of novel submicroscopic gains or losses of genetic material. We illustrate the power of this approach in two patients. Patient 1 had a cytogenetically visible deletion of chromosome X and the molecular analysis was used to specify the gene content of the deletion and the prognosis of the child. Patient 2 had a seemingly normal karyotype and the analysis revealed a small recurrent deletion of chromosome 1 likely to be responsible for his phenotype. However, the genetic dissection of MR and autism is complicated by high heterogeneity of the genetic aberrations among patients and by broad variability of phenotypic effects of individual genetic defects.","[Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Sedlacek, Z (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Uvalu 84, Prague, Czech Republic.","zdenek.sedlacek@lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic [MZOFNM2005]; European Commission [FP6 043318, FP7 223692]","Supported by grants MZOFNM2005 from the Ministry of Health of the Czech Republic, and INCORE (FP6 043318) and CHERISH (FP7 223692) from the European Commission.",null,21,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1871-6784",null,null,"NEW BIOTECHNOL","New Biotech.","FEB 15",2012,29,3,null,null,null,null,321,324,null,"10.1016/j.nbt.2010.10.006",null,4,"Biochemical Research Methods; Biotechnology & Applied Microbiology","Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology","901ZQ","WOS:000301008800009"]
[null,null,null,null,"J","Kriz, J; Kozak, J; Zedka, M",null,null,null,"Kriz, Jiri; Kozak, Jiri; Zedka, Milan",null,null,"Primary motor cortex inhibition in spinal, cord injuries","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"spinal cord injury; transcranial magnetic stimulation; intracortical inhibition; corticospinal pathway","TRANSCRANIAL MAGNETIC STIMULATION; INTERVAL INTRACORTICAL INHIBITION; CORTICOCORTICAL INHIBITION; CORTICOSPINAL SYSTEM; CORTICAL INHIBITION; FMRI REVEALS; EXCITABILITY; FACILITATION; REORGANIZATION; LESIONS","OBJECTIVES AND METHODS: Excitability changes in the primary motor cortex in 17 spinal-cord injured (SCI) patients and 10 controls were studied with paired-pulse transcranial magnetic stimulation. The paired pulses were applied at inter-stimulus intervals (IS!) of 2 ms and 15 ms while motor evoked potentials (MEP) were recorded in the biceps brachii (Bic), the abductor pollicis brevis (APB) and the tibialis anterior (TA) muscles. RESULTS: The study revealed a significant decrease in cortical motor excitability in the first weeks after SCI concerning the representation of both the affected muscles innervated from spinal segments below the lesion, and the spared muscles rostral to the lesion. In the patients with motor-incomplete injury, but not in those with motor-complete injury, the initial cortical inhibition of affected muscles was temporarily reduced 2-3 months following injury. The degree of inhibition in cortical areas representing the spared muscles was observed to be smaller in patients with no voluntary TA activity compared to patients with some activity remaining in the TA. Surprisingly, motor-cortical inhibition was observed not only at ISI 2 ms but also at ISI 15 ms. The inhibition persisted in patients who returned for a follow-up measurement 2-3 years later. CONCLUSION: The present data showed different evaluation of cortical excitability between patients with complete and incomplete spinal cord lesion. Our results provide more insight into the pathophysiology of SCI and contribute to the ongoing discussion about the recovery process and therapy of SCI patients.","[Kriz, Jiri] Charles Univ Prague, Fac Med 2, Dept Rehabil & Sports Med, Spinal Cord Unit, Prague 15006 5, Czech Republic; [Kriz, Jiri; Kozak, Jiri] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Kozak, Jiri] Charles Univ Prague, Fac Med 2, Pain Management & Res Ctr, Prague 15006 5, Czech Republic; [Zedka, Milan] Hop Nestle CHUV, Unite Neurol & Neurorehabil Pediat, Lausanne, Switzerland","Kriz, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Rehabil & Sports Med, Spinal Cord Unit, V Uvalu 84, Prague 15006 5, Czech Republic.","jiri.kriz@fnmotol.cz",null,null,"'Movement without help' Foundation","The authors would like to express their gratitude to Ms. Michaela Berkova for her assistance with data collection. They also appreciate the kind support by Prof. Vladimir Komarek, the Head of the Child Neurology Department, and Prof Pavel Kolar, the Head of the Rehabilitation and Physical Medicine Department of the University Hospital Motol in Prague. The study was supported by the 'Movement without help' Foundation.",null,59,0,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2012,33,4,null,null,null,null,431,441,null,null,null,11,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","026FH","WOS:000310259500013"]
[null,null,null,null,"J","Nedelka, T; Schlenker, J; Riedlbauchova, L; Mazanec, R",null,null,null,"Nedelka, T.; Schlenker, J.; Riedlbauchova, L.; Mazanec, R.",null,null,"Recurrence Quantification Analysis of Heart Rate Variability in Early Diagnosis of Diabetic Autonomic Neuropathy","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"diabetic autonomic neuropathy; cardiac autonomic neuropathy; diabetes mellitus; heart rate variability; spectral analysis; recurrence analysis","SPECTRAL-ANALYSIS; BLOOD-PRESSURE; RATE DYNAMICS; MELLITUS; TIME; PREDICTION; THRESHOLD; SIGNAL; RISK; PLOT","Introduction: Detection of autonomic dysfunction in subclinical stages of diabetic cardiovascular autonomic neuropathy is highly important and helps in therapeutic management. Evaluation of cardiovascular function is usually based on heart rate variability (HRV) linear data analysis in time and frequency domains. However, autonomic control of heart rate is complex and could be described by non-linear analysis. In our study, non-linear recurrence quantification analysis (RQA) was used. Methods: We analyzed RQA during orthostatic test in 20 patients with type 2 diabetes (mean age 54 years). Results were compared to sex and age-matched group of 20 healthy controls (mean age 53 years). Cross-comparison between RQA, time- and frequency-domains analysis during the supine rest phase of orthostatic test was also performed. Results: There was significant increase in percentage of recurrences in diabetic patients compared to controls in the following variables: determinism (p<0.0001), laminarity (p<0.0002), length of the longest diagonal line Lmax (p=0.026) and mean length of vertical lines trapping time (p=0.0214) in both phases of the orthostatic test. We found significant increase in determinism, laminarity and trapping time in the supine rest phase. However, the Lmax parameter remained insignificant compared to the control group and results were similar to previous studies. Conclusion: Reduction of complexity in cardiovascular regulation was found in diabetic patients compared to age-matched controls. In comparison to standard methods, RQA appears to be more sensitive in diagnostics of subclinical cardiovascular autonomic neuropathy. RQA may be useful as an additional approach to time and frequency domain analysis of HRV.","[Nedelka, T.; Schlenker, J.; Mazanec, R.] Neurol Klin Dospelych 2 LF UK & FN Motole, Prague 15006 5, Czech Republic; [Nedelka, T.] Fak Biomed Inzenyrstiv CVUT, Prague, Czech Republic; [Riedlbauchova, L.] Kardiol Klin 2 LF UK & FN Motole, Prague, Czech Republic","Nedelka, T (reprint author), Neurol Klin Dospelych 2 LF UK & FN Motole, V Uvalu 84, Prague 15006 5, Czech Republic.","tnedelka@post.cz",null,null,null,null,null,38,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,6,null,null,null,null,721,728,null,null,null,8,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","039JU","WOS:000311242700008"]
[null,null,null,null,"J","Vanecek, V; Zablotskii, V; Forostyak, S; Ruzicka, J; Herynek, V; Babic, M; Jendelova, P; Kubinova, S; Dejneka, A; Sykova, E",null,null,null,"Vanecek, Vaclav; Zablotskii, Vitalii; Forostyak, Serhiy; Ruzicka, Jiri; Herynek, Vit; Babic, Michal; Jendelova, Pavla; Kubinova, Sarka; Dejneka, Alexandr; Sykova, Eva",null,null,"Highly efficient magnetic targeting of mesenchymal stem cells in spinal cord injury","INTERNATIONAL JOURNAL OF NANOMEDICINE",null,null,"English","Article",null,null,null,null,null,"magnetism; mesenchymal stem cell; nanoparticle; spinal cord injury; modeling","IRON-OXIDE NANOPARTICLES; MARROW STROMAL CELLS; BONE-MARROW; CEREBROSPINAL-FLUID; LUMBAR PUNCTURE; RESONANCE TRACKING; DELIVERY; BRAIN; TRANSPLANTATION; REGENERATION","The transplantation of mesenchymal stem cells (MSC) is currently under study as a therapeutic approach for spinal cord injury, and the number of transplanted cells that reach the lesioned tissue is one of the critical parameters. In this study, intrathecally transplanted cells labeled with superparamagnetic iron oxide nanoparticles were guided by a magnetic field and successfully targeted near the lesion site in the rat spinal cord. Magnetic resonance imaging and histological analysis revealed significant differences in cell numbers and cell distribution near the lesion site under the magnet in comparison to control groups. The cell distribution correlated well with the calculated distribution of magnetic forces exerted on the transplanted cells in the subarachnoid space and lesion site. The kinetics of the cells' accumulation near the lesion site is described within the framework of a mathematical model that reveals those parameters critical for cell targeting and suggests ways to enhance the efficiency of magnetic cell delivery. In particular, we show that the targeting efficiency can be increased by using magnets that produce spatially modulated stray fields. Such magnetic systems with tunable geometric parameters may provide the additional level of control needed to enhance the efficiency of stem cell delivery in spinal cord injury.","[Vanecek, Vaclav; Forostyak, Serhiy; Ruzicka, Jiri; Jendelova, Pavla; Kubinova, Sarka; Sykova, Eva] Inst Expt Med AS CR, Prague 14220 4, Czech Republic; [Zablotskii, Vitalii; Dejneka, Alexandr] Inst Phys AS CR, Prague, Czech Republic; [Herynek, Vit] Inst Clin & Expt Med, MR Unit, Prague, Czech Republic; [Babic, Michal] Inst Macromol Chem AS CR, Prague, Czech Republic; [Vanecek, Vaclav; Forostyak, Serhiy; Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic","Vanecek, V (reprint author), Inst Expt Med AS CR, Videnska 1083, Prague 14220 4, Czech Republic.","vanecek@biomed.cas.cz","Babic, Michal/B-7075-2013",null,"Grant Agency of the Czech Republic [P304/12/1370, P304/11/0731, P304/11/0189, P304/11/0653]; Grant Agency of the Academy of Sciences of the Czech Republic [AVOZ50390703, IAA500390902, AV0Z10100522]","This work was supported by the Grant Agency of the Czech Republic (P304/12/1370, P304/11/0731, P304/11/0189, P304/11/0653) and the Grant Agency of the Academy of Sciences of the Czech Republic (AVOZ50390703, IAA500390902, AV0Z10100522). The authors thank James Dutt for his critical reading of the manuscript.",null,47,5,5,"DOVE MEDICAL PRESS LTD","ALBANY","PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND","1178-2013",null,null,"INT J NANOMED","Int. J. Nanomed.",null,2012,7,null,null,null,null,null,3719,3730,null,"10.2147/IJN.S32824",null,12,"Nanoscience & Nanotechnology; Pharmacology & Pharmacy","Science & Technology - Other Topics; Pharmacology & Pharmacy","974BI","WOS:000306404400001"]
[null,null,null,null,"J","Krulisova, V; Balascakova, M; Skalicka, V; Piskackova, T; Holubova, A; Paderova, J; Krenkova, P; Dvorakova, L; Zemkova, D; Kracmar, P; Chovancova, B; Vavrova, V; Stambergova, A; Votava, F; Macek, M",null,null,null,"Krulisova, Veronika; Balascakova, Miroslava; Skalicka, Veronika; Piskackova, Tereza; Holubova, Andrea; Paderova, Jana; Krenkova, Petra; Dvorakova, Lenka; Zemkova, Dana; Kracmar, Petr; Chovancova, Blanka; Vavrova, Vera; Stambergova, Alexandra; Votava, Felix; Macek, Milan, Jr.",null,null,"Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA","EUROPEAN JOURNAL OF PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"Newborn screening; Cystic fibrosis (MIM 219700); Cystic fibrosis transmembrane conductance regulator gene; Immunoreactive trypsinogen; Pancreatitis-associated protein; Sweat test","PANCREATITIS-ASSOCIATED PROTEIN; IMMUNOREACTIVE TRYPSINOGEN; GUIDELINES; DIAGNOSIS; CONSENSUS; PROGRAMS; OUTCOMES; INFANTS","Cystic fibrosis (CF) is a life-threatening disease for which early diagnosis following newborn screening (NBS) improves the prognosis. We performed a prospective assessment of the immunoreactive trypsinogen (IRT)/DNA/IRT protocol currently in use nationwide, versus the IRT/pancreatitis-associated protein (PAP) and IRT/PAP/DNA CF NBS protocols. Dried blood spots (DBS) from 106,522 Czech newborns were examined for IRT concentrations. In the IRT/DNA/IRT protocol, DNA-testing was performed for IRT a parts per thousand yenaEuro parts per thousand 65 ng/mL. Newborns with IRT a parts per thousand yenaEuro parts per thousand 200 ng/mL and no detected cystic fibrosis transmembrane conductance regulator gene (CFTR) mutations were recalled for a repeat IRT. In the same group of newborns, for both parallel protocols, PAP was measured in DBS with IRT a parts per thousand yenaEuro parts per thousand 50 ng/mL. In PAP-positive newborns (i.e., a parts per thousand yen1.8 if IRT 50-99.9 or a parts per thousand yen1.0 if IRT a parts per thousand yenaEuro parts per thousand 100, all in ng/mL), DNA-testing followed as part of the IRT/PAP/DNA protocol. Newborns with at least one CFTR mutation in the IRT/DNA/IRT and IRT/PAP/DNA protocols; a positive PAP in IRT/PAP; or a high repeat IRT in IRT/DNA/IRT were referred for sweat testing. Conclusion: the combined results of the utilized protocols led to the detection of 21 CF patients, 19 of which were identified using the IRT/DNA/IRT protocol, 16 using IRT/PAP, and 15 using IRT/PAP/DNA. Decreased cut-offs for PAP within the IRT/PAP protocol would lead to higher sensitivity but would increase false positives. Within the IRT/PAP/DNA protocol, decreased PAP cut-offs would result in high sensitivity, an acceptable number of false positives, and would reduce the number of DNA analyses. Thus, we concluded that the IRT/PAP/DNA protocol would represent the most suitable protocol in our conditions.","[Krulisova, Veronika; Balascakova, Miroslava; Piskackova, Tereza; Holubova, Andrea; Paderova, Jana; Krenkova, Petra; Dvorakova, Lenka; Stambergova, Alexandra; Macek, Milan, Jr.] Charles Univ Prague, Univ Hosp Motol, Dept Biol & Med Genet, Prague 15006 5, Czech Republic; [Krulisova, Veronika; Balascakova, Miroslava; Skalicka, Veronika; Piskackova, Tereza; Holubova, Andrea; Paderova, Jana; Krenkova, Petra; Dvorakova, Lenka; Zemkova, Dana; Vavrova, Vera; Stambergova, Alexandra; Macek, Milan, Jr.] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; [Skalicka, Veronika; Zemkova, Dana; Vavrova, Vera] Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Prague 15006 5, Czech Republic; [Kracmar, Petr; Chovancova, Blanka; Votava, Felix] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Pediat, Prague 15006 5, Czech Republic; [Kracmar, Petr; Chovancova, Blanka; Votava, Felix] Charles Univ Prague, Fac Med 3, Prague 15006 5, Czech Republic","Macek, M (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Biol & Med Genet, V Uvalu 84, Prague 15006 5, Czech Republic.","milan.macek.jr@lfmotol.cuni.cz",null,null,"Czech Ministry of Health [IGA NS 9986-3/2008]","This study was supported by a grant from the Czech Ministry of Health: IGA NS 9986-3/2008 to FV. We would like to acknowledge all collaborating primary care physicians and clinicians from neonatal units who we could not list individually. We would like to thank Mr Thomas Secrest for linguistic proofreading of the final manuscript. Finally, we would like to thank all participants of the parallel CF NBS research protocols.",null,24,3,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,null,"EUR J PEDIATR","Eur. J. Pediatr.","AUG",2012,171,8,null,null,null,null,1223,1229,null,"10.1007/s00431-012-1747-z",null,7,"Pediatrics","Pediatrics","977RM","WOS:000306682100011"]
[null,null,null,null,"J","Schwabova, J; Zahalka, F; Komarek, V; Maly, T; Hrasky, P; Gryc, T; Cakrt, O; Zumrova, A",null,null,null,"Schwabova, J.; Zahalka, F.; Komarek, V.; Maly, T.; Hrasky, P.; Gryc, T.; Cakrt, O.; Zumrova, A.",null,null,"Uses of the postural stability test for differential diagnosis of hereditary ataxias","JOURNAL OF THE NEUROLOGICAL SCIENCES",null,null,"English","Article",null,null,null,null,null,"Ataxia; Sensory ataxia; Cerebellar ataxia; Coordination impairment; Spinocerebellar ataxia type 2; Friedreich ataxia; Differential diagnosis; Centre of pressure","SPINOCEREBELLAR ATAXIA; CEREBELLAR-ATAXIA; FRIEDREICH ATAXIA; MOVEMENTS; SCALE; DISEASE; HUMANS; STANCE; SWAY","Friedreich's ataxia (FRDA) and spinocerebellar ataxia type 2 (SCA 2) are among the most commonly diagnosed hereditary ataxias in Czech Republic. Although criteria differentiate the ataxias, disorder onset symptoms may be similar. Our goal was to determine whether and to what degree of validity posturographic examination may be utilized, with the aim of differential diagnosis; which specific posturographic parametres are suitable for differential diagnosis; and which differences in FRDA and SCA 2 patient posturographic findings may be established. 17 SCA 2 and 12 FRDA patients were examined with ten healthy controls. A multi-sensor tenzometric platform was used for posturographic examination. Toe standing position was added to basic tests, including standing position with and without visual control. There was no difference between patients in standing position with visual control but there were distinct differences between FRDA and SCA 2 patients, based on upright stance without visual control and medio-lateral deviation. There were no differences between patients in toe standing position, suggesting not only the cerebellum, but also deep sensation, helps to create the so-called adaptive controller. Posturography is attested to as a useful method for differential diagnosis of hereditary ataxias and provides neurophysiological findings in cerebellar and sensoric ataxias. (C) 2012 Elsevier B.V. All rights reserved.","[Schwabova, J.] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague 15006 5, Czech Republic; [Schwabova, J.; Komarek, V.; Cakrt, O.; Zumrova, A.] Motol Univ Hosp, Prague 15006 5, Czech Republic; [Komarek, V.; Zumrova, A.] Charles Univ Prague, Dept Paediat Neurol, Fac Med 2, Prague 15006 5, Czech Republic; [Zahalka, F.; Maly, T.; Hrasky, P.; Gryc, T.] Charles Univ Prague, Res Sport Ctr, Fac Phys Educ & Sport, Prague 16252 6, Czech Republic; [Cakrt, O.] Charles Univ Prague, Dept Rehabil & Sport Med, Fac Med 2, Prague 15006 5, Czech Republic","Schwabova, J (reprint author), Charles Univ Prague, Dept Neurol, Fac Med 2, Uvalu 84, Prague 15006 5, Czech Republic.","schwabova@gmail.com",null,null,"GAUK (Grant agency of Charles University in Prague) [96909]; IGA MZCR (Ministry of Health of the Czech Republic - Internal Grant Agency) [100005-4]; GACR (Czech Science Foundation) [P407/11/P784]; MSM [002160864]; VZ FNM MZO [0064203-6505]","Supported by GAUK (Grant agency of Charles University in Prague) 96909; IGA MZCR (Ministry of Health of the Czech Republic - Internal Grant Agency) 100005-4; GACR P407/11/P784 (Czech Science Foundation); MSM 002160864 and VZ FNM MZO 0064203-6505.",null,33,2,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0022-510X",null,null,"J NEUROL SCI","J. Neurol. Sci.","MAY 15",2012,316,41671,null,null,null,null,79,85,null,"10.1016/j.jns.2012.01.022",null,7,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","930XK","WOS:000303177900015"]
[null,null,null,null,"J","Snajderova, M; Riccardi, VM; Petrak, B; Zemkova, D; Zapletalova, J; Mardesic, T; Petrakova, A; Lanska, V; Marikova, T; Bendova, S; Havlovicova, M; Kaluzova, M",null,null,null,"Snajderova, Marta; Riccardi, Vincent M.; Petrak, Borivoj; Zemkova, Daniela; Zapletalova, Jirina; Mardesic, Tonko; Petrakova, Alena; Lanska, Vera; Marikova, Tatiana; Bendova, Sarka; Havlovicova, Marketa; Kaluzova, Marie",null,null,"The importance of advanced parental age in the origin of neurofibromatosis type 1","AMERICAN JOURNAL OF MEDICAL GENETICS PART A",null,null,"English","Article",null,null,null,null,null,"parental age; advanced paternal age; advanced maternal age; neurofibromatosis type 1; sporadic cases","ADVANCED PATERNAL AGE; NF1 GENE; MUTATION-RATE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; MONOZYGOTIC TWINS; RISK; EPIDEMIOLOGY; DISCORDANT; DIAGNOSIS; DELETIONS","Von Recklinghausen neurofibromatosis (NF1) is an autosomal dominant disorder with a prevalence about 1/3,000 (1/2,0001/5,000 in various population-based studies). About 3050% of cases are sporadic, resulting from a new mutation. NF1 is fully penetrant by mid-childhood, stigmata, and medical problems (neurological, dermatological, endocrine, ophthalmological, oncological) are highly variable. Advanced paternal age (APA) has been known to increase the risk of new germline mutations that contribute to the presence of a variety of genetic diseases in the human population. The trend in developed countries has been toward higher parental age due to various reasons. In a cross-sectional study, in two university hospital centers, data on parental age of 103 children (41 female) born between 1976 and 2005 with sporadic NF1 were analyzed. Parental age at birth was compared with the Czech general population matched to birth year. The mean NF1 sporadic case paternal age at birth was 32.0 years (95% CI 30.733.3 years) compared with 28.8 years (95% CI 28.629.1 years) in the general population (P?<?0.001). The mean maternal age at birth was 27.4 years (95% CI 26.328.5 years) compared with 25.8 years (95% CI 25.526.0 years) in the general population (P?<?0.05). The case-control difference in the father's age was higher than it was for the mother's age. Sporadic NF1 cases accounted for 35.6% of our entire NF1 cohort. We confirmed an association of advanced parental and particularly paternal age with the occurrence of sporadic NF1. (c) 2012 Wiley Periodicals, Inc.","[Petrak, Borivoj; Kaluzova, Marie] Charles Univ Prague, Dept Child Neurol, Sch Med 2, Prague 15006 5, Czech Republic; [Snajderova, Marta; Petrak, Borivoj; Zemkova, Daniela; Marikova, Tatiana; Bendova, Sarka; Havlovicova, Marketa; Kaluzova, Marie] Charles Univ Prague, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Riccardi, Vincent M.] Neurofibromatosis Inst, La Crescenta, CA USA; [Snajderova, Marta; Zemkova, Daniela] Charles Univ Prague, Dept Pediat, Sch Med 2, Prague 15006 5, Czech Republic; [Zapletalova, Jirina] Palacky Univ, Dept Pediat, Sch Med, CR-77147 Olomouc, Czech Republic; [Zapletalova, Jirina] Univ Hosp, Olomouc, Czech Republic; [Mardesic, Tonko] Sanat Pronatal, Dept Reprod Med, Prague, Czech Republic; [Petrakova, Alena] European Ctr Dis Prevent & Control, Stockholm, Sweden; [Lanska, Vera] Inst Clin & Expt Med, Dept Stat, Prague, Czech Republic; [Marikova, Tatiana; Bendova, Sarka; Havlovicova, Marketa] Charles Univ Prague, Inst Biol & Med Genet, Sch Med 2, Prague 15006 5, Czech Republic","Petrak, B (reprint author), Charles Univ Prague, Dept Child Neurol, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","borivoj.petrak@post.cz",null,null,"Ministry of Health of the Czech Republic [MZ0FNM2005, 6503]; Academy of Sciences of the Czech Republic [AVCR1ET 101210513, GAUK200072]","This study was supported by a Research Project of the Ministry of Health of the Czech Republic MZ0FNM2005, 6503 and the Academy of Sciences of the Czech Republic AVCR1ET 101210513, GAUK200072.",null,40,2,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1552-4825",null,null,"AM J MED GENET A","Am. J. Med. Genet. A","MAR",2012,"158A",3,null,null,null,null,519,523,null,"10.1002/ajmg.a.34413",null,5,"Genetics & Heredity","Genetics & Heredity","895LU","WOS:000300498500007"]
[null,null,null,null,"J","Prochazka, P; Libra, A; Zemanova, Z; Hrebackova, J; Poljakova, J; Hrabeta, J; Buncek, M; Stiborova, M; Eckschlager, T",null,null,null,"Prochazka, Pavel; Libra, Antonin; Zemanova, Zuzana; Hrebackova, Jana; Poljakova, Jitka; Hrabeta, Jan; Buncek, Martin; Stiborova, Marie; Eckschlager, Tomas",null,null,"Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells","CANCER SCIENCE",null,null,"English","Article",null,null,null,null,null,null,"COMPARATIVE GENOMIC HYBRIDIZATION; ANTICANCER DRUG ELLIPTICINE; MULTIDRUG-RESISTANT; ANTITUMOR AGENTS; DNA; EXPRESSION; LINES; CHEMOTHERAPY; DOXORUBICIN; CISPLATIN","Most high-risk neuroblastomas develop resistance to cytostatics and therefore there is a need to develop new drugs. In previous studies, we found that ellipticine induces apoptosis in human neuroblastoma cells. We also investigated whether ellipticine was able to induce resistance in the UKF-NB-4 neuroblastoma line and concluded that it may be possible after long-term treatment with increasing concentrations of ellipticine. The aim of the present study was to investigate the mechanisms responsible for ellipticine resistance. To elucidate the mechanisms involved, we used the ellipticine-resistant subline UKF-NB-4ELLI and performed comparative genomic hybridization, multicolor and interphase FISH, expression microarray, real-time RT-PCR, flow cytometry and western blotting analysis of proteins. On the basis of our results, it appears that ellipticine resistance in neuroblastoma is caused by a combination of overexpression of Bcl-2, efflux or degradation of the drug and downregulation of topoisomerases. Other mechanisms, such as upregulation of enzymes involved in oxidative phosphorylation, cellular respiration, V-ATPases, aerobic respiration or spermine synthetase, as well as reduced growth rate, may also be involved. Some changes are expressed at the DNA level, including gains, amplifications or deletions. The present study demonstrates that resistance to ellipticine is caused by a combination of mechanisms. (Cancer Sci 2012; 103: 334341)","[Prochazka, Pavel; Hrebackova, Jana; Poljakova, Jitka; Hrabeta, Jan; Eckschlager, Tomas] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague, Czech Republic; [Prochazka, Pavel; Hrebackova, Jana; Poljakova, Jitka; Hrabeta, Jan; Eckschlager, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Zemanova, Zuzana] Charles Univ Prague, Inst Clin Biochem & Lab Diagnost, Sch Med 1, Prague, Czech Republic; [Poljakova, Jitka; Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, Prague, Czech Republic; [Libra, Antonin; Buncek, Martin] Generi Biotech Sro, Hradec Kralove, Czech Republic","Eckschlager, T (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague, Czech Republic.","eckschlagertomas@yahoo.com","Prochazka, Pavel/G-4759-2012",null,"Ministry of Education, Youth and Sports of Czech Republic (MSM) [MSM0021620813]; Grant agency of Czech Republic (GACR) [GACR P301/10/0356]","This work was supported by grants MSM0021620813 from the Ministry of Education, Youth and Sports of Czech Republic (MSM) and GACR P301/10/0356 from Grant agency of Czech Republic (GACR). The authors thank Professor J. Cinatl for supplying the cell lines.",null,41,2,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1347-9032",null,null,"CANCER SCI","Cancer Sci.","FEB",2012,103,2,null,null,null,null,334,341,null,"10.1111/j.1349-7006.2011.02137.x",null,8,"Oncology","Oncology","884UJ","WOS:000299734000026"]
[null,null,null,null,"J","Stechova, K; Kolar, M; Blatny, R; Halbhuber, Z; Vcelakova, J; Hubackova, M; Petruzelkova, L; Sumnik, Z; Obermannova, B; Pithova, P; Stavikova, V; Krivjanska, M; Neuwirth, A; Kolouskova, S; Filipp, D",null,null,null,"Stechova, K.; Kolar, M.; Blatny, R.; Halbhuber, Z.; Vcelakova, J.; Hubackova, M.; Petruzelkova, L.; Sumnik, Z.; Obermannova, B.; Pithova, P.; Stavikova, V.; Krivjanska, M.; Neuwirth, A.; Kolouskova, S.; Filipp, D.",null,null,"Healthy First-Degree Relatives of Patients with Type 1 Diabetes Exhibit Significant Differences in Basal Gene Expression Pattern of Immunocompetent Cells Compared to Controls: Expression Pattern as Predeterminant of Autoimmune Diabetes","SCANDINAVIAN JOURNAL OF IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,null,"BLOOD MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; T-CELLS; MICROARRAY ANALYSIS; IN-VITRO; DISEASE; MELLITUS; ONSET; RISK; PATHOGENESIS","Expression features of genetic landscape which predispose an individual to the type 1 diabetes are poorly understood. We addressed this question by comparing gene expression profile of freshly isolated peripheral blood mononuclear cells isolated from either patients with type 1 diabetes (T1D), or their first-degree relatives or healthy controls. Our aim was to establish whether a distinct type of prodiabetogenic gene expression pattern in the group of relatives of patients with T1D could be identified. Whole-genome expression profile of nine patients with T1D, their ten first-degree relatives and ten healthy controls was analysed using the human high-density expression microarray chip. Functional aspects of candidate genes were assessed using the MetaCore software. The highest number of differentially expressed genes (547) was found between the autoantibody-negative healthy relatives and the healthy controls. Some of them represent genes critically involved in the regulation of innate immune responses such as TLR signalling and CCR3 signalling in eosinophiles, humoral immune reactions such as BCR pathway, costimulation and cytokine responses mediated by CD137, CD40 and CD28 signalling and IL-1 proinflammatory pathway. Our data demonstrate that expression profile of healthy relatives of patients with T1D is clearly distinct from the pattern found in the healthy controls. That especially concerns differential activation status of genes and signalling pathways involved in proinflammatory processes and those of innate immunity and humoral reactivity. Thus, we posit that the study of the healthy relatives gene expression pattern is instrumental for the identification of novel markers associated with the development of diabetes.","[Stechova, K.] Univ Hosp Motol, Lab Autoimmune Dis, Dept Paediat, Prague 15006 5, Motol, Czech Republic; [Stechova, K.; Vcelakova, J.; Hubackova, M.; Petruzelkova, L.; Sumnik, Z.; Obermannova, B.; Stavikova, V.; Kolouskova, S.] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Kolar, M.; Krivjanska, M.] Inst Mol Genet AS CR, Lab Genom & Bioinformat, Prague, Czech Republic; [Blatny, R.; Halbhuber, Z.] Cent European Biosyst, Prague, Czech Republic; [Pithova, P.] Charles Univ Prague, Fac Med 2, Dept Internal Med, Prague, Czech Republic; [Neuwirth, A.; Filipp, D.] Acad Sci Czech Republic, Inst Mol Genet, Dept Immunobiol, Prague, Czech Republic","Stechova, K (reprint author), Univ Hosp Motol, Lab Autoimmune Dis, Dept Paediat, Uvalu 84, Prague 15006 5, Motol, Czech Republic.","katerina.stechova@lfmotol.cuni.cz","Kolar, Michal/A-3307-2012","Kolar, Michal/0000-0002-4593-1525","Czech Ministry of Education [NPVII 2B06019]; Academy of Sciences of the Czech Republic [AVOZ50520514]; Ministry of Education, Youth and Sports, Czech Republic [IMUDIAB 2B08066]","This work was supported by project NPVII 2B06019 Czech Ministry of Education and partially by Grant AVOZ50520514 from the Academy of Sciences of the Czech Republic. KS, AN and DF were also supported by Grant IMUDIAB 2B08066 from the Ministry of Education, Youth and Sports, Czech Republic.",null,45,2,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0300-9475",null,null,"SCAND J IMMUNOL","Scand. J. Immunol.","FEB",2012,75,2,null,null,null,null,210,219,null,"10.1111/j.1365-3083.2011.02637.x",null,10,"Immunology","Immunology","874VE","WOS:000298985400010"]
[null,null,null,null,"J","Prosecka, E; Buzgo, M; Rampichova, M; Kocourek, T; Kochova, P; Vyslouzilova, L; Tvrdik, D; Jelinek, M; Lukas, D; Amler, E",null,null,null,"Prosecka, Eva; Buzgo, Matej; Rampichova, Michala; Kocourek, Tomas; Kochova, Petra; Vyslouzilova, Lucie; Tvrdik, Daniel; Jelinek, Miroslav; Lukas, David; Amler, Evzen",null,null,"Thin-Layer Hydroxyapatite Deposition on a Nanofiber Surface Stimulates Mesenchymal Stem Cell Proliferation and Their Differentiation into Osteoblasts","JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY",null,null,"English","Article",null,null,null,null,null,null,"PULSED-LASER DEPOSITION; IN-VITRO; BIOMEDICAL APPLICATIONS; ELECTROSPUN NANOFIBERS; DELIVERY-SYSTEM; GENE DELIVERY; SCAFFOLDS; TISSUE; BONE; RELEASE","Pulsed laser deposition was proved as a suitable method for hydroxyapatite (HA) coating of coaxial poly-epsilon-caprolactone/polyvinylalcohol (PCL/PVA) nanofibers. The fibrous morphology of PCL/PVA nanofibers was preserved, if the nanofiber scaffold was coated with thin layers of HA (200 nm and 400 nm). Increasing thickness of HA, however, resulted in a gradual loss of fibrous character. In addition, biomechanical properties were improved after HA deposition on PCL/PVA nanofibers as the value of Young's moduli of elasticity significantly increased. Clearly, thin-layer hydroxyapatite deposition on a nanofiber surface stimulated mesenchymal stem cell viability and their differentiation into osteoblasts. The optimal depth of HA was 800 nm.","[Prosecka, Eva; Buzgo, Matej; Rampichova, Michala; Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Prague 14240, Czech Republic; [Prosecka, Eva; Buzgo, Matej; Rampichova, Michala; Amler, Evzen] Charles Univ Prague, Fac Med 2, Dept Biophys, Prague 15006 5, Czech Republic; [Kocourek, Tomas] Czech Tech Univ, Dept Nat Sci, Prague 16636 6, Czech Republic; [Kochova, Petra] Univ W Bohemia, Fac Sci Appl, Dept Mech, Plzen 30614, Czech Republic; [Vyslouzilova, Lucie; Lukas, David] Tech Univ Liberec, Fac Text Engn, Dept Nonwoven Text, Liberec 46117, Czech Republic; [Tvrdik, Daniel] Charles Univ Prague, Gen Teaching Hosp, Fac Med 1, Inst Pathol, Prague 12800, Czech Republic; [Amler, Evzen] Czech Tech Univ, Fac Biomed Engn, Dept Med & Humanities, Kladno 27201, Czech Republic","Amler, E (reprint author), Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Videnska 1083, Prague 14240, Czech Republic.","evzen.amler@lfmotol.cuni.cz",null,null,"Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Ministry of Education, Youth, and Sports of the Czech Republic [2B06130]; Grant Agency of the Academy of Sciences [IAA500390702]; Grant Agency of the Charles University [96610, 97110, 330611, 384311, 164010]; Grant Agency of the Czech Republic [P304/10/1307, 109/09/P226]; Ministry of Education of the Czech Republic [ME 10145]; Internal Grant Agency Ministry of Health of the Czech Republic [NT12156-5/2011]; Czech Science Foundation [GA202/09/1151]","This paper was supported by the Academy of Sciences of the Czech Republic (institutional research plans AV0Z50390703 and AV0Z50390512), Ministry of Education, Youth, and Sports of the Czech Republic (research program NPV II 2B06130), Grant Agency of the Academy of Sciences (Grant no. IAA500390702), the Grant Agency of the Charles University (Grant no. 96610, 97110, 330611, 384311, 164010), Grant Agency of the Czech Republic (Grant P304/10/1307, 109/09/P226), The Ministry of Education of the Czech Republic, project ERA-NET CARSILA no. ME 10145, the Internal Grant Agency Ministry of Health of the Czech Republic (no. NT12156-5/2011), and Grant by Czech Science Foundation (Grant no. GA202/09/1151).",null,66,2,2,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","1110-7243",null,null,"J BIOMED BIOTECHNOL","J. Biomed. Biotechnol.",null,2012,null,null,null,null,null,null,null,null,428503,"10.1155/2012/428503",null,10,"Biotechnology & Applied Microbiology; Medicine, Research & Experimental","Biotechnology & Applied Microbiology; Research & Experimental Medicine","906WB","WOS:000301378600001"]
[null,null,null,null,"J","Brozkova, DS; Lastuvkova, J; Stepankova, H; Krutova, M; Trkova, M; Myska, P; Seeman, P",null,null,null,"Brozkova, D. Safka; Lastuvkova, J.; Stepankova, H.; Krutova, M.; Trkova, M.; Myska, P.; Seeman, P.",null,null,"DFNB49 is an important cause of non-syndromic deafness in Czech Roma patients but not in the general Czech population","CLINICAL GENETICS",null,null,"English","Article",null,null,null,null,null,"deafness; DFNB49; homozygosity mapping; MARVELD2; non-syndromic hearing loss; Roma","HEARING IMPAIRMENT; W24X MUTATION; GYPSIES; GJB2; NEUROPATHY","Due to endogamy, the Roma have a higher risk for autosomal recessive (AR) disorders. We used homozygosity mapping on single-nucleotide polymorphism chips in one Czech Roma consanguineous family with non-syndromic hearing loss (NSHL). The second largest homozygous region in a deaf patient was mapped to the previously reported DFNB49 region. The MARVELD2 gene was recently reported as a causal gene for NSHL DFNB49. Sequencing of the MARVELD2 gene revealed a previously reported homozygous mutation c.1331+2 T>C (IVS4 + 2 T>C) in the deaf child. Subsequently, the same mutation was found in two more Roma families from an additional 19 unrelated Czech Roma patients with deafness tested for the MARVELD2 gene. To explore the importance of MARVELD2 mutations and DFNB49 for the general Czech and Central European population with early hearing loss we also tested 40 unrelated Czech patients with AR NSHL. No pathogenic mutation in the MARVELD2 gene was found in a group of 40 Czech non-Roma patients. Mutations in the MARVELD2 gene seem to be a significant cause of early NSHL in Czech Roma and this gene should be tested in this group of patients after GJB2.","[Brozkova, D. Safka; Krutova, M.; Seeman, P.] Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague 15006, Czech Republic; [Brozkova, D. Safka; Krutova, M.; Myska, P.; Seeman, P.] Univ Hosp Motol, Prague 15006, Czech Republic; [Lastuvkova, J.] Reg Hlth Corp, Masaryk Hosp, BDepartment Med Genet, Usti Nad Labem, Czech Republic; [Stepankova, H.] Hosp Ceske Budejovice, Dept Clin Genet, Ceske Budejovice, Czech Republic; [Trkova, M.] Ctr Med Genet & Reprod Med GENNET, Prague, Czech Republic; [Myska, P.] Charles Univ Prague, Sch Med 2, Dept Otorhinolaryngol, Prague 15006, Czech Republic","Brozkova, DS (reprint author), Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, V Uvalu 84, Prague 15006, Czech Republic.","dana.brozkova@seznam.cz",null,null,"GAUK [309]; IGA MZCR NS [10552-3]","This study was supported by the GAUK 309 and IGA MZCR NS 10552-3.",null,14,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0009-9163","1399-0004",null,"CLIN GENET","Clin. Genet.","DEC",2012,82,6,null,null,null,null,579,582,null,"10.1111/j.1399-0004.2011.01817.x",null,4,"Genetics & Heredity","Genetics & Heredity","032ON","WOS:000310728700015"]
[null,null,null,null,"J","Dostalova, T; Eliasova, H; Seydlova, M; Broucek, J; Vavrickova, L",null,null,null,"Dostalova, Tatjana; Eliasova, Hana; Seydlova, Michaela; Broucek, Jaroslav; Vavrickova, Lenka",null,null,"The application of CamScan 2 in forensic dentistry","JOURNAL OF FORENSIC AND LEGAL MEDICINE",null,null,"English","Article",null,null,null,null,null,"Forensic science; Anthropology; Dentistry; CamScan 2; Superimposition; DNA","DNA; IDENTIFICATION; TEETH","Forensic dentistry plays a major role in body identification. The dental examination is very accurate and also, nowadays, in the time of a comprehensive fingerprint and DNA assessment, objectively supported. The identification, which is based on the dental documentation, leads up to 43-89% of a successful process. The purpose of the study is to describe the techniques employed by forensic odontology to identify human remains and also to provide details of some of the novel developments within this area. Comparative methods of dental identification of the unknown subject with pre-mortem clinical records, X-ray images, implant presence, superimposition and DNA analysis confirm the identity of the individual. It was shown that dental identification of a person is based on unique individual characteristics of the dentition and dental restorations, relative resistance of the mineralised dental tissues and dental restorations to changes resulting from decomposition and harsh environmental extremes such as conditions of temperature and violent physical forces. (c) 2012 Elsevier Ltd and Faculty of Forensic and Legal Medicine. All rights reserved.","[Dostalova, Tatjana; Seydlova, Michaela] Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, Prague 15006 5, Czech Republic; [Dostalova, Tatjana; Seydlova, Michaela] Fac Hosp Motol, Prague 15006 5, Czech Republic; [Eliasova, Hana] Inst Criminalist Prague, Dept Anthropol & Biol, Prague, Czech Republic; [Vavrickova, Lenka] Charles Univ Hradec Kralove, Dept Stomatol, Prague, Czech Republic","Dostalova, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat Stomatol, V Uvalu 84, Prague 15006 5, Czech Republic.","tatjana.dostalova@fnmotol.cz",null,null," [NT 13351-4 MZCR];  [VF 20102014007]","This project has been supported by the grant No. NT 13351-4 MZCR and project VF 20102014007.",null,17,0,0,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","1752-928X",null,null,"J FORENSIC LEG MED","J. Forensic Leg. Med.","OCT",2012,19,7,null,null,null,null,373,380,null,"10.1016/j.jflm.2012.04.015",null,8,"Medicine, Legal","Legal Medicine","000DM","WOS:000308366700002"]
[null,null,null,null,"J","Amlerova, J; Cavanna, AE; Bradac, O; Javurkova, A; Marusic, P",null,null,null,"Amlerova, Jana; Cavanna, Andrea E.; Bradac, Ondrej; Javurkova, Alena; Marusic, Petr",null,null,"Hyperfamiliarity in patients with temporal lobe epilepsy","EPILEPSY & BEHAVIOR",null,null,"English","Article",null,null,null,null,null,"Hyperfamiliarity; Face recognition; Temporal lobe epilepsy","HUMAN NEURAL SYSTEM; FACE PERCEPTION; DELUSIONAL MISIDENTIFICATIONS; UNKNOWN FACES; FAMOUS FACES; HUMAN BRAIN; RECOGNITION; PROSOPAGNOSIA; CORTEX; DISCRIMINATION","Hyperfamiliarity is a type of paramnesia characterized by an increased feeling of familiarity to unfamiliar faces. This dysfunction has been associated with frontal and temporal lobe pathology. The study investigated hyperfamiliarity in patients with temporal lobe epilepsy (TLE) by assessing their ability to recognize both familiar and unfamiliar faces. We evaluated 61 patients with pharmacoresistant TLE (33 right-sided, 28 left-sided) and 16 controls. The ability to recognize familiar faces was similar in patients and controls, although patients with left-sided TLE showed poorer performance in familiar face naming compared to both right-sided TLE patients and controls. Hyperfamiliarity was observed in a significantly higher number of patients with TLE compared to controls; in subgroup analysis, only right-sided TLE patients expressed hyper-familiarity. Overall, patients with right-sided TLE showed more severe impairment compared to patients with left-sided TLE. It is proposed that hyperfamiliarity can be a relatively common symptom in patients with treatment-refractory TLE and right-sided focus. (c) 2012 Elsevier Inc. All rights reserved.","[Amlerova, Jana; Marusic, Petr] Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Motol, Czech Republic; [Cavanna, Andrea E.] Univ Birmingham, Birmingham B15 2TT, W Midlands, England; [Cavanna, Andrea E.] UCL, Inst Neurol, London WC1E 6BT, England; [Bradac, Ondrej; Marusic, Petr] Charles Univ Prague, Dept Neurosurg, Fac Med 1, Cent Mil Hosp, Prague, Czech Republic; [Javurkova, Alena] Univ Hosp Motol, Dept Psychol, Prague, Czech Republic","Marusic, P (reprint author), Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Motol, Czech Republic.","petr.marusic@fnmotol.cz",null,null,"IGA MZCR [NT/11536-5]; GAUK [200 084/999]","This work was supported by grant projects IGA MZCR NT/11536-5 and GAUK 200 084/999.",null,27,0,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1525-5050",null,null,"EPILEPSY BEHAV","Epilepsy Behav.","JUL",2012,24,3,null,null,null,null,332,335,null,"10.1016/j.yebeh.2012.04.116",null,4,"Behavioral Sciences; Clinical Neurology; Psychiatry","Behavioral Sciences; Neurosciences & Neurology; Psychiatry","958AS","WOS:000305208900008"]
[null,null,null,null,"J","Durila, M; Bronsky, J; Harustiak, T; Pazdro, A; Pechova, M; Cvachovec, K",null,null,null,"Durila, Miroslav; Bronsky, J.; Harustiak, T.; Pazdro, Alexander; Pechova, Marta; Cvachovec, Karel",null,null,"Early diagnostic markers of sepsis after oesophagectomy (including thromboelastography)","BMC ANESTHESIOLOGY",null,null,"English","Article",null,null,null,null,null,"Sepsis; Biochemical; Hematological; Thromboelastography","RESPONSE SYNDROME SIRS; OF-THE-LITERATURE; INFECTIOUS COMPLICATIONS; INDUCED CHOLESTASIS; ABDOMINAL-SURGERY; ORGAN FAILURE; PROCALCITONIN; COAGULATION; INTERLEUKIN-6; CANCER","Background: Early diagnosis of sepsis and its differentiation from the noninfective SIRS is very important in order that treatment can be initiated in a timely and appropriate way. In this study we investigated standard haematological and biochemical parameters and thromboelastography (TEG) in patients who had undergone surgical resection of the oesophagus to find out if changes in any of these parameters could help in early differentiation between SIRS and sepsis development. Methods: We enrolled 43 patients (aged 41-74 years) of whom 38 were evaluable. Blood samples were obtained on the morning of surgery and then at 24-hour intervals for the next 6 days. Samples were analysed for procalcitonin (PCT), C-reactive protein (CRP), interleukin-6 (IL-6), aspartate transaminase (AST), alanine transaminase (ALT), lactate, white blood count (WBC), D-dimers, antithrombin (AT), international normalised ratio (INR), activated partial thromboplastin time (APTT) and parameters of TEG. Results: Significant differences between patients who developed sepsis during this period (9 patients) and SIRS were found in ALT on Day 1, in AST on Days 1-4, in PCT on Days 2-6; in CRP on Days 3-6; in IL-6 on Days 2-5; in leucocytes on Days 2, 3 and 6; and in D-dimers on Days 2 and 4. Significance values ranged from p < 0.0001 to p < 0.05. Conclusions: Sequential measurements of ALT, AST, PCT and IL-6 during the early postoperative period can be used for early differentiation of sepsis and postoperative SIRS after oesophagectomy. Among the coagulation parameters measured, only D-dimer concentrations appeared to be helpful in this process. TEG does not seem to be a useful early predictor of sepsis development; however it can be used to differentiate sepsis and SIRS from Day 5 after surgery.","[Durila, Miroslav; Cvachovec, Karel] Charles Univ Prague, Dept Anesthesiol & Crit Care Med, Fac Med 2, Prague 15006 5, Czech Republic; [Durila, Miroslav; Cvachovec, Karel] Charles Univ Prague, Inst Postgrad Med Educ, Prague 15006 5, Czech Republic; [Bronsky, J.] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague 15006 5, Czech Republic; [Harustiak, T.; Pazdro, Alexander] Fac Med 1, Dept Surg 3, Prague, Czech Republic; [Pechova, Marta] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague 15006 5, Czech Republic","Durila, M (reprint author), Charles Univ Prague, Dept Anesthesiol & Crit Care Med, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","durila4@yahoo.com",null,null,"grant agency of Charles University [21509]; Second Medical Faculty of the Charles University","This study was supported by the grant agency of Charles University (No. 21509). Editorial assistance was provided by Jane Tricker of Elmcroft Editorial Services Ltd, and was funded by the Second Medical Faculty of the Charles University.",null,23,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2253",null,null,"BMC ANESTHESIOL","BMC Anesthesiol.","JUN 28",2012,12,null,null,null,null,null,null,null,12,"10.1186/1471-2253-12-12",null,7,"Anesthesiology","Anesthesiology","088MX","WOS:000314840100001"]
[null,null,null,null,"J","Dvorakova, HM; Szitanyi, P; Dvorak, P; Janda, J; Seeman, T; Zieg, J; Lanska, V; Kotaska, K; Pitha, J",null,null,null,"Dvorakova, H. M.; Szitanyi, P.; Dvorak, P.; Janda, J.; Seeman, T.; Zieg, J.; Lanska, V.; Kotaska, K.; Pitha, J.",null,null,"Determinants of Premature Atherosclerosis in Children With End-Stage Renal Disease","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Atherosclerosis; Children; Carotid intima-media thickness; End-stage renal disease","INTIMA-MEDIA THICKNESS; BLOOD-PRESSURE RESEARCH; YOUNG-ADULTS; CAROTID-ARTERY; CARDIOVASCULAR-DISEASE; KIDNEY-DISEASE; RISK-FACTORS; TRANSPLANTATION; EPIDEMIOLOGY; ADOLESCENTS","Cardiovascular disease is a major cause of morbidity and mortality in young adults with end-stage renal disease (ESRD), but its basis is still not well understood. We therefore evaluated the determinants of atherosclerosis in children with ESRD. A total of 37 children with ESRD (with 31 who had undergone transplantation) were examined and compared to a control group comprising 22 healthy children. The common carotid intimamedia thickness (CIMT) was measured by ultrasound as a marker of preclinical atherosclerosis. The association of CIMT with anthropometrical data, blood pressure, plasma lipid levels, and other biochemical parameters potentially related to cardiovascular disease was evaluated. Children with ESRD had significantly higher CIMT, blood pressure, and levels of lipoprotein (a), urea, creatinine, ferritin, homocysteine, and serum uric acid as well as significantly lower values of apolipoprotein A. The atherogenic index of plasma (log(triglycerides/HDL cholesterol)) was also higher in patients with ESRD; however, this difference reached only borderline significance. In addition, a negative correlation was found between CIMT and serum albumin and bilirubin in the ESRD group, and this correlation was independent of age and body mass index. In the control group, a significant positive correlation was observed between CIMT and ferritin levels. Factors other than traditional cardiovascular properties, such as the antioxidative capacity of circulating blood, may be of importance during the early stages of atherosclerosis in children with end-stage renal disease.","[Dvorakova, H. M.] Univ Hosp Prague Motol, Dept Neonatol, Prague 15006 5, Czech Republic; [Dvorakova, H. M.; Pitha, J.] Inst Clin & Expt Med, Lab Atherosclerosis Res, Prague, Czech Republic; [Szitanyi, P.] Univ Gen Teaching Hosp, Dept Pediat & Adolescent Med, Prague, Czech Republic; [Dvorak, P.] Thomayer Univ Hosp, Dept Pediat, Prague, Czech Republic; [Janda, J.; Seeman, T.; Zieg, J.] Univ Hosp Prague Motol, Dept Pediat, Prague 15006, Czech Republic; [Lanska, V.] Inst Clin & Expt Med, Dept Stat, Prague, Czech Republic; [Kotaska, K.] Univ Hosp Prague Motol, Dept Clin Biochem & Pathobiochem, Prague 15006 5, Czech Republic","Dvorakova, HM (reprint author), Univ Hosp Prague Motol, Dept Neonatol, Uvalu 84, Prague 15006 5, Czech Republic.","dvorakovahm@centrum.cz",null,null,"Centre for Cardiovascular Research [1M0510]; Czech Ministry of Health [NR 7900-5]","This work was supported by the Centre for Cardiovascular Research (1M0510) and by the Czech Ministry of Health (grant NR 7900-5). Technical assistance from candidates of medicine Sugitha Sureshkumar and Romana Dembovska is gratefully acknowledged.",null,34,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2012,61,1,null,null,null,null,53,61,null,null,null,9,"Physiology","Physiology","917RC","WOS:000302195300006"]
[null,null,null,null,"J","Vlckova, M; Trkova, M; Zemanova, Z; Hancarova, M; Novotna, D; Raskova, D; Puchmajerova, A; Drabova, J; Zmitkova, Z; Tan, Y; Sedlacek, Z",null,null,null,"Vlckova, M.; Trkova, M.; Zemanova, Z.; Hancarova, M.; Novotna, D.; Raskova, D.; Puchmajerova, A.; Drabova, J.; Zmitkova, Z.; Tan, Y.; Sedlacek, Z.",null,null,"Mechanism and Genotype-Phenotype Correlation of Two Proximal 6q Deletions Characterized Using mBAND, FISH, Array CGH, and DNA Sequencing","CYTOGENETIC AND GENOME RESEARCH",null,null,"English","Article",null,null,null,null,null,"Array CGH; Centromere fission; Deletion junction; Marker chromosome; Proximal 6q deletion","INTERSTITIAL DELETIONS; MACULAR DYSTROPHY; GENE; CENTROMERE; MUTATION; 6Q16.1; ELOVL4; DELAY","Proximal 6q deletions have a milder phenotype than middle and distal 6q deletions. We describe 2 patients with non-overlapping deletions of about 15 and 19 Mb, respectively, which subdivide the proximal 6q region into 2 parts. The aberrations were identified using karyotyping and analysed using mBAND and array CGH. The unaffected mother of the first patient carried a mosaic karyotype with the deletion in all metaphases analysed and a small supernumerary marker formed by the deleted material in about 77% of cells. Her chromosome 6 centromeric signal was split between the deleted chromosome and the marker, suggesting that this deletion arose through the centromere fission mechanism. In this family the location of the proximal breakpoint in the centromere prevented cloning of the deletion junction, but the junction of the more distal deletion in the second patient was cloned and sequenced. This analysis showed that the latter aberration was most likely caused by non-homologous end joining. The second patient also had a remarkably more severe phenotype which could indicate a partial overlap of his deletion with the middle 6q interval. The phenotypes of both patients could be partly correlated with the gene content of their deletions and with phenotypes of other published patients. Copyright (C) 2011 S. Karger AG, Basel","[Vlckova, M.; Hancarova, M.; Novotna, D.; Puchmajerova, A.; Drabova, J.; Zmitkova, Z.; Tan, Y.; Sedlacek, Z.] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, CZ-15000 Prague 5, Czech Republic; [Vlckova, M.; Hancarova, M.; Novotna, D.; Puchmajerova, A.; Drabova, J.; Zmitkova, Z.; Tan, Y.; Sedlacek, Z.] Univ Hosp Motol, CZ-15000 Prague 5, Czech Republic; [Zemanova, Z.] Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Fac Med 1, CZ-15000 Prague 5, Czech Republic; [Zemanova, Z.] Gen Univ Hosp, Prague, Czech Republic","Sedlacek, Z (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Plzenska 130-221, CZ-15000 Prague 5, Czech Republic.","zdenek.sedlacek@lfmotol.cuni.cz",null,null,"CHERISH (EC) [223692]; Wellcome Trust;  [MZOFNM2005];  [MZOVFN2005]","Supported by grants MZOFNM2005, MZOVFN2005, and CHERISH (EC FP7 223692). The study makes use of data generated by the DECIPHER Consortium (http://decipher.sanger.ac.uk) funded by the Wellcome Trust.",null,21,0,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1424-8581",null,null,"CYTOGENET GENOME RES","Cytogenet. Genome Res.",null,2012,136,1,null,null,null,null,15,20,null,"10.1159/000334709",null,6,"Cell Biology; Genetics & Heredity","Cell Biology; Genetics & Heredity","886QG","WOS:000299868300003"]
[null,null,null,null,"J","Fiser, K; Sieger, T; Schumich, A; Wood, B; Irving, J; Mejstrikova, E; Dworzak, MN",null,null,null,"Fiser, Karel; Sieger, Tomas; Schumich, Angela; Wood, Brent; Irving, Julie; Mejstrikova, Ester; Dworzak, Michael N.",null,null,"Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data","CYTOMETRY PART A",null,null,"English","Article",null,null,null,null,null,"hierarchical clustering; minimal residual disease; acute lymphoblastic leukemia; support vector machines; multiparameter flow cytometry","ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE","Flow cytometry is a valuable tool in research and diagnostics including minimal residual disease (MRD) monitoring of hematologic malignancies. However, its gradual advancement toward increasing numbers of fluorescent parameters leads to information rich datasets, which are challenging to analyze by standard gating and do not reflect the multidimensionality of the data.","[Fiser, Karel; Mejstrikova, Ester] Charles Univ Prague, Sch Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Fiser, Karel; Irving, Julie] Newcastle Univ, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Sieger, Tomas] Czech Tech Univ, Fac Elect Engn, Dept Cybernet, CR-16635 Prague, Czech Republic; [Schumich, Angela; Dworzak, Michael N.] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Wood, Brent] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA","Fiser, K (reprint author), Charles Univ Prague, Sch Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic.","karel.fiser@lfmotol.cuni.cz",null,null,"JGW Patterson Foundation, UK [BH070348]; Czech Ministry of Education [MSM0021620813]","Grant sponsor: JGW Patterson Foundation, UK; Grant number: BH070348; Grant sponsor: Czech Ministry of Education; Grant number: MSM0021620813;",null,16,8,8,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1552-4922",null,null,"CYTOM PART A","Cytom. Part A","JAN",2012,"81A",1,null,null,null,null,25,34,null,"10.1002/cyto.a.21148",null,10,"Biochemical Research Methods; Cell Biology","Biochemistry & Molecular Biology; Cell Biology","862KH","WOS:000298089100009"]
[null,null,null,null,"J","Rampichova, M; Martinova, L; Kostakova, E; Filova, E; Mickova, A; Buzgo, M; Michalek, J; Pradny, M; Necas, A; Lukas, D; Amler, E",null,null,null,"Rampichova, Michala; Martinova, Lenka; Kostakova, Eva; Filova, Eva; Mickova, Andrea; Buzgo, Matej; Michalek, Jiri; Pradny, Martin; Necas, Alois; Lukas, David; Amler, Evzen",null,null,"A simple drug anchoring microfiber scaffold for chondrocyte seeding and proliferation","JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"2-HYDROXYETHYL METHACRYLATE; OSTEOCHONDRAL DEFECT; ARTICULAR-CARTILAGE; RABBIT KNEE; IN-VITRO; ELECTROSPUN; LIPOSOMES; MEMBRANE; DELIVERY; REPAIR","The structural properties of microfiber meshes made from poly(2-hydroxyethyl methacrylate) (PHEMA) were found to significantly depend on the chemical composition and subsequent cross-linking and nebulization processes. PHEMA microfibres showed promise as scaffolds for chondrocyte seeding and proliferation. Moreover, the peak liposome adhesion to PHEMA microfiber scaffolds observed in our study resulted in the development of a simple drug anchoring system. Attached foetal bovine serum-loaded liposomes significantly improved both chondrocyte adhesion and proliferation. In conclusion, fibrous scaffolds from PHEMA are promising materials for tissue engineering and, in combination with liposomes, can serve as a simple drug delivery tool.","[Rampichova, Michala; Mickova, Andrea; Buzgo, Matej; Amler, Evzen] Charles Univ Prague, Dept Biophys, Fac Med 2, Prague 15006 5, Czech Republic; [Rampichova, Michala; Filova, Eva; Mickova, Andrea; Buzgo, Matej; Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Prague 6, Czech Republic; [Martinova, Lenka; Kostakova, Eva; Lukas, David] Tech Univ Liberec, Fac Text Engn, Dept Nonwoven Text, Liberec, Czech Republic; [Michalek, Jiri; Pradny, Martin] Acad Sci Czech Republic, Inst Macromol Chem, Vvi, Prague 6, Czech Republic; [Michalek, Jiri; Pradny, Martin] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Fac Med 2, Prague 15006 5, Czech Republic; [Necas, Alois] Univ Vet & Pharmaceut Sci Brno, Fac Vet Med, Small Anim Clin, Dept Surg & Orthoped, Brno, Czech Republic; [Amler, Evzen] Czech Tech Univ, Fac Biomed Engn, CR-16635 Prague, Czech Republic","Amler, E (reprint author), Charles Univ Prague, Dept Biophys, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","evzen.amler@lfmotol.cuni.cz","Michalek, Jiri/D-7251-2013",null,"Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Ministry of Education, Youth and Sports of the Czech Republic [NPV II 2B06130, 1M0510, ME10145]; Grant Agency of the Academy of Sciences [IAA500390702]; Czech Science Foundation [GA202/09/1151]; IGA MZCR [NT12156]; Grant Agency of the Charles University [122508]","The authors would like to acknowledge J. Farberova from the Technical University of Liberec for measurements of fiber diameters and Sam Norris for proof reading of this manuscript. Supported by the Academy of Sciences of the Czech Republic (institutional research plans AV0Z50390703 and AV0Z50390512), the Ministry of Education, Youth and Sports of the Czech Republic (research programs NPV II 2B06130 and 1M0510, research project CARSILA number ME10145), the Grant Agency of the Academy of Sciences Grant No. IAA500390702 and by the Czech Science Foundation Grant No. GA202/09/1151, IGA MZCR, No. NT12156, and the Grant Agency of the Charles University Grant No. 122508.",null,33,6,6,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0957-4530","1573-4838",null,"J MATER SCI-MATER M","J. Mater. Sci.-Mater. Med.","FEB",2012,23,2,null,null,null,null,555,563,null,"10.1007/s10856-011-4518-x",null,9,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","910MF","WOS:000301640800035"]
[null,null,null,null,"J","Skoumalova, A; Madlova, P; Topinkova, E",null,null,null,"Skoumalova, Alice; Madlova, Pavla; Topinkova, Eva",null,null,"End products of lipid peroxidation in erythrocyte membranes in Alzheimer's disease","CELL BIOCHEMISTRY AND FUNCTION",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; oxidative stress; lipid peroxidation; erythrocytes; lipofuscin-like pigments","MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; MARKERS; BRAIN; DEMENTIA; PLASMA; SPLEEN; CORTEX; DAMAGE; BLOOD","Alzheimer's disease (AD) is accompanied by oxidative stress in the brain. Because the brain tissue is rich in polyunsaturated fatty acids, it is prone to the free radical attack resulting in lipid peroxidation. Intermediates of lipid peroxidation may diffuse from the primary site, cross the bloodbrain barrier and modify erythrocyte membranes in the bloodstream. We exposed isolated erythrocyte membranes from patients with AD and the control group to in vitro free radical damage and monitored the accumulation of the end products of lipid peroxidation, lipofuscin-like pigments (LFPs), by fluorescence spectroscopy. LFPs were analyzed by means of tridimensional and synchronous fluorescence spectroscopy. The levels of LFP formed during in vitro peroxidation were significantly higher in erythrocyte membranes from patients with AD compared with the control group. Furthermore, the chemical composition of LFP in AD was different from the control group. The analysis of the specific modifications of erythrocyte membranes in AD is of great medical importance regarding the need of a diagnostic blood biomarker. Copyright (C) 2011 John Wiley & Sons, Ltd.","[Skoumalova, Alice] Charles Univ Prague, Dept Med Chem & Biochem, Fac Med 2, Prague 15006, Czech Republic; [Madlova, Pavla; Topinkova, Eva] Charles Univ Prague, Fac Med 1, Dept Geriatr, Prague 15006, Czech Republic; [Madlova, Pavla; Topinkova, Eva] Gen Fac Hosp Prague, Prague, Czech Republic","Skoumalova, A (reprint author), Charles Univ Prague, Dept Med Chem & Biochem, Fac Med 2, Plzenska 221-130, Prague 15006, Czech Republic.","alice.skoumalova@lfmotol.cuni.cz",null,null,"Czech Science Foundation [303/09/P049]","This research was supported by The Czech Science Foundation, grant number 303/09/P049. [Correction added after online publication on 6 March 2012: the research support grant number has been changed]",null,24,2,2,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","0263-6484",null,null,"CELL BIOCHEM FUNCT","Cell Biochem. Funct.","APR",2012,30,3,null,null,null,null,205,210,null,"10.1002/cbf.1836",null,6,"Biochemistry & Molecular Biology; Cell Biology","Biochemistry & Molecular Biology; Cell Biology","919TN","WOS:000302352000006"]
[null,null,null,null,"J","Stulik, J; Barna, M; Kryl, J",null,null,null,"Stulik, J.; Barna, M.; Kryl, J.",null,null,"Surgical Treatment for Atlantoaxial Osteoarthritis (AAOA): A Prospective Study of Twenty-Seven Patients","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"atlantoaxial osteoarthritis; atlantoaxial fixation; C1-C2 fusion; polyaxial screw-rod system","LATERAL MASS OSTEOARTHRITIS; POLYAXIAL SCREW; CERVICAL-SPINE; NECK PAIN; JOINT; FIXATION; DISORDERS","PURPOSE OF THE STUDY Atlantoaxial osteoarthritis (AAOA) is a clinical syndrome with signs distinctly different from those of degenerative sub-axial spine disease. Its diagnosis may long be delayed, partly because of insufficient knowledge and partly due to difficulties in interpreting both anteroposterior and lateral radiographs. The aim of this prospective study was to evaluate the first 27 AAOA patients treated at our department. MATERIAL From 2001 we performed atlantoaxial fixation with fusion in a total of 29 patients with painful arthritis of the atlantoaxial complex. The 27 patients treated before the end of 2010 were enrolled in the study and analysed in detail. This group included 13 women and 14 men aged between 35 and 72 years, with an average age of 53.5 years. In all patients atlantoaxial fixation was performed using the polyaxial screw-rod system according to Harms. METHODS The patients were followed up at 6 and 12 weeks, 6 and 12 months and then once a year after surgery. X-ray examinations were done at the same intervals as clinical examinations; functional radiographs were made at 12 to 14 weeks after surgery. The definitive analysis of the group was made in the range of 4 to 59 months (average, 25.7 months) after the primary operation. Patients' subjective evaluation was based on NPDI and VAS scores and a question of whether the patient would undergo the surgery again. Objective evaluation included clinical outcomes - pain and neurological findings; radiographic results stability and healing of C1-C2 fusion; and complications during surgery and in early and late postoperative periods. As intra-operative complications were regarded those associated with the surgical approach, nerve injury and vertebral artery injury. Early post-operative complications included poor wound healing and changes in the patient's neurological status, late complications included instrumentation failure and infection. Patients' clinical status (NPDI, VAS) was statistically evaluated using the one-way ANOVA. RESULTS The mean VAS score was pre-operatively 7.0 and post-operatively 5.6 at 3 months, 5.0 at 6 months, 5.1 at 1 year; 3.9 at 2 years and 4.0 at 3 years. The mean NPDI value was pre-operatively 39.6 and post-operatively 38.7 at 3 months, 36.0 at 6 months, 34.5 at 1 year, 34.3 at 2 years and 33.1 at 3 years. The question of willingness to undergo the same operation again was answered in the affirmative by 21 patients (77.8%), in the negative by five (18.5%) and one patient did not know (3.7%). Complete bone fusion, as assessed by radiography or CT scanning, was achieved in 26 out of 27 patients (96.3%). In one patient the result was ambiguous but, at 3 months as well as the next follow-ups, C1-C2 complex stability was found. DISCUSSION All patients in our group underwent a unified system of clinical, radiological, CT and MRI examination. In the decision-making process, emphasis was placed on a correlation of clinical findings with CT scanning results. All patients were operated on from the posterior approach using the Harms method, and radiological outcomes were similar to those of Grob et al. who used the Magerl s technique of C1-C2 fixation. The VAS and NPDI scores demonstrated significant improvement as early as 3 post-operative months, with still further improvement in the following period. The stable clinical status of the patients was achieved at 2 years after surgery. From the practical standpoint we were interested in an answer to the question of whether the patients would be willing to undergo the procedure again. Almost 80% of affirmative answers testified to the correct choice of treatment. The values found corresponded to those reported by Grob at al. CONCLUSIONS Patients with painful osteoarthritis refractory to conservative treatment will benefit from atlantoaxial fixation and fusion. For the patient, restricted cervical rotation is acceptable in return for pain relief. From the surgical point of view, the risk of complications associated with the operative technique did not exceed a tolerable rate.","[Stulik, J.; Barna, M.; Kryl, J.] Spondylochirurgicke oddeleni FN Motol, Prague 15006 5, Czech Republic","Stulik, J (reprint author), Spondylochirurgicke oddeleni FN Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","janstulik.spine@seznam.cz",null,null,null,null,null,21,1,1,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2012,79,1,null,null,null,null,31,36,null,null,null,6,"Orthopedics","Orthopedics","907BI","WOS:000301392400004"]
[null,null,null,null,"J","Ryska, O; Martinek, J; Filipkova, T; Dolezel, R; Juhasova, J; Motlik, J; Zavoral, M; Ryska, M",null,null,null,"Ryska, Ondrej; Martinek, Jan; Filipkova, Tereza; Dolezel, Radek; Juhasova, Jana; Motlik, Jan; Zavoral, Miroslav; Ryska, Miroslav",null,null,"Single loop-and-clips technique (KING closure) for gastrotomy closure after transgastric ovariectomy: a survival experiment","VIDEOSURGERY AND OTHER MINIINVASIVE TECHNIQUES",null,null,"English","Article",null,null,null,null,null,"natural orifice transluminal endoscopic surgery; gastric closure; clips; endoloop","TRANSLUMINAL ENDOSCOPIC SURGERY; QUEENS CLOSURE; PORCINE MODEL; MODALITIES","Introduction: A safe closure technique of transluminal access is essential for the widespread application of natural orifice transluminal endoscopic surgery (NOTES). Aim: To evaluate the feasibility and effectiveness of a novel single loop-and-clips closure technique (KING closure). Material and methods: An experimental survival study using female laboratory pigs was performed. A gastrotomy was performed using a standard percutaneous endoscopic gastrostomy technique. A peritoneoscopy with an ovariectomy was then performed with a double-channel endoscope, on a total of 14 pigs. Two different techniques of gastrotomy closure were analysed: a loop-and-clips closure technique (n = 7) and a standard closure using endoclips (n = 7). After a follow-up period of 30 days, the animals were euthanized for post-mortem examination. Results: In the \"loop-and-clip\" closure group, the correct placement of an endoloop and clips was achieved in all animals. At necropsy, no animal showed signs of an abscess or peritonitis. Histological examination demonstrated a patent full-thickness gastric wall closure without evidence of local complications in all instances. In the \"clips\" group, the gastrotomy closure was assessed as probably unsafe in three animals. At necropsy 3 (42.9%) abscesses and 1(14.3%) case of peritonitis were found. Conclusions: A single loop-and-clips closure technique (KING closure) represents a feasible, simple and effective method of gastric incision closure. It appears to be superior to the standard endoscopic closure technique using clips.","[Ryska, Ondrej; Dolezel, Radek; Ryska, Miroslav] Charles Univ Prague, Dept Surg, Fac Med 2, Prague 16000 6, Czech Republic; [Ryska, Ondrej; Martinek, Jan; Dolezel, Radek; Zavoral, Miroslav; Ryska, Miroslav] Cent Mil Hosp, Prague 16000 6, Czech Republic; [Martinek, Jan; Zavoral, Miroslav] Charles Univ Prague, Dept Internal Med, Fac Med 1, Prague 16000 6, Czech Republic; [Filipkova, Tereza] Domazlice Hosp, Dept Surg, Domazlice, Czech Republic; [Juhasova, Jana; Motlik, Jan] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Libechov, Czech Republic","Ryska, O (reprint author), Charles Univ Prague, Dept Surg, Fac Med 2, U Vojenske Nemocnice 1200, Prague 16000 6, Czech Republic.","ondrejryska@centrum.cz",null,null,"Academy of Sciences of the Czech Republic (institutional research plan) [AV0Z50450515];  [IGA- NS9994-4]","Supported by a grant from IGA- NS9994-4 and by the Academy of Sciences of the Czech Republic (institutional research plan AV0Z50450515).",null,16,1,1,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1895-4588",null,null,"VIDEOSURGERY MINIINV","Videosurgery Miniinvasive Tec.",null,2012,7,4,null,null,null,null,233,239,null,"10.5114/wiitm.2011.28870",null,7,"Surgery","Surgery","062OE","WOS:000312928400002"]
[null,null,null,null,"J","Brozkova, DS; Lastuvkova, J; Machalova, E; Lisonova, J; Trkova, M; Seeman, P",null,null,null,"Brozkova, Dana Safka; Lastuvkova, Jana; Machalova, Eliska; Lisonova, Jana; Trkova, Marie; Seeman, Pavel",null,null,"DFNB35 due to a novel mutation in the ESRRB gene in a Czech consanguineous family","INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"DFNB35; ESRRB; Homozygosity mapping; Non-syndromic hearing loss","HEARING IMPAIRMENT; DEAFNESS; MAP","Objectives: Non-syndromic hearing loss (NSHL) is a genetically heterogeneous disorder with mostly autosomal recessive inheritance. So far 40 genes and the same amount of loci with as yet unknown genes were described with autosomal recessive NSHL. Patients and methods: A consanguineous Czech family with a child with NSHL was genotyped using SNP array and homozygous regions were compared with previously reported DFNB loci. Results: GRXCR1 and ESRRB genes associated with autosomal recessive NSHL were located in two of the eight homozygous regions detected by SNP array genotyping. Mutation p.R291L in a homozygous state was found in the deaf child, the parents were heterozygous. The entire coding region of the ESRRB gene was sequenced in additional 39 patients of Czech origin with early NSHL and only two variants, p.V413I and p.P386S, were found in homozygous state, but are considered to be polymorphisms. Conclusion: Homozygosity mapping is a powerful method for identification of genes in heterogeneous recessive diseases. This is the first report of DFNB35 mutations in the Czech Republic and it seems to be a rare cause of NSHL Additional mutations in ESRRB gene were reported in Pakistan, Tunisia and Turkey. (C) 2012 Elsevier Ireland Ltd. All rights reserved.","[Brozkova, Dana Safka; Machalova, Eliska; Lisonova, Jana; Seeman, Pavel] Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague 15006, Czech Republic; [Brozkova, Dana Safka; Machalova, Eliska; Lisonova, Jana; Seeman, Pavel] Univ Hosp Motol, Prague, Czech Republic; [Lastuvkova, Jana] Reg Hlth Corp, Masaryk Hosp, Dept Med Genet, Usti Nad Labem, Czech Republic; [Trkova, Marie] Ctr Med Genet & Reprod Med GENNET, Prague, Czech Republic","Brozkova, DS (reprint author), Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Uvalu 84, Prague 15006, Czech Republic.","dana.brozkova@seznam.cz",null,null,"Ministry of Health, Czech Republic, University Hospital Motol, Prague [00064203]","Supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague,Czech Republic).",null,14,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0165-5876","1872-8464",null,"INT J PEDIATR OTORHI","Int. J. Pediatr. Otorhinolaryngol.","NOV",2012,76,11,null,null,null,null,1681,1684,null,"10.1016/j.ijporl.2012.08.006",null,4,"Otorhinolaryngology; Pediatrics","Otorhinolaryngology; Pediatrics","042HY","WOS:000311463500029"]
[null,null,null,null,"J","Melter, O; Tkadlec, J; Sedlacek, I",null,null,null,"Melter, Oto; Tkadlec, Jan; Sedlacek, Ivo",null,null,"A simple and cost-effective cover-glass test for the differentiation between staphylococci and micrococci in clinical laboratory","JOURNAL OF MICROBIOLOGICAL METHODS",null,null,"English","Article",null,null,null,null,null,"Cover-glass test; Differentiation; Staphylococci; Micrococci","SP-NOV; IDENTIFICATION; RESISTANCE; ANIMALS; SKIN","A cover-glass placed on a heavily inoculated culture plate clearly differentiates facultatively anaerobic staphylococci growing underneath the cover-glass after overnight incubation from nongrowing aerobic micrococci. Even if there are some exceptions, all medically significant staphylococci can grow in the test. Thus, the test provides a cost-effective and highly specific tool for separation of both genera which fundamentally differ in their pathogenicity. (c) 2012 Elsevier B.V. All rights reserved.","[Melter, Oto; Tkadlec, Jan] Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Prague 15006 5, Motol, Czech Republic; [Sedlacek, Ivo] Masaryk Univ, Fac Sci, CS-61137 Brno, Czech Republic","Melter, O (reprint author), Charles Univ Prague, Dept Med Microbiol, Fac Med 2, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","oto.melter@lfmotol.cuni.cz",null,null,"Internal Grant Agency (IGA) of the Ministry of Health of the Czech Republic [NT12395-5/2011]; Grant Agency of the Czech Republic [GA310/09/0459]","This study was supported by grant No. NT12395-5/2011 from the Internal Grant Agency (IGA) of the Ministry of Health of the Czech Republic awarded to Oto Melter and by grant No. GA310/09/0459 from the Grant Agency of the Czech Republic awarded to Roman Pantucek. We thank E. Kodytkova from the National Institute of Public Health, Prague, for linguistic revision of the manuscript.",null,24,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0167-7012",null,null,"J MICROBIOL METH","J. Microbiol. Methods","JUN",2012,89,3,null,null,null,null,213,215,null,"10.1016/j.mimet.2012.03.006",null,3,"Biochemical Research Methods; Microbiology","Biochemistry & Molecular Biology; Microbiology","948MG","WOS:000304506700011"]
[null,null,null,null,"J","Charvatova, Z; Ostadalova, I; Zicha, J; Kunes, J; Maxova, H; Ostadal, B",null,null,null,"Charvatova, Z.; Ostadalova, I.; Zicha, J.; Kunes, J.; Maxova, H.; Ostadal, B.",null,null,"Cardiac Tolerance to Ischemia in Neonatal Spontaneously Hypertensive Rats","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Cardiac tolerance to ischemia; Neonatal spontaneously hypertensive rats; Conctractile function; Ischemic preconditioning; Chronic hypoxia","MITOCHONDRIAL-FUNCTION; HYPERTROPHIED HEARTS; CONTRACTILE PERFORMANCE; ONTOGENIC ASPECTS; BLOOD-PRESSURE; HYPOXIA; INJURY; RECOVERY; SUSCEPTIBILITY; RESPONSIVENESS","Hypertension is the risk factor of serious cardiovascular diseases, such as ischemic heart disease and atherosclerosis. The aim of the present study was to analyze the development of cardiac tolerance to ischemia in neonatal spontaneously hypertensive rats (SHR) and possible protective effect of ischemic preconditioning (IP) or adaptation to intermittent high-altitude hypoxia (IHAH). For this purpose we used 1- and 10-day-old pups of SHR and their normotensive control Wistar Kyoto rats (WKY). Isolated hearts were perfused in the Langendorff mode with Krebs-Henseleit solution at constant pressure, temperature and rate. Cardiac tolerance to ischemia was expressed as a percentage of baseline values of developed force (DF) after global ischemia. IP was induced by three 3-min periods of global ischemia, each separated by 5-min periods of reperfusion. IHAH was simulated in barochamber (8 h/day, 5000 m) from postnatal day 1 to 10. Cardiac tolerance to ischemia in 1-day-old SHR was higher than in WKY. In both strains tolerance decreased after birth, and the difference disappeared. The high cardiac resistance in 1- and 10-day-old SHR and WKY could not be further increased by both IP and adaptation to IHAH. It may be concluded that hearts from newborn SHR are more tolerant to ischemia/reperfusion injury as compared to age-matched WKY; cardiac resistance decreased in both strains during the first ten days, similarly as in Wistar rats.","[Charvatova, Z.; Maxova, H.] Charles Univ Prague, Fac Med 2, Dept Pathophysiol, Prague 15000 5, Czech Republic; [Charvatova, Z.; Ostadalova, I.; Zicha, J.; Kunes, J.; Maxova, H.; Ostadal, B.] Cardiovasc Res Ctr, Prague, Czech Republic; [Ostadalova, I.; Zicha, J.; Kunes, J.; Ostadal, B.] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic","Charvatova, Z (reprint author), Charles Univ Prague, Fac Med 2, Dept Pathophysiol, Plzenska 221, Prague 15000 5, Czech Republic.","zuzana.charvatova@lfmotol.cuni.cz","Zicha, Josef/B-1349-2012; Ostadal, Bohuslav/F-7387-2014","Zicha, Josef/0000-0001-6051-6541; ","MSMT [1M0510];  [AV0Z 50110509]","This study was supported by grant of MSMT 1M0510 and grant AV0Z 50110509.",null,37,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2012,61,null,null,1,null,null,"S145","S153",null,null,null,9,"Physiology","Physiology","983QL","WOS:000307133700011"]
[null,null,null,null,"J","Babjuk, M; Oosterlinck, W; Sylvester, R; Kaasinen, E; Bohle, A; Palou-Redorta, J; Roupret, M",null,null,null,"Babjuk, M.; Oosterlinck, W.; Sylvester, R.; Kaasinen, E.; Boehle, A.; Palou-Redorta, J.; Roupret, M.",null,null,"EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update","ACTAS UROLOGICAS ESPANOLAS",null,null,"Spanish","Article",null,null,null,null,null,"Bacillus Calmette-Guerin (BCG); Bladder cancer; Cystectomy; Cystoscopy; Diagnosis; European Association of Urology Guidelines; Follow-up; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR); Urothelial carcinoma","BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL CARCINOMA; RANDOMIZED CLINICAL-TRIALS; IMMEDIATE POSTOPERATIVE INSTILLATION; INTRAVESICAL MITOMYCIN-C; LONG-TERM EFFICACY; PHASE-III TRIAL; IN-SITU; TRANSURETHRAL RESECTION; EUROPEAN ORGANIZATION","Context and objective: To present the 2011 European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC). Evidence acquisition: Literature published between 2004 and 2010 on the diagnosis and treatment of NMIBC was systematically reviewed. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned. Evidence synthesis: Tumours staged as Ta, T1, or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection (TUR) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TUR is essential for the patient's prognosis. Where the initial resection is incomplete or where a high-grade or T1 tumour is detected, a second TUR should be performed within 2-6 wk. In papillary tumours, the risks of both recurrence and progression may be estimated for individual patients using the scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups (separately for recurrence and progression) is pivotal to recommending adjuvant treatment. For patients with a low risk of tumour recurrence and progression, one immediate instillation of chemotherapy is recommended. Patients with an intermediate or high risk of recurrence and an intermediate risk of progression should receive one immediate instillation of chemotherapy followed by a minimum of 1 yr of bacillus Calmette-Guerin (BCG) intravesical immunotherapy or further instillations of chemotherapy. Papillary tumours with a high risk of progression and CIS should receive intravesical BCG for 1 yr. Cystectomy may be offered to the highest risk patients, and it is at least recommended in BCG failure patients. Conclusions: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. (C) 2011 AEU. Published by Elsevier Espana, S.L. All rights reserved.","[Babjuk, M.] Charles Univ, Serv Urol, Hosp Motol, Segunda Fac Med, Prague, Czech Republic; [Oosterlinck, W.] Hosp Univ Gante, Serv Urol, Gante, Belgium; [Sylvester, R.] Oficina Cent Org Europea Invest & Tratamiento Can, Dept Bioestadist, Bruselas, Belgium; [Kaasinen, E.] Hosp Hyvinkaa, Serv Urol, Hyvinkaa, Finland; [Boehle, A.] Hosp HELIOS Agnes Karll, Serv Urol, Bad Schwartau, Germany; [Palou-Redorta, J.] Univ Autonoma Barcelona, Serv Urol, Fundacio Puigvert, E-08193 Barcelona, Spain; [Roupret, M.] Hosp Publ Paris, Serv Urol, Hosp Pitie Salpetriere, GHU Est, Paris, France; [Roupret, M.] Univ Paris 06, Fac Med Pierre & Marie Curie, Paris, France","Babjuk, M (reprint author), Charles Univ, Serv Urol, Hosp Motol, Segunda Fac Med, Prague, Czech Republic.","Marek.badjuk@lfmotol.cuni.cz",null,null,null,null,null,72,16,16,"ENE EDICIONES SL","MADRID","REDACCION, ADMINISTRACION & PUBLICIDAD, ORURO 9 - BAJO IZDA, MADRID, 28016, SPAIN","0210-4806",null,null,"ACTAS UROL ESP","Actas Urol. Esp.","JUL-AUG",2012,36,7,null,null,null,null,389,402,null,"10.1016/j.acuro.2011.12.001",null,14,"Urology & Nephrology","Urology & Nephrology","982ER","WOS:000307025500001"]
[null,null,null,null,"J","Ryska, O; Pantoflicek, T; Laszikova, E; Prazak, J; Koblihova, E; Ryska, M",null,null,null,"Ryska, Ondrej; Pantoflicek, Tomas; Laszikova, Eva; Prazak, Josef; Koblihova, Eva; Ryska, Miroslav",null,null,"Artificial liver support system reduces intracranial pressure more effectively than bioartificial system: an experimental study","INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS",null,null,"English","Article",null,null,null,null,null,"Acute liver failure; Bioartificial liver support system; Fractionated plasma separation and absorption; Intracranial pressure","FULMINANT HEPATIC-FAILURE; ENCEPHALOPATHY; PIGS; MULTICENTER; SURVIVAL; WORKSHOP; BRAIN","Objectives: Extracorporeal liver support (ELS) may play a role in bridging therapy in patients with acute liver failure (ALF). The aim of this study was to compare the influence of nonbiological and biological methods on intracranial pressure (ICP) in an animal model of ALF. Methods: A surgical devascularization model of ALF in pigs (35-40 kg) was used. Elimination therapy started after the onset of hypoglycemia. Biochemical parameters (bilirubin, ammonia, lactate, etc.) as well as ICP and cerebral perfusion pressure (CPP) were monitored for 12 hours. Of the total 31 pigs with ALF, 14 animals were treated by fractionated plasma separation and absorption (FPSA), 10 were treated with a bioartificial liver (BAL), and 7 animals were used as a control group. Results: FPSA and BAL treatment started on average 3 hours 17 minutes and 2 hours 21 minutes, after devascularization and lasted for 5 hours 54 minutes and 5 hours 43 minutes, respectively. Ammonia levels were lower in the FPSA group, and bilirubin levels differed significantly in both the FPSA and BAL groups compared with controls. However, ICP values were reduced more effectively in pigs treated by FPSA: 19.1 vs. 27.0 mm Hg at 9 hours, 22.5 vs. 28.7 mm Hg at 11 hours, and 24.0 vs. 33.0 mm Hg at 12 hours (p<0.05). Conclusions: The artificial liver support system FPSA reduced ICP values more effectively than the Performer O. Liver RanD BAL system. Compared with this BAL system, the nonbiological elimination method of FPSA is a simpler application with the advantage that it can be applied in a more continuous way.","[Ryska, Ondrej] Charles Univ Prague, Fac Hosp, Fac Med 1, Dept Surg, Prague, Czech Republic; [Pantoflicek, Tomas; Koblihova, Eva; Ryska, Miroslav] Charles Univ Prague, Fac Med 2, Dept Surg, Prague, Czech Republic; [Laszikova, Eva] Cent Mil Hosp, Dept Anaesthesiol, Prague, Czech Republic; [Pantoflicek, Tomas; Laszikova, Eva; Ryska, Miroslav] Charles Univ Prague, Fac Med 2, Ctr Cell & Tissue Therapy, Prague, Czech Republic; [Prazak, Josef] Charles Univ Prague, Fac Med 2, Dept Anaesthesiol Resuscitat & Intens Care, Prague, Czech Republic","Ryska, O (reprint author), Biskupcova 89, Prague 13000 3, Czech Republic.","ondrejryska@centrum.cz",null,null,"Research Centre, Prague [LN00A065]; Internal Grant Agency, Czech Ministry of Health [NT 11463, S8120]","Financial support was received from the Research Centre, Prague (no. LN00A065), and the Internal Grant Agency, Czech Ministry of Health (nos. NT 11463 and S8120).",null,28,1,1,"WICHTIG EDITORE","MILAN","72/74 VIA FRIULI, 20135 MILAN, ITALY","0391-3988",null,null,"INT J ARTIF ORGANS","Int. J. Artif. Organs","JUL",2012,35,7,null,null,null,null,503,510,null,"10.5301/ijao.5000099",null,8,"Engineering, Biomedical; Transplantation","Engineering; Transplantation","002HF","WOS:000308522000004"]
[null,null,null,null,"J","Lassuthova, P; Gregor, M; Sarnova, L; Machalova, E; Sedlacek, R; Seeman, P",null,null,null,"Lassuthova, Petra; Gregor, Martin; Sarnova, Lenka; Machalova, Eliska; Sedlacek, Radek; Seeman, Pavel",null,null,"Clinical, In Silico, and Experimental Evidence for Pathogenicity of Two Novel Splice Site Mutations in the SH3TC2 Gene","JOURNAL OF NEUROGENETICS",null,null,"English","Article",null,null,null,null,null,"exon trapping; peripheral neuropathy; SH3TC2 gene; splice site mutation","MARIE-TOOTH 4C; MUSCULAR-ATROPHY; NEUROPATHY; DISEASE; RECOGNITION; FEATURES; MOTOR","Charcot-Marie-Tooth (CMT) neuropathy is the most common inherited neuromuscular disorder. CMT is genetically very heterogeneous. Mutations in the SH3TC2 gene cause Charcot-Marie-Tooth neuropathy type 4C (CMT4C), a demyelinating form with autosomal recessive inheritance. In this study, two novel splice site mutations in the SH3TC2 gene have been studied (c.279G -> A, c.3676-8G -> A). Mutation c.279G -> A was detected on one allele in two unrelated families with CMT4C in combination with a known pathogenic mutation (c.2860 C -> T in one family, c.505T -> C in the other) on the second allele of SH3TC2 gene. Variant c.3676-8G -> A was detected in two patients from unrelated families on one allele of the SH3TC2 gene in combination with c.2860C -> T mutation on the other allele. Several in silico tests were performed and exon trap experiments were undertaken in order to prove the effect of both mutations on proper splicing of SH3TC2. Fragments of SH3TC2 were subcloned into pET01 exon trap vector (Mobitec) and transfected into COS-7 cells. Aberrant splicing was predicted in silico for both mutations, which was confirmed by exon trap analysis. For c.279G -> A mutation, 19 bases from intron 3 are retained in cDNA. The mutation c.3676-8G -> A produces a novel splice acceptor site for exon 17 and complex changes in splicing were observed. We present evidence that mutations c.279G -> A and c.3676-8G -> A in the SH3TC2 gene cause aberrant splicing and are therefore pathogenic and causal for CMT4C.","[Lassuthova, Petra; Machalova, Eliska; Seeman, Pavel] Charles Univ Prague, DNA Lab, Dept Paediat Neurol, Fac Med 2, Prague, Czech Republic; [Lassuthova, Petra; Machalova, Eliska; Seeman, Pavel] Univ Hosp Motol, Prague, Czech Republic; [Gregor, Martin; Sarnova, Lenka; Machalova, Eliska; Sedlacek, Radek] Acad Sci Czech Republic, Inst Mol Genet, Dept Transgen Models Dis, Prague, Czech Republic","Lassuthova, P (reprint author), Charles Univ Prague, DNA Lab, Dept Paediat Neurol, Fac Med 2, Uvalu 84, Prague, Czech Republic.","petra.lassuthova@gmail.com",null,null,"IGA MH CR NT [11521-4]; GACR [P303/10/2044]","The study was supported by IGA MH CR NT 11521-4 and GACR P303/10/2044.",null,20,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0167-7063",null,null,"J NEUROGENET","J. Neurogenet.","SEP",2012,26,41732,null,null,null,null,413,420,null,"10.3109/01677063.2012.711398",null,8,"Genetics & Heredity; Neurosciences","Genetics & Heredity; Neurosciences & Neurology","045FB","WOS:000311679300021"]
[null,null,null,null,"J","Svehlik, M; Kraus, T; Steinwender, G; Zwick, EB; Ladecky, M; Szabo, Z; Linhart, WE",null,null,null,"Svehlik, M.; Kraus, T.; Steinwender, G.; Zwick, E. B.; Ladecky, M.; Szabo, Z.; Linhart, W. E.",null,null,"Repeated Multilevel Botulinum Toxin A Treatment Maintains Long-Term Walking Ability in Children with Cerebral Palsy","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"English","Article",null,null,null,null,null,"cerebral palsy; botulinum toxin A; gait","CLINICAL-TRIAL; MOTOR FUNCTION; EQUINUS FOOT; SPASTICITY; GAIT","Aims: Botulinum toxin type A (BoNT-A) offers a targeted form of therapy to reduce spasticity and has become a standard form of treatment in children with cerebral palsy (CP). However, the effects of repeated BoNT-A treatment over a longer periods of time are not well known. We hypothesized that children treated with multi-level, high-dose, repeated BoNT-A applications would not deteriorate in their gait function over a minimum period of four years. Materials and methodology: Gait in 18 children with spastic diplegic CP, mean age 6 years 9 months, Gross Motor Function Classification System I-III, treated according to the concept of integrated BoNT-A application over a minimum of four years was evaluated using the kinematic and kinetic gait analysis. The main outcome measure was the Gait Deviation Index (GDI). Results: The mean follow-up time was 5 years and 9 months (SD 1 year 5 months). Each child received a mean of 1.02 (SD 0.37) applications of BoNT-A per year. The gait function assessed by GDI remained unchanged. However, gait kinematic and kinetic parameters revealed some intra-individual changes and documented an evolution of gait pattern. The majority of improvements occurred at the level of ankle, while hip function was deteriorating despite the therapy. Conclusions: The study demonstrated that integrated multilevel BoNT-A treatment can be effective in maintaining the same level of walking in children with spastic diplegic cerebral palsy over a period of more than five years. The described integrated approach has limitations in the management of hip flexor and hamstrings tightness.","[Svehlik, M.; Kraus, T.; Steinwender, G.; Zwick, E. B.; Linhart, W. E.] Med Univ Graz, Dept Paediat Surg, A-8036 Graz, Austria; [Svehlik, M.] Charles Univ Prague, Fac Med 2, Dept Paediat & Adult Orthopaed & Traumalol, Prague, Czech Republic; [Ladecky, M.; Szabo, Z.] Czech Tech Univ, Fac Biomed Engn, Kladno, Czech Republic","Svehlik, M (reprint author), Med Univ Graz, Dept Paediat Surg, Auenbruggerpl 34, A-8036 Graz, Austria.","martin.svehlik@medunigraz.at",null,null,null,null,null,20,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,6,null,null,null,null,737,741,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","039JU","WOS:000311242700010"]
[null,null,null,null,"J","Barna, M; Kucera, A; Hladikova, M; Kucera, M",null,null,null,"Barna, M.; Kucera, A.; Hladikova, M.; Kucera, M.",null,null,"Randomized Double-Blind Study: Wound-Healing Effects of a Symphytum Herb Extract Cream (Symphytum x uplandicum NYMAN) in Children","ARZNEIMITTELFORSCHUNG-DRUG RESEARCH",null,null,"English","Article",null,null,null,null,null,"comfrey; Symphytum herb extract; topical application; wound healing; abrasions","DICLOFENAC GEL; OINTMENT; ANKLE; DISTORTIONS; EFFICACY; MULTICENTER","The wound healing effects of the topically applied preparation Traumaplant (R) containing a concentrate (10% active ingredient) from the aerial parts of medicinal comfrey (Symphytum x uplandicum NYMAN) were examined in a randomized, controlled, clinical double-blind study. An otherwise identical low-dose preparation (1% active ingredient) was used as a control. The study population consisted of 108 children aged 3-12 years (n = 54/group) with fresh abrasions. A 50% healing rate was reached 0.9 days earlier with the higher than with the lower concentration cream. The difference in the healing rate (0.38 +/- 0.18/day [95% CI 0.33-0.4] vs. 0.26 +/- 0.14/day [95% CI 0.222-0.297]) was statistically significant (p = 0.0002). Physicians and children/parents both rated the efficacy of the 10% cream as significantly better than that of the control preparation (physicians' assessment after 2-3 and 7-9 days for verum vs. control: 90.7 and 92.6% vs. 55.6 and 74.0% of the healing rates were rated as \"good\" or \"very good\", respectively; p = 0.0004 and 0.01). In subgroup analyses, there was no significant influence on the healing rate of the time elapsed between the accident and the first consultation, the wound surface, the affected body part, the origin of the injury and gender. There were no reported adverse effects or problems with tolerability such as local skin irritations. The results justify application of the Symphytum herb extract cream in children with blunt traumata with or without abrasions.","[Barna, M.; Kucera, M.] Charles Univ Prague, Fac Med 2, Dept Sports Med & Rehabil, CZ-15006 Prague 5, Czech Republic; [Kucera, A.] Charles Univ Prague, Fac Med 2, Dept Pediat Surg, Motol Hosp, CZ-15006 Prague 5, Czech Republic; [Hladikova, M.] Charles Univ Prague, Fac Med 2, Dept Med Informat, CZ-15006 Prague 5, Czech Republic","Kucera, A (reprint author), Charles Univ Prague, Fac Med 2, Dept Sports Med & Rehabil, V Uvalu 85, CZ-15006 Prague 5, Czech Republic.","miroslav.kucera@lfmotol.cuni.cz",null,null,"Harras Pharma Curarina GmbH (Munich, Germany)","The study was financially supported by Harras Pharma Curarina GmbH (Munich, Germany). The study medication was provided by the sponsor. The authors alone are responsible for designing, conducting and analyzing the study and for publication of the data.",null,20,3,3,"GEORG THIEME VERLAG KG","STUTTGART","RUDIGERSTR 14, D-70469 STUTTGART, GERMANY","0004-4172",null,null,"ARZNEIMITTELFORSCH","Arzneimittelforschung-Drug Res.","JUN",2012,62,6,null,null,null,null,285,289,null,"10.1055/s-0032-1308981",null,5,"Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy","Pharmacology & Pharmacy; Chemistry","989ZE","WOS:000307600000005"]
[null,null,null,null,"J","Khalil, MA; Hrabeta, J; Cipro, S; Stiborova, M; Vicha, A; Eckschlager, T",null,null,null,"Khalil, M. A.; Hrabeta, J.; Cipro, S.; Stiborova, M.; Vicha, A.; Eckschlager, T.",null,null,"Neuroblastoma stem cells - mechanisms of chemoresistance and histonedeacetylase inhibitors","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"Cancer stem cells; CD 133; Neuroblastomam; Histone deacetylase inhibitors","TUMOR-INITIATING CELLS; DISTINCT SIDE POPULATION; HEMATOPOIETIC STEM; VALPROIC ACID; PROGENITOR CELLS; SELF-RENEWAL; SOLID TUMORS; CANCER; CD133; EXPRESSION","Cancer stem cells (CSCs) form a small proportion of tumor cells that have stem cell properties: self-renewal capacity, the ability to develop into different lineages and proliferative potential. The interest in CSCs emerged from their expected role in initiation, progression and recurrence of many tumors. They are generally resistant to conventional chemotherapy and radiotherapy. There are two hypotheses about their origin: The first assumes that CSCs may arise from normal stem cells, and the second supposes that differentiated cells acquire the properties of CSCs. Both hypotheses are not mutually exclusive, as it is possible that CSCs have a diverse origin in different tumors. CD133+ cells (CD133 is marker of CSC in some tumors) isolated from NBL, osteosarcoma and Ewing sarcoma cell lines are resistant to cisplatin, carboplatin, etoposide and doxorubicin than the CD133- ones. Being resistant to chemotherapy, there were many attempts to target CSCs epigenetically including the use of histone deacetylase inhibitors. The diverse influence of valproic acid (histone deacetylase inhibitor) on normal and cancer stem cells was proved in different experiments. We have found an increase percentage of CD 133+ NBL cells after their incubation with VPA in a dose that does not induce apoptosis. Further researches on CSCs and clinical application for their detection are necessary: (i) to define the CSC function in carcinogenesis, cancer development and their role in metastasis; (ii) to find a specific marker for CSCs in different tumors; (iii) to explain the role of different pathways that determine their behavior and (iv) to explain mechanisms of chemoresistance of CSCs.","[Khalil, M. A.; Hrabeta, J.; Vicha, A.; Eckschlager, T.] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006, Czech Republic; [Khalil, M. A.; Hrabeta, J.; Cipro, S.; Vicha, A.; Eckschlager, T.] Univ Hosp Motol, Prague 15006, Czech Republic; [Cipro, S.] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15006, Czech Republic; [Stiborova, M.] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 15006, Czech Republic","Eckschlager, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Uvalu 84, Prague 15006, Czech Republic.","tomas.eckschlager@lfmotol.cuni.cz",null,null,"project for conceptual development of research organization [00064203];  [GACR P301/10/0356]","This study was supported by grant GACR P301/10/0356 and by the project for conceptual development of research organization 00064203.",null,71,1,1,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2012,59,6,null,null,null,null,737,746,null,"10.4149/neo_2012_093",null,10,"Oncology","Oncology","033SB","WOS:000310820200018"]
[null,null,null,null,"J","Vanousova, D; Cerny, R; Zakoucka, H; Kozner, P; Jilich, D; Lisy, J; Hercogova, J; Machala, L",null,null,null,"Vanousova, D.; Cerny, R.; Zakoucka, H.; Kozner, P.; Jilich, D.; Lisy, J.; Hercogova, J.; Machala, L.",null,null,"Neurosyphilis","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"syphilis; neurosyphilis; diagnosis; therapy","PALLIDUM SUBSP PALLIDUM; TREPONEMA-PALLIDUM; CEREBROSPINAL-FLUID; SYPHILIS; PENICILLIN; PREGNANCY; ADULTS; SERUM; MODEL","Syphilis is an old disease and its incidence in developed countries decreased in the second half of the last century. However, at present, syphilis is on increase again. Since 1990, when the incidence was lowest, the incidence of syphilis in the Czech Republic increased more than six-fold with HIV+ homosexual men and drug addicts being the highest risk groups. The CNS can be involved at any stage of syphilis; early forms of neurosyphilis currently predominate, whereas late complications rarely occur. The diagnosis of syphilis is based on serological tests. A combination of both nonspecific (nontreponemal) and specific (treponemal) methods are used for screening; specific tests are used for confirmation. Clinical symptomatology of neurosyphilis is very variable and comprehensive analysis of cerebrospinal fluid including specific and nonspecific serologic tests plays a crucial role in diagnostics. Legislation requires all cases of diagnosed syphilis to be reported and treated. Neurosyphilis is treated with benzylpenicillin as a standard, other antibiotics are less effective. After completing the therapy, all patients are followed up long-term by a venereologist. Considering the complex clinical and laboratory symptomatology of neurosyphilis, correct diagnosis and optimal therapeutic decision requires close cooperation between a neurologist, venereologist and laboratory specialist.","[Machala, L.] 3 LF UK, Klin Infekcnich Nemoci, Prague 18081 8, Czech Republic; [Vanousova, D.; Hercogova, J.] 2 LF UK, Dermatovenerolog klin, Prague, Czech Republic; [Cerny, R.] 2 LF UK, Neurolog Klin Dospelych, Prague, Czech Republic; [Cerny, R.; Lisy, J.] FN Motole, Prague, Czech Republic; [Zakoucka, H.] Statni Zdravotni Ustav, Narodni Referencni Lab Prosyfilis, Prague, Czech Republic; [Kozner, P.] Nemocnice Bulovce, Ocni Oddeleni, Prague, Czech Republic; [Jilich, D.] 1 LF UK, Klin Infekcnich Tropickych Nemoci, Prague, Czech Republic; [Lisy, J.] 2 LF UK, Klin Zobrazovacich Metod, Prague, Czech Republic","Machala, L (reprint author), 3 LF UK, Klin Infekcnich Nemoci, Budinova 2, Prague 18081 8, Czech Republic.","ladimachala@centrum.cz","Cerny, Rudolf/C-7759-2014",null,null,null,null,44,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,3,null,null,null,null,297,302,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","966EH","WOS:000305819900004"]
[null,null,null,null,"J","Nikolai, T; Bezdicek, O; Vyhnalek, M; Hort, J",null,null,null,"Nikolai, Tomas; Bezdicek, Ondrej; Vyhnalek, Martin; Hort, Jakub",null,null,"Mild cognitive impairment: diagnostic unit or stadium preceding dementia?","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"mild cognitive impairment; dementia syndrome; Alzheimer disease; neuropsychological assessment; diagnostic procedures","ALZHEIMERS ASSOCIATION WORKGROUPS; NATIONAL INSTITUTE; INTRAINDIVIDUAL VARIABILITY; DISEASE; RECOMMENDATIONS; GUIDELINES; MCI; PERFORMANCE","Mild cognitive impairment: diagnostic unit or stadium preceding dementia? T. Nikolai, O. Bezdicek, M. Vyhnalek, J. Hort Mild cognitive impairment (MCI) refers to the clinical condition between normal aging and dementia in which persons experience memory loss to a greater extent than one would expect for age, yet they do not meet currently accepted criteria for dementia syndrome. It introduces a clinical concept in progress which is an expression of foregoing research on preclinical stages of dementia and is interconnected with normal aging and cognitive changes in old age. Neuropsychological assessment plays a substantial role in the diagnosis of MCI, especially in the case of identification of different MCI-subtypes (subclassifications) or typical profiles of cognitive performance in prodromal phases of neurodegenerative diseases. However, neuropsychological batteries are challenged mainly by intraindividual variability of aging subjects. A clinical approach to the assessment of MCI - that currently dominates the field - combines normative with criterion-based comparison standards which are basically merged into a broader clinical differential reasoning. In conclusion, the usage of different methods is necessary to evaluate the possible risk of developing a neurodegenerative disease in subjects with MCI (neuropsychological assessment, magnetic resonance imaging, biochemical, genetic / Apolipoprotein E/ and neuropsychiatric examination).","[Nikolai, Tomas; Vyhnalek, Martin; Hort, Jakub] Kognitivni Ctr, Neurol Klin UK, Prague, Czech Republic; [Nikolai, Tomas; Bezdicek, Ondrej] Ctr Klinickych Neuroved, Neurol Klin, Prague, Czech Republic","Hort, J (reprint author), Kognitivni Ctr, Neurol Klin UK, Prague, Czech Republic.","jakub.hort@seznam.cz",null,null,null,null,"Aarsland D, 2011, CURR NEUROL NEUROSCI, V11, P371, DOI 10.1007/s11910-011-0203-1; Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Barbeau E, 2004, NEUROLOGY, V62, P1317; Bezdicek O, 2011, CESK SLOV NEUROL N, V74, P36; Burton CL, 2006, J CLIN EXP NEUROPSYC, V28, P67, DOI 10.1080/13803390490918318; Buschke H., 2010, IACD S EARL DIAGN BI; Busse A, 2003, PSYCHOL MED, V33, P1029, DOI 10.1017/S0033291703007839; Cattell R. B., 1957, PERSONALITY MOTIVATI; Crook T., 1986, DEV NEUROPSYCHOL, V2, P261; Dubois B, 2004, LANCET NEUROL, V3, P246, DOI 10.1016/S1474-4422(04)00710-0; Fabrigoule C., 2006, MILD COGNITIVE IMPAI, P31; Fox NC, 1998, BRAIN, V121, P1631, DOI 10.1093/brain/121.9.1631; Gainotti G, 2010, CURR ALZHEIMER RES, V7, P271; Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5; Hort J, 2007, P NATL ACAD SCI USA, V104, P4042, DOI 10.1073/pnas.0611314104; Hort J., 2007, PAMET JEJI PORUCHY; Hultsch D. F., 2008, HDB AGING COGNITION, P491; Hummelova-Fanfrdlova Z, 2009, CESK PSYCHOL, V53, P376; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; Jak AJ, 2009, AM J GERIAT PSYCHIAT, V17, P368, DOI 10.1097/JGP.0b013e31819431d5; KRAL VA, 1962, CAN MED ASSOC J, V86, P257; Laczo J, 2009, BEHAV BRAIN RES, V202, P252, DOI 10.1016/j.bbr.2009.03.041; Laing H., 2007, NEUROPSYCHOLOGICKA B; Lemere CA, 2010, NAT REV NEUROL, V6, P108, DOI 10.1038/nrneurol.2009.219; Levy R, 1994, Int Psychogeriatr, V6, P63, DOI 10.1017/S1041610294001626; Lezak MD, 2004, NEUROPSYCHOLOGICAL A; Maruta C, 2011, EUR J NEUROL, V18, P279, DOI 10.1111/j.1468-1331.2010.03134.x; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Miller B. L., 2009, BEHAV NEUROLOGY DEME; Minati L, 2009, AM J ALZHEIMERS DIS, V24, P95, DOI 10.1177/1533317508328602; Nesselroade J. R., 2004, RES HUMAN DEV, V1, P9, DOI 10.1207/s15427617rhd0101&2_3; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Plhakova A., 2011, UCEBNICE OBECNE PSYC; Poreh A. M., 2006, QUANTIFIED PROCESS A, P3; Reisberg B., 2008, ALZHEIMERS DEMENT S1, V4, P98; Ressner P, 2008, CESK SLOV NEUROL N, V71, P494; Ritchie K, 2001, NEUROLOGY, V56, P37; Salthouse TA, 2007, NEUROPSYCHOLOGY, V21, P401, DOI 10.1037/0894-4105.21.4.401; Schretlen DJ, 2003, J INT NEUROPSYCH SOC, V9, P864, DOI 10.1017/S1355617703960061; Smith G., 2006, MILD COGNITIVE IMPAI, P131; Solomon PR, 1998, ARCH NEUROL-CHICAGO, V55, P349, DOI 10.1001/archneur.55.3.349; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Strauss E, 2002, J INT NEUROPSYCH SOC, V8, P893, DOI 10.1017/S1355617702870035; Tierney M. C., 2006, MILD COGNITIVE IMPAI, P163; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922; Topinkova E., 2002, NEUROLOGIE PRO PRAXI, V6, P323; Tuokko HA., 2006, MILD COGNITIVE IMPAI, P3",50,0,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2012,56,4,null,null,null,null,374,390,null,null,null,17,"Psychology, Multidisciplinary","Psychology","010IU","WOS:000309088900007"]
[null,null,null,null,"J","Borsky, J; Jana, V; Michal, J; Jiri, K; Dana, H; Miroslav, T; Milos, C; Zdenek, K; Jaroslav, F; Jan, J; Jiri, Z; Renata, P; Miroslav, P",null,null,null,"Borsky, Jiri; Jana, Veleminska; Michal, Jurovcik; Jiri, Kozak; Dana, Hechtova; Miroslav, Tvrdek; Milos, Cerny; Zdenek, Kabelka; Jaroslav, Fajstavr; Jan, Janota; Jiri, Zach; Renata, Peterkova; Miroslav, Peterka",null,null,"Successful early neonatal repair of cleft lip within first 8 days of life","INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"Total cleft lip and palate; Neonate; Malformation; Cheiloplasty; Nose; Scare; 3D evaluation","SEXUAL-DIMORPHISM; PALATE; INFANTS; CHEILOPLASTY; DEFORMITIES; MORPHOLOGY; ALVEOLUS; CHILDREN; SHAPE","Objective: In the children born with a cleft lip, surgery is the first step in correcting the inborn anomaly. In comparison with usually made 3-month surgery, benefits of the surgery in neonates have been reported: a very good wound healing, feeding facilitation, and good socialization of a child from neonatal age. The aims of the present study were to perform cheiloplasty in early newborns affected by the total cleft lip and palate (CLP) by the technique modified to search for optimum aesthetic result, and to assess the surgery outcome from qualitative and quantitative aspects. Methods: The operations were performed by the same surgeon in 97 neonates 1-8 days old during 2005-2008. The original technique by Tennison was modified and used. Aesthetic outcome of the surgery was evaluated according to scar visibility, and the shape and symmetry of the lip and nose. The effect of cheiloplasty on the formation of the upper jaw segments was evaluated in a sample of unilateral CLP patients using the 3D-finite element scaling analysis (FESA). We compared 3D models of dental plaster casts made prior to lip surgery (in neonates under 8 days of age) and prior to palate surgery (at 12 months of age). Results: Only the children in excellent health state and without an associated inborn defect were allowed to pass the operation. There were no per-operative complications (except the correction of tracheal tube position in several cases). The parents appreciated bringing home a neonate with no visible cleft. This aspect not only facilitated baby feeding, but had important positive psycho-social impact on the whole family. The wound healing and aesthetic effect of the cheiloplasty were very good. The scar was barely visible and lip and nose were symmetric in majority of children. After lip closure, the growth and approximation of jaw segments was observed. This aspect was also associated with incisors development in the anterior portion of the segment including premaxilla. Conclusions: Our results show, that early neonatal lip surgery of CLP is promising technique with very good aesthetic results and important positive psychological impact on the child and its family. (C) 2012 Elsevier Ireland Ltd. All rights reserved.","[Borsky, Jiri; Miroslav, Tvrdek; Miroslav, Peterka] Charles Univ Prague, Plast Surg Clin, Fac Hosp Kralovske Vinohrady, Prague 15500 5, Czech Republic; [Borsky, Jiri; Miroslav, Tvrdek; Miroslav, Peterka] Charles Univ Prague, Fac Med 3, Prague 15500 5, Czech Republic; [Jana, Veleminska] Charles Univ Prague, Dept Anthropol & Human Genet, Fac Sci, Prague 15500 5, Czech Republic; [Michal, Jurovcik; Zdenek, Kabelka; Jaroslav, Fajstavr] Charles Univ Prague, ENT Clin, Fac Med 2, Prague 15500 5, Czech Republic; [Michal, Jurovcik; Jiri, Kozak; Dana, Hechtova; Milos, Cerny; Zdenek, Kabelka; Jaroslav, Fajstavr] Fac Hosp Motol, Prague, Czech Republic; [Jiri, Kozak] Charles Univ Prague, Pediat Stomatol Clin, Fac Med 2, Prague 15500 5, Czech Republic; [Dana, Hechtova] Charles Univ Prague, Anesthesiol & Resuscitat Clin, Fac Med 2, Prague 15500 5, Czech Republic; [Milos, Cerny] Charles Univ Prague, Obstet & Gynecol Clin, Dept Newborns, Intens Care Unit,Fac Med 2, Prague 15500 5, Czech Republic; [Jan, Janota; Jiri, Zach] Thomayer Hosp, Dept Neonatol, Prague, Czech Republic; [Renata, Peterkova; Miroslav, Peterka] Acad Sci CR, Inst Expt Med, Prague, Czech Republic","Michal, J (reprint author), Charles Univ Prague, ENT, Clin Fac Med 2, Pavrovskeho 2501-10, Prague 15500 5, Czech Republic.","jurovcik@volny.cz",null,null,"Ministry of Education, Youth and Sports of the Czech Republic [MSM 0021620843]; Ministry of Health of the Czech Republic; project for conceptual development of research organization [00064203];  [10012-4/2008];  [MZ02005]","The technical assistance of Mrs. B. Rokytova is highly acknowledged. The authors thank Dr. J. Dutt for English revision of the manuscript. This research has been supported by research grants MSM 0021620843 from the Ministry of Education, Youth and Sports of the Czech Republic, and NS 10012-4/2008 and Research Intent MZ02005 and from the Ministry of Health of the Czech Republic and by the project for conceptual development of research organization 00064203.",null,32,2,2,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0165-5876","1872-8464",null,"INT J PEDIATR OTORHI","Int. J. Pediatr. Otorhinolaryngol.","NOV",2012,76,11,null,null,null,null,1616,1626,null,"10.1016/j.ijporl.2012.07.031",null,11,"Otorhinolaryngology; Pediatrics","Otorhinolaryngology; Pediatrics","042HY","WOS:000311463500016"]
[null,null,null,null,"J","Rozkovcova, E; Dostalova, T; Markova, M; Broukal, Z",null,null,null,"Rozkovcova, Eva; Dostalova, Tatjana; Markova, Marie; Broukal, Zdenek",null,null,"The Third Molar as an Age Marker in Adolescents: New Approach to Age Evaluation","JOURNAL OF FORENSIC SCIENCES",null,null,"English","Article",null,null,null,null,null,"forensic science; dentistry; third molar development; dental age indicator","CHRONOLOGICAL AGE; 3RD-MOLAR DEVELOPMENT; ROOT DEVELOPMENT; RELIABILITY; MATURITY; CHILDREN","Adolescence is a relatively short period between childhood and adulthood. It is very difficult to determine adulthood based on biological indicators. The third molar may be considered a potential age marker for the period between the ages of 1621. Our study evaluated a set of 1700 panoramic radiographs of individuals aged between 5 and 21 years. Results confirmed the statistically significant difference in the course of third molars development. The mean deviation for individuals with one third molar agenesis is -0.98 years, for individuals with two third molars agenesis -1.89 years, and with three molars agenesis -3.28 years. Thus, the extent of the deviation is directly proportional to the number of unformed third molars. The calculation of age according to the mean of stages of all third molars could lead to the underestimation of age. No intergender differences were found. Age determination using third molars could be used for forensic purposes.","[Dostalova, Tatjana] Charles Univ Prague, Dept Paediat Stomatol, Fac Med 2, Prague 15006 5, Czech Republic; [Dostalova, Tatjana] Fac Hosp Motol, Prague 15006 5, Czech Republic; [Rozkovcova, Eva; Markova, Marie] Charles Univ Prague, Dept Stomatol, Fac Med 1, Prague 12108 2, Czech Republic; [Rozkovcova, Eva; Markova, Marie] Gen Univ Hosp Prague, Prague 12108 2, Czech Republic; [Broukal, Zdenek] Charles Univ Prague, Fac Med 1, Inst Clin & Expt Stomatol, Prague 12111 2, Czech Republic; [Broukal, Zdenek] Gen Univ Hospitalin Prague, Prague 12111 2, Czech Republic","Dostalova, T (reprint author), Charles Univ Prague, Dept Paediat Stomatol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","tatjana.dostalova@fnmotol.cz",null,null," [9991-4];  [13351- 4 IGA MZCR]","Study supported by Project No. 9991-4 and 13351- 4 IGA MZCR.",null,28,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0022-1198",null,null,"J FORENSIC SCI","J. Forensic Sci.","SEP",2012,57,5,null,null,null,null,1323,1328,null,"10.1111/j.1556-4029.2012.02238.x",null,6,"Medicine, Legal","Legal Medicine","000MX","WOS:000308391500027"]
[null,null,null,null,"J","Zwick, EB; Svehlik, M; Kraus, T; Steinwender, G; Linhart, WE",null,null,null,"Zwick, Ernst B.; Svehlik, Martin; Kraus, Tanja; Steinwender, Gerhard; Linhart, Wolfgang E.",null,null,"Does gender influence the long-term outcome of single-event multilevel surgery in spastic cerebral palsy?","JOURNAL OF PEDIATRIC ORTHOPAEDICS-PART B",null,null,"English","Article",null,null,null,null,null,"cerebral palsy; gait; gender; Gillette Gait Index; surgery","GILLETTE-GAIT-INDEX; AMBULANT CHILDREN; SEX","This study compared the long-term outcome of single-event multilevel surgery in spastic diplegic cerebral palsy (CP) on the basis of sex. We hypothesized that boys would have a worse outcome than girls. Thirty-four children (19 boys and 15 girls) with diplegic spastic CP and a minimal follow-up of 10 years were included. The Gillette Gait Index was the main outcome measure. We found no differences in surgical treatment, and both groups initially benefited from the surgery. However, although girls maintained the enhanced level of walking, walking ability in boys deteriorated constantly. Such a finding suggests that sex might have an important influence on treatment outcomes in children with CP. J Pediatr Orthop B 21:448-451 (C) 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.","[Svehlik, Martin] Med Univ Graz, Dept Paediat Surg, Paediat Orthopaed Unit, Dept Paediat Orthopaed, Graz, Austria; [Svehlik, Martin] Charles Univ Prague, Dept Children & Adult Orthopaed, Fac Med 2, Prague, Czech Republic","Svehlik, M (reprint author), Med Univ Graz, Dept Paediat Surg, Paediat Orthopaed Unit, Dept Paediat Orthopaed, Auenbruggerpl 34, Graz, Austria.","martin.spejlik@seznam.cz",null,null,null,null,null,23,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1060-152X",null,null,"J PEDIATR ORTHOP B","J. Pediatr. Orthop.-Part B","SEP",2012,21,5,null,null,null,null,448,451,null,"10.1097/BPB.0b013e32834d4daa",null,4,"Orthopedics; Pediatrics","Orthopedics; Pediatrics","983NE","WOS:000307125200015"]
[null,null,null,null,"J","Goetz, M; Yeh, CB; Ondrejka, I; Akay, A; Herczeg, I; Dobrescu, I; Kim, BN; Jin, XM; Riley, AW; Martenyi, F; Harrison, G; Treuer, T",null,null,null,"Goetz, Michal; Yeh, Chin-Bin; Ondrejka, Igor; Akay, Aynur; Herczeg, Ilona; Dobrescu, Iuliana; Kim, Boong Nyun; Jin, Xingming; Riley, Anne W.; Martenyi, Ferenc; Harrison, Gavan; Treuer, Tamas",null,null,"A 12-Month Prospective, Observational Study of Treatment Regimen and Quality of Life Associated With ADHD in Central and Eastern Europe and Eastern Asia","JOURNAL OF ATTENTION DISORDERS",null,null,"English","Article",null,null,null,null,null,"attention deficit hyperactivity disorder; quality of life; observational study","ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; DSM-IV ADHD; OPPOSITIONAL DEFIANT DISORDER; TURKISH CHILDREN; ADOLESCENTS; DIAGNOSIS; ATOMOXETINE; PREVALENCE; SUBTYPES","Objectives: This prospective, observational, non-randomized study aimed to describe the relationship between treatment regimen prescribed and the quality of life (QoL) of ADHD patients in countries of Central and Eastern Europe (CEE) and Eastern Asia over 12 months. Methods: 977 Male and female patients aged 6-17 years seeking treatment for symptoms of ADHD were assessed using the Child and Adolescent Symptom Inventory-4 Parent Checklists, and the Clinical Global Impressions-ADHD-Severity scale. QoL was assessed using the Child Health and Illness Profile-Child Edition parent report form. Patients were grouped according to whether they were prescribed psycho-and/or pharmacotherapy (treatment) or not (no/'other' treatment). Results: No statistically significant differences were observed between cohorts (treatment vs. no/'other' treatment) in terms of change in QoL, although there was improvement over 12 months, with a greater improvement experienced by patients in the treatment cohort in both study regions (CEE and Eastern Asia). Psychoeducation/counselling and methylphenidate were the predominant ADHD treatments prescribed. Conclusions: Although both treatment and no/'other' treatment cohorts showed improvements in mean QoL over 12 months, the difference was small and not statistically significant. A major limitation was the higher than anticipated number of patients switching treatments, predominantly from the no/'other' treatment cohort. (J. of Att. Dis. 2012; 16(1) 44-59)","[Martenyi, Ferenc] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA; [Goetz, Michal] Charles Univ Prague, Fac Med 2, Diagnost Unit Pediat Psychiat, Prague, Czech Republic; [Yeh, Chin-Bin] Tri Serv Gen Hosp, Taipei, Taiwan; [Ondrejka, Igor] Comenius Univ, Clin Psychiat, Jessenius Fac Med, Martin, Slovakia; [Akay, Aynur] Dokuz Eylul Univ, Sch Med, Fac Med, Izmir, Turkey; [Herczeg, Ilona] Heim Pal Hosp, Budapest, Hungary; [Dobrescu, Iuliana] AI Obregia Psychiat Hosp, UMF Carol Davila, Bucharest, Romania; [Kim, Boong Nyun] Seoul Natl Univ Hosp, Seoul 110744, South Korea; [Jin, Xingming] Shanghai Jiao Tong Univ, Shanghai 200030, Peoples R China; [Riley, Anne W.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Harrison, Gavan] Eli Lilly Pty Ltd, Intercontinental Informat Sci, Sydney, NSW, Australia; [Treuer, Tamas] Eli Lilly Area Med Ctr, Vienna, Austria","Martenyi, F (reprint author), Lilly Corp Ctr, Lilly Res Labs, 75-03-F5 Room 301I,DC 30, Indianapolis, IN 46285 USA.","martenyife@lilly.com","Kim, Boong Nyun/J-5397-2012",null,"Eli Lilly and Company Ltd, Indianapolis, United States","This research was sponsored by Eli Lilly and Company Ltd, Indianapolis, United States. Writing and editorial support for this manuscript was provided by MediTech Media Asia Pacific Pte Ltd, Sydney, Australia.",null,48,1,1,"SAGE PUBLICATIONS INC","THOUSAND OAKS","2455 TELLER RD, THOUSAND OAKS, CA 91320 USA","1087-0547",null,null,"J ATTEN DISORD","J. Atten. Disord.","JAN",2012,16,1,null,null,null,null,44,59,null,"10.1177/1087054710381480",null,16,"Psychology, Developmental; Psychiatry","Psychology; Psychiatry","866AP","WOS:000298352300005"]
[null,null,null,null,"J","Kopkan, L; Huskova, Z; Sporkova, A; Varcabova, S; Honetschlagerova, Z; Hwang, SH; Tsai, HJ; Hammock, BD; Imig, JD; Kramer, HJ; Burgelova, M; Vojtiskova, A; Kujal, P; Vernerova, Z; Cervenka, L",null,null,null,"Kopkan, Libor; Huskova, Zuzana; Sporkova, Alexandra; Varcabova, Sarka; Honetschlaegerova, Zuzana; Hwang, Sung Hee; Tsai, Hsing-Ju; Hammock, Bruce D.; Imig, John D.; Kramer, Herbert J.; Buergelova, Marcela; Vojtiskova, Alzbeta; Kujal, Petr; Vernerova, Zdenka; Cervenka, Ludek",null,null,"Soluble Epoxide Hydrolase Inhibition Exhibits Antihypertensive Actions Independently of Nitric Oxide in Mice with Renovascular Hypertension","KIDNEY & BLOOD PRESSURE RESEARCH",null,null,"English","Article",null,null,null,null,null,"Two-kidney, one-clip Goldblatt hypertension; Cytochrome P450 metabolites; Epoxyeicosatrienoic acids; Soluble epoxide hydrolase; Renin-angiotensin system; Sodium excretion; Nitric oxide; Endothelial nitric oxide synthase","REN-2 TRANSGENIC RATS; II-DEPENDENT HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; BLOOD-PRESSURE; CYTOCHROME-P-450 METABOLITES; EPOXYEICOSATRIENOIC ACIDS; ENDOTHELIAL DYSFUNCTION; ARACHIDONIC-ACID; RENAL-FUNCTION; KNOCKOUT MICE","Objective: The present study was performed to examine whether the blood pressure (BP)-lowering effects of soluble epoxide hydrolase (sEH) inhibition in two-kidney, one-clip (2K1C) Goldblatt hypertension are nitric oxide (NO) dependent. Methods: Mice lacking the endothelial NO synthase (eNOS) gene (eNOS-/-) and their wild-type controls (eNOS+/+) underwent clipping of one renal artery. BP was monitored by radiotelemetry and the treatment with the sEH inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)cyclohex-yl-oxy]-benzoic acid (c-AUCB) was initiated on day 25 after clipping and lasted for 14 days. Renal concentrations of epoxyeicosatrienoic acids (EETs) and their inactive metabolite dihydroxyeicosatrienoic acids (DHETs) were measured in the nonclipped kidney. Renal NO synthase (NOS) activity was determined by measuring the rate of formation of L-[C-14]citruline from L-[C-14]arginine. Results: Treatment with the sEH inhibitor elicited similar BP decreases that were associated with increases in daily sodium excretion in 2K1C eNOS+/+ as well as 2K1C eNOS-/- mice. In addition, treatment with the sEH inhibitor increased the ratio of EETs/DHETs in the nonclipped kidney of 2K1C eNOS+/+ as well as 2K1C eNOS-/- mice. Treatment with the sEH inhibitor did not alter renal NOS activity in any of the experimental groups. Conclusions: Collectively, our present data suggest that the BP-lowering effects of chronic sEH inhibition in 2K1C mice are mainly associated with normalization of the reduced availability of biologically active EETs in the nonclipped kidney and their direct natriuretic actions. Copyright (C) 2012 S. Karger AG, Basel","[Kopkan, Libor; Huskova, Zuzana; Sporkova, Alexandra; Varcabova, Sarka; Honetschlaegerova, Zuzana; Buergelova, Marcela; Vojtiskova, Alzbeta; Kujal, Petr; Vernerova, Zdenka; Cervenka, Ludek] Inst Clin & Expt Med, Ctr Expt Med, CZ-14000 Prague 4, Czech Republic; [Kujal, Petr; Vernerova, Zdenka] Charles Univ Prague, Dept Pathol, Fac Med 3, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic; [Hwang, Sung Hee; Tsai, Hsing-Ju; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; [Hwang, Sung Hee; Tsai, Hsing-Ju; Hammock, Bruce D.] UCD Canc Ctr, Davis, CA USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, Bonn, Germany","Cervenka, L (reprint author), Inst Clin & Expt Med, Ctr Med Expt, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz",null,null,"Internal Grant Agency of the Ministry of Health [NT/11230-4, NT/12171-5]; Ministry of Education, Youth and Sports [MSMT-Kontakt LH 11116]; German Research Foundation (Deutsche Forschungsgemeinschaft; DFG), Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]; German Academic Exchange Service (Deutscher Akademischer Austauschdienst; DAAD), Bonn-Prague University; European Commission [CZ.2.16/3.1.00/22126]; Czech Science Foundation (GACR) [P303/10/P170]; NIH [HL59699, DK38226, R01 HL059699]; Howard Hughes Foundation; NIEHS [R01 ES02710, R01 Es013933, P42 Es013933]","This study was supported by grants NT/11230-4 and NT/12171-5 awarded by the Internal Grant Agency of the Ministry of Health to M. B and Z.H. L.C. is a recipient of grant MSMT-Kontakt LH 11116 from the Ministry of Education, Youth and Sports for the support of the international research cooperation and this study was also supported by this grant.H.J.K. was supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft; DFG), Bonn (Kra 436/14-2 and 436 TSE 113/57/0-1) and the German Academic Exchange Service (Deutscher Akademischer Austauschdienst; DAAD), Bonn-Prague University partnership. This study also received financial support from the European Commission by the Operational Program Prague - Competitiveness; project 'CEVKOON' (#CZ.2.16/3.1.00/22126). A. S. is supported by grant P303/10/P170 awarded by Czech Science Foundation (GACR). J.D.I. is an Established Investigator of the American Heart Association and these studies were supported by NIH grants HL59699 and DK38226. S. H. H. was supported in part by the Howard Hughes Foundation and a fellowship from the NIEHS Supported Basic Research Program. Partial support was provided by NIEHS Grant R01 ES02710, R01 Es013933 and P42 Es013933 and NIH Grant R01 HL059699 awarded to B. D. H. B. D. H. is a George and Judy Marcus Senior Fellow of the American Asthma Foundation.",null,39,1,1,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096",null,null,"KIDNEY BLOOD PRESS R","Kidney Blood Pressure Res.",null,2012,35,6,null,null,null,null,595,607,null,"10.1159/000339883",null,13,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","Physiology; Urology & Nephrology; Cardiovascular System & Cardiology","083KB","WOS:000314461100027"]
[null,null,null,null,"J","Hess, L; Votava, M; Sliva, J; Malek, J; Kurzova, A; Stein, K",null,null,null,"Hess, L.; Votava, M.; Sliva, J.; Malek, J.; Kurzova, A.; Stein, K.",null,null,"Ephedrine accelerates psychomotor recovery from anesthesia in macaque monkeys","JOURNAL OF MEDICAL PRIMATOLOGY",null,null,"English","Article",null,null,null,null,null,"alpha2-adrenergic agonist; anaesthesia; ephedrine; ketamine; primate","KETAMINE; PHENYLEPHRINE; MEDETOMIDINE; VALUES","Background Ephedrine is used in treatment of hypotension during anesthesia. We investigated its effects on the psychomotor recovery and its potential adverse reactions on cardiorespiratory functions in rhesus monkeys. Methods The monkeys received 50 mu g/kg medetomidine, 2.0 mg/kg S-ketamine with 150 IU hyaluronidase i.m. Pulse rate, blood pressure and saturation of haemoglobin were monitored for 20 minutes. Thereafter, 1 mg/kg of ephedrine or a placebo was administered i.m. and behavioural changes, pulse rate, blood pressure and saturation of haemoglobin were monitored every 5 minutes. Results Ephedrine shortened recovery from anaesthesia from 80.4 +/- 25.8 to 14.83 +/- 13.70 minutes. Ephedrine also increased oxygen saturation of haemoglobin and systolic blood pressure and caused significant decrease in pulse rate 5 minutes after its administration. Conclusions Ephedrine can be successfully used to accelerate psychomotor recovery after the use of common anesthetic protocols combining dissociative anesthetic agent and alpha 2-adrenoceptor agonist in primates.","[Sliva, J.] Charles Univ Prague, Fac Med 3, Dept Pharmacol, Prague 10, Czech Republic; [Hess, L.] Inst Clin & Expt Med, Lab Expt Anaesthesiol, Prague, Czech Republic; [Votava, M.] Charles Univ Prague, Fac Med 2, Dept Pharmacol, Prague 10, Czech Republic; [Malek, J.; Kurzova, A.] Charles Univ Prague, Fac Med 3, Dept Anaesthesiol & Crit Care Med, Prague 10, Czech Republic; [Stein, K.] Mil Hlth Insurance Co, Prague, Czech Republic","Sliva, J (reprint author), Charles Univ Prague, Fac Med 3, Dept Pharmacol, Ruska 87, Prague 10, Czech Republic.","jiri.sliva@lfmotol.cuni.cz",null,null,"Czech Ministry of Health [IGA MZ NS/10503-3]","This work was supported by the grant IGA MZ NS/10503-3 from the Czech Ministry of Health.",null,15,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0047-2565",null,null,"J MED PRIMATOL","J. Med. Primatol.","AUG",2012,41,4,null,null,null,null,251,255,null,"10.1111/j.1600-0684.2012.00545.x",null,5,"Veterinary Sciences; Zoology","Veterinary Sciences; Zoology","978IO","WOS:000306734200003"]
[null,null,null,null,"J","Simsa, J; Hoch, J; East, B; Leffler, J; Ryska, M; Belina, F; Dolezel, R; Gatek, J; Varga, J",null,null,null,"Simsa, J.; Hoch, J.; East, B.; Leffler, J.; Ryska, M.; Belina, F.; Dolezel, R.; Gatek, J.; Varga, J.",null,null,"Lymph node micrometastases in gastric cancer: final results of the Czech multicentre study","EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA",null,null,"English","Article",null,null,null,null,null,"Gastric cancer; Lymphadenectomy; Lymph node micrometastases; Isolated tumour cells","PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CANCER; CARCINOMA; MORBIDITY","Background Lymphadenectomy is an important part of surgical treatment of gastric cancer. Using immunohistochemistry or RT-PCR, small deposits of tumour cells, called micrometastases (MM) and isolated tumour cells (ITC) are found in some of the lymph nodes, which were found negative after a standard examination in haematoxylin eosin (H-E). The aim of this multicentre study was to assess their clinical and prognostic significance. Methods Multicentre, prospective, nonrandomized clinical trial on-going in four Czech centres. The study enrolled patients after radical resection for gastric cancer. All lymph nodes were examined in standard H-E staining, lymph nodes producing negative results were then processed using detailed immunohistochemistry (IHC) with anti-cellular cytokeratin antibody (AE1/AE3, Immunotech). Results A total of 93 patients following radical surgery for gastric cancer, across the four participating centres were included in the study between the 1st January 2009 and 31st December 2011. A total of 42 patients (representing 45.2 % of the cohort) underwent a resection, while the remaining 51 had a total gastrectomy (54.8 %). A total of 1,588 lymph nodes were found and examined, with the average number of nodes per patient being 17.1. Metastases by H-E stain were found in 441 nodes (27.8 %). The remaining lymph nodes which showed negative after processing in H-E were then examined with IHC. Nodular MM was found in 43 nodes (2.7 %), then the ITC in 74 nodes (4.7 %). No statistically significant difference was observed when comparing the length of survival among patients with negative node findings (H-E negative, IHC negative) and patients with minimal node affection (H-E negative, IHC positive), p = 0.494. Likewise there was no statistically significant difference within the sub-group of patients with minimal node affection between patients with micrometastases (MM) and patients with isolated tumour cells (ITC), p = 0.925. Conclusions The results of this study indicate that the presence of nodal MM and ITC in gastric cancer is not linked to the worsening of the prognosis of patients. Financially, technically and the time-consuming method of processing nodes with IHC cannot yet be recommended as part of the routine histological examination.","[Simsa, J.; Varga, J.] Charles Univ Prague, Fac Med 1, Dept Surg, Prague 14059 4, Czech Republic; [Simsa, J.] Thomayer Hosp, Prague 14059 4, Czech Republic; [Hoch, J.; East, B.; Leffler, J.; Ryska, M.; Belina, F.; Dolezel, R.] Charles Univ Prague, Fac Med 2, Dept Surg, Prague 14059 4, Czech Republic; [Ryska, M.; Belina, F.; Dolezel, R.] Cent Mil Hosp Prague, Prague, Czech Republic; [Gatek, J.] Tomas Bata Univ Zlin, Dept Surg, Zlin, Czech Republic; [Gatek, J.] Atlas Hosp Zlin, Zlin, Czech Republic; [Varga, J.] Bulovka Fac Hosp Prague, Prague, Czech Republic; [Hoch, J.; East, B.; Leffler, J.] Motol Fac Hosp Prague, Prague, Czech Republic","Simsa, J (reprint author), Charles Univ Prague, Fac Med 1, Dept Surg, Videska 800, Prague 14059 4, Czech Republic.","jaromir.simsa@ftn.cz",null,null,null,null,null,19,0,0,"SPRINGER WIEN","WIEN","SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA","1682-8631",null,null,"EUR SURG","Eur. Surg.","DEC",2012,44,6,null,null,null,null,388,393,null,"10.1007/s10353-012-0178-4",null,6,"Surgery","Surgery","057HJ","WOS:000312553500005"]
[null,null,null,null,"J","Babic, M; Horak, D; Jendelova, P; Herynek, V; Proks, V; Vanecek, V; Lesny, P; Sykova, E",null,null,null,"Babic, Michal; Horak, Daniel; Jendelova, Pavla; Herynek, Vit; Proks, Vladimir; Vanecek, Vaclav; Lesny, Petr; Sykova, Eva",null,null,"The use of dopamine-hyaluronate associate-coated maghemite nanoparticles to label cells","INTERNATIONAL JOURNAL OF NANOMEDICINE",null,null,"English","Article",null,null,null,null,null,"nanoparticles; dopamine; hyaluronate; cell labeling; magnetic","IRON-OXIDE NANOPARTICLES; MESENCHYMAL STEM-CELLS; IN-VIVO TRACKING; MAGNETIC NANOPARTICLES; VITRO; EFFICIENCY; PARTICLES; CANCER; ACID","Sodium hyaluronate (HA) was associated with dopamine (DPA) and introduced as a coating for maghemite (gamma-Fe2O3) nanoparticles obtained by the coprecipitation of iron(II) and iron(III) chlorides and oxidation with sodium hypochlorite. The effects of the DPA anchorage of HA on the gamma-Fe2O3 surface on the physicochemical properties of the resulting colloids were investigated. Nanoparticles coated at three different DPA-HA/gamma-Fe2O3 and DPA/HA ratios were chosen for experiments with rat bone marrow mesenchymal stem cells and human chondrocytes. The nanoparticles were internalized into rat bone marrow mesenchymal stem cells via endocytosis as confirmed by Prussian Blue staining. The efficiency of mesenchymal stem cell labeling was analyzed. From among the investigated samples, efficient cell labeling was achieved by using DPA-HA-gamma-Fe2O3 nanoparticles with DPA-HA/gamma-Fe2O3 = 0.45 (weight/weight) and DPA/HA = 0.038 (weight/weight) ratios. The particles were used as a contrast agent in magnetic resonance imaging for the labeling and visualization of cells.","[Babic, Michal; Horak, Daniel; Proks, Vladimir] Acad Sci Czech Republic, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic; [Babic, Michal; Horak, Daniel; Jendelova, Pavla; Herynek, Vit; Proks, Vladimir; Vanecek, Vaclav; Lesny, Petr; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Jendelova, Pavla; Vanecek, Vaclav; Lesny, Petr; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 16206 6, Czech Republic; [Herynek, Vit] Inst Clin & Expt Med, Prague, Czech Republic","Horak, D (reprint author), Acad Sci Czech Republic, Inst Macromol Chem, Heyrovsky Sq 2, CR-16206 Prague 6, Czech Republic.","horak@imc.cas.cz","Babic, Michal/B-7075-2013",null,"Grant Agency of the Czech Republic [203/09/1242, P207/12/J013, P304/12/1370]; European Commission [259796]; Center for Cell Therapy and Tissue Repair [1M0538]","The financial support of the Grant Agency of the Czech Republic (grant 203/09/1242, P207/12/J013, and P304/12/1370), the European Commission (DiaTools project no 259796) and the Center for Cell Therapy and Tissue Repair (No 1M0538) is gratefully acknowledged. The authors thank James Dutt for critical reading of the manuscript.",null,35,0,0,"DOVE MEDICAL PRESS LTD","ALBANY","PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND","1178-2013",null,null,"INT J NANOMED","Int. J. Nanomed.",null,2012,7,null,null,null,null,null,1461,1474,null,"10.2147/IJN.S28658",null,14,"Nanoscience & Nanotechnology; Pharmacology & Pharmacy","Science & Technology - Other Topics; Pharmacology & Pharmacy","924YV","WOS:000302728100001"]
[null,null,null,null,"J","Fencl, F; Malina, M; Stara, V; Zieg, J; Mixova, D; Seeman, T; Blahova, K",null,null,null,"Fencl, Filip; Malina, Michal; Stara, Veronika; Zieg, Jakub; Mixova, Dana; Seeman, Tomas; Blahova, Kveta",null,null,"Discordant expression of a new WT1 gene mutation in a family with monozygotic twins presenting with congenital nephrotic syndrome","EUROPEAN JOURNAL OF PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"Congenital nephrotic syndrome; WT1 gene; Infant; Renal failure; Nephroblastoma","DENYS-DRASH-SYNDROME; TUMOR-SUPPRESSOR GENE; WILMS-TUMOR; STEROID-RESISTANT; PSEUDOHERMAPHRODITISM; NEPHROPATHY; PATIENT","Congenital nephrotic syndrome (CNS) is a heterogeneous group of diseases with different causes and prognoses. Two thirds of cases of NS in the first year of life are caused by mutations in four genes (NPHS1, NPHS2, WT1, and LAMB2). The mutation of WT1 gene can lead to Denys-Drash syndrome (DDS). We report on female monozygotic twins with CNS presenting at 7 and 8 weeks of age with anuric renal failure. Both twins were treated by peritoneal dialysis. Renal biopsy proved diffuse mesangial sclerosis. Genetic analysis detected a new heterozygote WT1 mutation R434P in both twins. One child developed a unilateral nephroblastoma. Both twins died because of complications of CNS (sepsis and extensive thrombosis of central venous system/sepsis and sudden heart failure) at ages 23 weeks/13.5 months, respectively. DNA analysis showed the same WT1 mutation in the father, who showed at his age of 41 years no clinical consequences of this mutation and no signs of DDS. In conclusion, we report the third family with monozygotic twins with DDS due to WT1 mutation. The DDS has very rapidly led to end-stage renal failure and death in both twins which is in striking contrast to the manifestation in their father.","[Fencl, Filip; Malina, Michal; Stara, Veronika; Zieg, Jakub; Seeman, Tomas; Blahova, Kveta] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 15006 5, Czech Republic; [Fencl, Filip; Malina, Michal; Stara, Veronika; Zieg, Jakub; Mixova, Dana; Seeman, Tomas; Blahova, Kveta] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Mixova, Dana] Charles Univ Prague, Fac Med 2, Dept Anesthesiol & Resuscitat, Prague 15006 5, Czech Republic","Fencl, F (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat, V Uvalu 84, Prague 15006 5, Czech Republic.","filip.fencl@gmail.com","Malina, Michal/A-5037-2012",null,"GAUK (Grant Agency of the Charles University) [910 10]; Ministry of Health Czech Republic VZ [0006420301]","This work was supported by grant GAUK (Grant Agency of the Charles University) No. 910 10 and grant of the Ministry of Health Czech Republic VZ No. 0006420301. We would like to thank Dr. Beata Lipska, Ph.D. for the help with correct nomenclature of WT1 mutations.",null,20,4,6,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,null,"EUR J PEDIATR","Eur. J. Pediatr.","JAN",2012,171,1,null,null,null,null,121,124,null,"10.1007/s00431-011-1497-3",null,4,"Pediatrics","Pediatrics","870GM","WOS:000298657300015"]
[null,null,null,null,"J","Beranova, S; Hrdlicka, M",null,null,null,"Beranova, Stepanka; Hrdlicka, Michal",null,null,"Early diagnosis and screening of autism spectrum disorders","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"autism; autism spectrum disorders; early diagnosis; screening","PERVASIVE DEVELOPMENTAL DISORDERS; TRAITS QUESTIONNAIRE ESAT; YOUNG-CHILDREN; MODIFIED CHECKLIST; AGE; TODDLERS; POPULATION; LIFE; RECOGNITION; INFANCY","Current findings on high prevalence (up to 1%) of autism spectrum disorders (ASD) encourage further research in the field of early identification of these disorders. The article presents a review of current knowledge on early autistic symptomatology as well as on the methods of early diagnosis of ASD. Main screening studies carried out both on general population and samples of high-risk siblings of children already diagnosed with ASD are analysed. Parameters of following screening tests are discussed - Checklist for Autism in Toddlers (CHAT), Modified Checklist for Autism in Toddlers (M-CHAT), Quantitative Checklist for Autism in Toddlers (Q-CHAT), Early Screening of Autistic Traits (ESAT), Infant Toddler Checklist (ITC) and First Year Inventory (FYI). In the end of the article the importance of early intervention is emphasized.","[Beranova, Stepanka; Hrdlicka, Michal] Charles Univ, LF 2, Detska Psychiat Klin, FN Motol, Prague 15006 5, Motol, Czech Republic","Beranova, S (reprint author), Charles Univ, LF 2, Detska Psychiat Klin, FN Motol, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","Michal.Hrdlicka@fnmotol.cz",null,null,null,null,null,54,2,2,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2012,56,2,null,null,null,null,167,177,null,null,null,11,"Psychology, Multidisciplinary","Psychology","941MN","WOS:000303967400007"]
[null,null,null,null,"J","Knotek, P; Pouzar, M; Buzgo, M; Krizkova, B; Vlcek, M; Mickova, A; Plencner, M; Navesnik, J; Amler, E; Belina, P",null,null,null,"Knotek, Petr; Pouzar, Miloslav; Buzgo, Matej; Krizkova, Barbora; Vlcek, Milan; Mickova, Andrea; Plencner, Martin; Navesnik, Jakub; Amler, Evzen; Belina, Petr",null,null,"Cryogenic grinding of electrospun poly-epsilon-caprolactone mesh submerged in liquid media","MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS",null,null,"English","Article",null,null,null,null,null,"Cryogenic grinding; Poly-epsilon-caprolactone; Nano/micro-mesh; Microsystem; Characterization","MESENCHYMAL STEM-CELLS; IN-VITRO; DRUG-DELIVERY; SURFACE-TENSION; MICROSPHERES; SCAFFOLDS; COMPOSITE; NANOPARTICLES; MICROCARRIERS; FABRICATION","In this paper, the treatment of poly-epsilon-caprolactone (PCL) nano/micro-mesh system by cryogenic grinding and subsequent characterization of obtained product is described. The PCL nano/micro-mesh layer submerged in appropriate liquid was cryogenically ground and obtained particles were characterized employing mainly laser diffraction and scanning electron microscopy (SEM). In the ground sample, different types of particles (fibrous particles, fibrous fragments, agglomerates with and without an internal fibrous structure, lamellae and nanoparticles) were identified, described and quantified. Parameters of cryogenic grinding (weight of sample, type of liquid medium, and influence of sample storage) were optimized to maximize the yield of particles with desired features. The potential of the system for cell scaffolding was demonstrated by cultivation of 3T3 fibroblasts on the produced microparticles. (C) 2012 Elsevier B.V. All rights reserved.","[Pouzar, Miloslav; Navesnik, Jakub] Univ Pardubice, Inst Environm & Chem Engn, Pardubice 53012, Czech Republic; [Knotek, Petr] Univ Pardubice, Fac Chem Technol, Pardubice 53210, Czech Republic; [Buzgo, Matej; Mickova, Andrea; Plencner, Martin; Amler, Evzen] Charles Univ Prague, Dept Biophys, Fac Med 2, Prague 15006 5, Czech Republic; [Buzgo, Matej; Mickova, Andrea; Plencner, Martin; Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Vvi, Prague 14220 4, Czech Republic; [Krizkova, Barbora] Univ Pardubice, Dept Biol & Biochem Sci, Pardubice 53012, Czech Republic; [Vlcek, Milan] Acad Sci Czech Republic, Inst Macromol Chem, Vvi, CR-16206 Prague, Czech Republic; [Belina, Petr] Univ Pardubice, Dept Inorgan Technol, Pardubice 53012, Czech Republic","Pouzar, M (reprint author), Univ Pardubice, Inst Environm & Chem Engn, Studentska 573, Pardubice 53012, Czech Republic.","milan.pouzar@upce.cz","Knotek, Petr/J-6608-2012; Vlcek, Milan/C-7317-2013","Vlcek, Milan/0000-0002-3670-884X","EU [214539];  [VZ 0021627501];  [MSM 0021627502]","Support from the project VZ 0021627501 is acknowledged by P. Knotek and to the Project MSM 0021627502 by M. Pouzar. M. Buzgo, A Mickova, M. Plencner and E. Amler are acknowledged for support from EU project BIOSCENT ID No. 214539, to Ministry of Education of the Czech Republic project ERA-NET CARSILA No. ME 10145 and to projects 99610, 330611, and 384311 from the Grant Agency of Charles University.",null,48,1,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0928-4931",null,null,"MAT SCI ENG C-MATER","Mater. Sci. Eng. C-Mater. Biol. Appl.","AUG 1",2012,32,6,null,null,null,null,1366,1374,null,"10.1016/j.msec.2012.04.012",null,9,"Materials Science, Biomaterials","Materials Science","969BO","WOS:000306030900007"]
[null,null,null,null,"J","Arientova, S; Schramlova, J; Ambrozova, H; Maresova, V; Holub, M",null,null,null,"Arientova, Simona; Schramlova, Jana; Ambrozova, Helena; Maresova, Vilma; Holub, Michal",null,null,"Electron microscopy in the diagnosis of viral gastroenteritis in hospitalised children in the Czech Republic","FOLIA MICROBIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"MOLECULAR EPIDEMIOLOGY; NOROVIRUS INFECTION; HUMAN ROTAVIRUS; PREVALENCE; VIRUSES; BANGLADESH; ARGENTINA; DIARRHEA; VIETNAM; INFANTS","Our study has been aimed at demonstrating the main role of viruses in the aetiology of acute gastroenteritis in children less than 5 years old and at pointing out the diagnostic potential of electron microscopy in the diagnosis of viral gastroenteritis. A prospective study was conducted to analyse the aetiology of diarrhoeal diseases in children less than 5 years of age admitted to the Department of Infectious Diseases between September 2006 and December 2008. All children were tested by faecal culture, latex agglutination and electron microscopy. A total of 832 children were included in the study. An aetiological agent was detected in 788 children (94.6 %). A bacterial aetiology was found in 22 (2.6 %) children and bacterial-viral co-infection was found in 146 (17.6 %) patients. The most frequent causative agents of gastroenteritis in children were viruses, which were detected in 620 (74.5 %) patients. The main causes of viral gastroenteritis were rotaviruses (detected in 410 children), followed by caliciviruses (42), coronaviruses (28), adenoviruses (19) and astroviruses (14). Dual viral infections were detected in 107 children, with rotavirus-calicivirus co-infection being the most common. Electron microscopy proved to be a more sensitive method in comparison with the latex agglutination test for the diagnosis of rotaviruses and adenoviruses. The major role of viruses in diarrhoeal diseases among children under 5 years of age in the Czech Republic has been confirmed. The diagnostic potential of electron microscopy, particularly in small outbreaks of gastroenteritis, was clearly shown.","[Arientova, Simona; Holub, Michal] Charles Univ Prague, Fac Med 1, Univ Hosp Bulovka, Dept Infect & Trop Dis, Prague 18081, Czech Republic; [Ambrozova, Helena; Maresova, Vilma] Charles Univ Prague, Fac Med 2, Univ Hosp Bulovka, Dept Infect Dis 1, Prague 18081, Czech Republic; [Schramlova, Jana] Natl Inst Publ Hlth, Natl Reference Lab Direct Diag Viruses Borrelia &, Prague, Czech Republic","Arientova, S (reprint author), Charles Univ Prague, Fac Med 1, Univ Hosp Bulovka, Dept Infect & Trop Dis, Budinova 2, Prague 18081, Czech Republic.","simonaa@centrum.cz","Holub, Michal/D-5182-2009","Holub, Michal/0000-0003-1894-2605",null,null,null,32,1,1,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632",null,null,"FOLIA MICROBIOL","Folia Microbiol.","MAY",2012,57,3,null,null,null,null,177,182,null,"10.1007/s12223-012-0109-6",null,6,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","937SX","WOS:000303680100003"]
[null,null,null,null,"J","Majerova, V; Kalincik, T; Laczo, J; Vyhnalek, M; Hort, J; Bojar, M; Ruzicka, E; Roth, J",null,null,null,"Majerova, Veronika; Kalincik, Tomas; Laczo, Jan; Vyhnalek, Martin; Hort, Jakub; Bojar, Martin; Ruzicka, Evzen; Roth, Jan",null,null,"Disturbance of real space navigation in moderately advanced but not in early Huntington's disease","JOURNAL OF THE NEUROLOGICAL SCIENCES",null,null,"English","Article",null,null,null,null,null,"Egocentric navigation; Allocentric navigation; Morris Water Maze; Blue Velvet Arena; Hippocampus; Striatum","MILD COGNITIVE IMPAIRMENT; SPATIAL NAVIGATION; HUMAN HIPPOCAMPUS; CAUDATE-NUCLEUS; VISUOSPATIAL COGNITION; ALZHEIMERS-DISEASE; WATER MAZE; MEMORY; ORIENTATION; RATS","Background: Visuospatial skills including spatial navigation are known to be impaired in Huntington's disease. Spatial navigation comprises two navigational frameworks, allocentric and egocentric. Several studies have associated the allocentric navigation with the hippocampus and the egocentric navigation with the striatum. The striatum is predominantly impaired from the early stages of Huntington's disease. Objective: To find whether spatial navigation impairment is present in the early stages of Huntington's disease and to test the hypothesis that the egocentric navigation is predominantly affected compared to the allocentric navigation. Methods: In nineteen patients with Huntington's disease the egocentric and the allocentric navigation skills were tested using the Blue Velvet Arena, a human analog of Morris Water Maze, and compared to nineteen age and gender-matched healthy controls. Cognitive functions, with emphasis on the executive functions, were also assessed. Results: The spatial navigation skills deteriorated with the increasing motor impairment in Huntington's disease. These changes only became apparent in patients with moderate functional impairment. No difference between the egocentric and the allocentric skills was seen. Discussion: Spatial navigation deficit is not an early marker of the cognitive dysfunction in Huntington's disease. We speculate that the striatal circuitry that is known to degenerate early in the course of Huntington's disease is not directly associated with the spatial navigation. (C) 2011 Elsevier B.V. All rights reserved.","[Majerova, Veronika; Kalincik, Tomas; Ruzicka, Evzen; Roth, Jan] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague 12800 2, Czech Republic; [Majerova, Veronika; Kalincik, Tomas; Ruzicka, Evzen; Roth, Jan] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague 12800 2, Czech Republic; [Majerova, Veronika; Kalincik, Tomas; Ruzicka, Evzen; Roth, Jan] Gen Univ Hosp Prague, Prague 12800 2, Czech Republic; [Laczo, Jan; Vyhnalek, Martin; Hort, Jakub; Bojar, Martin] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Laczo, Jan; Vyhnalek, Martin; Hort, Jakub; Bojar, Martin] Charles Univ Prague, Fac Med 2, Dept Neurol, Memory Disorders Unit, Prague 15006 5, Czech Republic; [Laczo, Jan; Vyhnalek, Martin; Hort, Jakub] St Annes Univ, Hosp Brno, Int Clin Res Ctr, Brno 65691, Czech Republic","Majerova, V (reprint author), Neurol Klin 1, LF UK & VFN Katerinska 30, Prague 12808 2, Czech Republic.","v.majerova@gmail.com","Kalincik, Tomas/A-6911-2008",null,"Czech Ministry of Education [MSM 0021620849]; Grant Agency of the Czech Republic [309/09/1053, 309/09/0286]; European Regional Development Fund [CZ.1.05/1.1.00/02.0123]; Ministry of Education, Youth and Sports of the Czech Republic [1M0517, LC554, AV0Z50110509]","This work was supported by the Czech Ministry of Education, research program MSM 0021620849, Grant Agency of the Czech Republic Grants 309/09/1053 and 309/09/0286, European Regional Development Fund Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123), Ministry of Education, Youth and Sports of the Czech Republic Grants 1M0517 and LC554, and research project AV0Z50110509.",null,47,1,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0022-510X",null,null,"J NEUROL SCI","J. Neurol. Sci.","JAN 15",2012,312,41671,null,null,null,null,86,91,null,"10.1016/j.jns.2011.08.016",null,6,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","880YJ","WOS:000299446200018"]
[null,null,null,null,"J","Neuwirth, A; Dobes, J; Oujezdska, J; Ballek, O; Benesova, M; Sumnik, Z; Vcelakova, J; Kolouskova, S; Obermannova, B; Kolar, M; Stechova, K; Filipp, D",null,null,null,"Neuwirth, Ales; Dobes, Jan; Oujezdska, Jana; Ballek, Ondrej; Benesova, Martina; Sumnik, Zdenek; Vcelakova, Jana; Kolouskova, Stanislava; Obermannova, Barbora; Kolar, Michal; Stechova, Katerina; Filipp, Dominik",null,null,"Eosinophils from patients with type 1 diabetes mellitus express high level of myeloid alpha-defensins and myeloperoxidase","CELLULAR IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Type 1 diabetes; alpha-Defensin; Myeloperoxidase; Granulocyte; Eosinophil","INNATE IMMUNITY; MODEL; GRANULOCYTES","Type 1 diabetes (T1D) is an autoimmune disease caused by T-cell mediated destruction of pancreatic beta cells. Recently, small cationic alpha-defensin molecules have been implicated in the pathogenesis of certain inflammatory and autoimmune diseases. The purpose of this study was to assess the alpha-defensin expression in patients with T1D and elucidate the cellular source of their production. Our results show that 30% of patients exhibit increased levels of alpha-defensin mRNAs in their capillary blood. Quantitative RT-PCR performed on FACS-sorted granulocytes identified CD15(dull)/CD14(weak) population as the cellular source of alpha-defensins. Surprisingly, this granulocyte subpopulation displayed augmentation of alpha-defensin expression in all T1D patients tested. The determination of cell surface markers, expression of cell-specific genes and confocal microscopy identified CD15(dull)/CD14(weak) cells as eosinophils. The presence of transcriptionally active eosinophils in diabetic patients suggests that eosinophils could be a part of an intricate innate immune cellular network involved in the development of diabetes. (C) 2012 Elsevier Inc. All rights reserved.","[Neuwirth, Ales; Dobes, Jan; Oujezdska, Jana; Ballek, Ondrej; Benesova, Martina; Filipp, Dominik] Inst Mol Genet AS CR, Immunobiol Lab, CZ-14220 Prague 4, Czech Republic; [Sumnik, Zdenek; Vcelakova, Jana; Kolouskova, Stanislava; Obermannova, Barbora; Stechova, Katerina] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic; [Sumnik, Zdenek; Vcelakova, Jana; Kolouskova, Stanislava; Obermannova, Barbora; Stechova, Katerina] Univ Hosp Motol, Prague, Czech Republic; [Kolar, Michal] Inst Mol Genet AS CR, Lab Genom & Bioinformat, CZ-14220 Prague 4, Czech Republic","Filipp, D (reprint author), Inst Mol Genet AS CR, Immunobiol Lab, Videnska 1083, CZ-14220 Prague 4, Czech Republic.","dominik.filipp@img.cas.cz","Kolar, Michal/A-3307-2012","Kolar, Michal/0000-0002-4593-1525","Ministry of Education, Youth and Sports, Czech Republic [IMUDIAB 2B08066, NPVII 2B06019]; Academy of Sciences of the Czech Republic [AVOZ50520514]; Grant Agency of Charles University (GAUK), Czech Republic [408211]","We thank Zdenek Cimburek from the Flow Cytometry Facility at the Institute of Molecular Genetics for expert technical assistance and Jasper Manning for helpful comments on the manuscript. This work was supported by Grant IMUDIAB 2B08066 from the Ministry of Education, Youth and Sports, Czech Republic and Grant AVOZ50520514 from the Academy of Sciences of the Czech Republic. JD is supported by Grant No. 408211 from Grant Agency of Charles University (GAUK), Czech Republic. KS is supported by Grant NPVII 2B06019 from the Ministry of Education, Youth and Sports, Czech Republic.",null,26,1,1,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0008-8749",null,null,"CELL IMMUNOL","Cell. Immunol.",null,2012,273,2,null,null,null,null,158,163,null,"10.1016/j.cellimm.2011.12.001",null,6,"Cell Biology; Immunology","Cell Biology; Immunology","905LE","WOS:000301272900009"]
[null,null,null,null,"J","Barna, M; Stulik, J; Kryl, J; Vyskocil, T; Nesnidal, P",null,null,null,"Barna, M.; Stulik, J.; Kryl, J.; Vyskocil, T.; Nesnidal, P.",null,null,"ProDisc-C Total Disc Replacement. A Four-Year Prospective Monocentric Study","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"ProDisc-C; Cervical Total Disc Replacement; heterotopic ossification","BRYAN CERVICAL DISC; HETEROTOPIC OSSIFICATION; DEGENERATIVE DISEASE; SINGLE-LEVEL; ARTHROPLASTY; PROSTHESIS; FUSION; CLASSIFICATION; ARTHRODESIS; EXPERIENCE","PURPOSE OF THE STUDY To present the results of an independent prospective monocentric study of patients with ProDisc-C Total Disc Replacement (CTDR) followed up for 4 years, and to analyse the most frequent late complications, in particular heterotopic ossification. MATERIAL In the period from October 2004 to May 2006, a total of 61 patients underwent ProDisc-C CTDR involving one or two segments at the Department of Spinal Surgery, University Hospital in Motol. This study included 39 patients who were followed up for at least 4 years. With the exception of one patient operated on two segments, the patients were treated by ProDisc-C CTDR at one level. METHODS In the study, only the surgical procedure recommended by the implant manufacturer (Synthes, USA) was used and all operations were performed by a team with the same leading surgeon. Clinical assessment. The patients were examined before surgery, immediately after it and at 6 and 12 weeks and 6, 12, 24 and 48 months post-operatively. At each follow-up, responses to the questionnaire were obtained, and the patients' health status was evaluated on the basis of Neck Disability Index (NDI) and Visual Analogue Score (VAS) values for cervical spine and radicular pain, the use of analgesics and personal satisfaction Radiographic assessment. Pre- and post-operative radiographs were taken in antero-posterior and lateral projection, and flexion, extension and lateral bending films were obtained The height of the intervertebral disc space at the affected level was measured and range of motion in flexion and extension was evaluated together with the adjacent levels. In addition, subsidence, loosening, failure or displacement of the implant was assessed, as well as the presence of heterotopic ossification. The results were statistically analysed using Student's t-test. RESULTS The clinical results at 1, 2 and 4 years of follow-up were as follows: NDI values, 44.9 pre-operatively, 26.1, 25.8 and 25.1 post-operatively, improvement by 44.1% after 4 years; VAS for cervical spine pain, 5.8 pre-operatively, 3.0, 2.7 and 2.7 postoperatively, improvement after 4 years by 53.7%; VAS for radicular pain, 6.3 pre-operatively, 2.9, 2.9 and 2.7 postoperatively, improvement by 57.1% after 4 years. The radiographic findings showed the average intervertebral disc space height of 3.2 mm at the affected level before and 7.4 mm after surgery, with no significant change in the following period. The average range of disc motion at the affected level was 4.2 degrees before and 11.1 degrees after surgery, with 11.4 degrees at 4 years of follow-up. During that period, heterotopic ossification was recorded in 10 (25%) treated discs, with five of them (12.5%) classified as grade III or IV. Spontaneous fusion across the disc replacement level was found in three cases (7.5%). Two patients (5%) developed kyphosis at the affected disc level. The statistical analysis showed a significant difference between the pre-operative VAS values and those at 6 post-operative weeks for both cervical spine and radicular pain (t = 4.4 and t = 5.3, respectively; p <0.05). No significant difference in VAS values was found between 6 weeks and 3 months after surgery for either condition (t = 1.69 and t = 0.3; p > 0.05). Changes in VAS values in the following period were minimal and non-significant. The differences in NDI values before surgery and at 6 weeks after it, and between 6 weeks and 3 months post-operatively were significant (t = 11, p < 0.05 and t = 3.8, p < 0.05, respectively). In the following period, changes in the values were minimal and non-significant. DISCUSSION Short-term studies on various types of cervical disc replacement have been optimistic and reported good clinical results and few complications. However, with longer follow-ups there has been an increasing incidence of heterotopic ossification as the most frequent late complication. Although the number of patients diagnosed with it is growing, heterotopic ossification influences the patient's clinical problems only little. What are its causes and how to prevent it are questions to be fully answered yet CONCLUSIONS Heterotopic ossification is the most frequent late complication of total disc replacement. Many factors may be responsible for its development and therefore its prevention is not clear. The correct indication and appropriate surgical technique are most often recommended, and are considered also by the authors to be most important. Restricted motion at the treated segment/s has no significant effect on the patient's clinical status.","[Barna, M.; Stulik, J.; Kryl, J.; Vyskocil, T.; Nesnidal, P.] LF UK, Spondylochirurg Oddeleni, FN Motol, Prague 15006 5, Czech Republic; [Barna, M.; Stulik, J.; Kryl, J.; Vyskocil, T.; Nesnidal, P.] FN Motol, Chirurg Klin 3, LF UK 1, Prague 15006 5, Czech Republic; [Stulik, J.] FN Motol, Ortoped Klin Defi & Dospelych, LF UK 2, Prague 15006 5, Czech Republic","Barna, M (reprint author), LF UK, Spondylochirurg Oddeleni, FN Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","m.barna@email.cz",null,null,null,null,null,33,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2012,79,6,null,null,null,null,512,519,null,null,null,8,"Orthopedics","Orthopedics","065IZ","WOS:000313143300006"]
[null,null,null,null,"J","Novotna, B; Jendelova, P; Kapcalova, M; Rossner, P; Turnovcova, K; Bagryantseva, Y; Babic, M; Horak, D; Sykova, E",null,null,null,"Novotna, Bozena; Jendelova, Pavla; Kapcalova, Miroslava; Rossner, Pavel, Jr.; Turnovcova, Karolina; Bagryantseva, Yana; Babic, Michal; Horak, Daniel; Sykova, Eva",null,null,"Oxidative damage to biological macromolecules in human bone marrow mesenchymal stromal cells labeled with various types of iron oxide nanoparticles","TOXICOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"Iron oxide nanoparticles; Oxidative damage; Human bone marrow mesenchymal stromal cells","SPINAL-CORD-INJURY; MAGNETIC-RESONANCE TRACKING; EMBRYONIC STEM-CELLS; IN-VIVO TRACKING; DNA-DAMAGE; LIPID-PEROXIDATION; COMET ASSAY; SUPERPARAMAGNETIC NANOPARTICLES; BIOMEDICAL APPLICATIONS; INTRACELLULAR UPTAKE","The biological effects of several superparamagnetic iron oxide nanoparticles (SPIONs) varying in their surface coating were tested using human bone marrow mesenchymal stromal cells from two donors - hBMSCs-1 and hBMSCs-2. The measurements were performed at two intervals - after 72 h exposure to the nanoparticles and after an additional 72 h cell growth without nanoparticles. The dose of SPIONs used (15.4 mu g Fe/ml) was selected as being sufficient for in vivo cell tracking using magnetic resonance imaging (MRI). Concerning cell viability and cell death, only the hBMSCs-2 seemed to be sensitive to the action of SPIONs. However, an increase of oxidative injury to lipids, proteins and DNA as a consequence of exposure to SPIONs was detected in cells from both donors. Particularly the levels of lipid peroxidation were high and increased further with time, regardless of the type of nanoparticle. Lowering intracellular label concentrations and authenticating oxidative stress levels using in vivo experiments are required to ensure the safety of SPIONs for biomedical applications. (C) 2012 Elsevier Ireland Ltd. All rights reserved.","[Novotna, Bozena] Acad Sci Czech Republic, Inst Expt Med, Dept Genet Ecotoxicol, Prague 14220 4, Czech Republic; [Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; [Babic, Michal; Horak, Daniel] Acad Sci Czech Republic, Inst Macromol Chem, Prague 16200 6, Czech Republic","Novotna, B (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Genet Ecotoxicol, Videnska 1083, Prague 14220 4, Czech Republic.","novotna@biomed.cas.cz","Babic, Michal/B-7075-2013",null," [AV0Z50390703];  [AV0Z50390512];  [1M0538];  [GA CR 309/08/H079];  [GA CR 203/09/1242];  [GA CR P304/12/1370]","This study was supported by the grants AV0Z50390703, AV0Z50390512, 1M0538, GA CR 309/08/H079, GA CR 203/09/1242 and GA CR P304/12/1370. We thank Katarina Masinova for TEM images and James Dutt for critical reading of the manuscript.",null,75,12,13,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0378-4274",null,null,"TOXICOL LETT","Toxicol. Lett.","APR 5",2012,210,1,null,null,null,null,53,63,null,"10.1016/j.toxlet.2012.01.008",null,11,"Toxicology","Toxicology","928ZA","WOS:000303029800007"]
[null,null,null,null,"J","Zitka, O; Skalickova, S; Gumulec, J; Masarik, M; Adam, V; Hubalek, J; Trnkova, L; Kruseova, J; Eckschlager, T; Kizek, R",null,null,null,"Zitka, Ondrei; Skalickova, Sylvie; Gumulec, Jaromir; Masarik, Michal; Adam, Vojtech; Hubalek, Jaromir; Trnkova, Libuse; Kruseova, Jarmila; Eckschlager, Tomas; Kizek, Rene",null,null,"Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients","ONCOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"glutathione; paediatric tumour patients; oxidative stress; high performance liquid chromatography with electrochemical detection","GLUTATHIONE SYNTHESIS; RHEUMATOID-ARTHRITIS; DIABETES-MELLITUS; PARKINSON-DISEASE; LIQUID-CHROMATOGRAPHY; PLASMA GLUTATHIONE; ALZHEIMER-DISEASE; FREE-RADICALS; CANCER; BLOOD","Oxidative stress causes profound alterations of various biological structures, including cellular membranes, lipids, proteins and nucleic acids, and it is involved in numerous malignancies. Reduced glutathione (GSH) is considered to be one of the most important scavengers of reactive oxygen species (ROS), and its ratio with oxidised glutathione (GSSG) may be used as a marker of oxidative stress. The main aim of this study was to determine GSH:GSSG ratio in the blood serum of paediatric cancer patients to use this ratio as a potential marker of oxidative stress. The whole procedure was optimised and the recoveries for both substances were greater than 80% under the optimised conditions. We analysed a group of paediatric patients (n=116) with various types of cancer, including neuroblastoma, anaplastic ependymoma, germ cell tumour, genital tract tumour, lymphadenopathy, rhabdomyosarcoma, nephroblastoma, Ewing's sarcoma, osteosarcoma, Hodgkin's lymphoma, medulloblastoma and retinoblastoma. We simultaneously determined the levels of reduced and oxidised glutathione, and thus, its ratio in the blood serum of the patients. The highest ratio was observed in retinoblastoma patients and the lowest in anaplastic ependymoma. We were able to distinguish between the diagnoses based on the results of the obtained GSH:GSSG ratio.","[Zitka, Ondrei; Skalickova, Sylvie; Gumulec, Jaromir; Masarik, Michal; Adam, Vojtech; Hubalek, Jaromir; Trnkova, Libuse; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Brno 61300, Czech Republic; [Zitka, Ondrei; Hubalek, Jaromir] Brno Univ Technol, Dept Microelect, Fac Elect Engn & Commun, Brno 61200, Czech Republic; [Zitka, Ondrei; Masarik, Michal; Adam, Vojtech; Hubalek, Jaromir; Trnkova, Libuse; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, Brno 61600, Czech Republic; [Gumulec, Jaromir; Masarik, Michal] Masaryk Univ, Fac Med, Dept Pathol Physiol, Brno 62500, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, Brno 62500, Czech Republic; [Kruseova, Jarmila; Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Hematol & Oncol, Fac Med 2, Prague 15006, Czech Republic; [Kruseova, Jarmila; Eckschlager, Tomas] Univ Hosp Motol, Prague 15006, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, 1 Zemedelska, Brno 61300, Czech Republic.","kizeke@sci.muni.cz","Gumulec, Jaromir/D-7638-2012; Hubalek, Jaromir/D-7753-2012; Masarik, Michal/D-9920-2012","Gumulec, Jaromir/0000-0002-9658-3444; ","NANOSEMED GA AV [KAN208130801]; NanoBioTECell GA CR [102/11/1068]; CEITEC [CZ.1.05/1.1.00/02.0068]; Project for Conceptual Development of Research Organization [00064203]","Financial support from NANOSEMED GA AV (Grant No. KAN208130801), NanoBioTECell GA CR (Grant No. 102/11/1068), CEITEC (Grant No. CZ.1.05/1.1.00/02.0068) and and the Project for Conceptual Development of Research Organization (00064203) is gratefully acknowledged.",null,50,6,9,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1792-1074",null,null,"ONCOL LETT","Oncol. Lett.","DEC",2012,4,6,null,null,null,null,1247,1253,null,"10.3892/ol.2012.931",null,7,"Oncology","Oncology","036JF","WOS:000311021500020"]
[null,null,null,null,"J","Kulijewicz-Nawrot, M; Verkhratsky, A; Chvatal, A; Sykova, E; Rodriguez, JJ",null,null,null,"Kulijewicz-Nawrot, Magdalena; Verkhratsky, Alexei; Chvatal, Alexander; Sykova, Eva; Rodriguez, Jose J.",null,null,"Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer's disease","JOURNAL OF ANATOMY",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; astroglia; cognition; medial prefrontal cortex; plasticity","FIBRILLARY ACIDIC PROTEIN; PHASEOLUS-VULGARIS-LEUKOAGGLUTININ; NUCLEUS-REUNIENS-THALAMI; LONG-TERM POTENTIATION; MIDLINE THALAMUS; FRONTOTEMPORAL DEMENTIA; HIPPOCAMPAL-FORMATION; NEURONAL DENSITY; ANIMAL-MODEL; RAT","Alzheimers disease (AD) is a progressive neurodegenerative disorder characterized by the loss of cognitive functions, reflecting pathological damage to the medial prefrontal cortex (mPFC) as well as to the hippocampus and the entorhinal cortex. Astrocytes maintain the internal homeostasis of the CNS and are fundamentally involved in neuropathological processes, including AD. Here, we analysed the astrocytic cytoskeletal changes within the mPFC of a triple transgenic mouse model of AD (3 x Tg-AD) by measuring the surface area and volume of glial fibrillary acidic protein (GFAP)-positive profiles in relation to the build-up and presence of amyloid-beta (A beta), and compared the results with those found in non-transgenic control animals at different ages. 3 x Tg-AD animals showed clear astroglial cytoskeletal atrophy, which appeared at an early age (3 months; 33% and 47% decrease in GFAP-positive surface area and volume, respectively) and remained throughout the disease progression at 9, 12 and 18 months old (29% and 36%; 37% and 35%; 43% and 37%, respectively). This atrophy was independent of A beta accumulation, as only a few GFAP-positive cells were localized around A beta aggregates, which suggests no direct relationship with A beta toxicity. Thus, our results indicate that the progressive reduction in astrocytic branching and domain in the mPFC can account for the integrative dysfunction leading to the cognitive deficits and memory disturbances observed in AD.","[Kulijewicz-Nawrot, Magdalena; Verkhratsky, Alexei; Chvatal, Alexander; Sykova, Eva; Rodriguez, Jose J.] ASCR, Inst Expt Med, Prague, Czech Republic; [Verkhratsky, Alexei] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Verkhratsky, Alexei; Rodriguez, Jose J.] Basque Fdn Sci, IKERBASQUE, Bilbao, Spain; [Verkhratsky, Alexei; Rodriguez, Jose J.] Univ Basque Country UPV EHU, Dept Neurosci, Leioa, Spain; [Verkhratsky, Alexei] CIBERNED, Leioa, Spain; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Rodriguez, JJ (reprint author), Univ Basque Country UPV EHU, IKERBASQUE, Dept Neurosci, Technol Pk,Bldg 205,Floor 1, Zamudio 48170, Bizkaia, Spain.","j.rodriguez-arellano@ikerbasque.org","Verkhratsky, Alexei/J-4527-2013","Verkhratsky, Alexei/0000-0003-2592-9898","Alzheimer's Research Trust [ART/PG2004A/1]; Grant Agency of the Czech Republic [GACR 309/09/1696, GACR 304/11/0184, GACR 305/08/1381, GACR 305/08/1384]; Spanish Government; Plan Nacional de I+D+I; ISCIII- Subdireccion General de Evaluacion y Fomento de la Investigacion [PI10/02738]; Government of the Basque Country [AE-2010-1-28, AEGV10/16]; EC [PITN-GA-2008-214003]","This study was supported by an Alzheimer's Research Trust Programme Grant (ART/PG2004A/1) to J.J.R. and A.V., grants from the Grant Agency of the Czech Republic to J.J.R. (GACR 309/09/1696), to E.S. and J.J.R. (GACR 304/11/0184), and to A.V. (GACR 305/08/1381, GACR 305/08/1384). Support from the Spanish Government, Plan Nacional de I+D+I 2008-2011 and ISCIII- Subdireccion General de Evaluacion y Fomento de la Investigacion (PI10/02738) to J.J.R. and A.V., and the Government of the Basque Country (AE-2010-1-28, AEGV10/16) to J.J.R. is gratefully acknowledged. M.K.-N. is supported by the EC FP7 project AXREGEN (PITN-GA-2008-214003). The authors would also like to thank Miss Chia-Yu Yeh for all of her help in the verification and correction of the fine details of the manuscript, and her support during the submission progress. Finally, the authors would like to express their gratitude to Mr James Dutt for critical reading of the manuscript.",null,70,8,8,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0021-8782","1469-7580",null,"J ANAT","J. Anat.","SEP",2012,221,3,null,null,null,null,252,262,null,"10.1111/j.1469-7580.2012.01536.x",null,11,"Anatomy & Morphology","Anatomy & Morphology","980VO","WOS:000306922500006"]
[null,null,null,null,"J","Ryvolova, M; Adam, V; Eckschlager, T; Stiborova, M; Kizek, R",null,null,null,"Ryvolova, Marketa; Adam, Vojtech; Eckschlager, Tomas; Stiborova, Marie; Kizek, Rene",null,null,"Study of DNA-ellipticine interaction by capillary electrophoresis with laser-induced fluorescence detection","ELECTROPHORESIS",null,null,"English","Article",null,null,null,null,null,"Capillary electrophoresis; DNA; Drugs; Ellipticine; Tumor disease","ANTICANCER DRUG ELLIPTICINE; PERFORMANCE LIQUID-CHROMATOGRAPHY; ADDUCT FORMATION; ALKALOID ELLIPTICINE; INTERCALATING DRUGS; DUAL FLUORESCENCE; AGENT ELLIPTICINE; CYTOCHROMES P450; CANCER-CELLS; IN-VIVO","Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole), an alkaloid isolated from Apocynaceae plants, exhibits an antitumor activity, which is exceptionally high against several specific types of tumors. Ellipticine is also interesting as an anticancer drug as it has limited side effects and lacks of hematological toxicity. Various methods to study intercalating activity of this drug have been developed. However, to our best knowledge, capillary electrophoresis (CE) as a technique combining high separation resolution with various detection options has never been used for these purposes. In this study, a novel separation method based on CE with laser-induced fluorescence (CE-LIF) detection has been developed for the determination of ellipticine and for the monitoring of ellipticineDNA interaction. Sodium acetate (50 mM, pH 4.5) was used as a background electrolyte and LIF detection at ?ex = 488 nm. The limit of detection for ellipticine was determined to be 5 x 10(-8) M. A total of 20% dimethyl sulfoxide was found optimal as sample solvent. Additionally, intercalation of ellipticine into the double-stranded DNA was investigated. Signal corresponding to ellipticine was decreasing and a new peak appeared and was growing. It can be concluded that CE-LIF is a method applicable to in vitro studies of ellipticineDNA complexes.","[Ryvolova, Marketa; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Ryvolova, Marketa] Brno Univ Technol, Dept Microelect, Fac Elect Engn & Commun, Brno, Czech Republic; [Ryvolova, Marketa; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, Prague, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Ryvolova, Marketa/D-8243-2012",null," [CYTORES GA CR P301/10/0356];  [CEITEC CZ.1.05/1.1.00/02.0068]","Financial support from the following projects CYTORES GA CR P301/10/0356 and CEITEC CZ.1.05/1.1.00/02.0068 is greatly acknowledged.",null,46,4,4,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0173-0835",null,null,"ELECTROPHORESIS","Electrophoresis","JUN",2012,33,11,null,null,null,null,1545,1549,null,"10.1002/elps.201200056",null,5,"Biochemical Research Methods; Chemistry, Analytical","Biochemistry & Molecular Biology; Chemistry","965FW","WOS:000305753600008"]
[null,null,null,null,"J","Stiborova, M; Poljakova, J; Eckschlager, T; Kizek, R; Frei, E",null,null,null,"Stiborova, Marie; Poljakova, Jitka; Eckschlager, Tomas; Kizek, Rene; Frei, Eva",null,null,"Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the P-32-postlabeling technique","BIOMEDICAL PAPERS-OLOMOUC",null,null,"English","Article",null,null,null,null,null,"ellipticine; doxorubicin; neuroblastoma; DNA adducts; P-32-postlabeling; cancer","ANTICANCER DRUG ELLIPTICINE; TOPOISOMERASE-II; GENOTOXIC MECHANISM; MASS-SPECTROMETRY; ANTITUMOR DRUGS; CANCER-CELLS; ADRIAMYCIN; FORMALDEHYDE; ANTHRACYCLINE; 13-HYDROXYELLIPTICINE","Background. Ellipticine and doxorubicin are antineoplastic agents, whose action is based mainly on DNA damage such as intercalation, inhibition of topoisomerase II and formation of covalent DNA adducts. The key target to resolve which of these mechanisms are responsible for ellipticine and doxorubicin anticancer effects is the development of suitable methods for identifying their individual DNA-damaging effects. Here, the P-32-postlabeling method was tested to detect covalent DNA adducts formed by ellipticine and doxorubicin. Methods. The standard procedure of P-32-postlabeling assay, this procedure under ATP-deficient conditions, the version using extraction of adducts with n-butanol and the nuclease P1 enrichment version were used to analyze ellipticine- and/or doxorubicin-derived DNA adducts. Results. Two covalent ellipticine-derived DNA adducts, which are associated with cytotoxicity of ellipticine to human UKF-NB-3 and UKF-NB-4 neuroblastoma cell lines, were detected by the P-32-postlabeling method. These adducts are identical to those formed by the ellipticine metabolites, 13-hydroxy- and 12-hydroxyellipticine. In contrast, no covalent adducts formed by doxorubicin in DNA of these neuroblastoma cells and in DNA incubated with this drug and formaldehyde in vitro were detectable by the P-32-postlabeling assay. Conclusions. The results presented in this paper are the first to demonstrate that in contrast to covalent DNA adducts formed by ellipticine, the adducts generated by formaldehyde-mediated covalent binding of doxorubicin to DNA are not detectable by the P-32-postlabeling assay. No DNA adducts were, detectable either in vitro, in incubations of DNA with doxorubicin or in DNA of neuroblastoma cells treated with this drug. The results also suggest that covalent binding of ellipticine to DNA of UKF-NB-3 and UKF-NB-4 neuroblastoma cell lines is the predominant mechanism responsible for the cytotoxicity of this drug. To understand the mechanisms of doxorubicin anticancer effects on neuroblastoma cells, development of novel methods for identifying covalent doxorubicin-derived DNA adducts is the major challenge for further research.","[Stiborova, Marie; Poljakova, Jitka] Charles Univ Prague, Dept Biochem, Fac Sci, Prague 12840 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, Prague 15006 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Brno 61300, Czech Republic; [Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, Brno 61600, Czech Republic; [Frei, Eva] German Canc Res Ctr, Div Prevent Oncol, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany","Stiborova, M (reprint author), Charles Univ Prague, Dept Biochem, Fac Sci, Albertov 2030, Prague 12840 2, Czech Republic.","marie.stiborova@natur.cuni.cz",null,null,"Grant Agency of the Czech Republic [P301/10/0356]; CEITEC [CZ.1.05/1.1.00/02.0068]","We thank Prof. J. Cinatl, Jr. (J. W. Goethe University, Frankfurt, Germany) for providing cell lines. The work is supported by the Grant Agency of the Czech Republic (grant P301/10/0356) and CEITEC CZ.1.05/1.1.00/02.0068.",null,38,4,4,"PALACKY UNIV, MEDICAL FAC","OLOMOUC","CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC","1213-8118",null,null,"BIOMED PAP","Biomed. Pap-Olomouc",null,2012,156,2,null,null,null,null,115,121,null,"10.5507/bp.2012.043",null,7,"Engineering, Biomedical; Medicine, Research & Experimental","Engineering; Research & Experimental Medicine","974AI","WOS:000306401700005"]
[null,null,null,null,"J","Martinek, J; Ryska, O; Filipkova, T; Dolezel, R; Juhas, S; Motlik, J; Holubova, M; Nosek, V; Rotnaglova, B; Zavoral, M; Ryska, M",null,null,null,"Martinek, Jan; Ryska, Ondrej; Filipkova, Tereza; Dolezel, Radek; Juhas, Stefan; Motlik, Jan; Holubova, Monika; Nosek, Vladimir; Rotnaglova, Barbora; Zavoral, Miroslav; Ryska, Miroslav",null,null,"Natural orifice transluminal endoscopic surgery vs laparoscopic ovariectomy: Complications and inflammatory response","WORLD JOURNAL OF GASTROENTEROLOGY",null,null,"English","Article",null,null,null,null,null,"Natural orifice transluminal endoscopic surgery; Laparoscopy; Ovariectomy; Systemic inflammatory response","CHOLECYSTECTOMY; THROMBOCYTOPENIA; MODEL","AIM: To compare natural orifice transluminal endoscopic surgery (NOTES) vs standard laparoscopic ovariectomy in mini pigs with respect to technical aspects, complications and parameters of systemic inflammatory response. METHODS: This was a randomized, experimental, survival study. Ten female mini pigs underwent NOTES transgastric ovariectomy (NOTES group) and ten female mini pigs underwent laparoscopic ovariectomy (LAP group). A \"percutaneous endoscopic gastrostomy\" approach with guidewire and sphincterotome was used for gastrotomy creation. The ovary was resected using standard biopsy forceps and a snare. The access site was closed using a \"KING\" closure with a single endoloop and several clips. In the laparoscopic group, a three-port laparoscopy and an ovariectomy were performed with the use of standard laparoscopic devices. C-reactive protein (CRP), white blood count and interleukin (IL)-6 plasma levels were used as indicators of systemic inflammatory response. All animals were euthanized 28 d after surgery. RESULTS: All animals survived without complications. The mean procedure time was 41.3 min +/- 17.6 min (NOTES group) and 25.7 min +/- 5.25 min (LAP group, P < 0.02). Postmortem examinations demonstrated that 50% and 70% of animals were free of any complications in the NOTES and LAP groups, respectively. The remaining animals developed minor complications (adhesions) in a comparable frequency between the two groups. In the NOTES group, one animal developed a small intramural gastric abscess close to the gastrotomy site. A minor serous exudate that was present in 50% and 40% of the animals in the NOTES and laparoscopy groups, respectively, was not considered a complication. In both groups CRP levels increased significantly on the 2nd and 7th postoperative days (POD) and returned to normal after 28 d. On POD 2, an increase of CRP level was significantly higher in the NOTES group compared to the LAP group. Values of IL-6 did not differ from baseline values in either of the groups postoperatively. Interestingly, the platelet count decreased significantly on POD 2, but returned close to baseline values on POD 7 and PODs 28-30. CONCLUSION: Both NOTES and laparoscopic ovariectomies had a similar frequency of minor complications. However, the NOTES technique produced an increased systemic inflammatory response on POD 2. (c) 2012 Baishideng. All rights reserved.","[Martinek, Jan; Rotnaglova, Barbora; Zavoral, Miroslav] Charles Univ Prague, Univ Mil Hosp, Fac Med 1, Dept Internal Med, Prague 16000, Czech Republic; [Ryska, Ondrej; Dolezel, Radek; Ryska, Miroslav] Charles Univ Prague, Univ Mil Hosp, Fac Med 2, Dept Surg, Prague 16000, Czech Republic; [Filipkova, Tereza] Domazlice Hosp, Dept Surg, Domazlice 34401, Czech Republic; [Juhas, Stefan; Motlik, Jan; Holubova, Monika] Acad Sci, Inst Anim Physiol & Genet, Libechov 27721, Czech Republic; [Nosek, Vladimir] Jablonec Hosp, Dept Gastroenterol, Jablonec Nad Nisou 46601, Czech Republic","Martinek, J (reprint author), Charles Univ Prague, Univ Mil Hosp, Fac Med 1, Dept Internal Med, Vojenska Nemocnice 1200, Prague 16000, Czech Republic.","jan.martinek@volny.cz",null,null,"IGA [NS9994-4]; Academy of Sciences of the Czech Republic (institutional research plan) [AV0Z50450515]","Supported by A Grant from IGA- NS9994-4; and the Academy of Sciences of the Czech Republic (institutional research plan AV0Z50450515)",null,23,3,4,"BAISHIDENG PUBL GRP CO LTD","WANCHAI","ROOM 1701, 17-F, HENAN BUILDING, NO. 90, JAFFE RD, WANCHAI, HONG KONG 100025, PEOPLES R CHINA","1007-9327",null,null,"WORLD J GASTROENTERO","World J. Gastroenterol.","JUL 21",2012,18,27,null,null,null,null,3558,3564,null,"10.3748/wjg.v18.i27.3558",null,7,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","980KP","WOS:000306892400010"]
[null,null,null,null,"J","Curila, K; Benesova, L; Penicka, M; Minarik, M; Zemanek, D; Veselka, J; Widimsky, P; Gregor, P",null,null,null,"Curila, Karol; Benesova, Lucie; Penicka, Martin; Minarik, Marek; Zemanek, David; Veselka, Josef; Widimsky, Petr; Gregor, Pavel",null,null,"Spectrum and clinical manifestations of mutations in genes responsible for hypertrophic cardiomyopathy","ACTA CARDIOLOGICA",null,null,"English","Article",null,null,null,null,null,"Hypertrophic cardiomyopathy; gene; mutation; phenotype","BINDING PROTEIN-C; COMPOUND","Introduction Hypertrophic cardiomyopathy (HCM) is a cardiovascular disease with autosomal dominant inheritance. It is caused by mutations in the genes coding for structural and/or regulatory proteins found in the sarcomere of cardiomyocytes. A group of genes, including the heavy chain of beta-myosin (MYH7), myosin binding protein C (MYBPC3), cardiac troponin I (TNNI3) and cardiac troponin T (TNNT2) are frequently affected by causal mutations. While exact mutation frequency data has been obtained for various populations, no screening has been reported for Central European populations. Patients and methods We performed a complete sequencing of MYH7, MYBPC3,TNNI3 and TNNT2 genes in 100 HCM patients. Results We discovered mutations in a total of 40 patients (40%), including 4 patients with double mutations. A total of 35 different mutation types were detected, of which 17 were novel. The contributions from individual genes were: 24 mutations in MYBPC3 (54.5%), 14 in MYH7 (31.8%), 4 in TNNI3 (9%) and 2 mutations in TNNT2 (4.5%). We have observed a wide variability in disease manifestation across the different genes/mutation types. In addition, we have discovered differences in both frequency and distribution of mutations of the two most common genes (MYBPC3 and MYH7) compared to other populations. Conclusion The most common gene responsible for HCM in our study population was MYBPC3, followed by MYH7,TNNI3 and TNNT2. Phenotypic heterogeneity, as well as the dissimilarity to other populations, prevents effective use of a pre-screening test, which would be directed at the most common mutation hotspots, in our population.","[Curila, Karol] Charles Univ Prague, Dept Cardiol, Med Sch 3, Cardioctr,Fac Med 3, Prague 10034, Czech Republic; [Curila, Karol; Penicka, Martin; Widimsky, Petr; Gregor, Pavel] Univ Hosp Kralovske Vinohrady, Prague 10034, Czech Republic; [Benesova, Lucie; Minarik, Marek] Genomac Int, Lab Mol Genet & Oncol, Prague, Czech Republic; [Zemanek, David; Veselka, Josef] Fac Hosp Motol, Ctr Cardiovasc, Prague, Czech Republic","Curila, K (reprint author), Charles Univ Prague, Dept Cardiol, Med Sch 3, Cardioctr,Fac Med 3, Srobarova 50, Prague 10034, Czech Republic.","curila@fnkv.cz",null,null,"IGA MZ CR [NR 9164]","This work was supported by IGA MZ CR grant NR 9164.",null,19,3,4,"ACTA CARDIOLOGICA","BRUSSELS","AVENUE CIRCULAIRE 138A, 1180 BRUSSELS, BELGIUM","0001-5385",null,null,"ACTA CARDIOL","Acta Cardiol.","FEB",2012,67,1,null,null,null,null,23,29,null,"10.2143/AC.67.1.2146562",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","078GH","WOS:000314086200004"]
[null,null,null,null,"J","Burrel, S; Bonnafous, P; Hubacek, P; Agut, H; Boutolleau, D",null,null,null,"Burrel, Sonia; Bonnafous, Pascale; Hubacek, Petr; Agut, Henri; Boutolleau, David",null,null,"Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity","ANTIVIRAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Herpes simplex virus; Thymidine kinase; Acyclovir phosphorylation activity; Nonradioactive method","GENOTYPIC CHARACTERIZATION; DNA-POLYMERASE; PHENOTYPIC CHARACTERIZATION; ANTIVIRAL DRUGS; GENETIC CONTENT; RESISTANT; TYPE-1; TRANSPLANTATION; POLYMORPHISM; MUTAGENESIS","The acyclic analogue of guanosine acyclovir (ACV) constitutes the first-line drug for the treatment of herpes simplex virus (HSV) infections. ACV activation requires primophosphorylation by virus-encoded HSV thymidine kinase (TK). In 95% of cases, HSV resistance to ACV is associated with mutations located in TK. The aim of this work was to address the question of the potential involvement of novel HSV-1 and HSV-2 TK mutations in reduced susceptibility to ACV using a novel nonradioactive method, based on luminescent quantitation of ADP, for the evaluation of in vitro phosphorylation activity of TK. All recombinant TKs tested exhibited significantly lower ACV phosphorylation activities in comparison with those of reference KOS or gHSV-2 TKs (p < 0.015), therefore indicating that amino acid changes Y53D, L170P, R176W, A207P (HSV-1) and S66P, A725, I101S, M183I (HSV-2) were likely to be involved in HSV resistance to ACV. (C) 2012 Elsevier B.V. All rights reserved.","[Burrel, Sonia; Bonnafous, Pascale; Agut, Henri; Boutolleau, David] Univ Paris 06, DETIV ER1, Paris, France; [Burrel, Sonia; Agut, Henri; Boutolleau, David] Grp Hosp Univ La Pitie Salpetriere Charles Foix, AP HP, Serv Virol, Paris, France; [Hubacek, Petr] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Hubacek, Petr] Univ Hosp Motol, Dept Med Microbiol, Prague, Czech Republic","Boutolleau, D (reprint author), Grp Hosp Pitie Salpetriere, AP HP, Serv Virol, 83 Blvd Hop, F-75651 Paris 13, France.","david.boutolleau@psl.aphp.fr","Boutolleau, David/D-9610-2014","Boutolleau, David/0000-0001-9401-4662","Association pour la Recherche sur les Infections Virales (ARIV)","This work was supported in part by the Association pour la Recherche sur les Infections Virales (ARIV).",null,28,3,3,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0166-3542",null,null,"ANTIVIR RES","Antiviral Res.","DEC",2012,96,3,null,null,null,null,386,390,null,"10.1016/j.antiviral.2012.09.016",null,5,"Pharmacology & Pharmacy; Virology","Pharmacology & Pharmacy; Virology","056UY","WOS:000312518100014"]
[null,null,null,null,"J","Sulakova, T; Janda, J; Cerna, J; Janstova, V; Feber, J",null,null,null,"Sulakova, T.; Janda, J.; Cerna, J.; Janstova, V.; Feber, J.",null,null,"Assessment of arterial stiffness from ambulatory blood pressure monitoring in children with diabetes mellitus type-1 (DMT1)","JOURNAL OF HUMAN HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"pulse pressure; arterial ambulatory stiffness index; ambulatory BP monitoring; diabetes mellitus type-1; children","WHITE COAT HYPERTENSION; PULSE PRESSURE; RESISTANT HYPERTENSION; ELDERLY-PEOPLE; INDEX; RISK; CHILDHOOD; MORTALITY","Pulse pressure (PP) and ambulatory arterial stiffness index (AASI) can be calculated from ambulatory blood pressure (BP) monitoring (ABPM) and have been suggested as markers of arterial stiffness and predictors of cardiovascular mortality. We retrospectively evaluated PP and AASI from ABPM records in 84 children (43 boys) with diabetes mellitus type-1 (DMT1) compared with 27 non-diabetic normotensive children. Based on office BP and ABPM, patients with DMT1 were divided into three groups: 24/84 (29%) had hypertension (DM HTN), 33/84 (39%) were normotensive (DM NT) and 27/84 (32%) had white-coat hypertension (DM WCH). DM WCH and DM HTN patients had significantly higher PP when compared with DM NT and NT patients alone (47.62 +/- 7.31 and 47.43 +/- 8.68 versus 41.45 +/- 4.44 and 42.18 +/- 5.97, respectively, P = 0.0002). Similarly, AASI was significantly elevated in both DM WCH and DM HTN patients when compared with NT patients (0.35 +/- 0.14 and 0.36 +/- 0.15 versus 0.23 +/- 0.15, respectively, P = 0.007). In conclusion, children with DMT1 and hypertension, including WCH, had significantly higher PP and AASI levels when compared with normotensive patients. This suggests that these children may be at an increased risk for developing cardiovascular complications later on in life. Journal of Human Hypertension (2012) 26, 357-364; doi:10.1038/jhh.2011.38; published online 5 May 2011","[Sulakova, T.; Cerna, J.; Janstova, V.] Univ Hosp Ostrava, Dept Pediat, Ostrava 70852, Czech Republic; [Janda, J.] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Feber, J.] Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON K1H 8L1, Canada","Sulakova, T (reprint author), Univ Hosp Ostrava, Dept Pediat, 17 Listopadu 1790, Ostrava 70852, Czech Republic.","terezie.sulakova@fnspo.cz",null,null,null,null,null,35,3,3,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0950-9240",null,null,"J HUM HYPERTENS","J. Hum. Hypertens.","JUN",2012,26,6,null,null,null,null,357,364,null,"10.1038/jhh.2011.38",null,8,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","940VW","WOS:000303922200003"]
[null,null,null,null,"J","Kruger, A; Ostadal, P; Vondrakova, D; Janotka, M; Herget, J",null,null,null,"Krueger, A.; Ostadal, P.; Vondrakova, D.; Janotka, M.; Herget, J.",null,null,"Nitrotyrosine and Nitrate/Nitrite Levels in Cardiac Arrest Survivors Treated With Endovascular Hypothermia","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Cardiac arrest; Hypothermia; Nitrotyrosine; Nitrates/nitrites; Oxidative stress","INTERNATIONAL LIAISON COMMITTEE; CARDIOVASCULAR CARE COMMITTEE; AMERICAN-HEART-ASSOCIATION; NITRIC-OXIDE; THERAPEUTIC HYPOTHERMIA; SYNDROME EPIDEMIOLOGY; MODERATE HYPOTHERMIA; CLINICAL CARDIOLOGY; REPERFUSION INJURY; OXIDATIVE STRESS","The protective effect of therapeutic hypothermia in cardiac arrest survivors (CAS) has been previously well documented. Animal studies have indicated that attenuation of tissue oxidative stress (OS) may be involved in the mechanisms that lead to the beneficial effect of hypothermia. The extent of OS and nitric oxide (NO) production in adult CAS treated with endovascular hypothermia is, however, unknown. A total of 11 adult patients who experienced cardiac arrest out of hospital were included in the present study, and all were treated with mild hypothermia using the Thermogard XP (Alsius, USA) endovascular system. A target core temperature of 33 degrees C was maintained for 24 hours, with a subsequent rewarming rate of 0.15 degrees C per hour, followed by normothermia at 36.8 degrees C. Blood samples for the measurement of nitrotyrosine and nitrate/nitrite levels were drawn at admission and every 6 hours thereafter for two days. During the hypothermic period, the levels of nitrotyrosine and nitrates/nitrites were comparable with baseline values. During the rewarming period, serum levels of both parameters gradually increased and, during the normothermic period, the levels were significantly higher compared with hypothermic levels (nitrotyrosine, P<0.001; nitrates/nitrites, P<0.05). In our study, significantly lower levels of nitrotyrosine and nitrates/nitrites were demonstrated during hypothermia compared with levels during the normothermic period in adult CAS. These data suggest that attenuation of OS and NO production may be involved in the protective effect of hypothermia in adult CAS.","[Krueger, A.; Ostadal, P.; Vondrakova, D.; Janotka, M.] Homolce Hosp, Dept Cardiol, Ctr Cardiovasc, Prague 15030, Czech Republic; [Herget, J.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic","Ostadal, P (reprint author), Homolce Hosp, Dept Cardiol, Ctr Cardiovasc, Prague 15030, Czech Republic.","ostadal@yahoo.com",null,null,"Czech Ministry of Health [NT12153]","This study was supported by a grant from the Czech Ministry of Health, Nr. NT12153.",null,20,3,3,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2012,61,4,null,null,null,null,425,430,null,null,null,6,"Physiology","Physiology","011VO","WOS:000309194600011"]
[null,null,null,null,"J","Majer, F; Vlaskova, H; Krol, L; Kalina, T; Kubanek, M; Stolnaya, L; Dvorakova, L; Elleder, M; Sikora, J",null,null,null,"Majer, F.; Vlaskova, H.; Krol, L.; Kalina, T.; Kubanek, M.; Stolnaya, L.; Dvorakova, L.; Elleder, M.; Sikora, J.",null,null,"Danon disease: A focus on processing of the novel LAMP2 mutation and comments on the beneficial use of peripheral white blood cells in the diagnosis of LAMP2 deficiency","GENE",null,null,"English","Article",null,null,null,null,null,"Danon disease; Lysosomal-associated membrane protein 2; Cardiomyopathy; White blood cells; Polychromatic flow cytometry; X-chromosome inactivation","X-CHROMOSOME INACTIVATION; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; CHAPERONE-MEDIATED AUTOPHAGY; GLYCOGEN-STORAGE-DISEASE; CLASS-II PRESENTATION; HYPERTROPHIC CARDIOMYOPATHY; CLINICAL INVOLVEMENT; MULTIPLE TISSUES; PROTEIN LAMP-2; FLOW-CYTOMETRY","Danon disease (DD) is a monogenic X-linked disorder characterized by cardiomyopathy, skeletal myopathy and variable degrees of intellectual disability. DD develops due to mutations in the gene encoding lysosomal-associated membrane protein 2 (LAMP2). We report on a family exhibiting the clinical phenotype comprising of hypertrophic cardiomyopathy and ventricular pre-excitation, myopia and mild myopathy in two male patients and cardiomyopathy and myopia in a female patient. The diagnoses of DD in this family was based on the assessment of the clinical phenotypes and the absence of LAMP2 in skeletal and/or cardiac muscle biopsy specimens. Sequence analysis of the LAMP2 gene and its mRNA revealed. a novel LAMP2 mutation (c.940delG) in all three patients. Approximately 25% of the female patient's cardiomyocytes were LAMP2 positive apparently due to she unfavorable skewing of X chromosome inactivation. We further performed qualitative LAMP2 immunohistochemistry on peripheral white blood cells using the smear technique and revealed the absence cif LAMP2 in the male patients. LAMP2 expression was further assessed in granulocytes, CD4 + and CD8 + T lymphocytes, CD20 + B lymphocytes, CD14 + monocytes and CD56 + natural killer cells by quantitative polychromatic flow cytometry. Whereas the male DD patients lacked LAMP2 in all WBC populations, the female patient expressed LAMP2 in 15.1% and 12.8% of monocytes and granulocytes, respectively. LAMP2 expression ratiometrics of highly vs. weakly expressing WBC populations discriminated the DD patients from the healthy controls. WBCs are thus suitable for initial LAMP2 expression testing when DD is a differential diagnostic option. Moreover, flow cytometry represents a quantitative method to assess the skewing of LAMP2 expression in female heterozygotes. Because LAMP2 is a major protein constituent of the membranes of a number of lysosome-related organelles, we also tested the exocytic capacity of the lytic granules from CD8 + T lymphocytes in the patient samples. The degranulation triggered by a specific stimulus (anti-CD3 antibody) was normal. Therefore, this process can be considered LAMP2 independent in human T cells. The c.940delG mutation results in a putatively truncated protein (p.A314QfsX32), which lacks the transmembrane domain and the cytosolic tail of the wild-type LAMP2. We tested whether this variant becomes exocytosed because of a failure in targeting to late endosomes/lysosomes. Western blotting of cardiac muscle, WBCs and cultured skin fibroblasts (and their culture media) showed no intra- or Extracellular truncated LAMP2. By comparing the expression pattern and intracellular targeting in cultured skin fibroblasts of normal LAMP2 isoforms (A, B and C) tagged with green fluorescent protein (GFP) and the A31.4Qfs32-GFP fusion, we found that the A314Qfs32-GFP protein is not even expressed. These observations suggest that the truncated protein is unstable and is co-translationally or early post-translationally degraded. (C) 2012 Elsevier B.V. All rights reserved.","[Majer, F.; Vlaskova, H.; Stolnaya, L.; Dvorakova, L.; Elleder, M.; Sikora, J.] Charles Univ Prague, Fac Med 1, Inst Inherited Metab Disorders, Prague 12808 2, Czech Republic; [Krol, L.; Kalina, T.] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague 15006, Czech Republic; [Kubanek, M.] Inst Clin & Expt Med, Dept Cardiol, Prague 14021, Czech Republic","Sikora, J (reprint author), Charles Univ Prague, Fac Med 1, Inst Inherited Metab Disorders, Ke Karlovu 2, Prague 12808 2, Czech Republic.","jakub.sikora@lf1.cuni.cz",null,null,"International Society of Advancement of Cytometry;  [0021620806];  [IGA MZNS/10342-3/2009];  [IGA MZ NS/9996-4]","This work was supported by the Research Project no. 0021620806 and partly by the grant IGA MZNS/10342-3/2009. T.K. and L.K. were supported by the grant IGA MZ NS/9996-4 and T.K. is supported as \"ISAC Scholar\" by the International Society of Advancement of Cytometry. The authors would further like to acknowledge the following colleagues - Dr. Zamecnik (Department of Pathology and Molecular Medicine, 2nd Medical School, Charles University in Prague), Dr. Snorek (Department of Cardiology, Hospital Ceske Budejovice); Dr. Ridzon (Neurological Clinic, Thomayer University Hospital); Drs. Maluskova and Honsova (Department of Clinical and Transplantation Pathology); Drs. Kotrc and Malek (Department of Cardiology); and Dr. Pirk (Department of Cardiovascular Surgery). All the latter colleagues are from the Institute for Clinical and Experimental Medicine, Prague, Czech Republic.",null,66,2,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0378-1119",null,null,"GENE","Gene","MAY 1",2012,498,2,null,null,null,null,183,195,null,"10.1016/j.gene.2012.02.004",null,13,"Genetics & Heredity","Genetics & Heredity","927EA","WOS:000302888700007"]
[null,null,null,null,"J","Melichercik, P; Jahoda, D; Nyc, O; Klapkova, E; Bartak, V; Landor, I; Pokorny, D; Judl, T; Sosna, A",null,null,null,"Melichercik, P.; Jahoda, D.; Nyc, O.; Klapkova, E.; Bartak, V.; Landor, I.; Pokorny, D.; Judl, T.; Sosna, A.",null,null,"Bone grafts as vancomycin carriers in local therapy of resistant infections","FOLIA MICROBIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"LATE HEMATOGENOUS INFECTION; STAPHYLOCOCCUS-AUREUS; IN-VITRO; CLINICAL-USE; ANTIBIOTICS; ALLOGRAFT; RELEASE","The level of an antibiotic capable of inhibiting the etiological agent at the site of infection is an essential prerequisite for successful antibiotic therapy. In some cases, locally applied antibiotics may compensate for limitations of systemic administration and shorten systemic therapy. We aimed at verifying to what extent vancomycin (Van) bound to ground bone grafts is usable in the treatment of serious infections. The levels of released Van significantly exceeded the Van minimum inhibitory concentration, which can suppress Van-sensitive staphylococci and Van intermediate Staphylococcus aureus, for the whole period of a 16-day measurement. Our results indicate that bone grafts can be used as Van carriers in therapy of osteomyelitis caused by Van-sensitive Staphylococcus strains.","[Melichercik, P.; Jahoda, D.; Bartak, V.; Landor, I.; Pokorny, D.; Judl, T.; Sosna, A.] Charles Univ Prague, Clin Orthoped 1, Fac Med 1, Prague 15006 5, Czech Republic; [Melichercik, P.; Jahoda, D.; Nyc, O.; Klapkova, E.; Bartak, V.; Landor, I.; Pokorny, D.; Judl, T.; Sosna, A.] Motol Fac Hosp, Prague 15006 5, Czech Republic; [Nyc, O.] Charles Univ Prague, Inst Med Microbiol, Fac Med 2, Prague 15006 5, Czech Republic; [Klapkova, E.] Charles Univ Prague, Inst Clin Biochem & Pathobiochem, Fac Med 2, Prague 15006 5, Czech Republic","Jahoda, D (reprint author), Charles Univ Prague, Clin Orthoped 1, Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic.","david.jahoda@post.cz",null,null,"project MZCR [00064203]","The financial support by the project MZCR for conceptual development of research organization 00064203 is gratefully acknowledged.",null,31,1,1,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632",null,null,"FOLIA MICROBIOL","Folia Microbiol.","SEP",2012,57,5,null,null,null,null,459,462,null,"10.1007/s12223-011-0093-2",null,4,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","988RW","WOS:000307509300011"]
[null,null,null,null,"J","Kalo, Z; Landa, K; Dolezal, T; Voko, Z",null,null,null,"Kalo, Z.; Landa, K.; Dolezal, T.; Voko, Z.",null,null,"Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries","EUROPEAN JOURNAL OF CANCER CARE",null,null,"English","Article",null,null,null,null,null,"policy; cancer; health technology assessment; Central-Eastern Europe; National Institute for Health and Clinical Excellence","TECHNOLOGY-ASSESSMENT; ECONOMIC EVALUATIONS; LESSONS; POLICY; COSTS; MODEL","The health burden of malignancies is greater in Central-Eastern Europe than in Western Europe. Furthermore, these countries have more limited healthcare resources, and therefore transparent decision criteria for innovative cancer therapies, including the assessment of cost-effectiveness, are an absolute necessity. Transferability of good-quality technology assessment reports, especially those prepared by National Institute for Health and Clinical Excellence (NICE) in the UK, could be highly beneficial to prevent duplication of efforts and save resources for local technology assessment. Our objective was to summarise key factors influencing the transferability of NICE recommendations in oncology for policy makers and oncologists in Central-Eastern Europe without personal experience in health technology assessment. In general, NICE recommendations are not transferable without adjustment of the analyses to local data. Even if the recommendation is positive, the conclusion can still be negative in lower-income countries, mainly due to relative price differences and the significance of the local budget impact. Technologies with negative NICE recommendations can still be cost-effective in Central-Eastern Europe due to the worse health status and therefore the greater potential health gain of the targeted population. The appropriateness of reimbursement decisions must be improved in Central-Eastern Europe, but copying NICE recommendations without local adjustment may do more harm than good.","[Kalo, Z.] Eotvos Lorand Univ, Fac Social Sci, Inst Econ, Hlth Econ Res Ctr, H-1117 Budapest, Hungary; [Kalo, Z.; Voko, Z.] Syreon Res Inst, Budapest, Hungary; [Landa, K.] Cent & Eastern European Soc Technol Assessment Hl, Krakow, Poland; [Dolezal, T.] Charles Univ Prague, Fac Med 2, Dept Pharmacol, Prague, Czech Republic; [Dolezal, T.] Inst Hlth Econ & Technol Assessment IHETA, Prague, Czech Republic; [Voko, Z.] Eotvos Lorand Univ, Fac Social Sci, Dept Hlth Policy & Hlth Econ, H-1117 Budapest, Hungary","Kalo, Z (reprint author), Eotvos Lorand Univ, Fac Social Sci, Inst Econ, Hlth Econ Res Ctr, Pazmany Peter Setany 1-A, H-1117 Budapest, Hungary.","kalo@tatk.elte.hu","Kalo, Zoltan/G-7582-2011","Kalo, Zoltan/0000-0001-7762-2607","GlaxoSmithKline Ltd","GlaxoSmithKline Ltd provided an unrestricted research grant to Syreon Research Institute to review the transferability of international health technology assessment recommendations. GlaxoSmithKline Ltd had no influence on the review process and was not involved in writing the manuscript. Authors summarised their independent professional opinion and take full responsibility for potential errors in the manuscript.",null,25,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0961-5423",null,null,"EUR J CANCER CARE","Eur. J. Cancer Care","JUL",2012,21,4,null,null,null,null,442,449,null,"10.1111/j.1365-2354.2012.01351.x",null,8,"Oncology; Health Care Sciences & Services; Nursing; Rehabilitation","Oncology; Health Care Sciences & Services; Nursing; Rehabilitation","957BX","WOS:000305134700004"]
[null,null,null,null,"J","Popelova, J; Kotaska, K; Cerny, S; Prokopova, M; Rubacek, M",null,null,null,"Popelova, Jana; Kotaska, Karel; Cerny, Stepan; Prokopova, Milena; Rubacek, Miroslav",null,null,"Range and Distribution of NT-proBNP Values in Stable Corrected Congenital Heart Disease of Various Types","CANADIAN JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"BRAIN NATRIURETIC PEPTIDE; RIGHT-VENTRICULAR FUNCTION; MAGNETIC-RESONANCE; PROGNOSTIC VALUE; FAILURE SYNDROME; GREAT-ARTERIES; ADULTS; DIAGNOSIS; TRANSPOSITION; GUIDELINES","Background: Elevated levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are an expected finding in many adults with congenital heart disease (ACHD) but no reports have described the range of values within different diagnostic groups. Methods: Between the years 2003 and 2011 we measured NT-proBNP in consecutive ACHD patients attending the outpatient department. Further NT-proBNP analysis was performed on 705 blood samples from 394 stable patients with the defect corrected. The results were compared among different diagnostic groups and with a control group of healthy volunteers. Results: The median value of NT-proBNP in the whole cohort was signifinatly higher than in the control group (211 vs 42 pg/mL; P < 0.0001). The median value of NT-proBNP in pg/mL and the percentage of normal NT-proBNP values in the listed diagnostic groups were as follows: coarctation of the aorta (COA), 97 (64%); pulmonary stenosis (PS), 160 (48%); secundum atrial septal defect (ASD), 254 (44%); incomplete atrioventricular septal defect (AVSD), 211 (32%); ventricular septal defect (VSD), 154 (58%); tetralogy of Fallot (TOF), 177 (38%); transposition of the great arteries (TGA) after Mustard, 237 (20%) or Senning correction, 143 (39%); Ebstein anomaly 287, (26%); pulmonary atresia (PA), 327 (18%); and complex defects after Fontan procedure, 184 (31%). Conclusions: Normal levels of NT-proBNP were found most often in patients after the correction of coarctation of the aorta and ventricular septal defect with the highest levels found in pulmonary atresia and Ebstein anomaly. Our results may serve as reference values for different ACHD groups.","[Popelova, Jana; Cerny, Stepan; Rubacek, Miroslav] Hosp Na Homolce, Dept Cardiac Surg, Prague 15030 5, Czech Republic; [Kotaska, Karel] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Hosp Motol, Fac Med 2, Prague, Czech Republic; [Prokopova, Milena] Hosp Na Homolce, Dept Cardiol, Prague 15030 5, Czech Republic","Popelova, J (reprint author), Hosp Na Homolce, Dept Cardiac Surg, Roentgenova 2, Prague 15030 5, Czech Republic.","jana.popelova@homolka.cz",null,null,"Czech Ministry of Health [MZOFNM2005 (VZMZO 64203-6306)]","This article was written with research project support from the Czech Ministry of Health MZOFNM2005 (VZMZO 64203-6306).",null,25,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0828-282X",null,null,"CAN J CARDIOL","Can. J. Cardiol.","JUL-AUG",2012,28,4,null,null,null,null,471,476,null,"10.1016/j.cjca.2012.01.015",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","988PG","WOS:000307502400014"]
[null,null,null,null,"J","Votava, F; Novotna, D; Kracmar, P; Vinohradska, H; Stahlova-Hrabincova, E; Vrzalova, Z; Neumann, D; Malikova, J; Lebl, J; Matern, D",null,null,null,"Votava, Felix; Novotna, Dana; Kracmar, Petr; Vinohradska, Hana; Stahlova-Hrabincova, Eva; Vrzalova, Zuzana; Neumann, David; Malikova, Jana; Lebl, Jan; Matern, Dietrich",null,null,"Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance","EUROPEAN JOURNAL OF PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"Newborn screening; Congenital adrenal hyperplasia; 17-Hydroxyprogesterone; CYP21 gene","21-HYDROXYLASE DEFICIENCY; VALUES","The aims were to summarize the experience and to determine the performance metrics of newborn screening (NBS) for congenital adrenal hyperplasia (CAH) in the Czech Republic. 17-Hydroxyprogesterone (17OHP) was measured in NBS samples prospectively in 545,026 newborns and retrospectively in 31 CAH patients born outside the study period. A total of 2,811 screened newborns had abnormal 17OHP; CAH was confirmed in 46 probands. One patient with a severe-moderate genotype of CAH had 17OHP below the cut-off and was diagnosed clinically. This corresponds to a screening sensitivity of 98% and a false positive rate (FPR) of 0.51%. The median of 17OHP in the most severe genotypes was 484 nmol/L (n = 21); in severe/moderate, 321 nmol/L (n = 30); in moderate, 61 nmol/L (n = 20); and in mild genotypes, 31 nmol/L (n = 7). NBS is efficient to detect severe CAH but may fail to detect milder variants. However, the FPR is too high but could be improved by application of a second tier test.","[Votava, Felix; Kracmar, Petr] Charles Univ Prague, Fac Med 3, Prague 10034 10, Czech Republic; [Votava, Felix; Kracmar, Petr] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Pediat, Prague 10034 10, Czech Republic; [Novotna, Dana] Masaryk Univ, Dept Pediat, Univ Hosp, Brno, Czech Republic; [Novotna, Dana; Vinohradska, Hana; Stahlova-Hrabincova, Eva; Vrzalova, Zuzana; Neumann, David] Masaryk Univ, Fac Med, Brno, Czech Republic; [Vinohradska, Hana] Masaryk Univ, Dept Clin Biochem, Univ Hosp, Brno, Czech Republic; [Stahlova-Hrabincova, Eva; Vrzalova, Zuzana] Masaryk Univ, Ctr Mol Biol & Gene Therapy, Univ Hosp, Brno, Czech Republic; [Neumann, David] Charles Univ Prague, Fac Med, Prague 10034 10, Czech Republic; [Neumann, David] Charles Univ Prague, Dept Pediat, Univ Hosp Hradec Kralove, Prague 10034 10, Czech Republic; [Malikova, Jana; Lebl, Jan] Charles Univ Prague, Fac Med 2, Prague 10034 10, Czech Republic; [Malikova, Jana; Lebl, Jan] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Prague 10034 10, Czech Republic; [Matern, Dietrich] Mayo Clin, Coll Med, Biochem Genet Lab, Rochester, MN USA","Votava, F (reprint author), Charles Univ Prague, Fac Med 3, Srobarova 50, Prague 10034 10, Czech Republic.","votava@fnkv.cz",null,null,"Czech Ministry of Health [9981-3, NT12213]; Czech Ministry of Education [MSM0021620814, MSMT LC06023]","The authors are very grateful to Dr A.M. Wallace, Department of Clinical Biochemistry, Glasgow, Scotland, and Mark McCann, Minnesota Department of Health, St. Paul, Minnesota, USA for 17OHP measurements in NBS samples. The study was supported by the Czech Ministry of Health, project IGA numbers 9981-3 and NT12213 and by the Czech Ministry of Education, project numbers MSM0021620814 and grant numbers MSMT LC06023.",null,20,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,null,"EUR J PEDIATR","Eur. J. Pediatr.","JUN",2012,171,6,null,null,null,null,935,940,null,"10.1007/s00431-011-1656-6",null,6,"Pediatrics","Pediatrics","945WC","WOS:000304306100008"]
[null,null,null,null,"J","Nesnidal, P; Stulik, J; Barna, M",null,null,null,"Nesnidal, P.; Stulik, J.; Barna, M.",null,null,"Spinal Cord Concussion: A Retrospective Study of Twenty-Four Patients","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"spinal cord concussion; spinal cord injury; spinal trauma; SCIWORA","RADIOGRAPHIC ABNORMALITY; INJURY; CHILDREN; PATHOMECHANICS; NEURAPRAXIA; TRAUMA","PURPOSE OF THE STUDY Spinal cord concussion is characterised as fully reversible, temporary inhibition of conductive function due to trauma, without signs of structural changes. Although neurological deficit is usually related to the severity of spinal injury, this is different in spinal cord concussion. The aim of this retrospective study was to evaluate a group of 24 patients with spinal cord concussion, to design a diagnostic algorithm and propose an effective therapy with a good prognosis for the patients. MATERIAL We reviewed clinical records of 9 768 patients hospitalised at the Department of Spinal Surgery, University Hospital in Motol, from September 2002 till December 2010, and of 457 patients treated at other departments of the Hospital between January 2008 and December 2010; this was a total of 10 225 patients. The data were retrospectively analysed and only the patients with a clear history of trauma and subsequent conservative therapy were selected to comprise a group characterised by the generally known criteria of spinal cord concussion: (1) spinal injury with immediate neurological deficit of varying degree; (2) neurological deficit corresponding to the level of spinal injury; (3) recovery of neurological function within 72 hours of injury; (4) no morphological evidence of injury to the spinal structures obtained by imaging methods. This group comprised 24 patients. METHODS The patients were followed up from 6 to 95 months, with a mean of 46 months and a median of 48 months, at intervals of 6 and 12 weeks and 6 and 12 months after injury, and then every following year. The recorded information included the patient's age at the time of injury, their gender, the mechanism of injury, reports on alcohol consumption, the first detected neurological deficit, its development immediately after injury, during the hospital stay and at follow-ups in the out-patient department, methylprednisolone administration according to the National Acute Spinal Cord Injury Study (NASCIS) 2, and findings of imaging methods, particularly MRI. RESULTS Our group consisted of 22 men (91.7%) and two women (8.3%), with an average age of 29 years; the average age was 30 years in men and 18.5 years in women. Seven patients (29.2%) were younger than 18 years, with an average of 16.14 years; the remaining 17 patients (70.8%) were older than 18 years, with an average of 34.35 years. The major mechanisms of injury included falls from a height in 10 patients (41.7%) and injury due to alcohol consumption in five patients (20.1%). Clinical findings involved lesions of the medullary cone in 12 (50.0%), cervical spinal cord in seven (29.2%) and thoracic spinal cord in five (20.8%) patients. Motor function deficit was present in all patients, of whom 10 (41.2%) showed a complete loss of motor function. Impaired sensory function was found in 21 (87.5%) patients. One patient had perianal and genital sensory deficit and one (4.2%) had urinary retention. Neither radiograms nor CT scans showed traumatic changes in any of the patients; MRI findings free of any traumatic spinal changes were recorded in 21 patients (87.5%). One patient had oedema of the T5 and T8 vertebral bodies. No complications were recorded. All patients experienced rapid resolution of neurological deficit, which occurred within 6 hours of injury in two (8.4%), within 12 hours in two (8.4%), within 24 hours in 12 (50.0%) and within 48 hours in six (25.0%) patients, and later than 48 hours after injury in two patients (8.4%). However, recovery always occurred within 72 hours of injury. DISCUSSION A good prognosis for patients with this injury is supported by our findings, because all patients experienced rapid resolution of neurological deficit within 72 hours of injury. This result is in agreement with the relevant international studies reporting no serious complications associated with spinal trauma. There are no clear recommendations for administration of high doses of methylprednisolone according to the NASCIS system. CONCLUSIONS Spinal cord concussion is not a frequent injury; in our study, it accounted for 3.54% of the patients with trauma histories out of the total number of 678 patients, or for 2.40% out of 997 injured spinal levels. The first steps should be the same as in any other injury to the spinal cord. An early examination of the patient with imaging methods including MRI is of primary importance. At present administration of methylprednisolone according to the NASCIS system is disputable. The patient diagnosed with spinal cord concussion has a good prognosis, with rehabilitation as the main therapeutic approach.","[Nesnidal, P.; Stulik, J.; Barna, M.] Spondylochirurg Oddeleni FN Motol, Prague 15006 5, Czech Republic; [Stulik, J.] III Chirurg Klin 1 LF UK Praha, Prague, Czech Republic; [Stulik, J.] Ortoped Klin Deti & Dospelych 2 LF UK Praha, Prague, Czech Republic","Nesnidal, P (reprint author), Spondylochirurg Oddeleni FN Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","pnesnidal@centrum.cz",null,null,null,null,null,33,1,1,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2012,79,2,null,null,null,null,150,155,null,null,null,6,"Orthopedics","Orthopedics","932KB","WOS:000303288900010"]
[null,null,null,null,"J","Kolenova, A; Mejstrikova, E; Fidlerova, K; Fronkova, E; Plank, L; Szepe, P; Jindrova, J; Sejnova, D; Zakoyicova, A; Kaiserova, E",null,null,null,"Kolenova, A.; Mejstrikova, E.; Fidlerova, K.; Fronkova, E.; Plank, L.; Szepe, P.; Jindrova, J.; Sejnova, D.; Zakoyicova, A.; Kaiserova, E.",null,null,"Uncommon leukemic case of anaplastic large cell lymphoma diagnosed through a typical chromosomal abnormality t(2;5) with a null phenotype and aberrant expression of NG2 and CD13","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"anaplastic large cell lymphoma; NG2-chondroitin sulphate proteoglycan neuron-glial antigen 2; ALK- anaplastic lymphoma kinase protein","OF-THE-LITERATURE; ANTIGEN EXPRESSION; PERIPHERAL-BLOOD; CONCERTED ACTION; BONE-MARROW; INVOLVEMENT; PCR; IMMUNOGLOBULIN; REARRANGEMENTS; CHILDHOOD","Anaplastic large cell lymphoma represents approximately 10-15 % of pediatric non-Hodgkin lymphomas. Leukemic presentation is very rare, and in particular, the null phenotype ALCL without typical anaplastic morphology together with aberrant expression of CD13 and/or CD11b represents a diagnostic challenge. We report a case of a 9 year-old boy with leukemic presentation of ALCL with the typical translocation t(2;5) (p23;q35); in this patient, the only positive antigens identified by immunophenotyping were CD13, NG2 HLA-DR, and CD38. To our knowledge, aberrant expression of NG2 has never been reported in ALCL cases (Tab. 1, Fig. 6, Ref. 20) Full Text in PDF www.elis.sk.","[Kolenova, A.; Jindrova, J.; Sejnova, D.] Comenius Univ, Fac Med, Univ Childrens Hosp, Dept Pediat Oncol, Bratislava, Slovakia; [Fidlerova, K.; Zakoyicova, A.; Kaiserova, E.] Natl Inst Oncol, Dept Oncol & Genet, Bratislava, Slovakia; [Plank, L.; Szepe, P.] Jessenius Fac Med, Dept Pathol, Martin, Slovakia; [Mejstrikova, E.; Fronkova, E.] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic","Kolenova, A (reprint author), Zahumenska 3, SK-84601 Bratislava, Slovakia.","sasa.kolenova@gmail.com",null,null,null,null,null,20,1,1,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248",null,null,"BRATISL MED J","Bratisl. Med. J.",null,2012,113,7,null,null,null,null,404,408,null,"10.4149/BLL_2012_091",null,5,"Medicine, General & Internal","General & Internal Medicine","981BS","WOS:000306941100003"]
[null,null,null,null,"J","Patkova, J; Vojtisek, M; Tuma, J; Vozeh, F; Knotkova, J; Santorova, P; Wilhelm, J",null,null,null,"Patkova, Jana; Vojtisek, Max; Tuma, Jan; Vozeh, Frantisek; Knotkova, Jana; Santorova, Pavlina; Wilhelm, Jiri",null,null,"Evaluation of lipofuscin-like pigments as an index of lead-induced oxidative damage in the brain","EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY",null,null,"English","Article",null,null,null,null,null,"Lead; Brain; Oxidative stress; Free radicals; Fluorescence spectra","LIPID-PEROXIDATION; RAT-BRAIN; FREE-RADICALS; EXPOSURE; NEUROTOXICITY; ERYTHROCYTES; LIPOSOMES; TOXICITY; CELLS; LIVER","This study was carried out to investigate the role of lead in the development of oxidative stress in the brain. We examined the rate of lipid peroxidation and we determined lipid fluorescence products (lipofuscin-like pigments - LFP) as a marker of lipid peroxidation after short in vitro incubation of rat brain homogenates with lead acetate (10(-2), 10(-4), 10(-6) M lead acetate, 2 h). Simultaneously we examined by the same method in vivo indices of oxidative stress in brains of mice exposed for 12 weeks to 0.2% lead acetate in drinking water. The results show that the concentration of LFP in rat brain homogenates increased significantly after 2 h incubation with 10(-2) M lead acetate as compared to controls (P < 0.0001). This effect was not observed in lower doses of lead acetate (10(-4) and 10(-6) M). After the long-term exposure of mice to 0.2% lead acetate, pronounced accumulation of lead and significantly increased concentration of LFP (P < 0.004) in the brains of exposed animals as compared to controls were observed. The evidence for the formation of specific fluorophores originating from oxidative damage was shown also in qualitative changes in 3D spectral arrays and synchronous spectra. The presented results proved the influence of lead on the activation of radical reactions in the brain after short in vitro exposure of rat brain as well as within long-term in vivo exposure in mice using lipofuscin-like pigments as an indicator of oxidative stress. (C) 2010 Elsevier GmbH. All rights reserved.","[Patkova, Jana] Charles Univ Prague, Fac Med 3, Dept Nutr, Prague 10000, Czech Republic; [Vojtisek, Max; Knotkova, Jana] Natl Inst Publ Hlth, Prague 10042, Czech Republic; [Tuma, Jan; Vozeh, Frantisek] Charles Univ Prague, Fac Med Pilsen, Dept Pathophysiol, Plzen 30166, Czech Republic; [Santorova, Pavlina; Wilhelm, Jiri] Charles Univ Prague, Fac Med 2, Dept Med Chem & Biochem, Prague 15006, Czech Republic","Patkova, J (reprint author), Charles Univ Prague, Fac Med 3, Dept Nutr, Ruska 87, Prague 10000, Czech Republic.","jpatkova@gmail.com","Tuma, Jan/A-1572-2010; Wilhelm, Jiri/C-6252-2012",null,"Ministry of Education, Youth and Sport of the Czech Republic [VZ MSM 021620816, COST B 30/2007 OC 152]","The work was supported by the research projects VZ MSM 021620816 and by the Grant COST B 30/2007 OC 152 of the Ministry of Education, Youth and Sport of the Czech Republic.",null,31,1,1,"ELSEVIER GMBH, URBAN & FISCHER VERLAG","JENA","OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY","0940-2993",null,null,"EXP TOXICOL PATHOL","Exp. Toxicol. Pathol.","JAN",2012,64,41671,null,null,null,null,51,56,null,"10.1016/j.etp.2010.06.005",null,6,"Pathology; Toxicology","Pathology; Toxicology","875LC","WOS:000299030400008"]
[null,null,null,null,"J","Ehler, E; Novotna, A; Mares, M; Musova, Z; Mrklovsky, M",null,null,null,"Ehler, Edvard; Novotna, Alena; Mares, Miroslav; Musova, Zuzana; Mrklovsky, Milan",null,null,"Myotonic dystrophy type 2 and multiple sclerosis: Case report","CLINICAL NEUROLOGY AND NEUROSURGERY",null,null,"English","Article",null,null,null,null,null,"Myotonic dystrophy; Multiple sclerosis; Magnetic resonance imaging; Oligoclonal bands","MYASTHENIA-GRAVIS",null,"[Ehler, Edvard; Novotna, Alena; Mares, Miroslav] Pardubice Reg Hosp Inc, Neurol Clin, Pardubice 53203, Czech Republic; [Ehler, Edvard; Novotna, Alena; Mares, Miroslav] Univ Pardubice, Fac Hlth Studies, Pardubice 53203, Czech Republic; [Musova, Zuzana] Fac Hosp Motol, Prague 15006 5, Czech Republic; [Mrklovsky, Milan] Pardubice Reg Hosp Inc, Dept Radiol, Pardubice 53203, Czech Republic","Ehler, E (reprint author), Pardubice Reg Hosp Inc, Neurol Clin, Kyjevska 44, Pardubice 53203, Czech Republic.","edvard.ehler@nemocnice-pardubice.cz",null,null,null,null,null,5,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0303-8467",null,null,"CLIN NEUROL NEUROSUR","Clin. Neurol. Neurosurg.","DEC",2012,114,10,null,null,null,null,1358,1360,null,"10.1016/j.clineuro.2012.03.034",null,3,"Clinical Neurology; Surgery","Neurosciences & Neurology; Surgery","046KQ","WOS:000311764300019"]
[null,null,null,null,"J","Guerreiro, H; Vlasak, A; Horinek, D; Tichy, M; Lisy, J; Vanek, P; Liby, P; Hoza, D; Benes, V; Nimsky, C",null,null,null,"Guerreiro, Helena; Vlasak, Ales; Horinek, Daniel; Tichy, Michal; Lisy, Jiri; Vanek, Petr; Liby, Petr; Hoza, David; Benes, Vladimir; Nimsky, Christopher",null,null,"Bobble-head doll syndrome: therapeutic outcome and long-term follow-up in four children","ACTA NEUROCHIRURGICA",null,null,"English","Article",null,null,null,null,null,"Bobble-head doll syndrome; Suprasellar cyst; Neuroendoscopy; Ventriculocystostomy; Ventriculocystocisternostomy","SUPRASELLAR ARACHNOID CYSTS; THIRD VENTRICULAR CYST; SLIT-VALVE MECHANISM; OF-THE-LITERATURE; HYDROCEPHALUS","Bobble-head doll syndrome (BHDS) is a complex syndrome with the dominant symptom of repetitive anteroposterior head movement. Only 57 patients are quoted in the literature. The etiology of this syndrome remains unknown and no standard treatment has yet been established. We hereby report four cases treated at our department. All the patients presented a psychomotor retardation due to an obstructive hydrocephalus. All the patients were treated using neuroendoscopic techniques: two with ventriculocystostomy, and two with ventriculocystocisternostomy. Cyst decompression was achieved in all four cases and clinical recovery was evident in three of the four patients observed. After surgery, BHDS persisted longer the more the subsequent treatment was delayed. In this article, we provide a concise overview of the theories of pathogenesis, presentation, and management of this syndrome. Based on our own experience, we state that the method of choice should be the neuroendoscopy and this must be performed promptly after diagnosis is made.","[Guerreiro, Helena; Horinek, Daniel; Hoza, David] St Anness Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Guerreiro, Helena; Vlasak, Ales; Tichy, Michal; Liby, Petr] Univ Hosp Motol, Dept Neurosurg, Prague, Czech Republic; [Horinek, Daniel; Nimsky, Christopher] Univ Marburg, Dept Neurosurg, Fac Med, Marburg, Germany; [Horinek, Daniel; Vanek, Petr; Benes, Vladimir] Charles Univ Prague, Dept Neurosurg, Fac Med 1, Cent Mil Hosp, Prague, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Dept Radiol, Fac Med 2, Prague, Czech Republic","Guerreiro, H (reprint author), St Anness Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic.","helena_guerreiro@hotmail.com","Nimsky, Christopher/E-3702-2014",null,"European Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]","This project is supported by the European Regional Development Fund-Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123).",null,22,0,0,"SPRINGER WIEN","WIEN","SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA","0001-6268",null,null,"ACTA NEUROCHIR","Acta Neurochir.","NOV",2012,154,11,null,null,null,null,2043,2049,null,"10.1007/s00701-012-1458-2",null,7,"Clinical Neurology; Surgery","Neurosciences & Neurology; Surgery","023YM","WOS:000310073900011"]
[null,null,null,null,"J","Mestak, O; Mestak, J; Pokorna, K; Bruna, J; Sukop, A",null,null,null,"Mestak, Ondrej; Mestak, Jan; Pokorna, Katerina; Bruna, Josef; Sukop, Andrej",null,null,"Unusual regression of severe recurrent lymphatic malformation of a face after contraception and pregnancy","GYNECOLOGICAL ENDOCRINOLOGY",null,null,"English","Article",null,null,null,null,null,"Contraception; face; lymphatic malformation; pregnancy","MANAGEMENT; NECK; HEAD","We report the case of a female who had suffered from progressive lymphatic malformation in the orbito-temporal region since childhood. Many surgical interventions were performed, including radical excision and shunt drainage. Despite aggressive surgical treatment, recurrence was observed after every intervention. Eventually, the condition regressed after the patient began taking a contraceptive. Moreover, it virtually disappeared after pregnancy.","[Mestak, Ondrej; Mestak, Jan] Charles Univ Prague, Fac Med 1, Dept Plast Surg, Prague, Czech Republic; [Pokorna, Katerina] Charles Univ Prague, Fac Med 3, Prague Psychiat Ctr, Prague, Czech Republic; [Bruna, Josef] Charles Univ Prague, Fac Med 2, Dept Radiol, Prague, Czech Republic; [Sukop, Andrej] Charles Univ Prague, Fac Med 3, Dept Plast Surg, Prague, Czech Republic","Mestak, O (reprint author), Budinova 2, Prague 18081 8, Czech Republic.","mestak@gmail.com","Mestak, Ondrej/B-8082-2011","Mestak, Ondrej/0000-0002-3213-1051","Ministry of Health of the Czech Republic [IGA NT 11 382-6/2010]","Research grant IGA NT 11 382-6/2010, Ministry of Health of the Czech Republic.",null,5,0,0,"INFORMA HEALTHCARE","NEW YORK","52 VANDERBILT AVE, NEW YORK, NY 10017 USA","0951-3590",null,null,"GYNECOL ENDOCRINOL","Gynecol. Endocrinol.","OCT",2012,28,10,null,null,null,null,764,766,null,"10.3109/09513590.2012.664190",null,3,"Endocrinology & Metabolism; Obstetrics & Gynecology","Endocrinology & Metabolism; Obstetrics & Gynecology","008HY","WOS:000308949200003"]
[null,null,null,null,"J","Kolasa, K; Kalo, Z; Zah, V; Dolezal, T",null,null,null,"Kolasa, Katarzyna; Kalo, Zoltan; Zah, Vladimir; Dolezal, Tomas",null,null,"Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries","EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH",null,null,"English","Article",null,null,null,null,null,"Central Eastern European countries; health technology assessment; Transparency Directive","COST-EFFECTIVENESS ANALYSIS; DECISION-MAKING; ASSESS PROJECT; THRESHOLDS; CONDUCT; POLAND","A total of 7 years after the addition of Poland, the Czech Republic and Hungary to the EU, the pricing and reimbursement regulations introduced in these countries are still considered to be not fully compliant with Directive 89/105/EEC, commonly referred to as the 'Transparency Directive' (TD). The TD aims to ensure the transparency of the pricing and reimbursement processes for medicinal products established by the member states. Among the most difficult barriers on the way to successful implementation of the TD discussed are meeting the timelines indicated by the TD, the implementation of objective and verifiable criteria for decisions, and the availability of remedies for negative decisions. Health technology assessment (HTA) has been introduced in to the reimbursement systems in Poland, the Czech Republic and Hungary almost simultaneously to their accession to the EU. Even though Central Eastern European (CEE) countries faced similar challenges during the transformation to a democratic system, certain differences in the extent to which HTA principles have been implemented in these countries could be distinguished. Hence, it is thought-provoking to consider the different views of HTA experts on the role of HTA in the adaptation of the TD in the CEE region. The key objective of this article will be to discuss whether the adaptation of HTA principles has supported or only triggered additional challenges in the process of successful implementation of the TD in the CEE region. In particular, the article will discuss whether the introduction of mandatory HTA recommendations or explicit willingness-to-pay threshold would encourage or discourage implementation of the TD. The importance of the independent HTA agency as a condition for successful introduction of the TD will also be debated.","[Kolasa, Katarzyna] Warsaw Med Univ, Dept Pharmacoecon, Warsaw, Poland; [Kalo, Zoltan] Eotvos Lorand Univ, Hlth Econ Res Ctr, Budapest, Hungary; [Zah, Vladimir] ZRx Outcomes Res Inc, Toronto, ON, Canada; [Dolezal, Tomas] Inst Hlth Econ & Technol Assessment, Prague, Czech Republic; [Dolezal, Tomas] Charles Univ Prague, Dept Pharmacol, Fac Med 2, Prague, Czech Republic","Kolasa, K (reprint author), Warsaw Med Univ, Dept Pharmacoecon, Warsaw, Poland.","kkolasa@wum.edu.pl","Kalo, Zoltan/G-7582-2011","Kalo, Zoltan/0000-0001-7762-2607",null,null,null,30,0,0,"EXPERT REVIEWS","LONDON","UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND","1473-7167",null,null,"EXPERT REV PHARM OUT","Expert Rev. Pharmacoecon. Outcomes Res.","JUN",2012,12,3,null,null,null,null,283,287,null,"10.1586/ERP.12.12",null,5,"Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy","Health Care Sciences & Services; Pharmacology & Pharmacy","994NX","WOS:000307938600012"]
[null,null,null,null,"J","Barna, M; Stulik, J; Fencl, F",null,null,null,"Barna, M.; Stulik, J.; Fencl, F.",null,null,"Metatropic Dysplasia as the Cause of Atlantoaxial Instability, Spinal Stenosis and Myelopathy. Case Report and Literature Review","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"metatropic dysplasia; atlantodental dislocation; apnoea; decompression","TERM-FOLLOW-UP; CERVICOMEDULLARY COMPRESSION; DWARFISM; ACHONDROPLASIA; COMPLICATIONS","We present the case of a patient, aged 4 years and 10 months, with metatropic dysplasia. The baby had repeated apnoeic episodes, bradycardia and cardiac arrests and was diagnosed with foramen magnum stenosis and atlantodental dislocation. The episodes were markedly associated with neck movements. Considering this clinical presentation, we performed laminectomy of the atlas, foramen magnum enlargement and decompression followed by dorsal C0-C2 stabilisation with allogeneic bone chips. After the operation, apnoeic episodes did not recur.","[Barna, M.; Stulik, J.] Spondylochirurg Oddeleni FN Motol, Prague 15006 5, Czech Republic; [Stulik, J.] III Chirurg Klin 1 LF UK Praha, Prague, Czech Republic; [Stulik, J.] Ortoped Klin Deti & Dospelych 2 LF UK Praha, Prague, Czech Republic; [Fencl, F.] Pediat Klin 2 LF UK Praha, Prague, Czech Republic","Barna, M (reprint author), Spondylochirurg Oddeleni FN Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","m.barna@email.cz",null,null,null,null,null,18,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2012,79,2,null,null,null,null,169,174,null,null,null,6,"Orthopedics","Orthopedics","932KB","WOS:000303288900014"]
[null,null,null,null,"J","Absolonova, K; Dobisikova, M; Beran, M; Zocova, J; Veleminsky, P",null,null,null,"Absolonova, Karolina; Dobisikova, Miluse; Beran, Michal; Zocova, Jarmila; Veleminsky, Petr",null,null,"The temperature of cremation and its effect on the microstructure of the human rib compact bone","ANTHROPOLOGISCHER ANZEIGER",null,null,"English","Article",null,null,null,null,null,"histomorphometry; human rib; compact bone; burned bone; cremation temperature","ELECTRON-MICROSCOPE OBSERVATIONS; TRANSFORM INFRARED-SPECTROSCOPY; BURNED BONE; FORENSIC ANTHROPOLOGY; DEATH ESTIMATION; AGE ESTIMATION; HUMAN REMAINS; HISTOMORPHOMETRY; DNA","The presented study deals with the effect of the cremation temperature on the microstructure and morphology of the human compact bone. The biological material consisted of samples from ribs of recent Central European origin belonging to individuals of known age, sex and cause of death. Each bone sample was divided into several sections. One section remained unburned and the rest were burned at 700, 800 and 1000 degrees C. A few samples were burned also at the temperature of 600 degrees C. The undecalcified unstained ground cross-sections were made from burned and unburned bones; photographed and analysed using the SigmaScan Pro 5 programme. During burning, both the macroscopic and microscopic dimensions of the bone shrink, including the measures of the individual microstructures. The percentual representation of the area of individual microstructures on the area of the cross-section decreases. The number of individual microstructures per mm(2) of the compact bone cross-section increases. Most microstructural variables demonstrated statistically significant differences at the individual temperatures of cremation. The burned bones showed a large scale of the colours, especially at 700 degrees C.","[Absolonova, Karolina] Charles Univ Prague, Fac Sci, Dept Anthropol & Human Genet, Prague, Czech Republic; [Dobisikova, Miluse; Veleminsky, Petr] Natl Museum, Dept Anthropol, Prague, Czech Republic; [Beran, Michal] Charles Univ Prague, Inst Med Legale, Fac Med 2, Prague, Czech Republic; [Beran, Michal] Charles Univ Prague, Fac Hosp Na Bulovce Prague, Prague, Czech Republic","Absolonova, K (reprint author), Vysehradska 7, Prague 12800 2, Czech Republic.","karolina.absolonova@seznam.cz",null,null,null,null,null,51,0,0,"E SCHWEIZERBARTSCHE VERLAGS","STUTTGART","NAEGELE U OBERMILLER, SCIENCE PUBLISHERS, JOHANNESSTRASSE 3A, D 70176 STUTTGART, GERMANY","0003-5548",null,null,"ANTHROPOL ANZ","Anthropol. Anz.",null,2012,69,4,null,null,null,null,439,460,null,"10.1127/0003-5548/2012/0213",null,22,"Anthropology","Anthropology","047ZR","WOS:000311880500005"]
[null,null,null,null,"J","Nunvar, J; Drevinek, P; Licha, I",null,null,null,"Nunvar, J.; Drevinek, P.; Licha, I.",null,null,"DNA profiling of Stenotrophomonas maltophilia by PCR targeted to its species-specific repetitive palindromic sequences","LETTERS IN APPLIED MICROBIOLOGY",null,null,"English","Article",null,null,null,null,null,"genotyping; polymerase chain reaction; pulsed field gel electrophoresis","FIELD GEL-ELECTROPHORESIS; AMPLIFIED POLYMORPHIC DNA; ARBITRARILY PRIMED PCR; XANTHOMONAS-MALTOPHILIA; GENUS STENOTROPHOMONAS; BACTERIAL GENOMES; CYSTIC-FIBROSIS; STRAINS; IDENTIFICATION; DIVERSITY","Aims: The aim of this study was to develop a simple protocol for a PCR-based fingerprinting of Stenotrophomonas maltophilia (SmrepPCR) that utilizes primers complementary to repetitive extragenic palindromic elements (REPs) of this micro-organism. Methods and Results: The relatedness of 34 isolates of environmental and clinical origin was investigated by two SmrepPCRs with two different primers, gyrB sequencing and Xbal macrorestriction followed by pulsed field gel electrophoresis. While SmrepPCR (with primer DER) results matched data obtained from the analysis of gyrB nucleotide sequences and identified several clonal complexes, Xba/ macrorestriction shovved high level of heterogeneity between isolates. The macrorestriction-based clustering of isolates did not correspond to both gyrB and DIR-SmrepPCR grouping. Conclusions: Our results show that SmrepPCR-inferred relationship of isolates is in a good agreement with sequence based methods. The combined information from all methods used suggests that rapid evolution of S. maltophilia genomes might be predominantly due to high rate of rearrangements caused by mobile genetic elements. Significance and Impact of the Study: The presented method is an inexpensive and easy to perform alternative to genotype S. maitophilia isolates and to study their population genetics. SmrepPCR demonstrates the usefulness of species specific repetitive elements in genomic analyses","[Nunvar, J.; Licha, I.] Charles Univ Prague, Fac Sci, Dept Genet & Microbiol, CR-12844 Prague 2, Czech Republic; [Drevinek, P.] Charles Univ Prague, Fac Med 2, Dept Paediat, CR-12844 Prague 2, Czech Republic; [Drevinek, P.] Univ Hosp Motol, Prague, Czech Republic","Nunvar, J (reprint author), Charles Univ Prague, Fac Sci, Dept Genet & Microbiol, Vinicna 5, CR-12844 Prague 2, Czech Republic.","nunvar@natur.cuni.cz",null,null,"Research Center from the Ministry of Education, Youth and Sports of the Czech Republic [LC06066]; Charles University (SVV) [261214]","The authors would like to thank these who kindly provided their isolates: Maria Brennerova (Institute of Microbiology AS CR, Prague, Czech Republic) for strain env15, Dana Elhottoya (Institute of Soil Biology AS CR, Ceske Budejovice, Czech Republic) for strains env1-env14 and Alexandr Nemec (National Institute of Public Health, Prague, Czech Republic) for strains cli1-1.0 and cf9. We are further indebted to Alexandr Nemec for helpful comments on the manuscript. Tereza Huckova is acknowledged for carrying out preliminary experiments. This work was supported by Research Center LC06066 from the Ministry of Education, Youth and Sports of the Czech Republic and by the Charles University (SVV project no. 261214).",null,32,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0266-8254",null,null,"LETT APPL MICROBIOL","Lett. Appl. Microbiol.","JAN",2012,54,1,null,null,null,null,59,66,null,"10.1111/j.1472-765X.2011.03172.x",null,8,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","861KS","WOS:000298018400009"]
[null,null,null,null,"J","Sobotkova, V; Osecka, T; Jelinek, M; Blatny, M; Hrdicka, M",null,null,null,"Sobotkova, Veronika; Osecka, Terezie; Jelinek, Martin; Blatny, Marek; Hrdicka, Michal",null,null,"Community violence exposure and school bullying and their relationship to antisocial behavior in early adolescence","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"antisocial behavior; exposure to violence; school bullying","NO SAFE HAVEN; PROTECTIVE FACTORS; URBAN YOUTH; CHILDREN; NEIGHBORHOODS; DELINQUENCY; MULTILEVEL; PREDICTOR; RISK","Community violence exposure and school bullying and their relationship to antisocial behavior in early adolescence V. Sobotkova, T. Osecka, M. Jelinek, M. Blatny, M. Hrdlicka Objectives. The study deals with antisocial behavior of school children in urban areas, its typology and relationship to exposure to violence in the community and to school bullying. Subjects and settings. Participants were adolescents participating in international project The Social and Health Assessment (SAHA) that aims to assess risk and protective factors for psychosocial adjustment of children and youth. The sample consisted of 12 year-old and 14-year-old students from schools in 13 regional capitals. The sample consisted of 2.973 persons (53 % girls, mean age 13.5 years, SD = 1.1): 12 years old cohort consisting of 1.447 adolescents - 54 % of girls; 14 years old cohort consisting of 1.526 adolescents - 53 % of girls. SAHA was used to measure antisocial behavior, exposure to violence and school bullying. Hypothesis. Created empirical types of adolescents with varying degrees of antisocial behavior differ in violence exposure, types with higher levels of antisocial behavior are exposed to a greater extent to violence and lower extent to bullying as objects. Statistical analysis. Non-hierarchical cluster analysis (k-means) to identify four types of antisocial behavior. Types comparision in violence exposure and bullying (Kruskal-Wallis test, Dunn post-hoc tests). Results. Authors found relationships between exposure to violence (community and bullying) and the type of behavior (exposure to violence as a witness (chi(2) = 265.7, df = 3, p<0.01), exposure to violence as a victim (chi(2) = 236.6, df = 3, p<0.01); object of bullying (chi(2) = 263.4, df = 3, p<0.01). The highest rates of exposure to violence in all three variables have adolescents with the highest rates of antisocial behavior. Study limitation. Bullying from aggressor's point of view and cyberbullying were not analysed.","[Sobotkova, Veronika; Osecka, Terezie; Jelinek, Martin; Blatny, Marek] Psychol Ustav AV CR, Brno 60200, Czech Republic; [Hrdicka, Michal] LF UK & FN Motol, Detska Psychiat Klin 2, Prague, Czech Republic","Sobotkova, V (reprint author), Psychol Ustav AV CR, Veveri 97, Brno 60200, Czech Republic.","veronika@psu.cas.cz",null,null,null,null,null,44,0,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X","1804-6436",null,"CESK PSYCHOL","Cesk. Psychol.",null,2012,56,5,null,null,null,null,409,419,null,null,null,11,"Psychology, Multidisciplinary","Psychology","042KF","WOS:000311469400002"]
[null,null,null,null,"J","Sramek, J; Kryl, J; Sebesta, P",null,null,null,"Sramek, J.; Kryl, J.; Sebesta, P.",null,null,"An Extensive Epidural Abscess of Cervicothoracic Spine Resolved by a Combined Approach - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"English","Article",null,null,null,null,null,"spinal epidural abscess; combined approach","SURGICAL-TREATMENT","This case report describes a methodology for removal of epidural abscess located at the anterior side of spinal canal with tetraplegia AIS (ASIA - American Spinal Injury Association Impairment Scale) grade B. The abscess was first evacuated by the anterolateral Smith-Robinson approach using Caspar distractor. No other instrumentation was used. T6-T7 laminectomy and decompression was performed two weeks later to manage residual abscess. This improved motor strength to AIS grade D. MRI examination confirmed that the abscess was completely healed without postlaminectomic kyphosis. The anterior approach eliminated a risk of cervical spine kyphosis.","[Sramek, J.] ProSpine Clin, Bogen, Germany; [Sramek, J.] Czech Tech Univ, Fac Biomed Ingeneering, CR-16635 Prague, Czech Republic; [Kryl, J.] Teaching Hosp Motol, Dept Spinal Surg, Prague, Czech Republic","Sramek, J (reprint author), Smeralova 359-17, Prague 17000 7, Czech Republic.","jiri.sramek@spinesurgery.cz",null,null,null,null,null,14,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,3,null,null,null,null,378,380,null,null,null,3,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","966EH","WOS:000305819900018"]
[null,null,null,null,"J","Stehlik, D; Pytlik, R; Rychtrmocova, H; Kideryova, L; Vesela, R; Kopecny, Z; Trc, T; Trneny, M",null,null,null,"Stehlik, D.; Pytlik, R.; Rychtrmocova, H.; Kideryova, L.; Vesela, R.; Kopecny, Z.; Trc, T.; Trneny, M.",null,null,"Xenogeneic Protein-Free Cultivation of Mesenchymal Stromal Cells - Towards Clinical Applications","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,"BMP; cell therapy; multipotent mesenchymal stromal cells; growth factors; EGF; PDGF; M-CSF; IFGF; differentiation; orthopaedic surgery","VERSUS-HOST-DISEASE; STEM-CELLS; BONE-MARROW; IN-VITRO; PDGF-BB; GROWTH; DIFFERENTIATION; CULTURE; RETENTION; THERAPIES","We have studied a rapid cultivation method for human mesenchymal stromal cells based on CellGro (TM) medium and human serum, supplemented with insulin, ascorbic acid, dexamethasone, epidermal growth factor, platelet-derived growth factor BB, macrophage colony-stimulating factor and fibroblast growth factor 2. This study has shown that rapid expansion of human multipotent mesenchymal stromal cells using human serum could not be achieved without addition of growth factors. Furthermore, we have found that insulin and, quite probably, epidermal growth factor may be omitted from our formula without loss of colony-forming capacity or total cell yield. On the other hand, dexamethasone, ascorbic acid and fibroblast growth factor 2 were necessary for the growth and colony-forming capacity of multipotent mesenchymal stromal cells, while platelet-derived growth factor BB prevented their differentiation into adipogenic lineage. Moreover, multipotent mesenchymal stromal cells cultivated in our system expressed higher levels of bone morphogenetic protein 2, but not bone morphogenetic protein 7, than cells cultivated in alpha-MEM with foetal bovine serum. This shows that our system promotes differentiation of mesenchymal cells towards osteogenic and chondrogenic lineages, making them more suitable for bone and cartilage engineering than cells grown in conventional media. Furthermore, we have proved that these cells may be conveniently cultivated in a closed system, in vessels certified for clinical use (RoboFlask (TM)), making the transfer of our cultivation technology to good clinical practice easier and more convenient.",null,"Stehlik, D (reprint author), Charles Univ Prague, Fac Med 2, Dept Children & Adult Orthopaed Surg, V Uvalu 84, Prague 15600 5, Czech Republic.","stehlikd@seznam.cz",null,null,"Ministry of Health of the Czech Republic [NT/13531-4]","This work was exclusively supported by grant NT/13531-4 from the Ministry of Health of the Czech Republic.",null,39,0,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2012,58,3,null,null,null,null,106,114,null,null,null,9,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","969ZR","WOS:000306098400003"]
[null,null,null,null,"J","Latta, J; Zamecnik, J; Ehler, E",null,null,null,"Latta, J.; Zamecnik, J.; Ehler, E.",null,null,"Paraneoplastic Polymyositis - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"dysphagia; neck muscles weakness; EMG; creatinkinase; muscle biopsy; paraneoplastic polymyositis","INFLAMMATORY MYOPATHIES; CANCER; DIAGNOSIS","Clinical findings, biochemical results and EMG investigation are important in the diagnosis of myopathy, and muscle biopsy is unavoidable for its further differentiation. In an older man with muscle pain and rapid development of muscle weakness with head-drop and dysphagia, polymyositis with focal endomysial CD8+ lymphocytic infiltrates was diagnosed on muscle biopsy. Once the patient had been hospitalized, an advanced carcinoma of the prostate and anti-Ri paraneoplastic antibodies were found. A paraneoplastic polymyositis was diagnosed, which is a rare diagnosis in patients with prostate cancer.","[Latta, J.; Ehler, E.] Neurol Klin FZS UP & Pardubicka Krajska Nemocnice, Pardubice 53003, Czech Republic; [Zamecnik, J.] 2 LF UK & FN Motole, Ustav Patol & Mol Med, Prague, Czech Republic","Latta, J (reprint author), Neurol Klin FZS UP & Pardubicka Krajska Nemocnice, Kyjevska 44, Pardubice 53003, Czech Republic.","janci82@gmail.com",null,null,null,null,null,22,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,1,null,null,null,null,80,83,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","902HF","WOS:000301028500012"]
[null,null,null,null,"J","Bolcha, M; Bartos, R; Mrazkova, L; Sames, M",null,null,null,"Bolcha, M.; Bartos, R.; Mrazkova, L.; Sames, M.",null,null,"A Dorsal Neurenteric Cyst of the Craniocervical Junction - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"English","Article",null,null,null,null,null,"neurenteric cyst; craniocervical junction; medullary compression; enterogenous cyst; spinal dysraphism","CRANIOVERTEBRAL JUNCTION; CERVICAL-SPINE; MR","A neurenteric cyst (NEC) is a very rare diagnosis. These congenital lesions are defined as cysts lined by mucin-secreting epithelium, resembling that of the gastrointestinal tract. A neurenteric cyst can develop anywhere along the neuraxis, although it is predominantly found at the lower cervical and upper thoracic spinal level. The goal of surgical treatment is complete excision of the cyst, including its capsule. The authors present a case report and a review of all published similar cases.","[Bolcha, M.; Bartos, R.; Sames, M.] Univ JE Purkyne, Masaryk Hosp, Dept Neurosurg, Usti Nad Labem 40113, Czech Republic; [Mrazkova, L.] Masaryk Hosp, Dept Radiol, Usti Nad Labem, Czech Republic","Bolcha, M (reprint author), Univ JE Purkyne, Masaryk Hosp, Dept Neurosurg, Socialni Pece 3316-12A, Usti Nad Labem 40113, Czech Republic.","martin.bolcha@mnul.cz",null,null,null,null,"AGNOLI AL, 1984, J NEUROSURG, V61, P834, DOI 10.3171/jns.1984.61.5.0834; BREEZE RE, 1990, J NEUROSURG, V73, P788, DOI 10.3171/jns.1990.73.5.0788; BROOKS BS, 1993, AM J NEURORADIOL, V14, P735; Chaynes P, 1998, NEURORADIOLOGY, V40, P374; Clare I, 2006, Australas Radiol, V50, P59, DOI 10.1111/j.1440-1673.2005.01535.x; Filho F L, 2001, J Neurosurg, V94, P129, DOI 10.3171/spi.2001.94.1.0129; FRIEDBURG H, 1986, FORTSCHR RONTG NEUEN, V145, P315; Fuse T, 1998, SURG NEUROL, V50, P431, DOI 10.1016/S0090-3019(97)00280-2; Joynt RJ, 1992, CLIN NEUROLOGY, P31; Kim CY, 1999, CHILD NERV SYST, V15, P333; Kimura H, 2006, ACTA NEUROCHIR, V148, P347, DOI 10.1007/s00701-005-0714-0; MACDONALD RL, 1991, NEUROSURGERY, V28, P583; MACKENZIE IRA, 1991, J NEUROL NEUROSUR PS, V54, P572, DOI 10.1136/jnnp.54.7.572; Menezes AH, 2006, NEUROSURGERY, V58, P97, DOI 10.1227/01.NEU.0000192160.79897.25; Puusepp M., 1934, REV NEUROL, V2, P879; RODACKI MA, 1987, NEURORADIOLOGY, V29, P588; Wagner HJ, 1998, NEUROPEDIATRICS, V29, P212, DOI 10.1055/s-2007-973563; Weiss MA, 1996, AM J NEURORADIOL, V17, P386; Zahos PA, 1996, J SPINAL DISORD, V9, P536; Zulch KJ, 1979, HISTOLOGICAL TYPING",20,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,3,null,null,null,null,363,367,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","966EH","WOS:000305819900015"]
[null,null,null,null,"J","Babula, P; Masarik, M; Adam, V; Eckschlager, T; Stiborova, M; Trnkova, L; Skutkova, H; Provaznik, I; Hubalek, J; Kizek, R",null,null,null,"Babula, Petr; Masarik, Michal; Adam, Vojtech; Eckschlager, Tomas; Stiborova, Marie; Trnkova, Libuse; Skutkova, Helena; Provaznik, Ivo; Hubalek, Jaromir; Kizek, Rene",null,null,"Mammalian metallothioneins: properties and functions","METALLOMICS",null,null,"English","Review",null,null,null,null,null,null,"INHIBITORY FACTOR METALLOTHIONEIN-3; BREAST-CANCER CELLS; ARRAYS IDENTIFY METALLOTHIONEIN-3; CADMIUM CHLORIDE INTOXICATION; INDUCED OXIDATIVE STRESS; METAL-THIOLATE CLUSTERS; HYPOXIA-INDUCIBLE GENE; TRANSCRIPTION-FACTOR-I; ASCITES TUMOR-CELLS; FACTOR-KAPPA-B","Metallothioneins (MT) are a family of ubiquitous proteins, whose role is still discussed in numerous papers, but their affinity to some metal ions is undisputable. These cysteine-rich proteins are connected with antioxidant activity and protective effects on biomolecules against free radicals, especially reactive oxygen species. In this review, the connection between zinc(II) ions, reactive oxygen species, heavy metal ions and metallothioneins is demonstrated with respect to effect of these proteins on cell proliferation and a possible negative role in resistance to heavy metal-based and non-heavy metal-based drugs.","[Babula, Petr; Masarik, Michal; Adam, Vojtech; Trnkova, Libuse; Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Babula, Petr] Univ Vet & Pharmaceut Sci Brno, Fac Pharm, Dept Nat Drugs, CZ-61242 Brno, Czech Republic; [Masarik, Michal] Fac Med, Dept Pathol Physiol, CZ-62500 Brno, Czech Republic; [Adam, Vojtech; Hubalek, Jaromir; Kizek, Rene] Mendel Univ, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Trnkova, Libuse] Fac Sci, Dept Chem, CZ-62500 Brno, Czech Republic; [Skutkova, Helena; Provaznik, Ivo] Brno Univ Technol, Fac Elect Engn & Commun, Dept Biomed Engn, CZ-61200 Brno, Czech Republic; [Hubalek, Jaromir] Brno Univ Technol, Fac Elect Engn & Commun, Dept Microelect, CZ-61200 Brno, Czech Republic","Kizek, R (reprint author), Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic.","kizek@sci.muni.cz","Masarik, Michal/D-9920-2012; Adam, Vojtech/D-7686-2012; Hubalek, Jaromir/D-7753-2012; Provaznik, Ivo/F-4121-2012; Skutkova, Helena/D-5194-2014",null,"CEITEC [CZ.1.05/1.1.00/02.0068]; CYTORES GA CR [P301/10/0356]; NANOSEMED GA AV [KAN208130801]; NanoBioTECell GA CR [102/11/1068]","Financial support from CEITEC CZ.1.05/1.1.00/02.0068, CYTORES GA CR P301/10/0356, NANOSEMED GA AV KAN208130801 and NanoBioTECell GA CR 102/11/1068 is gratefully acknowledged.",null,214,18,18,"ROYAL SOC CHEMISTRY","CAMBRIDGE","THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND","1756-5901",null,null,"METALLOMICS","Metallomics",null,2012,4,8,null,null,null,null,739,750,null,"10.1039/c2mt20081c",null,12,"Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","979WX","WOS:000306854900002"]
[null,null,null,null,"J","Gumulec, J; Masarik, M; Krizkova, S; Hlavna, M; Babula, P; Hrabec, R; Rovny, A; Masarikova, M; Sochor, J; Adam, V; Eckschlager, T; Kizek, R",null,null,null,"Gumulec, J.; Masarik, M.; Krizkova, S.; Hlavna, M.; Babula, P.; Hrabec, R.; Rovny, A.; Masarikova, M.; Sochor, J.; Adam, V.; Eckschlager, T.; Kizek, R.",null,null,"Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"cancer; tumor marker; immunodetection; electrochemistry; polymerase chain reaction; mRNA","TUMOR-CELL LINES; BRDICKA REACTION; MESSENGER-RNA; BLOOD-SERUM; EXPRESSION; CARCINOMA; PSA; CARCINOGENESIS; BIOMARKERS; CADMIUM","Current diagnostic techniques are inefficient in distinguishing latent and low-risk forms of prostate cancer from high-risk forms. The present study is focused on determination of putative tumor markers of aggressive high-grade forms of prostate cancer. Potential markers were determined in blood sera of 133 patients (82 cases and 51 controls) and in cell lines (Gleason score 9-derived 22Rv1 and normal tissue derived PNT1A) on mRNA and protein levels. Alpha-methylacyl-CoA racemase (AMACR), metallothionein classes 1A and 2A (MT1A and MT2A) were determined and compared to prostate specific antigen (PSA) levels. On mRNA level, significantly increased expression of MT2A (2.4-fold), PSA (2.6-fold) and AMACR (8.4-fold) and insignificantly (1.9-fold) elevated MT1A in 22Rv1 compared to non-tumor PNT1A were determined. On protein level, significant enhancement of free PSA and total PSA in tumor cell line was evident. AMACR protein was 1.5-fold elevated in tumor line (below the level of significance). Contrary to mRNA, significantly (p = 0.01) reduced level of MT protein in tumor lines was determined. In the case of serum level, significantly enhanced MT level (4.5-fold) in patients' sera was found. No significant changes were observed in the case of AMACR. These findings indicate possible alternative role of MT to PSA prostate cancer marker. In addition, level of AMACR is distinctly higher in the Gleason score 9 in serum of patients and MT shows a descending trend in relation to Gleason score.","[Gumulec, J.; Masarik, M.; Krizkova, S.; Babula, P.; Masarikova, M.; Sochor, J.; Adam, V.; Kizek, R.] Mendel Univ Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Gumulec, J.; Masarik, M.; Hlavna, M.] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-62500 Brno, Czech Republic; [Gumulec, J.; Masarik, M.; Krizkova, S.; Babula, P.; Masarikova, M.; Sochor, J.; Adam, V.; Kizek, R.] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Hrabec, R.; Rovny, A.] St Annes Univ Hosp Brno, Dept Urol, CZ-65691 Brno, Czech Republic; [Eckschlager, T.] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, T.] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Sochor, Jiri/E-1135-2012; Krizkova, Sona/E-9617-2012; Gumulec, Jaromir/D-7638-2012","Gumulec, Jaromir/0000-0002-9658-3444","IGA MZ [NS10200-3]","Financial support from IGA MZ NS10200-3 is greatly acknowledged.",null,72,14,16,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2012,59,2,null,null,null,null,191,200,null,"10.4149/neo_2012_025",null,10,"Oncology","Oncology","902ZW","WOS:000301083700010"]
[null,null,null,null,"J","Turner, D; Levine, A; Escher, JC; Griffiths, AM; Russell, RK; Dignass, A; Dias, JA; Bronsky, J; Braegger, CP; Cucchiara, S; de Ridder, L; Fagerberg, UL; Hussey, S; Hugot, JP; Kolacek, S; Kolho, KL; Lionetti, P; Pcerregaard, A; Potapov, A; Rintala, R; Serban, DE; Staiano, A; Sweeny, B; Veerman, G; Veres, G; Wilson, DC; Ruemmele, FM",null,null,null,"Turner, Dan; Levine, Arie; Escher, Johanna C.; Griffiths, Anne M.; Russell, Richard K.; Dignass, Axel; Dias, Jorge Amil; Bronsky, Jiri; Braegger, Christian P.; Cucchiara, Salvatore; de Ridder, Lissy; Fagerberg, Ulrika L.; Hussey, Seamus; Hugot, Jean-Pierre; Kolacek, Sanja; Kolho, Kaija Leena; Lionetti, Paolo; Pcerregaard, Anders; Potapov, Alexander; Rintala, Risto; Serban, Daniela E.; Staiano, Annamaria; Sweeny, Brian; Veerman, Gigi; Veres, Gabor; Wilson, David C.; Ruemmele, Frank M.",null,null,"Management of Pediatric Ulcerative Colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines","JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION",null,null,"English","Article",null,null,null,null,null,"children; clinical guidelines; European Crohn's and Colitis Organization; European Society for Paediatric Gastroenterology; Hepatology, and Nutrition, management; Pediatric Ulcerative Colitis Activity Index; ulcerative colitis","INFLAMMATORY-BOWEL-DISEASE; POUCH-ANAL ANASTOMOSIS; PRIMARY SCLEROSING CHOLANGITIS; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; ORAL 5-AMINOSALICYLIC ACID; CONTROLLED MULTICENTER TRIAL; DOSE URSODEOXYCHOLIC ACID; POPULATION-BASED COHORT; BONE-MINERAL DENSITY","Background and Aims: Pediatric ulcerative colitis (UC) shares many features with adult-onset disease but there are some unique considerations; therefore, therapeutic approaches have to be adapted to these particular needs. We aimed to formulate guidelines for managing UC in children based on a systematic review (SR) of the literature and a robust consensus process. The present article is a product of a joint effort of the European Crohn's and Colitis Organization (ECCO) and the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). Methods: A group of 27 experts in pediatric IBD participated in an iterative consensus process including 2 face-to-face meetings, following an open call to ESPGHAN and ECCO members. A list of 23 predefined questions were addressed by working subgroups based on a SR of the literature. Results: A total of 40 formal recommendations and 68 practice points were endorsed with a consensus rate of at least 89% regarding initial evaluation, how to monitor disease activity, the role of endoscopic evaluation, medical and surgical therapy, timing and choice of each medication, the role of combined therapy, and when to stop medications. A management flowchart, based on the Pediatric Ulcerative Colitis Activity Index (PUCAI), is presented. Conclusions: These guidelines provide clinically useful points to guide the management of UC in children. Taken together, the recommendations offer a standardized protocol that allows effective, timely management and monitoring of the disease course, while acknowledging that each patient is unique.","[Turner, Dan] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Jerusalem, Israel; [Levine, Arie] Tel Aviv Univ, Wolfson Med Ctr, IL-69978 Tel Aviv, Israel; [Escher, Johanna C.; de Ridder, Lissy] ErasmusMC Sophia Childrens Hosp, Rotterdam, Netherlands; [Griffiths, Anne M.] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Russell, Richard K.] Yorkhill Hosp, Glasgow, Lanark, Scotland; [Dignass, Axel] Agaples Markus Hosp, Frankfurt, Germany; [Dias, Jorge Amil] Hosp Sao Joao, Oporto, Portugal; [Bronsky, Jiri] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Bronsky, Jiri] Univ Hosp Motol, Prague, Czech Republic; [Braegger, Christian P.] Univ Childrens Hosp, Zurich, Switzerland; [Cucchiara, Salvatore] Univ Roma La Sapienza, Pediat Gastroenterol & Liver Unit, Rome, Italy; [Fagerberg, Ulrika L.] Karolinska Inst, Clin Res Ctr, Vastmanland Cty Hosp, Stockholm, Sweden; [Hussey, Seamus] Our Ladys Hosp Sick Children, Crumlin Dublin, Ireland; [Hugot, Jean-Pierre] Univ Paris 04, Hop Robert Debre, Paris, France; [Kolacek, Sanja] Univ Zagreb, Sch Med, Childrens Hosp, Med Ctr Sestre Milosrdnice, Zagreb 41000, Croatia; [Kolho, Kaija Leena] Univ Helsinki, Childrens Hosp, Helsinki, Finland; [Kolho, Kaija Leena] Univ Helsinki, FIN-00014 Helsinki, Finland; [Lionetti, Paolo] Univ Florence, Meyer Hosp, Florence, Italy; [Pcerregaard, Anders] Hvidovre Univ Hosp, Copenhagen, Denmark; [Potapov, Alexander] Childrens Hlth Russian Acad Med Sci, Moscow, Russia; [Serban, Daniela E.] Univ Med & Pharm Iuliu Hatieganu, Cluj Napoca, Romania; [Staiano, Annamaria] Univ Naples Federico II, Naples, Italy; [Sweeny, Brian] UZ Brussels, Brussels, Belgium; [Veerman, Gigi] Semmelweis Univ, Budapest, Hungary; [Veres, Gabor] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland; [Ruemmele, Frank M.] Univ Paris 04, Hop Necker Enfants Malad, APHP, Paris, France","Turner, D (reprint author), Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Jerusalem, Israel.","tumerjd2001@gmail.com","de Ridder, Lissy/A-1897-2013",null,"NHS Research Scotland; Catherine McEwan Foundation; Yorkhill IBD fund; MSD; Abbott; Dr Falk; Ferring; Nestle; Centocor; Janssen; Merck; Shire; Janssen Biologics; Advisory Board for MSD; Advisory Board for Abbott; Tillotts AB; Otsuka Pharma Scandinavia AB; Schering-Plough AB; Tillotts Pharma; Hospital for Sick Children (PUCAI royalties); Proctor Gamble; Johnson Johnson; Falk; Biocodex; Danone; Falk Foundation; Meadjohnson","R.K.R. is supported by a NHS Research Scotland career fellowship award. The work of the IBD team at Yorkhill, Glasgow, was supported by the Catherine McEwan Foundation and the Yorkhill IBD fund. R.K.R. received consultation fee, research grant, or honorarium, from MSD, Abbott, Dr Falk, Ferring, and Nestle; A.M.G. received consultation fee, research support, or speaking fee from Centocor, Janssen, Merck, Abbott, and Shire; J.C.E. received consultation fee and research grant from MSD and Janssen Biologics; J.A.D. received consultation fee from Advisory Boards for MSD, Abbott; L.d.R. received consultation fee from MSD and Shire; J.B. received consultation fee from MSD; U.L.F. received lecture fee or travel grant from Tillotts AB, Otsuka Pharma Scandinavia AB, and Schering-Plough AB; A.P. received speaker's fee from MSD, and is a consultant for Swedish Orphan Biovitrum (Shire); K.L.K. received consultation fee from Abbott, MSD, and Tillotts Pharma; A.D. served as scientific advisory member for Ferring, MSD, Centocor, Abbott, UCB, PDL, Shire, and received lecture honoraria from Ferring, Falk Foundation, MSD, Merckle Recordati, Abbott, UCB, Shire, Otsuka, Vifor, and Immundiagnostik; S.K. received honorarium from MSD, Abbott, Nestle, and Nutricia; D.T. received consultation fee, research grant, or honorarium, from MSD, Shire, Janssen, Hospital for Sick Children (PUCAI royalties), Proctor & Gamble, and Johnson & Johnson; A.L. received consultation fee, research grants, or honoraria, from MSD, Falk, Janssen, and Nestle; G.V. is a consultant to MSD, Shire, and Danone; D.C.W. received consultation fees or honoraria from MSD, Abbott, Ferring, and Nestle; F.M.R. received consultation fees, research grants, or lecture honoraria from Abbott, Biocodex, Centocor, Danone, Falk Foundation, Ferring, Johnson & Johnson, Meadjohnson, MSD, Nestle, and Shire.",null,266,12,12,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0277-2116",null,null,"J PEDIATR GASTR NUTR","J. Pediatr. Gastroenterol. Nutr.","SEP",2012,55,3,null,null,null,null,340,361,null,"10.1097/MPG.0b013e3182662233",null,22,"Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","998YS","WOS:000308276900024"]
[null,null,null,null,"J","de Bie, CI; Buderus, S; Sandhu, BK; de Ridder, L; Paerregaard, A; Veres, G; Dias, JA; Escher, JC",null,null,null,"de Bie, Charlotte I.; Buderus, Stephan; Sandhu, Bhupinder K.; de Ridder, Lissy; Paerregaard, Anders; Veres, Gabor; Dias, Jorge Amil; Escher, Johanna C.",null,"EUROKIDS Porto IBD Working Grp ESP","Diagnostic Workup of Paediatric Patients With Inflammatory Bowel Disease in Europe: Results of a 5-Year Audit of the EUROKIDS Registry","JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION",null,null,"English","Article",null,null,null,null,null,"diagnostic workup; diagnostic yield; inflammatory bowel disease; OGD; paediatrics","POLYP SURVEILLANCE GUIDELINES; CROHNS-DISEASE; MR ENTEROGRAPHY; CT ENTEROGRAPHY; TERMINAL ILEUM; CHILDREN; POPULATION; COLONOSCOPY; ADHERENCE; IBD","Objective: In 2005, the Inflammatory Bowel Disease (IBD) Working Group of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition published consensus guidelines on the diagnostic workup of paediatric IBD, the Porto criteria. According to these guidelines, children suspected of having IBD should undergo an oesophagogastroduodenoscopy (OGD), ileocolonoscopy, and (except in cases of definitive ulcerative colitis) adequate imaging of the small bowel. To audit and evaluate the diagnostic workup of paediatric patients with IBD in Europe, the Working Group created EUROKIDS, a prospective, Web-based registry of newly diagnosed paediatric patients with IBD. Methods: Patients with IBD (ages 0-18 years) were registered in 44 centres in 18 countries. Data on diagnostic workup were analysed according to the year of diagnosis, type of IBD, and centre size. Diagnostic yield of OGD and ileal intubation were evaluated. Results: Between 2004 and 2009, 2087 newly diagnosed patients were correctly registered. Both OGD and ileocolonoscopy had been performed in 64% of all of the patients and increased significantly from year 1 (52 %) to 5 (71%, P<0.001). Small-bowel follow-through use decreased during the years (year 1 n = 213, year 5 n=108; P<0.001), whereas magnetic resonance imaging use increased (year 1 n = 25, year 5 n = 171; P<0.001). Patients diagnosed as having Crohn disease (CD, 59%) and ulcerative colitis (58%) were more likely to have had a complete diagnostic workup than patients diagnosed as having IBD unclassified (45%). In CD, the diagnostic yield of OGD was 7.5% and the yield of ileal intubation was 13%. Conclusions: The quality of diagnostic workup in paediatric patients with IBD increased steadily between 2004 and 2009. Small-bowel imaging by magnetic resonance imaging superseded the use of small-bowel follow-through. OGD and ileal intubation contributed to a definitive diagnosis of CD.","[de Bie, Charlotte I.; de Ridder, Lissy; Escher, Johanna C.] Erasmus MC Sophia Childrens Hosp, Dept Paediat Gastroenterol, NL-3015 GJ Rotterdam, Netherlands; [Buderus, Stephan] St Marien Hosp, Dept Paediat, Bonn, Germany; [Sandhu, Bhupinder K.] Royal Hosp Children, Dept Paediat Gastroenterol, Bristol, Avon, England; [Paerregaard, Anders] Hvidovre Univ Hosp, Dept Paediat, Copenhagen, Denmark; [Veres, Gabor] Semmelweis Univ, Dept Paediat 1, Budapest, Hungary; [Dias, Jorge Amil] Hosp Sao Joao, Dept Paediat, Oporto, Portugal","Escher, JC (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Paediat Gastroenterol, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.","j.escher@erasmusmc.nl","de Ridder, Lissy/A-1897-2013",null,"ESPGHAN","The EUROKIDS project received financial support from ESPGHAN.","Albert JG, 2005, GUT, V54, P1721, DOI 10.1136/gut.2005.069427; Auvin S, 2005, J PEDIATR GASTR NUTR, V41, P49, DOI 10.1097/01.MPG.0000162479.74277.86; Batres LA, 2002, J PEDIATR GASTR NUTR, V35, P320, DOI 10.1097/01.MPG.0000025355.04164.17; Benchimol EI, 2009, GUT, V58, P1490, DOI 10.1136/gut.2009.188383; Bousvaros A, 2007, J PEDIAT GASTROENTER, V44, P653; De Matos V, 2008, J PEDIATR GASTR NUTR, V46, P392, DOI 10.1097/MPG.0b013e31812e95e1; Heyman MB, 2005, J PEDIATR, V146, P35, DOI 10.1016/j.jpeds.2004.08.043; Horsthuis K, 2010, J PEDIATR GASTR NUTR, V51, P603, DOI 10.1097/MPG.0b013e3181dee5bd; IBD Working Group of the European Society for Paediatric Gastroenterology, 2005, J PEDIAT GASTROENTER, V41, P1; Jakobsen C, 2011, INFLAMM BOWEL DIS, V17, P2541, DOI 10.1002/ibd.21654; Kottachchi D, 2009, CAN J GASTROENTEROL, V23, P613; Laghi A, 2003, GUT, V52, P393, DOI 10.1136/gut.52.3.393; Lee SS, 2009, RADIOLOGY, V251, P751, DOI 10.1148/radiol.2513081184; Lemberg DA, 2005, J GASTROEN HEPATOL, V20, P1696, DOI 10.1111/j.1440-1746.2005.03954.x; Levine A, 2011, INFLAMM BOWEL DIS, V17, P1314, DOI 10.1002/ibd.21493; Mossop H, 2008, J PEDIATR GASTR NUTR, V47, P123, DOI 10.1097/MPG.0b013e318156a834; O'Connor A, 2011, EUR J CANCER PREV, V20, P40, DOI 10.1097/CEJ.0b013e32833ecc5f; Orel R, 2009, J PEDIATR GASTR NUTR, V48, P579, DOI 10.1097/MPG.0b013e318164d903; Paerregaard A, 2009, INFLAMM BOWEL DIS, V15, P1101, DOI 10.1002/ibd.20862; Palmer L, 2009, AM J GASTROENTEROL, V104, P2816, DOI 10.1038/ajg.2009.480; Pilleul F, 2005, GASTROEN CLIN BIOL, V29, P803, DOI 10.1016/S0399-8320(05)86351-1; Saini SD, 2009, J CLIN GASTROENTEROL, V43, P554, DOI 10.1097/MCG.0b013e31818242ad; Satsangi J, 2006, GUT, V55, P749, DOI 10.1136/gut.2005.082909; Sauer CG, 2011, INFLAMM BOWEL DIS, V17, P2326, DOI 10.1002/ibd.21626; Sawczenko A, 2001, LANCET, V357, P1093, DOI 10.1016/S0140-6736(00)04309-9; Sawczenko A, 2003, ARCH DIS CHILD, V88, P995, DOI 10.1136/adc.88.11.995; Siddiki HA, 2009, AM J ROENTGENOL, V193, P113, DOI 10.2214/AJR.08.2027; Terheggen G, 2008, ENDOSCOPY, V40, P656, DOI 10.1055/s-2008-1077445; Van Assche G, 2010, J CROHNS COLITIS, V4, P63, DOI 10.1016/j.crohns.2009.09.009; Van Assche G, 2010, J CROHNS COLITIS, V4, P7, DOI 10.1016/j.crohns.2009.12.003; Wagnon JH, 2009, INFLAMM BOWEL DIS, V15, P1082, DOI 10.1002/ibd.20857",31,12,12,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0277-2116",null,null,"J PEDIATR GASTR NUTR","J. Pediatr. Gastroenterol. Nutr.","MAR",2012,54,3,null,null,null,null,374,380,null,"10.1097/MPG.0b013e318231d984",null,7,"Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","898RT","WOS:000300760200013"]
[null,null,null,null,"J","Dospivova, D; Smerkova, K; Ryvolova, M; Hynek, D; Adam, V; Kopel, P; Stiborova, M; Eckschlager, T; Hubalek, J; Kizek, R",null,null,null,"Dospivova, Dana; Smerkova, Kristyna; Ryvolova, Marketa; Hynek, David; Adam, Vojtech; Kopel, Pavel; Stiborova, Marie; Eckschlager, Tomas; Hubalek, Jaromir; Kizek, Rene",null,null,"Catalytic Electrochemical Analysis of Platinum in Pt-DNA Adducts","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"cisplatin; square wave voltammetry; differential pulse voltammetry; DNA; metallomics","SQUARE-WAVE VOLTAMMETRY; ADSORPTIVE STRIPPING VOLTAMMETRY; MODIFIED ELECTRODE SURFACE; HETEROCYCLIC AMINE LIGAND; PLASMA-MASS SPECTROMETRY; EARLY SOMATIC EMBRYOS; CAPILLARY-ELECTROPHORESIS; HEAVY-METALS; CYCLIC VOLTAMMETRY; CISPLATIN-DNA","Using of platinum based cytostatic drugs in tumour diseases treatment results in the need to detect these drugs in biological samples and to determine and study the Pt-DNA adducts, which is highly important for investigation of cisplatin-resistance developed during anti-tumour treatment. The aim of this study was not only electrochemical detection of cisplatin with the use of formazone method but also preparation of platinum-DNA complex and platinum content detection in DNA. Primarily, we optimized manual electrochemical detection using differential pulse voltammetry (DPV) for PtCl2 and cisplatin. The detection detection limits (3 S/N) were estimated as 10 pM and 30 nM for PtCl2 and cisplatin, respectively. Further, we automated the optimized method and reached 50 pM detection limit for PtCl2, but the method was proved to be versatile also for detection of cisplatin, which was verified by determination of cisplatin added cell culture medium. The method was also used to monitor the content of cisplatin bound into DNA and was verified by agarose gel electrophoresis. Moreover, we used UV irradiation and ultrasound to study changes in Pt-DNA adducts using above optimized DPV for detection of platinum signals and square wave voltammetry for detection of DNA signals. The suggested method could be applied for measurements of low volumes of isolated DNA due to the low detection limits and versatility.","[Dospivova, Dana; Smerkova, Kristyna; Ryvolova, Marketa; Hynek, David; Adam, Vojtech; Kopel, Pavel; Hubalek, Jaromir; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Ryvolova, Marketa; Hynek, David; Adam, Vojtech; Kopel, Pavel; Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Dospivova, D (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Kizek, Rene/D-7748-2012; Smerkova, Kristyna/F-3892-2012; Hynek, David/E-5702-2012; Adam, Vojtech/D-7686-2012; Ryvolova, Marketa/D-8243-2012; Hubalek, Jaromir/D-7753-2012; Dospivova, Dana/E-5697-2012; Kopel, Pavel/E-5711-2012",null,"CYTORES GA CR [P301/10/0356]; NANIMEL GA CR [102/08/1546]; CEITEC [CZ.1.05/1.1.00/02.0068]","Financial support from CYTORES GA CR P301/10/0356, NANIMEL GA CR 102/08/1546 and CEITEC CZ.1.05/1.1.00/02.0068 is highly acknowledged.",null,112,11,11,"ESG","BELGRADE","BORIVOJA STEVANOVICA 25-7, BELGRADE, 11000, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","APR",2012,7,4,null,null,null,null,3072,3088,null,null,null,17,"Electrochemistry","Electrochemistry","947FF","WOS:000304413000024"]
[null,null,null,null,"J","Gumulec, J; Sochor, J; Hlavna, M; Sztalmachova, M; Krizkova, S; Babula, P; Hrabec, R; Rovny, A; Adam, V; Eckschlager, T; Kizek, R; Masarik, M",null,null,null,"Gumulec, Jaromir; Sochor, Jiri; Hlavna, Marian; Sztalmachova, Marketa; Krizkova, Sona; Babula, Petr; Hrabec, Roman; Rovny, Arne; Adam, Vojtech; Eckschlager, Tomas; Kizek, Rene; Masarik, Michal",null,null,"Caveolin-1 as a potential high-risk prostate cancer biomarker","ONCOLOGY REPORTS",null,null,"English","Article",null,null,null,null,null,"prostate cancer; tumour marker; prognostic marker; immunodetection; electrochemistry; polymerase chain reaction; molecular biology techniques","ACTIVATED PROTEIN-KINASE; METHYLACYL-COA RACEMASE; OXIDATIVE STRESS; BREAST-CANCER; ANTIOXIDANT CAPACITY; ELECTROCHEMICAL DETECTION; TYROSINE PHOSPHORYLATION; SURVIVAL/CLONAL GROWTH; LIQUID-CHROMATOGRAPHY; PROGNOSTIC MARKER","Current diagnostic techniques of prostate cancer cannot efficiently distinguish the latent and low-risk forms from the high-risk significant forms of prostate cancer. Caveolin-1 (Cav-1), except other functions, plays an important role in cell transformation and the process of tumorigenesis. Furthermore, Cav-1 is involved in metastatic processes. It has also been shown that Cav-1 expression is induced under stress conditions, such as oxidative stress. The present study focused on the determination of prognostic markers of aggressive (high-grade) forms of prostate cancer. We determined serum Cav-1 and serum markers of antioxidant activity-glutathione (GSH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), Trolox equivalent antioxidant capacity (TEAC), ferric-reducing antioxidant power (FRAP), N,N-dimethyl-1,4-diaminobenzene (DMPD), free radicals method (FRK) and blue chromium peroxide (Cro) in 97 serum samples (82 prostate cancer patients and 15 controls). We found insignificant differences in Cav-1 between the sera of patients and controls (5.69 in the cancer group vs. 5.42 ng/ml in the control group). However, we found a significant (p<0.004) 2.8-fold elevation of Cav-1 in high tumour stages (TNM T4) compared to lower stages and a significant positive association with histological grading (r=0.29, p=0.028). We also found that in patients with high serum Cav-1 the antioxidant capacity of the body is reduced. These findings indicate that Cav-1 may be an interesting tool for the prediction of disease burden.","[Gumulec, Jaromir; Hlavna, Marian; Sztalmachova, Marketa; Masarik, Michal] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-62500 Brno, Czech Republic; [Gumulec, Jaromir; Sochor, Jiri; Sztalmachova, Marketa; Krizkova, Sona; Babula, Petr; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Sochor, Jiri; Krizkova, Sona; Babula, Petr; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Hrabec, Roman; Rovny, Arne] St Annes Univ Hosp Brno, Dept Urol, CZ-65691 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic","Masarik, M (reprint author), Masaryk Univ, Fac Med, Dept Pathol Physiol, Kamenice 5, CZ-62500 Brno, Czech Republic.","masarik@med.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Sochor, Jiri/E-1135-2012; Krizkova, Sona/E-9617-2012; Gumulec, Jaromir/D-7638-2012; Sztalmachova, Marketa/F-4144-2012","Gumulec, Jaromir/0000-0002-9658-3444; ","IGA [MZ NS10200-3]; CEITEC [CZ.1.05/1.1.00/02.0068]","Financial support from IGA MZ NS10200-3 and CEITEC CZ.1.05/1.1.00/02.0068 is greatly acknowledged.",null,75,11,11,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1021-335X",null,null,"ONCOL REP","Oncol. Rep.","MAR",2012,27,3,null,null,null,null,831,841,null,"10.3892/or.2011.1587",null,11,"Oncology","Oncology","890AY","WOS:000300118700033"]
[null,null,null,null,"J","Hubka, V; Kubatova, A; Mallatova, N; Sedlacek, P; Melichar, J; Skorepova, M; Mencl, K; Lyskova, P; Sramkova, B; Chudickova, M; Hamal, P; Kolarik, M",null,null,null,"Hubka, Vit; Kubatova, Alena; Mallatova, Nada; Sedlacek, Petr; Melichar, Jan; Skorepova, Magdalena; Mencl, Karel; Lyskova, Pavlina; Sramkova, Blanka; Chudickova, Milada; Hamal, Petr; Kolarik, Miroslav",null,null,"Rare and new etiological agents revealed among 178 clinical Aspergillus strains obtained from Czech patients and characterized by molecular sequencing","MEDICAL MYCOLOGY",null,null,"English","Article",null,null,null,null,null,"invasive aspergillosis; non-dermatophytic onychomycosis; otomycosis; galactomannan index; chronic granulomatous disease","CHRONIC GRANULOMATOUS-DISEASE; INVASIVE ASPERGILLOSIS; BROTH MICRODILUTION; ONYCHOMYCOSIS; IDENTIFICATION; INFECTIONS; PCR; DNA","A collection of 178 Aspergillus isolates, recovered from Czech patients, mostly from 2007-2011, was subjected to multilocus DNA sequence typing using the ITS region, beta-tubulin, and calmodulin genes. An unusually wide spectrum of etiologic agents that included 36 species of Aspergillus is discussed in the context of recent taxonomic and clinical reports. Invasive aspergillosis (IA), onychomycosis, and otitis externa were the predominant clinical entities. Five cases due to species newly proven as etiologic agents of human mycoses, as well as cases with unique clinical manifestations caused by unusual agents are discussed in more detail. Three species (i.e., A. insulicola, A. westerdijkiae and A. tritici) were identified as the confirmed etiologic agents of non-dermatophytic onychomycosis. Emericella rugulosa was recovered from a premature newborn with a fatal necrotising disseminated infection and is reported for only the second time as the cause of IA. Furthermore, we document the first infection due to A. calidoustus in a patient with chronic granulomatous disease. The infection manifested as a latent brain aspergilloma with an unusual clinical-laboratory finding. In addition to the well-known agents of human mycosis, several rarely isolated or poorly documented species were identified. An undescribed cryptic species related to A. versicolor was found to be common among isolates linked to proven and probable onychomycosis. An isolate representing A. fresenii, or an unnamed sister species, were causal agents of otomycosis. Three well defined, and tentative new species belonging to section Cervini, Candidi and Aspergillus (Eurotium spp.), were associated with cases of probable onychomycosis.","[Hubka, Vit; Kubatova, Alena; Kolarik, Miroslav] Charles Univ Prague, Fac Sci, Dept Bot, Prague 12801 2, Czech Republic; [Hubka, Vit; Chudickova, Milada; Kolarik, Miroslav] Acad Sci Czech Republic, Inst Microbiol, Lab Fungal Genet & Metab, Prague, Czech Republic; [Mallatova, Nada] Charles Univ Prague, Hosp Ceske Budejovice, Lab Mycol & Parasitol, Prague 12801 2, Czech Republic; [Sedlacek, Petr] Charles Univ Prague, Motol Univ Hosp, Dept Pediat Hematol & Oncol, Prague 12801 2, Czech Republic; [Melichar, Jan] Inst Care Mother & Child, Prague, Czech Republic; [Skorepova, Magdalena] Charles Univ Prague, Fac Med 1, Dept Dermatol & Venerol, Prague 12801 2, Czech Republic; [Melichar, Jan; Skorepova, Magdalena] Gen Univ Hosp Prague, Prague, Czech Republic; [Mencl, Karel] Pardubice Reg Hosp Inc, Dept Clin Microbiol, Prague, Czech Republic; [Lyskova, Pavlina; Sramkova, Blanka] Inst Publ Hlth, Med Mycol Lab, Prague, Czech Republic; [Hamal, Petr] Palacky Univ, Fac Med & Dent, Dept Microbiol, CR-77147 Olomouc, Czech Republic","Hubka, V (reprint author), Charles Univ Prague, Fac Sci, Dept Bot, Benatska 2, Prague 12801 2, Czech Republic.","vit.hubka@seznam.cz","Kolarik, Miroslav/A-1680-2008","Kolarik, Miroslav/0000-0003-4016-0335","Ministry of Education, Czech Republic [MSM6007665801, MSM0021620828, MSM6198959223, AV0Z50200510]","This work was supported by the grants of the Ministry of Education, Czech Republic, Nos. MSM6007665801, MSM0021620828, MSM6198959223 and AV0Z50200510. The authors wish to thank Dagmar Kozakova from Department of Botany in Prague for the lyophilisation of the cultures.",null,29,9,9,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","1369-3786",null,null,"MED MYCOL","Med. Mycol.","AUG",2012,50,6,null,null,null,null,601,610,null,"10.3109/13693786.2012.667578",null,10,"Mycology; Veterinary Sciences","Mycology; Veterinary Sciences","975AS","WOS:000306479700006"]
[null,null,null,null,"J","Krizkova, S; Ryvolova, M; Hynek, D; Eckschlager, T; Hodek, P; Masarik, M; Adam, V; Kizek, R",null,null,null,"Krizkova, Sona; Ryvolova, Marketa; Hynek, David; Eckschlager, Tomas; Hodek, Petr; Masarik, Michal; Adam, Vojtech; Kizek, Rene",null,null,"Immunoextraction of zinc proteins from human plasma using chicken yolk antibodies immobilized onto paramagnetic particles and their electrophoretic analysis","ELECTROPHORESIS",null,null,"English","Article",null,null,null,null,null,"Electrochemistry; Magnetic particles; Metallomics; Zincome","ATOMIC-ABSORPTION SPECTROPHOTOMETRY; INDUCED-BREAKDOWN SPECTROSCOPY; HUMAN BLOOD-SERUM; METALLOTHIONEIN DETECTION; AFFINITY-CHROMATOGRAPHY; MASS SPECTROMETRY; BRDICKA REACTION; BOUND ZINC; BINDING; IONS","Zinc(II) as the only transition metal lacking redox activity is an essential part of approximately 10% proteins as a cofactor of these proteins. Considering the fact that there are numerous zinc(II) containing proteins, proteomics and metallomics studies aimed on them require accurate methods for preparation of real biological samples prior to their subsequent analysis using 2DE and MS. For this purpose, we suggested a new method based on chicken anti-zinc antibodies and magnetizable particles. Antibodies were covalently immobilized to the surface of paramagnetic beads activated with tosyl group. Binding of the antibody to the beads was confirmed by secondary anti-chicken antibody conjugated with horseradish peroxidase. The immunoextraction conditions, such as concentration of the beads (618 mu g/mL of the sample), time of immunoextraction (634 min), pH and composition of the elution buffer, and time of extraction (48300 s) were optimized. Subsequently, zinc proteins were extracted from human plasma and total concentration of zinc was monitored by electrochemical detection in the extracts. Under optimal conditions it was possible to monitor the proteins and zinc removal from the sample by chip CE, SDS-PAGE, and indirectly using electrochemistry.","[Krizkova, Sona; Ryvolova, Marketa; Hynek, David; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Krizkova, Sona; Ryvolova, Marketa; Hynek, David; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic; [Hodek, Petr] Charles Univ Prague, Dept Biochem, Fac Sci, Prague, Czech Republic; [Masarik, Michal] Masaryk Univ, Fac Med, Dept Pathol Physiol, Brno, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Krizkova, Sona/E-9617-2012; Hynek, David/E-5702-2012; Ryvolova, Marketa/D-8243-2012",null,"Liga proti rakovine Praha; NANOSEMED GA AV [KAN208130801]; NanoBioTECell GACR [P102/11/1068]; CEITEC [CZ.1.05/1.1.00/02.0068]","Financial support from Liga proti rakovine Praha 2012, NANOSEMED GA AV KAN208130801, NanoBioTECell GACR P102/11/1068, and CEITEC CZ.1.05/1.1.00/02.0068 is highly acknowledged. The authors wish to express their thanks to Natalie Matijescukova for excellent technical assistance.",null,49,9,9,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0173-0835",null,null,"ELECTROPHORESIS","Electrophoresis","JUL",2012,33,12,null,null,null,null,1824,1832,null,"10.1002/elps.201100638",null,9,"Biochemical Research Methods; Chemistry, Analytical","Biochemistry & Molecular Biology; Chemistry","965UJ","WOS:000305792500018"]
[null,null,null,null,"J","Slyskova, J; Naccarati, A; Pardini, B; Polakova, V; Vodickova, L; Smerhovsky, Z; Levy, M; Lipska, L; Liska, V; Vodicka, P",null,null,null,"Slyskova, Jana; Naccarati, Alessio; Pardini, Barbara; Polakova, Veronika; Vodickova, Ludmila; Smerhovsky, Zdenek; Levy, Miroslav; Lipska, Ludmila; Liska, Vaclav; Vodicka, Pavel",null,null,"Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls","MUTAGENESIS",null,null,"English","Article",null,null,null,null,null,null,"REDUCED DNA-REPAIR; COMET ASSAY; LUNG-CANCER; GENETIC POLYMORPHISMS; MOLECULAR-MECHANISMS; PRIMARY LYMPHOCYTES; XPC POLYMORPHISMS; CELL CARCINOMA; NECK-CANCER; RISK","Alteration of DNA integrity is a potential cause of cancer and it is assumed that reduced DNA repair capacity and accumulation of DNA damage may represent intermediate markers in carcinogenesis. In this case-control study, DNA damage and nucleotide excision repair capacity (NER-DRC) were assessed in association with sporadic colorectal cancer (CRC). Both parameters were quantified by comet assay in blood cells of 70 untreated incident patients and 70 age-matched healthy controls. mRNA expression and polymorphisms in relevant NER genes were concurrently analyzed. The aim of this study was to characterize incident CRC patients for NER-DRC and to clarify possible relations between investigated variables. Comet assay and mRNA expression analysis showed that CRC patients differ in repair capacity as compared to controls. Patients had a lower NER-DRC and simultaneously they exhibited higher endogenous DNA damage (for both P < 0.001). Accumulation of DNA damage and decreasing NER-DRC behaved as independent modulating parameters strongly associated with CRC. Expression levels of 6 out of 9 studied genes differed between groups (P < 0.001), but none of them was related to DRC or to any of the studied NER polymorphisms. However, in patients only, XPC Ala499Val modulated expression levels of XPC, XPB and XPD gene, whereas XPC Lys939Gln was associated with XPA expression level in controls (for all P < 0.05). This study provides evidence on altered DRC and DNA damage levels in sporadic CRC and proposes the relevance of the NER pathway in this malignancy. Further, alterations in a complex multigene process like DNA repair may be better characterized by functional quantification of repair capacity than by quantification of individual genes transcripts or gene variants alone.","[Slyskova, Jana; Naccarati, Alessio; Pardini, Barbara; Polakova, Veronika; Vodickova, Ludmila; Vodicka, Pavel] Acad Sci Czech Republic, Dept Mol Biol Canc, Inst Expt Med, Prague 14220, Czech Republic; [Slyskova, Jana] Charles Univ Prague, Dept Genet & Microbiol, Fac Sci, Prague 12000 2, Czech Republic; [Slyskova, Jana; Polakova, Veronika; Vodickova, Ludmila; Vodicka, Pavel] Charles Univ Prague, Inst Biol & Med Genet, Fac Med 1, Prague 12000 2, Czech Republic; [Vodickova, Ludmila; Smerhovsky, Zdenek] Natl Inst Publ Hlth, Dept Toxicogen, Prague 10000 10, Czech Republic; [Vodickova, Ludmila; Smerhovsky, Zdenek] Natl Inst Publ Hlth, Dept Occupat Hlth, Prague 10000 10, Czech Republic; [Smerhovsky, Zdenek] Charles Univ Prague, Inst Epidemiol, Fac Med 2, Prague 16000 6, Czech Republic; [Levy, Miroslav; Lipska, Ludmila] Charles Univ Prague, Dept Surg, Fac Med 1, Prague 14200 4, Czech Republic; [Levy, Miroslav; Lipska, Ludmila] Thomayer Univ Hosp, Prague 14200 4, Czech Republic; [Liska, Vaclav] Charles Univ Prague, Dept Surg, Teaching Hosp, Plzen 30400, Czech Republic; [Liska, Vaclav] Charles Univ Prague, Med Sch Pilsen, Plzen 30400, Czech Republic","Vodicka, P (reprint author), Acad Sci Czech Republic, Dept Mol Biol Canc, Inst Expt Med, Videnska 1083, Prague 14220, Czech Republic.","pvodicka@biomed.cas.cz","Lipska, Ludmila/H-1759-2011",null,"Grant Agency of the Czech Republic [CZ:GACR:GAP 304/10/1286]; EEA/Norway; Czech Republic state budget by means of the Research Support Fund [A/CZ0046/2/0012]; Internal Grant Agency of the Ministry of Health [CZ:IGA:NS10230-3]","Grant Agency of the Czech Republic: CZ:GACR:GAP 304/10/1286, EEA/Norway Grants; Czech Republic state budget by means of the Research Support Fund: A/CZ0046/2/0012; Internal Grant Agency of the Ministry of Health: CZ:IGA:NS10230-3.",null,60,8,8,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0267-8357",null,null,"MUTAGENESIS","Mutagenesis","MAR",2012,27,2,null,null,"SI",null,225,232,null,"10.1093/mutage/ger088",null,8,"Genetics & Heredity; Toxicology","Genetics & Heredity; Toxicology","888YI","WOS:000300040200012"]
[null,null,null,null,"J","Dubsky, M; Kubinova, S; Sirc, J; Voska, L; Zajicek, R; Zajicova, A; Lesny, P; Jirkovska, A; Michalek, J; Munzarova, M; Holan, V; Sykova, E",null,null,null,"Dubsky, Michal; Kubinova, Sarka; Sirc, Jakub; Voska, Ludek; Zajicek, Robert; Zajicova, Alena; Lesny, Petr; Jirkovska, Alexandra; Michalek, Jiri; Munzarova, Marcela; Holan, Vladimir; Sykova, Eva",null,null,"Nanofibers prepared by needleless electrospinning technology as scaffolds for wound healing","JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE",null,null,"English","Article",null,null,null,null,null,null,"MESENCHYMAL STEM-CELLS; DRUG-DELIVERY; REGENERATIVE MEDICINE; POLYMERIC NANOFIBERS; ULCERS; SKIN; KERATINOCYTES; PARAMETERS; MOLECULES; DRESSINGS","Electrospun gelatin and poly-epsilon-caprolactone (PCL) nanofibers were prepared using needleless technology and their biocompatibility and therapeutic efficacy have been characterized in vitro in cell cultures and in an experimental model of a skin wound. Human dermal fibroblasts, keratinocytes and mesenchymal stem cells seeded on the nanofibers revealed that both nanofibers promoted cell adhesion and proliferation. The effect of nanofibers on wound healing was examined using a full thickness wound model in rats and compared with a standard control treatment with gauze. Significantly faster wound closure was found with gelatin after 5 and 10 days of treatment, but no enhancement with PCL nanofibers was observed. Histological analysis revealed enhanced epithelialisation, increased depth of granulation tissue and increased density of myofibroblasts in the wound area with gelatin nanofibers. The results show that gelatin nanofibers produced by needleless technology accelerate wound healing and may be suitable as a scaffold for cell transfer and skin regeneration.","[Dubsky, Michal; Voska, Ludek; Jirkovska, Alexandra] Inst Clin & Expt Med, Prague 14021 4, Czech Republic; [Dubsky, Michal; Kubinova, Sarka; Lesny, Petr; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Sirc, Jakub; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, Prague, Czech Republic; [Zajicek, Robert] Charles Univ Prague, Prague Burn Ctr, Fac Med 3, Prague, Czech Republic; [Zajicek, Robert] Charles Univ Prague, Teaching Hosp Kralovske Vinohrady, Prague, Czech Republic; [Zajicova, Alena; Holan, Vladimir] Acad Sci Czech Republic, Inst Mol Genet, Prague, Czech Republic; [Michalek, Jiri; Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Munzarova, Marcela] Elmarco Ltd, Liberec, Czech Republic","Dubsky, M (reprint author), Inst Clin & Expt Med, Videnska 1958-9, Prague 14021 4, Czech Republic.","michal.dubsky@gmail.com","Michalek, Jiri/D-7251-2013; Dubsky, Michal/G-7879-2012",null,"Grant Agency of the Czech Republic [304/07/1129]; Grant Agency of the Academy of Science of the Czech Republic [KAN200520804, IAA500390902]; Ministry of Education, Youth and Sports of the Czech Republic [2B06130, 1M0538, 1M0506]; Ministry of Health of the Czech Republic [MZO00023001]","The financial support of the Grant Agency of the Czech Republic (No. 304/07/1129), the Grant Agency of the Academy of Science of the Czech Republic (KAN200520804 and IAA500390902), the Ministry of Education, Youth and Sports of the Czech Republic (2B06130, 1M0538, 1M0506) and the Ministry of Health of the Czech Republic (MZO00023001) is gratefully acknowledged.",null,47,7,8,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0957-4530",null,null,"J MATER SCI-MATER M","J. Mater. Sci.-Mater. Med.","APR",2012,23,4,null,null,null,null,931,941,null,"10.1007/s10856-012-4577-7",null,11,"Engineering, Biomedical; Materials Science, Biomaterials","Engineering; Materials Science","919RE","WOS:000302345400008"]
[null,null,null,null,"J","Hynek, D; Krejcova, L; Zitka, O; Adam, V; Trnkova, L; Sochor, J; Stiborova, M; Eckschlager, T; Hubalek, J; Kizek, R",null,null,null,"Hynek, David; Krejcova, Ludmila; Zitka, Ondrej; Adam, Vojtech; Trnkova, Libuse; Sochor, Jiri; Stiborova, Marie; Eckschlager, Tomas; Hubalek, Jaromir; Kizek, Rene",null,null,"Electrochemical Study of Doxorubicin Interaction with Different Sequences of Single Stranded Oligonucleotides, Part I","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"intercalating drug; doxorubicin; hetero-nucleotides; square wave voltammetry; adsorptive transfer stripping technique; DNA","IMPLANTATION-MODIFIED ELECTRODE; DNA-BASE PAIRS; CARBON-PASTE ELECTRODES; SQUARE-WAVE VOLTAMMETRY; PROSTATE-CANCER; BREAST-CANCER; PARAMAGNETIC MICROPARTICLES; ELIMINATION VOLTAMMETRY; GRAPHITE ELECTRODE; ANTICANCER DRUG","Doxorubicin is a known anticancer drug intercalating into dsDNA. The mechanism of interaction of doxorubicin with ssDNA is not clear. In this study, adsorptive transfer stripping technique coupled with square wave voltammetry was used for studying of interaction of doxorubicin with single stranded oligonucleotides (ssODN) in various ratios (1:1, 1:2 and 1:5) and interaction times (0-300 min.). When comparing the results for three ratios of the mixture between drug and ssODN we found that the interval of peak intensities of oligonucleotide reduced with the increasing ratio of oligonucleotide-doxorubicin, i.e. for ratio 1:1 it is 25-85 %, for ratio 1:2 it is 16-60 % and for ratio 1:5 it is 19-51 %. The interval of relative signal intensities of doxorubicin ranges from 8 to 100 % for ratio 1:1, 22-100 % for ratios 1:2 and 1:5. The results showed the assumption that DOXO peak height increased with increasing concentration of the drug intercalated into ssODN, but the signals CA peaks changes during the interaction suggest the changes in the structure of ssODN.","[Hynek, David; Krejcova, Ludmila; Zitka, Ondrej; Adam, Vojtech; Sochor, Jiri; Hubalek, Jaromir; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Hynek, David; Krejcova, Ludmila; Zitka, Ondrej; Adam, Vojtech; Trnkova, Libuse; Sochor, Jiri; Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Dept Chem, Fac Sci, CZ-61137 Brno, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Res Ctr Environm Chem & Ecotoxicol, Fac Sci, CZ-61137 Brno, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, CZ-12840 Prague 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Dept Microelect, Fac Elect Engn & Commun, CZ-61600 Brno, Czech Republic","Hynek, D (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Zitka, Ondrej/E-1107-2012; Sochor, Jiri/E-1135-2012; Hynek, David/E-5702-2012; Krejcova, Ludmila/E-8440-2012",null,"CYTORES GA CR [P301/10/0356]; NANIMEL GA CR [102/08/1546]; CEITEC [CZ.1.05/1.1.00/02.0068]","Financial support from CYTORES GA CR P301/10/0356, NANIMEL GA CR 102/08/1546 and CEITEC CZ.1.05/1.1.00/02.0068 is highly acknowledged. The results were presented at 11th Workshop of Physical Chemists end Electrochemists held in Brno, Czech Republic.",null,100,7,7,"ELECTROCHEMICAL SCIENCE GROUP","BELGRADE","A SPOMENICE 7/12 , 19210 BOR, BELGRADE, VJ 12, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","JAN",2012,7,1,null,null,null,null,13,33,null,null,null,21,"Electrochemistry","Electrochemistry","924XD","WOS:000302723700002"]
[null,null,null,null,"J","Hynek, D; Krejcova, L; Zitka, O; Adam, V; Trnkova, L; Sochor, J; Stiborova, M; Eckschlager, T; Hubalek, J; Kizek, R",null,null,null,"Hynek, David; Krejcova, Ludmila; Zitka, Ondrej; Adam, Vojtech; Trnkova, Libuse; Sochor, Jiri; Stiborova, Marie; Eckschlager, Tomas; Hubalek, Jaromir; Kizek, Rene",null,null,"Electrochemical Study of Doxorubicin Interaction with Different Sequences of Double Stranded Oligonucleotides, Part II","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"intercalating drug; doxorubicin; hetero-nucleotides; square wave voltammetry; adsorptive transfer stripping technique; adriamycin; DNA","PYROLYTIC-GRAPHITE ELECTRODE; DNA HYBRIDIZATION ASSAYS; SQUARE-WAVE VOLTAMMETRY; ELIMINATION VOLTAMMETRY; CANCER-CELLS; STRIPPING VOLTAMMETRY; BIOSENSOR; ACID; DRUG; BEHAVIOR","Interaction of low molecular weight compounds with DNA is one of general mechanisms utilized for an effective anticancer therapy. The anthracycline doxorubicin is one of the drugs that represent the compound with such effect. In our previous work [Hynek et al., Int. J. Electrochem, Sci. 7 (2012) xx] the electrochemical behaviour of doxorubicin interaction with single stranded ODN by using adsorptive transfer stripping square wave voltammetry was described. This paper is focused on the study of interaction of doxorubicin with double stranded ODNs (dsODNs) using the same technique. Here, we used four dsODNs possessing different primary structuresand observed the changes in their electrochemical behaviour after their treatment with three concentrations of doxorubicin for 5 hours. The changes found are discussed and differences in behaviours of individual dsODNs described and associated with their structure.","[Hynek, David; Krejcova, Ludmila; Zitka, Ondrej; Adam, Vojtech; Sochor, Jiri; Hubalek, Jaromir; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Hynek, David; Krejcova, Ludmila; Zitka, Ondrej; Adam, Vojtech; Trnkova, Libuse; Sochor, Jiri; Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Dept Chem, Fac Sci, CZ-61137 Brno, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Res Ctr Environm Chem & Ecotoxicol, Fac Sci, CZ-61137 Brno, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, CZ-12840 Prague 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Dept Microelect, Fac Elect Engn & Commun, CZ-61600 Brno, Czech Republic","Hynek, D (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Zitka, Ondrej/E-1107-2012; Sochor, Jiri/E-1135-2012; Hynek, David/E-5702-2012; Krejcova, Ludmila/E-8440-2012",null,"CYTORES GA CR [P301/10/0356]; NANIMEL GA CR [102/08/1546]; CEITEC [CZ.1.05/1.1.00/02.0068]","Financial support from CYTORES GA CR P301/10/0356, NANIMEL GA CR 102/08/1546 and CEITEC CZ.1.05/1.1.00/02.0068 is highly acknowledged. The results were presented at 11th Workshop of Physical Chemists end Electrochemists held in Brno, Czech Republic.",null,59,7,7,"ELECTROCHEMICAL SCIENCE GROUP","BELGRADE","A SPOMENICE 7/12 , 19210 BOR, BELGRADE, VJ 12, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","JAN",2012,7,1,null,null,null,null,34,49,null,null,null,16,"Electrochemistry","Electrochemistry","924XD","WOS:000302723700003"]
[null,null,null,null,"J","Pohanka, M; Sochor, J; Ruttkay-Nedecky, B; Cernei, N; Adam, V; Hubalek, J; Stiborova, M; Eckschlager, T; Kizek, R",null,null,null,"Pohanka, Miroslav; Sochor, Jiri; Ruttkay-Nedecky, Branislav; Cernei, Natalia; Adam, Vojtech; Hubalek, Jaromir; Stiborova, Marie; Eckschlager, Tomas; Kizek, Rene",null,null,"Automated assay of the potency of natural antioxidants using pipetting robot and spectrophotometry","JOURNAL OF APPLIED BIOMEDICINE",null,null,"English","Article",null,null,null,null,null,"DPPH; FRAP; ABTS; DMPD; free radicals; antioxidant","POWER FRAP; MELATONIN; CAPACITY; EXTRACT; ACID","In the food industry, in the process of creating new agricultural plant products, and in the testing of anti-cancer drugs there is often a need to assay multiple samples of low molecular weight antioxidants, plant samples and foods rich in antioxidants, with minimal additional costs and low degrees of uncertainty. With these demands in mind, we decided to study the fully automated assay of antioxidants using not only automated sample measurements but also automated processing of samples and application of reagents. The automated pipetting system epMotion 5075 and the automated spectrophotometer BS 400 were chosen for the assay purposes. Five methods were introduced for the automation: 2-diphenyl-1-picrylhydrazyl (DPPH) test, ferric reducing antioxidant power (FRAP) method, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) based test, N,N-dimethyl-1,4-diaminobenzene (DMPD) based test and the free radicals method. Samples containing one of the four antioxidants (standard rutin, quercitrin, ferulic and gallic acid) in a range 1-1000 mu g/ml were used throughout. All of the tested methods were found suitable for implementation in an automated assay. However, some of them, such as the ABTS test failed to assay all tested antioxidants. The coefficients of determination were also unequal. From the analytical point of view, FRAP methods provided the most reliable results in the automated assay; because of the capacity of the method, approximately 240 samples per hour (one sample per 15 seconds) can be assayed using the automated protocol. We were encouraged by the data received and we expect further interest in the practical performance of such automation. As a mean of testing the robustness of our method, in the next step of our study, oxidative status was assessed in model cell lines derived from prostate cancer (PC-3, PNT1A and 22RV1) that were cultured on ellipticine (0, 0.5, 1, 1.5, 2, 2.5, 5, 7.5, 10, 15 mu mol/l) supplemented agar. Antioxidant activity was assessed (DPPH, ABTS, FRAP, DMPD, FR) and calculated on the phenolic antioxidant level (rutin, quercitrin, ferulic and gallic acid), and thus an estimation was formulated of the oxidative stress as a result of the impact of anti-cancer drugs. It can be demonstrated that the new method has wide applicability.","[Sochor, Jiri; Ruttkay-Nedecky, Branislav; Cernei, Natalia; Adam, Vojtech; Hubalek, Jaromir; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Brno 61300, Czech Republic; [Pohanka, Miroslav] Univ Def, Fac Mil Hlth Sci, Hradec Kralove, Czech Republic; [Sochor, Jiri; Ruttkay-Nedecky, Branislav; Cernei, Natalia; Adam, Vojtech; Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, Brno, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, Prague, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, Brno 61300, Czech Republic.","kizek@sci.muni.cz","Sochor, Jiri/E-1135-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Ruttkay-Nedecky, Branislav/E-8435-2012; Cernei, Natalia Vladimirovna/E-9237-2012; Pohanka, Miroslav /D-7607-2012; Hubalek, Jaromir/D-7753-2012","Pohanka, Miroslav /0000-0001-8804-8356; ","CEITEC [CZ.1.05/1.1.00/02.0068]; CYTORES GA CR [P301/10/0356]; GA AV NANOSEMED [KAN20813081]","Financial supports from the projects CEITEC CZ.1.05/1.1.00/02.0068, CYTORES GA CR P301/10/0356 and GA AV NANOSEMED KAN20813081 are kindly acknowledged.",null,20,7,7,"UNIV SOUTH BOHEMIA","CESKA BUDEJOVICE","FAC HEALTH & SOCIAL STUD, JIROVCOVA, CESKA BUDEJOVICE, 370 04, CZECH REPUBLIC","1214-021X",null,null,"J APPL BIOMED","J. Appl. Biomed.",null,2012,10,3,null,null,null,null,155,167,null,"10.2478/v10136-012-0006-y",null,13,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","944GX","WOS:000304188400003"]
[null,null,null,null,"J","Roupret, M; Zigeuner, R; Palou, J; Boehle, A; Kaasinen, E; Sylvester, R; Babjuk, M; Oosterlinck, W",null,null,null,"Roupret, M.; Zigeuner, R.; Palou, J.; Boehle, A.; Kaasinen, E.; Sylvester, R.; Babjuk, M.; Oosterlinck, W.",null,null,"European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update","ACTAS UROLOGICAS ESPANOLAS",null,null,"Spanish","Article",null,null,null,null,null,"Guidelines; Urothelial carcinoma; Prognosis; Urinary markers; Renal pelvis; Ureter; Laparoscopy; Ureteroscopy; Nephroureterectomy","LAPAROSCOPIC RADICAL NEPHROURETERECTOMY; SINGLE-CENTER EXPERIENCE; IN-SITU HYBRIDIZATION; LONG-TERM EXPERIENCE; RENAL PELVIS; PROGNOSTIC-FACTORS; CALMETTE-GUERIN; MULTIINSTITUTIONAL ANALYSIS; MICROSATELLITE INSTABILITY; URETEROSCOPIC MANAGEMENT","Context: The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper urinary tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to incorporate present recommendations into daily clinical practice. Objective: This paper provides a brief overview of the EAU guidelines on UUT-UCC as an aid to clinicians in their daily practice. Evidence acquisition: The recommendations provided in the current guidelines are based on a thorough review of available UUT-UCC guidelines and papers identified using a systematic search of Medline. Data on urothelial malignancies and UUT-UCCs in the literature were searched using Medline with the following keywords: urinary tract cancer, urothelial carcinomas, upper urinary tract, carcinoma, transitional cell, renal pelvis, ureter, bladder cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. A panel of experts weighted the references. Evidence synthesis: There is a lack of data in the current literature to provide strong recommendations due to the rarity of the disease. A number of recent multicentre studies are now available, whereas earlier publications were based only on limited populations. However, most of these studies have been retrospective analyses. The TNM classification 2009 is recommended. Recommendations are given for diagnosis as well as for radical and conservative treatment; prognostic factors are also discussed. Recommendations are provided for patient follow-up after different therapeutic options. Conclusions: These guidelines contain information for the diagnosis and treatment of individual patients according to a current standardised approach. When determining the optimal treatment regimen, physicians must take into account each individual patient's specific clinical characteristics with regard to renal function including medical comorbidities; tumour location, grade and stage; and molecular marker status. (C) 2011 AEU. Published by Elsevier Espana, S.L. All rights reserved.","[Roupret, M.] Univ Paris 06, Pitie Salpetriere Hosp, AP HP, Dept Urol,GHU Est,Fac Med Pierre & Marie Curie, Paris, France; [Zigeuner, R.] Univ Med Graz, Dept Urol, Graz, Austria; [Palou, J.] Fundacio Puigvert, Dept Urol, Barcelona, Spain; [Boehle, A.] Hosp HELIOS Agnes Karll, Serv Urol, D-23611 Bad Schwartau, Alemania, Germany; [Kaasinen, E.] Hosp Hyvinkaa, Serv Urol, Hysinkaa, Finland; [Sylvester, R.] Org Europea Invest & Tratamiento Canc, Dept Bioestadist, Bruselas, Belgium; [Babjuk, M.] Charles Univ Prague, Segunda Fac Med, Hosp Motol, Serv Urol, Prague, Czech Republic; [Oosterlinck, W.] Hosp Univ Ghent, Serv Urol, Ghent, Belgium","Roupret, M (reprint author), Univ Paris 06, Pitie Salpetriere Hosp, AP HP, Dept Urol,GHU Est,Fac Med Pierre & Marie Curie, Paris, France.","morgan.roupret@psl.aphp.fr",null,null,null,null,null,118,7,7,"ENE EDICIONES SL","MADRID","REDACCION, ADMINISTRACION & PUBLICIDAD, ORURO 9 - BAJO IZDA, MADRID, 28016, SPAIN","0210-4806",null,null,"ACTAS UROL ESP","Actas Urol. Esp.","JAN",2012,36,1,null,null,null,null,2,14,null,"10.1016/j.acuro.2011.09.001",null,13,"Urology & Nephrology","Urology & Nephrology","879TU","WOS:000299355900002"]
[null,null,null,null,"J","Danen-van Oorschot, AA; Kuipers, JE; Arentsen-Peters, S; Schotte, D; de Haas, V; Trka, J; Baruchel, A; Reinhardt, D; Pieters, R; Zwaan, CM; van den Heuvel-Eibrink, MM",null,null,null,"Danen-van Oorschot, Astrid A.; Kuipers, Jenny E.; Arentsen-Peters, Susan; Schotte, Diana; de Haas, Valerie; Trka, Jan; Baruchel, Andre; Reinhardt, Dirk; Pieters, Rob; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.",null,null,"Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia","PEDIATRIC BLOOD & CANCER",null,null,"English","Article",null,null,null,null,null,"miR-29a; miR-155; miR-196; miRNAs; pediatric AML","ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; MICRORNA EXPRESSION; DOWN-REGULATION; GENE-MUTATIONS; AML; TRIALS; CHILDHOOD; MIR-196B; MLL","Background miRNAs regulate gene expression, and thus play an important role in critical cellular processes. Aberrant miRNA expression patterns have been found in various types of cancer. So far, information about the expression of miRNAs in pediatric acute myeloid leukemia is limited. Procedure. We studied expression of miR-29a, -155, -196a, and -196b by stem-loop based RT-qPCR in 82 pediatric acute myeloid leukemia patients selected to represent relevant cytogenetic and molecular subgroups. Results. High miR-196a and -b expression was observed in patients carrying MLL gene rearrangements (P < 0.001), NPM1 mutations (P < 0.001), or FLT3-ITD in a cytogenetically normal background (P <= 0.02), compared to all other patients. In contrast, CEBPA mutated cases had a low expression of miR-196a and -b (P <= 0.001). Expression of miR-196a and -b was correlated with expression of neighboring HOXA and HOXB genes (Spearman's r = 0.46-0.82, P < 0.01). Expression of miR-155 was not related to cytogenetic features but high expression of miR-155 was observed in FLT3-ITD (P <= 0.001) and NPM1-mutated cases (P = 0.04). Lower miR-29a expression was mainly observed in MLL-rearranged pediatric acute myeloid leukemia, specifically in cases carrying t(10; 11) (P < 0.001). Conclusions. We show aberrant expression of specific miRNAs in clinically relevant cytogenetic and molecular subgroups of pediatric acute myeloid leukemia, suggesting a role for these miRNAs in the underlying biology in these specific subgroups. Pediatr Blood Cancer 2012;58:715-721. (C) 2011 Wiley Periodicals, Inc.","[Danen-van Oorschot, Astrid A.; Kuipers, Jenny E.; Arentsen-Peters, Susan; Schotte, Diana; Pieters, Rob; Zwaan, C. Michel; van den Heuvel-Eibrink, Marry M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3000 CB Rotterdam, Netherlands; [de Haas, Valerie] DCOG, The Hague, Netherlands; [Trka, Jan] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Baruchel, Andre] Hop St Louis, Dept Pediat Hematol, Paris, France; [Reinhardt, Dirk] Hannover Med Sch, Dept Pediat Hematol & Oncol, D-3000 Hannover, Germany","van den Heuvel-Eibrink, MM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Room Sp 2568,Dr Molewaterpl 60,POB 2060, NL-3000 CB Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","KOCR Foundation; Children Cancer Free Foundation (KIKA)","Grant sponsor: KOCR Foundation; Grant sponsor: Children Cancer Free Foundation (KIKA).",null,43,6,6,"WILEY PERIODICALS, INC","MALDEN","COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA","1545-5009",null,null,"PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","MAY",2012,58,5,null,null,null,null,715,721,null,"10.1002/pbc.23279",null,7,"Oncology; Hematology; Pediatrics","Oncology; Hematology; Pediatrics","901RM","WOS:000300984500010"]
[null,null,null,null,"J","Kellermayer, R; Mir, SAV; Nagy-Szakal, D; Cox, SB; Dowd, SE; Kaplan, JL; Sun, Y; Reddy, S; Bronsky, J; Winter, HS",null,null,null,"Kellermayer, Richard; Mir, Sabina A. V.; Nagy-Szakal, Dorottya; Cox, Stephen B.; Dowd, Scot E.; Kaplan, Jess L.; Sun, Yan; Reddy, Sahna; Bronsky, Jiri; Winter, Harland S.",null,null,"Microbiota Separation and C-reactive Protein Elevation in Treatment-naive Pediatric Granulomatous Crohn Disease","JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION",null,null,"English","Article",null,null,null,null,null,"Crohn disease; fungi; granuloma; inflammatory bowel disease; microbiota","INFLAMMATORY-BOWEL-DISEASE; EPITHELIOID GRANULOMAS; ULCERATIVE-COLITIS; MUCOSAL FLORA; COLONIZATION; EPIDEMIOLOGY; PREVALENCE; DIVERSITY; FREQUENCY; CHILDREN","Objectives: In patients with inflammatory bowel diseases (IBDs), the presence of noncaseating mucosal granuloma is sufficient for diagnosing Crohn disease (CD) and may represent a specific immune response or microbial-host interaction. The cause of granulomas in CD is unknown and their association with the intestinal microbiota has not been addressed with high-throughput methodologies. Methods: The mucosal microbiota from 3 different pediatric centers was studied with 454 pyrosequencing of the bacterial 16S rRNA gene and the fungal small subunit (SSU) ribosomal region in transverse colonic biopsy specimens from 26 controls and 15 treatment-naive pediatric CD cases. Mycobacterium avium subspecies paratuberculosis (MAP) was tested with real-time polymerase chain reaction. The correlation of granulomatous inflammation with C-reactive protein was expanded to 86 treatment-naive CD cases. Results: The CD microbiota separated from controls by distance-based redundancy analysis (P = 0.035). Mucosal granulomata found in any portion of the intestinal tract associated with an augmented colonic bacterial microbiota divergence (P = 0.013). The granuloma-based microbiota separation persisted even when research center bias was eliminated (P = 0.04). Decreased Roseburia and Ruminococcus in granulomatous CD were important in this separation; however, principal coordinates analysis did not reveal partitioning of the groups. CRP levels >1 mg/dL predicted the presence of mucosal granulomata (odds ratio 28 [6-134.32]; 73% sensitivity, 91% specificity). Conclusions: Granulomatous CD associates with microbiota separation and C-reactive protein elevation in treatment-naive children; however, overall dysbiosis in pediatric CD appears rather limited. Geographical/center bias should be accounted for in future multicenter microbiota studies.","[Kellermayer, Richard; Mir, Sabina A. V.; Nagy-Szakal, Dorottya; Reddy, Sahna] Texas Childrens Hosp, ARS, USDA, Dept Pediat,Baylor Coll Med,Childrens Nutr Res Ct, Houston, TX 77030 USA; [Cox, Stephen B.; Sun, Yan] Res & Testing Lab, Lubbock, TX USA; [Dowd, Scot E.] Mol Res MR DNA, Shallowater, TX USA; [Kaplan, Jess L.; Winter, Harland S.] MassGen Hosp Children, Dept Pediat, Boston, MA USA; [Bronsky, Jiri] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Bronsky, Jiri] Univ Hosp Motol, Prague, Czech Republic","Kellermayer, R (reprint author), Baylor Coll Med, Sect Pediat Gastroenterol Hepatol & Nutr, 6621 Fannin St,CC1010-00, Houston, TX 77030 USA.","kellerma@bcm.edu",null,null,"Broad Medical Research Program; Broad Foundation [IBD-0252]; Child Health Research Career Development Agency of the Baylor College of Medicine [5K12 HD041648]; Public Health Service [DK56338]; Texas Medical Center Digestive Diseases Center; Baylor biorepository; Pediatric IBD Foundation","R.K. was supported in part by the Broad Medical Research Program, the Broad Foundation (IBD-0252), the Child Health Research Career Development Agency of the Baylor College of Medicine (NIH # 5K12 HD041648), and Public Health Service grant DK56338, funding the Texas Medical Center Digestive Diseases Center, which supported the Baylor biorepository as well. The biorepository of MassGeneral Hospital was supported by the Pediatric IBD Foundation, and H.W. was supported in part by philanthropic support from Martin Schlaff. The other authors report no conflicts of interest.",null,46,5,5,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0277-2116",null,null,"J PEDIATR GASTR NUTR","J. Pediatr. Gastroenterol. Nutr.","SEP",2012,55,3,null,null,null,null,243,250,null,"10.1097/MPG.0b013e3182617c16",null,8,"Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics","998YS","WOS:000308276900004"]
[null,null,null,null,"J","Hynek, D; Krizkova, S; Krejcova, L; Gumulec, J; Ryvolova, M; Cernei, N; Masarik, M; Adam, V; Trnkova, L; Stiborova, M; Eckschlager, T; Hubalek, J; Kizek, R",null,null,null,"Hynek, David; Krizkova, Sona; Krejcova, Ludmila; Gumulec, Jaromir; Ryvolova, Marketa; Cernei, Natalia; Masarik, Michal; Adam, Vojtech; Trnkova, Libuse; Stiborova, Marie; Eckschlager, Tomas; Hubalek, Jaromir; Kizek, Rene",null,null,"Femtogram Electroanalytical Detection of Prostatic Specific Antigen by Brdicka Reaction","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"prostate specific antigen; electrochemical detection; electrophoresis; voltammetry; adsorptive transfer stripping technique; catalytic signal; protein","CANCER BIOMARKER PROTEINS; BOVINE SERUM-ALBUMIN; TUMOR-MARKERS; ELECTROCHEMICAL DETECTION; METALLOTHIONEIN DETECTION; AMPEROMETRIC IMMUNOSENSOR; GEL-ELECTROPHORESIS; ENZYME-IMMUNOASSAY; CARBON NANOTUBES; BLOOD-SERUM","Prostatic-specific antigen is considered as the best marker for prostate cancer. Due to the importance of PSA for diagnostic purposes it is not surprising that there are tested and optimized various methods for its determination. In spite of such intensive research in the field of electrochemical detection of some by-products connected with concentration of PSA, electrochemical behaviour of PSA has not been studied yet. The aim of this study was to investigate electrochemical catalytic signals of PSA using differential pulse voltammetry Brdicka reaction. The catalytic signals were studied using adsorptive transfer stripping technique as well as directly in the electrochemical cell. Nevertheless, we primarily tested detection of PSA by standard immunoanalysis and by gel and capillary chip electrophoresis to investigate behaviour of this protein in electric field. Both electrophoretic methods showed that the most intensive band of PSA was determined at 37 kDa under reducing conditions and at 26 kDa under non-reducing. Band at 37 kDa corresponds to a reduced, and at 26 kDa to non-reduced PSA. Studying of basic electrochemical behaviour of PSA was primarily carried out using standard electrochemical cell and HMDE as a working electrode. Co(NH3)(6)Cl-3 (1 mM) was used as a supporting electrolyte. Temperature of the electrolyte was maintained at 4 degrees C. The effects of accumulation time and concentration of Co(NH3)(6)Cl-3 as a key component of supporting electrolyte were studied. Time of accumulation of 240 s and 1.00 mM Co(NH3)(6)Cl-3 were found the optimal for detection of PSA in electrochemical cell. Further, we used adsorptive transfer stripping technique coupled with differential pulse voltammetry Brdicka reaction for detection of PSA. Two temperatures of adsorption as 4 degrees C and 20 degrees C and several times of adsorption as 40, 60, 80, 120, 180, 240, 360 and 420 s were tested. Under the optimized conditions (4 degrees C temperature of adsorption and 240 s time of adsorption) calibration curve with the following equation y = 36.865x - 11.949, R-2 = 0.9911 within the concentration interval from 1 to 1,500 pg/ml was measured. Detection limit of PSA expressed as 3 S/N was estimated down to 1 fg of PSA in 0.5 mu l.","[Hynek, David; Krizkova, Sona; Krejcova, Ludmila; Gumulec, Jaromir; Ryvolova, Marketa; Cernei, Natalia; Masarik, Michal; Adam, Vojtech; Trnkova, Libuse; Hubalek, Jaromir; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Hynek, David; Krizkova, Sona; Krejcova, Ludmila; Ryvolova, Marketa; Cernei, Natalia; Adam, Vojtech; Trnkova, Libuse; Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Gumulec, Jaromir; Masarik, Michal] Masaryk Univ, Dept Pathol Physiol, Fac Med, CZ-62500 Brno, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Dept Chem, Fac Sci, CZ-61137 Brno, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, CZ-12840 Prague 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Dept Microelect, Fac Elect Engn & Commun, CZ-61600 Brno, Czech Republic","Hynek, D (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Ryvolova, Marketa/D-8243-2012; Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Masarik, Michal/D-9920-2012; Hynek, David/E-5702-2012; Krejcova, Ludmila/E-8440-2012; Cernei, Natalia Vladimirovna/E-9237-2012; Krizkova, Sona/E-9617-2012; Gumulec, Jaromir/D-7638-2012","Gumulec, Jaromir/0000-0002-9658-3444","NanoBioTECell [GA CR P102/11/1068, GACR 301/09/P436]; CEITEC [CZ.1.05/1.1.00/02.0068]","Financial support from NanoBioTECell GA CR P102/11/1068, GACR 301/09/P436 and CEITEC CZ.1.05/1.1.00/02.0068 is highly acknowledged. The authors wish to express their thanks to Daniel Vicha for excellent technical assistance. The results were presented at 11th Workshop of Physical Chemists end Electrochemists held in Brno, Czech Republic.",null,89,5,5,"ELECTROCHEMICAL SCIENCE GROUP","BELGRADE","A SPOMENICE 7/12 , 19210 BOR, BELGRADE, VJ 12, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","MAR",2012,7,3,null,null,null,null,1749,1766,null,null,null,18,"Electrochemistry","Electrochemistry","924ZR","WOS:000302730300002"]
[null,null,null,null,"J","Prochazkova, D; Haisel, D; Pavlikova, D; Schnablova, R; Szakova, J; Vytasek, R; Wilhelmova, N",null,null,null,"Prochazkova, D.; Haisel, D.; Pavlikova, D.; Schnablova, R.; Szakova, J.; Vytasek, R.; Wilhelmova, N.",null,null,"The effect of risk elements in soil to nitric oxide metabolism in tobacco plants","PLANT SOIL AND ENVIRONMENT",null,null,"English","Article",null,null,null,null,null,"nitrate reductase; nitrosoglutathione reductase; nitrotyrosine; Nicotiana tabacum L.","S-NITROSOGLUTATHIONE REDUCTASE; NITROSATIVE STRESS; NITRATE REDUCTASE; CADMIUM STRESS; PEA-PLANTS; SENESCENCE; CYTOKININ; LEAVES; EXPRESSION; TOLERANCE","We studied changes of endogenous nitric oxide content (NO) and of reactive nitrogen species metabolism in transgenic tobacco with prolonged life span (SAG) and in wild tobacco (WT) cultivated in the control and in the polluted soil. There was no difference in the metal accumulation between WT and SAG plants however SAG ones showed better ability to cope with risk elements, as they retained higher membrane stability index and chlorophyll content together with better photochemical efficiency and lower deepoxidation status. Risk elements induced higher NO production in the youngest leaves of both plant types. Low and middle leaves of both WT and SAG plants showed similar activities of nitrate reductase and nitrosoglutathione reductase. Increase of nitrotyrosine content in leaf soluble proteins suggests that risk elements induced nitrosative stress in both plant types.","[Prochazkova, D.] Acad Sci Czech Republic, Inst Expt Bot, Vvi, Prague 6, Czech Republic; [Pavlikova, D.; Szakova, J.] Czech Univ Life Sci Prague, Fac Agrobiol Food & Nat Resources, Prague, Czech Republic; [Vytasek, R.] Charles Univ Prague, Dept Med Chem & Biochem, Prague, Czech Republic","Prochazkova, D (reprint author), Acad Sci Czech Republic, Inst Expt Bot, Vvi, Rozvojova 263, Prague 6, Czech Republic.","prochazkovad@ueb.cas.cz","Vytasek, Richard/C-7571-2014; Prochazkova, Dagmar/F-7806-2014",null,"Czech Science Foundation [P501/11/1239]","Supported by the Czech Science Foundation, Grant No. P501/11/1239.",null,31,4,5,"CZECH ACADEMY AGRICULTURAL SCIENCES","PRAGUE","TESNOV 17, PRAGUE, 00000, CZECH REPUBLIC","1214-1178",null,null,"PLANT SOIL ENVIRON","Plant Soil Environ.","OCT",2012,58,10,null,null,null,null,435,440,null,null,null,6,"Agronomy","Agriculture","031RO","WOS:000310660200001"]
[null,null,null,null,"J","Caniza, MA; Hunger, SP; Schrauder, A; Valsecchi, MG; Pui, CH; Masera, G",null,null,null,"Caniza, Miguela A.; Hunger, Stephen P.; Schrauder, Andre; Valsecchi, Maria Grazia; Pui, Ching-Hon; Masera, Giuseppe",null,"Int Study Grp Childhood ALL","The Controversy of Varicella Vaccination in Children With Acute Lymphoblastic Leukemia","PEDIATRIC BLOOD & CANCER",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia; immunization; mortality; pediatric; vaccination; varicella zoster virus","UNITED-STATES; IMMUNOCOMPROMISED CHILDREN; IMMUNIZATION; CANADA; IMPACT; EXPERIENCE; COVERAGE; THERAPY; PROGRAM; DISEASE","Background. The available guidelines for varicella vaccination of susceptible children with acute lymphoblastic leukemia (ALL) have become increasingly conservative. However, vaccination of those who have remained in continuous complete remission for 1 year and are receiving chemotherapy is still considered a reasonable option. There is little available data to allow a comparison of the risk versus benefit of vaccinating these patients. Procedure. We retrospectively reviewed mortality due to varicella in the records of 15 pediatric ALL study groups throughout Europe, Asia, and North America during the period 1984-2008. Results. We found that 20 of 35,128 children with ALL (0.057%; 95% confidence interval [CI], 0.037-0.088%) died of VZV infection. The mortality rate was lower in North America (3 of 11,558 children, 0.026%; 95% CI, 0.009-0.076%) than in the Asian countries (2 of 4,882 children, 0.041%; 95% CI, 0.011-0.149%) and in Europe (15 of 18,688 children, 0.080%; 95% CI, 0.049-0.132%) consistent with the generally higher rate of VZV vaccination in North America. Fourteen of the 20 patients (70%) died during the first year of treatment for ALL. One death was attributed to varicella vaccination. Conclusions. The negligible rate of fatal varicella infection in children with ALL, the risk that accompanies vaccination, and the necessity of withholding chemotherapy for vaccination appear to outweigh the potential benefit of varicella vaccination for children during treatment of ALL. Pediatr Blood Cancer 2012; 58: 12-16. (C) 2010 Wiley Periodicals, Inc.","[Caniza, Miguela A.] St Jude Childrens Hosp, Dept Infect Dis, Memphis, TN 38105 USA; [Caniza, Miguela A.; Pui, Ching-Hon] St Jude Childrens Hosp, Int Outreach Program, Memphis, TN 38105 USA; [Caniza, Miguela A.; Pui, Ching-Hon] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA; [Hunger, Stephen P.] Univ Colorado Denver Sch Med, Dept Pediat, Aurora, CO USA; [Hunger, Stephen P.] Childrens Hosp, Aurora, CO USA; [Schrauder, Andre] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany; [Valsecchi, Maria Grazia; Masera, Giuseppe] Univ Milano Bicocca, Ctr Biostat, Dept Pediat, San Gerardo Hosp, Monza, Italy; [Pui, Ching-Hon] St Jude Childrens Hosp, Dept Oncol, Memphis, TN 38105 USA","Caniza, MA (reprint author), St Jude Childrens Hosp, Dept Infect Dis, MS 721,262 Danny Thomas Pl, Memphis, TN 38105 USA.","miguela.caniza@stjude.org",null,null,"National Institutes of Health [CA21765]; American Lebanese Syrian Associated Charities (ALSAC)","Grant sponsor: National Institutes of Health; Grant number: CA21765; Grant sponsor: American Lebanese Syrian Associated Charities (ALSAC).","ALLAERT FA, 2009, J PUBLIC HLTH, V17, P71, DOI 10.1007/s10389-008-0218-5; ARBETER AM, 1990, PEDIATRICS, V85, P338; ASANO Y, 1994, PEDIATRICS, V94, P524; BALDO V, 2007, EUR SURVEILL, V12; Biondi A, 2009, Leukemia, V23, P2318, DOI 10.1038/leu.2009.211; Bonanni P, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-26; Brown LD, 2001, STAT SCI, V16, P101; Jain N., 2008, Morbidity and Mortality Weekly Report, V57, P1100; FELDMAN S, 1975, PEDIATRICS, V56, P388; FELDMAN S, 1987, PEDIATRICS, V80, P465; GERSHON AA, 1992, J INFECT DIS, V166, pS63; GERSHON AA, 1986, PEDIATRICS, V78, P757; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; Hill G, 2005, PEDIATRICS, V116, pE525, DOI 10.1542/peds.2005-0219; Kwong JC, 2008, VACCINE, V26, P6006, DOI 10.1016/j.vaccine.2008.08.016; LaRussa P, 1996, J INFECT DIS, V174, pS320; Lerner-Geva L, 2009, HUM VACCINES, V5, P136; Lin YH, 2009, J MICROBIOL IMMUNOL, V42, P5; Marin M, 2008, PEDIATRICS, V122, pE744, DOI 10.1542/peds.2008-0567; *NAT ADV COMM IMM, 2008, CAN IMM GUID; Pickering LK, 2009, RED BOOK 2009 REPORT, P714; PICKERING LK, 2006, RED BOOK 2006 REPORT, P711; Prucker C, 2009, LEUKEMIA, V23, P1264, DOI 10.1038/leu.2009.12; Pui CH, 2009, NEW ENGL J MED, V360, P2730, DOI 10.1056/NEJMoa0900386; Pui CH, 1998, NEW ENGL J MED, V339, P605; Pui CH, 2003, INT J HEMATOL, V78, P383, DOI 10.1007/BF02983810; RASCH G, 2004, EUR SURVEILL, V8; ROWLAND P, 1995, J CLIN ONCOL, V13, P1697; Schrauder A, 2007, LANCET, V369, P1232, DOI 10.1016/S0140-6736(07)60567-4; Seward JF, 2002, JAMA-J AM MED ASSOC, V287, P606, DOI 10.1001/jama.287.5.606; *STIKO, 2004, EPIDEMIOL B, V30, P235; Wooten K. G., 2007, Morbidity and Mortality Weekly Report, V56, P880; Wootton SH, 2008, PEDIATR INFECT DIS J, V27, P112, DOI 10.1097/INF.0b013e31815948b5; 2004, IASR, V25, P318",34,5,5,"WILEY PERIODICALS, INC","SAN FRANCISCO","ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA","1545-5009",null,null,"PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","JAN",2012,58,1,null,null,null,null,12,16,null,"10.1002/pbc.22759",null,5,"Oncology; Hematology; Pediatrics","Oncology; Hematology; Pediatrics","856LD","WOS:000297641300005"]
[null,null,null,null,"J","Pohanka, M; Hynek, D; Kracmarova, A; Kruseova, J; Ruttkay-Nedecky, B; Sochor, J; Adam, V; Hubalek, J; Masarik, M; Eckschlager, T; Kizek, R",null,null,null,"Pohanka, Miroslav; Hynek, David; Kracmarova, Alzbeta; Kruseova, Jarmila; Ruttkay-Nedecky, Branislav; Sochor, Jiri; Adam, Vojtech; Hubalek, Jaromir; Masarik, Michal; Eckschlager, Tomas; Kizek, Rene",null,null,"Voltammetry Assay for Assessment of Oxidative Stress linked Pathologies in Brain Tumor suffered Childhood Patients","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"biosensor; electrochemistry; stress; cancer; medulloblastoma; neuroblastoma; glioblastoma; brain cancer; redox status","PROSTATE-CANCER BIOMARKER; ALPHA-LIPOIC ACID; SERUM URIC-ACID; BRDICKA REACTION; ANTIOXIDANT CAPACITY; CYCLIC VOLTAMMETRY; CELL LINES; ELECTROCHEMICAL DETECTION; HEALTHY-SUBJECTS; REDOX STATUS","Oxidative stress plays an important role in cancers due to several reasons including metabolism disorder and hypoxia in tissue near the cancer. Numerous researchers have reported participation of oxidative stress in the cancer pathology. However, the mechanism is not well understood. In this study, we investigated oxidative stress development and depletion of antioxidants in blood samples from medulloblastoma, neuroblastoma, glioblastoma and central nervous system cancer suffered childhood patients. The blood samples were analyzed using square wave voltammetry (SWV), dimethyl-4-phenylenediamine method (DMPD), 2'-azinobis 3-ethylbenzothiazoline-6-sulfonic acid (ABTS), free radical method (FR), ferric reducing antioxidant power (FRAP), reduced and oxidized glutathione, and metallothionein. We proved significant correlation between the markers. The findings demonstrate crucial role of oxidative stress and antioxidants levels regulation in the cancer suffered patients.","[Pohanka, Miroslav; Kracmarova, Alzbeta] Univ Def, Fac Mil Hlth Sci, CZ-50001 Hradec Kralove, Czech Republic; [Pohanka, Miroslav; Hynek, David; Ruttkay-Nedecky, Branislav; Sochor, Jiri; Adam, Vojtech; Hubalek, Jaromir; Masarik, Michal; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Hynek, David; Sochor, Jiri; Adam, Vojtech; Hubalek, Jaromir; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Kruseova, Jarmila; Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15060 Prague 5, Czech Republic; [Kruseova, Jarmila; Eckschlager, Tomas] Univ Hosp Motol, CZ-15060 Prague 5, Czech Republic; [Hubalek, Jaromir] Brno Univ Technol, Fac Elect Engn & Commun, Dept Microelect, CZ-61600 Brno, Czech Republic","Pohanka, M (reprint author), Univ Def, Fac Mil Hlth Sci, Trebesska 1575, CZ-50001 Hradec Kralove, Czech Republic.","kizek@sci.muni.cz","Pohanka, Miroslav /D-7607-2012; Sochor, Jiri/E-1135-2012; Hubalek, Jaromir/D-7753-2012; Masarik, Michal/D-9920-2012","Pohanka, Miroslav /0000-0001-8804-8356; ","CEITEC [CZ.1.05/1.1.00/02.0068]","Financial support from CEITEC CZ.1.05/1.1.00/02.0068 is highly acknowledged. A long-term organization development plan 1011 (Faculty of Military Health Sciences, University of Defence, Czech Republic) and the project for conceptual development of research organization 00064203 are acknowledged as well.",null,61,4,4,"ELECTROCHEMICAL SCIENCE GROUP","BELGRADE","A SPOMENICE 7/12 , 19210 BOR, BELGRADE, VJ 12, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","DEC",2012,7,12,null,null,null,null,11978,11992,null,null,null,15,"Electrochemistry","Electrochemistry","062QT","WOS:000312936700026"]
[null,null,null,null,"J","Schaefer, F; Borzych-Duzalka, D; Azocar, M; Munarriz, RL; Sever, L; Aksu, N; Barbosa, LS; Galan, YS; Xu, H; Coccia, PA; Szabo, A; Wong, W; Salim, R; Vidal, E; Pottoore, S; Warady, BA",null,null,null,"Schaefer, Franz; Borzych-Duzalka, Dagmara; Azocar, Marta; Loza Munarriz, Reyner; Sever, Lale; Aksu, Nejat; Sanchez Barbosa, Lorena; Silva Galan, Yajaira; Xu, Hong; Coccia, Paula A.; Szabo, Attila; Wong, William; Salim, Rosana; Vidal, Enrico; Pottoore, Stephen; Warady, Bradley A.",null,"IPPN Investigators","IMPACT OF GLOBAL ECONOMIC DISPARITIES ON PRACTICES AND OUTCOMES OF CHRONIC PERITONEAL DIALYSIS IN CHILDREN: INSIGHTS FROM THE INTERNATIONAL PEDIATRIC PERITONEAL DIALYSIS NETWORK REGISTRY","PERITONEAL DIALYSIS INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"Children; economics; developing countries; patient survival; technique survival; growth; registry","RENAL REPLACEMENT THERAPY; TRENDS","Background, Objectives, and Methods: The number of patients on chronic peritoneal dialysis (CPD) is increasing rapidly on a global scale. We analyzed the International Pediatric Peritoneal Dialysis Network (IPPN) registry, a global database active in 33 countries spanning a wide range in gross national income (GNI), to identify the impact of economic conditions on CPD practices and outcomes in children and adolescents.. Results: We observed close associations of GNI with the fraction of very young patients on dialysis, the presence and number of comorbidities, the prevalence of patients with unexplained causes of end-stage kidney disease, and the rate of culture-negative peritonitis. The prevalence of automated PD increased with GNI, but was 46% even in the lowest GNI stratum. The GNI stratum also affected the use of biocompatible peritoneal dialysis fluids, enteral tube feeding, calcium-free phosphate binders, active vitamin D analogs, and erythropoiesis-stimulating agents (ESAs). Patient mortality was strongly affected by GNI (hazard ratio per $10 000: 3.3; 95% confidence interval: 2.0 to 5.5) independently of young patient age and the number of comorbidities present. Patients from low-income countries tended to die more often from infections unrelated to CPD (5 of 9 vs 15 of 61, p = 0.1). The GNI was also a strong independent predictor of standardized height (p < 0.0001), adding to the impact of congenital renal disease, anuria, age at PD start, and dialysis vintage. Patients from the lower economic strata (GNI < $18 000) had higher serum parathyroid hormone (PTH) and lower serum calcium, and achieved lower hemoglobin concentrations. No impact of GNI was observed with regard to CPD technique survival or peritonitis incidence.. Conclusions: We conclude that CPD is practiced successfully, albeit with major regional variation related to economic differences, in children around the globe. The variations encompass the acceptance of very young patients and those with associated comorbidities to chronic dialysis programs, the use of automated PD and expensive drugs, and the diagnostic management of peritonitis. These variations in practice related to economic difference do not appear to affect PD technique survival; however, economic conditions seem to affect mortality on dialysis and standardized height, a marker of global child morbidity. Perit Dial Int 2012; 32(4): 399-409","[Schaefer, Franz; Borzych-Duzalka, Dagmara] Ctr Pediat & Adolescent Med, Div Pediat Nephrol, D-69120 Heidelberg, Germany; [Borzych-Duzalka, Dagmara] Med Univ Gdansk, Dept Pediat Nephrol, Gdansk, Poland; [Azocar, Marta] Hosp Ninos Luis Calvo Mackenna, Santiago, Chile; [Loza Munarriz, Reyner] Cayetano Heredia Hosp, Lima, Peru; [Sever, Lale] Cerrahpasa Med Sch, Dept Pediat Nephrol, Istanbul, Turkey; [Aksu, Nejat] Tepecik Teaching & Res Hosp, Dept Pediat, Izmir, Turkey; [Sanchez Barbosa, Lorena] Pediat Hosp Med Ctr SXXI, Cuahutemoc, Mexico; [Silva Galan, Yajaira] Hosp Infantil Nicaragua, Managua, Nicaragua; [Xu, Hong] Fudan Univ, Childrens Hosp, Shanghai 200433, Peoples R China; [Coccia, Paula A.] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina; [Szabo, Attila] Semmelweis Univ, Dept Pediat 1, H-1085 Budapest, Hungary; [Wong, William] Starship Childrens Hosp, Auckland, New Zealand; [Salim, Rosana] Rennius SA, Salta, Argentina; [Vidal, Enrico] Univ Padua, Dialysis & Transplant Unit, Padua, Italy; [Pottoore, Stephen] Childrens Med Ctr, Dallas, TX 75235 USA; [Warady, Bradley A.] Childrens Mercy Hosp, Kansas City, MO 64108 USA","Schaefer, F (reprint author), Ctr Pediat & Adolescent Med, Div Pediat Nephrol, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.","franz.schaefer@med.uni-heidelberg.de","Ariceta, Gema/J-4100-2012",null,"International Society for Peritoneal Dialysis; Baxter Health Care; Fresenius Medical Care; Ipsen; Pfizer; IBM; Sandoz","The authors thank Anja Sander, biostatistician at the Institute of Medical Biometry and Informatics at Heidelberg University, for helpful statistical advice. We gratefully acknowledge the support of the International Society for Peritoneal Dialysis, Baxter Health Care, Fresenius Medical Care, Ipsen, Pfizer, IBM, and Sandoz. Last but not least, we appreciate the continued dedicated support of the IPPN by members of the medical and nursing staffs in all collaborating centers.","Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Chadha V, 2010, PEDIATR NEPHROL, V25, P425, DOI 10.1007/s00467-008-1113-6; Furth SL, 2002, PEDIATRICS, V109, P909, DOI 10.1542/peds.109.5.909; Grassmann A, 2005, NEPHROL DIAL TRANSPL, V20, P2587, DOI 10.1093/ndt/gfi159; Hooi LS, 2005, KIDNEY INT, V67, pS70, DOI 10.1111/j.1523-1755.2005.09418.x; Jain AK, 2012, J AM SOC NEPHROL, V23, P533, DOI 10.1681/ASN.2011060607; Just PM, 2008, NEPHROL DIAL TRANSPL, V23, P2365, DOI 10.1093/ndt/gfm939; Kuczmarski RJ, 2002, VITAL HLTH STAT, V11, P1; Schaefer F, 2007, KIDNEY INT, V72, P1374, DOI 10.1038/sj.ki.5002523; Schaefer F, 2011, NAT REV NEPHROL, V7, P659, DOI 10.1038/nrneph.2011.135; Schaefer F, 2009, PEDIAT NEPHROLOGY, P1714; Schmitt CP, 2011, INT J NEPHROL; The World Bank, WE CLASS COUNTR; United States Department of Health and Human Services Public Health Service National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U.S. Renal Data System (USRDS), 2011, 2011 ANN DAT REP ATL; van Stralen KJ, 2010, PEDIATR NEPHROL, V25, P1379, DOI 10.1007/s00467-010-1472-7; Wang Y, 2006, INT J PEDIATR OBES, V1, P11, DOI 10.1080/17477160600586747; White SL, 2008, B WORLD HEALTH ORGAN, V86, P229, DOI 10.2471/BLT.07.041715; WHO Muticentre Growth Reference Study Group, 2006, ACTA PAEDIATR, V450, P76, DOI DOI 10.1080/08035320500495548",18,4,4,"MULTIMED INC","TORONTO","66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA","0896-8608",null,null,"PERITON DIALYSIS INT","Perit. Dial. Int.","JUL-AUG",2012,32,4,null,null,null,null,399,409,null,"10.3747/pdi.2012.00126",null,11,"Urology & Nephrology","Urology & Nephrology","002JS","WOS:000308528700006"]
[null,null,null,null,"J","Zitka, O; Kominkova, M; Skalickova, S; Skutkova, H; Provaznik, I; Eckschlager, T; Stiborova, M; Adam, V; Trnkova, L; Kizek, R",null,null,null,"Zitka, Ondrej; Kominkova, Marketa; Skalickova, Sylvie; Skutkova, Helena; Provaznik, Ivo; Eckschlager, Tomas; Stiborova, Marie; Adam, Vojtech; Trnkova, Libuse; Kizek, Rene",null,null,"Hydrodynamic Voltammograms Profiling of Metallothionein Fragment","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"Metallothionein; Peptides; Flow Injection Analysis; High Throughput Analysis; Bioinformatics; Bioanalysis, Electrochemistry, Carbon Electrode; Sulfhydryl Group","PERFORMANCE LIQUID-CHROMATOGRAPHY; FLOW-INJECTION ANALYSIS; 56-61 MT-I; BRDICKA REACTION; ELECTROCHEMICAL DETECTION; CARBON ELECTRODES; ELECTROPHORETIC ANALYSIS; MERCURY-ELECTRODE; HEAVY-METALS; VOLTAMMETRY","Metallothionein is intracellular metal binding protein. It can bind essential zinc ions and also toxic metals like cadmium. In cancer research the problem of resistance of cancer cells against anticancer drugs was described. In this study we optimized an electrochemical method for exploring the differences in electrochemical signals in dependence on amino acid sequence in metallothionein. For this purpose we selected the number of fragments based on bioinformatic processing, synthesized them and made high throughput electrochemical analysis. Designed electrochemical analysis was based on automated flow injection analysis with amperometric detector using Coulochem III. Detection was carried out by glassy carbon electrode. We measured hydrodynamic voltammograms (HDVs) for 23 selected metallothionein fragments within the potential range from 100 to 1200 mV. We estimated the maxima of oxidation by processing of cumulative HDV. The oxidation maxima were dependent on amino acid composition, whereas fragments from human isoforms and some saltwater fishes' species had the highest maxima (900 mV). On the opposite side fragments of other mammals like horse, mouse and bull had the lowest potential maxima (700 mV). This should be related with the binding capacity for metal ions.","[Zitka, Ondrej; Kominkova, Marketa; Skalickova, Sylvie; Adam, Vojtech; Trnkova, Libuse; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Zitka, Ondrej; Adam, Vojtech; Trnkova, Libuse; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Skutkova, Helena; Provaznik, Ivo] Brno Univ Technol, Fac Elect Engn & Commun, Dept Biomed Engn, CZ-61200 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic","Zitka, O (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Provaznik, Ivo/F-4121-2012; Skutkova, Helena/D-5194-2014",null,"IGA MENDELU [IGA IP23/2012]; NANOSEMED GA AV [KAN208130801]; CEITEC [CZ.1.05/1.1.00/02.0068]; project for conceptual development of research organization [00064203]","This work has been supported by IGA MENDELU IGA IP23/2012, NANOSEMED GA AV KAN208130801, CEITEC CZ.1.05/1.1.00/02.0068 and by the project for conceptual development of research organization 00064203.",null,50,3,3,"ELECTROCHEMICAL SCIENCE GROUP","BELGRADE","A SPOMENICE 7/12 , 19210 BOR, BELGRADE, VJ 12, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","NOV",2012,7,11,null,null,null,null,10544,10561,null,null,null,18,"Electrochemistry","Electrochemistry","062QH","WOS:000312934600015"]
[null,null,null,null,"J","Palma, M; Hansson, L; Choudhury, A; Nasman-Glaser, B; Eriksson, I; Adamson, L; Rossmann, E; Widen, K; Horvath, R; Kokhaei, P; Vertuani, S; Mellstedt, H; Osterborg, A",null,null,null,"Palma, Marzia; Hansson, Lotta; Choudhury, Aniruddha; Nasman-Glaser, Barbro; Eriksson, Ingrid; Adamson, Lars; Rossmann, Eva; Widen, Karin; Horvath, Rudolf; Kokhaei, Parviz; Vertuani, Simona; Mellstedt, Hakan; Osterborg, Anders",null,null,"Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria","CANCER IMMUNOLOGY IMMUNOTHERAPY",null,null,"English","Article",null,null,null,null,null,"CLL; Dendritic cells; Immunotherapy; Cyclophosphamide; Regulatory T cells; GM-CSF","REGULATORY T-CELLS; B-CLL; CANCER-IMMUNOTHERAPY; MULTIPLE-MYELOMA; CLINICAL-TRIAL; ANTIGEN; TRANSPLANTATION; VACCINES; INDUCTION; PEPTIDE","We previously demonstrated that autologous dendritic cells that have endocytosed apoptotic bodies of chronic lymphocytic leukemia (CLL) cells (Apo-DC) can stimulate antileukemic T cell responses in vitro. In this phase I study, we vaccinated 15 asymptomatic CLL patients at five time points with Apo-DC administered intradermally either alone (cohort I), or in combination with subcutaneous granulocyte-macrophage-colony-stimulating-factor (GM-CSF) (cohort II) or with GM-CSF and intravenous low-dose cyclophosphamide (cohort III). Aim of the study was to evaluate the safety and immunogenicity of Apo-DC alone or in combination with GM-CSF and low-dose cyclophosphamide in CLL patients. All patients completed the vaccination schedule without dose-limiting toxicity. No objective clinical responses were seen. Vaccine-induced leukemia-specific immune responses were evaluated by IFN-gamma ELISpot and proliferation assays over a 52 weeks observation period and immune response criteria were defined. According to these criteria, 10/15 patients were defined as immune responders. The frequency of immune-responding patients was higher in cohorts II (3/5) and III (5/5) than in cohort I (2/5). In order to further characterize the induced immune response, estimation of secreted cytokines and CD107-degranulation assay were performed. Clustering of T and CLL cells was observed in CD107-degranulation assay and visualized by confocal microscopy. Additionally, assessment of regulatory T cells (T-regs) revealed their significantly lower frequencies in immune responders versus non-responders (P < 0.0001). Cyclophosphamide did not reduce T-regs frequency. In conclusion, vaccination with Apo-DC + GM-CSF and cyclophosphamide was safe and elicited anti-CLL immune responses that correlated inversely with T-regs levels. Lack of clinical responses highlights the necessity to develop more potent vaccine strategies in B cell malignancies.","[Mellstedt, Hakan] Karolinska Univ Hosp Solna, Dept Oncol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden; [Palma, Marzia; Hansson, Lotta; Choudhury, Aniruddha; Nasman-Glaser, Barbro; Eriksson, Ingrid; Adamson, Lars; Rossmann, Eva; Widen, Karin; Horvath, Rudolf; Kokhaei, Parviz; Vertuani, Simona; Mellstedt, Hakan; Osterborg, Anders] Karolinska Inst, Dept Oncol & Pathol, Canc Ctr Karolinska, Stockholm, Sweden; [Palma, Marzia; Hansson, Lotta; Rossmann, Eva; Osterborg, Anders] Karolinska Univ Hosp Solna, Dept Hematol, S-17176 Stockholm, Sweden; [Choudhury, Aniruddha] Univ Queensland, Ctr Immune & Targeted Therapy, Brisbane, Qld, Australia; [Horvath, Rudolf] Charles Univ Prague, Inst Immunol, Sch Med 2, Prague, Czech Republic; [Kokhaei, Parviz] Semnan Med Univ, Dept Immunol, Semnan, Iran","Mellstedt, H (reprint author), Karolinska Univ Hosp Solna, Dept Oncol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden.","hakan.mellstedt@karolinska.se",null,null,"Swedish Cancer Society; Cancer Society in Stockholm; King Gustav V Jubilee Fund; Cancer and Allergy Foundation; Karolinska Institutet Foundations; EU [LSHB-CT-2004-512074]; DC-THERA; Stockholm County Council; IMTAC; Miltenyi Biotec GmbH","Supported by grants from The Swedish Cancer Society, The Cancer Society in Stockholm, King Gustav V Jubilee Fund, The Cancer and Allergy Foundation, The Karolinska Institutet Foundations, the EU-grant LSHB-CT-2004-512074; DC-THERA, The Stockholm County Council; IMTAC and Miltenyi Biotec GmbH. For excellent secretarial help, we thank Ms. Leila Relander.",null,41,3,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-7004",null,null,"CANCER IMMUNOL IMMUN","Cancer Immunol. Immunother.","JUN",2012,61,6,null,null,null,null,865,879,null,"10.1007/s00262-011-1149-5",null,15,"Oncology; Immunology","Oncology; Immunology","950AU","WOS:000304621900011"]
[null,null,null,null,"J","Sheardova, K; Hort, J; Rektorova, I; Rusina, R; Linek, V; Bartos, A",null,null,null,"Sheardova, K.; Hort, J.; Rektorova, I.; Rusina, R.; Linek, V.; Bartos, A.",null,null,"Dementia Diagnosis and Treatment in Czech Neurological and Psychiatric Practices","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; dementia; management; cholinesterase inhibitors; Czech Republic","ALZHEIMERS-DISEASE; EUROPE; MANAGEMENT; BATTERY","The aim of the study: The aim of this study was to obtain comprehensive information about standard practice in management of dementia among specialists responsible for the care of patients with cognitive deterioration in the Czech Republic. Methods: The data were collected by the means of structured questionnaires completed by neurologists, psychiatrists and geriatricians during seminars focused on cognitive topics. Results: 152 specialists were participating in the study. The respondents saw the mean of 27 patients with cognitive deficit monthly, 33% of whom suffer from Alzheimer disease. Neurologists diagnosed equal proportions of patients with mild cognitive impairment, and with mild to moderate stages of dementia; psychiatrists and geriatricians mostly diagnose patients at the moderate stage of the disease. Nearly all of the neurologists and half of the psychiatrists examined their patients by MRI or CT prior to starting therapy. SPECT was mainly used by neurologists (42%). The majority of patients took cholinesterase inhibitor (ChEI) for 2-3 years. Half of the specialists occasionally used dual therapy with ChEI and memantine. Nootropics were administered more frequently by psychiatrists. All the respondents prescribed an Selective Serotonin Reuptake Inhibitors (SSRI) for the therapy of coinciding depression. Conclusion: Dementia was managed by the majority of specialists according to the EFNS guidelines. The early stages of the disease were mostly handled by neurologists, who also tend to employ more sophisticated diagnostic tools in differential diagnosis of dementia.","[Sheardova, K.; Hort, J.] St Annes Univ Hosp, Int Clin Res Ctr Neurol, Brno 65691, Czech Republic; [Hort, J.] Charles Univ Prague, Motol Teaching Hosp, Dept Neurol, CR-11636 Prague 1, Czech Republic; [Rektorova, I.] Masaryk Univ, St Annes Teaching Hosp, CEITEC, Dept Neurol 1, Brno, Czech Republic; [Rusina, R.] Inst Postgrad Med Educ, Dept Neurol, Prague, Czech Republic; [Rusina, R.] Thomayer Teaching Hosp, Prague, Czech Republic; [Linek, V.] Gen Teaching Hosp, Dept Neurol, Prague, Czech Republic; [Bartos, A.] Charles Univ Prague, Teaching Hosp Kralovske Vinohrady, Fac Med 3, Prague, Czech Republic; [Bartos, A.] Prague Psychiat Ctr, Prague, Czech Republic","Sheardova, K (reprint author), St Annes Univ Hosp, Int Clin Res Ctr Neurol, Pekarska 53, Brno 65691, Czech Republic.","ksheard@sendme.cz",null,null,null,null,null,13,3,3,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,2,null,null,null,null,208,211,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","932MA","WOS:000303294000011"]
[null,null,null,null,"J","Vaneckova, I; Kujal, P; Huskova, Z; Vanourkova, Z; Vernerova, Z; Chabova, VC; Skaroupkova, P; Kramer, HJ; Tesar, V; Cervenka, L",null,null,null,"Vaneckova, Ivana; Kujal, Petr; Huskova, Zuzana; Vanourkova, Zdenka; Vernerova, Zdenka; Chabova, Vera Certikova; Skaroupkova, Petra; Kramer, Herbert J.; Tesar, Vladimir; Cervenka, Ludek",null,null,"Effects of Combined Endothelin A Receptor and Renin-Angiotensin System Blockade on the Course of End-Organ Damage in 5/6 Nephrectomized Ren-2 Hypertensive Rats","KIDNEY & BLOOD PRESSURE RESEARCH",null,null,"English","Article",null,null,null,null,null,"5/6 nephrectomy; Endothelin receptor type A; AT(1) receptor blocker; End-organ damage; Hypertension","BLOOD-PRESSURE; TRANSGENIC RATS; ACE-INHIBITOR; RENAL LESIONS; ANG-II; KIDNEY; MODEL; PROGRESSION; REGRESSION; REDUCTION","Our previous studies in rats with ablation nephrectomy have shown similar cardiorenal protective effects of renin-angiotensin system (RAS)-dependent treatment (combination of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker) and RAS-independent treatment (combination of alpha- and beta-adrenoreceptor antagonist and diuretics). Moreover, selective blockade of endothelin (ET) receptor type A (ETA) improved survival rate and attenuated hypertension and organ damage in Ren-2 transgenic rats. Therefore, we were interested in whether ETA receptor blockade could have additive effects to the classical blockade of the RAS. Transgenic rats underwent 5/6 renal ablation at the age of 2 months and were treated for 20 weeks with RAS blockers alone (angiotensin II receptor blocker - losartan, and angiotensin-converting enzyme inhibitor - trandolapril), ETA receptor blocker alone (atrasentan) or with the combination of RAS and ETA receptor blockade. RAS blockade normalized blood pressure and improved survival. It decreased cardiac hypertrophy and proteinuria as well as tissue angiotensin II and ET-1 levels. In contrast, ETA receptor blockade only partially improved survival rate, reduced blood pressure, attenuated the development of cardiac hypertrophy and transiently reduced proteinuria. However, no additive cardio-and renoprotective effects of ETA and RAS blockade were noted at the end of the study. Copyright (c) 2012 S. Karger AG, Basel","[Vaneckova, Ivana] Acad Sci Czech Republic, Inst Physiol Vvi, CZ-14220 Prague 4, Czech Republic; [Vaneckova, Ivana; Huskova, Zuzana; Vanourkova, Zdenka; Chabova, Vera Certikova; Cervenka, Ludek] Charles Univ Prague, Cardiovasc Res Ctr, Prague, Czech Republic; [Kujal, Petr; Vernerova, Zdenka] Charles Univ Prague, Dept Pathol, Fac Med 3, Prague, Czech Republic; [Chabova, Vera Certikova; Tesar, Vladimir] Charles Univ Prague, Dept Nephrol, Fac Med 1, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague, Czech Republic; [Kujal, Petr; Huskova, Zuzana; Vanourkova, Zdenka; Vernerova, Zdenka; Chabova, Vera Certikova; Skaroupkova, Petra; Cervenka, Ludek] Inst Clin & Expt Med, Dept Expt Med, Prague, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, Bonn, Germany","Vaneckova, I (reprint author), Acad Sci Czech Republic, Inst Physiol Vvi, Videnska 1083, CZ-14220 Prague 4, Czech Republic.","ivanava@biomed.cas.cz","Vaneckova, Ivana/B-5543-2012",null,"Internal Grant Agency of the Ministry of Health [NS 10500-3, NT/12171-5]; Institute for Clinical and Experimental Medicine [MZO 00023001, NS/10499-3]; German Research Foundation, Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]; German Academic Exchange Service (Deutscher Akademischer Austauschdienst), Bonn-Prague University partnership; Internal Grant Agency of the Ministry of Health of the Czech Republic [NS/9703-4]; European Commission through the Operational Program Prague - Competitiveness, project `CEVKOON' [CZ.2.16/3.1.00/22126]; Ministry of Education, Youth and Sports [LH 11116]","This study was supported by grant No. NS 10500-3 awarded by the Internal Grant Agency of the Ministry of Health to V.C.C. Z.H. has received the institutional financial support of the Institute for Clinical and Experimental Medicine (MZO 00023001) and grant No. NS/10499-3, and support from the Internal Grant Agency of the Ministry of Health. H.J.K. was supported by grants from the German Research Foundation, Bonn (Kra 436/14-2 and 436 TSE 113/57/0-1), and the German Academic Exchange Service (Deutscher Akademischer Austauschdienst), Bonn-Prague University partnership. L.C. was also supported by grant No. NS/9703-4 awarded by the Internal Grant Agency of the Ministry of Health of the Czech Republic. This study also received financial support from the European Commission through the Operational Program Prague - Competitiveness, project `CEVKOON' (CZ.2.16/3.1.00/22126). Z.H. is also supported by grant No. NT/12171-5 awarded by the Internal Grant Agency of the Ministry of Health. L.C. is a recipient of a grant MSMT-Kontakt (LH 11116) from the Ministry of Education, Youth and Sports for the support of the international research cooperation.",null,34,3,3,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096","1423-0143",null,"KIDNEY BLOOD PRESS R","Kidney Blood Pressure Res.",null,2012,35,5,null,null,null,null,382,392,null,"10.1159/000336823",null,11,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","Physiology; Urology & Nephrology; Cardiovascular System & Cardiology","963BH","WOS:000305594600011"]
[null,null,null,null,"J","Neu, AM; Sander, A; Borzych-Duzalka, D; Watson, AR; Valles, PG; Ha, IS; Patel, H; Askenazi, D; Balasz-Chmielewska, I; Lauronen, J; Groothoff, JW; Feber, J; Schaefer, F; Warady, BA",null,null,null,"Neu, Alicia M.; Sander, Anja; Borzych-Duzalka, Dagmara; Watson, Alan R.; Valles, Patricia G.; Ha, Il Soo; Patel, Hiren; Askenazi, David; Balasz-Chmielewska, Irena; Lauronen, Jouni; Groothoff, Jaap W.; Feber, Janusz; Schaefer, Franz; Warady, Bradley A.",null,"IPPN Investigators","COMORBIDITIES IN CHRONIC PEDIATRIC PERITONEAL DIALYSIS PATIENTS: A REPORT OF THE INTERNATIONAL PEDIATRIC PERITONEAL DIALYSIS NETWORK","PERITONEAL DIALYSIS INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"Pediatric; comorbidities; syndrome; outcomes; hospitalization; mortality","STAGE RENAL-DISEASE; CHILDREN; MORTALITY; RISK; HOSPITALIZATION; HEMODIALYSIS; ADOLESCENTS; INITIATION; DEATH","Background, Objectives, and Methods: Hospitalization and mortality rates in pediatric dialysis patients remain unacceptably high. Although studies have associated the presence of comorbidities with an increased risk for death in a relatively small number of pediatric dialysis patients, no large-scale study had set out to describe the comorbidities seen in pediatric dialysis patients or to evaluate the impact of those comorbidities on outcomes beyond the newborn period. In the present study, we evaluated the prevalence of comorbidities in a large international cohort of pediatric chronic peritoneal dialysis (CPD) patients from the International Pediatric Peritoneal Dialysis Network registry and began to assess potential associations between those comorbidities and hospitalization rates and mortality. Results: Information on comorbidities was available for 1830 patients 0-19 years of age at dialysis initiation. Median age at dialysis initiation was 9.1 years [interquartile range (IQR): 10.9], median follow-up for calculation of hospitalization rates was 15.2 months (range: 0.2 - 80.9 months), and total follow-up time in the registry was 2095 patient-years. At least 1 comorbidity had been reported for 602 of the patients (32.9%), with 283 (15.5%) having cognitive impairment; 230 (12.6%), motor impairment; 167 (9.1%), cardiac abnormality; 76 (4.2%), pulmonary abnormality; 212 (11.6%), ocular abnormality; and 101 (5.5%), hearing impairment. Of the 150 patients (8.2%) that had a defined syndrome, 85% had at least 1 nonrenal comorbidity, and 64% had multiple comorbidities. The presence of at least 1 comorbidity was associated with a higher hospitalization rate [hospital days per 100 observation days: 1.7 (IQR: 5.8) vs 1.2 (IQR: 3.9), p = 0.001] and decreased patient survival (4-year survival rate: 73% vs 90%, p < 0.0001). Conclusions: Nearly one third of pediatric CPD patients in a large international cohort had at least 1 comorbidity, and multiple comorbidities were frequently reported among patients with a defined syndrome. Preliminary analysis suggests an association between comorbidity and poor outcome in those patients. As this powerful international registry matures, further multivariate analyses will be important to more clearly define the impact of comorbidities on hospitalization rates and mortality in pediatric CPD patients. Perit Dial Int 2012; 32(4): 410-418","[Neu, Alicia M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Sander, Anja] Univ Heidelberg, Inst Med Biometry & Informat, Heidelberg, Germany; [Borzych-Duzalka, Dagmara; Balasz-Chmielewska, Irena] Med Univ Gdansk, Gdansk, Poland; [Watson, Alan R.] Nottingham Childrens Hosp, Childrens Renal & Urol Unit, Nottingham, England; [Valles, Patricia G.] Hosp Humberto Notti, Mendoza, Argentina; [Ha, Il Soo] Seoul Natl Univ Childrens Hosp, Seoul, South Korea; [Patel, Hiren] Nationwide Childrens Hosp, Columbus, OH USA; [Askenazi, David] Univ Alabama Birmingham, Birmingham, AL USA; [Lauronen, Jouni] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Lauronen, Jouni] Finnish Red Cross Blood Serv, Helsinki, Finland; [Groothoff, Jaap W.] Univ Amsterdam, Emma Childrens Hosp AMC, Amsterdam, Netherlands; [Feber, Janusz] Childrens Hosp Eastern Ontario, Ottawa, ON, Canada; [Schaefer, Franz] Univ Heidelberg, Heidelberg, Germany; [Warady, Bradley A.] Childrens Mercy Hosp, Kansas City, MO USA","Neu, AM (reprint author), 200 N Wolfe St,Room 3065, Baltimore, MD 21287 USA.","aneu1@jhmi.edu","Ariceta, Gema/J-4100-2012; Patel, Hiren/E-3835-2011",null,"International Society for Peritoneal Dialysis; Baxter Health Care; Fresenius Medical Care; Ipsen; Pfizer; IBM; Sandoz","The authors gratefully acknowledge the support of the International Society for Peritoneal Dialysis, Baxter Health Care, Fresenius Medical Care, Ipsen, Pfizer, IBM, and Sandoz. We also appreciate the continued dedicated support of the IPPN by the members of the medical and nursing staffs in all collaborating centers.","Amaral S, 2006, J AM SOC NEPHROL, V17, P2878, DOI 10.1681/ASN.2005111215; Amaral S, 2008, CLIN J AM SOC NEPHRO, V3, P759, DOI 10.2215/CJN.02720707; Furth SL, 2002, PEDIATR NEPHROL, V17, P450; Furth SL, 2002, PEDIATRICS, V109, P909, DOI 10.1542/peds.109.5.909; Harambat J, 2012, PEDIATR NEPHROL, V27, P363, DOI 10.1007/s00467-011-1939-1; Hijazi R, 2009, J PEDIATR, V155, P111, DOI 10.1016/j.jpeds.2009.01.007; McDonald SP, 2004, NEW ENGL J MED, V350, P2654, DOI 10.1056/NEJMoa031643; North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS), 2011, 2011 ANN DIAL REP; Samuel SM, 2011, CLIN J AM SOC NEPHRO, V6, P1094, DOI 10.2215/CJN.04920610; Schaefer F, 2012, PERITON DIALYSIS INT, V32, P399, DOI 10.3747/pdi.2012.00126; Tabatabaeifar M, 2009, PEDIATR NEPHROL, V24, P2361, DOI 10.1007/s00467-009-1287-6; Tsai HL, 2010, PERITON DIALYSIS INT, V30, P233, DOI 10.3747/pdi.2008.00278; United States Department of Health and Human Services Public Health Service National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U.S. Renal Data System (USRDS), 2011, 2011 ANN DAT REP ATL; Warady BA, 2003, PEDIATR NEPHROL, V18, P1055, DOI 10.1007/s00467-003-1214-1; Weber S, 2006, J AM SOC NEPHROL, V17, P2864, DOI 10.1681/ASN.2006030277; Wong CS, 2002, KIDNEY INT, V61, P630, DOI 10.1046/j.1523-1755.2002.00169.x; Wood EG, 2001, AM J KIDNEY DIS, V37, P573, DOI 10.1053/ajkd.2001.22083",17,3,3,"MULTIMED INC","TORONTO","66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA","0896-8608",null,null,"PERITON DIALYSIS INT","Perit. Dial. Int.","JUL-AUG",2012,32,4,null,null,null,null,410,418,null,"10.3747/pdi.2012.00124",null,9,"Urology & Nephrology","Urology & Nephrology","002JS","WOS:000308528700007"]
[null,null,null,null,"J","Kestlerova, A; Feyereisl, J; Frisova, V; Mechurova, A; Sula, K; Zima, T; Belacek, J; Madar, J",null,null,null,"Kestlerova, A.; Feyereisl, J.; Frisova, V.; Mechurova, A.; Sula, K.; Zima, T.; Belacek, J.; Madar, J.",null,null,"Immunological and biochemical markers in preeclampsia","JOURNAL OF REPRODUCTIVE IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Preeclampsia; Cell-mediated immunity; Anti-cardiolipin autoantibodies; Trophoblast; Immunoglobulins","ANTIPHOSPHOLIPID ANTIBODIES; PREGNANCY; INFLAMMATION","A basic precondition for the development of preeclampsia is the presence of placental trophoblast cells in the maternal blood circulation. On the other hand, while trophoblast cells are present in the blood of all pregnant women, preeclampsia occurs in only 2-5% of them. Evidently, other factors play a crucial role. The aim of this study was to compare a set of selected immunological factors (anti-cardiolipin autoantibodies, trophoblast-induced cell-mediated immunity, C3 and C4 complement components) and biochemical factors (serum immunoglobulins IgA, IgG, IgM) among three groups of women with uncomplicated pregnancy, gestational hypertension, or preeclampsia. Blood samples were taken 2-12 h before delivery. In the preeclampsia group, there was a significantly higher number of women positive for anti-cardiolipin autoantibodies, trophoblast-induced cell-mediated immunity was elevated, serum IgG was elevated and C4 complement component was reduced. We conclude that both elevated autoimmune reactivity and the higher immune reactivity to trophoblast may contribute to the onset of preeclampsia. (C) 2012 Published by Elsevier Ireland Ltd.","[Madar, J.] Inst Care Mother & Child, Dept Reprod Immunol, CZ-14710 Prague 4, Czech Republic; [Frisova, V.] Profema Fetal Med Ctr Ltd, Prague, Czech Republic; [Frisova, V.] Charles Univ Prague, Dept Radiol, Fac Hosp Motol, Prague, Czech Republic; [Frisova, V.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Kestlerova, A.; Zima, T.] Charles Univ Prague, Inst Clin Biochem & Lab Diagnost, Fac Med 1, Prague, Czech Republic; [Kestlerova, A.; Zima, T.] Charles Univ Prague, Gen Teaching Hosp, Prague, Czech Republic; [Belacek, J.] Charles Univ Prague, Inst Biophys & Informat, Fac Med 1, Prague, Czech Republic","Madar, J (reprint author), Inst Care Mother & Child, Dept Reprod Immunol, Podolske Nabrezi 157, CZ-14710 Prague 4, Czech Republic.","jindrich.madar@upmd.eu",null,null," [RVO-VFN64165/2012]","This study was supported by research project RVO-VFN64165/2012. The authors are indebted to Ms. Caroline Sharp for her linguistic help.",null,23,2,2,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0165-0378",null,null,"J REPROD IMMUNOL","J. Reprod. Immunol.","DEC",2012,96,41671,null,null,null,null,90,94,null,"10.1016/j.jri.2012.10.002",null,5,"Immunology; Reproductive Biology","Immunology; Reproductive Biology","063BD","WOS:000312969900011"]
[null,null,null,null,"J","Komenda, M; Schwarz, D; Feberova, J; Stipek, S; Mihal, V; Dusek, L",null,null,null,"Komenda, Martin; Schwarz, Daniel; Feberova, Jitka; Stipek, Stanislav; Mihal, Vladimir; Dusek, Ladislau",null,null,"Medical faculties educational network: Multidimensional quality assessment","COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE",null,null,"English","Article",null,null,null,null,null,"Educational portal; E-learning; Computer communication network; E-publishing; Quality assessment tools; Medical education","WEB PORTALS; INSTRUMENT; MODEL","Today, World Wide Web technology provides many opportunities in the disclosure of electronic learning and teaching content. The MEFANET project (MEdical FAculties NEIWork) has initiated international, effective and open cooperation among all Czech and Slovak medical faculties in the medical education fields. This paper introduces the original MEFANET educational web portal platform. Its main aim is to present the unique collaborative environment, which combines the sharing of electronic educational resources with the use tools for their quality evaluation. It is in fact a complex e-publishing system, which consists of ten standalone portal instances and one central gateway. The fundamental principles of the developed system and used technologies are reported here, as well as procedures of a new multidimensional quality assessment. (c) 2012 Elsevier Ireland Ltd. All rights reserved.","[Komenda, Martin; Schwarz, Daniel; Dusek, Ladislau] Masaryk Univ, Inst Biostat & Anal, CS-60177 Brno, Czech Republic; [Feberova, Jitka] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Stipek, Stanislav] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Mihal, Vladimir] Palacky Univ Olomouc, Fac Med & Dent, Olomouc, Czech Republic","Komenda, M (reprint author), Masaryk Univ, Inst Biostat & Anal, CS-60177 Brno, Czech Republic.","komenda@iba.muni.cz","Dusek, Ladislav/G-8794-2013",null,"European Social Fund; state budget of the Czech Republic;  [102/09/H083];  [CZ.1.07/2.4.00/12.0050]","This work was supported by the grant project GACR no. 102/09/H083 and by the project CZ.1.07/2.4.00/12.0050 funded from European Social Fund and the state budget of the Czech Republic.",null,26,2,2,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0169-2607",null,null,"COMPUT METH PROG BIO","Comput. Meth. Programs Biomed.","DEC",2012,108,3,null,null,null,null,900,909,null,"10.1016/j.cmpb.2012.05.002",null,10,"Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Medical Informatics","Computer Science; Engineering; Medical Informatics","049IN","WOS:000311976100003"]
[null,null,null,null,"J","Soldanova, M; Leseticky, O; Komarkova, L; Dostalova, T; Smutny, V; Spidlen, M",null,null,null,"Soldanova, Milada; Leseticky, Ondrej; Komarkova, Lenka; Dostalova, Tatjana; Smutny, Vladimir; Spidlen, Milos",null,null,"Effectiveness of treatment of adult patients with the straightwire technique and the lingual two-dimensional appliance","EUROPEAN JOURNAL OF ORTHODONTICS",null,null,"English","Article",null,null,null,null,null,null,"MANDIBULAR ANTERIOR ALIGNMENT; ARCH FORM; ORTHODONTICS; DISCOMFORT; STABILITY; RELAPSE","The aim of this prospective study was to compare the outcome of orthodontic therapy using two different therapeutic strategies: the labial straightwire (SW) technique and the lingual two-dimensional (2D) technique on the lower dental arch. The sample included 50 subjects (39 females and 11 males) with a complete dentition and an Angle Class I malocclusion with crowding who were treated non-extraction. The subjects were divided into two groups: group A, consisted of 25 patients (19 females and 6 males), who were treated with the lingual 2D technique, and group B, 25 patients (20 females and 5 males) treated using the labial SW appliance (Roth system). Changes in the position of the lower incisors to the A-Po and mandibular lines were measured on cephalograms and those in the transverse and sagittal planes on individual sectors of the dental arch from 2D images of model casts obtained before and after the active phase of orthodontic treatment. Standard statistical methods were used for evaluation. Both methods (when used with appropriate indications) showed comparable results. The lingual 2D technique also represents an aesthetically favourable solution for adult patients.","[Leseticky, Ondrej; Komarkova, Lenka] Univ Econ, Inst Healthcare Serv Management, Prague, Czech Republic; [Dostalova, Tatjana] Charles Univ Prague, Fac Med 2, Dept Pediat Dent, Prague, Czech Republic; [Smutny, Vladimir] Czech Tech Univ, Dept Cybernet, Ctr Machine Percept, CR-16635 Prague, Czech Republic; [Spidlen, Milos] Palacky Univ, Fac Med, Clin Dent Med, CR-77147 Olomouc, Czech Republic; [Soldanova, Milada] Private Off, Jindrichuv Hradec, Czech Republic","Soldanova, M (reprint author), Nadrazni 293-2, Jindrichuv Hradec 37701, Czech Republic.","msoldanova@volny.cz","Smutny, Vladimir/A-2498-2013","Smutny, Vladimir/0000-0002-9692-8908","ZIMOLEZ; IGA MZCR [9991-4, IG632080];  [NPVII 2C06019]","Project NPVII 2C06019 (Modeling and Acquisition of Medical Knowledge); 'ZIMOLEZ'; the IGA MZCR 9991-4, IG632080 projects.",null,31,2,2,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0141-5387",null,null,"EUR J ORTHODONT","Eur. J. Orthodont.","DEC",2012,34,6,null,null,null,null,674,680,null,"10.1093/ejo/cjr059",null,7,"Dentistry, Oral Surgery & Medicine","Dentistry, Oral Surgery & Medicine","048SS","WOS:000311933700004"]
[null,null,null,null,"J","Sztalmachova, M; Hlavna, M; Gumulec, J; Holubova, M; Babula, P; Balvan, J; Sochor, J; Tanhauserova, V; Raudenska, M; Krizkova, S; Adam, V; Eckschlager, T; Kizek, R; Masarik, M",null,null,null,"Sztalmachova, Marketa; Hlavna, Marian; Gumulec, Jaromir; Holubova, Monika; Babula, Petr; Balvan, Jan; Sochor, Jiri; Tanhauserova, Veronika; Raudenska, Martina; Krizkova, Sona; Adam, Vojtech; Eckschlager, Tomas; Kizek, Rene; Masarik, Michal",null,null,"Effect of zinc(II) ions on the expression of pro- and anti-apoptotic factors in high-grade prostate carcinoma cells","ONCOLOGY REPORTS",null,null,"English","Article",null,null,null,null,null,"apoptosis; prostate cancer; prognostic marker; Bcl-2; p53; polymerase chain reaction; thiol group; fluorescence microscopy","NF-KAPPA-B; CANCER CELLS; CAPILLARY-ELECTROPHORESIS; METALLOTHIONEIN DETECTION; RADICAL PROSTATECTOMY; RADIATION-THERAPY; ROS GENERATION; BCL-2 FAMILY; C-JUN; KI-67","Several typical characteristics of prostate tissue have been identified including the ability to accumulate zinc(II). However, this feature of prostate cells is lost during carcinogenesis and, thus, prostate cells are unable to accumulate zinc(II) ions in high levels. Therefore, we can expect that zinc(II) ions can significantly contribute to the progression of tumour disease and to the ability of prostate cell lines to metastasize. In this study, we aimed our attention on determining the expression of Bcl-2, c-Fos, c-Jun, Ki-67, NF-kappa B and p53 genes in two prostate cell lines, as the 22Rv1 cell line, a model of aggressive partially androgen-sensitive prostate cancer and the PNT1A cell line, a normal prostate cell line model. Moreover, we were interested in the mechanisms through which exposure of these cell lines to zinc(II) ions could influence expression of the above-mentioned genes. We found that zinc(II) ions caused elevated expression of Ki-67, a marker of proliferation, extremely low expression of p53, high expression of Bcl-2 and no changes in the expression of p53. Our experimental data show different effect of zinc(II) ions on expression of the above-mentioned regulatory genes, which may give us more information on their impact on cancer development and progression with possible using for cancer therapy.","[Sztalmachova, Marketa; Hlavna, Marian; Gumulec, Jaromir; Holubova, Monika; Balvan, Jan; Tanhauserova, Veronika; Raudenska, Martina; Masarik, Michal] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-62500 Brno, Czech Republic; [Sztalmachova, Marketa; Gumulec, Jaromir; Sochor, Jiri; Krizkova, Sona; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Hlavna, Marian; Babula, Petr] Univ Vet & Pharmaceut Sci, Fac Pharm, Dept Nat Drugs, CZ-61242 Brno, Czech Republic; [Babula, Petr; Sochor, Jiri; Krizkova, Sona; Adam, Vojtech; Kizek, Rene; Masarik, Michal] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Masarik, M (reprint author), Masaryk Univ, Fac Med, Dept Pathol Physiol, Kamenice 5, CZ-62500 Brno, Czech Republic.","masarik@med.muni.cz","Sochor, Jiri/E-1135-2012; Masarik, Michal/D-9920-2012; Krizkova, Sona/E-9617-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Balvan, Jan/I-2945-2012; Gumulec, Jaromir/D-7638-2012; Sztalmachova, Marketa/F-4144-2012; Raudenska, Martina/F-9187-2012","Gumulec, Jaromir/0000-0002-9658-3444; ","CYTORES [P301/10/0356]; CEITEC [CZ.1.05/1.1.00/02.0068]; LPR [00064203]","Financial support from CYTORES P301/10/0356, CEITEC CZ.1.05/1.1.00/02.0068 and LPR 2011 and project for conceptual development of research organization 00064203 was greatly acknowledged.",null,52,2,2,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1021-335X",null,null,"ONCOL REP","Oncol. Rep.","SEP",2012,28,3,null,null,null,null,806,814,null,null,null,9,"Oncology","Oncology","984SA","WOS:000307210600007"]
[null,null,null,null,"J","Stefano, GB; Kralickova, M; Ptacek, R; Kuzelova, R; Esch, T; Kream, RM",null,null,null,"Stefano, George B.; Kralickova, Milena; Ptacek, Radek; Kuzelova, Rana; Esch, Tobias; Kream, Richard M.",null,null,"Low dose morphine adjuvant therapy for enhanced efficacy of antipsychotic drug action: Potential involvement of endogenous morphine in the pathophysiology of schizophrenia","MEDICAL SCIENCE MONITOR",null,null,"English","Article",null,null,null,null,null,"schizophrenia; dopamine; serotonin; morphine; mu opioid receptors; antipsychotic drugs; nicotinic receptors","HEALTHY-VOLUNTEERS; RECEPTOR-BINDING; SEROTONIN; COGNITION; PAIN","Major thematic threads linking extensive preclinical and clinical efforts have established a working mechanistic scheme whereby atypical antipsychotic drugs ameliorate negative DSM IV diagnostic criteria by effecting relatively potent blockade of serotonin (5-HT) (2A) receptors coupled with weaker antagonism of dopamine D(2) receptors in frontal cortical areas. These contentions are more or less supported by in vitro binding experiments employing cloned receptors on cultured cells, although significant functional involvement of 5-HT(2C) receptors has also been proposed. It is interesting that a key statistical analysis indicates a major shift in usage back to typical antipsychotic agents for management of schizophrenia from 1995-2008, whereas off-label usage of atypical antipsychotic agents was markedly increased or expanded for bipolar affective disorder. Importantly, meta-analyses generally did not support efficacy differences between the other atypical antipsychotics compared with the older typical agents. A critical examination of putative functional linkages of morphine and its type-selective mu opioid receptor to higher order cortical regulation of cognitive processes may provide novel insights into human behavioral processes that are severely impaired in schizophrenia spectrum disorders.","[Stefano, George B.; Esch, Tobias; Kream, Richard M.] SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA; [Kralickova, Milena] Charles Univ Prague, Fac Med Pilsen, Dept Histol & Embryol, Prague, Czech Republic; [Ptacek, Radek; Kuzelova, Rana] Charles Univ Prague, Fac Med 1, Psychiat Clin, Prague, Czech Republic; [Kuzelova, Rana] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Esch, Tobias] Coburg Univ Appl Sci, Div Integrat Hlth Promot, Coburg, Germany","Stefano, GB (reprint author), SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA.","gstefano@sunynri.org","Ptacek, Radek/C-6696-2009; Esch, Tobias/J-3812-2013","Esch, Tobias/0000-0001-5176-4367","MitoGenetics, LLC","Supported in part by a grant from MitoGenetics, LLC",null,33,2,2,"INT SCIENTIFIC LITERATURE, INC","SMITHTOWN","361 FOREST LANE, SMITHTOWN, NY 11787 USA","1234-1010",null,null,"MED SCI MONITOR","Med. Sci. Monitor","JUL",2012,18,7,null,null,null,null,"HY23","HY26",null,null,null,4,"Medicine, Research & Experimental","Research & Experimental Medicine","980HD","WOS:000306883300001"]
[null,null,null,null,"J","Hubacek, JA; Stanek, V; Gebauerova, M; Poledne, R; Aschermann, M; Skalicka, H; Matouskova, J; Kruger, A; Penicka, M; Hrabakova, H; Veselka, J; Hajek, P; Lanska, V; Adamkova, V; Pitha, J",null,null,null,"Hubacek, J. A.; Stanek, V.; Gebauerova, M.; Poledne, R.; Aschermann, M.; Skalicka, H.; Matouskova, J.; Kruger, A.; Penicka, M.; Hrabakova, H.; Veselka, J.; Hajek, P.; Lanska, V.; Adamkova, V.; Pitha, J.",null,null,"Association between a Marker on Chromosome 9 and Acute Coronary Syndrome Confirmatory Study on Czech Population","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,"acute coronary syndrome; ANRIL; polymorphism; chromosome 9; CDKN2A; CDKN2B","HEART-DISEASE; LOCUS; GENOTYPE; 9P21.3; HEALTH; ANRIL; RISK; APOE","Myocardial infarction (MI) is the leading cause of death in industrialized countries. All the classical risk factors for MI are responsible for approximately 50 % of MI cases. Attention has therefore recently been attracted to those genetic variants that are not associated with conventional risk factors. One of them is the marker rs10757274 in the \"gene-free\" zone on chromosome 9, which has been repeatedly recognized as a risk factor for development of MI in Western populations. We analysed the relationship between the rs10757274 variant on chromosome 9 and risk of the acute coronary syndrome (ACS) in Czech population. The rs10757274 (A > G) variant was successfully analysed (CR = 99.4 % for patients and 98.4 % for controls) by PCR-RFLP in consecutively examined 1,046 men and 281 women with ACS (age below 65 years) and in population-based controls -1,162 men and 1,355 women (aged up to 65 years). ANOVA and chi(2) were used for statistical analysis. We confirmed that GC homozygotes are more frequent (codominant model of analysis) among patients with myocardial infarction than in the control group both in men (28.5 % vs. 22.0 %, P = 0.0001, OR 1.73, 95 % CI 1.36-2.19) and women (32.0 % vs. 24.6 %, P = 0.02, OR 1.62, 95 A CI 1.13-2.34). However, rs10757274 polymorphism was not associated with the classical risk factors either in control population or in ACS patients. We conclude that the rs10757274 variant at 9p23.1 is an important genetic risk factor for ACS development in the Czech population.","[Hubacek, J. A.; Stanek, V.; Gebauerova, M.; Poledne, R.; Lanska, V.; Adamkova, V.; Pitha, J.] Inst Clin & Expt Med, Prague, Czech Republic; [Aschermann, M.; Skalicka, H.] Gen Univ Hosp, Dept Internal Med 2, Prague, Czech Republic; [Matouskova, J.; Kruger, A.] Homolka Hosp, Dept Cardiol, Prague, Czech Republic; [Penicka, M.; Hrabakova, H.] Univ Hosp Kralovske Vinohrady, Dept Cardiol, Cardiocenter, Prague, Czech Republic; [Veselka, J.; Hajek, P.] Teaching Hosp Motol, Dept Cardiol, Prague, Czech Republic; [Adamkova, V.] Univ S Bohemia, Fac Hlth & Social Studies, Ceske Budejovice, Czech Republic","Hubacek, JA (reprint author), IKEM DEM LMG, Videnska 1958-9, Prague 14021 4, Czech Republic.","jahb@ikem.cz",null,null,"Ministry of Health of the Czech Republic [00023001, NT 12217-5]","Supported by the project of Ministry of Health of the Czech Republic for development of research organization 00023001 (IKEM, Prague, Czech Republic) - Institutional support and project NT 12217-5 (IGA. MH. CR).",null,21,2,2,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2012,58,5,null,null,null,null,203,208,null,null,null,6,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","050MX","WOS:000312058500004"]
[null,null,null,null,"J","Vranova, J; Arenbergerova, M; Arenberger, P; Stanek, J; Vrana, A; Zivcak, J; Rosina, J",null,null,null,"Vranova, J.; Arenbergerova, M.; Arenberger, P.; Stanek, J.; Vrana, A.; Zivcak, J.; Rosina, J.",null,null,"Incidence of cutaneous malignant melanoma in the Czech Republic: The risks of sun exposure for adolescents","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"UV radiation; cutaneous melanoma; adolescents; prevention campaign; risk factors; biomedical engineering","SKIN-CANCER; MELANOCYTIC NEVI; CHILDREN; EPIDEMIOLOGY; PREVENTION; PROTECTION; SUNSCREEN; AUSTRALIA; TOBACCO; EUROPE","The Czech Republic reported one of the highest incidence rate in cutaneous melanoma (CM) in Europe and because this incidence has been increasing, mainly among young people, the main goal of our study was to establish sun exposure behavior risk factors for CM formation and to evaluate whether the young generation of Czechs is exposed to a higher risk of CM than the older generation. A questionnaire-based case-control study was conducted. We obtained 978 completed questionnaires: 216 from patients with CM and 762 from healthy respondents. The healthy individuals were further divided to adolescents (n = 460) and older respondents (n = 302). Three logistic regression models were developed: 1. patients with CM vs. healthy older respondents, 2. adolescents vs. healthy older respondents, and 3. patients with CM vs. adolescents. The main risk factors for all three models were the number of sunburn episodes and the use of the sunscreen in the childhood. The most alarming results for adolescents included: all day sun exposure, including times of maximum risk (11 AM to 3 PM), inadequate use of sunscreen in adulthood, and frequent mountain holidays. Our results show that sun-safety in the young generation is satisfactory, when the responsibility for sun exposure behavior is in the hands of their parents; however, when children become adolescents, they become immune to sun-safety and risk prevention campaigns and their behavior becomes much more risky. Our results further suggest the sun-safety campaigns need to be modified in such a way as to have greater impact and influence on adolescent sun-risk behaviors.","[Vranova, J.; Stanek, J.; Rosina, J.] Charles Univ Prague, Dept Med Biophys & Med Informat, Fac Med 3, Prague, Czech Republic; [Vranova, J.; Rosina, J.] Czech Tech Univ, Fac Biomed Engn, Kladno, Czech Republic; [Arenbergerova, M.] Charles Univ Prague, Dept Dermatovenerol, Fac Med 3, Prague, Czech Republic; [Vrana, A.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Zivcak, J.] Tech Univ Kosice, Dept Biomed Engn Automat & Measurement, Fac Mech Engn, Kosice, Slovakia","Vranova, J (reprint author), Charles Univ Prague, Dept Med Biophys & Med Informat, Fac Med 3, Prague, Czech Republic.","jana.vranova@lf3.cuni.cz",null,null,null,null,null,39,2,2,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2012,59,3,null,null,null,null,316,325,null,"10.4149/neo_2012_041",null,10,"Oncology","Oncology","914QO","WOS:000301966700011"]
[null,null,null,null,"J","Cernohorska, H; Klimesova, S; Lepsa, L; Jinoch, P; Milcova, A; Schmuczerova, J; Topinka, J; Labaj, J",null,null,null,"Cernohorska, Heda; Klimesova, Sarka; Lepsa, Ludek; Jinoch, Pavel; Milcova, Alena; Schmuczerova, Jana; Topinka, Jan; Labaj, Juraj",null,null,"Influence of immunization with non-genotoxic PAH-KLH conjugates on the resistance of organisms exposed to benzo(a)pyrene","MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS",null,null,"English","Article",null,null,null,null,null,"Anti-PAN antibodies; DNA adducts; ELISA; Genotoxicity; HepG2 cells; P-32-postlabelling","POLYCYCLIC AROMATIC-HYDROCARBONS; EPOXIDE-DNA ADDUCTS; COKE-OVEN WORKERS; CANCER-RISK; ANTIBODIES; CARCINOGENESIS; INDUCTION; METABOLISM; MODULATION; ACTIVATION","Polycyclic aromatic hydrocarbons (PAH) are recognized as common environmental pollutants released into the environment from many natural as well as man-made sources, and some have been classified as potent carcinogens. The main representative of the carcinogenic PAN is benzo(a)pyrene (B(a)P) which is known to induce genotoxic effects in vitro and in vivo, detected as PAN-DNA adducts. Long-term PAH exposure may be accompanied by an immunological response with the formation of antibodies against PAH as well as against PAH-DNA adducts. This paper describes the use of four PAH-keyhole-limpet haemocyanin (KLH) conjugates for the induction of specific and cross-reactive anti-PAH antibodies and focuses on the potential protective effects of anti-PAH antibodies produced after immunization of mice. In the in vitro experiments with HepG-2 cells, the genotoxicity of the PAH-KLH conjugates and the neutralizing effect of induced anti-PAH antibodies were evaluated. The titer of specific anti-PAH antibodies in sera and the amounts of DNA adducts in liver homogenates from immunized mice were investigated in vivo. The results show that anti-PAH antibodies of class IgG were induced during immunization. All the PAH-KLH conjugates tested were non-genotoxic and did not induce detectable DNA adducts in HepG2 cells or in the liver of immunized mice. The results show that only B(a)P-specific and B(a)P cross-reactive antibodies are able to neutralize B(a)P or its activated metabolites, which was revealed by a sudden decrease in the titer of anti-B(a)P antibodies in mouse sera after exposure to B(a)P. Furthermore, the anti-B(a)P antibodies produced by immunization were effective in reducing the amount of DNA adducts in mouse livers after intraperitoneal (i.p.) exposure to B(a)P. The results suggest that immunization with PAH-KLH conjugates can protect organisms against the adverse effects of carcinogenic PAH. (C) 2011 Elsevier B.V. All rights reserved.","[Cernohorska, Heda; Lepsa, Ludek; Jinoch, Pavel; Labaj, Juraj] Vidia Ltd, Dept Res & Dev, Jesenice 25242, Czech Republic; [Cernohorska, Heda] Univ Pardubice, Fac Chem Technol, Pardubice, Czech Republic; [Klimesova, Sarka] Univ Hosp Bulovka, Dept Pneumol & Thorac Surg, Prague, Czech Republic; [Milcova, Alena; Schmuczerova, Jana; Topinka, Jan] AS CR, Lab Genet Ecotoxicol, Inst Expt Med, Prague, Czech Republic","Labaj, J (reprint author), Vidia Ltd, Dept Res & Dev, Safinou 365-2, Jesenice 25242, Czech Republic.","cernohorska@vidia.cz; sarka.klimes@atlas.cz; lepsa@vidia.cz; jinoch@vidia.cz; amilcova@biomed.cas.cz; janasch@biomed.cas.cz; jtopinka@biomed.cas.cz; labaj@vidia.cz",null,null,"Ministry of Education, Youth and Sports of the Czech Republic [2B06150]","This work was supported by the Ministry of Education, Youth and Sports of the Czech Republic (Grant # 2B06150).","ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Binkova B, 2000, MUTAT RES-GEN TOX EN, V471, P57, DOI 10.1016/S1383-5718(00)00111-X; Boffetta P, 1997, CANCER CAUSE CONTROL, V8, P444, DOI 10.1023/A:1018465507029; Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082; De Buck SS, 2005, CARCINOGENESIS, V26, P835, DOI 10.1093/carcin/bgi010; De Buck SS, 2005, J PHARMACOL EXP THER, V313, P640, DOI 10.1124/jpet.104.081034; DERAAT WK, 1991, SCI TOTAL ENVIRON, V103, P1, DOI 10.1016/0048-9697(91)90348-I; Farmer PB, 2003, MUTAT RES-REV MUTAT, V544, P397, DOI 10.1016/j.mrrev.2003.09.002; Galati R, 2001, J EXP CLIN CANC RES, V20, P359; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107; HARRIS CC, 1985, P NATL ACAD SCI USA, V82, P6672, DOI 10.1073/pnas.82.19.6672; HAUGEN A, 1986, CANCER RES, V46, P4178; IARC, 1983, POL AR COMP 1; LEE BM, 1993, IMMUNOL LETT, V36, P117, DOI 10.1016/0165-2478(93)90042-Z; Lewtas J, 2007, MUTAT RES-REV MUTAT, V636, P95, DOI 10.1016/j.mrrev.2007.08.003; LIOY PJ, 1990, TOXICOL IND HEALTH, V6, P209; Loh MM, 2007, ENVIRON HEALTH PERSP, V115, P1160, DOI 10.1289/ehp.9884; McCarty KM, 2009, ENVIRON HEALTH PERSP, V117, P552, DOI 10.1289/ehp.0800119; MOOLTEN FL, 1978, NATURE, V272, P614, DOI 10.1038/272614a0; NEWMAN MJ, 1988, J CLIN INVEST, V82, P145, DOI 10.1172/JCI113563; Phillips DH, 1999, MUTAGENESIS, V14, P301, DOI 10.1093/mutage/14.3.301; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; SHAMSUDDIN AKM, 1985, CANCER RES, V45, P66; Shimada T., 2006, DRUG METAB PHARMACOK, V24, P176; SILBART LK, 1989, SCIENCE, V243, P1462, DOI 10.1126/science.2928780; Verdina A, 1996, CARCINOGENESIS, V17, P1705, DOI 10.1093/carcin/17.8.1705; WAKABAYASHI K, 1992, CANCER RES, V52, pS2092; Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010",28,1,2,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1383-5718",null,null,"MUTAT RES-GEN TOX EN","Mutat. Res. Genet. Toxicol. Environ. Mutagen.","FEB 18",2012,742,41671,null,null,null,null,2,10,null,"10.1016/j.mrgentox.2011.10.016",null,9,"Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology","900AB","WOS:000300857900002"]
[null,null,null,null,"J","Bednarik, J; Ambler, Z; Opavsky, J; Keller, O; Rokyta, R; Mazanec, R; Lejcko, J; Kozak, J; Suchy, M; Pata, M; Kozeny, P",null,null,null,"Bednarik, J.; Ambler, Z.; Opavsky, J.; Keller, O.; Rokyta, R.; Mazanec, R.; Lejcko, J.; Kozak, J.; Suchy, M.; Pata, M.; Kozeny, P.",null,null,"Guidelines for Pharmacotherapy of Neuropathic Pain","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"neuropathic pain; pharmacotherapy; painful polyneuropathy; trigeminal neuralgia; postherpetic neuralgia","EFNS GUIDELINES; PHARMACOLOGICAL-TREATMENT; SCREENING QUESTIONNAIRE; GENERAL-POPULATION; RECOMMENDATIONS; VALIDATION; SCALE; MANAGEMENT; ORIGIN","The guidelines were developed by a Task Force of the Czech Neurological Society and The Czech Pain Society. The major recommendations were adapted from the key international guidelines: The EFNS guidelines by Attal et al [6] and The guidelines of the Neuropathic Pain Special Interest Group part of the The International Association for the Study of Pain by Dworkin et al [7]. Level of evidence of all recommendations was classified according to the EFNS classification by Brainin et al [10]. Recommendations were stratified as a treatment of the first, second and third lines, separately for painful polyneuropathies including diabetic polyneuropathy, trigeminal neuralgia, postherpetic neuralgia and other localised peripheral neuropathic pain, central pain, cancer neuropathic pain, HIV neuropathy, neuropathic pain with comorbidities, and recommended combinations of drugs. In addition, the entire process of pharmacological treatment has been defined, including the diagnosis of neuropathic pain, classification, characteristics and mechanisms of action of the drugs used for pharmacotherapy of neuropathic pain.",null,"Bednarik, J (reprint author), Neurol Klin LF MU & FN Brno, Jihlavska 20, Brno 62500, Czech Republic.","jbednar@fnbrno.cz",null,null,null,null,"Attal N, 2006, EUR J NEUROL, V13, P1153, DOI 10.1111/j.1468-1331.2006.01511.x; Attal N, 2010, EUR J NEUROL, V17, P1113, DOI 10.1111/j.1468-1331.2010.02999.x; Bednarik J, 2010, CESK SLOV NEUROL N, V73, P579; Bennett M, 2001, PAIN, V92, P147, DOI 10.1016/S0304-3959(00)00482-6; Bennett MI, 2005, J PAIN, V6, P149, DOI 10.1016/j.jpain.2004.11.007; Bennett MI, 2007, PAIN, V127, P199, DOI 10.1016/j.pain.2006.10.034; Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024; Bouhassira D, 2005, PAIN, V114, P29, DOI 10.1016/j.pain.2004.12.010; Bouhassira D, 2008, PAIN, V136, P380, DOI 10.1016/j.pain.2007.08.013; Brainin M, 2004, EUR J NEUROL, V11, P577, DOI 10.1111/j.1468-1331.2004.00867.x; Cruccu G, 2010, EUR J NEUROL, V17, P1010, DOI 10.1111/j.1468-1331.2010.02969.x; Dworkin RH, 2003, ARCH NEUROL-CHICAGO, V60, P1524, DOI 10.1001/archneur.60.11.1524; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Finnerup NB, 2005, PAIN, V118, P289, DOI 10.1016/j.pain.2005.08.013; Freynhagen R, 2006, CURR MED RES OPIN, V22, P1911, DOI 10.1185/030079906X132488; Galer BS, 1997, NEUROLOGY, V48, P332; Jensen MP, 2006, CLIN J PAIN, V22, P97, DOI 10.1097/01.ajp.0000173018.64741.62; Krause SJ, 2003, CLIN J PAIN, V19, P306, DOI 10.1097/00002508-200309000-00004; Merskey H., 1994, CLASSIFICATION CHRON; National Institute for Health and Clinical Excellence, 2010, NEUR PAIN PHARM MAN; Portenoy R, 2006, CURR MED RES OPIN, V22, P1555, DOI 10.1185/030079906X115702; Torrance N, 2006, J PAIN, V7, P281, DOI 10.1016/j.jpain.2005.11.008; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59",23,2,2,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,1,null,null,null,null,93,101,null,null,null,9,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","902HF","WOS:000301028500015"]
[null,null,null,null,"J","Hlavna, M; Raudenska, M; Hudcova, K; Gumulec, J; Sztalmachova, M; Tanhauserova, V; Babula, P; Adam, V; Eckschlager, T; Kizek, R; Masarik, M",null,null,null,"Hlavna, Marian; Raudenska, Martina; Hudcova, Kristyna; Gumulec, Jaromir; Sztalmachova, Marketa; Tanhaeuserova, Veronika; Babula, Petr; Adam, Vojtech; Eckschlager, Tomas; Kizek, Rene; Masarik, Michal",null,null,"MicroRNAs and zinc metabolism-related gene expression in prostate cancer cell lines treated with zinc(II) ions","INTERNATIONAL JOURNAL OF ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"miRNA; prostate cancer; polymerase chain reaction; metallothionein; zinc(II) ions","TUMOR PROGRESSION; DOWN-REGULATION; CARCINOMA; RECEPTOR; MECHANISMS; APOPTOSIS; PROTEIN; BREAST; ALPHA; METALLOTHIONEINS","MicroRNAs (miRNAs) are a large class of single-stranded RNA molecules involved in post-transcriptional gene silencing. miRNAs not only regulate various developmental and physiological processes but also are involved in cancer development. Additionally, they can be considered as biomarkers of some pathological processes. The aim of this study was to determine the expression levels of selected miRNA and zinc(II)-related genes (ZIP-1, BAX, MT2A and MT1A) in the non-tumor PNT1A prostate cell line in comparison with the prostate cancer cell lines 22Rv1, PC-3 and LNCaP after zinc(II) treatment. Using bioinformatic approaches we selected miRNAs with putative binding sites in the 3'UTR regions in Metallothionein 1A and 2A as miRNA 23a, 141, 224, 296-3p, 320, 375 and 376. We observed significantly higher expression of miRNA 23a in all tumor lines compared to non-tumor PNT1A (13.6-fold in 22Rv1, 7.3-fold in PC-3, 8.3-fold in LNCaP, p<0.01). We also observed that the 22Rv1 cell line has significantly higher expression of miRNA 224 in comparison to other cell lines. In addition, all tumor cell lines expressed significantly higher levels of miRNA 375 in comparison to non-tumor PNT1A (87.1-fold in 22Rv1, nearly 2,000-fold in PC-3, 56.3-fold in LNCaP, p<0.01). Nevertheless, miRNA 375 and 23a expression levels strongly suggest their potential to contribute to the diagnosis of prostate cancer and miRNA 224 eventually may be suitable for classification of primary tumors. The expression of miRNA 224 in 22Rv1 cell line was negatively correlated with increasing zinc(II) concentration only. Our experiments revealed significant negative correlation of miRNA 376 and MT2A in 22Rv1 and a negative correlation between miRNA 224 and MTIA in PC-3 cells which may denote possible direct regulation of MT genes by specific miRNAs in prostate cancer.","[Hlavna, Marian; Raudenska, Martina; Hudcova, Kristyna; Gumulec, Jaromir; Sztalmachova, Marketa; Tanhaeuserova, Veronika; Masarik, Michal] Masaryk Univ, Dept Pathol Physiol, Fac Med, CZ-62500 Brno, Czech Republic; [Raudenska, Martina; Sztalmachova, Marketa; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Gumulec, Jaromir; Adam, Vojtech; Kizek, Rene; Masarik, Michal] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Hlavna, Marian; Babula, Petr] Univ Vet & Pharmaceut Sci, Fac Pharm, Dept Nat Drugs, CZ-61242 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Masarik, M (reprint author), Masaryk Univ, Dept Pathol Physiol, Fac Med, Kamenice 5, CZ-62500 Brno, Czech Republic.","masarik@med.muni.cz","Gumulec, Jaromir/D-7638-2012; Raudenska, Martina/F-9187-2012; Sztalmachova, Marketa/F-4144-2012; Masarik, Michal/D-9920-2012","Gumulec, Jaromir/0000-0002-9658-3444; ","NanoBioTECell GA CR [P102/11/1068]; CEITEC [CZ.1.05/1.1.00/02.0068]; project for conceptual development of research organization [00064203]","Financial support from NanoBioTECell GA CR P102/11/1068, doc Ceitec.02/2012 (JG), CEITEC CZ.1.05/1.1.00/02.0068 and project for conceptual development of research organization 00064203 is highly acknowledged.",null,50,1,1,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1019-6439",null,null,"INT J ONCOL","Int. J. Oncol.","DEC",2012,41,6,null,null,null,null,2237,2244,null,"10.3892/ijo.2012.1655",null,8,"Oncology","Oncology","043YZ","WOS:000311587900039"]
[null,null,null,null,"J","Laco, J; Kamaradova, K; Vitkova, P; Sehnalkova, E; Dvorakova, S; Vaclavikova, E; Sykorova, V; Kaspirkova, J; Skalova, A; Ryska, A",null,null,null,"Laco, Jan; Kamaradova, Katerina; Vitkova, Pavla; Sehnalkova, Eva; Dvorakova, Sarka; Vaclavikova, Eliska; Sykorova, Vlasta; Kaspirkova, Jana; Skalova, Alena; Ryska, Ales",null,null,"Cribriform adenocarcinoma of minor salivary glands may express galectin-3, cytokeratin 19, and HBME-1 and contains polymorphisms of RET and H-RAS proto-oncogenes","VIRCHOWS ARCHIV",null,null,"English","Article",null,null,null,null,null,"Salivary gland; Tongue; Cribriform adenocarcinoma; RET proto-oncogene; H-RAS protooncogene","MEDULLARY-THYROID CARCINOMA; HUMAN-PAPILLOMAVIRUS; CELL-DIFFERENTIATION; TUMORS; TONGUE; MUTATIONS; SENESCENCE; LESIONS; ORIGIN; CANCER","The aim of the study was to further elucidate the immunohistochemical and genetic characteristics of cribriform adenocarcinoma of minor salivary glands (CAMSG). The study comprised five CAMSG from two males and three females, aged 21-72 years. Four tumors were localized at the base of tongue and one in the floor of mouth. At the time of diagnosis, four tumors had metastasised to regional lymph nodes. After tumor resection, two patients were treated by radiotherapy and one by chemoradiotherapy. During the follow-up (median 14 months), two patients developed lymph node metastasis. Microscopically, all tumors showed cribriform, papillary, follicular, and microcystic growth patterns. The tumor cells displayed vesicular nuclei with intranuclear grooves. Immunohistochemically, all tumors showed expression of cytokeratin (CK) 7, CK8, CK18, vimentin, smooth muscle actin, calponin, S-100 protein, and p16 protein. In addition, we observed expression of galectin-3, CK19, and HBME-1, but not of thyroglobulin and TTF-1. No mutations of RET, BRAF, K-RAS, H-RAS, and N-RAS proto-oncogenes were detected. However, in RET proto-oncogene, we found polymorphisms Gly691Ser (exon 11) and Ser904Ser (exon 15) in one case, p.Leu769Leu (exon 13) in one case, and variant p.IVS14-24 G/A of intron 14 in two cases, and in H-RAS proto-oncogene we found polymorphism 81 T-C (exon 1) in three cases. Thyroglobulin and TTF-1 are the only useful markers in the differential diagnosis between CAMSG and papillary thyroid carcinoma as both tumors may express galectin-3, CK19, and HBME-1. The RET, H-RAS, and N-RAS proto-oncoogenes are not mutated in CAMSG.","[Laco, Jan; Ryska, Ales] Charles Univ Prague, Fingerland Dept Pathol, Fac Med, Hradec Kralove 50005, Czech Republic; [Laco, Jan; Ryska, Ales] Fac Hosp, Hradec Kralove 50005, Czech Republic; [Kamaradova, Katerina] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Kamaradova, Katerina] Fac Hosp Motol, Prague, Czech Republic; [Vitkova, Pavla] Hosp Ceske Budejovice, Dept Pathol, Budweis, Czech Republic; [Sehnalkova, Eva] Silesian Hosp, Dept Pathol, Opava, Czech Republic; [Dvorakova, Sarka; Vaclavikova, Eliska; Sykorova, Vlasta] Inst Endocrinol, Dept Mol Endocrinol, Prague, Czech Republic; [Kaspirkova, Jana; Skalova, Alena] Biopt Lab, Plzen, Czech Republic; [Skalova, Alena] Charles Univ Prague, Fac Med, Dept Pathol, Plzen, Czech Republic","Laco, J (reprint author), Charles Univ Prague, Fingerland Dept Pathol, Fac Med, Sokolska 581, Hradec Kralove 50005, Czech Republic.","lacoj@lfhk.cuni.cz",null,null,"PRVOUK of Charles University in Prague, Czech Republic;  [IGA MH CR NT 13901-4]","The authors thank Mrs. M. Zakova for her excellent technical support and Vladimir Horava Jr., M. D., Sarka Solecka, M. D., Tomas Vanek, M. D., Jana Hatlova, M. D., and Radomir Lana, M. D., for kindly providing patients' (cases 4 and 5) clinicopathological data. This study was supported by the project PRVOUK of Charles University in Prague, Czech Republic, and by grant IGA MH CR NT 13901-4.",null,30,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0945-6317",null,null,"VIRCHOWS ARCH","Virchows Arch.","NOV",2012,461,5,null,null,null,null,531,540,null,"10.1007/s00428-012-1320-1",null,10,"Pathology","Pathology","029ZK","WOS:000310537200007"]
[null,null,null,null,"J","Malikova, H; Kramska, L; Liscak, R; Vojtech, Z; Prochazka, T; Mareckova, I; Lukavsky, J; Druga, R",null,null,null,"Malikova, Hana; Kramska, Lenka; Liscak, Roman; Vojtech, Zdenek; Prochazka, Tomas; Mareckova, Iva; Lukavsky, Jiri; Druga, Rastislav",null,null,"Stereotactic radiofrequency amygdalohippocampectomy for the treatment of temporal lobe epilepsy: Do good neuropsychological and seizure outcomes correlate with hippocampal volume reduction?","EPILEPSY RESEARCH",null,null,"English","Article",null,null,null,null,null,"Epilepsy; Stereotactic surgery; Neuropsychological outcome; Hippocampus","SELECTIVE AMYGDALOHIPPOCAMPECTOMY; PROSPECTIVE MULTICENTER; COGNITIVE CHANGE; MEMORY; RESECTION; SURGERY; LOBECTOMY; SHRINKAGE; SCLEROSIS; REMNANT","Temporal lobe surgery bears the risk of a decline of neuropsychological functions. Stereotactic radiofrequency amygdalohippocampectomy (SAHE) represents an alternative to mesial temporal lobe epilepsy (MTLE) surgery. This study compared neuropsychological results with MRI volumetry of the residual hippocampus. We included 35 patients with drug-resistant MTLE treated by SAHE. MRI volumetry and neuropsychological examinations were performed before and 1 year after SAHE. Each year after SAHE clinical seizure outcome was assessed. One year after SANE 77% of patients were assessed as Engel Class I, 14% of patients was classified as Engel II and in 9% of patients treatment failed. Two years after SAHE 76% of subjects were classified as Engel Class I, 15% of patients was assessed as Engel II and in 9% of patients treatment failed. Hippocampal volume reduction was 58 +/- 17% on the left and 54 +/- 27% on the right side. One year after SANE, intelligence quotients of treated patients increased. Patients showed significant improvement in verbal memory (p = 0.039) and the semantic long-term memory subtest (LTM) (p = 0.003). Patients treated on the right side improved in verbal memory, delayed recall and LTM. No changes in memory were found in patients treated on the left side. There was a trend between the larger extent of the hippocampal reduction and improvement in visual memory in speech-side operated. (C) 2012 Elsevier B.V. All rights reserved.","[Malikova, Hana] Na Homolce Hosp, Dept Radiol, Prague 15000 5, Czech Republic; [Kramska, Lenka; Vojtech, Zdenek; Prochazka, Tomas; Mareckova, Iva] Na Homolce Hosp, Dept Neurol, Prague 15000 5, Czech Republic; [Liscak, Roman] Na Homolce Hosp, Dept Stereotact & Radiat Neurosurg, Prague 15000 5, Czech Republic; [Lukavsky, Jiri] Acad Sci Czech Republic, Inst Psychol, Prague 11000 1, Czech Republic; [Druga, Rastislav] Charles Univ Prague, Fac Med 2, Inst Anat, Prague 12000 2, Czech Republic","Malikova, H (reprint author), Na Homolce Hosp, Dept Radiol, Roentgenova 2, Prague 15000 5, Czech Republic.","hana.malikova@homolka.cz","Lukavsky, Jiri/G-1533-2011","Lukavsky, Jiri/0000-0002-1082-229X",null,null,null,44,1,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0920-1211",null,null,"EPILEPSY RES","Epilepsy Res.","NOV",2012,102,41671,null,null,null,null,34,44,null,"10.1016/j.eplepsyres.2012.04.017",null,11,"Clinical Neurology","Neurosciences & Neurology","043FX","WOS:000311529400005"]
[null,null,null,null,"J","Horak, P; Mara, M; Dundr, P; Kubinova, K; Kuzel, D; Hudecek, R; Chmel, R",null,null,null,"Horak, Petr; Mara, Michal; Dundr, Pavel; Kubinova, Kristyna; Kuzel, David; Hudecek, Robert; Chmel, Roman",null,null,"Effect of a Selective Progesterone Receptor Modulator on Induction of Apoptosis in Uterine Fibroids In Vivo","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY",null,null,"English","Article",null,null,null,null,null,null,"LOW-DOSE MIFEPRISTONE; MENSTRUAL BLOOD-LOSS; ULIPRISTAL ACETATE; MEDICAL-TREATMENT; ASOPRISNIL J867; LEIOMYOMA CELLS; EXPRESSION; GROWTH; PROLIFERATION; THERAPY","Aim. To determine if hormonal treatment induces apoptosis in uterine fibroids. Methods. Immunohistochemical examination of fibroid tissue, using avidin-biotin complex and cleaved caspase-3 antibody for detecting apoptosis, was performed in premenopausal women who underwent 12-week treatment with oral SPRM (6 patients with 5 mg and 5 patients with 10 mg of ulipristal acetate per day) or gonadoliberin agonist (GnRHa, 17 patients) and subsequent myomectomy or hysterectomy for symptomatic uterine fibroids. Ten patients with no presurgical hormonal treatment were used as controls. Results. Apoptosis was present in a significantly higher proportion of patients treated with ulipristal acetate compared to GnRHa (P = 0.01) and to patients with no hormonal treatment (P = 0.01). In contrast to an AI of 158.9 in SPRM patients, the mean AI was 27.5 and 2.0 in GnRHa and control groups, respectively. No statistical difference in the AI was observed between the two groups of patients treated with ulipristal acetate (5 mg or 10 mg). Conclusion. Treatment with ulipristal acetate induces apoptosis in uterine fibroid cells. This effect of SPRM may contribute to their positive clinical effect on uterine fibroids.","[Horak, Petr; Mara, Michal; Kubinova, Kristyna; Kuzel, David] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 1, Prague 12800, Czech Republic; [Dundr, Pavel] Charles Univ Prague, Inst Pathol, Fac Med 1, Prague 12800, Czech Republic; [Hudecek, Robert] Univ Hosp Brno, Dept Obstet & Gynaecol, Brno 62500, Czech Republic; [Chmel, Roman] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Prague 15006, Czech Republic","Kubinova, K (reprint author), Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 1, Apolinarska 18, Prague 12800, Czech Republic.","kristynakubinova@gmail.com",null,null,"Ministry of Health of the Czech Republic [IGA NS 9798-4]","This study was supported by a grant IGA NS 9798-4 from the Ministry of Health of the Czech Republic.",null,47,1,1,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","1687-8337",null,null,"INT J ENDOCRINOL","Int. J. Endocrinol.",null,2012,null,null,null,null,null,null,null,null,436174,"10.1155/2012/436174",null,6,"Endocrinology & Metabolism","Endocrinology & Metabolism","991NA","WOS:000307706900001"]
[null,null,null,null,"J","Melenovsky, V; Skaroupkova, P; Benes, J; Torresova, V; Kobkan, L; Cervenka, L",null,null,null,"Melenovsky, Vojtech; Skaroupkova, Petra; Benes, Jan; Torresova, Vera; Kobkan, Libor; Cervenka, Ludek",null,null,"The Course of Heart Failure Development and Mortality in Rats with Volume Overload due to Aorto-Caval Fistula","KIDNEY & BLOOD PRESSURE RESEARCH",null,null,"English","Article",null,null,null,null,null,"Heart failure; Volume overload; Mortality; Cardiac hypertrophy; Experimental models","INDUCED CARDIAC-HYPERTROPHY; SURVIVAL; MODEL","Background: There are only few studies documenting the long-term outcome of aorto-caval fistula (ACF) in rats, a model of volume overload heart failure (HF). The aim of the present study was to describe HF-related morbidity and mortality, and to examine the relation between cardiac hypertrophy and survival. Methods: Adult male Wistar rats underwent needle ACF or sham operation and 71 animals surviving the acute procedure with patent ACF were followed for 52 weeks. Results: By the end of the study, 72% of the ACF animals deceased and 82% developed HF signs. Of the HF rats, 65% died (median: 3 weeks after HF onset). Before death, body weight increased by 9% followed by a final drop. 28% ACF rats died suddenly, without preceding HF. Sudden death occurred earlier and in the rats with a trend to larger hearts (p = 0.07). In the whole ACF cohort, heart weight (heart weight/body weight ratio) was inversely associated with the length of survival (r = -0.51, p < 0.001). Conclusion: The median survival of ACF Wistar rats is 43 weeks, longer than reported in other rat strains. Increased heart weight is associated with higher mortality and a significant number of animals die suddenly. Copyright (C) 2011 S. Karger AG, Basel","[Melenovsky, Vojtech; Benes, Jan] Inst Clin & Expt Med IKEM, Dept Cardiol, CZ-14021 Prague 4, Czech Republic; [Skaroupkova, Petra; Torresova, Vera; Kobkan, Libor] Inst Clin & Expt Med IKEM, Cardiovasc Res Ctr, CZ-14021 Prague 4, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Melenovsky, V (reprint author), Inst Clin & Expt Med IKEM, Dept Cardiol, Videnska 1958-9, CZ-14021 Prague 4, Czech Republic.","vojtech.melenovsky@ikem.cz",null,null,"EU [CZ.2.16/3.1.00/22126]; Ministry of Health [MZO-00023001, NS10497-3/2009]; Ministry of Education [MSMT-1MO510]; Grant Agency of the Czech Republic [305/09/1390]","This work was supported by the EU Operational Program Prague - Competitiveness, project 'CEVKOON' (CZ.2.16/3.1.00/22126 to L.C.), by the Ministry of Health (MZO-00023001 to V.M. and L.C., NS10497-3/2009 to V.M.), the Ministry of Education (MSMT-1MO510 to V.M., J.B. and L.C.) and by the Grant Agency of the Czech Republic (305/09/1390 to V.M.).",null,26,1,1,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096",null,null,"KIDNEY BLOOD PRESS R","Kidney Blood Pressure Res.",null,2012,35,3,null,null,null,null,167,173,null,"10.1159/000331562",null,7,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","Physiology; Urology & Nephrology; Cardiovascular System & Cardiology","932EP","WOS:000303273500005"]
[null,null,null,null,"J","Cerny, I; Budesinsky, M; Pouzar, V; Vyklicky, V; Krausova, B; Vyklicky, L",null,null,null,"Cerny, Ivan; Budesinsky, Milos; Pouzar, Vladimir; Vyklicky, Vojtech; Krausova, Barbora; Vyklicky, Ladislav, Jr.",null,null,"Neuroactive steroids with perfluorobenzoyl group","STEROIDS",null,null,"English","Article",null,null,null,null,null,"Neuroactive steroids; Synthesis; Perfluorobenzoates; NMDA receptor","PERFLUOROPHENYL AZIDES; GABA(A) RECEPTORS; DERIVATIVES; INVERSION; INHIBITOR; ANALOGS","During an initial study in searching for the alternative derivatives suitable for photolabeling of neuroactive steroids, perfluorobenzoates and perfluorobenzamides in position 17 of 5 beta-androstan-3 alpha-ol were synthesized from the corresponding 17-hydroxy and 17-amino derivatives. After transformation into glutamates or sulfates, 17 alpha-epimers had comparable inhibitory activity at NMDA receptors to the natural neurosteroid (20-oxo-5 beta-pregnan-3 beta-yl sulfate), however, were more potent (2- to 36-fold) than their 17 beta-substituted analogs. In one case, fluorine in position 4' of perfluorobenzoate group was substituted with azide and activity of the final glutamate was retained comparing with the corresponding perfluorobenzoate. The series was expanded with perfluorobenzoyl derivatives of pregnanolone: Perfluorobenzamide of glutamate and perfluorobenzoate of 11 alpha-hydroxy pregnanolone were prepared and tested. From nine tested compounds, four of them exhibit very good inhibition activity and can serve as promising leads for photolabeling experiments. (c) 2012 Elsevier Inc. All rights reserved.","[Cerny, Ivan; Budesinsky, Milos; Pouzar, Vladimir] Acad Sci Czech Republic, Inst Organ Chem & Biochem, Vvi, CR-16610 Prague 6, Czech Republic; [Vyklicky, Vojtech; Krausova, Barbora; Vyklicky, Ladislav, Jr.] Acad Sci Czech Republic, Inst Physiol, Vvi, CR-14220 Prague, Czech Republic; [Vyklicky, Vojtech] Charles Univ Prague, Fac Med 2, Prague 15006, Czech Republic","Cerny, I (reprint author), Acad Sci Czech Republic, Inst Organ Chem & Biochem, Vvi, Flemingovo Nam 2, CR-16610 Prague 6, Czech Republic.","cerny@uochb.cas.cz","Vyklicky, Ladislav/C-1851-2012",null,"GACR [P304/12/G069, P303/12/1464]; TACR [TE01020028]; Research Projects of the AS CR (RVO) [61388963, 67985823]","We thank Mrs. L. Klouckova and Mrs. M. Kuntosova for excellent technical assistance. Dr. S. Vasickova was taking the IR spectra and Dr. P. Fiedler was interpreting them. Mass spectra were measured by the staff of the Laboratory of Mass Spectrometry (Dr. J. Cvacka, Head). Elemental analyses were carried out in the Analytical Laboratory (Dr. S. Matejkova, Head). This work was supported by the GACR (P304/12/G069; P303/12/1464), TACR (TE01020028), and Research Projects of the AS CR (RVO: 61388963 and 67985823.",null,24,0,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0039-128X",null,null,"STEROIDS","Steroids","OCT",2012,77,12,null,null,null,null,1233,1241,null,"10.1016/j.steroids.2012.07.004",null,9,"Biochemistry & Molecular Biology; Endocrinology & Metabolism","Biochemistry & Molecular Biology; Endocrinology & Metabolism","029FS","WOS:000310480800008"]
[null,null,null,null,"J","Pospisilova, D; Cmejlova, J; Ludikova, B; Stary, J; Cerna, Z; Hak, J; Timr, P; Petrtylova, K; Blatny, J; Vokurka, S; Cmejla, R",null,null,null,"Pospisilova, Dagmar; Cmejlova, Jana; Ludikova, Barbora; Stary, Jan; Cerna, Zdena; Hak, Jiri; Timr, Pavel; Petrtylova, Kvetoslava; Blatny, Jan; Vokurka, Samuel; Cmejla, Radek",null,null,"The Czech National Diamond-Blackfan Anemia Registry: Clinical data and ribosomal protein mutations update","BLOOD CELLS MOLECULES AND DISEASES",null,null,"English","Article",null,null,null,null,null,null,"ADENOSINE-DEAMINASE ACTIVITY; GENE; IDENTIFICATION; S19; ERYTHROPOIESIS; DISEASES; PATIENT; UK; L5","Diamond-Blackfan anemia is a rare inherited bone marrow failure syndrome diagnosed in early infancy that is characterized by a (a) macrocytic anemia with no other significant cytopenia, (b) reticulocytopenia, and (c) normal bone marrow cellularity with a paucity of erythroid precursors. Physical anomalies are often present. Mutations in several ribosomal proteins have been associated with the disease. Here we present a detailed description of 39 patients from 34 families enrolled in the Czech National Diamond-Blackfan Anemia Registry. Erythrocyte adenosine deaminase activity and serum erythropoietin levels were measured and bone marrow analysis and clonogenic assays were carried out. Twenty-two different ribosomal proteins were sequenced. We identified mutations in five different ribosomal proteins in 28/39 patients (71.8%) from 23/34 families (67.6%). Several new mutations are described. The most interesting data relate to genotype-phenotype correlations. All patients with ribosomal protein L5 or ribosomal protein L11 mutations have a thumb defect usually with one or more other anomalies. Most of these patients were born small for gestational age and currently have short stature. We also described five patients with a ribosomal protein S26 mutation. All of the latter are transfusion-dependent and they exhibit skeletal abnormalities rather than thumb or craniofacial deformities. Patients with ribosomal protein S19 seem to bear mildest associated anomalies, usually in a craniofacial region. (C) 2012 Elsevier Inc. All rights reserved.","[Pospisilova, Dagmar; Ludikova, Barbora] Palacky Univ, Dept Paediat, Olomouc 77200, Czech Republic; [Cmejlova, Jana; Cmejla, Radek] Inst Hematol & Blood Transfus, Dept Cell Physiol, Prague, Czech Republic; [Stary, Jan] Charles Univ Prague, Sch Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Cerna, Zdena] Charles Univ Hosp, Dept Paediat, Plzen, Czech Republic; [Hak, Jiri] Charles Univ Hosp, Dept Paediat, Hradec Kralove, Czech Republic; [Timr, Pavel] Reg Hosp Ceske Budejovice, Dept Pediat, Ceske Budejovice, Czech Republic; [Petrtylova, Kvetoslava] Univ Hosp Motol, Dept Blood Bank, Prague, Czech Republic; [Blatny, Jan] Masaryk Univ, Childrens Univ Hosp Brno, Dept Paediat Haematol, CS-60177 Brno, Czech Republic; [Vokurka, Samuel] Charles Univ Hosp, Dept Haematol, Plzen, Czech Republic","Pospisilova, D (reprint author), Palacky Univ, Dept Paediat, IP Pavlova 6, Olomouc 77200, Czech Republic.","dagmar.pospisilova@fnol.cz",null,null,"Ministry of Health of the Czech Republic [00023736, NT11059]; Ministry of Education of the Czech Republic [MSM 6198959205]","This work was supported by grants from the Ministry of Health of the Czech Republic 00023736 and NT11059 and Ministry of Education of the Czech Republic MSM 6198959205.",null,36,0,1,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1079-9796",null,null,"BLOOD CELL MOL DIS","Blood Cells Mol. Dis.","APR 15",2012,48,4,null,null,null,null,209,218,null,"10.1016/j.bcmd.2012.02.002",null,10,"Hematology","Hematology","919NE","WOS:000302333800002"]
[null,null,null,null,"J","Ehler, E; Ridzon, P; Nakladalova, M; Urban, P; Mazanec, R; Fenclova, Z; Matulova, H; Otruba, P; Latta, J",null,null,null,"Ehler, E.; Ridzon, P.; Nakladalova, M.; Urban, P.; Mazanec, R.; Fenclova, Z.; Matulova, H.; Otruba, P.; Latta, J.",null,null,"Neurophysiological Diagnosis of the Ulnar Nerve Damage at the Elbow","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"ulnar nerve; expert opinion; neurophysiological investigation","NEUROPATHY; CONDUCTION; MONONEUROPATHY; ENTRAPMENT; DISORDERS","Damage to the ulnar nerve most frequently develops around the elbow region. Some occupations are associated with a chronic trauma to the ulnar nerve at the elbow and the resulting damage could be, under ceratin circumstances, classified as an occupational disease. Neurophysiological investigation is essential for the diagnosis of the ulnar nerve damage at the elbow. Reliable localization of the damage to the elbow region is prerequisite. Determination of the severity of the ulnar nerve damage is also important. For the purposes of obtaining an expert opinion, a standardized investigation guaranteeing comparable results from all EMG laboratories, is required. The authors discuss in detail the specific methodological parameters of a neurophysiological investigation of the ulnar nerve at the elbow. An investigational protocol is proposed that assesses the ulnar nerve in rectangular elbow flexion with the nerve stimulation at 4 cm below and 6 cm above the elbow and with registration from both, m. abductor digiti minimi and m. inteosseus dorsalis primus. Finally, the authors present the results from their own sample of patients assessed with the proposed protocol.","[Ehler, E.; Latta, J.] FZS UPa & Pardubicka Krajska Nemocnice As, Neurol Klin, Pardubice 53203, Czech Republic; [Ridzon, P.] IPVZ & Thomayerova Nemocnice, Neurol Klin, Prague, Czech Republic; [Ridzon, P.; Urban, P.; Fenclova, Z.] LF UK & VFN, Klin Pracovniho Lekarstvi 1, Prague, Czech Republic; [Nakladalova, M.] LF UP & FN, Klin Pracovniho Lekarstvi, Olomouc, Czech Republic; [Urban, P.; Fenclova, Z.] Statni Zdravotni Ustav, Prague, Czech Republic; [Mazanec, R.] LF UK & FN Motole, Neurol Klin 2, Prague, Czech Republic; [Matulova, H.] LF UK & FN Hradec Kralove, Neurol Klin, Prague, Czech Republic; [Otruba, P.] LF UP & FN Olomouc, Neurol Klin, Olomouc, Czech Republic","Ehler, E (reprint author), FZS UPa & Pardubicka Krajska Nemocnice As, Neurol Klin, Pardubice 53203, Czech Republic.","edvard.ehler@nemocnice-pardubice.cz","Fenclova, Zdenka/D-8542-2014",null,null,null,"Campbell WW, 1999, MUSCLE NERVE, V22, P408; Azrieli Y, 2003, MUSCLE NERVE, V27, P46, DOI 10.1002/mus.10293; Beekman R, 2004, MUSCLE NERVE, V30, P202, DOI 10.1002/mus.20093; Bleecker ML, 1994, OCCUPATIONAL CLIN NE; Dawson DM, 1999, ENTRAPMENT NEUROPATH; Dunselman HHAM, 2008, J NEUROL NEUROSUR PS, V79, P1364, DOI 10.1136/jnnp.2008.145110; Ehler E, 2002, MONONEUROPATIE; Feinberg E, 1999, TOP CLIN CHIROPR, V6, P20; Feuerstein M, 2003, PAIN, V102, P51, DOI 10.1016/S0304-3959(02)00339-1; Friedrich JM, 2011, MUSCLE NERVE, V43, P596; Herrmann DN, 2001, MUSCLE NERVE, V24, P698, DOI 10.1002/mus.1058; Joon SY, 2010, ARCH PHYS MED REHAB, V91, P318; Kadanka Z, 2003, VESTNIK MZD CR, V10, P3; Kadanka Z, 1994, PRAKTICKA ELEKTROMYO; KANAKAMEDALA RV, 1988, ARCH PHYS MED REHAB, V69, P959; Kern RZ, 2003, CAN J NEUROL SCI, V30, P314; Kimura J, 2006, HDB CLIN NEUROPHYSIO, V7; KINCAID JC, 1986, ARCH NEUROL-CHICAGO, V43, P44; Kitzinger H B, 2005, Handchir Mikrochir Plast Chir, V37, P276, DOI 10.1055/s-2005-865861; Kothari MJ, 1998, ARCH PHYS MED REHAB, V79, P87, DOI 10.1016/S0003-9993(98)90214-3; Landau ME, 2003, MUSCLE NERVE, V27, P570, DOI 10.1002/mus.10352; Landau ME, 2005, MUSCLE NERVE, V32, P815, DOI 10.1002/mus.20420; Lukas E, 1967, PRAC LEK, V19, P26; Marras C, 1999, MUSCLE NERVE, V22, P1132, DOI 10.1002/(SICI)1097-4598(199908)22:8<1132::AID-MUS20>3.0.CO;2-9; Merlevede K, 2000, MUSCLE NERVE, V23, P478, DOI 10.1002/(SICI)1097-4598(200004)23:4<478::AID-MUS4>3.0.CO;2-4; ODUSOTE K, 1979, CAN J NEUROL SCI, V6, P403; Richardson JK, 2001, MUSCLE NERVE, V24, P551, DOI 10.1002/mus.1039; Shakir A, 2004, MUSCLE NERVE, V29, P585, DOI 10.1002/mus.10513; Stewart JD, 2000, FOCAL PERIPHERAL NEU; STEWART JD, 1987, J NEUROL NEUROSUR PS, V50, P252, DOI 10.1136/jnnp.50.3.252; Takahashi N, 2011, MUSCLE NERVE, V43, P129, DOI 10.1002/mus.21864; Todnem K, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-52; van Rijn RM, 2009, RHEUMATOLOGY, V48, P528, DOI 10.1093/rheumatology/kep013",33,1,1,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,3,null,null,null,null,320,325,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","966EH","WOS:000305819900008"]
[null,null,null,null,"J","Zelinka, T; Masek, M; Vlkova, J; Kasalicky, M; Michalsky, D; Holaj, R; Petrak, O; Strauch, B; Rosa, J; Dvorakova, J; Widimsky, J",null,null,null,"Zelinka, Tomas; Masek, Martin; Vlkova, Jana; Kasalicky, Mojmir; Michalsky, David; Holaj, Robert; Petrak, Ondrej; Strauch, Branislav; Rosa, Jan; Dvorakova, Jana; Widimsky, Jiri, Jr.",null,null,"Discrepant Results of Adrenal Venous Sampling in Seven Patients with Primary Aldosteronism","KIDNEY & BLOOD PRESSURE RESEARCH",null,null,"English","Article",null,null,null,null,null,"Primary aldosteronism; Adrenal venous sampling; Aldosterone; Cortisol","PRIMARY HYPERALDOSTERONISM; VEIN; DIAGNOSIS; PREVALENCE; SUBTYPES; TIME","Background: Adrenal venous sampling serves as a discrimination between uni- and bilateral forms of primary aldosteronism (PA). Even correctly performed adrenal venous sampling may lead to non-diagnostic results in some cases. Results: We describe 7 subjects with PA in whom correct cannulation of adrenal veins (high selectivity index defined as cortisol((adrenal))/cortisol((periphery)) ratio) was associated with aldosterone (ALDO) suppression (ALDO/cortisol((adrenal))/ALDO/cortisol((periphery)) ratio <1) in the left adrenal gland and in whom all subjects underwent a successful adrenalectomy on the right side. In 3 subjects, samples from the right side with lower selectivity indexes (1.11-1.7) compared to those samples with a higher index of selectivity (10.4-44.9) pointed to lateralization. Next, 2 subjects were operated because of relatively large adrenal masses in the right adrenal gland on CT despite ALDO suppression on this side. One subject presented with high selectivity indexes from the right side (19.5 and 37.6), but only one sample showed ALDO secretion. Patient 7 was treated with right-sided adrenalectomy despite a low lateralization index (ALDO/cortisol((right))/ALDO/cortisol((left)) 1.78). Conclusions: Our results document some uncertainties in interpreting results of adrenal venous sampling in subjects with PA which may result from deep catheter insertion, anomalous venous drainage, or fluctuations in ALDO secretion. copyright (C) 2012 S. Karger AG, Basel","[Zelinka, Tomas; Holaj, Robert; Petrak, Ondrej; Strauch, Branislav; Rosa, Jan; Dvorakova, Jana; Widimsky, Jiri, Jr.] First Fac Med & Gen Univ Hosp, Med Dept 3, Hypertens Unit, Dept Endocrinol & Metab, CZ-12808 Prague 2, Czech Republic; [Masek, Martin; Vlkova, Jana] First Fac Med & Gen Univ Hosp, Dept Radiol, Prague, Czech Republic; [Kasalicky, Mojmir; Michalsky, David] First Fac Med & Gen Univ Hosp, Surg Dept 1, Clin Dept Abdominal Thorac Surg & Traumatol, Prague, Czech Republic; [Kasalicky, Mojmir] Cent Mil Hosp, Dept Surg, Prague, Czech Republic","Zelinka, T (reprint author), First Fac Med & Gen Univ Hosp, Med Dept 3, Hypertens Unit, Dept Endocrinol & Metab, U Nemocnice 1, CZ-12808 Prague 2, Czech Republic.","tzeli@lf1.cuni.cz",null,null,"Czech Ministry of Education [0021620807]","Supported by a research project of Czech Ministry of Education 0021620807.","Ceral J, 2010, EUR J ENDOCRINOL, V162, P101, DOI 10.1530/EJE-09-0217; Daunt N, 2005, RADIOGRAPHICS, V25, pS143, DOI 10.1148/rg.25si055514; Doppman JL, 1996, RADIOLOGY, V198, P309; Funder JW, 2008, J CLIN ENDOCR METAB, V93, P3266, DOI 10.1210/jc.2008-0104; Huang WT, 2010, CLIN NEPHROL, V73, P392; Kempers MJE, 2009, ANN INTERN MED, V151, P329; Matsuura T, 2008, AM J ROENTGENOL, V191, P402, DOI 10.2214/AJR.07.3338; Miotto D, 2009, HYPERTENSION, V54, P885, DOI 10.1161/HYPERTENSIONAHA.109.134759; MONKHOUSE WS, 1986, J ANAT, V146, P105; Mulatero P, 2010, HYPERTENSION, V55, P667, DOI 10.1161/HYPERTENSIONAHA.109.146613; Mulatero P, 2009, CURR HYPERTENS REP, V11, P217, DOI 10.1007/s11906-009-0038-1; Murashima M, 2009, J HUM HYPERTENS, V23, P292, DOI 10.1038/jhh.2008.108; Omura M, 2009, J HYPERTENS, V27, pS293; Rossi GP, 2001, J CLIN ENDOCR METAB, V86, P1083, DOI 10.1210/jc.86.3.1083; Rossi GP, 2006, J AM COLL CARDIOL, V48, P2293, DOI 10.1016/j.jacc.2006.07.059; Rossi GP, 2008, J NEPHROL, V21, P455; Seccia TM, 2009, HYPERTENSION, V53, P761, DOI 10.1161/HYPERTENSIONAHA.108.128553; SIRAGY HM, 1995, J CLIN ENDOCR METAB, V80, P28, DOI 10.1210/jc.80.1.28; Stewart PM, 2010, CLIN ENDOCRINOL, V72, P146, DOI 10.1111/j.1365-2265.2009.03714.x; Stowasser M, 2003, TRENDS ENDOCRIN MET, V14, P310, DOI 10.1016/S1043-2760(03)00112-7; Strauch B, 2003, J HUM HYPERTENS, V17, P349, DOI 10.1038/sj.jhh.1001554; Tanemoto M, 2007, J HYPERTENS, V25, P480, DOI 10.1097/HJH.0b013e328011d80a; Tanemoto M, 2009, EUR J ENDOCRINOL, V160, P459, DOI 10.1530/EJE-08-0840; Young WF, 2009, CLIN ENDOCRINOL, V70, P14, DOI 10.1111/j.1365-2265.2008.03450.x",24,1,1,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1420-4096","1423-0143",null,"KIDNEY BLOOD PRESS R","Kidney Blood Pressure Res.",null,2012,35,4,null,null,null,null,205,210,null,"10.1159/000330720",null,6,"Physiology; Urology & Nephrology; Peripheral Vascular Disease","Physiology; Urology & Nephrology; Cardiovascular System & Cardiology","939VC","WOS:000303846100001"]
[null,null,null,null,"J","Verner, J; Kabathova, J; Tomancova, A; Pavlova, S; Tichy, B; Mraz, M; Brychtova, Y; Krejci, M; Zdrahal, Z; Trbusek, M; Volejnikova, J; Sedlacek, P; Doubek, M; Mayer, J; Pospisilova, S",null,null,null,"Verner, Jan; Kabathova, Jitka; Tomancova, Alexandra; Pavlova, Sarka; Tichy, Boris; Mraz, Marek; Brychtova, Yvona; Krejci, Marta; Zdrahal, Zbynek; Trbusek, Martin; Volejnikova, Jana; Sedlacek, Petr; Doubek, Michael; Mayer, Jiri; Pospisilova, Sarka",null,null,"Gene expression profiling of acute graft-vs-host disease after hematopoietic stem cell transplantation","EXPERIMENTAL HEMATOLOGY",null,null,"English","Article",null,null,null,null,null,null,"MONONUCLEAR-CELLS; ACUTE GVHD; BLOOD; MICROARRAYS; BIOMARKERS; THERAPY","Acute graft-vs-host disease (aGVHD) is a frequent, life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Despite that, there are no reliable molecular markers reflecting the onset or clinical course of aGVHD. We performed a pilot study on gene expression profiling in peripheral blood mononuclear cells taken from 15 patients with hematological malignancies who underwent allo-HSCT and developed aGVHD. Based on survival rates after aGVHD, patients were divided into two groups-favorable (all patients alive; median follow-up 40 months) vs unfavorable group (all patients died; median survival 2 months). Two-hundred and eighty genes differentially expressed between these two groups were identified; among them, genes responsible for cytokine signaling, inflammatory response, and regulation of cell cycle were over-represented; interleukin-8, GOS2, ANXA3, and NR4A2 were upregulated in the unfavorable group, CDKN1C was downregulated in the same group. Interestingly, the same genes were also described as overexpressed in connection with autoimmune diseases. This indicates an involvement of similar immune regulatory pathways also in aGVHD. Our data support use of gene expression profiling at aGVHD onset for a prediction of its outcomes. (C) 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.","[Pospisilova, Sarka] Univ Hosp Brno, CMBGT IHOK, Dept Internal Med Hematol & Oncol, Ctr Mol Biol & Gene Therapy, Brno 61300, Czech Republic; [Verner, Jan; Kabathova, Jitka; Tomancova, Alexandra; Pavlova, Sarka; Tichy, Boris; Mraz, Marek; Brychtova, Yvona; Krejci, Marta; Trbusek, Martin; Doubek, Michael; Mayer, Jiri; Pospisilova, Sarka] Masaryk Univ, Fac Med, Brno, Czech Republic; [Verner, Jan; Kabathova, Jitka; Pavlova, Sarka; Tichy, Boris; Mraz, Marek; Zdrahal, Zbynek; Trbusek, Martin; Doubek, Michael; Mayer, Jiri; Pospisilova, Sarka] Masaryk Univ, Cent European Inst Technol, Brno, Czech Republic; [Volejnikova, Jana; Sedlacek, Petr] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Volejnikova, Jana; Sedlacek, Petr] Univ Hosp Motol, Prague, Czech Republic","Pospisilova, S (reprint author), Univ Hosp Brno, CMBGT IHOK, Dept Internal Med Hematol & Oncol, Ctr Mol Biol & Gene Therapy, Cernopolni 9, Brno 61300, Czech Republic.","sarka.pospisilova@fnbrno.cz","Pavlova, Sarka/D-2139-2011; Verner, Jan/E-1042-2012; Tichy, Boris/C-1314-2009; Zdrahal, Zbynek/D-9491-2012","Tichy, Boris/0000-0001-9252-7974; ","IGA MZCR [NS9683-3/2008]; European Regional Development Fund [CZ.1.05/1.1.00/02.0068, CZ.1.07/2.3.00/20.0045]; CELL-The Czech Leukemic Study Group for Life; Fresenius Biotech GmbH;  [MSM0021622430]","This work was supported by IGA MZCR NS9683-3/2008, MSM0021622430, the project CEITEC-Central European Institute of Technology (CZ.1.05/1.1.00/02.0068) from European Regional Development Fund, SuPReMMe-Support of Professional Growth and International Integration of Research Teams in the Field of Molecular Medicine (CZ.1.07/2.3.00/20.0045) and CELL-The Czech Leukemic Study Group for Life.MK and JM have received research support from Fresenius Biotech GmbH. No financial interest/relationships relating to the topic of this article have been declared by the remaining authors.",null,26,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0301-472X",null,null,"EXP HEMATOL","Exp. Hematol.","NOV",2012,40,11,null,null,null,null,899,905,null,"10.1016/j.exphem.2012.06.011",null,7,"Hematology; Medicine, Research & Experimental","Hematology; Research & Experimental Medicine","025IO","WOS:000310182400004"]
[null,null,null,null,"J","Brennan, D; Jary, D; Kurg, A; Berik, E; Justice, J; Aherne, M; Macek, M; Galvin, P",null,null,null,"Brennan, Des; Jary, Dorothee; Kurg, Ants; Berik, Evgeny; Justice, John; Aherne, Margaret; Macek, Milan; Galvin, Paul",null,null,"A hybrid approach to device integration on a genetic analysis platform","MEASUREMENT SCIENCE & TECHNOLOGY",null,null,"English","Article",null,null,null,null,null,"microfluidics; integration; EWOD; hybridization","DNA HYBRIDIZATION; SYSTEM; AMPLIFICATION; MICROCHANNEL; DROPLETS; CHIP; PCR","Point-of-care (POC) systems require significant component integration to implement biochemical protocols associated with molecular diagnostic assays. Hybrid platforms where discrete components are combined in a single platform are a suitable approach to integration, where combining multiple device fabrication steps on a single substrate is not possible due to incompatible or costly fabrication steps. We integrate three devices each with a specific system functionality: (i) a silicon electro-wetting-on-dielectric (EWOD) device to move and mix sample and reagent droplets in an oil phase, (ii) a polymer microfluidic chip containing channels and reservoirs and (iii) an aqueous phase glass microarray for fluorescence microarray hybridization detection. The EWOD device offers the possibility of fully integrating on-chip sample preparation using nanolitre sample and reagent volumes. A key challenge is sample transfer from the oil phase EWOD device to the aqueous phase microarray for hybridization detection. The EWOD device, waveguide performance and functionality are maintained during the integration process. An on-chip biochemical protocol for arrayed primer extension (APEX) was implemented for single nucleotide polymorphism (SNiP) analysis. The prepared sample is aspirated from the EWOD oil phase to the aqueous phase microarray for hybridization. A bench-top instrumentation system was also developed around the integrated platform to drive the EWOD electrodes, implement APEX sample heating and image the microarray after hybridization.","[Brennan, Des; Justice, John; Aherne, Margaret; Galvin, Paul] Natl Univ Ireland Univ Coll Cork, Tyndall Natl Inst, Cork, Ireland; [Jary, Dorothee] CEA LETI, Dept Technol Biol & Hlth, F-38054 Grenoble, France; [Kurg, Ants; Berik, Evgeny] Asper Biotech Ltd, EE-50410 Tartu, Estonia; [Kurg, Ants] Univ Tartu, CEA Inst Mol & Cell Biol, EE-51010 Tartu, Estonia; [Macek, Milan] Charles Univ Prague, Inst Biol & Med Genet, CZ-15006 Prague 5, Czech Republic","Brennan, D (reprint author), Natl Univ Ireland Univ Coll Cork, Tyndall Natl Inst, Cork, Ireland.","des.brennan@tyndall.ie",null,null,"European Commission [NMP4-CT-2005-016833]","We would like to acknowledge the financial support of the European Commission under project number NMP4-CT-2005-016833.",null,19,0,0,"IOP PUBLISHING LTD","BRISTOL","TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND","0957-0233",null,null,"MEAS SCI TECHNOL","Meas. Sci. Technol.","OCT",2012,23,10,null,null,null,null,null,null,105704,"10.1088/0957-0233/23/10/105704",null,8,"Engineering, Multidisciplinary; Instruments & Instrumentation","Engineering; Instruments & Instrumentation","007XD","WOS:000308920800047"]
[null,null,null,null,"J","Habalova, V; Klimcakova, L; Zidzik, J; Vasovcak, P; Kristian, P; Valkova, I; Schreter, I; Salagovic, J",null,null,null,"Habalova, Viera; Klimcakova, Lucia; Zidzik, Jozef; Vasovcak, Peter; Kristian, Pavol; Valkova, Ivana; Schreter, Ivan; Salagovic, Jan",null,null,"Closed tube method for rapid screening of IL28B polymorphisms involved in response to hepatitis C treatment","MOLECULAR AND CELLULAR PROBES",null,null,"English","Article",null,null,null,null,null,"Hepatitis C; IL28B polymorphism; Small amplicon; Melting analysis","SINGLE-NUCLEOTIDE POLYMORPHISMS; MELTING ANALYSIS; RIBAVIRIN THERAPY; GENETIC-VARIATION; INTERFERON; CLEARANCE; VIRUS","Background & aim: Hepatitis C is a liver disease caused by the hepatitis C virus. Interferon and ribavirin combination therapy has been a standard treatment of chronic hepatitis C. But only about 50% of patients have positive response to treatment and achieve so called sustained virological response. Recent studies indicate association of several single nucleotide polymorphisms near IL28B gene and response of hepatitis C patients to combined interferon/ribavirin treatment. In this study, rapid, specific and cost-effective small amplicon genotyping method for the two clinically important polymorphisms, rs12979860 C > T and rs8099917 T > G, near the IL28B gene is described. Methods: The distribution of genotypes of 181 HCV-uninfected Slovak Caucasians was analyzed using this novel method, based on a real-time melting analysis of the small amplicon. Results and conclusions: The frequency of wild-type (TT) homozygotes for rs8099917 was 66.30%, frequency of heterozygotes (TG) was 30.94% and we found only 2.76% subjects homozygous for risk G allele (allelic frequencies: T = 81.77%, G = 18.23%) were found. The frequency of wild-type genotype (CC) for rs12979860 was 49.72%, frequencies of heterozygous (CT) and risk-allele homozygous genotypes (TT) were 39.78% and 10.50%, respectively (allele frequencies: C = 69.61%, T = 30.39%). Statistically significant differences in the distribution of the alleles between the men and the women were not found. The novel method developed in our laboratory proved to be simple and highly customizable. (C) 2012 Elsevier Ltd. All rights reserved.","[Habalova, Viera; Klimcakova, Lucia; Zidzik, Jozef; Salagovic, Jan] Safarik Univ, Fac Med, Dept Med Biol, Kosice 04066, Slovakia; [Kristian, Pavol; Valkova, Ivana; Schreter, Ivan] Safarik Univ, Fac Med, Dept Infectol & Travel Med, Kosice 04190, Slovakia; [Vasovcak, Peter] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic; [Vasovcak, Peter] Univ Hosp Motol, Prague, Czech Republic","Zidzik, J (reprint author), Safarik Univ, Fac Med, Dept Med Biol, Tr SNP 1, Kosice 04066, Slovakia.","jozef.zidzik@upjs.sk",null,null,"project the NEXO 2 (Network of Excellence in Oncology) [049/2009/2.1/OPVaV]; Ministry of Education, Slovakia [VEGA 1/0368/10]","This study was supported by the project the NEXO 2 (Network of Excellence in Oncology) under contract no. 049/2009/2.1/OPVaV (50%) and by the grant VEGA 1/0368/10 from the Ministry of Education, Slovakia (50%).",null,21,0,0,"ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD","LONDON","24-28 OVAL RD, LONDON NW1 7DX, ENGLAND","0890-8508",null,null,"MOL CELL PROBE","Mol. Cell. Probes","AUG",2012,26,4,null,null,null,null,159,163,null,"10.1016/j.mcp.2012.04.001",null,5,"Biochemical Research Methods; Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Cell Biology","Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Cell Biology","963XQ","WOS:000305658700003"]
[null,null,null,null,"J","Rockova, S; Rada, V; Nevoral, J; Marsik, P; Vlkova, E; Bunesova, V",null,null,null,"Rockova, Sarka; Rada, Vojtech; Nevoral, Jiri; Marsik, Petr; Vlkova, Eva; Bunesova, Vera",null,null,"Inter-species differences in the growth of bifidobacteria cultured on human milk oligosaccharides","FOLIA MICROBIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"COMPONENTS; INFANTS","Human milk (HM) contains as the third most abundant component around 200 different structures of human milk oligosaccharides (HMOs). HMOs are the first and irreplaceable prebiotics for infants, supporting bifidobacteria as the most important bacterial group in an infant intestine. The aim of our study was to test the growth of bifidobacteria in HM and on HMOs. Bifidobacteria were isolated from two groups of infants. The first one (eight strains) were isolated from infants who had bifidobacteria in their feces but, after a short period of time (4 to 24 days), bifidobacteria were no longer detected in their feces (disappeared bifidobacteria [DB]). The second group of bifidobacteria (eight strains) originated from infants with continual presence of bifidobacteria in their feces (persistent bifidobacteria [PB]). There were significant differences (p < 0.05) between DB and PB groups in the ability of the strains to grow in HM. PB grew in HM, reaching counts higher than 7 log CFU/ml. In contrast, counts of DB decreased from 5 to 4.3 log CFU/ml after cultivation in HM. The final pH after cultivation of bifidobacteria on HMOs was 6.2 and 4.9 in DP and PB groups, respectively. In general, Bifidobacterium bifidum and B. breve species were able to utilize HMOs, while B. adolescentis and B. longum subsp. longum species did not. The ability to grow in HM and to utilize HMOs seem to be important properties of bifidobacteria which are able to colonize infant intestinal tract.","[Rockova, Sarka; Rada, Vojtech; Vlkova, Eva; Bunesova, Vera] Czech Univ Life Sci, Fac Agrobiol Food & Nat Resources, Dept Microbiol Nutr & Dietet, Prague 16521 6, Czech Republic; [Nevoral, Jiri] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague 15006 5, Czech Republic; [Marsik, Petr] Acad Sci Czech Republic, Joint Lab Inst Expt Bot, CR-16502 Prague 6, Czech Republic; [Marsik, Petr] Res Inst Crop Prod, Prague 16502 6, Czech Republic","Rada, V (reprint author), Czech Univ Life Sci, Fac Agrobiol Food & Nat Resources, Dept Microbiol Nutr & Dietet, Kamycka 129, Prague 16521 6, Czech Republic.","rada@af.czu.cz",null,null,"Ministry of Education, Youth and Sports of Czech Republic, grant of the Danone Institute [6046070901]","This study was supported by grant MSM No. 6046070901 of Ministry of Education, Youth and Sports of Czech Republic, grant of the Danone Institute. We also thank Dr. Ingrid Kocourkova from the Institute for the Care of Mother and Child (Prague, Czech Republic) for supplying us with HM samples.",null,12,0,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632","1874-9356",null,"FOLIA MICROBIOL","Folia Microbiol.","JUL",2012,57,4,null,null,null,null,321,324,null,"10.1007/s12223-012-0134-5",null,4,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","968KQ","WOS:000305980400016"]
[null,null,null,null,"J","Witso, E; Cinek, O; Tapia, G; Rasmussen, T; Stene, LC; Ronningen, KS",null,null,null,"Witso, Elisabet; Cinek, Ondrej; Tapia, German; Rasmussen, Trond; Stene, Lars C.; Ronningen, Kjersti S.",null,null,"HLA-DRB1-DQA1-DQB1 Genotype and Frequency of Enterovirus in Longitudinal Monthly Fecal Samples from Healthy Infants","VIRAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,null,"DEPENDENT DIABETES-MELLITUS; BETA-CELL AUTOIMMUNITY; ENCEPHALOMYOCARDITIS VIRUS; YOUNG DAISY; HLA; INFECTIONS; RISK; IDDM; GENETICS; ANTIGENS","Enterovirus infections may be involved in the etiology of type 1 diabetes (T1D), which is strongly associated with certain human leukocyte antigen (HLA) class II haplotypes. Our aim was to assess whether HLA genotypes conferring varying degrees of risk for T1D were associated with enterovirus gut infections. From the general Norwegian population, 190 healthy infants at high-risk for T1D (DR4-DQ8/DR3-DQ2), and 383 infants without this genotype were identified. Non-DR4-DQ8/DR3-DQ2 genotypes were further categorized as conferring either an increased-to-moderate risk (DR4-DQ8 or DR3-DQ2), were protective (DQB1*06:02), or were neutral (all other genotypes). A total of 4626 monthly fecal samples taken between age 3 and 12mo were tested for enterovirus RNA using real-time PCR. Enterovirus prevalence was 11.5% among high-risk children, and 12.2% in other children (adjusted odds ratio: 1.23, p = 0.12). The prevalence was 11.3% in those with increased-to-moderate risk, 13.0% in the protective group, and 12.6% in the neutral group (likelihood ratio test, 3 d.f.: p = 0.37). In conclusion, there was no statistically significant association between HLA genotype and the occurrence of human enterovirus gut infections.","[Witso, Elisabet; Tapia, German; Rasmussen, Trond; Stene, Lars C.] Norwegian Inst Publ Hlth, N-0403 Oslo, Norway; [Cinek, Ondrej] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Ronningen, Kjersti S.] Oslo Univ Hosp, Rikshosp, Dept Paediat, Oslo, Norway","Witso, E (reprint author), Norwegian Inst Publ Hlth, Postboks 4404 Nydalen, N-0403 Oslo, Norway.","elisabet.witso@fhi.no",null,null,"Norwegian Organization for Health and Rehabilitation [2008/0182]; Ministry of Health of the Czech Republic [IGA MZ 11465-5]; Research Council of Norway [135893/330, 155300/320, 156477/730, 166515/V50]; Norwegian Diabetes Association; Sigurd K. Thoresen's Legacy","This study and the MIDIA project were funded by the Norwegian Organization for Health and Rehabilitation (2008/0182), the Ministry of Health of the Czech Republic (IGA MZ 11465-5), the Research Council of Norway (grants 135893/330, 155300/320, 156477/730, and 166515/V50), the Norwegian Diabetes Association, and Sigurd K. Thoresen's Legacy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,34,0,0,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","0882-8245",null,null,"VIRAL IMMUNOL","Viral Immunol.","JUN",2012,25,3,null,null,null,null,187,192,null,"10.1089/vim.2012.0001",null,6,"Immunology; Virology","Immunology; Virology","959BO","WOS:000305285000003"]
[null,null,null,null,"J","d'Alquen, D; De Boeck, K; Bradley, J; Vavrova, V; Dembski, B; Wagner, TOF; Pfalz, A; Hebestreit, H",null,null,null,"d'Alquen, Daniela; De Boeck, Kris; Bradley, Judy; Vavrova, Vera; Dembski, Birgit; Wagner, Thomas O. F.; Pfalz, Annette; Hebestreit, Helge",null,null,"Quality assessment of expert answers to lay questions about cystic fibrosis from various language zones in Europe: the ECORN-CF project","BMC MEDICAL RESEARCH METHODOLOGY",null,null,"English","Article",null,null,null,null,null,null,"INTERNET; DISEASE; FORUM","Background: The European Centres of Reference Network for Cystic Fibrosis (ECORN-CF) established an Internet forum which provides the opportunity for CF patients and other interested people to ask experts questions about CF in their mother language. The objectives of this study were to: 1) develop a detailed quality assessment tool to analyze quality of expert answers, 2) evaluate the intra-and inter-rater agreement of this tool, and 3) explore changes in the quality of expert answers over the time frame of the project. Methods: The quality assessment tool was developed by an expert panel. Five experts within the ECORN-CF project used the quality assessment tool to analyze the quality of 108 expert answers published on ECORN-CF from six language zones. 25 expert answers were scored at two time points, one year apart. Quality of answers was also assessed at an early and later period of the project. Individual rater scores and group mean scores were analyzed for each expert answer. Results: A scoring system and training manual were developed analyzing two quality categories of answers: content and formal quality. For content quality, the grades based on group mean scores for all raters showed substantial agreement between two time points, however this was not the case for the grades based on individual rater scores. For formal quality the grades based on group mean scores showed only slight agreement between two time points and there was also poor agreement between time points for the individual grades. The inter-rater agreement for content quality was fair (mean kappa value 0.232 +/- 0.036, p < 0.001) while only slight agreement was observed for the grades of the formal quality (mean kappa value 0.105 +/- 0.024, p < 0.001). The quality of expert answers was rated high (four language zones) or satisfactory (two language zones) and did not change over time. Conclusions: The quality assessment tool described in this study was feasible and reliable when content quality was assessed by a group of raters. Within ECORN-CF, the tool will help ensure that CF patients all over Europe have equal possibility of access to high quality expert advice on their illness.","[d'Alquen, Daniela; Hebestreit, Helge] Univ Hosp Wuerzburg, Dept Pediat, D-97080 Wurzburg, Germany; [De Boeck, Kris] Univ Hosp Leuven, Dept Pediat, B-3000 Louvain, Belgium; [Bradley, Judy] Univ Ulster, Hlth & Rehabil Sci Res Inst, Newtownabbey BT37 0QB, North Ireland; [Bradley, Judy] Adult CF Ctr, Newtownabbey BT37 0QB, North Ireland; [Vavrova, Vera] Charles Univ Prague, Sch Med 2, Cyst Fibrosis Ctr, Prague 15006 5, Czech Republic; [Dembski, Birgit] CF Europe Bonn, D-53117 Bonn, Germany; [Dembski, Birgit] CF Assoc, D-53117 Bonn, Germany; [Wagner, Thomas O. F.; Pfalz, Annette] Goethe Univ Hosp Frankfurt, Dept Pneumol, D-60590 Frankfurt, Germany","d'Alquen, D (reprint author), Univ Hosp Wuerzburg, Dept Pediat, Josef Schneider Str 2, D-97080 Wurzburg, Germany.","DAlquen_D@kinderklinik.uni-wuerzburg.de",null,null,"German Research Foundation (DFG); University of Wuerzburg; European Union; Christiane Herzog Stiftung","This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing.The project ECORN-CF has received funding from the European Union in the framework of the Public Health Programme from May 1, 2007 until April 30, 2010. Furthermore, the 'Christiane Herzog Stiftung', a donation of the former German President's wife, has given an extra co-funding. The continuation of the ECORN-CF project since May 1, 2010 has been enabled with the support of the following partners: Christiane Herzog Stiftung (donation of the former German President's wife), Mukoviszidose e.V. (German CF patient organisation), ECFS (European Cystic Fibrosis Society), CFE (Cystic Fibrosis Europe), Vaincre La Mucoviscidose, Belgische Vereniging voor Strijd tegen Mucoviscidose/Association Belge de Lutte contre la Mucoviscidose. More detailed information can be found on the Copyright/Imprint section of the ECORN-CF website.",null,14,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2288",null,null,"BMC MED RES METHODOL","BMC Med. Res. Methodol.","FEB 6",2012,12,null,null,null,null,null,null,null,11,"10.1186/1471-2288-12-11",null,11,"Health Care Sciences & Services","Health Care Sciences & Services","914HY","WOS:000301941600001"]
[null,null,null,null,"J","Medova, E; Fialova, E; Mlcek, M; Slavicek, J; Dohnalova, A; Charvat, J; Zakovicova, E; Kittnar, O",null,null,null,"Medova, E.; Fialova, E.; Mlcek, M.; Slavicek, J.; Dohnalova, A.; Charvat, J.; Zakovicova, E.; Kittnar, O.",null,null,"QT Dispersion and Electrocardiographic Changes in Women With Gestational Diabetes Mellitus","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"QT dispersion; Electrocardiography; Gestational diabetes mellitus","ACUTE MYOCARDIAL-INFARCTION; PREGNANCY; REPRODUCIBILITY; HYPERGLYCEMIA; MORPHOLOGY; INTERVALS","Gestational diabetes mellitus (GDM) represents additional risks to both mother and infant. Moreover it increases a woman's risk of cardiovascular disease in the postpartum. The aim of our study was therefore to detect changes of both the QT dispersion and the electrical heart field that could be typical for GDM. Body surface potential maps were obtained using the Cardiac 112.2 device from 26 young women with GDM and 54 young healthy pregnant women in the 36th week of pregnancy. The same recordings were obtained from 18 healthy women in the same age (19-36 years). The average QT dispersion (+/- SD) in women suffering from GDM was significantly higher (107 +/- 25 ms) both than in those with physiological pregnancy (73 +/- 18 ms) and than in the normal subjects (34 +/- 12 ms) (P<0.001). Moreover we have found in GDM patients shorter QRS complex 82.0 +/- 6.8 ms vs. 89.5 +/- 8.2 ms in healthy pregnant women and 90.8 +/- 7.9 ms in the control group (p=0.011), more horizontal electrical heart axis [16.4 +/- 20.1 vs. 42.4 +/- 28.7 and 74.6 +/- 39.2 respectively (P<0.05)] and lower some depolarization and repolarization amplitudes on isopotential and isointegral maps. According to these results we suppose that described electrocardiographic changes reflect a deterioration of the complete process of ventricular depolarization and repolarization in GDM.","[Fialova, E.; Mlcek, M.; Slavicek, J.; Dohnalova, A.; Kittnar, O.] Charles Univ Prague, Fac Med 1, Inst Physiol, Prague 12800 2, Czech Republic; [Medova, E.] Charles Univ Prague, Fac Med 1, Dept Anaesthesiol & Intens Care, Prague 12800 2, Czech Republic; [Charvat, J.] Charles Univ Prague, Fac Med 2, Dept Internal Med, Prague 12800 2, Czech Republic; [Zakovicova, E.] NsP Medissimo, Bratislava, Slovakia","Kittnar, O (reprint author), Charles Univ Prague, Fac Med 1, Inst Physiol, Albertov 5, Prague 12800 2, Czech Republic.","okittnar@lf1.cuni.cz",null,null," [PRVOUK-P38/LF1/10]","This work was supported by PRVOUK-P38/LF1/10 grant.",null,25,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2012,61,null,null,2,null,null,"S49","S55",null,null,null,7,"Physiology","Physiology","026FM","WOS:000310260000007"]
[null,null,null,null,"J","Adamovicova, M; Fabriciova, K; Jakubikova, M; Prihodova, I; Klement, P; Sykora, P; Dusl, M; Abicht, A; Zeman, J; Seeman, P; Honzik, T",null,null,null,"Adamovicova, M.; Fabriciova, K.; Jakubikova, M.; Prihodova, I.; Klement, P.; Sykora, P.; Dusl, M.; Abicht, A.; Zeman, J.; Seeman, P.; Honzik, T.",null,null,"Congenital Myasthenia as a Cause of Respiratory Failure in two Infants and a Toddler - Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"congenital myasthenic syndrome; respiratory failure; neuromuscular transmission disorders; muscle hypotonia; muscle weakness","PLATE ACETYLCHOLINESTERASE DEFICIENCY; COLQ MUTATIONS; EPHEDRINE","Congenital myasthenic syndromes (CMS) are rare autosomal recessive disorders of neuromuscular transmission. They manifest early, but although symptoms can be improved with treatment, they often remain unrecognized. In our region, CMS with mutations of CHNE gene is well known and is particularly common in the gypsy ethnic group. However, there also are other, much more severe types, such as COLQ CMS that may be complicated by respiratory failure. In COLO CMS, decomposition of acetylcholine at a synapse is disrupted. The synapse is overloaded and, therefore, syntostigmine as well as acetylcholinesterase inhibitors worsen the symptoms. Ephedrine is the treatment of choice. Apnoea monitor and resuscitation training in parents can be life-saving. In cases where both pathogenic mutations are known, prenatal or preimplantation diagnostics are available. We present three CMS patients who suffered from respiratory crises at an early age. The outcome was variable a boy died at 6 months of age, a 7-year old girl needs nocturnal ventilation support and walks 10 meters, an adult patient has minimal sequelae. In two patients, COLQ mutations have been confirmed as a cause of CMS and COLQ CMS is suspected in the remaining patient (patient P2).","[Adamovicova, M.; Klement, P.; Zeman, J.; Honzik, T.] 1 LF UK & VFN, Klin Detskeho & Dorostoveho Lekarstvi, Prague 12109 2, Czech Republic; [Fabriciova, K.] LF UK & DFNsP Bratislava, Detska Klin 1, Bratislava, Slovakia; [Jakubikova, M.; Prihodova, I.] 1 LF UK & VFN, Neurol Klin, Prague 12109 2, Czech Republic; [Jakubikova, M.; Prihodova, I.] 1 LF UK & VFN, Ctr Klinickych Neuroved, Prague 12109 2, Czech Republic; [Sykora, P.] LF UK & DFNsP Bratislava, Klin Detskej Neurol, Bratislava, Slovakia; [Seeman, P.] 2 LF UK & FN Motole, Klin Detske Neurol, Prague, Czech Republic; [Seeman, P.] Ctr Lekarske Genetiky Gennet, Prague, Czech Republic","Adamovicova, M (reprint author), 1 LF UK & VFN, Klin Detskeho & Dorostoveho Lekarstvi, Ke Karlovu 2, Prague 12109 2, Czech Republic.","adamovicova.m@seznam.cz",null,null,null,null,null,16,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,6,null,null,null,null,757,762,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","039JU","WOS:000311242700014"]
[null,null,null,null,"J","Pitha, J; Bednarik, J; Zapletalova, O; Schutzner, J; Zamecnik, J; Ambler, Z; Pata, M; Suchy, M",null,null,null,"Pitha, J.; Bednarik, J.; Zapletalova, O.; Schuetzner, J.; Zamecnik, J.; Ambler, Z.; Pata, M.; Suchy, M.",null,null,"Guideline for the Diagnosis and Therapy of Myasthenia Gravis","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"myasthenia gravis; key recommendations; diagnosis; treatment; centralized care","MANAGEMENT","The Czech Neurological Society taskforce in collaboration with other professionals has developed a clinical standard for the diagnosis and treatment of myasthenia gravis. The development of the standard was prompted by the need to unify the diagnosis and treatment of myasthenia gravis, to monitor side and adverse effects of modern drugs and to verify their effectiveness, to monitor the effectiveness of care and to ensure efficient use of resources and diagnostic and therapeutic efforts in order to improve the quality of care provided. Key recommendations are based on the international guidelines, formulated by the EFNS [2] and the Euromyasthenia panel (2008) [3]. The level of evidence for all recommendations was classified according to the EFNS classification by Brainin et al [4].","[Pitha, J.] 1 LF UK & VFN Praze, CNS, NMS,Neurol Klin,CLS JEP, SNIL,Vedouci Lekar Ctr Lecbumyathenia Gravis, Prague, Czech Republic; [Pata, M.; Suchy, M.] Narodni Referencni Ctr Praha, Prague, Czech Republic","Pitha, J (reprint author), 1 LF UK & VFN Praha, Neurol Klin, Katerinska 30, Prague 12000 2, Czech Republic.","pithaj@seznam.cz",null,null,null,null,"Ambler Z, 2010, NEUROL PROPRAXI, V11, P81; Angelini C, 2011, CLIN DRUG INVEST, V31, P1, DOI 10.2165/11584740-000000000-00000; Auriel E, 2011, MUSCLE NERVE, V43, P893, DOI 10.1002/mus.22077; Blaha M, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/419520; Brainin M, 2004, EUR J NEUROL, V11, P577, DOI 10.1111/j.1468-1331.2004.00867.x; Gagner M, 2002, MINIMALLY INVASIVE E; Guptill JT, 2010, CURR OPIN NEUROL, V23, P530, DOI 10.1097/WCO.0b013e32833c0982; Kaminski HJ, 2009, MYASTHENIA GRAVIS RE, P577; Kupersmith MJ, 2005, BRIT J OPHTHALMOL, V89, P1330, DOI 10.1136/bjo.2004.063404; Mantegazza R, 2011, NEUROPSYCH DIS TREAT, V7, P151, DOI 10.2147/NDT.S8915; McGrogan A, 2010, NEUROEPIDEMIOLOGY, V34, P171, DOI 10.1159/000279334; Minami N, 2011, J NEUROL SCI, V300, P59, DOI 10.1016/j.jns.2010.09.033; Oh S. J., 1988, ELECTROMYOGRAPHY NEU; Pearson FG, 1995, THORACIC SURG; Pit'ha J, 1998, CESK SLOV NEUROL N, V61, P7; Pitha J, 2010, MYASTHENIA GRAVIS OS; Sanders DB, 2004, MYASTHENIA GRAVIS DI, P10; SANDERS DB, 1986, MUSCLE NERVE, V9, P809, DOI 10.1002/mus.880090904; Shah AK, MYASTHENIA GRAVIS; Shields TW, 1991, MEDIASTINAL SURG; Skeie GO, 2010, EUR J NEUROL, V17, P893, DOI 10.1111/j.1468-1331.2010.03019.x; Spalek P, 2008, CESK SLOV NEUROL N, V71, P7; Stalberg E, 1994, SINGLE FIBER ELECTRO; TRONTELJ JV, 1986, J NEUROL NEUROSUR PS, V49, P677, DOI 10.1136/jnnp.49.6.677; Vincent A, 2008, MYASTHENIA GRAVIS CL",25,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,2,null,null,null,null,244,252,null,null,null,9,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","932MA","WOS:000303294000019"]
[null,null,null,null,"J","Hromadnikova, I; Kotlabova, K; Doucha, J; Dlouha, K; Krotta, L",null,null,null,"Hromadnikova, Ilona; Kotlabova, Katerina; Doucha, Jindrich; Dlouha, Klara; Krotta, Ladislav",null,null,"Absolute and Relative Quantification of Placenta-Specific MicroRNAs in Maternal Circulation with Placental Insufficiency-Related Complications","JOURNAL OF MOLECULAR DIAGNOSTICS",null,null,"English","Article",null,null,null,null,null,null,"FREE FETAL DNA; INTRAUTERINE GROWTH RESTRICTION; HYPERMETHYLATED RASSF1A; TROPHOBLASTIC INVASION; PRENATAL-DIAGNOSIS; EARLY-PREGNANCY; PREECLAMPSIA; PLASMA; APOPTOSIS; EXPRESSION","Placental insufficiency related complications are one of the leading causes of maternal and perinatal morbidity and mortality. This study investigated the quantification of placenta-specific microRNAs (miRNAs) in the maternal circulation during gestation in a cohort of women with normally progressing pregnancies, the differentiation between placental insufficiency related complications and normally progressing pregnancies, and the differentiation between placental insufficiency and normally progressing pregnancies during the early stages of gestation. Both absolute and relative quantification of placenta-specific miRNAs (ie, miR-516-5p, miR-517*, miR-518b, miR-520a*, miR-520h, miR-525, and miR-526a) was determined in 50 women with normally progressing pregnancies, 32 with complicated pregnancies [21 with preeclampsia with or without intrauterine growth retardation (IUGR) and 11 with IUGR, and 7 women with pregnancies at various gestational stages who later developed preeclampsia and/or IUGR using real-time PCR and a comparative C-T method relative to normalization factor (ie, geometric mean of ubiquitous miR-16 and let-7d). Both quantification approaches revealed significant increases in extracellular placenta specific miRNA levels over time in women with normally progressing pregnancies; however, they were not able to differentiate between normally progressing and complicated pregnancies at the time of preeclampsia and/or IUGR onset. Nevertheless, significant elevation of extracellular miRNA levels was observed during early gestation (ie, within the 12th to 16th weeks) in pregnancies with later onset of preeclampsia and/or IUGR. Early gestation extracellular miRNA screening can differentiate between women with normally progressing pregnancies and those who may later develop placental insufficiency related complications. (J Mol Diagn 2012, 14:160-167; DOI. 10.1016/j.jmoldx.2011.11.003)","[Hromadnikova, Ilona; Kotlabova, Katerina] Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Prague 10000 10, Czech Republic; [Doucha, Jindrich; Dlouha, Klara] Charles Univ Prague, Clin Obstet & Gynecol, Univ Hosp Motol, Fac Med 2, Prague 10000 10, Czech Republic; [Krotta, Ladislav] Inst Care Mother & Child, Prague, Czech Republic","Hromadnikova, I (reprint author), Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Ruska 87, Prague 10000 10, Czech Republic.","ilona.hromadnikova@lf3.cuni.cz",null,null,"projects MSM [0021620806]; GAUK [260707/SVV/2010]","Supported by grant projects MSM 0021620806 and GAUK 260707/SVV/2010.",null,40,11,12,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1525-1578",null,null,"J MOL DIAGN","J. Mol. Diagn.","MAR",2012,14,2,null,null,null,null,160,167,null,"10.1016/j.jmoldx.2011.11.003",null,8,"Pathology","Pathology","901ZF","WOS:000301007700008"]
[null,null,null,null,"J","Klozar, J; Cada, Z; Koslabova, E",null,null,null,"Klozar, Jan; Cada, Zdenek; Koslabova, Eva",null,null,"Complications of total laryngectomy in the era of chemoradiation","EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"Total laryngectomy; Surgical complications; Pharyngocutaneous fistula; Chemoradiation; Salvage surgery","POSTLARYNGECTOMY PHARYNGOCUTANEOUS FISTULA; SALVAGE TOTAL LARYNGECTOMY; ORGAN PRESERVATION THERAPY; PREDISPOSING FACTORS; HEAD; CHEMOTHERAPY; RECURRENCE; SURGERY; CANCER","As more total laryngectomies (TLE) are nowadays performed as salvage procedures, the rate of postoperative complications increases. The primary aim was to report the rates of postoperative local complications for total laryngectomy in patients with previous radiotherapy or chemoradiotherapy (RT/CRT) in comparison with primary TLE data. We attempted to identify patient- and tumor-related factors predictive of postoperative pharyngocutaneous fistula (PCF) formation. The secondary aims were to analyze the survival rate in relation to postoperative complications and to study prognostic factors of survival in TLE patients. A retrospective study was conducted in 208 patients. Logistic regression was used to determine the most significant risk factors for fistula formation. Survival was analyzed by the Kaplan-Meier method, log-rank test, and Cox multivariate regression. PCF developed in 20.7% of cases. In the group of patients with previous RT/CRT, the fistula rate was significantly higher (34%). In multivariate analysis, significant risk factors for fistula formation were previous radiotherapy or chemoradiotherapy (p = 0.02), higher N classification (p = 0.03), and procedure performed by a less experienced surgeon (p = 0.003). The survival and recurrence rates were not influenced by PCF formation. The overall survival rates were lower in patients with previous RT/CRT and in patients with lymph node involvement.","[Klozar, Jan; Cada, Zdenek; Koslabova, Eva] Charles Univ Prague, Prague Motol Univ Hosp, Dept Otolaryngol Head & Neck Surg, Fac Med 1, Prague 15006, Czech Republic","Klozar, J (reprint author), Charles Univ Prague, Prague Motol Univ Hosp, Dept Otolaryngol Head & Neck Surg, Fac Med 1, V Uvalu 84,Praha 5, Prague 15006, Czech Republic.","jan.klozar@lfmotol.cuni.cz",null,null,null,null,null,15,7,8,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0937-4477",null,null,"EUR ARCH OTO-RHINO-L","Eur. Arch. Oto-Rhino-Laryn.","JAN",2012,269,1,null,null,null,null,289,293,null,"10.1007/s00405-011-1598-7",null,5,"Otorhinolaryngology","Otorhinolaryngology","870FT","WOS:000298655300043"]
[null,null,null,null,"J","Smilek, P; Neuwirthova, J; Jarkovsky, J; Dusek, L; Rottenberg, J; Kostrica, R; Srovnal, J; Hajduch, M; Drabek, J; Klozar, J",null,null,null,"Smilek, P.; Neuwirthova, J.; Jarkovsky, J.; Dusek, L.; Rottenberg, J.; Kostrica, R.; Srovnal, J.; Hajduch, M.; Drabek, J.; Klozar, J.",null,null,"Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"HNSCC; EGFR; KRAS; EGFR gene expression","GENE COPY NUMBER; COLORECTAL-CANCER; LUNG-CANCER; UNDERSTANDING RESISTANCE; CLINICAL-RESPONSE; BREAST-CANCER; CETUXIMAB; INHIBITORS; GEFITINIB; AMPLIFICATION","Epidermal growth factor receptor (EGFR) is an important therapeutic target and a poor prognosis factor in head and neck squamous cell carcinoma (HNSCC). The aim of the study was to analyze EGFR expression and KRAS and EGFR mutational status and to correlate it with treatment response to anti-EGFR therapy combined with radiotherapy in 29 patients with advanced head and neck squamous cell carcinomas (HNSCC). EGFR gene expression normalized to GAPDH and EGFR variant type III (EGFRvIII) was detected in tumor tissue using real time reverse transcription -PCR. The mutational status of the EGFR and KRAS genes was investigated by real time PCR with sequence specific primers. Gene expression median values were 3.1x10(8) GAPDH gene copies per mu g of RNA, and 8x10(6) EGFR gene copies per mu g of RNA. The median EGFR/GADPH ratio reached 0.14. Patients, who achieved complete response after Cetuximab combined with radiotherapy, had significantly higher expression of the EGFR gene in tumors than patients with partial remission or patient without treatment response. An EGFRvIII mutation was found in 20.7% of patients and no association was found between this mutation and treatment response. 27 patients (93.1%) had an EGFR gene wild type tumor, and deletion in exon 19 was found in two patients with a poor clinical outcome. Most of the patients (82.8%) had a KRAS wild type tumor; a p.Gly12Cys was found in three patients and a p.Gly12Val mutation in one. Presence of a p.Gly12Val mutation in the KRAS gene was associated with an absence of response to treatment. Conclusion: Our data suggest that KRAS mutation (p.Gly12Val) and somatic EGFR mutation located in exon 19 may contribute to the limited clinical response to therapy with cetuximab + radiotherapy. Higher EGFR gene expression serves as an independent indicator of good clinical response to EGFR-targeted therapy + radiotherapy.","[Smilek, P.; Neuwirthova, J.; Rottenberg, J.; Kostrica, R.] Masaryk Univ, Dept Otorhinolaryngol & Head & Neck Surg, Brno, Czech Republic; [Smilek, P.; Neuwirthova, J.; Rottenberg, J.; Kostrica, R.] St Annes Fac Hosp Brno, Brno, Czech Republic; [Srovnal, J.; Hajduch, M.; Drabek, J.] Palacky Univ, Inst Mol & Translat Med, Expt Med Lab, Olomouc, Czech Republic; [Srovnal, J.; Hajduch, M.; Drabek, J.] Fac Hosp Olomouc, Olomouc, Czech Republic; [Jarkovsky, J.; Dusek, L.] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic; [Klozar, J.] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Prague, Czech Republic","Smilek, P (reprint author), Masaryk Univ, Dept Otorhinolaryngol & Head & Neck Surg, Brno, Czech Republic.","smilek@med.muni.cz","Drabek, Jiri/A-6135-2008; Dusek, Ladislav/G-8794-2013","Drabek, Jiri/0000-0002-5747-6478; ","grant IGA MZCR [NS 10108-4]","This study was supported by the grant IGA MZCR No. NS 10108-4.",null,36,7,7,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2012,59,5,null,null,null,null,508,515,null,"10.4149/neo_2012_065",null,8,"Oncology","Oncology","993LF","WOS:000307860500005"]
[null,null,null,null,"J","Slanar, O; Dupal, P; Matouskova, O; Vondrackova, H; Pafko, P; Perlik, F",null,null,null,"Slanar, O.; Dupal, P.; Matouskova, O.; Vondrackova, H.; Pafko, P.; Perlik, F.",null,null,"Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"analgesia; tramadol; acute pain; polymorphism; arthroscopy","CZECH POPULATION; PHARMACOKINETICS; METABOLITES; GENOTYPE; C3435T; IMPACT","Objectives: The aim of our study was to evaluate impact of CYP2D6 and MDR1 polymorphisms on the analgesic efficacy of tramadol in patients after a knee arthroscopy. Background : Pharmacokinetics of tramadol and its metabolites is stereoselective and displays high interindividual variability correlating with polymorphic CYP2D6 in the population. Available data provide controversial results regarding the analgesic efficacy of tramadol in subjects with different CYP2D6 genotypes. Methods: Pain intensity was assessed using visual analogue scale at 2 and 24 hours after the knee arthroscopy in 156 patients. Polymorphisms CYP2D6*3,*4,*5,*6, and gene duplication and C3435T in MDR1 gene were analyzed by PCR - RFLP. Results: Mean VAS(2h) value in the whole study group was 44.0 +/- 16.5 mm. Mean pain difference, was lowest in the UM group and highest in the PM group. The pain difference varied significantly among the CYP2D6 subgroups (F = 4.29; p = 0.006) with significant differences between homEM vs hetEM, homEM vs PM, and UM vs PM subgroups. There were no significant differences among MDR1 subgroups with regards of pain difference. Mean tramadol consumption was 2.47 +/- 1.17 mg/kg during the 24 h period. There were no significant differences in the drug consumption, reporting of adverse reactions, need for rescue analgesic medication or verbal description of pain among the CYP2D6,or MDR1 genotype subgroups. Conclusion: CYP2D6 plays a significant role in tramadol analgesic efficacy. The non-opioid analgesia in PMs was associated with better subjective pain relief in patients after a knee arthroscopy (Tab. 3, Ref. 18). Full Text in PDF www.elis.sk.","[Slanar, O.; Matouskova, O.; Vondrackova, H.; Perlik, F.] Charles Univ Prague, Fac Med 1, Inst Pharmacol, CZ-12800 Prague 2, Czech Republic; [Slanar, O.; Matouskova, O.; Vondrackova, H.; Perlik, F.] Charles Univ Prague, Gen Teaching Hosp, CZ-12800 Prague 2, Czech Republic; [Dupal, P.] Charles Univ Prague, Dept Orthopaed, Fac Med 1, CZ-12800 Prague 2, Czech Republic; [Dupal, P.; Pafko, P.] Charles Univ Prague, Univ Hosp Motol, CZ-12800 Prague 2, Czech Republic; [Pafko, P.] Charles Univ Prague, Dept Surg 3, Fac Med 1, CZ-12800 Prague 2, Czech Republic","Slanar, O (reprint author), Charles Univ Prague, Fac Med 1, Inst Pharmacol, Albertov 4, CZ-12800 Prague 2, Czech Republic.","oslan@lfl.cuni.cz",null,null,"GACR [305/08/P069]","This study has been supported by a GACR grant No. 305/08/P069.",null,19,4,5,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248",null,null,"BRATISL MED J","Bratisl. Med. J.",null,2012,113,3,null,null,null,null,152,155,null,"10.4149/BLL_2012_036",null,4,"Medicine, General & Internal","General & Internal Medicine","920EQ","WOS:000302385900005"]
[null,null,null,null,"J","Kubus, P; Materna, O; Gebauer, RA; Matejka, T; Gebauer, R; Tlaskal, T; Janousek, J",null,null,null,"Kubus, Petr; Materna, Ondrej; Gebauer, Roman A.; Matejka, Tomas; Gebauer, Roman; Tlaskal, Tomas; Janousek, Jan",null,null,"Permanent epicardial pacing in children: long-term results and factors modifying outcome","EUROPACE",null,null,"English","Article",null,null,null,null,null,"Pacing; Epicardial; Children; Atrioventricular block; Congenital heart disease","CONGENITAL HEART-DISEASE; DUAL-CHAMBER; CARDIAC RESYNCHRONIZATION; VENOUS OBSTRUCTION; PEDIATRIC-PATIENTS; YOUNG; LEADS; EXPERIENCE; PACEMAKER; SITE","To evaluate the results of permanent epicardial pacing in children. All consecutive patients from one country (n 119, period 19772009) undergoing permanent epicardial pacemaker implantation at 18 years of age (median 1.8 years, inter-quartile range 0.36.4 years) were studied retrospectively. Median patient follow up was 6.4 years (inter-quartile range 2.911.1 years); 207 generators, 89 atrial and 153 ventricular pacing leads were implanted. The probability of absence of any pacing system dysfunction was 70.1 and 47.2 at 5 and 10 years after implantation, respectively. Overall probability of continued epicardial pacing was 92.8 and 76.1 at 5 and 10 years, respectively, and increased in the recent implantation era (post-2000, P 0.04). The use of steroid-eluting leads decreased the risk of exit block with a hazard ratio (HR) of 0.20 [95 confidence interval (CI) 0.090.44, P 0.001)]. The use of bipolar Medtronic 4968 leads reduced the risk of surgical reintervention because of fracture, insulation break, outgrowth or exit block in comparison to the unipolar 4965 lead design (HR 0.12, 95 CI 0.040.40, P 0.001). The AutoCapture feature (HR 0.08, 95 CI 0.020.36, P 0.001) and steroid-eluting leads (HR 0.30, 95 CI 0.110.84, P 0.021) decreased the risk of battery depletion. The probability of continued epicardial pacing in children was 76 at 10 years after implantation, increased for implantation in recent years, and allowed transvenous pacing to be deferred to a significantly greater age. The use of bipolar steroid-eluting leads and of a beat-to-beat capture tracking feature significantly increased pacing system longevity and decreased the need for surgical reinterventions.","[Kubus, Petr; Materna, Ondrej; Matejka, Tomas; Gebauer, Roman; Tlaskal, Tomas; Janousek, Jan] Univ Hosp Motol, Kardioctr, Prague 15006, Czech Republic; [Kubus, Petr; Materna, Ondrej; Matejka, Tomas; Gebauer, Roman; Tlaskal, Tomas; Janousek, Jan] Univ Hosp Motol, Cardiovasc Res Ctr, Prague 15006, Czech Republic; [Gebauer, Roman A.] Univ Leipzig, Ctr Heart, Dept Paediat Cardiol, D-04289 Leipzig, Germany","Kubus, P (reprint author), Fak Nemocnice Motole, Detske Kardioctr, V Uvalu 84, Prague 15006, Czech Republic.","peter.kubus@lfmotol.cuni.cz",null,null,"University Hospital Motol [MZOFNM2005]","This work was supported by the research project of University Hospital Motol no. MZOFNM2005.",null,22,3,5,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1099-5129",null,null,"EUROPACE","Europace","APR",2012,14,4,null,null,null,null,509,514,null,"10.1093/europace/eur327",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","919DO","WOS:000302301800012"]
[null,null,null,null,"J","Zemanova, M; Novak, F; Vitek, P; Pazdro, A; Smejkal, M; Pazdrova, G; Petruzelka, L",null,null,null,"Zemanova, M.; Novak, F.; Vitek, P.; Pazdro, A.; Smejkal, M.; Pazdrova, G.; Petruzelka, L.",null,null,"Outcomes of patients with oesophageal cancer treated with preoperative chemoradiotherapy, followed by tumor resection: influence of nutritional factors","JOURNAL OF BUON",null,null,"English","Article",null,null,null,null,null,"neoadjuvant chemoradiotherapy; nutritional support; oesophageal cancer; serum albumin; weight loss","SURVIVAL; CHEMOTHERAPY; METAANALYSIS; WEIGHT; IMPACT","Purpose: To assess the impact of clinical and nutritional factors on overall survival (OS) and time to disease progression of oesophageal cancer patients treated with neoadjuvant chemoradiotherapy (CRT) and surgery. Methods: We retrospectively studied and analysed several clinical and nutritional factors, such as performance status, weight changes before and during CRT, dysphagia, nutritional support, and serum albumin to see whether they exerted any impact on OS and time to disease progression. Results: In 107 patients the average weight loss was 9.7% from the onset of signs of disease to the beginning of therapy and 3% during CRT In univariate analysis, significant unfavorable impact on survival was proved for low performance status, severe dysphagia, need for nasogastric tube insertion, above-average weight loss before treatment, weight loss >5% during CRT, and serum albumin <= 35 g/l before or after CRT Patients supported by oral nutritional supplements (ONS) had higher probability to attain full dosage of CRT and radical resection than did those obtaining dietary advice alone. In multivariate analysis, serum albumin level, nasogastric (NG) tube insertion and pretreatment body weight loss were independent prognostic factors for OS, while serum albumin level after CRT and NG tube insertion were prognosticators for time to progression. Conclusion: Serum albumin level can serve as a useful prognostic factor for the outcome of patients with oesophageal cancer treated with neoadjuvant CRT and surgery. Appropriate nutritional support of these patients increased the probability of attaining full dosage of CRT and radical disease resection.","[Zemanova, M.; Pazdrova, G.; Petruzelka, L.] Charles Univ Prague, Clin Oncol, Fac Med 1, Prague 12808 2, Czech Republic; [Zemanova, M.; Novak, F.] Gen Univ Hosp Prague, Prague 12808 2, Czech Republic; [Novak, F.] Charles Univ Prague, Clin Internal Med 4, Fac Med 1, Prague 12808 2, Czech Republic; [Vitek, P.] Charles Univ Prague, Inst Radiat Oncol, Fac Med 1, Prague 12808 2, Czech Republic; [Vitek, P.] Univ Hosp Bulovka Prague, Prague, Czech Republic; [Pazdro, A.; Smejkal, M.] Charles Univ Prague, Clin Surg 3, Fac Med 1, Prague 12808 2, Czech Republic; [Pazdro, A.; Smejkal, M.] Univ Hosp Motol Prague, Prague, Czech Republic","Zemanova, M (reprint author), Charles Univ Prague, Clin Oncol, Fac Med 1, U Nemocnice 2, Prague 12808 2, Czech Republic.","milada.zemanova@vfn.cz",null,null,"Ministry of Health of the Czech Republic [IGA MZ (CR) NT/12331-5/2011]","This study was supported by the grant NO: IGA MZ (CR) NT/12331-5/2011 of the Ministry of Health of the Czech Republic.",null,16,4,4,"ZERBINIS MEDICAL PUBL","ATHENS","42 ANTIFILOU STR, ATHENS, 157 71, GREECE","1107-0625",null,null,"J BUON","J. BUON","APR-JUN",2012,17,2,null,null,null,null,310,316,null,null,null,7,"Oncology","Oncology","970WV","WOS:000306163900016"]
[null,null,null,null,"J","Marcus, KA; Janousek, J; Barends, ME; Weijers, G; de Korte, CL; Kapusta, L",null,null,null,"Marcus, Karen A.; Janousek, Jan; Barends, Marlieke E.; Weijers, Gert; de Korte, Chris L.; Kapusta, Livia",null,null,"Synchronicity of systolic deformation in healthy pediatric and young adult subjects: a two-dimensional strain echocardiography study","AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"child; reference value","CARDIAC-RESYNCHRONIZATION THERAPY; CONGENITAL HEART-DISEASE; LEFT-VENTRICULAR MASS; RIGHT-INTRAVENTRICULAR DYSSYNCHRONY; OF-CARDIOLOGY-FOUNDATION; BUNDLE-BRANCH BLOCK; DILATED CARDIOMYOPATHY; CLINICAL-CARDIOLOGY; MYOCARDIAL STRAIN; SPECKLE-TRACKING","Marcus KA, Janousek J, Barends ME, Weijers G, de Korte C. L, Kupusta L. Synchronicity of systolic deformation in healthy pediatric and young adult subjects: a two-dimensional strain echocardiography study. Am J Physiol Heart Circ Physiol 302: H196-H205, 2012. First published October, 7, 2011; doi:10.1152/ajpheart.00740.2011.-Two-dimensional speckle tracking echocardiography (2DSTE) offers valuable information in the echocardiographic assessment of ventricular myocardial function. It enables the quantification and timing of systolic ventricular myocardial deformation. In addition, 2DSTE can be used to identify mechanical dyssynchrony, which is an important parameter in predicting the response to cardiac resynchronization therapy for heart failure. Detailed knowledge of normal timing of systolic deformation and its degree of synchronicity in children is lacking. We aimed to establish the normal timing of left ventricular myocardial systolic deformation using 2DSTE in a large cohort of healthy children and young adults. Transthoracic echocardiograms were acquired in 195 healthy subjects (139 children and 56 young adult <40 yr of age) and were retrospectively analyzed. Time to peak systolic longitudinal, circumferential, and radial strain was determined by means of speckle tracking. Strong, statistically significant relations between age as well as various anthropometric variables (e. g., heart rate) and timing of systolic deformation (P < 0.0001) were present. The extent of dyssynchronous deformation increased with age. This is the first report that establishes reference values per cardiac segment for time to peak systolic myocardial strain values in all three directions assessed with 2DSTE in a large pediatric and young adult cohort. We emphasize the need for using age-specific reference values as well as heart rate correction for the adequate interpretation of 2DSTE measurements.","[Marcus, Karen A.; Barends, Marlieke E.; Kapusta, Livia] Radboud Univ Nijmegen, Med Ctr, Childrens Heart Ctr, NL-6500 HB Nijmegen, Netherlands; [Weijers, Gert; de Korte, Chris L.] Radboud Univ Nijmegen, Med Ctr, Clin Phys Lab, NL-6500 HB Nijmegen, Netherlands; [Kapusta, Livia] Edith Wolfson Med Ctr, Pediat Cardiol Unit, Holon, Israel; [Janousek, Jan] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Janousek, Jan] Univ Hosp Motol, Kardioctr, Prague, Czech Republic","Marcus, KA (reprint author), Radboud Univ Nijmegen, Med Ctr, Childrens Heart Ctr, M325-04-004 KG,POB 9101, NL-6500 HB Nijmegen, Netherlands.","k.marcus@cukz.umcn.nl","Weijers, Gerrit/B-3762-2011; de Korte, Chris/C-1077-2008","de Korte, Chris/0000-0002-1987-6948",null,null,null,71,4,4,"AMER PHYSIOLOGICAL SOC","BETHESDA","9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA","0363-6135",null,null,"AM J PHYSIOL-HEART C","Am. J. Physiol.-Heart Circul. Physiol.","JAN",2012,302,1,null,null,null,null,"H196","H205",null,"10.1152/ajpheart.00740.2011",null,10,"Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease","Cardiovascular System & Cardiology; Physiology","870BJ","WOS:000298643800019"]
[null,null,null,null,"J","Kolar, M; Szabo, P; Dvorankova, B; Lacina, L; Gabius, HJ; Strnad, H; Sachova, J; Vlcek, C; Plzak, J; Chovanec, M; Cada, Z; Betka, J; Fik, Z; Paces, J; Kovarova, H; Motlik, J; Jarkovska, K; Smetana, K",null,null,null,"Kolar, Michal; Szabo, Pavol; Dvorankova, Barbora; Lacina, Lukas; Gabius, Hans-Joachim; Strnad, Hynek; Sachova, Jana; Vlcek, Cestmir; Plzak, Jan; Chovanec, Martin; Cada, Zdenek; Betka, Jan; Fik, Zdenek; Paces, Jan; Kovarova, Hana; Motlik, Jan; Jarkovska, Karla; Smetana, Karel, Jr.",null,null,"Upregulation of IL-6, IL-8 and CXCL-1 production in dermal fibroblasts by normal/malignant epithelial cells in vitro: Immunohistochemical and transcriptomic analyses","BIOLOGY OF THE CELL",null,null,"English","Article",null,null,null,null,null,"CXCL-1; IL-6; IL-8; squamous cell carcinoma; wound healing","HUMAN COLORECTAL-CARCINOMA; STROMAL FIBROBLASTS; GROWTH-FACTORS; HUMAN KERATINOCYTES; PANCREATIC-CANCER; GENE-EXPRESSION; POOR-PROGNOSIS; NECK-CANCER; ORAL-CAVITY; SUGAR CODE","Background information Considering an analogy between wound healing and tumour progression, we studied chemokine and cytokine transcription and expression in normal fibroblasts by co-culture and in situ. Results Whole-genome transcriptome profiling revealed strong upregulation for the interleukin (IL)-6, IL-8 and the chemokine CXCL-1 in in vitro co-cultures of normal fibroblasts with either normal or malignant epithelial cells compared to fibroblast cultures. The same ILs/chemokines were distinctly upregulated in clinical samples of squamous cell carcinoma when compared with paired normal mucosae. Analysis of culture supernatants showed that during the course of co-culture of the fibroblasts with the epithelial cells, IL-6, IL-8 and CXCL-1 were secreted to the culture medium. Experiments with addition of any of the proteins to the culture medium supported the notion that these ILs/chemokines strongly contributed to maintenance of a low-differentiation phenotype of epithelial cells, evaluated by the detection of keratin-8. Simultaneous addition of all factors increased the extent of the effect. These studies were extended by experiments with epithelial cells, either cultured in medium conditioned by preceding use for malignant keratinocytes without and in the presence of normal or cancer-associated fibroblasts or medium containing antibodies against IL-6, IL-8 and CXCL-1. Conclusions Our results indicate an analogy between wound healing and tumour growth, support the importance of epithelialmesenchymal interaction in this model system and establish a potential bio-inspired anticancer therapy.","[Szabo, Pavol; Dvorankova, Barbora; Lacina, Lukas; Smetana, Karel, Jr.] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Kolar, Michal; Szabo, Pavol; Dvorankova, Barbora; Strnad, Hynek; Sachova, Jana; Vlcek, Cestmir; Paces, Jan] Acad Sci Czech Republic, Inst Mol Genet, Lab Genom & Bioinformat, Prague, Czech Republic; [Lacina, Lukas] ASTAR, Inst Med Biol, Singapore, Singapore; [Gabius, Hans-Joachim] Univ Munich, Inst Physiol Chem, Fac Vet Med, D-8000 Munich, Germany; [Plzak, Jan; Chovanec, Martin; Cada, Zdenek; Betka, Jan; Fik, Zdenek] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Prague, Czech Republic; [Kovarova, Hana; Motlik, Jan; Jarkovska, Karla] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Libechov, Czech Republic","Smetana, K (reprint author), Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic.","karel.smetana@lf1.cuni.cz","Strnad, Hynek/B-7361-2008; Kolar, Michal/A-3307-2012","Strnad, Hynek/0000-0002-0141-8340; Kolar, Michal/0000-0002-4593-1525","Charles University in Prague under a Specific University Research Project [264510]; project UNCE [204013]; PRVOUK [27-1]; Ministry of Health of the Czech Republic [NT13488]; Academy of Sciences of the Czech Republic [AV0Z50520514]","This study was supported by Charles University in Prague under a Specific University Research Project (264510), project UNCE (204013) and PRVOUK (27-1); by the Ministry of Health of the Czech Republic (NT13488) and by the Academy of Sciences of the Czech Republic (AV0Z50520514).",null,58,3,3,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0248-4900",null,null,"BIOL CELL","Biol. Cell","DEC",2012,104,12,null,null,null,null,738,751,null,"10.1111/boc.201200018",null,14,"Cell Biology","Cell Biology","048KQ","WOS:000311910700006"]
[null,null,null,null,"J","Popelka, S; Hromadka, R; Bartak, V; Sosna, A",null,null,null,"Popelka, S.; Hromadka, R.; Bartak, V.; Sosna, A.",null,null,"Bilateral Arthrodesis of the Medial Foot Joints in a Patient with Rheumatoid Arthritis","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"rheumatoid arthritis; arthrodesis of medial foot joints; pes planovalgus; tibialis posterior muscle","TIBIALIS POSTERIOR TENDON; ISOLATED TALONAVICULAR ARTHRODESIS; LAPIDUS PROCEDURE; DEFORMITY; HINDFOOT; DYSFUNCTION; MANAGEMENT; OSTEOTOMY; CADAVERS; RUPTURE","Patients with rheumatoid arthritis (RA) often have foot problems. The subtalar and particularly talonavicular joints are affected most frequently. The posterior tibial tendon has an important role in mid-foot stability. In RA patients, chronic inflammation of this tendon or talonavicular joint arthritis can results in posterior tibial tendon rupture. This leads to a collapsed talonavicular joint and forefoot instability, first with talonavicular and later Chopart's joint involvement. This shows as a planovalgus foot, with the forefoot in pronation and the heel in valgus deviation. In a 61-year-old RA patient, ruptures of the posterior tibial tendon due to rheumatoid inflammation occurred bilaterally, with subsequent deviation and instability of the forefoot. Arthrodesis with a medial column screw-Midfoot Fusion Bolt was carried out on the left foot and 4 months later on the right foot. At 7 months after the left and 4 months after the right foot surgery, the patient was free from pain, both feet were stable under loading and the forefoot was firm. The planovalgus deformity was corrected, as well as a valgus deviation of the great toe. Radiography showed a good position of the screws and complete healing of the medial foot joints.","[Popelka, S.] FN Motol, LF UK 1, Ortopedicka Klin 1, Prague 15000 6, Czech Republic; [Hromadka, R.] Anatomicky Ustav 1 LF UK Praha, Prague, Czech Republic; [Popelka, S.; Hromadka, R.; Bartak, V.; Sosna, A.] 1 Ortopedicka Klin 1 LF UK Praha FN Motol, Prague, Czech Republic","Popelka, S (reprint author), FN Motol, LF UK 1, Ortopedicka Klin 1, Uvalu 84, Prague 15000 6, Czech Republic.","mudr.popelka@volny.cz",null,null,null,null,null,22,1,3,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2012,79,1,null,null,null,null,74,79,null,null,null,6,"Orthopedics","Orthopedics","907BI","WOS:000301392400012"]
[null,null,null,null,"J","Zabrodsky, M; Boucek, J; Kastner, J; Kuchar, M; Chovanec, M; Betka, J",null,null,null,"Zabrodsky, M.; Boucek, J.; Kastner, J.; Kuchar, M.; Chovanec, M.; Betka, J.",null,null,"Immediate revision in patients with bilateral recurrent laryngeal nerve palsy after thyroid and parathyroid surgery. How worthy is it?","ACTA OTORHINOLARYNGOLOGICA ITALICA",null,null,"English","Article",null,null,null,null,null,"Bilateral recurrent laryngeal nerve palsy; Immediate revision; Functional recovery; Thyroid surgery","RISK; INJURY","The aim of the present study was to determine whether immediate revision surgery has benefits for patients with iatrogenic bilateral recurrent laryngeal nerve (RLN) palsy. From January 1, 2004 to January 30, 2011, 29 consecutive patients underwent immediate revision after total thyroidectomy. The cohort comprised 29 patients, 2 males and 27 females, aged 23 to 76 years (median 52 years). Identification of the type and extent of injury of each branch was reported in the protocol, and reconstruction was performed whenever possible. A complete transection of the nerve or one of its branches was found in 14 and 5 nerves, respectively. In three patients, the nerve was completely or partially transected on both sides. Seven anatomically intact nerves were injured by loaded ligature, in one case there was a sign of thermal damage and four nerves showed signs of excessive manipulation (thinning of the nerve trunk). Primary end-to-end anastomosis was performed in seven completely transected RLN and four transected anterior branches of RLN. None of the reconstructed nerve trunks or its branches regained function, although good muscle tone was observed. 23 of 38 intact nerves (61%) regained function, and normal vocalcord mobility on both sides was restored in only four patients. In all cases with regained vocal-cord mobility, functional recovery occurred within 3 months after primary surgery. In conclusion, immediate revision after thyroidectomy may help to indicate the type of RLN damage, which is a predictor of functional recovery and one of major factors influencing future therapeutic management.","[Zabrodsky, M.; Boucek, J.; Kastner, J.; Kuchar, M.; Chovanec, M.; Betka, J.] Charles Univ Prague, Fac Med 1, Dept Otolaryngol Head & Neck Surg, Prague 15006, Czech Republic","Zabrodsky, M (reprint author), Charles Univ Prague, Fac Med 1, Dept Otolaryngol Head & Neck Surg, V Uvalu 84,5 Motol, Prague 15006, Czech Republic.","mzabrodsky@tiscali.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NS 9901]","This study was supported by the grant NS 9901 of the Internal Grant Agency of the Ministry of Health of the Czech Republic.",null,18,2,2,"PACINI EDITORE","PISA","VIA DELLA GHERARDESCA-ZONA INDUSTRIALE OSPEDALETTO, 56121 PISA, ITALY","0392-100X",null,null,"ACTA OTORHINOLARYNGO","Acta Otorhinolaryngol. Ital.","AUG",2012,32,4,null,null,null,null,222,228,null,null,null,7,"Otorhinolaryngology","Otorhinolaryngology","080GG","WOS:000314229000002"]
[null,null,null,null,"J","Hromadka, R; Bartak, V; Sosna, A; Popelka, S",null,null,null,"Hromadka, R.; Bartak, V.; Sosna, A.; Popelka, S.",null,null,"Release of the Lateral Structures of the First Metatarsophalangeal Joint during Hallux Valgus Surgery","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"hallux valgus; hallux varus; lateral release; first metatarsophalangeal joint; conjoined tendon; transverse metatarsal ligament","VARUS; PREVENTION; OPERATION; OSTEOTOMY","PURPOSE OF THE STUDY Operations of hallux valgus deformity are very well known in orthopaedic surgery. The important part of these procedures is the release of soft tissue on the lateral side of the first metatarsophalangeal joint. Soft tissue procedures became routinely used in the 1920s and 1930s and several techniques of soft tissue release have been published in the past seventy years. We found several inaccuracies between the anatomy published and the routine clinical performance. The purpose of the study was to describe the anatomy of the first metatarsophalangeal joint's lateral part, especially the adductor hallucis muscle attachment, and to assess to what extent the lateral structures of the first metatarsophalangeal joint should be released to correct hallux valgus deformity. MATERIAL We described and compared the anatomy of the lateral part of the first metatarsophalangeal joint on 30 dissected specimens obtained from cadavers that met the criteria of hallux valgus deformity. METHODS The standard preparation method was used for anatomical dissection; whole leg specimens including the pelvic girdle were fixed in formaldehyde, acetone, ethyl-alcohol and glycerol. The detailed course and shape of the adductor muscle attachment was described as well as its relation to the lateral sesamoid bone, lateral portion of the flexor hallucis brevis and the transverse metatarsal ligament. Dissection of the joint's lateral capsule was used to show the course of the lateral collateral ligament, sesamoid ligament and conjoined tendon of the adductor hallucis and flexor hallucis brevis muscles. Subsequently, we released the lateral sesamoid ligament with a standard longitudinal cut and then released the conjoined tendon and lateral collateral ligament at the level of the joint gap in the frontal plane. We evaluated the proposed technique in terms of the extent of soft tissue release and the size of tenotomy necessary to correct the deformity. RESULTS The mean valgus deformity was 32 degrees (range, 18 degrees to 50 degrees). We were not able to define space between the medial border of the adductor hallucis and the flexor hallucis brevis in 23 cases (77%). The mean size of release was 6.4 mm (range, 5 to 15 mm) and the width of a conjoined tendon at the level of release was 11.2 mm (range, 8 to 15 mm). We did not achieve satisfactory release with our technique in two cases (7%, deviation 45 degrees and 50 degrees). DISCUSSION We compared our results with those of similar anatomical studies. We found several inaccuracies in anatomical descriptions of the adductor hallucis attachment. We confirmed the difficulty in separation of the adductor hallucis from the lateral head of the flexor hallucis brevis in total tenotomy of the adductor. Our technique was successful in releasing the first metatarsophalangeal joint's lateral structures. CONCLUSIONS Our study showed than even partial tenotomy of the conjoined tendon of the adductor hallucis and flexor hallucis brevis muscles is successful in correcting hallux valgus deformity. The release has to be combined with release of the lateral sesamoid ligament.","[Hromadka, R.; Bartak, V.; Sosna, A.; Popelka, S.] Ortoped Klin 1 LF UK Praha, Prague 15006 5, Czech Republic; [Hromadka, R.; Bartak, V.; Sosna, A.; Popelka, S.] FN Motol, Prague 15006 5, Czech Republic; [Hromadka, R.] Anat Ustav 1 LF UK Praha, Prague, Czech Republic","Hromadka, R (reprint author), Ortoped Klin 1 LF UK Praha, V Uvalu 84, Prague 15006 5, Czech Republic.","rastislav.hromadka@lf1.cuni.cz",null,null,null,null,null,29,2,2,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","JUN",2012,79,3,null,null,null,null,222,227,null,null,null,6,"Orthopedics","Orthopedics","972TP","WOS:000306303700004"]
[null,null,null,null,"J","Krysl, D; Deykun, K; Lambert, L; Pokorny, J; Mares, J",null,null,null,"Krysl, D.; Deykun, K.; Lambert, L.; Pokorny, J.; Mares, J.",null,null,"PERIFOCAL AND REMOTE BLOOD-BRAIN BARRIER DISRUPTION IN CORTICAL PHOTOTHROMBOTIC ISCHEMIC LESION AND ITS MODULATION BY THE CHOICE OF ANESTHESIA","JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,"anesthesia; blood-brain barrier; cerebral ischemia; ketamine; pentobarbital; photothrombosis; stroke","FOCAL CEREBRAL-ISCHEMIA; METHYL-D-ASPARTATE; ARTERY OCCLUSION; PROTEIN EXTRAVASATION; DNA FRAGMENTATION; VASOGENIC EDEMA; PLASMA-PROTEINS; NEURONAL UPTAKE; NMDA RECEPTORS; RATS","We assessed blood-brain barrier (BBB) disruption in early stage of photothrombotic focal cerebral ischemia in the rat. We specifically looked for contralateral changes in BBB permeability and tested the influence of two anesthetics on the results. Adult Wistar rats were randomly anesthetized with pentobarbital (PB) or ketamine-xylazine (KX). Rats received intravenously (i.v.) Rose Bengal followed by Evans Blue (EB). Stereotactically defined spots on denuded skull were irradiated by laser (532 nm) for 18 min. Twenty four hours later, rats were killed, brains perfused, fixated, sectioned and slices analyzed by fluorescence microscopy. Volume of necrosis and volume of EB-albumin extravasation were calculated. Evidence of BBB breakdown in remote brain areas was sought and compared to sham handled controls. BBB disruption was consistently present, frequently with EB-albumin accumulating cells. Total lesion volume did not significantly differ among groups (TLVPB=9.4 +/- 1.3 mm(3) vs. TLVKX=8.3 +/- 2.1 mm(3)); same was true for the volume of necrosis (NVPB=5.1 +/- 0.7 mm(3) vs. NVKX=6.3 +/- 1.9 mm(3)). However, volume of EB-albumin extravasation area was significantly smaller in K X group (EBEVPB=4.3 +/- 0.8 mm(3) vs. EBEVKX=2.0 +/- 0.5 mm(3); p=0.0293). Median background EB-fluorescence signal density was higher in PB group (p<0.0001). Furthermore, regional increase in EB-fluorescence was found in two animals in PB group. Our study shows that anesthesia with NMDA-antagonist ketamine and alpha 2-adrenergic agonist xylazine may reduce BBB breakdown in photothrombosis. Pentobarbital anesthesia lead to increased BBB permeability in the contralateral hemisphere.","[Krysl, D.; Deykun, K.; Lambert, L.; Mares, J.] Charles Univ Prague, Dept Normal Pathol & Clin Physiol, Fac Med 3, Prague 12000 2, Czech Republic; [Krysl, D.] Charles Univ Prague, Dept Neurol, Fac Med 2, Motol Hosp, Prague 12000 2, Czech Republic; [Pokorny, J.] Charles Univ Prague, Dept Physiol, Fac Med 1, Prague 12000 2, Czech Republic","Krysl, D (reprint author), Charles Univ Prague, Dept Normal Pathol & Clin Physiol, Fac Med 3, 4 Ke Karlovu St, Prague 12000 2, Czech Republic.","dkrysl@gmail.com",null,null,"Charles Univesity Pregue [UNCE204010, 264706/SVV/2012]; Ministry of Education, Youth and Sports [CMS 110/2012]","The work was supported by following grants: Charles Univesity Pregue, research project UNCE204010; Charles Univesity Pregue, 264706/SVV/2012; Ministry of Education, Youth and Sports CMS 110/2012.",null,41,2,2,"POLISH PHYSIOLOGICAL SOC","GRZEGORZECKA","JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16 GRZEGORZECKA, POLAND","0867-5910",null,null,"J PHYSIOL PHARMACOL","J. Physiol. Pharmacol.","APR",2012,63,2,null,null,null,null,127,132,null,null,null,6,"Physiology","Physiology","964BZ","WOS:000305670000003"]
[null,null,null,null,"J","Trkova, M; Becvarova, V; Hynek, M; Hnykova, L; Hlavova, E; Kreckova, G; Kulovany, E; Cutka, D; Zatloukalova, J; Markova, K; Sukova, M; Horacek, J; Stejskal, D",null,null,null,"Trkova, Marie; Becvarova, Vera; Hynek, Martin; Hnykova, Lenka; Hlavova, Eva; Kreckova, Gabriela; Kulovany, Eduard; Cutka, David; Zatloukalova, Jitka; Markova, Kristyna; Sukova, Martina; Horacek, Jiri; Stejskal, David",null,null,"SNP Array and Phenotype Correlation Shows That FLI1 Deletion Per se is Not Responsible for Thrombocytopenia Development in Jacobsen Syndrome","AMERICAN JOURNAL OF MEDICAL GENETICS PART A",null,null,"English","Article",null,null,null,null,null,"Jacobsen syndrome; 11q terminal deletion; thrombocytopenia; FLI1 gene","PARTIAL MONOSOMY 11Q; PRENATAL-DIAGNOSIS; TERMINAL DELETION; DISTAL 11Q; MOLECULAR CHARACTERIZATION; FETAL BOWEL; EXPRESSION; MARKER; CHILD","Jacobsen syndrome (JBS) is a rare chromosomal disorder caused by terminal deletion of the long arm of chromosome 11. We report on four prenatally diagnosed patients with JBS with variable prenatal and postnatal phenotypes and 11q deletions of varying sizes. Precise characterization of the deleted region in three patients was performed by SNP arrays. The severity of both the prenatal and postnatal phenotypes did not correlate with the size of the haploinsufficient region. Despite the large difference in the deletion size (nearly 6 Mb), both of the live-born patients had similar phenotypes corresponding to JBS. However, one of the most prominent features of JBS, thrombocytopenia, was only present in the live-born boy. The girl, who had a significantly longer deletion spanning all four genes suspected of being causative of JBS-related thrombocytopenia (FLI1, ETS1, NFRKB, and JAM3), did not manifest a platelet phenotype. Therefore, our findings do not support the traditional view of deletion size correlation in JBS or the causative role of FLI1, ETS1, NFRKB, and JAM3 deletion per se for the development of disease-related thrombocytopenia. (C) 2012 Wiley Periodicals, Inc.","[Trkova, Marie; Becvarova, Vera; Hynek, Martin; Hnykova, Lenka; Hlavova, Eva; Kulovany, Eduard; Markova, Kristyna; Horacek, Jiri; Stejskal, David] Gennet, Ctr Fetal Med, Prague 17000 7, Czech Republic; [Kreckova, Gabriela; Zatloukalova, Jitka] Gennet, Ctr Fetal Med, Liberec, Czech Republic; [Cutka, David] Ctr Med Genet, Ceske Budejovice, Czech Republic; [Sukova, Martina] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic","Trkova, M (reprint author), Gennet, Ctr Fetal Med, Kostelni 9, Prague 17000 7, Czech Republic.","marie.trkova@gennet.cz",null,null,null,null,null,27,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1552-4825",null,null,"AM J MED GENET A","Am. J. Med. Genet. A","OCT",2012,"158A",10,null,null,null,null,2545,2550,null,"10.1002/ajmg.a.35537",null,6,"Genetics & Heredity","Genetics & Heredity","023XK","WOS:000310070700027"]
[null,null,null,null,"J","Hromadka, R; Bartak, V; Sosna, A; Popelka, S",null,null,null,"Hromadka, R.; Bartak, V.; Sosna, A.; Popelka, S.",null,null,"MEDIN Implant of the First Metatarsophalangeal Joint","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"hallux rigidus; hallux limitus; total joint replacement; hemiarthroplasty; metatarsophalangeal joint","HALLUX-RIGIDUS; ARTHROPLASTY; REPLACEMENT; PLUS; WEAR","PURPOSE OF THE STUDY Hemiarthoplasty or total replacement of the first metatarsophalangeal (MTP) joint has been used in orthopaedic surgery for the last 60 year, but good post-operative outcomes have been achieved only in the last ten years. Joint replacement is mainly used in stage 3 and stage 4 hallux rigidus conditions for which arthrodesis is not indicated. The operation on the first MTP joint has its place in the present-day orthopaedics. This study describes anatomical measurements and the development of the first Czech implant (MEDIN Orthopaedics) to replace this joint. MATERIAL AND METHODS Thirty cadaver specimens were used to develop basic shapes of phalangeal and metatarsal components. A standard technique was used for anatomical dissection of the first MTP joint. Fifteen specimens were cut in the sagittal plane and fifteen in the transverse plane in order to open the intramedullary cavity of the proximal phalanx of the great toe and the first metatarsal bone. The basic shapes of phalangeal and metatarseal components were designed based on the shape of cortical bone of their inner surfaces. Data for the shape, size and scale of articular components were obtained by measurement on 58 dry bone specimens of the first metatarsus and on 30 calibrated X-ray images. In order to adjust the scale and size of components, the final shape and the range of implant size were tested on 50 specimens of dissected lower extremities fixed in formaldehyde, acetone, ethyl-alcohol and glycerol. RESULTS The new type of a first MTP implant designed by us was based on cone-shaped anchor components coated with hydroxyapatite. The implants can be used in hemiarthroplasty or total joint replacement. The metatarsal insert was designed with a declination angle of 20 degrees to facilitate good dorsiflexion and with a flattening to ensure good function of the sesamoid bones, The phalangeal articular insert was made of either CoCr alloy or low-weight polyethylene for use in hemiarthroplasty and total joint replacement, respectively. DISCUSSION The new implants are designed for treatment of stage 3 or stage 4 hallux rigidus. We recommend to use hemiarthroplasty or total joint replacement only in the case of first metatarsal head destruction or severe joint destruction due to rheumatoid arthritis. CONSLUSIONS Our anatomical study of the first MTP joint, proximal phalanx of the great toe and first metatarsal bone was used to design the first Czech implant of this joint.","[Hromadka, R.; Bartak, V.; Sosna, A.; Popelka, S.] Ortoped Klin 1 LF UK Praha, Prague 15006 6, Czech Republic; [Hromadka, R.; Bartak, V.; Sosna, A.; Popelka, S.] FN Motol, Prague 15006 6, Czech Republic; [Hromadka, R.] Anat Ustav 1 LF UK Praha, Prague, Czech Republic","Hromadka, R (reprint author), Ortoped Klin 1 LF UK Praha, V Uvalu 84, Prague 15006 6, Czech Republic.","rastislav.hromadka@lf1.cuni.cz",null,null,null,null,null,34,1,1,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2012,79,2,null,null,null,null,124,130,null,null,null,7,"Orthopedics","Orthopedics","932KB","WOS:000303288900005"]
[null,null,null,null,"J","Skoloudik, L; Vokurka, J; Simakova, E",null,null,null,"Skoloudik, Lukas; Vokurka, Jan; Simakova, Eva",null,null,"Mechanical treatment and autoclaving of middle ear ossicles from cholesteatomatous ears","CENTRAL EUROPEAN JOURNAL OF MEDICINE",null,null,"English","Article",null,null,null,null,null,"Cholesteatoma; Autoclaving; Autograft ossiculoplasty","AUTOGRAFT OSSICULOPLASTY; CORTICAL BONE; RECONSTRUCTION; HISTOPATHOLOGY; IMPLANTS; DISEASE; INCUS","Aim of the study: The authors present a prospective histomorphological study of middle ear ossicles, harvested from cholesteatomous ears, to evaluate for presence of residual cholesteatoma after mechanical treatment and short-time autoclaving. Sixty ossicles were used as specimens in this study. The ossicles were grouped as follows: Group A - ossicles stripped and burred using a fine diamond burr under microscopic control. Group B - ossicles autoclaved for 4 min at 134A degrees C after mechanical burring under microscopic control. In group A, 30 ossicles were histologicaly examined after mechanical treatment. The residual disease was found in one badly eroded ossicle. In group B, 30 ossicles were histologicaly examined after mechanical treatment and autoclaving. That treatment eliminated cholesteatoma in all cases. The difference of results in these two treatment methods was not statistically significant. Authors recommend using mechanical cleaning in cases of mildly eroded ossicles. In cases of badly eroded ossicles authors recommend to either apply a combination of mechanical and autoclaving treatment. The study proved that 4 minutes of autoclaving at 134A degrees C after mechanical cleaning provides safe bone autografts.","[Skoloudik, Lukas] Charles Univ Prague, Fac Med, Dept Otorhinolaryngol, Hradec Kralove 50038 1, Czech Republic; [Skoloudik, Lukas; Simakova, Eva] Univ Hosp, Hradec Kralove 50038 1, Czech Republic; [Vokurka, Jan] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Prague 12108 2, Czech Republic; [Vokurka, Jan] Univ Hosp Motol, Prague 12108 2, Czech Republic; [Simakova, Eva] Charles Univ Prague, Fac Med, Fingerlands Dept Pathol, Hradec Kralove 50038 1, Czech Republic","Skoloudik, L (reprint author), Charles Univ Prague, Fac Med, Dept Otorhinolaryngol, Hradec Kralove 50038 1, Czech Republic.","lukas.skoloudik@seznam.cz",null,null,null,null,null,21,1,1,"VERSITA","WARSAW","SOLIPSKA 14A-1, 02-482 WARSAW, POLAND","1895-1058",null,null,"CENT EUR J MED","Cent. Eur. J. Med.","APR",2012,7,2,null,null,null,null,194,197,null,"10.2478/s11536-011-0140-z",null,4,"Medicine, General & Internal","General & Internal Medicine","889EB","WOS:000300055200010"]
[null,null,null,null,"J","Machovcova, A",null,null,null,"Machovcova, Alena",null,null,"The Frequency of Contact Allergy in Children and Adolescents in the Czech Republic","ACTA DERMATOVENEROLOGICA CROATICA",null,null,"English","Article",null,null,null,null,null,"allergic contact sensitivity; asymptomatic children population; epicutaneous tests; most common allergens","PATCH TESTS; ATOPIC-DERMATITIS; COMMON ALLERGENS; SENSITIZATION; SCHOOLCHILDREN; PREVALENCE; DECREASE; DISEASES; INFANTS; ADULTS","The objective of our study was to determine the prevalence of contact hypersensitivity in asymptomatic Czech school-children. We recruited 236 Prague asymptomatic schoolchildren for epicutaneous tests. The children were tested with European baseline series (25 allergens). A total of 218 children (114 boys and 104 girls) completed the study. Of these, 67 (30.7%) children had one or more positive reactions to tested allergens. Nickel, neomycin and potassium dichromate were the most prevalent allergens detected in our study. Our findings may support the notion that allergic contact sensitization in children is not so rare and children, especially those with chronic dermatitis, should be patch tested regularly.","Fac Hosp Motol, Dept Dermatol, Prague 15006 5, Czech Republic","Machovcova, A (reprint author), Fac Hosp Motol, Dept Dermatol, Prague 15006 5, Czech Republic.","alena.machovcova@fnmotol.cz",null,null,null,null,null,39,1,1,"CROATION DERMATOVENEROLOGICAL SOC","ZAGREB","ZAGREB UNIV HOSPITAL CTR, UNIV DEPT DERMATOLOGY & VENEROLOGY, SALATA 4, ZAGREB, 10000, CROATIA","1330-027X",null,null,"ACTA DERMATOVENER CR","Acta Dermatovenerol. Croat.",null,2012,20,2,null,null,null,null,75,79,null,null,null,5,"Dermatology","Dermatology","986CH","WOS:000307317800001"]
[null,null,null,null,"J","Fencl, P; Belohlavek, O; Harustiak, T; Zemanova, M",null,null,null,"Fencl, Pavel; Belohlavek, Otakar; Harustiak, Tomas; Zemanova, Milada",null,null,"The analysis of factors affecting the threshold on repeated F-18-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma","NUCLEAR MEDICINE COMMUNICATIONS",null,null,"English","Article",null,null,null,null,null,"esophageal carcinoma; 2-deoxy-2-[F-18]fluoro-D-glucose; neoadjuvant chemotherapy; positron emission tomography Response Criteria in Solid Tumors; positron emission tomography/computed tomography; reproducibility; threshold","POSITRON-EMISSION-TOMOGRAPHY; WHOLE-BODY PET; ESOPHAGOGASTRIC JUNCTION; NEOADJUVANT THERAPY; MALIGNANT-TUMORS; UPTAKE VALUES; CANCER; REPRODUCIBILITY; CHEMOTHERAPY; TRIALS","Background When applying the PET Response Criteria in Solid Tumors protocol, a threshold value based on standardized uptake value corrected to lean body mass (SUL) in liver parenchyma, or in the blood pool, is used: to metabolically specify a measurable lesion; to calculate metabolic tumor volume (mTV) and its product total lesion glycolysis (TLG); and as a limit for response measurement. The problem with using changes in glucose metabolism as a marker for response to therapy is its reproducibility on test-retest examinations. Therefore, before the evaluation of tumor treatment response, we verified our diagnostic protocol for homogeneity using the PET Response Criteria in Solid Tumors quality parameters. In addition, we analyzed the effect of the time span between examinations on the average value of SUL (SULMEAN) in liver parenchyma at three different points: first at baseline (BL), after the first course of chemotherapy (ChT1), and finally after finishing therapy (ChT3). We also analyzed the influence of SULMEAN variation on mTV and TLG. Methods Eighty-four patients with esophageal cancer were prospectively examined at BL using 2-deoxy-2-[F-18]fluoro-D-glucose (F-18-FDG)-PET/CT; 53 of 84 patients were examined after ChT1, 47 of 84 after ChT3, and 41 of 84 underwent all three examinations. Coefficient of variance (CV) and relative differences (RDw) were assessed for test-retest liver SUL values. The influence of liver SULMEAN to mTV and TLG was modeled on BL examinations by artificial changes in liver SULMEAN by +/- 20%. Results No significant differences were found in test-retest liver SULMEAN values. Comparing BL with ChT1, BL with ChT3, and ChT1 with ChT3, the CV of the liver SULMEAN was 10.4, 10.7, and 10.3%; nevertheless, in 34.0, 38.3, and 36.6% of these examinations, respectively, the liver average SULMEAN values exceeded the limit for inclusion in the study; that is, the difference was less than +/- 0.3 U and +/- 20%. The corresponding CV of blood background was 14.9, 16.5, and 17.2%. The artificial decrease of -20% in the liver SULMEAN resulted in an increase of +43.6% in mTV and of +20.4% in TLG, whereas an increase of +20% in the liver SULMEAN resulted in a decrease of -20.6% in mTV and -11.9% in TLG. Conclusion SULMEAN values in reference tissues (liver parenchyma or descending aorta) measured before chemotherapy did not differ significantly from those measured during chemotherapy. The CV of liver SULMEAN was comparable to that seen in published data, but some patients had to be excluded from the study because of the individual variability of their mean liver SULMEAN, which consequently hinders the clinical usage of mTV and TLG. Even in the standardized protocol, all potential sources of variability should be minimized. Nucl Med Commun 33:1188-1194 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Fencl, Pavel; Belohlavek, Otakar] Charles Univ Prague, Hosp Homolce, PET Ctr, Prague 15030 5, Czech Republic; [Harustiak, Tomas] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Clin Surg 3, Prague 15030 5, Czech Republic; [Zemanova, Milada] Charles Univ Prague, Gen Teaching Hosp, Fac Med 1, Clin Oncol, Prague 15030 5, Czech Republic","Fencl, P (reprint author), Charles Univ Prague, Hosp Homolce, PET Ctr, Roentgenova 2, Prague 15030 5, Czech Republic.","pavel.fencl@homolka.cz",null,null,"Ministry of Health of the Czech Republic [NT12331-5/2011]","The study was supported by the grant of Ministry of Health of the Czech Republic NT12331-5/2011.",null,29,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0143-3636",null,null,"NUCL MED COMMUN","Nucl. Med. Commun.","NOV",2012,33,11,null,null,null,null,1188,1194,null,"10.1097/MNM.0b013e3283573d0d",null,7,"Radiology, Nuclear Medicine & Medical Imaging","Radiology, Nuclear Medicine & Medical Imaging","020HS","WOS:000309800200011"]
[null,null,null,null,"J","Skovrankova, J; Petras, M",null,null,null,"Skovrankova, Jitka; Petras, Marek",null,null,"Persistence of humoral immunity to tetanus and diphtheria in hematopoietic stem cell transplant recipients after post-transplant immunization","PEDIATRIC BLOOD & CANCER",null,null,"English","Article",null,null,null,null,null,"diphtheria antibodies; HSCT recipient; persistence of humoral immunity; post-transplant vaccination; tetanus antibodies","BONE-MARROW-TRANSPLANTATION; ANTIBODY-RESPONSE; VACCINATION; POLIOVIRUS; VACCINES","Background Persistence of humoral immunity was evaluated in 82 hematopoietic stem cell transplant recipients up to 12.5 years after post-transplant immunization against tetanus and diphtheria. Procedure New immunization, initiated at least 12 months after transplantation, consisted of an average three-dose schedule of vaccine administration on day 1, month 3, and month 12. Serological data were collected at pre-transplant, post-transplant, vaccination, and post-vaccination time points. Results The first vaccination dose elicited a seroprotective response in most recipients, but the complete vaccine series (usually three-dose schedule) reinforced the specific immunity in most vaccinated cases, that is, 100% and 95.8% seroprotection against tetanus and diphtheria, respectively. Geometric mean concentration post-vaccination tetanus and diphtheria antibody levels persisted at 1.9?IU (95% CI: 1.232.94?IU/ml) and 0.20?IU (95% CI: 0.110.38?IU/ml) for 7 years, respectively. However, diphtheria antibodies were lost not significantly but much faster and more often than tetanus antibodies, though the seroprotection rates against tetanus and diphtheria remained favorable, that is, 100% (95% CI: 85.2100%) and 87% (95% CI: 59.598.3%), respectively. Conclusions Full post-transplant revaccination resulted in long-term persistence of humoral immunity against tetanus and diphtheria in SCT recipients, for an average of 8.6 and 9.0 years, respectively. Pediatr Blood Cancer 2012; 59: 908913. (C) 2012 Wiley Periodicals, Inc.","[Petras, Marek] Interimun Spol Sro, Immunol Lab, Pardubice 53009, Czech Republic; [Skovrankova, Jitka] Univ Hosp Motol, Childrens Vaccinat Ctr, Prague, Czech Republic","Petras, M (reprint author), Interimun Spol Sro, Immunol Lab, Karla Sipka 282, Pardubice 53009, Czech Republic.","petras@vakciny.net",null,null,null,null,null,10,0,0,"WILEY PERIODICALS, INC","SAN FRANCISCO","ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA","1545-5009",null,null,"PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","NOV",2012,59,5,null,null,null,null,908,913,null,"10.1002/pbc.24186",null,6,"Oncology; Hematology; Pediatrics","Oncology; Hematology; Pediatrics","004BW","WOS:000308656100025"]
[null,null,null,null,"J","Le Brun, P; Klovrzova, S",null,null,null,"Le Brun, Paul; Klovrzova, Sylva",null,null,"Safe aseptic preparation in the pharmacy and on the ward","EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE",null,null,"English","Article",null,null,null,null,null,null,"INTRAVENOUS DRUG ERRORS; SEVERITY","Injectable medicines are prepared prior to use on the wards and in the pharmacy. In this article, we describe how to organise this process. A risk based approach is suggested to direct the aseptic preparation policy in a hospital. Examples from the Czech Republic and The Netherlands are used.","[Le Brun, Paul] Cent Hosp Pharm, NL-2504 AC The Hague, Netherlands; [Klovrzova, Sylva] Univ Hosp Motol, Dept Hosp Pharm, Prague, Czech Republic","Le Brun, P (reprint author), Cent Hosp Pharm, POB 43100, NL-2504 AC The Hague, Netherlands.","p.lebrun@ahz.nl",null,null,null,null,null,10,0,0,"BMJ PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","2047-9956",null,null,"EUR J HOSP PHARM-S P","Eur. J. Hosp. Pharm.-Sci. Pract.","OCT",2012,19,5,null,null,null,null,474,476,null,"10.1136/ejhpharm-2012-000193",null,3,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","042PD","WOS:000311482300023"]
[null,null,null,null,"J","Popelka, S; Hromadka, R; Vavrik, P; Bartak, V; Popelka, S; Sosna, A",null,null,null,"Popelka, Stanislav; Hromadka, Rastislav; Vavrik, Pavel; Bartak, Vladislav; Popelka, Stanislav, Jr.; Sosna, Antonin",null,null,"Hypermobility of the first metatarsal bone in patients with Rheumatoid arthritis treated by lapidus procedure","BMC MUSCULOSKELETAL DISORDERS",null,null,"English","Article",null,null,null,null,null,"Lapidus procedure; Instability of the cuneometatarsal joint; Hypermobility of the first metatarsal bone; Rheumatoid arthritis; Hallux valgus","HALLUX-VALGUS DEFORMITY; 1ST-RAY MOBILITY; RAY MOBILITY; OSTEOTOMY; DEVICE; FOOT","Background: Foot deformities and related problems of the forefoot are very common in patients with rheumatoid arthritis. The laxity of the medial cuneometatarsal joint and its synovitis are important factors in the development of forefoot deformity. The impaired joint causes the first metatarsal bone to become unstable in the frontal and sagittal planes. In this retrospective study we evaluated data of patients with rheumatoid arthritis who underwent Lapidus procedure. We evaluated the role of the instability in a group of patients, focusing mainly on the clinical symptoms and X-ray signs of the instability. Methods: The study group included 125 patients with rheumatoid arthritis. The indications of the Lapidus procedure were a hallux valgus deformity greater than 15 degrees and varus deformity of the first metatarsal bone with the intermetatarsal angle greater than 15 degrees on anterio-posterior weight-bearing X-ray. Results: Data of 143 Lapidus procedures of 125 patients with rheumatoid arthritis, who underwent surgery between 2004 and 2010 was evaluated. Signs and symptoms of the first metatarsal bone instability was found in 92 feet (64.3%) in our group. The AOFAS score was 48.6 before and 87.6 six months after the foot reconstruction. Nonunion of the medial cuneometatarsal joint arthrodesis on X-rays occurred in seven feet (4.9%). Conclusion: The Lapidus procedure provides the possibility to correct the first metatarsal bone varus position and its instability, as well as providing the possibility to achieve a painless foot for walking. We recommend using the procedure as a preventive surgery in poorly symptomatic patients with rheumatoid arthritis in case of the first metatarsal bone hypermobility.","[Popelka, Stanislav; Hromadka, Rastislav; Vavrik, Pavel; Bartak, Vladislav; Sosna, Antonin] Charles Univ Prague, Orthopaed Clin 1, Fac Med 1, Prague 15006 5, Czech Republic; [Hromadka, Rastislav] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 15006 5, Czech Republic; [Popelka, Stanislav, Jr.] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic","Popelka, S (reprint author), Charles Univ Prague, Orthopaed Clin 1, Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic.","mudr.popelka@volny.cz",null,null,"Ministry of Health, Czech Republic [00064203]","The authors declare that they have no financial and non-financial competing conflict of interest. The study was supported by the project of Ministry of Health, Czech Republic, for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic).",null,37,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-2474",null,null,"BMC MUSCULOSKEL DIS","BMC Musculoskelet. Disord.","AUG 20",2012,13,null,null,null,null,null,null,null,148,"10.1186/1471-2474-13-148",null,7,"Orthopedics; Rheumatology","Orthopedics; Rheumatology","052JO","WOS:000312194100001"]
[null,null,null,null,"J","Andrsova, I; Valaskova, I; Kubus, P; Vit, P; Gaillyova, R; Kadlecova, J; Manouskova, L; Novotny, T",null,null,null,"Andrsova, Irena; Valaskova, Iveta; Kubus, Peter; Vit, Pavel; Gaillyova, Renata; Kadlecova, Jitka; Manouskova, Lenka; Novotny, Tomas",null,null,"Clinical Characteristics and Mutational Analysis of the RyR2 Gene in Seven Czech Families with Catecholaminergic Polymorphic Ventricular Tachycardia","PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"exercise testing; polymorphic ventricular tachycardia; RyR2","SUDDEN CARDIAC DEATH; FOLLOW-UP; ARRHYTHMIAS; FEATURES; DISEASE","Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare hereditary arrhythmia. The onset of clinical symptoms usually occurs during childhood, and is typically related to exercise. The aim of our study was to describe the clinical characteristics of seven Czech families with CPVT and the results of mutational analysis of the RyR2 gene in these families. Methods: The subjects and their relatives were investigated at the participating departments. They underwent basic clinical investigation, and history was focused on possible CPVT symptoms, that is, syncopes during exercise. Bicycle ergometry was performed to obtain electrocardiogram recording during adrenergic stimulation. In all the investigated individuals, blood samples were taken for mutation analysis of the RyR2 gene. Results: To date, seven families have been investigated, comprising 11 adults and 13 children. In seven CPVT patients, the indication for examination was syncope during exercise. Diagnosis was confirmed by bicycle ergometry-induced polymorphic ventricular tachycardia. In one relative, polymorphic ventricular tachycardia was also induced. All eight affected individuals were treated with beta-blockers and in two, a cardioverter-defibrillator was implanted due to recurrent syncopi. Coding variants of the RyR2 gene were found in four probands. Conclusions: This is a systematic description of CPVT families in the Czech Republic. Our data support the importance of exercise testing for the diagnosis of CPVT. In addition, RyR2 gene coding variants were found in 50% of affected individuals. (PACE 2012;15)","[Andrsova, Irena; Manouskova, Lenka; Novotny, Tomas] Univ Hosp Brno, Dept Internal Med & Cardiol, Brno 62500, Czech Republic; [Valaskova, Iveta; Gaillyova, Renata; Kadlecova, Jitka] Univ Hosp Brno, Dept Med Genet, Brno 62500, Czech Republic; Masaryk Univ, Fac Med, Brno, Czech Republic; [Kubus, Peter] Univ Hosp Motol, Childrens Heart Ctr, Prague, Czech Republic; [Vit, Pavel] Univ Hosp Brno, Dept Pediat, Brno 62500, Czech Republic","Novotny, T (reprint author), Univ Hosp Brno, Dept Internal Med & Cardiol, Jihlavska 20, Brno 62500, Czech Republic.","novotny-t@seznam.cz","Valaskova, Iveta/F-5734-2014",null,"Ministry of Education, Youth and Sports of the Czech Republic [2B08061]","The research was supported by grant 2B08061 of the Ministry of Education, Youth and Sports of the Czech Republic.",null,19,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0147-8389",null,null,"PACE","PACE-Pacing Clin. Electrophysiol.","JUL",2012,35,7,null,null,null,null,798,803,null,"10.1111/j.1540-8159.2012.03399.x",null,6,"Cardiac & Cardiovascular Systems; Engineering, Biomedical","Cardiovascular System & Cardiology; Engineering","967HM","WOS:000305897500018"]
[null,null,null,null,"J","Grendel, T; Sokolsky, J; Vascakova, A; Hudak, V; Chovanec, M; Sabol, F; Andre, S; Kaltner, H; Gabius, HJ; Frankovicova, M; Lences, P; Betka, J; Smetana, K; Gal, P",null,null,null,"Grendel, T.; Sokolsky, J.; Vascakova, A.; Hudak, V.; Chovanec, M.; Sabol, F.; Andre, S.; Kaltner, H.; Gabius, H. -J.; Frankovicova, M.; Lences, P.; Betka, J.; Smetana, K., Jr.; Gal, P.",null,null,"Early Stages of Trachea Healing Process: (Immuno/Lectin) Histochemical Monitoring of Selected Markers and Adhesion/Growth-Regulatory Endogenous Lectins","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,"wound healing; tissue repair; regeneration; galectin; glycophenotype; tracheotomy","SUGAR CODE; EPIDERMAL-CELLS; EXPRESSION; SKIN; GALECTIN-1; CARCINOMA; BINDING; RATS; COMPLICATIONS; FUNCTIONALITY","Tracheotomy may be associated with numerous acute and chronic complications including extensive formation of granulation tissue. The emerging functional versatility of the adhesion/growth-regulatory galectins prompted us to perform a histochemical study of wound healing using rat trachea as model. By using non-cross-reactive antibodies and the labelled tissue lectins we addressed the issue of the presence and regulation of galectin reactivity during trachea wound healing. Beside localization of high-molecular-weight keratin, wide-spectrum cytokeratin, keratins 10 and 14, a-smooth muscle actin, vimentin, fibronectin, and Sox-2, galectins -1, -2, and -3 and their reactivity profiles were measured in frozen sections of wounded and control trachea specimens 7, 14, and 28 days after trauma. A clear trend for decreased galectin-1 presence and increased reactivity for galectin-1 was revealed from day 7 to day 28. Sox-2-positive cells were present after seven days and found in the wound bed. Interestingly, several similarities were observed in comparison to skin wound healing including regulation of galectin-1 parameters.","[Gal, P.] E Slovak Inst Cardiovasc Dis, Dept Biomed Res, Kosice 04011, Slovakia; [Sabol, F.] E Slovak Inst Cardiovasc Dis, Clin Heart Surg, Kosice 04011, Slovakia; [Frankovicova, M.] E Slovak Inst Cardiovasc Dis, Clin Vasc Surg, Kosice 04011, Slovakia; [Grendel, T.; Sokolsky, J.; Vascakova, A.; Hudak, V.; Lences, P.] Pavol Jozef Safarik Univ, Dept Anesthesiol & Intens Med 1, Kosice, Slovakia; [Grendel, T.; Sokolsky, J.; Vascakova, A.; Hudak, V.; Lences, P.] Louis Pasteur Univ Hosp, Kosice, Slovakia; [Chovanec, M.; Smetana, K., Jr.] Charles Univ Prague, Inst Anat, Prague, Czech Republic; [Gal, P.] Charles Univ Prague, Inst Histol & Embryol, Fac Med 1, Prague, Czech Republic; [Chovanec, M.; Betka, J.] Charles Univ Prague, Clin Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Prague, Czech Republic; [Chovanec, M.; Betka, J.] Univ Hosp Motol, Prague, Czech Republic; [Andre, S.; Kaltner, H.; Gabius, H. -J.] Univ Munich, Inst Physiol Chem, Fac Vet Med, D-8000 Munich, Germany; [Gal, P.] Univ Vet Med & Pharm, Dept Pathol Anat, Kosice, Slovakia","Gal, P (reprint author), E Slovak Inst Cardiovasc Dis, Dept Biomed Res, Ondavska 8, Kosice 04011, Slovakia.","ga-lovci@yahoo.com",null,null,"EC [260600]; Slovak Grant Agency of Ministry of Education (VEGA) [1/1095/11]; Charles University in Prague","This study was supported by the EC research program GlycoHIT (contract ID 260600), Slovak Grant Agency of Ministry of Education (VEGA No. 1/1095/11), and Charles University in Prague (project for support of specific university student research).",null,35,0,0,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2012,58,4,null,null,null,null,135,143,null,null,null,9,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","998WZ","WOS:000308272400001"]
[null,null,null,null,"J","Pala, M; Odrazka, K; Holeckova, P; Vitek, P; Kubes, J; Podlesak, T; Klozar, J; Petruzelka, L",null,null,null,"Pala, M.; Odrazka, K.; Holeckova, P.; Vitek, P.; Kubes, J.; Podlesak, T.; Klozar, J.; Petruzelka, L.",null,null,"Postoperative radiochemotherapy with weekly cisplatin in patients with head and neck cancer Single-institution outcome analysis","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"head and neck cancer; postoperative radiochemotherapy; concomitant chemotherapy; cisplatin","SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; PHASE-III TRIAL; RADIATION-THERAPY; RANDOMIZED-TRIAL; CONCOMITANT CHEMOTHERAPY; PUBLISHED LITERATURE; RADIOTHERAPY; METAANALYSIS; IRRADIATION","The objective of this study was to evaluate the feasibility, toxicity and efficacy of postoperative radiochemotherapy with weekly cisplatin in locoregionally advanced or high risk head and neck cancer in a single institutional setting. Patients with head and neck cancer of stage III/IV or patients with insufficient margins of resection were included in the study. Radiotherapy consisted of 70 Gy/ 7 weeks/ 35 fraction after R1/2 resection and 60-64 Gy/ 6-6,5 weeks/ 30-32 fraction after R0 resection, respectively. All patients received concurrent cisplatin 40 mg/m(2) weekly. Between 7/2002 and 12/2008, 100 consecutive patients [WHO <= 2, male to female ratio 84/16, median age 54 years] were treated. Tumors of the oropharynx were the most frequent (49%) and stage IV was predominant (86%). 96% patients received the full radiation treatment as planned, median total tumor dose was 66 Gy. Omission of weekly cisplatin had been occurring frequently, the most frequent reason for its early cessation were hematological toxicities (34%). Grade 3/4 mucosal toxicity developed in 32%. No death was observed during the treatment. The late toxicities were acceptable, predominantly subcutaneous fibrosis and xerostomia in most of the cases. We recorded six cases of osteonecrosis. Two and half year overall survival, locoregional control, time to progression and disease free survival were 64%, 88%, 79% and 59%, respectively. Postoperative radiochemotherapy with weekly cisplatin is toxic, but tolerable and highly effective in terms of locoregional control and survival. Multivariete analysis revealed that the only prognostic factor for survival was primary surgery at the University centre.","[Pala, M.; Holeckova, P.; Vitek, P.; Kubes, J.; Petruzelka, L.] Univ Hosp Na Bulovce, Inst Radiat Oncol, Prague, Czech Republic; [Pala, M.; Odrazka, K.; Holeckova, P.; Vitek, P.; Kubes, J.; Klozar, J.; Petruzelka, L.] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Odrazka, K.] Multiscan & Pardubice Reg Hosp, Dept Radiat Oncol, Pardubice, Czech Republic; [Odrazka, K.] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Odrazka, K.] Inst Postgrad Med Educ, Prague, Czech Republic; [Podlesak, T.] Univ Hosp Na Bulovce, Dept Otorhinolaryngol, Prague, Czech Republic; [Klozar, J.] Univ Hosp Motol, Dept Otorhinolaryngol & Head & Neck Surg, Prague, Czech Republic","Pala, M (reprint author), Univ Hosp Na Bulovce, Inst Radiat Oncol, Prague, Czech Republic.","palamila@tiscali.cz",null,null,null,null,null,30,0,0,"VEDA, SLOVAK ACAD SCIENCES","BRASTISLAVA","DUBRAVSKA CESTA 9, 842 34 BRASTISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2012,59,2,null,null,null,null,129,136,null,"10.4149/neo_2012_017",null,8,"Oncology","Oncology","902ZW","WOS:000301083700002"]
[null,null,null,null,"J","Boucek, J; Chovanec, M; Vokral, J; Cerny, L; Kluh, J; Cada, Z; Profant, O; Zabrodsky, M; Kuchar, M; Zverina, E; Betka, J; Fanta, O; Skrivan, J",null,null,null,"Boucek, J.; Chovanec, M.; Vokral, J.; Cerny, L.; Kluh, J.; Cada, Z.; Profant, O.; Zabrodsky, M.; Kuchar, M.; Zverina, E.; Betka, J.; Fanta, O.; Skrivan, J.",null,null,"Baha as a Solution for Single-Sided Deafness after Vestibular Schwannoma Surgery","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"vestibular schwannoma; single-sided deafness; osseointegration; Baha implant","ANCHORED HEARING-AIDS; IMPLANT; BENEFIT; BRAIN","Single-sided deafness (SSD) impairs quality of life in vestibular schwannoma surgery (VS) patients. The SSD patients suffer from multiple audiological difficulties, inability to identify a direction of a sound and to discriminate sounds coming from the affected side, presenting particularly as an impairment of speech recognition in noisy environments, are the most disabling. The Bone-Anchored Hearing Aid (Baha) represents the most effective option for rehabilitation of hearing in SSD patients. This device transforms sound into vibrations that are directly conducted to the cranial bones using a titanium implant. Thanks to a firm anchoring of the implant to the bone by a process of osseointegration, vibration energy is conveyed into the fluid of the inner ear. In SSD patients, the sound is transferred from the impaired side into the functioning contralateral cochlea. Nine SSD patients after VS surgery had been implanted between September 2010 and December 2011. The quality of life in SSD patients was evaluated with a questionnaire. 89% of our patients use Baha every day for 8 to 12 hours. Baha is the only known effective solution for SSD patients.","[Boucek, J.; Chovanec, M.; Kluh, J.; Cada, Z.; Profant, O.; Zabrodsky, M.; Kuchar, M.; Zverina, E.; Betka, J.; Skrivan, J.] 1 LF UK & FN Motole, Klin Otorinolaryngol & Chirurg Hlavy & Krku, Prague 15006 5, Czech Republic; [Vokral, J.; Cerny, L.] 1 LF UK & FN Praze, Foniatricka Klin, Prague, Czech Republic; [Fanta, O.] UK Praze, Fak Telesne Vychovy & Sportu, Katedra Anat Biomech, Prague, Czech Republic; [Profant, O.] Ostav Expt Med AV CR, Oddeleni Neurofyziol Sluchu, Vvi, Prague, Czech Republic","Boucek, J (reprint author), 1 LF UK & FN Motole, Klin Otorinolaryngol & Chirurg Hlavy & Krku, V Uvalu 84, Prague 15006 5, Czech Republic.","Jan.Boucek@fnmotol.cz",null,null,null,null,"Betka J, 1990, Czech Med, V13, P124; BRANEMARK P I, 1969, Scandinavian Journal of Plastic and Reconstructive Surgery, V3, P81; Cakrt O, 2010, EUR ARCH OTO-RHINO-L, V267, P1355, DOI 10.1007/s00405-010-1227-x; Christensen L, 2010, ARCH OTOLARYNGOL, V136, P175, DOI 10.1001/archoto.2009.203; Colletti V, 2005, OTOLARYNG HEAD NECK, V133, P126, DOI 10.1016/j.otohns.2005.03.022; de Wolf MJF, 2010, OTOL NEUROTOL, V31, P766, DOI 10.1097/MAO.0b013e3181e3d740; Gottlow J, 2010, OTOL NEUROTOL, V31, P832, DOI 10.1097/MAO.0b013e3181dfbbab; Jacob R, 2011, HNO, V59, P453, DOI 10.1007/s00106-011-2321-0; King AJ, 2000, P NATL ACAD SCI USA, V97, P11821, DOI 10.1073/pnas.97.22.11821; Kompis M, 2011, ADV OTO-RHINO-LARYNG, V71, P103, DOI 10.1159/000323591; Mazzoni A, 2011, ACTA OTORHINOLARYNGO, V31, P76; Mudry A, 2011, ADV OTO-RHINO-LARYNG, V71, P1, DOI 10.1159/000323569; Noble W, 2004, INT J AUDIOL, V43, P100, DOI 10.1080/14992020400050015; Rabelo de Freitas M, 2011, AUDIOL NEURO-OTOL, V17, P71; Samii M, 1997, NEUROSURGERY, V40, P248, DOI 10.1097/00006123-199702000-00005; Schroder SA, 2010, OTOL NEUROTOL, V31, P404, DOI 10.1097/MAO.0b013e3181d27cc0; Sennerby L, 2010, OTOL NEUROTOL, V31, P840, DOI 10.1097/MAO.0b013e3181de4b79; Skrivan J, 2007, Prague Med Rep, V108, P256; Skrivan J, 2003, Cas Lek Cesk, V142, P29; Skrivan J, 2010, Prague Med Rep, V111, P25; Skrivan J, 2004, Otolaryngol Pol, V58, P69; Stelzig Yvonne, 2011, J Med Case Rep, V5, P343, DOI 10.1186/1752-1947-5-343; Timmer FCA, 2011, LARYNGOSCOPE, V121, P1359, DOI 10.1002/lary.21763; TJELLSTROM A, 1980, ACTA OTO-LARYNGOL, V89, P85, DOI 10.3109/00016488009127113; Vrabec P, 2008, CESK SLOV NEUROL N, V71, P453; Zvĕrina E, 1983, Cesk Neurol Neurochir, V46, P287; Zverina Eduard, 2010, Cas Lek Cesk, V149, P269; Zverina E, 2000, J LARYNGOL OTOL, V114, P54",28,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,5,null,null,null,null,602,605,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","010IJ","WOS:000309087800010"]
[null,null,null,null,"J","Skoumalova, A; Hort, J",null,null,null,"Skoumalova, Alice; Hort, Jakub",null,null,"Blood markers of oxidative stress in Alzheimer's disease","JOURNAL OF CELLULAR AND MOLECULAR MEDICINE",null,null,"English","Review",null,null,null,null,null,"Alzheimer disease; blood markers; oxidative stress; lipid peroxidation","MILD COGNITIVE IMPAIRMENT; ANTIOXIDANT ENZYME-ACTIVITIES; LIPID-PEROXIDATION; CEREBROSPINAL-FLUID; PARKINSONS-DISEASE; VASCULAR DEMENTIA; PROTEIN OXIDATION; DNA-DAMAGE; IN-VIVO; CARBONYL PROTEINS","Alzheimer's disease (AD) represents a highly common form of dementia, but can be diagnosed in the earlier stages before dementia onset. Early diagnosis is crucial for successful therapeutic intervention. The introduction of new diagnostic biomarkers for AD is aimed at detecting underlying brain pathology. These biomarkers reflect structural or biochemical changes related to AD. Examination of cerebrospinal fluid has many drawbacks; therefore, the search for sensitive and specific blood markers is ongoing. Investigation is mainly focused on upstream processes, among which oxidative stress in the brain is of particular interest. Products of oxidative stress may diffuse into the blood and evaluating them can contribute to diagnosis of AD. However, results of blood oxidative stress markers are not consistent among various studies, as documented in this review. To find a specific biochemical marker for AD, we should concentrate on specific metabolic products formed in the brain. Specific fluorescent intermediates of brain lipid peroxidation may represent such candidates as the composition of brain phospholipids is unique. They are small lipophilic molecules and can diffuse into the blood stream, where they can then be detected. We propose that these fluorescent products are potential candidates for blood biomarkers of AD.","[Skoumalova, Alice] Charles Univ Prague, Fac Med 2, Dept Med Chem & Biochem, Prague 15006, Czech Republic; [Hort, Jakub] Charles Univ Prague, Fac Med 2, Dept Neurol, Memory Disorders Clin, Prague 15006, Czech Republic; [Hort, Jakub] Univ Hosp Motol, Prague, Czech Republic; [Hort, Jakub] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic","Skoumalova, A (reprint author), Charles Univ Prague, Fac Med 2, Dept Med Chem & Biochem, Plzenska 221-130, Prague 15006, Czech Republic.","alice.skoumalova@lfmotol.cuni.cz",null,null,"Internal Grant Agency of the Ministry of Health [NS10331]; Grant Agency of Charles University [74308, 604912]; Grant Agency of the Czech Republic [309/09/1053, 303/09/P049]; European Regional Development Fund - Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]","This research was supported by the Internal Grant Agency of the Ministry of Health (NS10331), the Grant Agency of Charles University (74308, 604912), the Grant Agency of the Czech Republic (309/09/1053, 303/09/P049), and the European Regional Development Fund - Project FNUSA-ICRC (CZ.1.05/1.1.00/02.0123).",null,89,5,5,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1582-1838",null,null,"J CELL MOL MED","J. Cell. Mol. Med.","OCT",2012,16,10,null,null,null,null,2291,2300,null,"10.1111/j.1582-4934.2012.01585.x",null,10,"Cell Biology; Medicine, Research & Experimental","Cell Biology; Research & Experimental Medicine","012LK","WOS:000309237500005"]
[null,null,null,null,"J","Maxova, H; Herget, J; Vizek, M",null,null,null,"Maxova, H.; Herget, J.; Vizek, M.",null,null,"Lung Mast Cells and Hypoxic Pulmonary Hypertension","PHYSIOLOGICAL RESEARCH",null,null,"English","Review",null,null,null,null,null,"Pulmonary hypertension; Mast cells; Hypoxia; Tissue remodeling","VASCULAR SMOOTH-MUSCLE; SERINE ELASTASE INHIBITOR; TIMP-1 GENE-TRANSFER; MATRIX METALLOPROTEINASES; DISODIUM-CROMOGLYCATE; CROMOLYN SODIUM; NITRIC-OXIDE; IN-VITRO; RATS; VASOCONSTRICTION","Hypoxic pulmonary hypertension (HPH) is a syndrome characterized by the increase of pulmonary vascular tone and the structural remodeling of peripheral pulmonary arteries. Mast cells have an important role in many inflammatory diseases and they are also involved in tissue remodeling. Tissue hypoxia is associated with mast cell activation and the release of proteolytic enzymes, angiogenic and growth factors which mediate tissue destruction and remodeling in a variety of physiological and pathological conditions. Here we focused on the role of mast cells in the pathogenesis of hypoxic pulmonary hypertension from the past to the present.","[Maxova, H.; Vizek, M.] Charles Univ Prague, Dept Pathophysiol, Fac Med 2, Prague 15000 5, Czech Republic; [Herget, J.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague 15000 5, Czech Republic; [Maxova, H.; Herget, J.; Vizek, M.] Cardiovasc Res Ctr, Prague, Czech Republic","Maxova, H (reprint author), Charles Univ Prague, Dept Pathophysiol, Fac Med 2, Plzenska 221, Prague 15000 5, Czech Republic.","hana.maxova@lfmotol.cuni.cz","Herget, Jan/I-6313-2012",null,"Centre for Cardiovascular Research [1M0510]; Grant Agency of the Czech Republic [305/08/0108]","This work was supported by the Grant Agency of the Czech Republic (No. 305/08/0108) and by the Centre for Cardiovascular Research (No. 1M0510). Mr. Jack Coling is gratefully acknowledged for his language revision of the manuscript.",null,95,1,4,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2012,61,1,null,null,null,null,1,11,null,null,null,11,"Physiology","Physiology","917RC","WOS:000302195300001"]
[null,null,null,null,"J","Rob, L; Robova, H; Chmel, R; Komar, M; Halaska, M; Skapa, P",null,null,null,"Rob, Lukas; Robova, Helena; Chmel, Roman; Komar, Matej; Halaska, Michael; Skapa, Petr",null,null,"Surgical options in early cervical cancer","INTERNATIONAL JOURNAL OF HYPERTHERMIA",null,null,"English","Review",null,null,null,null,null,"Cervical cancer; fertility-sparing surgery; individually tailored surgery; sentinel lymph node; surgical treatment","SPARING RADICAL HYSTERECTOMY; SENTINEL LYMPH-NODES; NERVE PLEXUS TRAUMA; NEOADJUVANT CHEMOTHERAPY; PARAMETRIAL INVOLVEMENT; PELVIC LYMPHADENECTOMY; UTERINE CERVIX; MICROINVASIVE ADENOCARCINOMA; PATHOLOGICAL EVALUATION; CONSERVATIVE SURGERY","Cancer of the cervix is the second most common cancer in women worldwide and the fourth leading cause of cancer mortality in women. Early cervical cancer stage IB1 includes a broad range of disease from clinically undetectable microinvasive cancer to bulky tumours that infiltrated the entire cervix. This article reviews the literature about risk factors and surgical radicality and fertility-sparing surgery in early cervical cancer. The review evaluates selection criteria, preoperative management and the most frequent surgical procedures used for individually tailored surgery for cervical cancer.","[Rob, Lukas; Robova, Helena; Chmel, Roman; Komar, Matej; Halaska, Michael] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Div Gynaecol Oncol, Prague 15000 5, Czech Republic; [Skapa, Petr] Charles Univ Prague, Dept Pathol Anat & Mol Med, Fac Med 2, Prague 15000 5, Czech Republic","Rob, L (reprint author), Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Div Gynaecol Oncol, Vuvalu 84, Prague 15000 5, Czech Republic.","lukas.rob@lfmotol.cuni.cz",null,null," [IGA MZ CR NS9914-4]","This work is supported by grant IGA MZ CR NS9914-4. The authors alone are responsible for the content and writing of the paper.",null,85,1,1,"INFORMA HEALTHCARE","NEW YORK","52 VANDERBILT AVE, NEW YORK, NY 10017 USA","0265-6736",null,null,"INT J HYPERTHER","Int. J. Hyperthermia",null,2012,28,6,null,null,null,null,489,500,null,"10.3109/02656736.2012.675116",null,12,"Oncology; Radiology, Nuclear Medicine & Medical Imaging","Oncology; Radiology, Nuclear Medicine & Medical Imaging","990YW","WOS:000307669000003"]
[null,null,null,null,"J","Gazova, I; Vlcek, K; Nedelska, Z; Mokrisova, I; Hyncicova, E; Laczo, J; Hort, J",null,null,null,"Gazova, I.; Vlcek, K.; Nedelska, Z.; Mokrisova, I.; Hyncicova, E.; Laczo, J.; Hort, J.",null,null,"Spatial Navigation in Physiological and Pathological Ageing","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"spatial navigation; physiological ageing; pathological ageing; mild cognitive impairment; Alzheimer's disease","MILD COGNITIVE IMPAIRMENT; MORRIS WATER TASK; ALZHEIMERS-DISEASE; PLACE NAVIGATION; AGE-DIFFERENCES; MEMORY; HUMANS; DIAGNOSIS; HIPPOCAMPUS; SEX","Spatial navigation is a process of determining and maintaining a course or trajectory from one place to another. There is a mild progressive decline of spatial navigation in the course of physiological ageing. Nevertheless, severe spatial navigation deficit might be the first sign of incipient Alzheimer's disease at the stage of mild cognitive impairment, before the full dementia syndrome develops. Patients with mild cognitive impairment with memory deficit of hippocampal type, manifested by encoding and retrieval impairment, are at very high risk of Alzheimer's disease. These patients have the same pattern of spatial navigation impairment as patients with mild Alzheimer's disease. Spatial navigation testing in older patients and a development of computerized tests for routine clinical use thus represent a possibility to further investigate this cognitive domain as well as an opportunity of an early diagnosis of Alzheimer's disease. Spatial navigation in humans is of great significance for translational research as spatial navigation tests form a major part of basic cognitive research and are also used in preclinical testing of cognitive drugs in laboratory animals.","[Gazova, I.; Nedelska, Z.; Mokrisova, I.; Hyncicova, E.; Laczo, J.; Hort, J.] 2 LF & FN Motole, UK Praze, Neurol Klin, Kognitivni Ctr, Prague, Czech Republic","Gazova, I (reprint author), LF UK & FN Motole, Neurol Klin 2, Uvalu 84, Prague 15006 5, Czech Republic.","ivana.gazova1@gmail.com","Vlcek, Kamil/B-9620-2012","Vlcek, Kamil/0000-0001-7152-3093",null,null,null,43,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,4,null,null,null,null,411,414,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","987RO","WOS:000307435000003"]
[null,null,null,null,"J","Mokrisova, I; Valis, M; Hort, J",null,null,null,"Mokrisova, I.; Valis, M.; Hort, J.",null,null,"Emotional Memory - Pathophysiology and Clinical Associations","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"emotional memory; amygdala; memory deficits; Alzheimer's disease","MEDIAL TEMPORAL-LOBE; ALZHEIMERS-DISEASE; AMYGDALAR VOLUME; FRONTOTEMPORAL DEMENTIA; PSYCHOLOGICAL SYMPTOMS; PSYCHIATRIC-SYMPTOMS; DOUBLE DISSOCIATION; CONSOLIDATION; HUMANS; BRAIN","The amygdala is the main structure involved in emotional memory. This independent memory system is linked to emotional events and interacts with other brain structures (hippocampus, prefrontal cortex, hypothalamus), affecting final memories. Emotional memory is a non-declarative memory but relates to and cooperates with declarative memory. In some pathological states, characterized by amygdalar atrophy and dysfunction, a variety of changes have been reported, including memory deficits of both systems, behavioral changes and reduced attention span. This results in reduced patient quality of life and a greater burden on caregivers. This applies, for example, to patients with Alzheimer's disease as they have great difficulty with emotional face recognition.","[Mokrisova, I.; Hort, J.] 2 LF UK & FN Motole, Neurol Klin, Kognitivni Ctr, Prague 150065, Czech Republic; [Valis, M.] Oddelenf Urgentni Med FN Hradec Kralove, Hradec Kralove, Czech Republic; [Hort, J.] FN Sv Anny Brne, Mezinarodni Ctr Klin Vyzkumu, Brno, Czech Republic","Hort, J (reprint author), 2 LF UK & FN Motole, Neurol Klin, Kognitivni Ctr, Uvalu 84, Prague 150065, Czech Republic.","jakub.hort@seznam.cz",null,null,null,null,null,47,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,5,null,null,null,null,546,551,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","010IJ","WOS:000309087800002"]
[null,null,null,null,"J","Urbanova, B; Tomek, A; Mikulik, R; Magerova, H; Sheardova, K; Horinek, D; Hort, J",null,null,null,"Urbanova, B.; Tomek, A.; Mikulik, R.; Magerova, H.; Sheardova, K.; Horinek, D.; Hort, J.",null,null,"Vascular Risk Factors and Alzheimer's Disease","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"Alzheimer's disease; vascular hypothesis; vascular risk factors; white matter lesions; microbleeds; neurosonology","WHITE-MATTER LESIONS; MILD COGNITIVE IMPAIRMENT; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; BLOOD-PRESSURE; SYSTOLIC HYPERTENSION; TRANSCRANIAL DOPPLER; CEREBRAL MICROBLEEDS; APOLIPOPROTEIN-E; ROTTERDAM-SCAN","In this paper, we summarize current knowledge on the impact of vascular brain changes and vascular risk factors on the development and course of Alzheimer's disease. The authors discuss the time relation and interactions between vascular and neurohistopathological changes typical for Alzheimer's disease, commenting on possible underlying mechanisms of their origin. Neuroimaging methods to detect vascular changes in the brain are described; findings of these methods are correlated with an impact on cognitive functions and on the risk of developing Alzheimer's disease reported in the literature. The most common structural changes associated with vascular pathology are white matter lesions and cerebral microbleeds detectable on MRI. Perfusion SPECT and neurosonology monitor functional changes in cerebral perfusion. Detailed description of vascular changes in patients with Alzheimer's disease could become a significant parameter in predicting the disease progression in patients with mild cognitive impairment or incipient dementia and assist in determining the risk of dementia in asymptomatic seniors. Neurosonology, an inexpensive, readily available and non-invasive examination of vascular parameters, is a promising monitoring method.","[Urbanova, B.; Tomek, A.; Magerova, H.; Hort, J.] Neurol Klin 2 LF UK & FN Motole, Prague 15006 5, Czech Republic; [Mikulik, R.; Sheardova, K.] Mezinarodni Ctr Klinickeho Vyzkumu ICRC, Neurol Klin FN Sv Anny Brne, Brno, Czech Republic; [Horinek, D.; Hort, J.] Mezinarodni Ctr Klinickeho Vyzkumu ICRC, FN Sv Anny Brne, Brno, Czech Republic; [Horinek, D.] Neurochirurg Klin 1 LF UK & UVN Praha, Prague, Czech Republic","Urbanova, B (reprint author), Neurol Klin 2 LF UK & FN Motole, V Uvalu 84, Prague 15006 5, Czech Republic.","barbora.urbanova@gmail.com",null,null,null,null,null,80,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2012,75,6,null,null,null,null,694,699,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","039JU","WOS:000311242700004"]
[null,null,null,null,"J","Goetz, M; Surman, CBH; Mlynarova, E; Krsek, P",null,null,null,"Goetz, Michal; Surman, Craig Bruce Hackett; Mlynarova, Eliska; Krsek, Pavel",null,null,"Status Epilepticus Associated With the Administration of Long-Acting Methylphenidate in a 7-Year-Old Girl","JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY",null,null,"English","Letter",null,null,null,null,null,null,"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT-HYPERACTIVITY DISORDER; FOCAL CORTICAL DYSPLASIA; EPILEPSY; CLASSIFICATION; CHILDREN",null,"[Goetz, Michal] Charles Univ Prague, Fac Med 2, Dept Child & Adolescent Psychiat, Univ Hosp Motol, Prague, Czech Republic; [Surman, Craig Bruce Hackett] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Clin & Res Program Pediat Psychopharmacol & Adult, Boston, MA USA; [Mlynarova, Eliska] Univ Hosp Motol, Dept Radiol, Prague, Czech Republic; [Krsek, Pavel] Charles Univ Prague, Fac Med 2, Dept Child Neurol, Univ Hosp Motol, Prague, Czech Republic","Goetz, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Child & Adolescent Psychiat, Univ Hosp Motol, Prague, Czech Republic.","michal.goetz@lfmotol.cuni.cz",null,null,null,null,null,14,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0271-0749",null,null,"J CLIN PSYCHOPHARM","J. Clin. Psychopharmacol.","APR",2012,32,2,null,null,null,null,300,302,null,"10.1097/JCP.0b013e3182499a16",null,3,"Pharmacology & Pharmacy; Psychiatry","Pharmacology & Pharmacy; Psychiatry","903MQ","WOS:000301121100033"]
[null,null,null,null,"J","Maly, MA; Majek, P; Reicheltova, Z; Kotlin, R; Suttnar, J; Oravec, M; Veselka, J; Dyr, JE",null,null,null,"Maly, Martin A.; Majek, Pavel; Reicheltova, Zuzana; Kotlin, Roman; Suttnar, Jiri; Oravec, Milan; Veselka, Josef; Dyr, Jan E.",null,null,"Proteomic analysis of plasma samples from acute coronary syndrome patients - The pilot study","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Letter",null,null,null,null,null,"Proteomics; Mass spectrometry; Acute coronary syndrome; Atherosclerosis","PROTEIN; LUNG",null,"[Maly, Martin A.; Oravec, Milan; Veselka, Josef] Charles Univ Prague, Sch Med 2, Dept Cardiol, Prague, Czech Republic; [Majek, Pavel; Reicheltova, Zuzana; Kotlin, Roman; Suttnar, Jiri; Dyr, Jan E.] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic","Maly, MA (reprint author), Univ Hosp Motol, Dept Cardiol, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","martin.maly@fnmotol.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828",null,null,null,13,1,1,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273",null,null,"INT J CARDIOL","Int. J. Cardiol.","MAY 17",2012,157,1,null,null,null,null,126,128,null,"10.1016/j.ijcard.2012.03.045",null,3,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","931HK","WOS:000303206800036"]
[null,null,null,null,"J","Ryvolova, M; Chomoucka, J; Drbohlavova, J; Kopel, P; Babula, P; Hynek, D; Adam, V; Eckschlager, T; Hubalek, J; Stiborova, M; Kaiser, J; Kizek, R",null,null,null,"Ryvolova, Marketa; Chomoucka, Jana; Drbohlavova, Jana; Kopel, Pavel; Babula, Petr; Hynek, David; Adam, Vojtech; Eckschlager, Tomas; Hubalek, Jaromir; Stiborova, Marie; Kaiser, Jozef; Kizek, Rene",null,null,"Modern Micro and Nanoparticle-Based Imaging Techniques","SENSORS",null,null,"English","Review",null,null,null,null,null,"imaging techniques; nanoparticles; fluorescence; magnetic resonance imaging","INDUCED BREAKDOWN SPECTROSCOPY; SCANNING ELECTROCHEMICAL MICROSCOPY; SEMICONDUCTOR QUANTUM DOTS; IRON-OXIDE NANOPARTICLES; TRANSMISSION ELECTRON-MICROSCOPY; ATOMIC-FORCE MICROSCOPY; CORRECTED STEM-EELS; IN-VIVO; GOLD NANOPARTICLES; MAGNETIC NANOPARTICLES","The requirements for early diagnostics as well as effective treatment of insidious diseases such as cancer constantly increase the pressure on development of efficient and reliable methods for targeted drug/gene delivery as well as imaging of the treatment success/failure. One of the most recent approaches covering both the drug delivery as well as the imaging aspects is benefitting from the unique properties of nanomaterials. Therefore a new field called nanomedicine is attracting continuously growing attention. Nanoparticles, including fluorescent semiconductor nanocrystals (quantum dots) and magnetic nanoparticles, have proven their excellent properties for in vivo imaging techniques in a number of modalities such as magnetic resonance and fluorescence imaging, respectively. In this article, we review the main properties and applications of nanoparticles in various in vitro imaging techniques, including microscopy and/or laser breakdown spectroscopy and in vivo methods such as magnetic resonance imaging and/or fluorescence-based imaging. Moreover the advantages of the drug delivery performed by nanocarriers such as iron oxides, gold, biodegradable polymers, dendrimers, lipid based carriers such as liposomes or micelles are also highlighted.","[Ryvolova, Marketa; Chomoucka, Jana; Drbohlavova, Jana; Kopel, Pavel; Babula, Petr; Hynek, David; Adam, Vojtech; Hubalek, Jaromir; Kaiser, Jozef; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Ryvolova, Marketa; Kopel, Pavel; Hynek, David; Adam, Vojtech; Kizek, Rene] Mendel Univ, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, Prague, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, CZ-12840 Prague 2, Czech Republic","Kizek, R (reprint author), Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic.","marketa.ryvolova@seznam.cz; chomoucka@feec.vutbr.cz; drbohla@feec.vutbr.cz; paulko@centrum.cz; petr_babula@email.cz; d.hynek@email.cz; vojtech.adam@mendelu.cz; tomas.eckschlager@fnmotol.cz; hubalek@feec.vutbr.cz; stiborov@yahoo.com; kaiser@fme.vutbr.cz; kizek@sci.muni.cz","Hubalek, Jaromir/D-7753-2012; Kopel, Pavel/E-5711-2012; Drbohlavova, Jana/D-8082-2012",null," [CEITEC CZ.1.05/1.1.00/02.0068];  [GACR 102/10/P618];  [NanoBioTECell GACR P102/11/1068]","Financial support from the following projects CEITEC CZ.1.05/1.1.00/02.0068, GACR 102/10/P618, NanoBioTECell GACR P102/11/1068 project for conceptual development of research organization 00064203 is highly acknowledged.",null,189,11,11,"MDPI AG","BASEL","POSTFACH, CH-4005 BASEL, SWITZERLAND","1424-8220",null,null,"SENSORS-BASEL","Sensors","NOV",2012,12,11,null,null,null,null,14792,14820,null,"10.3390/s121114792",null,29,"Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation","Chemistry; Electrochemistry; Instruments & Instrumentation","041VO","WOS:000311429500030"]
[null,null,null,null,"J","Kubinova, S; Sykova, E",null,null,null,"Kubinova, Sarka; Sykova, Eva",null,null,"Biomaterials combined with cell therapy for treatment of spinal cord injury","REGENERATIVE MEDICINE",null,null,"English","Review",null,null,null,null,null,"biomaterial; cell therapy; scaffold; spinal cord injury; stem cell; tissue engineering","NEURAL STEM-CELLS; POLY(2-HYDROXYETHYL METHACRYLATE) SCAFFOLDS; MAGNETIC-RESONANCE TRACKING; OLFACTORY-ENSHEATHING GLIA; SEEDED GUIDANCE CHANNELS; AXONAL REGENERATION; SCHWANN-CELLS; FUNCTIONAL RECOVERY; BIODEGRADABLE HYDROGEL; DELAYED IMPLANTATION","Spinal cord injury (SCI) is a devastating traumatic injury resulting in paralysis or sensory deficits due to tissue damage and the poor ability of axons to regenerate across the lesion. Despite extensive research, there is still no effective treatment that would restore lost function after SCI. A possible therapeutic approach would be to bridge the area of injury with a bioengineered scaffold that would create a stimulatory environment as well as provide guidance cues for the re-establishment of damaged axonal connections. Advanced scaffold design aims at the fabrication of complex materials providing the concomitant delivery of cells, neurotrophic factors or other bioactive substances to achieve a synergistic effect for treatment. This review summarizes the current utilization of scaffolding materials for SCI treatment in terms of their physicochemical properties and emphasizes their use in combination with various cell types, as well as with other combinatorial approaches promoting spinal cord repair.","[Kubinova, Sarka; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Dept Neurosci, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic","Kubinova, S (reprint author), Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic.","sarka.k@biomed.cas.c2",null,null,"Grant Agency of the Czech Republic [108/10/1560, P304/11/0731, P304/11/0653]; Grant Agency of the Academy of Sciences of the Czech Republic [1AA500390902, KAN200520804]; Ministry of Education, Youth and Sport of the Czech Republic [1M0538]","The financial support of the Grant Agency of the Czech Republic (108/10/1560, P304/11/0731, P304/11/0653), the Grant Agency of the Academy of Sciences of the Czech Republic (1AA500390902, KAN200520804) and the Ministry of Education, Youth and Sport of the Czech Republic (1M0538) is gratefully acknowledged. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",null,130,7,9,"FUTURE MEDICINE LTD","LONDON","UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND","1746-0751",null,null,"REGEN MED","Regen. Med.","MAR",2012,7,2,null,null,null,null,207,224,null,"10.2217/RME.11.121",null,18,"Cell & Tissue Engineering; Engineering, Biomedical","Cell Biology; Engineering","906EH","WOS:000301327200012"]
[null,null,null,null,"J","Stepan-Buksakowska, I; Keller, J; Laczo, J; Rulseh, A; Hort, J; Lisy, J; Charvat, F; Rocek, M; Horinek, D",null,null,null,"Stepan-Buksakowska, Irena; Keller, Jiri; Laczo, Jan; Rulseh, Aaron; Hort, Jakub; Lisy, Jiri; Charvat, Frantisek; Rocek, Miloslav; Horinek, Daniel",null,null,"Diffusion tensor imaging in Alzheimer disease and mild cognitive impairment","NEUROLOGIA I NEUROCHIRURGIA POLSKA",null,null,"English","Review",null,null,null,null,null,"Alzheimer disease; diffusion tensor imaging; mild cognitive impairment","WHITE-MATTER INTEGRITY; VOXEL-BASED MORPHOMETRY; SPATIAL STATISTICS; WATER DIFFUSION; MRI; BRAIN; DEGENERATION; DEMENTIA; DAMAGE; TRACT","A wide range of imaging studies provides growing support for the potential role of diffusion tensor imaging (DTI) in evaluating microstructural white matter integrity in Alzheimer disease (AD) and mild cognitive impairment (MCI). Our review aims to present DTI principles, post-processing and analysis frameworks and to report the results of particular studies. The distribution of AD-related white matter abnormalities is widely discussed in the light of deteriorated connectivity within certain tracts due to secondary white matter degeneration; primary alterations are also assumed to contribute to the pattern. The question whether it is more effective to assess the whole-brain diffusion or to directly concentrate on specific regions remains an interesting issue. Assessing white matter microstructure alterations, as evaluated by group-level differences of tensor-derived parameters, may be a promising neuroimaging tool for differential diagnosis between AD, MCI and other cognitive disorders, as well as being particularly helpful in the interpretation of underlying pathological processes.","[Stepan-Buksakowska, Irena; Lisy, Jiri; Rocek, Miloslav] Charles Univ Prague, Dept Radiol, Fac Med 2, Prague 15006, Czech Republic; [Stepan-Buksakowska, Irena; Lisy, Jiri; Rocek, Miloslav] Univ Hosp Matol Prague, Prague, Czech Republic; [Stepan-Buksakowska, Irena; Laczo, Jan; Hort, Jakub; Horinek, Daniel] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Keller, Jiri; Rulseh, Aaron] Na Homolce Hosp, Radiodiagnost Dept, Prague, Czech Republic; [Keller, Jiri] Charles Univ Prague, Fac Med 3, Dept Neurol, Prague 15006, Czech Republic; [Laczo, Jan; Hort, Jakub] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague 15006, Czech Republic; [Charvat, Frantisek] Cent Mil Hosp, Dept Radiodiagnost, Prague, Czech Republic; [Horinek, Daniel] Charles Univ Prague, Dept Neurosurg, Fac Med 1, Prague 15006, Czech Republic; [Laczo, Jan; Hort, Jakub] Univ Hosp Motol, Prague, Czech Republic","Stepan-Buksakowska, I (reprint author), Charles Univ Prague, Dept Radiol, Fac Med 2, Uvalu 84, Prague 15006, Czech Republic.","buksakowska@wp.pl",null,null,"Ministry of Health's Departmental Research and Development Programme III [IGA NT 11536]; Ministry of Education [MSM 0021620816]; European Regional Development Fund [CZ.1.05/1.1.00/02.0123]","This work was supported by IGA NT 11536 from the Ministry of Health's Departmental Research and Development Programme III and Research Goal MSM 0021620816 from the Ministry of Education.Supported by European Regional Development Fund - Project EN USA-ICRC (No. CZ.1.05/1.1.00/02.0123).",null,57,0,1,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","0028-3843",null,null,"NEUROL NEUROCHIR POL","Neurol. Neurochir. Pol.","SEP-OCT",2012,46,5,null,null,null,null,462,471,null,"10.5114/ninp.2012.31357",null,10,"Clinical Neurology","Neurosciences & Neurology","044US","WOS:000311649800007"]
[null,null,null,null,"J","Stefano, GB; Ptacek, R; Kuzelova, H; Kream, RM",null,null,null,"Stefano, G. B.; Ptacek, R.; Kuzelova, H.; Kream, R. M.",null,null,"Endogenous Morphine: Up-to-Date Review 2011","FOLIA BIOLOGICA",null,null,"English","Review",null,null,null,null,null,"endogenous morphine; dopamine; catecholamine; nitric oxide; nitric oxide synthase","BENZYLISOQUINOLINE ALKALOID BIOSYNTHESIS; OXIDE-COUPLED REGULATION; WHITE BLOOD-CELLS; NITRIC-OXIDE; OPIUM POPPY; IN-VITRO; MITOCHONDRIAL PROCESSES; NORCOCLAURINE SYNTHASE; GANGLIONIC MORPHINE; NEUROBLASTOMA-CELLS","Positive evolutionary pressure has apparently preserved the ability to synthesize chemically authentic morphine, albeit in homeopathic concentrations, throughout animal phyla. Despite the establishment of a progressively rigorous and mechanistically focused historical literature extending from the mid 1970s to the mid 1980s that supported the expression of chemically authentic morphine by animal cellular and organ systems, prejudicial scepticism and early dismissal by scientists and clinicians most often obscured widespread acceptance of the biological importance and medical implications of endogenous morphine. The current critical paper presents and evaluates key recent coordinated studies in endogenous morphine research, highlighting those that have advanced our understanding of the functional roles of cognate alkaloid-selective mu(3) and mu(4) opiate receptors. We propose that the expression of endogenous morphine by animal and human cells is designed to mediate homeopathic regulation of metabolic activity via activation of cognate mu(3) and mu(4) receptors that serve as transductive conduits for short-circuit Ca++ fluxes. The implications of endogenous morphine coupling to nitric oxide regulation of mitochondrial function, with special reference to the cardiovascular system, are now formulated after many years of neglect.","[Stefano, G. B.; Kream, R. M.] SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA; [Stefano, G. B.; Ptacek, R.; Kuzelova, H.] Charles Univ Prague, Fac Med 1, Dept Psychiat, Prague, Czech Republic; [Stefano, G. B.; Ptacek, R.; Kuzelova, H.] Charles Univ Prague, Gen Univ Hosp, Prague, Czech Republic; [Kuzelova, H.] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic","Stefano, GB (reprint author), SUNY Coll Old Westbury, Neurosci Res Inst, POB 210, Old Westbury, NY 11568 USA.","gstefano@sunynri.org","Ptacek, Radek/C-6696-2009",null,null,null,null,50,4,4,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2012,58,2,null,null,null,null,49,56,null,null,null,8,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","930LJ","WOS:000303140600001"]
[null,null,null,null,"J","Andersen, LK; Hercogova, J; Wollina, U; Davis, MDP",null,null,null,"Andersen, Louise K.; Hercogova, Jana; Wollina, Uwe; Davis, Mark D. P.",null,null,"Climate change and skin disease: a review of the English-language literature","INTERNATIONAL JOURNAL OF DERMATOLOGY",null,null,"English","Review",null,null,null,null,null,null,"VECTOR IXODES-SCAPULARIS; ECOLOGICAL NICHE MODELS; SOFT-TISSUE INFECTIONS; CUTANEOUS LEISHMANIASIS; TSUNAMI SURVIVORS; RANGE EXPANSION; UNITED-STATES; NEW-ORLEANS; TRANSMISSION; VARIABILITY","Climate change describes variation in regional or global climates over time. The question of how climate change affects skin disease remains largely unanswered. We reviewed the English-language literature describing the influence of climate change on skin. Relatively few publications detail aspects of how climate change affects skin. Direct effects include the effects of extreme weather events, and indirect effects include the effects of longer-term changes in patterns of infections and infestations worldwide. The effect of climate change on skin is unclear, and more studies on this topic are needed.","[Andersen, Louise K.; Davis, Mark D. P.] Mayo Clin, Div Clin Dermatol, Rochester, MN 55905 USA; [Hercogova, Jana] Charles Univ Prague, Bulovka Univ Hosp, Dept Dermatol, Prague, Czech Republic; [Wollina, Uwe] Tech Univ Dresden, Acad Teaching Hosp, Dept Dermatol & Allergol, D-01062 Dresden, Germany","Davis, MDP (reprint author), Mayo Clin, Div Clin Dermatol, 200 1st St SW, Rochester, MN 55905 USA.","davis.mark2@mayo.edu",null,null,null,null,null,48,2,3,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0011-9059",null,null,"INT J DERMATOL","Int. J. Dermatol.","JUN",2012,51,6,null,null,null,null,656,661,null,"10.1111/j.1365-4632.2011.05258.x",null,6,"Dermatology","Dermatology","945DU","WOS:000304253800003"]
[null,null,null,null,"J","Kream, RM; Kuzelova, H; Kralickova, M; Ptacek, R; Stefano, GB",null,null,null,"Kream, Richard M.; Kuzelova, Hana; Kralickova, Milena; Ptacek, Radek; Stefano, George B.",null,null,"Co-Morbidity and Self Medication in Schizophrenia: Involvement of Endogenous Morphine Signaling Mechanisms","CURRENT DRUG TARGETS",null,null,"English","Review",null,null,null,null,null,"Schizophrenia; comorbidity; self-medication; endogenous morphine; dopamine; catecholamines","COCAINE-EVOKED RELEASE; CENTRAL-NERVOUS-SYSTEM; WHITE BLOOD-CELLS; IN-VIVO; PSYCHIATRIC IMPLICATIONS; GANGLIONIC MORPHINE; ALCOHOL DEPENDENCE; OPIATE-RECEPTORS; OPIOID RECEPTORS; USE DISORDERS","For over 30 years, empirical studies have demonstrated expression of chemically authentic morphine by diverse animal tissues and organs systems. De novo biosynthesis of endogenous morphine by animal cells displays striking similarities to the multi-enzyme mediated biosynthetic pathway previously characterized in great biochemical and molecular detail in opium poppy (Papaver somniferum). The committed enzyme step within this pathway involves an asymmetric Pictet-Spengler condensation of dopamine (DA) and 3,4 dihydroxyphenylacetaldehyde (DOPAL), the oxidation product of L-3,4-dihydroxyphenylalanine (L-DOPA), to form the essential intermediate precursor tetrahydropapaveroline (THP). We have hypothesized that endogenous morphine is synthesized within peripheral sites via conversion of THP in a regulated biosynthetic pathway, or conversely, THP may be directly transported into the CNS and converted to endogenous morphine within a similar biosynthetic pathway. The fundamental chemical relationship of the prototype catecholamine DA and its immediate precursor L-DOPA to endogenous morphine expression indicates a novel reciprocally interactive mechanism that links catecholamine and \"morphinergic\" pathways in the activation and inhibition of key physiological responses, including higher order neural integration. Dysregulation of interactive DAergic and \"morphinergic\" signaling pathways within CNS foci may contribute to the etiological factors driving co-morbid behavioral syndromes in major psychiatric disorders. Our short review is designed to provide insights on comorbidity and self-medication in schizophrenia from a novel perspective involving endogenous morphine signaling mechanisms.","[Kream, Richard M.; Stefano, George B.] SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA; [Kream, Richard M.; Kuzelova, Hana; Ptacek, Radek; Stefano, George B.] Charles Univ Prague, Fac Med 1, Psychiat Clin, Ctr Cognit & Mol Neurosci, Prague, Czech Republic; [Kralickova, Milena] Charles Univ Prague, Fac Med, Inst Histol & Embryol, Plzen, Czech Republic","Kream, RM (reprint author), SUNY Coll Old Westbury, Neurosci Res Inst, POB 210, Old Westbury, NY 11568 USA.","RMKream@sunynri.org","Ptacek, Radek/C-6696-2009",null,"Mito-Genetics, LLC","This work was supported in part by a grant from Mito-Genetics, LLC.",null,53,0,0,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","1389-4501",null,null,"CURR DRUG TARGETS","Curr. Drug Targets","OCT",2012,13,11,null,null,null,null,1454,1457,null,null,null,4,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","999ZM","WOS:000308355300011"]
[null,null,null,null,"J","Sorbi, S; Hort, J; Erkinjuntti, T; Fladby, T; Gainotti, G; Gurvit, H; Nacmias, B; Pasquier, F; Popescu, BO; Rektorova, I; Religa, D; Rusina, R; Rossor, M; Schmidt, R; Stefanova, E; Warren, JD; Scheltens, P",null,null,null,"Sorbi, S.; Hort, J.; Erkinjuntti, T.; Fladby, T.; Gainotti, G.; Gurvit, H.; Nacmias, B.; Pasquier, F.; Popescu, B. O.; Rektorova, I.; Religa, D.; Rusina, R.; Rossor, M.; Schmidt, R.; Stefanova, E.; Warren, J. D.; Scheltens, P.",null,"EFNS Scientist Panel Dementia","EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia","EUROPEAN JOURNAL OF NEUROLOGY",null,null,"English","Review",null,null,null,null,null,"dementia; diagnosis; guideline; management; recommendation; review; treatment","CREUTZFELDT-JAKOB-DISEASE; NORMAL-PRESSURE HYDROCEPHALUS; FRONTOTEMPORAL LOBAR DEGENERATION; PROGRESSIVE SUPRANUCLEAR PALSY; VASCULAR COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; RANDOMIZED CONTROLLED-TRIAL; MULTIPLE SYSTEM ATROPHY; HUMAN PRION DISEASE; ALZHEIMERS-DISEASE","Background and objectives The last version of the EFNS dementia guidelines is from 2007. In 2010, the revised guidelines for Alzheimer's disease (AD) were published. The current guidelines involve the revision of the dementia syndromes outside of AD, notably vascular cognitive impairment, frontotemporal lobar degeneration, dementia with Lewy bodies, corticobasal syndrome, progressive supranuclear palsy, Parkinson's disease dementia, Huntington's disease, prion diseases, normal-pressure hydrocephalus, limbic encephalitis and other toxic and metabolic disorders. The aim is to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists and other specialist physicians responsible for the care of patients with dementing disorders. It represents a statement of minimum desirable standards for practice guidance. Methods The task force working group reviewed evidence from original research articles, meta-analyses and systematic reviews, published by June 2011. The evidence was classified (I, II, III, IV) and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. Results and conclusions New recommendations and good practice points are made for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers. All recommendations were revised as compared with the previous EFNS guidelines. The specialist neurologist together with primary care physicians play an important role in the assessment, interpretation and treatment of symptoms, disability and needs of dementia patients.","[Sorbi, S.; Nacmias, B.] Univ Florence, Dept Neurol & Psychiat Sci, I-50134 Florence, Italy; [Hort, J.] Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Fac Med 2, Prague, Czech Republic; [Hort, J.] Univ Hosp Motol, Prague, Czech Republic; [Erkinjuntti, T.] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland; [Erkinjuntti, T.] Univ Helsinki, Dept Neurol Sci, Helsinki, Finland; [Fladby, T.] Akershus Univ Hosp, Dept Neurol, Lorenskog, Norway; [Fladby, T.] Univ Oslo, Fac Div Akershus Univ Hosp, Oslo, Norway; [Gainotti, G.] Catholic Univ, Policlin Gemelli, Neuropsychol Serv, Rome, Italy; [Gurvit, H.] Istanbul Univ, Behav Neurol & Movement Disorders Unit, Dept Neurol, Istanbul Fac Med, Istanbul, Turkey; [Pasquier, F.] Univ Lille Nord France, UDSL, Lille, France; [Popescu, B. O.] Carol Davila Univ Med & Pharm, Sch Med, Univ Hosp, Dept Neurol, Bucharest, Romania; [Rektorova, I.] Masaryk Univ, St Annes Hosp, Fac Med, Dept Neurol 1, Brno, Czech Republic; [Rektorova, I.] Masaryk Univ, Appl Neurosci Res Grp, Brno, Czech Republic; [Religa, D.] Polish Acad Sci, Med Res Ctr, Dept Neurodegenerat Disorders, Warsaw, Poland; [Religa, D.] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden; [Rusina, R.] Thomayer Teaching Hosp, Dept Neurol, Prague, Czech Republic; [Rusina, R.] Inst Postgrad Educ Med, Prague, Czech Republic; [Rossor, M.; Warren, J. D.] UCL, UCL Inst Neurol, Dept Neurodegenerat, Dementia Res Ctr, London, England; [Schmidt, R.] Med Univ Graz, Dept Neurol, Graz, Austria; [Stefanova, E.] Univ Belgrade, Sch Med, Inst Neurol, Belgrade, Serbia; [Scheltens, P.] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Scheltens, P.] Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, Amsterdam, Netherlands","Sorbi, S (reprint author), Univ Florence, Dept Neurol & Psychiat Sci, Largo Brambilla 3, I-50134 Florence, Italy.","sorbi@unifi.it",null,null,null,null,null,188,16,16,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1351-5101",null,null,"EUR J NEUROL","Eur. J. Neurol.","SEP",2012,19,9,null,null,null,null,1159,"+",null,"10.1111/j.1468-1331.2012.03784.x",null,27,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","991VC","WOS:000307729700014"]
[null,null,null,null,"J","Zitka, O; Ryvolova, M; Hubalek, J; Eckschlager, T; Adam, V; Kizek, R",null,null,null,"Zitka, Ondrej; Ryvolova, Marketa; Hubalek, Jaromir; Eckschlager, Tomas; Adam, Vojtech; Kizek, Rene",null,null,"From Amino Acids to Proteins as Targets for Metal-based Drugs","CURRENT DRUG METABOLISM",null,null,"English","Review",null,null,null,null,null,"Metallomics; metals; amino acid; peptide; protein; interactions; nanotechnology","ION AFFINITY-CHROMATOGRAPHY; HUMAN HEALTH; HEAVY-METAL; THALLIUM TOXICITY; MERCURY TOXICITY; OXIDATIVE STRESS; L-CYSTEINE; STRUCTURAL-CHARACTERIZATION; DEVELOPMENTAL TOXICITY; SILVER NANOPARTICLES","Metallomics and metalloproteomics are emerging fields addressing the role, uptake, transport and storage of trace metals ions both toxic and essential for an organism. Research areas related to the understanding of the mechanisms of life processes associated to metals are covered. Similarly to the genome and proteome terms, metallome was introduced to refer to metalloproteins, metalloenzymes and other metal-containing biomolecules in a biological system. This review aims to give an overview of metal ions behaviour in organisms. The interactions of metals with biomolecules such as amino acids, peptides and protein are the main focus. Special attention is paid to the application of nanotechnology-based techniques using these interactions for medical purposes such as diagnostics, imaging and therapy.","[Zitka, Ondrej; Ryvolova, Marketa; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Zitka, Ondrej; Ryvolova, Marketa; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Hubalek, Jaromir] Brno Univ Technol, Dept Microelect, Fac Elect Engn & Commun, CZ-61600 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Ryvolova, Marketa/D-8243-2012; Hubalek, Jaromir/D-7753-2012; Adam, Vojtech/D-7686-2012; Kizek, Rene/D-7748-2012; Zitka, Ondrej/E-1107-2012",null,"CEITEC [CZ.1.05/1.1.00/02.0068]; GA AV [IAA401990701]; NANOSEMED GA AV [KAN208130801]; NANIMEL GACR [102/08/1546]; GACR [P301/10/0356]","Financial support from CEITEC CZ.1.05/1.1.00/02.0068, GA AV IAA401990701, NANOSEMED GA AV KAN208130801, NANIMEL GACR 102/08/1546 and GACR P301/10/0356 is highly acknowledged.",null,252,9,9,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","1389-2002",null,null,"CURR DRUG METAB","Curr. Drug Metab.","MAR",2012,13,3,null,null,null,null,306,320,null,null,null,15,"Biochemistry & Molecular Biology; Pharmacology & Pharmacy","Biochemistry & Molecular Biology; Pharmacology & Pharmacy","896YS","WOS:000300608000007"]
[null,null,null,null,"J","Pego, AP; Kubinova, S; Cizkova, D; Vanicky, I; Mar, FM; Sousa, MM; Sykova, E",null,null,null,"Pego, Ana Paula; Kubinova, Sarka; Cizkova, Dasa; Vanicky, Ivo; Mar, Fernando Milhazes; Sousa, Monica Mendes; Sykova, Eva",null,null,"Regenerative medicine for the treatment of spinal cord injury: more than just promises?","JOURNAL OF CELLULAR AND MOLECULAR MEDICINE",null,null,"English","Review",null,null,null,null,null,"spinal cord injury; cell therapies; stem cells; clinical trials; biomaterials; growth factors; gene therapy; conditioning lesion","EMBRYONIC STEM-CELLS; OLFACTORY-ENSHEATHING GLIA; MESENCHYMAL STROMAL CELLS; COLONY-STIMULATING FACTOR; POLY(2-HYDROXYETHYL METHACRYLATE) SCAFFOLDS; PERIPHERAL-NERVE REGENERATION; TEMPLATED AGAROSE SCAFFOLDS; ADULT SENSORY NEURONS; BONE-MARROW; FUNCTIONAL RECOVERY","Spinal cord injury triggers a complex set of events that lead to tissue healing without the restoration of normal function due to the poor regenerative capacity of the spinal cord. Nevertheless, current knowledge about the intrinsic regenerative ability of central nervous system axons, when in a supportive environment, has made the prospect of treating spinal cord injury a reality. Among the range of strategies under investigation, cell-based therapies offer the most promising results, due to the multifactorial roles that these cells can fulfil. However, the best cell source is still a matter of debate, as are clinical issues that include the optimal cell dose as well as the timing and route of administration. In this context, the role of biomaterials is gaining importance. These can not only act as vehicles for the administered cells but also, in the case of chronic lesions, can be used to fill the permanent cyst, thus creating a more favourable and conducive environment for axonal regeneration in addition to serving as local delivery systems of therapeutic agents to improve the regenerative milieu. Some of the candidate molecules for the future are discussed in view of the knowledge derived from studying the mechanisms that facilitate the intrinsic regenerative capacity of central nervous system neurons. The future challenge for the multidisciplinary teams working in the field is to translate the knowledge acquired in basic research into effective combinatorial therapies to be applied in the clinic.","[Pego, Ana Paula] Univ Porto, INEB Inst Engn Biomed, P-4150180 Oporto, Portugal; [Pego, Ana Paula] Univ Porto, Fac Engn FEUP, P-4150180 Oporto, Portugal; [Kubinova, Sarka; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague 4, Czech Republic; [Cizkova, Dasa; Vanicky, Ivo] Slovak Acad Sci, Inst Neurobiol, Ctr Excellence Brain Res, Kosice 04001, Slovakia; [Cizkova, Dasa; Vanicky, Ivo] Univ Vet Med & Pharm, Kosice, Slovakia; [Mar, Fernando Milhazes; Sousa, Monica Mendes] Univ Porto, IBMC Inst Biol Mol & Celular, Nerve Regenerat Grp, P-4150180 Oporto, Portugal; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague 5, Czech Republic; [Pego, Ana Paula] ICBAS, Oporto, Portugal","Pego, AP (reprint author), Univ Porto, INEB Inst Engn Biomed, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.","apego@ineb.up.pt","Pego, Ana Paula/C-6942-2012; Sousa, Monica/K-4367-2013","Pego, Ana Paula/0000-0001-5169-328X; Sousa, Monica/0000-0002-4524-2260","FEDER funds through the Programa Operacional Factores de Competitividade - COMPETE; Portuguese funds through the Fundacao para a Ciencia e a Tecnologia [PTDC/SAU-GMG/111761/2009, HMSP-ICT/0020/2010, PEst-C/SAU/LA0002/2011]; Grant Agency of the Czech Republic [108/10/1560, P304/11/0731, P304/11/0653]; Grant Agency of the Academy of Science of the Czech Republic [IAA500390902]; Grant Agency of the Slovak Academy of Sciences [VEGA 2/0114/11, APVV 0472-11]; Center of Excellence for Brain Research Slovak Academy of Sciences;  [MVTS-COST BM-1002-NANONET]","This review is an initiative of REMEDIC, a Network on Regenerative Medicine of the European Science Foundation. The financial support of the FEDER funds through the Programa Operacional Factores de Competitividade - COMPETE and Portuguese funds through the Fundacao para a Ciencia e a Tecnologia (contracts PTDC/SAU-GMG/111761/2009, HMSP-ICT/0020/2010 and PEst-C/SAU/LA0002/2011), the Grant Agency of the Czech Republic (108/10/1560, P304/11/0731 and P304/11/0653), the Grant Agency of the Academy of Science of the Czech Republic (IAA500390902), MVTS-COST BM-1002-NANONET, the Grant Agency of the Slovak Academy of Sciences (VEGA 2/0114/11 and APVV 0472-11) and the Center of Excellence for Brain Research Slovak Academy of Sciences is gratefully acknowledged.",null,182,5,5,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1582-4934",null,null,"J CELL MOL MED","J. Cell. Mol. Med.","NOV",2012,16,11,null,null,null,null,2564,2582,null,"10.1111/j.1582-4934.2012.01603.x",null,19,"Cell Biology; Medicine, Research & Experimental","Cell Biology; Research & Experimental Medicine","030FM","WOS:000310555200002"]
[null,null,null,null,"J","Lotti, TM; Berti, SF; Hercogova, J; Huggins, RH; Lee, BW; Janniger, CK; Schwartz, RA",null,null,null,"Lotti, T. M.; Berti, S. F.; Hercogova, J.; Huggins, R. H.; Lee, B. W.; Janniger, C. K.; Schwartz, R. A.",null,null,"Vitiligo: recent insights and new therapeutic approaches","GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA",null,null,"English","Review",null,null,null,null,null,"Skin diseases; Vitiligo; Autoimmunity","MONOCHROMATIC EXCIMER LIGHT; CHILDHOOD VITILIGO; GENERALIZED VITILIGO; UV-B; AUTOIMMUNE-DISEASES; MELANOCYTE LOSS; T-CELLS; 308 NM; REPIGMENTATION; ASSOCIATION","Vitiligo represents a selective destruction of the melanocytes. It is a relatively common, probably autoimmune disorder that affects people of all backgrounds and both genders. No particular group seems to be preferentially affected. Half of vitiligo patients have an onset before the age of 18 years. In regions where leprosy is endemic, individuals with vitiligo are often stigmatized due to similarities in appearance between the two diseases. We will review this important subject, emphasizing the latest therapeutic advances.","[Huggins, R. H.; Lee, B. W.; Janniger, C. K.; Schwartz, R. A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [Lotti, T. M.] Univ G Marconi, Rome, Italy; [Berti, S. F.] A Mayer Hosp, Florence, Italy; [Hercogova, J.] Charles Univ Prague, Dept Dermatol, Fac Med 2, Prague, Czech Republic","Schwartz, RA (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, 185 S Orange Ave, Newark, NJ 07103 USA.","roschwar@cal.berkeley.edu",null,null,null,null,null,86,0,0,"EDIZIONI MINERVA MEDICA","TURIN","CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY","0392-0488","1827-1820",null,"GIORN ITAL DERMAT V","G. Ital. Dermatol. Venereol.","DEC",2012,147,6,null,null,null,null,637,647,null,null,null,11,"Dermatology","Dermatology","050HL","WOS:000312043800015"]
[null,null,null,null,"J","Skutkova, H; Babula, P; Stiborova, M; Eckschlager, T; Trnkova, L; Provaznik, I; Hubalek, J; Kizek, R; Adam, V",null,null,null,"Skutkova, Helena; Babula, Petr; Stiborova, Marie; Eckschlager, Tomas; Trnkova, Libuse; Provaznik, Ivo; Hubalek, Jaromir; Kizek, Rene; Adam, Vojtech",null,null,"Structure, Polymorphisms and Electrochemistry of Mammalian Metallothioneins - A Review","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Review",null,null,null,null,null,"Metallothionein; Isoforms; Bioinformatics; Data Analysis; Phylogeny; DNA Sequencing; Electrochemistry; Voltammetry; Brdicka Reaction; Peak H","INHIBITORY FACTOR METALLOTHIONEIN-3; SINGLE-NUCLEOTIDE POLYMORPHISMS; DIFFERENTIAL-PULSE VOLTAMMETRY; TRANSGENIC TOBACCO PLANTS; GLUTATHIONE-S-TRANSFERASE; TYPE-2 DIABETES-MELLITUS; METAL-THIOLATE CLUSTERS; CARBON-PASTE ELECTRODE; TUMOR-SUPPRESSOR ROLE; BRDICKA REACTION","Mammalian metallothioneins (MTs) are cysteine-rich low-molecular mass proteins with numerous functions including toxic metal detoxification, as a metal chaperone and maintenance of metal ion homeostasis. Four major isoforms (MT-1 through MT-4) have been identified in mammals. In this review, the functions of the isoforms are summarized. Moreover, polymorphisms of MTs genes and their connection with cancerogenesis and cancer diagnostics are described. The interesting properties of MTs are closely related with structure, which can be studied by modern bioinformatics approaches and electrochemical methods. The advantages of the mentioned approaches and methods are discussed.","[Skutkova, Helena; Provaznik, Ivo] Brno Univ Technol, Fac Elect Engn & Commun, Dept Biomed Engn, CZ-61600 Brno, Czech Republic; [Babula, Petr; Provaznik, Ivo] St Annes Univ Hosp Brno, Int Clin Res Ctr, CZ-65691 Brno, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Trnkova, Libuse; Hubalek, Jaromir; Kizek, Rene; Adam, Vojtech] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Kizek, Rene; Adam, Vojtech] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic","Skutkova, H (reprint author), Brno Univ Technol, Fac Elect Engn & Commun, Dept Biomed Engn, Tech 3058-10, CZ-61600 Brno, Czech Republic.","vojtech.adam@mendelu.cz","Provaznik, Ivo/F-4121-2012; Hubalek, Jaromir/D-7753-2012; Skutkova, Helena/D-5194-2014",null,"NanoBioTECell [GA CR P102/11/1068]; FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]","Financial support from NanoBioTECell GA CR P102/11/1068 and FNUSA-ICRC CZ.1.05/1.1.00/02.0123 is highly acknowledged.",null,146,0,0,"ELECTROCHEMICAL SCIENCE GROUP","BELGRADE","A SPOMENICE 7/12 , 19210 BOR, BELGRADE, VJ 12, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","DEC",2012,7,12,null,null,null,null,12415,12431,null,null,null,17,"Electrochemistry","Electrochemistry","062QT","WOS:000312936700062"]
[null,null,null,null,"J","Stefano, GB; Mantione, KJ; Kralickova, M; Ptacek, R; Kuzelova, H; Esch, T; Kream, RM",null,null,null,"Stefano, George B.; Mantione, Kirk J.; Kralickova, Milena; Ptacek, Radek; Kuzelova, Hana; Esch, Tobias; Kream, Richard M.",null,null,"Parkinson's disease, L-DOPA, and endogenous morphine: A revisit","MEDICAL SCIENCE MONITOR",null,null,"English","Review",null,null,null,null,null,"dopamine; L-DOPA; Parkinson's disease; morphine; tetrahydropapaveroline","NITRIC-OXIDE RELEASE; WHITE BLOOD-CELLS; COCAINE-EVOKED RELEASE; VENTRAL TEGMENTAL AREA; TETRAHYDROISOQUINOLINE ALKALOIDS; RAT-BRAIN; IN-VIVO; OPIATE ALKALOIDS; INVERTEBRATE GANGLIA; SYNTHESIZE MORPHINE","Clinical observations stemming from widespread employment of restorative L-3,4-dihydroxyphenylalanine (L-DOPA) therapy for management of dyskinesia in Parkinson's Disease (PD) patients implicate a regulatory role for endogenous morphine in central nervous system dopamine neurotransmission. Reciprocally, it appears that restorative L-DOPA administration has provided us with a compelling in vivo pharmacological model for targeting peripheral sites involved in endogenous morphine expression in human subjects. The biological activities underlying endogenous morphine expression and its interaction with its major precursor dopamine strongly suggest that endogenous morphine systems are reciprocally dysregulated in PD. These critical issues are examined from historical and current perspectives within our short review.","[Stefano, George B.; Mantione, Kirk J.; Ptacek, Radek; Esch, Tobias; Kream, Richard M.] SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA; [Stefano, George B.; Ptacek, Radek; Kuzelova, Hana; Kream, Richard M.] Charles Univ Prague, Fac Med 1, Clin Psychiat 1, Prague, Czech Republic; [Kralickova, Milena] Charles Univ Prague, Dept Histol & Embryol, Fac Med Pilsen, Prague, Czech Republic; [Kuzelova, Hana] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Esch, Tobias] Coburg Univ Appl Sci, Div Integrat Hlth Promot, Coburg, Germany","Kream, RM (reprint author), SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA.","rmkream@sunynri.org","Ptacek, Radek/C-6696-2009; Esch, Tobias/J-3812-2013","Esch, Tobias/0000-0001-5176-4367",null,null,null,88,0,0,"INT SCIENTIFIC LITERATURE, INC","SMITHTOWN","361 FOREST LANE, SMITHTOWN, NY 11787 USA","1234-1010",null,null,"MED SCI MONITOR","Med. Sci. Monitor","AUG",2012,18,8,null,null,null,null,"RA133","RA137",null,null,null,5,"Medicine, Research & Experimental","Research & Experimental Medicine","003IO","WOS:000308604800025"]
[null,null,null,null,"J","Wu, IB; Lambert, C; Lotti, TM; Hercogova, J; Sintim-Damoa, A; Schwartz, RA",null,null,null,"Wu, I. B.; Lambert, C.; Lotti, T. M.; Hercogova, J.; Sintim-Damoa, A.; Schwartz, R. A.",null,null,"Melasma","GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA",null,null,"English","Review",null,null,null,null,null,"Melanosis; Skin diseases; Hypopigmention","RETINOIC ACID; 4-PERCENT HYDROQUINONE; IMPROVES MELASMA; CLINICAL-TRIAL; TRETINOIN; SKIN; EFFICACY; SAFETY; AGENT","Melasma is a common disorder of hyperpigmentation that is present most commonly in reproductive age women with brown or black skin colors. The lesions of melasma are characteristically distributed in a symmetric manner on the sun-exposed areas of the face and neck. The precise pathogenesis of the disorder is unknown, but a number of etiologic agents have been implicated as its cause. These include ultraviolet radiation, hormonal alterations such as those evident during pregnancy, thyroid dysfunction, and phototoxic and anti-seizure drugs. The pathophysiology of melasma is believed to involve excess production of melanin or an increase in the number of melanocytes in the skin. This is confirmed by histological analysis of melasma, which shows an increased number of melanocytes along with an enhanced capability of these cells to produce melanin. Lack of an understanding of the precise pathogenesis of the condition has led to a large number of treatments for melasma. These therapies include hypopigmenting agents, chemical peels, lasers, and dermabrasion. Further investigations into this disorder may lead to more specific and effective treatments in the future.","[Wu, I. B.; Lambert, C.; Sintim-Damoa, A.; Schwartz, R. A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [Lotti, T. M.] Univ Rome G Marconi, Rome, Italy; [Hercogova, J.] Charles Univ Prague, Prague, Czech Republic","Schwartz, RA (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, 185 S Orange Ave, Newark, NJ 07103 USA.","roschwar@cal.berkeley.edu",null,null,null,null,null,42,0,0,"EDIZIONI MINERVA MEDICA","TURIN","CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY","0392-0488",null,null,"GIORN ITAL DERMAT V","G. Ital. Dermatol. Venereol.","AUG",2012,147,4,null,null,null,null,413,418,null,null,null,6,"Dermatology","Dermatology","013JV","WOS:000309302600010"]
[null,null,null,null,"J","Pokorny, D; Slouf, M; Fulin, P",null,null,null,"Pokorny, D.; Slouf, M.; Fulin, P.",null,null,"Current Knowledge on the Effect of Technology and Sterilization on the Structure, Properties and Longevity of UHMWPE in Total Joint Replacement","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Review",null,null,null,null,null,"polyethylene; UHMWPE; cross-linking; arthroplasty; total hip arthroplasty; oxidative degradation; vitamin E; sequential irradiation; total joint replacements","TOTAL HIP-ARTHROPLASTY; POLYETHYLENE WEAR DEBRIS; MOLECULAR-WEIGHT POLYETHYLENE; CROSS-LINKED POLYETHYLENE; GAMMA-STERILIZATION; CLINICAL-PERFORMANCE; IMPACT; KNEE; OXIDATION; IRRADIATION","Ultrahigh molecular weight polyethylene (UHMWPE) is the most frequently used bearing surface in currently used total joint replacements (TJR). According to the literature available, UHMWPE is the best polymer material, in terms of biocompatibility, mechanical properties and wear resistance, for this application. In spite of this fact, UHMWPE wear (i.e., release of microscopic particles from the polymer surface) remains one of the main reasons of TJR failures. Consequently, the wear of UHMWPE is a subject of intensive study by both materials scientists and orthopaedic surgeons. The structure and properties of UHMWPE strongly depend on the way of processing and post-processing modifications. The processing includes polymer resin preparation (microparticles about 100 pm in size) and resin consolidation (forming bulk material). Post-processing modifications aim at increasing wear resistance and oxidation stability which are regarded as major factors involved in TJR failure. In order to maintain high purity materials for medical application, it is not allowed to use additional chemicals during the modification processes. The only exception is the use of vitamin E, a natural stabilizer and antioxidant. Considering all the above mentioned facts, the modifications can be based on (I) ionizing radiation such as gamma rays or accelerated electrons, (II) thermal modification, (Ill) additional stabilization with vitamin E, and (IV) sterilization. According to the modifications, we usually differentiate three generations of UHMWPE. The 1st generation UHMWPE is not modified except for obligatory sterilization. The sterilization procedures based on chemical procedures (formaldehyde vapours, hot water) have lately been forbidden, abandoned and replaced by gamma-irradiation with doses of 25-45 kGy. In the course of time, sterilization by means of gamma-irradiation showed to be unsuitable due to oxidative degradation of UHMWPE, which resulted in lower wear resistance, worse material properties and a decrease in longevity of joint replacements. The 2nd generation UHMWPE or highly cross-linked UHMWPE is material treated with ionizing radiation (gamma-rays or accelerated electrons) at higher doses (usually 50-100 kGy). The irradiation is followed by thermal treatment in order to eliminate residual radicals and limit oxidative degradation that occurs in the 1st generation UHMWPE types. Finally, the material is sterilized usually by modern procedures using ethylene oxide or gas plasma neither of which causes oxidative degradation (as opposed to gamma-irradiation sterilization). The 3rd generation UHMWPE is basically the same as that of the 2nd generation. The main difference consists in slightly better mechanical properties (strength, fatigue) and further stabilization to oxidative degradation. This is achieved by special procedures, some of which are either controversial (sequential irradiation) or well-accepted by a great majority of the orthopaedic community (vitamin E stabilization). Only the future will show whether the difference between the 2nd and 3rd generations of UHMWPE will play any role in increasing TJR longevity and therefore the quality of its performance. The final objective of all of UHMWPE modifications is, as already mentioned, to increase wear resistance, oxidative resistance and mechanical performance of the polymer. These changes, especially an increase in wear resistance, have been confirmed to prolong the longevity of total joint replacements based on UHMWPE.","[Pokorny, D.; Fulin, P.] FN Motol, I Ortoped Klin 1 LF UK Praha 1, Prague 15006 5, Czech Republic; [Slouf, M.] Ustav Makromol Chem AV CR, Vvi, Prague, Czech Republic","Pokorny, D (reprint author), FN Motol, I Ortoped Klin 1 LF UK Praha 1, V Uvalu 84, Prague 15006 5, Czech Republic.","david.pokorny@LF1.cuni.cz",null,null,null,null,null,31,4,4,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","JUN",2012,79,3,null,null,null,null,213,221,null,null,null,9,"Orthopedics","Orthopedics","972TP","WOS:000306303700003"]
[null,null,null,null,"J","Laczo, J; Andel, R; Vyhnalek, M; Vlcek, K; Magerova, H; Varjassyova, A; Nedelska, Z; Gazova, I; Bojar, M; Sheardova, K; Hort, J",null,null,null,"Laczo, J.; Andel, R.; Vyhnalek, M.; Vlcek, K.; Magerova, H.; Varjassyova, A.; Nedelska, Z.; Gazova, I.; Bojar, M.; Sheardova, K.; Hort, J.",null,null,"From Morris Water Maze to Computer Tests in the Prediction of Alzheimer's Disease","NEURODEGENERATIVE DISEASES",null,null,"English","Article; Proceedings Paper","10th International Conference on Alzheimers and Parkinsons Diseases (AD/PD)","MAR 09-13, 2011","Barcelona, SPAIN",null,null,"Mild cognitive impairment; Alzheimer's disease; Morris Water Maze; Hidden Goal Task; Spatial navigation; Computer tests","MILD COGNITIVE IMPAIRMENT; DIAGNOSIS","Background: Spatial navigation performance in the Hidden Goal Task (HGT), a real-space human analogue of the Morris Water Maze, can identify amnestic mild cognitive impairment (aMCI) patients with memory impairment of the hippocampal type, a known indicator of incipient Alzheimer's disease (AD). Objective: Contrast results from computer versus real-space versions of the HGT. Methods: A total of 42 aMCI patients were clinically and neuropsychologically classified into: (1) memory impairment of the hippocampal type - the hippocampal aMCI (HaMCI; n = 10) and (2) isolated retrieval impairment - the nonhippocampal aMCI (NHaMCI; n = 32). Results were compared to the control (n = 28) and AD (n = 21) groups. Results: The HaMCI group, although similar to the NHaMCI group with respect to overall cognitive impairment, performed poorer on the computer version of the HGT and yielded parallel results to the real-space version. The two versions were strongly correlated. Conclusions: Both versions of the HGT can reliably identify aMCI with pronounced memory impairment of the hippocampal type. The computer version of the HGT may be a useful, relatively inexpensive screening tool for early detection of individuals at a high risk of AD. Copyright (C) 2011 S. Karger AG, Basel","[Laczo, J.; Vyhnalek, M.; Magerova, H.; Varjassyova, A.; Nedelska, Z.; Gazova, I.; Bojar, M.; Hort, J.] Charles Univ Prague, Fac Med 2, Dept Neurol, Memory Disorders Unit, CZ-15006 Prague, Czech Republic; [Laczo, J.; Andel, R.; Vyhnalek, M.; Vlcek, K.; Nedelska, Z.; Gazova, I.; Sheardova, K.; Hort, J.] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Laczo, J.; Vyhnalek, M.; Magerova, H.; Varjassyova, A.; Nedelska, Z.; Gazova, I.; Bojar, M.; Hort, J.] Charles Univ Prague, Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Vlcek, K.] Acad Sci Czech Republic, Dept Neurophysiol Memory, Prague, Czech Republic; [Andel, R.] Univ S Florida, Sch Aging Studies, Tampa, FL USA","Hort, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Neurol, Memory Disorders Unit, V Uvalu 84, CZ-15006 Prague, Czech Republic.","jakub.hort@seznam.cz","Vlcek, Kamil/B-9620-2012","Vlcek, Kamil/0000-0001-7152-3093",null,null,null,14,8,8,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1660-2854",null,null,"NEURODEGENER DIS","Neurodegener. Dis.",null,2012,10,41730,null,null,null,null,153,157,null,"10.1159/000333121",null,5,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","937LS","WOS:000303660600031"]
[null,null,null,null,"J","Vaclavikova, E; Kavalcova, L; Skaba, R; Dvorakova, S; Macokova, P; Rouskova, B; Bendlova, B",null,null,null,"Vaclavikova, Eliska; Kavalcova, Lucie; Skaba, Richard; Dvorakova, Sarka; Macokova, Pavla; Rouskova, Blanka; Bendlova, Bela",null,null,"Hirschsprung's disease and medullary thyroid carcinoma: 15-year experience with molecular genetic screening of the RET proto-oncogene","PEDIATRIC SURGERY INTERNATIONAL",null,null,"English","Article; Proceedings Paper","24th International Symposium on Paediatric Surgical Research","SEP 08-10, 2011","Graz, AUSTRIA",null,null,"Hirschsprung's disease; RET proto-oncogene; Medullary thyroid carcinoma; Germline mutation; Genetics","ENDOCRINE NEOPLASIA TYPE-2; MUTATIONS; RISK; ACTIVATION; FREQUENCY; DOMAIN; 2A","Purpose Inactivating germline mutations in the RET proto-oncogene are the major genetic cause of Hirschsprung's disease (HD). In some cases, HD can be associated with medullary thyroid carcinoma (MTC) that is commonly caused by activating RET mutations. Methods The retrospective and prospective genetic analyses of 157 patients with HD operated on between December 1979 and June 2011 were carried out. DNA was isolated from peripheral leukocytes. HD patients and family members were tested for RET mutations by direct sequencing and single-strand conformation polymorphism methods. Results RET mutations were detected in 16 patients (10%). Association with MTC was found in two families, other eight families had a mutation with potentially high risk of MTC development and four novel mutations were detected. Total colonic aganglionosis was noted to have a high mutation detection rate (40%). Three patients underwent total thyroidectomy (two had clinical manifestation of MTC, one C-cell hyperplasia). Conclusion Results show the benefit of systematic RET mutation screening in HD patients in order to identify the risk of MTC in the preclinical stage of the disease. All patients should be tested for RET mutations at least in exon 10, and now additionally in exon 11 and 13, as well.","[Vaclavikova, Eliska; Dvorakova, Sarka; Bendlova, Bela] Inst Endocrinol, Dept Mol Endocrinol, Prague 11694 1, Czech Republic; [Vaclavikova, Eliska] Charles Univ Prague, Dept Biochem, Fac Sci, Prague 12840 2, Czech Republic; [Kavalcova, Lucie; Skaba, Richard; Rouskova, Blanka] Charles Univ Prague, Dept Pediat Surg, Fac Med 2, Prague 15006 5, Czech Republic; [Kavalcova, Lucie; Skaba, Richard; Macokova, Pavla; Rouskova, Blanka] Hosp Motol, Prague 15006 5, Czech Republic; [Macokova, Pavla] Charles Univ Prague, Dept Pathol, Fac Med 2, Prague 15006 5, Czech Republic","Vaclavikova, E (reprint author), Inst Endocrinol, Dept Mol Endocrinol, Narodni Trida 8, Prague 11694 1, Czech Republic.","evaclavikova@endo.cz",null,null,null,null,null,29,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0179-0358",null,null,"PEDIATR SURG INT","Pediatr. Surg. Int.","FEB",2012,28,2,null,null,null,null,123,128,null,"10.1007/s00383-011-2993-2",null,6,"Pediatrics; Surgery","Pediatrics; Surgery","897TJ","WOS:000300679700003"]
[null,null,null,null,"J","Zieg, J; Dusek, J; Marejkova, M; Limrova, P; Blazek, D; Pavlicek, P; Grega, M; Janda, J; Blahova, K",null,null,null,"Zieg, Jakub; Dusek, Jiri; Marejkova, Monika; Limrova, Petra; Blazek, Daniel; Pavlicek, Petr; Grega, Marek; Janda, Jan; Blahova, Kveta",null,null,"Fatal case of diarrhea-associated hemolytic uremic syndrome with severe neurologic involvement","PEDIATRICS INTERNATIONAL",null,null,"English","Letter",null,null,null,null,null,null,"RISK-FACTORS; SYSTEM; O157",null,"[Zieg, Jakub] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Pediat, Prague 15600 5, Czech Republic; [Blazek, Daniel; Pavlicek, Petr] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Anesthesiol & Resuscitat, Prague 15600 5, Czech Republic; [Grega, Marek] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Pathol & Mol Med, Prague 15600 5, Czech Republic; [Marejkova, Monika] Natl Inst Publ Hlth, Natl Reference Lab Escherichia Coli & Shigellas, Prague, Czech Republic","Zieg, J (reprint author), Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Pediat, V Uvalu 84, Prague 15600 5, Czech Republic.","jakubzieg@hotmail.com",null,null,null,null,null,5,3,3,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1328-8067",null,null,"PEDIATR INT","Pediatr. Int.","FEB",2012,54,1,null,null,null,null,166,167,null,"10.1111/j.1442-200X.2011.03533.x",null,2,"Pediatrics","Pediatrics","897RA","WOS:000300671100036"]
[null,null,null,null,"J","Spacek, M; Veselka, J",null,null,null,"Spacek, Miloslav; Veselka, Josef",null,null,"Bovine arch","ARCHIVES OF MEDICAL SCIENCE",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Spacek, Miloslav; Veselka, Josef] Motol Univ Hosp, Dept Cardiol, Cardiovasc Ctr, Prague 15006 5, Czech Republic","Veselka, J (reprint author), Motol Univ Hosp, Dept Cardiol, Cardiovasc Ctr, Uvalu 84, Prague 15006 5, Czech Republic.","veselka.josef@seznam.cz",null,null,null,null,null,3,1,1,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922",null,null,"ARCH MED SCI","Arch. Med. Sci.","FEB",2012,8,1,null,null,null,null,166,167,null,"10.5114/aoms.2012.27297",null,2,"Medicine, General & Internal","General & Internal Medicine","909HC","WOS:000301553600028"]
[null,null,null,null,"J","Havlin, J; Matousovic, K; Schuck, O; Charvat, J; Horackova, M",null,null,null,"Havlin, Jan; Matousovic, Karel; Schuck, Otto; Charvat, Jiri; Horackova, Miroslava",null,null,"The use of sodium-chloride difference and chloride-sodium ratio in the evaluation of metabolic acidosis in critically ill patients","EUROPEAN JOURNAL OF PEDIATRICS",null,null,"English","Letter",null,null,null,null,null,null,"ANION GAP",null,"[Havlin, Jan; Matousovic, Karel; Schuck, Otto; Charvat, Jiri; Horackova, Miroslava] Charles Univ Prague, Fac Med 2, Dept Med, Prague 15006 5, Czech Republic","Havlin, J (reprint author), Hlubocepska 49, Prague 15200 5, Czech Republic.","havlin.jan@post.cz",null,null,null,null,null,4,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,null,"EUR J PEDIATR","Eur. J. Pediatr.","NOV",2012,171,11,null,null,null,null,1719,1719,null,"10.1007/s00431-012-1833-2",null,1,"Pediatrics","Pediatrics","033PQ","WOS:000310810700023"]
[null,null,null,null,"J","Jonasova, A; Cermak, J; Vondrakova, J; Siskova, M; Hochova, I; Kadlckova, E; Cerna, O; Sykora, M; Vozobulova, V; Seifertova, N; Michalova, K; Zemanova, Z; Brezinova, J; Belohlavkova, P; Kostecka, A; Neuwirtova, R",null,null,null,"Jonasova, Anna; Cermak, Jaroslav; Vondrakova, Jana; Siskova, Magda; Hochova, Ivana; Kadlckova, Eva; Cerna, Olga; Sykora, Michal; Vozobulova, Vera; Seifertova, Nadezda; Michalova, Kyra; Zemanova, Zuzana; Brezinova, Jana; Belohlavkova, Petra; Kostecka, Arnost; Neuwirtova, Radana",null,null,"Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q-MDS (IPSS low and intermediate-1)","LEUKEMIA RESEARCH",null,null,"English","Letter",null,null,null,null,null,null,"MYELODYSPLASTIC SYNDROMES; IMPACT",null,"[Jonasova, Anna; Siskova, Magda; Neuwirtova, Radana] Charles Univ Prague, Dept Med 1, Gen Univ Hosp, Prague 12820 2, Czech Republic; [Jonasova, Anna; Siskova, Magda; Michalova, Kyra; Zemanova, Zuzana; Neuwirtova, Radana] Charles Univ Prague, Fac Med 1, Prague 12820 2, Czech Republic; [Michalova, Kyra; Zemanova, Zuzana] Charles Univ Prague, Ctr Oncocytogenet, Inst Clin Biochem & Lab Diagnost, Gen Univ Hosp, Prague 12820 2, Czech Republic; [Cermak, Jaroslav; Michalova, Kyra; Brezinova, Jana; Kostecka, Arnost] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic; [Belohlavkova, Petra] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; [Vondrakova, Jana] Univ Hosp Olomouc, Olomouc, Czech Republic; [Hochova, Ivana] Univ Hosp Motol, Prague, Czech Republic; [Kadlckova, Eva] Hosp Zlin, Zlin, Czech Republic; [Cerna, Olga] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Sykora, Michal; Seifertova, Nadezda] Hosp Ceske Budejovice, Ceske Budejovice, Czech Republic; [Vozobulova, Vera] Univ Hosp Plzen, Plzen, Czech Republic","Jonasova, A (reprint author), Charles Univ Prague, Dept Med 1, Gen Univ Hosp, U Nemocnice 2, Prague 12820 2, Czech Republic.","atjonas@hotmail.com",null,null,null,null,null,5,2,2,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0145-2126",null,null,"LEUKEMIA RES","Leuk. Res.","DEC",2012,36,12,null,null,null,null,"E222","E224",null,"10.1016/j.leukres.2012.08.002",null,3,"Oncology; Hematology","Oncology; Hematology","031LR","WOS:000310642500003"]
[null,null,null,null,"J","Vondrys, D; Lischke, R",null,null,null,"Vondrys, David; Lischke, Robert",null,null,"Endoscopic management of post-lung transplantation anastomotic stenosis: metallic, silicone or biodegradable stents Reply","EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY",null,null,"English","Letter",null,null,null,null,null,"Lung transplantation; Bronchial stenosis; Metallic stents; Silicone stents; Biodegradable stents",null,null,"[Vondrys, David] Med Univ Innsbruck, Dept Cardiac Surg, Congenital Cardiac Serv, A-6020 Innsbruck, Austria; [Lischke, Robert] Univ Hosp Motol, Dept Surg, Prague, Czech Republic","Vondrys, D (reprint author), Med Univ Innsbruck, Dept Cardiac Surg, Congenital Cardiac Serv, Anichstr 35, A-6020 Innsbruck, Austria.","david.vondrys@uki.at",null,null,null,null,null,4,1,1,"OXFORD UNIV PRESS INC","CARY","JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA","1010-7940",null,null,"EUR J CARDIO-THORAC","Eur. J. Cardio-Thorac. Surg.","MAY",2012,41,5,null,null,null,null,1217,1218,null,"10.1093/ejcts/ezr187",null,2,"Cardiac & Cardiovascular Systems; Respiratory System; Surgery","Cardiovascular System & Cardiology; Respiratory System; Surgery","930TA","WOS:000303161800080"]
[null,null,null,null,"J","Cohen, MI; Triedman, JK; Cannon, BC; Davis, AM; Drago, F; Janousek, J; Klein, GJ; Law, IH; Morady, FJ; Paul, T; Perry, JC; Sanatani, S; Tanel, RE",null,null,null,"Cohen, Mitchell I.; Triedman, John K.; Cannon, Bryan C.; Davis, Andrew M.; Drago, Fabrizio; Janousek, Jan; Klein, George J.; Law, Ian H.; Morady, Fred J.; Paul, Thomas; Perry, James C.; Sanatani, Shubhayan; Tanel, Ronn E.",null,"Writing Comm Members","PACES/HRS Expert Consensus Statement on the Management of the Asymptomatic Young Patient with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic Pattern","HEART RHYTHM",null,null,"English","Editorial Material",null,null,null,null,null,"Ablation; HRS/PACES Consensus Statement; Preexcitation; Wolff-Parkinson-White syndrome","RADIOFREQUENCY CATHETER ABLATION; CONGENITAL HEART-DISEASE; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; ACCESSORY PATHWAY CONDUCTION; PEDIATRIC CARDIAC ABLATION; SHORT REFRACTORY PERIOD; SOCIETY-OF-CARDIOLOGY; TERM-FOLLOW-UP; SUDDEN-DEATH; NATURAL-HISTORY",null,"[Cohen, Mitchell I.] Arizona Pediat Cardiol Consultants, Phoenix, AZ USA; [Cohen, Mitchell I.] Phoenix Childrens Hosp, Phoenix, AZ USA; [Triedman, John K.] Childrens Hosp, Boston, MA 02115 USA; [Cannon, Bryan C.] Mayo Clin, Rochester, MN USA; [Davis, Andrew M.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Drago, Fabrizio] Bambino Gesu Pediat Hosp, Rome, Italy; [Janousek, Jan] Univ Hosp Motol, Childrens Heart Ctr, Prague, Czech Republic; [Klein, George J.] Univ Western Ontario, London, ON N6A 3K7, Canada; [Law, Ian H.] Univ Iowa, Childrens Hosp, Iowa City, IA USA; [Morady, Fred J.] Univ Michigan Hlth Syst, Ann Arbor, MI USA; [Paul, Thomas] Univ Gottingen, Gottingen, Germany; [Perry, James C.] Rady Childrens Hosp UCSD, San Diego, CA USA; [Sanatani, Shubhayan] British Columbia Childrens Hosp, Vancouver, BC V6H 3V4, Canada; [Tanel, Ronn E.] UCSF Benioff Childrens Hosp, San Francisco, CA USA","Cohen, MI (reprint author), Arizona Pediat Cardiol Consultants, Phoenix, AZ USA.",null,null,null,null,null,null,161,23,25,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1547-5271",null,null,"HEART RHYTHM","Heart Rhythm","JUN",2012,9,6,null,null,null,null,1006,"U192",null,"10.1016/j.hrthm.2012.03.050",null,19,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","944ZS","WOS:000304242900038"]
[null,null,null,null,"J","Geda, YE; Nedelska, Z",null,null,null,"Geda, Yonas E.; Nedelska, Zuzana",null,null,"Mild Cognitive Impairment: A Subset of Minor Neurocognitive Disorder?","AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY",null,null,"English","Editorial Material",null,null,null,null,null,"Aging; dementia; mild cognitive impairment","ALZHEIMERS ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; DISEASE; RECOMMENDATIONS; DEMENTIA; PREVALENCE; HEALTH; MEN; MCI","The field of aging and dementia is increasingly preoccupied with identification of the asymptomatic phenotype of Alzheimer disease (AD). A quick glance at historical landmarks in the field indicates that the agenda and priorities of the field have evolved over time. The initial focus of research was dementia. In the late 1980s and 1990s, dementia researchers reported that some elderly persons are neither demented nor cognitively normal. Experts coined various terms to describe the gray zone between normal cognitive aging and dementia, including mild cognitive impairment. Advances made in epidemiologic, neuroimaging, and biomarkers research emboldened the field to seriously pursue the avenue of identifying asymptomatic AD. Accurate \"diagnosis\" of the phenotype has also evolved over time. For example, the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Task Force is contemplating to use the terms major and minor neurocognitive disorders. The six papers published in this edition of the journal pertain to mild cognitive impairment, which is envisaged to become a subset of minor neurocognitive disorders. These six studies have three points in common: 1) All of them are observational studies; 2) they have generated useful hypotheses or made important observations without necessarily relying on expensive biomarkers; and 3) Based on the new National Institute on Aging and the Alzheimer's Association guidelines, all the studies addressed the symptomatic phase of AD. Questionnaire-based observational studies will continue to be useful until such a time that validated biomarkers, be it chemical or neuroimaging, become widely available and reasonably affordable. (Am J Geriatr Psychiatry 2012; 20:821-826)","[Geda, Yonas E.] Mayo Clin, Dept Psychiat & Psychol, Coll Med, Scottsdale, AZ 85259 USA; [Nedelska, Zuzana] Mayo Clin, Dept Neurol, Scottsdale, AZ 85259 USA; [Geda, Yonas E.; Nedelska, Zuzana] Int Clin Res Ctr, Brno, Czech Republic","Geda, YE (reprint author), Mayo Clin, Dept Psychiat & Psychol, Coll Med, Collaborat Res Bldg,13400 E Shea Blvd, Scottsdale, AZ 85259 USA.","geda.yonas@mayo.edu",null,null,null,null,"Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Crook T., 1986, DEV NEUROPSYCHOL, V2, P261; Delbaere K, 2012, AM J GERIAT PSYCHIAT, V20, P845, DOI 10.1097/JGP.0b013e31824afbc4; Di Carlo A, 2007, NEUROLOGY, V68, P1909, DOI 10.1212/01.wnl.0000263132.99055.0d; FLICKER C, 1991, NEUROLOGY, V41, P1006; Ganguli M, 2011, AM J GERIAT PSYCHIAT, V19, P205, DOI 10.1097/JGP.0b013e3182051ab4; Gomez-Tortosa E, 2012, AM J GERIAT PSYCHIAT, V20, P827, DOI 10.1097/JGP.0b013e31823038c6; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hughes TF, 2012, AM J GERIAT PSYCHIAT, V20, P836, DOI 10.1097/JGP.0b013e3182423961; Hulley SB, 2007, DESIGNING CLIN RES; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jefferson AL, 2006, ARCH CLIN NEUROPSYCH, V21, P405, DOI 10.1016/j.acn.2006.06.001; Jonsson T, 2012, NATURE; KRAL VA, 1962, CAN MED ASSOC J, V86, P257; Levy R, 1994, Int Psychogeriatr, V6, P63, DOI 10.1017/S1041610294001626; Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1385, DOI 10.1001/archneur.60.10.1385; Mayeux Richard, 2004, NeuroRx, V1, P182, DOI 10.1007/BF03206601; MCKHANN G, 1984, NEUROLOGY, V34, P939; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Petersen RC, 2010, NEUROLOGY, V75, P889, DOI 10.1212/WNL.0b013e3181f11d85; REISBERG B, 1988, PSYCHOPHARMACOL BULL, V24, P661; Roberts RO, 2012, NEUROLOGY, V78, P342, DOI 10.1212/WNL.0b013e3182452862; Sachdev PS, 2012, AM J GERIAT PSYCHIAT, V20, P854, DOI 10.1097/JGP.0b013e31825461b0; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; Schneider LS, 2010, LANCET NEUROL, V9, P1044, DOI 10.1016/S1474-4422(10)70246-5; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Szklo M, 2007, EPIDEMIOLOGY BASICS",30,2,2,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1064-7481",null,null,"AM J GERIAT PSYCHIAT","Am. J. Geriatr. Psychiatr.","OCT",2012,20,10,null,null,null,null,821,826,null,"10.1097/JGP.0b013e31826abc00",null,6,"Geriatrics & Gerontology; Gerontology; Psychiatry","Geriatrics & Gerontology; Psychiatry","012EW","WOS:000309219300001"]
[null,null,null,null,"J","Tachezy, R; Hrbacek, J; Heracek, J; Salakova, M; Smahelova, J; Ludvikova, V; Svec, A; Urban, M; Hamsikova, E",null,null,null,"Tachezy, Ruth; Hrbacek, Jan; Heracek, Jiri; Salakova, Martina; Smahelova, Jana; Ludvikova, Viera; Svec, Alexandr; Urban, Michael; Hamsikova, Eva",null,null,"HPV persistence and its oncogenic role in prostate tumors","JOURNAL OF MEDICAL VIROLOGY",null,null,"English","Article",null,null,null,null,null,"DNA; antibodies; PCR; prostate cancer; men; reservoir","HUMAN-PAPILLOMAVIRUS INFECTION; POLYMERASE-CHAIN-REACTION; RISK-FACTORS; GENERAL PRIMERS; NECK-CANCER; PCR METHOD; DNA; ASSOCIATION; VIRUS; WOMEN","HPV has carcinogenic effects at several anatomical sites in women and men. Whether the presence of HPV in the genitourinary tract of men is associated with a higher prostate cancer risk has been a matter of research for a long-time and the results are still not fully conclusive. Similarly, the question of the reservoir of HPV infection in men is not clearly resolved. HPV DNA presence and types were evaluated by means of polymerase chain reaction in the tissue of 146 patients with benign prostate hyperplasia and prostate cancer. HPV-specific antibodies were analyzed by enzyme-linked immunosorbent assay in the sera of all patients and 172 controls. In addition, 256 biopsies taken from non-tumorous tissues were analyzed. No statistically significant differences were observed in HPV DNA prevalence between patients with benign prostate hyperplasia (2%) and patients with prostatic cancer (2%; P?=?1.000). The seropositivity rates did not differ significantly between groups of subjects except for antibodies against HPV 6 VLPs which were found more often in prostate cancer patients (adjusted P?=?0.018). Similarly, no difference in the seroprevalence rates for HPV 16 E6 and/or E7 oncoproteins between groups of patients and healthy controls was detected. The overall HPV prevalence in 256 healthy tissue samples was 4%. The results indicate that HPV infection is not associated with prostate oncogenesis in men. However, they imply that multiple tissues of the male genitourinary tract may be important reservoirs for the transmission of some HPV types. J. Med. Virol. 84:16361645, 2012. (c) 2012 Wiley Periodicals, Inc.","[Tachezy, Ruth; Salakova, Martina; Smahelova, Jana; Ludvikova, Viera; Hamsikova, Eva] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague 2, Czech Republic; [Hrbacek, Jan] Charles Univ Prague, Dept Urol, Motol Univ Hosp, Fac Med 2, Prague, Czech Republic; [Heracek, Jiri; Urban, Michael] Charles Univ Prague, Kralovske Vinohrady Univ Hosp, Fac Med 3, Dept Urol, Prague, Czech Republic; [Svec, Alexandr] James Cook Hosp, Dept Cellular Pathol, Middlesbrough, Cleveland, England","Tachezy, R (reprint author), Inst Hematol & Blood Transfus, Dept Expt Virol, U Nemocnice 1, CR-12820 Prague 2, Czech Republic.","rutach@uhkt.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NS10656-3, NS9984]","Grant sponsor: Internal Grant Agency of the Ministry of Health of the Czech Republic; Grant numbers: NS10656-3, NS9984.",null,46,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0146-6615",null,null,"J MED VIROL","J. Med. Virol.","OCT",2012,84,10,null,null,null,null,1636,1645,null,"10.1002/jmv.23367",null,10,"Virology","Virology","996QF","WOS:000308106500019"]
[null,null,null,null,"J","Bunka, F; Budinsky, P; Cechova, M; Drienovsky, V; Pachlova, V; Matoulkova, D; Kuban, V; Bunkova, L",null,null,null,"Bunka, Frantisek; Budinsky, Pavel; Cechova, Marketa; Drienovsky, Viliam; Pachlova, Vendula; Matoulkova, Dagmar; Kuban, Vlastimil; Bunkova, Leona",null,null,"Content of biogenic amines and polyamines in beers from the Czech Republic","JOURNAL OF THE INSTITUTE OF BREWING",null,null,"English","Article",null,null,null,null,null,"beer; biogenic amines; health risk; storage","PERFORMANCE LIQUID-CHROMATOGRAPHY; FOODS; NACL","Altogether 114 samples of alcoholic and non-alcoholic bottled beer produced in 28 breweries in the Czech Republic were monitored for levels of biogenic amines (BA) and polyamines (PA). The beers were analysed immediately after purchase and then at the end of the best-before period (storage temperature 8 +/- 1 degrees C). The concentrations of histamine, phenylethylamine and tryptamine in the studied samples were very low (mostly under 30 mg L-1). The studied PA spermine and spermidine also occurred in small amounts. Nevertheless, the levels of tyramine, putrescine and cadaverine reached significant values, especially in alcoholic beers. In almost 25% of the tested samples of alcoholic beers (at the end of the best-before period), the total amount of all the monitored BA and PA exceeded the 'healthy' level of 100 mg L-1, which is considered toxicologically significant, especially in alcoholic beverages. Copyright (C) 2012 The Institute of Brewing & Distilling","[Bunka, Frantisek; Cechova, Marketa; Drienovsky, Viliam; Pachlova, Vendula; Kuban, Vlastimil] Tomas Bata Univ Zlin, Fac Technol, Dept Food Technol & Microbiol, Zlin 76001, Czech Republic; [Budinsky, Pavel] Fac Hosp Motol, Prague 15006, Czech Republic; [Matoulkova, Dagmar] Res Inst Brewing & Malting, Prague 12044 2, Czech Republic; [Bunkova, Leona] Tomas Bata Univ Zlin, Fac Technol, Dept Environm Protect Engn, Zlin 76001, Czech Republic","Bunka, F (reprint author), Tomas Bata Univ Zlin, Fac Technol, Dept Food Technol & Microbiol, Nam TG Masaryka 5555, Zlin 76001, Czech Republic.","bunka@ft.utb.cz","Kuban, Vlastimil/H-6439-2012; Bunkova, Leona/H-6391-2012",null,"Grant Agency of the Czech Republic [GACR 503/11/1417]; TBU in Zlin [IGA/FT/2012/027]","The financial support from the Grant Agency of the Czech Republic (grant no. GACR 503/11/1417) and the internal grant from TBU in Zlin (no. IGA/FT/2012/027) are gratefully acknowledged.",null,17,1,1,"INST BREWING","LONDON","33 CLARGES STREET, LONDON W1Y 8EE, ENGLAND","0046-9750",null,null,"J I BREWING","J. Inst. Brew.",null,2012,118,2,null,null,null,null,213,216,null,"10.1002/jib.31",null,4,"Food Science & Technology","Food Science & Technology","016AD","WOS:000309488700011"]
[null,null,null,null,"J","Danne, T; Aschemeier, B; Perfetti, R",null,null,null,"Danne, Thomas; Aschemeier, Baerbel; Perfetti, Riccardo",null,"SWEET Grp","SWEET - where are we heading with international type 1 diabetes registries?","PEDIATRIC DIABETES",null,null,"English","Editorial Material",null,null,null,null,null,null,"ADOLESCENTS; CHILDREN",null,"[Danne, Thomas; Aschemeier, Baerbel] Childrens Hosp AUF DER BULT, D-30173 Hannover, Germany; [Perfetti, Riccardo] Sanofi Rech, Global Med Affairs, F-75008 Paris, France","Danne, T (reprint author), Childrens Hosp AUF DER BULT, D-30173 Hannover, Germany.","danne@hka.de",null,null,null,null,"Alsanaa H, 2011, PEDIAT DIABETES S15, V12, P90; Danne T, 2001, DIABETES CARE, V24, P1342, DOI 10.2337/diacare.24.8.1342; Hanberger L, 2012, DIABETES RES CLIN PR, V96, P331, DOI 10.1016/j.diabres.2012.01.016; Hills Sarah, 2011, J Diabetes Sci Technol, V5, P794; Rosenbauer J, 2012, DIABETES CARE, V35, P80, DOI 10.2337/dc11-0993",5,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1399-543X",null,null,"PEDIATR DIABETES","Pediatr. Diabetes","SEP",2012,13,null,null,16,"SI",null,1,4,null,"10.1111/j.1399-5448.2012.00906.x",null,4,"Endocrinology & Metabolism; Pediatrics","Endocrinology & Metabolism; Pediatrics","996OO","WOS:000308100400001"]
[null,null,null,null,"J","Richter, S; Gebauer, R; Hindricks, G; Brugada, P",null,null,null,"Richter, Sergio; Gebauer, Roman; Hindricks, Gerhard; Brugada, Pedro",null,null,"A Classic Electrocardiographic Manifestation of Catecholaminergic Polymorphic Ventricular Tachycardia","JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY",null,null,"English","Editorial Material",null,null,null,null,null,null,null,null,"[Richter, Sergio] Univ Leipzig, Ctr Heart, Dept Electrophysiol, D-04289 Leipzig, Germany; [Brugada, Pedro] Free Univ Brussels UZ Brussel VUB, Cardiovasc Ctr, Heart Rhythm Management Ctr, Brussels, Belgium","Richter, S (reprint author), Univ Leipzig, Ctr Heart, Dept Electrophysiol, Strumpellstr 39, D-04289 Leipzig, Germany.","s.richter@med.uni-leipzig.de",null,null,null,null,null,0,1,1,"WILEY-BLACKWELL","MALDEN","COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA","1045-3873",null,null,"J CARDIOVASC ELECTR","J. Cardiovasc. Electrophysiol.","MAY",2012,23,5,null,null,null,null,560,560,null,"10.1111/j.1540-8167.2011.02138.x",null,1,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","937MH","WOS:000303662100019"]
[null,null,null,null,"J","Ciliberti, P; Muthialu, N; Tann, O; Kostolny, M; Marek, J",null,null,null,"Ciliberti, Paolo; Muthialu, Nagarajan; Tann, Oliver; Kostolny, Martin; Marek, Jan",null,null,"Multimodality Imaging of a Rare Complex Vascular Ring in an Infant Left Pulmonary Sling Associated With Aorto-Pulmonary Window, Aberrant Right Subclavian Artery, and With Complete Tracheal Rings","JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY",null,null,"English","Editorial Material",null,null,null,null,null,null,null,null,"[Ciliberti, Paolo; Muthialu, Nagarajan; Tann, Oliver; Kostolny, Martin; Marek, Jan] Great Ormond St Hosp Sick Children, Cardiothorac Unit, London, England; [Muthialu, Nagarajan; Tann, Oliver; Kostolny, Martin; Marek, Jan] UCL, Inst Cardiovasc Sci, London, England","Ciliberti, P (reprint author), Great Ormond St Hosp Sick Children, Cardiothorac Unit, London, England.",null,null,null,null,null,null,0,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0735-1097",null,null,"J AM COLL CARDIOL","J. Am. Coll. Cardiol.","DEC 25",2012,60,25,null,null,null,null,"E165","E165",null,"10.1016/j.jacc.2012.05.069",null,1,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","056YG","WOS:000312527000001"]
[null,null,null,null,"J","Paech, C; Flosdorff, P; Gebauer, RA",null,null,null,"Paech, Christian; Flosdorff, Patrick; Gebauer, Roman Antonin",null,null,"Pharmacologic Cardiac Resynchronization of a 1-Year-Old Boy With Severe Left Ventricular Dysfunction","PEDIATRIC CARDIOLOGY",null,null,"English","Editorial Material",null,null,null,null,null,"Wolff-Parkinson-White syndrome; Left ventricular dysfunction; Cardiac dyssynchrony; Resynchronization; Pediatrics","PROPAFENONE; CHILDREN","Postero-septal accessory pathways (AP) are a rare cause of intraventricular dyssynchrony and severe LV dysfunction in children. Beside the common treatment with radiofrequency ablation of septal substrates we present the case of a successful pharmacologic resynchronization in a 13/12 years old male toddler with Wolff-Parkinson-White syndrome (WPW) and severe LV dysfunction (left ventricular biplane EF of 31 %) due to intraventricular dyssynchrony with septal to posterior wall motion delay (SPWMD) of 350 ms. Interventricular mechanical delay (IVMD) was 65 ms. Using propafenone, pharmacologic cardiac resynchronization could be achieved. Pharmacologic resynchronization should be considered as safe and effective alternative to catheter ablation in very young children.","[Paech, Christian; Flosdorff, Patrick; Gebauer, Roman Antonin] Univ Leipzig, Dept Pediat Cardiol, Ctr Heart, D-04289 Leipzig, Germany","Paech, C (reprint author), Univ Leipzig, Dept Pediat Cardiol, Ctr Heart, Strumpellstr 39, D-04289 Leipzig, Germany.","christian.paech@med.uni-leipzig.de; patrick.flosdorff@gmail.com; roman.gebauer@med.uni-leipzig.de",null,null,null,null,"Friedman RA, 2002, PACE, V25, P1000, DOI 10.1046/j.1460-9592.2002.01000.x; Janousek J, 1998, AM J CARDIOL, V81, P1121, DOI 10.1016/S0002-9149(98)00142-8; PAUL T, 1994, PEDIATR CARDIOL, V15, P190, DOI 10.1007/BF00800674; Tomaske M, 2008, EUROPACE, V10, P181, DOI 10.1093/europace/eun005",4,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0172-0643",null,null,"PEDIATR CARDIOL","Pediatr. Cardiol.","OCT",2012,33,7,null,null,null,null,1213,1215,null,"10.1007/s00246-012-0310-z",null,3,"Cardiac & Cardiovascular Systems; Pediatrics","Cardiovascular System & Cardiology; Pediatrics","006OJ","WOS:000308828200036"]
[null,null,null,null,"J","Witt, H; Beer, S; Rosendahl, J; Chen, JM; Chandak, GR; Masamune, A; Bence, M; Szmola, R; Oracz, G; Macek, M; Bhatia, E; Steigenberger, S; Lasher, D; Buhler, F; Delaporte, C; Tebbing, J; Ludwig, M; Pilsak, C; Saum, K; Bugert, P; Masson, E; Paliwal, S; Bhaskar, S; Sobczynska-Tomaszewska, A; Bak, D; Balascak, I; Choudhuri, G; Reddy, DN; Rao, GV; Thomas, V; Kume, K; Nakano, E; Kakuta, Y; Shimosegawa, T; Durko, L; Szabo, A; Schnur, A; Hegyi, P; Rakonczay, Z; Pfutzer, R; Schneider, A; Groneberg, DA; Braun, M; Schmidt, H; Witt, U; Friess, H; Algul, H; Landt, O; Schuelke, M; Kruger, R; Wiedenmann, B; Schmidt, F; Zimmer, KP; Kovacs, P; Stumvoll, M; Bluher, M; Muller, T; Janecke, A; Teich, N; Grutzmann, R; Schulz, HU; Mossner, J; Keim, V; Lohr, M; Ferec, C; Sahin-Toth, M",null,null,null,"Witt, Heiko; Beer, Sebastian; Rosendahl, Jonas; Chen, Jian-Min; Chandak, Giriraj Ratan; Masamune, Atsushi; Bence, Melinda; Szmola, Richard; Oracz, Grzegorz; Macek, Milan, Jr.; Bhatia, Eesh; Steigenberger, Sandra; Lasher, Denise; Buehler, Florence; Delaporte, Catherine; Tebbing, Johanna; Ludwig, Maren; Pilsak, Claudia; Saum, Karolin; Bugert, Peter; Masson, Emmanuelle; Paliwal, Sumit; Bhaskar, Seema; Sobczynska-Tomaszewska, Agnieszka; Bak, Daniel; Balascak, Ivan; Choudhuri, Gourdas; Reddy, D. Nageshwar; Rao, G. Venkat; Thomas, Varghese; Kume, Kiyoshi; Nakano, Eriko; Kakuta, Yoichi; Shimosegawa, Tooru; Durko, Lukasz; Szabo, Andras; Schnur, Andrea; Hegyi, Peter; Rakonczay, Zoltan, Jr.; Pfuetzer, Roland; Schneider, Alexander; Groneberg, David Alexander; Braun, Markus; Schmidt, Hartmut; Witt, Ulrike; Friess, Helmut; Alguel, Hana; Landt, Olfert; Schuelke, Markus; Krueger, Renate; Wiedenmann, Bertram; Schmidt, Frank; Zimmer, Klaus-Peter; Kovacs, Peter; Stumvoll, Michael; Blueher, Matthias; Mueller, Thomas; Janecke, Andreas; Teich, Niels; Gruetzmann, Robert; Schulz, Hans-Ulrich; Moessner, Joachim; Keim, Volker; Loehr, Matthias; Ferec, Claude; Sahin-Toth, Miklos",null,null,"Variants in CPA1 are strongly associated with early onset chronic pancreatitis","NATURE GENETICS",null,null,"English","Article",null,null,null,null,null,null,"CATIONIC TRYPSINOGEN GENE; HEREDITARY PANCREATITIS; MUTATION; CTRC; INHIBITOR; PRSS1","Chronic pancreatitis is an inflammatory disorder of the pancreas. We analyzed CPA1, encoding carboxypeptidase A1, in subjects with nonalcoholic chronic pancreatitis (cases) and controls in a German discovery set and three replication sets. Functionally impaired variants were present in 29/944 (3.1%) German cases and 5/3,938 (0.1%) controls (odds ratio (OR) = 24.9, P = 1.5 x 10(-16)). The association was strongest in subjects aged = 10 years (9.7%; OR = 84.0, P = 4.1 x 10(-24)). In the replication sets, defective CPA1 variants were present in 8/600 (1.3%) cases and 9/2,432 (0.4%) controls from Europe (P = 0.01), 5/230 (2.2%) cases and 0/264 controls from India (P = 0.02) and 5/247 (2.0%) cases and 0/341 controls from Japan (P = 0.013). The mechanism by which CPA1 variants confer increased pancreatitis risk may involve misfolding-induced endoplasmic reticulum stress rather than elevated trypsin activity, as is seen with other genetic risk factors for this disease.","[Witt, Heiko; Steigenberger, Sandra; Lasher, Denise; Buehler, Florence; Delaporte, Catherine; Tebbing, Johanna; Ludwig, Maren; Pilsak, Claudia; Saum, Karolin] Tech Univ Munich, Else Kroner Fresenius Zentrum Ernahrungsme EKFZ, Freising Weihenstephan, Germany; [Witt, Heiko; Steigenberger, Sandra; Lasher, Denise; Buehler, Florence; Delaporte, Catherine; Tebbing, Johanna; Ludwig, Maren; Pilsak, Claudia; Saum, Karolin] TUM, ZIEL, Freising Weihenstephan, Germany; [Witt, Heiko] TUM, Dept Pediat, Klinikum Rechts Isar MRI, Munich, Germany; [Bence, Melinda; Szmola, Richard; Szabo, Andras; Schnur, Andrea; Sahin-Toth, Miklos] Boston Univ, Henry M Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02215 USA; [Rosendahl, Jonas; Moessner, Joachim; Keim, Volker] Univ Leipzig, Div Gastroenterol, Dept Internal Med Neurol & Dermatol, D-04109 Leipzig, Germany; [Chen, Jian-Min; Masson, Emmanuelle; Ferec, Claude] Etab Francais Sang EFS Bretagne, INSERM, U1078, Brest, France; [Chen, Jian-Min; Masson, Emmanuelle; Ferec, Claude] Univ Bretagne Occidentale, Fac Med & Sci Sante, Brest, France; [Chandak, Giriraj Ratan; Paliwal, Sumit; Bhaskar, Seema] CSIR, CCMB, Hyderabad, Andhra Pradesh, India; [Masamune, Atsushi; Kume, Kiyoshi; Nakano, Eriko; Kakuta, Yoichi; Shimosegawa, Tooru] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Sendai, Miyagi 980, Japan; [Szmola, Richard] Semmelweis Univ, Dept Med 2, H-1085 Budapest, Hungary; [Oracz, Grzegorz] Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol & Immunol, Warsaw, Poland; [Macek, Milan, Jr.] Univ Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Macek, Milan, Jr.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Bhatia, Eesh] Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Lucknow, Uttar Pradesh, India; [Bugert, Peter] Heidelberg Univ, Med Fac Mannheim, Inst Transfus Med & Immunol, Mannheim, Germany; [Sobczynska-Tomaszewska, Agnieszka] MedGen Hlth Care Ctr, Warsaw, Poland; [Sobczynska-Tomaszewska, Agnieszka; Bak, Daniel] Inst Mother & Child Hlth, Dept Med Genet, Warsaw, Poland; [Balascak, Ivan] Univ Hosp Motol, Dept Neonatol, Clin Obstet & Gynecol, Prague, Czech Republic; [Balascak, Ivan] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Choudhuri, Gourdas] Sanjay Gandhi Postgrad Inst Med Sci, Dept Gastroenterol, Lucknow, Uttar Pradesh, India; [Reddy, D. Nageshwar; Rao, G. Venkat] Asian Inst Gastroenterol, Hyderabad, Andhra Pradesh, India; [Thomas, Varghese] Med Coll Hosp, Dept Gastroenterol, Calicut, Kerala, India; [Durko, Lukasz] Med Univ Lodz, Dept Digest Tract Dis, Lodz, Poland; [Schnur, Andrea; Hegyi, Peter; Rakonczay, Zoltan, Jr.] Univ Szeged, Dept Med 1, Szeged, Hungary; [Pfuetzer, Roland] Klinikum Dobeln, Dept Internal Med, Dobeln, Germany; [Schneider, Alexander] Heidelberg Univ, Univ Med Mannheim, Dept Med 2, Mannheim, Germany; [Groneberg, David Alexander; Braun, Markus] Goethe Univ Frankfurt, Inst Occupat Med, D-60054 Frankfurt, Germany; [Schmidt, Hartmut] Univ Hosp Munster, Dept Transplant Med, Munster, Germany; [Witt, Ulrike; Friess, Helmut] TUM, Dept Surg, Munich, Germany; [Alguel, Hana] TUM, Dept Gastroenterol, Munich, Germany; [Landt, Olfert] TIB MOLBIOL, Berlin, Germany; [Schuelke, Markus] Campus Virchow Klinikum, Dept Neuropediat, Charite, Berlin, Germany; [Schuelke, Markus] Campus Virchow Klinikum, Charite, NeuroCure Clin Res Ctr, Berlin, Germany; [Krueger, Renate] Campus Virchow Klinikum, Charite, Dept Pediat, Div Pediat Pulmonol, Berlin, Germany; [Wiedenmann, Bertram] Campus Virchow Klinikum, Charite, Dept Internal Med, Div Gastroenterol & Hepatol, Berlin, Germany; [Schmidt, Frank] Univ Halle Wittenberg, Dept Pediat, D-06108 Halle, Germany; [Zimmer, Klaus-Peter] Univ Giessen, Dept Pediat, D-35390 Giessen, Germany; [Kovacs, Peter; Stumvoll, Michael; Blueher, Matthias] Univ Leipzig, Div Endocrinol, Dept Internal Med Neurol & Dermatol, D-04109 Leipzig, Germany; [Kovacs, Peter; Stumvoll, Michael; Blueher, Matthias] Univ Leipzig, Integriertes Forsch & Behandlungszentrum IFB Adip, D-04109 Leipzig, Germany; [Mueller, Thomas; Janecke, Andreas] Med Univ Innsbruck, Dept Kinder & Jugendheilkunde, Univ Klin Padiat 1, A-6020 Innsbruck, Austria; [Janecke, Andreas] Med Univ Innsbruck, Sekt Humangenet, A-6020 Innsbruck, Austria; [Teich, Niels] Practice Digest & Metab Dis, Leipzig, Germany; [Gruetzmann, Robert] Univ Klinikum Dresden, Dept Surg, Dresden, Germany; [Schulz, Hans-Ulrich] Otto Von Guericke Univ, Dept Surg, Magdeburg, Germany; [Loehr, Matthias] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden","Witt, H (reprint author), Tech Univ Munich, Else Kroner Fresenius Zentrum Ernahrungsme EKFZ, Freising Weihenstephan, Germany.","heiko.witt@lrz.tum.de; miklos@bu.edu",null,null,"Deutsche Forschungsgemeinschaft (DFG) [Wi 2036/2-2, Wi 2036/2-3, RO 3929/1-1, RO 3939/2-1]; Else Kroner-Fresenius-Foundation (EKFS); Colora Stiftung gGmbH; US National Institutes of Health (NIH) [R01DK058088, R01DK082412, R01DK082412-S2, R01DK095753]; Rosztoczy Foundation; Hungarian Academy of Sciences; INSERM; Programme Hospitalier de Recherche Clinique [PHRC R 08-04]; French Association des Pancreatites Chroniques Hereditaires; Czech Ministry of Health conceptual development project of research organization University Hospital Motol in Prague [00064203]; Council of Scientific and Industrial Research (CSIR), Ministry of Science and Technology, Government of India, India; Japan Society for the Promotion of Science [23591008]; Research Committee of Intractable Pancreatic Diseases by the Ministry of Health, Labour and Welfare of Japan;  [CZ.2.16/3.1.00/24022OPPK]","The authors thank all study participants and the members of the Gesellschaft fur Padiatrische Gastroenterologie und Ernahrung (GPGE) for providing clinical data and blood samples. The authors also thank C. Ruffert (Leipzig), K. Krohn, K. Schon and B. Oelzner (Interdisziplinares Zentrum fur Klinische Forschung (IZKF) core unit DNA technologies, Leipzig), V. Sahin-Toth (Boston) and K. R. Mani (CCMB, Hyderabad) for excellent technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) grants Wi 2036/2-2 and Wi 2036/2-3 (to H. W.) and RO 3929/1-1 and RO 3939/2-1 (to J.R.), the Else Kroner-Fresenius-Foundation (EKFS) (to H. W.), a grant of the Colora Stiftung gGmbH (to J.R.), US National Institutes of Health (NIH) grants R01DK058088, R01DK082412, R01DK082412-S2 and R01DK095753 (to M.S.-T.), fellowships from the Rosztoczy Foundation (to M. Bence and A. Schnur), the Bolyai postdoctoral fellowship from the Hungarian Academy of Sciences (to R. S.), INSERM, the Programme Hospitalier de Recherche Clinique (PHRC R 08-04), the French Association des Pancreatites Chroniques Hereditaires and its president N. Meslet, the Czech Ministry of Health conceptual development project of research organization University Hospital Motol in Prague (00064203) and grants CZ.2.16/3.1.00/24022OPPK (to M. M.), the Council of Scientific and Industrial Research (CSIR), Ministry of Science and Technology, Government of India, India grant GENESIS (to G. R. C.), a Grant-in-Aid from the Japan Society for the Promotion of Science (# 23591008 to A. M.) and the Research Committee of Intractable Pancreatic Diseases provided by the Ministry of Health, Labour and Welfare of Japan (to A. M. and T. S.).",null,17,1,1,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","1061-4036",null,null,"NAT GENET","Nature Genet.","OCT",2013,45,10,null,null,"SI",null,1216,"U359",null,"10.1038/ng.2730",null,7,"Genetics & Heredity","Genetics & Heredity","225UQ","WOS:000324989600018"]
[null,null,null,null,"J","Cheng, DT; Kim, DK; Cockayne, DA; Belousov, A; Bitter, H; Cho, MH; Duvoix, A; Edwards, LD; Lomas, DA; Miller, BE; Reynaert, N; Tal-Singer, R; Wouters, EFM; Agusti, A; Fabbri, LM; Rames, A; Visvanathan, S; Rennard, SI; Jones, P; Parmar, H; MacNee, W; Wolff, G; Silverman, EK; Mayer, RJ; Pillai, SG",null,null,null,"Cheng, Donavan T.; Kim, Deog Kyeom; Cockayne, Debra A.; Belousov, Anton; Bitter, Hans; Cho, Michael H.; Duvoix, Annelyse; Edwards, Lisa D.; Lomas, David A.; Miller, Bruce E.; Reynaert, Niki; Tal-Singer, Ruth; Wouters, Emiel F. M.; Agusti, Alvar; Fabbri, Leonardo M.; Rames, Alex; Visvanathan, Sudha; Rennard, Stephen I.; Jones, Paul; Parmar, Harsukh; MacNee, William; Wolff, Gerhard; Silverman, Edwin K.; Mayer, Ruth J.; Pillai, Sreekumar G.",null,"TESRA Investigator; ECLIPSE Investigator","Systemic Soluble Receptor for Advanced Glycation Endproducts Is a Biomarker of Emphysema and Associated with AGER Genetic Variants in Patients with Chronic Obstructive Pulmonary Disease","AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE",null,null,"English","Article",null,null,null,null,null,"single-nucleotide polymorphism; lung density; DLCO","CORONARY-ARTERY-DISEASE; ACUTE LUNG INJURY; END-PRODUCTS; COPD; RAGE; FIBROSIS; INFLAMMATION; POLYMORPHISM; POPULATION; DEFICIENT","Rationale: Emphysema in chronic obstructive pulmonary disease (COPD) can be characterized by high-resolution chest computed tomography (HRCT); however, the repeated use of HRCT is limited because of concerns regarding radiation exposure and cost. Objectives: To evaluate biomarkers associated with emphysema and COPD-related clinical characteristics, and to assess the relationships of soluble receptor for advanced glycation endproducts (sRAGE), a candidate systemic biomarker identified in this study, with single-nucleotide polymorphisms (SNPs) in the gene coding for RAGE (AGER locus) and with clinical characteristics. Methods: Circulating levels of 111 biomarkers were analyzed for association with clinical characteristics in 410 patients with COPD enrolled in the TESRA study. sRAGE was also measured in the ECLIPSE cohort in 1,847 patients with COPD, 298 smokers and 204 nonsmokers. The association between 21 SNPs in the AGER locus with sRAGE levels and clinical characteristics was also investigated. Measurements and Main Results: sRAGE was identified as a biomarker of diffusing capacity of carbon monoxide and lung density in the TESRA cohort. In the ECLIPSE cohort, lower sRAGE levels were associated with increased emphysema, increased Global Initiative for Chronic Obstructive Lung Disease stage, and COPD disease status. The associations with emphysema in both cohorts remained significant after covariate adjustment (P < 0.0001). One SNP in the AGER locus, rs2070600, was associated with circulating sRAGE levels both in TESRA (P = 0.0014) and ECLIPSE (7.07 x 10(-16)), which exceeded genome-wide significance threshold. Another SNP (rs2071288) was also associated with sRAGE levels (P = 0.01) and diffusing capacity of carbonmonoxide (P = 0.01) in the TESRA study. Conclusions: Lower circulating sRAGE levels are associated with emphysema severity and genetic polymorphisms in the AGER locus are associated with systemic sRAGE levels.","[Cheng, Donavan T.; Cockayne, Debra A.; Bitter, Hans; Visvanathan, Sudha; Parmar, Harsukh; Wolff, Gerhard; Pillai, Sreekumar G.] Hoffmann La Roche Inc, Nutley, NJ 07110 USA; [Cheng, Donavan T.] Mem Sloan Kettering Canc, New York, NY USA; [Kim, Deog Kyeom] Seoul Natl Univ, Div Pulm & Crit Care Med, Boramae Med Ctr, Seoul, South Korea; [Kim, Deog Kyeom; Cho, Michael H.; Silverman, Edwin K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med, Boston, MA 02115 USA; [Cockayne, Debra A.] Boston Sci, San Jose, CA USA; [Belousov, Anton] Hoffmann La Roche, Penzberg, Germany; [Bitter, Hans] Novartis Inst Biomed Res, Cambridge, MA USA; [Duvoix, Annelyse; Lomas, David A.] Univ Cambridge, Dept Med, Cambridge Inst Med Res, Cambridge CB2 2QQ, England; [Duvoix, Annelyse; Lomas, David A.] UCL, Fac Med Sci, Div Med, London, England; [Edwards, Lisa D.] GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC USA; [Miller, Bruce E.; Tal-Singer, Ruth; Mayer, Ruth J.] GlaxoSmithKline Res & Dev Ltd, King Of Prussia, PA USA; [Reynaert, Niki; Wouters, Emiel F. M.] Maastricht Univ, Med Ctr, Dept Resp Med, Maastricht, Netherlands; [Agusti, Alvar] Univ Barcelona, Inst Torax, Hosp Clin, IDIBAPS, Barcelona, Spain; [Fabbri, Leonardo M.] Univ Modena & Reggio Emilia, Dept Resp Dis, Modena, Italy; [Rames, Alex] Hoffmann La Roche AG, Basel, Switzerland; [Visvanathan, Sudha] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; [Rennard, Stephen I.] Univ Nebraska Med Ctr, Omaha, NE USA; [Jones, Paul] Univ London, London, England; [Parmar, Harsukh] EMD Serono, Billerica, MA USA; [MacNee, William] Queens Med Res Inst, Edinburgh, Midlothian, Scotland; [Wolff, Gerhard] Mitsubishi Tanabe, Warren, NJ USA","Pillai, SG (reprint author), Eli Lilly & Co, Lilly Corp Ctr, DC1522, Indianapolis, IN 46285 USA.","pillaisreekumar@yahoo.com","Reynaert, Niki/C-5491-2014",null,"GlaxoSmithKline; Roche Pharmaceuticals","The ECLIPSE study was supported by GlaxoSmithKline and the TESRA study was supported by Roche Pharmaceuticals.","Alexiou P, 2010, CURR MED CHEM, V17, P2232; Balasubbu S, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-158; Buckley ST, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/917108; Calfee CS, 2008, THORAX, V63, P1083, DOI 10.1136/thx.2008.095588; Castaldi PJ, 2011, AM J RESP CELL MOL, V45, P1147, DOI 10.1165/rcmb.2011-0055OC; Cockayne DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038629; Cotes J E, 1993, Eur Respir J Suppl, V16, P41; Coxson HO, 2013, LANCET RESP MED, V1, P129; Daborg J, 2010, J NEURAL TRANSM, V117, P861, DOI 10.1007/s00702-010-0437-0; de Torres JP, 2007, CHEST, V132, P1932, DOI 10.1378/chest.07-1490; Englert JM, 2008, AM J PATHOL, V172, P583, DOI 10.2353/ajpath.2008.070569; Falcone C, 2005, ARTERIOSCL THROM VAS, V25, P1032, DOI 10.1161/01.ATV.0000160342.20342.00; Ferhani N, 2010, AM J RESP CRIT CARE, V181, P917, DOI 10.1164/rccm.200903-0340OC; Fineschi S, 2013, AM J RESP CELL MOL, V48, P164, DOI 10.1165/rcmb.2012-0111OC; Forbes JM, 2011, DIABETOLOGIA, V54, P1032, DOI 10.1007/s00125-011-2058-z; Gaens KHJ, 2009, J CLIN ENDOCR METAB, V94, P5174, DOI 10.1210/jc.2009-1067; Gietema HA, 2011, ACAD RADIOL, V18, P661, DOI 10.1016/j.acra.2011.01.011; Gopal P, 2012, EUR J CLIN INVEST, V42, P807, DOI 10.1111/j.1365-2362.2012.02646.x; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Haruna A, 2010, CHEST, V138, P635, DOI 10.1378/chest.09-2836; Jones P. W., 2011, AM J RESP CRIT CARE, V183, pA6418; Li KS, 2010, J NEURAL TRANSM, V117, P97, DOI 10.1007/s00702-009-0334-6; Li Y, 2011, CANCER PREV RES, V4, P43, DOI 10.1158/1940-6207.CAPR-10-0151; Lu WX, 2011, CLIN ENDOCRINOL, V75, P470, DOI 10.1111/j.1365-2265.2011.04079.x; Makam M, 2009, P NATL ACAD SCI USA, V106, P5779, DOI 10.1073/pnas.0813410106; Miniati M, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-37; Pietzsch J, 2009, AMINO ACIDS, V36, P381, DOI 10.1007/s00726-008-0097-7; Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419; Pullerits R, 2005, ARTHRITIS RES THER, V7, pR817, DOI 10.1186/ar1749; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Queisser MA, 2008, AM J RESP CELL MOL, V39, P337, DOI 10.1165/rcmb.2007-0244OC; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Smith DJ, 2011, EUR RESPIR J, V37, P516, DOI 10.1183/09031936.00029310; Soler AM, 2011, NAT GENET, V43, P1082; Stoel BC, 2004, INVEST RADIOL, V39, P681, DOI 10.1097/00004424-200411000-00006; Stogsdill MP, 2013, AM J RESP CELL MOL, V49, P128, DOI 10.1165/rcmb.2013-0013OC; Suchankova P, 2012, J PSYCHIATR NEUROSCI, V37, P122, DOI 10.1503/jpn.110024; Sukkar MB, 2012, EUR RESPIR J, V39, P721, DOI 10.1183/09031936.00022011; Uchida T, 2006, AM J RESP CRIT CARE, V173, P1008, DOI 10.1164/rccm.200509-1477OC; Vestbo J, 2008, EUR RESPIR J, V31, P869, DOI 10.1183/09031936.00111707; Young RP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016476; Wilson DO, 2008, AM J RESP CRIT CARE, V178, P738, DOI 10.1164/rccm.200803-435OC; Wu LA, 2011, RESP MED, V105, P329, DOI 10.1016/j.rmed.2010.11.001; Young RP, 2011, EUR RESPIR J, V38, P743, DOI 10.1183/09031936.00041711",45,8,8,"AMER THORACIC SOC","NEW YORK","61 BROADWAY, FL 4, NEW YORK, NY 10006 USA","1073-449X","1535-4970",null,"AM J RESP CRIT CARE","Am. J. Respir. Crit. Care Med.","OCT 15",2013,188,8,null,null,null,null,948,957,null,"10.1164/rccm.201302-0247OC",null,10,"Critical Care Medicine; Respiratory System","General & Internal Medicine; Respiratory System","236IW","WOS:000325789700015"]
[null,null,null,null,"J","Eckert, C; Henze, G; Seeger, K; Hagedorn, N; Mann, G; Panzer-Grumayer, R; Peters, C; Klingebiel, T; Borkhardt, A; Schrappe, M; Schrauder, A; Escherich, G; Sramkova, L; Niggli, F; Hitzler, J; von Stackelberg, A",null,null,null,"Eckert, Cornelia; Henze, Guenter; Seeger, Karlheinz; Hagedorn, Nikola; Mann, Georg; Panzer-Gruemayer, Renate; Peters, Christina; Klingebiel, Thomas; Borkhardt, Arndt; Schrappe, Martin; Schrauder, Andre; Escherich, Gabriele; Sramkova, Lucie; Niggli, Felix; Hitzler, Johann; von Stackelberg, Arend",null,null,"Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"GENE REARRANGEMENTS; CLINICAL-SIGNIFICANCE; PROGNOSTIC-FACTORS; RECEPTOR GENES; COMPETING RISK; 1ST RELAPSE; IMMUNOGLOBULIN; TRIALS; TESTS; RARE","Purpose In children with intermediate risk of relapse of acute lymphoblastic leukemia (ALL), it is essential to identify patients in need of treatment intensification. We hypothesized that the prognosis of patients with unsatisfactory reduction of minimal residual disease (MRD) can be improved by allogeneic hematopoietic stem-cell transplantation (HSCT). Patients and Methods In the Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) 2002, patients with an MRD level of >= 10(-3) (n = 99) at the end of induction therapy were allocated to HSCT, whereas those with an MRD level less than 10(-3) (n = 109) continued to receive chemotherapy. MRD was quantified by real-time polymerase chain reaction for clone-specific T-cell receptor/immunoglobulin gene rearrangements. Results The probability of event-free survival for patients with MRD >= 10(-3) was 64% +/- 5% in ALL-REZ BFM 2002 compared with 18% +/- 7% in the predecessor study ALL-REZ BFM P95/96 (P < .001). This was mainly achieved by reducing the cumulative incidence of subsequent relapse (CIR) at 8 years from 59% +/- 9% to 27% +/- 5% (P < .001). The favorable prognosis of patients with MRD less than 10(-3) could be confirmed in those with a late combined or isolated bone marrow B-cell precursor (BCP) -ALL relapse (CIR, 20% +/- 5%), whereas patients with an early combined BCP-ALL relapse had an unfavorable outcome (CIR, 63% +/- 13%; P < .001). Conclusion Allogeneic HSCT markedly improved the prognosis of patients with intermediate risk of relapse of ALL and unsatisfactory MRD response. As a result, outcomes in this group approximated those of patients with favorable MRD response. Patients with early combined relapse require treatment intensification even in case of favorable MRD response, demonstrating the prognostic impact of time to relapse. (C) 2013 by American Society of Clinical Oncology","[Eckert, Cornelia; Henze, Guenter; Seeger, Karlheinz; Hagedorn, Nikola; von Stackelberg, Arend] Charite, D-13353 Berlin, Germany; [Klingebiel, Thomas] Goethe Univ Hosp Frankfurt, Hosp Children & Adolescents, Frankfurt, Germany; [Borkhardt, Arndt] Univ Dusseldorf, Dusseldorf, Germany; [Schrappe, Martin; Schrauder, Andre] Univ Schleswig Holstein, Kiel, Germany; [Escherich, Gabriele] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Mann, Georg; Panzer-Gruemayer, Renate; Peters, Christina] Med Univ Vienna, St Anna Childrens Res Inst & Childrens Hosp, Vienna, Austria; [Mann, Georg; Panzer-Gruemayer, Renate; Peters, Christina] Med Univ Vienna, St Anna Childrens Res Inst, Vienna, Austria; [Sramkova, Lucie] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Sramkova, Lucie] Univ Hosp Motol & Childhood Leukemia Invest Pragu, Prague, Czech Republic; [Niggli, Felix] Univ Childrens Hosp, Zurich, Switzerland; [Hitzler, Johann] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada","Eckert, C (reprint author), Charite, Dept Pediat Oncol Hematol, Augustenburger Pl 1, D-13353 Berlin, Germany.","cornelia.eckert@charite.de",null,null,"Deutsche Kinderkrebsstiftung; German Federal Ministry of Education and Research; Deutsche Jose Carreras Leukamiestiftung; Deutsche Krebshilfe e.V.","Supported by the Deutsche Kinderkrebsstiftung, which funded the minimal residual disease (MRD) studies and the Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) 2002; the German Federal Ministry of Education and Research, which funded the Competence Network Pediatric Oncology that collaborated on front-line MRD studies; the Deutsche Jose Carreras Leukamiestiftung, which funded the international principal investigator (A. v. S.); and the Deutsche Krebshilfe e.V., which supported the ALL-REZ BFM P95/96 clinical trial.",null,32,0,0,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X","1527-7755",null,"J CLIN ONCOL","J. Clin. Oncol.","JUL 20",2013,31,21,null,null,null,null,2736,"+",null,"10.1200/JCO.2012.48.5680",null,12,"Oncology","Oncology","301NJ","WOS:000330538700023"]
[null,null,null,null,"J","Connolly, SJ; Wallentin, L; Ezekowitz, MD; Eikelboom, J; Oldgren, J; Reilly, PA; Brueckmann, M; Pogue, J; Alings, M; Amerena, JV; Avezum, A; Baumgartner, I; Budaj, AJ; Chen, JH; Dans, AL; Darius, H; Di Pasquale, G; Ferreira, J; Flaker, GC; Flather, MD; Franzosi, MG; Golitsyn, SP; Halon, DA; Heidbuchel, H; Hohnloser, SH; Huber, K; Jansky, P; Kamensky, G; Keltai, M; Kim, SS; Lau, CP; Le Heuzey, JY; Lewis, BS; Liu, LL; Nanas, J; Omar, R; Pais, P; Pedersen, KE; Piegas, LS; Raev, D; Smith, PJ; Talajic, M; Tan, RS; Tanomsup, S; Toivonen, L; Vinereanu, D; Xavier, D; Zhu, J; Wang, SQ; Duffy, CO; Themeles, E; Yusuf, S",null,null,null,"Connolly, Stuart J.; Wallentin, Lars; Ezekowitz, Michael D.; Eikelboom, John; Oldgren, Jonas; Reilly, Paul A.; Brueckmann, Martina; Pogue, Janice; Alings, Marco; Amerena, John V.; Avezum, Alvaro; Baumgartner, Iris; Budaj, Andrzej J.; Chen, Jyh-Hong; Dans, Antonio L.; Darius, Harald; Di Pasquale, Giuseppe; Ferreira, Jorge; Flaker, Greg C.; Flather, Marcus D.; Franzosi, Maria Grazia; Golitsyn, Sergey P.; Halon, David A.; Heidbuchel, Hein; Hohnloser, Stefan H.; Huber, Kurt; Jansky, Petr; Kamensky, Gabriel; Keltai, Matyas; Kim, Sung Soon; Lau, Chu-Pak; Le Heuzey, Jean-Yves; Lewis, Basil S.; Liu, Lisheng; Nanas, John; Omar, Razali; Pais, Prem; Pedersen, Knud E.; Piegas, Leopoldo S.; Raev, Dimitar; Smith, Pal J.; Talajic, Mario; Tan, Ru San; Tanomsup, Supachai; Toivonen, Lauri; Vinereanu, Dragos; Xavier, Denis; Zhu, Jun; Wang, Susan Q.; Duffy, Christine O.; Themeles, Ellison; Yusuf, Salim",null,null,"The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study","CIRCULATION",null,null,"English","Article",null,null,null,null,null,"atrial fibrillation; dabigatran; hemorrhage; stroke","WARFARIN","Background During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses. Methods and Results Patients randomly assigned to dabigatran in RE-LY were eligible for the Long-term Multicenter Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) trial if they had not permanently discontinued study medication at the time of their final RE-LY study visit. Enrolled patients continued to receive the double-blind dabigatran dose received in RE-LY, for up to 28 months of follow up after RE-LY (median follow-up, 2.3 years). There were 5851 patients enrolled, representing 48% of patients originally randomly assigned to receive dabigatran in RE-LY and 86% of RELY-ABLE-eligible patients. Rates of stroke or systemic embolism were 1.46% and 1.60%/y on dabigatran 150 and 110 mg twice daily, respectively (hazard ratio, 0.91; 95% confidence interval, 0.69-1.20). Rates of major hemorrhage were 3.74% and 2.99%/y on dabigatran 150 and 110 mg (hazard ratio, 1.26; 95% confidence interval, 1.04-1.53). Rates of death were 3.02% and 3.10%/y (hazard ratio, 0.97; 95% confidence interval, 0.80-1.19). Rates of hemorrhagic stroke were 0.13% and 0.14%/y. Conclusions During 2.3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death. Clinical Trial Registration URL: . Unique identifier: NCT00808067.","[Connolly, Stuart J.; Eikelboom, John; Pogue, Janice; Themeles, Ellison; Yusuf, Salim] McMaster Univ & Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; [Wallentin, Lars; Oldgren, Jonas] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden; [Wallentin, Lars; Oldgren, Jonas] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Reilly, Paul A.; Wang, Susan Q.; Duffy, Christine O.] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; [Brueckmann, Martina] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany; [Brueckmann, Martina] Heidelberg Univ, Fac Med Mannheim, Mannheim, Germany; [Alings, Marco] WCN, Amphia Ziekenhuis, Breda, Netherlands; [Amerena, John V.] Deakin Univ, Geelong, Vic 3217, Australia; [Avezum, Alvaro; Piegas, Leopoldo S.] Dante Pazzanese Inst Cardiol, Sao Paulo, Brazil; [Baumgartner, Iris] Univ Hosp Bern, Swiss Cardiovasc Ctr, CH-3010 Bern, Switzerland; [Budaj, Andrzej J.] Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland; [Chen, Jyh-Hong] Natl Cheng Kung Univ, Tainan 70101, Taiwan; [Dans, Antonio L.] Univ Philippines, Manila, Philippines; [Darius, Harald] Vivantes Neukoelln Med Ctr, Berlin, Germany; [Di Pasquale, Giuseppe] Maggiore Hosp, Bologna, Italy; [Flather, Marcus D.] Lankenau Inst Med Res, Wynnewood, PA USA; [Flather, Marcus D.] Ctr Heart, Wynnewood, PA USA; [Franzosi, Maria Grazia] Ist Mario Negri, Milan, Italy; [Golitsyn, Sergey P.] Russian Cardiol Res Ctr, Moscow, Russia; [Halon, David A.; Lewis, Basil S.] Lady Davis Carmel Med Ctr, Haifa, Israel; [Heidbuchel, Hein] Univ Leuven, Louvain, Belgium; [Hohnloser, Stefan H.] Goethe Univ Frankfurt, Frankfurt, Germany; [Huber, Kurt] Wilhelminenhosp, Vienna, Austria; [Jansky, Petr] Univ Hosp Motol, Prague, Czech Republic; [Kamensky, Gabriel] Univ Hosp Bratislava, Bratislava, Slovakia; [Keltai, Matyas] Semmelweis Univ, Hungarian Inst Cardiol, H-1085 Budapest, Hungary; [Kim, Sung Soon] Yonsei Univ, Coll Med, Seoul, South Korea; [Lau, Chu-Pak] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China; [Le Heuzey, Jean-Yves] Univ Paris 05, AP HP, Hop Georges Pompidou, Paris, France; [Liu, Lisheng] Fu Wai Hosp, Chinese Hypertens League Inst, Beijing, Peoples R China; [Nanas, John] Univ Athens, Athens 11528, Greece; [Omar, Razali] Inst Jantung Negara, Kuala Lumpur, Malaysia; [Pais, Prem] St Johns Med Coll, Bangalore, Karnataka, India; [Pais, Prem] Res Inst, Bangalore, Karnataka, India; [Pedersen, Knud E.; Xavier, Denis] Odense Univ Hosp, DK-5000 Odense, Denmark; [Raev, Dimitar] Inst Med, Minist Interior, Sofia, Bulgaria; [Smith, Pal J.] Akershus Univ Hosp, Nordbyhagen, Norway; [Talajic, Mario] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada; [Tan, Ru San] Natl Heart Ctr, Singapore, Singapore; [Tanomsup, Supachai] Mahidol Univ, Ramathibodi Hosp, Bangkok, Thailand; [Toivonen, Lauri] Univ Helsinki Hosp, Helsinki, Finland; [Vinereanu, Dragos] Univ Med & Pharm Carol Davila, Bucharest, Romania; [Zhu, Jun] Fuwai Hosp, CAMS & PUMC, Beijing, Peoples R China","Connolly, SJ (reprint author), Populat Hlth Res Inst, 237 Barton St, East Hamilton, ON L8L 2X2, Canada.","connostu@phri.ca",null,null,"Boehringer Ingelheim","Drs Connolly, Yusuf, Ezekowitz, and Wallentin received research grant support from Boehringer Ingelheim and also received honoraria for consulting and lectures. Drs Reilly, Brueckmann, and Wang and Christine Duffy are employees of Boehringer Ingelheim. Dr Pogue and Ellison Themeles report no conclicts. The other authors received research support for participation in the study as national coordinators.",null,9,11,12,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322",null,null,"CIRCULATION","Circulation","JUL 16",2013,128,3,null,null,null,null,237,243,null,"10.1161/CIRCULATIONAHA.112.001139",null,7,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","Cardiovascular System & Cardiology","184NJ","WOS:000321897400018"]
[null,null,null,null,"J","Kaspers, GJL; Zimmermann, M; Reinhardt, D; Gibson, BES; Tamminga, RYJ; Aleinikova, O; Armendariz, H; Dworzak, M; Ha, SY; Hasle, H; Hovi, L; Maschan, A; Bertrand, Y; Leverger, GG; Razzouk, BI; Rizzari, C; Smisek, P; Smith, O; Stark, B; Creutzig, U",null,null,null,"Kaspers, Gertjan J. L.; Zimmermann, Martin; Reinhardt, Dirk; Gibson, Brenda E. S.; Tamminga, Rienk Y. J.; Aleinikova, Olga; Armendariz, Hortensia; Dworzak, Michael; Ha, Shau-Yin; Hasle, Henrik; Hovi, Liisa; Maschan, Alexei; Bertrand, Yves; Leverger, Guy G.; Razzouk, Bassem I.; Rizzari, Carmelo; Smisek, Petr; Smith, Owen; Stark, Batia; Creutzig, Ursula",null,null,"Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group","JOURNAL OF CLINICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ACUTE MYELOGENOUS LEUKEMIA; ANTHRACYCLINE CARDIOTOXICITY; INITIAL TREATMENT; PHASE-II; CHILDREN; AML; THERAPY; CYTARABINE; SURVIVAL; LONG","Purpose In pediatric relapsed acute myeloid leukemia (AML), optimal reinduction therapy is unknown. Studies suggest that liposomal daunorubicin (DNX; DaunoXome; Galen, Craigavon, United Kingdom) is effective and less cardiotoxic, which is important in this setting. These considerations led to a randomized phase III study by the International Berlin-Frankfurt-Munster Study Group. Patients and Methods Patients with relapsed or primary refractory non-French-American-British type M3 AML who were younger than 21 years of age were eligible. Patients were randomly assigned to fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) or to FLAG plus DNX in the first reinduction course. The primary end point was status of the bone marrow (BM) sampled shortly before the second course of chemotherapy (the day 28 BM). Data are presented according to intention-to-treat for all 394 randomly assigned patients (median follow-up, 4.0 years). Results The complete remission (CR) rate was 64%, and the 4-year probability of survival (pOS) was 38% (SE, 3%). The day 28 BM status (available in 359 patients) was good (<= 20% leukemic blasts) in 80% of patients randomly assigned to FLAG/DNX and 70% for patients randomly assigned to FLAG (P = .04). Concerning secondary end points, the CR rate was 69% with FLAG/DNX and 59% with FLAG (P = .07), but overall survival was similar. However, core-binding factor (CBF) AML treated with FLAG/DNX resulted in pOS of 82% versus 58% with FLAG (P = .04). Grade 3 to 4 toxicity was essentially similar in both groups. Conclusion DNX added to FLAG improves early treatment response in pediatric relapsed AML. Overall long-term survival was similar, but CBF-AML showed an improved survival with FLAG/DNX. International collaboration proved feasible and resulted in the best outcome for pediatric relapsed AML reported thus far. J Clin Oncol 31:599-607. (C) 2013 by American Society of Clinical Oncology","[Kaspers, Gertjan J. L.] Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlands; [Kaspers, Gertjan J. L.; Tamminga, Rienk Y. J.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Tamminga, Rienk Y. J.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9713 AV Groningen, Netherlands; [Zimmermann, Martin; Reinhardt, Dirk; Creutzig, Ursula] Hannover Med Sch, Berlin Frankfurt Munster Acute Myeloid Leukemia B, D-30623 Hannover, Germany; [Gibson, Brenda E. S.] Royal Hosp Sick Children, United Kingdom Childrens Canc & Leukaemia Grp UK, Glasgow G3 8SJ, Lanark, Scotland; [Aleinikova, Olga] Belarus Res Ctr Pediat Oncol & Hematol, Minsk Region, Byelarus; [Armendariz, Hortensia] Hosp Sor M Ludovica, Grp Argentino Tratamiento Leucemia Aguda, La Plata, Buenos Aires, Argentina; [Dworzak, Michael] Med Univ Vienna, St Anna Childrens Hosp, BFM AML Grp, Vienna, Austria; [Dworzak, Michael] Med Univ Vienna, Childrens Canc Res Inst, Vienna, Austria; [Ha, Shau-Yin] Queen Mary Hosp, Hong Kong Paediat Haematol & Oncol Study Grp, Pokfulam, Hong Kong, Peoples R China; [Hasle, Henrik] Aarhus Univ, Hosp Skejby, Nord Soc Pediat Hematol & Oncol NOPHO, DK-8000 Aarhus C, Denmark; [Hovi, Liisa] Univ Helsinki, NOPHO, Hosp Children & Adolescents, Helsinki, Finland; [Maschan, Alexei] Russian Inst Pediat Hematol, Moscow, Russia; [Bertrand, Yves] European Org Res Treatment Canc, Inst Hematol & Oncol Pediat, Childrens Leukemia Cooperat Grp, Lyon, France; [Leverger, Guy G.] Hop Enfants Armand Trousseau, Unite Oncohematol Pediat, French Acute Lymphoblast Leukemia Study Grp, Paris, France; [Razzouk, Bassem I.] St Judes Children Res Hosp, Memphis, TN USA; [Razzouk, Bassem I.] Peyton Manning Childrens Hosp St Vincent, Childrens Ctr Canc & Blood Dis, Indianapolis, IN USA; [Rizzari, Carmelo] S Gerardo Hosp, Assoc Italiana Ematol Oncol Pediat, Monza, Italy; [Smisek, Petr] Charles Univ Prague, Univ Hosp Motol, Czech Republ Pediat Hematol Working Grp, Prague, Czech Republic; [Smith, Owen] Our Ladys Childrens Hosp, UK CCLG, Dublin, Ireland; [Stark, Batia] Schneider Childrens Med Ctr Israel, Ctr Pediat Hematol Oncol, Petah Tiqwa, Israel","Kaspers, GJL (reprint author), Vrije Univ Amsterdam, Med Ctr, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.","gjl.kaspers@vumc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056",null,null,null,33,8,9,"AMER SOC CLINICAL ONCOLOGY","ALEXANDRIA","2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA","0732-183X",null,null,"J CLIN ONCOL","J. Clin. Oncol.","FEB 10",2013,31,5,null,null,null,null,599,607,null,"10.1200/JCO.2012.43.7384",null,9,"Oncology","Oncology","088FY","WOS:000314820400018"]
[null,null,null,null,"J","Janousek, J; van Geldorp, IE; Krupickova, S; Rosenthal, E; Nugent, K; Tomaske, M; Fruh, A; Elders, J; Hiippala, A; Kerst, G; Gebauer, RA; Kubus, P; Frias, P; Gabbarini, F; Clur, SA; Nagel, B; Ganame, J; Papagiannis, J; Marek, J; Tisma-Dupanovic, S; Tsao, S; Nurnberg, JH; Wren, C; Friedberg, M; de Guillebon, M; Volaufova, J; Prinzen, FW; Delhaas, T",null,null,null,"Janousek, Jan; van Geldorp, Irene E.; Krupickova, Sylvia; Rosenthal, Eric; Nugent, Kelly; Tomaske, Maren; Fruh, Andreas; Elders, Jan; Hiippala, Anita; Kerst, Gunter; Gebauer, Roman A.; Kubus, Peter; Frias, Patrick; Gabbarini, Fulvio; Clur, Sally-Ann; Nagel, Bert; Ganame, Javier; Papagiannis, John; Marek, Jan; Tisma-Dupanovic, Svjetlana; Tsao, Sabrina; Nuernberg, Jan-Hendrik; Wren, Christopher; Friedberg, Mark; de Guillebon, Maxime; Volaufova, Julia; Prinzen, Frits W.; Delhaas, Tammo",null,"Assoc European Pediat Cardiology","Permanent Cardiac Pacing in Children: Choosing the Optimal Pacing Site A Multicenter Study","CIRCULATION",null,null,"English","Article",null,null,null,null,null,"heart block; heart failure; pacemakers; pacing; pediatrics","COMPLETE ATRIOVENTRICULAR-BLOCK; LEFT-VENTRICULAR FUNCTION; RESYNCHRONIZATION THERAPY; HEART-FAILURE; DUAL-CHAMBER; YOUNG; ATRIAL; TRIAL; DYSSYNCHRONY; SYNCHRONY","Background-We evaluated the effects of the site of ventricular pacing on left ventricular (LV) synchrony and function in children requiring permanent pacing. Methods and Results-One hundred seventy-eight children (aged < 18 years) from 21 centers with atrioventricular block and a structurally normal heart undergoing permanent pacing were studied cross-sectionally. Median age at evaluation was 11.2 (interquartile range, 6.3-15.0) years. Median pacing duration was 5.4 (interquartile range, 3.1-8.8) years. Pacing sites were the free wall of the right ventricular (RV) outflow tract (n=8), lateral RV (n=44), RV apex (n=61), RV septum (n=29), LV apex (n=12), LV midlateral wall (n=17), and LV base (n=7). LV synchrony, pump function, and contraction efficiency were significantly affected by pacing site and were superior in children paced at the LV apex/LV midlateral wall. LV dyssynchrony correlated inversely with LV ejection fraction (R=0.80, P=0.031). Pacing from the RV outflow tract/lateral RV predicted significantly decreased LV function (LV ejection fraction < 45%; odds ratio, 10.72; confidence interval, 2.07-55.60; P=0.005), whereas LV apex/LV midlateral wall pacing was associated with preserved LV function (LV ejection fraction >= 55%; odds ratio, 8.26; confidence interval, 1.46-47.62; P=0.018). Presence of maternal autoantibodies, gender, age at implantation, duration of pacing, DDD mode, and QRS duration had no significant impact on LV ejection fraction. Conclusions-The site of ventricular pacing has a major impact on LV mechanical synchrony, efficiency, and pump function in children who require lifelong pacing. Of the sites studied, LV apex/LV midlateral wall pacing has the greatest potential to prevent pacing-induced reduction of cardiac pump function. (Circulation. 2013;127:613-623.)","[Janousek, Jan; Krupickova, Sylvia; Kubus, Peter] Univ Hosp Motol, Childrens Heart Ctr, Prague 15006 5, Czech Republic; [van Geldorp, Irene E.] Maastricht Univ, Med Ctr, Cardiovasc Res Inst Maastricht, Dept Pediat Cardiol, Maastricht, Netherlands; [Rosenthal, Eric; Nugent, Kelly] Evelina Childrens Hosp, London, England; [Tomaske, Maren] Univ Childrens Hosp, Zurich, Switzerland; [Fruh, Andreas] Oslo Univ Hosp, Oslo, Norway; [Elders, Jan] Radboud Univ Nijmegen Med Ctr, Dept Cardiol, Nijmegen, Netherlands; [Hiippala, Anita] Univ Helsinki, Childrens Hosp, Dept Pediat Cardiol, Helsinki, Finland; [Hiippala, Anita] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Kerst, Gunter] Univ Klin Kindermed & Jugendmed, Tubingen, Germany; [Gebauer, Roman A.] Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, D-04109 Leipzig, Germany; [Frias, Patrick] Childrens Hosp Atlanta, Dept Pediat Cardiol, Atlanta, GA USA; [Gabbarini, Fulvio] Childrens Hosp Regina Margherita, Div Pediat Cardiol, Turin, Italy; [Clur, Sally-Ann] Emma Childrens Hosp, Acad Med Ctr, Amsterdam, Netherlands; [Clur, Sally-Ann] Ctr Congenital Heart Anomalies Amsterdam Leiden, Leiden, Netherlands; [Nagel, Bert] Med Univ Graz, Childrens Hosp, Div Pediat Cardiol, Graz, Austria; [Ganame, Javier] Univ Hosp Leuven, Dept Pediat Cardiol, Louvain, Belgium; [Papagiannis, John] Mitera Childrens Hosp, Div Pediat Cardiol, Maroussi, Greece; [Marek, Jan] Great Ormond St Hosp Sick Children, Dept Pediat Cardiol, London, England; [Tisma-Dupanovic, Svjetlana] Childrens Mercy Hosp & Clin, Cardiol Sect, Kansas City, MO USA; [Tsao, Sabrina] Childrens Mem Hosp, Div Cardiol, Chicago, IL 60614 USA; [Nuernberg, Jan-Hendrik] Klinikum Links Weser, Abt Pediat Cardiol, Bremen, Germany; [Wren, Christopher] Natl Hlth Serv Fdn Trust, Newcastle Upon Tyne Hosp, Dept Pediat Cardiol, Newcastle Upon Tyne, Tyne & Wear, England; [Friedberg, Mark] Hosp Sick Children, Div Cardiol, Toronto, ON M5G 1X8, Canada; [de Guillebon, Maxime] Bordeaux Univ Hosp, Hop Cardiol Haut Leveque, Dept Congenital Heart Dis, Bordeaux, France; [Volaufova, Julia] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, Biostat Program, New Orleans, LA USA; [Prinzen, Frits W.] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Physiol, Maastricht, Netherlands; [Delhaas, Tammo] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Biomed Engn, Maastricht, Netherlands","Janousek, J (reprint author), Univ Hosp Motol, Childrens Heart Ctr, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.janousek@lfmotol.cuni.cz","Rosenthal, Eric/I-7469-2012","Rosenthal, Eric/0000-0003-3030-9749","Internal Grant Agency of the Ministry of Health of the Czech Republic [NT 12321-3/2011]; Project for Conceptual Development of Research Organization (Ministry of Health, Czech Republic) [00064203]; Dr E. Dekker Grant for Research Fellow in Pediatric Cardiology, Dutch Heart Foundation [NHS-2010T078]; Medtronic; Boston Scientific; MSD; EBR Systems; Proteus Biomedical","Drs Janousek, Kubus, and Krupickova were supported by a grant of the Internal Grant Agency of the Ministry of Health of the Czech Republic (NT 12321-3/2011) and by the Project for Conceptual Development of Research Organization (Ministry of Health, Czech Republic) grant 00064203 (University Hospital Motol, Prague, Czech Republic). Dr van Geldorp was supported by a Dr E. Dekker Grant for Research Fellow in Pediatric Cardiology, Dutch Heart Foundation (NHS-2010T078).Dr Prinzen received research grants from Medtronic, Boston Scientific, MSD, EBR Systems, and Proteus Biomedical.",null,35,2,2,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0009-7322",null,null,"CIRCULATION","Circulation","FEB 5",2013,127,5,null,null,null,null,613,623,null,"10.1161/CIRCULATIONAHA.112.115428",null,11,"Cardiac & Cardiovascular Systems; Peripheral Vascular Disease","Cardiovascular System & Cardiology","086NN","WOS:000314691700015"]
[null,null,null,null,"J","Pruhova, S; Dusatkova, P; Neumann, D; Hollay, E; Cinek, O; Lebl, J; Sumnik, Z",null,null,null,"Pruhova, Stepanka; Dusatkova, Petra; Neumann, David; Hollay, Erik; Cinek, Ondrej; Lebl, Jan; Sumnik, Zdenek",null,null,"Two Cases of Diabetic Ketoacidosis in HNF1A-MODY Linked to Severe Dehydration: Is it time to change the diagnostic criteria for MODY?","DIABETES CARE",null,null,"English","Article",null,null,null,null,null,null,"MANAGEMENT","OBJECTIVE Hepatocyte nuclear factor-1A maturity-onset diabetes of the young (HNF1A-MODY) is a monogenic form of diabetes caused by heterozygous mutations in HNF1A. Currently, a history of diabetic ketoacidosis (DKA) is an exclusion criterion for genetic testing for MODY.HISTORY AND EXAMINATION In this article, we describe two unrelated patients aged 17 and 24 years with severe DKA developed several years after the diagnosis of HNF1A-MODY.INVESTIGATION Both patients were treated with insulin, but their metabolic control was poor (HbA(1c) 15%, 140 mmol/mol and 13%, 119 mmol/mol, respectively) due to noncompliance and missed insulin injections. In both patients, DKA followed a course of recurrent vomiting with dehydration and prerenal acute kidney injury. Their glycemia, blood pH, and base excess at admission were 97 mmol/L [1,748 mg/dL], 6.80, and -33 mmol/L (patient 1) and 34 mmol/L [613 mg/dL], 7.03, and -14 mmol/L (patient 2).CONCLUSIONS This anecdotal observation supports the notion that a history of DKA does not exclude MODY.","[Pruhova, Stepanka; Dusatkova, Petra; Cinek, Ondrej; Lebl, Jan; Sumnik, Zdenek] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic; [Pruhova, Stepanka; Dusatkova, Petra; Hollay, Erik; Cinek, Ondrej; Lebl, Jan; Sumnik, Zdenek] Univ Hosp Motol, Prague, Czech Republic; [Neumann, David] Charles Univ Prague, Fac Med Hradec Kralove, Dept Paediat, Hradec Kralove, Czech Republic; [Neumann, David] Univ Hosp, Hradec Kralove, Czech Republic; [Hollay, Erik] Charles Univ Prague, Fac Med 2, Dept Internal Med, Prague, Czech Republic","Pruhova, S (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic.","stepanka.pruhova@fnmotol.cz",null,null,"Czech Ministry of Health [NT 11402]; Project for the Conceptual Development of Research Organisation (University Hospital Motol, Prague, Czech Republic) [00064203/6001]","The study was supported by a grant from the Czech Ministry of Health (grant NT 11402) and by the Project for the Conceptual Development of Research Organisation 00064203/6001 (University Hospital Motol, Prague, Czech Republic).",null,5,0,0,"AMER DIABETES ASSOC","ALEXANDRIA","1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA","0149-5992",null,null,"DIABETES CARE","Diabetes Care","SEP",2013,36,9,null,null,null,null,2573,2574,null,"10.2337/dc13-0058",null,2,"Endocrinology & Metabolism","Endocrinology & Metabolism","205CZ","WOS:000323420200041"]
[null,null,null,null,"J","Babjuk, M; Burger, M; Zigeuner, R; Shariat, SF; van Rhijn, BWG; Comperat, E; Sylvester, RJ; Kaasinen, E; Bohle, A; Redorta, JP; Roupret, M",null,null,null,"Babjuk, Marko; Burger, Maximilian; Zigeuner, Richard; Shariat, Shahrokh F.; van Rhijn, Bas W. G.; Comperat, Eva; Sylvester, Richard J.; Kaasinen, Eero; Boehle, Andreas; Palou Redorta, Joan; Roupret, Morgan",null,null,"EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013","EUROPEAN UROLOGY",null,null,"English","Article",null,null,null,null,null,"Bacillus Calmette-Guerin (BCG); Bladder cancer; Cystectomy; Cystoscopy; Diagnosis; EAU Guidelines; Follow-up; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR); Urothelial carcinoma","BACILLUS-CALMETTE-GUERIN; TRANSITIONAL-CELL CARCINOMA; RANDOMIZED CLINICAL-TRIALS; INTRAVESICAL MITOMYCIN-C; IMMEDIATE POSTOPERATIVE INSTILLATION; T1 PAPILLARY CARCINOMA; FOLLOW-UP CYSTOSCOPY; CARE PROTEOMIC ASSAY; LONG-TERM EFFICACY; PHASE-III TRIAL","Context: The first European Association of Urology (EAU) guidelines on bladder cancer were published in 2002 [1]. Since then, the guidelines have been continuously updated. Objective: To present the 2013 EAU guidelines on non-muscle-invasive bladder cancer (NMIBC). Evidence acquisition: Literature published between 2010 and 2012 on the diagnosis and treatment of NMIBC was systematically reviewed. Previous guidelines were updated, and the levels of evidence and grades of recommendation were assigned. Evidence synthesis: Tumours staged as Ta, T1, or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection (TUR) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TUR is essential for the patient's prognosis. Where the initial resection is incomplete, where there is no muscle in the specimen, or where a high-grade or T1 tumour is detected, a second TUR should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the EORTC scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups is pivotal to recommending adjuvant treatment. For patients with a low-risk tumour, one immediate instillation of chemotherapy is recommended. Patients with an intermediate-risk tumour should receive one immediate instillation of chemotherapy followed by 1 yr of full-dose bacillus Calmette-Guerin (BCG) intravesical immunotherapy or by further instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at highest risk of tumour progression, immediate radical cystectomy should be considered. Cystectomy is recommended in BCG-refractory tumours. The long version of the guidelines is available from the EAU Web site: http://www.uroweb.org/guidelines/. Conclusions: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. Patient summary: The EAU Panel on Non-muscle Invasive Bladder Cancer released an updated version of their guidelines. Current clinical studies support patient selection into different risk groups; low, intermediate and high risk. These risk groups indicate the likelihood of the development of a new (recurrent) cancer after initial treatment (endoscopic resection) or progression to more aggressive (muscle-invasive) bladder cancer and are most important for the decision to provide chemo-or immunotherapy (bladder installations). Surgical removal of the bladder (radical cystectomy) should only be considered in patients who have failed chemo-or immunotherapy, or who are in the highest risk group for progression. (C) 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.","[Babjuk, Marko] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, Prague 15006 5, Czech Republic; [Burger, Maximilian] Univ Wurzburg, Med Ctr, Dept Urol & Paediat Urol, D-97070 Wurzburg, Germany; [Zigeuner, Richard] Med Univ Graz, Dept Urol, Graz, Austria; [Shariat, Shahrokh F.] Med Univ Vienna, Vienna Gen Hosp, Dept Urol, Vienna, Austria; [van Rhijn, Bas W. G.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg Oncol Urol, Amsterdam, Netherlands; [Comperat, Eva] UPMC, Hop Pitie Salpetriere, Dept Pathol, Paris, France; [Sylvester, Richard J.] EORTC Headquarters, Dept Biostat, Brussels, Belgium; [Kaasinen, Eero] Hyvinkaa Hosp, Dept Surg, Hyvinkaa, Finland; [Boehle, Andreas] HELIOS Agnes Karll Krankenhaus, Dept Urol, Bad Schwartau, Germany; [Palou Redorta, Joan] Univ Autonoma Barcelona, Dept Urol, Fundacio Puigvert, E-08193 Barcelona, Spain; [Roupret, Morgan] Hop La Pitie Salpetriere, AP HP, Serv Urol, F-75013 Paris, France; [Roupret, Morgan] Univ Paris 06, GRC5, ONCOTYPE Uro, Inst Univ Cancerol, F-75005 Paris, France","Babjuk, M (reprint author), Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, VUvalu 84, Prague 15006 5, Czech Republic.","marek.babjuk@lfmotol.cuni.cz",null,null,"Bayer Healthcare; Pfizer; Roche; Novartis; GSK; Astellas; Pfizer Foundation","Marko Babjuk certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Marko Babjuk receives company speaker honoraria from GE Healthcare and GSK. Maximilian Burger is a company consultant for Photocure ASA, Astellas, and Ipsen Pharma. He receives company speaker honoraria from Ipsen Pharma, Astellas, Springer, and Novartis. He participates in trials for Photocure SA and Ipsen Pharma. Richard Zigeuner receives company speaker honoraria from Pfizer, Bayer Healthcare, Roche, Novartis, GSK, and Amgen. He receives fellowships and travel grants from Bayer Healthcare, Pfizer, Roche, Novartis, GSK, and Astellas. He receives research grants from Bayer Healthcare. Shahrokh F. Shariat is a company consultant for Ferring Pharmaceuticals and participates in trials for Alere Inc. on NMP22. He is the inventor or co-inventor of the following patents: Shariat S, Slawin K, inventors. Methods to determine prognosis after therapy for prostate cancer. US patent application serial number: Docket # 60/266,976. Filed May 31, 2001; Shariat S, Lerner S, Slawin K, inventors. Methods to determine prognosis after therapy for bladder cancer. US patent application serial number: Docket # 675.003 US1. Filed June 1, 2001; Shariat S, Slawin K, Kattan M, Scardino P, inventors. Pre- and posttreatment nomograms for predicting recurrence in patients with clinically localized prostate cancer that includes the blood markers interlukin-6 soluble receptor and transforming growth. Slawin K, Kattan M, Shariat S, Stephenson A, Scardino P, inventors. Nomogram for predicting outcome of salvage radiotherapy for suspected local recurrence of prostate cancer after radical prostatectomy. US patent applcation serial number: Docket #. Fi; Shariat S, inventor. Solube Fas: a promising novel urinary marker for the detection of bladder transitional cell carcinoma (UTSD: 1666). US patent application serial in process. Bas W.G. van Rhijn and Eva Comperat have nothing to disclose. Richard J. Sylvester is a company consultant for Spectrum and Allergan. Eero Kaasinen receives research grants from Pfizer Foundation and Pfizer (for a research group). Andreas Bohle receives company speaker honoraria from Sanofi-Aventis, Medac, Bard, and Fresenius. Joan Palou Redorta is a company consultant for Sanofi-Pasteur and Allergan, receives company speaker honoraria from Sanofi-Pasteur and General Electric, and participates in trials for General Electric. Morgan Roupret is a company consultant for Lilly and GSK; he participates in trials for Takeda.",null,108,11,11,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","OCT",2013,64,4,null,null,null,null,639,653,null,"10.1016/j.eururo.2013.06.003",null,15,"Urology & Nephrology","Urology & Nephrology","211VQ","WOS:000323939900028"]
[null,null,null,null,"J","Malina, M; Gulati, A; Bagga, A; Majid, MA; Simkova, E; Schaefer, F",null,null,null,"Malina, Michal; Gulati, Ashima; Bagga, Arvind; Majid, Mohammad A.; Simkova, Eva; Schaefer, Franz",null,null,"Peripheral Gangrene in Children With Atypical Hemolytic Uremic Syndrome","PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"hemolytic uremic syndrome; complement membrane attack complex","THROMBOTIC THROMBOCYTOPENIC PURPURA; COMPLEMENT; ECULIZUMAB","Atypical hemolytic uremic syndrome (aHUS) is a thrombotic micro-angiopathy with severe clinical manifestation, frequent recurrence, and poor long-term prognosis. It is usually caused by abnormalities in complement regulation. We report 2 cases of children affected by a catastrophic extrarenal complication. A 4-year-old Indian girl developed gangrene of the finger tips 2 days after initial presentation of aHUS. Factor H autoantibodies were identified. Renal function continued to decline despite daily plasma exchanges, and she was started on peritoneal dialysis 5 days after admission. The distal tips of the left hand remained gangrenous with a line of demarcation. Three weeks later, she did not return for follow-up and died at home because of dialysis-related complications. An Arabic girl developed end-stage renal disease due to aHUS in the fourth month after birth. A de novo activating C3 mutation was found. At age 9 months, she suddenly developed ischemic changes in fingers of both hands and several toes. The lesions progressed, and several finger tips became gangrenous despite intense plasma exchange therapy. The decision was made to administer complement blocking therapy with the C5 antibody eculizumab. All nonnecrotic digits rapidly regained perfusion. The 3 already gangrenous fingers healed with loss of the end phalanges. During maintenance, eculizumab aHUS activity subsided completely and some late recovery of renal function was observed. aHUS may present by thrombotic macroangiopathy of small peripheral arteries. Eculizumab appears effective in preserving tissue viability if administered before gangrene occurs and should be considered as first-line rescue therapy in such cases. Pediatrics 2013; 131:e331-e335","[Malina, Michal; Schaefer, Franz] Ctr Pediat & Adolescent Med, Div Pediat Nephrol, D-69120 Heidelberg, Germany; [Malina, Michal] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Malina, Michal] Univ Hosp Motol, Prague, Czech Republic; [Gulati, Ashima; Bagga, Arvind] All India Inst Med Sci, Dept Pediat, New Delhi, India; [Majid, Mohammad A.; Simkova, Eva] Dubai Hosp, Dept Pediat, Dubai, U Arab Emirates","Schaefer, F (reprint author), Ctr Pediat & Adolescent Med, Div Pediat Nephrol, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.","franz.schaefer@med.uni-heidelberg.de",null,null,"EU Commission for rare kidney disease research (EURenOmics)","This work was supported by a grant of the EU Commission for rare kidney disease research (EURenOmics).",null,19,3,4,"AMER ACAD PEDIATRICS","ELK GROVE VILLAGE","141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA","0031-4005",null,null,"PEDIATRICS","Pediatrics","JAN",2013,131,1,null,null,null,null,"E331","E335",null,"10.1542/peds.2012-0903",null,5,"Pediatrics","Pediatrics","063PO","WOS:000313012400042"]
[null,null,null,null,"J","Rink, M; Xylinas, E; Margulis, V; Cha, EK; Ehdaie, B; Raman, JD; Chun, FK; Matsumoto, K; Lotan, Y; Furberg, H; Babjuk, M; Pycha, A; Wood, CG; Karakiewicz, PI; Fisch, M; Scherr, DS; Shariat, SF",null,null,null,"Rink, Michael; Xylinas, Evanguelos; Margulis, Vitaly; Cha, Eugene K.; Ehdaie, Behfar; Raman, Jay D.; Chun, Felix K.; Matsumoto, Kazumasa; Lotan, Yair; Furberg, Helena; Babjuk, Marek; Pycha, Armin; Wood, Christopher G.; Karakiewicz, Pierre I.; Fisch, Margit; Scherr, Douglas S.; Shariat, Shahrokh F.",null,"Upper Tract Urothelial Carcinoma C","Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy","EUROPEAN UROLOGY",null,null,"English","Article",null,null,null,null,null,"Smoking; Urothelial carcinoma; Transitional cell carcinoma; Upper urinary tract; Radical nephroureterectomy; Dose-response relationship; Recurrence; Survival; Prognosis","UPPER URINARY-TRACT; TRANSITIONAL-CELL-CARCINOMA; CANCER-SPECIFIC SURVIVAL; INVASIVE BLADDER-CANCER; CIGARETTE-SMOKING; RECURRENCE; RISK; STAGE; GRADE","Background: Cigarette smoking is a common risk factor for developing upper tract urothelial carcinoma (UTUC). Objective: To assess the impact of cigarette smoking status, cumulative smoking exposure, and time from cessation on oncologic UTUC outcomes in patients treated with radical nephroureterectomy (RNU). Design, setting, and participants: A total of 864 patients underwent RNU at five institutions. The median follow-up in this retrospective study was 50 mo. Smoking history included smoking status, quantity of cigarettes per day (CPD), duration in years, and years from smoking cessation. The cumulative smoking exposure was categorized as light-short-term (<= 19 CPD and <= 19.9 yr), moderate (all combinations except light-short-term and heavy-long-term), and heavy-long-term (>= 20 CPD and >= 20 yr). Interventions: RNU with or without lymph node dissection. No patient received neoadjuvant chemotherapy. Outcome measurements and statistical analysis: Univariable and multivariable logistic regression and competing risk regression analyses assessed the effects of smoking on oncologic outcomes. Results and limitations: A total of 244 patients (28.2%) never smoked; 297 (34.4%) and 323 (37.4%) were former and current smokers, respectively. Among smokers, 87 (10.1%), 331 (38.3%), and 202 (23.4%) were light-short-term, moderate, and heavy-long-term smokers, respectively. Current smoking status, smoking >= 20 CPD, >= 20 yr, and heavy-long-term smoking were associated with advanced disease (p values <= 0.004), greater likelihood of disease recurrence (p values <= 0.01), and cancer-specific mortality (p values <= 0.05) on multivariable analyses that adjusted for standard features. Patients who quit smoking >= 10 yr prior to RNU did not differ from never smokers regarding advanced tumor stages, disease recurrence, and cancer-specific mortality, but they had better oncologic outcomes then current smokers and those patients who quit smoking <10 yr prior to RNU. The study is limited by its retrospective nature. Conclusions: Cigarette smoking is significantly associated with advanced disease stages, disease recurrence, and cancer-specific mortality in patients treated with RNU for UTUC. Current smokers and those with a heavy and long-term smoking exposure have the highest risk for poor oncologic outcomes. Smoking cessation >10 yr prior to RNU seems to mitigate some detrimental effects. These results underscore the need for smoking cessation and prevention programs. (C) 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.","[Rink, Michael; Xylinas, Evanguelos; Cha, Eugene K.; Ehdaie, Behfar; Scherr, Douglas S.; Shariat, Shahrokh F.] Weill Cornell Med Coll, New York Presbyterian Hosp, Dept Urol, New York, NY USA; [Rink, Michael; Chun, Felix K.; Fisch, Margit] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany; [Xylinas, Evanguelos] Univ Paris 05, Dept Urol, Cochin Hosp, APHP, Paris, France; [Margulis, Vitaly; Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Raman, Jay D.] Penn State Milton S Hershey Med Ctr, Dept Urol, Hershey, PA USA; [Matsumoto, Kazumasa] Kitasato Univ, Sch Med, Dept Urol, Sagamihara, Kanagawa 228, Japan; [Furberg, Helena] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; [Babjuk, Marek] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, Prague, Czech Republic; [Pycha, Armin] Gen Hosp Bolzano, Dept Urol, Bolzano, Italy; [Wood, Christopher G.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; [Karakiewicz, Pierre I.] Univ Montreal, Dept Urol, Montreal, PQ, Canada; [Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Med Oncol, New York, NY USA","Shariat, SF (reprint author), Cornell Univ, Weill Med Coll, Dept Urol, New York Presbyterian Hosp, 525 East 68th St,Box 94,Starr 900, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,"Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust","Shahrokh F. Shariat certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Michael Rink is a speaker for Pfizer Pharma. He is supported by the Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust. Shahrokh F. Shariat is on the advisory board of Ferring Pharma. The other authors have nothing to disclose.",null,30,5,5,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","JUN",2013,63,6,null,null,null,null,1082,1090,null,"10.1016/j.eururo.2012.06.029",null,9,"Urology & Nephrology","Urology & Nephrology","146TT","WOS:000319115900022"]
[null,null,null,null,"J","Rink, M; Furberg, H; Zabor, EC; Xylinas, E; Babjuk, M; Pycha, A; Lotan, Y; Karakiewicz, PI; Novara, G; Robinson, BD; Montorsi, F; Chun, FK; Scherr, DS; Shariat, SF",null,null,null,"Rink, Michael; Furberg, Helena; Zabor, Emily C.; Xylinas, Evanguelos; Babjuk, Marko; Pycha, Armin; Lotan, Yair; Karakiewicz, Pierre I.; Novara, Giacomo; Robinson, Brian D.; Montorsi, Francesco; Chun, Felix K.; Scherr, Douglas S.; Shariat, Shahrokh F.",null,null,"Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Non-muscle-invasive Bladder Cancer","EUROPEAN UROLOGY",null,null,"English","Article",null,null,null,null,null,"Smoking; Urothelial carcinoma; Non-muscle-invasive bladder cancer; Recurrence; Progression; Survival; Dose-response relationship","TRANSITIONAL-CELL-CARCINOMA; RANDOMIZED CLINICAL-TRIALS; CIGARETTE-SMOKING; UROTHELIAL CARCINOMA; UNITED-STATES; RISK; RECURRENCE; STAGE; PROGRESSION; METAANALYSIS","Background: Cigarette smoking is the best-established risk factor for urothelial carcinoma (UC) development, but the impact on oncologic outcomes remains poorly understood. Objective: To analyse the effects of smoking status, cumulative exposure, and time from smoking cessation on the prognosis of patients with primary non-muscle-invasive bladder cancer (NMIBC). Design, setting, and participants: We collected smoking data from 2043 patients with primary NMIBC. Smoking variables included smoking status, average number of cigarettes smoked per day (CPD), duration in years, and time since smoking cessation. Lifetime cumulative smoking exposure was categorised as light short term (<= 19 CPD, <= 19.9 yr), light long term (<= 19 CPD, >= 20 yr), heavy short term (>= 20 CPD, <= 19.9 yr) and heavy long term (>= 20 CPD, >= 20 yr). The median follow-up in this retrospective study was 49 mo. Interventions: Transurethral resection of the bladder with or without intravesical instillation therapy. Outcome measurements and statistical analysis: Univariable and multivariable logistic regression and competing risk regression analyses assessed the effects of smoking on outcomes. Results and limitations: There was no difference in clinicopathologic factors among never (24%), former (47%), and current smokers (29%). Smoking status was associated with the cumulative incidence of disease progression in multivariable analysis (p = 0.003); current smokers had the highest cumulative incidences. Among current and former smokers, cumulative smoking exposure was associated with disease recurrence (p < 0.001), progression (p < 0.001), and overall survival (p < 0.001) in multivariable analyses that adjusted for the effects of standard clinicopathologic factors and smoking status; heavy long-term smokers had the worst outcomes, followed by light long-term, heavy short-term, and light short-term smokers. Smoking cessation > 10 yr reduced the risk of disease recurrence (hazard ratio [HR]: 0.66; 95% confidence interval [CI], 0.52-0.84; p < 0.001) and progression (HR: 0.42; 95% CI, 0.22-0.83; p = 0.036) in multivariable analyses. The study is limited by its retrospective nature. Conclusions: Smoking status and a higher cumulative smoking exposure are associated with worse prognosis in patients with NMIBC. Smoking cessation >10 yr abrogates this detrimental effect. These findings underscore the need for integrated smoking cessation and prevention programmes in the management of NMIBC patients. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.","[Rink, Michael; Xylinas, Evanguelos; Robinson, Brian D.; Scherr, Douglas S.; Shariat, Shahrokh F.] New York Presbyterian Hosp, Dept Urol, Weill Cornell Med Coll, New York, NY USA; [Rink, Michael; Chun, Felix K.] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany; [Furberg, Helena; Zabor, Emily C.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; [Xylinas, Evanguelos] Paris Descartes Univ, Cochin Hosp, APHP, Dept Urol, Paris, France; [Babjuk, Marko] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, Prague, Czech Republic; [Pycha, Armin] Gen Hosp Bolzano, Dept Urol, Bolzano, Italy; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Karakiewicz, Pierre I.] Univ Montreal, Dept Urol, Montreal, PQ, Canada; [Novara, Giacomo] Univ Padua, Dept Urol, Padua, Italy; [Robinson, Brian D.] New York Presbyterian Hosp, Dept Pathol & Lab Med, Weill Cornell Med Coll, New York, NY USA; [Montorsi, Francesco] Univ Vita Salute San Raffaele, Dept Urol, Milan, Italy; [Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Med Oncol, New York, NY USA","Shariat, SF (reprint author), Cornell Univ, New York Presbyterian Hosp, Dept Urol, Weill Med Coll, 525 E 68th St,Box 94,Starr 900, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,"New York Community Trust","Shahrokh F. Shariat certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Dr Michael Rink is a speaker for Pfizer Pharma; Dr Giacomo Novara is a speaker and advisory board member for Astellas, Dendreon, GlaxoSmithKline, Lilly, Pierre Fabre Pharma, Recordati, and Takeda; Dr Shahrokh F. Shariat is an advisory board member for Ferring Pharma. In addition, Dr Rink is supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust.",null,33,5,5,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","APR",2013,63,4,null,null,null,null,724,732,null,"10.1016/j.eururo.2012.08.025",null,9,"Urology & Nephrology","Urology & Nephrology","093LC","WOS:000315192400033"]
[null,null,null,null,"J","Rink, M; Zabor, EC; Furberg, H; Xylinas, E; Ehdaie, B; Novara, G; Babjuk, M; Pycha, A; Lotan, Y; Trinh, QD; Chun, FK; Lee, RK; Karakiewicz, PI; Fisch, M; Robinson, BD; Scherr, DS; Shariat, SF",null,null,null,"Rink, Michael; Zabor, Emily C.; Furberg, Helena; Xylinas, Evanguelos; Ehdaie, Behfar; Novara, Giacomo; Babjuk, Marko; Pycha, Armin; Lotan, Yair; Quoc-Dien Trinh; Chun, Felix K.; Lee, Richard K.; Karakiewicz, Pierre I.; Fisch, Margit; Robinson, Brian D.; Scherr, Douglas S.; Shariat, Shahrokh F.",null,null,"Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy","EUROPEAN UROLOGY",null,null,"English","Article",null,null,null,null,null,"Smoking; Urothelial carcinoma; Muscle-invasive bladder cancer; Recurrence; Progression; Survival; Dose response; Radical cystectomy","TRANSITIONAL-CELL-CARCINOMA; TRACT UROTHELIAL CARCINOMA; CIGARETTE-SMOKING; LUNG-CANCER; RISK; RECURRENCE; STAGE; ASSOCIATION; DIAGNOSIS; SURVIVAL","Background: Cigarette smoking is the best-established risk factor for urothelial carcinoma development. Objective: To elucidate the association of pretreatment smoking status, cumulative exposure, and time since smoking cessation on outcomes of patients with urothelial carcinoma of the bladder (UCB) treated with radical cystectomy (RC). Design, setting, and participants: We retrospectively collected clinicopathologic and smoking variables, including smoking status, number of cigarettes per day (CPD), duration in years, and time since smoking cessation, for 1506 patients treated with RC for UCB. Lifetime cumulative smoking exposure was categorized as light short-term (<= 20 CPD for <= 20 yr), light long-term (<= 20 CPD for >20 yr), heavy short-term (>20 CPD for <20 yr), and heavy long-term (>20 CPD for >20 yr). Intervention: RC and bilateral lymph node (LN) dissection without neoadjuvant chemotherapy. Outcome measurements and statistical analysis: Logistic regression and competing risk analyses assessed the association of smoking with disease recurrence, cancer-specific mortality, and overall mortality. Results and limitations: There was no difference in clinicopathologic factors between patients who had never smoked (20%), former smokers (46%), and current smokers (34%). Smoking status was associated with the cumulative incidence of disease recurrence (p = 0.004) and cancer-specific mortality (p = 0.016) in univariable analyses and with disease recurrence in multivariable analysis (p = 0.02); current smokers had the highest cumulative incidences. Among ever smokers, cumulative smoking exposure was associated with advanced tumor stages (p < 0.001), LN metastasis (p = 0.002), disease recurrence (p < 0.001), cancer-specific mortality (p = 0.001), and overall mortality (p = 0.037) in multivariable analyses that adjusted for standard characteristics; heavy long-term smokers had the worst outcomes, followed by light long-term, heavy short-term, and light short-term smokers. Smoking cessation >= 10 yr mitigated the risk of disease recurrence (hazard ratio [HR]: 0.44; p < 0.001), cancer-specific mortality (HR: 0.42; p < 0.001), and overall mortality (HR: 0.69; p = 0.012) in multivariable analyses. The study is limited by its retrospective nature. Conclusions: Smoking is associated with worse prognosis after RC for UCB. This association seems to be dose-dependent, and its effects are mitigated by >10 yr smoking cessation. Health care practitioners should counsel smokers regarding the detrimental effects of smoking and the benefits of smoking cessation on UCB etiology and prognosis. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.","[Rink, Michael; Xylinas, Evanguelos; Ehdaie, Behfar; Lee, Richard K.; Robinson, Brian D.; Scherr, Douglas S.; Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Urol, New York, NY USA; [Rink, Michael; Chun, Felix K.; Fisch, Margit] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany; [Zabor, Emily C.; Furberg, Helena] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; [Xylinas, Evanguelos] Paris Descartes Univ, Cochin Hosp, AP HP, Dept Urol, Paris, France; [Novara, Giacomo] Univ Padua, Dept Urol, Padua, Italy; [Babjuk, Marko] Charles Univ Prague, Fac Med 2, Hosp Motol, Dept Urol, Prague, Czech Republic; [Pycha, Armin] Gen Hosp Bolzano, Dept Urol, Bolzano, Italy; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Quoc-Dien Trinh; Karakiewicz, Pierre I.] Univ Montreal, Dept Urol, Montreal, PQ, Canada; [Robinson, Brian D.] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Pathol, New York, NY USA; [Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Med Oncol, New York, NY USA","Shariat, SF (reprint author), Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Dept Urol, 525 East 68th St,Box 94,Starr 900, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,"New York Community Trust","Michael Rink is supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust.",null,30,4,4,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","SEP",2013,64,3,null,null,null,null,456,464,null,"10.1016/j.eururo.2012.11.039",null,9,"Urology & Nephrology","Urology & Nephrology","211VF","WOS:000323938700032"]
[null,null,null,null,"J","Shariat, SF; Rink, M; Ehdaie, B; Xylinas, E; Babjuk, M; Merseburger, AS; Svatek, RS; Cha, EK; Tagawa, ST; Fajkovic, H; Novara, G; Karakiewicz, PI; Trinh, QD; Daneshmand, S; Lotan, Y; Kassouf, W; Fritsche, HM; Chun, FK; Sonpavde, G; Joual, A; Scherr, DS; Gonen, M",null,null,null,"Shariat, Shahrokh F.; Rink, Michael; Ehdaie, Behfar; Xylinas, Evanguelos; Babjuk, Marek; Merseburger, Axel S.; Svatek, Robert S.; Cha, Eugene K.; Tagawa, Scott T.; Fajkovic, Harun; Novara, Giacomo; Karakiewicz, Pierre I.; Quoc-Dien Trinh; Daneshmand, Siamak; Lotan, Yair; Kassouf, Wassim; Fritsche, Hans-Martin; Chun, Felix K.; Sonpavde, Guru; Joual, Abdennabi; Scherr, Douglas S.; Gonen, Mithat",null,null,"Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy","EUROPEAN UROLOGY",null,null,"English","Article",null,null,null,null,null,"Radical cystectomy; Bladder cancer; Urothelial carcinoma; Lymph node; Lymphovascular invasion; Prognosis; Survival; Adjuvant chemotherapy","TRANSITIONAL-CELL CARCINOMA; LYMPH-NODES; LYMPHOVASCULAR INVASION; PELVIC LYMPHADENECTOMY; MINIMUM NUMBER; SURVIVAL; IMPACT; METASTASIS; RECURRENCE; DISEASE","Background: Radical cystectomy (RC) with pelvic lymph node dissection (PLND) is the standard of care for high-risk non-muscle-invasive and muscle-invasive bladder cancer (BCa). Objective: To develop a model that allows quantification of the likelihood that a pathologically node-negative patient has, indeed, no positive nodes. Design, setting, and participants: We analyzed data from 4335 patients treated with RC and PLND without neoadjuvant chemotherapy at 12 international academic centers. Interventions: Patients underwent RC and PLND. Outcome measurements and statistical analysis: We estimated the sensitivity of pathologic nodal staging using a beta-binomial model and developed a pathologic (postoperative) nodal staging score (pNSS) that represents the probability that a patient is correctly staged as node negative as a function of the number of examined nodes. Results and limitations: Overall, the probability of missing a positive node decreases with the increasing number of nodes examined (52% if 3 nodes are examined, 40% if 5 are examined, and 26% if 10 are examined). The proportion of having a positive node increased proportionally with advancing pathologic T stage and lymphovascular invasion (LVI). Patients with LVI who had 25 examined nodes would have a pNSS of 80% (pT1), 88% (pT2), and 66% (pT3-T4), whereas 10 examined nodes were sufficient for pNSS exceeding 90% in patients without LVI and pT0-T2 tumors. This study is limited because of its retrospective design and multicenter nature. Conclusions: We developed a tool that estimates the likelihood of lymph node (LN) metastasis in BCa patients treated with RC by evaluating the number of examined nodes, the pathologic T stage, and LVI. The pNSS indicates the adequacy of nodal staging in LN-negative patients. This tool could help to refine clinical decision making regarding adjuvant chemotherapy, follow-up scheduling, and inclusion in clinical trials. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.","[Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, Brady Urol Hlth Ctr, New York, NY 10065 USA; [Rink, Michael; Chun, Felix K.] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Xylinas, Evanguelos] Paris Descartes Univ, Cochin Hosp, APHP, Paris, France; [Babjuk, Marek] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Merseburger, Axel S.] Hannover Med Sch, Hannover, Germany; [Svatek, Robert S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Fajkovic, Harun] Gen Hosp St Poelten, St Polten, Austria; [Novara, Giacomo] Univ Padua, Padua, Italy; [Karakiewicz, Pierre I.; Quoc-Dien Trinh] Univ Montreal, Montreal, PQ, Canada; [Daneshmand, Siamak] Univ So Calif, Los Angeles, CA USA; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Kassouf, Wassim] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Fritsche, Hans-Martin] Univ Regensburg, Caritas St Josef Med Ctr, D-93053 Regensburg, Germany; [Sonpavde, Guru] Baylor Coll Med, Houston, TX 77030 USA; [Joual, Abdennabi] IBN Rochel Hosp, Casablanca, Morocco; [Gonen, Mithat] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA","Shariat, SF (reprint author), New York Presbyterian Hosp, Weill Cornell Med Coll, Brady Urol Hlth Ctr, 525 E 68th St,Box 94,Starr 900, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,"The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust","Shahrokh F. Shariat certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Dr. Michael Rink is supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust and a speaker for Pfizer Pharma. S. F. Shariat is an advisory board member of Ferring Pharma. S. Daneshmand is a speaker for Endo Pharmaceuticals.",null,34,4,4,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","FEB",2013,63,2,null,null,null,null,371,378,null,"10.1016/j.eururo.2012.06.008",null,8,"Urology & Nephrology","Urology & Nephrology","071FE","WOS:000313572100033"]
[null,null,null,null,"J","Liba, Z; Sebronova, V; Komarek, V; Sediva, A; Sedlacek, P",null,null,null,"Liba, Zuzana; Sebronova, Vera; Komarek, Vladimir; Sediva, Anna; Sedlacek, Petr",null,null,"Prevalence and treatment of anti-NMDA receptor encephalitis","LANCET NEUROLOGY",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Liba, Zuzana; Sebronova, Vera; Komarek, Vladimir] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Neurol, Prague 15006, Czech Republic; [Sediva, Anna] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Immunol, Prague 15006, Czech Republic; [Sedlacek, Petr] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Hematol & Oncol, Prague 15006, Czech Republic","Liba, Z (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat Neurol, Prague 15006, Czech Republic.","zuzana.liba@gmail.com",null,null,null,null,null,5,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1474-4422",null,null,"LANCET NEUROL","Lancet Neurol.","MAY",2013,12,5,null,null,null,null,424,425,null,null,null,2,"Clinical Neurology","Neurosciences & Neurology","142ZS","WOS:000318836700010"]
[null,null,null,null,"J","Esparza-Gordillo, J; Schaarschmidt, H; Liang, LM; Cookson, W; Bauerfeind, A; Lee-Kirsch, MA; Nemat, K; Henderson, J; Paternoster, L; Harper, JI; Mangold, E; Nothen, MM; Ruschendorf, F; Kerscher, T; Marenholz, I; Matanovic, A; Lau, S; Keil, T; Bauer, CP; Kurek, M; Ciechanowicz, A; Macek, M; Franke, A; Kabesch, M; Hubner, N; Abecasis, G; Weidinger, S; Moffatt, M; Lee, YA",null,null,null,"Esparza-Gordillo, Jorge; Schaarschmidt, Heidi; Liang, Liming; Cookson, William; Bauerfeind, Anja; Lee-Kirsch, Min-Ae; Nemat, Katja; Henderson, John; Paternoster, Lavinia; Harper, John I.; Mangold, Elisabeth; Nothen, Markus M.; Rueschendorf, Franz; Kerscher, Tamara; Marenholz, Ingo; Matanovic, Anja; Lau, Susanne; Keil, Thomas; Bauer, Carl-Peter; Kurek, Michael; Ciechanowicz, Andrzej; Macek, Milan; Franke, Andre; Kabesch, Michael; Hubner, Norbert; Abecasis, Goncalo; Weidinger, Stephan; Moffatt, Miriam; Lee, Young-Ae",null,null,"A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis","JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Atopic dermatitis; persistent atopic dermatitis; prognosis; inflammation; soluble IL-6 receptor; single nucleotide polymorphism; longitudinal study; population-based cohort; candidate association study; genetic risk factor","BIRTH COHORT; FOLLOW-UP; ASTHMA; ASSOCIATION; DISEASE; CHILDREN; MECHANISMS; CHILDHOOD; MUTATIONS; PATHWAYS","Background: Atopic dermatitis (AD) is a common inflammatory skin disease. Previous studies have revealed shared genetic determinants among different inflammatory disorders, suggesting that markers associated with immune-related traits might also play a role in AD. Objective: We sought to identify novel genetic risk factors for AD. Methods: We examined the results of all genome-wide association studies from a public repository and selected 318 genetic markers that were significantly associated with any inflammatory trait. These markers were considered candidates and tested for association with AD in a 3-step approach including 7 study populations with 7130 patients with AD and 9253 control subjects. Results: A functional amino acid change in the IL-6 receptor (IL-6R Asp358Ala; rs2228145) was significantly associated with AD (odds ratio [OR], 1.15; P = 5 x 10(-9)). Interestingly, investigation of 2 independent population-based birth cohorts showed that IL-6R 358Ala specifically predisposes to the persistent form of AD (ORpersistent AD = 1.22, P = .0008; ORtransient (AD) = 1.04, P = .54). This variant determines the balance between the classical membrane-bound versus soluble IL-6R signaling pathways. Carriers of 358Ala had increased serum levels of soluble IL-6R (P 5 4 3 10 214), with homozygote carriers showing a 2-fold increase. Moreover, we demonstrate that soluble IL-6R levels were higher in patients with AD than in control subjects (46.0 vs 37.8 ng/mL, P = .001). Additional AD risk variants were identified in RAD50, RUNX3, and ERBB3. Conclusion: Our study supports the importance of genetic variants influencing inflammation in the etiology of AD. Moreover, we identified a functional genetic variant in IL6R influencing disease prognosis and specifically predisposing to persistent AD.","[Esparza-Gordillo, Jorge; Kerscher, Tamara; Marenholz, Ingo; Matanovic, Anja; Lee, Young-Ae] Charite Univ Med Berlin, Pediat Allergol Expt & Clin Res Ctr, Berlin, Germany; [Esparza-Gordillo, Jorge; Bauerfeind, Anja; Rueschendorf, Franz; Kerscher, Tamara; Marenholz, Ingo; Matanovic, Anja; Hubner, Norbert; Lee, Young-Ae] Max Delbruck Ctr Mol Med, Berlin, Germany; [Schaarschmidt, Heidi; Franke, Andre] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Liang, Liming] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Liang, Liming] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Cookson, William; Moffatt, Miriam] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Lee-Kirsch, Min-Ae; Nemat, Katja] Tech Univ Dresden, Klin Kinder & Jugendmed, Dresden, Germany; [Henderson, John; Paternoster, Lavinia] Univ Bristol, Dept Community Based Med, Bristol BS8 1TH, Avon, England; [Harper, John I.] Great Ormond St Hosp Sick Children, Dept Paediat Dermatol, London WC1N 3JH, England; [Mangold, Elisabeth; Nothen, Markus M.] Univ Bonn, Inst Human Genet, Bonn, Germany; [Nothen, Markus M.] Univ Bonn, Life & Brain Ctr, Dept Genom, Bonn, Germany; [Lau, Susanne] Charite, Berlin, Germany; [Keil, Thomas] Charite, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Bauer, Carl-Peter] Tech Univ Munich, Dept Pediat, D-80290 Munich, Germany; [Kurek, Michael] Pomeranian Med Univ, Dept Clin Allergol, Szczecin, Poland; [Ciechanowicz, Andrzej] Pomeranian Med Univ, Dept Lab Diagnost & Mol Med, Szczecin, Poland; [Macek, Milan] Charles Univ Prague, Med Sch & Fac 2, Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Kabesch, Michael] Univ Childrens Hosp Regensburg KUNO, Dept Pediat Pneumol & Allergy, Regensburg, Germany; [Abecasis, Goncalo] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA; [Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol Venereol & Allergy, Kiel, Germany","Lee, YA (reprint author), Charite Campus Buch, Pediat Allergol Expt & Clin Res Ctr, Lindenberger Weg 80, D-13125 Berlin, Germany.","yolee@mdc-berlin.de","Weidinger, Stephan/C-8461-2011; Franke, Andre/B-2151-2010","Franke, Andre/0000-0003-1530-5811","German Ministry of Education and Research (BMBF); Wellcome Trust; ThermoFisher Scientific; Nutricia GmbH; Novartis Pharma AG; Bencard Allergie GmbH; UK Medical Research Council; European Union FP7 Programme; DFG; European Respiratory Society; EIAACI; American Thoracic Society; Novartis; GlaxoSmithKline; BMBF; European Union; BMBF-NGFN","J. Esparza-Gordillo, T. Kerscher, I. Marenholz, and A. Matanovic have received grants from the German Ministry of Education and Research (BMBF). W. Cookson and M. Moffatt have received grants from Wellcome Trust. K. Nemat has received payment for lectures from ThermoFisher Scientific, Nutricia GmbH, Novartis Pharma AG, HAL Allergy Group, and Bencard Allergie GmbH. J. Henderson has received grants from Wellcome Trust and UK Medical Research Council and has grants/grants pending from UK Medical Research Council and European Union FP7 Programme. M. M. Nothen is employed by the University of Bonn; has grants/grants pending with German Research Foundation (DFG), BMBF, and the National Institutes of Health; and has received payment for lectures, including service on speakers' bureaus, from Arztekammer Brandenburg. S. Lau has received grants from DFG, has consultant arrangements with Merck, and has received payment for lectures, including service on speakers' bureaus from SymbioPharm Euro. T. Keil has received grants from the DFG; is employed by Charite Berlin, Germany; and has grants/grants pending from EU MeDall and iFAAM. M. Macek has received grants from University Hospital Motol. M. Kabesch has received grants from the European Union, BMBF, and DFG; has received payment for lectures, including service on speakers' bureaus, for the European Respiratory Society, EIAACI, the American Thoracic Society, Novartis, and GlaxoSmithKline. N. Hubner has grants/grants pending from BMBF, European Union. S. Weidinger has received grants from BMBF-NGFN; is a board member for Astellas Atopic Dermatitis European Expert Committee and Novartis Study Board, Urticaria; has grants/grants pending from Excellence Cluster Inflammation at Interfaces, a grant from the Fritz Thyssen Stiftung, and two grants from DFG; and has received payment for lectures, including service on speakers' bureaus, for Novartis. Y.-A. Lee has received grants from BMBF and has grants/grants pending from DFG. The rest of the authors declare that they have no relevant conflicts of interest.",null,38,3,3,"MOSBY-ELSEVIER","NEW YORK","360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA","0091-6749",null,null,"J ALLERGY CLIN IMMUN","J. Allergy Clin. Immunol.","AUG",2013,132,2,null,null,null,null,371,377,null,"10.1016/j.jaci.2013.01.057",null,7,"Allergy; Immunology","Allergy; Immunology","194KL","WOS:000322631700014"]
[null,null,null,null,"J","Viskin, S; Wilde, AAM; Guevara-Valdivia, ME; Daoulah, A; Krahn, AD; Zipes, DP; Halkin, A; Shivkumar, K; Boyle, NG; Adler, A; Belhassen, B; Schapachnik, E; Asrar, F; Rosso, R",null,null,null,"Viskin, Sami; Wilde, Arthur A. M.; Guevara-Valdivia, Milton E.; Daoulah, Amin; Krahn, Andrew D.; Zipes, Douglas P.; Halkin, Amir; Shivkumar, Kalyanam; Boyle, Noel G.; Adler, Arnon; Belhassen, Bernard; Schapachnik, Edgardo; Asrar, Farhan; Rosso, Raphael",null,null,"Quinidine, A Life-Saving Medication for Brugada Syndrome, Is Inaccessible in Many Countries","JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"arrhythmic storm; Brugada syndrome; idiopathic ventricular fibrillation; implantable cardioverter-defibrillator; quinidine; ventricular fibrillation","IDIOPATHIC VENTRICULAR-FIBRILLATION; SHORT QT SYNDROME; ELECTRICAL STORM; ANTIARRHYTHMIC-DRUGS; EARLY REPOLARIZATION; IONIC BASIS; THERAPY; PATIENT; EFFICACY; MANAGEMENT","Objectives The aim of this study was to determine the availability of quinidine throughout the world. Background Quinidine is the only oral medication that is effective for preventing life-threatening ventricular arrhythmias due to Brugada syndrome and idiopathic ventricular fibrillation. However, because of its low price and restricted indication, this medication is not marketed in many countries. Methods We conducted a survey of the availability of quinidine by contacting professional medical societies and arrhythmia specialists worldwide. Physicians were e-mailed questionnaires requesting information concerning the quinidine preparation available at their hospital. We also requested information concerning cases of adverse arrhythmic events resulting from unavailability of quinidine. Results A total of 273 physicians from 131 countries provided information regarding the availability of quinidine. Quinidine was readily available in 19 countries (14%), not accessible in 99 countries (76%), and available only through specific regulatory processes that require 4 to 90 days for completion in 13 countries (10%). We were able to gather information concerning 22 patients who had serious arrhythmias probably related (10 cases) or possibility related (12 cases) to the absence of quinidine, including 2 fatalities possibly attributable to the unavailability of quinidine. Conclusions The lack of accessibility of quinidine is a serious medical hazard at the global level. (C) 2013 by the American College of Cardiology Foundation","[Viskin, Sami; Halkin, Amir; Adler, Arnon; Belhassen, Bernard; Rosso, Raphael] Tel Aviv Univ, Sackler Sch Med, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel; [Wilde, Arthur A. M.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Guevara-Valdivia, Milton E.] CMN La Raza IMSS, UMAE Hosp Especialidades Dr Antonio Fraga Mouret, Mexico City, DF, Mexico; [Daoulah, Amin] King Faisal Specialist Hosp & Res Ctr, Jeddah, Saudi Arabia; [Krahn, Andrew D.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Zipes, Douglas P.] Indiana Univ Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; [Boyle, Noel G.] Univ Calif Los Angeles, Cardiac Arrhythmia Ctr, Los Angeles, CA USA; [Schapachnik, Edgardo] Asociac Carlos Chagas, Buenos Aires, DF, Argentina; [Asrar, Farhan] McMaster Univ, Hamilton, ON, Canada","Viskin, S (reprint author), Tel Aviv Med Ctr & Sch Med, Dept Cardiol, Weizman 6, IL-64239 Tel Aviv, Israel.","samiviskin@gmail.com",null,null,null,null,"Antzelevitch C, 2001, J CARDIOVASC ELECTR, V12, P268, DOI 10.1046/j.1540-8167.2001.00268.x; Attaran A, 2001, JAMA-J AM MED ASSOC, V286, P1886, DOI 10.1001/jama.286.15.1886; BAUMAN JL, 1984, AM HEART J, V107, P425, DOI 10.1016/0002-8703(84)90081-4; BELHASSEN B, 1993, J CARDIOVASC ELECTR, V4, P356, DOI 10.1111/j.1540-8167.1993.tb01236.x; Belhassen B, 1999, J CARDIOVASC ELECTR, V10, P1301, DOI 10.1111/j.1540-8167.1999.tb00183.x; Belhassen B, 2004, CIRCULATION, V110, P1731, DOI 10.1161/01.CIR.0000143159.30585.90; BELHASSEN B, 1987, CIRCULATION, V75, P809; BELHASSEN B, 1981, PACE, V4, P92, DOI 10.1111/j.1540-8159.1981.tb03680.x; Belhassen B, 2009, PACE, V32, P294, DOI 10.1111/j.1540-8159.2008.02235.x; Belhassen B, 2004, HEART RHYTHM, V1, P352, DOI 10.1016/j.hrthm.2004.04.006; Brodsky MA, 1996, ARCH INTERN MED, V156, P2553, DOI 10.1001/archinte.156.22.2553; COPLEN SE, 1990, CIRCULATION, V82, P1106; ELSHERIF N, 1989, J AM COLL CARDIOL, V14, P252; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; Grace AA, 1998, NEW ENGL J MED, V338, P35; Haghjoo M, 2005, J CARDIOVASC ELECTR, V16, P674, DOI 10.1111/j.1540-8167.2005.40681.x; Haissaguerre M, 2009, J AM COLL CARDIOL, V53, P612, DOI 10.1016/j.jacc.2008.10.044; Haissaguerre M, 2008, NEW ENGL J MED, V358, P2016, DOI 10.1056/NEJMoa071968; Hermida JS, 2004, J AM COLL CARDIOL, V43, P1853, DOI 10.1016/j.jacc.2003.12.046; Jongman JY, 2007, NETH HEART J, V15, P151; Kaufman ES, 2007, J CARDIOVASC ELECTR, V18, P665, DOI 10.1111/j.1540-8167.2007.00815.x; Marquez MF, 2007, J CARDIOVASC ELECTR, V18, P234, DOI 10.1111/j.1540-8167.2006.00681.x; Marquez MF, 2005, PACE, V28, P870, DOI 10.1111/j.1540-8159.2005.00183.x; Mehrotra S, 2011, J CARDIOVASC ELECTR, V22, P594, DOI 10.1111/j.1540-8167.2010.01907.x; Mok NS, 2004, PACE, V27, P821, DOI 10.1111/j.1540-8159.2004.00537.x; Ohgo T, 2007, HEART RHYTHM, V4, P695, DOI 10.1016/j.hrthm.2007.02.014; Olsson G, 2010, HEART RHYTHM, V7, P864, DOI 10.1016/j.hrthm.2010.03.010; Bettiol Katia, 2005, Ital Heart J, V6, P601; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; The Cardiac Arrhythmia Suppression Trial (CAST) Investigators, 1989, N ENGL J MED, V321, P406; Vatta M, 2002, HUM MOL GENET, V11, P337, DOI 10.1093/hmg/11.3.337; Viskin S, 2007, EUROPACE, V9, P1105, DOI 10.1093/europace/eum181; VISKIN S, 1990, AM HEART J, V120, P661, DOI 10.1016/0002-8703(90)90025-S; Viskin S, 2009, J AM COLL CARDIOL, V53, P620, DOI 10.1016/j.jacc.2008.11.011; Viskin S, 2010, HEART RHYTHM, V7, P863, DOI 10.1016/j.hrthm.2010.03.011; Viskin S, 2009, HEART RHYTHM, V6, P401, DOI 10.1016/j.hrthm.2008.11.030; Wilde AAM, 2007, NETH HEART J, V15, P127; Wolpert C, 2005, J CARDIOVASC ELECTR, V16, P54, DOI 10.1046/j.1540-8167.2005.04470.x",38,3,3,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0735-1097",null,null,"J AM COLL CARDIOL","J. Am. Coll. Cardiol.","JUN 11",2013,61,23,null,null,null,null,2383,2387,null,"10.1016/j.jacc.2013.02.077",null,5,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","167AB","WOS:000320601400012"]
[null,null,null,null,"J","Burger, M; Oosterlinck, W; Konety, B; Chang, S; Gudjonsson, S; Pruthi, R; Soloway, M; Solsona, E; Sved, P; Babjuk, M; Brausi, MA; Cheng, C; Comperat, E; Dinney, C; Otto, W; Shah, J; Thurof, J; Witjes, JA",null,null,null,"Burger, Maximilian; Oosterlinck, Willem; Konety, Badrinath; Chang, Sam; Gudjonsson, Sigurdur; Pruthi, Raj; Soloway, Mark; Solsona, Eduardo; Sved, Paul; Babjuk, Marko; Brausi, Maurizio A.; Cheng, Christopher; Comperat, Eva; Dinney, Colin; Otto, Wolfgang; Shah, Jay; Thuerof, Joachim; Witjes, J. Alfred",null,null,"ICUD-EAU International Consultation on Bladder Cancer 2012: Non-Muscle-Invasive Urothelial Carcinoma of the Bladder","EUROPEAN UROLOGY",null,null,"English","Review",null,null,null,null,null,"Bacillus Calmette-Guerin (BCG); Bladder cancer; Cystoscopy; Diagnosis; Guidelines; Intravesical chemotherapy; Prognosis; Transurethral resection (TUR)","BACILLUS-CALMETTE-GUERIN; RANDOMIZED CLINICAL-TRIALS; INTRAVESICAL MITOMYCIN-C; LONG-TERM EFFICACY; HIGH-RISK; TRANSURETHRAL RESECTION; IN-SITU; POSTOPERATIVE INSTILLATION; FLUORESCENCE CYSTOSCOPY; TUMOR RECURRENCE","Context: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. Objective: To critically review the recent data on the management of NMIBC to arrive at a general consensus. Evidence acquisition: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. Evidence synthesis: The major findings are presented in an evidence-based fashion. We analyzed large retrospective and prospective studies. Conclusions: Urothelial cancer of the bladder staged Ta, T1, and carcinoma in situ (CIS), also indicated as NMIBC, poses greatly varying but uniformly demanding challenges to urologic care. On the one hand, the high recurrence rate and low progression rate with Ta low-grade demand risk-adapted treatment and surveillance to provide thorough care while minimizing treatment-related burden. On the other hand, the propensity of Ta high-grade, T1, and CIS to progress demands intense care and timely consideration of radical cystectomy. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.","[Witjes, J. Alfred] Radboud Univ Nijmegen, Dept Urol, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [Burger, Maximilian] Univ Wurzburg, Dept Urol & Pediat Urol, Med Ctr, Wurzburg, Germany; [Oosterlinck, Willem] Ghent Univ Hosp, Ghent, Belgium; [Konety, Badrinath] Univ Minnesota, Dept Urol, Minneapolis, MN USA; [Chang, Sam] Vanderbilt Univ, Sch Med, Dept Urol Surg, Nashville, TN 37212 USA; [Gudjonsson, Sigurdur] Skane Univ Hosp, Dept Clin Sci Urol, Malmo, Sweden; [Pruthi, Raj] Univ N Carolina, Dept Surg, Div Urol Surg, Chapel Hill, NC USA; [Soloway, Mark] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA; [Solsona, Eduardo] Inst Valenciano Oncol, Serv Urol, Valencia, Spain; [Sved, Paul] Univ Sydney, Sydney, NSW 2006, Australia; [Babjuk, Marko] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, Prague, Czech Republic; [Brausi, Maurizio A.] AUSL Modena, Dept Urol, Modena, Italy; [Cheng, Christopher] Singapore Gen Hosp, Dept Urol, Singapore 0316, Singapore; [Comperat, Eva] Univ Paris 06, Dept Pathol, AP HP, Fac Med Pierre & Marie Curie, Paris, France; [Dinney, Colin; Shah, Jay] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; [Otto, Wolfgang] Univ Regensburg, St Josef Med Ctr, Dept Urol, Regensburg, Germany; [Thuerof, Joachim] Johannes Gutenberg Univ Mainz, Dept Urol, Univ Med Ctr, Mainz, Germany","Witjes, JA (reprint author), Radboud Univ Nijmegen, Dept Urol, Med Ctr, Geert Grootepl S 10 659,POB 9101, NL-6500 HB Nijmegen, Netherlands.","F.Witjes@uro.umcn.nl","Witjes, Fred/N-9665-2013",null,null,null,null,51,16,16,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","JAN",2013,63,1,null,null,null,null,36,44,null,"10.1016/j.eururo.2012.08.061",null,9,"Urology & Nephrology","Urology & Nephrology","049SQ","WOS:000312004100010"]
[null,null,null,null,"J","Rink, M; Babjuk, M; Catto, JWF; Jichlinski, P; Shariat, SF; Stenzl, A; Stepp, H; Zaak, D; Witjes, JA",null,null,null,"Rink, Michael; Babjuk, Marko; Catto, James W. F.; Jichlinski, Patrice; Shariat, Shahrokh F.; Stenzl, Arnulf; Stepp, Herbert; Zaak, Dirk; Witjes, J. Alfred",null,null,"Hexyl Aminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non-Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature","EUROPEAN UROLOGY",null,null,"English","Review",null,null,null,null,null,"Non-muscle-invasive bladder cancer; Photodynamic diagnosis; Hexyl aminolevulinate; Tumour detection; Recurrence-free survival; Cost effectiveness; Urothelial cancer","TRANSITIONAL-CELL CARCINOMA; WHITE-LIGHT CYSTOSCOPY; BACILLUS-CALMETTE-GUERIN; POSITIVE URINE CYTOLOGY; 5-AMINOLEVULINIC ACID; TRANSURETHRAL RESECTION; PHOTODYNAMIC DIAGNOSIS; INTRAVESICAL INSTILLATION; PHASE-III; UROTHELIAL CARCINOMA","Context: Controversy exists regarding the therapeutic benefit and cost effectiveness of photodynamic diagnosis (PDD) with 5-aminolevulinic acid (5-ALA) or hexyl aminolevulinate (HAL) in addition to white-light cystoscopy (WLC) in the management of non-muscle-invasive bladder cancer (NMIBC). Objective: To systematically evaluate evidence regarding the therapeutic benefits and economic considerations of PDD in NMIBC detection and treatment. Evidence acquisition: We performed a critical review of PubMed/Medline, Embase, and the Cochrane Library in October 2012 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to the Consolidated Standards of Reporting Trials (CONSORT) and Standards for the Reporting of Diagnostic Accuracy Studies (STARD) criteria. Forty-four publications were selected for inclusion in this analysis. Evidence synthesis: Included reports used 5-ALA (in 26 studies), HAL (15 studies), or both (three studies) as photosensitising agents. PDD increased the detection of both papillary tumours (by 7-29%) and flat carcinoma in situ (CIS; by 25-30%) and reduced the rate of residual tumours after transurethral resection of bladder tumour (TURBT; by an average of 20%) compared to WLC alone. Superior recurrence-free survival (RFS) rates and prolonged RFS intervals were reported for PDD, compared to WLC in most studies. PDD did not appear to reduce disease progression. Our findings are limited by tumour heterogeneity and a lack of NMIBC risk stratification in many reports or adjustment for intravesical therapy use in most studies. Although cost effectiveness has been demonstrated for 5-ALA, it has not been studied for HAL. Conclusions: Moderately strong evidence exists that PDD improves tumour detection and reduces residual disease after TURBT compared with WLC. This has been shown to improve RFS but not progression to more advanced disease. Further work to evaluate cost effectiveness of PDD is required. (C) 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.","[Rink, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Urol, D-20246 Hamburg, Germany; [Babjuk, Marko] Charles Univ Prague, Dept Urol, Hosp Motol, Fac Med 2, Prague, Czech Republic; [Catto, James W. F.] Univ Sheffield, Inst Canc Studies, Sheffield, S Yorkshire, England; [Catto, James W. F.] Univ Sheffield, Acad Urol Unit, Sheffield, S Yorkshire, England; [Jichlinski, Patrice] CHUV Univ Hosp, Dept Urol, Lausanne, Switzerland; [Shariat, Shahrokh F.] Med Univ Vienna, Dept Urol, Vienna, Austria; [Stenzl, Arnulf] Univ Tubingen Hosp, Dept Urol, Tubingen, Germany; [Stepp, Herbert] Univ Hosp Munich, LIFE Ctr, Laser Forschungslab, Munich, Germany; [Zaak, Dirk] Hosp Traunstein, Dept Urol, Traunstein, Germany; [Witjes, J. Alfred] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 ED Nijmegen, Netherlands","Rink, M (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Urol, Martinistr 52, D-20246 Hamburg, Germany.","mrink@uke.de","Witjes, Fred/N-9665-2013",null,"GE Healthcare; immatics biotechnologies GmbH","Michael Rink certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Michael Rink received honoraria from Bayer and travel funding from GE Healthcare. Shahrokh F. Shariat is an advisory board member for Ferring Pharma. Arnulf Stenzl is a consultant for Ipsen Pharma, Novartis AG, Janssen, and Alere; he is speaker for GE Company, Novartis AG, Amgen, Janssen, and Ipsen Pharma as well as a researcher for Novartis AG, Johnson & Johnson, Amgen, Bayer AG, immatics biotechnologies GmbH, and Photocure ASA. He received a research grant from immatics biotechnologies GmbH. Herbert Stepp is co-inventor of a patent on the PDD light source characteristics, which is licensed to Karl Storz Company. Dirk Zaak received honoraria from GE Healthcare, Ipsen, and Photocure ASA; he is an advisory board member of GE Healthcare and Ipsen. J. Alfred Witjes has been an advisor to Sanofi Pasteur, Allergan, Ipsen, GE, and Photocure since 2011 and has received lecture honoraria from Ipsen.",null,70,1,1,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0302-2838",null,null,"EUR UROL","Eur. Urol.","OCT",2013,64,4,null,null,null,null,624,638,null,"10.1016/j.eururo.2013.07.007",null,15,"Urology & Nephrology","Urology & Nephrology","211VQ","WOS:000323939900027"]
[null,null,null,null,"J","Meyer, C; Hofmann, J; Burmeister, T; Groger, D; Park, TS; Emerenciano, M; de Oliveira, MP; Renneville, A; Villarese, P; Macintyre, E; Cave, H; Clappier, E; Mass-Malo, K; Zuna, J; Trka, J; De Braekeleer, E; De Braekeleer, M; Oh, SH; Tsaur, G; Fechina, L; van der Velden, VHJ; van Dongen, JJM; Delabesse, E; Binato, R; Silva, MLM; Kustanovich, A; Aleinikova, O; Harris, MH; Lund-Aho, T; Juvonen, V; Heidenreich, O; Vormoor, J; Choi, WWL; Jarosova, M; Kolenova, A; Bueno, C; Menendez, P; Wehner, S; Eckert, C; Talmant, P; Tondeur, S; Lippert, E; Launay, E; Henry, C; Ballerini, P; Lapillone, H; Callanan, MB; Cayuela, JM; Herbaux, C; Cazzaniga, G; Kakadiya, PM; Bohlander, S; Ahlmann, M; Choi, JR; Gameiro, P; Lee, DS; Krauter, J; Cornillet-Lefebvre, P; Kronnie, GT; Schafer, BW; Kubetzko, S; Alonso, CN; Stadt, UZ; Sutton, R; Venn, NC; Izraeli, S; Trakhtenbrot, L; Madsen, HO; Archer, P; Hancock, J; Cerveira, N; Teixeira, MR; Lo Nigro, L; Moricke, A; Stanulla, M; Schrappe, M; Sedek, L; Szczepanski, T; Zwaan, CM; Coenen, EA; van den Heuvel-Eibrink, MM; Strehl, S; Dworzak, M; Panzer-Grumayer, R; Dingermann, T; Klingebiel, T; Marschalek, R",null,null,null,"Meyer, C.; Hofmann, J.; Burmeister, T.; Groeger, D.; Park, T. S.; Emerenciano, M.; de Oliveira, M. Pombo; Renneville, A.; Villarese, P.; Macintyre, E.; Cave, H.; Clappier, E.; Mass-Malo, K.; Zuna, J.; Trka, J.; De Braekeleer, E.; De Braekeleer, M.; Oh, S. H.; Tsaur, G.; Fechina, L.; van der Velden, V. H. J.; van Dongen, J. J. M.; Delabesse, E.; Binato, R.; Silva, M. L. M.; Kustanovich, A.; Aleinikova, O.; Harris, M. H.; Lund-Aho, T.; Juvonen, V.; Heidenreich, O.; Vormoor, J.; Choi, W. W. L.; Jarosova, M.; Kolenova, A.; Bueno, C.; Menendez, P.; Wehner, S.; Eckert, C.; Talmant, P.; Tondeur, S.; Lippert, E.; Launay, E.; Henry, C.; Ballerini, P.; Lapillone, H.; Callanan, M. B.; Cayuela, J. M.; Herbaux, C.; Cazzaniga, G.; Kakadiya, P. M.; Bohlander, S.; Ahlmann, M.; Choi, J. R.; Gameiro, P.; Lee, D. S.; Krauter, J.; Cornillet-Lefebvre, P.; Kronnie, G. Te; Schaefer, B. W.; Kubetzko, S.; Alonso, C. N.; Stadt, U. Zur; Sutton, R.; Venn, N. C.; Izraeli, S.; Trakhtenbrot, L.; Madsen, H. O.; Archer, P.; Hancock, J.; Cerveira, N.; Teixeira, M. R.; Lo Nigro, L.; Moericke, A.; Stanulla, M.; Schrappe, M.; Sedek, L.; Szczepanski, T.; Zwaan, C. M.; Coenen, E. A.; van den Heuvel-Eibrink, M. M.; Strehl, S.; Dworzak, M.; Panzer-Gruemayer, R.; Dingermann, T.; Klingebiel, T.; Marschalek, R.",null,null,"The MLL recombinome of acute leukemias in 2013","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"MLL; chromosomal translocations; translocation partner genes; acute leukemia; ALL; AML","ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; BREAKPOINT CLUSTER REGION; ACUTE MYELOID-LEUKEMIA; FUSION PROTEIN; PROGNOSTIC-SIGNIFICANCE; HISTONE METHYLATION; DNA-DAMAGE; GENE; REARRANGEMENTS","Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize the chromosomal rearrangement of individual acute leukemia patients. We present data of the molecular characterization of 1590 MLL-rearranged biopsy samples obtained from acute leukemia patients. The precise localization of genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and novel TPGs identified. All patients were classified according to their gender (852 females and 745 males), age at diagnosis (558 infant, 416 pediatric and 616 adult leukemia patients) and other clinical criteria. Combined data of our study and recently published data revealed a total of 121 different MLL rearrangements, of which 79 TPGs are now characterized at the molecular level. However, only seven rearrangements seem to be predominantly associated with illegitimate recombinations of the MLL gene (similar to 90%): AFF1/AF4, MLLT3/AF9, MLLT1/ENL, MLLT10/AF10, ELL, partial tandem duplications (MLL PTDs) and MLLT4/AF6, respectively. The MLL breakpoint distributions for all clinical relevant subtypes (gender, disease type, age at diagnosis, reciprocal, complex and therapy-induced translocations) are presented. Finally, we present the extending network of reciprocal MLL fusions deriving from complex rearrangements.","[Meyer, C.; Hofmann, J.; Dingermann, T.; Marschalek, R.] Goethe Univ Frankfurt, Dept Biochem Chem & Pharm, Inst Pharmaceut Biol, ZAFES,DCAL, D-60439 Frankfurt, Germany; [Burmeister, T.; Groeger, D.] Charite Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; [Park, T. S.] Kyung Hee Univ, Sch Med, Dept Lab Med, Seoul, South Korea; [Emerenciano, M.] Inst Nacl Canc Rio de Janeiro, Pediat Hematol Oncol Program, Res Ctr, Rio De Janeiro, Brazil; [Renneville, A.] CHRU Lille, Lab Hematol Biol & Pathol Ctr, F-59037 Lille, France; [Renneville, A.] Canc Res Inst Lille, Team 3, INSERM, U837, Lille, France; [Villarese, P.; Macintyre, E.] Univ Paris 05, AP HP Necker Enfants Malades, Paris, France; [Cave, H.; Clappier, E.; Mass-Malo, K.] Paris Diderot Univ, AP HP Robert Debre, Dept Genet, Paris, France; [Zuna, J.; Trka, J.] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol Oncol, CLIP, Prague, Czech Republic; [De Braekeleer, E.; De Braekeleer, M.] Univ Bretagne Occidentale, Fac Med & Sci Sante, Lab Histol Embryol & Cytogenet, Brest, France; [De Braekeleer, E.; De Braekeleer, M.] INSERM, U1078, Brest, France; [Oh, S. H.] Inje Univ, Coll Med, Dept Lab Med, Pusan, South Korea; [Tsaur, G.; Fechina, L.] Reg Children Hosp 1, Res Inst Med Cell Technol, Pediat Oncol & Hematol Ctr, Ekaterinburg, Russia; [van der Velden, V. H. J.; van Dongen, J. J. M.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Delabesse, E.] CHU Purpan, Lab Hematol, Toulouse, France; [Binato, R.] Lab Celula Tronco CEMO INCA, Rio De Janeiro, Brazil; [Silva, M. L. M.] Lab Citogenet CEMO INCA, Rio De Janeiro, Brazil; [Kustanovich, A.; Aleinikova, O.] Belarusian Res Ctr Pediat Oncol Hematol & Immunol, Minsk, Byelarus; [Harris, M. H.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [Harris, M. H.] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA; [Lund-Aho, T.] Fimlab Labs, Lab Clin Genet, Tampere, Finland; [Juvonen, V.] Univ Turku, Dept Clin Chem, Turku, Finland; [Juvonen, V.] Univ Turku, TYKSLAB, Turku, Finland; [Juvonen, V.] Turku Univ, Cent Hosp, Turku, Finland; [Heidenreich, O.; Vormoor, J.] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Vormoor, J.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Choi, W. W. L.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Jarosova, M.] Palacky Univ, Fac Med & Dent, Dept Hematooncol, CR-77147 Olomouc, Czech Republic; [Kolenova, A.] Univ Childrens Hosp, Dept Pediat Hematol & Oncol, Bratislava, Slovakia; [Kolenova, A.] Comenius Univ, Sch Med, Bratislava, Slovakia; [Bueno, C.; Menendez, P.] Univ Granada, Ctr Genom & Oncol Res Pfizer, GENyO, Granada, Spain; [Bueno, C.; Menendez, P.] Univ Barcelona, Cell Therapy Program, Josep Carreras Leukemia Res Inst, Barcelona, Spain; [Wehner, S.; Klingebiel, T.] Goethe Univ Frankfurt, D-60439 Frankfurt, Germany; [Eckert, C.] Charite Dept Pediat Oncol & Hematol, Berlin, Germany; [Talmant, P.] CHU Nantes, Dept Hematol, F-44035 Nantes 01, France; Hop St Eloi, Hematol Lab, Inst Res Biotherapy, CHU Montpellier, Montpellier, France; [Tondeur, S.] NSERM, U847, Montpellier, France; [Lippert, E.] CHU Bordeaux, Lab Hematol, Bordeaux, France; [Launay, E.; Henry, C.] Hop Pontchaillou, CHU Rennes, Serv Cytogenet & Biol Cellulaire, Rennes, France; [Ballerini, P.; Lapillone, H.] Univ Paris 06, AP HP Trousseau A, Paris, France; [Callanan, M. B.] Inst Albert Bonniot, INSERM, U823, Grenoble, France; [Cayuela, J. M.] Paris Diderot Univ, AP HP St Louis, Lab Hematol, Paris, France; [Herbaux, C.] Ctr Hosp Valenciennes, Serv Hematol Immunol Cytogenet, Valenciennes, France; [Cazzaniga, G.] Clin Pediat Univ, Ctr Ric Tettamanti, Monza, Italy; [Kakadiya, P. M.; Bohlander, S.] Univ Marburg, Ctr Human Genet, Marburg, Germany; [Ahlmann, M.] Univ Childrens Hosp Muenster, Pediat Hematol & Oncol, Munster, Germany; [Choi, J. R.] Yonsei Univ, Coll Med, Dept Lab Med, Seoul, South Korea; [Gameiro, P.] Portuguese Inst Oncol Lisbon, UIPM, Hematooncol Lab, Lisbon, Portugal; [Lee, D. S.] Seoul Natl Univ, Coll Med, Dept Lab Med, Seoul, South Korea; [Krauter, J.] Hannover Med Sch, Clin Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany; [Cornillet-Lefebvre, P.] Hop Robert Debre, Lab Hematol, Reims, France; [Kronnie, G. Te] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy; [Schaefer, B. W.; Kubetzko, S.] Univ Childrens Hosp Zurich, Dept Oncol, Zurich, Switzerland; [Alonso, C. N.] Hosp Nacl Pediatr Prof Dr JP Garrahan, Serv Hematooncol, Buenos Aires, DF, Argentina; [Stadt, U. Zur] Univ Med Ctr Hamburg Eppendorf, Ctr Diagnost, Hamburg, Germany; [Sutton, R.; Venn, N. C.] Univ New S Wales, Childrens Canc Inst Australia, Sydney, NSW, Australia; [Izraeli, S.; Trakhtenbrot, L.] Tel Aviv Univ, Dept Pediat Hematooncol, Chaim Sheba Med Ctr, IL-69978 Tel Aviv, Israel; [Izraeli, S.; Trakhtenbrot, L.] Tel Aviv Univ, Canc Res Ctr, IL-69978 Tel Aviv, Israel; [Izraeli, S.; Trakhtenbrot, L.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Madsen, H. O.] Rigshosp, Univ Hosp, Dept Clin Immunol, DK-2100 Copenhagen, Denmark; [Archer, P.; Hancock, J.] North Bristol NHS Trust, Southmead Hosp, Bristol Genet Lab, Bristol, Avon, England; [Cerveira, N.; Teixeira, M. R.] Univ Porto, Dept Genet, Portuguese Oncol Inst Porto, P-4100 Oporto, Portugal; [Cerveira, N.; Teixeira, M. R.] Univ Porto, Biomed Sci Inst ICBAS, P-4100 Oporto, Portugal; [Lo Nigro, L.] Univ Catania, Ctr Pediat Hematol Oncol, Catania, Italy; [Moericke, A.; Stanulla, M.; Schrappe, M.] Univ Med Ctr Schleswig Holstein, Dept Pediat, Kiel, Germany; [Sedek, L.; Szczepanski, T.] Med Univ Silesia, Dept Pediat Hematol & Oncol, Zabrze, Poland; [Zwaan, C. M.; Coenen, E. A.; van den Heuvel-Eibrink, M. M.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Strehl, S.; Dworzak, M.; Panzer-Gruemayer, R.] Childrens Canc Res Inst, Vienna, Austria; [Strehl, S.; Dworzak, M.; Panzer-Gruemayer, R.] Med Univ Vienna, Vienna, Austria","Marschalek, R (reprint author), Goethe Univ Frankfurt, Dept Biochem Chem & Pharm, Inst Pharmaceut Biol, ZAFES,DCAL, Marie Curie Str 9, D-60439 Frankfurt, Germany.","Rolf.Marschalek@em.uni-frankfurt.de","Teixeira, Manuel/E-4885-2011",null,"German Children Cancer Aid [DKS 2011.09]; German Jose Carreras Leukemia Foundation [R 12/09, R 10/37f]","We thank all local doctors and biologists who provided clinical information and material. This work was made possible by and conducted within the framework of the International BFM Study Group. This study was supported by Grant DKS 2011.09 from the German Children Cancer Aid to RM. TB was supported by Grants R 12/09 and R 10/37f from the German Jose Carreras Leukemia Foundation. PM is an ICREA Professor from the Catalunya Government.",null,60,8,8,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924","1476-5551",null,"LEUKEMIA","Leukemia","NOV",2013,27,11,null,null,null,null,2165,2176,null,"10.1038/leu.2013.135",null,12,"Oncology; Hematology","Oncology; Hematology","250UV","WOS:000326882500007"]
[null,null,null,null,"J","Marsh, RA; Rao, K; Satwani, P; Lehmberg, K; Muller, I; Li, DD; Kim, MO; Fischer, A; Latour, S; Sedlacek, P; Barlogis, V; Hamamoto, K; Kanegane, H; Milanovich, S; Margolis, DA; Dimmock, D; Casper, J; Douglas, DN; Amrolia, PJ; Veys, P; Kumar, AR; Jordan, MB; Bleesing, JJ; Filipovich, AH",null,null,null,"Marsh, Rebecca A.; Rao, Kanchan; Satwani, Prakash; Lehmberg, Kai; Mueller, Ingo; Li, Dandan; Kim, Mi-Ok; Fischer, Alain; Latour, Sylvain; Sedlacek, Petr; Barlogis, Vincent; Hamamoto, Kazuko; Kanegane, Hirokazu; Milanovich, Sam; Margolis, David A.; Dimmock, David; Casper, James; Douglas, Dorothea N.; Amrolia, Persis J.; Veys, Paul; Kumar, Ashish R.; Jordan, Michael B.; Bleesing, Jack J.; Filipovich, Alexandra H.",null,null,"Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"LINKED LYMPHOPROLIFERATIVE SYNDROME; FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; DISEASE; MANIFESTATIONS; APOPTOSIS; SURVIVAL; JAPAN; MICE; SAP","There have been no studies on patient outcome after allogeneic hematopoietic cell transplantation (HCT) in patients with X-linked inhibitor of apoptosis (XIAP) deficiency. To estimate the success of HCT, we conducted an international survey of transplantation outcomes. Data were reported for 19 patients. Seven patients received busulfan-containing myeloablative conditioning (MAC) regimens. Eleven patients underwent reduced intensity conditioning (RIC) regimens predominantly consisting of alemtuzumab, fludarabine, and melphalan. One patient received an intermediate-intensity regimen. Survival was poor in the MAC group, with only 1 patient surviving (14%). Most deaths were from transplantation-related toxicities, including venoocclusive disease and pulmonary hemorrhage. Of the 11 patients who received RIC, 6 are currently surviving at a median of 570 days after HCT (55%). Preparative regimen and HLH activity affected outcomes, and of RIC patients reported to be in remission from HLH, survival is 86% (P = .03). We conclude that MAC regimens should not be used for patients with XIAP deficiency. It is possible that the loss of XIAP and its antiapoptotic functions contributes to the high incidence of toxicities observed with MAC regimens. RIC regimens should be pursued with caution and, if possible, efforts should be made to ensure HLH remission before HCT in these patients. (Blood. 2013;121(6):877-883)","[Marsh, Rebecca A.; Kumar, Ashish R.; Jordan, Michael B.; Bleesing, Jack J.; Filipovich, Alexandra H.] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immunodeficiency, Cincinnati, OH 45229 USA; [Rao, Kanchan; Amrolia, Persis J.; Veys, Paul] Great Ormond St Hosp Sick Children, Dept Haematol & Bone Marrow Transplantat, London, England; [Satwani, Prakash] Columbia Univ, Med Ctr, Morgan Stanley Childrens Hosp New York Presbyteri, Div Pediat Blood & Marrow Transplantat, New York, NY USA; [Lehmberg, Kai; Mueller, Ingo] Univ Med Ctr Hamburg Eppendorf, Clin Pediat Hematol & Oncol, Hamburg, Germany; [Li, Dandan; Kim, Mi-Ok] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Fischer, Alain] Univ Paris 05, Hop Necker, AP HP, INSERM,U768,Unite Immunol & Hematol,Inst Imagine, Paris, France; [Latour, Sylvain] Univ Paris 05, Hop Necker, INSERM, Inst Imagine,U768, Paris, France; [Sedlacek, Petr] Charles Univ Prague, Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Barlogis, Vincent] Hop Timone Enfants, Marseille, France; [Hamamoto, Kazuko] Hiroshima Red Cross Hosp, Dept Pediat, Hiroshima, Japan; [Kanegane, Hirokazu] Toyama Univ, Grad Sch Med, Dept Pediat, Toyama, Japan; [Milanovich, Sam; Margolis, David A.; Casper, James] Childrens Hosp Wisconsin, Med Coll Wisconsin, Div Pediat Hematol Oncol & Bone Marrow Transplant, Milwaukee, WI 53201 USA; [Dimmock, David] Med Coll Wisconsin, Dept Pediat, Div Genet, Milwaukee, WI 53226 USA; [Douglas, Dorothea N.] Arizona State Univ W, Coll Med, Phoenix Childrens Hosp, Phoenix, AZ 85069 USA","Marsh, RA (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, 3333 Burnet Ave, Cincinnati, OH 45229 USA.","rebecca.marsh@cchmc.org",null,null,"Clinical Immunology Society","R.A.M. is supported by a grant from the Clinical Immunology Society.",null,30,8,8,"AMER SOC HEMATOLOGY","WASHINGTON","2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","FEB 7",2013,121,6,null,null,null,null,877,883,null,"10.1182/blood-2012-06-432500",null,7,"Hematology","Hematology","088WO","WOS:000314868800008"]
[null,null,null,null,"J","Borzych-Duzalka, D; Bilginer, Y; Ha, IS; Bak, M; Rees, L; Cano, F; Munarriz, RL; Chua, A; Pesle, S; Emre, S; Urzykowska, A; Quiroz, L; Ruscasso, JD; White, C; Pape, L; Ramela, V; Printza, N; Vogel, A; Kuzmanovska, D; Simkova, E; Muller-Wiefel, DE; Sander, A; Warady, BA; Schaefer, F",null,null,null,"Borzych-Duzalka, Dagmara; Bilginer, Yelda; Ha, Il Soo; Bak, Mustafa; Rees, Lesley; Cano, Francisco; Loza Munarriz, Reyner; Chua, Annabelle; Pesle, Silvia; Emre, Sevinc; Urzykowska, Agnieszka; Quiroz, Lily; Dario Ruscasso, Javier; White, Colin; Pape, Lars; Ramela, Virginia; Printza, Nikoleta; Vogel, Andrea; Kuzmanovska, Dafina; Simkova, Eva; Mueller-Wiefel, Dirk E.; Sander, Anja; Warady, Bradley A.; Schaefer, Franz",null,"Int Pediat Peritoneal Dialysis Net","Management of Anemia in Children Receiving Chronic Peritoneal Dialysis","JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,null,"CHRONIC KIDNEY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; QUALITY-OF-LIFE; RENAL-FAILURE; HEMODIALYSIS-PATIENTS; PEDIATRIC-PATIENTS; EPOETIN-ALPHA; BONE-MARROW; ERYTHROPOIETIN; HYPERPARATHYROIDISM","Little information exists regarding the efficacy, modifiers, and outcomes of anemia management in children with CKD or ESRD. We assessed practices, effectors, and outcomes of anemia management in 1394 pediatric patients undergoing peritoneal dialysis (PD) who were prospectively followed in 30 countries. We noted that 25% of patients had hemoglobin levels below target (<10 g/dl or <9.5 g/dl in children older or younger than 2 years, respectively), with significant regional variation; levels were highest in North America and Europe and lowest in Asia and Turkey. Low hemoglobin levels were associated with low urine output, low serum albumin, high parathyroid hormone, high ferritin, and the use of bioincompatible PD fluid. Erythropoiesis-stimulating agents (ESAs) were prescribed to 92% of patients, and neither the type of ESA nor the dosing interval appeared to affect efficacy. The weekly ESA dose inversely correlated with age when scaled to weight but did not correlate with age when normalized to body surface area. ESA sensitivity was positively associated with residual diuresis and serum albumin and inversely associated with serum parathyroid hormone and ferritin. The prevalence of hypertension and left ventricular hypertrophy increased with the degree of anemia. Patient survival was positively associated with achieved hemoglobin and serum albumin and was inversely associated with ESA dose. In conclusion, control of anemia in children receiving long-term PD varies by region. ESA requirements are independent of age when dose is scaled to body surface area, and ESA resistance is associated with inflammation, fluid retention, and hyperparathyroidism. Anemia and high ESA dose requirements independently predict mortality. J Am Soc Nephrol 24: 665-676, 2013. doi: 10.1681/ASN.2012050433","[Borzych-Duzalka, Dagmara; Schaefer, Franz] Ctr Pediat & Adolescent Med, Div Pediat Nephrol, D-69120 Heidelberg, Germany; [Borzych-Duzalka, Dagmara] Med Univ Gdansk, Gdansk, Poland; [Bilginer, Yelda] Hacettepe Univ, Dept Pediat Nephrol, Ankara, Turkey; [Ha, Il Soo] Natl Univ Childrens Hosp, Seoul, South Korea; [Bak, Mustafa] Dr Behcet Uz Children Res & Educ Hosp, Izmir, Turkey; [Rees, Lesley] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Cano, Francisco] Hosp Ninos Luis Calvo Mackenna, Santiago, Chile; [Loza Munarriz, Reyner] Cayetano Heredia Hosp, Lima, Peru; [Chua, Annabelle] Texas Childrens Hosp, Houston, TX 77030 USA; [Pesle, Silvia] Hosp Pediat Humberto Notti, Mendoza, Argentina; [Emre, Sevinc] Istanbul Univ, Istanbul, Turkey; [Urzykowska, Agnieszka] Childrens Mem Hosp, Warsaw, Poland; [Quiroz, Lily] Roberto del Rio Hosp, Santiago, Chile; [Dario Ruscasso, Javier] Hosp Ninos Sor Maria Ludovica, Serv Nefrol, La Plata, Buenos Aires, Argentina; [White, Colin] BC Childrens Hosp, Vancouver, BC, Canada; [Pape, Lars] Hannover Med Sch, D-30623 Hannover, Germany; [Ramela, Virginia] SENNIAD, Montevideo, Uruguay; [Printza, Nikoleta] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece; [Vogel, Andrea] Pontificia Univ Catolica Chile, Santiago, Chile; [Kuzmanovska, Dafina] Pediat Clin, Nephrol Unit, Skopje, Macedonia; [Simkova, Eva] Dubai Hosp, Dubai, U Arab Emirates; [Mueller-Wiefel, Dirk E.] Univ Med Ctr, Hamburg, Germany; [Sander, Anja] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany; [Warady, Bradley A.] Childrens Mercy Hosp, Kansas City, MO 64108 USA","Schaefer, F (reprint author), Ctr Pediat & Adolescent Med, Div Pediat Nephrol, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.","franz.schaefer@med.uni-heidelberg.de","Rees, Lesley/C-5027-2008",null,"International Society for Peritoneal Dialysis; Baxter Health Care; Fresenius Medical Care; Ipsen; Pfizer; IBM","The authors gratefully acknowledge the support by the International Society for Peritoneal Dialysis, Baxter Health Care, Fresenius Medical Care, Ipsen, Pfizer, and IBM.","[Anonymous], 2012, NAT CLIN GUID CTR AN; Bakkaloglu SA, 2011, CLIN J AM SOC NEPHRO, V6, P1926, DOI 10.2215/CJN.05990710; Belsha CW, 1998, PEDIATR NEPHROL, V12, P298; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Borzych D, 2011, CLIN J AM SOC NEPHRO, V6, P1934, DOI 10.2215/CJN.11411210; Brancaccio D, 2004, J AM SOC NEPHROL, V15, pS21, DOI 10.1097/01.ASN.0000093369.09194.12; Chesney RW, 2006, PEDIATR NEPHROL, V21, P14, DOI 10.1007/s00467-005-2087-2; Cooker LA, 2001, PERITON DIALYSIS INT, V21, pS102; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; Fink JC, 2001, AM J KIDNEY DIS, V37, P348, DOI 10.1053/ajkd.2001.21305; Gallieni M, 2000, AM J NEPHROL, V20, P89, DOI 10.1159/000013563; Gerson A, 2004, AM J KIDNEY DIS, V44, P1017, DOI 10.1053/j.ajkd.2004.08.024; Glader B, 2007, NELSON TXB PEDIAT, P2003; Goodkin DA, 2011, J AM SOC NEPHROL, V22, P358, DOI 10.1681/ASN.2010020173; Hero M, 2005, J PEDIATR, V146, P245, DOI 10.1016/j.jpeds.2004.09.002; Ho M, 2003, N AM PEDIAT RENAL TR; Kalantar-Zadeh K, 2009, AM J KIDNEY DIS, V53, P823, DOI 10.1053/j.ajkd.2008.12.040; Khoury PR, 2009, J AM SOC ECHOCARDIOG, V22, P709, DOI 10.1016/j.echo.2009.03.003; Lai KN, 2010, NEPHRON CLIN PRACT, V116, pC11, DOI 10.1159/000314544; LAUER MS, 1994, AM J CARDIOL, V74, P487, DOI 10.1016/0002-9149(94)90909-1; McMahon LP, 2000, NEPHROL DIAL TRANSPL, V15, P1425, DOI 10.1093/ndt/15.9.1425; MILFORD DV, 1993, NEPHRON, V64, P645; Morakkabati N, 1996, EXP HEMATOL, V24, P392; Noh H, 2006, KIDNEY INT, V69, P2022, DOI 10.1038/sj.ki.5001506; Palis J, 1998, BLOOD REV, V12, P106, DOI 10.1016/S0268-960X(98)90022-4; Pattaragarn A, 2004, PERITON DIALYSIS INT, V24, P274; Pfeffer MA, 2009, AM J KIDNEY DIS, V54, P59, DOI 10.1053/j.ajkd.2009.04.008; RAO DS, 1993, NEW ENGL J MED, V328, P171, DOI 10.1056/NEJM199301213280304; Rodriguez W, 2008, PEDIATRICS, V121, P530, DOI 10.1542/peds.2007-1529; Sahin G, 2005, CLIN NEPHROL, V63, P402; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Smith KJ, 2003, CARDIOVASC RES, V59, P538, DOI 10.1016/S0008-6363(03)00468-1; Solomon SD, 2010, NEW ENGL J MED, V363, P1146, DOI 10.1056/NEJMoa1005109; Szczech LA, 2008, KIDNEY INT, V74, P791, DOI 10.1038/ki.2008.295; Vaziri ND, 2009, NEPHROL DIAL TRANSPL, V24, P1082, DOI 10.1093/ndt/gfn601; Warady BA, 2003, PEDIATR NEPHROL, V18, P1055, DOI 10.1007/s00467-003-1214-1; Warady BA, 2006, PEDIATR NEPHROL, V21, P1144, DOI 10.1007/s00467-006-0071-0; Witowski J, 2001, J AM SOC NEPHROL, V12, P2434; Zhang Y, 2004, AM J KIDNEY DIS, V44, P866, DOI 10.1053/j.ajkd.2004.08.002",39,3,3,"AMER SOC NEPHROLOGY","WASHINGTON","1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA","1046-6673",null,null,"J AM SOC NEPHROL","J. Am. Soc. Nephrol.","APR",2013,24,4,null,null,null,null,665,676,null,"10.1681/ASN.2012050433",null,12,"Urology & Nephrology","Urology & Nephrology","116ZK","WOS:000316921700018"]
[null,null,null,null,"J","de Rooij, JDE; Hollink, IHIM; Arentsen-Peters, STCJM; van Galen, JF; Beverloo, HB; Baruchel, A; Trka, J; Reinhardt, D; Sonneveld, E; Zimmermann, M; Alonzo, TA; Pieters, R; Meshinchi, S; van den Heuvel-Eibrink, MM; Zwaan, CM",null,null,null,"de Rooij, J. D. E.; Hollink, I. H. I. M.; Arentsen-Peters, S. T. C. J. M.; van Galen, J. F.; Beverloo, H. Berna; Baruchel, A.; Trka, J.; Reinhardt, D.; Sonneveld, E.; Zimmermann, M.; Alonzo, T. A.; Pieters, R.; Meshinchi, S.; van den Heuvel-Eibrink, M. M.; Zwaan, C. Michel",null,null,"NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern","LEUKEMIA",null,null,"English","Article",null,null,null,null,null,"NUP98; JARID1A; AML; HOX; cytogenetics; pediatric","ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC MALIGNANCIES; MUTATIONS; HETEROGENEITY; ADOLESCENTS; METHYLATION; CHILDREN; PROFILE","Cytogenetic abnormalities and early response to treatment are the main prognostic factors in acute myeloid leukemia (AML). Recently, NUP98/NSD1 (t(5;11)(q35;p15)), a cytogenetically cryptic fusion, was described as recurrent event in AML, characterized by dismal prognosis and HOXA/B gene overexpression. Using split-signal fluorescence in situ hybridization, other NUP98-rearranged pediatric AML cases were identified, including several acute megakaryoblastic leukemia (AMKL) cases with a cytogenetically cryptic fusion of NUP98 to JARID1A (t(11; 15)(p15; q35)). In this study we screened 105 pediatric AMKL cases to analyze the frequency of NUP98/JARID1A and other recurrent genetic abnormalities. NUP98/JARID1A was identified in 11/105 patients (10.5%). Other abnormalities consisted of RBM15/MKL1 (n = 16), CBFA2T3/GLIS2 (n = 13) and MLL-rearrangements (n = 13). Comparing NUP98/JARID1A-positive patients with other pediatric AMKL patients, no significant differences in sex, age and white blood cell count were found. NUP98/JARID1A was not an independent prognostic factor for 5-year overall (probability of overall survival (pOS)) or event-free survival (probability of event-free survival (pEFS)), although the 5-year pOS for the entire AMKL cohort was poor (42 +/- 6%). Cases with RBM15/MLK1 fared significantly better in terms of pOS and pEFS, although this was not independent from other risk factors in multivariate analysis. NUP98/JARID1A cases were characterized by HOXA/B gene overexpression, which is a potential druggable pathway. In conclusion, NUP98/JARID1A is a novel recurrent genetic abnormality in pediatric AMKL.","[de Rooij, J. D. E.; Hollink, I. H. I. M.; Arentsen-Peters, S. T. C. J. M.; Pieters, R.; van den Heuvel-Eibrink, M. M.; Zwaan, C. Michel] Erasmus MC Sophia Childrens Hosp, Dept Pediat Hematol Oncol, NL-3000 Rotterdam, Netherlands; [van Galen, J. F.; Beverloo, H. Berna] Erasmus Univ, Dept Clin Genet, Med Ctr, NL-3000 DR Rotterdam, Netherlands; [Baruchel, A.] Hop St Louis, Dept Hematol, Paris, France; [Trka, J.] Charles Univ Prague, Dept Pediat Hematol Oncol, Med Sch 2, Prague, Czech Republic; [Reinhardt, D.; Zimmermann, M.] Hannover Med Sch, AML BFM Study Grp, Hannover, Germany; [Sonneveld, E.] Dutch Childhood Oncol Grp DCOG, The Hague, Netherlands; [Alonzo, T. A.] Univ So Calif, Dept Biostat, Los Angeles, CA USA; [Meshinchi, S.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA","Zwaan, CM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Hematol Oncol, POB 2060, NL-3000 Rotterdam, Netherlands.","c.m.zwaan@erasmusmc.nl",null,null,null,null,null,34,2,2,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924","1476-5551",null,"LEUKEMIA","Leukemia","DEC",2013,27,12,null,null,null,null,2280,2288,null,"10.1038/leu.2013.87",null,9,"Oncology; Hematology","Oncology; Hematology","272KX","WOS:000328460600003"]
[null,null,null,null,"J","Daikeler, T; Labopin, M; Ruggeri, A; Crotta, A; Abinun, M; Hussein, AA; Carlson, K; Cornillon, J; Diez-Martin, JL; Gandemer, V; Faraci, M; Lindemans, C; O'Meara, A; Mialou, V; Renard, M; Sedlacek, P; Sirvent, A; Socie, G; Sora, F; Varotto, S; Sanz, J; Voswinkel, J; Vora, A; Yesilipek, MA; Herr, AL; Gluckman, E; Farge, D; Rocha, V",null,null,null,"Daikeler, Thomas; Labopin, Myriam; Ruggeri, Annalisa; Crotta, Alessandro; Abinun, Mario; Hussein, Ayad Ahmed; Carlson, Kristina; Cornillon, Jerome; Diez-Martin, Jose L.; Gandemer, Virginie; Faraci, Maura; Lindemans, Caroline; O'Meara, Anne; Mialou, Valerie; Renard, Marleen; Sedlacek, Petr; Sirvent, Anne; Socie, Gerard; Sora, Federica; Varotto, Stefania; Sanz, Jaime; Voswinkel, Jan; Vora, Ajay; Yesilipek, M. Akif; Herr, Andree-Laure; Gluckman, Eliane; Farge, Dominique; Rocha, Vanderson",null,null,"New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"STEM-CELL TRANSPLANTATION; HEMOLYTIC-ANEMIA; ANTI-CD20; RITUXIMAB; PATIENT","To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% +/- 1% at 1 year and 6.6% +/- 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P < .001). ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n = 9; autoimmune thrombocytopenia, n = 11; and immune neutropenia, n = 1) and other tissues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n = 1; membranous glomerulonephritis, n = 2; rheumatoid arthritis, n = 1; ulcerative colitis, n = 1; and systemic lupus erythematosus, n = 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs. (Blood. 2013; 121(6): 1059-1064)","[Daikeler, Thomas; Ruggeri, Annalisa; Crotta, Alessandro; Herr, Andree-Laure; Gluckman, Eliane; Rocha, Vanderson] Univ Paris 07, Hop St Louis, AP HP, Eurocord, Paris, France; [Daikeler, Thomas] Univ Basel Hosp, Dept Rheumatol, CH-4031 Basel, Switzerland; [Labopin, Myriam] Univ Paris 06, CEREST TC European Grp Blood & Marrow Transplanta, Serv Hematol & Therapie Cellulaire, Hop St Antoine,AP HP,Unite Mixte Rech S 938, Paris, France; [Abinun, Mario] Royal Victoria Infirm, Great N Childrens Hosp, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Hussein, Ayad Ahmed] King Hussein Canc Ctr, Bone Marrow & Stem Cell Transplantat Program, Amman, Jordan; [Carlson, Kristina] Univ Uppsala Hosp, Dept Haematol, Uppsala, Sweden; [Cornillon, Jerome] Inst Cancerol Lucien Neuwirth, Dept Hematol, St Etienne, France; [Diez-Martin, Jose L.] Hosp Gen Univ Gregorio Maranon, Dept Hematol, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain; [Gandemer, Virginie] Hop Rennes, Dept Pediat Hematol Oncol, Rennes, France; [Faraci, Maura] G Gaslini Childrens Res Inst, Dept Pediat Hematol Oncol, Genoa, Italy; [Lindemans, Caroline] Univ Med Ctr Utrecht, Dept Pediat Blood & Bone Marrow Transplantat, Utrecht, Netherlands; [O'Meara, Anne] Our Ladys Childrens Hosp, Dept Haematol & Oncol, Dublin, Ireland; [Mialou, Valerie] Inst Hematol & Oncol Pediat, Lyon, France; [Renard, Marleen] Univ Hosp, Dept Hematol, Louvain, Belgium; [Sedlacek, Petr] Univ Hosp Motol, Dept Paediat Haematol & Oncol Prague, Prague, Czech Republic; [Sirvent, Anne] Hop Archet, Dept OncoHematol, Nice, France; [Socie, Gerard] Hop St Louis, Bone Marrow Transplant Unit, Paris, France; [Sora, Federica] Univ Cattolica St Cuore, Inst Hematol, Rome, Italy; [Varotto, Stefania] Clin Oncoematol Pediat, Padua, Italy; [Sanz, Jaime] Hosp Infantil La Fe, Valencia, Spain; [Voswinkel, Jan] Hop St Antoine, AP HP, Dept Hematol, F-75571 Paris, France; [Vora, Ajay] Sheffield Childrens Hosp Fdn Trust, Dept Haematol, Sheffield, S Yorkshire, England; [Yesilipek, M. Akif] Akdeniz Univ, Sch Med, Dept Pediat Hematol, TR-07058 Antalya, Turkey; [Farge, Dominique] St Louis Hosp, Serv Med Interne & Pathol Vasc, Inserm U976, Paris, France; [Rocha, Vanderson] Univ Oxford, Oxford Hosp, Dept Haematol, Oxford, England","Daikeler, T (reprint author), Univ Basel Hosp, Dept Rheumatol, Petersgraben 4, CH-4031 Basel, Switzerland.","tdaikeler@uhbs.ch",null,null,"European League Against Rheumatism grant; Freiwillige Akademische Gesellschaft, Basel, Switzerland","T.D. was supported by a European League Against Rheumatism grant and by the Freiwillige Akademische Gesellschaft, Basel, Switzerland.",null,21,2,2,"AMER SOC HEMATOLOGY","WASHINGTON","2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","FEB 7",2013,121,6,null,null,null,null,1059,1064,null,"10.1182/blood-2012-07-445965",null,6,"Hematology","Hematology","088WO","WOS:000314868800027"]
[null,null,null,null,"J","Mirkowska, P; Hofmann, A; Sedek, L; Slamova, L; Mejstrikova, E; Szczepanski, T; Schmitz, M; Cario, G; Stanulla, M; Schrappe, M; van der Velden, VHJ; Bornhauser, BC; Wollscheid, B; Bourquin, JP",null,null,null,"Mirkowska, Paulina; Hofmann, Andreas; Sedek, Lukasz; Slamova, Lucie; Mejstrikova, Ester; Szczepanski, Tomasz; Schmitz, Maike; Cario, Gunnar; Stanulla, Martin; Schrappe, Martin; van der Velden, Vincent H. J.; Bornhauser, Beat C.; Wollscheid, Bernd; Bourquin, Jean-Pierre",null,null,"Leukemia surfaceome analysis reveals new disease-associated features","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; CHILDRENS ONCOLOGY GROUP; BONE-MARROW; LYMPHOCYTIC-LEUKEMIA; PROGNOSTIC-FACTORS; MASS CYTOMETRY; CELL-LINES; AIEOP-BFM; CHILDHOOD","A better description of the leukemia cell surface proteome (surfaceome) is a prerequisite for the development of diagnostic and therapeutic tools. Insights into the complexity of the surfaceome have been limited by the lack of suitable methodologies. We combined a leukemia xenograft model with the discovery-driven chemoproteomic Cell Surface Capture technology to explore the B-cell precursor acute lymphoblastic leukemia (BCP-ALL) surfaceome; 713 cell surface proteins, including 181 CD proteins, were detected through combined analysis of 19 BCP-ALL cases. Diagnostic immunophenotypes were recapitulated in each case, and subtype specific markers were detected. To identify new leukemia-associated markers, we filtered the surfaceome data set against gene expression information from sorted, normal hematopoietic cells. Nine candidate markers (CD18, CD63, CD31, CD97, CD102, CD157, CD217, CD305, and CD317) were validated by flow cytometry in patient samples at diagnosis and during chemotherapy. CD97, CD157, CD63, and CD305 accounted for the most informative differences between normal and malignant cells. The ALL surfaceome constitutes a valuable resource to assist the functional exploration of surface markers in normal and malignant lymphopoiesis. This unbiased approach will also contribute to the development of strategies that rely on complex information for multidimensional flow cytometry data analysis to improve its diagnostic applications.","[Mirkowska, Paulina; Schmitz, Maike; Bornhauser, Beat C.; Bourquin, Jean-Pierre] Univ Childrens Hosp Zurich, Dept Oncol, Zurich, Switzerland; [Mirkowska, Paulina; Hofmann, Andreas; Wollscheid, Bernd] ETH, Inst Mol Syst Biol, Dept Biol, CH-8093 Zurich, Switzerland; [Mirkowska, Paulina; Hofmann, Andreas; Schmitz, Maike] Life Sci Zurich Grad Sch, Zurich, Switzerland; [Mirkowska, Paulina; Schmitz, Maike; Bornhauser, Beat C.; Bourquin, Jean-Pierre] Univ Childrens Hosp Zurich, Childrens Res Ctr, Zurich, Switzerland; [Sedek, Lukasz; Szczepanski, Tomasz] Med Univ Silesia, Dept Pediat Hematol & Oncol, Zabrze, Katowice, Poland; [Slamova, Lucie; Mejstrikova, Ester] Charles Univ Prague, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Slamova, Lucie; Mejstrikova, Ester] Univ Hosp Motol, Prague, Czech Republic; [Cario, Gunnar; Stanulla, Martin; Schrappe, Martin] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany; [van der Velden, Vincent H. J.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands","Wollscheid, B (reprint author), ETH, Inst Mol Syst Biol, Dept Biol, Wolfgang Pauli Str 16, CH-8093 Zurich, Switzerland.","wbernd@ethz.ch; jean-pierre.bourquin@kispi.uzh.ch",null,null,"National Center of Competence in Research Neural Plasticity and Repair; Mach-Gaensslen Foundation; Swiss Cancer League; Empiris Foundation; Novartis Research Foundation; Swiss National Science Foundation; Hanne-Liebermann Foundation; Foundation Kind und Krebs; University of Zurich [GAUK 15710, P301/10/1877, NT13462]; University of Zurich, ERA-NET PRIOMEDCHILD","This work was supported by grants from National Center of Competence in Research Neural Plasticity and Repair (B.W.); the Mach-Gaensslen Foundation (B.W. and J.-P.B.); the Swiss Cancer League (J.-P.B.); the Empiris Foundation (J.-P.B.); the Novartis Research Foundation (J.-P.B.); the Swiss National Science Foundation (J.-P.B.); the Hanne-Liebermann Foundation and the Foundation Kind und Krebs (J.-P.B.); and the clinical research focus program \"human hemato-lymphatic diseases\" of the University of Zurich (J.-P.B.), GAUK 15710 (L. Slamova), P301/10/1877 (E.M. and L. Slamova), NT13462 (E.M.), and ERA-NET PRIOMEDCHILD (V.H.J.v.d.V. and T.S.).",null,49,1,1,"AMER SOC HEMATOLOGY","WASHINGTON","2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA","0006-4971","1528-0020",null,"BLOOD","Blood","JUN 20",2013,121,25,null,null,null,null,"E149","E159",null,"10.1182/blood-2012-11-468702",null,11,"Hematology","Hematology","184NR","WOS:000321898500001"]
[null,null,null,null,"J","Manchanda, R; Godfrey, M; Wong-Taylor, LA; Halaska, MJ; Burnell, M; Grabowski, JP; Gultekin, M; Haidopoulos, D; Zapardiel, I; Vranes, B; Kesic, V; Zola, P; Colombo, N; Verheijen, R; Bossart, M; Piek, J",null,null,null,"Manchanda, R.; Godfrey, M.; Wong-Taylor, L. A.; Halaska, M. J.; Burnell, M.; Grabowski, J. P.; Gultekin, M.; Haidopoulos, D.; Zapardiel, I.; Vranes, B.; Kesic, V.; Zola, P.; Colombo, N.; Verheijen, R.; Bossart, M.; Piek, J.",null,null,"The need for accredited training in gynaecological oncology: a report from the European Network of Young Gynaecological Oncologists (ENYGO)","ANNALS OF ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"accredited programme; ENYGO; ESGO; Europe; gynaecological oncology; training","FELLOWSHIP","Primary data on training experiences of European gynaecological oncology trainees are lacking. This study aims to evaluate trainee profile, satisfaction and factors affecting the training experience in gynaecological oncology in Europe. A web-based anonymous survey sent to ENYGO members/trainees in July 2011. It included sociodemographic information and a 22-item (1-5 Likert scale) questionnaire evaluating training experience in gynaecological oncology. Chi-square tests were used for evaluating the independence of categorical variables and t-test (parametric)/Mann-Whitney (non-parametric) tests for differences between two independent groups on continuous data. Cluster analysis was used to identify groupings in multivariate data and Cronbach's-alpha for questionnaire reliability. A multivariable linear regression model was used to assess the effect of variables on training satisfaction. One hundred and nineteen gynaecological-oncology trainees from 31 countries responded. The mean age was 37.4 (S.D, 5.3) years and 55.5% were in accredited training posts. Two clusters identified in the cohort (Calinski-Harabasz, CH = 47.35) differed mainly by accredited training (P = 0.003). The training-satisfaction score (TSS) had high reliability (Cronbach's alpha, 0.951) and was significantly associated with accredited posts (P < 0.0005), years of training (P = 0.001) and salary (P = 0.002). The TSS was independent of age (P = 0.360), working hours (P = 0.620), overtime-pay (P = 0.318), annual leave (P = 0.933), gender (P = 0.545) and marital status (P = 0.731). Accredited programme trainees scored significantly higher than others in 17 of 22 aspects of training. The areas of greater need included advanced laparoscopic/urological/colorectal surgery, radiation oncology, palliative-care, cancer genetics and research opportunities. Our data demonstrate the importance of accredited training and the need for harmonisation of gynaecological oncology training within Europe.","[Manchanda, R.; Godfrey, M.; Wong-Taylor, L. A.; Burnell, M.] UCL, Dept Gynaecol Oncol, EGA Inst Womens Hlth, London WC1E 6BT, England; [Halaska, M. J.] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, Prague, Czech Republic; [Grabowski, J. P.] Kliniken Essen Mitte, Dept Gynecol & Gynecol Oncol, Essen, Germany; [Gultekin, M.] Turkish Minist Hlth, Canc Control Dept, Ankara, Turkey; [Haidopoulos, D.] Alexandra Hosp, Gynecol Oncol Unit, Dept Obstet & Gynecol 1, Athens, Greece; [Zapardiel, I.] La Paz Univ Hosp, Gynaecol Oncol Unit, Madrid, Spain; [Vranes, B.; Kesic, V.] Clin Ctr Serbia, Inst Obstet & Gynecol, Belgrade, Serbia; [Zola, P.] Univ Turin, Turin, Italy; [Colombo, N.] European Inst Oncol, Milan, Italy; [Verheijen, R.] Univ Med Ctr Utrecht, Div Surg & Oncol Gynaecol, Utrecht, Netherlands; [Bossart, M.] Univ Freiburg, D-79106 Freiburg, Germany; [Piek, J.] Comprehens Canc Ctr South Locat TweeSteden Hosp, Tilburg, Netherlands","Manchanda, R (reprint author), Gynaecol Canc Res Ctr, UCL UCLH, EGA Inst Womens Hlth, First Floor,Maple House,149 Tottenham Court Rd, London W1T 7DN, England.","r.manchanda@ucl.ac.uk",null,null,"ESGO council; ENYGO by ESGO [E/01042012]","The authors would like to thank the various ENYGO national representatives and the ESGO council for their support. We are also grateful to Renata Brandtnerova for her administrative support.The study was funded through the ENYGO budget grant (grant number E/01042012) which was provided by ESGO.",null,17,1,1,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0923-7534",null,null,"ANN ONCOL","Ann. Oncol.","APR",2013,24,4,null,null,null,null,944,952,null,"10.1093/annonc/mds588",null,9,"Oncology","Oncology","113WY","WOS:000316701300012"]
[null,null,null,null,"J","Creutzig, U; Zimmermann, M; Bourquin, JP; Dworzak, MN; Fleischhack, G; Graf, N; Klingebiel, T; Kremens, B; Lehrnbecher, T; von Neuhoff, C; Ritter, J; Sander, A; Schrauder, A; von Stackelberg, A; Stary, J; Reinhardt, D",null,null,null,"Creutzig, Ursula; Zimmermann, Martin; Bourquin, Jean-Pierre; Dworzak, Michael N.; Fleischhack, Gudrun; Graf, Norbert; Klingebiel, Thomas; Kremens, Bernhard; Lehrnbecher, Thomas; von Neuhoff, Christine; Ritter, Joerg; Sander, Annette; Schrauder, Andre; von Stackelberg, Arend; Stary, Jan; Reinhardt, Dirk",null,null,"Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004","BLOOD",null,null,"English","Article",null,null,null,null,null,null,"HIGH-DOSE CYTARABINE; ANTHRACYCLINE CARDIOTOXICITY; CHILDHOOD-CANCER; CHILDREN; THERAPY; ADOLESCENTS; DOXORUBICIN; AML-BFM-98; IMPROVES","Outcomes of patients with acute myeloid leukemia (AML) improve significantly by intensification of induction. To further intensify anthracycline dosage without increasing cardiotoxicity, we compared potentially less cardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a higher-than-equivalent dose (80 vs 12 mg/m(2) per day for 3 days) during induction. In the multicenter therapy-optimization trial AML-BFM 2004, 521 of 611 pediatric patients (85%) were randomly assigned to L-DNR or idarubicin induction. Five-year results in both treatment arms were similar (overall survival 76% +/- 3% [L-DNR] vs 75% +/- 3% [idarubicin], P-logrank = .65; event-free survival [EFS] 59% +/- 3% vs 53% +/- 3%, P-logrank = .25; cumulative incidence of relapse 29% +/- 3% vs 31% +/- 3%, P-(Gray) = .75), as were EFS results for standard (72% +/- 5% vs 68% +/- 5%, P-logrank = .47) and high-risk (51% +/- 4% vs 46% +/- 4%, P-logrank = .45) patients. L-DNR resulted in significantly better probability of EFS in patients with t(8;21). Overall, treatment-related mortality was lower with L-DNR than idarubicin (2/257 vs 10/264 patients, P = .04). Grade 3/4 cardiotoxicity was rare after induction (4 L-DNR vs 5 idarubicin). Only 1 L-DNR and 3 idarubicin patients presented with subclinical or mild cardiomyopathy during follow-up. In conclusion, at the given dose, L-DNR has overall antileukemic activity comparable to idarubicin, promises to be more active in subgroups, and causes less treatment-related mortality. This trial was registered at www.clinicaltrials.gov as #NCT00111345.","[Creutzig, Ursula; Zimmermann, Martin; von Neuhoff, Christine; Sander, Annette; Reinhardt, Dirk] Hannover Med Sch, Hannover, Germany; [Bourquin, Jean-Pierre] Univ Zurich, Zurich, Switzerland; [Dworzak, Michael N.] St Anna Childrens Hosp, Dept Pediat, A-1090 Vienna, Austria; [Dworzak, Michael N.] Med Univ Vienna, Childrens Canc Res Inst, Vienna, Austria; [Fleischhack, Gudrun; Kremens, Bernhard] Univ Essen Gesamthsch, Dept Pediat Hematol, Essen, Germany; [Graf, Norbert] Univ Saarland, Sch Med, Dept Pediat Oncol & Hematol, Homburg, Germany; [Klingebiel, Thomas; Lehrnbecher, Thomas] Goethe Univ Frankfurt, Childrens Hosp, D-60054 Frankfurt, Germany; [Ritter, Joerg] Univ Childrens Hosp, Dept Pediat Hematol & Oncol, Munster, Germany; [Schrauder, Andre] Univ Childrens Hosp, Dept Pediat Hematol Oncol, Kiel, Germany; [von Stackelberg, Arend] Charite, Dept Pediat Oncol Hematol, D-13353 Berlin, Germany; [Stary, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Stary, Jan] Univ Hosp Motol, Czech Pediat Hematol Working Grp, Prague, Czech Republic","Creutzig, U (reprint author), Hannover Med Sch, Childrens Hosp, Dept Pediat Hematol & Oncol, AML BFM Trial Ctr, Carl Neuberg Str 1, D-30625 Hannover, Germany.","ursula@creutzig.de",null,null,"Deutsche Krebshilfe e.V.; Ministry of Health, Czech Republic [00064203]","This work was supported by the Deutsche Krebshilfe e.V. and partly by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic).",null,38,0,0,"AMER SOC HEMATOLOGY","WASHINGTON","2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA","0006-4971",null,null,"BLOOD","Blood","JUL 4",2013,122,1,null,null,null,null,37,43,null,"10.1182/blood-2013-02-484097",null,7,"Hematology","Hematology","184QW","WOS:000321909300009"]
[null,null,null,null,"J","Mestecky, J; Raska, M; Julian, BA; Gharavi, AG; Renfrow, MB; Moldoveanu, Z; Novak, L; Matousovic, K; Novak, J",null,"Abbas, AK; Galli, SJ; Howley, PM",null,"Mestecky, Jiri; Raska, Milan; Julian, Bruce A.; Gharavi, Ali G.; Renfrow, Matthew B.; Moldoveanu, Zina; Novak, Lea; Matousovic, Karel; Novak, Jan",null,null,"IgA Nephropathy: Molecular Mechanisms of the Disease","ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 8","Annual Review of Pathology-Mechanisms of Disease",null,"English","Review; Book Chapter",null,null,null,null,null,"O-glycosylation; hinge region; circulating immune complexes; galactose deficiency; polymeric IgA1; glycan-specific antibodies","GENOME-WIDE ASSOCIATION; HUMAN MESANGIAL CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; IGA1-CONTAINING IMMUNE-COMPLEXES; ABERRANTLY GLYCOSYLATED IGA1; RESONANCE MASS-SPECTROMETRY; HENOCH-SCHOENLEIN PURPURA; DOMAIN ANTIBODY FRAGMENTS; GALACTOSE-DEFICIENT IGA1; PROTEIN O-GLYCOSYLATION","Studies of molecular and cellular interactions involved in the pathogenesis of IgA nephropathy have revealed the autoimmune nature of this most common primary glomerulonephritis. In patients with this disease, altered glycan structures in the unique hinge region of the heavy chains of IgA1 molecules lead to the exposure of antigenic determinants, which are recognized by naturally occurring antiglycan antibodies of the IgG and/or IgA1 isotype. As a result, nephritogenic immune complexes form in the circulation and deposit in the glomerular mesangium. Deposited immune complexes induce proliferation of resident mesangial cells, increased production of extracellular matrix proteins and cytokines, and ultimately loss of glomerular function. Structural elucidation of the nature of these immune complexes and their biological activity should provide a rational basis for an effective, immunologically mediated inhibition of the formation of nephritogenic immune complexes that could be used as a disease-specific therapeutic approach.","[Mestecky, Jiri; Raska, Milan; Julian, Bruce A.; Moldoveanu, Zina; Novak, Jan] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Mestecky, Jiri; Julian, Bruce A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Renfrow, Matthew B.] Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35294 USA; [Novak, Lea] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Mestecky, Jiri] Acad Sci Czech Republic, Inst Microbiol, Dept Immunol, Prague 11000 3, Czech Republic; [Mestecky, Jiri] Charles Univ Prague, Sch Med 1, Inst Microbiol & Immunol, Prague 12108 2, Czech Republic; [Raska, Milan] Palacky Univ, Dept Immunol, Fac Med & Dent, CR-77147 Olomouc, Czech Republic; [Gharavi, Ali G.] Columbia Univ, Dept Med, Coll Phys & Surg, New York, NY 10032 USA; [Matousovic, Karel] Charles Univ Prague, Dept Med, Sch Med 2, Prague 15006 5, Czech Republic","Mestecky, J (reprint author), Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.","raskamil@uab.edu; jannovak@uab.edu",null,null,null,null,null,145,6,6,"ANNUAL REVIEWS","PALO ALTO","4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA","1553-4006",null,"978-0-8243-4308-8","ANNU REV PATHOL-MECH","Annu. Rev. Pathol.-Mech Dis.",null,2013,8,null,null,null,null,null,217,240,null,"10.1146/annurev-pathol-011110-130216",null,24,"Pathology","Pathology","BEX15","WOS:000318483400009"]
[null,null,null,null,"J","Brozkova, DS; Lassuthova, P; Neupauerova, J; Krutova, M; Haberlova, J; Stejskal, D; Seeman, P",null,null,null,"Brozkova, Dana Safka; Lassuthova, Petra; Neupauerova, Jana; Krutova, Marcela; Haberlova, Jana; Stejskal, David; Seeman, Pavel",null,null,"Czech family confirms the link between FBLN5 and Charcot-Marie-Tooth type 1 neuropathy","BRAIN",null,null,"English","Letter",null,null,null,null,null,null,"MACULAR DEGENERATION; CUTIS LAXA; FIBULIN-5; GENE",null,"[Brozkova, Dana Safka; Lassuthova, Petra; Neupauerova, Jana; Krutova, Marcela; Haberlova, Jana; Seeman, Pavel] Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, Prague 15006, Czech Republic; [Brozkova, Dana Safka; Lassuthova, Petra; Neupauerova, Jana; Krutova, Marcela; Haberlova, Jana; Seeman, Pavel] Univ Hosp Motol, Prague 15006, Czech Republic; [Stejskal, David] Ctr Med Genet & Reprod Med GENNET, Prague, Czech Republic","Brozkova, DS (reprint author), Charles Univ Prague, Sch Med 2, Dept Child Neurol, DNA Lab, V Uvalu 84, Prague 15006, Czech Republic.","dana.brozkova@lf2.cuni.cz",null,null,null,null,null,8,0,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0006-8950",null,null,"BRAIN","Brain","JUL",2013,136,null,7,null,null,null,null,null,"e232","10.1093/brain/aws333",null,4,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","173EF","WOS:000321060200001"]
[null,null,null,null,"J","Moore, DJ; Onoufriadis, A; Shoemark, A; Simpson, MA; zur Lage, PI; de Castro, SC; Bartoloni, L; Gallone, G; Petridi, S; Woollard, WJ; Antony, D; Schmidts, M; Didonna, T; Makrythanasis, P; Bevillard, J; Mongan, NP; Djakow, J; Pals, G; Lucas, JS; Marthin, JK; Nielsen, KG; Santoni, F; Guipponi, M; Hogg, C; Antonarakis, SE; Emes, RD; Chung, EMK; Greene, NDE; Blouin, JL; Jarman, AP; Mitchison, HM",null,null,null,"Moore, Daniel J.; Onoufriadis, Alexandros; Shoemark, Amelia; Simpson, Michael A.; zur Lage, Petra I.; de Castro, Sandra C.; Bartoloni, Lucia; Gallone, Giuseppe; Petridi, Stavroula; Woollard, Wesley J.; Antony, Dinu; Schmidts, Miriam; Didonna, Teresa; Makrythanasis, Periklis; Bevillard, Jeremy; Mongan, Nigel P.; Djakow, Jana; Pals, Gerard; Lucas, Jane S.; Marthin, June K.; Nielsen, Kim G.; Santoni, Federico; Guipponi, Michel; Hogg, Claire; Antonarakis, Stylianos E.; Emes, Richard D.; Chung, Eddie M. K.; Greene, Nicholas D. E.; Blouin, Jean-Louis; Jarman, Andrew P.; Mitchison, Hannah M.",null,null,"Mutations in ZMYND10, a Gene Essential for Proper Axonemal Assembly of Inner and Outer Dynein Arms in Humans and Flies, Cause Primary Ciliary Dyskinesia","AMERICAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,null,"OF-FUNCTION MUTATIONS; MECHANOSENSORY NEURONS; ELECTRON-MICROSCOPY; REGULATORY COMPLEX; DROSOPHILA; DEFECTS; FAMILY; DIFFERENTIATION; EXPRESSION; MOTILITY","Primary ciliary dyskinesia (PCD) is a ciliopathy characterized by airway disease, infertility, and laterality defects, often caused by dual loss of the inner dynein arms (IDAs) and outer dynein arms (ODAs), which power cilia and flagella beating. Using whole-exome and candidate-gene Sanger resequencing in PCD-affected families afflicted with combined IDA and ODA defects, we found that 6/38 (16%) carried biallelic mutations in the conserved zinc-finger gene BLU (ZMYND10). ZMYND10 mutations conferred dynein-arm loss seen at the ultrastructural and immunofluorescence level and complete cilia immotility, except in hypomorphic p.Val16Gly (c.47T>G) homozygote individuals, whose cilia retained a stiff and slowed beat. In mice, Zmynd10 mRNA is restricted to regions containing motile cilia. In a Drosophila model of PCD, Zmynd10 is exclusively expressed in cells with motile cilia: chordotonal sensory neurons and sperm. In these cells, P-element-mediated gene silencing caused IDA and ODA defects, proprioception deficits, and sterility due to immotile sperm. Drosophila Zmynd10 with an equivalent c.47T>G (p.Val16Gly) missense change rescued mutant male sterility less than the wild-type did. Tagged Drosophila ZMYND10 is localized primarily to the cytoplasm, and human ZMYND10 interacts with LRRC6, another cytoplasmically localized protein altered in PCD. Using a fly model of PCD, we conclude that ZMYND10 is a cytoplasmic protein required for IDA and ODA assembly and that its variants cause ciliary dysmotility and PCD with laterality defects.","[Moore, Daniel J.; zur Lage, Petra I.; Gallone, Giuseppe; Jarman, Andrew P.] Univ Edinburgh, Sch Biomed Sci, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland; [Onoufriadis, Alexandros; Petridi, Stavroula; Antony, Dinu; Schmidts, Miriam] UCL, Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England; [Onoufriadis, Alexandros; de Castro, Sandra C.; Petridi, Stavroula; Antony, Dinu; Schmidts, Miriam; Greene, Nicholas D. E.; Mitchison, Hannah M.] UCL, Inst Child Hlth, Birth Defects Res Ctr, London WC1N 1EH, England; [Shoemark, Amelia; Hogg, Claire] Royal Brompton & Harefield NHS Fdn Trust, Dept Paediat Resp Med, London SW3 6NP, England; [Simpson, Michael A.; Woollard, Wesley J.] Kings Coll London, Sch Med, Div Genet & Mol Med, Guys Hosp, London SE1 9RT, England; [de Castro, Sandra C.; Greene, Nicholas D. E.] UCL, Inst Child Hlth, Neural Dev Unit, London WC1N 1EH, England; [Bartoloni, Lucia; Didonna, Teresa; Makrythanasis, Periklis; Bevillard, Jeremy; Santoni, Federico; Guipponi, Michel; Antonarakis, Stylianos E.; Blouin, Jean-Louis] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva 4, Switzerland; [Mongan, Nigel P.; Emes, Richard D.] Univ Nottingham, Sch Vet Med & Sci, Loughborough LE12 5RD, Leics, England; [Djakow, Jana] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague 15006 5, Czech Republic; [Djakow, Jana] Motol Univ Hosp, Prague 15006 5, Czech Republic; [Pals, Gerard] Med Ctr, Med Ctr, Dept Clin Genet, NL-1077 MC Amsterdam, Netherlands; [Lucas, Jane S.] Univ Southampton, NIHR Resp Biomed Res Unit, Primary Ciliary Dyskinesia Ctr, Southampton SO16 6YD, Hants, England; [Lucas, Jane S.] Univ Hosp Southampton NHS Fdn Trust, Southampton SO16 6YD, Hants, England; [Marthin, June K.; Nielsen, Kim G.] Univ Copenhagen Hosp, Dept Paediat & Adolescent Med, Paediat Pulm Serv, DK-2100 Copenhagen, Denmark; [Guipponi, Michel; Antonarakis, Stylianos E.; Blouin, Jean-Louis] Univ Hosp Geneva, Div Med Genet, CH-1211 Geneva 4, Switzerland; [Antonarakis, Stylianos E.] Univ Geneva, Ctr Med Univ Geneva, Inst Genet & Genom, CH-1211 Geneva 4, Switzerland; [Emes, Richard D.] Univ Nottingham, Adv Data Anal Ctr, Loughborough LE12 5RD, Leics, England; [Chung, Eddie M. K.] UCL, Inst Child Hlth, Gen & Adolescent Paediat Unit, London WC1E 6DE, England","Jarman, AP (reprint author), Univ Edinburgh, Sch Biomed Sci, Ctr Integrat Physiol, George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.","andrew.jarman@ed.ac.uk","Lucas, Jane/C-3620-2013; Mongan, Nigel/B-7410-2011; Simpson, Michael/F-4737-2011","Simpson, Michael/0000-0002-8539-8753","Gebert Foundation; Swiss National Science Foundation [32003B_135709]; Milena Carvajal Pro-Kartagener Foundation of Geneva; Bodossakis Foundation; Action Medical Research UK Clinical Training Fellowship [RTF-1411]; Action Medical Research [GN1773, GN2101]; Newlife Foundation for Disabled Children UK [10-11/15]; Medical Research Council of Great Britain [MR/K018558/10]; Biotechnology and Biological Sciences Research Council; Medical Research Council;  [ERC 249968];  [SNF 144082]","We would like to thank all the primary ciliary dyskinesia (PCD)-affected families for their participation in the study, Fiona Copeland, and the UK PCD Family Support Group. We wish to acknowledge the contribution of Bjorn Afzelius, who originally ascertained the GVA-09 family. We thank Jeanette Dankert-Roelse, Maggie Meeks, Celia D. Delozier, and R. Mark Gardiner for family recruitment and their past involvement in the project. We thank Paul Griffin, Sarah Ollosson, Mellisa Dixon, Patricia Goggin, Claire Jackson, and Maria Philipsen for light and electron microscopy. We acknowledge technical assistance from Panagiotis Maghsoudlou, Corinne Gehrig, and Anne Vannier. The pBID-UASC-GV plasmid was a gift from B. McCabe. S.E.A. is supported by a Gebert Foundation grant and grants ERC 249968 and SNF 144082. J.-L.B. is supported by grants from the Swiss National Science Foundation (#32003B_135709). J.-L.B., L.B., and H.M.M. are supported by grants from the Milena Carvajal Pro-Kartagener Foundation of Geneva. P.M. is supported by a grant from the Bodossakis Foundation. M.S. is supported by an Action Medical Research UK Clinical Training Fellowship (RTF-1411). A.O., S.P., E.M.K.C., and H.M.M. are supported by Action Medical Research awards GN1773 and GN2101 and Newlife Foundation for Disabled Children UK award 10-11/15. P.I.z.L. and A.P.J. are supported by the Medical Research Council of Great Britain (MR/K018558/10). D.J.M. and G.G. are supported by studentships from the Biotechnology and Biological Sciences Research Council and the Medical Research Council, respectively.",null,66,4,4,"CELL PRESS","CAMBRIDGE","600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA","0002-9297",null,null,"AM J HUM GENET","Am. J. Hum. Genet.","AUG 8",2013,93,2,null,null,null,null,346,356,null,"10.1016/j.ajhg.2013.07.009",null,11,"Genetics & Heredity","Genetics & Heredity","202AP","WOS:000323186200015"]
[null,null,null,null,"J","Suls, A; Jaehn, JA; Kecskes, A; Weber, Y; Weckhuysen, S; Craiu, DC; Siekierska, A; Djemie, T; Afrikanova, T; Gormley, P; von Spiczak, S; Kluger, G; Iliescu, CM; Talvik, T; Talvik, I; Meral, C; Caglayan, HS; Giraldez, BG; Serratosa, J; Lemke, JR; Hoffman-Zacharska, D; Szczepanik, E; Barisic, N; Komarek, V; Hjalgrim, H; Moller, RS; Linnankivi, T; Dimova, P; Striano, P; Zara, F; Marini, C; Guerrini, R; Depienne, C; Baulac, S; Kuhlenbaumer, G; Crawford, AD; Lehesjoki, AE; de Witte, PAM; Palotie, A; Lerche, H; Esguerra, CV; De Jonghe, P; Helbig, I",null,null,null,"Suls, Arvid; Jaehn, Johanna A.; Kecskes, Angela; Weber, Yvonne; Weckhuysen, Sarah; Craiu, Dana C.; Siekierska, Aleksandra; Djemie, Tania; Afrikanova, Tatiana; Gormley, Padhraig; von Spiczak, Sarah; Kluger, Gerhard; Iliescu, Catrinel M.; Talvik, Tiina; Talvik, Inga; Meral, Cihan; Caglayan, Hande S.; Giraldez, Beatriz G.; Serratosa, Jose; Lemke, Johannes R.; Hoffman-Zacharska, Dorota; Szczepanik, Elzbieta; Barisic, Nina; Komarek, Vladimir; Hjalgrim, Helle; Moller, Rikke S.; Linnankivi, Tarja; Dimova, Petia; Striano, Pasquale; Zara, Federico; Marini, Carla; Guerrini, Renzo; Depienne, Christel; Baulac, Stephanie; Kuhlenbaeumer, Gregor; Crawford, Alexander D.; Lehesjoki, Anna-Elina; de Witte, Peter A. M.; Palotie, Aarno; Lerche, Holger; Esguerra, Camila V.; De Jonghe, Peter; Helbig, Ingo",null,"EuroEPINOMICS RES Consortium","De Novo Loss-of-Function Mutations in CHD2 Cause a Fever-Sensitive Myoclonic Epileptic Encephalopathy Sharing Features with Dravet Syndrome","AMERICAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,null,"AUTISM SPECTRUM DISORDERS; DNA-BINDING PROTEIN-2; GENE; PHENOTYPE; DELETION; DISEASE; MEMBER; RATES; SCN1A","Dravet syndrome is a severe epilepsy syndrome characterized by infantile onset of therapy-resistant, fever-sensitive seizures followed by cognitive decline. Mutations in SCN1A explain about 75% of cases with Dravet syndrome; 90% of these mutations arise de novo. We studied a cohort of nine Dravet-syndrome-affected individuals without an SCN1A mutation (these included some atypical cases with onset at up to 2 years of age) by using whole-exome sequencing in proband-parent trios. In two individuals, we identified a de novo loss-of-function mutation in CHD2 (encoding chromodomain helicase DNA binding protein 2). A third CHD2 mutation was identified in an epileptic proband of a second (stage 2) cohort. All three individuals with a CHD2 mutation had intellectual disability and fever-sensitive generalized seizures, as well as prominent myoclonic seizures starting in the second year of life or later. To explore the functional relevance of CHD2 haploinsufficiency in an in vivo model system, we knocked down chd2 in zebrafish by using targeted morpholino antisense oligomers. chd2-knockdown larvae exhibited altered locomotor activity, and the epileptic nature of this seizure-like behavior was confirmed by field-potential recordings that revealed epileptiform discharges similar to seizures in affected persons. Both altered locomotor activity and epileptiform discharges were absent in appropriate control larvae. Our study provides evidence that de novo loss-of-function mutations in CHD2 are a cause of epileptic encephalopathy with generalized seizures.","[Suls, Arvid; Weckhuysen, Sarah; Djemie, Tania; De Jonghe, Peter] VIB, Dept Mol Genet, Neurogenet Grp, B-2610 Antwerp, Belgium; [Suls, Arvid; Weckhuysen, Sarah; Djemie, Tania; De Jonghe, Peter] Univ Antwerp, Inst Born Bunge, Neurogenet Lab, B-2610 Antwerp, Belgium; [Jaehn, Johanna A.; von Spiczak, Sarah; Helbig, Ingo] Univ Kiel, Univ Med Ctr Schleswig Holstein, D-24105 Kiel, Germany; [Kecskes, Angela; Siekierska, Aleksandra; Afrikanova, Tatiana; Crawford, Alexander D.; de Witte, Peter A. M.; Esguerra, Camila V.] Univ Louvain, Dept Pharmaceut & Pharmacol Sci, Lab Mol Biodiscovery, B-3000 Louvain, Belgium; [Weber, Yvonne; Lerche, Holger] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurol & Epileptol, D-72076 Tubingen, Germany; [Craiu, Dana C.; Iliescu, Catrinel M.] Carol Davila Univ Med, Dept Neurol, Pediat Neurol Clin 2, Bucharest 050474, Romania; [Craiu, Dana C.; Iliescu, Catrinel M.] Carol Davila Univ Med, Dept Pediat Neurol, Bucharest 050474, Romania; [Craiu, Dana C.; Iliescu, Catrinel M.] Carol Davila Univ Med, Dept Psychiat, Bucharest 050474, Romania; [Craiu, Dana C.; Iliescu, Catrinel M.] Carol Davila Univ Med, Dept Neurosurg, Bucharest 050474, Romania; [Craiu, Dana C.; Iliescu, Catrinel M.] Prof Doctor Alexandru Obregia Clin Hosp, Pediat Neurol Clin, Bucharest 041914, Romania; [Gormley, Padhraig; Palotie, Aarno] Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; [Kluger, Gerhard] Schon Klin Vogtareuth, Tagesklin Neuropadiatrie, Epilepsiezentrum Kinder & Jugendliche, D-83569 Vogtareuth, Germany; [Talvik, Tiina; Talvik, Inga] Univ Tartu, Dept Pediat, EE-51014 Tartu, Estonia; [Talvik, Tiina; Talvik, Inga] Tartu Univ Hosp, Dept Neurol & Neurorehabil, Childrens Clin, EE-50406 Tartu, Estonia; [Meral, Cihan] GATA Haydarpasa Teaching Hosp, Dept Pediat Neurol, TR-34668 Istanbul, Turkey; [Caglayan, Hande S.] Bogazici Univ, Dept Mol Biol & Genet, TR-34342 Istanbul, Turkey; [Giraldez, Beatriz G.; Serratosa, Jose] Hosp Univ Fdn Jimenez Diaz, Epilepsy Unit, Madrid 28040, Spain; [Giraldez, Beatriz G.; Serratosa, Jose] Ctr Invest Biomed Red Enfermedades Raras, Madrid 28040, Spain; [Lemke, Johannes R.] Univ Childrens Hosp, Inselspital, Div Human Genet, CH-3010 Bern, Switzerland; [Hoffman-Zacharska, Dorota] Inst Mother & Child Hlth, Dept Med Genet, PL-01211 Warsaw, Poland; [Szczepanik, Elzbieta] Inst Mother & Child Hlth, Clin Neurol Child & Adolescents, PL-01211 Warsaw, Poland; [Barisic, Nina] Univ Zagreb, Sch Med, Univ Hosp Ctr Zagreb, Dept Paediat, Zagreb 10000, Croatia; [Komarek, Vladimir] Univ Hosp Motol, Child Neurol Dept, Prague 15006, Czech Republic; [Hjalgrim, Helle; Moller, Rikke S.] Danish Epilepsy Ctr, DK-4293 Dianalund, Denmark; [Hjalgrim, Helle] Univ Southern Denmark, Inst Reg Hlth Res, DK-5230 Odense, Denmark; [Linnankivi, Tarja] Univ Helsinki, Childrens Hosp, Helsinki 00029, Finland; [Linnankivi, Tarja] Univ Helsinki, Cent Hosp, Helsinki 00029, Finland; [Dimova, Petia] St Naum Univ Hosp Neurol & Psychiat, Clin Child Neurol, Sofia 1113, Bulgaria; [Striano, Pasquale] Univ Genoa, Dept Neurosci, Pediat Neurol & Muscular Dis Unit, I-16147 Genoa, Italy; [Striano, Pasquale] Univ Genoa, Dept Rehabil, I-16147 Genoa, Italy; [Striano, Pasquale] Univ Genoa, Dept Ophthalmol, I-16147 Genoa, Italy; [Striano, Pasquale] Univ Genoa, Dept Genet, I-16147 Genoa, Italy; [Striano, Pasquale] Univ Genoa, Dept Maternal & Child Hlth, I-16147 Genoa, Italy; [Striano, Pasquale] Gaslini Inst, I-16147 Genoa, Italy; [Zara, Federico] Gaslini Inst, Dept Neurosci, Neurogenet Lab, Pediat Neurol & Muscular Dis Unit, I-16147 Genoa, Italy; [Marini, Carla; Guerrini, Renzo] Univ Florence, Meyer Childrens Hosp, Pediat Neurol Unit, I-50132 Florence, Italy; [Marini, Carla; Guerrini, Renzo] Univ Florence, Meyer Childrens Hosp, Pediat Neurol Labs, I-50132 Florence, Italy; [Depienne, Christel; Baulac, Stephanie] Hop La Pitie Salpetriere, Ctr Rech, INSERM, Inst Cerveau & Moelle Epiniere,U975, F-75013 Paris, France; [Depienne, Christel; Baulac, Stephanie] Hop La Pitie Salpetriere, Ctr Rech, CNRS 7225, Inst Cerveau & Moelle Epiniere, F-75013 Paris, France; [Baulac, Stephanie] Univ Paris 06, UMR S 975, F-75013 Paris, France; [Depienne, Christel] Hop La Pitie Salpetriere, AP HP, Dept Genet & Cytogenet, Unite Fonct Neurogenet Mol & Cellulaire, F-75013 Paris, France; [Kuhlenbaeumer, Gregor] Univ Kiel, Inst Expt Med, Dept Neurol, D-24105 Kiel, Germany; [Crawford, Alexander D.] Univ Luxembourg, Luxembourg Ctr Syst Biomed, L-4362 Esch Sur Alzette, Luxembourg; [Lehesjoki, Anna-Elina] Folkhalsan Inst Genet, Helsinki 00290, Finland; [Lehesjoki, Anna-Elina] Univ Helsinki, Res Programs Unit, FIN-00290 Helsinki, Finland; [Lehesjoki, Anna-Elina] Univ Helsinki, Ctr Neurosci, FIN-00290 Helsinki, Finland; [Palotie, Aarno] Univ Helsinki, Inst Mol Med Finland, FIN-00290 Helsinki, Finland; [Palotie, Aarno] Broad Inst MIT & Harvard, Program Med & Populat Genet & Genet Anal Platform, Cambridge, MA 02142 USA","De Jonghe, P (reprint author), VIB, Dept Mol Genet, Neurogenet Grp, B-2610 Antwerp, Belgium.","peter.dejonghe@molgen.vib-ua.be","Esguerra, Camila/D-7657-2014","Esguerra, Camila/0000-0001-7891-1427","European Science Foundation; state budget of Romania; Scientific and Technological Research Council of Turkey; National Science Centre Poland [800/N-ESF-EuroEPINOMICS/10/2011/0]; MH CZ-DRO, University Hospital Motol, Prague [00064203]; \"Investissements d'avenir\" [ANR-10-IAIHU-06]; Academy of Finland [141549, 251704]; Folkhalsan Research Foundation; Wellcome Trust [WT089062, 098051]; Academy of Finland Center of Excellence in Complex Disease Genetics grants [213506, 129680]; European Community [HEALTH-F4-2007-201413]; Synaptic Systems grant [242167]; Sigrid Juselius Foundation; European Commission [261123]; Federal Ministry of Education and Research [NGENplus/EMINet 01GS08123, IonNeurONet 01GM1105A]; German Research Foundation (DFG) [Le1030/11-1]; German Society for Epileptology; Fund for Scientific Research Flanders (FWO); Flemish government Methusalem excellence grant; University of Antwerp","We thank the probands and their families for their cooperation. The research was supported by the EUROCORES program EuroEPINOMICS of the European Science Foundation; funds from the state budget of Romania, managed by the Executive Agency for Higher Education, Research, Development, and Innovation Funding for Project 6-EUROC; the Scientific and Technological Research Council of Turkey; National Science Centre Poland funding for project 800/N-ESF-EuroEPINOMICS/10/2011/0; MH CZ-DRO, University Hospital Motol, Prague (00064203); \"Investissements d'avenir\" ANR-10-IAIHU-06; the Academy of Finland (grant 141549) and Folkhalsan Research Foundation; Wellcome Trust grants WT089062 and 098051; Academy of Finland grant 251704; Academy of Finland Center of Excellence in Complex Disease Genetics grants 213506 and 129680; the European Community's Seventh Framework Programme (FP7/2007-2013) ENGAGE Consortium (grant HEALTH-F4-2007-201413); Synaptic Systems grant 242167; the Sigrid Juselius Foundation; European Commission FP7 project 261123 (gEUVADIS); Federal Ministry of Education and Research NGENplus/EMINet 01GS08123; IonNeurONet 01GM1105A; German Research Foundation (DFG) Le1030/11-1; the German Society for Epileptology; the Fund for Scientific Research Flanders (FWO); the Flemish government Methusalem excellence grant; and the University of Antwerp. We thank the VIB Genetic Service Facility and the institute of Clinical Molecular Biology in Kiel for providing Sanger sequencing, supported in part by DFG Cluster of Excellence \"Inflammation at Interfaces\" and \"Future Ocean.\" We thank technicians S. Greve, S. Arndt, and T. Henke for technical support. G.K. is a member of the DFG-funded Cluster of Excellence \"Inflammation at Interfaces.\" A.S. is a FWO postdoctoral fellow. T.D. and A.K. are Institute of Science and Technology PhD fellows.",null,34,1,1,"CELL PRESS","CAMBRIDGE","600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA","0002-9297","1537-6605",null,"AM J HUM GENET","Am. J. Hum. Genet.","NOV 7",2013,93,5,null,null,null,null,967,975,null,"10.1016/j.ajhg.2013.09.017",null,9,"Genetics & Heredity","Genetics & Heredity","252HU","WOS:000326996600017"]
[null,null,null,null,"J","Mahelkova, G; Filous, A; Odehnal, M; Cendelin, J",null,null,null,"Mahelkova, Gabriela; Filous, Ales; Odehnal, Milan; Cendelin, Jiri",null,null,"Corneal Changes Assessed Using Confocal Microscopy in Patients With Unilateral Buphthalmos","INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"corneal confocal microscopy; congenital glaucoma; corneal endothelial cells; buphthalmos; corneal epithelial cells","PRIMARY CONGENITAL GLAUCOMA; PEDIATRIC CATARACT-SURGERY; IN-VIVO; KERATOCYTE DENSITY; STEM-CELLS; THICKNESS; PROLIFERATION; ENDOTHELIUM; MAINTENANCE; CHILDHOOD","PURPOSE. To compare corneal structures in buphthalmic eyes and healthy eyes in patients with unilateral congenital glaucoma using a corneal confocal microscope. METHODS. Ten patients with unilateral buphthalmos (mean +/- SD age, 14.85 +/- 5.12 years) were examined using corneal confocal microscopy. The cell density and cell area of endothelial cells and superficial and basal epithelial cells and the number of keratocytes were evaluated. RESULTS. There was no significant difference between the cell density of superficial epithelial cells in buphthalmic eyes relative to healthy eyes (P = 0.1944). The cell density of basal epithelial cells was significantly higher (P = 0.0234) and the cell area was significantly smaller (P = 0.0181) in buphthalmic eyes relative to healthy eyes. There was no difference between the number of keratocytes in buphthalmic eyes and healthy eyes in the anterior stroma (P = 0.273) or in the posterior stroma (P = 0.0799). The cell density of endothelial cells was significantly lower and the cell area was significantly larger in buphthalmic eyes relative to healthy eyes (P = 0.0009). CONCLUSIONS. We demonstrated a lower cell density of endothelial cells in buphthalmic eyes. We found no differences in keratocyte density between the buphthalmic eyes and healthy eyes. The cell density of basal epithelial cells was higher in buphthalmic eyes. These differences could be due to buphthalmos or due to the previous surgical and medical therapies. Monitoring of these changes could help to contribute to accurate assessments regarding future ocular surgical procedures.","[Mahelkova, Gabriela; Filous, Ales; Odehnal, Milan; Cendelin, Jiri] Charles Univ Prague, Fac Med 2, Dept Ophthalmol, Motol Univ Hosp, Prague 5, Czech Republic; [Mahelkova, Gabriela] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague 5, Czech Republic; [Cendelin, Jiri] OFTA Eye Surg Ctr, Plzen, Czech Republic","Mahelkova, G (reprint author), Charles Univ Prague, Fac Med 2, Dept Ophthalmol, Prague 5, Czech Republic.","gabriela.mahelkova@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic - conceptual development of research organization; University Hospital Motol, Prague, Czech Republic [00064203]; Education for Competitiveness Operational Programme (ECOP) Prague [CZ.2.16/3.1.00/24022]","Supported by Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203, and the Education for Competitiveness Operational Programme (ECOP) Prague CZ.2.16/3.1.00/24022.",null,42,0,0,"ASSOC RESEARCH VISION OPHTHALMOLOGY INC","ROCKVILLE","12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA","0146-0404",null,null,"INVEST OPHTH VIS SCI","Invest. Ophthalmol. Vis. Sci.","JUN",2013,54,6,null,null,null,null,4048,4053,null,"10.1167/iovs.12-11165",null,6,"Ophthalmology","Ophthalmology","173YW","WOS:000321120700030"]
[null,null,null,null,"J","Krsek, P; Kudr, M; Jahodova, A; Komarek, V; Maton, B; Malone, S; Miller, I; Jayakar, P; Resnick, T; Duchowny, M",null,null,null,"Krsek, Pavel; Kudr, Martin; Jahodova, Alena; Komarek, Vladimir; Maton, Bruno; Malone, Stephen; Miller, Ian; Jayakar, Prasanna; Resnick, Trevor; Duchowny, Michael",null,null,"Localizing value of ictal SPECT is comparable to MRI and EEG in children with focal cortical dysplasia","EPILEPSIA",null,null,"English","Article",null,null,null,null,null,"Ictal SPECT; Focal cortical dysplasia; Epilepsy surgery; Completeness of resection; Outcome","TEMPORAL-LOBE EPILEPSY; EXTRATEMPORAL EPILEPSY; EPILEPTOGENIC ZONE; BASAL GANGLIA; SEIZURE FOCI; SUBTRACTION; SURGERY; LOCALIZATION; HYPERPERFUSION; IMAGE","Purpose To assess the predictive value of ictal single-photon emission computed tomography (SPECT) for outcome after excisional epilepsy surgery in a large population of children with focal cortical dysplasia (FCD). Methods One hundred seventy-three ictal SPECT studies in 106 children with histologically proven FCD were retrospectively analyzed. The extent and location of ictal hyperperfusion and completeness of surgical removal were assessed. Completeness of resection of epileptogenic regions defined by ictal SPECT, electroencephalography (EEG), and magnetic resonance imaging (MRI) were compared and correlated with postoperative seizure outcome. In addition, subcortical activation of the cerebellum, basal ganglia, and thalamus were analyzed. Key Findings The extent of hyperperfusion was focal or lobar in 58%, whereas multilobar activations occurred in only 32%; hemispheric or bilateral findings were rare. Favorable postsurgical seizure outcome was achieved in 67% patients with nonlocalized SPECT findings, 45% with nonresected ictal hyperperfusion, 36% with partially resected ictal hyperperfusion, and 86% when the zone of ictal hyperperfusion was completely resected (p= 0.000198). The favorable postsurgical outcome after complete removal of the SPECT hyperperfusion zone surpassed the 75% rate of seizure freedom in patients with removal of MRI/EEG-defined epileptogenic region. A similar predictive value of ictal SPECT for seizure outcome was found in nonoperated patients and subjects who were undergoing reoperation. Subcortical activation conferred no predictive value. Significance Ictal SPECT helps to define the epileptogenic zone in a high proportion of children with FCD undergoing surgical evaluation. Complete removal of both SPECT and MRI/EEG-defined regions is a strong predictor of surgical success and has important implications for surgical planning.","[Krsek, Pavel; Kudr, Martin; Jahodova, Alena; Komarek, Vladimir] Charles Univ Prague, Dept Pediat Neurol, Univ Hosp Motol, Fac Med 2, Prague, Czech Republic; [Maton, Bruno; Malone, Stephen; Miller, Ian; Jayakar, Prasanna; Resnick, Trevor; Duchowny, Michael] Miami Childrens Hosp, Dept Neurol, Inst Brain, Miami, FL USA; [Maton, Bruno; Malone, Stephen; Miller, Ian; Jayakar, Prasanna; Resnick, Trevor; Duchowny, Michael] Miami Childrens Hosp, Comprehens Epilepsy Program, Inst Brain, Miami, FL USA; [Resnick, Trevor; Duchowny, Michael] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA","Duchowny, M (reprint author), Univ Miami, Miller Sch Med, Dept Neurol, Brain Inst,Miami Childrens Hosp, 3200 SW 60th Court, Miami, FL 33136 USA.","michael.duchowny@mch.com",null,null,"Kontakt Program [ME09042]; GAUK [17010]; project for conceptual development of research organization [00064203];  [CZ.2.16/3.1.00/24022]","Supported by grants Kontakt Program ME09042, GAUK 17010, and CZ.2.16/3.1.00/24022, and by the project for conceptual development of research organization 00064203.",null,29,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0013-9580",null,null,"EPILEPSIA","Epilepsia","FEB",2013,54,2,null,null,null,null,351,358,null,"10.1111/epi.12059",null,8,"Clinical Neurology","Neurosciences & Neurology","087GT","WOS:000314750200019"]
[null,null,null,null,"J","Krsek, P; Jahodova, A; Kyncl, M; Kudr, M; Komarek, V; Jezdik, P; Jayakar, P; Miller, I; Korman, B; Rey, G; Resnick, T; Duchowny, M",null,null,null,"Krsek, Pavel; Jahodova, Alena; Kyncl, Martin; Kudr, Martin; Komarek, Vladimir; Jezdik, Petr; Jayakar, Prasanna; Miller, Ian; Korman, Brandon; Rey, Gustavo; Resnick, Trevor; Duchowny, Michael",null,null,"Predictors of seizure-free outcome after epilepsy surgery for pediatric tuberous sclerosis complex","EPILEPSIA",null,null,"English","Article",null,null,null,null,null,"Tuberous sclerosis complex; Epilepsy surgery; Completeness of resection; EEG; Seizure outcome","CORTICAL DYSPLASIA; CHILDREN; CHALLENGES; LESIONS","PurposeVariable predictors of postsurgical seizure outcome have been reported in children with tuberous sclerosis complex (TSC). We analyzed a large surgical series of pediatric TSC patients in order to identify prognostic factors crucial for selection of subjects for epilepsy surgery. MethodsThirty-three children with TSC who underwent excisional epilepsy surgery at Miami Children's Hospital were retrospectively reviewed. A total of 29 clinical, neuropsychological, electroencephalography (EEG), magnetic resonance imaging (MRI), and surgical variables were analyzed and related to seizure outcomes. Univariate Barnard's exact test, Wilcoxon's rank-sum test, and multivariate statistical Cox's model were used to examine the significance of associations between the variables and seizure outcome. Key FindingsEighteen patients (55%) have been seizure-free 2years after (final) surgery; postoperative complications occurred in five subjects (15%). Complete removal of epileptogenic tissue detected by both MRI and intracranial EEG, regional scalp interictal EEG patterns, and agreement of interictal and ictal EEG localization were the most powerful predictors of seizure-free outcome. Other significant predictors included occurrence of regional scalp ictal EEG patterns, fewer brain regions affected by tubers, presence of preoperative hemiparesis, and one-stage surgery. Remaining factors such as age at seizure onset, incidence of infantile spasms or other seizure types, duration of epilepsy, seizure frequency, mental retardation, as well as types and extent of resections did not influence outcome. SignificancePerioperative features rather than preoperative variables are the most important determinants of postsurgical seizure outcome in patients with TSC. Our findings may assist in the surgical management of these patients.","[Krsek, Pavel; Jahodova, Alena; Kudr, Martin; Komarek, Vladimir] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Pediat Neurol, Prague, Czech Republic; [Kyncl, Martin] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Radiol, Prague, Czech Republic; [Jezdik, Petr] Czech Tech Univ, Fac Elect, Dept Measurement, CR-16635 Prague, Czech Republic; [Jayakar, Prasanna; Miller, Ian; Resnick, Trevor; Duchowny, Michael] Miami Childrens Hosp, Inst Brain, Dept Neurol, Miami, FL USA; [Jayakar, Prasanna; Miller, Ian; Resnick, Trevor; Duchowny, Michael] Miami Childrens Hosp, Inst Brain, Comprehens Epilepsy Program, Miami, FL USA; [Korman, Brandon; Rey, Gustavo] Miami Childrens Hosp, Inst Brain, Neuropsychol Sect, Miami, FL USA; [Korman, Brandon; Rey, Gustavo] Miami Childrens Hosp, Miami, FL USA; [Resnick, Trevor; Duchowny, Michael] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA","Duchowny, M (reprint author), Univ Miami, Miami Childrens Hosp, Miller Sch Med, Dept Neurol,Brain Inst, 3200 SW 60th Court, Miami, FL 33136 USA.","michael.duchowny@mch.com",null,null,"IGA [NT13357-4/2012]; MH CZ - DRO, University Hospital Motol, Prague, Czech Republic [00064203]","Supported by grants IGA NT13357-4/2012 and by MH CZ - DRO, University Hospital Motol, Prague, Czech Republic 00064203.",null,32,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0013-9580","1528-1167",null,"EPILEPSIA","Epilepsia","NOV",2013,54,11,null,null,null,null,1913,1921,null,"10.1111/epi.12371",null,9,"Clinical Neurology","Neurosciences & Neurology","246PJ","WOS:000326551300012"]
[null,null,null,null,"J","Cvachovec, K",null,null,null,"Cvachovec, Karel",null,"Czech Soc Anaesthesiology","BOLDT: THE GREAT PRETENDER Boldt has never worked in the Czech Republic","BMJ-BRITISH MEDICAL JOURNAL",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Cvachovec, Karel; Czech Soc Anaesthesiology] Motol Univ Hosp, Prague 15006, Czech Republic; [Cvachovec, Karel] Motol Univ Hosp, Czech Soc Anaesthesiol & Intens Care Med, Prague 15006, Czech Republic","Cvachovec, K (reprint author), Motol Univ Hosp, Prague 15006, Czech Republic.","karel.cvachovec@fnmotol.cz",null,null,null,null,null,1,0,0,"BMJ PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","1756-1833",null,null,"BMJ-BRIT MED J","BMJ-British Medical Journal","APR 16",2013,346,null,null,null,null,null,null,null,"f2281","10.1136/bmj.f2281",null,1,"Medicine, General & Internal","General & Internal Medicine","131AO","WOS:000317962900030"]
[null,null,null,null,"J","Sundstrom, T; Daphu, I; Wendelbo, I; Hodneland, E; Lundervold, A; Immervoll, H; Skaftnesmo, KO; Babic, M; Jendelova, P; Sykova, E; Lund-Johansen, M; Bjerkvig, R; Thorsen, F",null,null,null,"Sundstrom, Terje; Daphu, Inderjit; Wendelbo, Ingvild; Hodneland, Erlend; Lundervold, Arvid; Immervoll, Heike; Skaftnesmo, Kai Ove; Babic, Michal; Jendelova, Pavla; Sykova, Eva; Lund-Johansen, Morten; Bjerkvig, Rolf; Thorsen, Frits",null,null,"Automated Tracking of Nanoparticle-labeled Melanoma Cells Improves the Predictive Power of a Brain Metastasis Model","CANCER RESEARCH",null,null,"English","Article",null,null,null,null,null,null,"IRON-OXIDE NANOPARTICLES; HUMAN TUMOR XENOGRAFTS; IN-VIVO MRI; MAGNETIC NANOPARTICLES; DRUG-SENSITIVITY; CANCER; BIOLOGY; TRIAL; FATE; MICE","Biologic and therapeutic advances in melanoma brain metastasis are hampered by the paucity of reproducible and predictive animal models. In this work, we developed a robust model of brain metastasis that empowers quantitative tracking of cellular dissemination and tumor progression. Human melanoma cells labeled with superparamagnetic iron oxide nanoparticles (SPION) were injected into the left cardiac ventricle of mice and visualized by MRI. We showed that SPION exposure did not affect viability, growth, or migration in multiple cell lines across several in vitro assays. Moreover, labeling did not impose changes in cell-cycle distribution or apoptosis. In vivo, several SPION-positive cell lines displayed similar cerebral imaging and histologic features. MRI-based automated quantification of labeled cells in the brain showed a sigmoid association between metastasis frequency and doses of inoculated cells. Validation of this fully automated quantification showed a strong correlation with manual signal registration (r(2) = 0.921, P < 0.001) and incidence of brain metastases (r(2) = 0.708, P < 0.001). Metastasis formation resembled the pattern seen in humans and was unaffected by SPION labeling (histology; tumor count, P = 0.686; survival, P = 0.547). In summary, we present here a highly reproducible animal model that can improve the predictive value of mechanistic and therapeutic studies of melanoma brain metastasis. Cancer Res; 73(8); 2445-56. (C) 2013 AACR.","[Sundstrom, Terje; Daphu, Inderjit; Wendelbo, Ingvild; Hodneland, Erlend; Lundervold, Arvid; Skaftnesmo, Kai Ove; Bjerkvig, Rolf; Thorsen, Frits] Univ Bergen, Dept Biomed, N-5009 Bergen, Norway; [Sundstrom, Terje; Lund-Johansen, Morten] Univ Bergen, Dept Surg Sci, N-5009 Bergen, Norway; [Sundstrom, Terje; Lund-Johansen, Morten] Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway; [Immervoll, Heike] Alesund Hosp, Dept Pathol, Alesund, Norway; [Babic, Michal] Acad Sci Czech Republic, Inst Macromol Chem, Dept Polymer Particles, Prague, Czech Republic; [Jendelova, Pavla; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Prague, Czech Republic; [Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Bjerkvig, Rolf] Ctr Rech Publ Sante, NorLux Neurooncol Lab, Luxembourg, Luxembourg","Thorsen, F (reprint author), Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway.","frits.thorsen@biomed.uib.no",null,null,"Western Norway Regional Health Authority [911645, 911558]; University of Bergen; Norwegian Cancer Society; Norwegian Research Council; Grant Agency of the Czech Republic [P304/12/1370]; Centre de Recherce Public de la Sante Luxembourg","This study was funded by the Western Norway Regional Health Authority (grants 911645 and 911558), the University of Bergen, the Norwegian Cancer Society, the Norwegian Research Council, the Grant Agency of the Czech Republic (grant P304/12/1370), and the Centre de Recherce Public de la Sante Luxembourg.",null,50,6,6,"AMER ASSOC CANCER RESEARCH","PHILADELPHIA","615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA","0008-5472",null,null,"CANCER RES","Cancer Res.","APR 15",2013,73,8,null,null,null,null,2445,2456,null,"10.1158/0008-5472.CAN-12-3514",null,12,"Oncology","Oncology","126ER","WOS:000317595800009"]
[null,null,null,null,"J","Beniczky, S; Aurlien, H; Brogger, JC; Fuglsang-Frederiksen, A; Martins-da-Silva, A; Trinka, E; Visser, G; Rubboli, G; Hjalgrim, H; Stefan, H; Rosen, I; Zarubova, J; Dobesberger, J; Alving, J; Andersen, KV; Fabricius, M; Atkins, MD; Neufeld, M; Plouin, P; Marusic, P; Pressler, R; Mameniskiene, R; Hopfengartner, R; Boas, WV; Wolf, P",null,null,null,"Beniczky, Sandor; Aurlien, Harald; Brogger, Jan C.; Fuglsang-Frederiksen, Anders; Martins-da-Silva, Antonio; Trinka, Eugen; Visser, Gerhard; Rubboli, Guido; Hjalgrim, Helle; Stefan, Hermann; Rosen, Ingmar; Zarubova, Jana; Dobesberger, Judith; Alving, Jorgen; Andersen, Kjeld V.; Fabricius, Martin; Atkins, Mary D.; Neufeld, Miri; Plouin, Perrine; Marusic, Petr; Pressler, Ronit; Mameniskiene, Ruta; Hopfengaertner, Ruediger; Boas, Walter van Emde; Wolf, Peter",null,null,"Standardized Computer-based Organized Reporting of EEG: SCORE","EPILEPSIA",null,null,"English","Article",null,null,null,null,null,"Assessment; Database; Definitions; EEG; Semiology; Terms","EPILEPTIFORM ACTIVITY; SEIZURES; EPILEPSY; DATABASE; CLASSIFICATION; REQUIREMENTS; COMMISSION","The electroencephalography (EEG) signal has a high complexity, and the process of extracting clinically relevant features is achieved by visual analysis of the recordings. The interobserver agreement in EEG interpretation is only moderate. This is partly due to the method of reporting the findings in free-text format. The purpose of our endeavor was to create a computer-based system for EEG assessment and reporting, where the physicians would construct the reports by choosing from predefined elements for each relevant EEG feature, as well as the clinical phenomena (for video-EEG recordings). A working group of EEG experts took part in consensus workshops in Dianalund, Denmark, in 2010 and 2011. The faculty was approved by the Commission on European Affairs of the International League Against Epilepsy (ILAE). The working group produced a consensus proposal that went through a pan-European review process, organized by the European Chapter of the International Federation of Clinical Neurophysiology. The Standardised Computer-based Organised Reporting of EEG (SCORE) software was constructed based on the terms and features of the consensus statement and it was tested in the clinical practice. The main elements of SCORE are the following: personal data of the patient, referral data, recording conditions, modulators, background activity, drowsiness and sleep, interictal findings, episodes (clinical or subclinical events), physiologic patterns, patterns of uncertain significance, artifacts, polygraphic channels, and diagnostic significance. The following specific aspects of the neonatal EEGs are scored: alertness, temporal organization, and spatial organization. For each EEG finding, relevant features are scored using predefined terms. Definitions are provided for all EEG terms and features. SCORE can potentially improve the quality of EEG assessment and reporting; it will help incorporate the results of computer-assisted analysis into the report, it will make possible the build-up of a multinational database, and it will help in training young neurophysiologists.","[Beniczky, Sandor; Rubboli, Guido; Hjalgrim, Helle; Alving, Jorgen; Atkins, Mary D.] Danish Epilepsy Ctr, Dept Clin Neurophysiol, DK-4293 Dianalund, Denmark; [Beniczky, Sandor; Fuglsang-Frederiksen, Anders] Univ Aarhus, Dept Clin Neurophysiol, Aarhus, Denmark; [Aurlien, Harald; Brogger, Jan C.] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway; [Aurlien, Harald; Brogger, Jan C.] Univ Bergen, Dept Clin Med, Bergen, Norway; [Martins-da-Silva, Antonio] Hosp Santo Antonio CHP, Dept Neurol Disorders, Oporto, Portugal; [Martins-da-Silva, Antonio] Univ Porto, UMIB ICBAS, P-4100 Oporto, Portugal; [Trinka, Eugen; Dobesberger, Judith] Paracelsus Med Univ, Dept Neurol, Salzburg, Austria; [Visser, Gerhard; Boas, Walter van Emde] Epilepsy Inst Netherlands SEIN, Dept Clin Neurophysiol, Heemstede, Netherlands; [Rubboli, Guido] Bellaria Hosp, IRCCS Inst Neurol Sci, Bologna, Italy; [Stefan, Hermann; Hopfengaertner, Ruediger] Univ Hosp Erlangen, Neurol Clin, Epilepsy Ctr, Erlangen, Germany; [Rosen, Ingmar] Lund Univ, Dept Clin Neurophysiol, Lund, Sweden; [Zarubova, Jana] Thomayer Hosp, Dept Neurol, Prague, Czech Republic; [Andersen, Kjeld V.; Fabricius, Martin] Univ Copenhagen, Glostrup Hosp, Dept Clin Neurophysiol, Copenhagen, Denmark; [Andersen, Kjeld V.] Normark Hosp, Ishoj, Denmark; [Neufeld, Miri] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, EEG & Epilepsy Unit, Dept Neurol, IL-69978 Tel Aviv, Israel; [Plouin, Perrine] Hop Necker Enfants Malad, Paris, France; [Marusic, Petr] Charles Univ Prague, Fac Med 2, Dept Neurol, Motol Univ Hosp, Prague, Czech Republic; [Pressler, Ronit] NHS Fdn Trust, Great Ormond St Hosp Children, London, England; [Mameniskiene, Ruta] Vilnius Univ Hosp Santariskiu Klinikos, Dept Neurol, Vilnius, Lithuania; [Mameniskiene, Ruta] Vilnius State Univ, Fac Med, Clin Neurol & Neurosurg, Vilnius, Lithuania; [Wolf, Peter] Danish Epilepsy Ctr, Dept Neurol, DK-4293 Dianalund, Denmark","Beniczky, S (reprint author), Danish Epilepsy Ctr, Visbys Alle 5, DK-4293 Dianalund, Denmark.","sbz@filadelfia.dk",null,null,null,null,null,28,5,5,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0013-9580",null,null,"EPILEPSIA","Epilepsia","JUN",2013,54,6,null,null,null,null,1112,1124,null,"10.1111/epi.12135",null,13,"Clinical Neurology","Neurosciences & Neurology","157CR","WOS:000319873800021"]
[null,null,null,null,"J","Rudnik-Schoneborn, S; Senderek, J; Jen, JC; Houge, G; Seeman, P; Puchmajerova, A; Graul-Neumann, L; Seidel, U; Korinthenberg, R; Kirschner, J; Seeger, J; Ryan, MM; Muntoni, F; Steinlin, M; Sztriha, L; Colomer, J; Hubner, C; Brockmann, K; Van Maldergem, L; Schiff, M; Holzinger, A; Barth, P; Reardon, W; Yourshaw, M; Nelson, SF; Eggermann, T; Zerres, K",null,null,null,"Rudnik-Schoeneborn, Sabine; Senderek, Jan; Jen, Joanna C.; Houge, Gunnar; Seeman, Pavel; Puchmajerova, Alena; Graul-Neumann, Luitgard; Seidel, Ulrich; Korinthenberg, Rudolf; Kirschner, Janbernd; Seeger, Juergen; Ryan, Monique M.; Muntoni, Francesco; Steinlin, Maja; Sztriha, Laszlo; Colomer, Jaume; Huebner, Christoph; Brockmann, Knut; Van Maldergem, Lionel; Schiff, Manuel; Holzinger, Andreas; Barth, Peter; Reardon, William; Yourshaw, Michael; Nelson, Stanley F.; Eggermann, Thomas; Zerres, Klaus",null,null,"Pontocerebellar hypoplasia type 1 Clinical spectrum and relevance of EXOSC3 mutations","NEUROLOGY",null,null,"English","Article",null,null,null,null,null,null,"WERDNIG-HOFFMANN DISEASE; SPINAL MUSCULAR-ATROPHY; HORN CELL DISEASE; CEREBELLAR HYPOPLASIA; OLIVOPONTOCEREBELLAR HYPOPLASIA; ONSET; CLASSIFICATION; DEGENERATION; INVOLVEMENT","Objectives: Pontocerebellar hypoplasia with spinal muscular atrophy, also known as PCH1, is a group of autosomal recessive disorders characterized by generalized muscle weakness and global developmental delay commonly resulting in early death. Gene defects had been discovered only in single patients until the recent identification of EXOSC3 mutations in several families with relatively mild course of PCH1. We aim to genetically stratify subjects in a large and well-defined cohort to define the clinical spectrum and genotype-phenotype correlation. Methods: We documented clinical, neuroimaging, and morphologic data of 37 subjects from 27 families with PCH1. EXOSC3 gene sequencing was performed in 27 unrelated index patients of mixed ethnicity. Results: Biallelic mutations in EXOSC3 were detected in 10 of 27 families (37%). The most common mutation among all ethnic groups was c.395A>C, p.D132A, responsible for 11 (55%) of the 20 mutated alleles and ancestral in origin. The mutation-positive subjects typically presented with normal pregnancy, normal birth measurements, and relative preservation of brainstem and cortical structures. Psychomotor retardation was profound in all patients but lifespan was variable, with 3 subjects surviving beyond the late teens. Abnormal oculomotor function was commonly observed in patients surviving beyond the first year. Major clinical features previously reported in PCH1, including intrauterine abnormalities, postnatal hypoventilation and feeding difficulties, joint contractures, and neonatal death, were rarely observed inmutation-positive infants but were typical among themutation-negative subjects. Conclusion: EXOSC3 mutations account for 30%-40% of patients with PCH1 with variability in survival and clinical severity that is correlated with the genotype. Neurology (R) 2013;80:438-446","[Rudnik-Schoeneborn, Sabine; Senderek, Jan; Eggermann, Thomas; Zerres, Klaus] Univ Hosp Aachen, Fac Med, Inst Human Genet, Aachen, Germany; [Jen, Joanna C.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Yourshaw, Michael; Nelson, Stanley F.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA; [Nelson, Stanley F.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA; [Nelson, Stanley F.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA; [Houge, Gunnar] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway; [Seeman, Pavel] Charles Univ Prague, Fac Med 2, Dept Child Neurol, Prague, Czech Republic; Univ Hosp, Prague, Czech Republic; [Puchmajerova, Alena] Univ Hosp Motol, Inst Biol & Med Genet, Prague, Czech Republic; [Graul-Neumann, Luitgard] Charite, Inst Med & Human Genet, D-13353 Berlin, Germany; [Seidel, Ulrich] Charite, Dept Pediat, D-13353 Berlin, Germany; [Huebner, Christoph] Charite, Dept Neuropediat, D-13353 Berlin, Germany; [Korinthenberg, Rudolf; Kirschner, Janbernd] Univ Med Ctr Freiburg, Dept Pediat, Freiburg, Germany; [Seeger, Juergen] German Clin Diagnost, Wiesbaden, Germany; [Ryan, Monique M.] Univ Melbourne, Murdoch Childrens Res Inst, Royal Childrens Hosp, Melbourne, Vic 3010, Australia; [Muntoni, Francesco] UCL Inst Child Hlth, London, England; [Muntoni, Francesco] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Steinlin, Maja] Univ Childrens Hosp Bern, Dept Neuropediat, Bern, Switzerland; [Sztriha, Laszlo] Univ Szeged, Dept Pediat, Szeged, Hungary; [Colomer, Jaume] Hosp St Joan de Deu, Serv Neurol, Unitat Patol Neuromuscular, Barcelona, Spain; [Brockmann, Knut] Univ Gottingen, Fac Med, Dept Pediat & Pediat Neurol, D-37073 Gottingen, Germany; [Van Maldergem, Lionel] Univ Franche Comte, Ctr Human Genet, F-25030 Besancon, France; [Schiff, Manuel] Hop Robert Debre, Dept Child Neurol & Metab Dis, F-75019 Paris, France; [Holzinger, Andreas] Univ Munich, Dr von Haunersches Kinderspital, Dept Pediat, Munich, Germany; [Senderek, Jan] Univ Munich, Friedrich Baur Inst, Munich, Germany; [Barth, Peter] Univ Hosp Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Div Pediat Neurol, Amsterdam, Netherlands; [Reardon, William] Our Ladys Hosp Sick Children, Dublin, Ireland","Rudnik-Schoneborn, S (reprint author), Univ Hosp Aachen, Fac Med, Inst Human Genet, Aachen, Germany.","srudnik-schoeneborn@ukaachen.de",null,null,"Deutsche Forschungsgemeinschaft [RU 746/1-1]; IZKF Biomat [N5-4]; Bioinformatics and Genomics Core of the UCLA Muscular Dystrophy Core Center within the Center for Duchenne Muscular Dystrophy [NIH/NIAMS P30AR057230]; NEI [EY015311]; NINDS [NS064183]; IGA MH NS [11523-4]; Great Ormond Street Children's Charity","Supported by the Deutsche Forschungsgemeinschaft (RU 746/1-1) for S.R.-S. and K.Z. and by IZKF Biomat (project N5-4) for S.R.-S. and J.S. The genotyping and analytical work was supported by the Bioinformatics and Genomics Core of the UCLA Muscular Dystrophy Core Center (NIH/NIAMS P30AR057230 to S.F.N.) within the Center for Duchenne Muscular Dystrophy. Also supported by NEI EY015311 and NINDS NS064183 (J.C. J.). P.S. is supported by IGA MH NS 11523-4. F.M. is supported by the Great Ormond Street Children's Charity.",null,25,5,5,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0028-3878",null,null,"NEUROLOGY","Neurology","JAN",2013,80,5,null,null,null,null,438,446,null,"10.1212/WNL.0b013e31827f0f66",null,9,"Clinical Neurology","Neurosciences & Neurology","079GW","WOS:000314159600011"]
[null,null,null,null,"J","Lipska, BS; Iatropoulos, P; Maranta, R; Caridi, G; Ozaltin, F; Anarat, A; Balat, A; Gellermann, J; Trautmann, A; Erdogan, O; Saeed, B; Emre, S; Bogdanovic, R; Azocar, M; Balasz-Chmielewska, I; Benetti, E; Caliskan, S; Mir, S; Melk, A; Ertan, P; Baskin, E; Jardim, H; Davitaia, T; Wasilewska, A; Drozdz, D; Szczepanska, M; Jankauskiene, A; Higuita, LMS; Ardissino, G; Ozkaya, O; Kuzma-Mroczkowska, E; Soylemezoglu, O; Ranchin, B; Medynska, A; Tkaczyk, M; Peco-Antic, A; Akil, I; Jarmolinski, T; Firszt-Adamczyk, A; Dusek, J; Simonetti, GD; Gok, F; Gheissari, A; Emma, F; Krmar, RT; Fischbach, M; Printza, N; Simkova, E; Mele, C; Ghiggeri, GM; Schaefer, F",null,null,null,"Lipska, Beata S.; Iatropoulos, Paraskevas; Maranta, Ramona; Caridi, Gianluca; Ozaltin, Fatih; Anarat, Ali; Balat, Ayse; Gellermann, Jutta; Trautmann, Agnes; Erdogan, Ozlem; Saeed, Bassam; Emre, Sevinc; Bogdanovic, Radovan; Azocar, Marta; Balasz-Chmielewska, Irena; Benetti, Elisa; Caliskan, Salim; Mir, Sevgi; Melk, Anette; Ertan, Pelin; Baskin, Esra; Jardim, Helena; Davitaia, Tinatin; Wasilewska, Anna; Drozdz, Dorota; Szczepanska, Maria; Jankauskiene, Augustina; Serna Higuita, Lina Maria; Ardissino, Gianluigi; Ozkaya, Ozan; Kuzma-Mroczkowska, Elzbieta; Soylemezoglu, Oguz; Ranchin, Bruno; Medynska, Anna; Tkaczyk, Marcin; Peco-Antic, Amira; Akil, Ipek; Jarmolinski, Tomasz; Firszt-Adamczyk, Agnieszka; Dusek, Jiri; Simonetti, Giacomo D.; Gok, Faysal; Gheissari, Alaleh; Emma, Francesco; Krmar, Rafael T.; Fischbach, Michel; Printza, Nikoleta; Simkova, Eva; Mele, Caterina; Ghiggeri, Gian Marco; Schaefer, Franz",null,"PodoNet Consortium","Genetic screening in adolescents with steroid-resistant nephrotic syndrome","KIDNEY INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"INF2; juvenile steroid-resistant nephrotic syndrome; NPHS2; WT1","FOCAL-SEGMENTAL GLOMERULOSCLEROSIS; PODOCIN MUTATIONS; WT1 MUTATIONS; NPHS2; PHENOTYPE; ALPHA-ACTININ-4; CHILDHOOD; CHILDREN; DISEASE; R229Q","Genetic screening paradigms for congenital and infantile nephrotic syndrome are well established; however, screening in adolescents has received only minor attention. To help rectify this, we analyzed an unselected adolescent cohort of the international PodoNet registry to develop a rational screening approach based on 227 patients with nonsyndromic steroid-resistant nephrotic syndrome aged 10-20 years. Of these, 21% had a positive family history. Autosomal dominant cases were screened for WT1, TRPC6, ACTN4, and INF2 mutations. All other patients had the NPHS2 gene screened, and WT1 was tested in sporadic cases. In addition, 40 sporadic cases had the entire coding region of INF2 tested. Of the autosomal recessive and the sporadic cases, 13 and 6%, respectively, were found to have podocin-associated nephrotic syndrome, and 56% of them were compound heterozygous for the nonneutral p.R229Q polymorphism. Four percent of the sporadic and 10% of the autosomal dominant cases had a mutation in WT1. Pathogenic INF2 mutations were found in 20% of the dominant but none of the sporadic cases. In a large cohort of adolescents including both familial and sporadic disease, NPHS2 mutations explained about 7% and WT1 4% of cases, whereas INF2 proved relevant only in autosomal dominant familial disease. Thus, screening of the entire coding sequence of NPHS2 and exons 8-9 of WT1 appears to be the most rational and cost-effective screening approach in sporadic juvenile steroid-resistant nephrotic syndrome.","[Lipska, Beata S.; Trautmann, Agnes; Schaefer, Franz] Heidelberg Univ, Ctr Pediat & Adolescent Med, Div Pediat Nephrol, Heidelberg, Germany; [Lipska, Beata S.] Med Univ Gdansk, Dept Biol & Genet, PL-80211 Gdansk, Poland; [Iatropoulos, Paraskevas; Maranta, Ramona; Mele, Caterina] Mario Negri Inst Pharmacol Res, Clin Res Ctr Rare Dis ALDO E CELE DACCO, I-24100 Bergamo, Italy; [Caridi, Gianluca; Ghiggeri, Gian Marco] Ist Giannina Gaslini, Lab Fisiopatol Uremia, I-16148 Genoa, Italy; [Caridi, Gianluca; Ghiggeri, Gian Marco] Ist Giannina Gaslini, UOC Nefrol Dialisi & Trapianto, I-16148 Genoa, Italy; [Ozaltin, Fatih] Hacettepe Univ, Fac Med, Dept Pediat Nephrol, TR-06100 Ankara, Turkey; [Ozaltin, Fatih] Hacettepe Univ, Fac Med, Dept Rheumatol, TR-06100 Ankara, Turkey; [Ozaltin, Fatih] Hacettepe Univ, Fac Med, Nephrogenet Lab, TR-06100 Ankara, Turkey; [Anarat, Ali] Cukurova Univ, Fac Med, Pediat Nephrol Dept, Adana, Turkey; [Balat, Ayse] Gaziantep Univ, Fac Med, Dept Pediat Nephrol, Gaziantep, Turkey; [Gellermann, Jutta] Charite Campus Virchow Klinikum, Klin Padiat Nephrol, Berlin, Germany; [Erdogan, Ozlem] Sami Ulus Childrens Hosp, Ankara, Turkey; [Saeed, Bassam] Kidney Hosp Damascus, Dept Pediat Nephrol, Damascus, Syria; [Emre, Sevinc] Istanbul Univ, Istanbul Fac Med, Dept Pediat Nephrol, Istanbul, Turkey; [Bogdanovic, Radovan] Inst Mother & Child Healthcare Serbia, Dept Nephrol, Belgrade, Serbia; [Azocar, Marta] Hosp Ninos Luis Calvo Mackenna, Fac Chile, Unidad Nefrol Infantil, Santiago, Chile; [Balasz-Chmielewska, Irena] Med Univ Gdansk, Dept Pediat & Adolescent Nephrol, Gdansk, Poland; [Benetti, Elisa] Agenda Osped Univ Padova, Dept Pediat, Pediat Nephrol Dialysis & Transplant Unit, Padua, Italy; [Caliskan, Salim] Istanbul Univ, Cerrahpasa Med Fac, Dept Pediat Nephrol, Istanbul, Turkey; [Mir, Sevgi] Ege Univ, Fac Med, Dept Pediat Nephrol, Izmir, Turkey; [Melk, Anette] MHH Childrens Hosp, Hannover, Germany; [Ertan, Pelin; Akil, Ipek] Celal Bayar Univ, Dept Pediat Nephrol, Manisa, Turkey; [Baskin, Esra] Baskent Univ Hosp, Dept Pediat Nephrol, Ankara, Turkey; [Jardim, Helena] Ctr Hosp Porto, Oporto, Portugal; [Davitaia, Tinatin] M Iashvili Children Cent Hosp, Tbilisi, Rep of Georgia; [Wasilewska, Anna] Univ Bialystok, Dept Pediat Nephrol, Bialystok, Poland; [Drozdz, Dorota] Jagiellonian Univ, Coll Med, Dialysis Unit, Dept Pediat Nephrol, Krakow, Poland; [Szczepanska, Maria] Med Univ Silesia, Dept & Clin Pediat, Dialysis Div Children, Zabrze, Poland; [Jankauskiene, Augustina] Vilnius Univ, Childrens Hosp, Vilnius, Lithuania; [Serna Higuita, Lina Maria] Hosp Pablo Tobon Uribe, Medellin, Antioquia, Colombia; [Ardissino, Gianluigi] IRCCS Fdn, Osped Maggiore Policlin, UOC Nefrol & Dialisi Pediat, Milan, Italy; [Ozkaya, Ozan] Ondokuz Mayis Univ, Fac Med, Dept Pediat Nephrol, Samsun, Turkey; [Kuzma-Mroczkowska, Elzbieta] Univ Warsaw, Dept Pediat Nephrol, Warsaw, Poland; [Soylemezoglu, Oguz] Gazi Univ Hosp, Pediat Nephrol Dept, Ankara, Turkey; [Ranchin, Bruno] Hop Femme Mere Enfant, Ctr Reference Malad Renales Rares, Serv Pediat, Lyon, France; [Ranchin, Bruno] Hop Femme Mere Enfant, Ctr Reference Malad Renales Rares, Inserm U820, Lyon, France; [Ranchin, Bruno] Univ Lyon, Lyon, France; [Medynska, Anna] Med Acad Wroclaw, Dept Pediat Nephrol, Wroclaw, Poland; [Tkaczyk, Marcin] Polish Mothers Mem Hosp, Res Inst, Dept Pediat & Immunol, Div Nephrol, Lodz, Poland; [Peco-Antic, Amira] Univ Childrens Hosp, Div Pediat Nephrol, Belgrade, Serbia; [Jarmolinski, Tomasz] Reg Hosp, Dept Pediat, Miedzyrzecz, Poland; [Firszt-Adamczyk, Agnieszka] Wojewodzki Szpital Dzieciecy, Oddzial Pediat Nefrol & Stacja Dializ, Torun, Poland; [Dusek, Jiri] Univ Hosp Motol, Dept Pediat 1, Prague, Czech Republic; [Simonetti, Giacomo D.] Univ Childrens Hosp, Inselspital Bern, Dept Pediat Nephrol, Bern, Switzerland; [Gok, Faysal] Gulhane Mil Med Acad, Ankara, Turkey; [Gheissari, Alaleh] Isfahan Univ Med Sci, St Al Zahra Hosp, Pediat Nephrol Dept, Esfahan, Iran; [Emma, Francesco] Osped Pediat Bambino, Nephrol & Dialysis Unit, Rome, Italy; [Krmar, Rafael T.] Karolinska Univ Hosp, Div Pediat, Stockholm, Sweden; [Fischbach, Michel] Hop Univ Strasbourg, Hop Hautepierre, Unite Dialyse Enfants, Serv Pediat 1, Strasbourg, France; [Printza, Nikoleta] Aristotle Univ Thessaloniki, Hippokrat Gen Hosp, Dept Pediat 1, GR-54006 Thessaloniki, Greece; [Simkova, Eva] Dubai Hosp, Dept Paediat, Dubai, U Arab Emirates","Lipska, BS (reprint author), Med Univ Gdansk, Dept Biol & Genet, Debinki 1, PL-80211 Gdansk, Poland.","b.lipska@gumed.edu.pl","Emma, Francesco/H-2116-2012",null,"E-Rare (PodoNet project); EU [305608]; Polish Ministry of Science and Education [N402631840]; German Research Foundation [Scha 477/11-1]; Chilean Fondecyt [11090045]; DAAD scholarship; Scientific and Technological Research Council of Turkey [108S417]; Hacettepe University [06A101008]","This work was financed by E-Rare (PodoNet project), the EU 7th Framework Programme (EURenOmics, grant 305608), the Polish Ministry of Science and Education grant N402631840, the German Research Foundation (Scha 477/11-1), and Chilean Fondecyt grant 11090045 (to MA). BSL was granted a DAAD scholarship. FO was supported by the Scientific and Technological Research Council of Turkey (grant 108S417) and by the Hacettepe University Infrastructure Project (grant 06A101008). We are grateful to Dr S Zietkiewicz from the Department of Molecular and Cellular Biology, Intercollegiate Faculty of Biotechnology at the University of Gdansk, Poland, for help with the in silico analyses.",null,37,4,5,"NATURE PUBLISHING GROUP","NEW YORK","75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA","0085-2538",null,null,"KIDNEY INT","Kidney Int.","JUL",2013,84,1,null,null,null,null,206,213,null,"10.1038/ki.2013.93",null,8,"Urology & Nephrology","Urology & Nephrology","172YV","WOS:000321044400026"]
[null,null,null,null,"J","Styczynski, J; Gil, L; Tridello, G; Ljungman, P; Donnelly, P; van der Velden, W; Omar, H; Martino, R; Halkes, C; Faraci, M; Theunissen, K; Kalwak, K; Hubacek, P; Sica, S; Nozzoli, C; Fagioli, F; Matthes, S; Diaz, MA; Migliavacca, M; Balduzzi, A; Tomaszewska, A; de la Camara, R; van Biezen, A; Hoek, J; Iacobelli, S; Einsele, H; Cesaro, S",null,null,null,"Styczynski, Jan; Gil, Lidia; Tridello, Gloria; Ljungman, Per; Donnelly, Peter; van der Velden, Walter; Omar, Hamdy; Martino, Rodrigo; Halkes, Constantijn; Faraci, Maura; Theunissen, Koen; Kalwak, Krzysztof; Hubacek, Petr; Sica, Simona; Nozzoli, Chiara; Fagioli, Franca; Matthes, Susanne; Diaz, Miguel A.; Migliavacca, Maddalena; Balduzzi, Adriana; Tomaszewska, Agnieszka; de la Camara, Rafael; van Biezen, Anja; Hoek, Jennifer; Iacobelli, Simona; Einsele, Hermann; Cesaro, Simone",null,"Infect Dis Working Party European","Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus-Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","CLINICAL INFECTIOUS DISEASES",null,null,"English","Article",null,null,null,null,null,"Epstein-Barr virus; post-transplant lymphoproliferative disorder; hematopoietic stem cell transplantation; risk factors; prognostic model","VERSUS-HOST-DISEASE; PROGNOSTIC-FACTORS; RECIPIENTS; LYMPHOMA; REACTIVATION; LYMPHOCYTES; PTLD; MANAGEMENT; LOAD; SCT","Background. The objective of this analysis was to investigate prognostic factors that influence the outcome of Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-based treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting. Methods. A total of 4466 allogeneic HSCTs performed between 1999 and 2011 in 19 European Group for Blood and Marrow Transplantation centers were retrospectively analyzed for PTLD, either biopsy-proven or probable disease. Results. One hundred forty-four cases of PTLD were identified, indicating an overall EBV-related PTLD frequency of 3.22%, ranging from 1.16% for matched-family donor, 2.86% for mismatched family donor, 3.97% in matched unrelated donors, and 11.24% in mismatched unrelated donor recipients. In total, 69.4% patients survived PTLD. Multivariable analysis showed that a poor response of PTLD to rituximab was associated with an age >= 30 years, involvement of extral-ymphoid tissue, acute GVHD, and a lack of reduction of immunosuppression upon PTLD diagnosis. In the prognostic model, the PTLD mortality increased with the increasing number of factors: 0-1, 2, or 3 factors being associated with mortality of 7%, 37%, and 72%, respectively (P < .0001). Immunosuppression tapering was associated with a lower PTLD mortality (16% vs 39%), and a decrease of EBV DNAemia in peripheral blood during therapy was predictive of better survival. Conclusions. More than two-thirds of patients with EBV-related PTLD survived after rituximab-based treatment. Reduction of immunosuppression was associated with improved outcome, whereas older age, extranodal disease, and acute graft-vs-host disease predicted poor outcome.","[Styczynski, Jan] Nicholas Copernicus Univ, Dept Pediat Hematol & Oncol, Coll Med, PL-85094 Bydgoszcz, Poland; [Gil, Lidia] Poznan Univ Med Sci, Dept Hematol, Poznan, Poland; [Tridello, Gloria; Cesaro, Simone] Policlin GB Rossi, Verona, Italy; [Ljungman, Per; Omar, Hamdy] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden; [Ljungman, Per] Karolinska Inst, Dept Med Huddinge, Div Hematol, Stockholm, Sweden; [Donnelly, Peter; van der Velden, Walter] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, NL-6525 ED Nijmegen, Netherlands; [Martino, Rodrigo] Hosp Santa Creu & Sant Pau, Barcelona, Spain; [Halkes, Constantijn] Leiden Univ Hosp, Leiden, Netherlands; [Faraci, Maura] G Gaslini Childrens Res Inst, Dept Hematol Oncol, Stem Cell Transplant Unit, Genoa, Italy; [Theunissen, Koen] Univ Leuven, Dept Hematol, Louvain, Belgium; [Kalwak, Krzysztof] Med Univ, Dept Pediat Transplantol Hematol & Oncol, Wroclaw, Poland; [Hubacek, Petr] Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Hubacek, Petr] Univ Hosp Motol, Dept Med Microbiol, Prague, Czech Republic; [Sica, Simona] Univ Cattolica S Cuore, Rome, Italy; [Nozzoli, Chiara] Careggi Hosp, Bone Marrow Transplantat Unit, Florence, Italy; [Fagioli, Franca] Oncoematol Pediat, Turin, Italy; [Matthes, Susanne] St Anna Childrens Hosp, Vienna, Austria; [Diaz, Miguel A.] Nino Jesus Childrens Hosp, Madrid, Spain; [Migliavacca, Maddalena; Balduzzi, Adriana] Clin Pediat Univ Milano Bicocca, Osped San Gerardo, Monza, Italy; [Tomaszewska, Agnieszka] Inst Hematol & Transfus Med, Warsaw, Poland; [de la Camara, Rafael] Hosp Princesa, Madrid, Spain; [van Biezen, Anja; Hoek, Jennifer] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, EBMT Data Off Leiden, NL-2300 RA Leiden, Netherlands; [Iacobelli, Simona] Univ Roma Tor Vergata, Ctr Interdipartimentale Biostat & Bioinformat, I-00173 Rome, Italy; [Einsele, Hermann] Univ Wurzburg, Dept Internal Med 2, Wurzburg, Germany; [Cesaro, Simone] Clin Oncoematol Pediat, Padua, Italy","Styczynski, J (reprint author), Nicholas Copernicus Univ, Dept Pediat Hematol & Oncol, Coll Med, Ul Curie Sklodowskiej 9, PL-85094 Bydgoszcz, Poland.","jstyczynski@cm.umk.pl",null,null,null,null,null,34,1,1,"OXFORD UNIV PRESS INC","CARY","JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA","1058-4838",null,null,"CLIN INFECT DIS","Clin. Infect. Dis.","SEP 15",2013,57,6,null,null,null,null,794,802,null,"10.1093/cid/cit391",null,9,"Immunology; Infectious Diseases; Microbiology","Immunology; Infectious Diseases; Microbiology","212YF","WOS:000324018100009"]
[null,null,null,null,"J","Rensing-Ehl, A; Janda, A; Lorenz, MR; Gladstone, BP; Fuchs, I; Abinun, M; Albert, M; Butler, K; Cant, A; Cseh, AM; Ebinger, M; Goldacker, S; Hambleton, S; Hebart, H; Houet, L; Kentouche, K; Kuhnle, I; Lehmberg, K; Mejstrikova, E; Niemeyer, C; Minkov, M; Neth, O; Duckers, G; Owens, S; Rosler, J; Schilling, FH; Schuster, V; Seidel, MG; Smisek, P; Sukova, M; Svec, P; Wiesel, T; Gathmann, B; Schwarz, K; Vach, W; Ehl, S; Speckmann, C",null,null,null,"Rensing-Ehl, Anne; Janda, Ales; Lorenz, Myriam R.; Gladstone, Beryl P.; Fuchs, Ilka; Abinun, Mario; Albert, Michael; Butler, Karina; Cant, Andrew; Cseh, Anna-Maria; Ebinger, Martin; Goldacker, Sigune; Hambleton, Sophie; Hebart, Holger; Houet, Leonora; Kentouche, Karim; Kuehnle, Ingrid; Lehmberg, Kai; Mejstrikova, Ester; Niemeyer, Charlotte; Minkov, Milen; Neth, Olaf; Dueckers, Gregor; Owens, Stephan; Roesler, Joachim; Schilling, Freimut H.; Schuster, Volker; Seidel, Markus G.; Smisek, Petr; Sukova, Martina; Svec, Peter; Wiesel, Thomas; Gathmann, Benjamin; Schwarz, Klaus; Vach, Werner; Ehl, Stephan; Speckmann, Carsten",null,null,"Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia","HAEMATOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"SYNDROME ALPS; MUTATIONS; COMMON; CLASSIFICATION","Clinical and genetic heterogeneity renders confirmation or exclusion of autoimmune lymphoproliferative syndrome difficult. To re-evaluate and improve the currently suggested diagnostic approach to patients with suspected FAS mutation, the most frequent cause of autoimmune lymphoproliferative syndrome, we prospectively determined 11 biomarkers in 163 patients with splenomegaly or lymphadenopathy and presumed or proven autoimmune cytopenia(s). Among 98 patients sequenced for FAS mutations in CD3(+)TCR alpha/CD4(-)CD8(-) \"double negative\" T cells, 32 had germline and six had somatic FAS mutations. The best a priori predictor of FAS mutations was the combination of vitamin B12 and soluble FAS ligand (cut-offs 1255 pg/mL and 559 pg/mL, respectively), which had a positive predictive value of 92% and a negative predictive value of 97%. We used these data to develop a web-based probability calculator for FAS mutations using the three most discriminatory biomarkers (vitamin B12, soluble FAS ligand, interleukin-10) of the 11 tested. Since more than 60% of patients with lymphoproliferation and autoimmune cytopenia(s) in our cohort did not harbor FAS mutations, 15% had somatic FAS mutations, and the predictive value of double-negative T-cell values was rather low (positive and negative predictive values of 61% and 77%, respectively), we argue that the previously suggested diagnostic algorithm based on determination of double-negative T cells and germline FAS sequencing, followed by biomarker analysis, is not efficient. We propose vitamin B12 and soluble FAS ligand assessment as the initial diagnostic step with subsequent decision on FAS sequencing supported by a probability-calculating tool.","[Rensing-Ehl, Anne; Janda, Ales; Fuchs, Ilka; Goldacker, Sigune; Houet, Leonora; Gathmann, Benjamin; Schwarz, Klaus; Ehl, Stephan; Speckmann, Carsten] Univ Med Ctr Freiburg, CCI, Freiburg, Germany; [Rensing-Ehl, Anne; Janda, Ales; Fuchs, Ilka; Goldacker, Sigune; Houet, Leonora; Gathmann, Benjamin; Schwarz, Klaus; Ehl, Stephan; Speckmann, Carsten] Univ Freiburg, Freiburg, Germany; [Gladstone, Beryl P.; Vach, Werner] Univ Freiburg, Univ Med Ctr Freiburg, Inst Med Biometry & Med Informat, Freiburg, Germany; [Lorenz, Myriam R.; Schwarz, Klaus] Univ Ulm, Inst Transfus Med, D-89069 Ulm, Germany; [Ehl, Stephan; Speckmann, Carsten] Univ Freiburg, Univ Med Ctr, Ctr Pediat & Adolescent Med, Freiburg, Germany; [Schwarz, Klaus] German Red Cross Blood Serv,Ulm, Inst Clin Transfus Med & Immunogenet Ulm, Ulm, Baden Wurttembe, Germany; [Abinun, Mario; Cant, Andrew; Hambleton, Sophie] Great North Childrens Hosp, Dept Pediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Albert, Michael] Dr von Haunersches Kinderspital, Dept Pediat Hematol Oncol, Munich, Germany; [Butler, Karina] Our Ladys Hosp Sick Children, Dublin, Ireland; [Cseh, Anna-Maria] Univ Med Ctr Freiburg, Freiburg, Germany; [Ebinger, Martin] Univ Med Ctr Tubingen, Dept Paediat Haematol Oncol, Tubingen, Germany; [Hebart, Holger] Stauferklinikum Schwaebisch Gmuend, Dept Internal Med, Mutlangen, Germany; [Kentouche, Karim] Jena Univ Hosp, Dept Pediat, Jena, Germany; [Kuehnle, Ingrid] Univ Gottingen, Dept Pediat, Gottingen, Germany; [Lehmberg, Kai] Univ Med Ctr Hamburg, Dept Pediat Hematol Oncol, Hamburg, Germany; [Mejstrikova, Ester; Smisek, Petr; Sukova, Martina] Charles Univ Prague, Med Sch 2, Univ Med Hosp, Dept Pediat Haematol & Oncol, Prague, Czech Republic; [Minkov, Milen] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Neth, Olaf] Virgen del Rocio Childrens Hosp, Seville, Spain; [Dueckers, Gregor] HELIOS Klinikum Krefeld, Dept Pediat, Krefeld, Germany; [Hambleton, Sophie] Newcastle Univ, Inst Cellular Immunol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Roesler, Joachim] Univ Clin Carl Gustav Carus, Dept Pediat, Dresden, Germany; [Schilling, Freimut H.] Olga Hosp, Dept Pediat Oncol & Hematol, Stuttgart, Germany; [Schuster, Volker] Univ Leipzig, Hosp Children & Adolescents, D-04109 Leipzig, Germany; [Seidel, Markus G.] Med Univ Graz, Graz, Austria; [Svec, Peter] Comenius Univ, Childrens Hosp, Dept Pediat Hematol & Oncol, Bratislava, Slovakia; [Wiesel, Thomas] Univ Witten Herdecke, Vest Kinder & Jugendklin Datteln, Witten, Germany","Ehl, S (reprint author), Univ Med Ctr Freiburg, CCI, Freiburg, Germany.","stephan.ehl@uniklinik-freiburg.de",null,null,"Bundesministerium fur Bildung und Forschung [BMBF 01 EO 0803, 01 GM 1111B]; European Society for Immunodeficiencies (ESID) by Baxter","This study was supported by the Bundesministerium fur Bildung und Forschung (BMBF 01 EO 0803 and 01 GM 1111B). Dr. A. Janda is a recipient of an unrestricted fellowship grant from the European Society for Immunodeficiencies (ESID) provided by Baxter.",null,20,0,0,"FERRATA STORTI FOUNDATION","PAVIA","VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY","0390-6078",null,null,"HAEMATOLOGICA","Haematologica","DEC",2013,98,12,null,null,null,null,1948,1955,null,"10.3324/haematol.2012.081901",null,8,"Hematology","Hematology","273OR","WOS:000328545500024"]
[null,null,null,null,"J","Korman, B; Krsek, P; Duchowny, M; Maton, B; Pacheco-Jacome, E; Rey, G",null,null,null,"Korman, Brandon; Krsek, Pavel; Duchowny, Michael; Maton, Bruno; Pacheco-Jacome, Esperanza; Rey, Gustavo",null,null,"Early seizure onset and dysplastic lesion extent independently disrupt cognitive networks","NEUROLOGY",null,null,"English","Article",null,null,null,null,null,null,"FOCAL CORTICAL DYSPLASIA; TEMPORAL-LOBE EPILEPSY; INTRACTABLE EPILEPSY; PEDIATRIC EPILEPSY; CHILDREN; BRAIN; MALFORMATIONS; INTELLIGENCE; FEATURES; SURGERY","Objective: To determine the most important factors influencing neuropsychological performance in children with intractable epilepsy due to focal cortical dysplasia and the nature of the interaction among significant variables. Methods: Surgical patients with histologically verified focal cortical dysplasia were retrospectively evaluated to determine the impact of histopathology, extent of lobar involvement, hemispheric laterality, age at onset, and duration of epilepsy on cognitive functioning. A composite neuropsychological variable was obtained by transforming data from 5 major cognitive domains using principal components analysis. Multiple regression was used to examine the unique contributions of predictor variables on composite cognition and Full Scale IQ. Data were qualitatively evaluated for nonstatistical trends. Results: Poor cognitive outcomes were associated with early age at onset of epilepsy (AOE) and wide-spread dysplastic involvement. Extent of dysplasia and AOE together accounted for 35% of Full Scale IQ variance, and 21% of composite cognitive performance. Each factor contributed independently to cognitive dysfunction. Conclusions: Early AOE disrupts critical periods of development and leads to poor cognitive outcome, but children with multilobar dysplasia are likely to have diminished cognitive skills regardless of AOE. Later AOE is not expected to mitigate deficits because of widespread pathology, nor would a localized lesion be likely to mollify the developmental deficits resulting from early AOE.","[Korman, Brandon; Duchowny, Michael; Rey, Gustavo] Miami Childrens Hosp, Inst Brain, Miami, FL 33155 USA; [Pacheco-Jacome, Esperanza] Miami Childrens Hosp, Div Radiol, Miami, FL USA; [Krsek, Pavel] Charles Univ Prague, Dept Pediat Neurol, Prague, Czech Republic; [Maton, Bruno] Sentara Heart Hosp, Div Neurol, Norfolk, VA USA","Korman, B (reprint author), Miami Childrens Hosp, Inst Brain, Miami, FL 33155 USA.","bkorman@mch.com",null,null,"Project for Conceptual Development of Research Organization [00064203]","Dr. Krsek was supported by the Project for Conceptual Development of Research Organization, grant 00064203. There are no potential conflicts of interest.",null,39,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0028-3878","1526-632X",null,"NEUROLOGY","Neurology","AUG 20",2013,81,8,null,null,null,null,745,751,null,null,null,7,"Clinical Neurology","Neurosciences & Neurology","304JV","WOS:000330743800012"]
[null,null,null,null,"J","Bhatti, SK; DiNicolantonio, JJ; Captain, BK; Lavie, CJ; Tomek, A; O'Keefe, JH",null,null,null,"Bhatti, Salman K.; DiNicolantonio, James J.; Captain, Becky K.; Lavie, Carl J.; Tomek, Ales; O'Keefe, James H.",null,null,"Neutralizing the Adverse Prognosis of Coronary Artery Calcium","MAYO CLINIC PROCEEDINGS",null,null,"English","Article",null,null,null,null,null,null,"HEART-DISEASE; ASYMPTOMATIC ADULTS; CARDIOVASCULAR RISK; TASK-FORCE; ASSOCIATION; TOMOGRAPHY; CARDIOLOGY; MARKERS; STRESS; PLAQUE","Objectives: To report and compare the outcomes and survival of patients with abnormal computed tomography-derived coronary artery calcium (CT-CAC) scores undergoing aggressive medical treatment at a cardiac prevention clinic. Patients and Methods: We conducted a retrospective analysis of 849 patients with intermediate risk based on the Framingham risk score and an abnormal CT-CAC score who were aggressively treated in a preventive cardiology risk factor modification program from June 23, 2000, to September 1, 2012. The primary outcome was a composite end point of myocardial infarction, resuscitated cardiac arrest, revascularization, and cardiovascular death. The effect of the CT-CAC subgroup on major adverse coronary heart disease events (MACEs) was evaluated by calculating hazard ratios with Cox proportional hazards regression modeling. The Centers for Disease Control and Prevention Wonder database was used to identify age- and sex-matched controls from the general population of Kansas and Missouri. Results: The mean age of the study patients was 65.4 years (58.4% men [496]). The median follow-up was 58 months, and the mean CT-CAC score was 336 Agatston units. Thirty-four patients (4.0%) reached the primary end point, including 4 deaths. The adjusted 10-year mortality rates were similar in the study group and control group (9.3 vs 10.6; P=.80). After adjustment, a CT-CAC score greater than 400 Agatston units correlated with a higher risk of MACEs (hazard ratio, 3.55; P=.01). Conclusion: These results suggest that intermediate-risk patients with abnormal CT-CAC scores when treated with intensive risk factor reduction have lower rates of MACEs than predicted by the Framingham risk score and the presence of coronary artery calcium. (c) 2013 Mayo Foundation for Medical Education and Research","[Bhatti, Salman K.; DiNicolantonio, James J.; Captain, Becky K.; O'Keefe, James H.] St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA; [Bhatti, Salman K.; O'Keefe, James H.] Univ Missourie Kansas City, Sch Med, Dept Internal Med, Kansas City, MO USA; [Lavie, Carl J.] Univ Queensland, Sch Med, Ochsner Clin Sch, John Ochsner Heart & Vasc Inst, New Orleans, LA USA; [Lavie, Carl J.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Dept Prevent Med, Baton Rouge, LA USA; [Tomek, Ales] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague, Czech Republic; [Tomek, Ales] Univ Hosp, Motol, Czech Republic","O'Keefe, JH (reprint author), St Lukes Mid Amer Heart Inst, 4330 Wornall Rd,Ste 2000, Kansas City, MO 64111 USA.","jokeefe@saint-lukes.org","Lavie, Carl/A-6014-2011",null,null,null,null,19,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0025-6196",null,null,"MAYO CLIN PROC","Mayo Clin. Proc.","AUG",2013,88,8,null,null,null,null,806,812,null,"10.1016/j.mayocp.2013.05.019",null,7,"Medicine, General & Internal","General & Internal Medicine","217CE","WOS:000324333400010"]
[null,null,null,null,"J","Kramarzova, K; Boublikova, L; Stary, J; Trka, J",null,null,null,"Kramarzova, K.; Boublikova, L.; Stary, J.; Trka, J.",null,"CLIP","Evaluation of WT1 expression in bone marrow vs peripheral blood samples of children with acute myeloid leukemia-impact on minimal residual disease detection","LEUKEMIA",null,null,"English","Letter",null,null,null,null,null,null,"GENE-EXPRESSION; TIME; QUANTIFICATION; PREDICTION; AML",null,"[Kramarzova, K.] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Kramarzova, K (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic.","jan.trka@lfmotol.cuni.cz",null,null,null,null,null,12,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","MAY",2013,27,5,null,null,null,null,1194,1196,null,"10.1038/leu.2012.291",null,4,"Oncology; Hematology","Oncology; Hematology","141AS","WOS:000318698300029"]
[null,null,null,null,"J","Disanto, G; Vcelakova, J; Pakpoor, J; Elangovan, RI; Sumnik, Z; Ulmannova, T; Ebers, GC; Ramagopalan, SV; Stechova, K",null,null,null,"Disanto, Giulio; Vcelakova, Jana; Pakpoor, Julia; Elangovan, Ramyiadarsini I.; Sumnik, Zdenek; Ulmannova, Tereza; Ebers, George C.; Ramagopalan, Sreeram V.; Stechova, Katerina",null,null,"DNA methylation in monozygotic quadruplets affected by type 1 diabetes","DIABETOLOGIA",null,null,"English","Letter",null,null,null,null,null,"DNA methylation; Epigenetics; Monozygotic quadruplet; Type 1 diabetes","GENOME-WIDE ASSOCIATION; METAANALYSIS; RISK; LOCI",null,"[Disanto, Giulio; Pakpoor, Julia; Elangovan, Ramyiadarsini I.; Ebers, George C.; Ramagopalan, Sreeram V.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Disanto, Giulio; Pakpoor, Julia; Elangovan, Ramyiadarsini I.; Ebers, George C.; Ramagopalan, Sreeram V.] Univ Oxford, Med Res Council Funct Genom Unit, Oxford OX1 3PT, England; [Vcelakova, Jana; Sumnik, Zdenek; Ulmannova, Tereza; Stechova, Katerina] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic; [Vcelakova, Jana; Sumnik, Zdenek; Ulmannova, Tereza; Stechova, Katerina] Univ Hosp Motol, Prague, Czech Republic; [Ramagopalan, Sreeram V.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England","Ramagopalan, SV (reprint author), Univ Oxford, Dept Physiol Anat & Genet, S Parks Rd, Oxford OX1 3PT, England.","sreeram.ramagopalan@dpag.ox.ac.uk",null,null,null,null,null,11,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0012-186X",null,null,"DIABETOLOGIA","Diabetologia","SEP",2013,56,9,null,null,null,null,2093,2095,null,"10.1007/s00125-013-2972-3",null,3,"Endocrinology & Metabolism","Endocrinology & Metabolism","200HV","WOS:000323059800029"]
[null,null,null,null,"J","Lutz, C; Woll, PS; Hall, G; Castor, A; Dreau, H; Cazzaniga, G; Zuna, J; Jensen, C; Clark, SA; Biondi, A; Mitchell, C; Ferry, H; Schuh, A; Buckle, V; Jacobsen, SEW; Enver, T",null,null,null,"Lutz, C.; Woll, P. S.; Hall, G.; Castor, A.; Dreau, H.; Cazzaniga, G.; Zuna, J.; Jensen, C.; Clark, S. A.; Biondi, A.; Mitchell, C.; Ferry, H.; Schuh, A.; Buckle, V.; Jacobsen, S-E W.; Enver, T.",null,null,"Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia","LEUKEMIA",null,null,"English","Letter",null,null,null,null,null,null,"STEM-CELLS; AIEOP-BFM; CHILDREN; TRIALS",null,"[Lutz, C.; Jensen, C.; Enver, T.] UCL, Inst Canc, LLR John Barrington Lab, London, England; [Woll, P. S.; Clark, S. A.; Ferry, H.; Buckle, V.; Jacobsen, S-E W.] Univ Oxford, WIMM, MRC MHU, Oxford, England; [Woll, P. S.; Clark, S. A.; Ferry, H.; Jacobsen, S-E W.] Univ Oxford, WIMM, Haematopoiet Stem Cell Lab, Oxford, England; [Hall, G.; Mitchell, C.] Oxford Radcliffe Hosp NHS Trust, Dept Paediat Haematol Oncol, Oxford, England; [Castor, A.] Univ Lund Hosp, Dept Paediat Haematol, S-22185 Lund, Sweden; [Dreau, H.] Oxford Radcliffe Hosp NHS Trust, Dept Haematol, Oxford, England; [Cazzaniga, G.; Biondi, A.] Clin Pediat Univ Milano Bicocca, Osped San Gerardo, Ctr Ric Tettamanti, Monza, Italy; [Zuna, J.] Charles Univ Prague, Dept Paediat Haematol Oncol, Fac Med 2, Prague, Czech Republic","Lutz, C (reprint author), Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany.","sten.jacobsen@imm.ox.ac.uk; t.enver@ucl.ac.uk","Schuh, Anna/D-8954-2014",null,null,null,null,15,2,2,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","MAY",2013,27,5,null,null,null,null,1204,1207,null,"10.1038/leu.2012.306",null,5,"Oncology; Hematology","Oncology; Hematology","141AS","WOS:000318698300032"]
[null,null,null,null,"J","Hermkens, MCH; van den Heuvel-Eibrink, MM; Arentsen-Peters, STCJM; Baruchel, A; Stary, J; Reinhardt, D; Zimmerman, M; de Haas, V; Pieters, R; Zwaan, CM",null,null,null,"Hermkens, M. C. H.; van den Heuvel-Eibrink, M. M.; Arentsen-Peters, S. T. C. J. M.; Baruchel, A.; Stary, J.; Reinhardt, D.; Zimmerman, M.; de Haas, V.; Pieters, R.; Zwaan, C. M.",null,null,"The clinical relevance of BAALC and ERG expression levels in pediatric AML","LEUKEMIA",null,null,"English","Letter",null,null,null,null,null,null,"ACUTE MYELOID-LEUKEMIA; UNFAVORABLE PROGNOSTIC MARKER; GENE-EXPRESSION; GROUP-B; OVEREXPRESSION; PROFILES; CANCER",null,"[Hermkens, M. C. H.; van den Heuvel-Eibrink, M. M.; Arentsen-Peters, S. T. C. J. M.; Pieters, R.; Zwaan, C. M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Baruchel, A.] Hop Robert Debre, CHU Paris, Dept Haematol, F-75019 Paris, France; [Stary, J.] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Reinhardt, D.; Zimmerman, M.] Med High Sch, Dept Pediat Oncol Hematol, AML BFM Study Grp, Hannover, Germany; [de Haas, V.] DCOG, The Hague, Netherlands","Hermkens, MCH (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands.","c.m.zwaan@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056",null,null,null,13,1,1,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","MAR",2013,27,3,null,null,null,null,735,737,null,"10.1038/leu.2012.233",null,3,"Oncology; Hematology","Oncology; Hematology","112JA","WOS:000316587300032"]
[null,null,null,null,"J","Aalbers, AM; van den Heuvel-Eibrink, MM; de Haas, V; te Marvelde, JG; de Jong, AX; van der Burg, M; Dworzak, M; Hasle, H; Locatelli, F; De Moerloose, B; Schmugge, M; Stary, J; Zecca, M; Zwaan, CM; van de Loosdrecht, AA; van Dongen, JJM; Niemeyer, CM; van der Velden, VHJ",null,null,null,"Aalbers, A. M.; van den Heuvel-Eibrink, M. M.; de Haas, V.; te Marvelde, J. G.; de Jong, A. X.; van der Burg, M.; Dworzak, M.; Hasle, H.; Locatelli, F.; De Moerloose, B.; Schmugge, M.; Stary, J.; Zecca, M.; Zwaan, C. M.; van de Loosdrecht, A. A.; van Dongen, J. J. M.; Niemeyer, C. M.; van der Velden, V. H. J.",null,null,"Applicability of a reproducible flow cytometry scoring system in the diagnosis of refractory cytopenia of childhood","LEUKEMIA",null,null,"English","Letter",null,null,null,null,null,null,"GRADE MYELODYSPLASTIC SYNDROMES; EUROPEAN LEUKEMIANET; WORKING GROUP; STANDARDIZATION; VALIDATION",null,"[Aalbers, A. M.; te Marvelde, J. G.; van der Burg, M.; van Dongen, J. J. M.; van der Velden, V. H. J.] Erasmus MC, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Aalbers, A. M.; van den Heuvel-Eibrink, M. M.; Zwaan, C. M.] Erasmus MC, Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [de Haas, V.; de Jong, A. X.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Dworzak, M.] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Dworzak, M.] Med Univ Vienna, Dept Pediat, Childrens Canc Res Inst, Vienna, Austria; [Hasle, H.] Aarhus Univ Hosp Skejby, Dept Pediat, Aarhus, Denmark; [Locatelli, F.] Univ Pavia, IRCCS Osped Bambino Gesu, Dept Pediat Hematol Oncol, Rome, Italy; [De Moerloose, B.] Ghent Univ Hosp, Dept Pediat Hematol Oncol, Ghent, Belgium; [Schmugge, M.] Univ Childrens Hosp, Dept Hematol, Zurich, Switzerland; [Stary, J.] Charles Univ Prague, Dept Pediat Hematol Oncol, Prague, Czech Republic; [Stary, J.] Univ Hosp Motol, Prague, Czech Republic; [Zecca, M.] Fdn IRCCS Policlin San Matteo, Dept Pediat Hematol, Pavia, Italy; [van de Loosdrecht, A. A.] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands; [Niemeyer, C. M.] Univ Freiburg, Div Pediat Hematol & Oncol, Dept Pediat & Adolescent Med, D-79106 Freiburg, Germany","Aalbers, AM (reprint author), Erasmus MC, Erasmus MC, Dept Immunol, Rotterdam, Netherlands.","v.h.j.vandervelden@erasmusmc.nl",null,null,null,null,null,12,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","SEP",2013,27,9,null,null,null,null,1923,1925,null,"10.1038/leu.2013.81",null,4,"Oncology; Hematology","Oncology; Hematology","214UT","WOS:000324162700019"]
[null,null,null,null,"J","Aalbers, AM; Calado, RT; Young, NS; Zwaan, CM; Wu, C; Kajigaya, S; Coenen, EA; Baruchel, A; Geleijns, K; de Haas, V; Kaspers, GJL; Kuijpers, TW; Reinhardt, D; Trka, J; Zimmermann, M; Pieters, R; van der Velden, VHJ; van den Heuvel-Eibrink, MM",null,null,null,"Aalbers, A. M.; Calado, R. T.; Young, N. S.; Zwaan, C. M.; Wu, C.; Kajigaya, S.; Coenen, E. A.; Baruchel, A.; Geleijns, K.; de Haas, V.; Kaspers, G. J. L.; Kuijpers, T. W.; Reinhardt, D.; Trka, J.; Zimmermann, M.; Pieters, R.; van der Velden, V. H. J.; van den Heuvel-Eibrink, M. M.",null,null,"Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia","LEUKEMIA",null,null,"English","Letter",null,null,null,null,null,null,"CELLS; ABERRATIONS; EXPRESSION",null,"[Aalbers, A. M.; Zwaan, C. M.; Coenen, E. A.; Pieters, R.; van den Heuvel-Eibrink, M. M.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Aalbers, A. M.; Geleijns, K.; van der Velden, V. H. J.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Aalbers, A. M.; Calado, R. T.; Young, N. S.; Wu, C.; Kajigaya, S.] NHLBI, Hematol Branch, Natl Inst Hlth, Bethesda, MD 20892 USA; [Calado, R. T.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, Ribeirao Preto, SP, Brazil; [Baruchel, A.] Hop Robert Debre, Dept Hematol, F-75019 Paris, France; [Geleijns, K.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands; [de Haas, V.; Kaspers, G. J. L.] DCOG, The Hague, Netherlands; [Kaspers, G. J. L.] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands; [Kuijpers, T. W.] Acad Med Ctr, Sanquin Res & Landsteiner Lab, Dept Blood Cell Res, Amsterdam, Netherlands; [Kuijpers, T. W.] Emma Childrens Hosp, Acad Med Ctr, Dept Pediat Hematol Immunol & Infect Dis, Amsterdam, Netherlands; [Reinhardt, D.; Zimmermann, M.] Hannover Med Sch, AML BFM Study Grp, Dept Pediat Hematol Oncol, Hannover, Germany; [Trka, J.] Charles Univ Prague, Sch Med 2, Dept Pediat Hematol Oncol, Prague, Czech Republic","Aalbers, AM (reprint author), Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl","Calado, Rodrigo/G-2619-2011",null,null,null,null,15,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0887-6924",null,null,"LEUKEMIA","Leukemia","AUG",2013,27,8,null,null,null,null,1786,1789,null,"10.1038/leu.2013.57",null,4,"Oncology; Hematology","Oncology; Hematology","197BP","WOS:000322823200029"]
[null,null,null,null,"J","Fialova, A; Partlova, S; Sojka, L; Hromadkova, H; Brtnicky, T; Fucikova, J; Kocian, P; Rob, L; Bartunkova, J; Spisek, R",null,null,null,"Fialova, Anna; Partlova, Simona; Sojka, Ludek; Hromadkova, Hana; Brtnicky, Tomas; Fucikova, Jitka; Kocian, Petr; Rob, Lukas; Bartunkova, Jirina; Spisek, Radek",null,null,"Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells","INTERNATIONAL JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"epithelial ovarian cancer; Th17; Treg; CCL22; recruitment","TUMOR SURVEILLANCE; PERIPHERAL-BLOOD; T(H)17 CELLS; LYMPHOCYTES; RECRUITMENT; CARCINOMA; SURVIVAL; GENERATION; RELEVANCE; GROWTH","The type of immune cells that are present within the tumor microenvironment can play a crucial role in the survival of patients. However, little is known about the dynamics of the tumor-infiltrating immune cells during disease progression. We studied the immune cells that infiltrated the tumor tissues of ovarian cancer patients at different stages of disease. The early stages of development of ovarian carcinomas were characterized by a strong Th17 immune response, whereas in stage II patients, recruitment of high numbers of Th1 cells was observed. In disseminated tumors (Stages III-IV), we detected a dominant population of Helios 1 activated regulatory T cells (Tregs) along with high numbers of monocytes/macrophages and myeloid dendritic cells (mDCs). Tumor-infiltrating Tregs had markedly lower expression of CCR4 than circulating Tregs, and the numbers of tumor-infiltrating Tregs significantly correlated with the levels of CCL22 in ovarian tumor cell culture supernatants, suggesting their recruitment via a CCR4/CCL22 interaction. CCL22 was mainly produced by tumor cells, monocytes/ macrophages and mDCs in the primary ovarian tumors, and its expression markedly increased in response to IFN gamma. Taken together, the specific recruitment of Tregs, probably triggered by inflammatory stimuli, leads to a significant immune suppression in the advanced stages of ovarian cancer.","[Fialova, Anna; Partlova, Simona; Sojka, Ludek; Hromadkova, Hana; Brtnicky, Tomas; Fucikova, Jitka; Kocian, Petr; Rob, Lukas; Bartunkova, Jirina; Spisek, Radek] Univ Hosp Motol, Prague, Czech Republic","Fialova, A (reprint author), Charles Univ Prague, Dept Immunol, Fac Med 2, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","anna.fialova@lfmotol.cuni.cz",null,null,"Czech Ministry of Education [MSM 0021620812]; Czech Ministry of Health [IGA NT12402-5]; Charles University [GAUK 3654/2011, 63310/2010]","Grant sponsor: Czech Ministry of Education; Grant number: MSM 0021620812; Grant sponsor: Czech Ministry of Health; Grant number: IGA NT12402-5; Grant sponsor: Charles University; Grant numbers: GAUK 3654/2011, 63310/2010",null,40,4,5,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0020-7136",null,null,"INT J CANCER","Int. J. Cancer","MAR 1",2013,132,5,null,null,null,null,1070,1079,null,"10.1002/ijc.27759",null,10,"Oncology","Oncology","078AU","WOS:000314071300009"]
[null,null,null,null,"J","Vesely, S; Jarolim, L; Schmidt, M; Minarik, I; Dusek, P; Babjuk, M",null,null,null,"Vesely, Stepan; Jarolim, Ladislav; Schmidt, Marek; Minarik, Ivo; Dusek, Pavel; Babjuk, Marko",null,null,"Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome","WORLD JOURNAL OF UROLOGY",null,null,"English","Article",null,null,null,null,null,"Prostate cancer; Prognosis; PSA; Radical prostatectomy","BIOCHEMICAL RECURRENCE; NATURAL-HISTORY; ANTIGEN NADIR; FREE SURVIVAL; CANCER; RISK; THERAPY; RELAPSE; PROGRESSION; HAZARD","Contemporary tools estimating increased risk of prostate cancer (PCa) relapse after radical prostatectomy (RP) are far from perfect and there has been an intensive search for additional predictive variables. We aimed to explore whether the parameters of postoperative ultrasensitive prostate-specific antigen (PSA) decline provide additional information for predicting PCa progression. A total of 319 consecutive men, with at least 2 years of follow-up after RP for clinically localized PCa were subjected to this study. Intensive postoperative measurements of ultrasensitive PSA resulted in total of 4028 PSA values available for statistical evaluation. Biochemical recurrence (BCR) was defined as PSA a parts per thousand yen0.2 ng/ml. The accuracy of predictive models was quantified with the area under the curve. Over a median follow-up of 43 months (24-99 months), 107 patients (34 %) experienced BCR after RP. In patients with BCR, significantly higher values of PSA nadir (p < 0.001) and a decreased time interval from surgery to reach PSA nadir (p < 0.001) were observed. A multivariable Cox regression model confirmed that PSA nadir > 0.01 ng/ml (HR 6.01, 95 % CI: 3.89-9.52) and time to PSA nadir < 3 months (HR 2.86, 95 % CI: 1.74-5.01) were independent predictors of BCR. The inclusion of PSA nadir and the time to PSA nadir into the model resulted in improvement of predictive accuracy by 16 % over the model designed on the basis of established parameters. Our results demonstrate that the level of PSA nadir and the time to PSA nadir determined by ultrasensitive assay significantly improve the identification of patients who are at high risk of disease recurrence after RP.","[Vesely, Stepan; Jarolim, Ladislav; Schmidt, Marek; Minarik, Ivo; Dusek, Pavel; Babjuk, Marko] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Urol, Prague 15200, Czech Republic","Vesely, S (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Urol, V Uvalu 84, Prague 15200, Czech Republic.","stepan.vesely@urology.gu.se",null,null,"IGA MZ CR [NT13472-4]","This study was supported by a research grant IGA MZ CR NT13472-4.",null,20,2,2,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0724-4983",null,null,"WORLD J UROL","World J. Urol.","APR",2013,31,2,null,null,null,null,299,304,null,"10.1007/s00345-012-0892-3",null,6,"Urology & Nephrology","Urology & Nephrology","119YZ","WOS:000317137400009"]
[null,null,null,null,"J","Robova, H; Rob, L; Halaska, MJ; Pluta, M; Skapa, P; Strnad, P; Lisy, J; Komar, M",null,null,null,"Robova, Helena; Rob, Lukas; Halaska, Michael J.; Pluta, Marek; Skapa, Petr; Strnad, Pavel; Lisy, Jiri; Komar, Matej",null,null,"High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer","GYNECOLOGIC ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"Cervical cancer; High-dose density neoadjuvant chemotherapy; Tumor volumometry; Quality of life","GYNECOLOGIC-ONCOLOGY-GROUP; RADICAL HYSTERECTOMY; RANDOMIZED-TRIAL; SQUAMOUS CARCINOMA; UTERINE CERVIX; FOLLOW-UP; PHASE-II; STAGE; SURGERY; RADIOTHERAPY","Objective. The endpoint of this prospective study is to evaluate response rate, survival and toxicity of high-dose density neoadjuvant chemotherapy (NAC) in bulky IB cervical cancer. Material and methods. Between January 1998 and December 2009, 154 women were enrolled into study. Three patients were withdrawn. Of the 151 women, 119 had stage IB2 cervical cancer (78.8%) and 32 had stage IB1 cancer (21.2%) infiltrating the whole cervical stroma. Women received 3-4 cycle cisplatin-75 mg/m(2) and ifosfamide-2 g/m(2) in cases of squamous-cell cancer or cisplatin-75 mg/m(2) and doxorubicin-35 mg/m(2) in adenocarcinoma every 10 days and then underwent radical hysterectomy type III. Patients who had non-resectable disease underwent chemoradiotherapy. Results. The overall response rate (reduction of tumor volume more than 50%) was 78.8%. Reduction of tumor volume less than 50% was seen in 15.2%. Tumor progression during chemotherapy occurred in nine patients (6.0%). There were positive lymph-nodes in 26 patients (18.3%) of the 142 that underwent surgery. 38 women underwent adjuvant radiotherapy (26.7%). There were 26 recurrences (17.2%). After surgery 20 women recurred from 142 (14.1%) and after primary radiotherapy 6 from 9 women recurred (66.7%). 25 of 151 women died from disease (16.5%). At the time of the study, surgery was performed in 118 women 5 or more years ago, 19 of them died of disease. Five-year specific survival is 83.6%. Grade 3-4 -neutropenia was found in only 7.3% of the women, and grade 3-4 thrombocytopenia were found in 1.3%. Conclusion. High-dose density NAC appears to be feasible in the treatment IB bulky cervical cancer and toxicity is acceptable. Adjuvant radiotherapy was used only in 26.7%. (C) 2012 Elsevier Inc. All rights reserved.","[Robova, Helena; Rob, Lukas; Halaska, Michael J.; Pluta, Marek; Strnad, Pavel; Komar, Matej] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, Prague 15000 5, Czech Republic; [Skapa, Petr] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15000 5, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Fac Med 2, Dept Radiol, Prague 15000 5, Czech Republic","Rob, L (reprint author), Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, V Uvalu 84, Prague 15000 5, Czech Republic.","lukas.rob@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic [00064203];  [MZ CR NT 13166]","This work is supported by grant MZ CR NT 13166 and by the project (Ministry of Health, Czech Republic) for conceptual development of research organisation 00064203 (University Hospital Motol, Prague, Czech Republic).",null,29,2,2,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0090-8258",null,null,"GYNECOL ONCOL","Gynecol. Oncol.","JAN",2013,128,1,null,null,null,null,49,53,null,"10.1016/j.ygyno.2012.10.002",null,5,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","068SQ","WOS:000313386900010"]
[null,null,null,null,"J","Honek, J; Zemanek, D; Veselka, J",null,null,null,"Honek, Jakub; Zemanek, David; Veselka, Josef",null,null,"Left Ventricular Outflow Tract Obstruction After Mitral Valve Repair Treated With Alcohol Septal Ablation","CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS",null,null,"English","Article",null,null,null,null,null,"alcohol septal ablation; ventricular outflow obstruction; mitral valve repair; invasive cardiology; hypertrophic cardiomyopathy","SYSTOLIC ANTERIOR MOTION; HYPERTROPHIC CARDIOMYOPATHY; MECHANISM; DISPLACEMENT","Left ventricular outflow tract (LVOT) obstruction due to systolic anterior motion of the mitral valve (SAM) occurs in 4-5% of patients after mitral valve repair. If conservative treatment is unsuccessful, reoperation is indicated. Treatment options include repeated mitral valve repair or valve replacement and septal myectomy if hypertrophy is present. We report a case of a patient with pre-operatively undiagnosed hypertrophic cardiomyopathy who suffered from progressive dyspnea post-operation due to severe LVOT obstruction with SAM. This case was successfully treated with catheter-based alcohol septal ablation. (c) 2013 Wiley Periodicals, Inc.","[Honek, Jakub; Zemanek, David; Veselka, Josef] Charles Univ Prague, Sch Med 2, Dept Cardiol, Univ Hosp Motol, Prague 15006 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Sch Med 2, Dept Cardiol, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","veselka.josef@seznam.cz",null,null,null,null,null,12,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1522-1946","1522-726X",null,"CATHETER CARDIO INTE","Catheter. Cardiovasc. Interv.","NOV 15",2013,82,6,null,null,null,null,"E821","E825",null,"10.1002/ccd.24870",null,5,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","246IU","WOS:000326532300010"]
[null,null,null,null,"J","Zemanek, D; Branny, M; Martinkovicova, L; Hajek, P; Maly, M; Tesar, D; Tomasov, P; Veselka, J",null,null,null,"Zemanek, David; Branny, Marian; Martinkovicova, Lucie; Hajek, Petr; Maly, Martin; Tesar, David; Tomasov, Pavol; Veselka, Josef",null,null,"Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"Percutaneous coronary intervention; Periprocedural myocardial infarction; Statin; Atorvastatin pretreatment","CARDIAC TROPONIN-I; PROGNOSTIC VALUE; ELEVATION; TRIAL; ANGIOPLASTY; IMPACT; DAMAGE; METAANALYSIS; REDUCTION; MORTALITY","Background: The aim of this randomized study was to investigate the effect of seven-day high-dose atorvastatin therapy on the incidence of peri-procedural myocardial infarction (PMI) in patients receiving long-term statin therapy. Methods: The patients with stable angina receiving statin therapy and referred for percutaneous coronary intervention (PCI) were randomized (ratio 1: 1) to a 7-day pre-treatment with atorvastatin of 80 mg daily and subsequent PCI (Atorvastatin group), or immediate PCI (Control group). The incidence of PMI was based on serum concentration of creatine kinase myocardial band (CK-MB) mass and troponin I (TnI), which were measured prior to and between 16 and 24 h post PCI. The values were considered as positive if they were elevated >= 3 times the upper limit normal. Results: We randomized 202 patients (male 67%, 65.5 +/- 9.2 years; 100 vs. 102 pts.). There were no significant differences in the baseline characteristics among the randomized groups. The incidence of PMI, based on post-interventional release of TnI and/or CK-MB mass was 15% in the Atorvastatin group vs. 14% in the Control group (p = 0.80). One patient (3%) in Atorvastatin group suffered from MI between randomization and PCI. Conclusions: These results suggest that 7-day pre-PCI therapy with high-dose atorvastatin did not reduce the occurrence of PMI in patients receiving chronic statin therapy. (C) 2013 Elsevier Ireland Ltd. All rights reserved.","[Zemanek, David; Martinkovicova, Lucie; Hajek, Petr; Maly, Martin; Tesar, David; Tomasov, Pavol; Veselka, Josef] Charles Univ Prague, Sch Med 2, Dept Cardiol, Prague 15021, Czech Republic; [Zemanek, David; Martinkovicova, Lucie; Hajek, Petr; Maly, Martin; Tesar, David; Tomasov, Pavol; Veselka, Josef] Univ Hosp Motol, Prague, Czech Republic; [Branny, Marian] Podlesi Hosp, Dept Cardiol, Ctr Cardiovasc, Trinec, Czech Republic","Zemanek, D (reprint author), Charles Univ Prague, Sch Med 2, Dept Cardiol, V Uvalu 84, Prague 15021, Czech Republic.","zejada@seznam.cz","Maly, Martin/H-1837-2011","Maly, Martin/0000-0001-7346-9828","Ministry of Health, Czech Republic [00064203]","This study was supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,21,1,1,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273","1874-1754",null,"INT J CARDIOL","Int. J. Cardiol.","OCT 3",2013,168,3,null,null,null,null,2494,2497,null,"10.1016/j.ijcard.2013.03.002",null,4,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","241RF","WOS:000326184400124"]
[null,null,null,null,"J","Gazova, I; Laczo, J; Rubinova, E; Mokrisova, I; Hyncicova, E; Andel, R; Vyhnalek, M; Sheardova, K; Coulson, EJ; Hort, J",null,null,null,"Gazova, Ivana; Laczo, Jan; Rubinova, Eva; Mokrisova, Ivana; Hyncicova, Eva; Andel, Ross; Vyhnalek, Martin; Sheardova, Katerina; Coulson, Elizabeth J.; Hort, Jakub",null,null,"Spatial navigation in young versus older adults","FRONTIERS IN AGING NEUROSCIENCE",null,null,"English","Article",null,null,null,null,null,"spatial navigation; aging; allocentric navigation; egocentric navigation; spatial learning; gender; Alzheimer's disease; hippocampus","MILD COGNITIVE IMPAIRMENT; MORRIS WATER TASK; SEX-DIFFERENCES; ALZHEIMERS-DISEASE; VIRTUAL ENVIRONMENT; AGE-DIFFERENCES; HUMAN ANALOG; PERFORMANCE; MEMORY; MAZE","Older age is associated with changes in the brain, including the medial temporal lobe, which may result in mild spatial navigation deficits, especially in allocentric navigation. The aim of the study was to characterize the profile of real-space allocentric (world-centered, hippocampus-dependent) and egocenric (body-centered, parietal lobe dependent) navigation and learning in young vs. older adults, and to assess a possible influence of gender. We recruited healthy participants without cognitice deficits on standard neuropsychological testing, white mater lesions or pronounced hippocampal atrophy: 24 young participants (18-26 yars old) and 44 older participants stratified as participants 60-70 years old (n = 24) and participants 71-84 years old (n = 20). All underwent spatial navigation testing in the real-space human analog of the Morris Water Maze, which has the advantage of assessing separately allocentric and egocentric navigation and learning. Of the eight consecutive trials, trials 2-8 were used to reduce bias by a rebound effect (more dramatic changes in performance between trials (p < 0.001), but not those 60-70 years old, showed deficits in allocentric navigation compared to the young participants. There were no differences in egocentric navigation. All theree groups showed spatial learning effect (p' s <= 0.01). There were no gender differences in spatial navigation and learning. Linear regression limited to older participants showed linear (beta = 0.30, p = 0.045) and quadratic (beta = 0.30, p = 0.046) effect of age on allocentric navigation. There was no effect of age on egocentric navigation. These results demonstrate that navigation deficits in older age may be limited to allocentric navigation, whereas egocentric navigation deficits in older age may be limited to allocentric navigation, pattern of spacial navigation impairment may help differentiate normal aging from prodromal Alzheimer's disease.","[Gazova, Ivana; Laczo, Jan; Mokrisova, Ivana; Hyncicova, Eva; Vyhnalek, Martin; Hort, Jakub] Charles Univ Prague, Dept Neurol, Fac Med 2, Memory Clin, Prague 15006 5, Czech Republic; [Gazova, Ivana; Laczo, Jan; Mokrisova, Ivana; Hyncicova, Eva; Vyhnalek, Martin; Hort, Jakub] Motol Univ Hosp, Prague, Czech Republic; [Gazova, Ivana; Laczo, Jan; Rubinova, Eva; Mokrisova, Ivana; Andel, Ross; Vyhnalek, Martin; Sheardova, Katerina; Hort, Jakub] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Coulson, Elizabeth J.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia","Laczo, J (reprint author), Charles Univ Prague, Dept Neurol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","janlaczo@seznam.cz","Coulson, Elizabeth/C-8766-2009",null,"Grant Agency of Charles University in Prague [546113, 624012]; European Regional Development Fund - Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; European Social Fund; State Budget of the Czech Republic; European Social Fund within the project Young Talent Incubator II [CZ.1.07/2.3.00/20.0117]; Ministry of Health, Czech Republic - conceptual development of research organization; University Hospital Motol, Prague, Czech Republic [00064203]; Institutional Support of Laboratory Research Grant [699002];  [AV0Z50110509];  [RVO:67985823]","We would like to thank Dr. K. Vlcek for technical support and J. Cerman and O. Lerch for help with data collection. Dr. Bures in memoriam for support and inventions. This study was supported by Grant Agency of Charles University in Prague Grants No. 546113 and 624012; European Regional Development Fund - Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123); European Social Fund and the State Budget of the Czech Republic; European Social Fund within the project Young Talent Incubator II (reg. no. CZ.1.07/2.3.00/20.0117); Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203; Institutional Support of Laboratory Research Grant No. 2/2012 (699002); and research projects AV0Z50110509 and RVO:67985823.",null,41,0,0,"FRONTIERS RESEARCH FOUNDATION","LAUSANNE","PO BOX 110, LAUSANNE, 1015, SWITZERLAND","1663-4365",null,null,"FRONT AGING NEUROSCI","Front. Aging Neurosci.","DEC 19",2013,5,null,null,null,null,null,null,null,null,"10.3389/fnagi.2013.00094",null,8,"Geriatrics & Gerontology; Neurosciences","Geriatrics & Gerontology; Neurosciences & Neurology","275CY","WOS:000328654600002"]
[null,null,null,null,"J","Buzgo, M; Jakubova, R; Mickova, A; Rampichova, M; Prosecka, E; Kochova, P; Lukas, D; Amler, E",null,null,null,"Buzgo, Matej; Jakubova, Radka; Mickova, Andrea; Rampichova, Michala; Prosecka, Eva; Kochova, Petra; Lukas, David; Amler, Evzen",null,null,"Time-regulated drug delivery system based on coaxially incorporated platelet alpha-granules for biomedical use","NANOMEDICINE",null,null,"English","Article",null,null,null,null,null,"alpha-granules; chondrocyte; core/shell material; electrospinning; encapsulation; growth factor; mesenchymal stem cell","MESENCHYMAL STEM-CELLS; TISSUE ENGINEERING APPLICATIONS; PEPTIDE-AMPHIPHILE NANOFIBERS; FIBROBLAST-GROWTH-FACTOR; RICH PLASMA; ELECTROSPUN NANOFIBERS; IN-VITRO; CONTROLLED-RELEASE; CHONDROGENIC DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION","Platelet derivatives serve as an efficient source of natural growth factors. In the current study, alpha-granules were incorporated into coaxial nanofibers. Materials & methods: A nanofiber scaffold containing a-granules was prepared by coaxial electrospinning. The biological potential of the nanofiber scaffold was evaluated in chondrocyte and mesenchymal stem cell cultivation studies. Additionally, the concentration of TGF-beta 1 was determined. Results: Microscopy studies showed that intact alpha-granules were incorporated into the coaxial nanofibers. The cultivation tests showed that the novel scaffold stimulated viability and extracellular matrix production of chondrocytes and mesenchymal stem cells. In addition, the concentration of growth factors necessary for the induction of cell proliferation significantly decreased. Conclusion: The system preserved alpha-granule bioactivity and stimulated cell viability and chondrogenic differentiation of mesenchymal stem cells. Core/shell nanofibers incorporating a-granules are a promising system for tissue engineering, particularly cartilage engineering.","[Buzgo, Matej; Jakubova, Radka; Mickova, Andrea; Rampichova, Michala; Prosecka, Eva; Amler, Evzen] Charles Univ Prague, Dept Biophys, Fac Med 2, Prague 15006 5, Czech Republic; [Buzgo, Matej; Jakubova, Radka; Mickova, Andrea; Rampichova, Michala; Prosecka, Eva; Amler, Evzen] Acad Sci Czech Republic, Vvi, Inst Expt Med, Prague 14220 4, Czech Republic; [Kochova, Petra] Univ W Bohemia, Dept Med, Fac Sci Appl, Plzen 30614, Czech Republic; [Lukas, David] Tech Univ Liberec, Dept Nonwovens, Liberec 46117, Czech Republic","Buzgo, M (reprint author), Charles Univ Prague, Dept Biophys, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","buzgo@labdemo.cz",null,null,"Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z503905120]; Agency of Charles University [330611, 384311, 626012]; Agency of Czech Republic [P304/10/1307]; Ministry of Education of the Czech Republic - Project ERA-NET CARSILA [ME 10145]; Czech Ministry of Health [NT12156]","This research was supported by the Academy of Sciences of the Czech Republic (institutional research plans AV0Z50390703 and AV0Z503905120), the Grant Agency of Charles University (grant no: 330611, 384311, 626012), Grant Agency of Czech Republic (grant no. P304/10/1307), the Ministry of Education of the Czech Republic - Project ERA-NET CARSILA no. ME 10145, Grant Agency of the Czech Ministry of Health (project no. NT12156). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",null,70,0,0,"FUTURE MEDICINE LTD","LONDON","UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND","1743-5889",null,null,"NANOMEDICINE-UK","Nanomedicine","JUL",2013,8,7,null,null,null,null,1137,1154,null,"10.2217/NNM.12.140",null,18,"Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology","Biotechnology & Applied Microbiology; Science & Technology - Other Topics","170LX","WOS:000320853500017"]
[null,null,null,null,"J","Seeman, T; Gilik, J",null,null,null,"Seeman, Tomas; Gilik, Jiri",null,null,"Long-Term Control of Ambulatory Hypertension in Children: Improving With Time But Still Not Achieving New Blood Pressure Goals","AMERICAN JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"blood pressure; children; control; hypertension; nocturnal BP; nondipping; ramipril","CHRONIC KIDNEY-DISEASE; PRACTICE GUIDELINES; TASK-FORCE; ADOLESCENTS; ASSOCIATION; MANAGEMENT; RECOMMENDATIONS; PROGRESSION; COMMITTEE; RAMIPRIL","Short-term therapy can decrease blood pressure (BP) to less than the 95th percentile in only about 50% of children. The aim of our study was to investigate the long-term control of hypertension (HT) in children using ambulatory BP monitoring (ABPM). We analyzed data from all children who started ramipril monotherapy in our center. Controlled HT was defined according to the most current guidelines as systolic and diastolic BP at daytime and nighttime < 90th percentile in primary HT and < 75th percentile in renoparenchymal HT. Thirty-eight children who were on therapy 1 year were included. Thirty-two children had renoparenchymal, and 6 had primary HT. The median age at the beginning of therapy was 13.6 years (range 4.118.0 years), and the median time of antihypertensive therapy was 2.6 years (range 1.011.8 years). Thirty-four percent of children received combination therapy; the median number of antihypertensive drugs was 1.5 drugs/patient (range 14). Sixty-eight percent of children had BP < 95th percentile, but only 34% of the children had controlled HT. Children with uncontrolled HT had a tendency to have a higher daytime diastolic BP index before the start of therapy than children with controlled HT (0.990.11 vs. 0.940.11; P 0.09). There was a significant decrease in prevalence of nondipping (from 47% to 16%; P 0.006) with therapy. This first pediatric study focusing on long-term control of HT using ABPM showed that long-term control of HT is better than short-term control, but still only one-third of children achieve the new BP goals. The low control of HT might be improved by more intensive therapy.","[Seeman, Tomas] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Seeman, Tomas] Charles Univ Prague, Fac Med Plzen, Biomed Ctr, Plzen, Czech Republic; [Gilik, Jiri] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Gilik, Jiri] Univ Hosp Motol, Ctr Cardiovasc Res, Prague, Czech Republic","Seeman, T (reprint author), Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic.","tomas.seeman@lfmotol.cuni.cz",null,null,"European Regional Development Fund [CZ.1.05/2.1.00/03.0076]; Ministry of Health, Czech Republic [00064203]","This study was supported by the project CZ.1.05/2.1.00/03.0076 from the European Regional Development Fund and by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic). We thank Ondrej Hradsky for performing regression analysis and Adam Whitley for reviewing the manuscript.",null,31,1,1,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0895-7061",null,null,"AM J HYPERTENS","Am. J. Hypertens.","JUL",2013,26,7,null,null,null,null,939,945,null,"10.1093/ajh/hpt048",null,7,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","159RM","WOS:000320063500015"]
[null,null,null,null,"J","Soucek, O; Zapletalova, J; Zemkova, D; Snajderova, M; Novotna, D; Hirschfeldova, K; Plasilova, I; Kolouskova, S; Rocek, M; Hlavka, Z; Lebl, J; Sumnik, Z",null,null,null,"Soucek, O.; Zapletalova, J.; Zemkova, D.; Snajderova, M.; Novotna, D.; Hirschfeldova, K.; Plasilova, I.; Kolouskova, S.; Rocek, M.; Hlavka, Z.; Lebl, J.; Sumnik, Z.",null,null,"Prepubertal Girls With Turner Syndrome and Children With Isolated SHOX Deficiency Have Similar Bone Geometry at the Radius","JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM",null,null,"English","Article",null,null,null,null,null,null,"LERI-WEILL DYSCHONDROSTEOSIS; IDIOPATHIC SHORT STATURE; QUANTITATIVE COMPUTED-TOMOGRAPHY; X-RAY ABSORPTIOMETRY; MINERAL DENSITY; GENE SHOX; PROXIMAL RADIUS; GROWTH FAILURE; PREVALENCE; FRACTURES","Context: The low bone mineral density (BMD) and alterations in bone geometry observed in patients with Turner syndrome (TS) are likely caused by hypergonadotropic hypogonadism and/or by haploinsufficiency of the SHOX gene. Objective: Our objective was to compare BMD, bone geometry, and strength at the radius between prepubertal girls with TS and children with isolated SHOX deficiency (SHOX-D) to test the hypothesis that the TS radial bone phenotype may be caused by SHOX-D. Design and Setting: This comparative cross-sectional study was performed between March 2008 and May 2011 in 5 large centers for pediatric endocrinology. Patients: Twenty-two girls with TS (mean age 10.3 years) and 10 children with SHOX-D (mean age 10.3 years) were assessed using peripheral quantitative computed tomography of the forearm. Main outcomes: BMD, bone geometry, and strength at 4% and 65% sites of the radius were evaluated. Results: Trabecular BMD was normal in TS (mean Z-score = -0.2 +/- 1.1, P = .5) as well as SHOX-D patients(mean Z-score = 0.5 +/- 1.5, P = .3). At the proximal radius, we observed increased total bone area (Z-scores = 0.9 +/- 1.5, P = .013, and 1.5 +/- 1.4, P = .001, for TS and SHOX-D patients, respectively) and thin cortex (Z-scores = -0.7 +/- 1.2, P = 0.013, and -2.0 +/- 1.2, P < .001, respectively) in both groups. Bone strength index was normal in TS as well as SHOX-D patients (Z-scores = 0.3 +/- 1.0, P = .2, and 0.1 +/- 1.3, P = .8, respectively). Conclusions: The similar bone geometry changes of the radius in TS and SHOX-D patients support the hypothesis that loss of 1 copy of SHOX is responsible for the radial bone phenotype associated with TS.","[Soucek, O.; Zemkova, D.; Snajderova, M.; Kolouskova, S.; Lebl, J.; Sumnik, Z.] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague 15006 5, Czech Republic; [Rocek, M.] Charles Univ Prague, Dept Radiol, Fac Med 2, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague 15006 5, Czech Republic; [Zapletalova, J.] Palacky Univ, Fac Med, Dept Pediat, Olomouc 77520, Czech Republic; Univ Hosp Olomouc, Olomouc 77520, Czech Republic; [Novotna, D.] Masaryk Univ, Dept Pediat, Fac Med, Brno 61300, Czech Republic; Univ Hosp Brno, Brno 61300, Czech Republic; [Hirschfeldova, K.] Charles Univ Prague, Inst Biol, Fac Med 1, Prague 12800 2, Czech Republic; [Hirschfeldova, K.] Charles Univ Prague, Dept Med Genet, Fac Med 1, Prague 12800 2, Czech Republic; Gen Univ Hosp, Prague 12800 2, Czech Republic; [Plasilova, I.] Charles Univ Prague, Dept Pediat, Fac Med, Hradec Kralove 50005, Czech Republic; Univ Hosp Hradec Kralove, Hradec Kralove 50005, Czech Republic; [Hlavka, Z.] Charles Univ Prague, Fac Math & Phys, Dept Probabil & Math Stat, CR-12116 Prague 2, Czech Republic","Soucek, O (reprint author), Charles Univ Prague, Dept Pediat, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","ondrej.soucek@lfmotol.cuni.cz",null,null,"Project (Ministry of Health, Czech Republic) for Conceptual Development of Research Organization [00064203]","This work was supported by the Project (Ministry of Health, Czech Republic) for Conceptual Development of Research Organization 00064203 (University Hospital Motol, Prague, Czech Republic).",null,39,0,1,"ENDOCRINE SOC","CHEVY CHASE","8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA","0021-972X",null,null,"J CLIN ENDOCR METAB","J. Clin. Endocrinol. Metab.","JUL",2013,98,7,null,null,null,null,"E1241","E1247",null,"10.1210/jc.2013-1113",null,7,"Endocrinology & Metabolism","Endocrinology & Metabolism","196MV","WOS:000322780600014"]
[null,null,null,null,"J","Buckova, M; Kasparova, M; Dostalova, T; Jelinkova, H; Sulc, J; Nemec, M; Fibrich, M; Bradna, P; Miyagi, M",null,null,null,"Buckova, M.; Kasparova, M.; Dostalova, T.; Jelinkova, H.; Sulc, J.; Nemec, M.; Fibrich, M.; Bradna, P.; Miyagi, M.",null,null,"Er:YAG and CTH:YAG laser radiation: contact versus non-contact enamel ablation and sonic-activated bulk composite placement","LASER PHYSICS",null,null,"English","Article",null,null,null,null,null,null,"DENTAL-TISSUES; IRRADIATION; YAG","Laser radiation can be used for effective caries removal and cavity preparation without significant thermal effects, collateral damage of tooth structure, or patient discomfort. The aim of this study was to compare the quality of tissue after contact or non-contact Er:YAG and CTH:YAG laser radiation ablation. The second goal was to increase the sealing ability of hard dental tissues using sonic-activated bulk filling material with change in viscosity during processing. The artificial caries was prepared in intact teeth to simulate a demineralized surface and then the Er:YAG or CTH:YAG laser radiation was applied. The enamel artificial caries was gently removed by the laser radiation and sonic-activated composite fillings were inserted. A stereomicroscope and then a scanning electron microscope were used to evaluate the enamel surface. Er:YAG contact mode ablation in enamel was quick and precise; the cavity was smooth with a keyhole shaped prism and rod relief arrangement without a smear layer. The sonic-activated filling material was consistently regularly distributed; no cracks or microleakage in the enamel were observed. CTH:YAG irradiation was able to clean but not ablate the enamel surface; in contact and also in non-contact mode there was evidence of melting and fusing of the enamel.","[Buckova, M.; Kasparova, M.; Dostalova, T.] Charles Univ Prague, Fac Med 2, Dept Stomatol, Prague 15006 5, Czech Republic; [Jelinkova, H.; Sulc, J.; Nemec, M.; Fibrich, M.] Czech Tech Univ, Fac Nucl Sci & Phys Engn, Prague 11519, Czech Republic; [Bradna, P.] Charles Univ Prague, Fac Med 1, UKES, Prague 12000, Czech Republic; [Miyagi, M.] Tohoku Inst Technol, Aoba Ku, Sendai, Miyagi 9893128, Japan","Buckova, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Stomatol, Uvalu 84, Prague 15006 5, Czech Republic.","tatjana.dostalova@fnmotol.cz","jingjing, cai/M-2687-2013",null,"IGA MZCR NT [13351-4]; Prvouk 28 project [00064203]; RVO [68407700]","This research has been supported by IGA MZCR NT 13351-4, Prvouk 28 project No 00064203 (FN MOTOL), and RVO 68407700.",null,18,0,0,"IOP PUBLISHING LTD","BRISTOL","TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND","1054-660X",null,null,"LASER PHYS","Laser Phys.","MAY",2013,23,5,null,null,null,null,null,null,55605,"10.1088/1054-660X/23/5/055605",null,8,"Optics; Physics, Applied","Optics; Physics","131QA","WOS:000318007600029"]
[null,null,null,null,"J","Dmytrenko, L; Cicanic, M; Anderova, M; Vorisek, I; Ottersen, OP; Sykova, E; Vargova, L",null,null,null,"Dmytrenko, Lesia; Cicanic, Michal; Anderova, Miroslava; Vorisek, Ivan; Ottersen, Ole Petter; Sykova, Eva; Vargova, Lydia",null,null,"The Impact of Alpha-Syntrophin Deletion on the Changes in Tissue Structure and Extracellular Diffusion Associated with Cell Swelling under Physiological and Pathological Conditions","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"AQUAPORIN-4 WATER CHANNELS; RAT SPINAL-CORD; CEREBRAL-ISCHEMIA; POTASSIUM CHANNEL; VOLUME CHANGES; GLIAL-CELLS; BRAIN; MICE; K+; SPACE","Aquaporin-4 (AQP4) is the primary cellular water channel in the brain and is abundantly expressed by astrocytes along the blood-brain barrier and brain-cerebrospinal fluid interfaces. Water transport via AQP4 contributes to the activity-dependent volume changes of the extracellular space (ECS), which affect extracellular solute concentrations and neuronal excitability. AQP4 is anchored by alpha-syntrophin (alpha-syn), the deletion of which leads to reduced AQP4 levels in perivascular and subpial membranes. We used the real-time iontophoretic method and/or diffusion-weighted magnetic resonance imaging to clarify the impact of alpha-syn deletion on astrocyte morphology and changes in extracellular diffusion associated with cell swelling in vitro and in vivo. In mice lacking alpha-syn, we found higher resting values of the apparent diffusion coefficient of water (ADC(W)) and the extracellular volume fraction (alpha). No significant differences in tortuosity (lambda) or non-specific uptake (k'), were found between alpha-syn-negative (alpha-syn -/-) and alpha-syn-positive (alpha-syn +/+) mice. The deletion of alpha-syn resulted in a significantly smaller relative decrease in alpha observed during elevated K+ (10 mM) and severe hypotonic stress (-100 mOsmol/l), but not during mild hypotonic stress (-50 mOsmol/l). After the induction of terminal ischemia/anoxia, the final values of ADC(W) as well as of the ECS volume fraction alpha indicate milder cell swelling in alpha-syn -/- in comparison with alpha-syn +/+ mice. Shortly after terminal ischemia/anoxia induction, the onset of a steep rise in the extracellular potassium concentration and an increase in lambda was faster in alpha-syn -/- mice, but the final values did not differ between alpha-syn -/- and alpha-syn +/+ mice. This study reveals that water transport through AQP4 channels enhances and accelerates astrocyte swelling. The substantially altered ECS diffusion parameters will likely affect the movement of neuroactive substances and/or trophic factors, which in turn may modulate the extent of tissue damage and/or drug distribution.","[Dmytrenko, Lesia; Cicanic, Michal; Anderova, Miroslava; Vorisek, Ivan; Sykova, Eva; Vargova, Lydia] Inst Expt Med AS CR, Vvi, Prague, Czech Republic; [Cicanic, Michal; Anderova, Miroslava; Vorisek, Ivan; Sykova, Eva; Vargova, Lydia] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Ottersen, Ole Petter] Univ Oslo, Ctr Mol Biol & Neurosci, Oslo, Norway; [Ottersen, Ole Petter] Univ Oslo, Dept Anat, Oslo, Norway","Vargova, L (reprint author), Inst Expt Med AS CR, Vvi, Prague, Czech Republic.","lydie.vargova@lfmotol.cuni.cz",null,null,"Grant Agency of the Czech Republic [309/09/1597, P303/11/2378, P304/12/G069]","This study was supported by the grants 309/09/1597, P303/11/2378 and P304/12/G069 from the Grant Agency of the Czech Republic. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,46,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","JUL 5",2013,8,7,null,null,null,null,null,null,"e68044","10.1371/journal.pone.0068044",null,12,"Multidisciplinary Sciences","Science & Technology - Other Topics","178DW","WOS:000321425300037"]
[null,null,null,null,"J","Dedeckova, K; Kalferstova, L; Strnad, H; Vavrova, J; Drevinek, P",null,null,null,"Dedeckova, Klara; Kalferstova, Lucie; Strnad, Hynek; Vavrova, Jolana; Drevinek, Pavel",null,null,"Novel diagnostic PCR assay for Burkholderia cenocepacia epidemic strain ST32 and its utility in monitoring infection in cystic fibrosis patients","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Article",null,null,null,null,null,null,"CEPACIA COMPLEX; SUBTRACTIVE HYBRIDIZATION; IDENTIFICATION; GENOME; DNA; PROVIDES; GENES","Background: A highly transmissible Burkholderia cenocepacia sequence type (ST) 32 strain caused a major outbreak at the Prague Cystic Fibrosis (CF) Centre in the late 1990s and early 2000s. Because a large number of CF patients were affected by ST32, a rapid and easy-to-use diagnostic tool for ST32 infection was urgently needed for the detection of new cases as well as for long-term surveillance. The present study sought to identify unique DNA sequences within the ST32 genome to develop an ST32 strain-specific PCR assay. Methods: Genomic subtractive hybridisation between B. cenocepacia ST32 and the closely related genome-sequenced strain B. cenocepacia ST28 identified a 325 bp long region that was absent in all but one Burkholderia strain, as demonstrated by our newly designed PCR. Results: Out of 57 strains, only B. cenocepacia ST33 cross-reacted with ST32, resulting in a PCR specificity of 98.2%. This specificity was further tested by various genotyping methods, which revealed the practical indistinguishibility of ST32 and ST33. The PCR sensitivity, checked on a panel of 50 ST32 clinical isolates, was 100%. A closer examination of the ST32-specific sequence revealed no significant homology apart from a fragment of the ISBmu3 transposase. Conclusions: This novel ST32-specific PCR assay allows the rapid and reliable detection of a globally distributed B. cenocepacia epidemic strain. Its routine use is especially well suited to infection surveillance programs for CF populations with a high rate of ST32 infection. This PCR method can also be used to detect ST33, a clonal variant of ST32. (C) 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Dedeckova, Klara; Kalferstova, Lucie; Vavrova, Jolana; Drevinek, Pavel] Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Prague 15006 5, Czech Republic; [Dedeckova, Klara; Kalferstova, Lucie; Vavrova, Jolana; Drevinek, Pavel] Univ Hosp Motol, Prague 15006 5, Czech Republic; [Strnad, Hynek] Acad Sci Czech Republic, Inst Mol Genet, Dept Genom & Bioinformat, CR-14220 Prague 4, Czech Republic; [Dedeckova, Klara; Kalferstova, Lucie; Drevinek, Pavel] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague 15006 5, Czech Republic","Drevinek, P (reprint author), Charles Univ Prague, Dept Med Microbiol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","pavel.drevinek@Lfmotol.cuni.cz","Strnad, Hynek/B-7361-2008","Strnad, Hynek/0000-0002-0141-8340","Grant Agency of Charles University in Prague [GAUK 307311]; Ministry of Health of the Czech Republic [NT12405-5]; University Hospital Motol [00064203]; Ministry of Education of the Czech Republic [LD11029]","This work was funded by grants from the Grant Agency of Charles University in Prague GAUK 307311, the Ministry of Health of the Czech Republic NT12405-5 and the project for conceptual development of research organisation 00064203 (University Hospital Motol), and the Ministry of Education of the Czech Republic LD11029.",null,21,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","SEP",2013,12,5,null,null,null,null,475,481,null,"10.1016/j.jcf.2012.12.007",null,7,"Respiratory System","Respiratory System","221MZ","WOS:000324664300009"]
[null,null,null,null,"J","Jiruska, P; Shtaya, ABY; Bodansky, DMS; Chang, WC; Gray, WP; Jefferys, JGR",null,null,null,"Jiruska, Premysl; Shtaya, Anan B. Y.; Bodansky, David M. S.; Chang, Wei-Chih; Gray, William P.; Jefferys, John G. R.",null,null,"Dentate gyrus progenitor cell proliferation after the onset of spontaneous seizures in the tetanus toxin model of temporal lobe epilepsy","NEUROBIOLOGY OF DISEASE",null,null,"English","Article",null,null,null,null,null,"Spontaneous seizures; Temporal lobe epilepsy; Neurogenesis; Tetanus toxin; Apoptosis","ADULT HIPPOCAMPAL NEUROGENESIS; LONG-TERM CHANGES; STATUS EPILEPTICUS; LEARNING-ABILITY; FEBRILE SEIZURES; LIMBIC SEIZURES; RAT HIPPOCAMPUS; PRECURSOR CELLS; KINDLING MODEL; STEM-CELLS","Temporal lobe epilepsy alters adult neurogenesis. Existing experimental evidence is mainly from chronic models induced by an initial prolonged status epilepticus associated with substantial cell death. In these models, neurogenesis increases after status epilepticus. To test whether status epilepticus is necessary for this increase, we examined precursor cell proliferation and neurogenesis after the onset of spontaneous seizures in a model of temporal lobe epilepsy induced by unilateral intrahippocampal injection of tetanus toxin, which does not cause status or, in most cases, detectable neuronal loss. We found a 4.5 times increase in BrdU labeling (estimating precursor cells proliferating during the 2nd week after injection of toxin and surviving at least up to 7 days) in dentate gyri of both injected and contralateral hippocampi of epileptic rats. Radiotelemetry revealed that the rats experienced 112+/-24 seizures, lasting 88+/-11 s each, over a period of 8.6+/-1.3 days from the first electrographic seizure. On the first day of seizures, their duration was a median of 103 s, and the median interictal period was 23 min, confirming the absence of experimentally defined status epilepticus. The total increase in cell proliferation/survival was due to significant population expansions of: radial glial-like precursor cells (type I; 7.2x), non-radial type neural precursors in the dentate gyrus stem cell niche (5.6x), and doublecortin-expressing neuroblasts (5.1x). We conclude that repeated spontaneous brief temporal lobe seizures are sufficient to promote increased hippocampal neurogenesis in the absence of status epilepticus. (C) 2013 Elsevier Inc. All rights reserved.","[Jiruska, Premysl; Bodansky, David M. S.; Chang, Wei-Chih; Jefferys, John G. R.] Univ Birmingham, Sch Clin & Expt Med, Neuronal Networks Grp, Birmingham B15 2TT, W Midlands, England; [Jiruska, Premysl] Acad Sci Czech Republic, Inst Physiol, Dept Dev Epileptol, CZ-14220 Prague, Czech Republic; [Jiruska, Premysl] Charles Univ Prague, Univ Hosp Motol, Sch Med 2, Dept Neurol, CZ-15006 Prague, Czech Republic; [Shtaya, Anan B. Y.] Southampton Univ Hosp Trust, Wessex Neurol Ctr, Southampton SO16 6YD, Hants, England; [Shtaya, Anan B. Y.; Gray, William P.] Univ Southampton, Fac Med Hlth & Life Sci, Sch Med Clin Neurosci, Southampton SO16 6YD, Hants, England; [Gray, William P.] Natl Inst Neurosci & Mental Hlth Res, Cardiff CF14 4XN, S Glam, Wales","Gray, WP (reprint author), Natl Inst Neurosci & Mental Hlth Res, LGF Henry Wellcome Bldg,Heath Pk, Cardiff CF14 4XN, S Glam, Wales.","graywp@Cardiff.ac.uk; J.G.R.Jefferys@bham.ac.uk",null,null,"Epilepsy Research UK [A0806, P1102]; FQMS Fellowship; Grant Agency of Czech Republic [GACR P303/10/0999]; MRC [G0802162]","This study is supported by the Epilepsy Research UK grant (A0806) to PJ and (P1102) to JJ, the FQMS Fellowship funding to AS and WPG, the Grant Agency of Czech Republic grant (GACR P303/10/0999) to PJ and the MRC grant G0802162 to JJ.",null,51,2,2,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0969-9961",null,null,"NEUROBIOL DIS","Neurobiol. Dis.","JUN",2013,54,null,null,null,null,null,492,498,null,"10.1016/j.nbd.2013.02.001",null,7,"Neurosciences","Neurosciences & Neurology","132EZ","WOS:000318052000047"]
[null,null,null,null,"J","Malina, M; Schaefer, B; Waldherr, R; Wuhl, E; Schaefer, F; Schmitt, CP",null,null,null,"Malina, Michal; Schaefer, Betti; Waldherr, Ruediger; Wuehl, Elke; Schaefer, Franz; Schmitt, Claus Peter",null,null,"Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,null,"ANCA-ASSOCIATED VASCULITIS; CLINICAL-FEATURES; CYCLOPHOSPHAMIDE; THERAPY","Rituximab has proven effective in the treatment of complicated granulomatosis with polyangiitis (Wegener's, GPA). Two controlled trials in adults demonstrated beneficial effects of rituximab compared to cyclophosphamide in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis to induce remission and to treat relapses. Pediatric experience with rituximab in GPA is limited; the impact on renal function is unknown. We report a female adolescent with GPA and necrotizing glomerulonephritis that lead to end-stage renal disease (ESRD). After 22 months of peritoneal dialysis, she still experienced relapses and major treatment-associated adverse effects. After a single dose of rituximab, she rapidly achieved clinical remission and, unexpectedly, steadily recovered glomerular filtration rate, plateauing at 25 ml/min/1.73 m(2). Peritoneal dialysis could be discontinued for 16 months. This case documents a potent beneficial effect of rituximab on renal manifestation of GPA even in long-established ESRD.","[Malina, Michal; Schaefer, Betti; Wuehl, Elke; Schaefer, Franz; Schmitt, Claus Peter] Heidelberg Univ, Div Pediat Nephrol, Ctr Pediat & Adolescent Med, D-69120 Heidelberg, Germany; [Malina, Michal] Charles Univ Prague, Dept Pediat, Fac Med 2, Prague, Czech Republic; [Malina, Michal] Univ Hosp Motol, Prague, Czech Republic","Schmitt, CP (reprint author), Heidelberg Univ, Div Pediat Nephrol, Ctr Pediat & Adolescent Med, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.","claus.peter.schmitt@med.uni-heidelberg.de",null,null,null,null,null,15,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","MAR",2013,28,3,null,null,null,null,511,514,null,"10.1007/s00467-012-2332-4",null,4,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","077OW","WOS:000314038000020"]
[null,null,null,null,"J","Krenkova, P; Piskackova, T; Holubova, A; Balascakova, M; Krulisova, V; Camajova, J; Turnovec, M; Libik, M; Norambuena, P; Stambergova, A; Dvorakova, L; Skalicka, V; Bartosova, J; Kucerova, T; Fila, L; Zemkova, D; Vavrova, V; Koudova, M; Macek, M; Krebsova, A; Macek, M",null,null,null,"Krenkova, Petra; Piskackova, Tereza; Holubova, Andrea; Balascakova, Miroslava; Krulisova, Veronika; Camajova, Jana; Turnovec, Marek; Libik, Malgorzata; Norambuena, Patricia; Stambergova, Alexandra; Dvorakova, Lenka; Skalicka, Veronika; Bartosova, Jana; Kucerova, Tereza; Fila, Libor; Zemkova, Dana; Vavrova, Vera; Koudova, Monika; Macek, Milan, Sr.; Krebsova, Alice; Macek, Milan, Jr.",null,null,"Distribution of CFTR mutations in the Czech population: Positive impact of integrated clinical and laboratory expertise, detection of novel/de novo alleles and relevance for related/derived populations","JOURNAL OF CYSTIC FIBROSIS",null,null,"English","Article",null,null,null,null,null,"Cystic fibrosis; Czech Republic; De novo CFTR mutation; Central Europe; Newborn screening","CYSTIC-FIBROSIS MUTATION; EUROPE; GENE; CONSENSUS","Background: This two decade long study presents a comprehensive overview of the CFTR mutation distribution in a representative cohort of 600 Czech CF patients derived from all regions of the Czech Republic. Methods: We examined the most common CF-causing mutations using the Elucigene CF-EU2v1 (TM) assay, followed by MLPA, mutation scanning and/or sequencing of the entire CFTR coding region and splice site junctions. Results: We identified 99.5% of all mutations (1194/1200 CFTR alleles) in the Czech CF population. Altogether 91 different CFTR mutations, of which 20 were novel, were detected. One case of de novo mutation and a novel polymorphism was revealed. Conclusion: The commercial assay achieved 90.7%, the MLPA added 1.0% and sequencing increased the detection rate by 7.8%. These comprehensive data provide a basis for the improvement of CF DNA diagnostics and/or newborn screening in our country. In addition, they are relevant to related Central European populations with lower mutation detection rates, as well as to the sizeable North American \"Bohemian diaspora\". (C) 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.","[Krenkova, Petra; Piskackova, Tereza; Holubova, Andrea; Balascakova, Miroslava; Krulisova, Veronika; Camajova, Jana; Turnovec, Marek; Libik, Malgorzata; Norambuena, Patricia; Stambergova, Alexandra; Dvorakova, Lenka; Koudova, Monika; Macek, Milan, Sr.; Krebsova, Alice; Macek, Milan, Jr.] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, CZ-15006 Prague 5, Czech Republic; [Krenkova, Petra; Piskackova, Tereza; Holubova, Andrea; Balascakova, Miroslava; Krulisova, Veronika; Camajova, Jana; Turnovec, Marek; Libik, Malgorzata; Norambuena, Patricia; Stambergova, Alexandra; Dvorakova, Lenka; Skalicka, Veronika; Bartosova, Jana; Kucerova, Tereza; Fila, Libor; Zemkova, Dana; Vavrova, Vera; Koudova, Monika; Macek, Milan, Sr.; Krebsova, Alice; Macek, Milan, Jr.] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Camajova, Jana] Reg Author Publ Hlth, Banska Bystrica, Slovakia; [Skalicka, Veronika; Bartosova, Jana; Kucerova, Tereza; Zemkova, Dana; Vavrova, Vera] Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-15006 Prague 5, Czech Republic; [Fila, Libor] Charles Univ Prague, Fac Med 2, Dept Pneumol, CZ-15006 Prague 5, Czech Republic; [Koudova, Monika] GHC Genet Ltd, Prague, Czech Republic; [Krebsova, Alice] Humboldt Univ, Dept Cardiol, Virchow Klinikum Charite, D-10099 Berlin, Germany","Macek, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","milan.macek.jr@lfmotol.cuni.cz",null,null,"Czech Ministry of Health [CZ.2.16/3.1.00/24022OPPK, 00064203]; European Commission [FP7-HEALTH-F4-2010-261469]","Supported by CZ.2.16/3.1.00/24022OPPK, \"Conceptual development project of research organization #00064203\" (University Hospital Motol, Prague) from the Czech Ministry of Health, PRVOUK UK 2. LF and the European Commission projects (Eurogentest; FP7-HEALTH-F4-2010-261469) to MM Jr. We would like to acknowledge all collaborating clinicians whom we could not list individually and current and previous colleagues Nikola Bila, Miroslava Hancarova, Magdalena Herova, Milada Matejickova, Jana Paderova and Inna Soldatova from our department. We would like to thank our partners and long-time foreign collaborators Drs. Marie-Pierre Audrezet, Jian-Min Chen, Claude Ferec and Bernard Mercier (Laboratoire de Genetique Moleculaire et d'Histocompatibilite, Centre Hospitalier Universitaire, Hopital Morvan, Brest, France) and Timothy W. Hefferon (National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA) for their invaluable assistance. We would also like to acknowledge the support of Dr. Garry R. Cutting (MsKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, U.S.A.) who supported this study in the early to mid nineties. Finally, we would like to thank the Czech CF Association (www.cfklub.cz) for their continuous support.",null,22,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-1993",null,null,"J CYST FIBROS","J. Cyst. Fibros","SEP",2013,12,5,null,null,null,null,532,537,null,"10.1016/j.jcf.2012.12.002",null,6,"Respiratory System","Respiratory System","221MZ","WOS:000324664300018"]
[null,null,null,null,"J","DiNicolantonio, JJ; Tomek, A",null,null,null,"DiNicolantonio, James J.; Tomek, Ales",null,null,"Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"Ticagrelor; Clopidogrel; Acute coronary syndrome; Myocardial infarction","ATLAS ACS 2; CLOPIDOGREL; REDUCTION; MORTALITY; TRACER","Objective: Ascertain platelet inhibition and patient outcomes (PLATO) trial conduct. Methods: We examined information from the FDA complete response review. Results: FDA Medical Review indicated that (1) patients on ticagrelor monitored by the study sponsor had a lower odds ratio for the primary endpoint (p = 0.0004) versus ticagrelor patients monitored by a third party Clinical Research Organisation (CRO) independent of the study sponsor, (2) a significant interaction existed between ticagrelor and regions monitored by the study sponsor for all cause mortality through study end in favor of ticagrelor (p = 0.006), (3) ticagrelor faired worse than clopidogrel when regions were monitored independent of the study sponsor by a third party Contract Research Organisation (United States, Russia and Georgia), (OR = 1.21, 95% CI: 0.91 to 1.59, p = 0.2022), (4) 46% of all primary endpoint events favoring ticagrelor came from just two countries (Poland and Hungary), (5) PLATO was easy to unblind by breaking open a clopidogrel/dummy clopidogrel tablet with at least 452 patients being unblinded prior to the database lock, (6) significantly more cardiac events submitted for clopidogrel counted in the primary analysis as a myocardial infarction (MI) compared to those submitted for ticagrelor (p < 0.0001), (7) significantly more ticagrelor subjects hospitalized after an index event/hospitalization were not being reported as having a primary event compared to clopidogrel (p = 0.002 in favor of ticagrelor), (8) site-reported MI was not significantly reduced with ticagrelor versus clopidogrel, (9) an estimated 23 definite or possible cardiovascular events or deaths on ticagrelor were either not submitted for adjudication, inactivated, deleted or were downgraded to \"softer\" endpoints (this was not shown in the FDA review for clopidogrel), and (10) four FDA reviewers voted for non-approval of ticagrelor. Discussion: The FDA report highlights what appear to be multiple serious deficiencies in the reporting of the PLATO results, which clinicians will not have gleaned from the primary publication alone. Individual clinicians may therefore wish to carefully reconsider their practice of ticagrelor prescription for this indication. Guideline bodies should also evaluate the information in its totality. (C) 2013 Elsevier Ireland Ltd. All rights reserved.","Wegmans Pharm, Ithaca, NY USA; Charles Univ Prague, Dept Neurol, Univ Hosp Motol, Fac Med 2, Prague, Czech Republic","DiNicolantonio, JJ (reprint author), 500 South Meadow St, Ithaca, NY 14850 USA.","jjdinicol@gmail.com",null,null,null,null,null,13,2,2,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273","1874-1754",null,"INT J CARDIOL","Int. J. Cardiol.","OCT 9",2013,168,4,null,null,null,null,4076,4080,null,"10.1016/j.ijcard.2013.07.020",null,5,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","242EG","WOS:000326219600151"]
[null,null,null,null,"J","Marejkova, M; Blahova, K; Janda, J; Fruth, A; Petras, P",null,null,null,"Marejkova, Monika; Blahova, Kveta; Janda, Jan; Fruth, Angelika; Petras, Petr",null,null,"Enterohemorrhagic Escherichia coli as Causes of Hemolytic Uremic Syndrome in the Czech Republic","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"CYTOLETHAL DISTENDING TOXIN; SPECTRUM-BETA-LACTAMASE; TANDEM-REPEAT ANALYSIS; TERM-FOLLOW-UP; UNITED-STATES; GENE-CLUSTER; TELLURITE RESISTANCE; MOLECULAR ANALYSIS; ENDOTHELIAL-CELLS; O104/H4 STRAIN","Background: Enterohemorrhagic Escherichia coli (EHEC) cause diarrhea-associated hemolytic uremic syndrome (D+ HUS) worldwide, but no systematic study of EHEC as the causative agents of HUS was performed in the Czech Republic. We analyzed stools of all patients with D+ HUS in the Czech Republic between 1998 and 2012 for evidence of EHEC infection. We determined virulence profiles, phenotypes, antimicrobial susceptibilities and phylogeny of the EHEC isolates. Methodology/Principal Findings: Virulence loci were identified using PCR, phenotypes and antimicrobial susceptibilities were determined using standard procedures, and phylogeny was assessed using multilocus sequence typing. During the 15-year period, EHEC were isolated from stools of 39 (69.4%) of 56 patients. The strains belonged to serotypes [fliC types] O157:H7/NM[fliC(H7)] (50% of which were sorbitol-fermenting; SF), O26: H11/NM[fliC(H11)], O55:NM[fliC(H7)], O111:NM[fliC(H8)], O145:H28[fliC(H28)], O172: NM[fliC(H25)], and Orough: NM[fliC(H25)]. O26: H11/NM[fliC(H11)] was the most common serotype associated with HUS (41% isolates). Five stx genotypes were identified, the most frequent being stx(2a) (71.1% isolates). Most strains contained EHEC-hlyA encoding EHEC hemolysin, and a subset (all SF O157: NM and one O157: H7) harbored cdtV encoding cytolethal distending toxin. espP alpha encoding serine protease EspP alpha was found in EHEC O157: H7, O26: H11/NM, and O145: H28, whereas O172: NM and Orough: NM strains contained espP gamma. All isolates contained eae encoding adhesin intimin, which belonged to subtypes beta (O26), gamma (O55, O145, O157), gamma 2/0 (O111), and epsilon (O172, Orough). Loci encoding other adhesins (efa1, lpfA(O26), lpfA(O157OI-141), lpfA(O157OI-154), iha) were usually associated with particular serotypes. Phylogenetic analysis demonstrated nine sequence types (STs) which correlated with serotypes. Of these, two STs (ST660 and ST1595) were not found in HUS-associated EHEC before. Conclusions/Significance: EHEC strains, including O157: H7 and non-O157: H7, are frequent causes of D+ HUS in the Czech Republic. Identification of unusual EHEC serotypes/STs causing HUS calls for establishment of an European collection of HUS-associated EHEC, enabling to study properties and evolution of these important pathogens.","[Marejkova, Monika; Petras, Petr] Natl Inst Publ Hlth, Natl Reference Lab E Coli & Shigella, Prague, Czech Republic; [Marejkova, Monika] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Blahova, Kveta; Janda, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Blahova, Kveta; Janda, Jan] Univ Hosp Motol, Prague, Czech Republic; [Fruth, Angelika] Robert Koch Inst, Natl Reference Ctr Salmonella & Other Enter Patho, Wernigerode, Germany","Marejkova, M (reprint author), Natl Inst Publ Hlth, Natl Reference Lab E Coli & Shigella, Prague, Czech Republic.","monmarej@szu.cz",null,null,null,null,null,81,1,1,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","SEP 6",2013,8,9,null,null,null,null,null,null,"e73927","10.1371/journal.pone.0073927",null,10,"Multidisciplinary Sciences","Science & Technology - Other Topics","224BO","WOS:000324856500066"]
[null,null,null,null,"J","DiNicolantonio, JJ; Tomek, A",null,null,null,"DiNicolantonio, James J.; Tomek, Ales",null,null,"Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"Ticagrelor; Clopidogrel; Misrepresentations",null,"Context: Ticagrelor, a novel, reversible, and oral P2Y12 receptor antagonist, was claimed to reduce all-cause mortality compared to clopidogrel in the PLATO trial. Objective: We sought to ascertain vital status follow-up for clopidogrel and ticagrelor to determine if any discrepancy existed by reviewing data from the FDA Complete Response Review. Results: The FDA Complete Response Review indicated misrepresentation of vital status follow-up by the sponsor's presenter at the Cardiovascular and Renal Drugs Advisory Committee. Instead of five patients with missing vital status follow-up, the FDA primary efficacy reviewer indicated that there was a minimum of 106 patients. Additionally and more concerning was the fact that significantly more patients on ticagrelor (3.1%, n - 289 patients) had incomplete vital status follow-up versus clopidogrel (2.6%, n - 242 patients, p - 0.04 for the difference). Conclusions: The Advisory Committee that voted in favor to approve ticagrelor was given misrepresented data, which may have affected the approval of ticagrelor. The fact that significantly more patients on ticagrelor had incomplete vital status follow-up versus clopidogrel challenges the claimed mortality benefit of ticagrelor and the approval of the PLATO trial. (C) 2013 Elsevier Ireland Ltd. All rights reserved.","Charles Univ Prague, Dept Neurol, Univ Hosp Motol, Fac Med 2, Prague, Czech Republic","DiNicolantonio, JJ (reprint author), 500 South Meadow St, Ithaca, NY 14850 USA.","jjdinicol@gmail.com",null,null,null,null,null,2,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273","1874-1754",null,"INT J CARDIOL","Int. J. Cardiol.","OCT 30",2013,169,2,null,null,null,null,145,146,null,"10.1016/j.ijcard.2013.08.085",null,2,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","246WV","WOS:000326572600015"]
[null,null,null,null,"J","Hejcl, A; Ruzicka, J; Kapcalova, M; Turnovcova, K; Krumbholcova, E; Pradny, M; Michalek, J; Cihlar, J; Jendelova, P; Sykova, E",null,null,null,"Hejcl, Ales; Ruzicka, Jiri; Kapcalova, Miroslava; Turnovcova, Karolina; Krumbholcova, Eva; Pradny, Martin; Michalek, Jiri; Cihlar, Jiri; Jendelova, Pavla; Sykova, Eva",null,null,"Adjusting the Chemical and Physical Properties of Hydrogels Leads to Improved Stem Cell Survival and Tissue Ingrowth in Spinal Cord Injury Reconstruction: A Comparative Study of Four Methacrylate Hydrogels","STEM CELLS AND DEVELOPMENT",null,null,"English","Article",null,null,null,null,null,null,"MARROW STROMAL CELLS; COLONY-STIMULATING FACTOR; NEGATIVE SURFACE-CHARGES; CHRONIC PARAPLEGIC RATS; FUNCTIONAL RECOVERY; 2-HYDROXYETHYL METHACRYLATE; POLYELECTROLYTE COMPLEXES; INTRATHECAL DELIVERY; AXONAL REGENERATION; HEMATOPOIETIC-CELLS","Currently, there is no effective strategy for the treatment of spinal cord injury (SCI). A suitable combination of modern hydrogel materials, modified to effectively bridge the lesion cavity, combined with appropriate stem cell therapy seems to be a promising approach to repair spinal cord damage. We demonstrate the synergic effect of porosity and surface modification of hydrogels on mesenchymal stem cell (MSC) adhesiveness in vitro and their in vivo survival in an experimental model of SCI. MSCs were seeded on four different hydrogels: hydroxypropylmethacrylate-RGD prepared by heterophase separation (HPMA-HS-RGD) and three other hydrogels polymerized in the presence of a solid porogen: HPMA-SP, HPMA-SP-RGD, and hydroxy ethyl methacrylate [2-(methacryloyloxy)ethyl] trimethylammonium chloride (HEMA-MOETACl). Their adhesion capability and cell survival were evaluated at 1, 7, and 14 days after the seeding of MSCs on the hydrogel scaffolds. The cell-polymer scaffolds were then implanted into hemisected rat spinal cord, and MSC survival in vivo and the ingrowth of endogenous tissue elements were evaluated 1 month after implantation. In vitro data demonstrated that HEMA-MOETACl and HPMA-SP-RGD hydrogels were superior in the number of cells attached. In vivo, the highest cell survival was found in the HEMA-MOETACl hydrogels; however, only a small ingrowth of blood vessels and axons was observed. Both HPMA-SP and HPMA-SP-RGD hydrogels showed better survival of MSCs compared with the HPMA-HS-RGD hydrogel. The RGD sequence attached to both types of HPMA hydrogels significantly influenced the number of blood vessels inside the implanted hydrogels. Further, the porous structure of HPMA-SP hydrogels promoted a statistically significant greater ingrowth of axons and less connective tissue elements into the implant. Our results demonstrate that the physical and chemical properties of the HPMA-SP-RGD hydrogel show the best combination for bridging a spinal cord lesion, while the HEMA-MOETACl hydrogel serves as the best carrier of MSCs.","[Hejcl, Ales; Ruzicka, Jiri; Kapcalova, Miroslava; Turnovcova, Karolina; Jendelova, Pavla; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Prague 14220 4, Czech Republic; [Hejcl, Ales] Univ JE Purkyne, Masaryk Hosp, Dept Neurosurg, Usti Nad Labem, Czech Republic; [Ruzicka, Jiri; Turnovcova, Karolina; Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Krumbholcova, Eva; Pradny, Martin; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, Prague 14220 4, Czech Republic; [Cihlar, Jiri] Univ JE Purkyne, Fac Sci, Dept Math, Usti Nad Labem, Czech Republic","Hejcl, A (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, Videnska 1083, Prague 14220 4, Czech Republic.","ales.hejcl@gmail.com",null,null," [IAA 500390902];  [GAUK521712];  [P304/11/P633];  [P108/10/1560]","The authors thank Hana Hronova, Lenka Kohoutova, Alena Vesela, and Pavlina Mackova for excellent technical assistance. They also thank James Dutt for a critical reading of the article. This study was supported by IAA 500390902, GAUK521712, P304/11/P633, and P108/10/1560.",null,63,0,0,"MARY ANN LIEBERT, INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1547-3287",null,null,"STEM CELLS DEV","Stem Cells Dev.","OCT 15",2013,22,20,null,null,null,null,2794,2805,null,"10.1089/scd.2012.0616",null,12,"Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation","Cell Biology; Hematology; Research & Experimental Medicine; Transplantation","227XK","WOS:000325148800010"]
[null,null,null,null,"J","Michalsky, D; Dvorak, P; Belacek, J; Kasalicky, M",null,null,null,"Michalsky, David; Dvorak, Petr; Belacek, Jaromir; Kasalicky, Mojmir",null,null,"Radical Resection of the Pyloric Antrum and Its Effect on Gastric Emptying After Sleeve Gastrectomy","OBESITY SURGERY",null,null,"English","Article",null,null,null,null,null,"Sleeve gastrectomy; Scintigraphy; Pyloric antrum; Gastric emptying","MORBID-OBESITY; PRESERVING GASTRECTOMY; BARIATRIC OPERATION; EXPERIENCE; BYPASS; VOLUME; SUMMIT; LEAKS; SIZE; RISK","The surgical technique of laparoscopic sleeve gastrectomy (LSG) has not been fully standardized yet and there is the unresolved question of what is the optimum size of retained pyloric antrum. The aim of our research was to prove that even after a radical resection of the pyloric antrum the physiological stomach evacuation function can still be preserved. Our study was based on 12 patients, who were randomly divided into two groups. Patients undergoing radical antrum resection (RA group) underwent gastric emptying scintigraphy to determine the evacuation half-time (T1/2) and food retention in the 90th minute of the test (%GE) both before the operation and 3 months afterward. Patients in whom the antrum was preserved (PA group) served as a control group for comparison of postoperative weight loss (in kilogram), decrease in body mass index (BMI), and decline in excess weight (%EWL). The resulting changes were statistically processed. In the RA group, the average time T1/2 declined from 57.5 to 32.25 min (p = 0.016) and average retention %GE dropped from 20.5 to 9.5 % (p = 0.073). Differences in the average values of weight, BMI, or %EWL between both groups were of no statistical significance (p > 0.8). In the RA group, an increase in gastric emptying postoperatively was noted. Complications such as failure of stomach evacuation were not observed in the RA group. Our results suggest that even more radical resection of the pyloric antrum performed by LSG is possible without concerns of postoperative disorder of the stomach evacuation function.","[Michalsky, David] Charles Univ Prague, Gen Fac Hosp, Dept Surg 1, Prague 12808 2, Czech Republic; [Michalsky, David; Dvorak, Petr] Charles Univ Prague, Fac Med 1, Prague 12808 2, Czech Republic; [Dvorak, Petr] Charles Univ Prague, Gen Fac Hosp, Dept Nucl Med, Prague 12808 2, Czech Republic; [Belacek, Jaromir] Charles Univ Prague, Inst Biophys & Informat, Fac Med 1, Prague 12808 2, Czech Republic; [Kasalicky, Mojmir] Charles Univ Prague, Surg Clin, Cent Mil Hosp, Prague 12808 2, Czech Republic; [Kasalicky, Mojmir] Charles Univ Prague, Fac Med 2, Prague 12808 2, Czech Republic","Michalsky, D (reprint author), Charles Univ Prague, Gen Fac Hosp, Dept Surg 1, Nemocnice 2, Prague 12808 2, Czech Republic.","david1m@volny.cz",null,null,null,null,null,37,2,3,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0960-8923",null,null,"OBES SURG","Obes. Surg.","APR",2013,23,4,null,null,null,null,567,573,null,"10.1007/s11695-012-0850-6",null,7,"Surgery","Surgery","108JM","WOS:000316289100020"]
[null,null,null,null,"J","Forostyak, O; Romanyuk, N; Verkhratsky, A; Sykova, E; Dayanithi, G",null,null,null,"Forostyak, Oksana; Romanyuk, Nataliya; Verkhratsky, Alexei; Sykova, Eva; Dayanithi, Govindan",null,null,"Plasticity of Calcium Signaling Cascades in Human Embryonic Stem Cell-Derived Neural Precursors","STEM CELLS AND DEVELOPMENT",null,null,"English","Article",null,null,null,null,null,null,"RAT SUPRAOPTIC NUCLEUS; IN-VITRO; NEURONAL DIFFERENTIATION; MAGNOCELLULAR NEURONS; STEM/PROGENITOR CELLS; ENDOPLASMIC-RETICULUM; FUNCTIONAL-PROPERTIES; PROGENITOR CELLS; NERVOUS-SYSTEM; SPINAL NEURONS","Human embryonic stem cell-derived neural precursors (hESC NPs) are considered to be a promising tool for cell-based therapy in central nervous system injuries and neurodegenerative diseases. The Ca2+ ion is an important intracellular messenger essential for the regulation of various cellular functions. We investigated the role and physiology of Ca2+ signaling to characterize the functional properties of CCTL14 hESC NPs during long-term maintenance in culture (in vitro). We analyzed changes in cytoplasmic Ca2+ concentration ([Ca2+](i)) evoked by high K+, adenosine-5'-triphosphate (ATP), glutamate, gamma-aminobutyric acid (GABA), and caffeine in correlation with the expression of various neuronal markers in different passages (P6 through P10) during the course of hESC differentiation. We found that only differentiated NPs from P7 exhibited significant and specific [Ca2+](i) responses to various stimuli. About 31% of neuronal-like P7 NPs exhibited spontaneous [Ca2+](i) oscillations. Pharmacological and immunocytochemical assays revealed that P7 NPs express L-and P/Q-type Ca2+ channels, P2X(2), P2X(3), P2X(7), and P2Y purinoreceptors, glutamate receptors, and ryanodine (RyR1 and RyR3) receptors. The ATP- and glutamate-induced [Ca2+](i) responses were concentration-dependent. Higher glutamate concentrations (over 100 mu M) caused cell death. Responses to ATP were observed in the presence or in the absence of extracellular Ca2+. These results emphasize the notion that with time in culture, these cells attain a transient period of operative Ca2+ signaling that is predictive of their ability to act as stem elements.","[Forostyak, Oksana; Dayanithi, Govindan] Acad Sci Czech Republic, Inst Expt Med, Dept Mol Neurophysiol, CZ-14220 Prague 4, Czech Republic; [Romanyuk, Nataliya; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Dept Neurosci, CZ-14220 Prague 4, Czech Republic; [Verkhratsky, Alexei] Univ Manchester, Sch Biol Sci, Manchester, Lancs, England; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Dayanithi, Govindan] Univ Montpellier 2, Inst Natl Sante & Rech Med, Unite Rech U710, Montpellier, France; [Dayanithi, Govindan] Ecole Prat Hautes Etud, Paris, France","Dayanithi, G (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Mol Neurophysiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.","gdaya@univ-montp2.fr","Verkhratsky, Alexei/J-4527-2013","Verkhratsky, Alexei/0000-0003-2592-9898","Centre National de la Recherche Scientifique, France; Grant Agency of the Czech Republic [GACR P304/11/2373, GACR P304/12/G069]; FP7 project AXREGEN [PITN-GA-2008-214003]; FP7 project Edu-GLIA Initial Training Network [PITN-GA-2009-237956]","G. Dayanithi is supported by the \"Centre National de la Recherche Scientifique,\" France. This work was supported by the grants GACR P304/11/2373 and GACR P304/12/G069 from the Grant Agency of the Czech Republic, the FP7 project AXREGEN (PITN-GA-2008-214003), and the FP7 project Edu-GLIA (PITN-GA-2009-237956) Initial Training Network. We thank Silvia Bernascone for her participation in preliminary experiments and Hana Voriskova, IEM ASCR, for help with the immunocytochemical staining. We thank Carl Zeiss, s.r.o. Prague, Czech Republic for support and consultation on imaging and fluorescence photometry systems. We are very grateful to James Dutt, IEM ASCR, for helpful discussions and critical reading of the article.",null,79,1,1,"MARY ANN LIEBERT, INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1547-3287","1557-8534",null,"STEM CELLS DEV","Stem Cells Dev.","MAY",2013,22,10,null,null,null,null,1506,1521,null,"10.1089/scd.2012.0624",null,16,"Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation","Cell Biology; Hematology; Research & Experimental Medicine; Transplantation","140VR","WOS:000318684900004"]
[null,null,null,null,"J","Martinek, J; Ryska, O; Tuckova, I; Filipkova, T; Dolezel, R; Juhas, S; Motlik, J; Zavoral, M; Ryska, M",null,null,null,"Martinek, J.; Ryska, O.; Tuckova, I.; Filipkova, T.; Dolezel, R.; Juhas, S.; Motlik, J.; Zavoral, M.; Ryska, M.",null,null,"Comparing over-the-scope clip versus endoloop and clips (KING closure) for access site closure: a randomized experimental study","SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES",null,null,"English","Article",null,null,null,null,null,"NOTES; Gastrotomy closure; Rectotomy closure; Over-the-scope clip; Endoloop; KING closure","TRANSLUMINAL ENDOSCOPIC SURGERY; GASTRIC CLOSURE; SURVIVAL; PERFORATIONS; FEASIBILITY; MODALITIES; SYSTEM","A safe technique is essential for successful access site closure in Natural Orifice Translumenal Endoscopic Surgery (NOTES) and for closures of iatrogenic perforations. To compare an over-the-scope clip (OTSC) versus an endoloop + endoclips closure technique (KING closure). 40 minipigs underwent NOTES peritoneoscopy with liver biopsy. Gastrotomies and rectotomies were closed with OTSC (n = 20; 10x stomach, 10x rectum) or KING closure (n = 20; 10x stomach, 10x rectum). The animals were euthanized 28 days after the procedure. The main outcome variables were technical feasibility, effectiveness, and healing. Stomach: All but one closure (KING) was successfully completed. The times of closure were similar between the techniques. At necropsy, all access sites were healed. In two animals (1x KING, 1x OTSC), an abscess, probably related to the closure technique, was found. Histologically, transmural healing with muscular bridging was observable in nine pigs for KING versus two pigs for OTSC closure (p = 0.003). Inflammation was present in three pigs for KING versus seven pigs for OTSC closure (p = 0.08). Rectum: All closures were successfully completed. The times of closure were similar between the techniques. At necropsy, all closure sites had healed. Transmural healing with muscular bridging was present in nine pigs for KING versus two pigs for OTSC closure (p = 0.003). Inflammation was present in two pigs for KING versus seven pigs for OTSC closure (p = 0.03). In one animal (OTSC), an enterocolic fistula developed in the proximity of the closure site. OTSC and KING closure are comparable closure techniques in terms of technical feasibility and effectiveness. KING closure provides a superior histological outcome compared with OTSC closure.","[Martinek, J.; Zavoral, M.] Inst Clin & Expt Med, Dept Hepatogastroenterol, Prague 14021 4, Czech Republic; [Ryska, O.; Dolezel, R.; Ryska, M.] Charles Univ Prague, Dept Surg, Fac Med 2, Mil Univ Hosp, Prague, Czech Republic; [Tuckova, I.] Mil Univ Hosp, Dept Pathol, Prague, Czech Republic; [Filipkova, T.] Domazlice Hosp, Dept Surg, Domazlice, Czech Republic; [Juhas, S.; Motlik, J.] Acad Sci Czech Republic, Inst Anim Physiol & Genet, Libechov, Czech Republic","Martinek, J (reprint author), Inst Clin & Expt Med, Dept Hepatogastroenterol, Videnska 1958, Prague 14021 4, Czech Republic.","jan.martinek@volny.cz",null,null,"Internal Grant Agency of the Czech Ministry of Health (IGA) [NS9994-4]; Academy of Sciences of the Czech Republic [AV0Z50450515]","Supported by grants from Internal Grant Agency of the Czech Ministry of Health (IGA, NS9994-4) and the Academy of Sciences of the Czech Republic (institutional research plan no. AV0Z50450515).",null,18,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0930-2794",null,null,"SURG ENDOSC","Surg. Endosc.","APR",2013,27,4,null,null,null,null,1203,1210,null,"10.1007/s00464-012-2576-x",null,8,"Surgery","Surgery","108JN","WOS:000316289200022"]
[null,null,null,null,"J","Skalova, D; Zidkova, J; Vohanka, S; Mazanec, R; Musova, Z; Vondracek, P; Mrazova, L; Kraus, J; Reblova, K; Fajkusova, L",null,null,null,"Skalova, Daniela; Zidkova, Jana; Vohanka, Stanislav; Mazanec, Radim; Musova, Zuzana; Vondracek, Petr; Mrazova, Lenka; Kraus, Josef; Reblova, Kamila; Fajkusova, Lenka",null,null,"CLCN1 Mutations in Czech Patients with Myotonia Congenita, In Silico Analysis of Novel and Known Mutations in the Human Dimeric Skeletal Muscle Chloride Channel","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"VARIABLE PENETRANCE; VOLTAGE-DEPENDENCE; MISSENSE MUTATIONS; GENE-MUTATIONS; DOMINANT; CLC-1; SPECTRUM; FAMILIES; HCLC-1; CIC-1","Myotonia congenita (MC) is a genetic disease caused by mutations in the skeletal muscle chloride channel gene (CLCN1) encoding the skeletal muscle chloride channel (ClC-1). Mutations of CLCN1 result in either autosomal dominant MC (Thomsen disease) or autosomal recessive MC (Becker disease). The ClC-1 protein is a homodimer with a separate ion pore within each monomer. Mutations causing recessive myotonia most likely affect properties of only the mutant monomer in the heterodimer, leaving the wild type monomer unaffected, while mutations causing dominant myotonia affect properties of both subunits in the heterodimer. Our study addresses two points: 1) molecular genetic diagnostics of MC by analysis of the CLCN1 gene and 2) structural analysis of mutations in the homology model of the human dimeric ClC-1 protein. In the first part, 34 different types of CLCN1 mutations were identified in 51 MC probands (14 mutations were new). In the second part, on the basis of the homology model we identified the amino acids which forming the dimer interface and those which form the Cl-ion pathway. In the literature, we searched for mutations of these amino acids for which functional analyses were performed to assess the correlation between localisation of a mutation and occurrence of a dominant-negative effect (corresponding to dominant MC). This revealed that both types of mutations, with and without a dominant-negative effect, are localised at the dimer interface while solely mutations without a dominant-negative effect occur inside the chloride channel. This work is complemented by structural analysis of the homology model which provides elucidation of the effects of mutations, including a description of impacts of newly detected missense mutations.","[Skalova, Daniela; Zidkova, Jana; Fajkusova, Lenka] Univ Hosp, Ctr Mol Biol & Gene Therapy, Brno, Czech Republic; [Skalova, Daniela; Zidkova, Jana; Reblova, Kamila; Fajkusova, Lenka] Masaryk Univ, Cent European Inst Technol, Brno, Czech Republic; [Vohanka, Stanislav] Univ Hosp Brno, Dept Neurol, Brno, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague, Czech Republic; [Mazanec, Radim; Musova, Zuzana; Kraus, Josef] Univ Hosp Motol, Prague, Czech Republic; [Musova, Zuzana] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Vondracek, Petr; Mrazova, Lenka] Univ Hosp Brno, Dept Child Neurol, Brno, Czech Republic; [Kraus, Josef] Charles Univ Prague, Sch Med 2, Dept Child Neurol, Prague, Czech Republic","Reblova, K (reprint author), Masaryk Univ, Cent European Inst Technol, Brno, Czech Republic.","kristina@physics.muni.cz; lfajkusova@fnbrno.cz",null,null,"Czech Ministry of Education; project \"CEITEC - Central European Institute of Technology\" [CZ.1.05/1.1.00/02.0068]; project SuPReMMe [CZ.1.07/2.3.00/20.0045]; project of the Internal Grant Agency of the Czech Ministry of Health [NT/14574-3]; project (Ministry of Health, Czech Republic) [65269705]","This work was funded by the Czech Ministry of Education, the project \"CEITEC - Central European Institute of Technology\" (CZ.1.05/1.1.00/02.0068), the project SuPReMMe (CZ.1.07/2.3.00/20.0045), and the project of the Internal Grant Agency of the Czech Ministry of Health (NT/14574-3) and supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 65269705 (University Hospital Brno, Brno, Czech Republic). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,50,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","DEC 11",2013,8,12,null,null,null,null,null,null,"e82549","10.1371/journal.pone.0082549",null,10,"Multidisciplinary Sciences","Science & Technology - Other Topics","276EG","WOS:000328730300097"]
[null,null,null,null,"J","de Bie, CI; Paerregaard, A; Kolacek, S; Ruemmele, FM; Koletzko, S; Fell, JME; Escher, JC",null,null,null,"de Bie, Charlotte I.; Paerregaard, Anders; Kolacek, Sanja; Ruemmele, Frank M.; Koletzko, Sibylle; Fell, John M. E.; Escher, Johanna C.",null,"EUROKIDS Porto Ibd Working Grp","Disease Phenotype at Diagnosis in Pediatric Crohn's Disease: 5-year Analyses of the EUROKIDS Registry","INFLAMMATORY BOWEL DISEASES",null,null,"English","Article",null,null,null,null,null,"Crohn's disease; pediatrics; Paris classification; disease phenotype; granulomas","INFLAMMATORY-BOWEL-DISEASE; POPULATION-BASED COHORT; PEYERS-PATCHES; INCREASING INCIDENCE; CHANGING PATTERN; CHILDREN; ONSET; AGE; UPDATE; PREVALENCE","Background: It has been speculated that pediatric Crohn's disease (CD) is a distinct disease entity, with probably different disease subtypes. We therefore aimed to accurately phenotype newly diagnosed pediatric CD by using the pediatric modification of the Montreal classification, the Paris classification. Methods: Information was collected from the EUROKIDS registry, a prospective, web-based registry of new-onset pediatric IBD patients in 17 European countries and Israel. When a complete diagnostic workup was performed (ileocolonoscopy, upper gastrointestinal [GI] endoscopy, small bowel imaging), CD patients were evaluated for ileocolonic disease extent, esophagogastroduodenal involvement, and jejunal/proximal ileal involvement. Disease behavior and the occurrence of granulomas were also analyzed. Results: In all, 582 pediatric CD patients could be classified according to the Paris classification. Isolated terminal ileal disease (+/- limited cecal disease) was seen at presentation in 16%, isolated colonic disease in 27%, ileocolonic disease in 53%, and isolated upper GI disease in 4% of patients. In total, 30% had esophagogastroduodenal involvement and 24% jejunal/proximal ileal disease. Patients with L2 disease were less likely to have esophagogastroduodenal involvement or stricturing disease than patients with L1 or L3 disease. Terminal ileal disease and stricturing disease behavior were more common in children diagnosed after 10 years of age than in younger patients. Granulomas were identified in 43% of patients. Conclusions: Accurate phenotyping is essential in pediatric CD, as this affects the management of individual patients. Disease phenotypes differ according to age at disease onset. The Paris classification is a useful tool to capture the variety of phenotypic characteristics of pediatric CD. (Inflamm Bowel Dis 2013; 19: 378-385)","[de Bie, Charlotte I.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Gastroenterol, NL-3015 GJ Rotterdam, Netherlands; [Paerregaard, Anders] Hvidovre Univ Hosp, Dept Pediat, Copenhagen, Denmark; [Kolacek, Sanja] Childrens Hosp, Referral Ctr Pediat Gastroenterol & Nutr, Zagreb, Croatia; [Ruemmele, Frank M.] Univ Paris 05, Hop Necker Enfants Malad, Assistance Publ Hop Paris, Pediat Gastroenterol Unit, Paris, France; [Koletzko, Sibylle] Univ Munich, Dr von Haunersches Kinderspital, Div Pediat Gastroenterol & Hepatol, Munich, Germany; [Fell, John M. E.] Chelsea & Westminster Hosp, Dept Pediat Gastroenterol, London, England","Escher, JC (reprint author), Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat, Dr Molewaterpl 60, NL-3015 GJ Rotterdam, Netherlands.","j.escher@erasmusmc.nl",null,null,"ESPGHAN","The EUROKIDS project received financial support from ESPGHAN.","Attard TM, 2004, INFLAMM BOWEL DIS, V10, P357, DOI 10.1097/00054725-200407000-00006; Barreau F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000523; Benchimol EI, 2011, INFLAMM BOWEL DIS, V17, P423, DOI 10.1002/ibd.21349; Benchimol EI, 2009, GUT, V58, P1490, DOI 10.1136/gut.2009.188383; Braegger CP, 2011, J PEDIATR GASTR NUTR, V53, P141, DOI 10.1097/MPG.0b013e318218be35; Castro M, 2008, INFLAMM BOWEL DIS, V14, P1246, DOI 10.1002/ibd.20470; Chouraki V, 2011, ALIMENT PHARM THER, V33, P1133, DOI 10.1111/j.1365-2036.2011.04628.x; Cosnes J, 2002, INFLAMM BOWEL DIS, V8, P244, DOI 10.1097/00054725-200207000-00002; de Bie CI, 2012, J PEDIATR GASTR NUTR, V54, P374, DOI 10.1097/MPG.0b013e318231d984; De Matos V, 2008, J PEDIATR GASTR NUTR, V46, P392, DOI 10.1097/MPG.0b013e31812e95e1; Dotson JL, 2010, J PEDIATR GASTR NUTR, V51, P140, DOI 10.1097/MPG.0b013e3181ca4db4; Gullberg E, 2006, ANN NY ACAD SCI, V1072, P218, DOI 10.1196/annals.1326.028; Gunesh S, 2008, ALIMENT PHARM THERAP, V27, P211, DOI 10.1111/j.1365-2036.2007.03576.x; Gupta N, 2008, AM J GASTROENTEROL, V103, P2092, DOI 10.1111/j.1572-0241.2008.02000.x; Henderson P, 2012, INFLAMM BOWEL DIS, V18, P999, DOI 10.1002/ibd.21797; Hildebrand H, 2003, GUT, V52, P1432, DOI 10.1136/gut.52.10.1432; IBD Working Group of the European Society for Paediatric Gastroenterology, 2005, J PEDIAT GASTROENTER, V41, P1; Jakobsen C, 2011, INFLAMM BOWEL DIS, V17, P2541, DOI 10.1002/ibd.21654; Keljo DJ, 2009, INFLAMM BOWEL DIS, V15, P383, DOI 10.1002/ibd.20767; Kugathasan S, 2003, J PEDIATR, V143, P525, DOI 10.1067/S0022-3476(03)00444-X; Lapidus A, 2006, WORLD J GASTROENTERO, V12, P75; Lazarev M, 2010, GASTROENTEROLOGY, V138, pS; Lehtinen P, 2011, INFLAMM BOWEL DIS, V17, P1778, DOI 10.1002/ibd.21550; Levine A, 2011, INFLAMM BOWEL DIS, V17, P1314, DOI 10.1002/ibd.21493; Loftus CG, 2007, INFLAMM BOWEL DIS, V13, P254, DOI 10.1002/ibd.20029; Louis E, 2003, GUT, V52, P552, DOI 10.1136/gut.52.4.552; Meinzer U, 2005, INFLAMM BOWEL DIS, V11, P639, DOI 10.1097/01.MIB.0000165114.10687.bf; Paerregaard A, 2009, INFLAMM BOWEL DIS, V15, P1101, DOI 10.1002/ibd.20862; Perminow G, 2009, SCAND J GASTROENTERO, V44, P446, DOI 10.1080/00365520802647434; Phavichitr N, 2003, J GASTROEN HEPATOL, V18, P329, DOI 10.1046/j.1440-1746.2003.02975.x; Sachar DB, 2005, AM J GASTROENTEROL, V100, P1547, DOI 10.1111/j.1572-0241.2005.40980.x; Sawczenko A, 2003, ARCH DIS CHILD, V88, P995, DOI 10.1136/adc.88.11.995; Shaoul R, 2009, DIGEST DIS SCI, V54, P142, DOI 10.1007/s10620-008-0326-7; Silverberg Mark S, 2005, Can J Gastroenterol, V19 Suppl A, p5A; Stone MA, 2003, EUR J GASTROEN HEPAT, V15, P1275, DOI 10.1097/01.meg.0000085500.1212.e2; Tang LY, 2006, CLIN GASTROENTEROL H, V4, P1130, DOI 10.1016/j.cgh.2006.06.021; Timmer A, 2011, J PEDIATR-US, V158, P467, DOI 10.1016/j.jpeds.2010.09.014; Van Limbergent J, 2008, GASTROENTEROLOGY, V135, P1114, DOI 10.1053/j.gastro.2008.06.081; VanKruiningen HJ, 1997, J CLIN GASTROENTEROL, V25, P470, DOI 10.1097/00004836-199709000-00017; Vernier-Massouille G, 2008, GASTROENTEROLOGY, V135, P1106, DOI 10.1053/j.gastro.2008.06.079",40,10,10,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1078-0998",null,null,"INFLAMM BOWEL DIS","Inflamm. Bowel Dis.","FEB",2013,19,2,null,null,null,null,378,385,null,"10.1002/ibd.23008",null,8,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","110MM","WOS:000316447300036"]
[null,null,null,null,"J","Levine, A; de Bie, CI; Turner, D; Cucchiara, S; Sladek, M; Murphy, MS; Escher, JC",null,null,null,"Levine, Arie; de Bie, Charlotte I.; Turner, Dan; Cucchiara, Salvatore; Sladek, Malgorzata; Murphy, M. Stephen; Escher, Johanna C.",null,"EUROKIDS Porto Ibd Working Grp","Atypical Disease Phenotypes in Pediatric Ulcerative Colitis: 5-year Analyses of the EUROKIDS Registry","INFLAMMATORY BOWEL DISEASES",null,null,"English","Article",null,null,null,null,null,"ulcerative colitis; inflammatory bowel disease; child; rectal sparing; Paris classification; Crohn's","INFLAMMATORY-BOWEL-DISEASE; PRIMARY SCLEROSING CHOLANGITIS; BACKWASH ILEITIS; PATHOLOGICAL FEATURES; CHILDREN; DEFINITION; PATCHINESS; BIOPSIES; PATTERNS","Background: Definitive diagnosis of pediatric ulcerative colitis (UC) may be particularly challenging since isolated colitis with overlapping features is common in pediatric Crohn's disease (CD), while atypical phenotypes of UC are not uncommon. The Paris classification allows more accurate phenotyping of atypical inflammatory bowel disease (IBD) patients. Our aim was to identify the prevalence of atypical disease patterns in new-onset pediatric UC using the Paris classification. Methods: Information was collected from the EUROKIDS Registry, an inception cohort of untreated pediatric IBD patients undergoing evaluation at diagnosis. Patients with IBD-unclassified were excluded. Patients with isolated Crohn's colitis served as a control group. Results: Data from 898 pediatric patients (643 UC, 255 CD colitis) were included. Extensive or pancolitis was present in 77% of UC patients and macroscopic rectal sparing in 5%. Rectal sparing was inversely associated with age (mean age with rectal sparing 9.9 years vs. 11.8 without; P = 0.02). Upper gastrointestinal (UGI) involvement occurred in 4% of patients. Erosions in the stomach were present in 3.1% of children, but frank ulcerations in 0.4%; 0.8% of children had erosions or ulcerations limited to the esophagus or duodenum. The corresponding UGI involvement in Crohn's colitis was 22%. A cecal patch occurred in 2% of patients. Conclusions: Extensive disease and rectal sparing are age-dependent phenotypes in pediatric UC. Rectal sparing, cecal patch, backwash ileitis, and gastric erosions are not uncommon at diagnosis, while gastric ulcerations and erosions in the duodenum or esophagus are. Recognition of atypical phenotypes in pediatric-onset UC is crucial to prevent misclassification of IBD. (Inflamm Bowel Dis 2013; 19: 370-377)","[Levine, Arie; Escher, Johanna C.] Tel Aviv Univ, Pediat Gastroenterol & Nutr Unit, E Wolfson Med Ctr, IL-58100 Tel Aviv, Israel; [de Bie, Charlotte I.] Sophia Childrens Univ Hosp, Dept Pediat Gastroenterol, Erasmus MC, Rotterdam, Netherlands; [Turner, Dan] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Pediat Gastroenterol Unit, Jerusalem, Israel; [Cucchiara, Salvatore] Univ Roma La Sapienza, Pediat Gastroenterol & Liver Unit, Rome, Italy; [Sladek, Malgorzata] Jagiellonnian Univ, Dept Pediat Gastroenterol & Nutr, Polish Amer Childrens Hosp, Coll Med, Krakow, Poland; [Murphy, M. Stephen] Univ Birmingham, Inst Child Hlth, Birmingham B15 2TT, W Midlands, England; [Murphy, M. Stephen] Birmingham Childrens Hosp, Birmingham, W Midlands, England","Levine, A (reprint author), Tel Aviv Univ, Pediat Gastroenterol & Nutr Unit, E Wolfson Med Ctr, IL-58100 Tel Aviv, Israel.","alevine@wolfson.health.gov.il",null,null,"ESPGHAN","See Appendix for the EUROKIDS Porto IBD Working Group of ESPGHAN. The EUROKIDS project received financial support from ESPGHAN.","Alexander F, 2003, J PEDIATR SURG, V38, P78, DOI 10.1053/jpsu.2003.50015; BERNSTEIN CN, 1995, GASTROINTEST ENDOSC, V42, P232, DOI 10.1016/S0016-5107(95)70097-8; Bousvaros A, 2007, J PEDIAT GASTROENTER, V44, P653; de Bie CI, 2012, J PEDIATR GASTR NUTR, V54, P374, DOI 10.1097/MPG.0b013e318231d984; Gasche C, 2000, INFLAMM BOWEL DIS, V6, P8; Glickman JN, 2004, AM J SURG PATHOL, V28, P190, DOI 10.1097/00000478-200402000-00006; Goldstein N, 2006, AM J CLIN PATHOL, V126, P365, DOI 10.1309/UAXMW3428PGNHJ3; Haskell H, 2005, AM J SURG PATHOL, V29, P1472, DOI 10.1097/01.pas.0000176435.19197.88; Heuschen UA, 2001, GASTROENTEROLOGY, V120, P841, DOI 10.1053/gast.2001.22434; Hyams JS, 2011, AM J GASTROENTEROL, V106, P981, DOI 10.1038/ajg.2010.493; IBD Working Group of the European Society for Paediatric Gastroenterology, 2005, J PEDIAT GASTROENTER, V41, P1, DOI DOI 10.1097/01.MPG.0000163736.30261.82; Joo M, 2009, AM J SURG PATHOL, V33, P854, DOI 10.1097/PAS.0b013e318196d018; Kim B, 1999, AM J GASTROENTEROL, V94, P3258; Kleer CG, 1998, AM J SURG PATHOL, V22, P983, DOI 10.1097/00000478-199808000-00008; Levine A, 2011, INFLAMM BOWEL DIS, V17, P1314, DOI 10.1002/ibd.21493; Loftus EV, 2005, GUT, V54, P91, DOI 10.1136/gut.2004.046615; MARKOWITZ J, 1993, AM J GASTROENTEROL, V88, P2034; Rajwal SR, 2004, J PEDIATR GASTR NUTR, V38, P66, DOI 10.1097/00005176-200401000-00015; Robert ME, 2004, AM J SURG PATHOL, V28, P183, DOI 10.1097/00000478-200402000-00005; Silverberg Mark S, 2005, Can J Gastroenterol, V19 Suppl A, p5A; Stange EF, 2008, J CROHNS COLITIS, V2, P1, DOI 10.1016/j.crohns.2007.11.001; Turner Dan, 2009, Curr Gastroenterol Rep, V11, P234; Van Limbergent J, 2008, GASTROENTEROLOGY, V135, P1114, DOI 10.1053/j.gastro.2008.06.081; Washington K, 2002, AM J SURG PATHOL, V26, P1441, DOI 10.1097/00000478-200211000-00006; Yantiss RK, 2006, AM J SURG PATHOL, V30, P165, DOI 10.1097/01.pas.0000189178.00440.bf; Ye BD, 2011, INFLAMM BOWEL DIS, V17, P1901, DOI 10.1002/ibd.21569",26,7,7,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1078-0998",null,null,"INFLAMM BOWEL DIS","Inflamm. Bowel Dis.","FEB",2013,19,2,null,null,null,null,370,377,null,"10.1002/ibd.23013",null,8,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","110MM","WOS:000316447300035"]
[null,null,null,null,"J","Esko, T; Mezzavilla, M; Nelis, M; Borel, C; Debniak, T; Jakkula, E; Julia, A; Karachanak, S; Khrunin, A; Kisfali, P; Krulisova, V; Kucinskiene, ZA; Rehnstrom, K; Traglia, M; Nikitina-Zake, L; Zimprich, F; Antonarakis, SE; Estivill, X; Glavac, D; Gut, I; Klovins, J; Krawczak, M; Kucinskas, V; Lathrop, M; Macek, M; Marsal, S; Meitinger, T; Melegh, B; Limborska, S; Lubinski, J; Paolotie, A; Schreiber, S; Toncheva, D; Toniolo, D; Wichmann, HE; Zimprich, A; Metspalu, M; Gasparini, P; Metspalu, A; D'Adamo, P",null,null,null,"Esko, Tonu; Mezzavilla, Massimo; Nelis, Mari; Borel, Christelle; Debniak, Tadeusz; Jakkula, Eveliina; Julia, Antonio; Karachanak, Sena; Khrunin, Andrey; Kisfali, Peter; Krulisova, Veronika; Kucinskiene, Zita Ausrele; Rehnstroem, Karola; Traglia, Michela; Nikitina-Zake, Liene; Zimprich, Fritz; Antonarakis, Stylianos E.; Estivill, Xavier; Glavac, Damjan; Gut, Ivo; Klovins, Janis; Krawczak, Michael; Kucinskas, Vaidutis; Lathrop, Mark; Macek, Milan; Marsal, Sara; Meitinger, Thomas; Melegh, Bela; Limborska, Svetlana; Lubinski, Jan; Paolotie, Aarno; Schreiber, Stefan; Toncheva, Draga; Toniolo, Daniela; Wichmann, H-Erich; Zimprich, Alexander; Metspalu, Mait; Gasparini, Paolo; Metspalu, Andres; D'Adamo, Pio",null,null,"Genetic characterization of northeastern Italian population isolates in the context of broader European genetic diversity","EUROPEAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,"population genetics; isolated population; genetic distance","GENOME-WIDE PATTERNS; PRINCIPAL-COMPONENTS; ASSOCIATION; DISEASE; HOMOZYGOSITY; HERITAGE; RUNS","Population genetic studies on European populations have highlighted Italy as one of genetically most diverse regions. This is possibly due to the country's complex demographic history and large variability in terrain throughout the territory. This is the reason why Italy is enriched for population isolates, Sardinia being the best-known example. As the population isolates have a great potential in disease-causing genetic variants identification, we aimed to genetically characterize a region from northeastern Italy, which is known for isolated communities. Total of 1310 samples, collected from six geographically isolated villages, were genotyped at > 4145 000 single-nucleotide polymorphism positions. Newly genotyped data were analyzed jointly with the available genome-wide data sets of individuals of European descent, including several population isolates. Despite the linguistic differences and geographical isolation the village populations still show the greatest genetic similarity to other Italian samples. The genetic isolation and small effective population size of the village populations is manifested by higher levels of genomic homozygosity and elevated linkage disequilibrium. These estimates become even more striking when the detected substructure is taken into account. The observed level of genetic isolation in Friuli-Venezia Giulia region is more extreme according to several measures of isolation compared with Sardinians, French Basques and northern Finns, thus proving the status of an isolate.","[Esko, Tonu; Nelis, Mari; Metspalu, Andres] Univ Tartu, Estonian Genome Ctr, EE-51010 Tartu, Estonia; [Esko, Tonu; Metspalu, Mait; Metspalu, Andres] Univ Tartu, Inst Mol & Cell Biol, Dept Biotechnol, EE-50090 Tartu, Estonia; [Esko, Tonu; Nelis, Mari; Metspalu, Mait; Metspalu, Andres] Estonian Bioctr, Tartu, Estonia; [Mezzavilla, Massimo; Gasparini, Paolo; D'Adamo, Pio] Univ Trieste, IRCCS Burlo Garofolo, Dept Reprod Sci & Dev, Trieste, Italy; [Borel, Christelle; Antonarakis, Stylianos E.] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland; [Debniak, Tadeusz; Lubinski, Jan] Pomeranian Med Univ, Int Hereditary Canc Ctr, Szczecin, Poland; [Debniak, Tadeusz; Lubinski, Jan] Pomeranian Med Univ, Dept Genet, Szczecin, Poland; [Jakkula, Eveliina; Paolotie, Aarno] Inst Mol Med Finland FIMM, Helsinki, Finland; [Jakkula, Eveliina; Paolotie, Aarno] Natl Inst Hlth & Welf, Helsinki, Finland; [Julia, Antonio; Marsal, Sara] Vall dHebron Hosp, Unit Invest Rheumatol, Barcelona, Spain; [Karachanak, Sena; Toncheva, Draga] Med Univ Sofia, Dept Med Genet, Sofia, Bulgaria; [Khrunin, Andrey; Limborska, Svetlana] Russian Acad Sci, Inst Mol Genet, Dept Mol Bases Human Genet, Moscow 123182, Russia; [Kisfali, Peter; Melegh, Bela] Univ Pecs, Dept Med Genet, Pecs, Hungary; [Krulisova, Veronika; Macek, Milan] Charles Univ Prague, Univ Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Krulisova, Veronika; Macek, Milan] Charles Univ Prague, Fac Med, Prague, Czech Republic; [Kucinskiene, Zita Ausrele; Kucinskas, Vaidutis] Vilnius Univ, Dept Human & Med Genet, Vilnius, Lithuania; [Rehnstroem, Karola; Paolotie, Aarno] Wellcome Trust Sanger Inst, Hinxton, England; [Traglia, Michela; Toniolo, Daniela] San Raffaele Res Inst, Div Genet & Cell Biol, Milan, Italy; [Nikitina-Zake, Liene; Klovins, Janis] Latvian Biomed Res & Study Ctr, Riga, Latvia; [Zimprich, Fritz; Zimprich, Alexander] Med Univ Vienna, Dept Clin Neurol, Vienna, Austria; [Estivill, Xavier] Ctr Genom Regulat CRG UPF, Barcelona, Spain; [Estivill, Xavier] CIBERESP, Barcelona, Spain; [Glavac, Damjan] Univ Ljubljana, Dept Mol Genet, Ljubljana, Slovenia; [Gut, Ivo] Ctr Nacl Danalisis Genom, Barcelona, Spain; [Lathrop, Mark] Ctr Natl Genotypage, Inst Genom, CEA, Evry, France; [Lathrop, Mark] McGill Univ, Montreal, PQ, Canada; [Lathrop, Mark] Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Meitinger, Thomas] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Human Genet, Neuherberg, Germany; [Meitinger, Thomas] Tech Univ Munich, Klinikum Rechts Isar, Inst Human Genet, D-80290 Munich, Germany; [Wichmann, H-Erich] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany; [Wichmann, H-Erich] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany","Metspalu, A (reprint author), Univ Tartu, Estonian Genome Ctr, Riia 23B, EE-51010 Tartu, Estonia.","Andres.Metspalu@ut.ee","Krawczak, Michael/A-8964-2010; Gasparini, Paolo/B-6173-2014; d'Adamo, Pio/G-4064-2011","d'Adamo, Pio/0000-0001-9367-4909","Estonian Basic Research grant [SF0180142s08, SF0270177As08]; Estonian Research Roadmap through Estonian Ministry of Education and Research [3.2.0304.11-0312]; Center of Excellence in Genomics (EXCEGEN); Development Fund of University of Tartu (SP1GVARENG); Estonian Science Foundation [8973];  [ENGAGE 201413];  [OPENGENE 245536];  [CZ.2.16/3.1.00/24022]","EGCUT received financing from FP7 grants (ENGAGE 201413, OPENGENE 245536), Estonian Basic Research grant SF0180142s08, Estonian Research Roadmap through Estonian Ministry of Education and Research (3.2.0304.11-0312), Center of Excellence in Genomics (EXCEGEN) and Development Fund of University of Tartu (SP1GVARENG). M Metspalu was supported by Estonian Basic Research grant SF0270177As08 and Estonian Science Foundation grant (8973). We acknowledge EGCUT personnel, especially Mr V Soo. Data analyzes were carried out in part in the High Performance Computing Center of University of Tartu. M Macek was supported by CZ.2.16/3.1.00/24022.",null,37,3,3,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813",null,null,"EUR J HUM GENET","Eur. J. Hum. Genet.","JUN",2013,21,6,null,null,null,null,659,665,null,"10.1038/ejhg.2012.229",null,7,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","151ZA","WOS:000319497700019"]
[null,null,null,null,"J","Soltesz, B; Toth, B; Shabashova, N; Bondarenko, A; Okada, S; Cypowyj, S; Abhyankar, A; Csorba, G; Tasko, S; Sarkadi, AK; Mehes, L; Rozsival, P; Neumann, D; Chernyshova, L; Tulassay, Z; Puel, A; Casanova, JL; Sediva, A; Litzman, J; Marodi, L",null,null,null,"Soltesz, Beata; Toth, Beata; Shabashova, Nadejda; Bondarenko, Anastasia; Okada, Satoshi; Cypowyj, Sophie; Abhyankar, Avinash; Csorba, Gabriella; Tasko, Szilvia; Sarkadi, Adrien Katalin; Mehes, Leonora; Rozsival, Pavel; Neumann, David; Chernyshova, Liudmyla; Tulassay, Zsolt; Puel, Anne; Casanova, Jean-Laurent; Sediva, Anna; Litzman, Jiri; Marodi, Laszlo",null,null,"New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe","JOURNAL OF MEDICAL GENETICS",null,null,"English","Article",null,null,null,null,null,null,"INTERCELLULAR-ADHESION MOLECULE-1; SEQUENCING-BASED DISCOVERY; DNA-BINDING DOMAIN; HYPER-IGE SYNDROME; INBORN-ERRORS; IL-17 IMMUNITY; J PROJECT; DEFICIENCY; EXPRESSION; AUTOIMMUNITY","Background Chronic mucocutaneous candidiasis disease (CMCD) may result from various inborn errors of interleukin (IL)-17-mediated immunity. Twelve of the 13 causal mutations described to date affect the coiled-coil domain (CCD) of STAT1. Several mutations, including R274W in particular, are recurrent, but the underlying mechanism is unclear. Objective To investigate and describe nine patients with CMCD in Eastern and Central Europe, to assess the biochemical impact of STAT1 mutations, to determine cytokines in supernatants of Candida-exposed blood cells, to determine IL-17-producing T cell subsets and to determine STAT1 haplotypes in a family with the c.820C>T (R274W) mutation. Results The novel c.537C>A (N179K) STAT1 mutation was gain-of-function (GOF) for -activated factor (GAF)-dependent cellular responses. In a Russian patient, the cause of CMCD was the newly identified c.854 A>G (Q285R) STAT1 mutation, which was also GOF for GAF-dependent responses. The c.1154C>T (T385M) mutation affecting the DNA-binding domain (DBD) resulted in a gain of STAT1 phosphorylation in a Ukrainian patient. Impaired Candida-induced IL-17A and IL-22 secretion by leucocytes and lower levels of intracellular IL-17 and IL-22 production by T cells were found in several patients. Haplotype studies indicated that the c.820C>T (R274W) mutation was recurrent due to a hotspot rather than a founder effect. Severe clinical phenotypes, including intracranial aneurysm, are presented. Conclusions The c.537C>A and c.854A>G mutations affecting the CCD and the c.1154C>T mutation affecting the DBD of STAT1 are GOF. The c.820C>T mutation of STAT1 in patients with CMCD is recurrent due to a hotspot. Patients carrying GOF mutations of STAT1 may develop multiple intracranial aneurysms by hitherto unknown mechanisms.","[Soltesz, Beata; Toth, Beata; Csorba, Gabriella; Tasko, Szilvia; Sarkadi, Adrien Katalin; Mehes, Leonora; Marodi, Laszlo] Debrecen Univ Med, Med & Hlth Sci Ctr, Dept Infect & Pediat Immunol, H-4032 Debrecen, Hungary; [Shabashova, Nadejda] Ilia Mechnikov North Western State Med Univ, Kashkin Res Inst Med Mycol, Dept Mycol Allergol & Immunol, St Petersburg, Russia; [Bondarenko, Anastasia; Chernyshova, Liudmyla] Natl Med Acad Postgrad Educ, Dept Pediat Infect Dis & Clin Immunol, Kiev, Ukraine; [Okada, Satoshi; Cypowyj, Sophie; Abhyankar, Avinash; Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, New York, NY 10021 USA; [Rozsival, Pavel; Neumann, David] Hradec Kralove Univ Hosp, Dept Pediat, Prague, Czech Republic; [Rozsival, Pavel; Neumann, David] Charles Univ Prague, Prague, Czech Republic; [Tulassay, Zsolt] Semmelweis Univ, Dept Internal Med 2, H-1085 Budapest, Hungary; [Puel, Anne; Casanova, Jean-Laurent] INSERM, U980, Necker Med Sch, Lab Human Genet Infect Dis,Necker Branch, Paris, France; [Puel, Anne; Casanova, Jean-Laurent] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Sediva, Anna] Motol Univ Hosp, Dept Immunol, Prague, Czech Republic; [Sediva, Anna] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Litzman, Jiri] Masaryk Univ, Fac Med, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Litzman, Jiri] St Annes Univ Hosp, Brno, Czech Republic","Marodi, L (reprint author), Debrecen Univ Med, Med & Hlth Sci Ctr, Dept Infect & Pediat Immunol, Nagyerdei Krt 98, H-4032 Debrecen, Hungary.","lmarodi@med.unideb.hu","Okada, Satoshi/B-8901-2011",null,"UD Faculty of Medicine Research Fund (Bridging Fund); 'VED-ELEM' project [TAMOP 4.2.2.A-11/1/KONV-2012-0023]; St Giles Foundation; National Center for Research Resources; National Center for Advancing Sciences (NCATS) from the National Institutes of Health [8UL1TR000043]; ANR [GENCMCD 11-BSV3-005-01]; AXA Research Fund","This work was supported in part by the UD Faculty of Medicine Research Fund (Bridging Fund 2012) and the TAMOP 4.2.2.A-11/1/KONV-2012-0023 'VED-ELEM' project to LM, St Giles Foundation grant to JLC, and the National Center for Research Resources and the National Center for Advancing Sciences (NCATS) grant number 8UL1TR000043 from the National Institutes of Health to JLC and SC, and ANR grant number GENCMCD 11-BSV3-005-01 to AP. SC was supported by the AXA Research Fund.",null,47,2,2,"BMJ PUBLISHING GROUP","LONDON","BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND","0022-2593",null,null,"J MED GENET","J. Med. Genet.","SEP",2013,50,9,null,null,null,null,567,578,null,"10.1136/jmedgenet-2013-101570",null,12,"Genetics & Heredity","Genetics & Heredity","205NE","WOS:000323450200001"]
[null,null,null,null,"J","Shroff, R; Stefanidis, CJ; Askiti, V; Edefonti, A; Testa, S; Ekim, M; Kavaz, A; Ariceta, G; Bakkaloglu, S; Fischbach, M; Klaus, G; Zurowska, A; Holtta, T; Jankauskiene, A; Vondrak, K; Vande Walle, J; Schmitt, CP; Watson, AR",null,null,null,"Shroff, Rukshana; Stefanidis, Constantinos J.; Askiti, Varvara; Edefonti, Alberto; Testa, Sara; Ekim, Mesiha; Kavaz, Asli; Ariceta, Gema; Bakkaloglu, Sevcan; Fischbach, Michel; Klaus, Guenter; Zurowska, Aleksandra; Holtta, Tuula; Jankauskiene, Augustina; Vondrak, Karel; Vande Walle, Johan; Schmitt, Claus Peter; Watson, Alan R.",null,"European Paediat Dialysis Working","Encapsulating peritoneal sclerosis in children on chronic PD: a survey from the European Paediatric Dialysis Working Group","NEPHROLOGY DIALYSIS TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"encapsulating peritoneal sclerosis; paediatrics; peritoneal dialysis; peritonitis; UF failure","DUTCH EPS; DIAGNOSIS; EXPERIENCE; MANAGEMENT; MEMBRANE; OUTCOMES; THERAPY; SYSTEM; JAPAN","Background. Encapsulating peritoneal sclerosis (EPS) is a rare complication of peritoneal dialysis (PD) that is associated with significant morbidity and mortality in adults. There are scarce data for children. We performed a 10-year survey to determine the prevalence, risk factors and outcome for EPS in children. Methods. Chronic PD patients in 14 dialysis units participating in the European Paediatric Dialysis Working Group between January 2001 and December 2010 were included in this study. Results. Twenty-two cases of EPS were reported (prevalence 1.5%; 8.7 per 1000 patient-years on PD). Median PD vintage was 5.9 (1.6-10.2) in EPS and 1.7 (0.7-7.7) years in the remainder of the PD population (P < 0.0001). EPS patients had a significantly higher peritonitis rate than non-EPS patients (P = 0.2). EPS was diagnosed while the child was on PD in 17 (77%), after conversion to haemodialysis (HD) in 3 and after transplantation in 2. Fifteen of 17 (88%) developed ultrafiltration (UF) failure. The median interval between UF failure and presentation with bowel obstruction was 2.8 (0.02-5.8) months. Twenty (91%) had clinical and radiological signs of bowel obstruction. Enterolysis was performed in 14 and 19 received immunosuppression or tamoxifen. Nine required parenteral nutrition. At final follow-up 4.8 (1.3-8.7) years after EPS diagnosis, 3 patients died, 11 had a functioning transplant and 8 were on HD. Conclusions. The prevalence of EPS in European children on PD is comparable with that of adult PD patients, but mortality from paediatric EPS is significantly lower. A high index of suspicion is required for the diagnosis of EPS in children with longer dialysis duration, a high peritonitis rate and UF failure.","[Shroff, Rukshana] Children NHS Fdn Trust, Great Ormond St Hosp, London, England; [Stefanidis, Constantinos J.; Askiti, Varvara] Childrens Hosp, A&P Kyriakou, Athens, Greece; [Edefonti, Alberto; Testa, Sara] Clin Pediat De Marchi, Milan, Italy; [Ekim, Mesiha; Kavaz, Asli] Ankara Univ Hosp, Ankara, Turkey; [Ariceta, Gema] Hosp Cruces, Baracaldo, Vizcaya, Spain; [Bakkaloglu, Sevcan] Gazi Univ Hosp, Ankara, Turkey; [Fischbach, Michel] Hop Hautepierre, Strasbourg, France; [Klaus, Guenter] KfH Pediat Kidney Ctr, Marburg, Germany; [Zurowska, Aleksandra] Univ Gdansk, Sch Med, PL-80952 Gdansk, Poland; [Holtta, Tuula] Univ Helsinki, Helsinki, Finland; [Jankauskiene, Augustina] Vilnius State Univ, Vilnius, Lithuania; [Vondrak, Karel] Univ Hosp Motol, Prague, Czech Republic; [Vande Walle, Johan] UZ Gent, Ghent, Belgium; [Schmitt, Claus Peter] Ctr Pediat & Adolescent Med, Heidelberg, Germany; [Watson, Alan R.] Nottingham Univ Hosp NHS Trust, Nottingham, England","Shroff, R (reprint author), Children NHS Fdn Trust, Great Ormond St Hosp, London, England.","rukshana.shroff@gosh.nhs.uk","Shroff, Rukshana/C-7347-2008; Gonzalez, iban/D-6804-2012","Gonzalez, iban/0000-0002-3108-058X",null,null,null,40,2,2,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0931-0509",null,null,"NEPHROL DIAL TRANSPL","Nephrol. Dial. Transplant.","JUL",2013,28,7,null,null,null,null,1908,1914,null,"10.1093/ndt/gfs603",null,7,"Transplantation; Urology & Nephrology","Transplantation; Urology & Nephrology","183ND","WOS:000321821900036"]
[null,null,null,null,"J","Wozniak, MB; Le Calvez-Kelm, F; Abedi-Ardekani, B; Byrnes, G; Durand, G; Carreira, C; Michelon, J; Janout, V; Holcatova, I; Foretova, L; Brisuda, A; Lesueur, F; McKay, J; Brennan, P; Scelo, G",null,null,null,"Wozniak, Magdalena B.; Le Calvez-Kelm, Florence; Abedi-Ardekani, Behnoush; Byrnes, Graham; Durand, Geoffroy; Carreira, Christine; Michelon, Jocelyne; Janout, Vladimir; Holcatova, Ivana; Foretova, Lenka; Brisuda, Antonin; Lesueur, Fabienne; McKay, James; Brennan, Paul; Scelo, Ghislaine",null,null,"Integrative Genome-Wide Gene Expression Profiling of Clear Cell Renal Cell Carcinoma in Czech Republic and in the United States","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"KIDNEY CANCER; DIFFERENTIAL EXPRESSION; BETA-CATENIN; RNA-SEQ; IDENTIFICATION; SURVIVAL; TUMOR; MICROARRAY; SIGNATURES; VHL","Gene expression microarray and next generation sequencing efforts on conventional, clear cell renal cell carcinoma (ccRCC) have been mostly performed in North American and Western European populations, while the highest incidence rates are found in Central/Eastern Europe. We conducted whole-genome expression profiling on 101 pairs of ccRCC tumours and adjacent non-tumour renal tissue from Czech patients recruited within the \"K2 Study'', using the Illumina HumanHT-12 v4 Expression BeadChips to explore the molecular variations underlying the biological and clinical heterogeneity of this cancer. Differential expression analysis identified 1650 significant probes (fold change >= 2 and false discovery rate <0.05) mapping to 630 up- and 720 down-regulated unique genes. We performed similar statistical analysis on the RNA sequencing data of 65 ccRCC cases from the Cancer Genome Atlas (TCGA) project and identified 60% (402) of the downregulated and 74% (469) of the upregulated genes found in the K2 series. The biological characterization of the significantly deregulated genes demonstrated involvement of downregulated genes in metabolic and catabolic processes, excretion, oxidation reduction, ion transport and response to chemical stimulus, while simultaneously upregulated genes were associated with immune and inflammatory responses, response to hypoxia, stress, wounding, vasculature development and cell activation. Furthermore, genome-wide DNA methylation analysis of 317 TCGA ccRCC/adjacent non-tumour renal tissue pairs indicated that deregulation of approximately 7% of genes could be explained by epigenetic changes. Finally, survival analysis conducted on 89 K2 and 464 TCGA cases identified 8 genes associated with differential prognostic outcomes. In conclusion, a large proportion of ccRCC molecular characteristics were common to the two populations and several may have clinical implications when validated further through large clinical cohorts.","[Wozniak, Magdalena B.; Le Calvez-Kelm, Florence; Abedi-Ardekani, Behnoush; Byrnes, Graham; Durand, Geoffroy; Carreira, Christine; Michelon, Jocelyne; Lesueur, Fabienne; McKay, James; Brennan, Paul; Scelo, Ghislaine] Int Agcy Res Canc, F-69372 Lyon, France; [Janout, Vladimir] Palacky Univ, CR-77147 Olomouc, Czech Republic; [Holcatova, Ivana] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague, Czech Republic; [Foretova, Lenka] Masaryk Mem Canc Inst, Dept Canc Epidemiol & Genet, Brno, Czech Republic; [Brisuda, Antonin] Univ Hosp Motol, Fac Med 2, Dept Urol, Prague, Czech Republic","Scelo, G (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.","SceloG@iarc.fr",null,null,"US NCI U01 [CA155309]; EC [241669]; European Regional Development Fund; State Budget of the Czech Republic (RECAMO) [CZ.1.05/2.1.00/03.0101]","This work was supported by the US NCI U01 grant # CA155309. Additional support for the Czech Republic sample collection and follow-up was provided by the EC FP7 CAGEKID project # 241669, and the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,64,2,2,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","MAR 5",2013,8,3,null,null,null,null,null,null,"e57886","10.1371/journal.pone.0057886",null,15,"Multidisciplinary Sciences","Science & Technology - Other Topics","099RC","WOS:000315637900059"]
[null,null,null,null,"J","Xylinas, E; Rink, M; Novara, G; Green, DA; Clozel, T; Fritsche, HM; Guillonneau, B; Lotan, Y; Kassouf, W; Tilki, D; Babjuk, M; Karakiewicz, PI; Montorsi, F; Abdennabi, J; Trinh, QD; Svatek, RS; Scherr, DS; Zerbib, M; Shariat, SF",null,null,null,"Xylinas, Evanguelos; Rink, Michael; Novara, Giacomo; Green, David A.; Clozel, Thomas; Fritsche, Hans-Martin; Guillonneau, Bertrand; Lotan, Yair; Kassouf, Wassim; Tilki, Derya; Babjuk, Marek; Karakiewicz, Pierre I.; Montorsi, Francesco; Abdennabi, Joual; Trinh, Quoc D.; Svatek, Robert S.; Scherr, Douglas S.; Zerbib, Marc; Shariat, Shahrokh F.",null,null,"Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy","ANNALS OF SURGICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,null,"BODY-MASS INDEX; INVASIVE BLADDER-CANCER; UROTHELIAL CARCINOMA; IMPACT; OUTCOMES; DISEASE","The presence of positive soft tissue surgical margins (STSM) at radical cystectomy (RC) is rare. Although some patients with STSM experience disease recurrence rapidly, some have long-term local disease control. We sought to describe the oncologic outcomes, identify predictors, and assess the impact of location and multifocality in patients with positive STSMs at RC. We retrospectively collected the data of 4,335 patients treated with RC and pelvic lymphadenectomy at 11 academic centers from 1981 to 2008. STSM was defined as the presence of tumor at inked areas of soft tissue on the RC specimen. Univariate and multivariate Cox regression models addressed recurrence-free survival and cancer-specific survival after surgery. STSM were identified in 231 patients (5 %). Actuarial recurrence-free survival estimates at 2 and 5 years after RC were 26 +/- A 3 and 21 +/- A 3 %, respectively. Actuarial cancer-specific survival estimates at 2 and 5 years after RC were 33 +/- A 3 and 25 +/- A 4 %, respectively. Higher body mass index (p = 0.050), higher tumor stage (p = 0.017), presence of grade 3 disease (p = 0.046), lymphovascular invasion (p = 0.003), and lymph node involvement (p = 0.003) were all independently associated with disease recurrence. Furthermore, higher tumor stage (p = 0.015), lymphovascular invasion (p = 0.006), and lymph node involvement (p = 0.006) were independently associated with cancer specific mortality. Location and multifocality of STSM were not associated with outcomes. Although most patients with STSM at RC had poor outcomes, more than one-fifth had durable cancer control. Pathologic features associated with disease recurrence in the general RC population also stratify patients with STSM into differential risk groups.","[Xylinas, Evanguelos; Rink, Michael; Green, David A.; Clozel, Thomas; Scherr, Douglas S.] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Urol, New York, NY USA; [Xylinas, Evanguelos; Zerbib, Marc] Paris Descartes Univ, Cochin Hosp, APHP, Dept Urol, Paris, France; [Rink, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany; [Novara, Giacomo] Univ Padua, Dept Urol, Padua, Italy; [Fritsche, Hans-Martin] Univ Regensburg, Caritas St Josef Med Ctr, Dept Urol, D-93053 Regensburg, Germany; [Guillonneau, Bertrand] Univ Paris 06, Diaconesses Hosp, Dept Urol, Paris, France; [Lotan, Yair; Svatek, Robert S.] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Kassouf, Wassim] McGill Univ, Dept Urol, Montreal, PQ, Canada; [Tilki, Derya] Univ Munich, Dept Urol, Dept Urol, Munich, Germany; [Babjuk, Marek] Charles Univ Prague, Hosp Motol, Fac Med 2, Dept Urol, Prague, Czech Republic; [Karakiewicz, Pierre I.; Trinh, Quoc D.] Univ Montreal, Dept Urol, Montreal, PQ, Canada; [Montorsi, Francesco] Univ Vita Salute San Raffaele, Dept Urol, Milan, Italy; [Abdennabi, Joual] IBN Rochd Univ Hosp, Dept Urol, Casablanca, Morocco; [Shariat, Shahrokh F.] New York Presbyterian Hosp, Div Med Oncol, Weill Cornell Med Coll, New York, NY USA","Xylinas, E (reprint author), New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Urol, New York, NY USA.","evanguelosxylinas@hotmail.com",null,null,null,null,null,21,2,2,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1068-9265",null,null,"ANN SURG ONCOL","Ann. Surg. Oncol.","MAR",2013,20,3,null,null,null,null,1027,1034,null,"10.1245/s10434-012-2708-5",null,8,"Oncology; Surgery","Oncology; Surgery","090RW","WOS:000314998000044"]
[null,null,null,null,"J","Watson, AR; Hayes, WN; Vondrak, K; Ariceta, G; Schmitt, CP; Ekim, M; Fischbach, M; Edefonti, A; Shroff, R; Holta, T; Zurowska, A; Klaus, G; Bakkaloglu, S; Stefanidos, C; Van de Walle, J",null,null,null,"Watson, Alan R.; Hayes, Wesley N.; Vondrak, Karel; Ariceta, Gema; Schmitt, Claus Peter; Ekim, Mesiha; Fischbach, Michel; Edefonti, Alberto; Shroff, Rukshana; Holta, Tuula; Zurowska, Aleksandra; Klaus, Gunter; Bakkaloglu, Sevan; Stefanidos, Constantinos; Van de Walle, Johan",null,"European Paediat Dialysis Working","Factors influencing choice of renal replacement therapy in European Paediatric Nephrology Units","PEDIATRIC NEPHROLOGY",null,null,"English","Article",null,null,null,null,null,"Choice of therapy; Renal replacement therapy; Dialysis; Pre-emptive transplantation; Psychosocial; Pediatric","CHRONIC KIDNEY-DISEASE; CHRONIC PERITONEAL-DIALYSIS; NUTRITIONAL MANAGEMENT; CHILDREN; TRANSPLANTATION; OUTCOMES; MODALITY; FAILURE; SUPPORT; HEMODIALYSIS","Many factors may impact upon choice of renal replacement therapy (RRT) for children and adolescents, including patient and family choice, patient size and distance from the renal centre as well as logistic issues such as facilities and staffing at the unit. We report a survey of factors influencing treatment choice in 14 European paediatric nephrology units. A questionnaire was developed by consensus and completed by 14 members of the European Paediatric Dialysis Working Group on facilities, staffing and family assessments impacting on choice of therapy as well as choice of therapy for 97 patients commencing initial RRT in 2011. All units offered all modalities of RRT, but there were limitations for pre-emptive transplantation (PET) and largely adult surgical dependence for creation of arteriovenous fistulae and transplantation. The average waiting time for a deceased donor kidney was 18.5 (range 3-36) months. Full time dietetic support was available in six of the 14 units. There was no social worker, psychology, play therapy or teaching support in three, two, seven and four units, respectively. Assessment by other members of the multidisciplinary team and home visits before choice of therapy was carried out in 50 % of units, and although all patients were discussed at team meetings, the medical opinion predominated. In terms of types of RRT, 50 % of patients were commenced on chronic peritoneal dialysis (PD), 34 % on haemodialysis (HD) and 16 % underwent pre-emptive transplantation (PET). Chronic PD predominated in patients aged < 5 years and HD predominated in those aged > 10 years. Patient and family choice and age or size of patient were predominant factors in choice of therapy with a predictable decline in renal function favouring PET and social factors HD. Chronic peritoneal dialysis predominated as primary choice of RRT, especially in younger children. The PET rates remain low. The influence of surgeons predominanted, and national transplant rules may be significant. Most units had insufficient multiprofessional support, which may impact upon initial choice of therapy as well as sustaining families through RRT.","[Watson, Alan R.; Hayes, Wesley N.] Nottingham Childrens Hosp, Childrens Renal & Urol Unit, Nottingham NG7 2UH, England; [Vondrak, Karel] Univ Hosp Motol, Prague, Czech Republic; [Ariceta, Gema] Hop Cruces, Baracaldo, Vizcaya, Spain; [Schmitt, Claus Peter] Ctr Paediat & Adolescent Med, Heidelberg, Germany; [Ekim, Mesiha] Ankara Univ Hosp, Ankara, Turkey; [Fischbach, Michel] Hosp Hautepierre, Strasbourg, France; [Edefonti, Alberto] Fdn IRCCS Policlin, Pediatr Marchi, Milan, Italy; [Shroff, Rukshana] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Holta, Tuula] Univ Helsinki, Childrens Hosp, Helsinki, Finland; [Zurowska, Aleksandra] Gdansk Univ Hosp, Sch Med, PL-80952 Gdansk, Poland; [Klaus, Gunter] KfH Paediat Kidney Ctr, Marburg, Germany; [Bakkaloglu, Sevan] Gazi Univ Hosp, Ankara, Turkey; [Stefanidos, Constantinos] A&P Kyriakou Childrens Hosp, Athens, Greece; [Van de Walle, Johan] Univ Hosp, Ghent, Belgium","Watson, AR (reprint author), Nottingham Childrens Hosp, Childrens Renal & Urol Unit, QMC Campus,Derby Rd, Nottingham NG7 2UH, England.","judith.hayes@nuh.nhs.uk","Shroff, Rukshana/C-7347-2008; Gonzalez, iban/D-6804-2012","Gonzalez, iban/0000-0002-3108-058X",null,null,null,46,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X","1432-198X",null,"PEDIATR NEPHROL","Pediatr. Nephrol.","DEC",2013,28,12,null,null,null,null,2361,2368,null,"10.1007/s00467-013-2555-z",null,8,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","244IG","WOS:000326380600017"]
[null,null,null,null,"J","Musak, L; Smerhovsky, Z; Halasova, E; Osina, O; Letkova, L; Vodickova, L; Polakova, V; Buchancova, J; Hemminki, K; Vodicka, P",null,null,null,"Musak, Ludovit; Smerhovsky, Zdenek; Halasova, Erika; Osina, Oto; Letkova, Lucia; Vodickova, Ludmila; Polakova, Veronika; Buchancova, Janka; Hemminki, Karl; Vodicka, Pavel",null,null,"Chromosomal damage among medical staff occupationally exposed to volatile anesthetics, antineoplastic drugs, and formaldehyde","SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH",null,null,"English","Article",null,null,null,null,null,"anesthesiologist; chromosomal aberration; health risk; hospital staff; occupational exposure; oncological department; pathological department","PERIPHERAL-BLOOD LYMPHOCYTES; DNA-REPAIR GENES; OPERATING-ROOM PERSONNEL; COMET ASSAY; INHALED ANESTHETICS; MICRONUCLEUS ASSAY; OXIDATIVE STRESS; DERMAL EXPOSURE; RISK-ASSESSMENT; NITROUS-OXIDE","Objectives Structural chromosomal aberrations in blood lymphocytes represent a biomarker for cellular damage caused by genotoxic carcinogens and are an indicator of increased cancer risk. We evaluated the association between frequencies of total chromosomal aberrations, chromatid- and chromosome-type aberrations, and occupational exposures to volatile anesthetics, antineoplastic agents, and formaldehyde among 601 medical professionals. Methods Chromosomal damage among exposed individuals and unexposed controls was determined by conventional cytogenetic analysis. We used binary logistic regression to evaluate the effects of workplace exposures and major confounders on chromosomal damage. Results Significantly higher frequencies of total chromosomal, chromatid-type and chromosome-type aberrations were observed among subjects occupationally exposed to volatile anesthetics, antineoplastic agents, and formaldehyde compared to age- and sex-matched controls (P<0.0001). The risk of an increased frequency of chromosomal aberrations was associated with exposure to anesthetics [odds ratio (OR) 3.9, 95% confidence interval (95% CI) 2.7-5.8], cytostatics (OR 2.7, 95% CI 1.9-3.9), and formaldehyde (OR 1.7, 95% CI 1.1-2.7). No other covariate contributed significantly to the model. Chromatid- and chromosome-type aberrations were associated with exposure to anesthetics and cytostatics without any contribution of other variables. Stratified data analysis showed the risk of increased chromosomal aberrations among non-smoking female nurses and physicians exposed to anesthetics, cytostatics and, partially, formaldehyde. Chromatid and chromosome exchanges were significantly higher in the exposed groups than among controls. Conclusion Our findings indicate that the presence of genotoxic compounds in operating rooms, oncological units, and pathological departments results in a significant increase of chromosomal damage (impair of chromosomal integrity) among medical workers employed in these facilities.","[Musak, Ludovit; Osina, Oto] Comenius Univ, Jessenius Fac Med, Clin Occupat Med & Toxicol, Martin, Slovakia; [Musak, Ludovit; Osina, Oto] Univ Hosp Martin, Martin, Slovakia; [Smerhovsky, Zdenek] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Halasova, Erika] Comenius Univ, Jessenius Fac Med, Dept Med Biol, Martin, Slovakia; [Letkova, Lucia] Comenius Univ, Jessenius Fac Med, Dept Med Biochem, Martin, Slovakia; [Vodickova, Ludmila; Polakova, Veronika; Vodicka, Pavel] Acad Sci Czech Republic, Inst Expt Med, Prague 14200, Czech Republic; [Vodickova, Ludmila; Polakova, Veronika; Vodicka, Pavel] Charles Univ Prague, Inst Biol & Med Genet, Fac Med 1, Prague, Czech Republic; [Buchancova, Janka] Comenius Univ, Jessenius Fac Med, Dept Publ Hlth, Martin, Slovakia; [Hemminki, Karl] German Canc Res Ctr Heidelberg DKFZ, Dept Mol Genet Epidemiol, Heidelberg, Germany","Vodicka, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Dept Mol Biol Canc, Videnska 1083, Prague 14200, Czech Republic.","pvodicka@biomed.cas.cz",null,null,"project \"Carcinogenic and toxic metals in working environment\" [26220220111]; EU; European Regional Development Fund; Slovak Ministry of Health [2007/48-UK-13]; Slovak Ministry of Education [VEGA1/0576/10]; Ministry of Education, Youth and Sport, Czech Republic [Prvouk-P27/LF1/1]","This work was supported by project \"Carcinogenic and toxic metals in working environment\" (code:26220220111), co-financed by EU sources and the European Regional Development Fund, Grant 2007/48-UK-13 from Slovak Ministry of Health, Grant VEGA1/0576/10 from Slovak Ministry of Education and Prvouk-P27/LF1/1 from Ministry of Education, Youth and Sport, Czech Republic (First Medical Faculty, Charles University, Prague, Czech Republic as a recipient).",null,54,1,1,"SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH","HELSINKI","TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND","0355-3140","1795-990X",null,"SCAND J WORK ENV HEA","Scand. J. Work Environ. Health","NOV",2013,39,6,null,null,null,null,618,630,null,"10.5271/sjweh.3358",null,13,"Public, Environmental & Occupational Health","Public, Environmental & Occupational Health","AD0ID","WOS:000332916800010"]
[null,null,null,null,"J","Handley, MT; Morris-Rosendahl, DJ; Brown, S; Macdonald, F; Hardy, C; Bem, D; Carpanini, SM; Borck, G; Martorell, L; Izzi, C; Faravelli, F; Accorsi, P; Pinelli, L; Basel-Vanagaite, L; Peretz, G; Abdel-Salam, GMH; Zaki, MS; Jansen, A; Mowat, D; Glass, I; Stewart, H; Mancini, G; Lederer, D; Roscioli, T; Giuliano, F; Plomp, AS; Rolfs, A; Graham, JM; Seemanova, E; Poo, P; Garcia-Cazorla, A; Edery, P; Jackson, IJ; Maher, ER; Aligianis, IA",null,null,null,"Handley, Mark T.; Morris-Rosendahl, Deborah J.; Brown, Stephen; Macdonald, Fiona; Hardy, Carol; Bem, Danai; Carpanini, Sarah M.; Borck, Guntram; Martorell, Loreto; Izzi, Claudia; Faravelli, Francesca; Accorsi, Patrizia; Pinelli, Lorenzo; Basel-Vanagaite, Lina; Peretz, Gabriela; Abdel-Salam, Ghada M. H.; Zaki, Maha S.; Jansen, Anna; Mowat, David; Glass, Ian; Stewart, Helen; Mancini, Grazia; Lederer, Damien; Roscioli, Tony; Giuliano, Fabienne; Plomp, Astrid S.; Rolfs, Arndt; Graham, John M.; Seemanova, Eva; Poo, Pilar; Garcia-Cazorla, Angels; Edery, Patrick; Jackson, Ian J.; Maher, Eamonn R.; Aligianis, Irene A.",null,null,"Mutation Spectrum in RAB3GAP1, RAB3GAP2, and RAB18 and GenotypePhenotype Correlations in Warburg Micro Syndrome and Martsolf Syndrome","HUMAN MUTATION",null,null,"English","Article",null,null,null,null,null,"Micro; Martsolf; Rab; RAB3GAP1; RAB3GAP2; RAB18","GTPASE-ACTIVATING PROTEIN; CONGENITAL CATARACT; MENTAL-RETARDATION; NONCATALYTIC SUBUNIT; GOLGI TRAFFICKING; LIPID DROPLETS; OPTIC ATROPHY; SHORT STATURE; 2ND FAMILY; 2 BROTHERS","Warburg Micro syndrome and Martsolf syndrome (MS) are heterogeneous autosomal-recessive developmental disorders characterized by brain, eye, and endocrine abnormalities. Causative biallelic germline mutations have been identified in RAB3GAP1, RAB3GAP2, or RAB18, each of which encode proteins involved in membrane trafficking. This report provides an up to date overview of all known disease variants identified in 29 previously published families and 52 new families. One-hundred and forty-four Micro and nine Martsolf families were investigated, identifying mutations in RAB3GAP1 in 41% of cases, mutations in RAB3GAP2 in 7% of cases, and mutations in RAB18 in 5% of cases. These are listed in Leiden Open source Variation Databases, which was created by us for all three genes. Genotypephenotype correlations for these genes have now established that the clinical phenotypes in Micro syndrome and MS represent a phenotypic continuum related to the nature and severity of the mutations present in the disease genes, with more deleterious mutations causing Micro syndrome and milder mutations causing MS. RAB18 has not yet been linked to the RAB3 pathways, but mutations in all three genes cause an indistinguishable phenotype, making it likely that there is some overlap. There is considerable genetic heterogeneity for these disorders and further gene identification will help delineate these pathways.","[Handley, Mark T.; Brown, Stephen; Carpanini, Sarah M.; Jackson, Ian J.; Aligianis, Irene A.] Univ Edinburgh, MRC, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; [Handley, Mark T.; Brown, Stephen; Carpanini, Sarah M.; Jackson, Ian J.; Aligianis, Irene A.] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland; [Morris-Rosendahl, Deborah J.] Albert Ludwigs Univ Med Ctr Freiburg, Inst Human Genet, Freiburg, Germany; [Macdonald, Fiona; Hardy, Carol] Birmingham Womens Hosp, West Midlands Reg Genet Lab, Birmingham, W Midlands, England; [Bem, Danai; Maher, Eamonn R.] Univ Birmingham, Ctr Rare Dis & Personalised Med, Sch Clin & Expt Med, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Borck, Guntram] Univ Ulm, Inst Human Genet, D-89069 Ulm, Germany; [Martorell, Loreto] Hosp St Joan de Deu, Mol Genet Sect, Barcelona, Spain; [Izzi, Claudia] Univ Brescia, Spedali Civili, Dept Obstet & Gynaecol, Brescia, Italy; [Faravelli, Francesca] Galliera Hosp, Div Med Genet, Genoa, Italy; [Accorsi, Patrizia] Spedali Civil Brescia, Dept Child Neurol & Psychiat, I-25125 Brescia, Italy; [Pinelli, Lorenzo] Spedali Civil Brescia, Dept Neuroradiol, I-25125 Brescia, Italy; [Basel-Vanagaite, Lina; Peretz, Gabriela] Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel; [Basel-Vanagaite, Lina; Peretz, Gabriela] Rabin Med Ctr, Raphael Recanati Genet Inst, Petah Tiqwa, Israel; [Basel-Vanagaite, Lina] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Abdel-Salam, Ghada M. H.; Zaki, Maha S.] Natl Res Ctr, Dept Clin Genet, Human Genet & Genome Res Div, Cairo, Egypt; [Jansen, Anna] UZ, Pediat Neurol Unit, Dept Pediat, Brussels, Belgium; [Mowat, David] Sydney Childrens Hosp, Dept Med Genet, Sydney, NSW, Australia; [Glass, Ian] Univ Washington, Dept Pediat, Div Genet & Dev Med, Seattle, WA 98195 USA; [Stewart, Helen] Clin Genet Churchill Hosp, Oxford, England; [Mancini, Grazia] Erasmus Univ, Dept Genet, Med Ctr, Rotterdam, Netherlands; [Lederer, Damien] Inst Pathol & Genet, Gosselies, Belgium; [Roscioli, Tony] Radboud Univ Nijmegen, Dept Human Genet, Nijmegen Ctr Mol Life Sci, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Roscioli, Tony] Sydney Childrens Hosp, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Roscioli, Tony] Univ New S Wales, Sydney, NSW, Australia; [Giuliano, Fabienne] Hop Archet 2, Ctr Hosp Univ Nice, Nice, France; [Plomp, Astrid S.] Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands; [Rolfs, Arndt] Univ Rostock, Albrecht Kossel Inst Neuroregenerat, D-18055 Rostock, Germany; [Rolfs, Arndt] Centogene AG Inst Rare Dis, Rostock, Germany; [Graham, John M.] Cedars Sinai Med Ctr, Div Clin Genet & Dysmorphol, Inst Med Genet, Los Angeles, CA 90048 USA; [Seemanova, Eva] Charles Univ Prague, Inst Biol & Med Genet, Sch Med 2, Prague, Czech Republic; [Poo, Pilar; Garcia-Cazorla, Angels] Hosp St Joan de Deu, Neurol Dept, Barcelona, Spain; [Morris-Rosendahl, Deborah J.; Edery, Patrick] Hosp Civils Lyon, Dept Genet, Bron, France; [Maher, Eamonn R.] Birmingham Womens Hosp NHS Trust, West Midlands Reg Genet Serv, Birmingham, W Midlands, England","Aligianis, IA (reprint author), Univ Edinburgh, Western Gen Hosp, MRC Human Genet Unit, IGMM, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.","Irene.Aligianis@igmm.ed.ac.uk","MAHER, EAMONN/A-9507-2008; Jansen, Anna/C-5208-2014","MAHER, EAMONN/0000-0002-6226-6918; ","Newlife: Molecular Investigations of Micro and Martsolf Syndromes [07-08/12]; MRC Human Genetics Unit Program leader Track Fellowship [RA1631, RA1905]; West Midlands Regional Genetics laboratory; UK Newlife Charity","Contract grant sponsors: Newlife: Molecular Investigations of Micro and Martsolf Syndromes (07-08/12); MRC Human Genetics Unit Program leader Track Fellowship (RA1631 and RA1905).We thank the families who helped with this research, many colleagues for referring affected families, the West Midlands Regional Genetics laboratory with whom we work closely, and the UK Newlife Charity for financial support. We are grateful to C. Teller for clinical information and E. Jantz-Schuble, A-S Kaiser, A. Steiert, C. Zeschnig, A. Gallacher, and S. McKay for technical assistance.",null,47,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1059-7794",null,null,"HUM MUTAT","Hum. Mutat.","MAY",2013,34,5,null,null,null,null,686,696,null,"10.1002/humu.22296",null,11,"Genetics & Heredity","Genetics & Heredity","126JM","WOS:000317610500002"]
[null,null,null,null,"J","Van Stralen, KJ; Verrina, E; Belingheri, M; Dudley, J; Dusek, J; Grenda, R; Macher, MA; Puretic, Z; Rubic, J; Rudaitis, S; Rudin, C; Schaefer, F; Jager, KJ",null,null,null,"Van Stralen, Karlijn J.; Verrina, Enrico; Belingheri, Mirco; Dudley, Jan; Dusek, Jiri; Grenda, Ryszard; Macher, Marie-Alice; Puretic, Zvonimir; Rubic, Jacek; Rudaitis, Sarunas; Rudin, Christoph; Schaefer, Franz; Jager, Kitty J.",null,"ESPN ERA-EDTA Registry","Impact of graft loss among kidney diseases with a high risk of post-transplant recurrence in the paediatric population","NEPHROLOGY DIALYSIS TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"disease recurrence; graft survival; kidney transplantation; paediatrics","HEMOLYTIC-UREMIC SYNDROME; RENAL REPLACEMENT THERAPY; HENOCH-SCHONLEIN PURPURA; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; LUPUS NEPHRITIS; KAPLAN-MEIER; TRANSPLANTATION; FAILURE; EXPERIENCE; ALLOGRAFT","Some kidney diseases tend to recur in the renal allograft after transplantation. We studied the risk of graft loss among primary renal diseases known for their high risk of recurrence and compared it with that of patients with hypoplasia and/or dysplasia. Within the European Society of Paediatric Nephrology and European Renal Association and European Dialysis and Transplant Association (ESPN/ERA-EDTA) registry, we studied children from 33 countries who received a kidney transplant before the age of 20 between 1990 and 2009. Patients were censored after 5 years of follow-up and cumulative incidence competing risk analysis was used to calculate survival curves. Patients with focal and segmental glomerulosclerosis (FSGS), haemolytic uraemic syndrome (HUS), membranoproliferative glomerulonephritis Type I or II (MPGN), IgA nephropathy or Henoch Schnlein Purpura (HSP/IgA) or systemic lupus erythomatosus (SLE) underwent pre-emptive transplantation significantly less often than patients with hypoplasia and/or dysplasia. The rate of living donation was lower among patients with FSGS and SLE than in patients with hypoplasia and/or dysplasia. In comparison with hypoplasia and/or dysplasia patients with a risk of 14.4, the 5-year risk of graft loss was significantly increased in patients with FSGS (25.7) and MPGN (32.4) while it was not significantly increased in children with HUS (18.9), HSP/IgA (16.3) or SLE (20.3). One-year graft survival strongly improved among HUS patients from 17.1 in 19951999 to 3.6 in 20052009 and was not accompanied by a decrease in the number of transplantations. The risk of graft loss is increased among specific causes of renal failure with a high risk of post-transplant recurrence. It seems likely that, due to anticipation of such risk, physicians perform less pre-emptive transplantation and provide fewer grafts from living related donors in patients with these conditions. Improved risk stratification by physicians, resulting in the identification of patients with HUS at higher or lower risk of recurrence, might explain the much improved graft survival rates.","[Van Stralen, Karlijn J.; Jager, Kitty J.] Univ Amsterdam, Acad Med Ctr, ESPN ERA EDTA Registry, Dept Med Informat, NL-1105 AZ Amsterdam, Netherlands; [Verrina, Enrico] G Gaslini Hosp, Dept Paediat Nephrol, Genoa, Italy; [Belingheri, Mirco] IRCCS Policlinico Maggiore Hosp Fdn, Pediat Nephrol Unit, Milan, Italy; [Dudley, Jan] Bristol Royal Hosp Children, Dept Paediat Nephrol, Bristol, Avon, England; [Dusek, Jiri] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Sch Med 2, Prague, Czech Republic; [Grenda, Ryszard; Rubic, Jacek] Childrens Mem Hlth Inst, Dept Nephrol & Kidney Transplantat, Warsaw, Poland; [Macher, Marie-Alice] Hop Robert Debre, Pediat Nephrol Unit, F-75019 Paris, France; [Puretic, Zvonimir] Univ Hosp Ctr Zagreb, Pediat Dialysis Unit, Zagreb, Croatia; [Rudaitis, Sarunas] Hosp Lithuanian Univ Hlth Sci, Clin Children Dis, Kaunas Clin, Kaunas, Lithuania; [Rudin, Christoph] Univ Childrens Hosp Basel, Dept Paediat Nephrol, Basel, Switzerland; [Schaefer, Franz] Heidelberg Univ, Ctr Pediat & Adolescent Med, Dept Paediat Nephrol, Heidelberg, Germany","Van Stralen, KJ (reprint author), Univ Amsterdam, Acad Med Ctr, ESPN ERA EDTA Registry, Dept Med Informat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.","k.j.vanstralen@amc.uva.nl",null,null,"European Renal Association; European Dialysis and Transplant Association (ERA-EDTA); European Society of Paediatric Nephrology (ESPN)","The ESPN/ERA-EDTA registry is funded by the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) and the European Society of Paediatric Nephrology (ESPN).",null,25,1,1,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0931-0509",null,null,"NEPHROL DIAL TRANSPL","Nephrol. Dial. Transplant.","APR",2013,28,4,null,null,null,null,1031,1038,null,"10.1093/ndt/gfs549",null,8,"Transplantation; Urology & Nephrology","Transplantation; Urology & Nephrology","126JQ","WOS:000317611000040"]
[null,null,null,null,"J","Harper, JC; Geraedts, J; Borry, P; Cornel, MC; Dondorp, W; Gianaroli, L; Harton, G; Milachich, T; Kaariainen, H; Liebaers, I; Morris, M; Sequeiros, J; Sermon, K; Shenfield, FO; Skirton, H; Soini, S; Spits, C; Veiga, A; Vermeesch, JR; Viville, S; de Wert, G; Macek, M",null,null,null,"Harper, Joyce C.; Geraedts, Joep; Borry, Pascal; Cornel, Martina C.; Dondorp, Wybo; Gianaroli, Luca; Harton, Gary; Milachich, Tanya; Kaariainen, Helena; Liebaers, Inge; Morris, Michael; Sequeiros, Jorge; Sermon, Karen; Shenfield, Franc Oise; Skirton, Heather; Soini, Sirpa; Spits, Claudia; Veiga, Anna; Vermeesch, Joris Robert; Viville, Stephane; de Wert, Guido; Macek, Milan, Jr.",null,"ESHG; ESHRE; EuroGentest2","Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy","EUROPEAN JOURNAL OF HUMAN GENETICS",null,null,"English","Article",null,null,null,null,null,null,"ESHRE PGD CONSORTIUM; EMBRYONIC STEM-CELLS; COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN PREIMPLANTATION EMBRYOS; EXTERNAL QUALITY ASSESSMENT; OF-THE-ART; TRANSMEMBRANE CONDUCTANCE REGULATOR; CONGENITAL BILATERAL ABSENCE; CLEAVAGE-STAGE EMBRYOS; IN-SITU HYBRIDIZATION","In March 2005, a group of experts from the European Society of Human Genetics and European Society of Human Reproduction and Embryology met to discuss the interface between genetics and assisted reproductive technology (ART), and published an extended background paper, recommendations and two Editorials. Seven years later, in March 2012, a follow-up interdisciplinary workshop was held, involving representatives of both professional societies, including experts from the European Union Eurogentest2 Coordination Action Project. The main goal of this meeting was to discuss developments at the interface between clinical genetics and ARTs. As more genetic causes of reproductive failure are now recognised and an increasing number of patients undergo testing of their genome before conception, either in regular health care or in the context of direct-to-consumer testing, the need for genetic counselling and preimplantation genetic diagnosis (PGD) may increase. Preimplantation genetic screening (PGS) thus far does not have evidence from randomised clinical trials to substantiate that the technique is both effective and efficient. Whole-genome sequencing may create greater challenges both in the technological and interpretational domains, and requires further reflection about the ethics of genetic testing in ART and PGD/PGS. Diagnostic laboratories should be reporting their results according to internationally accepted accreditation standards (International Standards Organisation - ISO 15189). Further studies are needed in order to address issues related to the impact of ART on epigenetic reprogramming of the early embryo. The legal landscape regarding assisted reproduction is evolving but still remains very heterogeneous and often contradictory. The lack of legal harmonisation and uneven access to infertility treatment and PGD/PGS fosters considerable cross-border reproductive care in Europe and beyond. The aim of this paper is to complement previous publications and provide an update of selected topics that have evolved since 2005.","[Harper, Joyce C.] UCL, Inst Womens Hlth, UCL Ctr PG&D, London WC1E 6HX, England; [Geraedts, Joep] Maastricht Univ, Res Inst GROW, Dept Genet & Cell Biol, Fac Hlth Med & Life Sci, Maastricht, Netherlands; [Borry, Pascal] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Louvain, Belgium; [Cornel, Martina C.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Clin Genet, Amsterdam, Netherlands; [Dondorp, Wybo; de Wert, Guido] Maastricht Univ, Res Inst GROW, Dept Hlth Eth & Soc, Fac Hlth Med & Life Sci, Maastricht, Netherlands; [Gianaroli, Luca] SIS Me R, Reprod Med Unit, Bologna, Italy; [Harton, Gary] Univ Kent, Sch Biosci, Canterbury, Kent, England; [Milachich, Tanya] MC Reprod Hlth, SAGBAL Hosp Dr Shterev, Sofia, Bulgaria; [Kaariainen, Helena; Soini, Sirpa] Natl Inst Hlth & Welf THL, Helsinki, Finland; [Liebaers, Inge] Vrije Univ Brussel, Ctr Med Genet, Brussels, Belgium; [Morris, Michael] Synlab Lausanne, Dept Mol Diagnost, Lausanne, Switzerland; [Sequeiros, Jorge] Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P-4100 Oporto, Portugal; [Sequeiros, Jorge] Univ Porto, Inst Mol & Cell Biol, P-4100 Oporto, Portugal; [Sermon, Karen; Spits, Claudia] Vrije Univ Brussel, Dept Embryol & Genet, Brussels, Belgium; [Shenfield, Franc Oise] UCL, Inst Womens Hlth, Reprod Med Unit, London WC1E 6HX, England; [Skirton, Heather] Univ Plymouth, Sch Nursing & Midwifery, Fac Hlth & Human Sci Educ & Soc, Plymouth PL4 8AA, Devon, England; [Veiga, Anna] Inst Univ Quiron Dexeus, Reprod Med Serv, Barcelona, Spain; [Vermeesch, Joris Robert] Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; [Viville, Stephane] Ctr Natl Rech Sci CNRS, Inst Genet & Mol & Cellular Biol IGBMC, UMR 1704, Illkirch Graffenstaden, France; [Macek, Milan, Jr.] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic; [Macek, Milan, Jr.] Fac Hosp Motol, Prague, Czech Republic","Harper, JC (reprint author), UCL, Inst Womens Hlth, UCL Ctr PG&D, 86-96 Chenies Mews, London WC1E 6HX, England.","joyce.harper@ucl.ac.uk",null,null,"EuroGentest2 European Union Coordination Action project [FP7-HEALTH-F4-2010-26146]; Czech Ministry of Health [00064203, NT/13770-4, CZ.2.16/3.1.00/24022]; FCT, Portuguese Ministry of Education and Science [PEst-C/SAU/LA0002/2011]; Flemish governmental grant FWO - Vlaanderen; European Society of Human Genetics; European Society of Human Reproduction and Embryology","We acknowledge the support of the EuroGentest2 European Union Coordination Action project (FP7-HEALTH-F4-2010-26146). MM was supported by the Czech Ministry of Health: 00064203, NT/13770-4 and CZ.2.16/3.1.00/24022. JS research is partly supported by PEst-C/SAU/LA0002/2011, from FCT, Portuguese Ministry of Education and Science. CS was supported by Flemish governmental grant FWO - Vlaanderen. This is a European Society of Human Genetics and European Society of Human Reproduction and Embryology endorsed and sponsored publication. Guest Editors: Milan Macek Jr., Joyce Harper, Joep Geraedts. Published with permission from the European Society of Human Genetics and European Society of Human Reproduction and Embryology (c) 2013, and in tandem with Human Reproduction. Copyright: European Society of Human Genetics and European Society of Human Reproduction and Embryology.",null,279,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","1018-4813","1476-5438",null,"EUR J HUM GENET","Eur. J. Hum. Genet.","NOV",2013,21,null,null,2,null,null,"S1","S21",null,"10.1038/ejhg.2013.219",null,21,"Biochemistry & Molecular Biology; Genetics & Heredity","Biochemistry & Molecular Biology; Genetics & Heredity","258DY","WOS:000327440600001"]
[null,null,null,null,"J","Pietrzak, A; Brzozowska, A; Lotti, T; Mosiewicz, J; Wysokinski, A; Mieczkowska, J; Hercogova, J; Bartosinska, J; Juszkiewicz-Borowiec, M; Chodorowska, G",null,null,null,"Pietrzak, Aldona; Brzozowska, Anna; Lotti, Torello; Mosiewicz, Jerzy; Wysokinski, Andrzej; Mieczkowska, Jolanta; Hercogova, Jana; Bartosinska, Joanna; Juszkiewicz-Borowiec, Maria; Chodorowska, Grazyna",null,null,"Future diagnosis, today's treatment cardiomyopathy in the course of psoriasis: a case report","DERMATOLOGIC THERAPY",null,null,"English","Article",null,null,null,null,null,"cardiac resynchronization therapy; cardiomyopathy; cardiovascular; psoriasis","CONGESTIVE-HEART-FAILURE; DILATED CARDIOMYOPATHY; METABOLIC SYNDROME; TRANSPLANTATION","Psoriasis is a relatively common, chronic skin disease of inflammatory origin. In recent years, public attention has been drawn to a more and more frequently observed relationship between psoriasis and cardiovascular disease. Nowadays, psoriasis is independently held responsible for increased cardiovascular mortality. It seems that the actual significance of the problem, together with a heart-related death risk for these patients is often underestimated. This study presents clinical evidence collected during a long-term observation and treatment of an 80-year-old psoriatic patient with concomitant diabetes, hypertension, and ischemic heart disease, whose overall clinical picture also suggested a congestive, inflammation-related cardiomyopathy with conduction disorders and severe heart failure. Despite the patient's advanced age and associated serious, long-established psoriasis-related problems, he was successfully treated with the use of interventional cardiology methods, as well as cardiac resynchronization therapy.","[Pietrzak, Aldona; Bartosinska, Joanna; Juszkiewicz-Borowiec, Maria; Chodorowska, Grazyna] Med Univ Lublin, Dept Dermatol Venereol & Paediat Dermatol, PL-20080 Lublin, Poland; [Brzozowska, Anna] Med Univ Lublin, Dept Oncol, PL-20080 Lublin, Poland; [Mosiewicz, Jerzy; Mieczkowska, Jolanta] Med Univ Lublin, Dept Internal Med, PL-20080 Lublin, Poland; [Wysokinski, Andrzej] Med Univ Lublin, Dept Cardiol, PL-20080 Lublin, Poland; [Lotti, Torello] Univ Rome G Marconi, Dept Dermatol, Rome, Italy; [Hercogova, Jana] Charles Univ Prague, Bulovka Univ Hosp, Fac Med 2, Dept Dermatol, Prague, Czech Republic","Pietrzak, A (reprint author), Med Univ Lublin, Dept Dermatol Venereol & Paediat Dermatol, 13 Radziwillowska St, PL-20080 Lublin, Poland.","aldonkapietrzak@o2.pl",null,null,null,null,null,14,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1396-0296","1529-8019",null,"DERMATOL THER","Dermatol. Ther.","NOV",2013,26,6,null,null,"SI",null,489,492,null,"10.1111/dth.12021",null,4,"Dermatology","Dermatology","266BK","WOS:000327997100010"]
[null,null,null,null,"J","Koslabova, E; Hamsikova, E; Salakova, M; Klozar, J; Foltynova, E; Salkova, E; Rotnaglova, E; Ludvikova, V; Tachezy, R",null,null,null,"Koslabova, Eva; Hamsikova, Eva; Salakova, Martina; Klozar, Jan; Foltynova, Eva; Salkova, Eva; Rotnaglova, Eliska; Ludvikova, Viera; Tachezy, Ruth",null,null,"Markers of HPV infection and survival in patients with head and neck tumors","INTERNATIONAL JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"HPV; head and neck cancer; antibodies; oral rinses; follow-up","CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN-PAPILLOMAVIRUS INFECTION; SQUAMOUS-CELL CARCINOMA; RISK-FACTORS; ORAL-CANCER; FOLLOW-UP; OROPHARYNGEAL CANCER; E7; E6; CLASSIFICATION","The purpose of this study was to determine whether changes in human papillomavirus (HPV) DNA prevalence in oral rinses and/or HPV-specific antibody levels in the sera of patients with oral/oropharyngeal cancer have prognostic significance. One hundred and forty-two patients with oral/oropharyngeal tumors were enrolled. The presence of HPV DNA was assayed in tumor tissue and oral rinses and HPV-specific antibodies were assessed in the sera. Oral rinses were collected before treatment and one year after the treatment. Sera were drawn before treatment, one month, and one year after the end of the treatment. Altogether, 59.2% of tumors were HPV positive. The presence of HPV DNA in the tumors correlated with HPV DNA positivity in oral rinses and with HPV-specific antibodies in the sera. Out of 66 patients with HPV-positive oral rinses at enrolment, 84.8% became negative at one-year follow-up, while most patients remained seropositive for HPV-specific antigens. However, the mean titers of HPV16 E6 and/or E7 antibodies at follow-up were significantly lower. Of 16 patients with recurrences at follow-up (alive on second sampling), six were positive at enrolment for HPV16 E6 and/or E7 antibodies. In five of these, no decrease in antibody levels was observed. Titers of antibodies specific for HPV16 capsid antigens did not change during the follow-up. Our data suggest that the detection of antibodies specific for the HPV 16 E6 and E7 oncoproteins may serve not only as a marker of HPV etiology, but also as a marker of recurrence and a prognostic indicator in patients with HPV-positive tumors. What's new? Do changes in the amount of HPV DNA detected orally indicate whether cancer will recur? In this paper, the authors collected oral rinses from 142 patients before and after treatment. They found that the presence of HPV in the oral rinse correlated with HPV DNA detected in the tumor tissues, but that by one year after treatment, the oral rinse usually came back negative for HPV despite the continuing presence of HPV in the tumor cells. On the other hand, the authors did find that lingering HPV antibodies in the bloodstream seemed to correlate with tumor recurrence, suggesting that antibody testing could be a good prognostic indicator in patients with HPV-positive tumors.","[Koslabova, Eva; Klozar, Jan; Foltynova, Eva; Rotnaglova, Eliska] Charles Univ Prague, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Motol Univ Hosp, Prague, Czech Republic; [Koslabova, Eva; Hamsikova, Eva; Salakova, Martina; Foltynova, Eva; Rotnaglova, Eliska; Ludvikova, Viera; Tachezy, Ruth] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague 2, Czech Republic; [Salkova, Eva] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague, Czech Republic","Tachezy, R (reprint author), Inst Hematol & Blood Transfus, Dept Expt Virol, U Nemocnice 1, CR-12820 Prague 2, Czech Republic.","rutach@uhkt.cz",null,null,"Internal Grant Agency of the Ministry of Health, Czech Republic [NT 12483]; Czech Science Foundation [P304/12/2244]","Grant sponsor: Internal Grant Agency of the Ministry of Health, Czech Republic; Grant number: NT 12483; Grant sponsor: Czech Science Foundation; Grant number: P304/12/2244",null,36,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0020-7136",null,null,"INT J CANCER","Int. J. Cancer","OCT 15",2013,133,8,null,null,null,null,1832,1839,null,"10.1002/ijc.28194",null,8,"Oncology","Oncology","198FW","WOS:000322908600008"]
[null,null,null,null,"J","Pitha, J; Lesna, K; Sekerkova, A; Poledne, R; Kovar, J; Lejskova, M; Dvorakova, H; Adamkova, S; Lanska, V; Bobak, M",null,null,null,"Pitha, Jan; Lesna, Kralova; Sekerkova, Alena; Poledne, Rudolf; Kovar, Jan; Lejskova, Magdalena; Dvorakova, Hana; Adamkova, Silvia; Lanska, Vera; Bobak, Martin",null,null,"Menopausal transition enhances the atherogenic risk of smoking in middle aged women","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"Menopausal transition; Smoking; Subclinical atherosclerosis; Reverse cholesterol transport; Endothelial progenitor cells; Sex hormones","ENDOTHELIAL PROGENITOR CELLS; INTIMA-MEDIA THICKNESS; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; CAROTID ATHEROSCLEROSIS; GENDER-DIFFERENCES; CIGARETTE-SMOKING; ASSOCIATION; CORONARY; MEN","Background: The presence of cardiovascular risk factors during the menopausal transition could be critical in the development of atherosclerosis. In the present study, we evaluated whether the menopausal transition has impact on traditional and newly discussed risk factors. Methods: Six hundred ninety nine women from population-based study underwent ultrasound measurement of the intima-media thickness of the common carotid arteries (CIMT) - Prague Pre and Postmenopausal Females study (3PMFs). In addition, 40 women selected according to reproductive and smoking status were examined with regard to number of circulating endothelial progenitor cells, markers of reverse cholesterol transport and sex hormones, including their fluctuation - Hormone Variability study (HVs). Results: Age, smoking, body mass index, systolic blood pressure and HDL cholesterol were independently associated with the CIMT in 3PMFs group. The increase in the CIMT with age was markedly steeper in current/past smokers than in non-smokers among perimenopausal women (p for equality of slopes=0.005). This difference was not observed in premenopausal and menopausal women. In the HVs group, endothelial progenitor cells and reverse cholesterol transport were substantially higher while triglycerides and fluctuation of free testosterone were lower in non-smokers than in smokers in menopausal transition. In contrast, in menopausal women, the fluctuation of free testosterone was higher in non-smokers; no other differences between smokers and non-smokers were detected. Conclusions: These results suggest that atherogenic effect of smoking may be enhanced during menopausal transition. The mechanism could be impaired reparative vascular processes, impaired reverse cholesterol transport and rapidly changing status of sex hormones. (c) 2012 Elsevier Ireland Ltd. All rights reserved.","[Pitha, Jan; Lesna, Kralova; Poledne, Rudolf; Kovar, Jan] Inst Clin & Expt Med, Lab Atherosclerosis Res, Prague 14021 4, Czech Republic; [Lejskova, Magdalena] Inst Postgrad Med Educ, Prague, Czech Republic; [Dvorakova, Hana] Charles Univ Prague, Fac Med 2, Dept Gynecol & Obstet Neonatol, Prague, Czech Republic; [Adamkova, Silvia] Inst Clin & Expt Med, Prague 14021 4, Czech Republic; [Lanska, Vera] Inst Clin & Expt Med, Med Stat Unit, Prague 14021 4, Czech Republic; [Bobak, Martin] UCL, Dept Epidemiol & Publ Hlth, London, England; [Sekerkova, Alena] Inst Clin & Expt Med, Dept Clin & Transplant Immunol, Prague 14021 4, Czech Republic","Pitha, J (reprint author), Inst Clin & Expt Med, Lab Atherosclerosis Res, Videnska 1958-9, Prague 14021 4, Czech Republic.","japi@medicon.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NS10511-3/2009]; EU by the Operational Program Prague - Competitiveness; project \"CEVKOON\" [CZ.2.16/3.1.00/22126]","The work was supported by institutional finance support from the Internal Grant Agency of the Ministry of Health of the Czech Republic, grant number: NS10511-3/2009. This study was also supported by the financial support from the EU by the Operational Program Prague - Competitiveness; project \"CEVKOON\" (#CZ.2.16/3.1.00/22126).",null,30,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273","1874-1754",null,"INT J CARDIOL","Int. J. Cardiol.","SEP 20",2013,168,1,null,null,null,null,190,196,null,"10.1016/j.ijcard.2012.09.095",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","231IL","WOS:000325409800044"]
[null,null,null,null,"J","Knebel, B; Kotzka, J; Lehr, S; Hartwig, S; Avci, H; Jacob, S; Nitzgen, U; Schiller, M; Marz, W; Hoffmann, MM; Seemanova, E; Haas, J; Muller-Wieland, D",null,null,null,"Knebel, Birgit; Kotzka, Jorg; Lehr, Stefan; Hartwig, Sonja; Avci, Haluk; Jacob, Sylvia; Nitzgen, Ulrike; Schiller, Martina; Maerz, Winfried; Hoffmann, Michael M.; Seemanova, Eva; Haas, Jutta; Muller-Wieland, Dirk",null,null,"A mutation in the c-Fos gene associated with congenital generalized lipodystrophy","ORPHANET JOURNAL OF RARE DISEASES",null,null,"English","Article",null,null,null,null,null,"Congenital lipodystrophy; Immediate early genes; Protein/DNA interaction; Transcriptional regulation","TRANSCRIPTIONAL REPRESSION; ADIPOCYTE DIFFERENTIATION; ADIPOGENESIS; PHOSPHORYLATION; METABOLISM; EXPRESSION; CROSSTALK; PROMOTER; ELEMENT; BONE","Background: Congenital generalized lipodystrophy (CGL) or Berardinelli-Seip congenital lipodystrophy (BSCL) is a rare genetic syndrome characterized by the absence of adipose tissue. As CGL is thought to be related to malfunctions in adipocyte development, genes involved in the mechanisms of adipocyte biology and maintenance or differentiation of adipocytes, especially transcription factors are candidates. Several genes (BSCL1-4) were found to be associated to the syndrome but not all CGL patients carry mutations in these genes. Methods and results: In a patient with CGL and insulin resistance we investigated the known candidate genes but the patient did not carry a relevant mutation. Analyses of the insulin activated signal transduction pathways in isolated fibroblasts of the patient revealed a postreceptor defect altering expression of the immediate early gene c-fos. Sequence analyses revealed a novel homozygous point mutation (c.-439, T -> A) in the patients' c-fos promoter. The point mutation was located upstream of the well characterized promoter elements in a region with no homology to any known cis-elements. The identified mutation was not detected in a total of n=319 non lipodystrophic probands. In vitro analyses revealed that the mutation facilitates the formation of a novel and specific protein/DNA complex. Using mass spectrometry we identified the proteins of this novel complex. Cellular investigations demonstrate that the wild type c-fos promoter can reconstitute the signaling defect in the patient, excluding further upstream signaling alterations, and vice versa the investigations with the c-fos promoter containing the identified mutation generally reduce basal and inducible c-fos transcription activity. As a consequence of the identified point mutation gene expression including c-Fos targeted genes is significantly altered, shown exemplified in cells of the patient. Conclusion: The immediate-early gene c-fos is one essential transcription factor to initiate adipocyte differentiation. According to the role of c-fos in adipocyte differentiation our findings of a mutation that initiates a repression mechanism at c-fos promoter features the hypothesis that diminished c-fos expression might play a role in CGL by interfering with adipocyte development.","[Knebel, Birgit; Kotzka, Jorg; Lehr, Stefan; Hartwig, Sonja; Avci, Haluk; Jacob, Sylvia; Nitzgen, Ulrike; Schiller, Martina] Univ Dusseldorf, Inst Clin Biochem & Pathobiochem, Leibniz Ctr Diabet Res, German Diabet Ctr, D-40225 Dusseldorf, Germany; [Maerz, Winfried] Med Univ Graz, Clin Inst Med 2, Graz, Austria; [Maerz, Winfried] Med Univ Graz, Chem Lab Diagnost, Graz, Austria; [Maerz, Winfried] Synlab Ctr Lab Diagnost Heidelberg, Heidelberg, Germany; [Hoffmann, Michael M.] Univ Med Ctr, Div Clin Chem, Freiburg, Germany; [Hoffmann, Michael M.] Univ Med Ctr, Dept Med, Freiburg, Germany; [Seemanova, Eva] Charles Univ Prague, Inst Biol & Med Genet, Med Sch 2, Dept Clin Genet, Prague, Czech Republic; [Haas, Jutta; Muller-Wieland, Dirk] Semmelweis Univ, Fac Med, Dept Gen Internal Med, Inst Diabet Res,Asklepios Clin St Georg, Hamburg, Germany","Muller-Wieland, D (reprint author), Semmelweis Univ, Fac Med, Dept Gen Internal Med, Inst Diabet Res,Asklepios Clin St Georg, Asklepios Campus Hamburg, Hamburg, Germany.","d.mueller-wieland@asklepios.com",null,null,"German Ministry of Education and Research [BMBF/01KS9502]; Koln Fortune Program/Faculty of Medicine, University of Cologne; German Diabetes Center, Duesseldorf; LiDia program of City of Hamburg","We thank the German Ministry of Education and Research (BMBF/01KS9502) and the Koln Fortune Program/Faculty of Medicine, University of Cologne, and the German Diabetes Center, Duesseldorf and the LiDia program of City of Hamburg for support.",null,36,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1750-1172",null,null,"ORPHANET J RARE DIS","Orphanet J. Rare Dis.","AUG 7",2013,8,null,null,null,null,null,null,null,119,"10.1186/1750-1172-8-119",null,12,"Medicine, Research & Experimental","Research & Experimental Medicine","199LU","WOS:000322996800001"]
[null,null,null,null,"J","Cheng, SH; Lau, KM; Li, CK; Chan, NPH; Ip, RKL; Cheng, CK; Lee, V; Shing, MMK; Leung, AWK; Ha, SY; Cheuk, DKL; Lee, ACW; Li, CH; Luk, CW; Ling, SC; Hrusak, O; Mejstrikova, E; Leung, Y; Ng, MHL",null,null,null,"Cheng, Suk Hang; Lau, Kin Mang; Li, Chi Kong; Chan, Natalie P. H.; Ip, Rosalina K. L.; Cheng, Chi Keung; Lee, Vincent; Shing, Matthew M. K.; Leung, Alex W. K.; Ha, Shau Yin; Cheuk, Daniel K. L.; Lee, Anselm C. W.; Li, Chak Ho; Luk, Chung Wing; Ling, Siu Cheung; Hrusak, Ondrej; Mejstrikova, Ester; Leung, Yonna; Ng, Margaret H. L.",null,null,"Minimal Residual Disease-Based Risk Stratification in Chinese Childhood Acute Lymphoblastic Leukemia by Flow Cytometry and Plasma DNA Quantitative Polymerase Chain Reaction","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"CANCER-PATIENTS; CLINICAL-SIGNIFICANCE; GENE REARRANGEMENTS; PROGNOSTIC-FACTORS; CHILDREN; QUANTIFICATION; CLASSIFICATION; MULTICENTER; INTEGRITY; CELLS","Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute lymphoblastic leukemia. In ALL-IC-BFM 2002 study, we employed a standardized method of flow cytometry MRD monitoring for multiple centers internationally using uniformed gating, and determined the relevant MRD-based risk stratification strategies in our local patient cohort. We also evaluated a novel method of PCR MRD quantitation using peripheral blood plasma. For the bone marrow flow MRD study, patients could be stratified into 3 risk groups according to MRD level using a single time-point at day-15 (Model I) (I-A: <0.1%, I-B: 0.1-10%, I-C: >10%), or using two time-points at day-15 and day-33 (Model II) (II-A: day-15<10% and day-33<0.01%, II-B: day-15 >= 10% or day-33 >= 0.01% but not both, II-C: day-15 >= 10% and day-33 >= 0.01%), which showed significantly superior prediction of relapse (p = .00047 and <0.0001 respectively). Importantly, patients with good outcome (frequency: 56.0%, event-free survival: 90.1%) could be more accurately predicted by Model II. In peripheral blood plasma PCR MRD investigation, patients with day-15-MRD >= 10(-4) were at a significantly higher risk of relapse (p = 0.0117). By multivariate analysis, MRD results from both methods could independently predict patients' prognosis, with 20-35-fold increase in risk of relapse for flow MRD I-C and II- C respectively, and 5.8-fold for patients having plasma MRD of >= 10(-4). We confirmed that MRD detection by flow cytometry is useful for prognostic evaluation in our Chinese cohort of childhood ALL after treatment. Moreover, peripheral blood plasma DNA MRD can be an alternative where bone marrow specimen is unavailable and as a less invasive method, which allows close monitoring.","[Cheng, Suk Hang; Lau, Kin Mang; Chan, Natalie P. H.; Ip, Rosalina K. L.; Cheng, Chi Keung; Leung, Yonna; Ng, Margaret H. L.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Li, Chi Kong; Shing, Matthew M. K.; Leung, Alex W. K.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; [Ha, Shau Yin; Cheuk, Daniel K. L.] Queen Mary Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; [Lee, Anselm C. W.; Li, Chak Ho] Tuen Mun Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; [Luk, Chung Wing] Queen Elizabeth Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; [Ling, Siu Cheung] Princess Margaret Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; [Hrusak, Ondrej; Mejstrikova, Ester] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Ng, Margaret H. L.] Chinese Univ Hong Kong, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China","Ng, MHL (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.","margaretng@cuhk.edu.hk",null,null,"Research Grant Council Earmarked Grant [4408/06M]; Children's Cancer Foundation of Hong Kong SAR","The study was supported by Research Grant Council Earmarked Grant 4408/06M, and Children's Cancer Foundation of Hong Kong SAR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,29,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","JUL 25",2013,8,7,null,null,null,null,null,null,"e69467","10.1371/journal.pone.0069467",null,10,"Multidisciplinary Sciences","Science & Technology - Other Topics","191SQ","WOS:000322433300040"]
[null,null,null,null,"J","Khrunin, AV; Khokhrin, DV; Filippova, IN; Esko, T; Nelis, M; Bebyakova, NA; Bolotova, NL; Klovins, J; Nikitina-Zake, L; Rehnstrom, K; Ripatti, S; Schreiber, S; Franke, A; Macek, M; Krulisova, V; Lubinski, J; Metspalu, A; Limborska, SA",null,null,null,"Khrunin, Andrey V.; Khokhrin, Denis V.; Filippova, Irina N.; Esko, Tonu; Nelis, Mari; Bebyakova, Natalia A.; Bolotova, Natalia L.; Klovins, Janis; Nikitina-Zake, Liene; Rehnstrom, Karola; Ripatti, Samuli; Schreiber, Stefan; Franke, Andre; Macek, Milan; Krulisova, Veronika; Lubinski, Jan; Metspalu, Andres; Limborska, Svetlana A.",null,null,"A Genome-Wide Analysis of Populations from European Russia Reveals a New Pole of Genetic Diversity in Northern Europe","PLOS ONE",null,null,"English","Article",null,null,null,null,null,null,"DIFFERENTIATION; HOMOZYGOSITY; PATTERNS; RUNS; POLYMORPHISMS; ASSOCIATION; ANCESTRY; LOCUS","Several studies examined the fine-scale structure of human genetic variation in Europe. However, the European sets analyzed represent mainly northern, western, central, and southern Europe. Here, we report an analysis of approximately 166,000 single nucleotide polymorphisms in populations from eastern (northeastern) Europe: four Russian populations from European Russia, and three populations from the northernmost Finno-Ugric ethnicities (Veps and two contrast groups of Komi people). These were compared with several reference European samples, including Finns, Estonians, Latvians, Poles, Czechs, Germans, and Italians. The results obtained demonstrated genetic heterogeneity of populations living in the region studied. Russians from the central part of European Russia (Tver, Murom, and Kursk) exhibited similarities with populations from central-eastern Europe, and were distant from Russian sample from the northern Russia (Mezen district, Archangelsk region). Komi samples, especially Izhemski Komi, were significantly different from all other populations studied. These can be considered as a second pole of genetic diversity in northern Europe (in addition to the pole, occupied by Finns), as they had a distinct ancestry component. Russians from Mezen and the Finnic-speaking Veps were positioned between the two poles, but differed from each other in the proportions of Komi and Finnic ancestries. In general, our data provides a more complete genetic map of Europe accounting for the diversity in its most eastern (northeastern) populations.","[Khrunin, Andrey V.; Khokhrin, Denis V.; Filippova, Irina N.; Limborska, Svetlana A.] Russian Acad Sci, Inst Mol Genet, Dept Mol Bases Human Genet, Moscow 123182, Russia; [Esko, Tonu; Nelis, Mari; Metspalu, Andres] Univ Tartu, Estonian Genome Ctr, EE-50090 Tartu, Estonia; [Esko, Tonu; Metspalu, Andres] Univ Tartu, Inst Mol & Cell Biol, Dept Biotechnol, EE-50090 Tartu, Estonia; [Esko, Tonu; Nelis, Mari; Metspalu, Andres] Estonian Bioctr, Tartu, Estonia; [Nelis, Mari] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland; [Bebyakova, Natalia A.] Northern State Med Univ, Deparment Med Biol & Genet, Arkhangelsk, Russia; [Bolotova, Natalia L.] Vologda State Pedag Univ, Deparment Ecol & Zool, Vologda, Russia; [Klovins, Janis; Nikitina-Zake, Liene] Latvian Biomed Res & Study Ctr, Riga, Latvia; [Rehnstrom, Karola; Ripatti, Samuli] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland; [Rehnstrom, Karola; Ripatti, Samuli] Wellcome Trust Sanger Institiute, Hinxton, England; [Schreiber, Stefan] Univ Kiel, Dept Internal Med 1, Popgen Biobank, Kiel, Germany; [Franke, Andre] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Macek, Milan; Krulisova, Veronika] Univ Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Macek, Milan; Krulisova, Veronika] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Lubinski, Jan] Pomeranian Med Univ, Szczecin, Poland","Khrunin, AV (reprint author), Russian Acad Sci, Inst Mol Genet, Dept Mol Bases Human Genet, Kurchatov Sq, Moscow 123182, Russia.","khrunin@img.ras.ru","Franke, Andre/B-2151-2010","Franke, Andre/0000-0003-1530-5811","Russian Academy of Sciences; Federal Support of Leading Scientific Schools [4294.2012.4]; Russian Basic Research Foundation; Ministry of education and science of Russian Federation [8805]; ENGAGE; OPENGENE; Estonian Government [SF0180142s08]; Estonian Research Roadmap through Estonian Ministry of Education and Research [3.2.0304.11-0312]; Center of Excellence in Genomics (EXCEGEN); University of Tartu [SP1GVARENG]; Czech Ministry of Health [NT/13770-4];  [CZ.2.16/3.1.00/24022]","This study was supported by grants from the Programs 'Molecular and Cell Biology' and 'Fundamental Science for Medicine' of the Russian Academy of Sciences; the Federal Support of Leading Scientific Schools (grant 4294.2012.4); Russian Basic Research Foundation and The Ministry of education and science of Russian Federation (project 8805). EGCUT received financing by (ENGAGE, OPENGENE), targeted financing from Estonian Government SF0180142s08, Estonian Research Roadmap through Estonian Ministry of Education and Research (3.2.0304.11-0312), Center of Excellence in Genomics (EXCEGEN) and Development Fund of University of Tartu (SP1GVARENG). MM was supported by CZ.2.16/3.1.00/24022, Institutional support for UH Motol (0064203) and by NT/13770-4 from the Czech Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",null,44,0,0,"PUBLIC LIBRARY SCIENCE","SAN FRANCISCO","1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA","1932-6203",null,null,"PLOS ONE","PLoS One","MAR 7",2013,8,3,null,null,null,null,null,null,"e58552","10.1371/journal.pone.0058552",null,9,"Multidisciplinary Sciences","Science & Technology - Other Topics","136BN","WOS:000318334500100"]
[null,null,null,null,"J","Jiruska, P; de Curtis, M; Jefferys, JGR; Schevon, CA; Schiff, SJ; Schindler, K",null,null,null,"Jiruska, Premysl; de Curtis, Marco; Jefferys, John G. R.; Schevon, Catherine A.; Schiff, Steven J.; Schindler, Kaspar",null,null,"Synchronization and desynchronization in epilepsy: controversies and hypotheses","JOURNAL OF PHYSIOLOGY-LONDON",null,null,"English","Review",null,null,null,null,null,null,"HIGH-FREQUENCY OSCILLATIONS; TEMPORAL-LOBE EPILEPSY; SEIZURE ONSET ZONE; FAST RIPPLES; EPILEPTIFORM ACTIVITY; NEURONAL-ACTIVITY; CHAOTIC SYSTEMS; IN-VITRO; SPATIOTEMPORAL DYNAMICS; PHASE SYNCHRONIZATION","Epilepsy has been historically seen as a functional brain disorder associated with excessive synchronization of large neuronal populations leading to a hypersynchronous state. Recent evidence showed that epileptiform phenomena, particularly seizures, result from complex interactions between neuronal networks characterized by heterogeneity of neuronal firing and dynamical evolution of synchronization. Desynchronization is often observed preceding seizures or during their early stages; in contrast, high levels of synchronization observed towards the end of seizures may facilitate termination. In this review we discuss cellular and network mechanisms responsible for such complex changes in synchronization. Recent work has identified cell-type-specific inhibitory and excitatory interactions, the dichotomy between neuronal firing and the non-local measurement of local field potentials distant to that firing, and the reflection of the neuronal dark matter problem in non-firing neurons active in seizures. These recent advances have challenged long-established views and are leading to a more rigorous and realistic understanding of the pathophysiology of epilepsy.","[Jiruska, Premysl] Acad Sci Czech Republic, Dept Dev Epileptol, Inst Physiol, CZ-14220 Prague 4, Krc, Czech Republic; [Jiruska, Premysl] Charles Univ Prague, Univ Hosp Motol Prague, Sch Med 2, Dept Neurol, CZ-15006 Prague, Czech Republic; [Jiruska, Premysl; Jefferys, John G. R.] Univ Birmingham, Sch Clin & Expt Med, Neuronal Networks Grp, Birmingham B15 2TT, W Midlands, England; [de Curtis, Marco] Fdn Ist Neurol Carlo Besta, Unit Expt Neurophysiol & Epileptol, Milan, Italy; [Schevon, Catherine A.] Columbia Univ, Dept Neurol, New York, NY USA; [Schiff, Steven J.] Penn State Univ, Dept Engn Sci & Mech, Ctr Neural Engn, University Pk, PA 16802 USA; [Schiff, Steven J.] Penn State Univ, Dept Neurosurg, Ctr Neural Engn, University Pk, PA 16802 USA; [Schiff, Steven J.] Penn State Univ, Dept Phys, Ctr Neural Engn, University Pk, PA 16802 USA; [Schindler, Kaspar] Univ Hosp Bern, Dept Neurol, CH-3010 Bern, Switzerland","Jiruska, P (reprint author), Acad Sci Czech Republic, Dept Dev Epileptol, Inst Physiol, Videnska 1083, CZ-14220 Prague 4, Krc, Czech Republic.","jiruskapremysl@gmail.com","Schindler, Kaspar/L-7115-2013","Schindler, Kaspar/0000-0002-2387-7767","Czech Ministry of Health [IGA NT/11460-4]; Epilepsy Research UK [P1102]; MRC [G0802162]; Swiss National Science Foundation [SNF320030 122010]; NIH [1R01EB014641-01]; US-German Collaborative Research in Computational Neuroscience (CRCNS); Medical Research Council [G0802162]","This work was supported by a Czech Ministry of Health Grant IGA NT/11460-4, Epilepsy Research UK grant (P1102), MRC Grant G0802162, Swiss National Science Foundation (project no. SNF320030 122010), NIH grant 1R01EB014641-01 US-German Collaborative Research in Computational Neuroscience (CRCNS), and Medical Research Council grant (G0802162). The authors declare no conflict of interest.",null,88,8,8,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0022-3751","1469-7793",null,"J PHYSIOL-LONDON","J. Physiol.-London","FEB",2013,591,4,null,null,null,null,787,797,null,"10.1113/jphysiol.2012.239590",null,11,"Neurosciences; Physiology","Neurosciences & Neurology; Physiology","092VB","WOS:000315150000007"]
[null,null,null,null,"J","Zurowska, AM; Fischbach, M; Watson, AR; Edefonti, A; Stefanidis, CJ",null,null,null,"Zurowska, Aleksandra M.; Fischbach, Michel; Watson, Alan R.; Edefonti, Alberto; Stefanidis, Constantinos J.",null,"European Paediat Dialysis Working","Clinical practice recommendations for the care of infants with stage 5 chronic kidney disease (CKD5)","PEDIATRIC NEPHROLOGY",null,null,"English","Review",null,null,null,null,null,"Infants; Neonates; Chronic kidney disease (CKD); Haemodialysis (HD); Peritoneal dialysis (PD)","CHRONIC-RENAL-FAILURE; CHRONIC PERITONEAL-DIALYSIS; HOC EUROPEAN COMMITTEE; YOUNG-CHILDREN; REPLACEMENT THERAPY; RISK-FACTORS; 1ST YEAR; TRANSPLANTATION; GUIDELINES; AGE","To provide recommendations for the care of infants with stage 5 chronic kidney disease (CKD5). European Paediatric Dialysis Working Group. Literature on clinical studies involving infants with CKD5 (end stage renal failure) and consensus discussions within the group. There has been an important change in attitudes towards offering RRT (renal replacement therapy) to both newborns and infants as data have accumulated on their improved survival and long-term outcomes. The management of this challenging group of patients differs in a number of ways from that of older children. The authors have summarised the basic recommendations for treating infants with CKD5 in order to support the multidisciplinary teams who endeavour on this difficult task.","[Zurowska, Aleksandra M.] Med Acad Gdansk, Dept Paediat & Adolescent Nephrol & Hypertens, PL-80211 Gdansk, Poland; [Fischbach, Michel] Hop Hautepierre, Strasbourg, France; [Watson, Alan R.] Nottingham Univ Hosp NHS Trust, Nottingham, England; [Edefonti, Alberto] Fdn Ca Granda IRCCS Osped Maggiore Policlin, Clin Pediat De Marchi, Milan, Italy; [Stefanidis, Constantinos J.] A&P Kyriakou Childrens Hosp, Athens, Greece","Zurowska, AM (reprint author), Med Acad Gdansk, Dept Paediat & Adolescent Nephrol & Hypertens, Ul Debinki 7, PL-80211 Gdansk, Poland.","azur@gumed.edu.pl",null,null,null,null,"Alam S, 2008, CURR OPIN UROL, V18, P413, DOI 10.1097/MOU.0b013e328302ede7; Beaunoyer M, 2007, PEDIATR TRANSPLANT, V11, P267, DOI 10.1111/j.1399-3046.2006.00644.x; Boehm M, 2005, PEDIATR NEPHROL, V20, P1478, DOI 10.1007/s00467-005-1953-2; Borzych D, 2010, KIDNEY INT, V78, P1295, DOI 10.1038/ki.2010.316; Broniszczak D, 2010, EUR J PEDIATR SURG, V20, P5, DOI 10.1055/s-0029-1234114; Burguet A, 2002, ARCH PEDIATRIE, V9, P489, DOI 10.1016/S0929-693X(01)00830-2; Canepa A, 2008, KIDNEY INT, V73, pS137, DOI 10.1038/sj.ki.5002615; Carey W, 2007, PEDIATRICS, V119, P468; Chavers B, 2007, PEDIATR TRANSPLANT, V11, P702, DOI 10.1111/j.1399-3046.2007.00768.x; COHEN C, 1987, PEDIATR NEPHROL, V1, P166; Coleman JE, 2001, PERITON DIALYSIS INT, V21, P323; Coulthard MG, 2002, ARCH DIS CHILD, V87, P511, DOI 10.1136/adc.87.6.511; Dart A, 2005, PEDIATR NEPHROL, V20, P683, DOI 10.1007/s00467-004-1783-7; Fauriel I, 2005, NEPHROL DIAL TRANSPL, V20, P2746, DOI 10.1093/ndt/gfi160; Fischbach M, 2003, PEDIATR NEPHROL, V18, P976, DOI 10.1007/s00467-003-1199-9; Fischbach M, 1996, PERITON DIALYSIS INT, V16S1, P10; Fischbach M, 2002, NEPHROL DIAL TRANSPL, V17, P380, DOI 10.1093/ndt/17.3.380; Fischbach Michel, 2003, Adv Perit Dial, V19, P265; Fischbach M, 2000, PERITON DIALYSIS INT, V20, P603; Fischbach M, 2004, NEPHROL DIAL TRANSPL, V19, P925, DOI 10.1093/ndt/gfg518; Fischbach M, 2009, PEDIATR NEPHROL, V24, P1633, DOI 10.1007/s00467-008-0979-7; Fischbach M, 2005, PEDIATR NEPHROL, V20, P1054, DOI 10.1007/s00467-005-1876-y; Gonzalez Celedon C, 2007, PEDIATR NEPHROL, V22, P1014, DOI 10.1007/s00467-007-0459-5; Haas S, 2003, J AM SOC NEPHROL, V14, P2632, DOI 10.1097/01.ASN.0000086475.83211.DF; Humar A, 2001, PEDIATR NEPHROL, V16, P941; Ismaili K, 2001, PEDIATR NEPHROL, V16, P260; Jander Anna, 2006, Przegl Lek, V63 Suppl 3, P72; Kari JA, 1999, PEDIATR NEPHROL, V13, P730; KDOQI Work Group, 2009, AM J KIDNEY DIS, V53, pS11; Klaus G, 2006, PEDIATR NEPHROL, V21, P151, DOI 10.1007/s00467-005-2082-7; Laakkonen H, 2008, NEPHROL DIAL TRANSPL, V23, P1747, DOI 10.1093/ndt/gfn035; Ledermann SE, 2002, PEDIATR NEPHROL, V17, P246; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Madden SJ, 2003, CHILD CARE HLTH DEV, V29, P55, DOI 10.1046/j.1365-2214.2003.00311.x; Mekahli D, 2010, CLIN J AM SOC NEPHRO, V5, P10, DOI 10.2215/CJN.05600809; Mencarelli F, 2009, PEDIATR NEPHROL, V24, P1039, DOI 10.1007/s00467-008-1084-7; Michallat Anne Cecile, 2005, Adv Perit Dial, V21, P195; Moudgil A, 2011, PEDIATR TRANSPLANT, V15, P167, DOI 10.1111/j.1399-3046.2010.01432.x; Nahas WC, 2009, PEDIATR TRANSPLANT, V13, P524, DOI 10.1111/j.1399-3046.2008.01112.x; Neu AM, 1998, PERITON DIALYSIS INT, V18, P440; Neuhaus TJ, 2004, PEDIATR NEPHROL, V19, P1334, DOI 10.1007/s00467-004-1597-7; Nusken E, 2010, KLIN PADIATR, V222, P252, DOI 10.1055/s-0030-1247509; Paglialonga F, 2009, PEDIATR NEPHROL, V24, P721, DOI 10.1007/s00467-007-0719-4; Paul A, 2011, J PEDIATR UROL, V7, P48, DOI 10.1016/j.jpurol.2010.01.018; Quan A, 1996, PEDIATR NEPHROL, V10, P728; Rees L, 2007, PERITON DIALYSIS INT, V27, pS180; Rees L, 2007, PEDIATR NEPHROL, V22, P1689, DOI 10.1007/s00467-006-0279-z; Rees L, 2009, PEDIATR NEPHROL, V24, P475, DOI 10.1007/s00467-007-0559-2; Rees L, 2011, J AM SOC NEPHROL, V22, P2303, DOI 10.1681/ASN.2010020192; Rheault MN, 2009, PEDIATR NEPHROL, V24, P2035, DOI 10.1007/s00467-009-1234-6; Ronnholm KAR, 2006, PEDIATR NEPHROL, V21, P751, DOI 10.1007/s00467-006-0084-8; Santos F, 2010, CLIN J AM SOC NEPHRO, V5, P1190, DOI 10.2215/CJN.07791109; Schmitt CP, 2011, PEDIATR NEPHROL, V26, P1137, DOI 10.1007/s00467-011-1863-4; Schmitt CP, 2009, PERITON DIALYSIS INT, V29, P465; Schmitt CP, 2007, NEPHROL DIAL TRANSPL, V22, P2038, DOI 10.1093/ndt/gfm148; Schroder CH, 2004, NEPHROL DIAL TRANSPL, V19, P782, DOI 10.1093/ndt/gfh098; Shaw V, 2003, ANN NESTLE, V61, P21; Shooter M, 2000, PEDIATR NEPHROL, V14, P347; Shroff R, 2003, PEDIATR NEPHROL, V18, P378, DOI 10.1007/s00467-003-1070-z; Shroff R, 2006, PEDIATR NEPHROL, V21, P257, DOI 10.1007/s00467-005-2067-6; Shroff R, 2009, PEDIATR NEPHROL, V24, P463, DOI 10.1007/s00467-007-0700-2; Sienna JL, 2010, PEDIATR NEPHROL, V25, P2115, DOI 10.1007/s00467-010-1586-y; Tong A, 2010, CHILD CARE HLTH DEV, V36, P549, DOI 10.1111/j.1365-2214.2010.01067.x; Uhlig K, 2006, KIDNEY INT, V70, P2058, DOI 10.1038/sj.ki.5001875; Van Dyck M, 1998, EUR J PEDIATR, V157, P59; Van Biesen W, 2002, SEMIN DIALYSIS, V15, P305, DOI 10.1046/j.1525-139X.2002.00075.x; van der Heijden BJ, 2004, PEDIATR NEPHROL, V19, P213, DOI 10.1007/s00467-003-1376-x; van Stralen KJ, 2010, PEDIATR NEPHROL, V25, P1379, DOI 10.1007/s00467-010-1472-7; Verrina E, 2009, PEDIATR NEPHROL, V24, P1453, DOI 10.1007/s00467-008-0848-4; Verrina E, 1995, ADV PERIT D, V11, P281; Vidal E, 2012, NEPHROL DIAL TRANSPL, V27, P388, DOI 10.1093/ndt/gfr322; von Schnakenburg C, 2006, PERITON DIALYSIS INT, V26, P69; Warady BA, 1999, PEDIATR NEPHROL, V13, P759; Warchol S, 2003, PERITON DIALYSIS INT, V23, P169; Watson AR, 2001, PERITON DIALYSIS INT, V21, P240; Watson AR, 2006, PERITON DIALYSIS INT, V26, P41; Wedekin M, 2010, CLIN J AM SOC NEPHRO, V5, P18, DOI 10.2215/CJN.03670609; Wood EG, 2001, AM J KIDNEY DIS, V37, P573, DOI 10.1053/ajkd.2001.22083; Wuhl E, 2007, AM J MED GENET A, V143A, P311, DOI 10.1002/ajmg.a.31564; Zurowska A, 2008, AM J KIDNEY DIS, V51, P455, DOI 10.1053/j.ajkd.2007.11.011",80,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0931-041X",null,null,"PEDIATR NEPHROL","Pediatr. Nephrol.","SEP",2013,28,9,null,null,null,null,1739,1748,null,"10.1007/s00467-012-2300-z",null,10,"Pediatrics; Urology & Nephrology","Pediatrics; Urology & Nephrology","190FB","WOS:000322323700003"]
[null,null,null,null,"J","Pastor, Z",null,null,null,"Pastor, Zlatko",null,null,"Female Ejaculation Orgasm vs. Coital Incontinence: A Systematic Review","JOURNAL OF SEXUAL MEDICINE",null,null,"English","Review",null,null,null,null,null,"Female Ejaculation; Squirting; Orgasmic Incontinence; Coital Incontinence; Female Prostate; Urinary Incontinence","QUALITY-OF-LIFE; URINARY-INCONTINENCE; DETRUSOR OVERACTIVITY; GRAFENBERG SPOT; SEXUAL FUNCTION; STRESS-INCONTINENCE; WOMEN; PROSTATE; INTERCOURSE; PREVALENCE","Introduction. Women may expel various kinds of fluids during sexual arousal and at orgasm. Their origins, quantity, compositions, and expulsion mechanisms depend on anatomical and pathophysiological dispositions and the degree of sexual arousal. These are natural sexual responses but may also represent symptoms of urinary incontinence. Aim. The study aims to clarify the etiology of fluid leakage at orgasm, distinguish between associated physiological sexual responses, and differentiate these phenomena from symptoms of illness. Methods. A systematic literature review was performed. EMBASE (OvidSP) and Web of Science databases were searched for the articles on various phenomena of fluid expulsions in women during sexual arousal and at orgasm. Main Outcome Measures. Articles included focused on female ejaculation and its variations, coital incontinence (CI), and vaginal lubrication. Results. Female ejaculation orgasm manifests as either a female ejaculation (FE) of a smaller quantity of whitish secretions from the female prostate or a squirting of a larger amount of diluted and changed urine. Both phenomena may occur simultaneously. The prevalence of FE is 10-54%. CI is divided into penetration and orgasmic forms. The prevalence of CI is 0.2-66%. Penetration incontinence occurs more frequently and is usually caused by stress urinary incontinence (SUI). Urodynamic diagnoses of detrusor overactivity (DOA) and SUI are observed in orgasmic incontinence. Conclusions. Fluid expulsions are not typically a part of female orgasm. FE and squirting are two different physiological components of female sexuality. FE was objectively evidenced only in tens of cases but its reported high prevalence is based mostly on subjective questionnaire research. Pathophysiology of squirting is rarely documented. CI is a pathological sign caused by urethral disorder, DOA, or a combination of both, and requires treatment. An in-depth appreciation of these similar but pathophysiologically distinct phenomena is essential for distinguishing normal, physiological sexual responses from signs of illness.","[Pastor, Zlatko] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Teaching Hosp Motol, Prague, Czech Republic; [Pastor, Zlatko] Charles Univ Prague, Inst Sexol, Fac Med 1, Prague, Czech Republic","Pastor, Z (reprint author), Narodni 25, Prague 11000 1, Czech Republic.","pastor.zlatko@volny.cz",null,null,null,null,null,61,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1743-6095",null,null,"J SEX MED","J. Sex. Med.","JUL",2013,10,7,null,null,null,null,1682,1691,null,"10.1111/jsm.12166",null,10,"Urology & Nephrology","Urology & Nephrology","174YT","WOS:000321195300004"]
[null,null,null,null,"J","Machac, S; Prochazka, M; Radvansky, J; Slaby, K",null,null,null,"Machac, Stanislav; Prochazka, Michal; Radvansky, Jiri; Slaby, Krystof",null,null,"Validation of Physical Activity Monitors in Individuals with Diabetes: Energy Expenditure Estimation by the Multisensor SenseWear Armband Pro3 and the Step Counter Omron HJ-720 Against Indirect Calorimetry During Walking","DIABETES TECHNOLOGY & THERAPEUTICS",null,null,"English","Article",null,null,null,null,null,null,"VALIDITY; ACCELEROMETER; PEDOMETERS; ACCURACY; ADULTS; FIELD; COST","Background: The purpose of this study is to test the agreement between energy expenditure estimate of the SenseWear (R) Armband Pro3 (SWA) (BodyMedia, Pittsburgh, PA) and the Omron HJ-720 (Omron Healthcare, Kyoto, Japan) step counter with indirect calorimetry (IC) as a gold standard in older individuals with type 1 and type 2 diabetes mellitus while walking on a treadmill. Subjects and Methods: In total, six men (60.3 +/- 3.1 years old) and 13 women (51.1 +/- 11.0 years old) with type 1 or type 2 diabetes mellitus were included in the study. Each subject performed three 15-min walking sessions with different combinations of speed and incline (3 km/h, 0%; 4 km/h, 0%; 5 km/h, 5%) on a treadmill. Energy expenditure (EE) was simultaneously measured by the SWA, Omron, and IC. Mean over-/underestimation and Pearson's correlation coefficients were used for statistical evaluation of the agreement between tested methods and IC. Results: At the speed of 3 km/h with 0% incline, mean overestimation of +81.19 +/- 23.81% was found for SWA (r = 0.79, P < 0.001) and +70.51 +/- 20.91% for Omron (r = 0.77, P < 0.001). At the speed of 4 km/h and 0% incline, mean overestimation found for SWA was +78.18 +/- 33.96% (r = 0.63, P < 0.01) and +75.77 +/- 33.36% for Omron (r = 0.52, P < 0.05). At the level of high-intensity exercise at the speed of 5 km/h and 5% incline, mean underestimation was -7.88 +/- 16.86% for SWA (r = 0.74, P < 0.001) and -7.37 +/- 16.07% for Omron (r = 0.75, P < 0.001). Conclusions: Both methods led to considerable overestimation of calculated EE in level walking and a relatively minor underestimation during fast uphill walking.","[Machac, Stanislav; Prochazka, Michal; Radvansky, Jiri; Slaby, Krystof] Charles Univ Prague, Fac Med 2, Dept Rehabil & Sports Med, Prague 15006, Czech Republic; [Machac, Stanislav; Prochazka, Michal; Radvansky, Jiri; Slaby, Krystof] Motol Univ Hosp, Prague 15006, Czech Republic; [Machac, Stanislav] Charles Univ Prague, Fac Phys Educ & Sport, Dept Physiotherapy, Prague 15006, Czech Republic","Machac, S (reprint author), Charles Univ Prague, Fac Med 2, Dept Rehabil & Sports Med, V Uvalu 84, Prague 15006, Czech Republic.","machac.s@seznam.cz",null,null," [SVV 2013-267603]","This study was conducted with the support of METABO project Controlling Chronic Diseases Related to Metabolic Disorders (ICT-2007-1-216270). The study was also supported by the university research grant SVV 2013-267603.",null,25,2,2,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1520-9156",null,null,"DIABETES TECHNOL THE","Diabetes Technol. Ther.","MAY",2013,15,5,null,null,null,null,413,418,null,"10.1089/dia.2012.0235",null,6,"Endocrinology & Metabolism","Endocrinology & Metabolism","137ZL","WOS:000318477700009"]
[null,null,null,null,"J","Figova, K; Hrabeta, J; Eckschlager, T",null,null,null,"Figova, K.; Hrabeta, J.; Eckschlager, T.",null,null,"Anticancer Efficiency of Reovirus in Normoxia and Hypoxia","FOLIA BIOLOGICA",null,null,"English","Article",null,null,null,null,null,"oncolytic virus; reovirus; hypoxia; apoptosis; autophagy; glioblastoma; medulloblastoma","DOWN-REGULATION; TUMOR HYPOXIA; CELL-DEATH; APOPTOSIS; RESISTANCE; CANCER; ONCOLYSIS; THERAPY; VIRUSES; PROTEIN","Oncolytic viruses infect, replicate in, and lyse tumour cells but spare the normal ones. One of oncolytic viruses is a naturally occurring replication-competent reovirus (RV), which preferentially kills tumour cells with activated Ras signaling pathways. The aim of this study was to survey effects of RV on brain tumour-derived cells in vitro under hypoxic conditions since hypoxia causes resistance to radio- and chemotherapy. This study demonstrates that RV replicates preferentially in tumour cells and that the virus is able to overcome cellular adaptation to hypoxia and infect and kill hypoxic tumour cells. RV can both replicate in hypoxic tumour microenvironment and cause the cytopathic effect, subsequently inducing cell death. We found that a large proportion of cells are killed in hypoxia (1% O-2) by caspase-independent mechanisms. Furthermore, we learned that the cell death induced by RV in hypoxic conditions is not caused by autophagy.","[Eckschlager, T.] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague 15006 5, Czech Republic; Univ Hosp Motol, Prague, Czech Republic","Eckschlager, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, V Uvalu 84, Prague 15006 5, Czech Republic.","tomas.eck-schlager@lfmotol.cuni.cz",null,null,"project for conceptual development of research organization [00064203]; GACR [P301/10/0356]","The study was supported by the project for conceptual development of research organization 00064203 and by GACR grant No. P301/10/0356.",null,34,2,2,"CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE","PRAGUE 6","FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC","0015-5500",null,null,"FOLIA BIOL-PRAGUE","Folia Biol.-Prague",null,2013,59,2,null,null,null,null,68,75,null,null,null,8,"Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology","Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Oncology; Cell Biology","242CP","WOS:000326215300002"]
[null,null,null,null,"J","Hvizdosova-Klescova, A; Uhlik, J; Malina, M; Vulterinova, H; Novotny, T; Vajner, L",null,null,null,"Hvizdosova-Klescova, A.; Uhlik, J.; Malina, M.; Vulterinova, H.; Novotny, T.; Vajner, L.",null,null,"Remodeling of fetoplacental arteries in rats due to chronic hypoxia","EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY",null,null,"English","Article",null,null,null,null,null,"Placenta; Immunohistochemistry; iNOS; eNOS; Electron microscopy; Morphometry","PULMONARY-HYPERTENSION; NITRIC-OXIDE; TROPHOBLAST INVASION; VASCULAR DEVELOPMENT; PLACENTA; VASOCONSTRICTION; PATHOGENESIS; EXPRESSION; RESISTANCE; DYSPLASIA","The increased fetoplacental vascular resistance due to chronic hypoxia cannot be explained by simple hypoxic vasoconstriction, as it sustains to some degree after recovery in normobaric environment. To verify a hypothesis that fetoplacental arteries undergo remodeling of their walls similar to remodeling of pulmonary arteries in hypoxic pulmonary hypertension, we used a model of the chronically hypoxic rat placenta. Han Wistar pregnant rats were exposed to 14-day hypoxia (10% of oxygen) during the 6th to 19th day of pregnancy. Chronic hypoxia elicited in both intraplacental (prelabyrinthine) and chorionic plate (insertion) arteries significant narrowing of their lumina. Irregular thickening of their adventitia due to an increase in collagen fibers as well as ground substance was observed; reticular fibers were fragmented. Because of remodeling of fetoplacental arteries, a model of chronically hypoxic rat placenta could simulate human preplacental hypoxia and consequent effects. (C) 2011 Elsevier GmbH. All rights reserved.","[Hvizdosova-Klescova, A.; Uhlik, J.; Novotny, T.; Vajner, L.] Charles Univ Prague, Fac Med 2, Dept Histol & Embryol, CZ-15006 Prague 5, Motol, Czech Republic; [Malina, M.] Fac Hosp Motol, Dept Pediat, CZ-15006 Prague 5, Motol, Czech Republic; [Vulterinova, H.] Sisters Mercy St Charles Borromeo Hosp Prague, Dept Med, CZ-11833 Prague 1, Lesser Town, Czech Republic","Vajner, L (reprint author), Charles Univ Prague, Fac Med 2, Dept Histol & Embryol, V Uvalu 84, CZ-15006 Prague 5, Motol, Czech Republic.","ludek.vajner@lfmotol.cuni.cz","Vajner, Ludek/C-5823-2014; Uhlik, Jiri/C-6282-2014",null,"Grant Agency of Charles University [53/2005]","This work was supported by grant no. 53/2005 of the Grant Agency of Charles University. We are also obliged to Mr. Thomas Cronin (a lector of the Department of Histology and Embryology, Charles University 2nd Faculty of Medicine) for his kind language review.",null,31,2,2,"ELSEVIER GMBH, URBAN & FISCHER VERLAG","JENA","OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY","0940-2993",null,null,"EXP TOXICOL PATHOL","Exp. Toxicol. Pathol.","JAN",2013,65,41671,null,null,null,null,97,103,null,"10.1016/j.etp.2011.06.006",null,7,"Pathology; Toxicology","Pathology; Toxicology","077CR","WOS:000314006000016"]
[null,null,null,null,"J","Spacek, M; Veselka, J",null,null,null,"Spacek, Miloslav; Veselka, Josef",null,null,"Carotid artery stenting - current status of the procedure","ARCHIVES OF MEDICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"carotid stenting; carotid endarterectomy; emboli protection device; transcranial Doppler","CEREBRAL PROTECTION DEVICES; SELF-EXPANDING STENTS; HIGH-RISK PATIENTS; RANDOMIZED-TRIAL; SURGERY-TRIAL; ENDOVASCULAR TREATMENT; SYMPTOMATIC PATIENTS; PATIENT SELECTION; MIDTERM OUTCOMES; 30-DAY OUTCOMES","Surgical carotid endarterectomy (CEA) was long considered the standard approach for the treatment of atherosclerotic carotid artery disease. This was based on results of several randomized trials demonstrating its effectiveness over the best medical therapy. In the past two decades, patients identified high-risk for surgery were offered carotid artery stenting (CAS) as a less invasive option. Despite its initial limitations, CAS has evolved into an elaborate method currently considered to be equivalent and in selected patients even preferable to CEA. However, outcomes of both procedures are highly operator dependent and a simple stratifying method to prioritize CAS, CEA or medical therapy only has not yet been proposed. In addition, recently published randomized trials highlighted the importance of proper patient selection and rigorous training contributing to low absolute rates of (procedural) adverse events. This review discusses the history and evidence for carotid revascularization and briefly presents technical aspects and innovations in CAS.","[Spacek, Miloslav; Veselka, Josef] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Cardiol,Cardiovasc Ctr, Prague 15000 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Cardiol, V Uvalu 84, Prague 15000 5, Czech Republic.","veselka.josef@seznam.cz",null,null,"Ministry of Health of the Czech Republic [00064203, NT13319]","The preparation of this article was supported by grants from the Ministry of Health of the Czech Republic: 00064203 and NT13319.",null,54,1,1,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922","1896-9151",null,"ARCH MED SCI","Arch. Med. Sci.","DEC",2013,9,6,null,null,null,null,1028,1034,null,"10.5114/aoms.2013.39216",null,7,"Medicine, General & Internal","General & Internal Medicine","290OO","WOS:000329768400010"]
[null,null,null,null,"J","Skapa, P; Robova, H; Rob, L; Zamecnik, J",null,null,null,"Skapa, Petr; Robova, Helena; Rob, Lukas; Zamecnik, Josef",null,null,"p16(INK4a) Immunoprofiles of Squamous Lesions of the Uterine Cervix-Implications for the Reclassification of Atypical Immature Squamous Metaplasia","PATHOLOGY & ONCOLOGY RESEARCH",null,null,"English","Article",null,null,null,null,null,"Uterine cervix; p16; Cytokeratin 17; Cervical intraepithelial neoplasia; Atypical immature squamous metaplasia; Flat condyloma","INTRAEPITHELIAL NEOPLASIA; HUMAN-PAPILLOMAVIRUS; P16 EXPRESSION; IN-SITU; GRADE; CELL; RISK; PROGRESSION; DIAGNOSIS; KI-67","p16(INK4a) immunoprofiles of non-precancerous and dysplastic squamous cervical lesions were defined and applied to the reclassification of atypical immature squamous metaplasia (AIM). The immunoexpression of cytokeratin 17 (CK 17) in AIM was also evaluated. Totally, 295 cervical cone biopsies representing squamous metaplasia, reactive changes, koilocytosis, flat condyloma, CIN I, CIN II, CIN III and AIM were subjected to p16(INK4a) immunohistochemistry. AIM cases were analyzed using CK 17 antibody. Typical p16(INK4a) immunoprofiles for the metaplastic, LSIL/HPV and HSIL phenotypes were recorded and used for the categorization of AIM into particular phenotype groups. Results were correlated with CK 17 immunoexpression. All CIN II and CIN III lesions, all but one case of CIN I and all flat condylomas overexpressed p16(INK4a). Other non-precancerous lesions, including koilocytosis, were predominantly negative. Contrary to the sporadic and focal immunostaining, diffuse positivity was associated with the dysplastic features of the lesion. CIN II and CIN III were characterized by a diffuse, strong/weak, full-thickness staining, whereas CIN I showed a heterogeneous diffuse/focal, weak/strong, lower half positivity. One third of AIM lesions may be reclassified as HSIL, one third as LSIL/HPV and one third shows metaplastic phenotype. All AIM cases with metaplastic and LSIL/HPV phenotypes expressed CK 17 diffusely, whereas focal positivity slightly prevailed in AIM with HSIL phenotype. We conclude that p16(INK4a) immunohistochemistry is a supporting method for the differential diagnosis of cervical lesions, which may be especially useful for the reclassification of AIM. The efficacy of CK 17 immunohistochemistry seems to be controversial for these purposes.","[Skapa, Petr; Zamecnik, Josef] Charles Univ Prague, Dept Pathol & Mol Med, Univ Hosp Motol, Sch Med 2, Prague 15006 5, Czech Republic; [Robova, Helena; Rob, Lukas] Charles Univ Prague, Dept Obstet & Gynecol, Univ Hosp Motol, Sch Med 2, Prague 15006 5, Czech Republic","Skapa, P (reprint author), Charles Univ Prague, Dept Pathol & Mol Med, Univ Hosp Motol, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","petr.skapa@lfmotol.cuni.cz",null,null,"Grant Agency of Charles University in Prague, Czech Republic [GAUK 85608]; Ministry of Health of the Czech Republic [00064203]","This study was supported by the research project of Grant Agency of Charles University in Prague, Czech Republic (GAUK 85608) and by the project of the Ministry of Health of the Czech Republic for conceptual development of research organization 00064203 University Hospital Motol, Prague, Czech Republic.",null,23,1,1,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","1219-4956",null,null,"PATHOL ONCOL RES","Pathol. Oncol. Res.","OCT",2013,19,4,null,null,null,null,707,714,null,"10.1007/s12253-013-9633-1",null,8,"Oncology; Pathology","Oncology; Pathology","221DU","WOS:000324638600012"]
[null,null,null,null,"J","Dudova, I; Hrdlicka, M",null,null,null,"Dudova, Iva; Hrdlicka, Michal",null,null,"Olfactory functions are not associated with autism severity in autism spectrum disorders","NEUROPSYCHIATRIC DISEASE AND TREATMENT",null,null,"English","Article",null,null,null,null,null,"autism spectrum disorders; psychopathology; Sniffin' Sticks; odor threshold; odor identification; odor pleasantness","ODOR DISCRIMINATION; EEG ABNORMALITIES; CHILDHOOD AUTISM; CHILDREN; IDENTIFICATION; CLASSIFICATION; ABILITY","Background: Changes in olfactory functions have been found in many neurodegenerative and psychiatric disorders, including autism spectrum disorders (ASDs). The aim of the present study was to evaluate the relationship between olfactory functions (odor-detection thresholds, odor identification, and odor preference) and autism severity and sensory-related behavior in children and adolescents with ASD. Subjects and methods: Our sample consisted of 35 high-functioning patients with ASD (mean age 10.8 +/- 3.6 years, 31 boys). Olfactory testing (threshold and identification) used the Sniffin' Sticks test. Odor pleasantness was assessed on a 5-point scale using the Identification part of the Sniffin' Sticks test. The severity of autistic psychopathology was measured using the Childhood Autism Rating Scale (CARS). Results: Using Spearman's correlation, we found no significant correlations between autism severity (as expressed by total CARS score) and odor-detection thresholds (R=0.144, P=0.409), odor identification (R=0.07, P=0.966), or odor pleasantness (R=-0.046, P=0.794). There was also no significant relationship between CARS item 9 (\"Taste, smell, and touch response and use\") and odor-detection thresholds (R=0.170, P=0.330), odor identification (R=0.282, P=0.100), or odor pleasantness (R=0.017, P=0.923). Conclusion: We did not find any significant relationship between the severity of autistic psychopathology and olfactory functions.","[Dudova, Iva; Hrdlicka, Michal] Univ Hosp Motol, Dept Child Psychiat, Prague, Czech Republic","Dudova, I (reprint author), Charles Univ Prague, Dept Child Psychiat, Fac Med 2, Univ Hosp Motol, 84 5 Uvalu, Prague 15006, Czech Republic.","iva.dudova@lfmotol.cuni.cz",null,null,"Ministry of Education, Youth and Sports, Czech Republic [COST LD11028]; Ministry of Health, Czech Republic (conceptual development of research organization, University Hospital Motol, Prague, Czech Republic) [00064203]","This study was supported by the Ministry of Education, Youth and Sports, Czech Republic (research grant COST LD11028) and by the Ministry of Health, Czech Republic (conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203). The authors would like to thank Thomas Secrest, MSc for his assistance with the English version of the manuscript.",null,25,1,1,"DOVE MEDICAL PRESS LTD","ALBANY","PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND","1176-6328","1178-2021",null,"NEUROPSYCH DIS TREAT","Neuropsychiatr. Dis. Treat.",null,2013,9,null,null,null,null,null,1847,1850,null,"10.2147/NDT.S54893",null,4,"Clinical Neurology; Psychiatry","Neurosciences & Neurology; Psychiatry","262MN","WOS:000327739600001"]
[null,null,null,null,"J","Brozkova, DS; Posadka, J; Lassuthova, P; Mazanec, R; Haberlova, J; Siskova, D; Sakmaryova, I; Neupauerova, J; Seeman, P",null,null,null,"Brozkova, Dana Safka; Posadka, Jan; Lassuthova, Petra; Mazanec, Radim; Haberlova, Jana; Siskova, Dana; Sakmaryova, Iva; Neupauerova, Jana; Seeman, Pavel",null,null,"Spectrum and frequencies of mutations in the MFN2 gene and its phenotypical expression in Czech hereditary motor and sensory neuropathy type II patients","MOLECULAR MEDICINE REPORTS",null,null,"English","Article",null,null,null,null,null,"axonal neuropathy; Mitofusin-2 gene; Charcot-Marie-Tooth neuropathy; hereditary motor and sensory neuropathy","CHARCOT-MARIE-TOOTH; MITOFUSIN 2 MUTATIONS; AXONAL NEUROPATHY; DISEASE; POPULATION; FEATURES; DATABASE; CMT2A","The axonal type of Charcot-Marie-Tooth (CMT) disorders is genetically heterogeneous, therefore the causal mutation is unlikely to be observed, even in clinically well characterized patients. Mitofusin-2 (MFN2) gene mutations are the most frequent cause of axonal CMT disorders in a number of populations. There are two phenotypes; early onset, which is severe and late onset, which is a milder phenotype. A cohort of 139 unrelated Czech patients with axonal neuropathy was selected for sequencing and multiplex ligation-dependent probe amplification analysis (MLPA) testing of the MFN2 gene. A total of 11 MFN2 mutations were detected, with eight pathogenic mutations and three potentially rare benign polymorphisms. MLPA testing in 64 unrelated patients did not detect any exon duplication or deletion. The frequency of the pathogenic mutations detected in Czech hereditary motor and sensory neuropathy type II (HMSN II) patients was 7.2%. Early onset was more frequent among pathogenic mutation cases. Therefore we propose to examine the MFN2 gene mainly in patients with early and severe axonal CMT.","[Brozkova, Dana Safka; Posadka, Jan; Lassuthova, Petra; Haberlova, Jana; Sakmaryova, Iva; Neupauerova, Jana; Seeman, Pavel] Charles Univ Prague, Dept Child Neurol, DNA Lab, Sch Med 2, Prague 15006, Czech Republic; [Mazanec, Radim] Charles Univ Prague, Sch Med 2, Dept Neurol, Prague 15006, Czech Republic; [Mazanec, Radim] Univ Hosp Motol, Prague 15006, Czech Republic; [Siskova, Dana] Thomayer Univ Hosp, Dept Child Neurol, Prague 14059, Czech Republic","Siskova, D (reprint author), Charles Univ Prague, Dept Child Neurol, DNA Lab, Sch Med 2, 84 V Uvalu, Prague 15006, Czech Republic.","dana.brozkova@seznam.cz",null,null,"MH CZ - DRO, University Hospital Motol, Prague, Czech Republic [00064203];  [IGA MH CZ NS 10554-3]","The study was supported by grant no. IGA MH CZ NS 10554-3 and by MH CZ - DRO, University Hospital Motol, Prague, Czech Republic 00064203.",null,25,0,0,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1791-2997","1791-3004",null,"MOL MED REP","Mol. Med. Rep.","DEC",2013,8,6,null,null,null,null,1779,1784,null,"10.3892/mmr.2013.1730",null,6,"Oncology; Medicine, Research & Experimental","Oncology; Research & Experimental Medicine","AA0KE","WOS:000330783200027"]
[null,null,null,null,"J","Spacek, M; Zemanek, D; Tomasov, P; Veselka, J",null,null,null,"Spacek, Miloslav; Zemanek, David; Tomasov, Pavol; Veselka, Josef",null,null,"Early Opening of Dormant Septal Collaterals During Alcohol Septal Ablation: A Possible Hazard of Remote Necrosis","CANADIAN JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"HYPERTROPHIC CARDIOMYOPATHY","Alcohol septal ablation has become a common method to relieve left ventricular outflow track gradient in selected patients with hypertrophic obstructive cardiomyopathy. There is only limited knowledge regarding inadvertent remote (nontarget) myocardial necrosis caused by septal collateral recruitment. Herein we describe a case of unexpected contrast medium leakage through newly opened septal collateral circulation immediately after low-dose ethanol injection suggesting that angiographic inspection of collateral recruitment is necessary in all cases of repeat ethanol injection.","[Spacek, Miloslav; Zemanek, David; Tomasov, Pavol; Veselka, Josef] Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Cardiol,CardioVasc Ctr, Prague 15000 5, Czech Republic","Spacek, M (reprint author), Charles Univ Prague, Sch Med 2, Univ Hosp Motol, Dept Cardiol, Vuvalu 84, Prague 15000 5, Czech Republic.","mildaspacek@gmail.com",null,null,"Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital Motol, Prague, Czech Republic [00064203]","Supported by Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203.",null,5,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0828-282X","1916-7075",null,"CAN J CARDIOL","Can. J. Cardiol.","NOV",2013,29,11,null,null,null,null,null,null,"1531.e5","10.1016/j.cjca.2013.07.003",null,3,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","242VG","WOS:000326270800032"]
[null,null,null,null,"J","Prazak, J; Laszikova, E; Pantoflicek, T; Ryska, O; Koblihova, E; Ryska, M",null,null,null,"Prazak, Josef; Laszikova, Eva; Pantoflicek, Tomas; Ryska, Ondrej; Koblihova, Eva; Ryska, Miroslav",null,null,"Cerebral microdialysis reflects the neuroprotective effect of fractionated plasma separation and adsorption in acute liver failure better and earlier than intracranial pressure: a controlled study in pigs","BMC GASTROENTEROLOGY",null,null,"English","Article",null,null,null,null,null,"Cerebral microdialysis; Intracranial pressure; Acute liver failure; Fractionated plasma separation and adsorption","FULMINANT HEPATIC-FAILURE; INTRACEREBRAL MICRODIALYSIS; AMMONIA NEUROTOXICITY; BRAIN EDEMA; MANAGEMENT; GLUTAMINE; CARE; HYPERAMMONEMIA; PRINCIPLES; SUPPORT","Background: Cerebral edema is a well-recognized and potentially fatal complication of acute liver failure (ALF). The effectiveness of treatments that address intracranial hypertension is generally assessed by measuring intracranial pressure (ICP). The aim of this study was to determine the role of cerebral microdialysis in monitoring the efficacy of fractionated plasma separation and adsorption (FPSA) treatment for ALF. We hypothesized that in ALF cerebral microdialysis reflects the benefits of FPSA treatment on cerebral edema before ICP. Methods: A surgical resection model of ALF was used in 21 pigs. We measured plasma ammonia concentration, brain concentrations of glucose, lactate, pyruvate, glutamate and glutamine, and ICP. Animals were randomized into three groups: in one group eight animals received 6 hours of FPSA treatment 2 hours after induction of ALF; in another group 10 animals received supportive treatment for ALF only; and in the final group three underwent sham surgery. Results: The ICP was significantly higher in the ALF group than in the FPSA group 9 hours after surgery. The lactate/pyruvate (L/P) ratio was significantly lower in the FPSA group than the ALF group 5 hours after surgery, before any significant difference in ICP was detected. Indeed, significant changes in the L/P ratio could be observed within 1 hour of treatment. Glutamine levels were significantly lower in the FPSA group than the ALF group between 6 hours and 10 hours after surgery. Conclusions: Brain lactate/pyruvate ratio and concentration of glutamine measured by cerebral microdialysis reflected the beneficial effects of FPSA treatment on cerebral metabolism more precisely and rapidly than ICP in pigs with fulminant ALF. The role of glutamine as a marker of the efficacy of FPSA treatment for ALF appears promising, but needs further evaluation.","[Prazak, Josef] Univ Basel Hosp, Dept Anaesthesiol & Intens Care, CH-4031 Basel, Switzerland; [Prazak, Josef] Charles Univ Prague, Fac Med 2, Dept Anaesthesiol Resuscitat & Intens Care, Prague, Czech Republic; [Laszikova, Eva] Fac Med 1, Dept Anaesthesiol & Resuscitat, Prague, Czech Republic; [Laszikova, Eva; Pantoflicek, Tomas; Ryska, Ondrej; Koblihova, Eva; Ryska, Miroslav] Cent Mil Hosp, Prague, Czech Republic; [Pantoflicek, Tomas; Ryska, Ondrej; Koblihova, Eva; Ryska, Miroslav] Charles Univ Prague, Fac Med 2, Dept Surg, Prague, Czech Republic","Prazak, J (reprint author), Univ Basel Hosp, Dept Anaesthesiol & Intens Care, CH-4031 Basel, Switzerland.","josef.prazak@usb.ch",null,null,"Ministry of Health [NT 11463]; IP ZRO, Czech Republic [MO1012]","Supported by grant NT 11463 of the Ministry of Health and IP ZRO MO1012, Czech Republic.",null,26,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1471-230X",null,null,"BMC GASTROENTEROL","BMC Gastroenterol.","JUN 8",2013,13,null,null,null,null,null,null,null,98,"10.1186/1471-230X-13-98",null,11,"Gastroenterology & Hepatology","Gastroenterology & Hepatology","168TK","WOS:000320728500001"]
[null,null,null,null,"J","Dzamba, D; Honsa, P; Anderova, M",null,null,null,"Dzamba, David; Honsa, Pavel; Anderova, Miroslava",null,null,"NMDA Receptors in Glial Cells: Pending Questions","CURRENT NEUROPHARMACOLOGY",null,null,"English","Article",null,null,null,null,null,"Astrocytes; ischemia; NG2 glia; NMDA receptors; oligodendrocyte progenitors; oligodendrocytes; polydendrocytes","METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; MOUSE CORTICAL ASTROCYTES; CULTURED HUMAN ASTROCYTES; CNS WHITE-MATTER; GLUTAMATE-RECEPTOR; IN-SITU; CEREBRAL-CORTEX; MESSENGER-RNA; RAT-BRAIN","Glutamate receptors of the N-methyl-D-aspartate (NMDA) type are involved in many cognitive processes, including behavior, learning and synaptic plasticity. For a long time NMDA receptors were thought to be the privileged domain of neurons; however, discoveries of the last 25 years have demonstrated their active role in glial cells as well. Despite the large number of studies in the field, there are many unresolved questions connected with NMDA receptors in glia that are still a matter of debate. The main objective of this review is to shed light on these controversies by summarizing results from all relevant works concerning astrocytes, oligodendrocytes and polydendrocytes (also known as NG2 glial cells) in experimental animals, further extended by studies performed on human glia. The results are divided according to the study approach to enable a better comparison of how findings obtained at the mRNA level correspond with protein expression or functionality. Furthermore, special attention is focused on the NMDA receptor subunits present in the particular glial cell types, which give them special characteristics different from those of neurons - for example, the absence of Mg2+ block and decreased Ca2+ permeability. Since glial cells are implicated in important physiological and pathophysiological roles in the central nervous system (CNS), the last part of this review provides an overview of glial NMDA receptors with respect to ischemic brain injury.","[Anderova, Miroslava] Inst Expt Med AS CR, Dept Cellular Neurophysiol, Prague, Czech Republic; [Anderova, Miroslava] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Anderova, M (reprint author), Inst Expt Med AS CR, Dept Cellular Neurophysiol, Prague, Czech Republic.","anderova@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [GACR: 309/08/1381, GACR P304/12/G069]; Grant Agency of the Charles University in Prague [GAUK 604212]","This study was supported by the grants GACR: 309/08/1381 and GACR P304/12/G069 from the Grant Agency of the Czech Republic and by the grant GAUK 604212 from the Grant Agency of the Charles University in Prague.",null,121,0,0,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","1570-159X",null,null,"CURR NEUROPHARMACOL","Curr. Neuropharmacol.","MAY",2013,11,3,null,null,null,null,250,262,null,null,null,13,"Neurosciences; Pharmacology & Pharmacy","Neurosciences & Neurology; Pharmacology & Pharmacy","133PV","WOS:000318152300002"]
[null,null,null,null,"J","Minarik, I; Last'ovicka, J; Budinsky, V; Kayserova, J; Spisek, R; Jarolim, L; Fialova, A; Babjuk, M; Bartunkova, J",null,null,null,"Minarik, Ivo; Last'ovicka, Jan; Budinsky, Vit; Kayserova, Jana; Spisek, Radek; Jarolim, Ladislav; Fialova, Anna; Babjuk, Marek; Bartunkova, Jirina",null,null,"Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma","IMMUNOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"Renal cell carcinoma; Dendritic cells; Regulatory T cells; Neutrophils; Tumor infiltration","TUMOR-INFILTRATING LYMPHOCYTES; HUMAN COLORECTAL-CANCER; METASTATIC MELANOMA; PERIPHERAL-BLOOD; PROGNOSTIC VALUE; OVARIAN-CANCER; POOR SURVIVAL; EXPRESSION; PROGRESSION; ACTIVATION","We evaluated dendritic cells (DC), regulatory T lymphocytes (Treg) and neutrophils in 37 patients with newly diagnosed renal cell carcinoma (RCC) in the tumor and peripheral blood (PB) and correlated these parameters with tumor staging (early-T1, 2, late-T3, 4 and metastatic disease). The number of myeloid and plasmacytoid DC in blood of RCC patients was higher than in healthy controls. The percentage of myeloid dendritic cells (mDC) from CD45+ cells in tumors was higher in comparison with peripheral blood irrespective of disease stage. Higher percentage of these cells expressed a maturation marker in the periphery in the early stage (CD83 expressing cells). The number of plasmacytoid dendritic cells (pDC) in PB was similar in both early and late stage groups, but the early group displayed a significantly higher percentage of pDC in tumor cell suspension. Neutrophil counts in the peripheral blood of RCC patients were higher than in healthy controls, but the counts in-both tumor stage groups were similar. The proportion of neutrophils from CD45+ cells was higher in late stage tumors. Higher percentage of Treg from CD4+ cells was detected in renal carcinoma tissue in comparison to PB with no difference between stages of the disease. Our results reflect the complex interplay between various cells of the immune system and the tumor microenvironment. Activation of dendritic cell subpopulations at early stages of the disease course is counterbalanced by the early appearance of T regulatory cells both in the periphery and tumor tissue. Later stages are characterized by the accumulation of neutrophils in the tumor. Appropriate timing of anticancer strategies, especially immunotherapy, should take these dynamics of the immune response in RCC patients into account. (C) 2013 Elsevier B.V. All rights reserved.","[Minarik, Ivo; Jarolim, Ladislav; Babjuk, Marek] Charles Univ Prague, Fac Med 2, Dept Urol, Prague 15006, Czech Republic; [Minarik, Ivo; Last'ovicka, Jan; Budinsky, Vit; Kayserova, Jana; Spisek, Radek; Jarolim, Ladislav; Fialova, Anna; Babjuk, Marek; Bartunkova, Jirina] Univ Hosp Motol, Prague 15006, Czech Republic; [Last'ovicka, Jan; Budinsky, Vit; Kayserova, Jana; Spisek, Radek; Fialova, Anna; Bartunkova, Jirina] Charles Univ Prague, Fac Med 2, Inst Immunol, Prague 15006, Czech Republic","Minarik, I (reprint author), Charles Univ Prague, Fac Med 2, Dept Urol, V Uvalu 84, Prague 15006, Czech Republic.","ivo.minarik@lfmotol.cuni.cz",null,null," [CZ.2.16/3.1.00/24022];  [GA UK 7753/2007];  [IGA NT11559-5]","This research was supported from the following projects: CZ.2.16/3.1.00/24022, GA UK 7753/2007 and IGA NT11559-5.",null,54,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0165-2478",null,null,"IMMUNOL LETT","Immunol. Lett.","MAY",2013,152,2,null,null,null,null,144,150,null,"10.1016/j.imlet.2013.05.010",null,7,"Immunology","Immunology","189UP","WOS:000322294100010"]
[null,null,null,null,"J","Hancarova, M; Vejvalkova, S; Trkova, M; Drabova, J; Dleskova, A; Vlckova, M; Sedlacek, Z",null,null,null,"Hancarova, Miroslava; Vejvalkova, Sarka; Trkova, Marie; Drabova, Jana; Dleskova, Alzbeta; Vlckova, Marketa; Sedlacek, Zdenek",null,null,"Identification of a patient with intellectual disability and de novo 3.7 Mb deletion supports the existence of a novel microdeletion syndrome in 2p14-p15","GENE",null,null,"English","Article",null,null,null,null,null,"2p14-p15 deletion; 2p15-p16.1 microdeletion syndrome; Copy number variation; Developmental delay; Intellectual disability; SNP array","MAP; PHENOTYPE","Microdeletions spanning 2p14-p15 have recently been described in two patients with developmental and speech delay and intellectual disability but no congenital malformations or severe facial dysmorphism. We report a 4-year-old boy with a de novo 3.7 Mb long deletion encompassing the region deleted in the previous cases. The patient had clinical features partly consistent with the published cases including intellectual disability, absent speech, microcephaly, long face, bulbous nasal tip and thin upper lip, but his overall clinical picture was more severe compared to the published patients. The identification of this additional patient and a detailed analysis of deletions identified in various patient cohorts and in normal individuals support the existence of a new rare microdeletion syndrome in 2p14-p15. Its critical region is in the vicinity of but clearly separate from the minimal region deleted in the well established 2p15-p16.1 microdeletion syndrome. A thorough comparison of the deletions and phenotypes indicates that multiple genes located in this region may be involved in intellectual functioning, and that some patients may show composite and more complex phenotypes due to deletions spanning both critical regions. (C) 2012 Elsevier B.V. All rights reserved.","[Hancarova, Miroslava; Vejvalkova, Sarka; Drabova, Jana; Dleskova, Alzbeta; Vlckova, Marketa; Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague 15000 5, Czech Republic; [Hancarova, Miroslava; Vejvalkova, Sarka; Drabova, Jana; Dleskova, Alzbeta; Vlckova, Marketa; Sedlacek, Zdenek] Univ Hosp Motol, Prague 15000 5, Czech Republic; [Trkova, Marie] Gennet, Prague, Czech Republic","Sedlacek, Z (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Plzenska 130-221, Prague 15000 5, Czech Republic.","zdenek.sedlacek@lfmotol.cuni.cz",null,null,"CHERISH [223692]; Czech grant for conceptual development of research organization [00064203];  [CZ.2.16/3.1.00/24022]","We thank the family of the patient for cooperation and the reviewers for helpful comments. Supported by CHERISH 223692, CZ.2.16/3.1.00/24022 and a Czech grant for conceptual development of research organization 00064203.",null,13,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0378-1119",null,null,"GENE","Gene","MAR",2013,516,1,null,null,null,null,158,161,null,"10.1016/j.gene.2012.12.027",null,4,"Genetics & Heredity","Genetics & Heredity","095XE","WOS:000315367500024"]
[null,null,null,null,"J","Koubsky, K; Durisova, J; Mikova, D; Herget, J",null,null,null,"Koubsky, Karel; Durisova, Jana; Mikova, Dana; Herget, Jan",null,null,"Chronic hypoxia inhibits tetrahydrobiopterin-induced NO production in rat lungs","RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY",null,null,"English","Article",null,null,null,null,null,"Hypoxia; Pulmonary hypertension; NO synthase; Tetrahydrobiopterin","NITRIC-OXIDE SYNTHASE; PULMONARY-HYPERTENSION; REACTIVE OXYGEN; RESISTANCE VESSELS; VASOCONSTRICTION","Tetrahydrobiopterin (BH4) is an essential cofactor for nitric oxide synthases (NOS). Oxidative stress oxidises BH4 to dihydrobioptein (BH2), resulting in the uncoupling of the two enzymatic domains of NOS and the production of superoxide rather than NO (NOS uncoupling). Oxidative stress is known to be increased in the early stage of chronic hypoxia. This study investigated the participation of NOS uncoupling in the early phase of hypoxia-induced pulmonary hypertension in rats. Rats were exposed to 10% O-2 for 4 days. We investigated the effect of BH4 in vitro on isolated rat lungs and isolated rat peripheral pulmonary blood vessels and in vivo on exhaled NO concentration in exhaled air. BH4 attenuated hypoxic pulmonary vasoconstriction in isolated lungs and its effect was reversed by L-NAME (NOS inhibitor). The main finding of the study is that the effect of BH4 was smaller in rats exposed to 4 days of hypoxia than in normoxic controls. The finding was similar in isolated pulmonary blood vessels. BH4 increased exhaled NO in both normoxic and hypoxic rats. This increase was blunted by L-NIL (specific iNOS inhibitor) and therefore attributable to iNOS. We conclude that BH4 increased NO production in both normoxic and hypoxic rats. The increase was, however, smaller in hypoxic lungs than in controls. We assume that the smaller increase in NO production in hypoxic lungs is due to the decreased BH4/BH2 ratio in chronic hypoxia and NOS uncoupling resulting from this condition. (C) 2012 Elsevier B.V. All rights reserved.","[Koubsky, Karel; Durisova, Jana; Mikova, Dana; Herget, Jan] Charles Univ Prague, Sch Med 2, Dept Physiol, Prague 15006 5, Czech Republic","Koubsky, K (reprint author), Charles Univ Prague, Sch Med 2, Dept Physiol, Plzenska 130-221, Prague 15006 5, Czech Republic.","karel.koubsky@gmail.com",null,null," [GACR 305/08/0108];  [IGA MZCR NT/13358]","This work is supported by Grant GACR 305/08/0108 and IGA MZCR NT/13358.",null,25,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1569-9048",null,null,"RESP PHYSIOL NEUROBI","Respir. Physiol. Neuro.","FEB 1",2013,185,3,null,null,null,null,547,552,null,"10.1016/j.resp.2012.11.012",null,6,"Physiology; Respiratory System","Physiology; Respiratory System","095GO","WOS:000315322900009"]
[null,null,null,null,"J","Dudova, I; Kocourkova, J",null,null,null,"Dudova, Iva; Kocourkova, Jana",null,null,"ADHD as a source of controversy - unambiguous attitudes or cooperation?","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"ADHD; neurobiology; pharmacotherapy; psychotherapy","ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; CHILDREN; NEUROBIOLOGY","ADHD as a source of controversy unambiguous attitudes or cooperation? I. Dudova, J. Kocourkova ADHD (Attention Deficit Hyperactivity Disorder) represents one of the most important disorders in child psychiatry and psychology. Despite multifactorial attitude to ADHD has predominantly been presented, this disorder keeps eliciting controversies in therapeutic approaches, both in psychopharmacological trends and in preferences of psychosocial interventions. The authors describe theoretical basis and therapeutical methods of both trends and show benefits of their reciprocal combination. Controversial attitudes proceed mainly from personal prejudices than from scientific incompatibility of different approaches.","[Dudova, Iva; Kocourkova, Jana] LF UK & FN Motol, Detska Psychiat Klin 2, Prague, Czech Republic","Dudova, I (reprint author), Detska Psychiat Klin FN Motol, V Uvalu 84, Prague 15000 5, Czech Republic.","Jana.Kocourkova@lfmotol.cuni.cz",null,null,null,null,null,38,0,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2013,57,2,null,null,null,null,190,197,null,null,null,8,"Psychology, Multidisciplinary","Psychology","134HA","WOS:000318199800010"]
[null,null,null,null,"J","Dudova, I; Hrdlicka, M",null,null,null,"Dudova, Iva; Hrdlicka, Michal",null,null,"Use of ADI-R and ADOS in diagnostics of autism","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"autism spectrum disorders; diagnosis; ADI-R; ADOS","SPECTRUM DISORDERS; OBSERVATION SCHEDULE; CHILDHOOD AUTISM; RATING-SCALE; COMBINING INFORMATION; MULTIPLE SOURCES; INTERVIEW; CHILDREN; CLASSIFICATION","The authors discuss two \"gold standard\" methods for the diagnosis of autism spectrum disorders: ADI-R (Autism Diagnostic Interview-Revised) and ADOS (Autism Diagnostic Observation Schedule), and review comparative studies that evaluate the methods. Some of the studies found the instruments to be diagnostically equivalent, other studies slightly favored ADOS. Sensitivity of both methods was high even when used alone. However, the combined use of ADI-R and ADOS led to higher diagnostic specificity. The authors also present two cases describing the parallel clinical use of ADI-R and ADOS as part of the diagnosis of two boys aged 8.8 and 4.2 years, respectively. Both cases effectively demonstrate the following theoretical assumption: whereas the reliability of both methods is comparable under optimal conditions, the use of ADI-R is significantly limited in cases when the cooperation of the parent(s) or caregiver is unreliable, limited, or impossible. In such cases, examination using ADOS is preferred.","[Dudova, Iva; Hrdlicka, Michal] LF UK, Detska Psychiat Klin 2, FN Motol, Prague, Czech Republic","Dudova, I (reprint author), Detska Psychiat Klin, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","iva.dudova@lfmotol.cuni.cz",null,null,null,null,null,21,0,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X","1804-6436",null,"CESK PSYCHOL","Cesk. Psychol.",null,2013,57,5,null,null,null,null,488,495,null,null,null,8,"Psychology, Multidisciplinary","Psychology","252IW","WOS:000326999400007"]
[null,null,null,null,"J","Frisova, V; Prosova, B; Mandian, N; Kyncl, M; Vlk, R; Rocek, M",null,null,null,"Frisova, Veronika; Prosova, Blanka; Mandian, Nima; Kyncl, Martin; Vlk, Radovan; Rocek, Miloslav",null,null,"Prenatal Diagnosis of Congenital Epulis by 2D/3D Ultrasound and Magnetic Resonance","FETAL DIAGNOSIS AND THERAPY",null,null,"English","Article",null,null,null,null,null,"Epulis; Congenital gingival granular cell tumor; Prenatal diagnosis; Ultrasonography; Fetal magnetic resonance imaging",null,"Congenital epulis is a rare benign oral cavity tumor that usually arises from the maxillary alveolar mucosa. It is also known as congenital gingival granular cell tumor. Prenatal diagnosis is uncommon and mostly confined to the third trimester. We report a case of congenital epulis, which was referred to our department at 35 weeks of gestation. Both images from our prenatal 2D/3D ultrasound (including Doppler technique) and magnetic resonance examination are presented. A baby girl weighing 2,800 g was delivered spontaneously at 36 weeks and 1 day. The newborn had to be intubated immediately after delivery. A simple excision of the mass was performed on the first day of neonatal life after clinical examination by our pediatric stomatologists confirmed the presence of a tumor resembling epulis. The correctness of this diagnosis was subsequently confirmed by histogenesis. Photographs from the operating room show the postnatal appearance of the tumor. The baby was discharged at the age of 19 days and has remained well at follow-up controls. Copyright (C) 2013 S. Karger AG, Basel","[Frisova, Veronika; Prosova, Blanka; Kyncl, Martin; Rocek, Miloslav] Charles Univ Prague, Fac Med 2, Dept Radiol, CZ-15006 Prague, Czech Republic; [Mandian, Nima] Charles Univ Prague, Fac Med 2, Dept Stomatol, CZ-15006 Prague, Czech Republic; [Vlk, Radovan] Charles Univ Prague, Fac Med 2, Dept Gynecol & Obstet, CZ-15006 Prague, Czech Republic; [Vlk, Radovan] Univ Hosp Motol, Prague, Czech Republic","Rocek, M (reprint author), Charles Univ Prague, Fac Med 2, Dept Radiol, V Uvalu 84, CZ-15006 Prague, Czech Republic.","Miloslav.Rocek@fnmotol.cz",null,null,"MZO MZOFNM","This work was supported by the grants of MZO MZOFNM2005.",null,5,0,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1015-3837",null,null,"FETAL DIAGN THER","Fetal Diagn. Ther.",null,2013,33,4,null,null,null,null,272,276,null,"10.1159/000346811",null,5,"Obstetrics & Gynecology","Obstetrics & Gynecology","156WL","WOS:000319854500012"]
[null,null,null,null,"J","Kocourkova, J; Dudova, I; Koutek, J",null,null,null,"Kocourkova, Jana; Dudova, Iva; Koutek, Jiri",null,null,"Asperger syndrome related suicidal behavior: two case studies","NEUROPSYCHIATRIC DISEASE AND TREATMENT",null,null,"English","Article",null,null,null,null,null,"Asperger syndrome; suicidal behavior; adolescence","AUTISM SPECTRUM DISORDERS; DIAGNOSIS; CHILDREN","Asperger syndrome hinders adaptation to developmental challenges during childhood and adolescence, particularly with regard to interpersonal relationships. Individuals with Asperger syndrome display lack of empathy and limited ability to understand social and emotional exchanges with other people. Individuals with Asperger syndrome are significantly exposed to the risk of suicidal behavior, especially during adolescence. The authors describe cases of suicidal behavior in two adolescent boys with Asperger syndrome.","[Kocourkova, Jana; Dudova, Iva; Koutek, Jiri] Charles Univ Prague, Fac Med 2, Univ Hosp Motol, Dept Child Psychiat, Prague 15006, Czech Republic","Kocourkova, J (reprint author), Charles Univ Prague, Fac Med 2, Univ Hosp Motol, Dept Child Psychiat, V Uvalu 84, Prague 15006, Czech Republic.","jana.kocourkova@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic","This paper was written within the Programme for the Development of Fields of Study at Charles University (P07 Psychosocial Aspects of the Quality of Human Life), supported by the Ministry of Health, Czech Republic. Conceptual development of research: University Hospital Motol, Prague, Czech Republic 00064203.",null,18,0,0,"DOVE MEDICAL PRESS LTD","ALBANY","PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND","1176-6328","1178-2021",null,"NEUROPSYCH DIS TREAT","Neuropsychiatr. Dis. Treat.",null,2013,9,null,null,null,null,null,1815,1819,null,"10.2147/NDT.549289",null,5,"Clinical Neurology; Psychiatry","Neurosciences & Neurology; Psychiatry","254SW","WOS:000327188300001"]
[null,null,null,null,"J","Koutek, J; Kocourkova, J",null,null,null,"Koutek, Jiri; Kocourkova, Jana",null,null,"Adaptation of patients hospitalized in childhood and adolescence after a suicide attempt","CESKOSLOVENSKA PSYCHOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"suicide attempt; catamnesis; adolescence; psychosocial adaptation; psychopathology; self-harm","BEHAVIOR; RISK; TRAUMA; YOUTH","Anonymous catamnestic questionnaire, focused on psychosocial adaptation and psychopathological symptoms including suicide behaviour was sent to 77 patients hospitalized in 2004-2005 after a suicide attempt. Return of the questionnaire was 29%, precisely 38% of those within reach. 23% of the sample are unemployed. 68% have sometimes wished to be dead or to hurt themselves, 36% have made suicide plans, 18% repeated suicide attempt, one respondent repeatedly. In 41% self-harm occurred, 36% have taken drugs in the course of last year. 27% drink alcohol more than once a week and 73% smoke cigarettes. Even though a psychiatric follow-up had been recommended to every patient discharged from the clinic, only a minority of them (36%) underwent it. To conclude, the reported problems indicate a persistent suicide risk.",null,"Koutek, J (reprint author), Detska Psychiat Klin FN Motol, Uvalu 84, Prague 15006 5, Czech Republic.","jiri.koutek@gmail.com",null,null,null,null,null,25,0,0,"ACADEMIA","PRAGUE 1","PUBL HOUSE CZECH ACAD SCI VODICKOVA 40, PRAGUE 1 112 29, CZECH REPUBLIC","0009-062X",null,null,"CESK PSYCHOL","Cesk. Psychol.",null,2013,57,4,null,null,null,null,372,378,null,null,null,7,"Psychology, Multidisciplinary","Psychology","221KD","WOS:000324656900007"]
[null,null,null,null,"J","Meluzinova, E; Libertinova, J",null,null,null,"Meluzinova, E.; Libertinova, J.",null,null,"Monitoring of the Biological Effect of Interferon Beta in the Treatment of Multiple Sclerosis","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"multiple sclerosis; interferon beta; neutralizing antibodies; myxovirus resistance protein A","NEUTRALIZING ANTIBODIES; THERAPY","Interferon beta (IFN-beta) is one of the first-line treatments in multiple sclerosis. Systematic monitoring of IFN-beta biological effect regular testing for the presence of neutralizing antibodies and an assessment of mRNA myxovirus resistance protein A levels should form an integral part of treatment with IFN-beta. Within the paper, the recommended approach to such monitoring is illustrated by a case report from our clinical practice.","[Meluzinova, E.; Libertinova, J.] 2 LF UK FN Motol, Ctr Pro Demyelinizacni Onemocneni, Neurol Klin, Prague 15006, Czech Republic","Meluzinova, E (reprint author), 2 LF UK FN Motol, Ctr Pro Demyelinizacni Onemocneni, Neurol Klin, Ovalu 84, Prague 15006, Czech Republic.","eva.meluzinova@fnmotol.cz",null,null,null,null,null,4,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,null,null,1,null,null,12,14,null,null,null,3,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","229AU","WOS:000325235000004"]
[null,null,null,null,"J","Palova, S; Charvat, J; Chlumsky, J",null,null,null,"Palova, S.; Charvat, J.; Chlumsky, J.",null,null,"Flow-mediated vasodilatation in the patients with anorexia nervosa","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"anorexia nervosa; flow-mediated vasodilatation; realimentation","ENDOTHELIAL FUNCTION; BRACHIAL-ARTERY; DYSFUNCTION; DILATION; ATHEROSCLEROSIS; VARIABILITY; MORTALITY; EVENTS; STRESS","Objective: To compare flow-mediated vasodilatation in patients with anorexia nervosa and healthy subjects. Background: Endothelial dysfunction is present in the patients with anorexia nervosa. However, flow-mediated vasodilatation in the patients with anorexia nervosa in comparison with control subjects has not been yet evaluated. Methods: Flow-mediated vasodilatation in the brachial artery was examined in 30 patients with anorexia nervosa admitted to metabolic care unit for realimentation and compared to 30 control subjects. Results: The average age of the patients with mental anorexia was 25.0 +/- 5.2 compared to 25.5 +/- 4.5 years of the healthy control subjects (NS). BMI was in 14.0 +/- 1.7 kg/m(2) in patients with anorexia nervosa comparing to 20.4 +/- 1.0 kg/m2 in the healthy control subjects (p<0.001). The baseline mean diameter of the right brachial artery was 0.33 +/- 0.06 cm in the anorexia nervosa patients and 0.35 +/- 0.05 cm in the control subjects (NS). The absolute increase of brachial artery size after reactive hyperemia was 0.029 +/- 0.006 cm (9%) in the anorexia nervosa patients and 0.039 +/- 0.006 cm (11 %) in the control subjects (p=0.002). After realimentation, the baseline mean diameter of the right brachial artery was comparable to the result before nutrition intervention -0.34 +/- 0.05 cm but brachial artery increase due to reactive hyperemia was 0.036 +/- 0.05 cm (10.5 %). It was for 19 % higher compared to the first examination (p<0.001) Conclusion: Flow-mediated vasodilatation is decreased in the patients with anorexia nervosa in comparison with the healthy control subjects and improves after realimentation (Tab. 1, Ref. 20). Full Text in PDF www.elis.sk.","[Charvat, J.] Charles Univ Prague, Fac Med 2, Dept Med, CZ-15006 Prague 5, Czech Republic; Fac Hosp Motol, Prague, Czech Republic","Charvat, J (reprint author), Charles Univ Prague, Fac Med 2, Dept Med, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","jiri.charvat@lfmotol.cuni.cz",null,null,null,null,null,20,0,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248","1336-0345",null,"BRATISL MED J","Bratisl. Med. J.",null,2013,114,11,null,null,null,null,634,636,null,"10.4149/BLL_2013_135",null,3,"Medicine, General & Internal","General & Internal Medicine","AA4KG","WOS:000331063900007"]
[null,null,null,null,"J","Svobodova, T; Djakow, J; Zemkova, D; Cipra, A; Pohunek, P; Lebl, J",null,null,null,"Svobodova, Tamara; Djakow, Jana; Zemkova, Daniela; Cipra, Adam; Pohunek, Petr; Lebl, Jan",null,null,"Impaired Growth during Childhood in Patients with Primary Ciliary Dyskinesia","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY",null,null,"English","Article",null,null,null,null,null,null,"LUNG TRANSPLANTATION; LONGITUDINAL GROWTH; CYSTIC-FIBROSIS; ADULT HEIGHT; FACTOR-I; CHILDREN; DISEASE; INFLAMMATION; DIAGNOSIS; FEATURES","Primary ciliary dyskinesia (PCD) leads to recurrent/chronic respiratory infections, resulting in chronic inflammation and potentially in chronic pulmonary disease with bronchiectasis. We analyzed longitudinal data on body length/height and body mass index (BMI) for 29 children and young adults with PCD aging 1.5-24 years (median, 14.5) who had been diagnosed at the age of 0.5-17 years (median, 8). Of these, 10 carried pathogenic mutations in either DNAH5 or DNAI1. In children with PCD, body length/height progressively decreased from +0.40 +/- 0.24 SDS (the 1st birthday), +0.16 +/- 0.23 SDS (3 years old), and -0.13 +/- 0.21 SDS (5 years old) to -0.54 +/- 0.19 SDS (7 years old; P = 0.01 versus 0), -0.67 +/- 0.21 SDS (9 years old; P = 0.005 versus 0), -0.52 +/- 0.24 SDS (11 years old; P = 0.04 versus 0), and -0.53 +/- 0.23 SDS (13 years old; P = 0.03 versus 0). These results reflect low growth rates during the childhood growth period. Thereafter, heights stabilized up to the age of 17 years. The growth deterioration was not dependent on sex or disease severity but was more pronounced in DNAH5 or DNAI1 mutation carriers. BMI did not differ from population standards, which suggests that nutritional deficits are not the cause of growth delay. We conclude that PCD leads to chronic deprivation with significant growth deterioration during childhood.","[Svobodova, Tamara; Djakow, Jana; Zemkova, Daniela; Pohunek, Petr; Lebl, Jan] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat, Prague 15006, Czech Republic; [Cipra, Adam] Masaryks Hosp, Dept Pediat, Usti Nad Labem 40011, Czech Republic","Lebl, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat, Prague 15006, Czech Republic.","jan.lebl@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic [NT11469-5]; Project for the Conceptual Development of Research Organizations (Motol University Hospital) [00064203-6001]","This study was supported by the Ministry of Health, Czech Republic (Grant IGA no. NT11469-5) and the Project for the Conceptual Development of Research Organizations 00064203-6001 (Motol University Hospital).",null,25,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","1687-8337","1687-8345",null,"INT J ENDOCRINOL","Int. J. Endocrinol.",null,2013,null,null,null,null,null,null,null,null,731423,"10.1155/2013/731423",null,5,"Endocrinology & Metabolism","Endocrinology & Metabolism","277BL","WOS:000328793300001"]
[null,null,null,null,"J","Zaloudikova, M; Herget, J; Vizek, M",null,null,null,"Zaloudikova, M.; Herget, J.; Vizek, M.",null,null,"Hypercapnia Attenuates the Hypoxia-Induced Blunting of the Reactivity in Chronically Hypoxic Rats","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Isolated pulmonary arteries; Hypoxia; Hypercapnia","SMALL PULMONARY-ARTERIES; HYPERTENSION; INJURY; VASOCONSTRICTION; MECHANISMS; TONE","Chronic hypoxia causes oxidative injury of pulmonary vessels and attenuates their reactivity to different stimuli. When combined with hypercapnia, biochemical markers of this injury are reduced but the effect of concomitant hypoxia and hypercapnia on vascular reactivity is not fully understood. This study was therefore designed to test whether hypercapnia can prevent also the hypoxia-induced loss of reactivity of pulmonary vessels. The reactivity of vessels from rats exposed either to hypoxia or hypoxia combined with hypercapnia was tested using a small vessel myograph (M 500A, Linton, Norfolk, GB). The second and third intrapulmonary branches of pulmonary arteries were isolated under a dissecting microscope from lungs of 8 control rats (group N), 6 rats exposed to hypoxia for 5 days (isobaric, 10 % O-2, group H) and 7 rats exposed to hypoxia combined with hypercapnia for 5 days (10 % O-2, 5 % CO2, group H+CO2). The transmural pressure was set by automatic normalization to 30 mm Hg. The vessel size did not vary among the groups. After stabilization we challenged the vessels twice with KCl (80 mM) and once with PGF(2 alpha) (0.1 mM). There were no significant differences in KCl induced contractions among the groups. The responses to PGF(2 alpha) were expressed as a ratio to the maximal tension obtained by the exposure to 80 mM KCl. Contractions induced by PGF(2 alpha) were markedly reduced in group H (0.07+/-0.02) and in group H+CO2 (0.26+/-0.03) in comparison with group N (0.83+/-0.07). The vessels of group H responded to PGF(2 alpha) less than those of group H+CO2. However we observed the attenuated reactivity also in group H+CO2 in comparison with N. Hypercapnia therefore partially blunted the hypoxia-induced loss of reactivity in pulmonary arteries. This finding supports the hypothesis that hypercapnia significantly alters the nature of lung injury induced by chronic hypoxia.","[Zaloudikova, M.; Vizek, M.] Charles Univ Prague, Dept Pathophysiol, Fac Med 2, Prague 15000, Czech Republic; [Herget, J.] Charles Univ Prague, Dept Physiol, Fac Med 2, Prague 15000, Czech Republic","Zaloudikova, M (reprint author), Charles Univ Prague, Dept Pathophysiol, Fac Med 2, Plzenska 221, Prague 15000, Czech Republic.","marie.zaloudikova@lfmotol.cuni.cz",null,null," [IGA NT 13358-4];  [GACR 13-01710S]","This study was partially supported by grants IGA NT 13358-4, GACR 13-01710S.",null,23,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408","1802-9973",null,"PHYSIOL RES","Physiol. Res.",null,2013,62,5,null,null,null,null,585,588,null,null,null,4,"Physiology","Physiology","258FM","WOS:000327444700013"]
[null,null,null,null,"J","Mazanec, R; Seeman, P; Seemanova, E",null,null,null,"Mazanec, R.; Seeman, P.; Seemanova, E.",null,null,"Oculopharyngeal Muscular Dystrophy in the Population of the Czech Republic","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"oculopharyngeal muscle dystrophy; PABPN1 protein; trinucleotid repeat expansion; ptosis; dysphagia; limb-girdle myopathy","MUTATION","Oculopharyngeal muscular dystrophy is an autosomal dominant muscular dystrophy due to amplification of the GCG triplet in the polyadenylate binding protein nuclear 1 gene (PABPN1) located on chromosome 14q11.2 q13. The first symptoms, usually facial muscle weakness, frequently occur in the fourth or sixth decade; other symptoms include dysphagia, progressive ptosis of the upper eyelids as well as weakness of limb-girdle muscles and sometimes anal or urethral sphincter weakness. The prevalence of the mutation varies depending on geographic region (the highest prevalence was found in Bukchara Jews in lzrael 1 : 600 and in Quebec 1: 1,000 and very low in France 1 : 200,000). This mutation is very stable and shows no anticipation phenomenon. We correlated the phenotype and genotype of 36 patients from five independent families and we found no correlation between the onset of symptoms, progression, severity of phenotype and number of triplet GCG repetitions. The prevalence of OPMD in the Czech Republic can only be estimated (35/10 million, i.e. 1 : 285,700) and carriers of mutation and permutation, respectively, are substantially more common, because the majority of young relatives of probands with 50% genetic risk refused presymptomatic testing.","[Mazanec, R.] LF UK & FN Motole, Neurol Klin 2, Prague 15006 5, Czech Republic; [Mazanec, R.; Seeman, P.] LF UK & FN Motole, DNA Lab Klin Detske Neurol 2, Prague 15006 5, Czech Republic; [Seeman, P.] Ctr Lekarske Genetiky Gennet, Prague, Czech Republic; [Seemanova, E.] LF UK & FN Motole, Oddeleni Klin Genetiky Ustavu Biol & Lekarske Gen, Prague 15006 5, Czech Republic","Mazanec, R (reprint author), LF UK & FN Motole, DNA Lab Klin Detske Neurol 2, V Uvalu 84, Prague 15006 5, Czech Republic.","radimmaz@hotmail.com",null,null,null,null,"Blumen SC, 2000, NEUROLOGY, V55, P1267; Blumen SC, 1997, NEUROMUSCULAR DISORD, V7, pS38, DOI 10.1016/S0960-8966(97)00080-1; Blumen SC, 2009, NEUROLOGY, V73, P596, DOI 10.1212/WNL.0b013e3181b388a3; Bouchard JP, 1997, NEUROMUSCULAR DISORD, V7, pS22, DOI 10.1016/S0960-8966(97)00077-1; Brais B, 1998, AM J HUM GENET, V63, P229; Brais B, 2002, NEUROMUSCULAR DISORD, P1101; BRAIS B, 1995, HUM MOL GENET, V4, P429, DOI 10.1093/hmg/4.3.429; Catoire H, 2008, HUM MOL GENET, V17, P2108, DOI 10.1093/hmg/ddn109; Davies JE, 2005, NAT MED, V11, P672, DOI 10.1038/nm1242; Dionne A, 2011, NEUROMUCULAR DISORDE, P87; Jones LK, 2010, CLIN NEUROPHYSIOL, V121, P870, DOI 10.1016/j.clinph.2010.01.022; McKusick VA, MENDELIAN INHERITANC; Piccolo G, 2011, MUSCLE NERVE, V43, P141, DOI 10.1002/mus.21842; Tome FMS, 1997, NEUROMUSCULAR DISORD, V7, pS63, DOI 10.1016/S0960-8966(97)00085-0",14,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,6,null,null,null,null,717,722,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","260GD","WOS:000327582100007"]
[null,null,null,null,"J","Schwabova, J; Brozkova, DS; Petrak, B; Mojzisova, M; Pavlickova, K; Haberlova, J; Mrazkova, L; Hedvicakova, P; Hornofova, L; Kaluzova, M; Fencl, F; Krutova, M; Zamecnik, J; Seeman, P",null,null,null,"Schwabova, Jaroslava; Brozkova, Dana Safka; Petrak, Borivoj; Mojzisova, Mahulena; Pavlickova, Klara; Haberlova, Jana; Mrazkova, Lenka; Hedvicakova, Petra; Hornofova, Ludmila; Kaluzova, Marie; Fencl, Filip; Krutova, Marcela; Zamecnik, Josef; Seeman, Pavel",null,null,"Homozygous EXOSC3 Mutation c.92G -> C, p.G31A is a Founder Mutation Causing Severe Pontocerebellar Hypoplasia Type 1 Among the Czech Roma","JOURNAL OF NEUROGENETICS",null,null,"English","Article",null,null,null,null,null,"pontocerebellar hypoplasia type 1; olivopontocerebellar hypoplasia; Roma; Romanies (gypsies); spinal muscular atrophies of childhood","SPINAL MUSCULAR-ATROPHY; INFANTILE OLIVOPONTOCEREBELLAR ATROPHY; DEGENERATION; DISEASE","Pontocerebellar hypoplasia type 1 (PCH1) is characterized by cerebellar and anterior horn motor neuron degeneration and loss, signs of spinal muscular atrophy plus. Patients manifest severe perinatal weakness, hypotonia, and respiratory insuffi ciency, causing death frequently before the age of 1 year. Recently, causative mutations in EXOSC3 were reported in a majority of PCH1 patients, but the detailed clinical phenotype caused by EXOSC3 mutations, genotype- phenotype correlations, and prevalent mutations in specifi c ethnic groups is not yet known. Three unrelated Czech Roma patients with PCH1 were investigated clinically, electrophysiologically, neuroradiologically, and neuropathologically (patients 1 and 2). The entire coding region of the EXOSC3 gene, including the adjacent intron sequences, was sequenced in all three patients. The same mutation c.92G -> C, p.G31A in EXOSC3 was found in all three affected patients in homozygous state and in heterozygous state in the parents from two of the families. Haplotype analysis with four fl anking microsatellite markers showed identical haplotype in 9 out of 11 haplotypes carrying the c.92G -> C, p.G31A mutation. Furthermore, four heterozygotes for this mutation were found in anonymous DNA samples from 90 unrelated Roma individuals. All four of these samples shared the same haplotype. No heterozygous sample was found among 120 anonymous DNA samples from Czech non-Roma individuals with no familial relation. It may therefore be concluded that EXOSC3 c.92G -> C, p.G31A mutation is a founder mutation with high prevalence among the Czech Roma causing a similar and particularly severe phenotype of PCH1. These observations from the Czech Roma may have consequences also for other Roma from other countries. PCH1 caused by EXOSC3 founder mutation c.92G -> C, p.G31A extends the list of autosomal recessive disorders rare among the general population but more frequent among Roma at least in the Czech Republic.","[Schwabova, Jaroslava; Brozkova, Dana Safka; Petrak, Borivoj; Haberlova, Jana; Kaluzova, Marie; Krutova, Marcela; Seeman, Pavel] Charles Univ Prague, Fac Med 2, Dept Child Neurol, Prague 15006 5, Motol, Czech Republic; [Schwabova, Jaroslava; Brozkova, Dana Safka; Petrak, Borivoj; Pavlickova, Klara; Haberlova, Jana; Mrazkova, Lenka; Hedvicakova, Petra; Hornofova, Ludmila; Kaluzova, Marie; Fencl, Filip; Krutova, Marcela; Zamecnik, Josef; Seeman, Pavel] Univ Hosp Motol, Prague 15006 5, Motol, Czech Republic; [Schwabova, Jaroslava] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague 15006 5, Motol, Czech Republic; [Mojzisova, Mahulena] Horovice Hosp, Prague, Czech Republic; [Pavlickova, Klara; Hornofova, Ludmila; Zamecnik, Josef] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 15006 5, Motol, Czech Republic; [Mrazkova, Lenka] Charles Univ Prague, Fac Med 2, Dept Radiol, Prague 15006 5, Motol, Czech Republic; [Hedvicakova, Petra] Charles Univ Prague, Fac Med 2, Inst Biol & Med Genet, Prague 15006 5, Motol, Czech Republic; [Fencl, Filip] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague 15006 5, Motol, Czech Republic","Schwabova, J (reprint author), Charles Univ Prague, Fac Med 2, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","schwabova@gmail.com",null,null,"project for conceptual development of research organization [00064203]; IGA MH CR NT [14348]","This work was Supported by a project for conceptual development of research organization 00064203 and by IGA MH CR NT 14348.",null,17,1,1,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0167-7063","1563-5260",null,"J NEUROGENET","J. Neurogenet.","DEC",2013,27,4,null,null,null,null,163,169,null,"10.3109/01677063.2013.814651",null,7,"Genetics & Heredity; Neurosciences","Genetics & Heredity; Neurosciences & Neurology","294IL","WOS:000330038700003"]
[null,null,null,null,"J","Marekova, D; Lesny, P; Jendelova, P; Michalek, J; Kostecka, P; Pradny, M; Martinova, L; Pantoflicek, T; Ryska, M; Sykova, E",null,null,null,"Marekova, Dana; Lesny, Petr; Jendelova, Pavla; Michalek, Jiri; Kostecka, Petra; Pradny, Martin; Martinova, Lenka; Pantoflicek, Tomas; Ryska, Miroslav; Sykova, Eva",null,null,"Hepatocyte Growth on Polycapronolactones and 2-Hydroxyethylmethacrylate Nanofiber Sheets Enhanced by Bone Marrow-Derived Mesenchymal Stromal Cells","HEPATO-GASTROENTEROLOGY",null,null,"English","Article",null,null,null,null,null,"Hepatocyte; Nanofibers; Bioartificial liver device; Liver failure; Biomaterials","ACUTE LIVER-FAILURE; STEM-CELLS; BIOARTIFICIAL LIVER; CONTROLLED-TRIAL; IN-VITRO; CULTURE; DIFFERENTIATION; TRANSPLANTATION; SURVIVAL; BIOREACTOR","Background/Aims: The development of hepatocyte-based Bioartificial Liver Assist Devices, intended for the therapy of chronic and fulminant liver failure, is one of the important tasks in the area of tissue engineering. New advances in the development of semipermeable non-woven nanofiber biomaterials and the co-cultivation of bone marrow mesenchymal stromal cells (BMSC) and hepatocytes could be utilized in order to maintain hepatocyte cultures in these devices. Methodology: We have compared rat hepatocyte growth on nanofiber biomaterials from different polymers, 2-hydroxyethylmethacrylate (HEMA) and ethoxyethylmethacrylate (EOEMA) copolymers, polyurethane (PUR), chitosan and polycapronolactone (PCL) spun from different solvent mixtures. Results: In all cases the adhesion of hepatocytes to nanofibers was significantly better/stronger than to unstructured polymer surfaces; coating the nanofibers with collagen did not increase cell adhesion. We found the best hepatocyte adhesion on HEMA/EOEMA copolymer nanofibers and PCL nanofibers spun from a mixture of ethylacetate and dimethyl sulphoxide. Using a migration assay, we observed the migration of BMSC towards hepatocytes; hepatocytes cocultivated with BMSC excreted lower amounts of stress enzymes. Conclusions: The results demonstrate that nonwoven nanofiber layers, particularly those containing BMSC, are a suitable biocompatible support for functional hepatocyte cultures and that they can be used in a laboratory bioreactor or potentially in clinical setting.","[Marekova, Dana; Lesny, Petr; Jendelova, Pavla; Kostecka, Petra; Sykova, Eva] Inst Expt Med AS CR, Vvi, Prague, Czech Republic; [Marekova, Dana; Lesny, Petr; Jendelova, Pavla; Pantoflicek, Tomas; Ryska, Miroslav; Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Michalek, Jiri; Pradny, Martin] Inst Macromol Chem AS CR, Vvi, Prague, Czech Republic; [Martinova, Lenka] Tech Univ Liberec, Dept Nonwovens, Liberec, Czech Republic; [Pantoflicek, Tomas; Ryska, Miroslav] Charles Univ Prague, Fac Med 2, Dept Surg, Prague, Czech Republic; [Pantoflicek, Tomas; Ryska, Miroslav] Cent Mil Hosp, Prague, Czech Republic","Marekova, D (reprint author), Inst Expt Med AS CR, Vvi, Prague, Czech Republic.",null,null,null," [GACR 304/07/1129];  [AVOZ50390703];  [KAN200520804];  [1M0538]","Supported by grants GACR 304/07/1129, AVOZ50390703, KAN200520804 and 1M0538.",null,34,1,1,"H G E UPDATE MEDICAL PUBLISHING S A","ATHENS","PO BOX 17257, ATHENS GR-10024, GREECE","0172-6390",null,null,"HEPATO-GASTROENTEROL","Hepato-Gastroenterol.","JUL-AUG",2013,60,125,null,null,null,null,1156,1163,null,"10.5754/hge11948",null,8,"Gastroenterology & Hepatology; Surgery","Gastroenterology & Hepatology; Surgery","298MJ","WOS:000330327700039"]
[null,null,null,null,"J","Riedlbauchova, L; Janousek, J; Veselka, J",null,null,null,"Riedlbauchova, Lucie; Janousek, Jan; Veselka, Josef",null,null,"Ablation of Hypertrophic Septum Using Radiofrequency Energy - An Alternative for Gradient Reduction in Patient With Hypertrophic Obstructive Cardiomyopathy?","JOURNAL OF INVASIVE CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"hypertrophic cardiomyopathy; septal ablation; radiofrequency ablation; electroanatomical mapping; echocardiography; magnetic resonance","FOLLOW-UP; SURVIVAL; REGISTRY","Introduction. Alcohol septal ablation and surgical myectomy represent accepted therapeutic options for treatment of symptomatic patients with hypertrophic obstructive cardiomyopathy. Long-term experience with radiofrequency ablation of arrhythmogenic substrates raised a question if this technique might be effective for left ventricular outflow tract (LVOT) gradient reduction. Case report. We report on a 63-year-old patient with recurrence of symptoms 1 year after alcohol septal ablation (ASA) leading originally to a significant reduction of both symptoms and gradient. Due to a new increase of gradient in the LVOT up to 200 mm Hg with corresponding worsening of symptoms and due to refusal of surgical myectomy by the patient, endocardial radiofrequency ablation of the septal hypertrophy (ERASH) was indicated. Radiofrequency ablation was performed in the LVOT using irrigated-tip ablation catheter; the target site was identified using intracardiac echocardiography and electroanatomical CARTO mapping. ERASH caused an immediate gradient reduction due to hypokinesis of the ablated septum. At 2-month follow-up exam, significant clinical improvement was observed, together with persistent gradient reduction assessed with Doppler echocardiography. Echocardiography and magnetic resonance revealed persistent septal hypokinesis and slight thinning of the ablated region. Conclusion. Septal ablation using radiofrequency energy may be a promising alternative or adjunct to the treatment of hypertrophic obstructive cardiomyopathy. Intracardiac echocardiography and electroanatomical CARTO mapping enable exact lesion placement and preservation of atrioventricular conduction.","[Riedlbauchova, Lucie; Veselka, Josef] Charles Univ Prague, Sch Med 2, Clin Cardiol, Prague 15006 5, Czech Republic; [Riedlbauchova, Lucie; Veselka, Josef] Univ Hosp Motol, Prague, Czech Republic; [Janousek, Jan] Univ Hosp Motol, Childrens Heart Ctr, Prague, Czech Republic","Riedlbauchova, L (reprint author), Charles Univ Prague, Sch Med 2, Dept Cardiol, V Uvalu 84, Prague 15006 5, Czech Republic.","lucie.riedlbauchova@fnmotol.cz",null,null,"Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital Motol, Prague, Czech Republic [00064203]","Supported by Ministry of Health, Czech Republic - conceptual development of research organization, University Hospital Motol, Prague, Czech Republic 00064203.",null,15,1,1,"H M P COMMUNICATIONS","MALVERN","83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA","1042-3931",null,null,"J INVASIVE CARDIOL","J. Invasive Cardiol.","JUN",2013,25,6,null,null,null,null,"E128","E132",null,null,null,5,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","173ZC","WOS:000321121300004"]
[null,null,null,null,"J","Kudr, M; Krsek, P; Marusic, P; Tomasek, M; Trnka, J; Michalova, K; Jaruskova, M; Sanda, J; Kyncl, M; Zamecnik, J; Rybar, J; Jahodova, A; Mohapl, M; Komarek, V; Tichy, M",null,null,null,"Kudr, Martin; Krsek, Pavel; Marusic, Petr; Tomasek, Martin; Trnka, Jiri; Michalova, Katerina; Jaruskova, Monika; Sanda, Jan; Kyncl, Martin; Zamecnik, Josef; Rybar, Jan; Jahodova, Alena; Mohapl, Milan; Komarek, Vladimir; Tichy, Michal",null,null,"SISCOM and FDG-PET in patients with non-lesional extratemporal epilepsy: correlation with intracranial EEG, histology, and seizure outcome","EPILEPTIC DISORDERS",null,null,"English","Article",null,null,null,null,null,"ictal SPECT; PET; focal cortical dysplasia; epilepsy surgery; MRI-negative epilepsy","FOCAL CORTICAL DYSPLASIA; PERI-ICTAL SPECT; PET/MRI COREGISTRATION; EPILEPTOGENIC ZONE; SURGERY; MRI; CHILDREN; LOCALIZATION; CORTEX; PATTERNS","Aims. To assess the practical localising value of subtraction ictal single-photon emission computed tomography (SISCOM) coregistered with MRI and F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with extratemporal epilepsy and normal MRI. Methods. We retrospectively studied a group of 14 patients who received surgery due to intractable epilepsy and who were shown to have focal cortical dysplasia, undetected by MRI, based on histological investigation. We coregistered preoperative SISCOM and PET images with postoperative MRI and visually determined whether the SISCOM focus, PET hypometabolic area, and cerebral cortex, exhibiting prominent abnormalities on intracranial EEG, were removed completely, incompletely, or not at all. These results and histopathological findings were compared with postoperative seizure outcome. Results. Two patients underwent one-stage multimodal image-guided surgery and the remaining 12 underwent long-term invasive EEG. SISCOM findings were localised for all but 1 patient. FDG-PET was normal in 3 subjects, 2 of whom had favourable postsurgical outcome (Engel class I and II). Complete resection of the SISCOM focus (n=3), the area of PET hypometabolism (n=2), or the cortical regions with intracranial EEG abnormalities (n=7) were predictive of favourable postsurgical outcome. Favourable outcome was also encountered in: 4 of 8 patients with incomplete resection and 1 of 2 with no resection of the SISCOM focus; 4 of 7 patients with incomplete resection and 1 of 2 with no resection of the PET hypometabolic area; and 2 of 7 patients with incomplete resection of the area corresponding to intracranial EEG abnormality. No correlation between histopathological FCD subtype and seizure outcome was observed. Conclusion. Complete resection of the dysplastic cortex localised by SISCOM, FDG-PET or intracranial EEG is a reliable predictor of favourable postoperative seizure outcome in patients with non-lesional extratemporal epilepsy.","[Kudr, Martin; Krsek, Pavel; Rybar, Jan; Jahodova, Alena; Komarek, Vladimir] Charles Univ Prague, Motol Univ Hosp, Dept Pediat Neurol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Marusic, Petr; Tomasek, Martin] Charles Univ Prague, Motol Univ Hosp, Dept Neurol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Trnka, Jiri] Charles Univ Prague, Gen Univ Hosp, Inst Nucl Med, Fac Med 1, CZ-15006 Prague 5, Czech Republic; [Michalova, Katerina] Charles Univ Prague, Motol Univ Hosp, Dept Nucl Med & Endocrinol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Sanda, Jan; Kyncl, Martin] Charles Univ Prague, Motol Univ Hosp, Dept Radiol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Motol Univ Hosp, Dept Pathol & Mol Med, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Mohapl, Milan] Charles Univ Prague, Mil Univ Hosp, Dept Neurosurg, Fac Med 1, CZ-15006 Prague 5, Czech Republic; [Tichy, Michal] Charles Univ Prague, Motol Univ Hosp, Dept Neurosurg, Fac Med 2, CZ-15006 Prague 5, Czech Republic","Krsek, P (reprint author), Charles Univ Prague, Motol Univ Hosp, Dept Pediat Neurol, Fac Med 2, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","pavel.krsek@post.cz",null,null,"Kontakt Program [ME09042]; project for conceptual development of research organization [00064203];  [GAUK 17010];  [CZ.2.16/3.1.00/24022]","This study was supported by grants GAUK 17010 (Martin Kudr), Kontakt Program ME09042 (Pavel Krsek), CZ.2.16/3.1.00/24022 (Pavel Krsek), and by the project for conceptual development of research organization 00064203 (Pavel Krsek).",null,35,1,1,"JOHN LIBBEY EUROTEXT LTD","MONTROUGE","127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE","1294-9361",null,null,"EPILEPTIC DISORD","Epileptic Disord.","MAR",2013,15,1,null,null,null,null,3,13,null,"10.1684/epd.2013.0560",null,11,"Clinical Neurology","Neurosciences & Neurology","126EF","WOS:000317594400002"]
[null,null,null,null,"J","Fencl, F; Blahova, K; Schlingmann, KP; Konrad, M; Seeman, T",null,null,null,"Fencl, Filip; Blahova, Kveta; Schlingmann, Karl Peter; Konrad, Martin; Seeman, Tomas",null,null,"Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene","EUROPEAN JOURNAL OF PEDIATRICS",null,null,"English","Article",null,null,null,null,null,"Idiopathic infantile hypercalcemia; CYP24A1 gene; Hypercalcemic crisis; Infant; Nephrocalcinosis","VITAMIN-D; PHARMACOKINETICS","We report on a male infant presenting at 4 months of age with failure to thrive, dehydration, hypotonia, lethargy, and vomiting. Laboratory and imaging tests revealed severe hypercalcemia (5.8 mmol/l), suppressed parathyroid hormone (0.41 pmol/l), hypercalciuria (8.0 mmol/mmol creatinine), elevated 25-hydroxyvitamin D3 (over 600 nmol/l), and nephrocalcinosis. These symptoms are characteristic of idiopathic infantile hypercalcemia (IIH, MIM 143880). Conservative therapy (parenteral rehydration, diuretics, corticosteroids, bisphosphonates, and vitamin D prophylaxis withdrawal) was not able to improve the symptoms and laboratory values, and acute hemodiafiltration was necessary to normalize hypercalcemia. Clinical symptoms resolved rapidly after normalization of serum calcium levels. Molecular genetic testing revealed a homozygous mutation (R396W) in the CYP24A1 gene (MIM 126065) encoding 25-hydroxyvitamin D3 24-hydroxylase, which is the key enzyme responsible for 1,25-dihydroxyvitamin D3 degradation. The CYP24A1 gene mutation leads to the increased sensitivity of the patients to even prophylactic doses of vitamin D and to the development of severe symptomatic hypercalcemia in patients with IIH. Conclusion: Our patient is only the thirteenth patient with IIH caused by mutation in the CYP24A1 gene and the first one needing acute hemodiafiltration for severe symptomatic hypercalcemic crisis. In all patients with suspected IIH the DNA analysis for CYP24A1 gene mutations should be performed regardless of the type of vitamin D supplementation and serum levels of vitamin D.","[Fencl, Filip; Blahova, Kveta; Seeman, Tomas] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague, Czech Republic; [Schlingmann, Karl Peter; Konrad, Martin] Univ Hosp Muenster, Dept Gen Pediat, Munster, Germany; [Fencl, Filip; Blahova, Kveta; Seeman, Tomas] Univ Hosp Motol, Dept Paediat, Prague 15006, Czech Republic","Fencl, F (reprint author), Univ Hosp Motol, Dept Paediat, V Uvalu 84, Prague 15006, Czech Republic.","filip.fencl@gmail.com",null,null,null,null,null,18,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-6199",null,null,"EUR J PEDIATR","Eur. J. Pediatr.","JAN",2013,172,1,null,null,null,null,45,49,null,"10.1007/s00431-012-1818-1",null,5,"Pediatrics","Pediatrics","069MV","WOS:000313441400008"]
[null,null,null,null,"J","Sumnik, Z; Matyskova, J; Hlavka, Z; Durdilova, L; Soucek, O; Zemkova, D",null,null,null,"Sumnik, Z.; Matyskova, J.; Hlavka, Z.; Durdilova, L.; Soucek, O.; Zemkova, D.",null,null,"Reference data for jumping mechanography in healthy children and adolescents aged 6-18 years","JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS",null,null,"English","Article",null,null,null,null,null,"Jumping Mechanography; Muscle; Children; Power; Force","GROUND REACTION FORCE; MUSCLE FUNCTION; BONE MASS; FEMALES; MUSCULOSKELETAL; PERFORMANCE; MECHANISMS; PEDIATRICS; ADULTS; TESTS","Objectives: To present gender-specific pediatric normative data on the main parameters of muscle function assessed using jumping mechanography. Methods: The study population included 796 non-selected Caucasian children and adolescents (432 girls and 364 boys) aged 6-19 years recruited from 6 primary schools and 3 high schools. Maximum peak power (P-max) was examined by a single two-legged jump, and maximum force (F-max) was examined by a multiple one-legged hopping. All measurements were performed using a portable force platform (Leonardo Mechanograph, Novotec). P-max, P-max/mass, F-max and F-max/body weight were analyzed as the main outcome parameters. LMS method was used to generate age-and weight-specific reference smooth curves. Results: Both P-max and F-max were strongly dependent on age and weight in both genders (all p<0.001). In prepubertal children, there was no intergender difference in P-max or F-max. Both parameters steadily increased in boys and plateaued in girls aged >13 years. Whereas P-max/mass was more dependent on anthropometric parameters, F-max/BW remained nearly constant with respect to age and weight. Conclusions: These reference data are intended to assist clinicians in the assessment of muscle function by jumping mechanography in pediatric patients.","[Sumnik, Z.; Matyskova, J.; Soucek, O.; Zemkova, D.] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat, Prague 15006, Czech Republic; [Matyskova, J.] Charles Univ Prague, Fac Sci, Dept Anthropol & Human Genet, Prague 15006, Czech Republic; [Matyskova, J.] Charles Univ Prague, Fac Math & Phys, Dept Stat, Prague 15006, Czech Republic; [Durdilova, L.] Charles Univ Prague, Fac Educ, Dept Special Educ, Prague 15006, Czech Republic","Sumnik, Z (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pediat, V Uvalu 84, Prague 15006, Czech Republic.","zdenek.sumnik@lfmotol.cuni.cz",null,null,"Ministry of Health, Czech Republic [00064203/6001]","We thank the research participants and their families and the schools where recruitment was undertaken. Financial support for this study was received from the Project of conceptual development of research organization No. 00064203/6001 (Ministry of Health, Czech Republic).",null,29,0,0,"JMNI","NAFPLION","7 SPILIADOU SQ, NAFPLION, 21 100, GREECE","1108-7161",null,null,"J MUSCULOSKEL NEURON","J. Musculoskelet. Neuronal Interact.","SEP",2013,13,3,null,null,null,null,297,311,null,null,null,15,"Neurosciences; Physiology","Neurosciences & Neurology; Physiology","261XB","WOS:000327696800005"]
[null,null,null,null,"J","Kavalcova, L; Skaba, R; Kyncl, M; Rouskova, B; Prochazka, A",null,null,null,"Kavalcova, Lucie; Skaba, Richard; Kyncl, Martin; Rouskova, Blanka; Prochazka, Ales",null,null,"The diagnostic value of MRI fistulogram and MRI distal colostogram in patients with anorectal malformations","JOURNAL OF PEDIATRIC SURGERY",null,null,"English","Article",null,null,null,null,null,"Anorectal malformations; MRI; Fistulogram; Pressure distal colostogram","SPINAL DYSRAPHISM; IMPERFORATE ANUS; ANOMALIES","Contrast fistulogram (FG) and distal pressure colostogram (DPCG) are standard diagnostic methods for the assessment of anorectal malformations. Pelvic magnetic resonance imaging (MRI) earned a place among essential diagnostic methods in preoperative investigations after the Currarino syndrome and a high incidence of associated spinal dysraphism were described. The aim of our study was to evaluate the possibility of substituting FG and DPCG by a modified pelvic MRI, e. g. MRI fistulogram (MRI-FG) and MRI colostogram (MRI-DPCG). The prospective study involved 29 patients with anorectal malformations who underwent a modified pelvic MRI. The length and course of fistulas and rectum, and the presence of sacral anomalies were studied on MRI images and compared with images obtained by radiologic examinations. Modified MRI brought identical results as contrast studies in 25 patients when related to the fistula and rectum length and course. MRI was more accurate for the detection of sacral anomalies. MRI-FG was the only imaging method used in the four most recent patients. The results support the assumption that conventional contrast examinations for the assessment of anorectal malformations can be replaced by MRI, thus reducing the radiation dose. (C) 2013 Elsevier Inc. All rights reserved.","[Kavalcova, Lucie; Skaba, Richard; Rouskova, Blanka] Charles Univ Prague, Dept Pediat Surg, Fac Med 2, Prague, Czech Republic; [Kavalcova, Lucie; Skaba, Richard; Kyncl, Martin; Rouskova, Blanka] Fac Motol Hosp, Prague 15006, Czech Republic; [Kyncl, Martin] Charles Univ Prague, Dept Imaging Methods, Fac Med 2, Prague, Czech Republic; [Prochazka, Ales] Inst Chem Technol, Dept Comp & Control Engn, CR-16628 Prague, Czech Republic","Kavalcova, L (reprint author), Fac Motol Hosp, Dept Pediat Surg, V Uvalu 84, Prague 15006, Czech Republic.","Lucie.Kavalcova@fnmotol.cz",null,null,"MH CZ-DRO, University Hospital Motol, Prague, Czech Republic [00064203]","This work was supported by MH CZ-DRO, University Hospital Motol, Prague, Czech Republic 00064203.",null,10,0,0,"W B SAUNDERS CO-ELSEVIER INC","PHILADELPHIA","1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA","0022-3468","1531-5037",null,"J PEDIATR SURG","J. Pediatr. Surg.","AUG",2013,48,8,null,null,null,null,1806,1809,null,"10.1016/j.jpedsurg.2013.06.006",null,4,"Pediatrics; Surgery","Pediatrics; Surgery","205AP","WOS:000323413000028"]
[null,null,null,null,"J","Prochazka, P; Hrabeta, J; Vicha, A; Cipro, S; Stejskalova, E; Musil, Z; Vodicka, P; Eckschlager, T",null,null,null,"Prochazka, Pavel; Hrabeta, Jan; Vicha, Ales; Cipro, Simon; Stejskalova, Eva; Musil, Zdenek; Vodicka, Pavel; Eckschlager, Tomas",null,null,"Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers","ONCOLOGY REPORTS",null,null,"English","Article",null,null,null,null,null,"high-risk neuroblastoma cell line; multiplex ligation-dependent probe amplification; fluorescent in situ hybridization; cisplatin resistance; 2p gain; MYCN amplification; MYCN expression","COMPARATIVE GENOMIC HYBRIDIZATION; N-MYC; INDUCED APOPTOSIS; RESISTANCE; GENE; AMPLIFICATION; TUMORS; OVEREXPRESSION; ONCOGENE; CANCER","Neuroblastoma is a tumor accounting for approximately 10% of all childhood malignancies and 50% of all childhood cancer-related deaths. MYCN gene copy number variation represents the most important prognostic factor in neuroblastoma. Prognostic significance of MYCN gene expression is more complicated and may depend on other factors such as MYCN gene copy number status. In the present study, we assessed MYCN gene expression using real-time RT-PCR following cisplatin treatment in three human neuroblastoma cell lines (UKF-NB-3, UKF-NB-4 and SK-N-AS) and their cisplatin-resistant counterparts. We also examined MYCN gene status and copy number (gain and amplification) variations using interphase and metaphase fluorescent in situ hybridization (FISH) and multiplex ligation-dependent probe amplification (MLPA). Only cisplatin-sensitive UKF-NB-4 cells exhibited decreased MYCN expression following treatment with cisplatin. Other sensitive neuroblastoma cells did not exhibit a change in MYCN expression. In contrast, cisplatin-resistant UKF-NB-4 and SK-N-AS cells exhibited increased MYCN expression irrespective of the number of MYCN copies or concentration of cisplatin in the medium. In MYCN-amplified neuroblastoma cells we did not observe any significant change in the number of MYCN copies after cisplatin treatment, whereas MYCN-non-amplified SK-N-AS cells revealed during cisplatin treatment an increased number of MYCN gene copies caused by 2p gain in the majority of cells by FISH. We postulated that cisplatin treatment does not result directly in altered transcription of MYCN. A functional change in MYCN mRNA levels and increased MYCN expression in cisplatin-resistant neuroblastoma cells do not have a clear relationship to MYCN copy numbers. These findings may further contribute to the understanding of cisplatin chemotherapy in connection with MYCN expression, and the possible copy number variations in MYCN neuroblastoma cells may be of importance since targeting of MYCN is being tested as neuroblastoma therapy.","[Prochazka, Pavel; Hrabeta, Jan; Vicha, Ales; Cipro, Simon; Stejskalova, Eva; Eckschlager, Tomas] Charles Univ Prague, Sch Med 2, Dept Paediat Hematol & Oncol, Prague 15006, Czech Republic; [Prochazka, Pavel; Hrabeta, Jan; Vicha, Ales; Cipro, Simon; Stejskalova, Eva; Eckschlager, Tomas] Univ Hosp Motol, Prague 15006, Czech Republic; [Prochazka, Pavel; Vodicka, Pavel] Acad Sci Czech Republic, Inst Expt Med, Prague 14200 4, Czech Republic; [Musil, Zdenek; Vodicka, Pavel] Charles Univ Prague, Inst Biol & Med Genet, Fac Med 1, Prague 12108 2, Czech Republic; [Musil, Zdenek; Vodicka, Pavel] Gen Teaching Hosp, Prague 12108 2, Czech Republic","Prochazka, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14200 4, Czech Republic.","proch.pavel@gmail.com","Prochazka, Pavel/G-4759-2012",null,"Grant Agency of the Czech Republic [P301/10/0356]; project for conceptual development of research organization [00064203]","We would like to thank Professor J. Cinatl Jr (Institute for Medical Virology, Hospital of the Johann Wolfgang Goethe University, Frankfurt/Main, Germany) for providing the UKF-NB-3 and UKF-NB-4 cell lines and their CDDP-resistant sublines. We also thank Alessio Naccarati (Institute of Experimental Medicine, Academy of Sciences of the Czech Republic) for his critical review. This research was supported by the Grant Agency of the Czech Republic (grant P301/10/0356) and by the project for conceptual development of research organization 00064203.",null,42,0,0,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1021-335X",null,null,"ONCOL REP","Oncol. Rep.","JUN",2013,29,6,null,null,null,null,2415,2421,null,"10.3892/or.2013.2383",null,7,"Oncology","Oncology","148GO","WOS:000319232800046"]
[null,null,null,null,"J","Hancarova, M; Simandlova, M; Drabova, J; Mannik, K; Kurg, A; Sedlacek, Z",null,null,null,"Hancarova, Miroslava; Simandlova, Martina; Drabova, Jana; Mannik, Katrin; Kurg, Ants; Sedlacek, Zdenek",null,null,"A patient with de novo 0.45Mb deletion of 2p16.1: The role of BCL11A, PAPOLG, REL, and FLJ16341 in the 2p15-p16.1 microdeletion syndrome","AMERICAN JOURNAL OF MEDICAL GENETICS PART A",null,null,"English","Article",null,null,null,null,null,"2p15-p16; 1 microdeletion syndrome; autism; copy number variation; developmental delay; intellectual disability; SNP array","COPY NUMBER; DEVELOPMENTAL DELAY; HUMAN GENOME; 2P15-16.1; GENES; DISORDERS; RESOURCES; PHENOTYPE; VARIANTS; FAMILY","The 2p15-p16.1 microdeletion syndrome is a novel, rare disorder characterized by developmental delay, intellectual disability, microcephaly, growth retardation, facial abnormalities, and other medical problems. We report here on an 11-year-old female showing clinical features consistent with the syndrome and carrying a de novo 0.45Mb long deletion of the paternally derived 2p16.1 allele. The deleted region contains only three protein-coding RefSeq genes, BCL11A, PAPOLG, and REL, and one long non-coding RNA gene FLJ16341. Based on close phenotypic similarities with six reported patients showing typical clinical features of the syndrome, we propose that the critical region can be narrowed down further, and that these brain expressed genes can be considered candidates for the features seen in this microdeletion syndrome. (c) 2013 Wiley Periodicals, Inc.","[Hancarova, Miroslava; Simandlova, Martina; Drabova, Jana; Sedlacek, Zdenek] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 15000 5, Czech Republic; [Hancarova, Miroslava; Simandlova, Martina; Drabova, Jana; Sedlacek, Zdenek] Univ Hosp Motol, Prague, Czech Republic; [Mannik, Katrin; Kurg, Ants] Univ Tartu, Inst Mol & Cell Biol, EE-50090 Tartu, Estonia","Sedlacek, Z (reprint author), Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 15000 5, Czech Republic.","zdenek.sedlacek@lfmotol.cuni.cz",null,null,"European Commission [223692 CHERISH, BM1004]; Czech Ministries of Education and Health [LD11028, 00064203]; Estonian Ministry of Education and Research [SF0180027s10]","Grant sponsor: European Commission; Grant number: 223692 CHERISH and BM1004; Grant sponsor: Czech Ministries of Education and Health; Grant numbers: LD11028 and 00064203; Grant sponsor: Estonian Ministry of Education and Research; Grant number: SF0180027s10.",null,27,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1552-4825",null,null,"AM J MED GENET A","Am. J. Med. Genet. A","APR",2013,"161A",4,null,null,null,null,865,870,null,"10.1002/ajmg.a.35783",null,6,"Genetics & Heredity","Genetics & Heredity","112YM","WOS:000316631300035"]
[null,null,null,null,"J","Blechova, Z; Trojanek, M; Kyncl, J; Castkova, J; John, J; Maly, M; Herrmannova, K; Maresova, V",null,null,null,"Blechova, Zuzana; Trojanek, Milan; Kyncl, Jan; Castkova, Jitka; John, Jerry; Maly, Marek; Herrmannova, Kristyna; Maresova, Vilma",null,null,"Clinical and laboratory features of viral hepatitis A in children","WIENER KLINISCHE WOCHENSCHRIFT",null,null,"English","Article",null,null,null,null,null,"Viral hepatitis A; Children; Hepatology; Epidemiology; Vaccination","UNITED-STATES; RISK-FACTORS; INFECTION; VACCINATION; COMMUNITY; OUTBREAK","Recent outbreaks of viral hepatitis A in non-endemic European countries and the potential outbreak risk in susceptible populations has led us to evaluate the clinical characteristics of children hospitalised with hepatitis A. Retrospective study included 118 children (68 boys and 50 girls) with the mean age of 8.5 years hospitalised at Hospital Na Bulovce in Prague from June 2008 to June 2009. The clinical course was symptomatic icteric in 57 (48.3 %) children, symptomatic anicteric in 23 (19.5 %), subclinical in 22 (18.6 %) and asymptomatic inapparent in 16 (13.6 %). The relapse of the disease occurred in three patients. There were no cases of fulminant hepatitis. The most frequent symptoms included jaundice (57 cases), abdominal pain/discomfort (38), vomiting (38), dark urine (37), subfebrility (29) and fever (25). Hepatic injury markers were substantially elevated in icteric patients, but moderate elevations were identified in anicteric and subclinical cases as well. Lower white blood cell and lymphocyte counts were independently associated with symptomatic and more severe clinical course. Active immunisation was provided to 22 patients, and as a post-exposure prophylaxis to 19 of them. The clinical course and laboratory parameters in vaccinated children were not significantly different from non-vaccinated children. The clinical course of hepatitis A was largely self-limiting and benign. Asymptomatic infections are frequent, representing risk for disease spread; however, they are associated with elevations of hepatic injury markers. The inclusion of significant proportion of asymptomatic cases that were identified and investigated only because of active epidemiological surveillance in the outbreak focus represents the particular asset of this study.","[Blechova, Zuzana; Trojanek, Milan; John, Jerry; Herrmannova, Kristyna; Maresova, Vilma] Charles Univ Prague, Dept Infect Dis 1, Fac Med 2, Hosp Na Bulovce, Prague 18081, Czech Republic; [Kyncl, Jan; Castkova, Jitka] Natl Inst Publ Hlth, Ctr Epidemiol & Microbiol, Prague, Czech Republic; [Kyncl, Jan] Charles Univ Prague, Dept Epidemiol, Fac Med 3, Prague 18081, Czech Republic; [Maly, Marek] Natl Inst Publ Hlth, Dept Biostat & Informat, Prague, Czech Republic","Trojanek, M (reprint author), Charles Univ Prague, Dept Infect Dis 1, Fac Med 2, Hosp Na Bulovce, Budinova 2, Prague 18081, Czech Republic.","mtrojanek@seznam.cz",null,null,null,null,null,30,0,0,"SPRINGER WIEN","WIEN","SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA","0043-5325",null,null,"WIEN KLIN WOCHENSCHR","Wien. Klin. Wochen.","FEB",2013,125,41732,null,null,null,null,83,90,null,"10.1007/s00508-012-0316-9",null,8,"Medicine, General & Internal","General & Internal Medicine","107WM","WOS:000316251500003"]
[null,null,null,null,"J","Kaprova-Pleskacova, J; Snajderova, M; Stoop, J; Koudova, M; Kocarek, E; Novotna, D; Drop, SLS; Obermannova, B; Lebl, J; Oosterhuis, JW; Looijenga, LHJ",null,null,null,"Kaprova-Pleskacova, J.; Snajderova, M.; Stoop, J.; Koudova, M.; Kocarek, E.; Novotna, D.; Drop, S. L. S.; Obermannova, B.; Lebl, J.; Oosterhuis, J. W.; Looijenga, L. H. J.",null,null,"45,X/46,X,psu dic(Y) Gonadal Dysgenesis: Influence of the Two Cell Lines on the Clinical Phenotype, Including Gonadal Histology","SEXUAL DEVELOPMENT",null,null,"English","Article",null,null,null,null,null,"Gonadal dysgenesis; Gonadal histology; KITLG; OCT3/4; Phenotype","CARCINOMA IN-SITU; TURNER-SYNDROME; TESTICULAR MICROLITHIASIS; Y-CHROMOSOME; GERM-CELLS; TESTIS; DIFFERENTIATION; GONADOBLASTOMA; EXPRESSION; DISORDERS","A child born with ambiguous genitalia (Prader III) was found to have a 45, X[92.2%]/46,X,psu dic(Y)(p12)[7.8%] karyotype in peripheral blood lymphocytes. The testosterone level was consistent with that of a normal male; however, gonadotropins were elevated. Ultrasound and endoscopy of the urogenital sinus revealed well-developed Mullerian structures. At 3.5 months, the child was operated for right-sided incarcerated hernia, and the gonad situated at the inguinal region was biopsied and classified as primitive testis. Based on the presence of Mullerian structures, anatomy of external genitalia and wish of the parents, the child was assigned female gender. She underwent removal of the left gonad at 4 months during another acute surgery; histology was similar to the right gonad. The rest of the right gonad was removed at 16 months, and feminizing genitoplasty took place at 3 years. The right and left gonad contained 28 and 22% of cells with a Y chromosome, respectively. During further histological examination, dysgenetic features of the gonads were discovered. Some germ cells displayed abnormal development based on the specific expression of immunohistochemical markers (OCT3/4, TSPY, KITLG), indicating a possible risk for future malignant germ cell tumor development. Contribution of the 45, X cell line to the phenotype was also observed: the patient developed celiac disease, and her growth pattern resembled that of Turner syndrome responding to growth hormone treatment. (C) 2013 S. Karger AG, Basel","[Kaprova-Pleskacova, J.; Snajderova, M.; Obermannova, B.; Lebl, J.] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague, Czech Republic; [Koudova, M.; Kocarek, E.; Novotna, D.] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic; [Stoop, J.; Oosterhuis, J. W.; Looijenga, L. H. J.] Sophia Childrens Univ Hosp, Univ Med Ctr Rotterdam, Josephine Nefkens Inst, Dept Pathol,Erasmus MC, Rotterdam, Netherlands; [Drop, S. L. S.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Endocrinol, Rotterdam, Netherlands","Kaprova-Pleskacova, J (reprint author), Univ Hosp Motol, Dept Pediat, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","pleskac.jana@seznam.cz",null,null,"ESPE; NovoNordisk A/S; Ministry of Health, Czech Republic [00064203]","This work was supported by the ESPE Research Fellowship granted by NovoNordisk A/S (J.K.-P.) and by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic) (M.S., J.L.).",null,23,0,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","1661-5425","1661-5433",null,"SEX DEV","Sex. Dev.",null,2013,7,6,null,null,null,null,282,288,null,"10.1159/000356173",null,7,"Developmental Biology","Developmental Biology","269SE","WOS:000328261400002"]
[null,null,null,null,"J","Prausova, J; Kubackova, K; Dusek, L; Vinakurau, S; Pikus, T; Malinova, B; Hoch, J; Kodet, R; Linke, Z",null,null,null,"Prausova, J.; Kubackova, K.; Dusek, L.; Vinakurau, S.; Pikus, T.; Malinova, B.; Hoch, J.; Kodet, R.; Linke, Z.",null,null,"Influence of neoadjuvant treatment of rectal carcinoma on operability and incidence of distant metastases","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"rectal carcinoma; neoadjuvant treatment; chemo-radiotherapy before surgery; angioinvasion","TOTAL MESORECTAL EXCISION; PREOPERATIVE RADIOTHERAPY; LOCAL-CONTROL; CANCER; CHEMORADIOTHERAPY; CHEMOTHERAPY; TRIAL; FLUOROURACIL; SURVIVAL; BENEFIT","In the Czech Republic, rectal carcinoma does not only represent a medical problem, but also a socioeconomic one. At our department, we treated totally 266 patients with rectal carcinoma in the years 1998 through 2006. Among our patients, neoadjuvant treatment led to a reduction in size of the tumour in 37.6 %, in 50.8 % the size did not change. In T3 tumours, the reduction in size was observed in 36.7 % of the patients and did not change in 56 %; in T4 tumours, the reduction in size was observed in 60% of the patients. In 88 % of the patients who underwent the operation, no residual tumour was found, in 9 % of patients, a residual tumour was detected. In 19 % of the patients, a local recurrence of the tumour was detected. A statistically significant relationship was proved between the appearance of the metastatic disease and the presence of angioinvasion and the size of the primary tumour according to the Duke's classification (Tab. 1, Fig. 4, Ref. 20). Full Text in PDF www.elis.sk.","[Prausova, J.; Kubackova, K.; Vinakurau, S.; Pikus, T.; Malinova, B.; Linke, Z.] Univ Hosp Motol, Dept Radiotherapy & Oncol, CZ-15006 Prague, Czech Republic; [Dusek, L.] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic; [Hoch, J.] Univ Hosp Motol, Dept Surg, CZ-15006 Prague, Czech Republic; [Kodet, R.] Univ Hosp Motol, Dept Pathol & Mol Med, CZ-15006 Prague, Czech Republic","Kubackova, K (reprint author), Univ Hosp Motol, Dept Radiotherapy & Oncol, V Uvalu 84, CZ-15006 Prague, Czech Republic.","katerina.kubackova@fnmotol.cz",null,null,null,null,null,19,0,0,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248","1336-0345",null,"BRATISL MED J","Bratisl. Med. J.",null,2013,114,8,null,null,null,null,469,473,null,"10.4149/BLL_2013_098",null,5,"Medicine, General & Internal","General & Internal Medicine","297QL","WOS:000330269900009"]
[null,null,null,null,"J","Raudenska, J; Javurkova, A; Kozak, J",null,null,null,"Raudenska, Jaroslava; Javurkova, Alena; Kozak, Jiri",null,null,"Fear of pain and movement in a patient with musculoskeletal chronic pain","NEUROENDOCRINOLOGY LETTERS",null,null,"English","Article",null,null,null,null,null,"chronic pain; fear associated with pain; cognitive-behavioural therapy","LOW-BACK-PAIN; AVOIDANCE BELIEFS; DISABILITY; MODEL; STATE","Pain-related fear may pose a serious barrier in the management of patients with chronic musculoskeletal pain, resulting in severe functional impairment in many cases. The paper describes the cognitive-behavioural therapy of a patient with a specific phobia (fear of pain and movement). The principal objective of the therapy was to educate the patient in strategies and skills to manage his fear and to verify the effect of the therapy. Both group and individual therapy was used. Group multimodal therapy of pain was provided by an interdisciplinary team of health care providers, specialising in pain management (psychotherapist, doctors and physiotherapists). The programme was based on operant therapy principles and included pacing and graded exercising and walking, relaxation, group education about ergonomics, and fear and pain relapse prevention. Reduction in the fear of pain and movement was achieved, and social bonds and physical and social activities improved after the psychotherapy, while the results were stable for two years.","[Raudenska, Jaroslava] Charles Univ Prague, Fac Med 2, Dept Clin Psychol, Prague 15006 5, Czech Republic; [Raudenska, Jaroslava] Motol Univ Hosp, Prague, Czech Republic; [Javurkova, Alena] Kralovske Vinohrady Univ Hosp, Dept Clin Psychol, Prague, Czech Republic; [Kozak, Jiri] Charles Univ Prague, Fac Med 2, Prague 15006 5, Czech Republic; [Kozak, Jiri] Motol Univ Hosp, Ctr Treatment & Res Painful Condit, Dept Rehabil & Sports Med, Prague, Czech Republic","Raudenska, J (reprint author), Charles Univ Prague, Motol Med Sch 2, Dept Clin Psychol, V Uvalu 84, Prague 15006 5, Czech Republic.","jaroslava.raudenska@fnmotol.cz",null,null,"Ministry of Health, Czech Republic - conceptual development of research organization, Motol University Hospital, Prague, Czech Republic [00064203]","This study was supported by Ministry of Health, Czech Republic - conceptual development of research organization, Motol University Hospital, Prague, Czech Republic 00064203. The authors would like to express their sincere gratitude towards dr. H. Laing for helping out with the language revision.",null,14,0,0,"MAGHIRA & MAAS PUBLICATIONS","STOCKHOLM","PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN","0172-780X",null,null,"NEUROENDOCRINOL LETT","Neuroendocrinol. Lett.",null,2013,34,6,null,null,null,null,514,517,null,null,null,4,"Endocrinology & Metabolism; Neurosciences","Endocrinology & Metabolism; Neurosciences & Neurology","AA2BN","WOS:000330900200008"]
[null,null,null,null,"J","Vcelakova, J; Blatny, R; Halbhuber, Z; Kolar, M; Neuwirth, A; Petruzelkova, L; Ulmannova, T; Kolouskova, S; Sumnik, Z; Pithova, P; Krivjanska, M; Filipp, D; Stechova, K",null,null,null,"Vcelakova, Jana; Blatny, Radek; Halbhuber, Zbynek; Kolar, Michal; Neuwirth, Ales; Petruzelkova, Lenka; Ulmannova, Tereza; Kolouskova, Stanislava; Sumnik, Zdenek; Pithova, Pavlina; Krivjanska, Maria; Filipp, Dominik; Stechova, Katerina",null,null,"The Effect of Diabetes-Associated Autoantigens on Cell Processes in Human PBMCs and Their Relevance to Autoimmune Diabetes Development","JOURNAL OF DIABETES RESEARCH",null,null,"English","Article",null,null,null,null,null,null,"GROWTH-FACTOR-BETA; BLOOD MONONUCLEAR-CELLS; TH17 CELLS; T-CELLS; GENE-EXPRESSION; MICROARRAY ANALYSIS; TGF-BETA; TYPE-1; DIFFERENTIATION; PATHOGENESIS","Type 1 Diabetes (T1D) is considered to be a T-helper- (Th-) 1 autoimmune disease; however, T1D pathogenesis likely involves many factors, and sufficient tools for autoreactive T cell detection for the study of this disease are currently lacking. In this study, using gene expression microarrays, we analysed the effect of diabetes-associated autoantigens on peripheral blood mononuclear cells (PBMCs) with the purpose of identifying (pre) diabetes-associated cell processes. Twelve patients with recent onset T1D, 18 first-degree relatives of the TD1 patients (DRL; 9/18 autoantibody positive), and 13 healthy controls (DV) were tested. PBMCs from these individuals were stimulated with a cocktail of diabetes-associated autoantigens (proinsulin, IA-2, and GAD65-derived peptides). After 72 hours, gene expression was evaluated by high-density gene microarray. The greatest number of functional differences was observed between relatives and controls (69 pathways), from which 15% of the pathways belonged to \"immune response-related\" processes. In the T1D versus controls comparison, more pathways (24%) were classified as \"immune response-related.\" Important pathways that were identified using data from the T1D versus controls comparison were pathways involving antigen presentation by MHCII, the activation of Th17 and Th22 responses, and cytoskeleton rearrangement-related processes. Genes involved in Th17 and TGF-beta cascades may represent novel, promising (pre) diabetes biomarkers.","[Vcelakova, Jana; Petruzelkova, Lenka; Ulmannova, Tereza; Kolouskova, Stanislava; Sumnik, Zdenek; Stechova, Katerina] Charles Univ Prague, Dept Paediat, Fac Med 2, Prague 15006, Czech Republic; [Vcelakova, Jana; Blatny, Radek; Halbhuber, Zbynek; Petruzelkova, Lenka; Ulmannova, Tereza; Kolouskova, Stanislava; Sumnik, Zdenek; Krivjanska, Maria; Stechova, Katerina] Univ Hosp Motol, Prague 15006, Czech Republic; [Blatny, Radek; Halbhuber, Zbynek; Krivjanska, Maria] Cent European Biosyst, Vestec 25242, Czech Republic; [Kolar, Michal] Inst Mol Genet AS CR, Lab Genom & Bioinformat, Prague, Czech Republic; [Neuwirth, Ales; Filipp, Dominik] Acad Sci Czech Republic, Inst Mol Genet, Dept Immunobiol, CR-14220 Prague, Czech Republic; [Pithova, Pavlina] Charles Univ Prague, Dept Internal Med, Fac Med 2, Prague 15006, Czech Republic","Vcelakova, J (reprint author), Charles Univ Prague, Dept Paediat, Fac Med 2, Uvalu 84, Prague 15006, Czech Republic.","jana.vcelakova@fnmotol.cz","Kolar, Michal/A-3307-2012","Kolar, Michal/0000-0002-4593-1525","Czech Ministry of Education [NPVII 2B06019]; Academy of Sciences of the Czech Republic [RVO: 68378050]; Ministry of Health of the Czech Republic [00064203]; Department of Paediatrics, 2nd Faculty of Medicine, Prague, Czech Republic [IPL 699 001]","This work was supported by project NPVII 2B06019 from the Czech Ministry of Education and partially by Grant RVO: 68378050 from the Academy of Sciences of the Czech Republic, as well as by the Ministry of Health of the Czech Republic through the conceptual development of research organisation 00064203 (University Hospital Motol, Prague, Czech Republic) and by IPL 699 001 (Department of Paediatrics, 2nd Faculty of Medicine, Prague, Czech Republic). The authors also like to acknowledge Miluse Hubackova, Vendula Stavikova, and Barbora Obermannova for the sampling of study subjects and samples processing.",null,38,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6745",null,null,"J DIABETES RES","J. Diabetes Res.",null,2013,null,null,null,null,null,null,null,null,589451,"10.1155/2013/589451",null,10,"Endocrinology & Metabolism; Medicine, Research & Experimental","Endocrinology & Metabolism; Research & Experimental Medicine","169XL","WOS:000320814000001"]
[null,null,null,null,"J","Kadlecova, A; Vyhnalek, M; Laczo, J; Andel, R; Sheardova, K; Urbanova, B; Nedelska, Z; Hudecek, D; Gazova, I; Lisy, J; Horinek, D; Hort, J",null,null,null,"Kadlecova, A.; Vyhnalek, M.; Laczo, J.; Andel, R.; Sheardova, K.; Urbanova, B.; Nedelska, Z.; Hudecek, D.; Gazova, I.; Lisy, J.; Horinek, D.; Hort, J.",null,null,"Inter-rater Variability in Assessing Hippocampal Atrophy Using Scheltens Scales","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"atrophy; hippocampus; visual scale; dementia; Alzheimer disease","MILD COGNITIVE IMPAIRMENT; TEMPORAL-LOBE ATROPHY; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; VISUAL ASSESSMENT; DIAGNOSIS; DEMENTIA; MRI; ASSOCIATION; GUIDELINES","Introduction: Recently, a great emphasis has been placed on early diagnosis of Alzheimer's disease (AD). The new diagnostic criteria for AD involve new methods such as detection of structural and metabolic changes in the brain. These include examination of hippocampal volume. Scheltens et al. introduced a visual rating scale for hippocampal atrophy assessment. Our aim was to determine inter-rater variability and to test practical application of this scale. Methods: MRI scans of 70 elderly persons with cognitive impairment and persons classified as cognitively normal were assessed by eight investigators. The investigators had a different degree of experience with Scheltens visual rating scale. Following a brief training, the investigators were asked to practice on 20 MRI brain scans in coronal plane. Correct scores were disclosed to all investigators. Subsequently, the investigators evaluated 70 study MRI scans. They were unaware of the participants' cognitive status. The variability was calculated for all investigators together and after dividing them into \"experienced\" (n = 4) and \"inexperienced\" (n = 4) group, where \"inexperienced\" refered to no previous knowledge of this visual rating scale. Results: Inter-rater agreement (kappa) was very high among all investigators for the right (K = 0.87) and left (K = 0.88) hippocampus. After dividing the raters into experienced and inexperienced, the inter-rater variability continued to be high in both groups for the right and left hippocampus. Conclusion: Scheltens visual rating scale is a simple and easy to use tool for hippocampal atrophy assessment even for inexperienced investigators. The final assessment variability was relatively low. We can recommend this visual rating scale for routine clinical use.","[Kadlecova, A.; Vyhnalek, M.; Laczo, J.; Urbanova, B.; Nedelska, Z.; Gazova, I.; Hort, J.] 2 LF UK & FN Motole, Neurol Klin, Kognit Ctr, Prague 15006, Czech Republic; [Kadlecova, A.; Vyhnalek, M.; Laczo, J.; Andel, R.; Nedelska, Z.; Hudecek, D.; Gazova, I.; Horinek, D.; Hort, J.] FN Sv Anny Brne, Mezinarodni Ctr Klin Vyzkumu, Brno, Czech Republic; [Andel, R.] Univ S Florida, Sch Aging Studies, Tampa, FL USA; [Sheardova, K.] FN Sv Anny Brne, Mezinarodni Ctr Klin Vyzkumu, Neurol Klin, Brno, Czech Republic; [Lisy, J.] 2 LF UK & FN Motole, Klin Zobrazovacich Metod, Prague, Czech Republic; [Horinek, D.] 1 LF UK & UVN Vojenska Fak Nemocnice Praha, Neurochirurg Klin, Prague, Czech Republic","Kadlecova, A (reprint author), 2 LF UK & FN Motole, Neurol Klin, Prague 15006, Czech Republic.","yooma@seznam.cz",null,null,null,null,null,24,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,5,null,null,null,null,603,607,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AB7QY","WOS:000331987000010"]
[null,null,null,null,"J","Kadlecova, A; Laczo, J; Vyhnalek, M; Sheardova, K; Horinek, D; Amlerova, J; Hudecek, D; Hort, J",null,null,null,"Kadlecova, A.; Laczo, J.; Vyhnalek, M.; Sheardova, K.; Horinek, D.; Amlerova, J.; Hudecek, D.; Hort, J.",null,null,"An Association between Depression and Emotion Recognition from the Facial Expression in Mild Cognitive Impairment","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"depression; facial expression; recognition of emotions; mild cognitive impairment; Alzheimer disease","ALZHEIMERS-DISEASE; DEMENTIA; SYMPTOMS; AMYGDALA; RISK; DEFICITS","Objective: Neuropsychiatric disorders are frequent in mild cognitive impairment (MCI) as indicated by cross-sectional studies. Depression is the most frequent disorder in MCI patients and its presence increases the risk of conversion into Alzheimer's disease. Two systems are responsible for neuropsychiatric disorders: the limbic system and fronto-subcortical connections. The structures involved in these systems are also responsible for emotion processing. Aim: The aim of the study was to establish whether MCI patients have a deficit in emotion recognition and whether they have more severe depression than a control group and to assess the relationship between severity of depression and the ability to recognize emotions from facial expression. Patients and methods: The study included 34 MCI patients and 23 controls. All subjects underwent routine neuropsychological testing (focused on memory, attention and speed of processing, executive, visuospatial and language functions). Emotional agnosia was examined by Facial Emotion Recognition Test and depression was assessed by geriatric depression scale. Results: MCI group performed worse than controls on recognition of facial emotions (p < 0.05), and this group was also significantly more depressive than controls (p < 0.05). No significant correlation was found between severity of depression and total emotion recognition (r = 0.15, p = 0.28). Severity of depression correlated with inability to recognize happiness (p < 0.05, r = 0.32). Conclusion: The ability to recognize emotions from facial expression is impaired in MCI patients and severity of depression contributes to inability of MCI patients to recognize happiness.","[Kadlecova, A.; Laczo, J.; Vyhnalek, M.; Amlerova, J.; Hort, J.] 2 LF UK, Kognitivni Centrum, Prague 15006 5, Czech Republic; [Kadlecova, A.; Laczo, J.; Vyhnalek, M.; Amlerova, J.; Hort, J.] FN Motole, Prague 15006 5, Czech Republic; [Kadlecova, A.; Laczo, J.; Vyhnalek, M.; Horinek, D.; Hudecek, D.; Hort, J.] FN Sv Anny, ICRC, Brno, Czech Republic; [Sheardova, K.] LF MU, Neurol Klin 1, Brno, Czech Republic; [Sheardova, K.] FN Sv Anny, ICRC, Brno, Czech Republic; [Horinek, D.] UVN Praha, Prague, Czech Republic","Kadlecova, A (reprint author), 2 LF UK, Neurol Klin Dospelych, V Uvalu 84, Prague 15006 5, Czech Republic.","yooma@seznam.cz",null,null,null,null,null,33,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,1,null,null,null,null,52,55,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","084QF","WOS:000314553500006"]
[null,null,null,null,"J","Petrak, B; Gabera, A; Filipova, H; Tomek, V; Puchmajerova, A; Mrazkova, L; Jahodova, A; Malikova, M; Cerny, M; Vrtel, R",null,null,null,"Petrak, B.; Gabera, A.; Filipova, H.; Tomek, V.; Puchmajerova, A.; Mrazkova, L.; Jahodova, A.; Malikova, M.; Cerny, M.; Vrtel, R.",null,null,"Tuberous Sclerosis Complex in Children Followed from Neonatal Period for Prenatally Diagnosed Cardiac Rhabdomyoma Two Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"tuberous sclerosis complex type 1, 2; cardiac rhabdomyoma; epilepsy; magnetic resonance imaging",null,"Tuberous Sclerosis Complex (TSC) is an autosomal dominant neurocutaneous disorder with incidence of 1: 6,000 and frequently occurring sporadic mutations in either TSC1 gene (type 1) or in TSC2 gene (type 2). Clinical manifestation is very variable with frequent formation of hamartomas and benign tumours. TSC is a multi-system disorder characterized by defined diagnostic criteria 11 major symptoms and nine minor ones. Benign cardiac tumour rhabdomyoma is one of the major symptoms and may be detected during prenatal period. We present two cases of children monitored from prenatal period for multiple cardiac rhabdomyomas and suspicious TSC diagnosis. TSC was diagnosed in both children based on clinical picture and later confirmed by DNA analysis. Both presented cases confirm the importance of follow-up by a paediatric neurologist of newborns with prenatally diagnosed cardiac rhabdomyoma so that early TSC diagnosis can be made and neurological complications, including epilepsy, monitored and treated in a timely manner.","[Petrak, B.; Jahodova, A.] LF UK & FN Motole, Klin Detske Neurol 2, Prague 15000, Czech Republic; [Gabera, A.] Krajska Zdravotni As, Masarykova Nemocnice, Detska Klin, Usti Nad Labem, Czech Republic; [Tomek, V.] LF UK & FN Motole, Detske Kardioctr 2, Prague 15000, Czech Republic; [Puchmajerova, A.; Malikova, M.] LF UK & FN Motole, Ustav Biol & Lekarske Genetiky 2, Prague 15000, Czech Republic; [Mrazkova, L.] LF UK & FN Motole, Klin Zobrazovacich Metod 2, Prague 15000, Czech Republic; [Cerny, M.] LF UK & FN Motole, Novorozenecke Odd S JIRP, Gynekologickoporodnicka Klin 2, Prague 15000, Czech Republic","Petrak, B (reprint author), LF UK & FN Motole, Klin Detske Neurol 2, V Uvalu 84, Prague 15000, Czech Republic.","borivoj.petrak@post.cz",null,null,null,null,"Bader RS, 2003, J PEDIATR, V143, P620, DOI 10.1067/S0022-3476(03)00494-3; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9; de Vries PJ, 2010, NEUROTHERAPEUTICS, V7, P275, DOI 10.1016/j.nurt.2010.05.001; Jozwiak S, 2011, EUR J PAEDIATR NEURO, V15, P424, DOI 10.1016/j.ejpn.2011.03.010; Jozwiak S, 2006, PEDIATRICS, V118, pE1146, DOI 10.1542/peds.2006-0504; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125, DOI 10.1111/j.1749-6632.1991.tb37754.x; Petrak B, 2012, CESKO SLOVENSKA PEDI, V67, P332; Roach ES, 1998, J CHILD NEUROL, V13, P624; Roach ES, 2004, J CHILD NEUROL, V19, P643",10,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,6,null,null,null,null,763,768,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","260GD","WOS:000327582100017"]
[null,null,null,null,"J","Darsova, D; Pochop, P; Korolova, M; Barakova, D; Dotrelova, D",null,null,null,"Darsova, D.; Pochop, P.; Korolova, M.; Barakova, D.; Dotrelova, D.",null,null,"Lyme Borreliosis as a Cause of Bilateral Neuroretinitis with Pronounced Unilateral Stellate Maculopathy in a 8-Year Old Girl","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"optic disc oedema; Lyme borreliosis; neuroborreliosis; neuroretinitis; maculopathy","NEUROBORRELIOSIS; DISEASE","Neuroretinitis is a less-known clinical entity presenting with inflammatory disc oedema and stellate maculopathy. It can be confused with papillitis, papilloedema, retinal periphlebitis in sarcoidosis, hypertensive retinopathy as well as with retinal vein occlusion or anterior ischemic optic neuropathy. It is most often associated with viral infections and cat-scratch fever, less common with syphilis and Lyme disease. The authors describe the clinical course of neuroretinitis in a 8-year-old girl who was referred to eye clinic with acute painless reduced corrected visual acuity (6/36) in the right eye. Ophthalmic examination revealed stellate maculopathy of the right eye and bilateral neuritis and periphlebitis, imitating sarcoidosis. Nevertheless, sarcoidosis was excluded by biochemical blood examination and lung imaging studies. It was not before detailed biochemical, cytological, immunological, viral and bacterial examination of cerebrospinal fluid were obtained that the diagnosis of Lyme neurro-boreliosis was confirmed. Knowledge of the typical ocular fundus picture in Lyme disease is essential for differential diagnosis of neuroretinitis. Our case report is a typical example of mutual collaboration between an ophthalmologist and neurologist that is essential for prompt clinical diagnosis and early referral for appropriate therapy.","[Darsova, D.; Pochop, P.; Korolova, M.; Barakova, D.; Dotrelova, D.] LF UK & FN Motole, Ocni Klin Deti & Dospelych 2, Prague 15006 5, Czech Republic","Darsova, D (reprint author), LF UK & FN Motole, Ocni Klin Deti & Dospelych 2, V Uvalu 84, Prague 15006 5, Czech Republic.","denisa.darsova@centrum.cz",null,null,null,null,"Blanc F, 2007, NEUROLOGY, V69, P953, DOI 10.1212/01.wnl.0000269672.17807.e0; Darsova D, 2011, CESK SLOV NEUROL N, V74, P197; Diblik P, 2006, LYMESKA BORELIOZA, P80; Gascon-Bayarri J, 2011, EUR J INTERN MED, V22, pE125, DOI 10.1016/j.ejim.2011.08.019; Kolek V, 2007, INTERNAL MED, V9, P310; Kosina P, 2009, CES SLOV PEDIAT, V64, P230; Kriz B, 2011, LYMESKA BORRELIOZA E; Lochhead J, 2001, EYE, V15, P799; Mikkila HO, 2000, OPHTHALMOLOGY, V107, P581, DOI 10.1016/S0161-6420(99)00128-1; BECH RW, 1991, ARCH OPHTHALMOL-CHIC, V109, P1673; Ray S, 2001, INT OPHTHALMOL CLIN, V41, P83, DOI 10.1097/00004397-200101000-00009; Rupprecht TA, 2008, MOL MED, V14, P205, DOI 10.2119/2007-00091.Rupprecht; Sauer A, 2009, CLIN INFECT DIS, V48, P756, DOI 10.1086/597041; Stanek G, 2009, CURR OPIN INFECT DIS, V22, P450, DOI 10.1097/QCO.0b013e32832ee880; Williams KE, 2004, OPHTHALMOLOGY, V111, P335, DOI 10.1016/S0161-6420(03)00663-8",15,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,2,null,null,null,null,229,234,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","120IG","WOS:000317163400017"]
[null,null,null,null,"J","Lassuthova, P; Sebron, V; Zamecnik, J; Haberlova, J; Baxova, A; Seeman, P",null,null,null,"Lassuthova, P.; Sebron, V.; Zamecnik, J.; Haberlova, J.; Baxova, A.; Seeman, P.",null,null,"X-linked Myotubular Myopathy: a Novel Mutation in the MTM-1 Gene - Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"MTM1 gene; myotubular myopathy; frameshift mutation","CENTRONUCLEAR MYOPATHIES","Mutations in the MTM1 gene cause X-linked myotubular myopathy (XLMTM). This is a serious, often lethal, condition. We report a family with two affected children - dizygotic twins. Boys were born in the 28th gestational week. Severe hypotonia and muscle weakness were present at birth and necessitated ventilatory support. Intensive care was terminated 26 and 35 days after birth, respectively, due to cardiac and renal failure. Hypotrophic muscle fibers, fetal myotubes and centrally located nuclei were present in muscle sections. All the available information led us to the diagnosis of XLMTM. The MTM1 gene was sequenced and a novel mutation c.82delA in exon 3 was identified. The mother of the patients is a heterozygous carrier of the mutation. This might well be the first report of genetically confirmed XLMTM in the Czech Republic. DNA test is now available and prenatal or preimplantation diagnosis might be offered to the family.","[Lassuthova, P.; Haberlova, J.; Seeman, P.] LF UK & FN Motole, Klin Detske Neurol 2, DNA Lab, Prague 15006 5, Czech Republic; [Sebron, V.] LF UK & VFN, Novorozenecke Oddeleni, Gynekol Porodnicke Klin 1, Prague, Czech Republic; [Zamecnik, J.] LF UK & FN Motole, Ustav Patol & Mol Med 2, Prague 15006 5, Czech Republic; [Baxova, A.] LF UK & VFN, Ustav Biol & Lekarske Genet 1, Prague, Czech Republic","Lassuthova, P (reprint author), LF UK & FN Motole, Klin Detske Neurol 2, DNA Lab, V Uvalu 84, Prague 15006 5, Czech Republic.","petra.lassuthova@gmail.com",null,null,null,null,"Bijarnia S, 2010, INDIAN J PEDIATR, V77, P431, DOI 10.1007/s12098-010-0057-6; McEntagart M, 2002, NEUROMUSCULAR DISORD, V12, P939, DOI 10.1016/S0960-8966(02)00153-0; Romero NB, 2011, SEMIN PEDIATR NEUROL, V18, P250, DOI 10.1016/j.spen.2011.10.006; Romero NB, 2010, NEUROMUSCULAR DISORD, V20, P223, DOI 10.1016/j.nmd.2010.01.014; Tachi N, 2001, PEDIATR NEUROL, V24, P297, DOI 10.1016/S0887-8994(01)00244-2; Tanner SM, 1999, NEUROMUSCULAR DISORD, V9, P41, DOI 10.1016/S0960-8966(98)00090-X; Tosch V, 2010, NEUROMUSCULAR DISORD, V20, P375, DOI 10.1016/j.nmd.2010.03.015",7,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,2,null,null,null,null,241,245,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","120IG","WOS:000317163400019"]
[null,null,null,null,"J","Amlerova, J; Laczo, J; Vlcek, K; Javurkova, A; Andel, R; Marusic, P",null,null,null,"Amlerova, Jana; Laczo, Jan; Vlcek, Kamil; Javurkova, Alena; Andel, Ross; Marusic, Petr",null,null,"Risk factors for spatial memory impairment in patients with temporal lobe epilepsy","EPILEPSY & BEHAVIOR",null,null,"English","Article",null,null,null,null,null,"Spatial navigation; Spatial memory; Temporal lobe epilepsy; Epilepsy onset; Epilepsy duration; Intelligence level","MILD COGNITIVE IMPAIRMENT; VIRTUAL-REALITY; NAVIGATION; LESIONS; HIPPOCAMPUS; HUMANS; TASK; RESECTIONS; LOBECTOMY; DEFICITS","At present, the risk factors for world-centered (allocentric) navigation impairment in patients with temporal lobe epilepsy (TLE) are not known. There is some evidence on the importance of the right hippocampus but other clinical features have not been investigated yet. In this study, we used an experimental human equivalent to the Morris water maze to examine spatial navigation performance in patients with drug-refractory unilateral TLE. We included 47 left-hemisphere speech dominant patients (25 right sided; 22 left sided). The aim of our study was to identify clinical and demographic characteristics of TLE patients who performed poorly in allocentric spatial memory tests. Our results demonstrate that poor spatial navigation is significantly associated with younger age at epilepsy onset, longer disease duration, and lower intelligence level. Allocentric navigation in TLE patients was impaired irrespective of epilepsy lateralization. Good and poor navigators did not differ in their age, gender, or preoperative/postoperative status. This study provides evidence on risk factors that increase the likelihood of allocentric navigation impairment in TLE patients. The results indicate that not only temporal lobe dysfunction itself but also low general cognitive abilities may contribute to the navigation impairment. (C) 2012 Elsevier Inc. All rights reserved.","[Amlerova, Jana; Laczo, Jan; Marusic, Petr] Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Motol, Czech Republic; [Laczo, Jan; Vlcek, Kamil; Andel, Ross] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Vlcek, Kamil] Acad Sci Czech Republ Vvi, Inst Physiol, Dept Neurophysiol Memory, Prague, Czech Republic; [Javurkova, Alena] Univ Hosp Motol, Dept Psychol, Prague, Czech Republic; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA","Marusic, P (reprint author), Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Motol, Czech Republic.","petr.marusic@fnmotol.cz","Vlcek, Kamil/B-9620-2012","Vlcek, Kamil/0000-0001-7152-3093","Grant Agency of the Czech Republic [309/09/1053]; Project FNUSA-ICRC from the European Regional Development Fund [CZ.1.05/1.1.00/02.0123];  [GAUK 200 084/999];  [AV0Z50110509]","This research was supported by the following grants: GAUK 200 084/999, grant No. 309/09/1053 from the Grant Agency of the Czech Republic, Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123) from the European Regional Development Fund and research project No. AV0Z50110509. The authors would like to thank Dr. D. Engova and Dr. P. Jiruska for their help and advice.",null,21,6,6,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1525-5050",null,null,"EPILEPSY BEHAV","Epilepsy Behav.","JAN",2013,26,1,null,null,null,null,57,60,null,"10.1016/j.yebeh.2012.10.025",null,4,"Behavioral Sciences; Clinical Neurology; Psychiatry","Behavioral Sciences; Neurosciences & Neurology; Psychiatry","070MN","WOS:000313511100010"]
[null,null,null,null,"J","Volejnikova, J; Mejstrikova, E; Dorge, P; Meissner, B; Zimmermannova, O; Svojgr, K; Stanulla, M; Cario, G; Schrappe, M; Stary, J; Hrusak, O; Trka, J; Fronkova, E",null,null,null,"Volejnikova, Jana; Mejstrikova, Ester; Doerge, Petra; Meissner, Barbara; Zimmermannova, Olga; Svojgr, Karel; Stanulla, Martin; Cario, Gunnar; Schrappe, Martin; Stary, Jan; Hrusak, Ondrej; Trka, Jan; Fronkova, Eva",null,null,"Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia","PEDIATRIC BLOOD & CANCER",null,null,"English","Article",null,null,null,null,null,"acute lymphoblastic leukemia (ALL); childhood; Ikaros; IKZF1; minimal residual disease (MRD)","EXPRESSION; GENE; CHILDREN; QUANTIFICATION; IDENTIFICATION; TRANSCRIPTS; DELETION; ISOFORM; REVEALS; RELAPSE","Background Recently, several studies have demonstrated a negative prognostic impact of Ikaros (IKZF1) gene alterations in acute lymphoblastic leukemia (ALL). However, controversies still exist regarding the impact of IKZF1 in current treatment protocols. Procedure We simultaneously detected IKZF1 gene deletions by multiplex ligation-dependent probe amplification and gene expression of IKZF1 isoforms in 206 children with BCR/ABL-negative ALL treated with ALL IC-BFM 2002 protocol, in which risk stratification was not based on minimal residual disease (MRD), and validated the results on a cohort of 189 patients treated with MRD-directed ALL-BFM 2000 protocol. Results Deletion of IKZF1 was present in 14 of 206 (7%) ALL IC patients. Interestingly, gene expression did not completely correlate with the deletion status in either cohort. Deletions were not always reflected in the gene expression of dominant-negative isoforms, and conversely, 7 of 395 (2%) non-deleted cases overexpressed dominant-negative isoform Ik6. IKZF1 deletions significantly affected event-free survival (EFS) of the ALL IC cohort (41 +/- 14% vs. 86 +/- 3%, P < 0.0001). Regarding IKZF1 isoforms, only Ik6 overexpression had negative prognostic impact (EFS 50 +/- 16% vs. 85 +/- 3%, P = 0.003). In multivariate analysis, which included ALL IC risk criteria, flow-cytometric MRD and IKZF1 alterations, day 15 MRD and IKZF1 deletion status displayed an independent prognostic impact. Conclusions We show that MRD-directed treatment diminishes prognostic impact of IKZF1 alterations. However, IKZF1 status alone or combined with day 15 flow cytometry can significantly improve risk stratification within BFM protocols at centers that do not perform antigen-receptor-based MRD monitoring. Pediatr Blood Cancer 2013; 60: 420-427. (C) 2012 Wiley Periodicals, Inc.","[Volejnikova, Jana; Mejstrikova, Ester; Zimmermannova, Olga; Svojgr, Karel; Stary, Jan; Hrusak, Ondrej; Trka, Jan; Fronkova, Eva] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Prague 15006, Czech Republic; [Volejnikova, Jana; Mejstrikova, Ester; Zimmermannova, Olga; Svojgr, Karel; Stary, Jan; Hrusak, Ondrej; Trka, Jan; Fronkova, Eva] Univ Hosp Motol, Prague, Czech Republic; [Doerge, Petra; Meissner, Barbara; Stanulla, Martin; Cario, Gunnar; Schrappe, Martin] Univ Med Ctr Schleswig Holstein, Dept Pediat, Kiel, Germany","Fronkova, E (reprint author), Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, V Uvalu 84, Prague 15006, Czech Republic.","eva.fronkova@lfmotol.cuni.cz",null,null,"Czech Ministry of Health [NT 12397-4]; German Federal Ministry of Education and Research (BMBF) [01GS0442]; Deutsche Krebshilfe; Madeleine Schickedanz Kinderkrebs-Stiftung; Charles University Prague [GAUK 363011]; GACR Centre of Excellence [P302/12/G101]","Grant sponsor: Czech Ministry of Health; Grant number: NT 12397-4; Grant sponsor: German Federal Ministry of Education and Research (BMBF; NGFN project number 01GS0442); Grant sponsor: Deutsche Krebshilfe; Grant sponsor: Madeleine Schickedanz Kinderkrebs-Stiftung; Grant sponsor: Charles University Prague; Grant number: GAUK 363011; Grant sponsor: GACR Centre of Excellence; Grant number: P302/12/G101.",null,32,3,3,"WILEY PERIODICALS, INC","SAN FRANCISCO","ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA","1545-5009",null,null,"PEDIATR BLOOD CANCER","Pediatr. Blood Cancer","MAR",2013,60,3,null,null,null,null,420,427,null,"10.1002/pbc.24299",null,8,"Oncology; Hematology; Pediatrics","Oncology; Hematology; Pediatrics","073ET","WOS:000313727000013"]
[null,null,null,null,"J","Hubacek, P; Hrdlickova, A; Spacek, M; Zajac, M; Muzikova, K; Sedlacek, P; Cetkovsky, P",null,null,null,"Hubacek, Petr; Hrdlickova, Alena; Spacek, Martin; Zajac, Miroslav; Muzikova, Katerina; Sedlacek, Petr; Cetkovsky, Petr",null,null,"Prevalence of chromosomally integrated HHV-6 in patients with malignant disease and healthy donors in the Czech Republic","FOLIA MICROBIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"INFECTION; VARIANT",null,"[Hubacek, Petr; Hrdlickova, Alena; Muzikova, Katerina; Sedlacek, Petr] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Hubacek, Petr; Zajac, Miroslav] Motol Univ Hosp, Dept Med Microbiol, CZ-15006 Prague 5, Czech Republic; [Spacek, Martin] Charles Univ Prague, Dept Clin Haematol, Fac Med 3, CZ-15006 Prague 5, Czech Republic; [Spacek, Martin] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Cetkovsky, Petr] Inst Hematol & Blood Transfus, Prague, Czech Republic","Hubacek, P (reprint author), Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, V Uvalu 84, CZ-15006 Prague 5, Czech Republic.","petr.hubacek@lfmotol.cuni.cz",null,null,"Ministry of Health of the Czech Republic [NS-9907]","The work is supported by grant of Ministry of Health of the Czech Republic NS-9907.",null,11,1,1,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632","1874-9356",null,"FOLIA MICROBIOL","Folia Microbiol.","JAN",2013,58,1,null,null,null,null,87,90,null,"10.1007/s12223-012-0180-z",null,4,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","056NJ","WOS:000312496800014"]
[null,null,null,null,"J","Sliva, J; Hess, L; Votava, M; Malek, J",null,null,null,"Sliva, Jiri; Hess, Ladislav; Votava, Martin; Malek, Jiri",null,null,"Endogenous ligands of benzodiazepine binding site have inverse agonistic properties","MEDICAL HYPOTHESES",null,null,"English","Article",null,null,null,null,null,null,"PANIC DISORDER; FLUMAZENIL; RECEPTOR; ANTAGONIST","Benzodiazepines have been widely used in clinical praxis for many decades. They act as GABA(A) receptor agonists and possess muscle-relaxant, hypnotic-sedative, anticonvulsant, and anxiolytic properties. Flumazenil acts as a benzodiazepine receptor antagonist (subunits alpha(1), alpha(2), alpha(3), and alpha(5)) or partial agonist (subunits alpha(4) and alpha(6)). It competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepines. In our experiments, administration of flumazenil in rabbits was surprisingly associated with anxiolytic effects similar to those of midazolam. Additionally, flumazenil significantly and dose-dependently decreased the total number of vocalizations in rats, i.e. it was anxiolytic. These observations seem to be in contrast to the effect of flumazenil in humans, where it is believed to produce mainly anxiogenic effects. It seems that in individuals, who exhibit anxiogenic behavior or in individuals with anticipation anxiety, flumazenil acts as an anxiolytic agent, while in individuals without any signs of anxiety, flumazenil can also act as anxiogenic agent. Thus, we hypothesize that flumazenil is associated with decreased intensity of anticipatory anxiety due to occupancy of benzodiazepine binding sites by an endogenous ligand with inverse agonistic properties. (C) 2013 Elsevier Ltd. All rights reserved.","[Sliva, Jiri; Votava, Martin] Charles Univ Prague, Dept Pharmacol, Fac Med 2, Prague 15006 5, Czech Republic; [Sliva, Jiri] Charles Univ Prague, Dept Pharmacol, Fac Med 3, Prague 10034 10, Czech Republic; [Hess, Ladislav] Inst Clin & Expt Med, Lab Expt Anaesthesiol, Prague, Czech Republic; [Malek, Jiri] Charles Univ Prague, Dept Anaesthesiol & Crit Care Med, Fac Med 3, Prague 10034 10, Czech Republic","Sliva, J (reprint author), Charles Univ Prague, Dept Pharmacol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","jiri.sliva@lfmotol.cuni.cz",null,null,"Czech Ministry of Health [IGA MZ NS/10503-3]","This work was supported by grant IGA MZ NS/10503-3 from the Czech Ministry of Health.",null,16,0,0,"CHURCHILL LIVINGSTONE","EDINBURGH","JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND","0306-9877","1532-2777",null,"MED HYPOTHESES","Med. Hypotheses","DEC",2013,81,6,null,null,null,null,1075,1077,null,"10.1016/j.mehy.2013.10.006",null,3,"Medicine, Research & Experimental","Research & Experimental Medicine","284QJ","WOS:000329334800025"]
[null,null,null,null,"J","Vanecek, V; Klima, K; Kohout, A; Foltan, R; Jirousek, O; Sedy, J; Stulik, J; Sykova, E; Jendelova, P",null,null,null,"Vanecek, Vaclav; Klima, Karel; Kohout, Ales; Foltan, Rene; Jirousek, Ondrej; Sedy, Jiri; Stulik, Jan; Sykova, Eva; Jendelova, Pavla",null,null,"The combination of mesenchymal stem cells and a bone scaffold in the treatment of vertebral body defects","EUROPEAN SPINE JOURNAL",null,null,"English","Article",null,null,null,null,null,"Vertebral body defect; Mesenchymal stem cells; Hydroxyapatite scaffold; Rat model","SPINAL-CORD-INJURY; STROMAL CELLS; MODEL; RAT; REPAIR; BETA; REGENERATION; RADIOGRAPHY; LYMPHOCYTES; SUBSTITUTE","Vertebral body defects represent one of the most common orthopedic challenges. In order to advance the transfer of stem cell therapies into orthopedic clinical practice, we performed this study to evaluate the safety and efficacy of a composite bioartificial graft based on a hydroxyapatite bone scaffold (CEM-OSTETICA (R)) combined with human mesenchymal stem cells (MSCs) in a rat model of vertebral body defects. Under general isoflurane anesthesia, a defect in the body of the L-2 vertebra was prepared and left to heal spontaneously (group 1), implanted with scaffold material alone (group 2), or implanted with a scaffold together with 0.5 million MSCs (group 3) or 5 million MSCs (group 4). The rats were killed 8 weeks after surgery. Histological and histomorphometrical evaluation of the implant as well as micro-CT imaging of the vertebrae were performed. We observed a significant effect on the formation of new bone tissue in the defect in group 4 when compared to the other groups and a reduced inflammatory reaction in both groups receiving a scaffold and MSCs. We did not detect any substantial pathological changes or tumor formation after graft implantation. MSCs in combination with a hydroxyapatite scaffold improved the repair of a model bone defect and might represent a safe and effective alternative in the treatment of vertebral bone defects.","[Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla] Acad Sci Czech Republic, Inst Expt Med, Prague 14220 4, Czech Republic; [Vanecek, Vaclav; Sykova, Eva; Jendelova, Pavla] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Klima, Karel; Foltan, Rene] Charles Univ Prague, Fac Med 1, Dept Oral & Maxillofacial Surg, Prague, Czech Republic; [Klima, Karel; Foltan, Rene] Gen Univ Hosp, Prague, Czech Republic; [Kohout, Ales] Charles Univ Prague, Fac Med, Fingerlands Dept Pathol, Hradec Kralove, Czech Republic; [Kohout, Ales] Teaching Hosp, Hradec Kralove, Czech Republic; [Jirousek, Ondrej] Acad Sci Czech Republic, Inst Theoret & Appl Mech, Prague 14220 4, Czech Republic; [Sedy, Jiri] Acad Sci Czech Republic, Inst Physiol, Prague 14220 4, Czech Republic; [Stulik, Jan] Univ Hosp Motol, Ctr Spinal Surg, Prague, Czech Republic","Jendelova, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.","jendel@biomed.cas.cz",null,null,"Grant Agency of the Czech Republic [GACR 304/10/0320, GACR304/12/0259]; Grant Agency of the Ministry of Health of the Czech Republic [NT13477]","This work was supported by the Grant Agency of the Czech Republic (GACR 304/10/0320, GACR304/12/0259), and Grant Agency of the Ministry of Health of the Czech Republic (NT13477). The authors thank James Dutt for his critical reading of the manuscript.",null,41,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0940-6719","1432-0932",null,"EUR SPINE J","Eur. Spine J.","DEC",2013,22,12,null,null,null,null,2777,2786,null,"10.1007/s00586-013-2991-2",null,10,"Clinical Neurology; Orthopedics","Neurosciences & Neurology; Orthopedics","264RV","WOS:000327899100014"]
[null,null,null,null,"J","Kruseova, J; Hynek, D; Adam, V; Kizek, R; Prusa, R; Hrabeta, J; Eckschlager, T",null,null,null,"Kruseova, Jarmila; Hynek, David; Adam, Vojtech; Kizek, Rene; Prusa, Richard; Hrabeta, Jan; Eckschlager, Tomas",null,null,"Serum Metallothioneins in Childhood Tumours-A Potential Prognostic Marker","INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES",null,null,"English","Article",null,null,null,null,null,"serum metallothioneins; children; solid tumours; treatment; differential pulse voltammetry Brdicka reaction","SQUAMOUS-CELL CARCINOMA; BRDICKA REACTION; ZINC HOMEOSTASIS; HEPATOCELLULAR-CARCINOMA; PROTECTIVE ROLE; BLOOD-SERUM; EXPRESSION; CANCER; CHEMORESISTANCE; OVEREXPRESSION","Metallothioneins (MT) are low molecular weight, cysteine-rich proteins maintaining metal ions homeostasis. They play a role in carcinogenesis and may also cause chemoresistance. The aim of the study was to explore the importance of MT serum levels in children suffering from malignant tumours. This prospective study involves examination of 865 samples from 172 patients with malignant tumours treated from 2008 to 2011 at University Hospital Motol. MT serum levels were determined using differential pulse voltammetry-Brdicka reaction. Mean MT level was 2.7 +/- 0.5 mu M. There was no statistically significant difference between MT levels in different tumours. We also did not find any correlation between MT levels and response to therapy or clinical stages. However, we found a positive correlation between MT levels and age (p = 0.009) and a negative correlation with absolute lymphocyte number (p = 0.001). The fact that patients who had early disease recurrence had lower MT levels during the treatment (complete remission 2.67 vs. recurring 2.34, p = 0.001) seems to be important for clinical practice. Accordingly we believe that there is benefit in further studies of serum MT levels in tumours.","[Kruseova, Jarmila; Hrabeta, Jan; Eckschlager, Tomas] 2nd Med Fac, Dept Paediat Haematol & Oncol, CZ-15006 Prague, Czech Republic; [Kruseova, Jarmila; Prusa, Richard; Hrabeta, Jan; Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague, Czech Republic; [Hynek, David; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Hynek, David; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Prusa, Richard] 2nd Med Fac, Dept Med Chem & Clin Biochem, CZ-15006 Prague, Czech Republic","Eckschlager, T (reprint author), 2nd Med Fac, Dept Paediat Haematol & Oncol, V Uvalu 84, CZ-15006 Prague, Czech Republic.","jarmila.kruseova@fnmotol.cz; d.hynek@email.cz; vojtech.adam@mendelu.cz; kizek@sci.muni.cz; richard.prusa@fnmotol.cz; janhrabeta@gmail.com; Tomas.Eckschlager@fnmotol.cz",null,null,"GACR [P301/10/0356]; project for conceptual development of research organization [00064203]; CEITEC [CZ.1.05/1.1.00/02.0068]","Financial support from GACR grant No P301/10/0356, the project for conceptual development of research organization 00064203 and CEITEC CZ.1.05/1.1.00/02.0068 is acknowledged.",null,75,0,0,"MDPI AG","BASEL","POSTFACH, CH-4005 BASEL, SWITZERLAND","1422-0067",null,null,"INT J MOL SCI","Int. J. Mol. Sci.","JUN",2013,14,6,null,null,null,null,12170,12185,null,"10.3390/ijms140612170",null,16,"Chemistry, Multidisciplinary","Chemistry","169IC","WOS:000320772500085"]
[null,null,null,null,"J","Mahdian, N; Dostalova, TJ; Danek, J; Nedoma, J; Kohout, J; Hubacek, M; Hlinakova, P",null,null,null,"Mahdian, Nima; Dostalova, Tat'jana; Danek, Josef; Nedoma, Jiri; Kohout, Josef; Hubacek, Milan; Hlinakova, Petra",null,null,"3D reconstruction of TMJ after resection of the cyst and the stress-strain analyses","COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE",null,null,"English","Article",null,null,null,null,null,"Maxillofacial surgery; Temporomandibular joint; Mathematical modeling; Contact problem; Linear elasticity; Finite element method","HUMAN JAW MUSCLES; PHYSIOLOGICAL CROSS-SECTION; MODEL","The aim of this article is 3D analysis of the temporomandibular joint (TMJ) patient, who underwent surgery, during which the right TMJ was resected along with the ramus of mandible and consequently the joint was reconstructed with subtotal replacement. The main goal is to give a suitable formulation of mathematical model, which describes the changes of stresses in TMJ incurred after the surgery The TMJ is a complex, sensitive and highly mobile joint which works bilaterally so each side influences the contralateral joint and because of this the distribution of the stresses is changed in the healthy joint as well. Detailed knowledge about function these are necessary for clinical application of temporomandibular joint prosthesis and also help us estimate the lifetime of the prosthesis a possibilities of alteration in the contra lateral joint components. The geometry for the 3D models is taken from the CT scan date and its numerical solution is based on the theory of semi-coercive unilateral contact problems in linear elasticity. This article provides medical part with case report, discretion of treatment, than the methods of mathematical modeling and his possibilities are described and finally results are reported. (C) 2012 Elsevier Ireland Ltd. All rights reserved.","[Mahdian, Nima; Dostalova, Tat'jana; Hubacek, Milan; Hlinakova, Petra] Charles Univ Prague, Dept Paediat Stomatol, Univ Hosp Motol, Med Fac 2, Prague 15006, Czech Republic; [Danek, Josef] Univ W Bohemia, Fac Sci Appl, NTIS, European Ctr Excellence, Plzen 30614, Czech Republic; [Danek, Josef] Acad Sci Czech Republic, Inst Comp Sci, Prague 18207, Czech Republic; [Kohout, Josef] Univ W Bohemia, Dept Comp Sci & Engn, Plzen 30614, Czech Republic","Danek, J (reprint author), Univ W Bohemia, Fac Sci Appl, NTIS, European Ctr Excellence, Univ 8, Plzen 30614, Czech Republic.","mandian@centrum.cz; Tatjana.Dostalova@fnmotol.cz; danek@kma.zcu.cz; nedoma@cs.cas.cz; besoft@kiv.zcu.cz; Milan.Hubacek@fnmotol.cz; 811@seznam.cz","Nedoma, Jiri/E-8735-2014",null,"European Regional Development Fund (ERDF) [CZ.1.05/1.1.00/02.0090]; IGA MZCR [NT/13351-4]; Institute of Computer Science [RVO:67985807]","The paper was partially supported by the European Regional Development Fund (ERDF), project \"NTIS - New Technologies for Information Society\", European Centre of Excellence, CZ.1.05/1.1.00/02.0090, by the Grant IGA MZCR NT/13351-4 and by the long-term strategic development financing of the Institute of Computer Science (RVO:67985807).",null,18,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0169-2607",null,null,"COMPUT METH PROG BIO","Comput. Meth. Programs Biomed.","JUN",2013,110,3,null,null,null,null,279,289,null,"10.1016/j.cmpb.2012.12.001",null,11,"Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Medical Informatics","Computer Science; Engineering; Medical Informatics","147PC","WOS:000319178500006"]
[null,null,null,null,"J","Groh, D; Seeman, P; Jilek, M; Popelar, J; Kabelka, Z; Syka, J",null,null,null,"Groh, D.; Seeman, P.; Jilek, M.; Popelar, J.; Kabelka, Z.; Syka, J.",null,null,"Hearing Function in Heterozygous Carriers of a Pathogenic GJB2 Gene Mutation","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"c.35delG mutation; Audiogram normalization; High-frequency audiometry; Otoacoustic emissions; High-frequency hearing loss","OTOACOUSTIC EMISSIONS; DEAFNESS; CONNEXIN-26; BRAIN","The most frequent hereditary hearing loss is caused by mutations in the GJB2 gene coding for the gap junction beta 2 protein Connexin 26 (Cx26). In contrast to many studies performed in patients with bi-allelic mutations, audiometric studies on heterozygotes are sparse and often contradictory. To evaluate hearing function in heterozygous carriers of the GJB2 c.35delG mutation, audiometry over the extended frequency range and the recording of otoacoustic emissions (OAEs), i.e., transient-evoked OAEs (TEOAEs) and distortion product OAEs (DPOAEs), were performed in a group of parents and grandparents of deaf children homozygous for the GJB2 c.35delG mutation. The comparison of audiograms between control and heterozygous subjects was enabled using audiogram normalization for age and sex. Hearing loss, estimated with this procedure, was found to be significantly larger in GJB2 c.35delG heterozygous females in comparison with controls for the frequencies of 8-16 kHz; the deterioration of hearing in heterozygous men in comparison with controls was not statisticaly significant. A comparison of TEOAE responses and DPOAE levels between GJB2 c.35delG heterozygotes and controls did not reveal any significant differences. The results prove the importance of using audiometry over the extended frequency range and audiogram normalization for age and sex to detect minor hearing impairments, even in a relatively small group of subjects of different ages.","[Groh, D.; Jilek, M.; Popelar, J.; Syka, J.] Acad Sci Czech Republic, Inst Expt Med, Dept Auditory Neurosci, Prague, Czech Republic; [Groh, D.; Kabelka, Z.] Charles Univ Prague, Fac Med 2, Dept Otorhinolaryngol, Prague 15006 5, Czech Republic; [Groh, D.; Seeman, P.; Kabelka, Z.] Univ Hosp Motol, Prague, Czech Republic; [Seeman, P.] Charles Univ Prague, Fac Med 2, Dept Pediat Neurol, Prague 15006 5, Czech Republic","Groh, D (reprint author), Charles Univ Prague, Fac Med 2, Dept ENT, V Uvalu 84, Prague 15006 5, Czech Republic.","daniel.groh@seznam.cz",null,null,"Ministry of Health, Czech Republic [00064203];  [GACR 304/12/1342];  [GACR P304/10/1872]","Supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic) and by grants GACR 304/12/1342 and GACR P304/10/1872. The preliminary data were presented at the 45th Inner Ear Biology Workshop, September 21-24, 2008, Ferrara, Italy, and published as an abstract in the Workshop Proceedings.",null,19,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2013,62,3,null,null,null,null,323,330,null,null,null,8,"Physiology","Physiology","176RX","WOS:000321322900011"]
[null,null,null,null,"J","Pruhova, S; Dusatkova, P; Kraml, PJ; Kulich, M; Prochazkova, Z; Broz, J; Zikmund, J; Cinek, O; Andel, M; Pedersen, O; Hansen, T; Lebl, J",null,null,null,"Pruhova, Stepanka; Dusatkova, Petra; Kraml, Pavel J.; Kulich, Michal; Prochazkova, Zdena; Broz, Jan; Zikmund, Jaroslav; Cinek, Ondrej; Andel, Michal; Pedersen, Oluf; Hansen, Torben; Lebl, Jan",null,null,"Chronic Mild Hyperglycemia in GCK-MODY Patients Does Not Increase Carotid Intima-Media Thickness","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY",null,null,"English","Article",null,null,null,null,null,null,"TYPE-2 DIABETES-MELLITUS; GLUCOSE-TOLERANCE TEST; GLUCOKINASE MUTATIONS; INSULIN-RESISTANCE; METABOLIC SYNDROME; ASSOCIATION; DISEASE; ATHEROSCLEROSIS; ABNORMALITY; FAMILIES","Aim. GCK-MODY is an autosomal dominant form of diabetes caused by heterozygous mutations in the glucokinase gene leading to a lifelong mild hyperglycemia. The risk of macrovascular complications is considered low, but studies are limited. We, therefore, investigated the carotid intima-media thickness (CIMT) as an indicator of macrovascular complications in a group of patients with GCK-MODY. Methods. Twenty-seven GCK mutation carriers and 24 controls recruited among their first-degree relatives were compared, all aging over 35 years. The CIMT was tested using a high-resolution B-mode carotid ultrasonography. Medical history, anthropometry, and biochemical blood workup were obtained. Results. The mean CIMT was 0.707 +/- 0.215mm (mean +/- SD) in GCK mutation carriers and 0.690 +/- 0.180mm in control individuals. When adjusted for age, gender, and family status, the estimated mean difference in CIMT between the two groups increased to 0.049mm (P = 0.19). No difference was detected for other characteristics, with the exception of fasting blood glucose (GCK-MODY 7.6mmol/L +/- 1.2 (136.4mg/dL); controls 5.3mmol/L +/- 0.3 (95.4mg/dL); P < 0.0001) and glycated hemoglobin HbA(1c) (GCK-MODY 6.9% +/- 1.0%, 52mmol/mol +/- 10; controls 5.7% +/- 0.4%, 39mmol/mol +/- 3; P < 0.0001). The frequency of myocardial infarction and ischemic stroke did not differ between groups. Conclusion. Our data indicate that the persistent hyperglycemia in GCK-MODY is associated with a low risk of developing diabetic macrovascular complications.","[Pruhova, Stepanka; Dusatkova, Petra; Cinek, Ondrej; Lebl, Jan] Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 15006, Czech Republic; [Pruhova, Stepanka; Dusatkova, Petra; Broz, Jan; Cinek, Ondrej; Lebl, Jan] Univ Hosp Motol, Prague 15006, Czech Republic; [Kraml, Pavel J.; Prochazkova, Zdena; Andel, Michal] Charles Univ Prague, Fac Med 3, Dept Internal Med 2, Prague 10081, Czech Republic; [Kraml, Pavel J.; Prochazkova, Zdena; Zikmund, Jaroslav; Andel, Michal] Univ Hosp Kralovske Vinohrady, Prague 10081, Czech Republic; [Kulich, Michal] Charles Univ Prague, Fac Math & Phys, Dept Probabil & Math Stat, Prague 18675, Czech Republic; [Broz, Jan] Charles Univ Prague, Fac Med 2, Dept Internal Med, Prague 15006, Czech Republic; [Zikmund, Jaroslav] Charles Univ Prague, Fac Med 3, Dept Pediat, Prague 10081, Czech Republic; [Pedersen, Oluf] Hagedorn Res Inst, DK-2820 Gentofte, Denmark; [Pedersen, Oluf] Univ Copenhagen, Fac Hlth Sci, Inst Biomed Sci, DK-2200 Copenhagen N, Denmark; [Pedersen, Oluf; Hansen, Torben] Univ Copenhagen, Fac Hlth Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark; [Hansen, Torben] Univ Southern Denmark, Fac Hlth Sci, DK-2820 Odense, Denmark","Pruhova, S (reprint author), Charles Univ Prague, Fac Med 2, Dept Pediat, Prague 15006, Czech Republic.","pruhova@seznam.cz","Kulich, Michal/B-1483-2013","Kulich, Michal/0000-0002-2812-8968","Internal Grant Agency of Czech Ministry of Health [NT11402]; University Hospital Motol, Prague, Czech Republic [00064203]","This study was supported by grants from the Internal Grant Agency of Czech Ministry of Health (NT11402) and from the Project for the Conceptual Development of Research Organisation 00064203 (University Hospital Motol, Prague, Czech Republic). The authors thank Klara Vesela for technical assistance. Thy are grateful to the study participants for their collaboration to increase medical understanding.",null,26,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","1687-8337",null,null,"INT J ENDOCRINOL","Int. J. Endocrinol.",null,2013,null,null,null,null,null,null,null,null,718254,"10.1155/2013/718254",null,5,"Endocrinology & Metabolism","Endocrinology & Metabolism","222AP","WOS:000324702500001"]
[null,null,null,null,"J","Tesfaye, H; Branova, R; Riha, P; Sedlacek, P; Vydra, J",null,null,null,"Tesfaye, Hundie; Branova, Romana; Riha, Petr; Sedlacek, Petr; Vydra, Jan",null,null,"Current challenges of body weight based intravenous busulfan dosing versus dose adjustment based on therapeutic drug monitoring","BIOMEDICAL PAPERS-OLOMOUC",null,null,"English","Article",null,null,null,null,null,"TDM; busulfan; HSCT; intraindividual variability; dose adjustment AUC","STEM-CELL TRANSPLANTATION; CHILDREN; PHARMACOKINETICS; ASSOCIATION; STRATEGY","Background. Busulfan in high doses is often used to substitute total body irradiation for bone marrow or hematopoietic stem cell transplantation (HSCT) conditioning therapy. Its considerable pharmacokinetic variability and worrying adverse effect in case of extreme exposure warrants pharmacokinetic monitoring in both oral and intravenous forms. Previous works suggested that test pharmacokinetic study enables dose prediction for all of the rest doses given every 6 hourly for four days. However, extensive case series observations and further studies indicate that the drug shows intra-individual variability challenging the first dose based prediction. Objectives. The principal aim of this communication is to describe typical cases, where dose prediction based on post initial doses concentrations measurement and consequent area under the concentration versus time curve (AUC) calculation may not be reliable and that may endanger the principal goal of the intervention. Patients and Methods. Data from three exemplary out layer cases have been processed from patients where prae-analysis provision of informed consent of a patient or the guardians in paediatric cases is standard. An adult male at age of 49 years, and two children (1 male and 1 female) both at age of 2 years, respectively have been treated with i.v. busulfan doses on body weight basis according to clinical protocol before HSCT. Sampling was started with trough concentration (immediately before the 5th dose) followed by samples immediately after the end of 2-4 h lasting infusion (peak), 4 h, and 6 h from the starting time of the infusion utilizing limited sample strategy. Busulfan concentrations were determined by high performance liquid chromatography (HPLC). AUC was calculated using the trapezoidal rule. Results. At initial measurement AUC in the adult patient and in the female infant case revealed unacceptably low exposure expressed by low AUC 496.4 mu g/L.h and 1284 mu g/L.h), respectively. In contrast, AUC C-trough-C-6 calculated according to the trapezoidal rule in the male child revealed overexposure expressed by AUC C-trough-C-6 11135 mu g.L.h, required another follow-up monitoring with or without dose adjustment. Conclusions. Our results demonstrate that even after i.v. busulfan administration, interindividual as well as intra-individual PK/PD variability is of great concern. The over all conclusions drown from these case series observation is to recommend inter-dose follow-up therapeutic drug monitoring instead of relaying on initial dose predictions as highly required tool to guarantee aimed target with careful interpretation of drug levels considering all influential factors. Thus, it is strongly suggested that follow-up AUC monitoring between doses may certainly help to reduce the risk of poor outcomes both in adult and paediatric HSCT patients.","[Tesfaye, Hundie; Branova, Romana] Charles Univ Prague, Fac Med 2, Div Clin Pharmacol, Dept Med Chem & Clin Biochem, Prague, Czech Republic; [Tesfaye, Hundie; Branova, Romana; Riha, Petr; Sedlacek, Petr] Fac Hosp Motol, Prague, Czech Republic; [Riha, Petr; Sedlacek, Petr] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Vydra, Jan] Inst Hematol & Blood Transfus, Prague, Czech Republic","Tesfaye, H (reprint author), Charles Univ Prague, Fac Med 2, Div Clin Pharmacol, Dept Med Chem & Clin Biochem, Prague, Czech Republic.",null,null,null,"Ministry of Health, Czech Republic","Supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic)",null,17,0,0,"PALACKY UNIV, MEDICAL FAC","OLOMOUC","CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC","1213-8118",null,null,"BIOMED PAP","Biomed. Pap-Olomouc",null,2013,157,null,null,1,null,null,"S79","S84",null,null,null,6,"Engineering, Biomedical; Medicine, Research & Experimental","Engineering; Research & Experimental Medicine","222KB","WOS:000324728600008"]
[null,null,null,null,"J","Tomek, A; Mat'oska, V; Kolarova, T; Neumann, J; Sramek, M; Sarbochova, I; Taborsky, L; Bojar, M; Goetz, P; Serebruany, VL",null,null,null,"Tomek, Ales; Mat'oska, Vaclav; Kolarova, Tereza; Neumann, Jiri; Sramek, Martin; Sarbochova, Ivana; Taborsky, Ludek; Bojar, Martin; Goetz, Petr; Serebruany, Victor L.",null,null,"The Bleeding Risk during Warfarin Therapy Is Associated with the Number of Variant Alleles of CYP2C9 and VKORC1 Genes","CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,"Warfarin; Bleeding risk; Major bleeding event; CYP2C9 gene; VKORC1 gene","ANTICOAGULATION-RELATED OUTCOMES; HEMORRHAGIC COMPLICATIONS; TREATED PATIENTS; POLYMORPHISMS","Background: Warfarin is commonly used for the treatment and prevention of arterial and venous thromboembolism but its use is hindered by the risk of bleeding. The main reason for this risk is a narrow therapeutic index and a wide response variability after warfarin treatment. These shortcomings affect clinical outcomes including bleeding complications and may be associated with variant polymorphisms in the CYP2C9 and VKORC1 genes. Aim: It was the aim of this study to assess the impact of the total variant allele count of CYP2C9 and VKORC1 genes on bleeding related to warfarin treatment. Methods: In a retrospective cohort-design study, patients were genotyped for polymorphisms in genes CYP2C9 (*1, *2, *3) and VKORC1 (haplotype A, B). Extensive clinical data were obtained. Adjusted hazard ratios (HR) for the occurrence of major bleeding events (MBE) were counted separately for the induction and maintenance phases of warfarin therapy. Results: Out of the 329 patients in our clinical database, 194 patients were eligible and included in the analysis. MBE occurred in 51 patients (26.3%) during a mean follow-up of 26 months: 6 patients (11.8%) experienced early MBE during warfarin initiation, and 45 MBE occurred during the maintenance phase. The adjusted HR for MBE risk for patients with any CYP2C9 variant allele was 1.962 [95% confidence interval (CI) 1.08-3.56, p = 0.027]; for the VKORC1 AA haplotype, HR was 1.841 (95% CI 0.97-3.48, p = 0.06), while for 3 variant allele carriers of both genes, HR was 4.34 (95% CI 1.95-9.65, p < 0.001). Despite the insignificant association of the VKORC1 genotype with bleeding in our study, we have noted a warfarin dose-dependent effect with risk significance ascending: CYP2C9 *1/*1 + VKORC1 B/B < CYP2C9 *1/*1 + VKORC1 A/B < CYP2C9 *1/*2 + VKORC1 B/B. Conclusion: Patients who are carriers of 3 variant alleles of the genes CYP2C9 and VKORC1 exhibited a significantly higher risk of MBE during the initiation and maintenance phases of warfarin therapy. Vigilant and careful management of patients with a higher variant allele count, including switching to newer anticoagulants, could be considered in this high-risk cohort. Copyright (C) 2013 S. Karger AG, Basel","[Tomek, Ales; Sramek, Martin; Sarbochova, Ivana; Bojar, Martin] Charles Univ Prague, Dept Neurol, Sch Med 2, CZ-15004 Prague 5, Czech Republic; [Goetz, Petr] Charles Univ Prague, Inst Med Genet, Sch Med 2, CZ-15004 Prague 5, Czech Republic; [Tomek, Ales; Mat'oska, Vaclav; Kolarova, Tereza; Taborsky, Ludek] Hosp Na Homolce, Mol Genet Lab, Prague, Czech Republic; [Neumann, Jiri] Hosp Chomutov, Dept Neurol, Chomutov, Czech Republic; [Serebruany, Victor L.] Johns Hopkins Univ, HeartDrug Res Labs, Baltimore, MD USA","Tomek, A (reprint author), Charles Univ Prague, Dept Neurol, Sch Med 2, V Uvalu 84, CZ-15004 Prague 5, Czech Republic.","ales.tomek@fnmotol.cz",null,null,"Grant Agency of the Ministry of Industry of the Czech Republic [FR-TI1/399]","This study was supported by the Grant Agency of the Ministry of Industry of the Czech Republic (FR-TI1/399).",null,22,0,0,"KARGER","BASEL","ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND","0008-6312",null,null,"CARDIOLOGY","Cardiology",null,2013,125,3,null,null,null,null,182,191,null,"10.1159/000350407",null,10,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","178KF","WOS:000321445900013"]
[null,null,null,null,"J","Teyssler, P; Trc, T; Kolostova, K; Bobek, V",null,null,null,"Teyssler, P.; Trc, T.; Kolostova, K.; Bobek, V.",null,null,"Recurrent Intra-Articular Bleeding Episodes in Haemophiliacs. Treatment Outcomes in the Patients at the University Hospital Motol in 1985-2005","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"haemophilic arthropathy; radiation synovectomy; surgical synovectomy","CHRONIC HEMOPHILIC SYNOVITIS; RADIOISOTOPE SYNOVECTOMY; RADIOACTIVE SYNOVECTOMY; EXPERIENCE; SYNOVIORTHESIS; CITRATE; JOINTS","PURPOSE OF THE STUDY Chronic synovitis is a common finding in people with haemophilia. It regularly appears after recurrent episodes of intra-articular bleeding. The bleeding originates from the subsynovial venous plexus underlying the capsule where a lack of thromboplastic activity has been demonstrated. Therefore, the changed synovium appears to be a treatment target. There are several methods which can be used to remove the synovial layer from the joint. The aim of our study was to asses the efficacy of different treatment approaches used in a group of haemophiliacs between 1985 and 2005 in our hospital. MATERIAL AND METHODS A group of 30 patients with bleeding disorders was evaluated in the study. There were 29 men with haemophilia and one woman with von Wilebrandt factor deficiency. Their age ranged from 6 to 18 (median 13) years. They underwent a total of 68 interventions including surgical synovectomy (n = 28), radionuclide synovectomy (n = 33) and corticosteroid instillation (n=7). The necessity of a repeat intervention was used as a criterion of successful treatment. RESULTS In the group of surgical synovectomies, 22% of the patients required repeat operations, in the group of radiation synovectomy, this was 9% and, in the group treated with corticosteroids, this was 43%. The average hospitalisation time was 50 days for surgical procedures (19-133 days) and 7 days for radiation synovectomy procedures (4-13 days). DISCUSSION In 1994 Merchan presented seven excellent or good results in a group of 10 knees evaluated 1 year after treatment with methylprednisolone. Six years later he reported that five years after completion of treatment, all results of the observed patients were poor\". Generally, corticosteroids will reduce synovitis in the majority of patients but the effect is temporary. A complete remission is a very rare situation under corticosteroid treatment. The experience with surgical synovectomies is not recent and this method is described as carrying a high risk of complications and requiring a high amount of coagulating factor consumption. There are several recent reports on the application of Yttrium-90: in Madrid they evaluated treated joints (knees, ankles and elbows, n = 66) in 44 patients aged from 9 to 39 years. The results were good in less than half of the knees and ankles. The treatment of elbows was more successful. It was recommended to perform synoviorthesis at the early stages of synovitis. In Israel, they reported that a decrease in the number of bleeding episodes was achieved in 80% of 115 patients treated with Yttrium-90; in 15% of them, bleeding in the treated joints stopped completely. In Izmir, Yttrium was used in the treatment of knees, elbows, ankles and also shoulders in children and young adults (3-25 years). The method was found to be safe and effective. Brazilian authors have experience with the treatment of knees, ankles, elbows and shoulders too; they have concluded that this method represents an important resource for the treatment of chronic haemophilic synovitis and markedly reduces joint bleeding frequency and pain, irrespective of the radiographic stage and inhibitor status. While the European Association of Nuclear Medicine (EANM) recommend using 186Re-sulfide for treatment in medium-sized joints, Chinese authors have published a study comparing the effect of using three different doses of 186Re-sulfide in the treatment of chronic synovitis in knees. Their patients have received an amount of radionuclide according to the thickness of their synovial layer measured on MRI, with the result that 22 patients exhibited significant reduction in synovial thickness. A reduction in the number of bleeding episodes was reached in 71% of the patients within an 18-month period. No significant differences were found among the groups receiving different radioactivity doses. In Turkey, 35 elbows, 26 ankles and two shoulders in 49 patients aged between 3 and 30 years were treated with 186Re. The patients were followed up from 6 months to 3 years. At 6 months after the procedure, 81% of the elbows and 86% of the ankles with grade II synovitis were free from bleeding, as well as 53% and 44% of the elbows and ankles with grade III synovitis, respectively. CONCLUSIONS Radiation synovectomy appears to be the method of choice in the treatment of recurrent bleeding in the joint cavity in people with haemophilia. The efficacy of surgical synovectomy is lower in comparison with radiation synovectomy. Risks associated with surgery and anaesthesia, the need of hospitalisation and a prolonged period of rehabilitation are bothering. On the contrary, the application of corticosteroids cannot be recommended as a good method to treat recurrent haemarthroses.","[Teyssler, P.; Trc, T.] LF UK & FN Motole, Klin Detske & Dospele Ortopedie & Traumatol 2, Prague, Czech Republic; [Teyssler, P.; Kolostova, K.; Bobek, V.] LF UK, Oddeleni Nadorove Biol 3, Prague, Czech Republic; [Bobek, V.] LF UK, Chirurg Klin 3, Prague, Czech Republic","Teyssler, P (reprint author), Nova Cesta 1552-22, Prague 14000 4, Czech Republic.","petr.teyssler@centrum.cz",null,null,null,null,"Alioglu B, 2010, HAEMOPHILIA, V16, P932, DOI 10.1111/j.1365-2516.2010.02276.x; [Anonymous], 2005, GUID MAN HEM; Corrigan JJ, 2003, HAEMOPHILIA, V9, P64, DOI 10.1046/j.1365-2516.2003.00676.x; DUNGL P., 2010, ORTOPEDIE, V4, P176; Gilbert MS, 2001, HAEMOPHILIA, V7, P3, DOI 10.1046/j.1365-2516.2001.00101.x; Heim M, 2001, HAEMOPHILIA, V7, P36, DOI 10.1046/j.1365-2516.2001.00108.x; Jansen NWD, 2008, BRIT J HAEMATOL, V143, P632, DOI 10.1111/j.1365-2141.2008.07386.x; Kavakli K, 2008, HAEMOPHILIA, V14, P518, DOI 10.1111/j.1365-2516.2008.01691.x; Kavakli K, 2006, HAEMOPHILIA, V12, P28, DOI 10.1111/j.1365-2516.2005.01175.x; KOMRSKA V., 2001, THESIS; Li P, 2004, HAEMOPHILIA, V10, P422, DOI 10.1111/j.1365-2516.2004.00913.x; Molho P, 1999, HAEMOPHILIA, V5, P115, DOI 10.1046/j.1365-2516.1999.00287.x; RODRIGUEZMERCHAN EC, 1994, REV CLIN ESP, V194, P480; Rodriguez-Merchan EC, 2007, HAEMOPHILIA, V13, P1, DOI 10.1111/j.1365-2516.2007.01532.x; RODRIGUEZ - MERCHAN E. C., 2000, MUSCULOSKELETAL ASPE; Rodriguez-Merchan EC, 2001, HAEMOPHILIA, V7, P34, DOI 10.1046/j.1365-2516.2001.00107.x; Teyssler P, 2013, HELL J NUCL MED, V16, P44, DOI 10.1967/s002449910071; Teyssler P, 2013, NUCL MED COMMUN, V34, P291, DOI 10.1097/MNM.0b013e32835ed50c; Thomas S, 2011, HAEMOPHILIA, V17, pE211, DOI 10.1111/j.1365-2516.2010.02379.x; WIEDEL J. D., 1986, MANAGEMENT MUSCULOSK, P47",20,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2013,80,6,null,null,null,null,396,399,null,null,null,4,"Orthopedics","Orthopedics","287NQ","WOS:000329549900005"]
[null,null,null,null,"J","Rampichova, M; Chvojka, J; Buzgo, M; Prosecka, E; Mikes, P; Vyslouzilova, L; Tvrdik, D; Kochova, P; Gregor, T; Lukas, D; Amler, E",null,null,null,"Rampichova, M.; Chvojka, J.; Buzgo, M.; Prosecka, E.; Mikes, P.; Vyslouzilova, L.; Tvrdik, D.; Kochova, P.; Gregor, T.; Lukas, D.; Amler, E.",null,null,"Elastic three-dimensional poly (epsilon-caprolactone) nanofibre scaffold enhances migration, proliferation and osteogenic differentiation of mesenchymal stem cells","CELL PROLIFERATION",null,null,"English","Article",null,null,null,null,null,null,null,"Objectives We prepared 3D poly (e-caprolactone) (PCL) nanofibre scaffolds and tested their use for seeding, proliferation, differentiation and migration of mesenchymal stem cell (MSCs). Materials and methods 3D nanofibres were prepared using a special collector for common electrospinning; simultaneously, a 2D PCL nanofibre layer was prepared using a classic plain collector. Both scaffolds were seeded with MSCs and biologically tested. MSC adhesion, migration, proliferation and osteogenic differentiation were investigated. Results The 3D PCL scaffold was characterized by having better biomechanical properties, namely greater elasticity and resistance against stress and strain, thus this scaffold will be able to find broad applications in tissue engineering. Clearly, while nanofibre layers of the 2D scaffold prevented MSCs from migrating through the conformation, cells infiltrated freely through the 3D scaffold. MSC adhesion to the 3D nanofibre PCL layer was also statistically more common than to the 2D scaffold (P < 0.05), and proliferation and viability of MSCs 2 or 3 weeks post-seeding, were also greater on the 3D scaffold. In addition, the 3D PCL scaffold was also characterized by displaying enhanced MSC osteogenic differentiation. Conclusions We draw the conclusion that all positive effects observed using the 3D PCL nanofibre scaffold are related to the larger fibre surface area available to the cells. Thus, the proposed 3D structure of the nanofibre layer will find a wide array of applications in tissue engineering and regenerative medicine.","[Rampichova, M.; Buzgo, M.; Prosecka, E.; Amler, E.] Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Prague 14240, Czech Republic; [Rampichova, M.; Buzgo, M.; Prosecka, E.; Amler, E.] Charles Univ Prague, Fac Med 2, Inst Biophys, Prague 15006 5, Motol, Czech Republic; [Chvojka, J.; Mikes, P.; Vyslouzilova, L.; Lukas, D.] Tech Univ Liberec, Fac Text Engn, Dept Nonwoven Text, Liberec 46117 1, Czech Republic; [Chvojka, J.] Tech Univ Liberec, Inst Nanomat Adv Technol & Innovat, Liberec 46117 1, Czech Republic; [Tvrdik, D.] Charles Univ Prague, Fac Med 1, Inst Pathol, Prague 12800, Czech Republic; [Kochova, P.] Univ W Bohemia, Fac Sci Appl, NTIS, European Ctr Excellence, Plzen 30614, Czech Republic; [Tvrdik, D.] Charles Univ Prague, Gen Teaching Hosp, Prague 12800, Czech Republic; [Gregor, T.] Univ W Bohemia, New Technol Res Ctr, Plzen 30614, Czech Republic","Rampichova, M (reprint author), Acad Sci Czech Republic, Inst Expt Med, Lab Tissue Engn, Videnska 1083, Prague 14240, Czech Republic.","m.rampichova@biomed.cas.cz",null,null,"Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Grant Agency of the Academy of Sciences [IAA500390702]; Grant Agency of the Charles University [96610, 97110, 330611, 384311, 164010, 626011]; Grant Agency of the Czech Republic [P304/10/1307]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NT12156]; Ministry of Education of the Czech Republic [ME 10145]; CENTEM project [CZ.1.05/2.1.00/03.0088]; ERDF as part of the Ministry of Education, Youth and Sports; European Centre of Excellence [CZ.1.05/1.1.00/02.0090]","This work was supported by the Academy of Sciences of the Czech Republic (institutional research plans AV0Z50390703 and AV0Z50390512), Grant Agency of the Academy of Sciences (grant No. IAA500390702), The Grant Agency of the Charles University (grant No., 96610, 97110, 330611, 384311, 164010, 626011), The Grant Agency of the Czech Republic (grant No. P304/10/1307), Internal Grant Agency of the Ministry of Health of the Czech Republic (grant No. NT12156) and The Ministry of Education of the Czech Republic - project ERA-NET CARSILA No. ME 10145. The result was developed within the CENTEM project, reg. no. CZ.1.05/2.1.00/03.0088, co-funded by the ERDF as part of the Ministry of Education, Youth and Sports' OP RDI programme and project 'NTIS - New Technologies for Information Society', European Centre of Excellence, CZ.1.05/1.1.00/02.0090.",null,0,6,6,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0960-7722",null,null,"CELL PROLIFERAT","Cell Prolif.","FEB",2013,46,1,null,null,null,null,23,37,null,"10.1111/cpr.12001",null,15,"Cell Biology","Cell Biology","066UF","WOS:000313245200003"]
[null,null,null,null,"J","Ruzicka, J; Romanyuk, N; Hejcl, A; Vetrik, M; Hruby, M; Cocks, G; Cihlar, J; Pradny, M; Price, J; Sykova, E; Jendelova, P",null,null,null,"Ruzicka, Jiri; Romanyuk, Nataliya; Hejcl, Ales; Vetrik, Miroslav; Hruby, Martin; Cocks, Graham; Cihlar, Jiri; Pradny, Martin; Price, Jack; Sykova, Eva; Jendelova, Pavia",null,null,"Treating spinal cord injury in rats with a combination of human fetal neural stem cells and hydrogels modified with serotonin","ACTA NEUROBIOLOGIAE EXPERIMENTALIS",null,null,"English","Article",null,null,null,null,null,"spinal cord injury; hemisection; neural stem cells; SPC-01; hydrogel; serotonin","NEUROTROPHIC FACTORS; LOCOMOTOR RECOVERY; SCHWANN-CELLS; GENE-THERAPY; REPAIR; TRANSPLANTATION; DIFFERENTIATION; SCAFFOLDS; GROWTH; INFLAMMATION","Currently, there is no effective strategy for the treatment of spinal cord injury (SCI). A combination of biomaterials and stem cell therapy seems to be a promising approach to increase regenerative potential after SCI. We evaluated the use of a cell-polymer construct based on a combination of the conditionally immortalized spinal progenitor cell line SPC-01_GFP3, derived from human fetal spinal cord tissue, with a serotonin-modified poly(2-hydroxyethyl methacrylate) hydrogel (pHEMA-5HT). We compared the effect of treatment with a pHEMA-5HT hydrogel seeded with SPC-01 _GFP3 cells, treatment with a pHEMA-5HT only and no treatment on functional outcome and tissue reconstruction in hemisected rats. Prior to transplantation the cell-polymer construct displayed a high potential to support the growth, proliferation and differentiation of SPC-01 cells in vitro. One month after surgery, combined hydrogel-cell treatment reduced astrogliosis and tissue atrophy and increased axonal and blood vessel ingrowth into the implant; however, two months later only the ingrowth of blood vessels remained increased. SPC-01_GFP3 cells survived well in vivo and expressed advanced markers of neuronal differentiation. However, a majority of the transplanted cells migrated out of the lesion and only rarely remained in the hydrogel. No differences among the groups in motor or sensory recovery were observed. Despite the support of the hydrogel as a cell carrier in vitro, and good results in vivo one month postsurgery, there was only a small effect on long term recovery, mainly due to the limited ability of the hydrogels to support the in vivo growth and differentiation of cells within the implant. Further modifications will be necessary to achieve stable long term improvement in functional outcome.","[Ruzicka, Jiri; Romanyuk, Nataliya; Hejcl, Ales; Sykova, Eva; Jendelova, Pavia] ASCR, Inst Expt Med, Prague, Czech Republic; [Ruzicka, Jiri; Sykova, Eva; Jendelova, Pavia] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic; [Hejcl, Ales] Masaryk Hosp, Dept Neurosurg, Usti Nad Labem, Czech Republic; [Vetrik, Miroslav; Hruby, Martin; Pradny, Martin] Inst Macromol Chem ASCR, Prague, Czech Republic; [Vetrik, Miroslav] Charles Univ Prague, Fac Sci, Prague, Czech Republic; [Cocks, Graham; Price, Jack] Kings Coll London, Inst Psychiat, London, England; [Cihlar, Jiri] JE Purkynje Univ Usti Nad Labem, Fac Sci, Dept Math, Usti Nad Labem, Czech Republic","Jendelova, P (reprint author), ASCR, Inst Expt Med, Prague, Czech Republic.","jendel@biomed.cas.cz",null,null," [GAUK521712];  [GA CR P108/10/1560];  [GA CR P304/11/P633];  [GA CR 13-00939S];  [GAAV IAA500390902]","We acknowledge the support provided by the grants GAUK521712, GA CR P108/10/1560, GA CR P304/11/P633, GA CR 13-00939S and GAAV IAA500390902.",null,37,3,3,"NENCKI INST EXPERIMENTAL BIOLOGY","WARSAW","UL PASTEURA 3, 02-093 WARSAW, POLAND","0065-1400",null,null,"ACTA NEUROBIOL EXP","Acta Neurobiol. Exp.",null,2013,73,1,null,null,null,null,102,115,null,null,null,14,"Neurosciences","Neurosciences & Neurology","134GH","WOS:000318197900008"]
[null,null,null,null,"J","Fila, L; Chladek, J; Maly, M; Musil, J",null,null,null,"Fila, L.; Chladek, J.; Maly, M.; Musil, J.",null,null,"Nitrites and nitrates in exhaled breath condensate in cystic fibrosis: relation to clinical parameters","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"cystic fibrosis; disease severity; exhaled breath condensate; nitrites; nitrates","LUNG-DISEASE; OXIDE METABOLITES; PSEUDOMONAS-AERUGINOSA; AIRWAY DISEASES; INFLAMMATION; CHILDREN; NO; DEFICIENCY; SEVERITY; ALVEOLAR","Objectives: To evaluate correlation of exhaled breath condensate (EBC) nitrite and nitrate concentrations with disease severity in cystic fibrosis (CF) patients. Background: Nitrites and nitrates are products of oxidative metabolism of nitric oxide. Impaired metabolism of nitric oxide plays a role in pathogenesis of CF. Methods: EBC was collected from 46 stable CF patients and from 21 healthy controls. EBC concentrations of nitrites and nitrates were correlated with parameters of lung disease and nutritional status and with systemic inflammatory markers. Results: EBC nitrates concentrations in CF patients were lower than in healthy subjects (5.8 vs 14.3 mu mol/l, p<0.001). They correlated positively with FEV1 (p=0.025) and serum albumin values (p=0.016) and negatively with chest radiograph Northern score (p=0.015) and serum C-reactive protein values (p=0.005). EEC nitrites concentrations in CF patients did not differ from those in healthy subjects and were not correlated to any studied parameter. Conclusions: EBC nitrates concentrations correlate with disease severity in CF patients and are lower than in healthy subjects (Tab. 4, Fig. 1, Ref. 48). Full Text in PDF www.elis.sk.","[Fila, L.] Charles Univ Prague, Dept Pulm, Fac Med 2, CZ-15006 Prague, Czech Republic; [Fila, L.] Univ Hosp Motol, CZ-15006 Prague, Czech Republic","Fila, L (reprint author), Charles Univ Prague, Dept Pulm, Fac Med 2, V Uvalu 84, CZ-15006 Prague, Czech Republic.","libor_fila@seznam.cz",null,null,"Ministry of Health of Czech Republic [IGA MZCR NR/8304-3]","This work was funded by grant of Ministry of Health of Czech Republic (IGA MZCR NR/8304-3). The authors wish to thank Ms. V. Lopotova for her help with the collection of EBC and preparation of samples for analyses, Ms. V. Flegrova for lung function tests, Ms. J. Prokopova for her help with EBC analyses, and Department of Clinical Biochemistry and Pathobiochemistry of Charles University, 2nd Faculty of Medicine, Prague, Czech Republic, for analyses of inflammatory markers.",null,48,1,1,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248","1336-0345",null,"BRATISL MED J","Bratisl. Med. J.",null,2013,114,9,null,null,null,null,503,507,null,"10.4149/BLL_2013_105",null,5,"Medicine, General & Internal","General & Internal Medicine","298MF","WOS:000330327300003"]
[null,null,null,null,"J","Kasparova, M; Grafova, L; Dvorak, P; Dostalova, T; Prochazka, A; Eliasova, H; Prusa, J; Kakawand, S",null,null,null,"Kasparova, Magdalena; Grafova, Lucie; Dvorak, Petr; Dostalova, Tatjana; Prochazka, Ales; Eliasova, Hana; Prusa, Josef; Kakawand, Soroush",null,null,"Possibility of reconstruction of dental plaster cast from 3D digital study models","BIOMEDICAL ENGINEERING ONLINE",null,null,"English","Article",null,null,null,null,null,"3D print; Rapid prototyping; Plaster cast; Dentistry","KOLMOGOROV-SMIRNOV TEST; TOOTH-SIZE; SURGERY; SYSTEM","Objectives: To compare traditional plaster casts, digital models and 3D printed copies of dental plaster casts based on various criteria. To determine whether 3D printed copies obtained using open source system RepRap can replace traditional plaster casts in dental practice. To compare and contrast the qualities of two possible 3D printing options - open source system RepRap and commercially available 3D printing. Design and settings: A method comparison study on 10 dental plaster casts from the Orthodontic department, Department of Stomatology, 2nd medical Faulty, Charles University Prague, Czech Republic. Material and methods: Each of 10 plaster casts were scanned by inEos Blue scanner and the printed on 3D printer RepRap [10 models] and ProJet HD3000 3D printer [1 model]. Linear measurements between selected points on the dental arches of upper and lower jaws on plaster casts and its 3D copy were recorded and statistically analyzed. Results: 3D printed copies have many advantages over traditional plaster casts. The precision and accuracy of the RepRap 3D printed copies of plaster casts were confirmed based on the statistical analysis. Although the commercially available 3D printing enables to print more details than the RepRap system, it is expensive and for the purpose of clinical use can be replaced by the cheaper prints obtained from RepRap printed copies. Conclusions: Scanning of the traditional plaster casts to obtain a digital model offers a pragmatic approach. The scans can subsequently be used as a template to print the plaster casts as required. Using 3D printers can replace traditional plaster casts primarily due to their accuracy and price.","[Kasparova, Magdalena; Dostalova, Tatjana; Kakawand, Soroush] Charles Univ Prague, Dept Stomatol, Fac Med 2, Prague 15006 5, Czech Republic; [Grafova, Lucie; Dvorak, Petr; Prochazka, Ales] Inst Chem Technol, Dept Comp & Control Engn, Fac Chem Engn, CR-16628 Prague 6, Czech Republic; [Prusa, Josef] InstPrusa Res Sro, Prague 11000, Czech Republic; [Eliasova, Hana] Inst Criminalist, Prague 17089, Czech Republic","Kasparova, M (reprint author), Charles Univ Prague, Dept Stomatol, Fac Med 2, 5 Uvalu 84, Prague 15006 5, Czech Republic.","kasparova@fnmotol.cz",null,null,"grant MSM [6046137306];  [IGA MZCR 13351-4];  [MI VF20102014007]","The work was supported by the research project IGA MZCR 13351-4, grant MSM No. 6046137306 and grant MI VF20102014007.",null,21,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1475-925X",null,null,"BIOMED ENG ONLINE","Biomed. Eng. Online","MAY 31",2013,12,null,null,null,null,null,null,null,49,"10.1186/1475-925X-12-49",null,11,"Engineering, Biomedical","Engineering","166MS","WOS:000320559500001"]
[null,null,null,null,"J","Chleborad, K; Zvara, K; Dostalova, T; Zvara, K; Hippmann, R; Ivancakova, R; Zvarova, J; Smidl, L; Trmal, J; Psutka, J",null,null,null,"Chleborad, Karel; Zvara, Karel, Jr.; Dostalova, Tatjana; Zvara, Karel; Hippmann, Radek; Ivancakova, Romana; Zvarova, Jana; Smidl, Lubos; Trmal, Jan; Psutka, Josef",null,null,"Evaluation of voice-based data entry to an electronic health record system for dentistry","BIOCYBERNETICS AND BIOMEDICAL ENGINEERING",null,null,"English","Article",null,null,null,null,null,"Dentistry; Medical documentation; Electronic health record; Automatic speech recognition",null,"This paper compares three methods of storage data of the patients in the field of dentistry: the paper dental card, a lifetime dental EHR controlled by keyboard and a lifetime dental EHR controlled by voice. The EuroMISE Center developed a pilot EHR application called MUDR Lite (multimedia distributed electronic health record). The study compares the elapsed time necessary to update/enter the information about the patient's dental status using the above mentioned three methods. The paper dental card is the most rapid method, but not the best for medical documentation and dentists. (C) 2013 Nalecz Institute of Biocybernetics and Biomedical Engineering. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","[Chleborad, Karel; Dostalova, Tatjana; Hippmann, Radek] Charles Univ Prague, Dept Stomatol, Sch Med 2, Prague 15006 5, Czech Republic; [Zvara, Karel, Jr.; Zvara, Karel; Zvarova, Jana] Charles Univ Prague, Fac Med 1, European Ctr Med Informat Stat & Epidemiol, Prague 15006 5, Czech Republic; [Zvara, Karel, Jr.; Zvara, Karel; Zvarova, Jana] Fac Math & Phys, Prague, Czech Republic; [Ivancakova, Romana] Charles Univ Prague, Dept Pediat Stomatol, Sch Med, Hradec Kralove, Czech Republic; [Smidl, Lubos; Trmal, Jan; Psutka, Josef] Univ West Bohemia, Dept Cybernet, Plzen, Czech Republic","Chleborad, K (reprint author), Charles Univ Prague, Dept Stomatol Children & Adults, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","karel.chleborad@tiscali.cz","Zvarova, Jana/B-5196-2014",null,"Ministry of Education of the Czech Republic [1M06014]; project PRVOUK [P28/LF1/6, P29/LF2, VF20102014007]","This project has been supported by Ministry of Education of the Czech Republic no. 1M06014 and by the project PRVOUK P28/LF1/6, P29/LF2 and VF20102014007.",null,19,0,0,"PWN-POLISH SCIENTIFIC PUBL","WARSAW","UL KS TROJDENA 4, WARSAW, 02-109, POLAND","0208-5216",null,null,"BIOCYBERN BIOMED ENG","Biocybern. Biomed. Eng.",null,2013,33,4,null,null,null,null,204,210,null,"10.1016/j.bbe.2013.09.003",null,7,"Engineering, Biomedical","Engineering","260DL","WOS:000327575100003"]
[null,null,null,null,"J","Mares, J; Szakacsova, M; Soukup, V; Duskova, J; Horinek, A; Babjuk, M",null,null,null,"Mares, J.; Szakacsova, M.; Soukup, V.; Duskova, J.; Horinek, A.; Babjuk, M.",null,null,"Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"bladder cancer; non-muscle invasive urothelial tumors; gene expression microarrays","TRANSITIONAL-CELL CARCINOMA; GENE-EXPRESSION PROFILES; PROGRESSION; IDENTIFICATION; STATISTICS; SIGNATURE; TUMOR","The aim of the study was to define specific genetic profile in Ta and Tl urinary bladder carcinoma patients with and without recurrence by gene expression microarrays. Eleven patients with the time to recurrence shorter than one year (patients with recurrence) and 11 patients with time to recurrence longer than 4 years (patients without recurrence) were enrolled. Data from microarrays were subjected to a panel of statistical analyses to identify bladder cancer recurrence-associated gene signatures. Initial screening using the GeneSpring and Bioconductor software tools revealed a putative set 47 genes differing in gene expression in both groups. After the validation, 33 genes manifested significant differences between both groups. The significant expression was observed in the group of patients without recurrence by 30 genes of which the highest differences were detected by ANXA1, ARHGEF4, FLJ32252, GNE, NINJ1, PRICKLE1, PSAT1, RNASE1, SPTAN1, SYNGR1, TNFSF15, TSPAN1, and WDR34. These genes code for signal transduction, vascular remodeling and vascular endothelial growth inhibition mainly. In the group with recurrence, 3 genes had significant differences, the highest differences were identified by two genes (PLOD2 and WDR72). Loci of genes with significant changes of gene expression were located on characteristic chromosomes for bladder cancer: 7 loci on chromosome 9, 8 loci on chromosomes 1, 2, 3, 12, 14, 15, 16, and 22. We have selected and validated 15 genes that are differentially expressed in superficial bladder cancer. We hope that this cohort of genes will serve as a promising pool of candidate biomarkers for early stage bladder cancer. Our results indicate that it maybe possible to identify patients with a low and high risk of disease recurrence at an early stage using a molecular profile.","[Mares, J.] Charles Univ Prague, Fac Med 2, Inst Biol & Med Genet, Prague 15000 5, Czech Republic; [Szakacsova, M.; Soukup, V.] Gen Teaching Hosp, Dept Urol, Prague 12000 2, Czech Republic; [Szakacsova, M.; Soukup, V.; Duskova, J.; Horinek, A.] Charles Univ Prague, Fac Med 1, Prague 12000 2, Czech Republic; [Duskova, J.] Gen Teaching Hosp, Dept Pathol Anat, Prague 12000 2, Czech Republic; [Horinek, A.] Gen Teaching Hosp, Inst Biol & Med Genet, Prague 12000 2, Czech Republic; [Babjuk, M.] Charles Univ Prague, Fac Med 2, Dept Urol, Hosp Motol, Prague 15000 5, Czech Republic","Mares, J (reprint author), Charles Univ Prague, Fac Med 2, Inst Biol & Med Genet, V Uvalu 84, Prague 15000 5, Czech Republic.","jaroslav.mares@lfmotol.cuni.cz",null,null," [VZ MSM00216200808];  [NT12417]","This study was supported by the Research Grant VZ MSM00216200808 and NT12417. We thank Mrs A. Soukupova, dr B. Ebner and dr C. Guelly for excellent technical assistance.",null,27,0,0,"VEDA, SLOVAK ACAD SCIENCES","BRATISLAVA","DUBRAVSKA CESTA 9, 842 34 BRATISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2013,60,3,null,null,null,null,295,301,null,"10.4149/neo_2013_0391",null,7,"Oncology","Oncology","202QS","WOS:000323235300009"]
[null,null,null,null,"J","Trojanek, M; Tomickova, D; Rohacova, H; Kosina, P; Gebousky, J; Dvorak, J; Chmelik, V; Batistova, K; Husa, P; Maixner, J; Sojkova, N; Zelena, H; Maresova, V; Stejskal, F",null,null,null,"Trojanek Milan; Tomickova Dora; Rohacova Hana; Kosina Pavel; Gebousky Jan; Dvorak Jan; Chmelik Vaclav; Batistova Kvetoslava; Husa Petr; Maixner Jan; Sojkova Nadezda; Zelena Hana; Maresova Vilma; Stejskal Frantisek",null,null,"Dengue Fever Cases in Czech Workers Returning from the Maldives","EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"dengue; flaviviruses; imported infections; fever","CLINICAL-FEATURES; DIAGNOSIS; PATHOGENESIS; INFECTION; TRAVELERS","Aim: The objective of this study is to present epidemiological characteristics and clinical symptoms of dengue fever cases in Czech workers who acquired the infection while working on the island of Fushivelavaru, Maldives. Furthermore, the study compares the sensitivity of novel direct detection assays, i.e. Real-Time Polymerase Chain Reaction (RT-PCR) and detection of Dengue NS1 antigen. Material and Methods: The retrospective study evaluated the clinical course of dengue fever cases in Czech workers returning from a job in the Maldives who were diagnosed with dengue virus infection from September 1 to October 31, 2012. The laboratory diagnosis of dengue fever was based on the serological detection of IgM and IgG antibodies, detection of dengue NS1 antigen by enzyme-linked immunosobent assay (ELISA), and detection of dengue virus DNA by RT-PCR. Results: The infection with dengue virus was confirmed in 18 males with a median age of 40 years (IQR 36-47) who returned from a job in the Maldives. Only one patient required admission to the hospital while the others were treated on an outpatient basis. The most frequently observed symptoms were fever (18), headache (9), muscle and joint pain (8 and 7, respectively), and rash (9). Typical laboratory findings were leukocytopenia and thrombocytopenia, a low CRP level, and elevated aminotransferase activity. The clinical course was uncomplicated in all patients. The dengue NS1 antigen detection (positive in all 10 patients with acute dengue fever) showed significantly higher sensitivity than the detection of viral RNA using RT-PCR (positive in 4 patients), p = 0.011. Conclusion: Although the vast majority of dengue fever cases are diagnosed among travellers returning from the tropics, the presented study points out the risks posed by dengue fever to long-term workers in endemic areas. The infection in the serologically nave hosts is usually uncomplicated; however, infected persons are at significant risk of developing a severe complicated clinical course if challenged by another serotype. Furthermore, sick leaves or premature departures cause a considerable economic burden to employers. In the diagnosis of acute dengue fever, preference should be given to highly sensitive and specific tests for the direct detection of dengue virus (NS1 antigen and RT-PCR assays).","[Trojanek Milan; Rohacova Hana; Maresova Vilma; Stejskal Frantisek] Univ Karlova Praze, Infekcni Klin 1, Iekarska Fak 2, Nemocnice Bulovce, Prague 18081 8, Czech Republic; [Trojanek Milan; Tomickova Dora; Rohacova Hana; Maresova Vilma; Stejskal Frantisek] Nemocnice Bulovce, Klin Infekcnich Tropickych & Parazitarnich Nemoci, Prague, Czech Republic; [Kosina Pavel; Gebousky Jan] Univ Karlova Praze, Klin Infekcnich Nemoci, Lekarska Fak Hradci Kralove, Prague 18081 8, Czech Republic; [Kosina Pavel; Gebousky Jan] Fak Nemocnice Hradci Kralove, Brno, Czech Republic; [Dvorak Jan] Univ Karlova Praze, Interni Klin, Iekarska Fak 2, Prague 18081 8, Czech Republic; [Dvorak Jan] Fak Nemocnice Motol, Prague, Czech Republic; [Chmelik Vaclav] Nemocnice Ceske Budejovice AS, Infekcni Oddeleni, Ceske Budejovice, Czech Republic; [Batistova Kvetoslava] Oblastni Nemocnice Pisek, Brno, Czech Republic; [Husa Petr] Masarykova Univ, Infekcni Klin, Lekarska Fak, Brno, Czech Republic; [Husa Petr] Fak Nemocnice Brno, Brno, Czech Republic; [Maixner Jan; Sojkova Nadezda] Zdravotni Ustav Se Sidlem Usti Labem, Oddeleni Virol, Prague, Czech Republic; [Zelena Hana] Zdravotni Ustav Se Sidlem, Narodni Referencni Lab Arbovirozy, Ostrave, Czech Republic; [Stejskal Frantisek] Univ Karlova Praze, Ustav Imunol & Mikrobiol, Iekarska Fak 1, Prague 18081 8, Czech Republic; [Stejskal Frantisek] Vseobecna Fak Nemocnice, Prague, Czech Republic; [Stejskal Frantisek] Krajska Nemocnice Liberec AS, Infekcni Oddeleni, Liberec, Czech Republic","Trojanek, M (reprint author), Univ Karlova Praze, Infekcni Klin 1, Iekarska Fak 2, Nemocnice Bulovce, Budinova 2, Prague 18081 8, Czech Republic.","milan.trojanek@bulovka.cz",null,null,null,null,null,11,0,0,"CESKA LEKARSKA SPOLECNOST J  EV  PURKYNE","PRAGUE","SOKOLSKA 31, PRAGUE, 00000, CZECH REPUBLIC","1210-7913",null,null,"EPIDEMIOL MIKROBI IM","Epidemiol. Mikrobiol. Imunol.",null,2013,62,3,null,null,null,null,100,105,null,null,null,6,"Immunology; Microbiology","Immunology; Microbiology","AA4KZ","WOS:000331065800002"]
[null,null,null,null,"J","Veselka, J; Lawrenz, T; Stellbrink, C; Zemanek, D; Branny, M; Januska, J; Groch, L; Dimitrow, P; Krejci, J; Dabrowski, M; Mizera, S; Kuhn, H",null,null,null,"Veselka, Josef; Lawrenz, Thorsten; Stellbrink, Christoph; Zemanek, David; Branny, Marian; Januska, Jaroslav; Groch, Ladislav; Dimitrow, Pawel; Krejci, Jan; Dabrowski, Maciej; Mizera, Stanislav; Kuhn, Horst",null,null,"Low Incidence of Procedure-Related Major Adverse Cardiac Events After Alcohol Septal Ablation for Symptomatic Hypertrophic Obstructive Cardiomyopathy","CANADIAN JOURNAL OF CARDIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"COMPLETE HEART-BLOCK; TRANSCORONARY ABLATION; DELAYED OCCURRENCE; ETHANOL; SURVIVAL; COMPLICATIONS; MULTICENTER; PREDICTORS; REDUCTION; THERAPY","Background: Alcohol septal ablation (ASA) is a catheter-based intervention that has been used as an alternative to surgical myectomy in highly symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). However, clinically relevant complications can result, including death and complete heart block (CHB) associated with syncope or resuscitation. This study was designed to evaluate the incidence of major ASA-related adverse cardiac events. Methods: This international multicentre retrospective study included 421 patients in 8 European centres who were treated using ASA from April 1998 to January 2011. Clinical and echocardiographic follow-up (3-6 months) was completed in 394 patients (94%). Results: ASA led to a significant reduction in symptoms and outflow gradients, with 0.7% mortality. A total of 70 patients (17%) experienced mostly transient CHB during and after the procedure; in 30% of them, CHB occurred or recurred later than 24 hours after ASA. Ninety-seven percent of CHB occurred up to the fifth day after ASA. Permanent pacemakers for CHB were implanted in 35 patients (8%). Multivariate analysis identified intraprocedural bundle branch block and age as independent predictors of CHB. Conclusions: The results of the multicentre study demonstrate that ASA appears safe and efficacious, with low early mortality. The most frequent major complication after ASA was CHB (17%), which occurred late or was recurrent in almost one-third of these patients; 8% of patients required permanent pacemaker implantation. Independent predictors of CHB development were intraprocedural bundle branch block and age. Difficulty in predicting CHB should lead to close post-procedural monitoring and hospital stays lasting at least 5 days.","[Veselka, Josef; Zemanek, David] Charles Univ Prague, Med Sch 2, Dept Cardiol, Prague, Czech Republic; [Veselka, Josef; Zemanek, David] Univ Hosp Motol, Prague, Czech Republic; [Lawrenz, Thorsten; Stellbrink, Christoph; Kuhn, Horst] Univ Witten Herdecke, Klinikum Bielefeld Mitte, Dept Cardiol & Internal Intens Care, Bielefeld, Germany; [Lawrenz, Thorsten; Stellbrink, Christoph; Kuhn, Horst] Univ Witten Herdecke, Dept Cardiol, Witten, Germany; [Januska, Jaroslav] Podlesi Hosp, Dept Cardiol, Trinec, Czech Republic; [Groch, Ladislav] Hosp Pleven, Dept Cardiol, Pleven, Bulgaria; [Dimitrow, Pawel] Jagiellonian Univ, Coll Med, Dept Cardiol 2, Krakow, Poland; [Krejci, Jan] St Annes Univ Hosp, Int Clin Res Ctr, Dept Internal Med Cardioangiol 1, Brno, Czech Republic; [Dabrowski, Maciej] Inst Cardiol, Dept Intervent Cardiol & Angiol, Warsaw, Poland; [Mizera, Stanislav] Natl Inst Cardiovasc Dis, Dept Cardiol, Bratislava, Slovakia","Veselka, J (reprint author), Dept Cardiol, Vuvalu 84, Prague 15000 5, Czech Republic.","veselka.josef@seznam.cz",null,null,"project for conceptual development of research organization [00064203]; Internal Grant Agency, Ministry of Health, Czech Republic [NT 11401-5]; European Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]","J.V. and D.Z. were supported by the project for conceptual development of research organization 00064203 and Grant NT 11401-5 from the Internal Grant Agency, Ministry of Health, Czech Republic. L.G. and J.K. were supported by the European Regional Development Fund-Project FNUSA-ICRC (No.CZ.1.05/1.1.00/02.0123).",null,30,2,2,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0828-282X","1916-7075",null,"CAN J CARDIOL","Can. J. Cardiol.","NOV",2013,29,11,null,null,null,null,1415,1421,null,"10.1016/j.cjca.2013.04.027",null,7,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","242VG","WOS:000326270800013"]
[null,null,null,null,"J","Blaha, K; Borsky, J; Kasparova, M; Steklacova, A; Zajickova, V; Pechova, M; Matejova, R; Kotaska, K; Dostalova, T",null,null,null,"Blaha, Karel; Borsky, Jiri; Kasparova, Magdalena; Steklacova, Anna; Zajickova, Veronika; Pechova, Marta; Matejova, Radka; Kotaska, Karel; Dostalova, Tatjana",null,null,"Concentrations of MMP-9 and TIMP-1 in lip tissue and their impact on cleft lip surgery healing","BIOMEDICAL PAPERS-OLOMOUC",null,null,"English","Article",null,null,null,null,null,"matrix metalloproteinases; cleft lip; wound healing","MATRIX METALLOPROTEINASES; DIFFERENTIAL EXPRESSION; WOUND REPAIR; NUDE-MICE; INHIBITORS","Aim. To compare aspects of wound healing after cleft lip surgery performed within one week of age and wound healing after surgery performed within 2 - 4 months of age, especially concentrations of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in tissue removed during surgery. Methods. 34 tissue samples (26 boys and 8 girls) were removed during surgery within one week of age (n=19) or within 2 - 4 months of age (n=15). Tissue samples were separated into epidermis, dermis and mucous membrane. Proteins were extracted in cacodylic buffer for 24 h at a temperature 2 - 8 degrees C. Total protein concentrations were examined using a modification of the Lowry method. Samples were examined using ELISA kit Amersham Biotrak Activity Assay (GE Healthcare UK) for detection of MMP-9 and TIMP-1 concentrations. Results. MMP-9: early surgery - epidermis 2.168+/-3.303 mu g/g of protein (mean+/-SD), dermis 1.251+/-1.848 mu g/g, 2 - 4 months surgery - epidermis 0.347+/-0.212 mu g/g, dermis 0.555+/-0.276 mu g/g. TIMP-1: early surgery - epidermis 1.762+/-2.162 mu g/g, dermis 1.628+/-0.822 mu g/g, mucous membrane 2.066+/-1.717 mu g/g, 2 - 4 months surgery - epidermis 1.881+/-2.810 mu g/g, dermis 3.117+/-1.540 mu g/g, mucous membrane 4.833+/-6.550 mu g/g. Conclusions. There were no significant differences in concentrations of protein MMP-9 in epidermis and dermis and TIMP-1 in epidermis and mucous membrane according to time of surgery. Significantly decreased levels of TIMP-1 in dermis were found in samples obtained from early surgery compared to levels in samples obtained from 2 - 4 months surgery.","[Blaha, Karel; Steklacova, Anna; Zajickova, Veronika; Pechova, Marta; Matejova, Radka; Kotaska, Karel] Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague, Czech Republic; [Blaha, Karel; Kasparova, Magdalena; Steklacova, Anna; Zajickova, Veronika; Pechova, Marta; Matejova, Radka; Kotaska, Karel; Dostalova, Tatjana] Fac Hosp Motol, Prague, Czech Republic; [Borsky, Jiri] Fac Hosp Kralovske Vinohrady, Dept Plast Surg, Prague, Czech Republic; [Kasparova, Magdalena; Dostalova, Tatjana] Charles Univ Prague, Dept Paediat Stomatol, Fac Med 2, Prague, Czech Republic","Blaha, K (reprint author), Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague, Czech Republic.","Blaha.Karel@fnmotol.cz",null,null,"IGA MZCR [NS/10012-4, 00064203]","This work was supported by IGA MZCR NS/10012-4 and 00064203 (FN Motol).",null,12,0,0,"PALACKY UNIV, MEDICAL FAC","OLOMOUC","CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC","1213-8118","1804-7521",null,"BIOMED PAP","Biomed. Pap-Olomouc",null,2013,157,4,null,null,null,null,363,366,null,"10.5507/bp.2012.088",null,4,"Engineering, Biomedical; Medicine, Research & Experimental","Engineering; Research & Experimental Medicine","281HQ","WOS:000329091500015"]
[null,null,null,null,"J","Vancikova, Z; Trojanek, M; Zemlickova, H; Blechova, Z; Motlova, J; Matejkova, J; Nyc, O; John, J; Maly, M; Maresova, V",null,null,null,"Vancikova, Zuzana; Trojanek, Milan; Zemlickova, Helena; Blechova, Zuzana; Motlova, Jitka; Matejkova, Jana; Nyc, Otakar; John, Jerry; Maly, Marek; Maresova, Vilma",null,null,"Pneumococcal urinary antigen positivity in healthy colonized children: is it age dependent?","WIENER KLINISCHE WOCHENSCHRIFT",null,null,"English","Article",null,null,null,null,null,"Streptococcus pneumoniae; Pneumococcal C-polysaccharide; Diagnostic tests; Pneumonia; Pediatrics","COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; HAEMOPHILUS-INFLUENZAE; PEDIATRIC-PATIENTS; DIAGNOSIS; CARRIAGE; ADULTS; BINAX; CARE; INFECTIONS","Pneumococcal urinary antigen test is a valuable tool for diagnosing pneumococcal pneumonia and meningitis in adults. Its use in children is generally not accepted because of nonspecificity at this age. It is frequently positive in asymptomatic nasopharyngeal carriers. The aim of our study was to assess the age limit from which the test is no longer positive in asymptomatic healthy carriers. A total of 197 children aged 36-83 months attending 9 day care centers in Prague were enrolled during February and March 2010. Nasopharyngeal swab specimens were collected from each participant and selectively cultivated. The presence of pneumococcal antigen in urine was detected by BinaxNOWA (R) S. pneumoniae kit. Streptococcus pneumoniae was cultivated in 53.3 % of healthy children with the highest colonization rate (59.3 %) in children aged 48-59 months. The most frequently colonizing serotypes were: 19F, 23F, 3, 19A, 6B and 4. The presence of pneumococcal antigen in urine decreased with age from 39.0 % in 36-47 months to 17.9 % in 72-83 months old (p = 0.031). The antigen positivity was serotype-dependent and more frequent in nonvaccinated children. We demonstrated age-dependent linear decrease of pneumococcal antigen excretion into urine in healthy children. The positivity rate of the test in children aged 72-83 months was similar to that referred in healthy adults, irrespective of colonization. To confirm this age limit for use of this test in diagnostics of pneumococcal diseases, further study in school-age children is justified.","[Trojanek, Milan; Blechova, Zuzana; John, Jerry; Maresova, Vilma] Charles Univ Prague, Dept Infect Dis 1, Fac Med 2, Prague 18081, Czech Republic; [Trojanek, Milan; Blechova, Zuzana; John, Jerry; Maresova, Vilma] Charles Univ Prague, Hosp Bulovce, Prague 18081, Czech Republic; [Vancikova, Zuzana] NH Hosp, Horovice Hosp, Dept Paediat, Horovice, Czech Republic; [Zemlickova, Helena] Natl Inst Publ Hlth, Natl Reference Lab Antibiot, Prague, Czech Republic; [Motlova, Jitka] Natl Inst Publ Hlth, Natl Reference Lab Streptococci & Enterococci, Prague, Czech Republic; [Matejkova, Jana; Nyc, Otakar] Charles Univ Prague, Inst Med Microbiol, Fac Med 2, Prague 18081, Czech Republic; [Matejkova, Jana; Nyc, Otakar] Charles Univ Prague, Motol Univ Hosp, Prague 18081, Czech Republic; [Maly, Marek] Natl Inst Publ Hlth, Ctr Biostat, Prague, Czech Republic","Trojanek, M (reprint author), Charles Univ Prague, Dept Infect Dis 1, Fac Med 2, Budinova 2, Prague 18081, Czech Republic.","mtrojanek@seznam.cz",null,null,"EEA from Iceland [A/CZ0046/2/0007]; EEA from Liechtenstein [A/CZ0046/2/0007]; EEA from Norway [A/CZ0046/2/0007]; Internal Grant Agency, Czech Ministry of Health [IGA 9643-4]","This study was kindly supported by Medial Ltd. by providing the kits for detection of pneumococcal antigen in urine. The authors did not receive any funding or financial assistance from the aforementioned company, neither was the sponsor involved in the design of the study, collection, analysis, interpretation of data, as well as in compilation or in decision to submit the manuscript. The study was partially supported by research grant A/CZ0046/2/0007 from Iceland, Liechtenstein and Norway via the EEA financial mechanism and by research grant IGA 9643-4 from the Internal Grant Agency, Czech Ministry of Health.",null,32,0,0,"SPRINGER WIEN","WIEN","SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA","0043-5325",null,null,"WIEN KLIN WOCHENSCHR","Wien. Klin. Wochen.","SEP",2013,125,"17-18",null,null,null,null,495,500,null,"10.1007/s00508-013-0405-4",null,6,"Medicine, General & Internal","General & Internal Medicine","219ZG","WOS:000324549800001"]
[null,null,null,null,"J","Soucek, O; Lebl, J; Zapletalova, J; Novotna, D; Plasilova, I; Kolouskova, S; Zemkova, D; Rocek, M; Hlavka, Z; Hirschfeldova, K; Sumnik, Z",null,null,null,"Soucek, O.; Lebl, J.; Zapletalova, J.; Novotna, D.; Plasilova, I.; Kolouskova, S.; Zemkova, D.; Rocek, M.; Hlavka, Z.; Hirschfeldova, K.; Sumnik, Z.",null,null,"Bone Geometry and Volumetric Bone Density at the Radius in Patients with Isolated SHOX Deficiency","EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES",null,null,"English","Article",null,null,null,null,null,"bone strength; pQCT; body disproportion; skeletal dysplasia","IDIOPATHIC SHORT STATURE; LERI-WEILL DYSCHONDROSTEOSIS; HOMEOBOX GENE SHOX; TURNER-SYNDROME; GROWTH FAILURE; PROXIMAL RADIUS; MINERAL DENSITY; HAPLOINSUFFICIENCY; CHILDREN; PREVALENCE","The short stature homeobox-containing gene (SHOX) plays an important role in bone development and growth. We aimed to assess bone geometry and volumetric bone mineral density at the radius in patients with isolated SHOX deficiency and to relate these bone parameters to the severity of disproportion between the upper and the lower body segment. 17 patients with isolated SHOX deficiency (median age 12.3 yrs, range 6.7-37.2, 12 children and 5 adults) were examined by peripheral quantitative CT (pQCT) at the non-dominant forearm. Results were expressed as Z-scores using published reference data. Linear regression analyses were performed to describe associations between pQCT parameters and the severity of disproportion expressed as sitting height to standing subischial leg height ratio. Trabecular volumetric bone mineral density (vBMD) at the distal radius was normal, whereas cortical vBMD was decreased (mean Z-scores 0.34+/-1.5, n.s., and -2.2+/-2.2, p < 0.001, respectively). Total bone cross-sectional area was enlarged at the diaphysis (2.1+/-1.2, p < 0.001), while cortical bone cross-sectional area was normal (-0.51+/-1.4, n.s.). Consequently, cortical thickness was decreased (-1.2+/-1.3, p < 0.01). The polar strength-strain index as a surrogate of long bone strength was normal (0.40+/-1.4, n.s.). We found no associations between pQCT parameters and the severity of disproportion. Conclusions: Patients with isolated SHOX deficiency are characterized by decreased cortical vBMD and cortical thickness and enlarged diaphysis. As similar changes have been described in girls with Turner syndrome, these findings suggest that haploinsufficiency of SHOX could cause characteristic skeletal anomalies at the radius.","[Soucek, O.; Lebl, J.; Kolouskova, S.; Zemkova, D.; Sumnik, Z.] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague 15006, Czech Republic; [Soucek, O.; Lebl, J.; Kolouskova, S.; Zemkova, D.; Rocek, M.; Sumnik, Z.] Univ Hosp Motol, Prague, Czech Republic; [Zapletalova, J.] Palacky Univ, Dept Paediat, Fac Med, CR-77147 Olomouc, Czech Republic; [Zapletalova, J.] Univ Hosp Olomouc, Olomouc, Czech Republic; [Novotna, D.] Masaryk Univ, Dept Paediat, Fac Med, Brno, Czech Republic; [Novotna, D.] Univ Hosp Brno, Brno, Czech Republic; [Plasilova, I.] Charles Univ Prague, Dept Paediat, Fac Med, Hradec Kralove, Czech Republic; [Plasilova, I.] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic; [Rocek, M.] Charles Univ Prague, Fac Med 2, Dept Radiol, Prague 15006, Czech Republic; [Hlavka, Z.] Charles Univ Prague, Dept Probabil & Math Stat, Fac Math & Phys, Prague 15006, Czech Republic; [Hirschfeldova, K.] Charles Univ Prague, Inst Biol, Fac Med 1, Prague 15006, Czech Republic; [Hirschfeldova, K.] Charles Univ Prague, Dept Med Genet, Fac Med 1, Prague 15006, Czech Republic; [Hirschfeldova, K.] Gen Univ Hosp, Prague, Czech Republic","Soucek, O (reprint author), Charles Univ Prague, Fac Med 2, Univ Hosp Motol, Dept Paediat, V Uvalu 84, Prague 15006, Czech Republic.","ondrej.soucek@lfmotol.cuni.cz",null,null,"Ministry of Health [00064203]","This work was supported by a grant from the Ministry of Health (Project for Conceptual Development of Research Organization 00064203). We would like to acknowledge all the patients participating in our study.",null,33,2,2,"JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH","STUTTGART","RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY","0947-7349",null,null,"EXP CLIN ENDOCR DIAB","Exp. Clin. Endocrinol. Diabet.","FEB",2013,121,2,null,null,null,null,109,114,null,"10.1055/s-0032-1333260",null,6,"Endocrinology & Metabolism","Endocrinology & Metabolism","098ON","WOS:000315558700009"]
[null,null,null,null,"J","Varjassyova, A; Horinek, D; Andel, R; Amlerova, J; Laczo, J; Sheardova, K; Magerova, H; Holmerova, I; Vyhnalek, M; Bradac, O; Geda, YE; Hort, J",null,null,null,"Varjassyova, Alexandra; Horinek, Daniel; Andel, Ross; Amlerova, Jana; Laczo, Jan; Sheardova, Katerina; Magerova, Hana; Holmerova, Iva; Vyhnalek, Martin; Bradac, Ondrej; Geda, Yonas E.; Hort, Jakub",null,null,"Recognition of Facial Emotional Expression in Amnestic Mild Cognitive Impairment","JOURNAL OF ALZHEIMERS DISEASE",null,null,"English","Article",null,null,null,null,null,"Assessment of cognitive disorders/dementia; cognitive aging; emotion; mild cognitive impairment; neuropsychiatric symptoms","ALZHEIMER-DISEASE; FACE PERCEPTION; NEUROPSYCHIATRIC SYMPTOMS; SOCIAL COGNITION; AMYGDALA ATROPHY; DEMENTIA; DEFICITS; MEMORY; PREVALENCE; INVENTORY","We examined whether recognition of facial emotional expression would be affected in amnestic mild cognitive impairment (aMCI). A total of 50 elderly persons met the initial inclusion criteria; 10 were subsequently excluded (Geriatric Depression Score > 5). 22 subjects were classified with aMCI based on published criteria (single domain aMCI [SD-aMCI], n = 10; multiple domain aMCI [MD-aMCI], n = 12); 18 subjects were cognitively normal. All underwent standard neurological and neuropsychological evaluations as well as tests of facial emotion recognition (FER) and famous faces identification (FFI). Among normal controls, FFI was negatively correlated with Mini-Mental Status Examination scores and positively correlated with executive function. Among patients with aMCI, FER was correlated with attention/speed of processing. No other correlations were significant. In a multinomial logistic regression model adjusted for age, gender, and education, a poorer score on FER, but not on FFI, was associated with greater odds of being classified as MD-aMCI (odds ratio [OR], 3.82; 95% confidence interval [CI], 1.05-13.91; p = 0.042). This association was not explained by memory or global cognitive score. There was no association between FER or FFI and SD-aMCI (OR, 1.13; 95% CI, 0.36-3.57; p = 0.836). Therefore, FER, but not FFI, may be impaired in MD-aMCI. This implies that in MD-aMCI, the tasks of FER and FFI may involve segregated neurocognitive networks.","[Geda, Yonas E.] Mayo Clin, Dept Psychiat & Psychol, Scottsdale, AZ 85259 USA; [Varjassyova, Alexandra; Amlerova, Jana; Laczo, Jan; Magerova, Hana; Vyhnalek, Martin; Hort, Jakub] Charles Univ Prague, Fac Med 2, Dept Neurol, Memory Disorders Clin, Prague, Czech Republic; [Varjassyova, Alexandra; Amlerova, Jana; Laczo, Jan; Magerova, Hana; Vyhnalek, Martin; Hort, Jakub] Univ Hosp Motol, Prague, Czech Republic; [Horinek, Daniel; Bradac, Ondrej] Charles Univ Prague, Sch Med 1, Dept Neurosurg, Prague, Czech Republic; [Horinek, Daniel; Bradac, Ondrej] Cent Mil Hosp, Prague, Czech Republic; [Holmerova, Iva] Czech Alzheimer Soc, Prague, Czech Republic; [Geda, Yonas E.] Mayo Clin, Dept Neurol, Scottsdale, AZ 85259 USA; [Geda, Yonas E.] Mayo Clin, Dept Hlth Sci Res, Scottsdale, AZ 85259 USA; [Varjassyova, Alexandra; Horinek, Daniel; Andel, Ross; Laczo, Jan; Sheardova, Katerina; Vyhnalek, Martin; Geda, Yonas E.; Hort, Jakub] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Horinek, Daniel] Univ Marburg, Dept Neurosurg, Marburg, Germany; [Andel, Ross] Univ S Florida, Sch Aging Studies, Tampa, FL USA","Geda, YE (reprint author), Mayo Clin, Dept Psychiat & Psychol, Collaborat Res Bldg,13400 E Shea Blvd, Scottsdale, AZ 85259 USA.","geda.yonas@mayo.edu",null,null,"European Union Regional Development Fund - Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; Internal Grant Agency of the Ministry of Health [NS10331]; Grant Agency of Charles University [74308]; Grant Agency of the Czech Republic [309/09/1053]; National Institutes of Health [K01 MH068351, AG006786]; RWJ (Harold Amos scholar) Foundation","This work was funded in part from the European Union Regional Development Fund - Project FNUSA-ICRC (CZ.1.05/1.1.00/02.0123), [Internal Grant Agency of the Ministry of Health (NS10331), Grant Agency of Charles University (74308), Grant Agency of the Czech Republic (309/09/1053)], National Institutes of Health (K01 MH068351, AG006786) and RWJ (Harold Amos scholar) Foundation.",null,56,2,2,"IOS PRESS","AMSTERDAM","NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS","1387-2877",null,null,"J ALZHEIMERS DIS","J. Alzheimers Dis.",null,2013,33,1,null,null,null,null,273,280,null,"10.3233/JAD-2012-120148",null,8,"Neurosciences","Neurosciences & Neurology","051UY","WOS:000312154400026"]
[null,null,null,null,"J","Krysl, D; Zamecnik, J; Senolt, L; Marusic, P",null,null,null,"Krysl, David; Zamecnik, Josef; Senolt, Ladislav; Marusic, Petr",null,null,"Chronic repetitive nonprogressive epilepsia partialis continua due to rheumatoid meningitis","SEIZURE-EUROPEAN JOURNAL OF EPILEPSY",null,null,"English","Article",null,null,null,null,null,"Status epilepticus; Rheumatoid arthritis; Meningitis; Magnetic resonance","PACHYMENINGITIS",null,"[Krysl, David; Marusic, Petr] Charles Univ Prague, Dept Neurol, Fac Med 2, Univ Hosp Motol, Prague, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Univ Hosp Motol, Prague, Czech Republic; [Senolt, Ladislav] Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic; [Senolt, Ladislav] Charles Univ Prague, Fac Med 1, Prague, Czech Republic","Krysl, D (reprint author), Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","dkrysl@gmail.com",null,null,null,null,null,9,1,1,"W B SAUNDERS CO LTD","LONDON","32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND","1059-1311",null,null,"SEIZURE-EUR J EPILEP","Seizure","JAN",2013,22,1,null,null,null,null,80,82,null,"10.1016/j.seizure.2012.10.006",null,3,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","084SU","WOS:000314560200018"]
[null,null,null,null,"J","Teyssler, P; Taborska, K; Kolostova, K; Bobek, V",null,null,null,"Teyssler, Petr; Taborska, Katerina; Kolostova, Katarina; Bobek, Vladimir",null,null,"Radiosynoviorthesis in hemophilic joints with yttrium-90 citrate and rhenium-186 sulfide and long term results","HELLENIC JOURNAL OF NUCLEAR MEDICINE",null,null,"English","Article",null,null,null,null,null,"Radiosynovectomy; Haemophiliac arthropathy; Yttrium; Rhenium; Clinical results","RADIOISOTOPE SYNOVECTOMY; RADIATION SYNOVECTOMY; CHRONIC SYNOVITIS; EXPERIENCE; SYNOVIORTHESIS; KNEE","Repeated bleeding in the joint cavities is the most annoying symptom and often has disabling effects in patients with hemophilia (PWH). Our aim was to study the effect of radiosynovectomy (RSO) with beta particle-emitting radiocolloids in the treatment of hemorhagic arthropathy. We have treated 22 joints from 18 patients with hemophilia A, from April 2008 to February 2012,5 knees, 11 elbows and 6 ankles. Joints were divided into two Groups, those treated with yttrium-90-citrate (Y-90-C) (5 knees, 2 of them twice)-Group I and those with rhenium-186-sulfide (Re-186-S) (11 elbows, 1 of them treated twice and 6 ankles)-Group II. A total of 25 treatments. Follow-up period was 3 months, 1 year and 3 years. Results showed a favourable subjective and a better objective result in all 5 joints of Group I and in 15/17 joints of Group II, respectively. Follow-up after 3 months showed significant improvement in Hemophilia Join Health Score (HJHS) after 20 treatments and steady score after 5 treatments. After 1 year, 19 treated joints had improved for the first time, 3 remained steady and 3 were not examined. After 3 years, 9 treated joints were HJHS steady, while 16 were not examined. One year after treatment, 13/14 joints of patients, aged 6-23 years showed better HJHS score, while 9/11 joints of patients aged 26-51 years, showed better HJHS. Synovial membrane thickness as measured by MRI in 8 joints, before and 3 months after treatment was not related to prognosis. In conclusion, in a small group of hemophilic patients with hemorrhagic arthropathy treated with Y-90-C and with Re-186-S, our study showed good results irrespective of age in 22/25 treatments after 3 months or 1 year. The thickness of synovial membrane in the 8 joints studied was not related to prognosis. Hell J Nucl Med 2013; 16(1): 44-49 Epub ahead of print: 26-3-2013 Published on line: 10 April 2013","[Teyssler, Petr; Kolostova, Katarina; Bobek, Vladimir] Charles Univ Prague, Dept Tumor Biol, Fac Med 3, Prague 10097, Czech Republic; [Teyssler, Petr] Charles Univ Prague, Clin Orthopaed & Traumatol Children & Adults, Fac Med 2, Prague 10097, Czech Republic; [Teyssler, Petr; Taborska, Katerina] Univ Hosp Motol, Prague, Czech Republic; [Taborska, Katerina] Charles Univ Prague, Dept Nucl Med & Endocrinol, Fac Med 2, Prague 10097, Czech Republic; [Bobek, Vladimir] Charles Univ Prague, Dept Surg, Fac Med 3, Prague 10097, Czech Republic; [Bobek, Vladimir] Univ Hosp Kralovske Vinohrady Prague, Prague, Czech Republic","Bobek, V (reprint author), Charles Univ Prague, Dept Tumor Biol, Fac Med 3, Ruska 87, Prague 10097, Czech Republic.","vbobek@centrum.cz",null,null,"Charles University in Prague, 3rd Faculty of Medicine, Prague, Czech Republic [P 27/2012]","Supported by the Research project P 27/2012 awarded by Charles University in Prague, 3rd Faculty of Medicine, Prague, Czech Republic.",null,16,1,1,"HELLENIC SOC NUCLEAR MEDICINE","THESSALONIKI","51 HERMU ST, THESSALONIKI, 546 23, GREECE","1790-5427",null,null,"HELL J NUCL MED","Hell. J. Nucl. Med.","JAN-APR",2013,16,1,null,null,null,null,44,49,null,null,null,6,"Radiology, Nuclear Medicine & Medical Imaging","Radiology, Nuclear Medicine & Medical Imaging","130AZ","WOS:000317886400008"]
[null,null,null,null,"J","Ambrozova, H; Maresova, V; Fajt, M; Pavlicek, P; Rohacova, H; Machova, I; Petras, P",null,null,null,"Ambrozova, Helena; Maresova, Vilma; Fajt, Martin; Pavlicek, Petr; Rohacova, Hana; Machova, Ivana; Petras, Petr",null,null,"The first case of fatal pneumonia caused by Panton-Valentine leukocidin-producing Staphylococcus aureus in an infant in the Czech Republic","FOLIA MICROBIOLOGICA",null,null,"English","Article",null,null,null,null,null,null,"SKIN INFECTIONS; METHICILLIN-RESISTANT; RECURRENT; STRAIN; GENE","Panton-Valentine leukocidin-producing strains of Staphylococcus aureus can cause severe skin and soft tissue infections and necrotizing pneumonia with a high mortality rate. This is a report on the first case of fatal pneumonia with mediastinitis in an infant in the Czech Republic. The causative agent was a methicillin-susceptible S. aureus strain with pronounced production of the PVL toxin and hyperproduction of enterotoxin A.","[Ambrozova, Helena; Maresova, Vilma; Rohacova, Hana] Charles Univ Prague, Bulovka Hosp, Dept Infect Dis 1, Fac Med 2, Prague, Czech Republic; [Fajt, Martin] Thomayer Hosp, Dept Paediat, Prague, Czech Republic; [Pavlicek, Petr] Charles Univ Prague, Motol Univ Hosp, Dept Anaesthesiol & Resuscitat, Fac Med 2, Prague, Czech Republic; [Machova, Ivana; Petras, Petr] Natl Inst Publ Hlth, Natl Reference Lab Staphylococci, Prague 10042, Czech Republic","Petras, P (reprint author), Natl Inst Publ Hlth, Natl Reference Lab Staphylococci, Srobarova 48, Prague 10042, Czech Republic.","petrasi@szu.cz",null,null,"Czech Science Foundation [310/09/0459]","The authors thank Assoc. Prof. Roman Pantucek, PhD, from the Faculty of Science, Masaryk University, Brno, for the detailed microbiological characterisation of the causative agent, Eva Kodytkova for her valuable help, and the National Reference Laboratory for Antibiotics, NIPH, Prague, for the antibiotic susceptibility testing. The study was supported by grant no. 310/09/0459 from the Czech Science Foundation.",null,19,0,0,"SPRINGER","DORDRECHT","VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS","0015-5632",null,null,"FOLIA MICROBIOL","Folia Microbiol.","MAY",2013,58,3,null,null,null,null,225,228,null,"10.1007/s12223-012-0200-z",null,4,"Biotechnology & Applied Microbiology; Microbiology","Biotechnology & Applied Microbiology; Microbiology","131EZ","WOS:000317976600007"]
[null,null,null,null,"J","Musova, Z; Sedlacek, Z; Mazanec, R; Klempir, J; Roth, J; Plevova, P; Vyhnalek, M; Kopeckova, M; Apltova, L; Krepelova, A; Zumrova, A",null,null,null,"Musova, Zuzana; Sedlacek, Zdenek; Mazanec, Radim; Klempir, Jiri; Roth, Jan; Plevova, Pavlina; Vyhnalek, Martin; Kopeckova, Marta; Apltova, Ludmila; Krepelova, Anna; Zumrova, Alena",null,null,"Spinocerebellar Ataxias Type 8, 12, and 17 and Dentatorubro-Pallidoluysian Atrophy in Czech Ataxic Patients","CEREBELLUM",null,null,"English","Article",null,null,null,null,null,"Spinocerebellar ataxia; Trinucleotide repeat; Amyotrophic lateral sclerosis; Multiple sclerosis","PROTEIN PHOSPHATASE 2A; CAG TRINUCLEOTIDE REPEAT; POLYGLUTAMINE EXPANSIONS; REGULATORY SUBUNIT; CEREBELLAR-ATAXIA; SCA12; GENE; FAMILIES; ANTICIPATION; INSTABILITY","Spinocerebellar ataxias (SCAs) are a heterogeneous group of neurodegenerative disorders currently associated with 27 genes. The most frequent types are caused by expansions in coding CAG repeats. The frequency of SCA subtypes varies among populations. We examined the occurrence of rare SCAs, SCA8, SCA12, SCA17 and dentatorubro-pallidoluysian atrophy (DRPLA), in the Czech population from where the data were missing. We analyzed causal gene expansions in 515 familial and sporadic ataxic patients negatively tested for SCA1-3 and SCA6-7. Pathogenic SCA8 and SCA17 expansions were identified in eight and five patients, respectively. Tay-Sachs disease was later diagnosed in one patient with an SCA8 expansion and the diagnosis of multiple sclerosis (MS) was suspected in two other patients with SCA8 expansions. These findings are probably coincidental, although the participation of SCA8 expansions in the susceptibility to MS and disease progression cannot be fully excluded. None of the patients had pathogenic SCA12 or DRPLA expansions. However, three patients had intermediate SCA12 alleles out of the normal range with 36 and 43 CAGs. Amyotrophic lateral sclerosis (ALS) was probable in the patient with 43 CAGs. This coincidence is remarkable, especially in the context with the recently identified predisposing role of longer SCA2 alleles in ALS. Five families with SCA17 represent a significant portion of ataxic patients and this should be reflected in the diagnostics of SCAs in the Czech population. SCA8 expansions must be considered after careful clinical evaluation.","[Musova, Zuzana; Sedlacek, Zdenek; Apltova, Ludmila; Krepelova, Anna] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic; [Musova, Zuzana; Sedlacek, Zdenek; Mazanec, Radim; Vyhnalek, Martin; Apltova, Ludmila; Krepelova, Anna; Zumrova, Alena] Univ Hosp Motol, Prague, Czech Republic; [Mazanec, Radim; Vyhnalek, Martin] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague, Czech Republic; [Klempir, Jiri; Roth, Jan] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague, Czech Republic; [Klempir, Jiri; Roth, Jan] Charles Univ Prague, Dept Neurol, Ctr Clin Neurosci, Prague, Czech Republic; [Klempir, Jiri; Roth, Jan] Gen Univ Hosp, Prague, Czech Republic; [Plevova, Pavlina] Univ Hosp Ostrava, Dept Med Genet, Ostrava, Czech Republic; [Kopeckova, Marta] Genomac Int, Prague, Czech Republic; [Zumrova, Alena] Charles Univ Prague, Dept Child Neurol, Fac Med 2, Prague, Czech Republic; [Vyhnalek, Martin] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic","Musova, Z (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague, Czech Republic.","zuzana.musova@fnmotol.cz",null,null,"Ministry of Health of the Czech Republic [NS10005-4]","This work was supported by grant NS10005-4 from the Ministry of Health of the Czech Republic. We thank Eva Balaziova (Praha), Jiri Berger (Plzen), Charouzdova Radka (Usti nad Labem), Jana Kalisova (Praha), Martin Kovar (Praha), Jolana Markova (Praha), Alena Novotna (Pardubice), Kamila Svetnicova (Praha), Dusan Tenora (Blansko), and Martin Valis (Hradec Kralove) for referring the patients and the affected families for cooperation.",null,44,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1473-4222",null,null,"CEREBELLUM","Cerebellum","APR",2013,12,2,null,null,null,null,155,161,null,"10.1007/s12311-012-0403-5",null,7,"Neurosciences","Neurosciences & Neurology","099RJ","WOS:000315638600003"]
[null,null,null,null,"J","Al-Hiti, H; Chovanec, M; Melenovsky, V; Vajnerova, O; Banasova, A; Kautzner, J; Herget, J",null,null,null,"Al-Hiti, H.; Chovanec, M.; Melenovsky, V.; Vajnerova, O.; Banasova, A.; Kautzner, J.; Herget, J.",null,null,"L-Arginine in Combination With Sildenafil Potentiates the Attenuation of Hypoxic Pulmonary Hypertension in Rats","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Pulmonary hypertension; Chronic hypoxia; L-arginine; Sildenafil","NITRIC-OXIDE; ARTERIAL-HYPERTENSION; ORAL SILDENAFIL; BLOOD-PRESSURE; INHIBITION; MONOPHOSPHATE; CIRCULATION; ACTIVATION; MODEL","Chronic hypoxia induces an increased production of nitric oxide (NO) in pulmonary prealveolar arterioles. Bioavailability of the NO in the pulmonary vessels correlates with concentration of L-arginine as well as activity of phosphodiesterase-5 enzyme (PDE-5). We tested a hypothesis whether a combination of L-arginine and PDE-5 inhibitor sildenafil has an additive effect in reduction of the hypoxic pulmonary hypertension (HPH) in rats. Animals were exposed to chronic normobaric hypoxia for 3 weeks. In the AH group, rats were administered L-arginine during chronic hypoxic exposure. In the SH group, rats were administered sildenafil during chronic hypoxic exposure. In the SAH group, rats were treated by the combination of L-arginine as well as sildenafil during exposure to chronic hypoxia. Mean PAP, structural remodeling of peripheral pulmonary arterioles (%DL) and RV/LV+S ratio was significantly decreased in the SAH group compared to hypoxic controls even decreased compared to the AH and the SH groups in first two measured parameters. Plasmatic concentration of cGMP and NOx were significantly lower in the SAH group compared to hypoxic controls. We demonstrate that NO synthase substrate L-arginine and phosphodiesterase-5 inhibitor sildenafil administered in combination are more potent in attenuation of the HPH compared to a treatment by substances given alone.","[Al-Hiti, H.; Melenovsky, V.; Kautzner, J.] Inst Clin & Expt Med, Dept Cardiol, Prague, Czech Republic; [Chovanec, M.] Na Homolce Hosp, Dept Cardiol, Prague, Czech Republic; [Chovanec, M.; Vajnerova, O.; Herget, J.] Charles Univ Prague, Sch Med 2, Dept Physiol, Prague 15000, Czech Republic; [Banasova, A.] Charles Univ Prague, Sch Med 2, Dept Pathophysiol, Prague 15000, Czech Republic","Chovanec, M (reprint author), Charles Univ Prague, Sch Med 2, Dept Physiol, Plzenska 130-221, Prague 15000, Czech Republic.","milan.chovanec@lfmotol.cuni.cz",null,null," [GACR 305/08/108];  [GAUK 78007];  [IGA NT/13358]","Supported by grants GACR 305/08/108, GAUK 78007, IGA NT/13358. We would like to express our gratitude to our laboratory assistants: Ms Olga Hnilickova and Ms Pavlina Smolkova for assisting the experiments. In addition, we would like to thank Ms Monika Taylor and Mr Jack Coling for helping us with the manuscript preparation.",null,36,0,0,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408","1802-9973",null,"PHYSIOL RES","Physiol. Res.",null,2013,62,6,null,null,null,null,589,595,null,null,null,7,"Physiology","Physiology","282JQ","WOS:000329167600001"]
[null,null,null,null,"J","Rampichova, M; Buzgo, M; Krizkova, B; Prosecka, E; Pouzar, M; Strajtova, L",null,null,null,"Rampichova, M.; Buzgo, M.; Krizkova, B.; Prosecka, E.; Pouzar, M.; Strajtova, L.",null,null,"Injectable Hydrogel Functionalised with Thrombocyte-Rich Solution and Microparticles for Accelerated Cartilage Regeneration","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"composite hydrogel; microparticles; nanofibres; thrombocytes; mesenchymal stem cells; cartilage","NORMAL HUMAN KERATINOCYTES; MESENCHYMAL STEM-CELLS; IN-VITRO; ARTICULAR-CARTILAGE; CHONDROCYTE PROLIFERATION; REPAIR; DEGRADATION; NANOFIBERS; DEFECTS; TISSUE","PURPOSE OF THE STUDY Articular cartilage defects arise due to injury or osteochondral disease such as osteonecrosis or osteochondritis dissecans. In adult patients cartilage has minimal ability to repair itself and the lesions develop into degenerative arthritis. Overcoming the low regenerative capacity of the cartilage cells and the Hayflick limit poses a challenge for the therapy of osteochondral defects. Composite scaffolds with appropriate biomechanical properties combined with a suitable blend of proliferation and differentiation factors could be a solution. The aim of this in vitro study was to develop a novel functionalised hydrogel with an integrated drug delivery system stimulating articular cartilage regeneration. MATERIAL AND METHODS Injectable collagen/hyaluronic acid/fibrin composite hydrogel was mixed with nanofibre-based microparticles. These were loaded with-ascorbic acid and dexamethasone. In addition, the effect of thrombocyte-rich solution (TRS) was studied. The gels seeded with mesenchymal stem cells (MSCs) were cultivated for 14 days. The viability, proliferation and morphology of the cells were evaluated using molecular and microscopic methods. Scaffold degradation was also assessed. RESULTS The cultivation study showed that MSCs remained viable in all experimental groups, which indicated good biocompatibility of the gel. However, the number of cells in the groups enriched with microparticles was lower than in the other groups. On the other hand, confocal microscopy showed higher cell viability and rounded morphology of the cells, which can be associated with chodrogenic differentiation. The scaffolds containing microparticles showed significantly higher stability during the 14-day experiment. DISCUSSION Our results suggest that the addition of microparticles to the scaffold improved cell differentiation into the chondrogenic lineage, resulting in a lower proliferation rate. Cell viability was better in the groups enriched with microparticles that served as an efficient drug delivery system. In addition, the presence of microparticles slowed down 'gel degradation which can help achieve sufficient stability of the system for the time frame required for cartilage regeneration. CONCLUSIONS The novel approach described here produced an efficient system where microparticles served as a drug delivery system and stabilised the gel for prolonged periods of time. These characteristics play an important role in the development of scaffolds for cartilage regeneration. In the future the results of these in vitro experiments will be verified in an in vivo study.","[Rampichova, M.] CB Bio Sro, Prague, Czech Republic; [Rampichova, M.; Buzgo, M.; Prosecka, E.] Univ Karlova Praze, Ustav Biofyziky, Lekarska Fak 2, Prague 5, Czech Republic; [Buzgo, M.] Student Sci Sro, Horni Podluzi, Czech Republic; [Krizkova, B.] Univ Pardubice, Katedra Biol & Biochem Ved, Pardubice 53012, Czech Republic; [Pouzar, M.] Univ Pardubice, Ustav Environm & Chem Inzenyrstvi, Pardubice 53012, Czech Republic; [Strajtova, L.] Narodni Tkanove Ctr As, Brno, Czech Republic","Krizkova, B (reprint author), Univ Pardubice, Katedra Biol & Biochem Ved, Studentska 573, Pardubice 53012, Czech Republic.","bara.krizkova@yahoo.com",null,null,null,null,"Akeda K, 2006, OSTEOARTHR CARTILAGE, V14, P1272, DOI 10.1016/j.joca.2006.05.008; Behravesh E, 2002, BIOMACROMOLECULES, V3, P1263, DOI 10.1021/bm020067; Buckwalter JA, 1998, AAOS INSTR COURS LEC, V47, P487; Cui ZW, 2011, J BIOMED MATER RES A, V98A, P159, DOI 10.1002/jbm.a.33093; Filova E, 2007, PHYSIOL RES, V56, pS5; Filova E, 2008, J BIOMED MATER RES B, V87B, P415, DOI 10.1002/jbm.b.31119; Fortier LA, 2002, J BONE JOINT SURG BR, V84B, P276, DOI 10.1302/0301-620X.84B2.11167; Haleem AM, 2010, CARTILAGE, V1, P253; Hangody L, 2003, J BONE JOINT SURG AM, V85A, P25; Jakubova R, 2011, CELL PROLIFERAT, V44, P183, DOI 10.1111/j.1365-2184.2011.00737.x; Kaps C, 2002, ARTHRITIS RHEUM, V46, P149, DOI 10.1002/1529-0131(200201)46:1<149::AID-ART10058>3.0.CO;2-W; Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342; Knotek P, 2012, MAT SCI ENG C-MATER, V32, P1366, DOI 10.1016/j.msec.2012.04.012; Liang D, 2007, ADV DRUG DELIVER REV, V59, P1392, DOI 10.1016/j.addr.2007.04.021; Louwerse RT, 2000, J BIOMED MATER RES, V49, P506, DOI 10.1002/(SICI)1097-4636(20000315)49:4<506::AID-JBM9>3.0.CO;2-A; Lukas D, 2008, J APPL PHYS, V103, DOI 10.1063/1.2907967; Milano G, 2010, OSTEOARTHR CARTILAGE, V18, P971, DOI 10.1016/j.joca.2010.03.013; Min BM, 2004, BIOMATERIALS, V25, P1289, DOI 10.1016/j.biomaterials.2003.08.045; Na K, 2007, J BIOTECHNOL, V128, P412, DOI 10.1016/j.jbiotec.2006.09.025; Noh HK, 2006, BIOMATERIALS, V27, P3934, DOI 10.1016/j.biomaterials.2006.03.016; Park JC, 2011, J CLIN PERIODONTOL, V38, P721, DOI 10.1111/j.1600-051X.2011.01716.x; Pham QP, 2006, BIOMACROMOLECULES, V7, P2796, DOI 10.1021/bm060680j; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prosecka E, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/428503; Prosecka E, 2011, J BIOMED MATER RES A, V99A, P307, DOI 10.1002/jbm.a.33189; Rampichova M, 2010, ASAIO J, V56, P563, DOI 10.1097/MAT.0b013e3181fcbe24; Rho KS, 2006, BIOMATERIALS, V27, P1452, DOI 10.1016/j.biomaterials.2005.08.004; Sill TJ, 2008, BIOMATERIALS, V29, P1989, DOI 10.1016/j.biomaterials.2008.01.011; Susan Liao, 2006, Biomedical Materials, V1, DOI 10.1088/1748-6041/1/3/R01",29,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","FEB",2013,80,1,null,null,null,null,82,88,null,null,null,7,"Orthopedics","Orthopedics","099EU","WOS:000315604900013"]
[null,null,null,null,"J","Macakova, E; Kopecka, M; Kukacka, Z; Veisova, D; Novak, P; Man, P; Obsil, T; Obsilova, V",null,null,null,"Macakova, Eva; Kopecka, Miroslava; Kukacka, Zdenek; Veisova, Dana; Novak, Petr; Man, Petr; Obsil, Tomas; Obsilova, Veronika",null,null,"Structural basis of the 14-3-3 protein-dependent activation of yeast neutral trehalase Nth1","BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS",null,null,"English","Article",null,null,null,null,null,"14-3-3; Bmh; Neutral trehalase; H/D exchange; Molecular modeling; Circular dichroism","CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; CIRCULAR-DICHROISM; MASS-SPECTROMETRY; SWISS-MODEL; BINDING; PHOSPHORYLATION; 14-3-3-PROTEINS; DETERMINANTS; INHIBITION","Background: Trehalases are highly conserved enzymes catalyzing the hydrolysis of trehalose in a wide range of organisms. The activity of yeast neutral trehalase Nth1 is regulated in a 14-3-3- and a calcium-dependent manner. The Bmh proteins (the yeast 14-3-3 isoforms) recognize phosphorylated Nth1 and enhance its enzymatic activity through an unknown mechanism. Methods: To investigate the structural basis of interaction between Nth1 and Bmh1, we used hydrogen/deuterium exchange coupled to mass spectrometry, circular dichroism spectroscopy and homology modeling to identify structural changes occurring upon the complex formation. Results: Our results show that the Bmh1 protein binding affects structural properties of several regions of phosphorylated Nth1 : the N-terminal segment containing phosphorylation sites responsible for Nth1 binding to Bmh, the region containing the calcium binding domain, and segments surrounding the active site of the catalytic trehalase domain. The complex formation between Bmh1 and phosphorylated Nth1, however, is not accompanied by the change in the secondary structure composition but rather the change in the tertiary structure. Conclusions: The 14-3-3 protein-dependent activation of Nth1 is based on the structural change of both the calcium binding domain and the catalytic trehalase domain. These changes likely increase the accessibility of the active site, thus resulting in Nth1 activation. General significance: The results presented here provide a structural view of the 14-3-3 protein-dependent activation of yeast neutral trehalase Nth1, which might be relevant to understand the process of Nth1 activity regulation as well as the role of the 14-3-3 proteins in the regulation of other enzymes. (c) 2013 Elsevier B.V. All rights reserved.","[Macakova, Eva; Kopecka, Miroslava; Veisova, Dana; Obsil, Tomas; Obsilova, Veronika] Acad Sci Czech Republic, Inst Physiol, Vvi, CR-14220 Prague, Czech Republic; [Macakova, Eva; Kopecka, Miroslava; Veisova, Dana] Charles Univ Prague, Fac Med 2, Prague 15006, Czech Republic; [Kukacka, Zdenek; Novak, Petr; Man, Petr] Acad Sci Czech Republic, Inst Microbiol, Vvi, CR-14220 Prague, Czech Republic; [Kukacka, Zdenek; Novak, Petr; Man, Petr] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12843, Czech Republic; [Obsil, Tomas] Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic","Obsilova, V (reprint author), Acad Sci Czech Republic, Inst Physiol, Vvi, Videnska 1083, CR-14220 Prague, Czech Republic.","obsilova@biomed.cas.cz","Obsilova, Veronika/B-7116-2012; Obsil, Tomas/B-7142-2012","Obsilova, Veronika/0000-0003-0851-7680; ","Czech Science Foundation [P207/11/0455]; Grant Agency of Charles University [644313, 350111]; Academy of Sciences of the Czech Republic (Research Project of the Institute of Physiology) [RVO: 67985823]; Academy of Sciences of the Czech Republic (Research Project of the Institute of Microbiology) [RVO: 61388971]; Ministry of Education, Youth and Sports of the Czech Republic [MSM0021620857]","This work was supported by the Czech Science Foundation (Project P207/11/0455); Grant Agency of Charles University (Grants 644313 and 350111); Academy of Sciences of the Czech Republic (Research Projects RVO: 67985823 of the Institute of Physiology and RVO: 61388971 of the Institute of Microbiology) and Ministry of Education, Youth and Sports of the Czech Republic (Research Project MSM0021620857).",null,42,3,3,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0304-4165",null,null,"BBA-GEN SUBJECTS","Biochim. Biophys. Acta-Gen. Subj.","OCT",2013,1830,10,null,null,null,null,4491,4499,null,"10.1016/j.bbagen.2013.05.025",null,9,"Biochemistry & Molecular Biology; Biophysics","Biochemistry & Molecular Biology; Biophysics","210SN","WOS:000323854900010"]
[null,null,null,null,"J","Amemori, T; Romanyuk, N; Jendelova, P; Herynek, V; Turnovcova, K; Prochazka, P; Kapcalova, M; Cocks, G; Price, J; Sykova, E",null,null,null,"Amemori, Takashi; Romanyuk, Nataliya; Jendelova, Pavla; Herynek, Vit; Turnovcova, Karolina; Prochazka, Pavel; Kapcalova, Miroslava; Cocks, Graham; Price, Jack; Sykova, Eva",null,null,"Human conditionally immortalized neural stem cells improve locomotor function after spinal cord injury in the rat","STEM CELL RESEARCH & THERAPY",null,null,"English","Article",null,null,null,null,null,"Human fetal neural stem cells; spinal cord injury; motor neuron differentiation; trophic support; neuroregeneration","STEM/PROGENITOR CELLS; STROMAL CELLS; GENE-THERAPY; RECOVERY; TRANSPLANTATION; STROKE; BRAIN; TIME; IMMUNOSUPPRESSION; TISSUE","Introduction: A growing number of studies have highlighted the potential of stem cell and more-differentiated neural cell transplantation as intriguing therapeutic approaches for neural repair after spinal cord injury (SCI). Methods: A conditionally immortalized neural stem cell line derived from human fetal spinal cord tissue (SPC-01) was used to treat a balloon-induced SCI. SPC-01 cells were implanted into the lesion 1 week after SCI. To determine the feasibility of tracking transplanted stem cells, a portion of the SPC-01 cells was labeled with poly-L-lysine-coated superparamagnetic iron-oxide nanoparticles, and the animals grafted with labeled cells underwent magnetic resonance imaging. Functional recovery was evaluated by using the BBB and plantar tests, and lesion morphology, endogenous axonal sprouting and graft survival, and differentiation were analyzed. Quantitative polymerase chain reaction (qPCR) was used to evaluate the effect of transplanted SPC-01 cells on endogenous regenerative processes. Results: Transplanted animals displayed significant motor and sensory improvement 2 months after SCI, when the cells robustly survived in the lesion and partially filled the lesion cavity. qPCR revealed the increased expression of rat and human neurotrophin and motor neuron genes. The grafted cells were immunohistologically positive for glial fibrillary acidic protein (GFAP); however, we found 25% of the cells to be positive for Nkx6.1, an early motor neuron marker. Spared white matter and the robust sprouting of growth-associated protein 43 (GAP43)(+) axons were found in the host tissue. Four months after SCI, the grafted cells matured into Islet2(+) and choline acetyltransferase (ChAT)+ neurons, and the graft was grown through with endogenous neurons. Grafted cells labeled with poly-L-lysine-coated superparamagnetic nanoparticles before transplantation were detected in the lesion on T-2-weighted images as hypointense spots that correlated with histologic staining for iron and the human mitochondrial marker MTCO2. Conclusions: The transplantation of SPC-01 cells produced significant early functional improvement after SCI, suggesting an early neurotrophic action associated with long-term restoration of the host tissue, making the cells a promising candidate for future cell therapy in patients with SCI.","[Amemori, Takashi; Romanyuk, Nataliya; Jendelova, Pavla; Turnovcova, Karolina; Prochazka, Pavel; Kapcalova, Miroslava; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic; [Herynek, Vit] Inst Clin & Expt Med, MR Unit, Dept Diagnost & Intervent Radiol, Prague, Czech Republic; [Cocks, Graham; Price, Jack] Kings Coll London, Inst Psychiat, London WC2R 2LS, England","Jendelova, P (reprint author), Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic.","jendel@biomed.cas.cz",null,null," [GA CR P304/12/1370 GA CR 13-00939S];  [P304/12/G069];  [LH12024];  [00023001IKEM]","This study was supported by the grants GA CR P304/12/1370 GA CR 13-00939S, P304/12/G069, LH12024, and Institutional grant 00023001IKEM (MZ CR). We thank James Dutt for critical reading of the manuscript.",null,43,3,3,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1757-6512",null,null,"STEM CELL RES THER","Stem Cell Res. Ther.","JUN 7",2013,4,null,null,null,null,null,null,null,null,"10.1186/scrt219",null,15,"Cell Biology; Medicine, Research & Experimental","Cell Biology; Research & Experimental Medicine","169LS","WOS:000320782300001"]
[null,null,null,null,"J","Kudr, M; Krsek, P; Maton, B; Malone, S; Jahodova, A; Jezdik, P; Komarek, V; Miller, I; Jayakar, P; Resnick, T; Duchowny, M",null,null,null,"Kudr, Martin; Krsek, Pavel; Maton, Bruno; Malone, Stephen; Jahodova, Alena; Jezdik, Petr; Komarek, Vladimir; Miller, Ian; Jayakar, Prasanna; Resnick, Trevor; Duchowny, Michael",null,null,"Predictive factors of ictal SPECT findings in paediatric patients with focal cortical dysplasia","EPILEPTIC DISORDERS",null,null,"English","Article",null,null,null,null,null,"Ictal SPECT; focal cortical dysplasia; epilepsy surgery","CEREBRAL-BLOOD-FLOW; TEMPORAL-LOBE SEIZURES; EPILEPSY SURGERY; EXTRATEMPORAL EPILEPSY; EPILEPTOGENIC ZONE; QUANTITATIVE-ANALYSIS; CLINICAL-USEFULNESS; INTRACRANIAL EEG; CHILDREN; MRI","Aims. To identify variables that influence the extent of ictal single-photon emission computed tomography (SPECT) findings in paediatric patients with focal cortical dysplasia (FCD). Methods. We visually evaluated 98 ictal SPECT studies from 67 children treated surgically for intractable epilepsy caused by FCD. SPECT findings were classified as \"non-localised\", \"well-localised\", and \"extensive\" and compared with parameters of injected seizures (seizure type and duration, injection time, and scalp EEG ictal pattern), presence of structural pathology on MRI, type of surgery performed after SPECT study, and histological findings. Results. A shorter injection time and duration of injected seizure was associated with more localised SPECT hyperperfusion. SPECT findings were not significantly influenced by type of injected seizure. Widespread ictal scalp EEG patterns were associated with extensive SPECT findings. Larger zones of hyperperfusion were more common in patients with lesional MRI and patients undergoing multilobar resections. SPECT studies demonstrating good localisation were more common in patients with mild malformations of cortical development. Conclusion. Early ictal SPECT radiotracer injection is crucial for successful localisation of the epileptogenic zone. Seizure duration, type of scalp EEG findings, and presence of structural pathology on MRI may influence the extent of ictal SPECT hyperperfusion, which was associated with certain types of epilepsy surgery as well as histopathological findings.","[Kudr, Martin; Krsek, Pavel; Jahodova, Alena; Jezdik, Petr; Komarek, Vladimir] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Paediat Neurol, Prague, Czech Republic; [Maton, Bruno; Malone, Stephen; Miller, Ian; Jayakar, Prasanna; Resnick, Trevor; Duchowny, Michael] Miami Childrens Hosp, Dept Neurol, Miami, FL USA; [Maton, Bruno; Malone, Stephen; Miller, Ian; Jayakar, Prasanna; Resnick, Trevor; Duchowny, Michael] Miami Childrens Hosp, Inst Brain, Comprehens Epilepsy Program, Miami, FL USA; [Resnick, Trevor; Duchowny, Michael] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA","Duchowny, M (reprint author), Univ Miami, Miller Sch Med, Miami Childrens Hosp, Dept Neurol,Brain Inst, 3200 SW 60th Court, Miami, FL 33136 USA.","michael.duchowny@mch.com",null,null,"Kontakt Program [ME09042]; Ministry of Health, Czech Republic; Conceptual Development of Research Organization, University Hospital Motol, Prague, Czech Republic [00064203];  [GAUK 17010];  [CZ.2.16/3.1.00/24022]","This study was supported by grants GAUK 17010 (Martin Kudr), Kontakt Program ME09042 (Pavel Krsek) and CZ.2.16/3.1.00/24022 (Pavel Krsek), and by the Ministry of Health, Czech Republic; Conceptual Development of Research Organization, University Hospital Motol, Prague, Czech Republic 00064203 (Pavel Krsek). None of the authors have any conflict of interest to disclose.",null,42,0,0,"JOHN LIBBEY EUROTEXT LTD","MONTROUGE","127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE","1294-9361","1950-6945",null,"EPILEPTIC DISORD","Epileptic Disord.","DEC",2013,15,4,null,null,null,null,383,391,null,"10.1684/epd.2013.0621",null,9,"Clinical Neurology","Neurosciences & Neurology","278QQ","WOS:000328905200003"]
[null,null,null,null,"J","Heger, Z; Cernei, N; Kudr, J; Gumulec, J; Blazkova, I; Zitka, O; Eckschlager, T; Stiborova, M; Adam, V; Kizek, R",null,null,null,"Heger, Zbynek; Cernei, Natalia; Kudr, Jiri; Gumulec, Jaromir; Blazkova, Iva; Zitka, Ondrej; Eckschlager, Tomas; Stiborova, Marie; Adam, Vojtech; Kizek, Rene",null,null,"A Novel Insight into the Cardiotoxicity of Antineoplastic Drug Doxorubicin","INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES",null,null,"English","Article",null,null,null,null,null,"myocardium; cardiomyopathy; interaction; amide bond; spectrophotometry; ion-exchange liquid chromatography","SKELETAL-MUSCLE; IN-VIVO; ANTHRACYCLINES; CARDIOMYOPATHY; METABOLISM; APOPTOSIS; DELIVERY; CANCER; GROWTH; DYSFUNCTION","Doxorubicin is a commonly used antineoplastic agent in the treatment of many types of cancer. Little is known about the interactions of doxorubicin with cardiac biomolecules. Serious cardiotoxicity including dilated cardiomyopathy often resulting in a fatal congestive heart failure may occur as a consequence of chemotherapy with doxorubicin. The purpose of this study was to determine the effect of exposure to doxorubicin on the changes in major amino acids in tissue of cardiac muscle (proline, taurine, glutamic acid, arginine, aspartic acid, leucine, glycine, valine, alanine, isoleucine, threonine, lysine and serine). An in vitro interaction study was performed as a comparison of amino acid profiles in heart tissue before and after application of doxorubicin. We found that doxorubicin directly influences myocardial amino acid representation even at low concentrations. In addition, we performed an interaction study that resulted in the determination of breaking points for each of analyzed amino acids. Lysine, arginine, -alanine, valine and serine were determined as the most sensitive amino acids. Additionally we compared amino acid profiles of myocardium before and after exposure to doxorubicin. The amount of amino acids after interaction with doxorubicin was significantly reduced (p = 0.05). This fact points at an ability of doxorubicin to induce changes in quantitative composition of amino acids in myocardium. Moreover, this confirms that the interactions between doxorubicin and amino acids may act as another factor most likely responsible for adverse effects of doxorubicin on myocardium.","[Heger, Zbynek; Cernei, Natalia; Kudr, Jiri; Gumulec, Jaromir; Blazkova, Iva; Zitka, Ondrej; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Cernei, Natalia; Gumulec, Jaromir; Zitka, Ondrej; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Gumulec, Jaromir] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-66243 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","heger@mendelu.cz; cernei.natalia3@gmail.com; george.kudr@centrum.cz; j.gumulec@gmail.com; iva.blazkova@seznam.cz; ZitkaO@seznam.cz; Tomas.Eckschlager@fnmotol.cz; stiborov@natur.cuni.cz; vojtech.adam@mendelu.cz; kizek@sci.muni.cz","Gumulec, Jaromir/D-7638-2012","Gumulec, Jaromir/0000-0002-9658-3444","CYTORES GACR [P301/10/0356]; CEITEC [CZ.1.05/1.1.00/02.0068]; MH CZ-DRO; University Hospital Motol, Prague, Czech Republic [00064203]; Liga proti rakovine LPR","Financial support from CYTORES GACR P301/10/0356, CEITEC CZ.1.05/1.1.00/02.0068, by MH CZ-DRO, University Hospital Motol, Prague, Czech Republic 00064203 and Liga proti rakovine LPR 2014 is highly acknowledged.",null,55,1,1,"MDPI AG","BASEL","POSTFACH, CH-4005 BASEL, SWITZERLAND","1422-0067",null,null,"INT J MOL SCI","Int. J. Mol. Sci.","NOV",2013,14,11,null,null,null,null,21629,21646,null,"10.3390/ijms141121629",null,18,"Chemistry, Multidisciplinary","Chemistry","274RR","WOS:000328624400027"]
[null,null,null,null,"J","Blazkova, I; Nguyen, HV; Dostalova, S; Kopel, P; Stanisavljevic, M; Vaculovicova, M; Stiborova, M; Eckschlager, T; Kizek, R; Adam, V",null,null,null,"Blazkova, Iva; Hoai Viet Nguyen; Dostalova, Simona; Kopel, Pavel; Stanisavljevic, Maja; Vaculovicova, Marketa; Stiborova, Marie; Eckschlager, Tomas; Kizek, Rene; Adam, Vojtech",null,null,"Apoferritin Modified Magnetic Particles as Doxorubicin Carriers for Anticancer Drug Delivery","INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES",null,null,"English","Article",null,null,null,null,null,"cancer; nanomedicine; magnetic particles; doxorubicin; nanoparticles","IRON-OXIDE NANOPARTICLES; BIOMEDICAL APPLICATIONS; MICROSPHERES; NANOCARRIERS; RELEASE; SYSTEMS; SIZE","Magnetic particle mediated transport in combination with nanomaterial based drug carrier has a great potential for targeted cancer therapy. In this study, doxorubicin encapsulation into the apoferritin and its conjugation with magnetic particles was investigated by capillary electrophoresis with laser-induced fluorescence detection (CE-LIF). The quantification of encapsulated doxorubicin was performed by fluorescence spectroscopy and compared to CE-LIF. Moreover, the significant enhancement of the doxorubicin signal was observed by addition of methanol into the sample solution.","[Blazkova, Iva; Hoai Viet Nguyen; Dostalova, Simona; Kopel, Pavel; Stanisavljevic, Maja; Vaculovicova, Marketa; Kizek, Rene; Adam, Vojtech] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Kopel, Pavel; Vaculovicova, Marketa; Kizek, Rene; Adam, Vojtech] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Adam, V (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","iva.blazkova@seznam.cz; nguyenviethoai@hus.edu.vn; esedinka@seznam.cz; paulko@centrum.cz; maja.stani85@gmail.com; marketa.ryvolova@seznam.cz; stiborov@yahoo.com; tomas.eckschlager@fnmotol.cz; kizek@sci.muni.cz; vojtech.adam@mendelu.cz","Dostalova, Simona/D-4951-2013; Kopel, Pavel/E-5711-2012",null,"CYTORES GA CR [P301/10/0356 (EA 14)]; CEITEC [CZ.1.05/1.1.00/02.0068]; IGA [IP22/2013]; MH CZ - DRO; University Hospital Motol, Prague, Czech Republic [00064203]; LPR","Financial support from CYTORES GA CR P301/10/0356 (EA 14), CEITEC CZ.1.05/1.1.00/02.0068, IGA IP22/2013, MH CZ - DRO, University Hospital Motol, Prague, Czech Republic 00064203 and LPR 2013 and by is highly acknowledged.",null,31,1,1,"MDPI AG","BASEL","POSTFACH, CH-4005 BASEL, SWITZERLAND","1422-0067",null,null,"INT J MOL SCI","Int. J. Mol. Sci.","JUL",2013,14,7,null,null,null,null,13391,13402,null,"10.3390/ijms140713391",null,12,"Chemistry, Multidisciplinary","Chemistry","188DH","WOS:000322171700029"]
[null,null,null,null,"J","Honetschlagerova, Z; Kitada, K; Huskova, Z; Sporkova, A; Kopkan, L; Burgelova, M; Varcabova, S; Nishiyama, A; Hwang, SH; Hammock, BD; Imig, JD; Kramer, HJ; Kujal, P; Vernerova, Z; Cervenka, L",null,null,null,"Honetschlaegerova, Zuzana; Kitada, Kento; Huskova, Zuzana; Sporkova, Alexandra; Kopkan, Libor; Buergelova, Marcela; Varcabova, Sarka; Nishiyama, Akira; Hwang, Sung Hee; Hammock, Bruce D.; Imig, John D.; Kramer, Herbert J.; Kujal, Petr; Vernerova, Zdenka; Cervenka, Ludek",null,null,"Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME","JOURNAL OF HYPERTENSION",null,null,"English","Article",null,null,null,null,null,"cytochrome P-450 metabolites; epoxyeicosatrienoic acids; malignant hypertension; nitric oxide; nitric oxide synthase; renin-angiotensin system; soluble epoxide hydrolase","REN-2 TRANSGENIC RATS; END-ORGAN DAMAGE; SALT-SENSITIVE HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; NITRIC-OXIDE SYNTHESIS; BLOOD-PRESSURE; ARACHIDONIC-ACID; RENAL-FUNCTION; BLOCKADE; KIDNEY","Objective: The present study was performed to investigate in a model of malignant hypertension if the antihypertensive actions of soluble epoxide hydrolase (sEH) inhibition are nitric oxide (NO)-dependent. Methods: ANG II-dependent malignant hypertension was induced through dietary administration for 3 days of the natural xenobiotic indole-3-carbinol (I3C) in Cyp1a1-Ren-2 transgenic rats. Blood pressure (BP) was monitored by radiotelemetry and treatment with the sEH inhibitor [cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyl-oxy]-benzoic acid (c-AUCB)] was started 48 h before administration of the diet containing I3C. In separate groups of rats, combined administration of the sEH inhibitor and the nonspecific NO synthase inhibitor [N omega-nitro-L-arginine methyl ester (L-NAME)] on the course of BP in I3C-induced and noninduced rats were evaluated. In addition, combined blockade of renin-angiotensin system (RAS) was superimposed on L-NAME administration in separate groups of rats. After 3 days of experimental protocols, the rats were prepared for renal functional studies and renal concentrations of epoxyeicosatrienoic acids (EETs) and their inactive metabolites dihydroxyeicosatrienoic acids (DHETEs) were measured. Results: Treatment with c-AUCB increased the renal EETs/DHETEs ratio, attenuated the increases in BP, and prevented the decreases in renal function and the development of renal damage in I3C-induced Cyp1a1-Ren-2 rats. The BP lowering and renoprotective actions of the treatment with the sEH inhibitor c-AUCB were completely abolished by concomitant administration of L-NAME and not fully rescued by double RAS blockade without altering the increased EETs/DHETEs ratio. Conclusion: Our current findings indicate that the antihypertensive actions of sEH inhibition in this ANG II-dependent malignant form of hypertension are dependent on the interactions of endogenous bioavailability of EETs and NO.","[Honetschlaegerova, Zuzana; Huskova, Zuzana; Sporkova, Alexandra; Kopkan, Libor; Buergelova, Marcela; Varcabova, Sarka; Kujal, Petr; Vernerova, Zdenka; Cervenka, Ludek] Inst Clin & Expt Med, Ctr Med Expt, CZ-14000 Prague 4, Czech Republic; [Kitada, Kento; Nishiyama, Akira] Kagawa Univ, Dept Pharmacol, Takamatsu, Kagawa 760, Japan; [Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; [Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, UCD Canc Ctr, Davis, CA 95616 USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI USA; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, Bonn, Germany; [Kujal, Petr; Vernerova, Zdenka] Charles Univ Prague, Dept Pathol, Fac Med 3, Prague, Czech Republic; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Cervenka, L (reprint author), Inst Clin & Expt Med, Ctr Med Expt, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz",null,null,"Internal Grant Agency of the Ministry of Health [NT/11230-4, NT/12171-5]; Ministry of Education, Youth and Sports [MSMT-Kontakt LH 11116]; German Research Foundation (Deutsche Forschungsgemeinschaft; DFG), Bonn [Kra 436/14-2, 436 TSE 113/57/0-1]; German Academic Exchange Service (Deutscher Akademischer Austauschdienst; DAAD), Bonn-Prague University partnership; European Commission by the Operational Program Prague - Competitiveness; project 'CEVKOON' [CZ.2.16/3.1.00/22126]; Czech Science Foundation (GACR) [P303/10/P170]; Marie Curie Fellowship from the European Commission Program PEOPLE [IRG 247847]; NIH [HL59699, DK38226, R01 HL059699]; Howard Hughes Foundation; NIEHS Supported Basic Research Program; NIEHS grant [R01 ES02710, R01 Es013933, P42 Es013933]","This study was supported by grants No. NT/11230-4 and NT/12171-5 awarded by the Internal Grant Agency of the Ministry of Health to M.B and Z.H. L.C. is a recipient of grant No. MSMT-Kontakt LH 11116 from the Ministry of Education, Youth and Sports for the support of the international research cooperation and this study was also supported by this grant.H.J.K. was supported by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft; DFG), Bonn (Kra 436/14-2 and 436 TSE 113/57/0-1) and the German Academic Exchange Service (Deutscher Akademischer Austauschdienst; DAAD), Bonn-Prague University partnership. This study also received financial support from the European Commission by the Operational Program Prague - Competitiveness; project 'CEVKOON' (#CZ.2.16/3.1.00/22126). A.S. is supported by grant No. P303/10/P170 awarded by Czech Science Foundation (GACR) and she is also a recipient of Marie Curie Fellowship from the European Commission Program PEOPLE (IRG 247847). J.D.I. is an Established Investigator of the American Heart Association and these studies were supported by NIH grants HL59699 and DK38226. S.H.H. was supported in part by the Howard Hughes Foundation and a fellowship from the NIEHS Supported Basic Research Program. The partial support was provided by NIEHS grant R01 ES02710, R01 Es013933 and P42 Es013933 and NIH grant R01 HL059699 awarded to B.D.H. B.D.H. is a George and Judy Marcus Senior Fellow of the American Asthma Foundation.",null,47,0,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0263-6352",null,null,"J HYPERTENS","J. Hypertens.","FEB",2013,31,2,null,null,null,null,321,332,null,"10.1097/HJH.0b013e32835b50aa",null,12,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","070GX","WOS:000313495700016"]
[null,null,null,null,"J","Varcabova, S; Huskova, Z; Kramer, HJ; Hwang, SH; Hammock, BD; Imig, JD; Kitada, K; Cervenka, L",null,null,null,"Varcabova, Sarka; Huskova, Zuzana; Kramer, Herbert J.; Hwang, Sung Hee; Hammock, Bruce D.; Imig, John D.; Kitada, Kento; Cervenka, Ludek",null,null,"Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal reninangiotensin system","CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY",null,null,"English","Article",null,null,null,null,null,"cytochrome P450 metabolites; epoxyeicosatrienoic acids; glomerular filtration rate; hypertension; pressure-natriuresis; renal blood flow; reninangiotensin system; soluble epoxide hydrolase","SPONTANEOUSLY HYPERTENSIVE RATS; II-DEPENDENT HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; PRESSURE-NATRIURESIS; EPOXYEICOSATRIENOIC ACIDS; ARACHIDONIC-ACID; BLOOD-PRESSURE; RENAL-FUNCTION; NITRIC-OXIDE; CYTOCHROME-P-450 METABOLITES","The aim of the present study was to evaluate the hypothesis that the antihypertensive effects of inhibition of soluble epoxide hydrolase (sEH) are mediated by increased intrarenal availability of epoxyeicosatrienoic acids (EETs), with consequent improvement in renal haemodynamic autoregulatory efficiency and the pressurenatriuresis relationship. Ren-2 transgenic rats (TGR), a model of angiotensin (Ang) II-dependent hypertension, and normotensive transgene-negative Hannover SpragueDawley (HanSD) rats were treated with the sEH inhibitor cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy)benzoic acid (c-AUCB; 26mg/L) for 48h. Then, the effects on blood pressure (BP), autoregulation of renal blood flow (RBF) and glomerular filtration rate (GFR), and on the pressurenatriuresis relationship in response to stepwise reductions in renal arterial pressure (RAP) were determined. Treatment with c-AUCB did not significantly change BP, renal autoregulation or pressure-natriuresis in normotensive HanSD rats. In contrast, c-AUCB treatment significantly reduced BP, increased intrarenal bioavailability of EETs and significantly suppressed AngII levels in TGR. However, treatment with c-AUCB did not significantly improve the autoregulatory efficiency of RBF and GFR in response to reductions of RAP and to restore the blunted pressurenatriuresis relationship in TGR. Together, the data indicate that the antihypertensive actions of sEH inhibition in TGR are predominantly mediated via significant suppression of intrarenal reninangiotensin system activity.","[Varcabova, Sarka; Huskova, Zuzana] Inst Clin & Expt Med, Ctr Med Expt, CZ-14000 Prague 4, Czech Republic; [Kramer, Herbert J.] Univ Bonn, Dept Med, Med Policlin, Nephrol Sect, Bonn, Germany; [Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; [Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, UC Davis Comprehens Canc Ctr, Davis, CA 95616 USA; [Imig, John D.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Kitada, Kento] Kagawa Univ, Dept Pharmacol, Takamatsu, Kagawa 760, Japan; [Cervenka, Ludek] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic","Cervenka, L (reprint author), Inst Clin & Expt Med, Ctr Med Expt, 1958-9 Videnska, CZ-14000 Prague 4, Czech Republic.","luce@medicon.cz",null,null,"Internal Grant Agency of the Ministry of Health of the Czech Republic [NT/12171-5]; Ministry of Health of the Czech Republic [00023001 (IKEM)]; Ministry of Education, Youth and Sports [MSMT-Kontakt LH 11116]; German Research Foundation (DFG) [Kra 436/14-2, 436 TSE 113/57/0-1]; Grant Agency of the Czech Republic (GACR) [305/08/P053]; European Union through the Operational Program Prague-Competitiveness project (CE-VKOON) [CZ.2.16/3.1.00/22126]; National Institutes of Health [HL59699, DK38226, R01 HL059699]; Howard Hughes Foundation; National Institute of the Environmental Health Science (NIEHS) [R01 ES02710, R01 Es013933, P42 Es013933]","This study was supported by grants from the Internal Grant Agency of the Ministry of Health of the Czech Republic (no. NT/12171-5 to ZH), the Ministry of Health of the Czech Republic (no. 00023001 (IKEM) to SV), the Ministry of Education, Youth and Sports (no. MSMT-Kontakt LH 11116 to LE), the German Research Foundation (DFG; Kra 436/14-2 and 436 TSE 113/57/0-1 to HJK), the Grant Agency of the Czech Republic (GACR) (no. 305/08/P053 to ZH), the European Union through the Operational Program Prague-Competitiveness project (CE-VKOON; no. CZ.2.16/3.1.00/22126), the National Institutes of Health (HL59699 and DK38226 to JDI; R01 HL059699 to BDH), the Howard Hughes Foundation (to SHH) and the National Institute of the Environmental Health Science (NIEHS; Supported Basic Research Program to SHH; R01 ES02710, R01 Es013933 and P42 Es013933 to BDH).",null,46,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0305-1870",null,null,"CLIN EXP PHARMACOL P","Clin. Exp. Pharmacol. Physiol.","APR",2013,40,4,null,null,null,null,273,281,null,"10.1111/1440-1681.12018",null,9,"Pharmacology & Pharmacy; Physiology","Pharmacology & Pharmacy; Physiology","116WT","WOS:000316914700004"]
[null,null,null,null,"J","Schwabova, J; Maly, T; Zahalke, F; Musova, Z; Apltova, L; Komarek, V; Zumrova, A",null,null,null,"Schwabova, J.; Maly, T.; Zahalke, F.; Musova, Z.; Apltova, L.; Komarek, V.; Zumrova, A.",null,null,"The Importance of Posterior Column Signs for Differential Diagnosis of Hereditary Ataxias","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"ataxia; cerebellar ataxia; Friedreich ataxia; sensory ataxia; spinocerebellar ataxia type 2","CEREBELLAR-ATAXIA; FRIEDREICH ATAXIA; POSTURAL STABILITY; REPEAT EXPANSION; ANTERIOR LOBE; TYPE-2; PATHOGENESIS; DISEASE; ATROPHY; STANCE","Hereditary spinocerebellar diseases have high inter- and intra-familiar variability in their onset, course and clinical manifestations. Therefore, recent scientific developments enabled and led to the current trend of verifying hereditary spinocerebellar ataxias at the molecular genetic level; detailed clinical and neurological analysis, on the basis of which these diseases were originally named and described, loses its importance. The goal of this research was to asctertain with posturographic testing whether posterior column involvement is so typical for Friedreich's ataxia that it may lead to targeted DNA diagnosis of spinocerebellar degeneration. Autosomal dominant spinocerebellar ataxia type 2 and Friedreich's ataxia are among the most common hereditary ataxias in the Czech Republic. Therefore, 17 patients with spinocerebellar ataxia type 2, 12 patients with Friedreich's ataxia and 10 healthy controls were subjected to standard posturographic examination. There was no difference between patients with spinocerebellar ataxia type 2 and Friedreich's ataxia in standing position with visual control but the examination clearly demonstrated a difference between patients and healthy controls (mediolateral deviation, anteroposterior deviation p < 0.01). Upright stance without visual control distinguished patients from healthy controls as well as patients with spinocerebellar ataxia type 2 and Friedreich's ataxia (mediolateral deviation p < 0.01). Our results indicate that, after evaluation of family history and other symptoms, clinical examination focused on cerebellar afferents and, even more appropriately, posturographic examination can be used to direct the first phase of DNA diagnosis as an objective correlate of neurological findings.","[Schwabova, J.] LF UK & FN Motole, Neurol Klin 2, Prague 15000, Czech Republic; [Schwabova, J.; Musova, Z.; Apltova, L.; Zumrova, A.] FN Motole, Ctr Hereditarnich Ataxii, Prague, Czech Republic; [Maly, T.; Zahalke, F.] FTVS UK, Lab Sportovni Motoriky, Prague, Czech Republic; [Musova, Z.; Apltova, L.] LF UK & FN Motole, Ustav Biol & Lekarske Genetiky 2, Prague, Czech Republic; [Komarek, V.; Zumrova, A.] LF UK & FN Motole, Klin Detske Neurol 2, Prague, Czech Republic","Schwabova, J (reprint author), LF UK & FN Motole, Neurol Klin 2, V Uvalu 84, Prague 15000, Czech Republic.","schwabova@gmail.com",null,null,null,null,"Bastian AJ, 1997, PHYS THER, V77, P672; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cancel G, 1997, HUM MOL GENET, V6, P709, DOI 10.1093/hmg/6.5.709; De Castro M, 2000, HUM GENET, V106, P86, DOI 10.1007/s004399900201; Della Nave R, 2008, NEUROIMAGE, V40, P19, DOI 10.1016/j.neuroimage.2007.11.050; DIAZ GO, 1990, NEUROLOGY, V40, P1369; Diehl B, 2010, NEUROGENETICS, V11, P261, DOI 10.1007/s10048-009-0233-x; DIENER HC, 1984, ELECTROEN CLIN NEURO, V57, P134, DOI 10.1016/0013-4694(84)90172-X; DIENER HC, 1984, J NEUROL NEUROSUR PS, V47, P679, DOI 10.1136/jnnp.47.7.679; DIENER HC, 1992, MOVEMENT DISORD, V7, P95, DOI 10.1002/mds.870070202; Engel KC, 2004, MOVEMENT DISORD, V19, P778, DOI 10.1002/mds.20121; HORAK FB, 1994, J NEUROPHYSIOL, V72, P479; JANSEN EC, 1982, ACTA NEUROL SCAND, V66, P93; Kapteyn T S, 1983, Agressologie, V24, P321; Koeppen AH, 2011, J NEUROL SCI, V303, P1, DOI 10.1016/j.jns.2011.01.010; MAURITZ KH, 1979, BRAIN, V102, P461, DOI 10.1093/brain/102.3.461; Pandolfo M, 2009, J NEUROL, V256, P9, DOI 10.1007/s00415-009-1003-2; Pandolfo M, 2009, J NEUROL, V256, P3, DOI 10.1007/s00415-009-1002-3; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Rub U, 2003, BRAIN, V126, P2257, DOI 10.1093/brain/awg234; Rub U, 2004, NEUROLOGY, V63, P1258; Rub U, 2005, NEUROPATH APPL NEURO, V31, P127, DOI 10.1111/j.1365-2990.2004.00617.x; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Schwabova J, 2012, J NEUROL SCI, V316, P79, DOI 10.1016/j.jns.2012.01.022; Schwabova J, 2009, ARCH INT J MED; Schwabova J, 2010, CESK SLOV NEUROL N, V73, P689; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; WINTER DA, 1995, GAIT POSTURE, V3, P193, DOI 10.1016/0966-6362(96)82849-9; Zumrova A, 2005, NEUROENDOCRINOL LETT, V26, P71",29,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,3,null,null,null,null,336,342,null,null,null,7,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","159AB","WOS:000320015300009"]
[null,null,null,null,"J","Grafova, L; Kasparova, M; Kakawand, S; Prochazka, A; Dostalova, T",null,null,null,"Grafova, L.; Kasparova, M.; Kakawand, S.; Prochazka, A.; Dostalova, T.",null,null,"Study of edge detection task in dental panoramic radiographs","DENTOMAXILLOFACIAL RADIOLOGY",null,null,"English","Article",null,null,null,null,null,"panoramic radiography; medical imaging; computer-assisted image processing","SEGMENTATION; DIAGNOSIS; SELECTION; SYSTEM","The purpose of this study is (1) to introduce a new approach for edge detection in orthopantograms (OPGs) and an improved automatic parameter selector for common edge detectors, (2) to present a comparison between our novel approach with common edge detectors and (3) to provide faster outputs without compromising quality. A new approach for edge detection based on statistical measures was introduced: (1) a set of N edge detection results is calculated from a given input image and a selected type of edge detector, (2) N correspondence maps are constructed from N edge detection results, (3) probabilities and average probabilities are computed, (4) an overall correspondence is evaluated for each correspondence map and (5) the correspondence map providing the best overall correspondence is taken as the result of edge detection procedure. A comparison with common edge detectors (the Roberts, Prewitt, Sobel, Laplacian of the Gaussian and Canny methods) with various parameter settings (304 combinations for each test image) was carried out. The methods were assessed objectively [edge mismatch error (EME), modified Hausdorff distance (MHD) and principal component analysis] and subjectively by experts in dentistry and based on time demands. The suitability of the new approach for edge detection in OPGs was confirmed by experts. The current conventional methods in edge detection in OPGs are inadequate (none of the tested methods reach an EME value or MHD value below 0.1). Our proposed approach for edge detection shows promising potential for its implementation in clinical dentistry. It enhances the accuracy of OPG interpretation and advances diagnosis and treatment planning.","[Grafova, L.; Prochazka, A.] Inst Chem Technol, Fac Chem Engn, Dept Comp & Control Engn, CR-16628 Prague 6, Czech Republic; [Kasparova, M.; Kakawand, S.; Dostalova, T.] Charles Univ Prague, Dept Stomatol, Fac Med 2, Prague, Czech Republic","Grafova, L (reprint author), Inst Chem Technol, Fac Chem Engn, Dept Comp & Control Engn, CR-16628 Prague 6, Czech Republic.","lucie.grafova@gmail.com",null,null,"MSMT [20/2013]; MSM [6046137306]; IGA MZCR [13351-4]","This work has been supported by the following grants: MSMT no. 20/2013, MSM 6046137306, IGA MZCR 13351-4 and MSM no. 6046137306.",null,34,0,0,"BRITISH INST RADIOLOGY","LONDON","36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND","0250-832X",null,null,"DENTOMAXILLOFAC RAD","Dentomaxillofac. Radiol.","JUL",2013,42,7,null,null,null,null,null,null,20120391,"10.1259/dmfr.20120391",null,12,"Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine & Medical Imaging","Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine & Medical Imaging","183DU","WOS:000321795100010"]
[null,null,null,null,"J","Liba-Vrabelova, Z; Kayserova, J; Komarek, V",null,null,null,"Liba-Vrabelova, Z.; Kayserova, J.; Komarek, V.",null,null,"Frequent Incidence of Lyme Neuroborreliosis in Children in the Czech Republic","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"Borrelia burgdorferi; Lyme neuroborreliosis; peripheral facial nerve palsy","CEREBROSPINAL-FLUID; INFLAMMATION; INFECTION; MONOCYTES","Introduction: Europe is an important endemic area for infection with the Borrelia burgdorferi sensu lato complex that includes several genospecies. Incidence and symptoms vary between areas. B. garinii has high affinity to the central nervous system and is the main genospecies in the Czech Republic. Correct diagnosis of Lyme neuroborreliosis (LNB) is crucial for its therapy. Diagnosis may be difficult and the infection may become chronic. The aim of this study was to determine the incidence of LNB and to establish clinical and laboratory findings in our pediatric patients. Methods: Retrospective evaluation of clinical and laboratory data obtained over a two-year period on 286 children with neurological symptoms (unconsciousness, focal deficit, headache, meningeal syndrome etc.) who underwent a lumbar puncture to exclude neuroinflammation. Antibodies against borrelia (and neurotrophic viruses) in the cerebrospinal fluid (CSF) and serum were determined. Cytological, immunological and biochemical analysis of CSF were performed as well as the PCR for the presence of borrelial DNA. Results: An association between neurological symptoms and borrelial infection was confirmed in 58 children (median age 7.44 years; range 0.5-17.5 years). Tick-bite was reported in 53% of children only and skin erythema in none of them. LNB was confirmed with laboratory tests in 53 children. The other 5 children had no laboratory signs of inflammation in the CNS. The main presentations of LNB were peripheral facial nerve palsy (PFNP) in 69% and meningitis in 15%. PFNP of borrelial etiology formed 53% of all PFNP in the period analyzed. Conclusion: LNB in children in the Czech Republic is very common. Comprehensive diagnostic approach, including lumbar puncture, is crucial. Correct therapy at the right time may prevent the chronic course of the disease.","[Liba-Vrabelova, Z.; Komarek, V.] 2 LF UK & FN Motole, Klin Detske Neurol, Prague, Czech Republic; [Kayserova, J.] 2 LF UK & FN Motole, Ustav Imunol, Prague, Czech Republic","Liba-Vrabelova, Z (reprint author), Klin Detske Neurol, V Uvalu 84, Prague 15006 5, Czech Republic.","zuzanavr@email.cz",null,null,null,null,null,26,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,1,null,null,null,null,63,69,null,null,null,7,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","084QF","WOS:000314553500008"]
[null,null,null,null,"J","Filova, E; Rampichova, M; Litvinec, A; Drzik, M; Mickova, A; Buzgo, M; Kost'akova, E; Martinova, L; Usvald, D; Prosecka, E; Uhlik, J; Motlik, J; Vajner, L; Amler, E",null,null,null,"Filova, Eva; Rampichova, Michala; Litvinec, Andrej; Drzik, Milan; Mickova, Andrea; Buzgo, Matej; Kost'akova, Eva; Martinova, Lenka; Usvald, Dusan; Prosecka, Eva; Uhlik, Jiri; Motlik, Jan; Vajner, Ludek; Amler, Evzen",null,null,"A cell-free nanofiber composite scaffold regenerated osteochondral defects in miniature pigs","INTERNATIONAL JOURNAL OF PHARMACEUTICS",null,null,"English","Article",null,null,null,null,null,"Cartilage; Fibrin; Nanofibers; Growth factors; Polyvinyl alcohol; Hyaluronic acid","AUTOLOGOUS CHONDROCYTE IMPLANTATION; FULL-THICKNESS DEFECTS; ARTICULAR-CARTILAGE; GROWTH-FACTOR; DELIVERY VEHICLES; HYALURONIC-ACID; DRUG-DELIVERY; RABBIT KNEE; STEM-CELLS; REPAIR","The aim of the study was to evaluate the effect of a cell-free hyaluronate/type I collagen/fibrin composite scaffold containing polyvinyl alcohol (PVA) nanofibers enriched with liposomes, basic fibroblast growth factor (bFGF) and insulin on the regeneration of osteochondral defects. A novel drug delivery system was developed on the basis of the intake effect of liposomes encapsulated in PVA nanofibers. Time-controlled release of insulin and bFGF improved MSC viability in vitro. Nanofibers functionalized with liposomes also improved the mechanical characteristics of the composite gel scaffold. In addition, time-controlled release of insulin and bFGF stimulated MSC recruitment from bone marrow in vivo. Cell-free composite scaffolds containing PVA nanofibers enriched with liposomes, bFGF, and insulin were implanted into seven osteochondral defects of miniature pigs. Control defects were left untreated. After 12 weeks, the composite scaffold had enhanced osteochondral regeneration towards hyaline cartilage and/or fibrocartilage compared with untreated defects that were filled predominantly with fibrous tissue. The cell-free composite scaffold containing PVA nanofibers, liposomes and growth factors enhanced migration of the cells into the defect, and their differentiation into chondrocytes; the scaffold was able to enhance the regeneration of osteochondral defects in minipigs. (C) 2013 Elsevier B. V. All rights reserved.","[Filova, Eva; Rampichova, Michala; Litvinec, Andrej; Mickova, Andrea; Buzgo, Matej; Prosecka, Eva; Amler, Evzen] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic; [Filova, Eva] Czech Tech Univ, Fac Biomed Engn, Kladno 27201, Czech Republic; [Rampichova, Michala; Mickova, Andrea; Buzgo, Matej; Prosecka, Eva; Amler, Evzen] Charles Univ Prague, Dept Biophys, Fac Med 2, Prague 15006, Czech Republic; [Litvinec, Andrej] Acad Sci Czech Republic, Inst Physiol, CR-14220 Prague, Czech Republic; [Drzik, Milan] Slovak Acad Sci, Inst Construct & Architecture, Bratislava 84503 45, Slovakia; [Kost'akova, Eva; Martinova, Lenka] Tech Univ Liberec, Text Fac, Liberec 46117, Czech Republic; [Usvald, Dusan] ASCR, Inst Anim Physiol & Genet, Libechov 27721, Czech Republic; [Uhlik, Jiri; Vajner, Ludek] Charles Univ Prague, Dept Histol & Embryol, Fac Med 2, Prague 15006, Czech Republic; [Amler, Evzen] Student Sci, Horni Podluzi 40757, Czech Republic","Filova, E (reprint author), Acad Sci Czech Republic, Inst Expt Med, Videnska 1083, Prague 14220, Czech Republic.","evafil@biomed.cas.cz","Vajner, Ludek/C-5823-2014; Uhlik, Jiri/C-6282-2014",null,"Academy of Sciences of the Czech Republic [AV0Z50390703, AV0Z50390512]; Ministry of Health of the Czech Republic [NT12156]; Ministry of Education, Youth and Sports of the Czech Republic [ME 10145]; Technology Agency of the Czech Republic [TA 01011466]; Czech Science Foundation [GAP304/10/1307]; Agency of Charles University [96610, 330611, 384311]; Slovak Research and Development Agency, Slovak Republic [APVV-0032-10]","We would like to thank Ing. Hynek Bene. s, Ph. D. for the TGA measurements. Our work has been supported by the Academy of Sciences of the Czech Republic (Institutional Research Plans AV0Z50390703 and AV0Z50390512), the Ministry of Health of the Czech Republic (grant no. NT12156), the Ministry of Education, Youth and Sports of the Czech Republic (project ERA-NET CARSILA No. ME 10145), Technology Agency of the Czech Republic (project TA 01011466), and by grants from the Czech Science Foundation (grant no. GAP304/10/1307) the Grant Agency of Charles University (grant no. 96610, 330611, and 384311), and the Slovak Research and Development Agency (contract APVV-0032-10), Slovak Republic.",null,62,3,3,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0378-5173",null,null,"INT J PHARMACEUT","Int. J. Pharm.","APR 15",2013,447,41671,null,null,null,null,139,149,null,"10.1016/j.ijpharm.2013.02.056",null,11,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","122HZ","WOS:000317310500017"]
[null,null,null,null,"J","Borgulova, I; Mazanec, R; Sakmaryova, I; Havlova, M; Brozkova, DS; Seeman, P",null,null,null,"Borgulova, I.; Mazanec, R.; Sakmaryova, I.; Havlova, M.; Brozkova, D. Safka; Seeman, P.",null,null,"Mosaicism for GJB1 mutation causes milder Charcot-Marie-Tooth X1 phenotype in a heterozygous man than in a manifesting heterozygous woman","NEUROGENETICS",null,null,"English","Article",null,null,null,null,null,"CMTX1; GJB1 gene; Somatic mutation; X-linked inheritance","SOMATIC MOSAICISM; DISEASE; NEUROPATHY; GENE","Charcot-Marie-Tooth (CMT) disease is a heterogeneous disorder of the peripheral nervous system that collectively affects approximately 1 in 2,500 individuals, thus making it the most common inherited neurologic disorder. X-linked inheritance may account for 10-20 % of CMT neuropathy. We report a Czech family with a 30-year-old woman affected by CMT since the age of 10 years, originally as an isolated case. Nerve conduction study (NCS) showed demyelinating neuropathy, and DNA testing revealed a novel heterozygous gap junction beta-1 protein (GJB1) mutation c.784_786delTA. The same mutation, but surprisingly in heterozygous state, was subsequently found in her subjectively healthy father and later also in one of her sisters but not in her two other sisters. NCS showed intermediate type of motor and sensory neuropathy in these two females manifesting heterozygotes and normal results in the other healthy sisters and one brother, all without the c.784_786delTA mutation. The father has a phenotype milder than his daughter and has only subclinical signs of CMT. The index female patient had normal karyotype 46, XX, and normal FISH for centromeric X chromosome. We concluded that the proband's father is a heterozygote due to the somatic mosaicism for the GJB1 mutation in his leukocytes (detected by DNA sequencing) and also in his germ cells as confirmed by the unexpectedly different genotypes in his four daughters. Quantitative analysis revealed a mutated signal in 25:75 allele proportion of mutated to healthy allele in the mosaic father. This study has important consequences for genetic counseling and prognosis in CMTX1 families.","[Borgulova, I.; Seeman, P.] Ctr Med Genet & Reprod Med GENNET, Prague, Czech Republic; [Borgulova, I.] Charles Univ Prague, Dept Genet & Microbiol, Fac Sci, Prague, Czech Republic; [Mazanec, R.] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague, Czech Republic; [Mazanec, R.; Sakmaryova, I.; Brozkova, D. Safka; Seeman, P.] Univ Hosp Motol, Prague, Czech Republic; [Sakmaryova, I.; Brozkova, D. Safka; Seeman, P.] Charles Univ Prague, Dept Child Neurol, DNA Lab, Fac Med 2, Prague, Czech Republic; [Havlova, M.] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague, Czech Republic; [Havlova, M.] Univ Gen, Prague, Czech Republic","Borgulova, I (reprint author), Charles Univ Prague, Dept Genet & Microbiol, Fac Sci, Prague, Czech Republic.","i.eliasova@seznam.cz",null,null,"IGA MH CR [NT 11521-4]","This study is supported by IGA MH CR No: NT 11521-4.",null,16,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","1364-6745","1364-6753",null,"NEUROGENETICS","Neurogenetics","NOV",2013,14,41732,null,null,null,null,189,195,null,"10.1007/s10048-013-0368-7",null,7,"Genetics & Heredity; Clinical Neurology","Genetics & Heredity; Neurosciences & Neurology","247SQ","WOS:000326641000004"]
[null,null,null,null,"J","Bessho, F; Takayama, N; Fronkova, E; Zuna, J",null,null,null,"Bessho, Fumio; Takayama, Nobuyuki; Fronkova, Eva; Zuna, Jan",null,null,"Reappearance of acute lymphoblastic leukemia 34 years after initial diagnosis: a case report and study of the origin of the reappeared blasts","INTERNATIONAL JOURNAL OF HEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"Acute lymphoblastic leukemia; Late relapse; Preleukemic stem cells","LATE-RELAPSING CHILDHOOD; GENE; DISEASE","Lymphoblasts of acute lymphoblastic leukemia origin reappeared in a male patient 34 years after the initial diagnosis. Comparison of DNA profiles of the initial and reappeared lymphoblasts revealed a partially identical sequence, indicating the possibility that these lymphoblasts may have been present as preleukemic stem cells at the time of diagnosis and remained dormant for a long period until additional events conferred proliferative activity to these dormant preleukemic stem cells. Thus, in some cases of very late relapse, the reappearance of lymphoblasts may not be due to the relapse of the original leukemic clone, but to a clonal progression of a pre-existing subclone derived from preleukemic stem cells.","[Bessho, Fumio] Kyorin Univ, Sch Med, Dept Pediat, Mitaka, Tokyo 1818611, Japan; [Takayama, Nobuyuki] Kyorin Univ, Dept Internal Med 2, Sch Med, Tokyo, Japan; [Fronkova, Eva; Zuna, Jan] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CLIP, Prague, Czech Republic","Bessho, F (reprint author), Kyorin Univ, Sch Med, Dept Pediat, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.","bessho@ks.kyorin-u.ac.jp",null,null,null,null,null,20,0,0,"SPRINGER JAPAN KK","TOKYO","CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN","0925-5710",null,null,"INT J HEMATOL","Int. J. Hematol.","APR",2013,97,4,null,null,null,null,525,528,null,"10.1007/s12185-013-1289-9",null,4,"Hematology","Hematology","124OY","WOS:000317475500014"]
[null,null,null,null,"J","Viktor, M; Bruno, S",null,null,null,"Viktor, Mravcik; Bruno, Sopko",null,null,"Prevalence Estimates of Problem Drug Users in the Czech Republic in 2006 and 2007 using the Capture-Recapture Method","EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"problem drug use; prevalence estimates; capture-recapture method; opiates/opioids; methamphetamine","EPIDEMIOLOGY; COUNTRIES; NORWAY","Background: An estimate of problem drug use prevalence is a substantial part of the monitoring of the epidemiological situation in drug use and its consequences and an important indicator for drug policy implementation. The capture-recapture method (CRM) is one of the most commonly used standard methods for this purpose worldwide. Methods and material: The CRM was used to estimate the numbers of problem drug users (PDU) and problem users of opiates/opioids (PUO) in the Czech Republic in 2006 and 2007. The following data sources were used: the General Health Insurance Company records of payments to out-and in-patient psychiatric care providers, records of admissions to psychiatric hospitals, replacement therapy register, and reports of newly diagnosed cases of viral hepatitis. Cases were defined as diagnoses F11, F15, and F19 according to the International Classification of Diseases, Tenth Revision (ICD-10) from the health insurance and admission records, the replacement therapy register covers PUO by definition, and injecting drug users were selected from reported cases of viral hepatitis. Log-linear analysis in Rcapture (R) was performed and the Akaike information criterion was used for model selection. Results: Altogether 12,882 and 13,505 individuals entered into analysis of PDUs and 5146 and 5409 individuals entered into analysis of PUO in 2006 and 2007, respectively. The estimates of PDUs were 23,900 (95% CI: 20,700-28,500) in 2006 and 31,000 (25,500-39,400) in 2007. The estimates of PUO were 6,864 (6,641-7,113) in 2006 and 7,096 (6,871-7,346) in 2007. The male/female ratio was 2.2/1. In PDU estimates, 83% were in the age range 15-34 and 17% were aged above 34; in PUO estimates, the respective rates were 80% and 20%. The prevalence rates of PDU in the age range 15-64 were 2.28 and 2.95 per 1,000 population in 2006 and 2007, respectively. The prevalence rates of PUO in the age range 15-64 were 0.65 and 0.67 per 1,000 in 2006 and 2007, respectively. The highest prevalence of both PDUs and PUO was observed in the Usti Region and Prague, followed by the Karlovy Vary, Plzen, and Central Bohemia Regions. Conclusion: PDU estimates in the Czech Republic obtained using the CRM are consistent with those derived by other methods. The major drawbacks are the quality of potential data sources and hassles in their acquisition and preparation. The interconnection of the available data sources also limits the validity and representativeness of estimates and therefore, another independent data source(s) should be sought in the future.","[Viktor, Mravcik; Bruno, Sopko] Narodni Monitorovaci Stredisko Pro Drogy Drogove, Prague, Czech Republic; [Viktor, Mravcik] LF UK VFN Praze, Klin Adiktol 1, Prague, Czech Republic; [Bruno, Sopko] LF UK FN Motol Praze, Ustav Lekarske Chem, Klin Biochem 2, Prague, Czech Republic","Viktor, M (reprint author), Urad Vlady CR, Narodni Monitorovaci Stredisko Pro Drogy Drogove, Nabr E Benese 4, Prague 11801 1, Czech Republic.","mravcik.viktor@vlada.cz",null,null,null,null,null,36,0,0,"CESKA LEKARSKA SPOLECNOST J  EV  PURKYNE","PRAGUE","SOKOLSKA 31, PRAGUE, 00000, CZECH REPUBLIC","1210-7913",null,null,"EPIDEMIOL MIKROBI IM","Epidemiol. Mikrobiol. Imunol.",null,2013,62,2,null,null,null,null,74,82,null,null,null,9,"Immunology; Microbiology","Immunology; Microbiology","228IE","WOS:000325178600005"]
[null,null,null,null,"J","Vyslouzilova, L; Krizkova, S; Anyz, J; Hynek, D; Hrabeta, J; Kruseova, J; Eckschlager, T; Adam, V; Stepankova, O; Kizek, R",null,null,null,"Vyslouzilova, Lenka; Krizkova, Sona; Anyz, Jiri; Hynek, David; Hrabeta, Jan; Kruseova, Jarmila; Eckschlager, Tomas; Adam, Vojtech; Stepankova, Olga; Kizek, Rene",null,null,"Use of brightness wavelet transformation for automated analysis of serum metallothioneins- and zinc-containing proteins by Western blots to subclassify childhood solid tumours","ELECTROPHORESIS",null,null,"English","Article",null,null,null,null,null,"Cancer; Metallothionein; Signal processing; Zinc","TRANSFER STRIPPING TECHNIQUE; NERVOUS-SYSTEM TUMORS; BRDICKA REACTION; CAPILLARY-ELECTROPHORESIS; NUTRITIONAL-STATUS; PROGNOSTIC-FACTORS; ANTIOXIDANT MICRONUTRIENTS; PROSTATE CARCINOMA; GENE-EXPRESSION; BLOOD-SERUM","In this study, we determined serum levels of metallothioneins (MTs) and zinc in children with solid tumours (neuroblastoma, Hodgkin lymphoma, medulloblastoma, osteosarcoma, Ewing sarcoma and nephroblastoma) by differential pulse voltammetry Brdicka reaction and ELISA. Zn(II) level in patients sera was 40% compared to controls, contrariwise, MT level was 4.2 x higher in patients. No significant differences among single diagnoses were found both for Zn(II) and MT. When determined Zn(II)/MT ratio, in controls its value was 24.6, but it was 2.6 in patients. After Western-blotting with anti-MT and anti-Zn chicken antibodies, variable intensities of the bands within the samples were observed. The brightness curve obtained for each sample both for MT- and Zn blots was further analysed to produce a list of band positions together with some complementary information related to the intensity of the observed bands by the optimised algorithm. We constructed from those profiles decision trees that enable to distinguish different groups of tumours. The blood samples were heat-treated, in which we supposed mainly MT, but samples contained other thermostable Zn-containing proteins that were helpful for identification of embryonal tumours with 88% accuracy and for identification of sarcomas with 78% accuracy. In MT blots the accuracies were 53 and 45%, respectively. Simultaneous analysis of MT and Zn blots did not increased accuracy of identification neither in embryonal tumours (80%) nor in sarcomas. Those results are promising not only from diagnostic point of view but particularly in the area of studying of individual MT isoforms and their aggregates in malignant tumours.","[Vyslouzilova, Lenka; Anyz, Jiri; Stepankova, Olga] Czech Tech Univ, Fac Elect Engn, Dept Cybernet, CR-16635 Prague, Czech Republic; [Krizkova, Sona; Hynek, David; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Krizkova, Sona; Hynek, David; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, Brno, Czech Republic; [Hrabeta, Jan; Kruseova, Jarmila; Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague, Czech Republic; [Hrabeta, Jan; Kruseova, Jarmila; Eckschlager, Tomas] Univ Hosp Motol, Prague, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz",null,null,"IGA MENDELU [TP6/2012]; CEITEC [CZ.1.05/1.1.00/02.0068]; EU ENIAC [120228]; Ministry of Health, Czech Republic [00064203]","This paper was financially supported by the IGA MENDELU TP6/2012, CEITEC CZ.1.05/1.1.00/02.0068, EU ENIAC Project No. 120228 MAS and the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic) is highly acknowledged.",null,62,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0173-0835",null,null,"ELECTROPHORESIS","Electrophoresis","JUN",2013,34,11,null,null,"SI",null,1637,1648,null,"10.1002/elps.201200561",null,12,"Biochemical Research Methods; Chemistry, Analytical","Biochemistry & Molecular Biology; Chemistry","157ZW","WOS:000319939300023"]
[null,null,null,null,"J","Ehrlichova, M; Mohelnikova-Duchonova, B; Hrdy, J; Brynychova, V; Mrhalova, M; Kodet, R; Rob, L; Pluta, M; Gut, I; Soucek, P; Vaclavikova, R",null,null,null,"Ehrlichova, Marie; Mohelnikova-Duchonova, Beatrice; Hrdy, Jiri; Brynychova, Veronika; Mrhalova, Marcela; Kodet, Roman; Rob, Lukas; Pluta, Marek; Gut, Ivan; Soucek, Pavel; Vaclavikova, Radka",null,null,"The association of taxane resistance genes with the clinical course of ovarian carcinoma","GENOMICS",null,null,"English","Article",null,null,null,null,null,"Ovarian carcinoma; Taxane; Resistance; Gene expression; Cytokinesis; Clinical course","BREAST-CANCER CELLS; REAL-TIME PCR; EXPRESSION; PACLITAXEL; APOPTOSIS; CYTOKINESIS; ACTIVATION; MECHANISMS; CASPASE-3","Taxane and platinum-based chemotherapy regimens are standard treatment for advanced ovarian carcinoma. Expression levels of putative markers of taxane resistance in carcinoma tissues and paired peritoneal samples (n = 55) and in 16 samples of ovaries without signs of carcinoma were compared with clinical data and the patients' time to progression. KIF14, PRC1, CIT and ABCC1 genes were significantly overexpressed in carcinomas when compared with normal ovarian tissues, while ABCB1 and CASP9 expression was decreased. Associations of protein expression of the proliferation marker Ki-67 with KIF14, PRC1, ABCB1 and CASP2 were found. Lastly, it was discovered that ABCB1 and CASP2 levels associated with FIGO stage and that the CIT level associated with the time to progression of ovarian carcinoma patients (P < 0.0001). In conclusion, ABCB1, CASP2, KIF14, PRC1 and CIT genes seem to associate with surrogate markers of ovarian carcinoma progression and CIT gene associates with therapy outcome. (C) 2013 Elsevier Inc. All rights reserved.","[Ehrlichova, Marie; Mohelnikova-Duchonova, Beatrice; Brynychova, Veronika; Gut, Ivan; Soucek, Pavel; Vaclavikova, Radka] Natl Inst Publ Hlth, Toxicogen Unit, Prague 10042 10, Czech Republic; [Hrdy, Jiri] Charles Univ Prague, Fac Med 1, Inst Microbiol & Immunol, Prague, Czech Republic; [Mohelnikova-Duchonova, Beatrice] Palacky Univ, Med Sch & Teaching Hosp, Dept Oncol, CR-77147 Olomouc, Czech Republic; [Brynychova, Veronika] Charles Univ Prague, Fac Med 3, Prague, Czech Republic; [Mrhalova, Marcela; Kodet, Roman] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Mrhalova, Marcela; Kodet, Roman; Rob, Lukas; Pluta, Marek] Motol Univ Hosp, Prague, Czech Republic; [Rob, Lukas; Pluta, Marek] Charles Univ Prague, Fac Med 2, Dept Gynecol & Obstet, Prague, Czech Republic","Vaclavikova, R (reprint author), Natl Inst Publ Hlth, Toxicogen Unit, Srobarova 48, Prague 10042 10, Czech Republic.","rvaclavikova@szu.cz",null,null,"Internal Grant Agency of the Czech Ministry of Health [NS9803-4]; European Regional Development Fund [ED2.1.00/03.0076]","This study was supported by grant from the Internal Grant Agency of the Czech Ministry of Health No. NS9803-4 to R.V. and L.R. and by the project ED2.1.00/03.0076 from the European Regional Development Fund to M.E., V.B., B.M. and P.S.",null,33,1,1,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","0888-7543",null,null,"GENOMICS","Genomics","AUG",2013,102,2,null,null,"SI",null,96,101,null,"10.1016/j.ygeno.2013.03.005",null,6,"Biotechnology & Applied Microbiology; Genetics & Heredity","Biotechnology & Applied Microbiology; Genetics & Heredity","197JW","WOS:000322848500004"]
[null,null,null,null,"J","Brabcova, D; Lovasova, V; Kohout, J; Zarubova, J; Komarek, V",null,null,null,"Brabcova, Dana; Lovasova, Vladimira; Kohout, Jiri; Zarubova, Jana; Komarek, Vladimir",null,null,"Improving the knowledge of epilepsy and reducing epilepsy-related stigma among children using educational video and educational drama-A comparison of the effectiveness of both interventions","SEIZURE-EUROPEAN JOURNAL OF EPILEPSY",null,null,"English","Article",null,null,null,null,null,"Epilepsy; Stigma; Educational video; Educational drama; Children; Effectiveness","QUALITY-OF-LIFE; PUBLIC-ATTITUDES; MENTAL-ILLNESS; PERCEPTION; PROGRAM; PEOPLE; ADOLESCENTS; INFORMATION; UNIVERSITY; AWARENESS","Purpose: This study was intended to compare the effectiveness of educational animated video and educational drama in improving the knowledge of epilepsy and reducing epilepsy-related stigma among children aged 9-11 years. Method: The first group of children involved in the study (n(1) = 762) watched a video and then completed a questionnaire on epilepsy. The second group (n(2) = 400) completed the questionnaire after participating in a drama. Both groups were retested 6 months later by the same questionnaire, which was also completed by a control group (n(3) = 180) not subjected to intervention. Results: Both groups subjected to intervention achieved significantly higher scores (P < 0.001) than the control group on knowledge of epilepsy and on attitudes towards children with the disease. Educational video was more effective than drama in improving knowledge of epilepsy. On the other hand, there was no significant difference (P > 0.05) between the two kinds of intervention regarding attitudes towards children with this disease. Conclusion: The results suggest that both interventions could be used to reduce epilepsy-related stigma in this age group. (C) 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","[Brabcova, Dana] Univ South Bohemia, Pedag Fac, Dept Pedag & Psychol, Ceske Budejovice 37115, Czech Republic; [Lovasova, Vladimira] Univ W Bohemia, Fac Educ, Dept Psychol, Plzen 30614, Czech Republic; [Kohout, Jiri] Univ W Bohemia, Fac Sci Appl, Dept Phys, Plzen 30614, Czech Republic; [Zarubova, Jana] Thomayer Univ Hosp, Dept Neurol, Prague, Czech Republic; [Komarek, Vladimir] Fac Hosp Motol, Dept Child Neurol, Prague, Czech Republic","Brabcova, D (reprint author), Univ South Bohemia, Pedag Fac, Dept Pedag & Psychol, Dukelska 7, Ceske Budejovice 37115, Czech Republic.","dannab@seznam.cz",null,null,"Quality of Life of Children Living with Epilepsy; GAJU [037/2010/S]","This research project was supported by Quality of Life of Children Living with Epilepsy implemented under the Promising Strategies 2010 Program, which is a program byIBE - the International Bureau for Epilepsy, and by the grant GAJU 037/2010/S.",null,37,1,1,"W B SAUNDERS CO LTD","LONDON","32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND","1059-1311",null,null,"SEIZURE-EUR J EPILEP","Seizure","APR",2013,22,3,null,null,null,null,179,184,null,"10.1016/j.seizure.2012.11.017",null,6,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","114AJ","WOS:000316711700003"]
[null,null,null,null,"J","Chovanec, M; Zverina, E; Profant, O; Skrivan, J; Cakrt, O; Lisy, J; Betka, J",null,null,null,"Chovanec, Martin; Zverina, Eduard; Profant, Oliver; Skrivan, Jiri; Cakrt, Ondrej; Lisy, Jiri; Betka, Jan",null,null,"Impact of video-endoscopy on the results of retrosigmoid-transmeatal microsurgery of vestibular schwannoma: prospective study","EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY",null,null,"English","Article",null,null,null,null,null,"Vestibular schwannoma; Acoustic neuroma; Endoscopy-assisted microsurgery; Retrosigmoid approach; Hearing preservation; Facial nerve","ACOUSTIC NEUROMA SURGERY; NERVE","Endoscopy-assisted microsurgery represents modern trend of treatment of the cerebellopontine angle (CPA) pathologies including vestibular schwannoma (VS). Endoscopes are used in adjunct to microscope to achieve better functional results with less morbidity. Angled optics, magnification and illumination enable superior view in the operative field. Consecutive 89 patients with untreated unilateral sporadic vestibular schwannoma undergoing tumor resection via a retrosigmoid approach during 2008-2010 were prospectively analysed. Endoscopy-assisted microsurgical (EA-MS) removal was performed in 39 cases (Grade 1: 2, Grade 2: 5, Grade 3: 9, Grade 4: 22, Grade 5: 1) and microsurgical (MS) removal was performed in 50 cases (Grade 1: 1, Grade 2: 3, Grade 3: 9, Grade 4: 34, Grade 5: 3). Minimally invasive approach with craniotomy a parts per thousand currency sign2.5 cm was employed for small tumors (Grade 1 and 2) in the EA-MS group. Endoscopic technique was used for monitoring of neuro-vascular anatomy in CPA, during dissection of the meatal portion of tumors, assessment of radicality and for identification of potential pathways for CSF leak formation. All cases in MS group were deemed as radically removed. In the EA-MS group, residual tumor tissue in the fundus of internal auditory canal not observable with microscope was identified with endoscope in four cases. Such cases were radicalized. Tumor recurrence was not observed during the follow-up in EA-MS group. There is a suspicious intrameatal tumor recurrence on the repeated MRI scan in one patient in the MS group. Neither mortality nor infection was observed. The most common complication was pseudomeningocele (EA-MS 20 cases; MS 23). It was managed with aspiration with or without tissue-gluing in all cases without the need for any surgical revision. Adjunctive use of endoscope in the EA-MS group identified potential pathways for CSF leak formation, which was not observable with the microscope in five patients. Improved cochlear nerve (EA-MS: 22, MS: 14; p = 0.012), brainstem auditory evoked potentials (EA-MS: 3 of 8, MS: 0 of 4) and hearing (EA-MS: 14 of 36, MS: 4 of 45; p = 0.001) preservation were observed in EA-MS group. Despite the trend for better useful hearing (Gardner-Robertson class 1 and 2) preservation (EA-MS: 8 of 26, MS: 1 of 16) there were no significant differences in the postoperative hearing handicap inventory in both groups. There were no differences in the postoperative tinnitus in both groups. Better facial nerve preservation (EA-MS: 39, MS: 44; p = 0.027) and excellent-very good (House-Brackmann 1 or 2) facial nerve function (EA-MS: 31, MS: 29; p = 0.035) were observed in EA-MS group. Postoperative compensation of vestibular lesion, symptoms typical for VS, patients assessed by dizziness handicap inventory, facial disability index were comparable in both studied groups. Adjunctive use of endoscope during the VS surgery due to its magnification and illumination enable superior view in the operative field. It is valuable for assessment of radicality of resection in the region of internal auditory meatus. Improved information about critical structures and tumor itself helps the surgeon to preserve facial nerve and in selected cases also hearing. These techniques can help to decrease incidence of postoperative complications.","[Chovanec, Martin; Zverina, Eduard; Profant, Oliver; Skrivan, Jiri; Betka, Jan] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Fac Hosp Motol, Prague 15006 5, Czech Republic; [Chovanec, Martin] Charles Univ Prague, Inst Anat, Fac Med 1, Prague 15006 5, Czech Republic; [Zverina, Eduard] Charles Univ Prague, Dept Neurosurg, Fac Hosp Kralovske Vinohrady, Fac Med 3, Prague 15006 5, Czech Republic; [Profant, Oliver] Acad Sci Czech Republic, Dept Auditory Neurosci, Inst Expt Med, Prague 14220 4, Czech Republic; [Cakrt, Ondrej] Charles Univ Prague, Dept Rehabil & Sport Med, Fac Med 2, Univ Hosp Motol, Prague 15006 5, Czech Republic; [Cakrt, Ondrej] Czech Tech Univ, Joint Ctr Biomed Engn, Fac Biomed Engn, CR-16635 Prague, Czech Republic; [Cakrt, Ondrej] Charles Univ Prague, Prague 15006 5, Czech Republic; [Lisy, Jiri] Charles Univ Prague, Dept Radiol, Fac Med 2, Fac Hosp Motol, Prague 15006 5, Czech Republic","Chovanec, M (reprint author), Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Fac Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","martin.chovanec@lf1.cuni.cz",null,null,"Internal Grant Agency of the Ministry of Health of Czech Republic [NS/9909-4]","This study was supported by the research project of Internal Grant Agency of the Ministry of Health of Czech Republic no. NS/9909-4. The authors are grateful to Ilja Merunka Bc. and Barbora Hajna Bc. for the help in preparation of the manuscript.",null,15,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0937-4477",null,null,"EUR ARCH OTO-RHINO-L","Eur. Arch. Oto-Rhino-Laryn.","MAR",2013,270,4,null,null,null,null,1277,1284,null,"10.1007/s00405-012-2112-6",null,8,"Otorhinolaryngology","Otorhinolaryngology","115NC","WOS:000316818000015"]
[null,null,null,null,"J","Knights, AJ; Fucikova, J; Pasam, A; Koernig, S; Cebon, J",null,null,null,"Knights, Ashley J.; Fucikova, Jitka; Pasam, Anupama; Koernig, Sandra; Cebon, Jonathan",null,null,"Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy","CANCER IMMUNOLOGY IMMUNOTHERAPY",null,null,"English","Article",null,null,null,null,null,"IAP antagonist; SMAC mimetic; Immunomodulatory; Dendritic cell; Cross-presentation","NF-KAPPA-B; DENDRITIC CELL-DEVELOPMENT; ALPHA-DEPENDENT APOPTOSIS; ANTIGEN DELIVERY; TUMOR-ANTIGEN; TNF-ALPHA; CROSS-PRESENTATION; SMAC MIMETICS; T-CELLS; ACTIVATION","Inhibitor of apoptosis proteins (IAPs) are critical in regulating apoptosis resistance in cancer. Antagonists of IAPs, such as LCL161, are in clinical development and show promise as anti-cancer agents for solid and hematological cancers, with preliminary data suggesting they may act as immunomodulators. IAP antagonists hypersensitize tumor cells to TNF-alpha-mediated apoptosis, an effect that may work in synergy with that of cancer vaccines. This study aimed to further investigate the immunomodulatory properties of LCL161 on human immune subsets. T lymphocytes treated with LCL161 demonstrated significantly enhanced cytokine secretion upon activation, with little effect on CD4 and CD8 T-cell survival or proliferation. LCL161 treatment of peripheral blood mononuclear cells significantly enhanced priming of na < ve T cells with synthetic peptides in vitro. Myeloid dendritic cells underwent phenotypic maturation upon IAP antagonism and demonstrated a reduced capacity to cross-present a tumor antigen-based vaccine. These effects are potentially mediated through an observed activation of the canonical and non-canonical NF-kappa B pathways, following IAP antagonism with a resulting upregulation of anti-apoptotic molecules. In conclusion, this study demonstrated the immunomodulatory properties of antagonists at physiologically relevant concentrations and indicates their combination with immunotherapy requires further investigation.","[Knights, Ashley J.; Pasam, Anupama] Austin Hosp, Ludwig Inst Canc Res Melbourne, Austin Branch, Heidelberg, Vic 3084, Australia; [Fucikova, Jitka] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Inst Immunol, Prague, Czech Republic; [Koernig, Sandra] CSL Ltd, Melbourne, Vic 3052, Australia","Cebon, J (reprint author), Austin Hosp, Ludwig Inst Canc Res Melbourne, Austin Branch, 145-163 Studley Rd, Heidelberg, Vic 3084, Australia.","Ashley.Knights@ludwig.edu.au; Jonathan.Cebon@ludwig.edu.au",null,null,"Victorian Government; NHMRC Independent Research Institutes Infrastructure Support Scheme; Ministry of Health, Czech Republic [IGA NT12402-5]","The contents of the published material are solely the responsibility of the Administering Institution, a Participating Institution or individual authors and do not reflect the views of NHMRC. LCL161 and LBW242 were provided by Dale Porter, Novartis Institutes for Biomedical Research, USA. NY-ESO-1/IS-COMATRIX was kindly provided by CSL Ltd. Melbourne. Buffy Coats were provided by the Red Cross Blood Service, Melbourne. We thank Rodica Stan for her helpful revision of the manuscript. Operational Infrastructure Support Program Funding of the Victorian Government and NHMRC Independent Research Institutes Infrastructure Support Scheme. JC is an NHMRC Practitioner Fellow. JF was supported by grant IGA NT12402-5 from the Ministry of Health, Czech Republic.",null,49,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0340-7004",null,null,"CANCER IMMUNOL IMMUN","Cancer Immunol. Immunother.","FEB",2013,62,2,null,null,null,null,321,335,null,"10.1007/s00262-012-1342-1",null,15,"Oncology; Immunology","Oncology; Immunology","087NN","WOS:000314768500011"]
[null,null,null,null,"J","Chernyshov, PV; Jirakova, A; Ho, RCM; Moed, H; Caldeira, AP; Alvarenga, TM; Park, CW; Hercogova, J",null,null,null,"Chernyshov, Pavel V.; Jirakova, Anna; Ho, Roger C. M.; Moed, Heleen; Caldeira, Antonio P.; Alvarenga, Tasssiana M.; Park, Chun W.; Hercogova, Jana",null,null,"An international multicenter study on quality of life and family quality of life in children with atopic dermatitis","INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY",null,null,"English","Article",null,null,null,null,null,"Atopic dermatitis; children; quality of life","PRESCHOOL-CHILDREN; DISEASE SEVERITY; ECZEMA; IMPACT; HEALTH; PREVALENCE; VALIDATION; BEHAVIOR; INFANTS; MOTHERS","Background: Atopic dermatitis (AD) has severe impact on the quality of life (QoL) of children suffering from the disease and their families. The infant's dermatitis quality of life index (IDQoL) and the dermatitis family impact questionnaire (DFI) were designed to study this impact. Aims: To compare the impact of AD on children and their families in different countries. Methods: 419 children with AD from six countries representing three continents under the age of 4 years were included into the study. English, Ukrainian, Czech, Portuguese, and Korean versions of the IDQoL and the DFI and Dutch version of the IDQoL questionnaires were used. Results: The highest scored items for the IDQoL and the DFI were rather similar. The IDQoL and the DFI results were well correlated with parental assessment of disease severity and between each other in all countries. Some differences mostly in the IDQoL assessment were found. Conclusion: Despite some reported peculiarities, parents in different counties assessed QoL and family QoL of their AD children in a similar way. The IDQoL and the DFI may be reliable initial measures for international studies. International study on the influence of the same treatment methods on the IDQoL and the DFI assessments is important.","[Chernyshov, Pavel V.] Natl Med Univ, Dept Dermatol & Venereol, UA-01601 Kiev, Ukraine; [Jirakova, Anna; Hercogova, Jana] Charles Univ Prague, Dept Dermatovenerol, Prague, Czech Republic; [Ho, Roger C. M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Psychol Med, Singapore 117595, Singapore; [Moed, Heleen] Erasmus MC Univ Med Ctr, Dept Gen Practice, Rotterdam, Netherlands; [Caldeira, Antonio P.] Univ Estadual Montes Claros, Dept Womens & Childrens Hlth, Montes Claros, Brazil; [Alvarenga, Tasssiana M.] Univ Estadual Montes Claros, Dept Dermatol, Montes Claros, Brazil; [Park, Chun W.] Hallym Univ, Coll Med, Dept Dermatol, Seoul, South Korea","Chernyshov, PV (reprint author), Natl Med Univ, Dept Dermatol & Venereol, 13 Bulvar Shevchenko, UA-01601 Kiev, Ukraine.","chernyshovpavel@ukr.net",null,null,null,null,null,31,1,1,"MEDKNOW PUBLICATIONS & MEDIA PVT LTD","MUMBAI","B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA","0378-6323",null,null,"INDIAN J DERMATOL VE","Indian J. Dermatol. Venereol. Leprol.","JAN-FEB",2013,79,1,null,null,null,null,52,58,null,"10.4103/0378-6323.104669",null,7,"Dermatology","Dermatology","067KM","WOS:000313292900008"]
[null,null,null,null,"J","Kalitova, P; Cakrt, O; Cada, Z; Profant, O; Chovanec, M; Betka, J; Jerabek, J",null,null,null,"Kalitova, P.; Cakrt, O.; Cada, Z.; Profant, O.; Chovanec, M.; Betka, J.; Jerabek, J.",null,null,"The Importance of Vestibular and Posturographic Evaluation in Patients with Vestibular Schwannoma","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"vestibular schwanoma; electronystagmography; posturography; postural equilibrium","ACOUSTIC NEUROMA; CLINICAL PRESENTATION; MANAGEMENT; MICROSURGERY; RADIOSURGERY","Aim: The aim of our study was to evaluate vestibular and posturographic findings in patients with vestibular schwannoma indicated for surgical removal. We focused particularly on evaluation of posturography. Materials and methods: The group consisted of 44 patients (19 women, 25 men) who underwent surgical removal of vestibular schwannoma at the Department of Otorhinolaryngology and Head and Neck Surgery, Faculty Hospital Motol, 1st Faculty of Medicine, Charles University, Prague between 2007 and 2010. Since all patients were indicated for surgery, the majority of the cohort were patients with the grade 4 disease (27). Before surgery, each patient underwent clinical vestibular examination, electronystagmographic recordings and posturography. The data were analysed using the independent sample T-test and cross-tabulations. A large number of variables were eliminated by factor analysis. Results: Statistical analysis revealed that the performance on the step quick turn test, a part of posturography, is the most typical parameter for vestibular pathology. Furthermore, we proved that younger age is associated with the presence of higher grade tumours. Conclusions: Our study confirmed the importance of posturography in the diagnosis of vestibular pathology in patients with vestibular schwannoma. Posturography should be added to electronystagmography as a standard diagnostic tool.","[Kalitova, P.; Cada, Z.; Profant, O.; Chovanec, M.; Betka, J.] LF UK & FN Motole, Klin Otorinolaryngol & Chirurg Hlavy & Krku, Prague 15006 5, Czech Republic; [Kalitova, P.] LF UK Praze, Fyziolog Ustav 1, Prague, Czech Republic; [Cakrt, O.] LF UK & FN Motole, Klin Rehabil Telovychovneho Lekarstvi 2, Prague 15006 5, Czech Republic; [Cada, Z.; Chovanec, M.] LF UK Praze, Anatom Ustav 1, Prague, Czech Republic; [Jerabek, J.] LF UK & FN Motole, Neurol Klin 2, Prague 15006 5, Czech Republic","Kalitova, P (reprint author), LF UK & FN Motole, Klin Otorinolaryngol & Chirurg Hlavy & Krku, Uvalu 84, Prague 15006 5, Czech Republic.","petra.kalitova@lf1.cuni.cz",null,null,null,null,"Anderson TD, 2000, OTOLARYNG HEAD NECK, V122, P643; [Anonymous], 2011, FRONT NEUROL; Betka J, 2008, OTORINOLARYNGOL FONI, V57, P221; Black RA, 2005, ARCH NEUROL-CHICAGO, V62, P290, DOI 10.1001/archneur.62.2.290; Borgmann H, 2011, ACTA OTO-LARYNGOL, V131, P498, DOI 10.3109/00016489.2010.536991; Matthies C, 1997, NEUROSURGERY, V40, P1; Cakrt O, 2012, CESK SLOV NEUROL N, V75, P88; Cakrt O, 2010, NEUROLOGY, V267, P1355; Cakrt O, 2010, EUR ARCH OTO-RHINO-L, V267, P1355, DOI 10.1007/s00405-010-1227-x; Charabi S, 1999, ACTA OTO-LARYNGOL, V119, P796; Day AS, 2008, ACTA OTO-LARYNGOL, V128, P756, DOI 10.1080/00016480701749240; Eggers SDZ, 2003, SEMIN NEUROL, V23, P47; Gouveris H, 2007, ACTA OTO-LARYNGOL, V127, P839, DOI 10.1080/00016480601075357; Hempel JM, 2006, EUR ARCH OTO-RHINO-L, V263, P714, DOI 10.1007/s00405-006-0054-6; Komatsuzaki A, 2001, J LARYNGOL OTOL, V115, P362; Selesnick SH, 1999, OTOLARYNG HEAD NECK, V120, P815, DOI 10.1016/S0194-5998(99)70319-0; SELESNICK SH, 1993, LARYNGOSCOPE, V103, P431; Shiffman F, 1973, Otolaryngol Clin North Am, V6, P189; Stangerup SE, 2004, J LARYNGOL OTOL, V118, P622; Wackym PA, 2005, OTOLARYNG CLIN N AM, V38, P653, DOI 10.1016/j.otc.2005.03.018; Zverina Eduard, 2010, Cas Lek Cesk, V149, P269",21,1,1,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,4,null,null,null,null,469,474,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","195HL","WOS:000322692800008"]
[null,null,null,null,"J","Krol, P; Bohm, M; Sula, V; Dytrych, P; Katra, R; Nemcova, D; Dolezalova, P",null,null,null,"Krol, P.; Boehm, M.; Sula, V.; Dytrych, P.; Katra, R.; Nemcova, D.; Dolezalova, P.",null,null,"PFAPA syndrome: clinical characteristics and treatment outcomes in a large single-centre cohort","CLINICAL AND EXPERIMENTAL RHEUMATOLOGY",null,null,"English","Article",null,null,null,null,null,"periodic fever; aphtous stomatitis; pharyngitis and cervical adenitis syndrome; diagnostic algorithm; outcome","PERIODIC FEVER SYNDROME; APHTHOUS STOMATITIS; CERVICAL ADENITIS; PHARYNGITIS; CHILDREN; TONSILLECTOMY; DIAGNOSIS; PROFILE","Objective This paper aims to describe clinical and laboratory features and disease outcome in a single-centre cohort of patients with PFAPA syndrome (Periodic Fever, Aphtous stomatitis, Pharyngitis, and Adenitis) and to test performance of diagnostic and therapeutic algorithms. Methods Patients fulfilling criteria were selected from the fever clinic population. Prospective follow-up together with recruitment of newly diagnosed patients followed pre-defined guidelines. Diagnostic and therapeutic algorithms and definitions of outcome and therapy response were formulated. Paired blood samples during febrile and afebrile periods were compared. Results Out of 176 patients referred for suspected periodic fever 125 children fulfilled criteria. Their age at onset was 23 months, median episode duration 3.5 days at 4-week intervals. Fever was associated with pharyngitis (91%), cervical adenitis (78%) and aphtae (41%). Among therapeutic options, episodic prednisone proved to be the most common first-line treatment. Administered to 77 patients, it reduced symptoms in 94%. Tonsillectomy led to the full symptom resolution in all 18 patients. Forty-six patients reached disease remission. Conclusion Distribution of typical symptoms, response to therapies and disease outcome in a large patient cohort were documented. We offer diagnostic and therapeutic algorithms that have proven effective during this prospective trial. Our findings support the general belief of benign nature of this aetiologically unclear condition, despite proportion of patients having persistent disease for years. Maintenance of normal findings in afebrile intervals, striking response to a single dose of prednisone and normal growth and development together with spontaneous tendency towards prolongation of afebrile intervals are important confirmatory features of PFAPA syndrome.","[Krol, P.; Boehm, M.; Nemcova, D.; Dolezalova, P.] Charles Univ Prague, Dept Paediat & Adolescent Med, Fac Med 1, Prague 12100 2, Czech Republic; [Sula, V.] Hosp Ceske Budejovice, Dept Paediat, Ceske Budejovice, Czech Republic; [Dytrych, P.; Katra, R.] Charles Univ Prague, Dept ENT, Fac Med 2, Prague 12100 2, Czech Republic","Dolezalova, P (reprint author), Charles Univ Prague, Dept Paediat & Adolescent Med, Fac Med 1, Ke Karlovu 2, Prague 12100 2, Czech Republic.","dolezalova.pavla@vfn.cz",null,null,"Charles University [GAUK 5260812008]","this work was supported by the Charles University Grant no. GAUK 5260812008.",null,29,0,0,"CLINICAL & EXPER RHEUMATOLOGY","PISA","VIA SANTA MARIA 31, 56126 PISA, ITALY","0392-856X",null,null,"CLIN EXP RHEUMATOL","Clin. Exp. Rheumatol.","NOV-DEC",2013,31,6,null,null,null,null,980,987,null,null,null,8,"Rheumatology","Rheumatology","301UF","WOS:000330556900025"]
[null,null,null,null,"J","Sobotkova, V; Blatny, M; Jelinek, M; Hrdlicka, M",null,null,null,"Sobotkova, Veronika; Blatny, Marek; Jelinek, Martin; Hrdlicka, Michal",null,null,"Antisocial Behavior in Adolescence: Typology and Relation to Family Context","JOURNAL OF EARLY ADOLESCENCE",null,null,"English","Article",null,null,null,null,null,"family; antisocial behavior; typology; adolescence","LIFE-COURSE-PERSISTENT; NO SAFE HAVEN; VIOLENCE EXPOSURE; SUBSTANCE USE; URBAN YOUTH; CHILDHOOD; CHILDREN; PREDICTORS; AGGRESSION; CULTURES","The study deals with the relationship between antisocial behavior in early adolescence and family environment. Sample consisted of 2,856 adolescents (53% girls, mean age 13.5 years, SD = 1.1) from urban areas in the Czech Republic. The Social and Health Assessment (SAHA), a school survey, was used to measure sociodemographic characteristics of the family, parent-child interactions, and antisocial behavior. K-means cluster analysis on the items of Antisocial Behavior Scale was used to identify types of adolescents differentiated on the basis of antisocial behavior. Four major clusters of adolescents were identified. Subsequently, adolescents from different clusters were compared on sociodemographic variables (Pearson's chi-square) and aspects of upbringing (analysis of variance [ANOVA]). While there were no substantial differences between adolescents from the different clusters in sociodemographic characteristics of their family (parental education, parents employment, family structure), there were significant differences in aspects of upbringing (consistence, involvement, control, warmth) between adolescents from clusters differentiated by antisocial behavior.","[Sobotkova, Veronika; Blatny, Marek; Jelinek, Martin] Acad Sci Czech Republic, Inst Psychol, Brno 60200, Czech Republic; [Hrdlicka, Michal] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Sobotkova, V (reprint author), Acad Sci Czech Republic, Inst Psychol, Veveri 97, Brno 60200, Czech Republic.","veronika@psu.cas.cz",null,null,null,null,null,66,0,0,"SAGE PUBLICATIONS INC","THOUSAND OAKS","2455 TELLER RD, THOUSAND OAKS, CA 91320 USA","0272-4316","1552-5449",null,"J EARLY ADOLESCENCE","J. Early Adolesc.","NOV",2013,33,8,null,null,"SI",null,1091,1115,null,"10.1177/0272431612445377",null,25,"Family Studies; Psychology, Developmental","Family Studies; Psychology","232EO","WOS:000325474100005"]
[null,null,null,null,"J","Ptacek, R; Kuzelova, H; Stefano, GB; Raboch, J; Kream, RM",null,null,null,"Ptacek, Radek; Kuzelova, Hana; Stefano, George B.; Raboch, Jiri; Kream, Richard M.",null,null,"Targeted D-4 Dopamine Receptors: Implications for Drug Discovery and Therapeutic Development","CURRENT DRUG TARGETS",null,null,"English","Article",null,null,null,null,null,"D4 receptors; DRD4; dopamine receptor gene; psychiatric disorders; schizophrenia; antipsychotics","NONMEDICATED ADHD BOYS; EXON-III POLYMORPHISM; ANTIPSYCHOTIC-DRUGS; GENE POLYMORPHISMS; ANTHROPOMETRIC CHANGES; ANTIDEPRESSANT DRUGS; CLOZAPINE RESPONSE; ALLELIC VARIATION; NO ASSOCIATION; SCHIZOPHRENIA","A wealth of preclinical and clinical literature has established functional associations of CNS dopamine (DA) and its multiple G protein-coupled receptor (GPCR) types in the integration of key neurological processes linked to complex behavioral activities. Conversely, an equivalent vast literature supports the role of aberrant CNS DA expression and DA receptor signaling in the etiology and persistence of major psychiatric illnesses and has established selective targeting of DA-ergic systems as a cornerstone of pharmacotherapeutic intervention and current neuroleptic drug development. The present short review focuses on potential functional/behavioral alterations linked to polymorphisms in the primary DNA sequence of the DA receptor type 4 (DRD4) gene in reference to major psychiatric illnesses. The potential clinical relevance of major polymorphisms of the DRD4 gene are discussed within the context of practical aspects of typical and atypical neuroleptic drug usage within afflicted populations of psychiatric patients. It is anticipated that additional complementary molecular, biochemical, and behavioral studies of DRD4 gene polymorphisms will provide essential information for selective targeting of heterogeneous populations of CNS D4 receptors and advance drug discovery and therapeutic development efforts for highly efficacious treatment of psychiatric illnesses.","[Ptacek, Radek; Kuzelova, Hana; Stefano, George B.; Raboch, Jiri; Kream, Richard M.] Charles Univ Prague, Fac Med 1, Psychiat Clin, Prague 12801 2, Czech Republic; [Kuzelova, Hana] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague 12801 2, Czech Republic; [Stefano, George B.; Kream, Richard M.] SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA","Ptacek, R (reprint author), Charles Univ Prague, Fac Med 1, Psychiat Clin, Ke Karlovu 12, Prague 12801 2, Czech Republic.","ptacek@neuro.cz",null,null,null,null,null,73,0,0,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","1389-4501",null,null,"CURR DRUG TARGETS","Curr. Drug Targets","APR",2013,14,4,null,null,null,null,507,512,null,null,null,6,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","116KJ","WOS:000316881100012"]
[null,null,null,null,"J","Brynychova, V; Hlavac, V; Ehrlichova, M; Vaclavikova, R; Pecha, V; Trnkova, M; Wald, M; Mrhalova, M; Kubackova, K; Pikus, T; Kodet, R; Kovar, J; Soucek, P",null,null,null,"Brynychova, Veronika; Hlavac, Viktor; Ehrlichova, Marie; Vaclavikova, Radka; Pecha, Vaclav; Trnkova, Marketa; Wald, Martin; Mrhalova, Marcela; Kubackova, Katerina; Pikus, Tomas; Kodet, Roman; Kovar, Jan; Soucek, Pavel",null,null,"Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression","FUTURE ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"breast cancer; caspase-2; prognosis; transcript","DNA-DAMAGE RESPONSE; CELL-DEATH; TUMOR SUPPRESSION; INDUCED APOPTOSIS; CANCER CELLS; ACTIVATION; EXPRESSION; PACLITAXEL; PROTEIN; GENES","Aim: A role of caspase-2 in chemotherapy-induced apoptosis has been suggested. Our study aimed to evaluate the prognostic and predictive importance of caspase-2 isoforms in breast cancer patients. Materials & methods: Caspase-2L and -2S transcript levels were determined in paired tumor and non-malignant control tissues from 64 patients after neoadjuvant chemotherapy and 100 pretreatment patients (general set) by real-time PCR with absolute quantification. Results: Low but statistically significant upregulation of caspase-2L in tumor versus control tissues was observed in both sets. Significant associations of the levels of caspase-2L, -2S or S/L ratio with clinical prognostic factors were observed. However, none of these associations were confirmed in both sets. Levels of caspase-2 isoforms or the S/L ratio did not significantly associate with progression-free survival in the general set or with chemotherapy response in the neoadjuvant set. Conclusion: Our results suggest that the role of caspase-2 isoforms in the progression of breast cancer may considerably differ between pre- and post-chemotherapy patients.","[Brynychova, Veronika; Hlavac, Viktor; Ehrlichova, Marie; Vaclavikova, Radka; Soucek, Pavel] Natl Inst Publ Hlth, Dept Toxicol & Safety, Toxicogen Unit, Prague 10042 10, Czech Republic; [Brynychova, Veronika; Hlavac, Viktor] Charles Univ Prague, Fac Med 3, Prague 10, Czech Republic; [Pecha, Vaclav] MEDICON, Dept Oncosurg, Prague 4, Czech Republic; [Trnkova, Marketa] BIOLAB Praha Ltd, Prague 6, Czech Republic; [Wald, Martin] Charles Univ Prague, Fac Med 2, Dept Surg, Prague 5, Czech Republic; [Wald, Martin; Mrhalova, Marcela; Kubackova, Katerina; Pikus, Tomas; Kodet, Roman] Motol Univ Hosp, Prague 5, Czech Republic; [Mrhalova, Marcela; Kodet, Roman] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague 5, Czech Republic; [Kubackova, Katerina; Pikus, Tomas] Charles Univ Prague, Fac Med 2, Dept Oncol & Radiotherapy, Prague 5, Czech Republic; [Kovar, Jan] Charles Univ Prague, Fac Med 3, Div Cell & Mol Biol, Prague 10, Czech Republic","Soucek, P (reprint author), Natl Inst Publ Hlth, Dept Toxicol & Safety, Toxicogen Unit, Srobarova 48, Prague 10042 10, Czech Republic.","psoucek@szu.cz",null,null,"Czech Science Foundation [301/09/0362]; Internal Grant Agency of the Czech Ministry of Health [13679-4]; research project of the Charles University in Prague [PRVOUK P27]","This work was supported by grants from the Czech Science Foundation (no. 301/09/0362) to J Kovar and M Ehrlichova, by the Internal Grant Agency of the Czech Ministry of Health (no.: 13679-4) to P Soucek, V Pecha and M Trnkova, and by the research project of the Charles University in Prague (PRVOUK P27) to J Kovar. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",null,31,0,0,"FUTURE MEDICINE LTD","LONDON","UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND","1479-6694",null,null,"FUTURE ONCOL","Future Oncol.","MAR",2013,9,3,null,null,null,null,427,438,null,"10.2217/FON.12.200",null,12,"Oncology","Oncology","104CJ","WOS:000315966900017"]
[null,null,null,null,"J","Absolonova, K; Veleminsky, P; Dobisikova, M; Beran, M; Zocova, J",null,null,null,"Absolonova, Karolina; Veleminsky, Petr; Dobisikova, Miluse; Beran, Michal; Zocova, Jarmila",null,null,"Histological Estimation of Age at Death from the Compact Bone of Burned and Unburned Human Ribs","JOURNAL OF FORENSIC SCIENCES",null,null,"English","Article",null,null,null,null,null,"forensic science; forensic anthropology; age estimation; histomorphometry; human rib; compact bone; burned bone","ANTERIOR CORTEX; MICROSCOPIC DETERMINATION; SKELETAL REMAINS; CORTICAL BONE; STERNAL END; HUMAN FEMUR; HISTOMORPHOMETRY; IMPACT","This study describes the estimation of age at death from the compact bone of burned and unburned human ribs. Bone samples came from individuals of known age, sex, and cause of death. Each bone was divided into four sections; three sections were burned at 700, 800, and 1000 degrees C. Undecalcified, unstained ground cross sections were photographed, and 28 variables were analyzed in the bones using SigmaScan Pro 5. Age-related as well as heat-induced microstructural changes were found. These changes were often very similar and made estimating the age at death difficult in the burned bones. Differences between the sexes were found in some variables, caused by both aging and also by the different behavior of some variables during burning. Regression equations were developed to estimate age at death for unburned bones (r2 = 0.579 and 0.707), bones burned at 700 degrees C (r2 = 0.453 and 0.501), and 800 degrees C (r2 = 0.334 and 0.340).","[Absolonova, Karolina] Charles Univ Prague, Dept Anthropol & Human Genet, Fac Sci, Prague 12800 2, Czech Republic; [Absolonova, Karolina] Univ Karlova, Ustav Imunol & Mikrobiol, Lekarska Fak 1, Prague 12800 2, Czech Republic; [Veleminsky, Petr; Dobisikova, Miluse] Natl Museum Prague, Dept Anthropol, Nat Hist Museum, Prague 11579 1, Czech Republic; [Beran, Michal] Charles Univ Prague, Inst Legal Med, Fac Med 2, Prague 18081 8, Czech Republic; [Beran, Michal] Charles Univ Prague, Fac Hosp Bulovce Prague, Prague 18081 8, Czech Republic","Absolonova, K (reprint author), Univ Karlova, Ustav Imunol & Mikrobiol, Lekarska Fak 1, Studnickova 7, Prague 12800 2, Czech Republic.","karolina.absolonova@seznam.cz",null,null,"Charles University Grant Agency [135808]; Natural History Museum of the National Museum in Prague [VZ PM MK 00002327201]","We thank the autopsy technicians from the Institute of Legal Medicine, 2nd Faculty of Medicine and Faculty Hospital Na Bulovce in Prague, Charles University for the biological material sampling. We also thank the staff of the Institute of Geochemistry, Mineralogy & Mineral Resources, Faculty of Science, Charles University for providing the electric combustion furnace and our colleagues from the Department of Palaeontology, Natural History Museum of the National Museum in Prague for the loan of a microscope and digital camera. This study was supported by the Charles University Grant Agency (Grant no. 135808) and by the Natural History Museum of the National Museum in Prague (Research Plan no. VZ PM MK 00002327201).",null,49,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0022-1198",null,null,"J FORENSIC SCI","J. Forensic Sci.","JAN",2013,58,null,null,1,"SI",null,"S135","S145",null,"10.1111/j.1556-4029.2012.02303.x",null,11,"Medicine, Legal","Legal Medicine","070YK","WOS:000313550400019"]
[null,null,null,null,"J","Dzupova, O; Rozsypal, H; Smiskova, D; Benes, J",null,null,null,"Dzupova, Olga; Rozsypal, Hanus; Smiskova, Dita; Benes, Jiri",null,null,"Listeria monocytogenes Meningitis in Adults: The Czech Republic Experience","BIOMED RESEARCH INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,null,"BACTERIAL-MENINGITIS; PREDICTORS; INFECTION; MORTALITY; DISEASE; UPDATE; IMPACT","Background. Listeria monocytogenes (LM) is currently the third most frequent pathogen of bacterial meningitis in adults. Methods. A prospective study of patients with LM meningitis in a Czech tertiary care hospital, carried out from 1997 to 2012. Results. Thirty-one patients were diagnosed with LM meningitis, which was 7% of a total of 440 adult patients with acute bacterial meningitis (ABM) over a 16-year period. Their median age was 63 years, range 26-80 years. Nineteen patients (61%) had underlying immunocompromising comorbidity; 15 patients (48%) were older than 65 years. Fourteen patients (45%) had arterial hypertension. The typical triad of fever, neck stiffness, and altered mental status was present in 21 patients (68%). The median count of cerebrospinal fluid (CSF) leukocytes was 680/mu L, protein level 2.6 g/L, and glucose ratio 0.28. Four patients (13%) died, and nine (29%) survived with moderate to severe sequelae. Conclusion. LM meningitis is known to affect immunosuppressed and elderly patients. Arterial hypertension seems to be another important predisposing factor. Clinical symptoms, CSF findings, and disease outcomes, did not significantly differ from other community-acquired ABM in our study, although the CSF leukocyte count was lower. Ampicillin showed good clinical and bacteriological efficacy in the majority of patients.","[Dzupova, Olga; Benes, Jiri] Charles Univ Prague, Fac Med 3, Dept Infect Dis, Na Bulovce Hosp, Prague 18081, Czech Republic; [Rozsypal, Hanus] Charles Univ Prague, Fac Med 1, Dept Infect Dis, Na Bulovce Hosp, Prague 18081, Czech Republic; [Smiskova, Dita] Charles Univ Prague, Fac Med 2, Dept Infect Dis, Na Bulovce Hosp, Prague 18081, Czech Republic","Dzupova, O (reprint author), Charles Univ Prague, Fac Med 3, Dept Infect Dis, Na Bulovce Hosp, Budinova 2, Prague 18081, Czech Republic.","olga.dzupova@lf3.cuni.cz",null,null,null,null,null,20,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","2314-6133",null,null,"BIOMED RES INT","Biomed Res. Int.",null,2013,null,null,null,null,null,null,null,null,846186,"10.1155/2013/846186",null,4,"Biotechnology & Applied Microbiology; Medicine, Research & Experimental","Biotechnology & Applied Microbiology; Research & Experimental Medicine","222OP","WOS:000324740900001"]
[null,null,null,null,"J","Krejci, J; Gregor, P; Zemanek, D; Vyskocilova, K; Curila, K; Stepanova, R; Novak, M; Groch, L; Veselka, J",null,null,null,"Krejci, Jan; Gregor, Pavel; Zemanek, David; Vyskocilova, Klaudia; Curila, Karol; Stepanova, Radka; Novak, Miroslav; Groch, Ladislav; Veselka, Josef",null,null,"Comparison of Long-Term Effect of Dual-Chamber Pacing and Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy","SCIENTIFIC WORLD JOURNAL",null,null,"English","Article",null,null,null,null,null,null,"OUTFLOW TRACT OBSTRUCTION; LEFT-VENTRICULAR HYPERTROPHY; FOLLOW-UP; PACEMAKER IMPLANTATION; SUBAORTIC STENOSIS; DOUBLE-BLIND; REDUCTION; CROSSOVER; BENEFITS; THERAPY","Introduction. Nonpharmacological treatment of patients with hypertrophic obstructive cardiomyopathy (HOCM) comprises surgical myectomy (SME), alcohol septal ablation (ASA), and dual-chamber (DDD) pacing. The aim of the study was to compare the long-term effect of DDD pacing and ASA in symptomatic HOCM patients. Patients and Methods. We evaluated retrospective data from three cardiocenters; there were 24 patients treated with DDD pacing included and 52 treated with ASA followed for 101 +/- 49 and 87 +/- 23 months, respectively. Results. In the group treated with DDD pacing, the left ventricle outflow tract gradient (LVOTG) decreased from 82 +/- 44mmHg to 21 +/- 21mmHg, and NYHA class improved from 2.7 +/- 0.5 to 2.1 +/- 0.6 (both P < 0.001). In the ASA-treated group, a decline in LVOTG from 73 +/- 38mmHg to 24 +/- 26 mmHg and reduction in NYHA class from 2.8 +/- 0.5 to 1.7 +/- 0.8 were observed (both P < 0.001). The LVOTG change was similar in both groups (P = 0.264), and symptoms were more affected by ASA (P = 0.001). Conclusion. ASA and DDD pacing were similarly effective in reducing LVOTG. The symptoms improvement was more expressed in patients treated with ASA.","[Krejci, Jan; Vyskocilova, Klaudia; Novak, Miroslav; Groch, Ladislav] St Annes Univ Hosp, Dept Cardiovasc Dis, Int Clin Res Ctr, Brno 65691, Czech Republic; [Krejci, Jan; Vyskocilova, Klaudia; Novak, Miroslav; Groch, Ladislav] Masaryk Univ, Brno 65691, Czech Republic; [Gregor, Pavel; Curila, Karol] Univ Hosp Kralovske Vinohrady, Cardioctr, Dept Internal Med Cardiol 3, Prague 10034, Czech Republic; [Gregor, Pavel; Curila, Karol] Charles Univ Prague, Med Sch 3, Prague 10034, Czech Republic; [Zemanek, David; Veselka, Josef] Charles Univ Prague, Dept Cardiol, Sch Med 2, Univ Hosp Motol, Prague 15006, Czech Republic; [Stepanova, Radka] St Annes Univ Hosp, Int Clin Res Ctr, Brno 65691, Czech Republic","Krejci, J (reprint author), St Annes Univ Hosp, Dept Cardiovasc Dis, Int Clin Res Ctr, Pekarska 53, Brno 65691, Czech Republic.","jan.krejci@fnusa.cz",null,null,"European Regional Development Fund-Project FNUSA-ICRC [CZ.1.05/1.1.00/02.0123]; Project for Conceptual Development of Research Organization [00064203]; Internal Grant Agency, Ministry of Health, Czech Republic [NT 11401-5]","Jan Krejci, Klaudia Vyskocilova, Radka Stepanova, Miroslav Novak, and Ladislav Groch were supported by the European Regional Development Fund-Project FNUSA-ICRC (no. CZ.1.05/1.1.00/02.0123). Josef Veselka and David Zemanek were supported by the Project for Conceptual Development of Research Organization 00064203 and Grant NT 11401-5 from the Internal Grant Agency, Ministry of Health, Czech Republic.",null,43,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","1537-744X",null,null,"SCI WORLD J","Sci. World J.",null,2013,null,null,null,null,null,null,null,null,629650,"10.1155/2013/629650",null,7,"Multidisciplinary Sciences","Science & Technology - Other Topics","256SE","WOS:000327333400001"]
[null,null,null,null,"J","Kulijewicz-Nawrot, M; Sykova, E; Chvatal, A; Verkhratsky, A; Rodriguez, JJ",null,null,null,"Kulijewicz-Nawrot, Magdalena; Sykova, Eva; Chvatal, Alexander; Verkhratsky, Alexei; Rodriguez, Jose J.",null,null,"Astrocytes and glutamate homoeostasis in Alzheimer's disease: a decrease in glutamine synthetase, but not in glutamate transporter-1, in the prefrontal cortex","ASN NEURO",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; astroglia; glial fibrillary acidic protein (GFAP); glutamate transporter-1 (GLT-1); glutamine synthetase; medial prefrontal cortex","FIBRILLARY ACIDIC PROTEIN; TRIPLE-TRANSGENIC MODEL; EXCITATORY AMINO-ACIDS; IN-SITU HYBRIDIZATION; MOUSE MODEL; CEREBROSPINAL-FLUID; MAMMALIAN BRAIN; METABOLIZING ENZYMES; NERVOUS-SYSTEM; NEURON LOSS","Astrocytes control tissue equilibrium and hence define the homoeostasis and function of the CNS (central nervous system). Being principal homoeostatic cells, astroglia are fundamental for various forms of neuropathology, including AD (Alzheimer's disease). AD is a progressive neurodegenerative disorder characterized by the loss of cognitive functions due to specific lesions in mnesic-associated regions, including the mPFC (medial prefrontal cortex). Here, we analyzed the expression of GS (glutamine synthetase) and GLT-1 (glutamate transporter-1) in astrocytes in the mPFC during the progression of AD in a triple-transgenic mouse model (3xTg-AD). GS is an astrocyte-specific enzyme, responsible for the intracellular conversion of glutamate into glutamine, whereas the removal of glutamate from the extracellular space is accomplished mainly by astroglia-specific GLT-1. We found a significant decrease in the numerical density (Nv, cells/mm(3)) of GS-positive astrocytes from early to middle ages (1-9 months; at the age of 1 month by 17%, 6 months by 27% and 9 months by 27% when compared with control animals) in parallel with a reduced expression of GS (determined by Western blots), which started at the age of 6 months and was sustained up to 12 months of age. We did not, however, find any changes in the expression of GLT-1, which implies an intact glutamate uptake mechanism. Our results indicate that the decrease in GS expression may underlie a gradual decline in the vital astrocyte-dependent glutamate-glutamine conversion pathway, which in turn may compromise glutamate homoeostasis, leading towards failures in synaptic connectivity with deficient cognition and memory.","[Kulijewicz-Nawrot, Magdalena; Sykova, Eva; Chvatal, Alexander] ASCR, Inst Expt Med, Prague 14320, Czech Republic; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic; [Sykova, Eva] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Verkhratsky, Alexei] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; [Verkhratsky, Alexei; Rodriguez, Jose J.] Basque Fdn Sci, IKERBASQUE, Bilbao 48011, Spain; [Verkhratsky, Alexei; Rodriguez, Jose J.] Univ Basque Country UPV EHU, Dept Neurosci, Leioa 48940, Spain","Verkhratsky, A (reprint author), Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England.","Alexej.Verkhratsky@manchester.ac.uk; j.rodriguez-arellano@ikerbasque.org","Verkhratsky, Alexei/J-4527-2013","Verkhratsky, Alexei/0000-0003-2592-9898","Alzheimer's Research Trust [ART/PG2004A/1]; Wellcome Trust; Grant Agency of the Czech Republic [GACR 309/09/1696, GACR 304/11/0184, GACR 305/08/1381, GACR 305/08/1384, P304/12/G069]; Spanish Government; FEDER; Government of the Basque Country [AE-2010-1-28, AEGV10/16, GV-2011111020]; European Commission FP7 project AXREGEN [PITN-GA-2008-214003]; Plan Nacional de I + D + I; ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion [PI10/02738]","This study was supported by the Alzheimer's Research Trust [programme grant number ART/PG2004A/1 (to J.J.R. and A.V.)], the Wellcome Trust and the Grant Agency of the Czech Republic [grant numbers GACR 309/09/1696 (to J.J.R.), GACR 304/11/0184 (to E.S. and J.J.R.), and GACR 305/08/1381 and GACR 305/08/1384 (to A.V.)]. Support from the Spanish Government, Plan Nacional de I + D + I 2008-2011 and ISCIII-Subdireccion General de Evaluacion y Fomento de la Investigacion [grant number PI10/02738] co-financed by FEDER (to J.J.R. and A.V.) and the Government of the Basque Country [grant numbers AE-2010-1-28, AEGV10/16, GV-2011111020] is gratefully acknowledged. M.K.-N. is supported by the European Commission FP7 project AXREGEN [grant number PITN-GA-2008-214003] and the Grant Agency of the Czech Republic [grant number P304/12/G069].",null,94,0,0,"PORTLAND PRESS LTD","LONDON","THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND","1759-0914",null,null,"ASN NEURO","ASN Neuro",null,2013,5,4,null,null,null,null,273,282,"e00123","10.1042/AN20130017",null,10,"Neurosciences","Neurosciences & Neurology","269SQ","WOS:000328262600004"]
[null,null,null,null,"J","Nagy, A; Jirincova, H; Havlickova, M; Dzupova, O; Herrmannova, K; Trojanek, M; Maresova, V; Novakova, L; Kyncl, J",null,null,null,"Nagy, Alexander; Jirincova, Helena; Havlickova, Martina; Dzupova, Olga; Herrmannova, Kristyna; Trojanek, Milan; Maresova, Vilma; Novakova, Ludmila; Kyncl, Jan",null,null,"Phylogenetic Analysis and Genotyping of A/H3N2 Influenza Viruses Isolated from Patients Hospitalised with Influenza-Like Illness Symptoms in the Na Bulovce Hospital in the Season 2011/2012","EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE",null,null,"Czech","Article",null,null,null,null,null,"influenza A virus, phylogenetic analysis; genotyping; hospitalization; clinical symptoms",null,"Influenza A virus is an important cause of acute respiratory infections (ARI). Clinical manifestations of ARI vary from mild or moderate to life-threatening conditions requiring intensive care. Given the segmented genome, a large natural reservoir of other influenza virus subtypes, and antibody selection pressure in the population, the virus is variable and genetically unstable. The phylogenetic analysis and genotyping of A/H3N2 influenza viruses isolated from patients hospitalised with influenza-like illness symptoms in the Na Bulovce Hospital in the season 2011/2012 support the assumption that the pathogenicity is a polygenic trait modifiable by the host health status and seems not to be unambiguously associated with any specific mutations.","[Nagy, Alexander; Jirincova, Helena; Havlickova, Martina; Novakova, Ludmila; Kyncl, Jan] Ctr Epidemiol & Mikrobiol, Statni Zdravotni Ustav, Prague, Czech Republic; [Dzupova, Olga; Herrmannova, Kristyna; Trojanek, Milan; Maresova, Vilma] Univ Karlova Praze, Lekarska Fak, Prague, Czech Republic; [Dzupova, Olga; Herrmannova, Kristyna; Trojanek, Milan; Maresova, Vilma] Nemocnice Bulovce, Klin Infekcnich Nemoci, Prague, Czech Republic","Nagy, A (reprint author), Statni Zdravotni Ustav, Narodni Referencni Lab Chripku, Srobarova 48, Prague 10042, Czech Republic.","alexandernagy17@hotmail.com",null,null,null,null,"Felsenstein J, 2004, PHYLIP PHYLOGENY INF; Garten RJ, 2009, SCIENCE, V325, P197, DOI 10.1126/science.1176225; Hall TA., 1999, NUCL ACIDS S SER, V41, P95; Krumbholz A, 2011, MED MICROBIOL IMMUN, V200, P69, DOI 10.1007/s00430-010-0176-8; Nagy A., 2012, VIRUS RES, V165, P126; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092",6,0,0,"CESKA LEKARSKA SPOLECNOST J  EV  PURKYNE","PRAGUE","SOKOLSKA 31, PRAGUE, 00000, CZECH REPUBLIC","1210-7913",null,null,"EPIDEMIOL MIKROBI IM","Epidemiol. Mikrobiol. Imunol.",null,2013,62,1,null,null,null,null,4,8,null,null,null,5,"Immunology; Microbiology","Immunology; Microbiology","228HV","WOS:000325177500002"]
[null,null,null,null,"J","Rozsypal, H; Jilich, D; Hubacek, P; Holub, M",null,null,null,"Rozsypal, H.; Jilich, D.; Hubacek, P.; Holub, M.",null,null,"Difficulties Diagnosing Progressive Multifocal Leukoencephalopathy in Patients Infected with the Human Immunodeficiency Virus - Case Reports","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"progressive multifocal leukoencephalopathy; human immunodeficiency virus; acquired immunodeficiency syndrome; JC virus","ACTIVE ANTIRETROVIRAL THERAPY; JC VIRUS; CEREBROSPINAL-FLUID; CLINICAL-COURSE; HIV-INFECTION; SURVIVAL; PATHOGENESIS; PROGNOSIS; EFFICACY; HAART","Progressive Multifocal Leukoencephalopathy (PML) is a focal inflammatory process of white brain matter induced by polyomaviral infection that affects HIV-positive individuals, patients with hematologic malignancies and recently also patients on a biological treatment. PML is a typical opportunistic infection of patients with AIDS. Examination with magnetic resonance imaging (MRI) and detection of JC virus (JCV) DNA in the cerebrospinal fluid (CSF) are the most important approaches to the diagnosis of PML. Case reports document that PML diagnosis is not easy. The disease may develop before the number of CD4+ lymphocytes drops below 100 cells/mu l. Appearance of lesions on a CT scan and MRI is not completely specific and may be mistaken for brain toxoplasmosis, an ischemic lesion or other intracranial processes; sometimes it can start with one lesion only, suggesting a unifocal process. The paper draws a reader's attention to the use of molecular biological diagnostics. It describes initial experience with JCV detection in the CSF using PCR in the Czech Republic and, at the same time, it discusses limited sensitivity of the method. PML prognosis is poor but disease progression can be slowed down by well managed combined antiretroviral therapy (cART). The initiation of cART in persons with severe immunodeficiency may in rare cases lead to paradoxical development of PML as a sign of immune reconstitution inflammatory syndrome (IRIS).","[Rozsypal, H.; Jilich, D.; Holub, M.] LF UK & Nemocnice Bulovce, Klin Infekcnich & Trop Nemoci 1, Prague 18081 8, Czech Republic; [Hubacek, P.] LF UK & FN Motole, Mol Genet Lab, Ustav Lekarske Mikrobiol, Prague, Czech Republic; [Hubacek, P.] LF UK & FN Motole, Klin Detske Hematol & Onkol 2, Prague, Czech Republic","Rozsypal, H (reprint author), LF UK & Nemocnice Bulovce, Klin Infekcnich & Trop Nemoci 1, Budinova 2, Prague 18081 8, Czech Republic.","rozsypalh@volny.cz",null,null,null,null,"Albrecht H, 1998, AIDS, V12, P1149, DOI 10.1097/00002030-199810000-00006; [Anonymous], 2009, CLIN INFECT DIS; Berenguer J, 2003, CLIN INFECT DIS, V36, P1047, DOI 10.1086/374048; Berger JR, 1998, ANN NEUROL, V44, P341, DOI 10.1002/ana.410440309; Bossolasco S, 2005, CLIN INFECT DIS, V40, P738, DOI 10.1086/427698; Cerny R, 2010, CESK SLOV NEUROL N, V73, P374; Cettomai D, 2009, ARCH NEUROL-CHICAGO, V66, P255, DOI 10.1001/archneurol.2008.557; Clifford DB, 1999, NEUROLOGY, V52, P623; Delobel P, 2004, AIDS, V18, P702, DOI 10.1097/01.aids.0000111470.61782.c4; De Luca A, 2008, AIDS, V22, P1759, DOI 10.1097/QAD.0b013e32830a5043; Dworkin MS, 1999, J INFECT DIS, V180, P621, DOI 10.1086/314937; EACS (European AIDS Clinical Society), 2011, GUIDELINES; Eggers C, 1999, J INFECT DIS, V180, P1690, DOI 10.1086/315087; Elphick GF, 2004, SCIENCE, V306, P1380, DOI 10.1126/science.1103492; Eng PM, 2006, NEUROLOGY, V67, P884, DOI 10.1212/01.wnl.0000233918.21986.9c; Engsig FN, 2009, J INFECT DIS, V199, P77, DOI 10.1086/595299; Falco V, 2008, JAIDS-J ACQ IMM DEF, V49, P26, DOI 10.1097/QAI.0b013e31817bec64; Focosi D, 2008, J INFECT DIS, V197, P328, DOI 10.1086/524877; Focosi D, 2007, J CLIN VIROL, V39, P63, DOI 10.1016/j.jcv.2007.03.001; Garcia De Viedma D, 2002, CLIN INFECT DIS, V34, P1568; Hall CD, 1998, NEW ENGL J MED, V338, P1345, DOI 10.1056/NEJM199805073381903; Hoffmann C, 2003, J NEUROL NEUROSUR PS, V74, P1142, DOI 10.1136/jnnp.74.8.1142; Khanna N, 2009, CLIN INFECT DIS, V48, P1459, DOI 10.1086/598335; Khanna N, 2009, J VIROL, V83, P4404, DOI 10.1128/JVI.02657-08; Knowles WA, 2003, J MED VIROL, V71, P115, DOI 10.1002/jmv.10450; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49; Marzocchetti A, 2009, NEUROLOGY, V73, P1551, DOI 10.1212/WNL.0b013e3181c0d4a1; Naess H, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-32; Nery Filipe, 2011, J Clin Med Res, V3, P17, DOI 10.4021/jocmr501w; OReilly S, 1997, LANCET, V350, P291, DOI 10.1016/S0140-6736(05)62256-8; PADGETT BL, 1973, J INFECT DIS, V127, P467; Royal W, 2003, J NEUROVIROL, V9, P411, DOI 10.1080/13550280390201740; Smith AB, 2010, POSTGRAD MED J, V86, P218, DOI 10.1136/pgmj.2009.087452; SZU, UD NAR REF LAB PRO A; Tan CS, 2010, LANCET NEUROL, V9, P425, DOI 10.1016/S1474-4422(10)70040-5; Tan K, 2009, NEUROLOGY, V72, P1458, DOI 10.1212/01.wnl.0000343510.08643.74; Tantisiriwat W, 1999, CLIN INFECT DIS, V28, P1152, DOI 10.1086/514762; Vaklavas C, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-256; Antinori A, 2001, J NEUROVIROL, V7, P323, DOI 10.1080/13550280152537184; Verma S, 2007, J INFECT DIS, V196, P709, DOI 10.1086/52051; VollmerHaase J, 1997, LANCET, V349, P1366, DOI 10.1016/S0140-6736(05)63201-1; Wang YH, 2009, J MED MICROBIOL, V58, P253, DOI 10.1099/jmm.0.004432-0; Weber T, 1997, J INFECT DIS, V176, P250, DOI 10.1086/514032; White MK, 2011, J INFECT DIS, V203, P578, DOI 10.1093/infdis/jiq097; Wyen C, 2004, JAIDS-J ACQ IMM DEF, V37, P1263, DOI 10.1097/01.qai.0000136093.47316.f3; Yousry TA, 2006, NEW ENGL J MED, V354, P924, DOI 10.1056/NEJMoa054693",46,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,4,null,null,null,null,501,507,null,null,null,7,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","195HL","WOS:000322692800015"]
[null,null,null,null,"J","Majerova, V; Musova, Z; Zumrova, A; Ruzicka, E; Roth, J",null,null,null,"Majerova, V.; Musova, Z.; Zumrova, A.; Ruzicka, E.; Roth, J.",null,null,"Spinocerebellar Ataxia 7-a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"spinocerebellar ataxia; cerebellar syndrome; retinal degeneration","DOMINANT CEREBELLAR-ATAXIA; ADCA TYPE-II; PIGMENTARY MACULAR DYSTROPHY; DE-NOVO EXPANSION; RETINAL DEGENERATION; CHROMOSOME 3P12-P21.1; HEREDITARY ATAXIAS; CLINICAL-FEATURES; REPEAT EXPANSION; GENETIC-ANALYSIS","Spinocerebellar ataxia 7 (SCA7) is a rare autosomal dominant neurodegenerative disorder caused by expansion of an unstable CAG triplet repeats encoding the polyglutamine chain in the corresponding protein, ataxin-7 on the 3rd chromosome. Typical clinical signs include cerebellar syndrome and visual impairment due to progressive macular dystrophy. In the Czech Republic, 1 case only of SCA7 has been diagnosed so far. The following case report presents a case of a 48 years old male patient with slow progression of typical signs of SCA7, except for retinal degeneration. The first symptom, visual disturbance, developed 15 years ago, followed later by balance and coordination disorder. At the age of 48 years, visual impairment remains the main complaint. During neurological examination, we identified mild cerebellar and pyramidal syndrome. The patient's mother died at the age of 65 years from an unknown neuropsychiatric disorder. Due to the rare occurrence of this disease, SCA7 in our patient was initially not considered as part of differential diagnosis and the delay between the first neurological examination and the diagnosis was almost 8 years.","[Majerova, V.; Ruzicka, E.; Roth, J.] 1 LF & VFN, Neurol Klin, UK Praze, Prague, Czech Republic; [Majerova, V.; Ruzicka, E.; Roth, J.] 1 LF & VFN, Ctr Klin Neuroved, UK Praze, Prague, Czech Republic; [Musova, Z.] LF UK & FN Motole, Ustav Biol & Lekarske Genet 2, Prague, Czech Republic; [Musova, Z.; Zumrova, A.] Ctr Hereditarnich Ataxii FN Motole, Prague, Czech Republic; [Zumrova, A.] LF UK & FN Motole, Klin Detske Neurol 2, Prague, Czech Republic","Roth, J (reprint author), LF UK & VFN, Neurol Klin 1, Katerinska 30, Prague 12808 2, Czech Republic.","jan1roth2@gmail.com",null,null,null,null,"Aleman TS, 2002, EXP EYE RES, V74, P737, DOI 10.1006/exer.2002.1169; Bandmann O, 2008, NEUROLOGY, V71, P542, DOI 10.1212/01.wnl.0000323932.90720.55; Bauer P, 2004, J NEUROL, V251, P1023, DOI 10.1007/s00415-004-0482-4; BENOMAR A, 1995, NAT GENET, V10, P84, DOI 10.1038/ng0595-84; BENOMAR A, 1994, ANN NEUROL, V35, P439, DOI 10.1002/ana.410350411; Benton CS, 1998, NEUROLOGY, V51, P1081; Chorea IHAIatWFoNWRGoHs, 1994, NEUROLOGY, V44, P1533; David G, 1998, HUM MOL GENET, V7, P165, DOI 10.1093/hmg/7.2.165; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Del-Favero J, 1998, HUM MOL GENET, V7, P177, DOI 10.1093/hmg/7.2.177; Duenas AM, 2006, BRAIN, V129, P1357, DOI 10.1093/brain/awl081; Durr Alexandra, 2000, Current Opinion in Neurology, V13, P407, DOI 10.1097/00019052-200008000-00007; ENEVOLDSON TP, 1994, BRAIN, V117, P445, DOI 10.1093/brain/117.3.445; Erichsen AK, 2009, BRAIN, V132, P1577, DOI 10.1093/brain/awp056; Giunti P, 1999, AM J HUM GENET, V64, P1594, DOI 10.1086/302406; GOUW LG, 1995, NAT GENET, V10, P89, DOI 10.1038/ng0595-89; GOUW LG, 1994, NEUROLOGY, V44, P1441; HARDING AE, 1993, ADV NEUROL, V61, P1; HARDING AE, 1982, BRAIN, V105, P1, DOI 10.1093/brain/105.1.1; HOLMBERG M, 1995, HUM MOL GENET, V4, P1441, DOI 10.1093/hmg/4.8.1441; Ishikawa Kinya, 2010, Rinsho Shinkeigaku, V50, P985; Johansson J, 1998, HUM MOL GENET, V7, P171, DOI 10.1093/hmg/7.2.171; Klockgether T, 1998, BRAIN, V121, P589, DOI 10.1093/brain/121.4.589; Klockgether T, 2011, MOVEMENT DISORD, V26, P1134, DOI 10.1002/mds.23559; KONIGSMA.BW, 1970, MEDICINE, V49, P227; Lebre AS, 2003, CYTOGENET GENOME RES, V100, P154, DOI 10.1159/000072850; LEONE M, 1995, ACTA NEUROL SCAND, V91, P183; Manto MU, 2005, CEREBELLUM, V4, P2, DOI 10.1080/14734220510007914; Nardacchione A, 1999, CLIN GENET, V56, P232, DOI 10.1034/j.1399-0004.1999.560309.x; Paulson HL, 2009, J NEURO-OPHTHALMOL, V29, P227, DOI 10.1097/WNO0b013e3181b416de; Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9; Silva MC, 1997, J CLIN EPIDEMIOL, V50, P1377, DOI 10.1016/S0895-4356(97)00202-3; Soong BW, 2007, CURR OPIN NEUROL, V20, P438, DOI 10.1097/WCO.0b013e3281fbd3dd; Stevanin G, 1998, HUM MOL GENET, V7, P1809, DOI 10.1093/hmg/7.11.1809; Stevanin G, 2000, EUR J HUM GENET, V8, P4, DOI 10.1038/sj.ejhg.5200403; Storey E, 2009, J NEUROL NEUROSUR PS, V80, P408, DOI 10.1136/jnnp.2008.159459; Teive HAG, 2009, ARQ NEURO-PSIQUIAT, V67, P1133, DOI 10.1590/S0004-282X2009000600035; van de Warrenburg BPC, 2002, NEUROLOGY, V58, P702",38,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,2,null,null,null,null,225,228,null,null,null,4,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","120IG","WOS:000317163400016"]
[null,null,null,null,"J","Chromecki, TF; Cha, EK; Fajkovic, H; Rink, M; Ehdaie, B; Svatek, RS; Karakiewicz, PI; Lotan, Y; Tilki, D; Bastian, PJ; Daneshmand, S; Kassouf, W; Durand, M; Novara, G; Fritsche, HM; Burger, M; Izawa, JI; Brisuda, A; Babjuk, M; Pummer, K; Shariat, SF",null,null,null,"Chromecki, Thomas F.; Cha, Eugene K.; Fajkovic, Harun; Rink, Michael; Ehdaie, Behfar; Svatek, Robert S.; Karakiewicz, Pierre I.; Lotan, Yair; Tilki, Derya; Bastian, Patrick J.; Daneshmand, Siamak; Kassouf, Wassim; Durand, Matthieu; Novara, Giacomo; Fritsche, Hans-Martin; Burger, Maximilian; Izawa, Jonathan I.; Brisuda, Antonin; Babjuk, Marek; Pummer, Karl; Shariat, Shahrokh F.",null,null,"Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy","BJU INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"bladder cancer; BMI; obesity; prognosis; radical cystectomy; survival; urothelial carcinoma","BODY-MASS INDEX; PREOPERATIVE PLASMA-LEVELS; BLADDER-CANCER; CELL CARCINOMA; RISK; SURVIVAL; IMPACT; MORTALITY; COHORT; ADULTS","What's known on the subject? and What does the study add? Little is known on the association between obesity and urothelial carcinoma of the bladder (UCB). Most studies have shown that higher body mass index (BMI) is associated with higher rates of perioperative complications. Only one study specifically investigated obesity and bladder cancer-specific outcomes and reported no significant association between higher BMI and disease-specific survival in patients with UCB treated with radical cystectomy. However, that study was limited by its small sample size and a high rate of preoperative therapies. In contrast to the only previous study evaluating the association of BMI with oncological outcomes in UCB, we found that obesity (BMI 30kg/m2) was associated with features of biologically aggressive UCB and clinical outcomes after radical cystectomy and, even when adjusting for the effects of standard clinicopathological features, obesity remained an independent predictor of cancer recurrence, cancer-specific mortality and overall mortality. Objective To investigate the association between body mass index (BMI) and oncological outcomes in patients after radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) in a large multi-institutional series. Patients and Methods Data were collected from 4118 patients treated with RC and pelvic lymphadenectomy for UCB. Patients receiving preoperative chemotherapy or radiotherapy were excluded. Univariable and multivariable models tested the effect of BMI on disease recurrence, cancer-specific mortality and overall mortality. BMI was analysed as a continuous and categorical variable (<25 vs 2529 vs 30kg/m2). Results Median BMI was 28.8kg/m2 (interquartile range 7.9); 25.3% had a BMI <25kg/m2, 32.5% had a BMI between 25 and 29.9kg/m2, and 42.2% had a BMI 30kg/m2. Patients with a higher BMI were older (P < 0.001), had higher tumour grade (P < 0.001), and were more likely to have positive soft tissue surgical margins (P = 0.006) compared with patients with lower BMI. In multivariable analyses that adjusted for the effects of standard clinicopathological features, BMI >30 was associated with higher risk of disease recurrence (hazard ratio (HR) 1.67, 95% confidence interval (CI) 1.461.91, P < 0.001), cancer-specific mortality (HR 1.43, 95% CI 1.241.66, P < 0.001), and overall mortality (HR 1.81, CI 1.602.05, P < 0.001). Themain limitation is the retrospective design of the study. Conclusions Obesity is associated with worse cancer-specific outcomes in patients treated with RC for UCB. Focusing on patient-modifiable factors such as BMI may have significant individual and public health implications in patients with invasive UCB.","[Chromecki, Thomas F.; Cha, Eugene K.; Fajkovic, Harun; Rink, Michael; Ehdaie, Behfar; Durand, Matthieu; Shariat, Shahrokh F.] Cornell Univ, Weill Med Coll, New York, NY 10065 USA; [Chromecki, Thomas F.; Pummer, Karl] Med Univ Graz, Graz, Austria; [Fajkovic, Harun] Landeskrankenhaus St Poelten, St Polten, Austria; [Rink, Michael] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Svatek, Robert S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Karakiewicz, Pierre I.] Univ Montreal, Montreal, PQ, Canada; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Tilki, Derya; Bastian, Patrick J.] Univ Munich, Klinikum Grosshadern, D-80539 Munich, Germany; [Daneshmand, Siamak] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Daneshmand, Siamak] Norris Comprehens Canc Ctr, Los Angeles, CA USA; [Kassouf, Wassim] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Novara, Giacomo] Univ Padua, Padua, Italy; [Fritsche, Hans-Martin; Burger, Maximilian] Univ Regensburg, Caritas St Josef Med Ctr, D-93053 Regensburg, Germany; [Izawa, Jonathan I.] Univ Western Ontario, London, ON, Canada; [Brisuda, Antonin; Babjuk, Marek] Charles Univ Prague, Hosp Motol, Fac Med 2, Prague, Czech Republic","Shariat, SF (reprint author), Cornell Univ, Weill Med Coll, Brady Urol Hlth Ctr, New York Presbyterian Hosp, 525 E 68th St,Starr 912A, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,null,null,null,26,6,6,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1464-4096",null,null,"BJU INT","BJU Int.","FEB",2013,111,2,null,null,null,null,249,255,null,"10.1111/j.1464-410X.2012.11322.x",null,7,"Urology & Nephrology","Urology & Nephrology","091DU","WOS:000315030200013"]
[null,null,null,null,"J","Rink, M; Lee, DJ; Kent, M; Xylinas, E; Fritsche, HM; Babjuk, M; Brisuda, A; Hansen, J; Green, DA; Aziz, A; Cha, EK; Novara, G; Chun, FK; Lotan, Y; Bastian, PJ; Tilki, D; Gontero, P; Pycha, A; Baniel, J; Mano, R; Ficarra, V; Trinh, QD; Tagawa, ST; Karakiewicz, PI; Scherr, DS; Sjoberg, DD; Shariat, SF",null,null,null,"Rink, Michael; Lee, Daniel J.; Kent, Matthew; Xylinas, Evanguelos; Fritsche, Hans-Martin; Babjuk, Marko; Brisuda, Antonin; Hansen, Jens; Green, David A.; Aziz, Atiqullah; Cha, Eugene K.; Novara, Giacomo; Chun, Felix K.; Lotan, Yair; Bastian, Patrick J.; Tilki, Derya; Gontero, Paolo; Pycha, Armin; Baniel, Jack; Mano, Roy; Ficarra, Vincenzo; Quoc-Dien Trinh; Tagawa, Scott T.; Karakiewicz, Pierre I.; Scherr, Douglas S.; Sjoberg, Daniel D.; Shariat, Shahrokh F.",null,"Bladder Canc Res Consortium","Predictors of cancer-specific mortality after disease recurrence following radical cystectomy","BJU INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"urothelial carcinoma; bladder cancer; recurrence; survival; prognosis","TRANSITIONAL-CELL CARCINOMA; INVASIVE BLADDER-CANCER; LONG-TERM-SURVIVAL; LYMPHOVASCULAR INVASION; UROTHELIAL CARCINOMA; PROGNOSTIC-FACTORS; NOMOGRAMS; VALIDATION; EXPRESSION; GUIDELINES","Study Type Therapy (case series) Level of Evidence4 What's known on the subject? and What does the study add? Outcomes after disease recurrence in patients with urothelial carcinoma of the bladder treated with radical cystectomy are variable, but the majority of patients die from the disease within 2 years after disease recurrence. Knowledge about prognostic factors that may influence survival after disease recurrence is limited. We found that outcomes after disease recurrence in patients with urothelial carcinoma of the bladder are significantly affected by common clinicopathological factors. In addition, a shorter time from surgery to disease recurrence is significantly associated with poor outcomes. These factors should be considered when scheduling salvage chemotherapy protocols/clinical trials. OBJECTIVE center dot To describe the natural history following disease recurrence after radical cystectomy (RC) and to identify prognostic factors that influence cancer-specific survival with special focus on time from RC to disease recurrence. METHODS center dot We identified 1545 patients from 16 international institutions who experienced disease recurrence after RC and bilateral lymphadenectomy. None of the patients received preoperative chemotherapy; 549 patients received adjuvant chemotherapy. center dot A multivariable Cox regression model addressed time to cancer-specific mortality after disease recurrence. RESULTS center dot The median cancer-specific survival time after disease recurrence was 6.9 months (95% CI 6.37.4). Overall, 1254 of 1545 patients died from urothelial carcinoma of the bladder and 47 patients died from other causes. The actuarial cancer-specific survival estimate at 12 months after disease recurrence was 32%. center dot On multivariable analysis, non-organ-confined tumour stages (hazard ratio [HR] 1.38, P= 0.002), lymph node metastasis (HR 1.25, P < 0.001), positive soft tissue surgical margin (HR 1.32, P= 0.002), female gender (HR 1.21, P= 0.003), advanced age (HR 1.16, P < 0.001) and a shorter interval from surgery to disease recurrence (P < 0.001) were significantly associated with cancer-specific mortality. center dot The adjusted risk of death from cancer within 1 year after disease recurrence for patients who recurred 6, 12 and 24 months after surgery was 70%, 64% and 60%, respectively. CONCLUSIONS center dot Over two-thirds of patients who experience disease recurrence of urothelial carcinoma of the bladder after RC die within 12 months. center dot Common clinicopathological factors are strongly associated with cancer-specific mortality. A shorter time from surgery to disease recurrence is significantly associated with poor outcomes. center dot Accurate risk stratification could help in patient counselling and decision-making regarding salvage treatment.","[Rink, Michael; Lee, Daniel J.; Xylinas, Evanguelos; Green, David A.; Cha, Eugene K.; Tagawa, Scott T.; Scherr, Douglas S.; Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA; [Kent, Matthew; Sjoberg, Daniel D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Rink, Michael; Hansen, Jens; Chun, Felix K.] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Fritsche, Hans-Martin; Aziz, Atiqullah] Univ Regensburg, Caritas St Josef Med Ctr, D-93053 Regensburg, Germany; [Bastian, Patrick J.; Tilki, Derya] Univ Munich, Klinikum Grosshadern, D-80539 Munich, Germany; [Xylinas, Evanguelos] Paris Descartes Univ, Cochin Hosp, APHP, Paris, France; [Babjuk, Marko; Brisuda, Antonin] Charles Univ Prague, Hosp Motol, Fac Med 2, Prague, Czech Republic; [Hansen, Jens; Quoc-Dien Trinh; Karakiewicz, Pierre I.] Univ Montreal, Montreal, PQ, Canada; [Novara, Giacomo; Ficarra, Vincenzo] Univ Padua, Padua, Italy; [Gontero, Paolo] Univ Turin, Urol Molinette Hosp 1, Turin, Italy; [Pycha, Armin] Gen Hosp Bolzano, Bolzano, Italy; [Baniel, Jack; Mano, Roy] Rabin Med Ctr, Petah Tiqwa, Israel","Shariat, SF (reprint author), Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Dept Urol, 525 East 68th St,Box 94,Starr 900, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,"New York Community Trust","We thank the members of the Bladder Cancer Research Consortium (BCRC): Evi Comploj, Siamak Daneshmand, Yves Fradet, Jonathan I. Izawa, Wassim Kassouf, Seth P. Lerner, Roman Mayr, Francesco Montorsi, Arthur I. Sagalowsky, Mark P. Schoenberg, Eila Skinner, Viktor Soukup, Robert S. Svatek and Bjoern G. Volkmer. Dr. Michael Rink and Dr. David A. Green are supported by the Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust.",null,26,4,4,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1464-4096",null,null,"BJU INT","BJU Int.","MAR",2013,111,"3B",null,null,null,null,"E30","E36",null,"10.1111/j.1464-410X.2012.11433.x",null,7,"Urology & Nephrology","Urology & Nephrology","099SU","WOS:000315642700002"]
[null,null,null,null,"J","Poljakova, J; Eckschlager, T; Cinatl, J; Kizek, R; Frei, E; Stiborova, M",null,null,null,"Poljakova, Jitka; Eckschlager, Tomas; Cinatl, Jindrich; Kizek, Rene; Frei, Eva; Stiborova, Marie",null,null,"Electrochemical Determination of Enzymes Metabolizing Ellipticine in Thyroid Cancer Cells - a Tool to Explain the Mechanism of Ellipticine Toxicity to these Cells","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"Ellipticine; Thyroid Cancer Cells; Cytotoxicity; Cytochrome P450; Peroxidase; Protein Expression; Western Blotting; DNA Adducts","ANTICANCER DRUG ELLIPTICINE; DNA ADDUCT FORMATION; PEROXIDASE-MEDIATED OXIDATION; HUMAN NEUROBLASTOMA-CELLS; CYTOCHROME-P450 1A1; AGENT ELLIPTICINE; IN-VIVO; SUDAN-I; ACTIVATION; 13-HYDROXYELLIPTICINE","The antineoplastic alkaloid ellipticine is a prodrug, the pharmacological efficiency of which is dependent on its cytochrome P450 (CYP)- and/or peroxidase-mediated activation to species forming DNA adducts in target tissues. Here, we found that this compound is cytotoxic to human BHT-101, B-CPAP and 8505-C thyroid cancer cells and blocks one or more phases of cell cycle in these cancer cells. Ellipticine toxicity to the thyroid cancer cells corresponded to levels of DNA adducts generated by the CYP- and/or peroxidase-mediated ellipticine metabolites, 12-hydroxy- and 13-hydroxyellipticine, in these cells. Cultivation of all tested cells under hypoxic conditions (1 % oxygen) led to a decrease in ellipticine toxicity. Such a lower sensitivity of cells to ellipticine correlates with a decrease in the formation of ellipticine-derived DNA adducts in these cells. Using Western blotting, the expression of CYP1A1, 1B1, 3A4, thyroid peroxidase (TPO), cyclooxygenase-1 (COX-1) and cytochrome b(5), the enzymes that catalyze, and/or influence ellipticine metabolism, was investigated in the cancer cells. Furthermore, the effects of ellipticine treatment on the expression levels of these proteins in thyroid cancer cells were also examined. The results indicate that the highest expression levels of cytochrome b(5) together with CYP1A1 and 3A4 determine the highest DNA adduct formation and cytotoxicity of ellipticine in B-CPAP cells. They also demonstrate that formation of covalent DNA adducts by ellipticine is the predominant mechanism responsible for its cytotoxicity in studied cells.","[Poljakova, Jitka; Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Pediat Hematol & Oncol, Sch Med 2, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Cinatl, Jindrich] Goethe Univ Frankfurt, Sch Med, Inst Med Virol, D-60596 Frankfurt, Germany; [Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Frei, Eva] German Canc Res Ctr, Div Prevent Oncol, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany","Poljakova, J (reprint author), Charles Univ Prague, Fac Sci, Dept Biochem, Albertov 2030, CZ-12840 Prague 2, Czech Republic.","stiborov@natur.cuni.cz",null,null,"Grant Agency of the Czech Republic [P301/10/0356]; Charles University in Prague [UNCE 204025/2012]; project for conceptual development of research organization [00064203]","The work has been supported by Grant Agency of the Czech Republic (grant P301/10/0356) and Charles University in Prague (grant UNCE 204025/2012) and by the project for conceptual development of research organization 00064203.",null,33,4,4,"ESG","BELGRADE","BORIVOJA STEVANOVICA 25-7, BELGRADE, 11000, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","FEB",2013,8,2,null,null,null,null,1573,1585,null,null,null,13,"Electrochemistry","Electrochemistry","112BE","WOS:000316565800003"]
[null,null,null,null,"J","Rink, M; Hansen, J; Cha, EK; Green, DA; Babjuk, M; Svatek, RS; Xylinas, E; Tagawa, ST; Faison, T; Novara, G; Karakiewicz, PI; Daneshmand, S; Lotan, Y; Kassouf, W; Fritsche, HM; Pycha, A; Comploj, E; Tilki, D; Bastian, PJ; Chun, FK; Dahlem, R; Scherr, DS; Shariat, SF",null,null,null,"Rink, Michael; Hansen, Jens; Cha, Eugene K.; Green, David A.; Babjuk, Marko; Svatek, Robert S.; Xylinas, Evanguelos; Tagawa, Scott T.; Faison, Talia; Novara, Giacomo; Karakiewicz, Pierre I.; Daneshmand, Siamak; Lotan, Yair; Kassouf, Wassim; Fritsche, Hans-Martin; Pycha, Armin; Comploj, Evi; Tilki, Derya; Bastian, Patrick J.; Chun, Felix K.; Dahlem, Roland; Scherr, Douglas S.; Shariat, Shahrokh F.",null,null,"Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy","BJU INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"radical cystectomy; bladder cancer; urothelial carcinoma; lymph node metastasis; nomogram; survival; adjuvant chemotherapy","INVASIVE BLADDER-CANCER; TRANSITIONAL-CELL CARCINOMA; LYMPHOVASCULAR INVASION; PELVIC LYMPHADENECTOMY; ADJUVANT CHEMOTHERAPY; UROTHELIAL CARCINOMA; URINARY-BLADDER; SURVIVAL; VALIDATION; RECURRENCE","Objectives To identify clinicopathological factors that predict outcomes in patients with a single lymph node (LN) metastasis (pN1) treated with radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB). LN metastasis is an established predictor of clinical outcomes in patients. While most patients with large LN burden experience disease recurrence, lymphadenectomy can be curative in patients with pN1 disease. Patients and Methods We analysed 381 patients with pN1 UCB from a multi-institutional cohort of 4335 patients with UCB treated with RC and lymphadenectomy without preoperative chemo-or radiotherapy. Subgroup analyses were performed for patients with >= 9 LNs removed and according to adjuvant chemotherapy administration (n = 215). Results The median (interquartile range, IQR) LN number was 15 (19) and the median (IQR) LN density was 6.7 (7.5)%. Within a median follow-up of 41 months, the mean (+/-SD) 2- and 5-year cancer-specific survival (CSS) rates were 55 (3)% and 46 (3)%, respectively. On multivariable analysis that adjusted for the effects of standard clinicopathological features, female gender (hazard ratio [HR] 1.48, P = 0.023), higher tumour stage (HR 1.68, P = 0.007), positive soft tissue surgical margin (STSM; HR 2.06, P = 0.004), higher LN density (HR 2.99, P = 0.025) and absence of adjuvant chemotherapy (HR 0.70, P = 0.026) were independently associated with CSS. In subgroup analyses of patients with >= 9 LNs removed, tumour stage and STSM status remained independent predictors for CSS (P = 0.009 and P < 0.001, respectively). Conclusions About half of the patients with pN1 UCB died from UCB within 5 years of RC. Pathological stage and STSM status are strong predictors for outcomes. Accurate prediction of the individual risk of CSS may help risk stratifying pN1 UCB in order to help improve clinical-decision making. Patients with pN1 UCB presenting with additional unfavourable risk factors need a closer follow-up scheduling and might receive adjuvant therapy.","[Rink, Michael; Cha, Eugene K.; Green, David A.; Xylinas, Evanguelos; Tagawa, Scott T.; Faison, Talia; Scherr, Douglas S.; Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA; [Rink, Michael; Hansen, Jens; Chun, Felix K.; Dahlem, Roland] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Hansen, Jens; Karakiewicz, Pierre I.] Univ Montreal, Montreal, PQ, Canada; [Babjuk, Marko] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Svatek, Robert S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Novara, Giacomo] Univ Padua, Padua, Italy; [Daneshmand, Siamak] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dallas, TX USA; [Kassouf, Wassim] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Fritsche, Hans-Martin] Univ Regensburg, Caritas St Josef Med Ctr, D-93053 Regensburg, Germany; [Pycha, Armin; Comploj, Evi] Gen Hosp Bolzano, Bolzano, Italy; [Tilki, Derya; Bastian, Patrick J.] Univ Munich, Hosp Grosshadern, Munich, Germany","Shariat, SF (reprint author), Weill Cornell Med Coll, Brady Urol Hlth Ctr, 525 E 68th St,Box 94,Starr 900, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,"Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust","Dr. Michael Rink and Dr. David A. Green are supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust.",null,34,3,4,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1464-4096",null,null,"BJU INT","BJU Int.","JAN",2013,111,1,null,null,null,null,74,84,null,"10.1111/j.1464-410X.2012.11356.x",null,11,"Urology & Nephrology","Urology & Nephrology","092ZG","WOS:000315160900018"]
[null,null,null,null,"J","Xylinas, E; Rink, M; Robinson, BD; Lotan, Y; Babjuk, M; Brisuda, A; Green, DA; Kluth, LA; Pycha, A; Fradet, Y; Faison, T; Lee, RK; Karakiewicz, PI; Zerbib, M; Scherr, DS; Shariat, SF",null,null,null,"Xylinas, Evanguelos; Rink, Michael; Robinson, Brian D.; Lotan, Yair; Babjuk, Marek; Brisuda, Antonin; Green, David A.; Kluth, Luis A.; Pycha, Armin; Fradet, Yves; Faison, Talia; Lee, Richard K.; Karakiewicz, Pierre I.; Zerbib, Marc; Scherr, Douglas S.; Shariat, Shahrokh F.",null,null,"Impact of histological variants ononcological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy","EUROPEAN JOURNAL OF CANCER",null,null,"English","Article",null,null,null,null,null,"Bladder cancer; Radical cystectomy; Urothelial carcinoma; Histology; Variant histology; Survival; Prognosis","TRANSITIONAL-CELL CARCINOMA; LYMPHOVASCULAR INVASION; CLINICAL-OUTCOMES; CANCER; DIFFERENTIATION; RECURRENCE; NEOADJUVANT; SURVIVAL","Objective: To investigate the impact of variant histologies of urothelial carcinoma of the bladder (UCB) on oncologic outcomes after radical cystectomy (RC). Materials and Methods: Data from 1984 UCB patients treated by RC without preoperative chemo-or radiotherapy were reviewed for histological differentiation and variants. We analysed the differences between pure UCB and UCB with variant histology, and those between the different histological variants using various stratifications. Results: Overall, 488 (24.6%) patients had UCB variants with squamous cell (11.4%) and glandular differentiation (3.8%) being the most common. Histological UCB variants were associated with advanced tumour stage, lymphovascular invasion and lymph node metastasis (all p-values <0.01) when compared to pure UCB. In univariable analyses, patients with non-squamous UCB variants were at significantly higher risk for disease recurrence and cancer-specific mortality than those with pure UCB patients (p-values = 0.001) and those with squamous cell differentiated UCB (p-values = 0.04); the latter two had the same risk. In multivariable analyses that adjusted for the effects of standard clinicopathologic characteristics, variant UCB histology was not associated with both survival end-points. Inpatients treated with adjuvant chemotherapy (n = 492) there was no difference in cancer-specific survival between pure UCB, squamous cell differentiated UCB and other histological UCB variants. Conclusions: A quarter of UCB patients treated with RC harboured histological UCB variants. Variant UCB histologies were associated with features of biologically aggressive disease. While variant UCB histology was associated with worse outcomes in univariable analyses, this effect did not remain significant in multivariable analyses. (C) 2013 Elsevier Ltd. All rights reserved.","[Xylinas, Evanguelos; Rink, Michael; Green, David A.; Kluth, Luis A.; Faison, Talia; Lee, Richard K.; Scherr, Douglas S.; Shariat, Shahrokh F.] Weill Cornell Med Coll, Dept Urol, New York, NY USA; [Shariat, Shahrokh F.] Weill Cornell Med Coll, Div Med Oncol, New York, NY USA; [Xylinas, Evanguelos; Zerbib, Marc] Paris Descartes Univ, APHP, Cochin Hosp, Dept Urol, Paris, France; [Kluth, Luis A.] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany; [Robinson, Brian D.] Weill Cornell Med Coll, Dept Pathol, New York, NY USA; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Babjuk, Marek; Brisuda, Antonin] Charles Univ Prague, Fac Med 2, Hosp Motol, Dept Urol, Prague, Czech Republic; [Pycha, Armin] Gen Hosp Bolzano, Dept Urol, Bolzano, Italy; [Fradet, Yves] Univ Laval, Dept Urol, Quebec City, PQ, Canada; [Karakiewicz, Pierre I.] Univ Montreal, Ctr Hlth, Dept Urol, Montreal, PQ, Canada","Shariat, SF (reprint author), Cornell Univ, Weill Med Coll, Dept Urol, Starr 900,525 East 68th St,Box 94, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,null,null,null,24,3,3,"ELSEVIER SCI LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND","0959-8049",null,null,"EUR J CANCER","Eur. J. Cancer","MAY",2013,49,8,null,null,null,null,1889,1897,null,"10.1016/j.ejca.2013.02.001",null,9,"Oncology","Oncology","139UN","WOS:000318610500011"]
[null,null,null,null,"J","Benesova, K; Forsterova, K; Votavova, H; Campr, V; Stritesky, J; Velenska, Z; Prochazka, B; Pytlik, R; Trneny, M",null,null,null,"Benesova, K.; Forsterova, K.; Votavova, H.; Campr, V.; Stritesky, J.; Velenska, Z.; Prochazka, B.; Pytlik, R.; Trneny, M.",null,null,"The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab","NEOPLASMA",null,null,"English","Article",null,null,null,null,null,"DLBCL; Hans; rituximab; GC; nonGC","R-CHOP; PROTEIN EXPRESSION; MOLECULAR SUBTYPES; CHEMOTHERAPY; CLASSIFICATION; SURVIVAL; THERAPY; VALUES; DLBCL","Diffuse large B-cell lymphoma (DLBCL) consists of at least two biologically and pathogenetically different subtypes, the germinal centre B-cell (GCB) and the activated B cell type (ABC). It has been suggested that immunohistochemistry can discriminate these subtypes as well. The aim of this study was to verify the validity of the most commonly used Hans algorithm in patients with DLBCL treated with anthracycline- based chemotherapy with rituximab. Immunohistochemical staining using standard protocols was performed on formalin fixed paraffin-embedded tissues. CD20, CD5, CD23, BCL2, CD10, BCL6, MUM1 and Ki67 antibodies were applied. Out of 120 examined cases 52 patients were evaluated as GCB type and 68 patients as having non-GCB, out of a set of 99 patients treated with immunochemotherapy 45 patients with GCB and 54 patients with non-GCB DLBCL were identified. In this set of patients, there was no statistically significant difference neither in overall survival (OS) (HR 1.47 95% CI 0.51-2.63; p=0.45) nor in progression free survival (PFS) (HR 1.57, 95 % CI 0.76-3.22; p=0.731) between both groups.","[Benesova, K.; Forsterova, K.; Votavova, H.; Pytlik, R.; Trneny, M.] Gen Teaching Hosp, Dept Med 1, Dept Hematol, Prague, Czech Republic; [Benesova, K.; Forsterova, K.; Votavova, H.; Stritesky, J.; Velenska, Z.; Pytlik, R.; Trneny, M.] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Campr, V.] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague, Czech Republic; [Stritesky, J.; Velenska, Z.] Gen Teaching Hosp, Dept Pathol, Prague, Czech Republic; [Prochazka, B.] Natl Publ Hlth Inst, Dept Biostat, Prague, Czech Republic","Benesova, K (reprint author), Gen Teaching Hosp, Dept Med 1, Dept Hematol, Prague, Czech Republic.","katerina.benesova@hotmail.com",null,null,"Ministry of Health, Czech Republic [NS9791-4/2008]","This work was supported by Ministry of Health, Czech Republic [Grant NS9791-4/2008].",null,24,3,3,"VEDA, SLOVAK ACAD SCIENCES","BRATISLAVA","DUBRAVSKA CESTA 9, 842 34 BRATISLAVA, SLOVAKIA","0028-2685",null,null,"NEOPLASMA","Neoplasma",null,2013,60,1,null,null,null,null,68,73,null,"10.4149/neo_2013_010",null,6,"Oncology","Oncology","159ZU","WOS:000320086600010"]
[null,null,null,null,"J","Rieken, M; Xylinas, E; Kluth, L; Crivelli, JJ; Chrystal, J; Faison, T; Lotan, Y; Karakiewicz, PI; Fajkovic, H; Babjuk, M; Kautzky-Willer, A; Bachmann, A; Scherr, DS; Shariat, SF",null,null,null,"Rieken, Malte; Xylinas, Evanguelos; Kluth, Luis; Crivelli, Joseph J.; Chrystal, James; Faison, Talia; Lotan, Yair; Karakiewicz, Pierre I.; Fajkovic, Harun; Babjuk, Marek; Kautzky-Willer, Alexandra; Bachmann, Alexander; Scherr, Douglas S.; Shariat, Shahrokh F.",null,null,"Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer","BJU INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"non-muscle-invasive bladder cancer; diabetes mellitus; metformin; outcomes","GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; URINARY-BLADDER; EAU GUIDELINES; MORTALITY; SURVIVAL; RISK; RECURRENCE; COHORT; THIAZOLIDINEDIONES","Objective To assess the association between diabetes mellitus (DM) and metformin use with prognosis and outcomes of non-muscle-invasive bladder cancer (NMIBC) Patients and Methods We retrospectively evaluated 1117 patients with NMIBC treated at four institutions between 1996 and 2007. Cox regression models were used to analyse the association of DM and metformin use with disease recurrence, disease progression, cancer-specific mortality and any-cause mortality. Results Of the 1117 patients, 125 (11.1%) had DM and 43 (3.8%) used metformin. Within a median (interquartile range) follow-up of 64 (22-106) months, 469 (42.0%) patients experienced disease recurrence, 103 (9.2%) experienced disease progression, 50 (4.5%) died from bladder cancer and 249 (22.3%) died from other causes. In multivariable Cox regression analyses, patients with DM who did not take metformin had a greater risk of disease recurrence (hazard ratio [HR]: 1.45, 95% confidence interval [CI] 1.09-1.94, P = 0.01) and progression (HR: 2.38, 95% CI 1.40-4.06, P = 0.001) but not any-cause mortality than patients without DM. DM with metformin use was independently associated with a lower risk of disease recurrence (HR: 0.50, 95% CI 0.27-0.94, P = 0.03). Conclusion Patients with DM and NMIBC who do not take metformin seem to be at an increased risk of disease recurrence and progression; metformin use seems to exert a protective effect with regard to disease recurrence. The mechanisms behind the impact of DM on patients with NMIBC and the potential protective effect of metformin need further elucidation.","[Rieken, Malte; Xylinas, Evanguelos; Kluth, Luis; Crivelli, Joseph J.; Chrystal, James; Faison, Talia; Scherr, Douglas S.; Shariat, Shahrokh F.] New York Presbyterian Hosp, Dept Urol, New York, NY USA; [Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA; [Rieken, Malte; Bachmann, Alexander] Univ Basel Hosp, Dept Urol, CH-4031 Basel, Switzerland; [Xylinas, Evanguelos] Paris Descartes Univ, Cochin Hosp, APHP, Dept Urol, Paris, France; [Kluth, Luis] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany; [Lotan, Yair] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Karakiewicz, Pierre I.] Univ Montreal, Dept Urol, Montreal, PQ, Canada; [Babjuk, Marek] Charles Univ Prague, Fac Med 2, Hosp Motol, Dept Urol, Prague, Czech Republic; Med Univ Vienna, Div Endocrinol & Metab, Dept Internal Med 3, Unit Gender Med, Vienna, Austria; [Kautzky-Willer, Alexandra; Shariat, Shahrokh F.] Med Univ Vienna, Dept Urol, A-1090 Vienna, Austria","Shariat, SF (reprint author), Med Univ Vienna, Dept Urol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.","sfshariat@gmail.com",null,null,"Swiss National Science Foundation","M. Rieken: Grant support from Swiss National Science Foundation",null,33,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1464-4096","1464-410X",null,"BJU INT","BJU Int.","DEC",2013,112,8,null,null,null,null,1105,1112,null,"10.1111/bju.12448",null,8,"Urology & Nephrology","Urology & Nephrology","244VR","WOS:000326418800016"]
[null,null,null,null,"J","Dubsky, M; Jirkovska, A; Bem, R; Fejfarova, V; Pagacova, L; Sixta, B; Varga, M; Langkramer, S; Sykova, E; Jude, EB",null,null,null,"Dubsky, M.; Jirkovska, A.; Bem, R.; Fejfarova, V.; Pagacova, L.; Sixta, B.; Varga, M.; Langkramer, S.; Sykova, E.; Jude, E. B.",null,null,"Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment","DIABETES-METABOLISM RESEARCH AND REVIEWS",null,null,"English","Article",null,null,null,null,null,"stem cell therapy; diabetic foot; critical limb ischaemia","CRITICAL LIMB ISCHEMIA; THERAPEUTIC ANGIOGENESIS; ARTERIAL-DISEASE; DOUBLE-BLIND; RESTORE-CLI; STEM-CELL; TRANSPLANTATION; ULCER; TRIAL; OBLITERANS","Background The aim of our study was to compare the effect of bone marrow mononuclear cell and peripheral blood progenitor cell therapies in patients with diabetic foot disease and critical limb ischaemia unresponsive to revascularization with conservative therapy. Methods Twenty-eight patients with diabetic foot disease (17 treated by bone marrow cells and 11 by peripheral blood cell) were included into an active group and 22 patients into a control group without cell treatment. Transcutaneous oxygen pressure and rate of major amputation, as the main outcome measures, were compared between bone marrow cells, peripheral blood cell and control groups over 6months; both cell therapy methods were also compared by the characteristics of cell suspensions. Possible adverse events were evaluated by changes of serum levels of angiogenic cytokines and retinal fundoscopic examination. Results The transcutaneous oxygen pressure increased significantly (p<0.05) compared with baseline in both active groups after 6months, with no significant differences between bone marrow cells and peripheral blood cell groups; however, no change of transcutaneous oxygen pressure in the control group was observed. The rate of major amputation by 6months was significantly lower in the active cell therapy group compared with that in the control group (11.1% vs. 50%, p=0.0032), with no difference between bone marrow cells and peripheral blood cell. A number of injected CD34+ cells and serum levels of angiogenic cytokines after treatment did not significantly differ between bone marrow cells and peripheral blood cell. Conclusions Our study showed a superior benefit of bone marrow cells and peripheral blood cell treatments of critical limb ischaemia in patients with diabetic foot disease when compared with conservative therapy. There was no difference between both cell therapy groups, and no patient demonstrated signs of systemic vasculogenesis. Copyright (c) 2013 John Wiley & Sons, Ltd.","[Dubsky, M.; Jirkovska, A.; Bem, R.; Fejfarova, V.] Diabet Ctr Prague, Prague, Czech Republic; [Pagacova, L.] Autotransfus Unit Prague, Prague, Czech Republic; [Sixta, B.; Varga, M.] Inst Clin & Expt Med Prague, Clin Transplant Surg, Prague, Czech Republic; [Dubsky, M.] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Langkramer, S.] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; [Sykova, E.] Czech Acad Sci Prague, Inst Expt Med, Prague, Czech Republic; [Jude, E. B.] Tameside Gen Hosp, Ctr Diabet, Ashton Under Lyne, Lancs, England","Dubsky, M (reprint author), Videnska 1958-9, Prague 14021 4, Czech Republic.","michal.dubsky@gmail.com",null,null,"Grant Agency of Charles University [GAUK 362311]; Ministry of Health of the Czech Republic [MZO 00023001]","This study was supported by a grant from the Grant Agency of Charles University (GAUK 362311) and a grant from the Ministry of Health of the Czech Republic (MZO 00023001).",null,43,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1520-7552",null,null,"DIABETES-METAB RES","Diabetes-Metab. Res. Rev.","JUL",2013,29,5,null,null,null,null,369,376,null,"10.1002/dmrr.2399",null,8,"Endocrinology & Metabolism","Endocrinology & Metabolism","176UF","WOS:000321330200007"]
[null,null,null,null,"J","Cocks, G; Romanyuk, N; Amemori, T; Jendelova, P; Forostyak, O; Jeffries, AR; Perfect, L; Thuret, S; Dayanithi, G; Sykova, E; Price, J",null,null,null,"Cocks, Graham; Romanyuk, Nataliya; Amemori, Takashi; Jendelova, Pavla; Forostyak, Oksana; Jeffries, Aaron R.; Perfect, Leo; Thuret, Sandrine; Dayanithi, Govindan; Sykova, Eva; Price, Jack",null,null,"Conditionally immortalized stem cell lines from human spinal cord retain regional identity and generate functional V2a interneurons and motorneurons","STEM CELL RESEARCH & THERAPY",null,null,"English","Article",null,null,null,null,null,"Neural stem cells; Spinal cord; V2a interneurons; Motoneurons; Voltage-operated Ca2+ channels; Spontaneous Ca2+ oscillations","EMBRYONIC RAT MOTONEURONS; NEURAL PROGENITOR CELLS; CALCIUM-CHANNEL; DIFFERENTIATION; TRANSPLANTATION; INJURY; SPECIFICATION; ACTIVATION; PROTEINS; RECOVERY","Introduction: The use of immortalized neural stem cells either as models of neural development in vitro or as cellular therapies in central nervous system (CNS) disorders has been controversial. This controversy has centered on the capacity of immortalized cells to retain characteristic features of the progenitor cells resident in the tissue of origin from which they were derived, and the potential for tumorogenicity as a result of immortalization. Here, we report the generation of conditionally immortalized neural stem cell lines from human fetal spinal cord tissue, which addresses these issues. Methods: Clonal neural stem cell lines were derived from 10-week-old human fetal spinal cord and conditionally immortalized with an inducible form of cMyc. The derived lines were karyotyped, transcriptionally profiled by microarray, and assessed against a panel of spinal cord progenitor markers with immunocytochemistry. In addition, the lines were differentiated and assessed for the presence of neuronal fate markers and functional calcium channels. Finally, a clonal line expressing eGFP was grafted into lesioned rat spinal cord and assessed for survival, differentiation characteristics, and tumorogenicity. Results: We demonstrate that these clonal lines (a) retain a clear transcriptional signature of ventral spinal cord progenitors and a normal karyotype after extensive propagation in vitro, (b) differentiate into relevant ventral neuronal subtypes with functional T-, L-, N-, and P/Q-type Ca2+ channels and spontaneous calcium oscillations, and (c) stably engraft into lesioned rat spinal cord without tumorogenicity. Conclusions: We propose that these cells represent a useful tool both for the in vitro study of differentiation into ventral spinal cord neuronal subtypes, and for examining the potential of conditionally immortalized neural stem cells to facilitate functional recovery after spinal cord injury or disease.","[Cocks, Graham; Jeffries, Aaron R.; Perfect, Leo; Thuret, Sandrine; Price, Jack] Kings Coll London, Dept Neurosci, James Black Ctr, London WC2R 2LS, England; [Romanyuk, Nataliya; Amemori, Takashi; Jendelova, Pavla; Forostyak, Oksana; Dayanithi, Govindan; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic; [Dayanithi, Govindan] INSERM, U710, Unite Rech, Montpellier, France; [Dayanithi, Govindan] Univ Montpellier 2, Ecole Prat Hautes Etud, F-75007 Paris, France","Price, J (reprint author), Kings Coll London, Dept Neurosci, James Black Ctr, 125 Coldharbour Lane, London WC2R 2LS, England.","jack.price@kcl.ac.uk",null,null,"Grant Agency of the Czech Republic [P304/11/2373]; NICHD;  [AV0Z50390703];  [GA AV: IAA500390902]","Grants: AV0Z50390703, GA AV: IAA500390902, The Charles Wolfson Charitable trust, EU 6th Framework Programme. G. Dayanithi and O. Forostyak were supported by the grant P304/11/2373 from the Grant Agency of the Czech Republic.The antibodies Isl1, Lhx3, and En1 were developed by TM Jessell and S Brenner-Morton. Pax6 was developed by A Kawakami, and Nkx6.1, developed by OD Madsen, was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA 52242, USA. We thank John Sindon and Erik Miljan for facilitating the generation of the SPC cell lines at ReNeuron plc, Dr. Michael Antoniou for providing the UCOE lentiviral construct, and Dr. James Dutt, IEM, ASCR, for helpful discussions and critical reading of the manuscript.",null,38,2,2,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","1757-6512",null,null,"STEM CELL RES THER","Stem Cell Res. Ther.","JUN 7",2013,4,null,null,null,null,null,null,null,69,"10.1186/scrt220",null,13,"Cell Biology; Medicine, Research & Experimental","Cell Biology; Research & Experimental Medicine","170PP","WOS:000320865700001"]
[null,null,null,null,"J","Cernei, N; Zitka, O; Skalickova, S; Gumulec, J; Sztalmachova, M; Rodrigo, MAM; Sochor, J; Masarik, M; Adam, V; Hubalek, J; Trnkova, L; Kruseova, J; Eckschlager, T; Kizek, R",null,null,null,"Cernei, Natalia; Zitka, Ondrej; Skalickova, Sylvie; Gumulec, Jaromir; Sztalmachova, Marketa; Rodrigo, Miguel Angel Merlos; Sochor, Jiri; Masarik, Michal; Adam, Vojtech; Hubalek, Jaromir; Trnkova, Libuse; Kruseova, Jarmila; Eckschlager, Tomas; Kizek, Rene",null,null,"Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line","ONCOLOGY REPORTS",null,null,"English","Article",null,null,null,null,null,"sarcosine; prostate cancer; metallothionein; antioxidant activity; chip electrophoresis; ion-exchange chromatography; Brdicka reaction","METHYLACYL-COA RACEMASE; BRDICKA REACTION; MARKER; CARCINOMA; ASSAY; EXPRESSION; ANTIGEN; TUMORS; FRUIT; PROGRESSION","Sarcosine is currently one of the most discussed markers of prostate cancer. It is involved in amino acid metabolism and methylation processes that occur during the progression of prostate cancer. In this study, we monitored the effect of the addition of sarcosine (0; 10; 250; 500; 1,000 and 1,500 mu M) in a time-dependent manner (0-72 h) on the PC-3 prostate cancer cell line. For the assessment of cell viability, the commonly used MTT test was employed. Furthermore, ion-exchange liquid chromatography was used for the determination of sarcosine content in the PC-3 cells. We also determined metallothionein (MT) levels by chip capillary electrophoresis and Brdicka reaction in the cells treated with sarcosine. Sarcosine levels in the cells increased in a concentration-dependent manner levels increased from only 270 nM with the lowest applied concentration of sarcosine (10 mu M) to 106 mu M with the highest applied concentration of sarcosine (1,500 mu M). There was a marginal change observed in the MT concentration. Finally, the antioxidant activity of the PC-3 cells was determined using five different spectrophotometric methods [2,2-diphenyl-1-picrylhydrazyl (DPPH), ferric reducing ability of plasma (FRAP), free radicals, N,N-dimethyl-p-phenylenediamine (DMPD) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS)]. A significant negative correlation was observed between DPPH and FRAP (r=-0.68 at P<0.001) and between DMPD and ABST (r=-0.64 at P<0.001). Additionally, as regards the correlation between MT and DPPH, a significant positive trend (r=0.62 at P<0.001) was observed.","[Cernei, Natalia; Zitka, Ondrej; Skalickova, Sylvie; Gumulec, Jaromir; Sztalmachova, Marketa; Rodrigo, Miguel Angel Merlos; Sochor, Jiri; Masarik, Michal; Adam, Vojtech; Hubalek, Jaromir; Trnkova, Libuse; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Zitka, Ondrej; Hubalek, Jaromir] Brno Univ Technol, Fac Elect Engn & Commun, Dept Microelect, CZ-61200 Brno, Czech Republic; [Zitka, Ondrej; Gumulec, Jaromir; Rodrigo, Miguel Angel Merlos; Masarik, Michal; Adam, Vojtech; Hubalek, Jaromir; Trnkova, Libuse; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Gumulec, Jaromir; Sztalmachova, Marketa; Masarik, Michal] Masaryk Univ, Fac Med, Dept Pathol Physiol, CZ-62500 Brno, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CZ-62500 Brno, Czech Republic; [Kruseova, Jarmila; Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Kruseova, Jarmila; Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Gumulec, Jaromir/D-7638-2012; Hubalek, Jaromir/D-7753-2012; Sochor, Jiri/E-1135-2012; Masarik, Michal/D-9920-2012","Gumulec, Jaromir/0000-0002-9658-3444; ","CEITEC [CZ.1.05/1.1.00/02.0068]; NanoBioTECell GACR [P102/11/1068]; CYTORES GACR [P301/10/0356]; project for conceptual development of research organization [00064203]","The present study was financially supported by CEITEC CZ.1.05/1.1.00/02.0068, NanoBioTECell GACR P102/11/1068, CYTORES GACR P301/10/0356 and project for conceptual development of research organization 00064203.",null,50,2,2,"SPANDIDOS PUBL LTD","ATHENS","POB 18179, ATHENS, 116 10, GREECE","1021-335X",null,null,"ONCOL REP","Oncol. Rep.","JUN",2013,29,6,null,null,null,null,2459,2466,null,"10.3892/or.2013.2389",null,8,"Oncology","Oncology","148GO","WOS:000319232800052"]
[null,null,null,null,"J","Billing, H; Sander, A; Susal, C; Ovens, J; Feneberg, R; Hocker, B; Vondrak, K; Grenda, R; Friman, S; Milford, DV; Lucan, M; Opelz, G; Tonshoff, B",null,null,null,"Billing, Heiko; Sander, Anja; Suesal, Caner; Ovens, Joerg; Feneberg, Reinhard; Hoecker, Britta; Vondrak, Karel; Grenda, Ryszard; Friman, Stybjorn; Milford, David V.; Lucan, Mihai; Opelz, Gerhard; Toenshoff, Burkhard",null,null,"Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients","TRANSPLANT INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"biopsy-proven acute rejection; human leukocyte antigen antibodies; pediatric renal transplantation; soluble CD30; steroid-free immunosuppression","HLA ANTIBODIES; ALLOGRAFT-REJECTION; KIDNEY; IMMUNOSUPPRESSION; TACROLIMUS; DIAGNOSIS; GROWTH","Biomarker-based post-transplant immune monitoring for the prediction of impending graft rejection requires validation in specific patient populations. Serum of 28 pediatric renal transplant recipients within the framework of a well-controlled prospective randomized trial was analyzed pre- and post-transplant for soluble CD30 (sCD30), a biomarker reflecting mainly T-cell reactivity, and anti-human leukocyte antigen (anti-HLA) antibody reactivity, a biomarker for B-cell activation. A sCD30 concentration 40.3U/ml on day 14 was able to discriminate between patients with or without biopsy-proven acute rejection (BPAR) with a sensitivity of 100% and a specificity of 76%. Six of seven patients (86%) with BPAR showed a sCD30 above this cut-off, whereas only 3/21 patients (14%) without BPAR had a sCD30 above this cut-off (P=0.004). For pre- and post-transplant anti-HLA class II reactivities by enzyme-linked immunosorbent assay, a cut-off value of 140 optical density was able to discriminate rejecters from nonrejecters with a sensitivity of 86% or 71% and a specificity of 81% or 90%, respectively. Withdrawal of steroids was associated with a approximately twofold higher serum sCD30 compared to controls, but did not affect anti-HLA reactivities. An increased post-transplant sCD30 serum concentration and positive pre- and post-transplant anti-HLA class II reactivities are informative biomarkers for impending BPAR in pediatric renal transplant recipients. (TWIST, Clinical Trial No: FG-506-02-43)","[Billing, Heiko; Feneberg, Reinhard; Hoecker, Britta; Toenshoff, Burkhard] Univ Childrens Hosp, Dept Pediat 1, D-69120 Heidelberg, Germany; [Sander, Anja; Opelz, Gerhard] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany; [Suesal, Caner; Ovens, Joerg] Heidelberg Univ, Dept Transplantat Immunol, Heidelberg, Germany; [Vondrak, Karel] Univ Hosp Prague Motol, Dept Pediat, Prague, Czech Republic; [Grenda, Ryszard] Childrens Mem Hlth Inst, Dept Nephrol Kidney Transplantat & Hypertens, Warsaw, Poland; [Friman, Stybjorn] Sahlgrens Univ Hosp, Transplant Inst, Gothenburg, Sweden; [Milford, David V.] Birmingham Childrens Hosp, Birmingham, W Midlands, England; [Lucan, Mihai] Clin Inst Urol & Renal Transplantat, Cluj Napoca, Romania","Tonshoff, B (reprint author), Univ Childrens Hosp, Dept Pediat 1, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.","burkhard.toenshoff@med.uni-heidelberg.de",null,null,"Astellas Pharma Europe Ltd, Staines, UK; Medical Faculty of the University of Heidelberg","This study was supported by a grant from Astellas Pharma Europe Ltd, Staines, UK. Britta Hocker has been awarded an Olympia Morata Grant by the Medical Faculty of the University of Heidelberg.",null,26,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0934-0874",null,null,"TRANSPL INT","Transpl. Int.","MAR",2013,26,3,null,null,null,null,331,338,null,"10.1111/tri.12049",null,8,"Surgery; Transplantation","Surgery; Transplantation","091EJ","WOS:000315031900017"]
[null,null,null,null,"J","Fik, Z; Valach, J; Chovanec, M; Mazanek, J; Kodet, R; Kodet, O; Tachezy, R; Foltynova, E; Andre, S; Kaltner, H; Gabius, HJ; Smetana, K",null,null,null,"Fik, Zdenek; Valach, Jaroslav; Chovanec, Martin; Mazanek, Jiri; Kodet, Roman; Kodet, Ondrej; Tachezy, Ruth; Foltynova, Eva; Andre, Sabine; Kaltner, Herbert; Gabius, Hans-Joachim; Smetana, Karel, Jr.",null,null,"Loss of adhesion/growth-regulatory galectin-9 from squamous cell epithelium in head and neck carcinomas","JOURNAL OF ORAL PATHOLOGY & MEDICINE",null,null,"English","Article",null,null,null,null,null,"agglutinin; basal cells; epithelium; keratin; lectin; tumor","TUMOR PROGRESSION; FUNCTIONAL GLYCOMICS; INCREASED EXPRESSION; NEUROBLASTOMA-CELLS; ORAL EPITHELIUM; BINDING-SITES; UP-REGULATION; RISK-FACTORS; SUGAR CODE; CANCER","Galectins are potent effectors of cell adhesion and growth regulation. Their expression as comples network necessitates systematic study of each member of this family. Toward this aim, we here focus on the tandem-repeat-type galectin-9. Its presence is monitored in normal squamous epithelium of the head and neck, the surgical margin, and four types of squamous cell carcinoma. Lectin presence was detected in cells of the basal layer of the epithelium. All galectin-9-negative epithelia showed aberrant positivity for keratins 14 and 19. The surgical margin presented either a normal pattern of galectin-9 and keratin presence or a mosaic-like presence/absence of galectin-9 and aberrant expression of both keratins 14 and 19. All studied specimens of squamous cell carcinoma were negative for galectin-9. When biotinylated galectin-9, or its N-terminal domain, was tested, no significant tissue reactivity for both probes was observed. Neuraminidase treatment generated reactivity to the N-domain. In conclusion, galectin-9 is expressed in the majority of samples of normal epithelium, along with regular presence of keratins 14 or 19. This lectin can represent a potential marker of normality in the cases of the studied squamous cell epithelia. J Oral Pathol Med (2013)42: 166-174","[Fik, Zdenek; Chovanec, Martin; Kodet, Ondrej; Smetana, Karel, Jr.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic; [Fik, Zdenek; Chovanec, Martin] Charles Univ Prague, Fac Med 1, Dept Otolaryngol Head & Neck Surg, Prague, Czech Republic; [Valach, Jaroslav; Mazanek, Jiri; Foltynova, Eva] Charles Univ Prague, Fac Med 1, Dept Stomatol, Prague, Czech Republic; [Kodet, Roman] Charles Univ Prague, Fac Med 2, Inst Pathol & Mol Med, Prague, Czech Republic; [Kodet, Ondrej] Charles Univ Prague, Fac Med 1, Dept Dermatovenereol, Prague, Czech Republic; [Tachezy, Ruth] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic; [Andre, Sabine; Kaltner, Herbert; Gabius, Hans-Joachim] Univ Munich, Inst Physiol Chem, Fac Vet Med, D-80539 Munich, Germany","Smetana, K (reprint author), Inst Anat, Fac Med 1, U Nemocnice 3, Prague 12800 2, Czech Republic.","karel.smetana@lf1.cuni.cz",null,null,"Charles University [264510]; UNCE [204013, PRVOUK/LF1/P27]; EC consortium GlycoHIT [260600]","This study was supported by the Charles University, project for the Support of Specific University Research No. 264510, UNCE 204013 and PRVOUK/LF1/P27 and the EC consortium GlycoHIT (contract no. 260600). Authors are grateful to Iva Burdova, Radana Kavkova, Marie Jindrakova and Vit Hajduch for excellent technical assistance.",null,56,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0904-2512",null,null,"J ORAL PATHOL MED","J. Oral Pathol. Med.","FEB",2013,42,2,null,null,null,null,166,173,null,"10.1111/j.1600-0714.2012.01185.x",null,8,"Dentistry, Oral Surgery & Medicine; Pathology","Dentistry, Oral Surgery & Medicine; Pathology","083NL","WOS:000314471200008"]
[null,null,null,null,"J","Klein, O; Ebert, LM; Zanker, D; Woods, K; Tan, BS; Fucikova, J; Behren, A; Davis, ID; Maraskovsky, E; Chen, WS; Cebon, J",null,null,null,"Klein, Oliver; Ebert, Lisa M.; Zanker, Damien; Woods, Katherine; Tan, Bee Shin; Fucikova, Jitka; Behren, Andreas; Davis, Ian D.; Maraskovsky, Eugene; Chen, Weisan; Cebon, Jonathan",null,null,"Flt3 ligand expands CD4+FoxP3+regulatory T cells in human subjects","EUROPEAN JOURNAL OF IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Flt3 ligand; Immune tolerance; Regulatory T (Treg) cells","DENDRITIC CELLS; IN-VIVO; REGULATORY CELLS; REG-CELLS; EXPRESSION; SUBSETS; INTERLEUKIN-2; HOMEOSTASIS; EXPANSION; THERAPY","CD4+CD25+FoxP3+ naturally occurring regulatory T (Treg) cells play a crucial role in the maintenance of immune tolerance and in preventing autoimmune pathology. Interventions that expand Treg cells are highly desirable, as they may offer novel treatment options in a variety of autoimmune and transplantation settings. Paralleling previous preclinical studies, we demonstrate here that administration of the hematopoietic growth factor Flt3L to human subjects increases the frequency and absolute number of Treg cells, and reduces the ratio of CD8+ T cells to Treg cells in the peripheral blood. The increase in Treg cells was due to enhanced Treg-cell proliferation rather than release of Treg cells from the thymus. Further studies revealed that Flt3L-induced proliferation of Treg cells was an indirect effect that occurred via the interaction of Treg cells with the Flt3L-expanded pool of CD1c+ myeloid dendritic cells. On the basis of these findings, Flt3L may represent a promising agent for promoting immune tolerance in a variety of clinical settings.","[Klein, Oliver; Ebert, Lisa M.; Zanker, Damien; Woods, Katherine; Tan, Bee Shin; Fucikova, Jitka; Behren, Andreas; Davis, Ian D.; Chen, Weisan; Cebon, Jonathan] Melbourne Ctr Clin Sci, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia; [Fucikova, Jitka] Charles Univ Prague, Univ Hosp Motol, Dept Immunol, Prague, Czech Republic; [Maraskovsky, Eugene] CSL Ltd, Parkville, Vic, Australia","Klein, O (reprint author), Melbourne Ctr Clin Sci, Ludwig Inst Canc Res, 147-163 Studley Rd, Heidelberg, Vic 3084, Australia.","oliver.klein@ludwig.edu.au","Ebert, Lisa/B-9530-2013; Davis, Ian/A-1430-2012","Davis, Ian/0000-0002-9066-8244","Cancer Council of Victoria; Ministry of Education, Czech Republic; Victorian Cancer Agency Clinician Researcher Fellowship","This work was supported by a Grant-in-Aid to LME and JC from the Cancer Council of Victoria and Operational Infrastructure Support from the Victorian State Government. EM is an employee of CSL Limited and an Honorary Senior Research Fellow of the Ludwig Institute for Cancer Research. JF was supported by a grant from the Ministry of Education, Czech Republic. IDD was supported by a Victorian Cancer Agency Clinician Researcher Fellowship and is an honorary NHMRC Practitioner Fellow. JC is an NHMRC Practitioner Fellow.",null,31,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0014-2980",null,null,"EUR J IMMUNOL","Eur. J. Immunol.","FEB",2013,43,2,null,null,null,null,533,539,null,"10.1002/eji.201242603",null,7,"Immunology","Immunology","091LN","WOS:000315051100026"]
[null,null,null,null,"J","Zitka, O; Kominkova, M; Skalickova, S; Skutkova, H; Provaznik, I; Eckschlager, T; Stiborova, M; Trnkova, L; Adam, V; Kizek, R",null,null,null,"Zitka, Ondrej; Kominkova, Marketa; Skalickova, Sylvie; Skutkova, Helena; Provaznik, Ivo; Eckschlager, Tomas; Stiborova, Marie; Trnkova, Libuse; Adam, Vojtech; Kizek, Rene",null,null,"Single Amino Acid Change in Metallothionein Metal-Binding Cluster Influences Interaction with Cisplatin","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"Aminoacid Sequence; Interaction Study; Metallothionein Fragments; Cisplatin; High Throughput Analysis; Interaction Constants","56-61 MT-I; BRDICKA REACTION; VOLTAMMETRY; RESISTANCE; CANCER; PLATINUM; THERAPY; TUMORS; HEAD; DNA","The issue of tumour cell resistance to anticancer drugs is a major problem in the treatment of this grave disease and it is still not satisfactorily explained. Its base lies in the interaction of a cytostatic with biomolecules synthesized by tumour cells. One of the generally accepted mechanisms of resistance to some metal based cytostatics is the overexpression of metallothionein in tumour cells. In this study, electrochemical profile of interaction between 23 sulphur-rich fragments of the metal-binding protein metallothionein and cisplatin was studied. To evaluate the results, interaction constants were suggested. Here, we found that the maximum increased interaction (more than 100 %) occurred, when conservative aminoacids were substituted for more than one position outside the cysteine cluster. On the contrary, amino acid substitution within the cysteine cluster led to a reduction in interaction constants (up to 10-25% of average). This result clearly indicates that aminoacids outside cysteine binding motif are of high importance for interactions of metallothionein with cisplatin. Based on the results it can be assumed that the substitution of individual aminoacids in the peptide chain of protein markedly influences the interaction with cisplatin, which could be used for designing new types of cytostatics.","[Zitka, Ondrej; Kominkova, Marketa; Skalickova, Sylvie; Trnkova, Libuse; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Zitka, Ondrej; Trnkova, Libuse; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Skutkova, Helena; Provaznik, Ivo] Brno Univ Technol, Fac Elect Engn & Commun, Dept Biomed Engn, CZ-61200 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic","Zitka, O (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Provaznik, Ivo/F-4121-2012; Skutkova, Helena/D-5194-2014",null," [CEITEC CZ.1.05/1.1.00/02.0068];  [CYTORES GA CR P301/10/0356];  [NANOSEMED GA AV KAN20813081];  [IGA IP23/2012];  [00064203]","Financial support from the following projects CEITEC CZ.1.05/1.1.00/02.0068, CYTORES GA CR P301/10/0356, NANOSEMED GA AV KAN20813081, IGA IP23/2012 and by the project for conceptual development of research organization 00064203 is highly acknowledged. The authors wish to express their thanks to Nadezda Spackova for critical evaluation of the paper.",null,24,2,2,"ESG","BELGRADE","BORIVOJA STEVANOVICA 25-7, BELGRADE, 11000, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","FEB",2013,8,2,null,null,null,null,2625,2634,null,null,null,10,"Electrochemistry","Electrochemistry","112BE","WOS:000316565800091"]
[null,null,null,null,"J","Rink, M; Xylinas, E; Trinh, QD; Lotan, Y; Margulis, V; Raman, JD; Fisch, M; Lee, RK; Chun, FK; Abdennabi, J; Seitz, C; Pycha, A; Zlotta, AR; Karakiewicz, PI; Babjuk, M; Scherr, DS; Shariat, SF",null,null,null,"Rink, Michael; Xylinas, Evanguelos; Quoc-Dien Trinh; Lotan, Yair; Margulis, Vitaly; Raman, Jay D.; Fisch, Margit; Lee, Richard K.; Chun, Felix K.; Abdennabi, Joual; Seitz, Christian; Pycha, Armin; Zlotta, Alexandre R.; Karakiewicz, Pierre I.; Babjuk, Marko; Scherr, Douglas S.; Shariat, Shahrokh F.",null,"UTUCC","Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes","BJU INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"smoking; gender; urothelial carcinoma; transitional cell carcinoma; upper urinary tract; radical nephroureterectomy; dose relationship; recurrence; survival","TRANSITIONAL-CELL-CARCINOMA; UPPER URINARY-TRACT; RADICAL NEPHROURETERECTOMY; BLADDER-CANCER; CIGARETTE-SMOKING; TUMOR LOCATION; IMPACT; STAGE; RISK; RECURRENCE","To evaluate the gender-specific differential effects of smoking habits and cumulative smoking exposure on outcomes in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). A total of 864 consecutive patients, comprising 553 (64%) men and 311 (36%) women, from five international institutions underwent RNU without neoadjuvant chemotherapy. Smoking history included smoking status (current, former or never), quantity of cigarettes per day (CPD), smoking duration in years and years since smoking cessation. Cumulative smoking exposure was categorized as light short-term (19 CPD and 19.9 years), moderate (all combinations except light short-term and heavy long-term), and heavy long-term (20 CPD and 20 years). Uni- and multivariable competing risk regression models were used to assess the associations with outcomes. Overall, 244 (28.2%), 297 (34.4%) and 323 (37.4%) patients were never, former and current smokers, respectively. There were no differences in smoking status, quantity and duration between the genders. In female ever smokers, 30 (9.6%), 121 (38.9%) and 67 (21.5%) were light short-term, moderate and heavy long-term smokers, respectively. Compared with men, female current smokers were more likely to experience disease recurrence in univariable analysis (P = 0.013). In heavy long-term smokers, female gender was significantly associated with disease recurrence (hazard ratio [HR] 1.7; P = 0.03) and cancer-specific mortality (HR 2.0; P = 0.009) in multivariable analysis that adjusted for standard clinico-pathological features. In female patients only, smoking quantity, duration and cumulative exposure were associated with disease recurrence and cancer-specific mortality on multivariable analyses (P 0.025). The impact of smoking on UTUC outcomes after RNU is gender-specific. Females who are current and heavy long-term smokers experience worse outcomes than their male counterparts. Further research is needed to elucidate the molecular mechanisms underlying the gender-specific differential effect of smoking on UTUC outcomes.","[Rink, Michael; Xylinas, Evanguelos; Lee, Richard K.; Scherr, Douglas S.; Shariat, Shahrokh F.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA; [Lotan, Yair; Margulis, Vitaly] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Raman, Jay D.] Penn State Milton S Hershey Med Ctr, Hershey, PA USA; [Rink, Michael; Fisch, Margit; Chun, Felix K.] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Xylinas, Evanguelos] Paris Descartes Univ, APHP, Cochin Hosp, Paris, France; [Quoc-Dien Trinh; Karakiewicz, Pierre I.] Univ Montreal, Montreal, PQ, Canada; [Zlotta, Alexandre R.] Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Zlotta, Alexandre R.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Toronto, ON, Canada; [Abdennabi, Joual] Univ Hosp Ibn Rochd, Casablanca, Morocco; [Seitz, Christian] Med Univ Vienna, Teaching Hosp, St John God Hosp, Vienna, Austria; [Pycha, Armin] Gen Hosp Bolzano, Bolzano, Italy; [Babjuk, Marko] Charles Univ Prague, Fac Med 2, Hosp Motol, Prague, Czech Republic","Shariat, SF (reprint author), Cornell Univ, Weill Med Coll, Dept Urol, New York Presbyterian Hosp, 525 East 68th St,Box 94,Starr 900, New York, NY 10065 USA.","sfshariat@gmail.com",null,null,"Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust","Michael Rink is supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust.",null,38,1,1,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1464-4096",null,null,"BJU INT","BJU Int.","SEP",2013,112,5,null,null,null,null,623,637,null,"10.1111/bju.12014",null,15,"Urology & Nephrology","Urology & Nephrology","197AL","WOS:000322819200018"]
[null,null,null,null,"J","Pisarik, P; Jelinek, M; Smetana, K; Dvorankova, B; Kocourek, T; Zemek, J; Chvostova, D",null,null,null,"Pisarik, Petr; Jelinek, Miroslav; Smetana, Karel, Jr.; Dvorankova, Barbora; Kocourek, Tomas; Zemek, Josef; Chvostova, Dagmar",null,null,"Study of optical properties and biocompatibility of DLC films characterized by sp(3) bonds","APPLIED PHYSICS A-MATERIALS SCIENCE & PROCESSING",null,null,"English","Article",null,null,null,null,null,null,"DIAMOND-LIKE CARBON; IMMERSION ION-IMPLANTATION; THIN-FILMS; AMORPHOUS-CARBON; SPECTROSCOPIC ELLIPSOMETRY; HUMAN KERATINOCYTES; PLASMA CVD; COATINGS; HEMOCOMPATIBILITY; THROMBOGENICITY","Optical and biomedical properties of diamond-like carbon (DLC) films of various sp(2), sp(3) bonds were studied. The layers were prepared by pulsed laser deposition (PLD) for laser energy densities from 4 J cm(-2) to 14 J cm(-2). The percentage of sp(2) and sp(3) bonds was calculated using X-ray photoelectron spectroscopy (XPS). In dependence on density the films contained up to 70 % of sp(3) bonds. Optical properties were measured using spectroscopic ellipsometry in region from 250 nm to 1000 nm (n=2.6-2.7; k=0.07-0.25) and by transmission measurement (from 200 nm to 1100 nm). The adhesion and growth of human fibroblasts and keratinocytes of DLC films were tested in vitro.","[Pisarik, Petr; Jelinek, Miroslav; Kocourek, Tomas; Zemek, Josef; Chvostova, Dagmar] Acad Sci Czech Republic, Inst Phys, VVI, Prague 18221 8, Czech Republic; [Pisarik, Petr; Jelinek, Miroslav; Kocourek, Tomas] Czech Tech Univ, Fac Biomed Engn, Kladno 27201, Czech Republic; [Smetana, Karel, Jr.; Dvorankova, Barbora] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 12800 2, Czech Republic; [Smetana, Karel, Jr.; Dvorankova, Barbora] Charles Univ Prague, Fac Med 2, Ctr Cell Therapy & Tissue Repair, Prague 15006 5, Czech Republic","Pisarik, P (reprint author), Acad Sci Czech Republic, Inst Phys, VVI, Na Slovance 2, Prague 18221 8, Czech Republic.","pisarik@fzu.cz",null,null,"Czech Technical University in Prague [SGS10/222/OHK4/2T/17, SGS11/078/OHK4/1T/17]; Institutional research plan [AV010100522]","We thank the Institutional research plan AV010100522 and grant of the Czech Technical University in Prague No. SGS10/222/OHK4/2T/17 and No. SGS11/078/OHK4/1T/17.",null,38,1,1,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0947-8396",null,null,"APPL PHYS A-MATER","Appl. Phys. A-Mater. Sci. Process.","JUL",2013,112,1,null,null,null,null,143,148,null,"10.1007/s00339-012-7216-8",null,6,"Materials Science, Multidisciplinary; Physics, Applied","Materials Science; Physics","162OG","WOS:000320274100024"]
[null,null,null,null,"J","Drbohlavova, J; Chomoucka, J; Adam, V; Ryvolova, M; Eckschlager, T; Hubalek, J; Kizek, R",null,null,null,"Drbohlavova, Jana; Chomoucka, Jana; Adam, Vojtech; Ryvolova, Marketa; Eckschlager, Tomas; Hubalek, Jaromir; Kizek, Rene",null,null,"Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine","CURRENT DRUG METABOLISM",null,null,"English","Article",null,null,null,null,null,"Nanotechnologies; nanoparticles; gene therapy; anticancer drugs; drug carriers; cancer; cytostatic; targeted therapy","SOLID LIPID NANOPARTICLES; MESOPOROUS SILICA NANOPARTICLES; MOLECULARLY IMPRINTED POLYMERS; PRODRUG THERAPY ADEPT; QUANTUM DOTS; GOLD NANOPARTICLES; CANCER-CELLS; IN-VIVO; TARGETED DELIVERY; CARBON NANOTUBES","This review provides a brief overview of the variety of carriers employed for targeted drug delivery used in cancer therapy and summarizes advantages and disadvantages of each approach. Particularly, the attention was paid to polymeric nanocarriers, liposomes, micelles, polyethylene glycol, poly(lactic-co-glycolic acid), dendrimers, gold and magnetic nanoparticles, quantum dots, silica nanoparticles, and carbon nanotubes. Further, this paper briefly focuses on several anticancer agents (paclitaxel, docetaxel, camptothecin, doxorubicin, daunorubicin, cisplatin, curcumin, and geldanamycin) and on the influence of their combination with nanoparticulate transporters to their properties such as cytotoxicity, short life time and/or solubility.","[Drbohlavova, Jana; Chomoucka, Jana; Hubalek, Jaromir] Brno Univ Technol, Fac Elect Engn & Commun, Dept Microelect, CZ-61600 Brno, Czech Republic; [Drbohlavova, Jana; Chomoucka, Jana; Adam, Vojtech; Ryvolova, Marketa; Hubalek, Jaromir; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Motol Univ Hosp, CZ-15006 Prague 5, Czech Republic","Kizek, R (reprint author), Mendel Univ Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Drbohlavova, Jana/D-8082-2012; Hubalek, Jaromir/D-7753-2012",null,"Grant Agency of the Czech Republic [GACR 102/11/1068]; project \"CEITEC - Central European Institute of Technology\" from European Regional Development Fund [CZ.1.05/1.1.00/02.0068]; project for conceptual development of research organization [00064203]","This work has been supported by Grant Agency of the Czech Republic under the contract GACR 102/11/1068, by the project \"CEITEC - Central European Institute of Technology\" CZ.1.05/1.1.00/02.0068 from European Regional Development Fund and by the project for conceptual development of research organization 00064203.",null,220,1,1,"BENTHAM SCIENCE PUBL LTD","SHARJAH","EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES","1389-2002",null,null,"CURR DRUG METAB","Curr. Drug Metab.","JUN",2013,14,5,null,null,null,null,547,564,null,null,null,18,"Biochemistry & Molecular Biology; Pharmacology & Pharmacy","Biochemistry & Molecular Biology; Pharmacology & Pharmacy","161AB","WOS:000320161000005"]
[null,null,null,null,"J","Hromadka, R; Bartak, V; Bek, J; Popelka, S; Bednarova, J; Popelka, S",null,null,null,"Hromadka, Rastislav; Bartak, Vladislav; Bek, Jiri; Popelka, Stanislav, Jr.; Bednarova, Jana; Popelka, Stanislav",null,null,"Lateral Release in Hallux Valgus Deformity: From Anatomic Study to Surgical Tip","JOURNAL OF FOOT & ANKLE SURGERY",null,null,"English","Article",null,null,null,null,null,"hallux valgus; lateral release of hallux valgus; reconstruction of forefoot; soft procedure of hallux valgus; tenotomy of adductor hallucis muscle","VARUS; PREVENTION; OPERATION","The important part of hallux valgus deformity operations, especially in the case of an incongruent joint, is the release of the soft tissue on the lateral side of the first metatarsophalangeal joint. The purpose of the present anatomic study was, with preparation of the lateral structures of the joint and lateral conjoined tendon, to provide a background for a surgical tip of the release of the joint for an additional metatarsal osteotomy. For the present study, we used 30 specimens (15 left and 15 right) from 19 cadavers at the Institute of Anatomy, First Faculty of Medicine, Charles Faculty (Prague, Czech Republic). Only specimens that met the criteria of hallux valgus were included in the present study. The technique was based on the incision of the lateral sesamoid ligament and partial tenotomy of the lateral conjoined tendon from the first interdigital web space. The release was done gradually with supination and abduction of the big toe to achieve the smallest size of the tenotomy. The median of the tenotomy size of the conjoined tendon was 6.5 (range 5 to 14) mm. The median size of the conjoined tendon in the frontal plane just ventral to the sesamoid bone was 10.6 (range 8 to 14) mm. The technique of the release, in which the big toe was abducted and supinated, can minimize the size of the lateral conjoined tendon release and can minimize the possibility of a postoperative deformity. (C) 2013 by the American College of Foot and Ankle Surgeons. All rights reserved.","[Hromadka, Rastislav; Bartak, Vladislav; Bek, Jiri; Popelka, Stanislav] Charles Univ Prague, Orthopaed Clin 1, Fac Med 1, Prague, Czech Republic; [Hromadka, Rastislav; Bednarova, Jana] Charles Univ Prague, Inst Anat, Fac Med 1, Prague, Czech Republic; [Popelka, Stanislav, Jr.] Charles Univ Prague, Fac Med 2, Prague, Czech Republic","Hromadka, R (reprint author), 1 LF UK FN Motol, Ortoped Klin 1, V Uvalu 84, Prague 15006 5, Czech Republic.","rastho@gmail.com",null,null,"Project (Ministry of Health, Czech Republic) for Conceptual Development of Research Organization [00064203]","Supported by the Project (Ministry of Health, Czech Republic) for Conceptual Development of Research Organization 00064203.",null,25,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1067-2516",null,null,"J FOOT ANKLE SURG","J. Foot Ankle Surg.","MAY-JUN",2013,52,3,null,null,null,null,298,302,null,"10.1053/j.jfas.2013.01.003",null,5,"Orthopedics; Surgery","Orthopedics; Surgery","133NH","WOS:000318144600005"]
[null,null,null,null,"J","Pastucha, D; Filipcikova, R; Horakova, D; Radova, L; Marinov, Z; Malincikova, J; Kocvrlich, M; Horak, S; Bezdickova, M; Dobias, M",null,null,null,"Pastucha, D.; Filipcikova, R.; Horakova, D.; Radova, L.; Marinov, Z.; Malincikova, J.; Kocvrlich, M.; Horak, S.; Bezdickova, M.; Dobias, M.",null,null,"The Incidence of Metabolic Syndrome in Obese Czech Children: the Importance of Early Detection of Insulin Resistance Using Homeostatic Indexes HOMA-IR and QUICKI","PHYSIOLOGICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Obesity; Metabolic syndrome; HOMA-IR; QUICKI; Children; Adolescents","NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; EDUCATION-PROGRAM; HUMAN-DISEASE; ADOLESCENTS; PREVALENCE; GLUCOSE; HYPERTENSION; SENSITIVITY; DEFINITION","Common alimentary obesity frequently occurs on a polygenic basis as a typical lifestyle disorder in the developed countries. It is associated with characteristic complex metabolic changes, which are the cornerstones for future metabolic syndrome development. The aims of our study were 1) to determine the incidence of metabolic syndrome (based on the diagnostic criteria defined by the International Diabetes Federation for children and adolescents) in Czech obese children, 2) to evaluate the incidence of insulin resistance according to HOMA-IR and QUICKI homeostatic indexes in obese children with and without metabolic syndrome, and 3) to consider the diagnostic value of these indexes for the early detection of metabolic syndrome in obese children. We therefore performed anthropometric and laboratory examinations to determine the incidence of metabolic syndrome and insulin resistance in the group of 274 children with obesity (128 boys and 146 girls) aged 9-17 years. Metabolic syndrome was found in 102 subjects (37 %). On the other hand, the presence of insulin resistance according to QUICKI <0.357 was identified in 86 % and according to HOMA-IR >3.16 in 53 % of obese subjects. This HOMA-IR limit was exceeded by 70 % children in the MS(+) group, but only by 43 % children in the MS(-) group (p<0.0001). However, a relatively high incidence of insulin resistance in obese children without metabolic syndrome raises a question whether the existing diagnostic criteria do not falsely exclude some cases of metabolic syndrome. On the basis of our results we suggest to pay a preventive attention also to obese children with insulin resistance even if they do not fulfill the actual diagnostic criteria for metabolic syndrome.","[Pastucha, D.; Malincikova, J.; Kocvrlich, M.; Horak, S.] Palacky Univ, Fac Med & Dent, Dept Sports & Exercise Med, CR-77147 Olomouc, Czech Republic; [Filipcikova, R.; Bezdickova, M.] Palacky Univ, Fac Med & Dent, Dept Anat, CR-77147 Olomouc, Czech Republic; [Horakova, D.] Palacky Univ, Fac Med & Dent, Dept Prevent Med, CR-77147 Olomouc, Czech Republic; [Radova, L.] Palacky Univ, Fac Med & Dent, Inst Mol & Translat Med, Lab Expt Med, CR-77147 Olomouc, Czech Republic; [Marinov, Z.] Univ Hosp Prague Motol, Outpatient Clin Treatment Child Obes, Prague, Czech Republic; [Dobias, M.] Palacky Univ, Fac Med & Dent, Dept Forens Med & Med Law, CR-77147 Olomouc, Czech Republic","Filipcikova, R (reprint author), Palacky Univ, Fac Med & Dent, Dept Anat, Hnevotinska 3, CR-77147 Olomouc, Czech Republic.","radka.filipcikova@upol.cz",null,null,"Operational Program of Research and Development for Innovations [CZ.1.05/2.1.00/01.0030];  [NT 11098-4/2010]","This study was supported by grant NT 11098-4/2010 and the infrastructural part of this project (Institute of Molecular and Translational Medicine) was supported by the Operational Program of Research and Development for Innovations (project CZ.1.05/2.1.00/01.0030).",null,33,1,1,"ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY","PRAGUE 4","VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC","0862-8408",null,null,"PHYSIOL RES","Physiol. Res.",null,2013,62,3,null,null,null,null,277,283,null,null,null,7,"Physiology","Physiology","176RX","WOS:000321322900006"]
[null,null,null,null,"J","Boussios, S; Han, SN; Fruscio, R; Halaska, MJ; Ottevanger, PB; Peccatori, FA; Koubkova, L; Pavlidis, N; Amant, F",null,null,null,"Boussios, S.; Han, S. N.; Fruscio, R.; Halaska, M. J.; Ottevanger, P. B.; Peccatori, F. A.; Koubkova, L.; Pavlidis, N.; Amant, F.",null,"ESGO Task Force Canc Pregnancy","Lung cancer in pregnancy: Report of nine cases from an international collaborative study","LUNG CANCER",null,null,"English","Article",null,null,null,null,null,"Lung cancer; Pregnancy; Gestation; Chemotherapy; Maternal and fetal outcome","BREAST-CANCER; CHEMOTHERAPY; ADENOCARCINOMA; PACLITAXEL; CARCINOMA; PLACENTA; PATIENT; CARBOPLATIN; INVOLVEMENT; CISPLATIN","Objective: Lung cancer is an uncommon diagnosis during pregnancy. The combination of smoking in young women, increased maternal age during pregnancy, and increasing incidence of lung cancer worldwide may cause an increase of pregnancy associated lung cancer. The aim of this study was to describe all cases of lung cancer during pregnancy, registered in the international Cancer in Pregnancy registration study (CIP study; www.cancerinpregnancy.org). Materials and methods: We present nine cases, all advanced lung cancer during the course of pregnancy. Collected data included demographic features of the study patients, cancer treatment, pregnancy outcome as well as maternal and fetal outcomes. Results and conclusion: Nine pregnant patients from 4 European centres with a median age of 33 years old (range, 26-42) were included. The median gestational age at diagnosis was 17 weeks (range, 6-28). All patients presented with metastatic disease including bone, lung, brain, spinal cord, pleura, lymph nodes, adrenal and liver. Histopathology was compatible with adenocarcinoma in 4 patients, non-small cell lung cancer with unidentified subtype in 2 patients and squamous-cell, large-cell and a poorly differentiated carcinoma in 3 patients, respectively. Eight patients were treated with systemic therapy, five of them during gestation. No responses were seen. The maternal postpartum outcome was poor with less than one year survival following delivery. One patient experienced a spontaneous abortion and three pregnancies were terminated. Five infants were all born premature due to poor maternal status by cesarean section, with a median gestational age of 30 weeks (range 26-33). To summarize, lung cancer in pregnancy has a dismal maternal outcome in our series. We add nine new cases and discuss both therapeutic and prognostic results. (C) 2013 Elsevier Ireland Ltd. All rights reserved.","[Boussios, S.; Pavlidis, N.] Ioannina Univ Hosp, Dept Med Oncol, Ioannina 45500, Greece; [Han, S. N.; Amant, F.] Katholieke Univ Leuven Hosp, Leuven Canc Inst LKI, B-3000 Louvain, Belgium; [Han, S. N.] Katholieke Univ Leuven, Dept Oncol, B-3000 Louvain, Belgium; [Fruscio, R.] Univ Milano Bicocca, San Gerardo Hosp, Div Obstet & Gynecol, I-20900 Monza, Italy; [Halaska, M. J.] Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 2, Prague 15000 5, Czech Republic; [Ottevanger, P. B.] Radboud Univ Nijmegen, Med Ctr, Dept Obstet & Gynaecol, NL-6500 HB Nijmegen, Netherlands; [Peccatori, F. A.] European Inst Oncol, Div Gynecol Oncol, Fertil & Procreat Oncol Unit, I-20141 Milan, Italy; [Koubkova, L.] Charles Univ Prague, Fac Med 2, Dept Pneumol, Prague 15000 5, Czech Republic","Amant, F (reprint author), UZ Leuven Gasthuisberg, Dept Gynecol & Obstet, Herestr 49, B-3000 Louvain, Belgium.","frederic.amant@uzleuven.be",null,null,"Belgian Cancer Plan, Ministry of Health, Belgium","FA is senior clinical investigator of the Research Fund Flanders (F.W.O.). This research is supported by the Belgian Cancer Plan, Ministry of Health, Belgium.",null,43,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0169-5002","1872-8332",null,"LUNG CANCER","Lung Cancer","DEC",2013,82,3,null,null,null,null,499,505,null,"10.1016/j.lungcan.2013.09.002",null,7,"Oncology; Respiratory System","Oncology; Respiratory System","268OY","WOS:000328181600019"]
[null,null,null,null,"J","Dimopoulou, A; Fischer, B; Gardeitchik, T; Schroter, P; Kayserili, H; Schlack, C; Li, Y; Brum, JM; Barisic, I; Castori, M; Spaich, C; Fletcher, E; Mahayri, Z; Bhat, M; Girisha, KM; Lachlan, K; Johnson, D; Phadke, S; Gupta, N; Simandlova, M; Kabra, M; David, A; Nijtmans, L; Chitayat, D; Tuysuz, B; Brancati, F; Mundlos, S; Van Maldergem, L; Morava, E; Wollnik, B; Kornak, U",null,null,null,"Dimopoulou, Aikaterini; Fischer, Bjorn; Gardeitchik, Thatjana; Schroeter, Phillipe; Kayserili, Hullya; Schlack, Claire; Li, Yun; Brum, Jaime Moritz; Barisic, Ingeborg; Castori, Marco; Spaich, Christiane; Fletcher, Elaine; Mahayri, Zeina; Bhat, Meenakshi; Girisha, Katta M.; Lachlan, Katherine; Johnson, Diana; Phadke, Shubha; Gupta, Neerja; Simandlova, Martina; Kabra, Madhulika; David, Albert; Nijtmans, Leo; Chitayat, David; Tuysuz, Beyhan; Brancati, Francesco; Mundlos, Stefan; Van Maldergem, Lionel; Morava, Eva; Wollnik, Bernd; Kornak, Uwe",null,null,"Genotype phenotype spectrum of PYCR1-related autosomal recessive cutis laxa","MOLECULAR GENETICS AND METABOLISM",null,null,"English","Article",null,null,null,null,null,"Autosomal recessive cutis laxa; PYCR1; Proline; Mitochondria; Segmental progeroid disorders","DELTA(1)-PYRROLINE-5-CARBOXYLATE SYNTHASE P5CS; BARSY SYNDROME; ALTERED GLYCOSYLATION; MISSENSE MUTATION; BRAIN DYSGENESIS; PYCR1 MUTATIONS; DEBRE TYPE; GENE; OSTEODYSPLASTICA; TRAFFICKING","Autosomal recessive cutis laxa type 2B (ARCL2B; OMIM # 612940) is a segmental progeroid disorder caused by mutations in PYCR1 encoding pyrroline-5-carboxylate reductase 1, which is part of the conserved proline de novo synthesis pathway. Here we describe 33 patients with PYCR1-related ARCL from 27 families with initial diagnoses varying between wrinkly skin syndrome, gerodermia osteodysplastica, De Barsy syndrome or more severe progeria syndromes. Given the difficult differential diagnosis of ARCL syndromes we performed a systematic comparison of clinical features of PYCR1-related ARCL. Intrauterine growth retardation, a characteristic triangular facial gestalt, psychomotor retardation, and hypotonia were the most relevant distinctive hallmarks of ARCL due to proline de novo synthesis defects. Corneal clouding or cataracts, athetoid movements, and finger contractures were rather rare features, but had a high predictive value. In our cohort we identified 20 different PYCR1 mutations of which seven were novel. Most of the mutations accumulated in exons 4 to 6. Missense alterations of highly conserved residues were most frequent followed by splice site changes and a single nonsense mutation. Analysis of genotype phenotype correlation revealed that patients with mutations in the first two exons had lower average clinical scores and absent or only mild intellectual disability. Structural analyses predicted interference with PYCR1 multimerization for a subset of missense mutations. These findings have implications for the clinics as well as the pathomechanism of PYCR1-related ARCL. (C) 2013 Elsevier Inc. All rights reserved.","[Dimopoulou, Aikaterini; Fischer, Bjorn; Schroeter, Phillipe; Schlack, Claire; Mundlos, Stefan; Kornak, Uwe] Charite, Inst Med Genet & Humangenet, D-13353 Berlin, Germany; [Fischer, Bjorn; Mundlos, Stefan; Kornak, Uwe] Max Planck Inst Mol Genet, FG Dev & Dis, D-14195 Berlin, Germany; [Gardeitchik, Thatjana; Nijtmans, Leo; Morava, Eva] Radboud Univ Nijmegen, Med Ctr, Dept Pediat, NL-6525 ED Nijmegen, Netherlands; [Kayserili, Hullya] Istanbul Univ, Istanbul Fac Med, Dept Med Genet, Istanbul, Turkey; [Li, Yun; Wollnik, Bernd] Univ Cologne, Inst Human Genet, D-50931 Cologne, Germany; [Li, Yun; Wollnik, Bernd] Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; [Li, Yun; Wollnik, Bernd] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50931 Cologne, Germany; [Brum, Jaime Moritz] Rede SARAH Hosp Reabil, Brasilia, DF, Brazil; [Barisic, Ingeborg] Childrens Univ Hosp Zagreb, Zagreb, Croatia; [Castori, Marco] Sapienza Univ, San Camillo Forlanini Hosp, Dept Mol Med Med Genet, Rome, Italy; [Spaich, Christiane] Olga Hosp, Inst Klin Genet, Klinikum Stuttgart, Stuttgart, Germany; [Fletcher, Elaine] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; [Mahayri, Zeina] Assad Univ Hosp, Cytogenet Unit, Damascus, Syria; [Bhat, Meenakshi] Ctr Human Genet, Bangalore, Karnataka, India; [Girisha, Katta M.] Manipal Univ, Kasturba Med Coll, Dept Pediat, Div Med Genet, Manipal, Karnataka, India; [Lachlan, Katherine] Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England; [Johnson, Diana] Sheffield Childrens NHS Fdn Trust, Dept Clin Genet, Sheffield, S Yorkshire, England; [Phadke, Shubha] Sanjay Gandhi Postgrad Inst Med Sci, Dept Med Genet, Lucknow, Uttar Pradesh, India; [Gupta, Neerja; Kabra, Madhulika] All India Inst Med Sci, Dept Pediat, New Delhi, India; [Simandlova, Martina] Charles Univ Prague, Motol Hosp, Clin Genet Unit, Prague, Czech Republic; [David, Albert] CHU Nantes, Clin Genet Unit, F-44035 Nantes 01, France; [Chitayat, David] Univ Toronto, Mt Sinai Hosp, Dept Obstet & Gynaecol, Prenatal Diag & Med Genet Program, Toronto, ON M5G 1X5, Canada; [Tuysuz, Beyhan] Istanbul Univ, Cerrahpasa Med Fac, Dept Pediat Genet, Istanbul, Turkey; [Brancati, Francesco] Gabriele Dannunzio Univ, Dept Med Oral & Biotechnol Sci, Chieti, Italy; [Brancati, Francesco] Policlin Tor Vergata Univ Hosp, Med Genet Unit, Rome, Italy; [Mundlos, Stefan] Charite, Berlin Brandenburg Ctr Regenerat Therapies, D-13353 Berlin, Germany; [Van Maldergem, Lionel] Univ Franche Comte, Ctr Human Genet, F-25030 Besancon, France; [Morava, Eva] Tulane Univ, Med Ctr, Hayward Genet Ctr, New Orleans, LA USA","Kornak, U (reprint author), Charite, Inst Med Genet & Humangenet, Augustenburger Pl 1, D-13353 Berlin, Germany.","uwe.kornak@charite.de","Fischer, Bjorn/D-7487-2013",null,"Deutsche Forschungsgemeinschaft [KO 2891/1-1]; Radboud University Nijmegen Medical Center IGMD","We are grateful to the patients and family members whose cooperation made this study possible. This study was funded by the Deutsche Forschungsgemeinschaft (KO 2891/1-1) to Uwe Kornak and the Radboud University Nijmegen Medical Center IGMD junior investigation grant",null,39,0,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1096-7192","1096-7206",null,"MOL GENET METAB","Mol. Genet. Metab.","NOV",2013,110,3,null,null,null,null,352,361,null,"10.1016/j.ymgme.2013.08.009",null,10,"Biochemistry & Molecular Biology; Genetics & Heredity; Medicine, Research & Experimental","Biochemistry & Molecular Biology; Genetics & Heredity; Research & Experimental Medicine","239WZ","WOS:000326058000025"]
[null,null,null,null,"J","Vancikova, Z; Freiberger, T; Vach, W; Trojanek, M; Rizzi, M; Janda, A",null,null,null,"Vancikova, Z.; Freiberger, T.; Vach, W.; Trojanek, M.; Rizzi, M.; Janda, A.",null,null,"X-linked Agammaglobulinemia in Community-acquired Pneumonia Cases Revealed by Immunoglobulin Level Screening at Hospital Admission","KLINISCHE PADIATRIE",null,null,"English","Article",null,null,null,null,null,"X-linked agammaglobulinemia; immunodeficiency; humoral immunity; community-acquired pneumonia; childhood","INTERDISCIPLINARY AWMF GUIDELINE; PRIMARY IMMUNODEFICIENCY; FEATURES; DISEASES; CHILDREN","In children with primary immunodeficiencies, the onset of symptoms precedes the diagnosis and the initiation of appropriate treatment by months or years. This delay in diagnosis is due to the fact that while these disorders are rare, some of the infections seen in immunodeficient patients are common. Defective antibody production represents the largest group among these disorders, with otitis, sinusitis and pneumonia as the most frequent initial manifestation. We performed a prospective study of humoral immunity in children hospitalized due to community-acquired pneumonia in tertiary care hospital. Out of 254 patients (131 boys, 123 girls, median age 4.5 years) recruited over 3 years, we found 2 boys (age 11 and 21 months) lacking serum immunoglobulins and circulating B cells. Subsequent genetic analysis confirmed diagnosis of X-linked agammaglobulinemia. Despite their immunodeficiency, the pneumonia was uncomplicated in both patients and did not call for immunological evaluation. However, the immunoglobulin screening at admission allowed for an early diagnosis of the immunodeficiency and timely initiation of immunoglobulin substitution, the key prerequisite for a favorable course of the disease. Conclusions: Simple and inexpensive immunoglobulin measurement during the management of hospitalized children with community-acquired pneumonia may help in early identification of patients with compromised humoral immunity and prevent serious complications.","[Vancikova, Z.] Charles Univ Prague, Fac Med 1, Dept Pediat, CR-11636 Prague 1, Czech Republic; [Vancikova, Z.] Charles Univ Prague, Thomayers Univ Hosp, CR-11636 Prague 1, Czech Republic; [Freiberger, T.] Masaryk Univ, Ctr Cardiovasc Surg & Transplantat, Mol Genet Lab, Brno, Czech Republic; [Freiberger, T.] Masaryk Univ, Dept Clin Immunol & Allergol, Brno, Czech Republic; [Vach, W.] Univ Freiburg, Univ Med Ctr, Inst Med Biometry & Med Informat, D-79108 Freiburg, Germany; [Trojanek, M.] Charles Univ Prague, Fac Med 2, Dept Infect Dis 1, CR-11636 Prague 1, Czech Republic; [Rizzi, M.; Janda, A.] Univ Freiburg, Univ Med Ctr, Ctr Chron Immunodeficiency, D-79108 Freiburg, Germany","Janda, A (reprint author), Univ Freiburg, Univ Med Ctr, Ctr Chron Immunodeficiency, Engesser Str 4, D-79108 Freiburg, Germany.","ales.janda@uniklinik-freiburg.de",null,null,"IGA MZCR [NS10398]; CEITEC - Central European Institute of Technology [SuPReMMe - CZ.1.07/2.3.00/20.0045]; European Society for Immunodeficiencies (ESID) by Baxter","We would like to acknowledge the contribution of Drs. E. Mejstrikova, M. Sukova, R. Zachova and B. Ravcukova in the care and diagnostics of the patients and Prof. J. Janda for his overall support. The study was supported by IGA MZCR NS10398 grant. Dr. T. Freiberger was partly supported by the project \"CEITEC - Central European Institute of Technology\" (SuPReMMe - CZ.1.07/2.3.00/20.0045). Dr. A. Janda is a recipient of an unrestricted fellowship grant from the European Society for Immunodeficiencies (ESID) provided by Baxter.",null,13,0,0,"GEORG THIEME VERLAG KG","STUTTGART","RUDIGERSTR 14, D-70469 STUTTGART, GERMANY","0300-8630","1439-3824",null,"KLIN PADIATR","Klinische Padiatr.","NOV",2013,225,6,null,null,null,null,339,342,null,"10.1055/s-0033-1354415",null,4,"Pediatrics","Pediatrics","252OH","WOS:000327015800010"]
[null,null,null,null,"J","Benes, J; Dzupova, O; Setina, M; Feuereisl, R; Svec, P; Pantucek, R",null,null,null,"Benes, Jiri; Dzupova, Olga; Setina, Marek; Feuereisl, Rudolf; Svec, Pavel; Pantucek, Roman",null,null,"Relapsing endocarditis caused by Enterococcus faecalis forming small colony variants","SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES",null,null,"English","Article",null,null,null,null,null,"Small colony variants; Enterococcus faecalis; infective endocarditis; relapsing infection","STAPHYLOCOCCUS-AUREUS; INFECTIVE ENDOCARDITIS; DIAGNOSIS; PERSISTENT; GUIDELINES; THERAPY","Small colony variants (SCVs) are subpopulations of a bacterial strain that differ in morphology, growth rate, metabolism, and antibiotic sensitivity from the parent line. They are associated with chronic and difficult-to-treat infections. SCV endocarditis is very rare and usually associated with intracardiac devices. Herein, we report a case of endocarditis caused by SCV-forming Enterococcus faecalis that affected the native heart without any known predisposition.","[Benes, Jiri; Dzupova, Olga] Charles Univ Prague, Fac Med 3, Dept Infect Dis, Na Bulovce Hosp, Prague, Czech Republic; [Setina, Marek] Charles Univ Prague, Fac Med 2, Dept Cardiovasc Surg, Univ Hosp Motol, Prague, Czech Republic; [Feuereisl, Rudolf] Na Bulovce Hosp, Dept Cardiol, Prague 18081, Czech Republic; [Svec, Pavel; Pantucek, Roman] Masaryk Univ, Fac Sci, Dept Expt Biol, CS-61137 Brno, Czech Republic","Dzupova, O (reprint author), Na Bulovce Hosp, Dept Infect Dis, Budinova 2, Prague 18081, Czech Republic.","olga.dzupova@lf3.cuni.cz","Svec, Pavel/B-1209-2008",null,"Charles University Prague [UNCE 204010]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NT12395-5/2011]; Ministry of Education, Youth and Sports of the Czech Republic [CZ.1.07/2.3.00/20.0183]","This publication was supported by Charles University Prague, Research Project UNCE 204010. The contribution of R. P. was supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic (Project NT12395-5/2011). P. S. acknowledges financial support from the Ministry of Education, Youth and Sports of the Czech Republic (Project CZ.1.07/2.3.00/20.0183). The authors declare no commercial relationship related to the submission.",null,18,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","0036-5548",null,null,"SCAND J INFECT DIS","Scand. J. Infect. Dis.","OCT",2013,45,10,null,null,null,null,800,803,null,"10.3109/00365548.2013.800227",null,4,"Infectious Diseases","Infectious Diseases","220JN","WOS:000324579200012"]
[null,null,null,null,"J","Jahromi, AH; Fronek, J; Kessaris, N; Bydawell, G; Patel, U; MacPhee, IAM",null,null,null,"Jahromi, Alireza Hamidian; Fronek, Jiri; Kessaris, Nicos; Bydawell, Gareth; Patel, Uday; MacPhee, Iain A. M.",null,null,"Acute Page Kidney Complicating Kidney Transplant Artery Stenting Presentation of a Case and Novel Management","IRANIAN JOURNAL OF KIDNEY DISEASES",null,null,"English","Article",null,null,null,null,null,"kidney transplantation; postoperative complications; stents; renal artery obstruction; hematoma","SINGLE-CENTER; STENOSIS; ANGIOPLASTY","We present a rare complication of transplant renal artery stenting in a patient who developed subcapsular hematoma and presented as acute page kidney. We discuss possible mechanisms and successful novel management using radiological-assisted decompression. We propose considering this alternative option before proceeding with surgical exploration and renal capsulotomy.","[Jahromi, Alireza Hamidian; Fronek, Jiri; Kessaris, Nicos; MacPhee, Iain A. M.] Univ London St Georges Hosp, Dept Renal Med & Transplantat, London SW17 0QT, England; [Jahromi, Alireza Hamidian] Louisiana State Unievers Hlth Sci Ctr Shreveport, Dept Surg, Los Angeles, CA USA; [Fronek, Jiri] Charles Univ Prague, Inst Clin & Expt Med, Prague, Czech Republic; [Fronek, Jiri] Charles Univ Prague, Fac Med 2, Prague, Czech Republic; [Bydawell, Gareth; Patel, Uday] St Georges Healthcare NHS Trust, Dept Radiol, London, England","MacPhee, IAM (reprint author), Univ London St Georges Hosp, Dept Renal Med & Transplantat, Blackshaw Rd, London SW17 0QT, England.","imacphee@sgul.ac.uk",null,null,null,null,null,14,0,0,"IRANIAN SOC NEPHROLGY","TEHRAN","APT 12, NO 63, SHAHEED TOUSI ST, DR GHARIB ST, KESHAVARZ BLVD, TEHRAN, 1419783311, IRAN","1735-8582","1735-8604",null,"IRAN J KIDNEY DIS","Iran. J. Kidney Dis.","SEP",2013,7,5,null,null,null,null,352,355,null,null,null,4,"Urology & Nephrology","Urology & Nephrology","239DH","WOS:000326002300006"]
[null,null,null,null,"J","Jedrzejczak, J; Marusic, P; Haldre, S; Majkowska-Zwolinska, B; Bojinova-Tchamova, V; Mameniskiene, R; Mindruta, I; Ravnik, IM; Szupera, Z; Sykora, P; Verzbickis, A; Daniluk, J",null,null,null,"Jedrzejczak, Joanna; Marusic, Petr; Haldre, Sulev; Majkowska-Zwolinska, Beata; Bojinova-Tchamova, Veneta; Mameniskiene, Ruta; Mindruta, Ioana; Ravnik, Igor M.; Szupera, Zoltan; Sykora, Pavol; Verzbickis, Aleksandrs; Daniluk, Jerzy",null,null,"Current status of epilepsy health care for adult patients from Central and Eastern European Union Countries-A survey of members of the Central Europe Epilepsy Experts Working Group","SEIZURE-EUROPEAN JOURNAL OF EPILEPSY",null,null,"English","Article",null,null,null,null,null,"Drug resistance; Epilepsy surgery; Pharmacoeconomics; Pharmacoresistance; Reimbursement",null,"Purpose: The aim of this survey was to review and compare the current approaches to epilepsy management in Central and Eastern EU (CEEU) countries. Method: The questionnaire was sent to ten invited experts from Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia. It focused on the treatment of adults. Results: The number of neurologists and epilepsy reference centers is highly variable in CEEU countries. None of the analyzed states has a formal specialization in epileptology. No universal state-approved criteria for reference centers exist in Czech Republic, Estonia, Hungary, Latvia, and Slovenia. Generally, the protocols for epilepsy treatment in CEEU countries, including drug-resistant epilepsy, are in accordance with international guidelines; however, most countries have their own national standards of care and some have local clinical guidelines. Also, the reimbursement systems for antiepileptic drugs in CEEU countries are highly variable. Seven countries have epilepsy surgery centers. The costs of epilepsy surgeries are fully reimbursed, procedures performed abroad may also be covered. The length of time spent on waiting lists for surgery following the completion of preoperative investigations varies from two weeks to three years. The fraction of patients who qualified and were operated on within 12 months ranges from 20% to 100%. Conclusion: The lack of unified procedures pertaining to the evaluation and therapy of epilepsy is reflected by marked differences in access to treatment modalities for patients from CEEU countries. (C) 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","[Jedrzejczak, Joanna] Med Ctr Postgrad Educ, Dept Neurol & Epileptol, PL-04305 Warsaw, Poland; [Marusic, Petr] Charles Univ Prague, Dept Neurol, Fac Med 2, Prague, Czech Republic; [Marusic, Petr] Univ Hosp Motol, Prague, Czech Republic; [Haldre, Sulev] Univ Tartu, Dept Neurol & Neurosurg, Tartu, Estonia; [Majkowska-Zwolinska, Beata] Fdn Epileptol, Epilepsy Diagnost & Therapeut Ctr, Warsaw, Poland; [Bojinova-Tchamova, Veneta] Univ Hosp Neurol & Psychiat, Clin Child Neurol, Sofia, Bulgaria; [Mameniskiene, Ruta] Vilnius State Univ, Ctr Neurol, Vilnius Univ Hosp Santariskiu Klinikos, Clin Neurol & Neurosurg,Fac Med, Vilnius, Lithuania; [Mindruta, Ioana] Univ Emergency Hosp, Dept Neurol, Bucharest, Romania; [Ravnik, Igor M.] Univ Med Ctr Ljubljana, Dept Child Adolescent & Dev Neurol, Div Pediat, Univ Childrens Hosp, Ljubljana, Slovenia; [Szupera, Zoltan] St Imre Hosp, Dept Neurol, Budapest, Hungary; [Sykora, Pavol] Childrens Teaching Hosp, Dept Child Neurol, Bratislava, Slovakia; [Verzbickis, Aleksandrs] Psychiat Hosp Jelgava, Outpatient Dept, Jelgava, Latvia; [Daniluk, Jerzy] GSK, Dept Med, Warsaw, Poland","Jedrzejczak, J (reprint author), Med Ctr Postgrad Educ, Dept Neurol & Epileptol, Czerniakowska St 231, PL-04305 Warsaw, Poland.","joannajedrzejczak6@wp.pl",null,null,"GlaxoSmithKline (GSK)","The scientific meeting on which this article is based (Central Europe Epilepsy Experts Working Group Meeting, January 2011, Warsaw, Poland) was initiated and supported by GlaxoSmithKline (GSK). Members of the Scientific Committee who developed the meeting program were selected by the Chairman, Professor Joanna Jedrzejczak, in consultation with GSK. Scientific Committee members were paid an honorarium for their participation in the meeting.",null,10,0,0,"W B SAUNDERS CO LTD","LONDON","32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND","1059-1311",null,null,"SEIZURE-EUR J EPILEP","Seizure","JUL",2013,22,6,null,null,null,null,452,456,null,"10.1016/j.seizure.2013.03.001",null,5,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","173PU","WOS:000321092200008"]
[null,null,null,null,"J","Manchanda, R; Halaska, MJ; Piek, JM; Grabowski, JP; Haidopoulos, D; Zapardiel, I; Gultekin, M; Vranes, B; Dallaku, K; Bossart, M",null,null,null,"Manchanda, Ranjit; Halaska, Michael J.; Piek, Jurgen M.; Grabowski, Jacek P.; Haidopoulos, Dimitrios; Zapardiel, Ignacio; Gultekin, Murat; Vranes, Boris; Dallaku, Kastriot; Bossart, Michaela",null,"ENYGO","The Need for More Workshops in Laparoscopic Surgery and Surgical Anatomy for European Gynaecological Oncology Trainees A Survey by the European Network of Young Gynaecological Oncologists","INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER",null,null,"English","Article",null,null,null,null,null,"ENYGO; Gynecologic oncology; Training; Laparoscopic surgery; Surgical anatomy; European","EDUCATION","Objective: The objective of this study was to highlight the relative preference of European gynecologic oncology trainees for workshops that could support and supplement their training needs. Methods: AWeb-based survey was sent to 900 trainees on the European Network of Young Gynaecological Oncologists database in November 2011. Respondents were asked to rate a 13-item questionnaire (using a 1- to 5-point Likert scale) on workshop topics they felt would most benefit their training requirements. Free text space for additional topics was also provided. Descriptive analysis was used to describe the mean scores reported for different items. A complete linkage hierarchical cluster analysis with Dendron plot was used to assess any clustering of data, and Cronbach alpha was used to assess the internal reliability of the questionnaire. Results: One hundred ninety trainees from 37 countries responded to the survey, giving a 21% response rate. The 3 most important topics reported were laparoscopic surgery; surgical anatomy, and imaging techniques in gynecologic oncology. The Dendron plot indicated 4 different clusters of workshops (research related skills, supportive ancillary skills, related nonsurgical subspecialties, and core surgical skills) reflecting different competencies trainees need to meet. There was no significant association between individual country of training and workshop preference. The mean duration of the workshop preferred by 71% of respondents was 2 days. Cronbach alpha of the 13-item questionnaire was 0.78, which suggests good internal consistency/reliability. Conclusions: This report for the first time highlights the relative importance and significance European trainees attach to some of their training needs in gynecologic oncology. Laparoscopic surgery, surgical anatomy, and imaging appear to be the 3 areas of greatest need. The European Society of Gynaecological Oncology, other national specialist societies, and institutions should direct additional training efforts at these areas.","[Manchanda, Ranjit] UCL, EGA Inst Womens Hlth, Dept Gynaecol Oncol, London WC1E 6BT, England; [Halaska, Michael J.] Charles Univ Prague, Fac Med 2, Dept Obstet & Gynecol, CR-11636 Prague 1, Czech Republic; [Piek, Jurgen M.] South Locat TweeSteden Hosp, Ctr Comprehens Canc, Tilburg, Netherlands; [Grabowski, Jacek P.] Kliniken Essen Mitte, Dept Gynecol & Gynecol Oncol, Essen, Germany; [Haidopoulos, Dimitrios] Alexandra Hosp, Gynecol Oncol Unit, Dept Obstet & Gynecol 1, Athens, Greece; [Zapardiel, Ignacio] La Paz Univ Hosp, Gynaecol Oncol Unit, Madrid, Spain; [Gultekin, Murat] Turkish Minist Hlth, Canc Control Dept, Ankara, Turkey; [Vranes, Boris] Clin Ctr Serbia, Inst Obstet & Gynecol, Belgrade, Serbia; [Dallaku, Kastriot] Obstet Gynecol Univ Hosp Koco Gliozheni, Tirana, Albania; [Bossart, Michaela] Univ Freiburg, Dept Obstet & Gynaecol, D-79106 Freiburg, Germany","Manchanda, R (reprint author), UCL UCLH, Gynaecol Canc Res Ctr, EGA Inst Womens Hlth, First Floor,Maple House,149 Tottenham Court Rd, London W1T 7DN, England.","r.manchanda@ucl.ac.uk",null,null,"European Network of Young Gynaecological Oncologists; ESGO council","The authors thank the ESGO council for their support. They also thank Renata Brandtnerova for her administrative support.",null,12,0,0,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1048-891X","1525-1438",null,"INT J GYNECOL CANCER","Int. J. Gynecol. Cancer","JUL",2013,23,6,null,null,null,null,1126,1131,null,"10.1097/IGC.0b013e31829703b0",null,6,"Oncology; Obstetrics & Gynecology","Oncology; Obstetrics & Gynecology","299CV","WOS:000330373600025"]
[null,null,null,null,"J","Petrikova, A; Dolezal, T; Klimes, J; Vocelka, M; Sedova, L; Kolar, J",null,null,null,"Petrikova, Alena; Dolezal, Tomas; Klimes, Jiri; Vocelka, Milan; Sedova, Liliana; Kolar, Jozef",null,null,"The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008","RHEUMATOLOGY INTERNATIONAL",null,null,"English","Article",null,null,null,null,null,"Health economics; Ankylosing spondylitis; Drug therapy; Quality of health care; Biologic agents","3 EUROPEAN COUNTRIES; PRODUCTIVITY COSTS; ARTHRITIS; RHEUMATOLOGY; DISABILITY","To investigate the burden of ankylosing spondylitis in the Czech Republic as a baseline for future health economic evaluations. Data were obtained from two cross-sectional studies Beda I (2005) and Beda II (2008), performed in 1,008 and 509 patients, respectively. Methodology used was Cost-of-Illness prevalence-based analysis bottom-up approach. Analysis was performed from payer (health insurance companies) and societal perspective (including productivity costs using friction cost approach). Mean age of sample in Beda I and Beda II was 50.2 and 52.5 years, male were present by 61.0 and 62.7 %; average disease duration was 23.0 and 26.4 years, respectively. Mean total annual costs per patient in the sample were a,not sign4,782 in Beda I and a,not sign5806 in Beda II. Average direct costs per patient in the sample per year are estimated at a,not sign1,812 (Beda I) and a,not sign2,588 (Beda II) with the average productivity costs a,not sign2,970 (Beda I) and a,not sign3,218 (Beda II). We observed a small decrement in percentage (6.7 %) of productivity costs for Beda II as an influence of higher consumption of biologic drugs, hence higher direct costs and possible productivity preservation. The largest direct cost burdens were spa procedures (45.3 %, Beda I) and biological drugs (52.8 %, Beda II). Unique analysis of the burden of the AS in the Central-Eastern Europe presents health care resource and cost consumption by comparing two cross-sectional prevalence-based studies. Further analysis should be carried to obtain data connecting health status with costs consumption in order to analyse the AS from this perspective.","[Petrikova, Alena; Klimes, Jiri; Kolar, Jozef] Charles Univ Prague, Dept Social & Clin Pharm, Fac Pharm, Prague, Czech Republic; [Petrikova, Alena; Kolar, Jozef] Univ Vet & Pharmaceut Sci, Dept Appl Pharm, Fac Pharm, Brno 61242, Czech Republic; [Dolezal, Tomas; Klimes, Jiri; Vocelka, Milan] iHETA, Prague, Czech Republic; [Dolezal, Tomas] Charles Univ Prague, Dept Pharmacol, Fac Med 2, Prague, Czech Republic; [Vocelka, Milan] Charles Univ Prague, Dept Pharmacol, Fac Med 3, Prague, Czech Republic; [Sedova, Liliana] Inst Rheumatol, Prague, Czech Republic","Petrikova, A (reprint author), Univ Vet & Pharmaceut Sci, Dept Appl Pharm, Fac Pharm, Palackeho 1-3, Brno 61242, Czech Republic.","petrikova.alena@gmail.com",null,null,"Ministry of Health of Czech Republic [000 000 23728]; Charles University in Prague [SVV 265 005]","Authors would like to acknowledge Mr. Vedral from patients organisation for the cooperation and consultation during the manuscript writing. This work was supported by grant number 000 000 23728 - Ministry of Health of Czech Republic, by grant number SVV 265 005 - Charles University in Prague.",null,22,0,0,"SPRINGER HEIDELBERG","HEIDELBERG","TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY","0172-8172",null,null,"RHEUMATOL INT","Rheumatol. Int.","JUL",2013,33,7,null,null,null,null,1813,1819,null,"10.1007/s00296-012-2542-x",null,7,"Rheumatology","Rheumatology","175UQ","WOS:000321259500022"]
[null,null,null,null,"J","Beier, R; Albert, MH; Bader, P; Borkhardt, A; Creutzig, U; Eyrich, M; Ehlert, K; Gruhn, B; Greil, J; Handgretinger, R; Holter, W; Klingebiel, T; Kremens, B; Lang, P; Mauz-Korholz, C; Meisel, R; Muller, I; Peters, C; Reinhardt, D; Sedlacek, P; Schulz, A; Schuster, FR; Schrauder, A; Strahm, B; Sykora, KW; Wossmann, W; Zimmermann, M; Sauer, MG",null,null,null,"Beier, R.; Albert, M. H.; Bader, P.; Borkhardt, A.; Creutzig, U.; Eyrich, M.; Ehlert, K.; Gruhn, B.; Greil, J.; Handgretinger, R.; Holter, W.; Klingebiel, T.; Kremens, B.; Lang, P.; Mauz-Koerholz, C.; Meisel, R.; Mueller, I.; Peters, C.; Reinhardt, D.; Sedlacek, P.; Schulz, A.; Schuster, F. R.; Schrauder, A.; Strahm, B.; Sykora, K. W.; Woessmann, W.; Zimmermann, M.; Sauer, M. G.",null,null,"Allo-SCT using BU, CY and melphalan for children with AML in second CR","BONE MARROW TRANSPLANTATION",null,null,"English","Article",null,null,null,null,null,"children; AML; BU; CY; melphalan; CR2","ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; CONDITIONING REGIMEN; PHASE-I; INTRAVENOUS BUSULFAN; PREPARATIVE REGIMEN; HOST-DISEASE; CYCLOPHOSPHAMIDE; ETOPOSIDE","Based on the results from the AML-BFM 98 trial, hematopoietic SCT (HSCT) is recommended for children with AML in second CR only. Here, we retrospectively analyze interphase data of children who underwent HSCT after myeloablative conditioning with BU, CY, and melphalan (BuCyMel) for AML in second remission (CR2) between 1998 and 2009. Out of 152 children, transplant data were available on 109 individuals. Sixty out of 109 children (55%) received BuCyMel. Median age at HSCT was 12.2 years (range 3.0; 18.3). GVHD prophylaxis mostly consisted of CsA and short term MTX with or without antithymocyte globulin. Matched-sibling donors were used for 6/60 analyzed recipients, the remainder either received grafts from matched unrelated (30/60) or mismatched donors. OS after 5 years was 62% (s.e. 6%), relapse incidence 35% (18/60 children) and treatment-related mortality accounted for 12% (7/60) of fatal events. In conclusion, even taking into account possible selection bias in this retrospective analysis, HSCT in CR2 using BuCyMel resulted in a respectable OS. Based on this data the prospective, controlled and centrally monitored AML SCT-BFM 2007 trial has started to recruit patients in January 2010 aiming to generate valid outcome data for further strategy decisions.","[Beier, R.; Creutzig, U.; Reinhardt, D.; Sykora, K. W.; Zimmermann, M.; Sauer, M. G.] Univ Med Hsch, Dept Pediat, Div Pediat Hematol & Oncol, D-30625 Hannover, Germany; [Albert, M. H.] Dr V Haunersches Kinderspital, Dept Pediat, Div Pediat Hematol & Oncol, Munich, Germany; [Bader, P.; Klingebiel, T.] Goethe Univ Frankfurt, Dept Pediat, Div Pediat Hematol & Oncol, D-60054 Frankfurt, Germany; [Borkhardt, A.; Meisel, R.; Schuster, F. R.] Univ Dusseldorf, Dept Pediat, Div Pediat Hematol & Oncol, D-40225 Dusseldorf, Germany; [Eyrich, M.] Univ Wurzburg, Dept Pediat, Div Pediat Hematol & Oncol, D-97070 Wurzburg, Germany; [Ehlert, K.] Univ Munster, Dept Pediat, Div Pediat Hematol & Oncol, D-48149 Munster, Germany; [Gruhn, B.] Univ Jena, Dept Pediat, Div Pediat Hematol & Oncol, Jena, Germany; [Greil, J.] Heidelberg Univ, Dept Pediat, Div Pediat Hematol & Oncol, Heidelberg, Germany; [Handgretinger, R.; Lang, P.] Univ Tubingen, Dept Pediat, Div Pediat Hematol & Oncol, Tubingen, Germany; [Holter, W.] Univ Erlangen Nurnberg, Dept Pediat, Div Pediat Hematol & Oncol, D-91054 Erlangen, Germany; [Kremens, B.] Univ Essen Gesamthsch, Dept Pediat, Div Pediat Hematol & Oncol, Essen, Germany; [Mauz-Koerholz, C.] Univ Halle, Dept Pediat, Div Pediat Hematol & Oncol, Halle, Germany; [Mueller, I.] Univ Hamburg Eppendorf, Dept Pediat, Div Pediat Hematol & Oncol, Hamburg, Germany; [Peters, C.] St Anna Kinderspital Vienna, Dept Pediat, Div Pediat Hematol & Oncol, Vienna, Austria; [Sedlacek, P.] Univ Hosp Motol, Dept Pediat, Div Pediat Hematol & Oncol, Prague, Czech Republic; [Schulz, A.] Univ Ulm, Dept Pediat, Div Pediat Hematol & Oncol, D-89069 Ulm, Germany; [Schrauder, A.] Univ Kiel, Dept Pediat, Div Pediat Hematol & Oncol, Kiel, Germany; [Strahm, B.] Univ Freiburg, Dept Pediat, Div Pediat Hematol & Oncol, Freiburg, Germany; [Woessmann, W.] Univ Giessen, Dept Pediat, Div Pediat Hematol & Oncol, D-35390 Giessen, Germany","Sauer, MG (reprint author), Univ Med Hsch, Dept Pediat Hematol & Oncol, OE 6780,Carl Neuberg Str 1, D-30625 Hannover, Germany.","sauer.martin@mh-hannover.de","Reinhardt, Dirk/D-3939-2011","Reinhardt, Dirk/0000-0003-4313-9056","German Ministry for Research and Education (BMBF, IFB-TX) [91]","We especially thank the AML-BFM study group, study nurses and physicians for their tremendous support collecting patient data. Rita Beier was supported by a grant of the German Ministry for Research and Education (BMBF, IFB-TX, Project 91). We thank Kirsten Mischke and Katja Arens for expert data management.",null,26,0,0,"NATURE PUBLISHING GROUP","LONDON","MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND","0268-3369",null,null,"BONE MARROW TRANSPL","Bone Marrow Transplant.","MAY",2013,48,5,null,null,null,null,651,656,null,"10.1038/bmt.2012.204",null,6,"Biophysics; Oncology; Hematology; Immunology; Transplantation","Biophysics; Oncology; Hematology; Immunology; Transplantation","141BH","WOS:000318699800005"]
[null,null,null,null,"J","Kensova, R; Kremplova, M; Smerkova, K; Zitka, O; Hynek, D; Adam, V; Beklova, M; Trnkova, L; Stiborova, M; Eckschlager, T; Hubalek, J; Kizek, R",null,null,null,"Kensova, Renata; Kremplova, Monika; Smerkova, Kristyna; Zitka, Ondrej; Hynek, David; Adam, Vojtech; Beklova, Miroslava; Trnkova, Libuse; Stiborova, Marie; Eckschlager, Tomas; Hubalek, Jaromir; Kizek, Rene",null,null,"Interactions of Platinum-Based Cytostatics with Metallothionein Revealed by Electrochemistry","INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"cisplatin; carboplatin; oxaliplatin; metallothionein; metallomics; voltammetry; flow injection analysis; anticancer therapy","DIFFERENTIAL-PULSE POLAROGRAPHY; CATHODIC STRIPPING VOLTAMMETRY; PLASMA-MASS SPECTROMETRY; FLOW-INJECTION ANALYSIS; CAPILLARY-ELECTROPHORESIS; BIOLOGICAL SAMPLES; CISPLATIN RESISTANCE; ANTITUMOR-ACTIVITY; CARBON ELECTRODES; ANTICANCER DRUGS","Platinum-based cytostatics play an important role in the chemotherapy of various tumour diseases. Therefore, it is not surprising that there is a great effort for studying of the cytostatics and their fate in an organism. In this study, we aimed our attention at determination of cisplatin, carboplatin and oxaliplatin using stationary and flow electrochemical methods. Primarily, determination of the platinum based cytostatics using differential pulse voltammetry at hanging mercury drop electrode was optimized. Under the optimal conditions (supporting electrolyte: 2 ml of 0.36 M sulphuric acid containing 0.24 ml of hydrazine (10 mM) and 0.01 ml of formaldehyde (37 % aqueous solution, v/v), pH of the supporting electrolyte: 1.8, potential of accumulation: -0.7 V, time of accumulation: 120 s), limits of detection were estimated (3 S/N) down to tens of pg per ml for the studied drugs. Further, we investigated the interactions of the characterized drugs with peptide fragments of protein metallothionein, because the overexpression of metallothionein in tumour cells belongs to the one of the generally accepted mechanisms of resistance to these cytostatics. For this purpose, flow injection analysis with electrochemical detection was utilized. As it is well evident from the obtained experimental data, interactions between peptide fragments and platinum-based complexes proceeded differently, where oxaliplatin demonstrated the highest ability to form complex.","[Kensova, Renata; Kremplova, Monika; Smerkova, Kristyna; Zitka, Ondrej; Hynek, David; Adam, Vojtech; Trnkova, Libuse; Hubalek, Jaromir; Kizek, Rene] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Kensova, Renata; Zitka, Ondrej; Hynek, David; Adam, Vojtech; Beklova, Miroslava; Trnkova, Libuse; Hubalek, Jaromir; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Zitka, Ondrej; Beklova, Miroslava] Univ Vet & Pharmaceut Sci Brno, Fac Vet Hyg & Ecol, Dept Vet Ecol & Environm Protect, Brno 61242, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic","Kensova, R (reprint author), Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.","kizek@sci.muni.cz","Hubalek, Jaromir/D-7753-2012",null,"CYTORES GA CR [P301/10/0356]; MSMT [6215712402]; NanoBioMetalNet [CZ.1.07/2.4.00/31.0023]; CEITEC [CZ.1.05/1.1.00/02.0068]","Financial support from CYTORES GA CR P301/10/0356, MSMT 6215712402, NanoBioMetalNet CZ.1.07/2.4.00/31.0023 and CEITEC CZ.1.05/1.1.00/02.0068 is highly acknowledged.",null,66,0,0,"ESG","BELGRADE","BORIVOJA STEVANOVICA 25-7, BELGRADE, 11000, SERBIA","1452-3981",null,null,"INT J ELECTROCHEM SC","Int. J. Electrochem. Sci.","APR",2013,8,4,null,null,null,null,4472,4484,null,null,null,13,"Electrochemistry","Electrochemistry","134NJ","WOS:000318217200009"]
[null,null,null,null,"J","Cejka, C; Rosina, J; Sirc, J; Michalek, J; Brunova, B; Cejkova, J",null,null,null,"Cejka, Cestmir; Rosina, Josef; Sirc, Jakub; Michalek, Jiri; Brunova, Blanka; Cejkova, Jitka",null,null,"The Reversibility of UV-B Induced Alterations in Optical Properties of the Rabbit Cornea Depends on Dose of UV Irradiation","PHOTOCHEMISTRY AND PHOTOBIOLOGY",null,null,"English","Article",null,null,null,null,null,null,"ULTRAVIOLET-RADIATION; ALDEHYDE DEHYDROGENASE; PHOTOREFRACTIVE KERATECTOMY; GLUTATHIONE-PEROXIDASE; ALCOHOL-DEHYDROGENASE; H-1-NMR SPECTROSCOPY; SUPEROXIDE-DISMUTASE; IMPRESSION CYTOLOGY; TREHALOSE TREATMENT; METABOLIC PROFILE","Solar UVB radiation evokes photokeratitis, accompanied by increased corneal hydration and changes in corneal transparency, resulting in increased light absorption. Corneal optical properties are disturbed and visual acuity decreased. The aim of this study was to investigate the reversibility of these UVB-induced changes. Rabbit corneas were irradiated with UVB doses of 0.5Jcm2 or 1.01Jcm2 during 4days. Some rabbits were sacrificed after the last irradiation and some 2months later. Corneas were investigated spectrophotometrically for light absorption, and corneal hydration was evaluated by central corneal thickness with an ultrasonic pachymeter. Corneal impression cytologies were examined immunohistochemically for proinflammatory cytokines and malondialdehyde. The increased corneal light absorption, hydration and the staining of immunohistochemical markers found in corneas after irradiation returned to normal values during 2months in corneas irradiated with the lower UVB dose. In contrast, in corneas irradiated with the higher UVB dose, a moderate but statistically significant increase in corneal light absorption, hydration and positive immunohistochemical stainings remained as residual changes. This was in contrast to normal corneas, where the staining of proinflammatory cytokines as well as malondialdehyde was negative. In conclusion, the reversibility of UVB-induced disturbances was dependent on UVB dose.","[Cejka, Cestmir; Cejkova, Jitka] Acad Sci Czech Republic, Inst Expt Med, Lab Eye Histochem & Pharmacol, Ctr Excellence, Prague, Czech Republic; [Rosina, Josef] Charles Univ Prague, Fac Med 3, Dept Med Biophys & Informat, Prague, Czech Republic; [Sirc, Jakub; Michalek, Jiri] Acad Sci Czech Republic, Inst Macromol Chem, Prague, Czech Republic; [Brunova, Blanka] Charles Univ Prague, Fac Med 2, Eye Clin Children & Adults, Prague, Czech Republic","Cejkova, J (reprint author), Acad Sci Czech Republic, Inst Expt Med, Lab Eye Histochem & Pharmacol, Ctr Excellence, Prague, Czech Republic.","cejkova@biomed.cas.cz","Michalek, Jiri/D-7251-2013",null,"Academy of Sciences of the Czech Republic [AVOZ50390512]","Supported by a grant from the Academy of Sciences of the Czech Republic AVOZ50390512.",null,66,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0031-8655",null,null,"PHOTOCHEM PHOTOBIOL","Photochem. Photobiol.","MAR-APR",2013,89,2,null,null,null,null,474,482,null,"10.1111/php.12010",null,9,"Biochemistry & Molecular Biology; Biophysics","Biochemistry & Molecular Biology; Biophysics","099TF","WOS:000315644100026"]
[null,null,null,null,"J","Honzik, T; Tesarova, M; Vinsova, K; Hansikova, H; Magner, M; Kratochvilova, H; Zamecnik, J; Zeman, J; Jesina, P",null,null,null,"Honzik, Tomas; Tesarova, Marketa; Vinsova, Kamila; Hansikova, Hana; Magner, Martin; Kratochvilova, Hana; Zamecnik, Josef; Zeman, Jiri; Jesina, Pavel",null,null,"Different laboratory and muscle biopsy findings in a family with an m.8851T > C mutation in the mitochondrial MTATP6 gene","MOLECULAR GENETICS AND METABOLISM",null,null,"English","Article",null,null,null,null,null,"Leigh syndrome; ATP synthase; Mitochondrial DNA m.8851T > C mutation","LEIGH-SYNDROME; ATP SYNTHASE; POINT MUTATION; ATPASE-6 GENE; DNA","We report the second known family with a very rare, maternally inherited missense m.8851T>C mutation in the mitochondrial MTATP6 gene. A failure to thrive, microcephaly, psychomotor retardation and hypotonia were present in a 3-year-old girl with a high mtDNA mutation load (87-97%). Ataxia and Leigh syndrome were subsequently documented in a neurological examination and brain MRI. A muscle biopsy demonstrated decreased ATP synthase and an accumulation of succinate dehydrogenase products, indicating mitochondrial myopathy. Her 36-year-old mother (68% blood heteroplasmy) developed peripheral neuropathy and muscle weakness at the age of 22 years. Our findings extend the clinical and laboratory phenotype associated with the m.8851T>C mutation. (C) 2012 Elsevier Inc. All rights reserved.","[Honzik, Tomas; Tesarova, Marketa; Vinsova, Kamila; Hansikova, Hana; Magner, Martin; Kratochvilova, Hana; Zeman, Jiri] Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague 12808 2, Czech Republic; [Honzik, Tomas; Tesarova, Marketa; Vinsova, Kamila; Hansikova, Hana; Magner, Martin; Kratochvilova, Hana; Zeman, Jiri; Jesina, Pavel] Gen Univ Hosp Prague, Prague 12808 2, Czech Republic; [Jesina, Pavel] Charles Univ Prague, Inst Inherited Metab Dis, Fac Med 1, Prague 12808 2, Czech Republic; [Zamecnik, Josef] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 12808 2, Czech Republic; [Zamecnik, Josef] Teaching Hosp Motol Prague, Prague, Czech Republic","Jesina, P (reprint author), Charles Univ Prague, Inst Inherited Metab Dis, Fac Med 1, Ke Karlovu 2, Prague 12808 2, Czech Republic.","pavel.jesina@vfn.cz",null,null," [PRVOUK-P24/LF1/3];  [RVO-VFN64165/2012]","Institutional support was provided by the research program PRVOUK-P24/LF1/3 and the institutional research project RVO-VFN64165/2012.",null,13,0,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1096-7192",null,null,"MOL GENET METAB","Mol. Genet. Metab.","JAN",2013,108,1,null,null,null,null,102,105,null,"10.1016/j.ymgme.2012.11.002",null,4,"Biochemistry & Molecular Biology; Genetics & Heredity; Medicine, Research & Experimental","Biochemistry & Molecular Biology; Genetics & Heredity; Research & Experimental Medicine","075BW","WOS:000313859800017"]
[null,null,null,null,"J","Hromadnikova, I; Kotlabova, K; Ondrackova, M; Kestlerova, A; Novotna, V; Hympanova, L; Doucha, J; Krofta, L",null,null,null,"Hromadnikova, Ilona; Kotlabova, Katerina; Ondrackova, Marketa; Kestlerova, Andrea; Novotna, Veronika; Hympanova, Lucie; Doucha, Jindrich; Krofta, Ladislav",null,null,"Circulating C19MC MicroRNAs in Preeclampsia, Gestational Hypertension, and Fetal Growth Restriction","MEDIATORS OF INFLAMMATION",null,null,"English","Article",null,null,null,null,null,null,"MATERNAL PLASMA; PLACENTAL INSUFFICIENCY; HYPERMETHYLATED RASSF1A; PRENATAL-DIAGNOSIS; SYNCYTIOTROPHOBLAST MICROPARTICLES; BIOCHEMICAL MARKERS; NORMAL-PREGNANCY; DNA; QUANTIFICATION; TROPHOBLAST","The objective of the study was to identify the profile of circulating C19MC microRNAs (miR-516-5p, miR-517*, miR-518b, miR-520a*, miR-520h, miR-525, and miR-526a) in patients with established preeclampsia (n = 63), fetal growth restriction (n = 27), and gestational hypertension (n = 23). We examined the correlation between plasmatic concentrations and expression levels of microRNAs and the severity of the disease with respect to clinical signs, requirements for the delivery, and Doppler ultrasound parameters. Using absolute and relative quantification approaches, increased extracellular C19MC microRNA levels (miR-516-5p, P = 0.037, P = 0.009; miR-517*, P = 0.033, P = 0.043; miR-520a*, P = 0.001, P = 0.009; miR-525, P = 0.026, P = 0.01; miR-526a, P = 0.03, P = 0.035) were detected in patients with preeclampsia. The association analysis pointed to no relationship between C19MC microRNA plasmatic concentrations and expression profile and identified risk factors for a poorer perinatal outcome. However, the dependence between the levels of plasmatic C19MC microRNAs and the pulsatility index in the middle cerebral artery and the values of cerebroplacental ratio was demonstrated. The study brought the interesting finding that the upregulation of miR-516-5p, miR-517*, miR-520a*, miR-525, and miR-526a is a characteristic phenomenon of established preeclampsia.","[Hromadnikova, Ilona; Kotlabova, Katerina; Ondrackova, Marketa; Hympanova, Lucie] Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Prague 10000, Czech Republic; [Kestlerova, Andrea; Novotna, Veronika; Hympanova, Lucie; Krofta, Ladislav] Charles Univ Prague, Inst Care Mother & Child, Fac Med 3, Prague 14700, Czech Republic; [Doucha, Jindrich] Charles Univ Prague, Fac Med 2, Clin Obstet & Gynecol, Prague 15006, Czech Republic","Hromadnikova, I (reprint author), Charles Univ Prague, Dept Mol Biol & Cell Pathol, Fac Med 3, Ruska 87, Prague 10000, Czech Republic.","ilona.hromadnikova@lf3.cuni.cz",null,null,"Grant Agency of Czech Republic [304/12/1352]; Charles University [PRVOUK P32]","The work was exclusively supported by the Grant Agency of Czech Republic (no. 304/12/1352) and partially supported by the Charles University Research Program PRVOUK P32.",null,55,0,0,"HINDAWI PUBLISHING CORPORATION","NEW YORK","410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA","0962-9351","1466-1861",null,"MEDIAT INFLAMM","Mediat. Inflamm.",null,2013,null,null,null,null,null,null,null,null,186041,"10.1155/2013/186041",null,12,"Cell Biology; Immunology","Cell Biology; Immunology","256QU","WOS:000327329800001"]
[null,null,null,null,"J","Kincses, ZT; Horinek, D; Szabo, N; Toth, E; Csete, G; Stepan-Buksakowska, I; Hort, J; Vecsei, L",null,null,null,"Kincses, Zsigmond Tamas; Horinek, Daniel; Szabo, Nikoletta; Toth, Eszter; Csete, Gergo; Stepan-Buksakowska, Irena; Hort, Jakub; Vecsei, Laszlo",null,null,"The Pattern of Diffusion Parameter Changes in Alzheimer's Disease, Identified by Means of Linked Independent Component Analysis","JOURNAL OF ALZHEIMERS DISEASE",null,null,"English","Article",null,null,null,null,null,"Alzheimer's disease; diffusion tensor imaging; linked independent component analysis; magnetic resonance imaging","MILD COGNITIVE IMPAIRMENT; WHITE-MATTER ABNORMALITIES; MAGNETIC-RESONANCE; MULTIPLE-SCLEROSIS; SPATIAL STATISTICS; TRACT INTEGRITY; BRAIN; DEGENERATION; MODEL; MRI","Several recent studies have indicated that white matter is affected in Alzheimer's disease (AD). Diffusion tensor imaging is a tool by which the white matter microstructure can be examined in vivo, and might offer a possibility for the identification of the pattern of white matter disintegration in AD. In the current analysis, we made use of a novel model-free analysis approach of linked independent component analysis to identify a motif of diffusion parameter alterations exemplifying AD. Analysis of the diffusion data of 16 AD patients and 17 age-matched healthy subjects revealed six independent components, two of which demonstrated differences between the patients and controls. Component #0 was dominated by axial diffusivity, but significant alterations in fractional anisotropy and mean and radial diffusivity were also detected. Alterations were found in regions of crossing of major white matter pathways, such as forceps, corona radiata, and superior longitudinal fascicle, as well as medio-temporal white matter. These results lend support to the coexistence of white matter disintegration of the late myelinating associating fibers and wallerian degeneration-related disintegration, in accordance with the retrogenesis and wallerian degeneration hypothesis.","[Kincses, Zsigmond Tamas; Szabo, Nikoletta; Toth, Eszter; Csete, Gergo; Vecsei, Laszlo] Univ Szeged, Albert Szent Gyorgyi Clin Ctr, Dept Neurol, H-6725 Szeged, Hungary; [Kincses, Zsigmond Tamas; Horinek, Daniel; Szabo, Nikoletta; Stepan-Buksakowska, Irena; Hort, Jakub] St Annes Univ Hosp Brno, Int Clin Res Ctr, Brno, Czech Republic; [Vecsei, Laszlo] Hungarian Acad Sci, Neurosci Res Grp, Szeged, Hungary; [Vecsei, Laszlo] Univ Szeged, Szeged, Hungary; [Hort, Jakub] Charles Univ Prague, Dept Neurol, Memory Disorders Clin, Fac Med 2, Prague, Czech Republic; [Stepan-Buksakowska, Irena; Hort, Jakub] Motol Univ Hosp, Prague, Czech Republic; [Stepan-Buksakowska, Irena] Charles Univ Prague, Dept Radiol, Fac Med 2, Prague, Czech Republic","Vecsei, L (reprint author), Univ Szeged, Albert Szent Gyorgyi Clin Ctr, Dept Neurol, Semmelweis U 6, H-6725 Szeged, Hungary.","vecsei.laszlo@med.u-szeged.hu",null,null,"IGA NS [10331]; International Research Center (FNUSA-ICRC) from the European Regional Development Fund [CZ.1.05/1.1.00/02.0123]; Neuroscience Research Group of the Hungarian Academy of Sciences and University of Szeged [OTKAPD104715, TAMOP-4.2.2.A-11/1/KONV-2012-0073, TAMOP-4.2.2/B-10/1-2010-0012]; MH CZ - DRO; University Hospital Motol, Prague, Czech Republic grant [00064203]","This research was supported by grant IGA NS 10331 by the International Research Center (FNUSA-ICRC, no. CZ.1.05/1.1.00/02.0123) from the European Regional Development Fund, the \"Neuroscience Research Group of the Hungarian Academy of Sciences and University of Szeged\" the OTKAPD104715, TAMOP-4.2.2.A-11/1/KONV-2012-0073, TAMOP-4.2.2/ B-10/1-2010-0012 and by MH CZ - DRO, University Hospital Motol, Prague, Czech Republic 00064203 grant.",null,61,0,0,"IOS PRESS","AMSTERDAM","NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS","1387-2877",null,null,"J ALZHEIMERS DIS","J. Alzheimers Dis.",null,2013,36,1,null,null,null,null,119,128,null,"10.3233/JAD-122431",null,10,"Neurosciences","Neurosciences & Neurology","159FJ","WOS:000320030200011"]
[null,null,null,null,"J","Attarbaschi, A; Beishuizen, A; Mann, G; Rosolen, A; Mori, T; Uyttebroeck, A; Niggli, F; Csoka, M; Krenova, Z; Mellgren, K; Kabickova, E; Chiang, AKS; Reiter, A; Williams, D; Burkhardt, B",null,null,null,"Attarbaschi, Andishe; Beishuizen, Auke; Mann, Georg; Rosolen, Angelo; Mori, Tetsuya; Uyttebroeck, Anne; Niggli, Felix; Csoka, Monika; Krenova, Zdenka; Mellgren, Karin; Kabickova, Edita; Chiang, Alan K. S.; Reiter, Alfred; Williams, Denise; Burkhardt, Birgit",null,"EICNHL; Int Berlin-Frankfurt-Munster I-BFM","Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a \"watch and wait\" strategy after complete resection","ANNALS OF HEMATOLOGY",null,null,"English","Article",null,null,null,null,null,"Follicular lymphoma; Complete resection; \"Watch and wait\"; Outcome","NON-HODGKINS-LYMPHOMA; CHILDHOOD; RITUXIMAB; CVP; CYCLOPHOSPHAMIDE; MANAGEMENT; HISTOLOGY; TESTIS; ADULTS","Data on clinical features and outcome in pediatric follicular lymphoma (pFL) are scarce. The aim of this retrospective study including 13 EICNHL and/or i-BFM study group members was to assess clinical characteristics and course in a series of 63 pFL patients. pFL was found to be associated with male gender (3:1), older age (72 % a parts per thousand yen10 years old), low serum LDH levels (< 500 U/l in 75 %), grade 3 histology (in 88 %), and limited disease (87 % stage I/II disease), mostly involving the peripheral lymph nodes. Forty-four out of sixty-three patients received any polychemotherapy and 1/63 rituximab only, while 17/63 underwent a \"watch and wait\" strategy. Of 36 stage I patients, 30 had complete resections. Only one patient relapsed; 2-year event-free survival and overall survival were 94 +/- 5 and 100 %, respectively, after a median follow-up of 2.2 years. Conclusively, treatment outcome in pFL seems to be excellent with risk-adapted chemotherapy or after complete resection and an observational strategy only.","[Attarbaschi, Andishe; Mann, Georg] St Anna Childrens Hosp, A-1090 Vienna, Austria; [Beishuizen, Auke] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands; [Rosolen, Angelo] Univ Padua, Padua, Italy; [Mori, Tetsuya] Natl Hosp Org Nagoya Med Ctr, Nagoya, Aichi, Japan; [Uyttebroeck, Anne] Univ Louvain, Louvain, Belgium; [Niggli, Felix] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Csoka, Monika] Semmelweis Univ, H-1085 Budapest, Hungary; [Krenova, Zdenka] Univ Hosp, Brno, Czech Republic; [Mellgren, Karin] Univ Gothenburg, Queen Silvias Hosp Children & Adolescents, Gothenburg, Sweden; [Kabickova, Edita] Univ Hosp, Prague, Czech Republic; [Chiang, Alan K. S.] Univ Hong Kong, Dept Pediat & Adolescent Med, Li Ka Shing Fac Med, Queen Mary Hosp, Pokfulam, Hong Kong, Peoples R China; [Reiter, Alfred; Burkhardt, Birgit] Univ Giessen, D-35390 Giessen, Germany; [Williams, Denise] Cambridge Univ Hosp Fdn Trust, Addenbrookes Hosp, Cambridge, England; [Burkhardt, Birgit] Univ Munster, D-48149 Munster, Germany","Attarbaschi, A (reprint author), St Anna Childrens Hosp, Kinderspitalgasse 6, A-1090 Vienna, Austria.","andishe.attarbaschi@stanna.at",null,null,"Cancer Research UK; Forschungshilfe Station Peiper (BFM Germany); St. Anna Kinderkrebsforschung (BFM Austria); Czech Ministry of Health (BFM Czech Republic) [00064203, 65269705]; Associazione Italiana Contro le Leucemie and Fondazione Citta della Speranza (AIEOP); Ministry of Health, Labor, and Welfare of Japan (JPLSG)","We thank all participating institutions and physicians for their support of the study. This EICNHL and i-BFM paper was written on behalf of the Berlin-Frankfurt-Munster (BFM) study group (Austria, Germany, Switzerland, Czech Republic), Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP), UK Children's Cancer and Leukemia study group (CCLG), Nordic Society of Pediatric Hematology and Oncology (NOPHO), Belgian Society of Pediatric Hematology and Oncology, Dutch Childhood Oncology Group (DCOG), Hungarian Pediatric Oncology Network, Japanese Pediatric Leukemia/Lymphoma study group (JPLSG), and Hong Kong Pediatric Hematology and Oncology study group (HKPHOSG). This work was supported by the Cancer Research UK, the Forschungshilfe Station Peiper (BFM Germany), the St. Anna Kinderkrebsforschung (BFM Austria), the Czech Ministry of Health supported projects for conceptual development of research organization 00064203 and 65269705 (BFM Czech Republic), the Associazione Italiana Contro le Leucemie and Fondazione Citta della Speranza (AIEOP), and the Ministry of Health, Labor, and Welfare of Japan (JPLSG).","Agrawal R, 2009, ARCH PATHOL LAB MED, V133, P142, DOI 10.1043/1543-2165-133.1.142; Burke GAA, 2003, BRIT J HAEMATOL, V121, P586; Anderson JR, 1998, ANN ONCOL, V9, P717, DOI 10.1023/A:1008265532487; Atra A, 1998, BRIT J HAEMATOL, V103, P220; Finn LS, 1999, CANCER, V85, P1626, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1626::AID-CNCR27>3.0.CO;2-0; Fujita N, 2011, LEUKEMIA LYMPHOMA, V52, P223, DOI 10.3109/10428194.2010.537794; Gerrard M, 2008, BRIT J HAEMATOL, V141, P840, DOI 10.1111/j.1365-2141.2008.07144.x; Goldman S, 2012, LEUKEMIA; Kansal R, 2002, AM J CLIN PATHOL, V117, P29; Kridel R, 2012, J CLIN INVEST, V122, P3424, DOI 10.1172/JCI63186; Kumar R, 2011, PEDIATR BLOOD CANCER, V57, P317, DOI 10.1002/pbc.23110; Lones MA, 2012, J PEDIAT HEMATOL ONC, V34, P68, DOI 10.1097/MPH.0b013e31820e4636; Lorsbach RB, 2002, BLOOD, V99, P1959, DOI 10.1182/blood.V99.6.1959; Louissaint A, 2012, BLOOD, V120, P2395, DOI 10.1182/blood-2012-05-429514; Marcus R, 2008, J CLIN ONCOL, V26, P4579, DOI 10.1200/JCO.2007.13.5376; Marcus R, 2005, BLOOD, V105, P1417, DOI 10.1182/blood-2004-08-3175; McNamara C, 2012, BRIT J HAEMATOL, V156, P446, DOI 10.1111/j.1365-2141.2011.08969.x; Meinhardt A, 2010, J CLIN ONCOL, V28, P3115, DOI 10.1200/JCO.2009.26.6791; MURPHY SB, 1980, SEMIN ONCOL, V7, P332; MURPHY SB, 1989, J CLIN ONCOL, V7, P186; Oschlies I, 2010, HAEMATOL-HEMATOL J, V95, P253, DOI 10.3324/haematol.2009.013177; Perkins SL, 2011, PEDIATR BLOOD CANCER, V57, P189, DOI 10.1002/pbc.23152; Pillon M, 2004, CANCER, V101, P385, DOI 10.1002/cncr.20382; PINTO A, 1990, MODERN PATHOL, V3, P308; Shankar A, 2012, EUR J CANCER, V48, P1700, DOI 10.1016/j.ejca.2011.10.018; Woessmann W, 2005, BLOOD, V105, P948, DOI 10.1182/blood-2004-03-0973",26,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0939-5555",null,null,"ANN HEMATOL","Ann. Hematol.","NOV",2013,92,11,null,null,null,null,1537,1541,null,"10.1007/s00277-013-1785-2",null,5,"Hematology","Hematology","230QQ","WOS:000325357600012"]
[null,null,null,null,"J","Ehler, E; Melekova, A; Latta, J; Mandysova, P; Vojtisek, P; Zamecnik, J",null,null,null,"Ehler, E.; Melekova, A.; Latta, J.; Mandysova, P.; Vojtisek, P.; Zamecnik, J.",null,null,"Inclusion Body Myositis with Neck Muscle Weakness and Positive Effect of Immunoglobulins - a Case Report","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Article",null,null,null,null,null,"inclusion body myositis; dysphagia; weakness; immunoglobulins","MYOPATHY","Inclusion body myositis is the most frequent inflammatory myopathy in patients aged 50 years and above. There is a chronic-progredient course of the disease without attacks and remissions. Typical clinical findings consist of proximal and distal weakness of extremity muscles and of axial muscles. Deep finger flexors of the upper extremities, quadriceps and muscles of the anterior compartment of the shin are severely affected. Dysphagia is a typical sign. Weakness of the neck muscles with a tilting head represents a rare and atypical form. We report a case of a 59-year old woman with progredient muscle weakness and atrophy with head tilting forward and dysphagia. Prednisone therapy was ineffective. After repeated intravenous administration of large immunoglobulin doses (60 g every four weeks), the posture of head a neck improved and dysphagia disappeared. One year into the treatment, immunoglobulin therapy is still highly effective.","[Ehler, E.; Melekova, A.; Latta, J.; Mandysova, P.] FZS Univ Pardubice, Pardubicke Krajske Nemocnice, Neurol Klin, AS, Pardubice 53203, Czech Republic; [Vojtisek, P.] FZS Univ Pardubice, Pardubicke Krajske Nemocnice, Interni Klin, AS, Pardubice 53203, Czech Republic; [Zamecnik, J.] LF UK FN Motole, Ustav Patol Mol Med 2, Prague, Czech Republic","Ehler, E (reprint author), FZS Univ Pardubice, Pardubicke Krajske Nemocnice, AS, Kyjevska 44, Pardubice 53203, Czech Republic.","eda.ehler@tiscali.cz",null,null,null,null,"Amato A, 2008, NEUROMUSCULAR DISORD; Ambler Z., 2004, NEUROL PRAX, V5, P150; Bednarik J, 2001, NEMOCI KOSTERNIHO SV; Bednarik J, 2010, CESK SLOV NEUROL N, V73, P570; Cox FM, 2011, BRAIN, V134, P3167, DOI 10.1093/brain/awr217; DeBleecker JL, 1996, J NEUROPATH EXP NEUR, V55, P563, DOI 10.1097/00005072-199605000-00009; Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718; Mahjneh I, 2002, J NEUROL, V249, P730, DOI 10.1007/s00415-002-0701-9; Needham M, 2007, LANCET NEUROL, V6, P620, DOI 10.1016/S1474-4422(07)70171-0; Oh SJ, 1998, CLIN ELECTROMYOGRAPH; Patwa HS, 2012, NEUROLOGY, V78, P1009, DOI 10.1212/WNL.0b013e31824de293; Pourmand R, 2009, FRONT NEUROL NEUROSC, V26, P120, DOI 10.1159/000212373; Solorzano GE, 2011, RHEUM DIS CLIN N AM, V37, P173, DOI 10.1016/j.rdc.2011.01.003",13,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859",null,null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,3,null,null,null,null,362,366,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","159AB","WOS:000320015300013"]
[null,null,null,null,"J","Brugada, J; Blom, N; Sarquella-Brugada, G; Blomstrom-Lundqvist, C; Deanfield, J; Janousek, J; Abrams, D; Bauersfeld, U; Brugada, R; Drago, F; de Groot, N; Happonen, JM; Hebe, J; Ho, SY; Marijon, E; Paul, T; Pfammatter, JP; Rosenthal, E",null,null,null,"Brugada, Josep; Blom, Nico; Sarquella-Brugada, Georgia; Blomstrom-Lundqvist, Carina; Deanfield, John; Janousek, Jan; Abrams, Dominic; Bauersfeld, Urs; Brugada, Ramon; Drago, Fabrizio; de Groot, Natasja; Happonen, Juha-Matti; Hebe, Joachim; Ho, Siew Yen; Marijon, Eloi; Paul, Thomas; Pfammatter, Jean-Pierre; Rosenthal, Eric",null,null,"Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement","EUROPACE",null,null,"English","Article",null,null,null,null,null,"Paediatrics; Arrhythmias; Antiarrhythmic drugs; Radiofrequency ablation; Electrical devices","CONGENITAL HEART-DISEASE; LONG-QT-SYNDROME; RADIOFREQUENCY CATHETER ABLATION; SUDDEN CARDIAC DEATH; IMPLANTABLE-CARDIOVERTER-DEFIBRILLATORS; POLYMORPHIC VENTRICULAR-TACHYCARDIA; JUNCTIONAL RECIPROCATING TACHYCARDIA; PARKINSON-WHITE-SYNDROME; INTRAATRIAL REENTRANT TACHYCARDIA; TERM-FOLLOW-UP","As a general rule, prescription of antiarrhythmic drugs requires a clear diagnosis with electrocardiographic documentation of a given arrhythmia. Riskbenefit analysis of drug therapy should be considered when facing an arrhythmia in a child.Prophylactic antiarrhythmic drug therapy is given only to protect the child from recurrent supraventricular tachycardia during this time span until the disease will eventually cease spontaneously.In the last decades, radiofrequency catheter ablation is progressively used as curative therapy for tachyarrhythmias in children and patients with or without CHD. Even in young children, procedures can be performed with high success rates and low complication rates as shown by several retrospective and prospective paediatric multi-centre studies. Three-dimensional mapping and non-fluoroscopic navigation techniques and enhanced catheter technology have further improved safety and efficacy even in CHD patients with complex arrhythmias. During last decades, cardiac devices (pacemakers and implantable cardiac defibrillator) have developed rapidly. The pacing generator size has diminished and the pacing leads have become progressively thinner. These developments have made application of cardiac pacing in children easier although no dedicated paediatric pacing systems exist.","[Brugada, Josep] Univ Barcelona, Dept Cardiol, Paediat Arrhythmia Unit, Hosp St Joan Deu Hosp Clin, E-08036 Barcelona, Spain; [Blom, Nico] Leiden Univ, Med Ctr, Dept Pediat Cardiol, NL-2300 RC Amsterdam, Netherlands; [Blom, Nico] Acad Med Ctr, NL-2300 RC Amsterdam, Netherlands; [Sarquella-Brugada, Georgia] Univ Barcelona, Hosp St Joan Deu, Dept Cardiol, Paediat Arrhythmia Unit, Barcelona 08950, Spain; [Blomstrom-Lundqvist, Carina] Uppsala Univ, Dept Cardiol, S-75236 Uppsala, Sweden; [Deanfield, John] Great Ormond St Hosp Sick Children, Cardiothorac Unit, London WC1N 3JH, England; [Janousek, Jan] Univ Hosp Motol, Childrens Heart Ctr, Prague 15006, Czech Republic; [Abrams, Dominic] Childrens Hosp, Dept Cardiol, Cardiac Elect Div, Boston, MA 02115 USA; [Bauersfeld, Urs] Kinderspital Zurich, Fak Med, CH-8032 Zurich, Switzerland; [Brugada, Ramon] Inst Invest Biomed Girona IdIBGi, Cardiovasc Genet Ctr, Girona 17003, Spain; [Drago, Fabrizio] Bambino Gesu Pediat Hosp & Res Inst, Pediat Cardiol & Heart Surg Dept, Arrhythmia Unit, I-00055 Palidoro, Fiumicino, Italy; [de Groot, Natasja] Erasmus MC, Dept Cardiol, NL-3015 GD Rotterdam, Netherlands; [Happonen, Juha-Matti] Univ Helsinki, Childrens Hosp, Dept Pediat Cardiol, FIN-00290 Helsinki, Finland; [Happonen, Juha-Matti] Univ Helsinki, Cent Hosp, FIN-00290 Helsinki, Finland; [Hebe, Joachim] Ctr Elect, D-28277 Bremen, Germany; [Ho, Siew Yen] Royal Brompton Hosp, Cardiac Morphol Unit, London SW3 6NP, England; [Ho, Siew Yen] Imperial Coll London, London SW3 6NP, England; [Marijon, Eloi] Hop Europeen Georges Pompidou, INSERM, U970, Paris Cardiovasc Res Ctr, F-75908 Paris, France; [Paul, Thomas] Univ Gottingen, Childrens Univ Hosp, Dept Pediat Cardiol & Intens Care Med, D-37073 Gottingen, Germany; [Pfammatter, Jean-Pierre] Univ Bern, CH-3010 Bern, Switzerland; [Rosenthal, Eric] Guys & St Thomas Hosp, Evelina Childrens Hosp, London SE1 7EH, England","Brugada, J (reprint author), Univ Barcelona, Dept Cardiol, Paediat Arrhythmia Unit, Hosp St Joan Deu Hosp Clin, E-08036 Barcelona, Spain.","Jbrugada@clinic.ub.es","Rosenthal, Eric/I-7469-2012","Rosenthal, Eric/0000-0003-3030-9749",null,null,null,340,3,3,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","1099-5129",null,null,"EUROPACE","Europace","SEP",2013,15,9,null,null,null,null,1337,1382,null,"10.1093/europace/eut082",null,46,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","211XL","WOS:000323945100023"]
[null,null,null,null,"J","Profant, O; Balogova, Z; Dezortova, M; Wagnerova, D; Hajek, M; Syka, J",null,null,null,"Profant, Oliver; Balogova, Zuzana; Dezortova, Monika; Wagnerova, Dita; Hajek, Milan; Syka, Josef",null,null,"Metabolic changes in the auditory cortex in presbycusis demonstrated by MR spectroscopy","EXPERIMENTAL GERONTOLOGY",null,null,"English","Article",null,null,null,null,null,"Presbycusis; Auditory cortex; MR spectroscopy; Glutamate; N-acetylaspartate; Lactate; GABA","MAGNETIC-RESONANCE-SPECTROSCOPY; AGE-RELATED LOSS; HEARING-LOSS; HUMAN BRAIN; COCHLEAR NUCLEUS; WHITE-MATTER; INFERIOR COLLICULUS; SPEECH-PERCEPTION; GLUTAMATE; GABA","In humans, aging is accompanied by the deterioration of the hearing function - presbycusis. The major etiology for presbycusis is the loss of hair cells in the inner ear; less well known are changes in the central auditory system. Therefore, we used 1 H magnetic resonance spectroscopy at 3 T tomograph to examine metabolite levels in the auditory cortex of three groups of subjects: young healthy subjects less than 30 years old and subjects older than 65 years either with mild presbycusis corresponding to their age or with expressed presbycusis. Hearing function in all subjects was examined by pure tone audiometry (125-16000 Hz). Significant differences were found in the concentrations of glutamate and N-acetylaspartate, with lower levels in aged subjects. Lactate was particularly increased in subjects with expressed presbycusis. Significant differences were not found in other metabolites, including GABA, between young and elderly subjects. The results demonstrate that the age-related changes of the inner ear are accompanied by a decrease in the excitatory neurotransmitter glutamate as well as a lactate increase in the auditory cortex that is more expressed in elderly subjects with large hearing threshold shifts. (C) 2013 Elsevier Inc. All rights reserved.","[Profant, Oliver; Balogova, Zuzana; Syka, Josef] Acad Sci Czech Republic, Inst Expt Med, Dept Auditory Neurosci, Prague, Czech Republic; [Dezortova, Monika; Wagnerova, Dita; Hajek, Milan] Inst Clin & Expt Med, Dept Diagnost & Intervent Radiol, MR Unit, Prague, Czech Republic; [Profant, Oliver; Balogova, Zuzana] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Prague 15006 5, Czech Republic","Profant, O (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept ENT, V Uvalu 84, Prague 15006 5, Czech Republic.","profant@biomed.cas.cz",null,null,"GACR [P304/10/1872]","This research was supported by the grant GACR P304/10/1872 and the Institutional Support 00023001IKEM of the Ministry of Health of the Czech Republic.",null,54,2,2,"PERGAMON-ELSEVIER SCIENCE LTD","OXFORD","THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND","0531-5565",null,null,"EXP GERONTOL","Exp. Gerontol.","AUG",2013,48,8,null,null,null,null,795,800,null,"10.1016/j.exger.2013.04.012",null,6,"Geriatrics & Gerontology","Geriatrics & Gerontology","181WI","WOS:000321700300014"]
[null,null,null,null,"J","Klozar, J; Koslabova, E; Kratochvil, V; Salakova, M; Tachezy, R",null,null,null,"Klozar, Jan; Koslabova, Eva; Kratochvil, Vit; Salakova, Martina; Tachezy, Ruth",null,null,"Nodal status is not a prognostic factor in patients with HPV-positive oral/oropharyngeal tumors","JOURNAL OF SURGICAL ONCOLOGY",null,null,"English","Article",null,null,null,null,null,"N classification; prognosis; failure rate; HPV","SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS INFECTION; OROPHARYNGEAL CANCER; RISK-FACTORS; ORAL-CANCER; TONSILLAR CARCINOMAS; FIELD CANCERIZATION; NECK-CANCER; HEAD; SURVIVAL","Objectives The primary aim is to compare the prognostic parameters in patients with HPV-positive and HPV-negative tumors. The secondary aim is to compare the patterns of treatment failure between these groups. Methods Analysis of prognostic factors in a group of 170 patients. Results High-risk HPV DNA was detected in 98 cases, 72 tumors were HPV negative. Both the overall and disease-specific survival rates were better in HPV-positive patients. In patients with HPV-negative tumors, the prognostic factors in univariate analysis were pT and pN classification, tumor stage, number of positive nodes, and extracapsular spread. Stage, pT, higher pN, and number of nodes maintained statistical significance after adjustment. None of the studied prognostic factors was significant in the group of patients with HPV-positive tumors. There was a significant difference in the localregional recurrence rates37% in HPV-negative cases and 18% in HPV-positive cases. Conclusion The characteristics of the extent of the disease in general and of regional lymph node metastasis in particular are probably much less important in the prediction of the outcome of HPV-positive than of HPV-negative tumors. Improved survival of patients with HPV-positive tumors is due mostly to the difference in the localregional failure rates. J. Surg. Oncol. 2013;107:625633. (c) 2012 Wiley Periodicals, Inc.","[Klozar, Jan; Koslabova, Eva; Kratochvil, Vit] Charles Univ Prague, Dept Otolaryngol Head & Neck Surg, Fac Med 1, Prague 15006 5, Czech Republic; [Koslabova, Eva; Salakova, Martina; Tachezy, Ruth] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague, Czech Republic","Klozar, J (reprint author), Charles Univ Prague, Dept Otolaryngol Head & Neck Surg, Fac Med 1, Univ Hosp Motol, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.klozar@lfmotol.cuni.cz",null,null,"Granting Agency, Ministry of Health, Czech Republic [NT/12483]","Grant sponsor: Granting Agency, Ministry of Health, Czech Republic; Grant number: NT/12483.",null,39,2,2,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0022-4790",null,null,"J SURG ONCOL","J. Surg. Oncol.","MAY",2013,107,6,null,null,null,null,625,633,null,"10.1002/jso.23292",null,9,"Oncology; Surgery","Oncology; Surgery","130SL","WOS:000317939400013"]
[null,null,null,null,"J","Plzak, J; Zabrodsky, M; Kastner, J; Betka, J; Klozar, J",null,null,null,"Plzak, Jan; Zabrodsky, Michal; Kastner, Jan; Betka, Jaroslav; Klozar, Jan",null,null,"Combined bipolar radiofrequency surgery of the tongue base and uvulopalatopharyngoplasty for obstructive sleep apnea","ARCHIVES OF MEDICAL SCIENCE",null,null,"English","Article",null,null,null,null,null,"radiofrequency; obstructive sleep apnea; uvulopalatopharyngoplasty","APNEA/HYPOPNEA SYNDROME; REDUCTION; ABLATION; PALATE","Introduction: The aim of the study was to investigate the effectiveness of combined bipolar radiofrequency surgery of the tongue base (RFBT) and uvulopalatopharyngoplasty (UPPP) in a single session for obstructive sleep apnea and whether this combination is safe and well tolerated. Material and methods: Seventy-nine patients with obstructive sleep apnea and both palatal and retroglossal obstruction underwent UPPP with bipolar RFBT. The control group consisted of 35 patients treated by UPPP alone. Results: The apnea-hypopnea index significantly decreased from 28.7 to 14.1. The oxygen desaturation index decreased from 15.1 to 10.3. Mean oxygen saturation was unchanged. Subjectively, the Epworth Sleepiness Scale was significantly improved from 10.6 to 7.3, and the snoring level decreased from 8.4 to 6.0. The overall treatment success rate increased from 41.9% for UPPP alone to 51.7% for UPPP + RFBT. No serious adverse events occurred. Two patients had postoperative bleeding from the tonsillar bed after UPPR Four patients had ulceration of the base of the tongue after RFBT with spontaneous cure. One patient had a taste change in half of the tongue that resolved within two months. Conclusions: Combined bipolar RFBT and UPPP in a single session is well tolerated and safe surgery in the treatment of obstructive sleep apnea. It is effective in reducing respiratory parameters and subjective symptoms of obstructive sleep apnea. Further advantages are a single session, simple feasibility, bipolar technique and short time of the procedure.","[Plzak, Jan; Zabrodsky, Michal; Kastner, Jan; Betka, Jaroslav; Klozar, Jan] Charles Univ Prague, Fac Hosp Motol, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Prague 15006 5, Czech Republic; [Plzak, Jan] Charles Univ Prague, Fac Med 1, Inst Anat, Prague 15006 5, Czech Republic","Plzak, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.plzak@lf1.cuni.cz",null,null,"Internal Grant Agency of MZCR [NT 13488, PRVOUK 27-1, SVV 266 513]","This work was supported by the Internal Grant Agency of MZCR NT 13488, PRVOUK 27-1 and SVV 266 513.",null,16,1,1,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922","1896-9151",null,"ARCH MED SCI","Arch. Med. Sci.","DEC",2013,9,6,null,null,null,null,1097,1101,null,"10.5114/aoms.2013.39226",null,5,"Medicine, General & Internal","General & Internal Medicine","290OO","WOS:000329768400020"]
[null,null,null,null,"J","Matouskova, O; Slanar, O; Adamkova, J; Pafko, P; Perlik, F; Adamek, S",null,null,null,"Matouskova, O.; Slanar, O.; Adamkova, J.; Pafko, P.; Perlik, F.; Adamek, S.",null,null,"Impact of MDR1 genetic polymorphisms on postoperative piritramide analgesia","BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY",null,null,"English","Article",null,null,null,null,null,"analgesia; piritramide; postoperative pain; adverse effects; polymorphism of MDR1","EXPRESSION; PAIN","Objectives: The aim of prospective study was to evaluate the therapeutic efficacy of piritramide in patients after removal of parathyroid glands in relation to MDR1 genotype. In the treatment of moderate acute postoperative pain, piritramide plays a major role. It is difficult to predict its optimal therapeutic efficacy and tolerability in individual patients. Methods: We compared the effect of piritramide in 56 patients after surgical removal of parathyroid glands in a prospective study. We evaluated pain intensity, pain difference and sum of pain difference (SPID) using visual analogue scale (VAS in mm) and adverse effects in the relationship with the MDR1 - polymorphism of G2677T/A. Results: In the wild-type group (2677GG), there was maximal pain difference of 30.6 +/- 24.9 and SPID of 209.33 +/- 95.80 while in genotype 2677TT and 2677GT, the corresponding values were 19.5 +/- 25.5 and 147.07 +/- 91.38, respectively. In group of patients with wild type of 2677GG genotype, there was 80 % of responders with more than 50 % reduction in VAS as compared to baseline while in group with carriers of 2677T allele, there are only 39 % of responders present (chi(2) = 5. 83; p = 0.016). Furthermore, the total consumption of piritramide was lower in comparison with the variant-allele carrying group (p = 0.008). The total incidence of adverse drug reactions was observed in 40 % of patients with wild type of 2677GG genotype when compared to 83% in the group carrying the variant allele (chi(2) = 7.92; p = 0.005). Significantly more patients in the wild-type group were satisfied with postoperative pain treatment in comparison to the variant allele group (chi(2) = 6. 49; p = 0.0109). Conclusion: We observed a better analgesic effect of piritramide and a decreased incidence of side effects in the wild-type genotype (2677GG) group, when compared with variant-allele carrying patients (Tab. 2, Fig. 1, Ref. 7). Full Text in PDF www.elis.sk.","[Matouskova, O.; Slanar, O.; Perlik, F.] Charles Univ Prague, Gen Teaching Hosp, Fac Med 1, Inst Pharmacol, Prague, Czech Republic; [Adamkova, J.; Pafko, P.; Adamek, S.] Charles Univ Prague, Univ Hosp Motol, Fac Med 1, Dept Surg 3, Prague, Czech Republic","Adamek, S (reprint author), 1st LF UK & FN Motol, Clin Surg 3, V Uvalu 84, CZ-15006 Prague 5, Motol, Czech Republic.","sadamek@post.cz",null,null," [VZ MSM 0021620849];  [VZ MSM 0021620820]","Supported in part by grants No. VZ MSM 0021620849 and VZ MSM 0021620820.",null,7,0,1,"COMENIUS UNIV","BRATISLAVA I","SCH MEDICINE, SPITALSKA 24, BRATISLAVA I, SK-813 72, SLOVAKIA","0006-9248",null,null,"BRATISL MED J","Bratisl. Med. J.",null,2013,114,3,null,null,null,null,133,135,null,"10.4149/BLL_2013_029",null,3,"Medicine, General & Internal","General & Internal Medicine","101EP","WOS:000315758300006"]
[null,null,null,null,"J","Kotlabova, K; Doucha, J; Chudoba, D; Calda, P; Dlouha, K; Hromadnikova, I",null,null,null,"Kotlabova, Katerina; Doucha, Jindrich; Chudoba, Daniel; Calda, Pavel; Dlouha, Klara; Hromadnikova, Ilona",null,null,"Extracellular chromosome 21-derived microRNAs in euploid & aneuploid pregnancies","INDIAN JOURNAL OF MEDICAL RESEARCH",null,null,"English","Article",null,null,null,null,null,"Aneuploidy; chromosome 21; Down syndrome; maternal plasma; microRNAs; real-time PCR; screening","MATERNAL SERUM MARKER; DOWN-SYNDROME; PLASMA; 1ST-TRIMESTER; TRISOMY-21; IDENTIFICATION; CIRCULATION; DIAGNOSIS; PROTEINS; MIRNAS","Background & objectives: Trisomy 21 is the most common chromosomal aneuploidy in live born infants. Recently, the over expression of chromosome 21-derived microRNAs (miR-99a, let-7c, miR-125b-2, miR-155 and miR-802) in human fetal hippocampus and heart samples from individuals with Down syndrome was observed. Therefore, concentrations and expression profile of extracellular chromosome 21-derived microRNAs were studied to verify their ability to distinguish noninvasively between pregnancies bearing euploid fetuses and those affected with Down syndrome. Methods: RNA enriched for small RNAs was isolated from plasma samples of 12 pregnant women with high risk of bearing Down syndrome foetuses (median gestation 18.5 wk), 12 women with normal course of gestation and 10 non-pregnant women. MicroRNA transcribed into cDNA using specific stem-loop primer was detected using real-time PCR assay. Simulation experiments using RNA pools of healthy non-pregnant individuals and aneuploid amniotic fluid samples in descending dilution ratio ranging from 1:1 to 1000:1 were used to test the detection limit of the technique for overexpressed chromosome 21-derived microRNAs specific for Down syndrome. The expression profile of the gene encoding microRNA was studied through the relative gene expression using the comparative Ct (threshold cycle) method. Concentrations of individual microRNAs were subtracted from the calibration curves in the course of analyses and expressed as pg of total RNA per milliliter of plasma. Results: Four of the five extracellular chromosome 21-derived microRNAs (miR-99a, let-7c, miR-125b-2 and miR-155) were reliably detected in plasma samples. Simulation experiments revealed the detection limit of aneuploidy at a ratio 100:1 for let-7c, miR-125b-2 and miR-155, and a ratio of 1000:1 for miR-99a. Overexpression of extracellular miR-99a, miR-125b-2 and miR-155 was observed in pregnant women compared to non-pregnant women. Similarly, increased concentrations of extracellular miR-99a and miR-125b-2 were detected in pregnant women than in non-pregnant women. The concentrations and relative gene expression of extracellular chromosome 21-derived microRNAs did not differ between the cohorts of pregnancies bearing euploid foetuses and those affected with Down syndrome. Interpretation & conclusions: Analysis of extracellular chromosome 21-derived microRNAs has no benefit for screening programmes and non-invasive diagnosis of Down syndrome.","[Kotlabova, Katerina; Hromadnikova, Ilona] Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Prague 10000 10, Czech Republic; [Doucha, Jindrich] Univ Hosp Motol, Clin Obstet & Gynaecol, Prague, Czech Republic; [Chudoba, Daniel] Univ Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Calda, Pavel] Charles Univ Prague, Gen Univ Hosp, Fac Med 1, Clin Obstet & Gynaecol, Prague, Czech Republic; [Dlouha, Klara] Inst Care Mother & Child, Prague, Czech Republic","Hromadnikova, I (reprint author), Charles Univ Prague, Fac Med 3, Dept Mol Biol & Cell Pathol, Ruska 87, Prague 10000 10, Czech Republic.","ilona.hromadnikova@lf3.cuni.cz",null,null,"GAUK (Grant Agency of Charles University, Czech Republic) [434011]; PRVOUK (Program for Progress of Scientific Fields on Charles University, Czech Republic) [P32]","This work was supported by GAUK (Grant Agency of Charles University, Czech Republic) no. 434011 and PRVOUK (Program for Progress of Scientific Fields on Charles University, Czech Republic) P32.",null,31,0,0,"INDIAN COUNCIL MEDICAL RES","NEW DELHI","PO BOX 4911 ANSARI NAGAR, NEW DELHI 110029, INDIA","0971-5916",null,null,"INDIAN J MED RES","Indian J. Med. Res.","DEC",2013,138,null,null,null,null,null,935,943,null,null,null,9,"Immunology; Medicine, General & Internal; Medicine, Research & Experimental","Immunology; General & Internal Medicine; Research & Experimental Medicine","AA1TV","WOS:000330879500022"]
[null,null,null,null,"J","Popelka, S; Vavrik, P; Landor, I; Bek, J; Popelka, S; Hromadka, R",null,null,null,"Popelka, S.; Vavrik, P.; Landor, I.; Bek, J.; Popelka, S.; Hromadka, R.",null,null,"Tibio-Talo-Calcaneal Arthrodesis with the Retrograde Intramedullary Nail MEDIN","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"retrograde nail; tibio-talo-calcaneal arthrodesis; rheumatoid arthritis; joint deviation; failed total ankle arthroplasty","TOTAL ANKLE REPLACEMENT; TIBIOTALOCALCANEAL ARTHRODESIS; MANAGEMENT; FRACTURES; SALVAGE; FUSION; PLATE","PURPOSE OF THE STUDY When the talus and the talocalcaneal joint are both affected, their fusion is the method of treatment. Ankle arthrodesis is carried out using various osteosynthetic materials such as external fixators, screws and plates. One of the options is retrograde nailing. Tibio-talo-calcaneal arthrodesis is frequently indicated in patients with rheumatoid arthritis (RA) in whom both the talus and the subtalar joint are often affected. MATERIAL AND METHODS A retrograde nail for tibio-talo-calcaneal arthrodesis was developed at our department in cooperation with MEDIN Company. This is a titanium double-curved nail, with the distal part bent at 8 degrees ventrally and 10 degrees laterally. It is inserted from the transfibular approach. RESULTS Sixty-two patients, 35 women and 27 men, were treated at our department from 2005. Since one patient had bilateral surgery, 63 ankles were included. The indications for arthrodesis involved rheumatoid arthritis in 42, post-traumatic arthritis in 10, failed ankle arthrodesis in two and failed total ankle arthroplasty in five ankles; tibial stress fractures close above the ankle in two RA patients, one patient with dermatomyositis and one with lupus erythematodes. The average age at the time of surgery was 64.2 years (range, 30 to 80). The average follow-up was 4.5 years (range, 1 to 9 years), Satisfaction with the treatment outcome and willingness to undergo surgery on the other side were reported by 82% of the patients. The AOFAS score improved from 35 to 74 points. Three (4.8 %) patients complained of painful feet due to the fact that exact correction of the calcaneus was not achieved and the heel after arthrodesis remained in a slightly varus position. Of them, two had a failed total ankle arthroplasty. Post-operative complications included early infection managed by antibiotic treatment and early surgical revision with irrigation.in two (3.2%) RA patients, who were undergoing biological therapy. Late infection developed at 2 to 3 years after surgery in three (4.3%) patients (two had RA). The infection was managed by revision surgery with nail removal and irrigation. All patients healed well. Necrosis of the talus and development of a pseudoarthrosis were recorded in four (6.4%) patients, who subsequently underwent nail removal and repeat fusion using an external fixator. DISCUSSION Retrograde nailing for tibio-talo-calcaneal arthrodesis is used by many authors. Its complication rate is comparable with the other methods of arthrodesis. CONCLUSIONS The use of tibio-talo-calcaneal arthrodesis aims at a painless and stable joint. Arthrodesis of the talus and the subtalar joint using a retrograde nail is an effective surgical treatment of the joints affected. It is especially recommended for RA patients who have severe deviations. Retrograde nailing provides a stable osteosynthesis which does not require plaster cast immobilisation. The double-curved nail allows for its insertion in the solid part of the calcaneus and helps avoiding injury to the neurovascular bundle.","[Popelka, S.; Vavrik, P.; Landor, I.; Bek, J.; Popelka, S.; Hromadka, R.] LF UK & FN Motol, I Ortopedicka Klin 1, Prague 15200 5, Czech Republic; [Hromadka, R.] LF UK Praha, Anatom Ustav 1, Prague, Czech Republic","Popelka, S (reprint author), LF UK & FN Motol, I Ortopedicka Klin 1, V Uvalu 84, Prague 15200 5, Czech Republic.","mudr.popelka@volny.cz",null,null,null,null,null,30,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","DEC",2013,80,6,null,null,null,null,400,406,null,null,null,7,"Orthopedics","Orthopedics","287NQ","WOS:000329549900006"]
[null,null,null,null,"J","Vida, VL; Torregrossa, G; De Franceschi, M; Padalino, MA; Belli, E; Berggren, H; Cicek, S; Ebels, T; Fragata, J; Hoel, TN; Horer, J; Hraska, V; Kostolny, M; Lindberg, H; Mueller, C; Pretre, R; Rosser, B; Rubay, J; Schreiber, C; Speggiorin, S; Tlaskal, T; Stellin, G",null,null,null,"Vida, Vladimiro L.; Torregrossa, Gianluca; De Franceschi, Marco; Padalino, Massimo A.; Belli, Emre; Berggren, Hakan; Cicek, Sertac; Ebels, Tjark; Fragata, Jose; Hoel, Tom N.; Horer, Jurgen; Hraska, Viktor; Kostolny, Martin; Lindberg, Harald; Mueller, Christoph; Pretre, Rene; Rosser, Barbara; Rubay, Jean; Schreiber, Christian; Speggiorin, Simone; Tlaskal, Tomas; Stellin, Giovanni",null,"ECHSA","Pediatric Coronary Artery Revascularization: A European Multicenter Study","ANNALS OF THORACIC SURGERY",null,null,"English","Article",null,null,null,null,null,null,"SWITCH OPERATION; GREAT-ARTERIES; SURGICAL-TREATMENT; BYPASS; TRANSPOSITION; CHILDREN; ANTICOAGULATION; ANOMALIES; KAWASAKI; DISEASE","Background. We sought to evaluate the hospital and midterm results of different surgical revascularization techniques in pediatric patients within the European Congenital Heart Surgeons Association. Methods. From 1973 to 2011, 80 patients from 13 European Congenital Heart Surgeons Association centers underwent 65 pediatric coronary artery bypass grafting (PCABG) and 27 other coronary artery procedures (OCAP; 12 patients had combined PCABG and other coronary artery procedures). Excluded were patients with Kawasaki disease. Median age at the time of coronary procedure was 2.3 years (range, 2 days to 16.9 years); 33 patients (41.2%) were younger then 12 months. An emergency procedure was necessary in 34 patients (42.5%). Results. Twelve patients (15%) died in the hospital; age at surgery (p = 0.02) and the need for an emergent procedure (p = 0.0004) were related to hospital mortality. Median follow-up time was 7.6 years (range, 0.9 to 23 years). There were 3 late cardiac deaths, all after a median time of 4 years (range, 9 months to 8.8 years) after PCABG. Fourteen patients (20.5%) presented with symptoms, including congestive heart failure (n = 10) and angina (n = 4), that were significantly associated with a low ejection fraction (p < 0.001) and the presence of moderate or severe mitral valve regurgitation (p = 0.0003). Six patients underwent a reintervention for impaired myocardial perfusion; all of them had a stenotic or atretic PCABG (p= 0.001), and the majority were symptomatic (5 of 6 patients; 83.3%; p = 0.001). Conclusions. Both PCABG and other coronary artery procedures are suitable surgical options in pediatric patients with impaired myocardial perfusion, which increases operative and midterm survival. Such population of patients needs to be followed for life to prevent and treat any possible cause of further myocardial ischemia. (C) 2013 by The Society of Thoracic Surgeons","Univ Padua, Pediat & Congenital Cardiac Surg Unit, I-35100 Padua, Italy; Univ Padua, Dept Thorac Cardiac & Vasc Sci, I-35100 Padua, Italy; Hosp Santa Marta, Sev Cirurgia Cardiotorac, Unidade Cardiaca Pediat, Lisbon, Portugal; Marie Lannelongue Hosp, Le Plessis Robinson, France; Queen Silvia Childrens Hosp, Childrens Heart Ctr, Gothenburg, Sweden; Anadolu Med Canter, Istanbul, Turkey; Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands; Univ Hosp, Riskshosp, Oslo, Norway; German Heart Canter Munich Clin Cardiovasc Surg, Munich, Germany; Asklepios Clin Sankt Augustin, German Pediat Heart Ctr, St Augustin, Germany; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; Univ Childrens Hosp, Zurich, Switzerland; Catholic Univ Louvain, Serv Chirurg Cardiovasc & Thorac, B-1200 Brussels, Belgium; Univ Hosp Motol, Childrens Heart Ctr, Prague, Czech Republic","Stellin, G (reprint author), Univ Padua, Pediat & Congenital Cardiac Surg Unit, Dept Thorac Cardiac & Vasc Sci, Via Giustiniani 2, I-35100 Padua, Italy.","giovanni.stellin@unipd.it",null,null,null,null,null,26,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0003-4975",null,null,"ANN THORAC SURG","Ann. Thorac. Surg.","SEP",2013,96,3,null,null,null,null,898,903,null,"10.1016/j.athoracsur.2013.05.006",null,6,"Cardiac & Cardiovascular Systems; Respiratory System; Surgery","Cardiovascular System & Cardiology; Respiratory System; Surgery","211VT","WOS:000323940200032"]
[null,null,null,null,"J","Betka, J; Hovorka, O; Boucek, J; Ulbrich, K; Etrych, T; Rihova, B",null,null,null,"Betka, Jaroslav; Hovorka, Ondrej; Boucek, Jan; Ulbrich, Karel; Etrych, Tomas; Rihova, Blanka",null,null,"Fine needle aspiration biopsy proves increased T-lymphocyte proliferation in tumor and decreased metastatic infiltration after treatment with doxorubicin bound to PHPMA copolymer carrier","JOURNAL OF DRUG TARGETING",null,null,"English","Article",null,null,null,null,null,"Doxorubicin conjugates; drug targeting; fine needle aspiration biopsy; metastatic spread; tumor microenvironment","CELL-DEATH; PHYSICOCHEMICAL CHARACTERIZATION; DRUG-DELIVERY; IMMUNOGENICITY; MICE; CHEMOTHERAPY; CARCINOMA; POLYMERS; IMMUNITY; THERAPY","Introduction: Fine needle aspiration biopsy (FNAB) is an easy method with an option of repetitive withdrawal of cell material. Methods: First, mice were inoculated with mouse T-lymphoma, after 10 d the samples from tumor, lymph nodes and spleen gained by FNAB and excision were analyzed by flow cytometry. Tumor progression was compared to the control group simultaneously. Then, 10 d after tumor cell inoculation free doxorubicin (DOX) or different PHPMA DOX conjugates were injected. Cell material was analyzed to detect subpopulations of lymphocyte infiltrate, and levels of cytokines in correlation with progression or regression of the disease. Results: FNAB has no influence on the tumor's growth or survival of experimental animals. After treatment with PHPMA conjugates there was a significant increase of T-lymphocyte subpopulations in tumor microenvironment compared to controls or free DOX, but only in mice with confirmed macroscopic regression of tumor within two weeks. Mice treated with conjugates showed significantly lower cancer infiltration of lymph nodes and spleen. Conclusion: FNAB provides a great benefit to in vivo monitoring of cell changes directly in the tumor after treatment. The number of infiltrating T-lymphocytes increases in correlation with consecutive tumor eradication after treatment with PHPMA. This proves that not only direct cytotoxic but also imunostimulating effect are necessary for successful treatment.","[Betka, Jaroslav; Hovorka, Ondrej; Boucek, Jan; Rihova, Blanka] ASCR, Inst Microbiol, Dept Immunol & Gnotobiol, Prague 14220 4, Czech Republic; [Betka, Jaroslav; Boucek, Jan] Charles Univ Prague, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg, Prague, Czech Republic; [Betka, Jaroslav; Boucek, Jan] Fac Hosp Motol, Prague, Czech Republic; [Ulbrich, Karel; Etrych, Tomas] ASCR, Inst Macromol Chem, Prague 14220 4, Czech Republic","Betka, J (reprint author), ASCR, Inst Microbiol, Dept Immunol & Gnotobiol, Vvi, Videnska 1083, Prague 14220 4, Czech Republic.","jara.betka@gmail.com",null,null,"Czech Science Foundation [P301/12/1254]","Grant of Czech Science Foundation P301/12/1254 is kindly acknowledged.",null,33,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","1061-186X",null,null,"J DRUG TARGET","J. Drug Target.","AUG",2013,21,7,null,null,null,null,648,661,null,"10.3109/1061186X.2013.792345",null,14,"Pharmacology & Pharmacy","Pharmacology & Pharmacy","186UD","WOS:000322070200004"]
[null,null,null,null,"J","Wagner, R; Razek, V; Grafe, F; Berlage, T; Janousek, J; Daehnert, I; Weidenbach, M",null,null,null,"Wagner, Robert; Razek, Vit; Graefe, Florentine; Berlage, Thomas; Janousek, Jan; Daehnert, Ingo; Weidenbach, Michael",null,null,"Effectiveness of Simulator-Based Echocardiography Training of Noncardiologists in Congenital Heart Diseases","ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES",null,null,"English","Article",null,null,null,null,null,"congenital heart defects; echocardiography; computer simulation; medical education; three-dimensional imaging","TARGETED NEONATAL ECHOCARDIOGRAPHY; UNIT PRACTICE GUIDELINES; TRANSTHORACIC ECHOCARDIOGRAPHY; MEDICAL-EDUCATION; REALITY SIMULATOR; RECOMMENDATIONS; ULTRASOUND; ANESTHESIOLOGISTS; PERFORMANCE; TECHNOLOGY","Background: Congenital heart diseases (CHD) are responsible for substantial morbidity and mortality in neonates. The preliminary diagnosis often is made by noncardiologists. For this reason, there is a huge demand of training in echocardiography of CHD. This is difficult to achieve due to limited resources of specialized centers. Objective: The goal of this study was to investigate the training effect of the echocardiography simulator EchoCom on trainee's ability to diagnose CHD. Design/Methods: We enrolled 10 residents for simulator-based training in echocardiography of CHD. All participants were instructed on the simulator's basic handling and had one hour to scan the first 9 datasets information (ventricular septal defect, atrial septal defect, atrioventricular septal defect, Tetralogy of Fallot, transposition of great arteries, congenital corrected transposition of great arteries, common arterial trunk, hypoplastic left heart syndrome, normal anatomy) and establish a diagnosis. No help was given except for support regarding simulator related issues. Afterward, 2 rounds of structured simulator based echocardiography training focused on echocardiographic anatomy, spatial orientation, standard views, and echocardiographic anatomy of different CHD followed. All participants completed a standardized questionnaire containing 10 multiple-choice (MC) questions focusing on basic theoretical knowledge in echocardiographic anatomy and common CHD. Results: Almost all of the residents invited from the affiliated children's hospital had little (20%) or no experience (80%) in echocardiography of CHD. Their Pretest and Posttest scores showed significant improvement for both, MC test and performance test, respectively. Conclusions: Our study showed that simulator-based training in echocardiography in CHD could be very effective and may assist with training outside the scope of CHD.","[Wagner, Robert; Graefe, Florentine; Daehnert, Ingo; Weidenbach, Michael] Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, D-04289 Leipzig, Germany; [Razek, Vit; Janousek, Jan] Univ Hosp Motol, Kardioctr, Prague, Czech Republic; [Razek, Vit; Janousek, Jan] Univ Hosp Motol, Cardiovasc Res Ctr, Prague, Czech Republic; [Berlage, Thomas] Fraunhofer Inst Appl Informat Technol, St Augustin, Germany","Wagner, R (reprint author), Univ Leipzig, Ctr Heart, Dept Paediat Cardiol, Strumpellstr 39, D-04289 Leipzig, Germany.","robert.wagner@med.uni-leipzig.de",null,null,null,null,null,29,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0742-2822",null,null,"ECHOCARDIOGR-J CARD","Echocardiography-J. Cardiovasc. Ultrasound Allied Tech.","JUL",2013,30,6,null,null,null,null,693,698,null,"10.1111/echo.12118",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","198UQ","WOS:000322948200021"]
[null,null,null,null,"J","Sterclova, M; Matej, R; Mandakova, P; Skibova, J; Vasakova, M",null,null,null,"Sterclova, Martina; Matej, Radoslav; Mandakova, Petra; Skibova, Jelena; Vasakova, Martina",null,null,"Role of interleukin 4 and its receptor in clinical presentation of chronic extrinsic allergic alveolitis: a pilot study","MULTIDISCIPLINARY RESPIRATORY MEDICINE",null,null,"English","Article",null,null,null,null,null,"Chronic extrinsic allergic alveolitis; High resolution computed tomography score; Interleukin 4; Interleukin 4 receptor; Sarcoidosis","EXPERIMENTAL HYPERSENSITIVITY PNEUMONITIS; IDIOPATHIC PULMONARY-FIBROSIS; BRONCHOALVEOLAR LAVAGE FLUID; SARCOIDOSIS; CELLS; LUNG; EXPRESSION; SMOKING; PERMEABILITY; DIFFERENCE","Background: Th-2 cytokine milieu including interleukin 4 (IL-4) was detected in fibrotic lung diseases. Chronic extrinsic allergic alveolitis (EAA) may be also accompanied by marked fibrogenesis. The aim of this study was to determine if IL-4 and its receptor (IL-4R-alpha) play any role in the clinical presentation and pathogenesis of chronic EAA. Methods: Twenty patients originally investigated for interstitial lung disease and finally diagnosed affected with chronic EAA and sarcoidosis were prospectively enrolled into the study. Concentrations of IL-4, IL-4R-aplha and total protein were assessed in the bronchoalveolar lavage fluid (BALF) of all enrolled subjects as well as high resolution computed tomography (HRCT) scores and pulmonary function tests. Results: BALF IL-4R-alpha and total protein concentrations were significantly higher in chronic EAA patients (p < 0.05). Concentrations of BALF IL-4R-alpha were significantly higher in men than in women (p < 0.05) in EAA group. Total protein BALF levels were significantly elevated in ex-smokers with EAA compared to nonsmokers (p < 0.05). A positive correlation (p < 0.01) between IL-4R-alpha BALF concentrations and HRCT interstitial scores were observed in chronic EAA group; the IL-4R-alpha/total protein ratio showed the same significant positive correlation. A negative correlation between lung function results and IL-4R-alpha, and IL-4R-alpha/total protein as well, was also found (p < 0.05). Conclusions: We suggest a clinical relevance for the IL-4/IL-4R axis in the etiopathogenesis of chronic EAA. IL-4R-alpha could serve as a potential biomarker of lung fibrogenesis.","[Sterclova, Martina; Vasakova, Martina] ThomayerHosp, Dept Resp Dis, Prague 14000 4, Czech Republic; [Matej, Radoslav] ThomayerHosp, Dept Pathol & Mol Med, Prague 14000 4, Czech Republic; [Mandakova, Petra] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic; [Skibova, Jelena] Inst Clin & Expt Med, Dept Med Stat, Prague 14021 4, Czech Republic","Sterclova, M (reprint author), ThomayerHosp, Dept Resp Dis, Videnska 800, Prague 14000 4, Czech Republic.","martina.sterclova@ftn.cz",null,null,"IGA Grant [G 1207 (NT13433-4/2012)]","This study was supported by an IGA Grant No G 1207 (NT13433-4/2012).",null,31,0,0,"BIOMED CENTRAL LTD","LONDON","236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND","2049-6958",null,null,"MULTIDISCIP RESP MED","Multidscip. Respir. Med.","MAY 30",2013,8,null,null,null,null,null,null,null,35,"10.1186/2049-6958-8-35",null,7,"Respiratory System","Respiratory System","200ZP","WOS:000323110800001"]
[null,null,null,null,"J","Plzak, J; Astl, J; Psychogios, G; Zenk, J; Lastuvka, P; Betka, J",null,null,null,"Plzak, J.; Astl, J.; Psychogios, G.; Zenk, J.; Lastuvka, P.; Betka, J.",null,null,"Current treatment strategies for papillary thyroid microcarcinoma","HNO",null,null,"German","Article",null,null,null,null,null,"Papillary thyroid carcinoma; Microcarcinoma; Thyroidectomy; Radioiodine therapy; Thyroglobulin","SURGICAL-TREATMENT; CARCINOMAS; CANCER; EXPERIENCE; RESECTION; PERIOD","The increase in the incidence of thyroid cancer is accompanied by a mortality rate that is stable or perhaps even slightly decreasing. This phenomenon is due to the increased frequency of papillary microcarcinomas (thyroid tumors with a diameter of less than 1 cm), which is presumably attributable to the improved diagnosis enabled by high resolution ultrasound and fine needle aspiration cytology. The American and European Thyroid Associations have recently published new guidelines for the diagnosis and therapy of differentiated thyroid tumors. These guidelines are aimed at minimizing the diagnostic and therapeutic procedures without reducing their effectiveness. This goal is particularly important for papillary thyroid microcarcinoma patients, who have an excellent prognosis and almost normal life expectancy. This article summarizes the history of thyroid surgery and introduces papillary thyroid microcarcinoma-an important topic in modern thyroid oncology. Current methods for diagnosis, treatment and follow-up care of this disease are discussed.","[Plzak, J.; Lastuvka, P.; Betka, J.] Charles Univ Prague, Univ Hosp Motol, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, Prague 15006 5, Czech Republic; [Psychogios, G.; Zenk, J.] Univ Klinikum Erlangen, Hals Nasen Ohren Klin, Erlangen, Germany","Plzak, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Otorhinolaryngol & Head & Neck Surg, Fac Med 1, V Uvalu 84, Prague 15006 5, Czech Republic.","jan.plzak@lf1.cuni.cz",null,null,null,null,null,28,0,0,"SPRINGER","NEW YORK","233 SPRING ST, NEW YORK, NY 10013 USA","0017-6192",null,null,"HNO","HNO","APR",2013,61,4,null,null,null,null,300,305,null,"10.1007/s00106-013-2679-2",null,6,"Otorhinolaryngology","Otorhinolaryngology","129PW","WOS:000317854900003"]
[null,null,null,null,"J","Stulik, J; Nesnidal, P; Kryl, J; Vyskocil, T; Barna, M",null,null,null,"Stulik, J.; Nesnidal, P.; Kryl, J.; Vyskocil, T.; Barna, M.",null,null,"Unstable Injuries to the Upper Cervical Spine in Children and Adolescents","ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA",null,null,"Czech","Article",null,null,null,null,null,"upper cervical spine; paediatric injury; paediatric spine; adolescent spine","HOSPITAL ADMISSIONS; FRACTURES; DISLOCATIONS; TRAUMA","PURPOSE OF THE STUDY Injuries to the upper cervical spine in children are rare and account for 0.6 to 9.5 % of all cervical spine injuries. We present a detailed analysis of the children and adolescents with unstable upper cervical spine injuries treated at our spinal centre. MATERIAL During 16 years of follow-up, unstable injury to the upper cervical spine was recorded in 23 children and adolescents. Two patients (8.7%) were treated conservatively and 21(91.3 %) underwent surgery. The patients were allocated by age to three groups: 0-9 year, 10-14 year and 15-18 year categories. Twenty patients were seen at the final clinical and radiographic follow-up. One patient died at 62 months after surgery and two patients unfit for transport were evaluated on the basis of mailed interviews. The interval between injury and final evaluation ranged from 6 to 137 months, with an average of 53.4 months. METHODS The patients treated conservatively first wore a Philadelphia collar, then a custom-made brace, and eventually a soft Schanze cervical collar to finish the healing process. Application of a halo vest was considered a surgical procedure and was used only in very small children. In unstable odontoid fractures, direct osteosynthesis with two cannulated titanium screws was performed from the anterior approach in older children while, in small children, transoral or submandibular retropharyngeal decompression to treat spinal stenosis caused by bone fragments was carried out and a halo vest was applied. Hangman's fractures were treated by anterior cervical discectomy, fusion with bone graft and anterior plate fixation. The other types of unstable fractures were managed from the posterior approach by occipitocervical fixation, atlantoaxial fixation or instrumented fusion extended caudally. The patients characteristics included gender, age, mechanism of injury, type of injury, neurological findings, type of therapy or surgery, complications and treatment outcome. Neurological status was evaluated using the Frankel classification. RESULTS The patient group comprised 14 boys (60.9 %) and nine girls (39.1 %), which gave a gender ratio of 3 : 2. The age of patients at injury ranged from 2 to 18 years, with an average of 11 years and 6 months.. The most frequent injuries included rotational or vertical atlantoaxial dislocation in eight (34.8%) and odontoid fractures in seven (30.4%) patients; atlas fracture was recorded in three (13.0 %) and hangman's fracture also in three (13.0%) patients; occipitocervical displacement was found in one (4.3 %) and complex atlantoaxial fracture also in one patient (4.3%). At the time of injury, 17 patients (73.9 %) had no neurological deficit (Frankel grade E), three had Frankel grade A (one paraplegic with a concomitant T5 spinal cord injury) and three had Frankel grade D neurological deficits. Of the six patients with neurological deficit, two showed improvement by one or two Frankel grades. The method of dorsal atlantoaxial fixation was used in eight patients (Magerl fixation in 2 and Harms method in 6). Direct osteosynthesis of an odontoid fracture was performed in four patients, halo fixation was applied in four, C2-C3 discectomy with tricortical bone grafting and plating was carried out in three, occipitocervical fixation was used in three patients, and direct atlas osteosynthesis, simple decompression and simple non-instrumented dorsal spondylodesis each was performed in one patient. Neither intra-operative complications nor post-operative complications related to the surgical technique were recorded. Osteoarthritis or bone non-union, as late post-operative complications, were found in two patients. All other patients showed bone healing by first intention in the desired extent. Superficial or deep wound infections were not recorded. DISCUSSION In the first age category, the number of boys and girls with injuries to the upper cervical spine was equal while, in the third one, the boys outnumbered the girls more.than twice. Of the 23 patients, 91.3 % were surgically treated; the anterior approach was used in approximately one third of the patients and the posterior approach in the rest of them. The high number of surgical interventions is due to the fact that the most serious paediatric spinal injuries are referred to our centre. CONCLUSIONS 1. Injuries to the upper cervical spine are most frequently found in the youngest children and in adolescents who, however, frequently have injury also to the lower cervical spine. 2. Neurological deficit is relatively frequent but ha's a better prognosis than in adults. The youngest children with mild deficits have the best prognosis. 3. The mortality rate in young children with upper cervical spine injuries is evidently high, mostly due to associated head, chest and abdomen trauma 4. Therapy, particularly in small children, is strictly individual.","[Stulik, J.; Nesnidal, P.; Kryl, J.; Vyskocil, T.; Barna, M.] FN Motol, Spondylochirurg Oddeleni, Prague 15006, Czech Republic; [Stulik, J.; Nesnidal, P.; Kryl, J.; Vyskocil, T.; Barna, M.] LF UK, Spondylochirurg Oddeleni, Chirurg Klin 1 3, Prague, Czech Republic; [Stulik, J.; Nesnidal, P.; Kryl, J.; Vyskocil, T.; Barna, M.] FN Motol, Prague 15006, Czech Republic","Stulik, J (reprint author), FN Motol, Spondylochirurg Oddeleni, V Uvalu 84, Prague 15006, Czech Republic.","jan.stulik@fnmotol.cz",null,null,null,null,null,20,0,0,"GALEN SRO","PRAGUE 5","NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC","0001-5415",null,null,"ACTA CHIR ORTHOP TR","Acta Chir. Orthop. Traumatol. Cechoslov.","APR",2013,80,2,null,null,null,null,106,113,null,null,null,8,"Orthopedics","Orthopedics","142YF","WOS:000318832800002"]
[null,null,null,null,"J","Jakubikova, M; Pitha, J; Latta, J; Ehler, E; Schutzner, J",null,null,null,"Jakubikova, Michala; Pitha, Jiri; Latta, Jan; Ehler, Edvard; Schutzner, Jan",null,null,"Myasthenia gravis, castleman disease, pemphigus, and anti-phospholipid syndrome","MUSCLE & NERVE",null,null,"English","Article",null,null,null,null,null,"anti-phospholipid syndrome; Castleman disease; interleukin-6; myasthenia gravis; pemphigus vulgaris","LYMPH-NODE HYPERPLASIA; BRONCHIOLITIS OBLITERANS; AUTOIMMUNE MYASTHENIA; RITUXIMAB; POEMS; CELLS; TUMOR","Introduction: Myasthenia gravis is an autoimmune disease marked by neuromuscular transmission failure at the neuromuscular junction. Castleman disease is a rare lymphoproliferative disease characterized by non-cancerous angiofolicular hyperplasia of lymphatic tissue. Methods and results: We describe a young man with rapid, successive manifestations of myasthenia gravis, a solitary form of Castleman disease, pemphigus vulgaris, and anti-phospholipid syndrome, which resulted in 2 ischemic cerebrovascular events that caused a severe central neurological deficit. Discussion: We were unable to find a similar case in the literature, but we hypothesize that the temporal concidence of these clinical entities may be related to a common immunological pathway, such as B-cell activation. Therefore, we treated the patient with an immunosuppressant and anticoagulant treatment, as well as rituximab, a monoclonal antibody therapy against CD20+. Muscle Nerve 47:447-451, 2013","[Jakubikova, Michala; Pitha, Jiri] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague 12801 2, Czech Republic; [Jakubikova, Michala; Pitha, Jiri] Charles Univ Prague, Ctr Clin Neurosci, Fac Med 1, Prague 12801 2, Czech Republic; [Jakubikova, Michala; Pitha, Jiri] Gen Univ Hosp, Prague 12801 2, Czech Republic; [Latta, Jan; Ehler, Edvard] Univ Pardubice, Dept Neurol, Pardubice 53203, Czech Republic; [Latta, Jan; Ehler, Edvard] Reg Hosp Pardubice, Fac Hlth Studies, Pardubice 53203, Czech Republic; [Schutzner, Jan] Charles Univ Prague, Dept Surg 3, Fac Med 1, Prague 15006 5, Czech Republic; [Schutzner, Jan] Univ Hosp Motol, Prague 15006 5, Czech Republic","Jakubikova, M (reprint author), Charles Univ Prague, Dept Neurol, Fac Med 1, Prague Katerinska 30, Prague 12801 2, Czech Republic.","michala.jakubikova@vfn.cz",null,null,"grant agency of Charles University [351011/2011]; Czech Ministry of Edcation [MSM 0021620849, PRVOUK-P26/LF1/4]","This article was prepared within the project \"Clinical, Laboratory and Socioeconomic Analysis in Patients with Myasthenia Gravis in Czech Republic\" (351011/2011), supported by the grant agency of Charles University. The investigation was also supported by research programs of the Czech Ministry of Edcation (MSM 0021620849 and PRVOUK-P26/LF1/4).",null,27,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0148-639X",null,null,"MUSCLE NERVE","Muscle Nerve","MAR",2013,47,3,null,null,null,null,447,451,null,"10.1002/mus.23657",null,5,"Clinical Neurology; Neurosciences","Neurosciences & Neurology","096KA","WOS:000315401500021"]
[null,null,null,null,"J","Profant, O; Burianova, J; Syka, J",null,null,null,"Profant, Oliver; Burianova, Jana; Syka, Josef",null,null,"The response properties of neurons in different fields of the auditory cortex in the rat","HEARING RESEARCH",null,null,"English","Article",null,null,null,null,null,null,"SPECIES-SPECIFIC VOCALIZATIONS; MEDIAL GENICULATE-BODY; FUNCTIONAL-ORGANIZATION; INFERIOR COLLICULUS; GUINEA-PIG; ALBINO-RAT; PYRAMIDAL NEURONS; IN-VIVO; FREQUENCY REPRESENTATION; AXON TERMINALS","The auditory cortex (AC) of the rat has been the subject of many studies, yet the details of its functional organization are still not well understood. We describe here the functional organization of the AC in young rats (strain Long Evans, aged 30-35 days, anesthetized with ketamine/xylazine) on the basis of the neuronal responses to acoustic stimuli. Based on the neuronal responses to broad band noise (BBN) and pure tone bursts, the AC may be divided into the primary auditory cortex (AI) and three other core fields: anterior (AAF), suprarhinal (SRAF) and posterior (PAF) as well as an unspecific region (UR) inserted between the AI and AAF. The core fields are surrounded by a belt area. Neurons in the AI, AAF, SRAF and PAF showed well defined characteristic frequencies (CF) in response to pure tone stimulation; in contrast, UR neurons responded only at high intensities without a clear CF. Neurons responding only to BBN stimulation were found mostly in the belt area. The putative borders between the core fields were determined by changes in their tonotopic gradient; however, no tonotopic organization was found in the PAP. Neurons with the shortest response latencies to BBN stimulation were found in layer 4 (L4) and layer 6 (L6) in the AI, while those with the longest latencies in the superficial layers (L1/2) of the belt area. Similar principles of responsiveness were observed when the spike rate in response to BBN stimulation was evaluated, with the highest rate present in L4 of the AI and the lowest in L1/2 of the belt area. According to the shape of the peristimulus time histograms, the responses of neurons in the AC of the rat may be classified as pure onset, sustained, onset-sustained, double peak or late onset. The most dominant in all fields, as well as in all layers, was the pure onset response. Our findings offer further cues for understanding the functional organization of the AC in the rat. (C) 2012 Elsevier B.V. All rights reserved.","[Profant, Oliver; Burianova, Jana; Syka, Josef] Acad Sci Czech Republic, Inst Expt Med, Dept Auditory Neurosci, Prague, Czech Republic; [Profant, Oliver] Charles Univ Prague, Fac Hosp Motol, Fac Med 1, Dept Otorhinolaryngol & Head & Neck Surg,Inst Pos, Prague 15006 5, Czech Republic","Profant, O (reprint author), Charles Univ Prague, Fac Med 1, Fac Hosp Motol, Dept ENT, V Uvalu 84, Prague 15006 5, Czech Republic.","profant@biomed.cas.cz",null,null," [GACR P303/12/1347];  [GACR P304/121G069]","The study was supported by grants GACR P303/12/1347 and GACR P304/121G069. We thank Jan Setnitka, Zbynek Sure and Daniel \"Suta for their assistance in this research.",null,78,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0378-5955",null,null,"HEARING RES","Hear. Res.","FEB",2013,296,null,null,null,null,null,51,59,null,"10.1016/j.heares.2012.11.021",null,9,"Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology","Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology","101FW","WOS:000315761600006"]
[null,null,null,null,"J","Boucek, J; Staffhorst, B; Grotenhuis, A; Kunst, H",null,null,null,"Boucek, Jan; Staffhorst, Bas; Grotenhuis, Andre; Kunst, Henricus",null,null,"Neuroaspergillosis Following Postoperative Radiotherapy for Temporal Bone Squamous Cell Carcinoma","JOURNAL OF INTERNATIONAL ADVANCED OTOLOGY",null,null,"English","Article",null,null,null,null,null,null,"NERVOUS-SYSTEM ASPERGILLOSIS; IMMUNOCOMPETENT PATIENT; VORICONAZOLE","Neuroaspergillosis usually manifests in immunocompromised patients. Here we present a case report of neuroaspergillosis in an immunocompetent host after postoperative radiotherapy for squamous cell carcinoma of temporal bone.","[Boucek, Jan; Staffhorst, Bas; Kunst, Henricus] Radboud Univ Nijmegen, Med Ctr, Dept ENT & HNS, NL-6525 ED Nijmegen, Netherlands; [Staffhorst, Bas] Radboud Univ Nijmegen, Med Ctr, Dept Anaesthesiol, NL-6525 ED Nijmegen, Netherlands; [Grotenhuis, Andre] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, NL-6525 ED Nijmegen, Netherlands; [Boucek, Jan] Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Univ Hosp Motol, Prague, Czech Republic","Boucek, J (reprint author), Charles Univ Prague, Dept Otorhinolaryngol Head & Neck Surg, Fac Med 1, Univ Hosp Motol, Prague, Czech Republic.","jboucek99@seznam.cz; basstaffhorst@gmail.com; J.Grotenhuis@nch.umcn.nl; H.Kunst@kno.umcn.nl",null,null,"grants IGA MZ CR [NT/11542-6, NT/11543-6]; Charles University in Prague [262510]","The work was supported by the grants IGA MZ CR (grant NT/11542-6 and NT/11543-6) and by the Charles University in Prague, Project for support of Specific University Research No. 262510.",null,17,0,0,"MEDITERRANEAN SOC OTOLOGY & AUDIOLOGY","ANKARA","SELANIK CADDESI 48, 3 KIZILAY, ANKARA, 00000, TURKEY","1308-7649",null,null,"J INT ADV OTOL","J. Int. Adv. Otol.",null,2013,9,2,null,null,null,null,273,278,null,null,null,6,"Otorhinolaryngology","Otorhinolaryngology","241YP","WOS:000326204900020"]
[null,null,null,null,"J","Slouf, M; Vackova, T; Nevoralova, M; Mikesova, J; Dybal, J; Pilar, J; Zhigunov, A; Kotek, J; Kredatusova, J; Fulin, P",null,null,null,"Slouf, Miroslav; Vackova, Tatana; Nevoralova, Martina; Mikesova, Jana; Dybal, Jiri; Pilar, Jan; Zhigunov, Alexander; Kotek, Jiri; Kredatusova, Jana; Fulin, Petr",null,null,"Ultrahigh Molecular Weight Polyethylene for Total Joint Replacements with Longer Lifetime","CHEMICKE LISTY",null,null,"Czech","Article",null,null,null,null,null,null,"UHMWPE","Ultrahigh molecular weight polyethylene (UHMWPE) is a key component of modern total joint replacements (TJR). The most frequently replaced human joints are hips and knees, followed by shoulders, elbows, etc. However, UHMWPE liners are the most loaded components of the implants. Consequently, the main material-related reasons of TJR failures are wear and oxidative degradation of the polymer. Resistance to wear (i.e. release of microscopic particles from the polymer surface) is increased by radiation-induced crosslinking. Oxidation stability (i.e. resistance of polymer to chain scissions and deterioration of mechanical properties) is enhanced by means of suitable thermal treatment and sterilization protocols. The most recent trend is to employ a biocompatible stabilizer - vitamin E - for further improvement and fine-tuning of UHMWPE performance. This review summarizes the recent developments in UHMWPE modifications, which come both from the author's institute and from the world, and which should further increase lifespan of total joint replacements.","[Slouf, Miroslav; Vackova, Tatana; Nevoralova, Martina; Mikesova, Jana; Dybal, Jiri; Pilar, Jan; Zhigunov, Alexander; Kotek, Jiri; Kredatusova, Jana] Acad Sci Czech Republic, Ustav Makromol Chem, Vvi, Prague 16206 6, Czech Republic; [Fulin, Petr] 1 LF UK, Ortoped Klin 1, Prague 15606 5, Czech Republic; [Fulin, Petr] FN Motol, Prague 15606 5, Czech Republic","Slouf, M (reprint author), Acad Sci Czech Republic, Ustav Makromol Chem, Vvi, Heyrovskeho Nam 2, Prague 16206 6, Czech Republic.","slouf@imc.cas.cz",null,null,null,null,null,20,0,0,"CHEMICKE LISTY","PRAGUE 6","NOVOTNEHO LAVKA 5, PRAGUE 6 116 68, CZECH REPUBLIC","0009-2770","1213-7103",null,"CHEM LISTY","Chem. Listy",null,2013,107,10,null,null,null,null,783,790,null,null,null,8,"Chemistry, Multidisciplinary","Chemistry","251XS","WOS:000326968000006"]
[null,null,null,null,"J","Robova, H; Rob, L; Halaska, MJ; Pluta, M; Skapa, P",null,null,null,"Robova, Helena; Rob, Lukas; Halaska, Michael Jiri; Pluta, Marek; Skapa, Petr",null,null,"Current status of sentinel lymph node mapping in the management of endometrial cancer","EXPERT REVIEW OF ANTICANCER THERAPY",null,null,"English","Review",null,null,null,null,null,"endometrial cancer; lymphadenectomy; sentinel lymph node; surgical staging","PARAAORTIC LYMPHADENECTOMY; HYSTEROSCOPIC INJECTION; DIAGNOSTIC-ACCURACY; BIOPSY; WOMEN; CARCINOMA; SPREAD; DYE","The prognosis of endometrial cancer (EC) is generally favorable, while lymph node status remains the most important prognostic factor. Sentinel lymph node mapping (SLNM) could help to find women in whom adjuvant therapy could be omitted. This review analyzes different techniques of injection and histopathologic elaboration of SLNM in EC. Results of studies on SLNM in ECs seem to be promising, but only a small series have been published so far. The studies are subdivided into three groups by the technique of injection (hysteroscopic, subserosal and cervical). Range of detection rate for SLNM varies from 45 to 100%. Hysteroscopic injection is not easy to learn; moreover, exact peritumoral injection in large tumors is often impossible. Subserosal administration of tracer is difficult during laparoscopic or robotic surgery. Cervical injection is quite a controversial technique because distribution of SLNs in ECs is different from cervical cancer; moreover, there is no large study using cervical injection with systematic pelvic and para-aortic lymphadenectomy.","[Robova, Helena; Rob, Lukas; Halaska, Michael Jiri; Pluta, Marek] Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 2, Prague 15000 5, Czech Republic; [Skapa, Petr] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 15000 5, Czech Republic","Rob, L (reprint author), Charles Univ Prague, Dept Obstet & Gynecol, Fac Med 2, V Uvalu 84, Prague 15000 5, Czech Republic.","lukas.rob@lfmotol.cuni.cz",null,null,"Czech Ministry of Health [MZ CR NT 11417]","This work was supported by a grant from the Czech Ministry of Health (MZ CR NT 11417). The authors have no other relevant affiliation or financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents receiving or pending, or royalties.",null,32,2,2,"EXPERT REVIEWS","LONDON","UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND","1473-7140",null,null,"EXPERT REV ANTICANC","Expert Rev. Anticancer Ther","JAN",2013,13,1,null,null,null,null,55,61,null,"10.1586/ERA.12.157",null,7,"Oncology","Oncology","089RM","WOS:000314927700013"]
[null,null,null,null,"J","Forostyak, S; Jendelova, P; Sykova, E",null,null,null,"Forostyak, Serhiy; Jendelova, Pavla; Sykova, Eva",null,null,"The role of mesenchymal stromal cells in spinal cord injury, regenerative medicine and possible clinical applications","BIOCHIMIE",null,null,"English","Review",null,null,null,null,null,"Stem cells; Regeneration; Neuroprotection; Cell-based therapy; Clinical trials","EMBRYONIC STEM-CELLS; AMYOTROPHIC-LATERAL-SCLEROSIS; NEURAL STEM/PROGENITOR CELLS; MAGNETIC-RESONANCE TRACKING; CHONDROITIN SULFATE PROTEOGLYCANS; CELLULAR INFLAMMATORY RESPONSE; ACUTE MYOCARDIAL-INFARCTION; COLONY-STIMULATING FACTOR; CENTRAL-NERVOUS-SYSTEM; BONE-MARROW","Diseases of the central nervous system still remain among the most challenging pathologies known to mankind, having no or limited therapeutic possibilities and a very pessimistic prognosis. Advances in stem cell biology in the last decade have shown that stem cells might provide an inexhaustible source of neurons and glia as well as exerting a neuroprotective effect on the host tissue, thus opening new horizons for tissue engineering and regenerative medicine. Here, we discuss the progress made in the cell-based therapy of spinal cord injury. An emphasis has been placed on the application of adult mesenchymal stromal cells (MSCs). We then review the latest and most significant results from in vitro and in vivo research focusing on the regenerative/neuroprotective properties of MSCs. We also attempt to correlate the effect of MSCs with the pathological events that are taking place in the nervous tissue after SCI. Finally, we discuss the results from preclinical and clinical trials involving different routes of MSC application into patients with neurological disorders of the spinal cord. (C) 2013 Published by Elsevier Masson SAS.","[Forostyak, Serhiy; Jendelova, Pavla; Sykova, Eva] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Forostyak, Serhiy; Jendelova, Pavla; Sykova, Eva] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic","Sykova, E (reprint author), Inst Expt Med AS CR, Dept Neurosci, Videnska 1083, Prague 14220 4, Czech Republic.","serhiy.forostyak@biomed.cas.cz; jendel@biomed.cas.cz; sykova@biomed.cas.cz",null,null," [CZ.1.07/2.3.00/30.0018];  [GA CR: 13-00939S];  [304/10/0320];  [304/11/0189];  [P304/12/G069]","This study was supported by the grants CZ.1.07/2.3.00/30.0018, GA CR: 13-00939S, 304/10/0320, 304/11/0189 and P304/12/G069.",null,179,1,1,"ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER","PARIS","23 RUE LINOIS, 75724 PARIS, FRANCE","0300-9084","1638-6183",null,"BIOCHIMIE","Biochimie","DEC",2013,95,12,null,null,null,null,2257,2270,null,"10.1016/j.biochi.2013.08.004",null,14,"Biochemistry & Molecular Biology","Biochemistry & Molecular Biology","263JR","WOS:000327805400008"]
[null,null,null,null,"J","Blahos, J",null,null,null,"Blahos, J., Jr.",null,null,"Canabis in the Development and Homeostasis of the Nerve System","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"endocannabinoid; cannabis; pregnancy","PRENATAL MARIJUANA EXPOSURE; CANNABINOID RECEPTORS; PERFORMANCE; NEURODEVELOPMENT; PSYCHOSIS; SYMPTOMS; BRAIN; AGE","Marihuana is one of the most frequently abused illicit drugs among adolescents and young adults. As such, exposure to psychoactive ingredients, with delta 9-tetrahydrocanabinol (THC) being the most prevalent, collide with critical periods of brain development. Firstly, in mothers who cease to abuse cannabis at the onset of pregnancy, THC and other lipid-soluble substances might still circulate in their blood at levels that may interfere with the brain development of the fetus. This is due to the chemical nature of THC and related substances; these are lipophilic and accumulate in the body fat. During pregnancy, the fat redistribution leads to release of cannabinoids into the blood stream. These substances readily cross placental barrier and enter fetal circulation. The second period of brain maturation that is influenced by THC exposure in many smokers is during puberty and is associated with an increased risk of neuropsychiatric consequences. The third negative aspect of cannabis abuse giving rise to neurodevelopmental disturbances is related to the \"quality\" of the newly developed species of the cannabis sativa plant with as much as 25 times higher concentration of THC than in the samples obtained a decade ago, not mentioning the availability of new synthetic cannabinoid-like ligands of obscure, usually Chinese origin. Legalization of cannabis may be beneficial in certain medical indications but, on the other hand, it might bring false anticipation of harmlessness. The purpose of this review article is to discuss potential side effects of marihuana use during periods of nervous system development both in utero and in adolescence.","[Blahos, J., Jr.] AV CR Vvi, Ustav Mol Genet, Oddeleni Mol Farmakol, Prague 14220 4, Czech Republic; [Blahos, J., Jr.] LF UK Praze, Farmakol Ustav 2, Prague, Czech Republic","Blahos, J (reprint author), AV CR Vvi, Ustav Mol Genet, Oddeleni Mol Farmakol, Videnska 1083, Prague 14220 4, Czech Republic.","blahos@img.cas.cz",null,null,null,null,"Arseneault L, 2002, BRIT MED J, V325, P1212, DOI 10.1136/bmj.325.7374.1212; Day NL, 2006, ADDICTION, V101, P1313, DOI 10.1111/j.1360-0443.2006.01523.x; Day NL, 2011, NEUROTOXICOL TERATOL, V33, P129, DOI 10.1016/j.ntt.2010.07.006; DiNieri JA, 2012, METHODS MOL BIOL, V829, P231, DOI 10.1007/978-1-61779-458-2_14; el Marroun H, 2008, DRUG ALCOHOL DEPEN, V98, P218, DOI 10.1016/j.drugalcdep.2008.05.010; Fergusson DM, 2003, PSYCHOL MED, V33, P15, DOI 10.1017/S0033291702006402; Fernandez-Ruiz J, 2000, TRENDS NEUROSCI, V23, P14, DOI 10.1016/S0166-2236(99)01491-5; Fried PA, 2005, NEUROTOXICOL TERATOL, V27, P231, DOI 10.1016/j.ntt.2004.11.003; Fried PA, 2003, NEUROTOXICOL TERATOL, V25, P427, DOI 10.1016/S0892-0362(03)00029-1; Glass M, 1997, NEUROSCIENCE, V77, P299, DOI 10.1016/S0306-4522(96)00428-9; Goldschmidt L, 2008, J AM ACAD CHILD PSY, V47, P254, DOI [10.1097/CHI.0b013e318160b3f0, 10.1097/chi.0b013e318160b3f0]; Gomez-Ruiz M, 2007, MOL NEUROBIOL, V36, P3, DOI 10.1007/s12035-007-0015-0; Gray KA, 2005, NEUROTOXICOL TERATOL, V27, P439, DOI 10.1016/j.ntt.2005.03.010; Harkany T, 2008, CURR OPIN NEUROBIOL, V18, P338, DOI 10.1016/j.conb.2008.08.007; Kano M, 2009, PHYSIOL REV, V89, P309, DOI 10.1152/physrev.00019.2008; Keimpema E, 2011, TRENDS PHARMACOL SCI, V32, P551, DOI 10.1016/j.tips.2011.05.004; Mackie K, 2005, LIFE SCI, V77, P1667, DOI 10.1016/j.lfs.2005.05.011; Mackie Ken, 2007, PLoS Biol, V5, pe280, DOI 10.1371/journal.pbio.0050280; Mackie K, 2008, J NEUROENDOCRINOL, V20, P10, DOI 10.1111/j.1365-2826.2008.01671.x; Mackie K, 2008, MOL CELL ENDOCRINOL, V286, pS60, DOI 10.1016/j.mce.2008.01.022; McGrath J, 2010, ARCH GEN PSYCHIAT, V67, P440, DOI 10.1001/archgenpsychiatry.2010.6; Mikasova L, 2008, P NATL ACAD SCI USA, V105, P18596, DOI 10.1073/pnas.0805959105; Morris CV, 2011, EUR J NEUROSCI, V34, P1574, DOI 10.1111/j.1460-9568.2011.07884.x; Psychoyos D, 2012, BIRTH DEFECTS RES B, V95, P137, DOI 10.1002/bdrb.20348; Trezza V, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00002",25,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,5,null,null,null,null,559,564,null,null,null,6,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","AB7QY","WOS:000331987000003"]
[null,null,null,null,"J","Seeman, T",null,null,null,"Seeman, Tomas",null,null,"Nonpharmacologic Treatment Is an Indispensable Part of Antihypertensive Therapy in All Hypertensive Children","AMERICAN JOURNAL OF HYPERTENSION",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Seeman, Tomas] Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Seeman, Tomas] Second Med Sch, Prague, Czech Republic; [Seeman, Tomas] Charles Univ Prague, Fac Med Plzen, Biomed Ctr, Plzen, Czech Republic","Seeman, T (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic.","tomas.seeman@lfmotol.cuni.cz",null,null,null,null,null,4,0,0,"OXFORD UNIV PRESS","OXFORD","GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND","0895-7061","1941-7225",null,"AM J HYPERTENS","Am. J. Hypertens.","DEC",2013,26,12,null,null,null,null,1460,1461,null,"10.1093/ajh/hpt189",null,2,"Peripheral Vascular Disease","Cardiovascular System & Cardiology","251IW","WOS:000326922700015"]
[null,null,null,null,"J","Hyncicova, E; Meluzinova, E; Vyhnalek, M; Libertinova, J; Kovarova, I; Nikolai, T; Hort, J; Laczo, J",null,null,null,"Hyncicova, E.; Meluzinova, E.; Vyhnalek, M.; Libertinova, J.; Kovarova, I.; Nikolai, T.; Hort, J.; Laczo, J.",null,null,"Cognitive Impairment in Early Stages of Multiple Sclerosis","CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE",null,null,"Czech","Review",null,null,null,null,null,"multiple sclerosis; clinically isolated syndrome; cognitive deficit; neuropsychological tests; magnetic resonance imaging","CLINICALLY ISOLATED SYNDROME; MINI-MENTAL-STATE; MAGNETIC-RESONANCE; MEMORY IMPAIRMENT; CORTICAL-LESIONS; CORPUS-CALLOSUM; ATROPHY; DYSFUNCTION; SPEED; MS","Multiple sclerosis (MS) is a chronic disease affecting brain and spinal cord and leading primarily to motor disability. Cognitive deficit in patients with MS are often neglected in routine clinical practise despite its significant impact on patients' quality of life. Recent studies have suggested that cognitive impairment is present in almost 65% of patients with MS even at the earliest stages of the disease - in patients with clinically isolated syndrome (CIS). The goal of this review was to summarize results of previous studies focused on cognitive deficit in patients with MS. We put particular emphasis on early stages of the disease including patients after the first clinical manifestation of the disease (CIS), who are likely to develop clinically definite multiple sclerosis (CDMS). We further describe the relationship between cognitive functions and structural changes on magnetic resonance imaging (MRI). We also mention the most commonly used neuropsychological batteries and pharmacological and non-pharmacological treatments of cognitive deficits in patients with MS. The final part of the review focuses on fatigue, depression and quality of life.","[Hyncicova, E.; Meluzinova, E.; Vyhnalek, M.; Libertinova, J.; Nikolai, T.; Hort, J.; Laczo, J.] LF UK & FN Motole, Neurol Klin 2, Prague 15006 5, Czech Republic; [Kovarova, I.; Nikolai, T.] LF UK & VFN Praze, Neurol Klin 1, Prague, Czech Republic","Meluzinova, E (reprint author), LF UK & FN Motole, Neurol Klin 2, V Uvalu 84, Prague 15006 5, Czech Republic.","eva.meluzinova@fnmotol.cz",null,null,null,null,"Achiron A, 2003, J NEUROL NEUROSUR PS, V74, P443, DOI 10.1136/jnnp.74.4.443; Amato MP, 2004, NEUROLOGY, V63, P89; Amato MP, 2007, ARCH NEUROL-CHICAGO, V64, P1157, DOI 10.1001/archneur.64.8.1157; Anhoque CF, 2011, ARQ NEURO-PSIQUIAT, V69, P882, DOI 10.1590/S0004-282X2011000700006; Arnett PA, 2001, J INT NEUROPSYCH SOC, V7, P665, DOI 10.1017/S1355617701766027; Audoin B, 2005, HUM BRAIN MAPP, V24, P216, DOI 10.1002/hbm.20083; Bagert B, 2002, CNS DRUGS, V16, P445, DOI 10.2165/00023210-200216070-00002; Benedict RHB, 2005, AM J NEURORADIOL, V26, P1824; Bergendal G, 2007, EUR NEUROL, V57, P193, DOI 10.1159/000099158; Bruce JM, 2007, J INT NEUROPSYCH SOC, V13, P544, DOI 10.1017/S1355617707070658; Calabrese M, 2010, ANN NEUROL, V67, P376, DOI 10.1002/ana.21906; Calabrese M, 2009, ARCH NEUROL-CHICAGO, V66, P1144, DOI 10.1001/archneurol.2009.174; Camp SJ, 1999, BRAIN, V122, P1341, DOI 10.1093/brain/122.7.1341; Chiaravalloti ND, 2008, LANCET NEUROL, V7, P1139, DOI 10.1016/S1474-4422(08)70259-X; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; Denney DR, 2008, J NEUROL SCI, V267, P129, DOI 10.1016/j.jns.2007.10.007; Denney DR, 2011, ARCH CLIN NEUROPSYCH, V26, P110, DOI 10.1093/arclin/acq104; Denney DR, 2004, J INT NEUROPSYCH SOC, V10, P948, DOI 10.1017/S1355617704107030; De Sonneville LMJ, 2002, NEUROPSYCHOLOGIA, V40, P1751, DOI 10.1016/S0028-3932(02)00041-6; Drew M, 2008, ARCH CLIN NEUROPSYCH, V23, P1, DOI 10.1016/j.acn.2007.09.005; Dusankova JB, 2012, CLIN NEUROPSYCHOL, V26, P1186, DOI 10.1080/13854046.2012.725101; Feinstein A, 2006, J NEUROL SCI, V245, P63, DOI 10.1016/j.jns.2005.08.020; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAFMAN J, 1991, ARCH NEUROL-CHICAGO, V48, P1072; GRANT I, 1984, J NEUROL NEUROSUR PS, V47, P250, DOI 10.1136/jnnp.47.3.250; Haase CG, 2003, BEHAV NEUROL, V14, P39; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1166, DOI 10.1016/j.neuropsychologia.2005.10.006; Honarmand K, 2011, J NEUROL, V258, P244, DOI 10.1007/s00415-010-5736-8; Houtchens MK, 2007, NEUROLOGY, V69, P1213, DOI 10.1212/01.wnl.0000276992.17011.b5; Huijbregts SCJ, 2004, NEUROLOGY, V63, P335; Hummelova-Fanfrdlova Z, 2009, CESK PSYCHOL, V53, P376; Janculjak D, 2002, CLIN NEUROL NEUROSUR, V104, P221, DOI 10.1016/S0303-8467(02)00042-2; Johnson SK, 2006, EXPLORE-NY, V2, P19, DOI 10.1016/j.explore.2005.10.007; Jonsson A, 2006, J NEUROL SCI, V245, P77, DOI 10.1016/j.jns.2005.09.016; Kalincik T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050101; Laatu S, 1999, J NEUROL SCI, V162, P152, DOI 10.1016/S0022-510X(98)00314-1; Leo GJ, 1988, J NEUROL REHABIL, V2, P123; Lin F, 2011, AM J NEURORADIOL, V32, P92, DOI 10.3174/ajnr.A2273; Mathuranath PS, 2007, NEUROL INDIA, V55, P106; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Obhlidalova I, 2012, CESK SLOV NEUROL N, V75, P170; Parmenter BA, 2007, J CLIN EXP NEUROPSYC, V29, P215, DOI 10.1080/13803390600672163; Potagas C, 2008, J NEUROL SCI, V267, P100, DOI 10.1016/j.jns.2007.10.002; RAO SM, 1991, NEUROLOGY, V41, P685; RAO SM, 1986, J CLIN EXP NEUROPSYC, V8, P503, DOI 10.1080/01688638608405173; Reuter F, 2011, MULT SCLER J, V17, P755, DOI 10.1177/1352458511398265; Rimkus Cde M, 2011, MULT SCLER INT, V2011; Sanchez MP, 2008, EUR J NEUROL, V15, P1091, DOI 10.1111/j.1468-1331.2008.02259.x; Schultheis MT, 2010, ARCH PHYS MED REHAB, V91, P465, DOI 10.1016/j.apmr.2009.09.026; Schulz D, 2006, J NEUROL, V253, P1002, DOI 10.1007/s00415-006-0145-8; Simioni S, 2007, SWISS MED WKLY, V137, P496; Steckova T, 2011, CESK SLOV NEUROL N, V74, P551; Tekok-Kilic A, 2007, NEUROIMAGE, V36, P1294; Thornton AE, 1997, NEUROPSYCHOLOGY, V11, P357, DOI 10.1037//0894-4105.11.3.357; Vaneckova M, 2012, EUR NEUROL, V68, P23, DOI 10.1159/000337683; Vleugels L, 2000, MULT SCLER, V6, P241, DOI 10.1177/135245850000600406; Winkelmann A, 2008, J NEUROL, V255, P309; Zajicek JP, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-88; Zakzanis KK, 2000, ARCH CLIN NEUROPSYCH, V15, P115, DOI 10.1016/S0887-6177(98)00157-7",59,0,0,"CZECH MEDICAL SOC","PRAGUE 2","SOKOLSKA 31, PRAGUE 2 120 26, CZECH REPUBLIC","1210-7859","1802-4041",null,"CESK SLOV NEUROL N","Cesk. Slov. Neurol. Neurochir.",null,2013,76,6,null,null,null,null,690,694,null,null,null,5,"Neurosciences; Surgery","Neurosciences & Neurology; Surgery","260GD","WOS:000327582100003"]
[null,null,null,null,"J","Vicha, A; Musil, Z; Pacak, K",null,null,null,"Vicha, Ales; Musil, Zdenek; Pacak, Karel",null,null,"Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options","CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY",null,null,"English","Review",null,null,null,null,null,"gene; mutation; paraganglioma; pheochromocytoma; succinate dehydrogenase","GERMLINE MUTATIONS; CANCER-THERAPY; MAX MUTATIONS; HYPOXIA; TMEM127; HEREDITARY; DEGRADATION; INHIBITOR; PATHWAY; HSP90","Purpose of review To summarize the recent advances in the genetics of pheochromocytoma and paraganglioma (PHEO/PGL), focusing on the new susceptibility genes and dividing PHEOs/PGLs into two groups based on their transcription profile. Recent findings Recently, TMEM127, MYC-associated factor X, and hypoxia-inducible factor (HIF) 2 alpha have been described in the pathogenesis of PHEOs/PGLs. Thus, now about 30-40% of these tumors are linked to the germline mutations, which also include mutations in the VHL, RET, NF1, SDHx, and SDHAF2 genes. Furthermore, PHEOs/PGLs have been divided into two groups, cluster 1 (SDHx/VHL) and cluster 2 (RET/NF1), based on the transcription profile revealed by genome-wide expression microarray analysis. Summary PHEOs/PGLs are the most inherited tumors among (neuro) endocrine tumors. Future approaches in genetics, including whole-genome sequencing, will allow the discovery of additional PHEO/PGL susceptibility genes. The current division of PHEOs/PGLs into cluster 1 and 2 provides us with additional knowledge related to the pathogenesis of these tumors, including the introduction of new treatment options for patients with metastatic PHEOs/PGLs. New discoveries related to the role of the HIF-1/HIF-2 alpha genes in the pathogenesis of almost all inherited PHEOs/PGLs may call for a new regrouping of these tumors and discoveries of new treatment targets.","[Vicha, Ales; Musil, Zdenek] Charles Univ Prague, Dept Pediat Hematol & Oncol, Fac Med 2, Univ Hosp Motol, Prague, Czech Republic; [Musil, Zdenek] Charles Univ Prague, Gen Teaching Hosp, Inst Biol & Med Genet, Fac Med 1, Prague, Czech Republic; [Pacak, Karel] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA","Pacak, K (reprint author), NICHD, Sect Med Neuroendocrinol, NIH, CRC, Bldg 10,1 East,Room 1-3140,10 Ctr Dr,MSC 1109, Bethesda, MD 20892 USA.","karel@mail.nih.gov",null,null,"Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Neurological Disorders and Stroke at the National Institutes of Health; project for the conceptual development of research organization [00064203]","The authors thank Victoria Martucci and Ankita Reddy for their technical assistance. This research was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, and the project for the conceptual development of research organization 00064203.",null,57,3,4,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1752-296X",null,null,"CURR OPIN ENDOCRINOL","Curr. Opin. Endocrinol. Diabetes Obes.","JUN",2013,20,3,null,null,null,null,186,191,null,"10.1097/MED.0b013e32835fcc45",null,6,"Endocrinology & Metabolism","Endocrinology & Metabolism","131VE","WOS:000318024200005"]
[null,null,null,null,"J","Teyssler, P; Kolostova, K; Bobek, V",null,null,null,"Teyssler, Petr; Kolostova, Katarina; Bobek, Vladimir",null,null,"Radionuclide synovectomy in haemophilic joints","NUCLEAR MEDICINE COMMUNICATIONS",null,null,"English","Review",null,null,null,null,null,"arthropathy; haemophilia; radionuclide therapy; radiosynovectomy","SM-153 PARTICULATE HYDROXYAPATITE; RADIATION SYNOVECTOMY; RADIOISOTOPE SYNOVECTOMY; RADIOACTIVE SYNOVECTOMY; CHRONIC SYNOVITIS; RECURRENT HEMARTHROSIS; RADIO SYNOVECTOMY; SHORT-TERM; SYNOVIORTHESIS; ARTHROPATHY","Chronic synovitis often occurs in people with haemophilia. Untreated chronic haemophilic synovitis affects the metabolism of chondrocytes, thus leading to haemophilic arthropathy. A recently introduced therapeutic protocol includes radiation synovectomy (RS), a safe and cost-effective therapeutic method, which has given satisfactory results in 75% of haemophiliacs with chronic hypertrophic synovitis. Because of its efficacy, we will discuss additional recommendations on the use of RS as a method of choice. The focus of this review is haemophilic arthropathy treatment, including its aetiopathogenesis, reasons for RS indication and its mechanism of action, and use of radioisotopes and other agents for treatment. Nucl Med Commun 34: 291-297 (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.","[Teyssler, Petr; Kolostova, Katarina; Bobek, Vladimir] Charles Univ Prague, Fac Med 3, Dept Tumor Biol, Prague 10097, Czech Republic; [Teyssler, Petr] Charles Univ Prague, Fac Med 2, Univ Hosp Motol, Dept Orthopaed, Prague 10097, Czech Republic; [Bobek, Vladimir] Charles Univ Prague, Fac Med 3, Dept Surg, Univ Hosp Kralovske Vinohrady, Prague 10097, Czech Republic","Bobek, V (reprint author), Charles Univ Prague, Fac Med 3, Dept Tumor Biol, Ruska 87, Prague 10097, Czech Republic.","vbobek@centrum.cz",null,null,"Charles University in Prague, 3rd Faculty of Medicine, Prague, Czech Republic;  [P 27/2012]","This study was supported by the research project P 27/2012 awarded by Charles University in Prague, 3rd Faculty of Medicine, Prague, Czech Republic.",null,52,2,2,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","0143-3636","1473-5628",null,"NUCL MED COMMUN","Nucl. Med. Commun.","APR",2013,34,4,null,null,null,null,291,297,null,"10.1097/MNM.0b013e32835ed50c",null,7,"Radiology, Nuclear Medicine & Medical Imaging","Radiology, Nuclear Medicine & Medical Imaging","281AR","WOS:000329072400002"]
[null,null,null,null,"J","Ruttkay-Nedecky, B; Nejdl, L; Gumulec, J; Zitka, O; Masarik, M; Eckschlager, T; Stiborova, M; Adam, V; Kizek, R",null,null,null,"Ruttkay-Nedecky, Branislav; Nejdl, Lukas; Gumulec, Jaromir; Zitka, Ondrej; Masarik, Michal; Eckschlager, Tomas; Stiborova, Marie; Adam, Vojtech; Kizek, Rene",null,null,"The Role of Metallothionein in Oxidative Stress","INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES",null,null,"English","Review",null,null,null,null,null,"metallothionein; free radicals; cellular oxidative stress; zinc; transcription factor; cancer","NF-KAPPA-B; TRANSCRIPTION FACTOR-IIIA; SUPPRESSOR PROTEIN P53; PROGRAMMED CELL-DEATH; OXYGEN FREE-RADICALS; NITRIC-OXIDE; ZINC-FINGER; REACTIVE OXYGEN; DNA-BINDING; TUMOR-SUPPRESSOR","Free radicals are chemical particles containing one or more unpaired electrons, which may be part of the molecule. They cause the molecule to become highly reactive. The free radicals are also known to play a dual role in biological systems, as they can be either beneficial or harmful for living systems. It is clear that there are numerous mechanisms participating on the protection of a cell against free radicals. In this review, our attention is paid to metallothioneins (MTs) as small, cysteine-rich and heavy metal-binding proteins, which participate in an array of protective stress responses. The mechanism of the reaction of metallothioneins with oxidants and electrophilic compounds is discussed. Numerous reports indicate that MT protects cells from exposure to oxidants and electrophiles, which react readily with sulfhydryl groups. Moreover, MT plays a key role in regulation of zinc levels and distribution in the intracellular space. The connections between zinc, MT and cancer are highlighted.","[Ruttkay-Nedecky, Branislav; Gumulec, Jaromir; Zitka, Ondrej; Masarik, Michal; Adam, Vojtech; Kizek, Rene] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Nejdl, Lukas; Zitka, Ondrej; Adam, Vojtech; Kizek, Rene] Mendel Univ Brno, Dept Chem & Biochem, Fac Agron, CZ-61300 Brno, Czech Republic; [Gumulec, Jaromir; Masarik, Michal] Masaryk Univ, Dept Pathol Physiol, Fac Med, CZ-61200 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Dept Biochem, Fac Sci, CZ-12840 Prague 2, Czech Republic","Kizek, R (reprint author), Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic.","brano.ruttkay@seznam.cz; lukasnejdl@gmail.com; j.gumulec@gmail.com; zitkao@seznam.cz; masarik@med.muni.cz; tomas.eckschlager@fnmotol.cz; stiborov@natur.cuni.cz; vojtech.adam@mendelu.cz; kizek@sci.muni.cz","Gumulec, Jaromir/D-7638-2012; Masarik, Michal/D-9920-2012","Gumulec, Jaromir/0000-0002-9658-3444; ","GA CR [P301/10/0356]; DOC [CEITEC.02/2012]; CEITEC [CZ.1.05/1.1.00/02.0068]; project for conceptual development of research organization [00064203]","Financial support from GA CR P301/10/0356, DOC CEITEC.02/2012, CEITEC CZ.1.05/1.1.00/02.0068 and the project for conceptual development of research organization 00064203 is highly acknowledged.",null,173,9,9,"MDPI AG","BASEL","POSTFACH, CH-4005 BASEL, SWITZERLAND","1422-0067",null,null,"INT J MOL SCI","Int. J. Mol. Sci.","MAR",2013,14,3,null,null,null,null,6044,6066,null,"10.3390/ijms14036044",null,23,"Chemistry, Multidisciplinary","Chemistry","112RH","WOS:000316609800090"]
[null,null,null,null,"J","Cernei, N; Heger, Z; Gumulec, J; Zitka, O; Masarik, M; Babula, P; Eckschlager, T; Stiborova, M; Kizek, R; Adam, V",null,null,null,"Cernei, Natalia; Heger, Zbynek; Gumulec, Jaromir; Zitka, Ondrej; Masarik, Michal; Babula, Petr; Eckschlager, Tomas; Stiborova, Marie; Kizek, Rene; Adam, Vojtech",null,null,"Sarcosine as a Potential Prostate Cancer Biomarker-A Review","INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES",null,null,"English","Review",null,null,null,null,null,"cancer of prostate; biomarkers; early diagnostic; prostatic specific antigen; non-invasive markers; urine; amino acids","GLYCINE-N-METHYLTRANSFERASE; DIGITAL RECTAL EXAMINATION; MASS-SPECTROMETRY; LIQUID-CHROMATOGRAPHY; MOLECULAR-BIOLOGY; SERUM SARCOSINE; URINE; METABOLOMICS; MARKER; GENE","Prostate cancer (CaP) is the most common type of tumour disease in men. Early diagnosis of cancer of the prostate is very important, because the sooner the cancer is detected, the better it is treated. According to that fact, there is great interest in the finding of new markers including amino acids, proteins or nucleic acids. Prostate specific antigen (PSA) is commonly used and is the most important biomarker of CaP. This marker can only be detected in blood and its sensitivity is approximately 80%. Moreover, early stages cannot be diagnosed using this protein. Currently, there does not exist a test for diagnosis of early stages of prostate cancer. This fact motivates us to find markers sensitive to the early stages of CaP, which are easily detected in body fluids including urine. A potential is therefore attributed to the non-protein amino acid sarcosine, which is generated by glycine-N-methyltransferase in its biochemical cycle. In this review, we summarize analytical methods for quantification of sarcosine as a CaP marker. Moreover, pathways of the connection of synthesis of sarcosine and CaP development are discussed.","[Cernei, Natalia; Gumulec, Jaromir; Zitka, Ondrej; Masarik, Michal; Babula, Petr; Kizek, Rene; Adam, Vojtech] Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic; [Cernei, Natalia; Heger, Zbynek; Gumulec, Jaromir; Zitka, Ondrej; Masarik, Michal; Babula, Petr; Kizek, Rene; Adam, Vojtech] Mendel Univ Brno, Fac Agron, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Gumulec, Jaromir; Masarik, Michal] Masaryk Univ, Dept Pathol Physiol, Fac Med, CZ-61200 Brno, Czech Republic; [Eckschlager, Tomas] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CZ-15006 Prague 5, Czech Republic; [Eckschlager, Tomas] Univ Hosp Motol, CZ-15006 Prague 5, Czech Republic; [Stiborova, Marie] Charles Univ Prague, Fac Sci, Dept Biochem, CZ-12840 Prague 2, Czech Republic","Adam, V (reprint author), Brno Univ Technol, Cent European Inst Technol, CZ-61600 Brno, Czech Republic.","cernei.natalia3@gmail.com; h12009@vfu.cz; j.gumulec@gmail.com; zitkao@seznam.cz; masarik@med.muni.cz; petr_babula@email.cz; tomas.eckschlager@fnmotol.cz; stiborov@natur.cuni.cz; kizek@sci.muni.cz; vojtech.adam@mendelu.cz","Gumulec, Jaromir/D-7638-2012; Masarik, Michal/D-9920-2012","Gumulec, Jaromir/0000-0002-9658-3444; ","LPR; CEITEC [CZ.1.05/1.1.00/02.0068]; MH CZ - DRO, University Hospital Motol, Prague, Czech Republic [00064203]","Financial support from LPR 2012, CEITEC CZ.1.05/1.1.00/02.0068 and by MH CZ - DRO, University Hospital Motol, Prague, Czech Republic 00064203 is highly acknowledged.",null,73,1,1,"MDPI AG","BASEL","POSTFACH, CH-4005 BASEL, SWITZERLAND","1422-0067",null,null,"INT J MOL SCI","Int. J. Mol. Sci.","JUL",2013,14,7,null,null,null,null,13893,13908,null,"10.3390/ijms140713893",null,16,"Chemistry, Multidisciplinary","Chemistry","188DH","WOS:000322171700060"]
[null,null,null,null,"J","Pastor, Z; Holla, K; Chmel, R",null,null,null,"Pastor, Zlatko; Holla, Katerina; Chmel, Roman",null,null,"The influence of combined oral contraceptives on female sexual desire: A systematic review","EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE",null,null,"English","Review",null,null,null,null,null,"Combined oral contraceptives; Sexual desire; Libido; Androgen; Testosterone; Oestrogen; Female sexuality","QUALITY-OF-LIFE; 3 MG DROSPIRENONE; POLYCYSTIC-OVARY-SYNDROME; ANDROGEN LEVELS; ETHINYL ESTRADIOL; HORMONAL CONTRACEPTIVES; CHLORMADINONE ACETATE; WOMEN; DYSFUNCTION; BEHAVIOR","Objectives To determine the relationship between the use of combined oral contraceptives (COCs) and sexual desire based on a systematic review of the literature. Methods MEDLINE Complete, Google Scholar and the Cochrane Library were searched for articles published between 1975 and 2011, reporting the effects of oral contraceptives on sexual desire. Reports fully meeting all the predefined criteria were analysed and included in a final reference list. In addition, a review of the reference list of selected articles was carried out. Results We evaluated 36 studies (1978-2011; 13,673 women). Of the COC users (n = 8,422), 85% reported an increase (n = 1,826) or no change (n = 5,358) in libido and 15% reported a decrease (n = 1,238). We found no significant difference in sexual desire in the case of COCs with 20-35 mu g ethinylestradiol; libido decreased only with pills containing 15 mu g ethinylestradiol. Conclusions The majority of COC users report no significant change in libido although in most studies a decline in plasma levels of free testosterone and an increase in those of sex hormone binding globulin were observed.","[Pastor, Zlatko; Chmel, Roman] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 2, Teaching Hosp Motol, Prague, Czech Republic; [Pastor, Zlatko; Holla, Katerina] Charles Univ Prague, Inst Sexol, Fac Med 1, Prague, Czech Republic","Pastor, Z (reprint author), Narodni 25, Prague 11000 1, Czech Republic.","pastor.zlatko@volny.cz",null,null,null,null,null,67,7,7,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","1362-5187",null,null,"EUR J CONTRACEP REPR","Eur. J. Contracept. Reprod. Health Care","FEB",2013,18,1,null,null,null,null,27,43,null,"10.3109/13625187.2012.728643",null,17,"Public, Environmental & Occupational Health; Obstetrics & Gynecology","Public, Environmental & Occupational Health; Obstetrics & Gynecology","072KG","WOS:000313669200005"]
[null,null,null,null,"J","Dhossche, DM; Goetz, M; Gazdag, G; Sienaert, P",null,null,null,"Dhossche, Dirk M.; Goetz, Michal; Gazdag, Gabor; Sienaert, Pascal",null,null,"New DSM-5 category \"unspecified catatonia' is a boost for pediatric catatonia: review and case reports","NEUROPSYCHIATRY",null,null,"English","Review",null,null,null,null,null,null,"NMDA-RECEPTOR ENCEPHALITIS; ELECTROCONVULSIVE-THERAPY; CHILDHOOD TRAUMA; MALIGNANT CATATONIA; SPECTRUM DISORDERS; PSYCHOTIC SYMPTOMS; CHILDREN; ADOLESCENTS; AUTISM; ECT","The creation in DSM-5 of a new category unspecified catatonia' aspires to improve diagnosis and treatment of catatonia in patients of all ages without diagnosable major psychotic, affective or medical disorders. Unspecified catatonia may be particularly beneficial in boosting recognition and treatment of pediatric catatonia that often occurs outside these disorders. Until now, pediatric catatonia has been poorly recognized. Benzodiazepines and electroconvulsive therapy are underutilized in pediatric catatonia, yet are safe and effective treatments without the risk of worsening catatonia or precipitating neuroleptic malignant syndrome. Unspecified catatonia should be considered when catatonic symptoms are present in children and adolescents with autistic and other developmental disorders, autoimmune encephalitides, tic disorders (with or without self-injury) and Tourette's syndrome, Kleine-Levin syndrome, post-traumatic reactions, pervasive refusal syndrome and other disorders. The aspirations of the unspecified catatonia' category to reduce morbidity and mortality and to increase further research are bound to be tested in the field of pediatric catatonia over the next few years. Changes in DSM-5 regarding the classification of catatonia are reviewed. Case reports are presented to illustrate the use of the new category, unspecified catatonia, in children and adolescents.","[Dhossche, Dirk M.] Univ Mississippi, Med Ctr, Dept Psychiat, Jackson, MS 39216 USA; [Goetz, Michal] Charles Univ Prague, Fac Med 2, Univ Hosp Motol, Dept Child Psychiat, Prague 15006 5, Czech Republic; [Gazdag, Gabor] Szent Istvan Hosp, Ctr Psychiat & Addict Med, H-1097 Budapest, Hungary; [Gazdag, Gabor] Szent Laszlo Hosp, Ctr Psychiat & Addict Med, H-1097 Budapest, Hungary; [Gazdag, Gabor] Semmelweis Univ, Fac Med, Dept Psychiat & Psychotherapy, H-1083 Budapest, Hungary; [Sienaert, Pascal] Katholieke Univ Leuven, Univ Psychiat Ctr, Dept Psychiat, B-3070 Kortenberg, Belgium","Dhossche, DM (reprint author), Univ Mississippi, Med Ctr, Dept Psychiat, 2500 North State St, Jackson, MS 39216 USA.","dirkdhossche@gmail.com",null,null,"Charles University in Prague; Eli Lilly and Company; Shire","M Goetz has received research support from Charles University in Prague. In the last 3 years he served as a speaker for Janssen-Cilag and Eli Lilly and Company. He has received travel grants to attend conferences in Child and Adolescent Psychiatry from Eli Lilly and Company, and Shire. P Sienaert has received honoraria as an independent speaker or as a consultant from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Janssen, Lundbeck, Bristol-Myers Squibb and Servier. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",null,63,0,0,"FUTURE MEDICINE LTD","LONDON","UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND","1758-2008",null,null,"NEUROPSYCHIATRY-LOND","Neuropsychiatry","AUG",2013,3,4,null,null,null,null,401,410,null,"10.2217/npy.13.42",null,10,"Neurosciences; Psychiatry","Neurosciences & Neurology; Psychiatry","202QK","WOS:000323233200012"]
[null,null,null,null,"J","Grunda, T; Marsalek, P; Sykorova, P",null,null,null,"Grunda, Tomas; Marsalek, Petr; Sykorova, Pavla",null,null,"Homonymous hemianopia and related visual defects: Restoration of vision after a stroke","ACTA NEUROBIOLOGIAE EXPERIMENTALIS",null,null,"English","Review",null,null,null,null,null,"homonymous hemianopia; cerebral stroke rehabilitation; scotoma; visual field deficit","CEREBRAL BLINDNESS; NEUROVISUAL REHABILITATION; FIELD EXPANSION; CORTEX; DISCRIMINATION; MECHANISMS; DEFICITS; NEURONS; SYSTEM; DAMAGE","The term homonymous hemianopia refers to visual impairment due to a post-chiasmatic brain lesion. Mammalian neurons of the central nervous system do not have the ability to regenerate. However, the cerebral cortex shows plasticity in certain cases. Motor or speech disorders due to frontal lobe brain damage can be improved with well-directed rehabilitation techniques. If such plasticity is possible, it raises the question whether specialized training could improve a cortical visual disorder. There is need for simple visual training which could be used in rehabilitation. A few different approaches have been developed to treat patients with hemianopia: (1) substitution including special devices, such as optical prisms; (2) compensation using intact residual abilities especially training of eye movements; (3) restitution which is based on stimulating the blind hemifield. The third method of rehabilitation is the most controversial; however, it has the largest potential. To support concepts of the targeted rehabilitation outlined here, first: further development of the theory of plasticity in visual pathways is required and second: the efficacy of the rehabilitation procedures has to be demonstrated by clinical evidence. We review methods and approaches of hemianopia rehabilitation and treatment. We also review results of contemporary clinical studies and meta-studies.","[Grunda, Tomas; Marsalek, Petr] Charles Univ Prague, Fac Med 1, Inst Pathol Physiol, Prague, Czech Republic; [Grunda, Tomas; Marsalek, Petr] Czech Tech Univ, Fac Biomed Engn, Kladno, Czech Republic; [Sykorova, Pavla] Charles Univ Prague, Fac Med 2, Dept Nucl Med & Endocrinol, Prague, Czech Republic","Marsalek, P (reprint author), Charles Univ Prague, Fac Med 1, Inst Pathol Physiol, Prague, Czech Republic.","Petr.Marsalek@lf1.cuni.cz",null,null,"Czech Ministry of Health program \"Medical Technology Assessment\" at the Czech Technical University [NT 11532]; Czech Ministry of Industry and Trade project at the Charles University in Prague [MPO FR-TI3/ 869]","Supported by the Czech Ministry of Health program NT 11532 \"Medical Technology Assessment\" at the Czech Technical University and by the Czech Ministry of Industry and Trade project MPO FR-TI3/ 869 at the Charles University in Prague. We thank the two anonymous reviewers for helpful comments, Eli Peli and Jiri Vrana for discussions, Tomas Mika and Helen Nathan for copy-editing. Special thanks are due to Jiri Kofranek and Veronika Sykorova for technical assistance.",null,53,0,0,"NENCKI INST EXPERIMENTAL BIOLOGY","WARSAW","UL PASTEURA 3, 02-093 WARSAW, POLAND","0065-1400",null,null,"ACTA NEUROBIOL EXP","Acta Neurobiol. Exp.",null,2013,73,2,null,null,null,null,237,249,null,null,null,13,"Neurosciences","Neurosciences & Neurology","182DB","WOS:000321720800003"]
[null,null,null,null,"J","Vacchelli, E; Vitale, I; Eggermont, A; Fridman, WH; Fucikova, J; Cremer, I; Galon, J; Tartour, E; Zitvogel, L; Kroemer, G; Galluzzi, L",null,null,null,"Vacchelli, Erika; Vitale, Ilio; Eggermont, Alexander; Fridman, Wolf Herve; Fucikova, Jitka; Cremer, Isabelle; Galon, Jerome; Tartour, Eric; Zitvogel, Laurence; Kroemer, Guido; Galluzzi, Lorenzo",null,null,"Trial Watch Dendritic cell-based interventions for cancer therapy","ONCOIMMUNOLOGY",null,null,"English","Review",null,null,null,null,null,"antigen-presenting cells; immunogenic cell death; monoclonal antibodies; plasmacytoid dendritic cells; regulatory T cells; Toll-like receptors","ANTITUMOR IMMUNE-RESPONSES; CYTOTOXIC T-LYMPHOCYTES; METASTATIC MELANOMA PATIENTS; ANTIGEN CROSS-PRESENTATION; INTERFERON-PRODUCING CELLS; COLONY-STIMULATING FACTOR; APOPTOTIC TUMOR-CELLS; II CLINICAL-TRIAL; IN-VIVO; PROSTATE-CANCER","Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer. Thus, the possibility of harnessing the elevated immunological potential of DCs for anticancer therapy has attracted considerable interest from both researchers and clinicians over the last decade. Alongside, several methods have been developed not only to isolate DCs from cancer patients, expand them, load them with tumor-associated antigens and hence generate highly immunogenic clinical grade infusion products, but also to directly target DCs in vivo. This intense experimental effort has culminated in 2010 with the approval by the US FDA of a DC-based preparation (sipuleucel-T, Provenge((R))) for the treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer. As an update to the latest Trial Watch dealing with this exciting field of research (October 2012), here we summarize recent advances in DC-based anticancer regimens, covering both high-impact studies that have been published during the last 13 mo and clinical trials that have been launched in the same period to assess the antineoplastic potential of this variant of cellular immunotherapy.","[Vacchelli, Erika; Galluzzi, Lorenzo] Gustave Roussy, Villejuif, France; [Vacchelli, Erika; Eggermont, Alexander; Zitvogel, Laurence] Univ Paris 11, Le Kremlin Bicetre, France; [Vacchelli, Erika; Kroemer, Guido] INSERM, U848, Villejuif, France; [Vitale, Ilio] Regina Elena Inst Canc Res, Rome, Italy; [Vitale, Ilio] Natl Inst Hlth, Rome, Italy; [Fridman, Wolf Herve; Fucikova, Jitka; Tartour, Eric; Kroemer, Guido; Galluzzi, Lorenzo] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Fridman, Wolf Herve; Fucikova, Jitka; Cremer, Isabelle; Galon, Jerome; Tartour, Eric; Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Paris, France; [Fridman, Wolf Herve; Fucikova, Jitka; Cremer, Isabelle] Ctr Rech Cordeliers, Equipe 13, Paris, France; [Fucikova, Jitka] Charles Univ & Univ Hosp Motol, Dept Immunol, Sch Med 2, Prague, Czech Republic; [Fucikova, Jitka] Sotio As, Prague, Czech Republic; [Cremer, Isabelle; Galon, Jerome] Univ Paris 06, Paris, France; [Galon, Jerome] Ctr Rech Cordeliers, Equipe 15, Paris, France; [Galon, Jerome] INSERM, U872, Paris, France; [Tartour, Eric] INSERM, U970, Paris, France; [Zitvogel, Laurence] INSERM, U1015, CICBT507, Villejuif, France; [Kroemer, Guido; Galluzzi, Lorenzo] Ctr Rech Cordeliers, Equipe 11 Iabelisee Ligue Natl Canc, Paris, France; [Kroemer, Guido] Gustave Roussy, Metabol & Cell Biol Platforms, Villejuif, France","Kroemer, G (reprint author), INSERM, U848, Villejuif, France.","kroemer@igr.fr; deadoc@vodafone.it",null,null,"European Commission (ArtForce); European Research Council (ERC); Agence National de la Recherche (ANR); Ligue Nationale contre le Cancer; Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); Associazione Italiana per la Ricerca sul Cancro (AIRC); Association pour la Recherche sur le Cancer (ARC), LabEx Immuno-Oncologie; Fondation de France; Fondation Bettencourt-Schueller; AXA Chair for Longevity Research; Canceropole Ile-de-France, Paris Alliance of Cancer Research Institutes (PACRI); Cancer Research for Personalized Medicine (CARPEM)","Jitka Fucikova works for Sotio a.s. (Prague, Czech Republic), which is actively investigating DC-based vaccines in both preclinical and clinical settings. Authors are supported by the European Commission (ArtForce); European Research Council (ERC); Agence National de la Recherche (ANR); Ligue Nationale contre le Cancer; Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); Associazione Italiana per la Ricerca sul Cancro (AIRC); Association pour la Recherche sur le Cancer (ARC), LabEx Immuno-Oncologie; Fondation de France; Fondation Bettencourt-Schueller; AXA Chair for Longevity Research; Canceropole Ile-de-France, Paris Alliance of Cancer Research Institutes (PACRI) and Cancer Research for Personalized Medicine (CARPEM).",null,368,3,3,"LANDES BIOSCIENCE","AUSTIN","1806 RIO GRANDE ST, AUSTIN, TX 78702 USA","2162-4011","2162-402X",null,"ONCOIMMUNOLOGY","OncoImmunology","OCT 1",2013,2,10,null,null,null,null,null,null,null,"10.4161/onci.25771",null,15,"Oncology; Immunology","Oncology; Immunology","262LO","WOS:000327737000020"]
[null,null,null,null,"J","Stefano, GB; Ptacek, R; Kuzelova, H; Mantione, KJ; Raboch, J; Papezova, H; Kream, RM",null,null,null,"Stefano, George B.; Ptacek, Radek; Kuzelova, Hana; Mantione, Kirk J.; Raboch, Jiri; Papezova, Hana; Kream, Richard M.",null,null,"Convergent dysregulation of frontal cortical cognitive and reward systems in eating disorders","MEDICAL SCIENCE MONITOR",null,null,"English","Review",null,null,null,null,null,"cognition; reward systems; eating disorders; frontal cortex; binge eating; bulimia; anorexia; dopamine; morphine","BODY-IMAGE DISTORTION; DEFICIT HYPERACTIVITY DISORDER; MU-OPIOID RECEPTOR; ANOREXIA-NERVOSA; BULIMIA-NERVOSA; PREFRONTAL CORTEX; ENDOGENOUS MORPHINE; FUNCTIONAL NEUROANATOMY; BEHAVIORAL FLEXIBILITY; SCHIZOPHRENIA","A substantive literature has drawn a compelling case for the functional involvement of mesolimbic/prefrontal cortical neural reward systems in normative control of eating and in the etiology and persistence of severe eating disorders that affect diverse human populations. Presently, we provide a short review that develops an equally compelling case for the importance of dysregulated frontal cortical cognitive neural networks acting in concert with regional reward systems in the regulation of complex eating behaviors and in the presentation of complex pathophysiological symptoms associated with major eating disorders. Our goal is to highlight working models of major eating disorders that incorporate complementary approaches to elucidate functionally interactive neural circuits defined by their regulatory neurochemical phenotypes. Importantly, we also review evidence-based linkages between widely studied psychiatric and neurodegenerative syndromes (e.g., autism spectrum disorders and Parkinson's disease) and co-morbid eating disorders to elucidate basic mechanisms involving dopaminergic transmission and its regulation by endogenously expressed morphine in these same cortical regions.","[Stefano, George B.; Ptacek, Radek; Kuzelova, Hana; Raboch, Jiri; Papezova, Hana; Kream, Richard M.] Charles Univ Prague, Fac Med 1, Ctr Mol & Cognit Neurosci, Prague, Czech Republic; [Stefano, George B.; Mantione, Kirk J.; Kream, Richard M.] SUNY Coll Old Westbury, Neurosci Res Inst, Old Westbury, NY 11568 USA; [Kuzelova, Hana] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic","Stefano, GB (reprint author), Charles Univ Prague, Fac Med 1, Ctr Mol & Cognit Neurosci, Prague, Czech Republic.","gstefano@sunynri.org",null,null,null,null,null,62,1,1,"INT SCIENTIFIC LITERATURE, INC","SMITHTOWN","361 FOREST LANE, SMITHTOWN, NY 11787 USA","1643-3750",null,null,"MED SCI MONITOR","Med. Sci. Monitor","MAY 10",2013,19,null,null,null,null,null,353,358,null,"10.12659/MSM.889133",null,6,"Medicine, Research & Experimental","Research & Experimental Medicine","159QE","WOS:000320059700001"]
[null,null,null,null,"J","Korczyn, AD; Schachter, SC; Brodie, MJ; Dalal, SS; Engel, J; Guekht, A; Hecimovic, H; Jerbi, K; Kanner, AM; Landmark, CJ; Mares, P; Marusic, P; Meletti, S; Mula, M; Patsalos, PN; Reuber, M; Ryvlin, P; Stillova, K; Tuchman, R; Rektor, I",null,null,null,"Korczyn, Amos D.; Schachter, Steven C.; Brodie, Martin J.; Dalal, Sarang S.; Engel, Jerome; Guekht, Alla; Hecimovic, Hrvoje; Jerbi, Karim; Kanner, Andres M.; Landmark, Cecilie Johannessen; Mares, Pavel; Marusic, Petr; Meletti, Stefano; Mula, Marco; Patsalos, Philip N.; Reuber, Markus; Ryvlin, Philippe; Stillova, Klara; Tuchman, Roberto; Rektor, Ivan",null,null,"Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)","EPILEPSY & BEHAVIOR",null,null,"English","Review",null,null,null,null,null,"Epilepsy; Behavior; EEG; Mind; Psychiatry; Psychology; Antiepileptic drugs; Cognition; Stress; Imaging; Social issues","TEMPORAL-LOBE EPILEPSY; MAJOR DEPRESSIVE DISORDER; POSITRON-EMISSION-TOMOGRAPHY; PSYCHIATRIC ADVERSE EVENTS; MAGNETIC-RESONANCE SPECTROSCOPY; FACIAL EMOTION RECOGNITION; AUTISM SPECTRUM DISORDER; GENERALIZED ANXIETY DISORDER; CLOZAPINE-RELATED SEIZURES; 5-HT1A RECEPTOR-BINDING","Epilepsy is, of course, not one disease but rather a huge number of disorders that can present with seizures. In common, they all reflect brain dysfunction. Moreover, they can affect the mind and, of course, behavior. While animals too may suffer from epilepsy, as far as we know, the electrical discharges are less likely to affect the mind and behavior, which is not surprising. While the epileptic seizures themselves are episodic, the mental and behavioral changes continue, in many cases, interictally. The episodic mental and behavioral manifestations are more dramatic, while the interictal ones are easier to study with anatomical and functional studies. The following extended summaries complement those presented in Part 1. (C) 2013 Published by Elsevier Inc.","[Korczyn, Amos D.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Ramat Aviv, Israel; [Schachter, Steven C.] Harvard Univ, Sch Med, Ctr Integrat Med & Innovat Technol, Boston, MA USA; [Brodie, Martin J.] Univ Glasgow, Western Infirm, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland; [Dalal, Sarang S.] Univ Konstanz, Zukunftskolleg, Constance, Germany; [Dalal, Sarang S.] Univ Konstanz, Dept Psychol, Constance, Germany; [Dalal, Sarang S.; Jerbi, Karim] Univ Lyon 1, INSERM U1028, CNRS UMR5292, Lyon Neurosci Res Ctr CRNL,Brain Dynam & Cognit T, F-69365 Lyon, France; [Engel, Jerome] UCLA Neurol, Los Angeles, CA USA; [Guekht, Alla] Russian Natl Res Med Univ, Moscow City Hosp Neuropsychiat 8, Moscow, Russia; [Hecimovic, Hrvoje] Univ Hosp, Dept Neurol, Zagreb Epilepsy Ctr, Zagreb, Croatia; [Kanner, Andres M.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Landmark, Cecilie Johannessen] Dept Pharm & Biomed Sci, Oslo, Norway; [Landmark, Cecilie Johannessen] Akershus Univ, Coll Appl Sci, Oslo, Norway; [Mares, Pavel] Acad Sci Czech Republic, Inst Physiol, Prague, Czech Republic; [Marusic, Petr] Charles Univ Prague, Dept Neurol, Motol Univ Hosp, Fac Med 2, Prague, Czech Republic; [Meletti, Stefano] Univ Modena & Reggio Emilia, Dept Biomed Sci Metab & Neurosci, Modena, Italy; [Mula, Marco] Amedeo Avogadro Univ, Novara, Italy; [Patsalos, Philip N.] London & Epilepsy Soc, UCL Inst Neurol, Dept Clin & Expt Epilepsy, Gerrards Cross, England; [Reuber, Markus] Univ Sheffield, Royal Hallamshire Hosp, Acad Neurol Unit, Sheffield S10 2JF, S Yorkshire, England; [Ryvlin, Philippe] Univ Lyon 1, UMR CNRS 5292, INSERM U1028, HCL TIGER,CRNL,Hop Neurol,Serv Neurol Fonct & Epi, F-69365 Lyon, France; [Stillova, Klara; Rektor, Ivan] Masaryk Univ, Brno Epilepsy Ctr, St Annes Hosp, Brno, Czech Republic; [Stillova, Klara; Rektor, Ivan] Masaryk Univ, Sch Med, Brno, Czech Republic; [Stillova, Klara; Rektor, Ivan] Cent European Inst Technol CEITEC, Brno, Czech Republic; [Tuchman, Roberto] Florida Int Univ, Herbert Wertheim Coll Med, Miami Childrens Hosp,Dan Marino Ctr, Autism & Neurodev Program,Dept Neurol, Miami, FL 33199 USA; [Tuchman, Roberto] Florida Int Univ, Herbert Wertheim Coll Med, Miami Childrens Hosp,Dan Marino Ctr, Autism & Neurodev Program,Dept Psychiat, Miami, FL 33199 USA","Rektor, I (reprint author), Masaryk Univ, Cent European Ctr Technol CEITEC, St Annes Hosp & Sch Med, Brno Epilepsy Ctr,Dept Neurol 1, Brno, Czech Republic.","irektor@med.muni.cz","Mares, Pavel/F-8903-2014",null,null,null,null,195,0,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1525-5050",null,null,"EPILEPSY BEHAV","Epilepsy Behav.","AUG",2013,28,2,null,null,null,null,283,302,null,"10.1016/j.yebeh.2013.03.012",null,20,"Behavioral Sciences; Clinical Neurology; Psychiatry","Behavioral Sciences; Neurosciences & Neurology; Psychiatry","178FE","WOS:000321429100027"]
[null,null,null,null,"J","Rektor, I; Schachter, SC; Arzy, S; Baloyannis, SJ; Bazil, C; Brazdil, M; Engel, J; Helmstaedter, G; Hesdorffer, DC; Jones-Gotman, M; Kesner, L; Komarek, V; Kramer, G; Leppik, IE; Mann, MW; Mula, M; Risse, GL; Stoker, GW; Trenite, DGAKN; Trimble, M; Tyrlikova, I; Korczyn, AD",null,null,null,"Rektor, Ivan; Schachter, Steven C.; Arzy, Shahar; Baloyannis, Stavros J.; Bazil, Carl; Brazdil, Milan; Engel, Jerome, Jr.; Helmstaedter, Gerhard; Hesdorffer, Dale C.; Jones-Gotman, Marilyn; Kesner, Ladislav; Komarek, Vladimir; Kraemer, Guenter; Leppik, Ilo E.; Mann, Michael W.; Mula, Marco; Risse, Gail L.; Stoker, Guy W.; Kasteleijn-Nolst Trenitee, Dorothee G. A.; Trimble, Michael; Tyrlikova, Ivana; Korczyn, Amos D.",null,null,"Epilepsy, behavior, and art (Epilepsy, Brain, and Mind, part 1)","EPILEPSY & BEHAVIOR",null,null,"English","Review",null,null,null,null,null,"Epilepsy; Art; Music; Behavior; Mind; Psychiatry; Hallucinations; Cognition; Stress; Crime","TEMPORAL-LOBE EPILEPSY; SLOW-WAVE SLEEP; COGNITIVE CONSEQUENCES; OLDER-ADULTS; NETWORK ORGANIZATION; VERBAL MEMORY; RISK-FACTORS; DEJA-VU; SEIZURES; SELF","Epilepsy is both a disease of the brain and the mind. Brain diseases, structural and/or functional, underlie the appearance of epilepsy, but the notion of epilepsy is larger and cannot be reduced exclusively to the brain. We can therefore look at epilepsy from two angles. The first perspective is intrinsic: the etiology and pathophysiology, problems of therapy, impact on the brain networks, and the \"mind\" aspects of brain functions - cognitive, emotional, and affective. The second perspective is extrinsic: the social interactions of the person with epilepsy, the influence of the surrounding environment, and the influences of epilepsy on society. All these aspects reaching far beyond the pure biological nature of epilepsy have been the topics of two International Congresses of Epilepsy, Brain, and Mind that were held in Prague, Czech Republic, in 2010 and 2012 (the third Congress will be held in Brno, Czech Republic on April 3-5, 2014; www.epilepsy-brain-mind2014.eu). Here, we present the first of two papers with extended summaries of selected presentations of the 2012 Congress that focused on epilepsy, behavior, and art. (C) 2013 Published by Elsevier Inc.","[Rektor, Ivan; Brazdil, Milan; Tyrlikova, Ivana] Masaryk Univ, Brno Epilepsy Ctr, St Annes Hosp, Brno, Czech Republic; [Rektor, Ivan; Brazdil, Milan; Tyrlikova, Ivana] Masaryk Univ, Sch Med, Brno, Czech Republic; [Rektor, Ivan; Brazdil, Milan; Tyrlikova, Ivana] Cent European Inst Technol CEITEC, Brno, Czech Republic; [Schachter, Steven C.] Harvard Univ, Sch Med, Ctr Integrat Med & Innovat Technol, Boston, MA USA; [Arzy, Shahar] Univ Hosp Geneva, Dept Neurol, EEG, Geneva, Switzerland; [Arzy, Shahar] Univ Hosp Geneva, Dept Neurol, Epilepsy Unit, Geneva, Switzerland; [Baloyannis, Stavros J.] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece; [Bazil, Carl] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Engel, Jerome, Jr.] UCLA Neurol, Los Angeles, CA USA; [Helmstaedter, Gerhard] Goethe Univ Frankfurt, Former Inst Hist Sci, D-50259 Pulheim, Germany; [Hesdorffer, Dale C.] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA; [Hesdorffer, Dale C.] Columbia Univ, Dept Epidemiol, New York, NY 10027 USA; [Jones-Gotman, Marilyn] McGill Univ, Dept Neurol & Neurol Surg, Montreal, PQ, Canada; [Kesner, Ladislav] Masaryk Univ, Dept Art Hist, Brno, Czech Republic; [Komarek, Vladimir] Charles Univ Prague, Epilepsy Ctr Motol, Sch Med 2, Dept Child Neurol, Prague, Czech Republic; [Kraemer, Guenter] Swiss Epilepsy Ctr, Zurich, Switzerland; [Leppik, Ilo E.; Risse, Gail L.] Univ Minnesota, MINCEP Epilepsy Care & Coll Pharm, Minneapolis, MN USA; [Mann, Michael W.] Hop St Anne Pr FX Roux, Dept Neurosurg, Paris, France; [Mula, Marco] Amedeo Avogadro Univ, Novara, Italy; [Stoker, Guy W.] Univ Coll Falmouth, Dartington Coll, Falmouth, England; [Kasteleijn-Nolst Trenitee, Dorothee G. A.] Univ Rome Sapienza II, Rome, Italy; [Kasteleijn-Nolst Trenitee, Dorothee G. A.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Trimble, Michael] Inst Neurol, London WC1N 3BG, England; [Korczyn, Amos D.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Ramat Aviv, Israel","Korczyn, AD (reprint author), Tel Aviv Univ, Dept Neurol, IL-69978 Ramat Aviv, Israel.","amoskor@tau.ac.il",null,null,null,null,null,163,0,0,"ACADEMIC PRESS INC ELSEVIER SCIENCE","SAN DIEGO","525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA","1525-5050",null,null,"EPILEPSY BEHAV","Epilepsy Behav.","AUG",2013,28,2,null,null,null,null,261,282,null,"10.1016/j.yebeh.2013.03.011",null,22,"Behavioral Sciences; Clinical Neurology; Psychiatry","Behavioral Sciences; Neurosciences & Neurology; Psychiatry","178FE","WOS:000321429100026"]
[null,null,null,null,"J","Mravcik, V; Strada, L; Stolfa, J; Bencko, V; Groshkova, T; Reimer, J; Schulte, B",null,null,null,"Mravcik, Viktor; Strada, Lisa; Stolfa, Josef; Bencko, Vladimir; Groshkova, Teodora; Reimer, Jens; Schulte, Bernd",null,null,"Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review","PATIENT PREFERENCE AND ADHERENCE",null,null,"English","Review",null,null,null,null,null,"hepatitis C virus; people who inject drugs; treatment uptake; adherence; efficacy","OPIATE SUBSTITUTION TREATMENT; PEGYLATED INTERFERON-ALPHA; VIRUS-INFECTION; PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2A; METHADONE-MAINTENANCE; ANTIVIRAL TREATMENT; SYRINGE EXCHANGE; NATURAL-HISTORY; VIRAL CLEARANCE","Introduction and methods: Hepatitis C virus (HCV) infections are highly prevalent amongst people who inject drugs (PWID). Despite well documented evidence of its effectiveness, suggested cost-effectiveness, and potential to reduce HCV prevalence rates, the uptake of antiviral HCV treatment by PWID is low. This nonsystematic literature review describes factors associated with the uptake, adherence, and efficacy of HCV treatment among PWID and discusses strategies to increase their uptake of treatment. Results: Low HCV treatment uptake among PWID is associated with a number of patient-related and provider-related barriers. Beliefs and fears about low efficacy and adverse effects on the patient's part are common. A substantial number of factors are associated with the chaotic lifestyle and altered social functioning of PWID, which are often associated with decompensation or relapsing into drug addiction. This may lead to perceived low adherence with treatment and low efficacy on the provider's part too, where lack of support, inadequate management of addiction, and other drug-related problems and poor treatment of side effects have been described. Practical issues such as the accessibility of treatment and finances also play a role. Strategies to improve the HCV treatment rate among PWID involve pretreatment management and assessment, a multidisciplinary approach, management of side effects, and enhanced education and counseling. Conclusion: Specific factors are associated with poorer treatment outcomes in PWID on the side of both the patient and the treatment system. However, given that PWID can achieve treatment adherence and sustained virologic response rates comparable with those in nondrug users, drug use per se should not be considered a criterion for exclusion from treatment. Further development of measures leading to higher uptake of treatment and adherence in PWID and appropriate adaptation of HCV treatment guidelines represent important tools in this regard.","[Mravcik, Viktor] Charles Univ Prague, Natl Monitoring Ctr Drugs & Drug Addict, Prague, Czech Republic; [Mravcik, Viktor] Charles Univ Prague, Dept Addictol, Fac Med 1, Prague, Czech Republic; [Strada, Lisa; Reimer, Jens; Schulte, Bernd] Univ Hamburg, Ctr Interdisciplinary Addict Res, Hamburg, Germany; [Stolfa, Josef] Inst Postgrad Med Educ, Dept Gen Practice, Prague, Czech Republic; [Stolfa, Josef] Charles Univ Prague, Dept Gen Practice, Fac Med 2, Prague, Czech Republic; [Bencko, Vladimir] Charles Univ Prague, Inst Hyg & Epidemiol, Fac Med 1, Prague, Czech Republic; [Groshkova, Teodora] European Monitoring Ctr Drugs & Drug Addict, Lisbon, Portugal","Mravcik, V (reprint author), Off Govt Czech Republ, Natl Monitoring Ctr Drugs & Drug Addict, Nabrezi E Benese 4, Prague 11801 1, Czech Republic.","mravcik.viktor@vlada.cz",null,null,"Internal Grant Agency of the Ministry of Health [IGA 10034-4]","This research was partly funded by the Internal Grant Agency of the Ministry of Health (grant number IGA 10034-4: Social costs of tobacco, alcohol, and illicit drugs in the Czech Republic). The funding body had no role in the review design, collection, analysis, and interpretation of data.",null,105,0,0,"DOVE MEDICAL PRESS LTD","ALBANY","PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND","1177-889X",null,null,"PATIENT PREFER ADHER","Patient Prefer. Adherence",null,2013,7,null,null,null,null,null,1067,1075,null,"10.2147/PPA.S49113",null,9,"Medicine, General & Internal","General & Internal Medicine","234YH","WOS:000325679700001"]
[null,null,null,null,"J","Aalbers, AM; Calado, RT; Young, NS; Zwaan, CM; Kajigaya, S; Baruchel, A; Geleijns, K; de Haas, V; Kaspers, GJL; Reinhardt, D; Trka, J; Kuijpers, TW; Pieters, R; van der Velden, VHJ; van den Heuvel-Eibrink, MM",null,null,null,"Aalbers, Anna M.; Calado, Rodrigo T.; Young, Neal S.; Zwaan, C. Michel; Kajigaya, Sachiko; Baruchel, Andre; Geleijns, Karin; de Haas, Valerie; Kaspers, Gertjan J. L.; Reinhardt, Dirk; Trka, Jan; Kuijpers, Taco W.; Pieters, Rob; van der Velden, Vincent H. J.; van den Heuvel-Eibrink, Marry M.",null,null,"Absence of SBDS mutations in sporadic paediatric acute myeloid leukaemia","BRITISH JOURNAL OF HAEMATOLOGY",null,null,"English","Letter",null,null,null,null,null,"acute myeloid leukaemia; SBDS; mutation analysis","SHWACHMAN-DIAMOND-SYNDROME; GENE",null,"[Aalbers, Anna M.; Zwaan, C. Michel; Pieters, Rob; van den Heuvel-Eibrink, Marry M.] Erasmus MC Sophia Childrens Hosp, Dept Paediat Oncol Haematol, Rotterdam, Netherlands; [Aalbers, Anna M.; Geleijns, Karin; van der Velden, Vincent H. J.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Aalbers, Anna M.; Calado, Rodrigo T.; Young, Neal S.; Kajigaya, Sachiko] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA; [Calado, Rodrigo T.] Univ Sao Paulo, Sch Med, Dept Internal Med, Ribeirao Preto, SP, Brazil; [Baruchel, Andre] Hop Robert Debre, Dept Paediat Haematol, F-75019 Paris, France; [Geleijns, Karin] Erasmus MC, Dept Neurol, Rotterdam, Netherlands; [de Haas, Valerie; Kaspers, Gertjan J. L.] Dutch Childhood Oncol Grp, The Hague, Netherlands; [Kaspers, Gertjan J. L.] Vrije Univ Amsterdam Med Ctr, Dept Paediat Oncol Haematol, Amsterdam, Netherlands; [Reinhardt, Dirk] Hannover Med Sch, Dept Paediat Haematol Oncol, AML BFM Study Grp, Hannover, Germany; [Trka, Jan] Charles Univ Prague, Dept Paediat Haematol Oncol, Med Sch 2, Prague, Czech Republic; [Kuijpers, Taco W.] Univ Amsterdam, Acad Med Ctr, Dept Blood Cell Res, Sanquin Res & Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands; [Kuijpers, Taco W.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Paediat Haematol Immunol & Infect Dis, NL-1105 AZ Amsterdam, Netherlands","Aalbers, AM (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Paediat Oncol Haematol, Rotterdam, Netherlands.","m.vandenheuvel@erasmusmc.nl","Reinhardt, Dirk/D-3939-2011; Calado, Rodrigo/G-2619-2011","Reinhardt, Dirk/0000-0003-4313-9056; ",null,null,null,10,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0007-1048",null,null,"BRIT J HAEMATOL","Br. J. Haematol.","FEB",2013,160,4,null,null,null,null,559,561,null,"10.1111/bjh.12134",null,3,"Hematology","Hematology","077ZO","WOS:000314068100018"]
[null,null,null,null,"J","Dostalova, T; Jelinkova, H; Sulc, J; Nemec, M; Buckova, M; Kasparova, M; Miyagi, M",null,"Rechmann, P; Fried, D",null,"Dostalova, Tat'jana; Jelinkova, Helena; Sulc, Jan; Nemec, Michal; Buckova, Michaela; Kasparova, Magdalena; Miyagi, Mitsunobu",null,null,"Contact versus non-contact ablation of the artificial enamel caries by Er:YAG and CTH:YAG laser radiation","LASERS IN DENTISTRY XIX","Proceedings of SPIE",null,"English","Proceedings Paper","Conference on Lasers in Dentistry XIX","FEB 03, 2013","San Francisco, CA","SPIE",null,"dentistry; Er:YAG laser; CTH:YAG laser; contact ablation; non-contact ablation","ER-YAG LASER; ASSISTED CAVITY PREPARATION; TOOTH STRUCTURE; ADHESION","The aim of study is to compare the ablation effect of contact and non-contact interaction of Er:YAG and CTH:YAG laser radiation with artificial enamel caries lesion. The artificial caries was prepared in intact teeth to simulate demineralized surface and the laser radiation was applied. Contact and non-contact ablation was compared. Two laser systems Er:YAG 2.94 mu m and CTH:YAG 2.1 mu m were used. The enamel artificial caries were gently removed by laser radiation and flow Sonic fill composite resin was inserted. Scanning electron microscope was use to evaluate the enamel surface.","[Dostalova, Tat'jana; Buckova, Michaela; Kasparova, Magdalena] Charles Univ Prague, Fac Med 2, Dept Stomatol, Prague 15006 5, Czech Republic","Dostalova, T (reprint author), Charles Univ Prague, Fac Med 2, Dept Stomatol, Prague 15006 5, Czech Republic.","tatjana.dostalova@fnmotol.cz",null,null,null,null,null,14,0,0,"SPIE-INT SOC OPTICAL ENGINEERING","BELLINGHAM","1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA","0277-786X",null,"978-0-8194-9335-4","PROC SPIE",null,null,2013,8566,null,null,null,null,null,null,null,null,"10.1117/12.2006219",null,8,"Dentistry, Oral Surgery & Medicine; Optics","Dentistry, Oral Surgery & Medicine; Optics","BGQ93","WOS:000323831400008"]
[null,null,null,null,"S","Hainerova, IA; Lebl, J",null,"Shamir, R; Turck, D; Phillip, M",null,"Hainerova, I. Aldhoon; Lebl, J.",null,null,"Treatment Options for Children with Monogenic Forms of Obesity","NUTRITION AND GROWTH","World Review of Nutrition and Dietetics",null,"English","Article; Proceedings Paper","1st International Conference on Nutrition and Growth","MAR 01-03, 2012","Paris, FRANCE",null,null,null,"EARLY-ONSET OBESITY; WEIGHT-LOSS; LEPTIN REPLACEMENT; BARIATRIC SURGERY; RECEPTOR GENE; MC4R; MUTATIONS; DEFICIENCY; HYPOGONADISM; PREVALENCE","Mutations in genes involved in energy balance regulation within the central nervous system lead to monogenic forms of obesities. Individuals with these mutations are characterized by early-onset obesity and in some cases by endocrine abnormalities. Carriers of leptin gene mutations are able to normalize their body weight after daily subcutaneous leptin administration. Pharmacotherapy targeting the specific-gene deficiencies has not clinically been tested in other monogenic obesities. Mutations in the melanocortin 4 receptor gene (MC4R) represent the most common monogenic cause of human obesity. Several treatment options have been investigated in subjects with MC4R mutations. Few studies showed that an intensive life-style intervention induces similar weight reduction in MC4R mutation carriers in comparison to MC4R mutation noncarriers. However, long-term body weight maintenance is hardly ever achieved in MC4R mutation carriers. Sibutramine, serotonin and noradrenalin reuptake inhibitor, in MC4R mutation carriers induced weight reduction and improved cardio-metabolic health risks. This result was also found in our homozygous MC4R mutation carrier. In vitro studies of melanocortin agonists efficiently activate mutated MC4R with impaired endogenous agonist functional response and thus, further research in the development of drugs for MC4R mutations is needed. An administration of intranasal adrenocorticotropic hormone was not shown to be effective in subjects with pro-opiomelanocortin gene mutations. Bariatric surgery has also been performed in few of MC4R mutation carriers. After gastric banding, lower body weight reduction and worse improvement of metabolic complications was found in MC4R mutation carriers versus noncarriers. However, preliminary results suggest that diversionary operations as gastric bypass represent a suitable method also for MC4R mutation carriers. In conclusion, the management of monogenic obesities still remains a challenge. Copyright (C) 2013 S. Karger AG, Basel","[Hainerova, I. Aldhoon] Charles Univ Prague, Fac Med 3, Dept Pediat, CZ-10034 Prague 10, Czech Republic; [Hainerova, I. Aldhoon] Charles Univ Prague, Fac Med 3, Ctr Res Diabet Metab & Nutr, CZ-10034 Prague 10, Czech Republic; [Lebl, J.] Charles Univ Prague, Fac Med 2, Dept Pediat, CZ-15006 Prague 5, Czech Republic","Hainerova, IA (reprint author), Charles Univ Prague, Fac Med 3, Dept Pediat, Srobarova 50, CZ-10034 Prague 10, Czech Republic.","ihainer@hotmail.com",null,null,"Czech research project of MSM VZ [0021620814]; Czech Ministry of Health IGA [NT 12342-5]","Supported by the Czech research project of MSM VZ No. 0021620814 and the Czech Ministry of Health IGA grant NT 12342-5.",null,30,0,0,"KARGER","BASEL","POSTFACH, CH-4009 BASEL, SWITZERLAND","0084-2230",null,"978-3-318-02265-0","WORLD REV NUTR DIET","World Rev.Nutr.Diet.",null,2013,106,null,null,null,null,null,105,112,null,"10.1159/000342556",null,8,"Nutrition & Dietetics","Nutrition & Dietetics","BEH97","WOS:000316645700016"]
[null,null,null,null,"J","Plotnicki, L; Kohl, CD; Hocker, B; Krupka, K; Rahmel, A; Pape, L; Hoyer, P; Marks, SD; Webb, NJA; Soylemezoglu, O; Topaloglu, R; Szabo, AJ; Seeman, T; Cornelissen, EAM; Knops, N; Grenda, R; Tonshoff, B",null,null,null,"Plotnicki, L.; Kohl, C. D.; Hoecker, B.; Krupka, K.; Rahmel, A.; Pape, L.; Hoyer, P.; Marks, S. D.; Webb, N. J. A.; Soeylemezoglu, O.; Topaloglu, R.; Szabo, A. J.; Seeman, T.; Cornelissen, E. A. Marlies; Knops, N.; Grenda, R.; Toenshoff, B.",null,null,"The CERTAIN Registry: A Novel, Web-Based Registry and Research Platform for Pediatric Renal Transplantation in Europe","TRANSPLANTATION PROCEEDINGS",null,null,"English","Article; Proceedings Paper","Berlin Symposium on Xenotransplantation / 24th International Congress of the Transplantation-Society (TTS)","JUL 13-19, 2012","Berlin, GERMANY","Transplantat Soc (TTS), Int Xenotransplantat Assoc (IXA)","Robert Koch Inst",null,null,"Background. The results of pediatric renal transplantation have improved markedly in the last decade. However, a number of relevant clinical problems remain, such as organ damage caused by chronic rejection, long-term toxicity of immunosuppressive therapy, difficulty in developing tolerance-inducing protocols, secondary cardiovascular comorbidity, post-transplantation lymphoproliferative disease, suboptimal longitudinal growth, quality of life, adherence to immunosuppressive medication, and structured transition programs to adult care. These unmet clinical needs require intense collaborative and interdisciplinary clinical research. We recently founded the Cooperative European Paediatric Renal TransplAnt INitiative (CERTAIN; www.certain-registry.eu) as a research network and platform built on a novel, web-based registry. Results. The registry's dataset provides essential information on generic kidney transplantation-related topics and also captures pediatric-specific topics, such as growth, physical and psychosocial development, and adherence. Due to its flexibility the system can be used as follows: (1) as a registry capturing a minimal or an extended dataset; (2) as a center and/or country-specific transplantation database; or (3) as a patient-specific electronic transplantation chart. The data can be exported directly from the CERTAIN web application into statistical software packages for scientific analyses. The rights regarding data ownership, evaluation, and publications are regulated in the registry's rules of procedure. Data quality is ensured by automatic software validation and a manual data review process. To avoid redundant data entry, CERTAIN has established interfaces for data change with Eurotransplant, the Collaborative Transplant Study (CTS), and the registry of the European Society of Pediatric Nephrology (ESPN) and European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) (ESPN/ERA-EDTA registry). CERTAIN fulfils all regulatory and ethical requirements of the European Union and Germany, in particular, regarding patients' data privacy and security. Conclusion. Using modern information technology, the recently established multinational CERTAIN Registry fills a gap, in Europe for collaborative 5research and quality assurance in the field of pediatric renal transplantation.","[Plotnicki, L.; Hoecker, B.; Toenshoff, B.] Univ Childrens Hosp, Dept Pediat 1, D-69120 Heidelberg, Germany; [Plotnicki, L.; Kohl, C. D.] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany; [Kohl, C. D.] Heidelberg Univ, Coordinat Ctr Clin Trials, Heidelberg, Germany; [Rahmel, A.] Eurotransplant Fdn, Leiden, Netherlands; [Pape, L.] Hannover Med Sch, Ctr Paediat & Adolescent Med, Hannover, Germany; [Hoyer, P.] Univ Childrens Hosp, Essen, Germany; [Marks, S. D.] Great Ormond St Hosp Sick Children, London WC1N 3JH, England; [Webb, N. J. A.] Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England; [Soeylemezoglu, O.] Gazi Univ, Ankara, Turkey; [Topaloglu, R.] Hacettepe Univ, Ankara, Turkey; [Szabo, A. J.] Semmelweis Univ, Dept Pediat 1, H-1085 Budapest, Hungary; [Seeman, T.] Charles Univ Prague, Univ Childrens Hosp Motol, Fac Med 2, Prague, Czech Republic; [Cornelissen, E. A. Marlies] Radboud UMC, Nijmegen, Netherlands; [Knops, N.] Univ Childrens Hosp, Louvain, Belgium; [Grenda, R.] Childrens Mem Hlth Inst, Warsaw, Poland","Plotnicki, L (reprint author), Univ Childrens Hosp, Dept Pediat 1, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.","lukasz.plotnicki@med.uni-heidelberg.de",null,null,null,null,null,4,1,1,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","0041-1345",null,null,"TRANSPL P","Transplant. Proc.","MAY",2013,45,4,null,null,null,null,1414,1417,null,"10.1016/j.transproceed.2013.01.007",null,4,"Immunology; Surgery; Transplantation","Immunology; Surgery; Transplantation","167JE","WOS:000320627500033"]
[null,null,null,null,"J","Hancarova, M; Simandlova, M; Drabova, J; Petrak, B; Koudova, M; Havlovicova, M; Sedlacek, Z",null,null,null,"Hancarova, Miroslava; Simandlova, Martina; Drabova, Jana; Petrak, Borivoj; Koudova, Monika; Havlovicova, Marketa; Sedlacek, Zdenek",null,null,"Chromosome 12q13.13 deletions involving the HOXC gene cluster: Phenotype and candidate genes","EUROPEAN JOURNAL OF MEDICAL GENETICS",null,null,"English","Letter",null,null,null,null,null,null,"INTELLECTUAL DISABILITY; EMBRYONIC-DEVELOPMENT; DIFFERENTIATION; HOMEOSIS",null,"[Hancarova, Miroslava; Simandlova, Martina; Drabova, Jana; Petrak, Borivoj; Koudova, Monika; Havlovicova, Marketa; Sedlacek, Zdenek] Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Prague 15000 5, Czech Republic; [Hancarova, Miroslava; Simandlova, Martina; Drabova, Jana; Petrak, Borivoj; Koudova, Monika; Havlovicova, Marketa; Sedlacek, Zdenek] Univ Hosp Motol, Prague 15000 5, Czech Republic","Sedlacek, Z (reprint author), Charles Univ Prague, Dept Biol & Med Genet, Fac Med 2, Plzenska 130-221, Prague 15000 5, Czech Republic.","zdenek.sedlacek@lfmotol.cuni.cz",null,null,null,null,null,11,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","1769-7212",null,null,"EUR J MED GENET","Eur. J. Med. Genet.","MAR",2013,56,3,null,null,null,null,171,173,null,"10.1016/j.ejmg.2012.12.003",null,3,"Genetics & Heredity","Genetics & Heredity","224MZ","WOS:000324892400009"]
[null,null,null,null,"J","Linhartova, K; Hubacek, P; Zemanek, D; Kodetova, D; Zajac, M; Setina, M; Veselka, J",null,null,null,"Linhartova, Katerina; Hubacek, Petr; Zemanek, David; Kodetova, Daniela; Zajac, Miroslav; Setina, Marek; Veselka, Josef",null,null,"Presence of the viral genome in the myocardial tissue of patients without clinical suspicion of myocarditis","CARDIOVASCULAR PATHOLOGY",null,null,"English","Letter",null,null,null,null,null,null,"ASSAY; DNA",null,"[Linhartova, Katerina; Zemanek, David; Veselka, Josef] Charles Univ Prague, Fac Med 2, Dept Cardiol, Prague, Czech Republic; [Hubacek, Petr; Zajac, Miroslav] Univ Hosp Motol, Dept Med Microbiol, Prague, Czech Republic; [Hubacek, Petr] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic; [Kodetova, Daniela] Charles Univ Prague, Fac Med 2, Dept Pathol & Mol Med, Prague, Czech Republic; [Setina, Marek] Charles Univ Prague, Fac Med 2, Dept Cardiac Surg, Prague, Czech Republic","Linhartova, K (reprint author), Charles Univ Prague, Fac Med 2, Dept Cardiol, Prague, Czech Republic.","linhartkaterina@atlas.cz",null,null,null,null,null,8,0,0,"ELSEVIER SCIENCE INC","NEW YORK","360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA","1054-8807","1879-1336",null,"CARDIOVASC PATHOL","Cardiovasc. Pathol.","JAN-FEB",2013,22,1,null,null,null,null,113,114,null,"10.1016/j.carpath.2012.06.009",null,2,"Cardiac & Cardiovascular Systems; Pathology","Cardiovascular System & Cardiology; Pathology","060FH","WOS:000312761400022"]
[null,null,null,null,"J","Zieg, J; Hacek, J",null,null,null,"Zieg, Jakub; Hacek, Jaromir",null,null,"Surprisingly favorable outcome in a patient with Goodpasture's disease","HEMODIALYSIS INTERNATIONAL",null,null,"English","Letter",null,null,null,null,null,null,null,null,"[Zieg, Jakub] Charles Univ Prague, Dept Pediat, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic; Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Univ Hosp Motol, Prague 15006, Czech Republic","Zieg, J (reprint author), Charles Univ Prague, Dept Pediat, Fac Med 2, Univ Hosp Motol, V Uvalu 84, Prague 15006, Czech Republic.","jakubzieg@hotmail.com",null,null,null,null,null,4,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1492-7535",null,null,"HEMODIAL INT","Hemodial. Int.","JAN",2013,17,1,null,null,null,null,135,137,null,"10.1111/j.1542-4758.2012.00708.x",null,3,"Urology & Nephrology","Urology & Nephrology","073OA","WOS:000313751100022"]
[null,null,null,null,"J","Goetz, M; Kitzlerova, E; Hrdlicka, M; Dhossche, D",null,null,null,"Goetz, Michal; Kitzlerova, Eva; Hrdlicka, Michal; Dhossche, Dirk",null,null,"Combined Use of Electroconvulsive Therapy and Amantadine in Adolescent Catatonia Precipitated by Cyber-Bullying","JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY",null,null,"English","Letter",null,null,null,null,null,null,"NEUROLEPTIC-MALIGNANT-SYNDROME; PSYCHOTIC SYMPTOMS; CHILDHOOD TRAUMA; DISORDER; OLANZAPINE; FEATURES",null,"[Goetz, Michal; Hrdlicka, Michal] Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Child & Adolescent Psychiat, Prague 15006 5, Czech Republic; [Kitzlerova, Eva] Charles Univ Prague, Gen Teaching Hosp Prague, Fac Med 1, Dept Psychiat, Prague 15006 5, Czech Republic; [Dhossche, Dirk] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Dept Psychiat, Jackson, MS 39216 USA","Goetz, M (reprint author), Charles Univ Prague, Univ Hosp Motol, Fac Med 2, Dept Child & Adolescent Psychiat, V Uvalu 84, Prague 15006 5, Czech Republic.","michal.goetz@lfmotol.cuni.cz",null,null,null,null,null,30,1,1,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1044-5463",null,null,"J CHILD ADOL PSYCHOP","J. Child Adolesc. Psychopharmacol.","APR",2013,23,3,null,null,null,null,228,231,null,"10.1089/cap.2012.0045",null,4,"Pediatrics; Pharmacology & Pharmacy; Psychiatry","Pediatrics; Pharmacology & Pharmacy; Psychiatry","130ZU","WOS:000317960700010"]
[null,null,null,null,"J","Palickova, M; Mocikova, H; Vernerova, Z; Campr, V; Kozak, T",null,null,null,"Palickova, Monika; Mocikova, Heidi; Vernerova, Zdenka; Campr, Vit; Kozak, Tomas",null,null,"BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma","LEUKEMIA & LYMPHOMA",null,null,"English","Letter",null,null,null,null,null,null,"CHEMOTHERAPY; STANDARD; DISEASE; CHOP",null,"[Palickova, Monika; Mocikova, Heidi; Kozak, Tomas] Charles Univ Prague, Dept Clin Hematol, Univ Hosp Kralovske Vinohrady, Fac Med 3, Prague, Czech Republic; [Vernerova, Zdenka] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Inst Pathol, Prague, Czech Republic; [Campr, Vit] Charles Univ Prague, Inst Pathol & Mol Med, Univ Hosp Motol, Fac Med 2, Prague, Czech Republic","Palickova, M (reprint author), Charles Univ Hosp Kralovske Vinohrady, Dept Clin Hematol, Fac Med 3, Srobarova 50, Prague 10034 10, Czech Republic.","palickova.monika@gmail.com","Kozak, Tomas/K-3561-2012",null,null,null,null,9,0,0,"INFORMA HEALTHCARE","LONDON","TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND","1042-8194",null,null,"LEUKEMIA LYMPHOMA","Leuk. Lymphoma","SEP",2013,54,9,null,null,null,null,2081,2082,null,"10.3109/10428194.2012.762514",null,2,"Oncology; Hematology","Oncology; Hematology","206BY","WOS:000323492400043"]
[null,null,null,null,"J","Klukowska, A; Komrska, V; Jansen, M; Laguna, P",null,null,null,"Klukowska, A.; Komrska, V.; Jansen, M.; Laguna, P.",null,null,"Response to the Letter to the Editor by Ewenstein BM and Reininger AJ","HAEMOPHILIA",null,null,"English","Letter",null,null,null,null,null,null,"PREVIOUSLY UNTREATED PATIENTS; SEVERE HEMOPHILIA-A; RECOMBINANT FACTOR-VIII; INHIBITOR DEVELOPMENT; PRODUCTS",null,"[Klukowska, A.; Laguna, P.] Med Univ Warsaw, Dept Paediat Haematol & Oncol, PL-00576 Warsaw, Poland; [Komrska, V.] Motol Univ Hosp, Prague, Czech Republic; [Jansen, M.] Octapharma AG, Vienna, Austria","Klukowska, A (reprint author), Med Univ Warsaw, Dept Pediat Haematol & Oncol, Marszalkowska 24, PL-00576 Warsaw, Poland.","aklukowska@poczta.onet.pl",null,null,null,null,null,9,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","1351-8216",null,null,"HAEMOPHILIA","Haemophilia","JUL",2013,19,4,null,null,null,null,"e257","e258",null,"10.1111/hae.12154",null,2,"Hematology","Hematology","166KA","WOS:000320552100008"]
[null,null,null,null,"J","Amler, E; Mickova, A; Buzgo, M",null,null,null,"Amler, Evzen; Mickova, Andrea; Buzgo, Matej",null,null,"Electrospun core/shell nanofibers: a promising system for cartilage and tissue engineering?","NANOMEDICINE",null,null,"English","Editorial Material",null,null,null,null,null,"core/shell nanofibers; drug delivery; electrospinning; tissue engineering","CORE-SHELL NANOFIBERS; GROWTH-FACTOR; DRUG-DELIVERY; RELEASE; SCAFFOLDS; FIBERS",null,"[Amler, Evzen; Mickova, Andrea; Buzgo, Matej] Charles Univ Prague, Fac Med 2, Dept Biophys, Prague 15006 5, Czech Republic; [Amler, Evzen; Mickova, Andrea; Buzgo, Matej] Acad Sci Czech Republic, Inst Expt Med, Prague 14220, Czech Republic; [Mickova, Andrea; Buzgo, Matej] Univ Prague, Univ Ctr Energy Efficient Bldng UCEEB, Kladno 27201, Czech Republic","Mickova, A (reprint author), Charles Univ Prague, Fac Med 2, Dept Biophys, V Uvalu 84, Prague 15006 5, Czech Republic.","andrea_mickova@labdemo.cz",null,null,null,null,null,23,2,2,"FUTURE MEDICINE LTD","LONDON","UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND","1743-5889","1748-6963",null,"NANOMEDICINE-UK","Nanomedicine","APR",2013,8,4,null,null,"SI",null,509,512,null,"10.2217/NNM.13.19",null,4,"Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology","Biotechnology & Applied Microbiology; Science & Technology - Other Topics","120NU","WOS:000317178200003"]
[null,null,null,null,"J","Dostalova, T; Jelinkova, H",null,null,null,"Dostalova, Tatjana; Jelinkova, Helena",null,null,"Lasers in Dentistry: Overview and Perspectives","PHOTOMEDICINE AND LASER SURGERY",null,null,"English","Editorial Material",null,null,null,null,null,null,"THERAPY; YAG; IRRADIATION; CARIES",null,"[Dostalova, Tatjana] Charles Univ Prague, Dept Stomatol, Fac Med 2, Prague 15006 5, Czech Republic; [Jelinkova, Helena] Czech Tech Univ, Fac Nucl Sci & Phys Engn, CR-11519 Prague, Czech Republic","Dostalova, T (reprint author), Charles Univ Prague, Dept Stomatol, Fac Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","tatjana.dostalova@fnmotol.cz",null,null,null,null,null,22,1,2,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","1549-5418",null,null,"PHOTOMED LASER SURG","Photomed. Laser Surg.","APR",2013,31,4,null,null,null,null,147,149,null,"10.1089/pho.2013.3493",null,3,"Surgery","Surgery","123NY","WOS:000317398200001"]
[null,null,null,null,"J","DiNicolantonio, JJ; Serebruany, VL; Tomek, A",null,null,null,"DiNicolantonio, James J.; Serebruany, Victor L.; Tomek, Ales",null,null,"Refuting the Ticagrelor-Aspirin Black Box Warning: And Proposing a Ticagrelor Early-PCI Black Box Warning","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Editorial Material",null,null,null,null,null,"Ticagrelor; Clopidogrel; Percutaneous Coronary Interventions; Clinical Trials","PLATO TRIAL; CLOPIDOGREL; OUTCOMES","Context: Ticagrelor, a novel reversible antiplatelet agent, has a black box warning to avoid maintenance doses of aspirin > 100 mg. However, a significant ticagrelor-early percutaneous coronary intervention (PCI) interaction exists. Objective: To discuss the inappropriateness of the black box warning for aspirin doses > 100 mg with ticagrelor and the appropriateness (and need) for a black box warning for ticagrelor patients needing early (within 24 hours of randomization) PCI. Results: The FDA Complete Response Review for ticagrelor indicates that aspirin doses >= 300 mg/daily was not a significant interaction. In the ticagrelor-aspirin >= 300 mg cohort, all-cause mortality (through study end) and cardiovascular (CV) mortality (through study end) were not significantly increased (HR = 1.27; 95% CI, 0.84-1.93, p = 0.262 and HR = 1.39; 95% CI: 0.87-2.2, p = 0.170), respectively. However, in patients treated with early (within 24 hours) PCI, ticagrelor significantly increased all-cause mortality (30 day: HR = 1.89; 95% CI: 1.26-2.81, p = 0.002, and through study end, HR = 1.41; 95% CI, 1.08-1.84, p = 0.012) and increased CV mortality (30 day: HR = 1.31; 95% CI: 0.97-1.77, p = 0.075, and through study end, HR = 1.35; 95% CI, 0.995-1.82, p = 0.054) compared to clopidogrel. Conclusions: Early-PCI was more prevalent in the US versus outside-US regions (61% versus 49%). The black box warning for the use of maintenance aspirin doses over 100 mg/daily with ticagrelor is inappropriate and ignores the more important, credible, and highly significant ticagrelor-early PCI adverse interaction in PLATO. (C) 2013 Elsevier Ireland Ltd. All rights reserved.","[DiNicolantonio, James J.] Wegmans Pharm, Ithaca, NY 14850 USA; [Serebruany, Victor L.] Johns Hopkins Univ, HeartDrug Res Labs, Towson, MD USA; [Tomek, Ales] Charles Univ Prague, Dept Neurol, Sch Med 2, Prague, Czech Republic","DiNicolantonio, JJ (reprint author), Wegmans Pharm, 500 South Meadow St, Ithaca, NY 14850 USA.","jjdinicol@gmail.com",null,null,null,null,null,5,1,1,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273","1874-1754",null,"INT J CARDIOL","Int. J. Cardiol.","OCT 3",2013,168,3,null,null,null,null,1721,1723,null,"10.1016/j.ijcard.2013.05.060",null,3,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","241RF","WOS:000326184400011"]
[null,null,null,null,"J","Rizzari, C; Conter, V; Stary, J; Colombini, A; Moericke, A; Schrappe, M",null,null,null,"Rizzari, Carmelo; Conter, Valentino; Stary, Jan; Colombini, Antonella; Moericke, Anja; Schrappe, Martin",null,null,"Optimizing asparaginase therapy for acute lymphoblastic leukemia","CURRENT OPINION IN ONCOLOGY",null,null,"English","Editorial Material",null,null,null,null,null,"acute lymphoblastic leukemia; asparaginase; childhood; hypersensitivity; silent inactivation","ESCHERICHIA-COLI-ASPARAGINASE; ERWINIA-ASPARAGINASE; PEDIATRIC-PATIENTS; CHILDREN; CHILDHOOD; CANCER; ANTIBODIES; BFM; LYMPHOMA; PROTOCOL","Asparaginases are important agents used in the treatment of children with acute lymphoblastic leukemia (ALL). Three types of asparaginase are currently available: two are derived from Escherichia coli [native asparaginase and pegylated asparaginase (PEG-asparaginase)] and one from Erwinia chrysanthemi (crisantaspase). All three products share the same mechanism of action but have different pharmacokinetic properties, which do not make them easily interchangeable. Among the known toxicities and side-effects, allergic reactions and silent inactivation represent the most important limitations to the prolonged use of any asparaginase product, with associated reduced therapeutic effects and poorer outcomes. Routine real time monitoring can help to identify patients with silent inactivation and facilitate a switch to a different product to ensure continued depletion of asparagine, completion of the treatment schedule and maintenance of outcomes. However, the most appropriate second-line treatment is still a matter of debate. PEG-asparaginase has lower immunogenicity and a longer half-life than native Escherichia coli (E. coli) asparaginase, which makes it useful for both first-line and second-line use with a reduced number of doses. However, PEG-asparaginase displays cross-reactivity with native E. coil asparaginase that may harm its therapeutic effects. Crisantaspase does not display cross-reactivity to either of the E. coli-derived products, which has made crisantaspase the second-line treatment option in a number of recent protocols. As crisantaspase has a much shorter biological half-life than the E. coli-derived products, the appropriate dosage and administration schedule are of paramount importance in delivering treatment with this product. In the ongoing trial AIEOP-BFM ALL 2009 (Associazione Italiana Ematologia Oncologia Pediatrica - Berlin-Franklin-Munster), in which PEG-asparaginase is used first-line, one dose of PEG-asparaginase is substituted by seven doses of crisantaspase given intravenously at 20000 IU/m(2) on alternate days when clinical allergy or silent inactivation is present. Based on the indications of different protocols, lack of cross-reactivity to the E. coli-derived products and taking into consideration regulatory factors and availability, crisantaspase may be considered a viable second-line therapy.","[Rizzari, Carmelo; Conter, Valentino; Colombini, Antonella] Univ Milano Bicocca, Dept Pediat, San Gerardo Hosp, I-20052 Monza, Italy; [Stary, Jan] Univ Hosp Motol, Prague, Czech Republic; [Moericke, Anja; Schrappe, Martin] Univ Med Ctr Schleswig Holstein, Kiel, Germany","Rizzari, C (reprint author), Univ Milano Bicocca, Dept Pediat, San Gerardo Hosp, Via Pergolesi 33, I-20052 Monza, Italy.","c.rizzari@hsgerardo.org",null,null,null,null,null,35,1,1,"LIPPINCOTT WILLIAMS & WILKINS","PHILADELPHIA","530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA","1040-8746",null,null,"CURR OPIN ONCOL","Curr. Opin. Oncol.","FEB",2013,25,null,null,1,null,null,"S1","S9",null,"10.1097/CCO.0b013e32835d7d85",null,9,"Oncology","Oncology","091VF","WOS:000315077200001"]
[null,null,null,null,"J","DiNicolantonio, JJ; D'Ascenzo, F; Tomek, A; Chatterjee, S; Niazi, AK; Biondi-Zoccai, G",null,null,null,"DiNicolantonio, James J.; D'Ascenzo, Fabrizio; Tomek, Ales; Chatterjee, Saurav; Niazi, Asfandyar K.; Biondi-Zoccai, Giuseppe",null,null,"Clopidogrel is safer than ticagrelor in regard to bleeds: A closer look at the PLATO trial","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Editorial Material",null,null,null,null,null,"Ticagrelor; Clopidogrel; Hemorrhagic events; Bleeds","ATLAS ACS 2; REDUCTION; MORTALITY; TRACER","Objective: To compare hemorrhagic events between clopidogrel and ticagrelor in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Methods: We examined the FDA Medical Review. Results: Compared to clopidogrel, ticagrelor significantly increased spontaneous bleeds, major bleeds, major plus minor bleeds, and major plus minor plus minimal bleeds. Ticagrelor also increased both major and fatal/life-threatening bleeds versus clopidogrel when CABG was performed between 24 and 96 h after stopping medication, which was also accompanied by a larger volume of chest tube drainage and transfusions. Moreover, ticagrelor increased CABG-related bleeding versus clopidogrel in those patients who did not wait until day 5 after stopping treatment to have CABG. Additionally, compared to clopidogrel, ticagrelor increased the risk of hematuria (RR = 1.91; 95% CI: 0.95-3.83), intracranial hemorrhage or subdural or other hematoma (RR 1.87; 95% CI: 1.02-3.42), subcutaneous hemorrhage, ecchymosis, hematoma (RR = 1.63; 95% CI: 0.84-3.17), epistaxis (RR = 1.49; 95% CI: 0.67-3.32), retroperitoneal hematoma or hemorrhage (RR = 1.49; 95% CI: 0.53-4.19), gastrointestinal/anal bleed (RR = 1.23; 95% CI: 0.93-1.64) and bleed/hematoma (RR = 1.21, 95% CI: 1.02-1.43). Conclusions: Clopidogrel is safer than ticagrelor in regard to bleeding. Additionally, ticagrelor's purported faster antiplatelet 'offset' is substantially longer than its pharmacokinetics indicate. Considering the fact that the mortality, stent thrombosis and myocardial infarction 'benefit' of ticagrelor have recently been challenged, and that the increase in stroke on ticagrelor has recently been shown to be worse than originally published, the decision to use ticagrelor over clopidogrel in the face of a higher risk for bleeds is not advised. (C) 2013 Elsevier Ireland Ltd. All rights reserved.","[DiNicolantonio, James J.] Wegmans Pharm, Ithaca, NY USA; [D'Ascenzo, Fabrizio] Univ Turin, Div Cardiol, I-10124 Turin, Italy; [Tomek, Ales] Charles Univ Prague, Dept Neurol, Univ Hosp Motol, Fac Med 2, Prague, Czech Republic; [Chatterjee, Saurav] Brown Univ, Providence, RI 02912 USA; [Chatterjee, Saurav] Providence VAMC, Providence, RI USA; [Niazi, Asfandyar K.] Shifa Coll Med, Islamabad, Pakistan; [Biondi-Zoccai, Giuseppe] Univ Roma La Sapienza, Dept Medicosurg Sci & Biotechnol, Latina, Italy","DiNicolantonio, JJ (reprint author), 500 South Meadow St, Ithaca, NY 14850 USA.","jjdinicol@gmail.com",null,null,null,null,null,13,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273","1874-1754",null,"INT J CARDIOL","Int. J. Cardiol.","OCT 3",2013,168,3,null,null,null,null,1739,1744,null,"10.1016/j.ijcard.2013.06.135",null,6,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","241RF","WOS:000326184400015"]
[null,null,null,null,"J","Serebruany, VL; DiNicolantonio, JJ; Can, MM; Dukhanin, A; Tomek, A",null,null,null,"Serebruany, Victor L.; DiNicolantonio, James J.; Can, Mehmet Mustafa; Dukhanin, Alexander; Tomek, Ales",null,null,"Mortality after clopidogrel in the non-invasive PLATO cohort and TRILOGY ACS trial: Another mismatched death paradox","INTERNATIONAL JOURNAL OF CARDIOLOGY",null,null,"English","Editorial Material",null,null,null,null,null,"Mortality; Acute coronary syndromes; Non invasive strategy; Clinical trials","ACUTE CORONARY SYNDROMES; TICAGRELOR; TRACER","Background: Excess mortality especially in the clopidogrel arm of the PLATO trial raise concerns of data integrity, and call for independent verification of vital records in the national death registries. Recently published data focused on outcomes in patients after non-invasive strategies yielded from the PLATO (PLATO-NIS) and TRILOGY ACS trials allowing comparison of all cause mortality (ACM) between trials. Methods: To compare the prorated over follow-up duration rates of ACM in the clopidogrel arms of PLATO-NIS cohort and TRILOGY ACS trial. Results: The background clinical characteristics indicate similar if not higher mortality should be expected in TRILOGY ACS. PLATO trial was almost half the duration with a mean follow-up of 277 days compared to TRILOGY ACS (513 days). Matching prorated over follow-up duration of ACM rates in the clopidogrel arm revealed 0.027/day or 9.86% yearly mortality in PLATO-NIS cohort (195 fatalities among 2615 patients enrolled). The ACM rates in TRILOGY ACS (409/4663) were only 0.017/day or 6.2% annually after clopidogrel, suggesting that the risk to die in the control PLATO-NIS group was 63% higher and barely missed significance (p = 0.051) compared to TRILOGY ACS. Conclusions: Prorated over length of follow-up PLATO-NIS mortality rates after clopidogrel far exceeded those observed in a similar medically managed patients in a TRILOGY ACS trial. The background clinical differences between trials are not responsible for the elevated PLATO-NIS mortality numbers. These data further challenge the death paradox reported in the overall PLATO trial and call for the urgent independent verification of vital records. (c) 2013 Elsevier Ireland Ltd. All rights reserved.","[Serebruany, Victor L.] Johns Hopkins Univ, HeartDrug Res Labs, Towson, MD 21204 USA; [DiNicolantonio, James J.] Wegmans Pharm, Ithaca, NY USA; [Can, Mehmet Mustafa] Bagcilar Res & Educ Hosp, Dept Cardiol, Istanbul, Turkey; [Dukhanin, Alexander] Pirogov Russian Natl Res Med Univ, Dept Mol Pharmacol & Radiobiol, Moscow, Russia; [Tomek, Ales] Charles Univ Prague, Sch Med 2, Dept Neurol, Prague, Czech Republic","Serebruany, VL (reprint author), Johns Hopkins Univ, HeartDrug Res Labs, Osler Med Bldg,7600 Osler Dr,Suite 307, Towson, MD 21204 USA.","heartdrug@aol.com",null,null,null,null,null,9,0,0,"ELSEVIER IRELAND LTD","CLARE","ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND","0167-5273","1874-1754",null,"INT J CARDIOL","Int. J. Cardiol.","SEP 30",2013,168,2,null,null,null,null,640,642,null,"10.1016/j.ijcard.2013.05.066",null,3,"Cardiac & Cardiovascular Systems","Cardiovascular System & Cardiology","231JN","WOS:000325412800024"]
[null,null,null,null,"J","Smrz, D; Bandara, G; Beaven, MA; Metcalfe, DD; Gilfillan, AM",null,null,null,"Smrz, Daniel; Bandara, Geethani; Beaven, Michael A.; Metcalfe, Dean D.; Gilfillan, Alasdair M.",null,null,"Prevention of F-actin assembly switches the response to SCF from chemotaxis to degranulation in human mast cells","EUROPEAN JOURNAL OF IMMUNOLOGY",null,null,"English","Article",null,null,null,null,null,"Chemotaxis; Degranulation; F-actin; Mast Cell; SCF","EPSILON-RI AGGREGATION; SIGNALING PATHWAYS; FILAMENTOUS ACTIN; MEDIATOR RELEASE; ACTIVATION; CALCIUM; IGE; KIT; PHOSPHORYLATION; REARRANGEMENT","Following antigen/IgE-mediated aggregation of high affinity IgE-receptors (Fc epsilon RI), mast cells (MCs) degranulate and release inflammatory mediators leading to the induction of allergic reactions including anaphylaxis. Migration of MCs to resident tissues and sites of inflammation is regulated by tissue chemotactic factors such as stem cell factor (SCF (KIT ligand)). Despite inducing similar early signaling events to antigen, chemotactic factors, including SCF, produce minimal degranulation in the absence of other stimuli. We therefore investigated whether processes regulating MC chemotaxis are rate limiting for MC mediator release. To investigate this issue, we disrupted actin polymerization, a requirement for MC chemotaxis, with latrunculin B and cytochalasin B, then examined chemotaxis and mediator release in human (hu)MCs induced by antigen or SCF. As expected, such disruption minimally affected early signaling pathways, but attenuated SCF-induced human mast cell chemotaxis. In contrast, SCF, in the absence of other stimuli, induced substantial degranulation in a concentration-dependent manner following actin disassembly. It also moderately enhanced antigen-mediated human mast cell degranulation which was further enhanced in the presence of SCF. These observations suggest that processes regulating cell migration limit MC degranulation as a consequence of cytoskeletal reorganization.","[Smrz, Daniel; Bandara, Geethani; Metcalfe, Dean D.; Gilfillan, Alasdair M.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Beaven, Michael A.] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA","Smrz, D (reprint author), Charles Univ Prague, Inst Immunol, Sch Med 2, V Uvalu 84, Prague 15006 5, Czech Republic.","daniel.smrz@lfmotol.cuni.cz","Smrz, Daniel/D-4853-2014",null,"Intramural Research programs within NIAID; NHLBI","Research in the authors' laboratories was supported by funding from the Intramural Research programs within NIAID (DS, DDM, and AMG) and NHLBI (MAB). We would like to thank Biological Imaging Facility (RTB/NIAID/NIH) for technical support in confocal image acquisition including Juraj Kabat for assistance in image post processing and analysis.",null,51,0,0,"WILEY-BLACKWELL","HOBOKEN","111 RIVER ST, HOBOKEN 07030-5774, NJ USA","0014-2980","1521-4141",null,"EUR J IMMUNOL","Eur. J. Immunol.","JUL",2013,43,7,null,null,null,null,1873,1882,null,"10.1002/eji.201243214",null,10,"Immunology","Immunology","261WO","WOS:000327695500022"]
[null,null,null,null,"J","Smrz, D; Bandara, G; Zhang, SL; Mock, BA; Beaven, MA; Metcalfe, DD; Gilfillan, AM",null,null,null,"Smrz, Daniel; Bandara, Geethani; Zhang, Shuling; Mock, Beverly A.; Beaven, Michael A.; Metcalfe, Dean D.; Gilfillan, Alasdair M.",null,null,"A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses","JOURNAL OF IMMUNOLOGICAL METHODS",null,null,"English","Article",null,null,null,null,null,"Degranulation; Fc epsilon RI; KIT; Mast cells; KIT; SCF","EPSILON-RI AGGREGATION; SIGNALING PATHWAYS; C-KIT; KINASE; RELEASE; GROWTH; CHEMOTAXIS; INDUCTION; MIGRATION; RECEPTOR","Activation of KIT, by its ligand, stem cell factor (SCF), results in the initiation of signal transduction pathways that influence mast cell survival and proliferation. Activating mutations in KIT have thus been linked to clonal MC proliferation associated with systemic mastocytosis. SCF also modulates MC function by inducing MC chemotaxis and by potentiating antigen (Ag)/IgE-mediated MC degranulation. Thus, mutations in KIT also have the potential to affect these processes in allergic and other mast cell-related diseases. Studies to determine how native and mutated KIT may modulate MC chemotaxis and activation have, however, been limited due to the lack of availability of a suitable functional MC line lacking native KIT which would allow transduction of KIT constructs. Here we describe a novel mouse MC line which allows the study of normal and mutated KIT constructs. These cells originated from a bone marrow-derived mouse MC culture out of which a rapidly dividing mast cell sub-population spontaneously arose. Over time, these cells lost KIT expression while continuing to express functional high affinity receptors for IgE (Fc epsilon RI). As a consequence, these cells degranulated in response to Ag/IgE but did not migrate nor show any evidence of potentiation of Ag/IgE degranulation in response to SCF. Retroviral transduction of the cells with a human (hu)KIT construct resulted in surface expression of huKIT which responded to huSCF by potentiation of Ag/IgE-induced degranulation and chemotaxis. This cell line thus presents a novel system to delineate how MC function is modulated by native and mutated KIT and for the identification of novel inhibitors of these processes. Published by Elsevier B.V.","[Smrz, Daniel; Bandara, Geethani; Metcalfe, Dean D.; Gilfillan, Alasdair M.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Zhang, Shuling; Mock, Beverly A.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Beaven, Michael A.] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA","Smrz, D (reprint author), Charles Univ Prague, Sch Med 2, Inst Immunol, V Uvalu 84, Prague 15006 5, Czech Republic.","daniel.smrz@lfmotol.cuni.cz","Smrz, Daniel/D-4853-2014",null,"NIAID; NHLBI; NCI","Research was supported by funding from the Intramural Research programs within NIAID (D.S., A.M.G., D.D.M.), and NHLBI (M.A.B) and NCI (S.Z. and B.A.M.). We would like to thank Biological Imaging Facility (RTB/NIAID/NIH) for the technical support in confocal image acquisition including Juraj Kabat for assistance in image post processing and analysis.",null,39,0,0,"ELSEVIER SCIENCE BV","AMSTERDAM","PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS","0022-1759",null,null,"J IMMUNOL METHODS","J. Immunol. Methods","APR",2013,390,41671,null,null,null,null,52,62,null,"10.1016/j.jim.2013.01.008",null,11,"Biochemical Research Methods; Immunology","Biochemistry & Molecular Biology; Immunology","123IB","WOS:000317380500007"]
[null,null,null,null,"J","Glaser, V; Pohunek, P",null,null,null,"Glaser, Vicki; Pohunek, Petr",null,null,"Interview with the Expert: Petr Pohunek, MD, PhD","PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY",null,null,"English","Editorial Material",null,null,null,null,null,null,null,null,"[Pohunek, Petr] Univ Hosp Motol, Dept Pediat, Prague 15006 5, Czech Republic; [Pohunek, Petr] Charles Univ Prague, Sch Med 2, Prague, Czech Republic; [Pohunek, Petr] Univ Hosp Motol, Div Pediat Resp Dis, Prague 15006 5, Czech Republic",null,"petr.pohunek@lfmotol.cuni.cz",null,null,null,null,null,0,0,0,"MARY ANN LIEBERT INC","NEW ROCHELLE","140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA","2151-321X",null,null,"PEDIAT ALLER IMM PUL","Pediatr. Allergy Immunol. Pulmonol.","MAR",2013,26,1,null,null,null,null,1,3,null,"10.1089/ped.2013.2317",null,3,"Allergy; Immunology; Pediatrics; Respiratory System","Allergy; Immunology; Pediatrics; Respiratory System","172JH","WOS:000320998500001"]
[null,null,null,null,"J","Veselka, J",null,null,null,"Veselka, Josef",null,null,"The time has come to move from coronary angiography to physiological assessment of coronary lesions","ARCHIVES OF MEDICAL SCIENCE",null,null,"English","Editorial Material",null,null,null,null,null,null,"FRACTIONAL FLOW RESERVE; INTRAVASCULAR ULTRASOUND; STENOSES",null,"[Veselka, Josef] Univ Hosp Motol, Dept Cardiol, Prague, Czech Republic; [Veselka, Josef] Charles Univ Prague, Sch Med 2, Prague 15000 5, Czech Republic","Veselka, J (reprint author), Charles Univ Prague, Univ Hosp Motol, Dept Cardiol, Sch Med 2, V Uvalu 84, Prague 15000 5, Czech Republic.","josef.veselka@fnmotol.cz",null,null,null,null,null,10,0,0,"TERMEDIA PUBLISHING HOUSE LTD","POZNAN","WENEDOW ST 9-1, POZNAN, 61-614, POLAND","1734-1922",null,null,"ARCH MED SCI","Arch. Med. Sci.","FEB",2013,9,1,null,null,null,null,1,2,null,"10.5114/aoms.2013.33342",null,2,"Medicine, General & Internal","General & Internal Medicine","102FJ","WOS:000315829900001"]

{"sheet":"krivka Jimp","index":3,"n_rows":104,"n_cols":9,"rows_kept":104,"cut":false,"hidden":false,"merged":[]}
["INTERPRETACE RIV BODŮ - PRŮBĚH KŘIVKY Jimp"]
["Cíl: pomoci uživatelům s orientací v hodnotách bodů"]
["Popis: dvě fiktivní oborové skupiny se 100 a 33 časopisy, seřazené podle výše IF a body, jež by článek v takovém časopise obdržel; modře zvýrazněny čtvrtiny, resp. třetiny pořadí."]
["Pmax - 100","P 100","Body RIV - 100","Pmax - 33","P - 33","Body RIV - 33"]
[100,1,{"$f":"10+295*((1-((B5-1)/(A5-1)))/(1+(((B5-1)/(A5-1))/(0.057))))","v":305},33,1,{"$f":"10+295*((1-((E5-1)/(D5-1)))/(1+(((E5-1)/(D5-1))/(0.057))))","v":305}]
[100,2,{"$f":"10+295*((1-((B6-1)/(A6-1)))/(1+(((B6-1)/(A6-1))/(0.057))))","v":258.06111696522657},33,2,{"$f":"10+295*((1-((E6-1)/(D6-1)))/(1+(((E6-1)/(D6-1))/(0.057))))","v":194.58392351274784}]
[100,3,223.4050765406254,33,3,141.91684100418411]
[100,4,196.76848316556752,33,4,111.08519900497514]
[100,5,175.65643471948562,33,5,90.84134615384616]
[100,6,158.51169782955935,33,6,76.530627198124279]
[100,7,144.31203298119041,33,7,65.87806748466258]
[100,8,132.35861741675237,33,8,57.639959202175888]
[100,9,122.15751667521805,33,9,51.078990228013033]
[100,10,113.34972341733251,33,10,45.730321507760536]
[100,11,105.66803042894587,33,11,41.286366711772672]
[100,12,98.909451421017849,33,12,37.535480349344979]
[100,13,92.917020914810408,33,13,34.327256944444443]
[100,14,87.567451590409277,33,14,31.55187533729088]
[100,15,82.762561726823805,33,15,29.12727502527806]
[100,16,78.423194303153622,33,16,26.990905848787449]
[100,17,74.484821882363804,33,17,25.094254937163377]
[100,18,70.894316124188492,33,18,23.399118147046323]
[100,19,67.607537114579372,33,19,21.875]
[100,20,64.587509637625288,33,20,20.497262773722632]
[100,21,61.803026166985148,33,21,19.245784457478006]
[100,22,59.22756446346132,33,22,18.103969505783386]
[100,23,56.838440111420617,33,23,17.058008730691739]
[100,24,54.616136577872439,33,24,16.096318079278117]
[100,25,52.543770873393385,33,25,15.209107806691449]
[100,26,50.606663838397019,33,26,14.388048016701461]
[100,27,48.791991909743068,33,27,13.62600632547441]
[100,28,47.088502894954516,33,28,12.916840133222316]
[100,29,45.486282436167997,33,29,12.255230686695279]
[100,30,43.976560921398267,33,30,11.636549441993253]
[100,31,42.551552899587577,33,31,11.056749622926093]
[100,32,41.204322790164561,33,32,10.512277601754814]
[100,33,39.928671997449719,33,33,10]
[100,34,38.719043552519224]
[100,35,37.570441187599329]
[100,36,36.478360357257088]
[100,37,35.438729198184568,null,null,null,null,null,"Doplnění:"]
[100,38,34.447857796121291,null,null,null,null,null,"Zobrazené křivky je ideální - v praxi se totiž časopisy často nacházejí i v několika kategoriích, takže body pro konkrétní časopise se určují z aritmetického průměru."]
[100,39,33.502394427514147,null,null,null,null,null,"Údaje pro výpočet lze nalézt na WoS-JCR (Journal Citation report) jako \"Journal Ranking\", viz příklad níže:"]
[100,40,32.599287682279424]
[100,41,31.735753565716543]
[100,42,30.909246832322104]
[100,43,30.117435929727343]
[100,44,29.358181033242193]
[100,45,28.629514735209398]
[100,46,27.929625022214324]
[100,47,27.256840230040861]
[100,48,26.609615713390195]
[100,49,25.986522006599181]
[100,50,25.38623428435481]
[100,51,24.807522958862748]
[100,52,24.249245273025792]
[100,53,23.710337768679629]
[100,54,23.189809525433553]
[100,55,22.686736079674063]
[100,56,22.200253945220389]
[100,57,21.729555667310159]
[100,58,21.273885350318469]
[100,59,20.832534607105259]
[100,60,20.404838884333959]
[100,61,19.990174123668936]
[100,62,19.587953723571868]
[100,63,19.197625770589713]
[100,64,18.818670512652417]
[100,65,18.45059805005528]
[100,66,{"$f":"10+295*((1-((B70-1)/(A70-1)))/(1+(((B70-1)/(A70-1))/(0.057))))","v":18.092946222555668}]
[100,67,17.745278673422387]
[100,68,17.407183073386285]
[100,69,17.078269489292939]
[100,70,16.758168883887301]
[100,71,16.446531734595403]
[100,72,16.143026760434743]
[100,73,15.847339747304972]
[100,74,15.559172462901977]
[100,75,15.278241653378199]
[100,76,15.004278114653474]
[100,77,14.737025831975798]
[100,78,14.476241181951284]
[100,79,14.221692191815215]
[100,80,13.973157851210377]
[100,81,13.730427472181031]
[100,82,13.493300093487067]
[100,83,13.261583925698574]
[100,84,13.03509583385039]
[100,85,12.813660854723736]
[100,86,12.597111746080779]
[100,87,12.385288565411432]
[100,88,12.178038275962567]
[100,89,11.975214378010103]
[100,90,11.776676563507074]
[100,91,11.582290392396725]
[100,92,11.391926989021449]
[100,93,11.205462757186895]
[100,94,11.022779112557403]
[100,95,10.843762231165259]
[100,96,10.66830281291297]
[100,97,10.496295859036037]
[100,98,10.327640462574164]
[100,99,10.162239610972279]
[100,100,10]